data_2ksy_residue save_MolProbity _Software.Sf_category software _Software.Sf_framecode MolProbity _Software.Entry_ID ? _Software.ID 1 _Software.Name MolProbity _Software.Version 4.0 _Software.Details . save_ save_CYRANGE _Software.Sf_category software _Software.Sf_framecode CYRANGE _Software.Entry_ID ? _Software.ID 2 _Software.Name CYRANGE _Software.Version 2.0 _Software.Details . save_ save_Structure_validation_residue _Structure_validation_residue.Sf_category structure_validation _Structure_validation_residue.Sf_framecode Structure_validation_residue _Structure_validation_residue.Entry_ID ? _Structure_validation_residue.List_ID 1 _Structure_validation_residue.PDB_accession_code 2ksy _Structure_validation_residue.Date_analyzed 2016-10-07 loop_ _Residue_analysis_software.Software_ID _Residue_analysis_software.Software_label _Residue_analysis_software.Method_ID _Residue_analysis_software.Method_label _Residue_analysis_software.Entry_ID _Residue_analysis_software.Structure_validation_oneline_list_ID 1 MolProbity . . ? 1 2 CYRANGE . . ? 1 stop_ loop_ _Residue_analysis.ID _Residue_analysis.PDB_model_num _Residue_analysis.Hydrogen_positions _Residue_analysis.MolProbity_flips _Residue_analysis.Cyrange_core_flag _Residue_analysis.Two_letter_chain_ID _Residue_analysis.PDB_strand_ID _Residue_analysis.PDB_residue_no _Residue_analysis.PDB_ins_code _Residue_analysis.PDB_residue_name _Residue_analysis.Assembly_ID _Residue_analysis.Entity_assembly_ID _Residue_analysis.Entity_ID _Residue_analysis.Comp_ID _Residue_analysis.Comp_index_ID _Residue_analysis.Clash_value _Residue_analysis.Clash_source_PDB_atom_name _Residue_analysis.Clash_destination_PDB_atom_name _Residue_analysis.Clash_destination_PDB_strand_ID _Residue_analysis.Clash_destination_PDB_residue_no _Residue_analysis.Clash_destination_PDB_ins_code _Residue_analysis.Clash_destination_PDB_residue_name _Residue_analysis.Cbeta_deviation_value _Residue_analysis.Rotamer_score _Residue_analysis.Rotamer_name _Residue_analysis.Ramachandran_phi _Residue_analysis.Ramachandran_psi _Residue_analysis.Ramachandran_score _Residue_analysis.Ramachandran_evaluation _Residue_analysis.Ramachandran_type _Residue_analysis.Bond_outlier_count _Residue_analysis.Worst_bond _Residue_analysis.Worst_bond_value _Residue_analysis.Worst_bond_sigma _Residue_analysis.Angle_outlier_count _Residue_analysis.Worst_angle _Residue_analysis.Worst_angle_value _Residue_analysis.Worst_angle_sigma _Residue_analysis.RNA_phosphate_perpendicular_outlier _Residue_analysis.RNA_suitness_score _Residue_analysis.RNA_suite_conformer _Residue_analysis.RNA_suite_triage _Residue_analysis.Max_b_factor _Residue_analysis.Tau_angle _Residue_analysis.Omega_dihedral _Residue_analysis.Disulfide_chi1 _Residue_analysis.Disulfide_chi2 _Residue_analysis.Disulfide_chi3 _Residue_analysis.Disulfide_ss_angle _Residue_analysis.Disulfide_ss _Residue_analysis.Disulfide_ss_angle_prime _Residue_analysis.Disulfide_chi2prime _Residue_analysis.Disulfide_chi1prime _Residue_analysis.Outlier_count_separate_geometry _Residue_analysis.Outlier_count _Residue_analysis.Entry_ID _Residue_analysis.Structure_validation_residue_list_ID . 001 nuclear orig core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.295 0 N-CA-C 112.292 -0.323 . . . . 0.0 112.292 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 67.1 tp -72.58 -35.5 67.95 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.873 0.368 . . . . 0.0 110.833 179.967 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 74.5 p -56.38 -29.64 61.72 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 115.953 -0.567 . . . . 0.0 111.589 -179.8 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 47.5 p -52.2 -35.19 48.51 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.407 -0.36 . . . . 0.0 111.335 -179.617 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 7' ' ' LEU . . . . . . . . . . . . . 3.9 mm? -61.28 -53.02 62.12 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.312 -0.404 . . . . 0.0 111.347 -179.751 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 8' ' ' PHE . . . . . . . . . . . . . 74.7 m-85 -60.93 -32.6 72.1 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-O 121.003 0.43 . . . . 0.0 110.696 179.943 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 9' ' ' TRP . . . . . 0.402 ' O ' HG13 ' A' ' 13' ' ' ILE . 26.0 m95 -66.39 -48.65 69.4 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 115.93 -0.577 . . . . 0.0 110.077 -179.986 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 82.1 mt -57.94 -51.07 71.15 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 115.654 -0.703 . . . . 0.0 110.542 179.526 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -57.41 -35.17 70.65 Favored Glycine 0 N--CA 1.45 -0.411 0 C-N-CA 120.739 -0.743 . . . . 0.0 111.8 179.369 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -65.33 -30.82 71.7 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 120.863 0.363 . . . . 0.0 110.504 179.558 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 13' ' ' ILE . . . . . 0.402 HG13 ' O ' ' A' ' 9' ' ' TRP . 80.9 mt -66.89 -46.43 85.14 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.217 0 CA-C-N 116.062 -0.517 . . . . 0.0 110.075 179.353 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -61.84 -31.29 77.77 Favored Glycine 0 N--CA 1.45 -0.367 0 C-N-CA 120.653 -0.784 . . . . 0.0 111.862 179.329 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 15' ' ' MET . . . . . 0.439 ' HE1' ' HB2' ' A' ' 47' ' ' ALA . 0.0 OUTLIER -67.03 -46.89 73.08 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-O 120.848 0.356 . . . . 0.0 110.626 179.33 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -56.53 -40.45 75.08 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.033 -0.531 . . . . 0.0 110.483 179.547 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 84.4 t -60.36 -48.07 89.82 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.861 179.653 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -65.62 -47.27 78.73 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.775 -0.726 . . . . 0.0 112.439 179.816 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 25.2 m -49.44 -47.43 48.19 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-O 120.637 0.256 . . . . 0.0 111.433 -179.258 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 94.6 mt -71.63 -44.67 63.95 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.481 -0.327 . . . . 0.0 111.516 -179.914 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -55.14 -35.11 64.37 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.384 -0.371 . . . . 0.0 111.918 -179.436 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 22' ' ' PHE . . . . . 0.509 ' HB2' HG23 ' A' ' 41' ' ' VAL . 4.2 m-85 -91.07 -29.56 17.25 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.557 -0.292 . . . . 0.0 111.777 -179.207 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -70.31 -51.02 33.28 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.966 0.412 . . . . 0.0 111.524 -179.362 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 24' ' ' TRP . . . . . . . . . . . . . 5.8 t-105 -66.42 -50.01 64.85 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-N 115.881 -0.6 . . . . 0.0 110.999 -179.778 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.328 -0.34 0 CA-C-N 116.49 -0.323 . . . . 0.0 111.002 179.989 . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.278 0 N-CA-C 112.291 -0.324 . . . . 0.0 112.291 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 38.6 mt-10 -69.99 -20.66 63.28 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.779 0.323 . . . . 0.0 110.645 179.776 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 34' ' ' ARG . . . . . . . . . . . . . 99.8 mtt180 -49.09 -29.09 4.74 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 115.862 -0.608 . . . . 0.0 111.535 -179.862 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 21.4 mmm180 -64.3 -46.98 81.26 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-O 120.783 0.325 . . . . 0.0 111.041 179.905 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 90.2 m-85 -69.2 -32.01 71.01 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.162 179.875 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 37' ' ' TYR . . . . . . . . . . . . . 43.4 m-85 -71.97 -54.75 8.99 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.085 -0.507 . . . . 0.0 111.41 -179.485 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 14.6 p -56.76 -36.34 48.91 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-O 120.972 0.415 . . . . 0.0 110.441 -179.995 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 40.9 m -64.85 -50.19 67.6 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 115.758 -0.655 . . . . 0.0 110.41 179.219 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 40' ' ' LEU . . . . . 0.571 HD11 HD13 ' A' ' 43' ' ' ILE . 57.7 tp -61.0 -38.28 85.47 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 115.573 -0.739 . . . . 0.0 110.657 179.741 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . 0.509 HG23 ' HB2' ' A' ' 22' ' ' PHE . 95.8 t -69.48 -34.0 59.9 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.453 0 CA-C-N 115.932 -0.576 . . . . 0.0 109.975 179.011 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -61.22 -42.31 99.75 Favored Glycine 0 N--CA 1.449 -0.483 0 CA-C-N 115.615 -0.721 . . . . 0.0 112.892 179.905 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 43' ' ' ILE . . . . . 0.571 HD13 HD11 ' A' ' 40' ' ' LEU . 38.9 pt -70.03 -44.0 78.74 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.153 0 CA-C-N 116.952 0.376 . . . . 0.0 111.31 -179.786 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 44' ' ' SER . . . . . 0.436 ' N ' HG13 ' A' ' 43' ' ' ILE . 38.7 t -66.29 -25.98 67.11 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-O 120.985 0.421 . . . . 0.0 110.713 179.461 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -79.85 -52.69 4.56 Favored Glycine 0 C--N 1.33 0.233 0 C-N-CA 121.033 -0.603 . . . . 0.0 112.907 -179.295 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 15.3 pt -57.88 -36.95 57.79 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.248 0 CA-C-O 121.148 0.499 . . . . 0.0 110.33 179.978 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 47' ' ' ALA . . . . . 0.71 ' HB1' ' HE2' ' A' ' 205' ' ' LYS . . . -68.2 -42.05 80.45 Favored 'General case' 0 C--N 1.326 -0.45 0 CA-C-N 115.81 -0.632 . . . . 0.0 110.78 178.716 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 48' ' ' ALA . . . . . 0.436 ' HB2' ' HB3' ' A' ' 15' ' ' MET . . . -54.48 -42.66 70.99 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 115.881 -0.599 . . . . 0.0 112.038 -179.451 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 49' ' ' VAL . . . . . 0.4 ' O ' HG13 ' A' ' 53' ' ' VAL . 31.0 m -73.42 -36.24 47.93 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.24 0 N-CA-C 111.606 0.224 . . . . 0.0 111.606 -179.437 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -62.49 -40.39 96.54 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-O 121.001 0.429 . . . . 0.0 111.285 179.792 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 51' ' ' TYR . . . . . 0.429 ' HH ' ' HA ' ' A' ' 198' ' ' VAL . 4.2 m-85 -70.58 -40.2 73.42 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-N 115.997 -0.547 . . . . 0.0 110.726 -179.613 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -63.13 -42.26 99.47 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 115.882 -0.599 . . . . 0.0 111.459 179.999 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 53' ' ' VAL . . . . . 0.49 ' O ' HG23 ' A' ' 58' ' ' VAL . 33.0 m -70.28 -49.71 52.22 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.209 0 CA-C-N 116.71 -0.223 . . . . 0.0 111.057 -179.865 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 54' ' ' MET . . . . . 0.486 ' N ' HG22 ' A' ' 53' ' ' VAL . 73.1 mtm -60.75 -32.29 71.59 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-O 121.099 0.476 . . . . 0.0 109.916 179.429 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -63.26 -22.9 67.16 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 115.552 -0.749 . . . . 0.0 111.283 179.677 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 80.2 mt -89.1 -14.35 36.45 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.459 -0.337 . . . . 0.0 111.033 -179.906 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 102.53 -2.99 49.77 Favored Glycine 0 C--N 1.33 0.248 0 C-N-CA 120.689 -0.767 . . . . 0.0 113.352 179.371 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 58' ' ' VAL . . . . . 0.49 HG23 ' O ' ' A' ' 53' ' ' VAL . 15.8 m -78.63 154.25 4.97 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.166 0 CA-C-N 116.981 0.39 . . . . 0.0 111.145 -179.901 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 59' ' ' GLY . . . . . 0.424 ' HA3' ' CG ' ' A' ' 71' ' ' PRO . . . 80.69 -2.39 79.3 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.89 -0.671 . . . . 0.0 112.859 -179.943 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 60' ' ' TRP . . . . . . . . . . . . . 23.2 m0 -78.28 121.49 24.49 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 120.724 0.297 . . . . 0.0 110.503 179.718 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 61' ' ' VAL . . . . . 0.459 HG12 ' HE1' ' A' ' 117' ' ' MET . 7.3 p -112.8 132.25 22.37 Favored Pre-proline 0 CA--C 1.533 0.29 0 CA-C-N 116.416 -0.356 . . . . 0.0 111.343 -179.796 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 72.0 Cg_endo -77.45 145.56 23.78 Favored 'Trans proline' 0 C--N 1.35 0.638 0 C-N-CA 122.51 2.14 . . . . 0.0 112.512 179.941 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 96.6 t -142.65 94.08 0.54 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 115.872 -0.604 . . . . 0.0 110.926 -179.94 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . 57.67 -89.55 0.02 OUTLIER 'General case' 0 C--N 1.332 -0.178 0 CA-C-N 116.13 -0.486 . . . . 0.0 111.418 179.96 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 12.8 pt-20 -119.79 -19.93 7.79 Favored 'General case' 0 C--O 1.233 0.204 0 CA-C-O 120.806 0.336 . . . . 0.0 110.872 -179.987 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 66' ' ' ARG . . . . . 0.543 HH22 ' HA ' ' A' ' 183' ' ' PRO . 13.1 ptm180 -101.93 166.29 10.72 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.385 179.83 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 35.3 m -125.72 123.89 39.85 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-O 120.975 0.417 . . . . 0.0 111.462 -179.725 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 23.4 t -101.29 147.16 8.54 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.221 0 CA-C-N 115.88 -0.6 . . . . 0.0 110.284 179.41 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 69' ' ' PHE . . . . . . . . . . . . . 46.8 m-85 -106.94 112.41 25.36 Favored 'General case' 0 C--N 1.328 -0.329 0 N-CA-C 110.03 -0.359 . . . . 0.0 110.03 -179.363 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 70' ' ' VAL . . . . . 0.517 ' HB ' ' HD3' ' A' ' 71' ' ' PRO . 21.7 t -68.96 -49.89 24.04 Favored Pre-proline 0 C--N 1.327 -0.408 0 N-CA-C 112.455 0.539 . . . . 0.0 112.455 -178.891 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 71' ' ' PRO . . . . . 0.517 ' HD3' ' HB ' ' A' ' 70' ' ' VAL . 31.8 Cg_exo -58.55 -25.97 76.68 Favored 'Trans proline' 0 C--N 1.35 0.627 0 C-N-CA 121.983 1.788 . . . . 0.0 112.174 179.97 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 72' ' ' ARG . . . . . 0.405 ' HB2' ' SD ' ' A' ' 54' ' ' MET . 46.3 ttp180 -72.52 -53.27 12.52 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.975 0.417 . . . . 0.0 110.665 179.932 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 73' ' ' TYR . . . . . 0.521 ' HH ' ' HB1' ' A' ' 116' ' ' ALA . 23.0 m-85 -65.2 -38.07 89.29 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 115.831 -0.622 . . . . 0.0 110.694 179.934 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 74' ' ' ILE . . . . . 0.429 ' HA ' HD12 ' A' ' 77' ' ' ILE . 0.4 OUTLIER -70.32 -37.62 71.6 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 N-CA-C 110.008 -0.367 . . . . 0.0 110.008 179.583 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 31.2 t70 -57.24 -38.61 74.06 Favored 'General case' 0 CA--C 1.521 -0.138 0 N-CA-C 109.453 -0.573 . . . . 0.0 109.453 178.991 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 76' ' ' TRP . . . . . . . . . . . . . 45.4 m0 -66.8 -39.72 87.85 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 115.553 -0.749 . . . . 0.0 110.27 179.375 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 77' ' ' ILE . . . . . 0.429 HD12 ' HA ' ' A' ' 74' ' ' ILE . 89.3 mt -60.49 -28.93 43.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 115.953 -0.567 . . . . 0.0 110.788 179.551 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 43.1 mt -91.97 -29.19 16.77 Favored 'General case' 0 C--N 1.33 -0.255 0 N-CA-C 112.275 0.472 . . . . 0.0 112.275 179.96 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 66.8 p -89.38 -52.09 5.22 Favored 'General case' 0 N--CA 1.464 0.27 0 N-CA-C 113.506 0.928 . . . . 0.0 113.506 -177.725 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 80' ' ' THR . . . . . 0.432 ' N ' ' HD2' ' A' ' 81' ' ' PRO . 86.1 m -47.3 -55.03 17.47 Favored Pre-proline 0 C--N 1.328 -0.34 0 N-CA-C 112.773 0.657 . . . . 0.0 112.773 -178.683 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 81' ' ' PRO . . . . . 0.432 ' HD2' ' N ' ' A' ' 80' ' ' THR . 36.1 Cg_endo -63.2 -20.82 71.7 Favored 'Trans proline' 0 C--N 1.351 0.69 0 C-N-CA 121.55 1.5 . . . . 0.0 111.06 179.997 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 82' ' ' LEU . . . . . 0.404 ' HB3' HG21 ' A' ' 43' ' ' ILE . 0.1 OUTLIER -76.2 -34.8 59.29 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 115.364 -0.834 . . . . 0.0 109.94 179.558 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 47.9 mm -69.25 -52.74 30.28 Favored 'Isoleucine or valine' 0 CA--C 1.522 -0.126 0 CA-C-N 115.849 -0.614 . . . . 0.0 110.205 179.429 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 27.7 m -59.64 -31.16 46.38 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.215 0 N-CA-C 109.614 -0.513 . . . . 0.0 109.614 178.912 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 85' ' ' TYR . . . . . . . . . . . . . 85.2 t80 -63.69 -36.54 84.19 Favored 'General case' 0 N--CA 1.454 -0.246 0 CA-C-N 115.657 -0.701 . . . . 0.0 109.188 178.457 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 86' ' ' PHE . . . . . . . . . . . . . 8.0 t80 -61.42 -44.87 96.38 Favored 'General case' 0 C--O 1.231 0.121 0 CA-C-N 115.636 -0.711 . . . . 0.0 109.457 178.87 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 3.7 mm? -61.66 -34.11 75.14 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 115.453 -0.794 . . . . 0.0 110.153 179.177 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 88' ' ' GLY . . . . . 0.478 ' HA2' HD11 ' A' ' 93' ' ' LEU . . . -69.08 -29.45 72.28 Favored Glycine 0 N--CA 1.449 -0.462 0 C-N-CA 120.812 -0.709 . . . . 0.0 112.252 179.695 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 95.9 mt -71.66 -39.48 70.29 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 121.028 0.442 . . . . 0.0 110.362 179.69 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 42.8 mt -61.14 -59.73 4.88 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 115.796 -0.638 . . . . 0.0 110.872 179.782 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 91' ' ' ALA . . . . . 0.439 ' HB3' ' HB1' ' A' ' 149' ' ' ALA . . . -70.25 -54.79 11.22 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.081 -0.509 . . . . 0.0 111.339 -179.833 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 98.85 68.77 0.91 Allowed Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.787 -0.72 . . . . 0.0 112.212 -179.861 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 93' ' ' LEU . . . . . 0.516 HD21 ' HB3' ' A' ' 97' ' ' GLU . 8.1 mp -72.0 -174.35 1.21 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.775 0.322 . . . . 0.0 110.945 -179.824 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 94' ' ' ASP . . . . . 0.432 ' HB3' ' OE2' ' A' ' 97' ' ' GLU . 10.2 t70 -97.28 -177.12 3.73 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.868 -179.73 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 95' ' ' SER . . . . . 0.403 ' H ' ' CG ' ' A' ' 94' ' ' ASP . 77.9 p -65.58 -45.34 83.62 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.574 -179.369 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 36.2 mtp180 -74.14 -39.48 63.27 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-O 121.246 0.546 . . . . 0.0 110.438 -179.657 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 97' ' ' GLU . . . . . 0.516 ' HB3' HD21 ' A' ' 93' ' ' LEU . 0.3 OUTLIER -58.01 -44.68 87.38 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-N 115.457 -0.792 . . . . 0.0 111.039 -179.826 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 98' ' ' PHE . . . . . 0.414 ' O ' HG12 ' A' ' 102' ' ' ILE . 2.2 m-85 -61.52 -35.47 77.82 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.956 0.408 . . . . 0.0 110.502 179.543 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -70.08 -25.97 74.91 Favored Glycine 0 N--CA 1.451 -0.359 0 C-N-CA 120.7 -0.762 . . . . 0.0 112.144 179.795 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 96.4 mt -73.17 -43.71 57.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 N-CA-C 111.841 0.311 . . . . 0.0 111.841 -179.819 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 25.7 m -69.45 -39.16 78.33 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-O 120.676 0.275 . . . . 0.0 111.716 -179.389 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 102' ' ' ILE . . . . . 0.414 HG12 ' O ' ' A' ' 98' ' ' PHE . 42.0 mm -73.65 -41.0 55.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.582 -0.281 . . . . 0.0 111.621 -179.435 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 13.9 t -63.76 -35.97 82.34 Favored 'General case' 0 C--N 1.332 -0.153 0 CA-C-O 120.775 0.322 . . . . 0.0 110.884 -179.948 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 56.5 tp -67.52 -43.77 79.99 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.288 179.766 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 105' ' ' ASN . . . . . 0.521 ' N ' HD21 ' A' ' 105' ' ' ASN . 0.9 OUTLIER -62.72 -27.3 69.17 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.532 179.57 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 91.9 m -69.4 -52.15 29.77 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.054 -0.521 . . . . 0.0 111.502 -179.912 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 7.5 p -66.09 -36.35 77.23 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.214 0 CA-C-N 116.38 -0.373 . . . . 0.0 111.226 -179.976 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 51.0 t -62.85 -54.68 30.57 Favored 'Isoleucine or valine' 0 C--O 1.234 0.281 0 CA-C-N 116.294 -0.412 . . . . 0.0 110.866 179.746 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 109' ' ' MET . . . . . . . . . . . . . 5.6 tpp -61.66 -26.82 68.26 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.049 -0.523 . . . . 0.0 110.383 179.897 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 29.7 tp -73.05 -31.98 64.77 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.062 -0.517 . . . . 0.0 110.226 179.487 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -64.31 -51.17 64.79 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 115.926 -0.579 . . . . 0.0 110.284 179.225 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . -62.76 -44.26 97.75 Favored Glycine 0 CA--C 1.518 0.248 0 C-N-CA 120.796 -0.716 . . . . 0.0 112.42 179.539 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 113' ' ' PHE . . . . . 0.448 ' HZ ' HG11 ' A' ' 70' ' ' VAL . 0.8 OUTLIER -47.98 -61.01 2.18 Favored 'General case' 0 C--N 1.333 -0.141 0 CA-C-O 120.911 0.386 . . . . 0.0 110.397 179.592 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -69.83 -18.25 63.44 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.025 -0.534 . . . . 0.0 110.797 179.918 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -57.14 -49.06 74.98 Favored Glycine 0 C--N 1.333 0.389 0 C-N-CA 120.79 -0.719 . . . . 0.0 111.9 179.375 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 116' ' ' ALA . . . . . 0.521 ' HB1' ' HH ' ' A' ' 73' ' ' TYR . . . -78.55 -15.51 58.48 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-O 120.782 0.325 . . . . 0.0 111.376 179.817 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 117' ' ' MET . . . . . 0.459 ' HE1' HG12 ' A' ' 61' ' ' VAL . 23.1 mmt -88.22 19.18 3.85 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 116.384 -0.371 . . . . 0.0 111.612 -179.553 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 118' ' ' VAL . . . . . 0.404 HG22 ' HB3' ' A' ' 123' ' ' ARG . 35.7 m -84.64 141.62 38.97 Favored Pre-proline 0 C--N 1.329 -0.315 0 CA-C-O 120.57 0.224 . . . . 0.0 111.285 -179.846 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 119' ' ' PRO . . . . . . . . . . . . . 93.4 Cg_endo -87.07 -2.43 7.98 Favored 'Trans proline' 0 N--CA 1.459 -0.513 0 C-N-CA 122.77 2.314 . . . . 0.0 112.36 179.797 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -144.12 -110.05 0.7 Allowed Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.789 -0.72 . . . . 0.0 112.684 -179.911 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 42.9 pt -133.29 11.8 1.42 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.23 0 CA-C-O 120.681 0.277 . . . . 0.0 111.468 -179.646 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 46.9 mt-10 -59.24 -18.23 35.17 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.344 -0.389 . . . . 0.0 111.015 179.912 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 123' ' ' ARG . . . . . 0.586 ' HA ' HD11 ' A' ' 126' ' ' LEU . 11.1 ptt180 -50.45 -37.15 36.71 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.05 -0.523 . . . . 0.0 111.946 -179.661 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 124' ' ' TYR . . . . . . . . . . . . . 28.4 m-85 -51.19 -35.54 36.85 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.844 0.354 . . . . 0.0 111.171 -179.828 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 125' ' ' ALA . . . . . . . . . . . . . . . -74.8 -49.65 20.03 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.141 -0.481 . . . . 0.0 111.008 179.878 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 126' ' ' LEU . . . . . 0.586 HD11 ' HA ' ' A' ' 123' ' ' ARG . 6.5 mp -52.51 -55.67 20.48 Favored 'General case' 0 C--N 1.332 -0.182 0 CA-C-N 115.999 -0.546 . . . . 0.0 110.327 179.964 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 127' ' ' PHE . . . . . . . . . . . . . 10.9 t80 -64.51 -28.84 69.93 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 115.909 -0.587 . . . . 0.0 110.155 179.45 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 128' ' ' GLY . . . . . . . . . . . . . . . -49.16 -48.53 32.16 Favored Glycine 0 N--CA 1.449 -0.451 0 C-N-CA 120.121 -1.038 . . . . 0.0 110.593 178.79 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 129' ' ' MET . . . . . 0.605 ' HE1' ' HA2' ' A' ' 130' ' ' GLY . 0.0 OUTLIER -72.29 -31.72 65.98 Favored 'General case' 0 N--CA 1.452 -0.365 0 N-CA-C 109.079 -0.712 . . . . 0.0 109.079 178.467 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 130' ' ' GLY . . . . . 0.605 ' HA2' ' HE1' ' A' ' 129' ' ' MET . . . -61.52 -33.18 83.89 Favored Glycine 0 C--N 1.333 0.411 0 CA-C-N 115.749 -0.66 . . . . 0.0 112.035 179.458 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 131' ' ' ALA . . . . . 0.404 ' O ' ' HB3' ' A' ' 134' ' ' PHE . . . -74.8 -53.35 9.31 Favored 'General case' 0 N--CA 1.452 -0.326 0 CA-C-O 120.743 0.306 . . . . 0.0 110.362 179.648 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 40.8 t -55.15 -49.0 75.59 Favored 'Isoleucine or valine' 0 C--O 1.234 0.253 0 N-CA-C 109.462 -0.57 . . . . 0.0 109.462 178.783 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -59.68 -39.13 83.49 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 115.504 -0.771 . . . . 0.0 110.323 178.589 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 134' ' ' PHE . . . . . 0.461 ' CZ ' ' HA ' ' A' ' 172' ' ' ALA . 65.4 t80 -55.1 -51.13 67.37 Favored 'General case' 0 N--CA 1.451 -0.388 0 CA-C-N 115.892 -0.594 . . . . 0.0 110.367 179.68 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 135' ' ' ILE . . . . . 0.469 ' HA ' HG22 ' A' ' 138' ' ' VAL . 60.2 mt -56.15 -32.05 33.31 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.238 0 CA-C-N 115.946 -0.57 . . . . 0.0 110.112 179.24 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . -61.67 -41.24 99.56 Favored Glycine 0 N--CA 1.447 -0.598 0 C-N-CA 120.16 -1.019 . . . . 0.0 111.343 178.69 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 137' ' ' LEU . . . . . . . . . . . . . 30.0 tp -69.57 -50.71 42.08 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 115.846 -0.177 . . . . 0.0 111.09 179.935 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 138' ' ' VAL . . . . . 0.546 ' HA ' HD11 ' A' ' 141' ' ' LEU . 5.2 m -55.96 -32.62 33.53 Favored 'Isoleucine or valine' 0 C--O 1.234 0.245 0 CA-C-O 121.31 0.576 . . . . 0.0 109.754 179.478 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 139' ' ' TYR . . . . . 0.405 ' O ' ' N ' ' A' ' 143' ' ' GLY . 65.9 t80 -60.09 -48.09 83.16 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 115.353 -0.839 . . . . 0.0 109.412 178.511 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 37.0 m-85 -58.95 -35.5 73.23 Favored 'General case' 0 C--N 1.332 -0.169 0 CA-C-N 115.938 -0.573 . . . . 0.0 110.576 179.096 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 141' ' ' LEU . . . . . 0.546 HD11 ' HA ' ' A' ' 138' ' ' VAL . 95.6 mt -55.56 -46.74 77.13 Favored 'General case' 0 C--N 1.332 -0.174 0 CA-C-N 116.322 -0.399 . . . . 0.0 110.27 179.504 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 9.2 p -105.39 15.04 7.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 115.926 -0.579 . . . . 0.0 110.828 179.752 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 143' ' ' GLY . . . . . 0.405 ' N ' ' O ' ' A' ' 139' ' ' TYR . . . -90.86 -130.66 4.68 Favored Glycine 0 CA--C 1.52 0.393 0 C-N-CA 120.913 -0.661 . . . . 0.0 112.9 -179.627 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 144' ' ' PRO . . . . . . . . . . . . . 45.3 Cg_exo -57.23 -25.44 64.66 Favored 'Trans proline' 0 C--N 1.351 0.686 0 C-N-CA 122.585 2.19 . . . . 0.0 112.726 -179.632 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 145' ' ' MET . . . . . . . . . . . . . 60.6 mtt -56.76 -25.13 54.44 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.355 -0.384 . . . . 0.0 111.134 -179.896 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 146' ' ' THR . . . . . . . . . . . . . 78.1 p -63.83 -51.2 65.77 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.112 -0.495 . . . . 0.0 111.685 -179.786 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 43.6 mt-10 -75.56 -28.64 59.09 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.371 -0.377 . . . . 0.0 111.62 -179.252 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 148' ' ' SER . . . . . . . . . . . . . 36.8 t -70.53 -44.66 67.09 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.743 0.306 . . . . 0.0 111.208 -179.469 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 149' ' ' ALA . . . . . 0.439 ' HB1' ' HB3' ' A' ' 91' ' ' ALA . . . -77.92 -42.99 31.28 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.324 -0.398 . . . . 0.0 111.923 -179.53 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 150' ' ' SER . . . . . 0.564 ' HA ' ' HG2' ' A' ' 157' ' ' LYS . 47.5 t -63.65 -8.0 8.89 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.548 -179.504 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 151' ' ' GLN . . . . . . . . . . . . . 47.5 mt-30 -125.54 17.34 8.18 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.668 0.271 . . . . 0.0 111.279 -179.955 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 152' ' ' ARG . . . . . 0.582 ' HD2' HG13 ' A' ' 156' ' ' ILE . 3.6 tmt_? -93.24 -51.81 4.84 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-O 120.967 0.413 . . . . 0.0 110.509 179.782 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 153' ' ' SER . . . . . 0.63 ' HB3' HG12 ' A' ' 156' ' ' ILE . 20.0 t -157.42 172.41 18.63 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 115.904 -0.589 . . . . 0.0 110.451 179.304 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 154' ' ' SER . . . . . . . . . . . . . 79.0 p -71.62 -42.18 67.95 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.278 -0.419 . . . . 0.0 111.006 179.744 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -76.87 -25.72 64.04 Favored Glycine 0 C--N 1.331 0.265 0 C-N-CA 120.834 -0.698 . . . . 0.0 113.093 -179.669 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 156' ' ' ILE . . . . . 0.63 HG12 ' HB3' ' A' ' 153' ' ' SER . 27.7 mm -57.89 -38.48 66.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-O 120.551 0.215 . . . . 0.0 111.519 -179.718 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 157' ' ' LYS . . . . . 0.564 ' HG2' ' HA ' ' A' ' 150' ' ' SER . 35.8 mtmm -56.72 -39.91 74.77 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-O 120.806 0.336 . . . . 0.0 111.214 179.908 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 43.7 t -70.95 -48.1 55.28 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.569 -179.315 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 159' ' ' LEU . . . . . 0.454 ' O ' ' HB2' ' A' ' 163' ' ' LEU . 9.9 mt -68.18 -28.89 67.67 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 116.482 -0.326 . . . . 0.0 111.65 -179.609 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 160' ' ' TYR . . . . . . . . . . . . . 83.8 t80 -73.95 -45.91 47.41 Favored 'General case' 0 C--N 1.326 -0.429 0 N-CA-C 112.061 0.393 . . . . 0.0 112.061 -178.941 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 30.9 m -66.57 -43.89 90.34 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.419 0 N-CA-C 112.169 0.433 . . . . 0.0 112.169 -179.007 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 162' ' ' ARG . . . . . . . . . . . . . 35.3 mmt180 -68.68 -41.69 78.86 Favored 'General case' 0 C--N 1.328 -0.349 0 N-CA-C 111.884 0.327 . . . . 0.0 111.884 -178.906 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 163' ' ' LEU . . . . . 0.605 ' HG ' ' HB2' ' A' ' 208' ' ' PHE . 7.7 mp -73.79 -50.06 22.38 Favored 'General case' 0 C--N 1.329 -0.326 0 N-CA-C 112.015 0.376 . . . . 0.0 112.015 -179.182 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 164' ' ' ARG . . . . . 0.449 ' HG2' ' HB3' ' A' ' 141' ' ' LEU . 6.4 tmm_? -59.45 -50.12 75.18 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.624 -0.262 . . . . 0.0 111.577 -179.139 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 165' ' ' ASN . . . . . 0.549 ' N ' HD21 ' A' ' 165' ' ' ASN . 0.8 OUTLIER -61.29 -51.41 69.02 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.45 -0.341 . . . . 0.0 111.524 -179.464 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 166' ' ' LEU . . . . . 0.475 ' O ' ' HG ' ' A' ' 170' ' ' LEU . 4.9 tt -60.76 -54.85 40.22 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.457 -0.338 . . . . 0.0 111.865 -179.198 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 167' ' ' THR . . . . . 0.417 ' O ' ' HB2' ' A' ' 171' ' ' TRP . 64.5 m -55.17 -54.22 45.98 Favored 'General case' 0 C--N 1.329 -0.292 0 N-CA-C 112.898 0.703 . . . . 0.0 112.898 -178.585 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 168' ' ' VAL . . . . . 0.448 HG13 ' N ' ' A' ' 169' ' ' VAL . 9.9 p -55.1 -40.51 55.12 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.195 0 N-CA-C 112.418 0.525 . . . . 0.0 112.418 -178.924 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 169' ' ' VAL . . . . . 0.448 ' N ' HG13 ' A' ' 168' ' ' VAL . 58.5 t -60.47 -65.11 0.5 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 N-CA-C 111.874 0.324 . . . . 0.0 111.874 -179.159 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 170' ' ' LEU . . . . . 0.475 ' HG ' ' O ' ' A' ' 166' ' ' LEU . 1.0 OUTLIER -61.3 -29.2 69.72 Favored 'General case' 0 C--N 1.329 -0.283 0 C-N-CA 121.166 -0.213 . . . . 0.0 111.41 -179.273 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 171' ' ' TRP . . . . . 0.417 ' HB2' ' O ' ' A' ' 167' ' ' THR . 2.8 m0 -71.03 -35.3 71.93 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-O 120.934 0.397 . . . . 0.0 110.038 178.983 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 172' ' ' ALA . . . . . 0.461 ' HA ' ' CZ ' ' A' ' 134' ' ' PHE . . . -68.32 -6.61 25.09 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 115.872 -0.604 . . . . 0.0 110.62 179.572 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 173' ' ' ILE . . . . . 0.472 ' O ' HG12 ' A' ' 177' ' ' ILE . 40.4 mm -85.9 -22.19 7.39 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 115.873 -0.603 . . . . 0.0 110.798 179.515 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 174' ' ' TYR . . . . . 0.582 ' N ' ' HD2' ' A' ' 175' ' ' PRO . 12.9 m-85 -54.22 -50.81 82.57 Favored Pre-proline 0 CA--C 1.533 0.299 0 CA-C-N 116.159 -0.473 . . . . 0.0 112.109 -179.684 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 175' ' ' PRO . . . . . 0.582 ' HD2' ' N ' ' A' ' 174' ' ' TYR . 8.1 Cg_endo -50.65 -27.75 20.46 Favored 'Trans proline' 0 C--N 1.352 0.752 0 C-N-CA 122.067 1.845 . . . . 0.0 112.355 -179.797 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 176' ' ' PHE . . . . . 0.442 ' O ' ' HG ' ' A' ' 180' ' ' LEU . 49.5 m-85 -80.59 -46.43 15.71 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.291 -0.413 . . . . 0.0 111.668 -179.995 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 177' ' ' ILE . . . . . 0.472 HG12 ' O ' ' A' ' 173' ' ' ILE . 3.5 mm -66.19 -36.35 77.19 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.497 0 N-CA-C 112.299 0.481 . . . . 0.0 112.299 -178.211 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 178' ' ' TRP . . . . . 0.461 ' HH2' ' HB2' ' A' ' 123' ' ' ARG . 67.8 t90 -73.94 -45.95 47.21 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-O 120.907 0.384 . . . . 0.0 110.772 179.602 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 179' ' ' LEU . . . . . 0.421 HD13 HD22 ' A' ' 180' ' ' LEU . 2.5 tm? -67.92 -49.6 60.91 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 115.921 -0.581 . . . . 0.0 111.403 -179.077 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 180' ' ' LEU . . . . . 0.461 HD23 HD11 ' A' ' 187' ' ' LEU . 22.7 mt -77.7 -47.23 19.65 Favored 'General case' 0 C--N 1.328 -0.358 0 N-CA-C 111.812 0.301 . . . . 0.0 111.812 -179.165 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . -58.75 -178.21 0.96 Allowed Glycine 0 C--N 1.337 0.591 0 C-N-CA 120.256 -0.973 . . . . 0.0 112.772 -179.98 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 182' ' ' PRO . . . . . 0.569 ' HA ' ' HB2' ' A' ' 186' ' ' ALA . 85.7 Cg_exo -47.81 -44.32 27.14 Favored 'Trans proline' 0 CA--C 1.536 0.623 0 C-N-CA 122.967 2.445 . . . . 0.0 113.802 -179.97 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 183' ' ' PRO . . . . . 0.543 ' HA ' HH22 ' A' ' 66' ' ' ARG . 51.8 Cg_exo -55.3 -9.95 2.79 Favored 'Trans proline' 0 C--N 1.354 0.833 0 C-N-CA 122.154 1.902 . . . . 0.0 113.199 -179.736 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 184' ' ' GLY . . . . . 0.411 ' HA3' ' O ' ' A' ' 179' ' ' LEU . . . -123.21 -87.39 0.81 Allowed Glycine 0 N--CA 1.45 -0.387 0 C-N-CA 120.421 -0.895 . . . . 0.0 112.901 -179.887 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 185' ' ' VAL . . . . . . . . . . . . . 8.6 m -120.43 -7.02 10.53 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-O 120.773 0.321 . . . . 0.0 111.779 -179.603 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 186' ' ' ALA . . . . . 0.569 ' HB2' ' HA ' ' A' ' 182' ' ' PRO . . . 56.18 85.36 0.07 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.116 -0.493 . . . . 0.0 111.716 179.576 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 187' ' ' LEU . . . . . 0.461 HD11 HD23 ' A' ' 180' ' ' LEU . 18.8 mt -91.78 -49.25 6.36 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.93 0.395 . . . . 0.0 110.878 179.528 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 188' ' ' LEU . . . . . . . . . . . . . 96.6 mt -90.13 -154.99 0.35 Allowed 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 115.839 -0.619 . . . . 0.0 110.947 -179.661 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 189' ' ' THR . . . . . 0.459 ' HB ' HG22 ' A' ' 192' ' ' VAL . 58.8 m -92.6 136.17 25.56 Favored Pre-proline 0 C--N 1.329 -0.326 0 CA-C-N 116.05 -0.523 . . . . 0.0 110.568 -179.719 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 190' ' ' PRO . . . . . . . . . . . . . 2.2 Cg_endo -45.5 -37.69 15.23 Favored 'Trans proline' 0 C--N 1.35 0.652 0 C-N-CA 122.837 2.358 . . . . 0.0 112.776 -179.747 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 191' ' ' THR . . . . . . . . . . . . . 41.7 p -74.24 -45.42 48.09 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 116.487 -0.324 . . . . 0.0 111.415 -179.835 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 192' ' ' VAL . . . . . 0.459 HG22 ' HB ' ' A' ' 189' ' ' THR . 96.9 t -59.66 -52.79 56.9 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.302 -0.408 . . . . 0.0 111.415 -179.781 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 193' ' ' ASP . . . . . . . . . . . . . 25.9 t70 -54.6 -48.2 72.46 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.946 -179.761 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 194' ' ' VAL . . . . . 0.51 ' O ' HG22 ' A' ' 198' ' ' VAL . 40.6 t -55.22 -44.03 73.22 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.241 0 CA-C-N 116.376 -0.375 . . . . 0.0 110.492 179.492 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 195' ' ' ALA . . . . . . . . . . . . . . . -52.46 -42.91 64.61 Favored 'General case' 0 C--N 1.332 -0.185 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.778 179.895 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 196' ' ' LEU . . . . . . . . . . . . . 62.5 mt -67.8 -40.27 83.9 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.785 179.356 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 197' ' ' ILE . . . . . 0.418 HD12 ' HB ' ' A' ' 177' ' ' ILE . 12.0 mm -59.39 -60.87 1.82 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 115.766 -0.652 . . . . 0.0 111.405 -179.847 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 198' ' ' VAL . . . . . 0.51 HG22 ' O ' ' A' ' 194' ' ' VAL . 1.3 m -53.94 -34.85 26.61 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.439 0 CA-C-O 121.544 0.687 . . . . 0.0 109.566 179.053 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 199' ' ' TYR . . . . . . . . . . . . . 63.8 t80 -66.57 -33.56 75.94 Favored 'General case' 0 C--N 1.323 -0.587 0 CA-C-N 114.639 -1.164 . . . . 0.0 110.575 179.722 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 200' ' ' LEU . . . . . 0.435 ' O ' HG12 ' A' ' 203' ' ' VAL . 26.6 mt -66.67 -41.77 87.62 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.088 -0.505 . . . . 0.0 111.315 -179.897 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 201' ' ' ASP . . . . . . . . . . . . . 5.0 m-20 -74.83 -37.94 62.14 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-O 121.253 0.549 . . . . 0.0 110.044 179.499 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 202' ' ' LEU . . . . . . . . . . . . . 40.5 tp -70.6 -26.79 63.67 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 115.256 -0.884 . . . . 0.0 111.559 -179.343 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 203' ' ' VAL . . . . . 0.435 HG12 ' O ' ' A' ' 200' ' ' LEU . 14.2 p -81.73 -36.7 14.59 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.13 0 CA-C-N 116.765 -0.198 . . . . 0.0 110.813 -179.141 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 204' ' ' THR . . . . . . . . . . . . . 65.8 m -63.43 -58.56 6.67 Favored 'General case' 0 C--N 1.329 -0.305 0 C-N-CA 120.713 -0.395 . . . . 0.0 110.642 179.169 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 205' ' ' LYS . . . . . 0.71 ' HE2' ' HB1' ' A' ' 47' ' ' ALA . 57.7 mttp -60.88 -58.01 10.26 Favored 'General case' 0 C--N 1.328 -0.361 0 N-CA-C 112.609 0.596 . . . . 0.0 112.609 -178.464 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 56.5 t -71.77 -37.36 62.02 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 N-CA-C 112.317 0.488 . . . . 0.0 112.317 -178.432 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 207' ' ' GLY . . . . . 0.515 ' O ' HG13 ' A' ' 211' ' ' ILE . . . -56.92 -61.67 7.24 Favored Glycine 0 CA--C 1.517 0.18 0 C-N-CA 120.665 -0.779 . . . . 0.0 113.793 -178.799 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 208' ' ' PHE . . . . . 0.605 ' HB2' ' HG ' ' A' ' 163' ' ' LEU . 0.9 OUTLIER -72.73 -27.25 61.93 Favored 'General case' 0 C--O 1.222 -0.368 0 CA-C-N 117.571 0.686 . . . . 0.0 110.771 -179.31 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 209' ' ' GLY . . . . . 0.496 ' O ' ' HB1' ' A' ' 212' ' ' ALA . . . -63.34 -32.73 85.15 Favored Glycine 0 N--CA 1.448 -0.542 0 N-CA-C 111.629 -0.588 . . . . 0.0 111.629 178.471 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 210' ' ' PHE . . . . . . . . . . . . . 0.8 OUTLIER -74.06 -47.81 34.09 Favored 'General case' 0 CA--C 1.515 -0.397 0 N-CA-C 108.221 -1.029 . . . . 0.0 108.221 178.543 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 211' ' ' ILE . . . . . 0.515 HG13 ' O ' ' A' ' 207' ' ' GLY . 4.4 mt -63.43 -27.52 43.18 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.434 0 N-CA-C 107.678 -1.23 . . . . 0.0 107.678 176.83 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 212' ' ' ALA . . . . . 0.496 ' HB1' ' O ' ' A' ' 209' ' ' GLY . . . -62.76 -40.81 98.42 Favored 'General case' 0 N--CA 1.451 -0.418 0 CA-C-N 114.447 -1.252 . . . . 0.0 110.622 -179.788 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 213' ' ' LEU . . . . . . . . . . . . . 86.4 mt -69.44 -47.29 64.54 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 115.171 -0.922 . . . . 0.0 111.44 -179.501 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 214' ' ' ASP . . . . . . . . . . . . . 14.3 t70 -56.32 -53.1 61.34 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.391 -0.368 . . . . 0.0 111.079 -179.944 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 215' ' ' ALA . . . . . . . . . . . . . . . -56.88 -56.24 24.22 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.06 -0.518 . . . . 0.0 111.341 -179.813 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 216' ' ' ALA . . . . . . . . . . . . . . . -56.78 -32.13 65.34 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.234 -179.897 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 217' ' ' ALA . . . . . . . . . . . . . . . -64.73 -34.38 78.18 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.298 -0.41 . . . . 0.0 110.197 179.793 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 218' ' ' THR . . . . . . . . . . . . . 93.0 m . . . . . 0 C--N 1.328 -0.33 0 CA-C-N 115.789 -0.641 . . . . 0.0 110.76 179.536 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.322 0 N-CA-C 112.672 -0.171 . . . . 0.0 112.672 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 81.9 mt -65.64 -36.65 84.32 Favored 'General case' 0 N--CA 1.45 -0.436 0 CA-C-O 120.804 0.335 . . . . 0.0 111.117 -179.844 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 67.1 p -57.21 -30.64 64.73 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.01 -0.541 . . . . 0.0 111.725 -179.651 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 27.3 p -58.8 -38.32 78.32 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 116.524 -0.307 . . . . 0.0 111.344 -179.609 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 7' ' ' LEU . . . . . . . . . . . . . 4.2 mm? -63.5 -51.45 65.49 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.106 -179.941 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 8' ' ' PHE . . . . . 0.448 ' O ' ' HB3' ' A' ' 51' ' ' TYR . 74.1 m-85 -61.2 -33.23 73.13 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.512 179.928 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 9' ' ' TRP . . . . . 0.467 ' O ' HG13 ' A' ' 13' ' ' ILE . 9.1 m95 -66.15 -38.52 88.31 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 116.067 -0.515 . . . . 0.0 110.241 179.999 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 73.2 mt -65.7 -32.63 74.3 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 115.787 -0.642 . . . . 0.0 110.005 179.464 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -71.02 -33.64 65.31 Favored Glycine 0 N--CA 1.448 -0.517 0 C-N-CA 120.953 -0.642 . . . . 0.0 111.757 179.129 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -70.02 -32.43 70.58 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 120.889 0.376 . . . . 0.0 110.53 179.315 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 13' ' ' ILE . . . . . 0.467 HG13 ' O ' ' A' ' 9' ' ' TRP . 73.8 mt -66.95 -53.81 30.65 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.233 0 CA-C-N 116.021 -0.536 . . . . 0.0 110.577 179.721 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -64.11 -25.09 69.28 Favored Glycine 0 N--CA 1.451 -0.366 0 C-N-CA 120.657 -0.783 . . . . 0.0 112.042 179.677 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 15' ' ' MET . . . . . 0.51 ' HB3' ' HB3' ' A' ' 48' ' ' ALA . 0.0 OUTLIER -72.54 -54.47 9.11 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.559 0.219 . . . . 0.0 110.933 179.82 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 3.9 mm? -53.13 -45.72 68.47 Favored 'General case' 0 C--N 1.332 -0.179 0 CA-C-N 116.403 -0.362 . . . . 0.0 110.921 179.527 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 83.7 t -61.06 -40.29 85.18 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.153 0 CA-C-N 116.372 -0.376 . . . . 0.0 110.457 179.666 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -67.68 -41.73 88.81 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.859 -0.686 . . . . 0.0 111.802 179.188 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 16.3 m -51.14 -53.76 31.44 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.989 0.423 . . . . 0.0 110.711 -179.982 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 62.6 mt -71.71 -32.22 67.55 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 115.786 -0.643 . . . . 0.0 111.083 179.84 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -58.33 -56.67 19.13 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.793 -179.605 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 4.7 m-85 -71.11 -30.75 66.91 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.409 -0.359 . . . . 0.0 111.337 -179.128 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -64.03 -51.24 65.11 Favored 'General case' 0 C--N 1.327 -0.4 0 N-CA-C 112.369 0.507 . . . . 0.0 112.369 -179.17 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 24' ' ' TRP . . . . . 0.532 ' HA ' ' CE3' ' A' ' 24' ' ' TRP . 2.4 t-105 -86.67 -26.76 24.15 Favored 'General case' 0 N--CA 1.442 -0.842 0 N-CA-C 113.326 0.861 . . . . 0.0 113.326 -177.655 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.314 -0.947 0 N-CA-C 109.586 -0.524 . . . . 0.0 109.586 178.785 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.453 -0.215 0 N-CA-C 112.767 -0.133 . . . . 0.0 112.767 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 8.8 mm-40 -92.14 -23.6 19.36 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.794 0.331 . . . . 0.0 110.949 -179.964 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 34' ' ' ARG . . . . . . . . . . . . . 53.1 mtm180 -56.4 -28.34 59.04 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.156 -0.475 . . . . 0.0 111.848 -179.677 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 19.0 tpp180 -55.27 -59.05 5.33 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-O 120.744 0.307 . . . . 0.0 111.408 -179.634 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 42.3 m-85 -71.96 -34.81 69.29 Favored 'General case' 0 C--N 1.33 -0.244 0 N-CA-C 112.333 0.494 . . . . 0.0 112.333 -178.783 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 37' ' ' TYR . . . . . . . . . . . . . 29.4 m-85 -70.39 -56.25 7.13 Favored 'General case' 0 N--CA 1.464 0.226 0 N-CA-C 111.619 0.229 . . . . 0.0 111.619 -179.221 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 77.9 t -56.85 -37.23 52.85 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.232 0 CA-C-O 120.8 0.333 . . . . 0.0 110.87 179.799 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 21.9 m -62.25 -51.18 68.75 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.845 179.313 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 18.1 tp -59.87 -50.93 71.86 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 115.926 -0.579 . . . . 0.0 110.792 179.978 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 65.3 t -58.84 -34.09 51.31 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.373 0 CA-C-N 115.775 -0.648 . . . . 0.0 109.998 179.169 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -58.76 -41.81 96.11 Favored Glycine 0 N--CA 1.448 -0.542 0 C-N-CA 120.829 -0.7 . . . . 0.0 111.657 179.429 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 43' ' ' ILE . . . . . 0.504 HD11 HD11 ' A' ' 83' ' ' ILE . 1.1 mt -61.75 -51.16 75.97 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.176 0 CA-C-O 120.847 0.356 . . . . 0.0 110.508 179.201 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 79.3 p -62.2 -23.27 66.53 Favored 'General case' 0 C--N 1.333 -0.132 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.088 179.756 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -77.55 -56.94 3.72 Favored Glycine 0 C--N 1.33 0.225 0 C-N-CA 120.832 -0.699 . . . . 0.0 112.406 179.916 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 46' ' ' ILE . . . . . 0.494 ' HB ' HD11 ' A' ' 78' ' ' LEU . 13.1 pt -58.49 -37.14 62.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-O 121.051 0.453 . . . . 0.0 110.721 179.77 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 47' ' ' ALA . . . . . 0.572 ' HB1' ' HE2' ' A' ' 205' ' ' LYS . . . -68.46 -41.02 80.78 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 115.97 -0.559 . . . . 0.0 110.89 179.113 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 48' ' ' ALA . . . . . 0.51 ' HB3' ' HB3' ' A' ' 15' ' ' MET . . . -55.69 -42.09 74.67 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-N 115.805 -0.634 . . . . 0.0 111.763 -179.486 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 49' ' ' VAL . . . . . 0.468 ' O ' HG11 ' A' ' 53' ' ' VAL . 8.6 m -75.56 -37.44 36.98 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.545 -0.298 . . . . 0.0 111.6 -179.516 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -60.61 -43.59 97.26 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 121.035 0.445 . . . . 0.0 111.061 179.809 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 51' ' ' TYR . . . . . 0.448 ' HB3' ' O ' ' A' ' 8' ' ' PHE . 43.3 m-85 -73.1 -32.38 64.94 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-N 115.933 -0.576 . . . . 0.0 110.484 -179.77 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -69.34 -38.97 78.41 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-N 115.897 -0.592 . . . . 0.0 111.1 179.549 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 53' ' ' VAL . . . . . 0.468 HG11 ' O ' ' A' ' 49' ' ' VAL . 33.3 m -74.62 -47.39 39.04 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.224 0 CA-C-N 116.418 -0.356 . . . . 0.0 110.573 180.0 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 54' ' ' MET . . . . . 0.439 ' N ' HG21 ' A' ' 53' ' ' VAL . 75.3 mtm -61.37 -31.77 71.67 Favored 'General case' 0 N--CA 1.455 -0.178 0 N-CA-C 109.62 -0.511 . . . . 0.0 109.62 179.058 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 55' ' ' ALA . . . . . 0.436 ' HB3' ' HB2' ' A' ' 8' ' ' PHE . . . -69.31 -22.83 63.76 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 115.588 -0.733 . . . . 0.0 110.933 179.215 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 63.8 mt -87.51 0.12 56.02 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 116.167 -0.469 . . . . 0.0 111.409 -179.797 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 90.5 -21.49 32.12 Favored Glycine 0 N--CA 1.452 -0.261 0 C-N-CA 120.564 -0.827 . . . . 0.0 113.115 179.522 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 13.7 p -68.36 148.7 11.68 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.215 0 CA-C-N 116.887 0.344 . . . . 0.0 110.822 179.955 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 92.44 -5.06 77.37 Favored Glycine 0 N--CA 1.45 -0.403 0 C-N-CA 120.648 -0.787 . . . . 0.0 112.403 -179.573 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 60' ' ' TRP . . . . . . . . . . . . . 15.9 m0 -86.19 108.09 18.19 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.55 0.214 . . . . 0.0 110.954 -179.861 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 61' ' ' VAL . . . . . 0.408 HG11 HG23 ' A' ' 68' ' ' VAL . 7.5 p -111.8 128.26 25.69 Favored Pre-proline 0 CA--C 1.533 0.317 0 CA-C-N 116.52 -0.309 . . . . 0.0 111.108 179.804 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 73.8 Cg_endo -75.23 155.27 41.85 Favored 'Trans proline' 0 C--N 1.35 0.645 0 C-N-CA 122.422 2.082 . . . . 0.0 112.648 -179.679 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 80.7 t -143.21 89.73 0.4 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 115.826 -0.625 . . . . 0.0 110.858 179.929 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . 59.9 -86.86 0.02 OUTLIER 'General case' 0 C--N 1.331 -0.199 0 CA-C-N 116.065 -0.516 . . . . 0.0 111.467 179.953 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 6.2 mp0 -121.52 -19.64 6.84 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 116.286 -0.415 . . . . 0.0 110.652 179.962 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 66' ' ' ARG . . . . . . . . . . . . . 45.6 mtm180 -101.24 161.52 13.56 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 115.919 -0.582 . . . . 0.0 110.499 179.913 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 56.2 m -122.44 137.63 54.81 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.35 -0.386 . . . . 0.0 111.269 -179.804 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 68' ' ' VAL . . . . . 0.445 HG22 ' HG2' ' A' ' 117' ' ' MET . 21.7 m -127.37 146.64 32.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.025 -0.534 . . . . 0.0 110.802 179.772 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 69' ' ' PHE . . . . . . . . . . . . . 23.1 m-85 -109.44 112.18 24.15 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.154 -179.261 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 70' ' ' VAL . . . . . 0.538 ' HB ' ' HD3' ' A' ' 71' ' ' PRO . 13.0 t -62.95 -49.61 80.89 Favored Pre-proline 0 C--N 1.324 -0.508 0 CA-C-N 116.227 -0.442 . . . . 0.0 112.021 -178.901 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 71' ' ' PRO . . . . . 0.538 ' HD3' ' HB ' ' A' ' 70' ' ' VAL . 38.2 Cg_exo -60.74 -18.46 55.98 Favored 'Trans proline' 0 C--N 1.35 0.616 0 C-N-CA 122.039 1.826 . . . . 0.0 112.985 -179.663 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 72' ' ' ARG . . . . . 0.476 ' NH2' HG13 ' A' ' 197' ' ' ILE . 77.5 ttt180 -76.08 -55.6 5.44 Favored 'General case' 0 C--O 1.235 0.303 0 CA-C-O 120.796 0.331 . . . . 0.0 111.86 -179.093 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 73' ' ' TYR . . . . . . . . . . . . . 27.1 m-85 -67.52 -36.15 80.49 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-O 120.817 0.342 . . . . 0.0 110.321 -179.545 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 74' ' ' ILE . . . . . 0.487 ' O ' HD22 ' A' ' 78' ' ' LEU . 0.3 OUTLIER -67.14 -43.05 88.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 N-CA-C 109.686 -0.487 . . . . 0.0 109.686 179.344 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 75' ' ' ASP . . . . . 0.564 ' HA ' HD21 ' A' ' 78' ' ' LEU . 12.0 t70 -51.95 -40.72 61.3 Favored 'General case' 0 CA--C 1.519 -0.226 0 N-CA-C 109.534 -0.543 . . . . 0.0 109.534 179.009 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 76' ' ' TRP . . . . . . . . . . . . . 44.2 m0 -66.34 -35.5 80.51 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 115.794 -0.639 . . . . 0.0 110.825 179.425 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 77' ' ' ILE . . . . . 0.457 ' O ' ' HG2' ' A' ' 81' ' ' PRO . 88.0 mt -59.75 -40.73 83.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.094 -0.503 . . . . 0.0 112.318 -179.446 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 78' ' ' LEU . . . . . 0.564 HD21 ' HA ' ' A' ' 75' ' ' ASP . 0.6 OUTLIER -91.94 -28.34 17.31 Favored 'General case' 0 CA--C 1.535 0.371 0 N-CA-C 113.038 0.755 . . . . 0.0 113.038 -179.546 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 65.3 p -79.65 -53.09 7.17 Favored 'General case' 0 N--CA 1.469 0.511 0 N-CA-C 113.468 0.914 . . . . 0.0 113.468 -178.41 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 80' ' ' THR . . . . . 0.583 ' HB ' ' HD3' ' A' ' 81' ' ' PRO . 3.8 m -50.92 -54.02 41.6 Favored Pre-proline 0 CA--C 1.533 0.291 0 N-CA-C 112.409 0.522 . . . . 0.0 112.409 -178.27 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 81' ' ' PRO . . . . . 0.583 ' HD3' ' HB ' ' A' ' 80' ' ' THR . 32.3 Cg_exo -60.08 -22.41 69.51 Favored 'Trans proline' 0 C--N 1.351 0.687 0 C-N-CA 121.869 1.712 . . . . 0.0 111.761 179.723 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 82' ' ' LEU . . . . . . . . . . . . . 15.4 tp -74.32 -33.03 63.06 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.067 -0.515 . . . . 0.0 109.921 179.647 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 83' ' ' ILE . . . . . 0.504 HD11 HD11 ' A' ' 43' ' ' ILE . 35.4 mm -68.79 -53.03 29.24 Favored 'Isoleucine or valine' 0 C--O 1.235 0.309 0 CA-C-N 115.845 -0.616 . . . . 0.0 110.037 179.04 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 30.8 m -61.67 -30.18 47.75 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.221 0 CA-C-N 116.085 -0.507 . . . . 0.0 109.832 179.043 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 85' ' ' TYR . . . . . . . . . . . . . 44.2 t80 -66.82 -34.68 78.35 Favored 'General case' 0 N--CA 1.454 -0.251 0 CA-C-N 115.665 -0.698 . . . . 0.0 109.386 178.724 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 86' ' ' PHE . . . . . . . . . . . . . 18.9 t80 -59.2 -51.45 69.94 Favored 'General case' 0 CA--C 1.519 -0.234 0 CA-C-N 115.735 -0.666 . . . . 0.0 109.427 178.983 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 10.5 mp -60.51 -32.29 71.32 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 115.55 -0.75 . . . . 0.0 110.04 179.28 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 88' ' ' GLY . . . . . 0.419 ' HA2' HD11 ' A' ' 93' ' ' LEU . . . -68.59 -28.21 73.32 Favored Glycine 0 N--CA 1.449 -0.438 0 C-N-CA 120.751 -0.738 . . . . 0.0 111.697 179.382 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 75.9 mt -72.49 -39.25 67.82 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-O 120.982 0.42 . . . . 0.0 110.278 179.43 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 70.5 mt -59.9 -53.1 61.86 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 115.76 -0.654 . . . . 0.0 110.603 179.569 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 91' ' ' ALA . . . . . 0.491 ' HB2' ' HB2' ' A' ' 149' ' ' ALA . . . -72.33 -52.07 17.81 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.126 -0.488 . . . . 0.0 111.062 179.89 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 97.21 57.24 1.08 Allowed Glycine 0 N--CA 1.453 -0.228 0 C-N-CA 120.817 -0.706 . . . . 0.0 112.207 -179.899 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 93' ' ' LEU . . . . . 0.558 HD23 ' HG2' ' A' ' 145' ' ' MET . 8.9 mp -60.5 172.65 0.84 Allowed 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 121.045 0.45 . . . . 0.0 111.35 -179.704 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 94' ' ' ASP . . . . . 0.402 ' HB2' ' HG2' ' A' ' 97' ' ' GLU . 8.0 m-20 -82.63 172.55 12.82 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-N 115.904 -0.589 . . . . 0.0 110.634 179.907 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 38.3 t -56.24 -48.68 76.04 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.206 -179.839 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 99.2 mtt180 -70.4 -43.38 70.15 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.268 -0.424 . . . . 0.0 111.196 -179.835 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 97' ' ' GLU . . . . . 0.556 ' HB3' HD21 ' A' ' 93' ' ' LEU . 21.5 mm-40 -52.19 -48.0 65.26 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.991 -179.59 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 98' ' ' PHE . . . . . 0.429 ' O ' HG12 ' A' ' 102' ' ' ILE . 11.6 m-85 -57.5 -45.2 85.18 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-O 120.988 0.423 . . . . 0.0 110.19 179.177 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -62.59 -26.43 68.36 Favored Glycine 0 N--CA 1.45 -0.417 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.421 179.811 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 97.1 mt -73.28 -47.4 46.76 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.238 0 N-CA-C 111.876 0.324 . . . . 0.0 111.876 -179.632 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 26.5 m -69.19 -35.13 66.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 N-CA-C 111.9 0.333 . . . . 0.0 111.9 -179.169 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 102' ' ' ILE . . . . . 0.429 HG12 ' O ' ' A' ' 98' ' ' PHE . 48.6 mm -72.23 -47.92 51.17 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.25 0 CA-C-N 116.674 -0.239 . . . . 0.0 111.596 -179.294 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 14.4 t -60.22 -37.63 80.92 Favored 'General case' 0 C--O 1.234 0.273 0 CA-C-O 121.02 0.438 . . . . 0.0 110.879 179.895 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 104' ' ' LEU . . . . . 0.431 ' O ' HG12 ' A' ' 107' ' ' VAL . 31.3 tp -60.52 -50.15 74.68 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 115.975 -0.557 . . . . 0.0 110.512 179.648 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 105' ' ' ASN . . . . . 0.554 ' N ' HD21 ' A' ' 105' ' ' ASN . 0.8 OUTLIER -59.27 -31.69 69.33 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.012 179.778 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 96.9 m -61.01 -57.82 11.0 Favored 'General case' 0 C--N 1.331 -0.204 0 CA-C-N 116.547 -0.297 . . . . 0.0 111.478 -179.292 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 107' ' ' VAL . . . . . 0.431 HG12 ' O ' ' A' ' 104' ' ' LEU . 14.2 p -56.4 -35.46 43.76 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.242 -0.436 . . . . 0.0 110.742 -179.912 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . 0.416 HG21 ' O ' ' A' ' 104' ' ' LEU . 82.1 t -61.68 -57.8 10.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.038 -0.528 . . . . 0.0 111.424 179.624 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 109' ' ' MET . . . . . 0.502 ' HG2' ' O ' ' A' ' 105' ' ' ASN . 5.4 mmt -58.39 -35.2 71.64 Favored 'General case' 0 C--N 1.333 -0.146 0 CA-C-N 116.546 -0.297 . . . . 0.0 110.928 -179.683 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 8.3 mt -68.39 -33.17 73.77 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.307 -0.406 . . . . 0.0 110.696 179.785 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -61.75 -45.0 95.8 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 121.153 0.502 . . . . 0.0 109.745 178.989 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . -73.81 -33.34 57.89 Favored Glycine 0 N--CA 1.448 -0.507 0 CA-C-N 115.595 -0.729 . . . . 0.0 111.384 179.111 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 113' ' ' PHE . . . . . . . . . . . . . 1.1 t80 -53.27 -73.53 0.04 OUTLIER 'General case' 0 N--CA 1.455 -0.186 0 CA-C-O 121.093 0.473 . . . . 0.0 109.749 179.298 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -63.1 -21.44 66.18 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 115.68 -0.691 . . . . 0.0 110.805 179.618 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -52.57 -49.24 53.46 Favored Glycine 0 C--N 1.335 0.473 0 C-N-CA 120.785 -0.721 . . . . 0.0 112.155 179.492 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -78.38 -15.75 58.36 Favored 'General case' 0 C--N 1.326 -0.414 0 N-CA-C 111.698 0.258 . . . . 0.0 111.698 179.939 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 117' ' ' MET . . . . . 0.445 ' HG2' HG22 ' A' ' 68' ' ' VAL . 57.6 mtt -102.35 15.6 28.69 Favored 'General case' 0 C--N 1.332 -0.194 0 CA-C-O 120.687 0.279 . . . . 0.0 111.731 -179.295 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 19.2 m -65.62 150.26 96.33 Favored Pre-proline 0 C--N 1.329 -0.303 0 CA-C-N 116.509 -0.314 . . . . 0.0 111.213 179.9 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 119' ' ' PRO . . . . . . . . . . . . . 91.5 Cg_endo -80.97 4.48 6.94 Favored 'Trans proline' 0 C--N 1.348 0.529 0 C-N-CA 122.508 2.139 . . . . 0.0 112.501 179.68 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -170.31 -123.71 0.7 Allowed Glycine 0 C--N 1.33 0.231 0 C-N-CA 120.637 -0.792 . . . . 0.0 112.747 -179.816 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 26.2 pt -105.44 9.77 9.3 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-O 120.698 0.285 . . . . 0.0 111.467 -179.716 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 13.9 mm-40 -58.0 -19.23 29.46 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-O 120.95 0.405 . . . . 0.0 110.75 179.626 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 123' ' ' ARG . . . . . 0.485 ' HB2' ' HH2' ' A' ' 178' ' ' TRP . 23.2 ptt180 -51.5 -35.37 39.98 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 115.67 -0.695 . . . . 0.0 111.903 -179.781 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 124' ' ' TYR . . . . . . . . . . . . . 25.7 m-85 -57.29 -35.31 69.65 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.807 0.337 . . . . 0.0 110.891 -179.875 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 125' ' ' ALA . . . . . . . . . . . . . . . -74.35 -48.97 24.8 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.064 179.813 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 6.9 mp -53.33 -52.48 59.02 Favored 'General case' 0 C--N 1.332 -0.158 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.787 -179.981 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 127' ' ' PHE . . . . . . . . . . . . . 6.6 t80 -64.38 -37.54 87.87 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.281 -0.418 . . . . 0.0 110.684 179.999 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 128' ' ' GLY . . . . . . . . . . . . . . . -46.42 -45.02 16.52 Favored Glycine 0 C--N 1.332 0.337 0 C-N-CA 120.118 -1.039 . . . . 0.0 110.959 179.265 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 129' ' ' MET . . . . . 0.4 ' HE3' ' N ' ' A' ' 130' ' ' GLY . 0.5 OUTLIER -70.46 -38.04 74.39 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 120.868 0.366 . . . . 0.0 110.073 178.722 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 130' ' ' GLY . . . . . 0.4 ' N ' ' HE3' ' A' ' 129' ' ' MET . . . -63.61 -30.81 78.73 Favored Glycine 0 C--N 1.333 0.365 0 C-N-CA 121.056 -0.592 . . . . 0.0 112.951 -179.816 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -74.48 -53.56 9.26 Favored 'General case' 0 CA--C 1.519 -0.22 0 CA-C-N 116.779 0.29 . . . . 0.0 110.369 179.94 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 43.1 t -57.42 -40.33 73.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 N-CA-C 109.251 -0.648 . . . . 0.0 109.251 178.766 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -66.09 -37.09 84.9 Favored 'General case' 0 N--CA 1.452 -0.34 0 CA-C-N 115.218 -0.901 . . . . 0.0 110.041 178.893 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 134' ' ' PHE . . . . . 0.418 ' CZ ' ' HA ' ' A' ' 172' ' ' ALA . 82.9 t80 -57.01 -50.76 71.74 Favored 'General case' 0 N--CA 1.45 -0.461 0 CA-C-N 115.919 -0.582 . . . . 0.0 109.99 179.254 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 135' ' ' ILE . . . . . 0.473 ' HA ' HG21 ' A' ' 138' ' ' VAL . 57.6 mt -58.13 -30.81 40.21 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.342 0 CA-C-N 115.668 -0.696 . . . . 0.0 109.779 179.161 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 136' ' ' GLY . . . . . 0.417 ' O ' ' HB3' ' A' ' 139' ' ' TYR . . . -65.48 -38.07 94.42 Favored Glycine 0 N--CA 1.447 -0.58 0 C-N-CA 120.224 -0.988 . . . . 0.0 110.966 178.438 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 137' ' ' LEU . . . . . 0.455 HD11 HD22 ' A' ' 105' ' ' ASN . 29.2 tp -69.32 -46.78 66.26 Favored 'General case' 0 C--N 1.331 -0.205 0 N-CA-C 110.449 -0.204 . . . . 0.0 110.449 179.399 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 138' ' ' VAL . . . . . 0.505 ' HA ' HD11 ' A' ' 141' ' ' LEU . 4.6 m -62.13 -31.89 52.85 Favored 'Isoleucine or valine' 0 C--O 1.234 0.255 0 N-CA-C 109.029 -0.73 . . . . 0.0 109.029 178.882 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 139' ' ' TYR . . . . . 0.417 ' HB3' ' O ' ' A' ' 136' ' ' GLY . 45.6 t80 -60.99 -37.2 81.62 Favored 'General case' 0 N--CA 1.453 -0.317 0 CA-C-N 115.176 -0.92 . . . . 0.0 108.879 178.053 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 140' ' ' TYR . . . . . 0.507 ' HB3' ' SD ' ' A' ' 145' ' ' MET . 24.0 m-85 -70.25 -35.22 73.65 Favored 'General case' 0 C--N 1.332 -0.168 0 CA-C-N 115.489 -0.778 . . . . 0.0 110.122 178.478 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 141' ' ' LEU . . . . . 0.505 HD11 ' HA ' ' A' ' 138' ' ' VAL . 96.1 mt -55.55 -39.83 71.12 Favored 'General case' 0 C--O 1.232 0.149 0 CA-C-N 115.976 -0.556 . . . . 0.0 110.156 179.343 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 2.3 t -104.05 0.15 10.19 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 115.775 -0.648 . . . . 0.0 110.953 179.889 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . -72.89 -148.81 0.97 Allowed Glycine 0 CA--C 1.519 0.33 0 C-N-CA 120.965 -0.636 . . . . 0.0 112.876 -179.726 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 144' ' ' PRO . . . . . . . . . . . . . 31.8 Cg_endo -63.73 -23.56 69.34 Favored 'Trans proline' 0 C--N 1.347 0.497 0 C-N-CA 122.629 2.22 . . . . 0.0 112.523 -179.901 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 145' ' ' MET . . . . . 0.558 ' HG2' HD23 ' A' ' 93' ' ' LEU . 84.2 mtp -53.57 -58.37 7.4 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.451 -179.81 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 146' ' ' THR . . . . . . . . . . . . . 7.4 t -60.65 -32.2 71.39 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.382 -0.372 . . . . 0.0 111.337 -179.831 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 40.5 mt-10 -66.71 -34.65 78.33 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.283 -0.417 . . . . 0.0 111.071 -179.993 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 148' ' ' SER . . . . . . . . . . . . . 47.0 t -69.58 -45.32 68.94 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.051 -179.641 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 149' ' ' ALA . . . . . 0.537 ' HB3' HG22 ' A' ' 156' ' ' ILE . . . -63.88 -38.84 92.59 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.464 -179.665 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 150' ' ' SER . . . . . 0.578 ' HA ' ' HB2' ' A' ' 157' ' ' LYS . 81.8 p -67.54 -2.53 6.73 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.295 -0.411 . . . . 0.0 111.059 -179.817 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 151' ' ' GLN . . . . . . . . . . . . . 49.4 mt-30 -119.72 -1.64 10.53 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.26 -0.427 . . . . 0.0 111.244 -179.967 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 37.7 mmt180 -81.65 -51.6 8.04 Favored 'General case' 0 C--N 1.332 -0.185 0 CA-C-O 120.945 0.403 . . . . 0.0 110.746 179.712 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 153' ' ' SER . . . . . 0.53 ' HB3' HG12 ' A' ' 156' ' ' ILE . 23.1 t -158.17 172.28 18.68 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-N 115.865 -0.607 . . . . 0.0 110.544 179.254 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 154' ' ' SER . . . . . . . . . . . . . 39.6 t -69.91 -39.87 75.92 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-O 120.871 0.367 . . . . 0.0 110.317 179.418 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -76.99 -42.39 20.02 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.943 -0.646 . . . . 0.0 112.659 179.808 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 156' ' ' ILE . . . . . 0.537 HG22 ' HB3' ' A' ' 149' ' ' ALA . 36.5 mm -48.86 -37.45 9.11 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.162 0 CA-C-O 120.863 0.363 . . . . 0.0 111.495 -179.778 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 157' ' ' LYS . . . . . 0.578 ' HB2' ' HA ' ' A' ' 150' ' ' SER . 54.8 tttm -67.72 -36.36 80.46 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.277 -179.712 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 43.3 t -71.8 -42.22 67.32 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.658 -179.378 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 159' ' ' LEU . . . . . 0.412 ' O ' ' HB2' ' A' ' 163' ' ' LEU . 10.7 mp -67.42 -35.23 78.86 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.342 -0.39 . . . . 0.0 111.74 -179.372 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 160' ' ' TYR . . . . . . . . . . . . . 23.8 t80 -72.78 -46.84 51.19 Favored 'General case' 0 C--N 1.33 -0.274 0 N-CA-C 112.179 0.437 . . . . 0.0 112.179 -178.676 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 161' ' ' VAL . . . . . 0.412 HG21 ' N ' ' A' ' 162' ' ' ARG . 24.6 m -62.98 -45.95 97.55 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 N-CA-C 112.353 0.501 . . . . 0.0 112.353 -178.952 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 162' ' ' ARG . . . . . 0.412 ' N ' HG21 ' A' ' 161' ' ' VAL . 36.2 mmt180 -66.33 -42.71 87.79 Favored 'General case' 0 C--N 1.328 -0.329 0 N-CA-C 111.807 0.299 . . . . 0.0 111.807 -179.141 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 163' ' ' LEU . . . . . 0.467 ' HG ' ' HB2' ' A' ' 208' ' ' PHE . 6.1 mp -71.45 -43.86 65.87 Favored 'General case' 0 C--N 1.329 -0.297 0 N-CA-C 111.957 0.354 . . . . 0.0 111.957 -179.251 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 164' ' ' ARG . . . . . 0.472 ' HG3' ' N ' ' A' ' 165' ' ' ASN . 5.6 ppt_? -68.38 -40.71 81.29 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 120.456 0.169 . . . . 0.0 111.073 -179.374 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 165' ' ' ASN . . . . . 0.472 ' N ' ' HG3' ' A' ' 164' ' ' ARG . 0.9 OUTLIER -58.89 -48.0 82.96 Favored 'General case' 0 C--N 1.332 -0.19 0 CA-C-O 120.945 0.403 . . . . 0.0 110.558 179.35 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 166' ' ' LEU . . . . . 0.518 ' O ' ' HG ' ' A' ' 170' ' ' LEU . 4.1 tt -63.69 -48.39 77.32 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 116.109 -0.496 . . . . 0.0 111.017 -179.958 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 167' ' ' THR . . . . . 0.432 ' O ' ' HB2' ' A' ' 171' ' ' TRP . 93.0 m -57.4 -53.91 52.74 Favored 'General case' 0 C--N 1.33 -0.251 0 N-CA-C 112.426 0.528 . . . . 0.0 112.426 -178.971 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 168' ' ' VAL . . . . . 0.485 ' HB ' HD13 ' A' ' 141' ' ' LEU . 12.9 p -55.95 -40.75 64.6 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 N-CA-C 112.335 0.494 . . . . 0.0 112.335 -179.281 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 169' ' ' VAL . . . . . 0.44 HG22 ' O ' ' A' ' 165' ' ' ASN . 61.2 t -57.71 -65.8 0.39 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.389 0 N-CA-C 111.987 0.366 . . . . 0.0 111.987 -179.518 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 170' ' ' LEU . . . . . 0.518 ' HG ' ' O ' ' A' ' 166' ' ' LEU . 0.8 OUTLIER -65.18 -27.75 68.92 Favored 'General case' 0 C--N 1.331 -0.212 0 N-CA-C 112.146 0.425 . . . . 0.0 112.146 -178.813 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 171' ' ' TRP . . . . . 0.441 ' N ' HD12 ' A' ' 170' ' ' LEU . 6.9 m0 -71.77 -30.23 65.35 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.83 0.348 . . . . 0.0 110.612 179.615 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 172' ' ' ALA . . . . . 0.418 ' HA ' ' CZ ' ' A' ' 134' ' ' PHE . . . -73.7 -6.77 48.93 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.768 179.997 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 173' ' ' ILE . . . . . 0.542 HG21 HD13 ' A' ' 177' ' ' ILE . 23.6 mm -87.43 -21.63 7.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 115.93 -0.577 . . . . 0.0 110.771 179.739 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 174' ' ' TYR . . . . . 0.401 ' HD2' ' HA ' ' A' ' 171' ' ' TRP . 24.3 m-85 -54.86 -49.55 91.18 Favored Pre-proline 0 N--CA 1.464 0.228 0 CA-C-N 116.287 -0.415 . . . . 0.0 111.833 -179.796 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 175' ' ' PRO . . . . . . . . . . . . . 88.6 Cg_exo -47.02 -29.27 8.34 Favored 'Trans proline' 0 C--N 1.352 0.756 0 C-N-CA 122.131 1.887 . . . . 0.0 112.161 179.894 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 176' ' ' PHE . . . . . 0.426 ' O ' ' HG ' ' A' ' 180' ' ' LEU . 81.8 m-85 -80.47 -46.76 15.36 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 115.918 -0.583 . . . . 0.0 111.757 -179.965 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 177' ' ' ILE . . . . . 0.542 HD13 HG21 ' A' ' 173' ' ' ILE . 2.0 mm -64.49 -38.41 82.52 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.54 0 CA-C-N 116.166 -0.47 . . . . 0.0 112.177 -178.299 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 178' ' ' TRP . . . . . 0.485 ' HH2' ' HB2' ' A' ' 123' ' ' ARG . 60.2 t90 -73.83 -41.98 61.54 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.91 0.386 . . . . 0.0 110.779 179.67 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 179' ' ' LEU . . . . . 0.493 HD11 HD23 ' A' ' 180' ' ' LEU . 1.7 tm? -66.27 -49.95 65.39 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.066 -0.516 . . . . 0.0 111.078 -179.622 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 180' ' ' LEU . . . . . 0.538 HD21 HD13 ' A' ' 187' ' ' LEU . 14.0 mt -78.21 -47.94 16.91 Favored 'General case' 0 C--N 1.329 -0.301 0 N-CA-C 112.038 0.384 . . . . 0.0 112.038 -179.22 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . -54.32 177.94 0.27 Allowed Glycine 0 C--N 1.337 0.6 0 C-N-CA 120.649 -0.786 . . . . 0.0 113.066 -179.701 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 182' ' ' PRO . . . . . 0.439 ' HB2' ' HD3' ' A' ' 183' ' ' PRO . 71.9 Cg_exo -48.13 -44.93 27.12 Favored 'Trans proline' 0 CA--C 1.536 0.598 0 C-N-CA 122.908 2.405 . . . . 0.0 113.764 -179.793 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 183' ' ' PRO . . . . . 0.439 ' HD3' ' HB2' ' A' ' 182' ' ' PRO . 50.6 Cg_exo -54.85 -13.68 6.6 Favored 'Trans proline' 0 C--N 1.355 0.906 0 C-N-CA 122.028 1.819 . . . . 0.0 113.017 -179.845 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 184' ' ' GLY . . . . . . . . . . . . . . . -115.5 -101.05 2.3 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.517 -0.849 . . . . 0.0 112.635 -179.776 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 185' ' ' VAL . . . . . . . . . . . . . 9.0 m -105.98 -5.35 9.97 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-O 120.904 0.383 . . . . 0.0 111.305 -179.803 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 186' ' ' ALA . . . . . 0.41 ' HB2' ' HA ' ' A' ' 182' ' ' PRO . . . 55.17 85.4 0.06 Allowed 'General case' 0 C--N 1.331 -0.203 0 CA-C-N 115.991 -0.549 . . . . 0.0 111.991 179.302 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 187' ' ' LEU . . . . . 0.538 HD13 HD21 ' A' ' 180' ' ' LEU . 16.7 mt -92.21 -49.5 6.15 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.512 179.146 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 188' ' ' LEU . . . . . . . . . . . . . 95.5 mt -96.61 -160.96 0.83 Allowed 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 115.698 -0.683 . . . . 0.0 110.635 -179.944 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 189' ' ' THR . . . . . . . . . . . . . 1.9 t -99.76 146.49 31.94 Favored Pre-proline 0 C--N 1.329 -0.318 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.855 179.951 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 190' ' ' PRO . . . . . . . . . . . . . 86.9 Cg_exo -46.76 -44.09 22.53 Favored 'Trans proline' 0 C--N 1.349 0.567 0 C-N-CA 122.698 2.266 . . . . 0.0 113.244 -179.417 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 191' ' ' THR . . . . . . . . . . . . . 7.9 t -58.85 -43.4 90.78 Favored 'General case' 0 C--N 1.328 -0.345 0 N-CA-C 111.899 0.333 . . . . 0.0 111.899 -179.286 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 192' ' ' VAL . . . . . . . . . . . . . 45.7 t -71.77 -50.71 36.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.633 -0.258 . . . . 0.0 111.402 -179.743 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 193' ' ' ASP . . . . . . . . . . . . . 30.5 t70 -55.23 -45.34 75.98 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.452 -0.34 . . . . 0.0 111.066 -179.848 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 194' ' ' VAL . . . . . . . . . . . . . 74.6 t -64.34 -35.55 74.51 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.944 179.706 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 195' ' ' ALA . . . . . . . . . . . . . . . -56.97 -48.59 78.02 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 116.577 -0.283 . . . . 0.0 111.211 179.726 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 196' ' ' LEU . . . . . 0.404 ' O ' ' HB3' ' A' ' 199' ' ' TYR . 97.5 mt -67.76 -40.82 84.02 Favored 'General case' 0 N--CA 1.462 0.169 0 CA-C-O 120.708 0.289 . . . . 0.0 110.687 179.696 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 197' ' ' ILE . . . . . 0.482 HD12 ' HB ' ' A' ' 177' ' ' ILE . 11.2 mm -57.83 -60.25 2.41 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.373 179.256 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 198' ' ' VAL . . . . . 0.401 ' O ' ' HB2' ' A' ' 202' ' ' LEU . 76.3 t -52.02 -33.96 16.86 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.452 0 CA-C-N 115.486 -0.779 . . . . 0.0 109.574 178.324 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 199' ' ' TYR . . . . . 0.404 ' HB3' ' O ' ' A' ' 196' ' ' LEU . 68.5 t80 -69.27 -37.98 78.15 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 115.353 -0.84 . . . . 0.0 110.365 179.889 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 200' ' ' LEU . . . . . . . . . . . . . 42.0 mt -62.35 -45.71 91.97 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 115.667 -0.697 . . . . 0.0 111.212 -179.56 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 201' ' ' ASP . . . . . . . . . . . . . 7.3 m-20 -71.07 -43.64 67.38 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.114 -179.659 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 202' ' ' LEU . . . . . 0.401 ' HB2' ' O ' ' A' ' 198' ' ' VAL . 1.1 tt -59.95 -30.25 68.95 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 115.884 -0.598 . . . . 0.0 111.411 -179.476 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 203' ' ' VAL . . . . . 0.408 ' O ' ' HA3' ' A' ' 207' ' ' GLY . 48.5 t -81.43 -36.84 15.04 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.293 -0.412 . . . . 0.0 111.552 -178.726 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 204' ' ' THR . . . . . . . . . . . . . 71.0 m -62.46 -54.99 31.94 Favored 'General case' 0 C--N 1.328 -0.365 0 C-N-CA 120.508 -0.477 . . . . 0.0 111.009 179.497 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 205' ' ' LYS . . . . . 0.572 ' HE2' ' HB1' ' A' ' 47' ' ' ALA . 50.5 mttp -67.84 -59.13 3.53 Favored 'General case' 0 C--N 1.33 -0.245 0 N-CA-C 112.529 0.566 . . . . 0.0 112.529 -178.495 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 59.9 t -70.42 -37.55 70.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 N-CA-C 112.168 0.433 . . . . 0.0 112.168 -178.609 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 207' ' ' GLY . . . . . 0.526 ' O ' HG13 ' A' ' 211' ' ' ILE . . . -64.0 -60.66 6.96 Favored Glycine 0 N--CA 1.452 -0.254 0 C-N-CA 120.438 -0.887 . . . . 0.0 113.359 -178.866 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 208' ' ' PHE . . . . . 0.467 ' HB2' ' HG ' ' A' ' 163' ' ' LEU . 0.1 OUTLIER -65.25 -26.91 68.31 Favored 'General case' 0 C--O 1.224 -0.289 0 CA-C-N 117.051 0.425 . . . . 0.0 111.064 -179.289 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 209' ' ' GLY . . . . . 0.527 ' O ' ' HB1' ' A' ' 212' ' ' ALA . . . -69.39 -32.7 71.99 Favored Glycine 0 N--CA 1.447 -0.588 0 N-CA-C 111.593 -0.603 . . . . 0.0 111.593 178.726 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 210' ' ' PHE . . . . . . . . . . . . . 2.0 m-85 -74.56 -48.28 27.74 Favored 'General case' 0 CA--C 1.513 -0.462 0 N-CA-C 108.159 -1.052 . . . . 0.0 108.159 178.343 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 211' ' ' ILE . . . . . 0.526 HG13 ' O ' ' A' ' 207' ' ' GLY . 5.5 mt -62.03 -28.63 44.77 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.594 0 N-CA-C 107.517 -1.29 . . . . 0.0 107.517 176.423 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 212' ' ' ALA . . . . . 0.527 ' HB1' ' O ' ' A' ' 209' ' ' GLY . . . -62.53 -41.14 98.68 Favored 'General case' 0 N--CA 1.447 -0.587 0 CA-C-N 114.527 -1.215 . . . . 0.0 109.915 179.394 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 213' ' ' LEU . . . . . 0.41 ' HG ' ' O ' ' A' ' 209' ' ' GLY . 74.0 mt -70.31 -46.71 63.7 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-N 115.027 -0.988 . . . . 0.0 111.712 -179.826 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 214' ' ' ASP . . . . . . . . . . . . . 10.9 t70 -51.16 -54.86 21.36 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 120.923 0.392 . . . . 0.0 111.278 -179.476 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 215' ' ' ALA . . . . . 0.406 ' HB1' HD13 ' A' ' 159' ' ' LEU . . . -58.7 -52.79 64.19 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-N 115.978 -0.555 . . . . 0.0 111.367 -179.718 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 216' ' ' ALA . . . . . . . . . . . . . . . -58.92 -33.23 70.33 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.333 -0.394 . . . . 0.0 111.619 -179.586 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 217' ' ' ALA . . . . . . . . . . . . . . . -64.05 -36.11 82.92 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 121.012 0.434 . . . . 0.0 110.36 179.893 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 218' ' ' THR . . . . . . . . . . . . . 94.1 m . . . . . 0 C--N 1.328 -0.338 0 CA-C-N 115.69 -0.686 . . . . 0.0 110.977 179.572 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.288 0 N-CA-C 112.532 -0.227 . . . . 0.0 112.532 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 4' ' ' LEU . . . . . 0.411 ' HA ' HD21 ' A' ' 7' ' ' LEU . 70.9 mt -72.97 -36.13 67.04 Favored 'General case' 0 N--CA 1.449 -0.491 0 CA-C-O 120.878 0.371 . . . . 0.0 110.989 179.835 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 45.5 p -53.09 -37.84 62.03 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 115.877 -0.601 . . . . 0.0 111.874 -179.466 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 70.8 p -56.34 -40.54 74.61 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.438 -0.346 . . . . 0.0 111.579 -179.491 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 7' ' ' LEU . . . . . 0.473 HD23 ' HG1' ' A' ' 191' ' ' THR . 3.4 mm? -59.85 -52.49 65.21 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 116.402 -0.363 . . . . 0.0 110.967 179.997 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 8' ' ' PHE . . . . . . . . . . . . . 75.8 m-85 -58.5 -32.11 68.49 Favored 'General case' 0 C--N 1.331 -0.204 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.613 -179.907 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 9' ' ' TRP . . . . . 0.409 ' O ' HG12 ' A' ' 13' ' ' ILE . 17.1 m95 -67.19 -45.63 76.33 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.036 -0.529 . . . . 0.0 109.833 179.576 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 95.1 mt -58.1 -46.82 84.89 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 115.607 -0.724 . . . . 0.0 110.15 179.305 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -60.08 -34.56 84.3 Favored Glycine 0 N--CA 1.45 -0.415 0 C-N-CA 120.746 -0.74 . . . . 0.0 111.781 179.351 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -67.67 -30.4 69.93 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.767 0.317 . . . . 0.0 110.604 179.608 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 13' ' ' ILE . . . . . 0.409 HG12 ' O ' ' A' ' 9' ' ' TRP . 50.8 mm -67.35 -52.5 41.58 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.226 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.16 179.486 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -59.93 -34.67 84.13 Favored Glycine 0 N--CA 1.448 -0.503 0 C-N-CA 120.696 -0.764 . . . . 0.0 111.641 179.105 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 15' ' ' MET . . . . . 0.562 ' HE2' ' HD2' ' A' ' 205' ' ' LYS . 18.9 mmt -66.5 -40.42 89.24 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 120.666 0.269 . . . . 0.0 110.628 179.479 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -59.69 -40.46 87.92 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.313 -0.403 . . . . 0.0 110.149 179.353 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 60.5 t -61.4 -42.76 95.02 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.201 0 CA-C-N 116.058 -0.519 . . . . 0.0 110.53 179.34 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -69.36 -46.17 57.68 Favored Glycine 0 N--CA 1.452 -0.266 0 C-N-CA 120.793 -0.718 . . . . 0.0 111.927 179.626 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 24.6 m -50.69 -49.06 58.32 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-O 120.702 0.287 . . . . 0.0 111.249 -179.82 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 96.3 mt -72.06 -44.99 62.45 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 116.305 -0.407 . . . . 0.0 111.687 -179.85 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -59.78 -31.49 69.73 Favored 'General case' 0 C--N 1.329 -0.304 0 N-CA-C 112.095 0.405 . . . . 0.0 112.095 -179.007 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 12.8 m-85 -91.19 -30.71 16.51 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 120.667 0.27 . . . . 0.0 111.429 -179.329 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -72.89 -50.68 22.3 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.948 0.404 . . . . 0.0 111.341 -179.69 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 24' ' ' TRP . . . . . . . . . . . . . 3.6 t-105 -61.62 -38.51 87.91 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-N 115.784 -0.643 . . . . 0.0 111.069 -179.809 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.33 -0.28 0 CA-C-O 120.718 0.294 . . . . 0.0 111.221 179.992 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.351 0 N-CA-C 112.19 -0.364 . . . . 0.0 112.19 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 11.8 mm-40 -89.65 -20.6 23.47 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 121.009 0.433 . . . . 0.0 110.502 179.674 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 34' ' ' ARG . . . . . . . . . . . . . 34.2 ttm180 -52.09 -29.23 20.65 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 115.66 -0.7 . . . . 0.0 111.363 -179.862 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 41.8 ttm180 -59.39 -40.54 86.92 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-O 120.759 0.314 . . . . 0.0 110.845 179.861 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 91.8 m-85 -71.04 -32.4 69.13 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.878 179.753 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 37' ' ' TYR . . . . . . . . . . . . . 61.0 m-85 -70.55 -54.7 11.09 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 116.055 -0.52 . . . . 0.0 111.243 -179.743 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 11.0 p -57.17 -36.5 51.93 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-O 120.914 0.388 . . . . 0.0 110.479 179.649 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 26.3 m -65.38 -45.2 85.03 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 115.896 -0.593 . . . . 0.0 110.565 179.474 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 40' ' ' LEU . . . . . 0.506 HD13 HD13 ' A' ' 43' ' ' ILE . 51.5 tp -65.6 -38.48 89.59 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 115.949 -0.568 . . . . 0.0 110.483 179.556 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 97.3 t -67.34 -34.34 68.32 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.446 0 CA-C-N 115.789 -0.641 . . . . 0.0 110.253 179.429 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 42' ' ' GLY . . . . . 0.417 ' O ' HG12 ' A' ' 46' ' ' ILE . . . -64.01 -46.59 90.96 Favored Glycine 0 N--CA 1.448 -0.545 0 CA-C-N 115.76 -0.655 . . . . 0.0 112.971 179.991 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 43' ' ' ILE . . . . . 0.506 HD13 HD13 ' A' ' 40' ' ' LEU . 39.4 pt -63.04 -44.03 99.36 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.217 0 CA-C-N 116.847 0.323 . . . . 0.0 111.659 -179.558 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 44' ' ' SER . . . . . 0.444 ' N ' HG13 ' A' ' 43' ' ' ILE . 72.1 m -66.62 -27.19 67.5 Favored 'General case' 0 C--N 1.332 -0.159 0 CA-C-O 120.911 0.386 . . . . 0.0 110.808 179.604 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -78.56 -49.74 6.48 Favored Glycine 0 CA--C 1.519 0.286 0 C-N-CA 121.036 -0.602 . . . . 0.0 113.306 -179.256 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 46' ' ' ILE . . . . . 0.643 HD13 HD12 ' A' ' 78' ' ' LEU . 7.7 pt -58.09 -44.02 86.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-O 120.848 0.356 . . . . 0.0 111.04 -179.588 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 47' ' ' ALA . . . . . 0.514 ' HB1' ' HE2' ' A' ' 205' ' ' LYS . . . -67.73 -39.01 84.31 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-O 120.794 0.331 . . . . 0.0 110.578 179.077 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 48' ' ' ALA . . . . . 0.493 ' HB3' ' HB3' ' A' ' 15' ' ' MET . . . -55.0 -48.01 73.88 Favored 'General case' 0 C--N 1.332 -0.18 0 CA-C-N 116.11 -0.496 . . . . 0.0 111.579 -179.888 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 49' ' ' VAL . . . . . 0.402 HG22 ' O ' ' A' ' 46' ' ' ILE . 28.7 m -67.78 -34.28 66.69 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.473 -0.33 . . . . 0.0 111.275 -179.548 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -63.7 -37.63 88.06 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-O 120.986 0.422 . . . . 0.0 111.132 179.627 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 33.4 m-85 -72.67 -34.56 67.3 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 116.082 -0.508 . . . . 0.0 110.516 -179.766 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -68.25 -42.76 79.21 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 115.979 -0.555 . . . . 0.0 111.056 179.566 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 53' ' ' VAL . . . . . 0.417 HG23 ' N ' ' A' ' 54' ' ' MET . 33.0 m -69.62 -43.75 80.08 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.126 0 CA-C-N 116.44 -0.346 . . . . 0.0 110.876 179.978 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 54' ' ' MET . . . . . 0.533 ' HG2' ' HG2' ' A' ' 71' ' ' PRO . 74.6 mtm -65.03 -34.19 77.83 Favored 'General case' 0 CA--C 1.519 -0.222 0 N-CA-C 109.582 -0.525 . . . . 0.0 109.582 178.955 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -65.97 -17.31 64.59 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.414 -0.812 . . . . 0.0 111.009 179.49 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 95.9 mt -100.08 8.61 43.81 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.339 -0.391 . . . . 0.0 111.0 179.952 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 74.26 20.91 79.55 Favored Glycine 0 N--CA 1.45 -0.371 0 C-N-CA 120.809 -0.71 . . . . 0.0 112.492 179.991 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 24.9 t -92.19 130.72 40.89 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-O 120.784 0.326 . . . . 0.0 110.903 179.884 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 94.0 0.73 65.76 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.855 -0.688 . . . . 0.0 112.753 -179.911 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 60' ' ' TRP . . . . . . . . . . . . . 13.0 m0 -75.21 111.15 10.17 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.76 0.314 . . . . 0.0 110.89 179.864 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 8.4 p -110.77 132.0 21.83 Favored Pre-proline 0 C--N 1.33 -0.271 0 CA-C-N 116.344 -0.389 . . . . 0.0 111.059 179.887 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 74.4 Cg_endo -76.25 147.18 29.13 Favored 'Trans proline' 0 C--N 1.349 0.576 0 C-N-CA 122.372 2.048 . . . . 0.0 112.229 179.742 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 93.9 t -141.51 91.98 0.55 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 115.996 -0.547 . . . . 0.0 111.181 -179.791 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . 58.04 -87.79 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.01 -0.541 . . . . 0.0 111.771 179.574 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 9.0 tp10 -118.08 -21.43 8.26 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.452 -0.34 . . . . 0.0 111.251 -179.59 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 66' ' ' ARG . . . . . . . . . . . . . 99.6 mtt180 -107.03 162.98 13.37 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.368 -0.378 . . . . 0.0 110.63 179.875 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 33.4 m -118.96 124.6 47.43 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.968 0.414 . . . . 0.0 111.455 -179.843 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 68' ' ' VAL . . . . . 0.482 HG22 ' HB3' ' A' ' 117' ' ' MET . 57.7 t -103.6 146.64 10.95 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.361 0 CA-C-N 115.815 -0.63 . . . . 0.0 110.645 179.744 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 69' ' ' PHE . . . . . . . . . . . . . 16.8 m-85 -107.79 112.19 24.72 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.399 -0.364 . . . . 0.0 110.039 -179.688 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 70' ' ' VAL . . . . . 0.591 ' N ' ' HD2' ' A' ' 71' ' ' PRO . 21.5 t -66.73 -48.83 52.13 Favored Pre-proline 0 C--N 1.323 -0.56 0 CA-C-N 116.047 -0.524 . . . . 0.0 111.953 -179.285 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 71' ' ' PRO . . . . . 0.591 ' HD2' ' N ' ' A' ' 70' ' ' VAL . 18.2 Cg_endo -59.8 -17.78 45.24 Favored 'Trans proline' 0 C--N 1.35 0.654 0 C-N-CA 122.279 1.986 . . . . 0.0 113.183 -179.64 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 72' ' ' ARG . . . . . 0.417 HH22 HG23 ' A' ' 194' ' ' VAL . 23.9 ttm180 -78.46 -55.82 4.92 Favored 'General case' 0 C--O 1.234 0.278 0 C-N-CA 120.961 -0.296 . . . . 0.0 111.621 -179.607 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 73' ' ' TYR . . . . . 0.467 ' O ' HG13 ' A' ' 77' ' ' ILE . 95.2 m-85 -70.47 -31.64 68.87 Favored 'General case' 0 C--N 1.329 -0.29 0 C-N-CA 120.89 -0.324 . . . . 0.0 110.482 -179.652 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 74' ' ' ILE . . . . . 0.508 ' HA ' HD12 ' A' ' 77' ' ' ILE . 0.3 OUTLIER -69.5 -39.29 78.36 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 N-CA-C 109.259 -0.645 . . . . 0.0 109.259 178.716 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 75' ' ' ASP . . . . . 0.436 ' O ' ' HG ' ' A' ' 78' ' ' LEU . 14.8 t70 -57.23 -37.38 72.19 Favored 'General case' 0 N--CA 1.452 -0.334 0 N-CA-C 109.113 -0.699 . . . . 0.0 109.113 178.461 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 76' ' ' TRP . . . . . 0.428 ' HA ' ' OG1' ' A' ' 79' ' ' THR . 44.7 m0 -70.26 -34.03 72.31 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 115.611 -0.722 . . . . 0.0 110.527 179.086 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 77' ' ' ILE . . . . . 0.525 ' HA ' ' HG3' ' A' ' 109' ' ' MET . 94.2 mt -58.45 -38.71 71.66 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.236 0 CA-C-N 116.285 -0.416 . . . . 0.0 111.022 179.781 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 78' ' ' LEU . . . . . 0.643 HD12 HD13 ' A' ' 46' ' ' ILE . 1.1 pp -91.52 -34.12 14.9 Favored 'General case' 0 CA--C 1.536 0.41 0 N-CA-C 113.205 0.817 . . . . 0.0 113.205 -179.643 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 79' ' ' THR . . . . . 0.454 HG21 HG13 ' A' ' 46' ' ' ILE . 52.1 p -76.09 -52.5 10.01 Favored 'General case' 0 N--CA 1.47 0.538 0 N-CA-C 113.316 0.858 . . . . 0.0 113.316 -178.314 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 80' ' ' THR . . . . . 0.532 ' N ' ' HD2' ' A' ' 81' ' ' PRO . 3.9 m -50.76 -48.94 82.1 Favored Pre-proline 0 CA--C 1.532 0.255 0 N-CA-C 112.961 0.726 . . . . 0.0 112.961 -178.162 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 81' ' ' PRO . . . . . 0.532 ' HD2' ' N ' ' A' ' 80' ' ' THR . 28.9 Cg_endo -61.37 -25.31 79.97 Favored 'Trans proline' 0 C--N 1.352 0.717 0 C-N-CA 121.549 1.499 . . . . 0.0 111.631 -179.885 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 82' ' ' LEU . . . . . 0.449 ' HB3' HG22 ' A' ' 43' ' ' ILE . 0.1 OUTLIER -74.43 -34.76 63.3 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 115.876 -0.602 . . . . 0.0 110.23 179.698 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 49.6 mm -67.46 -53.64 30.41 Favored 'Isoleucine or valine' 0 C--O 1.234 0.253 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.029 179.165 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 33.0 m -59.94 -30.03 44.55 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.255 0 CA-C-N 115.959 -0.564 . . . . 0.0 109.552 178.96 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 85' ' ' TYR . . . . . . . . . . . . . 89.8 t80 -67.35 -33.39 75.15 Favored 'General case' 0 N--CA 1.454 -0.275 0 CA-C-N 115.536 -0.757 . . . . 0.0 109.591 178.772 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 86' ' ' PHE . . . . . . . . . . . . . 8.3 t80 -61.81 -50.72 71.16 Favored 'General case' 0 C--O 1.234 0.259 0 CA-C-N 115.769 -0.651 . . . . 0.0 109.87 179.317 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 8.0 mp -60.91 -31.1 70.62 Favored 'General case' 0 C--N 1.332 -0.193 0 CA-C-N 115.872 -0.604 . . . . 0.0 110.232 179.617 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -70.89 -27.67 71.88 Favored Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.971 -0.633 . . . . 0.0 112.122 179.461 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 73.4 mt -71.55 -45.52 62.06 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-O 120.94 0.4 . . . . 0.0 110.514 179.934 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 90' ' ' LEU . . . . . 0.444 HD11 HD21 ' A' ' 163' ' ' LEU . 98.0 mt -54.48 -43.21 71.55 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 115.797 -0.638 . . . . 0.0 111.477 -179.918 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 91' ' ' ALA . . . . . 0.44 ' HB3' ' HB3' ' A' ' 148' ' ' SER . . . -78.6 -54.99 5.55 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 116.488 -0.324 . . . . 0.0 111.399 -179.748 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 105.23 63.96 0.65 Allowed Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.89 -0.672 . . . . 0.0 112.331 179.98 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 93' ' ' LEU . . . . . 0.513 HD21 ' HB3' ' A' ' 97' ' ' GLU . 7.4 mp -80.69 172.62 13.52 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.794 0.33 . . . . 0.0 111.032 -179.874 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 94' ' ' ASP . . . . . . . . . . . . . 14.2 m-20 -89.19 164.9 14.78 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.099 -0.5 . . . . 0.0 110.808 179.841 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 80.7 p -53.92 -34.54 59.85 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.113 -0.494 . . . . 0.0 111.086 -179.954 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 41.5 mmt180 -72.61 -48.4 40.02 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.374 -179.631 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 97' ' ' GLU . . . . . 0.513 ' HB3' HD21 ' A' ' 93' ' ' LEU . 42.3 mt-10 -54.94 -49.23 71.86 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 116.404 -0.362 . . . . 0.0 111.134 -179.837 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 98' ' ' PHE . . . . . 0.463 ' O ' HG12 ' A' ' 102' ' ' ILE . 33.0 m-85 -55.25 -49.94 70.74 Favored 'General case' 0 C--N 1.332 -0.175 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.689 179.755 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -54.42 -32.68 52.58 Favored Glycine 0 N--CA 1.452 -0.286 0 C-N-CA 120.93 -0.652 . . . . 0.0 112.694 -179.756 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 96.4 mt -69.54 -43.07 80.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-O 120.882 0.372 . . . . 0.0 111.629 -179.684 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 61.0 t -71.87 -40.58 68.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.325 -0.398 . . . . 0.0 111.989 -179.225 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 102' ' ' ILE . . . . . 0.463 HG12 ' O ' ' A' ' 98' ' ' PHE . 38.0 mm -68.78 -41.24 82.26 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.363 0 N-CA-C 111.954 0.353 . . . . 0.0 111.954 -179.097 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 12.4 t -64.93 -44.5 89.31 Favored 'General case' 0 C--O 1.234 0.247 0 CA-C-O 120.679 0.276 . . . . 0.0 111.314 -179.719 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 104' ' ' LEU . . . . . 0.407 ' O ' HG23 ' A' ' 108' ' ' VAL . 9.2 tt -58.47 -44.18 89.21 Favored 'General case' 0 C--N 1.332 -0.164 0 CA-C-O 120.813 0.339 . . . . 0.0 110.252 179.776 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 105' ' ' ASN . . . . . 0.58 HD22 HD13 ' A' ' 137' ' ' LEU . 0.9 OUTLIER -56.29 -41.63 76.21 Favored 'General case' 0 N--CA 1.455 -0.179 0 CA-C-N 116.149 -0.478 . . . . 0.0 109.857 178.852 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 85.2 m -54.71 -40.14 68.91 Favored 'General case' 0 C--N 1.332 -0.157 0 CA-C-N 116.075 -0.511 . . . . 0.0 110.269 179.508 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 0.9 OUTLIER -67.45 -37.4 78.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 115.843 -0.617 . . . . 0.0 110.189 179.114 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . 0.46 ' HB ' ' HE2' ' A' ' 109' ' ' MET . 64.4 t -65.72 -52.04 54.99 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-N 115.33 -0.85 . . . . 0.0 111.686 -179.471 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 109' ' ' MET . . . . . 0.525 ' HG3' ' HA ' ' A' ' 77' ' ' ILE . 5.4 mmt -61.33 -39.72 91.57 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.35 -0.386 . . . . 0.0 111.18 -179.514 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 21.6 tp -64.42 -31.59 72.87 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.339 -0.392 . . . . 0.0 110.436 179.762 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -62.94 -56.59 15.85 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.528 179.344 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . -60.58 -36.8 92.25 Favored Glycine 0 C--N 1.329 0.193 0 C-N-CA 120.445 -0.883 . . . . 0.0 111.813 179.483 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 113' ' ' PHE . . . . . . . . . . . . . 10.1 t80 -49.45 -63.04 1.22 Allowed 'General case' 0 C--N 1.331 -0.222 0 CA-C-O 121.119 0.485 . . . . 0.0 110.201 179.429 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -69.66 -28.1 65.6 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 115.562 -0.744 . . . . 0.0 111.189 179.591 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -52.18 -35.87 43.16 Favored Glycine 0 C--N 1.332 0.316 0 CA-C-N 116.061 -0.518 . . . . 0.0 112.785 179.907 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -78.13 -44.81 25.04 Favored 'General case' 0 C--N 1.329 -0.316 0 N-CA-C 112.132 0.419 . . . . 0.0 112.132 -179.862 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 117' ' ' MET . . . . . 0.482 ' HB3' HG22 ' A' ' 68' ' ' VAL . 15.7 ptp -85.58 19.72 2.32 Favored 'General case' 0 C--N 1.33 -0.243 0 N-CA-C 112.149 0.426 . . . . 0.0 112.149 -179.007 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 118' ' ' VAL . . . . . 0.536 HG23 ' HB3' ' A' ' 123' ' ' ARG . 8.8 m -57.87 146.34 67.89 Favored Pre-proline 0 C--N 1.328 -0.332 0 CA-C-N 116.807 -0.178 . . . . 0.0 111.253 179.618 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 119' ' ' PRO . . . . . . . . . . . . . 71.8 Cg_endo -75.56 -9.06 19.87 Favored 'Trans proline' 0 C--N 1.347 0.476 0 C-N-CA 122.574 2.183 . . . . 0.0 112.381 -179.88 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -172.35 -122.95 0.68 Allowed Glycine 0 C--N 1.331 0.277 0 C-N-CA 120.662 -0.78 . . . . 0.0 112.711 -179.98 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 50.5 pt -83.38 8.06 1.39 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.23 0 CA-C-O 120.827 0.346 . . . . 0.0 111.334 -179.915 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 122' ' ' GLU . . . . . 0.464 ' HB2' ' HB ' ' A' ' 118' ' ' VAL . 11.7 mm-40 -58.57 -19.03 34.74 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.086 179.993 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 123' ' ' ARG . . . . . 0.536 ' HB3' HG23 ' A' ' 118' ' ' VAL . 12.6 ptt180 -52.33 -30.95 30.98 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.062 -0.517 . . . . 0.0 111.494 -179.842 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 124' ' ' TYR . . . . . . . . . . . . . 24.7 m-85 -71.96 -32.54 67.37 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.378 -0.373 . . . . 0.0 111.116 -179.686 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 125' ' ' ALA . . . . . . . . . . . . . . . -68.88 -51.07 44.14 Favored 'General case' 0 C--O 1.235 0.321 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.939 179.626 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 2.9 mm? -54.99 -55.85 26.28 Favored 'General case' 0 CA--C 1.52 -0.209 0 CA-C-N 116.015 -0.539 . . . . 0.0 110.882 -179.827 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 127' ' ' PHE . . . . . 0.481 ' HZ ' ' HB3' ' A' ' 175' ' ' PRO . 7.8 t80 -65.33 -33.25 75.52 Favored 'General case' 0 N--CA 1.45 -0.435 0 CA-C-N 116.258 -0.428 . . . . 0.0 111.466 -179.065 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 128' ' ' GLY . . . . . . . . . . . . . . . -49.67 -45.3 38.89 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 119.816 -1.183 . . . . 0.0 110.623 179.009 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 129' ' ' MET . . . . . . . . . . . . . 0.6 OUTLIER -71.71 -38.89 70.46 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 115.072 -0.564 . . . . 0.0 110.356 178.881 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -67.05 -27.41 73.44 Favored Glycine 0 C--N 1.331 0.283 0 CA-C-N 115.897 -0.592 . . . . 0.0 113.002 -179.613 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -74.85 -53.23 9.46 Favored 'General case' 0 C--N 1.328 -0.348 0 N-CA-C 110.012 -0.366 . . . . 0.0 110.012 179.86 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 95.9 t -57.23 -39.83 69.86 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.234 0 CA-C-O 121.347 0.594 . . . . 0.0 109.458 178.507 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -70.39 -34.17 72.24 Favored 'General case' 0 N--CA 1.452 -0.344 0 CA-C-N 115.297 -0.865 . . . . 0.0 110.69 179.423 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 134' ' ' PHE . . . . . 0.403 ' CZ ' ' HA ' ' A' ' 172' ' ' ALA . 50.2 t80 -55.4 -60.14 3.82 Favored 'General case' 0 N--CA 1.453 -0.304 0 CA-C-O 120.985 0.422 . . . . 0.0 110.164 179.689 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 135' ' ' ILE . . . . . 0.453 ' O ' HG21 ' A' ' 138' ' ' VAL . 0.0 OUTLIER -55.75 -34.74 37.24 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 115.764 -0.653 . . . . 0.0 109.854 178.975 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 136' ' ' GLY . . . . . 0.407 ' O ' ' HB3' ' A' ' 139' ' ' TYR . . . -58.1 -41.66 94.72 Favored Glycine 0 N--CA 1.449 -0.477 0 C-N-CA 120.389 -0.91 . . . . 0.0 111.488 178.777 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 137' ' ' LEU . . . . . 0.58 HD13 HD22 ' A' ' 105' ' ' ASN . 45.1 tp -66.05 -56.25 12.51 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-O 120.68 0.276 . . . . 0.0 110.446 179.215 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 138' ' ' VAL . . . . . 0.453 HG21 ' O ' ' A' ' 135' ' ' ILE . 2.7 m -55.12 -30.33 23.96 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.237 0 CA-C-O 121.134 0.492 . . . . 0.0 109.813 -179.994 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 139' ' ' TYR . . . . . 0.407 ' HB3' ' O ' ' A' ' 136' ' ' GLY . 12.2 t80 -61.8 -42.33 98.87 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 115.682 -0.69 . . . . 0.0 109.804 178.566 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 29.1 m-85 -69.29 -35.22 75.79 Favored 'General case' 0 C--N 1.333 -0.15 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.494 179.064 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 141' ' ' LEU . . . . . . . . . . . . . 11.0 mp -62.8 -27.22 69.16 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.502 179.578 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 142' ' ' VAL . . . . . 0.606 HG21 HH11 ' A' ' 164' ' ' ARG . 12.4 t -103.88 -11.6 9.28 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.226 0 CA-C-N 116.008 -0.542 . . . . 0.0 111.103 179.964 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . -76.66 -117.24 0.15 Allowed Glycine 0 CA--C 1.523 0.566 0 C-N-CA 120.937 -0.649 . . . . 0.0 113.115 -179.702 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 144' ' ' PRO . . . . . . . . . . . . . 47.2 Cg_endo -68.35 -23.51 38.2 Favored 'Trans proline' 0 C--N 1.35 0.638 0 C-N-CA 122.67 2.246 . . . . 0.0 113.195 -179.298 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 145' ' ' MET . . . . . 0.601 ' HB3' ' HH ' ' A' ' 160' ' ' TYR . 58.2 mtt -65.47 -30.27 71.03 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.676 0.274 . . . . 0.0 111.403 -179.775 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 146' ' ' THR . . . . . 0.41 ' OG1' ' HA ' ' A' ' 142' ' ' VAL . 82.9 m -81.16 -32.38 33.66 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.852 0.358 . . . . 0.0 111.345 -179.31 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 38.6 tt0 -75.92 -40.65 53.82 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.119 -179.919 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 148' ' ' SER . . . . . 0.44 ' HB3' ' HB3' ' A' ' 91' ' ' ALA . 46.0 t -70.3 -45.26 66.65 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.278 -0.419 . . . . 0.0 111.242 -179.473 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 149' ' ' ALA . . . . . . . . . . . . . . . -65.69 -32.33 73.82 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.27 -0.423 . . . . 0.0 111.416 -179.543 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 150' ' ' SER . . . . . . . . . . . . . 80.3 p -74.47 0.45 14.64 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.283 -0.417 . . . . 0.0 111.331 -179.717 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 151' ' ' GLN . . . . . . . . . . . . . 10.3 pt20 -136.3 9.84 3.22 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.54 -0.3 . . . . 0.0 110.996 179.787 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 1.5 tmt_? -83.84 -51.81 6.89 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-O 120.833 0.349 . . . . 0.0 110.435 179.997 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 153' ' ' SER . . . . . 0.644 ' HB2' HG12 ' A' ' 156' ' ' ILE . 20.8 m -157.54 172.47 18.5 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.024 -0.535 . . . . 0.0 110.507 179.314 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 154' ' ' SER . . . . . . . . . . . . . 48.1 t -73.05 -38.32 66.53 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.378 -0.374 . . . . 0.0 110.729 179.849 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -77.36 -27.55 59.4 Favored Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.944 -0.646 . . . . 0.0 112.718 179.993 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 156' ' ' ILE . . . . . 0.644 HG12 ' HB2' ' A' ' 153' ' ' SER . 38.1 mm -62.03 -35.44 68.52 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-O 120.799 0.333 . . . . 0.0 110.923 -179.944 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 157' ' ' LYS . . . . . . . . . . . . . 91.3 mttt -58.93 -55.55 33.75 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.067 -0.515 . . . . 0.0 111.617 -179.888 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 69.0 m -70.49 -38.58 74.38 Favored 'General case' 0 N--CA 1.463 0.21 0 N-CA-C 112.256 0.465 . . . . 0.0 112.256 -178.847 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 159' ' ' LEU . . . . . 0.421 HD12 HD11 ' A' ' 163' ' ' LEU . 39.0 tp -69.13 -36.25 77.26 Favored 'General case' 0 C--N 1.327 -0.411 0 N-CA-C 111.74 0.274 . . . . 0.0 111.74 -179.148 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 160' ' ' TYR . . . . . 0.601 ' HH ' ' HB3' ' A' ' 145' ' ' MET . 57.0 t80 -73.96 -46.11 46.05 Favored 'General case' 0 C--N 1.328 -0.366 0 N-CA-C 111.9 0.333 . . . . 0.0 111.9 -179.027 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 29.4 m -59.96 -41.73 87.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-O 120.721 0.296 . . . . 0.0 111.332 -179.634 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 162' ' ' ARG . . . . . 0.469 ' HG2' HG22 ' A' ' 211' ' ' ILE . 23.3 tpp180 -68.99 -39.89 79.11 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 120.944 0.402 . . . . 0.0 110.97 179.949 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 163' ' ' LEU . . . . . 0.535 ' HG ' ' HB2' ' A' ' 208' ' ' PHE . 4.5 mp -68.25 -44.32 75.9 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.069 -0.514 . . . . 0.0 111.668 -179.505 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 164' ' ' ARG . . . . . 0.606 HH11 HG21 ' A' ' 142' ' ' VAL . 18.4 ttp85 -72.01 -52.97 14.45 Favored 'General case' 0 C--N 1.329 -0.324 0 N-CA-C 112.125 0.417 . . . . 0.0 112.125 -179.003 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 165' ' ' ASN . . . . . 0.503 ' N ' HD21 ' A' ' 165' ' ' ASN . 0.9 OUTLIER -52.31 -46.31 65.93 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-O 121.056 0.455 . . . . 0.0 110.534 -179.291 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 166' ' ' LEU . . . . . 0.521 ' O ' ' HG ' ' A' ' 170' ' ' LEU . 6.8 tt -64.9 -52.08 58.45 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-N 115.809 -0.632 . . . . 0.0 111.141 179.955 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 167' ' ' THR . . . . . 0.479 ' O ' ' HB2' ' A' ' 171' ' ' TRP . 96.4 m -61.32 -54.09 48.34 Favored 'General case' 0 N--CA 1.463 0.185 0 N-CA-C 112.608 0.596 . . . . 0.0 112.608 -178.653 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 168' ' ' VAL . . . . . . . . . . . . . 94.0 t -52.2 -41.09 32.56 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.185 0 N-CA-C 112.134 0.42 . . . . 0.0 112.134 -179.284 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 169' ' ' VAL . . . . . . . . . . . . . 43.9 t -61.96 -64.63 0.6 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 N-CA-C 111.965 0.357 . . . . 0.0 111.965 -179.452 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 170' ' ' LEU . . . . . 0.521 ' HG ' ' O ' ' A' ' 166' ' ' LEU . 1.3 pp -62.55 -29.37 70.52 Favored 'General case' 0 C--N 1.331 -0.206 0 N-CA-C 112.081 0.4 . . . . 0.0 112.081 -178.777 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 171' ' ' TRP . . . . . 0.479 ' HB2' ' O ' ' A' ' 167' ' ' THR . 2.7 m0 -72.87 -30.78 64.25 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.842 0.353 . . . . 0.0 110.737 179.83 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 172' ' ' ALA . . . . . 0.403 ' HA ' ' CZ ' ' A' ' 134' ' ' PHE . . . -73.65 -6.21 45.29 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-O 121.093 0.473 . . . . 0.0 110.286 179.647 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 173' ' ' ILE . . . . . 0.464 ' O ' HG12 ' A' ' 177' ' ' ILE . 44.1 mm -85.14 -20.93 8.07 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.241 0 CA-C-N 115.678 -0.692 . . . . 0.0 110.484 179.148 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 174' ' ' TYR . . . . . . . . . . . . . 13.2 m-85 -53.21 -50.07 84.4 Favored Pre-proline 0 N--CA 1.464 0.268 0 CA-C-N 116.126 -0.488 . . . . 0.0 111.18 -179.867 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 175' ' ' PRO . . . . . 0.481 ' HB3' ' HZ ' ' A' ' 127' ' ' PHE . 93.1 Cg_exo -45.17 -33.07 7.78 Favored 'Trans proline' 0 C--N 1.351 0.684 0 C-N-CA 122.252 1.968 . . . . 0.0 112.152 179.308 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 176' ' ' PHE . . . . . 0.488 ' O ' ' HG ' ' A' ' 180' ' ' LEU . 85.4 m-85 -80.82 -50.12 10.23 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 115.772 -0.649 . . . . 0.0 112.023 -179.618 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 177' ' ' ILE . . . . . 0.464 HG12 ' O ' ' A' ' 173' ' ' ILE . 4.1 mm -63.42 -35.03 70.8 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.547 0 N-CA-C 112.546 0.573 . . . . 0.0 112.546 -177.867 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 178' ' ' TRP . . . . . . . . . . . . . 73.5 t90 -73.87 -52.37 13.2 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-O 120.887 0.375 . . . . 0.0 110.856 179.87 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 179' ' ' LEU . . . . . 0.436 ' O ' ' HA3' ' A' ' 184' ' ' GLY . 0.5 OUTLIER -64.83 -54.34 32.55 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.079 -0.51 . . . . 0.0 111.677 -179.004 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 180' ' ' LEU . . . . . 0.488 ' HG ' ' O ' ' A' ' 176' ' ' PHE . 27.9 mt -64.32 -49.09 73.09 Favored 'General case' 0 C--N 1.326 -0.448 0 C-N-CA 120.812 -0.355 . . . . 0.0 111.201 -179.529 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . -57.38 179.93 0.77 Allowed Glycine 0 C--N 1.338 0.651 0 C-N-CA 120.284 -0.96 . . . . 0.0 112.37 179.511 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 182' ' ' PRO . . . . . 0.627 ' HA ' ' HB2' ' A' ' 186' ' ' ALA . 89.0 Cg_exo -46.99 -45.04 21.89 Favored 'Trans proline' 0 CA--C 1.536 0.593 0 C-N-CA 122.969 2.446 . . . . 0.0 113.994 -179.657 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 183' ' ' PRO . . . . . 0.435 ' HD3' ' HB2' ' A' ' 182' ' ' PRO . 88.4 Cg_exo -48.14 -25.29 6.55 Favored 'Trans proline' 0 C--N 1.354 0.845 0 C-N-CA 122.303 2.002 . . . . 0.0 113.762 -179.509 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 184' ' ' GLY . . . . . 0.436 ' HA3' ' O ' ' A' ' 179' ' ' LEU . . . -112.86 -81.63 1.1 Allowed Glycine 0 C--N 1.334 0.437 0 C-N-CA 120.098 -1.049 . . . . 0.0 113.617 -179.443 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 185' ' ' VAL . . . . . . . . . . . . . 14.5 m -120.86 -8.6 10.27 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.203 0 N-CA-C 112.17 0.433 . . . . 0.0 112.17 -178.696 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 186' ' ' ALA . . . . . 0.627 ' HB2' ' HA ' ' A' ' 182' ' ' PRO . . . 57.56 85.9 0.08 Allowed 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.494 -0.321 . . . . 0.0 111.714 179.562 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 187' ' ' LEU . . . . . 0.484 HD13 HD22 ' A' ' 180' ' ' LEU . 17.9 mt -91.99 -49.33 6.28 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-O 120.963 0.411 . . . . 0.0 110.695 179.518 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 188' ' ' LEU . . . . . . . . . . . . . 86.2 mt -95.87 -158.39 0.65 Allowed 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 115.807 -0.633 . . . . 0.0 110.792 -179.766 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 189' ' ' THR . . . . . 0.475 HG22 HG22 ' A' ' 191' ' ' THR . 24.9 m -91.38 136.91 26.38 Favored Pre-proline 0 C--N 1.327 -0.378 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.566 -179.885 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 190' ' ' PRO . . . . . 0.43 ' O ' HG22 ' A' ' 194' ' ' VAL . 93.7 Cg_exo -44.35 -53.63 4.69 Favored 'Trans proline' 0 C--N 1.351 0.68 0 C-N-CA 122.559 2.172 . . . . 0.0 113.094 -179.786 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 191' ' ' THR . . . . . 0.475 HG22 HG22 ' A' ' 189' ' ' THR . 3.0 t -56.81 -36.8 70.34 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.703 0.287 . . . . 0.0 111.455 -179.721 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 192' ' ' VAL . . . . . 0.425 HG22 ' HB ' ' A' ' 189' ' ' THR . 92.7 t -70.46 -42.06 78.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.423 -0.353 . . . . 0.0 110.982 179.952 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 193' ' ' ASP . . . . . . . . . . . . . 24.8 t70 -61.6 -40.17 93.82 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.468 179.743 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 194' ' ' VAL . . . . . 0.43 HG22 ' O ' ' A' ' 190' ' ' PRO . 99.9 t -65.11 -35.88 76.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.026 -0.534 . . . . 0.0 110.229 179.323 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 195' ' ' ALA . . . . . . . . . . . . . . . -57.7 -48.4 79.66 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.846 179.48 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 196' ' ' LEU . . . . . . . . . . . . . 92.5 mt -67.9 -43.22 79.78 Favored 'General case' 0 C--N 1.332 -0.176 0 CA-C-N 116.417 -0.356 . . . . 0.0 110.816 179.634 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 197' ' ' ILE . . . . . 0.431 HD13 ' HA ' ' A' ' 197' ' ' ILE . 14.7 mm -57.86 -57.69 9.43 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.075 -0.511 . . . . 0.0 110.632 179.56 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 198' ' ' VAL . . . . . . . . . . . . . 74.7 t -55.15 -34.16 31.83 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.5 0 N-CA-C 109.078 -0.712 . . . . 0.0 109.078 178.317 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 199' ' ' TYR . . . . . . . . . . . . . 62.7 t80 -69.48 -30.66 68.59 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 115.205 -0.907 . . . . 0.0 110.62 179.843 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 200' ' ' LEU . . . . . 0.478 ' O ' HG13 ' A' ' 203' ' ' VAL . 32.1 mt -69.61 -47.69 62.63 Favored 'General case' 0 C--N 1.332 -0.153 0 CA-C-N 116.099 -0.5 . . . . 0.0 111.584 -179.56 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 201' ' ' ASP . . . . . . . . . . . . . 4.7 m-20 -70.62 -39.63 73.62 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-O 121.29 0.567 . . . . 0.0 110.192 179.757 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 202' ' ' LEU . . . . . . . . . . . . . 59.8 tp -71.13 -26.75 63.15 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 115.343 -0.844 . . . . 0.0 111.951 -179.292 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 203' ' ' VAL . . . . . 0.478 HG13 ' O ' ' A' ' 200' ' ' LEU . 9.3 p -79.34 -35.73 17.34 Favored 'Isoleucine or valine' 0 C--O 1.226 -0.153 0 C-N-CA 121.005 -0.278 . . . . 0.0 110.805 -179.483 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 204' ' ' THR . . . . . . . . . . . . . 95.8 m -65.71 -58.89 4.62 Favored 'General case' 0 C--N 1.329 -0.31 0 C-N-CA 120.748 -0.381 . . . . 0.0 110.797 179.33 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 205' ' ' LYS . . . . . 0.562 ' HD2' ' HE2' ' A' ' 15' ' ' MET . 60.9 mttp -58.17 -57.29 13.53 Favored 'General case' 0 C--N 1.329 -0.296 0 N-CA-C 112.061 0.393 . . . . 0.0 112.061 -178.9 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 59.8 t -71.04 -37.35 67.15 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.365 0 N-CA-C 112.326 0.491 . . . . 0.0 112.326 -178.702 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 207' ' ' GLY . . . . . 0.518 ' O ' HG13 ' A' ' 211' ' ' ILE . . . -58.07 -61.86 6.94 Favored Glycine 0 CA--C 1.518 0.267 0 C-N-CA 120.658 -0.782 . . . . 0.0 113.966 -178.605 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 208' ' ' PHE . . . . . 0.535 ' HB2' ' HG ' ' A' ' 163' ' ' LEU . 2.1 p90 -72.93 -27.36 61.81 Favored 'General case' 0 C--O 1.222 -0.38 0 CA-C-N 117.48 0.64 . . . . 0.0 110.75 -179.308 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 209' ' ' GLY . . . . . 0.493 ' O ' ' HB3' ' A' ' 212' ' ' ALA . . . -63.34 -34.17 89.23 Favored Glycine 0 N--CA 1.449 -0.473 0 N-CA-C 111.786 -0.525 . . . . 0.0 111.786 178.65 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 210' ' ' PHE . . . . . . . . . . . . . 0.7 OUTLIER -72.75 -47.46 46.7 Favored 'General case' 0 CA--C 1.514 -0.425 0 N-CA-C 108.239 -1.023 . . . . 0.0 108.239 178.379 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 211' ' ' ILE . . . . . 0.518 HG13 ' O ' ' A' ' 207' ' ' GLY . 4.8 mt -62.91 -27.48 43.2 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.465 0 N-CA-C 107.632 -1.248 . . . . 0.0 107.632 176.588 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 212' ' ' ALA . . . . . 0.493 ' HB3' ' O ' ' A' ' 209' ' ' GLY . . . -61.86 -41.67 98.12 Favored 'General case' 0 N--CA 1.45 -0.45 0 CA-C-N 114.436 -1.256 . . . . 0.0 110.622 -179.846 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 213' ' ' LEU . . . . . . . . . . . . . 99.1 mt -66.56 -50.39 63.29 Favored 'General case' 0 C--N 1.331 -0.202 0 CA-C-N 115.345 -0.843 . . . . 0.0 111.255 -179.872 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 214' ' ' ASP . . . . . . . . . . . . . 25.8 t70 -56.08 -54.41 45.29 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.282 -0.417 . . . . 0.0 111.152 -179.761 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 215' ' ' ALA . . . . . . . . . . . . . . . -57.44 -57.27 13.39 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.136 -0.484 . . . . 0.0 111.417 -179.865 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 216' ' ' ALA . . . . . . . . . . . . . . . -55.18 -33.48 63.04 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.353 -0.385 . . . . 0.0 111.331 -179.828 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 217' ' ' ALA . . . . . . . . . . . . . . . -61.72 -37.77 85.43 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 121.096 0.474 . . . . 0.0 110.129 179.426 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 218' ' ' THR . . . . . . . . . . . . . 98.4 m . . . . . 0 C--N 1.329 -0.288 0 CA-C-N 115.648 -0.705 . . . . 0.0 110.824 179.384 . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.307 0 N-CA-C 112.727 -0.149 . . . . 0.0 112.727 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 82.9 mt -59.2 -35.24 73.25 Favored 'General case' 0 N--CA 1.449 -0.483 0 CA-C-O 120.812 0.339 . . . . 0.0 111.273 -179.822 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 46.4 p -61.6 -34.91 76.44 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.11 -0.495 . . . . 0.0 111.795 -179.588 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 16.4 p -56.16 -35.64 67.41 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.333 -0.394 . . . . 0.0 111.507 -179.321 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 7' ' ' LEU . . . . . . . . . . . . . 3.6 mm? -61.81 -53.5 55.04 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.364 -0.38 . . . . 0.0 111.271 -179.752 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 8' ' ' PHE . . . . . 0.469 ' HB2' ' HB1' ' A' ' 55' ' ' ALA . 53.9 m-85 -59.18 -30.21 68.03 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.291 -0.413 . . . . 0.0 111.066 -179.631 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 9' ' ' TRP . . . . . . . . . . . . . 19.7 m95 -69.25 -46.76 66.5 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.345 -179.971 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 85.4 mt -62.3 -41.86 98.88 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 115.88 -0.6 . . . . 0.0 110.042 179.206 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -62.29 -33.72 86.96 Favored Glycine 0 N--CA 1.448 -0.509 0 C-N-CA 120.779 -0.724 . . . . 0.0 111.769 179.3 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -67.87 -34.48 76.76 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-O 120.84 0.352 . . . . 0.0 110.523 179.585 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 46.8 mm -62.68 -51.67 69.19 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.187 0 CA-C-N 116.029 -0.532 . . . . 0.0 110.505 179.451 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -60.18 -33.21 79.02 Favored Glycine 0 N--CA 1.449 -0.447 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.108 179.648 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 15' ' ' MET . . . . . 0.645 ' HE2' ' HD2' ' A' ' 205' ' ' LYS . 20.0 mmt -66.75 -47.05 73.44 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.624 0.25 . . . . 0.0 110.821 179.689 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -54.07 -42.14 68.95 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.301 179.583 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 79.6 t -61.26 -48.05 90.69 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-N 115.946 -0.57 . . . . 0.0 110.79 179.548 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -63.51 -46.34 92.67 Favored Glycine 0 C--N 1.331 0.272 0 C-N-CA 120.773 -0.727 . . . . 0.0 112.165 179.809 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 23.2 m -49.95 -43.19 49.86 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 120.726 0.298 . . . . 0.0 111.114 -179.644 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 81.8 mt -71.93 -47.06 55.15 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.284 -0.416 . . . . 0.0 111.446 179.905 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -57.61 -29.9 64.89 Favored 'General case' 0 C--N 1.33 -0.272 0 N-CA-C 111.982 0.364 . . . . 0.0 111.982 -179.525 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 22' ' ' PHE . . . . . 0.454 ' HB2' HG22 ' A' ' 41' ' ' VAL . 9.5 m-85 -89.42 -41.12 12.27 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.531 -0.304 . . . . 0.0 111.594 -179.097 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -65.58 -50.39 65.31 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.828 0.347 . . . . 0.0 111.38 -179.729 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 24' ' ' TRP . . . . . . . . . . . . . 1.1 t-105 -57.92 -50.3 73.81 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.078 -0.51 . . . . 0.0 111.057 179.884 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.328 -0.329 0 CA-C-N 116.284 -0.416 . . . . 0.0 111.221 -179.911 . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.258 0 N-CA-C 112.603 -0.199 . . . . 0.0 112.603 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 12.9 mm-40 -63.68 -24.31 67.73 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.835 0.35 . . . . 0.0 110.729 179.981 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 34' ' ' ARG . . . . . . . . . . . . . 75.6 ttt180 -50.56 -30.45 13.16 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 115.905 -0.588 . . . . 0.0 111.694 -179.77 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 88.2 mtm180 -59.24 -52.62 64.88 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.487 -0.324 . . . . 0.0 111.604 -179.677 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 86.3 m-85 -58.89 -27.58 65.36 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.51 -179.618 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 37' ' ' TYR . . . . . . . . . . . . . 72.7 m-85 -77.96 -53.81 7.02 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-N 116.292 -0.413 . . . . 0.0 111.08 -179.642 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 86.6 t -56.78 -36.9 50.86 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-O 121.024 0.44 . . . . 0.0 110.292 179.634 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 99.3 m -63.06 -50.52 70.28 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 115.759 -0.655 . . . . 0.0 110.164 179.153 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 40' ' ' LEU . . . . . 0.413 ' O ' HG13 ' A' ' 43' ' ' ILE . 53.7 tp -56.36 -43.46 79.18 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 115.441 -0.8 . . . . 0.0 110.252 179.44 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . 0.454 HG22 ' HB2' ' A' ' 22' ' ' PHE . 97.3 t -63.77 -34.35 67.52 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.253 0 CA-C-N 115.708 -0.678 . . . . 0.0 109.648 178.731 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -60.46 -35.34 88.6 Favored Glycine 0 N--CA 1.448 -0.524 0 CA-C-N 115.627 -0.715 . . . . 0.0 112.102 179.753 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 43' ' ' ILE . . . . . 0.584 HG23 ' HE3' ' A' ' 205' ' ' LYS . 0.3 OUTLIER -70.11 -57.77 7.23 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.159 0 CA-C-O 120.646 0.26 . . . . 0.0 110.796 179.704 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 67.1 m -62.89 -20.28 65.0 Favored 'General case' 0 C--O 1.232 0.153 0 CA-C-N 116.406 -0.361 . . . . 0.0 111.315 -179.732 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -77.99 -57.52 3.45 Favored Glycine 0 N--CA 1.452 -0.25 0 C-N-CA 120.778 -0.725 . . . . 0.0 112.8 -179.598 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 23.8 pt -58.87 -36.14 59.87 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.213 0 CA-C-O 120.958 0.409 . . . . 0.0 110.969 179.925 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 47' ' ' ALA . . . . . 0.53 ' HB3' ' HE2' ' A' ' 205' ' ' LYS . . . -67.63 -45.46 75.28 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.067 -0.515 . . . . 0.0 111.26 179.832 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 48' ' ' ALA . . . . . 0.504 ' HB2' ' HB3' ' A' ' 15' ' ' MET . . . -55.1 -43.81 74.36 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.106 -0.497 . . . . 0.0 111.829 -179.578 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 35.9 m -73.37 -34.17 42.6 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.353 0 CA-C-N 116.332 -0.395 . . . . 0.0 111.519 -179.325 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -65.78 -35.09 79.73 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-O 120.924 0.393 . . . . 0.0 110.869 179.925 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 26.7 m-85 -73.33 -40.03 64.78 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-N 115.96 -0.564 . . . . 0.0 110.518 179.96 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -63.84 -44.7 92.39 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 115.938 -0.574 . . . . 0.0 111.258 179.848 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 53' ' ' VAL . . . . . 0.432 HG21 ' N ' ' A' ' 54' ' ' MET . 34.2 m -68.56 -48.97 69.42 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.226 0 CA-C-N 116.404 -0.362 . . . . 0.0 110.868 179.923 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 54' ' ' MET . . . . . 0.432 ' N ' HG21 ' A' ' 53' ' ' VAL . 7.1 ttp -62.77 -30.1 71.2 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.126 179.852 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 55' ' ' ALA . . . . . 0.469 ' HB1' ' HB2' ' A' ' 8' ' ' PHE . . . -65.55 -40.04 92.39 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 115.849 -0.614 . . . . 0.0 111.023 179.336 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 95.3 mt -73.23 2.77 6.71 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.022 -0.536 . . . . 0.0 111.092 -179.864 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 90.7 7.37 66.69 Favored Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.685 -0.769 . . . . 0.0 112.592 179.942 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 41.3 t -74.46 135.85 26.5 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-O 120.864 0.364 . . . . 0.0 110.869 179.895 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 83.92 -2.55 87.4 Favored Glycine 0 N--CA 1.452 -0.286 0 C-N-CA 120.942 -0.647 . . . . 0.0 112.903 179.988 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 60' ' ' TRP . . . . . . . . . . . . . 12.0 m0 -73.74 102.32 3.95 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.56 0.219 . . . . 0.0 110.931 179.63 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 7.6 p -115.13 124.25 30.52 Favored Pre-proline 0 CA--C 1.536 0.414 0 CA-C-N 116.559 -0.291 . . . . 0.0 111.208 179.794 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 14.2 Cg_exo -69.47 157.3 61.44 Favored 'Trans proline' 0 C--N 1.353 0.796 0 C-N-CA 122.783 2.322 . . . . 0.0 112.744 -179.725 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 76.5 t -144.13 94.63 0.47 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.223 0 CA-C-N 115.856 -0.611 . . . . 0.0 110.98 179.88 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . 59.51 -86.42 0.02 OUTLIER 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 116.088 -0.506 . . . . 0.0 111.503 179.789 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 11.1 tp10 -118.16 -26.88 6.22 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-N 116.526 -0.306 . . . . 0.0 111.261 -179.723 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 66' ' ' ARG . . . . . . . . . . . . . 17.4 ptp180 -107.69 153.76 22.46 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.46 -0.336 . . . . 0.0 110.443 179.903 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 60.4 m -105.88 141.52 37.15 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-O 121.047 0.451 . . . . 0.0 111.543 -179.521 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 68' ' ' VAL . . . . . 0.458 HG21 ' HG3' ' A' ' 117' ' ' MET . 33.0 m -119.89 146.37 24.77 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 115.725 -0.67 . . . . 0.0 110.367 179.537 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 69' ' ' PHE . . . . . . . . . . . . . 22.1 m-85 -109.0 112.44 24.63 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 116.318 -0.401 . . . . 0.0 110.066 -179.398 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 70' ' ' VAL . . . . . 0.47 ' HB ' ' HD3' ' A' ' 71' ' ' PRO . 3.2 t -63.78 -48.98 78.41 Favored Pre-proline 0 C--N 1.326 -0.441 0 CA-C-N 116.274 -0.421 . . . . 0.0 111.905 -179.126 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 71' ' ' PRO . . . . . 0.47 ' HD3' ' HB ' ' A' ' 70' ' ' VAL . 47.4 Cg_exo -56.9 -18.06 26.3 Favored 'Trans proline' 0 C--N 1.351 0.698 0 C-N-CA 122.289 1.993 . . . . 0.0 112.877 -179.606 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 68.2 ttt180 -70.95 -55.79 7.6 Favored 'General case' 0 C--O 1.236 0.362 0 CA-C-O 120.886 0.374 . . . . 0.0 111.559 -179.323 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 73' ' ' TYR . . . . . 0.449 ' O ' HG13 ' A' ' 77' ' ' ILE . 7.0 m-85 -70.64 -34.45 72.08 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.439 -0.346 . . . . 0.0 110.281 -179.497 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 74' ' ' ILE . . . . . 0.44 ' HA ' HD11 ' A' ' 77' ' ' ILE . 0.4 OUTLIER -68.01 -37.98 79.15 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.226 0 CA-C-N 116.334 -0.394 . . . . 0.0 110.013 179.322 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 8.1 t70 -58.02 -39.56 78.65 Favored 'General case' 0 CA--C 1.518 -0.259 0 N-CA-C 109.045 -0.724 . . . . 0.0 109.045 178.806 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 76' ' ' TRP . . . . . . . . . . . . . 39.0 m0 -67.06 -31.56 72.15 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 115.612 -0.722 . . . . 0.0 110.584 179.108 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 77' ' ' ILE . . . . . 0.526 ' HA ' ' HG3' ' A' ' 109' ' ' MET . 85.8 mt -66.71 -32.8 59.66 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.233 0 CA-C-N 116.284 -0.416 . . . . 0.0 111.035 179.468 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 21.5 mt -91.16 -17.47 26.04 Favored 'General case' 0 C--N 1.327 -0.41 0 N-CA-C 112.149 0.426 . . . . 0.0 112.149 -179.515 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 79' ' ' THR . . . . . 0.501 ' HG1' ' H ' ' A' ' 80' ' ' THR . 76.9 p -103.4 -52.65 2.96 Favored 'General case' 0 CA--C 1.532 0.275 0 N-CA-C 113.784 1.031 . . . . 0.0 113.784 -177.915 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 80' ' ' THR . . . . . 0.663 ' HB ' ' HD3' ' A' ' 81' ' ' PRO . 29.4 m -51.36 -54.86 34.12 Favored Pre-proline 0 CA--C 1.531 0.246 0 N-CA-C 112.478 0.547 . . . . 0.0 112.478 -178.508 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 81' ' ' PRO . . . . . 0.663 ' HD3' ' HB ' ' A' ' 80' ' ' THR . 36.9 Cg_exo -60.51 -20.93 66.41 Favored 'Trans proline' 0 C--N 1.351 0.683 0 C-N-CA 121.575 1.516 . . . . 0.0 111.368 179.763 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 82' ' ' LEU . . . . . 0.407 HD22 HG22 ' A' ' 43' ' ' ILE . 17.3 tp -76.91 -33.34 57.77 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 115.812 -0.631 . . . . 0.0 110.302 179.751 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 48.9 mm -68.4 -52.06 40.91 Favored 'Isoleucine or valine' 0 C--O 1.233 0.221 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.055 179.109 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 34.5 m -61.86 -30.0 47.56 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.142 0 N-CA-C 109.545 -0.539 . . . . 0.0 109.545 178.728 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 85' ' ' TYR . . . . . . . . . . . . . 73.4 t80 -67.63 -33.35 74.78 Favored 'General case' 0 N--CA 1.454 -0.235 0 CA-C-N 115.546 -0.752 . . . . 0.0 109.615 178.873 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 86' ' ' PHE . . . . . . . . . . . . . 5.5 t80 -61.99 -51.67 67.11 Favored 'General case' 0 C--O 1.233 0.221 0 CA-C-N 115.697 -0.683 . . . . 0.0 109.822 179.204 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 8.7 mp -62.43 -29.5 70.55 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 115.755 -0.657 . . . . 0.0 110.101 179.476 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -71.49 -27.76 70.74 Favored Glycine 0 N--CA 1.449 -0.455 0 C-N-CA 120.799 -0.715 . . . . 0.0 111.569 179.237 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 72.6 mt -69.92 -45.57 67.24 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-O 121.074 0.464 . . . . 0.0 109.985 179.504 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 90' ' ' LEU . . . . . 0.438 ' HB3' HG21 ' A' ' 156' ' ' ILE . 64.7 mt -60.17 -30.43 69.33 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 115.582 -0.735 . . . . 0.0 110.741 179.616 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 91' ' ' ALA . . . . . 0.466 ' HA ' ' HA ' ' A' ' 149' ' ' ALA . . . -86.32 -29.44 23.02 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.264 -179.787 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 75.03 44.69 22.93 Favored Glycine 0 N--CA 1.452 -0.258 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.146 -179.902 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 93' ' ' LEU . . . . . 0.46 HD12 ' HE2' ' A' ' 145' ' ' MET . 30.1 mt -60.36 168.04 2.24 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.955 0.407 . . . . 0.0 111.206 -179.646 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 94' ' ' ASP . . . . . . . . . . . . . 5.5 m-20 -90.77 179.57 5.76 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 115.936 -0.575 . . . . 0.0 110.834 179.994 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 80.5 p -60.58 -42.83 97.48 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.906 -179.94 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 68.9 mtm180 -68.62 -49.77 56.6 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.108 -0.496 . . . . 0.0 111.027 -179.826 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 44.9 mt-10 -54.51 -47.6 72.9 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.335 -0.393 . . . . 0.0 111.033 -179.883 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 98' ' ' PHE . . . . . 0.429 ' O ' HG12 ' A' ' 102' ' ' ILE . 11.3 m-85 -60.29 -43.62 96.09 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.416 -0.357 . . . . 0.0 110.496 179.61 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -60.63 -27.53 66.37 Favored Glycine 0 N--CA 1.451 -0.358 0 C-N-CA 120.611 -0.804 . . . . 0.0 112.414 179.746 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 96.1 mt -73.9 -47.64 42.23 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.229 0 N-CA-C 111.875 0.324 . . . . 0.0 111.875 -179.537 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 27.7 m -69.49 -39.01 78.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 N-CA-C 111.731 0.271 . . . . 0.0 111.731 -179.353 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 102' ' ' ILE . . . . . 0.429 HG12 ' O ' ' A' ' 98' ' ' PHE . 43.3 mm -67.67 -46.55 82.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.55 -0.296 . . . . 0.0 111.347 -179.54 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 103' ' ' THR . . . . . 0.423 ' HA ' ' HG1' ' A' ' 106' ' ' THR . 14.7 t -62.42 -33.27 74.46 Favored 'General case' 0 C--O 1.233 0.187 0 CA-C-O 120.975 0.417 . . . . 0.0 110.404 179.643 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -58.84 -52.04 67.42 Favored 'General case' 0 C--N 1.332 -0.191 0 CA-C-N 115.995 -0.548 . . . . 0.0 109.528 179.248 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 105' ' ' ASN . . . . . 0.558 ' N ' HD21 ' A' ' 105' ' ' ASN . 0.8 OUTLIER -56.72 -35.45 68.56 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 115.736 -0.666 . . . . 0.0 110.53 179.455 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 106' ' ' THR . . . . . 0.423 ' HG1' ' HA ' ' A' ' 103' ' ' THR . 39.3 m -55.6 -50.9 68.88 Favored 'General case' 0 C--N 1.332 -0.169 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.996 179.918 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 0.9 OUTLIER -60.5 -39.67 81.97 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.223 0 CA-C-O 121.174 0.512 . . . . 0.0 110.39 179.6 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 81.0 t -63.66 -39.91 87.12 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-N 115.506 -0.77 . . . . 0.0 111.285 -179.821 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 109' ' ' MET . . . . . 0.526 ' HG3' ' HA ' ' A' ' 77' ' ' ILE . 28.6 mmt -67.17 -51.35 54.8 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.078 -0.51 . . . . 0.0 111.329 -179.568 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 21.1 tp -58.95 -34.73 72.09 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-N 115.96 -0.564 . . . . 0.0 110.927 -179.592 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -61.11 -57.09 13.98 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.18 -179.994 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . -67.23 -28.03 73.62 Favored Glycine 0 N--CA 1.45 -0.374 0 C-N-CA 120.724 -0.75 . . . . 0.0 112.143 179.68 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 113' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER -57.67 -75.09 0.05 OUTLIER 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 121.035 0.445 . . . . 0.0 110.132 179.817 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -61.45 -26.43 67.87 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 115.793 -0.639 . . . . 0.0 111.095 179.771 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -53.06 -50.07 52.97 Favored Glycine 0 C--N 1.331 0.28 0 C-N-CA 121.028 -0.606 . . . . 0.0 112.616 -179.974 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 116' ' ' ALA . . . . . 0.541 ' HB3' ' HB3' ' A' ' 183' ' ' PRO . . . -77.65 -16.42 58.54 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.672 0.272 . . . . 0.0 111.613 -179.739 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 117' ' ' MET . . . . . 0.458 ' HG3' HG21 ' A' ' 68' ' ' VAL . 29.7 ttm -101.85 19.22 18.69 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.407 -0.361 . . . . 0.0 111.341 -179.506 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 118' ' ' VAL . . . . . 0.545 HG22 ' HB3' ' A' ' 123' ' ' ARG . 21.4 m -70.15 145.49 93.75 Favored Pre-proline 0 C--N 1.33 -0.245 0 CA-C-N 116.432 -0.349 . . . . 0.0 111.502 179.982 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 119' ' ' PRO . . . . . . . . . . . . . 85.9 Cg_endo -93.4 15.8 1.33 Allowed 'Trans proline' 0 N--CA 1.456 -0.732 0 C-N-CA 122.997 2.465 . . . . 0.0 112.353 179.419 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -164.62 -120.38 0.52 Allowed Glycine 0 C--N 1.332 0.339 0 C-N-CA 120.66 -0.781 . . . . 0.0 112.674 -179.564 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 40.9 pt -114.68 9.84 7.74 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.232 0 CA-C-O 120.723 0.297 . . . . 0.0 111.493 -179.727 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 45.7 mt-10 -58.84 -18.08 29.48 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.304 -0.407 . . . . 0.0 110.699 179.725 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 123' ' ' ARG . . . . . 0.545 ' HB3' HG22 ' A' ' 118' ' ' VAL . 10.2 ptp180 -50.5 -33.24 20.65 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 115.794 -0.639 . . . . 0.0 111.642 -179.959 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 124' ' ' TYR . . . . . . . . . . . . . 19.3 m-85 -73.11 -32.63 65.07 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.428 -0.351 . . . . 0.0 111.513 -179.459 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 125' ' ' ALA . . . . . . . . . . . . . . . -74.32 -56.11 5.25 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.386 -0.37 . . . . 0.0 111.398 -179.492 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -55.09 -44.19 74.66 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.904 -179.931 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 127' ' ' PHE . . . . . . . . . . . . . 5.4 t80 -70.92 -37.21 72.89 Favored 'General case' 0 C--N 1.33 -0.279 0 C-N-CA 120.898 -0.321 . . . . 0.0 110.575 179.825 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 128' ' ' GLY . . . . . . . . . . . . . . . -46.79 -46.85 19.03 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.167 -1.016 . . . . 0.0 110.844 179.052 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 129' ' ' MET . . . . . . . . . . . . . 0.4 OUTLIER -69.69 -38.84 77.16 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 115.367 -0.417 . . . . 0.0 109.894 178.781 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -62.87 -29.3 73.71 Favored Glycine 0 C--N 1.333 0.38 0 CA-C-N 115.892 -0.595 . . . . 0.0 112.792 -179.893 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -74.29 -53.61 9.37 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 120.761 0.315 . . . . 0.0 110.317 179.871 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 28.3 t -58.03 -40.07 75.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 N-CA-C 109.321 -0.622 . . . . 0.0 109.321 178.741 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -68.64 -33.4 73.94 Favored 'General case' 0 N--CA 1.454 -0.259 0 CA-C-N 115.387 -0.824 . . . . 0.0 110.342 179.177 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 134' ' ' PHE . . . . . . . . . . . . . 44.1 t80 -57.77 -55.14 38.7 Favored 'General case' 0 N--CA 1.452 -0.34 0 CA-C-N 116.132 -0.486 . . . . 0.0 109.752 179.239 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 135' ' ' ILE . . . . . 0.432 ' O ' HG23 ' A' ' 138' ' ' VAL . 39.2 mt -57.69 -31.87 40.97 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 115.673 -0.694 . . . . 0.0 109.86 178.861 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . -64.19 -35.31 91.81 Favored Glycine 0 N--CA 1.448 -0.515 0 C-N-CA 120.488 -0.863 . . . . 0.0 111.577 179.13 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 137' ' ' LEU . . . . . . . . . . . . . 38.9 tp -73.44 -51.13 18.3 Favored 'General case' 0 C--N 1.331 -0.205 0 CA-C-O 120.628 0.252 . . . . 0.0 110.51 179.492 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 138' ' ' VAL . . . . . 0.432 HG23 ' O ' ' A' ' 135' ' ' ILE . 4.0 m -57.37 -30.96 37.04 Favored 'Isoleucine or valine' 0 C--O 1.233 0.208 0 N-CA-C 109.376 -0.601 . . . . 0.0 109.376 179.048 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 139' ' ' TYR . . . . . . . . . . . . . 24.9 t80 -66.19 -43.34 87.12 Favored 'General case' 0 C--N 1.332 -0.196 0 CA-C-N 115.324 -0.853 . . . . 0.0 110.15 178.706 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 140' ' ' TYR . . . . . 0.425 ' HB3' ' SD ' ' A' ' 145' ' ' MET . 11.9 m-85 -53.06 -51.62 61.22 Favored 'General case' 0 C--O 1.231 0.13 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.514 179.355 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 141' ' ' LEU . . . . . . . . . . . . . 70.5 mt -53.39 -53.56 49.39 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 115.726 -0.67 . . . . 0.0 111.213 -179.788 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 17.2 t -73.42 -11.29 14.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.113 -0.494 . . . . 0.0 111.334 -179.623 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . -71.45 -140.91 0.26 Allowed Glycine 0 CA--C 1.52 0.354 0 C-N-CA 120.832 -0.699 . . . . 0.0 112.635 -179.799 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 144' ' ' PRO . . . . . . . . . . . . . 32.2 Cg_endo -62.99 -23.25 74.08 Favored 'Trans proline' 0 C--N 1.347 0.493 0 C-N-CA 122.486 2.124 . . . . 0.0 112.121 -179.991 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 145' ' ' MET . . . . . 0.46 ' HE2' HD12 ' A' ' 93' ' ' LEU . 82.4 mtp -57.61 -27.9 63.18 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 116.024 -0.535 . . . . 0.0 110.975 179.921 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 146' ' ' THR . . . . . . . . . . . . . 60.0 m -71.89 -40.79 68.64 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.308 -0.406 . . . . 0.0 111.042 179.82 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 2.2 mp0 -74.25 -27.57 60.83 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.008 -179.835 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 148' ' ' SER . . . . . . . . . . . . . 49.1 m -70.19 -43.16 71.33 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.388 -0.369 . . . . 0.0 111.085 -179.882 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 149' ' ' ALA . . . . . 0.466 ' HA ' ' HA ' ' A' ' 91' ' ' ALA . . . -77.84 -44.08 28.41 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.845 -179.457 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 150' ' ' SER . . . . . . . . . . . . . 66.3 m -63.72 -21.97 66.67 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.388 -0.369 . . . . 0.0 111.443 -179.451 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 151' ' ' GLN . . . . . . . . . . . . . 78.7 mt-30 -106.87 6.49 29.41 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.51 -0.314 . . . . 0.0 111.298 -179.784 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 30.2 tpt180 -82.58 -50.31 8.92 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.437 -0.347 . . . . 0.0 110.729 179.823 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 153' ' ' SER . . . . . 0.515 ' HB2' HG13 ' A' ' 156' ' ' ILE . 45.8 m -154.55 149.34 26.59 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.824 179.267 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 154' ' ' SER . . . . . . . . . . . . . 42.7 t -55.24 -40.37 70.83 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.113 -0.494 . . . . 0.0 111.055 179.947 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -75.01 -35.93 48.23 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.79 -0.719 . . . . 0.0 112.562 179.994 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 156' ' ' ILE . . . . . 0.515 HG13 ' HB2' ' A' ' 153' ' ' SER . 68.9 mt -60.95 -36.22 70.58 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-O 120.707 0.289 . . . . 0.0 111.307 -179.948 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 157' ' ' LYS . . . . . . . . . . . . . 88.6 tttt -52.9 -45.66 67.64 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-N 116.187 -0.461 . . . . 0.0 111.499 -179.783 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 48.4 t -71.83 -37.41 70.32 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 121.003 0.43 . . . . 0.0 111.29 -179.558 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 159' ' ' LEU . . . . . . . . . . . . . 78.0 mt -65.85 -39.18 90.52 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-N 115.936 -0.575 . . . . 0.0 111.643 -179.413 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 160' ' ' TYR . . . . . . . . . . . . . 45.5 t80 -73.94 -44.37 55.19 Favored 'General case' 0 C--N 1.327 -0.401 0 N-CA-C 112.155 0.428 . . . . 0.0 112.155 -178.647 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 161' ' ' VAL . . . . . 0.4 HG23 ' N ' ' A' ' 162' ' ' ARG . 30.8 m -59.86 -43.96 93.15 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 N-CA-C 112.226 0.454 . . . . 0.0 112.226 -178.916 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 162' ' ' ARG . . . . . 0.429 ' O ' HD11 ' A' ' 166' ' ' LEU . 93.8 mtt180 -69.16 -50.74 44.98 Favored 'General case' 0 C--N 1.33 -0.269 0 N-CA-C 112.18 0.437 . . . . 0.0 112.18 -179.134 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 163' ' ' LEU . . . . . . . . . . . . . 7.5 mp -65.71 -43.83 87.92 Favored 'General case' 0 C--N 1.33 -0.254 0 N-CA-C 111.789 0.292 . . . . 0.0 111.789 -179.06 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 164' ' ' ARG . . . . . . . . . . . . . 6.1 tmm_? -57.42 -50.98 71.26 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-N 116.56 -0.291 . . . . 0.0 111.004 -179.693 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 165' ' ' ASN . . . . . 0.503 ' N ' HD21 ' A' ' 165' ' ' ASN . 0.9 OUTLIER -53.04 -44.99 67.81 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-O 120.934 0.397 . . . . 0.0 110.346 179.809 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 166' ' ' LEU . . . . . 0.451 ' HB3' ' CE1' ' A' ' 208' ' ' PHE . 1.5 mt -60.05 -48.65 80.82 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 115.931 -0.577 . . . . 0.0 111.2 179.478 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 167' ' ' THR . . . . . 0.553 ' HA ' HD11 ' A' ' 170' ' ' LEU . 12.0 m -53.68 -51.0 64.59 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.021 -0.536 . . . . 0.0 112.218 -178.265 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 168' ' ' VAL . . . . . . . . . . . . . 27.0 t -59.26 -40.6 81.66 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.566 0 N-CA-C 112.105 0.409 . . . . 0.0 112.105 -179.061 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 169' ' ' VAL . . . . . 0.412 ' O ' HG12 ' A' ' 173' ' ' ILE . 83.9 t -66.08 -66.82 0.45 Allowed 'Isoleucine or valine' 0 CA--C 1.533 0.3 0 N-CA-C 113.557 0.947 . . . . 0.0 113.557 -178.194 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 170' ' ' LEU . . . . . 0.553 HD11 ' HA ' ' A' ' 167' ' ' THR . 0.4 OUTLIER -61.66 -32.18 72.34 Favored 'General case' 0 N--CA 1.467 0.388 0 N-CA-C 112.974 0.731 . . . . 0.0 112.974 -177.529 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 171' ' ' TRP . . . . . 0.484 ' HB2' ' O ' ' A' ' 167' ' ' THR . 21.4 m0 -73.53 -29.54 62.52 Favored 'General case' 0 C--N 1.329 -0.323 0 C-N-CA 120.371 -0.531 . . . . 0.0 111.087 -179.619 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 172' ' ' ALA . . . . . . . . . . . . . . . -72.24 -7.87 51.68 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-O 121.011 0.434 . . . . 0.0 110.253 179.499 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 173' ' ' ILE . . . . . 0.476 HG21 HD12 ' A' ' 177' ' ' ILE . 18.5 mm -88.92 -25.42 5.75 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.21 0 CA-C-N 115.789 -0.642 . . . . 0.0 110.939 179.528 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 174' ' ' TYR . . . . . 0.481 ' HD1' ' HA ' ' A' ' 171' ' ' TRP . 16.1 m-85 -54.62 -48.54 94.94 Favored Pre-proline 0 CA--C 1.531 0.218 0 CA-C-N 116.104 -0.498 . . . . 0.0 112.156 -179.384 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 175' ' ' PRO . . . . . . . . . . . . . 74.8 Cg_exo -47.07 -29.99 9.55 Favored 'Trans proline' 0 C--N 1.352 0.747 0 C-N-CA 121.909 1.739 . . . . 0.0 111.808 179.677 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 176' ' ' PHE . . . . . 0.481 ' O ' ' HG ' ' A' ' 180' ' ' LEU . 72.0 m-85 -80.35 -49.89 10.89 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 115.713 -0.676 . . . . 0.0 111.37 179.687 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 177' ' ' ILE . . . . . 0.476 HD12 HG21 ' A' ' 173' ' ' ILE . 3.6 mm -59.28 -36.25 62.5 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.525 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.722 -178.632 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 178' ' ' TRP . . . . . 0.402 ' O ' ' HB2' ' A' ' 183' ' ' PRO . 58.7 t90 -73.3 -51.82 16.18 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-O 121.066 0.46 . . . . 0.0 110.658 179.879 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 179' ' ' LEU . . . . . 0.506 HD12 HG22 ' A' ' 185' ' ' VAL . 1.4 tm? -61.07 -53.4 57.54 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 115.701 -0.681 . . . . 0.0 111.56 -179.159 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 180' ' ' LEU . . . . . 0.591 HD22 HD12 ' A' ' 187' ' ' LEU . 12.5 mt -74.78 -29.47 61.13 Favored 'General case' 0 C--N 1.327 -0.385 0 N-CA-C 112.2 0.444 . . . . 0.0 112.2 -178.861 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . -71.42 -177.66 27.28 Favored Glycine 0 N--CA 1.45 -0.407 0 C-N-CA 119.977 -1.106 . . . . 0.0 112.173 179.777 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 182' ' ' PRO . . . . . 0.424 ' N ' ' CD ' ' A' ' 183' ' ' PRO . 76.8 Cg_exo -47.93 -43.36 30.05 Favored 'Trans proline' 0 CA--C 1.538 0.681 0 C-N-CA 122.649 2.233 . . . . 0.0 113.386 179.527 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 183' ' ' PRO . . . . . 0.541 ' HB3' ' HB3' ' A' ' 116' ' ' ALA . 65.9 Cg_exo -41.54 -31.87 1.27 Allowed 'Trans proline' 0 C--N 1.358 1.046 0 C-N-CA 122.609 2.206 . . . . 0.0 113.601 179.824 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 184' ' ' GLY . . . . . . . . . . . . . . . -130.03 -107.65 1.24 Allowed Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.413 -0.899 . . . . 0.0 112.323 180.0 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 185' ' ' VAL . . . . . 0.513 ' O ' HG21 ' A' ' 185' ' ' VAL . 27.4 m -92.41 89.87 2.96 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.44 0 CA-C-O 121.414 0.626 . . . . 0.0 110.365 179.668 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 186' ' ' ALA . . . . . . . . . . . . . . . -56.94 86.7 0.01 OUTLIER 'General case' 0 C--N 1.325 -0.491 0 CA-C-N 115.687 -0.688 . . . . 0.0 111.855 -179.448 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 187' ' ' LEU . . . . . 0.591 HD12 HD22 ' A' ' 180' ' ' LEU . 12.5 mt -74.8 -48.91 22.8 Favored 'General case' 0 C--N 1.331 -0.199 0 CA-C-O 120.985 0.422 . . . . 0.0 110.361 179.236 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 188' ' ' LEU . . . . . . . . . . . . . 63.4 mt -97.8 -147.97 0.32 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 115.775 -0.648 . . . . 0.0 110.65 -179.87 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 189' ' ' THR . . . . . . . . . . . . . 1.2 t -111.8 148.46 39.0 Favored Pre-proline 0 C--N 1.331 -0.231 0 CA-C-N 116.276 -0.42 . . . . 0.0 110.813 -179.964 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 190' ' ' PRO . . . . . . . . . . . . . 7.3 Cg_endo -49.12 -42.14 39.75 Favored 'Trans proline' 0 C--N 1.349 0.57 0 C-N-CA 123.027 2.485 . . . . 0.0 113.261 -179.474 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 191' ' ' THR . . . . . . . . . . . . . 7.6 t -59.54 -40.86 88.6 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.65 0.262 . . . . 0.0 111.598 -179.341 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 192' ' ' VAL . . . . . . . . . . . . . 42.3 t -71.94 -47.92 53.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.499 -0.319 . . . . 0.0 111.398 -179.809 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 193' ' ' ASP . . . . . . . . . . . . . 30.7 t70 -57.99 -51.2 70.65 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.742 0.306 . . . . 0.0 111.038 -179.815 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 194' ' ' VAL . . . . . . . . . . . . . 97.8 t -59.88 -36.15 64.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.883 179.973 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 195' ' ' ALA . . . . . . . . . . . . . . . -58.1 -46.1 86.1 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.542 -0.299 . . . . 0.0 110.942 179.697 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 196' ' ' LEU . . . . . . . . . . . . . 86.3 mt -65.69 -41.34 92.5 Favored 'General case' 0 C--N 1.332 -0.171 0 CA-C-N 116.368 -0.378 . . . . 0.0 110.404 179.596 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 197' ' ' ILE . . . . . . . . . . . . . 19.9 mm -58.56 -58.26 7.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 115.995 -0.548 . . . . 0.0 110.239 179.366 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 198' ' ' VAL . . . . . . . . . . . . . 94.6 t -53.27 -34.52 22.39 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.416 0 CA-C-N 115.736 -0.665 . . . . 0.0 109.276 178.281 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 199' ' ' TYR . . . . . . . . . . . . . 65.4 t80 -69.7 -33.66 72.83 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 115.295 -0.866 . . . . 0.0 110.519 179.604 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 200' ' ' LEU . . . . . . . . . . . . . 40.7 mt -69.6 -39.62 77.14 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 115.855 -0.611 . . . . 0.0 111.019 -179.807 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 201' ' ' ASP . . . . . 0.452 ' HB3' ' NZ ' ' A' ' 205' ' ' LYS . 9.6 m-20 -72.86 -32.23 65.28 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.41 179.749 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 202' ' ' LEU . . . . . 0.458 ' O ' ' HB ' ' A' ' 206' ' ' VAL . 3.7 mt -73.04 -33.13 65.51 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 115.656 -0.702 . . . . 0.0 112.014 -179.376 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 203' ' ' VAL . . . . . 0.45 ' O ' ' HA3' ' A' ' 207' ' ' GLY . 7.8 p -77.9 -36.66 22.39 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-O 120.582 0.23 . . . . 0.0 111.432 -178.801 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 204' ' ' THR . . . . . . . . . . . . . 19.1 m -68.91 -53.62 20.06 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-O 120.877 0.37 . . . . 0.0 111.407 -179.956 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 205' ' ' LYS . . . . . 0.645 ' HD2' ' HE2' ' A' ' 15' ' ' MET . 43.9 mttp -70.73 -58.68 3.39 Favored 'General case' 0 C--N 1.327 -0.405 0 N-CA-C 112.435 0.531 . . . . 0.0 112.435 -178.569 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 206' ' ' VAL . . . . . 0.458 ' HB ' ' O ' ' A' ' 202' ' ' LEU . 48.1 t -72.25 -37.43 58.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 N-CA-C 111.952 0.353 . . . . 0.0 111.952 -178.878 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 207' ' ' GLY . . . . . 0.493 ' O ' HG13 ' A' ' 211' ' ' ILE . . . -65.37 -59.88 7.32 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.442 -0.885 . . . . 0.0 112.516 -179.366 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 208' ' ' PHE . . . . . 0.482 ' O ' ' N ' ' A' ' 212' ' ' ALA . 2.1 m-30 -54.19 -45.17 72.1 Favored 'General case' 0 C--O 1.222 -0.388 0 N-CA-C 109.947 -0.39 . . . . 0.0 109.947 179.772 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 209' ' ' GLY . . . . . 0.451 ' O ' ' HG ' ' A' ' 213' ' ' LEU . . . -59.07 -34.22 78.28 Favored Glycine 0 N--CA 1.448 -0.515 0 CA-C-N 115.376 -0.829 . . . . 0.0 112.821 179.43 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 210' ' ' PHE . . . . . . . . . . . . . 1.2 m-85 -70.26 -46.8 63.67 Favored 'General case' 0 CA--C 1.515 -0.369 0 N-CA-C 108.754 -0.832 . . . . 0.0 108.754 179.163 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 211' ' ' ILE . . . . . 0.493 HG13 ' O ' ' A' ' 207' ' ' GLY . 2.6 mt -67.4 -27.42 38.7 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.473 0 N-CA-C 107.416 -1.327 . . . . 0.0 107.416 176.846 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 212' ' ' ALA . . . . . 0.482 ' N ' ' O ' ' A' ' 208' ' ' PHE . . . -66.84 -40.09 87.83 Favored 'General case' 0 N--CA 1.449 -0.525 0 CA-C-N 114.32 -1.309 . . . . 0.0 110.214 -179.991 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 213' ' ' LEU . . . . . 0.451 ' HG ' ' O ' ' A' ' 209' ' ' GLY . 69.7 mt -70.68 -54.77 10.59 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 114.991 -1.004 . . . . 0.0 111.744 -179.555 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 214' ' ' ASP . . . . . . . . . . . . . 20.6 t70 -54.38 -47.19 72.95 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-O 120.758 0.313 . . . . 0.0 111.42 -179.464 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 215' ' ' ALA . . . . . . . . . . . . . . . -63.69 -56.17 17.8 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.309 -0.405 . . . . 0.0 111.171 -179.781 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 216' ' ' ALA . . . . . . . . . . . . . . . -56.24 -31.22 63.33 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.834 179.924 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 217' ' ' ALA . . . . . . . . . . . . . . . -65.97 -40.56 91.38 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 115.991 -0.549 . . . . 0.0 110.431 179.767 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 218' ' ' THR . . . . . . . . . . . . . 72.7 m . . . . . 0 C--N 1.329 -0.299 0 CA-C-N 115.957 -0.565 . . . . 0.0 110.437 179.41 . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.251 0 N-CA-C 112.685 -0.166 . . . . 0.0 112.685 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 96.6 mt -61.04 -35.44 76.91 Favored 'General case' 0 N--CA 1.448 -0.529 0 CA-C-O 120.758 0.313 . . . . 0.0 111.118 179.961 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 46.6 p -51.48 -36.92 46.52 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 116.013 -0.54 . . . . 0.0 111.68 -179.472 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 20.4 p -56.79 -38.94 73.23 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.209 -0.451 . . . . 0.0 111.576 -179.542 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 7' ' ' LEU . . . . . . . . . . . . . 3.9 mm? -61.81 -53.51 54.88 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.265 -0.425 . . . . 0.0 111.304 -179.716 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 8' ' ' PHE . . . . . . . . . . . . . 68.5 m-85 -55.43 -31.93 62.3 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.255 -0.429 . . . . 0.0 111.108 -179.607 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 9' ' ' TRP . . . . . 0.403 ' O ' HG12 ' A' ' 13' ' ' ILE . 21.7 m95 -66.01 -42.78 89.26 Favored 'General case' 0 C--N 1.326 -0.447 0 N-CA-C 109.695 -0.484 . . . . 0.0 109.695 179.694 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 84.6 mt -61.08 -38.97 88.14 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 115.62 -0.718 . . . . 0.0 110.238 179.223 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -65.84 -35.55 91.0 Favored Glycine 0 N--CA 1.449 -0.437 0 C-N-CA 120.85 -0.691 . . . . 0.0 111.865 179.349 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -65.6 -32.58 74.23 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-O 120.892 0.377 . . . . 0.0 110.672 179.585 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 13' ' ' ILE . . . . . 0.403 HG12 ' O ' ' A' ' 9' ' ' TRP . 50.5 mm -67.35 -51.03 56.94 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.245 0 CA-C-N 116.034 -0.53 . . . . 0.0 110.654 179.667 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -58.6 -31.6 67.45 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.141 179.669 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 15' ' ' MET . . . . . 0.616 ' HE1' ' HD2' ' A' ' 205' ' ' LYS . 23.9 mmt -69.89 -40.91 75.38 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-O 120.722 0.296 . . . . 0.0 110.64 179.661 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -57.47 -43.66 84.23 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.307 179.54 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 42.5 t -61.41 -49.83 82.86 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.214 0 CA-C-N 116.065 -0.516 . . . . 0.0 110.955 179.846 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -62.36 -48.27 83.59 Favored Glycine 0 C--N 1.331 0.285 0 C-N-CA 120.651 -0.785 . . . . 0.0 112.206 179.708 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 50.3 m -49.93 -41.13 45.55 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-O 120.67 0.271 . . . . 0.0 111.378 -179.754 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 52.3 mt -72.53 -46.06 56.35 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.329 -0.396 . . . . 0.0 111.41 179.903 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -60.59 -29.71 69.37 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.315 -0.402 . . . . 0.0 111.654 -179.604 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 22' ' ' PHE . . . . . 0.427 ' HB2' HG22 ' A' ' 41' ' ' VAL . 5.1 m-85 -91.23 -30.01 16.88 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.515 -0.311 . . . . 0.0 111.436 -179.56 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -72.66 -50.55 24.26 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-O 120.949 0.404 . . . . 0.0 110.997 -179.971 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 24' ' ' TRP . . . . . . . . . . . . . 2.8 t-105 -61.23 -39.49 90.48 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-N 115.737 -0.665 . . . . 0.0 110.501 179.806 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.329 -0.321 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.756 179.549 . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.257 0 N-CA-C 112.6 -0.2 . . . . 0.0 112.6 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 22.8 mm-40 -61.31 -21.14 63.7 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.757 0.313 . . . . 0.0 111.007 -179.935 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 34' ' ' ARG . . . . . . . . . . . . . 48.6 ttp180 -51.17 -29.63 14.4 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 116.043 -0.526 . . . . 0.0 111.271 -179.959 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 35' ' ' ARG . . . . . 0.403 ' CZ ' HD21 ' A' ' 89' ' ' LEU . 51.8 ttp180 -59.47 -48.19 82.58 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.326 -0.397 . . . . 0.0 111.075 -179.994 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 53.5 m-85 -64.43 -34.61 78.59 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.984 -179.922 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 37' ' ' TYR . . . . . . . . . . . . . 63.6 m-85 -66.84 -54.15 25.32 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 115.993 -0.549 . . . . 0.0 111.05 -179.762 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 77.7 t -56.98 -37.05 52.67 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.242 0 CA-C-O 120.889 0.376 . . . . 0.0 110.455 179.723 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 24.2 m -66.73 -40.24 88.27 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 121.355 0.598 . . . . 0.0 110.171 179.044 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 12.7 tp -65.5 -41.87 92.75 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 115.258 -0.883 . . . . 0.0 110.372 179.757 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . 0.427 HG22 ' HB2' ' A' ' 22' ' ' PHE . 59.7 t -69.68 -34.17 59.85 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.426 0 CA-C-N 115.561 -0.745 . . . . 0.0 110.312 179.379 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 42' ' ' GLY . . . . . 0.464 ' O ' HG12 ' A' ' 46' ' ' ILE . . . -59.26 -46.57 93.63 Favored Glycine 0 N--CA 1.448 -0.541 0 C-N-CA 120.971 -0.633 . . . . 0.0 112.554 179.999 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 43' ' ' ILE . . . . . 0.465 HG23 HD23 ' A' ' 82' ' ' LEU . 10.2 pt -65.63 -51.57 61.21 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.157 0 N-CA-C 111.729 0.27 . . . . 0.0 111.729 -179.767 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 48.1 t -63.84 -24.19 67.65 Favored 'General case' 0 C--O 1.234 0.247 0 CA-C-O 120.924 0.392 . . . . 0.0 111.396 -179.762 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -78.14 -59.05 3.02 Favored Glycine 0 CA--C 1.518 0.22 0 C-N-CA 120.92 -0.657 . . . . 0.0 113.466 -178.856 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 46' ' ' ILE . . . . . 0.464 HG12 ' O ' ' A' ' 42' ' ' GLY . 17.7 pt -57.79 -35.29 50.62 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.207 0 CA-C-O 120.751 0.31 . . . . 0.0 110.957 -179.606 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 47' ' ' ALA . . . . . 0.633 ' HB1' ' HE2' ' A' ' 205' ' ' LYS . . . -67.62 -40.12 84.7 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-O 120.841 0.353 . . . . 0.0 110.085 178.559 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 48' ' ' ALA . . . . . 0.492 ' HB2' ' HB3' ' A' ' 15' ' ' MET . . . -54.48 -43.39 71.69 Favored 'General case' 0 C--N 1.334 -0.101 0 CA-C-N 115.987 -0.551 . . . . 0.0 111.291 179.801 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 49' ' ' VAL . . . . . 0.464 ' O ' HG12 ' A' ' 53' ' ' VAL . 21.4 m -75.62 -34.36 28.88 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.221 0 CA-C-N 116.463 -0.335 . . . . 0.0 111.452 -179.82 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -59.12 -45.5 90.75 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.824 0.345 . . . . 0.0 111.392 -179.849 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 51' ' ' TYR . . . . . 0.579 ' HH ' ' HB2' ' A' ' 201' ' ' ASP . 57.6 m-85 -73.16 -40.15 65.08 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 115.919 -0.582 . . . . 0.0 111.257 -179.31 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -60.64 -47.03 88.04 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 115.886 -0.597 . . . . 0.0 111.318 -179.921 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 53' ' ' VAL . . . . . 0.464 HG12 ' O ' ' A' ' 49' ' ' VAL . 16.8 m -71.89 -43.14 69.07 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.243 0 CA-C-N 116.324 -0.398 . . . . 0.0 110.969 -179.876 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 54' ' ' MET . . . . . . . . . . . . . 17.0 ttp -63.71 -29.49 70.71 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 121.085 0.469 . . . . 0.0 110.101 179.509 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -63.84 -36.22 83.2 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 115.63 -0.714 . . . . 0.0 111.539 179.773 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 78.6 mt -80.99 13.15 2.85 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.475 -0.33 . . . . 0.0 111.427 -179.626 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 84.39 -2.21 88.09 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.638 -0.792 . . . . 0.0 112.87 179.712 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 55.0 t -68.83 141.69 17.14 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-O 120.732 0.301 . . . . 0.0 110.768 179.777 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 59' ' ' GLY . . . . . 0.596 ' HA3' ' HD3' ' A' ' 71' ' ' PRO . . . 86.18 -16.07 45.62 Favored Glycine 0 N--CA 1.45 -0.411 0 C-N-CA 120.595 -0.812 . . . . 0.0 112.275 -179.857 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 60' ' ' TRP . . . . . . . . . . . . . 13.7 m0 -66.88 92.94 0.24 Allowed 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 120.825 0.345 . . . . 0.0 110.602 179.665 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 7.1 p -96.23 123.25 55.57 Favored Pre-proline 0 C--N 1.328 -0.347 0 CA-C-N 116.303 -0.408 . . . . 0.0 111.211 -179.832 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 46.5 Cg_endo -68.41 141.03 49.89 Favored 'Trans proline' 0 C--N 1.35 0.649 0 C-N-CA 122.403 2.068 . . . . 0.0 112.231 179.93 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 60.2 t -137.31 92.69 0.91 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.046 -0.525 . . . . 0.0 111.172 -179.789 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . 58.09 -88.93 0.02 OUTLIER 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 116.178 -0.465 . . . . 0.0 111.514 179.789 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 45.4 mt-10 -120.42 -17.98 8.01 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 116.486 -0.324 . . . . 0.0 110.856 179.973 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 66' ' ' ARG . . . . . . . . . . . . . 20.9 mmm180 -105.03 165.51 11.03 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 116.064 -0.516 . . . . 0.0 110.344 179.776 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 38.4 m -122.52 143.15 49.9 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-O 120.834 0.349 . . . . 0.0 111.201 -179.805 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 40.0 t -125.19 146.0 31.6 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.02 -0.537 . . . . 0.0 110.879 -179.991 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 69' ' ' PHE . . . . . . . . . . . . . 8.3 m-85 -109.31 114.32 27.9 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.371 -0.377 . . . . 0.0 110.161 179.837 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 70' ' ' VAL . . . . . 0.603 HG11 ' HD3' ' A' ' 71' ' ' PRO . 1.3 p -68.26 -35.64 7.58 Favored Pre-proline 0 CA--C 1.542 0.653 0 N-CA-C 112.945 0.72 . . . . 0.0 112.945 -179.34 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 71' ' ' PRO . . . . . 0.603 ' HD3' HG11 ' A' ' 70' ' ' VAL . 61.9 Cg_endo -71.16 -20.82 27.97 Favored 'Trans proline' 0 C--N 1.359 1.116 0 C-N-CA 121.822 1.681 . . . . 0.0 113.266 -179.352 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 66.7 ttt180 -74.23 -54.96 6.65 Favored 'General case' 0 C--N 1.329 -0.32 0 N-CA-C 112.019 0.377 . . . . 0.0 112.019 -178.993 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 73' ' ' TYR . . . . . 0.48 ' O ' HG13 ' A' ' 77' ' ' ILE . 65.9 m-85 -74.08 -32.84 63.42 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.533 -0.303 . . . . 0.0 111.526 -178.803 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 0.3 OUTLIER -70.23 -44.53 77.72 Favored 'Isoleucine or valine' 0 C--O 1.234 0.257 0 C-N-CA 120.615 -0.434 . . . . 0.0 110.18 179.486 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 22.9 t70 -58.33 -35.89 72.58 Favored 'General case' 0 CA--C 1.52 -0.2 0 N-CA-C 109.094 -0.706 . . . . 0.0 109.094 178.959 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 76' ' ' TRP . . . . . 0.42 ' HA ' ' OG1' ' A' ' 79' ' ' THR . 44.7 m0 -64.95 -34.9 79.53 Favored 'General case' 0 C--N 1.332 -0.164 0 CA-C-N 115.769 -0.651 . . . . 0.0 110.228 178.801 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 77' ' ' ILE . . . . . 0.49 HG12 ' HB3' ' A' ' 109' ' ' MET . 98.0 mt -66.21 -30.42 49.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 115.981 -0.554 . . . . 0.0 110.745 179.561 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 82.0 mt -91.88 -17.89 24.58 Favored 'General case' 0 CA--C 1.532 0.257 0 N-CA-C 112.278 0.473 . . . . 0.0 112.278 179.644 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 79' ' ' THR . . . . . 0.42 ' OG1' ' HA ' ' A' ' 76' ' ' TRP . 46.9 p -94.65 -51.65 4.64 Favored 'General case' 0 N--CA 1.465 0.319 0 N-CA-C 112.974 0.731 . . . . 0.0 112.974 -178.486 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 80' ' ' THR . . . . . 0.52 ' N ' ' HD2' ' A' ' 81' ' ' PRO . 27.5 m -50.25 -51.03 66.81 Favored Pre-proline 0 C--N 1.328 -0.354 0 N-CA-C 112.95 0.722 . . . . 0.0 112.95 -178.425 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 81' ' ' PRO . . . . . 0.52 ' HD2' ' N ' ' A' ' 80' ' ' THR . 19.4 Cg_endo -57.94 -23.57 60.44 Favored 'Trans proline' 0 C--N 1.352 0.732 0 C-N-CA 121.526 1.484 . . . . 0.0 111.703 -179.48 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 82' ' ' LEU . . . . . 0.465 HD23 HG23 ' A' ' 43' ' ' ILE . 3.5 mp -76.91 -38.36 53.63 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 115.923 -0.58 . . . . 0.0 110.704 179.834 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 49.9 mm -65.42 -53.44 39.82 Favored 'Isoleucine or valine' 0 C--O 1.234 0.267 0 CA-C-O 120.936 0.398 . . . . 0.0 110.221 179.371 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 26.8 m -60.68 -31.66 49.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.04 -0.527 . . . . 0.0 109.774 178.983 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 85' ' ' TYR . . . . . . . . . . . . . 87.7 t80 -67.81 -34.09 76.07 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-N 115.697 -0.683 . . . . 0.0 109.442 178.755 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 86' ' ' PHE . . . . . . . . . . . . . 1.8 t80 -58.95 -51.82 68.39 Favored 'General case' 0 C--O 1.233 0.225 0 CA-C-N 115.828 -0.624 . . . . 0.0 109.81 179.319 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 7.8 mp -63.87 -33.63 76.13 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 115.865 -0.607 . . . . 0.0 110.013 179.216 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -61.44 -28.34 69.35 Favored Glycine 0 N--CA 1.449 -0.454 0 C-N-CA 120.784 -0.722 . . . . 0.0 111.566 179.191 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 89' ' ' LEU . . . . . 0.403 HD21 ' CZ ' ' A' ' 35' ' ' ARG . 82.1 mt -79.04 -36.61 40.76 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.953 0.406 . . . . 0.0 110.165 179.325 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 97.0 mt -63.18 -37.67 88.13 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 115.821 -0.627 . . . . 0.0 111.017 179.802 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 91' ' ' ALA . . . . . 0.507 ' HB3' ' HB2' ' A' ' 148' ' ' SER . . . -87.22 -54.57 4.23 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.328 -179.837 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 103.33 70.6 0.84 Allowed Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.831 -0.699 . . . . 0.0 112.415 -179.775 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 93' ' ' LEU . . . . . 0.571 HD11 ' HG2' ' A' ' 145' ' ' MET . 7.5 mp -87.99 166.8 14.23 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.81 0.338 . . . . 0.0 111.047 -179.843 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 94' ' ' ASP . . . . . . . . . . . . . 7.9 m-20 -84.5 174.35 10.11 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.887 179.779 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 88.8 p -60.09 -35.72 75.82 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.308 -0.406 . . . . 0.0 111.004 -179.788 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 69.7 mtm180 -72.9 -48.79 34.2 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.148 -179.835 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 97' ' ' GLU . . . . . 0.564 ' HB2' ' HB3' ' A' ' 93' ' ' LEU . 37.5 mt-10 -56.16 -46.59 79.23 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.295 -0.412 . . . . 0.0 111.235 -179.73 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 98' ' ' PHE . . . . . . . . . . . . . 6.5 m-85 -55.88 -50.59 70.23 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.366 -0.379 . . . . 0.0 111.07 -179.951 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -55.59 -34.28 60.14 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.858 -0.687 . . . . 0.0 112.637 -179.867 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 97.8 mt -66.82 -44.13 89.31 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.207 0 CA-C-O 120.773 0.32 . . . . 0.0 111.803 -179.748 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 25.0 t -68.59 -46.93 79.24 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.369 0 CA-C-N 116.263 -0.426 . . . . 0.0 111.936 -179.045 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 102' ' ' ILE . . . . . . . . . . . . . 36.2 mm -63.64 -48.63 85.87 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 CA-C-N 116.283 -0.417 . . . . 0.0 111.922 -179.014 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 12.0 t -61.04 -37.2 81.75 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-O 120.761 0.315 . . . . 0.0 111.23 -179.528 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 10.1 tt -60.91 -42.93 99.01 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.411 179.721 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 105' ' ' ASN . . . . . 0.582 HD22 HD13 ' A' ' 137' ' ' LEU . 0.8 OUTLIER -67.68 -26.35 66.15 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.605 179.614 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 56.6 m -63.5 -53.57 49.98 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 115.941 -0.572 . . . . 0.0 111.149 179.82 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 7.8 p -63.93 -36.13 75.7 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.162 0 CA-C-N 116.336 -0.393 . . . . 0.0 111.127 179.919 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 79.6 t -63.3 -51.71 67.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-O 121.201 0.524 . . . . 0.0 110.604 179.44 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 109' ' ' MET . . . . . 0.498 ' HE2' HG21 ' A' ' 80' ' ' THR . 3.5 tpp -60.49 -33.73 73.02 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 115.67 -0.695 . . . . 0.0 110.422 179.759 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 20.8 tp -68.91 -33.52 73.88 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 115.9 -0.591 . . . . 0.0 110.166 179.693 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 111' ' ' ALA . . . . . 0.417 ' HB1' ' HE2' ' A' ' 129' ' ' MET . . . -59.7 -57.1 14.39 Favored 'General case' 0 C--N 1.332 -0.179 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.177 179.315 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . -57.31 -41.22 92.92 Favored Glycine 0 CA--C 1.518 0.233 0 C-N-CA 120.598 -0.81 . . . . 0.0 112.116 179.164 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 113' ' ' PHE . . . . . . . . . . . . . 1.5 t80 -47.16 -67.79 0.25 Allowed 'General case' 0 C--N 1.333 -0.137 0 CA-C-O 121.127 0.489 . . . . 0.0 110.081 179.473 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -64.43 -21.09 66.54 Favored 'General case' 0 C--N 1.326 -0.449 0 CA-C-N 115.512 -0.767 . . . . 0.0 110.864 179.661 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 115' ' ' GLY . . . . . 0.416 ' HA2' HD11 ' A' ' 126' ' ' LEU . . . -52.96 -49.38 55.37 Favored Glycine 0 C--N 1.333 0.375 0 C-N-CA 121.008 -0.615 . . . . 0.0 112.367 179.912 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -78.08 -15.79 58.59 Favored 'General case' 0 C--N 1.324 -0.506 0 N-CA-C 111.665 0.246 . . . . 0.0 111.665 179.742 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 117' ' ' MET . . . . . . . . . . . . . 36.1 ttm -100.94 19.89 16.49 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.497 -0.32 . . . . 0.0 111.674 -179.091 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 118' ' ' VAL . . . . . 0.455 HG22 ' HB3' ' A' ' 123' ' ' ARG . 28.3 m -74.11 147.5 85.84 Favored Pre-proline 0 C--N 1.328 -0.36 0 CA-C-N 116.559 -0.291 . . . . 0.0 111.305 179.789 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 119' ' ' PRO . . . . . . . . . . . . . 81.3 Cg_endo -88.94 -6.28 5.68 Favored 'Trans proline' 0 N--CA 1.457 -0.622 0 C-N-CA 122.688 2.259 . . . . 0.0 112.283 179.683 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -148.4 -114.69 0.78 Allowed Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.711 -0.757 . . . . 0.0 112.915 -179.783 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 44.7 pt -122.59 14.56 5.58 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 CA-C-O 120.802 0.334 . . . . 0.0 111.39 -179.51 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 36.9 mt-10 -63.4 -18.85 64.14 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.134 -179.999 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 123' ' ' ARG . . . . . 0.455 ' HB3' HG22 ' A' ' 118' ' ' VAL . 35.9 ptt180 -53.41 -32.42 49.56 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.106 -0.497 . . . . 0.0 111.925 -179.544 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 124' ' ' TYR . . . . . . . . . . . . . 91.5 m-85 -72.54 -31.41 65.27 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 116.476 -0.329 . . . . 0.0 111.466 -179.652 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 125' ' ' ALA . . . . . . . . . . . . . . . -74.51 -58.28 3.39 Favored 'General case' 0 C--O 1.237 0.44 0 CA-C-O 121.196 0.522 . . . . 0.0 111.573 -179.374 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 126' ' ' LEU . . . . . 0.416 HD11 ' HA2' ' A' ' 115' ' ' GLY . 0.7 OUTLIER -56.49 -37.24 70.1 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 115.701 -0.681 . . . . 0.0 110.511 179.789 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 127' ' ' PHE . . . . . . . . . . . . . 7.8 t80 -69.37 -42.6 74.99 Favored 'General case' 0 N--CA 1.453 -0.311 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.114 179.304 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 128' ' ' GLY . . . . . . . . . . . . . . . -48.09 -35.33 13.52 Favored Glycine 0 C--N 1.333 0.379 0 N-CA-C 110.673 -0.971 . . . . 0.0 110.673 178.746 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 129' ' ' MET . . . . . 0.417 ' HE2' ' HB1' ' A' ' 111' ' ' ALA . 0.2 OUTLIER -72.03 -43.67 64.63 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 115.154 -0.523 . . . . 0.0 109.877 178.619 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -67.25 -22.22 72.6 Favored Glycine 0 N--CA 1.449 -0.474 0 C-N-CA 120.869 -0.682 . . . . 0.0 112.378 179.602 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 131' ' ' ALA . . . . . 0.418 ' O ' ' HB3' ' A' ' 134' ' ' PHE . . . -74.61 -53.9 8.48 Favored 'General case' 0 CA--C 1.519 -0.234 0 CA-C-O 120.739 0.304 . . . . 0.0 110.211 179.681 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 58.1 t -58.32 -39.47 74.24 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.319 0 N-CA-C 108.535 -0.913 . . . . 0.0 108.535 178.096 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -62.77 -37.44 86.67 Favored 'General case' 0 N--CA 1.451 -0.378 0 CA-C-N 114.915 -1.039 . . . . 0.0 110.198 178.767 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 134' ' ' PHE . . . . . 0.418 ' HB3' ' O ' ' A' ' 131' ' ' ALA . 68.0 t80 -55.64 -50.09 71.11 Favored 'General case' 0 N--CA 1.453 -0.325 0 CA-C-N 116.159 -0.473 . . . . 0.0 109.88 179.364 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 135' ' ' ILE . . . . . 0.478 ' O ' HG22 ' A' ' 138' ' ' VAL . 59.0 mt -59.54 -32.45 49.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 115.667 -0.697 . . . . 0.0 110.14 179.228 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . -59.46 -41.76 97.25 Favored Glycine 0 N--CA 1.449 -0.494 0 C-N-CA 120.409 -0.901 . . . . 0.0 111.271 179.054 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 137' ' ' LEU . . . . . 0.582 HD13 HD22 ' A' ' 105' ' ' ASN . 42.7 tp -65.85 -55.61 16.17 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 120.666 0.27 . . . . 0.0 110.722 179.541 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 138' ' ' VAL . . . . . 0.6 ' HB ' HH22 ' A' ' 164' ' ' ARG . 2.5 m -54.79 -32.3 25.79 Favored 'Isoleucine or valine' 0 C--O 1.234 0.267 0 CA-C-O 121.125 0.488 . . . . 0.0 109.802 -179.506 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 139' ' ' TYR . . . . . . . . . . . . . 10.2 t80 -61.43 -42.31 98.54 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 115.654 -0.703 . . . . 0.0 109.964 178.293 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 28.1 m-85 -65.99 -42.37 89.89 Favored 'General case' 0 C--N 1.332 -0.184 0 CA-C-N 116.11 -0.496 . . . . 0.0 111.002 179.517 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 141' ' ' LEU . . . . . 0.427 ' HA ' ' SD ' ' A' ' 145' ' ' MET . 10.8 mp -56.62 -32.86 65.71 Favored 'General case' 0 N--CA 1.462 0.139 0 CA-C-N 116.356 -0.384 . . . . 0.0 110.883 -179.973 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 21.6 t -97.05 -12.75 8.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.82 179.662 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . -76.33 -123.83 0.19 Allowed Glycine 0 CA--C 1.522 0.529 0 C-N-CA 120.845 -0.693 . . . . 0.0 112.932 -179.721 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 144' ' ' PRO . . . . . . . . . . . . . 31.7 Cg_exo -58.87 -29.95 91.58 Favored 'Trans proline' 0 C--N 1.351 0.659 0 C-N-CA 122.596 2.198 . . . . 0.0 112.726 -179.672 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 145' ' ' MET . . . . . 0.571 ' HG2' HD11 ' A' ' 93' ' ' LEU . 60.1 mtt -58.7 -26.98 64.42 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.316 -0.402 . . . . 0.0 111.235 -179.893 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 146' ' ' THR . . . . . . . . . . . . . 24.0 m -81.08 -33.67 33.2 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-N 116.119 -0.491 . . . . 0.0 111.478 -179.058 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 15.0 tp10 -71.89 -43.43 65.41 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.98 -179.896 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 148' ' ' SER . . . . . 0.507 ' HB2' ' HB3' ' A' ' 91' ' ' ALA . 61.7 m -71.98 -40.15 68.79 Favored 'General case' 0 C--N 1.327 -0.405 0 N-CA-C 112.334 0.494 . . . . 0.0 112.334 -179.205 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 149' ' ' ALA . . . . . . . . . . . . . . . -76.68 -44.64 32.85 Favored 'General case' 0 C--N 1.33 -0.278 0 N-CA-C 113.395 0.887 . . . . 0.0 113.395 -177.974 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 150' ' ' SER . . . . . . . . . . . . . 54.2 m -69.12 -14.29 62.92 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.909 0.385 . . . . 0.0 110.85 -178.495 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 151' ' ' GLN . . . . . . . . . . . . . 3.0 mp0 -116.56 10.38 14.46 Favored 'General case' 0 C--N 1.324 -0.502 0 CA-C-N 115.928 -0.578 . . . . 0.0 111.494 -179.462 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 72.2 ttt180 -82.99 -51.94 7.12 Favored 'General case' 0 C--N 1.334 -0.102 0 CA-C-O 120.868 0.366 . . . . 0.0 110.943 -179.968 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 153' ' ' SER . . . . . 0.57 ' HB2' HG12 ' A' ' 156' ' ' ILE . 17.6 m -157.45 172.18 19.04 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 116.032 -0.531 . . . . 0.0 110.861 179.596 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 154' ' ' SER . . . . . . . . . . . . . 67.9 m -71.09 -37.3 72.41 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.687 179.636 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -76.82 -35.0 41.24 Favored Glycine 0 N--CA 1.452 -0.276 0 C-N-CA 120.887 -0.673 . . . . 0.0 112.568 179.908 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 156' ' ' ILE . . . . . 0.57 HG12 ' HB2' ' A' ' 153' ' ' SER . 41.4 mm -56.42 -37.72 52.51 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-O 120.887 0.375 . . . . 0.0 110.92 -179.972 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 157' ' ' LYS . . . . . . . . . . . . . 24.3 ttpp -60.98 -32.9 72.45 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.903 179.82 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 47.1 m -70.9 -45.23 64.7 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.073 -179.863 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 159' ' ' LEU . . . . . 0.476 ' O ' ' HB2' ' A' ' 163' ' ' LEU . 11.2 mt -65.67 -36.12 82.76 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.338 -0.392 . . . . 0.0 111.07 179.931 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 160' ' ' TYR . . . . . 0.471 ' O ' ' HB3' ' A' ' 164' ' ' ARG . 57.3 t80 -65.57 -47.86 74.36 Favored 'General case' 0 C--N 1.329 -0.317 0 N-CA-C 112.206 0.447 . . . . 0.0 112.206 -178.952 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 161' ' ' VAL . . . . . 0.426 HG21 ' N ' ' A' ' 162' ' ' ARG . 17.3 m -62.17 -49.28 84.69 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 N-CA-C 112.304 0.483 . . . . 0.0 112.304 -178.608 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 162' ' ' ARG . . . . . 0.426 ' N ' HG21 ' A' ' 161' ' ' VAL . 81.9 mtt180 -68.46 -46.11 70.66 Favored 'General case' 0 C--N 1.329 -0.291 0 N-CA-C 112.076 0.398 . . . . 0.0 112.076 -179.044 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 163' ' ' LEU . . . . . 0.476 ' HB2' ' O ' ' A' ' 159' ' ' LEU . 1.7 mp -67.67 -54.95 15.35 Favored 'General case' 0 C--N 1.328 -0.332 0 N-CA-C 112.243 0.46 . . . . 0.0 112.243 -178.62 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 164' ' ' ARG . . . . . 0.6 HH22 ' HB ' ' A' ' 138' ' ' VAL . 25.2 tpt180 -55.78 -54.89 38.91 Favored 'General case' 0 N--CA 1.465 0.292 0 N-CA-C 112.629 0.603 . . . . 0.0 112.629 -178.46 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 165' ' ' ASN . . . . . . . . . . . . . 13.8 m-80 -58.0 -49.25 77.5 Favored 'General case' 0 C--N 1.33 -0.255 0 N-CA-C 112.071 0.397 . . . . 0.0 112.071 -178.75 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 166' ' ' LEU . . . . . . . . . . . . . 4.4 tt -63.45 -55.37 24.73 Favored 'General case' 0 C--N 1.325 -0.47 0 N-CA-C 111.876 0.325 . . . . 0.0 111.876 -179.262 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 167' ' ' THR . . . . . . . . . . . . . 53.7 m -57.02 -52.92 63.34 Favored 'General case' 0 C--N 1.328 -0.368 0 N-CA-C 113.037 0.754 . . . . 0.0 113.037 -178.613 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 168' ' ' VAL . . . . . . . . . . . . . 7.9 p -57.5 -41.22 78.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 N-CA-C 112.482 0.549 . . . . 0.0 112.482 -178.529 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 169' ' ' VAL . . . . . 0.463 ' CG1' ' N ' ' A' ' 170' ' ' LEU . 0.4 OUTLIER -63.72 -54.07 36.76 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.443 0 N-CA-C 111.867 0.321 . . . . 0.0 111.867 -178.76 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 170' ' ' LEU . . . . . 0.463 ' N ' ' CG1' ' A' ' 169' ' ' VAL . 3.0 pp -68.03 -31.12 70.57 Favored 'General case' 0 C--N 1.33 -0.268 0 C-N-CA 121.173 -0.211 . . . . 0.0 111.543 -178.562 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 171' ' ' TRP . . . . . 0.429 ' N ' HD13 ' A' ' 170' ' ' LEU . 3.3 m0 -72.29 -28.59 63.19 Favored 'General case' 0 C--N 1.329 -0.295 0 N-CA-C 109.952 -0.388 . . . . 0.0 109.952 178.895 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 172' ' ' ALA . . . . . . . . . . . . . . . -76.0 -6.87 53.03 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-N 115.919 -0.582 . . . . 0.0 110.554 -179.821 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 173' ' ' ILE . . . . . 0.48 ' O ' HG12 ' A' ' 177' ' ' ILE . 34.1 mm -85.86 -21.12 7.75 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.204 0 CA-C-N 115.719 -0.673 . . . . 0.0 110.853 179.41 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 174' ' ' TYR . . . . . . . . . . . . . 11.8 m-85 -53.76 -50.22 84.83 Favored Pre-proline 0 CA--C 1.53 0.194 0 CA-C-N 116.313 -0.403 . . . . 0.0 111.799 -179.446 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 175' ' ' PRO . . . . . . . . . . . . . 74.5 Cg_exo -50.42 -29.9 25.5 Favored 'Trans proline' 0 C--N 1.349 0.572 0 C-N-CA 122.191 1.927 . . . . 0.0 112.517 179.84 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 176' ' ' PHE . . . . . 0.432 ' HD2' ' HA ' ' A' ' 173' ' ' ILE . 38.9 m-85 -80.44 -50.24 10.35 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.233 -0.44 . . . . 0.0 111.846 -179.707 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 177' ' ' ILE . . . . . 0.488 ' HB ' HD12 ' A' ' 197' ' ' ILE . 5.7 mm -65.65 -33.54 64.29 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.519 0 N-CA-C 112.27 0.47 . . . . 0.0 112.27 -178.229 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 178' ' ' TRP . . . . . 0.431 ' HH2' ' HB2' ' A' ' 123' ' ' ARG . 88.7 t90 -72.86 -56.53 5.08 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.873 0.368 . . . . 0.0 110.807 -179.925 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 179' ' ' LEU . . . . . 0.449 HD21 HD21 ' A' ' 180' ' ' LEU . 0.6 OUTLIER -63.04 -54.23 41.33 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 115.931 -0.577 . . . . 0.0 111.324 -179.36 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 180' ' ' LEU . . . . . 0.449 HD21 HD21 ' A' ' 179' ' ' LEU . 43.3 mt -64.67 -41.41 96.1 Favored 'General case' 0 C--N 1.331 -0.213 0 C-N-CA 120.832 -0.347 . . . . 0.0 111.068 -179.607 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . -62.6 -178.79 3.98 Favored Glycine 0 C--N 1.334 0.43 0 C-N-CA 119.952 -1.118 . . . . 0.0 112.002 179.103 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 182' ' ' PRO . . . . . 0.437 ' HB2' ' HD3' ' A' ' 183' ' ' PRO . 83.2 Cg_exo -47.84 -44.8 26.17 Favored 'Trans proline' 0 CA--C 1.536 0.58 0 C-N-CA 122.741 2.294 . . . . 0.0 113.74 179.962 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 183' ' ' PRO . . . . . 0.437 ' HD3' ' HB2' ' A' ' 182' ' ' PRO . 84.1 Cg_exo -47.04 -22.51 2.15 Favored 'Trans proline' 0 C--N 1.356 0.933 0 C-N-CA 122.209 1.939 . . . . 0.0 113.286 -179.688 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 184' ' ' GLY . . . . . . . . . . . . . . . -126.12 -124.12 2.74 Favored Glycine 0 C--N 1.333 0.367 0 C-N-CA 120.305 -0.95 . . . . 0.0 112.926 179.874 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 185' ' ' VAL . . . . . 0.403 ' CG2' ' HA ' ' A' ' 180' ' ' LEU . 19.4 m -61.28 -25.31 36.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 N-CA-C 112.281 0.474 . . . . 0.0 112.281 -179.248 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 186' ' ' ALA . . . . . 0.43 ' HB1' ' HA ' ' A' ' 182' ' ' PRO . . . 57.65 85.41 0.09 Allowed 'General case' 0 N--CA 1.465 0.318 0 CA-C-O 120.832 0.348 . . . . 0.0 111.7 179.555 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 187' ' ' LEU . . . . . 0.44 HD11 HD22 ' A' ' 180' ' ' LEU . 10.7 mt -92.88 -49.27 6.13 Favored 'General case' 0 C--N 1.332 -0.184 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.359 179.911 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 188' ' ' LEU . . . . . . . . . . . . . 53.7 mt -95.47 -161.43 0.86 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 115.988 -0.551 . . . . 0.0 111.691 -179.052 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 189' ' ' THR . . . . . . . . . . . . . 9.9 m -91.5 137.06 26.09 Favored Pre-proline 0 C--N 1.33 -0.261 0 CA-C-N 115.77 -0.65 . . . . 0.0 110.682 -179.716 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 190' ' ' PRO . . . . . . . . . . . . . 96.4 Cg_exo -44.65 -46.01 12.76 Favored 'Trans proline' 0 C--N 1.35 0.655 0 C-N-CA 122.812 2.341 . . . . 0.0 113.539 -179.735 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 191' ' ' THR . . . . . . . . . . . . . 6.7 t -59.1 -36.83 75.8 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.822 0.344 . . . . 0.0 111.329 -179.764 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 192' ' ' VAL . . . . . . . . . . . . . 58.0 t -74.79 -53.63 16.19 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.22 -0.446 . . . . 0.0 111.696 -179.591 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 193' ' ' ASP . . . . . . . . . . . . . 23.9 m-20 -56.45 -48.36 77.22 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.45 -0.341 . . . . 0.0 110.973 -179.588 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 194' ' ' VAL . . . . . . . . . . . . . 78.0 t -61.92 -36.38 73.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.432 179.602 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 195' ' ' ALA . . . . . . . . . . . . . . . -56.28 -42.34 77.33 Favored 'General case' 0 C--N 1.331 -0.197 0 CA-C-N 116.344 -0.389 . . . . 0.0 110.823 179.335 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 196' ' ' LEU . . . . . . . . . . . . . 96.1 mt -67.19 -38.86 86.09 Favored 'General case' 0 C--N 1.332 -0.174 0 CA-C-O 120.952 0.406 . . . . 0.0 110.332 179.486 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 197' ' ' ILE . . . . . 0.488 HD12 ' HB ' ' A' ' 177' ' ' ILE . 21.6 mm -59.79 -52.6 59.19 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 115.937 -0.574 . . . . 0.0 110.18 179.153 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 198' ' ' VAL . . . . . . . . . . . . . 90.8 t -57.26 -34.15 45.17 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.458 0 N-CA-C 108.908 -0.775 . . . . 0.0 108.908 178.179 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 199' ' ' TYR . . . . . . . . . . . . . 46.0 t80 -69.44 -30.3 68.19 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-N 115.115 -0.948 . . . . 0.0 110.568 179.46 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 200' ' ' LEU . . . . . . . . . . . . . 48.2 mt -70.25 -42.37 72.27 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 115.944 -0.571 . . . . 0.0 111.158 -179.854 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 201' ' ' ASP . . . . . 0.579 ' HB2' ' HH ' ' A' ' 51' ' ' TYR . 12.3 m-20 -73.3 -34.65 65.84 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-O 121.167 0.508 . . . . 0.0 110.15 179.378 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 202' ' ' LEU . . . . . . . . . . . . . 2.5 mt -70.78 -31.33 68.07 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 115.562 -0.745 . . . . 0.0 111.795 -179.799 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 203' ' ' VAL . . . . . . . . . . . . . 11.9 p -77.18 -37.1 25.42 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.235 0 C-N-CA 120.946 -0.302 . . . . 0.0 111.209 -179.143 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 204' ' ' THR . . . . . . . . . . . . . 68.0 m -65.13 -57.49 8.44 Favored 'General case' 0 C--O 1.222 -0.392 0 C-N-CA 120.76 -0.376 . . . . 0.0 111.318 179.718 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 205' ' ' LYS . . . . . 0.633 ' HE2' ' HB1' ' A' ' 47' ' ' ALA . 60.6 mttp -65.13 -55.51 18.3 Favored 'General case' 0 C--N 1.326 -0.414 0 N-CA-C 112.301 0.482 . . . . 0.0 112.301 -178.716 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 59.2 t -65.31 -47.18 88.17 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 N-CA-C 111.841 0.312 . . . . 0.0 111.841 -179.606 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 207' ' ' GLY . . . . . . . . . . . . . . . -63.94 -59.62 8.34 Favored Glycine 0 C--N 1.331 0.28 0 C-N-CA 120.708 -0.758 . . . . 0.0 112.771 -179.795 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 208' ' ' PHE . . . . . 0.42 ' O ' ' N ' ' A' ' 212' ' ' ALA . 4.1 t80 -54.71 -40.74 69.52 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.672 0.272 . . . . 0.0 110.97 179.965 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 209' ' ' GLY . . . . . 0.461 ' O ' ' HB1' ' A' ' 212' ' ' ALA . . . -69.78 -38.65 76.63 Favored Glycine 0 C--N 1.329 0.189 0 CA-C-N 115.877 -0.601 . . . . 0.0 113.356 -179.558 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 210' ' ' PHE . . . . . . . . . . . . . 1.4 m-85 -69.66 -39.95 76.75 Favored 'General case' 0 CA--C 1.51 -0.571 0 N-CA-C 107.649 -1.241 . . . . 0.0 107.649 179.118 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 211' ' ' ILE . . . . . . . . . . . . . 29.9 mt -69.73 -28.6 37.84 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.87 0 CA-C-N 114.235 -1.348 . . . . 0.0 107.416 176.737 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 212' ' ' ALA . . . . . 0.461 ' HB1' ' O ' ' A' ' 209' ' ' GLY . . . -68.08 -38.8 82.78 Favored 'General case' 0 N--CA 1.447 -0.59 0 CA-C-N 114.293 -1.321 . . . . 0.0 110.637 179.856 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 213' ' ' LEU . . . . . . . . . . . . . 96.4 mt -70.6 -53.09 17.3 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 115.257 -0.883 . . . . 0.0 112.043 -179.238 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 214' ' ' ASP . . . . . . . . . . . . . 45.0 m-20 -52.09 -53.06 47.11 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.443 -0.344 . . . . 0.0 111.636 -179.428 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 215' ' ' ALA . . . . . 0.424 ' HB1' HD21 ' A' ' 159' ' ' LEU . . . -59.68 -57.36 13.26 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.344 -0.389 . . . . 0.0 111.818 -179.511 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 216' ' ' ALA . . . . . . . . . . . . . . . -58.11 -31.73 67.43 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.441 -0.345 . . . . 0.0 111.601 -179.519 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 217' ' ' ALA . . . . . . . . . . . . . . . -62.24 -42.16 99.06 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 121.015 0.436 . . . . 0.0 110.151 179.832 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 218' ' ' THR . . . . . . . . . . . . . 97.2 m . . . . . 0 C--N 1.329 -0.314 0 CA-C-N 115.827 -0.624 . . . . 0.0 110.33 179.154 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.353 0 N-CA-C 112.384 -0.286 . . . . 0.0 112.384 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 59.4 tp -74.42 -35.52 63.41 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 120.844 0.355 . . . . 0.0 111.101 179.886 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 65.2 p -62.64 -30.06 71.09 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.517 -179.626 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 6' ' ' THR . . . . . 0.509 ' HG1' HD23 ' A' ' 7' ' ' LEU . 36.1 p -55.11 -35.46 64.68 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.44 -0.345 . . . . 0.0 111.118 -179.92 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 7' ' ' LEU . . . . . 0.509 HD23 ' HG1' ' A' ' 6' ' ' THR . 4.2 mm? -56.65 -53.26 59.77 Favored 'General case' 0 C--N 1.331 -0.205 0 CA-C-N 116.082 -0.508 . . . . 0.0 111.052 -179.974 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 8' ' ' PHE . . . . . 0.615 ' HB2' ' HB2' ' A' ' 55' ' ' ALA . 67.9 m-85 -60.96 -36.41 79.32 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.873 -179.958 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 9' ' ' TRP . . . . . . . . . . . . . 30.4 m95 -61.4 -44.16 97.63 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.047 -179.876 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 51.8 mt -60.94 -42.65 98.59 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 115.638 -0.71 . . . . 0.0 110.239 179.246 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -62.09 -29.94 74.22 Favored Glycine 0 N--CA 1.448 -0.549 0 C-N-CA 120.69 -0.766 . . . . 0.0 111.888 179.259 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -72.58 -33.51 66.8 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-O 120.698 0.285 . . . . 0.0 110.968 179.719 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 13' ' ' ILE . . . . . 0.403 ' O ' HG23 ' A' ' 17' ' ' VAL . 83.3 mt -64.16 -54.32 32.7 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.226 0 CA-C-N 116.343 -0.39 . . . . 0.0 110.749 179.758 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -66.02 -34.15 87.59 Favored Glycine 0 N--CA 1.452 -0.291 0 C-N-CA 120.685 -0.769 . . . . 0.0 112.227 179.833 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 15' ' ' MET . . . . . 0.525 ' SD ' ' HA ' ' A' ' 44' ' ' SER . 52.7 tpp -65.69 -49.79 67.27 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.733 0.301 . . . . 0.0 110.646 179.986 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 51.0 mt -53.42 -42.23 66.84 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.506 179.382 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 17' ' ' VAL . . . . . 0.403 HG23 ' O ' ' A' ' 13' ' ' ILE . 99.5 t -58.89 -41.46 82.98 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.226 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.125 179.128 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -64.76 -40.49 97.43 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.606 -0.806 . . . . 0.0 111.49 179.029 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 3.6 m -50.97 -54.17 26.69 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.883 0.373 . . . . 0.0 111.102 179.917 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 75.2 mt -71.74 -39.72 69.88 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.061 -0.518 . . . . 0.0 111.454 -179.887 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -54.71 -43.88 72.95 Favored 'General case' 0 C--N 1.329 -0.316 0 N-CA-C 112.381 0.512 . . . . 0.0 112.381 -178.953 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 4.3 m-85 -84.36 -28.24 27.14 Favored 'General case' 0 C--N 1.329 -0.315 0 N-CA-C 111.889 0.329 . . . . 0.0 111.889 -178.969 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -64.98 -51.48 61.48 Favored 'General case' 0 C--N 1.326 -0.442 0 N-CA-C 112.59 0.589 . . . . 0.0 112.59 -178.965 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 24' ' ' TRP . . . . . 0.501 ' HA ' ' CE3' ' A' ' 24' ' ' TRP . 2.3 t-105 -87.1 -26.75 23.5 Favored 'General case' 0 N--CA 1.442 -0.827 0 N-CA-C 113.383 0.882 . . . . 0.0 113.383 -177.497 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.318 -0.778 0 C-N-CA 120.636 -0.426 . . . . 0.0 109.947 178.896 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.306 0 N-CA-C 112.445 -0.262 . . . . 0.0 112.445 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 9.0 mm-40 -89.27 -20.59 23.91 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.776 0.322 . . . . 0.0 110.872 -179.957 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 34' ' ' ARG . . . . . . . . . . . . . 92.8 mtt180 -56.35 -28.7 59.86 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.129 -0.487 . . . . 0.0 111.385 -179.815 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 99.2 mtt180 -54.96 -56.46 19.44 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-O 120.863 0.363 . . . . 0.0 111.286 -179.807 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 76.1 m-85 -71.29 -40.16 71.06 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.944 -179.052 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 37' ' ' TYR . . . . . . . . . . . . . 20.7 m-85 -65.52 -56.3 13.12 Favored 'General case' 0 C--N 1.329 -0.305 0 N-CA-C 111.707 0.262 . . . . 0.0 111.707 -179.08 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 89.3 t -57.08 -37.17 53.9 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.326 0 CA-C-O 120.724 0.297 . . . . 0.0 110.935 179.981 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 15.2 m -64.36 -51.55 62.73 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 121.037 0.446 . . . . 0.0 110.748 179.33 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 40' ' ' LEU . . . . . 0.4 HD11 HD13 ' A' ' 43' ' ' ILE . 61.1 tp -59.22 -50.83 72.5 Favored 'General case' 0 C--O 1.235 0.306 0 CA-C-N 115.877 -0.601 . . . . 0.0 110.641 179.913 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 96.4 t -59.78 -34.4 55.54 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 115.974 -0.557 . . . . 0.0 109.62 178.902 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -57.22 -39.28 89.82 Favored Glycine 0 N--CA 1.447 -0.603 0 CA-C-N 115.644 -0.707 . . . . 0.0 111.767 179.407 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 43' ' ' ILE . . . . . 0.456 HG23 ' HE3' ' A' ' 205' ' ' LYS . 1.0 OUTLIER -65.65 -53.12 42.48 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.205 0 CA-C-O 120.832 0.348 . . . . 0.0 110.128 179.306 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 44' ' ' SER . . . . . 0.525 ' HA ' ' SD ' ' A' ' 15' ' ' MET . 83.0 p -61.86 -21.2 64.47 Favored 'General case' 0 C--N 1.333 -0.146 0 CA-C-N 116.104 -0.498 . . . . 0.0 111.12 179.985 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -76.25 -59.23 3.4 Favored Glycine 0 N--CA 1.452 -0.265 0 C-N-CA 120.726 -0.75 . . . . 0.0 112.662 -179.737 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 20.7 pt -61.0 -35.68 66.96 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-O 120.724 0.297 . . . . 0.0 111.425 -179.79 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 47' ' ' ALA . . . . . 0.557 ' HB3' ' HE2' ' A' ' 205' ' ' LYS . . . -67.06 -43.87 81.56 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.843 0.354 . . . . 0.0 111.065 179.478 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -54.78 -49.33 71.16 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.094 -0.503 . . . . 0.0 111.359 -179.749 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 26.9 m -67.75 -34.14 65.96 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.328 -0.396 . . . . 0.0 111.09 -179.718 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -62.75 -38.65 91.41 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-O 121.12 0.486 . . . . 0.0 110.657 179.576 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 51' ' ' TYR . . . . . 0.436 ' OH ' ' HB2' ' A' ' 201' ' ' ASP . 30.6 m-85 -72.93 -31.42 64.6 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-N 115.763 -0.653 . . . . 0.0 110.169 179.852 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -70.04 -42.52 72.8 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-N 115.749 -0.659 . . . . 0.0 111.091 179.609 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 53' ' ' VAL . . . . . 0.442 HG22 ' N ' ' A' ' 54' ' ' MET . 32.9 m -69.43 -45.5 78.48 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.197 0 CA-C-N 116.548 -0.296 . . . . 0.0 110.985 -179.848 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 54' ' ' MET . . . . . 0.442 ' N ' HG22 ' A' ' 53' ' ' VAL . 76.7 mtm -64.66 -31.06 72.12 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-O 121.034 0.445 . . . . 0.0 110.094 179.319 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 55' ' ' ALA . . . . . 0.615 ' HB2' ' HB2' ' A' ' 8' ' ' PHE . . . -74.46 -15.35 60.9 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 115.672 -0.694 . . . . 0.0 111.403 179.637 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 69.6 mt -92.1 -13.36 30.92 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.458 -0.337 . . . . 0.0 111.492 -179.697 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 104.2 -20.92 39.07 Favored Glycine 0 N--CA 1.452 -0.263 0 C-N-CA 120.52 -0.848 . . . . 0.0 113.112 179.8 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 58' ' ' VAL . . . . . 0.424 HG13 ' O ' ' A' ' 53' ' ' VAL . 11.7 p -67.08 149.61 11.52 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-N 116.861 0.331 . . . . 0.0 110.623 179.989 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 88.09 -14.47 58.92 Favored Glycine 0 N--CA 1.449 -0.471 0 C-N-CA 120.663 -0.779 . . . . 0.0 111.774 -179.155 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 60' ' ' TRP . . . . . . . . . . . . . 18.2 m0 -76.02 97.77 4.12 Favored 'General case' 0 C--N 1.331 -0.197 0 CA-C-O 120.836 0.35 . . . . 0.0 110.673 179.917 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 61' ' ' VAL . . . . . 0.471 HG13 HG23 ' A' ' 68' ' ' VAL . 5.2 p -100.32 129.26 28.41 Favored Pre-proline 0 C--N 1.328 -0.327 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.81 179.766 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 73.5 Cg_endo -73.97 146.22 36.91 Favored 'Trans proline' 0 C--N 1.35 0.619 0 C-N-CA 122.478 2.118 . . . . 0.0 112.245 -179.826 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 92.1 t -140.37 95.35 0.78 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.181 -179.67 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . 57.94 -91.42 0.03 OUTLIER 'General case' 0 C--N 1.331 -0.212 0 CA-C-N 116.123 -0.489 . . . . 0.0 111.27 -179.969 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -122.57 -11.78 8.22 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-O 120.968 0.413 . . . . 0.0 110.702 179.715 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 66' ' ' ARG . . . . . 0.423 HH22 HH12 ' A' ' 123' ' ' ARG . 16.9 ptp180 -105.52 165.6 11.03 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 115.9 -0.591 . . . . 0.0 110.364 179.454 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 61.5 m -126.33 141.51 51.88 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 120.965 0.412 . . . . 0.0 111.357 -179.842 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 68' ' ' VAL . . . . . 0.503 HG22 ' HG3' ' A' ' 117' ' ' MET . 9.1 m -133.25 146.18 32.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 115.942 -0.572 . . . . 0.0 110.669 179.575 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 69' ' ' PHE . . . . . . . . . . . . . 5.8 m-85 -107.59 118.31 36.4 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-O 121.049 0.452 . . . . 0.0 110.389 -179.056 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 70' ' ' VAL . . . . . 0.597 HG13 ' HD3' ' A' ' 71' ' ' PRO . 1.3 p -67.1 -35.32 8.63 Favored Pre-proline 0 CA--C 1.54 0.583 0 CA-C-N 115.687 -0.688 . . . . 0.0 112.829 -178.978 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 71' ' ' PRO . . . . . 0.597 ' HD3' HG13 ' A' ' 70' ' ' VAL . 8.7 Cg_exo -70.38 -18.65 33.94 Favored 'Trans proline' 0 C--N 1.356 0.948 0 C-N-CA 121.902 1.734 . . . . 0.0 112.66 -179.37 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 46.8 ttp180 -75.16 -54.3 7.36 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.55 -0.295 . . . . 0.0 111.791 -178.948 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 73' ' ' TYR . . . . . 0.409 ' O ' HG13 ' A' ' 77' ' ' ILE . 18.4 m-85 -67.66 -37.1 81.9 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.755 0.312 . . . . 0.0 110.491 -179.569 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 0.4 OUTLIER -68.39 -38.37 79.25 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.219 0 CA-C-N 116.293 -0.412 . . . . 0.0 110.139 179.526 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 19.5 t70 -59.65 -36.97 77.45 Favored 'General case' 0 CA--C 1.52 -0.199 0 N-CA-C 109.712 -0.477 . . . . 0.0 109.712 179.08 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 76' ' ' TRP . . . . . . . . . . . . . 46.0 m0 -65.03 -41.67 95.07 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 115.781 -0.645 . . . . 0.0 110.081 179.427 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 77' ' ' ILE . . . . . 0.409 HG13 ' O ' ' A' ' 73' ' ' TYR . 66.7 mt -61.79 -28.64 44.62 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.425 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.902 179.544 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 29.8 mt -90.74 -27.98 18.59 Favored 'General case' 0 CA--C 1.531 0.232 0 N-CA-C 112.481 0.549 . . . . 0.0 112.481 -179.376 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 64.6 p -91.28 -43.44 9.8 Favored 'General case' 0 C--N 1.329 -0.322 0 N-CA-C 113.002 0.741 . . . . 0.0 113.002 -178.022 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 80' ' ' THR . . . . . 0.553 ' N ' ' HD2' ' A' ' 81' ' ' PRO . 38.9 p -52.33 -45.01 94.96 Favored Pre-proline 0 C--N 1.328 -0.356 0 N-CA-C 113.072 0.767 . . . . 0.0 113.072 -179.044 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 81' ' ' PRO . . . . . 0.553 ' HD2' ' N ' ' A' ' 80' ' ' THR . 35.8 Cg_endo -62.99 -23.03 74.11 Favored 'Trans proline' 0 C--N 1.354 0.847 0 C-N-CA 121.406 1.404 . . . . 0.0 111.776 -179.78 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 82' ' ' LEU . . . . . 0.428 HD21 HG12 ' A' ' 43' ' ' ILE . 7.5 mp -76.82 -43.03 38.09 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 115.779 -0.646 . . . . 0.0 111.365 -179.494 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 83' ' ' ILE . . . . . 0.418 HD12 HD12 ' A' ' 43' ' ' ILE . 39.8 mm -63.29 -53.85 40.51 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.413 -0.358 . . . . 0.0 110.955 -179.851 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 33.5 m -60.05 -36.95 70.63 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.222 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.467 179.668 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 85' ' ' TYR . . . . . . . . . . . . . 69.8 t80 -63.48 -32.85 74.42 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.098 -0.501 . . . . 0.0 109.809 179.246 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 86' ' ' PHE . . . . . . . . . . . . . 6.0 t80 -61.64 -51.91 66.54 Favored 'General case' 0 C--O 1.233 0.193 0 CA-C-N 115.973 -0.558 . . . . 0.0 109.963 179.34 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 8.5 mp -61.06 -31.85 71.5 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 115.859 -0.61 . . . . 0.0 110.169 179.199 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -71.13 -27.87 71.2 Favored Glycine 0 N--CA 1.45 -0.392 0 C-N-CA 120.871 -0.68 . . . . 0.0 111.787 179.321 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 71.1 mt -73.13 -34.82 66.34 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-O 120.972 0.415 . . . . 0.0 110.38 179.517 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 74.8 mt -66.47 -35.66 80.82 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 115.761 -0.654 . . . . 0.0 111.303 -179.984 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -87.93 -32.33 18.96 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.589 -179.472 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 82.83 55.14 3.04 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.675 -0.774 . . . . 0.0 112.195 -179.72 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 93' ' ' LEU . . . . . 0.494 HD12 ' HE3' ' A' ' 145' ' ' MET . 33.8 mt -69.44 167.24 17.04 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.899 0.381 . . . . 0.0 111.128 -179.815 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 94' ' ' ASP . . . . . . . . . . . . . 18.4 t70 -86.15 168.29 14.14 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 115.987 -0.551 . . . . 0.0 110.361 179.683 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 80.8 p -57.62 -33.13 67.93 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.439 -0.346 . . . . 0.0 110.974 179.972 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 98.2 mtt180 -73.82 -53.47 10.18 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.208 179.944 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 44.0 mt-10 -53.76 -42.14 67.9 Favored 'General case' 0 C--N 1.332 -0.175 0 CA-C-N 116.362 -0.381 . . . . 0.0 110.914 -179.892 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 98' ' ' PHE . . . . . 0.401 ' O ' HG12 ' A' ' 102' ' ' ILE . 9.0 m-85 -59.91 -46.86 88.0 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.77 179.668 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -58.82 -29.59 64.87 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.816 -0.707 . . . . 0.0 112.56 -179.922 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 95.1 mt -73.51 -42.36 56.11 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.243 0 CA-C-O 120.872 0.368 . . . . 0.0 111.436 -179.847 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 42.1 t -68.61 -43.89 83.08 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.365 0 CA-C-N 116.329 -0.396 . . . . 0.0 111.208 -179.815 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 102' ' ' ILE . . . . . 0.401 HG12 ' O ' ' A' ' 98' ' ' PHE . 42.2 mm -68.53 -46.36 80.32 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.355 0 CA-C-N 116.086 -0.506 . . . . 0.0 111.688 -179.338 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 14.6 t -58.44 -35.85 72.75 Favored 'General case' 0 C--O 1.232 0.161 0 CA-C-O 120.778 0.323 . . . . 0.0 110.673 179.945 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 30.1 tp -62.84 -45.99 90.03 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.036 179.124 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 105' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -62.58 -25.75 68.24 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 115.978 -0.555 . . . . 0.0 110.712 179.354 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 24.6 m -68.57 -52.1 35.47 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.371 -0.377 . . . . 0.0 111.491 -179.803 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 10.9 p -70.24 -40.57 78.16 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.212 0 CA-C-N 116.429 -0.35 . . . . 0.0 111.888 -179.428 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . 0.509 ' HA ' ' HE1' ' A' ' 129' ' ' MET . 73.1 t -62.66 -58.46 7.48 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.254 0 CA-C-O 120.977 0.418 . . . . 0.0 111.458 -179.74 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 109' ' ' MET . . . . . 0.578 ' N ' ' SD ' ' A' ' 109' ' ' MET . 0.0 OUTLIER -58.39 -32.46 68.62 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 115.957 -0.565 . . . . 0.0 110.827 -179.396 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 28.4 tp -67.69 -35.29 78.54 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.296 -0.411 . . . . 0.0 110.089 179.292 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -60.88 -49.11 78.8 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-N 115.989 -0.551 . . . . 0.0 110.167 179.155 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . -59.82 -33.83 79.95 Favored Glycine 0 N--CA 1.45 -0.43 0 C-N-CA 120.574 -0.822 . . . . 0.0 111.716 179.271 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 113' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER -54.71 -65.04 0.65 Allowed 'General case' 0 C--N 1.332 -0.191 0 CA-C-O 121.052 0.454 . . . . 0.0 110.226 179.326 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -66.43 -30.53 70.91 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 115.609 -0.723 . . . . 0.0 111.575 -179.64 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -52.12 -51.08 43.04 Favored Glycine 0 C--N 1.332 0.358 0 C-N-CA 121.059 -0.591 . . . . 0.0 112.988 -179.644 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 116' ' ' ALA . . . . . 0.451 ' HB2' ' HB3' ' A' ' 183' ' ' PRO . . . -78.09 -15.45 58.87 Favored 'General case' 0 C--N 1.327 -0.405 0 N-CA-C 111.829 0.307 . . . . 0.0 111.829 -179.558 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 117' ' ' MET . . . . . 0.503 ' HG3' HG22 ' A' ' 68' ' ' VAL . 35.5 ttm -106.23 17.0 24.12 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.79 0.328 . . . . 0.0 111.277 -179.425 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 118' ' ' VAL . . . . . 0.477 HG13 ' N ' ' A' ' 123' ' ' ARG . 15.9 m -63.81 148.57 94.46 Favored Pre-proline 0 C--N 1.331 -0.239 0 CA-C-N 116.414 -0.357 . . . . 0.0 111.413 179.847 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 119' ' ' PRO . . . . . . . . . . . . . 88.7 Cg_endo -82.66 -1.64 10.64 Favored 'Trans proline' 0 C--N 1.347 0.461 0 C-N-CA 122.605 2.204 . . . . 0.0 112.273 179.58 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -157.6 -121.18 0.65 Allowed Glycine 0 C--N 1.33 0.246 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.522 -179.994 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 1.9 pp -106.69 12.93 8.43 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.207 0 CA-C-O 120.866 0.365 . . . . 0.0 111.291 -179.932 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 41.9 mt-10 -59.97 -17.49 38.47 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.012 -0.54 . . . . 0.0 111.293 179.929 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 123' ' ' ARG . . . . . 0.477 ' N ' HG13 ' A' ' 118' ' ' VAL . 27.6 ptt180 -50.37 -29.66 10.52 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-N 116.118 -0.492 . . . . 0.0 111.853 -179.757 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 124' ' ' TYR . . . . . . . . . . . . . 28.9 m-85 -67.64 -33.03 74.14 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.771 0.319 . . . . 0.0 111.201 -179.783 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 125' ' ' ALA . . . . . . . . . . . . . . . -72.38 -48.54 40.84 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.254 -0.43 . . . . 0.0 111.426 -179.982 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 3.3 mm? -54.6 -55.58 27.9 Favored 'General case' 0 C--N 1.331 -0.206 0 CA-C-N 116.351 -0.386 . . . . 0.0 110.987 -179.673 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 127' ' ' PHE . . . . . 0.443 ' HZ ' ' HB3' ' A' ' 175' ' ' PRO . 6.7 t80 -64.97 -39.2 93.12 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.185 -0.462 . . . . 0.0 111.456 -179.304 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 128' ' ' GLY . . . . . . . . . . . . . . . -46.44 -45.72 16.83 Favored Glycine 0 C--O 1.237 0.322 0 C-N-CA 120.228 -0.987 . . . . 0.0 111.261 179.531 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 129' ' ' MET . . . . . 0.509 ' HE1' ' HA ' ' A' ' 108' ' ' VAL . 0.3 OUTLIER -68.87 -40.18 79.41 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 115.348 -0.426 . . . . 0.0 109.907 178.986 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -68.56 -21.13 74.43 Favored Glycine 0 N--CA 1.449 -0.464 0 CA-C-N 115.701 -0.682 . . . . 0.0 112.486 179.972 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 131' ' ' ALA . . . . . 0.431 ' O ' ' HB3' ' A' ' 134' ' ' PHE . . . -75.5 -54.16 7.47 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-O 120.621 0.248 . . . . 0.0 110.596 179.886 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 46.5 t -62.94 -40.46 89.02 Favored 'Isoleucine or valine' 0 C--O 1.234 0.249 0 N-CA-C 108.839 -0.8 . . . . 0.0 108.839 178.417 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -66.82 -32.04 73.06 Favored 'General case' 0 N--CA 1.452 -0.352 0 CA-C-N 115.124 -0.943 . . . . 0.0 110.184 178.828 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 134' ' ' PHE . . . . . 0.431 ' HB3' ' O ' ' A' ' 131' ' ' ALA . 38.5 t80 -56.78 -55.61 32.14 Favored 'General case' 0 N--CA 1.452 -0.353 0 N-CA-C 109.738 -0.467 . . . . 0.0 109.738 179.402 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 135' ' ' ILE . . . . . 0.49 ' O ' HG22 ' A' ' 138' ' ' VAL . 47.9 mt -56.8 -32.71 39.19 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.407 0 CA-C-N 115.583 -0.735 . . . . 0.0 109.979 179.409 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . -59.92 -37.81 93.17 Favored Glycine 0 N--CA 1.448 -0.522 0 C-N-CA 120.113 -1.041 . . . . 0.0 110.94 178.567 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 137' ' ' LEU . . . . . . . . . . . . . 46.6 tp -71.12 -50.26 35.47 Favored 'General case' 0 N--CA 1.454 -0.247 0 CA-C-N 115.719 -0.241 . . . . 0.0 110.611 179.499 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 138' ' ' VAL . . . . . 0.525 ' HA ' HD11 ' A' ' 141' ' ' LEU . 3.7 m -57.8 -30.62 38.21 Favored 'Isoleucine or valine' 0 CA--C 1.521 -0.164 0 N-CA-C 109.23 -0.656 . . . . 0.0 109.23 179.138 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 139' ' ' TYR . . . . . . . . . . . . . 39.3 t80 -63.52 -39.8 95.37 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 115.246 -0.888 . . . . 0.0 109.173 178.205 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 22.3 m-85 -65.28 -31.97 73.38 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 115.733 -0.667 . . . . 0.0 110.256 178.617 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 141' ' ' LEU . . . . . 0.525 HD11 ' HA ' ' A' ' 138' ' ' VAL . 56.8 mt -65.06 -36.71 85.22 Favored 'General case' 0 CA--C 1.519 -0.222 0 CA-C-O 121.35 0.595 . . . . 0.0 109.591 179.973 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 16.6 m -98.0 0.08 10.44 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.822 0 CA-C-N 115.112 -0.949 . . . . 0.0 111.081 -179.866 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . -81.82 -135.35 1.97 Allowed Glycine 0 CA--C 1.521 0.447 0 C-N-CA 121.035 -0.603 . . . . 0.0 113.058 -179.486 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 144' ' ' PRO . . . . . . . . . . . . . 18.3 Cg_endo -58.32 -24.85 70.06 Favored 'Trans proline' 0 C--N 1.349 0.599 0 C-N-CA 122.726 2.284 . . . . 0.0 112.527 -179.664 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 145' ' ' MET . . . . . 0.494 ' HE3' HD12 ' A' ' 93' ' ' LEU . 62.0 mtt -59.96 -25.91 65.59 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 121.14 0.495 . . . . 0.0 110.798 179.788 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 146' ' ' THR . . . . . . . . . . . . . 17.5 m -73.79 -51.2 17.2 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 115.636 -0.711 . . . . 0.0 112.364 -178.802 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 45.7 mt-10 -75.85 -28.76 58.32 Favored 'General case' 0 C--N 1.328 -0.327 0 N-CA-C 111.856 0.317 . . . . 0.0 111.856 -178.845 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 148' ' ' SER . . . . . . . . . . . . . 37.1 t -70.66 -48.09 56.64 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-O 120.746 0.307 . . . . 0.0 111.607 -179.103 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 149' ' ' ALA . . . . . . . . . . . . . . . -74.7 -44.74 48.55 Favored 'General case' 0 C--N 1.329 -0.324 0 N-CA-C 111.994 0.368 . . . . 0.0 111.994 -179.068 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 150' ' ' SER . . . . . . . . . . . . . 87.7 p -63.65 -11.83 28.73 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.647 0.261 . . . . 0.0 111.273 -179.629 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 151' ' ' GLN . . . . . . . . . . . . . 25.5 mt-30 -124.37 21.75 8.62 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.333 -0.394 . . . . 0.0 111.248 -179.702 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 28.9 tpt180 -92.02 -51.43 5.2 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.916 0.389 . . . . 0.0 110.418 179.659 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 153' ' ' SER . . . . . 0.636 ' HB3' HG12 ' A' ' 156' ' ' ILE . 32.4 t -157.43 167.76 29.29 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.09 -0.505 . . . . 0.0 110.71 179.092 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 154' ' ' SER . . . . . . . . . . . . . 44.8 t -67.65 -36.3 80.5 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-O 120.968 0.413 . . . . 0.0 110.608 179.476 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -76.97 -36.84 34.71 Favored Glycine 0 N--CA 1.451 -0.361 0 C-N-CA 120.97 -0.633 . . . . 0.0 112.887 -179.912 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 156' ' ' ILE . . . . . 0.636 HG12 ' HB3' ' A' ' 153' ' ' SER . 39.7 mm -52.83 -36.24 23.1 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.21 0 CA-C-O 120.722 0.296 . . . . 0.0 111.315 -179.922 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 157' ' ' LYS . . . . . . . . . . . . . 85.3 tttt -54.38 -49.14 70.54 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.75 -179.611 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 42.8 t -63.97 -48.43 76.47 Favored 'General case' 0 C--N 1.33 -0.245 0 N-CA-C 111.891 0.33 . . . . 0.0 111.891 -179.189 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 159' ' ' LEU . . . . . 0.429 HD23 HD12 ' A' ' 163' ' ' LEU . 2.8 tt -67.36 -28.56 68.06 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-O 120.943 0.401 . . . . 0.0 110.673 -179.622 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 160' ' ' TYR . . . . . . . . . . . . . 25.3 t80 -73.57 -47.72 38.38 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.87 -179.245 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 161' ' ' VAL . . . . . 0.452 HG22 ' N ' ' A' ' 162' ' ' ARG . 31.0 m -62.46 -42.72 96.8 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.391 0 N-CA-C 112.414 0.524 . . . . 0.0 112.414 -178.565 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 162' ' ' ARG . . . . . 0.452 ' N ' HG22 ' A' ' 161' ' ' VAL . 22.3 mmm180 -68.6 -49.81 56.43 Favored 'General case' 0 C--N 1.328 -0.362 0 N-CA-C 111.746 0.276 . . . . 0.0 111.746 -178.747 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 163' ' ' LEU . . . . . 0.429 HD12 HD23 ' A' ' 159' ' ' LEU . 7.6 mp -70.2 -39.15 75.36 Favored 'General case' 0 C--N 1.328 -0.335 0 N-CA-C 112.195 0.443 . . . . 0.0 112.195 -178.722 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 164' ' ' ARG . . . . . 0.445 ' NH1' ' HA ' ' A' ' 141' ' ' LEU . 21.9 tpp180 -58.37 -54.37 47.75 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 120.751 0.31 . . . . 0.0 110.786 -179.783 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 165' ' ' ASN . . . . . 0.536 ' N ' HD21 ' A' ' 165' ' ' ASN . 0.8 OUTLIER -57.06 -37.82 72.36 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.005 -0.543 . . . . 0.0 110.18 179.812 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 166' ' ' LEU . . . . . 0.55 HD11 HD12 ' A' ' 211' ' ' ILE . 3.6 mt -61.24 -56.3 22.22 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 115.914 -0.585 . . . . 0.0 111.562 179.877 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 167' ' ' THR . . . . . 0.481 ' O ' ' HB2' ' A' ' 171' ' ' TRP . 16.7 m -54.31 -54.42 40.49 Favored 'General case' 0 C--N 1.331 -0.202 0 N-CA-C 112.198 0.444 . . . . 0.0 112.198 -177.981 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 168' ' ' VAL . . . . . . . . . . . . . 42.1 t -52.64 -41.75 38.66 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.603 0 N-CA-C 112.594 0.59 . . . . 0.0 112.594 -179.3 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 169' ' ' VAL . . . . . 0.506 ' O ' HG12 ' A' ' 173' ' ' ILE . 74.7 t -71.21 -68.08 0.42 Allowed 'Isoleucine or valine' 0 CA--C 1.531 0.245 0 N-CA-C 113.988 1.107 . . . . 0.0 113.988 -177.446 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 170' ' ' LEU . . . . . 0.48 HD11 ' HA ' ' A' ' 167' ' ' THR . 0.3 OUTLIER -57.61 -36.47 71.81 Favored 'General case' 0 N--CA 1.467 0.39 0 N-CA-C 112.835 0.68 . . . . 0.0 112.835 -177.382 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 171' ' ' TRP . . . . . 0.481 ' HB2' ' O ' ' A' ' 167' ' ' THR . 7.9 m0 -70.97 -34.21 71.19 Favored 'General case' 0 C--N 1.329 -0.321 0 C-N-CA 120.477 -0.489 . . . . 0.0 111.356 -179.785 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 172' ' ' ALA . . . . . 0.413 ' HA ' ' CZ ' ' A' ' 134' ' ' PHE . . . -72.4 -7.08 47.84 Favored 'General case' 0 C--N 1.332 -0.182 0 C-N-CA 120.797 -0.361 . . . . 0.0 110.862 179.848 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 173' ' ' ILE . . . . . 0.506 HG12 ' O ' ' A' ' 169' ' ' VAL . 50.8 mm -87.59 -25.75 5.98 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.23 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.795 179.607 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 174' ' ' TYR . . . . . . . . . . . . . 38.8 m-85 -55.0 -49.02 94.5 Favored Pre-proline 0 CA--C 1.531 0.216 0 CA-C-N 116.253 -0.431 . . . . 0.0 111.684 -179.741 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 175' ' ' PRO . . . . . 0.443 ' HB3' ' HZ ' ' A' ' 127' ' ' PHE . 79.9 Cg_exo -45.8 -30.94 7.2 Favored 'Trans proline' 0 C--N 1.352 0.739 0 C-N-CA 122.169 1.913 . . . . 0.0 111.954 179.422 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 176' ' ' PHE . . . . . 0.464 ' O ' ' HG ' ' A' ' 180' ' ' LEU . 86.3 m-85 -80.08 -49.16 12.14 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 115.81 -0.632 . . . . 0.0 111.388 179.83 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 177' ' ' ILE . . . . . 0.485 HD11 HG22 ' A' ' 173' ' ' ILE . 3.8 mm -60.16 -36.94 71.23 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.551 0 N-CA-C 112.307 0.484 . . . . 0.0 112.307 -178.49 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 178' ' ' TRP . . . . . . . . . . . . . 76.5 t90 -73.35 -44.45 58.74 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.942 0.401 . . . . 0.0 110.619 -179.87 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 179' ' ' LEU . . . . . . . . . . . . . 1.4 tm? -67.51 -54.3 21.27 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 115.952 -0.567 . . . . 0.0 111.155 -179.48 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 180' ' ' LEU . . . . . 0.531 HD21 HD13 ' A' ' 187' ' ' LEU . 16.5 mt -68.42 -50.3 53.78 Favored 'General case' 0 C--N 1.328 -0.327 0 N-CA-C 111.992 0.367 . . . . 0.0 111.992 -179.021 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . -54.62 176.35 0.44 Allowed Glycine 0 C--N 1.337 0.602 0 C-N-CA 120.219 -0.991 . . . . 0.0 112.861 -179.948 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 182' ' ' PRO . . . . . 0.448 ' HB2' ' HD3' ' A' ' 183' ' ' PRO . 83.8 Cg_exo -45.3 -44.77 15.88 Favored 'Trans proline' 0 C--N 1.349 0.583 0 C-N-CA 122.92 2.413 . . . . 0.0 113.599 179.692 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 183' ' ' PRO . . . . . 0.451 ' HB3' ' HB2' ' A' ' 116' ' ' ALA . 88.7 Cg_exo -46.38 -23.42 2.08 Favored 'Trans proline' 0 C--N 1.356 0.944 0 C-N-CA 122.277 1.985 . . . . 0.0 113.122 179.815 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 184' ' ' GLY . . . . . . . . . . . . . . . -123.53 -127.07 3.19 Favored Glycine 0 C--N 1.331 0.298 0 C-N-CA 120.554 -0.831 . . . . 0.0 112.797 -179.901 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 185' ' ' VAL . . . . . . . . . . . . . 16.5 m -60.05 -19.9 18.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 N-CA-C 111.992 0.368 . . . . 0.0 111.992 -179.541 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 186' ' ' ALA . . . . . . . . . . . . . . . 57.51 87.18 0.07 Allowed 'General case' 0 C--N 1.331 -0.2 0 CA-C-O 120.712 0.291 . . . . 0.0 111.4 179.863 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 187' ' ' LEU . . . . . 0.531 HD13 HD21 ' A' ' 180' ' ' LEU . 21.2 mt -91.95 -49.59 6.15 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.299 -0.41 . . . . 0.0 111.079 -179.821 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 188' ' ' LEU . . . . . . . . . . . . . 90.5 mt -103.52 -161.65 0.85 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 115.961 -0.563 . . . . 0.0 110.983 -179.82 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 189' ' ' THR . . . . . . . . . . . . . 1.6 t -92.44 147.04 33.6 Favored Pre-proline 0 C--N 1.329 -0.298 0 CA-C-N 116.079 -0.509 . . . . 0.0 111.061 -179.83 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 190' ' ' PRO . . . . . . . . . . . . . 9.2 Cg_endo -52.58 -33.15 57.16 Favored 'Trans proline' 0 C--N 1.349 0.579 0 C-N-CA 122.772 2.315 . . . . 0.0 112.422 -179.949 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 191' ' ' THR . . . . . . . . . . . . . 80.6 p -62.73 -43.73 98.06 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.34 -0.391 . . . . 0.0 111.033 179.882 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 192' ' ' VAL . . . . . . . . . . . . . 30.3 t -71.51 -46.62 62.55 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 115.94 -0.573 . . . . 0.0 111.118 -179.857 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 193' ' ' ASP . . . . . . . . . . . . . 34.3 t70 -56.78 -51.59 68.35 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.398 -0.365 . . . . 0.0 111.139 -179.749 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 194' ' ' VAL . . . . . . . . . . . . . 76.3 t -61.06 -36.56 73.31 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.391 -0.368 . . . . 0.0 110.988 179.818 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 195' ' ' ALA . . . . . . . . . . . . . . . -56.01 -48.15 76.47 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.493 -0.321 . . . . 0.0 111.168 179.89 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 196' ' ' LEU . . . . . . . . . . . . . 72.1 mt -67.38 -41.39 85.1 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.421 -0.354 . . . . 0.0 110.713 179.83 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 197' ' ' ILE . . . . . . . . . . . . . 17.2 mm -57.13 -56.08 16.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.473 179.407 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 198' ' ' VAL . . . . . . . . . . . . . 71.5 t -52.9 -35.03 21.25 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.417 0 CA-C-N 115.509 -0.769 . . . . 0.0 109.471 178.612 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 199' ' ' TYR . . . . . . . . . . . . . 53.3 t80 -70.54 -36.31 73.62 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 115.333 -0.849 . . . . 0.0 110.594 179.661 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 200' ' ' LEU . . . . . . . . . . . . . 73.0 mt -64.44 -38.74 92.1 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 115.658 -0.701 . . . . 0.0 111.343 -179.63 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 201' ' ' ASP . . . . . 0.436 ' HB2' ' OH ' ' A' ' 51' ' ' TYR . 0.8 OUTLIER -73.6 -32.32 64.04 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-O 121.04 0.447 . . . . 0.0 110.39 179.663 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 202' ' ' LEU . . . . . 0.417 ' O ' ' HB ' ' A' ' 206' ' ' VAL . 3.7 mt -71.64 -32.52 68.02 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 115.831 -0.622 . . . . 0.0 111.92 -179.649 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 203' ' ' VAL . . . . . 0.477 ' O ' ' HA3' ' A' ' 207' ' ' GLY . 7.4 p -78.83 -37.02 19.7 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-O 120.639 0.257 . . . . 0.0 111.375 -178.927 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 204' ' ' THR . . . . . . . . . . . . . 26.2 m -72.87 -49.99 26.56 Favored 'General case' 0 C--N 1.326 -0.448 0 C-N-CA 120.728 -0.389 . . . . 0.0 111.31 179.696 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 205' ' ' LYS . . . . . 0.557 ' HE2' ' HB3' ' A' ' 47' ' ' ALA . 54.5 mttp -69.98 -59.26 3.03 Favored 'General case' 0 C--N 1.326 -0.421 0 N-CA-C 112.165 0.431 . . . . 0.0 112.165 -178.8 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 206' ' ' VAL . . . . . 0.417 ' HB ' ' O ' ' A' ' 202' ' ' LEU . 48.6 t -74.69 -37.61 43.34 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.25 0 N-CA-C 111.964 0.357 . . . . 0.0 111.964 -178.727 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 207' ' ' GLY . . . . . 0.477 ' HA3' ' O ' ' A' ' 203' ' ' VAL . . . -62.86 -56.63 19.88 Favored Glycine 0 N--CA 1.45 -0.379 0 C-N-CA 120.258 -0.972 . . . . 0.0 112.01 -179.405 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 208' ' ' PHE . . . . . 0.513 ' O ' ' N ' ' A' ' 212' ' ' ALA . 3.1 m-85 -53.95 -47.75 70.98 Favored 'General case' 0 C--O 1.22 -0.469 0 N-CA-C 109.896 -0.409 . . . . 0.0 109.896 179.606 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 209' ' ' GLY . . . . . 0.477 ' O ' ' HG ' ' A' ' 213' ' ' LEU . . . -53.9 -35.21 52.9 Favored Glycine 0 N--CA 1.45 -0.374 0 CA-C-N 115.091 -0.959 . . . . 0.0 113.399 179.585 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 210' ' ' PHE . . . . . . . . . . . . . 5.2 m-85 -72.46 -47.23 50.52 Favored 'General case' 0 CA--C 1.512 -0.498 0 N-CA-C 108.716 -0.846 . . . . 0.0 108.716 179.801 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 211' ' ' ILE . . . . . 0.55 HD12 HD11 ' A' ' 166' ' ' LEU . 3.6 mt -65.05 -26.93 41.11 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.65 0 N-CA-C 107.665 -1.235 . . . . 0.0 107.665 176.444 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 212' ' ' ALA . . . . . 0.513 ' N ' ' O ' ' A' ' 208' ' ' PHE . . . -68.44 -38.66 81.37 Favored 'General case' 0 N--CA 1.45 -0.466 0 CA-C-N 114.3 -1.318 . . . . 0.0 110.422 -179.869 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 213' ' ' LEU . . . . . 0.477 ' HG ' ' O ' ' A' ' 209' ' ' GLY . 47.2 mt -69.82 -54.31 14.16 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-N 115.301 -0.863 . . . . 0.0 111.636 -179.498 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 214' ' ' ASP . . . . . . . . . . . . . 14.6 m-20 -52.21 -54.66 28.2 Favored 'General case' 0 C--O 1.234 0.26 0 CA-C-N 116.389 -0.369 . . . . 0.0 111.326 -179.514 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 215' ' ' ALA . . . . . . . . . . . . . . . -57.48 -54.87 41.92 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.357 -0.383 . . . . 0.0 111.036 179.984 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 216' ' ' ALA . . . . . . . . . . . . . . . -57.52 -30.73 65.39 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.28 179.925 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 217' ' ' ALA . . . . . . . . . . . . . . . -64.02 -38.34 90.73 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.557 -179.918 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 218' ' ' THR . . . . . . . . . . . . . 69.7 m . . . . . 0 C--N 1.33 -0.26 0 CA-C-N 115.82 -0.627 . . . . 0.0 111.247 179.855 . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.323 0 N-CA-C 112.514 -0.235 . . . . 0.0 112.514 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 55.3 tp -74.02 -36.31 64.45 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.685 0.279 . . . . 0.0 111.21 -179.88 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 82.6 p -66.3 -29.97 70.29 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.432 -0.349 . . . . 0.0 111.409 -179.693 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 22.7 p -54.22 -35.13 62.09 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.269 179.996 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 7' ' ' LEU . . . . . . . . . . . . . 3.9 mm? -57.66 -53.13 61.66 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.111 -0.495 . . . . 0.0 111.172 -179.971 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 8' ' ' PHE . . . . . 0.539 ' HB2' ' HB3' ' A' ' 55' ' ' ALA . 77.8 m-85 -59.07 -35.66 73.75 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.346 -0.388 . . . . 0.0 110.762 179.858 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 9' ' ' TRP . . . . . . . . . . . . . 47.5 m95 -64.67 -45.91 84.67 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.024 -0.534 . . . . 0.0 110.059 -179.824 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . 0.408 ' HA ' HD12 ' A' ' 13' ' ' ILE . 87.2 mt -61.08 -37.83 84.11 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-N 115.545 -0.752 . . . . 0.0 110.154 179.333 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -65.82 -35.46 90.9 Favored Glycine 0 N--CA 1.448 -0.53 0 C-N-CA 120.814 -0.708 . . . . 0.0 111.486 179.124 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -67.44 -31.21 71.24 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 120.977 0.418 . . . . 0.0 110.476 179.448 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 13' ' ' ILE . . . . . 0.413 ' O ' HG22 ' A' ' 17' ' ' VAL . 88.5 mt -64.68 -54.22 32.78 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.235 0 CA-C-N 115.864 -0.607 . . . . 0.0 110.214 179.418 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -65.99 -32.45 82.6 Favored Glycine 0 N--CA 1.45 -0.377 0 C-N-CA 120.61 -0.805 . . . . 0.0 111.637 179.109 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 15' ' ' MET . . . . . 0.488 ' SD ' ' HA ' ' A' ' 44' ' ' SER . 51.3 tpp -65.83 -40.16 91.53 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-O 120.823 0.344 . . . . 0.0 110.448 179.657 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 1.6 mm? -64.02 -37.98 89.4 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-N 116.08 -0.509 . . . . 0.0 110.207 179.173 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 17' ' ' VAL . . . . . 0.413 HG22 ' O ' ' A' ' 13' ' ' ILE . 72.0 t -59.04 -42.63 86.91 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.205 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.158 179.07 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -68.8 -46.2 61.63 Favored Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.731 -0.747 . . . . 0.0 111.679 178.965 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 47.9 m -50.25 -46.66 55.08 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 120.865 0.364 . . . . 0.0 111.081 179.896 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 93.6 mt -72.19 -45.75 59.08 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.035 -0.529 . . . . 0.0 111.639 179.939 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -58.85 -30.85 68.0 Favored 'General case' 0 C--N 1.329 -0.296 0 N-CA-C 112.081 0.4 . . . . 0.0 112.081 -179.23 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 13.0 m-85 -90.79 -31.36 16.54 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 120.666 0.27 . . . . 0.0 111.509 -179.252 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -71.63 -50.28 32.22 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 121.101 0.477 . . . . 0.0 111.173 -179.811 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 24' ' ' TRP . . . . . . . . . . . . . 3.1 t-105 -61.43 -43.82 98.19 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-N 115.614 -0.721 . . . . 0.0 111.329 -179.624 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.328 -0.338 0 CA-C-O 120.698 0.285 . . . . 0.0 111.057 -179.989 . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.25 0 N-CA-C 112.153 -0.379 . . . . 0.0 112.153 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 10.0 mm-40 -90.59 -20.68 22.32 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 120.752 0.311 . . . . 0.0 110.83 179.838 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 34' ' ' ARG . . . . . . . . . . . . . 54.3 mtp180 -48.43 -29.49 4.12 Favored 'General case' 0 C--N 1.333 -0.151 0 CA-C-N 115.997 -0.547 . . . . 0.0 111.547 -179.819 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 75.2 mtp180 -60.85 -48.38 82.07 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.44 -0.346 . . . . 0.0 111.023 -179.899 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 62.9 m-85 -68.66 -31.66 70.94 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.021 -0.536 . . . . 0.0 111.362 -179.678 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 37' ' ' TYR . . . . . . . . . . . . . 53.6 m-85 -69.4 -54.49 14.13 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.301 -0.409 . . . . 0.0 111.279 -179.498 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 85.3 t -57.08 -36.7 52.04 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.249 0 CA-C-O 121.011 0.434 . . . . 0.0 110.525 179.729 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 30.3 m -64.38 -49.43 71.65 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 115.789 -0.641 . . . . 0.0 110.502 179.354 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 30.5 tp -55.99 -47.73 77.17 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.718 -0.674 . . . . 0.0 110.286 179.614 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 62.3 t -62.24 -34.32 63.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 115.733 -0.667 . . . . 0.0 110.016 178.95 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -57.85 -38.77 89.96 Favored Glycine 0 N--CA 1.448 -0.501 0 C-N-CA 120.859 -0.686 . . . . 0.0 112.035 179.684 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 43' ' ' ILE . . . . . 0.534 HG23 ' HE3' ' A' ' 205' ' ' LYS . 0.2 OUTLIER -68.44 -53.42 28.26 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.186 0 CA-C-O 120.825 0.345 . . . . 0.0 110.698 179.583 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 44' ' ' SER . . . . . 0.488 ' HA ' ' SD ' ' A' ' 15' ' ' MET . 45.8 m -59.11 -24.47 63.0 Favored 'General case' 0 C--N 1.333 -0.146 0 CA-C-N 116.136 -0.484 . . . . 0.0 111.466 -179.777 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -75.89 -57.16 4.19 Favored Glycine 0 CA--C 1.518 0.281 0 C-N-CA 120.766 -0.731 . . . . 0.0 113.106 -179.333 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 17.0 pt -58.17 -35.71 54.19 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-O 120.818 0.342 . . . . 0.0 111.262 -179.602 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 47' ' ' ALA . . . . . 0.665 ' HB2' ' HE2' ' A' ' 205' ' ' LYS . . . -67.73 -44.39 77.71 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-O 120.966 0.412 . . . . 0.0 110.943 179.158 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -54.38 -44.46 72.29 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 115.791 -0.641 . . . . 0.0 111.723 -179.385 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 34.2 m -71.54 -34.04 51.48 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.228 0 CA-C-N 116.532 -0.304 . . . . 0.0 111.415 -179.63 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -64.34 -37.33 87.13 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 121.046 0.45 . . . . 0.0 110.874 179.695 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 51' ' ' TYR . . . . . 0.424 ' OH ' ' HB2' ' A' ' 201' ' ' ASP . 33.2 m-85 -73.36 -36.19 66.07 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 115.946 -0.57 . . . . 0.0 110.62 179.979 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -65.99 -38.97 89.88 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 115.826 -0.625 . . . . 0.0 111.025 179.796 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 53' ' ' VAL . . . . . 0.474 HG22 ' N ' ' A' ' 54' ' ' MET . 33.6 m -74.81 -50.35 25.9 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.194 0 CA-C-N 116.588 -0.278 . . . . 0.0 111.05 -179.887 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 54' ' ' MET . . . . . 0.474 ' N ' HG22 ' A' ' 53' ' ' VAL . 75.8 mtm -58.02 -29.69 65.51 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-O 121.009 0.433 . . . . 0.0 110.309 179.514 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 55' ' ' ALA . . . . . 0.539 ' HB3' ' HB2' ' A' ' 8' ' ' PHE . . . -73.85 -25.92 60.31 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 115.786 -0.643 . . . . 0.0 111.278 179.732 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 74.6 mt -80.28 -8.37 59.44 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.276 -0.42 . . . . 0.0 111.622 -179.625 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 102.31 -17.48 53.63 Favored Glycine 0 N--CA 1.453 -0.226 0 C-N-CA 120.438 -0.887 . . . . 0.0 113.054 179.671 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 12.7 p -69.43 150.86 10.21 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.957 0.379 . . . . 0.0 110.439 179.717 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 75.55 27.24 63.67 Favored Glycine 0 N--CA 1.449 -0.472 0 C-N-CA 120.723 -0.751 . . . . 0.0 111.731 -178.946 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 60' ' ' TRP . . . . . . . . . . . . . 13.8 m0 -108.7 99.15 8.55 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-O 120.947 0.403 . . . . 0.0 110.285 -179.879 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 61' ' ' VAL . . . . . 0.485 ' HB ' HG22 ' A' ' 68' ' ' VAL . 25.6 t -97.77 110.69 56.45 Favored Pre-proline 0 C--N 1.325 -0.459 0 CA-C-N 115.877 -0.601 . . . . 0.0 111.526 -179.299 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 17.2 Cg_exo -67.2 138.87 48.49 Favored 'Trans proline' 0 C--N 1.35 0.606 0 C-N-CA 122.577 2.184 . . . . 0.0 111.866 179.678 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 93.1 t -139.96 92.17 0.65 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.38 -179.694 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . 56.65 -91.7 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.117 -0.492 . . . . 0.0 111.85 179.656 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 42.9 mt-10 -115.23 -17.61 11.31 Favored 'General case' 0 C--N 1.332 -0.195 0 CA-C-O 120.837 0.351 . . . . 0.0 111.054 -179.652 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 66' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -104.81 165.56 10.99 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.285 179.77 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 91.0 m -130.09 118.81 22.08 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-N 116.295 -0.411 . . . . 0.0 111.414 -179.573 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 68' ' ' VAL . . . . . 0.485 HG22 ' HB ' ' A' ' 61' ' ' VAL . 18.5 m -100.37 141.51 17.18 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.377 0 CA-C-N 115.991 -0.55 . . . . 0.0 110.53 179.495 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 69' ' ' PHE . . . . . . . . . . . . . 24.2 m-85 -109.84 122.75 48.24 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.276 -0.42 . . . . 0.0 110.248 -179.428 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 70' ' ' VAL . . . . . 0.59 HG13 ' HD3' ' A' ' 71' ' ' PRO . 1.3 p -68.13 -35.97 8.33 Favored Pre-proline 0 CA--C 1.54 0.573 0 N-CA-C 112.549 0.574 . . . . 0.0 112.549 -179.541 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 71' ' ' PRO . . . . . 0.59 ' HD3' HG13 ' A' ' 70' ' ' VAL . 5.7 Cg_exo -71.48 -19.87 28.0 Favored 'Trans proline' 0 C--N 1.359 1.122 0 C-N-CA 121.942 1.762 . . . . 0.0 112.47 -179.729 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 56.5 ttt180 -68.68 -55.28 11.95 Favored 'General case' 0 C--O 1.236 0.378 0 CA-C-N 116.403 -0.362 . . . . 0.0 111.67 -179.181 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 73' ' ' TYR . . . . . 0.438 ' O ' HG13 ' A' ' 77' ' ' ILE . 28.2 m-85 -72.17 -30.16 64.71 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.492 -0.322 . . . . 0.0 110.655 -179.418 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 74' ' ' ILE . . . . . 0.471 ' HA ' HD12 ' A' ' 77' ' ' ILE . 0.4 OUTLIER -72.52 -38.29 59.31 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.237 0 N-CA-C 109.829 -0.434 . . . . 0.0 109.829 179.253 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 12.9 t70 -59.11 -38.69 80.15 Favored 'General case' 0 CA--C 1.518 -0.257 0 N-CA-C 109.322 -0.621 . . . . 0.0 109.322 178.861 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 76' ' ' TRP . . . . . . . . . . . . . 45.6 m0 -65.73 -37.74 87.23 Favored 'General case' 0 C--N 1.331 -0.21 0 CA-C-N 115.702 -0.681 . . . . 0.0 110.358 179.166 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 77' ' ' ILE . . . . . 0.503 ' O ' ' HG2' ' A' ' 81' ' ' PRO . 89.5 mt -62.4 -30.67 49.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.468 178.973 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 41.7 mt -92.06 -19.81 21.96 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.07 -0.514 . . . . 0.0 112.222 -179.717 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 73.6 p -101.28 -52.99 3.12 Favored 'General case' 0 N--CA 1.463 0.205 0 N-CA-C 113.446 0.906 . . . . 0.0 113.446 -178.033 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 80' ' ' THR . . . . . 0.642 ' HB ' ' HD3' ' A' ' 81' ' ' PRO . 59.8 m -48.74 -53.97 31.75 Favored Pre-proline 0 C--N 1.331 -0.219 0 N-CA-C 112.406 0.521 . . . . 0.0 112.406 -178.838 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 81' ' ' PRO . . . . . 0.642 ' HD3' ' HB ' ' A' ' 80' ' ' THR . 31.5 Cg_exo -59.87 -23.4 72.29 Favored 'Trans proline' 0 C--N 1.353 0.805 0 C-N-CA 121.718 1.612 . . . . 0.0 111.772 179.965 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 82' ' ' LEU . . . . . . . . . . . . . 18.4 tp -76.93 -33.11 57.74 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.043 -0.526 . . . . 0.0 110.469 179.68 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 83' ' ' ILE . . . . . 0.417 HD11 HG21 ' A' ' 43' ' ' ILE . 35.0 mm -68.26 -53.71 26.96 Favored 'Isoleucine or valine' 0 C--O 1.234 0.244 0 CA-C-N 116.367 -0.379 . . . . 0.0 110.036 179.246 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 20.7 m -59.98 -30.98 46.65 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.23 0 N-CA-C 109.415 -0.587 . . . . 0.0 109.415 178.506 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 85' ' ' TYR . . . . . . . . . . . . . 80.8 t80 -66.38 -31.49 72.3 Favored 'General case' 0 N--CA 1.454 -0.242 0 CA-C-N 115.382 -0.827 . . . . 0.0 109.637 178.764 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 86' ' ' PHE . . . . . . . . . . . . . 14.6 t80 -64.33 -51.34 63.88 Favored 'General case' 0 C--O 1.232 0.169 0 CA-C-N 115.819 -0.628 . . . . 0.0 109.865 179.385 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 7.4 mp -60.8 -36.04 78.03 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 115.729 -0.668 . . . . 0.0 110.253 179.445 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -67.24 -27.67 73.54 Favored Glycine 0 N--CA 1.45 -0.395 0 C-N-CA 120.904 -0.665 . . . . 0.0 112.082 179.657 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 40.5 mt -71.66 -42.55 67.37 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-O 121.027 0.441 . . . . 0.0 110.421 179.801 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 90' ' ' LEU . . . . . 0.403 ' HB3' HG23 ' A' ' 156' ' ' ILE . 81.0 mt -56.13 -42.43 76.89 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 115.688 -0.687 . . . . 0.0 111.198 -179.971 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 91' ' ' ALA . . . . . 0.58 ' HB3' ' HB1' ' A' ' 149' ' ' ALA . . . -79.3 -45.99 18.59 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.311 -0.404 . . . . 0.0 111.393 -179.597 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 97.73 50.66 1.63 Allowed Glycine 0 N--CA 1.45 -0.373 0 C-N-CA 120.712 -0.756 . . . . 0.0 112.229 -179.583 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 93' ' ' LEU . . . . . 0.49 HD23 ' HB3' ' A' ' 97' ' ' GLU . 10.8 mp -61.61 171.55 1.5 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.958 0.409 . . . . 0.0 111.24 -179.891 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 94' ' ' ASP . . . . . . . . . . . . . 24.2 t70 -90.46 167.61 12.47 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 115.963 -0.562 . . . . 0.0 110.462 179.722 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 47.3 t -55.04 -35.42 64.46 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.355 -0.384 . . . . 0.0 111.107 179.983 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 5.3 mmp_? -73.83 -50.49 20.18 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.09 -0.504 . . . . 0.0 111.33 -179.858 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 97' ' ' GLU . . . . . 0.49 ' HB3' HD23 ' A' ' 93' ' ' LEU . 46.6 mt-10 -52.37 -45.2 65.66 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.34 -0.391 . . . . 0.0 111.291 -179.606 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 98' ' ' PHE . . . . . . . . . . . . . 28.2 m-85 -59.55 -46.69 88.16 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.488 -0.324 . . . . 0.0 110.864 179.824 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -57.67 -28.58 60.21 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.524 -0.846 . . . . 0.0 112.466 179.848 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 79.6 mt -73.83 -48.7 38.26 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.181 0 N-CA-C 112.125 0.417 . . . . 0.0 112.125 -179.563 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 29.4 m -67.98 -41.75 84.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 N-CA-C 112.049 0.388 . . . . 0.0 112.049 -179.001 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 102' ' ' ILE . . . . . 0.459 HG21 ' HB3' ' A' ' 81' ' ' PRO . 50.9 mm -63.88 -49.35 82.22 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.675 -0.239 . . . . 0.0 111.505 -179.463 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 15.3 t -59.72 -34.75 73.33 Favored 'General case' 0 C--O 1.233 0.208 0 CA-C-O 120.951 0.405 . . . . 0.0 110.643 179.873 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 1.3 tm? -56.29 -54.08 49.67 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.008 -0.542 . . . . 0.0 109.698 179.05 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 105' ' ' ASN . . . . . 0.627 ' N ' HD21 ' A' ' 105' ' ' ASN . 0.8 OUTLIER -58.23 -34.03 69.99 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 115.591 -0.731 . . . . 0.0 110.83 179.605 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 85.4 m -56.54 -43.79 80.24 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.295 -0.411 . . . . 0.0 110.734 179.803 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 1.5 t -66.81 -42.18 88.87 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-O 121.2 0.524 . . . . 0.0 110.348 179.383 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 93.5 t -57.99 -51.17 73.99 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.386 0 CA-C-N 115.318 -0.856 . . . . 0.0 111.679 -179.722 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 109' ' ' MET . . . . . 0.463 ' HE2' HG21 ' A' ' 80' ' ' THR . 1.5 mpp? -65.22 -37.52 87.53 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.37 -179.588 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 32.4 tp -66.71 -31.5 72.2 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 116.39 -0.368 . . . . 0.0 110.58 -179.893 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -65.42 -52.56 52.5 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.394 179.487 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . -66.26 -31.43 79.07 Favored Glycine 0 N--CA 1.449 -0.434 0 C-N-CA 120.749 -0.738 . . . . 0.0 111.883 179.37 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 113' ' ' PHE . . . . . . . . . . . . . 0.4 OUTLIER -57.14 -70.69 0.12 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 121.032 0.444 . . . . 0.0 110.061 179.567 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 114' ' ' ALA . . . . . 0.446 ' HB3' HD23 ' A' ' 126' ' ' LEU . . . -64.09 -18.55 64.49 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 115.72 -0.673 . . . . 0.0 110.758 179.577 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -57.77 -53.62 43.79 Favored Glycine 0 C--N 1.332 0.314 0 C-N-CA 120.943 -0.646 . . . . 0.0 112.263 179.802 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 116' ' ' ALA . . . . . 0.51 ' HB2' ' HB3' ' A' ' 183' ' ' PRO . . . -77.48 -14.98 59.56 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.784 0.326 . . . . 0.0 111.271 179.927 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 117' ' ' MET . . . . . . . . . . . . . 17.9 mmt -86.33 13.71 7.71 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.129 -0.487 . . . . 0.0 111.589 -179.504 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 20.4 m -87.22 143.03 33.99 Favored Pre-proline 0 C--N 1.33 -0.255 0 CA-C-O 120.563 0.221 . . . . 0.0 111.371 -179.916 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 119' ' ' PRO . . . . . . . . . . . . . 68.2 Cg_endo -92.56 -2.66 3.76 Favored 'Trans proline' 0 N--CA 1.455 -0.776 0 C-N-CA 122.945 2.43 . . . . 0.0 112.267 179.441 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -132.81 -117.66 1.86 Allowed Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.779 -0.724 . . . . 0.0 112.805 -179.668 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 39.6 pt -123.26 12.97 5.31 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.234 0 CA-C-O 120.654 0.264 . . . . 0.0 111.547 -179.514 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 37.7 mt-10 -61.23 -18.65 59.4 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.375 -0.375 . . . . 0.0 110.822 179.912 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 123' ' ' ARG . . . . . 0.458 ' HB2' ' HH2' ' A' ' 178' ' ' TRP . 23.0 ptt180 -51.93 -33.79 38.92 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 115.927 -0.579 . . . . 0.0 111.615 -179.84 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 124' ' ' TYR . . . . . . . . . . . . . 59.0 m-85 -67.49 -33.3 74.81 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.459 -0.337 . . . . 0.0 111.397 -179.622 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 125' ' ' ALA . . . . . . . . . . . . . . . -72.71 -56.46 5.25 Favored 'General case' 0 C--O 1.237 0.411 0 CA-C-O 121.105 0.479 . . . . 0.0 111.073 179.835 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 126' ' ' LEU . . . . . 0.446 HD23 ' HB3' ' A' ' 114' ' ' ALA . 1.3 mt -55.24 -48.1 74.44 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 115.729 -0.669 . . . . 0.0 110.395 179.847 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 127' ' ' PHE . . . . . 0.426 ' HZ ' ' HB3' ' A' ' 175' ' ' PRO . 9.2 t80 -67.76 -30.76 70.3 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.11 -0.496 . . . . 0.0 110.334 179.316 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 128' ' ' GLY . . . . . . . . . . . . . . . -49.12 -50.58 27.76 Favored Glycine 0 N--CA 1.449 -0.441 0 C-N-CA 120.125 -1.036 . . . . 0.0 110.553 178.734 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 129' ' ' MET . . . . . 0.643 ' HE2' ' HA2' ' A' ' 130' ' ' GLY . 0.0 OUTLIER -70.84 -28.24 64.45 Favored 'General case' 0 N--CA 1.453 -0.293 0 N-CA-C 109.02 -0.733 . . . . 0.0 109.02 178.283 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 130' ' ' GLY . . . . . 0.643 ' HA2' ' HE2' ' A' ' 129' ' ' MET . . . -60.09 -41.63 98.14 Favored Glycine 0 C--N 1.335 0.48 0 CA-C-N 115.772 -0.649 . . . . 0.0 112.441 179.364 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -71.04 -49.43 44.99 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-O 120.66 0.267 . . . . 0.0 110.503 179.733 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 57.7 t -57.4 -43.72 83.07 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.217 0 CA-C-O 121.139 0.495 . . . . 0.0 109.81 179.068 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -65.86 -33.01 74.87 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 115.538 -0.756 . . . . 0.0 110.603 179.193 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 134' ' ' PHE . . . . . . . . . . . . . 71.6 t80 -59.02 -54.62 45.11 Favored 'General case' 0 N--CA 1.451 -0.385 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.038 179.58 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 135' ' ' ILE . . . . . 0.47 ' O ' HG22 ' A' ' 138' ' ' VAL . 38.2 mt -57.19 -30.38 34.74 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.312 0 CA-C-N 115.805 -0.634 . . . . 0.0 109.916 178.98 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . -62.88 -37.37 94.79 Favored Glycine 0 N--CA 1.447 -0.601 0 C-N-CA 120.31 -0.948 . . . . 0.0 111.301 178.877 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 137' ' ' LEU . . . . . 0.49 HD12 HD22 ' A' ' 105' ' ' ASN . 21.4 tp -71.45 -51.77 22.05 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 120.582 0.23 . . . . 0.0 110.8 179.536 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 138' ' ' VAL . . . . . 0.47 HG22 ' O ' ' A' ' 135' ' ' ILE . 3.9 m -56.15 -31.9 32.92 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.213 0 CA-C-O 121.299 0.571 . . . . 0.0 109.479 179.377 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 139' ' ' TYR . . . . . . . . . . . . . 35.3 t80 -63.99 -44.67 91.96 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 115.29 -0.868 . . . . 0.0 110.136 178.882 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 140' ' ' TYR . . . . . 0.454 ' HB3' ' SD ' ' A' ' 145' ' ' MET . 23.6 m-85 -54.65 -47.01 74.04 Favored 'General case' 0 C--N 1.332 -0.167 0 CA-C-N 115.974 -0.557 . . . . 0.0 111.006 179.622 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 141' ' ' LEU . . . . . . . . . . . . . 93.2 mt -59.04 -40.81 86.23 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.252 -0.431 . . . . 0.0 111.064 -179.885 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 37.8 t -79.73 -12.46 13.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-O 121.063 0.459 . . . . 0.0 110.823 179.902 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . -70.88 -140.64 0.2 Allowed Glycine 0 CA--C 1.522 0.471 0 C-N-CA 120.989 -0.624 . . . . 0.0 112.715 -179.913 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 144' ' ' PRO . . . . . . . . . . . . . 56.6 Cg_endo -70.1 -22.77 30.07 Favored 'Trans proline' 0 C--N 1.349 0.575 0 C-N-CA 122.767 2.312 . . . . 0.0 112.894 -179.93 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 145' ' ' MET . . . . . 0.454 ' SD ' ' HB3' ' A' ' 140' ' ' TYR . 81.0 mtp -52.5 -53.48 45.4 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.281 -0.418 . . . . 0.0 111.794 -179.223 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 146' ' ' THR . . . . . . . . . . . . . 10.2 t -62.45 -32.83 73.75 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.726 0.298 . . . . 0.0 111.586 -179.53 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 45.0 mt-10 -71.35 -32.64 68.78 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.309 -0.405 . . . . 0.0 111.087 -179.837 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 148' ' ' SER . . . . . . . . . . . . . 59.6 m -70.23 -36.6 74.62 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.114 -0.494 . . . . 0.0 111.21 -179.788 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 149' ' ' ALA . . . . . 0.58 ' HB1' ' HB3' ' A' ' 91' ' ' ALA . . . -75.47 -39.46 58.64 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.265 -0.425 . . . . 0.0 111.69 -179.585 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 150' ' ' SER . . . . . . . . . . . . . 69.8 m -66.19 -4.39 7.54 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.39 -0.368 . . . . 0.0 111.217 -179.792 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 151' ' ' GLN . . . . . . . . . . . . . 47.8 mt-30 -124.59 14.53 8.77 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.389 -0.369 . . . . 0.0 111.303 -179.907 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 31.9 tpt180 -91.74 -51.55 5.18 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 120.972 0.415 . . . . 0.0 110.653 179.786 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 153' ' ' SER . . . . . 0.569 ' HB2' HG12 ' A' ' 156' ' ' ILE . 45.4 m -157.54 172.63 18.2 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 115.87 -0.604 . . . . 0.0 110.576 179.466 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 154' ' ' SER . . . . . . . . . . . . . 47.9 t -67.53 -41.84 83.69 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.393 -0.367 . . . . 0.0 110.769 179.841 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -76.69 -35.89 39.19 Favored Glycine 0 C--N 1.332 0.312 0 C-N-CA 120.85 -0.691 . . . . 0.0 112.804 -179.946 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 156' ' ' ILE . . . . . 0.569 HG12 ' HB2' ' A' ' 153' ' ' SER . 39.9 mm -56.23 -39.37 59.23 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.224 0 CA-C-O 120.729 0.299 . . . . 0.0 111.46 -179.729 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 157' ' ' LYS . . . . . . . . . . . . . 62.3 tttp -61.92 -51.08 69.6 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.296 -0.411 . . . . 0.0 111.329 -179.758 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 51.4 m -64.87 -35.41 81.04 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.37 -0.377 . . . . 0.0 111.499 -179.154 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 159' ' ' LEU . . . . . 0.506 HD21 ' HB1' ' A' ' 215' ' ' ALA . 10.8 mt -68.84 -59.28 3.19 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-N 116.312 -0.403 . . . . 0.0 111.655 -179.507 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 160' ' ' TYR . . . . . . . . . . . . . 19.4 t80 -52.45 -44.97 65.82 Favored 'General case' 0 C--N 1.327 -0.374 0 N-CA-C 112.228 0.455 . . . . 0.0 112.228 -178.947 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 161' ' ' VAL . . . . . 0.447 HG23 ' N ' ' A' ' 162' ' ' ARG . 36.0 m -63.65 -45.8 96.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 N-CA-C 112.504 0.557 . . . . 0.0 112.504 -178.289 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 162' ' ' ARG . . . . . 0.476 ' O ' HD11 ' A' ' 166' ' ' LEU . 99.4 mtt180 -63.65 -49.72 72.1 Favored 'General case' 0 C--N 1.327 -0.377 0 N-CA-C 111.78 0.289 . . . . 0.0 111.78 -179.009 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 163' ' ' LEU . . . . . 0.471 ' HG ' ' O ' ' A' ' 159' ' ' LEU . 11.0 mt -67.7 -39.86 84.35 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.39 -0.368 . . . . 0.0 111.345 -178.873 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 164' ' ' ARG . . . . . . . . . . . . . 4.1 tmm_? -59.11 -47.78 84.0 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.446 -0.343 . . . . 0.0 110.756 -179.847 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 165' ' ' ASN . . . . . 0.489 ' N ' HD21 ' A' ' 165' ' ' ASN . 0.9 OUTLIER -56.02 -48.74 75.39 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.303 -0.408 . . . . 0.0 110.297 179.708 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 166' ' ' LEU . . . . . 0.476 HD11 ' O ' ' A' ' 162' ' ' ARG . 1.4 mt -57.89 -45.82 85.85 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.016 -0.538 . . . . 0.0 110.763 179.364 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 167' ' ' THR . . . . . 0.502 ' HA ' HD13 ' A' ' 170' ' ' LEU . 13.9 m -54.4 -51.42 64.91 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-N 115.936 -0.574 . . . . 0.0 112.051 -178.767 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 168' ' ' VAL . . . . . . . . . . . . . 49.3 t -57.76 -40.02 73.62 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.449 0 N-CA-C 111.903 0.334 . . . . 0.0 111.903 -179.386 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 169' ' ' VAL . . . . . 0.418 ' O ' HG12 ' A' ' 173' ' ' ILE . 93.0 t -66.74 -67.69 0.39 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 N-CA-C 113.622 0.971 . . . . 0.0 113.622 -177.947 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 170' ' ' LEU . . . . . 0.502 HD13 ' HA ' ' A' ' 167' ' ' THR . 0.4 OUTLIER -61.14 -34.06 74.39 Favored 'General case' 0 N--CA 1.463 0.222 0 N-CA-C 112.899 0.703 . . . . 0.0 112.899 -177.475 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 171' ' ' TRP . . . . . 0.487 ' HB2' ' O ' ' A' ' 167' ' ' THR . 26.9 m0 -72.59 -30.64 64.55 Favored 'General case' 0 C--N 1.327 -0.401 0 C-N-CA 120.612 -0.435 . . . . 0.0 111.514 -179.283 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 172' ' ' ALA . . . . . . . . . . . . . . . -73.04 -7.86 53.15 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-O 121.036 0.446 . . . . 0.0 110.474 179.916 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 173' ' ' ILE . . . . . 0.488 ' O ' HG12 ' A' ' 177' ' ' ILE . 37.3 mm -88.7 -26.05 5.66 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.222 0 CA-C-N 115.808 -0.633 . . . . 0.0 110.784 179.564 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 174' ' ' TYR . . . . . 0.436 ' HD1' ' HA ' ' A' ' 171' ' ' TRP . 24.1 m-85 -54.28 -49.02 92.75 Favored Pre-proline 0 N--CA 1.462 0.17 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.933 -179.197 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 175' ' ' PRO . . . . . 0.426 ' HB3' ' HZ ' ' A' ' 127' ' ' PHE . 82.8 Cg_exo -45.85 -32.74 9.63 Favored 'Trans proline' 0 C--N 1.351 0.675 0 C-N-CA 121.898 1.732 . . . . 0.0 111.798 179.555 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 176' ' ' PHE . . . . . 0.456 ' O ' ' HG ' ' A' ' 180' ' ' LEU . 60.1 m-85 -80.98 -50.77 9.29 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 115.692 -0.686 . . . . 0.0 111.717 -179.995 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 177' ' ' ILE . . . . . 0.488 HG12 ' O ' ' A' ' 173' ' ' ILE . 10.8 mm -58.69 -38.33 71.01 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.567 0 CA-C-N 116.015 -0.539 . . . . 0.0 111.897 -178.283 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 178' ' ' TRP . . . . . 0.458 ' HH2' ' HB2' ' A' ' 123' ' ' ARG . 83.4 t90 -65.88 -56.26 12.74 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-O 120.875 0.369 . . . . 0.0 110.894 -179.951 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 179' ' ' LEU . . . . . 0.536 ' HG ' HG23 ' A' ' 185' ' ' VAL . 34.0 tp -64.1 -55.24 23.42 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 115.971 -0.559 . . . . 0.0 112.066 -178.689 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 180' ' ' LEU . . . . . 0.546 HD21 HD11 ' A' ' 187' ' ' LEU . 10.1 mt -62.69 -28.65 70.09 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.661 -0.245 . . . . 0.0 111.283 -179.171 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . -72.18 -171.61 17.0 Favored Glycine 0 N--CA 1.45 -0.419 0 C-N-CA 119.929 -1.129 . . . . 0.0 111.922 179.157 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 182' ' ' PRO . . . . . 0.421 ' N ' ' HD2' ' A' ' 183' ' ' PRO . 71.4 Cg_exo -49.84 -43.63 40.08 Favored 'Trans proline' 0 CA--C 1.538 0.708 0 C-N-CA 122.759 2.306 . . . . 0.0 113.756 179.609 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 183' ' ' PRO . . . . . 0.51 ' HB3' ' HB2' ' A' ' 116' ' ' ALA . 60.7 Cg_exo -39.37 -55.74 1.46 Allowed 'Trans proline' 0 C--N 1.358 1.036 0 C-N-CA 122.73 2.287 . . . . 0.0 113.904 -179.414 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 184' ' ' GLY . . . . . . . . . . . . . . . -115.79 -111.91 2.78 Favored Glycine 0 N--CA 1.45 -0.387 0 C-N-CA 120.203 -0.999 . . . . 0.0 112.672 -179.551 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 185' ' ' VAL . . . . . 0.536 HG23 ' HG ' ' A' ' 179' ' ' LEU . 35.8 m -76.39 84.74 0.74 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.466 0 CA-C-O 121.467 0.651 . . . . 0.0 110.693 -179.74 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 186' ' ' ALA . . . . . . . . . . . . . . . -62.9 84.07 0.02 OUTLIER 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 115.73 -0.668 . . . . 0.0 111.361 179.999 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 187' ' ' LEU . . . . . 0.546 HD11 HD21 ' A' ' 180' ' ' LEU . 5.0 mt -77.27 -48.99 16.01 Favored 'General case' 0 C--N 1.332 -0.181 0 CA-C-O 120.964 0.411 . . . . 0.0 110.64 179.73 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 188' ' ' LEU . . . . . . . . . . . . . 83.1 mt -92.41 -162.13 0.9 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 115.811 -0.631 . . . . 0.0 111.378 -179.421 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 189' ' ' THR . . . . . . . . . . . . . 88.4 m -94.58 136.57 23.05 Favored Pre-proline 0 C--N 1.328 -0.349 0 CA-C-N 115.708 -0.678 . . . . 0.0 110.729 -179.974 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 190' ' ' PRO . . . . . . . . . . . . . 80.0 Cg_exo -45.33 -43.68 16.84 Favored 'Trans proline' 0 C--N 1.35 0.609 0 C-N-CA 122.561 2.174 . . . . 0.0 112.63 179.743 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 191' ' ' THR . . . . . . . . . . . . . 82.6 p -58.72 -46.39 87.46 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.329 -0.396 . . . . 0.0 111.042 179.922 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 192' ' ' VAL . . . . . . . . . . . . . 87.6 t -63.14 -47.37 92.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.117 -0.492 . . . . 0.0 111.195 -179.983 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 193' ' ' ASP . . . . . . . . . . . . . 22.3 t70 -54.83 -48.12 73.24 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.055 -0.521 . . . . 0.0 111.311 -179.705 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 194' ' ' VAL . . . . . . . . . . . . . 99.7 t -64.35 -36.12 76.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.281 -0.418 . . . . 0.0 110.887 -179.848 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 195' ' ' ALA . . . . . . . . . . . . . . . -58.2 -46.03 86.54 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.413 -0.358 . . . . 0.0 111.04 179.915 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 196' ' ' LEU . . . . . 0.403 ' O ' ' HG ' ' A' ' 200' ' ' LEU . 94.1 mt -67.01 -42.07 85.6 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.419 -0.355 . . . . 0.0 110.38 179.713 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 197' ' ' ILE . . . . . . . . . . . . . 18.7 mm -57.31 -57.83 8.46 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.231 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.398 179.256 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 198' ' ' VAL . . . . . . . . . . . . . 91.0 t -52.65 -34.82 20.08 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.493 0 CA-C-N 115.598 -0.728 . . . . 0.0 109.328 178.618 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 199' ' ' TYR . . . . . . . . . . . . . 64.4 t80 -70.41 -35.36 73.39 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 115.288 -0.869 . . . . 0.0 110.73 179.704 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 200' ' ' LEU . . . . . 0.403 ' HG ' ' O ' ' A' ' 196' ' ' LEU . 73.1 mt -66.15 -41.34 90.54 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 115.762 -0.654 . . . . 0.0 111.322 -179.485 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 201' ' ' ASP . . . . . 0.424 ' HB2' ' OH ' ' A' ' 51' ' ' TYR . 9.9 m-20 -71.81 -31.83 66.97 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 116.29 -0.414 . . . . 0.0 110.482 179.879 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 202' ' ' LEU . . . . . 0.446 ' O ' ' HB ' ' A' ' 206' ' ' VAL . 3.6 mt -72.66 -34.11 67.02 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 115.831 -0.622 . . . . 0.0 111.997 -179.558 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 203' ' ' VAL . . . . . 0.475 ' O ' ' HA3' ' A' ' 207' ' ' GLY . 7.7 p -75.42 -36.68 36.34 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-O 120.609 0.242 . . . . 0.0 111.177 -179.032 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 204' ' ' THR . . . . . . . . . . . . . 25.6 m -68.41 -55.26 12.54 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-O 120.879 0.371 . . . . 0.0 111.397 179.789 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 205' ' ' LYS . . . . . 0.665 ' HE2' ' HB2' ' A' ' 47' ' ' ALA . 54.3 mttp -68.6 -58.96 3.5 Favored 'General case' 0 C--N 1.328 -0.359 0 N-CA-C 112.397 0.517 . . . . 0.0 112.397 -178.599 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 206' ' ' VAL . . . . . 0.446 ' HB ' ' O ' ' A' ' 202' ' ' LEU . 76.6 t -73.3 -38.13 53.19 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 N-CA-C 112.217 0.451 . . . . 0.0 112.217 -178.702 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 207' ' ' GLY . . . . . 0.475 ' HA3' ' O ' ' A' ' 203' ' ' VAL . . . -63.85 -59.78 8.17 Favored Glycine 0 N--CA 1.452 -0.261 0 C-N-CA 120.341 -0.933 . . . . 0.0 112.514 -179.324 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 208' ' ' PHE . . . . . 0.512 ' O ' ' N ' ' A' ' 212' ' ' ALA . 1.8 m-30 -54.53 -47.89 72.61 Favored 'General case' 0 C--O 1.221 -0.407 0 N-CA-C 109.795 -0.446 . . . . 0.0 109.795 179.515 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 209' ' ' GLY . . . . . 0.404 ' O ' ' HB1' ' A' ' 212' ' ' ALA . . . -54.29 -35.07 54.73 Favored Glycine 0 N--CA 1.448 -0.508 0 CA-C-N 115.366 -0.834 . . . . 0.0 113.144 179.558 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 210' ' ' PHE . . . . . . . . . . . . . 1.9 m-85 -69.69 -47.67 62.41 Favored 'General case' 0 CA--C 1.515 -0.403 0 N-CA-C 108.677 -0.86 . . . . 0.0 108.677 179.334 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 211' ' ' ILE . . . . . 0.408 HG13 ' O ' ' A' ' 207' ' ' GLY . 4.0 mt -66.14 -27.47 40.9 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.486 0 N-CA-C 107.587 -1.264 . . . . 0.0 107.587 176.757 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 212' ' ' ALA . . . . . 0.512 ' N ' ' O ' ' A' ' 208' ' ' PHE . . . -67.4 -39.07 85.52 Favored 'General case' 0 N--CA 1.448 -0.536 0 CA-C-N 114.302 -1.317 . . . . 0.0 110.018 -179.768 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 213' ' ' LEU . . . . . . . . . . . . . 80.7 mt -70.21 -38.05 75.19 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 114.991 -1.004 . . . . 0.0 111.275 -179.841 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 214' ' ' ASP . . . . . . . . . . . . . 26.9 t70 -60.3 -55.09 37.87 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 116.328 -0.396 . . . . 0.0 111.016 -179.808 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 215' ' ' ALA . . . . . 0.506 ' HB1' HD21 ' A' ' 159' ' ' LEU . . . -61.05 -50.89 71.49 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.758 179.709 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 216' ' ' ALA . . . . . . . . . . . . . . . -57.45 -32.49 66.98 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.946 179.683 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 217' ' ' ALA . . . . . . . . . . . . . . . -62.72 -43.3 99.15 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-N 116.086 -0.506 . . . . 0.0 110.17 179.544 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 218' ' ' THR . . . . . . . . . . . . . 91.8 m . . . . . 0 C--N 1.331 -0.229 0 CA-C-N 115.897 -0.592 . . . . 0.0 110.472 179.267 . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.422 0 N-CA-C 112.744 -0.143 . . . . 0.0 112.744 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 52.0 tp -74.15 -35.47 64.05 Favored 'General case' 0 C--N 1.331 -0.21 0 CA-C-O 120.867 0.365 . . . . 0.0 110.752 179.928 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 64.9 p -64.15 -32.61 74.24 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.014 -0.539 . . . . 0.0 111.276 -179.99 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 15.9 p -52.87 -35.4 57.71 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.264 -179.647 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 7' ' ' LEU . . . . . . . . . . . . . 4.2 mm? -60.8 -53.34 58.52 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.242 -179.814 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 8' ' ' PHE . . . . . . . . . . . . . 64.0 m-85 -60.08 -32.7 71.2 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.928 0.394 . . . . 0.0 110.641 -179.986 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 9' ' ' TRP . . . . . 0.428 ' O ' HG13 ' A' ' 13' ' ' ILE . 35.8 m95 -67.08 -41.69 85.93 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 115.943 -0.571 . . . . 0.0 110.092 179.622 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 82.5 mt -61.57 -52.75 63.15 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 115.721 -0.672 . . . . 0.0 110.205 179.244 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -53.48 -36.46 53.77 Favored Glycine 0 N--CA 1.449 -0.492 0 C-N-CA 120.775 -0.726 . . . . 0.0 111.612 178.766 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -64.07 -34.68 78.58 Favored 'General case' 0 C--N 1.332 -0.191 0 CA-C-O 120.91 0.386 . . . . 0.0 110.226 179.258 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 13' ' ' ILE . . . . . 0.428 HG13 ' O ' ' A' ' 9' ' ' TRP . 80.1 mt -66.13 -48.48 81.3 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.219 0 CA-C-N 115.884 -0.598 . . . . 0.0 110.363 179.268 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -60.94 -32.96 81.81 Favored Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.662 -0.78 . . . . 0.0 111.482 179.35 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 15' ' ' MET . . . . . 0.536 ' HB3' ' HB2' ' A' ' 48' ' ' ALA . 0.0 OUTLIER -67.99 -42.68 80.39 Favored 'General case' 0 C--N 1.331 -0.218 0 CA-C-O 120.92 0.391 . . . . 0.0 110.553 179.186 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 32.4 tp -57.8 -41.41 82.09 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.029 -0.532 . . . . 0.0 110.442 179.474 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 89.4 t -64.65 -51.03 72.68 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.22 0 CA-C-N 115.824 -0.625 . . . . 0.0 111.094 179.972 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -62.03 -49.51 74.57 Favored Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.686 -0.769 . . . . 0.0 112.183 179.913 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 19' ' ' THR . . . . . 0.465 ' HG1' ' HB3' ' A' ' 44' ' ' SER . 51.9 m -49.77 -41.58 44.58 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-O 120.752 0.31 . . . . 0.0 111.326 -179.561 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 78.1 mt -72.07 -48.59 43.05 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.272 -0.422 . . . . 0.0 111.427 179.836 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -59.5 -29.64 68.0 Favored 'General case' 0 C--N 1.329 -0.296 0 N-CA-C 112.192 0.442 . . . . 0.0 112.192 -179.284 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 8.0 m-85 -88.11 -45.57 10.04 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-O 120.661 0.267 . . . . 0.0 111.53 -179.307 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -60.7 -50.37 73.76 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.884 0.373 . . . . 0.0 111.589 -179.615 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 24' ' ' TRP . . . . . . . . . . . . . 2.0 t-105 -58.54 -44.19 89.53 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 116.007 -0.542 . . . . 0.0 111.119 -179.727 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.328 -0.351 0 CA-C-O 120.854 0.359 . . . . 0.0 110.998 -179.998 . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.246 0 N-CA-C 112.435 -0.266 . . . . 0.0 112.435 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 11.0 mm-40 -92.12 -24.64 19.05 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.841 0.353 . . . . 0.0 110.83 179.959 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 34' ' ' ARG . . . . . . . . . . . . . 78.6 mtm180 -50.48 -29.24 9.94 Favored 'General case' 0 C--N 1.332 -0.177 0 CA-C-N 115.943 -0.572 . . . . 0.0 111.575 -179.647 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 41.3 mmt180 -60.45 -46.5 89.82 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.767 0.318 . . . . 0.0 111.33 -179.904 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 76.6 m-85 -69.88 -30.58 68.06 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.282 -0.417 . . . . 0.0 111.456 -179.605 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 37' ' ' TYR . . . . . . . . . . . . . 62.8 m-85 -70.62 -55.12 9.51 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.289 -0.414 . . . . 0.0 111.302 -179.619 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 60.7 t -57.04 -37.84 57.19 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-O 120.957 0.408 . . . . 0.0 110.453 179.774 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 41.8 m -63.58 -47.98 79.29 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 115.847 -0.615 . . . . 0.0 110.316 179.209 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 27.6 tp -57.4 -48.21 79.69 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 115.52 -0.764 . . . . 0.0 110.539 179.677 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 76.3 t -60.63 -34.48 58.78 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.231 0 CA-C-N 115.717 -0.674 . . . . 0.0 110.382 179.242 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -60.03 -40.18 96.68 Favored Glycine 0 N--CA 1.449 -0.484 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.118 179.824 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 43' ' ' ILE . . . . . 0.511 HG22 ' HE3' ' A' ' 205' ' ' LYS . 0.4 OUTLIER -65.2 -53.86 35.74 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-O 120.728 0.299 . . . . 0.0 111.008 179.583 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 44' ' ' SER . . . . . 0.465 ' HB3' ' HG1' ' A' ' 19' ' ' THR . 49.1 m -60.31 -25.75 66.0 Favored 'General case' 0 C--N 1.332 -0.181 0 CA-C-O 120.793 0.33 . . . . 0.0 111.37 -179.942 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -78.42 -51.74 5.49 Favored Glycine 0 CA--C 1.519 0.313 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.978 -179.54 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 21.8 pt -58.97 -38.73 75.41 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.217 0 CA-C-O 120.873 0.368 . . . . 0.0 111.035 -179.976 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 47' ' ' ALA . . . . . 0.604 ' HB2' ' HE2' ' A' ' 205' ' ' LYS . . . -67.85 -45.0 75.85 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.544 179.636 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 48' ' ' ALA . . . . . 0.536 ' HB2' ' HB3' ' A' ' 15' ' ' MET . . . -54.54 -41.58 69.9 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.069 -0.514 . . . . 0.0 112.024 -179.295 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 30.4 m -76.79 -34.35 22.84 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.36 0 CA-C-N 116.48 -0.327 . . . . 0.0 111.815 -179.21 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -66.92 -36.39 82.14 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 120.91 0.386 . . . . 0.0 111.101 179.922 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 51' ' ' TYR . . . . . 0.411 ' HH ' ' HA ' ' A' ' 198' ' ' VAL . 3.3 m-85 -73.29 -40.09 64.83 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 115.987 -0.551 . . . . 0.0 110.452 179.951 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -62.79 -49.91 73.1 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-N 115.726 -0.67 . . . . 0.0 111.227 179.854 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 53' ' ' VAL . . . . . 0.439 ' O ' HG22 ' A' ' 58' ' ' VAL . 27.6 m -63.83 -46.02 95.48 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.218 0 CA-C-N 116.366 -0.379 . . . . 0.0 110.749 -179.975 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 54' ' ' MET . . . . . 0.468 ' HB2' ' HB2' ' A' ' 71' ' ' PRO . 11.0 ttp -64.11 -29.73 70.84 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.313 179.756 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -63.0 -23.71 67.58 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 115.871 -0.604 . . . . 0.0 110.926 179.442 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 54.0 mt -94.47 -8.85 37.31 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-N 116.079 -0.51 . . . . 0.0 110.726 179.812 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 57' ' ' GLY . . . . . 0.419 ' HA2' ' CD1' ' A' ' 60' ' ' TRP . . . 75.19 30.66 58.55 Favored Glycine 0 N--CA 1.451 -0.361 0 C-N-CA 120.876 -0.678 . . . . 0.0 112.953 179.723 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 58' ' ' VAL . . . . . 0.439 HG22 ' O ' ' A' ' 53' ' ' VAL . 26.3 m -84.04 18.2 0.37 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-O 120.808 0.337 . . . . 0.0 111.504 179.992 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -152.87 6.6 0.45 Allowed Glycine 0 N--CA 1.449 -0.485 0 C-N-CA 120.751 -0.737 . . . . 0.0 112.888 179.947 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 60' ' ' TRP . . . . . 0.419 ' CD1' ' HA2' ' A' ' 57' ' ' GLY . 34.5 m0 -71.95 121.5 19.21 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-O 120.783 0.325 . . . . 0.0 110.48 179.921 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 7.5 p -114.91 128.59 25.78 Favored Pre-proline 0 CA--C 1.533 0.303 0 CA-C-N 116.263 -0.426 . . . . 0.0 111.388 -179.733 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 65.0 Cg_endo -73.95 144.01 33.73 Favored 'Trans proline' 0 C--N 1.351 0.686 0 C-N-CA 122.396 2.064 . . . . 0.0 112.107 179.719 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 59.0 t -137.83 90.42 0.72 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.384 0 CA-C-N 116.086 -0.506 . . . . 0.0 111.061 -179.645 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . 58.43 -88.05 0.02 OUTLIER 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 116.116 -0.493 . . . . 0.0 111.587 -179.996 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 45.6 mt-10 -119.19 -19.96 8.16 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-O 120.775 0.321 . . . . 0.0 110.958 179.995 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 66' ' ' ARG . . . . . . . . . . . . . 9.9 ptp180 -103.23 165.19 11.17 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.268 -0.423 . . . . 0.0 110.449 179.651 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 53.9 m -123.35 129.64 51.6 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.937 0.398 . . . . 0.0 111.472 -179.677 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 99.2 t -109.73 146.33 15.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 115.889 -0.596 . . . . 0.0 110.492 179.644 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 69' ' ' PHE . . . . . . . . . . . . . 30.3 m-85 -105.59 115.47 30.3 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 121.049 0.452 . . . . 0.0 110.484 -179.474 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 70' ' ' VAL . . . . . 0.617 HG11 ' HD3' ' A' ' 71' ' ' PRO . 0.3 OUTLIER -67.98 -36.29 9.13 Favored Pre-proline 0 CA--C 1.54 0.58 0 CA-C-N 115.863 -0.608 . . . . 0.0 112.601 -179.48 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 71' ' ' PRO . . . . . 0.617 ' HD3' HG11 ' A' ' 70' ' ' VAL . 7.7 Cg_exo -71.09 -19.12 30.28 Favored 'Trans proline' 0 C--N 1.357 1.016 0 C-N-CA 122.21 1.94 . . . . 0.0 113.308 -179.198 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 43.0 ttm180 -76.35 -55.09 5.87 Favored 'General case' 0 C--N 1.331 -0.206 0 N-CA-C 112.372 0.508 . . . . 0.0 112.372 -178.505 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 73' ' ' TYR . . . . . 0.441 ' O ' HG13 ' A' ' 77' ' ' ILE . 68.5 m-85 -71.19 -36.76 72.06 Favored 'General case' 0 C--N 1.329 -0.286 0 C-N-CA 120.841 -0.344 . . . . 0.0 110.956 -179.248 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 0.3 OUTLIER -64.95 -40.43 89.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 N-CA-C 109.766 -0.457 . . . . 0.0 109.766 179.309 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 12.0 t70 -60.23 -37.51 80.55 Favored 'General case' 0 CA--C 1.518 -0.251 0 N-CA-C 109.437 -0.579 . . . . 0.0 109.437 178.772 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 76' ' ' TRP . . . . . . . . . . . . . 46.6 m0 -64.03 -31.44 72.63 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 115.899 -0.591 . . . . 0.0 110.319 179.478 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 77' ' ' ILE . . . . . 0.508 ' O ' ' HG2' ' A' ' 81' ' ' PRO . 61.8 mt -71.28 -31.72 44.79 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.478 178.963 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 25.6 mt -91.82 -15.13 28.66 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.172 -0.467 . . . . 0.0 112.165 -179.707 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 79' ' ' THR . . . . . 0.496 ' HG1' ' H ' ' A' ' 80' ' ' THR . 79.8 p -104.61 -52.97 2.78 Favored 'General case' 0 N--CA 1.465 0.296 0 N-CA-C 113.614 0.968 . . . . 0.0 113.614 -177.891 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 80' ' ' THR . . . . . 0.566 ' HB ' ' HD3' ' A' ' 81' ' ' PRO . 4.5 m -52.66 -53.68 51.41 Favored Pre-proline 0 C--N 1.331 -0.237 0 N-CA-C 112.36 0.504 . . . . 0.0 112.36 -178.369 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 81' ' ' PRO . . . . . 0.566 ' HD3' ' HB ' ' A' ' 80' ' ' THR . 52.6 Cg_exo -57.01 -23.43 52.01 Favored 'Trans proline' 0 C--N 1.352 0.752 0 C-N-CA 121.612 1.541 . . . . 0.0 111.68 179.543 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 82' ' ' LEU . . . . . . . . . . . . . 18.0 tp -76.76 -33.19 58.1 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 115.926 -0.579 . . . . 0.0 110.054 179.604 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 83' ' ' ILE . . . . . 0.441 HD11 HG23 ' A' ' 43' ' ' ILE . 37.6 mm -69.36 -53.37 25.49 Favored 'Isoleucine or valine' 0 C--O 1.232 0.161 0 CA-C-N 116.007 -0.542 . . . . 0.0 110.386 179.226 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 29.0 m -59.36 -32.8 49.34 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.183 0 N-CA-C 109.8 -0.444 . . . . 0.0 109.8 179.005 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 85' ' ' TYR . . . . . . . . . . . . . 55.4 t80 -64.66 -34.57 78.6 Favored 'General case' 0 N--CA 1.454 -0.272 0 CA-C-N 115.657 -0.701 . . . . 0.0 109.561 178.801 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 86' ' ' PHE . . . . . . . . . . . . . 8.8 t80 -61.48 -51.82 67.07 Favored 'General case' 0 C--O 1.232 0.181 0 CA-C-N 115.635 -0.711 . . . . 0.0 110.232 179.507 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 7.3 mp -61.71 -31.93 72.11 Favored 'General case' 0 C--N 1.331 -0.204 0 CA-C-N 116.136 -0.483 . . . . 0.0 110.116 179.49 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -71.59 -27.57 70.89 Favored Glycine 0 N--CA 1.449 -0.44 0 CA-C-N 115.8 -0.636 . . . . 0.0 111.795 179.31 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 42.0 mt -72.07 -39.2 69.18 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.919 0.39 . . . . 0.0 110.538 179.733 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 53.6 mt -58.5 -45.8 88.01 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 115.782 -0.645 . . . . 0.0 111.106 -179.967 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 91' ' ' ALA . . . . . 0.515 ' HB3' ' HB1' ' A' ' 149' ' ' ALA . . . -79.88 -54.94 5.35 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.403 -179.728 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 102.84 65.64 0.73 Allowed Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.826 -0.702 . . . . 0.0 112.346 -179.888 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 93' ' ' LEU . . . . . 0.436 HD12 ' HG2' ' A' ' 145' ' ' MET . 8.1 mp -71.93 172.04 10.67 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.804 0.335 . . . . 0.0 111.053 179.998 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 94' ' ' ASP . . . . . 0.435 ' HB2' ' HG2' ' A' ' 97' ' ' GLU . 10.1 m-20 -78.54 174.3 11.5 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.811 179.942 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 71.4 p -61.62 -51.27 69.19 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.176 -0.466 . . . . 0.0 111.215 -179.858 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 97.8 mtt180 -65.39 -42.15 92.93 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.374 -179.66 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 97' ' ' GLU . . . . . 0.435 ' HG2' ' HB2' ' A' ' 94' ' ' ASP . 10.3 mm-40 -52.49 -50.76 62.1 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.311 -0.404 . . . . 0.0 111.163 -179.625 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 98' ' ' PHE . . . . . 0.436 ' O ' HG12 ' A' ' 102' ' ' ILE . 12.2 m-85 -56.18 -46.23 79.44 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.354 -0.385 . . . . 0.0 110.683 179.633 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -60.54 -29.67 70.09 Favored Glycine 0 N--CA 1.448 -0.505 0 C-N-CA 120.688 -0.768 . . . . 0.0 112.34 179.978 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 96.6 mt -73.87 -42.63 53.59 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.238 0 CA-C-O 120.786 0.327 . . . . 0.0 111.717 -179.853 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 39.8 t -70.61 -42.58 77.98 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 CA-C-N 116.427 -0.351 . . . . 0.0 111.519 -179.335 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 102' ' ' ILE . . . . . 0.436 HG12 ' O ' ' A' ' 98' ' ' PHE . 49.2 mm -64.92 -45.78 93.72 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.368 -0.378 . . . . 0.0 111.552 -179.548 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 13.7 t -62.22 -35.52 79.14 Favored 'General case' 0 C--O 1.233 0.211 0 CA-C-O 120.847 0.356 . . . . 0.0 110.661 179.879 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 104' ' ' LEU . . . . . 0.432 ' O ' HG22 ' A' ' 108' ' ' VAL . 29.8 tp -57.39 -53.82 53.86 Favored 'General case' 0 C--N 1.331 -0.202 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.258 179.241 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 105' ' ' ASN . . . . . 0.599 ' N ' HD21 ' A' ' 105' ' ' ASN . 0.8 OUTLIER -56.25 -36.67 68.81 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 115.952 -0.567 . . . . 0.0 110.433 179.709 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 30.6 m -54.92 -43.41 73.28 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.511 179.621 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 1.2 t -65.64 -39.49 85.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-O 121.274 0.559 . . . . 0.0 110.187 179.206 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . 0.449 ' HB ' ' HE2' ' A' ' 109' ' ' MET . 41.7 t -60.03 -53.16 52.4 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.38 0 CA-C-N 115.291 -0.868 . . . . 0.0 111.782 -179.728 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 109' ' ' MET . . . . . 0.455 ' HE3' HG22 ' A' ' 80' ' ' THR . 8.0 mmt -61.85 -41.86 98.34 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-N 116.306 -0.406 . . . . 0.0 111.257 -179.284 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 28.6 tp -60.21 -30.27 69.27 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 116.377 -0.374 . . . . 0.0 110.461 -179.906 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -66.55 -54.87 18.97 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.552 179.217 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . -60.02 -36.22 89.66 Favored Glycine 0 N--CA 1.452 -0.24 0 C-N-CA 120.497 -0.859 . . . . 0.0 111.722 179.373 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 113' ' ' PHE . . . . . . . . . . . . . 0.9 OUTLIER -56.1 -75.09 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 121.051 0.453 . . . . 0.0 110.357 179.647 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -58.44 -29.72 66.37 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 115.679 -0.691 . . . . 0.0 111.418 -179.91 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -52.3 -49.12 52.2 Favored Glycine 0 C--N 1.331 0.254 0 C-N-CA 121.075 -0.583 . . . . 0.0 112.726 -179.993 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -77.71 -16.87 58.16 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-O 120.697 0.284 . . . . 0.0 111.458 -179.976 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 117' ' ' MET . . . . . . . . . . . . . 38.3 ttm -100.95 18.08 20.57 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.352 -0.385 . . . . 0.0 111.321 -179.387 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 118' ' ' VAL . . . . . 0.482 HG22 ' HB3' ' A' ' 123' ' ' ARG . 27.1 m -70.05 148.31 96.03 Favored Pre-proline 0 C--N 1.329 -0.302 0 CA-C-N 116.451 -0.34 . . . . 0.0 111.15 179.794 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 119' ' ' PRO . . . . . . . . . . . . . 90.6 Cg_endo -83.7 -3.77 10.63 Favored 'Trans proline' 0 C--N 1.348 0.52 0 C-N-CA 122.567 2.178 . . . . 0.0 112.136 179.719 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -156.25 -141.51 3.21 Favored Glycine 0 N--CA 1.453 -0.229 0 C-N-CA 120.926 -0.654 . . . . 0.0 112.452 -179.981 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 41.0 pt -84.71 18.87 0.37 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.229 0 CA-C-O 120.845 0.355 . . . . 0.0 111.062 -179.99 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 122' ' ' GLU . . . . . 0.442 ' HB2' ' HB ' ' A' ' 118' ' ' VAL . 12.3 mm-40 -67.52 -18.01 64.88 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.0 -0.545 . . . . 0.0 111.36 -179.926 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 123' ' ' ARG . . . . . 0.482 ' HB3' HG22 ' A' ' 118' ' ' VAL . 0.0 OUTLIER -51.11 -30.2 15.56 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-N 116.424 -0.353 . . . . 0.0 111.457 -179.532 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 124' ' ' TYR . . . . . . . . . . . . . 34.6 m-85 -70.23 -32.52 70.42 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-O 120.735 0.302 . . . . 0.0 111.202 -179.717 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 125' ' ' ALA . . . . . . . . . . . . . . . -67.88 -52.2 39.33 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.268 -0.423 . . . . 0.0 110.887 179.88 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 3.2 mm? -53.24 -54.44 36.07 Favored 'General case' 0 CA--C 1.521 -0.168 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.581 179.69 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 127' ' ' PHE . . . . . 0.481 ' HZ ' ' HB3' ' A' ' 175' ' ' PRO . 9.4 t80 -62.33 -35.74 80.03 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.082 -179.63 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 128' ' ' GLY . . . . . . . . . . . . . . . -47.23 -48.1 20.76 Favored Glycine 0 C--N 1.332 0.314 0 C-N-CA 119.925 -1.131 . . . . 0.0 110.287 178.718 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 129' ' ' MET . . . . . . . . . . . . . 0.4 OUTLIER -71.21 -31.41 67.55 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 115.019 -0.591 . . . . 0.0 109.697 178.379 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -60.96 -41.09 99.25 Favored Glycine 0 C--N 1.332 0.359 0 CA-C-N 115.821 -0.627 . . . . 0.0 112.753 -179.864 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -71.28 -51.92 21.75 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.644 0.259 . . . . 0.0 110.518 179.807 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 57.4 t -55.04 -39.95 52.19 Favored 'Isoleucine or valine' 0 C--O 1.233 0.226 0 CA-C-O 121.3 0.571 . . . . 0.0 109.694 178.95 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -70.77 -37.35 73.36 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 115.407 -0.815 . . . . 0.0 110.658 179.602 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 134' ' ' PHE . . . . . . . . . . . . . 43.6 t80 -56.62 -53.35 58.64 Favored 'General case' 0 N--CA 1.451 -0.386 0 CA-C-O 120.995 0.426 . . . . 0.0 109.984 179.567 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 135' ' ' ILE . . . . . . . . . . . . . 48.4 mt -58.02 -33.48 46.46 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.405 0 CA-C-N 115.787 -0.642 . . . . 0.0 109.838 179.227 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . -58.82 -40.73 95.47 Favored Glycine 0 N--CA 1.448 -0.53 0 C-N-CA 120.394 -0.908 . . . . 0.0 111.473 178.905 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 137' ' ' LEU . . . . . . . . . . . . . 53.5 tp -69.73 -45.04 69.05 Favored 'General case' 0 N--CA 1.455 -0.193 0 CA-C-O 120.693 0.282 . . . . 0.0 110.588 179.411 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 138' ' ' VAL . . . . . . . . . . . . . 98.8 t -56.05 -40.99 66.9 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.9 0 CA-C-O 121.222 0.534 . . . . 0.0 109.896 179.231 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 139' ' ' TYR . . . . . . . . . . . . . 29.4 t80 -59.05 -47.14 86.31 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 115.416 -0.811 . . . . 0.0 110.612 178.937 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 22.9 m-85 -54.52 -37.77 65.74 Favored 'General case' 0 C--N 1.332 -0.16 0 CA-C-N 116.39 -0.368 . . . . 0.0 110.911 179.942 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 141' ' ' LEU . . . . . 0.426 HD23 ' SD ' ' A' ' 145' ' ' MET . 79.8 mt -60.89 -50.7 72.37 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-O 120.905 0.383 . . . . 0.0 110.366 179.502 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 22.0 t -70.52 -15.21 18.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.034 -0.53 . . . . 0.0 110.723 179.531 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . -70.37 -140.24 0.16 Allowed Glycine 0 CA--C 1.521 0.461 0 C-N-CA 121.015 -0.612 . . . . 0.0 112.842 -179.88 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 144' ' ' PRO . . . . . . . . . . . . . 42.0 Cg_exo -56.64 -23.69 50.35 Favored 'Trans proline' 0 C--N 1.35 0.639 0 C-N-CA 122.641 2.227 . . . . 0.0 112.63 -179.794 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 145' ' ' MET . . . . . 0.436 ' HG2' HD12 ' A' ' 93' ' ' LEU . 54.5 mtt -57.93 -31.65 67.01 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.391 -0.368 . . . . 0.0 111.429 -179.867 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 146' ' ' THR . . . . . . . . . . . . . 25.0 m -74.11 -48.34 30.24 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.278 -0.419 . . . . 0.0 112.05 -179.061 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 45.1 mt-10 -72.92 -29.02 62.81 Favored 'General case' 0 C--N 1.329 -0.302 0 N-CA-C 111.762 0.282 . . . . 0.0 111.762 -179.157 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 148' ' ' SER . . . . . 0.429 ' HB3' ' HB1' ' A' ' 91' ' ' ALA . 46.8 t -70.76 -47.81 57.68 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.519 -0.31 . . . . 0.0 111.497 -179.179 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 149' ' ' ALA . . . . . 0.515 ' HB1' ' HB3' ' A' ' 91' ' ' ALA . . . -73.54 -43.23 60.44 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.378 -0.374 . . . . 0.0 111.865 -179.259 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 150' ' ' SER . . . . . 0.463 ' HA ' ' HB3' ' A' ' 157' ' ' LYS . 42.8 t -65.51 -8.4 19.34 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.457 -0.338 . . . . 0.0 111.286 -179.613 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 151' ' ' GLN . . . . . . . . . . . . . 46.2 mt-30 -124.89 15.73 8.59 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.454 -0.339 . . . . 0.0 111.161 179.999 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 31.3 tpt180 -90.79 -52.02 5.08 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 121.093 0.473 . . . . 0.0 110.275 179.646 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 153' ' ' SER . . . . . 0.578 ' HB2' HG12 ' A' ' 156' ' ' ILE . 24.6 m -158.02 172.69 17.98 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 115.719 -0.673 . . . . 0.0 110.473 179.228 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 154' ' ' SER . . . . . . . . . . . . . 78.3 p -70.55 -38.69 74.19 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.335 -0.393 . . . . 0.0 110.482 179.438 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -77.87 -38.01 28.22 Favored Glycine 0 N--CA 1.452 -0.265 0 C-N-CA 121.04 -0.6 . . . . 0.0 112.845 179.781 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 156' ' ' ILE . . . . . 0.578 HG12 ' HB2' ' A' ' 153' ' ' SER . 39.0 mm -53.4 -44.48 55.08 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.202 0 N-CA-C 111.917 0.34 . . . . 0.0 111.917 -179.204 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 157' ' ' LYS . . . . . 0.463 ' HB3' ' HA ' ' A' ' 150' ' ' SER . 18.9 ptpt -65.78 -30.88 71.59 Favored 'General case' 0 C--N 1.329 -0.288 0 N-CA-C 111.714 0.264 . . . . 0.0 111.714 -179.225 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 47.8 t -71.7 -48.37 47.76 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 121.076 0.465 . . . . 0.0 111.077 -179.539 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 159' ' ' LEU . . . . . 0.475 ' O ' ' HB2' ' A' ' 163' ' ' LEU . 8.4 mp -71.53 -29.81 65.19 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 115.875 -0.602 . . . . 0.0 111.313 -179.785 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 160' ' ' TYR . . . . . 0.428 ' HH ' ' HB3' ' A' ' 145' ' ' MET . 92.8 t80 -70.73 -44.84 65.99 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.397 -0.365 . . . . 0.0 111.739 -179.402 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 28.6 m -66.05 -42.34 91.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 N-CA-C 111.624 0.231 . . . . 0.0 111.624 -179.365 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 162' ' ' ARG . . . . . . . . . . . . . 95.7 mtt180 -67.99 -44.71 75.99 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.796 0.331 . . . . 0.0 111.497 -179.808 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 163' ' ' LEU . . . . . 0.475 ' HB2' ' O ' ' A' ' 159' ' ' LEU . 4.5 mp -71.55 -54.16 11.41 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.264 -0.426 . . . . 0.0 112.039 -179.19 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 164' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -53.05 -41.64 65.01 Favored 'General case' 0 C--N 1.328 -0.353 0 N-CA-C 111.957 0.354 . . . . 0.0 111.957 -178.783 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 165' ' ' ASN . . . . . 0.509 ' N ' HD21 ' A' ' 165' ' ' ASN . 0.9 OUTLIER -67.03 -52.31 43.93 Favored 'General case' 0 C--N 1.329 -0.318 0 N-CA-C 112.013 0.375 . . . . 0.0 112.013 -179.114 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 166' ' ' LEU . . . . . 0.431 ' O ' ' HG ' ' A' ' 170' ' ' LEU . 0.0 OUTLIER -67.45 -33.13 74.5 Favored 'General case' 0 C--N 1.329 -0.288 0 N-CA-C 111.643 0.238 . . . . 0.0 111.643 -178.871 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 167' ' ' THR . . . . . 0.457 ' O ' ' HB2' ' A' ' 171' ' ' TRP . 27.5 m -63.04 -53.83 47.72 Favored 'General case' 0 C--N 1.332 -0.195 0 N-CA-C 111.939 0.348 . . . . 0.0 111.939 -179.976 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 168' ' ' VAL . . . . . 0.417 HG13 ' N ' ' A' ' 169' ' ' VAL . 9.9 p -59.28 -40.07 80.41 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.242 0 CA-C-N 116.486 -0.325 . . . . 0.0 111.541 -178.924 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 169' ' ' VAL . . . . . 0.417 ' N ' HG13 ' A' ' 168' ' ' VAL . 74.0 t -57.14 -65.38 0.41 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.563 -0.29 . . . . 0.0 111.45 -179.767 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 170' ' ' LEU . . . . . 0.431 ' HG ' ' O ' ' A' ' 166' ' ' LEU . 2.7 pp -63.09 -29.78 71.08 Favored 'General case' 0 C--N 1.331 -0.228 0 N-CA-C 111.908 0.336 . . . . 0.0 111.908 -179.085 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 171' ' ' TRP . . . . . 0.457 ' HB2' ' O ' ' A' ' 167' ' ' THR . 2.5 m0 -72.51 -31.47 65.37 Favored 'General case' 0 C--N 1.331 -0.21 0 C-N-CA 120.797 -0.361 . . . . 0.0 110.761 179.612 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 172' ' ' ALA . . . . . . . . . . . . . . . -72.94 -6.24 43.92 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-O 121.055 0.455 . . . . 0.0 110.367 179.439 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 173' ' ' ILE . . . . . 0.571 HG21 HD12 ' A' ' 177' ' ' ILE . 37.2 mm -82.89 -25.99 8.19 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.206 0 CA-C-N 115.771 -0.649 . . . . 0.0 110.999 179.791 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 174' ' ' TYR . . . . . 0.447 ' HB2' ' HD3' ' A' ' 175' ' ' PRO . 49.9 m-85 -54.55 -50.7 83.95 Favored Pre-proline 0 N--CA 1.464 0.272 0 CA-C-N 116.353 -0.385 . . . . 0.0 111.671 -179.665 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 175' ' ' PRO . . . . . 0.481 ' HB3' ' HZ ' ' A' ' 127' ' ' PHE . 97.2 Cg_exo -45.19 -30.29 4.96 Favored 'Trans proline' 0 C--N 1.35 0.647 0 C-N-CA 122.186 1.924 . . . . 0.0 112.403 179.65 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 176' ' ' PHE . . . . . 0.443 ' O ' ' HG ' ' A' ' 180' ' ' LEU . 65.8 m-85 -80.57 -49.67 11.01 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 115.979 -0.555 . . . . 0.0 111.989 -179.729 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 177' ' ' ILE . . . . . 0.571 HD12 HG21 ' A' ' 173' ' ' ILE . 2.3 mm -61.59 -37.37 77.74 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.53 0 N-CA-C 112.723 0.638 . . . . 0.0 112.723 -177.693 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 178' ' ' TRP . . . . . . . . . . . . . 63.0 t90 -72.55 -44.9 61.48 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 120.875 0.369 . . . . 0.0 110.823 179.7 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 179' ' ' LEU . . . . . 0.433 ' O ' ' HA3' ' A' ' 184' ' ' GLY . 2.5 tm? -67.15 -49.25 65.43 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 115.907 -0.588 . . . . 0.0 111.72 -179.0 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 180' ' ' LEU . . . . . 0.443 ' HG ' ' O ' ' A' ' 176' ' ' PHE . 23.1 mt -77.24 -45.28 26.98 Favored 'General case' 0 C--N 1.326 -0.424 0 N-CA-C 111.982 0.364 . . . . 0.0 111.982 -178.796 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . -57.32 178.91 0.88 Allowed Glycine 0 C--N 1.334 0.47 0 C-N-CA 120.438 -0.887 . . . . 0.0 112.82 -179.878 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 182' ' ' PRO . . . . . 0.561 ' N ' ' HD2' ' A' ' 183' ' ' PRO . 71.5 Cg_exo -47.78 -46.06 22.41 Favored 'Trans proline' 0 CA--C 1.537 0.67 0 C-N-CA 123.0 2.466 . . . . 0.0 114.177 -179.709 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 183' ' ' PRO . . . . . 0.561 ' HD2' ' N ' ' A' ' 182' ' ' PRO . 16.9 Cg_endo -57.53 -9.92 6.05 Favored 'Trans proline' 0 C--N 1.355 0.885 0 C-N-CA 122.02 1.813 . . . . 0.0 113.246 -179.409 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 184' ' ' GLY . . . . . 0.433 ' HA3' ' O ' ' A' ' 179' ' ' LEU . . . -116.23 -86.8 1.3 Allowed Glycine 0 N--CA 1.45 -0.379 0 C-N-CA 120.536 -0.84 . . . . 0.0 112.722 179.781 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 185' ' ' VAL . . . . . 0.411 HG23 ' O ' ' A' ' 179' ' ' LEU . 9.0 m -123.47 -4.1 7.18 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.246 0 CA-C-O 120.781 0.324 . . . . 0.0 111.544 -179.817 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 186' ' ' ALA . . . . . 0.56 ' HB2' ' HA ' ' A' ' 182' ' ' PRO . . . 54.56 84.83 0.06 Allowed 'General case' 0 N--CA 1.463 0.195 0 CA-C-N 116.113 -0.494 . . . . 0.0 111.828 179.557 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 187' ' ' LEU . . . . . 0.401 HD13 HD21 ' A' ' 180' ' ' LEU . 14.8 mt -92.1 -48.72 6.58 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-O 120.973 0.416 . . . . 0.0 110.906 179.509 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 188' ' ' LEU . . . . . . . . . . . . . 89.7 mt -96.82 -152.91 0.4 Allowed 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 115.883 -0.599 . . . . 0.0 111.014 -179.575 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 189' ' ' THR . . . . . . . . . . . . . 86.5 m -96.37 136.25 22.04 Favored Pre-proline 0 C--N 1.33 -0.261 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.712 -179.71 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 190' ' ' PRO . . . . . . . . . . . . . 88.7 Cg_exo -46.48 -43.07 22.75 Favored 'Trans proline' 0 C--N 1.349 0.585 0 C-N-CA 122.459 2.106 . . . . 0.0 112.855 -179.825 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 191' ' ' THR . . . . . . . . . . . . . 82.0 p -65.41 -38.64 90.57 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.376 -0.375 . . . . 0.0 111.731 -179.601 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 192' ' ' VAL . . . . . . . . . . . . . 58.1 t -71.78 -53.71 19.44 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.394 -0.366 . . . . 0.0 111.415 -179.628 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 193' ' ' ASP . . . . . . . . . . . . . 26.5 t70 -54.19 -47.97 71.48 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.244 -0.435 . . . . 0.0 111.049 -179.867 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 194' ' ' VAL . . . . . 0.431 ' O ' HG22 ' A' ' 198' ' ' VAL . 46.7 t -60.13 -40.18 82.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.281 -0.418 . . . . 0.0 110.674 179.769 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 195' ' ' ALA . . . . . . . . . . . . . . . -52.86 -44.64 66.97 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.928 179.756 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 196' ' ' LEU . . . . . . . . . . . . . 94.5 mt -68.42 -36.19 78.71 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.096 179.711 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 197' ' ' ILE . . . . . 0.516 HD11 ' HB ' ' A' ' 177' ' ' ILE . 12.4 mm -61.31 -59.83 3.66 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.203 179.911 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 198' ' ' VAL . . . . . 0.431 HG22 ' O ' ' A' ' 194' ' ' VAL . 2.8 m -54.08 -35.36 28.79 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.47 0 CA-C-O 121.669 0.747 . . . . 0.0 109.523 179.307 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 199' ' ' TYR . . . . . . . . . . . . . 74.9 t80 -64.59 -41.6 96.14 Favored 'General case' 0 C--N 1.321 -0.658 0 CA-C-N 114.454 -1.248 . . . . 0.0 110.482 179.577 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 200' ' ' LEU . . . . . 0.402 ' HB3' ' CZ ' ' A' ' 174' ' ' TYR . 23.2 mt -59.04 -46.55 87.94 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 115.747 -0.66 . . . . 0.0 111.08 -179.885 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 201' ' ' ASP . . . . . . . . . . . . . 8.6 m-20 -69.95 -33.52 72.22 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 121.089 0.471 . . . . 0.0 110.426 179.709 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 202' ' ' LEU . . . . . . . . . . . . . 1.2 tt -66.54 -33.53 75.88 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 115.604 -0.725 . . . . 0.0 110.738 -179.93 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 203' ' ' VAL . . . . . 0.45 ' O ' ' HA3' ' A' ' 207' ' ' GLY . 42.3 t -76.66 -36.94 28.2 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 115.88 -0.6 . . . . 0.0 111.552 -179.007 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 204' ' ' THR . . . . . . . . . . . . . 36.5 m -64.58 -56.12 16.01 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-O 120.894 0.378 . . . . 0.0 111.679 -179.869 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 205' ' ' LYS . . . . . 0.604 ' HE2' ' HB2' ' A' ' 47' ' ' ALA . 48.9 mttp -69.03 -58.62 3.85 Favored 'General case' 0 C--N 1.326 -0.421 0 N-CA-C 112.576 0.584 . . . . 0.0 112.576 -178.351 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 48.9 t -71.57 -38.12 66.32 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 N-CA-C 112.064 0.394 . . . . 0.0 112.064 -178.515 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 207' ' ' GLY . . . . . 0.489 ' O ' HG12 ' A' ' 211' ' ' ILE . . . -63.38 -59.62 8.63 Favored Glycine 0 N--CA 1.453 -0.23 0 C-N-CA 120.579 -0.819 . . . . 0.0 112.86 -179.319 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 208' ' ' PHE . . . . . 0.509 ' O ' ' N ' ' A' ' 212' ' ' ALA . 1.8 m-30 -54.88 -47.91 73.67 Favored 'General case' 0 C--O 1.221 -0.405 0 N-CA-C 110.18 -0.304 . . . . 0.0 110.18 -179.633 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 209' ' ' GLY . . . . . 0.407 ' O ' ' HB3' ' A' ' 212' ' ' ALA . . . -53.46 -32.36 45.27 Favored Glycine 0 N--CA 1.45 -0.432 0 CA-C-N 115.623 -0.717 . . . . 0.0 112.488 178.937 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 210' ' ' PHE . . . . . . . . . . . . . 3.0 m-85 -71.94 -45.96 59.24 Favored 'General case' 0 CA--C 1.516 -0.34 0 N-CA-C 108.694 -0.854 . . . . 0.0 108.694 178.769 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 211' ' ' ILE . . . . . 0.489 HG12 ' O ' ' A' ' 207' ' ' GLY . 2.4 mm -66.12 -27.5 41.0 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.51 0 N-CA-C 107.256 -1.387 . . . . 0.0 107.256 176.655 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 212' ' ' ALA . . . . . 0.509 ' N ' ' O ' ' A' ' 208' ' ' PHE . . . -68.67 -40.13 80.28 Favored 'General case' 0 N--CA 1.447 -0.582 0 CA-C-N 113.965 -1.471 . . . . 0.0 110.925 -179.34 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 213' ' ' LEU . . . . . . . . . . . . . 65.1 mt -70.26 -55.51 9.07 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 115.314 -0.857 . . . . 0.0 112.07 -179.164 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 214' ' ' ASP . . . . . . . . . . . . . 20.1 t70 -56.45 -50.56 71.33 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.859 0.361 . . . . 0.0 111.352 -179.429 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 215' ' ' ALA . . . . . . . . . . . . . . . -57.69 -55.39 35.49 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.467 -179.781 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 216' ' ' ALA . . . . . . . . . . . . . . . -60.59 -31.19 70.35 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.273 -0.421 . . . . 0.0 111.321 -179.697 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 217' ' ' ALA . . . . . . . . . . . . . . . -62.62 -35.82 80.82 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.342 -0.39 . . . . 0.0 110.264 179.609 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 218' ' ' THR . . . . . . . . . . . . . 86.7 m . . . . . 0 C--N 1.329 -0.285 0 CA-C-N 115.887 -0.597 . . . . 0.0 110.614 179.24 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.299 0 N-CA-C 112.605 -0.198 . . . . 0.0 112.605 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 94.5 mt -56.72 -35.55 68.67 Favored 'General case' 0 N--CA 1.449 -0.514 0 CA-C-O 120.868 0.366 . . . . 0.0 111.242 -179.859 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 42.9 p -63.4 -39.01 93.34 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.08 -0.509 . . . . 0.0 111.774 -179.414 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 18.7 p -52.84 -35.33 57.22 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-N 116.484 -0.325 . . . . 0.0 111.538 -179.442 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 7' ' ' LEU . . . . . . . . . . . . . 3.8 mm? -60.62 -53.13 61.13 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.37 -0.377 . . . . 0.0 111.245 -179.755 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 8' ' ' PHE . . . . . 0.43 ' HB2' ' HB2' ' A' ' 55' ' ' ALA . 64.4 m-85 -61.67 -30.84 70.99 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.304 -0.407 . . . . 0.0 111.014 -179.726 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 9' ' ' TRP . . . . . 0.463 ' O ' HG12 ' A' ' 13' ' ' ILE . 34.9 m95 -66.79 -43.3 84.31 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 116.226 -0.443 . . . . 0.0 109.966 179.939 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 87.5 mt -65.51 -49.02 70.54 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 115.615 -0.721 . . . . 0.0 110.526 179.638 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -58.47 -32.22 68.19 Favored Glycine 0 N--CA 1.449 -0.475 0 C-N-CA 120.559 -0.829 . . . . 0.0 111.677 179.3 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -68.69 -35.43 77.18 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 120.842 0.353 . . . . 0.0 110.615 179.453 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 13' ' ' ILE . . . . . 0.463 HG12 ' O ' ' A' ' 9' ' ' TRP . 46.8 mm -64.73 -53.98 35.59 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.205 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.609 179.566 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -60.71 -32.83 80.2 Favored Glycine 0 N--CA 1.45 -0.432 0 C-N-CA 120.718 -0.753 . . . . 0.0 111.7 179.477 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 15' ' ' MET . . . . . 0.582 ' SD ' ' HA ' ' A' ' 44' ' ' SER . 54.0 tpp -64.33 -50.98 65.66 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.792 0.33 . . . . 0.0 110.619 179.896 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -52.77 -40.58 63.3 Favored 'General case' 0 C--N 1.332 -0.192 0 CA-C-N 116.021 -0.536 . . . . 0.0 110.355 179.538 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 97.6 t -59.94 -42.86 90.86 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.219 0 CA-C-N 116.034 -0.53 . . . . 0.0 110.541 179.534 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -66.12 -43.39 93.35 Favored Glycine 0 N--CA 1.452 -0.272 0 C-N-CA 120.771 -0.728 . . . . 0.0 111.74 179.067 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 17.8 m -50.28 -46.56 55.22 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 115.556 -0.322 . . . . 0.0 111.48 -179.762 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 86.0 mt -71.76 -39.85 69.71 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.316 -0.402 . . . . 0.0 111.772 -179.74 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -61.64 -31.52 71.63 Favored 'General case' 0 C--N 1.33 -0.272 0 N-CA-C 111.987 0.366 . . . . 0.0 111.987 -179.219 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 4.9 m-85 -90.75 -33.34 15.78 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-O 120.731 0.301 . . . . 0.0 111.421 -179.599 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -69.3 -50.0 50.71 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.973 0.416 . . . . 0.0 111.19 -179.824 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 24' ' ' TRP . . . . . . . . . . . . . 2.4 t-105 -61.57 -47.54 85.06 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 115.805 -0.634 . . . . 0.0 111.169 -179.842 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.331 -0.23 0 CA-C-O 120.782 0.325 . . . . 0.0 110.692 179.715 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.517 0.201 0 N-CA-C 112.781 -0.127 . . . . 0.0 112.781 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 33.3 mm-40 -87.28 -20.93 26.13 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.811 0.339 . . . . 0.0 111.015 -179.85 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 34' ' ' ARG . . . . . . . . . . . . . 42.3 ttm180 -53.12 -31.96 44.94 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.596 -179.546 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 15.3 tpp180 -61.64 -44.47 96.92 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 120.836 0.351 . . . . 0.0 110.874 -179.908 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 54.9 m-85 -68.69 -31.04 69.86 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.91 179.978 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 37' ' ' TYR . . . . . . . . . . . . . 44.2 m-85 -70.43 -53.6 15.81 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.219 -179.897 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 71.2 t -56.8 -36.4 49.38 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.194 0 CA-C-O 121.008 0.432 . . . . 0.0 110.265 179.615 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 24.0 m -63.89 -47.92 78.71 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 115.673 -0.694 . . . . 0.0 110.296 179.213 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 40' ' ' LEU . . . . . 0.552 HD13 HD13 ' A' ' 43' ' ' ILE . 45.5 tp -58.46 -47.79 82.88 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 115.678 -0.692 . . . . 0.0 110.153 179.493 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 57.6 t -60.33 -34.57 58.06 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.365 0 CA-C-N 115.645 -0.707 . . . . 0.0 109.804 178.906 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -59.97 -37.09 92.14 Favored Glycine 0 N--CA 1.448 -0.559 0 C-N-CA 120.784 -0.722 . . . . 0.0 111.591 179.479 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 43' ' ' ILE . . . . . 0.552 HD13 HD13 ' A' ' 40' ' ' LEU . 1.3 mt -65.26 -57.98 8.84 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.195 0 CA-C-O 120.833 0.349 . . . . 0.0 110.468 179.391 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 44' ' ' SER . . . . . 0.582 ' HA ' ' SD ' ' A' ' 15' ' ' MET . 64.7 m -57.51 -23.01 47.76 Favored 'General case' 0 C--N 1.332 -0.173 0 CA-C-N 116.037 -0.529 . . . . 0.0 111.71 -179.67 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -76.64 -59.17 3.32 Favored Glycine 0 CA--C 1.52 0.353 0 C-N-CA 120.638 -0.792 . . . . 0.0 112.912 -179.614 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 21.6 pt -58.42 -35.89 56.27 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.239 0 CA-C-O 120.91 0.386 . . . . 0.0 111.263 -179.796 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 47' ' ' ALA . . . . . 0.611 ' HB3' ' HE2' ' A' ' 205' ' ' LYS . . . -67.42 -45.77 75.13 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.309 179.626 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -54.42 -44.77 72.7 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.878 -179.183 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 27.0 m -73.29 -34.2 43.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 N-CA-C 111.845 0.313 . . . . 0.0 111.845 -179.363 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -65.92 -33.95 77.01 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.869 0.366 . . . . 0.0 111.266 -179.785 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 51' ' ' TYR . . . . . 0.532 ' HH ' ' HB2' ' A' ' 201' ' ' ASP . 5.3 m-85 -72.99 -47.03 48.78 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 115.987 -0.551 . . . . 0.0 110.611 -179.943 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -58.81 -44.34 90.8 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 115.652 -0.703 . . . . 0.0 111.812 -179.562 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 53' ' ' VAL . . . . . 0.466 HG22 ' N ' ' A' ' 54' ' ' MET . 34.7 m -69.96 -51.72 37.43 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.183 0 CA-C-N 116.64 -0.254 . . . . 0.0 111.429 -179.549 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 54' ' ' MET . . . . . 0.466 ' N ' HG22 ' A' ' 53' ' ' VAL . 8.3 ttp -59.14 -29.28 67.3 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 121.064 0.459 . . . . 0.0 110.287 -179.964 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 55' ' ' ALA . . . . . 0.43 ' HB2' ' HB2' ' A' ' 8' ' ' PHE . . . -67.74 -32.2 72.65 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 115.703 -0.68 . . . . 0.0 111.329 179.698 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 96.6 mt -79.93 16.66 1.12 Allowed 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.282 -0.417 . . . . 0.0 111.102 -179.875 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 81.15 -4.93 68.82 Favored Glycine 0 N--CA 1.451 -0.365 0 C-N-CA 120.501 -0.857 . . . . 0.0 112.087 -179.656 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 58' ' ' VAL . . . . . 0.418 ' HB ' ' O ' ' A' ' 53' ' ' VAL . 77.0 t -66.25 142.34 16.89 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-O 120.799 0.333 . . . . 0.0 110.779 179.698 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 87.31 -22.28 16.66 Favored Glycine 0 N--CA 1.448 -0.558 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.529 -179.703 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 60' ' ' TRP . . . . . . . . . . . . . 13.5 m0 -60.21 99.22 0.07 Allowed 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 120.745 0.307 . . . . 0.0 110.327 179.823 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 61' ' ' VAL . . . . . 0.404 ' HA ' ' HD3' ' A' ' 62' ' ' PRO . 7.7 p -98.27 129.82 29.77 Favored Pre-proline 0 C--N 1.328 -0.328 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.412 -179.593 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 62' ' ' PRO . . . . . 0.404 ' HD3' ' HA ' ' A' ' 61' ' ' VAL . 12.1 Cg_exo -71.96 136.36 27.24 Favored 'Trans proline' 0 C--N 1.349 0.588 0 C-N-CA 122.628 2.219 . . . . 0.0 112.042 179.824 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 64.6 t -132.13 89.78 1.14 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.396 0 CA-C-N 116.054 -0.521 . . . . 0.0 110.876 -179.94 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . 58.54 -84.54 0.02 OUTLIER 'General case' 0 C--N 1.333 -0.138 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.26 -179.739 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 11.3 pt-20 -124.57 -19.9 5.26 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-O 121.104 0.478 . . . . 0.0 110.351 179.724 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 66' ' ' ARG . . . . . . . . . . . . . 59.3 mtp180 -95.39 166.03 12.08 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 115.576 -0.738 . . . . 0.0 110.676 179.814 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 54.1 m -129.2 122.32 29.5 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.996 179.862 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 15.1 t -111.17 146.27 16.4 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.368 0 CA-C-N 116.082 -0.508 . . . . 0.0 110.929 -179.972 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 69' ' ' PHE . . . . . . . . . . . . . 12.0 m-85 -101.9 112.76 25.49 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.134 -0.484 . . . . 0.0 110.177 -179.803 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 70' ' ' VAL . . . . . 0.584 HG12 ' HD3' ' A' ' 71' ' ' PRO . 0.6 OUTLIER -69.31 -33.35 3.88 Favored Pre-proline 0 CA--C 1.543 0.697 0 N-CA-C 113.089 0.774 . . . . 0.0 113.089 -179.302 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 71' ' ' PRO . . . . . 0.584 ' HD3' HG12 ' A' ' 70' ' ' VAL . 11.3 Cg_exo -69.57 -22.26 33.19 Favored 'Trans proline' 0 C--N 1.357 0.985 0 C-N-CA 121.952 1.768 . . . . 0.0 112.993 -179.073 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 72' ' ' ARG . . . . . 0.451 ' HD2' HG23 ' A' ' 197' ' ' ILE . 50.5 ttp180 -68.6 -55.04 12.88 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.902 0.382 . . . . 0.0 111.663 -179.124 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 73' ' ' TYR . . . . . . . . . . . . . 61.4 m-85 -72.14 -35.06 68.98 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.417 -0.356 . . . . 0.0 110.875 -179.483 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 74' ' ' ILE . . . . . 0.485 ' HA ' HD12 ' A' ' 77' ' ' ILE . 0.3 OUTLIER -65.87 -38.45 82.2 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.189 0 N-CA-C 109.476 -0.564 . . . . 0.0 109.476 179.01 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 17.8 t70 -60.21 -37.64 80.9 Favored 'General case' 0 N--CA 1.453 -0.278 0 N-CA-C 109.147 -0.686 . . . . 0.0 109.147 178.692 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 76' ' ' TRP . . . . . . . . . . . . . 52.1 m0 -65.7 -34.99 79.47 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 115.681 -0.69 . . . . 0.0 110.345 179.06 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 77' ' ' ILE . . . . . 0.485 HD12 ' HA ' ' A' ' 74' ' ' ILE . 77.4 mt -66.26 -31.84 55.44 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.299 -0.409 . . . . 0.0 110.5 179.504 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 22.3 mt -91.6 -21.47 20.81 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.052 -0.522 . . . . 0.0 112.097 -179.725 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 81.5 p -102.86 -53.25 2.89 Favored 'General case' 0 N--CA 1.463 0.215 0 N-CA-C 113.536 0.939 . . . . 0.0 113.536 -177.924 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 80' ' ' THR . . . . . 0.565 ' HB ' ' HD3' ' A' ' 81' ' ' PRO . 4.9 m -48.57 -53.32 36.85 Favored Pre-proline 0 CA--C 1.53 0.21 0 N-CA-C 112.32 0.489 . . . . 0.0 112.32 -178.223 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 81' ' ' PRO . . . . . 0.565 ' HD3' ' HB ' ' A' ' 80' ' ' THR . 31.6 Cg_exo -61.29 -21.41 71.67 Favored 'Trans proline' 0 C--N 1.351 0.71 0 C-N-CA 121.722 1.615 . . . . 0.0 111.857 179.631 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 82' ' ' LEU . . . . . . . . . . . . . 17.3 tp -76.64 -36.56 57.31 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-N 116.076 -0.511 . . . . 0.0 110.677 -179.983 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 1.9 mp -68.39 -51.92 42.39 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.174 0 CA-C-O 120.803 0.335 . . . . 0.0 110.157 179.094 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 26.6 m -60.18 -31.92 49.29 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.225 0 N-CA-C 109.582 -0.525 . . . . 0.0 109.582 179.026 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 85' ' ' TYR . . . . . . . . . . . . . 74.9 t80 -66.66 -31.27 71.84 Favored 'General case' 0 N--CA 1.452 -0.33 0 CA-C-N 115.698 -0.683 . . . . 0.0 109.372 178.542 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 86' ' ' PHE . . . . . . . . . . . . . 2.0 t80 -62.65 -51.81 65.79 Favored 'General case' 0 C--O 1.231 0.103 0 CA-C-N 115.743 -0.662 . . . . 0.0 109.829 179.061 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 8.0 mp -63.67 -29.2 70.47 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 115.658 -0.701 . . . . 0.0 110.467 179.556 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -70.53 -28.49 71.0 Favored Glycine 0 N--CA 1.449 -0.465 0 C-N-CA 120.843 -0.694 . . . . 0.0 112.007 179.559 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 79.8 mt -75.32 -42.38 54.64 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-O 120.929 0.395 . . . . 0.0 110.605 179.474 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 72.4 mt -57.71 -32.65 67.6 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 115.887 -0.597 . . . . 0.0 110.766 179.744 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 91' ' ' ALA . . . . . 0.46 ' HB3' ' HB3' ' A' ' 148' ' ' SER . . . -88.9 -34.02 17.1 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.104 -0.498 . . . . 0.0 111.208 179.891 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 84.28 53.77 3.19 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.853 -0.689 . . . . 0.0 112.401 179.926 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 93' ' ' LEU . . . . . 0.497 HD13 ' HE3' ' A' ' 145' ' ' MET . 55.0 mt -59.39 162.96 4.31 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 120.897 0.38 . . . . 0.0 111.109 -179.907 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 94' ' ' ASP . . . . . . . . . . . . . 18.4 m-20 -77.17 -178.37 5.02 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.069 -0.514 . . . . 0.0 110.923 179.878 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 50.8 m -63.64 -50.98 67.19 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.083 -0.508 . . . . 0.0 111.197 -179.881 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 14.2 ptm180 -73.65 -35.63 65.29 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.308 -0.405 . . . . 0.0 111.293 -179.596 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 19.9 mm-40 -54.96 -45.68 74.97 Favored 'General case' 0 C--N 1.331 -0.197 0 CA-C-N 116.56 -0.291 . . . . 0.0 110.771 -179.977 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 98' ' ' PHE . . . . . 0.469 ' O ' HG12 ' A' ' 102' ' ' ILE . 10.6 m-85 -60.86 -36.06 78.2 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-O 120.92 0.39 . . . . 0.0 110.272 179.422 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -67.19 -27.53 73.5 Favored Glycine 0 N--CA 1.449 -0.5 0 C-N-CA 120.589 -0.815 . . . . 0.0 112.225 179.511 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 97.0 mt -73.83 -44.88 51.12 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.198 0 N-CA-C 111.855 0.317 . . . . 0.0 111.855 -179.783 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 35.3 m -69.35 -40.78 80.5 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 N-CA-C 112.256 0.465 . . . . 0.0 112.256 -178.806 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 102' ' ' ILE . . . . . 0.469 HG12 ' O ' ' A' ' 98' ' ' PHE . 46.1 mm -68.53 -48.49 71.97 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.697 -0.229 . . . . 0.0 111.456 -179.501 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 14.2 t -60.42 -33.77 72.99 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-O 120.983 0.42 . . . . 0.0 110.645 179.875 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 104' ' ' LEU . . . . . 0.428 HD23 ' HE2' ' A' ' 140' ' ' TYR . 48.4 tp -60.44 -53.56 56.08 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 115.954 -0.567 . . . . 0.0 110.428 179.578 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 105' ' ' ASN . . . . . 0.609 ' N ' HD21 ' A' ' 105' ' ' ASN . 0.8 OUTLIER -61.22 -25.19 66.88 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 115.892 -0.594 . . . . 0.0 110.835 179.845 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 28.6 m -64.31 -54.13 38.02 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.258 179.961 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 12.5 p -64.85 -36.11 76.84 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.245 0 CA-C-N 116.504 -0.316 . . . . 0.0 111.194 -179.962 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 92.6 t -64.78 -52.76 50.26 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.246 0 CA-C-O 120.84 0.352 . . . . 0.0 110.89 179.743 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 109' ' ' MET . . . . . . . . . . . . . 1.9 tpp -60.06 -32.13 70.65 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.06 -0.518 . . . . 0.0 110.758 179.774 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 36.4 tp -75.21 -30.17 60.52 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 115.974 -0.557 . . . . 0.0 110.261 179.46 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -60.94 -52.4 65.18 Favored 'General case' 0 C--N 1.331 -0.199 0 CA-C-N 116.081 -0.508 . . . . 0.0 110.308 179.337 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . -70.58 -38.43 68.35 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.636 -0.792 . . . . 0.0 111.851 179.268 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 113' ' ' PHE . . . . . . . . . . . . . 1.9 t80 -53.87 -63.21 1.22 Allowed 'General case' 0 C--N 1.332 -0.194 0 CA-C-O 120.849 0.356 . . . . 0.0 110.063 179.349 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -69.62 -17.43 63.52 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.135 178.949 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -55.48 -52.62 46.69 Favored Glycine 0 C--N 1.333 0.389 0 CA-C-N 115.871 -0.604 . . . . 0.0 112.042 179.545 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 116' ' ' ALA . . . . . 0.576 ' HB3' ' HB3' ' A' ' 183' ' ' PRO . . . -77.41 -14.69 59.65 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-O 120.763 0.316 . . . . 0.0 111.192 -179.962 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 117' ' ' MET . . . . . . . . . . . . . 23.2 mmt -87.24 6.88 30.98 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.284 -0.417 . . . . 0.0 111.947 -179.413 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 118' ' ' VAL . . . . . 0.428 HG22 ' HB3' ' A' ' 123' ' ' ARG . 16.5 m -80.43 145.52 59.57 Favored Pre-proline 0 C--N 1.331 -0.206 0 CA-C-O 120.498 0.19 . . . . 0.0 111.322 -179.9 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 119' ' ' PRO . . . . . . . . . . . . . 85.9 Cg_endo -85.14 -6.59 9.33 Favored 'Trans proline' 0 C--N 1.348 0.509 0 C-N-CA 122.689 2.26 . . . . 0.0 112.099 179.51 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -133.17 -143.2 4.96 Favored Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.871 -0.68 . . . . 0.0 112.615 -179.894 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 121' ' ' ILE . . . . . 0.421 ' H ' HG13 ' A' ' 121' ' ' ILE . 2.7 pp -101.31 11.46 7.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-O 120.782 0.325 . . . . 0.0 111.308 -179.908 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 9.9 mm-40 -59.47 -19.08 45.09 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.047 179.975 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 123' ' ' ARG . . . . . 0.453 ' HB2' ' HH2' ' A' ' 178' ' ' TRP . 16.4 ptt180 -52.04 -34.55 43.74 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.037 -0.529 . . . . 0.0 111.538 -179.786 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 124' ' ' TYR . . . . . . . . . . . . . 49.6 m-85 -61.18 -33.13 72.96 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-O 120.748 0.308 . . . . 0.0 110.884 -179.956 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 125' ' ' ALA . . . . . . . . . . . . . . . -72.4 -50.58 25.47 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.278 -0.419 . . . . 0.0 110.666 179.55 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 7.3 mp -54.53 -54.22 44.11 Favored 'General case' 0 C--N 1.332 -0.18 0 CA-C-N 116.018 -0.537 . . . . 0.0 110.182 179.726 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 127' ' ' PHE . . . . . . . . . . . . . 8.9 t80 -63.15 -37.08 85.79 Favored 'General case' 0 N--CA 1.451 -0.409 0 CA-C-N 115.973 -0.558 . . . . 0.0 110.784 179.724 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 128' ' ' GLY . . . . . . . . . . . . . . . -46.22 -45.0 15.48 Favored Glycine 0 C--N 1.332 0.306 0 C-N-CA 120.19 -1.005 . . . . 0.0 110.918 179.109 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 129' ' ' MET . . . . . . . . . . . . . 0.4 OUTLIER -69.82 -37.74 76.34 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 115.311 -0.444 . . . . 0.0 109.85 178.646 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -61.99 -34.25 88.29 Favored Glycine 0 C--N 1.332 0.335 0 CA-C-N 115.677 -0.692 . . . . 0.0 112.942 -179.872 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -71.41 -53.77 12.95 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.697 0.284 . . . . 0.0 110.52 179.908 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 38.4 t -56.85 -39.95 68.16 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-O 121.439 0.638 . . . . 0.0 109.38 178.899 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -66.9 -35.37 79.85 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 115.151 -0.931 . . . . 0.0 110.532 179.357 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 134' ' ' PHE . . . . . . . . . . . . . 86.4 t80 -55.37 -55.27 33.53 Favored 'General case' 0 N--CA 1.452 -0.337 0 CA-C-O 121.012 0.434 . . . . 0.0 110.019 179.428 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 135' ' ' ILE . . . . . 0.436 ' HA ' HG23 ' A' ' 138' ' ' VAL . 29.6 mt -56.28 -33.95 38.84 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.295 0 CA-C-N 115.761 -0.654 . . . . 0.0 109.913 179.136 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . -61.99 -40.66 99.19 Favored Glycine 0 N--CA 1.448 -0.547 0 C-N-CA 120.299 -0.953 . . . . 0.0 111.321 178.812 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 137' ' ' LEU . . . . . 0.449 HD12 HD22 ' A' ' 105' ' ' ASN . 64.8 tp -69.33 -53.1 21.3 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-O 120.532 0.205 . . . . 0.0 111.04 179.97 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 138' ' ' VAL . . . . . 0.436 HG23 ' HA ' ' A' ' 135' ' ' ILE . 4.9 m -55.43 -34.62 34.87 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.167 0 N-CA-C 109.521 -0.548 . . . . 0.0 109.521 179.775 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 139' ' ' TYR . . . . . . . . . . . . . 21.4 t80 -61.58 -40.9 96.4 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 115.454 -0.794 . . . . 0.0 110.403 178.548 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 140' ' ' TYR . . . . . 0.428 ' HE2' HD23 ' A' ' 104' ' ' LEU . 20.9 m-85 -64.89 -52.17 57.97 Favored 'General case' 0 C--N 1.332 -0.189 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.673 -179.848 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 141' ' ' LEU . . . . . 0.495 HD12 ' N ' ' A' ' 142' ' ' VAL . 3.6 pp -64.27 -18.23 64.37 Favored 'General case' 0 N--CA 1.463 0.176 0 N-CA-C 111.74 0.274 . . . . 0.0 111.74 -179.271 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 142' ' ' VAL . . . . . 0.495 ' N ' HD12 ' A' ' 141' ' ' LEU . 5.2 p -109.36 -2.77 10.23 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-O 120.898 0.38 . . . . 0.0 110.924 179.866 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . -99.81 -102.51 2.44 Favored Glycine 0 CA--C 1.522 0.503 0 C-N-CA 120.767 -0.73 . . . . 0.0 113.104 -179.849 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 144' ' ' PRO . . . . . . . . . . . . . 58.2 Cg_endo -70.15 -27.87 24.07 Favored 'Trans proline' 0 C--N 1.348 0.503 0 C-N-CA 122.628 2.219 . . . . 0.0 113.285 -179.313 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 145' ' ' MET . . . . . 0.497 ' HE3' HD13 ' A' ' 93' ' ' LEU . 50.7 mtt -62.68 -39.07 92.78 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.669 0.271 . . . . 0.0 111.461 -179.583 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 146' ' ' THR . . . . . . . . . . . . . 67.2 p -66.21 -43.6 86.28 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.456 -0.338 . . . . 0.0 111.448 -179.524 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 39.7 mt-10 -70.45 -33.69 71.58 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.344 -0.389 . . . . 0.0 111.268 -179.651 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 148' ' ' SER . . . . . 0.46 ' HB3' ' HB3' ' A' ' 91' ' ' ALA . 48.0 t -70.34 -44.55 67.94 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.357 -0.383 . . . . 0.0 111.464 -179.485 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 149' ' ' ALA . . . . . . . . . . . . . . . -73.74 -33.94 64.54 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.339 -0.391 . . . . 0.0 111.399 -179.699 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 150' ' ' SER . . . . . 0.421 ' HB2' ' NZ ' ' A' ' 157' ' ' LYS . 81.0 p -67.33 -5.76 15.74 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 121.007 0.432 . . . . 0.0 110.657 179.783 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 151' ' ' GLN . . . . . . . . . . . . . 74.0 mt-30 -110.3 5.28 21.55 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 115.899 -0.591 . . . . 0.0 111.336 -179.812 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 31.2 ttt180 -91.8 -52.64 4.64 Favored 'General case' 0 C--N 1.331 -0.23 0 C-N-CA 120.902 -0.319 . . . . 0.0 111.213 -179.895 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 153' ' ' SER . . . . . 0.626 ' HB3' HG12 ' A' ' 156' ' ' ILE . 20.5 t -157.67 172.44 18.52 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.444 -0.344 . . . . 0.0 111.002 179.327 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 154' ' ' SER . . . . . 0.53 ' H ' ' HG ' ' A' ' 153' ' ' SER . 72.6 p -73.41 -41.7 62.98 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.705 179.576 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -72.64 -29.59 65.37 Favored Glycine 0 N--CA 1.452 -0.288 0 C-N-CA 120.804 -0.712 . . . . 0.0 112.334 179.88 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 156' ' ' ILE . . . . . 0.626 HG12 ' HB3' ' A' ' 153' ' ' SER . 34.6 mm -58.99 -38.45 73.86 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-O 120.84 0.352 . . . . 0.0 111.066 179.862 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 157' ' ' LYS . . . . . 0.421 ' NZ ' ' HB2' ' A' ' 150' ' ' SER . 21.3 ttmm -65.06 -47.86 75.82 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.129 -0.487 . . . . 0.0 111.085 179.811 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 69.1 m -60.65 -43.3 97.74 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 115.981 -0.554 . . . . 0.0 111.69 -179.042 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 159' ' ' LEU . . . . . 0.561 ' O ' ' HG ' ' A' ' 163' ' ' LEU . 3.7 tp -66.5 -58.59 4.9 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-O 120.943 0.401 . . . . 0.0 110.66 -179.861 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 160' ' ' TYR . . . . . . . . . . . . . 30.1 t80 -51.14 -36.23 39.68 Favored 'General case' 0 C--N 1.326 -0.416 0 N-CA-C 113.302 0.853 . . . . 0.0 113.302 -178.13 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 30.7 m -73.27 -47.04 48.25 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.373 0 N-CA-C 112.159 0.429 . . . . 0.0 112.159 -177.791 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 162' ' ' ARG . . . . . . . . . . . . . 24.2 ttm180 -63.68 -41.23 98.18 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-O 120.953 0.406 . . . . 0.0 111.014 -179.701 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 163' ' ' LEU . . . . . 0.561 ' HG ' ' O ' ' A' ' 159' ' ' LEU . 6.6 mt -70.38 -50.34 39.76 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 115.89 -0.595 . . . . 0.0 111.712 -179.197 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 164' ' ' ARG . . . . . 0.556 ' HG3' HD21 ' A' ' 165' ' ' ASN . 0.4 OUTLIER -58.14 -40.96 82.69 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.517 -0.31 . . . . 0.0 110.917 -178.986 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 165' ' ' ASN . . . . . 0.556 HD21 ' HG3' ' A' ' 164' ' ' ARG . 0.9 OUTLIER -58.46 -51.34 70.28 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-O 120.832 0.349 . . . . 0.0 110.295 179.545 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 166' ' ' LEU . . . . . 0.508 ' O ' ' HG ' ' A' ' 170' ' ' LEU . 2.3 tt -59.39 -54.74 43.25 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 115.93 -0.577 . . . . 0.0 111.712 -179.931 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 167' ' ' THR . . . . . 0.46 ' N ' HD23 ' A' ' 166' ' ' LEU . 52.6 m -55.08 -53.03 61.12 Favored 'General case' 0 C--N 1.33 -0.245 0 N-CA-C 112.773 0.657 . . . . 0.0 112.773 -178.398 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 168' ' ' VAL . . . . . . . . . . . . . 75.4 t -53.96 -42.23 53.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 N-CA-C 112.329 0.492 . . . . 0.0 112.329 -179.004 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 169' ' ' VAL . . . . . . . . . . . . . 72.7 t -60.93 -64.74 0.57 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 N-CA-C 112.124 0.416 . . . . 0.0 112.124 -179.225 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 170' ' ' LEU . . . . . 0.508 ' HG ' ' O ' ' A' ' 166' ' ' LEU . 0.4 OUTLIER -61.92 -34.12 75.49 Favored 'General case' 0 N--CA 1.465 0.276 0 N-CA-C 112.354 0.502 . . . . 0.0 112.354 -178.815 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 171' ' ' TRP . . . . . 0.53 ' HE1' ' HG1' ' A' ' 204' ' ' THR . 6.1 m0 -68.06 -29.56 68.56 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-O 120.792 0.33 . . . . 0.0 110.634 179.629 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 172' ' ' ALA . . . . . . . . . . . . . . . -73.92 -7.12 51.14 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.759 179.781 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 173' ' ' ILE . . . . . 0.485 ' O ' HG12 ' A' ' 177' ' ' ILE . 28.8 mm -87.68 -21.46 7.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 115.839 -0.619 . . . . 0.0 110.526 179.476 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 174' ' ' TYR . . . . . 0.41 ' HD2' ' HA ' ' A' ' 171' ' ' TRP . 8.2 m-85 -53.84 -48.38 93.81 Favored Pre-proline 0 CA--C 1.528 0.105 0 CA-C-N 116.055 -0.52 . . . . 0.0 111.681 -179.567 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 175' ' ' PRO . . . . . 0.403 ' CD ' ' N ' ' A' ' 174' ' ' TYR . 83.2 Cg_exo -46.65 -32.15 11.38 Favored 'Trans proline' 0 C--N 1.351 0.667 0 C-N-CA 121.831 1.687 . . . . 0.0 111.95 179.358 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 176' ' ' PHE . . . . . 0.42 ' HD2' ' HA ' ' A' ' 173' ' ' ILE . 84.3 m-85 -81.1 -49.79 10.43 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 115.697 -0.683 . . . . 0.0 111.799 179.867 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 177' ' ' ILE . . . . . 0.485 HG12 ' O ' ' A' ' 173' ' ' ILE . 8.5 mm -61.01 -38.83 80.36 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.498 0 N-CA-C 112.708 0.633 . . . . 0.0 112.708 -177.896 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 178' ' ' TRP . . . . . 0.453 ' HH2' ' HB2' ' A' ' 123' ' ' ARG . 78.5 t90 -71.58 -51.88 21.05 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.79 0.328 . . . . 0.0 111.213 -179.735 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 179' ' ' LEU . . . . . 0.477 HD23 HD23 ' A' ' 180' ' ' LEU . 0.6 OUTLIER -64.55 -55.08 22.82 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.323 -0.399 . . . . 0.0 111.601 -178.997 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 180' ' ' LEU . . . . . 0.477 HD23 HD23 ' A' ' 179' ' ' LEU . 32.4 mt -65.96 -37.64 86.52 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 116.341 -0.39 . . . . 0.0 111.345 -179.332 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . -60.53 176.15 4.25 Favored Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 119.988 -1.101 . . . . 0.0 112.33 179.589 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 182' ' ' PRO . . . . . 0.443 ' HB2' ' HD3' ' A' ' 183' ' ' PRO . 88.3 Cg_exo -46.63 -44.97 20.69 Favored 'Trans proline' 0 CA--C 1.536 0.607 0 C-N-CA 122.681 2.254 . . . . 0.0 113.402 179.912 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 183' ' ' PRO . . . . . 0.576 ' HB3' ' HB3' ' A' ' 116' ' ' ALA . 97.3 Cg_exo -45.31 -35.25 11.23 Favored 'Trans proline' 0 C--N 1.356 0.926 0 C-N-CA 122.328 2.019 . . . . 0.0 113.439 179.89 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 184' ' ' GLY . . . . . . . . . . . . . . . -110.29 -123.23 4.52 Favored Glycine 0 C--N 1.332 0.344 0 C-N-CA 120.299 -0.953 . . . . 0.0 113.204 -179.453 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 185' ' ' VAL . . . . . . . . . . . . . 8.1 m -63.04 -26.93 42.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 N-CA-C 112.16 0.43 . . . . 0.0 112.16 -179.225 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 186' ' ' ALA . . . . . 0.443 ' HB3' ' HA ' ' A' ' 182' ' ' PRO . . . 60.25 81.05 0.19 Allowed 'General case' 0 C--N 1.331 -0.207 0 N-CA-C 111.858 0.318 . . . . 0.0 111.858 179.48 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 187' ' ' LEU . . . . . . . . . . . . . 6.9 mt -92.8 -49.78 5.9 Favored 'General case' 0 C--N 1.332 -0.156 0 CA-C-O 120.995 0.426 . . . . 0.0 111.012 179.587 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 188' ' ' LEU . . . . . . . . . . . . . 95.2 mt -89.32 -166.7 1.66 Allowed 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 115.795 -0.639 . . . . 0.0 111.247 -179.48 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 189' ' ' THR . . . . . . . . . . . . . 74.9 m -94.08 136.13 23.95 Favored Pre-proline 0 C--N 1.328 -0.357 0 CA-C-N 115.781 -0.645 . . . . 0.0 110.626 -179.811 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 190' ' ' PRO . . . . . . . . . . . . . 2.4 Cg_endo -44.99 -38.58 13.66 Favored 'Trans proline' 0 C--N 1.35 0.61 0 C-N-CA 122.854 2.369 . . . . 0.0 112.649 -179.983 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 191' ' ' THR . . . . . . . . . . . . . 71.2 p -61.98 -42.95 99.7 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-O 120.965 0.412 . . . . 0.0 110.911 179.711 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 192' ' ' VAL . . . . . . . . . . . . . 88.8 t -71.29 -53.54 20.7 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 115.92 -0.582 . . . . 0.0 111.434 -179.816 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 193' ' ' ASP . . . . . . . . . . . . . 29.3 t70 -54.49 -52.01 63.28 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.242 -0.436 . . . . 0.0 111.442 -179.396 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 194' ' ' VAL . . . . . 0.438 ' O ' HG23 ' A' ' 198' ' ' VAL . 71.1 t -59.23 -38.22 73.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.371 -0.377 . . . . 0.0 110.614 -179.874 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 195' ' ' ALA . . . . . . . . . . . . . . . -55.22 -44.86 75.8 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.754 179.605 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 196' ' ' LEU . . . . . . . . . . . . . 95.6 mt -68.36 -35.86 78.35 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.934 179.461 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 197' ' ' ILE . . . . . 0.451 HG23 ' HD2' ' A' ' 72' ' ' ARG . 11.0 mm -59.49 -61.09 1.61 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.06 -0.518 . . . . 0.0 110.874 179.96 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 198' ' ' VAL . . . . . 0.438 HG23 ' O ' ' A' ' 194' ' ' VAL . 1.4 m -55.74 -35.0 37.83 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.462 0 CA-C-O 121.626 0.727 . . . . 0.0 109.191 178.772 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 199' ' ' TYR . . . . . . . . . . . . . 86.7 t80 -64.04 -32.5 74.07 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-N 114.56 -1.2 . . . . 0.0 110.415 179.336 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 200' ' ' LEU . . . . . . . . . . . . . 38.1 mt -71.11 -37.78 72.36 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 115.99 -0.55 . . . . 0.0 110.648 179.591 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 201' ' ' ASP . . . . . 0.532 ' HB2' ' HH ' ' A' ' 51' ' ' TYR . 7.9 m-20 -74.58 -32.98 62.55 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 115.953 -0.567 . . . . 0.0 110.161 179.63 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 202' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -72.52 -28.45 62.87 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 115.29 -0.868 . . . . 0.0 111.623 -179.527 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 203' ' ' VAL . . . . . . . . . . . . . 9.6 p -82.17 -37.78 14.99 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.18 0 N-CA-C 111.946 0.35 . . . . 0.0 111.946 -178.805 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 204' ' ' THR . . . . . 0.53 ' HG1' ' HE1' ' A' ' 171' ' ' TRP . 86.5 m -69.6 -41.87 75.16 Favored 'General case' 0 C--N 1.328 -0.337 0 C-N-CA 120.821 -0.352 . . . . 0.0 111.569 179.93 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 205' ' ' LYS . . . . . 0.611 ' HE2' ' HB3' ' A' ' 47' ' ' ALA . 59.7 mttp -76.52 -57.93 3.58 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.398 -0.365 . . . . 0.0 111.557 -178.872 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 60.4 t -69.47 -36.83 73.34 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.372 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.471 -179.503 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 207' ' ' GLY . . . . . . . . . . . . . . . -66.44 -52.76 32.87 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.615 -0.802 . . . . 0.0 112.43 -179.326 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 208' ' ' PHE . . . . . 0.426 ' O ' ' N ' ' A' ' 212' ' ' ALA . 11.3 t80 -55.21 -49.86 70.87 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-O 120.748 0.309 . . . . 0.0 110.941 179.771 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 209' ' ' GLY . . . . . 0.438 ' O ' ' HB3' ' A' ' 212' ' ' ALA . . . -63.64 -37.46 94.77 Favored Glycine 0 N--CA 1.451 -0.339 0 CA-C-N 115.632 -0.713 . . . . 0.0 113.985 -179.184 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 210' ' ' PHE . . . . . . . . . . . . . 0.6 OUTLIER -68.65 -46.66 68.57 Favored 'General case' 0 CA--C 1.512 -0.484 0 N-CA-C 108.217 -1.031 . . . . 0.0 108.217 179.272 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 211' ' ' ILE . . . . . . . . . . . . . 92.8 mt -64.9 -28.21 44.26 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.702 0 N-CA-C 107.694 -1.224 . . . . 0.0 107.694 176.656 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 212' ' ' ALA . . . . . 0.438 ' HB3' ' O ' ' A' ' 209' ' ' GLY . . . -68.29 -45.71 72.33 Favored 'General case' 0 N--CA 1.449 -0.492 0 CA-C-N 114.419 -1.264 . . . . 0.0 111.087 -179.851 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 213' ' ' LEU . . . . . . . . . . . . . 92.8 mt -70.55 -55.32 9.16 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-N 115.442 -0.799 . . . . 0.0 112.415 -178.828 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 214' ' ' ASP . . . . . . . . . . . . . 31.9 m-20 -53.11 -52.1 59.76 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.713 0.292 . . . . 0.0 111.607 -179.295 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 215' ' ' ALA . . . . . . . . . . . . . . . -62.14 -57.77 10.29 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 116.339 -0.391 . . . . 0.0 111.691 -179.438 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 216' ' ' ALA . . . . . . . . . . . . . . . -56.4 -34.85 67.11 Favored 'General case' 0 C--N 1.332 -0.188 0 CA-C-N 116.469 -0.332 . . . . 0.0 111.469 -179.537 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 217' ' ' ALA . . . . . . . . . . . . . . . -60.55 -40.7 92.55 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-O 121.048 0.452 . . . . 0.0 110.082 179.703 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 218' ' ' THR . . . . . . . . . . . . . 95.9 m . . . . . 0 C--N 1.33 -0.253 0 CA-C-N 115.659 -0.7 . . . . 0.0 110.71 179.331 . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.368 0 N-CA-C 112.582 -0.207 . . . . 0.0 112.582 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 92.7 mt -74.04 -35.25 64.3 Favored 'General case' 0 N--CA 1.449 -0.508 0 CA-C-O 120.858 0.361 . . . . 0.0 110.94 179.88 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 5' ' ' THR . . . . . 0.453 ' HG1' ' N ' ' A' ' 6' ' ' THR . 55.1 p -54.44 -38.84 66.76 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 115.928 -0.578 . . . . 0.0 111.718 -179.587 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 6' ' ' THR . . . . . 0.578 ' HG1' HD23 ' A' ' 7' ' ' LEU . 72.0 p -54.81 -35.52 63.98 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.451 -0.34 . . . . 0.0 111.619 -179.578 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 7' ' ' LEU . . . . . 0.578 HD23 ' HG1' ' A' ' 6' ' ' THR . 3.9 mm? -60.14 -53.29 59.45 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.317 -0.401 . . . . 0.0 111.272 -179.748 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 8' ' ' PHE . . . . . 0.519 ' HB2' ' HB1' ' A' ' 55' ' ' ALA . 75.8 m-85 -64.17 -34.53 78.29 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.994 -179.645 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 9' ' ' TRP . . . . . . . . . . . . . 21.5 m95 -62.34 -46.17 89.88 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-O 121.074 0.464 . . . . 0.0 109.835 179.939 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 41.9 mt -63.11 -35.88 81.75 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 115.629 -0.714 . . . . 0.0 110.154 179.138 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -69.66 -28.85 71.71 Favored Glycine 0 N--CA 1.448 -0.545 0 CA-C-N 115.643 -0.708 . . . . 0.0 111.784 179.419 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -73.71 -30.8 63.05 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-O 120.896 0.379 . . . . 0.0 110.473 179.526 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 13' ' ' ILE . . . . . 0.402 ' O ' HG21 ' A' ' 17' ' ' VAL . 50.2 mm -68.39 -54.33 22.36 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.124 0 CA-C-N 116.058 -0.519 . . . . 0.0 110.442 179.221 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -61.42 -37.39 94.02 Favored Glycine 0 N--CA 1.448 -0.534 0 C-N-CA 120.661 -0.781 . . . . 0.0 111.744 179.43 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 15' ' ' MET . . . . . 0.518 ' SD ' ' HA ' ' A' ' 44' ' ' SER . 55.5 tpp -63.65 -44.36 94.04 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.845 0.355 . . . . 0.0 110.44 179.527 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -54.82 -42.13 71.5 Favored 'General case' 0 C--N 1.332 -0.187 0 CA-C-N 115.943 -0.572 . . . . 0.0 110.02 179.291 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 17' ' ' VAL . . . . . 0.402 HG21 ' O ' ' A' ' 13' ' ' ILE . 45.0 t -58.94 -44.55 91.19 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.188 0 CA-C-N 116.011 -0.54 . . . . 0.0 110.328 179.404 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -64.45 -40.44 97.74 Favored Glycine 0 C--N 1.332 0.337 0 C-N-CA 120.852 -0.689 . . . . 0.0 111.726 179.124 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 11.8 m -53.45 -48.18 69.05 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-O 120.839 0.352 . . . . 0.0 110.988 -179.943 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 97.2 mt -71.75 -36.13 70.33 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.513 -179.977 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -58.14 -38.01 75.75 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 116.528 -0.305 . . . . 0.0 111.586 -179.761 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 22' ' ' PHE . . . . . 0.408 ' HB2' HG22 ' A' ' 41' ' ' VAL . 4.0 m-85 -90.91 -28.22 18.24 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.347 -0.388 . . . . 0.0 111.394 -179.457 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -69.81 -50.8 39.43 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.961 0.41 . . . . 0.0 111.503 -179.444 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 24' ' ' TRP . . . . . . . . . . . . . 5.5 t-105 -66.19 -43.26 87.34 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 115.842 -0.617 . . . . 0.0 111.111 -179.659 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.329 -0.316 0 CA-C-O 120.94 0.4 . . . . 0.0 110.866 179.799 . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.363 0 N-CA-C 112.472 -0.251 . . . . 0.0 112.472 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 16.3 mm-40 -83.57 -21.68 32.56 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 120.689 0.28 . . . . 0.0 110.994 179.929 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 34' ' ' ARG . . . . . . . . . . . . . 60.1 ttp180 -52.11 -30.5 26.54 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-N 116.158 -0.473 . . . . 0.0 111.252 -179.645 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 80.2 ttt180 -61.28 -42.55 98.83 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.871 0.367 . . . . 0.0 110.761 179.879 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 66.4 m-85 -70.75 -30.47 66.99 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.054 -0.521 . . . . 0.0 110.925 179.941 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 37' ' ' TYR . . . . . . . . . . . . . 59.2 m-85 -72.37 -56.13 5.96 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.324 -179.44 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 52.1 t -57.05 -37.4 54.94 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.189 0 CA-C-O 120.955 0.407 . . . . 0.0 110.766 -179.826 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 33.8 m -60.73 -51.01 71.19 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 115.863 -0.608 . . . . 0.0 110.628 179.521 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 40' ' ' LEU . . . . . 0.488 HD12 HD11 ' A' ' 43' ' ' ILE . 66.0 tp -60.86 -46.89 88.79 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 115.838 -0.619 . . . . 0.0 110.63 179.694 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . 0.408 HG22 ' HB2' ' A' ' 22' ' ' PHE . 90.0 t -56.7 -35.24 44.96 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.242 0 CA-C-N 115.884 -0.598 . . . . 0.0 110.041 179.289 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -61.74 -40.95 99.49 Favored Glycine 0 N--CA 1.448 -0.527 0 C-N-CA 120.673 -0.775 . . . . 0.0 111.504 179.175 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 43' ' ' ILE . . . . . 0.49 HD13 HD12 ' A' ' 83' ' ' ILE . 18.7 mt -57.46 -56.62 14.2 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.22 0 CA-C-O 120.76 0.314 . . . . 0.0 110.933 179.318 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 44' ' ' SER . . . . . 0.518 ' HA ' ' SD ' ' A' ' 15' ' ' MET . 49.7 m -58.71 -26.35 63.82 Favored 'General case' 0 C--N 1.332 -0.182 0 CA-C-N 116.315 -0.402 . . . . 0.0 111.482 -179.696 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -73.53 -53.99 7.05 Favored Glycine 0 CA--C 1.518 0.229 0 C-N-CA 120.681 -0.771 . . . . 0.0 112.879 -179.625 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 19.6 pt -61.18 -38.38 79.59 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.222 0 CA-C-O 120.871 0.367 . . . . 0.0 111.377 -179.712 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 47' ' ' ALA . . . . . 0.611 ' HB3' ' HE2' ' A' ' 205' ' ' LYS . . . -67.71 -43.21 80.57 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.814 0.34 . . . . 0.0 111.002 179.602 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -54.75 -46.71 74.36 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 115.947 -0.569 . . . . 0.0 111.754 -179.531 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 49' ' ' VAL . . . . . 0.402 ' O ' HG13 ' A' ' 53' ' ' VAL . 31.4 m -68.59 -34.19 63.89 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.241 0 CA-C-N 116.527 -0.306 . . . . 0.0 111.275 -179.595 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -66.01 -37.07 84.98 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-O 120.884 0.373 . . . . 0.0 111.005 179.638 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 51' ' ' TYR . . . . . 0.408 ' OH ' ' HB2' ' A' ' 201' ' ' ASP . 26.7 m-85 -68.75 -38.75 80.34 Favored 'General case' 0 C--N 1.327 -0.413 0 CA-C-O 121.117 0.484 . . . . 0.0 110.084 179.772 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -65.29 -45.09 85.84 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 115.635 -0.712 . . . . 0.0 111.314 179.676 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 53' ' ' VAL . . . . . 0.461 HG21 ' N ' ' A' ' 54' ' ' MET . 27.6 m -67.76 -46.5 82.36 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.139 0 CA-C-O 120.794 0.33 . . . . 0.0 110.621 179.886 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 54' ' ' MET . . . . . 0.465 ' HG2' ' HG2' ' A' ' 71' ' ' PRO . 72.0 mtm -62.27 -30.44 71.12 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 121.156 0.503 . . . . 0.0 109.854 179.111 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 55' ' ' ALA . . . . . 0.519 ' HB1' ' HB2' ' A' ' 8' ' ' PHE . . . -74.28 -30.53 62.14 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 115.601 -0.727 . . . . 0.0 111.355 179.797 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 76.3 mt -77.37 -9.74 59.03 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.457 -0.338 . . . . 0.0 111.214 -179.764 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 95.31 -11.93 68.48 Favored Glycine 0 N--CA 1.452 -0.254 0 C-N-CA 120.666 -0.778 . . . . 0.0 113.017 179.729 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 8.8 p -74.29 140.58 17.38 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-O 120.846 0.355 . . . . 0.0 110.885 -179.97 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 59' ' ' GLY . . . . . 0.463 ' HA3' ' HG3' ' A' ' 71' ' ' PRO . . . 101.29 -9.71 57.76 Favored Glycine 0 N--CA 1.45 -0.377 0 C-N-CA 120.907 -0.663 . . . . 0.0 112.286 -179.715 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 60' ' ' TRP . . . . . . . . . . . . . 15.8 m0 -76.32 118.08 18.66 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-O 120.579 0.228 . . . . 0.0 110.393 179.67 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 61' ' ' VAL . . . . . 0.469 ' HA ' ' HD3' ' A' ' 62' ' ' PRO . 7.5 p -113.26 127.63 26.61 Favored Pre-proline 0 CA--C 1.533 0.321 0 CA-C-N 116.582 -0.281 . . . . 0.0 111.716 -179.603 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 62' ' ' PRO . . . . . 0.469 ' HD3' ' HA ' ' A' ' 61' ' ' VAL . 6.8 Cg_exo -74.03 146.61 37.25 Favored 'Trans proline' 0 C--N 1.351 0.685 0 C-N-CA 122.88 2.386 . . . . 0.0 112.159 179.518 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 75.5 t -139.71 90.42 0.6 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.044 179.859 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . 59.16 -86.12 0.02 OUTLIER 'General case' 0 C--N 1.331 -0.196 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.463 179.891 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 9.7 tp10 -122.42 -19.98 6.24 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 121.011 0.434 . . . . 0.0 110.653 -179.991 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 66' ' ' ARG . . . . . . . . . . . . . 18.4 ptp180 -100.76 165.82 11.18 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 115.893 -0.594 . . . . 0.0 110.373 179.878 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 26.3 m -125.42 139.66 53.46 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.886 0.374 . . . . 0.0 111.3 -179.838 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 21.5 t -124.17 146.57 29.46 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.238 0 CA-C-N 115.972 -0.558 . . . . 0.0 110.583 179.887 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 69' ' ' PHE . . . . . . . . . . . . . 27.5 m-85 -109.37 111.05 22.39 Favored 'General case' 0 C--N 1.331 -0.206 0 CA-C-N 116.41 -0.359 . . . . 0.0 110.062 -179.629 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 70' ' ' VAL . . . . . 0.589 ' N ' ' HD2' ' A' ' 71' ' ' PRO . 47.4 t -70.02 -49.82 18.15 Favored Pre-proline 0 C--N 1.325 -0.471 0 N-CA-C 112.759 0.651 . . . . 0.0 112.759 -179.186 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 71' ' ' PRO . . . . . 0.589 ' HD2' ' N ' ' A' ' 70' ' ' VAL . 11.3 Cg_endo -54.03 -19.12 14.94 Favored 'Trans proline' 0 C--N 1.352 0.739 0 C-N-CA 122.031 1.82 . . . . 0.0 112.339 -179.616 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 72' ' ' ARG . . . . . 0.44 ' HE ' HG22 ' A' ' 197' ' ' ILE . 32.1 ttt180 -77.02 -53.49 7.74 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.596 179.605 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 73' ' ' TYR . . . . . 0.421 ' O ' HG13 ' A' ' 77' ' ' ILE . 79.9 m-85 -66.37 -39.41 89.08 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 115.816 -0.629 . . . . 0.0 110.922 -179.811 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 0.3 OUTLIER -67.4 -36.35 76.24 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-N 116.348 -0.387 . . . . 0.0 110.043 179.504 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 12.6 t70 -61.02 -37.37 82.32 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.235 -0.439 . . . . 0.0 109.951 179.253 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 76' ' ' TRP . . . . . . . . . . . . . 48.6 m0 -66.3 -36.21 82.36 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 115.927 -0.579 . . . . 0.0 110.067 179.414 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 77' ' ' ILE . . . . . 0.498 ' O ' ' HG2' ' A' ' 81' ' ' PRO . 68.3 mt -66.54 -30.07 48.55 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.364 0 CA-C-N 115.959 -0.564 . . . . 0.0 110.91 179.511 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 53.4 mt -91.91 -21.95 20.32 Favored 'General case' 0 C--N 1.328 -0.347 0 N-CA-C 112.511 0.56 . . . . 0.0 112.511 -179.644 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 79' ' ' THR . . . . . 0.459 ' HG1' ' H ' ' A' ' 80' ' ' THR . 70.0 p -100.27 -52.0 3.5 Favored 'General case' 0 N--CA 1.464 0.269 0 N-CA-C 113.619 0.97 . . . . 0.0 113.619 -177.792 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 80' ' ' THR . . . . . 0.661 ' HB ' ' HD3' ' A' ' 81' ' ' PRO . 86.3 m -51.35 -55.35 29.65 Favored Pre-proline 0 CA--C 1.532 0.271 0 N-CA-C 112.421 0.526 . . . . 0.0 112.421 -178.502 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 81' ' ' PRO . . . . . 0.661 ' HD3' ' HB ' ' A' ' 80' ' ' THR . 52.0 Cg_exo -56.49 -20.13 32.13 Favored 'Trans proline' 0 C--N 1.352 0.762 0 C-N-CA 121.542 1.495 . . . . 0.0 111.481 179.574 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 82' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -76.63 -38.2 55.08 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 115.716 -0.675 . . . . 0.0 110.223 179.552 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 83' ' ' ILE . . . . . 0.49 HD12 HD13 ' A' ' 43' ' ' ILE . 16.7 mm -66.17 -51.24 61.68 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.16 0 CA-C-N 116.004 -0.543 . . . . 0.0 110.293 179.516 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 31.0 m -61.49 -31.76 51.48 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.166 0 N-CA-C 109.71 -0.478 . . . . 0.0 109.71 178.962 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 85' ' ' TYR . . . . . . . . . . . . . 83.4 t80 -66.48 -31.94 72.99 Favored 'General case' 0 N--CA 1.454 -0.249 0 CA-C-N 115.656 -0.702 . . . . 0.0 109.569 178.763 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 86' ' ' PHE . . . . . . . . . . . . . 11.5 t80 -63.69 -50.84 67.6 Favored 'General case' 0 C--O 1.233 0.185 0 CA-C-N 115.889 -0.596 . . . . 0.0 109.793 179.179 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 3.1 mt -61.02 -35.5 77.02 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 115.786 -0.643 . . . . 0.0 109.714 179.537 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -67.08 -28.14 73.68 Favored Glycine 0 N--CA 1.45 -0.393 0 CA-C-N 115.28 -0.873 . . . . 0.0 111.865 179.49 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 50.0 mt -72.59 -37.36 68.15 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.893 0.378 . . . . 0.0 110.277 179.534 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 41.5 mt -60.4 -50.6 72.96 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 115.741 -0.663 . . . . 0.0 110.73 179.617 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 91' ' ' ALA . . . . . 0.446 ' HB2' ' HB2' ' A' ' 148' ' ' SER . . . -71.52 -48.57 47.98 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 115.981 -0.554 . . . . 0.0 111.374 -179.815 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 96.88 62.66 0.93 Allowed Glycine 0 N--CA 1.452 -0.271 0 C-N-CA 120.764 -0.731 . . . . 0.0 112.399 -179.902 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 93' ' ' LEU . . . . . 0.554 ' HB3' ' HB2' ' A' ' 97' ' ' GLU . 7.1 mp -77.08 175.09 9.94 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.782 0.325 . . . . 0.0 110.868 -179.958 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 94' ' ' ASP . . . . . . . . . . . . . 13.0 m-20 -91.23 172.82 8.28 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.827 179.708 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 78.5 p -60.04 -36.55 77.52 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.246 -0.434 . . . . 0.0 111.09 -179.848 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 15.9 ptm180 -73.89 -43.54 58.16 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.06 -179.965 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 97' ' ' GLU . . . . . 0.554 ' HB2' ' HB3' ' A' ' 93' ' ' LEU . 37.1 mt-10 -57.59 -46.49 83.97 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.384 -0.371 . . . . 0.0 110.764 -179.926 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 98' ' ' PHE . . . . . . . . . . . . . 21.4 m-85 -60.25 -41.29 92.9 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.361 179.53 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -58.73 -32.55 69.91 Favored Glycine 0 N--CA 1.449 -0.469 0 C-N-CA 120.687 -0.768 . . . . 0.0 112.265 179.75 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 86.7 mt -73.51 -44.54 53.6 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-O 120.747 0.308 . . . . 0.0 111.675 -179.83 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 35.3 t -68.46 -48.8 70.77 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 CA-C-N 116.318 -0.401 . . . . 0.0 111.76 -179.252 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 102' ' ' ILE . . . . . 0.513 HG22 ' HB3' ' A' ' 81' ' ' PRO . 48.2 mm -63.56 -45.87 96.5 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.379 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.868 -179.357 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 6.0 t -62.02 -33.67 74.79 Favored 'General case' 0 C--N 1.332 -0.192 0 CA-C-O 120.867 0.365 . . . . 0.0 110.759 -179.813 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 48.5 tp -60.17 -53.28 59.59 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.221 179.348 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 105' ' ' ASN . . . . . 0.571 ' N ' HD21 ' A' ' 105' ' ' ASN . 0.8 OUTLIER -56.26 -31.31 63.47 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.063 -0.517 . . . . 0.0 110.115 179.38 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 24.8 m -61.88 -38.75 89.47 Favored 'General case' 0 C--N 1.332 -0.179 0 CA-C-N 116.038 -0.528 . . . . 0.0 109.996 179.078 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 1.8 t -70.35 -41.21 78.45 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.198 0 CA-C-N 116.051 -0.522 . . . . 0.0 109.964 178.97 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 54.0 t -57.22 -47.19 84.62 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 115.367 -0.833 . . . . 0.0 111.23 179.885 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 109' ' ' MET . . . . . . . . . . . . . 21.5 mmt -69.27 -32.31 71.41 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.017 -0.538 . . . . 0.0 111.124 -179.714 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 27.8 tp -65.3 -33.28 75.6 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-O 120.964 0.411 . . . . 0.0 110.324 179.793 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -68.82 -53.84 19.24 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 115.855 -0.611 . . . . 0.0 110.743 179.465 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . -63.09 -35.62 92.33 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.652 -0.785 . . . . 0.0 112.135 179.642 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 113' ' ' PHE . . . . . 0.405 ' HZ ' HG12 ' A' ' 70' ' ' VAL . 0.7 OUTLIER -55.63 -65.31 0.61 Allowed 'General case' 0 C--N 1.33 -0.255 0 CA-C-O 121.066 0.46 . . . . 0.0 110.249 179.6 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 114' ' ' ALA . . . . . 0.558 ' HB1' HD22 ' A' ' 126' ' ' LEU . . . -66.09 -22.55 66.41 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 115.722 -0.672 . . . . 0.0 110.951 179.816 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -55.8 -48.96 68.71 Favored Glycine 0 C--N 1.333 0.392 0 C-N-CA 120.659 -0.781 . . . . 0.0 111.85 179.401 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -78.32 -15.03 59.14 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-O 120.836 0.35 . . . . 0.0 111.016 179.508 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 117' ' ' MET . . . . . . . . . . . . . 32.3 tpp -91.58 18.73 7.02 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.105 -0.498 . . . . 0.0 111.497 -179.204 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 118' ' ' VAL . . . . . 0.468 HG23 ' HB3' ' A' ' 123' ' ' ARG . 27.5 m -88.57 139.1 29.71 Favored Pre-proline 0 C--N 1.33 -0.27 0 CA-C-N 116.633 -0.258 . . . . 0.0 111.308 -179.865 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 119' ' ' PRO . . . . . . . . . . . . . 95.4 Cg_endo -89.67 -10.08 3.81 Favored 'Trans proline' 0 N--CA 1.456 -0.697 0 C-N-CA 122.699 2.266 . . . . 0.0 112.195 179.371 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -128.64 -106.71 1.3 Allowed Glycine 0 C--N 1.331 0.305 0 C-N-CA 120.848 -0.691 . . . . 0.0 112.722 -179.74 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 2.6 pp -136.93 19.52 0.85 Allowed 'Isoleucine or valine' 0 C--N 1.332 -0.185 0 CA-C-O 120.742 0.306 . . . . 0.0 111.652 -179.713 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 41.3 mt-10 -65.05 -17.71 64.68 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.311 -0.404 . . . . 0.0 110.853 179.757 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 123' ' ' ARG . . . . . 0.468 ' HB3' HG23 ' A' ' 118' ' ' VAL . 12.2 ptt180 -50.16 -42.05 50.25 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 115.736 -0.666 . . . . 0.0 112.023 -179.64 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 124' ' ' TYR . . . . . . . . . . . . . 59.0 m-85 -57.56 -32.18 66.87 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.522 -0.308 . . . . 0.0 111.511 -179.239 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 125' ' ' ALA . . . . . . . . . . . . . . . -74.2 -56.29 5.07 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-O 121.03 0.443 . . . . 0.0 111.156 -179.728 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 126' ' ' LEU . . . . . 0.558 HD22 ' HB1' ' A' ' 114' ' ' ALA . 1.1 mt -53.25 -48.83 67.92 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 115.746 -0.661 . . . . 0.0 110.494 179.96 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 127' ' ' PHE . . . . . . . . . . . . . 7.0 t80 -63.65 -35.65 81.24 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.306 -0.406 . . . . 0.0 110.483 179.396 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 128' ' ' GLY . . . . . . . . . . . . . . . -47.22 -50.73 16.21 Favored Glycine 0 C--N 1.333 0.402 0 C-N-CA 120.055 -1.069 . . . . 0.0 110.609 178.854 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 129' ' ' MET . . . . . . . . . . . . . 0.5 OUTLIER -65.31 -34.31 78.03 Favored 'General case' 0 C--N 1.329 -0.314 0 N-CA-C 109.679 -0.489 . . . . 0.0 109.679 178.293 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -57.81 -51.61 57.1 Favored Glycine 0 C--N 1.331 0.284 0 CA-C-N 115.463 -0.789 . . . . 0.0 112.597 -179.973 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -58.91 -49.47 77.66 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 120.66 0.267 . . . . 0.0 110.684 179.865 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 132' ' ' VAL . . . . . 0.411 ' O ' HG13 ' A' ' 135' ' ' ILE . 49.9 t -54.55 -39.99 48.21 Favored 'Isoleucine or valine' 0 C--O 1.233 0.228 0 CA-C-O 121.269 0.557 . . . . 0.0 109.794 179.007 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -69.98 -34.19 73.05 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 115.474 -0.784 . . . . 0.0 110.947 179.469 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 134' ' ' PHE . . . . . 0.459 ' CZ ' ' HA ' ' A' ' 172' ' ' ALA . 51.9 t80 -56.87 -58.58 7.5 Favored 'General case' 0 CA--C 1.517 -0.294 0 CA-C-N 116.341 -0.39 . . . . 0.0 110.118 179.817 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 135' ' ' ILE . . . . . 0.442 ' O ' HG23 ' A' ' 138' ' ' VAL . 0.0 OUTLIER -55.6 -34.85 36.56 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 115.799 -0.637 . . . . 0.0 109.663 179.104 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . -58.19 -36.47 82.61 Favored Glycine 0 N--CA 1.448 -0.524 0 C-N-CA 120.447 -0.882 . . . . 0.0 111.482 178.944 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 137' ' ' LEU . . . . . 0.463 HD11 HD22 ' A' ' 105' ' ' ASN . 38.3 tp -71.91 -54.18 10.82 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-O 120.615 0.245 . . . . 0.0 110.721 179.537 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 138' ' ' VAL . . . . . 0.442 HG23 ' O ' ' A' ' 135' ' ' ILE . 3.4 m -55.92 -30.32 28.09 Favored 'Isoleucine or valine' 0 C--O 1.233 0.197 0 CA-C-O 121.312 0.577 . . . . 0.0 109.712 179.351 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 139' ' ' TYR . . . . . . . . . . . . . 31.4 t80 -63.58 -47.03 83.14 Favored 'General case' 0 N--CA 1.453 -0.285 0 CA-C-N 115.31 -0.859 . . . . 0.0 110.021 178.975 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 18.2 m-85 -57.38 -35.98 70.68 Favored 'General case' 0 C--N 1.332 -0.191 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.596 179.362 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 141' ' ' LEU . . . . . . . . . . . . . 69.5 mt -59.49 -54.69 43.7 Favored 'General case' 0 C--N 1.333 -0.152 0 CA-C-N 116.262 -0.426 . . . . 0.0 110.51 179.522 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 18.6 t -70.02 -15.79 19.58 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.246 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.765 179.597 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . -68.68 -138.67 0.08 OUTLIER Glycine 0 CA--C 1.522 0.469 0 C-N-CA 121.025 -0.607 . . . . 0.0 112.779 -179.899 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 144' ' ' PRO . . . . . . . . . . . . . 19.2 Cg_endo -59.11 -23.42 68.94 Favored 'Trans proline' 0 C--N 1.349 0.587 0 C-N-CA 122.672 2.248 . . . . 0.0 112.654 -179.723 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 145' ' ' MET . . . . . 0.524 ' HB3' ' HH ' ' A' ' 160' ' ' TYR . 45.5 mtt -59.07 -28.52 66.55 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.517 -0.311 . . . . 0.0 111.28 -179.997 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 146' ' ' THR . . . . . . . . . . . . . 35.2 m -80.45 -42.9 21.81 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.913 0.387 . . . . 0.0 111.194 -179.167 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 9.1 tp10 -70.42 -34.53 72.6 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 115.964 -0.562 . . . . 0.0 111.107 -179.818 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 148' ' ' SER . . . . . 0.446 ' HB2' ' HB2' ' A' ' 91' ' ' ALA . 64.2 m -70.47 -50.85 33.75 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.054 -179.41 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 149' ' ' ALA . . . . . 0.43 ' HB2' HG22 ' A' ' 156' ' ' ILE . . . -64.79 -38.38 90.8 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.332 -179.828 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 150' ' ' SER . . . . . . . . . . . . . 100.0 p -72.15 -4.29 28.26 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.896 179.856 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 151' ' ' GLN . . . . . . . . . . . . . 24.3 mt-30 -125.46 1.54 7.66 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.168 -179.98 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -80.34 -52.54 7.57 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-O 121.013 0.435 . . . . 0.0 110.333 179.883 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 153' ' ' SER . . . . . 0.569 ' HB2' HG12 ' A' ' 156' ' ' ILE . 44.3 m -158.22 171.01 20.98 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-N 115.83 -0.623 . . . . 0.0 110.49 179.18 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 154' ' ' SER . . . . . . . . . . . . . 64.1 m -71.21 -36.82 72.01 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 121.028 0.442 . . . . 0.0 110.059 179.127 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -76.93 -41.21 23.49 Favored Glycine 0 N--CA 1.45 -0.417 0 CA-C-N 115.785 -0.643 . . . . 0.0 112.386 179.611 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 156' ' ' ILE . . . . . 0.569 HG12 ' HB2' ' A' ' 153' ' ' SER . 38.1 mm -51.76 -38.17 21.81 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.196 0 CA-C-O 120.879 0.371 . . . . 0.0 111.177 179.91 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 157' ' ' LYS . . . . . . . . . . . . . 63.1 tttm -58.93 -42.92 90.88 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 115.961 -0.563 . . . . 0.0 110.92 -179.989 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 51.0 m -71.19 -40.94 70.91 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.547 -179.732 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 159' ' ' LEU . . . . . 0.418 ' O ' ' HB2' ' A' ' 163' ' ' LEU . 2.2 mm? -63.78 -38.72 92.17 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.418 -0.355 . . . . 0.0 111.601 -179.419 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 160' ' ' TYR . . . . . 0.524 ' HH ' ' HB3' ' A' ' 145' ' ' MET . 43.5 t80 -74.2 -46.79 39.71 Favored 'General case' 0 C--N 1.327 -0.38 0 N-CA-C 112.598 0.592 . . . . 0.0 112.598 -178.533 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 161' ' ' VAL . . . . . 0.417 HG22 ' N ' ' A' ' 162' ' ' ARG . 21.2 m -57.25 -48.83 81.59 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 N-CA-C 112.395 0.517 . . . . 0.0 112.395 -178.788 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 162' ' ' ARG . . . . . 0.417 ' N ' HG22 ' A' ' 161' ' ' VAL . 27.1 ttm180 -69.04 -45.92 69.21 Favored 'General case' 0 C--N 1.329 -0.324 0 N-CA-C 111.783 0.29 . . . . 0.0 111.783 -179.302 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 163' ' ' LEU . . . . . 0.662 ' HG ' ' HB2' ' A' ' 208' ' ' PHE . 6.6 mp -61.78 -49.75 75.12 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.451 -0.34 . . . . 0.0 111.733 -179.661 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 164' ' ' ARG . . . . . . . . . . . . . 4.0 tmt_? -62.64 -45.51 92.52 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.312 -0.404 . . . . 0.0 111.749 -179.036 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 165' ' ' ASN . . . . . 0.477 ' N ' HD21 ' A' ' 165' ' ' ASN . 0.9 OUTLIER -59.49 -52.19 66.62 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.783 0.325 . . . . 0.0 111.546 -179.434 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 166' ' ' LEU . . . . . 0.508 ' O ' ' HG ' ' A' ' 170' ' ' LEU . 4.6 tt -63.88 -53.41 50.9 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-O 120.852 0.358 . . . . 0.0 111.314 -179.552 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 167' ' ' THR . . . . . 0.44 ' O ' ' HB2' ' A' ' 171' ' ' TRP . 88.3 m -54.67 -53.09 59.37 Favored 'General case' 0 C--N 1.327 -0.381 0 N-CA-C 112.581 0.585 . . . . 0.0 112.581 -178.744 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 168' ' ' VAL . . . . . . . . . . . . . 9.1 p -56.74 -40.58 71.23 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.204 0 N-CA-C 112.158 0.429 . . . . 0.0 112.158 -178.753 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 169' ' ' VAL . . . . . . . . . . . . . 51.5 t -58.26 -65.37 0.44 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 N-CA-C 111.821 0.304 . . . . 0.0 111.821 -179.487 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 170' ' ' LEU . . . . . 0.508 ' HG ' ' O ' ' A' ' 166' ' ' LEU . 0.4 OUTLIER -64.48 -28.26 69.54 Favored 'General case' 0 C--N 1.331 -0.216 0 N-CA-C 111.982 0.364 . . . . 0.0 111.982 -178.865 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 171' ' ' TRP . . . . . 0.44 ' HB2' ' O ' ' A' ' 167' ' ' THR . 5.2 m0 -71.38 -31.18 67.01 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.848 0.356 . . . . 0.0 110.742 179.488 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 172' ' ' ALA . . . . . 0.459 ' HA ' ' CZ ' ' A' ' 134' ' ' PHE . . . -73.78 -6.4 46.75 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.861 -179.727 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 173' ' ' ILE . . . . . 0.51 HG23 HD12 ' A' ' 177' ' ' ILE . 13.9 mm -86.12 -21.46 7.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 115.927 -0.579 . . . . 0.0 110.806 179.629 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 174' ' ' TYR . . . . . . . . . . . . . 14.2 m-85 -54.27 -51.24 79.5 Favored Pre-proline 0 CA--C 1.531 0.236 0 CA-C-N 116.115 -0.493 . . . . 0.0 112.109 -179.535 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 175' ' ' PRO . . . . . . . . . . . . . 89.1 Cg_exo -47.4 -29.14 9.43 Favored 'Trans proline' 0 C--N 1.352 0.728 0 C-N-CA 121.998 1.798 . . . . 0.0 112.176 179.748 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 176' ' ' PHE . . . . . 0.44 ' O ' ' HG ' ' A' ' 180' ' ' LEU . 98.3 m-85 -80.52 -50.12 10.46 Favored 'General case' 0 CA--C 1.517 -0.323 0 CA-C-N 116.057 -0.52 . . . . 0.0 111.69 179.968 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 177' ' ' ILE . . . . . 0.521 ' O ' ' HD2' ' A' ' 182' ' ' PRO . 3.1 mm -58.4 -46.47 89.36 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.533 0 CA-C-N 115.884 -0.598 . . . . 0.0 112.073 -178.227 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 178' ' ' TRP . . . . . 0.484 ' HA ' ' HG2' ' A' ' 182' ' ' PRO . 75.1 t90 -62.5 -42.45 99.51 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 121.026 0.441 . . . . 0.0 110.974 -179.986 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 179' ' ' LEU . . . . . 0.562 HD13 HG22 ' A' ' 185' ' ' VAL . 1.2 tm? -67.27 -49.51 64.04 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 115.831 -0.622 . . . . 0.0 111.369 -179.061 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 180' ' ' LEU . . . . . 0.563 HD21 HD11 ' A' ' 187' ' ' LEU . 9.9 mt -76.95 -52.29 9.65 Favored 'General case' 0 CA--C 1.535 0.374 0 N-CA-C 112.498 0.555 . . . . 0.0 112.498 -178.474 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . -64.97 -84.1 0.08 OUTLIER Glycine 0 CA--C 1.522 0.521 0 C-N-CA 120.72 -0.752 . . . . 0.0 113.425 -179.557 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 182' ' ' PRO . . . . . 0.521 ' HD2' ' O ' ' A' ' 177' ' ' ILE . 75.0 Cg_exo -44.86 -179.79 0.0 OUTLIER 'Trans proline' 0 C--N 1.351 0.671 0 C-N-CA 123.567 2.845 . . . . 0.0 113.574 179.684 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 183' ' ' PRO . . . . . . . . . . . . . 82.8 Cg_exo -50.11 5.06 0.02 OUTLIER 'Trans proline' 0 C--N 1.354 0.864 0 C-N-CA 123.196 2.597 . . . . 0.0 115.274 -179.566 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 184' ' ' GLY . . . . . 0.504 ' H ' ' C ' ' A' ' 182' ' ' PRO . . . -55.32 -70.28 1.01 Allowed Glycine 0 C--N 1.335 0.514 0 C-N-CA 119.724 -1.226 . . . . 0.0 110.899 179.236 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 185' ' ' VAL . . . . . 0.562 HG22 HD13 ' A' ' 179' ' ' LEU . 3.6 m -135.65 -5.77 0.95 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.372 0 N-CA-C 111.722 0.267 . . . . 0.0 111.722 178.559 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 186' ' ' ALA . . . . . . . . . . . . . . . 41.99 81.19 0.03 OUTLIER 'General case' 0 N--CA 1.466 0.349 0 N-CA-C 112.43 0.529 . . . . 0.0 112.43 179.372 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 187' ' ' LEU . . . . . 0.563 HD11 HD21 ' A' ' 180' ' ' LEU . 7.0 mt -92.92 -49.47 6.03 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.767 0.318 . . . . 0.0 111.548 179.871 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 188' ' ' LEU . . . . . . . . . . . . . 89.3 mt -105.8 -166.56 1.22 Allowed 'General case' 0 C--N 1.33 -0.244 0 CA-C-O 121.073 0.463 . . . . 0.0 111.515 -179.261 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 189' ' ' THR . . . . . 0.425 ' HB ' HG22 ' A' ' 192' ' ' VAL . 4.7 m -82.72 136.12 45.25 Favored Pre-proline 0 C--N 1.328 -0.339 0 CA-C-N 115.668 -0.696 . . . . 0.0 110.685 -179.615 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 190' ' ' PRO . . . . . . . . . . . . . 84.5 Cg_exo -45.76 -48.64 12.0 Favored 'Trans proline' 0 C--N 1.349 0.559 0 C-N-CA 122.628 2.219 . . . . 0.0 113.026 -179.788 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 191' ' ' THR . . . . . . . . . . . . . 3.9 t -56.8 -39.69 74.59 Favored 'General case' 0 C--N 1.33 -0.255 0 N-CA-C 111.921 0.341 . . . . 0.0 111.921 -179.492 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 192' ' ' VAL . . . . . 0.425 HG22 ' HB ' ' A' ' 189' ' ' THR . 58.6 t -67.33 -53.58 31.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-O 120.877 0.37 . . . . 0.0 111.546 -179.55 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 193' ' ' ASP . . . . . . . . . . . . . 13.5 m-20 -59.0 -43.05 91.43 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.09 -179.636 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 194' ' ' VAL . . . . . . . . . . . . . 54.3 t -60.99 -36.16 70.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.345 -0.389 . . . . 0.0 110.404 179.497 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 195' ' ' ALA . . . . . . . . . . . . . . . -58.51 -46.42 86.78 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-N 116.346 -0.388 . . . . 0.0 110.404 179.232 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 196' ' ' LEU . . . . . . . . . . . . . 90.6 mt -62.66 -38.04 88.74 Favored 'General case' 0 C--N 1.332 -0.192 0 CA-C-N 116.055 -0.52 . . . . 0.0 110.323 179.309 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 197' ' ' ILE . . . . . 0.44 HG22 ' HE ' ' A' ' 72' ' ' ARG . 20.3 mm -61.36 -57.14 13.49 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 115.947 -0.57 . . . . 0.0 110.223 179.262 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 198' ' ' VAL . . . . . . . . . . . . . 83.9 t -52.75 -34.88 20.52 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.465 0 CA-C-N 115.734 -0.666 . . . . 0.0 109.243 178.374 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 199' ' ' TYR . . . . . . . . . . . . . 62.5 t80 -69.99 -33.62 72.28 Favored 'General case' 0 C--N 1.332 -0.176 0 CA-C-N 115.388 -0.824 . . . . 0.0 110.626 179.498 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 200' ' ' LEU . . . . . 0.487 ' O ' HG11 ' A' ' 203' ' ' VAL . 31.8 mt -68.87 -44.17 73.86 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 115.919 -0.582 . . . . 0.0 111.409 -179.685 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 201' ' ' ASP . . . . . 0.408 ' HB2' ' OH ' ' A' ' 51' ' ' TYR . 11.8 m-20 -67.39 -36.05 80.52 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-O 121.293 0.568 . . . . 0.0 109.963 179.476 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 202' ' ' LEU . . . . . . . . . . . . . 3.3 mt -74.35 -28.28 61.06 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 115.232 -0.895 . . . . 0.0 112.356 -179.394 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 203' ' ' VAL . . . . . 0.487 HG11 ' O ' ' A' ' 200' ' ' LEU . 11.6 p -77.25 -36.15 23.71 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.303 0 C-N-CA 120.757 -0.377 . . . . 0.0 111.21 -178.533 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 204' ' ' THR . . . . . . . . . . . . . 90.2 m -70.7 -58.49 3.59 Favored 'General case' 0 C--N 1.327 -0.389 0 C-N-CA 120.719 -0.392 . . . . 0.0 111.068 179.316 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 205' ' ' LYS . . . . . 0.611 ' HE2' ' HB3' ' A' ' 47' ' ' ALA . 56.6 mttp -57.33 -58.02 10.09 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.242 -0.436 . . . . 0.0 111.728 -178.785 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 39.7 t -71.17 -36.3 61.94 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.431 0 CA-C-N 116.015 -0.539 . . . . 0.0 111.977 -179.061 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 207' ' ' GLY . . . . . 0.558 ' O ' HG13 ' A' ' 211' ' ' ILE . . . -58.9 -61.5 7.29 Favored Glycine 0 C--N 1.33 0.229 0 C-N-CA 120.624 -0.798 . . . . 0.0 113.816 -178.445 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 208' ' ' PHE . . . . . 0.662 ' HB2' ' HG ' ' A' ' 163' ' ' LEU . 1.0 OUTLIER -72.23 -27.47 62.54 Favored 'General case' 0 C--O 1.223 -0.333 0 CA-C-N 117.473 0.636 . . . . 0.0 111.05 -179.08 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 209' ' ' GLY . . . . . 0.508 ' O ' ' HB2' ' A' ' 212' ' ' ALA . . . -64.07 -34.2 89.3 Favored Glycine 0 N--CA 1.45 -0.369 0 N-CA-C 112.009 -0.436 . . . . 0.0 112.009 178.825 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 210' ' ' PHE . . . . . . . . . . . . . 1.2 m-85 -73.71 -48.71 30.02 Favored 'General case' 0 CA--C 1.514 -0.432 0 N-CA-C 108.21 -1.034 . . . . 0.0 108.21 178.446 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 211' ' ' ILE . . . . . 0.558 HG13 ' O ' ' A' ' 207' ' ' GLY . 5.4 mt -61.66 -28.07 43.39 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.499 0 N-CA-C 107.646 -1.242 . . . . 0.0 107.646 176.815 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 212' ' ' ALA . . . . . 0.508 ' HB2' ' O ' ' A' ' 209' ' ' GLY . . . -63.7 -41.71 98.08 Favored 'General case' 0 N--CA 1.448 -0.565 0 CA-C-N 114.384 -1.28 . . . . 0.0 110.139 179.952 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 213' ' ' LEU . . . . . . . . . . . . . 93.0 mt -70.1 -54.27 13.76 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 115.044 -0.98 . . . . 0.0 111.545 -179.729 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 214' ' ' ASP . . . . . . . . . . . . . 14.6 t70 -52.82 -54.63 31.57 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.189 -0.459 . . . . 0.0 111.605 -179.504 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 215' ' ' ALA . . . . . . . . . . . . . . . -57.53 -57.2 13.74 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.046 -0.524 . . . . 0.0 111.781 -179.476 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 216' ' ' ALA . . . . . . . . . . . . . . . -55.1 -37.38 66.77 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.375 -0.375 . . . . 0.0 111.494 -179.636 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 217' ' ' ALA . . . . . . . . . . . . . . . -62.41 -32.89 73.8 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.382 179.799 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 218' ' ' THR . . . . . . . . . . . . . 94.4 m . . . . . 0 C--N 1.331 -0.237 0 CA-C-N 115.806 -0.633 . . . . 0.0 110.74 179.567 . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.307 0 N-CA-C 112.354 -0.299 . . . . 0.0 112.354 . . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 67.8 tp -74.22 -35.41 63.88 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 120.778 0.323 . . . . 0.0 110.796 179.723 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 69.9 p -69.62 -32.85 71.8 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.72 -179.697 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 29.0 p -54.93 -35.56 64.33 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.35 -0.386 . . . . 0.0 111.381 -179.644 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 7' ' ' LEU . . . . . . . . . . . . . 9.3 mp -59.24 -53.36 59.18 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.098 -0.501 . . . . 0.0 111.557 -179.813 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 8' ' ' PHE . . . . . 0.46 ' HB2' ' HB2' ' A' ' 55' ' ' ALA . 63.4 m-85 -59.95 -34.93 73.92 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.317 -0.402 . . . . 0.0 110.997 -179.73 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 9' ' ' TRP . . . . . . . . . . . . . 28.8 m95 -64.36 -47.61 78.62 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 116.058 -0.519 . . . . 0.0 110.357 -179.902 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 13.1 mt -58.32 -42.76 87.45 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 115.929 -0.578 . . . . 0.0 110.304 179.204 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -61.62 -34.58 89.03 Favored Glycine 0 N--CA 1.448 -0.545 0 C-N-CA 120.588 -0.815 . . . . 0.0 111.544 178.971 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -66.22 -33.15 75.1 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 120.616 0.246 . . . . 0.0 110.608 179.701 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 1.5 mt -63.21 -49.29 83.76 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.259 0 N-CA-C 109.347 -0.612 . . . . 0.0 109.347 178.987 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . 0.497 ' HA3' HD23 ' A' ' 202' ' ' LEU . . . -61.7 -24.82 64.76 Favored Glycine 0 N--CA 1.447 -0.584 0 C-N-CA 120.638 -0.791 . . . . 0.0 111.47 178.908 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 15' ' ' MET . . . . . 0.569 ' HB3' ' HB2' ' A' ' 48' ' ' ALA . 0.0 OUTLIER -77.3 -47.93 18.76 Favored 'General case' 0 C--N 1.331 -0.227 0 N-CA-C 111.763 0.283 . . . . 0.0 111.763 179.841 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 4.6 mm? -63.78 -39.22 93.72 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.778 0.323 . . . . 0.0 110.965 -179.958 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 17' ' ' VAL . . . . . 0.43 HG11 ' N ' ' A' ' 18' ' ' GLY . 8.5 p -68.09 -44.26 84.68 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.375 0 CA-C-O 121.388 0.613 . . . . 0.0 110.471 179.7 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . 0.43 ' N ' HG11 ' A' ' 17' ' ' VAL . . . -64.87 -49.79 61.47 Favored Glycine 0 C--N 1.319 -0.38 0 CA-C-N 114.928 -1.033 . . . . 0.0 111.349 179.135 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 19' ' ' THR . . . . . 0.474 HG23 HG11 ' A' ' 41' ' ' VAL . 94.2 m -54.11 -42.6 69.62 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-O 120.858 0.361 . . . . 0.0 111.008 179.828 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 67.6 mt -71.83 -42.96 66.36 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.061 -0.518 . . . . 0.0 111.264 179.947 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -59.02 -43.96 91.66 Favored 'General case' 0 C--N 1.329 -0.292 0 N-CA-C 111.805 0.298 . . . . 0.0 111.805 -179.797 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 22' ' ' PHE . . . . . 0.528 ' HB2' HG21 ' A' ' 41' ' ' VAL . 10.6 m-85 -75.53 -42.26 52.93 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.46 -0.337 . . . . 0.0 111.431 -179.291 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -61.79 -50.25 73.11 Favored 'General case' 0 C--N 1.33 -0.283 0 CA-C-O 120.814 0.34 . . . . 0.0 111.023 -179.845 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 24' ' ' TRP . . . . . . . . . . . . . 1.0 OUTLIER -57.92 -35.77 71.54 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.711 179.75 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.328 -0.346 0 CA-C-O 120.955 0.407 . . . . 0.0 110.627 179.56 . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.298 0 N-CA-C 112.192 -0.363 . . . . 0.0 112.192 . . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 26.7 mt-10 -91.32 -20.84 21.43 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.7 0.286 . . . . 0.0 110.764 179.999 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 34' ' ' ARG . . . . . . . . . . . . . 15.8 ptp180 -51.51 -31.25 23.17 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 116.106 -0.497 . . . . 0.0 111.48 -179.652 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 89.9 mtm180 -73.51 -52.9 11.96 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.503 -0.317 . . . . 0.0 111.502 -179.7 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 73.6 m-85 -61.74 -30.53 70.83 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.247 -0.433 . . . . 0.0 111.702 -179.483 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 37' ' ' TYR . . . . . . . . . . . . . 26.1 m-85 -76.19 -55.27 5.73 Favored 'General case' 0 C--N 1.329 -0.307 0 N-CA-C 111.799 0.296 . . . . 0.0 111.799 -179.129 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 83.8 t -56.89 -36.27 49.47 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-O 120.939 0.4 . . . . 0.0 110.59 179.91 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 54.9 m -64.08 -52.11 60.85 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 115.991 -0.549 . . . . 0.0 111.116 179.718 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 40' ' ' LEU . . . . . 0.437 HD12 ' HE1' ' A' ' 208' ' ' PHE . 7.8 tp -63.3 -50.74 68.88 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.722 -179.81 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . 0.528 HG21 ' HB2' ' A' ' 22' ' ' PHE . 96.9 t -55.27 -34.84 34.38 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.356 0 CA-C-N 116.132 -0.485 . . . . 0.0 109.962 178.887 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -62.52 -37.25 94.4 Favored Glycine 0 N--CA 1.448 -0.558 0 C-N-CA 120.821 -0.704 . . . . 0.0 111.616 179.069 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 43' ' ' ILE . . . . . 0.523 HD13 HD12 ' A' ' 83' ' ' ILE . 3.8 mt -62.54 -57.95 9.77 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.158 0 CA-C-O 120.824 0.345 . . . . 0.0 110.732 179.505 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 24.6 t -59.92 -24.79 64.63 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-N 116.293 -0.412 . . . . 0.0 110.983 -179.904 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -71.99 -57.25 5.88 Favored Glycine 0 N--CA 1.452 -0.242 0 C-N-CA 120.805 -0.712 . . . . 0.0 112.427 179.825 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 15.5 pt -59.74 -37.47 71.37 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.229 0 CA-C-O 120.823 0.344 . . . . 0.0 111.007 179.888 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 47' ' ' ALA . . . . . 0.555 ' HB3' ' HE2' ' A' ' 205' ' ' LYS . . . -67.76 -39.33 84.15 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 116.316 -0.402 . . . . 0.0 111.027 179.313 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 48' ' ' ALA . . . . . 0.569 ' HB2' ' HB3' ' A' ' 15' ' ' MET . . . -57.07 -47.2 81.57 Favored 'General case' 0 C--O 1.232 0.177 0 CA-C-N 116.076 -0.511 . . . . 0.0 111.617 -179.658 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 49' ' ' VAL . . . . . 0.469 ' O ' HG13 ' A' ' 53' ' ' VAL . 29.9 m -70.66 -33.64 53.79 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-N 116.11 -0.496 . . . . 0.0 111.414 -179.359 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -62.96 -44.43 96.08 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.932 0.396 . . . . 0.0 111.286 -179.571 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 51' ' ' TYR . . . . . 0.528 ' HH ' ' HB2' ' A' ' 201' ' ' ASP . 33.3 m-85 -73.87 -36.22 64.82 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 115.829 -0.623 . . . . 0.0 110.942 -179.419 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -62.74 -45.8 91.01 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 115.841 -0.618 . . . . 0.0 111.157 -179.992 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 53' ' ' VAL . . . . . 0.554 ' HB ' HG12 ' A' ' 58' ' ' VAL . 19.7 m -73.32 -43.51 56.53 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.147 -0.478 . . . . 0.0 111.036 -179.802 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 54' ' ' MET . . . . . 0.443 ' HG3' ' HE1' ' A' ' 60' ' ' TRP . 11.4 ttp -64.94 -29.65 70.6 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.284 179.89 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 55' ' ' ALA . . . . . 0.46 ' HB2' ' HB2' ' A' ' 8' ' ' PHE . . . -65.47 -37.32 86.51 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 115.885 -0.598 . . . . 0.0 111.014 179.254 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 87.2 mt -70.85 -11.47 60.98 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.082 -0.508 . . . . 0.0 111.215 -179.781 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 104.68 17.4 14.95 Favored Glycine 0 CA--C 1.518 0.227 0 C-N-CA 120.742 -0.742 . . . . 0.0 113.296 179.487 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 58' ' ' VAL . . . . . 0.554 HG12 ' HB ' ' A' ' 53' ' ' VAL . 0.4 OUTLIER -89.46 159.36 2.89 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.231 0 CA-C-N 116.913 0.356 . . . . 0.0 110.577 179.729 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 72.44 -12.52 3.38 Favored Glycine 0 N--CA 1.45 -0.412 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.387 -179.456 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 60' ' ' TRP . . . . . 0.443 ' HE1' ' HG3' ' A' ' 54' ' ' MET . 35.1 m0 -69.79 106.68 3.2 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-O 120.663 0.268 . . . . 0.0 110.883 -179.935 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 7.5 p -116.03 128.54 25.9 Favored Pre-proline 0 CA--C 1.533 0.312 0 CA-C-N 116.406 -0.361 . . . . 0.0 111.155 179.821 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 74.0 Cg_endo -75.72 148.48 32.62 Favored 'Trans proline' 0 C--N 1.35 0.646 0 C-N-CA 122.533 2.155 . . . . 0.0 112.441 179.923 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 96.6 t -137.76 91.53 0.79 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.005 -0.543 . . . . 0.0 111.036 -179.878 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . 59.11 -88.53 0.02 OUTLIER 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 116.03 -0.532 . . . . 0.0 111.438 179.961 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 65' ' ' GLU . . . . . 0.502 ' HB2' HH11 ' A' ' 66' ' ' ARG . 11.1 mm-40 -120.54 -18.51 7.79 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-O 120.907 0.384 . . . . 0.0 110.735 179.984 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 66' ' ' ARG . . . . . 0.502 HH11 ' HB2' ' A' ' 65' ' ' GLU . 10.5 mpt_? -102.78 162.62 12.78 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 115.938 -0.574 . . . . 0.0 110.439 179.916 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 31.6 m -123.37 139.9 53.56 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.964 0.411 . . . . 0.0 111.52 -179.654 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 18.0 m -130.3 146.12 34.56 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.375 0 CA-C-N 115.932 -0.576 . . . . 0.0 110.685 179.711 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 69' ' ' PHE . . . . . . . . . . . . . 9.9 m-85 -109.1 118.03 35.71 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-O 121.048 0.452 . . . . 0.0 110.224 -179.473 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 70' ' ' VAL . . . . . 0.605 HG11 ' HD3' ' A' ' 71' ' ' PRO . 0.5 OUTLIER -67.0 -34.44 7.33 Favored Pre-proline 0 CA--C 1.541 0.6 0 N-CA-C 112.883 0.697 . . . . 0.0 112.883 -179.295 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 71' ' ' PRO . . . . . 0.605 ' HD3' HG11 ' A' ' 70' ' ' VAL . 12.2 Cg_exo -69.63 -17.75 38.01 Favored 'Trans proline' 0 C--N 1.359 1.079 0 C-N-CA 122.259 1.973 . . . . 0.0 113.059 -179.165 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 45.3 ttp180 -74.76 -55.42 5.86 Favored 'General case' 0 C--N 1.33 -0.271 0 N-CA-C 112.276 0.473 . . . . 0.0 112.276 -178.514 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 73' ' ' TYR . . . . . 0.458 ' O ' HG13 ' A' ' 77' ' ' ILE . 24.9 m-85 -71.31 -33.55 69.79 Favored 'General case' 0 C--N 1.329 -0.325 0 C-N-CA 120.764 -0.374 . . . . 0.0 110.669 -179.418 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 0.3 OUTLIER -68.95 -39.73 80.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 N-CA-C 110.072 -0.344 . . . . 0.0 110.072 179.256 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 15.4 t70 -59.98 -37.3 79.23 Favored 'General case' 0 CA--C 1.52 -0.197 0 N-CA-C 109.423 -0.584 . . . . 0.0 109.423 179.023 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 76' ' ' TRP . . . . . 0.503 ' HB3' ' SD ' ' A' ' 109' ' ' MET . 49.2 m0 -65.29 -35.49 81.17 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 115.652 -0.703 . . . . 0.0 110.427 179.521 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 77' ' ' ILE . . . . . 0.466 ' O ' ' HG2' ' A' ' 81' ' ' PRO . 78.5 mt -68.12 -30.66 48.73 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.374 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.964 179.773 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 35.2 mt -91.81 -19.55 22.43 Favored 'General case' 0 C--N 1.327 -0.371 0 N-CA-C 112.23 0.456 . . . . 0.0 112.23 -179.76 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 79' ' ' THR . . . . . 0.482 ' HB ' ' HE3' ' A' ' 205' ' ' LYS . 79.3 p -102.35 -47.6 4.44 Favored 'General case' 0 N--CA 1.464 0.238 0 N-CA-C 113.458 0.91 . . . . 0.0 113.458 -177.932 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 80' ' ' THR . . . . . 0.635 ' HB ' ' HD3' ' A' ' 81' ' ' PRO . 80.3 m -51.28 -53.4 49.53 Favored Pre-proline 0 C--N 1.329 -0.297 0 N-CA-C 112.047 0.388 . . . . 0.0 112.047 -179.019 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 81' ' ' PRO . . . . . 0.635 ' HD3' ' HB ' ' A' ' 80' ' ' THR . 50.4 Cg_exo -55.83 -22.03 35.63 Favored 'Trans proline' 0 C--N 1.351 0.691 0 C-N-CA 121.612 1.542 . . . . 0.0 111.704 179.723 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 82' ' ' LEU . . . . . 0.477 ' HB2' ' O ' ' A' ' 79' ' ' THR . 2.8 mm? -76.77 -37.1 56.49 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 115.877 -0.601 . . . . 0.0 110.745 179.807 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 83' ' ' ILE . . . . . 0.523 HD12 HD13 ' A' ' 43' ' ' ILE . 11.9 mm -65.22 -53.76 36.78 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-O 120.857 0.36 . . . . 0.0 110.469 179.67 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 21.9 m -62.63 -31.27 51.5 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.176 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.251 179.335 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 85' ' ' TYR . . . . . . . . . . . . . 82.9 t80 -67.28 -32.44 73.44 Favored 'General case' 0 C--N 1.333 -0.135 0 CA-C-N 115.999 -0.546 . . . . 0.0 110.223 179.158 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 86' ' ' PHE . . . . . . . . . . . . . 9.2 t80 -64.72 -51.96 59.6 Favored 'General case' 0 C--N 1.331 -0.196 0 CA-C-N 116.118 -0.492 . . . . 0.0 109.839 179.37 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 9.2 mp -62.95 -30.45 71.58 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 115.806 -0.634 . . . . 0.0 110.098 179.477 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -69.25 -27.31 73.83 Favored Glycine 0 N--CA 1.448 -0.523 0 C-N-CA 120.914 -0.66 . . . . 0.0 111.546 178.943 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 58.0 mt -72.05 -46.16 58.04 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 120.974 0.416 . . . . 0.0 110.4 179.701 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 98.0 mt -59.27 -37.55 77.93 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 115.844 -0.616 . . . . 0.0 111.074 179.824 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -79.86 -32.75 40.46 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.231 -0.441 . . . . 0.0 111.4 -179.877 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 78.81 51.77 5.31 Favored Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.701 -0.761 . . . . 0.0 111.937 -179.737 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 93' ' ' LEU . . . . . 0.482 HD11 ' HE1' ' A' ' 145' ' ' MET . 35.2 mt -62.21 167.16 4.24 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.892 0.377 . . . . 0.0 111.103 -179.632 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 94' ' ' ASP . . . . . . . . . . . . . 28.6 t70 -85.47 168.96 14.07 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.618 179.839 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 75.0 m -54.34 -41.52 69.16 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.45 -0.341 . . . . 0.0 110.975 -179.989 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 34.0 ttm180 -73.89 -44.1 56.36 Favored 'General case' 0 C--N 1.331 -0.197 0 CA-C-N 116.398 -0.364 . . . . 0.0 110.94 179.732 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 97' ' ' GLU . . . . . 0.534 ' HA ' HD13 ' A' ' 100' ' ' ILE . 43.7 mt-10 -53.42 -47.08 69.92 Favored 'General case' 0 C--N 1.331 -0.197 0 CA-C-N 116.128 -0.487 . . . . 0.0 111.435 -179.484 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 98' ' ' PHE . . . . . . . . . . . . . 16.9 m-85 -58.03 -49.6 76.3 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-O 120.773 0.321 . . . . 0.0 110.7 179.64 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -58.28 -26.12 58.51 Favored Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.879 -0.677 . . . . 0.0 112.644 -179.95 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 100' ' ' ILE . . . . . 0.534 HD13 ' HA ' ' A' ' 97' ' ' GLU . 94.4 mt -71.56 -52.24 27.4 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-O 120.815 0.34 . . . . 0.0 111.638 -179.71 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 43.4 t -68.21 -37.77 78.58 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.38 0 CA-C-N 116.401 -0.363 . . . . 0.0 111.669 -179.378 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 102' ' ' ILE . . . . . . . . . . . . . 49.0 mm -68.22 -47.72 76.89 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.391 -0.368 . . . . 0.0 111.48 -179.628 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 11.1 t -62.03 -31.1 71.46 Favored 'General case' 0 C--N 1.332 -0.174 0 CA-C-O 120.804 0.335 . . . . 0.0 110.723 -179.935 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 53.3 tp -64.38 -52.98 55.53 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.701 179.556 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 105' ' ' ASN . . . . . 0.611 ' N ' HD21 ' A' ' 105' ' ' ASN . 0.8 OUTLIER -61.51 -26.19 67.76 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.079 -0.51 . . . . 0.0 110.946 179.929 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 40.3 m -65.65 -54.96 20.4 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 115.995 -0.548 . . . . 0.0 111.419 -179.66 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 11.3 p -64.7 -36.41 77.45 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.232 0 CA-C-N 116.366 -0.379 . . . . 0.0 111.215 -179.724 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 70.1 t -63.46 -49.21 83.63 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.244 0 CA-C-N 116.36 -0.382 . . . . 0.0 110.839 179.67 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 109' ' ' MET . . . . . 0.503 ' SD ' ' HB3' ' A' ' 76' ' ' TRP . 7.7 tpp -63.21 -37.41 87.13 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.749 -179.978 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 22.9 tp -65.9 -30.27 70.84 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-N 115.987 -0.552 . . . . 0.0 110.259 179.782 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -65.03 -54.77 25.12 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-N 115.939 -0.573 . . . . 0.0 110.391 179.354 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . -57.82 -39.67 91.83 Favored Glycine 0 C--N 1.333 0.382 0 C-N-CA 120.576 -0.821 . . . . 0.0 111.701 179.395 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 113' ' ' PHE . . . . . . . . . . . . . 1.3 t80 -51.33 -66.03 0.45 Allowed 'General case' 0 C--N 1.332 -0.181 0 CA-C-O 121.059 0.456 . . . . 0.0 109.934 179.255 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -59.84 -29.31 68.19 Favored 'General case' 0 C--N 1.327 -0.413 0 CA-C-N 115.501 -0.772 . . . . 0.0 111.471 179.809 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -52.4 -49.62 50.79 Favored Glycine 0 C--N 1.333 0.377 0 C-N-CA 120.901 -0.666 . . . . 0.0 112.452 179.85 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -77.88 -14.71 59.47 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-O 120.8 0.333 . . . . 0.0 111.168 179.692 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 117' ' ' MET . . . . . . . . . . . . . 24.3 mmt -93.7 15.16 17.02 Favored 'General case' 0 N--CA 1.463 0.185 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.732 -179.391 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 23.3 m -82.13 144.61 51.08 Favored Pre-proline 0 C--N 1.33 -0.267 0 CA-C-O 120.568 0.223 . . . . 0.0 111.565 -179.616 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 119' ' ' PRO . . . . . . . . . . . . . 84.9 Cg_endo -91.18 -9.0 3.15 Favored 'Trans proline' 0 N--CA 1.456 -0.684 0 C-N-CA 122.758 2.305 . . . . 0.0 112.348 179.471 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -132.5 -117.09 1.81 Allowed Glycine 0 C--N 1.332 0.312 0 C-N-CA 120.748 -0.739 . . . . 0.0 113.071 -179.649 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 41.7 pt -116.13 13.72 7.74 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.151 0 CA-C-O 120.723 0.297 . . . . 0.0 111.5 -179.552 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 44.1 mt-10 -62.59 -18.46 62.19 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 116.284 -0.416 . . . . 0.0 111.349 -179.737 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 123' ' ' ARG . . . . . . . . . . . . . 20.4 ptt180 -50.43 -39.44 47.48 Favored 'General case' 0 C--N 1.332 -0.166 0 CA-C-N 116.28 -0.418 . . . . 0.0 111.7 -179.66 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 124' ' ' TYR . . . . . . . . . . . . . 59.5 m-85 -65.87 -32.38 73.86 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-O 120.748 0.308 . . . . 0.0 110.997 -179.851 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 125' ' ' ALA . . . . . . . . . . . . . . . -70.05 -47.64 61.19 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.308 -0.406 . . . . 0.0 111.179 -179.913 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 2.6 mm? -54.16 -55.6 26.24 Favored 'General case' 0 C--O 1.233 0.209 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.904 179.924 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 127' ' ' PHE . . . . . . . . . . . . . 10.0 t80 -63.73 -36.77 84.95 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.305 -0.407 . . . . 0.0 111.033 -179.553 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 128' ' ' GLY . . . . . . . . . . . . . . . -46.81 -47.24 19.03 Favored Glycine 0 C--N 1.332 0.321 0 C-N-CA 120.019 -1.086 . . . . 0.0 111.033 179.182 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 129' ' ' MET . . . . . 0.4 ' HE2' ' N ' ' A' ' 130' ' ' GLY . 0.6 OUTLIER -66.96 -40.04 87.4 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 120.978 0.418 . . . . 0.0 109.994 178.788 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 130' ' ' GLY . . . . . 0.4 ' N ' ' HE2' ' A' ' 129' ' ' MET . . . -67.62 -22.9 73.7 Favored Glycine 0 N--CA 1.45 -0.379 0 CA-C-N 115.721 -0.672 . . . . 0.0 112.809 -179.997 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 131' ' ' ALA . . . . . 0.412 ' O ' ' HB3' ' A' ' 134' ' ' PHE . . . -74.63 -53.77 8.71 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.78 0.324 . . . . 0.0 110.423 -179.991 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 16.1 t -60.2 -40.39 83.44 Favored 'Isoleucine or valine' 0 C--O 1.236 0.36 0 N-CA-C 109.085 -0.709 . . . . 0.0 109.085 178.629 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -67.0 -34.55 77.99 Favored 'General case' 0 N--CA 1.451 -0.41 0 CA-C-N 115.125 -0.943 . . . . 0.0 110.302 179.054 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 134' ' ' PHE . . . . . 0.469 ' CZ ' ' HA ' ' A' ' 172' ' ' ALA . 19.4 t80 -56.47 -52.67 63.83 Favored 'General case' 0 N--CA 1.452 -0.352 0 CA-C-N 115.939 -0.573 . . . . 0.0 109.88 179.366 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 135' ' ' ILE . . . . . 0.493 ' O ' HG23 ' A' ' 138' ' ' VAL . 57.6 mt -57.06 -34.13 44.28 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.299 0 CA-C-N 115.742 -0.663 . . . . 0.0 109.857 179.189 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 136' ' ' GLY . . . . . 0.405 ' O ' ' HB3' ' A' ' 139' ' ' TYR . . . -59.99 -34.72 84.58 Favored Glycine 0 N--CA 1.448 -0.538 0 C-N-CA 120.08 -1.057 . . . . 0.0 110.843 178.418 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 137' ' ' LEU . . . . . 0.497 HD12 HD22 ' A' ' 105' ' ' ASN . 38.6 tp -71.11 -52.14 21.05 Favored 'General case' 0 N--CA 1.455 -0.223 0 CA-C-N 115.643 -0.278 . . . . 0.0 110.554 179.399 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 138' ' ' VAL . . . . . 0.493 HG23 ' O ' ' A' ' 135' ' ' ILE . 3.1 m -55.69 -33.92 34.83 Favored 'Isoleucine or valine' 0 C--O 1.233 0.211 0 N-CA-C 109.201 -0.666 . . . . 0.0 109.201 179.063 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 139' ' ' TYR . . . . . 0.405 ' HB3' ' O ' ' A' ' 136' ' ' GLY . 32.0 t80 -57.12 -45.93 83.07 Favored 'General case' 0 C--N 1.331 -0.22 0 N-CA-C 108.848 -0.797 . . . . 0.0 108.848 177.657 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 140' ' ' TYR . . . . . 0.512 ' HB3' ' SD ' ' A' ' 145' ' ' MET . 24.1 m-85 -64.53 -36.54 84.55 Favored 'General case' 0 C--N 1.331 -0.197 0 CA-C-N 115.675 -0.693 . . . . 0.0 109.99 178.422 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 141' ' ' LEU . . . . . 0.403 ' HB2' ' HA ' ' A' ' 138' ' ' VAL . 0.4 OUTLIER -54.06 -33.61 57.88 Favored 'General case' 0 C--N 1.333 -0.144 0 CA-C-N 115.874 -0.603 . . . . 0.0 110.39 179.142 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 142' ' ' VAL . . . . . 0.561 HG23 HH12 ' A' ' 164' ' ' ARG . 2.6 t -111.09 2.28 8.91 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 115.858 -0.61 . . . . 0.0 110.703 179.642 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . -74.26 -153.05 2.92 Favored Glycine 0 CA--C 1.519 0.338 0 C-N-CA 121.042 -0.599 . . . . 0.0 113.146 -179.415 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 144' ' ' PRO . . . . . . . . . . . . . 31.2 Cg_exo -59.06 -23.6 69.56 Favored 'Trans proline' 0 C--N 1.349 0.588 0 C-N-CA 122.844 2.363 . . . . 0.0 112.768 -179.697 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 145' ' ' MET . . . . . 0.512 ' SD ' ' HB3' ' A' ' 140' ' ' TYR . 80.9 mtp -57.57 -32.81 67.5 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-O 120.89 0.376 . . . . 0.0 111.088 -179.731 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 146' ' ' THR . . . . . . . . . . . . . 36.0 m -75.35 -50.04 17.18 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.087 -0.506 . . . . 0.0 111.452 -179.733 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 43.5 mt-10 -65.68 -29.44 69.99 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.319 -0.401 . . . . 0.0 111.477 -179.615 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 148' ' ' SER . . . . . . . . . . . . . 80.1 p -70.36 -50.04 43.0 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.365 -0.38 . . . . 0.0 110.795 -179.515 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 149' ' ' ALA . . . . . . . . . . . . . . . -69.46 -32.7 71.79 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.4 -179.982 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 150' ' ' SER . . . . . 0.51 ' HA ' ' HB3' ' A' ' 157' ' ' LYS . 90.8 p -68.56 -15.98 63.71 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.361 -179.529 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 151' ' ' GLN . . . . . . . . . . . . . 46.7 mt-30 -113.55 3.55 15.77 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.59 -0.277 . . . . 0.0 111.336 -179.779 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 21.2 tpp180 -75.23 -51.79 12.46 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-O 120.987 0.422 . . . . 0.0 110.536 179.924 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 153' ' ' SER . . . . . 0.625 ' HB3' HG12 ' A' ' 156' ' ' ILE . 8.7 t -157.77 172.48 18.41 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 115.794 -0.639 . . . . 0.0 110.306 179.025 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 154' ' ' SER . . . . . . . . . . . . . 48.7 m -70.01 -40.97 74.91 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.872 0.367 . . . . 0.0 110.846 179.794 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -77.44 -34.48 40.15 Favored Glycine 0 N--CA 1.45 -0.389 0 C-N-CA 120.89 -0.671 . . . . 0.0 113.03 -179.962 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 156' ' ' ILE . . . . . 0.625 HG12 ' HB3' ' A' ' 153' ' ' SER . 39.5 mm -54.93 -46.42 76.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 N-CA-C 112.147 0.425 . . . . 0.0 112.147 -179.237 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 157' ' ' LYS . . . . . 0.51 ' HB3' ' HA ' ' A' ' 150' ' ' SER . 21.7 pttp -60.62 -39.73 89.28 Favored 'General case' 0 C--N 1.328 -0.34 0 N-CA-C 111.727 0.269 . . . . 0.0 111.727 -179.133 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 59.4 m -65.76 -48.18 72.73 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-O 120.724 0.297 . . . . 0.0 111.76 -179.387 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 159' ' ' LEU . . . . . 0.637 HD11 ' HB3' ' A' ' 215' ' ' ALA . 45.9 tp -68.08 -31.24 70.73 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.382 -0.372 . . . . 0.0 111.197 -179.714 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 160' ' ' TYR . . . . . . . . . . . . . 45.1 t80 -74.15 -47.05 38.45 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.186 -0.461 . . . . 0.0 112.028 -178.988 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 161' ' ' VAL . . . . . 0.407 HG23 ' O ' ' A' ' 157' ' ' LYS . 23.7 m -61.51 -47.34 93.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 N-CA-C 112.149 0.426 . . . . 0.0 112.149 -178.841 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 162' ' ' ARG . . . . . . . . . . . . . 27.1 tpt180 -63.24 -49.2 75.08 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.791 0.329 . . . . 0.0 111.423 -179.369 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 163' ' ' LEU . . . . . . . . . . . . . 6.9 mp -64.73 -53.61 44.53 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.922 -179.266 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 164' ' ' ARG . . . . . 0.561 HH12 HG23 ' A' ' 142' ' ' VAL . 0.9 OUTLIER -59.37 -41.32 89.05 Favored 'General case' 0 CA--C 1.53 0.199 0 CA-C-N 116.373 -0.376 . . . . 0.0 111.99 -178.554 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 165' ' ' ASN . . . . . 0.411 ' N ' ' HG3' ' A' ' 164' ' ' ARG . 0.9 OUTLIER -57.25 -51.84 67.74 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-O 120.887 0.375 . . . . 0.0 110.744 179.921 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 166' ' ' LEU . . . . . 0.481 ' O ' ' HG ' ' A' ' 170' ' ' LEU . 3.9 tt -64.25 -43.15 95.76 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-N 115.954 -0.566 . . . . 0.0 111.639 -179.377 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 167' ' ' THR . . . . . 0.479 ' HA ' HD12 ' A' ' 170' ' ' LEU . 49.2 m -56.03 -53.74 53.35 Favored 'General case' 0 C--N 1.329 -0.296 0 N-CA-C 112.629 0.603 . . . . 0.0 112.629 -178.576 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 168' ' ' VAL . . . . . . . . . . . . . 9.7 p -61.99 -39.57 84.15 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 N-CA-C 111.956 0.354 . . . . 0.0 111.956 -179.455 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 169' ' ' VAL . . . . . 0.407 HG21 ' O ' ' A' ' 165' ' ' ASN . 46.8 t -55.78 -65.27 0.39 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 N-CA-C 112.558 0.577 . . . . 0.0 112.558 -179.174 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 170' ' ' LEU . . . . . 0.481 ' HG ' ' O ' ' A' ' 166' ' ' LEU . 0.3 OUTLIER -66.71 -24.45 66.25 Favored 'General case' 0 N--CA 1.464 0.229 0 N-CA-C 111.855 0.317 . . . . 0.0 111.855 -178.745 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 171' ' ' TRP . . . . . 0.446 ' HZ3' HD21 ' A' ' 137' ' ' LEU . 9.8 m0 -73.49 -29.27 62.4 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.999 0.428 . . . . 0.0 109.847 179.245 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 172' ' ' ALA . . . . . 0.469 ' HA ' ' CZ ' ' A' ' 134' ' ' PHE . . . -74.7 -8.5 56.58 Favored 'General case' 0 N--CA 1.451 -0.382 0 CA-C-N 115.827 -0.624 . . . . 0.0 110.065 179.232 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 173' ' ' ILE . . . . . 0.62 HG22 HD12 ' A' ' 177' ' ' ILE . 44.5 mm -89.06 -22.8 6.45 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.256 0 CA-C-N 115.516 -0.765 . . . . 0.0 110.405 178.936 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 174' ' ' TYR . . . . . 0.601 ' N ' ' HD2' ' A' ' 175' ' ' PRO . 12.1 m-85 -54.87 -50.26 87.13 Favored Pre-proline 0 N--CA 1.463 0.199 0 CA-C-N 116.047 -0.524 . . . . 0.0 111.831 -179.893 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 175' ' ' PRO . . . . . 0.601 ' HD2' ' N ' ' A' ' 174' ' ' TYR . 2.0 Cg_endo -45.56 -29.31 4.98 Favored 'Trans proline' 0 C--N 1.353 0.791 0 C-N-CA 122.359 2.039 . . . . 0.0 111.768 179.275 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 176' ' ' PHE . . . . . 0.429 ' O ' ' HG ' ' A' ' 180' ' ' LEU . 99.6 m-85 -79.98 -45.7 17.98 Favored 'General case' 0 CA--C 1.516 -0.335 0 CA-C-N 115.921 -0.582 . . . . 0.0 111.078 179.396 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 177' ' ' ILE . . . . . 0.62 HD12 HG22 ' A' ' 173' ' ' ILE . 3.1 mm -58.09 -44.75 87.95 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.613 0 CA-C-N 115.787 -0.642 . . . . 0.0 112.093 -178.491 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 178' ' ' TRP . . . . . 0.41 ' HA ' ' HG2' ' A' ' 182' ' ' PRO . 72.0 t90 -69.04 -38.55 79.2 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-O 121.088 0.471 . . . . 0.0 110.64 179.951 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 179' ' ' LEU . . . . . 0.441 ' O ' HG21 ' A' ' 185' ' ' VAL . 0.4 OUTLIER -66.44 -53.64 33.2 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-N 115.557 -0.747 . . . . 0.0 111.168 -179.273 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 180' ' ' LEU . . . . . 0.513 HD12 HD11 ' A' ' 187' ' ' LEU . 8.3 mt -77.75 -52.03 9.59 Favored 'General case' 0 C--N 1.328 -0.366 0 N-CA-C 112.307 0.484 . . . . 0.0 112.307 -178.674 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 181' ' ' GLY . . . . . 0.405 ' HA3' ' OD1' ' A' ' 193' ' ' ASP . . . -58.34 -85.25 0.04 OUTLIER Glycine 0 C--N 1.336 0.552 0 C-N-CA 120.447 -0.882 . . . . 0.0 112.797 -179.739 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 182' ' ' PRO . . . . . 0.496 ' C ' ' H ' ' A' ' 184' ' ' GLY . 89.2 Cg_exo -46.1 178.55 0.0 OUTLIER 'Trans proline' 0 C--N 1.349 0.599 0 C-N-CA 123.388 2.725 . . . . 0.0 112.954 179.088 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 183' ' ' PRO . . . . . . . . . . . . . 51.5 Cg_exo -56.82 12.25 0.03 OUTLIER 'Trans proline' 0 C--N 1.351 0.667 0 C-N-CA 122.862 2.375 . . . . 0.0 114.696 -179.558 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 184' ' ' GLY . . . . . 0.496 ' H ' ' C ' ' A' ' 182' ' ' PRO . . . -54.17 -65.08 3.72 Favored Glycine 0 C--N 1.335 0.484 0 C-N-CA 119.84 -1.172 . . . . 0.0 111.06 179.149 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 185' ' ' VAL . . . . . 0.441 HG21 ' O ' ' A' ' 179' ' ' LEU . 3.4 m -135.52 -3.27 1.01 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.368 0 N-CA-C 111.574 0.213 . . . . 0.0 111.574 178.813 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 186' ' ' ALA . . . . . . . . . . . . . . . 45.5 76.49 0.09 Allowed 'General case' 0 N--CA 1.463 0.198 0 N-CA-C 112.316 0.487 . . . . 0.0 112.316 179.324 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 187' ' ' LEU . . . . . 0.513 HD11 HD12 ' A' ' 180' ' ' LEU . 4.2 mt -92.49 -49.31 6.19 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.463 -0.335 . . . . 0.0 111.267 179.683 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 188' ' ' LEU . . . . . . . . . . . . . 92.3 mt -115.48 -168.59 1.43 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 121.087 0.47 . . . . 0.0 111.586 -179.502 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 189' ' ' THR . . . . . 0.432 HG22 ' HD2' ' A' ' 190' ' ' PRO . 96.7 m -76.96 135.28 67.36 Favored Pre-proline 0 C--N 1.329 -0.318 0 CA-C-N 115.667 -0.697 . . . . 0.0 111.039 -179.681 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 190' ' ' PRO . . . . . 0.432 ' HD2' HG22 ' A' ' 189' ' ' THR . 10.2 Cg_endo -50.29 -41.7 49.85 Favored 'Trans proline' 0 C--N 1.35 0.609 0 C-N-CA 122.684 2.256 . . . . 0.0 112.185 -179.967 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 191' ' ' THR . . . . . . . . . . . . . 41.5 p -57.2 -46.49 82.82 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.763 179.525 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 192' ' ' VAL . . . . . . . . . . . . . 60.3 t -59.13 -39.75 79.3 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.725 179.584 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 193' ' ' ASP . . . . . 0.405 ' OD1' ' HA3' ' A' ' 181' ' ' GLY . 7.9 t70 -57.72 -41.89 82.72 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 115.932 -0.576 . . . . 0.0 110.646 179.672 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 194' ' ' VAL . . . . . . . . . . . . . 52.5 t -64.71 -36.06 76.53 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 115.984 -0.553 . . . . 0.0 110.918 179.814 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 195' ' ' ALA . . . . . . . . . . . . . . . -59.4 -47.62 84.75 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.451 -0.341 . . . . 0.0 111.017 179.93 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 196' ' ' LEU . . . . . . . . . . . . . 95.9 mt -67.84 -43.13 80.22 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 120.793 0.33 . . . . 0.0 110.525 179.648 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 197' ' ' ILE . . . . . . . . . . . . . 15.5 mm -57.03 -58.89 4.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.012 -0.54 . . . . 0.0 110.296 179.381 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 198' ' ' VAL . . . . . . . . . . . . . 75.2 t -52.74 -34.71 20.25 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.439 0 CA-C-N 115.773 -0.648 . . . . 0.0 109.38 178.429 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 199' ' ' TYR . . . . . . . . . . . . . 46.0 t80 -70.25 -31.44 68.83 Favored 'General case' 0 C--N 1.331 -0.205 0 CA-C-N 115.587 -0.733 . . . . 0.0 110.421 179.678 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 200' ' ' LEU . . . . . . . . . . . . . 54.4 mt -74.07 -38.45 63.92 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 115.756 -0.656 . . . . 0.0 111.365 -179.722 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 201' ' ' ASP . . . . . 0.528 ' HB2' ' HH ' ' A' ' 51' ' ' TYR . 0.9 OUTLIER -71.44 -35.1 70.79 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 121.15 0.5 . . . . 0.0 110.121 179.483 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 202' ' ' LEU . . . . . 0.497 HD23 ' HA3' ' A' ' 14' ' ' GLY . 4.3 mt -67.21 -41.9 85.01 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 115.43 -0.805 . . . . 0.0 111.721 179.596 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 203' ' ' VAL . . . . . 0.446 ' O ' ' HA3' ' A' ' 207' ' ' GLY . 7.4 p -70.19 -36.82 69.42 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-N 116.376 -0.375 . . . . 0.0 111.946 -178.479 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 204' ' ' THR . . . . . . . . . . . . . 95.1 m -68.9 -57.46 5.5 Favored 'General case' 0 C--N 1.328 -0.353 0 C-N-CA 120.308 -0.557 . . . . 0.0 111.252 179.83 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 205' ' ' LYS . . . . . 0.555 ' HE2' ' HB3' ' A' ' 47' ' ' ALA . 41.7 mttp -67.0 -59.35 3.55 Favored 'General case' 0 C--N 1.328 -0.345 0 N-CA-C 112.714 0.635 . . . . 0.0 112.714 -178.311 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 25.5 t -73.87 -37.3 47.87 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.415 0 N-CA-C 112.184 0.438 . . . . 0.0 112.184 -178.29 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 207' ' ' GLY . . . . . 0.446 ' HA3' ' O ' ' A' ' 203' ' ' VAL . . . -66.89 -57.97 8.94 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.361 -0.923 . . . . 0.0 112.434 -179.309 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 208' ' ' PHE . . . . . 0.437 ' HE1' HD12 ' A' ' 40' ' ' LEU . 0.0 OUTLIER -62.6 -29.24 70.46 Favored 'General case' 0 C--N 1.329 -0.316 0 N-CA-C 110.439 -0.208 . . . . 0.0 110.439 -179.957 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 209' ' ' GLY . . . . . 0.486 ' O ' ' HB3' ' A' ' 212' ' ' ALA . . . -70.78 -36.13 66.32 Favored Glycine 0 N--CA 1.447 -0.574 0 N-CA-C 111.137 -0.785 . . . . 0.0 111.137 178.112 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 210' ' ' PHE . . . . . . . . . . . . . 1.0 OUTLIER -70.13 -43.09 71.65 Favored 'General case' 0 CA--C 1.512 -0.519 0 N-CA-C 107.508 -1.293 . . . . 0.0 107.508 178.37 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 211' ' ' ILE . . . . . . . . . . . . . 36.6 mt -67.41 -28.45 42.25 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.728 0 N-CA-C 107.277 -1.379 . . . . 0.0 107.277 176.502 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 212' ' ' ALA . . . . . 0.486 ' HB3' ' O ' ' A' ' 209' ' ' GLY . . . -66.88 -36.42 82.26 Favored 'General case' 0 N--CA 1.448 -0.549 0 CA-C-N 114.516 -1.22 . . . . 0.0 110.141 179.646 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 213' ' ' LEU . . . . . 0.401 ' HG ' ' O ' ' A' ' 209' ' ' GLY . 92.8 mt -70.31 -52.64 21.27 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 115.086 -0.961 . . . . 0.0 111.872 -179.678 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 214' ' ' ASP . . . . . . . . . . . . . 44.7 m-20 -53.21 -50.71 64.14 Favored 'General case' 0 C--N 1.331 -0.204 0 CA-C-N 116.292 -0.413 . . . . 0.0 111.837 -178.974 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 215' ' ' ALA . . . . . 0.637 ' HB3' HD11 ' A' ' 159' ' ' LEU . . . -65.48 -57.63 7.79 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.558 -0.292 . . . . 0.0 111.726 -179.243 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 216' ' ' ALA . . . . . . . . . . . . . . . -52.12 -43.38 63.94 Favored 'General case' 0 C--N 1.332 -0.184 0 CA-C-O 120.799 0.333 . . . . 0.0 111.497 -179.488 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 217' ' ' ALA . . . . . . . . . . . . . . . -59.05 -42.11 89.49 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.098 179.69 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 218' ' ' THR . . . . . . . . . . . . . 78.4 m . . . . . 0 C--N 1.331 -0.214 0 CA-C-N 115.584 -0.734 . . . . 0.0 110.983 179.715 . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.277 0 N-CA-C 112.692 -0.163 . . . . 0.0 112.692 . . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 56.2 tp -73.96 -35.82 64.56 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.817 0.341 . . . . 0.0 111.121 -179.913 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 60.7 p -68.08 -31.69 71.5 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.501 -179.59 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 21.3 p -52.31 -35.32 50.24 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.257 -0.429 . . . . 0.0 111.384 -179.772 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 7' ' ' LEU . . . . . . . . . . . . . 4.1 mm? -57.87 -53.75 54.74 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.26 -0.427 . . . . 0.0 111.364 -179.731 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 8' ' ' PHE . . . . . 0.536 ' HB2' ' HB3' ' A' ' 55' ' ' ALA . 63.4 m-85 -62.32 -33.29 74.39 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.31 -0.405 . . . . 0.0 110.763 -179.81 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 9' ' ' TRP . . . . . 0.457 ' O ' HG13 ' A' ' 13' ' ' ILE . 55.1 m95 -65.97 -40.83 91.59 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 116.029 -0.532 . . . . 0.0 110.101 -179.988 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 63.9 mt -66.48 -39.61 88.88 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 115.854 -0.612 . . . . 0.0 110.136 179.387 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -68.32 -28.8 73.11 Favored Glycine 0 N--CA 1.446 -0.665 0 C-N-CA 120.804 -0.712 . . . . 0.0 111.796 179.357 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -71.99 -33.87 68.46 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 120.786 0.327 . . . . 0.0 110.578 179.52 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 13' ' ' ILE . . . . . 0.457 HG13 ' O ' ' A' ' 9' ' ' TRP . 75.0 mt -64.95 -54.08 33.95 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.173 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.248 179.172 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -61.17 -39.05 96.61 Favored Glycine 0 N--CA 1.45 -0.42 0 C-N-CA 120.5 -0.857 . . . . 0.0 111.55 179.4 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 15' ' ' MET . . . . . 0.524 ' HE2' ' HD2' ' A' ' 205' ' ' LYS . 60.3 tpp -61.56 -41.44 97.37 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 120.868 0.366 . . . . 0.0 110.014 179.366 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 6.3 tt -57.53 -38.88 75.43 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 115.888 -0.596 . . . . 0.0 109.911 179.334 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 34.6 t -59.38 -46.65 92.44 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.221 0 CA-C-N 115.946 -0.57 . . . . 0.0 110.162 179.19 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -62.91 -41.96 99.77 Favored Glycine 0 N--CA 1.45 -0.375 0 C-N-CA 120.616 -0.802 . . . . 0.0 111.66 178.981 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 9.7 m -50.3 -49.19 54.36 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.698 0.285 . . . . 0.0 111.354 -179.942 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 87.5 mt -71.87 -42.09 67.25 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.694 -179.594 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -58.43 -33.42 69.67 Favored 'General case' 0 C--N 1.33 -0.265 0 N-CA-C 112.155 0.428 . . . . 0.0 112.155 -179.135 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 22' ' ' PHE . . . . . 0.418 ' HB2' HG21 ' A' ' 41' ' ' VAL . 6.8 m-85 -91.46 -37.09 13.39 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.851 0.358 . . . . 0.0 111.535 -179.526 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -64.7 -51.31 63.14 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.912 -179.231 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 24' ' ' TRP . . . . . . . . . . . . . 7.1 t-105 -63.42 -49.45 73.68 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-N 115.754 -0.657 . . . . 0.0 111.312 -179.295 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.328 -0.339 0 CA-C-O 120.879 0.371 . . . . 0.0 110.793 179.906 . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.264 0 N-CA-C 112.432 -0.267 . . . . 0.0 112.432 . . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 7.8 mm-40 -69.35 -20.47 63.85 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-O 120.759 0.314 . . . . 0.0 110.762 179.88 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 34' ' ' ARG . . . . . . . . . . . . . 75.0 ttt180 -48.67 -29.68 4.65 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 115.972 -0.558 . . . . 0.0 111.615 -179.688 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 37.4 ttm180 -58.34 -46.53 86.06 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-O 120.818 0.342 . . . . 0.0 111.046 -179.986 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 68.1 m-85 -69.51 -29.73 67.41 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.081 -0.508 . . . . 0.0 111.388 -179.678 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 37' ' ' TYR . . . . . . . . . . . . . 63.2 m-85 -73.96 -56.1 5.35 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.413 -179.478 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 60.3 t -57.09 -38.64 61.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-O 120.984 0.421 . . . . 0.0 110.682 179.891 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 48.9 m -62.31 -49.05 77.18 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 115.858 -0.61 . . . . 0.0 110.447 179.243 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 40' ' ' LEU . . . . . 0.472 HD11 HD12 ' A' ' 43' ' ' ILE . 46.4 tp -55.56 -45.57 77.26 Favored 'General case' 0 C--O 1.236 0.346 0 CA-C-N 115.612 -0.722 . . . . 0.0 110.233 179.495 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . 0.418 HG21 ' HB2' ' A' ' 22' ' ' PHE . 60.1 t -63.17 -34.31 66.09 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.345 0 CA-C-N 115.645 -0.707 . . . . 0.0 110.172 179.283 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -59.49 -35.19 84.46 Favored Glycine 0 N--CA 1.449 -0.44 0 C-N-CA 120.69 -0.767 . . . . 0.0 111.538 179.554 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 43' ' ' ILE . . . . . 0.51 HG21 ' HE3' ' A' ' 205' ' ' LYS . 1.0 OUTLIER -68.91 -54.71 18.9 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.229 0 CA-C-O 120.797 0.332 . . . . 0.0 110.591 179.331 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 44' ' ' SER . . . . . 0.462 ' HA ' ' SD ' ' A' ' 15' ' ' MET . 32.3 t -58.74 -24.95 62.46 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.306 -179.943 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -76.16 -55.35 4.81 Favored Glycine 0 N--CA 1.45 -0.405 0 C-N-CA 120.683 -0.77 . . . . 0.0 112.747 -179.791 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 20.3 pt -59.78 -36.81 68.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-O 120.745 0.307 . . . . 0.0 111.421 -179.793 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 47' ' ' ALA . . . . . 0.638 ' HB1' ' HE2' ' A' ' 205' ' ' LYS . . . -67.89 -44.51 76.84 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-N 116.395 -0.366 . . . . 0.0 111.243 179.708 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -54.46 -48.0 72.28 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 115.918 -0.583 . . . . 0.0 111.672 -179.398 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 49' ' ' VAL . . . . . 0.417 ' O ' HG13 ' A' ' 53' ' ' VAL . 18.0 m -68.33 -33.92 63.15 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-N 116.255 -0.429 . . . . 0.0 111.371 -179.481 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -66.06 -37.5 85.99 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 120.864 0.364 . . . . 0.0 111.275 179.97 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 51' ' ' TYR . . . . . 0.43 ' OH ' ' HB2' ' A' ' 201' ' ' ASP . 29.5 m-85 -70.82 -44.0 67.45 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.458 -179.829 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -61.14 -51.92 67.06 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-N 115.53 -0.759 . . . . 0.0 111.251 179.814 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 53' ' ' VAL . . . . . 0.417 HG13 ' O ' ' A' ' 49' ' ' VAL . 33.0 m -60.88 -50.95 78.43 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.2 0 CA-C-N 116.455 -0.338 . . . . 0.0 110.869 -179.976 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 54' ' ' MET . . . . . 0.524 ' HG3' ' HE1' ' A' ' 60' ' ' TRP . 8.8 ttp -60.34 -29.2 68.74 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 121.082 0.468 . . . . 0.0 109.792 179.499 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 55' ' ' ALA . . . . . 0.536 ' HB3' ' HB2' ' A' ' 8' ' ' PHE . . . -73.17 -30.6 63.68 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 115.71 -0.677 . . . . 0.0 110.843 179.043 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 87.4 mt -78.25 0.4 25.38 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.058 -179.865 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 92.0 -22.15 33.17 Favored Glycine 0 N--CA 1.45 -0.397 0 C-N-CA 120.63 -0.795 . . . . 0.0 113.127 179.776 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 12.5 p -67.79 142.8 16.01 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.176 0 CA-C-O 120.885 0.374 . . . . 0.0 110.77 -179.966 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 97.72 -11.66 64.55 Favored Glycine 0 N--CA 1.452 -0.287 0 C-N-CA 120.88 -0.676 . . . . 0.0 112.105 -179.329 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 60' ' ' TRP . . . . . 0.524 ' HE1' ' HG3' ' A' ' 54' ' ' MET . 28.6 m0 -78.49 115.09 17.96 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.685 0.279 . . . . 0.0 110.504 179.869 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 10.7 p -118.02 125.29 28.06 Favored Pre-proline 0 CA--C 1.532 0.287 0 CA-C-N 116.518 -0.31 . . . . 0.0 111.518 -179.838 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 17.1 Cg_exo -67.75 155.53 69.58 Favored 'Trans proline' 0 C--N 1.351 0.678 0 C-N-CA 122.553 2.168 . . . . 0.0 111.965 179.652 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 93.2 t -143.09 92.15 0.47 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-N 115.989 -0.55 . . . . 0.0 111.041 179.995 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . 58.41 -85.78 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.039 -0.528 . . . . 0.0 111.63 179.801 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 37.7 mt-10 -119.72 -22.57 6.81 Favored 'General case' 0 C--N 1.332 -0.192 0 CA-C-N 116.42 -0.355 . . . . 0.0 111.141 -179.659 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 66' ' ' ARG . . . . . . . . . . . . . 32.3 mmt180 -105.94 158.06 17.05 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.683 -179.872 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 92.9 m -111.68 131.11 55.52 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.905 0.384 . . . . 0.0 111.492 -179.635 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 68' ' ' VAL . . . . . 0.414 HG21 ' HB1' ' A' ' 116' ' ' ALA . 61.8 t -113.8 146.46 18.35 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 115.899 -0.591 . . . . 0.0 110.534 179.343 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 69' ' ' PHE . . . . . . . . . . . . . 44.6 m-85 -108.89 111.97 23.96 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-N 116.174 -0.467 . . . . 0.0 110.141 -179.447 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 70' ' ' VAL . . . . . 0.621 ' N ' ' HD2' ' A' ' 71' ' ' PRO . 21.8 t -69.2 -49.62 23.48 Favored Pre-proline 0 C--N 1.324 -0.535 0 CA-C-N 116.219 -0.446 . . . . 0.0 112.202 -179.252 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 71' ' ' PRO . . . . . 0.621 ' HD2' ' N ' ' A' ' 70' ' ' VAL . 6.3 Cg_endo -48.45 -26.27 8.55 Favored 'Trans proline' 0 C--N 1.353 0.779 0 C-N-CA 122.422 2.081 . . . . 0.0 112.63 -179.524 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 55.5 ttp180 -75.23 -53.79 8.21 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-O 120.922 0.392 . . . . 0.0 111.123 -179.934 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 73' ' ' TYR . . . . . . . . . . . . . 67.4 m-85 -65.27 -47.97 74.82 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.094 -0.503 . . . . 0.0 111.3 -179.574 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 0.3 OUTLIER -59.35 -41.45 84.33 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-N 116.499 -0.319 . . . . 0.0 110.557 179.884 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 31.7 t70 -59.23 -36.53 75.61 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-O 121.023 0.44 . . . . 0.0 109.916 179.283 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 76' ' ' TRP . . . . . . . . . . . . . 47.4 m0 -66.97 -31.27 71.72 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 115.786 -0.643 . . . . 0.0 110.627 179.798 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 77' ' ' ILE . . . . . 0.461 HG12 ' HB3' ' A' ' 109' ' ' MET . 51.0 mt -73.22 -28.87 26.75 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.614 179.479 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 43.7 mt -91.75 -20.35 21.63 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.985 179.872 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 71.0 p -101.63 -52.67 3.15 Favored 'General case' 0 C--N 1.332 -0.176 0 N-CA-C 113.432 0.901 . . . . 0.0 113.432 -177.817 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 80' ' ' THR . . . . . 0.659 ' HB ' ' HD3' ' A' ' 81' ' ' PRO . 26.9 m -51.24 -55.17 30.86 Favored Pre-proline 0 C--N 1.33 -0.242 0 N-CA-C 112.327 0.491 . . . . 0.0 112.327 -178.258 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 81' ' ' PRO . . . . . 0.659 ' HD3' ' HB ' ' A' ' 80' ' ' THR . 36.0 Cg_exo -60.86 -20.41 66.41 Favored 'Trans proline' 0 C--N 1.352 0.752 0 C-N-CA 121.613 1.542 . . . . 0.0 111.459 179.74 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 82' ' ' LEU . . . . . . . . . . . . . 14.7 tp -76.79 -33.77 58.01 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 115.823 -0.626 . . . . 0.0 110.258 179.599 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 83' ' ' ILE . . . . . 0.509 HD11 HD11 ' A' ' 43' ' ' ILE . 42.2 mm -70.01 -52.54 29.83 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.149 0 CA-C-N 116.087 -0.506 . . . . 0.0 110.296 179.096 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 29.8 m -59.51 -31.79 47.5 Favored 'Isoleucine or valine' 0 CA--C 1.52 -0.193 0 N-CA-C 109.736 -0.468 . . . . 0.0 109.736 178.693 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 85' ' ' TYR . . . . . . . . . . . . . 67.7 t80 -65.69 -33.54 76.12 Favored 'General case' 0 N--CA 1.453 -0.317 0 CA-C-N 115.636 -0.711 . . . . 0.0 109.334 178.72 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 86' ' ' PHE . . . . . . . . . . . . . 4.3 t80 -60.63 -51.71 68.26 Favored 'General case' 0 C--O 1.233 0.22 0 CA-C-N 115.646 -0.707 . . . . 0.0 109.719 178.858 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 9.1 mp -61.37 -31.22 71.11 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 115.741 -0.663 . . . . 0.0 110.506 179.526 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -71.89 -28.01 69.56 Favored Glycine 0 N--CA 1.449 -0.476 0 C-N-CA 120.81 -0.71 . . . . 0.0 112.144 179.801 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 65.5 mt -71.28 -45.06 64.0 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-O 120.877 0.37 . . . . 0.0 110.591 179.838 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 69.5 mt -58.44 -51.84 68.15 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 115.988 -0.551 . . . . 0.0 110.926 179.844 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 91' ' ' ALA . . . . . 0.475 ' HA ' ' HA ' ' A' ' 149' ' ' ALA . . . -61.69 -36.81 81.96 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.278 -0.419 . . . . 0.0 111.427 -179.872 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 88.38 49.56 3.66 Favored Glycine 0 N--CA 1.452 -0.271 0 C-N-CA 120.826 -0.702 . . . . 0.0 112.033 -179.633 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 93' ' ' LEU . . . . . 0.495 HD13 ' HE2' ' A' ' 145' ' ' MET . 71.6 mt -67.53 178.55 1.58 Allowed 'General case' 0 C--N 1.328 -0.349 0 CA-C-O 120.917 0.389 . . . . 0.0 111.357 -179.662 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 94' ' ' ASP . . . . . . . . . . . . . 20.6 t70 -106.18 167.05 10.07 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-N 116.019 -0.537 . . . . 0.0 110.448 179.75 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 65.7 m -52.72 -34.99 55.01 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 116.46 -0.337 . . . . 0.0 111.26 -179.889 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 12.7 ptm180 -73.32 -46.79 47.39 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.381 -0.372 . . . . 0.0 111.066 -179.978 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 97' ' ' GLU . . . . . 0.454 ' HB2' ' HB3' ' A' ' 93' ' ' LEU . 45.9 mt-10 -57.74 -45.41 85.89 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.429 -0.35 . . . . 0.0 110.837 179.964 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 98' ' ' PHE . . . . . 0.466 ' O ' HG12 ' A' ' 102' ' ' ILE . 42.3 m-85 -60.18 -45.87 91.64 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.303 -0.408 . . . . 0.0 110.377 179.464 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -56.6 -30.0 58.54 Favored Glycine 0 N--CA 1.45 -0.414 0 C-N-CA 120.549 -0.834 . . . . 0.0 112.304 179.776 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 74.1 mt -73.5 -47.24 46.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 N-CA-C 112.097 0.406 . . . . 0.0 112.097 -179.761 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 1.1 p -70.52 -42.76 78.22 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-O 120.654 0.264 . . . . 0.0 111.634 -179.712 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 102' ' ' ILE . . . . . 0.466 HG12 ' O ' ' A' ' 98' ' ' PHE . 45.2 mm -62.13 -45.14 99.41 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.36 0 CA-C-N 116.426 -0.352 . . . . 0.0 111.042 -179.627 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 103' ' ' THR . . . . . 0.452 ' HA ' ' HG1' ' A' ' 106' ' ' THR . 13.6 t -66.88 -29.87 69.89 Favored 'General case' 0 C--N 1.332 -0.167 0 CA-C-O 120.817 0.341 . . . . 0.0 110.346 179.559 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 1.2 tm? -59.76 -56.06 26.51 Favored 'General case' 0 C--N 1.331 -0.206 0 N-CA-C 109.501 -0.555 . . . . 0.0 109.501 179.108 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 105' ' ' ASN . . . . . 0.606 ' N ' HD21 ' A' ' 105' ' ' ASN . 0.8 OUTLIER -57.3 -32.45 66.67 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 115.855 -0.611 . . . . 0.0 110.663 179.232 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 106' ' ' THR . . . . . 0.452 ' HG1' ' HA ' ' A' ' 103' ' ' THR . 58.0 m -57.65 -48.86 78.32 Favored 'General case' 0 C--N 1.332 -0.183 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.95 179.78 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 2.1 t -61.54 -40.85 87.94 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-O 121.149 0.5 . . . . 0.0 110.122 179.623 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 99.0 t -58.92 -43.73 89.25 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.377 0 CA-C-N 115.294 -0.867 . . . . 0.0 111.406 -179.956 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 109' ' ' MET . . . . . 0.461 ' HB3' HG12 ' A' ' 77' ' ' ILE . 15.3 mmt -70.51 -41.51 72.52 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.666 -179.332 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 32.5 tp -59.65 -31.09 69.21 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-O 120.882 0.372 . . . . 0.0 110.569 -179.872 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -70.15 -53.48 17.04 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.758 179.649 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . -59.58 -45.62 95.33 Favored Glycine 0 C--N 1.331 0.299 0 C-N-CA 120.707 -0.759 . . . . 0.0 112.301 179.751 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 113' ' ' PHE . . . . . . . . . . . . . 1.5 t80 -50.97 -60.5 3.03 Favored 'General case' 0 C--N 1.332 -0.171 0 CA-C-O 120.996 0.427 . . . . 0.0 110.116 179.488 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 114' ' ' ALA . . . . . 0.453 ' HB2' HD21 ' A' ' 126' ' ' LEU . . . -66.45 -19.81 65.89 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 115.733 -0.667 . . . . 0.0 110.6 179.451 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -59.0 -45.84 94.61 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.86 -0.686 . . . . 0.0 112.042 179.646 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 116' ' ' ALA . . . . . 0.414 ' HB1' HG21 ' A' ' 68' ' ' VAL . . . -78.16 -21.2 50.56 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.804 0.335 . . . . 0.0 111.359 179.67 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 117' ' ' MET . . . . . . . . . . . . . 24.8 mmt -83.24 19.87 1.4 Allowed 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.846 -179.253 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 118' ' ' VAL . . . . . 0.525 HG23 ' HB3' ' A' ' 123' ' ' ARG . 24.7 m -90.73 141.67 27.13 Favored Pre-proline 0 C--N 1.329 -0.294 0 CA-C-O 120.646 0.26 . . . . 0.0 111.614 -179.717 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 119' ' ' PRO . . . . . . . . . . . . . 97.3 Cg_endo -92.52 -6.75 3.05 Favored 'Trans proline' 0 N--CA 1.455 -0.774 0 C-N-CA 122.882 2.388 . . . . 0.0 112.379 179.455 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -139.41 -115.38 1.27 Allowed Glycine 0 C--N 1.332 0.314 0 C-N-CA 120.589 -0.815 . . . . 0.0 113.023 -179.586 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 38.3 pt -119.29 15.03 6.85 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.233 0 CA-C-O 120.686 0.279 . . . . 0.0 111.67 -179.345 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 10.9 mm-40 -62.11 -18.61 61.33 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.383 -0.371 . . . . 0.0 110.99 179.752 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 123' ' ' ARG . . . . . 0.525 ' HB3' HG23 ' A' ' 118' ' ' VAL . 24.2 ptt180 -54.54 -33.42 60.05 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 115.973 -0.558 . . . . 0.0 111.785 -179.751 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 124' ' ' TYR . . . . . . . . . . . . . 37.3 m-85 -65.73 -32.22 73.65 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 120.829 0.347 . . . . 0.0 111.108 -179.593 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 125' ' ' ALA . . . . . . . . . . . . . . . -72.62 -56.17 5.73 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.0 179.92 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 126' ' ' LEU . . . . . 0.453 HD21 ' HB2' ' A' ' 114' ' ' ALA . 1.3 mt -55.68 -45.44 77.77 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 115.789 -0.642 . . . . 0.0 110.488 -179.991 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 127' ' ' PHE . . . . . . . . . . . . . 7.6 t80 -67.3 -37.37 83.27 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.464 179.612 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 128' ' ' GLY . . . . . . . . . . . . . . . -47.1 -45.03 20.14 Favored Glycine 0 C--N 1.332 0.331 0 C-N-CA 120.2 -1.0 . . . . 0.0 110.748 178.866 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 129' ' ' MET . . . . . 0.407 ' HE3' ' N ' ' A' ' 130' ' ' GLY . 0.4 OUTLIER -70.95 -35.85 72.35 Favored 'General case' 0 C--N 1.328 -0.328 0 N-CA-C 109.826 -0.435 . . . . 0.0 109.826 178.578 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 130' ' ' GLY . . . . . 0.407 ' N ' ' HE3' ' A' ' 129' ' ' MET . . . -62.67 -36.38 93.19 Favored Glycine 0 C--N 1.332 0.354 0 CA-C-N 115.777 -0.647 . . . . 0.0 112.626 -179.926 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -69.66 -53.34 19.13 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.602 0.239 . . . . 0.0 110.42 179.78 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 54.5 t -55.38 -39.99 55.31 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.234 0 CA-C-O 121.376 0.608 . . . . 0.0 109.595 178.879 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -69.12 -35.29 76.26 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 115.278 -0.874 . . . . 0.0 110.51 179.316 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 134' ' ' PHE . . . . . 0.401 ' CZ ' ' HA ' ' A' ' 172' ' ' ALA . 73.5 t80 -56.94 -57.58 11.89 Favored 'General case' 0 N--CA 1.451 -0.415 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.146 179.823 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 135' ' ' ILE . . . . . 0.483 ' O ' HG22 ' A' ' 138' ' ' VAL . 0.0 OUTLIER -56.18 -32.84 35.48 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.002 -0.545 . . . . 0.0 109.61 178.761 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . -57.33 -39.15 89.9 Favored Glycine 0 N--CA 1.447 -0.58 0 C-N-CA 120.302 -0.951 . . . . 0.0 111.086 178.389 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 137' ' ' LEU . . . . . . . . . . . . . 27.8 tp -68.3 -53.84 21.58 Favored 'General case' 0 C--N 1.331 -0.197 0 CA-C-O 120.579 0.228 . . . . 0.0 110.644 179.212 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 138' ' ' VAL . . . . . 0.483 HG22 ' O ' ' A' ' 135' ' ' ILE . 3.0 m -56.15 -30.24 29.07 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.204 0 CA-C-O 121.137 0.494 . . . . 0.0 109.742 179.482 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 139' ' ' TYR . . . . . . . . . . . . . 35.2 t80 -63.7 -44.22 94.29 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 115.441 -0.8 . . . . 0.0 110.202 178.945 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 37.8 m-85 -63.04 -34.95 78.68 Favored 'General case' 0 C--N 1.331 -0.198 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.696 179.434 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 141' ' ' LEU . . . . . . . . . . . . . 89.7 mt -62.92 -51.11 68.21 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.005 -179.943 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 15.0 p -81.87 -11.01 12.31 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.358 0 CA-C-N 116.076 -0.511 . . . . 0.0 111.032 -179.874 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . -72.32 -130.31 0.12 Allowed Glycine 0 CA--C 1.521 0.44 0 C-N-CA 120.973 -0.632 . . . . 0.0 112.988 -179.68 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 144' ' ' PRO . . . . . . . . . . . . . 33.1 Cg_endo -64.34 -23.57 65.46 Favored 'Trans proline' 0 C--N 1.349 0.586 0 C-N-CA 122.549 2.166 . . . . 0.0 112.521 -179.696 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 145' ' ' MET . . . . . 0.495 ' HE2' HD13 ' A' ' 93' ' ' LEU . 45.6 mtt -54.65 -34.43 62.17 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.352 -0.385 . . . . 0.0 111.446 -179.888 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 146' ' ' THR . . . . . . . . . . . . . 53.9 p -71.62 -37.47 70.9 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 116.53 -0.304 . . . . 0.0 111.584 -179.74 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 43.4 mt-10 -71.98 -37.48 69.88 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.374 -0.376 . . . . 0.0 111.203 -179.586 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 148' ' ' SER . . . . . . . . . . . . . 66.5 m -70.35 -40.09 74.29 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.152 -0.477 . . . . 0.0 111.454 -179.684 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 149' ' ' ALA . . . . . 0.475 ' HA ' ' HA ' ' A' ' 91' ' ' ALA . . . -74.9 -48.36 25.17 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.354 -0.385 . . . . 0.0 111.832 -179.397 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 150' ' ' SER . . . . . . . . . . . . . 47.1 t -61.07 -23.04 65.17 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.358 -0.383 . . . . 0.0 111.316 -179.652 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 151' ' ' GLN . . . . . . . . . . . . . 49.1 mt-30 -108.78 13.49 24.95 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.455 -0.339 . . . . 0.0 111.209 -179.849 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 30.7 tpt180 -89.77 -52.02 5.21 Favored 'General case' 0 C--N 1.332 -0.194 0 CA-C-O 120.933 0.397 . . . . 0.0 110.616 179.751 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 153' ' ' SER . . . . . 0.586 ' HB2' HG12 ' A' ' 156' ' ' ILE . 13.2 m -157.57 172.69 18.1 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 115.852 -0.613 . . . . 0.0 110.331 179.426 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 154' ' ' SER . . . . . . . . . . . . . 94.9 p -67.75 -44.87 76.52 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.798 0.332 . . . . 0.0 110.899 179.844 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 155' ' ' GLY . . . . . 0.401 ' O ' HD23 ' A' ' 159' ' ' LEU . . . -76.7 -38.24 32.41 Favored Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 121.096 -0.573 . . . . 0.0 113.219 -179.684 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 156' ' ' ILE . . . . . 0.586 HG12 ' HB2' ' A' ' 153' ' ' SER . 36.1 mm -48.07 -37.75 7.12 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.229 0 CA-C-O 120.704 0.288 . . . . 0.0 111.404 -179.527 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 157' ' ' LYS . . . . . . . . . . . . . 87.5 tttt -64.76 -42.03 95.44 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 116.351 -0.386 . . . . 0.0 111.316 -179.93 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 85.9 p -71.28 -46.33 61.07 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.94 0.4 . . . . 0.0 111.375 -179.48 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 159' ' ' LEU . . . . . 0.401 HD23 ' O ' ' A' ' 155' ' ' GLY . 4.1 mm? -61.61 -36.29 80.28 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-N 116.006 -0.543 . . . . 0.0 111.558 -179.595 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 160' ' ' TYR . . . . . . . . . . . . . 46.9 t80 -74.25 -46.86 38.84 Favored 'General case' 0 C--N 1.33 -0.274 0 N-CA-C 112.668 0.618 . . . . 0.0 112.668 -178.73 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 21.6 m -58.57 -45.23 90.49 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 N-CA-C 112.277 0.473 . . . . 0.0 112.277 -178.712 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 162' ' ' ARG . . . . . . . . . . . . . 99.9 mtt180 -68.71 -44.78 73.2 Favored 'General case' 0 C--N 1.328 -0.363 0 N-CA-C 111.781 0.289 . . . . 0.0 111.781 -179.38 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 163' ' ' LEU . . . . . 0.668 ' HG ' ' HB2' ' A' ' 208' ' ' PHE . 6.0 mp -67.37 -54.18 22.76 Favored 'General case' 0 C--N 1.328 -0.368 0 N-CA-C 112.006 0.373 . . . . 0.0 112.006 -179.199 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 164' ' ' ARG . . . . . . . . . . . . . 3.7 tmm_? -56.25 -53.12 60.95 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.348 -0.387 . . . . 0.0 111.998 -179.071 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 165' ' ' ASN . . . . . 0.487 ' N ' HD21 ' A' ' 165' ' ' ASN . 0.9 OUTLIER -54.43 -51.73 64.01 Favored 'General case' 0 C--N 1.331 -0.204 0 CA-C-O 120.788 0.327 . . . . 0.0 111.81 -179.332 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 166' ' ' LEU . . . . . 0.447 ' O ' ' HG ' ' A' ' 170' ' ' LEU . 4.5 tt -60.29 -53.33 59.0 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-N 116.357 -0.383 . . . . 0.0 111.548 -179.31 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 167' ' ' THR . . . . . . . . . . . . . 63.7 m -55.85 -52.74 62.98 Favored 'General case' 0 C--N 1.329 -0.295 0 N-CA-C 113.167 0.803 . . . . 0.0 113.167 -178.767 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 168' ' ' VAL . . . . . 0.407 HG11 ' O ' ' A' ' 165' ' ' ASN . 8.2 p -56.84 -41.23 75.48 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.209 0 N-CA-C 112.226 0.454 . . . . 0.0 112.226 -178.451 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 169' ' ' VAL . . . . . 0.417 HG22 ' O ' ' A' ' 165' ' ' ASN . 74.5 t -58.3 -63.47 0.69 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.395 0 CA-C-N 116.542 -0.299 . . . . 0.0 111.534 -179.716 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 170' ' ' LEU . . . . . 0.451 ' H ' ' HG ' ' A' ' 170' ' ' LEU . 0.8 OUTLIER -64.3 -28.26 69.59 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.551 -0.295 . . . . 0.0 111.769 -179.292 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 171' ' ' TRP . . . . . . . . . . . . . 4.5 m0 -71.11 -29.96 65.92 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 121.151 0.501 . . . . 0.0 110.216 179.146 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 172' ' ' ALA . . . . . 0.401 ' HA ' ' CZ ' ' A' ' 134' ' ' PHE . . . -71.49 -7.1 45.32 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 115.495 -0.775 . . . . 0.0 110.967 -179.962 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 173' ' ' ILE . . . . . 0.515 ' O ' HG12 ' A' ' 177' ' ' ILE . 16.1 mm -86.75 -23.2 6.82 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.032 -0.531 . . . . 0.0 111.243 -179.993 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 174' ' ' TYR . . . . . 0.41 ' HB2' ' HD3' ' A' ' 175' ' ' PRO . 29.0 m-85 -54.11 -49.94 87.18 Favored Pre-proline 0 N--CA 1.464 0.273 0 CA-C-N 116.409 -0.36 . . . . 0.0 111.89 -179.426 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 175' ' ' PRO . . . . . 0.41 ' HD3' ' HB2' ' A' ' 174' ' ' TYR . 71.2 Cg_exo -48.45 -31.65 18.53 Favored 'Trans proline' 0 C--N 1.351 0.663 0 C-N-CA 121.935 1.757 . . . . 0.0 112.338 179.797 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 176' ' ' PHE . . . . . 0.469 ' O ' ' HG ' ' A' ' 180' ' ' LEU . 82.0 m-85 -80.38 -50.39 10.2 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.005 -0.543 . . . . 0.0 111.882 -179.843 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 177' ' ' ILE . . . . . 0.515 HG12 ' O ' ' A' ' 173' ' ' ILE . 5.3 mm -62.12 -36.16 72.75 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.534 0 N-CA-C 112.562 0.579 . . . . 0.0 112.562 -178.016 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 178' ' ' TRP . . . . . 0.446 ' HH2' ' HB2' ' A' ' 123' ' ' ARG . 83.8 t90 -69.74 -50.18 45.98 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.738 0.304 . . . . 0.0 111.007 179.973 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 179' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -68.99 -55.06 12.03 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.262 -0.426 . . . . 0.0 111.582 -179.159 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 180' ' ' LEU . . . . . 0.571 HD23 HD12 ' A' ' 187' ' ' LEU . 43.3 mt -60.42 -46.75 88.89 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 116.501 -0.318 . . . . 0.0 111.29 -179.473 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . -56.61 177.43 0.85 Allowed Glycine 0 C--N 1.335 0.512 0 C-N-CA 120.384 -0.912 . . . . 0.0 112.715 179.636 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 182' ' ' PRO . . . . . 0.443 ' HB2' ' HD3' ' A' ' 183' ' ' PRO . 83.7 Cg_exo -47.15 -45.24 22.1 Favored 'Trans proline' 0 CA--C 1.536 0.575 0 C-N-CA 122.878 2.385 . . . . 0.0 113.697 -179.802 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 183' ' ' PRO . . . . . 0.443 ' HD3' ' HB2' ' A' ' 182' ' ' PRO . 79.7 Cg_exo -46.38 -29.95 7.66 Favored 'Trans proline' 0 C--N 1.356 0.922 0 C-N-CA 122.195 1.93 . . . . 0.0 113.171 -179.796 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 184' ' ' GLY . . . . . . . . . . . . . . . -114.5 -121.3 3.55 Favored Glycine 0 C--N 1.332 0.342 0 C-N-CA 120.335 -0.936 . . . . 0.0 113.001 -179.896 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 185' ' ' VAL . . . . . . . . . . . . . 16.6 m -64.49 -18.57 23.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 N-CA-C 112.02 0.378 . . . . 0.0 112.02 -179.46 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 186' ' ' ALA . . . . . . . . . . . . . . . 56.39 87.55 0.06 Allowed 'General case' 0 N--CA 1.463 0.209 0 CA-C-O 120.731 0.301 . . . . 0.0 111.453 179.585 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 187' ' ' LEU . . . . . 0.571 HD12 HD23 ' A' ' 180' ' ' LEU . 18.8 mt -92.05 -49.67 6.09 Favored 'General case' 0 C--N 1.332 -0.195 0 CA-C-O 120.904 0.383 . . . . 0.0 111.367 -179.867 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 188' ' ' LEU . . . . . . . . . . . . . 95.2 mt -106.79 -156.7 0.59 Allowed 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.165 -0.471 . . . . 0.0 111.027 -179.574 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 189' ' ' THR . . . . . . . . . . . . . 1.6 t -96.27 149.18 35.58 Favored Pre-proline 0 C--N 1.329 -0.304 0 CA-C-N 116.056 -0.52 . . . . 0.0 111.203 -179.686 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 190' ' ' PRO . . . . . . . . . . . . . 9.9 Cg_endo -51.42 -37.41 61.39 Favored 'Trans proline' 0 C--N 1.349 0.582 0 C-N-CA 122.75 2.3 . . . . 0.0 112.688 -179.869 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 191' ' ' THR . . . . . . . . . . . . . 70.2 p -58.93 -48.66 80.7 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.97 0.415 . . . . 0.0 110.975 179.947 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 192' ' ' VAL . . . . . . . . . . . . . 40.6 t -67.45 -48.48 77.13 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 115.882 -0.599 . . . . 0.0 111.566 -179.772 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 193' ' ' ASP . . . . . . . . . . . . . 22.4 t70 -56.45 -51.92 66.64 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.31 -0.405 . . . . 0.0 111.497 -179.586 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 194' ' ' VAL . . . . . . . . . . . . . 79.7 t -58.68 -35.86 57.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.439 -0.346 . . . . 0.0 110.898 179.929 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 195' ' ' ALA . . . . . . . . . . . . . . . -57.57 -44.88 85.62 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.4 -0.363 . . . . 0.0 110.856 179.708 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 196' ' ' LEU . . . . . . . . . . . . . 96.0 mt -68.08 -44.0 77.26 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-N 116.329 -0.396 . . . . 0.0 110.53 179.433 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 197' ' ' ILE . . . . . . . . . . . . . 18.7 mm -56.95 -59.34 3.21 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 115.986 -0.552 . . . . 0.0 110.635 179.53 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 198' ' ' VAL . . . . . . . . . . . . . 79.5 t -52.21 -34.94 18.66 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.509 0 CA-C-N 115.688 -0.687 . . . . 0.0 109.594 178.6 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 199' ' ' TYR . . . . . . . . . . . . . 48.0 t80 -70.52 -32.35 69.79 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 115.47 -0.786 . . . . 0.0 110.819 179.885 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 200' ' ' LEU . . . . . 0.426 ' O ' HG11 ' A' ' 203' ' ' VAL . 21.6 mt -69.99 -40.51 75.29 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 115.973 -0.558 . . . . 0.0 111.458 -179.673 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 201' ' ' ASP . . . . . 0.43 ' HB2' ' OH ' ' A' ' 51' ' ' TYR . 12.8 m-20 -71.83 -35.79 70.01 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-O 121.293 0.568 . . . . 0.0 109.991 179.471 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 202' ' ' LEU . . . . . . . . . . . . . 3.0 mt -69.71 -31.36 69.34 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 115.306 -0.861 . . . . 0.0 111.856 -179.734 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 203' ' ' VAL . . . . . 0.426 HG11 ' O ' ' A' ' 200' ' ' LEU . 13.1 p -76.7 -36.06 26.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 C-N-CA 121.004 -0.279 . . . . 0.0 110.911 -179.087 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 204' ' ' THR . . . . . 0.408 ' O ' ' CD1' ' A' ' 208' ' ' PHE . 53.7 m -63.8 -58.41 6.9 Favored 'General case' 0 C--N 1.33 -0.279 0 C-N-CA 120.585 -0.446 . . . . 0.0 111.389 179.376 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 205' ' ' LYS . . . . . 0.638 ' HE2' ' HB1' ' A' ' 47' ' ' ALA . 52.2 mttp -65.06 -58.31 6.39 Favored 'General case' 0 N--CA 1.464 0.231 0 N-CA-C 112.494 0.553 . . . . 0.0 112.494 -178.347 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 42.6 t -68.42 -36.81 76.4 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.475 0 N-CA-C 112.168 0.432 . . . . 0.0 112.168 -178.898 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 207' ' ' GLY . . . . . 0.534 ' O ' HG13 ' A' ' 211' ' ' ILE . . . -60.2 -60.76 8.03 Favored Glycine 0 N--CA 1.453 -0.226 0 C-N-CA 120.682 -0.771 . . . . 0.0 114.035 -178.349 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 208' ' ' PHE . . . . . 0.668 ' HB2' ' HG ' ' A' ' 163' ' ' LEU . 0.1 OUTLIER -71.55 -26.83 62.79 Favored 'General case' 0 C--O 1.224 -0.287 0 CA-C-N 117.277 0.539 . . . . 0.0 111.653 -178.643 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 209' ' ' GLY . . . . . 0.486 ' O ' ' HB2' ' A' ' 212' ' ' ALA . . . -67.6 -32.44 78.57 Favored Glycine 0 N--CA 1.449 -0.457 0 N-CA-C 111.853 -0.499 . . . . 0.0 111.853 178.966 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 210' ' ' PHE . . . . . . . . . . . . . 0.9 OUTLIER -73.21 -48.29 36.31 Favored 'General case' 0 CA--C 1.514 -0.43 0 N-CA-C 108.291 -1.003 . . . . 0.0 108.291 178.532 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 211' ' ' ILE . . . . . 0.534 HG13 ' O ' ' A' ' 207' ' ' GLY . 5.3 mt -63.48 -27.96 44.04 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.535 0 N-CA-C 107.626 -1.25 . . . . 0.0 107.626 176.715 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 212' ' ' ALA . . . . . 0.486 ' HB2' ' O ' ' A' ' 209' ' ' GLY . . . -63.72 -40.83 97.71 Favored 'General case' 0 N--CA 1.449 -0.483 0 CA-C-N 114.45 -1.25 . . . . 0.0 110.881 179.887 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 213' ' ' LEU . . . . . . . . . . . . . 97.3 mt -69.98 -55.0 10.75 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 115.273 -0.876 . . . . 0.0 112.17 -179.135 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 214' ' ' ASP . . . . . . . . . . . . . 36.2 t70 -53.81 -55.03 30.23 Favored 'General case' 0 C--O 1.234 0.27 0 CA-C-O 120.758 0.313 . . . . 0.0 111.498 -179.417 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 215' ' ' ALA . . . . . . . . . . . . . . . -56.99 -53.06 62.29 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.306 -0.406 . . . . 0.0 111.159 -179.878 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 216' ' ' ALA . . . . . . . . . . . . . . . -58.73 -31.35 68.22 Favored 'General case' 0 C--N 1.332 -0.187 0 CA-C-N 116.443 -0.344 . . . . 0.0 111.286 -179.891 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 217' ' ' ALA . . . . . . . . . . . . . . . -61.82 -39.7 92.7 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 121.076 0.465 . . . . 0.0 109.991 179.573 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 218' ' ' THR . . . . . . . . . . . . . 97.9 m . . . . . 0 C--N 1.331 -0.228 0 CA-C-N 115.726 -0.67 . . . . 0.0 110.793 179.299 . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.453 -0.216 0 N-CA-C 112.577 -0.209 . . . . 0.0 112.577 . . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 32.0 tp -74.83 -36.46 62.41 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-O 120.779 0.323 . . . . 0.0 111.215 -179.913 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 81.5 p -59.43 -29.84 68.05 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.082 -0.508 . . . . 0.0 111.372 -179.641 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 31.3 p -53.55 -35.91 61.27 Favored 'General case' 0 C--N 1.331 -0.196 0 CA-C-N 116.231 -0.441 . . . . 0.0 111.413 -179.798 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 7' ' ' LEU . . . . . . . . . . . . . 3.9 mm? -61.15 -51.09 70.52 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 116.382 -0.372 . . . . 0.0 111.224 -179.774 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 8' ' ' PHE . . . . . . . . . . . . . 83.9 m-85 -60.33 -36.39 77.83 Favored 'General case' 0 C--N 1.331 -0.198 0 CA-C-O 120.978 0.418 . . . . 0.0 110.775 179.871 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 9' ' ' TRP . . . . . 0.433 ' O ' HG12 ' A' ' 13' ' ' ILE . 21.7 m95 -63.58 -41.9 98.34 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 115.781 -0.645 . . . . 0.0 109.897 179.827 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 87.6 mt -60.87 -45.0 96.28 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 115.549 -0.75 . . . . 0.0 110.392 179.315 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -64.42 -26.76 70.94 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.715 -0.755 . . . . 0.0 111.965 179.368 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -74.37 -30.51 62.01 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.772 0.32 . . . . 0.0 110.755 179.716 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 13' ' ' ILE . . . . . 0.433 HG12 ' O ' ' A' ' 9' ' ' TRP . 51.6 mm -69.62 -54.39 19.71 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.227 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.62 179.776 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -61.84 -34.76 89.85 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.582 -0.818 . . . . 0.0 112.033 179.64 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 15' ' ' MET . . . . . 0.506 ' SD ' ' HA ' ' A' ' 44' ' ' SER . 49.1 tpp -66.52 -45.8 78.29 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 120.778 0.323 . . . . 0.0 110.39 179.71 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -54.19 -41.46 68.62 Favored 'General case' 0 C--N 1.331 -0.206 0 CA-C-N 116.053 -0.521 . . . . 0.0 109.759 179.196 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 17' ' ' VAL . . . . . 0.429 HG23 ' O ' ' A' ' 13' ' ' ILE . 63.5 t -59.8 -43.21 91.29 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.187 0 CA-C-N 115.8 -0.636 . . . . 0.0 110.263 179.302 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -65.3 -40.31 96.48 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.694 -0.765 . . . . 0.0 111.58 178.95 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 15.5 m -53.79 -48.84 69.42 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.876 0.369 . . . . 0.0 110.991 -179.997 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 20' ' ' LEU . . . . . 0.401 ' O ' ' HB3' ' A' ' 24' ' ' TRP . 89.2 mt -71.61 -35.05 70.36 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.038 -0.528 . . . . 0.0 111.152 179.894 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -64.06 -34.2 77.48 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.166 -0.47 . . . . 0.0 112.252 -179.332 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 22' ' ' PHE . . . . . 0.458 ' HB2' HG22 ' A' ' 41' ' ' VAL . 4.1 m-85 -90.29 -37.81 13.82 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.67 0.271 . . . . 0.0 111.512 -179.045 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -64.85 -50.75 65.4 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 121.004 0.43 . . . . 0.0 111.731 -179.542 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 24' ' ' TRP . . . . . 0.401 ' HB3' ' O ' ' A' ' 20' ' ' LEU . 5.0 t-105 -63.42 -51.54 65.3 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 115.803 -0.635 . . . . 0.0 111.174 -179.605 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.328 -0.336 0 CA-C-N 116.36 -0.382 . . . . 0.0 111.162 -179.842 . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.313 0 N-CA-C 112.359 -0.297 . . . . 0.0 112.359 . . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 17.6 mm-40 -66.38 -20.51 66.09 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.674 0.273 . . . . 0.0 111.141 179.897 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 34' ' ' ARG . . . . . . . . . . . . . 93.0 mtt180 -48.25 -34.07 9.69 Favored 'General case' 0 C--N 1.332 -0.192 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.623 -179.491 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 82.7 mtp180 -59.01 -52.67 64.77 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-O 120.841 0.353 . . . . 0.0 111.078 -179.83 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 73.4 m-85 -61.22 -29.5 69.86 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 116.058 -0.519 . . . . 0.0 111.189 -179.953 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 37' ' ' TYR . . . . . . . . . . . . . 42.8 m-85 -73.3 -52.62 13.28 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.347 -179.758 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 91.2 t -57.03 -36.92 52.49 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.243 0 CA-C-O 121.064 0.459 . . . . 0.0 110.265 179.536 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 25.6 m -68.07 -46.08 72.03 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 115.649 -0.705 . . . . 0.0 110.467 179.35 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 15.8 tp -60.38 -45.51 93.28 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 115.628 -0.715 . . . . 0.0 110.51 179.877 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . 0.458 HG22 ' HB2' ' A' ' 22' ' ' PHE . 98.4 t -65.18 -34.02 67.66 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.476 0 CA-C-N 115.843 -0.617 . . . . 0.0 110.125 179.221 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 42' ' ' GLY . . . . . 0.431 ' O ' HG12 ' A' ' 46' ' ' ILE . . . -55.86 -51.57 54.43 Favored Glycine 0 N--CA 1.449 -0.485 0 CA-C-N 115.697 -0.683 . . . . 0.0 112.759 179.854 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 43' ' ' ILE . . . . . 0.599 HG21 HD21 ' A' ' 82' ' ' LEU . 10.7 pt -63.76 -48.93 84.29 Favored 'Isoleucine or valine' 0 C--O 1.231 0.12 0 CA-C-N 116.972 0.386 . . . . 0.0 111.473 -179.963 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 44' ' ' SER . . . . . 0.506 ' HA ' ' SD ' ' A' ' 15' ' ' MET . 47.8 t -60.51 -26.62 66.98 Favored 'General case' 0 CA--C 1.529 0.147 0 CA-C-O 120.968 0.413 . . . . 0.0 111.116 179.831 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -75.85 -60.44 3.16 Favored Glycine 0 CA--C 1.517 0.179 0 C-N-CA 120.966 -0.635 . . . . 0.0 113.206 -179.278 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 46' ' ' ILE . . . . . 0.431 HG12 ' O ' ' A' ' 42' ' ' GLY . 9.3 pt -57.95 -34.83 49.69 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-O 120.738 0.304 . . . . 0.0 111.339 -179.444 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 47' ' ' ALA . . . . . 0.679 ' HB2' ' HE2' ' A' ' 205' ' ' LYS . . . -67.22 -44.03 80.56 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.526 -0.306 . . . . 0.0 111.035 179.277 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -54.39 -47.07 73.12 Favored 'General case' 0 C--O 1.232 0.151 0 CA-C-N 116.273 -0.421 . . . . 0.0 111.179 -179.975 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 49' ' ' VAL . . . . . 0.421 ' O ' HG13 ' A' ' 53' ' ' VAL . 14.5 m -71.81 -34.11 50.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.292 -0.413 . . . . 0.0 111.004 179.704 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -60.07 -41.32 92.13 Favored 'General case' 0 N--CA 1.462 0.172 0 CA-C-O 121.006 0.432 . . . . 0.0 111.012 179.422 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 38.8 m-85 -73.25 -34.76 66.02 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 115.877 -0.601 . . . . 0.0 110.496 -179.883 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -66.58 -44.86 81.09 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 115.923 -0.581 . . . . 0.0 111.052 179.599 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 53' ' ' VAL . . . . . 0.45 HG21 ' N ' ' A' ' 54' ' ' MET . 31.2 m -66.61 -45.49 88.39 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.137 0 CA-C-N 116.47 -0.332 . . . . 0.0 110.87 -179.997 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 54' ' ' MET . . . . . 0.45 ' N ' HG21 ' A' ' 53' ' ' VAL . 73.1 mtm -64.27 -34.49 78.23 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-O 121.183 0.516 . . . . 0.0 109.941 179.251 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -63.61 -23.29 67.32 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 115.432 -0.804 . . . . 0.0 111.103 179.515 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 93.2 mt -94.12 -5.37 47.39 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 116.262 -0.426 . . . . 0.0 111.077 -179.864 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 98.12 19.42 23.84 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.636 -0.792 . . . . 0.0 112.935 179.743 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 59.7 t -83.61 135.4 24.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-O 120.739 0.304 . . . . 0.0 110.853 179.861 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 59' ' ' GLY . . . . . 0.515 ' HA3' ' HD3' ' A' ' 71' ' ' PRO . . . 81.03 -4.84 68.7 Favored Glycine 0 N--CA 1.45 -0.423 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.599 -179.806 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 60' ' ' TRP . . . . . . . . . . . . . 14.3 m0 -67.3 90.75 0.23 Allowed 'General case' 0 C--N 1.33 -0.248 0 CA-C-O 120.655 0.264 . . . . 0.0 110.836 179.97 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 61' ' ' VAL . . . . . 0.425 ' HA ' ' HD3' ' A' ' 62' ' ' PRO . 7.0 p -101.36 130.0 25.75 Favored Pre-proline 0 C--N 1.33 -0.277 0 CA-C-N 116.415 -0.357 . . . . 0.0 111.266 179.914 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 62' ' ' PRO . . . . . 0.425 ' HD3' ' HA ' ' A' ' 61' ' ' VAL . 7.7 Cg_exo -73.84 148.17 40.56 Favored 'Trans proline' 0 C--N 1.35 0.64 0 C-N-CA 122.966 2.444 . . . . 0.0 112.33 179.938 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 86.6 t -143.18 93.73 0.5 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.141 -0.481 . . . . 0.0 111.073 -179.956 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . 59.4 -88.31 0.02 OUTLIER 'General case' 0 C--N 1.332 -0.157 0 CA-C-N 116.129 -0.487 . . . . 0.0 111.485 179.846 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 12.6 pt-20 -123.9 -17.15 6.39 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.292 -0.413 . . . . 0.0 110.763 -179.851 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 66' ' ' ARG . . . . . . . . . . . . . 32.7 ptt180 -105.77 159.7 15.8 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 115.902 -0.59 . . . . 0.0 110.532 -179.925 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 40.0 m -119.23 138.54 52.91 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-O 120.902 0.382 . . . . 0.0 111.466 -179.646 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 68' ' ' VAL . . . . . 0.407 HG23 HG11 ' A' ' 61' ' ' VAL . 14.8 m -125.82 146.49 31.48 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.412 0 CA-C-N 115.846 -0.615 . . . . 0.0 110.732 179.666 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 69' ' ' PHE . . . . . . . . . . . . . 17.7 m-85 -108.78 115.7 30.59 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.195 -179.423 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 70' ' ' VAL . . . . . 0.564 HG11 ' HD3' ' A' ' 71' ' ' PRO . 0.3 OUTLIER -68.08 -33.47 5.01 Favored Pre-proline 0 CA--C 1.54 0.579 0 N-CA-C 112.749 0.648 . . . . 0.0 112.749 -179.24 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 71' ' ' PRO . . . . . 0.564 ' HD3' HG11 ' A' ' 70' ' ' VAL . 17.6 Cg_exo -66.39 -32.31 41.03 Favored 'Trans proline' 0 C--N 1.358 1.078 0 C-N-CA 121.781 1.654 . . . . 0.0 112.389 -178.989 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 61.8 ttp180 -65.56 -51.13 62.11 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 121.178 0.513 . . . . 0.0 109.845 179.419 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 73' ' ' TYR . . . . . . . . . . . . . 45.9 m-85 -63.67 -46.92 83.4 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 115.522 -0.763 . . . . 0.0 110.697 179.752 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 74' ' ' ILE . . . . . 0.405 ' HA ' HD13 ' A' ' 77' ' ' ILE . 0.4 OUTLIER -63.62 -34.84 70.22 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.308 -0.405 . . . . 0.0 110.175 179.64 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 28.6 t70 -58.31 -39.37 79.2 Favored 'General case' 0 C--N 1.332 -0.157 0 N-CA-C 109.497 -0.557 . . . . 0.0 109.497 179.263 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 76' ' ' TRP . . . . . 0.455 ' HA ' ' HG1' ' A' ' 79' ' ' THR . 53.1 m0 -67.44 -37.13 82.52 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 115.728 -0.669 . . . . 0.0 110.485 179.479 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 77' ' ' ILE . . . . . 0.422 ' O ' ' HG2' ' A' ' 81' ' ' PRO . 66.8 mt -59.74 -34.07 54.31 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 CA-C-N 115.971 -0.559 . . . . 0.0 110.844 179.79 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 20.0 mt -91.79 -27.03 18.26 Favored 'General case' 0 C--N 1.329 -0.313 0 N-CA-C 112.655 0.613 . . . . 0.0 112.655 -179.581 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 79' ' ' THR . . . . . 0.455 ' HG1' ' HA ' ' A' ' 76' ' ' TRP . 78.6 p -90.49 -52.74 4.76 Favored 'General case' 0 N--CA 1.464 0.267 0 N-CA-C 113.747 1.017 . . . . 0.0 113.747 -177.688 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 80' ' ' THR . . . . . 0.623 ' HB ' ' HD3' ' A' ' 81' ' ' PRO . 33.1 m -48.35 -54.06 29.1 Favored Pre-proline 0 CA--C 1.531 0.228 0 N-CA-C 112.804 0.668 . . . . 0.0 112.804 -178.126 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 81' ' ' PRO . . . . . 0.623 ' HD3' ' HB ' ' A' ' 80' ' ' THR . 49.0 Cg_exo -56.43 -27.38 67.86 Favored 'Trans proline' 0 C--N 1.351 0.702 0 C-N-CA 121.572 1.515 . . . . 0.0 111.683 -179.76 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 82' ' ' LEU . . . . . 0.599 HD21 HG21 ' A' ' 43' ' ' ILE . 12.9 tp -76.96 -32.95 57.66 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 115.882 -0.599 . . . . 0.0 110.655 -179.999 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 48.5 mm -65.95 -53.85 33.52 Favored 'Isoleucine or valine' 0 C--O 1.233 0.215 0 N-CA-C 110.05 -0.352 . . . . 0.0 110.05 179.06 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 12.6 m -60.6 -29.93 45.76 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.26 0 N-CA-C 109.253 -0.647 . . . . 0.0 109.253 178.43 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 85' ' ' TYR . . . . . . . . . . . . . 66.3 t80 -65.53 -34.34 78.02 Favored 'General case' 0 N--CA 1.455 -0.215 0 CA-C-N 115.432 -0.804 . . . . 0.0 109.252 178.354 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 86' ' ' PHE . . . . . . . . . . . . . 2.1 t80 -61.31 -51.47 68.72 Favored 'General case' 0 C--O 1.231 0.129 0 CA-C-N 115.762 -0.654 . . . . 0.0 109.623 179.217 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 7.4 mp -64.0 -31.38 72.55 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 115.801 -0.636 . . . . 0.0 110.119 179.414 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -66.6 -27.78 73.39 Favored Glycine 0 N--CA 1.449 -0.459 0 C-N-CA 120.807 -0.711 . . . . 0.0 111.742 179.322 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 88.6 mt -75.96 -44.93 37.54 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 120.81 0.338 . . . . 0.0 110.691 179.586 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 80.3 mt -54.97 -38.24 67.53 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 115.904 -0.589 . . . . 0.0 110.859 179.898 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -84.34 -54.02 5.07 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.058 -0.519 . . . . 0.0 111.079 179.953 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 100.14 65.13 0.81 Allowed Glycine 0 N--CA 1.452 -0.234 0 C-N-CA 120.887 -0.673 . . . . 0.0 112.416 179.989 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 93' ' ' LEU . . . . . 0.503 ' HB3' ' HB2' ' A' ' 97' ' ' GLU . 6.9 mp -81.51 165.63 21.02 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-O 120.795 0.331 . . . . 0.0 110.746 179.932 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 94' ' ' ASP . . . . . . . . . . . . . 9.0 m-20 -82.75 178.0 8.4 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.837 179.928 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 82.5 p -64.11 -34.47 78.11 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.07 -0.513 . . . . 0.0 111.072 -179.983 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 84.6 mtm180 -73.6 -51.27 17.42 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.279 -0.418 . . . . 0.0 111.094 -179.751 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 97' ' ' GLU . . . . . 0.503 ' HB2' ' HB3' ' A' ' 93' ' ' LEU . 20.2 mt-10 -57.39 -44.4 84.44 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.453 -0.34 . . . . 0.0 110.748 -179.842 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 98' ' ' PHE . . . . . . . . . . . . . 1.7 m-85 -57.46 -50.58 72.58 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.311 -0.404 . . . . 0.0 110.933 179.812 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -54.45 -34.8 55.21 Favored Glycine 0 N--CA 1.452 -0.278 0 C-N-CA 120.883 -0.675 . . . . 0.0 112.584 -179.966 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 96.5 mt -66.74 -43.17 90.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-O 120.89 0.376 . . . . 0.0 111.632 -179.823 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 59.6 t -69.17 -44.26 80.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.629 -179.545 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 102' ' ' ILE . . . . . . . . . . . . . 37.7 mm -65.52 -46.69 89.06 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.378 0 CA-C-N 116.405 -0.361 . . . . 0.0 111.629 -179.227 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 15.3 t -61.85 -35.93 79.74 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 120.643 0.259 . . . . 0.0 111.258 -179.588 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 29.4 tp -62.62 -46.68 87.17 Favored 'General case' 0 C--N 1.332 -0.169 0 CA-C-O 120.843 0.354 . . . . 0.0 110.761 179.781 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 105' ' ' ASN . . . . . 0.55 ' N ' HD21 ' A' ' 105' ' ' ASN . 0.9 OUTLIER -64.73 -26.18 68.25 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.69 179.697 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 53.8 m -67.1 -55.23 15.14 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.124 -0.489 . . . . 0.0 111.401 -179.927 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 7.1 p -62.43 -38.53 81.53 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.193 0 CA-C-N 116.477 -0.329 . . . . 0.0 111.103 -179.841 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 59.4 t -62.58 -44.75 99.65 Favored 'Isoleucine or valine' 0 C--O 1.234 0.269 0 CA-C-O 121.051 0.453 . . . . 0.0 110.573 179.545 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 109' ' ' MET . . . . . . . . . . . . . 7.7 tpp -67.38 -25.69 66.09 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 115.979 -0.555 . . . . 0.0 110.113 179.594 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 20.2 tp -75.93 -30.95 58.9 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 115.764 -0.653 . . . . 0.0 110.296 179.633 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -66.83 -54.23 24.6 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 115.934 -0.575 . . . . 0.0 110.72 179.662 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . -62.1 -47.55 89.1 Favored Glycine 0 C--N 1.331 0.283 0 C-N-CA 120.627 -0.797 . . . . 0.0 111.976 179.558 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 113' ' ' PHE . . . . . . . . . . . . . 3.4 t80 -50.5 -58.08 6.61 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.717 0.294 . . . . 0.0 110.68 179.362 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -71.95 -16.82 62.1 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.687 179.587 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -60.4 -48.69 84.94 Favored Glycine 0 C--N 1.331 0.295 0 C-N-CA 121.091 -0.576 . . . . 0.0 112.412 179.948 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 116' ' ' ALA . . . . . 0.432 ' HB3' ' HB3' ' A' ' 183' ' ' PRO . . . -77.83 -15.05 59.35 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-O 120.773 0.321 . . . . 0.0 111.361 179.991 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 117' ' ' MET . . . . . . . . . . . . . 25.4 mmt -90.29 14.32 13.04 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.298 -0.41 . . . . 0.0 111.6 -179.433 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 118' ' ' VAL . . . . . 0.452 HG23 ' HB3' ' A' ' 123' ' ' ARG . 26.0 m -82.16 143.72 49.44 Favored Pre-proline 0 C--N 1.331 -0.229 0 CA-C-N 116.649 -0.251 . . . . 0.0 111.196 -179.959 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 119' ' ' PRO . . . . . . . . . . . . . 67.8 Cg_endo -92.9 -1.48 3.64 Favored 'Trans proline' 0 N--CA 1.457 -0.668 0 C-N-CA 122.907 2.405 . . . . 0.0 112.416 179.551 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -138.18 -114.16 1.23 Allowed Glycine 0 C--N 1.333 0.371 0 C-N-CA 120.694 -0.765 . . . . 0.0 113.029 -179.655 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 37.0 pt -126.15 13.13 3.99 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.188 0 CA-C-O 120.781 0.324 . . . . 0.0 111.683 -179.564 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 12.2 mm-40 -61.27 -18.8 60.24 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.332 -0.395 . . . . 0.0 111.187 -179.986 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 123' ' ' ARG . . . . . 0.452 ' HB3' HG23 ' A' ' 118' ' ' VAL . 28.0 ptt180 -50.65 -38.26 45.42 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 116.0 -0.545 . . . . 0.0 111.672 -179.828 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 124' ' ' TYR . . . . . . . . . . . . . 57.5 m-85 -64.9 -33.5 76.17 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.401 -0.363 . . . . 0.0 111.241 -179.605 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 125' ' ' ALA . . . . . . . . . . . . . . . -71.98 -56.0 6.44 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 120.946 0.403 . . . . 0.0 111.204 -179.998 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 1.2 mt -52.11 -52.36 51.98 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 115.923 -0.58 . . . . 0.0 111.011 -179.871 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 127' ' ' PHE . . . . . . . . . . . . . 11.6 t80 -64.0 -37.66 88.24 Favored 'General case' 0 N--CA 1.453 -0.304 0 C-N-CA 120.778 -0.369 . . . . 0.0 110.866 179.927 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 128' ' ' GLY . . . . . . . . . . . . . . . -46.47 -44.6 16.28 Favored Glycine 0 C--N 1.332 0.349 0 C-N-CA 120.227 -0.987 . . . . 0.0 110.95 179.35 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 129' ' ' MET . . . . . . . . . . . . . 0.3 OUTLIER -70.56 -37.01 73.94 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 115.392 -0.404 . . . . 0.0 109.947 178.839 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -68.77 -26.92 74.24 Favored Glycine 0 C--N 1.331 0.3 0 CA-C-N 115.842 -0.617 . . . . 0.0 112.94 -179.872 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 131' ' ' ALA . . . . . 0.448 ' O ' ' HB3' ' A' ' 134' ' ' PHE . . . -74.66 -53.6 9.0 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.821 0.343 . . . . 0.0 110.208 179.869 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 58.0 t -58.56 -39.92 77.19 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 N-CA-C 109.09 -0.707 . . . . 0.0 109.09 178.486 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -66.87 -35.31 79.74 Favored 'General case' 0 N--CA 1.453 -0.313 0 CA-C-N 115.276 -0.875 . . . . 0.0 110.412 179.21 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 134' ' ' PHE . . . . . 0.448 ' HB3' ' O ' ' A' ' 131' ' ' ALA . 17.6 t80 -54.26 -56.63 16.49 Favored 'General case' 0 N--CA 1.455 -0.208 0 CA-C-N 116.128 -0.487 . . . . 0.0 109.889 179.425 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 135' ' ' ILE . . . . . 0.443 ' O ' HG23 ' A' ' 138' ' ' VAL . 34.7 mt -56.69 -33.4 40.26 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.323 0 CA-C-N 115.564 -0.744 . . . . 0.0 110.082 179.388 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . -59.87 -35.99 88.57 Favored Glycine 0 N--CA 1.449 -0.447 0 C-N-CA 120.241 -0.981 . . . . 0.0 111.108 178.679 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 137' ' ' LEU . . . . . 0.55 HD11 HD22 ' A' ' 105' ' ' ASN . 56.1 tp -70.86 -55.49 8.38 Favored 'General case' 0 N--CA 1.453 -0.276 0 CA-C-N 115.772 -0.214 . . . . 0.0 110.671 179.376 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 138' ' ' VAL . . . . . 0.443 HG23 ' O ' ' A' ' 135' ' ' ILE . 3.1 m -54.87 -30.3 22.83 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.222 0 N-CA-C 109.171 -0.677 . . . . 0.0 109.171 179.715 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 139' ' ' TYR . . . . . . . . . . . . . 27.1 t80 -62.49 -43.61 98.39 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 115.168 -0.923 . . . . 0.0 109.956 178.083 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 22.2 m-85 -67.48 -44.35 78.78 Favored 'General case' 0 C--O 1.232 0.151 0 CA-C-N 116.301 -0.409 . . . . 0.0 110.467 179.011 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 141' ' ' LEU . . . . . . . . . . . . . 11.0 mp -55.02 -32.57 61.94 Favored 'General case' 0 C--N 1.332 -0.183 0 CA-C-N 116.004 -0.544 . . . . 0.0 111.253 -179.719 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 10.8 p -101.44 -10.19 8.99 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-O 121.055 0.455 . . . . 0.0 110.693 179.929 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . -75.99 -135.54 0.56 Allowed Glycine 0 CA--C 1.522 0.476 0 CA-C-N 115.852 -0.613 . . . . 0.0 112.693 -179.902 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 144' ' ' PRO . . . . . . . . . . . . . 50.0 Cg_exo -53.25 -23.95 24.98 Favored 'Trans proline' 0 C--N 1.347 0.478 0 C-N-CA 122.659 2.239 . . . . 0.0 113.055 -179.688 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 145' ' ' MET . . . . . 0.553 ' HB3' ' HH ' ' A' ' 160' ' ' TYR . 41.2 mtt -57.33 -38.01 73.41 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-O 120.67 0.271 . . . . 0.0 111.549 -179.623 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 146' ' ' THR . . . . . . . . . . . . . 60.4 p -65.45 -49.06 70.55 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.443 -0.344 . . . . 0.0 111.686 -179.443 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 43.9 mt-10 -71.48 -25.4 62.26 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.422 -0.354 . . . . 0.0 111.532 -179.462 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 148' ' ' SER . . . . . . . . . . . . . 48.2 t -68.89 -46.28 68.78 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-O 120.935 0.398 . . . . 0.0 110.827 -179.574 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 149' ' ' ALA . . . . . 0.492 ' HB1' HG22 ' A' ' 156' ' ' ILE . . . -78.13 -32.14 50.25 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.028 -0.533 . . . . 0.0 111.357 -179.858 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 150' ' ' SER . . . . . . . . . . . . . 41.6 t -63.07 -14.83 53.08 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.02 -0.536 . . . . 0.0 111.555 -179.603 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 151' ' ' GLN . . . . . . . . . . . . . 9.8 pt20 -110.71 17.2 20.87 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.659 -0.246 . . . . 0.0 111.624 -179.747 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 29.7 mmt180 -98.64 -52.51 3.59 Favored 'General case' 0 C--N 1.332 -0.184 0 C-N-CA 120.856 -0.338 . . . . 0.0 110.803 179.613 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 153' ' ' SER . . . . . 0.604 ' HB3' HG12 ' A' ' 156' ' ' ILE . 21.0 t -158.1 172.2 18.84 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.792 179.007 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 154' ' ' SER . . . . . . . . . . . . . 43.3 t -71.94 -38.4 69.83 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.307 -0.406 . . . . 0.0 110.385 179.303 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -76.87 -37.68 33.02 Favored Glycine 0 N--CA 1.45 -0.384 0 C-N-CA 120.924 -0.655 . . . . 0.0 112.647 179.8 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 156' ' ' ILE . . . . . 0.604 HG12 ' HB3' ' A' ' 153' ' ' SER . 37.8 mm -52.25 -39.79 28.77 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.236 0 CA-C-O 120.724 0.297 . . . . 0.0 111.431 -179.563 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 157' ' ' LYS . . . . . . . . . . . . . 56.0 tttm -69.65 -34.59 74.22 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-N 116.318 -0.401 . . . . 0.0 111.138 -179.921 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 46.5 t -72.25 -39.96 68.06 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 120.942 0.401 . . . . 0.0 111.309 -179.208 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 159' ' ' LEU . . . . . 0.404 HD11 ' HB1' ' A' ' 215' ' ' ALA . 12.9 mt -72.58 -35.19 67.86 Favored 'General case' 0 C--N 1.326 -0.449 0 CA-C-N 116.066 -0.516 . . . . 0.0 111.315 -179.314 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 160' ' ' TYR . . . . . 0.553 ' HH ' ' HB3' ' A' ' 145' ' ' MET . 37.5 t80 -70.38 -42.36 71.83 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.648 -0.251 . . . . 0.0 111.599 -179.075 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 23.0 m -65.06 -43.91 95.87 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-O 120.719 0.295 . . . . 0.0 111.367 -179.644 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 162' ' ' ARG . . . . . . . . . . . . . 21.2 mmm180 -69.29 -46.53 66.96 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.914 0.387 . . . . 0.0 111.248 179.994 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 163' ' ' LEU . . . . . . . . . . . . . 1.3 mp -61.79 -54.8 37.33 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 115.971 -0.559 . . . . 0.0 111.702 -179.548 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 164' ' ' ARG . . . . . . . . . . . . . 25.4 ttp85 -58.09 -48.23 80.8 Favored 'General case' 0 C--N 1.331 -0.237 0 N-CA-C 112.459 0.54 . . . . 0.0 112.459 -178.843 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 165' ' ' ASN . . . . . 0.464 ' N ' HD21 ' A' ' 165' ' ' ASN . 0.9 OUTLIER -52.34 -51.38 59.1 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-O 120.942 0.401 . . . . 0.0 110.719 -179.205 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 166' ' ' LEU . . . . . 0.528 ' O ' ' HG ' ' A' ' 170' ' ' LEU . 3.6 tt -65.41 -41.48 93.58 Favored 'General case' 0 C--N 1.324 -0.515 0 CA-C-N 116.089 -0.505 . . . . 0.0 111.36 -179.895 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 167' ' ' THR . . . . . 0.401 ' O ' ' HB2' ' A' ' 171' ' ' TRP . 51.1 m -65.18 -54.11 34.69 Favored 'General case' 0 C--N 1.331 -0.232 0 N-CA-C 112.51 0.559 . . . . 0.0 112.51 -178.465 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 168' ' ' VAL . . . . . . . . . . . . . 9.1 p -54.47 -40.46 49.54 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-O 120.644 0.259 . . . . 0.0 111.67 -179.385 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 169' ' ' VAL . . . . . 0.436 HG22 ' O ' ' A' ' 165' ' ' ASN . 55.5 t -59.72 -65.11 0.49 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.486 -0.324 . . . . 0.0 111.634 -179.844 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 170' ' ' LEU . . . . . 0.528 ' HG ' ' O ' ' A' ' 166' ' ' LEU . 2.0 pp -62.79 -27.14 69.09 Favored 'General case' 0 C--N 1.33 -0.262 0 N-CA-C 112.139 0.422 . . . . 0.0 112.139 -178.806 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 171' ' ' TRP . . . . . 0.439 ' HZ3' HD22 ' A' ' 137' ' ' LEU . 1.8 m0 -73.35 -32.48 64.56 Favored 'General case' 0 C--N 1.33 -0.245 0 C-N-CA 120.588 -0.445 . . . . 0.0 110.707 179.69 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 172' ' ' ALA . . . . . 0.409 ' HA ' ' CZ ' ' A' ' 134' ' ' PHE . . . -67.94 -7.76 31.26 Favored 'General case' 0 CA--C 1.52 -0.208 0 CA-C-O 121.345 0.593 . . . . 0.0 110.157 179.287 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 173' ' ' ILE . . . . . 0.554 ' O ' HG12 ' A' ' 177' ' ' ILE . 9.0 mm -84.15 -36.26 11.79 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.555 0 CA-C-N 114.954 -1.021 . . . . 0.0 111.501 -179.03 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 174' ' ' TYR . . . . . 0.54 ' N ' ' HD2' ' A' ' 175' ' ' PRO . 70.2 m-85 -55.56 -51.66 78.26 Favored Pre-proline 0 C--N 1.328 -0.33 0 N-CA-C 112.507 0.558 . . . . 0.0 112.507 -178.9 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 175' ' ' PRO . . . . . 0.54 ' HD2' ' N ' ' A' ' 174' ' ' TYR . 26.7 Cg_endo -60.19 -41.12 53.98 Favored 'Trans proline' 0 C--N 1.349 0.57 0 C-N-CA 122.107 1.871 . . . . 0.0 113.359 -178.776 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 176' ' ' PHE . . . . . 0.523 ' CE2' ' HA ' ' A' ' 173' ' ' ILE . 0.1 OUTLIER -79.83 -37.83 34.18 Favored 'General case' 0 C--N 1.329 -0.32 0 C-N-CA 120.609 -0.437 . . . . 0.0 112.12 -178.413 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 177' ' ' ILE . . . . . 0.554 HG12 ' O ' ' A' ' 173' ' ' ILE . 32.4 mm -63.76 -47.33 91.49 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.614 0 CA-C-O 120.873 0.368 . . . . 0.0 110.032 178.425 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 178' ' ' TRP . . . . . . . . . . . . . 60.5 t90 -52.91 -29.61 29.46 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 115.788 -0.642 . . . . 0.0 109.857 179.202 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 179' ' ' LEU . . . . . 0.404 HD13 ' O ' ' A' ' 179' ' ' LEU . 0.9 OUTLIER -72.76 -37.56 67.63 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 115.359 -0.837 . . . . 0.0 110.689 179.898 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 180' ' ' LEU . . . . . 0.415 ' HG ' ' O ' ' A' ' 176' ' ' PHE . 0.9 OUTLIER -78.31 -51.79 9.59 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.548 -0.296 . . . . 0.0 111.626 -179.399 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . -51.13 171.8 0.2 Allowed Glycine 0 C--N 1.336 0.551 0 C-N-CA 120.941 -0.647 . . . . 0.0 113.292 -179.685 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 182' ' ' PRO . . . . . 0.576 ' N ' ' HD2' ' A' ' 183' ' ' PRO . 2.5 Cg_endo -42.68 -47.81 7.59 Favored 'Trans proline' 0 C--N 1.351 0.661 0 C-N-CA 123.316 2.678 . . . . 0.0 114.015 -179.837 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 183' ' ' PRO . . . . . 0.576 ' HD2' ' N ' ' A' ' 182' ' ' PRO . 9.4 Cg_endo -50.04 -29.93 23.2 Favored 'Trans proline' 0 C--N 1.357 0.992 0 C-N-CA 122.269 1.979 . . . . 0.0 112.62 -179.754 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 184' ' ' GLY . . . . . . . . . . . . . . . -95.93 -105.08 2.12 Favored Glycine 0 N--CA 1.45 -0.368 0 C-N-CA 120.716 -0.754 . . . . 0.0 112.73 -179.904 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 185' ' ' VAL . . . . . . . . . . . . . 0.9 OUTLIER -109.4 -0.37 9.68 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-O 120.672 0.272 . . . . 0.0 111.654 -179.525 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 186' ' ' ALA . . . . . . . . . . . . . . . 55.31 84.88 0.07 Allowed 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.26 -0.427 . . . . 0.0 111.74 179.535 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 187' ' ' LEU . . . . . 0.405 ' HG ' ' HA ' ' A' ' 180' ' ' LEU . 16.4 mt -92.3 -49.44 6.16 Favored 'General case' 0 C--N 1.332 -0.162 0 CA-C-O 121.041 0.448 . . . . 0.0 110.676 179.452 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 188' ' ' LEU . . . . . . . . . . . . . 72.8 mt -102.81 -160.64 0.79 Allowed 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 115.763 -0.653 . . . . 0.0 111.282 -179.409 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 189' ' ' THR . . . . . 0.416 ' HB ' HG22 ' A' ' 192' ' ' VAL . 10.4 m -88.11 136.64 31.85 Favored Pre-proline 0 C--N 1.33 -0.249 0 CA-C-N 115.866 -0.607 . . . . 0.0 110.615 -179.805 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 190' ' ' PRO . . . . . . . . . . . . . 82.1 Cg_exo -46.58 -49.74 11.55 Favored 'Trans proline' 0 C--N 1.35 0.607 0 C-N-CA 122.614 2.209 . . . . 0.0 113.053 -179.63 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 191' ' ' THR . . . . . . . . . . . . . 7.1 t -61.4 -35.6 77.95 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.485 -0.325 . . . . 0.0 111.77 -179.478 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 192' ' ' VAL . . . . . 0.416 HG22 ' HB ' ' A' ' 189' ' ' THR . 89.3 t -71.45 -47.09 60.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-O 120.833 0.349 . . . . 0.0 111.278 -179.708 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 193' ' ' ASP . . . . . . . . . . . . . 24.4 t70 -58.93 -43.98 91.27 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.752 -179.944 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 194' ' ' VAL . . . . . . . . . . . . . 78.3 t -63.16 -37.98 80.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.929 179.787 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 195' ' ' ALA . . . . . . . . . . . . . . . -57.22 -46.56 82.83 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.484 -0.325 . . . . 0.0 111.093 179.829 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 196' ' ' LEU . . . . . 0.417 ' O ' ' HB3' ' A' ' 199' ' ' TYR . 80.8 mt -67.75 -33.44 74.87 Favored 'General case' 0 C--N 1.332 -0.188 0 CA-C-N 116.381 -0.372 . . . . 0.0 110.633 179.691 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 197' ' ' ILE . . . . . 0.494 HD12 HD12 ' A' ' 200' ' ' LEU . 21.1 mm -64.57 -50.48 75.69 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.112 179.126 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 198' ' ' VAL . . . . . . . . . . . . . 85.0 t -56.72 -34.08 42.11 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.478 0 N-CA-C 108.707 -0.849 . . . . 0.0 108.707 178.171 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 199' ' ' TYR . . . . . 0.417 ' HB3' ' O ' ' A' ' 196' ' ' LEU . 80.5 t80 -68.38 -43.72 76.69 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 114.939 -1.028 . . . . 0.0 110.167 179.544 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 200' ' ' LEU . . . . . 0.494 HD12 HD12 ' A' ' 197' ' ' ILE . 65.0 mt -56.61 -55.02 39.25 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 115.496 -0.775 . . . . 0.0 111.172 -179.667 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 201' ' ' ASP . . . . . . . . . . . . . 11.6 m-20 -64.82 -38.07 89.74 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.85 179.918 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 202' ' ' LEU . . . . . . . . . . . . . 23.5 tp -64.99 -26.05 68.12 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 115.703 -0.681 . . . . 0.0 111.393 -179.554 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 203' ' ' VAL . . . . . 0.422 HG12 HD23 ' A' ' 170' ' ' LEU . 45.0 t -82.58 -36.55 13.54 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.365 0 CA-C-N 116.635 -0.257 . . . . 0.0 111.454 -179.397 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 204' ' ' THR . . . . . . . . . . . . . 88.2 m -63.51 -49.18 74.55 Favored 'General case' 0 C--N 1.329 -0.318 0 C-N-CA 120.773 -0.371 . . . . 0.0 111.319 179.837 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 205' ' ' LYS . . . . . 0.679 ' HE2' ' HB2' ' A' ' 47' ' ' ALA . 61.0 mttp -73.32 -46.79 47.38 Favored 'General case' 0 C--N 1.326 -0.429 0 N-CA-C 111.934 0.346 . . . . 0.0 111.934 -178.926 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 94.9 t -74.14 -50.57 27.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-O 120.572 0.225 . . . . 0.0 111.398 -179.805 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 207' ' ' GLY . . . . . . . . . . . . . . . -60.0 -58.19 15.43 Favored Glycine 0 CA--C 1.519 0.292 0 C-N-CA 121.112 -0.566 . . . . 0.0 112.862 179.988 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 208' ' ' PHE . . . . . 0.443 ' O ' ' N ' ' A' ' 212' ' ' ALA . 4.3 t80 -56.27 -44.35 79.66 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.601 0.239 . . . . 0.0 110.744 179.75 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 209' ' ' GLY . . . . . 0.439 ' HA2' ' HB3' ' A' ' 212' ' ' ALA . . . -66.36 -37.7 93.0 Favored Glycine 0 C--N 1.33 0.243 0 CA-C-N 115.811 -0.631 . . . . 0.0 113.41 -179.686 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 210' ' ' PHE . . . . . . . . . . . . . 1.7 m-85 -69.14 -43.85 73.52 Favored 'General case' 0 CA--C 1.51 -0.592 0 N-CA-C 107.64 -1.244 . . . . 0.0 107.64 178.99 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 211' ' ' ILE . . . . . . . . . . . . . 79.8 mt -65.76 -29.62 47.54 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.827 0 N-CA-C 107.193 -1.41 . . . . 0.0 107.193 176.319 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 212' ' ' ALA . . . . . 0.443 ' N ' ' O ' ' A' ' 208' ' ' PHE . . . -68.94 -34.92 76.14 Favored 'General case' 0 N--CA 1.449 -0.483 0 CA-C-N 114.437 -1.256 . . . . 0.0 109.969 179.413 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 213' ' ' LEU . . . . . . . . . . . . . 57.6 mt -70.35 -55.34 9.37 Favored 'General case' 0 C--N 1.331 -0.205 0 CA-C-N 115.056 -0.975 . . . . 0.0 111.458 -179.55 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 214' ' ' ASP . . . . . . . . . . . . . 16.7 t70 -59.48 -26.88 65.63 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.284 -0.416 . . . . 0.0 110.59 179.974 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 215' ' ' ALA . . . . . 0.404 ' HB1' HD11 ' A' ' 159' ' ' LEU . . . -71.04 -57.69 4.29 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 115.906 -0.588 . . . . 0.0 111.521 -179.911 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 216' ' ' ALA . . . . . . . . . . . . . . . -62.76 -37.49 86.84 Favored 'General case' 0 C--N 1.332 -0.187 0 CA-C-N 116.43 -0.35 . . . . 0.0 111.267 -179.702 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 217' ' ' ALA . . . . . . . . . . . . . . . -60.06 -42.98 95.66 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.312 -0.404 . . . . 0.0 110.3 179.531 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 218' ' ' THR . . . . . . . . . . . . . 98.3 m . . . . . 0 C--N 1.329 -0.284 0 CA-C-N 115.865 -0.607 . . . . 0.0 110.57 179.405 . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.3 0 N-CA-C 112.72 -0.152 . . . . 0.0 112.72 . . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 59.0 tp -74.44 -38.16 63.08 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.886 0.375 . . . . 0.0 110.988 -179.967 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 40.6 p -65.0 -29.57 70.5 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 115.936 -0.574 . . . . 0.0 111.442 -179.74 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 17.8 p -51.92 -35.22 44.92 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.278 -0.419 . . . . 0.0 111.561 -179.497 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 7' ' ' LEU . . . . . . . . . . . . . 4.0 mm? -58.22 -53.4 58.73 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.332 -0.395 . . . . 0.0 111.216 -179.877 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 8' ' ' PHE . . . . . 0.403 ' HB2' ' HB2' ' A' ' 55' ' ' ALA . 74.2 m-85 -61.47 -35.21 77.0 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.826 179.998 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 9' ' ' TRP . . . . . . . . . . . . . 55.2 m95 -64.74 -41.26 96.07 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 115.991 -0.55 . . . . 0.0 110.227 179.916 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 44.9 mt -62.37 -46.46 88.54 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 115.817 -0.629 . . . . 0.0 110.461 179.53 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . 0.403 ' O ' ' HG2' ' A' ' 15' ' ' MET . . . -61.99 -32.57 82.62 Favored Glycine 0 N--CA 1.45 -0.425 0 C-N-CA 120.703 -0.761 . . . . 0.0 111.817 179.369 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -67.56 -34.26 76.7 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-O 120.83 0.348 . . . . 0.0 110.707 179.852 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 65.6 mt -65.97 -46.94 86.9 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.238 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.144 179.396 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -59.83 -33.48 78.43 Favored Glycine 0 N--CA 1.45 -0.388 0 C-N-CA 120.726 -0.75 . . . . 0.0 111.712 179.208 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 15' ' ' MET . . . . . 0.643 ' HE2' ' HD2' ' A' ' 205' ' ' LYS . 24.1 mmt -70.33 -40.56 74.08 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 120.861 0.362 . . . . 0.0 110.507 179.425 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 27.9 tp -57.66 -39.31 76.77 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.047 -0.524 . . . . 0.0 110.562 179.792 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 56.1 t -67.28 -48.0 79.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.062 -0.517 . . . . 0.0 110.89 179.973 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -62.57 -49.33 74.45 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.705 -0.759 . . . . 0.0 111.86 179.507 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 38.2 m -49.65 -44.49 47.7 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-O 120.721 0.296 . . . . 0.0 111.279 -179.828 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 79.6 mt -72.14 -44.32 63.31 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.244 -0.434 . . . . 0.0 111.664 179.819 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -60.93 -29.93 69.91 Favored 'General case' 0 C--N 1.329 -0.299 0 N-CA-C 112.18 0.437 . . . . 0.0 112.18 -179.14 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 22' ' ' PHE . . . . . 0.464 ' HB2' HG23 ' A' ' 41' ' ' VAL . 8.7 m-85 -90.61 -34.57 15.42 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.757 0.313 . . . . 0.0 111.411 -179.31 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -67.58 -50.61 57.55 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 121.038 0.447 . . . . 0.0 111.319 -179.764 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 24' ' ' TRP . . . . . . . . . . . . . 4.7 t-105 -62.18 -37.16 84.19 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-N 115.698 -0.683 . . . . 0.0 111.187 -179.899 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.329 -0.325 0 CA-C-O 120.853 0.359 . . . . 0.0 111.118 -179.994 . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.326 0 N-CA-C 112.87 -0.092 . . . . 0.0 112.87 . . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 13.7 mm-40 -86.69 -21.47 26.65 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.663 0.268 . . . . 0.0 111.106 -179.654 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 34' ' ' ARG . . . . . . . . . . . . . 37.2 ttm180 -54.54 -29.63 51.5 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.31 -0.405 . . . . 0.0 111.416 -179.401 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 55.0 ttp180 -59.17 -40.87 86.96 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.852 0.358 . . . . 0.0 110.828 -179.899 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 63.7 m-85 -72.74 -31.21 64.78 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.123 -0.489 . . . . 0.0 110.997 -179.971 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 37' ' ' TYR . . . . . . . . . . . . . 65.9 m-85 -70.34 -54.85 10.84 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.197 -179.876 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 78.4 t -57.14 -38.99 63.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-O 120.873 0.368 . . . . 0.0 110.573 179.776 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 19.1 m -63.19 -50.48 70.14 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 115.929 -0.578 . . . . 0.0 110.79 179.405 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 40' ' ' LEU . . . . . 0.608 HD12 HD13 ' A' ' 43' ' ' ILE . 41.4 tp -56.99 -45.77 82.74 Favored 'General case' 0 C--O 1.235 0.323 0 CA-C-N 115.693 -0.685 . . . . 0.0 110.739 179.937 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . 0.464 HG23 ' HB2' ' A' ' 22' ' ' PHE . 94.3 t -62.16 -33.56 59.24 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.497 0 CA-C-N 116.103 -0.498 . . . . 0.0 109.698 179.001 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -58.17 -48.78 81.11 Favored Glycine 0 N--CA 1.45 -0.378 0 CA-C-N 115.49 -0.777 . . . . 0.0 113.135 179.888 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 43' ' ' ILE . . . . . 0.608 HD13 HD12 ' A' ' 40' ' ' LEU . 17.0 pt -64.72 -47.02 90.45 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.215 0 CA-C-N 117.213 0.506 . . . . 0.0 111.599 -179.61 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 67.9 m -61.92 -27.88 69.13 Favored 'General case' 0 C--O 1.232 0.149 0 CA-C-O 120.907 0.384 . . . . 0.0 110.945 179.496 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -79.45 -52.86 4.6 Favored Glycine 0 CA--C 1.517 0.212 0 CA-C-N 115.934 -0.575 . . . . 0.0 113.423 -179.119 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 46' ' ' ILE . . . . . 0.501 HG13 HG23 ' A' ' 79' ' ' THR . 7.2 pt -57.81 -40.22 74.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-O 121.001 0.429 . . . . 0.0 111.002 -179.613 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 47' ' ' ALA . . . . . 0.595 ' HB2' ' HE2' ' A' ' 205' ' ' LYS . . . -68.31 -42.82 78.83 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.21 179.195 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 48' ' ' ALA . . . . . 0.405 ' HB1' ' HB3' ' A' ' 15' ' ' MET . . . -54.24 -43.18 70.69 Favored 'General case' 0 C--O 1.232 0.16 0 CA-C-N 116.326 -0.397 . . . . 0.0 111.763 -179.339 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 32.5 m -73.28 -34.22 43.38 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 116.492 -0.322 . . . . 0.0 111.445 -179.572 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -64.07 -37.79 88.73 Favored 'General case' 0 C--N 1.332 -0.174 0 CA-C-O 120.897 0.379 . . . . 0.0 111.217 179.827 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 35.6 m-85 -72.18 -39.27 68.77 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 115.996 -0.547 . . . . 0.0 110.704 -179.623 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -62.82 -50.52 70.63 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 115.944 -0.571 . . . . 0.0 111.301 179.739 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 18.5 m -65.6 -43.06 94.13 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.189 0 CA-C-N 116.365 -0.379 . . . . 0.0 111.281 -179.666 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 54' ' ' MET . . . . . 0.452 ' HG3' ' HE1' ' A' ' 60' ' ' TRP . 10.9 ttp -68.55 -29.98 68.66 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.886 0.374 . . . . 0.0 110.306 179.897 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 55' ' ' ALA . . . . . 0.403 ' HB2' ' HB2' ' A' ' 8' ' ' PHE . . . -64.67 -36.86 85.65 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 115.939 -0.573 . . . . 0.0 110.939 179.328 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 86.7 mt -74.45 -1.0 19.23 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.061 -0.518 . . . . 0.0 111.245 -179.681 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 92.78 4.31 65.48 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.668 -0.777 . . . . 0.0 112.448 179.987 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 46.8 t -74.08 144.63 12.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-O 120.819 0.342 . . . . 0.0 111.187 -179.915 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 59' ' ' GLY . . . . . 0.402 ' HA3' ' HD3' ' A' ' 71' ' ' PRO . . . 76.7 5.86 84.09 Favored Glycine 0 CA--C 1.519 0.335 0 C-N-CA 120.946 -0.645 . . . . 0.0 112.815 -179.975 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 60' ' ' TRP . . . . . 0.452 ' HE1' ' HG3' ' A' ' 54' ' ' MET . 24.7 m0 -81.8 118.06 22.58 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.684 0.278 . . . . 0.0 111.076 -179.908 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 61' ' ' VAL . . . . . 0.457 HG13 ' HE1' ' A' ' 117' ' ' MET . 7.3 p -115.49 126.33 27.87 Favored Pre-proline 0 CA--C 1.533 0.313 0 CA-C-N 116.491 -0.322 . . . . 0.0 111.307 179.757 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 9.2 Cg_exo -72.13 142.69 38.52 Favored 'Trans proline' 0 C--N 1.349 0.603 0 C-N-CA 122.705 2.27 . . . . 0.0 112.081 179.739 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 98.1 t -142.36 94.33 0.57 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.064 179.968 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . 58.58 -90.14 0.03 OUTLIER 'General case' 0 C--N 1.332 -0.182 0 CA-C-N 115.973 -0.558 . . . . 0.0 111.622 179.857 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 18.5 mm-40 -117.36 -21.53 8.65 Favored 'General case' 0 C--N 1.332 -0.161 0 CA-C-N 116.39 -0.368 . . . . 0.0 111.048 -179.694 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 66' ' ' ARG . . . . . . . . . . . . . 30.7 ptt180 -107.17 158.64 16.94 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.174 -0.467 . . . . 0.0 110.629 179.911 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 60.5 m -117.76 115.24 24.62 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.386 -0.37 . . . . 0.0 111.651 -179.514 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 21.0 t -87.47 146.79 5.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 115.92 -0.582 . . . . 0.0 110.415 179.436 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 69' ' ' PHE . . . . . . . . . . . . . 26.6 m-85 -108.03 114.19 27.92 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-O 120.903 0.382 . . . . 0.0 110.096 -179.557 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 70' ' ' VAL . . . . . 0.584 ' N ' ' HD2' ' A' ' 71' ' ' PRO . 12.4 t -67.7 -48.98 41.19 Favored Pre-proline 0 C--N 1.324 -0.524 0 CA-C-N 115.921 -0.582 . . . . 0.0 112.117 -178.982 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 71' ' ' PRO . . . . . 0.584 ' HD2' ' N ' ' A' ' 70' ' ' VAL . 30.0 Cg_endo -62.64 -17.67 59.88 Favored 'Trans proline' 0 C--N 1.351 0.677 0 C-N-CA 122.166 1.91 . . . . 0.0 112.508 -179.64 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 34.2 ttp180 -69.75 -55.4 9.99 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.431 -0.349 . . . . 0.0 111.53 -179.455 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 73' ' ' TYR . . . . . 0.487 ' O ' HG13 ' A' ' 77' ' ' ILE . 74.0 m-85 -70.99 -36.39 72.47 Favored 'General case' 0 C--N 1.33 -0.264 0 C-N-CA 120.854 -0.338 . . . . 0.0 110.602 -179.577 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 0.3 OUTLIER -64.78 -41.43 92.17 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.199 0 N-CA-C 109.935 -0.394 . . . . 0.0 109.935 179.291 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 10.7 t70 -56.97 -38.1 72.51 Favored 'General case' 0 CA--C 1.518 -0.276 0 N-CA-C 109.007 -0.738 . . . . 0.0 109.007 178.531 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 76' ' ' TRP . . . . . 0.435 ' HA ' ' OG1' ' A' ' 79' ' ' THR . 44.6 m0 -66.88 -30.31 70.44 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 115.588 -0.733 . . . . 0.0 110.895 179.27 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 77' ' ' ILE . . . . . 0.522 ' O ' ' HG2' ' A' ' 81' ' ' PRO . 69.8 mt -67.13 -36.54 77.18 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.302 -0.408 . . . . 0.0 111.032 179.842 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 78' ' ' LEU . . . . . 0.55 HD13 HG22 ' A' ' 79' ' ' THR . 2.7 pp -91.59 -23.24 19.95 Favored 'General case' 0 C--N 1.326 -0.448 0 N-CA-C 112.76 0.652 . . . . 0.0 112.76 -179.871 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 79' ' ' THR . . . . . 0.55 HG22 HD13 ' A' ' 78' ' ' LEU . 40.9 p -88.05 -53.77 4.56 Favored 'General case' 0 N--CA 1.471 0.582 0 N-CA-C 113.49 0.922 . . . . 0.0 113.49 -179.011 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 80' ' ' THR . . . . . 0.614 ' HB ' ' HD3' ' A' ' 81' ' ' PRO . 18.2 m -53.69 -55.45 35.3 Favored Pre-proline 0 C--N 1.331 -0.21 0 N-CA-C 113.192 0.812 . . . . 0.0 113.192 -177.475 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 81' ' ' PRO . . . . . 0.614 ' HD3' ' HB ' ' A' ' 80' ' ' THR . 77.1 Cg_exo -53.45 -25.47 32.04 Favored 'Trans proline' 0 C--N 1.35 0.63 0 C-N-CA 121.567 1.511 . . . . 0.0 112.09 -179.842 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 82' ' ' LEU . . . . . . . . . . . . . 11.5 tp -76.69 -33.17 58.24 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.171 179.521 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 83' ' ' ILE . . . . . 0.43 HD13 HG22 ' A' ' 43' ' ' ILE . 36.6 mm -66.54 -53.37 36.32 Favored 'Isoleucine or valine' 0 C--O 1.234 0.255 0 CA-C-N 116.172 -0.467 . . . . 0.0 109.955 178.678 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 33.8 m -61.21 -30.05 47.06 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.217 0 CA-C-N 115.887 -0.597 . . . . 0.0 109.61 178.875 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 85' ' ' TYR . . . . . . . . . . . . . 85.4 t80 -67.92 -31.41 71.15 Favored 'General case' 0 N--CA 1.453 -0.285 0 CA-C-N 115.566 -0.743 . . . . 0.0 109.379 178.758 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 86' ' ' PHE . . . . . . . . . . . . . 7.6 t80 -62.51 -51.51 67.13 Favored 'General case' 0 N--CA 1.455 -0.211 0 CA-C-N 115.755 -0.657 . . . . 0.0 109.598 179.087 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 7.2 mt -61.91 -33.06 73.54 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 115.813 -0.631 . . . . 0.0 109.913 179.205 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -66.58 -27.66 73.31 Favored Glycine 0 N--CA 1.452 -0.293 0 CA-C-N 115.25 -0.886 . . . . 0.0 112.044 179.425 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 65.4 mt -74.18 -44.48 53.29 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-O 121.028 0.442 . . . . 0.0 110.749 179.826 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 78.4 mt -61.23 -31.85 71.63 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 115.823 -0.626 . . . . 0.0 111.151 -179.937 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -88.36 -38.77 14.84 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.328 -0.396 . . . . 0.0 111.788 -179.433 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 85.09 70.62 1.33 Allowed Glycine 0 CA--C 1.517 0.187 0 C-N-CA 120.701 -0.761 . . . . 0.0 112.145 -179.316 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 93' ' ' LEU . . . . . 0.463 HD13 ' HE2' ' A' ' 145' ' ' MET . 20.0 mt -87.58 169.11 12.45 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.906 0.384 . . . . 0.0 111.371 -179.447 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 94' ' ' ASP . . . . . 0.447 ' HB3' ' HG3' ' A' ' 97' ' ' GLU . 18.6 t70 -79.77 161.56 25.64 Favored 'General case' 0 C--N 1.332 -0.168 0 CA-C-N 116.027 -0.533 . . . . 0.0 110.599 179.661 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 71.0 m -55.91 -44.79 78.61 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.418 -0.356 . . . . 0.0 111.126 -179.972 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 10.2 mpt_? -68.78 -48.02 64.72 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.169 -179.804 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 97' ' ' GLU . . . . . 0.447 ' HG3' ' HB3' ' A' ' 94' ' ' ASP . 47.3 mt-10 -53.95 -38.7 65.23 Favored 'General case' 0 C--O 1.234 0.238 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.839 -179.931 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 98' ' ' PHE . . . . . 0.467 ' O ' HG12 ' A' ' 102' ' ' ILE . 5.6 m-85 -60.08 -49.96 75.58 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.392 179.4 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -59.26 -26.16 61.15 Favored Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.705 -0.759 . . . . 0.0 112.515 179.97 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 100' ' ' ILE . . . . . 0.437 HD11 ' HA ' ' A' ' 97' ' ' GLU . 97.7 mt -68.85 -50.61 52.98 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.194 0 CA-C-O 120.803 0.335 . . . . 0.0 111.527 -179.921 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 29.6 m -70.59 -36.24 64.83 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.369 0 CA-C-N 116.437 -0.347 . . . . 0.0 111.748 -179.567 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 102' ' ' ILE . . . . . 0.58 HG22 ' HB3' ' A' ' 81' ' ' PRO . 49.5 mm -67.0 -46.72 84.11 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.626 -0.261 . . . . 0.0 111.35 -179.707 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 15.3 t -63.51 -35.32 80.09 Favored 'General case' 0 C--O 1.233 0.201 0 CA-C-O 120.75 0.309 . . . . 0.0 110.954 179.925 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 104' ' ' LEU . . . . . 0.414 ' O ' HG22 ' A' ' 108' ' ' VAL . 2.8 tm? -57.52 -53.75 54.62 Favored 'General case' 0 C--N 1.331 -0.199 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.259 179.54 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 105' ' ' ASN . . . . . 0.585 HD22 HD13 ' A' ' 137' ' ' LEU . 0.8 OUTLIER -55.71 -37.93 69.06 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.498 179.527 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 44.0 m -55.19 -41.72 72.31 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-O 120.886 0.374 . . . . 0.0 110.467 179.576 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 2.1 t -64.5 -37.59 80.41 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.198 0 CA-C-O 121.38 0.61 . . . . 0.0 109.867 178.99 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . 0.414 HG22 ' O ' ' A' ' 104' ' ' LEU . 26.1 t -61.49 -50.16 81.48 Favored 'Isoleucine or valine' 0 C--O 1.236 0.361 0 CA-C-N 115.089 -0.959 . . . . 0.0 111.502 -179.91 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 109' ' ' MET . . . . . 0.459 ' HE1' HG21 ' A' ' 80' ' ' THR . 9.1 mmt -63.02 -37.14 85.99 Favored 'General case' 0 C--N 1.331 -0.2 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.872 -179.838 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 31.8 tp -62.04 -33.84 75.13 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.54 179.776 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -64.75 -52.06 58.98 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 115.988 -0.551 . . . . 0.0 110.711 179.473 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . -62.23 -39.13 97.29 Favored Glycine 0 C--N 1.331 0.252 0 C-N-CA 120.484 -0.865 . . . . 0.0 112.137 179.5 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 113' ' ' PHE . . . . . . . . . . . . . 0.5 OUTLIER -52.86 -72.69 0.05 Allowed 'General case' 0 C--N 1.33 -0.255 0 CA-C-O 121.052 0.453 . . . . 0.0 110.454 179.825 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 114' ' ' ALA . . . . . 0.474 ' HB2' HD23 ' A' ' 126' ' ' LEU . . . -65.46 -12.66 54.66 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 115.708 -0.678 . . . . 0.0 111.385 -179.899 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -66.31 -43.58 92.51 Favored Glycine 0 C--N 1.33 0.238 0 C-N-CA 120.804 -0.712 . . . . 0.0 112.69 -179.959 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -78.06 -25.73 47.89 Favored 'General case' 0 C--N 1.329 -0.29 0 N-CA-C 112.154 0.427 . . . . 0.0 112.154 -179.721 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 117' ' ' MET . . . . . 0.457 ' HE1' HG13 ' A' ' 61' ' ' VAL . 67.5 mtt -91.81 19.42 6.55 Favored 'General case' 0 C--N 1.329 -0.292 0 N-CA-C 111.868 0.321 . . . . 0.0 111.868 -179.164 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 118' ' ' VAL . . . . . 0.52 HG23 ' HB3' ' A' ' 123' ' ' ARG . 17.5 m -68.33 138.88 91.85 Favored Pre-proline 0 C--N 1.329 -0.324 0 CA-C-O 120.54 0.21 . . . . 0.0 111.169 179.862 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 119' ' ' PRO . . . . . . . . . . . . . 95.1 Cg_endo -86.6 11.56 3.25 Favored 'Trans proline' 0 C--N 1.348 0.55 0 C-N-CA 122.554 2.17 . . . . 0.0 112.339 179.922 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -164.6 -120.7 0.53 Allowed Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.86 -0.686 . . . . 0.0 112.616 -179.811 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 42.3 pt -113.89 14.04 8.22 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.219 0 CA-C-O 120.812 0.339 . . . . 0.0 111.319 -179.861 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 49.0 mt-10 -61.38 -17.53 54.49 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.081 -0.509 . . . . 0.0 111.082 179.808 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 123' ' ' ARG . . . . . 0.52 ' HB3' HG23 ' A' ' 118' ' ' VAL . 14.7 ptt180 -50.44 -29.33 10.03 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.003 -0.544 . . . . 0.0 111.769 -179.821 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 124' ' ' TYR . . . . . . . . . . . . . 33.2 m-85 -74.79 -31.93 61.87 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.46 -0.336 . . . . 0.0 111.302 -179.461 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 125' ' ' ALA . . . . . . . . . . . . . . . -73.0 -56.47 5.08 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-N 116.296 -0.411 . . . . 0.0 111.045 -179.776 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 126' ' ' LEU . . . . . 0.474 HD23 ' HB2' ' A' ' 114' ' ' ALA . 1.3 mt -54.62 -46.52 73.89 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 115.968 -0.56 . . . . 0.0 110.676 179.826 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 127' ' ' PHE . . . . . . . . . . . . . 4.9 t80 -68.22 -37.37 80.76 Favored 'General case' 0 N--CA 1.453 -0.319 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.648 179.766 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 128' ' ' GLY . . . . . . . . . . . . . . . -46.38 -44.15 15.35 Favored Glycine 0 C--N 1.333 0.387 0 C-N-CA 120.14 -1.029 . . . . 0.0 110.607 178.941 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 129' ' ' MET . . . . . 0.494 ' HE3' ' N ' ' A' ' 130' ' ' GLY . 6.0 tmm? -69.52 -41.54 75.86 Favored 'General case' 0 C--N 1.328 -0.357 0 N-CA-C 109.357 -0.608 . . . . 0.0 109.357 178.266 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 130' ' ' GLY . . . . . 0.494 ' N ' ' HE3' ' A' ' 129' ' ' MET . . . -55.49 -39.49 74.2 Favored Glycine 0 N--CA 1.452 -0.278 0 CA-C-N 115.724 -0.671 . . . . 0.0 113.044 -179.711 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -70.03 -53.12 19.03 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.699 0.285 . . . . 0.0 110.609 179.955 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 53.0 t -54.93 -39.93 51.08 Favored 'Isoleucine or valine' 0 C--O 1.233 0.215 0 CA-C-O 121.307 0.575 . . . . 0.0 109.607 178.88 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -69.25 -35.99 76.69 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 115.381 -0.827 . . . . 0.0 110.279 179.391 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 134' ' ' PHE . . . . . . . . . . . . . 47.6 t80 -58.48 -52.95 63.48 Favored 'General case' 0 N--CA 1.45 -0.43 0 CA-C-N 115.932 -0.577 . . . . 0.0 109.817 179.281 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 135' ' ' ILE . . . . . 0.461 ' O ' HG22 ' A' ' 138' ' ' VAL . 45.2 mt -58.34 -30.52 40.55 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.282 0 CA-C-N 115.699 -0.682 . . . . 0.0 109.741 178.892 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 136' ' ' GLY . . . . . 0.425 ' O ' ' HB3' ' A' ' 139' ' ' TYR . . . -59.47 -42.69 97.71 Favored Glycine 0 N--CA 1.447 -0.574 0 C-N-CA 120.42 -0.895 . . . . 0.0 111.364 178.867 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 137' ' ' LEU . . . . . 0.585 HD13 HD22 ' A' ' 105' ' ' ASN . 53.8 tp -67.24 -54.62 19.29 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.565 0.222 . . . . 0.0 110.666 179.316 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 138' ' ' VAL . . . . . 0.461 HG22 ' O ' ' A' ' 135' ' ' ILE . 3.0 m -54.71 -30.4 22.38 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.134 0 CA-C-O 121.08 0.466 . . . . 0.0 109.805 -179.672 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 139' ' ' TYR . . . . . 0.425 ' HB3' ' O ' ' A' ' 136' ' ' GLY . 20.8 t80 -61.68 -48.14 82.16 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 115.526 -0.761 . . . . 0.0 110.076 178.227 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 37.5 m-85 -63.27 -40.32 97.06 Favored 'General case' 0 C--O 1.232 0.156 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.971 179.537 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 141' ' ' LEU . . . . . . . . . . . . . 11.1 mp -54.63 -55.06 33.48 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.09 -179.824 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 10.7 p -76.95 -15.93 14.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-O 121.024 0.44 . . . . 0.0 110.985 179.911 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . -73.55 -133.34 0.22 Allowed Glycine 0 CA--C 1.522 0.528 0 C-N-CA 120.867 -0.683 . . . . 0.0 112.812 -179.883 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 144' ' ' PRO . . . . . . . . . . . . . 52.2 Cg_exo -55.5 -28.56 64.98 Favored 'Trans proline' 0 C--N 1.349 0.579 0 C-N-CA 122.746 2.297 . . . . 0.0 112.885 -179.653 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 145' ' ' MET . . . . . 0.463 ' HE2' HD13 ' A' ' 93' ' ' LEU . 43.2 mtt -56.67 -36.31 69.43 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.382 -0.372 . . . . 0.0 111.352 -179.875 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 146' ' ' THR . . . . . . . . . . . . . 24.7 m -68.09 -48.0 66.71 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.836 -179.303 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 20.0 mm-40 -71.16 -26.31 62.93 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.557 -0.292 . . . . 0.0 111.369 -179.544 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 148' ' ' SER . . . . . . . . . . . . . 47.7 t -70.71 -49.47 46.66 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.312 -0.403 . . . . 0.0 111.312 -179.557 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 149' ' ' ALA . . . . . . . . . . . . . . . -75.1 -33.87 61.67 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.074 -0.512 . . . . 0.0 111.678 -179.416 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 150' ' ' SER . . . . . . . . . . . . . 43.5 t -67.24 -12.74 60.88 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.328 -179.636 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 151' ' ' GLN . . . . . . . . . . . . . 77.7 mt-30 -119.03 12.1 12.65 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.486 -0.325 . . . . 0.0 111.42 -179.756 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 31.4 tpt180 -84.56 -51.36 6.94 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 120.81 0.338 . . . . 0.0 110.865 -179.759 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 153' ' ' SER . . . . . 0.626 ' HB3' HG12 ' A' ' 156' ' ' ILE . 18.3 t -157.69 172.46 18.48 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 116.119 -0.492 . . . . 0.0 110.715 179.41 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 154' ' ' SER . . . . . . . . . . . . . 47.0 t -68.86 -41.05 78.93 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.303 -0.408 . . . . 0.0 110.802 179.787 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -76.69 -35.79 39.49 Favored Glycine 0 N--CA 1.452 -0.259 0 C-N-CA 120.98 -0.629 . . . . 0.0 112.974 -179.909 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 156' ' ' ILE . . . . . 0.626 HG12 ' HB3' ' A' ' 153' ' ' SER . 43.1 mm -55.34 -36.82 41.99 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.237 0 CA-C-O 120.714 0.292 . . . . 0.0 111.518 -179.769 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 157' ' ' LYS . . . . . 0.618 ' HB3' ' HZ2' ' A' ' 157' ' ' LYS . 6.5 ttpm? -59.51 -53.75 54.53 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 116.415 -0.357 . . . . 0.0 111.759 -179.45 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 42.8 t -67.37 -41.01 85.75 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.445 -0.343 . . . . 0.0 111.714 -179.198 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 159' ' ' LEU . . . . . 0.449 ' O ' HD23 ' A' ' 159' ' ' LEU . 4.1 tt -67.72 -34.55 77.08 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 116.432 -0.349 . . . . 0.0 111.045 -179.554 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 160' ' ' TYR . . . . . . . . . . . . . 67.6 t80 -73.88 -45.81 48.6 Favored 'General case' 0 C--N 1.33 -0.278 0 N-CA-C 112.026 0.38 . . . . 0.0 112.026 -179.165 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 22.7 m -59.82 -43.55 92.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 N-CA-C 111.673 0.249 . . . . 0.0 111.673 -179.252 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 162' ' ' ARG . . . . . 0.454 HH22 ' HB2' ' A' ' 215' ' ' ALA . 86.8 mtm180 -68.99 -38.02 79.06 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.77 0.319 . . . . 0.0 111.218 -179.977 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 163' ' ' LEU . . . . . 0.545 ' HG ' ' HB2' ' A' ' 208' ' ' PHE . 3.4 mp -69.5 -54.17 15.51 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.643 -179.58 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 164' ' ' ARG . . . . . . . . . . . . . 4.7 tmm_? -58.71 -53.54 57.2 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.545 -179.236 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 165' ' ' ASN . . . . . 0.501 ' N ' HD21 ' A' ' 165' ' ' ASN . 0.9 OUTLIER -53.59 -52.12 60.81 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 120.876 0.37 . . . . 0.0 111.659 -179.273 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 166' ' ' LEU . . . . . 0.491 ' O ' ' HG ' ' A' ' 170' ' ' LEU . 2.1 tt -61.09 -53.33 58.46 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.065 -0.516 . . . . 0.0 111.771 -179.129 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 167' ' ' THR . . . . . 0.498 ' O ' ' HB2' ' A' ' 171' ' ' TRP . 86.0 m -55.47 -53.7 53.02 Favored 'General case' 0 C--N 1.327 -0.395 0 N-CA-C 112.8 0.667 . . . . 0.0 112.8 -178.661 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 168' ' ' VAL . . . . . . . . . . . . . 89.7 t -54.64 -44.61 70.4 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.244 0 N-CA-C 112.371 0.508 . . . . 0.0 112.371 -178.563 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 169' ' ' VAL . . . . . 0.413 HG22 ' O ' ' A' ' 165' ' ' ASN . 75.4 t -58.43 -64.79 0.5 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.421 0 N-CA-C 112.149 0.426 . . . . 0.0 112.149 -178.962 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 170' ' ' LEU . . . . . 0.491 ' HG ' ' O ' ' A' ' 166' ' ' LEU . 1.4 pp -62.3 -29.75 70.65 Favored 'General case' 0 C--N 1.33 -0.255 0 N-CA-C 112.011 0.374 . . . . 0.0 112.011 -178.863 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 171' ' ' TRP . . . . . 0.498 ' HB2' ' O ' ' A' ' 167' ' ' THR . 2.2 m0 -71.88 -31.2 66.21 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.861 0.362 . . . . 0.0 110.939 179.827 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 172' ' ' ALA . . . . . . . . . . . . . . . -72.18 -6.1 40.36 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.667 179.962 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 173' ' ' ILE . . . . . 0.52 HG23 HD12 ' A' ' 177' ' ' ILE . 29.0 mm -85.24 -21.28 7.91 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.188 0 CA-C-N 115.764 -0.653 . . . . 0.0 111.141 179.79 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 174' ' ' TYR . . . . . . . . . . . . . 28.0 m-85 -54.44 -50.47 84.98 Favored Pre-proline 0 N--CA 1.466 0.326 0 CA-C-N 116.437 -0.347 . . . . 0.0 111.673 -179.836 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 175' ' ' PRO . . . . . . . . . . . . . 86.7 Cg_exo -45.87 -29.9 6.32 Favored 'Trans proline' 0 C--N 1.353 0.777 0 C-N-CA 122.233 1.955 . . . . 0.0 112.358 179.844 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 176' ' ' PHE . . . . . 0.428 ' O ' ' HG ' ' A' ' 180' ' ' LEU . 92.1 m-85 -80.15 -49.3 11.88 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 115.976 -0.556 . . . . 0.0 111.699 -179.822 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 177' ' ' ILE . . . . . 0.52 HD12 HG23 ' A' ' 173' ' ' ILE . 2.9 mm -60.3 -38.0 75.93 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.528 0 CA-C-N 116.024 -0.535 . . . . 0.0 112.008 -178.459 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 178' ' ' TRP . . . . . . . . . . . . . 70.4 t90 -73.32 -44.9 58.13 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.864 0.364 . . . . 0.0 110.922 179.748 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 179' ' ' LEU . . . . . 0.42 ' O ' ' HA3' ' A' ' 184' ' ' GLY . 1.5 tm? -65.46 -54.22 31.55 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 115.998 -0.546 . . . . 0.0 111.246 -179.323 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 180' ' ' LEU . . . . . 0.428 ' HG ' ' O ' ' A' ' 176' ' ' PHE . 18.8 mt -72.46 -45.39 59.73 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.542 -0.299 . . . . 0.0 111.631 -179.267 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . -55.35 175.69 0.71 Allowed Glycine 0 C--N 1.336 0.537 0 C-N-CA 120.487 -0.863 . . . . 0.0 112.896 179.646 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 182' ' ' PRO . . . . . 0.594 ' HA ' ' HB2' ' A' ' 186' ' ' ALA . 72.2 Cg_exo -48.07 -45.34 25.64 Favored 'Trans proline' 0 CA--C 1.536 0.596 0 C-N-CA 122.983 2.455 . . . . 0.0 113.86 -179.994 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 183' ' ' PRO . . . . . 0.443 ' HD3' ' HB2' ' A' ' 182' ' ' PRO . 52.2 Cg_exo -53.96 -13.34 4.39 Favored 'Trans proline' 0 C--N 1.355 0.92 0 C-N-CA 122.056 1.837 . . . . 0.0 112.916 -179.853 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 184' ' ' GLY . . . . . 0.42 ' HA3' ' O ' ' A' ' 179' ' ' LEU . . . -115.93 -86.34 1.28 Allowed Glycine 0 N--CA 1.45 -0.414 0 C-N-CA 120.377 -0.916 . . . . 0.0 112.871 -179.779 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 185' ' ' VAL . . . . . . . . . . . . . 6.6 m -124.59 -5.06 6.48 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 N-CA-C 112.169 0.433 . . . . 0.0 112.169 -179.495 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 186' ' ' ALA . . . . . 0.594 ' HB2' ' HA ' ' A' ' 182' ' ' PRO . . . 53.41 86.59 0.04 OUTLIER 'General case' 0 N--CA 1.463 0.224 0 CA-C-N 116.479 -0.328 . . . . 0.0 111.682 179.606 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 187' ' ' LEU . . . . . . . . . . . . . 14.1 mt -92.15 -49.36 6.23 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.396 -0.366 . . . . 0.0 111.452 179.851 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 188' ' ' LEU . . . . . 0.413 HD11 ' N ' ' A' ' 188' ' ' LEU . 6.9 mp -92.93 -88.97 0.21 Allowed 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.361 -0.381 . . . . 0.0 111.272 -179.256 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 189' ' ' THR . . . . . . . . . . . . . 1.8 t -169.82 148.7 3.28 Favored Pre-proline 0 C--N 1.325 -0.483 0 CA-C-N 116.01 -0.541 . . . . 0.0 111.078 -179.55 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 190' ' ' PRO . . . . . . . . . . . . . 10.2 Cg_endo -51.99 -42.86 56.17 Favored 'Trans proline' 0 C--N 1.35 0.649 0 C-N-CA 122.798 2.332 . . . . 0.0 113.152 -179.761 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 191' ' ' THR . . . . . . . . . . . . . 5.4 t -56.4 -44.74 80.57 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-O 120.689 0.281 . . . . 0.0 111.336 -179.59 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 192' ' ' VAL . . . . . . . . . . . . . 38.5 t -70.56 -43.62 77.62 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.389 -0.369 . . . . 0.0 111.088 179.846 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 193' ' ' ASP . . . . . . . . . . . . . 11.3 t70 -55.62 -49.16 73.56 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.942 179.867 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 194' ' ' VAL . . . . . . . . . . . . . 85.9 t -63.03 -36.98 78.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.05 -179.985 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 195' ' ' ALA . . . . . . . . . . . . . . . -59.24 -48.41 81.74 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.491 -0.322 . . . . 0.0 110.979 179.827 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 196' ' ' LEU . . . . . . . . . . . . . 65.0 mt -67.91 -43.61 78.84 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.307 -0.406 . . . . 0.0 110.641 179.761 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 197' ' ' ILE . . . . . 0.424 HD11 ' HB ' ' A' ' 177' ' ' ILE . 17.6 mm -56.51 -59.78 2.59 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 115.961 -0.563 . . . . 0.0 110.444 179.435 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 198' ' ' VAL . . . . . . . . . . . . . 76.8 t -53.06 -34.69 21.5 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.496 0 CA-C-N 115.601 -0.727 . . . . 0.0 109.467 178.512 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 199' ' ' TYR . . . . . . . . . . . . . 64.9 t80 -70.24 -31.61 69.09 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 115.524 -0.762 . . . . 0.0 110.588 179.692 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 200' ' ' LEU . . . . . 0.46 ' O ' HG11 ' A' ' 203' ' ' VAL . 32.2 mt -73.23 -43.44 61.21 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 115.841 -0.618 . . . . 0.0 111.484 -179.478 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 201' ' ' ASP . . . . . . . . . . . . . 10.5 m-20 -71.94 -36.81 70.02 Favored 'General case' 0 C--N 1.327 -0.413 0 CA-C-O 121.251 0.548 . . . . 0.0 110.087 179.511 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 202' ' ' LEU . . . . . . . . . . . . . 39.5 tp -72.73 -27.78 62.25 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 115.311 -0.859 . . . . 0.0 111.779 -179.293 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 203' ' ' VAL . . . . . 0.46 HG11 ' O ' ' A' ' 200' ' ' LEU . 12.3 p -78.71 -35.94 18.96 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.215 0 C-N-CA 120.854 -0.338 . . . . 0.0 110.779 -179.087 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 204' ' ' THR . . . . . . . . . . . . . 97.2 m -66.48 -59.0 4.05 Favored 'General case' 0 C--N 1.329 -0.304 0 C-N-CA 120.598 -0.441 . . . . 0.0 110.861 179.34 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 205' ' ' LYS . . . . . 0.643 ' HD2' ' HE2' ' A' ' 15' ' ' MET . 62.7 mttp -58.76 -57.78 11.5 Favored 'General case' 0 C--N 1.331 -0.209 0 N-CA-C 112.14 0.422 . . . . 0.0 112.14 -178.675 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 49.8 t -70.55 -37.35 69.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 N-CA-C 112.324 0.49 . . . . 0.0 112.324 -178.823 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 207' ' ' GLY . . . . . 0.539 ' O ' HG13 ' A' ' 211' ' ' ILE . . . -55.76 -62.07 6.72 Favored Glycine 0 CA--C 1.518 0.242 0 C-N-CA 120.614 -0.803 . . . . 0.0 113.873 -178.608 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 208' ' ' PHE . . . . . 0.545 ' HB2' ' HG ' ' A' ' 163' ' ' LEU . 3.0 p90 -72.86 -27.63 62.03 Favored 'General case' 0 C--O 1.221 -0.416 0 CA-C-N 117.457 0.628 . . . . 0.0 110.925 -179.231 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 209' ' ' GLY . . . . . 0.494 ' O ' ' HB3' ' A' ' 212' ' ' ALA . . . -62.06 -34.78 90.12 Favored Glycine 0 N--CA 1.449 -0.447 0 N-CA-C 111.91 -0.476 . . . . 0.0 111.91 178.761 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 210' ' ' PHE . . . . . . . . . . . . . 1.2 m-85 -73.59 -48.23 34.35 Favored 'General case' 0 CA--C 1.513 -0.456 0 N-CA-C 108.153 -1.055 . . . . 0.0 108.153 178.398 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 211' ' ' ILE . . . . . 0.539 HG13 ' O ' ' A' ' 207' ' ' GLY . 4.8 mt -61.61 -27.48 42.17 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.51 0 N-CA-C 107.784 -1.191 . . . . 0.0 107.784 176.711 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 212' ' ' ALA . . . . . 0.494 ' HB3' ' O ' ' A' ' 209' ' ' GLY . . . -63.57 -41.75 98.37 Favored 'General case' 0 N--CA 1.45 -0.474 0 CA-C-N 114.478 -1.237 . . . . 0.0 110.664 -179.775 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 213' ' ' LEU . . . . . . . . . . . . . 95.3 mt -69.29 -53.04 21.75 Favored 'General case' 0 C--N 1.332 -0.162 0 CA-C-N 115.26 -0.882 . . . . 0.0 111.398 -179.68 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 214' ' ' ASP . . . . . . . . . . . . . 9.6 m-20 -55.7 -48.66 74.75 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-O 120.878 0.37 . . . . 0.0 110.746 -179.997 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 215' ' ' ALA . . . . . 0.454 ' HB2' HH22 ' A' ' 162' ' ' ARG . . . -59.44 -57.33 13.44 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 115.988 -0.551 . . . . 0.0 110.958 179.721 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 216' ' ' ALA . . . . . . . . . . . . . . . -56.36 -31.55 63.9 Favored 'General case' 0 C--N 1.332 -0.187 0 CA-C-N 116.06 -0.518 . . . . 0.0 111.065 -179.998 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 217' ' ' ALA . . . . . . . . . . . . . . . -62.68 -39.26 93.38 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.407 179.615 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 218' ' ' THR . . . . . . . . . . . . . 79.1 m . . . . . 0 C--N 1.329 -0.296 0 CA-C-N 115.81 -0.632 . . . . 0.0 111.044 179.682 . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.303 0 N-CA-C 112.506 -0.238 . . . . 0.0 112.506 . . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 50.6 tp -73.88 -36.13 64.77 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.786 0.327 . . . . 0.0 110.948 179.87 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 73.7 p -61.39 -29.71 70.09 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.115 -0.493 . . . . 0.0 111.19 179.946 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 23.1 p -53.46 -35.42 60.51 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.09 -0.504 . . . . 0.0 111.071 -179.904 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 7' ' ' LEU . . . . . . . . . . . . . 4.1 mm? -60.25 -53.44 57.65 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.034 -0.53 . . . . 0.0 111.101 179.991 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 8' ' ' PHE . . . . . . . . . . . . . 81.4 m-85 -59.89 -37.1 78.44 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 120.964 0.412 . . . . 0.0 110.806 179.951 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 9' ' ' TRP . . . . . . . . . . . . . 35.9 m95 -63.57 -41.58 98.39 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 115.897 -0.592 . . . . 0.0 110.173 -179.972 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 38.5 mt -64.85 -49.02 72.2 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-N 115.767 -0.651 . . . . 0.0 110.159 179.244 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -57.19 -28.09 58.33 Favored Glycine 0 N--CA 1.447 -0.571 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.216 179.293 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -74.09 -38.48 63.87 Favored 'General case' 0 C--N 1.332 -0.186 0 CA-C-O 120.714 0.292 . . . . 0.0 110.79 179.636 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 63.6 mt -61.87 -54.18 38.04 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.31 -0.404 . . . . 0.0 110.436 179.475 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -60.96 -35.23 90.25 Favored Glycine 0 N--CA 1.45 -0.41 0 C-N-CA 120.591 -0.814 . . . . 0.0 111.676 179.257 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 15' ' ' MET . . . . . 0.533 ' SD ' ' HA ' ' A' ' 44' ' ' SER . 47.5 tpp -64.51 -39.98 94.79 Favored 'General case' 0 N--CA 1.454 -0.246 0 N-CA-C 110.167 -0.309 . . . . 0.0 110.167 179.343 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -59.91 -37.55 79.76 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 116.018 -0.537 . . . . 0.0 109.571 179.1 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 94.0 t -59.07 -50.5 79.53 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.172 0 CA-C-N 115.937 -0.574 . . . . 0.0 110.107 179.1 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -61.45 -45.33 96.6 Favored Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.64 -0.791 . . . . 0.0 111.726 179.163 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 32.8 m -51.7 -44.76 63.28 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-O 120.678 0.275 . . . . 0.0 111.301 -179.858 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 81.2 mt -71.59 -36.54 70.89 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.321 -0.4 . . . . 0.0 111.172 179.904 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -63.23 -33.29 75.17 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.348 -0.387 . . . . 0.0 111.338 -179.873 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 4.1 m-85 -90.86 -28.76 17.94 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.296 -0.411 . . . . 0.0 111.185 -179.472 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -71.77 -50.69 27.69 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.943 0.402 . . . . 0.0 111.118 179.919 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 24' ' ' TRP . . . . . . . . . . . . . 3.2 t-105 -64.41 -44.66 90.53 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 115.86 -0.609 . . . . 0.0 110.938 -179.946 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.329 -0.3 0 CA-C-O 120.895 0.379 . . . . 0.0 110.915 179.776 . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.454 -0.144 0 N-CA-C 112.588 -0.205 . . . . 0.0 112.588 . . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 2.9 mp0 -68.34 -20.86 64.76 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 120.727 0.299 . . . . 0.0 110.944 -179.957 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 34' ' ' ARG . . . . . . . . . . . . . 78.9 ttt180 -57.63 -28.95 64.15 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.501 -179.619 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 27.7 tpt180 -59.17 -48.4 81.75 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.704 0.288 . . . . 0.0 111.508 -179.607 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 80.7 m-85 -64.96 -29.81 70.76 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.432 -0.349 . . . . 0.0 111.427 -179.511 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 37' ' ' TYR . . . . . . . . . . . . . 52.2 m-85 -74.31 -54.27 8.01 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.413 -0.358 . . . . 0.0 111.342 -179.521 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 83.3 t -56.93 -36.32 49.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-O 120.969 0.414 . . . . 0.0 110.372 179.747 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 53.8 m -65.78 -51.53 58.29 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 115.846 -0.616 . . . . 0.0 110.929 179.518 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 40' ' ' LEU . . . . . 0.46 HD13 HD13 ' A' ' 43' ' ' ILE . 54.2 tp -59.23 -48.12 82.79 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 115.986 -0.552 . . . . 0.0 110.802 -179.94 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 67.6 t -57.86 -34.88 49.44 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.075 -0.511 . . . . 0.0 109.976 179.058 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -62.4 -36.23 92.82 Favored Glycine 0 N--CA 1.447 -0.606 0 C-N-CA 120.738 -0.744 . . . . 0.0 111.724 179.563 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 43' ' ' ILE . . . . . 0.465 HG12 HD21 ' A' ' 82' ' ' LEU . 1.9 mt -65.25 -55.14 21.79 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.187 0 CA-C-O 120.903 0.383 . . . . 0.0 110.935 179.629 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 44' ' ' SER . . . . . 0.533 ' HA ' ' SD ' ' A' ' 15' ' ' MET . 77.9 p -59.7 -26.23 65.42 Favored 'General case' 0 C--N 1.331 -0.201 0 CA-C-N 115.92 -0.582 . . . . 0.0 111.782 -179.529 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -76.16 -54.97 4.97 Favored Glycine 0 CA--C 1.52 0.39 0 C-N-CA 120.573 -0.823 . . . . 0.0 112.858 -179.513 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 46' ' ' ILE . . . . . 0.418 ' O ' HG21 ' A' ' 49' ' ' VAL . 20.5 pt -59.25 -35.8 59.91 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.219 0 CA-C-O 120.974 0.416 . . . . 0.0 111.13 -179.935 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 47' ' ' ALA . . . . . 0.618 ' HB3' ' HE2' ' A' ' 205' ' ' LYS . . . -68.16 -45.56 73.16 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.031 179.341 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -54.83 -41.94 71.32 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 115.87 -0.605 . . . . 0.0 111.769 -179.448 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 49' ' ' VAL . . . . . 0.418 HG21 ' O ' ' A' ' 46' ' ' ILE . 19.3 m -72.42 -34.19 47.89 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-N 116.521 -0.308 . . . . 0.0 111.138 -179.519 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -67.0 -34.73 78.4 Favored 'General case' 0 C--N 1.331 -0.2 0 CA-C-O 120.872 0.368 . . . . 0.0 111.227 179.853 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 28.3 m-85 -72.44 -41.34 66.25 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.623 -179.737 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -64.04 -46.71 83.2 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 115.769 -0.65 . . . . 0.0 111.245 -179.816 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 53' ' ' VAL . . . . . 0.475 HG21 ' N ' ' A' ' 54' ' ' MET . 31.9 m -62.96 -53.61 44.39 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.159 0 CA-C-N 116.425 -0.352 . . . . 0.0 111.039 -179.903 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 54' ' ' MET . . . . . 0.475 ' N ' HG21 ' A' ' 53' ' ' VAL . 74.0 mtm -60.08 -31.1 69.7 Favored 'General case' 0 C--N 1.332 -0.182 0 CA-C-O 120.996 0.426 . . . . 0.0 110.289 179.659 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -64.9 -37.88 89.1 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 115.758 -0.655 . . . . 0.0 111.196 179.363 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 93.3 mt -71.15 -2.75 16.83 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.462 -179.586 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 93.66 -5.85 73.73 Favored Glycine 0 N--CA 1.45 -0.368 0 C-N-CA 120.597 -0.811 . . . . 0.0 112.925 179.702 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 58' ' ' VAL . . . . . 0.427 HG23 ' O ' ' A' ' 53' ' ' VAL . 1.5 m -72.64 154.2 7.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-O 120.718 0.294 . . . . 0.0 110.33 179.714 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 73.85 19.27 79.75 Favored Glycine 0 N--CA 1.45 -0.373 0 C-N-CA 120.483 -0.865 . . . . 0.0 112.188 -179.433 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 60' ' ' TRP . . . . . . . . . . . . . 22.0 m0 -99.11 99.26 10.24 Favored 'General case' 0 C--N 1.33 -0.259 0 N-CA-C 109.981 -0.377 . . . . 0.0 109.981 179.824 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 61' ' ' VAL . . . . . 0.521 ' HB ' HG23 ' A' ' 68' ' ' VAL . 61.4 t -97.95 109.51 51.75 Favored Pre-proline 0 C--N 1.324 -0.507 0 CA-C-N 115.996 -0.547 . . . . 0.0 111.542 -179.113 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 39.6 Cg_endo -66.2 135.74 41.35 Favored 'Trans proline' 0 C--N 1.35 0.639 0 C-N-CA 122.532 2.155 . . . . 0.0 112.085 179.731 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 80.9 t -137.89 95.13 1.06 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.38 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.387 -179.604 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . 58.11 -90.16 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.111 -0.495 . . . . 0.0 111.566 179.855 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 44.7 mt-10 -115.45 -24.67 8.26 Favored 'General case' 0 C--N 1.332 -0.193 0 CA-C-O 120.842 0.353 . . . . 0.0 111.157 -179.842 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 66' ' ' ARG . . . . . 0.416 ' N ' ' HD2' ' A' ' 66' ' ' ARG . 9.3 mpt_? -105.74 154.07 20.99 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.415 179.871 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 90.7 m -117.39 115.5 25.33 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.892 0.377 . . . . 0.0 111.433 -179.696 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 68' ' ' VAL . . . . . 0.521 HG23 ' HB ' ' A' ' 61' ' ' VAL . 29.0 m -83.81 146.34 6.99 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.368 0 CA-C-N 115.914 -0.584 . . . . 0.0 110.891 179.672 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 69' ' ' PHE . . . . . . . . . . . . . 64.8 m-85 -108.92 115.87 30.9 Favored 'General case' 0 N--CA 1.443 -0.794 0 CA-C-N 116.273 -0.421 . . . . 0.0 110.185 -179.377 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 70' ' ' VAL . . . . . 0.53 ' HB ' ' HD3' ' A' ' 71' ' ' PRO . 24.5 t -67.49 -49.6 40.84 Favored Pre-proline 0 C--N 1.325 -0.477 0 N-CA-C 112.616 0.599 . . . . 0.0 112.616 -178.932 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 71' ' ' PRO . . . . . 0.53 ' HD3' ' HB ' ' A' ' 70' ' ' VAL . 15.4 Cg_exo -67.08 -17.93 51.16 Favored 'Trans proline' 0 C--N 1.351 0.702 0 C-N-CA 122.315 2.01 . . . . 0.0 113.091 -178.918 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 67.2 ttt180 -66.66 -55.5 14.92 Favored 'General case' 0 C--O 1.237 0.396 0 CA-C-O 120.838 0.351 . . . . 0.0 111.626 -179.404 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 73' ' ' TYR . . . . . 0.466 ' O ' HG13 ' A' ' 77' ' ' ILE . 65.4 m-85 -71.52 -34.54 70.15 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.486 -0.324 . . . . 0.0 110.603 -179.453 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 74' ' ' ILE . . . . . 0.495 ' HA ' HD11 ' A' ' 77' ' ' ILE . 0.4 OUTLIER -66.48 -37.86 80.5 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.242 0 N-CA-C 109.833 -0.432 . . . . 0.0 109.833 179.182 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 13.8 t70 -59.14 -38.95 80.89 Favored 'General case' 0 CA--C 1.517 -0.288 0 N-CA-C 109.128 -0.693 . . . . 0.0 109.128 178.62 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 76' ' ' TRP . . . . . . . . . . . . . 51.1 m0 -65.58 -32.67 74.38 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 115.59 -0.732 . . . . 0.0 110.236 179.138 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 77' ' ' ILE . . . . . 0.495 HD11 ' HA ' ' A' ' 74' ' ' ILE . 69.0 mt -68.76 -28.61 40.55 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.25 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.078 178.984 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 34.0 mt -92.22 -20.43 21.18 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 115.772 -0.649 . . . . 0.0 112.332 179.949 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 82.1 p -103.93 -52.94 2.85 Favored 'General case' 0 N--CA 1.465 0.279 0 N-CA-C 114.025 1.12 . . . . 0.0 114.025 -177.295 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 80' ' ' THR . . . . . 0.444 ' N ' ' HD2' ' A' ' 81' ' ' PRO . 25.3 m -50.41 -54.81 30.86 Favored Pre-proline 0 C--N 1.329 -0.317 0 N-CA-C 113.016 0.747 . . . . 0.0 113.016 -178.007 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 81' ' ' PRO . . . . . 0.444 ' HD2' ' N ' ' A' ' 80' ' ' THR . 20.5 Cg_endo -59.78 -21.27 62.86 Favored 'Trans proline' 0 C--N 1.35 0.654 0 C-N-CA 121.346 1.364 . . . . 0.0 111.141 -179.655 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 82' ' ' LEU . . . . . 0.465 HD21 HG12 ' A' ' 43' ' ' ILE . 13.4 tp -77.13 -33.55 56.76 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 115.58 -0.736 . . . . 0.0 109.829 179.436 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 83' ' ' ILE . . . . . 0.46 HD13 HD12 ' A' ' 43' ' ' ILE . 35.2 mm -70.29 -53.44 23.08 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.191 0 CA-C-N 115.984 -0.553 . . . . 0.0 109.848 179.063 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 33.9 m -59.51 -30.19 43.98 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.183 0 N-CA-C 109.546 -0.539 . . . . 0.0 109.546 178.863 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 85' ' ' TYR . . . . . . . . . . . . . 68.3 t80 -69.74 -32.57 71.18 Favored 'General case' 0 N--CA 1.454 -0.26 0 CA-C-N 115.537 -0.756 . . . . 0.0 109.623 178.873 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 86' ' ' PHE . . . . . . . . . . . . . 9.9 t80 -61.33 -51.93 66.78 Favored 'General case' 0 C--O 1.232 0.149 0 CA-C-N 115.919 -0.582 . . . . 0.0 109.857 179.326 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 8.1 mp -61.01 -33.16 72.83 Favored 'General case' 0 C--N 1.332 -0.189 0 CA-C-N 115.873 -0.603 . . . . 0.0 110.08 179.374 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -67.22 -27.74 73.56 Favored Glycine 0 N--CA 1.449 -0.49 0 C-N-CA 120.836 -0.697 . . . . 0.0 111.755 179.233 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 79.3 mt -72.89 -42.95 63.08 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-O 120.924 0.392 . . . . 0.0 110.468 179.622 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 54.9 mt -59.59 -43.83 93.57 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 115.822 -0.626 . . . . 0.0 110.972 179.878 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 91' ' ' ALA . . . . . 0.436 ' HB2' ' HB3' ' A' ' 149' ' ' ALA . . . -74.46 -55.05 6.39 Favored 'General case' 0 C--N 1.331 -0.21 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.325 -179.886 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 103.55 51.62 0.96 Allowed Glycine 0 N--CA 1.452 -0.251 0 C-N-CA 120.843 -0.694 . . . . 0.0 112.447 179.959 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 93' ' ' LEU . . . . . 0.531 HD23 ' HB3' ' A' ' 97' ' ' GLU . 7.9 mp -65.77 170.83 4.83 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.875 0.369 . . . . 0.0 111.193 -179.884 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 94' ' ' ASP . . . . . . . . . . . . . 5.5 m-20 -85.05 164.66 18.09 Favored 'General case' 0 C--N 1.33 -0.239 0 CA-C-N 116.057 -0.519 . . . . 0.0 110.435 179.643 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 46.8 t -55.86 -34.63 65.65 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.326 -0.397 . . . . 0.0 110.97 -179.753 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 96' ' ' ARG . . . . . 0.463 ' HA ' ' NE ' ' A' ' 96' ' ' ARG . 5.6 tpm_? -73.69 -44.87 55.41 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.254 -0.43 . . . . 0.0 111.195 -179.914 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 97' ' ' GLU . . . . . 0.531 ' HB3' HD23 ' A' ' 93' ' ' LEU . 39.1 mt-10 -54.58 -47.39 73.36 Favored 'General case' 0 C--N 1.333 -0.129 0 CA-C-N 116.274 -0.421 . . . . 0.0 111.102 -179.777 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 98' ' ' PHE . . . . . 0.47 ' O ' HG12 ' A' ' 102' ' ' ILE . 41.1 m-85 -58.31 -48.85 79.19 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.859 0.362 . . . . 0.0 110.571 179.489 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -54.25 -29.89 46.67 Favored Glycine 0 N--CA 1.45 -0.383 0 C-N-CA 120.662 -0.78 . . . . 0.0 112.466 179.816 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 100' ' ' ILE . . . . . 0.481 HD12 ' HA ' ' A' ' 97' ' ' GLU . 66.6 mt -73.81 -48.32 39.99 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.229 0 N-CA-C 112.02 0.378 . . . . 0.0 112.02 -179.735 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 1.4 p -68.84 -41.76 82.34 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.246 0 N-CA-C 112.044 0.387 . . . . 0.0 112.044 -179.404 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 102' ' ' ILE . . . . . 0.47 HG12 ' O ' ' A' ' 98' ' ' PHE . 42.6 mm -64.58 -48.24 85.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.774 -0.194 . . . . 0.0 111.368 -179.358 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 14.7 t -60.95 -34.24 74.42 Favored 'General case' 0 C--N 1.332 -0.166 0 CA-C-O 120.83 0.347 . . . . 0.0 110.385 179.784 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 104' ' ' LEU . . . . . 0.448 HD23 ' HE2' ' A' ' 140' ' ' TYR . 38.0 tp -62.02 -52.92 62.02 Favored 'General case' 0 C--N 1.332 -0.174 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.251 179.296 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 105' ' ' ASN . . . . . 0.551 ' N ' HD21 ' A' ' 105' ' ' ASN . 0.8 OUTLIER -56.95 -27.4 61.13 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.765 179.524 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 30.9 m -64.9 -56.97 10.12 Favored 'General case' 0 C--N 1.332 -0.183 0 CA-C-N 116.313 -0.403 . . . . 0.0 111.481 -179.863 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 7.4 p -58.93 -36.19 60.39 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.144 0 CA-C-O 120.852 0.358 . . . . 0.0 111.087 -179.892 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 91.4 t -61.84 -49.47 84.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.099 -0.5 . . . . 0.0 111.133 179.816 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 109' ' ' MET . . . . . 0.457 ' HG2' ' O ' ' A' ' 105' ' ' ASN . 17.7 mmt -64.52 -31.51 72.75 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.244 -0.434 . . . . 0.0 111.104 179.974 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 27.7 tp -68.05 -36.18 79.45 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.247 179.675 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -62.66 -53.67 51.02 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.067 -0.515 . . . . 0.0 110.539 179.48 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . -62.23 -40.97 99.68 Favored Glycine 0 C--N 1.332 0.327 0 C-N-CA 120.638 -0.791 . . . . 0.0 111.868 179.362 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 113' ' ' PHE . . . . . 0.404 ' HZ ' HG13 ' A' ' 70' ' ' VAL . 1.4 t80 -48.88 -68.58 0.17 Allowed 'General case' 0 CA--C 1.52 -0.18 0 N-CA-C 109.858 -0.423 . . . . 0.0 109.858 179.33 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 114' ' ' ALA . . . . . 0.497 ' HA ' ' HB2' ' A' ' 117' ' ' MET . . . -67.49 -15.48 63.69 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-N 115.924 -0.58 . . . . 0.0 110.213 179.365 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 115' ' ' GLY . . . . . 0.479 ' O ' HG23 ' A' ' 118' ' ' VAL . . . -53.65 -49.81 56.25 Favored Glycine 0 C--N 1.336 0.557 0 C-N-CA 120.978 -0.629 . . . . 0.0 111.561 179.299 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 116' ' ' ALA . . . . . 0.438 ' HB3' HG12 ' A' ' 68' ' ' VAL . . . -79.36 -22.11 44.86 Favored 'General case' 0 C--N 1.321 -0.638 0 N-CA-C 111.878 0.325 . . . . 0.0 111.878 179.902 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 117' ' ' MET . . . . . 0.497 ' HB2' ' HA ' ' A' ' 114' ' ' ALA . 0.2 OUTLIER -76.67 19.45 0.27 Allowed 'General case' 0 C--N 1.328 -0.33 0 N-CA-C 112.363 0.505 . . . . 0.0 112.363 -178.84 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 118' ' ' VAL . . . . . 0.479 HG23 ' O ' ' A' ' 115' ' ' GLY . 23.3 m -123.67 138.71 30.78 Favored Pre-proline 0 C--N 1.33 -0.278 0 C-N-CA 121.131 -0.227 . . . . 0.0 111.369 179.823 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 119' ' ' PRO . . . . . . . . . . . . . 77.4 Cg_endo -96.63 23.47 0.33 Allowed 'Trans proline' 0 N--CA 1.455 -0.787 0 C-N-CA 123.19 2.593 . . . . 0.0 112.769 179.892 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -139.73 -159.16 7.87 Favored Glycine 0 C--N 1.332 0.308 0 C-N-CA 120.493 -0.86 . . . . 0.0 113.215 -179.578 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 14.3 mm -80.33 1.89 2.7 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.205 0 CA-C-O 121.136 0.493 . . . . 0.0 110.938 -179.77 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 33.6 mt-10 -59.34 -37.39 77.71 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 115.799 -0.637 . . . . 0.0 110.89 -179.991 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 123' ' ' ARG . . . . . 0.524 ' HB2' ' HH2' ' A' ' 178' ' ' TRP . 3.7 ptp180 -50.6 -32.99 20.41 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.018 -0.537 . . . . 0.0 111.654 -179.659 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 124' ' ' TYR . . . . . . . . . . . . . 91.3 m-85 -71.57 -33.2 68.88 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.385 -0.371 . . . . 0.0 111.236 -179.645 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 125' ' ' ALA . . . . . . . . . . . . . . . -70.07 -50.86 36.8 Favored 'General case' 0 C--O 1.237 0.405 0 CA-C-O 120.995 0.426 . . . . 0.0 110.047 179.194 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 8.2 mp -55.55 -54.04 48.94 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 115.695 -0.684 . . . . 0.0 110.074 179.345 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 127' ' ' PHE . . . . . . . . . . . . . 11.0 t80 -63.53 -35.73 81.44 Favored 'General case' 0 N--CA 1.452 -0.374 0 CA-C-N 115.782 -0.645 . . . . 0.0 110.611 179.958 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 128' ' ' GLY . . . . . . . . . . . . . . . -47.46 -44.48 21.87 Favored Glycine 0 C--N 1.332 0.313 0 C-N-CA 120.228 -0.987 . . . . 0.0 110.805 179.138 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 129' ' ' MET . . . . . . . . . . . . . 0.3 OUTLIER -70.51 -36.56 73.83 Favored 'General case' 0 N--CA 1.453 -0.318 0 N-CA-C 109.828 -0.434 . . . . 0.0 109.828 178.688 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -66.52 -28.56 73.81 Favored Glycine 0 C--N 1.332 0.342 0 CA-C-N 115.702 -0.681 . . . . 0.0 112.839 -179.993 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -74.67 -53.7 8.81 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-O 120.699 0.285 . . . . 0.0 110.358 179.83 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 98.4 t -57.84 -39.91 73.49 Favored 'Isoleucine or valine' 0 C--O 1.234 0.276 0 N-CA-C 109.024 -0.732 . . . . 0.0 109.024 178.433 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -67.23 -33.92 76.37 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 115.123 -0.944 . . . . 0.0 110.642 179.269 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 134' ' ' PHE . . . . . 0.427 ' CZ ' ' HA ' ' A' ' 172' ' ' ALA . 74.6 t80 -56.43 -55.81 28.92 Favored 'General case' 0 N--CA 1.449 -0.484 0 CA-C-O 120.926 0.393 . . . . 0.0 109.951 179.388 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 135' ' ' ILE . . . . . 0.423 ' O ' HG21 ' A' ' 138' ' ' VAL . 40.1 mt -56.58 -33.23 39.14 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.298 0 CA-C-N 115.761 -0.654 . . . . 0.0 109.876 178.942 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . -61.44 -36.9 93.24 Favored Glycine 0 N--CA 1.447 -0.574 0 C-N-CA 120.424 -0.893 . . . . 0.0 111.456 179.067 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 137' ' ' LEU . . . . . 0.469 HD12 HD22 ' A' ' 105' ' ' ASN . 47.9 tp -72.22 -54.02 10.85 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-O 120.527 0.203 . . . . 0.0 110.633 179.657 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 138' ' ' VAL . . . . . 0.423 HG21 ' O ' ' A' ' 135' ' ' ILE . 3.4 m -56.17 -31.51 32.08 Favored 'Isoleucine or valine' 0 C--O 1.233 0.192 0 CA-C-O 121.242 0.544 . . . . 0.0 109.676 179.462 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 139' ' ' TYR . . . . . . . . . . . . . 24.9 t80 -63.41 -46.96 83.98 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 115.432 -0.804 . . . . 0.0 110.311 178.819 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 140' ' ' TYR . . . . . 0.448 ' HE2' HD23 ' A' ' 104' ' ' LEU . 17.2 m-85 -58.89 -37.98 77.84 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.626 179.638 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 141' ' ' LEU . . . . . . . . . . . . . 62.6 mt -57.61 -48.2 80.07 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.189 179.542 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 17.1 t -78.31 -12.58 13.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 115.943 -0.571 . . . . 0.0 110.658 179.654 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 143' ' ' GLY . . . . . 0.414 ' HA3' ' HD2' ' A' ' 144' ' ' PRO . . . -72.44 -134.62 0.18 Allowed Glycine 0 CA--C 1.521 0.425 0 C-N-CA 120.982 -0.627 . . . . 0.0 112.906 -179.845 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 144' ' ' PRO . . . . . 0.414 ' HD2' ' HA3' ' A' ' 143' ' ' GLY . 20.7 Cg_endo -60.43 -23.72 75.76 Favored 'Trans proline' 0 C--N 1.349 0.586 0 C-N-CA 122.647 2.231 . . . . 0.0 112.593 -179.658 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 145' ' ' MET . . . . . . . . . . . . . 55.1 mtt -59.33 -36.73 76.2 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.507 -0.315 . . . . 0.0 111.303 -179.865 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 146' ' ' THR . . . . . . . . . . . . . 86.2 m -79.63 -42.33 25.09 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.508 -0.314 . . . . 0.0 111.431 -179.154 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 8.8 tp10 -61.84 -41.46 97.83 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.243 -179.784 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 148' ' ' SER . . . . . . . . . . . . . 48.7 m -70.61 -46.32 63.59 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.263 -0.426 . . . . 0.0 111.614 -179.325 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 149' ' ' ALA . . . . . 0.436 ' HB3' ' HB2' ' A' ' 91' ' ' ALA . . . -68.33 -30.71 69.75 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.3 -0.409 . . . . 0.0 111.892 -179.206 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 150' ' ' SER . . . . . . . . . . . . . 43.3 t -72.36 -5.9 39.62 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.439 -0.346 . . . . 0.0 111.656 -179.275 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 151' ' ' GLN . . . . . . . . . . . . . 10.3 pt20 -133.55 5.79 3.74 Favored 'General case' 0 C--N 1.33 -0.251 0 N-CA-C 111.649 0.24 . . . . 0.0 111.649 -179.835 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 1.6 tmt_? -73.69 -51.88 15.15 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-O 120.994 0.426 . . . . 0.0 110.251 179.946 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 153' ' ' SER . . . . . 0.607 ' HB2' HG12 ' A' ' 156' ' ' ILE . 49.1 m -158.1 172.08 19.06 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-N 115.759 -0.655 . . . . 0.0 110.256 179.227 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 154' ' ' SER . . . . . . . . . . . . . 88.6 p -70.65 -37.67 73.76 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-O 120.883 0.373 . . . . 0.0 110.474 179.542 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -76.98 -30.26 55.95 Favored Glycine 0 N--CA 1.452 -0.276 0 C-N-CA 120.935 -0.65 . . . . 0.0 112.751 -179.914 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 156' ' ' ILE . . . . . 0.607 HG12 ' HB2' ' A' ' 153' ' ' SER . 39.1 mm -64.48 -39.21 84.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-O 120.765 0.317 . . . . 0.0 111.243 -179.988 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 157' ' ' LYS . . . . . . . . . . . . . 87.1 tttt -63.55 -41.28 98.44 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 116.306 -0.406 . . . . 0.0 111.624 -179.37 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 87.9 p -71.34 -48.33 51.02 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-O 120.956 0.408 . . . . 0.0 111.493 -179.338 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 159' ' ' LEU . . . . . 0.516 HD21 ' HB2' ' A' ' 215' ' ' ALA . 17.4 mt -66.77 -31.85 72.75 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 116.084 -0.507 . . . . 0.0 111.726 -179.269 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 160' ' ' TYR . . . . . . . . . . . . . 50.9 t80 -74.25 -46.79 39.3 Favored 'General case' 0 C--N 1.327 -0.372 0 N-CA-C 112.051 0.389 . . . . 0.0 112.051 -178.841 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 24.4 m -60.12 -44.74 95.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 N-CA-C 111.848 0.314 . . . . 0.0 111.848 -179.154 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 162' ' ' ARG . . . . . 0.445 ' HG2' HG22 ' A' ' 211' ' ' ILE . 22.3 tpp180 -68.88 -40.88 79.01 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.755 0.312 . . . . 0.0 111.638 -179.598 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 163' ' ' LEU . . . . . 0.617 ' HG ' ' HB2' ' A' ' 208' ' ' PHE . 6.3 mp -69.23 -55.14 11.45 Favored 'General case' 0 C--N 1.329 -0.323 0 N-CA-C 112.77 0.656 . . . . 0.0 112.77 -178.724 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 164' ' ' ARG . . . . . 0.413 ' HG3' ' H ' ' A' ' 165' ' ' ASN . 5.0 ppt_? -61.04 -45.5 94.5 Favored 'General case' 0 C--N 1.328 -0.339 0 N-CA-C 112.28 0.474 . . . . 0.0 112.28 -178.316 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 165' ' ' ASN . . . . . 0.413 ' H ' ' HG3' ' A' ' 164' ' ' ARG . 9.5 m-80 -59.88 -51.48 69.5 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.763 0.316 . . . . 0.0 111.28 -179.736 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 166' ' ' LEU . . . . . 0.466 ' O ' ' HG ' ' A' ' 170' ' ' LEU . 3.2 tt -61.21 -50.84 71.49 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.461 -179.511 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 167' ' ' THR . . . . . 0.444 ' O ' ' HB2' ' A' ' 171' ' ' TRP . 92.1 m -55.01 -53.32 57.31 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 115.911 -0.586 . . . . 0.0 112.514 -178.999 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 168' ' ' VAL . . . . . . . . . . . . . 85.3 t -55.16 -43.97 72.67 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.236 0 N-CA-C 112.044 0.387 . . . . 0.0 112.044 -178.803 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 169' ' ' VAL . . . . . . . . . . . . . 72.3 t -56.41 -65.05 0.42 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 N-CA-C 111.969 0.359 . . . . 0.0 111.969 -179.288 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 170' ' ' LEU . . . . . 0.466 ' HG ' ' O ' ' A' ' 166' ' ' LEU . 0.7 OUTLIER -64.76 -28.08 69.33 Favored 'General case' 0 C--N 1.331 -0.238 0 N-CA-C 112.238 0.458 . . . . 0.0 112.238 -178.852 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 171' ' ' TRP . . . . . 0.444 ' HB2' ' O ' ' A' ' 167' ' ' THR . 4.0 m0 -71.13 -30.01 65.96 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-O 121.006 0.431 . . . . 0.0 110.495 179.495 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 172' ' ' ALA . . . . . 0.427 ' HA ' ' CZ ' ' A' ' 134' ' ' PHE . . . -72.67 -6.36 43.85 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 115.917 -0.583 . . . . 0.0 111.056 -179.722 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 173' ' ' ILE . . . . . 0.492 ' O ' HG12 ' A' ' 177' ' ' ILE . 21.6 mm -87.29 -21.82 7.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 115.93 -0.577 . . . . 0.0 111.288 -179.972 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 174' ' ' TYR . . . . . 0.586 ' N ' ' HD2' ' A' ' 175' ' ' PRO . 37.0 m-85 -54.35 -51.24 79.66 Favored Pre-proline 0 CA--C 1.532 0.267 0 N-CA-C 111.955 0.354 . . . . 0.0 111.955 -179.762 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 175' ' ' PRO . . . . . 0.586 ' HD2' ' N ' ' A' ' 174' ' ' TYR . 5.3 Cg_endo -48.41 -29.57 13.76 Favored 'Trans proline' 0 C--N 1.352 0.717 0 C-N-CA 122.106 1.87 . . . . 0.0 112.299 -179.967 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 176' ' ' PHE . . . . . 0.467 ' HD2' ' HA ' ' A' ' 173' ' ' ILE . 58.9 m-85 -80.84 -49.45 11.05 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.044 -0.525 . . . . 0.0 112.053 -179.885 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 177' ' ' ILE . . . . . 0.501 ' HB ' HD13 ' A' ' 197' ' ' ILE . 4.4 mm -62.47 -34.79 66.55 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.496 0 N-CA-C 112.389 0.515 . . . . 0.0 112.389 -178.155 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 178' ' ' TRP . . . . . 0.524 ' HH2' ' HB2' ' A' ' 123' ' ' ARG . 70.0 t90 -73.71 -46.7 44.56 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-O 121.03 0.443 . . . . 0.0 110.766 179.551 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 179' ' ' LEU . . . . . 0.401 ' O ' HG21 ' A' ' 185' ' ' VAL . 1.7 tm? -69.5 -48.42 60.64 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 115.856 -0.611 . . . . 0.0 111.396 -179.172 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 180' ' ' LEU . . . . . 0.578 HD21 HD13 ' A' ' 187' ' ' LEU . 42.2 mt -75.15 -46.62 33.13 Favored 'General case' 0 C--N 1.327 -0.395 0 N-CA-C 111.911 0.338 . . . . 0.0 111.911 -179.153 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . -58.35 -179.59 1.06 Allowed Glycine 0 C--N 1.336 0.582 0 C-N-CA 120.256 -0.973 . . . . 0.0 112.383 179.767 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 182' ' ' PRO . . . . . 0.535 ' HA ' ' HB3' ' A' ' 186' ' ' ALA . 84.7 Cg_exo -47.05 -44.05 23.84 Favored 'Trans proline' 0 CA--C 1.535 0.571 0 C-N-CA 122.834 2.356 . . . . 0.0 113.94 -179.97 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 183' ' ' PRO . . . . . 0.416 ' HD3' ' HB2' ' A' ' 182' ' ' PRO . 74.7 Cg_exo -51.19 -17.71 4.12 Favored 'Trans proline' 0 C--N 1.355 0.891 0 C-N-CA 122.257 1.971 . . . . 0.0 113.456 -179.707 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 184' ' ' GLY . . . . . . . . . . . . . . . -120.51 -92.02 1.27 Allowed Glycine 0 C--N 1.332 0.343 0 C-N-CA 120.207 -0.997 . . . . 0.0 113.294 -179.743 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 185' ' ' VAL . . . . . 0.401 HG21 ' O ' ' A' ' 179' ' ' LEU . 17.8 m -106.39 -13.0 9.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 N-CA-C 112.152 0.427 . . . . 0.0 112.152 -179.004 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 186' ' ' ALA . . . . . 0.535 ' HB3' ' HA ' ' A' ' 182' ' ' PRO . . . 58.36 86.78 0.08 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.794 0.33 . . . . 0.0 111.469 179.848 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 187' ' ' LEU . . . . . 0.578 HD13 HD21 ' A' ' 180' ' ' LEU . 22.8 mt -91.79 -49.02 6.48 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 120.953 0.406 . . . . 0.0 110.968 179.909 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 188' ' ' LEU . . . . . . . . . . . . . 77.5 mt -95.87 -151.66 0.35 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 115.939 -0.573 . . . . 0.0 111.339 -179.365 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 189' ' ' THR . . . . . . . . . . . . . 29.0 m -96.96 137.45 21.31 Favored Pre-proline 0 C--N 1.331 -0.221 0 CA-C-N 115.922 -0.581 . . . . 0.0 110.852 -179.483 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 190' ' ' PRO . . . . . . . . . . . . . 82.0 Cg_exo -46.95 -29.86 8.97 Favored 'Trans proline' 0 C--N 1.349 0.577 0 C-N-CA 122.478 2.118 . . . . 0.0 112.692 179.9 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 191' ' ' THR . . . . . . . . . . . . . 76.7 p -77.4 -40.6 43.08 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.486 -0.324 . . . . 0.0 111.412 -179.948 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 192' ' ' VAL . . . . . . . . . . . . . 61.7 t -72.09 -53.27 20.47 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.289 -0.414 . . . . 0.0 111.564 -179.608 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 193' ' ' ASP . . . . . . . . . . . . . 30.7 m-20 -52.15 -48.79 64.74 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.36 -0.382 . . . . 0.0 111.015 -179.921 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 194' ' ' VAL . . . . . 0.464 ' O ' HG21 ' A' ' 198' ' ' VAL . 55.3 t -62.38 -36.38 74.41 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.645 179.724 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 195' ' ' ALA . . . . . . . . . . . . . . . -56.27 -39.84 73.28 Favored 'General case' 0 C--N 1.332 -0.155 0 CA-C-N 116.348 -0.387 . . . . 0.0 110.571 179.344 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 196' ' ' LEU . . . . . . . . . . . . . 96.4 mt -68.43 -39.62 81.49 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.018 -0.537 . . . . 0.0 110.557 179.251 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 197' ' ' ILE . . . . . 0.501 HD13 ' HB ' ' A' ' 177' ' ' ILE . 18.3 mm -60.43 -60.38 2.67 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.254 0 CA-C-N 115.856 -0.611 . . . . 0.0 111.238 179.957 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 198' ' ' VAL . . . . . 0.464 HG21 ' O ' ' A' ' 194' ' ' VAL . 3.3 m -52.98 -36.05 23.36 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.4 0 CA-C-O 121.596 0.712 . . . . 0.0 109.808 179.003 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 199' ' ' TYR . . . . . . . . . . . . . 37.1 t80 -67.97 -33.04 73.89 Favored 'General case' 0 C--N 1.321 -0.666 0 CA-C-N 114.629 -1.168 . . . . 0.0 110.849 179.858 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 200' ' ' LEU . . . . . 0.447 ' O ' HG12 ' A' ' 203' ' ' VAL . 25.5 mt -68.71 -41.85 78.52 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 121.13 0.49 . . . . 0.0 110.844 179.927 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 201' ' ' ASP . . . . . . . . . . . . . 15.8 m-20 -70.09 -33.18 71.56 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-O 121.321 0.581 . . . . 0.0 109.727 179.109 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 202' ' ' LEU . . . . . . . . . . . . . 3.1 mt -72.33 -31.14 65.41 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 115.213 -0.903 . . . . 0.0 112.014 -179.741 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 203' ' ' VAL . . . . . 0.493 ' O ' ' HA3' ' A' ' 207' ' ' GLY . 13.0 p -76.44 -35.91 27.64 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 C-N-CA 121.06 -0.256 . . . . 0.0 110.958 -178.621 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 204' ' ' THR . . . . . . . . . . . . . 88.8 m -67.66 -58.24 5.01 Favored 'General case' 0 C--N 1.326 -0.443 0 C-N-CA 120.651 -0.42 . . . . 0.0 111.289 179.498 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 205' ' ' LYS . . . . . 0.618 ' HE2' ' HB3' ' A' ' 47' ' ' ALA . 48.7 mttp -62.15 -58.49 7.59 Favored 'General case' 0 C--N 1.329 -0.303 0 N-CA-C 112.21 0.448 . . . . 0.0 112.21 -178.513 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 44.5 t -70.35 -36.22 65.96 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.48 0 CA-C-N 116.025 -0.534 . . . . 0.0 112.068 -178.836 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 207' ' ' GLY . . . . . 0.532 ' O ' HG13 ' A' ' 211' ' ' ILE . . . -58.33 -61.66 7.15 Favored Glycine 0 N--CA 1.452 -0.271 0 C-N-CA 120.634 -0.793 . . . . 0.0 113.844 -178.128 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 208' ' ' PHE . . . . . 0.617 ' HB2' ' HG ' ' A' ' 163' ' ' LEU . 0.8 OUTLIER -72.69 -27.61 62.19 Favored 'General case' 0 C--O 1.221 -0.436 0 CA-C-N 117.515 0.657 . . . . 0.0 110.854 -179.12 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 209' ' ' GLY . . . . . 0.487 ' O ' ' HB1' ' A' ' 212' ' ' ALA . . . -64.1 -31.87 82.29 Favored Glycine 0 N--CA 1.45 -0.399 0 N-CA-C 111.546 -0.622 . . . . 0.0 111.546 178.697 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 210' ' ' PHE . . . . . . . . . . . . . 0.5 OUTLIER -74.79 -47.9 28.32 Favored 'General case' 0 CA--C 1.514 -0.41 0 N-CA-C 108.425 -0.954 . . . . 0.0 108.425 178.451 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 211' ' ' ILE . . . . . 0.532 HG13 ' O ' ' A' ' 207' ' ' GLY . 4.3 mt -63.69 -27.61 43.27 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.45 0 N-CA-C 107.712 -1.218 . . . . 0.0 107.712 176.787 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 212' ' ' ALA . . . . . 0.487 ' HB1' ' O ' ' A' ' 209' ' ' GLY . . . -62.46 -46.1 90.02 Favored 'General case' 0 N--CA 1.449 -0.524 0 CA-C-N 114.469 -1.242 . . . . 0.0 110.549 -179.888 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 213' ' ' LEU . . . . . . . . . . . . . 95.8 mt -70.33 -46.03 65.01 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 115.182 -0.917 . . . . 0.0 111.864 -179.437 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 214' ' ' ASP . . . . . . . . . . . . . 19.9 t70 -56.06 -55.19 35.89 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.466 -0.334 . . . . 0.0 111.604 -179.299 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 215' ' ' ALA . . . . . 0.516 ' HB2' HD21 ' A' ' 159' ' ' LEU . . . -58.95 -53.14 61.77 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.327 -0.397 . . . . 0.0 111.406 -179.559 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 216' ' ' ALA . . . . . . . . . . . . . . . -53.14 -45.08 68.24 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.506 -179.666 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 217' ' ' ALA . . . . . . . . . . . . . . . -55.85 -39.86 72.06 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-O 121.062 0.458 . . . . 0.0 110.301 179.738 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 218' ' ' THR . . . . . . . . . . . . . 92.1 m . . . . . 0 C--N 1.329 -0.306 0 CA-C-N 115.634 -0.712 . . . . 0.0 110.861 179.48 . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.33 0 N-CA-C 112.768 -0.133 . . . . 0.0 112.768 . . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 32.5 tp -74.16 -35.35 64.04 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.808 0.337 . . . . 0.0 110.884 179.967 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 74.7 p -61.67 -30.56 70.81 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.132 -0.486 . . . . 0.0 111.411 -179.985 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 29.0 p -58.98 -36.12 74.36 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-O 120.783 0.325 . . . . 0.0 111.07 -179.852 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 7' ' ' LEU . . . . . . . . . . . . . 4.5 mm? -56.61 -52.06 66.28 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.861 179.862 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 8' ' ' PHE . . . . . 0.544 ' HB2' ' HB2' ' A' ' 55' ' ' ALA . 83.5 m-85 -58.1 -37.84 75.29 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.223 179.477 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 9' ' ' TRP . . . . . . . . . . . . . 15.8 m95 -63.0 -41.81 99.68 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 115.987 -0.551 . . . . 0.0 110.102 -179.987 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 84.9 mt -59.74 -43.87 94.06 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 115.617 -0.719 . . . . 0.0 110.09 179.299 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -61.36 -33.97 86.54 Favored Glycine 0 N--CA 1.448 -0.516 0 C-N-CA 120.656 -0.783 . . . . 0.0 111.554 179.168 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -66.96 -31.23 71.66 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-O 120.912 0.387 . . . . 0.0 110.376 179.447 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 75.5 mt -66.06 -47.52 84.7 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.245 0 CA-C-N 115.985 -0.552 . . . . 0.0 110.097 179.343 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -60.63 -39.43 96.54 Favored Glycine 0 N--CA 1.45 -0.409 0 C-N-CA 120.758 -0.734 . . . . 0.0 111.7 179.315 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 15' ' ' MET . . . . . 0.498 ' HE3' ' HB1' ' A' ' 47' ' ' ALA . 0.1 OUTLIER -63.54 -41.06 98.46 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 120.665 0.269 . . . . 0.0 110.575 179.422 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -55.98 -50.66 70.21 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.758 179.841 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 35.6 t -59.6 -46.4 93.19 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.389 -179.792 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -63.96 -48.5 75.32 Favored Glycine 0 C--N 1.331 0.262 0 C-N-CA 120.718 -0.753 . . . . 0.0 112.437 179.919 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 19' ' ' THR . . . . . 0.421 HG23 HG11 ' A' ' 41' ' ' VAL . 31.9 m -50.6 -44.24 56.97 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-O 120.723 0.297 . . . . 0.0 111.131 -179.774 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 95.2 mt -72.35 -40.28 67.48 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.622 179.907 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -63.19 -33.78 76.21 Favored 'General case' 0 C--N 1.331 -0.196 0 N-CA-C 112.065 0.395 . . . . 0.0 112.065 -179.294 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 22' ' ' PHE . . . . . 0.506 ' HB2' HG22 ' A' ' 41' ' ' VAL . 7.6 m-85 -86.2 -33.7 20.7 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.657 0.265 . . . . 0.0 111.658 -179.131 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -73.6 -50.7 19.85 Favored 'General case' 0 C--N 1.329 -0.297 0 N-CA-C 111.991 0.367 . . . . 0.0 111.991 -179.206 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 24' ' ' TRP . . . . . . . . . . . . . 2.7 t-105 -58.99 -46.62 87.7 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 116.029 -0.532 . . . . 0.0 111.239 -179.503 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.328 -0.361 0 CA-C-O 120.828 0.347 . . . . 0.0 110.925 179.796 . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.3 0 N-CA-C 112.562 -0.215 . . . . 0.0 112.562 . . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 9.1 mm-40 -60.63 -21.07 62.32 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 120.698 0.285 . . . . 0.0 110.989 179.868 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 34' ' ' ARG . . . . . . . . . . . . . 38.6 ttm180 -48.44 -34.99 11.96 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-N 115.969 -0.559 . . . . 0.0 111.525 -179.758 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 70.3 mtm180 -55.1 -54.84 38.08 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.314 -0.403 . . . . 0.0 111.303 -179.986 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 82.0 m-85 -59.7 -28.7 67.53 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.097 -179.946 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 37' ' ' TYR . . . . . . . . . . . . . 52.5 m-85 -71.97 -52.42 17.18 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.3 -0.409 . . . . 0.0 111.314 -179.893 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 59.8 t -57.69 -39.26 69.3 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.219 0 CA-C-O 121.116 0.484 . . . . 0.0 110.528 179.658 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 19.6 m -62.81 -50.93 69.05 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 115.576 -0.738 . . . . 0.0 110.715 179.403 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 19.6 tp -57.57 -50.21 73.86 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 115.652 -0.704 . . . . 0.0 110.578 -179.997 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . 0.506 HG22 ' HB2' ' A' ' 22' ' ' PHE . 85.5 t -59.02 -34.9 54.39 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.235 0 CA-C-N 115.856 -0.611 . . . . 0.0 110.236 179.142 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -59.19 -39.56 94.66 Favored Glycine 0 N--CA 1.448 -0.505 0 C-N-CA 120.834 -0.698 . . . . 0.0 112.06 179.652 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 43' ' ' ILE . . . . . 0.479 HG12 HD12 ' A' ' 82' ' ' LEU . 1.2 mt -64.84 -55.59 20.15 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.193 0 CA-C-O 120.683 0.278 . . . . 0.0 110.728 179.567 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 51.3 m -57.72 -23.81 53.7 Favored 'General case' 0 C--O 1.232 0.178 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.181 -179.963 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -78.18 -56.23 3.79 Favored Glycine 0 CA--C 1.518 0.251 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.668 -179.772 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 26.6 pt -58.31 -35.4 53.49 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.215 0 CA-C-O 121.08 0.467 . . . . 0.0 110.912 179.944 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 47' ' ' ALA . . . . . 0.589 ' HB3' ' HE2' ' A' ' 205' ' ' LYS . . . -67.51 -46.74 71.99 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-N 116.031 -0.531 . . . . 0.0 111.307 179.346 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 48' ' ' ALA . . . . . 0.48 ' HB3' ' HB3' ' A' ' 15' ' ' MET . . . -54.87 -40.6 69.87 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 116.04 -0.527 . . . . 0.0 111.951 -179.485 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 25.1 m -73.08 -34.69 46.04 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 CA-C-N 116.63 -0.259 . . . . 0.0 111.516 -179.207 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -65.96 -38.18 87.93 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-O 121.145 0.498 . . . . 0.0 110.749 179.346 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 51' ' ' TYR . . . . . 0.441 ' HB3' ' O ' ' A' ' 8' ' ' PHE . 42.9 m-85 -73.09 -28.31 62.21 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-N 115.813 -0.631 . . . . 0.0 109.734 179.466 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -72.35 -38.88 68.48 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 115.419 -0.809 . . . . 0.0 110.97 179.517 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 53' ' ' VAL . . . . . 0.528 ' O ' HG22 ' A' ' 58' ' ' VAL . 33.8 m -73.95 -47.49 42.53 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.159 0 CA-C-N 116.402 -0.363 . . . . 0.0 110.78 -179.941 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 54' ' ' MET . . . . . 0.46 ' N ' HG23 ' A' ' 53' ' ' VAL . 75.0 mtm -57.75 -36.44 72.1 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-O 121.241 0.543 . . . . 0.0 109.949 179.094 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 55' ' ' ALA . . . . . 0.544 ' HB2' ' HB2' ' A' ' 8' ' ' PHE . . . -68.91 -11.69 60.86 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 115.317 -0.856 . . . . 0.0 111.705 179.876 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 47.4 mt -97.57 -4.21 38.15 Favored 'General case' 0 C--N 1.33 -0.259 0 N-CA-C 111.944 0.35 . . . . 0.0 111.944 -179.475 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 105.13 -23.0 31.77 Favored Glycine 0 CA--C 1.52 0.352 0 C-N-CA 120.373 -0.917 . . . . 0.0 114.004 179.23 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 58' ' ' VAL . . . . . 0.528 HG22 ' O ' ' A' ' 53' ' ' VAL . 16.3 m -62.05 160.41 2.21 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.128 0 CA-C-N 117.722 0.761 . . . . 0.0 109.768 179.343 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 59' ' ' GLY . . . . . 0.651 ' HA3' ' HD3' ' A' ' 71' ' ' PRO . . . 79.58 -25.56 2.86 Favored Glycine 0 N--CA 1.441 -1.033 0 C-N-CA 119.999 -1.096 . . . . 0.0 112.71 -178.844 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 60' ' ' TRP . . . . . . . . . . . . . 11.6 m0 -67.77 80.13 0.19 Allowed 'General case' 0 C--N 1.327 -0.388 0 N-CA-C 110.176 -0.305 . . . . 0.0 110.176 179.561 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 4.7 p -90.83 119.35 68.96 Favored Pre-proline 0 C--N 1.33 -0.266 0 CA-C-N 116.461 -0.336 . . . . 0.0 111.202 -179.747 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 35.8 Cg_exo -60.49 119.44 6.63 Favored 'Trans proline' 0 C--N 1.35 0.615 0 C-N-CA 122.451 2.101 . . . . 0.0 112.176 179.841 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 78.4 t -117.21 99.59 8.54 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.364 0 CA-C-N 115.931 -0.577 . . . . 0.0 110.918 179.914 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . 59.9 -85.65 0.02 OUTLIER 'General case' 0 C--N 1.332 -0.174 0 CA-C-N 116.095 -0.502 . . . . 0.0 111.254 -179.926 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 53.8 mm-40 -126.74 -26.69 3.18 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.335 179.521 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 66' ' ' ARG . . . . . . . . . . . . . 34.5 ptt180 -95.41 164.23 12.9 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 115.823 -0.626 . . . . 0.0 110.306 179.474 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 13.8 m -114.94 132.02 56.7 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.848 0.356 . . . . 0.0 111.265 -179.999 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 29.4 t -116.78 145.77 22.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.023 -0.535 . . . . 0.0 110.634 179.728 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 69' ' ' PHE . . . . . . . . . . . . . 10.8 m-85 -102.09 119.8 39.39 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-O 120.917 0.389 . . . . 0.0 110.659 -179.357 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 70' ' ' VAL . . . . . 0.58 HG22 ' HD3' ' A' ' 71' ' ' PRO . 1.2 m -69.67 -35.57 5.7 Favored Pre-proline 0 CA--C 1.544 0.727 0 N-CA-C 113.05 0.759 . . . . 0.0 113.05 -179.344 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 71' ' ' PRO . . . . . 0.651 ' HD3' ' HA3' ' A' ' 59' ' ' GLY . 8.4 Cg_exo -70.56 -19.87 31.78 Favored 'Trans proline' 0 C--N 1.358 1.055 0 C-N-CA 122.579 2.186 . . . . 0.0 112.88 -178.146 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 72' ' ' ARG . . . . . 0.428 ' NH2' ' HG3' ' A' ' 183' ' ' PRO . 38.5 ttp180 -64.72 -53.46 46.84 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-O 120.949 0.404 . . . . 0.0 110.66 -179.916 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 73' ' ' TYR . . . . . . . . . . . . . 19.6 m-85 -73.19 -37.36 66.51 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.572 -179.97 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 74' ' ' ILE . . . . . 0.437 HG22 ' HA ' ' A' ' 71' ' ' PRO . 0.4 OUTLIER -64.08 -39.86 87.0 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 N-CA-C 109.877 -0.416 . . . . 0.0 109.877 179.439 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 33.9 t70 -64.06 -34.8 78.84 Favored 'General case' 0 CA--C 1.516 -0.362 0 N-CA-C 108.882 -0.785 . . . . 0.0 108.882 178.868 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 76' ' ' TRP . . . . . 0.425 ' HB3' ' SD ' ' A' ' 109' ' ' MET . 44.5 m0 -66.42 -28.1 68.35 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 115.531 -0.759 . . . . 0.0 110.251 179.064 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 77' ' ' ILE . . . . . 0.492 ' O ' ' HG2' ' A' ' 81' ' ' PRO . 85.0 mt -75.89 -28.75 19.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-O 121.184 0.516 . . . . 0.0 109.69 178.827 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 52.0 mt -91.55 -18.32 24.27 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 115.758 -0.655 . . . . 0.0 111.446 179.183 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 76.1 p -104.22 -50.98 3.22 Favored 'General case' 0 N--CA 1.464 0.225 0 N-CA-C 113.278 0.844 . . . . 0.0 113.278 -178.084 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 80' ' ' THR . . . . . 0.658 ' HB ' ' HD3' ' A' ' 81' ' ' PRO . 40.2 m -51.98 -55.19 32.89 Favored Pre-proline 0 CA--C 1.53 0.19 0 N-CA-C 111.947 0.351 . . . . 0.0 111.947 -178.642 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 81' ' ' PRO . . . . . 0.658 ' HD3' ' HB ' ' A' ' 80' ' ' THR . 40.6 Cg_exo -58.72 -21.8 57.97 Favored 'Trans proline' 0 C--N 1.352 0.748 0 C-N-CA 121.426 1.417 . . . . 0.0 111.133 179.406 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 82' ' ' LEU . . . . . 0.479 HD12 HG12 ' A' ' 43' ' ' ILE . 0.2 OUTLIER -76.36 -43.42 40.99 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 115.555 -0.748 . . . . 0.0 109.999 179.638 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 50.4 mm -63.76 -52.38 57.9 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.192 0 CA-C-N 116.074 -0.512 . . . . 0.0 110.424 179.512 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 29.3 m -57.98 -33.79 47.11 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.202 0 N-CA-C 109.738 -0.467 . . . . 0.0 109.738 179.104 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 85' ' ' TYR . . . . . . . . . . . . . 61.6 t80 -62.1 -36.13 80.79 Favored 'General case' 0 N--CA 1.454 -0.27 0 CA-C-N 115.796 -0.638 . . . . 0.0 109.463 178.601 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 86' ' ' PHE . . . . . . . . . . . . . 13.0 t80 -59.7 -49.12 78.98 Favored 'General case' 0 C--O 1.232 0.183 0 CA-C-N 115.641 -0.709 . . . . 0.0 109.726 179.0 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 3.9 mm? -56.42 -41.8 76.96 Favored 'General case' 0 C--N 1.332 -0.176 0 CA-C-N 115.696 -0.684 . . . . 0.0 110.02 179.334 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -66.51 -27.97 73.46 Favored Glycine 0 N--CA 1.45 -0.397 0 CA-C-N 115.721 -0.672 . . . . 0.0 112.432 179.748 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 87.9 mt -71.0 -33.05 70.02 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.973 0.416 . . . . 0.0 110.516 179.814 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 95.6 mt -73.53 -30.98 63.42 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 115.884 -0.598 . . . . 0.0 111.134 179.824 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -88.47 -28.58 20.75 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.452 -0.34 . . . . 0.0 111.694 -179.603 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 80.62 58.05 2.78 Favored Glycine 0 N--CA 1.452 -0.3 0 C-N-CA 120.72 -0.752 . . . . 0.0 111.93 -179.5 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 93' ' ' LEU . . . . . 0.464 HD13 ' HE3' ' A' ' 145' ' ' MET . 94.5 mt -74.97 177.75 6.1 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.986 0.422 . . . . 0.0 111.506 -179.384 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 94' ' ' ASP . . . . . . . . . . . . . 9.9 m-20 -102.13 171.3 7.57 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-N 115.818 -0.628 . . . . 0.0 110.654 179.666 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 45.8 t -57.4 -36.91 71.91 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.292 -0.413 . . . . 0.0 111.192 -179.63 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 15.2 ptm180 -73.5 -48.12 35.75 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.467 -0.333 . . . . 0.0 111.343 -179.846 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 48.0 mt-10 -53.18 -45.69 68.65 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.303 -0.408 . . . . 0.0 111.079 -179.846 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 98' ' ' PHE . . . . . 0.45 ' O ' HG12 ' A' ' 102' ' ' ILE . 26.3 m-85 -59.25 -49.48 77.67 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.673 179.611 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -55.77 -28.02 51.25 Favored Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.811 -0.709 . . . . 0.0 112.862 -179.754 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 93.5 mt -73.77 -49.05 37.16 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 N-CA-C 111.914 0.339 . . . . 0.0 111.914 -179.641 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 33.1 m -70.58 -32.55 50.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 N-CA-C 111.962 0.356 . . . . 0.0 111.962 -179.251 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 102' ' ' ILE . . . . . 0.477 HG21 ' HB3' ' A' ' 81' ' ' PRO . 50.2 mm -74.93 -43.0 46.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.536 -0.302 . . . . 0.0 111.426 -179.573 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 14.7 t -63.52 -34.0 76.82 Favored 'General case' 0 C--O 1.232 0.134 0 CA-C-O 121.075 0.464 . . . . 0.0 110.116 179.532 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 104' ' ' LEU . . . . . 0.424 ' O ' HG23 ' A' ' 108' ' ' VAL . 42.8 tp -61.82 -57.11 13.11 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 115.796 -0.638 . . . . 0.0 110.072 179.101 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 105' ' ' ASN . . . . . 0.603 ' N ' HD21 ' A' ' 105' ' ' ASN . 0.8 OUTLIER -55.95 -25.82 45.3 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 115.967 -0.561 . . . . 0.0 110.873 179.411 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 79.0 m -64.07 -57.53 9.36 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.422 -0.353 . . . . 0.0 111.205 -179.93 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 7.1 p -62.25 -35.83 71.29 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.211 0 CA-C-N 116.394 -0.366 . . . . 0.0 110.952 179.916 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . 0.424 HG23 ' O ' ' A' ' 104' ' ' LEU . 84.6 t -62.87 -56.99 14.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-O 121.052 0.453 . . . . 0.0 110.783 179.645 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 109' ' ' MET . . . . . 0.425 ' SD ' ' HB3' ' A' ' 76' ' ' TRP . 5.5 tpp -58.07 -32.43 68.03 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 115.793 -0.639 . . . . 0.0 110.932 -179.729 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 22.4 tp -66.93 -35.97 81.19 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.243 179.663 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -62.46 -44.12 97.18 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 115.855 -0.611 . . . . 0.0 110.491 179.312 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . -64.17 -44.7 95.28 Favored Glycine 0 N--CA 1.452 -0.278 0 C-N-CA 120.751 -0.737 . . . . 0.0 112.289 179.519 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 113' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -51.04 -63.73 1.04 Allowed 'General case' 0 C--N 1.333 -0.149 0 CA-C-O 121.075 0.464 . . . . 0.0 110.347 179.765 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -67.31 -16.71 64.42 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 115.782 -0.645 . . . . 0.0 110.862 179.575 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -60.85 -47.01 93.34 Favored Glycine 0 C--N 1.332 0.35 0 C-N-CA 120.768 -0.729 . . . . 0.0 112.267 179.7 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -78.48 -22.57 47.29 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 120.666 0.27 . . . . 0.0 111.631 179.796 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 117' ' ' MET . . . . . . . . . . . . . 1.1 mpt? -87.11 18.33 3.7 Favored 'General case' 0 C--N 1.332 -0.162 0 CA-C-N 116.53 -0.304 . . . . 0.0 111.712 -179.705 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 118' ' ' VAL . . . . . 0.469 HG22 ' HB3' ' A' ' 123' ' ' ARG . 27.3 m -76.13 147.69 80.28 Favored Pre-proline 0 C--N 1.327 -0.37 0 CA-C-N 116.668 -0.242 . . . . 0.0 111.305 179.99 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 119' ' ' PRO . . . . . . . . . . . . . 67.7 Cg_endo -84.55 -15.78 6.01 Favored 'Trans proline' 0 C--N 1.347 0.476 0 C-N-CA 122.667 2.245 . . . . 0.0 112.645 -179.987 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -143.68 -110.79 0.75 Allowed Glycine 0 C--N 1.333 0.369 0 C-N-CA 120.462 -0.875 . . . . 0.0 113.282 -179.53 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 47.9 pt -111.16 11.59 8.61 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.218 0 N-CA-C 111.783 0.29 . . . . 0.0 111.783 -179.225 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 15.7 mm-40 -58.39 -19.06 32.79 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.867 0.365 . . . . 0.0 110.815 179.819 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 123' ' ' ARG . . . . . 0.469 ' HB3' HG22 ' A' ' 118' ' ' VAL . 32.0 ptt180 -53.09 -30.02 33.83 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 115.714 -0.675 . . . . 0.0 111.843 -179.817 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 124' ' ' TYR . . . . . . . . . . . . . 48.5 m-85 -75.3 -32.62 61.03 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 116.316 -0.402 . . . . 0.0 111.907 -178.985 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 125' ' ' ALA . . . . . . . . . . . . . . . -70.68 -55.65 8.23 Favored 'General case' 0 C--O 1.238 0.453 0 CA-C-O 121.121 0.486 . . . . 0.0 110.892 179.953 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 1.3 mt -55.85 -46.07 78.31 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 115.591 -0.732 . . . . 0.0 110.607 -179.613 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 127' ' ' PHE . . . . . 0.47 ' HZ ' ' HB3' ' A' ' 175' ' ' PRO . 3.0 t80 -67.29 -39.01 85.95 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.442 -0.345 . . . . 0.0 110.555 179.618 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 128' ' ' GLY . . . . . . . . . . . . . . . -46.44 -43.72 15.1 Favored Glycine 0 C--O 1.237 0.284 0 C-N-CA 120.129 -1.034 . . . . 0.0 111.09 179.356 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 129' ' ' MET . . . . . 0.414 ' HE2' ' N ' ' A' ' 130' ' ' GLY . 0.4 OUTLIER -70.92 -40.34 72.16 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 121.014 0.435 . . . . 0.0 110.263 178.999 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 130' ' ' GLY . . . . . 0.414 ' N ' ' HE2' ' A' ' 129' ' ' MET . . . -66.32 -26.4 72.62 Favored Glycine 0 N--CA 1.452 -0.254 0 CA-C-N 115.727 -0.67 . . . . 0.0 113.018 -179.691 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -75.08 -53.66 8.5 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 120.664 0.269 . . . . 0.0 110.588 179.98 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 56.2 t -59.27 -41.01 82.7 Favored 'Isoleucine or valine' 0 C--O 1.234 0.275 0 N-CA-C 109.203 -0.666 . . . . 0.0 109.203 178.7 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -67.54 -34.53 77.26 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-N 115.207 -0.906 . . . . 0.0 110.549 179.214 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 134' ' ' PHE . . . . . . . . . . . . . 39.8 t80 -55.86 -54.77 40.55 Favored 'General case' 0 N--CA 1.452 -0.344 0 CA-C-N 116.209 -0.451 . . . . 0.0 109.992 179.485 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 135' ' ' ILE . . . . . 0.462 ' HA ' HG22 ' A' ' 138' ' ' VAL . 33.1 mt -58.15 -31.89 42.97 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 CA-C-N 115.711 -0.677 . . . . 0.0 110.116 179.164 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . -59.27 -44.89 96.17 Favored Glycine 0 N--CA 1.449 -0.488 0 C-N-CA 120.401 -0.904 . . . . 0.0 112.119 179.124 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 137' ' ' LEU . . . . . 0.572 HD13 HD22 ' A' ' 105' ' ' ASN . 13.9 tp -70.76 -52.02 23.38 Favored 'General case' 0 C--N 1.33 -0.258 0 C-N-CA 121.055 -0.258 . . . . 0.0 111.173 -179.867 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 138' ' ' VAL . . . . . 0.462 HG22 ' HA ' ' A' ' 135' ' ' ILE . 4.2 m -54.53 -31.56 23.49 Favored 'Isoleucine or valine' 0 C--O 1.232 0.168 0 N-CA-C 109.604 -0.517 . . . . 0.0 109.604 -179.737 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 139' ' ' TYR . . . . . . . . . . . . . 13.9 t80 -63.69 -44.53 93.41 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 115.616 -0.72 . . . . 0.0 109.596 178.16 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 24.9 m-85 -59.01 -42.83 91.06 Favored 'General case' 0 C--O 1.233 0.189 0 CA-C-N 115.971 -0.559 . . . . 0.0 111.05 179.402 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 141' ' ' LEU . . . . . 0.487 ' HA ' ' SD ' ' A' ' 145' ' ' MET . 9.4 mp -55.59 -49.76 71.91 Favored 'General case' 0 N--CA 1.462 0.17 0 CA-C-N 116.429 -0.351 . . . . 0.0 110.994 -179.774 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 12.6 p -82.46 -10.27 11.97 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.364 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.99 -179.98 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 143' ' ' GLY . . . . . 0.472 ' O ' HG22 ' A' ' 146' ' ' THR . . . -74.99 -144.97 1.1 Allowed Glycine 0 CA--C 1.521 0.455 0 C-N-CA 121.05 -0.595 . . . . 0.0 112.889 -179.766 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 144' ' ' PRO . . . . . . . . . . . . . 78.1 Cg_exo -50.07 -23.27 9.05 Favored 'Trans proline' 0 C--N 1.348 0.537 0 C-N-CA 122.794 2.329 . . . . 0.0 112.93 -179.934 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 145' ' ' MET . . . . . 0.487 ' SD ' ' HA ' ' A' ' 141' ' ' LEU . 27.4 mtt -52.4 -43.87 65.02 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.392 -0.367 . . . . 0.0 111.636 -179.681 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 146' ' ' THR . . . . . 0.472 HG22 ' O ' ' A' ' 143' ' ' GLY . 8.3 t -76.67 -31.77 57.51 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-O 120.907 0.384 . . . . 0.0 110.862 -179.471 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 34.0 tt0 -64.5 -40.4 95.59 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 115.989 -0.55 . . . . 0.0 110.769 179.858 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 148' ' ' SER . . . . . . . . . . . . . 55.5 m -70.41 -46.88 63.1 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.75 -179.972 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 149' ' ' ALA . . . . . . . . . . . . . . . -62.38 -32.41 73.21 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 115.935 -0.575 . . . . 0.0 111.19 -179.995 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 150' ' ' SER . . . . . . . . . . . . . 48.1 t -70.56 -1.64 11.66 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.815 179.843 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 151' ' ' GLN . . . . . . . . . . . . . 48.8 mt-30 -120.18 1.64 10.83 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.121 -0.491 . . . . 0.0 111.168 -179.832 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 26.6 mmm180 -81.88 -52.45 7.08 Favored 'General case' 0 C--N 1.332 -0.171 0 CA-C-O 121.11 0.481 . . . . 0.0 110.51 179.699 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 153' ' ' SER . . . . . 0.541 ' HB2' HG12 ' A' ' 156' ' ' ILE . 25.3 m -157.41 172.31 18.81 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-N 115.599 -0.728 . . . . 0.0 110.842 179.296 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 154' ' ' SER . . . . . . . . . . . . . 81.0 p -70.41 -39.1 74.64 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.303 -0.408 . . . . 0.0 110.709 179.579 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -77.21 -39.35 27.2 Favored Glycine 0 CA--C 1.518 0.269 0 C-N-CA 121.057 -0.592 . . . . 0.0 112.905 -179.83 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 156' ' ' ILE . . . . . 0.541 HG12 ' HB2' ' A' ' 153' ' ' SER . 35.6 mm -49.73 -38.92 14.08 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.175 0 CA-C-O 120.774 0.321 . . . . 0.0 111.823 -179.616 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 157' ' ' LYS . . . . . . . . . . . . . 64.7 tttm -66.72 -37.91 85.63 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-N 116.304 -0.407 . . . . 0.0 111.363 -179.559 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 49.5 m -71.38 -37.91 71.56 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 121.003 0.43 . . . . 0.0 111.157 -178.815 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 159' ' ' LEU . . . . . 0.552 ' O ' ' HG ' ' A' ' 163' ' ' LEU . 31.3 mt -70.6 -56.79 5.66 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-N 116.043 -0.526 . . . . 0.0 111.13 -179.642 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 160' ' ' TYR . . . . . 0.432 ' OH ' ' HB3' ' A' ' 145' ' ' MET . 31.9 t80 -51.88 -41.83 62.2 Favored 'General case' 0 C--N 1.325 -0.466 0 N-CA-C 112.416 0.524 . . . . 0.0 112.416 -178.764 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 161' ' ' VAL . . . . . 0.409 HG22 ' N ' ' A' ' 162' ' ' ARG . 30.5 m -66.28 -49.07 78.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 N-CA-C 112.022 0.379 . . . . 0.0 112.022 -178.529 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 162' ' ' ARG . . . . . 0.409 ' N ' HG22 ' A' ' 161' ' ' VAL . 98.4 mtt180 -66.02 -49.38 67.94 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.768 0.318 . . . . 0.0 111.731 -179.205 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 163' ' ' LEU . . . . . 0.552 ' HG ' ' O ' ' A' ' 159' ' ' LEU . 19.7 mt -60.65 -55.43 33.32 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.635 -179.164 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 164' ' ' ARG . . . . . 0.408 ' HG3' ' N ' ' A' ' 165' ' ' ASN . 3.8 ppt_? -58.85 -38.71 79.34 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.363 -0.38 . . . . 0.0 111.959 -178.967 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 165' ' ' ASN . . . . . 0.411 ' O ' HG21 ' A' ' 169' ' ' VAL . 0.9 OUTLIER -56.6 -53.62 55.49 Favored 'General case' 0 C--O 1.237 0.408 0 CA-C-O 120.751 0.31 . . . . 0.0 111.133 -178.383 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 166' ' ' LEU . . . . . 0.462 ' O ' ' HG ' ' A' ' 170' ' ' LEU . 0.2 OUTLIER -68.01 -28.89 67.81 Favored 'General case' 0 C--N 1.326 -0.439 0 C-N-CA 120.588 -0.445 . . . . 0.0 110.267 -179.917 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 167' ' ' THR . . . . . 0.417 ' O ' ' HB2' ' A' ' 171' ' ' TRP . 21.7 m -61.19 -53.35 57.98 Favored 'General case' 0 N--CA 1.462 0.131 0 CA-C-N 116.313 -0.403 . . . . 0.0 111.259 179.743 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 168' ' ' VAL . . . . . . . . . . . . . 60.4 t -60.04 -40.64 83.79 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 115.826 -0.624 . . . . 0.0 111.799 -179.054 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 169' ' ' VAL . . . . . 0.411 HG21 ' O ' ' A' ' 165' ' ' ASN . 93.9 t -56.74 -65.5 0.39 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 C-N-CA 120.914 -0.314 . . . . 0.0 111.739 -179.69 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 170' ' ' LEU . . . . . 0.462 ' HG ' ' O ' ' A' ' 166' ' ' LEU . 1.1 pp -62.8 -33.11 74.52 Favored 'General case' 0 C--N 1.33 -0.269 0 N-CA-C 112.467 0.543 . . . . 0.0 112.467 -178.576 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 171' ' ' TRP . . . . . 0.417 ' HB2' ' O ' ' A' ' 167' ' ' THR . 2.2 m0 -69.01 -31.28 69.99 Favored 'General case' 0 N--CA 1.463 0.22 0 C-N-CA 120.846 -0.341 . . . . 0.0 110.844 179.644 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 172' ' ' ALA . . . . . . . . . . . . . . . -74.53 -7.08 51.93 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-O 120.909 0.385 . . . . 0.0 110.587 -179.768 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 173' ' ' ILE . . . . . 0.515 HG21 HD13 ' A' ' 177' ' ' ILE . 40.6 mm -85.48 -21.84 7.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 115.787 -0.642 . . . . 0.0 110.865 179.62 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 174' ' ' TYR . . . . . . . . . . . . . 26.9 m-85 -54.56 -50.05 87.59 Favored Pre-proline 0 N--CA 1.464 0.242 0 CA-C-N 116.33 -0.396 . . . . 0.0 111.542 -179.975 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 175' ' ' PRO . . . . . 0.47 ' HB3' ' HZ ' ' A' ' 127' ' ' PHE . 86.8 Cg_exo -46.93 -30.79 10.16 Favored 'Trans proline' 0 C--N 1.352 0.749 0 C-N-CA 122.121 1.88 . . . . 0.0 112.215 179.575 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 176' ' ' PHE . . . . . 0.466 ' HD2' ' HA ' ' A' ' 173' ' ' ILE . 76.8 m-85 -80.38 -48.81 12.35 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 115.928 -0.578 . . . . 0.0 111.65 -179.768 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 177' ' ' ILE . . . . . 0.515 HD13 HG21 ' A' ' 173' ' ' ILE . 3.4 mm -63.47 -34.24 66.25 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.516 0 CA-C-N 116.374 -0.375 . . . . 0.0 111.881 -178.5 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 178' ' ' TRP . . . . . 0.42 ' HH2' ' HB2' ' A' ' 123' ' ' ARG . 73.8 t90 -74.03 -48.78 27.7 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 121.041 0.448 . . . . 0.0 110.449 179.438 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 179' ' ' LEU . . . . . 0.471 HD11 HD22 ' A' ' 180' ' ' LEU . 1.9 tm? -63.55 -52.3 61.7 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 115.68 -0.691 . . . . 0.0 111.239 -179.395 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 180' ' ' LEU . . . . . 0.594 HD23 HD13 ' A' ' 187' ' ' LEU . 15.6 mt -76.73 -41.83 43.56 Favored 'General case' 0 C--N 1.329 -0.324 0 N-CA-C 112.076 0.398 . . . . 0.0 112.076 -178.914 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . -58.18 179.02 1.26 Allowed Glycine 0 C--N 1.334 0.456 0 C-N-CA 120.166 -1.016 . . . . 0.0 112.426 179.759 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 182' ' ' PRO . . . . . 0.429 ' HB2' ' HD3' ' A' ' 183' ' ' PRO . 72.0 Cg_exo -47.27 -45.29 22.47 Favored 'Trans proline' 0 CA--C 1.536 0.61 0 C-N-CA 122.741 2.294 . . . . 0.0 113.798 -179.856 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 183' ' ' PRO . . . . . 0.429 ' HD3' ' HB2' ' A' ' 182' ' ' PRO . 71.6 Cg_exo -49.49 -22.98 6.91 Favored 'Trans proline' 0 C--N 1.356 0.955 0 C-N-CA 122.223 1.949 . . . . 0.0 113.121 -179.786 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 184' ' ' GLY . . . . . . . . . . . . . . . -119.07 -132.99 4.58 Favored Glycine 0 N--CA 1.449 -0.448 0 C-N-CA 120.484 -0.865 . . . . 0.0 112.906 -179.824 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 185' ' ' VAL . . . . . . . . . . . . . 13.3 m -58.75 -21.02 17.93 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.396 0 N-CA-C 112.13 0.418 . . . . 0.0 112.13 -179.485 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 186' ' ' ALA . . . . . . . . . . . . . . . 55.61 87.18 0.05 Allowed 'General case' 0 N--CA 1.463 0.194 0 CA-C-O 120.74 0.305 . . . . 0.0 111.391 179.906 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 187' ' ' LEU . . . . . 0.594 HD13 HD23 ' A' ' 180' ' ' LEU . 15.8 mt -91.75 -49.54 6.21 Favored 'General case' 0 C--N 1.332 -0.195 0 CA-C-N 116.291 -0.413 . . . . 0.0 111.341 -179.713 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 188' ' ' LEU . . . . . . . . . . . . . 68.6 mt -96.85 -155.07 0.47 Allowed 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 115.923 -0.58 . . . . 0.0 110.991 -179.573 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 189' ' ' THR . . . . . 0.458 ' HG1' HG22 ' A' ' 191' ' ' THR . 1.9 t -101.6 146.74 32.76 Favored Pre-proline 0 C--N 1.328 -0.367 0 CA-C-N 116.001 -0.545 . . . . 0.0 110.817 -179.987 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 190' ' ' PRO . . . . . . . . . . . . . 86.5 Cg_exo -47.09 -45.2 21.97 Favored 'Trans proline' 0 C--N 1.348 0.502 0 C-N-CA 122.694 2.262 . . . . 0.0 113.35 -179.528 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 191' ' ' THR . . . . . 0.458 HG22 ' HG1' ' A' ' 189' ' ' THR . 5.6 t -56.58 -39.95 74.4 Favored 'General case' 0 C--N 1.329 -0.316 0 N-CA-C 112.061 0.393 . . . . 0.0 112.061 -179.338 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 192' ' ' VAL . . . . . . . . . . . . . 40.6 t -73.37 -53.82 17.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 N-CA-C 111.909 0.337 . . . . 0.0 111.909 -179.435 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 193' ' ' ASP . . . . . . . . . . . . . 19.0 m-20 -58.36 -50.11 74.84 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.516 -0.311 . . . . 0.0 111.217 -179.829 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 194' ' ' VAL . . . . . . . . . . . . . 78.0 t -59.9 -36.33 66.04 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 116.339 -0.392 . . . . 0.0 110.691 179.557 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 195' ' ' ALA . . . . . . . . . . . . . . . -56.26 -47.85 77.72 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 116.397 -0.365 . . . . 0.0 111.121 179.792 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 196' ' ' LEU . . . . . . . . . . . . . 91.6 mt -64.99 -35.39 81.02 Favored 'General case' 0 C--N 1.332 -0.177 0 CA-C-O 120.771 0.319 . . . . 0.0 110.464 179.658 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 197' ' ' ILE . . . . . 0.493 HD12 ' HB ' ' A' ' 177' ' ' ILE . 19.6 mm -61.46 -53.8 43.7 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-O 121.142 0.496 . . . . 0.0 110.022 178.972 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 198' ' ' VAL . . . . . . . . . . . . . 98.3 t -54.91 -34.32 30.81 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.47 0 CA-C-N 115.344 -0.844 . . . . 0.0 109.33 178.471 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 199' ' ' TYR . . . . . . . . . . . . . 68.8 t80 -69.35 -40.4 77.53 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 115.083 -0.962 . . . . 0.0 110.246 179.925 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 200' ' ' LEU . . . . . . . . . . . . . 38.1 mt -61.72 -41.56 97.79 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 115.74 -0.663 . . . . 0.0 111.371 -179.773 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 201' ' ' ASP . . . . . 0.412 ' HB2' ' HH ' ' A' ' 51' ' ' TYR . 0.9 OUTLIER -71.87 -40.39 68.98 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.041 -179.807 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 202' ' ' LEU . . . . . . . . . . . . . 2.7 mt -65.2 -33.71 76.66 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.119 -0.491 . . . . 0.0 111.617 -179.401 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 203' ' ' VAL . . . . . 0.521 ' O ' ' HA3' ' A' ' 207' ' ' GLY . 65.9 t -77.31 -36.07 23.4 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.384 0 CA-C-O 120.74 0.305 . . . . 0.0 111.381 -179.12 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 204' ' ' THR . . . . . . . . . . . . . 88.8 m -66.46 -58.61 4.9 Favored 'General case' 0 C--N 1.325 -0.497 0 C-N-CA 120.745 -0.382 . . . . 0.0 111.298 179.95 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 205' ' ' LYS . . . . . 0.589 ' HE2' ' HB3' ' A' ' 47' ' ' ALA . 36.1 mttp -68.13 -58.75 3.96 Favored 'General case' 0 C--N 1.328 -0.338 0 N-CA-C 112.489 0.551 . . . . 0.0 112.489 -178.348 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 17.9 t -73.46 -37.0 49.77 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.369 0 N-CA-C 112.084 0.401 . . . . 0.0 112.084 -178.281 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 207' ' ' GLY . . . . . 0.521 ' HA3' ' O ' ' A' ' 203' ' ' VAL . . . -59.35 -60.05 9.52 Favored Glycine 0 N--CA 1.452 -0.278 0 C-N-CA 120.313 -0.946 . . . . 0.0 112.502 -179.36 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 208' ' ' PHE . . . . . 0.513 ' O ' ' N ' ' A' ' 212' ' ' ALA . 1.2 m-30 -58.48 -43.76 89.09 Favored 'General case' 0 C--O 1.221 -0.402 0 CA-C-N 117.111 0.456 . . . . 0.0 110.069 179.739 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 209' ' ' GLY . . . . . 0.448 ' O ' ' HB1' ' A' ' 212' ' ' ALA . . . -53.72 -37.89 57.99 Favored Glycine 0 CA--C 1.518 0.239 0 CA-C-N 115.501 -0.772 . . . . 0.0 113.957 -179.923 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 210' ' ' PHE . . . . . . . . . . . . . 2.6 m-85 -70.01 -48.68 57.12 Favored 'General case' 0 CA--C 1.515 -0.39 0 N-CA-C 108.906 -0.775 . . . . 0.0 108.906 179.664 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 211' ' ' ILE . . . . . 0.426 HG13 ' O ' ' A' ' 207' ' ' GLY . 5.3 mt -63.87 -27.43 42.82 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.569 0 N-CA-C 107.47 -1.308 . . . . 0.0 107.47 176.629 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 212' ' ' ALA . . . . . 0.513 ' N ' ' O ' ' A' ' 208' ' ' PHE . . . -68.37 -38.61 81.56 Favored 'General case' 0 N--CA 1.449 -0.488 0 CA-C-N 114.173 -1.376 . . . . 0.0 110.481 -179.866 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 213' ' ' LEU . . . . . . . . . . . . . 52.9 mt -65.44 -54.65 25.4 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-N 115.139 -0.937 . . . . 0.0 111.093 -179.811 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 214' ' ' ASP . . . . . . . . . . . . . 15.8 m-20 -60.57 -27.05 67.4 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.367 -0.379 . . . . 0.0 110.466 179.746 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 215' ' ' ALA . . . . . . . . . . . . . . . -68.94 -57.77 5.04 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.073 -0.512 . . . . 0.0 111.193 -179.964 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 216' ' ' ALA . . . . . . . . . . . . . . . -63.28 -31.27 72.37 Favored 'General case' 0 C--N 1.331 -0.21 0 CA-C-N 116.332 -0.395 . . . . 0.0 110.972 -179.974 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 217' ' ' ALA . . . . . . . . . . . . . . . -64.64 -37.56 87.98 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.045 -0.525 . . . . 0.0 110.433 179.73 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 218' ' ' THR . . . . . . . . . . . . . 99.1 m . . . . . 0 C--N 1.33 -0.27 0 CA-C-N 115.817 -0.628 . . . . 0.0 110.508 179.456 . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.238 0 N-CA-C 112.34 -0.304 . . . . 0.0 112.34 . . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 4' ' ' LEU . . . . . 0.498 HD13 HG21 ' A' ' 194' ' ' VAL . 47.6 tp -74.12 -36.95 64.23 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-O 120.849 0.356 . . . . 0.0 110.989 179.934 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 70.8 p -59.44 -31.99 69.8 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.077 -0.51 . . . . 0.0 111.665 -179.616 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 6' ' ' THR . . . . . 0.515 ' HG1' HD22 ' A' ' 7' ' ' LEU . 32.3 p -55.62 -35.45 65.9 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-O 120.844 0.354 . . . . 0.0 111.191 -179.773 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 7' ' ' LEU . . . . . 0.515 HD22 ' HG1' ' A' ' 6' ' ' THR . 4.0 mm? -58.98 -53.05 62.81 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.123 -0.49 . . . . 0.0 111.087 179.952 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 8' ' ' PHE . . . . . . . . . . . . . 73.6 m-85 -58.81 -33.11 70.01 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 116.34 -0.391 . . . . 0.0 110.817 179.932 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 9' ' ' TRP . . . . . 0.425 ' O ' HG13 ' A' ' 13' ' ' ILE . 27.8 m95 -66.35 -46.61 76.18 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 116.013 -0.54 . . . . 0.0 110.152 -179.862 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 94.1 mt -59.82 -42.07 92.7 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 115.651 -0.704 . . . . 0.0 110.347 179.377 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -63.42 -30.42 77.53 Favored Glycine 0 N--CA 1.449 -0.496 0 C-N-CA 120.712 -0.756 . . . . 0.0 111.724 179.348 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -73.19 -30.79 63.78 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.795 0.331 . . . . 0.0 110.82 179.678 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 13' ' ' ILE . . . . . 0.425 HG13 ' O ' ' A' ' 9' ' ' TRP . 67.0 mt -67.61 -54.7 21.22 Favored 'Isoleucine or valine' 0 C--O 1.233 0.206 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.399 179.473 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -62.46 -35.09 91.23 Favored Glycine 0 N--CA 1.449 -0.474 0 C-N-CA 120.716 -0.755 . . . . 0.0 111.399 179.209 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 15' ' ' MET . . . . . 0.486 ' SD ' ' HA ' ' A' ' 44' ' ' SER . 45.5 tpp -62.75 -41.96 99.45 Favored 'General case' 0 N--CA 1.453 -0.294 0 CA-C-O 120.814 0.34 . . . . 0.0 110.209 179.376 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -59.46 -37.74 78.96 Favored 'General case' 0 C--N 1.331 -0.201 0 N-CA-C 109.635 -0.505 . . . . 0.0 109.635 178.893 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 46.5 t -59.24 -43.23 89.28 Favored 'Isoleucine or valine' 0 C--O 1.232 0.176 0 CA-C-N 116.033 -0.531 . . . . 0.0 110.134 179.143 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -68.25 -42.89 81.98 Favored Glycine 0 C--N 1.331 0.291 0 C-N-CA 120.795 -0.717 . . . . 0.0 111.884 179.187 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 9.9 m -50.14 -46.24 53.74 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.698 0.285 . . . . 0.0 111.352 -179.604 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 92.7 mt -72.01 -43.17 65.46 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.271 -0.422 . . . . 0.0 111.618 -179.712 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -58.31 -33.23 69.25 Favored 'General case' 0 C--N 1.33 -0.267 0 N-CA-C 112.048 0.388 . . . . 0.0 112.048 -179.252 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 5.3 m-85 -90.57 -37.67 13.68 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 120.624 0.249 . . . . 0.0 111.495 -179.367 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -65.91 -51.18 60.83 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.874 0.369 . . . . 0.0 111.659 -179.507 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 24' ' ' TRP . . . . . . . . . . . . . 3.4 t-105 -60.44 -52.87 63.37 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-N 115.948 -0.569 . . . . 0.0 111.145 -179.66 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.328 -0.363 0 CA-C-N 116.358 -0.383 . . . . 0.0 111.032 179.942 . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.247 0 N-CA-C 112.569 -0.212 . . . . 0.0 112.569 . . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 11.0 pt-20 -58.94 -20.53 53.0 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 120.644 0.259 . . . . 0.0 111.255 179.893 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 34' ' ' ARG . . . . . . . . . . . . . 74.2 mtp180 -49.2 -29.43 5.61 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.379 -179.89 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 98.9 mtt180 -60.21 -46.62 89.13 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.82 0.343 . . . . 0.0 111.057 179.899 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 52.7 m-85 -66.79 -42.66 85.62 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.176 -0.466 . . . . 0.0 111.068 -179.933 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 37' ' ' TYR . . . . . . . . . . . . . 51.9 m-85 -63.45 -51.82 64.08 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.213 -0.448 . . . . 0.0 111.449 -179.6 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 78.2 t -56.81 -36.73 50.51 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-O 121.005 0.431 . . . . 0.0 110.222 179.662 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 17.4 m -65.35 -47.85 75.05 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 115.852 -0.613 . . . . 0.0 110.257 178.976 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 48.8 tp -56.11 -45.84 79.32 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 115.665 -0.698 . . . . 0.0 110.096 179.21 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 96.5 t -60.81 -34.48 59.38 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.249 0 CA-C-N 115.698 -0.683 . . . . 0.0 109.983 179.068 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -57.03 -44.17 93.02 Favored Glycine 0 N--CA 1.447 -0.593 0 C-N-CA 120.813 -0.708 . . . . 0.0 111.834 179.599 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 43' ' ' ILE . . . . . 0.528 HG23 ' HE3' ' A' ' 205' ' ' LYS . 0.3 OUTLIER -63.1 -51.58 69.81 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.179 0 CA-C-O 120.7 0.286 . . . . 0.0 110.951 179.501 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 44' ' ' SER . . . . . 0.486 ' HA ' ' SD ' ' A' ' 15' ' ' MET . 87.5 p -60.41 -29.33 68.91 Favored 'General case' 0 C--O 1.232 0.155 0 CA-C-O 120.841 0.353 . . . . 0.0 111.305 -179.981 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -77.34 -51.31 6.16 Favored Glycine 0 CA--C 1.519 0.322 0 C-N-CA 120.668 -0.777 . . . . 0.0 113.11 -179.344 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 46' ' ' ILE . . . . . 0.623 HD12 HD11 ' A' ' 78' ' ' LEU . 12.4 pt -58.62 -37.53 65.8 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.242 0 CA-C-O 120.936 0.398 . . . . 0.0 110.979 -179.839 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 47' ' ' ALA . . . . . 0.558 ' HB1' ' HE2' ' A' ' 205' ' ' LYS . . . -67.87 -44.03 78.02 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.124 -0.489 . . . . 0.0 111.426 179.47 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -55.19 -43.25 74.22 Favored 'General case' 0 C--N 1.332 -0.194 0 CA-C-N 116.05 -0.523 . . . . 0.0 112.051 -179.326 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 35.5 m -73.2 -35.29 46.87 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.245 0 CA-C-O 120.684 0.278 . . . . 0.0 111.461 -179.541 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -63.29 -39.21 93.95 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-O 121.035 0.445 . . . . 0.0 110.965 179.955 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 24.5 m-85 -73.08 -38.96 66.23 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-N 115.817 -0.629 . . . . 0.0 110.648 -179.831 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -62.64 -45.46 92.73 Favored 'General case' 0 C--N 1.327 -0.413 0 CA-C-N 115.983 -0.553 . . . . 0.0 111.255 179.854 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 53' ' ' VAL . . . . . 0.498 HG21 ' N ' ' A' ' 54' ' ' MET . 32.3 m -66.43 -52.9 41.57 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.122 0 CA-C-N 116.504 -0.316 . . . . 0.0 111.056 -179.949 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 54' ' ' MET . . . . . 0.498 ' N ' HG21 ' A' ' 53' ' ' VAL . 76.0 mtm -58.35 -34.96 71.22 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-O 121.156 0.503 . . . . 0.0 110.134 179.508 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -63.31 -29.49 70.8 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 115.588 -0.733 . . . . 0.0 111.322 179.474 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 96.3 mt -79.23 -8.23 58.87 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.383 -0.371 . . . . 0.0 111.383 -179.633 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 98.75 -6.89 60.77 Favored Glycine 0 N--CA 1.45 -0.368 0 C-N-CA 120.531 -0.842 . . . . 0.0 113.018 179.545 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 58' ' ' VAL . . . . . 0.493 HG12 ' O ' ' A' ' 53' ' ' VAL . 3.8 p -75.26 154.4 6.3 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.235 0 CA-C-N 116.906 0.353 . . . . 0.0 110.636 179.926 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 76.3 22.77 72.62 Favored Glycine 0 N--CA 1.452 -0.261 0 C-N-CA 120.634 -0.794 . . . . 0.0 112.275 -179.408 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 60' ' ' TRP . . . . . . . . . . . . . 19.1 m0 -104.75 100.88 10.52 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-O 120.972 0.415 . . . . 0.0 110.043 179.967 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 61' ' ' VAL . . . . . 0.446 ' HB ' HG21 ' A' ' 68' ' ' VAL . 57.3 t -97.01 107.58 38.49 Favored Pre-proline 0 C--N 1.327 -0.389 0 CA-C-N 115.894 -0.594 . . . . 0.0 111.521 -179.448 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 31.3 Cg_endo -63.53 135.0 47.18 Favored 'Trans proline' 0 C--N 1.35 0.613 0 C-N-CA 122.384 2.056 . . . . 0.0 111.894 179.461 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 85.8 t -136.68 94.02 1.12 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.38 0 CA-C-N 116.109 -0.496 . . . . 0.0 111.319 -179.43 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . 57.38 -88.95 0.02 OUTLIER 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.485 179.905 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 38.0 tt0 -117.65 -22.8 7.89 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-O 120.913 0.387 . . . . 0.0 110.638 179.981 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 66' ' ' ARG . . . . . . . . . . . . . 41.5 mmt180 -102.79 157.64 16.82 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.039 -0.528 . . . . 0.0 110.225 179.747 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 26.2 m -124.14 116.43 22.73 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-O 120.869 0.366 . . . . 0.0 111.334 -179.854 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 68' ' ' VAL . . . . . 0.521 HG11 ' HA ' ' A' ' 117' ' ' MET . 24.0 m -90.77 145.53 7.31 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 115.986 -0.552 . . . . 0.0 110.84 179.664 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 69' ' ' PHE . . . . . . . . . . . . . 42.5 m-85 -109.65 111.35 22.77 Favored 'General case' 0 N--CA 1.441 -0.918 0 N-CA-C 109.879 -0.415 . . . . 0.0 109.879 -179.819 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 70' ' ' VAL . . . . . 0.563 ' N ' ' HD2' ' A' ' 71' ' ' PRO . 38.6 t -60.73 -50.11 86.66 Favored Pre-proline 0 C--N 1.326 -0.427 0 CA-C-N 116.42 -0.355 . . . . 0.0 111.903 -179.042 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 71' ' ' PRO . . . . . 0.563 ' HD2' ' N ' ' A' ' 70' ' ' VAL . 36.6 Cg_endo -64.7 -17.84 60.78 Favored 'Trans proline' 0 C--N 1.35 0.638 0 C-N-CA 122.288 1.992 . . . . 0.0 112.971 -179.343 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 37.3 ttp180 -70.95 -55.24 8.79 Favored 'General case' 0 C--O 1.235 0.321 0 C-N-CA 121.025 -0.27 . . . . 0.0 111.332 -179.492 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 73' ' ' TYR . . . . . 0.456 ' O ' HG13 ' A' ' 77' ' ' ILE . 5.7 m-85 -68.48 -34.52 76.08 Favored 'General case' 0 C--N 1.332 -0.185 0 C-N-CA 120.686 -0.406 . . . . 0.0 109.994 179.911 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 74' ' ' ILE . . . . . 0.523 ' HA ' HD11 ' A' ' 77' ' ' ILE . 0.4 OUTLIER -67.72 -36.75 77.03 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.173 0 CA-C-N 116.174 -0.467 . . . . 0.0 110.123 179.526 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 11.3 t70 -60.5 -37.61 81.68 Favored 'General case' 0 CA--C 1.518 -0.262 0 N-CA-C 109.188 -0.671 . . . . 0.0 109.188 178.749 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 76' ' ' TRP . . . . . . . . . . . . . 40.6 m0 -69.86 -28.1 65.38 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 115.638 -0.71 . . . . 0.0 110.562 179.247 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 77' ' ' ILE . . . . . 0.551 ' HA ' ' HG3' ' A' ' 109' ' ' MET . 96.3 mt -68.56 -36.27 73.89 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.34 179.596 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 78' ' ' LEU . . . . . 0.623 HD11 HD12 ' A' ' 46' ' ' ILE . 0.7 OUTLIER -90.75 -26.76 19.33 Favored 'General case' 0 C--N 1.328 -0.358 0 N-CA-C 112.81 0.671 . . . . 0.0 112.81 -179.65 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 79' ' ' THR . . . . . 0.512 HG23 HD11 ' A' ' 78' ' ' LEU . 64.8 p -84.71 -52.27 6.2 Favored 'General case' 0 C--N 1.327 -0.374 0 N-CA-C 113.71 1.004 . . . . 0.0 113.71 -178.548 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 80' ' ' THR . . . . . 0.669 ' HB ' ' HD3' ' A' ' 81' ' ' PRO . 34.0 m -53.42 -56.12 27.73 Favored Pre-proline 0 CA--C 1.533 0.314 0 N-CA-C 112.567 0.581 . . . . 0.0 112.567 -177.902 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 81' ' ' PRO . . . . . 0.669 ' HD3' ' HB ' ' A' ' 80' ' ' THR . 43.5 Cg_exo -58.33 -19.21 41.88 Favored 'Trans proline' 0 C--N 1.352 0.744 0 C-N-CA 121.728 1.618 . . . . 0.0 111.956 179.966 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 82' ' ' LEU . . . . . . . . . . . . . 16.2 tp -76.72 -35.66 57.67 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.078 179.575 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 83' ' ' ILE . . . . . 0.452 HD11 HG21 ' A' ' 43' ' ' ILE . 41.3 mm -69.57 -51.27 43.25 Favored 'Isoleucine or valine' 0 C--O 1.233 0.222 0 CA-C-N 115.926 -0.579 . . . . 0.0 110.379 179.214 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 33.0 m -60.95 -31.96 51.16 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.212 0 N-CA-C 109.505 -0.554 . . . . 0.0 109.505 179.062 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 85' ' ' TYR . . . . . 0.405 ' O ' ' HG ' ' A' ' 89' ' ' LEU . 81.3 t80 -65.42 -33.6 76.32 Favored 'General case' 0 N--CA 1.453 -0.291 0 CA-C-N 115.559 -0.746 . . . . 0.0 109.344 178.739 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 86' ' ' PHE . . . . . . . . . . . . . 3.0 t80 -61.87 -50.93 70.26 Favored 'General case' 0 C--O 1.233 0.235 0 CA-C-N 115.617 -0.719 . . . . 0.0 110.066 179.436 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 6.1 mt -62.95 -29.15 70.58 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 115.905 -0.589 . . . . 0.0 110.316 179.778 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -70.56 -28.06 71.62 Favored Glycine 0 N--CA 1.451 -0.323 0 CA-C-N 115.486 -0.779 . . . . 0.0 112.026 179.542 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 89' ' ' LEU . . . . . 0.405 ' HG ' ' O ' ' A' ' 85' ' ' TYR . 91.2 mt -74.91 -41.99 58.66 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.92 0.391 . . . . 0.0 110.772 179.744 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 97.6 mt -63.99 -36.41 83.88 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 115.959 -0.564 . . . . 0.0 111.123 179.927 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -77.19 -53.92 7.14 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.352 -0.385 . . . . 0.0 111.131 -179.854 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 107.8 52.67 0.69 Allowed Glycine 0 C--N 1.33 0.248 0 C-N-CA 120.899 -0.667 . . . . 0.0 112.213 -179.726 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 93' ' ' LEU . . . . . 0.505 HD11 ' HE2' ' A' ' 145' ' ' MET . 64.8 mt -75.82 162.24 28.33 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-O 120.909 0.385 . . . . 0.0 111.04 -179.773 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 94' ' ' ASP . . . . . . . . . . . . . 7.0 m-20 -88.86 175.14 7.58 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.707 179.881 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 65.3 m -60.44 -35.2 75.27 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.255 -179.767 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 96' ' ' ARG . . . . . 0.448 ' HG3' ' N ' ' A' ' 97' ' ' GLU . 10.5 ptp180 -73.64 -46.65 45.48 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 116.312 -0.404 . . . . 0.0 111.251 -179.842 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 97' ' ' GLU . . . . . 0.448 ' N ' ' HG3' ' A' ' 96' ' ' ARG . 42.0 mt-10 -57.02 -40.47 76.73 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.326 -0.397 . . . . 0.0 111.08 -179.68 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 98' ' ' PHE . . . . . 0.424 ' O ' HG12 ' A' ' 102' ' ' ILE . 13.5 m-85 -62.63 -50.3 71.75 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.772 179.656 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -55.29 -30.44 55.07 Favored Glycine 0 N--CA 1.452 -0.253 0 C-N-CA 120.647 -0.787 . . . . 0.0 112.695 -179.906 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 100' ' ' ILE . . . . . 0.402 ' O ' HG23 ' A' ' 103' ' ' THR . 86.8 mt -72.13 -47.78 52.52 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-O 120.864 0.364 . . . . 0.0 111.561 -179.735 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 43.2 t -67.67 -48.68 75.38 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.371 0 CA-C-N 116.289 -0.414 . . . . 0.0 111.516 -179.572 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 102' ' ' ILE . . . . . 0.424 HG12 ' O ' ' A' ' 98' ' ' PHE . 34.9 mm -59.15 -47.19 91.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.898 -179.23 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 103' ' ' THR . . . . . 0.402 HG23 ' O ' ' A' ' 100' ' ' ILE . 14.2 t -60.81 -36.26 78.58 Favored 'General case' 0 C--O 1.234 0.245 0 CA-C-O 120.772 0.32 . . . . 0.0 110.879 -179.968 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 3.0 tm? -57.01 -50.65 72.06 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-N 116.344 -0.389 . . . . 0.0 110.043 179.15 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 105' ' ' ASN . . . . . 0.404 ' O ' ' HG2' ' A' ' 109' ' ' MET . 16.6 m-80 -59.39 -31.42 69.22 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.014 -0.539 . . . . 0.0 110.674 179.368 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 41.5 m -56.92 -47.85 79.62 Favored 'General case' 0 C--O 1.232 0.177 0 CA-C-O 120.836 0.35 . . . . 0.0 110.154 179.329 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 1.9 t -61.06 -42.12 91.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 115.996 -0.547 . . . . 0.0 109.963 179.107 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 66.4 t -57.72 -45.69 86.84 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 115.171 -0.922 . . . . 0.0 111.669 -179.723 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 109' ' ' MET . . . . . 0.551 ' HG3' ' HA ' ' A' ' 77' ' ' ILE . 16.0 mmt -67.71 -44.33 77.92 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.712 -179.27 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 32.9 tp -60.64 -39.61 88.94 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-O 120.766 0.317 . . . . 0.0 110.806 -179.747 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -58.48 -54.67 44.46 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.685 179.635 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . -66.41 -32.3 81.45 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.387 179.632 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 113' ' ' PHE . . . . . . . . . . . . . 0.7 OUTLIER -52.77 -71.34 0.07 Allowed 'General case' 0 C--N 1.331 -0.202 0 CA-C-O 120.945 0.402 . . . . 0.0 110.183 179.829 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 114' ' ' ALA . . . . . 0.427 ' HB2' HD23 ' A' ' 126' ' ' LEU . . . -64.47 -22.6 67.01 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 115.796 -0.638 . . . . 0.0 110.975 179.742 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -53.57 -49.37 57.71 Favored Glycine 0 C--N 1.331 0.269 0 C-N-CA 121.025 -0.607 . . . . 0.0 112.518 179.985 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 116' ' ' ALA . . . . . 0.525 ' HB3' ' HB3' ' A' ' 183' ' ' PRO . . . -78.06 -18.14 56.15 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-O 120.742 0.306 . . . . 0.0 111.464 -179.899 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 117' ' ' MET . . . . . 0.521 ' HA ' HG11 ' A' ' 68' ' ' VAL . 33.3 ttm -99.31 19.57 15.22 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.32 -0.4 . . . . 0.0 111.556 -179.161 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 118' ' ' VAL . . . . . 0.444 HG22 ' HB3' ' A' ' 123' ' ' ARG . 25.1 m -71.34 143.33 87.89 Favored Pre-proline 0 C--N 1.33 -0.279 0 CA-C-N 116.524 -0.307 . . . . 0.0 111.514 179.993 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 119' ' ' PRO . . . . . . . . . . . . . 92.2 Cg_endo -89.49 14.89 2.09 Favored 'Trans proline' 0 N--CA 1.456 -0.677 0 C-N-CA 122.715 2.277 . . . . 0.0 112.418 179.373 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -166.07 -118.37 0.44 Allowed Glycine 0 C--N 1.334 0.421 0 C-N-CA 120.644 -0.789 . . . . 0.0 112.834 -179.668 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 2.0 pp -119.89 13.37 6.64 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.183 0 CA-C-O 120.675 0.274 . . . . 0.0 111.597 -179.595 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 43.6 mt-10 -62.62 -17.98 61.35 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.865 179.722 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 123' ' ' ARG . . . . . 0.444 ' HB3' HG22 ' A' ' 118' ' ' VAL . 3.2 ptp180 -50.28 -28.07 7.17 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 115.834 -0.621 . . . . 0.0 111.93 -179.764 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 124' ' ' TYR . . . . . . . . . . . . . 29.2 m-85 -71.42 -33.53 69.5 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.632 0.254 . . . . 0.0 111.385 -179.592 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 125' ' ' ALA . . . . . . . . . . . . . . . -74.21 -55.93 5.49 Favored 'General case' 0 C--O 1.235 0.315 0 CA-C-O 120.79 0.328 . . . . 0.0 111.184 179.918 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 126' ' ' LEU . . . . . 0.427 HD23 ' HB2' ' A' ' 114' ' ' ALA . 1.1 mp -52.16 -51.12 59.95 Favored 'General case' 0 C--N 1.332 -0.182 0 CA-C-N 116.041 -0.527 . . . . 0.0 110.313 179.79 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 127' ' ' PHE . . . . . . . . . . . . . 10.4 t80 -65.46 -30.36 71.14 Favored 'General case' 0 N--CA 1.452 -0.354 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.089 179.308 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 128' ' ' GLY . . . . . . . . . . . . . . . -48.19 -52.93 16.63 Favored Glycine 0 N--CA 1.449 -0.461 0 C-N-CA 120.196 -1.002 . . . . 0.0 110.757 178.848 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 129' ' ' MET . . . . . 0.631 ' HE2' ' HA2' ' A' ' 130' ' ' GLY . 0.0 OUTLIER -70.36 -27.24 64.18 Favored 'General case' 0 C--N 1.328 -0.367 0 N-CA-C 109.036 -0.727 . . . . 0.0 109.036 178.515 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 130' ' ' GLY . . . . . 0.631 ' HA2' ' HE2' ' A' ' 129' ' ' MET . . . -59.7 -45.27 95.99 Favored Glycine 0 C--N 1.333 0.366 0 CA-C-N 115.745 -0.661 . . . . 0.0 112.558 179.607 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -69.8 -47.53 62.5 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-O 120.738 0.304 . . . . 0.0 110.421 179.751 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 65.4 t -56.32 -44.31 79.4 Favored 'Isoleucine or valine' 0 C--O 1.235 0.293 0 CA-C-O 121.261 0.553 . . . . 0.0 109.662 178.865 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -63.25 -35.22 79.62 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 115.57 -0.741 . . . . 0.0 110.465 179.231 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 134' ' ' PHE . . . . . . . . . . . . . 72.6 t80 -56.92 -54.56 45.25 Favored 'General case' 0 N--CA 1.451 -0.375 0 CA-C-O 120.984 0.421 . . . . 0.0 110.156 179.494 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 135' ' ' ILE . . . . . 0.442 ' O ' HG23 ' A' ' 138' ' ' VAL . 39.8 mt -56.6 -31.05 33.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 115.733 -0.667 . . . . 0.0 110.198 179.285 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . -62.73 -42.41 99.69 Favored Glycine 0 N--CA 1.447 -0.607 0 C-N-CA 120.221 -0.99 . . . . 0.0 111.344 178.922 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 137' ' ' LEU . . . . . 0.422 ' HG ' HD12 ' A' ' 141' ' ' LEU . 64.9 tp -67.12 -52.64 39.29 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-O 120.464 0.174 . . . . 0.0 111.033 179.778 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 138' ' ' VAL . . . . . 0.442 HG23 ' O ' ' A' ' 135' ' ' ILE . 4.5 m -54.31 -34.43 27.87 Favored 'Isoleucine or valine' 0 CA--C 1.52 -0.177 0 N-CA-C 109.728 -0.471 . . . . 0.0 109.728 -179.642 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 139' ' ' TYR . . . . . . . . . . . . . 35.6 t80 -58.56 -46.49 86.76 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 115.785 -0.643 . . . . 0.0 109.633 178.05 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 24.6 m-85 -63.65 -40.78 97.73 Favored 'General case' 0 C--N 1.333 -0.111 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.486 179.105 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 141' ' ' LEU . . . . . 0.498 ' HA ' ' SD ' ' A' ' 145' ' ' MET . 11.2 mp -59.14 -25.64 64.04 Favored 'General case' 0 C--N 1.332 -0.186 0 CA-C-N 116.073 -0.512 . . . . 0.0 110.973 179.982 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 15.7 t -107.9 -5.18 10.5 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.254 0 CA-C-N 116.24 -0.437 . . . . 0.0 110.875 179.851 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . -75.81 -133.2 0.41 Allowed Glycine 0 CA--C 1.522 0.487 0 C-N-CA 120.874 -0.679 . . . . 0.0 112.704 179.993 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 144' ' ' PRO . . . . . . . . . . . . . 48.7 Cg_exo -55.55 -24.17 43.3 Favored 'Trans proline' 0 C--N 1.35 0.639 0 C-N-CA 122.5 2.133 . . . . 0.0 112.868 -179.732 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 145' ' ' MET . . . . . 0.505 ' HE2' HD11 ' A' ' 93' ' ' LEU . 57.5 mtt -54.15 -32.91 56.6 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 116.402 -0.363 . . . . 0.0 111.408 -179.864 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 146' ' ' THR . . . . . . . . . . . . . 79.1 p -65.9 -49.25 68.7 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.3 -0.409 . . . . 0.0 111.937 -179.407 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 14.1 mm-40 -74.89 -25.39 58.9 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.734 0.302 . . . . 0.0 111.766 -179.394 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 148' ' ' SER . . . . . . . . . . . . . 45.9 t -70.1 -45.43 66.95 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.834 0.35 . . . . 0.0 111.098 -179.623 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 149' ' ' ALA . . . . . 0.42 ' HB3' HG23 ' A' ' 156' ' ' ILE . . . -78.33 -35.14 48.06 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.119 -0.492 . . . . 0.0 111.849 -179.582 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 150' ' ' SER . . . . . 0.529 ' HA ' ' HG2' ' A' ' 157' ' ' LYS . 35.7 t -69.71 0.72 5.12 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.303 -0.408 . . . . 0.0 111.44 -179.539 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 151' ' ' GLN . . . . . . . . . . . . . 49.1 mt-30 -134.3 15.53 3.78 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.512 -0.313 . . . . 0.0 111.207 179.877 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 6.7 tpm_? -91.6 -51.89 5.04 Favored 'General case' 0 C--N 1.332 -0.195 0 CA-C-O 120.906 0.384 . . . . 0.0 110.772 179.954 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 153' ' ' SER . . . . . 0.633 ' HB3' HG12 ' A' ' 156' ' ' ILE . 24.3 t -157.76 172.6 18.2 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 115.978 -0.555 . . . . 0.0 110.746 179.256 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 154' ' ' SER . . . . . 0.5 ' HA ' ' NZ ' ' A' ' 157' ' ' LYS . 77.7 p -70.49 -40.68 73.45 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.427 -0.351 . . . . 0.0 110.859 179.727 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -77.08 -28.59 58.2 Favored Glycine 0 CA--C 1.521 0.41 0 C-N-CA 121.07 -0.585 . . . . 0.0 113.389 -179.631 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 156' ' ' ILE . . . . . 0.633 HG12 ' HB3' ' A' ' 153' ' ' SER . 33.4 mm -56.77 -37.68 54.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-O 120.678 0.275 . . . . 0.0 111.522 -179.507 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 157' ' ' LYS . . . . . 0.529 ' HG2' ' HA ' ' A' ' 150' ' ' SER . 36.7 mtmm -58.96 -41.26 87.04 Favored 'General case' 0 C--N 1.327 -0.393 0 N-CA-C 112.178 0.436 . . . . 0.0 112.178 -179.527 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 71.2 m -70.57 -48.32 55.9 Favored 'General case' 0 C--N 1.33 -0.256 0 N-CA-C 111.958 0.355 . . . . 0.0 111.958 -179.003 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 159' ' ' LEU . . . . . . . . . . . . . 3.8 mm? -67.68 -30.2 69.67 Favored 'General case' 0 C--N 1.327 -0.384 0 N-CA-C 111.789 0.292 . . . . 0.0 111.789 -179.373 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 160' ' ' TYR . . . . . . . . . . . . . 72.4 t80 -73.98 -47.41 37.48 Favored 'General case' 0 C--N 1.329 -0.3 0 N-CA-C 112.313 0.486 . . . . 0.0 112.313 -179.06 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 161' ' ' VAL . . . . . 0.409 HG21 ' N ' ' A' ' 162' ' ' ARG . 27.3 m -64.25 -43.17 97.21 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.373 0 N-CA-C 112.347 0.499 . . . . 0.0 112.347 -178.616 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 162' ' ' ARG . . . . . 0.448 ' NE ' ' HA ' ' A' ' 162' ' ' ARG . 6.7 tpm_? -68.96 -49.27 59.47 Favored 'General case' 0 C--N 1.328 -0.33 0 N-CA-C 112.001 0.371 . . . . 0.0 112.001 -178.904 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 163' ' ' LEU . . . . . . . . . . . . . 8.1 mp -67.62 -43.23 80.88 Favored 'General case' 0 C--N 1.329 -0.313 0 N-CA-C 111.928 0.344 . . . . 0.0 111.928 -179.149 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 164' ' ' ARG . . . . . . . . . . . . . 3.4 tmm_? -56.88 -50.79 71.43 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 120.695 0.283 . . . . 0.0 110.683 179.965 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 165' ' ' ASN . . . . . 0.519 ' N ' HD21 ' A' ' 165' ' ' ASN . 0.9 OUTLIER -57.29 -42.27 81.39 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.998 0.427 . . . . 0.0 110.301 179.576 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 166' ' ' LEU . . . . . 0.449 ' HB3' ' CE1' ' A' ' 208' ' ' PHE . 2.7 mt -58.7 -52.18 66.79 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 115.83 -0.623 . . . . 0.0 111.097 179.344 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 167' ' ' THR . . . . . 0.507 ' HA ' HD12 ' A' ' 170' ' ' LEU . 3.1 m -54.59 -51.86 63.95 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 115.733 -0.667 . . . . 0.0 112.442 -178.454 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 168' ' ' VAL . . . . . . . . . . . . . 59.2 t -57.26 -40.36 73.34 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.504 0 N-CA-C 112.485 0.55 . . . . 0.0 112.485 -178.894 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 169' ' ' VAL . . . . . 0.476 ' O ' HG12 ' A' ' 173' ' ' ILE . 98.2 t -68.03 -66.7 0.49 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 N-CA-C 113.499 0.926 . . . . 0.0 113.499 -177.912 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 170' ' ' LEU . . . . . 0.507 HD12 ' HA ' ' A' ' 167' ' ' THR . 0.4 OUTLIER -59.89 -33.2 71.52 Favored 'General case' 0 N--CA 1.467 0.386 0 N-CA-C 112.887 0.699 . . . . 0.0 112.887 -177.71 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 171' ' ' TRP . . . . . 0.476 ' H ' HD11 ' A' ' 170' ' ' LEU . 25.9 m0 -73.54 -30.51 63.12 Favored 'General case' 0 C--N 1.329 -0.296 0 C-N-CA 120.57 -0.452 . . . . 0.0 111.473 -179.429 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 172' ' ' ALA . . . . . . . . . . . . . . . -73.2 -7.53 51.84 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.944 0.402 . . . . 0.0 110.348 179.455 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 173' ' ' ILE . . . . . 0.534 HG22 HD13 ' A' ' 177' ' ' ILE . 31.4 mm -88.75 -24.5 6.03 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.15 0 CA-C-N 115.877 -0.601 . . . . 0.0 110.758 179.402 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 174' ' ' TYR . . . . . 0.591 ' N ' ' HD2' ' A' ' 175' ' ' PRO . 21.4 m-85 -55.11 -50.29 87.35 Favored Pre-proline 0 CA--C 1.53 0.192 0 N-CA-C 112.216 0.45 . . . . 0.0 112.216 -179.614 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 175' ' ' PRO . . . . . 0.591 ' HD2' ' N ' ' A' ' 174' ' ' TYR . 4.1 Cg_endo -47.06 -28.47 7.45 Favored 'Trans proline' 0 C--N 1.352 0.762 0 C-N-CA 122.148 1.899 . . . . 0.0 112.1 179.976 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 176' ' ' PHE . . . . . 0.5 ' O ' ' HG ' ' A' ' 180' ' ' LEU . 92.2 m-85 -80.27 -49.97 10.85 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.31 179.568 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 177' ' ' ILE . . . . . 0.534 HD13 HG22 ' A' ' 173' ' ' ILE . 2.8 mm -59.71 -37.38 70.83 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.581 0 CA-C-N 115.995 -0.548 . . . . 0.0 111.781 -178.593 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 178' ' ' TRP . . . . . . . . . . . . . 70.7 t90 -73.58 -45.38 53.57 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.915 0.388 . . . . 0.0 110.856 179.814 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 179' ' ' LEU . . . . . 0.448 ' O ' ' HA3' ' A' ' 184' ' ' GLY . 1.9 tm? -65.09 -53.12 50.29 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 115.976 -0.556 . . . . 0.0 111.417 -179.233 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 180' ' ' LEU . . . . . 0.521 HD22 HD11 ' A' ' 187' ' ' LEU . 11.1 mt -71.79 -42.96 66.46 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 116.705 -0.225 . . . . 0.0 111.515 -179.208 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . -58.54 175.41 2.56 Favored Glycine 0 C--N 1.335 0.493 0 C-N-CA 120.472 -0.87 . . . . 0.0 112.664 179.772 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 182' ' ' PRO . . . . . 0.594 ' HA ' ' HB1' ' A' ' 186' ' ' ALA . 73.1 Cg_exo -47.91 -44.27 27.72 Favored 'Trans proline' 0 C--N 1.349 0.581 0 C-N-CA 122.767 2.312 . . . . 0.0 113.38 179.791 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 183' ' ' PRO . . . . . 0.525 ' HB3' ' HB3' ' A' ' 116' ' ' ALA . 73.4 Cg_exo -52.08 -17.19 5.41 Favored 'Trans proline' 0 C--N 1.355 0.905 0 C-N-CA 122.119 1.88 . . . . 0.0 112.84 179.557 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 184' ' ' GLY . . . . . 0.448 ' HA3' ' O ' ' A' ' 179' ' ' LEU . . . -114.74 -82.79 1.08 Allowed Glycine 0 N--CA 1.45 -0.379 0 C-N-CA 120.644 -0.789 . . . . 0.0 112.942 -179.715 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 185' ' ' VAL . . . . . . . . . . . . . 8.4 m -129.71 -4.16 2.89 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.24 0 N-CA-C 112.349 0.5 . . . . 0.0 112.349 -179.376 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 186' ' ' ALA . . . . . 0.594 ' HB1' ' HA ' ' A' ' 182' ' ' PRO . . . 52.22 89.56 0.03 OUTLIER 'General case' 0 N--CA 1.464 0.241 0 CA-C-O 120.72 0.295 . . . . 0.0 111.635 179.752 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 187' ' ' LEU . . . . . 0.521 HD11 HD22 ' A' ' 180' ' ' LEU . 24.3 mt -92.24 -49.49 6.15 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.443 -0.344 . . . . 0.0 111.678 -179.81 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 188' ' ' LEU . . . . . . . . . . . . . 88.7 mt -93.27 -93.93 0.16 Allowed 'General case' 0 C--N 1.331 -0.23 0 CA-C-O 120.799 0.333 . . . . 0.0 111.23 -179.604 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 189' ' ' THR . . . . . . . . . . . . . 2.2 t -161.44 145.02 9.62 Favored Pre-proline 0 C--N 1.326 -0.418 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.957 179.979 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 190' ' ' PRO . . . . . . . . . . . . . 74.7 Cg_exo -49.15 -40.24 42.05 Favored 'Trans proline' 0 C--N 1.349 0.596 0 C-N-CA 122.747 2.298 . . . . 0.0 113.137 -179.601 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 191' ' ' THR . . . . . . . . . . . . . 38.3 p -58.97 -44.52 91.53 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.795 0.331 . . . . 0.0 111.515 -179.621 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 192' ' ' VAL . . . . . . . . . . . . . 37.2 t -72.65 -46.12 55.5 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.266 -179.947 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 193' ' ' ASP . . . . . . . . . . . . . 32.6 t70 -55.1 -44.07 74.59 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.388 -0.369 . . . . 0.0 111.006 179.844 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 194' ' ' VAL . . . . . 0.498 HG21 HD13 ' A' ' 4' ' ' LEU . 79.8 t -68.64 -36.02 72.66 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.032 179.902 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 195' ' ' ALA . . . . . . . . . . . . . . . -59.12 -46.77 87.48 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-O 120.671 0.272 . . . . 0.0 110.977 179.734 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 196' ' ' LEU . . . . . . . . . . . . . 88.3 mt -67.83 -41.02 83.68 Favored 'General case' 0 C--N 1.332 -0.192 0 CA-C-O 120.841 0.353 . . . . 0.0 110.577 179.576 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 197' ' ' ILE . . . . . . . . . . . . . 17.6 mm -59.16 -58.41 7.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.011 -0.54 . . . . 0.0 110.225 179.203 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 198' ' ' VAL . . . . . . . . . . . . . 75.7 t -52.53 -34.79 19.62 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.432 0 CA-C-N 115.633 -0.712 . . . . 0.0 109.199 178.226 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 199' ' ' TYR . . . . . . . . . . . . . 67.5 t80 -70.23 -33.39 71.6 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 115.227 -0.897 . . . . 0.0 110.811 179.965 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 200' ' ' LEU . . . . . . . . . . . . . 36.5 mt -68.65 -40.78 80.08 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.039 -0.528 . . . . 0.0 111.375 -179.597 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 201' ' ' ASP . . . . . . . . . . . . . 8.1 m-20 -71.49 -31.64 67.34 Favored 'General case' 0 C--N 1.327 -0.413 0 CA-C-O 121.117 0.484 . . . . 0.0 110.038 179.447 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 202' ' ' LEU . . . . . . . . . . . . . 3.3 mt -71.01 -33.74 70.67 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 115.546 -0.752 . . . . 0.0 111.955 -179.671 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 203' ' ' VAL . . . . . 0.501 HG13 HD23 ' A' ' 170' ' ' LEU . 7.8 p -77.1 -36.39 24.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 N-CA-C 111.593 0.22 . . . . 0.0 111.593 -178.743 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 204' ' ' THR . . . . . . . . . . . . . 57.5 m -70.58 -52.25 22.81 Favored 'General case' 0 C--N 1.327 -0.372 0 C-N-CA 120.682 -0.407 . . . . 0.0 111.6 179.735 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 205' ' ' LYS . . . . . 0.558 ' HE2' ' HB1' ' A' ' 47' ' ' ALA . 53.8 mttp -70.53 -59.12 3.02 Favored 'General case' 0 C--N 1.327 -0.385 0 N-CA-C 112.27 0.47 . . . . 0.0 112.27 -178.67 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 23.3 t -72.87 -37.82 55.4 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.357 0 CA-C-N 116.333 -0.394 . . . . 0.0 111.724 -178.814 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 207' ' ' GLY . . . . . 0.532 ' O ' HG12 ' A' ' 211' ' ' ILE . . . -62.71 -59.04 9.81 Favored Glycine 0 N--CA 1.452 -0.286 0 C-N-CA 120.353 -0.927 . . . . 0.0 112.429 -179.641 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 208' ' ' PHE . . . . . 0.473 ' O ' ' N ' ' A' ' 212' ' ' ALA . 2.2 m-30 -53.66 -49.95 66.85 Favored 'General case' 0 C--O 1.221 -0.4 0 CA-C-O 120.798 0.332 . . . . 0.0 110.112 179.992 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 209' ' ' GLY . . . . . 0.412 ' O ' ' HB3' ' A' ' 212' ' ' ALA . . . -54.19 -31.42 49.42 Favored Glycine 0 N--CA 1.449 -0.487 0 CA-C-N 115.444 -0.798 . . . . 0.0 112.456 178.927 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 210' ' ' PHE . . . . . . . . . . . . . 1.8 m-85 -72.41 -48.73 39.1 Favored 'General case' 0 C--N 1.328 -0.33 0 N-CA-C 108.764 -0.828 . . . . 0.0 108.764 178.755 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 211' ' ' ILE . . . . . 0.532 HG12 ' O ' ' A' ' 207' ' ' GLY . 0.6 OUTLIER -63.7 -27.21 42.43 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.297 0 N-CA-C 107.246 -1.39 . . . . 0.0 107.246 176.685 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 212' ' ' ALA . . . . . 0.473 ' N ' ' O ' ' A' ' 208' ' ' PHE . . . -68.03 -43.66 78.24 Favored 'General case' 0 N--CA 1.448 -0.534 0 CA-C-N 114.044 -1.434 . . . . 0.0 110.764 -179.418 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 213' ' ' LEU . . . . . . . . . . . . . 71.5 mt -70.52 -54.98 10.05 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 115.191 -0.913 . . . . 0.0 112.112 -179.19 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 214' ' ' ASP . . . . . . . . . . . . . 29.4 t70 -54.96 -54.44 42.76 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.392 -0.367 . . . . 0.0 111.858 -179.099 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 215' ' ' ALA . . . . . . . . . . . . . . . -58.44 -57.16 14.14 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 116.312 -0.404 . . . . 0.0 111.898 -179.344 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 216' ' ' ALA . . . . . . . . . . . . . . . -57.57 -33.97 68.71 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.331 -0.395 . . . . 0.0 111.682 -179.367 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 217' ' ' ALA . . . . . . . . . . . . . . . -61.06 -41.58 96.88 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.953 0.406 . . . . 0.0 110.451 179.887 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 218' ' ' THR . . . . . . . . . . . . . 95.9 m . . . . . 0 C--N 1.329 -0.321 0 CA-C-N 115.829 -0.623 . . . . 0.0 110.896 179.737 . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.28 0 N-CA-C 112.33 -0.308 . . . . 0.0 112.33 . . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 49.8 tp -74.38 -35.54 63.49 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-O 120.778 0.323 . . . . 0.0 111.06 -179.974 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 69.1 p -61.06 -30.32 70.26 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.361 -179.751 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 28.0 p -54.56 -35.49 63.33 Favored 'General case' 0 C--N 1.331 -0.2 0 CA-C-N 116.278 -0.419 . . . . 0.0 111.248 -179.965 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 7' ' ' LEU . . . . . . . . . . . . . 4.0 mm? -56.65 -52.3 65.43 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 115.951 -0.568 . . . . 0.0 111.103 -179.903 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 8' ' ' PHE . . . . . 0.486 ' HB2' ' HB1' ' A' ' 55' ' ' ALA . 62.9 m-85 -64.47 -31.96 73.38 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.34 -0.391 . . . . 0.0 110.934 -179.989 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 9' ' ' TRP . . . . . . . . . . . . . 35.3 m95 -65.61 -41.69 92.47 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.173 -179.92 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 56.1 mt -67.17 -32.43 73.51 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-N 115.761 -0.654 . . . . 0.0 109.962 179.377 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -73.65 -27.72 66.74 Favored Glycine 0 N--CA 1.446 -0.67 0 CA-C-N 115.665 -0.698 . . . . 0.0 111.702 179.3 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -73.62 -33.91 64.78 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.834 0.35 . . . . 0.0 110.543 179.396 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 13' ' ' ILE . . . . . 0.428 ' O ' HG23 ' A' ' 17' ' ' VAL . 48.8 mm -68.22 -54.2 23.66 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.232 0 CA-C-N 116.002 -0.545 . . . . 0.0 110.397 179.423 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -59.18 -40.06 95.28 Favored Glycine 0 N--CA 1.45 -0.385 0 C-N-CA 120.635 -0.793 . . . . 0.0 111.48 179.221 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 15' ' ' MET . . . . . 0.509 ' SD ' ' HA ' ' A' ' 44' ' ' SER . 52.7 tpp -62.1 -43.6 98.49 Favored 'General case' 0 N--CA 1.453 -0.301 0 N-CA-C 109.99 -0.374 . . . . 0.0 109.99 179.295 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 45.4 tp -55.19 -38.18 68.02 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 115.746 -0.661 . . . . 0.0 110.222 179.184 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 17' ' ' VAL . . . . . 0.428 HG23 ' O ' ' A' ' 13' ' ' ILE . 44.2 t -62.13 -42.09 93.75 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.215 0 CA-C-N 115.891 -0.595 . . . . 0.0 109.971 179.243 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -66.26 -42.52 94.11 Favored Glycine 0 C--N 1.331 0.272 0 C-N-CA 120.69 -0.767 . . . . 0.0 111.58 178.928 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 7.9 m -52.09 -49.82 62.82 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.812 0.339 . . . . 0.0 111.074 179.945 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 95.0 mt -71.91 -35.6 69.73 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.435 179.926 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -62.21 -34.55 76.69 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.68 0.276 . . . . 0.0 111.648 -179.569 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 11.0 m-85 -89.95 -30.33 17.89 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.478 -0.328 . . . . 0.0 111.434 -179.442 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -72.88 -50.03 26.31 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.479 -0.328 . . . . 0.0 111.228 -179.941 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 24' ' ' TRP . . . . . . . . . . . . . 1.1 t-105 -60.66 -43.42 97.67 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.054 -0.521 . . . . 0.0 111.012 179.907 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.33 -0.282 0 CA-C-N 116.334 -0.393 . . . . 0.0 110.907 179.927 . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.317 0 N-CA-C 111.77 -0.532 . . . . 0.0 111.77 . . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 31.9 mm-40 -91.93 -20.16 21.7 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-O 120.792 0.33 . . . . 0.0 110.686 179.819 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 34' ' ' ARG . . . . . . . . . . . . . 55.4 ttp180 -47.95 -31.68 5.52 Favored 'General case' 0 C--N 1.332 -0.162 0 CA-C-N 115.974 -0.557 . . . . 0.0 111.385 -179.81 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 40.4 ttm180 -61.23 -49.46 77.02 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-O 120.856 0.36 . . . . 0.0 110.894 -179.943 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 75.9 m-85 -70.04 -37.47 75.59 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.025 -0.534 . . . . 0.0 111.568 -179.593 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 37' ' ' TYR . . . . . . . . . . . . . 35.3 m-85 -65.74 -54.75 22.95 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.318 -0.401 . . . . 0.0 111.516 -179.396 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 90.6 t -56.7 -38.18 56.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-O 120.918 0.39 . . . . 0.0 110.667 179.894 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 17.4 m -61.68 -50.95 70.42 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 115.933 -0.576 . . . . 0.0 110.616 179.346 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 40' ' ' LEU . . . . . 0.433 HD13 HD13 ' A' ' 43' ' ' ILE . 40.2 tp -59.71 -50.52 73.52 Favored 'General case' 0 C--O 1.235 0.333 0 CA-C-N 115.745 -0.661 . . . . 0.0 110.831 179.894 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 60.2 t -56.1 -34.3 38.53 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 115.834 -0.621 . . . . 0.0 110.294 179.26 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -60.94 -43.59 99.18 Favored Glycine 0 N--CA 1.45 -0.411 0 C-N-CA 120.739 -0.743 . . . . 0.0 111.826 179.597 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 43' ' ' ILE . . . . . 0.433 HD13 HD13 ' A' ' 40' ' ' LEU . 1.3 mt -58.55 -51.92 65.81 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.195 0 CA-C-O 120.792 0.329 . . . . 0.0 110.791 179.426 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 44' ' ' SER . . . . . 0.509 ' HA ' ' SD ' ' A' ' 15' ' ' MET . 44.7 m -59.66 -27.02 66.02 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.557 -179.772 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -73.79 -56.55 5.35 Favored Glycine 0 CA--C 1.519 0.33 0 C-N-CA 120.643 -0.789 . . . . 0.0 113.002 -179.588 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 24.3 pt -58.46 -35.45 54.41 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.214 0 CA-C-O 121.025 0.441 . . . . 0.0 111.295 -179.856 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 47' ' ' ALA . . . . . 0.584 ' HB3' ' HE2' ' A' ' 205' ' ' LYS . . . -66.98 -49.25 65.97 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.586 179.851 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -54.16 -44.39 71.42 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 115.983 -0.553 . . . . 0.0 111.962 -179.112 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 30.1 m -68.29 -34.24 64.99 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 C-N-CA 120.98 -0.288 . . . . 0.0 111.073 -179.731 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -67.54 -37.06 82.15 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-O 121.016 0.436 . . . . 0.0 110.939 179.264 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 38.7 m-85 -68.54 -38.76 81.11 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.028 -0.533 . . . . 0.0 110.214 -179.948 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -65.02 -50.71 65.19 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 115.804 -0.635 . . . . 0.0 111.088 179.592 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 53' ' ' VAL . . . . . 0.468 HG23 ' N ' ' A' ' 54' ' ' MET . 25.3 m -60.78 -47.9 91.16 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.109 0 CA-C-N 116.527 -0.306 . . . . 0.0 110.85 -179.939 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 54' ' ' MET . . . . . 0.478 ' HG2' ' HG2' ' A' ' 71' ' ' PRO . 74.3 mtm -62.42 -31.55 72.26 Favored 'General case' 0 C--N 1.331 -0.225 0 N-CA-C 109.607 -0.516 . . . . 0.0 109.607 179.068 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 55' ' ' ALA . . . . . 0.486 ' HB1' ' HB2' ' A' ' 8' ' ' PHE . . . -72.69 -22.49 60.9 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 115.527 -0.761 . . . . 0.0 110.981 179.583 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 81.0 mt -87.42 -5.52 58.81 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.118 179.996 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 90.15 -14.68 61.55 Favored Glycine 0 N--CA 1.45 -0.418 0 C-N-CA 120.622 -0.799 . . . . 0.0 112.911 179.765 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 9.0 p -69.5 141.64 17.01 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-O 120.85 0.357 . . . . 0.0 110.801 179.885 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 59' ' ' GLY . . . . . 0.407 ' HA3' ' HG3' ' A' ' 71' ' ' PRO . . . 92.39 -5.62 77.74 Favored Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.868 -0.682 . . . . 0.0 112.153 -179.268 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 60' ' ' TRP . . . . . . . . . . . . . 19.6 m0 -80.1 111.98 16.97 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-O 120.578 0.228 . . . . 0.0 110.785 179.919 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 61' ' ' VAL . . . . . 0.492 HG11 HG22 ' A' ' 68' ' ' VAL . 7.1 p -115.02 128.75 25.66 Favored Pre-proline 0 CA--C 1.533 0.315 0 CA-C-N 116.512 -0.313 . . . . 0.0 110.951 179.566 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 71.7 Cg_endo -76.39 156.0 36.76 Favored 'Trans proline' 0 C--N 1.35 0.629 0 C-N-CA 122.47 2.113 . . . . 0.0 112.725 -179.873 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 84.2 t -143.15 89.89 0.41 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 115.764 -0.653 . . . . 0.0 110.599 179.879 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . 58.71 -88.38 0.02 OUTLIER 'General case' 0 C--N 1.331 -0.196 0 CA-C-N 116.115 -0.493 . . . . 0.0 111.306 -179.756 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 45.5 mt-10 -120.5 -17.78 8.02 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 116.386 -0.37 . . . . 0.0 110.828 179.807 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 66' ' ' ARG . . . . . 0.455 ' HA ' ' HE ' ' A' ' 66' ' ' ARG . 3.0 mmp_? -100.29 163.5 12.37 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.25 179.672 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 85.3 m -125.83 133.91 51.82 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 121.023 0.439 . . . . 0.0 111.516 -179.673 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 68' ' ' VAL . . . . . 0.492 HG22 HG11 ' A' ' 61' ' ' VAL . 17.9 m -123.3 144.69 32.02 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-N 115.857 -0.611 . . . . 0.0 110.469 179.417 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 69' ' ' PHE . . . . . . . . . . . . . 19.4 m-85 -110.45 112.21 23.98 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.359 -0.382 . . . . 0.0 110.109 -179.217 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 70' ' ' VAL . . . . . 0.618 ' N ' ' HD2' ' A' ' 71' ' ' PRO . 28.3 t -66.02 -47.49 62.83 Favored Pre-proline 0 C--N 1.323 -0.553 0 CA-C-N 116.234 -0.439 . . . . 0.0 112.01 -179.362 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 71' ' ' PRO . . . . . 0.618 ' HD2' ' N ' ' A' ' 70' ' ' VAL . 13.9 Cg_endo -57.15 -22.22 46.9 Favored 'Trans proline' 0 C--N 1.351 0.709 0 C-N-CA 121.982 1.788 . . . . 0.0 111.773 179.518 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 60.7 ttp180 -75.91 -53.3 8.63 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.585 179.694 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 73' ' ' TYR . . . . . . . . . . . . . 69.3 m-85 -64.6 -45.76 85.56 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 115.967 -0.56 . . . . 0.0 110.709 179.912 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 0.4 OUTLIER -60.86 -36.56 72.46 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 N-CA-C 109.807 -0.442 . . . . 0.0 109.807 179.362 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 24.3 t70 -60.38 -37.97 82.44 Favored 'General case' 0 C--N 1.331 -0.209 0 N-CA-C 109.466 -0.568 . . . . 0.0 109.466 178.918 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 76' ' ' TRP . . . . . . . . . . . . . 47.4 m0 -67.08 -29.2 68.9 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 115.717 -0.674 . . . . 0.0 110.289 179.452 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 77' ' ' ILE . . . . . 0.421 ' O ' ' HG2' ' A' ' 81' ' ' PRO . 73.7 mt -72.4 -30.42 34.77 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.373 0 CA-C-N 115.838 -0.619 . . . . 0.0 110.626 179.395 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 40.2 mt -91.88 -16.69 26.33 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.209 -0.451 . . . . 0.0 111.989 -179.954 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 76.7 p -101.97 -49.02 4.06 Favored 'General case' 0 N--CA 1.464 0.262 0 N-CA-C 113.465 0.913 . . . . 0.0 113.465 -178.27 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 80' ' ' THR . . . . . 0.662 ' HB ' ' HD3' ' A' ' 81' ' ' PRO . 44.2 m -53.11 -54.46 44.2 Favored Pre-proline 0 CA--C 1.531 0.22 0 N-CA-C 112.226 0.454 . . . . 0.0 112.226 -178.338 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 81' ' ' PRO . . . . . 0.662 ' HD3' ' HB ' ' A' ' 80' ' ' THR . 34.2 Cg_exo -61.12 -19.72 64.64 Favored 'Trans proline' 0 C--N 1.352 0.735 0 C-N-CA 121.552 1.502 . . . . 0.0 111.28 179.578 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 82' ' ' LEU . . . . . . . . . . . . . 13.1 tp -76.89 -36.56 56.61 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 115.66 -0.7 . . . . 0.0 110.558 179.909 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 35.2 mm -68.02 -52.54 37.83 Favored 'Isoleucine or valine' 0 C--O 1.233 0.235 0 CA-C-N 116.308 -0.405 . . . . 0.0 110.08 179.251 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 30.9 m -59.58 -32.74 49.78 Favored 'Isoleucine or valine' 0 CA--C 1.52 -0.195 0 N-CA-C 109.482 -0.562 . . . . 0.0 109.482 178.796 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 85' ' ' TYR . . . . . . . . . . . . . 89.5 t80 -62.65 -34.63 77.46 Favored 'General case' 0 N--CA 1.454 -0.258 0 CA-C-N 115.528 -0.76 . . . . 0.0 109.163 178.595 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 86' ' ' PHE . . . . . . . . . . . . . 11.3 t80 -61.36 -51.72 67.65 Favored 'General case' 0 N--CA 1.456 -0.126 0 CA-C-N 115.561 -0.745 . . . . 0.0 109.879 179.201 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 7.6 mp -58.6 -36.43 74.0 Favored 'General case' 0 C--N 1.331 -0.202 0 CA-C-N 115.89 -0.595 . . . . 0.0 110.194 179.426 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 88' ' ' GLY . . . . . 0.441 ' HA2' HD11 ' A' ' 93' ' ' LEU . . . -64.93 -28.1 73.04 Favored Glycine 0 N--CA 1.45 -0.399 0 C-N-CA 120.916 -0.659 . . . . 0.0 112.165 179.575 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 86.5 mt -74.08 -41.25 61.97 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.902 0.382 . . . . 0.0 110.741 179.732 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 74.8 mt -58.73 -47.56 84.19 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 115.913 -0.585 . . . . 0.0 111.158 -179.756 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -74.77 -42.44 58.17 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.376 -0.375 . . . . 0.0 111.149 -179.875 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 93.06 55.96 1.54 Allowed Glycine 0 N--CA 1.45 -0.422 0 C-N-CA 120.832 -0.699 . . . . 0.0 112.466 -179.945 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 93' ' ' LEU . . . . . 0.509 HD23 ' HB3' ' A' ' 97' ' ' GLU . 9.7 mp -67.71 -176.4 0.64 Allowed 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.809 0.338 . . . . 0.0 110.908 -179.943 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 94' ' ' ASP . . . . . . . . . . . . . 10.4 m-20 -113.47 172.97 6.64 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.472 -179.929 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 45.4 t -54.03 -36.27 62.85 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.312 -0.404 . . . . 0.0 111.372 -179.759 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 96' ' ' ARG . . . . . 0.404 ' O ' HG13 ' A' ' 100' ' ' ILE . 29.3 mmm180 -73.98 -47.88 34.21 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 116.279 -0.419 . . . . 0.0 111.457 -179.85 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 97' ' ' GLU . . . . . 0.509 ' HB3' HD23 ' A' ' 93' ' ' LEU . 47.6 mt-10 -60.19 -44.59 94.96 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-O 120.912 0.387 . . . . 0.0 110.584 -179.387 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 98' ' ' PHE . . . . . 0.425 ' O ' HG12 ' A' ' 102' ' ' ILE . 12.8 m-85 -59.91 -47.95 83.66 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 115.869 -0.605 . . . . 0.0 110.514 179.325 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -55.22 -32.02 56.86 Favored Glycine 0 N--CA 1.452 -0.276 0 C-N-CA 120.799 -0.715 . . . . 0.0 112.697 179.922 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 100' ' ' ILE . . . . . 0.432 ' O ' HG23 ' A' ' 103' ' ' THR . 89.5 mt -69.51 -54.0 21.91 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.222 0 CA-C-O 120.956 0.408 . . . . 0.0 111.676 -179.894 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 17.2 t -64.7 -42.79 96.0 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.355 0 CA-C-N 116.136 -0.484 . . . . 0.0 111.933 -179.203 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 102' ' ' ILE . . . . . 0.425 HG12 ' O ' ' A' ' 98' ' ' PHE . 48.8 mm -63.67 -53.13 48.69 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-N 116.326 -0.397 . . . . 0.0 111.698 -179.325 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 103' ' ' THR . . . . . 0.432 HG23 ' O ' ' A' ' 100' ' ' ILE . 12.8 t -55.03 -35.38 64.39 Favored 'General case' 0 C--O 1.234 0.244 0 CA-C-O 120.869 0.366 . . . . 0.0 110.726 -179.909 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 104' ' ' LEU . . . . . 0.464 HD21 ' HE2' ' A' ' 140' ' ' TYR . 29.3 tp -61.08 -49.45 77.26 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.296 179.216 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 105' ' ' ASN . . . . . 0.575 ' N ' HD21 ' A' ' 105' ' ' ASN . 0.8 OUTLIER -59.1 -26.36 64.62 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.054 -0.521 . . . . 0.0 110.562 179.808 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 33.2 m -66.47 -54.16 27.22 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.276 -0.42 . . . . 0.0 111.158 179.697 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 12.8 p -66.25 -36.29 77.04 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.152 0 CA-C-N 116.486 -0.325 . . . . 0.0 111.356 -179.834 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 73.7 t -62.62 -56.86 14.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-O 120.885 0.374 . . . . 0.0 111.104 -179.949 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 109' ' ' MET . . . . . . . . . . . . . 7.1 tpp -60.48 -31.66 70.67 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.451 179.998 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 110' ' ' LEU . . . . . 0.476 ' C ' HD21 ' A' ' 110' ' ' LEU . 5.0 tt -64.19 -37.86 88.97 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-N 115.81 -0.632 . . . . 0.0 109.595 178.714 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -60.78 -50.58 72.86 Favored 'General case' 0 C--N 1.333 -0.137 0 CA-C-N 115.883 -0.598 . . . . 0.0 110.827 179.671 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . -59.38 -45.91 94.72 Favored Glycine 0 C--N 1.331 0.263 0 C-N-CA 120.687 -0.768 . . . . 0.0 112.074 179.645 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 113' ' ' PHE . . . . . . . . . . . . . 3.0 t80 -49.73 -65.66 0.53 Allowed 'General case' 0 C--N 1.333 -0.128 0 CA-C-O 120.91 0.386 . . . . 0.0 110.382 179.696 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -64.79 -17.77 64.5 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 115.901 -0.59 . . . . 0.0 110.952 179.927 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -57.24 -52.32 52.2 Favored Glycine 0 N--CA 1.45 -0.385 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.045 179.579 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -78.32 -15.06 59.11 Favored 'General case' 0 C--N 1.328 -0.351 0 N-CA-C 111.984 0.364 . . . . 0.0 111.984 179.904 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 117' ' ' MET . . . . . 0.421 ' SD ' HG21 ' A' ' 68' ' ' VAL . 26.0 mmt -80.88 19.86 0.82 Allowed 'General case' 0 N--CA 1.464 0.259 0 N-CA-C 112.182 0.438 . . . . 0.0 112.182 -178.985 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 118' ' ' VAL . . . . . 0.495 HG21 ' N ' ' A' ' 123' ' ' ARG . 17.6 m -113.24 157.74 40.16 Favored Pre-proline 0 C--N 1.328 -0.343 0 CA-C-N 116.756 -0.202 . . . . 0.0 111.208 179.819 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 119' ' ' PRO . . . . . 0.427 ' HD2' ' HB ' ' A' ' 118' ' ' VAL . 69.2 Cg_endo -73.96 -24.44 15.17 Favored 'Trans proline' 0 C--N 1.347 0.493 0 C-N-CA 122.414 2.076 . . . . 0.0 112.382 179.667 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . 152.56 151.86 5.8 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.831 179.935 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 18.9 mm 73.73 -46.94 0.17 Allowed 'Isoleucine or valine' 0 N--CA 1.466 0.334 0 C-N-CA 122.956 0.503 . . . . 0.0 111.715 -179.821 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 14.3 mm-40 -60.17 -28.25 67.78 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.103 180.0 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 123' ' ' ARG . . . . . 0.536 ' HD3' ' HA2' ' A' ' 184' ' ' GLY . 6.5 ptp180 -60.23 -29.49 68.8 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.012 -0.54 . . . . 0.0 111.03 179.896 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 124' ' ' TYR . . . . . . . . . . . . . 30.2 m-85 -69.24 -32.15 71.18 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 115.84 -0.618 . . . . 0.0 111.349 -179.707 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 125' ' ' ALA . . . . . . . . . . . . . . . -73.32 -56.41 5.11 Favored 'General case' 0 C--O 1.236 0.364 0 CA-C-O 121.05 0.452 . . . . 0.0 111.03 179.961 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 1.4 mt -56.04 -50.47 70.84 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.814 -0.63 . . . . 0.0 110.719 -179.926 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 127' ' ' PHE . . . . . 0.438 ' HZ ' ' HB3' ' A' ' 175' ' ' PRO . 9.4 t80 -65.69 -36.19 82.93 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.378 -0.374 . . . . 0.0 110.229 179.459 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 128' ' ' GLY . . . . . . . . . . . . . . . -46.29 -44.54 15.36 Favored Glycine 0 C--N 1.332 0.347 0 C-N-CA 120.171 -1.014 . . . . 0.0 110.822 178.925 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 129' ' ' MET . . . . . . . . . . . . . 0.5 OUTLIER -71.83 -36.47 70.2 Favored 'General case' 0 N--CA 1.453 -0.315 0 N-CA-C 109.833 -0.432 . . . . 0.0 109.833 178.663 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -63.13 -33.08 86.27 Favored Glycine 0 C--N 1.333 0.364 0 CA-C-N 115.794 -0.639 . . . . 0.0 112.867 -179.756 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -74.11 -53.87 9.0 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.681 0.277 . . . . 0.0 110.454 -179.99 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 44.2 t -56.91 -39.94 68.54 Favored 'Isoleucine or valine' 0 C--O 1.234 0.26 0 N-CA-C 109.344 -0.613 . . . . 0.0 109.344 178.764 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -67.4 -36.46 81.33 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 115.305 -0.862 . . . . 0.0 110.167 178.986 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 134' ' ' PHE . . . . . . . . . . . . . 84.7 t80 -56.6 -50.63 71.41 Favored 'General case' 0 N--CA 1.452 -0.335 0 CA-C-N 116.126 -0.488 . . . . 0.0 109.81 179.394 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 135' ' ' ILE . . . . . 0.444 ' O ' HG21 ' A' ' 138' ' ' VAL . 52.8 mt -59.28 -33.53 51.2 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.38 0 CA-C-N 115.67 -0.695 . . . . 0.0 110.207 179.204 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . -63.02 -41.09 99.95 Favored Glycine 0 N--CA 1.448 -0.548 0 C-N-CA 120.209 -0.996 . . . . 0.0 111.292 178.87 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 137' ' ' LEU . . . . . 0.453 HD13 HD22 ' A' ' 105' ' ' ASN . 57.9 tp -67.11 -53.94 26.07 Favored 'General case' 0 N--CA 1.454 -0.269 0 CA-C-O 120.499 0.19 . . . . 0.0 110.889 179.733 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 138' ' ' VAL . . . . . 0.444 HG21 ' O ' ' A' ' 135' ' ' ILE . 4.9 m -54.48 -33.84 27.43 Favored 'Isoleucine or valine' 0 C--O 1.233 0.205 0 CA-C-O 121.09 0.471 . . . . 0.0 109.746 -179.696 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 139' ' ' TYR . . . . . . . . . . . . . 24.2 t80 -59.8 -42.96 94.57 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 115.621 -0.718 . . . . 0.0 109.864 178.299 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 140' ' ' TYR . . . . . 0.464 ' HE2' HD21 ' A' ' 104' ' ' LEU . 25.8 m-85 -65.19 -45.74 83.59 Favored 'General case' 0 C--N 1.333 -0.142 0 CA-C-N 116.083 -0.508 . . . . 0.0 111.13 179.38 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 141' ' ' LEU . . . . . . . . . . . . . 10.6 mp -54.48 -32.65 58.2 Favored 'General case' 0 C--N 1.332 -0.171 0 CA-C-N 116.283 -0.417 . . . . 0.0 111.178 -179.745 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 11.1 p -106.84 -2.41 9.98 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-N 116.233 -0.44 . . . . 0.0 111.121 -179.812 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . -75.61 -120.61 0.13 Allowed Glycine 0 CA--C 1.522 0.469 0 C-N-CA 120.829 -0.701 . . . . 0.0 112.68 -179.848 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 144' ' ' PRO . . . . . . . . . . . . . 56.1 Cg_endo -69.64 -23.65 31.09 Favored 'Trans proline' 0 C--N 1.348 0.54 0 C-N-CA 122.489 2.126 . . . . 0.0 112.433 179.923 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 145' ' ' MET . . . . . 0.413 ' HB3' ' OH ' ' A' ' 160' ' ' TYR . 48.8 mtt -53.62 -58.85 5.7 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.103 -0.499 . . . . 0.0 111.84 -179.712 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 146' ' ' THR . . . . . . . . . . . . . 9.0 t -56.03 -32.45 64.04 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.327 -0.397 . . . . 0.0 111.888 -179.118 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 43.0 mt-10 -70.41 -41.16 73.31 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.645 -0.252 . . . . 0.0 111.329 -179.735 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 148' ' ' SER . . . . . . . . . . . . . 67.4 m -69.74 -41.81 74.76 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.432 -0.349 . . . . 0.0 111.304 -179.329 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 149' ' ' ALA . . . . . . . . . . . . . . . -70.23 -37.54 75.0 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.255 -0.429 . . . . 0.0 111.444 -179.656 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 150' ' ' SER . . . . . . . . . . . . . 75.8 m -68.2 -4.12 12.93 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.381 -0.372 . . . . 0.0 111.057 179.98 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 151' ' ' GLN . . . . . . . . . . . . . 50.4 mt-30 -117.66 4.29 12.33 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.333 -0.394 . . . . 0.0 111.043 179.876 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 7.9 tpm_? -83.81 -51.81 6.9 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 120.971 0.415 . . . . 0.0 110.617 179.863 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 153' ' ' SER . . . . . 0.527 ' HB2' HG12 ' A' ' 156' ' ' ILE . 35.3 m -157.65 172.9 17.69 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 115.768 -0.651 . . . . 0.0 110.544 179.612 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 154' ' ' SER . . . . . . . . . . . . . 66.4 p -71.86 -37.92 70.14 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-O 120.828 0.347 . . . . 0.0 110.433 179.432 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -76.63 -34.71 43.23 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 121.001 -0.619 . . . . 0.0 112.646 179.848 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 156' ' ' ILE . . . . . 0.527 HG12 ' HB2' ' A' ' 153' ' ' SER . 34.2 mm -59.52 -36.76 66.59 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-O 120.84 0.353 . . . . 0.0 111.167 179.958 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 157' ' ' LYS . . . . . . . . . . . . . 86.4 tttt -61.23 -54.99 37.25 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 116.078 -0.51 . . . . 0.0 111.524 -179.713 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 49.0 m -66.39 -38.99 88.76 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.964 -179.152 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 159' ' ' LEU . . . . . . . . . . . . . 6.4 tt -68.55 -37.05 79.6 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.725 -0.216 . . . . 0.0 111.546 -179.119 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 160' ' ' TYR . . . . . 0.413 ' OH ' ' HB3' ' A' ' 145' ' ' MET . 37.7 t80 -74.09 -47.43 36.53 Favored 'General case' 0 C--N 1.33 -0.265 0 N-CA-C 111.807 0.299 . . . . 0.0 111.807 -179.087 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 27.9 m -57.21 -41.73 78.57 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-O 120.674 0.273 . . . . 0.0 111.453 -179.332 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 162' ' ' ARG . . . . . . . . . . . . . 32.5 tpt180 -68.96 -43.92 74.01 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-O 120.867 0.365 . . . . 0.0 111.204 -179.913 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 163' ' ' LEU . . . . . 0.483 ' HG ' ' HB2' ' A' ' 208' ' ' PHE . 3.9 mp -62.41 -47.41 84.22 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 115.917 -0.583 . . . . 0.0 111.973 -179.247 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 164' ' ' ARG . . . . . 0.468 ' HG3' ' N ' ' A' ' 165' ' ' ASN . 4.5 ptt180 -67.64 -40.86 84.55 Favored 'General case' 0 C--N 1.329 -0.288 0 N-CA-C 111.829 0.307 . . . . 0.0 111.829 -178.926 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 165' ' ' ASN . . . . . 0.468 ' N ' ' HG3' ' A' ' 164' ' ' ARG . 0.9 OUTLIER -58.77 -52.07 67.28 Favored 'General case' 0 C--N 1.327 -0.372 0 N-CA-C 111.946 0.35 . . . . 0.0 111.946 -179.231 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 166' ' ' LEU . . . . . . . . . . . . . 3.0 pp -68.22 -44.29 76.09 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.707 0.289 . . . . 0.0 111.455 -179.485 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 167' ' ' THR . . . . . . . . . . . . . 71.5 m -58.48 -50.87 72.18 Favored 'General case' 0 C--N 1.331 -0.218 0 N-CA-C 112.198 0.444 . . . . 0.0 112.198 -179.402 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 168' ' ' VAL . . . . . 0.425 HG13 ' N ' ' A' ' 169' ' ' VAL . 9.2 p -61.7 -41.12 89.22 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 N-CA-C 111.713 0.264 . . . . 0.0 111.713 -179.014 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 169' ' ' VAL . . . . . 0.425 ' N ' HG13 ' A' ' 168' ' ' VAL . 55.1 t -60.98 -59.41 4.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-O 120.769 0.318 . . . . 0.0 111.175 -179.883 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 170' ' ' LEU . . . . . 0.59 HD21 HG13 ' A' ' 203' ' ' VAL . 3.9 pp -61.86 -31.63 71.91 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.358 -0.383 . . . . 0.0 110.982 -179.455 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 171' ' ' TRP . . . . . . . . . . . . . 3.4 m0 -72.07 -32.08 66.71 Favored 'General case' 0 N--CA 1.463 0.205 0 CA-C-O 120.89 0.376 . . . . 0.0 110.095 178.952 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 172' ' ' ALA . . . . . . . . . . . . . . . -69.07 -7.17 33.37 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 115.982 -0.554 . . . . 0.0 110.692 179.646 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 173' ' ' ILE . . . . . 0.488 ' O ' HG12 ' A' ' 177' ' ' ILE . 29.2 mm -88.19 -26.65 5.65 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.263 0 CA-C-N 115.939 -0.573 . . . . 0.0 110.919 179.794 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 174' ' ' TYR . . . . . 0.427 ' HB2' ' HD3' ' A' ' 175' ' ' PRO . 34.4 m-85 -53.77 -48.81 92.25 Favored Pre-proline 0 C--N 1.332 -0.163 0 CA-C-N 116.311 -0.404 . . . . 0.0 111.574 -179.737 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 175' ' ' PRO . . . . . 0.438 ' HB3' ' HZ ' ' A' ' 127' ' ' PHE . 84.8 Cg_exo -47.93 -32.39 17.69 Favored 'Trans proline' 0 C--N 1.352 0.722 0 C-N-CA 122.007 1.805 . . . . 0.0 112.199 179.558 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 176' ' ' PHE . . . . . 0.426 ' O ' ' HG ' ' A' ' 180' ' ' LEU . 81.5 m-85 -80.76 -50.59 9.67 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.059 -0.519 . . . . 0.0 111.803 -179.931 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 177' ' ' ILE . . . . . 0.488 HG12 ' O ' ' A' ' 173' ' ' ILE . 6.8 mm -62.07 -30.86 49.64 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.585 0 CA-C-N 116.104 -0.498 . . . . 0.0 112.022 -178.338 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 178' ' ' TRP . . . . . 0.426 ' HH2' ' HB2' ' A' ' 123' ' ' ARG . 73.9 t90 -73.6 -47.42 40.48 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-O 120.854 0.359 . . . . 0.0 110.662 179.714 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 179' ' ' LEU . . . . . 0.433 HD21 HD23 ' A' ' 180' ' ' LEU . 0.7 OUTLIER -70.96 -54.61 10.69 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 115.97 -0.559 . . . . 0.0 111.409 -179.287 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 180' ' ' LEU . . . . . 0.433 HD23 HD21 ' A' ' 179' ' ' LEU . 24.8 mt -64.78 -38.02 89.58 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.556 -0.293 . . . . 0.0 111.151 -179.779 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . -61.73 178.46 4.43 Favored Glycine 0 C--N 1.334 0.453 0 C-N-CA 120.086 -1.054 . . . . 0.0 112.231 179.185 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 182' ' ' PRO . . . . . 0.438 ' HB2' ' HD3' ' A' ' 183' ' ' PRO . 75.2 Cg_exo -48.02 -45.33 25.45 Favored 'Trans proline' 0 CA--C 1.534 0.507 0 C-N-CA 122.827 2.351 . . . . 0.0 113.613 179.856 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 183' ' ' PRO . . . . . 0.438 ' HD3' ' HB2' ' A' ' 182' ' ' PRO . 82.4 Cg_exo -46.65 -29.84 8.21 Favored 'Trans proline' 0 C--N 1.356 0.954 0 C-N-CA 122.14 1.894 . . . . 0.0 113.232 -179.788 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 184' ' ' GLY . . . . . 0.536 ' HA2' ' HD3' ' A' ' 123' ' ' ARG . . . -115.81 -128.19 4.28 Favored Glycine 0 N--CA 1.449 -0.453 0 C-N-CA 120.249 -0.977 . . . . 0.0 113.129 -179.663 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 185' ' ' VAL . . . . . . . . . . . . . 13.0 m -58.13 -27.33 31.65 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 N-CA-C 112.18 0.437 . . . . 0.0 112.18 -179.429 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 186' ' ' ALA . . . . . . . . . . . . . . . 59.34 82.25 0.15 Allowed 'General case' 0 C--N 1.33 -0.251 0 N-CA-C 111.983 0.364 . . . . 0.0 111.983 179.445 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 187' ' ' LEU . . . . . 0.513 ' HB2' HD11 ' A' ' 188' ' ' LEU . 8.6 mt -92.47 -49.59 6.05 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-O 121.039 0.447 . . . . 0.0 110.721 179.381 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 188' ' ' LEU . . . . . 0.513 HD11 ' HB2' ' A' ' 187' ' ' LEU . 6.9 mp -87.4 -166.38 1.56 Allowed 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 115.696 -0.684 . . . . 0.0 111.489 -179.233 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 189' ' ' THR . . . . . . . . . . . . . 10.2 m -94.39 137.43 22.71 Favored Pre-proline 0 C--N 1.33 -0.265 0 CA-C-N 115.743 -0.662 . . . . 0.0 110.498 -179.94 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 190' ' ' PRO . . . . . 0.413 ' O ' HG21 ' A' ' 194' ' ' VAL . 87.6 Cg_exo -44.31 -47.01 11.2 Favored 'Trans proline' 0 C--N 1.35 0.612 0 C-N-CA 122.661 2.241 . . . . 0.0 113.097 -179.859 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 191' ' ' THR . . . . . . . . . . . . . 6.8 t -59.27 -39.47 83.02 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 120.817 0.342 . . . . 0.0 111.28 -179.906 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 192' ' ' VAL . . . . . . . . . . . . . 58.8 t -70.58 -45.42 74.44 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.262 -0.426 . . . . 0.0 111.171 -179.952 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 193' ' ' ASP . . . . . . . . . . . . . 30.5 t70 -57.54 -43.85 84.7 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.294 -0.412 . . . . 0.0 110.678 179.937 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 194' ' ' VAL . . . . . 0.413 HG21 ' O ' ' A' ' 190' ' ' PRO . 98.1 t -64.28 -35.72 74.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 115.944 -0.571 . . . . 0.0 110.559 179.743 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 195' ' ' ALA . . . . . . . . . . . . . . . -59.19 -47.87 83.72 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 120.824 0.345 . . . . 0.0 110.793 179.551 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 196' ' ' LEU . . . . . . . . . . . . . 61.3 mt -67.83 -40.73 83.71 Favored 'General case' 0 C--N 1.332 -0.172 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.705 179.681 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 197' ' ' ILE . . . . . . . . . . . . . 14.3 mm -59.98 -58.18 8.37 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.239 0 CA-C-N 116.041 -0.527 . . . . 0.0 110.348 179.436 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 198' ' ' VAL . . . . . . . . . . . . . 64.1 t -52.28 -34.21 18.05 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.515 0 CA-C-N 115.599 -0.728 . . . . 0.0 109.311 178.469 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 199' ' ' TYR . . . . . 0.408 ' O ' HG22 ' A' ' 203' ' ' VAL . 64.9 t80 -69.32 -41.16 77.08 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 115.378 -0.828 . . . . 0.0 110.401 179.83 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 200' ' ' LEU . . . . . 0.407 HD11 HG13 ' A' ' 177' ' ' ILE . 31.4 mt -59.03 -54.81 42.91 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 115.563 -0.744 . . . . 0.0 111.524 -179.521 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 201' ' ' ASP . . . . . . . . . . . . . 10.7 m-20 -60.23 -38.64 84.04 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.322 -0.399 . . . . 0.0 110.888 -179.853 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 202' ' ' LEU . . . . . . . . . . . . . 2.0 mt -66.81 -28.43 68.37 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 115.868 -0.606 . . . . 0.0 111.409 -179.637 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 203' ' ' VAL . . . . . 0.59 HG13 HD21 ' A' ' 170' ' ' LEU . 41.3 t -79.47 -36.37 17.72 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.439 -0.346 . . . . 0.0 110.841 -179.055 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 204' ' ' THR . . . . . 0.434 ' O ' ' CD1' ' A' ' 208' ' ' PHE . 27.7 m -63.46 -58.32 7.43 Favored 'General case' 0 C--N 1.324 -0.512 0 C-N-CA 120.575 -0.45 . . . . 0.0 110.928 179.768 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 205' ' ' LYS . . . . . 0.584 ' HE2' ' HB3' ' A' ' 47' ' ' ALA . 44.2 mttp -66.32 -58.57 5.04 Favored 'General case' 0 C--N 1.331 -0.229 0 N-CA-C 112.624 0.602 . . . . 0.0 112.624 -178.254 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 43.8 t -70.83 -36.68 65.46 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.374 0 N-CA-C 112.182 0.438 . . . . 0.0 112.182 -178.444 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 207' ' ' GLY . . . . . 0.504 ' O ' HG13 ' A' ' 211' ' ' ILE . . . -61.54 -60.38 8.3 Favored Glycine 0 N--CA 1.452 -0.234 0 C-N-CA 120.58 -0.819 . . . . 0.0 113.598 -178.561 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 208' ' ' PHE . . . . . 0.483 ' HB2' ' HG ' ' A' ' 163' ' ' LEU . 0.1 OUTLIER -70.83 -26.66 63.38 Favored 'General case' 0 N--CA 1.464 0.249 0 CA-C-N 117.14 0.47 . . . . 0.0 111.515 -178.9 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 209' ' ' GLY . . . . . 0.489 ' O ' ' HB2' ' A' ' 212' ' ' ALA . . . -68.29 -32.65 76.24 Favored Glycine 0 N--CA 1.449 -0.49 0 N-CA-C 111.81 -0.516 . . . . 0.0 111.81 179.084 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 210' ' ' PHE . . . . . . . . . . . . . 0.8 OUTLIER -71.62 -48.47 47.74 Favored 'General case' 0 CA--C 1.512 -0.494 0 N-CA-C 108.053 -1.092 . . . . 0.0 108.053 178.491 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 211' ' ' ILE . . . . . 0.504 HG13 ' O ' ' A' ' 207' ' ' GLY . 4.9 mt -63.61 -27.75 43.58 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.544 0 N-CA-C 107.645 -1.243 . . . . 0.0 107.645 176.65 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 212' ' ' ALA . . . . . 0.489 ' HB2' ' O ' ' A' ' 209' ' ' GLY . . . -64.42 -40.97 96.79 Favored 'General case' 0 N--CA 1.45 -0.463 0 CA-C-N 114.583 -1.19 . . . . 0.0 110.5 179.793 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 213' ' ' LEU . . . . . . . . . . . . . 91.5 mt -70.52 -55.07 9.78 Favored 'General case' 0 N--CA 1.461 0.105 0 CA-C-N 115.489 -0.778 . . . . 0.0 111.748 -179.671 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 214' ' ' ASP . . . . . . . . . . . . . 25.1 m-20 -53.98 -49.92 67.73 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.28 -0.418 . . . . 0.0 111.648 -179.273 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 215' ' ' ALA . . . . . . . . . . . . . . . -59.8 -57.51 12.6 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.372 -0.376 . . . . 0.0 111.48 -179.633 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 216' ' ' ALA . . . . . . . . . . . . . . . -57.66 -35.31 70.38 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.31 -0.405 . . . . 0.0 111.421 -179.703 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 217' ' ' ALA . . . . . . . . . . . . . . . -63.67 -31.75 73.02 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 121.001 0.429 . . . . 0.0 110.424 179.831 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 218' ' ' THR . . . . . . . . . . . . . 93.8 m . . . . . 0 C--N 1.33 -0.256 0 CA-C-N 115.759 -0.655 . . . . 0.0 110.79 179.532 . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.342 0 N-CA-C 112.789 -0.124 . . . . 0.0 112.789 . . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 49.2 tp -74.1 -35.37 64.18 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-O 120.782 0.325 . . . . 0.0 110.921 179.951 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 82.7 p -62.34 -31.63 72.29 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.447 -179.774 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 28.9 p -54.23 -35.78 62.81 Favored 'General case' 0 C--N 1.332 -0.175 0 CA-C-N 116.368 -0.378 . . . . 0.0 111.276 -179.906 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 7' ' ' LEU . . . . . . . . . . . . . 4.2 mm? -59.79 -50.73 72.66 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.202 -179.847 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 8' ' ' PHE . . . . . 0.559 ' HB2' ' HB3' ' A' ' 55' ' ' ALA . 64.2 m-85 -65.5 -34.91 79.37 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.9 -179.829 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 9' ' ' TRP . . . . . 0.4 ' O ' HG12 ' A' ' 13' ' ' ILE . 29.4 m95 -65.27 -44.77 87.0 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.292 -179.668 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 75.3 mt -60.51 -41.43 94.33 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 115.639 -0.71 . . . . 0.0 110.095 179.396 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -64.86 -34.65 90.46 Favored Glycine 0 N--CA 1.448 -0.501 0 C-N-CA 120.677 -0.773 . . . . 0.0 111.667 179.304 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -65.5 -31.32 72.33 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-O 120.849 0.357 . . . . 0.0 110.388 179.602 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 13' ' ' ILE . . . . . 0.4 HG12 ' O ' ' A' ' 9' ' ' TRP . 42.3 mm -67.72 -48.47 75.89 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 116.032 -0.531 . . . . 0.0 110.153 179.339 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -61.57 -28.12 69.2 Favored Glycine 0 N--CA 1.45 -0.386 0 C-N-CA 120.698 -0.763 . . . . 0.0 111.81 179.436 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 15' ' ' MET . . . . . 0.541 ' HE1' ' HD2' ' A' ' 205' ' ' LYS . 23.2 mmt -75.07 -39.43 60.87 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.731 0.3 . . . . 0.0 110.645 179.693 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 20.6 tp -59.09 -40.64 85.9 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.312 179.345 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 41.3 t -69.94 -45.52 76.49 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.215 0 CA-C-N 115.902 -0.59 . . . . 0.0 111.114 -179.938 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -63.84 -49.59 67.07 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.562 -0.827 . . . . 0.0 111.686 179.635 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 19' ' ' THR . . . . . 0.41 HG21 HG11 ' A' ' 41' ' ' VAL . 85.1 m -50.24 -45.23 53.92 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 115.448 -0.376 . . . . 0.0 111.014 179.767 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 77.9 mt -71.89 -39.3 69.68 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.382 179.764 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -64.1 -30.62 71.67 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.659 0.266 . . . . 0.0 111.528 -179.626 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 22' ' ' PHE . . . . . 0.518 ' HB2' HG21 ' A' ' 41' ' ' VAL . 6.3 m-85 -90.84 -31.12 16.58 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.503 -0.317 . . . . 0.0 111.113 -179.388 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -71.58 -49.78 37.27 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-O 120.907 0.384 . . . . 0.0 110.841 179.797 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 24' ' ' TRP . . . . . . . . . . . . . 1.2 t-105 -60.32 -41.61 93.85 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 115.893 -0.594 . . . . 0.0 110.72 179.797 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.328 -0.341 0 CA-C-N 116.356 -0.384 . . . . 0.0 110.665 179.619 . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.342 0 N-CA-C 112.561 -0.216 . . . . 0.0 112.561 . . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 45.8 mt-10 -85.58 -20.82 28.98 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.672 0.272 . . . . 0.0 111.05 179.953 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 34' ' ' ARG . . . . . . . . . . . . . 56.7 ttp180 -50.44 -29.51 10.45 Favored 'General case' 0 C--N 1.332 -0.175 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.339 -179.761 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 37.2 mmt180 -64.59 -43.92 92.3 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.329 -0.396 . . . . 0.0 110.953 179.981 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 64.8 m-85 -69.36 -33.76 73.56 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 116.13 -0.486 . . . . 0.0 111.44 -179.596 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 37' ' ' TYR . . . . . . . . . . . . . 54.2 m-85 -70.81 -53.01 16.93 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.533 -179.386 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 87.4 t -56.82 -36.79 50.75 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.249 0 CA-C-O 121.18 0.514 . . . . 0.0 110.21 179.509 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 40.9 m -66.76 -47.53 71.93 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 115.51 -0.768 . . . . 0.0 110.525 179.222 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 40' ' ' LEU . . . . . 0.409 ' O ' HG13 ' A' ' 43' ' ' ILE . 21.9 tp -57.1 -47.57 80.73 Favored 'General case' 0 C--O 1.235 0.3 0 CA-C-N 115.67 -0.695 . . . . 0.0 110.787 179.881 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . 0.518 HG21 ' HB2' ' A' ' 22' ' ' PHE . 94.8 t -63.05 -34.81 68.74 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-N 115.81 -0.632 . . . . 0.0 110.249 179.436 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -58.78 -39.79 94.18 Favored Glycine 0 N--CA 1.449 -0.471 0 CA-C-N 115.689 -0.687 . . . . 0.0 112.238 179.667 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 43' ' ' ILE . . . . . 0.584 HG23 ' HE3' ' A' ' 205' ' ' LYS . 0.1 OUTLIER -67.93 -50.97 54.54 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.166 0 CA-C-O 120.695 0.283 . . . . 0.0 110.984 179.851 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 50.5 m -63.59 -25.28 68.16 Favored 'General case' 0 C--N 1.331 -0.199 0 CA-C-O 120.824 0.345 . . . . 0.0 110.945 179.895 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -77.81 -52.15 5.55 Favored Glycine 0 N--CA 1.452 -0.263 0 C-N-CA 120.949 -0.643 . . . . 0.0 112.865 -179.542 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 46' ' ' ILE . . . . . 0.561 HD11 HD12 ' A' ' 78' ' ' LEU . 10.5 pt -58.32 -40.92 79.82 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.242 0 CA-C-O 120.874 0.369 . . . . 0.0 110.975 -179.75 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 47' ' ' ALA . . . . . 0.634 ' HB3' ' HE2' ' A' ' 205' ' ' LYS . . . -68.12 -40.24 82.58 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.124 179.468 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 48' ' ' ALA . . . . . 0.465 ' HB3' ' HB3' ' A' ' 15' ' ' MET . . . -54.59 -45.42 73.61 Favored 'General case' 0 C--O 1.233 0.197 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.31 -179.666 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 27.6 m -73.05 -33.9 44.0 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.257 -0.429 . . . . 0.0 111.26 -179.68 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -61.67 -37.75 85.22 Favored 'General case' 0 C--N 1.331 -0.21 0 CA-C-O 121.102 0.477 . . . . 0.0 110.576 179.256 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 51' ' ' TYR . . . . . 0.482 ' HB3' ' O ' ' A' ' 8' ' ' PHE . 29.6 m-85 -72.85 -35.63 67.28 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 115.767 -0.651 . . . . 0.0 110.266 179.682 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -66.08 -40.88 91.18 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 115.798 -0.637 . . . . 0.0 111.082 179.3 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 53' ' ' VAL . . . . . 0.411 HG23 ' N ' ' A' ' 54' ' ' MET . 27.6 m -74.1 -41.52 52.03 Favored 'Isoleucine or valine' 0 C--O 1.231 0.123 0 CA-C-N 116.47 -0.332 . . . . 0.0 111.016 179.95 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 54' ' ' MET . . . . . 0.58 ' HG2' ' HG2' ' A' ' 71' ' ' PRO . 72.0 mtm -64.93 -36.21 83.65 Favored 'General case' 0 CA--C 1.519 -0.233 0 CA-C-O 121.171 0.51 . . . . 0.0 109.831 179.128 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 55' ' ' ALA . . . . . 0.559 ' HB3' ' HB2' ' A' ' 8' ' ' PHE . . . -69.55 -16.71 63.47 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 115.489 -0.778 . . . . 0.0 111.193 179.764 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 73.5 mt -97.06 2.55 51.48 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.328 -0.396 . . . . 0.0 111.407 -179.632 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 84.75 3.23 88.28 Favored Glycine 0 N--CA 1.452 -0.258 0 C-N-CA 120.628 -0.796 . . . . 0.0 112.941 179.66 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 49.2 t -69.87 132.94 32.67 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-O 120.631 0.253 . . . . 0.0 110.907 179.875 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 59' ' ' GLY . . . . . 0.653 ' HA3' ' HD3' ' A' ' 71' ' ' PRO . . . 88.56 -13.01 63.45 Favored Glycine 0 N--CA 1.449 -0.476 0 C-N-CA 120.656 -0.783 . . . . 0.0 112.487 -179.866 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 60' ' ' TRP . . . . . . . . . . . . . 15.5 m0 -66.2 89.46 0.13 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.833 0.349 . . . . 0.0 110.7 179.901 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 61' ' ' VAL . . . . . 0.474 HG11 HG23 ' A' ' 68' ' ' VAL . 4.0 p -101.52 132.32 21.94 Favored Pre-proline 0 CA--C 1.532 0.265 0 CA-C-N 116.266 -0.424 . . . . 0.0 110.928 179.928 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 62' ' ' PRO . . . . . 0.434 ' HD3' ' HA ' ' A' ' 61' ' ' VAL . 4.6 Cg_exo -76.94 151.21 30.83 Favored 'Trans proline' 0 C--N 1.35 0.617 0 C-N-CA 122.673 2.249 . . . . 0.0 112.494 -179.763 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 73.3 t -142.32 91.84 0.5 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 115.964 -0.562 . . . . 0.0 110.804 179.774 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . 59.56 -87.43 0.02 OUTLIER 'General case' 0 N--CA 1.463 0.183 0 CA-C-N 116.097 -0.501 . . . . 0.0 111.529 179.962 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 10.3 pt-20 -124.21 -16.26 6.51 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.903 0.383 . . . . 0.0 110.673 179.972 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 66' ' ' ARG . . . . . 0.422 HH11 ' HD2' ' A' ' 66' ' ' ARG . 64.6 mtt180 -104.58 160.77 14.68 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 115.922 -0.581 . . . . 0.0 110.362 179.535 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 37.2 m -120.97 142.66 49.56 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.971 0.415 . . . . 0.0 111.473 -179.613 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 68' ' ' VAL . . . . . 0.474 HG23 HG11 ' A' ' 61' ' ' VAL . 15.3 m -131.68 145.04 35.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 115.799 -0.637 . . . . 0.0 110.552 179.609 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 69' ' ' PHE . . . . . . . . . . . . . 16.7 m-85 -109.48 115.84 30.68 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.364 -0.38 . . . . 0.0 110.365 -179.358 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 70' ' ' VAL . . . . . 0.638 HG13 ' HD3' ' A' ' 71' ' ' PRO . 0.8 OUTLIER -64.59 -36.79 19.28 Favored Pre-proline 0 CA--C 1.541 0.627 0 N-CA-C 112.701 0.63 . . . . 0.0 112.701 -179.321 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 71' ' ' PRO . . . . . 0.653 ' HD3' ' HA3' ' A' ' 59' ' ' GLY . 61.4 Cg_endo -70.52 -20.81 30.77 Favored 'Trans proline' 0 C--N 1.36 1.154 0 C-N-CA 121.934 1.756 . . . . 0.0 113.382 -179.451 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 46.6 ttp180 -73.06 -55.13 6.93 Favored 'General case' 0 C--O 1.235 0.323 0 N-CA-C 111.658 0.244 . . . . 0.0 111.658 -179.031 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 73' ' ' TYR . . . . . 0.43 ' O ' HG13 ' A' ' 77' ' ' ILE . 11.8 m-85 -65.84 -37.54 86.46 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.907 0.384 . . . . 0.0 110.022 -179.883 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 74' ' ' ILE . . . . . 0.503 ' HA ' HD13 ' A' ' 77' ' ' ILE . 0.4 OUTLIER -67.22 -41.23 86.5 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.219 0 CA-C-N 116.058 -0.519 . . . . 0.0 110.631 179.704 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 75' ' ' ASP . . . . . 0.433 ' HA ' HD22 ' A' ' 78' ' ' LEU . 17.7 t70 -55.08 -39.7 69.57 Favored 'General case' 0 CA--C 1.519 -0.245 0 N-CA-C 109.584 -0.524 . . . . 0.0 109.584 179.235 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 76' ' ' TRP . . . . . . . . . . . . . 30.7 m0 -68.44 -32.52 72.6 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 115.927 -0.579 . . . . 0.0 110.683 179.61 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 77' ' ' ILE . . . . . 0.601 ' HA ' ' HG3' ' A' ' 109' ' ' MET . 92.2 mt -60.95 -41.64 89.79 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.245 0 CA-C-N 116.104 -0.498 . . . . 0.0 111.954 -179.828 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 78' ' ' LEU . . . . . 0.561 HD12 HD11 ' A' ' 46' ' ' ILE . 0.7 OUTLIER -91.38 -30.02 16.76 Favored 'General case' 0 CA--C 1.536 0.409 0 N-CA-C 113.392 0.886 . . . . 0.0 113.392 -178.883 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 46.0 p -75.2 -53.32 9.01 Favored 'General case' 0 N--CA 1.47 0.558 0 N-CA-C 113.447 0.906 . . . . 0.0 113.447 -178.275 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 80' ' ' THR . . . . . 0.56 ' N ' ' HD2' ' A' ' 81' ' ' PRO . 7.3 m -51.47 -48.95 85.04 Favored Pre-proline 0 C--N 1.329 -0.312 0 N-CA-C 112.948 0.721 . . . . 0.0 112.948 -178.36 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 81' ' ' PRO . . . . . 0.56 ' HD2' ' N ' ' A' ' 80' ' ' THR . 23.3 Cg_endo -58.99 -26.35 81.2 Favored 'Trans proline' 0 C--N 1.351 0.659 0 C-N-CA 121.72 1.613 . . . . 0.0 111.846 -179.511 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 82' ' ' LEU . . . . . . . . . . . . . 14.1 tp -76.73 -36.5 57.12 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 115.908 -0.587 . . . . 0.0 110.557 179.991 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 83' ' ' ILE . . . . . 0.458 HD13 HD11 ' A' ' 43' ' ' ILE . 38.8 mm -67.91 -51.22 51.96 Favored 'Isoleucine or valine' 0 C--O 1.234 0.275 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.137 179.086 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 27.0 m -61.14 -31.13 49.24 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.214 0 CA-C-N 116.014 -0.539 . . . . 0.0 109.632 179.129 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 85' ' ' TYR . . . . . . . . . . . . . 58.6 t80 -65.23 -34.47 78.44 Favored 'General case' 0 N--CA 1.452 -0.332 0 CA-C-N 115.638 -0.71 . . . . 0.0 109.36 178.965 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 86' ' ' PHE . . . . . . . . . . . . . 4.2 t80 -61.39 -51.63 67.98 Favored 'General case' 0 C--O 1.231 0.131 0 CA-C-N 115.586 -0.734 . . . . 0.0 110.064 179.222 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 7.4 mt -65.05 -28.69 69.65 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 121.309 0.576 . . . . 0.0 109.772 179.66 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -72.57 -27.43 69.43 Favored Glycine 0 N--CA 1.45 -0.41 0 CA-C-N 115.2 -0.909 . . . . 0.0 111.545 179.139 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 52.8 mt -73.21 -43.35 61.42 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 121.006 0.431 . . . . 0.0 110.549 179.652 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 59.1 mt -60.14 -33.19 71.82 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 115.707 -0.679 . . . . 0.0 111.047 179.887 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 91' ' ' ALA . . . . . 0.524 ' HB3' ' HB2' ' A' ' 148' ' ' SER . . . -85.76 -47.97 9.25 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.514 -179.532 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 89.27 61.15 1.41 Allowed Glycine 0 N--CA 1.45 -0.378 0 C-N-CA 120.811 -0.709 . . . . 0.0 112.383 -179.742 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 93' ' ' LEU . . . . . 0.41 HD13 ' HG2' ' A' ' 145' ' ' MET . 6.5 mp -72.76 179.12 3.78 Favored 'General case' 0 C--N 1.332 -0.184 0 CA-C-O 120.753 0.311 . . . . 0.0 110.866 -179.951 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 94' ' ' ASP . . . . . . . . . . . . . 30.3 m-20 -85.5 175.3 8.9 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.883 179.948 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 48.9 m -61.69 -46.71 88.52 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.1 -179.74 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 96' ' ' ARG . . . . . 0.403 ' O ' HG13 ' A' ' 100' ' ' ILE . 80.1 ttt180 -71.94 -45.36 61.42 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.934 -179.953 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 97' ' ' GLU . . . . . 0.457 ' HA ' HD13 ' A' ' 100' ' ' ILE . 19.1 mm-40 -52.51 -46.02 66.48 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.158 -179.802 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 98' ' ' PHE . . . . . 0.451 ' O ' HG12 ' A' ' 102' ' ' ILE . 2.2 m-85 -55.33 -50.87 68.52 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.384 -0.371 . . . . 0.0 110.236 179.385 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -60.85 -30.38 72.8 Favored Glycine 0 N--CA 1.45 -0.383 0 C-N-CA 120.862 -0.685 . . . . 0.0 112.627 -179.949 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 100' ' ' ILE . . . . . 0.457 HD13 ' HA ' ' A' ' 97' ' ' GLU . 94.5 mt -64.04 -43.3 97.52 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-O 120.89 0.376 . . . . 0.0 111.393 -179.857 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 29.4 t -72.26 -41.42 66.12 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.38 0 CA-C-N 116.34 -0.391 . . . . 0.0 111.592 179.976 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 102' ' ' ILE . . . . . 0.451 HG12 ' O ' ' A' ' 98' ' ' PHE . 35.2 mm -65.38 -40.07 87.27 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 CA-C-N 116.416 -0.357 . . . . 0.0 111.65 -179.266 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 11.0 t -67.92 -40.36 83.37 Favored 'General case' 0 C--O 1.234 0.239 0 CA-C-O 120.713 0.292 . . . . 0.0 110.939 -179.958 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 104' ' ' LEU . . . . . 0.411 ' O ' HG22 ' A' ' 108' ' ' VAL . 29.2 tp -55.34 -51.54 66.4 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-N 116.349 -0.387 . . . . 0.0 110.079 179.311 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 105' ' ' ASN . . . . . 0.56 ' N ' HD21 ' A' ' 105' ' ' ASN . 0.8 OUTLIER -58.05 -37.31 74.16 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 115.855 -0.611 . . . . 0.0 110.461 179.465 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 31.0 m -54.61 -41.1 69.56 Favored 'General case' 0 C--N 1.332 -0.184 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.659 179.706 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 0.6 OUTLIER -69.24 -36.42 72.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-O 121.258 0.551 . . . . 0.0 110.0 179.245 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . 0.411 HG22 ' O ' ' A' ' 104' ' ' LEU . 60.7 t -63.87 -42.63 96.47 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 115.406 -0.816 . . . . 0.0 111.571 -179.677 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 109' ' ' MET . . . . . 0.601 ' HG3' ' HA ' ' A' ' 77' ' ' ILE . 6.9 mmt -70.07 -44.04 69.92 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.407 -0.36 . . . . 0.0 110.961 -179.624 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 21.4 tp -60.73 -32.18 71.46 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 116.349 -0.387 . . . . 0.0 110.38 179.966 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -65.27 -56.63 11.65 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.019 -0.537 . . . . 0.0 110.612 179.398 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . -60.88 -30.0 71.94 Favored Glycine 0 C--N 1.332 0.334 0 C-N-CA 120.644 -0.789 . . . . 0.0 112.117 179.655 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 113' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER -57.68 -69.0 0.19 Allowed 'General case' 0 C--N 1.33 -0.266 0 CA-C-O 121.015 0.436 . . . . 0.0 110.255 179.585 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -64.6 -29.13 70.15 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 115.79 -0.641 . . . . 0.0 111.414 -179.969 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -51.92 -51.2 41.21 Favored Glycine 0 C--N 1.332 0.324 0 C-N-CA 121.081 -0.58 . . . . 0.0 112.672 -179.888 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -77.99 -15.01 59.31 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-O 120.542 0.21 . . . . 0.0 111.553 -179.781 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 117' ' ' MET . . . . . . . . . . . . . 37.5 ttm -100.67 18.46 19.24 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-O 120.692 0.282 . . . . 0.0 111.436 -179.464 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 118' ' ' VAL . . . . . 0.487 HG12 ' N ' ' A' ' 123' ' ' ARG . 27.4 m -74.03 144.76 82.65 Favored Pre-proline 0 C--N 1.328 -0.327 0 CA-C-N 116.692 -0.231 . . . . 0.0 111.141 179.802 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 119' ' ' PRO . . . . . . . . . . . . . 97.0 Cg_endo -87.53 -10.11 5.53 Favored 'Trans proline' 0 N--CA 1.458 -0.568 0 C-N-CA 122.709 2.273 . . . . 0.0 112.484 179.756 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -136.72 -108.26 0.89 Allowed Glycine 0 C--N 1.331 0.302 0 C-N-CA 120.706 -0.759 . . . . 0.0 112.907 -179.629 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 34.3 pt -124.53 12.26 4.72 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.156 0 CA-C-O 120.652 0.263 . . . . 0.0 111.664 -179.548 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 41.7 mt-10 -58.24 -18.26 25.18 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.779 0.323 . . . . 0.0 111.03 179.722 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 123' ' ' ARG . . . . . 0.487 ' N ' HG12 ' A' ' 118' ' ' VAL . 4.9 ptm180 -50.6 -31.39 15.77 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 116.107 -0.497 . . . . 0.0 111.504 -179.868 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 124' ' ' TYR . . . . . . . . . . . . . 30.4 m-85 -70.28 -33.03 71.08 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.458 -0.337 . . . . 0.0 111.017 -179.735 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 125' ' ' ALA . . . . . . . . . . . . . . . -71.24 -50.12 36.22 Favored 'General case' 0 C--O 1.235 0.333 0 CA-C-N 116.298 -0.41 . . . . 0.0 110.942 179.687 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 3.1 mm? -53.6 -52.76 58.77 Favored 'General case' 0 C--N 1.333 -0.137 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.53 179.739 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 127' ' ' PHE . . . . . 0.437 ' HZ ' ' HB3' ' A' ' 175' ' ' PRO . 6.5 t80 -64.88 -37.21 86.87 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.316 -0.402 . . . . 0.0 111.231 -179.615 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 128' ' ' GLY . . . . . . . . . . . . . . . -46.16 -47.75 15.4 Favored Glycine 0 C--O 1.237 0.283 0 C-N-CA 119.705 -1.235 . . . . 0.0 110.517 179.192 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 129' ' ' MET . . . . . . . . . . . . . 0.5 OUTLIER -72.18 -34.91 68.79 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 115.178 -0.511 . . . . 0.0 110.101 178.665 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -62.99 -37.26 94.66 Favored Glycine 0 C--N 1.332 0.331 0 CA-C-N 115.804 -0.634 . . . . 0.0 113.347 -179.515 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -73.56 -52.61 12.9 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.788 0.294 . . . . 0.0 110.755 -179.781 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 62.2 t -55.61 -42.0 66.93 Favored 'Isoleucine or valine' 0 C--O 1.234 0.28 0 CA-C-O 121.331 0.586 . . . . 0.0 109.546 179.128 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -68.69 -37.35 79.49 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 115.342 -0.844 . . . . 0.0 110.669 179.407 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 134' ' ' PHE . . . . . . . . . . . . . 87.7 t80 -55.88 -54.78 40.44 Favored 'General case' 0 N--CA 1.452 -0.363 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.135 179.669 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 135' ' ' ILE . . . . . 0.436 ' O ' HG23 ' A' ' 138' ' ' VAL . 32.8 mt -56.38 -33.53 38.49 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.363 0 CA-C-N 115.884 -0.598 . . . . 0.0 110.126 179.303 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . -61.65 -39.64 97.67 Favored Glycine 0 N--CA 1.449 -0.484 0 C-N-CA 120.072 -1.061 . . . . 0.0 111.295 178.784 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 137' ' ' LEU . . . . . 0.536 HD12 HD22 ' A' ' 105' ' ' ASN . 31.1 tp -68.75 -54.02 18.44 Favored 'General case' 0 C--N 1.332 -0.185 0 CA-C-O 120.598 0.237 . . . . 0.0 111.173 179.933 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 138' ' ' VAL . . . . . 0.436 HG23 ' O ' ' A' ' 135' ' ' ILE . 3.3 m -55.85 -31.68 30.59 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.176 0 CA-C-O 121.182 0.515 . . . . 0.0 109.9 179.957 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 139' ' ' TYR . . . . . . . . . . . . . 21.3 t80 -66.19 -38.62 88.45 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 115.429 -0.805 . . . . 0.0 110.289 178.674 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 19.2 m-85 -65.28 -32.14 73.64 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 116.097 -0.501 . . . . 0.0 111.055 179.377 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 141' ' ' LEU . . . . . 0.461 HD22 ' SD ' ' A' ' 145' ' ' MET . 75.1 mt -69.9 -41.49 74.65 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-O 121.039 0.447 . . . . 0.0 110.351 -179.508 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 24.2 m -84.84 -10.58 11.53 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.631 0 CA-C-N 115.72 -0.673 . . . . 0.0 111.159 179.957 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . -76.91 -118.78 0.16 Allowed Glycine 0 CA--C 1.52 0.405 0 C-N-CA 120.894 -0.669 . . . . 0.0 112.986 -179.551 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 144' ' ' PRO . . . . . . . . . . . . . 55.8 Cg_endo -69.25 -30.19 25.08 Favored 'Trans proline' 0 C--N 1.349 0.6 0 C-N-CA 122.47 2.113 . . . . 0.0 112.825 -179.411 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 145' ' ' MET . . . . . 0.562 ' HB3' ' HH ' ' A' ' 160' ' ' TYR . 53.1 mtt -55.59 -31.14 61.97 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-O 120.726 0.298 . . . . 0.0 111.484 -179.664 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 146' ' ' THR . . . . . . . . . . . . . 14.3 m -71.12 -44.2 66.1 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.284 -0.416 . . . . 0.0 111.723 -179.45 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 43.6 mt-10 -75.92 -29.04 58.23 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.385 -0.371 . . . . 0.0 111.844 -179.411 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 148' ' ' SER . . . . . 0.524 ' HB2' ' HB3' ' A' ' 91' ' ' ALA . 66.2 m -70.26 -47.05 63.03 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 120.736 0.303 . . . . 0.0 111.281 -179.327 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 149' ' ' ALA . . . . . . . . . . . . . . . -72.6 -34.93 67.74 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.289 -0.414 . . . . 0.0 111.242 -179.833 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 150' ' ' SER . . . . . . . . . . . . . 47.7 t -70.42 -8.19 48.95 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.965 179.943 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 151' ' ' GLN . . . . . . . . . . . . . 47.9 mt-30 -122.32 10.04 9.85 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.262 -0.426 . . . . 0.0 111.255 -179.875 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 152' ' ' ARG . . . . . 0.58 ' HE ' HG13 ' A' ' 156' ' ' ILE . 1.2 tmm_? -85.05 -51.33 6.74 Favored 'General case' 0 C--N 1.332 -0.19 0 CA-C-O 120.979 0.418 . . . . 0.0 110.363 179.669 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 153' ' ' SER . . . . . 0.554 ' HB2' HG12 ' A' ' 156' ' ' ILE . 49.1 m -157.48 172.56 18.35 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 115.751 -0.659 . . . . 0.0 110.667 179.434 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 154' ' ' SER . . . . . . . . . . . . . 46.6 t -69.38 -42.17 75.52 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.339 -0.392 . . . . 0.0 110.76 179.754 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -77.28 -32.75 46.73 Favored Glycine 0 N--CA 1.452 -0.275 0 C-N-CA 120.948 -0.644 . . . . 0.0 113.029 -179.831 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 156' ' ' ILE . . . . . 0.58 HG13 ' HE ' ' A' ' 152' ' ' ARG . 32.2 mm -57.23 -38.65 62.72 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.199 0 CA-C-N 116.776 0.288 . . . . 0.0 111.356 -179.753 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 157' ' ' LYS . . . . . 0.44 ' O ' ' HB ' ' A' ' 161' ' ' VAL . 58.3 tttp -62.47 -43.48 98.72 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.385 -0.37 . . . . 0.0 111.372 -179.735 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 93.8 p -70.98 -48.32 53.95 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 116.102 -0.499 . . . . 0.0 111.551 -179.102 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 159' ' ' LEU . . . . . 0.432 ' O ' ' HB2' ' A' ' 163' ' ' LEU . 10.5 tt -62.08 -42.54 99.31 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.176 -179.395 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 160' ' ' TYR . . . . . 0.562 ' HH ' ' HB3' ' A' ' 145' ' ' MET . 77.6 t80 -71.59 -36.87 71.0 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 116.263 -0.426 . . . . 0.0 111.987 -179.077 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 161' ' ' VAL . . . . . 0.517 HG11 ' N ' ' A' ' 162' ' ' ARG . 1.1 t -58.4 -53.64 43.69 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.686 0 N-CA-C 111.699 0.259 . . . . 0.0 111.699 -179.181 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 162' ' ' ARG . . . . . 0.517 ' N ' HG11 ' A' ' 161' ' ' VAL . 97.3 mtt180 -69.89 -41.15 75.13 Favored 'General case' 0 C--N 1.329 -0.317 0 N-CA-C 112.04 0.385 . . . . 0.0 112.04 -179.174 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 163' ' ' LEU . . . . . 0.432 ' HB2' ' O ' ' A' ' 159' ' ' LEU . 2.7 mp -62.49 -56.14 20.93 Favored 'General case' 0 C--N 1.329 -0.314 0 N-CA-C 112.277 0.473 . . . . 0.0 112.277 -178.674 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 164' ' ' ARG . . . . . 0.438 ' NE ' ' ND2' ' A' ' 165' ' ' ASN . 5.4 ppt_? -62.42 -40.63 97.18 Favored 'General case' 0 C--N 1.328 -0.356 0 N-CA-C 112.002 0.371 . . . . 0.0 112.002 -178.361 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 165' ' ' ASN . . . . . 0.438 ' ND2' ' NE ' ' A' ' 164' ' ' ARG . 0.9 OUTLIER -54.73 -53.29 56.89 Favored 'General case' 0 C--O 1.237 0.402 0 CA-C-O 120.826 0.346 . . . . 0.0 111.557 -179.373 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 166' ' ' LEU . . . . . 0.475 ' O ' ' HG ' ' A' ' 170' ' ' LEU . 0.1 OUTLIER -67.67 -31.59 71.67 Favored 'General case' 0 C--N 1.331 -0.238 0 C-N-CA 120.847 -0.341 . . . . 0.0 111.022 -179.146 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 167' ' ' THR . . . . . 0.436 ' O ' ' HB2' ' A' ' 171' ' ' TRP . 17.7 m -59.75 -53.02 62.81 Favored 'General case' 0 C--N 1.333 -0.147 0 CA-C-O 120.842 0.353 . . . . 0.0 111.304 179.814 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 168' ' ' VAL . . . . . . . . . . . . . 58.4 t -58.97 -41.27 82.66 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.385 0 CA-C-N 115.785 -0.643 . . . . 0.0 111.749 -179.103 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 169' ' ' VAL . . . . . 0.405 HG21 ' O ' ' A' ' 165' ' ' ASN . 88.8 t -59.34 -64.87 0.51 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 N-CA-C 112.383 0.512 . . . . 0.0 112.383 -179.236 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 170' ' ' LEU . . . . . 0.475 ' HG ' ' O ' ' A' ' 166' ' ' LEU . 1.6 pp -61.04 -36.3 79.19 Favored 'General case' 0 N--CA 1.463 0.214 0 N-CA-C 112.219 0.451 . . . . 0.0 112.219 -178.67 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 171' ' ' TRP . . . . . 0.436 ' HB2' ' O ' ' A' ' 167' ' ' THR . 3.0 m0 -67.73 -29.4 68.62 Favored 'General case' 0 C--N 1.331 -0.231 0 C-N-CA 120.914 -0.314 . . . . 0.0 110.946 179.843 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 172' ' ' ALA . . . . . . . . . . . . . . . -73.28 -7.07 49.98 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 116.337 -0.392 . . . . 0.0 110.986 -179.938 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 173' ' ' ILE . . . . . 0.545 HG23 HD11 ' A' ' 177' ' ' ILE . 19.2 mm -87.97 -21.0 7.21 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.067 -0.515 . . . . 0.0 110.876 179.88 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 174' ' ' TYR . . . . . 0.4 ' N ' ' CD ' ' A' ' 175' ' ' PRO . 13.0 m-85 -53.67 -48.53 92.95 Favored Pre-proline 0 CA--C 1.531 0.235 0 CA-C-N 116.249 -0.432 . . . . 0.0 111.478 -179.752 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 175' ' ' PRO . . . . . 0.437 ' HB3' ' HZ ' ' A' ' 127' ' ' PHE . 92.4 Cg_exo -46.48 -31.77 10.31 Favored 'Trans proline' 0 C--N 1.352 0.756 0 C-N-CA 122.173 1.915 . . . . 0.0 112.117 179.059 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 176' ' ' PHE . . . . . 0.454 ' HD2' ' HA ' ' A' ' 173' ' ' ILE . 80.5 m-85 -80.25 -40.67 26.53 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 115.927 -0.578 . . . . 0.0 111.421 -179.893 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 177' ' ' ILE . . . . . 0.545 HD11 HG23 ' A' ' 173' ' ' ILE . 2.3 mm -65.2 -41.55 91.92 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.533 0 CA-C-N 116.346 -0.388 . . . . 0.0 111.838 -178.651 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 178' ' ' TRP . . . . . . . . . . . . . 63.9 t90 -73.65 -44.62 56.37 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.902 0.382 . . . . 0.0 111.064 -179.952 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 179' ' ' LEU . . . . . 0.433 ' O ' HG21 ' A' ' 185' ' ' VAL . 1.9 tm? -64.31 -51.86 61.36 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 115.952 -0.567 . . . . 0.0 111.451 -179.151 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 180' ' ' LEU . . . . . 0.524 HD23 HD11 ' A' ' 187' ' ' LEU . 20.7 mt -77.48 -44.98 27.04 Favored 'General case' 0 C--N 1.328 -0.336 0 N-CA-C 111.974 0.361 . . . . 0.0 111.974 -178.711 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 181' ' ' GLY . . . . . 0.4 ' C ' ' HD2' ' A' ' 183' ' ' PRO . . . -57.5 174.99 1.91 Allowed Glycine 0 C--N 1.335 0.494 0 C-N-CA 120.365 -0.921 . . . . 0.0 112.771 179.927 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 182' ' ' PRO . . . . . 0.567 ' N ' ' HD2' ' A' ' 183' ' ' PRO . 1.7 Cg_endo -44.99 -45.6 13.93 Favored 'Trans proline' 0 CA--C 1.537 0.671 0 C-N-CA 123.228 2.619 . . . . 0.0 113.84 179.615 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 183' ' ' PRO . . . . . 0.567 ' HD2' ' N ' ' A' ' 182' ' ' PRO . 18.5 Cg_endo -58.54 -4.75 1.97 Allowed 'Trans proline' 0 C--N 1.356 0.937 0 C-N-CA 121.967 1.778 . . . . 0.0 113.017 -179.762 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 184' ' ' GLY . . . . . 0.43 ' HA3' ' O ' ' A' ' 179' ' ' LEU . . . -122.09 -87.93 0.91 Allowed Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.63 -0.795 . . . . 0.0 112.636 179.94 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 185' ' ' VAL . . . . . 0.433 HG21 ' O ' ' A' ' 179' ' ' LEU . 4.3 m -123.63 -4.64 7.19 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 N-CA-C 111.658 0.244 . . . . 0.0 111.658 -179.822 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 186' ' ' ALA . . . . . 0.565 ' HB3' ' HA ' ' A' ' 182' ' ' PRO . . . 51.62 88.88 0.03 OUTLIER 'General case' 0 N--CA 1.462 0.156 0 CA-C-N 116.398 -0.364 . . . . 0.0 111.367 179.833 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 187' ' ' LEU . . . . . 0.524 HD11 HD23 ' A' ' 180' ' ' LEU . 20.2 mt -91.76 -49.4 6.29 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.396 -0.366 . . . . 0.0 111.774 -179.502 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 188' ' ' LEU . . . . . . . . . . . . . 87.5 mt -97.36 -94.3 0.22 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.462 -0.336 . . . . 0.0 111.539 -179.138 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 189' ' ' THR . . . . . . . . . . . . . 1.8 t -160.42 149.36 13.72 Favored Pre-proline 0 C--N 1.327 -0.39 0 CA-C-N 116.284 -0.416 . . . . 0.0 111.282 -179.499 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 190' ' ' PRO . . . . . . . . . . . . . 72.9 Cg_exo -50.37 -42.98 46.25 Favored 'Trans proline' 0 C--N 1.349 0.557 0 C-N-CA 122.591 2.194 . . . . 0.0 112.932 -179.853 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 191' ' ' THR . . . . . 0.457 ' HG1' ' H ' ' A' ' 192' ' ' VAL . 70.9 p -55.33 -46.55 76.35 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-O 120.77 0.319 . . . . 0.0 111.514 -179.729 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 192' ' ' VAL . . . . . 0.457 ' H ' ' HG1' ' A' ' 191' ' ' THR . 39.4 t -68.36 -50.6 55.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.626 -179.745 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 193' ' ' ASP . . . . . . . . . . . . . 30.8 t70 -55.24 -49.58 71.66 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.752 0.311 . . . . 0.0 111.284 -179.824 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 194' ' ' VAL . . . . . . . . . . . . . 76.1 t -59.62 -36.44 65.28 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.886 179.914 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 195' ' ' ALA . . . . . . . . . . . . . . . -58.71 -46.72 86.68 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.41 -0.359 . . . . 0.0 110.968 179.848 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 196' ' ' LEU . . . . . . . . . . . . . 85.3 mt -67.71 -40.17 84.3 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.348 -0.387 . . . . 0.0 110.615 179.692 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 197' ' ' ILE . . . . . . . . . . . . . 16.2 mm -59.97 -59.86 3.38 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 CA-C-N 115.988 -0.551 . . . . 0.0 110.302 179.388 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 198' ' ' VAL . . . . . . . . . . . . . 76.3 t -52.78 -34.26 19.81 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.515 0 CA-C-N 115.458 -0.792 . . . . 0.0 109.454 178.394 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 199' ' ' TYR . . . . . . . . . . . . . 65.7 t80 -70.07 -34.96 73.85 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.222 -0.899 . . . . 0.0 110.63 179.753 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 200' ' ' LEU . . . . . . . . . . . . . 28.0 mt -67.95 -39.02 83.47 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 115.845 -0.616 . . . . 0.0 111.27 -179.631 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 201' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -71.9 -32.35 67.31 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-N 116.099 -0.501 . . . . 0.0 110.776 179.804 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 202' ' ' LEU . . . . . . . . . . . . . 3.7 mt -70.91 -36.5 72.72 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.0 -0.545 . . . . 0.0 111.736 -179.556 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 203' ' ' VAL . . . . . 0.472 ' O ' ' HA3' ' A' ' 207' ' ' GLY . 11.8 p -74.62 -36.32 40.5 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.613 -0.267 . . . . 0.0 111.643 -179.008 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 204' ' ' THR . . . . . . . . . . . . . 43.7 m -67.69 -57.21 6.78 Favored 'General case' 0 C--N 1.326 -0.44 0 C-N-CA 120.84 -0.344 . . . . 0.0 111.53 -179.969 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 205' ' ' LYS . . . . . 0.634 ' HE2' ' HB3' ' A' ' 47' ' ' ALA . 60.0 mttp -69.49 -59.02 3.25 Favored 'General case' 0 C--N 1.329 -0.299 0 N-CA-C 112.549 0.574 . . . . 0.0 112.549 -178.472 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 22.1 t -72.57 -37.53 56.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 N-CA-C 112.158 0.429 . . . . 0.0 112.158 -178.473 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 207' ' ' GLY . . . . . 0.472 ' HA3' ' O ' ' A' ' 203' ' ' VAL . . . -61.51 -55.36 29.34 Favored Glycine 0 CA--C 1.517 0.195 0 C-N-CA 120.51 -0.852 . . . . 0.0 112.922 -179.464 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 208' ' ' PHE . . . . . 0.483 ' O ' ' N ' ' A' ' 212' ' ' ALA . 2.4 m-30 -61.03 -41.58 96.84 Favored 'General case' 0 C--O 1.221 -0.399 0 N-CA-C 110.026 -0.361 . . . . 0.0 110.026 -179.882 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 209' ' ' GLY . . . . . 0.474 ' O ' ' HB2' ' A' ' 212' ' ' ALA . . . -58.26 -37.57 87.4 Favored Glycine 0 N--CA 1.451 -0.33 0 CA-C-N 115.372 -0.831 . . . . 0.0 112.873 179.492 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 210' ' ' PHE . . . . . . . . . . . . . 2.7 m-85 -68.79 -49.56 57.61 Favored 'General case' 0 CA--C 1.514 -0.407 0 N-CA-C 108.548 -0.908 . . . . 0.0 108.548 179.238 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 211' ' ' ILE . . . . . . . . . . . . . 64.9 mt -63.2 -27.45 43.13 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.553 0 N-CA-C 107.61 -1.256 . . . . 0.0 107.61 176.658 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 212' ' ' ALA . . . . . 0.483 ' N ' ' O ' ' A' ' 208' ' ' PHE . . . -67.99 -38.02 82.18 Favored 'General case' 0 N--CA 1.448 -0.557 0 CA-C-N 114.488 -1.233 . . . . 0.0 110.527 -179.802 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 213' ' ' LEU . . . . . . . . . . . . . 89.2 mt -70.26 -52.52 22.43 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-N 115.373 -0.831 . . . . 0.0 111.53 -179.606 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 214' ' ' ASP . . . . . . . . . . . . . 24.5 m-20 -57.89 -52.41 65.62 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.396 -0.366 . . . . 0.0 110.954 -179.878 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 215' ' ' ALA . . . . . . . . . . . . . . . -57.25 -53.57 56.66 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.216 179.817 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 216' ' ' ALA . . . . . . . . . . . . . . . -59.98 -31.33 69.8 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-N 116.22 -0.445 . . . . 0.0 111.319 179.947 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 217' ' ' ALA . . . . . . . . . . . . . . . -62.19 -38.67 89.97 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-O 120.949 0.404 . . . . 0.0 110.281 179.651 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 218' ' ' THR . . . . . . . . . . . . . 93.5 m . . . . . 0 C--N 1.33 -0.264 0 CA-C-N 115.821 -0.627 . . . . 0.0 110.635 179.322 . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.397 0 N-CA-C 112.224 -0.35 . . . . 0.0 112.224 . . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 60.5 tp -73.92 -35.55 64.63 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-O 120.881 0.372 . . . . 0.0 110.822 -179.982 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 64.0 p -61.59 -29.94 70.35 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 115.958 -0.565 . . . . 0.0 111.399 -179.819 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 26.9 p -55.37 -35.61 65.45 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 116.365 -0.38 . . . . 0.0 111.118 -179.725 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 7' ' ' LEU . . . . . . . . . . . . . 9.3 mp -55.98 -53.71 53.58 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.093 179.898 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 8' ' ' PHE . . . . . . . . . . . . . 65.1 m-85 -62.43 -34.23 76.37 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.716 -179.887 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 9' ' ' TRP . . . . . . . . . . . . . 37.8 m95 -64.46 -41.3 96.59 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-O 121.214 0.53 . . . . 0.0 109.896 179.69 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 86.2 mt -65.91 -31.53 72.51 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-N 115.303 -0.862 . . . . 0.0 110.052 179.227 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . 0.45 ' O ' ' HG2' ' A' ' 15' ' ' MET . . . -68.22 -34.04 79.65 Favored Glycine 0 N--CA 1.448 -0.526 0 C-N-CA 120.823 -0.703 . . . . 0.0 111.43 179.268 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -69.45 -37.18 77.23 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.839 0.352 . . . . 0.0 110.421 179.415 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 50.1 mm -62.41 -53.44 47.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 115.918 -0.583 . . . . 0.0 110.939 179.601 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -56.33 -42.03 88.24 Favored Glycine 0 C--N 1.33 0.245 0 C-N-CA 120.747 -0.74 . . . . 0.0 112.161 179.889 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 15' ' ' MET . . . . . 0.698 ' HE1' ' HD2' ' A' ' 205' ' ' LYS . 24.5 mmt -63.45 -41.87 98.64 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.737 0.303 . . . . 0.0 110.53 179.613 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 39.7 tp -54.19 -40.6 67.71 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.051 -0.522 . . . . 0.0 110.601 179.835 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 41.3 t -65.41 -49.03 80.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 115.963 -0.562 . . . . 0.0 111.067 179.955 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -63.31 -47.67 85.73 Favored Glycine 0 C--N 1.331 0.251 0 C-N-CA 120.769 -0.729 . . . . 0.0 112.219 179.724 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 19' ' ' THR . . . . . 0.431 HG21 HG13 ' A' ' 41' ' ' VAL . 24.9 m -50.32 -44.18 54.09 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-O 120.665 0.269 . . . . 0.0 111.295 -179.973 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 56.9 mt -71.43 -38.73 71.34 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 116.343 -0.39 . . . . 0.0 111.282 179.973 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -60.77 -32.18 71.5 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.242 -0.436 . . . . 0.0 111.549 -179.551 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 22' ' ' PHE . . . . . 0.511 ' HB2' HG22 ' A' ' 41' ' ' VAL . 2.8 m-85 -90.75 -34.46 15.34 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.419 -0.355 . . . . 0.0 111.209 -179.481 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -64.88 -48.49 74.06 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.245 -179.822 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 24' ' ' TRP . . . . . . . . . . . . . 3.6 t-105 -68.03 -53.63 24.34 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 115.906 -0.588 . . . . 0.0 111.25 -179.617 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.329 -0.315 0 CA-C-O 120.862 0.363 . . . . 0.0 111.114 -179.99 . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.453 -0.216 0 N-CA-C 112.523 -0.231 . . . . 0.0 112.523 . . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 45.7 mt-10 -68.98 -20.72 64.18 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.69 0.281 . . . . 0.0 111.064 -179.901 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 34' ' ' ARG . . . . . . . . . . . . . 99.9 mtt180 -49.28 -31.15 8.44 Favored 'General case' 0 C--N 1.332 -0.174 0 CA-C-N 116.123 -0.49 . . . . 0.0 111.681 -179.665 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 23.2 ttp180 -64.62 -47.89 76.91 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-O 120.805 0.336 . . . . 0.0 110.816 179.829 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 76.1 m-85 -67.12 -29.52 69.28 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.123 -0.489 . . . . 0.0 111.047 179.859 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 37' ' ' TYR . . . . . . . . . . . . . 35.5 m-85 -71.48 -52.62 17.41 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.3 -179.628 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 84.9 t -56.75 -36.61 49.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-O 121.077 0.465 . . . . 0.0 110.263 179.664 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 17.3 m -69.07 -51.12 42.15 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 115.686 -0.688 . . . . 0.0 110.865 179.392 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 11.4 tp -55.48 -50.81 68.92 Favored 'General case' 0 C--O 1.237 0.43 0 CA-C-N 115.914 -0.584 . . . . 0.0 110.707 -179.972 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . 0.511 HG22 ' HB2' ' A' ' 22' ' ' PHE . 60.0 t -62.1 -34.46 63.59 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.367 0 CA-C-N 115.675 -0.693 . . . . 0.0 110.287 179.29 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 42' ' ' GLY . . . . . 0.432 ' O ' HG12 ' A' ' 46' ' ' ILE . . . -60.21 -34.91 86.36 Favored Glycine 0 N--CA 1.449 -0.493 0 C-N-CA 120.864 -0.684 . . . . 0.0 112.337 179.949 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 43' ' ' ILE . . . . . 0.595 HG21 ' HE3' ' A' ' 205' ' ' LYS . 0.3 OUTLIER -71.83 -58.47 5.05 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.218 0 CA-C-O 120.752 0.311 . . . . 0.0 110.944 179.901 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 80.7 p -61.03 -20.59 62.71 Favored 'General case' 0 C--N 1.332 -0.153 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.262 -179.621 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -79.51 -57.15 3.19 Favored Glycine 0 CA--C 1.519 0.287 0 C-N-CA 120.792 -0.718 . . . . 0.0 112.94 -179.327 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 46' ' ' ILE . . . . . 0.432 HG12 ' O ' ' A' ' 42' ' ' GLY . 16.5 pt -58.36 -36.25 57.61 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.213 0 CA-C-O 120.976 0.417 . . . . 0.0 111.071 -179.994 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 47' ' ' ALA . . . . . 0.637 ' HB2' ' HE2' ' A' ' 205' ' ' LYS . . . -68.15 -45.94 72.17 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-N 116.079 -0.51 . . . . 0.0 111.314 179.518 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -54.71 -40.41 69.18 Favored 'General case' 0 C--N 1.332 -0.186 0 CA-C-N 116.271 -0.422 . . . . 0.0 111.909 -179.451 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 35.7 m -76.01 -34.11 26.36 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.384 0 CA-C-N 116.452 -0.34 . . . . 0.0 111.482 -179.318 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -65.03 -36.54 84.69 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.905 0.383 . . . . 0.0 111.033 179.718 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 38.1 m-85 -73.29 -39.8 65.06 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.021 -0.536 . . . . 0.0 110.685 -179.862 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -63.29 -46.72 85.43 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 115.92 -0.582 . . . . 0.0 111.527 179.86 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 53' ' ' VAL . . . . . 0.401 HG23 ' N ' ' A' ' 54' ' ' MET . 30.4 m -67.77 -46.14 83.04 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.19 0 CA-C-N 116.341 -0.39 . . . . 0.0 111.109 -179.78 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 54' ' ' MET . . . . . 0.437 ' HG3' ' HE1' ' A' ' 60' ' ' TRP . 13.3 ttp -64.44 -29.31 70.36 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.995 0.426 . . . . 0.0 110.294 179.834 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -64.36 -32.23 73.75 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 115.919 -0.582 . . . . 0.0 111.092 179.502 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 97.4 mt -82.85 6.26 18.97 Favored 'General case' 0 C--N 1.331 -0.204 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.197 -179.674 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 94.33 -5.25 70.97 Favored Glycine 0 N--CA 1.452 -0.265 0 C-N-CA 120.667 -0.778 . . . . 0.0 112.759 179.787 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 58.8 t -62.66 140.52 19.34 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.243 0 CA-C-O 120.701 0.286 . . . . 0.0 110.825 179.861 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 85.89 -23.64 8.91 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.615 -179.859 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 60' ' ' TRP . . . . . 0.437 ' HE1' ' HG3' ' A' ' 54' ' ' MET . 13.3 m0 -61.08 108.02 0.82 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.806 0.336 . . . . 0.0 110.722 179.909 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 7.4 p -118.67 131.58 24.23 Favored Pre-proline 0 CA--C 1.533 0.293 0 CA-C-N 116.343 -0.39 . . . . 0.0 111.469 -179.863 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 57.7 Cg_endo -71.9 147.77 50.36 Favored 'Trans proline' 0 C--N 1.35 0.637 0 C-N-CA 122.481 2.121 . . . . 0.0 112.501 179.842 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 76.8 t -141.91 99.19 0.82 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 115.92 -0.582 . . . . 0.0 111.019 -179.813 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . 58.72 -85.82 0.02 OUTLIER 'General case' 0 C--N 1.332 -0.172 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.229 -179.927 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 41.2 mt-10 -127.96 -20.39 3.84 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.319 179.723 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 66' ' ' ARG . . . . . . . . . . . . . 18.6 ptp180 -100.26 164.3 12.01 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 115.773 -0.649 . . . . 0.0 110.148 179.709 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 44.5 m -123.15 138.26 54.7 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-O 120.935 0.398 . . . . 0.0 111.213 -179.779 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 68' ' ' VAL . . . . . 0.459 HG12 ' HB3' ' A' ' 117' ' ' MET . 23.9 m -125.48 146.06 31.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.012 -0.54 . . . . 0.0 110.849 179.792 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 69' ' ' PHE . . . . . . . . . . . . . 8.5 m-85 -104.85 114.97 29.5 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.044 -179.732 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 70' ' ' VAL . . . . . 0.602 HG13 ' HD3' ' A' ' 71' ' ' PRO . 0.5 OUTLIER -66.94 -32.08 4.55 Favored Pre-proline 0 CA--C 1.54 0.58 0 N-CA-C 112.849 0.685 . . . . 0.0 112.849 -179.241 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 71' ' ' PRO . . . . . 0.602 ' HD3' HG13 ' A' ' 70' ' ' VAL . 14.5 Cg_exo -68.39 -18.04 44.07 Favored 'Trans proline' 0 C--N 1.36 1.157 0 C-N-CA 121.944 1.763 . . . . 0.0 112.704 -179.603 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 59.0 ttt180 -72.97 -55.2 6.9 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.767 0.317 . . . . 0.0 111.637 -179.224 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 73' ' ' TYR . . . . . . . . . . . . . 4.0 m-85 -71.8 -34.44 69.39 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.482 -0.326 . . . . 0.0 110.74 -179.143 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 0.4 OUTLIER -69.38 -41.2 80.75 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.192 0 CA-C-N 116.515 -0.311 . . . . 0.0 110.333 179.736 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 11.3 t70 -58.36 -37.64 75.62 Favored 'General case' 0 CA--C 1.518 -0.256 0 N-CA-C 109.427 -0.583 . . . . 0.0 109.427 178.901 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 76' ' ' TRP . . . . . 0.482 ' HB3' ' SD ' ' A' ' 109' ' ' MET . 42.6 m0 -64.97 -38.56 91.36 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 115.567 -0.742 . . . . 0.0 110.824 179.531 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 77' ' ' ILE . . . . . 0.502 ' O ' ' HG2' ' A' ' 81' ' ' PRO . 83.7 mt -66.54 -28.63 43.95 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-N 116.39 -0.368 . . . . 0.0 110.894 179.633 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 53.9 mt -91.47 -21.13 21.08 Favored 'General case' 0 C--N 1.327 -0.41 0 N-CA-C 112.044 0.387 . . . . 0.0 112.044 -179.969 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 71.5 p -102.3 -52.68 3.07 Favored 'General case' 0 CA--C 1.531 0.219 0 N-CA-C 113.425 0.898 . . . . 0.0 113.425 -178.099 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 80' ' ' THR . . . . . 0.624 ' HB ' ' HD3' ' A' ' 81' ' ' PRO . 26.2 m -50.2 -54.78 30.29 Favored Pre-proline 0 CA--C 1.532 0.283 0 N-CA-C 112.749 0.648 . . . . 0.0 112.749 -178.513 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 81' ' ' PRO . . . . . 0.624 ' HD3' ' HB ' ' A' ' 80' ' ' THR . 52.7 Cg_exo -57.1 -23.7 54.23 Favored 'Trans proline' 0 C--N 1.351 0.696 0 C-N-CA 121.513 1.475 . . . . 0.0 111.35 179.63 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 82' ' ' LEU . . . . . . . . . . . . . 16.4 tp -76.96 -32.72 57.5 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 115.445 -0.798 . . . . 0.0 109.764 179.39 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 40.4 mm -66.44 -54.38 26.63 Favored 'Isoleucine or valine' 0 C--O 1.233 0.185 0 CA-C-N 115.835 -0.62 . . . . 0.0 110.514 179.329 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 27.5 m -61.13 -31.07 49.09 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.31 0 N-CA-C 109.378 -0.601 . . . . 0.0 109.378 179.092 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 85' ' ' TYR . . . . . 0.409 ' O ' ' HG ' ' A' ' 89' ' ' LEU . 80.4 t80 -61.64 -35.58 78.33 Favored 'General case' 0 N--CA 1.453 -0.282 0 CA-C-N 115.593 -0.73 . . . . 0.0 109.155 178.338 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 86' ' ' PHE . . . . . . . . . . . . . 34.1 t80 -61.9 -49.67 75.26 Favored 'General case' 0 CA--C 1.52 -0.178 0 CA-C-N 115.78 -0.645 . . . . 0.0 109.623 179.046 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 3.9 mm? -57.71 -32.8 67.75 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 115.655 -0.702 . . . . 0.0 110.034 179.131 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -73.15 -27.43 68.37 Favored Glycine 0 N--CA 1.451 -0.305 0 CA-C-N 115.642 -0.708 . . . . 0.0 112.826 179.784 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 89' ' ' LEU . . . . . 0.409 ' HG ' ' O ' ' A' ' 85' ' ' TYR . 94.3 mt -72.39 -44.42 62.54 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.904 0.383 . . . . 0.0 111.084 -179.622 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 70.3 mt -70.49 -27.29 64.09 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 115.986 -0.552 . . . . 0.0 111.363 -179.748 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 91' ' ' ALA . . . . . 0.505 ' HA ' ' HB1' ' A' ' 149' ' ' ALA . . . -87.49 -52.65 5.23 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.426 -0.352 . . . . 0.0 111.239 -179.93 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 90.31 59.96 1.42 Allowed Glycine 0 N--CA 1.451 -0.361 0 C-N-CA 120.93 -0.652 . . . . 0.0 112.418 -179.966 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 93' ' ' LEU . . . . . 0.557 HD22 ' HB3' ' A' ' 97' ' ' GLU . 8.1 mp -71.28 -174.72 1.07 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.741 0.305 . . . . 0.0 110.845 -179.894 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 94' ' ' ASP . . . . . 0.444 ' HB2' ' OE2' ' A' ' 97' ' ' GLU . 12.5 m-20 -94.09 -172.16 2.75 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 121.023 0.439 . . . . 0.0 111.545 -179.446 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 43.5 m -67.8 -48.98 64.75 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 115.836 -0.62 . . . . 0.0 111.657 -179.266 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 31.9 ttm180 -73.33 -41.01 64.0 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 121.05 0.452 . . . . 0.0 110.619 -179.338 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 97' ' ' GLU . . . . . 0.557 ' HB3' HD22 ' A' ' 93' ' ' LEU . 0.3 OUTLIER -56.47 -45.83 80.72 Favored 'General case' 0 C--N 1.326 -0.449 0 CA-C-N 115.692 -0.686 . . . . 0.0 111.069 179.983 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 98' ' ' PHE . . . . . 0.429 ' O ' HG12 ' A' ' 102' ' ' ILE . 1.2 m-85 -60.79 -43.97 97.41 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.338 -0.392 . . . . 0.0 110.731 179.63 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -64.8 -29.73 76.08 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.901 -0.666 . . . . 0.0 112.639 -179.995 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 93.1 mt -68.29 -41.68 83.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-O 120.756 0.313 . . . . 0.0 111.249 -179.81 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 34.2 t -68.07 -41.16 84.12 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.411 0 CA-C-N 116.264 -0.425 . . . . 0.0 111.432 -179.573 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 102' ' ' ILE . . . . . 0.429 HG12 ' O ' ' A' ' 98' ' ' PHE . 42.0 mm -68.67 -51.36 46.64 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.447 -0.342 . . . . 0.0 111.44 -179.756 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 15.3 t -56.86 -32.21 65.59 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-O 120.916 0.389 . . . . 0.0 111.04 -179.894 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 104' ' ' LEU . . . . . 0.426 HD21 HD13 ' A' ' 137' ' ' LEU . 33.7 tp -66.06 -48.41 71.14 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.573 179.483 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 105' ' ' ASN . . . . . 0.536 ' N ' HD21 ' A' ' 105' ' ' ASN . 0.9 OUTLIER -62.52 -27.0 68.85 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.045 179.972 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 89.2 m -70.21 -53.36 17.41 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.334 -0.394 . . . . 0.0 111.419 -179.887 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 8.8 p -65.6 -37.07 79.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.296 -0.411 . . . . 0.0 111.304 -179.652 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 55.6 t -65.41 -50.16 74.33 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.249 0 CA-C-N 116.43 -0.35 . . . . 0.0 110.958 179.86 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 109' ' ' MET . . . . . 0.482 ' SD ' ' HB3' ' A' ' 76' ' ' TRP . 7.2 tpp -64.12 -33.54 75.99 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.622 -179.899 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 110' ' ' LEU . . . . . 0.478 HD22 ' C ' ' A' ' 110' ' ' LEU . 3.4 tt -63.06 -41.62 99.5 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-N 115.921 -0.581 . . . . 0.0 109.706 179.052 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -58.12 -47.83 82.08 Favored 'General case' 0 C--N 1.331 -0.203 0 CA-C-N 115.824 -0.625 . . . . 0.0 110.494 179.536 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . -68.47 -32.68 75.57 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.64 -0.791 . . . . 0.0 111.929 179.374 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 113' ' ' PHE . . . . . . . . . . . . . 0.5 OUTLIER -51.79 -68.45 0.17 Allowed 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 121.058 0.456 . . . . 0.0 109.998 179.566 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -70.48 -24.02 62.79 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 115.586 -0.733 . . . . 0.0 111.155 179.819 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -54.08 -40.86 67.68 Favored Glycine 0 C--N 1.331 0.282 0 C-N-CA 121.149 -0.548 . . . . 0.0 112.994 -179.699 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -77.81 -39.15 44.77 Favored 'General case' 0 C--N 1.328 -0.326 0 N-CA-C 112.142 0.423 . . . . 0.0 112.142 -179.429 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 117' ' ' MET . . . . . 0.459 ' HB3' HG12 ' A' ' 68' ' ' VAL . 19.3 ptp -91.4 19.74 5.84 Favored 'General case' 0 C--N 1.329 -0.324 0 N-CA-C 111.788 0.292 . . . . 0.0 111.788 -179.287 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 118' ' ' VAL . . . . . 0.502 HG23 ' HB3' ' A' ' 123' ' ' ARG . 5.0 m -54.08 149.45 18.37 Favored Pre-proline 0 C--N 1.33 -0.282 0 CA-C-N 116.598 -0.274 . . . . 0.0 111.231 179.723 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 119' ' ' PRO . . . . . . . . . . . . . 90.3 Cg_endo -87.34 3.97 6.24 Favored 'Trans proline' 0 N--CA 1.458 -0.581 0 C-N-CA 122.64 2.227 . . . . 0.0 112.236 179.622 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -168.37 -133.96 1.64 Allowed Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.786 -0.721 . . . . 0.0 112.457 -179.951 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 42.4 pt -99.18 18.01 2.77 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.246 0 CA-C-O 120.885 0.374 . . . . 0.0 111.182 -179.834 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 45.1 mt-10 -67.51 -18.46 65.05 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.274 -179.975 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 123' ' ' ARG . . . . . 0.502 ' HB3' HG23 ' A' ' 118' ' ' VAL . 20.5 ptt180 -53.07 -29.82 32.52 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 116.222 -0.444 . . . . 0.0 111.67 -179.678 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 124' ' ' TYR . . . . . . . . . . . . . 28.2 m-85 -67.48 -34.41 77.1 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.589 -0.278 . . . . 0.0 110.795 -179.858 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 125' ' ' ALA . . . . . . . . . . . . . . . -74.78 -56.08 5.16 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.17 -179.978 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 1.1 mt -52.49 -54.34 33.81 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 115.908 -0.587 . . . . 0.0 110.961 -179.86 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 127' ' ' PHE . . . . . . . . . . . . . 8.8 t80 -62.78 -36.4 82.99 Favored 'General case' 0 C--N 1.331 -0.231 0 C-N-CA 120.847 -0.341 . . . . 0.0 110.567 179.756 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 128' ' ' GLY . . . . . . . . . . . . . . . -47.31 -43.98 20.15 Favored Glycine 0 C--N 1.332 0.314 0 C-N-CA 120.136 -1.031 . . . . 0.0 111.153 179.154 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 129' ' ' MET . . . . . 0.41 ' HE2' ' N ' ' A' ' 130' ' ' GLY . 0.3 OUTLIER -71.87 -37.05 70.26 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 120.865 0.364 . . . . 0.0 110.026 178.868 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 130' ' ' GLY . . . . . 0.41 ' N ' ' HE2' ' A' ' 129' ' ' MET . . . -67.18 -28.19 73.67 Favored Glycine 0 N--CA 1.45 -0.378 0 CA-C-N 115.822 -0.626 . . . . 0.0 112.688 -179.722 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -74.81 -54.18 7.79 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.624 0.25 . . . . 0.0 110.67 -179.953 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 31.7 t -57.95 -41.17 79.55 Favored 'Isoleucine or valine' 0 C--O 1.235 0.318 0 N-CA-C 109.129 -0.693 . . . . 0.0 109.129 178.698 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -66.29 -35.8 81.32 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 115.173 -0.921 . . . . 0.0 110.106 178.929 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 134' ' ' PHE . . . . . 0.414 ' CZ ' ' HA ' ' A' ' 172' ' ' ALA . 57.9 t80 -57.48 -50.9 71.55 Favored 'General case' 0 N--CA 1.45 -0.469 0 CA-C-N 115.937 -0.574 . . . . 0.0 110.022 179.548 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 135' ' ' ILE . . . . . 0.496 ' HA ' HG22 ' A' ' 138' ' ' VAL . 60.2 mt -56.64 -33.59 40.39 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.312 0 CA-C-N 115.911 -0.586 . . . . 0.0 109.663 178.95 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . -63.21 -35.21 91.76 Favored Glycine 0 N--CA 1.447 -0.568 0 C-N-CA 120.249 -0.977 . . . . 0.0 111.205 178.507 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 137' ' ' LEU . . . . . 0.426 HD13 HD21 ' A' ' 104' ' ' LEU . 29.1 tp -73.43 -52.13 14.82 Favored 'General case' 0 C--N 1.332 -0.158 0 N-CA-C 110.422 -0.214 . . . . 0.0 110.422 179.612 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 138' ' ' VAL . . . . . 0.581 ' HA ' HD12 ' A' ' 141' ' ' LEU . 4.9 m -55.95 -30.55 28.72 Favored 'Isoleucine or valine' 0 C--O 1.234 0.28 0 N-CA-C 109.069 -0.715 . . . . 0.0 109.069 178.92 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 139' ' ' TYR . . . . . 0.413 ' O ' ' N ' ' A' ' 143' ' ' GLY . 49.8 t80 -64.82 -41.96 95.35 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 114.958 -1.019 . . . . 0.0 109.337 178.462 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 19.4 m-85 -65.02 -33.0 74.99 Favored 'General case' 0 C--N 1.333 -0.143 0 CA-C-N 116.036 -0.529 . . . . 0.0 109.791 178.577 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 141' ' ' LEU . . . . . 0.581 HD12 ' HA ' ' A' ' 138' ' ' VAL . 81.9 mt -61.21 -36.38 79.75 Favored 'General case' 0 C--O 1.232 0.149 0 CA-C-N 115.977 -0.556 . . . . 0.0 109.895 179.078 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 2.9 t -109.27 10.48 8.96 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-N 115.751 -0.659 . . . . 0.0 110.658 179.729 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 143' ' ' GLY . . . . . 0.413 ' N ' ' O ' ' A' ' 139' ' ' TYR . . . -85.52 -147.6 9.81 Favored Glycine 0 CA--C 1.519 0.291 0 C-N-CA 120.968 -0.634 . . . . 0.0 113.008 -179.511 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 144' ' ' PRO . . . . . . . . . . . . . 51.3 Cg_exo -52.98 -24.87 26.11 Favored 'Trans proline' 0 C--N 1.349 0.579 0 C-N-CA 122.716 2.278 . . . . 0.0 112.754 -179.799 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 145' ' ' MET . . . . . 0.448 ' HG2' HD11 ' A' ' 93' ' ' LEU . 55.3 mtt -53.22 -39.15 63.55 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 116.352 -0.385 . . . . 0.0 111.244 179.975 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 146' ' ' THR . . . . . . . . . . . . . 81.2 p -62.1 -51.2 68.89 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.794 -179.36 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 147' ' ' GLU . . . . . 0.452 ' O ' ' HG2' ' A' ' 151' ' ' GLN . 40.0 mt-10 -74.1 -18.06 60.86 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.394 -0.366 . . . . 0.0 111.249 -179.534 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 148' ' ' SER . . . . . . . . . . . . . 44.6 t -71.21 -47.69 55.9 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.764 0.316 . . . . 0.0 111.231 -179.807 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 149' ' ' ALA . . . . . 0.505 ' HB1' ' HA ' ' A' ' 91' ' ' ALA . . . -78.02 -31.99 50.79 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.128 -0.487 . . . . 0.0 112.242 -178.975 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 150' ' ' SER . . . . . . . . . . . . . 70.2 m -62.68 -6.67 3.79 Favored 'General case' 0 C--N 1.328 -0.337 0 N-CA-C 111.993 0.368 . . . . 0.0 111.993 -179.384 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 151' ' ' GLN . . . . . 0.452 ' HG2' ' O ' ' A' ' 147' ' ' GLU . 67.0 mm-40 -111.58 17.14 20.27 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.731 -0.213 . . . . 0.0 111.095 -179.775 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 25.6 mtp180 -101.71 -52.24 3.25 Favored 'General case' 0 C--N 1.331 -0.201 0 CA-C-O 120.832 0.349 . . . . 0.0 111.351 -179.839 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 153' ' ' SER . . . . . 0.551 ' HB3' HG12 ' A' ' 156' ' ' ILE . 31.5 t -156.83 172.27 18.93 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.959 179.691 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 154' ' ' SER . . . . . . . . . . . . . 61.4 m -73.05 -39.78 65.64 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 116.257 -0.428 . . . . 0.0 110.65 179.679 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -76.6 -28.81 58.78 Favored Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.904 -0.665 . . . . 0.0 112.7 -179.936 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 156' ' ' ILE . . . . . 0.551 HG12 ' HB3' ' A' ' 153' ' ' SER . 25.8 mm -58.37 -42.45 84.05 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.233 0 CA-C-O 120.764 0.316 . . . . 0.0 111.486 -179.96 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 157' ' ' LYS . . . . . . . . . . . . . 25.0 ttpp -63.31 -42.24 99.0 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.272 -0.422 . . . . 0.0 111.499 -179.496 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 46.5 t -65.23 -47.68 75.98 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.418 -0.355 . . . . 0.0 111.88 -179.257 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 159' ' ' LEU . . . . . 0.405 ' O ' HD11 ' A' ' 163' ' ' LEU . 4.9 tt -66.13 -34.68 78.61 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.507 -0.315 . . . . 0.0 111.241 -179.396 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 160' ' ' TYR . . . . . . . . . . . . . 58.4 t80 -73.69 -46.16 48.01 Favored 'General case' 0 C--N 1.327 -0.382 0 N-CA-C 112.365 0.506 . . . . 0.0 112.365 -178.767 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 28.8 m -59.97 -46.52 93.99 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 N-CA-C 112.171 0.434 . . . . 0.0 112.171 -178.933 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 162' ' ' ARG . . . . . . . . . . . . . 79.0 ttt180 -65.61 -46.04 80.85 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.71 0.291 . . . . 0.0 111.552 -179.331 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 163' ' ' LEU . . . . . 0.405 HD11 ' O ' ' A' ' 159' ' ' LEU . 7.8 mp -65.44 -52.02 56.13 Favored 'General case' 0 C--N 1.329 -0.317 0 N-CA-C 112.106 0.41 . . . . 0.0 112.106 -179.186 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 164' ' ' ARG . . . . . 0.425 ' HG3' ' N ' ' A' ' 165' ' ' ASN . 5.7 ppt_? -58.62 -43.34 89.62 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.598 -0.274 . . . . 0.0 111.605 -178.861 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 165' ' ' ASN . . . . . 0.425 ' N ' ' HG3' ' A' ' 164' ' ' ARG . 0.9 OUTLIER -55.97 -49.44 73.57 Favored 'General case' 0 C--N 1.331 -0.202 0 CA-C-O 121.129 0.49 . . . . 0.0 110.427 179.513 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 166' ' ' LEU . . . . . 0.482 ' O ' ' HG ' ' A' ' 170' ' ' LEU . 3.1 tt -60.15 -50.04 75.24 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 115.563 -0.744 . . . . 0.0 111.681 -179.52 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 167' ' ' THR . . . . . 0.482 ' O ' ' HB2' ' A' ' 171' ' ' TRP . 60.1 m -56.41 -54.01 50.63 Favored 'General case' 0 C--N 1.331 -0.232 0 N-CA-C 112.324 0.49 . . . . 0.0 112.324 -178.796 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 168' ' ' VAL . . . . . . . . . . . . . 45.4 t -52.27 -43.8 40.43 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.227 0 N-CA-C 112.339 0.496 . . . . 0.0 112.339 -179.764 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 169' ' ' VAL . . . . . . . . . . . . . 72.8 t -59.92 -65.75 0.44 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 N-CA-C 113.016 0.747 . . . . 0.0 113.016 -178.47 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 170' ' ' LEU . . . . . 0.482 ' HG ' ' O ' ' A' ' 166' ' ' LEU . 0.7 OUTLIER -63.08 -37.78 88.56 Favored 'General case' 0 C--N 1.33 -0.26 0 N-CA-C 112.593 0.59 . . . . 0.0 112.593 -178.163 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 171' ' ' TRP . . . . . 0.482 ' HB2' ' O ' ' A' ' 167' ' ' THR . 2.9 m0 -64.25 -27.58 69.15 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.832 0.349 . . . . 0.0 110.771 179.813 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 172' ' ' ALA . . . . . 0.414 ' HA ' ' CZ ' ' A' ' 134' ' ' PHE . . . -72.48 -6.93 47.19 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.948 -179.818 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 173' ' ' ILE . . . . . 0.478 ' O ' HG12 ' A' ' 177' ' ' ILE . 28.8 mm -88.4 -21.24 7.05 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 115.952 -0.567 . . . . 0.0 111.175 -179.985 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 174' ' ' TYR . . . . . 0.403 ' N ' ' CD ' ' A' ' 175' ' ' PRO . 8.7 m-85 -53.59 -48.25 93.74 Favored Pre-proline 0 N--CA 1.464 0.261 0 CA-C-N 116.339 -0.392 . . . . 0.0 111.93 -179.375 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 175' ' ' PRO . . . . . 0.403 ' CD ' ' N ' ' A' ' 174' ' ' TYR . 84.6 Cg_exo -48.43 -33.27 22.52 Favored 'Trans proline' 0 C--N 1.351 0.667 0 C-N-CA 121.854 1.703 . . . . 0.0 112.048 179.588 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 176' ' ' PHE . . . . . 0.453 ' HD2' ' HA ' ' A' ' 173' ' ' ILE . 60.9 m-85 -80.9 -50.35 9.87 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 115.873 -0.603 . . . . 0.0 111.954 -179.905 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 177' ' ' ILE . . . . . 0.478 HG12 ' O ' ' A' ' 173' ' ' ILE . 13.6 mm -60.25 -32.08 49.86 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.443 0 CA-C-N 116.279 -0.418 . . . . 0.0 112.036 -178.386 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 178' ' ' TRP . . . . . 0.445 ' HH2' ' HB2' ' A' ' 123' ' ' ARG . 82.0 t90 -73.18 -52.06 15.52 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.91 0.386 . . . . 0.0 110.81 179.928 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 179' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -68.76 -54.77 14.07 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-N 115.989 -0.55 . . . . 0.0 111.484 -179.119 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 180' ' ' LEU . . . . . 0.502 HD23 HD11 ' A' ' 187' ' ' LEU . 26.6 mt -64.06 -29.7 70.82 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.55 -0.295 . . . . 0.0 111.298 -179.37 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . -69.12 -175.79 12.24 Favored Glycine 0 N--CA 1.449 -0.44 0 C-N-CA 119.817 -1.183 . . . . 0.0 111.629 178.957 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 182' ' ' PRO . . . . . 0.512 ' HG3' ' HA ' ' A' ' 190' ' ' PRO . 82.3 Cg_exo -47.47 -43.54 27.07 Favored 'Trans proline' 0 CA--C 1.537 0.669 0 C-N-CA 122.678 2.252 . . . . 0.0 113.76 179.943 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 183' ' ' PRO . . . . . 0.417 ' CD ' ' N ' ' A' ' 182' ' ' PRO . 83.4 Cg_exo -43.07 -51.77 5.31 Favored 'Trans proline' 0 C--N 1.356 0.957 0 C-N-CA 122.491 2.127 . . . . 0.0 114.065 -179.744 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 184' ' ' GLY . . . . . . . . . . . . . . . -102.74 -123.95 5.36 Favored Glycine 0 C--N 1.335 0.515 0 C-N-CA 119.942 -1.123 . . . . 0.0 113.631 -179.063 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 185' ' ' VAL . . . . . . . . . . . . . 23.6 m -54.09 -33.33 24.49 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.405 0 N-CA-C 112.647 0.61 . . . . 0.0 112.647 -178.95 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 186' ' ' ALA . . . . . . . . . . . . . . . 58.92 83.35 0.13 Allowed 'General case' 0 N--CA 1.464 0.246 0 CA-C-O 120.675 0.274 . . . . 0.0 111.624 179.786 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 187' ' ' LEU . . . . . 0.502 HD11 HD23 ' A' ' 180' ' ' LEU . 7.7 mt -92.32 -49.92 5.91 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-O 120.902 0.382 . . . . 0.0 111.351 179.795 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 188' ' ' LEU . . . . . 0.442 HD13 ' HB2' ' A' ' 187' ' ' LEU . 7.3 mp -79.79 -164.59 0.68 Allowed 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.001 -0.545 . . . . 0.0 111.197 -179.268 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 189' ' ' THR . . . . . 0.468 ' HB ' HG23 ' A' ' 192' ' ' VAL . 20.8 m -91.08 137.46 26.46 Favored Pre-proline 0 C--N 1.329 -0.295 0 CA-C-N 115.868 -0.605 . . . . 0.0 110.634 -179.73 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 190' ' ' PRO . . . . . 0.512 ' HA ' ' HG3' ' A' ' 182' ' ' PRO . 92.3 Cg_exo -44.23 -37.24 9.87 Favored 'Trans proline' 0 C--N 1.35 0.656 0 C-N-CA 122.519 2.146 . . . . 0.0 113.278 -179.649 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 191' ' ' THR . . . . . 0.404 HG21 HG22 ' A' ' 189' ' ' THR . 6.2 t -78.52 -40.82 34.05 Favored 'General case' 0 C--N 1.33 -0.275 0 N-CA-C 111.683 0.253 . . . . 0.0 111.683 -179.616 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 192' ' ' VAL . . . . . 0.468 HG23 ' HB ' ' A' ' 189' ' ' THR . 96.9 t -62.52 -48.69 87.08 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-O 120.658 0.266 . . . . 0.0 111.463 -179.729 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 193' ' ' ASP . . . . . . . . . . . . . 21.6 m-20 -56.0 -46.58 78.7 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.397 -0.365 . . . . 0.0 111.089 -179.714 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 194' ' ' VAL . . . . . . . . . . . . . 71.0 t -59.34 -37.07 67.36 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.412 -0.358 . . . . 0.0 110.739 179.547 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 195' ' ' ALA . . . . . . . . . . . . . . . -59.32 -41.71 89.72 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.303 -0.408 . . . . 0.0 110.608 179.534 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 196' ' ' LEU . . . . . . . . . . . . . 98.1 mt -67.3 -38.4 84.95 Favored 'General case' 0 C--N 1.333 -0.143 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.197 179.248 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 197' ' ' ILE . . . . . . . . . . . . . 15.8 mm -60.57 -56.24 19.06 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.242 0 CA-C-N 115.901 -0.59 . . . . 0.0 110.248 179.122 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 198' ' ' VAL . . . . . . . . . . . . . 93.7 t -54.28 -34.58 28.01 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.516 0 CA-C-N 115.623 -0.717 . . . . 0.0 109.321 178.303 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 199' ' ' TYR . . . . . . . . . . . . . 29.7 t80 -69.83 -32.99 71.71 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 115.112 -0.949 . . . . 0.0 110.609 179.794 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 200' ' ' LEU . . . . . 0.439 ' O ' HG13 ' A' ' 203' ' ' VAL . 23.0 mt -69.86 -39.33 76.41 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 115.97 -0.559 . . . . 0.0 111.024 179.984 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 201' ' ' ASP . . . . . . . . . . . . . 15.2 m-20 -72.95 -34.6 66.64 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-O 121.204 0.526 . . . . 0.0 110.103 179.625 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 202' ' ' LEU . . . . . . . . . . . . . 3.1 mt -75.01 -27.13 59.99 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 115.514 -0.766 . . . . 0.0 111.749 -179.439 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 203' ' ' VAL . . . . . 0.439 HG13 ' O ' ' A' ' 200' ' ' LEU . 10.9 p -79.61 -36.36 17.47 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.334 0 C-N-CA 120.834 -0.347 . . . . 0.0 110.856 -178.924 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 204' ' ' THR . . . . . . . . . . . . . 96.9 m -67.87 -58.27 4.85 Favored 'General case' 0 C--N 1.328 -0.333 0 C-N-CA 120.933 -0.307 . . . . 0.0 110.902 179.212 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 205' ' ' LYS . . . . . 0.698 ' HD2' ' HE1' ' A' ' 15' ' ' MET . 60.5 mttp -60.52 -58.29 9.11 Favored 'General case' 0 C--N 1.331 -0.212 0 N-CA-C 112.067 0.395 . . . . 0.0 112.067 -178.937 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 52.8 t -67.69 -37.02 77.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 N-CA-C 111.818 0.303 . . . . 0.0 111.818 -179.303 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 207' ' ' GLY . . . . . 0.404 ' HA3' ' O ' ' A' ' 203' ' ' VAL . . . -53.55 -60.48 8.19 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.908 -0.663 . . . . 0.0 113.975 -178.818 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 208' ' ' PHE . . . . . 0.475 ' O ' ' N ' ' A' ' 212' ' ' ALA . 1.1 p90 -75.45 -26.75 58.53 Favored 'General case' 0 C--O 1.219 -0.513 0 CA-C-N 117.317 0.559 . . . . 0.0 111.778 -179.14 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 209' ' ' GLY . . . . . 0.465 ' O ' ' HB3' ' A' ' 212' ' ' ALA . . . -66.4 -35.24 89.88 Favored Glycine 0 N--CA 1.452 -0.267 0 C-N-CA 121.491 -0.385 . . . . 0.0 112.202 179.597 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 210' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER -75.75 -44.86 39.54 Favored 'General case' 0 CA--C 1.514 -0.433 0 N-CA-C 108.316 -0.994 . . . . 0.0 108.316 178.742 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 211' ' ' ILE . . . . . . . . . . . . . 44.3 mt -65.6 -27.55 41.85 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.55 0 N-CA-C 107.91 -1.144 . . . . 0.0 107.91 176.86 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 212' ' ' ALA . . . . . 0.475 ' N ' ' O ' ' A' ' 208' ' ' PHE . . . -62.37 -45.47 93.02 Favored 'General case' 0 N--CA 1.451 -0.418 0 CA-C-N 114.741 -1.118 . . . . 0.0 110.508 179.89 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 213' ' ' LEU . . . . . . . . . . . . . 93.9 mt -69.73 -54.55 13.22 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 115.151 -0.931 . . . . 0.0 111.676 -179.181 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 214' ' ' ASP . . . . . . . . . . . . . 19.5 t70 -55.21 -41.52 72.11 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.331 -0.395 . . . . 0.0 111.511 -179.608 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 215' ' ' ALA . . . . . . . . . . . . . . . -70.25 -57.7 4.59 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.407 -0.36 . . . . 0.0 111.781 -179.419 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 216' ' ' ALA . . . . . . . . . . . . . . . -55.59 -34.92 65.26 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.5 -0.318 . . . . 0.0 111.428 -179.541 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 217' ' ' ALA . . . . . . . . . . . . . . . -67.02 -41.02 87.33 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.506 179.894 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 218' ' ' THR . . . . . . . . . . . . . 42.3 m . . . . . 0 C--N 1.33 -0.28 0 CA-C-N 115.775 -0.648 . . . . 0.0 110.916 179.707 . . . . . . . . 0 0 . 1 . 021 nuclear orig core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.266 0 N-CA-C 112.626 -0.189 . . . . 0.0 112.626 . . . . . . . . . 0 0 . 1 . 021 nuclear orig core ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 31.1 tp -73.95 -35.47 64.53 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-O 120.837 0.351 . . . . 0.0 110.727 -179.967 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 74.0 p -58.23 -30.99 66.94 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.079 -0.51 . . . . 0.0 111.519 -179.863 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 30.9 p -54.29 -35.71 62.88 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.377 -0.374 . . . . 0.0 111.2 -179.964 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 7' ' ' LEU . . . . . . . . . . . . . 4.1 mm? -60.22 -52.23 66.17 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.883 179.868 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 8' ' ' PHE . . . . . 0.428 ' HB2' ' HB3' ' A' ' 55' ' ' ALA . 58.2 m-85 -62.82 -30.92 71.85 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.031 -0.532 . . . . 0.0 110.909 -179.981 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 9' ' ' TRP . . . . . . . . . . . . . 21.5 m95 -67.5 -46.87 71.65 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.087 -0.506 . . . . 0.0 110.212 -179.797 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 88.9 mt -59.67 -38.44 81.49 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 115.69 -0.687 . . . . 0.0 110.343 179.411 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -65.04 -34.24 89.32 Favored Glycine 0 N--CA 1.448 -0.506 0 C-N-CA 120.679 -0.772 . . . . 0.0 111.866 179.36 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -67.91 -32.48 72.97 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-O 120.883 0.373 . . . . 0.0 110.62 179.554 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 70.2 mt -65.22 -53.42 40.8 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 115.91 -0.586 . . . . 0.0 110.624 179.611 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -64.21 -40.16 97.74 Favored Glycine 0 N--CA 1.451 -0.364 0 C-N-CA 120.6 -0.81 . . . . 0.0 112.198 179.72 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 15' ' ' MET . . . . . 0.659 ' HE3' ' HD2' ' A' ' 205' ' ' LYS . 12.5 mmt -63.14 -47.96 80.49 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.676 0.274 . . . . 0.0 110.99 179.797 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 16' ' ' LEU . . . . . 0.674 ' O ' HD22 ' A' ' 20' ' ' LEU . 50.9 tp -54.4 -55.71 25.92 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.329 -179.877 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 46.9 t -56.97 -33.36 42.05 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-O 120.958 0.409 . . . . 0.0 110.45 -179.355 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -67.26 -49.88 49.19 Favored Glycine 0 N--CA 1.452 -0.297 0 N-CA-C 111.185 -0.766 . . . . 0.0 111.185 179.483 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 19' ' ' THR . . . . . 0.608 HG23 HD23 ' A' ' 20' ' ' LEU . 1.4 m -53.39 -43.45 67.89 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 115.28 -0.46 . . . . 0.0 110.84 179.518 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 20' ' ' LEU . . . . . 0.674 HD22 ' O ' ' A' ' 16' ' ' LEU . 0.5 OUTLIER -69.79 -41.96 74.41 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-N 115.755 -0.657 . . . . 0.0 111.943 -179.559 . . . . . . . . 3 3 . 1 . 021 nuclear orig core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -59.38 -32.14 69.87 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.521 -0.309 . . . . 0.0 111.795 -179.344 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 22' ' ' PHE . . . . . 0.492 ' HB2' HG23 ' A' ' 41' ' ' VAL . 5.8 m-85 -90.96 -28.66 17.9 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.711 0.291 . . . . 0.0 111.256 -179.722 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -70.33 -50.72 36.22 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 121.007 0.432 . . . . 0.0 111.576 -179.716 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 24' ' ' TRP . . . . . . . . . . . . . 4.6 t-105 -66.06 -38.91 89.51 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 115.867 -0.606 . . . . 0.0 111.494 -179.438 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.33 -0.256 0 CA-C-O 120.836 0.35 . . . . 0.0 110.77 179.712 . . . . . . . . 0 0 . 1 . 021 nuclear orig core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.453 -0.209 0 N-CA-C 112.86 -0.096 . . . . 0.0 112.86 . . . . . . . . . 0 0 . 1 . 021 nuclear orig core ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 2.7 mp0 -66.42 -20.88 66.18 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.898 0.38 . . . . 0.0 110.933 -179.846 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 34' ' ' ARG . . . . . . . . . . . . . 99.2 mtt180 -51.4 -29.54 16.06 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 115.914 -0.584 . . . . 0.0 111.679 -179.776 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 31.1 mmm180 -67.17 -44.78 78.83 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.393 -0.367 . . . . 0.0 111.42 -179.731 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 78.3 m-85 -70.54 -31.35 68.36 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.466 -0.333 . . . . 0.0 110.983 -179.946 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 37' ' ' TYR . . . . . . . . . . . . . 48.5 m-85 -72.11 -51.33 21.93 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 116.327 -0.397 . . . . 0.0 111.228 -179.757 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 10.7 p -57.27 -36.21 51.43 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-O 120.994 0.426 . . . . 0.0 109.979 179.344 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 24.0 m -66.22 -43.83 85.55 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 115.629 -0.714 . . . . 0.0 110.584 179.127 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 40' ' ' LEU . . . . . 0.576 HD13 ' HA2' ' A' ' 209' ' ' GLY . 0.3 OUTLIER -62.64 -50.51 70.92 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-O 121.585 0.707 . . . . 0.0 110.501 179.559 . . . . . . . . 3 3 . 1 . 021 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . 0.492 HG23 ' HB2' ' A' ' 22' ' ' PHE . 43.8 t -62.87 -33.49 60.64 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.626 0 CA-C-N 115.435 -0.802 . . . . 0.0 110.316 179.43 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 42' ' ' GLY . . . . . 0.44 ' O ' HG12 ' A' ' 46' ' ' ILE . . . -58.07 -47.79 86.93 Favored Glycine 0 N--CA 1.448 -0.527 0 CA-C-N 115.635 -0.712 . . . . 0.0 112.822 179.889 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 43' ' ' ILE . . . . . 0.56 HD12 HD23 ' A' ' 40' ' ' LEU . 9.0 pt -65.43 -51.32 65.35 Favored 'Isoleucine or valine' 0 C--O 1.233 0.201 0 CA-C-N 117.019 0.409 . . . . 0.0 111.502 -179.704 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 60.5 m -63.61 -20.47 65.69 Favored 'General case' 0 C--O 1.233 0.188 0 CA-C-O 120.92 0.39 . . . . 0.0 110.79 -179.899 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -80.61 -58.58 2.67 Favored Glycine 0 N--CA 1.452 -0.287 0 C-N-CA 121.008 -0.615 . . . . 0.0 113.103 -179.301 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 46' ' ' ILE . . . . . 0.446 ' O ' HG23 ' A' ' 49' ' ' VAL . 14.7 pt -58.19 -36.6 58.22 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.185 0 CA-C-O 120.881 0.372 . . . . 0.0 110.949 -179.758 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 47' ' ' ALA . . . . . 0.614 ' HB3' ' HE2' ' A' ' 205' ' ' LYS . . . -68.78 -42.54 77.27 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.704 178.776 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -54.39 -40.49 68.24 Favored 'General case' 0 C--O 1.232 0.181 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.329 -179.786 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 49' ' ' VAL . . . . . 0.446 HG23 ' O ' ' A' ' 46' ' ' ILE . 17.9 m -76.22 -34.1 25.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.487 -0.324 . . . . 0.0 110.98 -179.883 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -61.42 -39.96 92.7 Favored 'General case' 0 C--N 1.332 -0.165 0 CA-C-O 121.141 0.496 . . . . 0.0 110.715 179.215 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 51' ' ' TYR . . . . . 0.41 ' HB3' ' O ' ' A' ' 8' ' ' PHE . 43.5 m-85 -73.19 -35.93 66.47 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 115.651 -0.704 . . . . 0.0 110.439 179.84 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -66.68 -39.95 88.36 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 115.885 -0.598 . . . . 0.0 111.261 179.558 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 53' ' ' VAL . . . . . 0.406 HG12 ' O ' ' A' ' 49' ' ' VAL . 33.5 m -74.42 -42.44 49.79 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.173 0 CA-C-N 116.362 -0.381 . . . . 0.0 110.972 -179.785 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 54' ' ' MET . . . . . . . . . . . . . 70.7 mtm -65.27 -31.17 72.18 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 121.111 0.481 . . . . 0.0 109.852 179.118 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 55' ' ' ALA . . . . . 0.428 ' HB3' ' HB2' ' A' ' 8' ' ' PHE . . . -67.82 -18.56 64.88 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 115.544 -0.753 . . . . 0.0 111.188 179.52 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 96.5 mt -98.84 8.68 44.71 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.196 179.957 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 81.22 16.81 73.33 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.587 -0.816 . . . . 0.0 112.604 -179.993 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 58.0 t -84.53 137.19 21.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-O 120.794 0.33 . . . . 0.0 110.888 179.907 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 59' ' ' GLY . . . . . 0.48 ' HA3' ' HD3' ' A' ' 71' ' ' PRO . . . 85.08 -7.79 73.53 Favored Glycine 0 N--CA 1.449 -0.478 0 C-N-CA 120.776 -0.726 . . . . 0.0 112.476 -179.942 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 60' ' ' TRP . . . . . . . . . . . . . 12.0 m0 -65.36 99.21 0.39 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.642 0.258 . . . . 0.0 110.863 179.955 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 5.1 p -107.31 128.32 26.21 Favored Pre-proline 0 C--N 1.329 -0.298 0 CA-C-N 116.356 -0.384 . . . . 0.0 111.141 179.885 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 58.3 Cg_endo -71.68 141.11 37.1 Favored 'Trans proline' 0 C--N 1.349 0.581 0 C-N-CA 122.25 1.967 . . . . 0.0 112.039 179.817 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 61.1 t -137.39 90.77 0.77 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.356 0 CA-C-N 116.075 -0.511 . . . . 0.0 111.249 -179.621 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . 59.96 -85.49 0.02 OUTLIER 'General case' 0 C--N 1.331 -0.202 0 CA-C-N 116.0 -0.545 . . . . 0.0 111.42 179.948 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 11.6 pt-20 -121.81 -22.69 5.7 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.886 0.374 . . . . 0.0 110.937 -179.966 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 66' ' ' ARG . . . . . . . . . . . . . 84.8 mtm180 -104.72 156.78 17.69 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.041 -0.527 . . . . 0.0 110.802 -179.919 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 40.9 m -113.61 130.62 56.35 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.981 179.854 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 26.3 t -113.61 146.33 18.34 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.394 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.973 179.943 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 69' ' ' PHE . . . . . . . . . . . . . 16.8 m-85 -104.33 116.68 32.57 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 116.209 -0.451 . . . . 0.0 109.919 -179.894 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 70' ' ' VAL . . . . . 0.592 HG11 ' HD3' ' A' ' 71' ' ' PRO . 0.8 OUTLIER -66.73 -35.58 9.84 Favored Pre-proline 0 CA--C 1.541 0.612 0 N-CA-C 112.602 0.593 . . . . 0.0 112.602 -179.424 . . . . . . . . 3 3 . 1 . 021 nuclear orig core ' A' A ' 71' ' ' PRO . . . . . 0.592 ' HD3' HG11 ' A' ' 70' ' ' VAL . 9.5 Cg_exo -70.77 -22.39 27.51 Favored 'Trans proline' 0 C--N 1.36 1.138 0 C-N-CA 122.032 1.821 . . . . 0.0 112.815 -179.508 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 67.6 ttt180 -68.56 -55.63 11.0 Favored 'General case' 0 C--N 1.329 -0.323 0 N-CA-C 112.157 0.429 . . . . 0.0 112.157 -178.791 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 73' ' ' TYR . . . . . 0.503 ' O ' HG13 ' A' ' 77' ' ' ILE . 73.7 m-85 -73.53 -33.74 64.88 Favored 'General case' 0 C--N 1.328 -0.328 0 C-N-CA 120.863 -0.335 . . . . 0.0 110.892 -179.112 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 74' ' ' ILE . . . . . 0.451 ' HA ' HD12 ' A' ' 77' ' ' ILE . 0.3 OUTLIER -67.57 -41.27 85.59 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 N-CA-C 109.703 -0.48 . . . . 0.0 109.703 179.164 . . . . . . . . 3 3 . 1 . 021 nuclear orig core ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 27.0 t70 -58.85 -37.54 76.7 Favored 'General case' 0 CA--C 1.519 -0.242 0 N-CA-C 109.241 -0.651 . . . . 0.0 109.241 178.703 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 76' ' ' TRP . . . . . 0.439 ' HB3' ' SD ' ' A' ' 109' ' ' MET . 48.6 m0 -66.12 -31.13 71.8 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 115.624 -0.717 . . . . 0.0 110.575 179.337 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 77' ' ' ILE . . . . . 0.503 HG13 ' O ' ' A' ' 73' ' ' TYR . 76.1 mt -69.41 -29.6 42.57 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.353 0 CA-C-O 121.036 0.446 . . . . 0.0 110.333 178.973 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 24.8 mt -91.45 -15.84 28.23 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 115.984 -0.553 . . . . 0.0 111.986 179.898 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 73.6 p -101.84 -52.6 3.15 Favored 'General case' 0 N--CA 1.464 0.225 0 N-CA-C 113.06 0.763 . . . . 0.0 113.06 -178.613 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 80' ' ' THR . . . . . 0.662 ' HB ' ' HD3' ' A' ' 81' ' ' PRO . 62.8 m -51.26 -56.26 21.79 Favored Pre-proline 0 CA--C 1.533 0.291 0 N-CA-C 112.854 0.687 . . . . 0.0 112.854 -178.287 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 81' ' ' PRO . . . . . 0.662 ' HD3' ' HB ' ' A' ' 80' ' ' THR . 52.2 Cg_exo -57.43 -25.12 64.54 Favored 'Trans proline' 0 C--N 1.353 0.766 0 C-N-CA 121.517 1.478 . . . . 0.0 111.613 -179.945 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 82' ' ' LEU . . . . . . . . . . . . . 12.3 tp -77.14 -32.96 56.75 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 115.741 -0.663 . . . . 0.0 110.393 179.838 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 47.4 mm -67.56 -53.34 32.55 Favored 'Isoleucine or valine' 0 C--O 1.232 0.164 0 CA-C-N 116.377 -0.374 . . . . 0.0 110.227 179.17 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 84' ' ' VAL . . . . . 0.43 HG11 HD12 ' A' ' 137' ' ' LEU . 24.6 m -60.73 -29.96 46.1 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.224 0 N-CA-C 108.897 -0.779 . . . . 0.0 108.897 178.411 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 85' ' ' TYR . . . . . . . . . . . . . 93.4 t80 -65.28 -30.29 71.14 Favored 'General case' 0 N--CA 1.453 -0.297 0 CA-C-N 115.395 -0.82 . . . . 0.0 109.248 178.371 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 86' ' ' PHE . . . . . . . . . . . . . 31.6 t80 -65.44 -51.95 56.62 Favored 'General case' 0 CA--C 1.519 -0.212 0 CA-C-N 115.811 -0.631 . . . . 0.0 109.623 178.988 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 87' ' ' LEU . . . . . 0.573 HD21 HD21 ' A' ' 141' ' ' LEU . 6.0 mp -63.22 -28.85 70.32 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 115.803 -0.635 . . . . 0.0 109.854 179.117 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -68.35 -27.98 73.49 Favored Glycine 0 N--CA 1.449 -0.478 0 C-N-CA 120.707 -0.759 . . . . 0.0 111.256 178.833 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 46.4 mt -76.19 -34.33 59.31 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-O 120.963 0.411 . . . . 0.0 110.282 179.012 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 88.9 mt -79.41 -23.69 43.06 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 115.937 -0.574 . . . . 0.0 110.984 179.681 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 91' ' ' ALA . . . . . 0.429 ' HA ' ' HB1' ' A' ' 149' ' ' ALA . . . -88.46 -45.46 9.93 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.249 -179.903 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 91.92 57.8 1.47 Allowed Glycine 0 N--CA 1.451 -0.364 0 C-N-CA 120.802 -0.713 . . . . 0.0 112.611 -179.833 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 93' ' ' LEU . . . . . 0.423 HD21 ' HB3' ' A' ' 97' ' ' GLU . 10.6 mp -74.07 176.94 6.06 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-O 120.758 0.313 . . . . 0.0 110.779 179.836 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 94' ' ' ASP . . . . . 0.504 ' H ' ' HB2' ' A' ' 97' ' ' GLU . 5.7 m-20 -99.23 -167.0 1.41 Allowed 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.095 -179.947 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 48.8 m -67.58 -49.63 62.25 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 115.903 -0.589 . . . . 0.0 111.509 -179.542 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 96' ' ' ARG . . . . . 0.425 ' O ' HG13 ' A' ' 100' ' ' ILE . 31.4 tpt180 -74.08 -39.77 63.21 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-O 120.904 0.383 . . . . 0.0 110.601 -179.457 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 97' ' ' GLU . . . . . 0.504 ' HB2' ' H ' ' A' ' 94' ' ' ASP . 0.3 OUTLIER -55.53 -47.19 76.7 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 115.824 -0.626 . . . . 0.0 111.391 -179.757 . . . . . . . . 3 3 . 1 . 021 nuclear orig core ' A' A ' 98' ' ' PHE . . . . . 0.436 ' O ' HG12 ' A' ' 102' ' ' ILE . 3.3 m-85 -62.53 -41.53 98.92 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.487 -0.324 . . . . 0.0 110.879 179.675 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -65.47 -26.33 71.78 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.553 -0.832 . . . . 0.0 112.66 -179.777 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 100' ' ' ILE . . . . . 0.425 HG13 ' O ' ' A' ' 96' ' ' ARG . 96.5 mt -73.4 -48.82 40.41 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-O 120.688 0.28 . . . . 0.0 111.648 -179.663 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 17.0 m -64.82 -37.78 81.05 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.498 -0.319 . . . . 0.0 111.691 -179.649 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 102' ' ' ILE . . . . . 0.436 HG12 ' O ' ' A' ' 98' ' ' PHE . 49.5 mm -71.55 -49.48 46.34 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.452 -0.34 . . . . 0.0 111.41 -179.757 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 14.0 t -59.74 -30.94 69.18 Favored 'General case' 0 C--N 1.332 -0.164 0 CA-C-O 120.825 0.345 . . . . 0.0 110.938 -179.933 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 104' ' ' LEU . . . . . 0.436 HD22 ' HE2' ' A' ' 140' ' ' TYR . 46.3 tp -65.49 -54.37 29.2 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.465 179.498 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 105' ' ' ASN . . . . . 0.612 ' N ' HD21 ' A' ' 105' ' ' ASN . 0.7 OUTLIER -56.91 -26.45 59.25 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 115.996 -0.547 . . . . 0.0 110.764 179.827 . . . . . . . . 3 3 . 1 . 021 nuclear orig core ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 39.6 m -68.4 -56.76 7.38 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.13 -0.486 . . . . 0.0 111.38 -179.855 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 13.2 p -60.45 -36.66 70.98 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.16 0 CA-C-N 116.524 -0.307 . . . . 0.0 111.335 -179.779 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . 0.403 HG23 ' O ' ' A' ' 104' ' ' LEU . 93.3 t -66.36 -50.24 69.31 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-O 120.957 0.408 . . . . 0.0 111.005 179.716 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 109' ' ' MET . . . . . 0.439 ' SD ' ' HB3' ' A' ' 76' ' ' TRP . 10.0 tpp -59.95 -36.33 76.86 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 115.954 -0.566 . . . . 0.0 110.62 179.948 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 23.1 tp -65.19 -34.27 77.98 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.037 -0.528 . . . . 0.0 110.291 179.607 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -60.01 -51.28 70.32 Favored 'General case' 0 C--N 1.331 -0.218 0 CA-C-N 116.041 -0.527 . . . . 0.0 110.339 179.263 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . -62.21 -39.27 97.47 Favored Glycine 0 C--N 1.331 0.269 0 C-N-CA 120.604 -0.808 . . . . 0.0 111.911 179.245 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 113' ' ' PHE . . . . . . . . . . . . . 2.2 t80 -47.43 -68.22 0.21 Allowed 'General case' 0 C--N 1.332 -0.196 0 CA-C-O 121.063 0.459 . . . . 0.0 110.203 179.318 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 114' ' ' ALA . . . . . 0.401 ' HB2' HD22 ' A' ' 126' ' ' LEU . . . -65.12 -21.66 66.83 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 115.512 -0.767 . . . . 0.0 110.856 179.453 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -53.58 -45.03 68.3 Favored Glycine 0 C--N 1.334 0.423 0 C-N-CA 121.068 -0.587 . . . . 0.0 112.496 179.992 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -77.88 -23.59 48.73 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.721 0.295 . . . . 0.0 111.55 179.744 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 117' ' ' MET . . . . . . . . . . . . . 65.3 mtt -96.0 19.15 12.01 Favored 'General case' 0 C--N 1.331 -0.2 0 CA-C-N 116.29 -0.414 . . . . 0.0 111.613 -179.473 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 118' ' ' VAL . . . . . 0.49 HG12 ' N ' ' A' ' 123' ' ' ARG . 19.3 m -68.34 142.61 94.79 Favored Pre-proline 0 C--N 1.328 -0.338 0 CA-C-N 116.71 -0.223 . . . . 0.0 111.586 -179.902 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 119' ' ' PRO . . . . . . . . . . . . . 98.4 Cg_endo -88.0 6.09 5.11 Favored 'Trans proline' 0 N--CA 1.459 -0.513 0 C-N-CA 122.761 2.307 . . . . 0.0 112.524 179.593 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -166.09 -115.15 0.31 Allowed Glycine 0 C--N 1.332 0.327 0 C-N-CA 120.697 -0.763 . . . . 0.0 112.803 -179.814 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 43.5 pt -111.4 12.68 8.58 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.216 0 CA-C-O 120.698 0.285 . . . . 0.0 111.43 -179.634 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 11.2 mm-40 -58.83 -18.88 36.43 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.37 -0.377 . . . . 0.0 110.991 -179.993 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 123' ' ' ARG . . . . . 0.49 ' N ' HG12 ' A' ' 118' ' ' VAL . 17.5 ptt180 -53.32 -30.01 36.76 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.017 -0.538 . . . . 0.0 111.484 -179.964 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 124' ' ' TYR . . . . . . . . . . . . . 29.7 m-85 -76.5 -32.45 58.32 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.352 -0.385 . . . . 0.0 110.927 179.924 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 125' ' ' ALA . . . . . . . . . . . . . . . -72.38 -56.1 6.0 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.067 179.924 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 126' ' ' LEU . . . . . 0.401 HD22 ' HB2' ' A' ' 114' ' ' ALA . 1.5 mt -56.13 -54.08 49.43 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 115.888 -0.596 . . . . 0.0 110.829 -179.89 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 127' ' ' PHE . . . . . . . . . . . . . 11.0 t80 -64.86 -35.9 82.63 Favored 'General case' 0 N--CA 1.453 -0.306 0 C-N-CA 120.738 -0.385 . . . . 0.0 110.694 179.623 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 128' ' ' GLY . . . . . . . . . . . . . . . -47.53 -44.16 21.93 Favored Glycine 0 C--N 1.332 0.337 0 C-N-CA 120.054 -1.069 . . . . 0.0 110.825 179.111 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 129' ' ' MET . . . . . . . . . . . . . 0.2 OUTLIER -71.77 -37.24 70.5 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.991 0.424 . . . . 0.0 109.99 178.78 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -67.69 -27.59 73.59 Favored Glycine 0 N--CA 1.452 -0.29 0 CA-C-N 115.653 -0.703 . . . . 0.0 112.761 -179.852 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -75.04 -53.85 8.18 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-O 120.696 0.284 . . . . 0.0 110.48 179.944 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 45.4 t -58.54 -40.09 77.65 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.206 0 N-CA-C 109.064 -0.717 . . . . 0.0 109.064 178.546 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -69.09 -35.0 76.01 Favored 'General case' 0 N--CA 1.451 -0.389 0 CA-C-N 115.133 -0.939 . . . . 0.0 110.445 179.174 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 134' ' ' PHE . . . . . 0.434 ' CZ ' ' HA ' ' A' ' 172' ' ' ALA . 76.2 t80 -57.51 -55.27 36.95 Favored 'General case' 0 N--CA 1.451 -0.376 0 N-CA-C 109.763 -0.458 . . . . 0.0 109.763 179.492 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 135' ' ' ILE . . . . . 0.468 ' HA ' HG23 ' A' ' 138' ' ' VAL . 34.7 mt -57.25 -31.5 38.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 115.687 -0.688 . . . . 0.0 109.642 178.888 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . -65.77 -36.11 91.82 Favored Glycine 0 N--CA 1.446 -0.669 0 C-N-CA 120.386 -0.911 . . . . 0.0 111.017 178.537 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 137' ' ' LEU . . . . . 0.43 HD12 HG11 ' A' ' 84' ' ' VAL . 39.1 tp -71.47 -53.23 14.64 Favored 'General case' 0 N--CA 1.454 -0.25 0 N-CA-C 110.355 -0.239 . . . . 0.0 110.355 179.321 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 138' ' ' VAL . . . . . 0.468 HG23 ' HA ' ' A' ' 135' ' ' ILE . 5.0 m -56.36 -31.86 34.12 Favored 'Isoleucine or valine' 0 C--O 1.233 0.194 0 N-CA-C 109.08 -0.711 . . . . 0.0 109.08 178.929 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 139' ' ' TYR . . . . . . . . . . . . . 39.0 t80 -61.41 -45.82 92.74 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 115.367 -0.833 . . . . 0.0 110.127 178.54 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 140' ' ' TYR . . . . . 0.436 ' HE2' HD22 ' A' ' 104' ' ' LEU . 27.4 m-85 -60.95 -37.67 83.2 Favored 'General case' 0 C--N 1.332 -0.157 0 CA-C-N 116.29 -0.414 . . . . 0.0 110.724 179.543 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 141' ' ' LEU . . . . . 0.573 HD21 HD21 ' A' ' 87' ' ' LEU . 83.5 mt -61.92 -35.0 77.1 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.615 179.916 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 17.1 t -96.25 -4.75 10.08 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.071 -0.513 . . . . 0.0 110.546 179.581 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . -74.12 -134.36 0.29 Allowed Glycine 0 CA--C 1.52 0.398 0 C-N-CA 121.129 -0.558 . . . . 0.0 112.885 -179.809 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 144' ' ' PRO . . . . . . . . . . . . . 34.1 Cg_exo -59.91 -23.96 74.5 Favored 'Trans proline' 0 C--N 1.349 0.578 0 C-N-CA 122.752 2.301 . . . . 0.0 112.839 -179.536 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 145' ' ' MET . . . . . 0.433 ' HA ' ' HG ' ' A' ' 148' ' ' SER . 59.1 mtt -53.66 -28.69 34.66 Favored 'General case' 0 C--N 1.332 -0.179 0 CA-C-N 116.34 -0.391 . . . . 0.0 111.417 -179.854 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 146' ' ' THR . . . . . . . . . . . . . 74.9 p -70.34 -50.43 39.12 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.233 -0.44 . . . . 0.0 112.063 -179.219 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 47.4 mt-10 -73.62 -24.13 59.99 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.546 -0.297 . . . . 0.0 111.797 -179.025 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 148' ' ' SER . . . . . 0.433 ' HG ' ' HA ' ' A' ' 145' ' ' MET . 81.4 p -70.78 -49.14 49.76 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 116.444 -0.343 . . . . 0.0 111.645 -179.281 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 149' ' ' ALA . . . . . 0.429 ' HB1' ' HA ' ' A' ' 91' ' ' ALA . . . -77.98 -38.83 44.21 Favored 'General case' 0 C--N 1.329 -0.319 0 N-CA-C 112.237 0.458 . . . . 0.0 112.237 -179.026 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 150' ' ' SER . . . . . . . . . . . . . 68.4 m -60.92 -8.13 2.92 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.537 -0.302 . . . . 0.0 111.705 -179.382 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 151' ' ' GLN . . . . . . . . . . . . . 78.2 mt-30 -119.02 25.19 10.36 Favored 'General case' 0 C--N 1.329 -0.296 0 N-CA-C 111.588 0.218 . . . . 0.0 111.588 -179.812 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 49.6 mtp180 -103.25 -52.24 3.07 Favored 'General case' 0 C--N 1.331 -0.197 0 CA-C-O 120.868 0.366 . . . . 0.0 111.153 179.717 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 153' ' ' SER . . . . . 0.558 ' HB3' HG12 ' A' ' 156' ' ' ILE . 32.8 t -157.02 169.16 25.44 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-N 115.981 -0.554 . . . . 0.0 110.854 179.407 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 154' ' ' SER . . . . . . . . . . . . . 37.0 t -70.39 -35.75 73.68 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.659 179.784 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -76.71 -31.47 53.71 Favored Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.883 -0.675 . . . . 0.0 112.503 179.827 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 156' ' ' ILE . . . . . 0.558 HG12 ' HB3' ' A' ' 153' ' ' SER . 36.2 mm -61.72 -37.63 78.48 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.234 0 CA-C-O 120.651 0.262 . . . . 0.0 111.1 -179.97 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 157' ' ' LYS . . . . . . . . . . . . . 57.8 tptt -60.73 -55.49 32.59 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 116.306 -0.407 . . . . 0.0 111.871 -179.445 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 62.2 m -60.61 -45.35 94.35 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.323 -0.398 . . . . 0.0 111.885 -179.125 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 159' ' ' LEU . . . . . . . . . . . . . 8.3 tt -68.35 -32.6 72.81 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-N 116.336 -0.393 . . . . 0.0 111.499 -179.198 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 160' ' ' TYR . . . . . . . . . . . . . 79.9 t80 -73.53 -45.62 52.61 Favored 'General case' 0 C--N 1.33 -0.261 0 N-CA-C 111.858 0.318 . . . . 0.0 111.858 -179.148 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 30.0 m -62.81 -40.85 90.28 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.363 0 N-CA-C 111.772 0.286 . . . . 0.0 111.772 -179.292 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 162' ' ' ARG . . . . . . . . . . . . . 29.1 tpt180 -69.35 -45.68 68.83 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.772 0.32 . . . . 0.0 111.388 -179.632 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 163' ' ' LEU . . . . . 0.584 ' HG ' ' HB2' ' A' ' 208' ' ' PHE . 4.3 mp -69.62 -52.5 25.43 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.806 -179.294 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 164' ' ' ARG . . . . . . . . . . . . . 4.6 tmm_? -53.88 -54.01 44.6 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.393 -0.367 . . . . 0.0 111.338 -179.163 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 165' ' ' ASN . . . . . 0.523 ' N ' HD21 ' A' ' 165' ' ' ASN . 0.9 OUTLIER -56.67 -43.78 80.74 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.937 0.398 . . . . 0.0 110.441 179.715 . . . . . . . . 3 3 . 1 . 021 nuclear orig core ' A' A ' 166' ' ' LEU . . . . . 0.548 ' O ' ' HG ' ' A' ' 170' ' ' LEU . 5.6 tp -57.84 -54.53 45.92 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 115.858 -0.61 . . . . 0.0 111.067 -179.938 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 167' ' ' THR . . . . . 0.543 ' HA ' HD12 ' A' ' 170' ' ' LEU . 89.0 m -54.07 -52.25 61.52 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 115.966 -0.561 . . . . 0.0 112.21 -178.925 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 168' ' ' VAL . . . . . . . . . . . . . 94.5 t -53.92 -40.14 43.46 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.366 0 N-CA-C 112.141 0.423 . . . . 0.0 112.141 -179.172 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 169' ' ' VAL . . . . . 0.454 HG23 ' O ' ' A' ' 165' ' ' ASN . 75.2 t -65.82 -65.57 0.56 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.326 0 N-CA-C 112.346 0.498 . . . . 0.0 112.346 -178.959 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 170' ' ' LEU . . . . . 0.571 HD21 HG13 ' A' ' 203' ' ' VAL . 1.0 OUTLIER -61.66 -28.78 69.63 Favored 'General case' 0 C--N 1.33 -0.25 0 N-CA-C 112.544 0.572 . . . . 0.0 112.544 -178.428 . . . . . . . . 3 3 . 1 . 021 nuclear orig core ' A' A ' 171' ' ' TRP . . . . . 0.505 ' N ' HD11 ' A' ' 170' ' ' LEU . 4.8 m0 -74.1 -30.77 62.5 Favored 'General case' 0 C--N 1.33 -0.277 0 C-N-CA 120.538 -0.465 . . . . 0.0 110.842 179.801 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 172' ' ' ALA . . . . . 0.434 ' HA ' ' CZ ' ' A' ' 134' ' ' PHE . . . -66.51 -7.87 22.75 Favored 'General case' 0 CA--C 1.516 -0.344 0 CA-C-O 121.273 0.559 . . . . 0.0 110.026 179.163 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 173' ' ' ILE . . . . . 0.564 ' O ' HG12 ' A' ' 177' ' ' ILE . 6.6 mm -87.19 -35.81 9.02 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.624 0 CA-C-N 115.123 -0.944 . . . . 0.0 111.47 -178.966 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 174' ' ' TYR . . . . . 0.519 ' N ' ' HD2' ' A' ' 175' ' ' PRO . 55.5 m-85 -54.95 -52.09 73.86 Favored Pre-proline 0 C--N 1.329 -0.323 0 N-CA-C 112.75 0.648 . . . . 0.0 112.75 -178.91 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 175' ' ' PRO . . . . . 0.519 ' HD2' ' N ' ' A' ' 174' ' ' TYR . 28.4 Cg_endo -61.99 -39.57 49.52 Favored 'Trans proline' 0 C--N 1.348 0.539 0 C-N-CA 121.963 1.775 . . . . 0.0 113.419 -178.351 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 176' ' ' PHE . . . . . 0.509 ' CE2' ' HA ' ' A' ' 173' ' ' ILE . 0.1 OUTLIER -79.99 -38.15 32.76 Favored 'General case' 0 C--N 1.329 -0.304 0 C-N-CA 120.688 -0.405 . . . . 0.0 111.904 -178.786 . . . . . . . . 3 3 . 1 . 021 nuclear orig core ' A' A ' 177' ' ' ILE . . . . . 0.564 HG12 ' O ' ' A' ' 173' ' ' ILE . 31.7 mm -62.42 -43.58 98.36 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.477 0 N-CA-C 109.723 -0.473 . . . . 0.0 109.723 178.285 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 178' ' ' TRP . . . . . . . . . . . . . 70.3 t90 -60.87 -27.68 68.31 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 115.687 -0.688 . . . . 0.0 109.418 178.789 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 179' ' ' LEU . . . . . . . . . . . . . 1.4 tm? -74.04 -45.8 47.32 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 115.187 -0.915 . . . . 0.0 110.764 -179.963 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 180' ' ' LEU . . . . . 0.466 ' HB3' HD12 ' A' ' 187' ' ' LEU . 4.8 mt -71.33 -49.34 43.54 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.615 -0.266 . . . . 0.0 111.394 -179.372 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . -52.61 174.81 0.2 Allowed Glycine 0 C--N 1.334 0.43 0 C-N-CA 120.659 -0.781 . . . . 0.0 112.937 -179.954 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 182' ' ' PRO . . . . . 0.508 ' HA ' ' HB1' ' A' ' 186' ' ' ALA . 76.4 Cg_exo -46.93 -45.35 21.01 Favored 'Trans proline' 0 CA--C 1.536 0.602 0 C-N-CA 122.853 2.368 . . . . 0.0 113.796 -179.874 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 183' ' ' PRO . . . . . 0.452 ' HD3' ' HB2' ' A' ' 182' ' ' PRO . 79.5 Cg_exo -49.27 -23.48 6.98 Favored 'Trans proline' 0 C--N 1.355 0.908 0 C-N-CA 122.24 1.96 . . . . 0.0 113.194 -179.787 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 184' ' ' GLY . . . . . . . . . . . . . . . -108.74 -99.06 2.58 Favored Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.466 -0.873 . . . . 0.0 113.069 -179.57 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 185' ' ' VAL . . . . . . . . . . . . . 3.5 m -109.07 -5.49 10.89 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 N-CA-C 111.726 0.269 . . . . 0.0 111.726 -179.231 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 186' ' ' ALA . . . . . 0.508 ' HB1' ' HA ' ' A' ' 182' ' ' PRO . . . 55.14 87.28 0.05 OUTLIER 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.366 -0.379 . . . . 0.0 111.629 179.542 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 187' ' ' LEU . . . . . 0.466 HD12 ' HB3' ' A' ' 180' ' ' LEU . 23.5 mt -91.81 -48.97 6.5 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.332 -0.394 . . . . 0.0 110.779 179.637 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 188' ' ' LEU . . . . . . . . . . . . . 55.6 mt -106.9 -154.14 0.51 Allowed 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 115.835 -0.621 . . . . 0.0 110.642 -179.905 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 189' ' ' THR . . . . . . . . . . . . . 2.6 t -97.52 146.16 30.92 Favored Pre-proline 0 C--N 1.329 -0.315 0 CA-C-N 116.406 -0.361 . . . . 0.0 110.918 179.905 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 190' ' ' PRO . . . . . . . . . . . . . 9.6 Cg_endo -50.14 -38.46 50.58 Favored 'Trans proline' 0 C--N 1.349 0.597 0 C-N-CA 122.862 2.374 . . . . 0.0 112.769 -179.594 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 191' ' ' THR . . . . . . . . . . . . . 81.6 p -58.25 -44.34 88.27 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.911 0.386 . . . . 0.0 111.249 -179.842 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 192' ' ' VAL . . . . . . . . . . . . . 35.1 t -71.85 -43.13 69.41 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.391 0 CA-C-N 116.03 -0.532 . . . . 0.0 111.401 -179.708 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 193' ' ' ASP . . . . . . . . . . . . . 21.1 t70 -56.55 -49.01 76.07 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.403 -0.362 . . . . 0.0 111.186 -179.783 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 194' ' ' VAL . . . . . . . . . . . . . 78.2 t -64.42 -38.15 81.82 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.372 0 CA-C-N 116.262 -0.426 . . . . 0.0 111.198 -179.723 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 195' ' ' ALA . . . . . . . . . . . . . . . -54.15 -48.59 70.69 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 116.518 -0.31 . . . . 0.0 111.482 -179.802 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 196' ' ' LEU . . . . . 0.447 ' O ' ' HB3' ' A' ' 199' ' ' TYR . 94.3 mt -65.65 -39.96 91.97 Favored 'General case' 0 C--N 1.332 -0.166 0 CA-C-O 120.777 0.322 . . . . 0.0 110.814 179.884 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 197' ' ' ILE . . . . . . . . . . . . . 24.7 mm -58.73 -53.42 47.52 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.37 0 CA-C-O 121.017 0.437 . . . . 0.0 110.198 179.307 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 198' ' ' VAL . . . . . . . . . . . . . 87.6 t -55.07 -34.64 32.57 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.459 0 CA-C-N 115.582 -0.736 . . . . 0.0 109.04 178.215 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 199' ' ' TYR . . . . . 0.447 ' HB3' ' O ' ' A' ' 196' ' ' LEU . 79.7 t80 -69.73 -32.58 71.2 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 114.98 -1.009 . . . . 0.0 110.643 179.635 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 200' ' ' LEU . . . . . 0.467 HD13 HG21 ' A' ' 173' ' ' ILE . 68.2 mt -69.17 -41.04 77.74 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 115.756 -0.656 . . . . 0.0 111.697 -179.373 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 201' ' ' ASP . . . . . . . . . . . . . 9.5 m-20 -71.39 -36.31 71.34 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 121.162 0.506 . . . . 0.0 110.451 179.529 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 202' ' ' LEU . . . . . 0.406 ' O ' ' HB ' ' A' ' 206' ' ' VAL . 1.2 mm? -65.99 -33.64 76.27 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 115.462 -0.79 . . . . 0.0 111.918 -179.731 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 203' ' ' VAL . . . . . 0.571 HG13 HD21 ' A' ' 170' ' ' LEU . 9.0 p -79.07 -36.3 18.31 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 N-CA-C 111.885 0.328 . . . . 0.0 111.885 -178.241 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 204' ' ' THR . . . . . . . . . . . . . 94.1 m -64.77 -58.93 4.91 Favored 'General case' 0 C--N 1.328 -0.343 0 C-N-CA 120.082 -0.647 . . . . 0.0 111.101 179.642 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 205' ' ' LYS . . . . . 0.659 ' HD2' ' HE3' ' A' ' 15' ' ' MET . 60.1 mttp -68.35 -57.83 5.31 Favored 'General case' 0 C--N 1.33 -0.281 0 N-CA-C 112.774 0.657 . . . . 0.0 112.774 -178.028 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 206' ' ' VAL . . . . . 0.406 ' HB ' ' O ' ' A' ' 202' ' ' LEU . 19.3 t -71.16 -37.17 65.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 N-CA-C 112.02 0.378 . . . . 0.0 112.02 -178.654 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 207' ' ' GLY . . . . . 0.494 ' O ' HG13 ' A' ' 211' ' ' ILE . . . -61.75 -61.1 7.12 Favored Glycine 0 N--CA 1.452 -0.263 0 C-N-CA 120.577 -0.821 . . . . 0.0 113.72 -178.997 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 208' ' ' PHE . . . . . 0.584 ' HB2' ' HG ' ' A' ' 163' ' ' LEU . 0.1 OUTLIER -68.84 -29.95 68.38 Favored 'General case' 0 C--O 1.222 -0.362 0 CA-C-N 117.799 0.799 . . . . 0.0 110.8 -179.292 . . . . . . . . 3 3 . 1 . 021 nuclear orig core ' A' A ' 209' ' ' GLY . . . . . 0.576 ' HA2' HD13 ' A' ' 40' ' ' LEU . . . -62.07 -35.66 91.78 Favored Glycine 0 N--CA 1.45 -0.368 0 CA-C-N 116.189 -0.46 . . . . 0.0 112.418 179.4 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 210' ' ' PHE . . . . . . . . . . . . . 3.3 m-85 -72.68 -47.38 47.79 Favored 'General case' 0 CA--C 1.513 -0.461 0 N-CA-C 108.513 -0.921 . . . . 0.0 108.513 178.81 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 211' ' ' ILE . . . . . 0.494 HG13 ' O ' ' A' ' 207' ' ' GLY . 3.7 mt -62.8 -27.32 42.8 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.58 0 N-CA-C 107.192 -1.41 . . . . 0.0 107.192 176.468 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 212' ' ' ALA . . . . . 0.505 ' HB3' ' O ' ' A' ' 209' ' ' GLY . . . -67.43 -36.55 81.44 Favored 'General case' 0 N--CA 1.45 -0.468 0 CA-C-N 114.308 -1.314 . . . . 0.0 110.171 179.56 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 213' ' ' LEU . . . . . 0.424 ' HG ' ' O ' ' A' ' 209' ' ' GLY . 81.3 mt -70.17 -53.38 17.45 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 115.012 -0.994 . . . . 0.0 111.594 -179.649 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 214' ' ' ASP . . . . . . . . . . . . . 16.5 m-20 -57.44 -51.54 69.02 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.827 0.346 . . . . 0.0 111.227 -179.592 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 215' ' ' ALA . . . . . . . . . . . . . . . -56.63 -57.25 13.19 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.226 -179.762 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 216' ' ' ALA . . . . . . . . . . . . . . . -58.4 -33.81 70.06 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.275 -0.421 . . . . 0.0 111.387 -179.741 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 217' ' ' ALA . . . . . . . . . . . . . . . -61.04 -34.68 75.25 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 121.029 0.442 . . . . 0.0 110.137 179.635 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 218' ' ' THR . . . . . . . . . . . . . 91.5 m . . . . . 0 C--N 1.331 -0.231 0 CA-C-N 115.716 -0.675 . . . . 0.0 110.821 179.48 . . . . . . . . 0 0 . 1 . 022 nuclear orig core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.261 0 N-CA-C 112.719 -0.152 . . . . 0.0 112.719 . . . . . . . . . 0 0 . 1 . 022 nuclear orig core ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -73.74 -40.67 63.35 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.858 0.361 . . . . 0.0 110.772 -179.929 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 76.4 p -60.52 -29.49 69.15 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.329 -179.842 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 13.6 p -57.38 -36.13 70.87 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.502 -179.715 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 7' ' ' LEU . . . . . . . . . . . . . 4.1 mm? -57.56 -53.16 61.29 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-N 116.328 -0.396 . . . . 0.0 111.165 -179.839 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 8' ' ' PHE . . . . . 0.457 ' HB2' ' HB2' ' A' ' 55' ' ' ALA . 78.9 m-85 -60.91 -33.48 73.2 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 120.866 0.365 . . . . 0.0 110.752 179.901 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 9' ' ' TRP . . . . . . . . . . . . . 18.9 m95 -63.78 -45.34 90.16 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-O 121.245 0.545 . . . . 0.0 109.678 179.82 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 72.3 mt -63.45 -34.34 77.55 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-N 115.383 -0.826 . . . . 0.0 110.12 179.302 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -66.29 -37.02 92.5 Favored Glycine 0 N--CA 1.449 -0.46 0 C-N-CA 120.77 -0.728 . . . . 0.0 111.596 179.179 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -66.74 -33.18 75.06 Favored 'General case' 0 C--N 1.332 -0.17 0 CA-C-O 120.961 0.41 . . . . 0.0 110.303 179.337 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 45.0 mm -65.19 -50.79 71.99 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.212 0 CA-C-N 115.904 -0.589 . . . . 0.0 110.235 179.099 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -59.35 -31.42 69.88 Favored Glycine 0 N--CA 1.449 -0.466 0 C-N-CA 120.773 -0.727 . . . . 0.0 111.836 179.394 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 15' ' ' MET . . . . . 0.647 ' HE1' ' HD2' ' A' ' 205' ' ' LYS . 22.0 mmt -70.87 -45.61 64.11 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-O 120.686 0.279 . . . . 0.0 110.583 179.586 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 21.8 tp -54.66 -38.31 66.78 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.668 179.59 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 64.2 t -67.06 -47.54 81.76 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.191 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.03 179.927 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -64.65 -49.45 64.22 Favored Glycine 0 C--N 1.331 0.281 0 C-N-CA 120.684 -0.77 . . . . 0.0 112.17 179.679 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 22.2 m -49.56 -46.22 48.55 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-O 120.72 0.295 . . . . 0.0 111.12 -179.807 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 85.6 mt -72.22 -40.01 68.11 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-N 116.359 -0.382 . . . . 0.0 111.403 179.646 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -61.28 -30.17 70.31 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.454 -0.339 . . . . 0.0 111.817 -179.484 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 22' ' ' PHE . . . . . 0.515 ' HB2' HG21 ' A' ' 41' ' ' VAL . 13.7 m-85 -90.74 -40.43 11.84 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.735 0.302 . . . . 0.0 111.149 -179.622 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -62.75 -50.71 69.97 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.343 -179.732 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 24' ' ' TRP . . . . . . . . . . . . . 2.2 t-105 -60.96 -41.7 96.84 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 115.968 -0.56 . . . . 0.0 111.042 -179.945 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.329 -0.302 0 CA-C-O 120.877 0.37 . . . . 0.0 110.946 179.752 . . . . . . . . 0 0 . 1 . 022 nuclear orig core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.305 0 N-CA-C 112.593 -0.203 . . . . 0.0 112.593 . . . . . . . . . 0 0 . 1 . 022 nuclear orig core ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 12.7 mm-40 -69.34 -20.88 63.86 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-O 120.86 0.362 . . . . 0.0 110.917 179.95 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 34' ' ' ARG . . . . . . . . . . . . . 41.5 ttm180 -51.02 -29.01 11.38 Favored 'General case' 0 C--N 1.332 -0.185 0 CA-C-N 115.958 -0.564 . . . . 0.0 111.539 -179.772 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 86.4 mtm180 -61.99 -45.89 91.65 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.899 0.38 . . . . 0.0 110.917 -179.969 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 88.0 m-85 -67.55 -29.26 68.59 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.044 -0.526 . . . . 0.0 111.224 179.961 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 37' ' ' TYR . . . . . . . . . . . . . 51.7 m-85 -74.6 -54.11 8.08 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.255 -179.577 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 9.4 p -56.99 -36.6 51.18 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-O 120.949 0.405 . . . . 0.0 110.474 179.794 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 48.3 m -65.66 -51.37 60.04 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 115.901 -0.59 . . . . 0.0 110.608 179.493 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 16.6 tp -57.05 -47.24 81.43 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 115.832 -0.622 . . . . 0.0 110.624 179.702 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . 0.515 HG21 ' HB2' ' A' ' 22' ' ' PHE . 64.8 t -60.0 -34.74 57.45 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.41 0 CA-C-N 115.836 -0.62 . . . . 0.0 110.11 179.183 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -60.31 -36.2 90.3 Favored Glycine 0 N--CA 1.449 -0.448 0 C-N-CA 120.682 -0.77 . . . . 0.0 111.817 179.494 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 43' ' ' ILE . . . . . 0.542 HG22 ' HE3' ' A' ' 205' ' ' LYS . 0.8 OUTLIER -67.31 -57.27 10.38 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.139 0 CA-C-O 120.65 0.262 . . . . 0.0 110.817 179.44 . . . . . . . . 3 3 . 1 . 022 nuclear orig core ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 55.6 m -57.11 -25.0 58.07 Favored 'General case' 0 C--O 1.231 0.113 0 CA-C-N 116.42 -0.354 . . . . 0.0 111.188 -179.945 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -77.33 -54.71 4.59 Favored Glycine 0 CA--C 1.518 0.267 0 C-N-CA 120.793 -0.718 . . . . 0.0 113.162 -179.504 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 25.8 pt -58.06 -40.89 78.92 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.185 0 CA-C-O 120.93 0.395 . . . . 0.0 111.01 -179.647 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 47' ' ' ALA . . . . . 0.645 ' HB2' ' HE2' ' A' ' 205' ' ' LYS . . . -67.92 -38.62 83.13 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.004 179.205 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 48' ' ' ALA . . . . . 0.415 ' HB3' ' HB3' ' A' ' 15' ' ' MET . . . -55.41 -44.56 76.29 Favored 'General case' 0 C--O 1.232 0.152 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.733 -179.708 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 30.5 m -72.56 -33.82 46.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.544 -0.298 . . . . 0.0 111.141 -179.562 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -63.37 -36.62 84.31 Favored 'General case' 0 C--N 1.331 -0.206 0 CA-C-O 120.989 0.424 . . . . 0.0 110.748 179.473 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 28.5 m-85 -73.0 -36.25 67.0 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 115.915 -0.584 . . . . 0.0 110.442 179.794 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -65.47 -42.35 92.35 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 115.979 -0.555 . . . . 0.0 110.957 179.54 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 53' ' ' VAL . . . . . 0.458 HG22 ' N ' ' A' ' 54' ' ' MET . 25.4 m -71.48 -47.33 59.17 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.188 0 CA-C-N 116.451 -0.341 . . . . 0.0 110.83 179.821 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 54' ' ' MET . . . . . 0.474 ' HG2' ' HG2' ' A' ' 71' ' ' PRO . 72.6 mtm -62.14 -31.97 72.51 Favored 'General case' 0 C--N 1.332 -0.19 0 CA-C-O 121.058 0.456 . . . . 0.0 110.007 179.439 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 55' ' ' ALA . . . . . 0.457 ' HB2' ' HB2' ' A' ' 8' ' ' PHE . . . -67.31 -32.51 73.53 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 115.701 -0.681 . . . . 0.0 111.04 179.306 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 76.3 mt -79.77 -4.4 51.82 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.28 -179.871 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 90.82 -16.09 59.12 Favored Glycine 0 CA--C 1.518 0.234 0 C-N-CA 120.539 -0.839 . . . . 0.0 113.288 179.54 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 58' ' ' VAL . . . . . 0.418 HG13 ' O ' ' A' ' 53' ' ' VAL . 13.0 p -67.4 144.37 14.6 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 117.108 0.454 . . . . 0.0 110.819 -179.884 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 94.05 -12.47 69.12 Favored Glycine 0 N--CA 1.45 -0.412 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.053 -179.461 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 60' ' ' TRP . . . . . . . . . . . . . 13.3 m0 -80.02 111.15 16.08 Favored 'General case' 0 C--N 1.331 -0.213 0 N-CA-C 110.329 -0.249 . . . . 0.0 110.329 179.703 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 6.9 p -111.29 129.56 23.93 Favored Pre-proline 0 C--N 1.329 -0.305 0 CA-C-N 116.61 -0.268 . . . . 0.0 111.201 -179.866 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 60.1 Cg_endo -71.81 152.15 57.96 Favored 'Trans proline' 0 C--N 1.35 0.618 0 C-N-CA 122.373 2.048 . . . . 0.0 112.292 179.96 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 93.7 t -143.38 94.37 0.51 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 115.929 -0.578 . . . . 0.0 110.761 -179.74 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . 58.19 -87.04 0.02 OUTLIER 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.11 -179.813 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 12.1 mm-40 -120.84 -23.19 6.0 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.288 -0.415 . . . . 0.0 110.591 179.773 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 66' ' ' ARG . . . . . . . . . . . . . 20.3 mmm180 -98.69 165.95 11.56 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.013 -0.539 . . . . 0.0 110.449 179.994 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 88.1 m -128.1 123.36 34.31 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-O 120.898 0.38 . . . . 0.0 111.173 179.947 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 68' ' ' VAL . . . . . 0.407 HG11 ' HB1' ' A' ' 116' ' ' ALA . 27.3 m -106.73 146.68 12.89 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.054 -0.521 . . . . 0.0 110.702 179.834 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 69' ' ' PHE . . . . . . . . . . . . . 21.7 m-85 -106.59 112.92 26.13 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 116.132 -0.485 . . . . 0.0 109.989 -179.511 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 70' ' ' VAL . . . . . 0.566 ' N ' ' HD2' ' A' ' 71' ' ' PRO . 15.0 t -66.31 -47.9 58.82 Favored Pre-proline 0 C--N 1.322 -0.61 0 CA-C-N 116.24 -0.436 . . . . 0.0 112.076 -179.293 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 71' ' ' PRO . . . . . 0.566 ' HD2' ' N ' ' A' ' 70' ' ' VAL . 40.5 Cg_endo -66.16 -18.07 55.67 Favored 'Trans proline' 0 C--N 1.351 0.697 0 C-N-CA 122.115 1.877 . . . . 0.0 113.274 -179.327 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 72.3 ttt180 -72.85 -55.49 6.58 Favored 'General case' 0 C--O 1.235 0.296 0 CA-C-O 120.664 0.268 . . . . 0.0 111.712 -179.434 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 73' ' ' TYR . . . . . . . . . . . . . 71.5 m-85 -70.52 -31.58 68.72 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.524 -0.307 . . . . 0.0 110.769 -179.321 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 74' ' ' ILE . . . . . 0.406 ' HA ' HD12 ' A' ' 77' ' ' ILE . 0.4 OUTLIER -69.97 -39.56 77.59 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.229 0 N-CA-C 109.793 -0.447 . . . . 0.0 109.793 179.137 . . . . . . . . 3 3 . 1 . 022 nuclear orig core ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 18.8 t70 -58.55 -37.6 76.07 Favored 'General case' 0 CA--C 1.519 -0.232 0 N-CA-C 109.25 -0.648 . . . . 0.0 109.25 178.713 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 76' ' ' TRP . . . . . 0.461 ' HB3' ' SD ' ' A' ' 109' ' ' MET . 43.9 m0 -66.97 -34.99 78.97 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 115.742 -0.663 . . . . 0.0 110.194 178.926 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 77' ' ' ILE . . . . . 0.406 HD12 ' HA ' ' A' ' 74' ' ' ILE . 97.0 mt -65.43 -28.65 44.93 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 115.948 -0.569 . . . . 0.0 110.688 179.497 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 38.3 mt -91.86 -25.01 19.16 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.223 -0.444 . . . . 0.0 112.12 -179.955 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 79' ' ' THR . . . . . 0.46 ' HG1' ' H ' ' A' ' 80' ' ' THR . 67.2 p -92.69 -52.31 4.69 Favored 'General case' 0 N--CA 1.464 0.261 0 N-CA-C 113.671 0.989 . . . . 0.0 113.671 -177.74 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 80' ' ' THR . . . . . 0.46 ' H ' ' HG1' ' A' ' 79' ' ' THR . 33.4 m -49.33 -54.55 28.8 Favored Pre-proline 0 C--N 1.329 -0.314 0 N-CA-C 113.159 0.8 . . . . 0.0 113.159 -178.163 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 81' ' ' PRO . . . . . 0.427 ' HD2' ' N ' ' A' ' 80' ' ' THR . 36.6 Cg_endo -63.13 -19.11 68.02 Favored 'Trans proline' 0 C--N 1.351 0.674 0 C-N-CA 121.463 1.442 . . . . 0.0 111.376 -179.513 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 82' ' ' LEU . . . . . . . . . . . . . 14.1 tp -77.05 -33.54 57.24 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 115.643 -0.708 . . . . 0.0 110.256 179.727 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 83' ' ' ILE . . . . . 0.407 HD11 HD12 ' A' ' 43' ' ' ILE . 32.8 mm -68.89 -52.62 32.83 Favored 'Isoleucine or valine' 0 C--O 1.232 0.174 0 CA-C-N 115.98 -0.555 . . . . 0.0 109.867 179.05 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 27.9 m -61.21 -30.39 47.74 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.209 0 N-CA-C 109.513 -0.551 . . . . 0.0 109.513 178.797 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 85' ' ' TYR . . . . . . . . . . . . . 82.7 t80 -65.87 -32.91 74.69 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 115.48 -0.782 . . . . 0.0 109.347 178.741 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 86' ' ' PHE . . . . . . . . . . . . . 10.8 t80 -63.91 -51.74 63.08 Favored 'General case' 0 N--CA 1.456 -0.133 0 CA-C-N 115.681 -0.691 . . . . 0.0 109.956 179.219 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 8.8 mp -61.32 -32.66 72.53 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 115.701 -0.681 . . . . 0.0 110.457 179.67 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -68.71 -27.96 73.47 Favored Glycine 0 N--CA 1.45 -0.407 0 C-N-CA 120.731 -0.747 . . . . 0.0 111.65 179.368 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 47.5 mt -72.13 -41.8 66.77 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.87 0.367 . . . . 0.0 110.646 179.539 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 57.0 mt -65.16 -45.8 83.47 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 115.951 -0.568 . . . . 0.0 111.059 179.942 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 91' ' ' ALA . . . . . 0.465 ' HB3' ' HB3' ' A' ' 148' ' ' SER . . . -71.55 -55.2 8.28 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.318 -0.401 . . . . 0.0 111.167 -179.696 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 99.5 67.62 0.86 Allowed Glycine 0 CA--C 1.519 0.283 0 C-N-CA 120.812 -0.709 . . . . 0.0 112.684 179.893 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 9.2 mp -75.34 -172.74 1.85 Allowed 'General case' 0 C--N 1.33 -0.245 0 CA-C-O 120.74 0.305 . . . . 0.0 110.856 179.911 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 94' ' ' ASP . . . . . . . . . . . . . 6.7 m-20 -96.91 -173.98 2.86 Favored 'General case' 0 C--N 1.332 -0.174 0 CA-C-O 121.073 0.464 . . . . 0.0 111.266 -179.823 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 50.4 m -67.64 -51.58 48.34 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 115.78 -0.646 . . . . 0.0 111.308 -179.793 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 79.8 ttt180 -74.22 -34.86 63.82 Favored 'General case' 0 C--N 1.331 -0.197 0 CA-C-O 120.964 0.412 . . . . 0.0 110.575 -179.579 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -56.88 -45.15 82.72 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 115.687 -0.688 . . . . 0.0 111.241 -179.812 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 98' ' ' PHE . . . . . 0.418 ' O ' HG12 ' A' ' 102' ' ' ILE . 4.8 m-85 -62.17 -42.92 99.73 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.834 0.35 . . . . 0.0 110.71 179.487 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -62.6 -28.8 72.01 Favored Glycine 0 N--CA 1.45 -0.401 0 C-N-CA 120.8 -0.714 . . . . 0.0 112.682 -179.865 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 96.1 mt -72.46 -41.91 64.32 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.234 0 CA-C-O 120.873 0.368 . . . . 0.0 111.198 -179.927 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 53.8 t -67.45 -43.64 87.34 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.32 -179.932 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 102' ' ' ILE . . . . . 0.418 HG12 ' O ' ' A' ' 98' ' ' PHE . 43.0 mm -68.07 -49.59 66.49 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.63 -179.495 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 14.9 t -57.71 -33.59 68.57 Favored 'General case' 0 C--O 1.233 0.186 0 CA-C-O 120.762 0.315 . . . . 0.0 111.173 -179.701 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 41.2 tp -65.75 -48.16 72.84 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.3 -0.409 . . . . 0.0 110.545 179.601 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 105' ' ' ASN . . . . . 0.59 ' N ' HD21 ' A' ' 105' ' ' ASN . 0.8 OUTLIER -61.16 -26.08 67.45 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.766 179.758 . . . . . . . . 3 3 . 1 . 022 nuclear orig core ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 91.6 m -69.07 -57.6 5.2 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-N 116.378 -0.374 . . . . 0.0 111.425 -179.934 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 8.3 p -58.58 -37.32 64.3 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.237 0 CA-C-N 116.531 -0.304 . . . . 0.0 110.942 -179.816 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 73.9 t -66.46 -51.97 51.76 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.898 179.532 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 109' ' ' MET . . . . . 0.461 ' SD ' ' HB3' ' A' ' 76' ' ' TRP . 9.8 tpp -61.36 -32.61 72.52 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.018 -0.537 . . . . 0.0 110.387 179.753 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 10.0 mt -72.31 -30.29 64.64 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 115.848 -0.615 . . . . 0.0 109.939 179.38 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -60.06 -45.63 92.22 Favored 'General case' 0 CA--C 1.519 -0.234 0 N-CA-C 109.249 -0.649 . . . . 0.0 109.249 178.248 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . -70.26 -41.74 67.98 Favored Glycine 0 N--CA 1.449 -0.441 0 CA-C-N 115.501 -0.772 . . . . 0.0 111.19 178.392 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 113' ' ' PHE . . . . . . . . . . . . . 2.0 t80 -48.81 -65.95 0.48 Allowed 'General case' 0 CA--C 1.52 -0.186 0 N-CA-C 109.353 -0.61 . . . . 0.0 109.353 178.82 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 114' ' ' ALA . . . . . 0.484 ' HB1' HD22 ' A' ' 126' ' ' LEU . . . -64.41 -19.23 65.38 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 115.467 -0.788 . . . . 0.0 110.406 178.699 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -53.1 -51.1 48.59 Favored Glycine 0 C--N 1.335 0.488 0 C-N-CA 120.892 -0.671 . . . . 0.0 111.86 179.495 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 116' ' ' ALA . . . . . 0.407 ' HB1' HG11 ' A' ' 68' ' ' VAL . . . -78.02 -18.44 55.87 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-O 120.87 0.367 . . . . 0.0 110.948 179.279 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 117' ' ' MET . . . . . 0.464 ' HB2' ' HA ' ' A' ' 114' ' ' ALA . 22.3 mmt -81.9 18.56 1.28 Allowed 'General case' 0 C--N 1.331 -0.218 0 CA-C-N 116.015 -0.539 . . . . 0.0 111.673 -179.441 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 118' ' ' VAL . . . . . 0.432 HG11 ' N ' ' A' ' 123' ' ' ARG . 32.6 m -89.85 138.71 27.72 Favored Pre-proline 0 C--N 1.327 -0.371 0 CA-C-N 116.73 -0.213 . . . . 0.0 111.375 -179.95 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 119' ' ' PRO . . . . . . . . . . . . . 70.3 Cg_endo -89.98 -3.76 5.4 Favored 'Trans proline' 0 N--CA 1.456 -0.692 0 C-N-CA 122.73 2.286 . . . . 0.0 112.235 179.61 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -138.2 -110.83 0.97 Allowed Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.908 -179.765 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 46.8 pt -126.99 14.93 3.6 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.214 0 CA-C-O 120.738 0.304 . . . . 0.0 111.585 -179.384 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 25.6 mt-10 -61.74 -18.64 60.53 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-N 116.353 -0.385 . . . . 0.0 111.041 -179.8 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 123' ' ' ARG . . . . . 0.449 ' HB2' ' HH2' ' A' ' 178' ' ' TRP . 7.6 ptt180 -52.6 -30.12 29.5 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 115.976 -0.557 . . . . 0.0 112.085 -179.66 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 124' ' ' TYR . . . . . . . . . . . . . 50.9 m-85 -69.16 -32.44 71.79 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.794 0.331 . . . . 0.0 111.364 -179.668 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 125' ' ' ALA . . . . . . . . . . . . . . . -72.59 -56.14 5.81 Favored 'General case' 0 C--O 1.236 0.346 0 CA-C-N 116.304 -0.407 . . . . 0.0 111.296 -179.504 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 126' ' ' LEU . . . . . 0.484 HD22 ' HB1' ' A' ' 114' ' ' ALA . 1.2 mt -51.49 -45.35 62.79 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 115.839 -0.619 . . . . 0.0 110.922 -179.821 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 127' ' ' PHE . . . . . . . . . . . . . 3.6 t80 -67.65 -38.64 84.11 Favored 'General case' 0 C--N 1.33 -0.269 0 C-N-CA 120.874 -0.33 . . . . 0.0 110.394 179.581 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 128' ' ' GLY . . . . . . . . . . . . . . . -46.48 -43.1 14.56 Favored Glycine 0 C--N 1.332 0.337 0 C-N-CA 120.21 -0.995 . . . . 0.0 110.991 179.219 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 129' ' ' MET . . . . . 0.435 ' HE2' ' N ' ' A' ' 130' ' ' GLY . 0.4 OUTLIER -71.59 -41.32 69.13 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 115.383 -0.408 . . . . 0.0 110.18 179.04 . . . . . . . . 3 3 . 1 . 022 nuclear orig core ' A' A ' 130' ' ' GLY . . . . . 0.435 ' N ' ' HE2' ' A' ' 129' ' ' MET . . . -63.61 -28.98 73.34 Favored Glycine 0 C--N 1.332 0.321 0 C-N-CA 121.066 -0.588 . . . . 0.0 113.016 -179.665 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -74.69 -53.64 8.89 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.729 0.265 . . . . 0.0 110.529 -179.901 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 61.4 t -59.32 -40.47 81.52 Favored 'Isoleucine or valine' 0 C--O 1.234 0.289 0 N-CA-C 109.205 -0.665 . . . . 0.0 109.205 178.832 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -67.51 -34.08 76.38 Favored 'General case' 0 N--CA 1.452 -0.353 0 CA-C-N 115.201 -0.908 . . . . 0.0 110.48 179.175 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 134' ' ' PHE . . . . . 0.424 ' CZ ' ' HA ' ' A' ' 172' ' ' ALA . 82.2 t80 -56.04 -52.59 63.7 Favored 'General case' 0 N--CA 1.451 -0.417 0 CA-C-N 116.072 -0.513 . . . . 0.0 109.875 179.328 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 135' ' ' ILE . . . . . 0.478 ' HA ' HG23 ' A' ' 138' ' ' VAL . 53.3 mt -58.14 -34.31 49.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 115.798 -0.637 . . . . 0.0 109.855 179.094 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . -63.73 -36.62 93.56 Favored Glycine 0 C--N 1.334 0.422 0 C-N-CA 120.312 -0.947 . . . . 0.0 111.356 178.75 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 137' ' ' LEU . . . . . 0.4 HD13 HD22 ' A' ' 105' ' ' ASN . 35.1 tp -71.24 -53.56 13.95 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.7 0.286 . . . . 0.0 110.453 179.448 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 138' ' ' VAL . . . . . 0.478 HG23 ' HA ' ' A' ' 135' ' ' ILE . 5.3 m -55.98 -31.94 32.02 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.218 0 CA-C-O 121.164 0.507 . . . . 0.0 109.656 179.458 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 139' ' ' TYR . . . . . . . . . . . . . 38.6 t80 -60.82 -47.99 83.83 Favored 'General case' 0 N--CA 1.454 -0.228 0 CA-C-N 115.528 -0.76 . . . . 0.0 109.909 178.511 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 15.5 m-85 -56.5 -37.98 71.13 Favored 'General case' 0 C--N 1.334 -0.093 0 CA-C-N 116.056 -0.52 . . . . 0.0 110.81 179.22 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 141' ' ' LEU . . . . . . . . . . . . . 70.5 mt -64.28 -34.95 79.29 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.057 -0.519 . . . . 0.0 110.708 -179.853 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 13.8 t -94.29 -7.57 10.03 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.79 179.828 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . -73.89 -131.8 0.21 Allowed Glycine 0 CA--C 1.521 0.43 0 C-N-CA 120.891 -0.671 . . . . 0.0 112.673 -179.765 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 144' ' ' PRO . . . . . . . . . . . . . 28.1 Cg_endo -62.04 -23.7 75.95 Favored 'Trans proline' 0 C--N 1.347 0.478 0 C-N-CA 122.528 2.152 . . . . 0.0 112.673 -179.859 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 145' ' ' MET . . . . . . . . . . . . . 52.4 mtt -53.99 -32.02 52.78 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-O 120.661 0.267 . . . . 0.0 111.436 -179.815 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 146' ' ' THR . . . . . . . . . . . . . 73.2 p -72.06 -46.0 58.59 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.426 -0.352 . . . . 0.0 111.479 -179.693 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 42.4 mt-10 -72.7 -28.11 62.48 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.471 -179.64 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 148' ' ' SER . . . . . 0.465 ' HB3' ' HB3' ' A' ' 91' ' ' ALA . 32.6 t -70.32 -43.87 69.42 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-O 120.754 0.311 . . . . 0.0 111.105 -179.622 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 149' ' ' ALA . . . . . . . . . . . . . . . -75.11 -40.12 60.13 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.147 -0.479 . . . . 0.0 111.198 -179.838 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 150' ' ' SER . . . . . . . . . . . . . 69.0 m -63.61 -22.91 67.15 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.096 -179.909 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 151' ' ' GLN . . . . . . . . . . . . . 46.2 mt-30 -105.53 6.82 32.6 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.263 -0.426 . . . . 0.0 111.435 -179.751 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 31.9 tpt180 -84.11 -51.7 6.87 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.88 0.372 . . . . 0.0 110.542 179.646 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 153' ' ' SER . . . . . 0.545 ' HB3' HG12 ' A' ' 156' ' ' ILE . 23.1 t -157.67 169.98 23.43 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-N 115.902 -0.59 . . . . 0.0 110.449 179.091 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 154' ' ' SER . . . . . . . . . . . . . 82.7 p -71.01 -39.72 72.22 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.788 0.328 . . . . 0.0 110.5 179.555 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -77.09 -36.6 34.94 Favored Glycine 0 N--CA 1.452 -0.241 0 C-N-CA 120.864 -0.684 . . . . 0.0 112.595 179.752 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 156' ' ' ILE . . . . . 0.545 HG12 ' HB3' ' A' ' 153' ' ' SER . 28.4 mm -51.64 -38.18 21.17 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.215 0 CA-C-O 120.623 0.249 . . . . 0.0 111.438 -179.859 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 157' ' ' LYS . . . . . . . . . . . . . 63.6 tttp -60.03 -48.78 80.3 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.283 -0.417 . . . . 0.0 111.678 -179.795 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 41.3 t -63.78 -47.48 80.75 Favored 'General case' 0 C--N 1.328 -0.351 0 N-CA-C 111.96 0.355 . . . . 0.0 111.96 -179.095 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 159' ' ' LEU . . . . . 0.401 ' O ' HD22 ' A' ' 159' ' ' LEU . 1.6 tt -67.71 -31.81 72.02 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 116.494 -0.321 . . . . 0.0 111.28 -179.326 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 160' ' ' TYR . . . . . . . . . . . . . 79.9 t80 -74.05 -44.42 54.33 Favored 'General case' 0 C--N 1.329 -0.315 0 N-CA-C 111.946 0.35 . . . . 0.0 111.946 -179.218 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 161' ' ' VAL . . . . . 0.402 HG23 ' N ' ' A' ' 162' ' ' ARG . 30.4 m -62.01 -41.18 90.03 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 N-CA-C 111.691 0.256 . . . . 0.0 111.691 -179.205 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 162' ' ' ARG . . . . . 0.402 ' N ' HG23 ' A' ' 161' ' ' VAL . 94.7 mtt180 -67.87 -41.29 83.09 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-O 120.778 0.323 . . . . 0.0 111.312 -179.85 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 163' ' ' LEU . . . . . 0.594 ' HG ' ' HB2' ' A' ' 208' ' ' PHE . 7.1 mp -71.96 -54.93 8.46 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.302 -0.408 . . . . 0.0 112.064 -179.208 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 164' ' ' ARG . . . . . . . . . . . . . 4.8 tmm_? -53.97 -53.18 56.4 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.273 -0.422 . . . . 0.0 111.568 -179.408 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 165' ' ' ASN . . . . . 0.528 ' N ' HD21 ' A' ' 165' ' ' ASN . 0.9 OUTLIER -57.05 -51.75 68.02 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.4 -0.364 . . . . 0.0 111.368 -179.255 . . . . . . . . 3 3 . 1 . 022 nuclear orig core ' A' A ' 166' ' ' LEU . . . . . 0.465 ' O ' ' HG ' ' A' ' 170' ' ' LEU . 5.5 tt -58.28 -52.12 66.94 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.124 -0.489 . . . . 0.0 111.867 -179.241 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 167' ' ' THR . . . . . 0.458 ' O ' ' HB2' ' A' ' 171' ' ' TRP . 91.3 m -55.37 -53.38 56.94 Favored 'General case' 0 C--N 1.328 -0.34 0 N-CA-C 112.643 0.609 . . . . 0.0 112.643 -178.71 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 168' ' ' VAL . . . . . . . . . . . . . 96.3 t -55.21 -40.83 57.63 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.195 0 N-CA-C 112.312 0.486 . . . . 0.0 112.312 -178.558 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 169' ' ' VAL . . . . . . . . . . . . . 80.2 t -60.54 -64.66 0.57 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.39 0 N-CA-C 111.798 0.296 . . . . 0.0 111.798 -179.343 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 170' ' ' LEU . . . . . 0.465 ' HG ' ' O ' ' A' ' 166' ' ' LEU . 1.6 pp -63.98 -27.63 69.26 Favored 'General case' 0 C--N 1.33 -0.26 0 N-CA-C 112.08 0.4 . . . . 0.0 112.08 -178.781 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 171' ' ' TRP . . . . . 0.458 ' HB2' ' O ' ' A' ' 167' ' ' THR . 1.5 m0 -72.14 -31.14 65.71 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-O 120.926 0.393 . . . . 0.0 110.312 179.383 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 172' ' ' ALA . . . . . 0.424 ' HA ' ' CZ ' ' A' ' 134' ' ' PHE . . . -73.04 -6.19 43.87 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 115.816 -0.629 . . . . 0.0 110.615 179.94 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 173' ' ' ILE . . . . . 0.534 HG21 HD12 ' A' ' 177' ' ' ILE . 36.5 mm -87.78 -21.78 7.01 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.216 0 CA-C-N 115.838 -0.619 . . . . 0.0 111.132 179.787 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 174' ' ' TYR . . . . . . . . . . . . . 25.9 m-85 -54.57 -49.55 90.46 Favored Pre-proline 0 N--CA 1.465 0.3 0 CA-C-N 116.49 -0.323 . . . . 0.0 111.694 -179.913 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 175' ' ' PRO . . . . . 0.401 ' O ' ' HB2' ' A' ' 179' ' ' LEU . 82.7 Cg_exo -47.63 -28.37 9.13 Favored 'Trans proline' 0 C--N 1.353 0.768 0 C-N-CA 122.163 1.909 . . . . 0.0 112.259 179.912 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 176' ' ' PHE . . . . . 0.437 ' O ' ' HG ' ' A' ' 180' ' ' LEU . 95.9 m-85 -80.31 -49.61 11.31 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.026 -0.534 . . . . 0.0 111.72 -179.99 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 177' ' ' ILE . . . . . 0.534 HD12 HG21 ' A' ' 173' ' ' ILE . 2.6 mm -60.1 -45.12 96.14 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.537 0 N-CA-C 112.568 0.581 . . . . 0.0 112.568 -177.894 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 178' ' ' TRP . . . . . 0.449 ' HH2' ' HB2' ' A' ' 123' ' ' ARG . 80.5 t90 -66.63 -40.5 88.76 Favored 'General case' 0 N--CA 1.464 0.255 0 CA-C-O 121.095 0.474 . . . . 0.0 110.644 179.867 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 179' ' ' LEU . . . . . 0.529 HD11 HG22 ' A' ' 185' ' ' VAL . 0.9 OUTLIER -65.28 -52.43 54.31 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-N 115.732 -0.667 . . . . 0.0 111.272 -179.216 . . . . . . . . 3 3 . 1 . 022 nuclear orig core ' A' A ' 180' ' ' LEU . . . . . 0.478 HD22 HD12 ' A' ' 187' ' ' LEU . 9.8 mt -77.6 -52.44 9.02 Favored 'General case' 0 CA--C 1.532 0.266 0 N-CA-C 112.395 0.517 . . . . 0.0 112.395 -178.586 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . -59.89 -85.54 0.04 OUTLIER Glycine 0 C--N 1.333 0.389 0 C-N-CA 120.631 -0.795 . . . . 0.0 113.196 -179.578 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 182' ' ' PRO . . . . . 0.495 ' C ' ' H ' ' A' ' 184' ' ' GLY . 73.1 Cg_exo -45.01 178.04 0.0 OUTLIER 'Trans proline' 0 C--N 1.351 0.696 0 C-N-CA 123.368 2.712 . . . . 0.0 113.326 179.474 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 183' ' ' PRO . . . . . . . . . . . . . 62.2 Cg_exo -53.68 8.27 0.03 OUTLIER 'Trans proline' 0 C--N 1.352 0.713 0 C-N-CA 123.057 2.505 . . . . 0.0 114.991 -179.384 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 184' ' ' GLY . . . . . 0.495 ' H ' ' C ' ' A' ' 182' ' ' PRO . . . -53.69 -66.94 2.41 Favored Glycine 0 C--N 1.337 0.608 0 C-N-CA 119.795 -1.193 . . . . 0.0 110.971 179.01 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 185' ' ' VAL . . . . . 0.529 HG22 HD11 ' A' ' 179' ' ' LEU . 4.4 m -134.4 -4.61 1.21 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.389 0 CA-C-N 115.797 -0.202 . . . . 0.0 111.433 178.553 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 186' ' ' ALA . . . . . . . . . . . . . . . 43.85 79.01 0.05 OUTLIER 'General case' 0 N--CA 1.466 0.35 0 N-CA-C 112.289 0.477 . . . . 0.0 112.289 179.386 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 187' ' ' LEU . . . . . 0.478 HD12 HD22 ' A' ' 180' ' ' LEU . 4.9 mt -92.77 -49.83 5.88 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-O 120.71 0.291 . . . . 0.0 111.718 179.971 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 188' ' ' LEU . . . . . . . . . . . . . 96.0 mt -114.95 -166.45 1.11 Allowed 'General case' 0 C--N 1.331 -0.223 0 CA-C-O 120.983 0.421 . . . . 0.0 111.362 -179.169 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 189' ' ' THR . . . . . . . . . . . . . 3.0 t -85.77 148.11 47.76 Favored Pre-proline 0 C--N 1.328 -0.354 0 CA-C-N 115.826 -0.625 . . . . 0.0 111.279 -179.732 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 190' ' ' PRO . . . . . . . . . . . . . 78.2 Cg_exo -49.42 -44.59 33.98 Favored 'Trans proline' 0 C--N 1.348 0.524 0 C-N-CA 122.849 2.366 . . . . 0.0 113.503 -179.74 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 191' ' ' THR . . . . . . . . . . . . . 9.7 t -56.12 -34.51 66.14 Favored 'General case' 0 C--N 1.33 -0.276 0 N-CA-C 112.308 0.484 . . . . 0.0 112.308 -179.056 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 192' ' ' VAL . . . . . . . . . . . . . 19.1 t -72.06 -54.39 16.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 N-CA-C 111.851 0.315 . . . . 0.0 111.851 -179.204 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 193' ' ' ASP . . . . . . . . . . . . . 1.1 p30 -62.17 -46.14 90.3 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.699 0.285 . . . . 0.0 110.948 -179.735 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 194' ' ' VAL . . . . . . . . . . . . . 63.8 t -58.32 -35.94 55.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.331 -0.395 . . . . 0.0 110.44 179.4 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 195' ' ' ALA . . . . . . . . . . . . . . . -59.93 -48.25 82.45 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.281 -0.418 . . . . 0.0 111.141 179.918 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 196' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -67.88 -35.54 78.69 Favored 'General case' 0 N--CA 1.462 0.173 0 N-CA-C 109.882 -0.414 . . . . 0.0 109.882 179.543 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 197' ' ' ILE . . . . . . . . . . . . . 18.9 mm -58.43 -57.67 9.88 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.289 0 CA-C-N 115.922 -0.581 . . . . 0.0 109.776 178.949 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 198' ' ' VAL . . . . . . . . . . . . . 93.5 t -53.92 -35.27 27.56 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.44 0 N-CA-C 108.873 -0.788 . . . . 0.0 108.873 178.138 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 199' ' ' TYR . . . . . . . . . . . . . 17.7 t80 -70.76 -30.21 66.65 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 114.951 -1.022 . . . . 0.0 110.885 179.467 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 200' ' ' LEU . . . . . . . . . . . . . 34.9 mt -71.75 -44.0 64.81 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 116.048 -0.524 . . . . 0.0 111.703 -179.21 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 201' ' ' ASP . . . . . . . . . . . . . 11.9 m-20 -68.26 -35.21 77.54 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-O 121.117 0.484 . . . . 0.0 110.417 179.89 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 202' ' ' LEU . . . . . 0.433 ' O ' ' HB ' ' A' ' 206' ' ' VAL . 3.4 mt -70.89 -32.59 69.59 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 115.587 -0.733 . . . . 0.0 111.977 -179.507 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 203' ' ' VAL . . . . . 0.482 ' O ' ' HA3' ' A' ' 207' ' ' GLY . 12.5 p -78.17 -36.59 21.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 C-N-CA 121.102 -0.239 . . . . 0.0 111.376 -178.915 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 204' ' ' THR . . . . . 0.402 ' O ' ' CD1' ' A' ' 208' ' ' PHE . 45.4 m -64.73 -57.46 8.91 Favored 'General case' 0 C--N 1.325 -0.457 0 C-N-CA 120.494 -0.482 . . . . 0.0 111.134 179.655 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 205' ' ' LYS . . . . . 0.647 ' HD2' ' HE1' ' A' ' 15' ' ' MET . 47.4 mttp -70.2 -58.91 3.25 Favored 'General case' 0 C--N 1.33 -0.251 0 N-CA-C 112.791 0.663 . . . . 0.0 112.791 -178.071 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 206' ' ' VAL . . . . . 0.433 ' HB ' ' O ' ' A' ' 202' ' ' LEU . 23.3 t -70.08 -36.31 67.76 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.411 0 CA-C-N 116.454 -0.339 . . . . 0.0 111.832 -178.692 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 207' ' ' GLY . . . . . 0.484 ' O ' HG13 ' A' ' 211' ' ' ILE . . . -63.3 -60.25 7.78 Favored Glycine 0 N--CA 1.45 -0.382 0 C-N-CA 120.513 -0.851 . . . . 0.0 113.424 -178.844 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 208' ' ' PHE . . . . . 0.594 ' HB2' ' HG ' ' A' ' 163' ' ' LEU . 0.1 OUTLIER -66.47 -27.07 67.51 Favored 'General case' 0 C--O 1.225 -0.219 0 CA-C-N 117.3 0.55 . . . . 0.0 111.037 -179.136 . . . . . . . . 3 3 . 1 . 022 nuclear orig core ' A' A ' 209' ' ' GLY . . . . . 0.497 ' O ' ' HB2' ' A' ' 212' ' ' ALA . . . -69.72 -33.12 70.91 Favored Glycine 0 N--CA 1.448 -0.513 0 N-CA-C 111.683 -0.567 . . . . 0.0 111.683 178.852 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 210' ' ' PHE . . . . . . . . . . . . . 1.1 m-85 -70.85 -49.27 47.99 Favored 'General case' 0 CA--C 1.512 -0.494 0 N-CA-C 107.954 -1.128 . . . . 0.0 107.954 178.404 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 211' ' ' ILE . . . . . 0.484 HG13 ' O ' ' A' ' 207' ' ' GLY . 5.6 mt -62.59 -28.36 44.65 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.604 0 N-CA-C 107.618 -1.253 . . . . 0.0 107.618 176.572 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 212' ' ' ALA . . . . . 0.497 ' HB2' ' O ' ' A' ' 209' ' ' GLY . . . -65.05 -39.92 94.01 Favored 'General case' 0 N--CA 1.447 -0.59 0 CA-C-N 114.698 -1.137 . . . . 0.0 110.084 179.431 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 213' ' ' LEU . . . . . . . . . . . . . 88.4 mt -70.28 -53.16 18.05 Favored 'General case' 0 C--N 1.331 -0.203 0 CA-C-N 115.132 -0.94 . . . . 0.0 111.601 -179.772 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 214' ' ' ASP . . . . . . . . . . . . . 29.4 m-20 -54.01 -50.04 67.53 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.33 -0.395 . . . . 0.0 111.294 -179.38 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 215' ' ' ALA . . . . . . . . . . . . . . . -61.02 -56.42 21.26 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.289 -0.414 . . . . 0.0 111.362 -179.735 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 216' ' ' ALA . . . . . . . . . . . . . . . -56.26 -36.38 68.49 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.233 -0.439 . . . . 0.0 111.467 -179.543 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 217' ' ' ALA . . . . . . . . . . . . . . . -62.46 -40.87 98.01 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.291 -0.413 . . . . 0.0 110.392 179.765 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 218' ' ' THR . . . . . . . . . . . . . 90.9 m . . . . . 0 C--N 1.329 -0.306 0 CA-C-N 115.794 -0.639 . . . . 0.0 110.737 179.623 . . . . . . . . 0 0 . 1 . 023 nuclear orig core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.235 0 N-CA-C 112.625 -0.19 . . . . 0.0 112.625 . . . . . . . . . 0 0 . 1 . 023 nuclear orig core ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 59.6 tp -74.98 -38.0 61.77 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.832 0.349 . . . . 0.0 111.095 179.953 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 71.1 p -61.73 -32.59 72.82 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.096 -0.502 . . . . 0.0 111.207 -179.819 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 6' ' ' THR . . . . . 0.442 ' HG1' HD22 ' A' ' 7' ' ' LEU . 20.5 p -54.53 -35.86 63.64 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.127 -179.785 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 7' ' ' LEU . . . . . 0.442 HD22 ' HG1' ' A' ' 6' ' ' THR . 4.2 mm? -57.48 -52.86 63.66 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.809 179.836 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 8' ' ' PHE . . . . . 0.518 ' HB2' ' HB1' ' A' ' 55' ' ' ALA . 57.8 m-85 -64.87 -32.99 74.95 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 115.989 -0.551 . . . . 0.0 110.831 179.975 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 9' ' ' TRP . . . . . 0.407 ' O ' HG13 ' A' ' 13' ' ' ILE . 27.8 m95 -64.5 -44.7 90.13 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.978 0.418 . . . . 0.0 109.992 179.808 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 41.9 mt -61.8 -44.51 96.71 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 115.773 -0.649 . . . . 0.0 110.387 179.161 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -65.54 -29.22 74.67 Favored Glycine 0 N--CA 1.45 -0.433 0 C-N-CA 120.704 -0.76 . . . . 0.0 111.922 179.59 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -71.22 -33.42 69.88 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.624 0.25 . . . . 0.0 110.775 179.689 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 13' ' ' ILE . . . . . 0.407 HG13 ' O ' ' A' ' 9' ' ' TRP . 66.4 mt -66.33 -54.02 30.5 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.208 0 CA-C-O 120.9 0.381 . . . . 0.0 110.142 179.32 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -61.77 -38.07 95.34 Favored Glycine 0 N--CA 1.45 -0.432 0 C-N-CA 120.735 -0.745 . . . . 0.0 111.658 179.298 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 15' ' ' MET . . . . . . . . . . . . . 45.7 tpp -63.35 -43.51 97.5 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.794 0.331 . . . . 0.0 110.249 179.503 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -55.63 -38.96 70.2 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 115.969 -0.559 . . . . 0.0 109.834 179.23 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 98.8 t -59.91 -45.74 94.76 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.168 0 CA-C-N 115.954 -0.566 . . . . 0.0 109.926 178.955 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -62.74 -45.97 94.63 Favored Glycine 0 C--N 1.333 0.373 0 C-N-CA 120.476 -0.869 . . . . 0.0 111.448 178.801 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 23.7 m -51.86 -44.95 63.88 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 115.548 -0.326 . . . . 0.0 111.405 -179.888 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 85.4 mt -71.65 -42.98 66.9 Favored 'General case' 0 C--N 1.332 -0.184 0 CA-C-N 116.402 -0.363 . . . . 0.0 111.362 -179.921 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -56.89 -34.07 67.51 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.334 -0.393 . . . . 0.0 111.707 -179.662 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 22' ' ' PHE . . . . . 0.408 ' HB2' HG23 ' A' ' 41' ' ' VAL . 1.9 m-85 -90.96 -31.1 16.48 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.598 -0.274 . . . . 0.0 111.242 -179.418 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -68.31 -50.54 52.83 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.901 0.382 . . . . 0.0 111.543 -179.643 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 24' ' ' TRP . . . . . . . . . . . . . 5.3 t-105 -64.77 -42.27 95.24 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-N 115.898 -0.592 . . . . 0.0 111.119 -179.685 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.329 -0.312 0 CA-C-O 120.866 0.365 . . . . 0.0 110.643 179.764 . . . . . . . . 0 0 . 1 . 023 nuclear orig core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.249 0 N-CA-C 112.598 -0.201 . . . . 0.0 112.598 . . . . . . . . . 0 0 . 1 . 023 nuclear orig core ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 19.9 mm-40 -79.41 -20.65 47.06 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.82 0.343 . . . . 0.0 110.688 179.906 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 34' ' ' ARG . . . . . . . . . . . . . 52.0 ttp180 -55.11 -28.9 56.01 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.005 -0.543 . . . . 0.0 111.319 -179.784 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 31.1 mmm180 -55.04 -45.12 75.2 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.788 0.328 . . . . 0.0 111.28 -179.938 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 61.2 m-85 -69.05 -33.38 73.49 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.414 -179.528 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 37' ' ' TYR . . . . . . . . . . . . . 75.4 m-85 -72.69 -53.06 12.77 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.331 -0.395 . . . . 0.0 111.413 -179.238 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 11.5 p -56.75 -36.16 48.26 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.225 0 CA-C-O 121.092 0.472 . . . . 0.0 110.474 179.751 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 18.7 m -68.2 -46.9 69.34 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 115.714 -0.676 . . . . 0.0 110.718 179.276 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 40' ' ' LEU . . . . . 0.467 HD13 HD12 ' A' ' 43' ' ' ILE . 26.8 tp -61.18 -45.33 95.07 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 115.813 -0.631 . . . . 0.0 110.917 179.96 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . 0.408 HG23 ' HB2' ' A' ' 22' ' ' PHE . 95.7 t -62.97 -34.35 65.87 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.484 0 CA-C-N 115.988 -0.551 . . . . 0.0 110.284 179.471 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 42' ' ' GLY . . . . . 0.481 ' O ' HG13 ' A' ' 46' ' ' ILE . . . -58.62 -51.88 56.3 Favored Glycine 0 N--CA 1.448 -0.508 0 C-N-CA 120.902 -0.666 . . . . 0.0 112.921 -179.964 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 43' ' ' ILE . . . . . 0.526 HG21 HD22 ' A' ' 82' ' ' LEU . 18.0 pt -60.9 -49.16 85.79 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.161 0 CA-C-N 117.02 0.41 . . . . 0.0 111.566 -179.558 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 44' ' ' SER . . . . . 0.405 ' N ' HG13 ' A' ' 43' ' ' ILE . 41.0 t -61.32 -27.1 68.25 Favored 'General case' 0 C--N 1.332 -0.191 0 CA-C-O 120.889 0.375 . . . . 0.0 111.193 179.648 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -78.01 -47.59 8.35 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.803 -0.713 . . . . 0.0 113.217 -179.112 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 46' ' ' ILE . . . . . 0.481 HG13 ' O ' ' A' ' 42' ' ' GLY . 61.6 mt -59.14 -42.09 85.62 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.229 0 CA-C-O 120.846 0.355 . . . . 0.0 110.968 -179.75 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 47' ' ' ALA . . . . . 0.606 ' HB1' ' HE2' ' A' ' 205' ' ' LYS . . . -67.49 -40.83 85.25 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 116.333 -0.394 . . . . 0.0 111.084 179.336 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -54.65 -44.27 73.1 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 116.129 -0.487 . . . . 0.0 111.382 -179.771 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 49' ' ' VAL . . . . . 0.404 ' O ' HG12 ' A' ' 53' ' ' VAL . 33.3 m -75.36 -34.65 30.98 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.384 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.351 -179.742 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -62.17 -38.86 90.67 Favored 'General case' 0 C--N 1.332 -0.156 0 CA-C-O 120.965 0.412 . . . . 0.0 111.071 179.849 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 51' ' ' TYR . . . . . 0.418 ' HB3' ' O ' ' A' ' 8' ' ' PHE . 26.5 m-85 -72.77 -42.65 63.74 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 115.993 -0.549 . . . . 0.0 110.693 -179.861 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -62.5 -39.84 94.81 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 115.987 -0.551 . . . . 0.0 111.45 -179.919 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 53' ' ' VAL . . . . . 0.416 HG21 ' N ' ' A' ' 54' ' ' MET . 35.1 m -72.28 -48.71 47.19 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.16 0 CA-C-N 116.498 -0.319 . . . . 0.0 111.299 -179.679 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 54' ' ' MET . . . . . 0.435 ' HG3' ' HB2' ' A' ' 71' ' ' PRO . 74.0 mtm -61.85 -31.26 71.51 Favored 'General case' 0 C--N 1.331 -0.196 0 CA-C-O 120.979 0.419 . . . . 0.0 110.417 179.693 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 55' ' ' ALA . . . . . 0.518 ' HB1' ' HB2' ' A' ' 8' ' ' PHE . . . -70.42 -12.51 61.63 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 115.767 -0.652 . . . . 0.0 111.645 179.962 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 71.2 mt -97.71 -13.15 21.61 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 116.483 -0.326 . . . . 0.0 111.466 -179.78 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 105.18 -6.62 42.98 Favored Glycine 0 CA--C 1.52 0.353 0 C-N-CA 120.496 -0.859 . . . . 0.0 113.545 179.5 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 58' ' ' VAL . . . . . 0.41 HG22 ' O ' ' A' ' 53' ' ' VAL . 27.0 m -81.54 149.8 4.76 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.201 0 CA-C-N 117.185 0.492 . . . . 0.0 110.587 179.483 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 81.74 25.61 52.72 Favored Glycine 0 N--CA 1.45 -0.418 0 C-N-CA 120.588 -0.815 . . . . 0.0 111.768 -179.219 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 60' ' ' TRP . . . . . . . . . . . . . 17.9 m0 -104.23 95.06 5.71 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 121.101 0.477 . . . . 0.0 110.018 -179.897 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 6.0 t -91.24 124.21 62.08 Favored Pre-proline 0 C--N 1.324 -0.539 0 CA-C-N 115.712 -0.676 . . . . 0.0 111.405 -178.984 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 56.2 Cg_endo -71.81 136.42 27.72 Favored 'Trans proline' 0 C--N 1.35 0.649 0 C-N-CA 122.353 2.036 . . . . 0.0 112.345 -179.987 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 86.4 t -143.02 105.23 1.06 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.02 -0.537 . . . . 0.0 111.209 -179.573 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . 58.88 -90.08 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.295 -0.411 . . . . 0.0 111.361 179.921 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 41.2 tt0 -122.85 -25.71 4.57 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 116.306 -0.406 . . . . 0.0 110.52 179.901 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 66' ' ' ARG . . . . . . . . . . . . . 20.0 ttm180 -101.73 162.62 12.77 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 115.942 -0.572 . . . . 0.0 110.333 179.905 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 87.3 m -117.56 120.73 38.96 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-O 120.858 0.361 . . . . 0.0 111.648 -179.448 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 38.8 t -86.07 146.37 6.55 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 115.927 -0.579 . . . . 0.0 110.558 179.406 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 69' ' ' PHE . . . . . . . . . . . . . 29.8 m-85 -106.77 112.97 26.19 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 121.044 0.45 . . . . 0.0 110.177 -179.679 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 70' ' ' VAL . . . . . 0.582 HG11 ' HD3' ' A' ' 71' ' ' PRO . 0.3 OUTLIER -68.65 -33.92 4.95 Favored Pre-proline 0 CA--C 1.541 0.603 0 N-CA-C 113.217 0.821 . . . . 0.0 113.217 -179.108 . . . . . . . . 3 3 . 1 . 023 nuclear orig core ' A' A ' 71' ' ' PRO . . . . . 0.582 ' HD3' HG11 ' A' ' 70' ' ' VAL . 23.9 Cg_exo -63.71 -32.63 68.07 Favored 'Trans proline' 0 C--N 1.357 1.02 0 C-N-CA 121.766 1.644 . . . . 0.0 112.453 -179.276 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 40.0 ttm180 -69.82 -50.54 41.87 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 121.075 0.465 . . . . 0.0 110.352 179.464 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 73' ' ' TYR . . . . . 0.616 ' HH ' ' HB3' ' A' ' 116' ' ' ALA . 33.9 m-85 -65.94 -33.09 75.02 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 115.767 -0.651 . . . . 0.0 111.341 -179.706 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 0.4 OUTLIER -75.74 -38.73 37.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-O 121.02 0.438 . . . . 0.0 109.908 179.329 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 5.9 t70 -58.58 -32.77 69.26 Favored 'General case' 0 N--CA 1.455 -0.203 0 CA-C-N 115.975 -0.557 . . . . 0.0 109.965 179.294 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 76' ' ' TRP . . . . . . . . . . . . . 51.0 m0 -73.24 -46.23 51.31 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 115.914 -0.585 . . . . 0.0 110.568 179.204 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 77' ' ' ILE . . . . . 0.518 HG12 ' HB3' ' A' ' 109' ' ' MET . 88.2 mt -53.52 -29.94 17.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 115.941 -0.572 . . . . 0.0 111.253 -179.84 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 47.3 mt -91.07 -52.02 5.04 Favored 'General case' 0 CA--C 1.533 0.325 0 N-CA-C 112.521 0.563 . . . . 0.0 112.521 -179.541 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 79.7 p -71.49 -50.37 32.22 Favored 'General case' 0 N--CA 1.465 0.315 0 N-CA-C 113.931 1.085 . . . . 0.0 113.931 -177.688 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 80' ' ' THR . . . . . 0.503 HG23 ' HE2' ' A' ' 109' ' ' MET . 15.2 m -46.47 -53.32 24.75 Favored Pre-proline 0 CA--C 1.534 0.331 0 N-CA-C 112.78 0.659 . . . . 0.0 112.78 -178.173 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 81' ' ' PRO . . . . . 0.46 ' HD2' ' N ' ' A' ' 80' ' ' THR . 29.1 Cg_endo -61.99 -23.95 76.31 Favored 'Trans proline' 0 C--N 1.351 0.689 0 C-N-CA 121.639 1.559 . . . . 0.0 111.523 179.949 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 82' ' ' LEU . . . . . 0.526 HD22 HG21 ' A' ' 43' ' ' ILE . 15.6 tp -76.59 -32.62 58.23 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 115.751 -0.658 . . . . 0.0 110.156 179.507 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 41.8 mm -64.71 -53.55 40.83 Favored 'Isoleucine or valine' 0 C--O 1.235 0.304 0 CA-C-N 116.181 -0.463 . . . . 0.0 109.872 178.94 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 12.6 m -61.3 -30.33 47.71 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.228 0 N-CA-C 109.297 -0.631 . . . . 0.0 109.297 178.582 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 85' ' ' TYR . . . . . . . . . . . . . 87.4 t80 -66.82 -32.61 74.0 Favored 'General case' 0 N--CA 1.453 -0.282 0 CA-C-N 115.478 -0.783 . . . . 0.0 109.371 178.585 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 86' ' ' PHE . . . . . . . . . . . . . 3.5 t80 -61.34 -51.89 66.94 Favored 'General case' 0 C--O 1.232 0.17 0 CA-C-N 115.68 -0.691 . . . . 0.0 109.767 179.259 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 7.2 mp -62.37 -31.82 72.53 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 115.741 -0.663 . . . . 0.0 110.242 179.358 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -66.27 -28.06 73.44 Favored Glycine 0 N--CA 1.45 -0.412 0 C-N-CA 120.771 -0.728 . . . . 0.0 111.615 179.365 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 92.6 mt -75.4 -38.88 59.62 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.815 0.341 . . . . 0.0 110.53 179.426 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 94.2 mt -59.96 -43.34 95.1 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.042 -0.526 . . . . 0.0 111.097 179.859 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 91' ' ' ALA . . . . . 0.422 ' HB1' ' HB2' ' A' ' 149' ' ' ALA . . . -82.76 -52.22 6.96 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 116.253 -0.43 . . . . 0.0 111.369 -179.798 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 100.16 68.21 0.86 Allowed Glycine 0 N--CA 1.452 -0.284 0 C-N-CA 120.81 -0.71 . . . . 0.0 112.4 -179.941 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 93' ' ' LEU . . . . . 0.536 ' HB3' ' HB2' ' A' ' 97' ' ' GLU . 8.2 mp -77.29 177.69 7.72 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.905 0.383 . . . . 0.0 111.159 -179.862 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 94' ' ' ASP . . . . . . . . . . . . . 19.7 t70 -89.66 166.96 13.29 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 115.941 -0.572 . . . . 0.0 110.808 -179.986 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 52.8 m -55.68 -38.96 70.35 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.348 -0.387 . . . . 0.0 111.177 -179.806 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 37.6 mmt180 -73.46 -44.3 58.34 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.303 -0.408 . . . . 0.0 111.13 -179.981 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 97' ' ' GLU . . . . . 0.536 ' HB2' ' HB3' ' A' ' 93' ' ' LEU . 13.2 mm-40 -55.43 -47.99 75.11 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.859 -179.969 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 98' ' ' PHE . . . . . 0.418 ' O ' HG12 ' A' ' 102' ' ' ILE . 24.3 m-85 -57.1 -47.63 80.58 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.447 179.456 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -57.27 -29.83 60.55 Favored Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.438 179.828 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 97.3 mt -73.98 -44.28 51.06 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.171 0 CA-C-O 120.93 0.395 . . . . 0.0 111.555 -179.882 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 44.7 t -67.46 -46.41 83.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.062 -0.517 . . . . 0.0 111.929 -179.247 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 102' ' ' ILE . . . . . 0.418 HG12 ' O ' ' A' ' 98' ' ' PHE . 45.4 mm -62.22 -52.49 59.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.395 -0.366 . . . . 0.0 111.722 -179.272 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 14.7 t -57.29 -35.94 70.44 Favored 'General case' 0 C--N 1.332 -0.16 0 CA-C-O 120.849 0.357 . . . . 0.0 111.174 -179.74 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 104' ' ' LEU . . . . . 0.427 HD21 ' HE2' ' A' ' 140' ' ' TYR . 50.4 tp -61.02 -46.43 90.77 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.746 179.838 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 105' ' ' ASN . . . . . 0.57 ' N ' HD21 ' A' ' 105' ' ' ASN . 0.8 OUTLIER -65.46 -26.09 67.79 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.877 179.946 . . . . . . . . 3 3 . 1 . 023 nuclear orig core ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 61.4 m -65.44 -55.35 18.49 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.292 -0.413 . . . . 0.0 111.216 -179.975 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 7.3 p -61.87 -37.35 77.96 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.184 0 CA-C-N 116.532 -0.304 . . . . 0.0 110.995 -179.734 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . 0.4 HG21 ' O ' ' A' ' 104' ' ' LEU . 53.4 t -59.58 -50.14 81.07 Favored 'Isoleucine or valine' 0 C--O 1.235 0.303 0 CA-C-O 121.002 0.429 . . . . 0.0 110.589 179.364 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 109' ' ' MET . . . . . 0.518 ' HB3' HG12 ' A' ' 77' ' ' ILE . 3.0 tpp -63.46 -30.67 71.76 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 115.946 -0.57 . . . . 0.0 110.337 179.579 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 20.1 tp -68.59 -32.69 72.77 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.104 -0.498 . . . . 0.0 109.956 179.318 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 111' ' ' ALA . . . . . 0.428 ' O ' ' HB3' ' A' ' 126' ' ' LEU . . . -63.49 -56.69 14.08 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-N 115.736 -0.666 . . . . 0.0 110.418 179.25 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . -56.59 -42.99 91.08 Favored Glycine 0 C--N 1.331 0.252 0 C-N-CA 120.646 -0.788 . . . . 0.0 112.055 179.493 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 113' ' ' PHE . . . . . . . . . . . . . 6.5 t80 -47.28 -66.84 0.34 Allowed 'General case' 0 C--N 1.331 -0.222 0 CA-C-O 121.025 0.44 . . . . 0.0 110.956 179.55 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -63.25 -30.36 71.52 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 115.865 -0.607 . . . . 0.0 111.702 -179.401 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -52.11 -43.0 55.92 Favored Glycine 0 C--N 1.33 0.239 0 C-N-CA 121.057 -0.592 . . . . 0.0 112.96 -179.614 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 116' ' ' ALA . . . . . 0.616 ' HB3' ' HH ' ' A' ' 73' ' ' TYR . . . -78.22 -27.88 47.84 Favored 'General case' 0 C--N 1.328 -0.352 0 N-CA-C 112.172 0.434 . . . . 0.0 112.172 -179.643 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 117' ' ' MET . . . . . . . . . . . . . 66.1 mtt -95.66 19.45 11.16 Favored 'General case' 0 C--N 1.33 -0.282 0 N-CA-C 111.77 0.285 . . . . 0.0 111.77 -179.191 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 118' ' ' VAL . . . . . 0.547 HG22 ' HB3' ' A' ' 123' ' ' ARG . 18.2 m -64.79 149.53 95.97 Favored Pre-proline 0 C--N 1.329 -0.296 0 CA-C-N 116.577 -0.283 . . . . 0.0 111.128 179.602 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 119' ' ' PRO . . . . . . . . . . . . . 93.9 Cg_endo -84.89 -17.83 4.68 Favored 'Trans proline' 0 N--CA 1.459 -0.517 0 C-N-CA 122.504 2.136 . . . . 0.0 112.135 179.808 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -145.41 -123.27 1.58 Allowed Glycine 0 N--CA 1.45 -0.386 0 C-N-CA 120.714 -0.755 . . . . 0.0 112.79 -179.923 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 45.1 pt -96.44 10.86 5.27 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.222 0 CA-C-O 120.714 0.293 . . . . 0.0 111.541 -179.535 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 43.6 mt-10 -59.6 -17.75 35.62 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.331 -0.395 . . . . 0.0 111.166 179.9 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 123' ' ' ARG . . . . . 0.547 ' HB3' HG22 ' A' ' 118' ' ' VAL . 19.8 ptt180 -49.69 -34.96 20.08 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 116.307 -0.406 . . . . 0.0 111.46 -179.928 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 124' ' ' TYR . . . . . . . . . . . . . 49.3 m-85 -70.98 -32.41 69.23 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.438 -0.346 . . . . 0.0 111.041 179.997 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 125' ' ' ALA . . . . . . . . . . . . . . . -68.25 -52.02 38.64 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.012 179.595 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 126' ' ' LEU . . . . . 0.428 ' HB3' ' O ' ' A' ' 111' ' ' ALA . 2.6 mm? -53.61 -56.17 19.53 Favored 'General case' 0 CA--C 1.521 -0.141 0 CA-C-N 116.09 -0.504 . . . . 0.0 110.687 179.973 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 127' ' ' PHE . . . . . 0.458 ' HZ ' ' HB3' ' A' ' 175' ' ' PRO . 9.6 t80 -67.39 -29.6 69.15 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.741 -179.91 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 128' ' ' GLY . . . . . . . . . . . . . . . -47.14 -54.49 9.73 Favored Glycine 0 N--CA 1.451 -0.36 0 C-N-CA 119.991 -1.099 . . . . 0.0 110.768 178.968 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 129' ' ' MET . . . . . 0.697 ' HE1' ' HA2' ' A' ' 130' ' ' GLY . 0.0 OUTLIER -72.21 -27.56 62.62 Favored 'General case' 0 C--N 1.328 -0.359 0 N-CA-C 109.144 -0.687 . . . . 0.0 109.144 178.624 . . . . . . . . 3 3 . 1 . 023 nuclear orig core ' A' A ' 130' ' ' GLY . . . . . 0.697 ' HA2' ' HE1' ' A' ' 129' ' ' MET . . . -61.72 -37.46 94.29 Favored Glycine 0 C--N 1.334 0.435 0 CA-C-N 115.792 -0.64 . . . . 0.0 112.288 179.541 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -74.75 -52.3 11.88 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.754 0.311 . . . . 0.0 110.457 179.696 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 42.1 t -54.88 -47.33 75.58 Favored 'Isoleucine or valine' 0 C--O 1.234 0.257 0 CA-C-O 121.243 0.544 . . . . 0.0 109.602 178.981 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -65.45 -37.08 85.82 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 115.523 -0.762 . . . . 0.0 110.915 179.245 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 134' ' ' PHE . . . . . 0.411 ' CZ ' ' HA ' ' A' ' 172' ' ' ALA . 45.9 t80 -53.27 -54.02 42.34 Favored 'General case' 0 N--CA 1.452 -0.361 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.26 179.816 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 135' ' ' ILE . . . . . 0.462 ' O ' HG22 ' A' ' 138' ' ' VAL . 42.5 mt -59.66 -32.85 50.24 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 CA-C-N 115.85 -0.614 . . . . 0.0 110.23 179.473 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 136' ' ' GLY . . . . . 0.436 ' O ' ' HB3' ' A' ' 139' ' ' TYR . . . -58.93 -40.06 94.85 Favored Glycine 0 N--CA 1.449 -0.463 0 C-N-CA 120.153 -1.023 . . . . 0.0 111.236 178.706 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 137' ' ' LEU . . . . . 0.461 HD13 HD22 ' A' ' 105' ' ' ASN . 64.0 tp -69.61 -53.37 19.11 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 115.863 -0.169 . . . . 0.0 110.806 179.541 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 138' ' ' VAL . . . . . 0.462 HG22 ' O ' ' A' ' 135' ' ' ILE . 3.3 m -54.69 -31.38 23.82 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.144 0 N-CA-C 109.333 -0.617 . . . . 0.0 109.333 -179.915 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 139' ' ' TYR . . . . . 0.436 ' HB3' ' O ' ' A' ' 136' ' ' GLY . 44.1 t80 -60.19 -46.35 90.03 Favored 'General case' 0 N--CA 1.453 -0.29 0 CA-C-N 115.544 -0.753 . . . . 0.0 109.404 178.183 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 140' ' ' TYR . . . . . 0.427 ' HE2' HD21 ' A' ' 104' ' ' LEU . 22.2 m-85 -63.86 -42.33 97.58 Favored 'General case' 0 C--N 1.333 -0.132 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.526 178.813 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 141' ' ' LEU . . . . . 0.411 ' HA ' ' SD ' ' A' ' 145' ' ' MET . 11.0 mp -57.13 -27.62 61.99 Favored 'General case' 0 C--N 1.332 -0.173 0 CA-C-N 115.948 -0.569 . . . . 0.0 111.193 -179.743 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 142' ' ' VAL . . . . . 0.413 HG21 ' O ' ' A' ' 138' ' ' VAL . 12.0 t -106.15 -7.91 10.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-O 120.992 0.425 . . . . 0.0 110.926 179.866 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . -73.84 -133.71 0.25 Allowed Glycine 0 CA--C 1.522 0.48 0 C-N-CA 120.812 -0.709 . . . . 0.0 112.814 -179.849 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 144' ' ' PRO . . . . . . . . . . . . . 51.5 Cg_exo -55.57 -23.96 42.47 Favored 'Trans proline' 0 C--N 1.349 0.555 0 C-N-CA 122.672 2.248 . . . . 0.0 113.03 -179.693 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 145' ' ' MET . . . . . 0.411 ' SD ' ' HA ' ' A' ' 141' ' ' LEU . 54.9 mtt -53.77 -27.92 31.71 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-O 120.727 0.299 . . . . 0.0 111.497 -179.583 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 146' ' ' THR . . . . . . . . . . . . . 70.5 p -79.04 -32.99 45.11 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.357 -0.383 . . . . 0.0 110.991 -179.558 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 39.7 tt0 -73.93 -40.26 63.23 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 115.861 -0.609 . . . . 0.0 111.354 -179.636 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 148' ' ' SER . . . . . . . . . . . . . 46.9 t -70.0 -42.26 73.28 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.325 -0.398 . . . . 0.0 111.327 -179.524 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 149' ' ' ALA . . . . . 0.422 ' HB2' ' HB1' ' A' ' 91' ' ' ALA . . . -70.83 -40.27 72.51 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.443 -0.344 . . . . 0.0 111.827 -179.649 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 150' ' ' SER . . . . . 0.594 ' HA ' ' HG2' ' A' ' 157' ' ' LYS . 39.2 t -69.46 -0.02 5.88 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.516 -0.311 . . . . 0.0 111.431 -179.564 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 151' ' ' GLN . . . . . . . . . . . . . 46.1 mt-30 -132.52 6.47 4.09 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.583 -0.28 . . . . 0.0 111.238 179.955 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 25.7 tpt180 -78.73 -52.41 8.43 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-O 120.94 0.4 . . . . 0.0 110.671 179.994 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 153' ' ' SER . . . . . 0.646 ' HB2' HG12 ' A' ' 156' ' ' ILE . 19.8 m -157.51 172.52 18.42 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 115.829 -0.623 . . . . 0.0 110.359 179.183 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 154' ' ' SER . . . . . 0.466 ' HA ' ' NZ ' ' A' ' 157' ' ' LYS . 49.9 m -68.68 -41.08 79.75 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.775 0.321 . . . . 0.0 110.983 179.728 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -76.78 -35.5 39.92 Favored Glycine 0 CA--C 1.519 0.343 0 C-N-CA 120.982 -0.627 . . . . 0.0 113.427 -179.537 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 156' ' ' ILE . . . . . 0.646 HG12 ' HB2' ' A' ' 153' ' ' SER . 41.8 mm -50.15 -38.48 15.06 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.217 0 N-CA-C 111.764 0.283 . . . . 0.0 111.764 -179.421 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 157' ' ' LYS . . . . . 0.594 ' HG2' ' HA ' ' A' ' 150' ' ' SER . 33.3 mtmm -59.78 -40.28 87.72 Favored 'General case' 0 C--N 1.327 -0.371 0 N-CA-C 112.034 0.383 . . . . 0.0 112.034 -179.254 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 36.5 t -72.53 -47.26 49.73 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 121.047 0.451 . . . . 0.0 111.425 -179.046 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 159' ' ' LEU . . . . . 0.43 ' O ' ' HB2' ' A' ' 163' ' ' LEU . 10.2 mt -68.67 -29.17 67.58 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-N 115.986 -0.552 . . . . 0.0 111.534 -179.108 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 160' ' ' TYR . . . . . . . . . . . . . 77.9 t80 -72.63 -46.84 52.08 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.454 -0.339 . . . . 0.0 111.629 -179.336 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 161' ' ' VAL . . . . . 0.459 HG22 ' N ' ' A' ' 162' ' ' ARG . 27.3 m -62.42 -42.79 96.98 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 N-CA-C 111.84 0.311 . . . . 0.0 111.84 -179.154 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 162' ' ' ARG . . . . . 0.459 ' N ' HG22 ' A' ' 161' ' ' VAL . 77.3 mtp180 -68.84 -48.53 63.28 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 120.647 0.26 . . . . 0.0 111.53 -179.678 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 163' ' ' LEU . . . . . 0.43 ' HB2' ' O ' ' A' ' 159' ' ' LEU . 6.8 mp -67.5 -45.08 76.88 Favored 'General case' 0 CA--C 1.531 0.24 0 CA-C-N 116.388 -0.369 . . . . 0.0 111.968 -179.01 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 164' ' ' ARG . . . . . . . . . . . . . 4.3 tmm_? -57.78 -50.97 71.46 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-O 120.635 0.255 . . . . 0.0 110.867 -179.719 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 165' ' ' ASN . . . . . 0.468 ' N ' HD21 ' A' ' 165' ' ' ASN . 0.9 OUTLIER -55.37 -41.37 72.52 Favored 'General case' 0 N--CA 1.448 -0.567 0 CA-C-N 116.352 -0.385 . . . . 0.0 110.486 179.78 . . . . . . . . 3 3 . 1 . 023 nuclear orig core ' A' A ' 166' ' ' LEU . . . . . 0.478 ' O ' ' HG ' ' A' ' 170' ' ' LEU . 3.6 mt -58.16 -53.61 56.31 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 115.944 -0.571 . . . . 0.0 110.894 179.496 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 167' ' ' THR . . . . . 0.55 ' HA ' HD11 ' A' ' 170' ' ' LEU . 13.7 m -54.39 -52.58 61.23 Favored 'General case' 0 C--N 1.331 -0.204 0 N-CA-C 112.451 0.537 . . . . 0.0 112.451 -178.431 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 168' ' ' VAL . . . . . . . . . . . . . 85.9 t -54.96 -40.57 54.12 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.483 0 N-CA-C 112.612 0.597 . . . . 0.0 112.612 -178.724 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 169' ' ' VAL . . . . . 0.443 ' O ' HG12 ' A' ' 173' ' ' ILE . 68.7 t -69.18 -67.19 0.46 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 N-CA-C 113.526 0.936 . . . . 0.0 113.526 -177.894 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 170' ' ' LEU . . . . . 0.55 HD11 ' HA ' ' A' ' 167' ' ' THR . 0.4 OUTLIER -59.18 -34.58 72.29 Favored 'General case' 0 N--CA 1.465 0.323 0 N-CA-C 112.869 0.692 . . . . 0.0 112.869 -177.7 . . . . . . . . 3 3 . 1 . 023 nuclear orig core ' A' A ' 171' ' ' TRP . . . . . 0.493 ' H ' HD13 ' A' ' 170' ' ' LEU . 16.8 m0 -73.29 -31.52 64.1 Favored 'General case' 0 C--N 1.329 -0.29 0 C-N-CA 120.607 -0.437 . . . . 0.0 111.24 -179.507 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 172' ' ' ALA . . . . . 0.411 ' HA ' ' CZ ' ' A' ' 134' ' ' PHE . . . -71.17 -7.15 44.76 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-O 120.912 0.387 . . . . 0.0 110.337 179.52 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 173' ' ' ILE . . . . . 0.53 ' O ' HG12 ' A' ' 177' ' ' ILE . 38.6 mm -88.44 -28.12 5.41 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.173 0 CA-C-N 115.896 -0.593 . . . . 0.0 111.044 179.512 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 174' ' ' TYR . . . . . 0.491 ' HD2' ' HA ' ' A' ' 171' ' ' TRP . 19.2 m-85 -54.11 -48.71 93.33 Favored Pre-proline 0 N--CA 1.467 0.392 0 CA-C-N 116.523 -0.308 . . . . 0.0 111.699 -179.512 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 175' ' ' PRO . . . . . 0.458 ' HB3' ' HZ ' ' A' ' 127' ' ' PHE . 82.5 Cg_exo -45.36 -33.29 8.73 Favored 'Trans proline' 0 C--N 1.351 0.658 0 C-N-CA 121.964 1.776 . . . . 0.0 111.857 179.467 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 176' ' ' PHE . . . . . 0.491 ' O ' ' HG ' ' A' ' 180' ' ' LEU . 96.6 m-85 -80.97 -50.6 9.5 Favored 'General case' 0 CA--C 1.518 -0.287 0 CA-C-N 115.843 -0.617 . . . . 0.0 111.792 179.937 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 177' ' ' ILE . . . . . 0.53 HG12 ' O ' ' A' ' 173' ' ' ILE . 6.6 mm -58.17 -32.49 44.5 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.517 0 CA-C-N 115.927 -0.579 . . . . 0.0 112.56 -177.494 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 178' ' ' TRP . . . . . . . . . . . . . 84.3 t90 -73.45 -32.2 64.22 Favored 'General case' 0 CA--C 1.52 -0.205 0 CA-C-O 120.884 0.373 . . . . 0.0 110.577 179.629 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 179' ' ' LEU . . . . . 0.523 ' HG ' HG22 ' A' ' 185' ' ' VAL . 17.3 tp -81.88 -55.29 4.7 Favored 'General case' 0 C--N 1.322 -0.601 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.851 -179.478 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 180' ' ' LEU . . . . . 0.491 ' HG ' ' O ' ' A' ' 176' ' ' PHE . 7.0 mt -62.04 -51.33 68.42 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.109 -0.496 . . . . 0.0 111.287 -179.479 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 181' ' ' GLY . . . . . 0.44 ' HA3' ' OD1' ' A' ' 193' ' ' ASP . . . -65.7 -84.76 0.08 OUTLIER Glycine 0 C--N 1.332 0.316 0 C-N-CA 120.338 -0.934 . . . . 0.0 111.925 179.414 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 182' ' ' PRO . . . . . 0.54 ' HB3' ' HD2' ' A' ' 183' ' ' PRO . 81.7 Cg_exo -48.25 176.98 0.02 OUTLIER 'Trans proline' 0 C--N 1.35 0.631 0 C-N-CA 122.999 2.466 . . . . 0.0 112.244 178.743 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 183' ' ' PRO . . . . . 0.54 ' HD2' ' HB3' ' A' ' 182' ' ' PRO . 19.2 Cg_endo -59.95 16.03 0.04 OUTLIER 'Trans proline' 0 C--N 1.351 0.674 0 C-N-CA 122.58 2.187 . . . . 0.0 115.142 -178.908 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 184' ' ' GLY . . . . . 0.441 ' H ' ' C ' ' A' ' 182' ' ' PRO . . . -59.51 -45.51 95.46 Favored Glycine 0 C--N 1.336 0.562 0 C-N-CA 119.48 -1.343 . . . . 0.0 110.693 178.756 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 185' ' ' VAL . . . . . 0.523 HG22 ' HG ' ' A' ' 179' ' ' LEU . 2.5 m -148.94 -35.63 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.327 -0.4 0 CA-C-N 114.867 -0.666 . . . . 0.0 110.528 178.635 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 186' ' ' ALA . . . . . . . . . . . . . . . 66.82 77.77 0.27 Allowed 'General case' 0 N--CA 1.462 0.138 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.863 178.607 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 187' ' ' LEU . . . . . 0.459 HD11 HD23 ' A' ' 180' ' ' LEU . 4.2 mt -92.67 -46.66 7.47 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.608 179.502 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 188' ' ' LEU . . . . . . . . . . . . . 97.8 mt -111.28 -166.36 1.07 Allowed 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 115.948 -0.569 . . . . 0.0 111.267 -179.808 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 189' ' ' THR . . . . . 0.427 ' HB ' HG23 ' A' ' 192' ' ' VAL . 26.8 m -81.81 136.3 48.02 Favored Pre-proline 0 C--N 1.328 -0.355 0 CA-C-N 115.822 -0.626 . . . . 0.0 110.932 -179.966 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 190' ' ' PRO . . . . . . . . . . . . . 5.6 Cg_endo -48.56 -38.99 36.95 Favored 'Trans proline' 0 C--N 1.35 0.644 0 C-N-CA 122.713 2.276 . . . . 0.0 112.08 179.611 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 191' ' ' THR . . . . . . . . . . . . . 59.5 p -58.27 -44.71 88.53 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.24 -0.437 . . . . 0.0 110.584 179.613 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 192' ' ' VAL . . . . . 0.427 HG23 ' HB ' ' A' ' 189' ' ' THR . 75.1 t -60.23 -40.38 83.5 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.229 0 CA-C-N 115.867 -0.606 . . . . 0.0 110.649 179.433 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 193' ' ' ASP . . . . . 0.44 ' OD1' ' HA3' ' A' ' 181' ' ' GLY . 3.4 t70 -56.15 -45.23 79.72 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 115.777 -0.647 . . . . 0.0 110.989 179.834 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 194' ' ' VAL . . . . . . . . . . . . . 48.4 t -63.07 -36.99 78.17 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.053 -0.521 . . . . 0.0 110.944 -179.839 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 195' ' ' ALA . . . . . . . . . . . . . . . -57.24 -47.64 80.86 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 116.393 -0.367 . . . . 0.0 110.838 179.674 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 196' ' ' LEU . . . . . . . . . . . . . 89.3 mt -68.37 -44.95 74.06 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-N 116.308 -0.406 . . . . 0.0 110.903 179.661 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 197' ' ' ILE . . . . . . . . . . . . . 20.2 mm -55.63 -58.37 4.93 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.58 179.633 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 198' ' ' VAL . . . . . . . . . . . . . 77.2 t -52.15 -35.1 18.64 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.568 0 CA-C-N 115.469 -0.787 . . . . 0.0 109.514 178.629 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 199' ' ' TYR . . . . . . . . . . . . . 42.2 t80 -70.38 -33.42 71.39 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 115.521 -0.763 . . . . 0.0 110.62 179.691 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 200' ' ' LEU . . . . . 0.408 HD11 HG13 ' A' ' 177' ' ' ILE . 51.7 mt -67.13 -42.54 84.25 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-N 115.97 -0.559 . . . . 0.0 111.135 -179.683 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 201' ' ' ASP . . . . . . . . . . . . . 8.3 m-20 -72.85 -31.65 64.91 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-O 121.083 0.468 . . . . 0.0 110.235 179.656 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 202' ' ' LEU . . . . . 0.437 ' O ' ' HB ' ' A' ' 206' ' ' VAL . 3.3 mt -70.88 -31.57 68.28 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 115.65 -0.705 . . . . 0.0 112.082 -179.476 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 203' ' ' VAL . . . . . 0.416 ' O ' ' HA3' ' A' ' 207' ' ' GLY . 7.1 p -80.82 -37.01 15.95 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-O 120.637 0.256 . . . . 0.0 111.25 -178.815 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 204' ' ' THR . . . . . 0.436 ' O ' ' HB2' ' A' ' 208' ' ' PHE . 22.2 m -70.1 -48.8 56.14 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-O 120.836 0.351 . . . . 0.0 111.406 179.945 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 205' ' ' LYS . . . . . 0.606 ' HE2' ' HB1' ' A' ' 47' ' ' ALA . 62.7 mttp -72.94 -57.65 3.9 Favored 'General case' 0 C--N 1.326 -0.429 0 N-CA-C 112.129 0.418 . . . . 0.0 112.129 -179.004 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 206' ' ' VAL . . . . . 0.437 ' HB ' ' O ' ' A' ' 202' ' ' LEU . 51.7 t -70.98 -41.89 76.99 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-O 120.631 0.253 . . . . 0.0 111.626 -179.363 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 207' ' ' GLY . . . . . 0.419 ' O ' HD12 ' A' ' 211' ' ' ILE . . . -61.2 -59.6 9.74 Favored Glycine 0 C--N 1.33 0.216 0 C-N-CA 120.631 -0.795 . . . . 0.0 112.698 -179.766 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 208' ' ' PHE . . . . . 0.48 ' O ' ' N ' ' A' ' 212' ' ' ALA . 8.1 m-85 -54.29 -47.08 72.77 Favored 'General case' 0 C--O 1.222 -0.391 0 CA-C-O 121.058 0.456 . . . . 0.0 110.202 -179.986 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 209' ' ' GLY . . . . . 0.446 ' HA2' ' HB3' ' A' ' 212' ' ' ALA . . . -56.21 -32.87 60.57 Favored Glycine 0 N--CA 1.449 -0.454 0 CA-C-N 115.004 -0.998 . . . . 0.0 113.299 179.747 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 210' ' ' PHE . . . . . . . . . . . . . 2.2 m-85 -72.03 -46.02 58.65 Favored 'General case' 0 CA--C 1.513 -0.469 0 N-CA-C 108.811 -0.811 . . . . 0.0 108.811 179.556 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 211' ' ' ILE . . . . . 0.469 HD11 HD11 ' A' ' 166' ' ' LEU . 3.3 mt -67.59 -27.3 37.87 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.658 0 N-CA-C 107.625 -1.25 . . . . 0.0 107.625 176.481 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 212' ' ' ALA . . . . . 0.48 ' N ' ' O ' ' A' ' 208' ' ' PHE . . . -68.18 -43.54 77.94 Favored 'General case' 0 N--CA 1.452 -0.371 0 CA-C-N 114.415 -1.266 . . . . 0.0 110.785 -179.712 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 213' ' ' LEU . . . . . . . . . . . . . 81.0 mt -70.1 -54.18 14.16 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 115.329 -0.85 . . . . 0.0 111.221 -179.514 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 214' ' ' ASP . . . . . . . . . . . . . 12.8 t70 -55.51 -35.36 65.53 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.801 -179.865 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 215' ' ' ALA . . . . . . . . . . . . . . . -65.65 -57.92 6.95 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.024 -0.535 . . . . 0.0 111.338 -179.916 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 216' ' ' ALA . . . . . . . . . . . . . . . -61.43 -31.09 71.02 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.112 -0.495 . . . . 0.0 111.103 -179.892 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 217' ' ' ALA . . . . . . . . . . . . . . . -62.51 -40.0 95.32 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.31 179.776 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 218' ' ' THR . . . . . . . . . . . . . 93.7 m . . . . . 0 C--N 1.33 -0.256 0 CA-C-N 115.94 -0.573 . . . . 0.0 110.693 179.408 . . . . . . . . 0 0 . 1 . 024 nuclear orig core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.275 0 N-CA-C 112.5 -0.24 . . . . 0.0 112.5 . . . . . . . . . 0 0 . 1 . 024 nuclear orig core ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 67.0 tp -74.22 -36.6 63.96 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.795 0.331 . . . . 0.0 111.006 179.964 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 82.6 p -58.22 -32.96 68.81 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.531 -179.78 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 30.4 p -54.47 -34.9 62.4 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.343 -0.39 . . . . 0.0 111.109 -179.979 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 7' ' ' LEU . . . . . . . . . . . . . 4.3 mm? -58.22 -53.9 53.04 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 115.994 -0.548 . . . . 0.0 111.514 -179.732 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 8' ' ' PHE . . . . . 0.442 ' HB2' ' HB1' ' A' ' 55' ' ' ALA . 68.3 m-85 -64.22 -36.07 82.86 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.293 -0.412 . . . . 0.0 111.232 -179.484 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 9' ' ' TRP . . . . . . . . . . . . . 44.8 m95 -65.02 -48.98 71.99 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-O 121.098 0.475 . . . . 0.0 110.16 -179.675 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 79.9 mt -60.33 -38.7 84.57 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-N 115.587 -0.733 . . . . 0.0 110.532 179.685 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -65.03 -31.13 79.87 Favored Glycine 0 N--CA 1.448 -0.504 0 C-N-CA 120.647 -0.787 . . . . 0.0 111.642 179.199 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -71.13 -30.71 66.83 Favored 'General case' 0 N--CA 1.454 -0.231 0 CA-C-O 120.81 0.338 . . . . 0.0 110.56 179.393 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 71.8 mt -66.57 -54.61 24.07 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.235 0 CA-C-N 115.959 -0.564 . . . . 0.0 110.335 179.345 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -62.95 -35.56 92.22 Favored Glycine 0 N--CA 1.449 -0.455 0 C-N-CA 120.645 -0.788 . . . . 0.0 111.441 179.374 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 15' ' ' MET . . . . . 0.495 ' SD ' ' HA ' ' A' ' 44' ' ' SER . 53.1 tpp -62.9 -46.37 88.16 Favored 'General case' 0 C--N 1.329 -0.296 0 N-CA-C 110.088 -0.338 . . . . 0.0 110.088 179.358 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 16' ' ' LEU . . . . . 0.407 HD13 ' O ' ' A' ' 16' ' ' LEU . 0.8 OUTLIER -53.22 -39.99 64.16 Favored 'General case' 0 C--N 1.332 -0.187 0 CA-C-N 115.866 -0.606 . . . . 0.0 109.689 179.057 . . . . . . . . 3 3 . 1 . 024 nuclear orig core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 70.3 t -58.98 -45.55 92.09 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.206 0 CA-C-N 116.036 -0.529 . . . . 0.0 110.177 179.156 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -63.93 -42.73 98.22 Favored Glycine 0 N--CA 1.45 -0.392 0 C-N-CA 120.749 -0.739 . . . . 0.0 111.737 179.038 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 19' ' ' THR . . . . . 0.436 ' N ' ' HG ' ' A' ' 44' ' ' SER . 11.3 m -52.74 -46.51 67.48 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-O 120.847 0.356 . . . . 0.0 111.146 -179.806 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 92.3 mt -71.8 -39.02 70.15 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.337 -179.826 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -59.8 -33.65 72.02 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.574 -0.285 . . . . 0.0 111.698 -179.615 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 22' ' ' PHE . . . . . 0.42 ' HB2' HG23 ' A' ' 41' ' ' VAL . 4.5 m-85 -90.99 -34.83 14.99 Favored 'General case' 0 C--N 1.331 -0.196 0 CA-C-O 120.727 0.299 . . . . 0.0 111.52 -179.446 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -66.53 -50.98 61.39 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 120.93 0.395 . . . . 0.0 111.539 -179.464 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 24' ' ' TRP . . . . . . . . . . . . . 5.1 t-105 -65.42 -45.11 85.16 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 115.877 -0.601 . . . . 0.0 111.176 -179.715 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.328 -0.327 0 CA-C-O 120.854 0.359 . . . . 0.0 111.009 179.874 . . . . . . . . 0 0 . 1 . 024 nuclear orig core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.276 0 N-CA-C 112.494 -0.242 . . . . 0.0 112.494 . . . . . . . . . 0 0 . 1 . 024 nuclear orig core ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 12.4 mm-40 -72.49 -21.11 61.25 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.652 0.263 . . . . 0.0 110.945 -179.922 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 34' ' ' ARG . . . . . . . . . . . . . 79.0 ttt180 -51.57 -29.36 16.88 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 116.111 -0.495 . . . . 0.0 111.468 -179.607 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 80.2 ttt180 -60.19 -48.8 80.21 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.856 0.36 . . . . 0.0 110.882 179.896 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 59.4 m-85 -67.46 -29.87 69.43 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.028 -0.533 . . . . 0.0 111.139 179.896 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 37' ' ' TYR . . . . . . . . . . . . . 43.8 m-85 -72.13 -53.0 14.05 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.071 -0.513 . . . . 0.0 111.62 -179.365 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 96.7 t -56.92 -37.39 54.05 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-O 121.103 0.477 . . . . 0.0 110.129 179.594 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 38.1 m -65.72 -46.27 79.57 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 115.662 -0.699 . . . . 0.0 110.182 179.158 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 28.2 tp -59.67 -50.17 74.91 Favored 'General case' 0 C--O 1.235 0.318 0 CA-C-N 115.771 -0.649 . . . . 0.0 110.459 179.588 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . 0.42 HG23 ' HB2' ' A' ' 22' ' ' PHE . 61.3 t -59.1 -34.63 53.88 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.254 0 CA-C-N 115.842 -0.617 . . . . 0.0 109.938 179.186 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -59.07 -39.19 94.03 Favored Glycine 0 N--CA 1.449 -0.475 0 C-N-CA 120.727 -0.749 . . . . 0.0 111.832 179.252 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 43' ' ' ILE . . . . . 0.435 ' H ' HG13 ' A' ' 43' ' ' ILE . 0.9 OUTLIER -64.96 -57.08 12.63 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.153 0 CA-C-O 120.831 0.348 . . . . 0.0 110.786 179.402 . . . . . . . . 3 3 . 1 . 024 nuclear orig core ' A' A ' 44' ' ' SER . . . . . 0.495 ' HA ' ' SD ' ' A' ' 15' ' ' MET . 40.8 t -59.72 -24.21 63.81 Favored 'General case' 0 C--N 1.332 -0.168 0 CA-C-N 116.103 -0.499 . . . . 0.0 111.56 -179.691 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -74.15 -59.55 3.89 Favored Glycine 0 CA--C 1.518 0.262 0 C-N-CA 120.72 -0.752 . . . . 0.0 113.039 -179.647 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 21.1 pt -58.72 -35.02 53.54 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.19 0 CA-C-O 120.745 0.307 . . . . 0.0 111.286 -179.876 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 47' ' ' ALA . . . . . 0.554 ' HB2' ' HE2' ' A' ' 205' ' ' LYS . . . -65.98 -45.74 80.53 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-N 116.32 -0.4 . . . . 0.0 111.058 179.833 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -54.84 -52.18 63.58 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.246 -0.434 . . . . 0.0 111.216 -179.713 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 49' ' ' VAL . . . . . 0.403 ' O ' HG13 ' A' ' 53' ' ' VAL . 34.6 m -64.35 -34.04 66.66 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.393 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.821 179.931 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -65.23 -37.93 88.81 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.367 -0.379 . . . . 0.0 110.845 179.576 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 51' ' ' TYR . . . . . 0.406 ' HB3' ' O ' ' A' ' 8' ' ' PHE . 30.3 m-85 -70.79 -29.06 65.15 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.193 179.944 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -74.5 -41.67 60.29 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-N 115.613 -0.721 . . . . 0.0 111.184 179.59 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 53' ' ' VAL . . . . . 0.425 HG22 ' N ' ' A' ' 54' ' ' MET . 20.8 m -73.25 -43.52 56.99 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.125 0 CA-C-N 116.498 -0.319 . . . . 0.0 111.008 179.883 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 54' ' ' MET . . . . . 0.425 ' N ' HG22 ' A' ' 53' ' ' VAL . 72.8 mtm -63.49 -32.46 73.92 Favored 'General case' 0 C--N 1.332 -0.183 0 CA-C-O 121.038 0.447 . . . . 0.0 110.023 179.443 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 55' ' ' ALA . . . . . 0.442 ' HB1' ' HB2' ' A' ' 8' ' ' PHE . . . -65.23 -37.06 86.07 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 115.667 -0.697 . . . . 0.0 110.712 179.349 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 93.8 mt -76.5 -13.03 60.12 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 115.869 -0.605 . . . . 0.0 110.851 179.756 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 71.53 31.21 65.7 Favored Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.782 -0.723 . . . . 0.0 112.818 179.991 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 32.3 m -79.92 19.98 0.15 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.211 0 CA-C-O 120.834 0.35 . . . . 0.0 111.557 179.869 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -159.1 14.93 0.23 Allowed Glycine 0 N--CA 1.451 -0.358 0 C-N-CA 120.795 -0.717 . . . . 0.0 112.844 179.866 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 60' ' ' TRP . . . . . . . . . . . . . 41.0 m0 -81.09 107.57 14.01 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.728 0.299 . . . . 0.0 110.633 179.862 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 4.9 p -106.38 119.33 52.19 Favored Pre-proline 0 CA--C 1.533 0.306 0 CA-C-N 116.342 -0.39 . . . . 0.0 111.572 -179.624 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 16.8 Cg_exo -67.6 133.76 30.84 Favored 'Trans proline' 0 C--N 1.351 0.659 0 C-N-CA 122.35 2.033 . . . . 0.0 111.79 179.423 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 78.2 t -132.48 100.54 4.06 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.373 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.214 -179.716 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . 59.53 -86.85 0.02 OUTLIER 'General case' 0 C--N 1.331 -0.212 0 CA-C-N 116.043 -0.526 . . . . 0.0 111.265 -179.999 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 45.1 mt-10 -122.36 -27.26 4.49 Favored 'General case' 0 C--N 1.332 -0.195 0 CA-C-N 116.362 -0.381 . . . . 0.0 110.724 179.992 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 66' ' ' ARG . . . . . 0.436 ' HD2' ' N ' ' A' ' 66' ' ' ARG . 8.1 mpt_? -104.64 140.62 37.76 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.611 179.826 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 22.3 m -98.17 113.19 25.03 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.345 -0.389 . . . . 0.0 111.113 -179.74 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 26.3 t -85.11 146.84 6.06 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.354 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.474 179.498 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 69' ' ' PHE . . . . . . . . . . . . . 19.8 m-85 -108.51 115.17 29.59 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-O 120.91 0.386 . . . . 0.0 110.111 -179.315 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 70' ' ' VAL . . . . . 0.52 ' HB ' ' HD3' ' A' ' 71' ' ' PRO . 13.4 t -68.9 -49.35 26.81 Favored Pre-proline 0 C--N 1.323 -0.557 0 CA-C-N 115.946 -0.57 . . . . 0.0 112.243 -179.006 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 71' ' ' PRO . . . . . 0.52 ' HD3' ' HB ' ' A' ' 70' ' ' VAL . 29.5 Cg_exo -61.97 -17.48 56.1 Favored 'Trans proline' 0 C--N 1.35 0.608 0 C-N-CA 122.176 1.917 . . . . 0.0 112.449 -179.525 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 51.6 ttp180 -71.34 -54.68 9.97 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.482 -0.327 . . . . 0.0 111.43 -179.727 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 73' ' ' TYR . . . . . 0.428 ' O ' HG13 ' A' ' 77' ' ' ILE . 96.2 m-85 -69.74 -31.69 69.82 Favored 'General case' 0 C--N 1.331 -0.235 0 C-N-CA 120.919 -0.313 . . . . 0.0 110.648 -179.84 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 74' ' ' ILE . . . . . 0.484 ' HA ' HD11 ' A' ' 77' ' ' ILE . 0.3 OUTLIER -69.74 -38.56 76.44 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.18 0 N-CA-C 109.672 -0.492 . . . . 0.0 109.672 178.993 . . . . . . . . 3 3 . 1 . 024 nuclear orig core ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 11.4 t70 -59.08 -37.59 77.45 Favored 'General case' 0 N--CA 1.454 -0.24 0 N-CA-C 109.211 -0.663 . . . . 0.0 109.211 178.595 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 76' ' ' TRP . . . . . . . . . . . . . 53.6 m0 -67.97 -32.45 72.88 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 115.689 -0.687 . . . . 0.0 110.323 179.006 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 77' ' ' ILE . . . . . 0.484 HD11 ' HA ' ' A' ' 74' ' ' ILE . 97.6 mt -66.57 -29.37 46.29 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.362 179.232 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 48.9 mt -91.59 -19.98 22.15 Favored 'General case' 0 CA--C 1.532 0.277 0 CA-C-N 116.1 -0.5 . . . . 0.0 112.016 179.983 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 81.4 p -101.16 -52.63 3.22 Favored 'General case' 0 N--CA 1.465 0.323 0 N-CA-C 113.538 0.94 . . . . 0.0 113.538 -177.889 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 80' ' ' THR . . . . . 0.456 ' N ' ' HD2' ' A' ' 81' ' ' PRO . 61.3 m -46.69 -53.87 22.72 Favored Pre-proline 0 CA--C 1.533 0.296 0 N-CA-C 112.886 0.699 . . . . 0.0 112.886 -178.557 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 81' ' ' PRO . . . . . 0.456 ' HD2' ' N ' ' A' ' 80' ' ' THR . 35.0 Cg_endo -62.2 -22.16 73.71 Favored 'Trans proline' 0 C--N 1.35 0.622 0 C-N-CA 121.543 1.495 . . . . 0.0 111.603 -179.598 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 82' ' ' LEU . . . . . . . . . . . . . 16.2 tp -76.91 -33.31 57.77 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 115.657 -0.701 . . . . 0.0 110.234 179.674 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 28.1 mm -69.2 -53.18 26.86 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.226 0 CA-C-N 116.087 -0.506 . . . . 0.0 110.122 179.162 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 28.9 m -60.13 -31.97 49.32 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.218 0 N-CA-C 109.645 -0.502 . . . . 0.0 109.645 178.907 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 85' ' ' TYR . . . . . . . . . . . . . 79.8 t80 -65.12 -34.11 77.63 Favored 'General case' 0 N--CA 1.452 -0.366 0 CA-C-N 115.641 -0.709 . . . . 0.0 109.532 178.963 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 86' ' ' PHE . . . . . . . . . . . . . 7.9 t80 -62.62 -51.08 68.68 Favored 'General case' 0 C--N 1.333 -0.14 0 CA-C-N 115.768 -0.651 . . . . 0.0 110.247 179.404 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 9.3 mp -61.53 -36.05 79.46 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 115.992 -0.549 . . . . 0.0 110.407 179.785 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -66.33 -27.96 73.39 Favored Glycine 0 N--CA 1.45 -0.404 0 C-N-CA 120.767 -0.73 . . . . 0.0 111.875 179.282 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 75.9 mt -72.73 -40.88 65.74 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 120.994 0.426 . . . . 0.0 110.624 179.716 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 47.3 mt -58.44 -47.53 83.68 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 115.648 -0.706 . . . . 0.0 111.336 -179.644 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 91' ' ' ALA . . . . . 0.417 ' HB2' ' HB2' ' A' ' 149' ' ' ALA . . . -75.46 -54.52 6.9 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.635 -179.545 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 107.11 69.51 0.7 Allowed Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.854 -0.689 . . . . 0.0 112.009 -179.591 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 93' ' ' LEU . . . . . 0.524 HD21 ' HB3' ' A' ' 97' ' ' GLU . 8.5 mp -87.41 171.66 10.39 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.794 0.331 . . . . 0.0 111.131 -179.6 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 94' ' ' ASP . . . . . . . . . . . . . 8.9 m-20 -90.93 166.25 13.14 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.928 179.826 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 49.6 m -55.56 -33.02 63.49 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-N 116.312 -0.404 . . . . 0.0 111.029 -179.987 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 9.4 ptp180 -71.53 -48.05 51.25 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.842 179.88 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 97' ' ' GLU . . . . . 0.524 ' HB3' HD21 ' A' ' 93' ' ' LEU . 44.6 mt-10 -58.2 -45.14 88.16 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.923 -179.969 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 98' ' ' PHE . . . . . 0.426 ' O ' HG12 ' A' ' 102' ' ' ILE . 31.2 m-85 -59.1 -48.85 80.09 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.374 -0.375 . . . . 0.0 110.615 179.568 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -55.9 -31.07 58.07 Favored Glycine 0 N--CA 1.45 -0.381 0 C-N-CA 120.888 -0.672 . . . . 0.0 112.587 -179.775 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 98.0 mt -71.5 -44.29 71.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-O 120.798 0.332 . . . . 0.0 111.531 -179.94 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 39.7 t -68.12 -51.07 52.51 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.729 -179.344 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 102' ' ' ILE . . . . . 0.426 HG12 ' O ' ' A' ' 98' ' ' PHE . 34.0 mm -59.38 -50.0 81.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.325 -0.398 . . . . 0.0 111.771 -179.253 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 7.9 t -59.37 -36.11 75.14 Favored 'General case' 0 C--N 1.331 -0.204 0 CA-C-O 120.761 0.315 . . . . 0.0 110.911 -179.739 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 104' ' ' LEU . . . . . 0.4 ' O ' HG23 ' A' ' 108' ' ' VAL . 27.4 tp -63.03 -44.44 95.9 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.218 -0.447 . . . . 0.0 110.403 179.542 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 105' ' ' ASN . . . . . 0.574 ' N ' HD21 ' A' ' 105' ' ' ASN . 0.8 OUTLIER -63.66 -26.47 68.68 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 115.955 -0.566 . . . . 0.0 110.555 179.726 . . . . . . . . 3 3 . 1 . 024 nuclear orig core ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 84.7 m -67.15 -54.59 19.81 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 115.998 -0.546 . . . . 0.0 111.167 179.954 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 7.5 p -63.6 -36.59 76.98 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.213 0 CA-C-N 116.42 -0.354 . . . . 0.0 111.05 -179.895 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . 0.4 HG23 ' O ' ' A' ' 104' ' ' LEU . 72.3 t -65.74 -45.5 91.62 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.226 0 CA-C-N 116.386 -0.37 . . . . 0.0 110.894 179.496 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 109' ' ' MET . . . . . . . . . . . . . 8.7 tpp -65.15 -39.24 92.7 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.829 -179.82 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 29.0 tp -66.98 -30.75 70.95 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.215 179.701 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -62.5 -52.37 63.77 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 116.068 -0.515 . . . . 0.0 110.313 179.136 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . -67.62 -32.56 78.74 Favored Glycine 0 N--CA 1.45 -0.395 0 C-N-CA 120.566 -0.826 . . . . 0.0 111.649 179.127 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 113' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER -52.79 -75.89 0.03 OUTLIER 'General case' 0 C--N 1.332 -0.179 0 CA-C-O 121.008 0.432 . . . . 0.0 109.883 179.357 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -61.05 -21.43 63.62 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-N 115.619 -0.719 . . . . 0.0 110.646 179.206 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -52.57 -50.98 46.32 Favored Glycine 0 C--N 1.333 0.385 0 C-N-CA 120.905 -0.664 . . . . 0.0 112.125 179.739 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 116' ' ' ALA . . . . . 0.548 ' HB2' ' HB3' ' A' ' 183' ' ' PRO . . . -78.19 -15.7 58.58 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 121.008 0.432 . . . . 0.0 110.723 179.217 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 117' ' ' MET . . . . . . . . . . . . . 45.1 tpp -87.49 -5.95 58.58 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 115.883 -0.599 . . . . 0.0 111.502 -179.588 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 21.7 m -58.81 146.67 74.78 Favored Pre-proline 0 C--N 1.331 -0.219 0 CA-C-N 116.683 -0.235 . . . . 0.0 111.449 -179.608 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 119' ' ' PRO . . . . . . . . . . . . . 69.2 Cg_endo -90.76 -5.45 4.43 Favored 'Trans proline' 0 N--CA 1.455 -0.748 0 C-N-CA 122.912 2.408 . . . . 0.0 112.228 179.431 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -145.41 -127.99 1.98 Allowed Glycine 0 C--N 1.333 0.362 0 C-N-CA 120.867 -0.683 . . . . 0.0 112.84 -179.733 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 46.6 pt -99.16 11.56 6.21 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.212 0 CA-C-O 120.596 0.236 . . . . 0.0 111.595 -179.491 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 122' ' ' GLU . . . . . 0.436 ' O ' HD12 ' A' ' 126' ' ' LEU . 15.1 mm-40 -60.53 -21.03 62.05 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.754 0.311 . . . . 0.0 110.997 -179.914 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 123' ' ' ARG . . . . . 0.431 HH11 ' HD2' ' A' ' 123' ' ' ARG . 10.0 ptt180 -52.22 -34.47 45.91 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.027 -0.533 . . . . 0.0 111.471 -179.935 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 124' ' ' TYR . . . . . . . . . . . . . 39.6 m-85 -69.16 -32.08 71.16 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.531 -179.574 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 125' ' ' ALA . . . . . . . . . . . . . . . -72.88 -56.51 5.09 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-O 120.831 0.348 . . . . 0.0 111.098 -179.699 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 126' ' ' LEU . . . . . 0.436 HD12 ' O ' ' A' ' 122' ' ' GLU . 1.3 mp -57.26 -49.61 75.51 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.662 179.92 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 127' ' ' PHE . . . . . . . . . . . . . 7.5 t80 -66.45 -37.42 85.12 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.335 -0.393 . . . . 0.0 110.857 -179.991 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 128' ' ' GLY . . . . . . . . . . . . . . . -47.18 -46.29 21.1 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.057 -1.068 . . . . 0.0 110.904 179.045 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 129' ' ' MET . . . . . . . . . . . . . 0.3 OUTLIER -70.13 -35.77 74.31 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 115.388 -0.406 . . . . 0.0 110.041 178.848 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -68.09 -28.2 73.45 Favored Glycine 0 C--N 1.334 0.434 0 CA-C-N 115.88 -0.6 . . . . 0.0 112.94 -179.659 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -74.42 -53.65 9.15 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 120.722 0.296 . . . . 0.0 110.313 179.915 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 22.2 t -58.2 -42.69 84.04 Favored 'Isoleucine or valine' 0 C--O 1.235 0.338 0 N-CA-C 109.022 -0.733 . . . . 0.0 109.022 178.476 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -64.31 -35.27 80.32 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.264 -0.88 . . . . 0.0 110.351 179.086 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 134' ' ' PHE . . . . . . . . . . . . . 75.3 t80 -56.74 -50.67 71.54 Favored 'General case' 0 N--CA 1.453 -0.323 0 CA-C-N 116.284 -0.416 . . . . 0.0 109.901 179.447 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 135' ' ' ILE . . . . . 0.469 ' HA ' HG21 ' A' ' 138' ' ' VAL . 63.0 mt -57.44 -33.17 43.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 115.779 -0.646 . . . . 0.0 109.967 179.114 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 136' ' ' GLY . . . . . 0.433 ' O ' ' HB3' ' A' ' 139' ' ' TYR . . . -62.13 -40.62 99.19 Favored Glycine 0 N--CA 1.449 -0.478 0 C-N-CA 120.134 -1.032 . . . . 0.0 111.44 178.689 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 137' ' ' LEU . . . . . . . . . . . . . 26.8 tp -68.91 -49.91 54.01 Favored 'General case' 0 N--CA 1.455 -0.219 0 CA-C-O 120.43 0.157 . . . . 0.0 110.701 179.673 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 138' ' ' VAL . . . . . 0.516 ' HA ' HD12 ' A' ' 141' ' ' LEU . 4.7 m -58.2 -31.39 41.97 Favored 'Isoleucine or valine' 0 C--O 1.233 0.22 0 CA-C-O 121.338 0.589 . . . . 0.0 109.618 179.219 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 139' ' ' TYR . . . . . 0.433 ' HB3' ' O ' ' A' ' 136' ' ' GLY . 55.7 t80 -60.48 -43.21 97.21 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 115.34 -0.845 . . . . 0.0 109.302 178.373 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 36.7 m-85 -64.03 -32.72 74.38 Favored 'General case' 0 C--N 1.332 -0.16 0 CA-C-N 115.839 -0.619 . . . . 0.0 110.451 178.887 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 141' ' ' LEU . . . . . 0.516 HD12 ' HA ' ' A' ' 138' ' ' VAL . 95.3 mt -57.67 -47.43 82.32 Favored 'General case' 0 N--CA 1.462 0.168 0 CA-C-N 116.349 -0.387 . . . . 0.0 110.588 179.671 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 9.5 p -95.85 1.28 10.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.818 179.868 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . -75.95 -140.55 0.94 Allowed Glycine 0 CA--C 1.52 0.361 0 C-N-CA 120.99 -0.624 . . . . 0.0 112.878 -179.572 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 144' ' ' PRO . . . . . . . . . . . . . 19.5 Cg_endo -58.88 -23.92 69.9 Favored 'Trans proline' 0 C--N 1.347 0.488 0 C-N-CA 122.745 2.297 . . . . 0.0 112.685 -179.776 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 145' ' ' MET . . . . . . . . . . . . . 56.8 mtt -58.19 -33.13 68.94 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 120.806 0.336 . . . . 0.0 111.242 179.966 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 146' ' ' THR . . . . . . . . . . . . . 12.1 m -80.86 -32.35 35.05 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.385 -179.05 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 40.2 tt0 -71.8 -42.32 67.21 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-N 116.165 -0.47 . . . . 0.0 111.169 -179.743 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 148' ' ' SER . . . . . . . . . . . . . 58.2 m -70.61 -46.86 62.58 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-N 116.263 -0.426 . . . . 0.0 111.407 -179.432 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 149' ' ' ALA . . . . . 0.417 ' HB2' ' HB2' ' A' ' 91' ' ' ALA . . . -63.03 -41.33 99.49 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.309 -0.405 . . . . 0.0 111.742 -179.496 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 150' ' ' SER . . . . . . . . . . . . . 66.2 m -68.91 -0.58 5.73 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.38 -0.373 . . . . 0.0 111.501 -179.617 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 151' ' ' GLN . . . . . . . . . . . . . 44.8 mt-30 -129.09 3.69 5.26 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.628 -0.26 . . . . 0.0 111.246 179.991 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 31.0 tpt180 -76.42 -51.31 12.09 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.895 0.379 . . . . 0.0 110.651 -179.985 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 153' ' ' SER . . . . . 0.61 ' HB3' HG12 ' A' ' 156' ' ' ILE . 22.8 t -157.21 172.4 18.7 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-N 115.885 -0.598 . . . . 0.0 110.473 179.496 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 154' ' ' SER . . . . . . . . . . . . . 70.2 p -67.65 -41.22 84.18 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.382 -0.372 . . . . 0.0 110.912 179.937 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -77.07 -37.03 33.71 Favored Glycine 0 CA--C 1.519 0.305 0 C-N-CA 120.961 -0.638 . . . . 0.0 113.158 -179.657 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 156' ' ' ILE . . . . . 0.61 HG12 ' HB3' ' A' ' 153' ' ' SER . 42.4 mm -52.66 -37.22 24.19 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.186 0 CA-C-O 120.628 0.252 . . . . 0.0 111.56 -179.47 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 157' ' ' LYS . . . . . . . . . . . . . 38.3 ttpt -60.29 -53.84 52.89 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.457 -0.338 . . . . 0.0 111.555 -179.629 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 48.9 m -63.5 -44.22 94.96 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 121.008 0.432 . . . . 0.0 111.468 -179.43 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 159' ' ' LEU . . . . . . . . . . . . . 6.0 tt -63.71 -37.94 89.23 Favored 'General case' 0 C--N 1.326 -0.438 0 CA-C-N 115.993 -0.549 . . . . 0.0 110.983 -179.485 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 160' ' ' TYR . . . . . . . . . . . . . 54.1 t80 -74.4 -46.84 37.68 Favored 'General case' 0 C--N 1.329 -0.317 0 N-CA-C 112.548 0.573 . . . . 0.0 112.548 -178.796 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 161' ' ' VAL . . . . . 0.43 HG23 ' N ' ' A' ' 162' ' ' ARG . 28.2 m -56.13 -44.65 79.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 N-CA-C 111.908 0.336 . . . . 0.0 111.908 -178.685 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 162' ' ' ARG . . . . . 0.449 ' O ' HD12 ' A' ' 166' ' ' LEU . 97.8 mtt180 -68.65 -49.44 59.11 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.746 0.308 . . . . 0.0 111.475 -179.452 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 163' ' ' LEU . . . . . . . . . . . . . 6.1 mp -63.46 -51.58 65.04 Favored 'General case' 0 C--N 1.33 -0.239 0 CA-C-N 116.232 -0.44 . . . . 0.0 112.034 -179.097 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 164' ' ' ARG . . . . . 0.426 HH11 HG23 ' A' ' 168' ' ' VAL . 5.2 tmm_? -53.42 -50.32 65.46 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.411 -0.358 . . . . 0.0 111.208 -179.406 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 165' ' ' ASN . . . . . 0.474 ' N ' HD21 ' A' ' 165' ' ' ASN . 0.9 OUTLIER -53.55 -42.28 67.32 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.894 0.378 . . . . 0.0 110.609 179.898 . . . . . . . . 3 3 . 1 . 024 nuclear orig core ' A' A ' 166' ' ' LEU . . . . . 0.504 ' O ' ' HG ' ' A' ' 170' ' ' LEU . 1.4 mt -58.31 -51.24 70.61 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 115.998 -0.546 . . . . 0.0 111.205 179.54 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 167' ' ' THR . . . . . 0.536 ' HA ' HD11 ' A' ' 170' ' ' LEU . 6.0 m -53.93 -53.88 46.62 Favored 'General case' 0 C--N 1.332 -0.178 0 N-CA-C 112.299 0.481 . . . . 0.0 112.299 -178.198 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 168' ' ' VAL . . . . . 0.426 HG23 HH11 ' A' ' 164' ' ' ARG . 25.2 t -53.66 -42.51 51.29 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.525 0 N-CA-C 112.327 0.492 . . . . 0.0 112.327 -179.432 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 169' ' ' VAL . . . . . . . . . . . . . 92.4 t -68.75 -66.73 0.49 Allowed 'Isoleucine or valine' 0 CA--C 1.532 0.281 0 N-CA-C 113.789 1.033 . . . . 0.0 113.789 -177.774 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 170' ' ' LEU . . . . . 0.536 HD11 ' HA ' ' A' ' 167' ' ' THR . 0.4 OUTLIER -59.62 -33.1 71.06 Favored 'General case' 0 N--CA 1.465 0.295 0 N-CA-C 113.01 0.744 . . . . 0.0 113.01 -177.565 . . . . . . . . 3 3 . 1 . 024 nuclear orig core ' A' A ' 171' ' ' TRP . . . . . 0.494 ' H ' HD13 ' A' ' 170' ' ' LEU . 19.6 m0 -73.43 -30.9 63.53 Favored 'General case' 0 C--N 1.329 -0.315 0 C-N-CA 120.411 -0.516 . . . . 0.0 111.171 -179.509 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 172' ' ' ALA . . . . . . . . . . . . . . . -70.99 -7.28 45.09 Favored 'General case' 0 C--N 1.33 -0.275 0 C-N-CA 120.847 -0.341 . . . . 0.0 110.817 179.453 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 173' ' ' ILE . . . . . 0.463 ' O ' HG12 ' A' ' 177' ' ' ILE . 22.9 mm -88.46 -27.07 5.5 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.21 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.951 179.627 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 174' ' ' TYR . . . . . 0.45 ' HD1' ' HA ' ' A' ' 171' ' ' TRP . 29.6 m-85 -54.02 -47.7 96.28 Favored Pre-proline 0 CA--C 1.529 0.143 0 CA-C-N 116.309 -0.405 . . . . 0.0 111.943 -179.286 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 175' ' ' PRO . . . . . 0.402 ' CD ' ' N ' ' A' ' 174' ' ' TYR . 81.8 Cg_exo -47.08 -34.86 17.98 Favored 'Trans proline' 0 C--N 1.35 0.625 0 C-N-CA 121.77 1.647 . . . . 0.0 111.852 179.093 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 176' ' ' PHE . . . . . 0.495 ' O ' ' HG ' ' A' ' 180' ' ' LEU . 67.6 m-85 -80.9 -51.02 9.04 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 115.749 -0.659 . . . . 0.0 111.554 179.729 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 177' ' ' ILE . . . . . 0.463 HG12 ' O ' ' A' ' 173' ' ' ILE . 31.5 mm -58.13 -30.48 39.42 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.558 0 CA-C-N 115.742 -0.663 . . . . 0.0 111.471 -178.674 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 178' ' ' TRP . . . . . 0.41 ' O ' ' HB2' ' A' ' 183' ' ' PRO . 90.7 t90 -73.77 -59.14 2.86 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-O 121.005 0.431 . . . . 0.0 110.865 179.791 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 179' ' ' LEU . . . . . 0.491 ' HG ' HG23 ' A' ' 185' ' ' VAL . 15.4 tp -61.31 -54.72 40.3 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 115.996 -0.547 . . . . 0.0 111.711 -178.989 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 180' ' ' LEU . . . . . 0.581 HD22 HD13 ' A' ' 187' ' ' LEU . 11.6 mt -63.65 -28.68 70.07 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 116.449 -0.341 . . . . 0.0 111.744 -179.112 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 181' ' ' GLY . . . . . 0.424 ' C ' ' HD2' ' A' ' 183' ' ' PRO . . . -73.96 -173.59 28.61 Favored Glycine 0 N--CA 1.451 -0.359 0 C-N-CA 120.05 -1.071 . . . . 0.0 111.823 179.422 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 182' ' ' PRO . . . . . 0.443 ' HG2' ' HD3' ' A' ' 183' ' ' PRO . 1.3 Cg_endo -47.01 -43.19 25.06 Favored 'Trans proline' 0 CA--C 1.541 0.831 0 C-N-CA 122.856 2.371 . . . . 0.0 113.789 179.561 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 183' ' ' PRO . . . . . 0.548 ' HB3' ' HB2' ' A' ' 116' ' ' ALA . 44.2 Cg_exo -37.86 -59.22 0.55 Allowed 'Trans proline' 0 C--N 1.357 0.989 0 C-N-CA 122.819 2.346 . . . . 0.0 114.12 -179.89 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 184' ' ' GLY . . . . . . . . . . . . . . . -115.65 -107.2 2.59 Favored Glycine 0 N--CA 1.45 -0.369 0 C-N-CA 120.162 -1.018 . . . . 0.0 113.174 -179.052 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 185' ' ' VAL . . . . . 0.524 HG22 ' HA ' ' A' ' 180' ' ' LEU . 26.8 m -76.81 86.11 0.81 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.405 0 CA-C-O 121.461 0.648 . . . . 0.0 111.021 -179.492 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 186' ' ' ALA . . . . . . . . . . . . . . . -63.38 85.27 0.03 OUTLIER 'General case' 0 C--N 1.323 -0.555 0 CA-C-N 115.683 -0.69 . . . . 0.0 111.08 179.67 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 187' ' ' LEU . . . . . 0.581 HD13 HD22 ' A' ' 180' ' ' LEU . 6.2 mt -78.99 -49.21 13.09 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 116.317 -0.402 . . . . 0.0 110.9 179.843 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 188' ' ' LEU . . . . . . . . . . . . . 3.9 mm? -94.98 -157.48 0.57 Allowed 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.034 -0.53 . . . . 0.0 111.437 -179.405 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 189' ' ' THR . . . . . 0.512 ' HB ' HG21 ' A' ' 192' ' ' VAL . 32.3 m -96.12 136.32 22.16 Favored Pre-proline 0 C--N 1.331 -0.218 0 CA-C-N 115.944 -0.571 . . . . 0.0 110.96 -179.654 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 190' ' ' PRO . . . . . 0.409 ' O ' HG23 ' A' ' 194' ' ' VAL . 80.6 Cg_exo -46.64 -42.98 23.61 Favored 'Trans proline' 0 C--N 1.35 0.639 0 C-N-CA 122.61 2.207 . . . . 0.0 113.022 -179.977 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 191' ' ' THR . . . . . . . . . . . . . 75.2 p -62.19 -45.78 91.83 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-O 120.792 0.33 . . . . 0.0 111.162 -179.822 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 192' ' ' VAL . . . . . 0.512 HG21 ' HB ' ' A' ' 189' ' ' THR . 58.9 t -60.04 -44.44 94.85 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.267 -0.424 . . . . 0.0 111.031 179.922 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 193' ' ' ASP . . . . . . . . . . . . . 28.2 t70 -56.81 -43.49 81.05 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.079 -0.509 . . . . 0.0 111.074 -179.935 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 194' ' ' VAL . . . . . 0.409 HG23 ' O ' ' A' ' 190' ' ' PRO . 93.1 t -63.06 -36.03 74.17 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.354 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.867 179.765 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 195' ' ' ALA . . . . . . . . . . . . . . . -58.62 -47.15 85.34 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.081 179.809 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 196' ' ' LEU . . . . . . . . . . . . . 57.5 mt -65.74 -37.52 86.6 Favored 'General case' 0 C--N 1.332 -0.177 0 CA-C-O 120.749 0.309 . . . . 0.0 110.591 179.714 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 197' ' ' ILE . . . . . . . . . . . . . 19.7 mm -61.55 -56.99 14.16 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.114 179.28 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 198' ' ' VAL . . . . . . . . . . . . . 73.0 t -52.39 -35.26 19.79 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.43 0 CA-C-N 115.743 -0.662 . . . . 0.0 109.519 178.472 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 199' ' ' TYR . . . . . . . . . . . . . 74.5 t80 -70.09 -38.55 75.7 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 115.228 -0.897 . . . . 0.0 110.583 179.849 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 200' ' ' LEU . . . . . . . . . . . . . 38.7 mt -63.65 -44.1 94.84 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 115.752 -0.658 . . . . 0.0 111.355 -179.607 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 201' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -72.03 -37.35 69.76 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.071 -0.513 . . . . 0.0 111.212 -179.753 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 202' ' ' LEU . . . . . 0.439 ' O ' ' HB ' ' A' ' 206' ' ' VAL . 3.2 mt -68.52 -30.8 69.69 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.686 -179.452 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 203' ' ' VAL . . . . . 0.491 ' O ' ' HA3' ' A' ' 207' ' ' GLY . 42.6 t -78.98 -36.57 18.77 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.437 0 CA-C-O 120.683 0.278 . . . . 0.0 111.125 -179.449 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 204' ' ' THR . . . . . . . . . . . . . 25.8 m -70.83 -50.83 31.17 Favored 'General case' 0 C--N 1.324 -0.519 0 C-N-CA 120.747 -0.381 . . . . 0.0 111.325 179.938 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 205' ' ' LYS . . . . . 0.554 ' HE2' ' HB2' ' A' ' 47' ' ' ALA . 50.5 mttp -71.99 -58.48 3.41 Favored 'General case' 0 C--N 1.328 -0.341 0 N-CA-C 112.313 0.486 . . . . 0.0 112.313 -178.629 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 206' ' ' VAL . . . . . 0.439 ' HB ' ' O ' ' A' ' 202' ' ' LEU . 61.9 t -74.82 -37.55 42.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 N-CA-C 111.817 0.303 . . . . 0.0 111.817 -178.983 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 207' ' ' GLY . . . . . 0.491 ' HA3' ' O ' ' A' ' 203' ' ' VAL . . . -63.07 -57.48 15.51 Favored Glycine 0 N--CA 1.452 -0.244 0 C-N-CA 120.372 -0.918 . . . . 0.0 112.117 -179.767 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 208' ' ' PHE . . . . . 0.523 ' O ' ' N ' ' A' ' 212' ' ' ALA . 4.8 m-85 -55.42 -49.05 73.43 Favored 'General case' 0 C--O 1.22 -0.478 0 N-CA-C 109.865 -0.42 . . . . 0.0 109.865 179.45 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 209' ' ' GLY . . . . . 0.433 ' HA2' ' HB1' ' A' ' 212' ' ' ALA . . . -53.71 -34.81 51.11 Favored Glycine 0 N--CA 1.451 -0.315 0 CA-C-N 115.183 -0.917 . . . . 0.0 113.382 179.641 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 210' ' ' PHE . . . . . . . . . . . . . 2.1 m-85 -70.7 -48.28 55.49 Favored 'General case' 0 CA--C 1.514 -0.427 0 N-CA-C 108.775 -0.824 . . . . 0.0 108.775 179.355 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 211' ' ' ILE . . . . . 0.408 HD11 HD13 ' A' ' 166' ' ' LEU . 5.6 mt -65.48 -27.59 42.11 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.608 0 N-CA-C 107.712 -1.218 . . . . 0.0 107.712 176.698 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 212' ' ' ALA . . . . . 0.523 ' N ' ' O ' ' A' ' 208' ' ' PHE . . . -68.59 -40.13 80.63 Favored 'General case' 0 N--CA 1.448 -0.555 0 CA-C-N 114.131 -1.395 . . . . 0.0 110.332 -179.763 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 213' ' ' LEU . . . . . . . . . . . . . 74.8 mt -70.16 -50.42 40.52 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 114.974 -1.012 . . . . 0.0 111.405 -179.572 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 214' ' ' ASP . . . . . . . . . . . . . 24.0 t70 -59.05 -49.9 76.12 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.931 -179.714 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 215' ' ' ALA . . . . . . . . . . . . . . . -56.57 -55.46 33.58 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.888 179.944 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 216' ' ' ALA . . . . . . . . . . . . . . . -62.0 -30.94 71.29 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.143 -0.48 . . . . 0.0 111.32 -179.95 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 217' ' ' ALA . . . . . . . . . . . . . . . -58.28 -43.56 88.03 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-O 120.966 0.412 . . . . 0.0 110.275 179.881 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 218' ' ' THR . . . . . . . . . . . . . 89.5 m . . . . . 0 C--N 1.33 -0.275 0 CA-C-N 115.826 -0.625 . . . . 0.0 110.355 179.287 . . . . . . . . 0 0 . 1 . 025 nuclear orig core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.301 0 N-CA-C 112.517 -0.233 . . . . 0.0 112.517 . . . . . . . . . 0 0 . 1 . 025 nuclear orig core ' A' A ' 4' ' ' LEU . . . . . 0.516 HD23 HG21 ' A' ' 194' ' ' VAL . 85.8 mt -74.48 -38.36 62.93 Favored 'General case' 0 N--CA 1.449 -0.477 0 CA-C-O 120.723 0.297 . . . . 0.0 111.509 -179.906 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 69.2 p -54.77 -37.33 65.88 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.138 -0.483 . . . . 0.0 112.03 -179.171 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 69.2 p -56.12 -35.19 66.82 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.481 -0.327 . . . . 0.0 111.548 -179.625 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 7' ' ' LEU . . . . . . . . . . . . . 4.0 mm? -63.2 -53.47 52.67 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.429 -0.35 . . . . 0.0 111.419 -179.648 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 8' ' ' PHE . . . . . 0.488 ' HB2' ' HB3' ' A' ' 55' ' ' ALA . 65.8 m-85 -60.25 -33.06 71.78 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.332 -0.395 . . . . 0.0 110.946 -179.586 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 9' ' ' TRP . . . . . . . . . . . . . 18.3 m95 -68.71 -49.36 59.49 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.246 -179.825 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 75.9 mt -59.39 -38.81 81.46 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 115.814 -0.63 . . . . 0.0 109.825 179.134 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -67.12 -36.24 90.04 Favored Glycine 0 N--CA 1.446 -0.64 0 CA-C-N 115.473 -0.785 . . . . 0.0 111.73 179.403 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -61.98 -33.38 74.21 Favored 'General case' 0 C--O 1.232 0.18 0 CA-C-O 121.037 0.446 . . . . 0.0 109.97 179.183 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 50.7 mm -65.61 -49.92 74.85 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 115.694 -0.685 . . . . 0.0 110.266 179.115 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -58.3 -36.24 82.36 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.798 -0.715 . . . . 0.0 112.218 179.539 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 15' ' ' MET . . . . . 0.708 ' HE3' ' HD2' ' A' ' 205' ' ' LYS . 19.3 mmt -66.21 -44.6 83.41 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.74 0.305 . . . . 0.0 110.783 179.733 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -53.79 -45.43 70.72 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 115.995 -0.548 . . . . 0.0 110.742 179.809 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 49.2 t -61.12 -43.94 97.3 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.238 0 CA-C-N 116.112 -0.495 . . . . 0.0 111.149 179.943 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -66.72 -43.95 90.65 Favored Glycine 0 N--CA 1.452 -0.256 0 C-N-CA 120.699 -0.762 . . . . 0.0 112.073 179.645 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 19.2 m -52.3 -42.72 64.02 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-O 120.675 0.274 . . . . 0.0 111.341 -179.776 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 80.9 mt -71.82 -44.8 63.3 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.406 -0.361 . . . . 0.0 111.554 -179.903 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -57.01 -32.59 66.29 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.37 -0.377 . . . . 0.0 111.759 -179.405 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 22' ' ' PHE . . . . . 0.439 ' HB2' HG21 ' A' ' 41' ' ' VAL . 10.0 m-85 -90.92 -38.63 12.77 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.537 -0.301 . . . . 0.0 111.62 -179.356 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -64.03 -50.49 68.24 Favored 'General case' 0 C--N 1.332 -0.166 0 CA-C-O 120.878 0.37 . . . . 0.0 111.25 -179.685 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 24' ' ' TRP . . . . . . . . . . . . . 1.3 t-105 -59.88 -49.84 76.13 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 115.958 -0.565 . . . . 0.0 110.68 179.685 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.329 -0.313 0 CA-C-N 116.266 -0.424 . . . . 0.0 111.033 179.88 . . . . . . . . 0 0 . 1 . 025 nuclear orig core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.373 0 N-CA-C 112.753 -0.139 . . . . 0.0 112.753 . . . . . . . . . 0 0 . 1 . 025 nuclear orig core ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 43.6 mt-10 -88.43 -21.49 24.22 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.686 0.279 . . . . 0.0 110.988 -179.937 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 34' ' ' ARG . . . . . . . . . . . . . 35.7 ttp180 -49.87 -35.25 22.67 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.141 -0.481 . . . . 0.0 111.527 -179.798 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 77.6 mtm180 -61.59 -54.33 44.48 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 120.85 0.357 . . . . 0.0 111.497 -179.772 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 59.4 m-85 -62.04 -30.02 70.69 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.134 -0.484 . . . . 0.0 111.421 -179.441 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 37' ' ' TYR . . . . . . . . . . . . . 32.5 m-85 -73.76 -56.11 5.4 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.503 -179.411 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 96.0 t -56.68 -36.7 49.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-O 120.98 0.419 . . . . 0.0 110.628 179.923 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 78.3 m -63.44 -51.62 64.92 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 115.872 -0.604 . . . . 0.0 110.918 179.713 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 40' ' ' LEU . . . . . 0.515 HD11 HD12 ' A' ' 43' ' ' ILE . 51.7 tp -61.29 -45.98 92.22 Favored 'General case' 0 C--O 1.236 0.35 0 CA-C-N 115.966 -0.561 . . . . 0.0 110.722 179.989 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . 0.439 HG21 ' HB2' ' A' ' 22' ' ' PHE . 85.8 t -60.13 -34.77 58.05 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.399 0 CA-C-N 115.684 -0.689 . . . . 0.0 109.858 178.974 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -63.15 -35.39 92.02 Favored Glycine 0 N--CA 1.445 -0.724 0 C-N-CA 120.877 -0.678 . . . . 0.0 112.026 179.592 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 43' ' ' ILE . . . . . 0.604 HG23 ' HE3' ' A' ' 205' ' ' LYS . 0.8 OUTLIER -66.23 -57.75 9.28 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.126 0 C-N-CA 121.074 -0.25 . . . . 0.0 111.148 179.811 . . . . . . . . 3 3 . 1 . 025 nuclear orig core ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 85.1 p -59.57 -21.56 60.48 Favored 'General case' 0 C--O 1.232 0.154 0 CA-C-N 116.485 -0.325 . . . . 0.0 111.554 -179.518 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -79.43 -56.23 3.46 Favored Glycine 0 CA--C 1.518 0.23 0 C-N-CA 120.843 -0.694 . . . . 0.0 113.063 -179.363 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 20.2 pt -58.2 -37.39 62.25 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.243 0 CA-C-O 121.138 0.494 . . . . 0.0 110.873 -179.896 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 47' ' ' ALA . . . . . 0.671 ' HB1' ' HE2' ' A' ' 205' ' ' LYS . . . -68.21 -45.26 73.82 Favored 'General case' 0 C--N 1.324 -0.525 0 CA-C-N 115.945 -0.571 . . . . 0.0 111.363 179.513 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -54.13 -42.71 69.79 Favored 'General case' 0 C--O 1.233 0.203 0 CA-C-N 116.299 -0.41 . . . . 0.0 111.807 -179.219 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 33.1 m -72.23 -34.5 49.77 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.363 0 CA-C-N 116.665 -0.243 . . . . 0.0 111.333 -179.517 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -66.9 -33.48 75.69 Favored 'General case' 0 CA--C 1.521 -0.146 0 CA-C-O 120.988 0.423 . . . . 0.0 110.73 179.402 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 3.0 m-30 -69.55 -40.72 76.66 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-N 115.909 -0.587 . . . . 0.0 110.12 179.784 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -61.44 -45.1 95.73 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 115.704 -0.68 . . . . 0.0 111.367 179.829 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 53' ' ' VAL . . . . . 0.486 HG23 ' N ' ' A' ' 54' ' ' MET . 25.3 m -67.62 -50.08 64.41 Favored 'Isoleucine or valine' 0 C--N 1.334 -0.087 0 C-N-CA 121.11 -0.236 . . . . 0.0 111.011 -179.956 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 54' ' ' MET . . . . . 0.514 ' HG2' ' HG2' ' A' ' 71' ' ' PRO . 74.7 mtm -58.04 -30.35 66.08 Favored 'General case' 0 CA--C 1.521 -0.172 0 CA-C-O 121.224 0.535 . . . . 0.0 109.866 179.336 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 55' ' ' ALA . . . . . 0.488 ' HB3' ' HB2' ' A' ' 8' ' ' PHE . . . -74.5 -33.93 62.93 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 115.414 -0.812 . . . . 0.0 111.365 179.526 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 74.8 mt -70.88 -5.19 28.78 Favored 'General case' 0 C--N 1.331 -0.203 0 CA-C-N 116.371 -0.377 . . . . 0.0 111.573 -179.416 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 98.8 -20.77 49.01 Favored Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.46 -0.876 . . . . 0.0 113.036 179.638 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 32.9 m -70.03 149.11 10.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-O 120.88 0.371 . . . . 0.0 110.826 179.805 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 59' ' ' GLY . . . . . 0.441 ' HA3' ' HG3' ' A' ' 71' ' ' PRO . . . 85.05 22.49 52.31 Favored Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.913 -0.661 . . . . 0.0 112.578 -179.47 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 60' ' ' TRP . . . . . . . . . . . . . 13.8 m0 -105.71 96.07 6.24 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-O 121.091 0.472 . . . . 0.0 109.986 -179.837 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 5.1 t -98.53 116.54 65.4 Favored Pre-proline 0 C--N 1.326 -0.435 0 CA-C-N 115.696 -0.683 . . . . 0.0 111.635 -178.87 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 57.1 Cg_endo -70.4 143.96 49.25 Favored 'Trans proline' 0 C--N 1.351 0.709 0 C-N-CA 122.437 2.092 . . . . 0.0 112.262 179.578 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 99.5 t -138.93 96.12 0.99 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.053 -0.521 . . . . 0.0 111.165 -179.88 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . 57.24 -88.1 0.02 OUTLIER 'General case' 0 C--N 1.331 -0.204 0 CA-C-N 116.189 -0.459 . . . . 0.0 111.439 179.781 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 45.7 mt-10 -121.85 -19.08 6.85 Favored 'General case' 0 C--N 1.332 -0.193 0 CA-C-N 116.433 -0.349 . . . . 0.0 110.939 179.935 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 66' ' ' ARG . . . . . . . . . . . . . 39.7 mmt180 -105.4 155.72 18.86 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.342 179.629 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 30.3 m -114.01 143.32 44.94 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-O 120.947 0.404 . . . . 0.0 111.351 -179.591 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 19.9 m -127.42 145.84 34.2 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.402 0 CA-C-N 115.83 -0.623 . . . . 0.0 110.818 179.659 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 69' ' ' PHE . . . . . . . . . . . . . 17.2 m-85 -110.73 115.6 29.84 Favored 'General case' 0 C--N 1.327 -0.38 0 N-CA-C 109.738 -0.467 . . . . 0.0 109.738 -179.63 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 70' ' ' VAL . . . . . 0.558 ' N ' ' HD2' ' A' ' 71' ' ' PRO . 59.4 t -68.43 -51.17 24.66 Favored Pre-proline 0 C--N 1.323 -0.559 0 N-CA-C 112.436 0.532 . . . . 0.0 112.436 -178.741 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 71' ' ' PRO . . . . . 0.558 ' HD2' ' N ' ' A' ' 70' ' ' VAL . 11.2 Cg_endo -54.87 -19.89 20.79 Favored 'Trans proline' 0 C--N 1.353 0.791 0 C-N-CA 122.089 1.859 . . . . 0.0 112.012 179.831 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 72' ' ' ARG . . . . . 0.419 ' NH2' HG13 ' A' ' 197' ' ' ILE . 53.1 ttt180 -74.96 -53.8 8.34 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.043 -0.526 . . . . 0.0 110.586 179.673 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 73' ' ' TYR . . . . . . . . . . . . . 75.8 m-85 -65.02 -36.91 85.91 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 115.774 -0.648 . . . . 0.0 110.704 -179.994 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 0.3 OUTLIER -70.05 -36.78 69.98 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 N-CA-C 109.744 -0.465 . . . . 0.0 109.744 179.048 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 12.3 t70 -56.52 -38.95 72.54 Favored 'General case' 0 CA--C 1.52 -0.176 0 CA-C-N 116.033 -0.531 . . . . 0.0 109.642 179.06 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 76' ' ' TRP . . . . . 0.509 ' HA ' ' HG1' ' A' ' 79' ' ' THR . 50.2 m0 -69.45 -38.54 77.84 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 115.615 -0.72 . . . . 0.0 110.624 179.418 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 92.5 mt -59.17 -28.77 39.97 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.725 179.674 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 35.4 mt -91.83 -26.91 18.29 Favored 'General case' 0 CA--C 1.533 0.293 0 N-CA-C 112.317 0.488 . . . . 0.0 112.317 -179.941 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 79' ' ' THR . . . . . 0.509 ' HG1' ' HA ' ' A' ' 76' ' ' TRP . 71.3 p -92.44 -52.24 4.75 Favored 'General case' 0 N--CA 1.466 0.342 0 N-CA-C 113.622 0.971 . . . . 0.0 113.622 -177.884 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 80' ' ' THR . . . . . 0.412 ' N ' ' HD2' ' A' ' 81' ' ' PRO . 89.0 m -47.3 -55.25 16.7 Favored Pre-proline 0 C--N 1.329 -0.325 0 N-CA-C 112.858 0.688 . . . . 0.0 112.858 -178.418 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 81' ' ' PRO . . . . . 0.412 ' HD2' ' N ' ' A' ' 80' ' ' THR . 37.2 Cg_endo -64.19 -18.99 65.42 Favored 'Trans proline' 0 C--N 1.35 0.614 0 C-N-CA 121.495 1.463 . . . . 0.0 111.232 -179.833 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 82' ' ' LEU . . . . . . . . . . . . . 18.4 tp -76.93 -33.6 57.72 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 115.529 -0.759 . . . . 0.0 110.169 179.641 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 41.2 mm -70.12 -52.23 32.29 Favored 'Isoleucine or valine' 0 C--O 1.232 0.175 0 CA-C-N 116.058 -0.519 . . . . 0.0 110.101 179.203 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 27.9 m -60.61 -30.47 46.89 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.179 0 N-CA-C 109.63 -0.507 . . . . 0.0 109.63 178.795 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 85' ' ' TYR . . . . . . . . . . . . . 81.1 t80 -65.33 -35.79 82.07 Favored 'General case' 0 N--CA 1.453 -0.28 0 CA-C-N 115.542 -0.754 . . . . 0.0 109.276 178.684 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 86' ' ' PHE . . . . . . . . . . . . . 7.2 t80 -61.15 -50.13 74.41 Favored 'General case' 0 C--O 1.234 0.237 0 CA-C-N 115.633 -0.712 . . . . 0.0 109.919 179.186 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 8.8 mp -62.23 -31.84 72.44 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 115.838 -0.619 . . . . 0.0 109.861 179.384 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -68.96 -27.69 73.69 Favored Glycine 0 N--CA 1.449 -0.459 0 C-N-CA 120.856 -0.688 . . . . 0.0 111.678 179.113 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 82.7 mt -73.72 -37.36 65.17 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-O 120.948 0.404 . . . . 0.0 110.482 179.549 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 90' ' ' LEU . . . . . 0.409 HD11 HD23 ' A' ' 163' ' ' LEU . 93.6 mt -64.3 -42.67 96.26 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 115.945 -0.571 . . . . 0.0 111.144 179.9 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -80.13 -54.99 5.25 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.4 -179.654 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 95.37 67.88 1.0 Allowed Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.814 -0.708 . . . . 0.0 112.132 -179.733 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 6.6 mp -71.21 -171.13 0.55 Allowed 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.783 0.325 . . . . 0.0 111.033 -179.71 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 94' ' ' ASP . . . . . 0.414 ' HB2' ' OE2' ' A' ' 97' ' ' GLU . 5.9 m-20 -96.43 -173.41 2.76 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-N 116.246 -0.433 . . . . 0.0 111.28 -179.807 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 47.5 t -67.52 -51.26 53.04 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 115.946 -0.57 . . . . 0.0 111.624 -179.425 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 96' ' ' ARG . . . . . 0.428 ' O ' HG13 ' A' ' 100' ' ' ILE . 31.6 mmt180 -73.72 -40.07 63.83 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 120.944 0.402 . . . . 0.0 110.699 -179.505 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 97' ' ' GLU . . . . . 0.497 ' HA ' HD12 ' A' ' 100' ' ' ILE . 0.3 OUTLIER -55.48 -47.39 76.21 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 115.763 -0.653 . . . . 0.0 111.501 -179.622 . . . . . . . . 3 3 . 1 . 025 nuclear orig core ' A' A ' 98' ' ' PHE . . . . . 0.422 ' O ' HG12 ' A' ' 102' ' ' ILE . 1.2 m-85 -57.13 -45.23 83.69 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.821 0.343 . . . . 0.0 110.796 179.813 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -62.68 -30.25 76.26 Favored Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.586 -179.92 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 100' ' ' ILE . . . . . 0.497 HD12 ' HA ' ' A' ' 97' ' ' GLU . 95.5 mt -65.65 -44.79 93.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-O 120.81 0.338 . . . . 0.0 111.221 -179.939 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 56.2 t -68.64 -43.89 82.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.322 -0.399 . . . . 0.0 111.51 -179.732 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 102' ' ' ILE . . . . . 0.422 HG12 ' O ' ' A' ' 98' ' ' PHE . 48.5 mm -61.45 -51.1 76.84 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.348 -0.387 . . . . 0.0 111.189 -179.789 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 14.9 t -61.35 -29.01 69.64 Favored 'General case' 0 C--O 1.232 0.153 0 CA-C-O 120.866 0.365 . . . . 0.0 110.614 179.925 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 1.4 tm? -59.6 -52.65 64.61 Favored 'General case' 0 C--N 1.331 -0.198 0 CA-C-N 116.073 -0.512 . . . . 0.0 109.807 179.217 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 105' ' ' ASN . . . . . 0.539 ' N ' HD21 ' A' ' 105' ' ' ASN . 0.8 OUTLIER -64.33 -26.18 68.37 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 115.965 -0.561 . . . . 0.0 111.024 179.732 . . . . . . . . 3 3 . 1 . 025 nuclear orig core ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 53.7 m -63.95 -56.7 13.26 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.38 -0.373 . . . . 0.0 111.478 -179.795 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 7.2 p -62.33 -36.47 74.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.272 -0.422 . . . . 0.0 111.214 -179.851 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 81.3 t -65.59 -54.41 28.37 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.197 0 CA-C-N 116.376 -0.375 . . . . 0.0 111.01 179.817 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 109' ' ' MET . . . . . . . . . . . . . 11.2 tpp -59.58 -36.29 75.94 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.94 -179.766 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 30.2 tp -66.52 -32.94 74.6 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.309 -0.405 . . . . 0.0 110.226 179.779 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -62.02 -54.21 44.68 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 115.97 -0.559 . . . . 0.0 110.683 179.526 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . -56.87 -36.51 73.25 Favored Glycine 0 C--N 1.331 0.283 0 C-N-CA 120.605 -0.807 . . . . 0.0 112.044 179.549 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 113' ' ' PHE . . . . . . . . . . . . . 2.6 t80 -54.06 -63.67 1.07 Allowed 'General case' 0 C--N 1.332 -0.186 0 CA-C-O 120.918 0.389 . . . . 0.0 110.262 179.589 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 114' ' ' ALA . . . . . 0.4 ' O ' HG12 ' A' ' 118' ' ' VAL . . . -62.25 -28.29 69.6 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 115.88 -0.6 . . . . 0.0 111.172 179.942 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 115' ' ' GLY . . . . . 0.451 ' N ' ' HG ' ' A' ' 126' ' ' LEU . . . -52.22 -52.88 33.84 Favored Glycine 0 C--N 1.333 0.363 0 C-N-CA 121.081 -0.58 . . . . 0.0 112.729 179.971 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -77.91 -15.06 59.3 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-O 120.711 0.291 . . . . 0.0 111.535 179.84 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 117' ' ' MET . . . . . . . . . . . . . 0.5 OUTLIER -93.83 19.34 8.99 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.468 -0.333 . . . . 0.0 111.488 -179.704 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 118' ' ' VAL . . . . . 0.4 HG12 ' O ' ' A' ' 114' ' ' ALA . 33.2 m -84.55 146.74 47.73 Favored Pre-proline 0 C--N 1.331 -0.223 0 CA-C-N 116.594 -0.276 . . . . 0.0 111.335 179.86 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 119' ' ' PRO . . . . . . . . . . . . . 96.6 Cg_endo -87.91 1.92 6.64 Favored 'Trans proline' 0 N--CA 1.458 -0.593 0 C-N-CA 122.709 2.273 . . . . 0.0 112.233 179.325 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -155.55 -138.39 2.56 Favored Glycine 0 C--N 1.332 0.334 0 C-N-CA 120.806 -0.711 . . . . 0.0 112.79 -179.674 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 47.1 pt -88.55 8.72 2.64 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.193 0 CA-C-O 120.645 0.26 . . . . 0.0 111.523 -179.634 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 38.4 mt-10 -60.07 -18.55 47.61 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.423 -0.353 . . . . 0.0 111.11 -179.853 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 123' ' ' ARG . . . . . . . . . . . . . 2.6 ptp180 -52.07 -33.8 40.86 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.176 -0.465 . . . . 0.0 111.737 -179.871 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 124' ' ' TYR . . . . . . . . . . . . . 40.8 m-85 -65.01 -32.67 74.51 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.599 -0.273 . . . . 0.0 111.362 -179.659 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 125' ' ' ALA . . . . . . . . . . . . . . . -68.73 -52.96 25.05 Favored 'General case' 0 C--O 1.237 0.419 0 CA-C-O 120.79 0.328 . . . . 0.0 111.064 179.909 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 126' ' ' LEU . . . . . 0.451 ' HG ' ' N ' ' A' ' 115' ' ' GLY . 2.6 mm? -49.86 -54.32 20.17 Favored 'General case' 0 CA--C 1.52 -0.187 0 CA-C-N 116.016 -0.538 . . . . 0.0 110.61 -179.988 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 127' ' ' PHE . . . . . 0.509 ' HZ ' ' HB3' ' A' ' 175' ' ' PRO . 7.1 t80 -67.5 -31.53 71.73 Favored 'General case' 0 N--CA 1.452 -0.35 0 CA-C-N 116.285 -0.416 . . . . 0.0 111.074 -179.652 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 128' ' ' GLY . . . . . . . . . . . . . . . -46.38 -48.38 16.2 Favored Glycine 0 C--N 1.331 0.283 0 C-N-CA 119.793 -1.194 . . . . 0.0 110.737 179.07 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 129' ' ' MET . . . . . 0.501 ' HE3' ' N ' ' A' ' 130' ' ' GLY . 6.0 tmm? -70.43 -45.79 65.18 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 115.139 -0.53 . . . . 0.0 109.894 178.75 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 130' ' ' GLY . . . . . 0.501 ' N ' ' HE3' ' A' ' 129' ' ' MET . . . -57.37 -29.63 60.6 Favored Glycine 0 C--N 1.331 0.265 0 CA-C-N 115.85 -0.614 . . . . 0.0 113.174 -179.315 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -75.02 -53.65 8.55 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-O 120.702 0.287 . . . . 0.0 110.58 -179.798 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 60.0 t -57.67 -42.08 80.77 Favored 'Isoleucine or valine' 0 C--O 1.234 0.252 0 CA-C-O 121.372 0.606 . . . . 0.0 109.672 178.815 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -68.9 -33.47 73.81 Favored 'General case' 0 N--CA 1.451 -0.377 0 CA-C-N 115.272 -0.877 . . . . 0.0 110.781 179.441 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 134' ' ' PHE . . . . . . . . . . . . . 70.5 t80 -54.59 -57.42 11.51 Favored 'General case' 0 N--CA 1.451 -0.394 0 CA-C-O 121.01 0.433 . . . . 0.0 110.031 179.542 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 135' ' ' ILE . . . . . 0.429 ' O ' HG23 ' A' ' 138' ' ' VAL . 26.4 mt -57.22 -33.27 42.88 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.388 0 CA-C-N 115.728 -0.669 . . . . 0.0 109.891 178.87 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . -59.26 -39.46 94.63 Favored Glycine 0 N--CA 1.448 -0.52 0 C-N-CA 120.31 -0.948 . . . . 0.0 111.511 178.851 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 137' ' ' LEU . . . . . . . . . . . . . 54.6 tp -68.68 -55.34 11.74 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-O 120.715 0.293 . . . . 0.0 110.729 179.549 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 138' ' ' VAL . . . . . 0.429 HG23 ' O ' ' A' ' 135' ' ' ILE . 2.8 m -55.86 -32.08 31.64 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.24 0 CA-C-O 121.45 0.643 . . . . 0.0 109.478 179.747 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 139' ' ' TYR . . . . . . . . . . . . . 9.8 t80 -64.23 -36.89 85.55 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 115.28 -0.873 . . . . 0.0 109.995 178.667 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 16.1 m-85 -66.18 -53.15 40.87 Favored 'General case' 0 C--N 1.332 -0.186 0 CA-C-N 115.959 -0.564 . . . . 0.0 111.332 179.669 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 141' ' ' LEU . . . . . 0.533 HD13 HG23 ' A' ' 142' ' ' VAL . 3.0 pp -64.31 -17.12 63.36 Favored 'General case' 0 C--N 1.333 -0.148 0 CA-C-O 120.657 0.265 . . . . 0.0 111.268 -179.418 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 142' ' ' VAL . . . . . 0.533 HG23 HD13 ' A' ' 141' ' ' LEU . 47.1 t -94.93 -22.71 5.3 Favored 'Isoleucine or valine' 0 C--O 1.233 0.208 0 CA-C-O 121.054 0.454 . . . . 0.0 110.366 178.343 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . -74.25 -124.6 0.12 Allowed Glycine 0 CA--C 1.524 0.612 0 C-N-CA 121.114 -0.565 . . . . 0.0 113.485 -179.234 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 144' ' ' PRO . . . . . . . . . . . . . 46.6 Cg_endo -67.55 -23.13 43.62 Favored 'Trans proline' 0 C--N 1.35 0.642 0 C-N-CA 122.769 2.313 . . . . 0.0 113.253 -179.157 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 145' ' ' MET . . . . . 0.482 ' HB3' ' OH ' ' A' ' 160' ' ' TYR . 5.7 mtt -52.18 -57.61 9.13 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.508 -0.315 . . . . 0.0 111.658 -179.609 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 146' ' ' THR . . . . . . . . . . . . . 8.8 t -62.78 -32.2 73.32 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.488 -0.324 . . . . 0.0 111.719 -179.343 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 147' ' ' GLU . . . . . 0.414 ' HA ' ' HG ' ' A' ' 150' ' ' SER . 45.6 mt-10 -70.57 -33.9 71.61 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.425 -0.352 . . . . 0.0 111.311 -179.609 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 148' ' ' SER . . . . . . . . . . . . . 38.8 m -70.52 -49.87 43.62 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.956 0.408 . . . . 0.0 110.843 -179.889 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 149' ' ' ALA . . . . . 0.474 ' HB1' HG23 ' A' ' 156' ' ' ILE . . . -64.05 -35.23 80.06 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 115.992 -0.549 . . . . 0.0 111.757 -179.553 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 150' ' ' SER . . . . . 0.442 ' HA ' ' HB2' ' A' ' 157' ' ' LYS . 86.3 p -67.71 -5.59 16.71 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.379 -0.373 . . . . 0.0 111.232 -179.664 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 151' ' ' GLN . . . . . . . . . . . . . 78.9 mt-30 -115.3 -1.16 12.98 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.503 -0.317 . . . . 0.0 111.338 179.947 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 32.4 mmt180 -80.97 -51.63 8.33 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-O 120.843 0.354 . . . . 0.0 110.989 179.812 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 153' ' ' SER . . . . . 0.533 ' HB3' HG12 ' A' ' 156' ' ' ILE . 27.5 t -158.08 172.41 18.48 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 116.141 -0.482 . . . . 0.0 110.844 179.635 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 154' ' ' SER . . . . . . . . . . . . . 50.8 m -71.59 -40.47 69.85 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.285 -0.416 . . . . 0.0 110.455 179.327 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -76.75 -31.97 51.86 Favored Glycine 0 N--CA 1.452 -0.281 0 C-N-CA 121.013 -0.613 . . . . 0.0 112.708 179.916 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 156' ' ' ILE . . . . . 0.533 HG12 ' HB3' ' A' ' 153' ' ' SER . 29.5 mm -60.14 -38.21 76.17 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.229 0 CA-C-O 120.834 0.349 . . . . 0.0 111.131 -179.896 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 157' ' ' LYS . . . . . 0.442 ' HB2' ' HA ' ' A' ' 150' ' ' SER . 61.7 tttm -66.85 -50.87 61.14 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.327 -179.601 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 48.5 t -62.72 -39.45 94.08 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.3 -0.409 . . . . 0.0 111.549 -179.464 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 159' ' ' LEU . . . . . 0.413 ' O ' HD13 ' A' ' 163' ' ' LEU . 32.0 tp -71.11 -33.45 70.15 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.364 -0.38 . . . . 0.0 111.211 -179.477 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 160' ' ' TYR . . . . . 0.482 ' OH ' ' HB3' ' A' ' 145' ' ' MET . 48.3 t80 -73.24 -46.82 47.93 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.569 -0.287 . . . . 0.0 111.473 -179.559 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 161' ' ' VAL . . . . . 0.42 HG22 ' N ' ' A' ' 162' ' ' ARG . 27.8 m -58.52 -45.4 90.24 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 CA-C-N 116.718 -0.219 . . . . 0.0 111.531 -179.408 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 162' ' ' ARG . . . . . 0.42 ' N ' HG22 ' A' ' 161' ' ' VAL . 40.7 mmt180 -65.05 -39.71 93.69 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-O 120.854 0.359 . . . . 0.0 111.324 -179.723 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 163' ' ' LEU . . . . . 0.591 ' HG ' ' HB2' ' A' ' 208' ' ' PHE . 6.3 mp -70.2 -46.84 63.73 Favored 'General case' 0 C--N 1.328 -0.366 0 N-CA-C 112.453 0.538 . . . . 0.0 112.453 -179.149 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 164' ' ' ARG . . . . . . . . . . . . . 5.8 ppt_? -70.96 -47.71 57.44 Favored 'General case' 0 C--N 1.33 -0.262 0 N-CA-C 112.107 0.41 . . . . 0.0 112.107 -178.418 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 165' ' ' ASN . . . . . . . . . . . . . 16.2 m-80 -57.75 -49.24 77.24 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-O 120.761 0.315 . . . . 0.0 111.129 -179.847 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 166' ' ' LEU . . . . . 0.452 ' O ' ' HG ' ' A' ' 170' ' ' LEU . 5.8 tt -63.57 -52.35 61.43 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.533 -179.427 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 167' ' ' THR . . . . . . . . . . . . . 98.7 m -56.4 -53.27 59.38 Favored 'General case' 0 C--N 1.33 -0.26 0 N-CA-C 112.528 0.566 . . . . 0.0 112.528 -178.88 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 168' ' ' VAL . . . . . . . . . . . . . 72.1 t -54.08 -45.15 65.24 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.225 0 N-CA-C 112.016 0.376 . . . . 0.0 112.016 -179.127 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 169' ' ' VAL . . . . . . . . . . . . . 54.2 t -55.39 -64.45 0.47 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 N-CA-C 111.831 0.308 . . . . 0.0 111.831 -179.387 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 170' ' ' LEU . . . . . 0.452 ' HG ' ' O ' ' A' ' 166' ' ' LEU . 1.1 pp -62.67 -29.68 70.82 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.657 -0.247 . . . . 0.0 111.626 -179.39 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 171' ' ' TRP . . . . . . . . . . . . . 4.1 m0 -69.79 -32.32 70.73 Favored 'General case' 0 C--N 1.332 -0.183 0 CA-C-O 121.126 0.488 . . . . 0.0 110.184 179.207 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 172' ' ' ALA . . . . . . . . . . . . . . . -71.83 -6.5 42.12 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 115.595 -0.73 . . . . 0.0 110.996 -179.848 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 173' ' ' ILE . . . . . 0.468 ' O ' HG12 ' A' ' 177' ' ' ILE . 48.2 mm -85.41 -23.76 7.09 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.245 0 CA-C-N 115.99 -0.55 . . . . 0.0 110.736 179.647 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 174' ' ' TYR . . . . . 0.408 ' N ' ' CD ' ' A' ' 175' ' ' PRO . 20.6 m-85 -54.08 -48.48 93.95 Favored Pre-proline 0 N--CA 1.464 0.232 0 CA-C-N 116.341 -0.39 . . . . 0.0 111.203 179.791 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 175' ' ' PRO . . . . . 0.509 ' HB3' ' HZ ' ' A' ' 127' ' ' PHE . 93.3 Cg_exo -44.6 -33.2 6.51 Favored 'Trans proline' 0 C--N 1.351 0.697 0 C-N-CA 122.287 1.991 . . . . 0.0 112.097 178.894 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 176' ' ' PHE . . . . . 0.499 ' O ' ' HG ' ' A' ' 180' ' ' LEU . 93.0 m-85 -80.63 -50.32 10.1 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 115.691 -0.686 . . . . 0.0 111.851 -179.876 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 177' ' ' ILE . . . . . 0.468 HG12 ' O ' ' A' ' 173' ' ' ILE . 4.6 mm -63.78 -30.91 51.18 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.56 0 N-CA-C 112.533 0.568 . . . . 0.0 112.533 -177.966 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 178' ' ' TRP . . . . . . . . . . . . . 84.0 t90 -73.7 -45.67 50.88 Favored 'General case' 0 C--N 1.331 -0.2 0 CA-C-O 120.833 0.349 . . . . 0.0 110.904 179.904 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 179' ' ' LEU . . . . . 0.507 HD23 HD21 ' A' ' 180' ' ' LEU . 0.5 OUTLIER -73.86 -54.82 7.14 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.027 -0.533 . . . . 0.0 111.635 -179.053 . . . . . . . . 3 3 . 1 . 025 nuclear orig core ' A' A ' 180' ' ' LEU . . . . . 0.516 HD22 HD12 ' A' ' 187' ' ' LEU . 16.6 mt -62.41 -46.34 89.02 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.563 -0.29 . . . . 0.0 111.378 -179.245 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . -54.64 173.55 0.77 Allowed Glycine 0 CA--C 1.523 0.536 0 C-N-CA 120.296 -0.954 . . . . 0.0 112.514 179.707 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 182' ' ' PRO . . . . . 0.449 ' HB2' ' HD3' ' A' ' 183' ' ' PRO . 86.9 Cg_exo -45.95 -45.3 17.65 Favored 'Trans proline' 0 CA--C 1.536 0.615 0 C-N-CA 122.813 2.342 . . . . 0.0 113.801 -179.849 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 183' ' ' PRO . . . . . 0.449 ' HD3' ' HB2' ' A' ' 182' ' ' PRO . 89.0 Cg_exo -45.37 -34.24 10.09 Favored 'Trans proline' 0 C--N 1.356 0.924 0 C-N-CA 122.281 1.987 . . . . 0.0 113.429 -179.828 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 184' ' ' GLY . . . . . . . . . . . . . . . -109.68 -123.75 4.71 Favored Glycine 0 C--N 1.333 0.368 0 C-N-CA 120.299 -0.953 . . . . 0.0 113.114 -179.652 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 185' ' ' VAL . . . . . . . . . . . . . 11.2 m -62.44 -21.77 27.93 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.218 0 N-CA-C 112.252 0.464 . . . . 0.0 112.252 -179.315 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 186' ' ' ALA . . . . . . . . . . . . . . . 57.12 85.63 0.08 Allowed 'General case' 0 N--CA 1.463 0.222 0 CA-C-O 120.862 0.363 . . . . 0.0 111.761 179.693 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 187' ' ' LEU . . . . . 0.516 HD12 HD22 ' A' ' 180' ' ' LEU . 12.6 mt -92.62 -49.66 5.99 Favored 'General case' 0 C--N 1.332 -0.192 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.375 179.806 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 188' ' ' LEU . . . . . 0.513 HD12 HG12 ' A' ' 192' ' ' VAL . 79.7 mt -101.41 -159.81 0.76 Allowed 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 115.946 -0.57 . . . . 0.0 111.1 -179.333 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 189' ' ' THR . . . . . . . . . . . . . 2.0 t -96.55 147.66 33.28 Favored Pre-proline 0 C--N 1.33 -0.277 0 CA-C-N 116.089 -0.505 . . . . 0.0 111.256 -179.793 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 190' ' ' PRO . . . . . 0.41 ' O ' HG22 ' A' ' 194' ' ' VAL . 77.1 Cg_exo -47.62 -39.29 29.77 Favored 'Trans proline' 0 C--N 1.351 0.685 0 C-N-CA 122.681 2.254 . . . . 0.0 112.74 179.967 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 191' ' ' THR . . . . . 0.444 ' HG1' ' N ' ' A' ' 192' ' ' VAL . 73.7 p -57.77 -44.05 85.94 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.315 -0.402 . . . . 0.0 111.357 -179.754 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 192' ' ' VAL . . . . . 0.513 HG12 HD12 ' A' ' 188' ' ' LEU . 40.8 t -68.25 -42.64 84.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.242 -0.436 . . . . 0.0 111.146 179.933 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 193' ' ' ASP . . . . . . . . . . . . . 25.6 t70 -58.29 -50.32 74.02 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.254 -0.43 . . . . 0.0 111.176 -179.849 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 194' ' ' VAL . . . . . 0.516 HG21 HD23 ' A' ' 4' ' ' LEU . 59.6 t -60.93 -35.71 66.89 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.35 -0.386 . . . . 0.0 110.982 179.896 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 195' ' ' ALA . . . . . . . . . . . . . . . -58.39 -48.39 80.8 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.466 -0.334 . . . . 0.0 111.143 179.858 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 196' ' ' LEU . . . . . . . . . . . . . 52.7 mt -68.27 -44.99 74.34 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.327 -0.397 . . . . 0.0 110.651 179.696 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 197' ' ' ILE . . . . . 0.419 HG13 ' NH2' ' A' ' 72' ' ' ARG . 20.2 mm -56.29 -59.12 3.16 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.368 0 CA-C-N 115.805 -0.634 . . . . 0.0 110.787 179.643 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 198' ' ' VAL . . . . . . . . . . . . . 49.3 t -52.26 -35.1 19.04 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.484 0 CA-C-N 115.657 -0.701 . . . . 0.0 109.55 178.728 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 199' ' ' TYR . . . . . . . . . . . . . 48.7 t80 -70.15 -32.1 69.92 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 115.482 -0.781 . . . . 0.0 110.523 179.641 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 200' ' ' LEU . . . . . 0.419 ' O ' HG12 ' A' ' 203' ' ' VAL . 40.8 mt -70.35 -43.97 69.12 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 115.903 -0.589 . . . . 0.0 111.553 -179.609 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 201' ' ' ASP . . . . . . . . . . . . . 8.5 m-20 -70.04 -38.37 75.83 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 121.087 0.47 . . . . 0.0 110.521 -179.971 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 202' ' ' LEU . . . . . 0.449 ' O ' HG21 ' A' ' 206' ' ' VAL . 2.7 mt -70.67 -33.09 70.56 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 115.721 -0.672 . . . . 0.0 111.95 -179.389 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 203' ' ' VAL . . . . . 0.462 ' O ' ' HA3' ' A' ' 207' ' ' GLY . 13.4 p -72.47 -36.08 53.34 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.297 0 C-N-CA 120.856 -0.338 . . . . 0.0 110.848 -178.651 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 204' ' ' THR . . . . . . . . . . . . . 82.4 m -66.29 -58.32 5.61 Favored 'General case' 0 C--N 1.328 -0.328 0 C-N-CA 120.797 -0.361 . . . . 0.0 111.47 179.443 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 205' ' ' LYS . . . . . 0.708 ' HD2' ' HE3' ' A' ' 15' ' ' MET . 57.3 mttp -61.1 -60.15 4.23 Favored 'General case' 0 C--N 1.329 -0.304 0 N-CA-C 112.974 0.731 . . . . 0.0 112.974 -177.697 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 206' ' ' VAL . . . . . 0.449 HG21 ' O ' ' A' ' 202' ' ' LEU . 1.0 OUTLIER -71.1 -36.31 62.35 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.434 0 N-CA-C 112.103 0.409 . . . . 0.0 112.103 -179.471 . . . . . . . . 3 3 . 1 . 025 nuclear orig core ' A' A ' 207' ' ' GLY . . . . . 0.548 ' O ' HG13 ' A' ' 211' ' ' ILE . . . -55.91 -61.48 7.39 Favored Glycine 0 C--N 1.331 0.258 0 C-N-CA 120.534 -0.841 . . . . 0.0 113.623 -178.691 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 208' ' ' PHE . . . . . 0.591 ' HB2' ' HG ' ' A' ' 163' ' ' LEU . 0.7 OUTLIER -72.35 -29.67 64.01 Favored 'General case' 0 C--O 1.224 -0.289 0 CA-C-N 117.433 0.617 . . . . 0.0 110.465 -179.632 . . . . . . . . 3 3 . 1 . 025 nuclear orig core ' A' A ' 209' ' ' GLY . . . . . 0.482 ' O ' ' HB3' ' A' ' 212' ' ' ALA . . . -64.66 -32.08 83.03 Favored Glycine 0 N--CA 1.448 -0.514 0 CA-C-N 115.89 -0.595 . . . . 0.0 111.916 179.24 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 210' ' ' PHE . . . . . . . . . . . . . 3.3 m-85 -73.39 -47.23 43.62 Favored 'General case' 0 CA--C 1.512 -0.5 0 N-CA-C 108.242 -1.021 . . . . 0.0 108.242 178.536 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 211' ' ' ILE . . . . . 0.548 HG13 ' O ' ' A' ' 207' ' ' GLY . 4.7 mt -63.81 -27.5 42.99 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.56 0 N-CA-C 107.342 -1.355 . . . . 0.0 107.342 176.273 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 212' ' ' ALA . . . . . 0.482 ' HB3' ' O ' ' A' ' 209' ' ' GLY . . . -64.85 -39.62 93.86 Favored 'General case' 0 N--CA 1.45 -0.463 0 CA-C-N 114.335 -1.302 . . . . 0.0 110.745 179.986 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 213' ' ' LEU . . . . . . . . . . . . . 48.6 mt -67.49 -49.55 62.99 Favored 'General case' 0 C--N 1.333 -0.128 0 CA-C-N 115.511 -0.768 . . . . 0.0 111.445 -179.565 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 214' ' ' ASP . . . . . . . . . . . . . 15.9 t70 -58.62 -51.08 71.45 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.938 0.399 . . . . 0.0 110.766 -179.908 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 215' ' ' ALA . . . . . . . . . . . . . . . -60.85 -53.42 57.5 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 115.936 -0.574 . . . . 0.0 111.214 -179.901 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 216' ' ' ALA . . . . . . . . . . . . . . . -53.32 -37.02 61.91 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.128 -179.963 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 217' ' ' ALA . . . . . . . . . . . . . . . -65.4 -33.87 76.96 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.108 -0.497 . . . . 0.0 110.347 179.577 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 218' ' ' THR . . . . . . . . . . . . . 67.0 m . . . . . 0 C--N 1.33 -0.263 0 CA-C-N 115.742 -0.663 . . . . 0.0 110.976 179.483 . . . . . . . . 0 0 . 1 . 026 nuclear orig core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.449 -0.439 0 N-CA-C 112.465 -0.254 . . . . 0.0 112.465 . . . . . . . . . 0 0 . 1 . 026 nuclear orig core ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -71.47 -37.43 71.33 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.909 0.385 . . . . 0.0 110.742 -179.971 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 65.4 p -64.19 -32.39 73.95 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.149 -179.967 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 11.8 p -57.29 -35.37 69.72 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.034 -0.53 . . . . 0.0 111.145 -179.818 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 7' ' ' LEU . . . . . . . . . . . . . 4.3 mm? -57.57 -50.94 71.47 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.295 -0.412 . . . . 0.0 111.154 179.793 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 8' ' ' PHE . . . . . 0.499 ' HB2' ' HB1' ' A' ' 55' ' ' ALA . 65.6 m-85 -65.84 -32.54 74.12 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.34 -0.391 . . . . 0.0 110.916 -179.706 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 9' ' ' TRP . . . . . 0.421 ' O ' HG13 ' A' ' 13' ' ' ILE . 23.2 m95 -67.09 -49.89 63.45 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-N 116.065 -0.516 . . . . 0.0 110.388 -179.524 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 89.5 mt -59.18 -47.05 86.74 Favored 'General case' 0 C--N 1.326 -0.45 0 CA-C-N 115.72 -0.673 . . . . 0.0 109.973 179.57 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . 0.423 ' O ' ' HG2' ' A' ' 15' ' ' MET . . . -57.67 -42.96 94.55 Favored Glycine 0 N--CA 1.445 -0.722 0 C-N-CA 120.634 -0.794 . . . . 0.0 111.363 179.062 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -56.36 -35.31 67.54 Favored 'General case' 0 C--N 1.331 -0.196 0 CA-C-O 120.939 0.4 . . . . 0.0 110.68 179.737 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 13' ' ' ILE . . . . . 0.421 HG13 ' O ' ' A' ' 9' ' ' TRP . 63.7 mt -62.32 -46.46 96.37 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 CA-C-N 116.002 -0.545 . . . . 0.0 110.082 179.334 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . 0.426 ' HA3' HD23 ' A' ' 202' ' ' LEU . . . -59.41 -40.67 96.4 Favored Glycine 0 N--CA 1.45 -0.399 0 C-N-CA 120.799 -0.715 . . . . 0.0 112.512 179.666 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 15' ' ' MET . . . . . 0.423 ' HG2' ' O ' ' A' ' 11' ' ' GLY . 13.8 mmm -62.93 -39.14 93.68 Favored 'General case' 0 C--N 1.332 -0.189 0 CA-C-O 120.824 0.345 . . . . 0.0 110.656 -179.946 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -59.11 -45.18 91.56 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.029 -0.532 . . . . 0.0 110.582 179.741 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 51.1 t -59.21 -48.63 86.26 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.2 0 CA-C-N 116.354 -0.384 . . . . 0.0 110.98 179.965 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -63.69 -48.42 77.39 Favored Glycine 0 N--CA 1.452 -0.283 0 C-N-CA 120.805 -0.712 . . . . 0.0 112.438 179.926 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 19' ' ' THR . . . . . 0.447 HG21 HG13 ' A' ' 41' ' ' VAL . 47.6 m -49.71 -41.19 42.87 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.735 0.302 . . . . 0.0 111.552 -179.445 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 78.0 mt -72.04 -41.61 67.29 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.425 -0.352 . . . . 0.0 111.393 179.841 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -62.57 -29.91 70.93 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.309 -0.405 . . . . 0.0 111.792 -179.65 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 22' ' ' PHE . . . . . 0.516 ' HB2' HG21 ' A' ' 41' ' ' VAL . 3.4 m-85 -89.99 -34.84 15.84 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.501 -0.318 . . . . 0.0 111.261 -179.256 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -70.43 -49.84 44.61 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.455 -0.339 . . . . 0.0 111.238 -179.993 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 24' ' ' TRP . . . . . . . . . . . . . 1.2 t-105 -59.46 -39.24 83.02 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.045 -0.525 . . . . 0.0 110.899 179.974 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.328 -0.342 0 CA-C-N 116.293 -0.412 . . . . 0.0 110.992 179.938 . . . . . . . . 0 0 . 1 . 026 nuclear orig core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.453 -0.229 0 N-CA-C 112.711 -0.156 . . . . 0.0 112.711 . . . . . . . . . 0 0 . 1 . 026 nuclear orig core ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 38.5 mt-10 -90.53 -20.74 22.31 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-O 120.807 0.336 . . . . 0.0 110.812 179.951 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 34' ' ' ARG . . . . . . . . . . . . . 38.5 ttm180 -48.37 -29.36 3.9 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 115.9 -0.591 . . . . 0.0 111.68 -179.512 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 35' ' ' ARG . . . . . 0.423 ' NE ' ' HA ' ' A' ' 35' ' ' ARG . 5.5 mmp_? -59.23 -46.6 88.04 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.808 0.337 . . . . 0.0 111.118 179.923 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 73.8 m-85 -67.63 -30.23 69.74 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.252 -179.848 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 37' ' ' TYR . . . . . . . . . . . . . 76.5 m-85 -74.13 -54.7 7.24 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.538 -179.406 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 10.5 p -56.72 -36.18 48.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-O 120.979 0.418 . . . . 0.0 110.387 179.884 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 52.5 m -68.9 -49.96 53.69 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 115.617 -0.72 . . . . 0.0 110.559 179.216 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 40' ' ' LEU . . . . . 0.414 HD11 HD13 ' A' ' 43' ' ' ILE . 22.5 tp -55.53 -50.02 71.08 Favored 'General case' 0 C--O 1.237 0.438 0 CA-C-N 115.718 -0.674 . . . . 0.0 110.374 179.651 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . 0.516 HG21 ' HB2' ' A' ' 22' ' ' PHE . 83.7 t -59.36 -34.24 53.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 115.769 -0.65 . . . . 0.0 109.94 178.912 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -58.56 -38.25 90.83 Favored Glycine 0 N--CA 1.448 -0.547 0 C-N-CA 120.71 -0.757 . . . . 0.0 111.453 179.503 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 43' ' ' ILE . . . . . 0.414 HD13 HD11 ' A' ' 40' ' ' LEU . 2.4 mt -65.21 -59.31 4.31 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.217 0 CA-C-O 120.863 0.363 . . . . 0.0 110.593 179.464 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 77.6 p -59.56 -24.67 63.91 Favored 'General case' 0 C--N 1.331 -0.218 0 CA-C-N 115.991 -0.549 . . . . 0.0 111.344 -179.666 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -75.3 -57.69 4.21 Favored Glycine 0 CA--C 1.518 0.24 0 C-N-CA 120.745 -0.74 . . . . 0.0 112.861 -179.653 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 22.6 pt -58.25 -35.27 52.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-O 120.908 0.385 . . . . 0.0 110.762 -179.896 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 47' ' ' ALA . . . . . 0.551 ' HB1' ' HE2' ' A' ' 205' ' ' LYS . . . -63.91 -49.73 71.48 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.001 -0.545 . . . . 0.0 111.07 179.764 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -54.52 -36.55 64.37 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.857 179.999 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 0.5 OUTLIER -67.04 -42.99 89.21 Favored 'Isoleucine or valine' 0 N--CA 1.432 -1.371 0 CA-C-N 116.031 -0.531 . . . . 0.0 111.486 179.797 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -67.85 -33.67 75.21 Favored 'General case' 0 C--N 1.333 -0.137 0 CA-C-N 116.43 -0.35 . . . . 0.0 111.463 179.954 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 51' ' ' TYR . . . . . 0.44 ' O ' ' HB3' ' A' ' 8' ' ' PHE . 31.5 m-85 -70.59 -36.77 73.73 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.77 -179.525 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -71.55 -42.42 67.9 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-N 115.985 -0.552 . . . . 0.0 111.531 179.985 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 53' ' ' VAL . . . . . 0.444 HG21 ' N ' ' A' ' 54' ' ' MET . 35.5 m -67.06 -50.7 61.59 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.173 0 CA-C-N 116.556 -0.293 . . . . 0.0 111.451 -179.629 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 54' ' ' MET . . . . . 0.444 ' N ' HG21 ' A' ' 53' ' ' VAL . 78.1 mtm -61.14 -32.04 71.75 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-O 121.047 0.451 . . . . 0.0 110.296 179.775 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 55' ' ' ALA . . . . . 0.499 ' HB1' ' HB2' ' A' ' 8' ' ' PHE . . . -66.44 -38.43 87.38 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 115.753 -0.658 . . . . 0.0 111.015 179.42 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 97.2 mt -71.25 -12.88 61.69 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.039 -0.528 . . . . 0.0 111.238 -179.817 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 101.05 -21.03 45.13 Favored Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.649 -0.786 . . . . 0.0 112.817 179.819 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 30.1 m -66.63 138.58 22.66 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.238 0 CA-C-O 120.872 0.367 . . . . 0.0 111.018 -179.981 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 101.8 -11.52 57.67 Favored Glycine 0 N--CA 1.45 -0.402 0 C-N-CA 120.815 -0.707 . . . . 0.0 112.413 -179.7 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 60' ' ' TRP . . . . . . . . . . . . . 22.0 m0 -78.39 117.38 19.56 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.699 0.285 . . . . 0.0 110.727 179.793 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 10.0 p -109.99 129.54 23.83 Favored Pre-proline 0 C--N 1.329 -0.295 0 CA-C-N 116.438 -0.347 . . . . 0.0 111.078 179.836 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 86.5 Cg_endo -75.96 140.61 23.08 Favored 'Trans proline' 0 C--N 1.35 0.637 0 C-N-CA 122.404 2.07 . . . . 0.0 112.111 179.897 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 81.9 t -138.94 96.13 0.99 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.041 -0.527 . . . . 0.0 110.937 -179.767 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . 58.48 -86.71 0.02 OUTLIER 'General case' 0 C--N 1.332 -0.195 0 CA-C-N 116.001 -0.545 . . . . 0.0 111.315 -179.906 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 40.8 tt0 -121.04 -26.19 5.19 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.398 -0.364 . . . . 0.0 110.781 179.959 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 66' ' ' ARG . . . . . . . . . . . . . 76.0 ttt-85 -102.11 154.55 18.89 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.576 -179.954 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 86.0 m -113.37 121.24 43.76 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 120.882 0.373 . . . . 0.0 111.57 -179.741 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 68' ' ' VAL . . . . . 0.419 HG21 ' HA ' ' A' ' 117' ' ' MET . 21.8 t -93.21 146.89 5.88 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-N 115.978 -0.555 . . . . 0.0 110.374 179.344 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 69' ' ' PHE . . . . . . . . . . . . . 30.3 m-85 -106.87 112.31 25.21 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-O 120.836 0.351 . . . . 0.0 110.152 -179.494 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 70' ' ' VAL . . . . . 0.553 ' HB ' ' HD3' ' A' ' 71' ' ' PRO . 11.2 t -68.6 -50.22 26.61 Favored Pre-proline 0 C--N 1.326 -0.45 0 CA-C-N 115.986 -0.552 . . . . 0.0 112.361 -178.85 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 71' ' ' PRO . . . . . 0.553 ' HD3' ' HB ' ' A' ' 70' ' ' VAL . 24.6 Cg_exo -63.28 -18.35 64.41 Favored 'Trans proline' 0 C--N 1.351 0.7 0 C-N-CA 122.253 1.968 . . . . 0.0 113.068 -179.455 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 70.6 ttt180 -70.69 -55.48 8.6 Favored 'General case' 0 C--O 1.235 0.316 0 CA-C-O 120.88 0.371 . . . . 0.0 111.661 -179.33 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 73' ' ' TYR . . . . . . . . . . . . . 98.8 m-85 -71.86 -33.27 68.27 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.525 -0.307 . . . . 0.0 110.72 -179.519 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 0.3 OUTLIER -65.96 -37.67 80.37 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.307 0 N-CA-C 109.446 -0.575 . . . . 0.0 109.446 179.017 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 33.1 t70 -61.65 -37.33 83.65 Favored 'General case' 0 N--CA 1.453 -0.286 0 N-CA-C 109.251 -0.648 . . . . 0.0 109.251 178.734 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 76' ' ' TRP . . . . . . . . . . . . . 45.8 m0 -66.66 -29.91 70.05 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 115.642 -0.708 . . . . 0.0 110.114 179.019 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 77' ' ' ILE . . . . . 0.435 HG12 ' HB3' ' A' ' 109' ' ' MET . 97.0 mt -71.73 -29.62 34.84 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 115.87 -0.605 . . . . 0.0 110.737 179.447 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 51.8 mt -90.43 -17.17 27.66 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 116.0 -0.546 . . . . 0.0 111.776 179.994 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 79' ' ' THR . . . . . 0.4 ' O ' HG12 ' A' ' 83' ' ' ILE . 69.7 p -102.94 -52.63 3.01 Favored 'General case' 0 C--N 1.332 -0.189 0 N-CA-C 113.311 0.856 . . . . 0.0 113.311 -178.371 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 80' ' ' THR . . . . . 0.677 ' HB ' ' HD3' ' A' ' 81' ' ' PRO . 37.4 m -50.2 -55.7 23.15 Favored Pre-proline 0 CA--C 1.533 0.292 0 N-CA-C 112.537 0.569 . . . . 0.0 112.537 -178.284 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 81' ' ' PRO . . . . . 0.677 ' HD3' ' HB ' ' A' ' 80' ' ' THR . 39.2 Cg_exo -61.06 -21.07 70.42 Favored 'Trans proline' 0 C--N 1.351 0.666 0 C-N-CA 121.55 1.5 . . . . 0.0 111.587 179.818 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 82' ' ' LEU . . . . . . . . . . . . . 14.4 tp -76.99 -33.17 57.62 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 115.811 -0.631 . . . . 0.0 110.599 179.847 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 83' ' ' ILE . . . . . 0.4 HG12 ' O ' ' A' ' 79' ' ' THR . 36.3 mm -69.92 -53.45 23.84 Favored 'Isoleucine or valine' 0 C--O 1.232 0.173 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.214 179.326 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 84' ' ' VAL . . . . . 0.404 HG22 ' OD1' ' A' ' 105' ' ' ASN . 34.6 m -59.61 -32.46 49.22 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.224 0 N-CA-C 109.4 -0.592 . . . . 0.0 109.4 178.637 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 85' ' ' TYR . . . . . . . . . . . . . 68.7 t80 -60.68 -43.88 97.17 Favored 'General case' 0 N--CA 1.452 -0.356 0 CA-C-N 115.455 -0.793 . . . . 0.0 109.047 178.606 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 86' ' ' PHE . . . . . . . . . . . . . 2.1 t80 -53.52 -50.25 65.84 Favored 'General case' 0 C--O 1.233 0.199 0 CA-C-N 115.632 -0.713 . . . . 0.0 109.734 179.407 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 87' ' ' LEU . . . . . 0.499 ' HA ' HD11 ' A' ' 90' ' ' LEU . 8.9 mp -59.72 -28.34 67.25 Favored 'General case' 0 C--N 1.332 -0.188 0 CA-C-N 115.785 -0.643 . . . . 0.0 110.665 179.618 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -65.28 -42.45 96.2 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.65 -0.786 . . . . 0.0 111.903 179.697 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 8.8 mp -64.5 -37.22 86.77 Favored 'General case' 0 N--CA 1.45 -0.474 0 CA-C-O 121.118 0.485 . . . . 0.0 110.504 179.387 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 90' ' ' LEU . . . . . 0.499 HD11 ' HA ' ' A' ' 87' ' ' LEU . 97.9 mt -55.32 -59.07 5.31 Favored 'General case' 0 C--N 1.326 -0.455 0 CA-C-N 115.368 -0.833 . . . . 0.0 111.162 179.905 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 91' ' ' ALA . . . . . 0.499 ' HB2' ' HB2' ' A' ' 149' ' ' ALA . . . -71.69 -54.82 9.1 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.085 -0.507 . . . . 0.0 111.382 -179.79 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 110.88 59.46 0.48 Allowed Glycine 0 N--CA 1.45 -0.372 0 C-N-CA 120.95 -0.643 . . . . 0.0 112.255 -179.892 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 93' ' ' LEU . . . . . 0.472 HD21 ' HB3' ' A' ' 97' ' ' GLU . 8.9 mp -77.19 169.29 18.6 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.915 0.388 . . . . 0.0 111.133 -179.722 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 94' ' ' ASP . . . . . . . . . . . . . 9.7 m-20 -91.09 163.65 14.22 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.05 -0.523 . . . . 0.0 110.704 179.827 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 80.6 p -53.96 -27.56 32.05 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.331 -0.395 . . . . 0.0 110.988 -179.926 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 80.5 mtm180 -73.07 -53.43 11.09 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.299 -0.409 . . . . 0.0 110.757 179.81 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 97' ' ' GLU . . . . . 0.472 ' HB3' HD21 ' A' ' 93' ' ' LEU . 44.9 mt-10 -57.44 -39.41 76.19 Favored 'General case' 0 C--N 1.332 -0.191 0 CA-C-N 116.122 -0.49 . . . . 0.0 111.104 -179.857 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 98' ' ' PHE . . . . . 0.426 ' O ' HG12 ' A' ' 102' ' ' ILE . 12.6 m-85 -60.29 -51.54 69.12 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.366 -0.379 . . . . 0.0 110.857 179.969 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -59.31 -28.15 64.08 Favored Glycine 0 N--CA 1.452 -0.291 0 C-N-CA 120.675 -0.774 . . . . 0.0 112.497 -179.85 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 96.3 mt -73.4 -47.05 47.4 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-O 120.823 0.344 . . . . 0.0 111.345 -179.868 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 59.4 t -67.38 -43.2 87.89 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.399 0 CA-C-N 116.235 -0.438 . . . . 0.0 111.545 -179.675 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 102' ' ' ILE . . . . . 0.426 HG12 ' O ' ' A' ' 98' ' ' PHE . 49.5 mm -64.83 -48.92 82.4 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.386 -0.37 . . . . 0.0 111.4 -179.516 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 14.0 t -60.4 -31.05 70.0 Favored 'General case' 0 C--N 1.332 -0.169 0 CA-C-O 120.811 0.339 . . . . 0.0 110.814 -179.982 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 104' ' ' LEU . . . . . 0.432 HD22 ' HE2' ' A' ' 140' ' ' TYR . 45.6 tp -61.95 -54.45 41.58 Favored 'General case' 0 C--N 1.332 -0.185 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.382 179.486 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 105' ' ' ASN . . . . . 0.507 HD22 HD13 ' A' ' 137' ' ' LEU . 4.9 m120 -61.87 -25.48 67.57 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 116.053 -0.521 . . . . 0.0 110.959 -179.986 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 52.2 m -64.27 -54.89 26.24 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.343 -0.39 . . . . 0.0 111.12 179.992 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 13.4 p -64.14 -36.37 76.75 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.205 0 CA-C-N 116.382 -0.372 . . . . 0.0 111.049 -179.989 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . 0.414 HG22 ' O ' ' A' ' 104' ' ' LEU . 96.4 t -64.13 -52.65 53.44 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.761 179.664 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 109' ' ' MET . . . . . 0.435 ' HB3' HG12 ' A' ' 77' ' ' ILE . 9.7 tpp -62.11 -26.15 68.13 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 115.872 -0.604 . . . . 0.0 110.705 -179.973 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 29.7 tp -75.69 -33.87 60.38 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.163 -0.472 . . . . 0.0 110.204 179.396 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -62.13 -54.37 42.18 Favored 'General case' 0 C--N 1.332 -0.177 0 CA-C-N 115.924 -0.58 . . . . 0.0 110.377 179.301 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . -61.75 -37.32 94.09 Favored Glycine 0 N--CA 1.45 -0.388 0 C-N-CA 120.645 -0.788 . . . . 0.0 111.652 179.435 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 113' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER -48.23 -69.88 0.11 Allowed 'General case' 0 CA--C 1.521 -0.158 0 N-CA-C 109.755 -0.461 . . . . 0.0 109.755 179.219 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -65.1 -17.79 64.76 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 115.615 -0.72 . . . . 0.0 110.271 178.875 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 115' ' ' GLY . . . . . 0.458 ' HA2' HD23 ' A' ' 126' ' ' LEU . . . -52.52 -47.99 56.15 Favored Glycine 0 C--N 1.334 0.465 0 C-N-CA 121.005 -0.617 . . . . 0.0 111.791 179.45 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -78.26 -23.1 47.46 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-O 120.666 0.27 . . . . 0.0 111.571 179.705 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 117' ' ' MET . . . . . 0.419 ' HA ' HG21 ' A' ' 68' ' ' VAL . 40.9 ttm -94.8 19.2 10.44 Favored 'General case' 0 CA--C 1.533 0.305 0 CA-C-N 116.457 -0.338 . . . . 0.0 111.859 -179.257 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 118' ' ' VAL . . . . . 0.438 HG21 ' HB3' ' A' ' 123' ' ' ARG . 21.8 m -69.17 150.88 97.28 Favored Pre-proline 0 C--N 1.331 -0.227 0 CA-C-O 120.554 0.216 . . . . 0.0 111.17 179.736 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 119' ' ' PRO . . . . . . . . . . . . . 92.9 Cg_endo -81.29 -4.96 12.66 Favored 'Trans proline' 0 C--N 1.348 0.515 0 C-N-CA 122.699 2.266 . . . . 0.0 112.364 179.846 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -158.2 -131.23 1.26 Allowed Glycine 0 C--N 1.331 0.267 0 C-N-CA 120.834 -0.698 . . . . 0.0 112.653 -179.994 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 37.9 pt -97.48 10.88 5.79 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.226 0 CA-C-O 120.877 0.37 . . . . 0.0 111.161 -179.951 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 16.4 mm-40 -59.8 -18.12 41.13 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.016 -0.538 . . . . 0.0 111.096 179.8 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 123' ' ' ARG . . . . . 0.44 ' HB2' ' HH2' ' A' ' 178' ' ' TRP . 23.0 ptt180 -50.74 -28.9 10.1 Favored 'General case' 0 C--N 1.331 -0.197 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.778 -179.884 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 124' ' ' TYR . . . . . . . . . . . . . 38.1 m-85 -69.46 -32.91 72.13 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-O 120.828 0.347 . . . . 0.0 110.975 179.965 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 125' ' ' ALA . . . . . . . . . . . . . . . -73.52 -49.94 23.99 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.094 -0.503 . . . . 0.0 111.13 179.942 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 126' ' ' LEU . . . . . 0.458 HD23 ' HA2' ' A' ' 115' ' ' GLY . 7.9 mp -53.36 -55.49 24.49 Favored 'General case' 0 C--N 1.331 -0.201 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.316 179.771 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 127' ' ' PHE . . . . . 0.423 ' HZ ' ' HB3' ' A' ' 175' ' ' PRO . 9.7 t80 -62.82 -33.9 76.18 Favored 'General case' 0 N--CA 1.452 -0.372 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.264 179.568 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 128' ' ' GLY . . . . . . . . . . . . . . . -47.97 -43.23 23.9 Favored Glycine 0 C--N 1.333 0.394 0 C-N-CA 120.167 -1.016 . . . . 0.0 110.778 178.907 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 129' ' ' MET . . . . . . . . . . . . . 0.4 OUTLIER -71.27 -38.22 71.86 Favored 'General case' 0 C--N 1.329 -0.312 0 N-CA-C 109.786 -0.45 . . . . 0.0 109.786 178.565 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -65.72 -27.49 72.73 Favored Glycine 0 N--CA 1.451 -0.313 0 CA-C-N 115.757 -0.656 . . . . 0.0 112.695 179.907 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -74.77 -53.66 8.78 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.664 0.268 . . . . 0.0 110.545 179.828 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 132' ' ' VAL . . . . . 0.507 ' O ' HG13 ' A' ' 135' ' ' ILE . 38.7 t -57.2 -39.74 69.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-O 121.567 0.699 . . . . 0.0 109.311 178.675 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -70.99 -33.97 70.93 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-N 115.15 -0.932 . . . . 0.0 110.831 179.41 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 134' ' ' PHE . . . . . 0.439 ' CZ ' ' HA ' ' A' ' 172' ' ' ALA . 35.9 t80 -55.03 -59.22 5.04 Favored 'General case' 0 N--CA 1.453 -0.281 0 CA-C-N 116.353 -0.385 . . . . 0.0 110.397 179.809 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 135' ' ' ILE . . . . . 0.507 HG13 ' O ' ' A' ' 132' ' ' VAL . 0.2 OUTLIER -55.71 -36.63 43.52 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.368 0 CA-C-N 116.012 -0.54 . . . . 0.0 109.862 179.176 . . . . . . . . 3 3 . 1 . 026 nuclear orig core ' A' A ' 136' ' ' GLY . . . . . 0.402 ' O ' ' HB3' ' A' ' 139' ' ' TYR . . . -52.77 -42.28 59.06 Favored Glycine 0 C--N 1.334 0.437 0 C-N-CA 120.396 -0.907 . . . . 0.0 111.686 178.86 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 137' ' ' LEU . . . . . 0.507 HD13 HD22 ' A' ' 105' ' ' ASN . 49.1 tp -64.52 -49.25 72.02 Favored 'General case' 0 C--N 1.33 -0.261 0 N-CA-C 110.187 -0.301 . . . . 0.0 110.187 179.161 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 138' ' ' VAL . . . . . . . . . . . . . 59.9 t -54.82 -33.12 27.4 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.928 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.238 179.847 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 139' ' ' TYR . . . . . 0.402 ' HB3' ' O ' ' A' ' 136' ' ' GLY . 18.2 t80 -63.0 -43.32 99.13 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 115.867 -0.606 . . . . 0.0 110.112 178.74 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 140' ' ' TYR . . . . . 0.432 ' HE2' HD22 ' A' ' 104' ' ' LEU . 29.1 m-85 -63.75 -44.49 93.34 Favored 'General case' 0 C--N 1.332 -0.171 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.025 179.658 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 141' ' ' LEU . . . . . 0.436 ' HA ' ' SD ' ' A' ' 145' ' ' MET . 10.4 mp -55.99 -34.37 65.69 Favored 'General case' 0 C--N 1.332 -0.191 0 CA-C-N 116.449 -0.341 . . . . 0.0 110.96 179.887 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 22.2 t -94.62 -17.3 7.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.111 179.85 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . -68.96 -140.61 0.1 OUTLIER Glycine 0 CA--C 1.521 0.441 0 C-N-CA 121.034 -0.603 . . . . 0.0 113.218 -179.789 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 144' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_exo -51.88 -23.58 16.65 Favored 'Trans proline' 0 C--N 1.35 0.614 0 C-N-CA 122.841 2.361 . . . . 0.0 113.004 -179.597 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 145' ' ' MET . . . . . 0.436 ' SD ' ' HA ' ' A' ' 141' ' ' LEU . 34.9 mtt -54.1 -35.68 62.39 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.354 -0.384 . . . . 0.0 111.734 -179.648 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 146' ' ' THR . . . . . . . . . . . . . 46.0 p -79.1 -32.1 44.5 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.83 0.347 . . . . 0.0 111.265 -179.413 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 43.3 tt0 -61.96 -48.91 78.29 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 116.114 -0.494 . . . . 0.0 111.108 -179.917 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 148' ' ' SER . . . . . . . . . . . . . 51.6 m -70.56 -44.89 66.49 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.654 -179.342 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 149' ' ' ALA . . . . . 0.499 ' HB2' ' HB2' ' A' ' 91' ' ' ALA . . . -60.31 -55.08 38.0 Favored 'General case' 0 C--N 1.329 -0.291 0 N-CA-C 112.065 0.395 . . . . 0.0 112.065 -179.256 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 150' ' ' SER . . . . . 0.464 ' HA ' ' HB3' ' A' ' 157' ' ' LYS . 67.6 m -64.03 -8.03 10.48 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.415 -0.357 . . . . 0.0 111.09 -179.681 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 151' ' ' GLN . . . . . . . . . . . . . 24.2 mt-30 -120.99 7.51 10.36 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.342 -0.39 . . . . 0.0 111.193 179.959 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 152' ' ' ARG . . . . . 0.51 ' HE ' ' HA ' ' A' ' 152' ' ' ARG . 5.3 tpm_? -85.55 -52.49 5.79 Favored 'General case' 0 C--N 1.332 -0.165 0 CA-C-O 120.841 0.353 . . . . 0.0 110.678 179.944 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 153' ' ' SER . . . . . 0.621 ' HB2' HG12 ' A' ' 156' ' ' ILE . 18.6 m -158.24 172.9 17.53 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 115.949 -0.568 . . . . 0.0 110.617 179.168 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 154' ' ' SER . . . . . . . . . . . . . 48.4 t -72.17 -40.26 68.08 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.512 179.455 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -77.45 -30.21 54.19 Favored Glycine 0 CA--C 1.518 0.274 0 C-N-CA 120.986 -0.626 . . . . 0.0 112.998 179.917 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 156' ' ' ILE . . . . . 0.621 HG12 ' HB2' ' A' ' 153' ' ' SER . 34.9 mm -58.84 -46.76 90.87 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.226 0 N-CA-C 111.974 0.361 . . . . 0.0 111.974 -179.264 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 157' ' ' LYS . . . . . 0.464 ' HB3' ' HA ' ' A' ' 150' ' ' SER . 6.5 ptpp? -60.64 -35.67 76.76 Favored 'General case' 0 C--N 1.331 -0.234 0 N-CA-C 111.588 0.218 . . . . 0.0 111.588 -179.394 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 49.0 m -66.24 -44.53 83.46 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.941 0.401 . . . . 0.0 111.236 -179.752 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 159' ' ' LEU . . . . . 0.432 HD21 ' HB1' ' A' ' 215' ' ' ALA . 5.1 mt -68.64 -37.66 79.87 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.544 -179.743 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 160' ' ' TYR . . . . . . . . . . . . . 13.8 t80 -68.55 -43.24 77.1 Favored 'General case' 0 C--N 1.327 -0.407 0 N-CA-C 112.267 0.469 . . . . 0.0 112.267 -178.705 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 24.0 m -63.78 -46.21 95.07 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 C-N-CA 120.989 -0.284 . . . . 0.0 111.717 -179.23 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 162' ' ' ARG . . . . . . . . . . . . . 24.9 tpt180 -69.25 -48.63 61.32 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.815 0.34 . . . . 0.0 111.491 -179.76 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 163' ' ' LEU . . . . . . . . . . . . . 1.5 mp -60.89 -54.8 40.62 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.089 -0.505 . . . . 0.0 111.937 -179.183 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 164' ' ' ARG . . . . . . . . . . . . . 6.1 tmm_? -55.94 -50.52 70.53 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 116.073 -0.512 . . . . 0.0 112.179 -178.498 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 165' ' ' ASN . . . . . 0.466 ' N ' HD21 ' A' ' 165' ' ' ASN . 0.9 OUTLIER -52.7 -51.52 59.97 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-O 120.662 0.268 . . . . 0.0 111.458 -179.261 . . . . . . . . 3 3 . 1 . 026 nuclear orig core ' A' A ' 166' ' ' LEU . . . . . 0.498 ' O ' ' HG ' ' A' ' 170' ' ' LEU . 3.4 tt -62.6 -52.55 62.92 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 116.385 -0.37 . . . . 0.0 111.713 -179.566 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 167' ' ' THR . . . . . . . . . . . . . 85.1 m -54.72 -53.17 58.46 Favored 'General case' 0 C--N 1.329 -0.296 0 N-CA-C 112.734 0.642 . . . . 0.0 112.734 -178.64 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 168' ' ' VAL . . . . . . . . . . . . . 81.8 t -55.53 -44.34 75.94 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 N-CA-C 112.281 0.474 . . . . 0.0 112.281 -178.723 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 169' ' ' VAL . . . . . 0.405 HG21 ' O ' ' A' ' 165' ' ' ASN . 68.8 t -57.93 -65.19 0.45 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.367 0 N-CA-C 112.409 0.522 . . . . 0.0 112.409 -179.039 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 170' ' ' LEU . . . . . 0.498 ' HG ' ' O ' ' A' ' 166' ' ' LEU . 0.7 OUTLIER -62.4 -31.68 72.4 Favored 'General case' 0 C--N 1.332 -0.195 0 N-CA-C 112.453 0.538 . . . . 0.0 112.453 -178.355 . . . . . . . . 3 3 . 1 . 026 nuclear orig core ' A' A ' 171' ' ' TRP . . . . . . . . . . . . . 5.8 m0 -70.12 -31.2 68.62 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-O 120.816 0.341 . . . . 0.0 110.658 179.48 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 172' ' ' ALA . . . . . 0.439 ' HA ' ' CZ ' ' A' ' 134' ' ' PHE . . . -74.21 -6.86 50.3 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.799 -179.763 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 173' ' ' ILE . . . . . 0.496 ' O ' HG12 ' A' ' 177' ' ' ILE . 34.9 mm -85.95 -21.76 7.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 115.901 -0.59 . . . . 0.0 110.383 179.43 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 174' ' ' TYR . . . . . . . . . . . . . 15.7 m-85 -54.42 -50.72 83.5 Favored Pre-proline 0 N--CA 1.463 0.222 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.744 -179.735 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 175' ' ' PRO . . . . . 0.423 ' HB3' ' HZ ' ' A' ' 127' ' ' PHE . 80.3 Cg_exo -46.13 -31.02 8.22 Favored 'Trans proline' 0 C--N 1.352 0.732 0 C-N-CA 122.131 1.887 . . . . 0.0 112.155 179.83 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 176' ' ' PHE . . . . . 0.444 ' HD2' ' HA ' ' A' ' 173' ' ' ILE . 74.4 m-85 -80.7 -49.97 10.51 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.88 -0.6 . . . . 0.0 111.826 -179.783 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 177' ' ' ILE . . . . . 0.496 HG12 ' O ' ' A' ' 173' ' ' ILE . 5.3 mm -62.82 -36.33 75.03 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.525 0 N-CA-C 112.454 0.539 . . . . 0.0 112.454 -177.958 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 178' ' ' TRP . . . . . 0.44 ' HH2' ' HB2' ' A' ' 123' ' ' ARG . 71.3 t90 -71.27 -47.55 56.29 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.827 0.346 . . . . 0.0 110.997 -179.89 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 179' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -69.84 -54.57 12.9 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.677 -179.045 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 180' ' ' LEU . . . . . 0.555 HD21 HD13 ' A' ' 187' ' ' LEU . 26.4 mt -65.06 -39.42 93.24 Favored 'General case' 0 C--N 1.328 -0.355 0 C-N-CA 121.025 -0.27 . . . . 0.0 111.469 -179.252 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . -62.26 -179.38 3.93 Favored Glycine 0 C--N 1.335 0.474 0 C-N-CA 120.031 -1.08 . . . . 0.0 112.196 179.074 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 182' ' ' PRO . . . . . . . . . . . . . 72.6 Cg_exo -48.85 -44.12 32.89 Favored 'Trans proline' 0 CA--C 1.536 0.623 0 C-N-CA 122.784 2.323 . . . . 0.0 113.87 179.896 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 183' ' ' PRO . . . . . . . . . . . . . 87.8 Cg_exo -47.62 -26.92 7.11 Favored 'Trans proline' 0 C--N 1.356 0.947 0 C-N-CA 122.279 1.986 . . . . 0.0 113.398 -179.782 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 184' ' ' GLY . . . . . . . . . . . . . . . -120.02 -125.92 3.36 Favored Glycine 0 N--CA 1.45 -0.369 0 C-N-CA 120.271 -0.966 . . . . 0.0 113.212 -179.598 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 185' ' ' VAL . . . . . . . . . . . . . 6.1 m -60.45 -27.58 40.35 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.369 0 N-CA-C 112.319 0.489 . . . . 0.0 112.319 -179.315 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 186' ' ' ALA . . . . . . . . . . . . . . . 58.23 82.79 0.13 Allowed 'General case' 0 C--N 1.331 -0.214 0 CA-C-O 120.801 0.334 . . . . 0.0 111.697 179.613 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 187' ' ' LEU . . . . . 0.555 HD13 HD21 ' A' ' 180' ' ' LEU . 8.4 mt -92.21 -49.78 6.0 Favored 'General case' 0 C--N 1.333 -0.151 0 CA-C-N 116.297 -0.411 . . . . 0.0 111.271 179.853 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 188' ' ' LEU . . . . . 0.421 ' HB3' ' H ' ' A' ' 189' ' ' THR . 4.3 mm? -91.16 -161.3 0.8 Allowed 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.002 -0.545 . . . . 0.0 111.571 -179.051 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 189' ' ' THR . . . . . 0.433 ' HB ' HG23 ' A' ' 192' ' ' VAL . 21.6 m -92.76 137.86 23.89 Favored Pre-proline 0 C--N 1.329 -0.326 0 CA-C-N 115.704 -0.68 . . . . 0.0 110.917 -179.479 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 190' ' ' PRO . . . . . . . . . . . . . 95.5 Cg_exo -44.86 -50.04 8.97 Favored 'Trans proline' 0 C--N 1.35 0.626 0 C-N-CA 122.674 2.249 . . . . 0.0 113.259 -179.951 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 191' ' ' THR . . . . . 0.425 HG21 HG23 ' A' ' 189' ' ' THR . 9.7 t -56.26 -39.79 73.18 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-O 120.668 0.271 . . . . 0.0 111.434 -179.606 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 192' ' ' VAL . . . . . 0.433 HG23 ' HB ' ' A' ' 189' ' ' THR . 72.8 t -64.71 -48.66 83.69 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.358 -0.383 . . . . 0.0 111.102 179.93 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 193' ' ' ASP . . . . . . . . . . . . . 27.0 t70 -57.12 -44.58 83.44 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.136 -0.484 . . . . 0.0 111.063 -179.875 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 194' ' ' VAL . . . . . . . . . . . . . 89.3 t -60.82 -35.86 67.42 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.247 0 CA-C-N 116.132 -0.486 . . . . 0.0 110.776 179.953 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 195' ' ' ALA . . . . . . . . . . . . . . . -60.1 -47.83 84.26 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-N 116.429 -0.35 . . . . 0.0 111.003 179.583 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 196' ' ' LEU . . . . . . . . . . . . . 86.1 mt -66.58 -42.82 86.39 Favored 'General case' 0 C--N 1.332 -0.158 0 CA-C-N 116.388 -0.369 . . . . 0.0 110.5 179.489 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 197' ' ' ILE . . . . . . . . . . . . . 15.6 mm -56.99 -59.53 3.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.077 -0.51 . . . . 0.0 110.341 179.221 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 198' ' ' VAL . . . . . . . . . . . . . 52.9 t -52.16 -34.76 18.29 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.5 0 CA-C-N 115.717 -0.674 . . . . 0.0 109.375 178.388 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 199' ' ' TYR . . . . . . . . . . . . . 57.5 t80 -69.54 -32.91 72.01 Favored 'General case' 0 C--N 1.331 -0.204 0 CA-C-N 115.462 -0.79 . . . . 0.0 110.623 -179.844 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 200' ' ' LEU . . . . . . . . . . . . . 34.6 mt -67.75 -41.55 83.21 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 115.885 -0.598 . . . . 0.0 111.081 -179.896 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 201' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -73.48 -35.02 65.63 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-O 121.147 0.499 . . . . 0.0 110.273 179.447 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 202' ' ' LEU . . . . . 0.426 HD23 ' HA3' ' A' ' 14' ' ' GLY . 1.0 OUTLIER -69.45 -28.38 66.06 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 115.495 -0.775 . . . . 0.0 111.924 -179.823 . . . . . . . . 3 3 . 1 . 026 nuclear orig core ' A' A ' 203' ' ' VAL . . . . . . . . . . . . . 9.5 p -82.44 -37.75 14.68 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.183 0 N-CA-C 111.804 0.298 . . . . 0.0 111.804 -178.831 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 204' ' ' THR . . . . . . . . . . . . . 88.9 m -67.35 -41.71 84.68 Favored 'General case' 0 C--N 1.33 -0.279 0 C-N-CA 120.798 -0.361 . . . . 0.0 111.297 179.664 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 205' ' ' LYS . . . . . 0.551 ' HE2' ' HB1' ' A' ' 47' ' ' ALA . 57.3 mttp -78.39 -51.56 9.87 Favored 'General case' 0 C--N 1.326 -0.455 0 N-CA-C 112.238 0.458 . . . . 0.0 112.238 -178.601 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 84.8 t -73.22 -37.37 52.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 N-CA-C 111.735 0.272 . . . . 0.0 111.735 -179.514 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 207' ' ' GLY . . . . . . . . . . . . . . . -71.52 -52.62 12.08 Favored Glycine 0 N--CA 1.453 -0.219 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.603 -179.654 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 208' ' ' PHE . . . . . 0.443 ' O ' ' HB1' ' A' ' 212' ' ' ALA . 10.1 t80 -59.6 -40.46 87.54 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-O 120.71 0.29 . . . . 0.0 110.477 179.648 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 209' ' ' GLY . . . . . 0.466 ' O ' ' HB3' ' A' ' 212' ' ' ALA . . . -70.18 -39.27 72.39 Favored Glycine 0 N--CA 1.451 -0.315 0 CA-C-N 115.699 -0.682 . . . . 0.0 113.302 -179.734 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 210' ' ' PHE . . . . . . . . . . . . . 1.1 m-85 -68.35 -43.0 78.41 Favored 'General case' 0 CA--C 1.508 -0.67 0 N-CA-C 107.794 -1.187 . . . . 0.0 107.794 179.099 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 211' ' ' ILE . . . . . . . . . . . . . 85.7 mt -67.49 -28.85 43.52 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.815 0 CA-C-N 114.296 -1.32 . . . . 0.0 107.548 176.688 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 212' ' ' ALA . . . . . 0.466 ' HB3' ' O ' ' A' ' 209' ' ' GLY . . . -67.0 -40.86 87.43 Favored 'General case' 0 N--CA 1.45 -0.472 0 CA-C-N 114.599 -1.182 . . . . 0.0 110.494 179.876 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 213' ' ' LEU . . . . . . . . . . . . . 91.0 mt -70.35 -52.2 24.33 Favored 'General case' 0 C--N 1.33 -0.239 0 CA-C-N 115.304 -0.862 . . . . 0.0 111.754 -179.407 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 214' ' ' ASP . . . . . . . . . . . . . 45.4 m-20 -50.04 -54.63 18.98 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.218 -0.447 . . . . 0.0 111.847 -179.277 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 215' ' ' ALA . . . . . 0.432 ' HB1' HD21 ' A' ' 159' ' ' LEU . . . -60.46 -54.49 44.87 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.432 -0.349 . . . . 0.0 111.541 -179.448 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 216' ' ' ALA . . . . . . . . . . . . . . . -55.86 -32.51 63.71 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-O 120.926 0.394 . . . . 0.0 111.317 -179.763 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 217' ' ' ALA . . . . . . . . . . . . . . . -65.57 -39.89 92.15 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.03 -0.532 . . . . 0.0 110.601 179.877 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 218' ' ' THR . . . . . . . . . . . . . 54.7 m . . . . . 0 C--N 1.329 -0.296 0 CA-C-N 115.993 -0.549 . . . . 0.0 110.757 179.588 . . . . . . . . 0 0 . 1 . 027 nuclear orig core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.27 0 CA-C-O 120.464 -0.075 . . . . 0.0 112.975 . . . . . . . . . 0 0 . 1 . 027 nuclear orig core ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 24.7 tp -57.04 -35.21 69.04 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.828 0.347 . . . . 0.0 111.265 -179.693 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 74.1 p -54.87 -37.88 66.82 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 116.211 -0.45 . . . . 0.0 112.015 -179.637 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 32.1 p -53.84 -35.29 61.32 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 120.823 0.344 . . . . 0.0 111.44 -179.452 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 7' ' ' LEU . . . . . 0.422 HD21 ' O ' ' A' ' 191' ' ' THR . 9.0 mp -58.6 -53.42 58.58 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.227 -179.83 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 8' ' ' PHE . . . . . 0.462 ' HB2' ' HB2' ' A' ' 55' ' ' ALA . 69.9 m-85 -60.46 -32.47 71.42 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.002 -0.544 . . . . 0.0 110.887 -179.837 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 9' ' ' TRP . . . . . . . . . . . . . 32.2 m95 -64.4 -44.39 91.43 Favored 'General case' 0 C--N 1.327 -0.371 0 N-CA-C 109.563 -0.532 . . . . 0.0 109.563 179.612 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 78.8 mt -63.56 -36.76 84.87 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 115.472 -0.785 . . . . 0.0 110.09 179.243 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -64.22 -37.13 94.11 Favored Glycine 0 N--CA 1.448 -0.535 0 CA-C-N 115.619 -0.719 . . . . 0.0 111.806 179.332 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -65.45 -37.51 87.09 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-O 120.856 0.36 . . . . 0.0 110.337 179.634 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 50.1 mm -59.14 -50.22 80.55 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.222 0 CA-C-N 115.937 -0.574 . . . . 0.0 110.432 179.119 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -58.42 -35.09 77.78 Favored Glycine 0 N--CA 1.45 -0.411 0 C-N-CA 120.772 -0.727 . . . . 0.0 112.12 179.536 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 15' ' ' MET . . . . . 0.624 ' HE2' ' HD2' ' A' ' 205' ' ' LYS . 22.7 mmt -66.37 -43.29 86.35 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-O 120.752 0.311 . . . . 0.0 110.892 179.718 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -55.96 -43.71 77.79 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.462 179.739 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 60.6 t -60.71 -46.59 95.68 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.283 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.989 179.903 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -66.17 -49.2 59.13 Favored Glycine 0 C--N 1.33 0.246 0 C-N-CA 120.787 -0.72 . . . . 0.0 112.41 179.685 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 23.6 m -49.61 -42.94 46.08 Favored 'General case' 0 C--N 1.327 -0.39 0 C-N-CA 122.365 0.266 . . . . 0.0 111.579 -179.458 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 65.7 mt -72.38 -42.16 65.55 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.478 -0.328 . . . . 0.0 111.753 179.858 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -61.61 -30.09 70.46 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.312 -0.404 . . . . 0.0 111.577 -179.362 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 22' ' ' PHE . . . . . 0.525 ' HB2' HG23 ' A' ' 41' ' ' VAL . 6.5 m-85 -90.88 -30.76 16.74 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.41 -0.359 . . . . 0.0 111.262 -179.594 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -72.36 -50.38 27.08 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.956 0.407 . . . . 0.0 111.558 -179.548 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 24' ' ' TRP . . . . . . . . . . . . . 4.1 t-105 -62.68 -43.12 99.62 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 115.978 -0.556 . . . . 0.0 111.171 -179.72 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.329 -0.289 0 CA-C-N 116.398 -0.365 . . . . 0.0 110.862 179.855 . . . . . . . . 0 0 . 1 . 027 nuclear orig core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.518 0.253 0 N-CA-C 112.644 -0.183 . . . . 0.0 112.644 . . . . . . . . . 0 0 . 1 . 027 nuclear orig core ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 37.4 mt-10 -69.43 -25.69 64.24 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.742 0.306 . . . . 0.0 110.99 -179.941 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 34' ' ' ARG . . . . . . . . . . . . . 17.5 tpt180 -53.13 -28.72 27.23 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.076 -0.511 . . . . 0.0 111.478 -179.654 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 41.0 mmt180 -60.17 -43.31 95.91 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-O 120.833 0.349 . . . . 0.0 111.207 -179.843 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 82.0 m-85 -71.72 -29.73 64.87 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.294 -0.412 . . . . 0.0 111.348 -179.779 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 37' ' ' TYR . . . . . . . . . . . . . 70.0 m-85 -75.79 -54.98 6.09 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.189 -0.459 . . . . 0.0 111.182 -179.549 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 14.8 p -56.61 -36.52 48.64 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-O 121.007 0.432 . . . . 0.0 110.578 179.774 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 28.5 m -66.06 -51.07 61.54 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 115.9 -0.591 . . . . 0.0 110.82 179.457 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 40' ' ' LEU . . . . . 0.421 ' O ' HG13 ' A' ' 43' ' ' ILE . 49.3 tp -59.12 -47.77 84.07 Favored 'General case' 0 C--O 1.235 0.314 0 CA-C-N 115.922 -0.581 . . . . 0.0 110.886 179.964 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . 0.525 HG23 ' HB2' ' A' ' 22' ' ' PHE . 89.9 t -60.63 -34.73 59.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.097 179.195 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 42' ' ' GLY . . . . . 0.426 ' O ' HG12 ' A' ' 46' ' ' ILE . . . -60.98 -38.59 95.74 Favored Glycine 0 N--CA 1.447 -0.587 0 CA-C-N 115.712 -0.676 . . . . 0.0 112.309 179.751 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 43' ' ' ILE . . . . . 0.607 HG23 ' HE3' ' A' ' 205' ' ' LYS . 0.1 OUTLIER -66.97 -56.94 11.82 Favored 'Isoleucine or valine' 0 C--O 1.232 0.145 0 CA-C-O 120.651 0.262 . . . . 0.0 110.989 179.903 . . . . . . . . 3 3 . 1 . 027 nuclear orig core ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 48.1 t -62.39 -21.31 65.26 Favored 'General case' 0 C--O 1.233 0.185 0 CA-C-O 120.833 0.349 . . . . 0.0 111.241 -179.892 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -77.06 -58.53 3.39 Favored Glycine 0 CA--C 1.519 0.305 0 C-N-CA 120.754 -0.736 . . . . 0.0 112.642 -179.758 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 46' ' ' ILE . . . . . 0.426 HG12 ' O ' ' A' ' 42' ' ' GLY . 16.1 pt -58.32 -35.87 55.63 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.157 0 CA-C-O 120.932 0.396 . . . . 0.0 110.726 179.94 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 47' ' ' ALA . . . . . 0.664 ' HB2' ' HE2' ' A' ' 205' ' ' LYS . . . -67.96 -39.89 83.29 Favored 'General case' 0 C--N 1.326 -0.45 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.771 179.056 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -54.58 -47.29 73.49 Favored 'General case' 0 C--O 1.233 0.205 0 CA-C-N 116.007 -0.542 . . . . 0.0 111.046 179.897 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 27.5 m -72.08 -34.09 49.18 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.379 0 CA-C-N 116.047 -0.524 . . . . 0.0 111.009 -179.901 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -60.1 -41.49 92.65 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-O 121.017 0.436 . . . . 0.0 110.761 179.503 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 51' ' ' TYR . . . . . 0.41 ' HB3' ' O ' ' A' ' 8' ' ' PHE . 43.8 m-85 -73.24 -31.5 64.16 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 115.899 -0.592 . . . . 0.0 110.262 -179.982 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -66.26 -43.3 86.85 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 115.887 -0.597 . . . . 0.0 110.624 179.126 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 16.5 m -75.15 -37.72 40.54 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.166 0 CA-C-N 116.277 -0.419 . . . . 0.0 111.028 179.798 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 54' ' ' MET . . . . . 0.499 ' HG2' ' HG2' ' A' ' 71' ' ' PRO . 68.5 mtm -67.22 -34.42 77.43 Favored 'General case' 0 CA--C 1.52 -0.18 0 CA-C-O 121.213 0.53 . . . . 0.0 109.776 179.215 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 55' ' ' ALA . . . . . 0.462 ' HB2' ' HB2' ' A' ' 8' ' ' PHE . . . -66.53 -19.29 65.75 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-N 115.382 -0.827 . . . . 0.0 111.124 179.481 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 87.5 mt -94.95 -3.73 48.04 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.329 -0.396 . . . . 0.0 111.01 -179.927 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 85.57 24.48 42.63 Favored Glycine 0 C--N 1.331 0.271 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.712 179.939 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 58' ' ' VAL . . . . . 0.419 ' O ' ' HG3' ' A' ' 71' ' ' PRO . 48.3 t -86.84 142.36 13.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-O 120.714 0.293 . . . . 0.0 110.829 179.882 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 59' ' ' GLY . . . . . 0.619 ' HA3' ' HD3' ' A' ' 71' ' ' PRO . . . 81.33 -3.74 76.01 Favored Glycine 0 N--CA 1.449 -0.458 0 C-N-CA 120.807 -0.711 . . . . 0.0 112.569 -179.976 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 60' ' ' TRP . . . . . . . . . . . . . 14.4 m0 -70.73 101.08 2.0 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.809 0.338 . . . . 0.0 110.646 179.853 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 61' ' ' VAL . . . . . 0.413 ' HA ' ' HD3' ' A' ' 62' ' ' PRO . 3.2 p -105.5 125.42 33.46 Favored Pre-proline 0 CA--C 1.534 0.334 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.35 -179.982 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 62' ' ' PRO . . . . . 0.413 ' HD3' ' HA ' ' A' ' 61' ' ' VAL . 8.4 Cg_exo -71.52 148.32 53.67 Favored 'Trans proline' 0 C--N 1.35 0.644 0 C-N-CA 122.617 2.211 . . . . 0.0 112.06 179.729 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 77.9 t -142.23 92.43 0.52 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-N 116.112 -0.495 . . . . 0.0 110.894 -179.932 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . 59.67 -85.99 0.02 OUTLIER 'General case' 0 C--N 1.331 -0.209 0 CA-C-N 116.158 -0.473 . . . . 0.0 111.346 -179.865 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 10.2 tp10 -121.05 -24.61 5.52 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.438 -0.346 . . . . 0.0 110.604 179.902 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 66' ' ' ARG . . . . . . . . . . . . . 80.7 mtt180 -103.54 152.96 21.1 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.132 -0.486 . . . . 0.0 110.396 -179.88 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 94.1 m -116.0 127.41 54.91 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 120.955 0.407 . . . . 0.0 111.426 -179.536 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 10.7 t -104.71 146.26 12.18 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.24 0 CA-C-N 115.941 -0.572 . . . . 0.0 110.39 179.488 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 69' ' ' PHE . . . . . . . . . . . . . 12.2 m-85 -109.81 111.76 23.38 Favored 'General case' 0 N--CA 1.452 -0.358 0 N-CA-C 109.519 -0.549 . . . . 0.0 109.519 -179.572 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 70' ' ' VAL . . . . . 0.615 ' N ' ' HD2' ' A' ' 71' ' ' PRO . 0.5 OUTLIER -66.21 -40.42 35.77 Favored Pre-proline 0 C--N 1.321 -0.654 0 N-CA-C 112.428 0.529 . . . . 0.0 112.428 -179.507 . . . . . . . . 3 3 . 1 . 027 nuclear orig core ' A' A ' 71' ' ' PRO . . . . . 0.619 ' HD3' ' HA3' ' A' ' 59' ' ' GLY . 27.1 Cg_endo -63.23 -27.04 72.2 Favored 'Trans proline' 0 C--N 1.356 0.93 0 C-N-CA 121.779 1.652 . . . . 0.0 112.821 -179.03 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 61.0 ttp180 -73.25 -52.99 11.99 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 121.0 0.428 . . . . 0.0 110.212 179.629 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 73' ' ' TYR . . . . . 0.428 ' O ' HG13 ' A' ' 77' ' ' ILE . 52.9 m-85 -66.49 -34.4 77.84 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.012 -0.54 . . . . 0.0 110.716 179.758 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 74' ' ' ILE . . . . . 0.415 ' HB ' ' O ' ' A' ' 70' ' ' VAL . 0.4 OUTLIER -72.83 -37.69 55.39 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.209 0 CA-C-N 116.282 -0.417 . . . . 0.0 110.121 179.675 . . . . . . . . 3 3 . 1 . 027 nuclear orig core ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 18.2 t70 -58.02 -37.79 74.99 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-N 116.212 -0.449 . . . . 0.0 109.863 179.226 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 76' ' ' TRP . . . . . . . . . . . . . 53.3 m0 -68.69 -42.16 78.19 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 115.894 -0.594 . . . . 0.0 110.601 179.428 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 77' ' ' ILE . . . . . 0.473 ' O ' ' HG3' ' A' ' 81' ' ' PRO . 86.1 mt -58.72 -28.67 37.96 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.062 -0.517 . . . . 0.0 111.016 179.567 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 45.5 mt -92.03 -38.89 11.96 Favored 'General case' 0 CA--C 1.534 0.343 0 N-CA-C 112.551 0.574 . . . . 0.0 112.551 -179.614 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 74.8 p -82.99 -52.43 6.68 Favored 'General case' 0 N--CA 1.465 0.299 0 N-CA-C 113.929 1.085 . . . . 0.0 113.929 -177.422 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 80' ' ' THR . . . . . 0.455 ' N ' ' HD2' ' A' ' 81' ' ' PRO . 39.2 m -48.01 -54.28 25.69 Favored Pre-proline 0 C--N 1.33 -0.252 0 N-CA-C 113.089 0.774 . . . . 0.0 113.089 -178.132 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 81' ' ' PRO . . . . . 0.473 ' HG3' ' O ' ' A' ' 77' ' ' ILE . 25.1 Cg_endo -60.14 -21.09 64.57 Favored 'Trans proline' 0 C--N 1.351 0.689 0 C-N-CA 121.481 1.454 . . . . 0.0 111.397 -179.683 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 82' ' ' LEU . . . . . . . . . . . . . 17.6 tp -77.03 -32.95 57.41 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 115.633 -0.712 . . . . 0.0 110.005 179.555 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 83' ' ' ILE . . . . . 0.488 HD12 HD13 ' A' ' 43' ' ' ILE . 41.4 mm -67.9 -53.14 32.57 Favored 'Isoleucine or valine' 0 C--O 1.233 0.206 0 CA-C-N 116.059 -0.519 . . . . 0.0 109.909 178.976 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 35.9 m -60.87 -29.86 46.22 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.219 0 CA-C-N 115.97 -0.559 . . . . 0.0 109.513 178.975 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 85' ' ' TYR . . . . . . . . . . . . . 78.8 t80 -68.52 -32.8 73.01 Favored 'General case' 0 N--CA 1.453 -0.303 0 CA-C-N 115.569 -0.741 . . . . 0.0 109.623 178.792 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 86' ' ' PHE . . . . . . . . . . . . . 8.8 t80 -62.36 -51.21 68.5 Favored 'General case' 0 C--N 1.333 -0.117 0 CA-C-N 115.87 -0.605 . . . . 0.0 109.733 179.298 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 10.5 mp -61.61 -29.63 70.17 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-N 115.83 -0.623 . . . . 0.0 110.136 179.339 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -69.96 -27.85 72.56 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.899 -0.667 . . . . 0.0 111.889 179.362 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 88.1 mt -74.29 -44.57 52.17 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-O 120.994 0.426 . . . . 0.0 110.597 179.587 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 43.4 mt -63.27 -28.4 70.0 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 115.75 -0.659 . . . . 0.0 111.05 -179.976 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -88.46 -39.88 13.89 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.379 -179.628 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 88.14 59.43 1.67 Allowed Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.662 -0.78 . . . . 0.0 112.26 -179.736 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 93' ' ' LEU . . . . . 0.503 HD12 ' HE1' ' A' ' 145' ' ' MET . 45.6 mt -75.79 -175.97 3.17 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.849 0.357 . . . . 0.0 110.957 -179.883 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 94' ' ' ASP . . . . . . . . . . . . . 7.8 m-20 -109.12 171.93 7.14 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.057 -0.519 . . . . 0.0 110.709 179.847 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 66.2 m -55.07 -36.4 65.57 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.345 -179.653 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 96' ' ' ARG . . . . . 0.431 ' O ' HG13 ' A' ' 100' ' ' ILE . 38.1 ttp180 -73.26 -52.77 12.8 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.352 -0.386 . . . . 0.0 111.054 -179.687 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 47.9 mt-10 -53.14 -48.3 68.04 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.404 -0.362 . . . . 0.0 111.441 -179.48 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 98' ' ' PHE . . . . . 0.43 ' O ' HG12 ' A' ' 102' ' ' ILE . 18.1 m-85 -55.91 -52.07 65.39 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.524 -0.307 . . . . 0.0 111.112 179.921 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -57.66 -28.09 59.59 Favored Glycine 0 N--CA 1.452 -0.277 0 C-N-CA 120.771 -0.728 . . . . 0.0 112.768 -179.72 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 100' ' ' ILE . . . . . 0.431 HG13 ' O ' ' A' ' 96' ' ' ARG . 95.7 mt -72.51 -42.69 63.84 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-O 120.839 0.352 . . . . 0.0 111.279 -179.787 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 48.3 t -69.35 -48.62 66.5 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.439 0 CA-C-N 116.222 -0.444 . . . . 0.0 111.577 -179.534 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 102' ' ' ILE . . . . . 0.43 HG12 ' O ' ' A' ' 98' ' ' PHE . 34.2 mm -59.79 -48.93 85.73 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.736 -179.284 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 15.1 t -58.77 -38.34 78.27 Favored 'General case' 0 C--O 1.233 0.198 0 CA-C-O 120.707 0.289 . . . . 0.0 111.083 -179.813 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 104' ' ' LEU . . . . . 0.425 HD22 ' HE2' ' A' ' 140' ' ' TYR . 36.6 tp -58.98 -43.45 91.41 Favored 'General case' 0 C--N 1.332 -0.177 0 CA-C-O 120.986 0.422 . . . . 0.0 110.272 179.296 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 105' ' ' ASN . . . . . 0.621 ' N ' HD21 ' A' ' 105' ' ' ASN . 0.8 OUTLIER -65.87 -27.69 68.41 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-N 116.019 -0.537 . . . . 0.0 110.644 -179.981 . . . . . . . . 3 3 . 1 . 027 nuclear orig core ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 62.4 m -63.52 -57.31 10.59 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 116.372 -0.377 . . . . 0.0 111.031 -179.89 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 12.8 p -57.99 -36.35 56.01 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.184 0 CA-C-N 116.399 -0.364 . . . . 0.0 110.857 179.937 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . 0.403 HG22 ' O ' ' A' ' 104' ' ' LEU . 54.3 t -58.32 -45.39 89.4 Favored 'Isoleucine or valine' 0 C--O 1.234 0.282 0 CA-C-O 121.069 0.462 . . . . 0.0 110.675 179.351 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 109' ' ' MET . . . . . 0.445 ' HG2' ' O ' ' A' ' 105' ' ' ASN . 21.3 mmt -71.96 -31.81 66.67 Favored 'General case' 0 CA--C 1.516 -0.361 0 CA-C-N 115.921 -0.582 . . . . 0.0 110.57 179.942 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 110' ' ' LEU . . . . . 0.469 ' C ' HD23 ' A' ' 110' ' ' LEU . 4.0 tt -62.6 -34.14 76.4 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-N 115.98 -0.555 . . . . 0.0 109.54 178.854 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -67.78 -53.73 24.82 Favored 'General case' 0 C--N 1.332 -0.18 0 CA-C-N 115.761 -0.654 . . . . 0.0 110.667 179.468 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . -62.4 -38.89 97.04 Favored Glycine 0 C--N 1.332 0.309 0 C-N-CA 120.641 -0.79 . . . . 0.0 112.286 179.566 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 113' ' ' PHE . . . . . . . . . . . . . 4.3 t80 -53.61 -66.93 0.3 Allowed 'General case' 0 C--N 1.331 -0.236 0 CA-C-O 121.088 0.47 . . . . 0.0 110.194 179.718 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 114' ' ' ALA . . . . . 0.414 ' HB2' HD21 ' A' ' 126' ' ' LEU . . . -65.22 -17.67 64.68 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 115.767 -0.651 . . . . 0.0 110.491 179.287 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -58.54 -48.43 84.42 Favored Glycine 0 C--N 1.332 0.333 0 CA-C-N 115.784 -0.644 . . . . 0.0 111.914 179.42 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -78.32 -17.49 56.49 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.739 0.304 . . . . 0.0 110.988 179.322 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 117' ' ' MET . . . . . . . . . . . . . 21.1 mmt -84.95 13.9 5.49 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.098 -0.501 . . . . 0.0 111.353 -179.452 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 118' ' ' VAL . . . . . 0.473 HG21 ' HB3' ' A' ' 123' ' ' ARG . 33.6 m -81.4 139.01 48.03 Favored Pre-proline 0 C--N 1.33 -0.266 0 N-CA-C 111.838 0.31 . . . . 0.0 111.838 -179.398 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 119' ' ' PRO . . . . . . . . . . . . . 85.7 Cg_endo -92.22 -2.63 3.99 Favored 'Trans proline' 0 N--CA 1.455 -0.788 0 C-N-CA 122.91 2.407 . . . . 0.0 112.463 179.052 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -138.89 -110.34 0.91 Allowed Glycine 0 C--N 1.333 0.379 0 C-N-CA 120.675 -0.774 . . . . 0.0 112.863 -179.775 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 2.4 pp -127.07 15.29 3.56 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.192 0 N-CA-C 111.849 0.314 . . . . 0.0 111.849 -179.775 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 46.5 mt-10 -61.22 -18.54 58.83 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.906 0.384 . . . . 0.0 110.838 179.82 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 123' ' ' ARG . . . . . 0.556 ' HD2' ' HA2' ' A' ' 184' ' ' GLY . 24.4 ptt180 -51.46 -27.63 10.9 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 115.871 -0.604 . . . . 0.0 111.729 -179.92 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 124' ' ' TYR . . . . . . . . . . . . . 22.2 m-85 -75.15 -33.34 61.51 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.582 -0.281 . . . . 0.0 111.382 -179.524 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 125' ' ' ALA . . . . . . . . . . . . . . . -74.14 -56.64 4.67 Favored 'General case' 0 C--O 1.235 0.34 0 CA-C-O 120.96 0.41 . . . . 0.0 111.155 -179.933 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 126' ' ' LEU . . . . . 0.414 HD21 ' HB2' ' A' ' 114' ' ' ALA . 1.2 mt -53.48 -51.2 63.51 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.016 -0.538 . . . . 0.0 110.275 179.749 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 127' ' ' PHE . . . . . . . . . . . . . 11.0 t80 -65.29 -30.1 70.93 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.03 179.318 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 128' ' ' GLY . . . . . . . . . . . . . . . -49.02 -49.31 29.94 Favored Glycine 0 N--CA 1.45 -0.42 0 C-N-CA 120.179 -1.01 . . . . 0.0 110.581 178.703 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 129' ' ' MET . . . . . 0.596 ' HE3' ' HA2' ' A' ' 130' ' ' GLY . 0.0 OUTLIER -71.71 -27.84 63.29 Favored 'General case' 0 C--N 1.328 -0.351 0 N-CA-C 109.067 -0.716 . . . . 0.0 109.067 178.303 . . . . . . . . 3 3 . 1 . 027 nuclear orig core ' A' A ' 130' ' ' GLY . . . . . 0.596 ' HA2' ' HE3' ' A' ' 129' ' ' MET . . . -60.68 -41.23 98.88 Favored Glycine 0 C--N 1.332 0.36 0 CA-C-N 115.712 -0.676 . . . . 0.0 112.241 179.49 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -71.9 -48.99 41.71 Favored 'General case' 0 C--N 1.331 -0.21 0 CA-C-O 120.627 0.251 . . . . 0.0 110.403 179.668 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 57.2 t -55.68 -46.5 79.51 Favored 'Isoleucine or valine' 0 C--O 1.234 0.271 0 CA-C-O 121.302 0.573 . . . . 0.0 109.506 178.826 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -62.29 -38.19 88.39 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 115.397 -0.82 . . . . 0.0 110.507 178.962 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 134' ' ' PHE . . . . . . . . . . . . . 82.3 t80 -55.71 -53.47 56.15 Favored 'General case' 0 N--CA 1.452 -0.371 0 CA-C-N 116.058 -0.519 . . . . 0.0 110.305 179.793 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 135' ' ' ILE . . . . . 0.428 ' O ' HG23 ' A' ' 138' ' ' VAL . 47.5 mt -55.95 -32.08 32.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 115.841 -0.618 . . . . 0.0 110.193 179.573 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . -62.54 -42.6 99.68 Favored Glycine 0 N--CA 1.448 -0.522 0 C-N-CA 120.176 -1.012 . . . . 0.0 111.232 178.738 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 137' ' ' LEU . . . . . 0.561 HD12 HD22 ' A' ' 105' ' ' ASN . 61.0 tp -66.27 -54.42 25.13 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.583 0.23 . . . . 0.0 110.855 179.617 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 138' ' ' VAL . . . . . 0.428 HG23 ' O ' ' A' ' 135' ' ' ILE . 3.8 m -55.05 -31.56 25.67 Favored 'Isoleucine or valine' 0 C--O 1.232 0.184 0 N-CA-C 109.891 -0.411 . . . . 0.0 109.891 -179.7 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 139' ' ' TYR . . . . . . . . . . . . . 14.2 t80 -61.37 -42.83 99.34 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 115.871 -0.604 . . . . 0.0 109.748 178.313 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 140' ' ' TYR . . . . . 0.425 ' HE2' HD22 ' A' ' 104' ' ' LEU . 21.7 m-85 -66.95 -45.71 76.94 Favored 'General case' 0 CA--C 1.529 0.153 0 CA-C-N 116.034 -0.53 . . . . 0.0 111.096 179.262 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 141' ' ' LEU . . . . . . . . . . . . . 11.2 mp -52.4 -37.41 56.51 Favored 'General case' 0 N--CA 1.464 0.23 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.791 -179.417 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 8.6 p -104.58 -5.28 9.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-O 120.927 0.394 . . . . 0.0 111.394 -179.514 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 143' ' ' GLY . . . . . 0.419 ' HA3' ' HD2' ' A' ' 144' ' ' PRO . . . -75.51 -130.89 0.3 Allowed Glycine 0 CA--C 1.521 0.427 0 C-N-CA 120.768 -0.729 . . . . 0.0 113.009 -179.625 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 144' ' ' PRO . . . . . 0.419 ' HD2' ' HA3' ' A' ' 143' ' ' GLY . 13.2 Cg_endo -56.21 -23.47 45.46 Favored 'Trans proline' 0 C--N 1.348 0.549 0 C-N-CA 122.741 2.294 . . . . 0.0 112.658 -179.587 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 145' ' ' MET . . . . . 0.503 ' HE1' HD12 ' A' ' 93' ' ' LEU . 50.4 mtt -56.96 -29.22 63.02 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.286 -0.415 . . . . 0.0 111.696 -179.652 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 146' ' ' THR . . . . . . . . . . . . . 72.9 p -77.28 -34.65 55.62 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.837 0.351 . . . . 0.0 110.91 -179.531 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 36.9 tt0 -75.92 -32.25 59.51 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 115.989 -0.55 . . . . 0.0 111.028 -179.869 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 148' ' ' SER . . . . . . . . . . . . . 48.2 t -70.83 -47.43 59.45 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.502 -179.659 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 149' ' ' ALA . . . . . 0.43 ' HB1' HG21 ' A' ' 156' ' ' ILE . . . -70.76 -30.57 67.11 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.294 -0.412 . . . . 0.0 111.748 -179.39 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 150' ' ' SER . . . . . . . . . . . . . 78.4 p -69.12 0.0 5.29 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.38 -0.373 . . . . 0.0 111.12 -179.878 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 151' ' ' GLN . . . . . . . . . . . . . 77.0 mt-30 -121.99 9.58 9.99 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.378 -0.374 . . . . 0.0 111.494 -179.836 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 25.6 mmm180 -91.45 -53.16 4.44 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-O 121.1 0.476 . . . . 0.0 110.789 -179.994 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 153' ' ' SER . . . . . 0.646 ' HB2' HG12 ' A' ' 156' ' ' ILE . 23.5 m -158.3 172.22 18.76 Favored 'General case' 0 C--N 1.324 -0.509 0 CA-C-N 115.643 -0.708 . . . . 0.0 110.481 179.232 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 154' ' ' SER . . . . . . . . . . . . . 46.9 t -72.05 -37.08 69.76 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-O 120.977 0.418 . . . . 0.0 110.142 179.073 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -77.43 -35.38 37.32 Favored Glycine 0 N--CA 1.45 -0.423 0 CA-C-N 115.818 -0.628 . . . . 0.0 112.902 179.83 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 156' ' ' ILE . . . . . 0.646 HG12 ' HB2' ' A' ' 153' ' ' SER . 38.0 mm -52.72 -38.74 28.36 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.164 0 CA-C-O 120.687 0.28 . . . . 0.0 111.515 -179.56 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 157' ' ' LYS . . . . . . . . . . . . . 57.4 tptt -64.78 -40.53 95.41 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.434 -0.348 . . . . 0.0 111.175 -179.9 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 49.3 m -71.16 -42.73 68.74 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.415 -0.357 . . . . 0.0 111.342 -179.733 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 159' ' ' LEU . . . . . 0.481 HD23 HD12 ' A' ' 163' ' ' LEU . 4.7 tt -64.44 -40.83 96.47 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.998 -179.573 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 160' ' ' TYR . . . . . . . . . . . . . 29.0 t80 -73.29 -37.17 66.34 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.711 -179.204 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 161' ' ' VAL . . . . . 0.48 HG11 ' N ' ' A' ' 162' ' ' ARG . 1.0 OUTLIER -59.85 -50.52 79.78 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.746 0 CA-C-O 120.628 0.251 . . . . 0.0 111.623 -179.438 . . . . . . . . 3 3 . 1 . 027 nuclear orig core ' A' A ' 162' ' ' ARG . . . . . 0.48 ' N ' HG11 ' A' ' 161' ' ' VAL . 99.8 mtt180 -69.5 -34.82 74.87 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-O 120.929 0.395 . . . . 0.0 111.254 179.989 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 163' ' ' LEU . . . . . 0.647 ' HG ' ' HB2' ' A' ' 208' ' ' PHE . 1.2 mp -65.49 -55.12 19.61 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 115.945 -0.57 . . . . 0.0 112.173 -178.831 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 164' ' ' ARG . . . . . 0.411 ' HG3' ' N ' ' A' ' 165' ' ' ASN . 5.1 ppt_? -66.05 -41.22 91.13 Favored 'General case' 0 C--N 1.329 -0.286 0 N-CA-C 111.997 0.369 . . . . 0.0 111.997 -178.596 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 165' ' ' ASN . . . . . 0.411 ' N ' ' HG3' ' A' ' 164' ' ' ARG . 0.9 OUTLIER -54.35 -52.28 62.09 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-O 120.969 0.414 . . . . 0.0 111.024 -179.948 . . . . . . . . 3 3 . 1 . 027 nuclear orig core ' A' A ' 166' ' ' LEU . . . . . 0.511 ' O ' ' HG ' ' A' ' 170' ' ' LEU . 2.8 tt -64.99 -51.93 58.96 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 115.925 -0.579 . . . . 0.0 111.513 -179.377 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 167' ' ' THR . . . . . 0.44 ' O ' ' HB2' ' A' ' 171' ' ' TRP . 91.4 m -54.74 -52.81 61.37 Favored 'General case' 0 C--N 1.328 -0.357 0 N-CA-C 112.345 0.498 . . . . 0.0 112.345 -178.817 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 168' ' ' VAL . . . . . . . . . . . . . 53.0 t -54.54 -46.1 71.48 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 N-CA-C 112.22 0.452 . . . . 0.0 112.22 -179.044 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 169' ' ' VAL . . . . . . . . . . . . . 77.5 t -56.04 -65.18 0.4 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 N-CA-C 112.019 0.378 . . . . 0.0 112.019 -179.18 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 170' ' ' LEU . . . . . 0.511 ' HG ' ' O ' ' A' ' 166' ' ' LEU . 0.6 OUTLIER -63.65 -31.09 72.15 Favored 'General case' 0 C--N 1.328 -0.341 0 N-CA-C 112.43 0.53 . . . . 0.0 112.43 -178.486 . . . . . . . . 3 3 . 1 . 027 nuclear orig core ' A' A ' 171' ' ' TRP . . . . . 0.44 ' HB2' ' O ' ' A' ' 167' ' ' THR . 3.5 m0 -68.67 -30.87 69.65 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-O 120.941 0.4 . . . . 0.0 110.37 179.24 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 172' ' ' ALA . . . . . . . . . . . . . . . -73.03 -6.88 48.43 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 115.92 -0.582 . . . . 0.0 110.641 -179.991 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 173' ' ' ILE . . . . . 0.49 ' O ' HG12 ' A' ' 177' ' ' ILE . 29.0 mm -86.67 -22.2 7.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 115.818 -0.628 . . . . 0.0 111.203 -179.952 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 174' ' ' TYR . . . . . 0.411 ' HB2' ' HD3' ' A' ' 175' ' ' PRO . 25.5 m-85 -54.25 -49.8 88.28 Favored Pre-proline 0 N--CA 1.464 0.245 0 CA-C-N 116.514 -0.312 . . . . 0.0 111.702 -179.771 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 175' ' ' PRO . . . . . 0.411 ' HD3' ' HB2' ' A' ' 174' ' ' TYR . 79.8 Cg_exo -49.01 -30.06 17.13 Favored 'Trans proline' 0 C--N 1.349 0.591 0 C-N-CA 121.97 1.78 . . . . 0.0 112.138 179.641 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 176' ' ' PHE . . . . . 0.437 ' HD2' ' HA ' ' A' ' 173' ' ' ILE . 46.8 m-85 -80.75 -50.0 10.43 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 115.985 -0.552 . . . . 0.0 111.663 -179.897 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 177' ' ' ILE . . . . . 0.49 HG12 ' O ' ' A' ' 173' ' ' ILE . 4.2 mm -63.13 -32.64 57.03 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.501 0 N-CA-C 112.364 0.505 . . . . 0.0 112.364 -178.037 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 178' ' ' TRP . . . . . . . . . . . . . 77.7 t90 -71.95 -50.94 24.68 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.934 0.397 . . . . 0.0 110.555 179.771 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 179' ' ' LEU . . . . . 0.519 HD23 HD21 ' A' ' 180' ' ' LEU . 0.7 OUTLIER -68.95 -54.71 13.89 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.001 -0.545 . . . . 0.0 111.482 -179.341 . . . . . . . . 3 3 . 1 . 027 nuclear orig core ' A' A ' 180' ' ' LEU . . . . . 0.535 HD22 HD12 ' A' ' 187' ' ' LEU . 39.3 mt -63.54 -43.68 96.39 Favored 'General case' 0 C--N 1.329 -0.324 0 C-N-CA 121.043 -0.263 . . . . 0.0 111.025 -179.729 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . -58.04 178.26 1.38 Allowed Glycine 0 CA--C 1.521 0.462 0 C-N-CA 120.12 -1.038 . . . . 0.0 112.12 179.085 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 182' ' ' PRO . . . . . 0.416 ' HB2' ' HD3' ' A' ' 183' ' ' PRO . 74.8 Cg_exo -47.45 -44.97 24.04 Favored 'Trans proline' 0 CA--C 1.536 0.611 0 C-N-CA 122.91 2.406 . . . . 0.0 113.918 -179.886 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 183' ' ' PRO . . . . . 0.416 ' HD3' ' HB2' ' A' ' 182' ' ' PRO . 86.7 Cg_exo -46.96 -26.91 5.29 Favored 'Trans proline' 0 C--N 1.355 0.874 0 C-N-CA 122.191 1.928 . . . . 0.0 113.364 -179.665 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 184' ' ' GLY . . . . . 0.556 ' HA2' ' HD2' ' A' ' 123' ' ' ARG . . . -120.5 -129.92 3.83 Favored Glycine 0 C--N 1.333 0.368 0 C-N-CA 120.29 -0.957 . . . . 0.0 113.081 -179.685 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 185' ' ' VAL . . . . . . . . . . . . . 15.4 m -54.68 -23.67 12.03 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 N-CA-C 112.066 0.395 . . . . 0.0 112.066 -179.526 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 186' ' ' ALA . . . . . . . . . . . . . . . 55.13 86.72 0.05 Allowed 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 116.446 -0.343 . . . . 0.0 111.659 179.509 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 187' ' ' LEU . . . . . 0.535 HD12 HD22 ' A' ' 180' ' ' LEU . 12.7 mt -92.3 -49.28 6.24 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.287 -0.415 . . . . 0.0 110.904 179.905 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 188' ' ' LEU . . . . . 0.443 HD11 HG11 ' A' ' 192' ' ' VAL . 78.2 mt -98.06 -161.93 0.91 Allowed 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 115.998 -0.546 . . . . 0.0 110.832 -179.72 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 189' ' ' THR . . . . . . . . . . . . . 2.3 t -98.41 146.93 32.41 Favored Pre-proline 0 C--N 1.329 -0.288 0 CA-C-N 116.132 -0.486 . . . . 0.0 110.766 179.993 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 190' ' ' PRO . . . . . . . . . . . . . 95.8 Cg_exo -44.41 -42.51 13.87 Favored 'Trans proline' 0 C--N 1.349 0.587 0 C-N-CA 122.763 2.309 . . . . 0.0 113.374 -179.511 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 191' ' ' THR . . . . . 0.422 ' O ' HD21 ' A' ' 7' ' ' LEU . 41.6 p -59.29 -44.74 92.47 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-O 120.78 0.324 . . . . 0.0 111.707 -179.596 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 192' ' ' VAL . . . . . 0.443 HG11 HD11 ' A' ' 188' ' ' LEU . 55.3 t -70.39 -51.52 37.34 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.42 0 N-CA-C 111.858 0.318 . . . . 0.0 111.858 -179.344 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 193' ' ' ASP . . . . . . . . . . . . . 20.7 m-20 -59.11 -51.98 67.7 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 116.444 -0.344 . . . . 0.0 111.626 -179.349 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 194' ' ' VAL . . . . . . . . . . . . . 69.2 t -58.88 -35.92 58.74 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.221 0 CA-C-O 120.712 0.292 . . . . 0.0 110.907 179.885 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 195' ' ' ALA . . . . . . . . . . . . . . . -57.33 -47.7 80.88 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.329 -0.396 . . . . 0.0 110.655 179.612 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 196' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -61.85 -40.44 95.36 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.301 -0.409 . . . . 0.0 110.424 179.355 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 197' ' ' ILE . . . . . 0.436 HD11 ' HB ' ' A' ' 177' ' ' ILE . 17.0 mm -57.25 -59.3 3.35 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.32 0 CA-C-N 115.939 -0.573 . . . . 0.0 110.062 179.019 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 198' ' ' VAL . . . . . . . . . . . . . 92.9 t -52.01 -35.1 18.13 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.426 0 CA-C-N 115.473 -0.785 . . . . 0.0 109.468 178.346 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 199' ' ' TYR . . . . . . . . . . . . . 59.3 t80 -70.24 -31.01 68.23 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 115.374 -0.83 . . . . 0.0 110.725 179.873 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 200' ' ' LEU . . . . . 0.424 ' O ' HG11 ' A' ' 203' ' ' VAL . 43.4 mt -73.23 -37.49 66.38 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 115.821 -0.627 . . . . 0.0 111.383 -179.736 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 201' ' ' ASP . . . . . . . . . . . . . 16.1 m-20 -73.84 -39.37 64.06 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-O 121.043 0.449 . . . . 0.0 110.498 179.663 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 202' ' ' LEU . . . . . . . . . . . . . 2.2 mt -69.9 -28.94 66.04 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 115.735 -0.666 . . . . 0.0 111.765 -179.465 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 203' ' ' VAL . . . . . 0.431 ' O ' ' HA3' ' A' ' 207' ' ' GLY . 12.3 p -78.17 -36.43 21.2 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.331 0 C-N-CA 121.094 -0.242 . . . . 0.0 110.962 -178.979 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 204' ' ' THR . . . . . . . . . . . . . 95.6 m -64.88 -58.43 6.2 Favored 'General case' 0 C--N 1.327 -0.399 0 C-N-CA 120.563 -0.455 . . . . 0.0 110.934 179.335 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 205' ' ' LYS . . . . . 0.664 ' HE2' ' HB2' ' A' ' 47' ' ' ALA . 54.4 mttp -61.86 -58.09 9.28 Favored 'General case' 0 C--N 1.329 -0.292 0 N-CA-C 112.343 0.497 . . . . 0.0 112.343 -178.395 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 51.0 t -71.83 -37.01 60.44 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.396 0 N-CA-C 112.428 0.529 . . . . 0.0 112.428 -178.515 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 207' ' ' GLY . . . . . 0.431 ' HA3' ' O ' ' A' ' 203' ' ' VAL . . . -57.59 -60.26 9.33 Favored Glycine 0 N--CA 1.455 -0.097 0 C-N-CA 120.704 -0.76 . . . . 0.0 113.416 -178.798 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 208' ' ' PHE . . . . . 0.647 ' HB2' ' HG ' ' A' ' 163' ' ' LEU . 0.3 OUTLIER -71.67 -27.13 62.85 Favored 'General case' 0 C--O 1.223 -0.3 0 CA-C-N 117.183 0.492 . . . . 0.0 110.562 -179.713 . . . . . . . . 3 3 . 1 . 027 nuclear orig core ' A' A ' 209' ' ' GLY . . . . . 0.456 ' O ' ' HB3' ' A' ' 212' ' ' ALA . . . -65.18 -33.86 88.08 Favored Glycine 0 N--CA 1.448 -0.521 0 N-CA-C 111.718 -0.553 . . . . 0.0 111.718 178.623 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 210' ' ' PHE . . . . . . . . . . . . . 0.6 OUTLIER -73.57 -44.93 56.16 Favored 'General case' 0 CA--C 1.512 -0.502 0 N-CA-C 107.757 -1.201 . . . . 0.0 107.757 178.321 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 211' ' ' ILE . . . . . 0.4 HD12 ' HA ' ' A' ' 208' ' ' PHE . 34.5 mt -64.73 -27.65 42.99 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.653 0 N-CA-C 107.649 -1.241 . . . . 0.0 107.649 176.646 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 212' ' ' ALA . . . . . 0.489 ' N ' ' O ' ' A' ' 208' ' ' PHE . . . -64.35 -44.02 92.78 Favored 'General case' 0 N--CA 1.45 -0.452 0 CA-C-N 114.505 -1.225 . . . . 0.0 110.6 -179.859 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 213' ' ' LEU . . . . . . . . . . . . . 97.6 mt -69.67 -46.08 66.91 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 115.308 -0.86 . . . . 0.0 111.487 -179.574 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 214' ' ' ASP . . . . . . . . . . . . . 36.3 m-20 -58.11 -47.15 84.14 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-O 120.85 0.357 . . . . 0.0 110.933 -179.952 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 215' ' ' ALA . . . . . . . . . . . . . . . -62.82 -54.05 44.9 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 115.992 -0.549 . . . . 0.0 111.239 -179.896 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 216' ' ' ALA . . . . . . . . . . . . . . . -56.36 -37.5 70.12 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-N 116.281 -0.418 . . . . 0.0 111.04 179.928 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 217' ' ' ALA . . . . . . . . . . . . . . . -63.33 -37.96 89.3 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.167 179.655 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 218' ' ' THR . . . . . . . . . . . . . 92.4 m . . . . . 0 C--N 1.328 -0.336 0 CA-C-N 115.677 -0.692 . . . . 0.0 110.605 179.334 . . . . . . . . 0 0 . 1 . 028 nuclear orig core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.367 0 N-CA-C 112.546 -0.222 . . . . 0.0 112.546 . . . . . . . . . 0 0 . 1 . 028 nuclear orig core ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 59.5 tp -74.12 -40.69 62.5 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-O 120.823 0.344 . . . . 0.0 110.889 179.945 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 61.3 p -60.79 -29.85 69.7 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.136 179.98 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 6' ' ' THR . . . . . 0.406 ' HG1' ' N ' ' A' ' 7' ' ' LEU . 10.9 p -53.11 -35.5 59.72 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 116.043 -0.526 . . . . 0.0 111.172 -179.785 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 7' ' ' LEU . . . . . 0.406 ' N ' ' HG1' ' A' ' 6' ' ' THR . 10.0 mp -57.22 -53.59 56.36 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.297 179.961 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 8' ' ' PHE . . . . . 0.483 ' O ' ' HB3' ' A' ' 51' ' ' TYR . 65.7 m-85 -59.4 -34.63 72.68 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.006 -0.543 . . . . 0.0 110.957 -179.599 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 9' ' ' TRP . . . . . . . . . . . . . 32.0 m95 -66.71 -41.81 87.37 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-N 116.296 -0.411 . . . . 0.0 110.099 179.831 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 84.2 mt -59.64 -48.4 81.82 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 115.88 -0.6 . . . . 0.0 110.26 179.233 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -61.22 -35.28 90.65 Favored Glycine 0 N--CA 1.449 -0.461 0 C-N-CA 120.621 -0.799 . . . . 0.0 111.587 179.169 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -63.29 -30.28 71.44 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.597 0.237 . . . . 0.0 110.442 179.41 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 47.9 mm -68.58 -54.12 23.21 Favored 'Isoleucine or valine' 0 CA--C 1.52 -0.189 0 CA-C-N 116.41 -0.359 . . . . 0.0 110.309 179.057 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -53.21 -30.67 39.95 Favored Glycine 0 N--CA 1.452 -0.281 0 C-N-CA 120.689 -0.767 . . . . 0.0 111.747 179.475 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 15' ' ' MET . . . . . 0.62 ' HB3' ' HB3' ' A' ' 48' ' ' ALA . 0.0 OUTLIER -76.77 -49.54 15.67 Favored 'General case' 0 C--O 1.223 -0.33 0 CA-C-O 120.564 0.221 . . . . 0.0 110.928 179.523 . . . . . . . . 3 3 . 1 . 028 nuclear orig core ' A' A ' 16' ' ' LEU . . . . . 0.403 HD23 ' HA ' ' A' ' 16' ' ' LEU . 0.4 OUTLIER -55.67 -50.87 69.1 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-O 120.78 0.324 . . . . 0.0 110.621 179.804 . . . . . . . . 3 3 . 1 . 028 nuclear orig core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 14.7 p -63.55 -46.31 95.35 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.377 0 CA-C-O 121.356 0.598 . . . . 0.0 110.718 179.824 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -58.97 -46.31 93.87 Favored Glycine 0 C--N 1.317 -0.484 0 CA-C-N 114.973 -1.012 . . . . 0.0 111.891 179.179 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 57.4 m -53.78 -45.06 70.55 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-O 120.707 0.289 . . . . 0.0 110.827 -179.839 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 81.7 mt -71.58 -39.68 70.42 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.273 -0.421 . . . . 0.0 110.766 179.376 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -60.42 -33.39 72.44 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.085 -0.507 . . . . 0.0 111.736 -179.767 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 22' ' ' PHE . . . . . 0.482 ' HB2' HG21 ' A' ' 41' ' ' VAL . 8.2 m-85 -91.15 -31.05 16.36 Favored 'General case' 0 N--CA 1.463 0.197 0 CA-C-O 120.753 0.311 . . . . 0.0 111.311 -179.679 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -68.72 -50.32 51.78 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.335 -179.514 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 24' ' ' TRP . . . . . . . . . . . . . 4.4 t-105 -64.18 -45.05 90.07 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-N 115.834 -0.621 . . . . 0.0 111.24 -179.595 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.33 -0.258 0 CA-C-O 120.858 0.361 . . . . 0.0 110.983 179.84 . . . . . . . . 0 0 . 1 . 028 nuclear orig core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.24 0 N-CA-C 112.457 -0.257 . . . . 0.0 112.457 . . . . . . . . . 0 0 . 1 . 028 nuclear orig core ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 28.7 mm-40 -86.63 -20.85 27.25 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 120.741 0.305 . . . . 0.0 110.953 -179.959 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 34' ' ' ARG . . . . . . . . . . . . . 14.7 ptm180 -48.9 -36.31 16.88 Favored 'General case' 0 C--N 1.332 -0.17 0 CA-C-N 116.076 -0.511 . . . . 0.0 111.668 -179.757 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 29.2 mmt180 -61.77 -50.47 72.22 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 120.874 0.368 . . . . 0.0 111.277 -179.686 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 46.6 m-85 -63.2 -30.58 71.7 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.044 -0.525 . . . . 0.0 111.473 -179.607 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 37' ' ' TYR . . . . . . . . . . . . . 39.1 m-85 -74.67 -55.8 5.49 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.641 -179.237 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 88.8 t -56.63 -36.85 49.81 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.205 0 CA-C-O 121.0 0.429 . . . . 0.0 110.485 179.914 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 90.7 m -63.97 -50.96 66.52 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 115.747 -0.661 . . . . 0.0 110.465 179.226 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 40' ' ' LEU . . . . . 0.453 HD12 HD12 ' A' ' 43' ' ' ILE . 40.4 tp -56.8 -50.16 73.18 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 115.549 -0.75 . . . . 0.0 110.809 -179.858 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . 0.482 HG21 ' HB2' ' A' ' 22' ' ' PHE . 69.0 t -57.76 -36.53 55.39 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 115.858 -0.61 . . . . 0.0 110.446 179.565 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -61.52 -36.1 92.08 Favored Glycine 0 N--CA 1.449 -0.493 0 C-N-CA 120.907 -0.663 . . . . 0.0 112.17 179.815 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 43' ' ' ILE . . . . . 0.519 HD11 HD12 ' A' ' 83' ' ' ILE . 2.0 mt -65.22 -56.94 13.08 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.234 0 CA-C-O 120.958 0.409 . . . . 0.0 110.802 179.713 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 32.4 t -58.26 -25.17 61.44 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 115.879 -0.601 . . . . 0.0 111.685 -179.5 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -73.83 -58.48 4.43 Favored Glycine 0 CA--C 1.517 0.191 0 C-N-CA 120.696 -0.764 . . . . 0.0 112.986 -179.576 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 46' ' ' ILE . . . . . 0.535 ' O ' HG22 ' A' ' 49' ' ' VAL . 15.8 pt -57.92 -35.87 53.63 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.221 0 CA-C-O 120.818 0.342 . . . . 0.0 110.924 -179.674 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 47' ' ' ALA . . . . . 0.628 ' HB1' ' HE2' ' A' ' 205' ' ' LYS . . . -67.04 -37.59 84.36 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.962 0.41 . . . . 0.0 110.261 178.754 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 48' ' ' ALA . . . . . 0.62 ' HB3' ' HB3' ' A' ' 15' ' ' MET . . . -60.57 -33.08 72.18 Favored 'General case' 0 C--N 1.332 -0.173 0 CA-C-N 115.736 -0.665 . . . . 0.0 111.343 179.889 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 49' ' ' VAL . . . . . 0.535 HG22 ' O ' ' A' ' 46' ' ' ILE . 1.3 m -76.54 -38.39 31.46 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.496 -0.32 . . . . 0.0 111.643 -179.425 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -62.95 -41.65 99.58 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-O 120.968 0.413 . . . . 0.0 111.393 -179.636 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 51' ' ' TYR . . . . . 0.483 ' HB3' ' O ' ' A' ' 8' ' ' PHE . 38.5 m-85 -72.74 -40.41 66.1 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-N 115.894 -0.594 . . . . 0.0 110.813 -179.283 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -63.13 -40.87 98.84 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-N 115.943 -0.571 . . . . 0.0 111.467 179.793 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 53' ' ' VAL . . . . . 0.452 HG12 ' O ' ' A' ' 49' ' ' VAL . 33.3 m -74.42 -50.56 26.47 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 N-CA-C 111.754 0.279 . . . . 0.0 111.754 -179.475 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 54' ' ' MET . . . . . 0.516 ' HG2' ' HG2' ' A' ' 71' ' ' PRO . 72.0 mtm -57.57 -30.2 65.06 Favored 'General case' 0 CA--C 1.521 -0.143 0 CA-C-O 121.013 0.435 . . . . 0.0 110.744 179.914 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -58.95 -36.97 75.7 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 115.601 -0.727 . . . . 0.0 111.643 -179.816 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 6.2 mp -87.2 4.38 42.71 Favored 'General case' 0 C--N 1.332 -0.173 0 CA-C-N 116.639 -0.255 . . . . 0.0 111.456 179.974 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 92.98 30.76 9.09 Favored Glycine 0 N--CA 1.452 -0.246 0 C-N-CA 120.674 -0.774 . . . . 0.0 113.111 179.526 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 73.7 t -88.63 130.19 38.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-O 120.71 0.29 . . . . 0.0 110.878 179.716 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 59' ' ' GLY . . . . . 0.567 ' HA3' ' HD3' ' A' ' 71' ' ' PRO . . . 87.59 -5.96 84.17 Favored Glycine 0 N--CA 1.448 -0.548 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.471 -179.815 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 60' ' ' TRP . . . . . . . . . . . . . 11.5 m0 -69.43 83.03 0.39 Allowed 'General case' 0 C--N 1.328 -0.358 0 CA-C-O 120.759 0.314 . . . . 0.0 110.59 179.835 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 6.5 p -98.99 132.25 23.94 Favored Pre-proline 0 C--N 1.33 -0.282 0 CA-C-N 116.351 -0.386 . . . . 0.0 111.298 -179.87 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 73.3 Cg_endo -75.75 148.33 32.33 Favored 'Trans proline' 0 C--N 1.35 0.612 0 C-N-CA 122.447 2.098 . . . . 0.0 112.169 179.68 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 83.7 t -141.98 97.27 0.71 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.351 -179.84 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . 57.38 -88.93 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.054 -0.521 . . . . 0.0 111.87 179.611 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 11.8 mm-40 -118.89 -20.94 7.97 Favored 'General case' 0 C--N 1.332 -0.174 0 CA-C-N 116.501 -0.318 . . . . 0.0 111.428 -179.486 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 66' ' ' ARG . . . . . . . . . . . . . 28.4 ptt180 -110.91 161.68 15.59 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.461 -0.336 . . . . 0.0 110.766 179.971 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 91.6 m -114.88 143.3 45.34 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.256 -0.429 . . . . 0.0 111.264 -179.8 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 68' ' ' VAL . . . . . 0.411 HG22 ' SD ' ' A' ' 117' ' ' MET . 30.1 m -129.14 146.51 34.14 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 115.954 -0.566 . . . . 0.0 110.924 179.943 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 69' ' ' PHE . . . . . . . . . . . . . 19.2 m-85 -106.38 117.54 34.31 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.123 -0.49 . . . . 0.0 109.833 -179.724 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 70' ' ' VAL . . . . . 0.559 HG11 ' HD3' ' A' ' 71' ' ' PRO . 1.4 p -68.77 -33.19 4.11 Favored Pre-proline 0 CA--C 1.543 0.692 0 N-CA-C 113.66 0.985 . . . . 0.0 113.66 -178.538 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 71' ' ' PRO . . . . . 0.567 ' HD3' ' HA3' ' A' ' 59' ' ' GLY . 14.2 Cg_exo -69.48 -19.11 37.87 Favored 'Trans proline' 0 C--N 1.356 0.942 0 C-N-CA 122.099 1.866 . . . . 0.0 113.46 -178.643 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 72' ' ' ARG . . . . . 0.453 ' HA ' ' HE ' ' A' ' 72' ' ' ARG . 0.9 OUTLIER -67.77 -55.27 13.7 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.917 0.389 . . . . 0.0 111.564 -179.449 . . . . . . . . 3 3 . 1 . 028 nuclear orig core ' A' A ' 73' ' ' TYR . . . . . 0.425 ' O ' HG13 ' A' ' 77' ' ' ILE . 14.2 m-85 -71.17 -33.19 69.76 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 116.081 -0.509 . . . . 0.0 111.315 -178.962 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 74' ' ' ILE . . . . . 0.401 ' HA ' HD12 ' A' ' 77' ' ' ILE . 0.3 OUTLIER -71.09 -44.93 74.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 C-N-CA 120.864 -0.334 . . . . 0.0 110.88 -179.773 . . . . . . . . 3 3 . 1 . 028 nuclear orig core ' A' A ' 75' ' ' ASP . . . . . 0.4 ' N ' ' CG2' ' A' ' 74' ' ' ILE . 37.4 t70 -58.99 -35.49 73.31 Favored 'General case' 0 N--CA 1.455 -0.183 0 N-CA-C 109.561 -0.533 . . . . 0.0 109.561 179.334 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 76' ' ' TRP . . . . . . . . . . . . . 50.2 m0 -66.0 -35.84 81.66 Favored 'General case' 0 C--N 1.332 -0.165 0 CA-C-N 116.029 -0.532 . . . . 0.0 110.129 179.141 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 77' ' ' ILE . . . . . 0.489 HG12 ' HB3' ' A' ' 109' ' ' MET . 96.4 mt -65.62 -30.78 51.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.028 -0.533 . . . . 0.0 110.718 179.378 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 69.7 mt -92.2 -20.46 21.17 Favored 'General case' 0 C--N 1.329 -0.294 0 N-CA-C 112.342 0.497 . . . . 0.0 112.342 -179.782 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 79' ' ' THR . . . . . 0.445 ' O ' ' HB2' ' A' ' 82' ' ' LEU . 62.7 p -94.39 -47.99 6.34 Favored 'General case' 0 N--CA 1.466 0.333 0 N-CA-C 112.845 0.683 . . . . 0.0 112.845 -178.406 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 80' ' ' THR . . . . . 0.571 ' N ' ' HD2' ' A' ' 81' ' ' PRO . 86.6 m -51.29 -48.72 85.07 Favored Pre-proline 0 C--N 1.328 -0.357 0 N-CA-C 112.545 0.572 . . . . 0.0 112.545 -179.319 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 81' ' ' PRO . . . . . 0.571 ' HD2' ' N ' ' A' ' 80' ' ' THR . 13.8 Cg_endo -56.02 -24.39 48.54 Favored 'Trans proline' 0 C--N 1.352 0.712 0 C-N-CA 121.536 1.491 . . . . 0.0 111.463 179.973 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 82' ' ' LEU . . . . . 0.492 HD22 HG12 ' A' ' 43' ' ' ILE . 7.2 mp -77.03 -46.03 25.14 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-N 115.707 -0.679 . . . . 0.0 110.847 179.9 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 83' ' ' ILE . . . . . 0.519 HD12 HD11 ' A' ' 43' ' ' ILE . 28.0 mm -60.8 -53.49 48.36 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.203 0 CA-C-N 116.305 -0.407 . . . . 0.0 110.527 179.655 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 84' ' ' VAL . . . . . 0.402 HG13 ' ND2' ' A' ' 105' ' ' ASN . 29.4 m -59.15 -35.47 57.7 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.211 0 CA-C-N 116.076 -0.511 . . . . 0.0 110.386 179.451 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 85' ' ' TYR . . . . . . . . . . . . . 72.7 t80 -65.51 -32.38 73.95 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.097 -0.501 . . . . 0.0 110.008 179.004 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 86' ' ' PHE . . . . . . . . . . . . . 1.4 t80 -61.54 -51.13 69.88 Favored 'General case' 0 C--N 1.333 -0.141 0 CA-C-N 115.963 -0.562 . . . . 0.0 109.707 179.547 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 6.9 mp -67.09 -31.57 72.15 Favored 'General case' 0 C--N 1.331 -0.2 0 CA-C-N 115.974 -0.557 . . . . 0.0 110.137 179.209 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -62.77 -28.01 70.96 Favored Glycine 0 N--CA 1.45 -0.418 0 C-N-CA 120.878 -0.677 . . . . 0.0 111.615 179.441 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 71.9 mt -78.45 -49.71 12.97 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.86 0.362 . . . . 0.0 110.536 179.411 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 96.1 mt -56.44 -32.5 64.97 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 115.994 -0.548 . . . . 0.0 110.649 179.608 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 91' ' ' ALA . . . . . 0.53 ' HB3' ' HB2' ' A' ' 148' ' ' SER . . . -83.67 -52.88 6.06 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 115.91 -0.587 . . . . 0.0 110.937 179.838 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 92' ' ' GLY . . . . . 0.452 ' HA3' HH21 ' A' ' 152' ' ' ARG . . . 90.68 71.82 1.23 Allowed Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.849 -0.691 . . . . 0.0 112.529 179.967 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 93' ' ' LEU . . . . . 0.495 HD13 ' HG2' ' A' ' 145' ' ' MET . 6.4 mp -84.18 -172.49 4.19 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-O 120.801 0.334 . . . . 0.0 110.912 -179.934 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 94' ' ' ASP . . . . . 0.426 ' HB2' ' OE2' ' A' ' 97' ' ' GLU . 4.6 m-20 -98.88 -172.24 2.25 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.201 -179.966 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 46.1 t -67.87 -52.91 31.09 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 115.994 -0.548 . . . . 0.0 111.527 -179.668 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 75.3 mtp180 -74.14 -35.38 64.07 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-O 120.893 0.378 . . . . 0.0 110.899 -179.358 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 97' ' ' GLU . . . . . 0.426 ' OE2' ' HB2' ' A' ' 94' ' ' ASP . 0.3 OUTLIER -60.8 -42.31 97.37 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 115.992 -0.549 . . . . 0.0 111.032 -179.873 . . . . . . . . 3 3 . 1 . 028 nuclear orig core ' A' A ' 98' ' ' PHE . . . . . . . . . . . . . 0.6 OUTLIER -61.69 -40.73 96.03 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.337 -0.392 . . . . 0.0 110.572 179.468 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -65.6 -31.55 80.4 Favored Glycine 0 N--CA 1.452 -0.27 0 C-N-CA 120.795 -0.717 . . . . 0.0 112.538 -179.932 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 96.7 mt -67.82 -43.3 86.28 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.209 0 CA-C-O 120.909 0.385 . . . . 0.0 111.239 -179.826 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 101' ' ' VAL . . . . . 0.53 HG11 ' HE3' ' A' ' 145' ' ' MET . 42.2 t -66.36 -50.49 67.27 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.358 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.367 -179.801 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 102' ' ' ILE . . . . . . . . . . . . . 48.6 mm -59.46 -49.57 83.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.59 -179.526 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 14.2 t -59.95 -29.97 68.76 Favored 'General case' 0 C--N 1.332 -0.181 0 CA-C-O 120.77 0.319 . . . . 0.0 110.903 -179.829 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -60.66 -57.0 14.56 Favored 'General case' 0 C--N 1.332 -0.178 0 CA-C-N 116.325 -0.398 . . . . 0.0 109.983 179.342 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 105' ' ' ASN . . . . . 0.402 ' ND2' HG13 ' A' ' 84' ' ' VAL . 32.7 m-80 -59.27 -26.4 64.91 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-N 116.022 -0.535 . . . . 0.0 110.782 179.533 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 76.3 m -61.49 -52.76 63.19 Favored 'General case' 0 C--N 1.332 -0.185 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.958 179.87 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 2.1 t -62.0 -37.21 77.76 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.248 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.59 179.966 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 70.3 t -60.14 -57.86 9.89 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 115.73 -0.668 . . . . 0.0 111.461 -179.898 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 109' ' ' MET . . . . . 0.489 ' HB3' HG12 ' A' ' 77' ' ' ILE . 3.7 tpp -56.91 -42.89 80.75 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.485 -179.55 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 24.1 tp -62.54 -31.0 71.71 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.318 -0.401 . . . . 0.0 110.693 -179.899 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -63.57 -55.7 21.75 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 116.038 -0.528 . . . . 0.0 110.655 179.545 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . -61.49 -36.7 92.96 Favored Glycine 0 N--CA 1.45 -0.389 0 C-N-CA 120.775 -0.726 . . . . 0.0 112.081 179.576 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 113' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER -52.25 -71.77 0.06 Allowed 'General case' 0 C--N 1.332 -0.174 0 CA-C-O 120.961 0.41 . . . . 0.0 110.195 179.619 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -63.9 -19.44 65.1 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 115.924 -0.58 . . . . 0.0 111.022 179.758 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 115' ' ' GLY . . . . . 0.454 ' HA2' HD21 ' A' ' 126' ' ' LEU . . . -54.8 -51.58 52.05 Favored Glycine 0 C--N 1.332 0.334 0 C-N-CA 120.86 -0.686 . . . . 0.0 111.841 179.611 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -78.2 -14.91 59.26 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-O 120.748 0.309 . . . . 0.0 111.227 179.659 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 117' ' ' MET . . . . . 0.411 ' SD ' HG22 ' A' ' 68' ' ' VAL . 23.5 mmt -90.59 17.07 7.93 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-N 116.358 -0.383 . . . . 0.0 111.739 -179.238 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 118' ' ' VAL . . . . . 0.4 HG21 ' HB3' ' A' ' 123' ' ' ARG . 34.4 m -81.1 144.01 53.85 Favored Pre-proline 0 C--N 1.33 -0.277 0 CA-C-O 120.505 0.193 . . . . 0.0 111.43 -179.845 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 119' ' ' PRO . . . . . . . . . . . . . 83.4 Cg_endo -82.49 -1.9 10.82 Favored 'Trans proline' 0 C--N 1.348 0.525 0 C-N-CA 122.55 2.167 . . . . 0.0 112.349 179.649 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -148.85 -129.1 1.77 Allowed Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.722 -0.751 . . . . 0.0 112.747 -179.878 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 39.8 pt -107.92 12.15 8.78 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.207 0 CA-C-O 120.676 0.274 . . . . 0.0 111.577 -179.729 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 43.9 mt-10 -60.25 -18.19 47.13 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.372 -0.376 . . . . 0.0 111.034 179.802 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 123' ' ' ARG . . . . . 0.422 ' HB2' ' HH2' ' A' ' 178' ' ' TRP . 15.7 ptt180 -50.08 -37.59 34.4 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 116.031 -0.532 . . . . 0.0 111.71 -179.578 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 124' ' ' TYR . . . . . . . . . . . . . 30.1 m-85 -58.46 -33.9 70.26 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.518 -0.31 . . . . 0.0 111.271 -179.628 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 125' ' ' ALA . . . . . . . . . . . . . . . -74.2 -49.75 22.15 Favored 'General case' 0 C--O 1.235 0.336 0 CA-C-O 120.909 0.385 . . . . 0.0 111.128 179.958 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 126' ' ' LEU . . . . . 0.454 HD21 ' HA2' ' A' ' 115' ' ' GLY . 7.4 mp -53.09 -46.46 68.66 Favored 'General case' 0 C--N 1.333 -0.144 0 CA-C-N 115.972 -0.558 . . . . 0.0 110.5 -179.928 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 127' ' ' PHE . . . . . 0.456 ' HZ ' ' HB3' ' A' ' 175' ' ' PRO . 4.8 t80 -67.23 -37.73 84.05 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.644 179.839 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 128' ' ' GLY . . . . . . . . . . . . . . . -46.38 -46.21 16.68 Favored Glycine 0 C--N 1.332 0.356 0 C-N-CA 120.193 -1.003 . . . . 0.0 110.911 179.237 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 129' ' ' MET . . . . . 0.401 ' HE3' ' N ' ' A' ' 130' ' ' GLY . 0.6 OUTLIER -68.1 -40.95 82.46 Favored 'General case' 0 C--N 1.327 -0.386 0 N-CA-C 109.749 -0.463 . . . . 0.0 109.749 178.48 . . . . . . . . 3 3 . 1 . 028 nuclear orig core ' A' A ' 130' ' ' GLY . . . . . 0.401 ' N ' ' HE3' ' A' ' 129' ' ' MET . . . -64.15 -23.15 67.73 Favored Glycine 0 N--CA 1.45 -0.411 0 CA-C-N 115.822 -0.626 . . . . 0.0 112.345 179.792 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -75.03 -53.54 8.73 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.717 0.294 . . . . 0.0 110.419 179.648 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 39.4 t -55.36 -40.33 56.77 Favored 'Isoleucine or valine' 0 C--O 1.233 0.217 0 CA-C-O 121.387 0.613 . . . . 0.0 109.638 178.799 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -69.79 -36.53 75.77 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 115.339 -0.846 . . . . 0.0 110.721 179.172 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 134' ' ' PHE . . . . . 0.443 ' CZ ' ' HA ' ' A' ' 172' ' ' ALA . 18.9 t80 -53.43 -60.06 3.79 Favored 'General case' 0 N--CA 1.454 -0.251 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.22 179.869 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 135' ' ' ILE . . . . . 0.494 ' O ' HG21 ' A' ' 138' ' ' VAL . 0.0 OUTLIER -56.11 -35.23 41.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 115.959 -0.564 . . . . 0.0 110.31 179.143 . . . . . . . . 3 3 . 1 . 028 nuclear orig core ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . -57.56 -43.13 94.31 Favored Glycine 0 N--CA 1.45 -0.398 0 C-N-CA 120.226 -0.987 . . . . 0.0 111.755 179.024 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 137' ' ' LEU . . . . . 0.451 HD13 ' C ' ' A' ' 137' ' ' LEU . 1.4 tm? -63.29 -58.22 7.85 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 121.016 0.436 . . . . 0.0 110.519 179.678 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 138' ' ' VAL . . . . . 0.494 HG21 ' O ' ' A' ' 135' ' ' ILE . 2.4 m -54.22 -31.77 22.55 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.466 0 CA-C-N 115.562 -0.744 . . . . 0.0 110.213 179.68 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 139' ' ' TYR . . . . . . . . . . . . . 17.3 t80 -64.26 -34.92 79.21 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 115.885 -0.598 . . . . 0.0 110.05 179.091 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 15.4 m-85 -68.43 -48.69 63.94 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 115.989 -0.55 . . . . 0.0 111.613 179.733 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 141' ' ' LEU . . . . . . . . . . . . . 4.0 pp -68.52 -16.23 63.81 Favored 'General case' 0 CA--C 1.53 0.178 0 C-N-CA 120.974 -0.29 . . . . 0.0 111.327 -179.33 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 142' ' ' VAL . . . . . 0.422 HG23 ' O ' ' A' ' 138' ' ' VAL . 95.2 t -101.17 -18.77 6.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-O 121.079 0.466 . . . . 0.0 110.57 178.801 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . -85.26 -123.46 1.25 Allowed Glycine 0 CA--C 1.522 0.498 0 C-N-CA 120.929 -0.653 . . . . 0.0 113.145 -179.342 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 144' ' ' PRO . . . . . . . . . . . . . 69.3 Cg_exo -52.15 -35.94 64.63 Favored 'Trans proline' 0 C--N 1.35 0.634 0 C-N-CA 122.722 2.281 . . . . 0.0 113.178 -179.392 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 145' ' ' MET . . . . . 0.53 ' HE3' HG11 ' A' ' 101' ' ' VAL . 40.3 mtt -55.36 -37.72 67.87 Favored 'General case' 0 C--N 1.331 -0.206 0 CA-C-O 120.751 0.31 . . . . 0.0 111.446 -179.798 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 146' ' ' THR . . . . . . . . . . . . . 18.3 m -68.28 -41.64 80.72 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.725 -179.368 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 42.6 mt-10 -75.77 -26.32 57.26 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.403 -0.362 . . . . 0.0 111.423 -179.543 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 148' ' ' SER . . . . . 0.53 ' HB2' ' HB3' ' A' ' 91' ' ' ALA . 68.9 m -70.65 -43.67 68.7 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.372 -0.376 . . . . 0.0 111.564 -179.402 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 149' ' ' ALA . . . . . 0.43 ' HB1' ' HA ' ' A' ' 91' ' ' ALA . . . -76.04 -32.34 59.29 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.781 0.324 . . . . 0.0 111.635 -179.441 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 150' ' ' SER . . . . . . . . . . . . . 86.7 p -69.46 -1.26 8.05 Favored 'General case' 0 C--N 1.326 -0.413 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.037 179.995 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 151' ' ' GLN . . . . . . . . . . . . . 77.2 mt-30 -118.69 0.26 11.44 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.097 -0.501 . . . . 0.0 111.331 -179.838 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 152' ' ' ARG . . . . . 0.452 HH21 ' HA3' ' A' ' 92' ' ' GLY . 38.9 mmt180 -82.26 -52.62 6.77 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-O 120.833 0.349 . . . . 0.0 111.004 -179.997 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 153' ' ' SER . . . . . 0.59 ' HB3' HG12 ' A' ' 156' ' ' ILE . 35.5 t -158.36 167.64 29.15 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.749 179.241 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 154' ' ' SER . . . . . . . . . . . . . 45.9 t -70.32 -34.85 73.18 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 121.037 0.446 . . . . 0.0 110.151 179.277 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -76.91 -37.92 32.14 Favored Glycine 0 N--CA 1.45 -0.368 0 C-N-CA 120.971 -0.633 . . . . 0.0 112.264 179.618 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 156' ' ' ILE . . . . . 0.59 HG12 ' HB3' ' A' ' 153' ' ' SER . 34.2 mm -53.51 -37.75 31.28 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.178 0 CA-C-O 120.897 0.379 . . . . 0.0 111.092 179.877 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 157' ' ' LYS . . . . . . . . . . . . . 39.9 ttpt -65.49 -32.29 73.82 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 116.078 -0.51 . . . . 0.0 111.441 -179.761 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 46.0 t -72.54 -47.93 44.27 Favored 'General case' 0 C--O 1.235 0.3 0 CA-C-O 121.143 0.497 . . . . 0.0 111.006 -179.604 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 159' ' ' LEU . . . . . 0.417 ' O ' HD12 ' A' ' 163' ' ' LEU . 0.4 OUTLIER -68.63 -39.74 80.62 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 115.923 -0.58 . . . . 0.0 110.976 -179.415 . . . . . . . . 3 3 . 1 . 028 nuclear orig core ' A' A ' 160' ' ' TYR . . . . . 0.449 ' OH ' ' HB3' ' A' ' 145' ' ' MET . 37.2 t80 -62.25 -47.15 85.63 Favored 'General case' 0 C--N 1.326 -0.419 0 N-CA-C 112.086 0.402 . . . . 0.0 112.086 -178.596 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 24.9 m -61.49 -45.97 97.54 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 C-N-CA 120.909 -0.316 . . . . 0.0 111.365 -179.488 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 162' ' ' ARG . . . . . . . . . . . . . 28.1 tpt180 -68.85 -38.48 79.81 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 121.005 0.431 . . . . 0.0 111.103 -179.955 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 163' ' ' LEU . . . . . 0.417 HD12 ' O ' ' A' ' 159' ' ' LEU . 1.7 mp -64.67 -55.5 19.74 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 115.72 -0.673 . . . . 0.0 112.095 -179.23 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 164' ' ' ARG . . . . . 0.598 ' HG3' HD21 ' A' ' 165' ' ' ASN . 22.7 ptt180 -64.59 -41.72 96.05 Favored 'General case' 0 C--N 1.333 -0.15 0 N-CA-C 111.828 0.307 . . . . 0.0 111.828 -178.671 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 165' ' ' ASN . . . . . 0.598 HD21 ' HG3' ' A' ' 164' ' ' ARG . 0.9 OUTLIER -54.4 -48.37 71.67 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.91 0.386 . . . . 0.0 110.771 -179.922 . . . . . . . . 3 3 . 1 . 028 nuclear orig core ' A' A ' 166' ' ' LEU . . . . . . . . . . . . . 3.9 tt -64.06 -54.23 37.35 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 116.026 -0.533 . . . . 0.0 111.431 -179.787 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 167' ' ' THR . . . . . 0.456 ' O ' ' HB2' ' A' ' 171' ' ' TRP . 34.4 m -57.24 -54.28 48.61 Favored 'General case' 0 C--N 1.329 -0.307 0 N-CA-C 112.868 0.692 . . . . 0.0 112.868 -178.568 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 168' ' ' VAL . . . . . . . . . . . . . 9.8 p -55.58 -41.59 64.84 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.243 0 N-CA-C 112.425 0.528 . . . . 0.0 112.425 -178.694 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 169' ' ' VAL . . . . . . . . . . . . . 48.7 t -59.82 -64.62 0.56 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 C-N-CA 121.122 -0.231 . . . . 0.0 111.488 -179.628 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 170' ' ' LEU . . . . . 0.434 HD13 HG12 ' A' ' 203' ' ' VAL . 1.3 pp -62.07 -27.18 68.72 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.64 -0.254 . . . . 0.0 111.295 -179.582 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 171' ' ' TRP . . . . . 0.456 ' HB2' ' O ' ' A' ' 167' ' ' THR . 2.0 m0 -70.73 -36.12 73.02 Favored 'General case' 0 CA--C 1.519 -0.217 0 CA-C-O 121.099 0.476 . . . . 0.0 109.739 178.772 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 172' ' ' ALA . . . . . 0.443 ' HA ' ' CZ ' ' A' ' 134' ' ' PHE . . . -71.33 -6.85 43.08 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 115.465 -0.788 . . . . 0.0 110.877 179.573 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 173' ' ' ILE . . . . . 0.475 ' O ' HG12 ' A' ' 177' ' ' ILE . 42.1 mm -85.67 -23.29 7.13 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.191 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.943 179.571 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 174' ' ' TYR . . . . . . . . . . . . . 29.3 m-85 -53.87 -49.58 88.65 Favored Pre-proline 0 CA--C 1.53 0.201 0 CA-C-N 116.363 -0.38 . . . . 0.0 111.607 -179.72 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 175' ' ' PRO . . . . . 0.456 ' HB3' ' HZ ' ' A' ' 127' ' ' PHE . 81.2 Cg_exo -47.46 -31.62 13.82 Favored 'Trans proline' 0 C--N 1.351 0.701 0 C-N-CA 122.177 1.918 . . . . 0.0 112.228 179.446 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 176' ' ' PHE . . . . . 0.463 ' O ' ' HG ' ' A' ' 180' ' ' LEU . 75.0 m-85 -80.39 -50.04 10.66 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.02 -0.536 . . . . 0.0 111.908 -179.856 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 177' ' ' ILE . . . . . 0.475 HG12 ' O ' ' A' ' 173' ' ' ILE . 6.4 mm -62.52 -35.84 72.03 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.556 0 CA-C-N 116.091 -0.504 . . . . 0.0 112.269 -178.144 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 178' ' ' TRP . . . . . 0.422 ' HH2' ' HB2' ' A' ' 123' ' ' ARG . 68.6 t90 -73.71 -43.1 60.18 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 121.001 0.429 . . . . 0.0 110.73 179.642 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 179' ' ' LEU . . . . . 0.407 ' O ' ' HA3' ' A' ' 184' ' ' GLY . 1.6 tm? -68.71 -51.25 43.61 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 115.765 -0.652 . . . . 0.0 111.188 -179.497 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 180' ' ' LEU . . . . . 0.54 HD23 HD11 ' A' ' 187' ' ' LEU . 13.8 mt -75.22 -47.24 29.16 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-N 116.442 -0.345 . . . . 0.0 111.78 -179.223 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . -57.01 178.91 0.73 Allowed Glycine 0 C--N 1.337 0.622 0 C-N-CA 120.415 -0.898 . . . . 0.0 112.71 179.858 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 182' ' ' PRO . . . . . 0.597 ' HA ' ' HB1' ' A' ' 186' ' ' ALA . 72.9 Cg_exo -47.73 -45.27 24.46 Favored 'Trans proline' 0 CA--C 1.536 0.582 0 C-N-CA 122.848 2.365 . . . . 0.0 113.762 -179.842 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 183' ' ' PRO . . . . . 0.444 ' HD3' ' HB2' ' A' ' 182' ' ' PRO . 76.2 Cg_exo -51.83 -16.98 4.62 Favored 'Trans proline' 0 C--N 1.356 0.945 0 C-N-CA 122.173 1.916 . . . . 0.0 113.145 -179.787 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 184' ' ' GLY . . . . . 0.407 ' HA3' ' O ' ' A' ' 179' ' ' LEU . . . -115.93 -90.91 1.66 Allowed Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.463 -0.875 . . . . 0.0 113.001 -179.749 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 185' ' ' VAL . . . . . . . . . . . . . 9.4 m -116.48 -7.66 12.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 N-CA-C 111.716 0.265 . . . . 0.0 111.716 -179.43 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 186' ' ' ALA . . . . . 0.597 ' HB1' ' HA ' ' A' ' 182' ' ' PRO . . . 56.66 85.69 0.08 Allowed 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.404 -0.362 . . . . 0.0 111.717 179.567 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 187' ' ' LEU . . . . . 0.54 HD11 HD23 ' A' ' 180' ' ' LEU . 20.9 mt -91.87 -49.45 6.24 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-O 120.927 0.394 . . . . 0.0 110.713 179.567 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 188' ' ' LEU . . . . . . . . . . . . . 95.6 mt -90.23 -154.48 0.33 Allowed 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 115.883 -0.599 . . . . 0.0 110.896 -179.962 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 189' ' ' THR . . . . . . . . . . . . . 29.8 m -95.99 134.89 23.21 Favored Pre-proline 0 C--N 1.328 -0.342 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.649 -179.862 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 190' ' ' PRO . . . . . . . . . . . . . 82.3 Cg_exo -44.99 -31.31 5.31 Favored 'Trans proline' 0 C--N 1.351 0.664 0 C-N-CA 122.592 2.195 . . . . 0.0 112.884 179.999 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 191' ' ' THR . . . . . . . . . . . . . 81.5 p -76.37 -42.05 45.94 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.481 -0.327 . . . . 0.0 111.326 -179.896 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 192' ' ' VAL . . . . . . . . . . . . . 58.3 t -70.08 -48.94 59.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.312 -0.404 . . . . 0.0 111.562 -179.504 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 193' ' ' ASP . . . . . . . . . . . . . 19.3 m-20 -53.78 -46.3 70.95 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.349 -0.387 . . . . 0.0 110.965 -179.89 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 194' ' ' VAL . . . . . . . . . . . . . 69.5 t -65.36 -36.05 76.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.28 -0.418 . . . . 0.0 110.883 179.712 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 195' ' ' ALA . . . . . . . . . . . . . . . -55.0 -44.45 74.51 Favored 'General case' 0 C--N 1.331 -0.199 0 CA-C-N 116.421 -0.354 . . . . 0.0 110.843 179.783 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 196' ' ' LEU . . . . . . . . . . . . . 91.2 mt -68.07 -39.05 83.03 Favored 'General case' 0 C--N 1.332 -0.195 0 CA-C-O 120.895 0.379 . . . . 0.0 110.387 179.26 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 197' ' ' ILE . . . . . 0.446 HD13 HD13 ' A' ' 200' ' ' LEU . 13.2 mm -58.57 -56.31 17.24 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-N 115.971 -0.559 . . . . 0.0 110.083 179.091 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 198' ' ' VAL . . . . . . . . . . . . . 73.6 t -53.6 -34.46 24.09 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.509 0 CA-C-N 115.442 -0.799 . . . . 0.0 109.368 178.208 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 199' ' ' TYR . . . . . . . . . . . . . 70.0 t80 -69.92 -31.43 69.2 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 115.203 -0.908 . . . . 0.0 110.628 180.0 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 200' ' ' LEU . . . . . 0.446 HD13 HD13 ' A' ' 197' ' ' ILE . 62.5 mt -67.75 -45.53 74.7 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 115.9 -0.591 . . . . 0.0 111.299 -179.73 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 201' ' ' ASP . . . . . . . . . . . . . 7.8 m-20 -70.56 -32.61 70.1 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 121.063 0.459 . . . . 0.0 110.396 179.957 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 202' ' ' LEU . . . . . . . . . . . . . 3.9 mt -66.81 -41.99 86.64 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 115.544 -0.753 . . . . 0.0 111.882 -179.892 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 203' ' ' VAL . . . . . 0.434 HG12 HD13 ' A' ' 170' ' ' LEU . 8.2 p -71.47 -37.01 62.81 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.366 0 N-CA-C 111.883 0.327 . . . . 0.0 111.883 -178.582 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 204' ' ' THR . . . . . 0.417 ' O ' ' HB2' ' A' ' 208' ' ' PHE . 24.5 m -65.37 -47.29 76.89 Favored 'General case' 0 C--N 1.329 -0.312 0 C-N-CA 120.832 -0.347 . . . . 0.0 111.674 -179.92 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 205' ' ' LYS . . . . . 0.628 ' HE2' ' HB1' ' A' ' 47' ' ' ALA . 60.4 mttp -79.3 -57.93 3.47 Favored 'General case' 0 C--N 1.326 -0.429 0 N-CA-C 112.168 0.432 . . . . 0.0 112.168 -178.225 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 44.4 t -67.33 -37.39 78.93 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.388 0 CA-C-N 116.331 -0.395 . . . . 0.0 111.522 -179.413 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 207' ' ' GLY . . . . . . . . . . . . . . . -70.75 -53.65 11.42 Favored Glycine 0 C--N 1.331 0.278 0 C-N-CA 120.663 -0.78 . . . . 0.0 112.668 -179.622 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 208' ' ' PHE . . . . . 0.417 ' HB2' ' O ' ' A' ' 204' ' ' THR . 5.4 t80 -57.3 -42.42 81.75 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 120.872 0.368 . . . . 0.0 110.67 179.699 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 209' ' ' GLY . . . . . 0.463 ' O ' ' HB3' ' A' ' 212' ' ' ALA . . . -69.93 -38.51 75.0 Favored Glycine 0 N--CA 1.452 -0.296 0 CA-C-N 115.405 -0.816 . . . . 0.0 113.417 -179.766 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 210' ' ' PHE . . . . . . . . . . . . . 1.1 m-85 -69.43 -38.7 77.96 Favored 'General case' 0 CA--C 1.51 -0.58 0 N-CA-C 107.944 -1.132 . . . . 0.0 107.944 179.201 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 211' ' ' ILE . . . . . . . . . . . . . 82.9 mt -70.67 -28.69 35.18 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.825 0 N-CA-C 107.133 -1.432 . . . . 0.0 107.133 176.353 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 212' ' ' ALA . . . . . 0.463 ' HB3' ' O ' ' A' ' 209' ' ' GLY . . . -68.14 -37.94 81.61 Favored 'General case' 0 N--CA 1.45 -0.469 0 CA-C-N 114.394 -1.276 . . . . 0.0 110.572 179.704 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 213' ' ' LEU . . . . . . . . . . . . . 88.3 mt -70.1 -53.44 17.38 Favored 'General case' 0 C--N 1.331 -0.198 0 CA-C-N 115.28 -0.873 . . . . 0.0 111.444 -179.608 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 214' ' ' ASP . . . . . . . . . . . . . 25.6 t70 -54.15 -36.32 63.19 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.308 -0.406 . . . . 0.0 110.933 -179.764 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 215' ' ' ALA . . . . . . . . . . . . . . . -67.29 -57.27 6.97 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.026 -0.534 . . . . 0.0 111.457 -179.935 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 216' ' ' ALA . . . . . . . . . . . . . . . -58.57 -43.03 89.28 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.414 -0.357 . . . . 0.0 111.218 -179.735 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 217' ' ' ALA . . . . . . . . . . . . . . . -57.76 -36.8 72.6 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.502 179.831 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 218' ' ' THR . . . . . . . . . . . . . 90.9 m . . . . . 0 C--N 1.33 -0.268 0 CA-C-N 115.905 -0.589 . . . . 0.0 110.802 179.558 . . . . . . . . 0 0 . 1 . 029 nuclear orig core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.253 0 N-CA-C 112.763 -0.135 . . . . 0.0 112.763 . . . . . . . . . 0 0 . 1 . 029 nuclear orig core ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 89.1 mt -64.28 -37.42 87.42 Favored 'General case' 0 N--CA 1.45 -0.46 0 CA-C-O 120.841 0.353 . . . . 0.0 111.199 -179.945 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 5' ' ' THR . . . . . 0.438 ' HA ' ' HD2' ' A' ' 8' ' ' PHE . 78.5 p -59.79 -37.34 78.82 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.047 -0.524 . . . . 0.0 111.968 -179.6 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 20.1 p -54.24 -36.88 64.02 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.45 -0.341 . . . . 0.0 111.515 -179.441 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 7' ' ' LEU . . . . . . . . . . . . . 4.2 mm? -61.9 -53.05 61.06 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.308 -0.406 . . . . 0.0 111.344 -179.705 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 8' ' ' PHE . . . . . 0.634 ' HB2' ' HB1' ' A' ' 55' ' ' ALA . 29.2 m-85 -61.99 -27.32 68.78 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.367 -0.379 . . . . 0.0 111.223 -179.574 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 9' ' ' TRP . . . . . . . . . . . . . 19.7 m95 -69.61 -44.61 70.35 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 121.008 0.433 . . . . 0.0 110.204 179.882 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 90.2 mt -65.72 -37.12 85.53 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 115.926 -0.579 . . . . 0.0 109.997 179.181 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -66.12 -32.9 83.72 Favored Glycine 0 N--CA 1.446 -0.677 0 CA-C-N 115.597 -0.729 . . . . 0.0 111.746 179.568 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -68.44 -37.29 80.11 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.856 0.36 . . . . 0.0 110.442 179.428 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 67.7 mt -59.47 -53.57 46.45 Favored 'Isoleucine or valine' 0 C--O 1.234 0.247 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.254 179.114 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -58.26 -34.78 75.38 Favored Glycine 0 C--N 1.332 0.36 0 C-N-CA 120.652 -0.785 . . . . 0.0 111.977 179.291 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 15' ' ' MET . . . . . 0.622 ' HE2' ' HD2' ' A' ' 205' ' ' LYS . 17.3 mmt -66.17 -41.23 90.59 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-O 120.772 0.32 . . . . 0.0 110.57 179.426 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 16' ' ' LEU . . . . . 0.409 HD23 ' HA ' ' A' ' 16' ' ' LEU . 0.3 OUTLIER -57.01 -40.74 77.2 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.067 -0.515 . . . . 0.0 109.95 179.371 . . . . . . . . 3 3 . 1 . 029 nuclear orig core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 60.5 t -60.28 -48.86 86.5 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.241 0 CA-C-N 115.856 -0.611 . . . . 0.0 110.655 179.358 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -63.34 -48.55 77.95 Favored Glycine 0 C--N 1.332 0.356 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.058 179.337 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 43.9 m -50.13 -43.26 51.74 Favored 'General case' 0 C--N 1.328 -0.366 0 C-N-CA 122.317 0.247 . . . . 0.0 111.434 -179.659 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 87.2 mt -71.51 -44.41 64.69 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.597 -0.274 . . . . 0.0 111.694 -179.781 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -61.45 -31.67 71.63 Favored 'General case' 0 C--N 1.33 -0.28 0 N-CA-C 111.866 0.321 . . . . 0.0 111.866 -179.589 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 6.9 m-85 -90.97 -35.37 14.72 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.693 0.283 . . . . 0.0 111.679 -179.32 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -66.84 -51.28 57.43 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-O 120.98 0.419 . . . . 0.0 111.781 -179.412 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 24' ' ' TRP . . . . . . . . . . . . . 7.3 t-105 -62.93 -50.68 69.87 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-N 115.804 -0.634 . . . . 0.0 110.891 -179.696 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.327 -0.379 0 CA-C-N 116.364 -0.38 . . . . 0.0 110.741 179.552 . . . . . . . . 0 0 . 1 . 029 nuclear orig core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.343 0 N-CA-C 112.454 -0.258 . . . . 0.0 112.454 . . . . . . . . . 0 0 . 1 . 029 nuclear orig core ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 36.3 mt-10 -63.1 -21.03 65.9 Favored 'General case' 0 C--N 1.331 -0.218 0 CA-C-O 120.697 0.284 . . . . 0.0 110.946 179.993 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 34' ' ' ARG . . . . . . . . . . . . . 5.0 tmt_? -50.43 -38.2 41.98 Favored 'General case' 0 C--N 1.332 -0.169 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.202 -179.93 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 29.7 mmt180 -64.5 -44.86 89.6 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 116.343 -0.39 . . . . 0.0 111.211 -179.928 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 57.1 m-85 -66.78 -31.06 71.44 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.113 -179.989 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 37' ' ' TYR . . . . . . . . . . . . . 32.2 m-85 -70.97 -52.32 20.46 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.087 -179.687 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 85.4 t -57.04 -36.84 52.24 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-O 121.141 0.496 . . . . 0.0 110.232 179.387 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 55.4 m -62.21 -50.32 72.26 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 115.629 -0.714 . . . . 0.0 110.8 179.489 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 40' ' ' LEU . . . . . 0.616 HD12 HD12 ' A' ' 43' ' ' ILE . 44.5 tp -63.06 -44.66 95.19 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 115.644 -0.707 . . . . 0.0 110.922 179.877 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 86.8 t -62.72 -34.04 63.34 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.43 0 CA-C-N 116.043 -0.526 . . . . 0.0 110.076 179.142 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 42' ' ' GLY . . . . . 0.433 ' O ' HG12 ' A' ' 46' ' ' ILE . . . -60.82 -49.76 75.1 Favored Glycine 0 N--CA 1.448 -0.546 0 CA-C-N 115.461 -0.79 . . . . 0.0 113.197 -179.897 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 43' ' ' ILE . . . . . 0.616 HD12 HD12 ' A' ' 40' ' ' LEU . 22.8 pt -62.29 -48.94 86.04 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.202 0 CA-C-N 117.03 0.415 . . . . 0.0 111.993 -179.296 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 44' ' ' SER . . . . . 0.407 ' N ' HG13 ' A' ' 43' ' ' ILE . 99.0 p -59.52 -29.56 67.96 Favored 'General case' 0 C--O 1.233 0.227 0 CA-C-O 120.993 0.425 . . . . 0.0 111.016 179.961 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -77.65 -54.57 4.54 Favored Glycine 0 N--CA 1.453 -0.207 0 C-N-CA 121.075 -0.583 . . . . 0.0 113.343 -179.07 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 46' ' ' ILE . . . . . 0.446 ' O ' HG21 ' A' ' 49' ' ' VAL . 10.3 pt -58.35 -36.23 57.42 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.248 0 CA-C-O 120.758 0.313 . . . . 0.0 111.143 -179.552 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 47' ' ' ALA . . . . . 0.639 ' HB1' ' HE2' ' A' ' 205' ' ' LYS . . . -68.32 -43.06 78.42 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-O 120.939 0.4 . . . . 0.0 110.443 178.621 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -55.16 -38.17 67.94 Favored 'General case' 0 C--N 1.332 -0.193 0 CA-C-N 115.805 -0.634 . . . . 0.0 111.823 -179.795 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 49' ' ' VAL . . . . . 0.446 HG21 ' O ' ' A' ' 46' ' ' ILE . 17.5 m -76.6 -34.35 23.84 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.221 0 CA-C-O 120.611 0.244 . . . . 0.0 111.457 -179.7 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . 0.4 ' N ' HG23 ' A' ' 49' ' ' VAL . . . -63.64 -38.41 91.03 Favored 'General case' 0 CA--C 1.52 -0.179 0 CA-C-O 121.037 0.446 . . . . 0.0 111.042 179.897 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 28.5 m-85 -72.57 -42.64 64.41 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-N 115.824 -0.625 . . . . 0.0 110.482 -179.773 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -59.99 -53.48 57.37 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-N 115.734 -0.666 . . . . 0.0 110.925 179.681 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 53' ' ' VAL . . . . . 0.431 HG22 ' N ' ' A' ' 54' ' ' MET . 31.3 m -60.21 -48.67 87.16 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.234 0 CA-C-N 116.317 -0.402 . . . . 0.0 110.874 179.936 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 54' ' ' MET . . . . . 0.431 ' N ' HG22 ' A' ' 53' ' ' VAL . 7.0 ttp -60.74 -29.11 69.18 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 121.206 0.527 . . . . 0.0 109.922 179.431 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 55' ' ' ALA . . . . . 0.634 ' HB1' ' HB2' ' A' ' 8' ' ' PHE . . . -75.58 -19.23 59.4 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 115.622 -0.717 . . . . 0.0 111.528 179.62 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 96.8 mt -89.09 -0.83 57.76 Favored 'General case' 0 C--N 1.331 -0.198 0 CA-C-N 116.454 -0.339 . . . . 0.0 111.523 -179.441 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 99.94 -22.56 39.71 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.583 -0.818 . . . . 0.0 113.14 179.521 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 34.0 m -73.05 147.33 9.9 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.202 0 CA-C-N 117.008 0.404 . . . . 0.0 110.568 179.729 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 59' ' ' GLY . . . . . 0.441 ' HA3' ' HD3' ' A' ' 71' ' ' PRO . . . 90.86 13.71 58.9 Favored Glycine 0 N--CA 1.448 -0.525 0 C-N-CA 120.694 -0.765 . . . . 0.0 111.869 -178.934 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 60' ' ' TRP . . . . . . . . . . . . . 13.3 m0 -103.34 98.42 8.33 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-O 121.14 0.495 . . . . 0.0 109.891 -179.978 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 20.8 t -91.4 117.03 67.58 Favored Pre-proline 0 C--N 1.323 -0.56 0 CA-C-N 115.524 -0.762 . . . . 0.0 111.209 -178.972 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 64.8 Cg_endo -73.12 135.9 23.7 Favored 'Trans proline' 0 C--N 1.35 0.617 0 C-N-CA 122.346 2.031 . . . . 0.0 112.435 -179.928 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 46.0 t -135.18 89.05 0.82 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 115.94 -0.573 . . . . 0.0 110.718 179.696 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . 55.97 -88.7 0.02 OUTLIER 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.021 -0.536 . . . . 0.0 111.538 -179.917 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 5.2 mp0 -116.78 -19.25 9.99 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-O 121.009 0.433 . . . . 0.0 110.745 -179.866 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 66' ' ' ARG . . . . . . . . . . . . . 67.8 mtp180 -98.22 166.18 11.52 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 115.677 -0.692 . . . . 0.0 110.564 179.938 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 39.4 m -136.83 125.79 24.29 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.886 0.374 . . . . 0.0 111.381 -179.882 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 11.3 t -109.7 146.31 15.25 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.04 -0.527 . . . . 0.0 110.691 179.767 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 69' ' ' PHE . . . . . . . . . . . . . 27.5 m-85 -108.19 115.24 29.75 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.82 0.343 . . . . 0.0 110.602 -179.717 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 70' ' ' VAL . . . . . 0.603 HG12 ' HD3' ' A' ' 71' ' ' PRO . 1.4 p -69.0 -35.42 6.19 Favored Pre-proline 0 CA--C 1.542 0.651 0 N-CA-C 113.148 0.795 . . . . 0.0 113.148 -179.317 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 71' ' ' PRO . . . . . 0.603 ' HD3' HG12 ' A' ' 70' ' ' VAL . 61.2 Cg_endo -70.49 -18.19 33.74 Favored 'Trans proline' 0 C--N 1.36 1.148 0 C-N-CA 121.741 1.627 . . . . 0.0 112.574 -179.399 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 72' ' ' ARG . . . . . 0.452 ' NH2' HG13 ' A' ' 197' ' ' ILE . 72.4 ttt180 -75.9 -54.49 6.81 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.277 -0.42 . . . . 0.0 111.835 -179.026 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 73' ' ' TYR . . . . . . . . . . . . . 83.4 m-85 -73.34 -35.68 66.06 Favored 'General case' 0 C--N 1.331 -0.21 0 C-N-CA 121.085 -0.246 . . . . 0.0 111.203 -179.103 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 0.3 OUTLIER -67.17 -43.87 88.2 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.238 0 C-N-CA 120.818 -0.353 . . . . 0.0 110.354 179.72 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 20.3 t70 -59.27 -35.87 74.5 Favored 'General case' 0 N--CA 1.455 -0.188 0 N-CA-C 109.267 -0.642 . . . . 0.0 109.267 178.986 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 76' ' ' TRP . . . . . 0.482 ' HB3' ' SD ' ' A' ' 109' ' ' MET . 39.3 m0 -64.0 -36.57 84.41 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 115.702 -0.681 . . . . 0.0 110.577 179.134 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 77' ' ' ILE . . . . . 0.469 ' O ' ' HG2' ' A' ' 81' ' ' PRO . 79.5 mt -67.29 -28.95 44.16 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.239 179.5 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 81.9 mt -91.33 -14.74 30.24 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.068 -0.515 . . . . 0.0 112.023 179.868 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 79' ' ' THR . . . . . 0.404 ' O ' HG12 ' A' ' 83' ' ' ILE . 70.1 p -104.38 -53.3 2.74 Favored 'General case' 0 N--CA 1.463 0.182 0 N-CA-C 113.272 0.842 . . . . 0.0 113.272 -178.652 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 80' ' ' THR . . . . . 0.628 ' HB ' ' HD3' ' A' ' 81' ' ' PRO . 8.9 m -51.75 -55.44 29.98 Favored Pre-proline 0 C--N 1.329 -0.296 0 N-CA-C 113.014 0.746 . . . . 0.0 113.014 -178.033 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 81' ' ' PRO . . . . . 0.628 ' HD3' ' HB ' ' A' ' 80' ' ' THR . 52.7 Cg_exo -56.96 -25.58 63.35 Favored 'Trans proline' 0 C--N 1.352 0.752 0 C-N-CA 121.505 1.47 . . . . 0.0 111.77 -179.799 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 82' ' ' LEU . . . . . 0.404 HD21 HG22 ' A' ' 43' ' ' ILE . 10.9 tp -76.83 -33.16 57.96 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 115.806 -0.634 . . . . 0.0 110.577 179.961 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 83' ' ' ILE . . . . . 0.404 HG12 ' O ' ' A' ' 79' ' ' THR . 43.5 mm -65.99 -52.75 45.27 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.204 0 CA-C-O 120.883 0.373 . . . . 0.0 110.201 179.176 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 33.7 m -61.42 -30.02 47.19 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.256 0 N-CA-C 109.472 -0.566 . . . . 0.0 109.472 178.759 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 85' ' ' TYR . . . . . . . . . . . . . 68.0 t80 -67.75 -30.64 70.16 Favored 'General case' 0 N--CA 1.452 -0.329 0 CA-C-N 115.391 -0.822 . . . . 0.0 109.588 178.568 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 86' ' ' PHE . . . . . . . . . . . . . 3.3 t80 -65.14 -49.78 68.55 Favored 'General case' 0 C--O 1.232 0.172 0 CA-C-N 115.823 -0.626 . . . . 0.0 109.766 179.069 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 6.5 mt -63.87 -30.8 71.85 Favored 'General case' 0 CA--C 1.518 -0.259 0 CA-C-N 115.878 -0.601 . . . . 0.0 109.742 179.468 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -69.86 -29.08 71.18 Favored Glycine 0 N--CA 1.449 -0.455 0 CA-C-N 115.291 -0.868 . . . . 0.0 112.167 179.74 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 54.1 mt -74.04 -38.93 63.85 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-O 120.913 0.387 . . . . 0.0 110.524 179.622 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 94.6 mt -63.71 -35.82 81.81 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.002 -0.545 . . . . 0.0 110.975 179.801 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 91' ' ' ALA . . . . . 0.402 ' HB3' ' OG ' ' A' ' 148' ' ' SER . . . -80.97 -54.77 5.28 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.351 -179.677 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 101.51 61.56 0.77 Allowed Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.791 -0.719 . . . . 0.0 112.369 -179.668 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 93' ' ' LEU . . . . . 0.475 ' HB3' ' HB2' ' A' ' 97' ' ' GLU . 6.8 mp -80.37 178.37 8.34 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-O 120.797 0.332 . . . . 0.0 110.907 -179.771 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 94' ' ' ASP . . . . . . . . . . . . . 22.4 m-20 -96.15 168.09 10.81 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.658 179.73 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 67.8 m -55.32 -35.09 64.77 Favored 'General case' 0 C--N 1.33 -0.239 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.256 -179.899 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 27.6 tpt180 -69.33 -54.01 16.74 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.412 -0.358 . . . . 0.0 110.895 -179.815 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 97' ' ' GLU . . . . . 0.475 ' HB2' ' HB3' ' A' ' 93' ' ' LEU . 32.9 mt-10 -53.82 -49.55 68.12 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.098 -0.501 . . . . 0.0 111.184 -179.639 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 98' ' ' PHE . . . . . 0.402 ' O ' HG12 ' A' ' 102' ' ' ILE . 25.4 m-85 -55.26 -51.19 67.43 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.397 -0.365 . . . . 0.0 111.002 179.902 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -56.9 -29.89 59.44 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.858 -0.687 . . . . 0.0 112.637 -179.74 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 77.4 mt -72.85 -43.26 60.45 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-O 120.85 0.357 . . . . 0.0 111.308 -179.903 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 61.3 t -68.29 -49.8 63.41 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.355 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.702 -179.435 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 102' ' ' ILE . . . . . 0.402 HG12 ' O ' ' A' ' 98' ' ' PHE . 39.9 mm -58.11 -52.23 61.11 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 CA-C-N 116.317 -0.401 . . . . 0.0 111.584 -179.367 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 14.7 t -58.28 -34.65 70.75 Favored 'General case' 0 C--N 1.331 -0.203 0 CA-C-O 120.746 0.308 . . . . 0.0 110.82 -179.801 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 104' ' ' LEU . . . . . 0.423 HD22 ' HE2' ' A' ' 140' ' ' TYR . 30.5 tp -61.61 -45.83 92.41 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.625 179.224 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 105' ' ' ASN . . . . . 0.574 ' N ' HD21 ' A' ' 105' ' ' ASN . 0.8 OUTLIER -64.83 -26.87 68.52 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.095 -0.502 . . . . 0.0 111.117 -179.818 . . . . . . . . 3 3 . 1 . 029 nuclear orig core ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 99.3 m -66.29 -57.37 7.66 Favored 'General case' 0 C--N 1.331 -0.204 0 CA-C-N 116.548 -0.296 . . . . 0.0 111.351 179.878 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 8.8 p -58.16 -36.32 56.8 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.213 0 CA-C-N 116.383 -0.372 . . . . 0.0 110.862 -179.88 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 59.9 t -64.82 -53.3 43.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.554 179.358 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 109' ' ' MET . . . . . 0.482 ' SD ' ' HB3' ' A' ' 76' ' ' TRP . 5.7 tpp -60.89 -31.06 70.56 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 115.941 -0.572 . . . . 0.0 110.417 179.885 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 11.9 mt -74.44 -30.34 61.85 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 115.976 -0.556 . . . . 0.0 110.267 179.507 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -62.43 -42.52 99.51 Favored 'General case' 0 C--N 1.332 -0.194 0 N-CA-C 109.514 -0.55 . . . . 0.0 109.514 178.607 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . -74.42 -39.18 43.25 Favored Glycine 0 N--CA 1.449 -0.438 0 N-CA-C 111.187 -0.765 . . . . 0.0 111.187 178.748 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 113' ' ' PHE . . . . . . . . . . . . . 0.7 OUTLIER -50.66 -70.92 0.07 Allowed 'General case' 0 C--N 1.332 -0.162 0 N-CA-C 109.539 -0.541 . . . . 0.0 109.539 179.02 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 114' ' ' ALA . . . . . 0.461 ' HA ' ' HB2' ' A' ' 117' ' ' MET . . . -64.13 -21.05 66.39 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 115.387 -0.824 . . . . 0.0 110.947 179.218 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 115' ' ' GLY . . . . . 0.457 ' HA2' HD23 ' A' ' 126' ' ' LEU . . . -52.25 -49.48 50.38 Favored Glycine 0 C--N 1.335 0.508 0 C-N-CA 120.765 -0.731 . . . . 0.0 111.925 179.635 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -78.5 -18.48 54.73 Favored 'General case' 0 C--N 1.325 -0.465 0 CA-C-O 120.85 0.357 . . . . 0.0 110.983 179.392 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 117' ' ' MET . . . . . 0.461 ' HB2' ' HA ' ' A' ' 114' ' ' ALA . 19.9 mmt -84.85 3.78 36.29 Favored 'General case' 0 C--N 1.332 -0.189 0 CA-C-N 116.103 -0.499 . . . . 0.0 112.03 -179.361 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 118' ' ' VAL . . . . . 0.475 HG23 ' HB3' ' A' ' 123' ' ' ARG . 35.5 m -66.31 146.32 99.03 Favored Pre-proline 0 C--N 1.328 -0.364 0 C-N-CA 121.046 -0.262 . . . . 0.0 111.407 -179.588 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 119' ' ' PRO . . . . . . . . . . . . . 92.9 Cg_endo -86.86 -11.35 5.61 Favored 'Trans proline' 0 C--N 1.348 0.535 0 C-N-CA 122.674 2.25 . . . . 0.0 112.226 179.781 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -140.27 -124.98 2.15 Favored Glycine 0 C--N 1.331 0.281 0 C-N-CA 120.84 -0.695 . . . . 0.0 112.795 -179.907 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 2.3 pp -109.94 18.15 7.06 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.187 0 CA-C-O 120.782 0.325 . . . . 0.0 111.695 -179.564 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 42.8 mt-10 -66.47 -18.53 65.41 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.306 -0.407 . . . . 0.0 111.159 -179.9 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 123' ' ' ARG . . . . . 0.475 ' HB3' HG23 ' A' ' 118' ' ' VAL . 17.8 ptt180 -50.47 -34.61 25.52 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.825 -179.516 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 124' ' ' TYR . . . . . . . . . . . . . 29.2 m-85 -61.5 -34.13 74.96 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.766 0.317 . . . . 0.0 111.13 -179.552 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 125' ' ' ALA . . . . . . . . . . . . . . . -74.5 -49.69 21.1 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.908 179.788 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 126' ' ' LEU . . . . . 0.457 HD23 ' HA2' ' A' ' 115' ' ' GLY . 7.3 mp -53.39 -49.15 67.84 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-N 116.051 -0.522 . . . . 0.0 110.588 179.921 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 127' ' ' PHE . . . . . . . . . . . . . 5.4 t80 -67.0 -37.77 84.78 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.821 179.958 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 128' ' ' GLY . . . . . . . . . . . . . . . -46.34 -43.09 13.98 Favored Glycine 0 C--N 1.332 0.338 0 C-N-CA 120.156 -1.021 . . . . 0.0 110.817 179.097 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 129' ' ' MET . . . . . 0.427 ' HE3' ' N ' ' A' ' 130' ' ' GLY . 0.8 OUTLIER -71.81 -39.05 70.11 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.921 0.391 . . . . 0.0 109.971 178.509 . . . . . . . . 3 3 . 1 . 029 nuclear orig core ' A' A ' 130' ' ' GLY . . . . . 0.427 ' N ' ' HE3' ' A' ' 129' ' ' MET . . . -60.95 -32.88 81.57 Favored Glycine 0 C--N 1.333 0.401 0 CA-C-N 115.916 -0.584 . . . . 0.0 113.043 -179.911 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -74.84 -53.87 8.32 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-O 120.669 0.271 . . . . 0.0 110.883 179.959 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 48.2 t -56.4 -40.35 66.54 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.228 0 CA-C-O 121.478 0.656 . . . . 0.0 109.477 179.055 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -68.52 -37.82 80.35 Favored 'General case' 0 N--CA 1.451 -0.424 0 CA-C-N 115.102 -0.954 . . . . 0.0 110.408 179.24 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 134' ' ' PHE . . . . . . . . . . . . . 79.5 t80 -54.64 -51.93 63.87 Favored 'General case' 0 N--CA 1.451 -0.388 0 CA-C-N 116.09 -0.505 . . . . 0.0 109.901 179.387 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 135' ' ' ILE . . . . . 0.46 ' O ' HG21 ' A' ' 138' ' ' VAL . 56.5 mt -58.75 -33.55 49.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 115.647 -0.706 . . . . 0.0 110.046 179.068 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . -58.4 -36.35 83.55 Favored Glycine 0 N--CA 1.449 -0.449 0 C-N-CA 120.239 -0.982 . . . . 0.0 111.136 178.616 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 137' ' ' LEU . . . . . . . . . . . . . 38.4 tp -71.1 -53.15 15.64 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 115.769 -0.216 . . . . 0.0 110.805 179.494 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 138' ' ' VAL . . . . . 0.46 HG21 ' O ' ' A' ' 135' ' ' ILE . 3.3 m -55.97 -32.55 33.38 Favored 'Isoleucine or valine' 0 C--O 1.232 0.137 0 CA-C-O 121.233 0.539 . . . . 0.0 109.863 179.483 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 139' ' ' TYR . . . . . . . . . . . . . 34.4 t80 -60.3 -50.15 74.78 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 115.5 -0.773 . . . . 0.0 110.303 178.894 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 140' ' ' TYR . . . . . 0.423 ' HE2' HD22 ' A' ' 104' ' ' LEU . 22.4 m-85 -56.9 -35.41 68.96 Favored 'General case' 0 C--N 1.332 -0.152 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.741 179.64 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 141' ' ' LEU . . . . . . . . . . . . . 96.0 mt -57.73 -52.0 67.23 Favored 'General case' 0 C--N 1.332 -0.172 0 CA-C-N 116.355 -0.384 . . . . 0.0 110.504 179.602 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 10.2 t -78.48 -10.35 12.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.09 -0.505 . . . . 0.0 110.778 179.672 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . -71.58 -131.39 0.11 Allowed Glycine 0 CA--C 1.521 0.45 0 C-N-CA 120.886 -0.673 . . . . 0.0 112.677 -179.887 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 144' ' ' PRO . . . . . . . . . . . . . 44.8 Cg_endo -67.84 -24.09 40.71 Favored 'Trans proline' 0 C--N 1.348 0.542 0 C-N-CA 122.403 2.069 . . . . 0.0 112.5 -179.888 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 145' ' ' MET . . . . . . . . . . . . . 45.2 mtt -55.41 -34.62 64.57 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 120.983 0.421 . . . . 0.0 111.063 179.876 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 146' ' ' THR . . . . . . . . . . . . . 27.4 m -70.78 -45.82 64.02 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 115.991 -0.55 . . . . 0.0 112.077 -179.181 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 46.3 mt-10 -72.22 -29.51 64.03 Favored 'General case' 0 C--N 1.328 -0.345 0 N-CA-C 111.846 0.313 . . . . 0.0 111.846 -179.101 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 148' ' ' SER . . . . . 0.402 ' OG ' ' HB3' ' A' ' 91' ' ' ALA . 42.0 p -70.15 -45.04 67.6 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.551 -0.295 . . . . 0.0 111.488 -179.241 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 149' ' ' ALA . . . . . . . . . . . . . . . -77.98 -39.84 41.13 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.772 0.32 . . . . 0.0 111.79 -179.514 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 150' ' ' SER . . . . . . . . . . . . . 40.3 t -65.82 -5.09 7.9 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.284 -0.416 . . . . 0.0 111.517 -179.536 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 151' ' ' GLN . . . . . . . . . . . . . 48.4 mt-30 -127.1 17.44 7.2 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.614 -0.266 . . . . 0.0 111.232 179.876 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 25.2 tpt180 -93.82 -52.04 4.62 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-O 120.817 0.341 . . . . 0.0 111.074 179.944 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 153' ' ' SER . . . . . 0.567 ' HB3' HG12 ' A' ' 156' ' ' ILE . 23.1 t -157.38 172.57 18.35 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.581 179.466 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 154' ' ' SER . . . . . . . . . . . . . 47.6 t -70.39 -39.8 74.33 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.773 0.32 . . . . 0.0 110.949 179.961 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -76.95 -34.7 41.54 Favored Glycine 0 CA--C 1.518 0.254 0 C-N-CA 120.862 -0.685 . . . . 0.0 112.986 -179.899 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 156' ' ' ILE . . . . . 0.567 HG12 ' HB3' ' A' ' 153' ' ' SER . 38.5 mm -54.46 -38.18 40.4 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 CA-C-O 120.605 0.24 . . . . 0.0 111.492 -179.664 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 157' ' ' LYS . . . . . . . . . . . . . 27.2 ttpp -68.22 -31.98 71.87 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.41 -0.359 . . . . 0.0 111.371 -179.724 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 53.5 m -71.39 -48.5 49.56 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-O 120.898 0.38 . . . . 0.0 111.411 -179.631 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 159' ' ' LEU . . . . . 0.485 HD22 ' HB1' ' A' ' 215' ' ' ALA . 14.3 mt -71.16 -35.48 71.67 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.607 -179.637 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 160' ' ' TYR . . . . . . . . . . . . . 76.3 t80 -64.95 -44.86 88.04 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.471 -0.331 . . . . 0.0 111.874 -179.098 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 31.0 m -67.35 -46.28 84.06 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 N-CA-C 111.927 0.343 . . . . 0.0 111.927 -179.172 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 162' ' ' ARG . . . . . . . . . . . . . 78.5 mtm180 -64.78 -35.9 82.57 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.73 0.3 . . . . 0.0 111.529 -179.631 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 163' ' ' LEU . . . . . 0.553 ' HG ' ' HB2' ' A' ' 208' ' ' PHE . 7.7 mp -76.87 -51.37 11.38 Favored 'General case' 0 C--N 1.328 -0.349 0 N-CA-C 112.179 0.437 . . . . 0.0 112.179 -179.074 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 164' ' ' ARG . . . . . 0.403 ' HG3' ' N ' ' A' ' 165' ' ' ASN . 5.6 ppt_? -62.11 -41.68 98.47 Favored 'General case' 0 C--N 1.328 -0.331 0 N-CA-C 112.064 0.394 . . . . 0.0 112.064 -178.514 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 165' ' ' ASN . . . . . 0.423 ' O ' HG11 ' A' ' 168' ' ' VAL . 17.4 m-80 -69.38 -51.38 37.18 Favored 'General case' 0 C--N 1.332 -0.188 0 CA-C-O 120.696 0.284 . . . . 0.0 111.616 -179.788 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 166' ' ' LEU . . . . . 0.471 ' O ' ' HG ' ' A' ' 170' ' ' LEU . 4.2 tt -60.32 -51.33 69.97 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-O 120.844 0.354 . . . . 0.0 111.421 -179.601 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 167' ' ' THR . . . . . . . . . . . . . 88.3 m -59.91 -52.54 64.98 Favored 'General case' 0 C--N 1.329 -0.317 0 N-CA-C 112.923 0.712 . . . . 0.0 112.923 -178.826 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 168' ' ' VAL . . . . . 0.423 HG11 ' O ' ' A' ' 165' ' ' ASN . 8.9 p -54.32 -40.28 47.44 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.195 0 N-CA-C 112.297 0.48 . . . . 0.0 112.297 -178.546 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 169' ' ' VAL . . . . . 0.41 ' N ' HG13 ' A' ' 168' ' ' VAL . 79.1 t -62.03 -64.37 0.65 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-N 116.574 -0.285 . . . . 0.0 111.621 -179.721 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 170' ' ' LEU . . . . . 0.471 ' HG ' ' O ' ' A' ' 166' ' ' LEU . 1.2 pp -60.59 -30.96 70.14 Favored 'General case' 0 C--N 1.33 -0.272 0 N-CA-C 111.97 0.359 . . . . 0.0 111.97 -179.011 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 171' ' ' TRP . . . . . . . . . . . . . 3.2 m0 -70.32 -35.09 73.42 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-O 120.928 0.394 . . . . 0.0 110.383 179.431 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 172' ' ' ALA . . . . . . . . . . . . . . . -69.3 -7.28 35.67 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 115.844 -0.617 . . . . 0.0 110.801 -179.793 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 173' ' ' ILE . . . . . 0.545 HG22 HD12 ' A' ' 177' ' ' ILE . 43.6 mm -84.78 -23.53 7.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 115.917 -0.583 . . . . 0.0 110.736 179.536 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 174' ' ' TYR . . . . . 0.411 ' HB2' ' HD3' ' A' ' 175' ' ' PRO . 22.2 m-85 -54.41 -51.16 80.48 Favored Pre-proline 0 N--CA 1.464 0.254 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.768 -179.89 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 175' ' ' PRO . . . . . 0.411 ' HD3' ' HB2' ' A' ' 174' ' ' TYR . 87.5 Cg_exo -46.84 -29.07 7.62 Favored 'Trans proline' 0 C--N 1.352 0.752 0 C-N-CA 122.225 1.95 . . . . 0.0 112.387 -179.905 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 176' ' ' PHE . . . . . 0.478 ' O ' ' HG ' ' A' ' 180' ' ' LEU . 81.0 m-85 -80.6 -49.81 10.8 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 115.992 -0.549 . . . . 0.0 111.802 -179.893 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 177' ' ' ILE . . . . . 0.545 HD12 HG22 ' A' ' 173' ' ' ILE . 2.4 mm -61.19 -37.15 76.83 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.54 0 CA-C-N 116.201 -0.454 . . . . 0.0 112.133 -178.043 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 178' ' ' TRP . . . . . . . . . . . . . 63.8 t90 -73.45 -41.08 63.66 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-O 120.84 0.352 . . . . 0.0 110.637 179.628 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 179' ' ' LEU . . . . . 0.436 HD12 HD22 ' A' ' 180' ' ' LEU . 2.6 tm? -68.54 -54.07 19.02 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 115.97 -0.559 . . . . 0.0 111.259 -179.426 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 180' ' ' LEU . . . . . 0.478 ' HG ' ' O ' ' A' ' 176' ' ' PHE . 11.9 mt -72.58 -46.49 54.05 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.541 -0.3 . . . . 0.0 111.489 -179.408 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 181' ' ' GLY . . . . . 0.406 ' HA3' ' OD1' ' A' ' 193' ' ' ASP . . . -55.1 173.13 0.99 Allowed Glycine 0 C--N 1.336 0.557 0 C-N-CA 120.558 -0.829 . . . . 0.0 112.682 179.865 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 182' ' ' PRO . . . . . 0.628 ' HA ' ' HB2' ' A' ' 186' ' ' ALA . 82.9 Cg_exo -47.78 -44.67 26.17 Favored 'Trans proline' 0 C--N 1.347 0.49 0 C-N-CA 122.776 2.317 . . . . 0.0 113.611 179.87 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 183' ' ' PRO . . . . . 0.432 ' HD3' ' HB2' ' A' ' 182' ' ' PRO . 57.6 Cg_exo -52.65 -14.85 3.6 Favored 'Trans proline' 0 C--N 1.355 0.877 0 C-N-CA 121.982 1.788 . . . . 0.0 112.551 179.633 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 184' ' ' GLY . . . . . . . . . . . . . . . -115.08 -81.03 0.93 Allowed Glycine 0 N--CA 1.45 -0.373 0 C-N-CA 120.776 -0.726 . . . . 0.0 112.678 -179.982 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 185' ' ' VAL . . . . . . . . . . . . . 6.3 m -132.05 -2.9 1.85 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.208 0 N-CA-C 112.409 0.522 . . . . 0.0 112.409 -179.572 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 186' ' ' ALA . . . . . 0.628 ' HB2' ' HA ' ' A' ' 182' ' ' PRO . . . 53.02 87.31 0.04 OUTLIER 'General case' 0 C--N 1.331 -0.22 0 CA-C-O 120.723 0.297 . . . . 0.0 111.642 179.78 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 187' ' ' LEU . . . . . 0.428 HD13 HD23 ' A' ' 180' ' ' LEU . 18.6 mt -92.01 -49.82 6.02 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 120.838 0.351 . . . . 0.0 111.406 179.934 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 188' ' ' LEU . . . . . . . . . . . . . 38.8 mt -94.84 -89.45 0.23 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.087 -0.506 . . . . 0.0 111.412 -179.325 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 189' ' ' THR . . . . . . . . . . . . . 1.1 t -165.36 148.34 6.93 Favored Pre-proline 0 C--N 1.325 -0.461 0 CA-C-N 115.856 -0.611 . . . . 0.0 111.06 -179.56 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 190' ' ' PRO . . . . . . . . . . . . . 12.1 Cg_endo -55.83 -30.31 76.17 Favored 'Trans proline' 0 C--N 1.347 0.494 0 C-N-CA 122.513 2.142 . . . . 0.0 112.427 -179.994 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 191' ' ' THR . . . . . . . . . . . . . 77.9 p -64.56 -45.28 87.78 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 121.012 0.434 . . . . 0.0 110.686 179.682 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 192' ' ' VAL . . . . . . . . . . . . . 25.4 t -73.89 -38.47 50.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 115.81 -0.632 . . . . 0.0 111.056 179.857 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 193' ' ' ASP . . . . . 0.436 ' OD1' HG22 ' A' ' 177' ' ' ILE . 14.5 t70 -59.49 -51.51 69.56 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.9 179.8 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 194' ' ' VAL . . . . . . . . . . . . . 94.6 t -64.34 -36.37 76.96 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-N 116.02 -0.536 . . . . 0.0 111.185 -179.896 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 195' ' ' ALA . . . . . . . . . . . . . . . -57.64 -48.68 78.79 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.695 0.283 . . . . 0.0 111.092 179.92 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 196' ' ' LEU . . . . . . . . . . . . . 63.0 mt -68.44 -43.27 77.47 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 116.389 -0.369 . . . . 0.0 110.589 179.617 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 197' ' ' ILE . . . . . 0.538 HD11 ' HB ' ' A' ' 177' ' ' ILE . 17.2 mm -56.2 -59.34 2.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 115.944 -0.571 . . . . 0.0 110.56 179.416 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 198' ' ' VAL . . . . . . . . . . . . . 61.0 t -52.3 -35.39 19.63 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.505 0 CA-C-N 115.594 -0.73 . . . . 0.0 109.433 178.62 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 199' ' ' TYR . . . . . . . . . . . . . 67.3 t80 -70.58 -31.14 68.04 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 115.244 -0.889 . . . . 0.0 110.916 -179.904 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 200' ' ' LEU . . . . . 0.436 ' O ' HG13 ' A' ' 203' ' ' VAL . 37.1 mt -71.88 -40.23 69.06 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 115.902 -0.59 . . . . 0.0 111.544 -179.545 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 201' ' ' ASP . . . . . . . . . . . . . 14.7 m-20 -72.81 -34.87 67.15 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-O 121.237 0.542 . . . . 0.0 110.114 179.519 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 202' ' ' LEU . . . . . 0.459 ' HG ' ' HE1' ' A' ' 15' ' ' MET . 2.5 mt -73.01 -29.28 62.91 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 115.415 -0.811 . . . . 0.0 111.601 -179.634 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 203' ' ' VAL . . . . . 0.436 HG13 ' O ' ' A' ' 200' ' ' LEU . 12.5 p -77.6 -36.25 22.77 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.382 0 C-N-CA 121.045 -0.262 . . . . 0.0 110.669 -179.083 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 204' ' ' THR . . . . . . . . . . . . . 98.6 m -65.49 -58.79 4.97 Favored 'General case' 0 C--N 1.329 -0.307 0 C-N-CA 120.596 -0.442 . . . . 0.0 110.994 179.306 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 205' ' ' LYS . . . . . 0.639 ' HE2' ' HB1' ' A' ' 47' ' ' ALA . 61.5 mttp -63.27 -58.1 8.27 Favored 'General case' 0 C--N 1.33 -0.24 0 N-CA-C 112.461 0.541 . . . . 0.0 112.461 -178.259 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 44.6 t -69.97 -37.54 72.94 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.412 0 N-CA-C 112.235 0.458 . . . . 0.0 112.235 -178.751 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 207' ' ' GLY . . . . . 0.504 ' O ' HG13 ' A' ' 211' ' ' ILE . . . -58.22 -61.83 6.97 Favored Glycine 0 CA--C 1.52 0.365 0 C-N-CA 120.67 -0.776 . . . . 0.0 114.059 -178.486 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 208' ' ' PHE . . . . . 0.553 ' HB2' ' HG ' ' A' ' 163' ' ' LEU . 0.9 OUTLIER -73.41 -27.04 61.24 Favored 'General case' 0 C--O 1.221 -0.414 0 CA-C-N 117.47 0.635 . . . . 0.0 110.802 -179.14 . . . . . . . . 3 3 . 1 . 029 nuclear orig core ' A' A ' 209' ' ' GLY . . . . . 0.485 ' O ' ' HB3' ' A' ' 212' ' ' ALA . . . -63.19 -32.39 83.99 Favored Glycine 0 N--CA 1.447 -0.626 0 N-CA-C 111.663 -0.575 . . . . 0.0 111.663 178.616 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 210' ' ' PHE . . . . . . . . . . . . . 1.3 m-85 -75.08 -46.91 31.52 Favored 'General case' 0 CA--C 1.514 -0.439 0 N-CA-C 108.37 -0.974 . . . . 0.0 108.37 178.336 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 211' ' ' ILE . . . . . 0.504 HG13 ' O ' ' A' ' 207' ' ' GLY . 4.1 mt -63.41 -27.59 43.34 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.411 0 N-CA-C 107.473 -1.306 . . . . 0.0 107.473 176.67 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 212' ' ' ALA . . . . . 0.485 ' HB3' ' O ' ' A' ' 209' ' ' GLY . . . -63.79 -41.23 97.98 Favored 'General case' 0 N--CA 1.45 -0.461 0 CA-C-N 114.303 -1.317 . . . . 0.0 110.634 -179.772 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 213' ' ' LEU . . . . . . . . . . . . . 72.9 mt -70.12 -50.17 43.43 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 115.179 -0.919 . . . . 0.0 111.783 -179.393 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 214' ' ' ASP . . . . . . . . . . . . . 21.7 t70 -53.24 -51.83 60.94 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.331 -0.395 . . . . 0.0 111.581 -179.315 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 215' ' ' ALA . . . . . 0.485 ' HB1' HD22 ' A' ' 159' ' ' LEU . . . -64.63 -55.32 20.99 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.379 -0.373 . . . . 0.0 111.772 -179.54 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 216' ' ' ALA . . . . . . . . . . . . . . . -51.87 -37.07 50.78 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 116.414 -0.357 . . . . 0.0 111.496 -179.707 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 217' ' ' ALA . . . . . . . . . . . . . . . -63.65 -44.26 94.36 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.997 0.427 . . . . 0.0 110.06 179.577 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 218' ' ' THR . . . . . . . . . . . . . 54.3 m . . . . . 0 C--N 1.33 -0.258 0 CA-C-N 115.669 -0.696 . . . . 0.0 110.626 179.376 . . . . . . . . 0 0 . 1 . 030 nuclear orig core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.338 0 N-CA-C 112.481 -0.248 . . . . 0.0 112.481 . . . . . . . . . 0 0 . 1 . 030 nuclear orig core ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 55.3 tp -74.26 -35.84 63.82 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.904 0.383 . . . . 0.0 110.801 179.785 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 68.3 p -64.22 -29.67 70.76 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 115.935 -0.575 . . . . 0.0 111.569 -179.74 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 6' ' ' THR . . . . . 0.54 ' HG1' HD22 ' A' ' 7' ' ' LEU . 29.9 p -52.8 -38.07 60.67 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.601 -179.52 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 7' ' ' LEU . . . . . 0.54 HD22 ' HG1' ' A' ' 6' ' ' THR . 3.4 mm? -59.4 -53.27 60.09 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.475 -0.33 . . . . 0.0 110.84 -179.798 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 8' ' ' PHE . . . . . 0.44 ' O ' ' HB3' ' A' ' 51' ' ' TYR . 73.9 m-85 -58.43 -36.2 73.28 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.594 179.879 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 9' ' ' TRP . . . . . . . . . . . . . 25.4 m95 -64.94 -41.03 95.87 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-O 121.161 0.505 . . . . 0.0 110.151 179.825 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 83.1 mt -62.35 -49.51 75.3 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 115.562 -0.744 . . . . 0.0 110.519 179.512 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -55.21 -34.81 59.19 Favored Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.683 -0.77 . . . . 0.0 111.999 179.291 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -67.86 -36.23 79.94 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-O 120.795 0.331 . . . . 0.0 110.847 179.745 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 91.1 mt -60.28 -54.16 38.79 Favored 'Isoleucine or valine' 0 C--O 1.234 0.241 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.668 179.556 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -63.02 -30.64 78.1 Favored Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 120.688 -0.768 . . . . 0.0 111.871 179.478 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 15' ' ' MET . . . . . 0.534 ' HB3' ' HB3' ' A' ' 48' ' ' ALA . 0.0 OUTLIER -64.46 -48.93 73.42 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.666 0.27 . . . . 0.0 110.835 179.656 . . . . . . . . 3 3 . 1 . 030 nuclear orig core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -57.7 -41.3 81.42 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.334 -0.393 . . . . 0.0 110.94 179.73 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 96.5 t -59.33 -42.57 87.73 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.25 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.554 179.503 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -70.44 -46.73 46.88 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.845 -0.693 . . . . 0.0 112.1 179.588 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 20.5 m -49.5 -45.39 47.03 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-O 120.78 0.324 . . . . 0.0 111.134 -179.755 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 68.3 mt -71.51 -36.74 71.17 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.099 179.618 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -64.09 -31.85 73.19 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.316 -0.402 . . . . 0.0 111.537 -179.801 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 22' ' ' PHE . . . . . 0.438 ' HB2' HG21 ' A' ' 41' ' ' VAL . 7.5 m-85 -90.28 -28.4 18.82 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-O 120.813 0.34 . . . . 0.0 110.939 -179.688 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -72.28 -50.56 26.17 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.176 -0.465 . . . . 0.0 111.288 -179.784 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 24' ' ' TRP . . . . . . . . . . . . . 5.5 t-105 -64.73 -40.07 94.7 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-N 115.73 -0.668 . . . . 0.0 111.195 -179.641 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.33 -0.258 0 CA-C-O 120.855 0.36 . . . . 0.0 110.936 179.622 . . . . . . . . 0 0 . 1 . 030 nuclear orig core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.338 0 N-CA-C 112.464 -0.254 . . . . 0.0 112.464 . . . . . . . . . 0 0 . 1 . 030 nuclear orig core ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 16.7 mm-40 -65.05 -23.67 67.25 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.562 0.22 . . . . 0.0 111.167 -179.891 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 34' ' ' ARG . . . . . . . . . . . . . 52.9 ttt180 -50.85 -30.74 15.27 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.367 -0.379 . . . . 0.0 111.29 -179.716 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 79.7 ttt180 -60.13 -50.69 72.71 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.294 -0.412 . . . . 0.0 111.011 -179.838 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 73.7 m-85 -61.74 -30.47 70.8 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.091 -0.504 . . . . 0.0 111.211 -179.847 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 37' ' ' TYR . . . . . . . . . . . . . 64.0 m-85 -70.88 -54.08 12.77 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.281 -0.418 . . . . 0.0 111.141 -179.805 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 61.8 t -56.99 -38.45 60.0 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.223 0 CA-C-O 120.959 0.409 . . . . 0.0 110.654 179.86 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 20.5 m -65.39 -51.18 62.15 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 115.832 -0.622 . . . . 0.0 110.864 179.645 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 40' ' ' LEU . . . . . 0.494 HD11 HD11 ' A' ' 43' ' ' ILE . 38.0 tp -56.98 -46.84 81.95 Favored 'General case' 0 C--O 1.236 0.343 0 CA-C-N 115.894 -0.593 . . . . 0.0 110.578 179.721 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . 0.438 HG21 ' HB2' ' A' ' 22' ' ' PHE . 62.9 t -60.26 -34.28 56.76 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.326 0 CA-C-N 115.857 -0.61 . . . . 0.0 110.3 179.083 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -61.27 -39.3 97.01 Favored Glycine 0 N--CA 1.448 -0.539 0 C-N-CA 120.743 -0.742 . . . . 0.0 111.988 179.925 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 43' ' ' ILE . . . . . 0.494 HD11 HD11 ' A' ' 40' ' ' LEU . 0.7 OUTLIER -65.13 -56.59 14.87 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.223 0 CA-C-O 120.827 0.346 . . . . 0.0 110.998 179.797 . . . . . . . . 3 3 . 1 . 030 nuclear orig core ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 36.3 t -57.24 -27.6 62.17 Favored 'General case' 0 C--N 1.332 -0.156 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.431 -179.747 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -76.2 -53.57 5.59 Favored Glycine 0 CA--C 1.519 0.342 0 C-N-CA 120.664 -0.779 . . . . 0.0 113.327 -179.288 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 19.7 pt -58.34 -40.03 76.5 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.168 0 CA-C-O 120.738 0.304 . . . . 0.0 111.522 -179.418 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 47' ' ' ALA . . . . . 0.669 ' HB2' ' HE2' ' A' ' 205' ' ' LYS . . . -67.44 -43.67 80.56 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-N 116.436 -0.347 . . . . 0.0 111.364 179.603 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 48' ' ' ALA . . . . . 0.534 ' HB3' ' HB3' ' A' ' 15' ' ' MET . . . -55.1 -43.76 74.32 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.079 -0.51 . . . . 0.0 111.831 -179.423 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 28.4 m -73.8 -33.89 38.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.454 -0.339 . . . . 0.0 111.503 -179.428 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -65.35 -38.54 90.39 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-O 120.927 0.394 . . . . 0.0 111.148 179.74 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 51' ' ' TYR . . . . . 0.44 ' HB3' ' O ' ' A' ' 8' ' ' PHE . 29.0 m-85 -73.06 -35.56 66.71 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 116.132 -0.486 . . . . 0.0 110.756 -179.736 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -63.9 -42.22 97.51 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.291 -0.413 . . . . 0.0 110.938 179.263 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 53' ' ' VAL . . . . . 0.416 HG21 ' N ' ' A' ' 54' ' ' MET . 21.7 m -74.87 -45.1 44.41 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.177 0 CA-C-N 116.271 -0.422 . . . . 0.0 111.42 -179.981 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 54' ' ' MET . . . . . 0.416 ' N ' HG21 ' A' ' 53' ' ' VAL . 70.6 mtm -62.74 -32.01 73.05 Favored 'General case' 0 C--N 1.332 -0.174 0 CA-C-O 120.952 0.406 . . . . 0.0 110.296 179.572 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -63.02 -18.05 62.9 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 115.772 -0.649 . . . . 0.0 111.01 179.476 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 81.8 mt -99.14 -9.16 24.15 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 115.998 -0.546 . . . . 0.0 110.933 179.771 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 73.59 31.1 61.1 Favored Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.809 -0.71 . . . . 0.0 112.96 179.784 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 32.6 m -81.24 14.5 0.45 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-O 120.907 0.384 . . . . 0.0 111.525 179.893 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -151.85 10.27 0.67 Allowed Glycine 0 N--CA 1.45 -0.389 0 C-N-CA 120.882 -0.675 . . . . 0.0 112.734 179.938 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 60' ' ' TRP . . . . . . . . . . . . . 38.4 m0 -78.33 109.52 12.54 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.631 0.253 . . . . 0.0 110.573 179.842 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 7.6 p -102.32 130.75 23.53 Favored Pre-proline 0 C--N 1.329 -0.294 0 CA-C-N 116.431 -0.35 . . . . 0.0 111.255 -179.723 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 7.8 Cg_exo -72.87 144.14 38.18 Favored 'Trans proline' 0 C--N 1.35 0.622 0 C-N-CA 122.675 2.25 . . . . 0.0 112.383 -179.851 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 85.9 t -143.85 96.29 0.53 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.201 0 CA-C-N 115.993 -0.549 . . . . 0.0 111.031 179.968 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . 60.58 -86.15 0.02 OUTLIER 'General case' 0 C--N 1.333 -0.122 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.223 -179.902 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 11.4 tp10 -124.66 -23.93 4.27 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-O 120.927 0.394 . . . . 0.0 110.38 179.793 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 66' ' ' ARG . . . . . . . . . . . . . 96.9 mtt180 -103.13 153.41 20.34 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 115.809 -0.632 . . . . 0.0 110.4 179.739 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 91.2 m -111.94 119.34 38.19 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-O 120.952 0.406 . . . . 0.0 111.671 -179.336 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 68' ' ' VAL . . . . . 0.526 HG13 ' HG3' ' A' ' 117' ' ' MET . 42.4 t -90.52 147.03 5.49 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-N 115.938 -0.574 . . . . 0.0 110.401 179.224 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 69' ' ' PHE . . . . . . . . . . . . . 21.9 m-85 -105.11 114.55 28.82 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-O 121.008 0.432 . . . . 0.0 110.247 -179.367 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 70' ' ' VAL . . . . . 0.545 ' HB ' ' HD3' ' A' ' 71' ' ' PRO . 13.6 t -68.83 -50.09 24.66 Favored Pre-proline 0 C--N 1.325 -0.486 0 CA-C-N 115.937 -0.574 . . . . 0.0 112.471 -178.856 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 71' ' ' PRO . . . . . 0.545 ' HD3' ' HB ' ' A' ' 70' ' ' VAL . 16.4 Cg_exo -66.57 -17.84 53.47 Favored 'Trans proline' 0 C--N 1.351 0.671 0 C-N-CA 122.252 1.968 . . . . 0.0 112.698 -179.304 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 72' ' ' ARG . . . . . 0.418 ' NH2' HG13 ' A' ' 197' ' ' ILE . 66.2 ttt180 -66.25 -55.31 16.76 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-O 120.866 0.365 . . . . 0.0 111.539 -179.346 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 73' ' ' TYR . . . . . 0.465 ' O ' HG13 ' A' ' 77' ' ' ILE . 77.7 m-85 -71.59 -33.76 69.31 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.38 -0.373 . . . . 0.0 110.687 -179.492 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 74' ' ' ILE . . . . . 0.404 ' HA ' HD11 ' A' ' 77' ' ' ILE . 0.4 OUTLIER -67.51 -36.84 77.55 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.2 0 N-CA-C 109.768 -0.456 . . . . 0.0 109.768 179.106 . . . . . . . . 3 3 . 1 . 030 nuclear orig core ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 24.0 t70 -60.52 -38.51 84.65 Favored 'General case' 0 CA--C 1.519 -0.219 0 N-CA-C 108.959 -0.756 . . . . 0.0 108.959 178.506 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 76' ' ' TRP . . . . . . . . . . . . . 37.5 m0 -66.72 -30.86 71.2 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 115.438 -0.801 . . . . 0.0 110.468 179.193 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 77' ' ' ILE . . . . . 0.465 HG13 ' O ' ' A' ' 73' ' ' TYR . 82.3 mt -68.58 -31.11 49.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-O 121.017 0.437 . . . . 0.0 110.554 179.241 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 34.4 mt -91.51 -17.55 25.51 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.11 -0.495 . . . . 0.0 112.137 -179.889 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 72.7 p -102.32 -52.77 3.05 Favored 'General case' 0 N--CA 1.464 0.27 0 N-CA-C 113.417 0.895 . . . . 0.0 113.417 -178.238 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 80' ' ' THR . . . . . 0.668 ' HB ' ' HD3' ' A' ' 81' ' ' PRO . 49.8 m -52.39 -56.01 26.49 Favored Pre-proline 0 CA--C 1.532 0.251 0 N-CA-C 112.643 0.608 . . . . 0.0 112.643 -178.306 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 81' ' ' PRO . . . . . 0.668 ' HD3' ' HB ' ' A' ' 80' ' ' THR . 38.8 Cg_exo -58.98 -21.1 56.68 Favored 'Trans proline' 0 C--N 1.351 0.69 0 C-N-CA 121.507 1.471 . . . . 0.0 111.478 -179.942 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 82' ' ' LEU . . . . . . . . . . . . . 15.2 tp -77.03 -33.12 57.42 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 115.699 -0.682 . . . . 0.0 110.328 179.695 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 83' ' ' ILE . . . . . 0.409 HD13 HD13 ' A' ' 43' ' ' ILE . 49.1 mm -69.64 -51.86 37.36 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.166 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.232 179.25 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 35.5 m -61.1 -31.05 48.99 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.227 0 N-CA-C 109.407 -0.59 . . . . 0.0 109.407 178.706 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 85' ' ' TYR . . . . . . . . . . . . . 89.9 t80 -64.43 -34.7 78.79 Favored 'General case' 0 N--CA 1.454 -0.269 0 CA-C-N 115.472 -0.786 . . . . 0.0 109.427 178.601 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 86' ' ' PHE . . . . . . . . . . . . . 12.0 t80 -62.97 -49.6 74.06 Favored 'General case' 0 C--O 1.232 0.146 0 CA-C-N 115.765 -0.652 . . . . 0.0 110.01 179.136 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 87' ' ' LEU . . . . . 0.485 HD12 HD23 ' A' ' 141' ' ' LEU . 5.3 mt -63.59 -33.06 74.78 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 115.733 -0.667 . . . . 0.0 109.852 179.839 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -66.67 -27.52 73.28 Favored Glycine 0 N--CA 1.449 -0.474 0 CA-C-N 115.377 -0.829 . . . . 0.0 111.555 179.251 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 61.9 mt -74.58 -43.78 54.02 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.763 0.316 . . . . 0.0 111.032 179.89 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 82.6 mt -60.47 -32.34 71.31 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.123 -0.489 . . . . 0.0 111.216 -179.94 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 91' ' ' ALA . . . . . 0.467 ' HB1' ' HG ' ' A' ' 148' ' ' SER . . . -83.83 -54.14 5.1 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.309 -0.405 . . . . 0.0 111.424 -179.732 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 103.93 68.32 0.76 Allowed Glycine 0 N--CA 1.45 -0.369 0 C-N-CA 120.808 -0.71 . . . . 0.0 112.491 -179.706 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 93' ' ' LEU . . . . . 0.563 HD23 ' HB3' ' A' ' 97' ' ' GLU . 6.5 mp -91.23 164.77 13.77 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.712 0.291 . . . . 0.0 110.733 -179.933 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 94' ' ' ASP . . . . . . . . . . . . . 1.8 p30 -87.82 177.43 7.0 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.356 -0.384 . . . . 0.0 110.915 179.807 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 48.1 t -60.39 -32.16 71.04 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.027 -0.533 . . . . 0.0 111.881 -179.418 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 38.8 mmt180 -73.31 -53.31 11.12 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.55 -0.295 . . . . 0.0 111.62 -179.332 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 97' ' ' GLU . . . . . 0.563 ' HB3' HD23 ' A' ' 93' ' ' LEU . 44.0 mt-10 -53.3 -47.25 69.38 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.314 -0.403 . . . . 0.0 111.388 -179.671 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 98' ' ' PHE . . . . . 0.432 ' O ' HG12 ' A' ' 102' ' ' ILE . 12.6 m-85 -58.29 -49.86 75.65 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.373 -0.376 . . . . 0.0 110.876 179.975 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -54.88 -30.45 53.18 Favored Glycine 0 CA--C 1.518 0.255 0 C-N-CA 120.751 -0.737 . . . . 0.0 112.776 -179.81 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 96.3 mt -73.95 -45.53 48.72 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.214 0 CA-C-O 120.841 0.353 . . . . 0.0 111.622 -179.708 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 47.6 t -65.95 -46.74 87.52 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.411 0 CA-C-N 116.147 -0.478 . . . . 0.0 111.91 -179.161 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 102' ' ' ILE . . . . . 0.432 HG12 ' O ' ' A' ' 98' ' ' PHE . 37.6 mm -63.17 -51.77 67.19 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 N-CA-C 111.905 0.335 . . . . 0.0 111.905 -179.101 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 15.2 t -55.95 -36.72 68.1 Favored 'General case' 0 C--O 1.234 0.248 0 CA-C-O 120.869 0.366 . . . . 0.0 110.952 -179.61 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 104' ' ' LEU . . . . . 0.403 ' O ' HG23 ' A' ' 108' ' ' VAL . 29.7 tp -61.37 -47.73 84.5 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.06 -0.518 . . . . 0.0 110.683 179.464 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 105' ' ' ASN . . . . . 0.59 ' N ' HD21 ' A' ' 105' ' ' ASN . 0.8 OUTLIER -61.55 -26.33 67.87 Favored 'General case' 0 C--N 1.326 -0.438 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.745 179.848 . . . . . . . . 3 3 . 1 . 030 nuclear orig core ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 66.2 m -66.46 -57.3 7.65 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 116.374 -0.375 . . . . 0.0 111.331 -179.926 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 9.1 p -58.27 -36.57 58.51 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.142 0 CA-C-O 120.727 0.298 . . . . 0.0 111.114 -179.881 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . 0.403 HG23 ' O ' ' A' ' 104' ' ' LEU . 68.3 t -57.84 -49.58 80.52 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.372 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.519 179.513 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 109' ' ' MET . . . . . 0.439 ' HG2' ' O ' ' A' ' 105' ' ' ASN . 20.6 mmt -64.35 -30.4 71.44 Favored 'General case' 0 CA--C 1.519 -0.248 0 CA-C-N 115.868 -0.605 . . . . 0.0 110.666 179.707 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 19.4 tp -66.34 -35.61 80.8 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.069 179.555 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -64.31 -51.38 63.76 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 115.903 -0.59 . . . . 0.0 110.601 179.462 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . -66.96 -37.33 92.07 Favored Glycine 0 C--N 1.331 0.262 0 C-N-CA 120.576 -0.821 . . . . 0.0 111.861 179.478 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 113' ' ' PHE . . . . . 0.402 ' HB2' ' O ' ' A' ' 109' ' ' MET . 1.0 OUTLIER -51.02 -70.03 0.1 Allowed 'General case' 0 C--N 1.332 -0.161 0 CA-C-O 121.05 0.452 . . . . 0.0 110.02 179.541 . . . . . . . . 3 3 . 1 . 030 nuclear orig core ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -67.43 -19.89 65.43 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 115.663 -0.699 . . . . 0.0 110.748 179.407 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 115' ' ' GLY . . . . . 0.445 ' HA2' HD23 ' A' ' 126' ' ' LEU . . . -53.67 -44.43 69.09 Favored Glycine 0 C--N 1.334 0.441 0 C-N-CA 120.915 -0.659 . . . . 0.0 111.8 179.533 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -78.49 -28.46 46.4 Favored 'General case' 0 C--N 1.327 -0.41 0 N-CA-C 111.639 0.237 . . . . 0.0 111.639 179.741 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 117' ' ' MET . . . . . 0.526 ' HG3' HG13 ' A' ' 68' ' ' VAL . 62.9 mtt -86.08 11.37 11.89 Favored 'General case' 0 N--CA 1.463 0.224 0 N-CA-C 112.16 0.429 . . . . 0.0 112.16 -179.162 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 118' ' ' VAL . . . . . 0.488 HG23 ' HB3' ' A' ' 123' ' ' ARG . 29.9 m -63.64 146.06 96.99 Favored Pre-proline 0 C--N 1.327 -0.374 0 C-N-CA 121.037 -0.265 . . . . 0.0 111.081 179.845 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 119' ' ' PRO . . . . . . . . . . . . . 92.0 Cg_endo -81.99 -4.59 12.01 Favored 'Trans proline' 0 C--N 1.347 0.478 0 C-N-CA 122.534 2.156 . . . . 0.0 112.25 179.821 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -156.43 -132.1 1.46 Allowed Glycine 0 C--N 1.331 0.293 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.735 -179.982 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 2.0 pp -100.31 22.46 1.58 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-O 120.838 0.352 . . . . 0.0 111.265 -179.833 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 10.8 mm-40 -70.72 -19.27 62.76 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.846 179.942 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 123' ' ' ARG . . . . . 0.488 ' HB3' HG23 ' A' ' 118' ' ' VAL . 12.7 ptt180 -50.55 -31.0 14.42 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 115.923 -0.58 . . . . 0.0 111.907 -179.67 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 124' ' ' TYR . . . . . . . . . . . . . 40.2 m-85 -65.13 -35.61 81.65 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.675 0.274 . . . . 0.0 110.919 -179.629 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 125' ' ' ALA . . . . . . . . . . . . . . . -72.74 -51.08 20.64 Favored 'General case' 0 C--O 1.235 0.311 0 CA-C-O 120.849 0.357 . . . . 0.0 110.604 179.248 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 126' ' ' LEU . . . . . 0.445 HD23 ' HA2' ' A' ' 115' ' ' GLY . 7.0 mp -51.55 -52.39 47.52 Favored 'General case' 0 CA--C 1.52 -0.191 0 CA-C-N 116.005 -0.543 . . . . 0.0 110.135 179.488 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 127' ' ' PHE . . . . . 0.474 ' HZ ' ' HB3' ' A' ' 175' ' ' PRO . 8.7 t80 -63.93 -35.79 81.82 Favored 'General case' 0 N--CA 1.451 -0.419 0 CA-C-N 115.848 -0.615 . . . . 0.0 110.533 179.523 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 128' ' ' GLY . . . . . . . . . . . . . . . -46.22 -45.51 15.62 Favored Glycine 0 C--N 1.333 0.38 0 C-N-CA 120.195 -1.002 . . . . 0.0 110.86 179.027 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 129' ' ' MET . . . . . . . . . . . . . 0.6 OUTLIER -69.47 -39.36 77.76 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 115.319 -0.441 . . . . 0.0 109.977 178.586 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -65.15 -27.89 72.89 Favored Glycine 0 C--N 1.331 0.299 0 CA-C-N 115.783 -0.644 . . . . 0.0 112.995 -179.842 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -74.61 -54.01 8.27 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.615 0.245 . . . . 0.0 110.406 -179.964 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 47.2 t -55.83 -40.54 62.31 Favored 'Isoleucine or valine' 0 C--O 1.234 0.241 0 CA-C-O 121.459 0.647 . . . . 0.0 109.285 178.786 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -69.1 -37.8 78.61 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 115.117 -0.947 . . . . 0.0 110.613 179.41 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 134' ' ' PHE . . . . . 0.428 ' CZ ' ' HA ' ' A' ' 172' ' ' ALA . 45.3 t80 -55.45 -52.71 62.72 Favored 'General case' 0 N--CA 1.45 -0.429 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.263 179.748 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 135' ' ' ILE . . . . . . . . . . . . . 43.7 mt -59.58 -32.75 49.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 115.915 -0.584 . . . . 0.0 109.935 179.308 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . -59.43 -40.45 96.14 Favored Glycine 0 N--CA 1.448 -0.535 0 C-N-CA 120.298 -0.954 . . . . 0.0 111.45 178.926 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 137' ' ' LEU . . . . . 0.411 HD13 HD22 ' A' ' 105' ' ' ASN . 22.4 tp -65.87 -53.07 44.5 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-O 120.683 0.277 . . . . 0.0 110.616 179.617 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 138' ' ' VAL . . . . . . . . . . . . . 13.1 t -55.48 -37.48 45.39 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.836 0 CA-C-O 121.114 0.483 . . . . 0.0 110.131 179.183 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 139' ' ' TYR . . . . . . . . . . . . . 29.9 t80 -57.84 -43.22 85.71 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 115.43 -0.805 . . . . 0.0 110.738 179.024 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 28.7 m-85 -64.17 -41.6 97.07 Favored 'General case' 0 C--N 1.332 -0.156 0 CA-C-N 116.406 -0.361 . . . . 0.0 111.467 -179.978 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 141' ' ' LEU . . . . . 0.485 HD23 HD12 ' A' ' 87' ' ' LEU . 95.4 mt -56.24 -50.34 71.59 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 116.42 -0.355 . . . . 0.0 111.143 -179.761 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 142' ' ' VAL . . . . . 0.557 HG23 HH12 ' A' ' 164' ' ' ARG . 7.7 p -83.78 -9.02 11.48 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.369 0 CA-C-O 121.153 0.501 . . . . 0.0 110.59 179.956 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . -73.34 -141.18 0.5 Allowed Glycine 0 CA--C 1.521 0.452 0 C-N-CA 120.881 -0.676 . . . . 0.0 112.579 179.929 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 144' ' ' PRO . . . . . . . . . . . . . 52.2 Cg_exo -54.69 -23.24 32.09 Favored 'Trans proline' 0 C--N 1.349 0.564 0 C-N-CA 122.588 2.192 . . . . 0.0 112.75 179.971 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 145' ' ' MET . . . . . 0.574 ' HB3' ' HH ' ' A' ' 160' ' ' TYR . 37.2 mtt -52.81 -59.22 4.76 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.479 -0.328 . . . . 0.0 111.831 -179.641 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 146' ' ' THR . . . . . . . . . . . . . 11.0 t -61.04 -31.71 71.35 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.423 -0.353 . . . . 0.0 111.588 -179.476 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 29.2 mm-40 -65.13 -44.0 90.11 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 120.839 0.352 . . . . 0.0 111.223 -179.942 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 148' ' ' SER . . . . . 0.467 ' HG ' ' HB1' ' A' ' 91' ' ' ALA . 80.0 p -70.24 -42.28 72.43 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.236 -179.32 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 149' ' ' ALA . . . . . . . . . . . . . . . -65.34 -40.42 93.62 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.377 -179.747 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 150' ' ' SER . . . . . 0.454 ' HA ' ' HB2' ' A' ' 157' ' ' LYS . 83.6 p -68.21 -6.8 25.51 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.784 -179.913 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 151' ' ' GLN . . . . . . . . . . . . . 63.3 mt-30 -110.48 -7.54 14.74 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.119 -0.492 . . . . 0.0 110.914 179.883 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 78.3 ttt180 -75.06 -52.47 10.96 Favored 'General case' 0 C--N 1.332 -0.193 0 CA-C-N 116.443 -0.344 . . . . 0.0 110.831 -179.883 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 153' ' ' SER . . . . . 0.595 ' HB3' HG12 ' A' ' 156' ' ' ILE . 22.8 t -158.04 170.62 21.88 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.667 179.238 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 154' ' ' SER . . . . . . . . . . . . . 51.3 m -70.22 -37.62 75.07 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.288 -0.415 . . . . 0.0 110.392 179.382 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -77.0 -39.0 28.88 Favored Glycine 0 CA--C 1.519 0.298 0 C-N-CA 120.984 -0.627 . . . . 0.0 112.674 179.821 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 156' ' ' ILE . . . . . 0.595 HG12 ' HB3' ' A' ' 153' ' ' SER . 39.6 mm -52.88 -35.65 22.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-O 120.922 0.392 . . . . 0.0 111.315 -179.81 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 157' ' ' LYS . . . . . 0.454 ' HB2' ' HA ' ' A' ' 150' ' ' SER . 86.4 tttt -69.83 -37.23 76.13 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 115.967 -0.561 . . . . 0.0 112.028 -179.436 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 67.6 p -72.05 -45.0 62.46 Favored 'General case' 0 C--N 1.331 -0.205 0 CA-C-O 120.784 0.326 . . . . 0.0 111.601 -178.719 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 159' ' ' LEU . . . . . . . . . . . . . 10.0 mt -67.05 -46.26 74.92 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.632 -179.078 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 160' ' ' TYR . . . . . 0.574 ' HH ' ' HB3' ' A' ' 145' ' ' MET . 55.1 t80 -61.58 -37.82 85.27 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.509 -0.314 . . . . 0.0 111.26 -179.468 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 161' ' ' VAL . . . . . 0.492 HG12 ' N ' ' A' ' 162' ' ' ARG . 1.2 t -63.23 -50.49 78.86 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.747 0 CA-C-N 116.529 -0.305 . . . . 0.0 111.64 -179.487 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 162' ' ' ARG . . . . . 0.492 ' N ' HG12 ' A' ' 161' ' ' VAL . 22.9 tpp180 -69.1 -34.86 75.76 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.44 -0.345 . . . . 0.0 111.439 -179.446 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 163' ' ' LEU . . . . . 0.567 ' HG ' ' HB2' ' A' ' 208' ' ' PHE . 3.2 mp -69.5 -45.02 69.89 Favored 'General case' 0 C--N 1.328 -0.37 0 CA-C-N 116.27 -0.423 . . . . 0.0 111.604 -179.408 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 164' ' ' ARG . . . . . 0.557 HH12 HG23 ' A' ' 142' ' ' VAL . 0.1 OUTLIER -71.95 -41.07 68.23 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.557 -0.292 . . . . 0.0 111.308 -179.125 . . . . . . . . 3 3 . 1 . 030 nuclear orig core ' A' A ' 165' ' ' ASN . . . . . 0.519 HD22 ' HE ' ' A' ' 164' ' ' ARG . 0.9 OUTLIER -57.25 -50.88 71.49 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.795 0.331 . . . . 0.0 111.05 179.953 . . . . . . . . 3 3 . 1 . 030 nuclear orig core ' A' A ' 166' ' ' LEU . . . . . . . . . . . . . 3.8 tt -64.17 -54.59 31.32 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.109 -0.496 . . . . 0.0 111.548 -179.47 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 167' ' ' THR . . . . . 0.426 ' O ' ' HB2' ' A' ' 171' ' ' TRP . 76.5 m -54.81 -53.13 59.21 Favored 'General case' 0 C--N 1.33 -0.277 0 N-CA-C 112.263 0.468 . . . . 0.0 112.263 -179.158 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 168' ' ' VAL . . . . . . . . . . . . . 55.1 t -55.06 -44.93 76.45 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.218 0 N-CA-C 112.328 0.492 . . . . 0.0 112.328 -178.999 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 169' ' ' VAL . . . . . 0.403 HG23 ' O ' ' A' ' 165' ' ' ASN . 43.9 t -55.91 -64.32 0.5 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-O 120.555 0.217 . . . . 0.0 111.544 -179.362 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 170' ' ' LEU . . . . . 0.607 HD11 HG13 ' A' ' 203' ' ' VAL . 1.1 pp -63.41 -28.56 70.06 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.661 -0.245 . . . . 0.0 111.642 -179.39 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 171' ' ' TRP . . . . . 0.426 ' HB2' ' O ' ' A' ' 167' ' ' THR . 3.5 m0 -70.54 -32.11 69.43 Favored 'General case' 0 C--N 1.333 -0.152 0 CA-C-O 120.998 0.427 . . . . 0.0 110.413 179.418 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 172' ' ' ALA . . . . . 0.428 ' HA ' ' CZ ' ' A' ' 134' ' ' PHE . . . -72.19 -6.68 44.53 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-N 115.822 -0.626 . . . . 0.0 111.102 -179.624 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 173' ' ' ILE . . . . . 0.545 ' O ' HG12 ' A' ' 177' ' ' ILE . 23.8 mm -87.54 -22.57 6.82 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.244 0 CA-C-N 116.083 -0.508 . . . . 0.0 111.17 179.925 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 174' ' ' TYR . . . . . 0.426 ' HB2' ' HD3' ' A' ' 175' ' ' PRO . 30.9 m-85 -53.79 -49.25 90.25 Favored Pre-proline 0 N--CA 1.464 0.265 0 CA-C-N 116.567 -0.288 . . . . 0.0 111.638 -179.537 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 175' ' ' PRO . . . . . 0.474 ' HB3' ' HZ ' ' A' ' 127' ' ' PHE . 86.5 Cg_exo -47.73 -32.97 17.83 Favored 'Trans proline' 0 C--N 1.351 0.677 0 C-N-CA 122.134 1.89 . . . . 0.0 112.164 179.523 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 176' ' ' PHE . . . . . 0.497 ' O ' ' HG ' ' A' ' 180' ' ' LEU . 88.2 m-85 -80.62 -50.36 10.06 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 115.911 -0.586 . . . . 0.0 112.18 -179.531 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 177' ' ' ILE . . . . . 0.545 HG12 ' O ' ' A' ' 173' ' ' ILE . 6.2 mm -60.22 -39.58 81.09 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.548 0 N-CA-C 112.609 0.596 . . . . 0.0 112.609 -177.777 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 178' ' ' TRP . . . . . 0.482 ' HH2' ' HB2' ' A' ' 123' ' ' ARG . 78.4 t90 -67.37 -39.3 85.68 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 120.721 0.296 . . . . 0.0 111.157 -179.669 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 179' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -77.88 -52.89 8.14 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 116.462 -0.335 . . . . 0.0 111.879 -179.01 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 180' ' ' LEU . . . . . 0.552 HD21 HD12 ' A' ' 187' ' ' LEU . 39.8 mt -61.66 -51.7 67.38 Favored 'General case' 0 C--N 1.328 -0.362 0 N-CA-C 111.699 0.259 . . . . 0.0 111.699 -179.114 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 181' ' ' GLY . . . . . 0.422 ' HA3' ' OD1' ' A' ' 193' ' ' ASP . . . -57.03 179.16 0.71 Allowed Glycine 0 C--N 1.336 0.557 0 C-N-CA 120.413 -0.898 . . . . 0.0 112.92 -179.883 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 182' ' ' PRO . . . . . 0.618 ' N ' ' HD2' ' A' ' 183' ' ' PRO . 80.8 Cg_exo -44.06 -46.56 11.04 Favored 'Trans proline' 0 C--N 1.35 0.654 0 C-N-CA 122.925 2.417 . . . . 0.0 113.915 179.865 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 183' ' ' PRO . . . . . 0.618 ' HD2' ' N ' ' A' ' 182' ' ' PRO . 1.0 OUTLIER -44.28 -30.44 3.61 Favored 'Trans proline' 0 C--N 1.358 1.062 0 C-N-CA 122.497 2.131 . . . . 0.0 113.172 -179.758 . . . . . . . . 3 3 . 1 . 030 nuclear orig core ' A' A ' 184' ' ' GLY . . . . . 0.437 ' HA2' ' HD2' ' A' ' 123' ' ' ARG . . . -117.73 -120.75 3.08 Favored Glycine 0 C--N 1.332 0.326 0 C-N-CA 120.392 -0.908 . . . . 0.0 113.19 179.89 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 185' ' ' VAL . . . . . . . . . . . . . 22.6 m -64.92 -16.77 20.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 N-CA-C 112.264 0.468 . . . . 0.0 112.264 -179.405 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 186' ' ' ALA . . . . . . . . . . . . . . . 55.51 88.75 0.04 OUTLIER 'General case' 0 C--N 1.332 -0.17 0 CA-C-O 120.872 0.368 . . . . 0.0 111.266 -179.899 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 187' ' ' LEU . . . . . 0.552 HD12 HD21 ' A' ' 180' ' ' LEU . 19.5 mt -91.8 -33.06 15.12 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.391 -179.603 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 188' ' ' LEU . . . . . 0.422 ' HB2' ' H ' ' A' ' 189' ' ' THR . 0.0 OUTLIER -134.27 -162.07 1.21 Allowed 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.868 0.366 . . . . 0.0 111.501 -179.494 . . . . . . . . 3 3 . 1 . 030 nuclear orig core ' A' A ' 189' ' ' THR . . . . . 0.422 ' H ' ' HB2' ' A' ' 188' ' ' LEU . 3.2 t -86.26 147.48 44.89 Favored Pre-proline 0 C--N 1.33 -0.24 0 CA-C-N 116.045 -0.525 . . . . 0.0 111.969 -178.873 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 190' ' ' PRO . . . . . . . . . . . . . 77.8 Cg_exo -51.02 -35.93 52.27 Favored 'Trans proline' 0 C--N 1.351 0.691 0 C-N-CA 122.581 2.187 . . . . 0.0 112.665 179.708 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 191' ' ' THR . . . . . . . . . . . . . 59.5 p -57.89 -40.8 81.17 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 121.052 0.453 . . . . 0.0 110.753 179.904 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 192' ' ' VAL . . . . . . . . . . . . . 41.4 t -74.96 -52.8 17.94 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-N 115.705 -0.679 . . . . 0.0 111.484 -179.871 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 193' ' ' ASP . . . . . 0.422 ' OD1' ' HA3' ' A' ' 181' ' ' GLY . 25.4 t70 -54.94 -51.93 64.59 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-N 116.31 -0.405 . . . . 0.0 111.142 -179.716 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 194' ' ' VAL . . . . . 0.511 ' O ' HG23 ' A' ' 198' ' ' VAL . 90.8 t -61.41 -36.96 76.45 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.357 0 CA-C-N 115.927 -0.579 . . . . 0.0 111.026 -179.832 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 195' ' ' ALA . . . . . 0.449 ' HA ' HD11 ' A' ' 7' ' ' LEU . . . -52.4 -48.58 65.58 Favored 'General case' 0 C--O 1.234 0.27 0 CA-C-O 120.91 0.386 . . . . 0.0 111.006 179.723 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 196' ' ' LEU . . . . . 0.488 ' O ' ' HB3' ' A' ' 199' ' ' TYR . 98.5 mt -68.3 -39.45 82.04 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 116.432 -0.349 . . . . 0.0 110.448 179.281 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 197' ' ' ILE . . . . . 0.418 HG13 ' NH2' ' A' ' 72' ' ' ARG . 15.5 mm -55.59 -60.36 1.79 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.358 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.178 179.92 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 198' ' ' VAL . . . . . 0.511 HG23 ' O ' ' A' ' 194' ' ' VAL . 3.3 m -52.19 -35.93 20.01 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.424 0 CA-C-O 121.359 0.6 . . . . 0.0 109.902 179.08 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 199' ' ' TYR . . . . . 0.488 ' HB3' ' O ' ' A' ' 196' ' ' LEU . 69.2 t80 -62.15 -47.02 86.41 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-N 115.062 -0.972 . . . . 0.0 110.095 179.224 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 200' ' ' LEU . . . . . 0.417 HD22 ' HB ' ' A' ' 173' ' ' ILE . 5.4 mp -55.78 -38.99 70.63 Favored 'General case' 0 N--CA 1.452 -0.367 0 CA-C-N 115.973 -0.558 . . . . 0.0 111.561 179.097 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 201' ' ' ASP . . . . . . . . . . . . . 16.0 m-20 -74.19 -41.88 60.73 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 121.063 0.458 . . . . 0.0 110.683 -179.974 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 202' ' ' LEU . . . . . . . . . . . . . 2.2 mt -63.18 -33.33 75.24 Favored 'General case' 0 C--N 1.327 -0.413 0 CA-C-N 115.624 -0.716 . . . . 0.0 111.682 -179.851 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 203' ' ' VAL . . . . . 0.607 HG13 HD11 ' A' ' 170' ' ' LEU . 10.8 p -78.26 -36.29 20.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.815 -0.175 . . . . 0.0 111.329 -178.696 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 204' ' ' THR . . . . . 0.427 ' O ' ' CD1' ' A' ' 208' ' ' PHE . 55.4 m -62.47 -58.64 6.89 Favored 'General case' 0 C--N 1.328 -0.331 0 C-N-CA 120.454 -0.499 . . . . 0.0 111.315 179.761 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 205' ' ' LYS . . . . . 0.669 ' HE2' ' HB2' ' A' ' 47' ' ' ALA . 49.5 mttp -69.07 -58.18 4.43 Favored 'General case' 0 N--CA 1.464 0.241 0 N-CA-C 112.849 0.685 . . . . 0.0 112.849 -177.921 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 26.1 t -68.92 -36.34 73.58 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.444 0 CA-C-N 116.401 -0.363 . . . . 0.0 111.89 -178.706 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 207' ' ' GLY . . . . . 0.556 ' O ' HG13 ' A' ' 211' ' ' ILE . . . -61.66 -60.45 8.13 Favored Glycine 0 N--CA 1.452 -0.273 0 C-N-CA 120.698 -0.763 . . . . 0.0 113.672 -178.619 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 208' ' ' PHE . . . . . 0.567 ' HB2' ' HG ' ' A' ' 163' ' ' LEU . 0.1 OUTLIER -71.58 -25.96 62.41 Favored 'General case' 0 C--O 1.224 -0.258 0 CA-C-N 117.383 0.591 . . . . 0.0 111.319 -178.976 . . . . . . . . 3 3 . 1 . 030 nuclear orig core ' A' A ' 209' ' ' GLY . . . . . 0.471 ' O ' ' HB2' ' A' ' 212' ' ' ALA . . . -68.55 -32.4 74.89 Favored Glycine 0 N--CA 1.449 -0.464 0 N-CA-C 111.676 -0.57 . . . . 0.0 111.676 179.077 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 210' ' ' PHE . . . . . . . . . . . . . 0.8 OUTLIER -72.87 -47.39 46.41 Favored 'General case' 0 CA--C 1.514 -0.421 0 N-CA-C 108.107 -1.072 . . . . 0.0 108.107 178.505 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 211' ' ' ILE . . . . . 0.556 HG13 ' O ' ' A' ' 207' ' ' GLY . 4.6 mt -64.85 -27.73 43.14 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.544 0 N-CA-C 107.629 -1.248 . . . . 0.0 107.629 176.677 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 212' ' ' ALA . . . . . 0.471 ' HB2' ' O ' ' A' ' 209' ' ' GLY . . . -63.86 -39.86 95.2 Favored 'General case' 0 N--CA 1.451 -0.412 0 CA-C-N 114.628 -1.169 . . . . 0.0 110.381 179.794 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 213' ' ' LEU . . . . . . . . . . . . . 92.8 mt -69.72 -54.42 13.84 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 115.215 -0.902 . . . . 0.0 111.252 -179.596 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 214' ' ' ASP . . . . . . . . . . . . . 18.5 m-20 -56.57 -44.94 81.49 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.968 0.413 . . . . 0.0 110.933 -179.819 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 215' ' ' ALA . . . . . . . . . . . . . . . -61.0 -58.19 9.47 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.055 -0.52 . . . . 0.0 111.004 179.969 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 216' ' ' ALA . . . . . . . . . . . . . . . -55.53 -30.43 60.71 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.84 179.923 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 217' ' ' ALA . . . . . . . . . . . . . . . -61.36 -41.59 97.31 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 115.874 -0.603 . . . . 0.0 109.685 179.525 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 218' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER . . . . . 0 C--N 1.329 -0.293 0 CA-C-N 115.437 -0.801 . . . . 0.0 109.994 178.64 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 1' ' ' MET . . . . . 0.411 ' HE2' ' HB2' ' A' ' 4' ' ' LEU . 70.2 mtm . . . . . 0 N--CA 1.486 1.329 0 CA-C-O 120.723 0.297 . . . . 0.0 110.822 . . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 13.4 p -96.38 -29.65 3.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.268 -0.423 . . . . 0.0 110.931 179.927 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -90.73 -15.43 56.6 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.869 -0.682 . . . . 0.0 112.292 179.802 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 4' ' ' LEU . . . . . 0.411 ' HB2' ' HE2' ' A' ' 1' ' ' MET . 67.1 tp -72.58 -35.5 67.95 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.873 0.368 . . . . 0.0 110.833 179.967 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 74.5 p -56.38 -29.64 61.72 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 115.953 -0.567 . . . . 0.0 111.589 -179.8 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 47.5 p -52.2 -35.19 48.51 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.407 -0.36 . . . . 0.0 111.335 -179.617 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 7' ' ' LEU . . . . . . . . . . . . . 3.9 mm? -61.28 -53.02 62.12 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.312 -0.404 . . . . 0.0 111.347 -179.751 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 8' ' ' PHE . . . . . . . . . . . . . 74.7 m-85 -60.93 -32.6 72.1 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-O 121.003 0.43 . . . . 0.0 110.696 179.943 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 9' ' ' TRP . . . . . 0.402 ' O ' HG13 ' A' ' 13' ' ' ILE . 26.0 m95 -66.39 -48.65 69.4 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 115.93 -0.577 . . . . 0.0 110.077 -179.986 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 82.1 mt -57.94 -51.07 71.15 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 115.654 -0.703 . . . . 0.0 110.542 179.526 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -57.41 -35.17 70.65 Favored Glycine 0 N--CA 1.45 -0.411 0 C-N-CA 120.739 -0.743 . . . . 0.0 111.8 179.369 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -65.33 -30.82 71.7 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 120.863 0.363 . . . . 0.0 110.504 179.558 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 13' ' ' ILE . . . . . 0.402 HG13 ' O ' ' A' ' 9' ' ' TRP . 80.9 mt -66.89 -46.43 85.14 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.217 0 CA-C-N 116.062 -0.517 . . . . 0.0 110.075 179.353 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -61.84 -31.29 77.77 Favored Glycine 0 N--CA 1.45 -0.367 0 C-N-CA 120.653 -0.784 . . . . 0.0 111.862 179.329 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 15' ' ' MET . . . . . 0.439 ' HE1' ' HB2' ' A' ' 47' ' ' ALA . 0.0 OUTLIER -67.03 -46.89 73.08 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-O 120.848 0.356 . . . . 0.0 110.626 179.33 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -56.53 -40.45 75.08 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.033 -0.531 . . . . 0.0 110.483 179.547 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 84.4 t -60.36 -48.07 89.82 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.861 179.653 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -65.62 -47.27 78.73 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.775 -0.726 . . . . 0.0 112.439 179.816 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 25.2 m -49.44 -47.43 48.19 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-O 120.637 0.256 . . . . 0.0 111.433 -179.258 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 94.6 mt -71.63 -44.67 63.95 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.481 -0.327 . . . . 0.0 111.516 -179.914 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -55.14 -35.11 64.37 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.384 -0.371 . . . . 0.0 111.918 -179.436 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 22' ' ' PHE . . . . . 0.509 ' HB2' HG23 ' A' ' 41' ' ' VAL . 4.2 m-85 -91.07 -29.56 17.25 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.557 -0.292 . . . . 0.0 111.777 -179.207 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -70.31 -51.02 33.28 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.966 0.412 . . . . 0.0 111.524 -179.362 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 24' ' ' TRP . . . . . . . . . . . . . 5.8 t-105 -66.42 -50.01 64.85 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-N 115.881 -0.6 . . . . 0.0 110.999 -179.778 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -68.07 -25.4 65.33 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.49 -0.323 . . . . 0.0 111.002 179.989 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -72.76 -41.66 49.1 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.821 -0.704 . . . . 0.0 112.512 -179.969 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 96.5 mtt180 -65.94 -25.69 67.25 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.875 0.369 . . . . 0.0 110.725 179.799 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 19.5 t70 -82.92 -10.37 58.85 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 115.969 -0.56 . . . . 0.0 110.92 179.953 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -70.42 179.96 2.29 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.176 -0.465 . . . . 0.0 111.308 -179.813 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -96.96 -157.17 30.94 Favored Glycine 0 N--CA 1.451 -0.359 0 C-N-CA 120.914 -0.66 . . . . 0.0 112.242 179.953 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 37.1 t -95.22 120.05 34.77 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.781 0.324 . . . . 0.0 110.738 179.82 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 125.18 -49.52 0.91 Allowed Glycine 0 N--CA 1.452 -0.278 0 C-N-CA 120.902 -0.666 . . . . 0.0 112.291 -179.647 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 38.6 mt-10 -69.99 -20.66 63.28 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.779 0.323 . . . . 0.0 110.645 179.776 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 34' ' ' ARG . . . . . . . . . . . . . 99.8 mtt180 -49.09 -29.09 4.74 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 115.862 -0.608 . . . . 0.0 111.535 -179.862 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 21.4 mmm180 -64.3 -46.98 81.26 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-O 120.783 0.325 . . . . 0.0 111.041 179.905 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 90.2 m-85 -69.2 -32.01 71.01 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.162 179.875 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 37' ' ' TYR . . . . . . . . . . . . . 43.4 m-85 -71.97 -54.75 8.99 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.085 -0.507 . . . . 0.0 111.41 -179.485 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 14.6 p -56.76 -36.34 48.91 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-O 120.972 0.415 . . . . 0.0 110.441 -179.995 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 40.9 m -64.85 -50.19 67.6 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 115.758 -0.655 . . . . 0.0 110.41 179.219 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 40' ' ' LEU . . . . . 0.571 HD11 HD13 ' A' ' 43' ' ' ILE . 57.7 tp -61.0 -38.28 85.47 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 115.573 -0.739 . . . . 0.0 110.657 179.741 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . 0.509 HG23 ' HB2' ' A' ' 22' ' ' PHE . 95.8 t -69.48 -34.0 59.9 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.453 0 CA-C-N 115.932 -0.576 . . . . 0.0 109.975 179.011 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -61.22 -42.31 99.75 Favored Glycine 0 N--CA 1.449 -0.483 0 CA-C-N 115.615 -0.721 . . . . 0.0 112.892 179.905 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 43' ' ' ILE . . . . . 0.571 HD13 HD11 ' A' ' 40' ' ' LEU . 38.9 pt -70.03 -44.0 78.74 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.153 0 CA-C-N 116.952 0.376 . . . . 0.0 111.31 -179.786 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 44' ' ' SER . . . . . 0.436 ' N ' HG13 ' A' ' 43' ' ' ILE . 38.7 t -66.29 -25.98 67.11 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-O 120.985 0.421 . . . . 0.0 110.713 179.461 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -79.85 -52.69 4.56 Favored Glycine 0 C--N 1.33 0.233 0 C-N-CA 121.033 -0.603 . . . . 0.0 112.907 -179.295 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 15.3 pt -57.88 -36.95 57.79 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.248 0 CA-C-O 121.148 0.499 . . . . 0.0 110.33 179.978 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 47' ' ' ALA . . . . . 0.71 ' HB1' ' HE2' ' A' ' 205' ' ' LYS . . . -68.2 -42.05 80.45 Favored 'General case' 0 C--N 1.326 -0.45 0 CA-C-N 115.81 -0.632 . . . . 0.0 110.78 178.716 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 48' ' ' ALA . . . . . 0.436 ' HB2' ' HB3' ' A' ' 15' ' ' MET . . . -54.48 -42.66 70.99 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 115.881 -0.599 . . . . 0.0 112.038 -179.451 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 49' ' ' VAL . . . . . 0.4 ' O ' HG13 ' A' ' 53' ' ' VAL . 31.0 m -73.42 -36.24 47.93 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.24 0 N-CA-C 111.606 0.224 . . . . 0.0 111.606 -179.437 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -62.49 -40.39 96.54 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-O 121.001 0.429 . . . . 0.0 111.285 179.792 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 51' ' ' TYR . . . . . 0.429 ' HH ' ' HA ' ' A' ' 198' ' ' VAL . 4.2 m-85 -70.58 -40.2 73.42 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-N 115.997 -0.547 . . . . 0.0 110.726 -179.613 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -63.13 -42.26 99.47 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 115.882 -0.599 . . . . 0.0 111.459 179.999 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 53' ' ' VAL . . . . . 0.49 ' O ' HG23 ' A' ' 58' ' ' VAL . 33.0 m -70.28 -49.71 52.22 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.209 0 CA-C-N 116.71 -0.223 . . . . 0.0 111.057 -179.865 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 54' ' ' MET . . . . . 0.486 ' N ' HG22 ' A' ' 53' ' ' VAL . 73.1 mtm -60.75 -32.29 71.59 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-O 121.099 0.476 . . . . 0.0 109.916 179.429 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -63.26 -22.9 67.16 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 115.552 -0.749 . . . . 0.0 111.283 179.677 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 80.2 mt -89.1 -14.35 36.45 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.459 -0.337 . . . . 0.0 111.033 -179.906 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 102.53 -2.99 49.77 Favored Glycine 0 C--N 1.33 0.248 0 C-N-CA 120.689 -0.767 . . . . 0.0 113.352 179.371 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 58' ' ' VAL . . . . . 0.49 HG23 ' O ' ' A' ' 53' ' ' VAL . 15.8 m -78.63 154.25 4.97 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.166 0 CA-C-N 116.981 0.39 . . . . 0.0 111.145 -179.901 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 59' ' ' GLY . . . . . 0.424 ' HA3' ' CG ' ' A' ' 71' ' ' PRO . . . 80.69 -2.39 79.3 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.89 -0.671 . . . . 0.0 112.859 -179.943 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 60' ' ' TRP . . . . . . . . . . . . . 23.2 m0 -78.28 121.49 24.49 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 120.724 0.297 . . . . 0.0 110.503 179.718 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 61' ' ' VAL . . . . . 0.459 HG12 ' HE1' ' A' ' 117' ' ' MET . 7.3 p -112.8 132.25 22.37 Favored Pre-proline 0 CA--C 1.533 0.29 0 CA-C-N 116.416 -0.356 . . . . 0.0 111.343 -179.796 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 72.0 Cg_endo -77.45 145.56 23.78 Favored 'Trans proline' 0 C--N 1.35 0.638 0 C-N-CA 122.51 2.14 . . . . 0.0 112.512 179.941 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 96.6 t -142.65 94.08 0.54 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 115.872 -0.604 . . . . 0.0 110.926 -179.94 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . 57.67 -89.55 0.02 OUTLIER 'General case' 0 C--N 1.332 -0.178 0 CA-C-N 116.13 -0.486 . . . . 0.0 111.418 179.96 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 12.8 pt-20 -119.79 -19.93 7.79 Favored 'General case' 0 C--O 1.233 0.204 0 CA-C-O 120.806 0.336 . . . . 0.0 110.872 -179.987 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 66' ' ' ARG . . . . . 0.543 HH22 ' HA ' ' A' ' 183' ' ' PRO . 13.1 ptm180 -101.93 166.29 10.72 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.385 179.83 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 35.3 m -125.72 123.89 39.85 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-O 120.975 0.417 . . . . 0.0 111.462 -179.725 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 23.4 t -101.29 147.16 8.54 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.221 0 CA-C-N 115.88 -0.6 . . . . 0.0 110.284 179.41 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 69' ' ' PHE . . . . . . . . . . . . . 46.8 m-85 -106.94 112.41 25.36 Favored 'General case' 0 C--N 1.328 -0.329 0 N-CA-C 110.03 -0.359 . . . . 0.0 110.03 -179.363 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 70' ' ' VAL . . . . . 0.517 ' HB ' ' HD3' ' A' ' 71' ' ' PRO . 21.7 t -68.96 -49.89 24.04 Favored Pre-proline 0 C--N 1.327 -0.408 0 N-CA-C 112.455 0.539 . . . . 0.0 112.455 -178.891 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 71' ' ' PRO . . . . . 0.517 ' HD3' ' HB ' ' A' ' 70' ' ' VAL . 31.8 Cg_exo -58.55 -25.97 76.68 Favored 'Trans proline' 0 C--N 1.35 0.627 0 C-N-CA 121.983 1.788 . . . . 0.0 112.174 179.97 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 72' ' ' ARG . . . . . 0.405 ' HB2' ' SD ' ' A' ' 54' ' ' MET . 46.3 ttp180 -72.52 -53.27 12.52 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.975 0.417 . . . . 0.0 110.665 179.932 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 73' ' ' TYR . . . . . 0.521 ' HH ' ' HB1' ' A' ' 116' ' ' ALA . 23.0 m-85 -65.2 -38.07 89.29 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 115.831 -0.622 . . . . 0.0 110.694 179.934 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 74' ' ' ILE . . . . . 0.429 ' HA ' HD12 ' A' ' 77' ' ' ILE . 0.4 OUTLIER -70.32 -37.62 71.6 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 N-CA-C 110.008 -0.367 . . . . 0.0 110.008 179.583 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 31.2 t70 -57.24 -38.61 74.06 Favored 'General case' 0 CA--C 1.521 -0.138 0 N-CA-C 109.453 -0.573 . . . . 0.0 109.453 178.991 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 76' ' ' TRP . . . . . . . . . . . . . 45.4 m0 -66.8 -39.72 87.85 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 115.553 -0.749 . . . . 0.0 110.27 179.375 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 77' ' ' ILE . . . . . 0.429 HD12 ' HA ' ' A' ' 74' ' ' ILE . 89.3 mt -60.49 -28.93 43.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 115.953 -0.567 . . . . 0.0 110.788 179.551 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 43.1 mt -91.97 -29.19 16.77 Favored 'General case' 0 C--N 1.33 -0.255 0 N-CA-C 112.275 0.472 . . . . 0.0 112.275 179.96 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 66.8 p -89.38 -52.09 5.22 Favored 'General case' 0 N--CA 1.464 0.27 0 N-CA-C 113.506 0.928 . . . . 0.0 113.506 -177.725 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 80' ' ' THR . . . . . 0.432 ' N ' ' HD2' ' A' ' 81' ' ' PRO . 86.1 m -47.3 -55.03 17.47 Favored Pre-proline 0 C--N 1.328 -0.34 0 N-CA-C 112.773 0.657 . . . . 0.0 112.773 -178.683 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 81' ' ' PRO . . . . . 0.432 ' HD2' ' N ' ' A' ' 80' ' ' THR . 36.1 Cg_endo -63.2 -20.82 71.7 Favored 'Trans proline' 0 C--N 1.351 0.69 0 C-N-CA 121.55 1.5 . . . . 0.0 111.06 179.997 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 82' ' ' LEU . . . . . 0.404 ' HB3' HG21 ' A' ' 43' ' ' ILE . 0.1 OUTLIER -76.2 -34.8 59.29 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 115.364 -0.834 . . . . 0.0 109.94 179.558 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 83' ' ' ILE . . . . . 0.504 HG13 H202 ' A' ' 301' ' ' RET . 47.9 mm -69.25 -52.74 30.28 Favored 'Isoleucine or valine' 0 CA--C 1.522 -0.126 0 CA-C-N 115.849 -0.614 . . . . 0.0 110.205 179.429 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 27.7 m -59.64 -31.16 46.38 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.215 0 N-CA-C 109.614 -0.513 . . . . 0.0 109.614 178.912 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 85' ' ' TYR . . . . . . . . . . . . . 85.2 t80 -63.69 -36.54 84.19 Favored 'General case' 0 N--CA 1.454 -0.246 0 CA-C-N 115.657 -0.701 . . . . 0.0 109.188 178.457 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 86' ' ' PHE . . . . . . . . . . . . . 8.0 t80 -61.42 -44.87 96.38 Favored 'General case' 0 C--O 1.231 0.121 0 CA-C-N 115.636 -0.711 . . . . 0.0 109.457 178.87 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 3.7 mm? -61.66 -34.11 75.14 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 115.453 -0.794 . . . . 0.0 110.153 179.177 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 88' ' ' GLY . . . . . 0.478 ' HA2' HD11 ' A' ' 93' ' ' LEU . . . -69.08 -29.45 72.28 Favored Glycine 0 N--CA 1.449 -0.462 0 C-N-CA 120.812 -0.709 . . . . 0.0 112.252 179.695 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 95.9 mt -71.66 -39.48 70.29 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 121.028 0.442 . . . . 0.0 110.362 179.69 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 42.8 mt -61.14 -59.73 4.88 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 115.796 -0.638 . . . . 0.0 110.872 179.782 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . 0.439 ' HB3' ' HB1' ' A' ' 149' ' ' ALA . . . -70.25 -54.79 11.22 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.081 -0.509 . . . . 0.0 111.339 -179.833 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 98.85 68.77 0.91 Allowed Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.787 -0.72 . . . . 0.0 112.212 -179.861 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 93' ' ' LEU . . . . . 0.516 HD21 ' HB3' ' A' ' 97' ' ' GLU . 8.1 mp -72.0 -174.35 1.21 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.775 0.322 . . . . 0.0 110.945 -179.824 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 94' ' ' ASP . . . . . 0.432 ' HB3' ' OE2' ' A' ' 97' ' ' GLU . 10.2 t70 -97.28 -177.12 3.73 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.868 -179.73 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 95' ' ' SER . . . . . 0.403 ' H ' ' CG ' ' A' ' 94' ' ' ASP . 77.9 p -65.58 -45.34 83.62 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.574 -179.369 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 36.2 mtp180 -74.14 -39.48 63.27 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-O 121.246 0.546 . . . . 0.0 110.438 -179.657 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 97' ' ' GLU . . . . . 0.516 ' HB3' HD21 ' A' ' 93' ' ' LEU . 0.3 OUTLIER -58.01 -44.68 87.38 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-N 115.457 -0.792 . . . . 0.0 111.039 -179.826 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 98' ' ' PHE . . . . . 0.414 ' O ' HG12 ' A' ' 102' ' ' ILE . 2.2 m-85 -61.52 -35.47 77.82 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.956 0.408 . . . . 0.0 110.502 179.543 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -70.08 -25.97 74.91 Favored Glycine 0 N--CA 1.451 -0.359 0 C-N-CA 120.7 -0.762 . . . . 0.0 112.144 179.795 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 96.4 mt -73.17 -43.71 57.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 N-CA-C 111.841 0.311 . . . . 0.0 111.841 -179.819 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 25.7 m -69.45 -39.16 78.33 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-O 120.676 0.275 . . . . 0.0 111.716 -179.389 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 102' ' ' ILE . . . . . 0.414 HG12 ' O ' ' A' ' 98' ' ' PHE . 42.0 mm -73.65 -41.0 55.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.582 -0.281 . . . . 0.0 111.621 -179.435 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 13.9 t -63.76 -35.97 82.34 Favored 'General case' 0 C--N 1.332 -0.153 0 CA-C-O 120.775 0.322 . . . . 0.0 110.884 -179.948 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 56.5 tp -67.52 -43.77 79.99 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.288 179.766 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 105' ' ' ASN . . . . . 0.521 ' N ' HD21 ' A' ' 105' ' ' ASN . 0.9 OUTLIER -62.72 -27.3 69.17 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.532 179.57 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 91.9 m -69.4 -52.15 29.77 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.054 -0.521 . . . . 0.0 111.502 -179.912 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 7.5 p -66.09 -36.35 77.23 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.214 0 CA-C-N 116.38 -0.373 . . . . 0.0 111.226 -179.976 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 51.0 t -62.85 -54.68 30.57 Favored 'Isoleucine or valine' 0 C--O 1.234 0.281 0 CA-C-N 116.294 -0.412 . . . . 0.0 110.866 179.746 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 109' ' ' MET . . . . . . . . . . . . . 5.6 tpp -61.66 -26.82 68.26 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.049 -0.523 . . . . 0.0 110.383 179.897 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 29.7 tp -73.05 -31.98 64.77 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.062 -0.517 . . . . 0.0 110.226 179.487 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -64.31 -51.17 64.79 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 115.926 -0.579 . . . . 0.0 110.284 179.225 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 112' ' ' GLY . . . . . 0.537 ' HA3' ' H22' ' A' ' 301' ' ' RET . . . -62.76 -44.26 97.75 Favored Glycine 0 CA--C 1.518 0.248 0 C-N-CA 120.796 -0.716 . . . . 0.0 112.42 179.539 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 113' ' ' PHE . . . . . 0.448 ' HZ ' HG11 ' A' ' 70' ' ' VAL . 0.8 OUTLIER -47.98 -61.01 2.18 Favored 'General case' 0 C--N 1.333 -0.141 0 CA-C-O 120.911 0.386 . . . . 0.0 110.397 179.592 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -69.83 -18.25 63.44 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.025 -0.534 . . . . 0.0 110.797 179.918 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -57.14 -49.06 74.98 Favored Glycine 0 C--N 1.333 0.389 0 C-N-CA 120.79 -0.719 . . . . 0.0 111.9 179.375 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 116' ' ' ALA . . . . . 0.521 ' HB1' ' HH ' ' A' ' 73' ' ' TYR . . . -78.55 -15.51 58.48 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-O 120.782 0.325 . . . . 0.0 111.376 179.817 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 117' ' ' MET . . . . . 0.459 ' HE1' HG12 ' A' ' 61' ' ' VAL . 23.1 mmt -88.22 19.18 3.85 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 116.384 -0.371 . . . . 0.0 111.612 -179.553 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 118' ' ' VAL . . . . . 0.404 HG22 ' HB3' ' A' ' 123' ' ' ARG . 35.7 m -84.64 141.62 38.97 Favored Pre-proline 0 C--N 1.329 -0.315 0 CA-C-O 120.57 0.224 . . . . 0.0 111.285 -179.846 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 119' ' ' PRO . . . . . . . . . . . . . 93.4 Cg_endo -87.07 -2.43 7.98 Favored 'Trans proline' 0 N--CA 1.459 -0.513 0 C-N-CA 122.77 2.314 . . . . 0.0 112.36 179.797 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -144.12 -110.05 0.7 Allowed Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.789 -0.72 . . . . 0.0 112.684 -179.911 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 42.9 pt -133.29 11.8 1.42 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.23 0 CA-C-O 120.681 0.277 . . . . 0.0 111.468 -179.646 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 46.9 mt-10 -59.24 -18.23 35.17 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.344 -0.389 . . . . 0.0 111.015 179.912 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 123' ' ' ARG . . . . . 0.586 ' HA ' HD11 ' A' ' 126' ' ' LEU . 11.1 ptt180 -50.45 -37.15 36.71 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.05 -0.523 . . . . 0.0 111.946 -179.661 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 124' ' ' TYR . . . . . . . . . . . . . 28.4 m-85 -51.19 -35.54 36.85 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.844 0.354 . . . . 0.0 111.171 -179.828 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 125' ' ' ALA . . . . . . . . . . . . . . . -74.8 -49.65 20.03 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.141 -0.481 . . . . 0.0 111.008 179.878 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 126' ' ' LEU . . . . . 0.586 HD11 ' HA ' ' A' ' 123' ' ' ARG . 6.5 mp -52.51 -55.67 20.48 Favored 'General case' 0 C--N 1.332 -0.182 0 CA-C-N 115.999 -0.546 . . . . 0.0 110.327 179.964 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 127' ' ' PHE . . . . . . . . . . . . . 10.9 t80 -64.51 -28.84 69.93 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 115.909 -0.587 . . . . 0.0 110.155 179.45 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 128' ' ' GLY . . . . . . . . . . . . . . . -49.16 -48.53 32.16 Favored Glycine 0 N--CA 1.449 -0.451 0 C-N-CA 120.121 -1.038 . . . . 0.0 110.593 178.79 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 129' ' ' MET . . . . . 0.605 ' HE1' ' HA2' ' A' ' 130' ' ' GLY . 0.0 OUTLIER -72.29 -31.72 65.98 Favored 'General case' 0 N--CA 1.452 -0.365 0 N-CA-C 109.079 -0.712 . . . . 0.0 109.079 178.467 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 130' ' ' GLY . . . . . 0.605 ' HA2' ' HE1' ' A' ' 129' ' ' MET . . . -61.52 -33.18 83.89 Favored Glycine 0 C--N 1.333 0.411 0 CA-C-N 115.749 -0.66 . . . . 0.0 112.035 179.458 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 131' ' ' ALA . . . . . 0.404 ' O ' ' HB3' ' A' ' 134' ' ' PHE . . . -74.8 -53.35 9.31 Favored 'General case' 0 N--CA 1.452 -0.326 0 CA-C-O 120.743 0.306 . . . . 0.0 110.362 179.648 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 40.8 t -55.15 -49.0 75.59 Favored 'Isoleucine or valine' 0 C--O 1.234 0.253 0 N-CA-C 109.462 -0.57 . . . . 0.0 109.462 178.783 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -59.68 -39.13 83.49 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 115.504 -0.771 . . . . 0.0 110.323 178.589 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 134' ' ' PHE . . . . . 0.461 ' CZ ' ' HA ' ' A' ' 172' ' ' ALA . 65.4 t80 -55.1 -51.13 67.37 Favored 'General case' 0 N--CA 1.451 -0.388 0 CA-C-N 115.892 -0.594 . . . . 0.0 110.367 179.68 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 135' ' ' ILE . . . . . 0.469 ' HA ' HG22 ' A' ' 138' ' ' VAL . 60.2 mt -56.15 -32.05 33.31 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.238 0 CA-C-N 115.946 -0.57 . . . . 0.0 110.112 179.24 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . -61.67 -41.24 99.56 Favored Glycine 0 N--CA 1.447 -0.598 0 C-N-CA 120.16 -1.019 . . . . 0.0 111.343 178.69 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 137' ' ' LEU . . . . . . . . . . . . . 30.0 tp -69.57 -50.71 42.08 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 115.846 -0.177 . . . . 0.0 111.09 179.935 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 138' ' ' VAL . . . . . 0.546 ' HA ' HD11 ' A' ' 141' ' ' LEU . 5.2 m -55.96 -32.62 33.53 Favored 'Isoleucine or valine' 0 C--O 1.234 0.245 0 CA-C-O 121.31 0.576 . . . . 0.0 109.754 179.478 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 139' ' ' TYR . . . . . 0.405 ' O ' ' N ' ' A' ' 143' ' ' GLY . 65.9 t80 -60.09 -48.09 83.16 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 115.353 -0.839 . . . . 0.0 109.412 178.511 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 37.0 m-85 -58.95 -35.5 73.23 Favored 'General case' 0 C--N 1.332 -0.169 0 CA-C-N 115.938 -0.573 . . . . 0.0 110.576 179.096 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 141' ' ' LEU . . . . . 0.546 HD11 ' HA ' ' A' ' 138' ' ' VAL . 95.6 mt -55.56 -46.74 77.13 Favored 'General case' 0 C--N 1.332 -0.174 0 CA-C-N 116.322 -0.399 . . . . 0.0 110.27 179.504 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 9.2 p -105.39 15.04 7.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 115.926 -0.579 . . . . 0.0 110.828 179.752 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 143' ' ' GLY . . . . . 0.405 ' N ' ' O ' ' A' ' 139' ' ' TYR . . . -90.86 -130.66 4.68 Favored Glycine 0 CA--C 1.52 0.393 0 C-N-CA 120.913 -0.661 . . . . 0.0 112.9 -179.627 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 144' ' ' PRO . . . . . . . . . . . . . 45.3 Cg_exo -57.23 -25.44 64.66 Favored 'Trans proline' 0 C--N 1.351 0.686 0 C-N-CA 122.585 2.19 . . . . 0.0 112.726 -179.632 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 145' ' ' MET . . . . . . . . . . . . . 60.6 mtt -56.76 -25.13 54.44 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.355 -0.384 . . . . 0.0 111.134 -179.896 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 146' ' ' THR . . . . . . . . . . . . . 78.1 p -63.83 -51.2 65.77 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.112 -0.495 . . . . 0.0 111.685 -179.786 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 43.6 mt-10 -75.56 -28.64 59.09 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.371 -0.377 . . . . 0.0 111.62 -179.252 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 148' ' ' SER . . . . . . . . . . . . . 36.8 t -70.53 -44.66 67.09 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.743 0.306 . . . . 0.0 111.208 -179.469 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 149' ' ' ALA . . . . . 0.439 ' HB1' ' HB3' ' A' ' 91' ' ' ALA . . . -77.92 -42.99 31.28 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.324 -0.398 . . . . 0.0 111.923 -179.53 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 150' ' ' SER . . . . . 0.564 ' HA ' ' HG2' ' A' ' 157' ' ' LYS . 47.5 t -63.65 -8.0 8.89 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.548 -179.504 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 151' ' ' GLN . . . . . . . . . . . . . 47.5 mt-30 -125.54 17.34 8.18 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.668 0.271 . . . . 0.0 111.279 -179.955 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 152' ' ' ARG . . . . . 0.582 ' HD2' HG13 ' A' ' 156' ' ' ILE . 3.6 tmt_? -93.24 -51.81 4.84 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-O 120.967 0.413 . . . . 0.0 110.509 179.782 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 153' ' ' SER . . . . . 0.63 ' HB3' HG12 ' A' ' 156' ' ' ILE . 20.0 t -157.42 172.41 18.63 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 115.904 -0.589 . . . . 0.0 110.451 179.304 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 154' ' ' SER . . . . . . . . . . . . . 79.0 p -71.62 -42.18 67.95 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.278 -0.419 . . . . 0.0 111.006 179.744 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -76.87 -25.72 64.04 Favored Glycine 0 C--N 1.331 0.265 0 C-N-CA 120.834 -0.698 . . . . 0.0 113.093 -179.669 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 156' ' ' ILE . . . . . 0.63 HG12 ' HB3' ' A' ' 153' ' ' SER . 27.7 mm -57.89 -38.48 66.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-O 120.551 0.215 . . . . 0.0 111.519 -179.718 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 157' ' ' LYS . . . . . 0.564 ' HG2' ' HA ' ' A' ' 150' ' ' SER . 35.8 mtmm -56.72 -39.91 74.77 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-O 120.806 0.336 . . . . 0.0 111.214 179.908 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 43.7 t -70.95 -48.1 55.28 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.569 -179.315 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 159' ' ' LEU . . . . . 0.454 ' O ' ' HB2' ' A' ' 163' ' ' LEU . 9.9 mt -68.18 -28.89 67.67 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 116.482 -0.326 . . . . 0.0 111.65 -179.609 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 160' ' ' TYR . . . . . . . . . . . . . 83.8 t80 -73.95 -45.91 47.41 Favored 'General case' 0 C--N 1.326 -0.429 0 N-CA-C 112.061 0.393 . . . . 0.0 112.061 -178.941 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 30.9 m -66.57 -43.89 90.34 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.419 0 N-CA-C 112.169 0.433 . . . . 0.0 112.169 -179.007 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 162' ' ' ARG . . . . . . . . . . . . . 35.3 mmt180 -68.68 -41.69 78.86 Favored 'General case' 0 C--N 1.328 -0.349 0 N-CA-C 111.884 0.327 . . . . 0.0 111.884 -178.906 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 163' ' ' LEU . . . . . 0.605 ' HG ' ' HB2' ' A' ' 208' ' ' PHE . 7.7 mp -73.79 -50.06 22.38 Favored 'General case' 0 C--N 1.329 -0.326 0 N-CA-C 112.015 0.376 . . . . 0.0 112.015 -179.182 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 164' ' ' ARG . . . . . 0.449 ' HG2' ' HB3' ' A' ' 141' ' ' LEU . 6.4 tmm_? -59.45 -50.12 75.18 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.624 -0.262 . . . . 0.0 111.577 -179.139 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 165' ' ' ASN . . . . . 0.549 ' N ' HD21 ' A' ' 165' ' ' ASN . 0.8 OUTLIER -61.29 -51.41 69.02 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.45 -0.341 . . . . 0.0 111.524 -179.464 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 166' ' ' LEU . . . . . 0.475 ' O ' ' HG ' ' A' ' 170' ' ' LEU . 4.9 tt -60.76 -54.85 40.22 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.457 -0.338 . . . . 0.0 111.865 -179.198 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 167' ' ' THR . . . . . 0.417 ' O ' ' HB2' ' A' ' 171' ' ' TRP . 64.5 m -55.17 -54.22 45.98 Favored 'General case' 0 C--N 1.329 -0.292 0 N-CA-C 112.898 0.703 . . . . 0.0 112.898 -178.585 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 168' ' ' VAL . . . . . 0.448 HG13 ' N ' ' A' ' 169' ' ' VAL . 9.9 p -55.1 -40.51 55.12 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.195 0 N-CA-C 112.418 0.525 . . . . 0.0 112.418 -178.924 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 169' ' ' VAL . . . . . 0.448 ' N ' HG13 ' A' ' 168' ' ' VAL . 58.5 t -60.47 -65.11 0.5 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 N-CA-C 111.874 0.324 . . . . 0.0 111.874 -179.159 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 170' ' ' LEU . . . . . 0.475 ' HG ' ' O ' ' A' ' 166' ' ' LEU . 1.0 OUTLIER -61.3 -29.2 69.72 Favored 'General case' 0 C--N 1.329 -0.283 0 C-N-CA 121.166 -0.213 . . . . 0.0 111.41 -179.273 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 171' ' ' TRP . . . . . 0.508 ' NE1' H203 ' A' ' 301' ' ' RET . 2.8 m0 -71.03 -35.3 71.93 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-O 120.934 0.397 . . . . 0.0 110.038 178.983 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 172' ' ' ALA . . . . . 0.461 ' HA ' ' CZ ' ' A' ' 134' ' ' PHE . . . -68.32 -6.61 25.09 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 115.872 -0.604 . . . . 0.0 110.62 179.572 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 173' ' ' ILE . . . . . 0.472 ' O ' HG12 ' A' ' 177' ' ' ILE . 40.4 mm -85.9 -22.19 7.39 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 115.873 -0.603 . . . . 0.0 110.798 179.515 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 174' ' ' TYR . . . . . 0.582 ' N ' ' HD2' ' A' ' 175' ' ' PRO . 12.9 m-85 -54.22 -50.81 82.57 Favored Pre-proline 0 CA--C 1.533 0.299 0 CA-C-N 116.159 -0.473 . . . . 0.0 112.109 -179.684 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 175' ' ' PRO . . . . . 0.582 ' HD2' ' N ' ' A' ' 174' ' ' TYR . 8.1 Cg_endo -50.65 -27.75 20.46 Favored 'Trans proline' 0 C--N 1.352 0.752 0 C-N-CA 122.067 1.845 . . . . 0.0 112.355 -179.797 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 176' ' ' PHE . . . . . 0.442 ' O ' ' HG ' ' A' ' 180' ' ' LEU . 49.5 m-85 -80.59 -46.43 15.71 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.291 -0.413 . . . . 0.0 111.668 -179.995 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 177' ' ' ILE . . . . . 0.472 HG12 ' O ' ' A' ' 173' ' ' ILE . 3.5 mm -66.19 -36.35 77.19 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.497 0 N-CA-C 112.299 0.481 . . . . 0.0 112.299 -178.211 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 178' ' ' TRP . . . . . 0.461 ' HH2' ' HB2' ' A' ' 123' ' ' ARG . 67.8 t90 -73.94 -45.95 47.21 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-O 120.907 0.384 . . . . 0.0 110.772 179.602 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 179' ' ' LEU . . . . . 0.421 HD13 HD22 ' A' ' 180' ' ' LEU . 2.5 tm? -67.92 -49.6 60.91 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 115.921 -0.581 . . . . 0.0 111.403 -179.077 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 180' ' ' LEU . . . . . 0.461 HD23 HD11 ' A' ' 187' ' ' LEU . 22.7 mt -77.7 -47.23 19.65 Favored 'General case' 0 C--N 1.328 -0.358 0 N-CA-C 111.812 0.301 . . . . 0.0 111.812 -179.165 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . -58.75 -178.21 0.96 Allowed Glycine 0 C--N 1.337 0.591 0 C-N-CA 120.256 -0.973 . . . . 0.0 112.772 -179.98 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 182' ' ' PRO . . . . . 0.569 ' HA ' ' HB2' ' A' ' 186' ' ' ALA . 85.7 Cg_exo -47.81 -44.32 27.14 Favored 'Trans proline' 0 CA--C 1.536 0.623 0 C-N-CA 122.967 2.445 . . . . 0.0 113.802 -179.97 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 183' ' ' PRO . . . . . 0.543 ' HA ' HH22 ' A' ' 66' ' ' ARG . 51.8 Cg_exo -55.3 -9.95 2.79 Favored 'Trans proline' 0 C--N 1.354 0.833 0 C-N-CA 122.154 1.902 . . . . 0.0 113.199 -179.736 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 184' ' ' GLY . . . . . 0.411 ' HA3' ' O ' ' A' ' 179' ' ' LEU . . . -123.21 -87.39 0.81 Allowed Glycine 0 N--CA 1.45 -0.387 0 C-N-CA 120.421 -0.895 . . . . 0.0 112.901 -179.887 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 185' ' ' VAL . . . . . . . . . . . . . 8.6 m -120.43 -7.02 10.53 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-O 120.773 0.321 . . . . 0.0 111.779 -179.603 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 186' ' ' ALA . . . . . 0.569 ' HB2' ' HA ' ' A' ' 182' ' ' PRO . . . 56.18 85.36 0.07 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.116 -0.493 . . . . 0.0 111.716 179.576 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 187' ' ' LEU . . . . . 0.461 HD11 HD23 ' A' ' 180' ' ' LEU . 18.8 mt -91.78 -49.25 6.36 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.93 0.395 . . . . 0.0 110.878 179.528 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 188' ' ' LEU . . . . . . . . . . . . . 96.6 mt -90.13 -154.99 0.35 Allowed 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 115.839 -0.619 . . . . 0.0 110.947 -179.661 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 189' ' ' THR . . . . . 0.459 ' HB ' HG22 ' A' ' 192' ' ' VAL . 58.8 m -92.6 136.17 25.56 Favored Pre-proline 0 C--N 1.329 -0.326 0 CA-C-N 116.05 -0.523 . . . . 0.0 110.568 -179.719 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 190' ' ' PRO . . . . . . . . . . . . . 2.2 Cg_endo -45.5 -37.69 15.23 Favored 'Trans proline' 0 C--N 1.35 0.652 0 C-N-CA 122.837 2.358 . . . . 0.0 112.776 -179.747 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 191' ' ' THR . . . . . . . . . . . . . 41.7 p -74.24 -45.42 48.09 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 116.487 -0.324 . . . . 0.0 111.415 -179.835 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 192' ' ' VAL . . . . . 0.459 HG22 ' HB ' ' A' ' 189' ' ' THR . 96.9 t -59.66 -52.79 56.9 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.302 -0.408 . . . . 0.0 111.415 -179.781 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 193' ' ' ASP . . . . . . . . . . . . . 25.9 t70 -54.6 -48.2 72.46 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.946 -179.761 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 194' ' ' VAL . . . . . 0.51 ' O ' HG22 ' A' ' 198' ' ' VAL . 40.6 t -55.22 -44.03 73.22 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.241 0 CA-C-N 116.376 -0.375 . . . . 0.0 110.492 179.492 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 195' ' ' ALA . . . . . . . . . . . . . . . -52.46 -42.91 64.61 Favored 'General case' 0 C--N 1.332 -0.185 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.778 179.895 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 196' ' ' LEU . . . . . . . . . . . . . 62.5 mt -67.8 -40.27 83.9 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.785 179.356 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 197' ' ' ILE . . . . . 0.418 HD12 ' HB ' ' A' ' 177' ' ' ILE . 12.0 mm -59.39 -60.87 1.82 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 115.766 -0.652 . . . . 0.0 111.405 -179.847 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 198' ' ' VAL . . . . . 0.51 HG22 ' O ' ' A' ' 194' ' ' VAL . 1.3 m -53.94 -34.85 26.61 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.439 0 CA-C-O 121.544 0.687 . . . . 0.0 109.566 179.053 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 199' ' ' TYR . . . . . . . . . . . . . 63.8 t80 -66.57 -33.56 75.94 Favored 'General case' 0 C--N 1.323 -0.587 0 CA-C-N 114.639 -1.164 . . . . 0.0 110.575 179.722 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 200' ' ' LEU . . . . . 0.435 ' O ' HG12 ' A' ' 203' ' ' VAL . 26.6 mt -66.67 -41.77 87.62 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.088 -0.505 . . . . 0.0 111.315 -179.897 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 201' ' ' ASP . . . . . . . . . . . . . 5.0 m-20 -74.83 -37.94 62.14 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-O 121.253 0.549 . . . . 0.0 110.044 179.499 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 202' ' ' LEU . . . . . . . . . . . . . 40.5 tp -70.6 -26.79 63.67 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 115.256 -0.884 . . . . 0.0 111.559 -179.343 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 203' ' ' VAL . . . . . 0.435 HG12 ' O ' ' A' ' 200' ' ' LEU . 14.2 p -81.73 -36.7 14.59 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.13 0 CA-C-N 116.765 -0.198 . . . . 0.0 110.813 -179.141 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 204' ' ' THR . . . . . . . . . . . . . 65.8 m -63.43 -58.56 6.67 Favored 'General case' 0 C--N 1.329 -0.305 0 C-N-CA 120.713 -0.395 . . . . 0.0 110.642 179.169 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 205' ' ' LYS . . . . . 0.71 ' HE2' ' HB1' ' A' ' 47' ' ' ALA . 57.7 mttp -60.88 -58.01 10.26 Favored 'General case' 0 C--N 1.328 -0.361 0 N-CA-C 112.609 0.596 . . . . 0.0 112.609 -178.464 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 56.5 t -71.77 -37.36 62.02 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 N-CA-C 112.317 0.488 . . . . 0.0 112.317 -178.432 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 207' ' ' GLY . . . . . 0.515 ' O ' HG13 ' A' ' 211' ' ' ILE . . . -56.92 -61.67 7.24 Favored Glycine 0 CA--C 1.517 0.18 0 C-N-CA 120.665 -0.779 . . . . 0.0 113.793 -178.799 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 208' ' ' PHE . . . . . 0.605 ' HB2' ' HG ' ' A' ' 163' ' ' LEU . 0.9 OUTLIER -72.73 -27.25 61.93 Favored 'General case' 0 C--O 1.222 -0.368 0 CA-C-N 117.571 0.686 . . . . 0.0 110.771 -179.31 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 209' ' ' GLY . . . . . 0.496 ' O ' ' HB1' ' A' ' 212' ' ' ALA . . . -63.34 -32.73 85.15 Favored Glycine 0 N--CA 1.448 -0.542 0 N-CA-C 111.629 -0.588 . . . . 0.0 111.629 178.471 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 210' ' ' PHE . . . . . . . . . . . . . 0.8 OUTLIER -74.06 -47.81 34.09 Favored 'General case' 0 CA--C 1.515 -0.397 0 N-CA-C 108.221 -1.029 . . . . 0.0 108.221 178.543 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 211' ' ' ILE . . . . . 0.515 HG13 ' O ' ' A' ' 207' ' ' GLY . 4.4 mt -63.43 -27.52 43.18 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.434 0 N-CA-C 107.678 -1.23 . . . . 0.0 107.678 176.83 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 212' ' ' ALA . . . . . 0.496 ' HB1' ' O ' ' A' ' 209' ' ' GLY . . . -62.76 -40.81 98.42 Favored 'General case' 0 N--CA 1.451 -0.418 0 CA-C-N 114.447 -1.252 . . . . 0.0 110.622 -179.788 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 213' ' ' LEU . . . . . . . . . . . . . 86.4 mt -69.44 -47.29 64.54 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 115.171 -0.922 . . . . 0.0 111.44 -179.501 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 214' ' ' ASP . . . . . . . . . . . . . 14.3 t70 -56.32 -53.1 61.34 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.391 -0.368 . . . . 0.0 111.079 -179.944 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 215' ' ' ALA . . . . . . . . . . . . . . . -56.88 -56.24 24.22 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.06 -0.518 . . . . 0.0 111.341 -179.813 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 216' ' ' ALA . . . . . . . . . . . . . . . -56.78 -32.13 65.34 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.234 -179.897 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 217' ' ' ALA . . . . . . . . . . . . . . . -64.73 -34.38 78.18 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.298 -0.41 . . . . 0.0 110.197 179.793 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 218' ' ' THR . . . . . . . . . . . . . 93.0 m -76.17 -32.61 59.13 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 115.789 -0.641 . . . . 0.0 110.76 179.536 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 219' ' ' LEU . . . . . 0.472 ' O ' ' HG2' ' A' ' 222' ' ' GLU . 69.4 mt -62.23 -41.16 98.16 Favored 'General case' 0 C--N 1.333 -0.15 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.697 -179.999 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 220' ' ' ARG . . . . . . . . . . . . . 35.9 ptt180 -83.89 -24.53 30.76 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.044 -0.525 . . . . 0.0 111.012 179.841 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 221' ' ' ALA . . . . . . . . . . . . . . . -77.24 -19.2 56.94 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.074 -0.512 . . . . 0.0 112.227 -179.38 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 222' ' ' GLU . . . . . 0.472 ' HG2' ' O ' ' A' ' 219' ' ' LEU . 10.2 pt-20 -70.1 -10.91 60.28 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-O 120.811 0.339 . . . . 0.0 110.722 -178.918 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 223' ' ' HIS . . . . . . . . . . . . . 1.6 p-80 -150.05 5.69 0.58 Allowed 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.058 -0.519 . . . . 0.0 111.285 -179.744 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 224' ' ' GLY . . . . . . . . . . . . . . . 60.46 82.49 0.07 OUTLIER Glycine 0 N--CA 1.452 -0.272 0 C-N-CA 120.659 -0.782 . . . . 0.0 112.368 -179.969 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 225' ' ' GLU . . . . . . . . . . . . . 25.8 mm-40 65.19 147.07 0.03 OUTLIER 'General case' 0 N--CA 1.463 0.182 0 CA-C-O 121.026 0.441 . . . . 0.0 111.411 -179.975 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 226' ' ' SER . . . . . . . . . . . . . 60.6 m -61.08 146.07 48.65 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 115.939 -0.573 . . . . 0.0 110.936 179.974 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 227' ' ' LEU . . . . . . . . . . . . . 93.5 mt -76.34 162.53 27.81 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.761 179.989 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 228' ' ' ALA . . . . . . . . . . . . . . . -155.19 -179.71 8.34 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.2 -0.454 . . . . 0.0 111.028 179.856 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 229' ' ' GLY . . . . . . . . . . . . . . . -73.44 160.89 53.99 Favored Glycine 0 N--CA 1.45 -0.388 0 C-N-CA 120.709 -0.758 . . . . 0.0 112.548 179.9 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 230' ' ' VAL . . . . . . . . . . . . . 21.7 m -128.21 149.02 32.71 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.229 0 CA-C-O 120.738 0.304 . . . . 0.0 111.038 179.948 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 231' ' ' ASP . . . . . . . . . . . . . 22.3 t70 -101.35 109.81 21.72 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.75 179.911 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 232' ' ' THR . . . . . . . . . . . . . 3.6 t -152.61 122.41 6.94 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.29 -179.785 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 233' ' ' ASP . . . . . . . . . . . . . 5.3 p-10 -101.76 135.41 43.35 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.017 -0.538 . . . . 0.0 110.598 179.668 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 234' ' ' THR . . . . . . . . . . . . . 51.2 m 58.37 89.32 0.11 Allowed Pre-proline 0 C--N 1.331 -0.222 0 CA-C-N 116.324 -0.398 . . . . 0.0 111.0 179.97 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 235' ' ' PRO . . . . . . . . . . . . . 31.5 Cg_endo -63.28 172.64 4.98 Favored 'Trans proline' 0 C--N 1.347 0.5 0 C-N-CA 122.636 2.224 . . . . 0.0 112.387 179.972 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 236' ' ' ALA . . . . . . . . . . . . . . . -96.82 119.02 34.52 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.944 -179.984 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 237' ' ' VAL . . . . . . . . . . . . . 27.3 m -81.66 148.86 5.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.262 179.957 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 238' ' ' ALA . . . . . . . . . . . . . . . -140.83 -31.95 0.59 Allowed 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.925 179.97 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 239' ' ' ASP . . . . . . . . . . . . . 5.5 p-10 -136.82 139.62 41.87 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.659 179.866 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 240' ' ' LEU . . . . . . . . . . . . . 61.1 tp -151.22 -36.01 0.14 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.306 -0.406 . . . . 0.0 111.068 -179.738 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 241' ' ' GLU . . . . . . . . . . . . . 10.7 tp10 63.98 112.94 0.03 OUTLIER 'General case' 0 C--N 1.332 -0.155 0 CA-C-N 116.176 -0.466 . . . . 0.0 111.126 179.935 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 242' ' ' HIS . . . . . . . . . . . . . 85.1 m-70 -81.45 146.72 30.1 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.123 -179.674 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 243' ' ' HIS . . . . . . . . . . . . . 36.5 t-80 -109.15 -18.18 13.69 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 115.945 -0.571 . . . . 0.0 110.622 179.924 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 244' ' ' HIS . . . . . . . . . . . . . 44.4 m80 -99.95 119.98 39.09 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.025 -0.534 . . . . 0.0 110.87 179.989 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 245' ' ' HIS . . . . . . . . . . . . . 60.1 t-80 -136.37 -40.9 0.64 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.68 179.865 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 246' ' ' HIS . . . . . . . . . . . . . 62.2 t-80 -131.87 116.11 16.77 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.068 -0.515 . . . . 0.0 110.862 -179.867 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 247' ' ' HIS . . . . . . . . . . . . . 58.5 t-80 . . . . . 0 C--O 1.249 1.03 0 CA-C-O 118.208 -0.901 . . . . 0.0 110.848 179.933 . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 301' ' ' RET . . . . . 0.537 ' H22' ' HA3' ' A' ' 112' ' ' GLY . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 93.8 mmm . . . . . 0 N--CA 1.486 1.358 0 CA-C-O 120.828 0.347 . . . . 0.0 110.834 . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 8.3 p -113.15 -11.46 11.97 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.087 -179.858 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -86.81 -42.81 6.26 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.839 -0.696 . . . . 0.0 112.672 179.994 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 81.9 mt -65.64 -36.65 84.32 Favored 'General case' 0 N--CA 1.45 -0.436 0 CA-C-O 120.804 0.335 . . . . 0.0 111.117 -179.844 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 67.1 p -57.21 -30.64 64.73 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.01 -0.541 . . . . 0.0 111.725 -179.651 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 27.3 p -58.8 -38.32 78.32 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 116.524 -0.307 . . . . 0.0 111.344 -179.609 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 7' ' ' LEU . . . . . . . . . . . . . 4.2 mm? -63.5 -51.45 65.49 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.106 -179.941 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 8' ' ' PHE . . . . . 0.448 ' O ' ' HB3' ' A' ' 51' ' ' TYR . 74.1 m-85 -61.2 -33.23 73.13 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.512 179.928 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 9' ' ' TRP . . . . . 0.467 ' O ' HG13 ' A' ' 13' ' ' ILE . 9.1 m95 -66.15 -38.52 88.31 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 116.067 -0.515 . . . . 0.0 110.241 179.999 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 73.2 mt -65.7 -32.63 74.3 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 115.787 -0.642 . . . . 0.0 110.005 179.464 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -71.02 -33.64 65.31 Favored Glycine 0 N--CA 1.448 -0.517 0 C-N-CA 120.953 -0.642 . . . . 0.0 111.757 179.129 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -70.02 -32.43 70.58 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 120.889 0.376 . . . . 0.0 110.53 179.315 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 13' ' ' ILE . . . . . 0.467 HG13 ' O ' ' A' ' 9' ' ' TRP . 73.8 mt -66.95 -53.81 30.65 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.233 0 CA-C-N 116.021 -0.536 . . . . 0.0 110.577 179.721 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -64.11 -25.09 69.28 Favored Glycine 0 N--CA 1.451 -0.366 0 C-N-CA 120.657 -0.783 . . . . 0.0 112.042 179.677 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 15' ' ' MET . . . . . 0.51 ' HB3' ' HB3' ' A' ' 48' ' ' ALA . 0.0 OUTLIER -72.54 -54.47 9.11 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.559 0.219 . . . . 0.0 110.933 179.82 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 3.9 mm? -53.13 -45.72 68.47 Favored 'General case' 0 C--N 1.332 -0.179 0 CA-C-N 116.403 -0.362 . . . . 0.0 110.921 179.527 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 83.7 t -61.06 -40.29 85.18 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.153 0 CA-C-N 116.372 -0.376 . . . . 0.0 110.457 179.666 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -67.68 -41.73 88.81 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.859 -0.686 . . . . 0.0 111.802 179.188 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 16.3 m -51.14 -53.76 31.44 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.989 0.423 . . . . 0.0 110.711 -179.982 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 62.6 mt -71.71 -32.22 67.55 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 115.786 -0.643 . . . . 0.0 111.083 179.84 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -58.33 -56.67 19.13 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.793 -179.605 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 4.7 m-85 -71.11 -30.75 66.91 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.409 -0.359 . . . . 0.0 111.337 -179.128 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -64.03 -51.24 65.11 Favored 'General case' 0 C--N 1.327 -0.4 0 N-CA-C 112.369 0.507 . . . . 0.0 112.369 -179.17 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 24' ' ' TRP . . . . . 0.532 ' HA ' ' CE3' ' A' ' 24' ' ' TRP . 2.4 t-105 -86.67 -26.76 24.15 Favored 'General case' 0 N--CA 1.442 -0.842 0 N-CA-C 113.326 0.861 . . . . 0.0 113.326 -177.655 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -46.86 -48.61 21.02 Favored 'General case' 0 C--N 1.314 -0.947 0 N-CA-C 109.586 -0.524 . . . . 0.0 109.586 178.785 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -74.35 -21.29 79.09 Favored Glycine 0 N--CA 1.45 -0.426 0 N-CA-C 110.039 -1.224 . . . . 0.0 110.039 177.354 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 27' ' ' ARG . . . . . 0.456 ' HA ' ' CE3' ' A' ' 24' ' ' TRP . 19.0 mtt180 59.88 77.49 0.31 Allowed 'General case' 0 CA--C 1.516 -0.34 0 CA-C-N 114.676 -0.762 . . . . 0.0 111.855 179.357 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 20.2 t70 50.97 86.76 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 115.638 -0.71 . . . . 0.0 111.046 178.975 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -76.01 158.57 31.75 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.4 -179.601 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -72.58 -79.13 0.48 Allowed Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.877 -0.677 . . . . 0.0 112.515 -179.967 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 31' ' ' SER . . . . . 0.41 ' HA ' ' NE ' ' A' ' 34' ' ' ARG . 44.3 t -156.63 -55.22 0.08 Allowed 'General case' 0 C--N 1.331 -0.239 0 CA-C-O 120.644 0.259 . . . . 0.0 111.183 -179.904 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -56.11 -28.39 53.84 Favored Glycine 0 C--N 1.33 0.231 0 C-N-CA 120.823 -0.703 . . . . 0.0 112.767 -179.97 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 8.8 mm-40 -92.14 -23.6 19.36 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.794 0.331 . . . . 0.0 110.949 -179.964 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 34' ' ' ARG . . . . . 0.41 ' NE ' ' HA ' ' A' ' 31' ' ' SER . 53.1 mtm180 -56.4 -28.34 59.04 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.156 -0.475 . . . . 0.0 111.848 -179.677 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 19.0 tpp180 -55.27 -59.05 5.33 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-O 120.744 0.307 . . . . 0.0 111.408 -179.634 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 42.3 m-85 -71.96 -34.81 69.29 Favored 'General case' 0 C--N 1.33 -0.244 0 N-CA-C 112.333 0.494 . . . . 0.0 112.333 -178.783 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 37' ' ' TYR . . . . . . . . . . . . . 29.4 m-85 -70.39 -56.25 7.13 Favored 'General case' 0 N--CA 1.464 0.226 0 N-CA-C 111.619 0.229 . . . . 0.0 111.619 -179.221 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 77.9 t -56.85 -37.23 52.85 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.232 0 CA-C-O 120.8 0.333 . . . . 0.0 110.87 179.799 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 21.9 m -62.25 -51.18 68.75 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.845 179.313 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 18.1 tp -59.87 -50.93 71.86 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 115.926 -0.579 . . . . 0.0 110.792 179.978 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 65.3 t -58.84 -34.09 51.31 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.373 0 CA-C-N 115.775 -0.648 . . . . 0.0 109.998 179.169 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -58.76 -41.81 96.11 Favored Glycine 0 N--CA 1.448 -0.542 0 C-N-CA 120.829 -0.7 . . . . 0.0 111.657 179.429 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 43' ' ' ILE . . . . . 0.504 HD11 HD11 ' A' ' 83' ' ' ILE . 1.1 mt -61.75 -51.16 75.97 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.176 0 CA-C-O 120.847 0.356 . . . . 0.0 110.508 179.201 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 79.3 p -62.2 -23.27 66.53 Favored 'General case' 0 C--N 1.333 -0.132 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.088 179.756 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -77.55 -56.94 3.72 Favored Glycine 0 C--N 1.33 0.225 0 C-N-CA 120.832 -0.699 . . . . 0.0 112.406 179.916 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 46' ' ' ILE . . . . . 0.494 ' HB ' HD11 ' A' ' 78' ' ' LEU . 13.1 pt -58.49 -37.14 62.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-O 121.051 0.453 . . . . 0.0 110.721 179.77 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 47' ' ' ALA . . . . . 0.572 ' HB1' ' HE2' ' A' ' 205' ' ' LYS . . . -68.46 -41.02 80.78 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 115.97 -0.559 . . . . 0.0 110.89 179.113 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 48' ' ' ALA . . . . . 0.51 ' HB3' ' HB3' ' A' ' 15' ' ' MET . . . -55.69 -42.09 74.67 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-N 115.805 -0.634 . . . . 0.0 111.763 -179.486 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 49' ' ' VAL . . . . . 0.468 ' O ' HG11 ' A' ' 53' ' ' VAL . 8.6 m -75.56 -37.44 36.98 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.545 -0.298 . . . . 0.0 111.6 -179.516 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -60.61 -43.59 97.26 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 121.035 0.445 . . . . 0.0 111.061 179.809 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 51' ' ' TYR . . . . . 0.448 ' HB3' ' O ' ' A' ' 8' ' ' PHE . 43.3 m-85 -73.1 -32.38 64.94 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-N 115.933 -0.576 . . . . 0.0 110.484 -179.77 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -69.34 -38.97 78.41 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-N 115.897 -0.592 . . . . 0.0 111.1 179.549 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 53' ' ' VAL . . . . . 0.468 HG11 ' O ' ' A' ' 49' ' ' VAL . 33.3 m -74.62 -47.39 39.04 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.224 0 CA-C-N 116.418 -0.356 . . . . 0.0 110.573 180.0 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 54' ' ' MET . . . . . 0.439 ' N ' HG21 ' A' ' 53' ' ' VAL . 75.3 mtm -61.37 -31.77 71.67 Favored 'General case' 0 N--CA 1.455 -0.178 0 N-CA-C 109.62 -0.511 . . . . 0.0 109.62 179.058 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 55' ' ' ALA . . . . . 0.436 ' HB3' ' HB2' ' A' ' 8' ' ' PHE . . . -69.31 -22.83 63.76 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 115.588 -0.733 . . . . 0.0 110.933 179.215 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 63.8 mt -87.51 0.12 56.02 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 116.167 -0.469 . . . . 0.0 111.409 -179.797 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 90.5 -21.49 32.12 Favored Glycine 0 N--CA 1.452 -0.261 0 C-N-CA 120.564 -0.827 . . . . 0.0 113.115 179.522 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 13.7 p -68.36 148.7 11.68 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.215 0 CA-C-N 116.887 0.344 . . . . 0.0 110.822 179.955 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 92.44 -5.06 77.37 Favored Glycine 0 N--CA 1.45 -0.403 0 C-N-CA 120.648 -0.787 . . . . 0.0 112.403 -179.573 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 60' ' ' TRP . . . . . . . . . . . . . 15.9 m0 -86.19 108.09 18.19 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.55 0.214 . . . . 0.0 110.954 -179.861 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 61' ' ' VAL . . . . . 0.408 HG11 HG23 ' A' ' 68' ' ' VAL . 7.5 p -111.8 128.26 25.69 Favored Pre-proline 0 CA--C 1.533 0.317 0 CA-C-N 116.52 -0.309 . . . . 0.0 111.108 179.804 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 73.8 Cg_endo -75.23 155.27 41.85 Favored 'Trans proline' 0 C--N 1.35 0.645 0 C-N-CA 122.422 2.082 . . . . 0.0 112.648 -179.679 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 80.7 t -143.21 89.73 0.4 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 115.826 -0.625 . . . . 0.0 110.858 179.929 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . 59.9 -86.86 0.02 OUTLIER 'General case' 0 C--N 1.331 -0.199 0 CA-C-N 116.065 -0.516 . . . . 0.0 111.467 179.953 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 6.2 mp0 -121.52 -19.64 6.84 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 116.286 -0.415 . . . . 0.0 110.652 179.962 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 66' ' ' ARG . . . . . . . . . . . . . 45.6 mtm180 -101.24 161.52 13.56 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 115.919 -0.582 . . . . 0.0 110.499 179.913 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 56.2 m -122.44 137.63 54.81 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.35 -0.386 . . . . 0.0 111.269 -179.804 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 68' ' ' VAL . . . . . 0.445 HG22 ' HG2' ' A' ' 117' ' ' MET . 21.7 m -127.37 146.64 32.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.025 -0.534 . . . . 0.0 110.802 179.772 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 69' ' ' PHE . . . . . . . . . . . . . 23.1 m-85 -109.44 112.18 24.15 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.154 -179.261 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 70' ' ' VAL . . . . . 0.538 ' HB ' ' HD3' ' A' ' 71' ' ' PRO . 13.0 t -62.95 -49.61 80.89 Favored Pre-proline 0 C--N 1.324 -0.508 0 CA-C-N 116.227 -0.442 . . . . 0.0 112.021 -178.901 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 71' ' ' PRO . . . . . 0.538 ' HD3' ' HB ' ' A' ' 70' ' ' VAL . 38.2 Cg_exo -60.74 -18.46 55.98 Favored 'Trans proline' 0 C--N 1.35 0.616 0 C-N-CA 122.039 1.826 . . . . 0.0 112.985 -179.663 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 72' ' ' ARG . . . . . 0.476 ' NH2' HG13 ' A' ' 197' ' ' ILE . 77.5 ttt180 -76.08 -55.6 5.44 Favored 'General case' 0 C--O 1.235 0.303 0 CA-C-O 120.796 0.331 . . . . 0.0 111.86 -179.093 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 73' ' ' TYR . . . . . . . . . . . . . 27.1 m-85 -67.52 -36.15 80.49 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-O 120.817 0.342 . . . . 0.0 110.321 -179.545 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 74' ' ' ILE . . . . . 0.487 ' O ' HD22 ' A' ' 78' ' ' LEU . 0.3 OUTLIER -67.14 -43.05 88.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 N-CA-C 109.686 -0.487 . . . . 0.0 109.686 179.344 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 75' ' ' ASP . . . . . 0.564 ' HA ' HD21 ' A' ' 78' ' ' LEU . 12.0 t70 -51.95 -40.72 61.3 Favored 'General case' 0 CA--C 1.519 -0.226 0 N-CA-C 109.534 -0.543 . . . . 0.0 109.534 179.009 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 76' ' ' TRP . . . . . . . . . . . . . 44.2 m0 -66.34 -35.5 80.51 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 115.794 -0.639 . . . . 0.0 110.825 179.425 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 77' ' ' ILE . . . . . 0.457 ' O ' ' HG2' ' A' ' 81' ' ' PRO . 88.0 mt -59.75 -40.73 83.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.094 -0.503 . . . . 0.0 112.318 -179.446 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 78' ' ' LEU . . . . . 0.564 HD21 ' HA ' ' A' ' 75' ' ' ASP . 0.6 OUTLIER -91.94 -28.34 17.31 Favored 'General case' 0 CA--C 1.535 0.371 0 N-CA-C 113.038 0.755 . . . . 0.0 113.038 -179.546 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 65.3 p -79.65 -53.09 7.17 Favored 'General case' 0 N--CA 1.469 0.511 0 N-CA-C 113.468 0.914 . . . . 0.0 113.468 -178.41 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 80' ' ' THR . . . . . 0.583 ' HB ' ' HD3' ' A' ' 81' ' ' PRO . 3.8 m -50.92 -54.02 41.6 Favored Pre-proline 0 CA--C 1.533 0.291 0 N-CA-C 112.409 0.522 . . . . 0.0 112.409 -178.27 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 81' ' ' PRO . . . . . 0.583 ' HD3' ' HB ' ' A' ' 80' ' ' THR . 32.3 Cg_exo -60.08 -22.41 69.51 Favored 'Trans proline' 0 C--N 1.351 0.687 0 C-N-CA 121.869 1.712 . . . . 0.0 111.761 179.723 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 82' ' ' LEU . . . . . . . . . . . . . 15.4 tp -74.32 -33.03 63.06 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.067 -0.515 . . . . 0.0 109.921 179.647 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 83' ' ' ILE . . . . . 0.504 HD11 HD11 ' A' ' 43' ' ' ILE . 35.4 mm -68.79 -53.03 29.24 Favored 'Isoleucine or valine' 0 C--O 1.235 0.309 0 CA-C-N 115.845 -0.616 . . . . 0.0 110.037 179.04 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 30.8 m -61.67 -30.18 47.75 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.221 0 CA-C-N 116.085 -0.507 . . . . 0.0 109.832 179.043 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 85' ' ' TYR . . . . . . . . . . . . . 44.2 t80 -66.82 -34.68 78.35 Favored 'General case' 0 N--CA 1.454 -0.251 0 CA-C-N 115.665 -0.698 . . . . 0.0 109.386 178.724 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 86' ' ' PHE . . . . . . . . . . . . . 18.9 t80 -59.2 -51.45 69.94 Favored 'General case' 0 CA--C 1.519 -0.234 0 CA-C-N 115.735 -0.666 . . . . 0.0 109.427 178.983 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 10.5 mp -60.51 -32.29 71.32 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 115.55 -0.75 . . . . 0.0 110.04 179.28 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 88' ' ' GLY . . . . . 0.419 ' HA2' HD11 ' A' ' 93' ' ' LEU . . . -68.59 -28.21 73.32 Favored Glycine 0 N--CA 1.449 -0.438 0 C-N-CA 120.751 -0.738 . . . . 0.0 111.697 179.382 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 75.9 mt -72.49 -39.25 67.82 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-O 120.982 0.42 . . . . 0.0 110.278 179.43 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 70.5 mt -59.9 -53.1 61.86 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 115.76 -0.654 . . . . 0.0 110.603 179.569 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . 0.491 ' HB2' ' HB2' ' A' ' 149' ' ' ALA . . . -72.33 -52.07 17.81 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.126 -0.488 . . . . 0.0 111.062 179.89 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 97.21 57.24 1.08 Allowed Glycine 0 N--CA 1.453 -0.228 0 C-N-CA 120.817 -0.706 . . . . 0.0 112.207 -179.899 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 93' ' ' LEU . . . . . 0.558 HD23 ' HG2' ' A' ' 145' ' ' MET . 8.9 mp -60.5 172.65 0.84 Allowed 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 121.045 0.45 . . . . 0.0 111.35 -179.704 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 94' ' ' ASP . . . . . 0.402 ' HB2' ' HG2' ' A' ' 97' ' ' GLU . 8.0 m-20 -82.63 172.55 12.82 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-N 115.904 -0.589 . . . . 0.0 110.634 179.907 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 38.3 t -56.24 -48.68 76.04 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.206 -179.839 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 99.2 mtt180 -70.4 -43.38 70.15 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.268 -0.424 . . . . 0.0 111.196 -179.835 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 97' ' ' GLU . . . . . 0.556 ' HB3' HD21 ' A' ' 93' ' ' LEU . 21.5 mm-40 -52.19 -48.0 65.26 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.991 -179.59 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 98' ' ' PHE . . . . . 0.429 ' O ' HG12 ' A' ' 102' ' ' ILE . 11.6 m-85 -57.5 -45.2 85.18 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-O 120.988 0.423 . . . . 0.0 110.19 179.177 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -62.59 -26.43 68.36 Favored Glycine 0 N--CA 1.45 -0.417 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.421 179.811 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 97.1 mt -73.28 -47.4 46.76 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.238 0 N-CA-C 111.876 0.324 . . . . 0.0 111.876 -179.632 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 26.5 m -69.19 -35.13 66.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 N-CA-C 111.9 0.333 . . . . 0.0 111.9 -179.169 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 102' ' ' ILE . . . . . 0.429 HG12 ' O ' ' A' ' 98' ' ' PHE . 48.6 mm -72.23 -47.92 51.17 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.25 0 CA-C-N 116.674 -0.239 . . . . 0.0 111.596 -179.294 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 14.4 t -60.22 -37.63 80.92 Favored 'General case' 0 C--O 1.234 0.273 0 CA-C-O 121.02 0.438 . . . . 0.0 110.879 179.895 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 104' ' ' LEU . . . . . 0.431 ' O ' HG12 ' A' ' 107' ' ' VAL . 31.3 tp -60.52 -50.15 74.68 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 115.975 -0.557 . . . . 0.0 110.512 179.648 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 105' ' ' ASN . . . . . 0.554 ' N ' HD21 ' A' ' 105' ' ' ASN . 0.8 OUTLIER -59.27 -31.69 69.33 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.012 179.778 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 96.9 m -61.01 -57.82 11.0 Favored 'General case' 0 C--N 1.331 -0.204 0 CA-C-N 116.547 -0.297 . . . . 0.0 111.478 -179.292 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 107' ' ' VAL . . . . . 0.431 HG12 ' O ' ' A' ' 104' ' ' LEU . 14.2 p -56.4 -35.46 43.76 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.242 -0.436 . . . . 0.0 110.742 -179.912 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . 0.416 HG21 ' O ' ' A' ' 104' ' ' LEU . 82.1 t -61.68 -57.8 10.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.038 -0.528 . . . . 0.0 111.424 179.624 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 109' ' ' MET . . . . . 0.502 ' HG2' ' O ' ' A' ' 105' ' ' ASN . 5.4 mmt -58.39 -35.2 71.64 Favored 'General case' 0 C--N 1.333 -0.146 0 CA-C-N 116.546 -0.297 . . . . 0.0 110.928 -179.683 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 8.3 mt -68.39 -33.17 73.77 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.307 -0.406 . . . . 0.0 110.696 179.785 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -61.75 -45.0 95.8 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 121.153 0.502 . . . . 0.0 109.745 178.989 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 112' ' ' GLY . . . . . 0.461 ' HA3' ' H22' ' A' ' 301' ' ' RET . . . -73.81 -33.34 57.89 Favored Glycine 0 N--CA 1.448 -0.507 0 CA-C-N 115.595 -0.729 . . . . 0.0 111.384 179.111 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 113' ' ' PHE . . . . . . . . . . . . . 1.1 t80 -53.27 -73.53 0.04 OUTLIER 'General case' 0 N--CA 1.455 -0.186 0 CA-C-O 121.093 0.473 . . . . 0.0 109.749 179.298 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -63.1 -21.44 66.18 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 115.68 -0.691 . . . . 0.0 110.805 179.618 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -52.57 -49.24 53.46 Favored Glycine 0 C--N 1.335 0.473 0 C-N-CA 120.785 -0.721 . . . . 0.0 112.155 179.492 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -78.38 -15.75 58.36 Favored 'General case' 0 C--N 1.326 -0.414 0 N-CA-C 111.698 0.258 . . . . 0.0 111.698 179.939 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 117' ' ' MET . . . . . 0.445 ' HG2' HG22 ' A' ' 68' ' ' VAL . 57.6 mtt -102.35 15.6 28.69 Favored 'General case' 0 C--N 1.332 -0.194 0 CA-C-O 120.687 0.279 . . . . 0.0 111.731 -179.295 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 19.2 m -65.62 150.26 96.33 Favored Pre-proline 0 C--N 1.329 -0.303 0 CA-C-N 116.509 -0.314 . . . . 0.0 111.213 179.9 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 119' ' ' PRO . . . . . . . . . . . . . 91.5 Cg_endo -80.97 4.48 6.94 Favored 'Trans proline' 0 C--N 1.348 0.529 0 C-N-CA 122.508 2.139 . . . . 0.0 112.501 179.68 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -170.31 -123.71 0.7 Allowed Glycine 0 C--N 1.33 0.231 0 C-N-CA 120.637 -0.792 . . . . 0.0 112.747 -179.816 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 26.2 pt -105.44 9.77 9.3 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-O 120.698 0.285 . . . . 0.0 111.467 -179.716 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 13.9 mm-40 -58.0 -19.23 29.46 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-O 120.95 0.405 . . . . 0.0 110.75 179.626 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 123' ' ' ARG . . . . . 0.485 ' HB2' ' HH2' ' A' ' 178' ' ' TRP . 23.2 ptt180 -51.5 -35.37 39.98 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 115.67 -0.695 . . . . 0.0 111.903 -179.781 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 124' ' ' TYR . . . . . . . . . . . . . 25.7 m-85 -57.29 -35.31 69.65 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.807 0.337 . . . . 0.0 110.891 -179.875 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 125' ' ' ALA . . . . . . . . . . . . . . . -74.35 -48.97 24.8 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.064 179.813 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 6.9 mp -53.33 -52.48 59.02 Favored 'General case' 0 C--N 1.332 -0.158 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.787 -179.981 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 127' ' ' PHE . . . . . . . . . . . . . 6.6 t80 -64.38 -37.54 87.87 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.281 -0.418 . . . . 0.0 110.684 179.999 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 128' ' ' GLY . . . . . . . . . . . . . . . -46.42 -45.02 16.52 Favored Glycine 0 C--N 1.332 0.337 0 C-N-CA 120.118 -1.039 . . . . 0.0 110.959 179.265 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 129' ' ' MET . . . . . 0.4 ' HE3' ' N ' ' A' ' 130' ' ' GLY . 0.5 OUTLIER -70.46 -38.04 74.39 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 120.868 0.366 . . . . 0.0 110.073 178.722 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 130' ' ' GLY . . . . . 0.4 ' N ' ' HE3' ' A' ' 129' ' ' MET . . . -63.61 -30.81 78.73 Favored Glycine 0 C--N 1.333 0.365 0 C-N-CA 121.056 -0.592 . . . . 0.0 112.951 -179.816 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -74.48 -53.56 9.26 Favored 'General case' 0 CA--C 1.519 -0.22 0 CA-C-N 116.779 0.29 . . . . 0.0 110.369 179.94 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 43.1 t -57.42 -40.33 73.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 N-CA-C 109.251 -0.648 . . . . 0.0 109.251 178.766 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -66.09 -37.09 84.9 Favored 'General case' 0 N--CA 1.452 -0.34 0 CA-C-N 115.218 -0.901 . . . . 0.0 110.041 178.893 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 134' ' ' PHE . . . . . 0.418 ' CZ ' ' HA ' ' A' ' 172' ' ' ALA . 82.9 t80 -57.01 -50.76 71.74 Favored 'General case' 0 N--CA 1.45 -0.461 0 CA-C-N 115.919 -0.582 . . . . 0.0 109.99 179.254 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 135' ' ' ILE . . . . . 0.473 ' HA ' HG21 ' A' ' 138' ' ' VAL . 57.6 mt -58.13 -30.81 40.21 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.342 0 CA-C-N 115.668 -0.696 . . . . 0.0 109.779 179.161 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 136' ' ' GLY . . . . . 0.417 ' O ' ' HB3' ' A' ' 139' ' ' TYR . . . -65.48 -38.07 94.42 Favored Glycine 0 N--CA 1.447 -0.58 0 C-N-CA 120.224 -0.988 . . . . 0.0 110.966 178.438 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 137' ' ' LEU . . . . . 0.455 HD11 HD22 ' A' ' 105' ' ' ASN . 29.2 tp -69.32 -46.78 66.26 Favored 'General case' 0 C--N 1.331 -0.205 0 N-CA-C 110.449 -0.204 . . . . 0.0 110.449 179.399 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 138' ' ' VAL . . . . . 0.505 ' HA ' HD11 ' A' ' 141' ' ' LEU . 4.6 m -62.13 -31.89 52.85 Favored 'Isoleucine or valine' 0 C--O 1.234 0.255 0 N-CA-C 109.029 -0.73 . . . . 0.0 109.029 178.882 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 139' ' ' TYR . . . . . 0.417 ' HB3' ' O ' ' A' ' 136' ' ' GLY . 45.6 t80 -60.99 -37.2 81.62 Favored 'General case' 0 N--CA 1.453 -0.317 0 CA-C-N 115.176 -0.92 . . . . 0.0 108.879 178.053 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 140' ' ' TYR . . . . . 0.507 ' HB3' ' SD ' ' A' ' 145' ' ' MET . 24.0 m-85 -70.25 -35.22 73.65 Favored 'General case' 0 C--N 1.332 -0.168 0 CA-C-N 115.489 -0.778 . . . . 0.0 110.122 178.478 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 141' ' ' LEU . . . . . 0.505 HD11 ' HA ' ' A' ' 138' ' ' VAL . 96.1 mt -55.55 -39.83 71.12 Favored 'General case' 0 C--O 1.232 0.149 0 CA-C-N 115.976 -0.556 . . . . 0.0 110.156 179.343 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 2.3 t -104.05 0.15 10.19 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 115.775 -0.648 . . . . 0.0 110.953 179.889 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . -72.89 -148.81 0.97 Allowed Glycine 0 CA--C 1.519 0.33 0 C-N-CA 120.965 -0.636 . . . . 0.0 112.876 -179.726 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 144' ' ' PRO . . . . . . . . . . . . . 31.8 Cg_endo -63.73 -23.56 69.34 Favored 'Trans proline' 0 C--N 1.347 0.497 0 C-N-CA 122.629 2.22 . . . . 0.0 112.523 -179.901 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 145' ' ' MET . . . . . 0.558 ' HG2' HD23 ' A' ' 93' ' ' LEU . 84.2 mtp -53.57 -58.37 7.4 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.451 -179.81 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 146' ' ' THR . . . . . . . . . . . . . 7.4 t -60.65 -32.2 71.39 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.382 -0.372 . . . . 0.0 111.337 -179.831 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 40.5 mt-10 -66.71 -34.65 78.33 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.283 -0.417 . . . . 0.0 111.071 -179.993 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 148' ' ' SER . . . . . . . . . . . . . 47.0 t -69.58 -45.32 68.94 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.051 -179.641 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 149' ' ' ALA . . . . . 0.537 ' HB3' HG22 ' A' ' 156' ' ' ILE . . . -63.88 -38.84 92.59 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.464 -179.665 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 150' ' ' SER . . . . . 0.578 ' HA ' ' HB2' ' A' ' 157' ' ' LYS . 81.8 p -67.54 -2.53 6.73 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.295 -0.411 . . . . 0.0 111.059 -179.817 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 151' ' ' GLN . . . . . . . . . . . . . 49.4 mt-30 -119.72 -1.64 10.53 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.26 -0.427 . . . . 0.0 111.244 -179.967 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 37.7 mmt180 -81.65 -51.6 8.04 Favored 'General case' 0 C--N 1.332 -0.185 0 CA-C-O 120.945 0.403 . . . . 0.0 110.746 179.712 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 153' ' ' SER . . . . . 0.53 ' HB3' HG12 ' A' ' 156' ' ' ILE . 23.1 t -158.17 172.28 18.68 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-N 115.865 -0.607 . . . . 0.0 110.544 179.254 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 154' ' ' SER . . . . . . . . . . . . . 39.6 t -69.91 -39.87 75.92 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-O 120.871 0.367 . . . . 0.0 110.317 179.418 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -76.99 -42.39 20.02 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.943 -0.646 . . . . 0.0 112.659 179.808 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 156' ' ' ILE . . . . . 0.537 HG22 ' HB3' ' A' ' 149' ' ' ALA . 36.5 mm -48.86 -37.45 9.11 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.162 0 CA-C-O 120.863 0.363 . . . . 0.0 111.495 -179.778 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 157' ' ' LYS . . . . . 0.578 ' HB2' ' HA ' ' A' ' 150' ' ' SER . 54.8 tttm -67.72 -36.36 80.46 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.277 -179.712 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 43.3 t -71.8 -42.22 67.32 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.658 -179.378 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 159' ' ' LEU . . . . . 0.412 ' O ' ' HB2' ' A' ' 163' ' ' LEU . 10.7 mp -67.42 -35.23 78.86 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.342 -0.39 . . . . 0.0 111.74 -179.372 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 160' ' ' TYR . . . . . . . . . . . . . 23.8 t80 -72.78 -46.84 51.19 Favored 'General case' 0 C--N 1.33 -0.274 0 N-CA-C 112.179 0.437 . . . . 0.0 112.179 -178.676 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 161' ' ' VAL . . . . . 0.412 HG21 ' N ' ' A' ' 162' ' ' ARG . 24.6 m -62.98 -45.95 97.55 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 N-CA-C 112.353 0.501 . . . . 0.0 112.353 -178.952 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 162' ' ' ARG . . . . . 0.412 ' N ' HG21 ' A' ' 161' ' ' VAL . 36.2 mmt180 -66.33 -42.71 87.79 Favored 'General case' 0 C--N 1.328 -0.329 0 N-CA-C 111.807 0.299 . . . . 0.0 111.807 -179.141 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 163' ' ' LEU . . . . . 0.467 ' HG ' ' HB2' ' A' ' 208' ' ' PHE . 6.1 mp -71.45 -43.86 65.87 Favored 'General case' 0 C--N 1.329 -0.297 0 N-CA-C 111.957 0.354 . . . . 0.0 111.957 -179.251 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 164' ' ' ARG . . . . . 0.472 ' HG3' ' N ' ' A' ' 165' ' ' ASN . 5.6 ppt_? -68.38 -40.71 81.29 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 120.456 0.169 . . . . 0.0 111.073 -179.374 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 165' ' ' ASN . . . . . 0.472 ' N ' ' HG3' ' A' ' 164' ' ' ARG . 0.9 OUTLIER -58.89 -48.0 82.96 Favored 'General case' 0 C--N 1.332 -0.19 0 CA-C-O 120.945 0.403 . . . . 0.0 110.558 179.35 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 166' ' ' LEU . . . . . 0.518 ' O ' ' HG ' ' A' ' 170' ' ' LEU . 4.1 tt -63.69 -48.39 77.32 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 116.109 -0.496 . . . . 0.0 111.017 -179.958 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 167' ' ' THR . . . . . 0.432 ' O ' ' HB2' ' A' ' 171' ' ' TRP . 93.0 m -57.4 -53.91 52.74 Favored 'General case' 0 C--N 1.33 -0.251 0 N-CA-C 112.426 0.528 . . . . 0.0 112.426 -178.971 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 168' ' ' VAL . . . . . 0.485 ' HB ' HD13 ' A' ' 141' ' ' LEU . 12.9 p -55.95 -40.75 64.6 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 N-CA-C 112.335 0.494 . . . . 0.0 112.335 -179.281 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 169' ' ' VAL . . . . . 0.44 HG22 ' O ' ' A' ' 165' ' ' ASN . 61.2 t -57.71 -65.8 0.39 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.389 0 N-CA-C 111.987 0.366 . . . . 0.0 111.987 -179.518 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 170' ' ' LEU . . . . . 0.518 ' HG ' ' O ' ' A' ' 166' ' ' LEU . 0.8 OUTLIER -65.18 -27.75 68.92 Favored 'General case' 0 C--N 1.331 -0.212 0 N-CA-C 112.146 0.425 . . . . 0.0 112.146 -178.813 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 171' ' ' TRP . . . . . 0.522 ' HE1' H203 ' A' ' 301' ' ' RET . 6.9 m0 -71.77 -30.23 65.35 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.83 0.348 . . . . 0.0 110.612 179.615 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 172' ' ' ALA . . . . . 0.418 ' HA ' ' CZ ' ' A' ' 134' ' ' PHE . . . -73.7 -6.77 48.93 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.768 179.997 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 173' ' ' ILE . . . . . 0.542 HG21 HD13 ' A' ' 177' ' ' ILE . 23.6 mm -87.43 -21.63 7.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 115.93 -0.577 . . . . 0.0 110.771 179.739 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 174' ' ' TYR . . . . . 0.401 ' HD2' ' HA ' ' A' ' 171' ' ' TRP . 24.3 m-85 -54.86 -49.55 91.18 Favored Pre-proline 0 N--CA 1.464 0.228 0 CA-C-N 116.287 -0.415 . . . . 0.0 111.833 -179.796 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 175' ' ' PRO . . . . . . . . . . . . . 88.6 Cg_exo -47.02 -29.27 8.34 Favored 'Trans proline' 0 C--N 1.352 0.756 0 C-N-CA 122.131 1.887 . . . . 0.0 112.161 179.894 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 176' ' ' PHE . . . . . 0.426 ' O ' ' HG ' ' A' ' 180' ' ' LEU . 81.8 m-85 -80.47 -46.76 15.36 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 115.918 -0.583 . . . . 0.0 111.757 -179.965 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 177' ' ' ILE . . . . . 0.542 HD13 HG21 ' A' ' 173' ' ' ILE . 2.0 mm -64.49 -38.41 82.52 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.54 0 CA-C-N 116.166 -0.47 . . . . 0.0 112.177 -178.299 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 178' ' ' TRP . . . . . 0.485 ' HH2' ' HB2' ' A' ' 123' ' ' ARG . 60.2 t90 -73.83 -41.98 61.54 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.91 0.386 . . . . 0.0 110.779 179.67 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 179' ' ' LEU . . . . . 0.493 HD11 HD23 ' A' ' 180' ' ' LEU . 1.7 tm? -66.27 -49.95 65.39 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.066 -0.516 . . . . 0.0 111.078 -179.622 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 180' ' ' LEU . . . . . 0.538 HD21 HD13 ' A' ' 187' ' ' LEU . 14.0 mt -78.21 -47.94 16.91 Favored 'General case' 0 C--N 1.329 -0.301 0 N-CA-C 112.038 0.384 . . . . 0.0 112.038 -179.22 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . -54.32 177.94 0.27 Allowed Glycine 0 C--N 1.337 0.6 0 C-N-CA 120.649 -0.786 . . . . 0.0 113.066 -179.701 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 182' ' ' PRO . . . . . 0.439 ' HB2' ' HD3' ' A' ' 183' ' ' PRO . 71.9 Cg_exo -48.13 -44.93 27.12 Favored 'Trans proline' 0 CA--C 1.536 0.598 0 C-N-CA 122.908 2.405 . . . . 0.0 113.764 -179.793 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 183' ' ' PRO . . . . . 0.439 ' HD3' ' HB2' ' A' ' 182' ' ' PRO . 50.6 Cg_exo -54.85 -13.68 6.6 Favored 'Trans proline' 0 C--N 1.355 0.906 0 C-N-CA 122.028 1.819 . . . . 0.0 113.017 -179.845 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 184' ' ' GLY . . . . . . . . . . . . . . . -115.5 -101.05 2.3 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.517 -0.849 . . . . 0.0 112.635 -179.776 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 185' ' ' VAL . . . . . . . . . . . . . 9.0 m -105.98 -5.35 9.97 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-O 120.904 0.383 . . . . 0.0 111.305 -179.803 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 186' ' ' ALA . . . . . 0.41 ' HB2' ' HA ' ' A' ' 182' ' ' PRO . . . 55.17 85.4 0.06 Allowed 'General case' 0 C--N 1.331 -0.203 0 CA-C-N 115.991 -0.549 . . . . 0.0 111.991 179.302 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 187' ' ' LEU . . . . . 0.538 HD13 HD21 ' A' ' 180' ' ' LEU . 16.7 mt -92.21 -49.5 6.15 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.512 179.146 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 188' ' ' LEU . . . . . . . . . . . . . 95.5 mt -96.61 -160.96 0.83 Allowed 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 115.698 -0.683 . . . . 0.0 110.635 -179.944 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 189' ' ' THR . . . . . . . . . . . . . 1.9 t -99.76 146.49 31.94 Favored Pre-proline 0 C--N 1.329 -0.318 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.855 179.951 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 190' ' ' PRO . . . . . . . . . . . . . 86.9 Cg_exo -46.76 -44.09 22.53 Favored 'Trans proline' 0 C--N 1.349 0.567 0 C-N-CA 122.698 2.266 . . . . 0.0 113.244 -179.417 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 191' ' ' THR . . . . . . . . . . . . . 7.9 t -58.85 -43.4 90.78 Favored 'General case' 0 C--N 1.328 -0.345 0 N-CA-C 111.899 0.333 . . . . 0.0 111.899 -179.286 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 192' ' ' VAL . . . . . . . . . . . . . 45.7 t -71.77 -50.71 36.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.633 -0.258 . . . . 0.0 111.402 -179.743 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 193' ' ' ASP . . . . . . . . . . . . . 30.5 t70 -55.23 -45.34 75.98 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.452 -0.34 . . . . 0.0 111.066 -179.848 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 194' ' ' VAL . . . . . . . . . . . . . 74.6 t -64.34 -35.55 74.51 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.944 179.706 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 195' ' ' ALA . . . . . . . . . . . . . . . -56.97 -48.59 78.02 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 116.577 -0.283 . . . . 0.0 111.211 179.726 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 196' ' ' LEU . . . . . 0.404 ' O ' ' HB3' ' A' ' 199' ' ' TYR . 97.5 mt -67.76 -40.82 84.02 Favored 'General case' 0 N--CA 1.462 0.169 0 CA-C-O 120.708 0.289 . . . . 0.0 110.687 179.696 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 197' ' ' ILE . . . . . 0.482 HD12 ' HB ' ' A' ' 177' ' ' ILE . 11.2 mm -57.83 -60.25 2.41 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.373 179.256 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 198' ' ' VAL . . . . . 0.401 ' O ' ' HB2' ' A' ' 202' ' ' LEU . 76.3 t -52.02 -33.96 16.86 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.452 0 CA-C-N 115.486 -0.779 . . . . 0.0 109.574 178.324 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 199' ' ' TYR . . . . . 0.404 ' HB3' ' O ' ' A' ' 196' ' ' LEU . 68.5 t80 -69.27 -37.98 78.15 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 115.353 -0.84 . . . . 0.0 110.365 179.889 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 200' ' ' LEU . . . . . . . . . . . . . 42.0 mt -62.35 -45.71 91.97 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 115.667 -0.697 . . . . 0.0 111.212 -179.56 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 201' ' ' ASP . . . . . . . . . . . . . 7.3 m-20 -71.07 -43.64 67.38 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.114 -179.659 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 202' ' ' LEU . . . . . 0.401 ' HB2' ' O ' ' A' ' 198' ' ' VAL . 1.1 tt -59.95 -30.25 68.95 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 115.884 -0.598 . . . . 0.0 111.411 -179.476 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 203' ' ' VAL . . . . . 0.408 ' O ' ' HA3' ' A' ' 207' ' ' GLY . 48.5 t -81.43 -36.84 15.04 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.293 -0.412 . . . . 0.0 111.552 -178.726 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 204' ' ' THR . . . . . . . . . . . . . 71.0 m -62.46 -54.99 31.94 Favored 'General case' 0 C--N 1.328 -0.365 0 C-N-CA 120.508 -0.477 . . . . 0.0 111.009 179.497 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 205' ' ' LYS . . . . . 0.572 ' HE2' ' HB1' ' A' ' 47' ' ' ALA . 50.5 mttp -67.84 -59.13 3.53 Favored 'General case' 0 C--N 1.33 -0.245 0 N-CA-C 112.529 0.566 . . . . 0.0 112.529 -178.495 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 59.9 t -70.42 -37.55 70.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 N-CA-C 112.168 0.433 . . . . 0.0 112.168 -178.609 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 207' ' ' GLY . . . . . 0.526 ' O ' HG13 ' A' ' 211' ' ' ILE . . . -64.0 -60.66 6.96 Favored Glycine 0 N--CA 1.452 -0.254 0 C-N-CA 120.438 -0.887 . . . . 0.0 113.359 -178.866 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 208' ' ' PHE . . . . . 0.467 ' HB2' ' HG ' ' A' ' 163' ' ' LEU . 0.1 OUTLIER -65.25 -26.91 68.31 Favored 'General case' 0 C--O 1.224 -0.289 0 CA-C-N 117.051 0.425 . . . . 0.0 111.064 -179.289 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 209' ' ' GLY . . . . . 0.527 ' O ' ' HB1' ' A' ' 212' ' ' ALA . . . -69.39 -32.7 71.99 Favored Glycine 0 N--CA 1.447 -0.588 0 N-CA-C 111.593 -0.603 . . . . 0.0 111.593 178.726 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 210' ' ' PHE . . . . . . . . . . . . . 2.0 m-85 -74.56 -48.28 27.74 Favored 'General case' 0 CA--C 1.513 -0.462 0 N-CA-C 108.159 -1.052 . . . . 0.0 108.159 178.343 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 211' ' ' ILE . . . . . 0.526 HG13 ' O ' ' A' ' 207' ' ' GLY . 5.5 mt -62.03 -28.63 44.77 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.594 0 N-CA-C 107.517 -1.29 . . . . 0.0 107.517 176.423 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 212' ' ' ALA . . . . . 0.527 ' HB1' ' O ' ' A' ' 209' ' ' GLY . . . -62.53 -41.14 98.68 Favored 'General case' 0 N--CA 1.447 -0.587 0 CA-C-N 114.527 -1.215 . . . . 0.0 109.915 179.394 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 213' ' ' LEU . . . . . 0.41 ' HG ' ' O ' ' A' ' 209' ' ' GLY . 74.0 mt -70.31 -46.71 63.7 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-N 115.027 -0.988 . . . . 0.0 111.712 -179.826 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 214' ' ' ASP . . . . . . . . . . . . . 10.9 t70 -51.16 -54.86 21.36 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 120.923 0.392 . . . . 0.0 111.278 -179.476 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 215' ' ' ALA . . . . . 0.406 ' HB1' HD13 ' A' ' 159' ' ' LEU . . . -58.7 -52.79 64.19 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-N 115.978 -0.555 . . . . 0.0 111.367 -179.718 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 216' ' ' ALA . . . . . . . . . . . . . . . -58.92 -33.23 70.33 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.333 -0.394 . . . . 0.0 111.619 -179.586 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 217' ' ' ALA . . . . . . . . . . . . . . . -64.05 -36.11 82.92 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 121.012 0.434 . . . . 0.0 110.36 179.893 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 218' ' ' THR . . . . . . . . . . . . . 94.1 m -72.09 -38.79 69.3 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 115.69 -0.686 . . . . 0.0 110.977 179.572 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 219' ' ' LEU . . . . . . . . . . . . . 54.3 mt -63.85 -33.7 76.27 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.163 -0.472 . . . . 0.0 111.018 -179.883 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 220' ' ' ARG . . . . . . . . . . . . . 45.9 mtp180 -83.64 -30.21 27.05 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.884 179.802 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 221' ' ' ALA . . . . . . . . . . . . . . . -72.24 -24.01 61.31 Favored 'General case' 0 C--N 1.331 -0.203 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.233 -179.992 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 222' ' ' GLU . . . . . . . . . . . . . 10.0 pt-20 -92.25 -26.66 18.05 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.987 0.422 . . . . 0.0 110.32 179.967 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 223' ' ' HIS . . . . . . . . . . . . . 77.5 m-70 62.17 -176.24 0.13 Allowed 'General case' 0 C--N 1.331 -0.206 0 CA-C-N 115.532 -0.758 . . . . 0.0 111.222 179.999 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 224' ' ' GLY . . . . . . . . . . . . . . . -159.95 129.1 2.11 Favored Glycine 0 N--CA 1.45 -0.372 0 C-N-CA 120.637 -0.792 . . . . 0.0 112.685 -179.904 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 225' ' ' GLU . . . . . . . . . . . . . 44.5 mt-10 59.93 101.41 0.02 OUTLIER 'General case' 0 C--N 1.331 -0.2 0 CA-C-O 120.976 0.417 . . . . 0.0 111.178 179.908 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 226' ' ' SER . . . . . . . . . . . . . 63.3 m -96.9 149.63 21.66 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 115.979 -0.555 . . . . 0.0 110.865 179.983 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 227' ' ' LEU . . . . . . . . . . . . . 71.6 mt -73.53 127.49 32.88 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.968 179.981 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 228' ' ' ALA . . . . . . . . . . . . . . . -105.79 -43.2 4.95 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.1 179.966 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 229' ' ' GLY . . . . . . . . . . . . . . . 170.62 -118.79 0.77 Allowed Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.681 -0.771 . . . . 0.0 112.726 -179.874 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 230' ' ' VAL . . . . . . . . . . . . . 50.8 t -72.27 140.71 17.59 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.197 0 CA-C-O 120.875 0.369 . . . . 0.0 111.213 -179.825 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 231' ' ' ASP . . . . . . . . . . . . . 6.0 p-10 -83.7 104.79 14.09 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.779 179.99 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 232' ' ' THR . . . . . . . . . . . . . 82.6 p -132.2 15.23 4.63 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.257 -179.867 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 233' ' ' ASP . . . . . . . . . . . . . 4.4 p30 -79.9 2.73 22.22 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.386 -0.37 . . . . 0.0 110.893 179.96 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 234' ' ' THR . . . . . . . . . . . . . 74.1 p -114.41 150.61 44.09 Favored Pre-proline 0 C--N 1.33 -0.254 0 CA-C-N 116.284 -0.416 . . . . 0.0 111.071 -179.998 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 235' ' ' PRO . . . . . . . . . . . . . 60.2 Cg_endo -72.19 -55.31 0.12 Allowed 'Trans proline' 0 C--N 1.347 0.456 0 C-N-CA 122.488 2.125 . . . . 0.0 112.605 -179.693 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 236' ' ' ALA . . . . . . . . . . . . . . . -82.12 173.47 12.12 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.353 -0.385 . . . . 0.0 111.464 -179.801 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 237' ' ' VAL . . . . . . . . . . . . . 11.5 p -144.09 141.15 24.85 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 115.948 -0.569 . . . . 0.0 110.855 179.939 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 238' ' ' ALA . . . . . . . . . . . . . . . -116.35 160.81 19.97 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.373 -0.376 . . . . 0.0 111.248 -179.791 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 239' ' ' ASP . . . . . . . . . . . . . 5.4 m-20 -94.01 164.06 13.24 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.854 -179.969 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 240' ' ' LEU . . . . . . . . . . . . . 2.4 pt? -155.26 4.14 0.2 Allowed 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.381 -0.372 . . . . 0.0 110.972 179.899 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 241' ' ' GLU . . . . . . . . . . . . . 43.9 mt-10 -126.18 129.6 49.32 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.736 179.953 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 242' ' ' HIS . . . . . . . . . . . . . 69.2 m80 -85.45 171.75 11.55 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.158 -179.646 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 243' ' ' HIS . . . . . . . . . . . . . 42.8 m80 62.01 109.04 0.02 OUTLIER 'General case' 0 C--N 1.332 -0.169 0 CA-C-N 115.895 -0.593 . . . . 0.0 111.408 179.79 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 244' ' ' HIS . . . . . . . . . . . . . 69.2 m80 -116.05 5.26 13.83 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.027 -0.533 . . . . 0.0 110.795 179.899 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 245' ' ' HIS . . . . . . . . . . . . . 61.4 m80 61.39 102.04 0.03 OUTLIER 'General case' 0 N--CA 1.462 0.163 0 CA-C-N 116.027 -0.533 . . . . 0.0 110.913 -179.914 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 246' ' ' HIS . . . . . . . . . . . . . 8.3 p80 -147.02 -178.56 6.27 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.266 -0.424 . . . . 0.0 110.971 -179.804 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 247' ' ' HIS . . . . . . . . . . . . . 58.6 t-80 . . . . . 0 C--O 1.249 1.046 0 CA-C-O 118.34 -0.838 . . . . 0.0 110.968 -179.931 . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 301' ' ' RET . . . . . 0.522 H203 ' HE1' ' A' ' 171' ' ' TRP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 1' ' ' MET . . . . . 0.595 ' HG2' ' H ' ' A' ' 3' ' ' GLY . 54.6 ttp . . . . . 0 N--CA 1.486 1.343 0 CA-C-O 120.794 0.33 . . . . 0.0 110.726 . . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 32.7 m -97.5 -7.25 9.37 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-N 116.268 -0.424 . . . . 0.0 111.389 -179.783 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 3' ' ' GLY . . . . . 0.595 ' H ' ' HG2' ' A' ' 1' ' ' MET . . . -72.43 -14.0 77.29 Favored Glycine 0 N--CA 1.452 -0.288 0 C-N-CA 120.814 -0.708 . . . . 0.0 112.532 -179.824 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 4' ' ' LEU . . . . . 0.411 ' HA ' HD21 ' A' ' 7' ' ' LEU . 70.9 mt -72.97 -36.13 67.04 Favored 'General case' 0 N--CA 1.449 -0.491 0 CA-C-O 120.878 0.371 . . . . 0.0 110.989 179.835 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 45.5 p -53.09 -37.84 62.03 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 115.877 -0.601 . . . . 0.0 111.874 -179.466 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 70.8 p -56.34 -40.54 74.61 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.438 -0.346 . . . . 0.0 111.579 -179.491 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 7' ' ' LEU . . . . . 0.473 HD23 ' HG1' ' A' ' 191' ' ' THR . 3.4 mm? -59.85 -52.49 65.21 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 116.402 -0.363 . . . . 0.0 110.967 179.997 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 8' ' ' PHE . . . . . . . . . . . . . 75.8 m-85 -58.5 -32.11 68.49 Favored 'General case' 0 C--N 1.331 -0.204 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.613 -179.907 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 9' ' ' TRP . . . . . 0.409 ' O ' HG12 ' A' ' 13' ' ' ILE . 17.1 m95 -67.19 -45.63 76.33 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.036 -0.529 . . . . 0.0 109.833 179.576 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 95.1 mt -58.1 -46.82 84.89 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 115.607 -0.724 . . . . 0.0 110.15 179.305 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -60.08 -34.56 84.3 Favored Glycine 0 N--CA 1.45 -0.415 0 C-N-CA 120.746 -0.74 . . . . 0.0 111.781 179.351 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -67.67 -30.4 69.93 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.767 0.317 . . . . 0.0 110.604 179.608 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 13' ' ' ILE . . . . . 0.409 HG12 ' O ' ' A' ' 9' ' ' TRP . 50.8 mm -67.35 -52.5 41.58 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.226 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.16 179.486 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -59.93 -34.67 84.13 Favored Glycine 0 N--CA 1.448 -0.503 0 C-N-CA 120.696 -0.764 . . . . 0.0 111.641 179.105 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 15' ' ' MET . . . . . 0.562 ' HE2' ' HD2' ' A' ' 205' ' ' LYS . 18.9 mmt -66.5 -40.42 89.24 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 120.666 0.269 . . . . 0.0 110.628 179.479 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -59.69 -40.46 87.92 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.313 -0.403 . . . . 0.0 110.149 179.353 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 60.5 t -61.4 -42.76 95.02 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.201 0 CA-C-N 116.058 -0.519 . . . . 0.0 110.53 179.34 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -69.36 -46.17 57.68 Favored Glycine 0 N--CA 1.452 -0.266 0 C-N-CA 120.793 -0.718 . . . . 0.0 111.927 179.626 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 24.6 m -50.69 -49.06 58.32 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-O 120.702 0.287 . . . . 0.0 111.249 -179.82 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 96.3 mt -72.06 -44.99 62.45 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 116.305 -0.407 . . . . 0.0 111.687 -179.85 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -59.78 -31.49 69.73 Favored 'General case' 0 C--N 1.329 -0.304 0 N-CA-C 112.095 0.405 . . . . 0.0 112.095 -179.007 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 12.8 m-85 -91.19 -30.71 16.51 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 120.667 0.27 . . . . 0.0 111.429 -179.329 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -72.89 -50.68 22.3 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.948 0.404 . . . . 0.0 111.341 -179.69 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 24' ' ' TRP . . . . . . . . . . . . . 3.6 t-105 -61.62 -38.51 87.91 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-N 115.784 -0.643 . . . . 0.0 111.069 -179.809 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -80.63 -24.19 39.22 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.718 0.294 . . . . 0.0 111.221 179.992 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -73.05 -43.03 41.94 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.722 -0.752 . . . . 0.0 112.577 179.976 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 12.2 ptp180 -66.98 -18.26 65.3 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 120.759 0.314 . . . . 0.0 111.085 -179.953 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 31.3 t70 -97.0 17.66 16.46 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-O 121.057 0.456 . . . . 0.0 110.686 -179.659 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -99.33 176.3 5.57 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 115.935 -0.575 . . . . 0.0 111.176 -179.914 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -104.63 167.08 15.21 Favored Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.805 -0.712 . . . . 0.0 112.419 -179.991 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 73.4 m -64.36 120.49 12.33 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 120.9 0.381 . . . . 0.0 110.772 -179.953 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 128.11 -50.19 0.9 Allowed Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.959 -0.638 . . . . 0.0 112.19 -179.78 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 11.8 mm-40 -89.65 -20.6 23.47 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 121.009 0.433 . . . . 0.0 110.502 179.674 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 34' ' ' ARG . . . . . . . . . . . . . 34.2 ttm180 -52.09 -29.23 20.65 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 115.66 -0.7 . . . . 0.0 111.363 -179.862 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 41.8 ttm180 -59.39 -40.54 86.92 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-O 120.759 0.314 . . . . 0.0 110.845 179.861 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 91.8 m-85 -71.04 -32.4 69.13 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.878 179.753 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 37' ' ' TYR . . . . . . . . . . . . . 61.0 m-85 -70.55 -54.7 11.09 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 116.055 -0.52 . . . . 0.0 111.243 -179.743 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 11.0 p -57.17 -36.5 51.93 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-O 120.914 0.388 . . . . 0.0 110.479 179.649 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 26.3 m -65.38 -45.2 85.03 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 115.896 -0.593 . . . . 0.0 110.565 179.474 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 40' ' ' LEU . . . . . 0.506 HD13 HD13 ' A' ' 43' ' ' ILE . 51.5 tp -65.6 -38.48 89.59 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 115.949 -0.568 . . . . 0.0 110.483 179.556 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 97.3 t -67.34 -34.34 68.32 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.446 0 CA-C-N 115.789 -0.641 . . . . 0.0 110.253 179.429 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . 0.417 ' O ' HG12 ' A' ' 46' ' ' ILE . . . -64.01 -46.59 90.96 Favored Glycine 0 N--CA 1.448 -0.545 0 CA-C-N 115.76 -0.655 . . . . 0.0 112.971 179.991 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 43' ' ' ILE . . . . . 0.506 HD13 HD13 ' A' ' 40' ' ' LEU . 39.4 pt -63.04 -44.03 99.36 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.217 0 CA-C-N 116.847 0.323 . . . . 0.0 111.659 -179.558 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 44' ' ' SER . . . . . 0.444 ' N ' HG13 ' A' ' 43' ' ' ILE . 72.1 m -66.62 -27.19 67.5 Favored 'General case' 0 C--N 1.332 -0.159 0 CA-C-O 120.911 0.386 . . . . 0.0 110.808 179.604 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -78.56 -49.74 6.48 Favored Glycine 0 CA--C 1.519 0.286 0 C-N-CA 121.036 -0.602 . . . . 0.0 113.306 -179.256 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 46' ' ' ILE . . . . . 0.643 HD13 HD12 ' A' ' 78' ' ' LEU . 7.7 pt -58.09 -44.02 86.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-O 120.848 0.356 . . . . 0.0 111.04 -179.588 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 47' ' ' ALA . . . . . 0.514 ' HB1' ' HE2' ' A' ' 205' ' ' LYS . . . -67.73 -39.01 84.31 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-O 120.794 0.331 . . . . 0.0 110.578 179.077 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 48' ' ' ALA . . . . . 0.493 ' HB3' ' HB3' ' A' ' 15' ' ' MET . . . -55.0 -48.01 73.88 Favored 'General case' 0 C--N 1.332 -0.18 0 CA-C-N 116.11 -0.496 . . . . 0.0 111.579 -179.888 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 49' ' ' VAL . . . . . 0.402 HG22 ' O ' ' A' ' 46' ' ' ILE . 28.7 m -67.78 -34.28 66.69 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.473 -0.33 . . . . 0.0 111.275 -179.548 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -63.7 -37.63 88.06 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-O 120.986 0.422 . . . . 0.0 111.132 179.627 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 33.4 m-85 -72.67 -34.56 67.3 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 116.082 -0.508 . . . . 0.0 110.516 -179.766 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -68.25 -42.76 79.21 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 115.979 -0.555 . . . . 0.0 111.056 179.566 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 53' ' ' VAL . . . . . 0.417 HG23 ' N ' ' A' ' 54' ' ' MET . 33.0 m -69.62 -43.75 80.08 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.126 0 CA-C-N 116.44 -0.346 . . . . 0.0 110.876 179.978 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 54' ' ' MET . . . . . 0.533 ' HG2' ' HG2' ' A' ' 71' ' ' PRO . 74.6 mtm -65.03 -34.19 77.83 Favored 'General case' 0 CA--C 1.519 -0.222 0 N-CA-C 109.582 -0.525 . . . . 0.0 109.582 178.955 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -65.97 -17.31 64.59 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.414 -0.812 . . . . 0.0 111.009 179.49 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 95.9 mt -100.08 8.61 43.81 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.339 -0.391 . . . . 0.0 111.0 179.952 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 74.26 20.91 79.55 Favored Glycine 0 N--CA 1.45 -0.371 0 C-N-CA 120.809 -0.71 . . . . 0.0 112.492 179.991 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 24.9 t -92.19 130.72 40.89 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-O 120.784 0.326 . . . . 0.0 110.903 179.884 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 94.0 0.73 65.76 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.855 -0.688 . . . . 0.0 112.753 -179.911 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 60' ' ' TRP . . . . . . . . . . . . . 13.0 m0 -75.21 111.15 10.17 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.76 0.314 . . . . 0.0 110.89 179.864 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 8.4 p -110.77 132.0 21.83 Favored Pre-proline 0 C--N 1.33 -0.271 0 CA-C-N 116.344 -0.389 . . . . 0.0 111.059 179.887 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 74.4 Cg_endo -76.25 147.18 29.13 Favored 'Trans proline' 0 C--N 1.349 0.576 0 C-N-CA 122.372 2.048 . . . . 0.0 112.229 179.742 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 93.9 t -141.51 91.98 0.55 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 115.996 -0.547 . . . . 0.0 111.181 -179.791 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . 58.04 -87.79 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.01 -0.541 . . . . 0.0 111.771 179.574 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 9.0 tp10 -118.08 -21.43 8.26 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.452 -0.34 . . . . 0.0 111.251 -179.59 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 66' ' ' ARG . . . . . . . . . . . . . 99.6 mtt180 -107.03 162.98 13.37 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.368 -0.378 . . . . 0.0 110.63 179.875 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 33.4 m -118.96 124.6 47.43 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.968 0.414 . . . . 0.0 111.455 -179.843 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 68' ' ' VAL . . . . . 0.482 HG22 ' HB3' ' A' ' 117' ' ' MET . 57.7 t -103.6 146.64 10.95 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.361 0 CA-C-N 115.815 -0.63 . . . . 0.0 110.645 179.744 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 69' ' ' PHE . . . . . . . . . . . . . 16.8 m-85 -107.79 112.19 24.72 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.399 -0.364 . . . . 0.0 110.039 -179.688 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 70' ' ' VAL . . . . . 0.591 ' N ' ' HD2' ' A' ' 71' ' ' PRO . 21.5 t -66.73 -48.83 52.13 Favored Pre-proline 0 C--N 1.323 -0.56 0 CA-C-N 116.047 -0.524 . . . . 0.0 111.953 -179.285 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 71' ' ' PRO . . . . . 0.591 ' HD2' ' N ' ' A' ' 70' ' ' VAL . 18.2 Cg_endo -59.8 -17.78 45.24 Favored 'Trans proline' 0 C--N 1.35 0.654 0 C-N-CA 122.279 1.986 . . . . 0.0 113.183 -179.64 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 72' ' ' ARG . . . . . 0.417 HH22 HG23 ' A' ' 194' ' ' VAL . 23.9 ttm180 -78.46 -55.82 4.92 Favored 'General case' 0 C--O 1.234 0.278 0 C-N-CA 120.961 -0.296 . . . . 0.0 111.621 -179.607 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 73' ' ' TYR . . . . . 0.467 ' O ' HG13 ' A' ' 77' ' ' ILE . 95.2 m-85 -70.47 -31.64 68.87 Favored 'General case' 0 C--N 1.329 -0.29 0 C-N-CA 120.89 -0.324 . . . . 0.0 110.482 -179.652 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 74' ' ' ILE . . . . . 0.508 ' HA ' HD12 ' A' ' 77' ' ' ILE . 0.3 OUTLIER -69.5 -39.29 78.36 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 N-CA-C 109.259 -0.645 . . . . 0.0 109.259 178.716 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 75' ' ' ASP . . . . . 0.436 ' O ' ' HG ' ' A' ' 78' ' ' LEU . 14.8 t70 -57.23 -37.38 72.19 Favored 'General case' 0 N--CA 1.452 -0.334 0 N-CA-C 109.113 -0.699 . . . . 0.0 109.113 178.461 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 76' ' ' TRP . . . . . 0.428 ' HA ' ' OG1' ' A' ' 79' ' ' THR . 44.7 m0 -70.26 -34.03 72.31 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 115.611 -0.722 . . . . 0.0 110.527 179.086 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 77' ' ' ILE . . . . . 0.525 ' HA ' ' HG3' ' A' ' 109' ' ' MET . 94.2 mt -58.45 -38.71 71.66 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.236 0 CA-C-N 116.285 -0.416 . . . . 0.0 111.022 179.781 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 78' ' ' LEU . . . . . 0.643 HD12 HD13 ' A' ' 46' ' ' ILE . 1.1 pp -91.52 -34.12 14.9 Favored 'General case' 0 CA--C 1.536 0.41 0 N-CA-C 113.205 0.817 . . . . 0.0 113.205 -179.643 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 79' ' ' THR . . . . . 0.454 HG21 HG13 ' A' ' 46' ' ' ILE . 52.1 p -76.09 -52.5 10.01 Favored 'General case' 0 N--CA 1.47 0.538 0 N-CA-C 113.316 0.858 . . . . 0.0 113.316 -178.314 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 80' ' ' THR . . . . . 0.532 ' N ' ' HD2' ' A' ' 81' ' ' PRO . 3.9 m -50.76 -48.94 82.1 Favored Pre-proline 0 CA--C 1.532 0.255 0 N-CA-C 112.961 0.726 . . . . 0.0 112.961 -178.162 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 81' ' ' PRO . . . . . 0.532 ' HD2' ' N ' ' A' ' 80' ' ' THR . 28.9 Cg_endo -61.37 -25.31 79.97 Favored 'Trans proline' 0 C--N 1.352 0.717 0 C-N-CA 121.549 1.499 . . . . 0.0 111.631 -179.885 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 82' ' ' LEU . . . . . 0.449 ' HB3' HG22 ' A' ' 43' ' ' ILE . 0.1 OUTLIER -74.43 -34.76 63.3 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 115.876 -0.602 . . . . 0.0 110.23 179.698 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 49.6 mm -67.46 -53.64 30.41 Favored 'Isoleucine or valine' 0 C--O 1.234 0.253 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.029 179.165 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 33.0 m -59.94 -30.03 44.55 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.255 0 CA-C-N 115.959 -0.564 . . . . 0.0 109.552 178.96 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 85' ' ' TYR . . . . . . . . . . . . . 89.8 t80 -67.35 -33.39 75.15 Favored 'General case' 0 N--CA 1.454 -0.275 0 CA-C-N 115.536 -0.757 . . . . 0.0 109.591 178.772 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 86' ' ' PHE . . . . . . . . . . . . . 8.3 t80 -61.81 -50.72 71.16 Favored 'General case' 0 C--O 1.234 0.259 0 CA-C-N 115.769 -0.651 . . . . 0.0 109.87 179.317 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 8.0 mp -60.91 -31.1 70.62 Favored 'General case' 0 C--N 1.332 -0.193 0 CA-C-N 115.872 -0.604 . . . . 0.0 110.232 179.617 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -70.89 -27.67 71.88 Favored Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.971 -0.633 . . . . 0.0 112.122 179.461 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 73.4 mt -71.55 -45.52 62.06 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-O 120.94 0.4 . . . . 0.0 110.514 179.934 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 90' ' ' LEU . . . . . 0.444 HD11 HD21 ' A' ' 163' ' ' LEU . 98.0 mt -54.48 -43.21 71.55 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 115.797 -0.638 . . . . 0.0 111.477 -179.918 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . 0.44 ' HB3' ' HB3' ' A' ' 148' ' ' SER . . . -78.6 -54.99 5.55 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 116.488 -0.324 . . . . 0.0 111.399 -179.748 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 105.23 63.96 0.65 Allowed Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.89 -0.672 . . . . 0.0 112.331 179.98 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 93' ' ' LEU . . . . . 0.513 HD21 ' HB3' ' A' ' 97' ' ' GLU . 7.4 mp -80.69 172.62 13.52 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.794 0.33 . . . . 0.0 111.032 -179.874 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 94' ' ' ASP . . . . . . . . . . . . . 14.2 m-20 -89.19 164.9 14.78 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.099 -0.5 . . . . 0.0 110.808 179.841 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 80.7 p -53.92 -34.54 59.85 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.113 -0.494 . . . . 0.0 111.086 -179.954 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 41.5 mmt180 -72.61 -48.4 40.02 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.374 -179.631 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 97' ' ' GLU . . . . . 0.513 ' HB3' HD21 ' A' ' 93' ' ' LEU . 42.3 mt-10 -54.94 -49.23 71.86 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 116.404 -0.362 . . . . 0.0 111.134 -179.837 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 98' ' ' PHE . . . . . 0.463 ' O ' HG12 ' A' ' 102' ' ' ILE . 33.0 m-85 -55.25 -49.94 70.74 Favored 'General case' 0 C--N 1.332 -0.175 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.689 179.755 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -54.42 -32.68 52.58 Favored Glycine 0 N--CA 1.452 -0.286 0 C-N-CA 120.93 -0.652 . . . . 0.0 112.694 -179.756 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 96.4 mt -69.54 -43.07 80.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-O 120.882 0.372 . . . . 0.0 111.629 -179.684 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 61.0 t -71.87 -40.58 68.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.325 -0.398 . . . . 0.0 111.989 -179.225 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 102' ' ' ILE . . . . . 0.463 HG12 ' O ' ' A' ' 98' ' ' PHE . 38.0 mm -68.78 -41.24 82.26 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.363 0 N-CA-C 111.954 0.353 . . . . 0.0 111.954 -179.097 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 12.4 t -64.93 -44.5 89.31 Favored 'General case' 0 C--O 1.234 0.247 0 CA-C-O 120.679 0.276 . . . . 0.0 111.314 -179.719 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 104' ' ' LEU . . . . . 0.407 ' O ' HG23 ' A' ' 108' ' ' VAL . 9.2 tt -58.47 -44.18 89.21 Favored 'General case' 0 C--N 1.332 -0.164 0 CA-C-O 120.813 0.339 . . . . 0.0 110.252 179.776 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 105' ' ' ASN . . . . . 0.58 HD22 HD13 ' A' ' 137' ' ' LEU . 0.9 OUTLIER -56.29 -41.63 76.21 Favored 'General case' 0 N--CA 1.455 -0.179 0 CA-C-N 116.149 -0.478 . . . . 0.0 109.857 178.852 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 85.2 m -54.71 -40.14 68.91 Favored 'General case' 0 C--N 1.332 -0.157 0 CA-C-N 116.075 -0.511 . . . . 0.0 110.269 179.508 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 0.9 OUTLIER -67.45 -37.4 78.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 115.843 -0.617 . . . . 0.0 110.189 179.114 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . 0.46 ' HB ' ' HE2' ' A' ' 109' ' ' MET . 64.4 t -65.72 -52.04 54.99 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-N 115.33 -0.85 . . . . 0.0 111.686 -179.471 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 109' ' ' MET . . . . . 0.525 ' HG3' ' HA ' ' A' ' 77' ' ' ILE . 5.4 mmt -61.33 -39.72 91.57 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.35 -0.386 . . . . 0.0 111.18 -179.514 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 21.6 tp -64.42 -31.59 72.87 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.339 -0.392 . . . . 0.0 110.436 179.762 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -62.94 -56.59 15.85 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.528 179.344 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . -60.58 -36.8 92.25 Favored Glycine 0 C--N 1.329 0.193 0 C-N-CA 120.445 -0.883 . . . . 0.0 111.813 179.483 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 113' ' ' PHE . . . . . . . . . . . . . 10.1 t80 -49.45 -63.04 1.22 Allowed 'General case' 0 C--N 1.331 -0.222 0 CA-C-O 121.119 0.485 . . . . 0.0 110.201 179.429 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -69.66 -28.1 65.6 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 115.562 -0.744 . . . . 0.0 111.189 179.591 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -52.18 -35.87 43.16 Favored Glycine 0 C--N 1.332 0.316 0 CA-C-N 116.061 -0.518 . . . . 0.0 112.785 179.907 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -78.13 -44.81 25.04 Favored 'General case' 0 C--N 1.329 -0.316 0 N-CA-C 112.132 0.419 . . . . 0.0 112.132 -179.862 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 117' ' ' MET . . . . . 0.482 ' HB3' HG22 ' A' ' 68' ' ' VAL . 15.7 ptp -85.58 19.72 2.32 Favored 'General case' 0 C--N 1.33 -0.243 0 N-CA-C 112.149 0.426 . . . . 0.0 112.149 -179.007 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 118' ' ' VAL . . . . . 0.536 HG23 ' HB3' ' A' ' 123' ' ' ARG . 8.8 m -57.87 146.34 67.89 Favored Pre-proline 0 C--N 1.328 -0.332 0 CA-C-N 116.807 -0.178 . . . . 0.0 111.253 179.618 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 119' ' ' PRO . . . . . . . . . . . . . 71.8 Cg_endo -75.56 -9.06 19.87 Favored 'Trans proline' 0 C--N 1.347 0.476 0 C-N-CA 122.574 2.183 . . . . 0.0 112.381 -179.88 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -172.35 -122.95 0.68 Allowed Glycine 0 C--N 1.331 0.277 0 C-N-CA 120.662 -0.78 . . . . 0.0 112.711 -179.98 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 50.5 pt -83.38 8.06 1.39 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.23 0 CA-C-O 120.827 0.346 . . . . 0.0 111.334 -179.915 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 122' ' ' GLU . . . . . 0.464 ' HB2' ' HB ' ' A' ' 118' ' ' VAL . 11.7 mm-40 -58.57 -19.03 34.74 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.086 179.993 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 123' ' ' ARG . . . . . 0.536 ' HB3' HG23 ' A' ' 118' ' ' VAL . 12.6 ptt180 -52.33 -30.95 30.98 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.062 -0.517 . . . . 0.0 111.494 -179.842 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 124' ' ' TYR . . . . . . . . . . . . . 24.7 m-85 -71.96 -32.54 67.37 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.378 -0.373 . . . . 0.0 111.116 -179.686 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 125' ' ' ALA . . . . . . . . . . . . . . . -68.88 -51.07 44.14 Favored 'General case' 0 C--O 1.235 0.321 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.939 179.626 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 2.9 mm? -54.99 -55.85 26.28 Favored 'General case' 0 CA--C 1.52 -0.209 0 CA-C-N 116.015 -0.539 . . . . 0.0 110.882 -179.827 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 127' ' ' PHE . . . . . 0.481 ' HZ ' ' HB3' ' A' ' 175' ' ' PRO . 7.8 t80 -65.33 -33.25 75.52 Favored 'General case' 0 N--CA 1.45 -0.435 0 CA-C-N 116.258 -0.428 . . . . 0.0 111.466 -179.065 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 128' ' ' GLY . . . . . . . . . . . . . . . -49.67 -45.3 38.89 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 119.816 -1.183 . . . . 0.0 110.623 179.009 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 129' ' ' MET . . . . . . . . . . . . . 0.6 OUTLIER -71.71 -38.89 70.46 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 115.072 -0.564 . . . . 0.0 110.356 178.881 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -67.05 -27.41 73.44 Favored Glycine 0 C--N 1.331 0.283 0 CA-C-N 115.897 -0.592 . . . . 0.0 113.002 -179.613 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -74.85 -53.23 9.46 Favored 'General case' 0 C--N 1.328 -0.348 0 N-CA-C 110.012 -0.366 . . . . 0.0 110.012 179.86 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 95.9 t -57.23 -39.83 69.86 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.234 0 CA-C-O 121.347 0.594 . . . . 0.0 109.458 178.507 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -70.39 -34.17 72.24 Favored 'General case' 0 N--CA 1.452 -0.344 0 CA-C-N 115.297 -0.865 . . . . 0.0 110.69 179.423 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 134' ' ' PHE . . . . . 0.513 ' HB2' H183 ' A' ' 301' ' ' RET . 50.2 t80 -55.4 -60.14 3.82 Favored 'General case' 0 N--CA 1.453 -0.304 0 CA-C-O 120.985 0.422 . . . . 0.0 110.164 179.689 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 135' ' ' ILE . . . . . 0.453 ' O ' HG21 ' A' ' 138' ' ' VAL . 0.0 OUTLIER -55.75 -34.74 37.24 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 115.764 -0.653 . . . . 0.0 109.854 178.975 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 136' ' ' GLY . . . . . 0.407 ' O ' ' HB3' ' A' ' 139' ' ' TYR . . . -58.1 -41.66 94.72 Favored Glycine 0 N--CA 1.449 -0.477 0 C-N-CA 120.389 -0.91 . . . . 0.0 111.488 178.777 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 137' ' ' LEU . . . . . 0.58 HD13 HD22 ' A' ' 105' ' ' ASN . 45.1 tp -66.05 -56.25 12.51 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-O 120.68 0.276 . . . . 0.0 110.446 179.215 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 138' ' ' VAL . . . . . 0.453 HG21 ' O ' ' A' ' 135' ' ' ILE . 2.7 m -55.12 -30.33 23.96 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.237 0 CA-C-O 121.134 0.492 . . . . 0.0 109.813 -179.994 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 139' ' ' TYR . . . . . 0.407 ' HB3' ' O ' ' A' ' 136' ' ' GLY . 12.2 t80 -61.8 -42.33 98.87 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 115.682 -0.69 . . . . 0.0 109.804 178.566 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 29.1 m-85 -69.29 -35.22 75.79 Favored 'General case' 0 C--N 1.333 -0.15 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.494 179.064 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 141' ' ' LEU . . . . . . . . . . . . . 11.0 mp -62.8 -27.22 69.16 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.502 179.578 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 142' ' ' VAL . . . . . 0.606 HG21 HH11 ' A' ' 164' ' ' ARG . 12.4 t -103.88 -11.6 9.28 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.226 0 CA-C-N 116.008 -0.542 . . . . 0.0 111.103 179.964 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . -76.66 -117.24 0.15 Allowed Glycine 0 CA--C 1.523 0.566 0 C-N-CA 120.937 -0.649 . . . . 0.0 113.115 -179.702 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 144' ' ' PRO . . . . . . . . . . . . . 47.2 Cg_endo -68.35 -23.51 38.2 Favored 'Trans proline' 0 C--N 1.35 0.638 0 C-N-CA 122.67 2.246 . . . . 0.0 113.195 -179.298 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 145' ' ' MET . . . . . 0.601 ' HB3' ' HH ' ' A' ' 160' ' ' TYR . 58.2 mtt -65.47 -30.27 71.03 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.676 0.274 . . . . 0.0 111.403 -179.775 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 146' ' ' THR . . . . . 0.41 ' OG1' ' HA ' ' A' ' 142' ' ' VAL . 82.9 m -81.16 -32.38 33.66 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.852 0.358 . . . . 0.0 111.345 -179.31 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 38.6 tt0 -75.92 -40.65 53.82 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.119 -179.919 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 148' ' ' SER . . . . . 0.44 ' HB3' ' HB3' ' A' ' 91' ' ' ALA . 46.0 t -70.3 -45.26 66.65 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.278 -0.419 . . . . 0.0 111.242 -179.473 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 149' ' ' ALA . . . . . . . . . . . . . . . -65.69 -32.33 73.82 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.27 -0.423 . . . . 0.0 111.416 -179.543 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 150' ' ' SER . . . . . . . . . . . . . 80.3 p -74.47 0.45 14.64 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.283 -0.417 . . . . 0.0 111.331 -179.717 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 151' ' ' GLN . . . . . . . . . . . . . 10.3 pt20 -136.3 9.84 3.22 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.54 -0.3 . . . . 0.0 110.996 179.787 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 1.5 tmt_? -83.84 -51.81 6.89 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-O 120.833 0.349 . . . . 0.0 110.435 179.997 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 153' ' ' SER . . . . . 0.644 ' HB2' HG12 ' A' ' 156' ' ' ILE . 20.8 m -157.54 172.47 18.5 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.024 -0.535 . . . . 0.0 110.507 179.314 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 154' ' ' SER . . . . . . . . . . . . . 48.1 t -73.05 -38.32 66.53 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.378 -0.374 . . . . 0.0 110.729 179.849 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -77.36 -27.55 59.4 Favored Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.944 -0.646 . . . . 0.0 112.718 179.993 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 156' ' ' ILE . . . . . 0.644 HG12 ' HB2' ' A' ' 153' ' ' SER . 38.1 mm -62.03 -35.44 68.52 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-O 120.799 0.333 . . . . 0.0 110.923 -179.944 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 157' ' ' LYS . . . . . . . . . . . . . 91.3 mttt -58.93 -55.55 33.75 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.067 -0.515 . . . . 0.0 111.617 -179.888 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 69.0 m -70.49 -38.58 74.38 Favored 'General case' 0 N--CA 1.463 0.21 0 N-CA-C 112.256 0.465 . . . . 0.0 112.256 -178.847 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 159' ' ' LEU . . . . . 0.421 HD12 HD11 ' A' ' 163' ' ' LEU . 39.0 tp -69.13 -36.25 77.26 Favored 'General case' 0 C--N 1.327 -0.411 0 N-CA-C 111.74 0.274 . . . . 0.0 111.74 -179.148 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 160' ' ' TYR . . . . . 0.601 ' HH ' ' HB3' ' A' ' 145' ' ' MET . 57.0 t80 -73.96 -46.11 46.05 Favored 'General case' 0 C--N 1.328 -0.366 0 N-CA-C 111.9 0.333 . . . . 0.0 111.9 -179.027 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 29.4 m -59.96 -41.73 87.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-O 120.721 0.296 . . . . 0.0 111.332 -179.634 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 162' ' ' ARG . . . . . 0.469 ' HG2' HG22 ' A' ' 211' ' ' ILE . 23.3 tpp180 -68.99 -39.89 79.11 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 120.944 0.402 . . . . 0.0 110.97 179.949 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 163' ' ' LEU . . . . . 0.535 ' HG ' ' HB2' ' A' ' 208' ' ' PHE . 4.5 mp -68.25 -44.32 75.9 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.069 -0.514 . . . . 0.0 111.668 -179.505 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 164' ' ' ARG . . . . . 0.606 HH11 HG21 ' A' ' 142' ' ' VAL . 18.4 ttp85 -72.01 -52.97 14.45 Favored 'General case' 0 C--N 1.329 -0.324 0 N-CA-C 112.125 0.417 . . . . 0.0 112.125 -179.003 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 165' ' ' ASN . . . . . 0.503 ' N ' HD21 ' A' ' 165' ' ' ASN . 0.9 OUTLIER -52.31 -46.31 65.93 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-O 121.056 0.455 . . . . 0.0 110.534 -179.291 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 166' ' ' LEU . . . . . 0.521 ' O ' ' HG ' ' A' ' 170' ' ' LEU . 6.8 tt -64.9 -52.08 58.45 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-N 115.809 -0.632 . . . . 0.0 111.141 179.955 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 167' ' ' THR . . . . . 0.479 ' O ' ' HB2' ' A' ' 171' ' ' TRP . 96.4 m -61.32 -54.09 48.34 Favored 'General case' 0 N--CA 1.463 0.185 0 N-CA-C 112.608 0.596 . . . . 0.0 112.608 -178.653 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 168' ' ' VAL . . . . . . . . . . . . . 94.0 t -52.2 -41.09 32.56 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.185 0 N-CA-C 112.134 0.42 . . . . 0.0 112.134 -179.284 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 169' ' ' VAL . . . . . . . . . . . . . 43.9 t -61.96 -64.63 0.6 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 N-CA-C 111.965 0.357 . . . . 0.0 111.965 -179.452 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 170' ' ' LEU . . . . . 0.521 ' HG ' ' O ' ' A' ' 166' ' ' LEU . 1.3 pp -62.55 -29.37 70.52 Favored 'General case' 0 C--N 1.331 -0.206 0 N-CA-C 112.081 0.4 . . . . 0.0 112.081 -178.777 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 171' ' ' TRP . . . . . 0.656 ' HE1' H203 ' A' ' 301' ' ' RET . 2.7 m0 -72.87 -30.78 64.25 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.842 0.353 . . . . 0.0 110.737 179.83 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 172' ' ' ALA . . . . . 0.403 ' HA ' ' CZ ' ' A' ' 134' ' ' PHE . . . -73.65 -6.21 45.29 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-O 121.093 0.473 . . . . 0.0 110.286 179.647 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 173' ' ' ILE . . . . . 0.464 ' O ' HG12 ' A' ' 177' ' ' ILE . 44.1 mm -85.14 -20.93 8.07 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.241 0 CA-C-N 115.678 -0.692 . . . . 0.0 110.484 179.148 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 174' ' ' TYR . . . . . . . . . . . . . 13.2 m-85 -53.21 -50.07 84.4 Favored Pre-proline 0 N--CA 1.464 0.268 0 CA-C-N 116.126 -0.488 . . . . 0.0 111.18 -179.867 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 175' ' ' PRO . . . . . 0.481 ' HB3' ' HZ ' ' A' ' 127' ' ' PHE . 93.1 Cg_exo -45.17 -33.07 7.78 Favored 'Trans proline' 0 C--N 1.351 0.684 0 C-N-CA 122.252 1.968 . . . . 0.0 112.152 179.308 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 176' ' ' PHE . . . . . 0.488 ' O ' ' HG ' ' A' ' 180' ' ' LEU . 85.4 m-85 -80.82 -50.12 10.23 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 115.772 -0.649 . . . . 0.0 112.023 -179.618 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 177' ' ' ILE . . . . . 0.464 HG12 ' O ' ' A' ' 173' ' ' ILE . 4.1 mm -63.42 -35.03 70.8 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.547 0 N-CA-C 112.546 0.573 . . . . 0.0 112.546 -177.867 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 178' ' ' TRP . . . . . . . . . . . . . 73.5 t90 -73.87 -52.37 13.2 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-O 120.887 0.375 . . . . 0.0 110.856 179.87 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 179' ' ' LEU . . . . . 0.436 ' O ' ' HA3' ' A' ' 184' ' ' GLY . 0.5 OUTLIER -64.83 -54.34 32.55 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.079 -0.51 . . . . 0.0 111.677 -179.004 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 180' ' ' LEU . . . . . 0.488 ' HG ' ' O ' ' A' ' 176' ' ' PHE . 27.9 mt -64.32 -49.09 73.09 Favored 'General case' 0 C--N 1.326 -0.448 0 C-N-CA 120.812 -0.355 . . . . 0.0 111.201 -179.529 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . -57.38 179.93 0.77 Allowed Glycine 0 C--N 1.338 0.651 0 C-N-CA 120.284 -0.96 . . . . 0.0 112.37 179.511 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 182' ' ' PRO . . . . . 0.627 ' HA ' ' HB2' ' A' ' 186' ' ' ALA . 89.0 Cg_exo -46.99 -45.04 21.89 Favored 'Trans proline' 0 CA--C 1.536 0.593 0 C-N-CA 122.969 2.446 . . . . 0.0 113.994 -179.657 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 183' ' ' PRO . . . . . 0.435 ' HD3' ' HB2' ' A' ' 182' ' ' PRO . 88.4 Cg_exo -48.14 -25.29 6.55 Favored 'Trans proline' 0 C--N 1.354 0.845 0 C-N-CA 122.303 2.002 . . . . 0.0 113.762 -179.509 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 184' ' ' GLY . . . . . 0.436 ' HA3' ' O ' ' A' ' 179' ' ' LEU . . . -112.86 -81.63 1.1 Allowed Glycine 0 C--N 1.334 0.437 0 C-N-CA 120.098 -1.049 . . . . 0.0 113.617 -179.443 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 185' ' ' VAL . . . . . . . . . . . . . 14.5 m -120.86 -8.6 10.27 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.203 0 N-CA-C 112.17 0.433 . . . . 0.0 112.17 -178.696 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 186' ' ' ALA . . . . . 0.627 ' HB2' ' HA ' ' A' ' 182' ' ' PRO . . . 57.56 85.9 0.08 Allowed 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.494 -0.321 . . . . 0.0 111.714 179.562 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 187' ' ' LEU . . . . . 0.484 HD13 HD22 ' A' ' 180' ' ' LEU . 17.9 mt -91.99 -49.33 6.28 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-O 120.963 0.411 . . . . 0.0 110.695 179.518 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 188' ' ' LEU . . . . . . . . . . . . . 86.2 mt -95.87 -158.39 0.65 Allowed 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 115.807 -0.633 . . . . 0.0 110.792 -179.766 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 189' ' ' THR . . . . . 0.475 HG22 HG22 ' A' ' 191' ' ' THR . 24.9 m -91.38 136.91 26.38 Favored Pre-proline 0 C--N 1.327 -0.378 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.566 -179.885 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 190' ' ' PRO . . . . . 0.43 ' O ' HG22 ' A' ' 194' ' ' VAL . 93.7 Cg_exo -44.35 -53.63 4.69 Favored 'Trans proline' 0 C--N 1.351 0.68 0 C-N-CA 122.559 2.172 . . . . 0.0 113.094 -179.786 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 191' ' ' THR . . . . . 0.475 HG22 HG22 ' A' ' 189' ' ' THR . 3.0 t -56.81 -36.8 70.34 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.703 0.287 . . . . 0.0 111.455 -179.721 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 192' ' ' VAL . . . . . 0.425 HG22 ' HB ' ' A' ' 189' ' ' THR . 92.7 t -70.46 -42.06 78.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.423 -0.353 . . . . 0.0 110.982 179.952 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 193' ' ' ASP . . . . . . . . . . . . . 24.8 t70 -61.6 -40.17 93.82 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.468 179.743 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 194' ' ' VAL . . . . . 0.43 HG22 ' O ' ' A' ' 190' ' ' PRO . 99.9 t -65.11 -35.88 76.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.026 -0.534 . . . . 0.0 110.229 179.323 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 195' ' ' ALA . . . . . . . . . . . . . . . -57.7 -48.4 79.66 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.846 179.48 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 196' ' ' LEU . . . . . . . . . . . . . 92.5 mt -67.9 -43.22 79.78 Favored 'General case' 0 C--N 1.332 -0.176 0 CA-C-N 116.417 -0.356 . . . . 0.0 110.816 179.634 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 197' ' ' ILE . . . . . 0.431 HD13 ' HA ' ' A' ' 197' ' ' ILE . 14.7 mm -57.86 -57.69 9.43 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.075 -0.511 . . . . 0.0 110.632 179.56 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 198' ' ' VAL . . . . . . . . . . . . . 74.7 t -55.15 -34.16 31.83 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.5 0 N-CA-C 109.078 -0.712 . . . . 0.0 109.078 178.317 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 199' ' ' TYR . . . . . . . . . . . . . 62.7 t80 -69.48 -30.66 68.59 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 115.205 -0.907 . . . . 0.0 110.62 179.843 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 200' ' ' LEU . . . . . 0.478 ' O ' HG13 ' A' ' 203' ' ' VAL . 32.1 mt -69.61 -47.69 62.63 Favored 'General case' 0 C--N 1.332 -0.153 0 CA-C-N 116.099 -0.5 . . . . 0.0 111.584 -179.56 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 201' ' ' ASP . . . . . . . . . . . . . 4.7 m-20 -70.62 -39.63 73.62 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-O 121.29 0.567 . . . . 0.0 110.192 179.757 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 202' ' ' LEU . . . . . . . . . . . . . 59.8 tp -71.13 -26.75 63.15 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 115.343 -0.844 . . . . 0.0 111.951 -179.292 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 203' ' ' VAL . . . . . 0.478 HG13 ' O ' ' A' ' 200' ' ' LEU . 9.3 p -79.34 -35.73 17.34 Favored 'Isoleucine or valine' 0 C--O 1.226 -0.153 0 C-N-CA 121.005 -0.278 . . . . 0.0 110.805 -179.483 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 204' ' ' THR . . . . . . . . . . . . . 95.8 m -65.71 -58.89 4.62 Favored 'General case' 0 C--N 1.329 -0.31 0 C-N-CA 120.748 -0.381 . . . . 0.0 110.797 179.33 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 205' ' ' LYS . . . . . 0.562 ' HD2' ' HE2' ' A' ' 15' ' ' MET . 60.9 mttp -58.17 -57.29 13.53 Favored 'General case' 0 C--N 1.329 -0.296 0 N-CA-C 112.061 0.393 . . . . 0.0 112.061 -178.9 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 59.8 t -71.04 -37.35 67.15 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.365 0 N-CA-C 112.326 0.491 . . . . 0.0 112.326 -178.702 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 207' ' ' GLY . . . . . 0.518 ' O ' HG13 ' A' ' 211' ' ' ILE . . . -58.07 -61.86 6.94 Favored Glycine 0 CA--C 1.518 0.267 0 C-N-CA 120.658 -0.782 . . . . 0.0 113.966 -178.605 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 208' ' ' PHE . . . . . 0.535 ' HB2' ' HG ' ' A' ' 163' ' ' LEU . 2.1 p90 -72.93 -27.36 61.81 Favored 'General case' 0 C--O 1.222 -0.38 0 CA-C-N 117.48 0.64 . . . . 0.0 110.75 -179.308 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 209' ' ' GLY . . . . . 0.493 ' O ' ' HB3' ' A' ' 212' ' ' ALA . . . -63.34 -34.17 89.23 Favored Glycine 0 N--CA 1.449 -0.473 0 N-CA-C 111.786 -0.525 . . . . 0.0 111.786 178.65 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 210' ' ' PHE . . . . . . . . . . . . . 0.7 OUTLIER -72.75 -47.46 46.7 Favored 'General case' 0 CA--C 1.514 -0.425 0 N-CA-C 108.239 -1.023 . . . . 0.0 108.239 178.379 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 211' ' ' ILE . . . . . 0.518 HG13 ' O ' ' A' ' 207' ' ' GLY . 4.8 mt -62.91 -27.48 43.2 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.465 0 N-CA-C 107.632 -1.248 . . . . 0.0 107.632 176.588 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 212' ' ' ALA . . . . . 0.493 ' HB3' ' O ' ' A' ' 209' ' ' GLY . . . -61.86 -41.67 98.12 Favored 'General case' 0 N--CA 1.45 -0.45 0 CA-C-N 114.436 -1.256 . . . . 0.0 110.622 -179.846 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 213' ' ' LEU . . . . . . . . . . . . . 99.1 mt -66.56 -50.39 63.29 Favored 'General case' 0 C--N 1.331 -0.202 0 CA-C-N 115.345 -0.843 . . . . 0.0 111.255 -179.872 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 214' ' ' ASP . . . . . . . . . . . . . 25.8 t70 -56.08 -54.41 45.29 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.282 -0.417 . . . . 0.0 111.152 -179.761 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 215' ' ' ALA . . . . . 0.401 ' O ' ' HG ' ' A' ' 219' ' ' LEU . . . -57.44 -57.27 13.39 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.136 -0.484 . . . . 0.0 111.417 -179.865 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 216' ' ' ALA . . . . . . . . . . . . . . . -55.18 -33.48 63.04 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.353 -0.385 . . . . 0.0 111.331 -179.828 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 217' ' ' ALA . . . . . . . . . . . . . . . -61.72 -37.77 85.43 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 121.096 0.474 . . . . 0.0 110.129 179.426 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 218' ' ' THR . . . . . . . . . . . . . 98.4 m -76.92 -35.0 57.65 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 115.648 -0.705 . . . . 0.0 110.824 179.384 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 219' ' ' LEU . . . . . 0.401 ' HG ' ' O ' ' A' ' 215' ' ' ALA . 81.3 mt -60.1 -39.6 86.74 Favored 'General case' 0 C--N 1.332 -0.17 0 CA-C-O 120.926 0.393 . . . . 0.0 110.529 179.666 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 220' ' ' ARG . . . . . . . . . . . . . 8.6 ptm180 -83.52 -24.25 31.75 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.396 179.485 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 221' ' ' ALA . . . . . . . . . . . . . . . -75.51 -24.93 56.87 Favored 'General case' 0 C--N 1.331 -0.204 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.179 179.798 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 222' ' ' GLU . . . . . . . . . . . . . 9.7 pt-20 -92.13 -24.16 19.2 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 121.084 0.469 . . . . 0.0 110.101 179.882 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 223' ' ' HIS . . . . . . . . . . . . . 57.6 m-70 64.83 164.76 0.15 Allowed 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 115.338 -0.846 . . . . 0.0 111.244 179.91 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 224' ' ' GLY . . . . . . . . . . . . . . . -93.08 72.83 1.34 Allowed Glycine 0 N--CA 1.452 -0.283 0 C-N-CA 120.846 -0.693 . . . . 0.0 112.518 -179.887 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 225' ' ' GLU . . . . . . . . . . . . . 8.3 tp10 -96.3 141.48 29.59 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-O 120.782 0.325 . . . . 0.0 110.767 179.85 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 226' ' ' SER . . . . . . . . . . . . . 42.8 m -73.17 175.4 6.81 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.242 -0.436 . . . . 0.0 110.809 -179.987 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 227' ' ' LEU . . . . . . . . . . . . . 4.1 mm? -94.47 134.13 37.33 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.082 -0.508 . . . . 0.0 110.704 179.903 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 228' ' ' ALA . . . . . . . . . . . . . . . -97.56 8.99 43.63 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.193 179.996 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 229' ' ' GLY . . . . . . . . . . . . . . . -82.96 -56.46 2.73 Favored Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.567 -179.977 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 230' ' ' VAL . . . . . . . . . . . . . 16.3 m -117.84 174.1 4.22 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-O 120.835 0.35 . . . . 0.0 111.283 -179.891 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 231' ' ' ASP . . . . . . . . . . . . . 5.8 m-20 -132.88 102.89 5.81 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.107 -0.497 . . . . 0.0 111.049 -179.947 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 232' ' ' THR . . . . . . . . . . . . . 8.4 t -132.78 -32.4 1.26 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.145 -0.48 . . . . 0.0 111.017 179.597 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 233' ' ' ASP . . . . . . . . . . . . . 3.7 p30 -128.64 152.73 48.03 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.717 179.679 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 234' ' ' THR . . . . . . . . . . . . . 69.1 p -96.46 143.04 25.43 Favored Pre-proline 0 C--N 1.33 -0.279 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.973 179.965 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 235' ' ' PRO . . . . . . . . . . . . . 32.5 Cg_exo -60.64 166.65 9.55 Favored 'Trans proline' 0 C--N 1.347 0.475 0 C-N-CA 122.435 2.09 . . . . 0.0 112.243 179.945 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 236' ' ' ALA . . . . . . . . . . . . . . . -70.68 171.12 10.95 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.095 179.844 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 237' ' ' VAL . . . . . . . . . . . . . 61.0 t 64.1 120.76 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.332 -0.155 0 CA-C-N 116.01 -0.541 . . . . 0.0 111.433 179.873 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 238' ' ' ALA . . . . . . . . . . . . . . . -54.81 144.13 23.47 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 115.971 -0.559 . . . . 0.0 111.211 -179.867 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 239' ' ' ASP . . . . . . . . . . . . . 8.5 m-20 -67.58 114.76 6.49 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.98 -179.801 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 240' ' ' LEU . . . . . . . . . . . . . 96.0 mt -82.95 118.15 23.28 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.036 -0.529 . . . . 0.0 110.776 179.874 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 241' ' ' GLU . . . . . . . . . . . . . 39.6 tt0 -108.9 -32.07 7.42 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.112 -179.813 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 242' ' ' HIS . . . . . . . . . . . . . 19.5 p80 -69.11 -15.81 63.52 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.363 -0.381 . . . . 0.0 110.934 -179.884 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 243' ' ' HIS . . . . . . . . . . . . . 60.1 t-80 -169.29 111.83 0.5 Allowed 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.302 -0.408 . . . . 0.0 110.952 -179.998 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 244' ' ' HIS . . . . . . . . . . . . . 15.9 t-80 -110.11 -49.44 3.07 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.829 179.788 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 245' ' ' HIS . . . . . . . . . . . . . 19.0 t60 -124.47 141.09 52.35 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.752 179.921 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 246' ' ' HIS . . . . . . . . . . . . . 60.1 m80 -61.32 107.63 0.8 Allowed 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.92 179.926 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 247' ' ' HIS . . . . . . . . . . . . . 8.7 p80 . . . . . 0 C--O 1.248 1.008 0 CA-C-O 118.097 -0.954 . . . . 0.0 110.964 -179.98 . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 301' ' ' RET . . . . . 0.656 H203 ' HE1' ' A' ' 171' ' ' TRP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 94.2 mmm . . . . . 0 N--CA 1.486 1.353 0 CA-C-O 120.818 0.342 . . . . 0.0 111.004 . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 14.7 p -117.6 -15.26 9.21 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.22 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.98 -179.957 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -81.42 -44.22 8.09 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.727 -179.717 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 82.9 mt -59.2 -35.24 73.25 Favored 'General case' 0 N--CA 1.449 -0.483 0 CA-C-O 120.812 0.339 . . . . 0.0 111.273 -179.822 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 46.4 p -61.6 -34.91 76.44 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.11 -0.495 . . . . 0.0 111.795 -179.588 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 16.4 p -56.16 -35.64 67.41 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.333 -0.394 . . . . 0.0 111.507 -179.321 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 7' ' ' LEU . . . . . . . . . . . . . 3.6 mm? -61.81 -53.5 55.04 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.364 -0.38 . . . . 0.0 111.271 -179.752 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 8' ' ' PHE . . . . . 0.469 ' HB2' ' HB1' ' A' ' 55' ' ' ALA . 53.9 m-85 -59.18 -30.21 68.03 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.291 -0.413 . . . . 0.0 111.066 -179.631 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 9' ' ' TRP . . . . . . . . . . . . . 19.7 m95 -69.25 -46.76 66.5 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.345 -179.971 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 85.4 mt -62.3 -41.86 98.88 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 115.88 -0.6 . . . . 0.0 110.042 179.206 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -62.29 -33.72 86.96 Favored Glycine 0 N--CA 1.448 -0.509 0 C-N-CA 120.779 -0.724 . . . . 0.0 111.769 179.3 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -67.87 -34.48 76.76 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-O 120.84 0.352 . . . . 0.0 110.523 179.585 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 46.8 mm -62.68 -51.67 69.19 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.187 0 CA-C-N 116.029 -0.532 . . . . 0.0 110.505 179.451 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -60.18 -33.21 79.02 Favored Glycine 0 N--CA 1.449 -0.447 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.108 179.648 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 15' ' ' MET . . . . . 0.645 ' HE2' ' HD2' ' A' ' 205' ' ' LYS . 20.0 mmt -66.75 -47.05 73.44 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.624 0.25 . . . . 0.0 110.821 179.689 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -54.07 -42.14 68.95 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.301 179.583 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 79.6 t -61.26 -48.05 90.69 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-N 115.946 -0.57 . . . . 0.0 110.79 179.548 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -63.51 -46.34 92.67 Favored Glycine 0 C--N 1.331 0.272 0 C-N-CA 120.773 -0.727 . . . . 0.0 112.165 179.809 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 23.2 m -49.95 -43.19 49.86 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 120.726 0.298 . . . . 0.0 111.114 -179.644 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 81.8 mt -71.93 -47.06 55.15 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.284 -0.416 . . . . 0.0 111.446 179.905 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -57.61 -29.9 64.89 Favored 'General case' 0 C--N 1.33 -0.272 0 N-CA-C 111.982 0.364 . . . . 0.0 111.982 -179.525 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 22' ' ' PHE . . . . . 0.454 ' HB2' HG22 ' A' ' 41' ' ' VAL . 9.5 m-85 -89.42 -41.12 12.27 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.531 -0.304 . . . . 0.0 111.594 -179.097 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -65.58 -50.39 65.31 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.828 0.347 . . . . 0.0 111.38 -179.729 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 24' ' ' TRP . . . . . . . . . . . . . 1.1 t-105 -57.92 -50.3 73.81 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.078 -0.51 . . . . 0.0 111.057 179.884 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -69.66 -23.46 63.47 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.284 -0.416 . . . . 0.0 111.221 -179.911 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -73.42 -42.65 40.71 Favored Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.808 -0.71 . . . . 0.0 112.651 179.92 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 18.5 mmm180 -61.42 -22.16 64.76 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-O 120.799 0.333 . . . . 0.0 110.991 -179.989 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 13.7 t70 -116.6 97.3 5.92 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.074 -0.512 . . . . 0.0 110.702 179.974 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -160.92 -66.26 0.06 Allowed 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.134 -179.833 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 160.5 -138.66 5.63 Favored Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.865 -0.683 . . . . 0.0 112.449 -179.937 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 58.1 m -119.98 125.89 49.49 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.808 0.337 . . . . 0.0 110.824 179.987 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 105.41 -53.48 0.65 Allowed Glycine 0 N--CA 1.452 -0.258 0 C-N-CA 120.875 -0.679 . . . . 0.0 112.603 179.925 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 12.9 mm-40 -63.68 -24.31 67.73 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.835 0.35 . . . . 0.0 110.729 179.981 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 34' ' ' ARG . . . . . . . . . . . . . 75.6 ttt180 -50.56 -30.45 13.16 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 115.905 -0.588 . . . . 0.0 111.694 -179.77 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 88.2 mtm180 -59.24 -52.62 64.88 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.487 -0.324 . . . . 0.0 111.604 -179.677 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 86.3 m-85 -58.89 -27.58 65.36 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.51 -179.618 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 37' ' ' TYR . . . . . . . . . . . . . 72.7 m-85 -77.96 -53.81 7.02 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-N 116.292 -0.413 . . . . 0.0 111.08 -179.642 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 86.6 t -56.78 -36.9 50.86 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-O 121.024 0.44 . . . . 0.0 110.292 179.634 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 99.3 m -63.06 -50.52 70.28 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 115.759 -0.655 . . . . 0.0 110.164 179.153 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 40' ' ' LEU . . . . . 0.413 ' O ' HG13 ' A' ' 43' ' ' ILE . 53.7 tp -56.36 -43.46 79.18 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 115.441 -0.8 . . . . 0.0 110.252 179.44 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . 0.454 HG22 ' HB2' ' A' ' 22' ' ' PHE . 97.3 t -63.77 -34.35 67.52 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.253 0 CA-C-N 115.708 -0.678 . . . . 0.0 109.648 178.731 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -60.46 -35.34 88.6 Favored Glycine 0 N--CA 1.448 -0.524 0 CA-C-N 115.627 -0.715 . . . . 0.0 112.102 179.753 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 43' ' ' ILE . . . . . 0.584 HG23 ' HE3' ' A' ' 205' ' ' LYS . 0.3 OUTLIER -70.11 -57.77 7.23 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.159 0 CA-C-O 120.646 0.26 . . . . 0.0 110.796 179.704 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 67.1 m -62.89 -20.28 65.0 Favored 'General case' 0 C--O 1.232 0.153 0 CA-C-N 116.406 -0.361 . . . . 0.0 111.315 -179.732 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -77.99 -57.52 3.45 Favored Glycine 0 N--CA 1.452 -0.25 0 C-N-CA 120.778 -0.725 . . . . 0.0 112.8 -179.598 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 23.8 pt -58.87 -36.14 59.87 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.213 0 CA-C-O 120.958 0.409 . . . . 0.0 110.969 179.925 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 47' ' ' ALA . . . . . 0.53 ' HB3' ' HE2' ' A' ' 205' ' ' LYS . . . -67.63 -45.46 75.28 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.067 -0.515 . . . . 0.0 111.26 179.832 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 48' ' ' ALA . . . . . 0.504 ' HB2' ' HB3' ' A' ' 15' ' ' MET . . . -55.1 -43.81 74.36 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.106 -0.497 . . . . 0.0 111.829 -179.578 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 35.9 m -73.37 -34.17 42.6 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.353 0 CA-C-N 116.332 -0.395 . . . . 0.0 111.519 -179.325 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -65.78 -35.09 79.73 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-O 120.924 0.393 . . . . 0.0 110.869 179.925 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 26.7 m-85 -73.33 -40.03 64.78 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-N 115.96 -0.564 . . . . 0.0 110.518 179.96 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -63.84 -44.7 92.39 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 115.938 -0.574 . . . . 0.0 111.258 179.848 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 53' ' ' VAL . . . . . 0.432 HG21 ' N ' ' A' ' 54' ' ' MET . 34.2 m -68.56 -48.97 69.42 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.226 0 CA-C-N 116.404 -0.362 . . . . 0.0 110.868 179.923 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 54' ' ' MET . . . . . 0.432 ' N ' HG21 ' A' ' 53' ' ' VAL . 7.1 ttp -62.77 -30.1 71.2 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.126 179.852 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 55' ' ' ALA . . . . . 0.469 ' HB1' ' HB2' ' A' ' 8' ' ' PHE . . . -65.55 -40.04 92.39 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 115.849 -0.614 . . . . 0.0 111.023 179.336 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 95.3 mt -73.23 2.77 6.71 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.022 -0.536 . . . . 0.0 111.092 -179.864 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 90.7 7.37 66.69 Favored Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.685 -0.769 . . . . 0.0 112.592 179.942 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 41.3 t -74.46 135.85 26.5 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-O 120.864 0.364 . . . . 0.0 110.869 179.895 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 83.92 -2.55 87.4 Favored Glycine 0 N--CA 1.452 -0.286 0 C-N-CA 120.942 -0.647 . . . . 0.0 112.903 179.988 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 60' ' ' TRP . . . . . . . . . . . . . 12.0 m0 -73.74 102.32 3.95 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.56 0.219 . . . . 0.0 110.931 179.63 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 7.6 p -115.13 124.25 30.52 Favored Pre-proline 0 CA--C 1.536 0.414 0 CA-C-N 116.559 -0.291 . . . . 0.0 111.208 179.794 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 14.2 Cg_exo -69.47 157.3 61.44 Favored 'Trans proline' 0 C--N 1.353 0.796 0 C-N-CA 122.783 2.322 . . . . 0.0 112.744 -179.725 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 76.5 t -144.13 94.63 0.47 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.223 0 CA-C-N 115.856 -0.611 . . . . 0.0 110.98 179.88 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . 59.51 -86.42 0.02 OUTLIER 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 116.088 -0.506 . . . . 0.0 111.503 179.789 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 11.1 tp10 -118.16 -26.88 6.22 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-N 116.526 -0.306 . . . . 0.0 111.261 -179.723 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 66' ' ' ARG . . . . . . . . . . . . . 17.4 ptp180 -107.69 153.76 22.46 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.46 -0.336 . . . . 0.0 110.443 179.903 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 60.4 m -105.88 141.52 37.15 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-O 121.047 0.451 . . . . 0.0 111.543 -179.521 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 68' ' ' VAL . . . . . 0.458 HG21 ' HG3' ' A' ' 117' ' ' MET . 33.0 m -119.89 146.37 24.77 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 115.725 -0.67 . . . . 0.0 110.367 179.537 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 69' ' ' PHE . . . . . . . . . . . . . 22.1 m-85 -109.0 112.44 24.63 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 116.318 -0.401 . . . . 0.0 110.066 -179.398 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 70' ' ' VAL . . . . . 0.47 ' HB ' ' HD3' ' A' ' 71' ' ' PRO . 3.2 t -63.78 -48.98 78.41 Favored Pre-proline 0 C--N 1.326 -0.441 0 CA-C-N 116.274 -0.421 . . . . 0.0 111.905 -179.126 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 71' ' ' PRO . . . . . 0.47 ' HD3' ' HB ' ' A' ' 70' ' ' VAL . 47.4 Cg_exo -56.9 -18.06 26.3 Favored 'Trans proline' 0 C--N 1.351 0.698 0 C-N-CA 122.289 1.993 . . . . 0.0 112.877 -179.606 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 68.2 ttt180 -70.95 -55.79 7.6 Favored 'General case' 0 C--O 1.236 0.362 0 CA-C-O 120.886 0.374 . . . . 0.0 111.559 -179.323 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 73' ' ' TYR . . . . . 0.449 ' O ' HG13 ' A' ' 77' ' ' ILE . 7.0 m-85 -70.64 -34.45 72.08 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.439 -0.346 . . . . 0.0 110.281 -179.497 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 74' ' ' ILE . . . . . 0.44 ' HA ' HD11 ' A' ' 77' ' ' ILE . 0.4 OUTLIER -68.01 -37.98 79.15 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.226 0 CA-C-N 116.334 -0.394 . . . . 0.0 110.013 179.322 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 8.1 t70 -58.02 -39.56 78.65 Favored 'General case' 0 CA--C 1.518 -0.259 0 N-CA-C 109.045 -0.724 . . . . 0.0 109.045 178.806 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 76' ' ' TRP . . . . . . . . . . . . . 39.0 m0 -67.06 -31.56 72.15 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 115.612 -0.722 . . . . 0.0 110.584 179.108 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 77' ' ' ILE . . . . . 0.526 ' HA ' ' HG3' ' A' ' 109' ' ' MET . 85.8 mt -66.71 -32.8 59.66 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.233 0 CA-C-N 116.284 -0.416 . . . . 0.0 111.035 179.468 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 21.5 mt -91.16 -17.47 26.04 Favored 'General case' 0 C--N 1.327 -0.41 0 N-CA-C 112.149 0.426 . . . . 0.0 112.149 -179.515 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 79' ' ' THR . . . . . 0.501 ' HG1' ' H ' ' A' ' 80' ' ' THR . 76.9 p -103.4 -52.65 2.96 Favored 'General case' 0 CA--C 1.532 0.275 0 N-CA-C 113.784 1.031 . . . . 0.0 113.784 -177.915 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 80' ' ' THR . . . . . 0.663 ' HB ' ' HD3' ' A' ' 81' ' ' PRO . 29.4 m -51.36 -54.86 34.12 Favored Pre-proline 0 CA--C 1.531 0.246 0 N-CA-C 112.478 0.547 . . . . 0.0 112.478 -178.508 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 81' ' ' PRO . . . . . 0.663 ' HD3' ' HB ' ' A' ' 80' ' ' THR . 36.9 Cg_exo -60.51 -20.93 66.41 Favored 'Trans proline' 0 C--N 1.351 0.683 0 C-N-CA 121.575 1.516 . . . . 0.0 111.368 179.763 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 82' ' ' LEU . . . . . 0.407 HD22 HG22 ' A' ' 43' ' ' ILE . 17.3 tp -76.91 -33.34 57.77 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 115.812 -0.631 . . . . 0.0 110.302 179.751 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 83' ' ' ILE . . . . . 0.423 HG13 H201 ' A' ' 301' ' ' RET . 48.9 mm -68.4 -52.06 40.91 Favored 'Isoleucine or valine' 0 C--O 1.233 0.221 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.055 179.109 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 34.5 m -61.86 -30.0 47.56 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.142 0 N-CA-C 109.545 -0.539 . . . . 0.0 109.545 178.728 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 85' ' ' TYR . . . . . . . . . . . . . 73.4 t80 -67.63 -33.35 74.78 Favored 'General case' 0 N--CA 1.454 -0.235 0 CA-C-N 115.546 -0.752 . . . . 0.0 109.615 178.873 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 86' ' ' PHE . . . . . . . . . . . . . 5.5 t80 -61.99 -51.67 67.11 Favored 'General case' 0 C--O 1.233 0.221 0 CA-C-N 115.697 -0.683 . . . . 0.0 109.822 179.204 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 8.7 mp -62.43 -29.5 70.55 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 115.755 -0.657 . . . . 0.0 110.101 179.476 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -71.49 -27.76 70.74 Favored Glycine 0 N--CA 1.449 -0.455 0 C-N-CA 120.799 -0.715 . . . . 0.0 111.569 179.237 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 72.6 mt -69.92 -45.57 67.24 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-O 121.074 0.464 . . . . 0.0 109.985 179.504 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 90' ' ' LEU . . . . . 0.438 ' HB3' HG21 ' A' ' 156' ' ' ILE . 64.7 mt -60.17 -30.43 69.33 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 115.582 -0.735 . . . . 0.0 110.741 179.616 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . 0.466 ' HA ' ' HA ' ' A' ' 149' ' ' ALA . . . -86.32 -29.44 23.02 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.264 -179.787 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 75.03 44.69 22.93 Favored Glycine 0 N--CA 1.452 -0.258 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.146 -179.902 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 93' ' ' LEU . . . . . 0.46 HD12 ' HE2' ' A' ' 145' ' ' MET . 30.1 mt -60.36 168.04 2.24 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.955 0.407 . . . . 0.0 111.206 -179.646 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 94' ' ' ASP . . . . . . . . . . . . . 5.5 m-20 -90.77 179.57 5.76 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 115.936 -0.575 . . . . 0.0 110.834 179.994 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 80.5 p -60.58 -42.83 97.48 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.906 -179.94 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 68.9 mtm180 -68.62 -49.77 56.6 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.108 -0.496 . . . . 0.0 111.027 -179.826 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 44.9 mt-10 -54.51 -47.6 72.9 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.335 -0.393 . . . . 0.0 111.033 -179.883 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 98' ' ' PHE . . . . . 0.429 ' O ' HG12 ' A' ' 102' ' ' ILE . 11.3 m-85 -60.29 -43.62 96.09 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.416 -0.357 . . . . 0.0 110.496 179.61 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -60.63 -27.53 66.37 Favored Glycine 0 N--CA 1.451 -0.358 0 C-N-CA 120.611 -0.804 . . . . 0.0 112.414 179.746 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 96.1 mt -73.9 -47.64 42.23 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.229 0 N-CA-C 111.875 0.324 . . . . 0.0 111.875 -179.537 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 27.7 m -69.49 -39.01 78.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 N-CA-C 111.731 0.271 . . . . 0.0 111.731 -179.353 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 102' ' ' ILE . . . . . 0.429 HG12 ' O ' ' A' ' 98' ' ' PHE . 43.3 mm -67.67 -46.55 82.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.55 -0.296 . . . . 0.0 111.347 -179.54 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 103' ' ' THR . . . . . 0.423 ' HA ' ' HG1' ' A' ' 106' ' ' THR . 14.7 t -62.42 -33.27 74.46 Favored 'General case' 0 C--O 1.233 0.187 0 CA-C-O 120.975 0.417 . . . . 0.0 110.404 179.643 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -58.84 -52.04 67.42 Favored 'General case' 0 C--N 1.332 -0.191 0 CA-C-N 115.995 -0.548 . . . . 0.0 109.528 179.248 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 105' ' ' ASN . . . . . 0.558 ' N ' HD21 ' A' ' 105' ' ' ASN . 0.8 OUTLIER -56.72 -35.45 68.56 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 115.736 -0.666 . . . . 0.0 110.53 179.455 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 106' ' ' THR . . . . . 0.423 ' HG1' ' HA ' ' A' ' 103' ' ' THR . 39.3 m -55.6 -50.9 68.88 Favored 'General case' 0 C--N 1.332 -0.169 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.996 179.918 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 0.9 OUTLIER -60.5 -39.67 81.97 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.223 0 CA-C-O 121.174 0.512 . . . . 0.0 110.39 179.6 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 81.0 t -63.66 -39.91 87.12 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-N 115.506 -0.77 . . . . 0.0 111.285 -179.821 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 109' ' ' MET . . . . . 0.526 ' HG3' ' HA ' ' A' ' 77' ' ' ILE . 28.6 mmt -67.17 -51.35 54.8 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.078 -0.51 . . . . 0.0 111.329 -179.568 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 21.1 tp -58.95 -34.73 72.09 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-N 115.96 -0.564 . . . . 0.0 110.927 -179.592 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -61.11 -57.09 13.98 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.18 -179.994 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 112' ' ' GLY . . . . . 0.503 ' HA3' ' H22' ' A' ' 301' ' ' RET . . . -67.23 -28.03 73.62 Favored Glycine 0 N--CA 1.45 -0.374 0 C-N-CA 120.724 -0.75 . . . . 0.0 112.143 179.68 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 113' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER -57.67 -75.09 0.05 OUTLIER 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 121.035 0.445 . . . . 0.0 110.132 179.817 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -61.45 -26.43 67.87 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 115.793 -0.639 . . . . 0.0 111.095 179.771 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -53.06 -50.07 52.97 Favored Glycine 0 C--N 1.331 0.28 0 C-N-CA 121.028 -0.606 . . . . 0.0 112.616 -179.974 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 116' ' ' ALA . . . . . 0.541 ' HB3' ' HB3' ' A' ' 183' ' ' PRO . . . -77.65 -16.42 58.54 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.672 0.272 . . . . 0.0 111.613 -179.739 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 117' ' ' MET . . . . . 0.458 ' HG3' HG21 ' A' ' 68' ' ' VAL . 29.7 ttm -101.85 19.22 18.69 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.407 -0.361 . . . . 0.0 111.341 -179.506 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 118' ' ' VAL . . . . . 0.545 HG22 ' HB3' ' A' ' 123' ' ' ARG . 21.4 m -70.15 145.49 93.75 Favored Pre-proline 0 C--N 1.33 -0.245 0 CA-C-N 116.432 -0.349 . . . . 0.0 111.502 179.982 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 119' ' ' PRO . . . . . . . . . . . . . 85.9 Cg_endo -93.4 15.8 1.33 Allowed 'Trans proline' 0 N--CA 1.456 -0.732 0 C-N-CA 122.997 2.465 . . . . 0.0 112.353 179.419 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -164.62 -120.38 0.52 Allowed Glycine 0 C--N 1.332 0.339 0 C-N-CA 120.66 -0.781 . . . . 0.0 112.674 -179.564 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 40.9 pt -114.68 9.84 7.74 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.232 0 CA-C-O 120.723 0.297 . . . . 0.0 111.493 -179.727 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 45.7 mt-10 -58.84 -18.08 29.48 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.304 -0.407 . . . . 0.0 110.699 179.725 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 123' ' ' ARG . . . . . 0.545 ' HB3' HG22 ' A' ' 118' ' ' VAL . 10.2 ptp180 -50.5 -33.24 20.65 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 115.794 -0.639 . . . . 0.0 111.642 -179.959 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 124' ' ' TYR . . . . . . . . . . . . . 19.3 m-85 -73.11 -32.63 65.07 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.428 -0.351 . . . . 0.0 111.513 -179.459 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 125' ' ' ALA . . . . . . . . . . . . . . . -74.32 -56.11 5.25 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.386 -0.37 . . . . 0.0 111.398 -179.492 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -55.09 -44.19 74.66 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.904 -179.931 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 127' ' ' PHE . . . . . . . . . . . . . 5.4 t80 -70.92 -37.21 72.89 Favored 'General case' 0 C--N 1.33 -0.279 0 C-N-CA 120.898 -0.321 . . . . 0.0 110.575 179.825 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 128' ' ' GLY . . . . . . . . . . . . . . . -46.79 -46.85 19.03 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.167 -1.016 . . . . 0.0 110.844 179.052 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 129' ' ' MET . . . . . . . . . . . . . 0.4 OUTLIER -69.69 -38.84 77.16 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 115.367 -0.417 . . . . 0.0 109.894 178.781 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -62.87 -29.3 73.71 Favored Glycine 0 C--N 1.333 0.38 0 CA-C-N 115.892 -0.595 . . . . 0.0 112.792 -179.893 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -74.29 -53.61 9.37 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 120.761 0.315 . . . . 0.0 110.317 179.871 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 28.3 t -58.03 -40.07 75.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 N-CA-C 109.321 -0.622 . . . . 0.0 109.321 178.741 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -68.64 -33.4 73.94 Favored 'General case' 0 N--CA 1.454 -0.259 0 CA-C-N 115.387 -0.824 . . . . 0.0 110.342 179.177 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 134' ' ' PHE . . . . . . . . . . . . . 44.1 t80 -57.77 -55.14 38.7 Favored 'General case' 0 N--CA 1.452 -0.34 0 CA-C-N 116.132 -0.486 . . . . 0.0 109.752 179.239 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 135' ' ' ILE . . . . . 0.432 ' O ' HG23 ' A' ' 138' ' ' VAL . 39.2 mt -57.69 -31.87 40.97 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 115.673 -0.694 . . . . 0.0 109.86 178.861 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . -64.19 -35.31 91.81 Favored Glycine 0 N--CA 1.448 -0.515 0 C-N-CA 120.488 -0.863 . . . . 0.0 111.577 179.13 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 137' ' ' LEU . . . . . . . . . . . . . 38.9 tp -73.44 -51.13 18.3 Favored 'General case' 0 C--N 1.331 -0.205 0 CA-C-O 120.628 0.252 . . . . 0.0 110.51 179.492 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 138' ' ' VAL . . . . . 0.432 HG23 ' O ' ' A' ' 135' ' ' ILE . 4.0 m -57.37 -30.96 37.04 Favored 'Isoleucine or valine' 0 C--O 1.233 0.208 0 N-CA-C 109.376 -0.601 . . . . 0.0 109.376 179.048 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 139' ' ' TYR . . . . . . . . . . . . . 24.9 t80 -66.19 -43.34 87.12 Favored 'General case' 0 C--N 1.332 -0.196 0 CA-C-N 115.324 -0.853 . . . . 0.0 110.15 178.706 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 140' ' ' TYR . . . . . 0.425 ' HB3' ' SD ' ' A' ' 145' ' ' MET . 11.9 m-85 -53.06 -51.62 61.22 Favored 'General case' 0 C--O 1.231 0.13 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.514 179.355 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 141' ' ' LEU . . . . . . . . . . . . . 70.5 mt -53.39 -53.56 49.39 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 115.726 -0.67 . . . . 0.0 111.213 -179.788 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 17.2 t -73.42 -11.29 14.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.113 -0.494 . . . . 0.0 111.334 -179.623 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . -71.45 -140.91 0.26 Allowed Glycine 0 CA--C 1.52 0.354 0 C-N-CA 120.832 -0.699 . . . . 0.0 112.635 -179.799 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 144' ' ' PRO . . . . . . . . . . . . . 32.2 Cg_endo -62.99 -23.25 74.08 Favored 'Trans proline' 0 C--N 1.347 0.493 0 C-N-CA 122.486 2.124 . . . . 0.0 112.121 -179.991 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 145' ' ' MET . . . . . 0.46 ' HE2' HD12 ' A' ' 93' ' ' LEU . 82.4 mtp -57.61 -27.9 63.18 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 116.024 -0.535 . . . . 0.0 110.975 179.921 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 146' ' ' THR . . . . . . . . . . . . . 60.0 m -71.89 -40.79 68.64 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.308 -0.406 . . . . 0.0 111.042 179.82 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 2.2 mp0 -74.25 -27.57 60.83 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.008 -179.835 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 148' ' ' SER . . . . . . . . . . . . . 49.1 m -70.19 -43.16 71.33 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.388 -0.369 . . . . 0.0 111.085 -179.882 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 149' ' ' ALA . . . . . 0.466 ' HA ' ' HA ' ' A' ' 91' ' ' ALA . . . -77.84 -44.08 28.41 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.845 -179.457 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 150' ' ' SER . . . . . . . . . . . . . 66.3 m -63.72 -21.97 66.67 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.388 -0.369 . . . . 0.0 111.443 -179.451 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 151' ' ' GLN . . . . . . . . . . . . . 78.7 mt-30 -106.87 6.49 29.41 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.51 -0.314 . . . . 0.0 111.298 -179.784 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 30.2 tpt180 -82.58 -50.31 8.92 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.437 -0.347 . . . . 0.0 110.729 179.823 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 153' ' ' SER . . . . . 0.515 ' HB2' HG13 ' A' ' 156' ' ' ILE . 45.8 m -154.55 149.34 26.59 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.824 179.267 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 154' ' ' SER . . . . . . . . . . . . . 42.7 t -55.24 -40.37 70.83 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.113 -0.494 . . . . 0.0 111.055 179.947 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -75.01 -35.93 48.23 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.79 -0.719 . . . . 0.0 112.562 179.994 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 156' ' ' ILE . . . . . 0.515 HG13 ' HB2' ' A' ' 153' ' ' SER . 68.9 mt -60.95 -36.22 70.58 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-O 120.707 0.289 . . . . 0.0 111.307 -179.948 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 157' ' ' LYS . . . . . . . . . . . . . 88.6 tttt -52.9 -45.66 67.64 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-N 116.187 -0.461 . . . . 0.0 111.499 -179.783 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 48.4 t -71.83 -37.41 70.32 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 121.003 0.43 . . . . 0.0 111.29 -179.558 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 159' ' ' LEU . . . . . . . . . . . . . 78.0 mt -65.85 -39.18 90.52 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-N 115.936 -0.575 . . . . 0.0 111.643 -179.413 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 160' ' ' TYR . . . . . . . . . . . . . 45.5 t80 -73.94 -44.37 55.19 Favored 'General case' 0 C--N 1.327 -0.401 0 N-CA-C 112.155 0.428 . . . . 0.0 112.155 -178.647 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 161' ' ' VAL . . . . . 0.4 HG23 ' N ' ' A' ' 162' ' ' ARG . 30.8 m -59.86 -43.96 93.15 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 N-CA-C 112.226 0.454 . . . . 0.0 112.226 -178.916 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 162' ' ' ARG . . . . . 0.429 ' O ' HD11 ' A' ' 166' ' ' LEU . 93.8 mtt180 -69.16 -50.74 44.98 Favored 'General case' 0 C--N 1.33 -0.269 0 N-CA-C 112.18 0.437 . . . . 0.0 112.18 -179.134 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 163' ' ' LEU . . . . . . . . . . . . . 7.5 mp -65.71 -43.83 87.92 Favored 'General case' 0 C--N 1.33 -0.254 0 N-CA-C 111.789 0.292 . . . . 0.0 111.789 -179.06 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 164' ' ' ARG . . . . . . . . . . . . . 6.1 tmm_? -57.42 -50.98 71.26 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-N 116.56 -0.291 . . . . 0.0 111.004 -179.693 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 165' ' ' ASN . . . . . 0.503 ' N ' HD21 ' A' ' 165' ' ' ASN . 0.9 OUTLIER -53.04 -44.99 67.81 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-O 120.934 0.397 . . . . 0.0 110.346 179.809 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 166' ' ' LEU . . . . . 0.451 ' HB3' ' CE1' ' A' ' 208' ' ' PHE . 1.5 mt -60.05 -48.65 80.82 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 115.931 -0.577 . . . . 0.0 111.2 179.478 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 167' ' ' THR . . . . . 0.553 ' HA ' HD11 ' A' ' 170' ' ' LEU . 12.0 m -53.68 -51.0 64.59 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.021 -0.536 . . . . 0.0 112.218 -178.265 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 168' ' ' VAL . . . . . . . . . . . . . 27.0 t -59.26 -40.6 81.66 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.566 0 N-CA-C 112.105 0.409 . . . . 0.0 112.105 -179.061 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 169' ' ' VAL . . . . . 0.412 ' O ' HG12 ' A' ' 173' ' ' ILE . 83.9 t -66.08 -66.82 0.45 Allowed 'Isoleucine or valine' 0 CA--C 1.533 0.3 0 N-CA-C 113.557 0.947 . . . . 0.0 113.557 -178.194 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 170' ' ' LEU . . . . . 0.553 HD11 ' HA ' ' A' ' 167' ' ' THR . 0.4 OUTLIER -61.66 -32.18 72.34 Favored 'General case' 0 N--CA 1.467 0.388 0 N-CA-C 112.974 0.731 . . . . 0.0 112.974 -177.529 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 171' ' ' TRP . . . . . 0.484 ' HB2' ' O ' ' A' ' 167' ' ' THR . 21.4 m0 -73.53 -29.54 62.52 Favored 'General case' 0 C--N 1.329 -0.323 0 C-N-CA 120.371 -0.531 . . . . 0.0 111.087 -179.619 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 172' ' ' ALA . . . . . . . . . . . . . . . -72.24 -7.87 51.68 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-O 121.011 0.434 . . . . 0.0 110.253 179.499 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 173' ' ' ILE . . . . . 0.476 HG21 HD12 ' A' ' 177' ' ' ILE . 18.5 mm -88.92 -25.42 5.75 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.21 0 CA-C-N 115.789 -0.642 . . . . 0.0 110.939 179.528 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 174' ' ' TYR . . . . . 0.481 ' HD1' ' HA ' ' A' ' 171' ' ' TRP . 16.1 m-85 -54.62 -48.54 94.94 Favored Pre-proline 0 CA--C 1.531 0.218 0 CA-C-N 116.104 -0.498 . . . . 0.0 112.156 -179.384 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 175' ' ' PRO . . . . . . . . . . . . . 74.8 Cg_exo -47.07 -29.99 9.55 Favored 'Trans proline' 0 C--N 1.352 0.747 0 C-N-CA 121.909 1.739 . . . . 0.0 111.808 179.677 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 176' ' ' PHE . . . . . 0.481 ' O ' ' HG ' ' A' ' 180' ' ' LEU . 72.0 m-85 -80.35 -49.89 10.89 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 115.713 -0.676 . . . . 0.0 111.37 179.687 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 177' ' ' ILE . . . . . 0.476 HD12 HG21 ' A' ' 173' ' ' ILE . 3.6 mm -59.28 -36.25 62.5 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.525 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.722 -178.632 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 178' ' ' TRP . . . . . 0.402 ' O ' ' HB2' ' A' ' 183' ' ' PRO . 58.7 t90 -73.3 -51.82 16.18 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-O 121.066 0.46 . . . . 0.0 110.658 179.879 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 179' ' ' LEU . . . . . 0.506 HD12 HG22 ' A' ' 185' ' ' VAL . 1.4 tm? -61.07 -53.4 57.54 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 115.701 -0.681 . . . . 0.0 111.56 -179.159 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 180' ' ' LEU . . . . . 0.591 HD22 HD12 ' A' ' 187' ' ' LEU . 12.5 mt -74.78 -29.47 61.13 Favored 'General case' 0 C--N 1.327 -0.385 0 N-CA-C 112.2 0.444 . . . . 0.0 112.2 -178.861 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . -71.42 -177.66 27.28 Favored Glycine 0 N--CA 1.45 -0.407 0 C-N-CA 119.977 -1.106 . . . . 0.0 112.173 179.777 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 182' ' ' PRO . . . . . 0.424 ' N ' ' CD ' ' A' ' 183' ' ' PRO . 76.8 Cg_exo -47.93 -43.36 30.05 Favored 'Trans proline' 0 CA--C 1.538 0.681 0 C-N-CA 122.649 2.233 . . . . 0.0 113.386 179.527 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 183' ' ' PRO . . . . . 0.541 ' HB3' ' HB3' ' A' ' 116' ' ' ALA . 65.9 Cg_exo -41.54 -31.87 1.27 Allowed 'Trans proline' 0 C--N 1.358 1.046 0 C-N-CA 122.609 2.206 . . . . 0.0 113.601 179.824 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 184' ' ' GLY . . . . . . . . . . . . . . . -130.03 -107.65 1.24 Allowed Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.413 -0.899 . . . . 0.0 112.323 180.0 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 185' ' ' VAL . . . . . 0.513 ' O ' HG21 ' A' ' 185' ' ' VAL . 27.4 m -92.41 89.87 2.96 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.44 0 CA-C-O 121.414 0.626 . . . . 0.0 110.365 179.668 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 186' ' ' ALA . . . . . . . . . . . . . . . -56.94 86.7 0.01 OUTLIER 'General case' 0 C--N 1.325 -0.491 0 CA-C-N 115.687 -0.688 . . . . 0.0 111.855 -179.448 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 187' ' ' LEU . . . . . 0.591 HD12 HD22 ' A' ' 180' ' ' LEU . 12.5 mt -74.8 -48.91 22.8 Favored 'General case' 0 C--N 1.331 -0.199 0 CA-C-O 120.985 0.422 . . . . 0.0 110.361 179.236 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 188' ' ' LEU . . . . . . . . . . . . . 63.4 mt -97.8 -147.97 0.32 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 115.775 -0.648 . . . . 0.0 110.65 -179.87 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 189' ' ' THR . . . . . . . . . . . . . 1.2 t -111.8 148.46 39.0 Favored Pre-proline 0 C--N 1.331 -0.231 0 CA-C-N 116.276 -0.42 . . . . 0.0 110.813 -179.964 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 190' ' ' PRO . . . . . . . . . . . . . 7.3 Cg_endo -49.12 -42.14 39.75 Favored 'Trans proline' 0 C--N 1.349 0.57 0 C-N-CA 123.027 2.485 . . . . 0.0 113.261 -179.474 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 191' ' ' THR . . . . . . . . . . . . . 7.6 t -59.54 -40.86 88.6 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.65 0.262 . . . . 0.0 111.598 -179.341 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 192' ' ' VAL . . . . . . . . . . . . . 42.3 t -71.94 -47.92 53.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.499 -0.319 . . . . 0.0 111.398 -179.809 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 193' ' ' ASP . . . . . . . . . . . . . 30.7 t70 -57.99 -51.2 70.65 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.742 0.306 . . . . 0.0 111.038 -179.815 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 194' ' ' VAL . . . . . . . . . . . . . 97.8 t -59.88 -36.15 64.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.883 179.973 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 195' ' ' ALA . . . . . . . . . . . . . . . -58.1 -46.1 86.1 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.542 -0.299 . . . . 0.0 110.942 179.697 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 196' ' ' LEU . . . . . . . . . . . . . 86.3 mt -65.69 -41.34 92.5 Favored 'General case' 0 C--N 1.332 -0.171 0 CA-C-N 116.368 -0.378 . . . . 0.0 110.404 179.596 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 197' ' ' ILE . . . . . . . . . . . . . 19.9 mm -58.56 -58.26 7.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 115.995 -0.548 . . . . 0.0 110.239 179.366 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 198' ' ' VAL . . . . . . . . . . . . . 94.6 t -53.27 -34.52 22.39 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.416 0 CA-C-N 115.736 -0.665 . . . . 0.0 109.276 178.281 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 199' ' ' TYR . . . . . . . . . . . . . 65.4 t80 -69.7 -33.66 72.83 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 115.295 -0.866 . . . . 0.0 110.519 179.604 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 200' ' ' LEU . . . . . . . . . . . . . 40.7 mt -69.6 -39.62 77.14 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 115.855 -0.611 . . . . 0.0 111.019 -179.807 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 201' ' ' ASP . . . . . 0.452 ' HB3' ' NZ ' ' A' ' 205' ' ' LYS . 9.6 m-20 -72.86 -32.23 65.28 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.41 179.749 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 202' ' ' LEU . . . . . 0.458 ' O ' ' HB ' ' A' ' 206' ' ' VAL . 3.7 mt -73.04 -33.13 65.51 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 115.656 -0.702 . . . . 0.0 112.014 -179.376 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 203' ' ' VAL . . . . . 0.45 ' O ' ' HA3' ' A' ' 207' ' ' GLY . 7.8 p -77.9 -36.66 22.39 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-O 120.582 0.23 . . . . 0.0 111.432 -178.801 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 204' ' ' THR . . . . . . . . . . . . . 19.1 m -68.91 -53.62 20.06 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-O 120.877 0.37 . . . . 0.0 111.407 -179.956 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 205' ' ' LYS . . . . . 0.645 ' HD2' ' HE2' ' A' ' 15' ' ' MET . 43.9 mttp -70.73 -58.68 3.39 Favored 'General case' 0 C--N 1.327 -0.405 0 N-CA-C 112.435 0.531 . . . . 0.0 112.435 -178.569 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 206' ' ' VAL . . . . . 0.458 ' HB ' ' O ' ' A' ' 202' ' ' LEU . 48.1 t -72.25 -37.43 58.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 N-CA-C 111.952 0.353 . . . . 0.0 111.952 -178.878 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 207' ' ' GLY . . . . . 0.493 ' O ' HG13 ' A' ' 211' ' ' ILE . . . -65.37 -59.88 7.32 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.442 -0.885 . . . . 0.0 112.516 -179.366 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 208' ' ' PHE . . . . . 0.482 ' O ' ' N ' ' A' ' 212' ' ' ALA . 2.1 m-30 -54.19 -45.17 72.1 Favored 'General case' 0 C--O 1.222 -0.388 0 N-CA-C 109.947 -0.39 . . . . 0.0 109.947 179.772 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 209' ' ' GLY . . . . . 0.451 ' O ' ' HG ' ' A' ' 213' ' ' LEU . . . -59.07 -34.22 78.28 Favored Glycine 0 N--CA 1.448 -0.515 0 CA-C-N 115.376 -0.829 . . . . 0.0 112.821 179.43 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 210' ' ' PHE . . . . . . . . . . . . . 1.2 m-85 -70.26 -46.8 63.67 Favored 'General case' 0 CA--C 1.515 -0.369 0 N-CA-C 108.754 -0.832 . . . . 0.0 108.754 179.163 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 211' ' ' ILE . . . . . 0.493 HG13 ' O ' ' A' ' 207' ' ' GLY . 2.6 mt -67.4 -27.42 38.7 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.473 0 N-CA-C 107.416 -1.327 . . . . 0.0 107.416 176.846 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 212' ' ' ALA . . . . . 0.482 ' N ' ' O ' ' A' ' 208' ' ' PHE . . . -66.84 -40.09 87.83 Favored 'General case' 0 N--CA 1.449 -0.525 0 CA-C-N 114.32 -1.309 . . . . 0.0 110.214 -179.991 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 213' ' ' LEU . . . . . 0.451 ' HG ' ' O ' ' A' ' 209' ' ' GLY . 69.7 mt -70.68 -54.77 10.59 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 114.991 -1.004 . . . . 0.0 111.744 -179.555 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 214' ' ' ASP . . . . . . . . . . . . . 20.6 t70 -54.38 -47.19 72.95 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-O 120.758 0.313 . . . . 0.0 111.42 -179.464 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 215' ' ' ALA . . . . . . . . . . . . . . . -63.69 -56.17 17.8 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.309 -0.405 . . . . 0.0 111.171 -179.781 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 216' ' ' ALA . . . . . . . . . . . . . . . -56.24 -31.22 63.33 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.834 179.924 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 217' ' ' ALA . . . . . . . . . . . . . . . -65.97 -40.56 91.38 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 115.991 -0.549 . . . . 0.0 110.431 179.767 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 218' ' ' THR . . . . . . . . . . . . . 72.7 m -62.93 -36.88 84.86 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 115.957 -0.565 . . . . 0.0 110.437 179.41 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 219' ' ' LEU . . . . . . . . . . . . . 43.1 mt -69.93 -32.78 71.23 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 115.891 -0.595 . . . . 0.0 110.606 179.732 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 220' ' ' ARG . . . . . . . . . . . . . 91.4 mtm180 -83.29 -23.2 32.73 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 116.064 -0.517 . . . . 0.0 111.021 179.952 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 221' ' ' ALA . . . . . . . . . . . . . . . -82.33 -28.32 31.69 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.378 -0.374 . . . . 0.0 111.288 -179.791 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 222' ' ' GLU . . . . . . . . . . . . . 10.6 pt-20 -91.76 -30.74 16.08 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.296 179.998 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 223' ' ' HIS . . . . . . . . . . . . . 56.4 m-70 64.82 131.34 0.02 OUTLIER 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 115.525 -0.761 . . . . 0.0 111.215 -179.981 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 224' ' ' GLY . . . . . . . . . . . . . . . -99.81 10.93 60.81 Favored Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.804 -0.712 . . . . 0.0 112.283 179.827 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 225' ' ' GLU . . . . . . . . . . . . . 12.6 pt-20 -167.9 157.73 10.15 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-O 120.926 0.393 . . . . 0.0 111.051 -179.903 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 226' ' ' SER . . . . . . . . . . . . . 30.8 p -143.16 -30.02 0.52 Allowed 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 115.898 -0.592 . . . . 0.0 110.577 179.639 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 227' ' ' LEU . . . . . . . . . . . . . 2.3 pt? -60.53 152.05 26.98 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 115.949 -0.569 . . . . 0.0 110.72 179.684 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 228' ' ' ALA . . . . . . . . . . . . . . . -91.51 -45.89 8.27 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.348 -0.387 . . . . 0.0 110.974 179.812 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 229' ' ' GLY . . . . . . . . . . . . . . . -157.67 -122.56 0.71 Allowed Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.802 -0.713 . . . . 0.0 112.336 179.944 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 230' ' ' VAL . . . . . . . . . . . . . 46.8 t -128.15 140.25 49.69 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-O 120.749 0.309 . . . . 0.0 110.87 179.826 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 231' ' ' ASP . . . . . . . . . . . . . 4.0 p-10 -92.01 121.92 34.04 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.015 -179.846 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 232' ' ' THR . . . . . . . . . . . . . 9.5 t -110.1 8.52 23.93 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 115.974 -0.557 . . . . 0.0 110.896 -179.952 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 233' ' ' ASP . . . . . . . . . . . . . 24.1 t70 -79.1 -27.81 42.97 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.105 -0.498 . . . . 0.0 111.0 -179.931 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 234' ' ' THR . . . . . . . . . . . . . 8.1 t -72.69 141.5 82.46 Favored Pre-proline 0 C--N 1.329 -0.309 0 CA-C-N 116.321 -0.4 . . . . 0.0 111.029 -179.934 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 235' ' ' PRO . . . . . . . . . . . . . 70.3 Cg_endo -74.68 108.26 2.66 Favored 'Trans proline' 0 C--N 1.348 0.518 0 C-N-CA 122.324 2.016 . . . . 0.0 112.518 179.843 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 236' ' ' ALA . . . . . . . . . . . . . . . -107.75 113.08 26.08 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.09 -0.505 . . . . 0.0 110.831 179.771 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 237' ' ' VAL . . . . . . . . . . . . . 35.0 m -100.62 150.37 5.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.256 -0.429 . . . . 0.0 111.426 -179.698 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 238' ' ' ALA . . . . . . . . . . . . . . . 59.38 99.58 0.02 OUTLIER 'General case' 0 C--N 1.333 -0.138 0 CA-C-N 115.876 -0.602 . . . . 0.0 111.479 179.973 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 239' ' ' ASP . . . . . . . . . . . . . 10.7 m-20 -143.04 -3.55 0.96 Allowed 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.868 179.871 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 240' ' ' LEU . . . . . . . . . . . . . 84.5 mt -91.3 3.74 54.12 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 116.264 -0.425 . . . . 0.0 110.921 179.855 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 241' ' ' GLU . . . . . . . . . . . . . 15.4 mm-40 58.34 21.56 8.44 Favored 'General case' 0 C--N 1.332 -0.176 0 CA-C-N 116.038 -0.528 . . . . 0.0 111.263 179.826 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 242' ' ' HIS . . . . . . . . . . . . . 59.4 t60 -137.83 118.77 14.27 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.851 0.358 . . . . 0.0 111.018 -179.953 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 243' ' ' HIS . . . . . . . . . . . . . 32.6 t60 -80.38 125.16 29.57 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.705 179.89 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 244' ' ' HIS . . . . . . . . . . . . . 64.1 m-70 -87.11 120.63 28.58 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.888 -179.969 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 245' ' ' HIS . . . . . . . . . . . . . 76.7 t60 -92.64 -62.24 1.43 Allowed 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.296 -0.411 . . . . 0.0 110.923 179.978 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 246' ' ' HIS . . . . . . . . . . . . . 31.0 p80 -89.83 138.31 31.6 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.999 -179.972 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 247' ' ' HIS . . . . . . . . . . . . . 57.2 m-70 . . . . . 0 C--O 1.249 1.028 0 CA-C-O 118.274 -0.869 . . . . 0.0 110.729 179.815 . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 301' ' ' RET . . . . . 0.503 ' H22' ' HA3' ' A' ' 112' ' ' GLY . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 83.5 mtp . . . . . 0 N--CA 1.486 1.33 0 CA-C-O 120.842 0.353 . . . . 0.0 111.011 . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 36.0 m -133.19 7.49 1.42 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.25 0 CA-C-N 116.071 -0.513 . . . . 0.0 111.049 179.941 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -104.84 -59.18 0.66 Allowed Glycine 0 C--N 1.331 0.286 0 C-N-CA 120.784 -0.722 . . . . 0.0 112.685 -179.897 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 96.6 mt -61.04 -35.44 76.91 Favored 'General case' 0 N--CA 1.448 -0.529 0 CA-C-O 120.758 0.313 . . . . 0.0 111.118 179.961 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 46.6 p -51.48 -36.92 46.52 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 116.013 -0.54 . . . . 0.0 111.68 -179.472 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 20.4 p -56.79 -38.94 73.23 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.209 -0.451 . . . . 0.0 111.576 -179.542 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 7' ' ' LEU . . . . . . . . . . . . . 3.9 mm? -61.81 -53.51 54.88 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.265 -0.425 . . . . 0.0 111.304 -179.716 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 8' ' ' PHE . . . . . . . . . . . . . 68.5 m-85 -55.43 -31.93 62.3 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.255 -0.429 . . . . 0.0 111.108 -179.607 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 9' ' ' TRP . . . . . 0.403 ' O ' HG12 ' A' ' 13' ' ' ILE . 21.7 m95 -66.01 -42.78 89.26 Favored 'General case' 0 C--N 1.326 -0.447 0 N-CA-C 109.695 -0.484 . . . . 0.0 109.695 179.694 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 84.6 mt -61.08 -38.97 88.14 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 115.62 -0.718 . . . . 0.0 110.238 179.223 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -65.84 -35.55 91.0 Favored Glycine 0 N--CA 1.449 -0.437 0 C-N-CA 120.85 -0.691 . . . . 0.0 111.865 179.349 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -65.6 -32.58 74.23 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-O 120.892 0.377 . . . . 0.0 110.672 179.585 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 13' ' ' ILE . . . . . 0.403 HG12 ' O ' ' A' ' 9' ' ' TRP . 50.5 mm -67.35 -51.03 56.94 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.245 0 CA-C-N 116.034 -0.53 . . . . 0.0 110.654 179.667 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -58.6 -31.6 67.45 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.141 179.669 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 15' ' ' MET . . . . . 0.616 ' HE1' ' HD2' ' A' ' 205' ' ' LYS . 23.9 mmt -69.89 -40.91 75.38 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-O 120.722 0.296 . . . . 0.0 110.64 179.661 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -57.47 -43.66 84.23 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.307 179.54 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 42.5 t -61.41 -49.83 82.86 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.214 0 CA-C-N 116.065 -0.516 . . . . 0.0 110.955 179.846 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -62.36 -48.27 83.59 Favored Glycine 0 C--N 1.331 0.285 0 C-N-CA 120.651 -0.785 . . . . 0.0 112.206 179.708 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 50.3 m -49.93 -41.13 45.55 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-O 120.67 0.271 . . . . 0.0 111.378 -179.754 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 52.3 mt -72.53 -46.06 56.35 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.329 -0.396 . . . . 0.0 111.41 179.903 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -60.59 -29.71 69.37 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.315 -0.402 . . . . 0.0 111.654 -179.604 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 22' ' ' PHE . . . . . 0.427 ' HB2' HG22 ' A' ' 41' ' ' VAL . 5.1 m-85 -91.23 -30.01 16.88 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.515 -0.311 . . . . 0.0 111.436 -179.56 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -72.66 -50.55 24.26 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-O 120.949 0.404 . . . . 0.0 110.997 -179.971 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 24' ' ' TRP . . . . . . . . . . . . . 2.8 t-105 -61.23 -39.49 90.48 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-N 115.737 -0.665 . . . . 0.0 110.501 179.806 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -80.69 -20.05 43.82 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.756 179.549 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -73.51 -46.85 23.87 Favored Glycine 0 C--N 1.331 0.271 0 C-N-CA 121.065 -0.588 . . . . 0.0 112.644 179.919 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 15.7 ptp180 -61.0 -20.16 62.15 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-O 120.804 0.335 . . . . 0.0 110.921 179.951 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 18.4 t70 -105.18 84.46 2.12 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.683 179.796 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -129.05 -175.15 3.47 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.032 -179.891 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -126.3 48.86 0.94 Allowed Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.701 -0.761 . . . . 0.0 112.671 -179.777 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 44.4 t 55.91 90.57 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.874 0.368 . . . . 0.0 111.171 179.871 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 137.68 -65.3 0.55 Allowed Glycine 0 N--CA 1.452 -0.257 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.6 179.684 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 22.8 mm-40 -61.31 -21.14 63.7 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.757 0.313 . . . . 0.0 111.007 -179.935 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 34' ' ' ARG . . . . . . . . . . . . . 48.6 ttp180 -51.17 -29.63 14.4 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 116.043 -0.526 . . . . 0.0 111.271 -179.959 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 35' ' ' ARG . . . . . 0.403 ' CZ ' HD21 ' A' ' 89' ' ' LEU . 51.8 ttp180 -59.47 -48.19 82.58 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.326 -0.397 . . . . 0.0 111.075 -179.994 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 53.5 m-85 -64.43 -34.61 78.59 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.984 -179.922 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 37' ' ' TYR . . . . . . . . . . . . . 63.6 m-85 -66.84 -54.15 25.32 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 115.993 -0.549 . . . . 0.0 111.05 -179.762 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 77.7 t -56.98 -37.05 52.67 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.242 0 CA-C-O 120.889 0.376 . . . . 0.0 110.455 179.723 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 24.2 m -66.73 -40.24 88.27 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 121.355 0.598 . . . . 0.0 110.171 179.044 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 12.7 tp -65.5 -41.87 92.75 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 115.258 -0.883 . . . . 0.0 110.372 179.757 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . 0.427 HG22 ' HB2' ' A' ' 22' ' ' PHE . 59.7 t -69.68 -34.17 59.85 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.426 0 CA-C-N 115.561 -0.745 . . . . 0.0 110.312 179.379 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . 0.464 ' O ' HG12 ' A' ' 46' ' ' ILE . . . -59.26 -46.57 93.63 Favored Glycine 0 N--CA 1.448 -0.541 0 C-N-CA 120.971 -0.633 . . . . 0.0 112.554 179.999 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 43' ' ' ILE . . . . . 0.465 HG23 HD23 ' A' ' 82' ' ' LEU . 10.2 pt -65.63 -51.57 61.21 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.157 0 N-CA-C 111.729 0.27 . . . . 0.0 111.729 -179.767 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 48.1 t -63.84 -24.19 67.65 Favored 'General case' 0 C--O 1.234 0.247 0 CA-C-O 120.924 0.392 . . . . 0.0 111.396 -179.762 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -78.14 -59.05 3.02 Favored Glycine 0 CA--C 1.518 0.22 0 C-N-CA 120.92 -0.657 . . . . 0.0 113.466 -178.856 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 46' ' ' ILE . . . . . 0.464 HG12 ' O ' ' A' ' 42' ' ' GLY . 17.7 pt -57.79 -35.29 50.62 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.207 0 CA-C-O 120.751 0.31 . . . . 0.0 110.957 -179.606 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 47' ' ' ALA . . . . . 0.633 ' HB1' ' HE2' ' A' ' 205' ' ' LYS . . . -67.62 -40.12 84.7 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-O 120.841 0.353 . . . . 0.0 110.085 178.559 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 48' ' ' ALA . . . . . 0.492 ' HB2' ' HB3' ' A' ' 15' ' ' MET . . . -54.48 -43.39 71.69 Favored 'General case' 0 C--N 1.334 -0.101 0 CA-C-N 115.987 -0.551 . . . . 0.0 111.291 179.801 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 49' ' ' VAL . . . . . 0.464 ' O ' HG12 ' A' ' 53' ' ' VAL . 21.4 m -75.62 -34.36 28.88 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.221 0 CA-C-N 116.463 -0.335 . . . . 0.0 111.452 -179.82 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -59.12 -45.5 90.75 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.824 0.345 . . . . 0.0 111.392 -179.849 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 51' ' ' TYR . . . . . 0.579 ' HH ' ' HB2' ' A' ' 201' ' ' ASP . 57.6 m-85 -73.16 -40.15 65.08 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 115.919 -0.582 . . . . 0.0 111.257 -179.31 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -60.64 -47.03 88.04 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 115.886 -0.597 . . . . 0.0 111.318 -179.921 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 53' ' ' VAL . . . . . 0.464 HG12 ' O ' ' A' ' 49' ' ' VAL . 16.8 m -71.89 -43.14 69.07 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.243 0 CA-C-N 116.324 -0.398 . . . . 0.0 110.969 -179.876 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 54' ' ' MET . . . . . . . . . . . . . 17.0 ttp -63.71 -29.49 70.71 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 121.085 0.469 . . . . 0.0 110.101 179.509 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -63.84 -36.22 83.2 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 115.63 -0.714 . . . . 0.0 111.539 179.773 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 78.6 mt -80.99 13.15 2.85 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.475 -0.33 . . . . 0.0 111.427 -179.626 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 84.39 -2.21 88.09 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.638 -0.792 . . . . 0.0 112.87 179.712 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 55.0 t -68.83 141.69 17.14 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-O 120.732 0.301 . . . . 0.0 110.768 179.777 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 59' ' ' GLY . . . . . 0.596 ' HA3' ' HD3' ' A' ' 71' ' ' PRO . . . 86.18 -16.07 45.62 Favored Glycine 0 N--CA 1.45 -0.411 0 C-N-CA 120.595 -0.812 . . . . 0.0 112.275 -179.857 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 60' ' ' TRP . . . . . . . . . . . . . 13.7 m0 -66.88 92.94 0.24 Allowed 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 120.825 0.345 . . . . 0.0 110.602 179.665 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 7.1 p -96.23 123.25 55.57 Favored Pre-proline 0 C--N 1.328 -0.347 0 CA-C-N 116.303 -0.408 . . . . 0.0 111.211 -179.832 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 46.5 Cg_endo -68.41 141.03 49.89 Favored 'Trans proline' 0 C--N 1.35 0.649 0 C-N-CA 122.403 2.068 . . . . 0.0 112.231 179.93 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 60.2 t -137.31 92.69 0.91 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.046 -0.525 . . . . 0.0 111.172 -179.789 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . 58.09 -88.93 0.02 OUTLIER 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 116.178 -0.465 . . . . 0.0 111.514 179.789 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 45.4 mt-10 -120.42 -17.98 8.01 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 116.486 -0.324 . . . . 0.0 110.856 179.973 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 66' ' ' ARG . . . . . . . . . . . . . 20.9 mmm180 -105.03 165.51 11.03 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 116.064 -0.516 . . . . 0.0 110.344 179.776 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 38.4 m -122.52 143.15 49.9 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-O 120.834 0.349 . . . . 0.0 111.201 -179.805 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 40.0 t -125.19 146.0 31.6 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.02 -0.537 . . . . 0.0 110.879 -179.991 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 69' ' ' PHE . . . . . . . . . . . . . 8.3 m-85 -109.31 114.32 27.9 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.371 -0.377 . . . . 0.0 110.161 179.837 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 70' ' ' VAL . . . . . 0.603 HG11 ' HD3' ' A' ' 71' ' ' PRO . 1.3 p -68.26 -35.64 7.58 Favored Pre-proline 0 CA--C 1.542 0.653 0 N-CA-C 112.945 0.72 . . . . 0.0 112.945 -179.34 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 71' ' ' PRO . . . . . 0.603 ' HD3' HG11 ' A' ' 70' ' ' VAL . 61.9 Cg_endo -71.16 -20.82 27.97 Favored 'Trans proline' 0 C--N 1.359 1.116 0 C-N-CA 121.822 1.681 . . . . 0.0 113.266 -179.352 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 66.7 ttt180 -74.23 -54.96 6.65 Favored 'General case' 0 C--N 1.329 -0.32 0 N-CA-C 112.019 0.377 . . . . 0.0 112.019 -178.993 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 73' ' ' TYR . . . . . 0.48 ' O ' HG13 ' A' ' 77' ' ' ILE . 65.9 m-85 -74.08 -32.84 63.42 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.533 -0.303 . . . . 0.0 111.526 -178.803 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 0.3 OUTLIER -70.23 -44.53 77.72 Favored 'Isoleucine or valine' 0 C--O 1.234 0.257 0 C-N-CA 120.615 -0.434 . . . . 0.0 110.18 179.486 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 22.9 t70 -58.33 -35.89 72.58 Favored 'General case' 0 CA--C 1.52 -0.2 0 N-CA-C 109.094 -0.706 . . . . 0.0 109.094 178.959 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 76' ' ' TRP . . . . . 0.42 ' HA ' ' OG1' ' A' ' 79' ' ' THR . 44.7 m0 -64.95 -34.9 79.53 Favored 'General case' 0 C--N 1.332 -0.164 0 CA-C-N 115.769 -0.651 . . . . 0.0 110.228 178.801 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 77' ' ' ILE . . . . . 0.49 HG12 ' HB3' ' A' ' 109' ' ' MET . 98.0 mt -66.21 -30.42 49.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 115.981 -0.554 . . . . 0.0 110.745 179.561 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 82.0 mt -91.88 -17.89 24.58 Favored 'General case' 0 CA--C 1.532 0.257 0 N-CA-C 112.278 0.473 . . . . 0.0 112.278 179.644 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 79' ' ' THR . . . . . 0.42 ' OG1' ' HA ' ' A' ' 76' ' ' TRP . 46.9 p -94.65 -51.65 4.64 Favored 'General case' 0 N--CA 1.465 0.319 0 N-CA-C 112.974 0.731 . . . . 0.0 112.974 -178.486 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 80' ' ' THR . . . . . 0.52 ' N ' ' HD2' ' A' ' 81' ' ' PRO . 27.5 m -50.25 -51.03 66.81 Favored Pre-proline 0 C--N 1.328 -0.354 0 N-CA-C 112.95 0.722 . . . . 0.0 112.95 -178.425 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 81' ' ' PRO . . . . . 0.52 ' HD2' ' N ' ' A' ' 80' ' ' THR . 19.4 Cg_endo -57.94 -23.57 60.44 Favored 'Trans proline' 0 C--N 1.352 0.732 0 C-N-CA 121.526 1.484 . . . . 0.0 111.703 -179.48 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 82' ' ' LEU . . . . . 0.465 HD23 HG23 ' A' ' 43' ' ' ILE . 3.5 mp -76.91 -38.36 53.63 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 115.923 -0.58 . . . . 0.0 110.704 179.834 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 49.9 mm -65.42 -53.44 39.82 Favored 'Isoleucine or valine' 0 C--O 1.234 0.267 0 CA-C-O 120.936 0.398 . . . . 0.0 110.221 179.371 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 26.8 m -60.68 -31.66 49.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.04 -0.527 . . . . 0.0 109.774 178.983 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 85' ' ' TYR . . . . . . . . . . . . . 87.7 t80 -67.81 -34.09 76.07 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-N 115.697 -0.683 . . . . 0.0 109.442 178.755 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 86' ' ' PHE . . . . . . . . . . . . . 1.8 t80 -58.95 -51.82 68.39 Favored 'General case' 0 C--O 1.233 0.225 0 CA-C-N 115.828 -0.624 . . . . 0.0 109.81 179.319 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 7.8 mp -63.87 -33.63 76.13 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 115.865 -0.607 . . . . 0.0 110.013 179.216 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -61.44 -28.34 69.35 Favored Glycine 0 N--CA 1.449 -0.454 0 C-N-CA 120.784 -0.722 . . . . 0.0 111.566 179.191 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 89' ' ' LEU . . . . . 0.403 HD21 ' CZ ' ' A' ' 35' ' ' ARG . 82.1 mt -79.04 -36.61 40.76 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.953 0.406 . . . . 0.0 110.165 179.325 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 97.0 mt -63.18 -37.67 88.13 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 115.821 -0.627 . . . . 0.0 111.017 179.802 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . 0.507 ' HB3' ' HB2' ' A' ' 148' ' ' SER . . . -87.22 -54.57 4.23 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.328 -179.837 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 103.33 70.6 0.84 Allowed Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.831 -0.699 . . . . 0.0 112.415 -179.775 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 93' ' ' LEU . . . . . 0.571 HD11 ' HG2' ' A' ' 145' ' ' MET . 7.5 mp -87.99 166.8 14.23 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.81 0.338 . . . . 0.0 111.047 -179.843 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 94' ' ' ASP . . . . . . . . . . . . . 7.9 m-20 -84.5 174.35 10.11 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.887 179.779 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 88.8 p -60.09 -35.72 75.82 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.308 -0.406 . . . . 0.0 111.004 -179.788 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 69.7 mtm180 -72.9 -48.79 34.2 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.148 -179.835 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 97' ' ' GLU . . . . . 0.564 ' HB2' ' HB3' ' A' ' 93' ' ' LEU . 37.5 mt-10 -56.16 -46.59 79.23 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.295 -0.412 . . . . 0.0 111.235 -179.73 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 98' ' ' PHE . . . . . . . . . . . . . 6.5 m-85 -55.88 -50.59 70.23 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.366 -0.379 . . . . 0.0 111.07 -179.951 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -55.59 -34.28 60.14 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.858 -0.687 . . . . 0.0 112.637 -179.867 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 97.8 mt -66.82 -44.13 89.31 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.207 0 CA-C-O 120.773 0.32 . . . . 0.0 111.803 -179.748 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 25.0 t -68.59 -46.93 79.24 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.369 0 CA-C-N 116.263 -0.426 . . . . 0.0 111.936 -179.045 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 102' ' ' ILE . . . . . . . . . . . . . 36.2 mm -63.64 -48.63 85.87 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 CA-C-N 116.283 -0.417 . . . . 0.0 111.922 -179.014 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 12.0 t -61.04 -37.2 81.75 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-O 120.761 0.315 . . . . 0.0 111.23 -179.528 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 10.1 tt -60.91 -42.93 99.01 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.411 179.721 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 105' ' ' ASN . . . . . 0.582 HD22 HD13 ' A' ' 137' ' ' LEU . 0.8 OUTLIER -67.68 -26.35 66.15 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.605 179.614 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 56.6 m -63.5 -53.57 49.98 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 115.941 -0.572 . . . . 0.0 111.149 179.82 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 7.8 p -63.93 -36.13 75.7 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.162 0 CA-C-N 116.336 -0.393 . . . . 0.0 111.127 179.919 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 79.6 t -63.3 -51.71 67.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-O 121.201 0.524 . . . . 0.0 110.604 179.44 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 109' ' ' MET . . . . . 0.498 ' HE2' HG21 ' A' ' 80' ' ' THR . 3.5 tpp -60.49 -33.73 73.02 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 115.67 -0.695 . . . . 0.0 110.422 179.759 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 20.8 tp -68.91 -33.52 73.88 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 115.9 -0.591 . . . . 0.0 110.166 179.693 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 111' ' ' ALA . . . . . 0.417 ' HB1' ' HE2' ' A' ' 129' ' ' MET . . . -59.7 -57.1 14.39 Favored 'General case' 0 C--N 1.332 -0.179 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.177 179.315 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 112' ' ' GLY . . . . . 0.59 ' HA3' ' H22' ' A' ' 301' ' ' RET . . . -57.31 -41.22 92.92 Favored Glycine 0 CA--C 1.518 0.233 0 C-N-CA 120.598 -0.81 . . . . 0.0 112.116 179.164 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 113' ' ' PHE . . . . . . . . . . . . . 1.5 t80 -47.16 -67.79 0.25 Allowed 'General case' 0 C--N 1.333 -0.137 0 CA-C-O 121.127 0.489 . . . . 0.0 110.081 179.473 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -64.43 -21.09 66.54 Favored 'General case' 0 C--N 1.326 -0.449 0 CA-C-N 115.512 -0.767 . . . . 0.0 110.864 179.661 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 115' ' ' GLY . . . . . 0.416 ' HA2' HD11 ' A' ' 126' ' ' LEU . . . -52.96 -49.38 55.37 Favored Glycine 0 C--N 1.333 0.375 0 C-N-CA 121.008 -0.615 . . . . 0.0 112.367 179.912 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -78.08 -15.79 58.59 Favored 'General case' 0 C--N 1.324 -0.506 0 N-CA-C 111.665 0.246 . . . . 0.0 111.665 179.742 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 117' ' ' MET . . . . . . . . . . . . . 36.1 ttm -100.94 19.89 16.49 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.497 -0.32 . . . . 0.0 111.674 -179.091 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 118' ' ' VAL . . . . . 0.455 HG22 ' HB3' ' A' ' 123' ' ' ARG . 28.3 m -74.11 147.5 85.84 Favored Pre-proline 0 C--N 1.328 -0.36 0 CA-C-N 116.559 -0.291 . . . . 0.0 111.305 179.789 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 119' ' ' PRO . . . . . . . . . . . . . 81.3 Cg_endo -88.94 -6.28 5.68 Favored 'Trans proline' 0 N--CA 1.457 -0.622 0 C-N-CA 122.688 2.259 . . . . 0.0 112.283 179.683 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -148.4 -114.69 0.78 Allowed Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.711 -0.757 . . . . 0.0 112.915 -179.783 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 44.7 pt -122.59 14.56 5.58 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 CA-C-O 120.802 0.334 . . . . 0.0 111.39 -179.51 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 36.9 mt-10 -63.4 -18.85 64.14 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.134 -179.999 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 123' ' ' ARG . . . . . 0.455 ' HB3' HG22 ' A' ' 118' ' ' VAL . 35.9 ptt180 -53.41 -32.42 49.56 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.106 -0.497 . . . . 0.0 111.925 -179.544 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 124' ' ' TYR . . . . . . . . . . . . . 91.5 m-85 -72.54 -31.41 65.27 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 116.476 -0.329 . . . . 0.0 111.466 -179.652 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 125' ' ' ALA . . . . . . . . . . . . . . . -74.51 -58.28 3.39 Favored 'General case' 0 C--O 1.237 0.44 0 CA-C-O 121.196 0.522 . . . . 0.0 111.573 -179.374 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 126' ' ' LEU . . . . . 0.416 HD11 ' HA2' ' A' ' 115' ' ' GLY . 0.7 OUTLIER -56.49 -37.24 70.1 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 115.701 -0.681 . . . . 0.0 110.511 179.789 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 127' ' ' PHE . . . . . . . . . . . . . 7.8 t80 -69.37 -42.6 74.99 Favored 'General case' 0 N--CA 1.453 -0.311 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.114 179.304 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 128' ' ' GLY . . . . . . . . . . . . . . . -48.09 -35.33 13.52 Favored Glycine 0 C--N 1.333 0.379 0 N-CA-C 110.673 -0.971 . . . . 0.0 110.673 178.746 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 129' ' ' MET . . . . . 0.417 ' HE2' ' HB1' ' A' ' 111' ' ' ALA . 0.2 OUTLIER -72.03 -43.67 64.63 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 115.154 -0.523 . . . . 0.0 109.877 178.619 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -67.25 -22.22 72.6 Favored Glycine 0 N--CA 1.449 -0.474 0 C-N-CA 120.869 -0.682 . . . . 0.0 112.378 179.602 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 131' ' ' ALA . . . . . 0.418 ' O ' ' HB3' ' A' ' 134' ' ' PHE . . . -74.61 -53.9 8.48 Favored 'General case' 0 CA--C 1.519 -0.234 0 CA-C-O 120.739 0.304 . . . . 0.0 110.211 179.681 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 58.1 t -58.32 -39.47 74.24 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.319 0 N-CA-C 108.535 -0.913 . . . . 0.0 108.535 178.096 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -62.77 -37.44 86.67 Favored 'General case' 0 N--CA 1.451 -0.378 0 CA-C-N 114.915 -1.039 . . . . 0.0 110.198 178.767 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 134' ' ' PHE . . . . . 0.418 ' HB3' ' O ' ' A' ' 131' ' ' ALA . 68.0 t80 -55.64 -50.09 71.11 Favored 'General case' 0 N--CA 1.453 -0.325 0 CA-C-N 116.159 -0.473 . . . . 0.0 109.88 179.364 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 135' ' ' ILE . . . . . 0.478 ' O ' HG22 ' A' ' 138' ' ' VAL . 59.0 mt -59.54 -32.45 49.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 115.667 -0.697 . . . . 0.0 110.14 179.228 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . -59.46 -41.76 97.25 Favored Glycine 0 N--CA 1.449 -0.494 0 C-N-CA 120.409 -0.901 . . . . 0.0 111.271 179.054 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 137' ' ' LEU . . . . . 0.582 HD13 HD22 ' A' ' 105' ' ' ASN . 42.7 tp -65.85 -55.61 16.17 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 120.666 0.27 . . . . 0.0 110.722 179.541 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 138' ' ' VAL . . . . . 0.6 ' HB ' HH22 ' A' ' 164' ' ' ARG . 2.5 m -54.79 -32.3 25.79 Favored 'Isoleucine or valine' 0 C--O 1.234 0.267 0 CA-C-O 121.125 0.488 . . . . 0.0 109.802 -179.506 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 139' ' ' TYR . . . . . . . . . . . . . 10.2 t80 -61.43 -42.31 98.54 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 115.654 -0.703 . . . . 0.0 109.964 178.293 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 28.1 m-85 -65.99 -42.37 89.89 Favored 'General case' 0 C--N 1.332 -0.184 0 CA-C-N 116.11 -0.496 . . . . 0.0 111.002 179.517 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 141' ' ' LEU . . . . . 0.427 ' HA ' ' SD ' ' A' ' 145' ' ' MET . 10.8 mp -56.62 -32.86 65.71 Favored 'General case' 0 N--CA 1.462 0.139 0 CA-C-N 116.356 -0.384 . . . . 0.0 110.883 -179.973 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 21.6 t -97.05 -12.75 8.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.82 179.662 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . -76.33 -123.83 0.19 Allowed Glycine 0 CA--C 1.522 0.529 0 C-N-CA 120.845 -0.693 . . . . 0.0 112.932 -179.721 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 144' ' ' PRO . . . . . . . . . . . . . 31.7 Cg_exo -58.87 -29.95 91.58 Favored 'Trans proline' 0 C--N 1.351 0.659 0 C-N-CA 122.596 2.198 . . . . 0.0 112.726 -179.672 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 145' ' ' MET . . . . . 0.571 ' HG2' HD11 ' A' ' 93' ' ' LEU . 60.1 mtt -58.7 -26.98 64.42 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.316 -0.402 . . . . 0.0 111.235 -179.893 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 146' ' ' THR . . . . . . . . . . . . . 24.0 m -81.08 -33.67 33.2 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-N 116.119 -0.491 . . . . 0.0 111.478 -179.058 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 15.0 tp10 -71.89 -43.43 65.41 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.98 -179.896 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 148' ' ' SER . . . . . 0.507 ' HB2' ' HB3' ' A' ' 91' ' ' ALA . 61.7 m -71.98 -40.15 68.79 Favored 'General case' 0 C--N 1.327 -0.405 0 N-CA-C 112.334 0.494 . . . . 0.0 112.334 -179.205 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 149' ' ' ALA . . . . . . . . . . . . . . . -76.68 -44.64 32.85 Favored 'General case' 0 C--N 1.33 -0.278 0 N-CA-C 113.395 0.887 . . . . 0.0 113.395 -177.974 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 150' ' ' SER . . . . . . . . . . . . . 54.2 m -69.12 -14.29 62.92 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.909 0.385 . . . . 0.0 110.85 -178.495 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 151' ' ' GLN . . . . . . . . . . . . . 3.0 mp0 -116.56 10.38 14.46 Favored 'General case' 0 C--N 1.324 -0.502 0 CA-C-N 115.928 -0.578 . . . . 0.0 111.494 -179.462 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 72.2 ttt180 -82.99 -51.94 7.12 Favored 'General case' 0 C--N 1.334 -0.102 0 CA-C-O 120.868 0.366 . . . . 0.0 110.943 -179.968 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 153' ' ' SER . . . . . 0.57 ' HB2' HG12 ' A' ' 156' ' ' ILE . 17.6 m -157.45 172.18 19.04 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 116.032 -0.531 . . . . 0.0 110.861 179.596 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 154' ' ' SER . . . . . . . . . . . . . 67.9 m -71.09 -37.3 72.41 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.687 179.636 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -76.82 -35.0 41.24 Favored Glycine 0 N--CA 1.452 -0.276 0 C-N-CA 120.887 -0.673 . . . . 0.0 112.568 179.908 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 156' ' ' ILE . . . . . 0.57 HG12 ' HB2' ' A' ' 153' ' ' SER . 41.4 mm -56.42 -37.72 52.51 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-O 120.887 0.375 . . . . 0.0 110.92 -179.972 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 157' ' ' LYS . . . . . . . . . . . . . 24.3 ttpp -60.98 -32.9 72.45 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.903 179.82 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 47.1 m -70.9 -45.23 64.7 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.073 -179.863 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 159' ' ' LEU . . . . . 0.476 ' O ' ' HB2' ' A' ' 163' ' ' LEU . 11.2 mt -65.67 -36.12 82.76 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.338 -0.392 . . . . 0.0 111.07 179.931 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 160' ' ' TYR . . . . . 0.471 ' O ' ' HB3' ' A' ' 164' ' ' ARG . 57.3 t80 -65.57 -47.86 74.36 Favored 'General case' 0 C--N 1.329 -0.317 0 N-CA-C 112.206 0.447 . . . . 0.0 112.206 -178.952 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 161' ' ' VAL . . . . . 0.426 HG21 ' N ' ' A' ' 162' ' ' ARG . 17.3 m -62.17 -49.28 84.69 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 N-CA-C 112.304 0.483 . . . . 0.0 112.304 -178.608 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 162' ' ' ARG . . . . . 0.426 ' N ' HG21 ' A' ' 161' ' ' VAL . 81.9 mtt180 -68.46 -46.11 70.66 Favored 'General case' 0 C--N 1.329 -0.291 0 N-CA-C 112.076 0.398 . . . . 0.0 112.076 -179.044 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 163' ' ' LEU . . . . . 0.476 ' HB2' ' O ' ' A' ' 159' ' ' LEU . 1.7 mp -67.67 -54.95 15.35 Favored 'General case' 0 C--N 1.328 -0.332 0 N-CA-C 112.243 0.46 . . . . 0.0 112.243 -178.62 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 164' ' ' ARG . . . . . 0.6 HH22 ' HB ' ' A' ' 138' ' ' VAL . 25.2 tpt180 -55.78 -54.89 38.91 Favored 'General case' 0 N--CA 1.465 0.292 0 N-CA-C 112.629 0.603 . . . . 0.0 112.629 -178.46 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 165' ' ' ASN . . . . . . . . . . . . . 13.8 m-80 -58.0 -49.25 77.5 Favored 'General case' 0 C--N 1.33 -0.255 0 N-CA-C 112.071 0.397 . . . . 0.0 112.071 -178.75 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 166' ' ' LEU . . . . . . . . . . . . . 4.4 tt -63.45 -55.37 24.73 Favored 'General case' 0 C--N 1.325 -0.47 0 N-CA-C 111.876 0.325 . . . . 0.0 111.876 -179.262 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 167' ' ' THR . . . . . . . . . . . . . 53.7 m -57.02 -52.92 63.34 Favored 'General case' 0 C--N 1.328 -0.368 0 N-CA-C 113.037 0.754 . . . . 0.0 113.037 -178.613 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 168' ' ' VAL . . . . . . . . . . . . . 7.9 p -57.5 -41.22 78.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 N-CA-C 112.482 0.549 . . . . 0.0 112.482 -178.529 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 169' ' ' VAL . . . . . 0.463 ' CG1' ' N ' ' A' ' 170' ' ' LEU . 0.4 OUTLIER -63.72 -54.07 36.76 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.443 0 N-CA-C 111.867 0.321 . . . . 0.0 111.867 -178.76 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 170' ' ' LEU . . . . . 0.463 ' N ' ' CG1' ' A' ' 169' ' ' VAL . 3.0 pp -68.03 -31.12 70.57 Favored 'General case' 0 C--N 1.33 -0.268 0 C-N-CA 121.173 -0.211 . . . . 0.0 111.543 -178.562 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 171' ' ' TRP . . . . . 0.429 ' N ' HD13 ' A' ' 170' ' ' LEU . 3.3 m0 -72.29 -28.59 63.19 Favored 'General case' 0 C--N 1.329 -0.295 0 N-CA-C 109.952 -0.388 . . . . 0.0 109.952 178.895 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 172' ' ' ALA . . . . . . . . . . . . . . . -76.0 -6.87 53.03 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-N 115.919 -0.582 . . . . 0.0 110.554 -179.821 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 173' ' ' ILE . . . . . 0.48 ' O ' HG12 ' A' ' 177' ' ' ILE . 34.1 mm -85.86 -21.12 7.75 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.204 0 CA-C-N 115.719 -0.673 . . . . 0.0 110.853 179.41 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 174' ' ' TYR . . . . . . . . . . . . . 11.8 m-85 -53.76 -50.22 84.83 Favored Pre-proline 0 CA--C 1.53 0.194 0 CA-C-N 116.313 -0.403 . . . . 0.0 111.799 -179.446 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 175' ' ' PRO . . . . . . . . . . . . . 74.5 Cg_exo -50.42 -29.9 25.5 Favored 'Trans proline' 0 C--N 1.349 0.572 0 C-N-CA 122.191 1.927 . . . . 0.0 112.517 179.84 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 176' ' ' PHE . . . . . 0.432 ' HD2' ' HA ' ' A' ' 173' ' ' ILE . 38.9 m-85 -80.44 -50.24 10.35 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.233 -0.44 . . . . 0.0 111.846 -179.707 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 177' ' ' ILE . . . . . 0.488 ' HB ' HD12 ' A' ' 197' ' ' ILE . 5.7 mm -65.65 -33.54 64.29 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.519 0 N-CA-C 112.27 0.47 . . . . 0.0 112.27 -178.229 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 178' ' ' TRP . . . . . 0.431 ' HH2' ' HB2' ' A' ' 123' ' ' ARG . 88.7 t90 -72.86 -56.53 5.08 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.873 0.368 . . . . 0.0 110.807 -179.925 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 179' ' ' LEU . . . . . 0.449 HD21 HD21 ' A' ' 180' ' ' LEU . 0.6 OUTLIER -63.04 -54.23 41.33 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 115.931 -0.577 . . . . 0.0 111.324 -179.36 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 180' ' ' LEU . . . . . 0.449 HD21 HD21 ' A' ' 179' ' ' LEU . 43.3 mt -64.67 -41.41 96.1 Favored 'General case' 0 C--N 1.331 -0.213 0 C-N-CA 120.832 -0.347 . . . . 0.0 111.068 -179.607 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . -62.6 -178.79 3.98 Favored Glycine 0 C--N 1.334 0.43 0 C-N-CA 119.952 -1.118 . . . . 0.0 112.002 179.103 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 182' ' ' PRO . . . . . 0.437 ' HB2' ' HD3' ' A' ' 183' ' ' PRO . 83.2 Cg_exo -47.84 -44.8 26.17 Favored 'Trans proline' 0 CA--C 1.536 0.58 0 C-N-CA 122.741 2.294 . . . . 0.0 113.74 179.962 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 183' ' ' PRO . . . . . 0.437 ' HD3' ' HB2' ' A' ' 182' ' ' PRO . 84.1 Cg_exo -47.04 -22.51 2.15 Favored 'Trans proline' 0 C--N 1.356 0.933 0 C-N-CA 122.209 1.939 . . . . 0.0 113.286 -179.688 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 184' ' ' GLY . . . . . . . . . . . . . . . -126.12 -124.12 2.74 Favored Glycine 0 C--N 1.333 0.367 0 C-N-CA 120.305 -0.95 . . . . 0.0 112.926 179.874 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 185' ' ' VAL . . . . . 0.403 ' CG2' ' HA ' ' A' ' 180' ' ' LEU . 19.4 m -61.28 -25.31 36.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 N-CA-C 112.281 0.474 . . . . 0.0 112.281 -179.248 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 186' ' ' ALA . . . . . 0.43 ' HB1' ' HA ' ' A' ' 182' ' ' PRO . . . 57.65 85.41 0.09 Allowed 'General case' 0 N--CA 1.465 0.318 0 CA-C-O 120.832 0.348 . . . . 0.0 111.7 179.555 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 187' ' ' LEU . . . . . 0.44 HD11 HD22 ' A' ' 180' ' ' LEU . 10.7 mt -92.88 -49.27 6.13 Favored 'General case' 0 C--N 1.332 -0.184 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.359 179.911 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 188' ' ' LEU . . . . . . . . . . . . . 53.7 mt -95.47 -161.43 0.86 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 115.988 -0.551 . . . . 0.0 111.691 -179.052 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 189' ' ' THR . . . . . . . . . . . . . 9.9 m -91.5 137.06 26.09 Favored Pre-proline 0 C--N 1.33 -0.261 0 CA-C-N 115.77 -0.65 . . . . 0.0 110.682 -179.716 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 190' ' ' PRO . . . . . . . . . . . . . 96.4 Cg_exo -44.65 -46.01 12.76 Favored 'Trans proline' 0 C--N 1.35 0.655 0 C-N-CA 122.812 2.341 . . . . 0.0 113.539 -179.735 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 191' ' ' THR . . . . . . . . . . . . . 6.7 t -59.1 -36.83 75.8 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.822 0.344 . . . . 0.0 111.329 -179.764 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 192' ' ' VAL . . . . . . . . . . . . . 58.0 t -74.79 -53.63 16.19 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.22 -0.446 . . . . 0.0 111.696 -179.591 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 193' ' ' ASP . . . . . . . . . . . . . 23.9 m-20 -56.45 -48.36 77.22 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.45 -0.341 . . . . 0.0 110.973 -179.588 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 194' ' ' VAL . . . . . . . . . . . . . 78.0 t -61.92 -36.38 73.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.432 179.602 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 195' ' ' ALA . . . . . . . . . . . . . . . -56.28 -42.34 77.33 Favored 'General case' 0 C--N 1.331 -0.197 0 CA-C-N 116.344 -0.389 . . . . 0.0 110.823 179.335 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 196' ' ' LEU . . . . . . . . . . . . . 96.1 mt -67.19 -38.86 86.09 Favored 'General case' 0 C--N 1.332 -0.174 0 CA-C-O 120.952 0.406 . . . . 0.0 110.332 179.486 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 197' ' ' ILE . . . . . 0.488 HD12 ' HB ' ' A' ' 177' ' ' ILE . 21.6 mm -59.79 -52.6 59.19 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 115.937 -0.574 . . . . 0.0 110.18 179.153 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 198' ' ' VAL . . . . . . . . . . . . . 90.8 t -57.26 -34.15 45.17 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.458 0 N-CA-C 108.908 -0.775 . . . . 0.0 108.908 178.179 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 199' ' ' TYR . . . . . . . . . . . . . 46.0 t80 -69.44 -30.3 68.19 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-N 115.115 -0.948 . . . . 0.0 110.568 179.46 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 200' ' ' LEU . . . . . . . . . . . . . 48.2 mt -70.25 -42.37 72.27 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 115.944 -0.571 . . . . 0.0 111.158 -179.854 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 201' ' ' ASP . . . . . 0.579 ' HB2' ' HH ' ' A' ' 51' ' ' TYR . 12.3 m-20 -73.3 -34.65 65.84 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-O 121.167 0.508 . . . . 0.0 110.15 179.378 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 202' ' ' LEU . . . . . . . . . . . . . 2.5 mt -70.78 -31.33 68.07 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 115.562 -0.745 . . . . 0.0 111.795 -179.799 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 203' ' ' VAL . . . . . . . . . . . . . 11.9 p -77.18 -37.1 25.42 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.235 0 C-N-CA 120.946 -0.302 . . . . 0.0 111.209 -179.143 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 204' ' ' THR . . . . . . . . . . . . . 68.0 m -65.13 -57.49 8.44 Favored 'General case' 0 C--O 1.222 -0.392 0 C-N-CA 120.76 -0.376 . . . . 0.0 111.318 179.718 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 205' ' ' LYS . . . . . 0.633 ' HE2' ' HB1' ' A' ' 47' ' ' ALA . 60.6 mttp -65.13 -55.51 18.3 Favored 'General case' 0 C--N 1.326 -0.414 0 N-CA-C 112.301 0.482 . . . . 0.0 112.301 -178.716 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 59.2 t -65.31 -47.18 88.17 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 N-CA-C 111.841 0.312 . . . . 0.0 111.841 -179.606 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 207' ' ' GLY . . . . . . . . . . . . . . . -63.94 -59.62 8.34 Favored Glycine 0 C--N 1.331 0.28 0 C-N-CA 120.708 -0.758 . . . . 0.0 112.771 -179.795 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 208' ' ' PHE . . . . . 0.42 ' O ' ' N ' ' A' ' 212' ' ' ALA . 4.1 t80 -54.71 -40.74 69.52 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.672 0.272 . . . . 0.0 110.97 179.965 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 209' ' ' GLY . . . . . 0.461 ' O ' ' HB1' ' A' ' 212' ' ' ALA . . . -69.78 -38.65 76.63 Favored Glycine 0 C--N 1.329 0.189 0 CA-C-N 115.877 -0.601 . . . . 0.0 113.356 -179.558 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 210' ' ' PHE . . . . . . . . . . . . . 1.4 m-85 -69.66 -39.95 76.75 Favored 'General case' 0 CA--C 1.51 -0.571 0 N-CA-C 107.649 -1.241 . . . . 0.0 107.649 179.118 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 211' ' ' ILE . . . . . . . . . . . . . 29.9 mt -69.73 -28.6 37.84 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.87 0 CA-C-N 114.235 -1.348 . . . . 0.0 107.416 176.737 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 212' ' ' ALA . . . . . 0.461 ' HB1' ' O ' ' A' ' 209' ' ' GLY . . . -68.08 -38.8 82.78 Favored 'General case' 0 N--CA 1.447 -0.59 0 CA-C-N 114.293 -1.321 . . . . 0.0 110.637 179.856 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 213' ' ' LEU . . . . . . . . . . . . . 96.4 mt -70.6 -53.09 17.3 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 115.257 -0.883 . . . . 0.0 112.043 -179.238 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 214' ' ' ASP . . . . . . . . . . . . . 45.0 m-20 -52.09 -53.06 47.11 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.443 -0.344 . . . . 0.0 111.636 -179.428 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 215' ' ' ALA . . . . . 0.424 ' HB1' HD21 ' A' ' 159' ' ' LEU . . . -59.68 -57.36 13.26 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.344 -0.389 . . . . 0.0 111.818 -179.511 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 216' ' ' ALA . . . . . . . . . . . . . . . -58.11 -31.73 67.43 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.441 -0.345 . . . . 0.0 111.601 -179.519 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 217' ' ' ALA . . . . . . . . . . . . . . . -62.24 -42.16 99.06 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 121.015 0.436 . . . . 0.0 110.151 179.832 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 218' ' ' THR . . . . . . . . . . . . . 97.2 m -67.44 -39.2 85.41 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 115.827 -0.624 . . . . 0.0 110.33 179.154 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 219' ' ' LEU . . . . . 0.489 ' O ' ' HG2' ' A' ' 222' ' ' GLU . 82.9 mt -58.77 -41.88 87.64 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 115.784 -0.644 . . . . 0.0 110.669 179.733 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 220' ' ' ARG . . . . . . . . . . . . . 36.0 ptt180 -83.96 -14.12 51.66 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.213 -0.448 . . . . 0.0 110.587 179.435 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 221' ' ' ALA . . . . . . . . . . . . . . . -82.55 -20.21 37.05 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.13 -0.486 . . . . 0.0 111.931 -179.57 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 222' ' ' GLU . . . . . 0.489 ' HG2' ' O ' ' A' ' 219' ' ' LEU . 11.4 pt-20 -67.17 -28.39 68.07 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-O 121.058 0.456 . . . . 0.0 110.352 -179.732 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 223' ' ' HIS . . . . . . . . . . . . . 84.2 m-70 -66.76 -24.82 66.26 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 115.68 -0.691 . . . . 0.0 110.908 -179.924 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 224' ' ' GLY . . . . . . . . . . . . . . . 73.04 -124.78 9.28 Favored Glycine 0 N--CA 1.452 -0.235 0 C-N-CA 120.85 -0.69 . . . . 0.0 112.458 179.91 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 225' ' ' GLU . . . . . . . . . . . . . 8.9 tp10 -163.95 148.81 10.42 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.83 0.348 . . . . 0.0 110.912 179.977 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 226' ' ' SER . . . . . . . . . . . . . 50.5 m -109.15 -32.17 7.32 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.889 179.966 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 227' ' ' LEU . . . . . . . . . . . . . 53.5 tp -61.36 143.2 56.19 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.067 -0.515 . . . . 0.0 110.884 179.903 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 228' ' ' ALA . . . . . . . . . . . . . . . -88.11 135.98 33.18 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.964 179.858 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 229' ' ' GLY . . . . . . . . . . . . . . . 139.21 138.68 3.69 Favored Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.807 -0.711 . . . . 0.0 112.302 -179.738 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 230' ' ' VAL . . . . . . . . . . . . . 5.6 m -119.8 29.74 2.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-O 120.874 0.369 . . . . 0.0 111.364 -179.911 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 231' ' ' ASP . . . . . . . . . . . . . 5.7 m-20 49.0 67.96 0.79 Allowed 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 115.695 -0.684 . . . . 0.0 110.832 -179.846 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 232' ' ' THR . . . . . . . . . . . . . 38.6 p -139.12 -65.46 0.48 Allowed 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.273 -0.422 . . . . 0.0 111.429 -179.538 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 233' ' ' ASP . . . . . . . . . . . . . 17.1 m-20 -88.79 -78.35 0.34 Allowed 'General case' 0 C--N 1.33 -0.239 0 CA-C-N 116.33 -0.396 . . . . 0.0 111.242 -179.631 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 234' ' ' THR . . . . . . . . . . . . . 81.9 p -140.87 146.07 42.36 Favored Pre-proline 0 C--N 1.33 -0.275 0 CA-C-N 116.363 -0.38 . . . . 0.0 111.021 -179.797 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 235' ' ' PRO . . . . . . . . . . . . . 58.5 Cg_endo -71.94 153.1 58.16 Favored 'Trans proline' 0 C--N 1.348 0.544 0 C-N-CA 122.298 1.998 . . . . 0.0 112.096 179.801 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 236' ' ' ALA . . . . . 0.5 ' O ' HG12 ' A' ' 237' ' ' VAL . . . 63.16 109.81 0.03 OUTLIER 'General case' 0 C--N 1.333 -0.139 0 CA-C-N 116.095 -0.502 . . . . 0.0 111.211 -179.893 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 237' ' ' VAL . . . . . 0.546 HG23 ' H ' ' A' ' 238' ' ' ALA . 0.5 OUTLIER 52.23 176.94 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.466 0.328 0 CA-C-N 115.882 -0.599 . . . . 0.0 111.606 -179.905 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 238' ' ' ALA . . . . . 0.546 ' H ' HG23 ' A' ' 237' ' ' VAL . . . -149.32 0.2 0.5 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.349 -0.387 . . . . 0.0 111.135 179.903 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 239' ' ' ASP . . . . . . . . . . . . . 7.8 m-20 59.89 98.1 0.03 OUTLIER 'General case' 0 C--N 1.332 -0.185 0 CA-C-N 116.019 -0.537 . . . . 0.0 111.411 179.78 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 240' ' ' LEU . . . . . . . . . . . . . 7.5 mp -111.96 104.74 13.03 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.08 -0.509 . . . . 0.0 110.692 179.717 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 241' ' ' GLU . . . . . . . . . . . . . 2.2 mp0 -96.38 0.73 50.99 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 116.293 -0.412 . . . . 0.0 110.921 179.986 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 242' ' ' HIS . . . . . . . . . . . . . 14.6 t-80 -88.37 118.85 28.28 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.299 -0.41 . . . . 0.0 110.855 179.936 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 243' ' ' HIS . . . . . . . . . . . . . 18.4 p-80 -85.71 171.17 11.83 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.041 -179.982 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 244' ' ' HIS . . . . . . . . . . . . . 56.1 t-80 -138.52 97.15 3.29 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 115.977 -0.556 . . . . 0.0 110.812 179.997 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 245' ' ' HIS . . . . . . . . . . . . . 58.8 m-70 60.05 106.0 0.02 OUTLIER 'General case' 0 C--N 1.331 -0.218 0 CA-C-N 116.115 -0.493 . . . . 0.0 111.32 -179.942 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 246' ' ' HIS . . . . . . . . . . . . . 12.4 p-80 -106.68 -14.19 15.08 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.067 -0.515 . . . . 0.0 110.8 179.771 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 247' ' ' HIS . . . . . . . . . . . . . 82.0 m-70 . . . . . 0 C--O 1.248 1.006 0 CA-C-O 118.218 -0.896 . . . . 0.0 110.946 -179.942 . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 301' ' ' RET . . . . . 0.59 ' H22' ' HA3' ' A' ' 112' ' ' GLY . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 59.9 ttp . . . . . 0 N--CA 1.486 1.348 0 CA-C-O 120.678 0.275 . . . . 0.0 110.865 . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 42.1 t 62.47 103.77 0.04 OUTLIER 'Isoleucine or valine' 0 C--N 1.332 -0.195 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.332 179.807 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . 145.07 -37.72 1.31 Allowed Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.846 -0.692 . . . . 0.0 112.384 179.976 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 59.4 tp -74.42 -35.52 63.41 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 120.844 0.355 . . . . 0.0 111.101 179.886 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 65.2 p -62.64 -30.06 71.09 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.517 -179.626 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 6' ' ' THR . . . . . 0.509 ' HG1' HD23 ' A' ' 7' ' ' LEU . 36.1 p -55.11 -35.46 64.68 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.44 -0.345 . . . . 0.0 111.118 -179.92 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 7' ' ' LEU . . . . . 0.509 HD23 ' HG1' ' A' ' 6' ' ' THR . 4.2 mm? -56.65 -53.26 59.77 Favored 'General case' 0 C--N 1.331 -0.205 0 CA-C-N 116.082 -0.508 . . . . 0.0 111.052 -179.974 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 8' ' ' PHE . . . . . 0.615 ' HB2' ' HB2' ' A' ' 55' ' ' ALA . 67.9 m-85 -60.96 -36.41 79.32 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.873 -179.958 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 9' ' ' TRP . . . . . . . . . . . . . 30.4 m95 -61.4 -44.16 97.63 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.047 -179.876 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 51.8 mt -60.94 -42.65 98.59 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 115.638 -0.71 . . . . 0.0 110.239 179.246 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -62.09 -29.94 74.22 Favored Glycine 0 N--CA 1.448 -0.549 0 C-N-CA 120.69 -0.766 . . . . 0.0 111.888 179.259 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -72.58 -33.51 66.8 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-O 120.698 0.285 . . . . 0.0 110.968 179.719 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 13' ' ' ILE . . . . . 0.403 ' O ' HG23 ' A' ' 17' ' ' VAL . 83.3 mt -64.16 -54.32 32.7 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.226 0 CA-C-N 116.343 -0.39 . . . . 0.0 110.749 179.758 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -66.02 -34.15 87.59 Favored Glycine 0 N--CA 1.452 -0.291 0 C-N-CA 120.685 -0.769 . . . . 0.0 112.227 179.833 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 15' ' ' MET . . . . . 0.525 ' SD ' ' HA ' ' A' ' 44' ' ' SER . 52.7 tpp -65.69 -49.79 67.27 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.733 0.301 . . . . 0.0 110.646 179.986 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 51.0 mt -53.42 -42.23 66.84 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.506 179.382 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . 0.403 HG23 ' O ' ' A' ' 13' ' ' ILE . 99.5 t -58.89 -41.46 82.98 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.226 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.125 179.128 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -64.76 -40.49 97.43 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.606 -0.806 . . . . 0.0 111.49 179.029 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 3.6 m -50.97 -54.17 26.69 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.883 0.373 . . . . 0.0 111.102 179.917 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 75.2 mt -71.74 -39.72 69.88 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.061 -0.518 . . . . 0.0 111.454 -179.887 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -54.71 -43.88 72.95 Favored 'General case' 0 C--N 1.329 -0.316 0 N-CA-C 112.381 0.512 . . . . 0.0 112.381 -178.953 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 4.3 m-85 -84.36 -28.24 27.14 Favored 'General case' 0 C--N 1.329 -0.315 0 N-CA-C 111.889 0.329 . . . . 0.0 111.889 -178.969 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -64.98 -51.48 61.48 Favored 'General case' 0 C--N 1.326 -0.442 0 N-CA-C 112.59 0.589 . . . . 0.0 112.59 -178.965 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 24' ' ' TRP . . . . . 0.501 ' HA ' ' CE3' ' A' ' 24' ' ' TRP . 2.3 t-105 -87.1 -26.75 23.5 Favored 'General case' 0 N--CA 1.442 -0.827 0 N-CA-C 113.383 0.882 . . . . 0.0 113.383 -177.497 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -47.28 -48.25 24.91 Favored 'General case' 0 C--N 1.318 -0.778 0 C-N-CA 120.636 -0.426 . . . . 0.0 109.947 178.896 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -70.34 -23.85 77.12 Favored Glycine 0 N--CA 1.449 -0.454 0 N-CA-C 109.427 -1.469 . . . . 0.0 109.427 177.478 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 27' ' ' ARG . . . . . 0.492 ' HG3' ' O ' ' A' ' 24' ' ' TRP . 16.0 mtm180 59.37 73.41 0.48 Allowed 'General case' 0 CA--C 1.512 -0.505 0 CA-C-N 114.384 -0.908 . . . . 0.0 111.859 178.63 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 28' ' ' ASP . . . . . 0.404 ' HB3' ' O ' ' A' ' 27' ' ' ARG . 4.4 t70 65.52 -71.34 0.08 Allowed 'General case' 0 N--CA 1.453 -0.319 0 CA-C-N 115.406 -0.815 . . . . 0.0 111.53 178.721 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . 64.41 -176.24 0.17 Allowed 'General case' 0 C--N 1.333 -0.133 0 CA-C-O 120.93 0.395 . . . . 0.0 111.317 179.234 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -82.9 -99.55 0.51 Allowed Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.809 -0.71 . . . . 0.0 112.768 -179.779 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 61.6 m -149.45 -27.57 0.27 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.646 0.26 . . . . 0.0 111.123 -179.653 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -63.98 -32.81 85.42 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.683 -0.77 . . . . 0.0 112.445 -179.988 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 9.0 mm-40 -89.27 -20.59 23.91 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.776 0.322 . . . . 0.0 110.872 -179.957 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 34' ' ' ARG . . . . . . . . . . . . . 92.8 mtt180 -56.35 -28.7 59.86 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.129 -0.487 . . . . 0.0 111.385 -179.815 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 99.2 mtt180 -54.96 -56.46 19.44 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-O 120.863 0.363 . . . . 0.0 111.286 -179.807 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 76.1 m-85 -71.29 -40.16 71.06 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.944 -179.052 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 37' ' ' TYR . . . . . . . . . . . . . 20.7 m-85 -65.52 -56.3 13.12 Favored 'General case' 0 C--N 1.329 -0.305 0 N-CA-C 111.707 0.262 . . . . 0.0 111.707 -179.08 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 89.3 t -57.08 -37.17 53.9 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.326 0 CA-C-O 120.724 0.297 . . . . 0.0 110.935 179.981 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 15.2 m -64.36 -51.55 62.73 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 121.037 0.446 . . . . 0.0 110.748 179.33 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 40' ' ' LEU . . . . . 0.4 HD11 HD13 ' A' ' 43' ' ' ILE . 61.1 tp -59.22 -50.83 72.5 Favored 'General case' 0 C--O 1.235 0.306 0 CA-C-N 115.877 -0.601 . . . . 0.0 110.641 179.913 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 96.4 t -59.78 -34.4 55.54 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 115.974 -0.557 . . . . 0.0 109.62 178.902 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -57.22 -39.28 89.82 Favored Glycine 0 N--CA 1.447 -0.603 0 CA-C-N 115.644 -0.707 . . . . 0.0 111.767 179.407 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 43' ' ' ILE . . . . . 0.456 HG23 ' HE3' ' A' ' 205' ' ' LYS . 1.0 OUTLIER -65.65 -53.12 42.48 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.205 0 CA-C-O 120.832 0.348 . . . . 0.0 110.128 179.306 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 44' ' ' SER . . . . . 0.525 ' HA ' ' SD ' ' A' ' 15' ' ' MET . 83.0 p -61.86 -21.2 64.47 Favored 'General case' 0 C--N 1.333 -0.146 0 CA-C-N 116.104 -0.498 . . . . 0.0 111.12 179.985 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -76.25 -59.23 3.4 Favored Glycine 0 N--CA 1.452 -0.265 0 C-N-CA 120.726 -0.75 . . . . 0.0 112.662 -179.737 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 20.7 pt -61.0 -35.68 66.96 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-O 120.724 0.297 . . . . 0.0 111.425 -179.79 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 47' ' ' ALA . . . . . 0.557 ' HB3' ' HE2' ' A' ' 205' ' ' LYS . . . -67.06 -43.87 81.56 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.843 0.354 . . . . 0.0 111.065 179.478 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -54.78 -49.33 71.16 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.094 -0.503 . . . . 0.0 111.359 -179.749 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 26.9 m -67.75 -34.14 65.96 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.328 -0.396 . . . . 0.0 111.09 -179.718 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -62.75 -38.65 91.41 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-O 121.12 0.486 . . . . 0.0 110.657 179.576 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 51' ' ' TYR . . . . . 0.436 ' OH ' ' HB2' ' A' ' 201' ' ' ASP . 30.6 m-85 -72.93 -31.42 64.6 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-N 115.763 -0.653 . . . . 0.0 110.169 179.852 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -70.04 -42.52 72.8 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-N 115.749 -0.659 . . . . 0.0 111.091 179.609 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 53' ' ' VAL . . . . . 0.442 HG22 ' N ' ' A' ' 54' ' ' MET . 32.9 m -69.43 -45.5 78.48 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.197 0 CA-C-N 116.548 -0.296 . . . . 0.0 110.985 -179.848 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 54' ' ' MET . . . . . 0.442 ' N ' HG22 ' A' ' 53' ' ' VAL . 76.7 mtm -64.66 -31.06 72.12 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-O 121.034 0.445 . . . . 0.0 110.094 179.319 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 55' ' ' ALA . . . . . 0.615 ' HB2' ' HB2' ' A' ' 8' ' ' PHE . . . -74.46 -15.35 60.9 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 115.672 -0.694 . . . . 0.0 111.403 179.637 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 69.6 mt -92.1 -13.36 30.92 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.458 -0.337 . . . . 0.0 111.492 -179.697 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 104.2 -20.92 39.07 Favored Glycine 0 N--CA 1.452 -0.263 0 C-N-CA 120.52 -0.848 . . . . 0.0 113.112 179.8 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 58' ' ' VAL . . . . . 0.424 HG13 ' O ' ' A' ' 53' ' ' VAL . 11.7 p -67.08 149.61 11.52 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-N 116.861 0.331 . . . . 0.0 110.623 179.989 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 88.09 -14.47 58.92 Favored Glycine 0 N--CA 1.449 -0.471 0 C-N-CA 120.663 -0.779 . . . . 0.0 111.774 -179.155 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 60' ' ' TRP . . . . . . . . . . . . . 18.2 m0 -76.02 97.77 4.12 Favored 'General case' 0 C--N 1.331 -0.197 0 CA-C-O 120.836 0.35 . . . . 0.0 110.673 179.917 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 61' ' ' VAL . . . . . 0.471 HG13 HG23 ' A' ' 68' ' ' VAL . 5.2 p -100.32 129.26 28.41 Favored Pre-proline 0 C--N 1.328 -0.327 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.81 179.766 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 73.5 Cg_endo -73.97 146.22 36.91 Favored 'Trans proline' 0 C--N 1.35 0.619 0 C-N-CA 122.478 2.118 . . . . 0.0 112.245 -179.826 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 92.1 t -140.37 95.35 0.78 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.181 -179.67 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . 57.94 -91.42 0.03 OUTLIER 'General case' 0 C--N 1.331 -0.212 0 CA-C-N 116.123 -0.489 . . . . 0.0 111.27 -179.969 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -122.57 -11.78 8.22 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-O 120.968 0.413 . . . . 0.0 110.702 179.715 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 66' ' ' ARG . . . . . 0.423 HH22 HH12 ' A' ' 123' ' ' ARG . 16.9 ptp180 -105.52 165.6 11.03 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 115.9 -0.591 . . . . 0.0 110.364 179.454 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 61.5 m -126.33 141.51 51.88 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 120.965 0.412 . . . . 0.0 111.357 -179.842 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 68' ' ' VAL . . . . . 0.503 HG22 ' HG3' ' A' ' 117' ' ' MET . 9.1 m -133.25 146.18 32.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 115.942 -0.572 . . . . 0.0 110.669 179.575 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 69' ' ' PHE . . . . . . . . . . . . . 5.8 m-85 -107.59 118.31 36.4 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-O 121.049 0.452 . . . . 0.0 110.389 -179.056 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 70' ' ' VAL . . . . . 0.597 HG13 ' HD3' ' A' ' 71' ' ' PRO . 1.3 p -67.1 -35.32 8.63 Favored Pre-proline 0 CA--C 1.54 0.583 0 CA-C-N 115.687 -0.688 . . . . 0.0 112.829 -178.978 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 71' ' ' PRO . . . . . 0.597 ' HD3' HG13 ' A' ' 70' ' ' VAL . 8.7 Cg_exo -70.38 -18.65 33.94 Favored 'Trans proline' 0 C--N 1.356 0.948 0 C-N-CA 121.902 1.734 . . . . 0.0 112.66 -179.37 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 46.8 ttp180 -75.16 -54.3 7.36 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.55 -0.295 . . . . 0.0 111.791 -178.948 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 73' ' ' TYR . . . . . 0.409 ' O ' HG13 ' A' ' 77' ' ' ILE . 18.4 m-85 -67.66 -37.1 81.9 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.755 0.312 . . . . 0.0 110.491 -179.569 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 0.4 OUTLIER -68.39 -38.37 79.25 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.219 0 CA-C-N 116.293 -0.412 . . . . 0.0 110.139 179.526 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 19.5 t70 -59.65 -36.97 77.45 Favored 'General case' 0 CA--C 1.52 -0.199 0 N-CA-C 109.712 -0.477 . . . . 0.0 109.712 179.08 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 76' ' ' TRP . . . . . . . . . . . . . 46.0 m0 -65.03 -41.67 95.07 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 115.781 -0.645 . . . . 0.0 110.081 179.427 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 77' ' ' ILE . . . . . 0.409 HG13 ' O ' ' A' ' 73' ' ' TYR . 66.7 mt -61.79 -28.64 44.62 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.425 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.902 179.544 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 29.8 mt -90.74 -27.98 18.59 Favored 'General case' 0 CA--C 1.531 0.232 0 N-CA-C 112.481 0.549 . . . . 0.0 112.481 -179.376 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 64.6 p -91.28 -43.44 9.8 Favored 'General case' 0 C--N 1.329 -0.322 0 N-CA-C 113.002 0.741 . . . . 0.0 113.002 -178.022 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 80' ' ' THR . . . . . 0.553 ' N ' ' HD2' ' A' ' 81' ' ' PRO . 38.9 p -52.33 -45.01 94.96 Favored Pre-proline 0 C--N 1.328 -0.356 0 N-CA-C 113.072 0.767 . . . . 0.0 113.072 -179.044 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 81' ' ' PRO . . . . . 0.553 ' HD2' ' N ' ' A' ' 80' ' ' THR . 35.8 Cg_endo -62.99 -23.03 74.11 Favored 'Trans proline' 0 C--N 1.354 0.847 0 C-N-CA 121.406 1.404 . . . . 0.0 111.776 -179.78 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 82' ' ' LEU . . . . . 0.428 HD21 HG12 ' A' ' 43' ' ' ILE . 7.5 mp -76.82 -43.03 38.09 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 115.779 -0.646 . . . . 0.0 111.365 -179.494 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 83' ' ' ILE . . . . . 0.418 HD12 HD12 ' A' ' 43' ' ' ILE . 39.8 mm -63.29 -53.85 40.51 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.413 -0.358 . . . . 0.0 110.955 -179.851 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 33.5 m -60.05 -36.95 70.63 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.222 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.467 179.668 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 85' ' ' TYR . . . . . . . . . . . . . 69.8 t80 -63.48 -32.85 74.42 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.098 -0.501 . . . . 0.0 109.809 179.246 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 86' ' ' PHE . . . . . . . . . . . . . 6.0 t80 -61.64 -51.91 66.54 Favored 'General case' 0 C--O 1.233 0.193 0 CA-C-N 115.973 -0.558 . . . . 0.0 109.963 179.34 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 8.5 mp -61.06 -31.85 71.5 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 115.859 -0.61 . . . . 0.0 110.169 179.199 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -71.13 -27.87 71.2 Favored Glycine 0 N--CA 1.45 -0.392 0 C-N-CA 120.871 -0.68 . . . . 0.0 111.787 179.321 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 71.1 mt -73.13 -34.82 66.34 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-O 120.972 0.415 . . . . 0.0 110.38 179.517 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 74.8 mt -66.47 -35.66 80.82 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 115.761 -0.654 . . . . 0.0 111.303 -179.984 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -87.93 -32.33 18.96 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.589 -179.472 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 82.83 55.14 3.04 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.675 -0.774 . . . . 0.0 112.195 -179.72 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 93' ' ' LEU . . . . . 0.494 HD12 ' HE3' ' A' ' 145' ' ' MET . 33.8 mt -69.44 167.24 17.04 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.899 0.381 . . . . 0.0 111.128 -179.815 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 94' ' ' ASP . . . . . . . . . . . . . 18.4 t70 -86.15 168.29 14.14 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 115.987 -0.551 . . . . 0.0 110.361 179.683 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 80.8 p -57.62 -33.13 67.93 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.439 -0.346 . . . . 0.0 110.974 179.972 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 98.2 mtt180 -73.82 -53.47 10.18 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.208 179.944 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 44.0 mt-10 -53.76 -42.14 67.9 Favored 'General case' 0 C--N 1.332 -0.175 0 CA-C-N 116.362 -0.381 . . . . 0.0 110.914 -179.892 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 98' ' ' PHE . . . . . 0.401 ' O ' HG12 ' A' ' 102' ' ' ILE . 9.0 m-85 -59.91 -46.86 88.0 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.77 179.668 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -58.82 -29.59 64.87 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.816 -0.707 . . . . 0.0 112.56 -179.922 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 95.1 mt -73.51 -42.36 56.11 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.243 0 CA-C-O 120.872 0.368 . . . . 0.0 111.436 -179.847 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 42.1 t -68.61 -43.89 83.08 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.365 0 CA-C-N 116.329 -0.396 . . . . 0.0 111.208 -179.815 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 102' ' ' ILE . . . . . 0.401 HG12 ' O ' ' A' ' 98' ' ' PHE . 42.2 mm -68.53 -46.36 80.32 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.355 0 CA-C-N 116.086 -0.506 . . . . 0.0 111.688 -179.338 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 14.6 t -58.44 -35.85 72.75 Favored 'General case' 0 C--O 1.232 0.161 0 CA-C-O 120.778 0.323 . . . . 0.0 110.673 179.945 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 30.1 tp -62.84 -45.99 90.03 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.036 179.124 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 105' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -62.58 -25.75 68.24 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 115.978 -0.555 . . . . 0.0 110.712 179.354 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 24.6 m -68.57 -52.1 35.47 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.371 -0.377 . . . . 0.0 111.491 -179.803 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 10.9 p -70.24 -40.57 78.16 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.212 0 CA-C-N 116.429 -0.35 . . . . 0.0 111.888 -179.428 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . 0.509 ' HA ' ' HE1' ' A' ' 129' ' ' MET . 73.1 t -62.66 -58.46 7.48 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.254 0 CA-C-O 120.977 0.418 . . . . 0.0 111.458 -179.74 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 109' ' ' MET . . . . . 0.578 ' N ' ' SD ' ' A' ' 109' ' ' MET . 0.0 OUTLIER -58.39 -32.46 68.62 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 115.957 -0.565 . . . . 0.0 110.827 -179.396 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 28.4 tp -67.69 -35.29 78.54 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.296 -0.411 . . . . 0.0 110.089 179.292 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -60.88 -49.11 78.8 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-N 115.989 -0.551 . . . . 0.0 110.167 179.155 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 112' ' ' GLY . . . . . 0.405 ' HA3' ' H22' ' A' ' 301' ' ' RET . . . -59.82 -33.83 79.95 Favored Glycine 0 N--CA 1.45 -0.43 0 C-N-CA 120.574 -0.822 . . . . 0.0 111.716 179.271 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 113' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER -54.71 -65.04 0.65 Allowed 'General case' 0 C--N 1.332 -0.191 0 CA-C-O 121.052 0.454 . . . . 0.0 110.226 179.326 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -66.43 -30.53 70.91 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 115.609 -0.723 . . . . 0.0 111.575 -179.64 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -52.12 -51.08 43.04 Favored Glycine 0 C--N 1.332 0.358 0 C-N-CA 121.059 -0.591 . . . . 0.0 112.988 -179.644 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 116' ' ' ALA . . . . . 0.451 ' HB2' ' HB3' ' A' ' 183' ' ' PRO . . . -78.09 -15.45 58.87 Favored 'General case' 0 C--N 1.327 -0.405 0 N-CA-C 111.829 0.307 . . . . 0.0 111.829 -179.558 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 117' ' ' MET . . . . . 0.503 ' HG3' HG22 ' A' ' 68' ' ' VAL . 35.5 ttm -106.23 17.0 24.12 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.79 0.328 . . . . 0.0 111.277 -179.425 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 118' ' ' VAL . . . . . 0.477 HG13 ' N ' ' A' ' 123' ' ' ARG . 15.9 m -63.81 148.57 94.46 Favored Pre-proline 0 C--N 1.331 -0.239 0 CA-C-N 116.414 -0.357 . . . . 0.0 111.413 179.847 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 119' ' ' PRO . . . . . . . . . . . . . 88.7 Cg_endo -82.66 -1.64 10.64 Favored 'Trans proline' 0 C--N 1.347 0.461 0 C-N-CA 122.605 2.204 . . . . 0.0 112.273 179.58 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -157.6 -121.18 0.65 Allowed Glycine 0 C--N 1.33 0.246 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.522 -179.994 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 1.9 pp -106.69 12.93 8.43 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.207 0 CA-C-O 120.866 0.365 . . . . 0.0 111.291 -179.932 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 41.9 mt-10 -59.97 -17.49 38.47 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.012 -0.54 . . . . 0.0 111.293 179.929 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 123' ' ' ARG . . . . . 0.477 ' N ' HG13 ' A' ' 118' ' ' VAL . 27.6 ptt180 -50.37 -29.66 10.52 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-N 116.118 -0.492 . . . . 0.0 111.853 -179.757 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 124' ' ' TYR . . . . . . . . . . . . . 28.9 m-85 -67.64 -33.03 74.14 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.771 0.319 . . . . 0.0 111.201 -179.783 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 125' ' ' ALA . . . . . . . . . . . . . . . -72.38 -48.54 40.84 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.254 -0.43 . . . . 0.0 111.426 -179.982 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 3.3 mm? -54.6 -55.58 27.9 Favored 'General case' 0 C--N 1.331 -0.206 0 CA-C-N 116.351 -0.386 . . . . 0.0 110.987 -179.673 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 127' ' ' PHE . . . . . 0.443 ' HZ ' ' HB3' ' A' ' 175' ' ' PRO . 6.7 t80 -64.97 -39.2 93.12 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.185 -0.462 . . . . 0.0 111.456 -179.304 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 128' ' ' GLY . . . . . . . . . . . . . . . -46.44 -45.72 16.83 Favored Glycine 0 C--O 1.237 0.322 0 C-N-CA 120.228 -0.987 . . . . 0.0 111.261 179.531 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 129' ' ' MET . . . . . 0.509 ' HE1' ' HA ' ' A' ' 108' ' ' VAL . 0.3 OUTLIER -68.87 -40.18 79.41 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 115.348 -0.426 . . . . 0.0 109.907 178.986 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -68.56 -21.13 74.43 Favored Glycine 0 N--CA 1.449 -0.464 0 CA-C-N 115.701 -0.682 . . . . 0.0 112.486 179.972 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 131' ' ' ALA . . . . . 0.431 ' O ' ' HB3' ' A' ' 134' ' ' PHE . . . -75.5 -54.16 7.47 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-O 120.621 0.248 . . . . 0.0 110.596 179.886 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 46.5 t -62.94 -40.46 89.02 Favored 'Isoleucine or valine' 0 C--O 1.234 0.249 0 N-CA-C 108.839 -0.8 . . . . 0.0 108.839 178.417 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -66.82 -32.04 73.06 Favored 'General case' 0 N--CA 1.452 -0.352 0 CA-C-N 115.124 -0.943 . . . . 0.0 110.184 178.828 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 134' ' ' PHE . . . . . 0.431 ' HB3' ' O ' ' A' ' 131' ' ' ALA . 38.5 t80 -56.78 -55.61 32.14 Favored 'General case' 0 N--CA 1.452 -0.353 0 N-CA-C 109.738 -0.467 . . . . 0.0 109.738 179.402 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 135' ' ' ILE . . . . . 0.49 ' O ' HG22 ' A' ' 138' ' ' VAL . 47.9 mt -56.8 -32.71 39.19 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.407 0 CA-C-N 115.583 -0.735 . . . . 0.0 109.979 179.409 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . -59.92 -37.81 93.17 Favored Glycine 0 N--CA 1.448 -0.522 0 C-N-CA 120.113 -1.041 . . . . 0.0 110.94 178.567 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 137' ' ' LEU . . . . . . . . . . . . . 46.6 tp -71.12 -50.26 35.47 Favored 'General case' 0 N--CA 1.454 -0.247 0 CA-C-N 115.719 -0.241 . . . . 0.0 110.611 179.499 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 138' ' ' VAL . . . . . 0.525 ' HA ' HD11 ' A' ' 141' ' ' LEU . 3.7 m -57.8 -30.62 38.21 Favored 'Isoleucine or valine' 0 CA--C 1.521 -0.164 0 N-CA-C 109.23 -0.656 . . . . 0.0 109.23 179.138 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 139' ' ' TYR . . . . . . . . . . . . . 39.3 t80 -63.52 -39.8 95.37 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 115.246 -0.888 . . . . 0.0 109.173 178.205 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 22.3 m-85 -65.28 -31.97 73.38 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 115.733 -0.667 . . . . 0.0 110.256 178.617 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 141' ' ' LEU . . . . . 0.525 HD11 ' HA ' ' A' ' 138' ' ' VAL . 56.8 mt -65.06 -36.71 85.22 Favored 'General case' 0 CA--C 1.519 -0.222 0 CA-C-O 121.35 0.595 . . . . 0.0 109.591 179.973 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 16.6 m -98.0 0.08 10.44 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.822 0 CA-C-N 115.112 -0.949 . . . . 0.0 111.081 -179.866 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . -81.82 -135.35 1.97 Allowed Glycine 0 CA--C 1.521 0.447 0 C-N-CA 121.035 -0.603 . . . . 0.0 113.058 -179.486 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 144' ' ' PRO . . . . . . . . . . . . . 18.3 Cg_endo -58.32 -24.85 70.06 Favored 'Trans proline' 0 C--N 1.349 0.599 0 C-N-CA 122.726 2.284 . . . . 0.0 112.527 -179.664 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 145' ' ' MET . . . . . 0.494 ' HE3' HD12 ' A' ' 93' ' ' LEU . 62.0 mtt -59.96 -25.91 65.59 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 121.14 0.495 . . . . 0.0 110.798 179.788 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 146' ' ' THR . . . . . . . . . . . . . 17.5 m -73.79 -51.2 17.2 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 115.636 -0.711 . . . . 0.0 112.364 -178.802 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 45.7 mt-10 -75.85 -28.76 58.32 Favored 'General case' 0 C--N 1.328 -0.327 0 N-CA-C 111.856 0.317 . . . . 0.0 111.856 -178.845 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 148' ' ' SER . . . . . . . . . . . . . 37.1 t -70.66 -48.09 56.64 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-O 120.746 0.307 . . . . 0.0 111.607 -179.103 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 149' ' ' ALA . . . . . . . . . . . . . . . -74.7 -44.74 48.55 Favored 'General case' 0 C--N 1.329 -0.324 0 N-CA-C 111.994 0.368 . . . . 0.0 111.994 -179.068 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 150' ' ' SER . . . . . . . . . . . . . 87.7 p -63.65 -11.83 28.73 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.647 0.261 . . . . 0.0 111.273 -179.629 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 151' ' ' GLN . . . . . . . . . . . . . 25.5 mt-30 -124.37 21.75 8.62 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.333 -0.394 . . . . 0.0 111.248 -179.702 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 28.9 tpt180 -92.02 -51.43 5.2 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.916 0.389 . . . . 0.0 110.418 179.659 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 153' ' ' SER . . . . . 0.636 ' HB3' HG12 ' A' ' 156' ' ' ILE . 32.4 t -157.43 167.76 29.29 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.09 -0.505 . . . . 0.0 110.71 179.092 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 154' ' ' SER . . . . . . . . . . . . . 44.8 t -67.65 -36.3 80.5 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-O 120.968 0.413 . . . . 0.0 110.608 179.476 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -76.97 -36.84 34.71 Favored Glycine 0 N--CA 1.451 -0.361 0 C-N-CA 120.97 -0.633 . . . . 0.0 112.887 -179.912 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 156' ' ' ILE . . . . . 0.636 HG12 ' HB3' ' A' ' 153' ' ' SER . 39.7 mm -52.83 -36.24 23.1 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.21 0 CA-C-O 120.722 0.296 . . . . 0.0 111.315 -179.922 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 157' ' ' LYS . . . . . . . . . . . . . 85.3 tttt -54.38 -49.14 70.54 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.75 -179.611 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 42.8 t -63.97 -48.43 76.47 Favored 'General case' 0 C--N 1.33 -0.245 0 N-CA-C 111.891 0.33 . . . . 0.0 111.891 -179.189 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 159' ' ' LEU . . . . . 0.429 HD23 HD12 ' A' ' 163' ' ' LEU . 2.8 tt -67.36 -28.56 68.06 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-O 120.943 0.401 . . . . 0.0 110.673 -179.622 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 160' ' ' TYR . . . . . . . . . . . . . 25.3 t80 -73.57 -47.72 38.38 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.87 -179.245 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 161' ' ' VAL . . . . . 0.452 HG22 ' N ' ' A' ' 162' ' ' ARG . 31.0 m -62.46 -42.72 96.8 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.391 0 N-CA-C 112.414 0.524 . . . . 0.0 112.414 -178.565 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 162' ' ' ARG . . . . . 0.452 ' N ' HG22 ' A' ' 161' ' ' VAL . 22.3 mmm180 -68.6 -49.81 56.43 Favored 'General case' 0 C--N 1.328 -0.362 0 N-CA-C 111.746 0.276 . . . . 0.0 111.746 -178.747 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 163' ' ' LEU . . . . . 0.429 HD12 HD23 ' A' ' 159' ' ' LEU . 7.6 mp -70.2 -39.15 75.36 Favored 'General case' 0 C--N 1.328 -0.335 0 N-CA-C 112.195 0.443 . . . . 0.0 112.195 -178.722 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 164' ' ' ARG . . . . . 0.445 ' NH1' ' HA ' ' A' ' 141' ' ' LEU . 21.9 tpp180 -58.37 -54.37 47.75 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 120.751 0.31 . . . . 0.0 110.786 -179.783 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 165' ' ' ASN . . . . . 0.536 ' N ' HD21 ' A' ' 165' ' ' ASN . 0.8 OUTLIER -57.06 -37.82 72.36 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.005 -0.543 . . . . 0.0 110.18 179.812 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 166' ' ' LEU . . . . . 0.55 HD11 HD12 ' A' ' 211' ' ' ILE . 3.6 mt -61.24 -56.3 22.22 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 115.914 -0.585 . . . . 0.0 111.562 179.877 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 167' ' ' THR . . . . . 0.481 ' O ' ' HB2' ' A' ' 171' ' ' TRP . 16.7 m -54.31 -54.42 40.49 Favored 'General case' 0 C--N 1.331 -0.202 0 N-CA-C 112.198 0.444 . . . . 0.0 112.198 -177.981 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 168' ' ' VAL . . . . . . . . . . . . . 42.1 t -52.64 -41.75 38.66 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.603 0 N-CA-C 112.594 0.59 . . . . 0.0 112.594 -179.3 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 169' ' ' VAL . . . . . 0.506 ' O ' HG12 ' A' ' 173' ' ' ILE . 74.7 t -71.21 -68.08 0.42 Allowed 'Isoleucine or valine' 0 CA--C 1.531 0.245 0 N-CA-C 113.988 1.107 . . . . 0.0 113.988 -177.446 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 170' ' ' LEU . . . . . 0.48 HD11 ' HA ' ' A' ' 167' ' ' THR . 0.3 OUTLIER -57.61 -36.47 71.81 Favored 'General case' 0 N--CA 1.467 0.39 0 N-CA-C 112.835 0.68 . . . . 0.0 112.835 -177.382 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 171' ' ' TRP . . . . . 0.481 ' HB2' ' O ' ' A' ' 167' ' ' THR . 7.9 m0 -70.97 -34.21 71.19 Favored 'General case' 0 C--N 1.329 -0.321 0 C-N-CA 120.477 -0.489 . . . . 0.0 111.356 -179.785 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 172' ' ' ALA . . . . . 0.413 ' HA ' ' CZ ' ' A' ' 134' ' ' PHE . . . -72.4 -7.08 47.84 Favored 'General case' 0 C--N 1.332 -0.182 0 C-N-CA 120.797 -0.361 . . . . 0.0 110.862 179.848 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 173' ' ' ILE . . . . . 0.506 HG12 ' O ' ' A' ' 169' ' ' VAL . 50.8 mm -87.59 -25.75 5.98 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.23 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.795 179.607 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 174' ' ' TYR . . . . . . . . . . . . . 38.8 m-85 -55.0 -49.02 94.5 Favored Pre-proline 0 CA--C 1.531 0.216 0 CA-C-N 116.253 -0.431 . . . . 0.0 111.684 -179.741 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 175' ' ' PRO . . . . . 0.443 ' HB3' ' HZ ' ' A' ' 127' ' ' PHE . 79.9 Cg_exo -45.8 -30.94 7.2 Favored 'Trans proline' 0 C--N 1.352 0.739 0 C-N-CA 122.169 1.913 . . . . 0.0 111.954 179.422 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 176' ' ' PHE . . . . . 0.464 ' O ' ' HG ' ' A' ' 180' ' ' LEU . 86.3 m-85 -80.08 -49.16 12.14 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 115.81 -0.632 . . . . 0.0 111.388 179.83 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 177' ' ' ILE . . . . . 0.485 HD11 HG22 ' A' ' 173' ' ' ILE . 3.8 mm -60.16 -36.94 71.23 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.551 0 N-CA-C 112.307 0.484 . . . . 0.0 112.307 -178.49 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 178' ' ' TRP . . . . . . . . . . . . . 76.5 t90 -73.35 -44.45 58.74 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.942 0.401 . . . . 0.0 110.619 -179.87 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 179' ' ' LEU . . . . . . . . . . . . . 1.4 tm? -67.51 -54.3 21.27 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 115.952 -0.567 . . . . 0.0 111.155 -179.48 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 180' ' ' LEU . . . . . 0.531 HD21 HD13 ' A' ' 187' ' ' LEU . 16.5 mt -68.42 -50.3 53.78 Favored 'General case' 0 C--N 1.328 -0.327 0 N-CA-C 111.992 0.367 . . . . 0.0 111.992 -179.021 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . -54.62 176.35 0.44 Allowed Glycine 0 C--N 1.337 0.602 0 C-N-CA 120.219 -0.991 . . . . 0.0 112.861 -179.948 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 182' ' ' PRO . . . . . 0.448 ' HB2' ' HD3' ' A' ' 183' ' ' PRO . 83.8 Cg_exo -45.3 -44.77 15.88 Favored 'Trans proline' 0 C--N 1.349 0.583 0 C-N-CA 122.92 2.413 . . . . 0.0 113.599 179.692 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 183' ' ' PRO . . . . . 0.451 ' HB3' ' HB2' ' A' ' 116' ' ' ALA . 88.7 Cg_exo -46.38 -23.42 2.08 Favored 'Trans proline' 0 C--N 1.356 0.944 0 C-N-CA 122.277 1.985 . . . . 0.0 113.122 179.815 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 184' ' ' GLY . . . . . . . . . . . . . . . -123.53 -127.07 3.19 Favored Glycine 0 C--N 1.331 0.298 0 C-N-CA 120.554 -0.831 . . . . 0.0 112.797 -179.901 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 185' ' ' VAL . . . . . . . . . . . . . 16.5 m -60.05 -19.9 18.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 N-CA-C 111.992 0.368 . . . . 0.0 111.992 -179.541 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 186' ' ' ALA . . . . . . . . . . . . . . . 57.51 87.18 0.07 Allowed 'General case' 0 C--N 1.331 -0.2 0 CA-C-O 120.712 0.291 . . . . 0.0 111.4 179.863 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 187' ' ' LEU . . . . . 0.531 HD13 HD21 ' A' ' 180' ' ' LEU . 21.2 mt -91.95 -49.59 6.15 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.299 -0.41 . . . . 0.0 111.079 -179.821 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 188' ' ' LEU . . . . . . . . . . . . . 90.5 mt -103.52 -161.65 0.85 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 115.961 -0.563 . . . . 0.0 110.983 -179.82 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 189' ' ' THR . . . . . . . . . . . . . 1.6 t -92.44 147.04 33.6 Favored Pre-proline 0 C--N 1.329 -0.298 0 CA-C-N 116.079 -0.509 . . . . 0.0 111.061 -179.83 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 190' ' ' PRO . . . . . . . . . . . . . 9.2 Cg_endo -52.58 -33.15 57.16 Favored 'Trans proline' 0 C--N 1.349 0.579 0 C-N-CA 122.772 2.315 . . . . 0.0 112.422 -179.949 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 191' ' ' THR . . . . . . . . . . . . . 80.6 p -62.73 -43.73 98.06 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.34 -0.391 . . . . 0.0 111.033 179.882 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 192' ' ' VAL . . . . . . . . . . . . . 30.3 t -71.51 -46.62 62.55 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 115.94 -0.573 . . . . 0.0 111.118 -179.857 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 193' ' ' ASP . . . . . . . . . . . . . 34.3 t70 -56.78 -51.59 68.35 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.398 -0.365 . . . . 0.0 111.139 -179.749 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 194' ' ' VAL . . . . . . . . . . . . . 76.3 t -61.06 -36.56 73.31 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.391 -0.368 . . . . 0.0 110.988 179.818 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 195' ' ' ALA . . . . . . . . . . . . . . . -56.01 -48.15 76.47 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.493 -0.321 . . . . 0.0 111.168 179.89 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 196' ' ' LEU . . . . . . . . . . . . . 72.1 mt -67.38 -41.39 85.1 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.421 -0.354 . . . . 0.0 110.713 179.83 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 197' ' ' ILE . . . . . . . . . . . . . 17.2 mm -57.13 -56.08 16.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.473 179.407 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 198' ' ' VAL . . . . . . . . . . . . . 71.5 t -52.9 -35.03 21.25 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.417 0 CA-C-N 115.509 -0.769 . . . . 0.0 109.471 178.612 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 199' ' ' TYR . . . . . . . . . . . . . 53.3 t80 -70.54 -36.31 73.62 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 115.333 -0.849 . . . . 0.0 110.594 179.661 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 200' ' ' LEU . . . . . . . . . . . . . 73.0 mt -64.44 -38.74 92.1 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 115.658 -0.701 . . . . 0.0 111.343 -179.63 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 201' ' ' ASP . . . . . 0.436 ' HB2' ' OH ' ' A' ' 51' ' ' TYR . 0.8 OUTLIER -73.6 -32.32 64.04 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-O 121.04 0.447 . . . . 0.0 110.39 179.663 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 202' ' ' LEU . . . . . 0.417 ' O ' ' HB ' ' A' ' 206' ' ' VAL . 3.7 mt -71.64 -32.52 68.02 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 115.831 -0.622 . . . . 0.0 111.92 -179.649 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 203' ' ' VAL . . . . . 0.477 ' O ' ' HA3' ' A' ' 207' ' ' GLY . 7.4 p -78.83 -37.02 19.7 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-O 120.639 0.257 . . . . 0.0 111.375 -178.927 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 204' ' ' THR . . . . . . . . . . . . . 26.2 m -72.87 -49.99 26.56 Favored 'General case' 0 C--N 1.326 -0.448 0 C-N-CA 120.728 -0.389 . . . . 0.0 111.31 179.696 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 205' ' ' LYS . . . . . 0.557 ' HE2' ' HB3' ' A' ' 47' ' ' ALA . 54.5 mttp -69.98 -59.26 3.03 Favored 'General case' 0 C--N 1.326 -0.421 0 N-CA-C 112.165 0.431 . . . . 0.0 112.165 -178.8 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 206' ' ' VAL . . . . . 0.417 ' HB ' ' O ' ' A' ' 202' ' ' LEU . 48.6 t -74.69 -37.61 43.34 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.25 0 N-CA-C 111.964 0.357 . . . . 0.0 111.964 -178.727 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 207' ' ' GLY . . . . . 0.477 ' HA3' ' O ' ' A' ' 203' ' ' VAL . . . -62.86 -56.63 19.88 Favored Glycine 0 N--CA 1.45 -0.379 0 C-N-CA 120.258 -0.972 . . . . 0.0 112.01 -179.405 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 208' ' ' PHE . . . . . 0.513 ' O ' ' N ' ' A' ' 212' ' ' ALA . 3.1 m-85 -53.95 -47.75 70.98 Favored 'General case' 0 C--O 1.22 -0.469 0 N-CA-C 109.896 -0.409 . . . . 0.0 109.896 179.606 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 209' ' ' GLY . . . . . 0.477 ' O ' ' HG ' ' A' ' 213' ' ' LEU . . . -53.9 -35.21 52.9 Favored Glycine 0 N--CA 1.45 -0.374 0 CA-C-N 115.091 -0.959 . . . . 0.0 113.399 179.585 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 210' ' ' PHE . . . . . . . . . . . . . 5.2 m-85 -72.46 -47.23 50.52 Favored 'General case' 0 CA--C 1.512 -0.498 0 N-CA-C 108.716 -0.846 . . . . 0.0 108.716 179.801 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 211' ' ' ILE . . . . . 0.55 HD12 HD11 ' A' ' 166' ' ' LEU . 3.6 mt -65.05 -26.93 41.11 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.65 0 N-CA-C 107.665 -1.235 . . . . 0.0 107.665 176.444 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 212' ' ' ALA . . . . . 0.513 ' N ' ' O ' ' A' ' 208' ' ' PHE . . . -68.44 -38.66 81.37 Favored 'General case' 0 N--CA 1.45 -0.466 0 CA-C-N 114.3 -1.318 . . . . 0.0 110.422 -179.869 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 213' ' ' LEU . . . . . 0.477 ' HG ' ' O ' ' A' ' 209' ' ' GLY . 47.2 mt -69.82 -54.31 14.16 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-N 115.301 -0.863 . . . . 0.0 111.636 -179.498 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 214' ' ' ASP . . . . . . . . . . . . . 14.6 m-20 -52.21 -54.66 28.2 Favored 'General case' 0 C--O 1.234 0.26 0 CA-C-N 116.389 -0.369 . . . . 0.0 111.326 -179.514 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 215' ' ' ALA . . . . . . . . . . . . . . . -57.48 -54.87 41.92 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.357 -0.383 . . . . 0.0 111.036 179.984 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 216' ' ' ALA . . . . . . . . . . . . . . . -57.52 -30.73 65.39 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.28 179.925 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 217' ' ' ALA . . . . . . . . . . . . . . . -64.02 -38.34 90.73 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.557 -179.918 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 218' ' ' THR . . . . . . . . . . . . . 69.7 m -72.75 -49.09 33.16 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 115.82 -0.627 . . . . 0.0 111.247 179.855 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 219' ' ' LEU . . . . . . . . . . . . . 25.4 mt -56.82 -29.07 62.41 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.955 -179.784 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 220' ' ' ARG . . . . . . . . . . . . . 79.3 ttt180 -83.82 -36.22 23.65 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.059 -0.518 . . . . 0.0 110.978 179.904 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 221' ' ' ALA . . . . . . . . . . . . . . . -62.76 -27.08 69.04 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.278 -0.419 . . . . 0.0 111.41 -179.837 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 222' ' ' GLU . . . . . 0.546 ' HG3' ' H ' ' A' ' 224' ' ' GLY . 11.0 pt-20 -92.0 -21.97 20.24 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 121.04 0.447 . . . . 0.0 110.398 -179.947 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 223' ' ' HIS . . . . . . . . . . . . . 65.7 m-70 59.21 19.06 7.1 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 115.649 -0.705 . . . . 0.0 111.245 179.551 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 224' ' ' GLY . . . . . 0.546 ' H ' ' HG3' ' A' ' 222' ' ' GLU . . . 88.58 45.41 4.93 Favored Glycine 0 N--CA 1.452 -0.272 0 C-N-CA 120.716 -0.754 . . . . 0.0 112.319 -179.929 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 225' ' ' GLU . . . . . . . . . . . . . 8.8 tp10 -121.82 144.91 48.55 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-O 120.827 0.346 . . . . 0.0 110.936 -179.957 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 226' ' ' SER . . . . . . . . . . . . . 31.6 t -136.89 -63.42 0.61 Allowed 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.287 -0.415 . . . . 0.0 111.154 -179.753 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 227' ' ' LEU . . . . . 0.441 ' HG ' ' H ' ' A' ' 229' ' ' GLY . 44.2 tp -103.98 119.79 39.67 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.266 -0.424 . . . . 0.0 111.077 -179.737 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 228' ' ' ALA . . . . . . . . . . . . . . . -92.02 3.97 54.08 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.021 179.815 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 229' ' ' GLY . . . . . 0.441 ' H ' ' HG ' ' A' ' 227' ' ' LEU . . . -71.96 -172.52 17.61 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.853 -0.689 . . . . 0.0 112.56 -179.967 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 230' ' ' VAL . . . . . . . . . . . . . 4.9 p -158.19 125.42 0.58 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-O 120.869 0.366 . . . . 0.0 111.017 -179.945 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 231' ' ' ASP . . . . . . . . . . . . . 11.8 m-20 -100.36 91.31 4.66 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.679 179.881 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 232' ' ' THR . . . . . . . . . . . . . 8.7 t -126.19 152.09 46.48 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.143 -0.481 . . . . 0.0 111.035 -179.912 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 233' ' ' ASP . . . . . . . . . . . . . 17.5 m-20 65.14 134.19 0.02 OUTLIER 'General case' 0 C--N 1.333 -0.143 0 CA-C-N 116.029 -0.532 . . . . 0.0 111.226 179.979 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 234' ' ' THR . . . . . . . . . . . . . 70.4 p -65.94 154.42 89.39 Favored Pre-proline 0 C--N 1.329 -0.306 0 CA-C-N 116.076 -0.511 . . . . 0.0 111.097 179.977 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 235' ' ' PRO . . . . . . . . . . . . . 73.5 Cg_endo -74.97 10.53 1.68 Allowed 'Trans proline' 0 C--N 1.348 0.527 0 C-N-CA 122.456 2.104 . . . . 0.0 112.529 -179.957 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 236' ' ' ALA . . . . . . . . . . . . . . . -101.49 106.95 18.12 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.309 -0.405 . . . . 0.0 111.287 -179.943 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 237' ' ' VAL . . . . . . . . . . . . . 22.2 t -116.52 121.3 67.31 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.192 0 CA-C-N 116.18 -0.463 . . . . 0.0 111.061 179.931 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 238' ' ' ALA . . . . . . . . . . . . . . . -81.0 -67.97 0.73 Allowed 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.217 179.98 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 239' ' ' ASP . . . . . . . . . . . . . 14.7 t70 -147.49 104.73 3.65 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.77 -179.996 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 240' ' ' LEU . . . . . . . . . . . . . 49.1 tp -114.77 -29.03 6.88 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.923 -179.829 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 241' ' ' GLU . . . . . . . . . . . . . 10.9 mm-40 -72.64 134.85 45.31 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.897 -179.98 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 242' ' ' HIS . . . . . . . . . . . . . 84.6 t60 -139.19 -45.34 0.46 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.599 179.834 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 243' ' ' HIS . . . . . . . . . . . . . 72.2 m80 -88.82 179.64 6.17 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.049 -0.523 . . . . 0.0 110.669 179.766 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 244' ' ' HIS . . . . . . . . . . . . . 95.5 m-70 -103.31 162.93 12.59 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.299 -0.409 . . . . 0.0 111.06 179.953 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 245' ' ' HIS . . . . . . . . . . . . . 65.5 m-70 60.91 -87.22 0.02 OUTLIER 'General case' 0 C--N 1.331 -0.206 0 CA-C-N 115.842 -0.617 . . . . 0.0 111.06 179.899 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 246' ' ' HIS . . . . . . . . . . . . . 56.6 m80 -102.66 168.61 9.15 Favored 'General case' 0 C--N 1.332 -0.172 0 CA-C-N 116.331 -0.395 . . . . 0.0 110.886 -179.903 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 247' ' ' HIS . . . . . . . . . . . . . 68.9 m-70 . . . . . 0 C--O 1.25 1.115 0 CA-C-O 118.314 -0.85 . . . . 0.0 111.057 179.938 . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 301' ' ' RET . . . . . 0.429 H201 ' NE1' ' A' ' 171' ' ' TRP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 96.7 mmm . . . . . 0 N--CA 1.486 1.333 0 CA-C-O 120.773 0.321 . . . . 0.0 110.919 . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 42.9 t -119.74 -32.99 1.56 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.976 179.82 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -82.06 -23.94 56.11 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.798 -0.715 . . . . 0.0 112.514 -179.961 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 55.3 tp -74.02 -36.31 64.45 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.685 0.279 . . . . 0.0 111.21 -179.88 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 82.6 p -66.3 -29.97 70.29 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.432 -0.349 . . . . 0.0 111.409 -179.693 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 22.7 p -54.22 -35.13 62.09 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.269 179.996 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 7' ' ' LEU . . . . . . . . . . . . . 3.9 mm? -57.66 -53.13 61.66 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.111 -0.495 . . . . 0.0 111.172 -179.971 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 8' ' ' PHE . . . . . 0.539 ' HB2' ' HB3' ' A' ' 55' ' ' ALA . 77.8 m-85 -59.07 -35.66 73.75 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.346 -0.388 . . . . 0.0 110.762 179.858 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 9' ' ' TRP . . . . . . . . . . . . . 47.5 m95 -64.67 -45.91 84.67 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.024 -0.534 . . . . 0.0 110.059 -179.824 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . 0.408 ' HA ' HD12 ' A' ' 13' ' ' ILE . 87.2 mt -61.08 -37.83 84.11 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-N 115.545 -0.752 . . . . 0.0 110.154 179.333 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -65.82 -35.46 90.9 Favored Glycine 0 N--CA 1.448 -0.53 0 C-N-CA 120.814 -0.708 . . . . 0.0 111.486 179.124 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -67.44 -31.21 71.24 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 120.977 0.418 . . . . 0.0 110.476 179.448 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 13' ' ' ILE . . . . . 0.413 ' O ' HG22 ' A' ' 17' ' ' VAL . 88.5 mt -64.68 -54.22 32.78 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.235 0 CA-C-N 115.864 -0.607 . . . . 0.0 110.214 179.418 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -65.99 -32.45 82.6 Favored Glycine 0 N--CA 1.45 -0.377 0 C-N-CA 120.61 -0.805 . . . . 0.0 111.637 179.109 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 15' ' ' MET . . . . . 0.488 ' SD ' ' HA ' ' A' ' 44' ' ' SER . 51.3 tpp -65.83 -40.16 91.53 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-O 120.823 0.344 . . . . 0.0 110.448 179.657 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 1.6 mm? -64.02 -37.98 89.4 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-N 116.08 -0.509 . . . . 0.0 110.207 179.173 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . 0.413 HG22 ' O ' ' A' ' 13' ' ' ILE . 72.0 t -59.04 -42.63 86.91 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.205 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.158 179.07 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -68.8 -46.2 61.63 Favored Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.731 -0.747 . . . . 0.0 111.679 178.965 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 47.9 m -50.25 -46.66 55.08 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 120.865 0.364 . . . . 0.0 111.081 179.896 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 93.6 mt -72.19 -45.75 59.08 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.035 -0.529 . . . . 0.0 111.639 179.939 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -58.85 -30.85 68.0 Favored 'General case' 0 C--N 1.329 -0.296 0 N-CA-C 112.081 0.4 . . . . 0.0 112.081 -179.23 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 13.0 m-85 -90.79 -31.36 16.54 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 120.666 0.27 . . . . 0.0 111.509 -179.252 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -71.63 -50.28 32.22 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 121.101 0.477 . . . . 0.0 111.173 -179.811 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 24' ' ' TRP . . . . . . . . . . . . . 3.1 t-105 -61.43 -43.82 98.19 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-N 115.614 -0.721 . . . . 0.0 111.329 -179.624 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -66.26 -25.3 66.81 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.698 0.285 . . . . 0.0 111.057 -179.989 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -71.07 -41.02 61.35 Favored Glycine 0 N--CA 1.452 -0.253 0 C-N-CA 120.817 -0.706 . . . . 0.0 112.503 -179.893 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 99.0 mtt180 -68.03 -26.96 66.14 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.838 0.352 . . . . 0.0 110.996 -179.99 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 23.9 t70 -94.3 9.17 39.2 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.046 -0.524 . . . . 0.0 110.86 -179.742 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -87.6 -177.77 5.95 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.201 -179.99 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -96.99 -149.23 25.27 Favored Glycine 0 N--CA 1.452 -0.254 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.643 -179.911 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 59.4 m -109.2 127.96 54.65 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.861 0.362 . . . . 0.0 110.797 179.966 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 112.66 -32.35 6.27 Favored Glycine 0 N--CA 1.452 -0.25 0 C-N-CA 120.873 -0.68 . . . . 0.0 112.153 -179.962 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 10.0 mm-40 -90.59 -20.68 22.32 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 120.752 0.311 . . . . 0.0 110.83 179.838 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 34' ' ' ARG . . . . . . . . . . . . . 54.3 mtp180 -48.43 -29.49 4.12 Favored 'General case' 0 C--N 1.333 -0.151 0 CA-C-N 115.997 -0.547 . . . . 0.0 111.547 -179.819 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 75.2 mtp180 -60.85 -48.38 82.07 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.44 -0.346 . . . . 0.0 111.023 -179.899 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 62.9 m-85 -68.66 -31.66 70.94 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.021 -0.536 . . . . 0.0 111.362 -179.678 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 37' ' ' TYR . . . . . . . . . . . . . 53.6 m-85 -69.4 -54.49 14.13 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.301 -0.409 . . . . 0.0 111.279 -179.498 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 85.3 t -57.08 -36.7 52.04 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.249 0 CA-C-O 121.011 0.434 . . . . 0.0 110.525 179.729 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 30.3 m -64.38 -49.43 71.65 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 115.789 -0.641 . . . . 0.0 110.502 179.354 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 30.5 tp -55.99 -47.73 77.17 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.718 -0.674 . . . . 0.0 110.286 179.614 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 62.3 t -62.24 -34.32 63.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 115.733 -0.667 . . . . 0.0 110.016 178.95 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -57.85 -38.77 89.96 Favored Glycine 0 N--CA 1.448 -0.501 0 C-N-CA 120.859 -0.686 . . . . 0.0 112.035 179.684 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 43' ' ' ILE . . . . . 0.534 HG23 ' HE3' ' A' ' 205' ' ' LYS . 0.2 OUTLIER -68.44 -53.42 28.26 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.186 0 CA-C-O 120.825 0.345 . . . . 0.0 110.698 179.583 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 44' ' ' SER . . . . . 0.488 ' HA ' ' SD ' ' A' ' 15' ' ' MET . 45.8 m -59.11 -24.47 63.0 Favored 'General case' 0 C--N 1.333 -0.146 0 CA-C-N 116.136 -0.484 . . . . 0.0 111.466 -179.777 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -75.89 -57.16 4.19 Favored Glycine 0 CA--C 1.518 0.281 0 C-N-CA 120.766 -0.731 . . . . 0.0 113.106 -179.333 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 17.0 pt -58.17 -35.71 54.19 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-O 120.818 0.342 . . . . 0.0 111.262 -179.602 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 47' ' ' ALA . . . . . 0.665 ' HB2' ' HE2' ' A' ' 205' ' ' LYS . . . -67.73 -44.39 77.71 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-O 120.966 0.412 . . . . 0.0 110.943 179.158 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -54.38 -44.46 72.29 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 115.791 -0.641 . . . . 0.0 111.723 -179.385 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 34.2 m -71.54 -34.04 51.48 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.228 0 CA-C-N 116.532 -0.304 . . . . 0.0 111.415 -179.63 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -64.34 -37.33 87.13 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 121.046 0.45 . . . . 0.0 110.874 179.695 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 51' ' ' TYR . . . . . 0.424 ' OH ' ' HB2' ' A' ' 201' ' ' ASP . 33.2 m-85 -73.36 -36.19 66.07 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 115.946 -0.57 . . . . 0.0 110.62 179.979 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -65.99 -38.97 89.88 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 115.826 -0.625 . . . . 0.0 111.025 179.796 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 53' ' ' VAL . . . . . 0.474 HG22 ' N ' ' A' ' 54' ' ' MET . 33.6 m -74.81 -50.35 25.9 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.194 0 CA-C-N 116.588 -0.278 . . . . 0.0 111.05 -179.887 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 54' ' ' MET . . . . . 0.474 ' N ' HG22 ' A' ' 53' ' ' VAL . 75.8 mtm -58.02 -29.69 65.51 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-O 121.009 0.433 . . . . 0.0 110.309 179.514 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 55' ' ' ALA . . . . . 0.539 ' HB3' ' HB2' ' A' ' 8' ' ' PHE . . . -73.85 -25.92 60.31 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 115.786 -0.643 . . . . 0.0 111.278 179.732 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 74.6 mt -80.28 -8.37 59.44 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.276 -0.42 . . . . 0.0 111.622 -179.625 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 102.31 -17.48 53.63 Favored Glycine 0 N--CA 1.453 -0.226 0 C-N-CA 120.438 -0.887 . . . . 0.0 113.054 179.671 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 12.7 p -69.43 150.86 10.21 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.957 0.379 . . . . 0.0 110.439 179.717 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 75.55 27.24 63.67 Favored Glycine 0 N--CA 1.449 -0.472 0 C-N-CA 120.723 -0.751 . . . . 0.0 111.731 -178.946 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 60' ' ' TRP . . . . . . . . . . . . . 13.8 m0 -108.7 99.15 8.55 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-O 120.947 0.403 . . . . 0.0 110.285 -179.879 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 61' ' ' VAL . . . . . 0.485 ' HB ' HG22 ' A' ' 68' ' ' VAL . 25.6 t -97.77 110.69 56.45 Favored Pre-proline 0 C--N 1.325 -0.459 0 CA-C-N 115.877 -0.601 . . . . 0.0 111.526 -179.299 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 17.2 Cg_exo -67.2 138.87 48.49 Favored 'Trans proline' 0 C--N 1.35 0.606 0 C-N-CA 122.577 2.184 . . . . 0.0 111.866 179.678 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 93.1 t -139.96 92.17 0.65 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.38 -179.694 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . 56.65 -91.7 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.117 -0.492 . . . . 0.0 111.85 179.656 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 42.9 mt-10 -115.23 -17.61 11.31 Favored 'General case' 0 C--N 1.332 -0.195 0 CA-C-O 120.837 0.351 . . . . 0.0 111.054 -179.652 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 66' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -104.81 165.56 10.99 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.285 179.77 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 91.0 m -130.09 118.81 22.08 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-N 116.295 -0.411 . . . . 0.0 111.414 -179.573 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 68' ' ' VAL . . . . . 0.485 HG22 ' HB ' ' A' ' 61' ' ' VAL . 18.5 m -100.37 141.51 17.18 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.377 0 CA-C-N 115.991 -0.55 . . . . 0.0 110.53 179.495 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 69' ' ' PHE . . . . . . . . . . . . . 24.2 m-85 -109.84 122.75 48.24 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.276 -0.42 . . . . 0.0 110.248 -179.428 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 70' ' ' VAL . . . . . 0.59 HG13 ' HD3' ' A' ' 71' ' ' PRO . 1.3 p -68.13 -35.97 8.33 Favored Pre-proline 0 CA--C 1.54 0.573 0 N-CA-C 112.549 0.574 . . . . 0.0 112.549 -179.541 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 71' ' ' PRO . . . . . 0.59 ' HD3' HG13 ' A' ' 70' ' ' VAL . 5.7 Cg_exo -71.48 -19.87 28.0 Favored 'Trans proline' 0 C--N 1.359 1.122 0 C-N-CA 121.942 1.762 . . . . 0.0 112.47 -179.729 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 56.5 ttt180 -68.68 -55.28 11.95 Favored 'General case' 0 C--O 1.236 0.378 0 CA-C-N 116.403 -0.362 . . . . 0.0 111.67 -179.181 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 73' ' ' TYR . . . . . 0.438 ' O ' HG13 ' A' ' 77' ' ' ILE . 28.2 m-85 -72.17 -30.16 64.71 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.492 -0.322 . . . . 0.0 110.655 -179.418 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 74' ' ' ILE . . . . . 0.471 ' HA ' HD12 ' A' ' 77' ' ' ILE . 0.4 OUTLIER -72.52 -38.29 59.31 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.237 0 N-CA-C 109.829 -0.434 . . . . 0.0 109.829 179.253 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 12.9 t70 -59.11 -38.69 80.15 Favored 'General case' 0 CA--C 1.518 -0.257 0 N-CA-C 109.322 -0.621 . . . . 0.0 109.322 178.861 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 76' ' ' TRP . . . . . . . . . . . . . 45.6 m0 -65.73 -37.74 87.23 Favored 'General case' 0 C--N 1.331 -0.21 0 CA-C-N 115.702 -0.681 . . . . 0.0 110.358 179.166 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 77' ' ' ILE . . . . . 0.503 ' O ' ' HG2' ' A' ' 81' ' ' PRO . 89.5 mt -62.4 -30.67 49.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.468 178.973 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 41.7 mt -92.06 -19.81 21.96 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.07 -0.514 . . . . 0.0 112.222 -179.717 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 73.6 p -101.28 -52.99 3.12 Favored 'General case' 0 N--CA 1.463 0.205 0 N-CA-C 113.446 0.906 . . . . 0.0 113.446 -178.033 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 80' ' ' THR . . . . . 0.642 ' HB ' ' HD3' ' A' ' 81' ' ' PRO . 59.8 m -48.74 -53.97 31.75 Favored Pre-proline 0 C--N 1.331 -0.219 0 N-CA-C 112.406 0.521 . . . . 0.0 112.406 -178.838 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 81' ' ' PRO . . . . . 0.642 ' HD3' ' HB ' ' A' ' 80' ' ' THR . 31.5 Cg_exo -59.87 -23.4 72.29 Favored 'Trans proline' 0 C--N 1.353 0.805 0 C-N-CA 121.718 1.612 . . . . 0.0 111.772 179.965 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 82' ' ' LEU . . . . . . . . . . . . . 18.4 tp -76.93 -33.11 57.74 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.043 -0.526 . . . . 0.0 110.469 179.68 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 83' ' ' ILE . . . . . 0.417 HD11 HG21 ' A' ' 43' ' ' ILE . 35.0 mm -68.26 -53.71 26.96 Favored 'Isoleucine or valine' 0 C--O 1.234 0.244 0 CA-C-N 116.367 -0.379 . . . . 0.0 110.036 179.246 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 20.7 m -59.98 -30.98 46.65 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.23 0 N-CA-C 109.415 -0.587 . . . . 0.0 109.415 178.506 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 85' ' ' TYR . . . . . . . . . . . . . 80.8 t80 -66.38 -31.49 72.3 Favored 'General case' 0 N--CA 1.454 -0.242 0 CA-C-N 115.382 -0.827 . . . . 0.0 109.637 178.764 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 86' ' ' PHE . . . . . . . . . . . . . 14.6 t80 -64.33 -51.34 63.88 Favored 'General case' 0 C--O 1.232 0.169 0 CA-C-N 115.819 -0.628 . . . . 0.0 109.865 179.385 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 7.4 mp -60.8 -36.04 78.03 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 115.729 -0.668 . . . . 0.0 110.253 179.445 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -67.24 -27.67 73.54 Favored Glycine 0 N--CA 1.45 -0.395 0 C-N-CA 120.904 -0.665 . . . . 0.0 112.082 179.657 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 40.5 mt -71.66 -42.55 67.37 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-O 121.027 0.441 . . . . 0.0 110.421 179.801 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 90' ' ' LEU . . . . . 0.403 ' HB3' HG23 ' A' ' 156' ' ' ILE . 81.0 mt -56.13 -42.43 76.89 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 115.688 -0.687 . . . . 0.0 111.198 -179.971 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . 0.58 ' HB3' ' HB1' ' A' ' 149' ' ' ALA . . . -79.3 -45.99 18.59 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.311 -0.404 . . . . 0.0 111.393 -179.597 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 97.73 50.66 1.63 Allowed Glycine 0 N--CA 1.45 -0.373 0 C-N-CA 120.712 -0.756 . . . . 0.0 112.229 -179.583 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 93' ' ' LEU . . . . . 0.49 HD23 ' HB3' ' A' ' 97' ' ' GLU . 10.8 mp -61.61 171.55 1.5 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.958 0.409 . . . . 0.0 111.24 -179.891 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 94' ' ' ASP . . . . . . . . . . . . . 24.2 t70 -90.46 167.61 12.47 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 115.963 -0.562 . . . . 0.0 110.462 179.722 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 47.3 t -55.04 -35.42 64.46 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.355 -0.384 . . . . 0.0 111.107 179.983 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 5.3 mmp_? -73.83 -50.49 20.18 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.09 -0.504 . . . . 0.0 111.33 -179.858 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 97' ' ' GLU . . . . . 0.49 ' HB3' HD23 ' A' ' 93' ' ' LEU . 46.6 mt-10 -52.37 -45.2 65.66 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.34 -0.391 . . . . 0.0 111.291 -179.606 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 98' ' ' PHE . . . . . . . . . . . . . 28.2 m-85 -59.55 -46.69 88.16 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.488 -0.324 . . . . 0.0 110.864 179.824 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -57.67 -28.58 60.21 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.524 -0.846 . . . . 0.0 112.466 179.848 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 79.6 mt -73.83 -48.7 38.26 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.181 0 N-CA-C 112.125 0.417 . . . . 0.0 112.125 -179.563 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 29.4 m -67.98 -41.75 84.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 N-CA-C 112.049 0.388 . . . . 0.0 112.049 -179.001 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 102' ' ' ILE . . . . . 0.459 HG21 ' HB3' ' A' ' 81' ' ' PRO . 50.9 mm -63.88 -49.35 82.22 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.675 -0.239 . . . . 0.0 111.505 -179.463 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 15.3 t -59.72 -34.75 73.33 Favored 'General case' 0 C--O 1.233 0.208 0 CA-C-O 120.951 0.405 . . . . 0.0 110.643 179.873 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 1.3 tm? -56.29 -54.08 49.67 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.008 -0.542 . . . . 0.0 109.698 179.05 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 105' ' ' ASN . . . . . 0.627 ' N ' HD21 ' A' ' 105' ' ' ASN . 0.8 OUTLIER -58.23 -34.03 69.99 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 115.591 -0.731 . . . . 0.0 110.83 179.605 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 85.4 m -56.54 -43.79 80.24 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.295 -0.411 . . . . 0.0 110.734 179.803 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 1.5 t -66.81 -42.18 88.87 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-O 121.2 0.524 . . . . 0.0 110.348 179.383 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 93.5 t -57.99 -51.17 73.99 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.386 0 CA-C-N 115.318 -0.856 . . . . 0.0 111.679 -179.722 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 109' ' ' MET . . . . . 0.463 ' HE2' HG21 ' A' ' 80' ' ' THR . 1.5 mpp? -65.22 -37.52 87.53 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.37 -179.588 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 32.4 tp -66.71 -31.5 72.2 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 116.39 -0.368 . . . . 0.0 110.58 -179.893 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -65.42 -52.56 52.5 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.394 179.487 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 112' ' ' GLY . . . . . 0.525 ' HA3' ' H22' ' A' ' 301' ' ' RET . . . -66.26 -31.43 79.07 Favored Glycine 0 N--CA 1.449 -0.434 0 C-N-CA 120.749 -0.738 . . . . 0.0 111.883 179.37 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 113' ' ' PHE . . . . . . . . . . . . . 0.4 OUTLIER -57.14 -70.69 0.12 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 121.032 0.444 . . . . 0.0 110.061 179.567 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 114' ' ' ALA . . . . . 0.446 ' HB3' HD23 ' A' ' 126' ' ' LEU . . . -64.09 -18.55 64.49 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 115.72 -0.673 . . . . 0.0 110.758 179.577 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -57.77 -53.62 43.79 Favored Glycine 0 C--N 1.332 0.314 0 C-N-CA 120.943 -0.646 . . . . 0.0 112.263 179.802 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 116' ' ' ALA . . . . . 0.51 ' HB2' ' HB3' ' A' ' 183' ' ' PRO . . . -77.48 -14.98 59.56 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.784 0.326 . . . . 0.0 111.271 179.927 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 117' ' ' MET . . . . . . . . . . . . . 17.9 mmt -86.33 13.71 7.71 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.129 -0.487 . . . . 0.0 111.589 -179.504 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 20.4 m -87.22 143.03 33.99 Favored Pre-proline 0 C--N 1.33 -0.255 0 CA-C-O 120.563 0.221 . . . . 0.0 111.371 -179.916 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 119' ' ' PRO . . . . . . . . . . . . . 68.2 Cg_endo -92.56 -2.66 3.76 Favored 'Trans proline' 0 N--CA 1.455 -0.776 0 C-N-CA 122.945 2.43 . . . . 0.0 112.267 179.441 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -132.81 -117.66 1.86 Allowed Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.779 -0.724 . . . . 0.0 112.805 -179.668 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 39.6 pt -123.26 12.97 5.31 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.234 0 CA-C-O 120.654 0.264 . . . . 0.0 111.547 -179.514 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 37.7 mt-10 -61.23 -18.65 59.4 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.375 -0.375 . . . . 0.0 110.822 179.912 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 123' ' ' ARG . . . . . 0.458 ' HB2' ' HH2' ' A' ' 178' ' ' TRP . 23.0 ptt180 -51.93 -33.79 38.92 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 115.927 -0.579 . . . . 0.0 111.615 -179.84 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 124' ' ' TYR . . . . . . . . . . . . . 59.0 m-85 -67.49 -33.3 74.81 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.459 -0.337 . . . . 0.0 111.397 -179.622 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 125' ' ' ALA . . . . . . . . . . . . . . . -72.71 -56.46 5.25 Favored 'General case' 0 C--O 1.237 0.411 0 CA-C-O 121.105 0.479 . . . . 0.0 111.073 179.835 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 126' ' ' LEU . . . . . 0.446 HD23 ' HB3' ' A' ' 114' ' ' ALA . 1.3 mt -55.24 -48.1 74.44 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 115.729 -0.669 . . . . 0.0 110.395 179.847 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 127' ' ' PHE . . . . . 0.426 ' HZ ' ' HB3' ' A' ' 175' ' ' PRO . 9.2 t80 -67.76 -30.76 70.3 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.11 -0.496 . . . . 0.0 110.334 179.316 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 128' ' ' GLY . . . . . . . . . . . . . . . -49.12 -50.58 27.76 Favored Glycine 0 N--CA 1.449 -0.441 0 C-N-CA 120.125 -1.036 . . . . 0.0 110.553 178.734 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 129' ' ' MET . . . . . 0.643 ' HE2' ' HA2' ' A' ' 130' ' ' GLY . 0.0 OUTLIER -70.84 -28.24 64.45 Favored 'General case' 0 N--CA 1.453 -0.293 0 N-CA-C 109.02 -0.733 . . . . 0.0 109.02 178.283 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 130' ' ' GLY . . . . . 0.643 ' HA2' ' HE2' ' A' ' 129' ' ' MET . . . -60.09 -41.63 98.14 Favored Glycine 0 C--N 1.335 0.48 0 CA-C-N 115.772 -0.649 . . . . 0.0 112.441 179.364 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -71.04 -49.43 44.99 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-O 120.66 0.267 . . . . 0.0 110.503 179.733 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 57.7 t -57.4 -43.72 83.07 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.217 0 CA-C-O 121.139 0.495 . . . . 0.0 109.81 179.068 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -65.86 -33.01 74.87 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 115.538 -0.756 . . . . 0.0 110.603 179.193 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 134' ' ' PHE . . . . . . . . . . . . . 71.6 t80 -59.02 -54.62 45.11 Favored 'General case' 0 N--CA 1.451 -0.385 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.038 179.58 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 135' ' ' ILE . . . . . 0.47 ' O ' HG22 ' A' ' 138' ' ' VAL . 38.2 mt -57.19 -30.38 34.74 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.312 0 CA-C-N 115.805 -0.634 . . . . 0.0 109.916 178.98 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . -62.88 -37.37 94.79 Favored Glycine 0 N--CA 1.447 -0.601 0 C-N-CA 120.31 -0.948 . . . . 0.0 111.301 178.877 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 137' ' ' LEU . . . . . 0.49 HD12 HD22 ' A' ' 105' ' ' ASN . 21.4 tp -71.45 -51.77 22.05 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 120.582 0.23 . . . . 0.0 110.8 179.536 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 138' ' ' VAL . . . . . 0.47 HG22 ' O ' ' A' ' 135' ' ' ILE . 3.9 m -56.15 -31.9 32.92 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.213 0 CA-C-O 121.299 0.571 . . . . 0.0 109.479 179.377 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 139' ' ' TYR . . . . . . . . . . . . . 35.3 t80 -63.99 -44.67 91.96 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 115.29 -0.868 . . . . 0.0 110.136 178.882 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 140' ' ' TYR . . . . . 0.454 ' HB3' ' SD ' ' A' ' 145' ' ' MET . 23.6 m-85 -54.65 -47.01 74.04 Favored 'General case' 0 C--N 1.332 -0.167 0 CA-C-N 115.974 -0.557 . . . . 0.0 111.006 179.622 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 141' ' ' LEU . . . . . . . . . . . . . 93.2 mt -59.04 -40.81 86.23 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.252 -0.431 . . . . 0.0 111.064 -179.885 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 37.8 t -79.73 -12.46 13.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-O 121.063 0.459 . . . . 0.0 110.823 179.902 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . -70.88 -140.64 0.2 Allowed Glycine 0 CA--C 1.522 0.471 0 C-N-CA 120.989 -0.624 . . . . 0.0 112.715 -179.913 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 144' ' ' PRO . . . . . . . . . . . . . 56.6 Cg_endo -70.1 -22.77 30.07 Favored 'Trans proline' 0 C--N 1.349 0.575 0 C-N-CA 122.767 2.312 . . . . 0.0 112.894 -179.93 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 145' ' ' MET . . . . . 0.454 ' SD ' ' HB3' ' A' ' 140' ' ' TYR . 81.0 mtp -52.5 -53.48 45.4 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.281 -0.418 . . . . 0.0 111.794 -179.223 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 146' ' ' THR . . . . . . . . . . . . . 10.2 t -62.45 -32.83 73.75 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.726 0.298 . . . . 0.0 111.586 -179.53 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 45.0 mt-10 -71.35 -32.64 68.78 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.309 -0.405 . . . . 0.0 111.087 -179.837 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 148' ' ' SER . . . . . . . . . . . . . 59.6 m -70.23 -36.6 74.62 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.114 -0.494 . . . . 0.0 111.21 -179.788 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 149' ' ' ALA . . . . . 0.58 ' HB1' ' HB3' ' A' ' 91' ' ' ALA . . . -75.47 -39.46 58.64 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.265 -0.425 . . . . 0.0 111.69 -179.585 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 150' ' ' SER . . . . . . . . . . . . . 69.8 m -66.19 -4.39 7.54 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.39 -0.368 . . . . 0.0 111.217 -179.792 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 151' ' ' GLN . . . . . . . . . . . . . 47.8 mt-30 -124.59 14.53 8.77 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.389 -0.369 . . . . 0.0 111.303 -179.907 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 31.9 tpt180 -91.74 -51.55 5.18 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 120.972 0.415 . . . . 0.0 110.653 179.786 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 153' ' ' SER . . . . . 0.569 ' HB2' HG12 ' A' ' 156' ' ' ILE . 45.4 m -157.54 172.63 18.2 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 115.87 -0.604 . . . . 0.0 110.576 179.466 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 154' ' ' SER . . . . . . . . . . . . . 47.9 t -67.53 -41.84 83.69 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.393 -0.367 . . . . 0.0 110.769 179.841 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -76.69 -35.89 39.19 Favored Glycine 0 C--N 1.332 0.312 0 C-N-CA 120.85 -0.691 . . . . 0.0 112.804 -179.946 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 156' ' ' ILE . . . . . 0.569 HG12 ' HB2' ' A' ' 153' ' ' SER . 39.9 mm -56.23 -39.37 59.23 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.224 0 CA-C-O 120.729 0.299 . . . . 0.0 111.46 -179.729 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 157' ' ' LYS . . . . . . . . . . . . . 62.3 tttp -61.92 -51.08 69.6 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.296 -0.411 . . . . 0.0 111.329 -179.758 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 51.4 m -64.87 -35.41 81.04 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.37 -0.377 . . . . 0.0 111.499 -179.154 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 159' ' ' LEU . . . . . 0.506 HD21 ' HB1' ' A' ' 215' ' ' ALA . 10.8 mt -68.84 -59.28 3.19 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-N 116.312 -0.403 . . . . 0.0 111.655 -179.507 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 160' ' ' TYR . . . . . . . . . . . . . 19.4 t80 -52.45 -44.97 65.82 Favored 'General case' 0 C--N 1.327 -0.374 0 N-CA-C 112.228 0.455 . . . . 0.0 112.228 -178.947 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 161' ' ' VAL . . . . . 0.447 HG23 ' N ' ' A' ' 162' ' ' ARG . 36.0 m -63.65 -45.8 96.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 N-CA-C 112.504 0.557 . . . . 0.0 112.504 -178.289 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 162' ' ' ARG . . . . . 0.476 ' O ' HD11 ' A' ' 166' ' ' LEU . 99.4 mtt180 -63.65 -49.72 72.1 Favored 'General case' 0 C--N 1.327 -0.377 0 N-CA-C 111.78 0.289 . . . . 0.0 111.78 -179.009 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 163' ' ' LEU . . . . . 0.471 ' HG ' ' O ' ' A' ' 159' ' ' LEU . 11.0 mt -67.7 -39.86 84.35 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.39 -0.368 . . . . 0.0 111.345 -178.873 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 164' ' ' ARG . . . . . . . . . . . . . 4.1 tmm_? -59.11 -47.78 84.0 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.446 -0.343 . . . . 0.0 110.756 -179.847 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 165' ' ' ASN . . . . . 0.489 ' N ' HD21 ' A' ' 165' ' ' ASN . 0.9 OUTLIER -56.02 -48.74 75.39 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.303 -0.408 . . . . 0.0 110.297 179.708 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 166' ' ' LEU . . . . . 0.476 HD11 ' O ' ' A' ' 162' ' ' ARG . 1.4 mt -57.89 -45.82 85.85 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.016 -0.538 . . . . 0.0 110.763 179.364 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 167' ' ' THR . . . . . 0.502 ' HA ' HD13 ' A' ' 170' ' ' LEU . 13.9 m -54.4 -51.42 64.91 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-N 115.936 -0.574 . . . . 0.0 112.051 -178.767 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 168' ' ' VAL . . . . . . . . . . . . . 49.3 t -57.76 -40.02 73.62 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.449 0 N-CA-C 111.903 0.334 . . . . 0.0 111.903 -179.386 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 169' ' ' VAL . . . . . 0.418 ' O ' HG12 ' A' ' 173' ' ' ILE . 93.0 t -66.74 -67.69 0.39 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 N-CA-C 113.622 0.971 . . . . 0.0 113.622 -177.947 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 170' ' ' LEU . . . . . 0.502 HD13 ' HA ' ' A' ' 167' ' ' THR . 0.4 OUTLIER -61.14 -34.06 74.39 Favored 'General case' 0 N--CA 1.463 0.222 0 N-CA-C 112.899 0.703 . . . . 0.0 112.899 -177.475 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 171' ' ' TRP . . . . . 0.487 ' HB2' ' O ' ' A' ' 167' ' ' THR . 26.9 m0 -72.59 -30.64 64.55 Favored 'General case' 0 C--N 1.327 -0.401 0 C-N-CA 120.612 -0.435 . . . . 0.0 111.514 -179.283 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 172' ' ' ALA . . . . . . . . . . . . . . . -73.04 -7.86 53.15 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-O 121.036 0.446 . . . . 0.0 110.474 179.916 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 173' ' ' ILE . . . . . 0.488 ' O ' HG12 ' A' ' 177' ' ' ILE . 37.3 mm -88.7 -26.05 5.66 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.222 0 CA-C-N 115.808 -0.633 . . . . 0.0 110.784 179.564 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 174' ' ' TYR . . . . . 0.436 ' HD1' ' HA ' ' A' ' 171' ' ' TRP . 24.1 m-85 -54.28 -49.02 92.75 Favored Pre-proline 0 N--CA 1.462 0.17 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.933 -179.197 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 175' ' ' PRO . . . . . 0.426 ' HB3' ' HZ ' ' A' ' 127' ' ' PHE . 82.8 Cg_exo -45.85 -32.74 9.63 Favored 'Trans proline' 0 C--N 1.351 0.675 0 C-N-CA 121.898 1.732 . . . . 0.0 111.798 179.555 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 176' ' ' PHE . . . . . 0.456 ' O ' ' HG ' ' A' ' 180' ' ' LEU . 60.1 m-85 -80.98 -50.77 9.29 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 115.692 -0.686 . . . . 0.0 111.717 -179.995 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 177' ' ' ILE . . . . . 0.488 HG12 ' O ' ' A' ' 173' ' ' ILE . 10.8 mm -58.69 -38.33 71.01 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.567 0 CA-C-N 116.015 -0.539 . . . . 0.0 111.897 -178.283 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 178' ' ' TRP . . . . . 0.458 ' HH2' ' HB2' ' A' ' 123' ' ' ARG . 83.4 t90 -65.88 -56.26 12.74 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-O 120.875 0.369 . . . . 0.0 110.894 -179.951 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 179' ' ' LEU . . . . . 0.536 ' HG ' HG23 ' A' ' 185' ' ' VAL . 34.0 tp -64.1 -55.24 23.42 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 115.971 -0.559 . . . . 0.0 112.066 -178.689 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 180' ' ' LEU . . . . . 0.546 HD21 HD11 ' A' ' 187' ' ' LEU . 10.1 mt -62.69 -28.65 70.09 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.661 -0.245 . . . . 0.0 111.283 -179.171 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . -72.18 -171.61 17.0 Favored Glycine 0 N--CA 1.45 -0.419 0 C-N-CA 119.929 -1.129 . . . . 0.0 111.922 179.157 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 182' ' ' PRO . . . . . 0.421 ' N ' ' HD2' ' A' ' 183' ' ' PRO . 71.4 Cg_exo -49.84 -43.63 40.08 Favored 'Trans proline' 0 CA--C 1.538 0.708 0 C-N-CA 122.759 2.306 . . . . 0.0 113.756 179.609 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 183' ' ' PRO . . . . . 0.51 ' HB3' ' HB2' ' A' ' 116' ' ' ALA . 60.7 Cg_exo -39.37 -55.74 1.46 Allowed 'Trans proline' 0 C--N 1.358 1.036 0 C-N-CA 122.73 2.287 . . . . 0.0 113.904 -179.414 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 184' ' ' GLY . . . . . . . . . . . . . . . -115.79 -111.91 2.78 Favored Glycine 0 N--CA 1.45 -0.387 0 C-N-CA 120.203 -0.999 . . . . 0.0 112.672 -179.551 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 185' ' ' VAL . . . . . 0.536 HG23 ' HG ' ' A' ' 179' ' ' LEU . 35.8 m -76.39 84.74 0.74 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.466 0 CA-C-O 121.467 0.651 . . . . 0.0 110.693 -179.74 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 186' ' ' ALA . . . . . . . . . . . . . . . -62.9 84.07 0.02 OUTLIER 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 115.73 -0.668 . . . . 0.0 111.361 179.999 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 187' ' ' LEU . . . . . 0.546 HD11 HD21 ' A' ' 180' ' ' LEU . 5.0 mt -77.27 -48.99 16.01 Favored 'General case' 0 C--N 1.332 -0.181 0 CA-C-O 120.964 0.411 . . . . 0.0 110.64 179.73 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 188' ' ' LEU . . . . . . . . . . . . . 83.1 mt -92.41 -162.13 0.9 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 115.811 -0.631 . . . . 0.0 111.378 -179.421 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 189' ' ' THR . . . . . . . . . . . . . 88.4 m -94.58 136.57 23.05 Favored Pre-proline 0 C--N 1.328 -0.349 0 CA-C-N 115.708 -0.678 . . . . 0.0 110.729 -179.974 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 190' ' ' PRO . . . . . . . . . . . . . 80.0 Cg_exo -45.33 -43.68 16.84 Favored 'Trans proline' 0 C--N 1.35 0.609 0 C-N-CA 122.561 2.174 . . . . 0.0 112.63 179.743 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 191' ' ' THR . . . . . . . . . . . . . 82.6 p -58.72 -46.39 87.46 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.329 -0.396 . . . . 0.0 111.042 179.922 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 192' ' ' VAL . . . . . . . . . . . . . 87.6 t -63.14 -47.37 92.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.117 -0.492 . . . . 0.0 111.195 -179.983 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 193' ' ' ASP . . . . . . . . . . . . . 22.3 t70 -54.83 -48.12 73.24 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.055 -0.521 . . . . 0.0 111.311 -179.705 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 194' ' ' VAL . . . . . . . . . . . . . 99.7 t -64.35 -36.12 76.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.281 -0.418 . . . . 0.0 110.887 -179.848 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 195' ' ' ALA . . . . . . . . . . . . . . . -58.2 -46.03 86.54 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.413 -0.358 . . . . 0.0 111.04 179.915 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 196' ' ' LEU . . . . . 0.403 ' O ' ' HG ' ' A' ' 200' ' ' LEU . 94.1 mt -67.01 -42.07 85.6 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.419 -0.355 . . . . 0.0 110.38 179.713 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 197' ' ' ILE . . . . . . . . . . . . . 18.7 mm -57.31 -57.83 8.46 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.231 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.398 179.256 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 198' ' ' VAL . . . . . . . . . . . . . 91.0 t -52.65 -34.82 20.08 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.493 0 CA-C-N 115.598 -0.728 . . . . 0.0 109.328 178.618 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 199' ' ' TYR . . . . . . . . . . . . . 64.4 t80 -70.41 -35.36 73.39 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 115.288 -0.869 . . . . 0.0 110.73 179.704 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 200' ' ' LEU . . . . . 0.403 ' HG ' ' O ' ' A' ' 196' ' ' LEU . 73.1 mt -66.15 -41.34 90.54 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 115.762 -0.654 . . . . 0.0 111.322 -179.485 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 201' ' ' ASP . . . . . 0.424 ' HB2' ' OH ' ' A' ' 51' ' ' TYR . 9.9 m-20 -71.81 -31.83 66.97 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 116.29 -0.414 . . . . 0.0 110.482 179.879 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 202' ' ' LEU . . . . . 0.446 ' O ' ' HB ' ' A' ' 206' ' ' VAL . 3.6 mt -72.66 -34.11 67.02 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 115.831 -0.622 . . . . 0.0 111.997 -179.558 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 203' ' ' VAL . . . . . 0.475 ' O ' ' HA3' ' A' ' 207' ' ' GLY . 7.7 p -75.42 -36.68 36.34 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-O 120.609 0.242 . . . . 0.0 111.177 -179.032 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 204' ' ' THR . . . . . . . . . . . . . 25.6 m -68.41 -55.26 12.54 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-O 120.879 0.371 . . . . 0.0 111.397 179.789 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 205' ' ' LYS . . . . . 0.665 ' HE2' ' HB2' ' A' ' 47' ' ' ALA . 54.3 mttp -68.6 -58.96 3.5 Favored 'General case' 0 C--N 1.328 -0.359 0 N-CA-C 112.397 0.517 . . . . 0.0 112.397 -178.599 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 206' ' ' VAL . . . . . 0.446 ' HB ' ' O ' ' A' ' 202' ' ' LEU . 76.6 t -73.3 -38.13 53.19 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 N-CA-C 112.217 0.451 . . . . 0.0 112.217 -178.702 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 207' ' ' GLY . . . . . 0.475 ' HA3' ' O ' ' A' ' 203' ' ' VAL . . . -63.85 -59.78 8.17 Favored Glycine 0 N--CA 1.452 -0.261 0 C-N-CA 120.341 -0.933 . . . . 0.0 112.514 -179.324 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 208' ' ' PHE . . . . . 0.512 ' O ' ' N ' ' A' ' 212' ' ' ALA . 1.8 m-30 -54.53 -47.89 72.61 Favored 'General case' 0 C--O 1.221 -0.407 0 N-CA-C 109.795 -0.446 . . . . 0.0 109.795 179.515 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 209' ' ' GLY . . . . . 0.404 ' O ' ' HB1' ' A' ' 212' ' ' ALA . . . -54.29 -35.07 54.73 Favored Glycine 0 N--CA 1.448 -0.508 0 CA-C-N 115.366 -0.834 . . . . 0.0 113.144 179.558 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 210' ' ' PHE . . . . . . . . . . . . . 1.9 m-85 -69.69 -47.67 62.41 Favored 'General case' 0 CA--C 1.515 -0.403 0 N-CA-C 108.677 -0.86 . . . . 0.0 108.677 179.334 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 211' ' ' ILE . . . . . 0.408 HG13 ' O ' ' A' ' 207' ' ' GLY . 4.0 mt -66.14 -27.47 40.9 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.486 0 N-CA-C 107.587 -1.264 . . . . 0.0 107.587 176.757 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 212' ' ' ALA . . . . . 0.512 ' N ' ' O ' ' A' ' 208' ' ' PHE . . . -67.4 -39.07 85.52 Favored 'General case' 0 N--CA 1.448 -0.536 0 CA-C-N 114.302 -1.317 . . . . 0.0 110.018 -179.768 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 213' ' ' LEU . . . . . . . . . . . . . 80.7 mt -70.21 -38.05 75.19 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 114.991 -1.004 . . . . 0.0 111.275 -179.841 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 214' ' ' ASP . . . . . . . . . . . . . 26.9 t70 -60.3 -55.09 37.87 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 116.328 -0.396 . . . . 0.0 111.016 -179.808 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 215' ' ' ALA . . . . . 0.506 ' HB1' HD21 ' A' ' 159' ' ' LEU . . . -61.05 -50.89 71.49 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.758 179.709 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 216' ' ' ALA . . . . . . . . . . . . . . . -57.45 -32.49 66.98 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.946 179.683 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 217' ' ' ALA . . . . . . . . . . . . . . . -62.72 -43.3 99.15 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-N 116.086 -0.506 . . . . 0.0 110.17 179.544 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 218' ' ' THR . . . . . . . . . . . . . 91.8 m -64.88 -46.99 79.46 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 115.897 -0.592 . . . . 0.0 110.472 179.267 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 219' ' ' LEU . . . . . 0.411 ' HG ' ' O ' ' A' ' 215' ' ' ALA . 30.1 mt -61.58 -26.46 67.98 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-O 121.302 0.573 . . . . 0.0 109.944 179.273 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 220' ' ' ARG . . . . . . . . . . . . . 56.7 ttp180 -84.49 -26.6 28.03 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 115.305 -0.861 . . . . 0.0 110.933 179.614 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 221' ' ' ALA . . . . . . . . . . . . . . . -82.64 -26.83 31.82 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.093 -0.503 . . . . 0.0 112.05 -179.191 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 222' ' ' GLU . . . . . . . . . . . . . 11.0 pt-20 -68.81 -15.62 63.56 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.862 0.363 . . . . 0.0 110.741 -179.486 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 223' ' ' HIS . . . . . . . . . . . . . 75.4 m-70 -73.38 -68.6 0.49 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.049 -0.523 . . . . 0.0 111.038 179.855 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 224' ' ' GLY . . . . . . . . . . . . . . . 90.89 -42.52 2.87 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.847 -0.692 . . . . 0.0 112.441 -179.864 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 225' ' ' GLU . . . . . . . . . . . . . 1.6 mp0 -60.1 134.38 57.0 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 120.919 0.39 . . . . 0.0 111.046 -179.825 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 226' ' ' SER . . . . . . . . . . . . . 24.7 m -124.12 170.32 10.82 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.808 -179.931 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 227' ' ' LEU . . . . . . . . . . . . . 7.4 mp -91.04 129.22 37.06 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.307 -0.406 . . . . 0.0 110.563 179.688 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 228' ' ' ALA . . . . . . . . . . . . . . . -145.75 144.9 30.61 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.426 -0.352 . . . . 0.0 111.056 179.934 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 229' ' ' GLY . . . . . . . . . . . . . . . 167.98 179.07 40.33 Favored Glycine 0 N--CA 1.45 -0.411 0 C-N-CA 120.623 -0.799 . . . . 0.0 112.603 -179.946 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 230' ' ' VAL . . . . . . . . . . . . . 6.8 p -156.18 139.88 7.9 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-O 120.848 0.356 . . . . 0.0 110.772 -179.997 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 231' ' ' ASP . . . . . . . . . . . . . 17.9 t70 -96.49 93.72 6.97 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.032 -179.799 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 232' ' ' THR . . . . . . . . . . . . . 10.1 t -122.29 -31.53 3.81 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.104 -0.498 . . . . 0.0 111.112 179.957 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 233' ' ' ASP . . . . . . . . . . . . . 21.7 t70 -150.66 -68.07 0.19 Allowed 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.304 -0.407 . . . . 0.0 110.941 179.996 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 234' ' ' THR . . . . . . . . . . . . . 5.1 t -133.66 142.77 45.06 Favored Pre-proline 0 C--N 1.328 -0.348 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.039 179.924 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 235' ' ' PRO . . . . . . . . . . . . . 37.4 Cg_endo -66.14 151.55 83.39 Favored 'Trans proline' 0 C--N 1.348 0.508 0 C-N-CA 122.402 2.068 . . . . 0.0 112.234 179.984 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 236' ' ' ALA . . . . . . . . . . . . . . . 60.02 97.93 0.03 OUTLIER 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 116.057 -0.519 . . . . 0.0 111.345 179.99 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 237' ' ' VAL . . . . . . . . . . . . . 80.1 t -91.36 111.5 23.97 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-N 116.107 -0.497 . . . . 0.0 111.104 179.924 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 238' ' ' ALA . . . . . . . . . . . . . . . -155.39 -12.53 0.11 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.087 -0.506 . . . . 0.0 111.072 179.928 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 239' ' ' ASP . . . . . . . . . . . . . 16.3 m-20 58.62 96.33 0.03 OUTLIER 'General case' 0 N--CA 1.463 0.176 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.854 -179.821 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 240' ' ' LEU . . . . . . . . . . . . . 61.9 mt -115.24 0.6 13.57 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.233 -0.44 . . . . 0.0 111.243 -179.748 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 241' ' ' GLU . . . . . . . . . . . . . 1.5 mp0 -81.99 162.63 22.58 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.424 -0.353 . . . . 0.0 110.667 179.768 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 242' ' ' HIS . . . . . . . . . . . . . 63.4 t60 -143.59 -44.44 0.28 Allowed 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.377 -0.374 . . . . 0.0 110.932 -179.881 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 243' ' ' HIS . . . . . . . . . . . . . 43.3 m80 -66.18 121.49 15.31 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.774 -179.974 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 244' ' ' HIS . . . . . . . . . . . . . 54.8 t-80 -134.44 114.01 12.44 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.287 -0.415 . . . . 0.0 110.973 179.938 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 245' ' ' HIS . . . . . . . . . . . . . 47.8 m80 -107.64 147.76 30.24 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.894 -179.94 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 246' ' ' HIS . . . . . . . . . . . . . 93.5 m-70 -93.77 -36.7 12.15 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.901 -179.967 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 247' ' ' HIS . . . . . . . . . . . . . 7.2 m80 . . . . . 0 C--O 1.25 1.11 0 CA-C-O 118.193 -0.908 . . . . 0.0 110.892 -179.962 . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 301' ' ' RET . . . . . 0.525 ' H22' ' HA3' ' A' ' 112' ' ' GLY . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 2.7 mpp? . . . . . 0 N--CA 1.486 1.375 0 CA-C-O 120.905 0.383 . . . . 0.0 110.867 . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 16.2 m -138.64 -39.95 0.31 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 115.971 -0.559 . . . . 0.0 111.251 -179.948 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -106.76 -13.37 22.21 Favored Glycine 0 N--CA 1.45 -0.422 0 C-N-CA 120.785 -0.721 . . . . 0.0 112.744 -179.989 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 52.0 tp -74.15 -35.47 64.05 Favored 'General case' 0 C--N 1.331 -0.21 0 CA-C-O 120.867 0.365 . . . . 0.0 110.752 179.928 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 64.9 p -64.15 -32.61 74.24 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.014 -0.539 . . . . 0.0 111.276 -179.99 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 15.9 p -52.87 -35.4 57.71 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.264 -179.647 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 7' ' ' LEU . . . . . . . . . . . . . 4.2 mm? -60.8 -53.34 58.52 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.242 -179.814 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 8' ' ' PHE . . . . . . . . . . . . . 64.0 m-85 -60.08 -32.7 71.2 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.928 0.394 . . . . 0.0 110.641 -179.986 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 9' ' ' TRP . . . . . 0.428 ' O ' HG13 ' A' ' 13' ' ' ILE . 35.8 m95 -67.08 -41.69 85.93 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 115.943 -0.571 . . . . 0.0 110.092 179.622 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 82.5 mt -61.57 -52.75 63.15 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 115.721 -0.672 . . . . 0.0 110.205 179.244 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -53.48 -36.46 53.77 Favored Glycine 0 N--CA 1.449 -0.492 0 C-N-CA 120.775 -0.726 . . . . 0.0 111.612 178.766 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -64.07 -34.68 78.58 Favored 'General case' 0 C--N 1.332 -0.191 0 CA-C-O 120.91 0.386 . . . . 0.0 110.226 179.258 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 13' ' ' ILE . . . . . 0.428 HG13 ' O ' ' A' ' 9' ' ' TRP . 80.1 mt -66.13 -48.48 81.3 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.219 0 CA-C-N 115.884 -0.598 . . . . 0.0 110.363 179.268 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -60.94 -32.96 81.81 Favored Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.662 -0.78 . . . . 0.0 111.482 179.35 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 15' ' ' MET . . . . . 0.536 ' HB3' ' HB2' ' A' ' 48' ' ' ALA . 0.0 OUTLIER -67.99 -42.68 80.39 Favored 'General case' 0 C--N 1.331 -0.218 0 CA-C-O 120.92 0.391 . . . . 0.0 110.553 179.186 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 32.4 tp -57.8 -41.41 82.09 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.029 -0.532 . . . . 0.0 110.442 179.474 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 89.4 t -64.65 -51.03 72.68 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.22 0 CA-C-N 115.824 -0.625 . . . . 0.0 111.094 179.972 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -62.03 -49.51 74.57 Favored Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.686 -0.769 . . . . 0.0 112.183 179.913 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 19' ' ' THR . . . . . 0.465 ' HG1' ' HB3' ' A' ' 44' ' ' SER . 51.9 m -49.77 -41.58 44.58 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-O 120.752 0.31 . . . . 0.0 111.326 -179.561 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 78.1 mt -72.07 -48.59 43.05 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.272 -0.422 . . . . 0.0 111.427 179.836 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -59.5 -29.64 68.0 Favored 'General case' 0 C--N 1.329 -0.296 0 N-CA-C 112.192 0.442 . . . . 0.0 112.192 -179.284 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 8.0 m-85 -88.11 -45.57 10.04 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-O 120.661 0.267 . . . . 0.0 111.53 -179.307 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -60.7 -50.37 73.76 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.884 0.373 . . . . 0.0 111.589 -179.615 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 24' ' ' TRP . . . . . . . . . . . . . 2.0 t-105 -58.54 -44.19 89.53 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 116.007 -0.542 . . . . 0.0 111.119 -179.727 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -74.98 -18.26 60.4 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-O 120.854 0.359 . . . . 0.0 110.998 -179.998 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -73.81 -48.31 17.16 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.849 -0.691 . . . . 0.0 112.493 179.923 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 21.4 mmm180 -57.98 -30.57 66.14 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-O 120.838 0.352 . . . . 0.0 110.908 -179.926 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 25.4 t70 -102.05 91.84 4.51 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.067 -0.515 . . . . 0.0 110.799 -179.958 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -169.96 -176.46 2.32 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.058 -0.519 . . . . 0.0 111.081 -179.962 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -92.04 177.54 39.93 Favored Glycine 0 N--CA 1.452 -0.275 0 C-N-CA 120.784 -0.722 . . . . 0.0 112.444 179.795 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 78.2 p -80.84 127.32 32.4 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.784 0.325 . . . . 0.0 111.057 -179.947 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 115.66 -27.95 8.06 Favored Glycine 0 N--CA 1.452 -0.246 0 C-N-CA 120.847 -0.692 . . . . 0.0 112.435 179.916 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 11.0 mm-40 -92.12 -24.64 19.05 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.841 0.353 . . . . 0.0 110.83 179.959 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 34' ' ' ARG . . . . . . . . . . . . . 78.6 mtm180 -50.48 -29.24 9.94 Favored 'General case' 0 C--N 1.332 -0.177 0 CA-C-N 115.943 -0.572 . . . . 0.0 111.575 -179.647 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 41.3 mmt180 -60.45 -46.5 89.82 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.767 0.318 . . . . 0.0 111.33 -179.904 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 76.6 m-85 -69.88 -30.58 68.06 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.282 -0.417 . . . . 0.0 111.456 -179.605 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 37' ' ' TYR . . . . . . . . . . . . . 62.8 m-85 -70.62 -55.12 9.51 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.289 -0.414 . . . . 0.0 111.302 -179.619 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 60.7 t -57.04 -37.84 57.19 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-O 120.957 0.408 . . . . 0.0 110.453 179.774 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 41.8 m -63.58 -47.98 79.29 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 115.847 -0.615 . . . . 0.0 110.316 179.209 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 27.6 tp -57.4 -48.21 79.69 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 115.52 -0.764 . . . . 0.0 110.539 179.677 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 76.3 t -60.63 -34.48 58.78 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.231 0 CA-C-N 115.717 -0.674 . . . . 0.0 110.382 179.242 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -60.03 -40.18 96.68 Favored Glycine 0 N--CA 1.449 -0.484 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.118 179.824 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 43' ' ' ILE . . . . . 0.511 HG22 ' HE3' ' A' ' 205' ' ' LYS . 0.4 OUTLIER -65.2 -53.86 35.74 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-O 120.728 0.299 . . . . 0.0 111.008 179.583 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 44' ' ' SER . . . . . 0.465 ' HB3' ' HG1' ' A' ' 19' ' ' THR . 49.1 m -60.31 -25.75 66.0 Favored 'General case' 0 C--N 1.332 -0.181 0 CA-C-O 120.793 0.33 . . . . 0.0 111.37 -179.942 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -78.42 -51.74 5.49 Favored Glycine 0 CA--C 1.519 0.313 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.978 -179.54 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 21.8 pt -58.97 -38.73 75.41 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.217 0 CA-C-O 120.873 0.368 . . . . 0.0 111.035 -179.976 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 47' ' ' ALA . . . . . 0.604 ' HB2' ' HE2' ' A' ' 205' ' ' LYS . . . -67.85 -45.0 75.85 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.544 179.636 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 48' ' ' ALA . . . . . 0.536 ' HB2' ' HB3' ' A' ' 15' ' ' MET . . . -54.54 -41.58 69.9 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.069 -0.514 . . . . 0.0 112.024 -179.295 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 30.4 m -76.79 -34.35 22.84 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.36 0 CA-C-N 116.48 -0.327 . . . . 0.0 111.815 -179.21 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -66.92 -36.39 82.14 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 120.91 0.386 . . . . 0.0 111.101 179.922 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 51' ' ' TYR . . . . . 0.411 ' HH ' ' HA ' ' A' ' 198' ' ' VAL . 3.3 m-85 -73.29 -40.09 64.83 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 115.987 -0.551 . . . . 0.0 110.452 179.951 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -62.79 -49.91 73.1 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-N 115.726 -0.67 . . . . 0.0 111.227 179.854 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 53' ' ' VAL . . . . . 0.439 ' O ' HG22 ' A' ' 58' ' ' VAL . 27.6 m -63.83 -46.02 95.48 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.218 0 CA-C-N 116.366 -0.379 . . . . 0.0 110.749 -179.975 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 54' ' ' MET . . . . . 0.468 ' HB2' ' HB2' ' A' ' 71' ' ' PRO . 11.0 ttp -64.11 -29.73 70.84 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.313 179.756 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -63.0 -23.71 67.58 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 115.871 -0.604 . . . . 0.0 110.926 179.442 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 54.0 mt -94.47 -8.85 37.31 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-N 116.079 -0.51 . . . . 0.0 110.726 179.812 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . 0.419 ' HA2' ' CD1' ' A' ' 60' ' ' TRP . . . 75.19 30.66 58.55 Favored Glycine 0 N--CA 1.451 -0.361 0 C-N-CA 120.876 -0.678 . . . . 0.0 112.953 179.723 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 58' ' ' VAL . . . . . 0.439 HG22 ' O ' ' A' ' 53' ' ' VAL . 26.3 m -84.04 18.2 0.37 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-O 120.808 0.337 . . . . 0.0 111.504 179.992 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -152.87 6.6 0.45 Allowed Glycine 0 N--CA 1.449 -0.485 0 C-N-CA 120.751 -0.737 . . . . 0.0 112.888 179.947 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 60' ' ' TRP . . . . . 0.419 ' CD1' ' HA2' ' A' ' 57' ' ' GLY . 34.5 m0 -71.95 121.5 19.21 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-O 120.783 0.325 . . . . 0.0 110.48 179.921 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 7.5 p -114.91 128.59 25.78 Favored Pre-proline 0 CA--C 1.533 0.303 0 CA-C-N 116.263 -0.426 . . . . 0.0 111.388 -179.733 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 65.0 Cg_endo -73.95 144.01 33.73 Favored 'Trans proline' 0 C--N 1.351 0.686 0 C-N-CA 122.396 2.064 . . . . 0.0 112.107 179.719 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 59.0 t -137.83 90.42 0.72 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.384 0 CA-C-N 116.086 -0.506 . . . . 0.0 111.061 -179.645 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . 58.43 -88.05 0.02 OUTLIER 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 116.116 -0.493 . . . . 0.0 111.587 -179.996 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 45.6 mt-10 -119.19 -19.96 8.16 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-O 120.775 0.321 . . . . 0.0 110.958 179.995 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 66' ' ' ARG . . . . . . . . . . . . . 9.9 ptp180 -103.23 165.19 11.17 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.268 -0.423 . . . . 0.0 110.449 179.651 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 53.9 m -123.35 129.64 51.6 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.937 0.398 . . . . 0.0 111.472 -179.677 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 99.2 t -109.73 146.33 15.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 115.889 -0.596 . . . . 0.0 110.492 179.644 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 69' ' ' PHE . . . . . . . . . . . . . 30.3 m-85 -105.59 115.47 30.3 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 121.049 0.452 . . . . 0.0 110.484 -179.474 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 70' ' ' VAL . . . . . 0.617 HG11 ' HD3' ' A' ' 71' ' ' PRO . 0.3 OUTLIER -67.98 -36.29 9.13 Favored Pre-proline 0 CA--C 1.54 0.58 0 CA-C-N 115.863 -0.608 . . . . 0.0 112.601 -179.48 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 71' ' ' PRO . . . . . 0.617 ' HD3' HG11 ' A' ' 70' ' ' VAL . 7.7 Cg_exo -71.09 -19.12 30.28 Favored 'Trans proline' 0 C--N 1.357 1.016 0 C-N-CA 122.21 1.94 . . . . 0.0 113.308 -179.198 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 43.0 ttm180 -76.35 -55.09 5.87 Favored 'General case' 0 C--N 1.331 -0.206 0 N-CA-C 112.372 0.508 . . . . 0.0 112.372 -178.505 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 73' ' ' TYR . . . . . 0.441 ' O ' HG13 ' A' ' 77' ' ' ILE . 68.5 m-85 -71.19 -36.76 72.06 Favored 'General case' 0 C--N 1.329 -0.286 0 C-N-CA 120.841 -0.344 . . . . 0.0 110.956 -179.248 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 0.3 OUTLIER -64.95 -40.43 89.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 N-CA-C 109.766 -0.457 . . . . 0.0 109.766 179.309 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 12.0 t70 -60.23 -37.51 80.55 Favored 'General case' 0 CA--C 1.518 -0.251 0 N-CA-C 109.437 -0.579 . . . . 0.0 109.437 178.772 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 76' ' ' TRP . . . . . . . . . . . . . 46.6 m0 -64.03 -31.44 72.63 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 115.899 -0.591 . . . . 0.0 110.319 179.478 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 77' ' ' ILE . . . . . 0.508 ' O ' ' HG2' ' A' ' 81' ' ' PRO . 61.8 mt -71.28 -31.72 44.79 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.478 178.963 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 25.6 mt -91.82 -15.13 28.66 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.172 -0.467 . . . . 0.0 112.165 -179.707 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 79' ' ' THR . . . . . 0.496 ' HG1' ' H ' ' A' ' 80' ' ' THR . 79.8 p -104.61 -52.97 2.78 Favored 'General case' 0 N--CA 1.465 0.296 0 N-CA-C 113.614 0.968 . . . . 0.0 113.614 -177.891 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 80' ' ' THR . . . . . 0.566 ' HB ' ' HD3' ' A' ' 81' ' ' PRO . 4.5 m -52.66 -53.68 51.41 Favored Pre-proline 0 C--N 1.331 -0.237 0 N-CA-C 112.36 0.504 . . . . 0.0 112.36 -178.369 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 81' ' ' PRO . . . . . 0.566 ' HD3' ' HB ' ' A' ' 80' ' ' THR . 52.6 Cg_exo -57.01 -23.43 52.01 Favored 'Trans proline' 0 C--N 1.352 0.752 0 C-N-CA 121.612 1.541 . . . . 0.0 111.68 179.543 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 82' ' ' LEU . . . . . . . . . . . . . 18.0 tp -76.76 -33.19 58.1 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 115.926 -0.579 . . . . 0.0 110.054 179.604 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 83' ' ' ILE . . . . . 0.441 HD11 HG23 ' A' ' 43' ' ' ILE . 37.6 mm -69.36 -53.37 25.49 Favored 'Isoleucine or valine' 0 C--O 1.232 0.161 0 CA-C-N 116.007 -0.542 . . . . 0.0 110.386 179.226 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 29.0 m -59.36 -32.8 49.34 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.183 0 N-CA-C 109.8 -0.444 . . . . 0.0 109.8 179.005 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 85' ' ' TYR . . . . . . . . . . . . . 55.4 t80 -64.66 -34.57 78.6 Favored 'General case' 0 N--CA 1.454 -0.272 0 CA-C-N 115.657 -0.701 . . . . 0.0 109.561 178.801 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 86' ' ' PHE . . . . . . . . . . . . . 8.8 t80 -61.48 -51.82 67.07 Favored 'General case' 0 C--O 1.232 0.181 0 CA-C-N 115.635 -0.711 . . . . 0.0 110.232 179.507 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 7.3 mp -61.71 -31.93 72.11 Favored 'General case' 0 C--N 1.331 -0.204 0 CA-C-N 116.136 -0.483 . . . . 0.0 110.116 179.49 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -71.59 -27.57 70.89 Favored Glycine 0 N--CA 1.449 -0.44 0 CA-C-N 115.8 -0.636 . . . . 0.0 111.795 179.31 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 42.0 mt -72.07 -39.2 69.18 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.919 0.39 . . . . 0.0 110.538 179.733 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 53.6 mt -58.5 -45.8 88.01 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 115.782 -0.645 . . . . 0.0 111.106 -179.967 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . 0.515 ' HB3' ' HB1' ' A' ' 149' ' ' ALA . . . -79.88 -54.94 5.35 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.403 -179.728 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 102.84 65.64 0.73 Allowed Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.826 -0.702 . . . . 0.0 112.346 -179.888 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 93' ' ' LEU . . . . . 0.436 HD12 ' HG2' ' A' ' 145' ' ' MET . 8.1 mp -71.93 172.04 10.67 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.804 0.335 . . . . 0.0 111.053 179.998 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 94' ' ' ASP . . . . . 0.435 ' HB2' ' HG2' ' A' ' 97' ' ' GLU . 10.1 m-20 -78.54 174.3 11.5 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.811 179.942 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 71.4 p -61.62 -51.27 69.19 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.176 -0.466 . . . . 0.0 111.215 -179.858 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 97.8 mtt180 -65.39 -42.15 92.93 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.374 -179.66 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 97' ' ' GLU . . . . . 0.435 ' HG2' ' HB2' ' A' ' 94' ' ' ASP . 10.3 mm-40 -52.49 -50.76 62.1 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.311 -0.404 . . . . 0.0 111.163 -179.625 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 98' ' ' PHE . . . . . 0.436 ' O ' HG12 ' A' ' 102' ' ' ILE . 12.2 m-85 -56.18 -46.23 79.44 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.354 -0.385 . . . . 0.0 110.683 179.633 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -60.54 -29.67 70.09 Favored Glycine 0 N--CA 1.448 -0.505 0 C-N-CA 120.688 -0.768 . . . . 0.0 112.34 179.978 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 96.6 mt -73.87 -42.63 53.59 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.238 0 CA-C-O 120.786 0.327 . . . . 0.0 111.717 -179.853 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 39.8 t -70.61 -42.58 77.98 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 CA-C-N 116.427 -0.351 . . . . 0.0 111.519 -179.335 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 102' ' ' ILE . . . . . 0.436 HG12 ' O ' ' A' ' 98' ' ' PHE . 49.2 mm -64.92 -45.78 93.72 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.368 -0.378 . . . . 0.0 111.552 -179.548 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 13.7 t -62.22 -35.52 79.14 Favored 'General case' 0 C--O 1.233 0.211 0 CA-C-O 120.847 0.356 . . . . 0.0 110.661 179.879 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 104' ' ' LEU . . . . . 0.432 ' O ' HG22 ' A' ' 108' ' ' VAL . 29.8 tp -57.39 -53.82 53.86 Favored 'General case' 0 C--N 1.331 -0.202 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.258 179.241 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 105' ' ' ASN . . . . . 0.599 ' N ' HD21 ' A' ' 105' ' ' ASN . 0.8 OUTLIER -56.25 -36.67 68.81 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 115.952 -0.567 . . . . 0.0 110.433 179.709 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 30.6 m -54.92 -43.41 73.28 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.511 179.621 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 1.2 t -65.64 -39.49 85.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-O 121.274 0.559 . . . . 0.0 110.187 179.206 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . 0.449 ' HB ' ' HE2' ' A' ' 109' ' ' MET . 41.7 t -60.03 -53.16 52.4 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.38 0 CA-C-N 115.291 -0.868 . . . . 0.0 111.782 -179.728 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 109' ' ' MET . . . . . 0.455 ' HE3' HG22 ' A' ' 80' ' ' THR . 8.0 mmt -61.85 -41.86 98.34 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-N 116.306 -0.406 . . . . 0.0 111.257 -179.284 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 28.6 tp -60.21 -30.27 69.27 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 116.377 -0.374 . . . . 0.0 110.461 -179.906 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -66.55 -54.87 18.97 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.552 179.217 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . -60.02 -36.22 89.66 Favored Glycine 0 N--CA 1.452 -0.24 0 C-N-CA 120.497 -0.859 . . . . 0.0 111.722 179.373 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 113' ' ' PHE . . . . . . . . . . . . . 0.9 OUTLIER -56.1 -75.09 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 121.051 0.453 . . . . 0.0 110.357 179.647 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -58.44 -29.72 66.37 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 115.679 -0.691 . . . . 0.0 111.418 -179.91 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -52.3 -49.12 52.2 Favored Glycine 0 C--N 1.331 0.254 0 C-N-CA 121.075 -0.583 . . . . 0.0 112.726 -179.993 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -77.71 -16.87 58.16 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-O 120.697 0.284 . . . . 0.0 111.458 -179.976 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 117' ' ' MET . . . . . . . . . . . . . 38.3 ttm -100.95 18.08 20.57 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.352 -0.385 . . . . 0.0 111.321 -179.387 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 118' ' ' VAL . . . . . 0.482 HG22 ' HB3' ' A' ' 123' ' ' ARG . 27.1 m -70.05 148.31 96.03 Favored Pre-proline 0 C--N 1.329 -0.302 0 CA-C-N 116.451 -0.34 . . . . 0.0 111.15 179.794 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 119' ' ' PRO . . . . . . . . . . . . . 90.6 Cg_endo -83.7 -3.77 10.63 Favored 'Trans proline' 0 C--N 1.348 0.52 0 C-N-CA 122.567 2.178 . . . . 0.0 112.136 179.719 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -156.25 -141.51 3.21 Favored Glycine 0 N--CA 1.453 -0.229 0 C-N-CA 120.926 -0.654 . . . . 0.0 112.452 -179.981 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 41.0 pt -84.71 18.87 0.37 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.229 0 CA-C-O 120.845 0.355 . . . . 0.0 111.062 -179.99 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 122' ' ' GLU . . . . . 0.442 ' HB2' ' HB ' ' A' ' 118' ' ' VAL . 12.3 mm-40 -67.52 -18.01 64.88 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.0 -0.545 . . . . 0.0 111.36 -179.926 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 123' ' ' ARG . . . . . 0.482 ' HB3' HG22 ' A' ' 118' ' ' VAL . 0.0 OUTLIER -51.11 -30.2 15.56 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-N 116.424 -0.353 . . . . 0.0 111.457 -179.532 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 124' ' ' TYR . . . . . . . . . . . . . 34.6 m-85 -70.23 -32.52 70.42 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-O 120.735 0.302 . . . . 0.0 111.202 -179.717 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 125' ' ' ALA . . . . . . . . . . . . . . . -67.88 -52.2 39.33 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.268 -0.423 . . . . 0.0 110.887 179.88 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 3.2 mm? -53.24 -54.44 36.07 Favored 'General case' 0 CA--C 1.521 -0.168 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.581 179.69 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 127' ' ' PHE . . . . . 0.481 ' HZ ' ' HB3' ' A' ' 175' ' ' PRO . 9.4 t80 -62.33 -35.74 80.03 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.082 -179.63 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 128' ' ' GLY . . . . . . . . . . . . . . . -47.23 -48.1 20.76 Favored Glycine 0 C--N 1.332 0.314 0 C-N-CA 119.925 -1.131 . . . . 0.0 110.287 178.718 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 129' ' ' MET . . . . . . . . . . . . . 0.4 OUTLIER -71.21 -31.41 67.55 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 115.019 -0.591 . . . . 0.0 109.697 178.379 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -60.96 -41.09 99.25 Favored Glycine 0 C--N 1.332 0.359 0 CA-C-N 115.821 -0.627 . . . . 0.0 112.753 -179.864 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -71.28 -51.92 21.75 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.644 0.259 . . . . 0.0 110.518 179.807 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 57.4 t -55.04 -39.95 52.19 Favored 'Isoleucine or valine' 0 C--O 1.233 0.226 0 CA-C-O 121.3 0.571 . . . . 0.0 109.694 178.95 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -70.77 -37.35 73.36 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 115.407 -0.815 . . . . 0.0 110.658 179.602 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 134' ' ' PHE . . . . . . . . . . . . . 43.6 t80 -56.62 -53.35 58.64 Favored 'General case' 0 N--CA 1.451 -0.386 0 CA-C-O 120.995 0.426 . . . . 0.0 109.984 179.567 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 135' ' ' ILE . . . . . . . . . . . . . 48.4 mt -58.02 -33.48 46.46 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.405 0 CA-C-N 115.787 -0.642 . . . . 0.0 109.838 179.227 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . -58.82 -40.73 95.47 Favored Glycine 0 N--CA 1.448 -0.53 0 C-N-CA 120.394 -0.908 . . . . 0.0 111.473 178.905 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 137' ' ' LEU . . . . . . . . . . . . . 53.5 tp -69.73 -45.04 69.05 Favored 'General case' 0 N--CA 1.455 -0.193 0 CA-C-O 120.693 0.282 . . . . 0.0 110.588 179.411 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 138' ' ' VAL . . . . . . . . . . . . . 98.8 t -56.05 -40.99 66.9 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.9 0 CA-C-O 121.222 0.534 . . . . 0.0 109.896 179.231 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 139' ' ' TYR . . . . . . . . . . . . . 29.4 t80 -59.05 -47.14 86.31 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 115.416 -0.811 . . . . 0.0 110.612 178.937 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 22.9 m-85 -54.52 -37.77 65.74 Favored 'General case' 0 C--N 1.332 -0.16 0 CA-C-N 116.39 -0.368 . . . . 0.0 110.911 179.942 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 141' ' ' LEU . . . . . 0.426 HD23 ' SD ' ' A' ' 145' ' ' MET . 79.8 mt -60.89 -50.7 72.37 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-O 120.905 0.383 . . . . 0.0 110.366 179.502 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 22.0 t -70.52 -15.21 18.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.034 -0.53 . . . . 0.0 110.723 179.531 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . -70.37 -140.24 0.16 Allowed Glycine 0 CA--C 1.521 0.461 0 C-N-CA 121.015 -0.612 . . . . 0.0 112.842 -179.88 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 144' ' ' PRO . . . . . . . . . . . . . 42.0 Cg_exo -56.64 -23.69 50.35 Favored 'Trans proline' 0 C--N 1.35 0.639 0 C-N-CA 122.641 2.227 . . . . 0.0 112.63 -179.794 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 145' ' ' MET . . . . . 0.436 ' HG2' HD12 ' A' ' 93' ' ' LEU . 54.5 mtt -57.93 -31.65 67.01 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.391 -0.368 . . . . 0.0 111.429 -179.867 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 146' ' ' THR . . . . . . . . . . . . . 25.0 m -74.11 -48.34 30.24 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.278 -0.419 . . . . 0.0 112.05 -179.061 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 45.1 mt-10 -72.92 -29.02 62.81 Favored 'General case' 0 C--N 1.329 -0.302 0 N-CA-C 111.762 0.282 . . . . 0.0 111.762 -179.157 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 148' ' ' SER . . . . . 0.429 ' HB3' ' HB1' ' A' ' 91' ' ' ALA . 46.8 t -70.76 -47.81 57.68 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.519 -0.31 . . . . 0.0 111.497 -179.179 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 149' ' ' ALA . . . . . 0.515 ' HB1' ' HB3' ' A' ' 91' ' ' ALA . . . -73.54 -43.23 60.44 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.378 -0.374 . . . . 0.0 111.865 -179.259 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 150' ' ' SER . . . . . 0.463 ' HA ' ' HB3' ' A' ' 157' ' ' LYS . 42.8 t -65.51 -8.4 19.34 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.457 -0.338 . . . . 0.0 111.286 -179.613 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 151' ' ' GLN . . . . . . . . . . . . . 46.2 mt-30 -124.89 15.73 8.59 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.454 -0.339 . . . . 0.0 111.161 179.999 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 31.3 tpt180 -90.79 -52.02 5.08 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 121.093 0.473 . . . . 0.0 110.275 179.646 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 153' ' ' SER . . . . . 0.578 ' HB2' HG12 ' A' ' 156' ' ' ILE . 24.6 m -158.02 172.69 17.98 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 115.719 -0.673 . . . . 0.0 110.473 179.228 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 154' ' ' SER . . . . . . . . . . . . . 78.3 p -70.55 -38.69 74.19 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.335 -0.393 . . . . 0.0 110.482 179.438 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -77.87 -38.01 28.22 Favored Glycine 0 N--CA 1.452 -0.265 0 C-N-CA 121.04 -0.6 . . . . 0.0 112.845 179.781 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 156' ' ' ILE . . . . . 0.578 HG12 ' HB2' ' A' ' 153' ' ' SER . 39.0 mm -53.4 -44.48 55.08 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.202 0 N-CA-C 111.917 0.34 . . . . 0.0 111.917 -179.204 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 157' ' ' LYS . . . . . 0.463 ' HB3' ' HA ' ' A' ' 150' ' ' SER . 18.9 ptpt -65.78 -30.88 71.59 Favored 'General case' 0 C--N 1.329 -0.288 0 N-CA-C 111.714 0.264 . . . . 0.0 111.714 -179.225 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 47.8 t -71.7 -48.37 47.76 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 121.076 0.465 . . . . 0.0 111.077 -179.539 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 159' ' ' LEU . . . . . 0.475 ' O ' ' HB2' ' A' ' 163' ' ' LEU . 8.4 mp -71.53 -29.81 65.19 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 115.875 -0.602 . . . . 0.0 111.313 -179.785 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 160' ' ' TYR . . . . . 0.428 ' HH ' ' HB3' ' A' ' 145' ' ' MET . 92.8 t80 -70.73 -44.84 65.99 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.397 -0.365 . . . . 0.0 111.739 -179.402 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 28.6 m -66.05 -42.34 91.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 N-CA-C 111.624 0.231 . . . . 0.0 111.624 -179.365 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 162' ' ' ARG . . . . . . . . . . . . . 95.7 mtt180 -67.99 -44.71 75.99 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.796 0.331 . . . . 0.0 111.497 -179.808 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 163' ' ' LEU . . . . . 0.475 ' HB2' ' O ' ' A' ' 159' ' ' LEU . 4.5 mp -71.55 -54.16 11.41 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.264 -0.426 . . . . 0.0 112.039 -179.19 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 164' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -53.05 -41.64 65.01 Favored 'General case' 0 C--N 1.328 -0.353 0 N-CA-C 111.957 0.354 . . . . 0.0 111.957 -178.783 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 165' ' ' ASN . . . . . 0.509 ' N ' HD21 ' A' ' 165' ' ' ASN . 0.9 OUTLIER -67.03 -52.31 43.93 Favored 'General case' 0 C--N 1.329 -0.318 0 N-CA-C 112.013 0.375 . . . . 0.0 112.013 -179.114 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 166' ' ' LEU . . . . . 0.431 ' O ' ' HG ' ' A' ' 170' ' ' LEU . 0.0 OUTLIER -67.45 -33.13 74.5 Favored 'General case' 0 C--N 1.329 -0.288 0 N-CA-C 111.643 0.238 . . . . 0.0 111.643 -178.871 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 167' ' ' THR . . . . . 0.457 ' O ' ' HB2' ' A' ' 171' ' ' TRP . 27.5 m -63.04 -53.83 47.72 Favored 'General case' 0 C--N 1.332 -0.195 0 N-CA-C 111.939 0.348 . . . . 0.0 111.939 -179.976 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 168' ' ' VAL . . . . . 0.417 HG13 ' N ' ' A' ' 169' ' ' VAL . 9.9 p -59.28 -40.07 80.41 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.242 0 CA-C-N 116.486 -0.325 . . . . 0.0 111.541 -178.924 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 169' ' ' VAL . . . . . 0.417 ' N ' HG13 ' A' ' 168' ' ' VAL . 74.0 t -57.14 -65.38 0.41 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.563 -0.29 . . . . 0.0 111.45 -179.767 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 170' ' ' LEU . . . . . 0.431 ' HG ' ' O ' ' A' ' 166' ' ' LEU . 2.7 pp -63.09 -29.78 71.08 Favored 'General case' 0 C--N 1.331 -0.228 0 N-CA-C 111.908 0.336 . . . . 0.0 111.908 -179.085 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 171' ' ' TRP . . . . . 0.46 ' HE1' H201 ' A' ' 301' ' ' RET . 2.5 m0 -72.51 -31.47 65.37 Favored 'General case' 0 C--N 1.331 -0.21 0 C-N-CA 120.797 -0.361 . . . . 0.0 110.761 179.612 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 172' ' ' ALA . . . . . . . . . . . . . . . -72.94 -6.24 43.92 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-O 121.055 0.455 . . . . 0.0 110.367 179.439 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 173' ' ' ILE . . . . . 0.571 HG21 HD12 ' A' ' 177' ' ' ILE . 37.2 mm -82.89 -25.99 8.19 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.206 0 CA-C-N 115.771 -0.649 . . . . 0.0 110.999 179.791 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 174' ' ' TYR . . . . . 0.447 ' HB2' ' HD3' ' A' ' 175' ' ' PRO . 49.9 m-85 -54.55 -50.7 83.95 Favored Pre-proline 0 N--CA 1.464 0.272 0 CA-C-N 116.353 -0.385 . . . . 0.0 111.671 -179.665 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 175' ' ' PRO . . . . . 0.481 ' HB3' ' HZ ' ' A' ' 127' ' ' PHE . 97.2 Cg_exo -45.19 -30.29 4.96 Favored 'Trans proline' 0 C--N 1.35 0.647 0 C-N-CA 122.186 1.924 . . . . 0.0 112.403 179.65 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 176' ' ' PHE . . . . . 0.443 ' O ' ' HG ' ' A' ' 180' ' ' LEU . 65.8 m-85 -80.57 -49.67 11.01 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 115.979 -0.555 . . . . 0.0 111.989 -179.729 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 177' ' ' ILE . . . . . 0.571 HD12 HG21 ' A' ' 173' ' ' ILE . 2.3 mm -61.59 -37.37 77.74 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.53 0 N-CA-C 112.723 0.638 . . . . 0.0 112.723 -177.693 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 178' ' ' TRP . . . . . . . . . . . . . 63.0 t90 -72.55 -44.9 61.48 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 120.875 0.369 . . . . 0.0 110.823 179.7 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 179' ' ' LEU . . . . . 0.433 ' O ' ' HA3' ' A' ' 184' ' ' GLY . 2.5 tm? -67.15 -49.25 65.43 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 115.907 -0.588 . . . . 0.0 111.72 -179.0 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 180' ' ' LEU . . . . . 0.443 ' HG ' ' O ' ' A' ' 176' ' ' PHE . 23.1 mt -77.24 -45.28 26.98 Favored 'General case' 0 C--N 1.326 -0.424 0 N-CA-C 111.982 0.364 . . . . 0.0 111.982 -178.796 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . -57.32 178.91 0.88 Allowed Glycine 0 C--N 1.334 0.47 0 C-N-CA 120.438 -0.887 . . . . 0.0 112.82 -179.878 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 182' ' ' PRO . . . . . 0.561 ' N ' ' HD2' ' A' ' 183' ' ' PRO . 71.5 Cg_exo -47.78 -46.06 22.41 Favored 'Trans proline' 0 CA--C 1.537 0.67 0 C-N-CA 123.0 2.466 . . . . 0.0 114.177 -179.709 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 183' ' ' PRO . . . . . 0.561 ' HD2' ' N ' ' A' ' 182' ' ' PRO . 16.9 Cg_endo -57.53 -9.92 6.05 Favored 'Trans proline' 0 C--N 1.355 0.885 0 C-N-CA 122.02 1.813 . . . . 0.0 113.246 -179.409 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 184' ' ' GLY . . . . . 0.433 ' HA3' ' O ' ' A' ' 179' ' ' LEU . . . -116.23 -86.8 1.3 Allowed Glycine 0 N--CA 1.45 -0.379 0 C-N-CA 120.536 -0.84 . . . . 0.0 112.722 179.781 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 185' ' ' VAL . . . . . 0.411 HG23 ' O ' ' A' ' 179' ' ' LEU . 9.0 m -123.47 -4.1 7.18 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.246 0 CA-C-O 120.781 0.324 . . . . 0.0 111.544 -179.817 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 186' ' ' ALA . . . . . 0.56 ' HB2' ' HA ' ' A' ' 182' ' ' PRO . . . 54.56 84.83 0.06 Allowed 'General case' 0 N--CA 1.463 0.195 0 CA-C-N 116.113 -0.494 . . . . 0.0 111.828 179.557 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 187' ' ' LEU . . . . . 0.401 HD13 HD21 ' A' ' 180' ' ' LEU . 14.8 mt -92.1 -48.72 6.58 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-O 120.973 0.416 . . . . 0.0 110.906 179.509 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 188' ' ' LEU . . . . . . . . . . . . . 89.7 mt -96.82 -152.91 0.4 Allowed 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 115.883 -0.599 . . . . 0.0 111.014 -179.575 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 189' ' ' THR . . . . . . . . . . . . . 86.5 m -96.37 136.25 22.04 Favored Pre-proline 0 C--N 1.33 -0.261 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.712 -179.71 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 190' ' ' PRO . . . . . . . . . . . . . 88.7 Cg_exo -46.48 -43.07 22.75 Favored 'Trans proline' 0 C--N 1.349 0.585 0 C-N-CA 122.459 2.106 . . . . 0.0 112.855 -179.825 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 191' ' ' THR . . . . . . . . . . . . . 82.0 p -65.41 -38.64 90.57 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.376 -0.375 . . . . 0.0 111.731 -179.601 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 192' ' ' VAL . . . . . . . . . . . . . 58.1 t -71.78 -53.71 19.44 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.394 -0.366 . . . . 0.0 111.415 -179.628 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 193' ' ' ASP . . . . . . . . . . . . . 26.5 t70 -54.19 -47.97 71.48 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.244 -0.435 . . . . 0.0 111.049 -179.867 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 194' ' ' VAL . . . . . 0.431 ' O ' HG22 ' A' ' 198' ' ' VAL . 46.7 t -60.13 -40.18 82.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.281 -0.418 . . . . 0.0 110.674 179.769 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 195' ' ' ALA . . . . . . . . . . . . . . . -52.86 -44.64 66.97 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.928 179.756 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 196' ' ' LEU . . . . . . . . . . . . . 94.5 mt -68.42 -36.19 78.71 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.096 179.711 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 197' ' ' ILE . . . . . 0.516 HD11 ' HB ' ' A' ' 177' ' ' ILE . 12.4 mm -61.31 -59.83 3.66 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.203 179.911 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 198' ' ' VAL . . . . . 0.431 HG22 ' O ' ' A' ' 194' ' ' VAL . 2.8 m -54.08 -35.36 28.79 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.47 0 CA-C-O 121.669 0.747 . . . . 0.0 109.523 179.307 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 199' ' ' TYR . . . . . . . . . . . . . 74.9 t80 -64.59 -41.6 96.14 Favored 'General case' 0 C--N 1.321 -0.658 0 CA-C-N 114.454 -1.248 . . . . 0.0 110.482 179.577 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 200' ' ' LEU . . . . . 0.402 ' HB3' ' CZ ' ' A' ' 174' ' ' TYR . 23.2 mt -59.04 -46.55 87.94 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 115.747 -0.66 . . . . 0.0 111.08 -179.885 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 201' ' ' ASP . . . . . . . . . . . . . 8.6 m-20 -69.95 -33.52 72.22 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 121.089 0.471 . . . . 0.0 110.426 179.709 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 202' ' ' LEU . . . . . . . . . . . . . 1.2 tt -66.54 -33.53 75.88 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 115.604 -0.725 . . . . 0.0 110.738 -179.93 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 203' ' ' VAL . . . . . 0.45 ' O ' ' HA3' ' A' ' 207' ' ' GLY . 42.3 t -76.66 -36.94 28.2 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 115.88 -0.6 . . . . 0.0 111.552 -179.007 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 204' ' ' THR . . . . . . . . . . . . . 36.5 m -64.58 -56.12 16.01 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-O 120.894 0.378 . . . . 0.0 111.679 -179.869 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 205' ' ' LYS . . . . . 0.604 ' HE2' ' HB2' ' A' ' 47' ' ' ALA . 48.9 mttp -69.03 -58.62 3.85 Favored 'General case' 0 C--N 1.326 -0.421 0 N-CA-C 112.576 0.584 . . . . 0.0 112.576 -178.351 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 48.9 t -71.57 -38.12 66.32 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 N-CA-C 112.064 0.394 . . . . 0.0 112.064 -178.515 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 207' ' ' GLY . . . . . 0.489 ' O ' HG12 ' A' ' 211' ' ' ILE . . . -63.38 -59.62 8.63 Favored Glycine 0 N--CA 1.453 -0.23 0 C-N-CA 120.579 -0.819 . . . . 0.0 112.86 -179.319 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 208' ' ' PHE . . . . . 0.509 ' O ' ' N ' ' A' ' 212' ' ' ALA . 1.8 m-30 -54.88 -47.91 73.67 Favored 'General case' 0 C--O 1.221 -0.405 0 N-CA-C 110.18 -0.304 . . . . 0.0 110.18 -179.633 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 209' ' ' GLY . . . . . 0.407 ' O ' ' HB3' ' A' ' 212' ' ' ALA . . . -53.46 -32.36 45.27 Favored Glycine 0 N--CA 1.45 -0.432 0 CA-C-N 115.623 -0.717 . . . . 0.0 112.488 178.937 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 210' ' ' PHE . . . . . . . . . . . . . 3.0 m-85 -71.94 -45.96 59.24 Favored 'General case' 0 CA--C 1.516 -0.34 0 N-CA-C 108.694 -0.854 . . . . 0.0 108.694 178.769 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 211' ' ' ILE . . . . . 0.489 HG12 ' O ' ' A' ' 207' ' ' GLY . 2.4 mm -66.12 -27.5 41.0 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.51 0 N-CA-C 107.256 -1.387 . . . . 0.0 107.256 176.655 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 212' ' ' ALA . . . . . 0.509 ' N ' ' O ' ' A' ' 208' ' ' PHE . . . -68.67 -40.13 80.28 Favored 'General case' 0 N--CA 1.447 -0.582 0 CA-C-N 113.965 -1.471 . . . . 0.0 110.925 -179.34 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 213' ' ' LEU . . . . . . . . . . . . . 65.1 mt -70.26 -55.51 9.07 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 115.314 -0.857 . . . . 0.0 112.07 -179.164 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 214' ' ' ASP . . . . . . . . . . . . . 20.1 t70 -56.45 -50.56 71.33 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.859 0.361 . . . . 0.0 111.352 -179.429 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 215' ' ' ALA . . . . . . . . . . . . . . . -57.69 -55.39 35.49 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.467 -179.781 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 216' ' ' ALA . . . . . 0.471 ' HA ' HD13 ' A' ' 219' ' ' LEU . . . -60.59 -31.19 70.35 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.273 -0.421 . . . . 0.0 111.321 -179.697 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 217' ' ' ALA . . . . . . . . . . . . . . . -62.62 -35.82 80.82 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.342 -0.39 . . . . 0.0 110.264 179.609 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 218' ' ' THR . . . . . . . . . . . . . 86.7 m -75.68 -34.19 60.43 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 115.887 -0.597 . . . . 0.0 110.614 179.24 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 219' ' ' LEU . . . . . 0.471 HD13 ' HA ' ' A' ' 216' ' ' ALA . 81.9 mt -61.97 -38.18 87.58 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 116.051 -0.522 . . . . 0.0 110.686 179.672 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 220' ' ' ARG . . . . . . . . . . . . . 87.3 mtm180 -84.49 -26.81 27.89 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 115.938 -0.574 . . . . 0.0 111.021 179.773 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 221' ' ' ALA . . . . . . . . . . . . . . . -77.53 -19.8 55.19 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.121 -0.49 . . . . 0.0 112.091 -179.342 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 222' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -70.04 -12.56 61.7 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-O 120.862 0.363 . . . . 0.0 110.862 -179.339 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 223' ' ' HIS . . . . . . . . . . . . . 94.2 m-70 -75.79 -68.62 0.55 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.072 -0.513 . . . . 0.0 111.13 -179.984 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 224' ' ' GLY . . . . . . . . . . . . . . . 157.84 19.6 0.03 OUTLIER Glycine 0 C--N 1.331 0.271 0 C-N-CA 120.675 -0.774 . . . . 0.0 112.637 179.938 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 225' ' ' GLU . . . . . . . . . . . . . 29.9 mm-40 -68.12 116.72 9.06 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 120.837 0.351 . . . . 0.0 110.943 -179.966 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 226' ' ' SER . . . . . . . . . . . . . 70.1 m -115.56 143.33 45.49 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.904 179.993 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 227' ' ' LEU . . . . . . . . . . . . . 3.6 mm? -101.22 -15.61 17.27 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.801 179.974 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 228' ' ' ALA . . . . . . . . . . . . . . . 52.78 26.92 4.86 Favored 'General case' 0 C--N 1.332 -0.181 0 CA-C-N 116.1 -0.5 . . . . 0.0 111.467 -179.95 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 229' ' ' GLY . . . . . . . . . . . . . . . 176.4 160.1 23.09 Favored Glycine 0 N--CA 1.453 -0.224 0 C-N-CA 120.866 -0.683 . . . . 0.0 112.45 179.916 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 230' ' ' VAL . . . . . . . . . . . . . 27.7 m -128.41 147.09 32.97 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.239 0 CA-C-O 120.871 0.367 . . . . 0.0 111.387 -179.897 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 231' ' ' ASP . . . . . . . . . . . . . 4.8 m-20 -104.8 95.75 6.1 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.086 -0.506 . . . . 0.0 110.81 179.868 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 232' ' ' THR . . . . . . . . . . . . . 79.7 p -120.95 120.55 35.8 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.122 -0.49 . . . . 0.0 111.088 -179.858 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 233' ' ' ASP . . . . . . . . . . . . . 5.0 p-10 -106.59 -47.86 3.67 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.873 -179.996 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 234' ' ' THR . . . . . . . . . . . . . 80.5 p -129.28 151.24 77.47 Favored Pre-proline 0 C--N 1.329 -0.293 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.969 179.866 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 235' ' ' PRO . . . . . . . . . . . . . 46.9 Cg_exo -56.02 133.93 61.02 Favored 'Trans proline' 0 C--N 1.347 0.494 0 C-N-CA 122.496 2.131 . . . . 0.0 112.363 -179.885 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 236' ' ' ALA . . . . . . . . . . . . . . . -78.55 121.07 24.14 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.029 -0.532 . . . . 0.0 111.028 179.918 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 237' ' ' VAL . . . . . . . . . . . . . 13.0 p -82.95 149.86 4.46 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.988 -179.893 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 238' ' ' ALA . . . . . . . . . . . . . . . -117.16 -56.15 2.27 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.077 179.995 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 239' ' ' ASP . . . . . . . . . . . . . 4.0 p30 -109.24 129.94 55.5 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.953 -179.942 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 240' ' ' LEU . . . . . . . . . . . . . 1.1 tm? -86.83 115.98 24.61 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.522 -179.944 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 241' ' ' GLU . . . . . . . . . . . . . 15.5 mm-40 -118.36 150.7 39.07 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.134 -0.484 . . . . 0.0 110.877 179.917 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 242' ' ' HIS . . . . . . . . . . . . . 24.6 p-80 -85.88 173.04 10.27 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.887 -179.974 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 243' ' ' HIS . . . . . . . . . . . . . 29.0 t-80 -84.63 138.48 32.67 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.895 -179.855 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 244' ' ' HIS . . . . . . . . . . . . . 99.4 m-70 -100.72 165.99 11.1 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.198 -0.456 . . . . 0.0 111.076 -179.91 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 245' ' ' HIS . . . . . . . . . . . . . 58.4 m80 -77.23 106.4 8.94 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.894 179.849 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 246' ' ' HIS . . . . . . . . . . . . . 68.3 m80 -105.15 156.0 18.5 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.01 -0.541 . . . . 0.0 110.861 179.944 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 247' ' ' HIS . . . . . . . . . . . . . 50.9 t-80 . . . . . 0 C--O 1.249 1.05 0 CA-C-O 118.334 -0.841 . . . . 0.0 110.844 -179.952 . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 301' ' ' RET . . . . . 0.46 H201 ' HE1' ' A' ' 171' ' ' TRP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 1' ' ' MET . . . . . 0.494 ' HG2' ' H ' ' A' ' 2' ' ' VAL . 0.0 OUTLIER . . . . . 0 N--CA 1.486 1.348 0 CA-C-O 120.818 0.342 . . . . 0.0 111.213 . . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 2' ' ' VAL . . . . . 0.494 ' H ' ' HG2' ' A' ' 1' ' ' MET . 8.8 p -154.2 17.16 0.05 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-O 121.02 0.438 . . . . 0.0 110.871 -179.888 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -155.41 -53.8 0.01 OUTLIER Glycine 0 C--N 1.332 0.331 0 C-N-CA 120.705 -0.759 . . . . 0.0 112.605 -179.76 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 94.5 mt -56.72 -35.55 68.67 Favored 'General case' 0 N--CA 1.449 -0.514 0 CA-C-O 120.868 0.366 . . . . 0.0 111.242 -179.859 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 42.9 p -63.4 -39.01 93.34 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.08 -0.509 . . . . 0.0 111.774 -179.414 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 18.7 p -52.84 -35.33 57.22 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-N 116.484 -0.325 . . . . 0.0 111.538 -179.442 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 7' ' ' LEU . . . . . . . . . . . . . 3.8 mm? -60.62 -53.13 61.13 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.37 -0.377 . . . . 0.0 111.245 -179.755 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 8' ' ' PHE . . . . . 0.43 ' HB2' ' HB2' ' A' ' 55' ' ' ALA . 64.4 m-85 -61.67 -30.84 70.99 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.304 -0.407 . . . . 0.0 111.014 -179.726 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 9' ' ' TRP . . . . . 0.463 ' O ' HG12 ' A' ' 13' ' ' ILE . 34.9 m95 -66.79 -43.3 84.31 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 116.226 -0.443 . . . . 0.0 109.966 179.939 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 87.5 mt -65.51 -49.02 70.54 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 115.615 -0.721 . . . . 0.0 110.526 179.638 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -58.47 -32.22 68.19 Favored Glycine 0 N--CA 1.449 -0.475 0 C-N-CA 120.559 -0.829 . . . . 0.0 111.677 179.3 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -68.69 -35.43 77.18 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 120.842 0.353 . . . . 0.0 110.615 179.453 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 13' ' ' ILE . . . . . 0.463 HG12 ' O ' ' A' ' 9' ' ' TRP . 46.8 mm -64.73 -53.98 35.59 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.205 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.609 179.566 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -60.71 -32.83 80.2 Favored Glycine 0 N--CA 1.45 -0.432 0 C-N-CA 120.718 -0.753 . . . . 0.0 111.7 179.477 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 15' ' ' MET . . . . . 0.582 ' SD ' ' HA ' ' A' ' 44' ' ' SER . 54.0 tpp -64.33 -50.98 65.66 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.792 0.33 . . . . 0.0 110.619 179.896 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -52.77 -40.58 63.3 Favored 'General case' 0 C--N 1.332 -0.192 0 CA-C-N 116.021 -0.536 . . . . 0.0 110.355 179.538 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 97.6 t -59.94 -42.86 90.86 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.219 0 CA-C-N 116.034 -0.53 . . . . 0.0 110.541 179.534 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -66.12 -43.39 93.35 Favored Glycine 0 N--CA 1.452 -0.272 0 C-N-CA 120.771 -0.728 . . . . 0.0 111.74 179.067 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 17.8 m -50.28 -46.56 55.22 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 115.556 -0.322 . . . . 0.0 111.48 -179.762 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 86.0 mt -71.76 -39.85 69.71 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.316 -0.402 . . . . 0.0 111.772 -179.74 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -61.64 -31.52 71.63 Favored 'General case' 0 C--N 1.33 -0.272 0 N-CA-C 111.987 0.366 . . . . 0.0 111.987 -179.219 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 4.9 m-85 -90.75 -33.34 15.78 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-O 120.731 0.301 . . . . 0.0 111.421 -179.599 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -69.3 -50.0 50.71 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.973 0.416 . . . . 0.0 111.19 -179.824 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 24' ' ' TRP . . . . . . . . . . . . . 2.4 t-105 -61.57 -47.54 85.06 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 115.805 -0.634 . . . . 0.0 111.169 -179.842 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -75.12 -19.44 59.91 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-O 120.782 0.325 . . . . 0.0 110.692 179.715 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -73.44 -45.77 28.45 Favored Glycine 0 N--CA 1.453 -0.22 0 C-N-CA 120.932 -0.651 . . . . 0.0 112.497 179.806 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 99.4 mtt180 -59.96 -26.41 65.98 Favored 'General case' 0 C--N 1.33 -0.239 0 CA-C-O 120.843 0.354 . . . . 0.0 111.038 -179.91 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 17.8 t70 -106.81 99.28 8.86 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.775 179.873 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -163.36 -167.91 1.57 Allowed 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.043 -179.772 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -89.64 -133.54 5.07 Favored Glycine 0 N--CA 1.45 -0.415 0 C-N-CA 120.751 -0.738 . . . . 0.0 112.445 179.94 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 32.0 t -127.0 125.84 42.14 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.822 0.344 . . . . 0.0 110.982 -179.932 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 106.1 -24.83 25.45 Favored Glycine 0 C--N 1.331 0.255 0 C-N-CA 120.78 -0.724 . . . . 0.0 112.781 179.553 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 33.3 mm-40 -87.28 -20.93 26.13 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.811 0.339 . . . . 0.0 111.015 -179.85 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 34' ' ' ARG . . . . . . . . . . . . . 42.3 ttm180 -53.12 -31.96 44.94 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.596 -179.546 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 15.3 tpp180 -61.64 -44.47 96.92 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 120.836 0.351 . . . . 0.0 110.874 -179.908 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 54.9 m-85 -68.69 -31.04 69.86 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.91 179.978 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 37' ' ' TYR . . . . . . . . . . . . . 44.2 m-85 -70.43 -53.6 15.81 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.219 -179.897 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 71.2 t -56.8 -36.4 49.38 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.194 0 CA-C-O 121.008 0.432 . . . . 0.0 110.265 179.615 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 24.0 m -63.89 -47.92 78.71 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 115.673 -0.694 . . . . 0.0 110.296 179.213 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 40' ' ' LEU . . . . . 0.552 HD13 HD13 ' A' ' 43' ' ' ILE . 45.5 tp -58.46 -47.79 82.88 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 115.678 -0.692 . . . . 0.0 110.153 179.493 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 57.6 t -60.33 -34.57 58.06 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.365 0 CA-C-N 115.645 -0.707 . . . . 0.0 109.804 178.906 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -59.97 -37.09 92.14 Favored Glycine 0 N--CA 1.448 -0.559 0 C-N-CA 120.784 -0.722 . . . . 0.0 111.591 179.479 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 43' ' ' ILE . . . . . 0.552 HD13 HD13 ' A' ' 40' ' ' LEU . 1.3 mt -65.26 -57.98 8.84 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.195 0 CA-C-O 120.833 0.349 . . . . 0.0 110.468 179.391 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 44' ' ' SER . . . . . 0.582 ' HA ' ' SD ' ' A' ' 15' ' ' MET . 64.7 m -57.51 -23.01 47.76 Favored 'General case' 0 C--N 1.332 -0.173 0 CA-C-N 116.037 -0.529 . . . . 0.0 111.71 -179.67 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -76.64 -59.17 3.32 Favored Glycine 0 CA--C 1.52 0.353 0 C-N-CA 120.638 -0.792 . . . . 0.0 112.912 -179.614 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 21.6 pt -58.42 -35.89 56.27 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.239 0 CA-C-O 120.91 0.386 . . . . 0.0 111.263 -179.796 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 47' ' ' ALA . . . . . 0.611 ' HB3' ' HE2' ' A' ' 205' ' ' LYS . . . -67.42 -45.77 75.13 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.309 179.626 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -54.42 -44.77 72.7 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.878 -179.183 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 27.0 m -73.29 -34.2 43.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 N-CA-C 111.845 0.313 . . . . 0.0 111.845 -179.363 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -65.92 -33.95 77.01 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.869 0.366 . . . . 0.0 111.266 -179.785 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 51' ' ' TYR . . . . . 0.532 ' HH ' ' HB2' ' A' ' 201' ' ' ASP . 5.3 m-85 -72.99 -47.03 48.78 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 115.987 -0.551 . . . . 0.0 110.611 -179.943 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -58.81 -44.34 90.8 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 115.652 -0.703 . . . . 0.0 111.812 -179.562 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 53' ' ' VAL . . . . . 0.466 HG22 ' N ' ' A' ' 54' ' ' MET . 34.7 m -69.96 -51.72 37.43 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.183 0 CA-C-N 116.64 -0.254 . . . . 0.0 111.429 -179.549 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 54' ' ' MET . . . . . 0.466 ' N ' HG22 ' A' ' 53' ' ' VAL . 8.3 ttp -59.14 -29.28 67.3 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 121.064 0.459 . . . . 0.0 110.287 -179.964 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 55' ' ' ALA . . . . . 0.43 ' HB2' ' HB2' ' A' ' 8' ' ' PHE . . . -67.74 -32.2 72.65 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 115.703 -0.68 . . . . 0.0 111.329 179.698 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 96.6 mt -79.93 16.66 1.12 Allowed 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.282 -0.417 . . . . 0.0 111.102 -179.875 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 81.15 -4.93 68.82 Favored Glycine 0 N--CA 1.451 -0.365 0 C-N-CA 120.501 -0.857 . . . . 0.0 112.087 -179.656 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 58' ' ' VAL . . . . . 0.418 ' HB ' ' O ' ' A' ' 53' ' ' VAL . 77.0 t -66.25 142.34 16.89 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-O 120.799 0.333 . . . . 0.0 110.779 179.698 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 87.31 -22.28 16.66 Favored Glycine 0 N--CA 1.448 -0.558 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.529 -179.703 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 60' ' ' TRP . . . . . . . . . . . . . 13.5 m0 -60.21 99.22 0.07 Allowed 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 120.745 0.307 . . . . 0.0 110.327 179.823 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 61' ' ' VAL . . . . . 0.404 ' HA ' ' HD3' ' A' ' 62' ' ' PRO . 7.7 p -98.27 129.82 29.77 Favored Pre-proline 0 C--N 1.328 -0.328 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.412 -179.593 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 62' ' ' PRO . . . . . 0.404 ' HD3' ' HA ' ' A' ' 61' ' ' VAL . 12.1 Cg_exo -71.96 136.36 27.24 Favored 'Trans proline' 0 C--N 1.349 0.588 0 C-N-CA 122.628 2.219 . . . . 0.0 112.042 179.824 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 64.6 t -132.13 89.78 1.14 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.396 0 CA-C-N 116.054 -0.521 . . . . 0.0 110.876 -179.94 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . 58.54 -84.54 0.02 OUTLIER 'General case' 0 C--N 1.333 -0.138 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.26 -179.739 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 11.3 pt-20 -124.57 -19.9 5.26 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-O 121.104 0.478 . . . . 0.0 110.351 179.724 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 66' ' ' ARG . . . . . . . . . . . . . 59.3 mtp180 -95.39 166.03 12.08 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 115.576 -0.738 . . . . 0.0 110.676 179.814 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 54.1 m -129.2 122.32 29.5 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.996 179.862 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 15.1 t -111.17 146.27 16.4 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.368 0 CA-C-N 116.082 -0.508 . . . . 0.0 110.929 -179.972 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 69' ' ' PHE . . . . . . . . . . . . . 12.0 m-85 -101.9 112.76 25.49 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.134 -0.484 . . . . 0.0 110.177 -179.803 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 70' ' ' VAL . . . . . 0.584 HG12 ' HD3' ' A' ' 71' ' ' PRO . 0.6 OUTLIER -69.31 -33.35 3.88 Favored Pre-proline 0 CA--C 1.543 0.697 0 N-CA-C 113.089 0.774 . . . . 0.0 113.089 -179.302 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 71' ' ' PRO . . . . . 0.584 ' HD3' HG12 ' A' ' 70' ' ' VAL . 11.3 Cg_exo -69.57 -22.26 33.19 Favored 'Trans proline' 0 C--N 1.357 0.985 0 C-N-CA 121.952 1.768 . . . . 0.0 112.993 -179.073 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 72' ' ' ARG . . . . . 0.451 ' HD2' HG23 ' A' ' 197' ' ' ILE . 50.5 ttp180 -68.6 -55.04 12.88 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.902 0.382 . . . . 0.0 111.663 -179.124 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 73' ' ' TYR . . . . . . . . . . . . . 61.4 m-85 -72.14 -35.06 68.98 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.417 -0.356 . . . . 0.0 110.875 -179.483 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 74' ' ' ILE . . . . . 0.485 ' HA ' HD12 ' A' ' 77' ' ' ILE . 0.3 OUTLIER -65.87 -38.45 82.2 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.189 0 N-CA-C 109.476 -0.564 . . . . 0.0 109.476 179.01 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 17.8 t70 -60.21 -37.64 80.9 Favored 'General case' 0 N--CA 1.453 -0.278 0 N-CA-C 109.147 -0.686 . . . . 0.0 109.147 178.692 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 76' ' ' TRP . . . . . . . . . . . . . 52.1 m0 -65.7 -34.99 79.47 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 115.681 -0.69 . . . . 0.0 110.345 179.06 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 77' ' ' ILE . . . . . 0.485 HD12 ' HA ' ' A' ' 74' ' ' ILE . 77.4 mt -66.26 -31.84 55.44 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.299 -0.409 . . . . 0.0 110.5 179.504 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 22.3 mt -91.6 -21.47 20.81 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.052 -0.522 . . . . 0.0 112.097 -179.725 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 81.5 p -102.86 -53.25 2.89 Favored 'General case' 0 N--CA 1.463 0.215 0 N-CA-C 113.536 0.939 . . . . 0.0 113.536 -177.924 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 80' ' ' THR . . . . . 0.565 ' HB ' ' HD3' ' A' ' 81' ' ' PRO . 4.9 m -48.57 -53.32 36.85 Favored Pre-proline 0 CA--C 1.53 0.21 0 N-CA-C 112.32 0.489 . . . . 0.0 112.32 -178.223 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 81' ' ' PRO . . . . . 0.565 ' HD3' ' HB ' ' A' ' 80' ' ' THR . 31.6 Cg_exo -61.29 -21.41 71.67 Favored 'Trans proline' 0 C--N 1.351 0.71 0 C-N-CA 121.722 1.615 . . . . 0.0 111.857 179.631 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 82' ' ' LEU . . . . . . . . . . . . . 17.3 tp -76.64 -36.56 57.31 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-N 116.076 -0.511 . . . . 0.0 110.677 -179.983 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 1.9 mp -68.39 -51.92 42.39 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.174 0 CA-C-O 120.803 0.335 . . . . 0.0 110.157 179.094 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 26.6 m -60.18 -31.92 49.29 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.225 0 N-CA-C 109.582 -0.525 . . . . 0.0 109.582 179.026 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 85' ' ' TYR . . . . . . . . . . . . . 74.9 t80 -66.66 -31.27 71.84 Favored 'General case' 0 N--CA 1.452 -0.33 0 CA-C-N 115.698 -0.683 . . . . 0.0 109.372 178.542 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 86' ' ' PHE . . . . . . . . . . . . . 2.0 t80 -62.65 -51.81 65.79 Favored 'General case' 0 C--O 1.231 0.103 0 CA-C-N 115.743 -0.662 . . . . 0.0 109.829 179.061 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 8.0 mp -63.67 -29.2 70.47 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 115.658 -0.701 . . . . 0.0 110.467 179.556 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -70.53 -28.49 71.0 Favored Glycine 0 N--CA 1.449 -0.465 0 C-N-CA 120.843 -0.694 . . . . 0.0 112.007 179.559 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 79.8 mt -75.32 -42.38 54.64 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-O 120.929 0.395 . . . . 0.0 110.605 179.474 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 72.4 mt -57.71 -32.65 67.6 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 115.887 -0.597 . . . . 0.0 110.766 179.744 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . 0.46 ' HB3' ' HB3' ' A' ' 148' ' ' SER . . . -88.9 -34.02 17.1 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.104 -0.498 . . . . 0.0 111.208 179.891 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 84.28 53.77 3.19 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.853 -0.689 . . . . 0.0 112.401 179.926 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 93' ' ' LEU . . . . . 0.497 HD13 ' HE3' ' A' ' 145' ' ' MET . 55.0 mt -59.39 162.96 4.31 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 120.897 0.38 . . . . 0.0 111.109 -179.907 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 94' ' ' ASP . . . . . . . . . . . . . 18.4 m-20 -77.17 -178.37 5.02 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.069 -0.514 . . . . 0.0 110.923 179.878 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 50.8 m -63.64 -50.98 67.19 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.083 -0.508 . . . . 0.0 111.197 -179.881 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 14.2 ptm180 -73.65 -35.63 65.29 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.308 -0.405 . . . . 0.0 111.293 -179.596 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 19.9 mm-40 -54.96 -45.68 74.97 Favored 'General case' 0 C--N 1.331 -0.197 0 CA-C-N 116.56 -0.291 . . . . 0.0 110.771 -179.977 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 98' ' ' PHE . . . . . 0.469 ' O ' HG12 ' A' ' 102' ' ' ILE . 10.6 m-85 -60.86 -36.06 78.2 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-O 120.92 0.39 . . . . 0.0 110.272 179.422 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -67.19 -27.53 73.5 Favored Glycine 0 N--CA 1.449 -0.5 0 C-N-CA 120.589 -0.815 . . . . 0.0 112.225 179.511 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 97.0 mt -73.83 -44.88 51.12 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.198 0 N-CA-C 111.855 0.317 . . . . 0.0 111.855 -179.783 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 35.3 m -69.35 -40.78 80.5 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 N-CA-C 112.256 0.465 . . . . 0.0 112.256 -178.806 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 102' ' ' ILE . . . . . 0.469 HG12 ' O ' ' A' ' 98' ' ' PHE . 46.1 mm -68.53 -48.49 71.97 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.697 -0.229 . . . . 0.0 111.456 -179.501 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 14.2 t -60.42 -33.77 72.99 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-O 120.983 0.42 . . . . 0.0 110.645 179.875 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 104' ' ' LEU . . . . . 0.428 HD23 ' HE2' ' A' ' 140' ' ' TYR . 48.4 tp -60.44 -53.56 56.08 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 115.954 -0.567 . . . . 0.0 110.428 179.578 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 105' ' ' ASN . . . . . 0.609 ' N ' HD21 ' A' ' 105' ' ' ASN . 0.8 OUTLIER -61.22 -25.19 66.88 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 115.892 -0.594 . . . . 0.0 110.835 179.845 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 28.6 m -64.31 -54.13 38.02 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.258 179.961 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 12.5 p -64.85 -36.11 76.84 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.245 0 CA-C-N 116.504 -0.316 . . . . 0.0 111.194 -179.962 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 92.6 t -64.78 -52.76 50.26 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.246 0 CA-C-O 120.84 0.352 . . . . 0.0 110.89 179.743 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 109' ' ' MET . . . . . . . . . . . . . 1.9 tpp -60.06 -32.13 70.65 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.06 -0.518 . . . . 0.0 110.758 179.774 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 36.4 tp -75.21 -30.17 60.52 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 115.974 -0.557 . . . . 0.0 110.261 179.46 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -60.94 -52.4 65.18 Favored 'General case' 0 C--N 1.331 -0.199 0 CA-C-N 116.081 -0.508 . . . . 0.0 110.308 179.337 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 112' ' ' GLY . . . . . 0.577 ' HA3' ' H22' ' A' ' 301' ' ' RET . . . -70.58 -38.43 68.35 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.636 -0.792 . . . . 0.0 111.851 179.268 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 113' ' ' PHE . . . . . . . . . . . . . 1.9 t80 -53.87 -63.21 1.22 Allowed 'General case' 0 C--N 1.332 -0.194 0 CA-C-O 120.849 0.356 . . . . 0.0 110.063 179.349 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -69.62 -17.43 63.52 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.135 178.949 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -55.48 -52.62 46.69 Favored Glycine 0 C--N 1.333 0.389 0 CA-C-N 115.871 -0.604 . . . . 0.0 112.042 179.545 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 116' ' ' ALA . . . . . 0.576 ' HB3' ' HB3' ' A' ' 183' ' ' PRO . . . -77.41 -14.69 59.65 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-O 120.763 0.316 . . . . 0.0 111.192 -179.962 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 117' ' ' MET . . . . . . . . . . . . . 23.2 mmt -87.24 6.88 30.98 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.284 -0.417 . . . . 0.0 111.947 -179.413 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 118' ' ' VAL . . . . . 0.428 HG22 ' HB3' ' A' ' 123' ' ' ARG . 16.5 m -80.43 145.52 59.57 Favored Pre-proline 0 C--N 1.331 -0.206 0 CA-C-O 120.498 0.19 . . . . 0.0 111.322 -179.9 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 119' ' ' PRO . . . . . . . . . . . . . 85.9 Cg_endo -85.14 -6.59 9.33 Favored 'Trans proline' 0 C--N 1.348 0.509 0 C-N-CA 122.689 2.26 . . . . 0.0 112.099 179.51 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -133.17 -143.2 4.96 Favored Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.871 -0.68 . . . . 0.0 112.615 -179.894 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 121' ' ' ILE . . . . . 0.421 ' H ' HG13 ' A' ' 121' ' ' ILE . 2.7 pp -101.31 11.46 7.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-O 120.782 0.325 . . . . 0.0 111.308 -179.908 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 9.9 mm-40 -59.47 -19.08 45.09 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.047 179.975 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 123' ' ' ARG . . . . . 0.453 ' HB2' ' HH2' ' A' ' 178' ' ' TRP . 16.4 ptt180 -52.04 -34.55 43.74 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.037 -0.529 . . . . 0.0 111.538 -179.786 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 124' ' ' TYR . . . . . . . . . . . . . 49.6 m-85 -61.18 -33.13 72.96 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-O 120.748 0.308 . . . . 0.0 110.884 -179.956 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 125' ' ' ALA . . . . . . . . . . . . . . . -72.4 -50.58 25.47 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.278 -0.419 . . . . 0.0 110.666 179.55 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 7.3 mp -54.53 -54.22 44.11 Favored 'General case' 0 C--N 1.332 -0.18 0 CA-C-N 116.018 -0.537 . . . . 0.0 110.182 179.726 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 127' ' ' PHE . . . . . . . . . . . . . 8.9 t80 -63.15 -37.08 85.79 Favored 'General case' 0 N--CA 1.451 -0.409 0 CA-C-N 115.973 -0.558 . . . . 0.0 110.784 179.724 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 128' ' ' GLY . . . . . . . . . . . . . . . -46.22 -45.0 15.48 Favored Glycine 0 C--N 1.332 0.306 0 C-N-CA 120.19 -1.005 . . . . 0.0 110.918 179.109 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 129' ' ' MET . . . . . . . . . . . . . 0.4 OUTLIER -69.82 -37.74 76.34 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 115.311 -0.444 . . . . 0.0 109.85 178.646 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -61.99 -34.25 88.29 Favored Glycine 0 C--N 1.332 0.335 0 CA-C-N 115.677 -0.692 . . . . 0.0 112.942 -179.872 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -71.41 -53.77 12.95 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.697 0.284 . . . . 0.0 110.52 179.908 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 38.4 t -56.85 -39.95 68.16 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-O 121.439 0.638 . . . . 0.0 109.38 178.899 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -66.9 -35.37 79.85 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 115.151 -0.931 . . . . 0.0 110.532 179.357 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 134' ' ' PHE . . . . . 0.445 ' HB2' H181 ' A' ' 301' ' ' RET . 86.4 t80 -55.37 -55.27 33.53 Favored 'General case' 0 N--CA 1.452 -0.337 0 CA-C-O 121.012 0.434 . . . . 0.0 110.019 179.428 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 135' ' ' ILE . . . . . 0.436 ' HA ' HG23 ' A' ' 138' ' ' VAL . 29.6 mt -56.28 -33.95 38.84 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.295 0 CA-C-N 115.761 -0.654 . . . . 0.0 109.913 179.136 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . -61.99 -40.66 99.19 Favored Glycine 0 N--CA 1.448 -0.547 0 C-N-CA 120.299 -0.953 . . . . 0.0 111.321 178.812 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 137' ' ' LEU . . . . . 0.449 HD12 HD22 ' A' ' 105' ' ' ASN . 64.8 tp -69.33 -53.1 21.3 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-O 120.532 0.205 . . . . 0.0 111.04 179.97 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 138' ' ' VAL . . . . . 0.436 HG23 ' HA ' ' A' ' 135' ' ' ILE . 4.9 m -55.43 -34.62 34.87 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.167 0 N-CA-C 109.521 -0.548 . . . . 0.0 109.521 179.775 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 139' ' ' TYR . . . . . . . . . . . . . 21.4 t80 -61.58 -40.9 96.4 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 115.454 -0.794 . . . . 0.0 110.403 178.548 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 140' ' ' TYR . . . . . 0.428 ' HE2' HD23 ' A' ' 104' ' ' LEU . 20.9 m-85 -64.89 -52.17 57.97 Favored 'General case' 0 C--N 1.332 -0.189 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.673 -179.848 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 141' ' ' LEU . . . . . 0.495 HD12 ' N ' ' A' ' 142' ' ' VAL . 3.6 pp -64.27 -18.23 64.37 Favored 'General case' 0 N--CA 1.463 0.176 0 N-CA-C 111.74 0.274 . . . . 0.0 111.74 -179.271 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 142' ' ' VAL . . . . . 0.495 ' N ' HD12 ' A' ' 141' ' ' LEU . 5.2 p -109.36 -2.77 10.23 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-O 120.898 0.38 . . . . 0.0 110.924 179.866 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . -99.81 -102.51 2.44 Favored Glycine 0 CA--C 1.522 0.503 0 C-N-CA 120.767 -0.73 . . . . 0.0 113.104 -179.849 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 144' ' ' PRO . . . . . . . . . . . . . 58.2 Cg_endo -70.15 -27.87 24.07 Favored 'Trans proline' 0 C--N 1.348 0.503 0 C-N-CA 122.628 2.219 . . . . 0.0 113.285 -179.313 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 145' ' ' MET . . . . . 0.497 ' HE3' HD13 ' A' ' 93' ' ' LEU . 50.7 mtt -62.68 -39.07 92.78 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.669 0.271 . . . . 0.0 111.461 -179.583 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 146' ' ' THR . . . . . . . . . . . . . 67.2 p -66.21 -43.6 86.28 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.456 -0.338 . . . . 0.0 111.448 -179.524 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 39.7 mt-10 -70.45 -33.69 71.58 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.344 -0.389 . . . . 0.0 111.268 -179.651 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 148' ' ' SER . . . . . 0.46 ' HB3' ' HB3' ' A' ' 91' ' ' ALA . 48.0 t -70.34 -44.55 67.94 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.357 -0.383 . . . . 0.0 111.464 -179.485 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 149' ' ' ALA . . . . . . . . . . . . . . . -73.74 -33.94 64.54 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.339 -0.391 . . . . 0.0 111.399 -179.699 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 150' ' ' SER . . . . . 0.421 ' HB2' ' NZ ' ' A' ' 157' ' ' LYS . 81.0 p -67.33 -5.76 15.74 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 121.007 0.432 . . . . 0.0 110.657 179.783 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 151' ' ' GLN . . . . . . . . . . . . . 74.0 mt-30 -110.3 5.28 21.55 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 115.899 -0.591 . . . . 0.0 111.336 -179.812 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 31.2 ttt180 -91.8 -52.64 4.64 Favored 'General case' 0 C--N 1.331 -0.23 0 C-N-CA 120.902 -0.319 . . . . 0.0 111.213 -179.895 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 153' ' ' SER . . . . . 0.626 ' HB3' HG12 ' A' ' 156' ' ' ILE . 20.5 t -157.67 172.44 18.52 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.444 -0.344 . . . . 0.0 111.002 179.327 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 154' ' ' SER . . . . . 0.53 ' H ' ' HG ' ' A' ' 153' ' ' SER . 72.6 p -73.41 -41.7 62.98 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.705 179.576 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -72.64 -29.59 65.37 Favored Glycine 0 N--CA 1.452 -0.288 0 C-N-CA 120.804 -0.712 . . . . 0.0 112.334 179.88 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 156' ' ' ILE . . . . . 0.626 HG12 ' HB3' ' A' ' 153' ' ' SER . 34.6 mm -58.99 -38.45 73.86 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-O 120.84 0.352 . . . . 0.0 111.066 179.862 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 157' ' ' LYS . . . . . 0.421 ' NZ ' ' HB2' ' A' ' 150' ' ' SER . 21.3 ttmm -65.06 -47.86 75.82 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.129 -0.487 . . . . 0.0 111.085 179.811 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 69.1 m -60.65 -43.3 97.74 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 115.981 -0.554 . . . . 0.0 111.69 -179.042 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 159' ' ' LEU . . . . . 0.561 ' O ' ' HG ' ' A' ' 163' ' ' LEU . 3.7 tp -66.5 -58.59 4.9 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-O 120.943 0.401 . . . . 0.0 110.66 -179.861 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 160' ' ' TYR . . . . . . . . . . . . . 30.1 t80 -51.14 -36.23 39.68 Favored 'General case' 0 C--N 1.326 -0.416 0 N-CA-C 113.302 0.853 . . . . 0.0 113.302 -178.13 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 30.7 m -73.27 -47.04 48.25 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.373 0 N-CA-C 112.159 0.429 . . . . 0.0 112.159 -177.791 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 162' ' ' ARG . . . . . . . . . . . . . 24.2 ttm180 -63.68 -41.23 98.18 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-O 120.953 0.406 . . . . 0.0 111.014 -179.701 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 163' ' ' LEU . . . . . 0.561 ' HG ' ' O ' ' A' ' 159' ' ' LEU . 6.6 mt -70.38 -50.34 39.76 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 115.89 -0.595 . . . . 0.0 111.712 -179.197 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 164' ' ' ARG . . . . . 0.556 ' HG3' HD21 ' A' ' 165' ' ' ASN . 0.4 OUTLIER -58.14 -40.96 82.69 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.517 -0.31 . . . . 0.0 110.917 -178.986 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 165' ' ' ASN . . . . . 0.556 HD21 ' HG3' ' A' ' 164' ' ' ARG . 0.9 OUTLIER -58.46 -51.34 70.28 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-O 120.832 0.349 . . . . 0.0 110.295 179.545 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 166' ' ' LEU . . . . . 0.508 ' O ' ' HG ' ' A' ' 170' ' ' LEU . 2.3 tt -59.39 -54.74 43.25 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 115.93 -0.577 . . . . 0.0 111.712 -179.931 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 167' ' ' THR . . . . . 0.46 ' N ' HD23 ' A' ' 166' ' ' LEU . 52.6 m -55.08 -53.03 61.12 Favored 'General case' 0 C--N 1.33 -0.245 0 N-CA-C 112.773 0.657 . . . . 0.0 112.773 -178.398 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 168' ' ' VAL . . . . . . . . . . . . . 75.4 t -53.96 -42.23 53.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 N-CA-C 112.329 0.492 . . . . 0.0 112.329 -179.004 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 169' ' ' VAL . . . . . . . . . . . . . 72.7 t -60.93 -64.74 0.57 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 N-CA-C 112.124 0.416 . . . . 0.0 112.124 -179.225 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 170' ' ' LEU . . . . . 0.508 ' HG ' ' O ' ' A' ' 166' ' ' LEU . 0.4 OUTLIER -61.92 -34.12 75.49 Favored 'General case' 0 N--CA 1.465 0.276 0 N-CA-C 112.354 0.502 . . . . 0.0 112.354 -178.815 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 171' ' ' TRP . . . . . 0.611 ' HE1' H203 ' A' ' 301' ' ' RET . 6.1 m0 -68.06 -29.56 68.56 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-O 120.792 0.33 . . . . 0.0 110.634 179.629 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 172' ' ' ALA . . . . . . . . . . . . . . . -73.92 -7.12 51.14 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.759 179.781 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 173' ' ' ILE . . . . . 0.485 ' O ' HG12 ' A' ' 177' ' ' ILE . 28.8 mm -87.68 -21.46 7.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 115.839 -0.619 . . . . 0.0 110.526 179.476 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 174' ' ' TYR . . . . . 0.41 ' HD2' ' HA ' ' A' ' 171' ' ' TRP . 8.2 m-85 -53.84 -48.38 93.81 Favored Pre-proline 0 CA--C 1.528 0.105 0 CA-C-N 116.055 -0.52 . . . . 0.0 111.681 -179.567 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 175' ' ' PRO . . . . . 0.403 ' CD ' ' N ' ' A' ' 174' ' ' TYR . 83.2 Cg_exo -46.65 -32.15 11.38 Favored 'Trans proline' 0 C--N 1.351 0.667 0 C-N-CA 121.831 1.687 . . . . 0.0 111.95 179.358 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 176' ' ' PHE . . . . . 0.42 ' HD2' ' HA ' ' A' ' 173' ' ' ILE . 84.3 m-85 -81.1 -49.79 10.43 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 115.697 -0.683 . . . . 0.0 111.799 179.867 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 177' ' ' ILE . . . . . 0.485 HG12 ' O ' ' A' ' 173' ' ' ILE . 8.5 mm -61.01 -38.83 80.36 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.498 0 N-CA-C 112.708 0.633 . . . . 0.0 112.708 -177.896 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 178' ' ' TRP . . . . . 0.453 ' HH2' ' HB2' ' A' ' 123' ' ' ARG . 78.5 t90 -71.58 -51.88 21.05 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.79 0.328 . . . . 0.0 111.213 -179.735 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 179' ' ' LEU . . . . . 0.477 HD23 HD23 ' A' ' 180' ' ' LEU . 0.6 OUTLIER -64.55 -55.08 22.82 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.323 -0.399 . . . . 0.0 111.601 -178.997 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 180' ' ' LEU . . . . . 0.477 HD23 HD23 ' A' ' 179' ' ' LEU . 32.4 mt -65.96 -37.64 86.52 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 116.341 -0.39 . . . . 0.0 111.345 -179.332 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . -60.53 176.15 4.25 Favored Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 119.988 -1.101 . . . . 0.0 112.33 179.589 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 182' ' ' PRO . . . . . 0.443 ' HB2' ' HD3' ' A' ' 183' ' ' PRO . 88.3 Cg_exo -46.63 -44.97 20.69 Favored 'Trans proline' 0 CA--C 1.536 0.607 0 C-N-CA 122.681 2.254 . . . . 0.0 113.402 179.912 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 183' ' ' PRO . . . . . 0.576 ' HB3' ' HB3' ' A' ' 116' ' ' ALA . 97.3 Cg_exo -45.31 -35.25 11.23 Favored 'Trans proline' 0 C--N 1.356 0.926 0 C-N-CA 122.328 2.019 . . . . 0.0 113.439 179.89 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 184' ' ' GLY . . . . . . . . . . . . . . . -110.29 -123.23 4.52 Favored Glycine 0 C--N 1.332 0.344 0 C-N-CA 120.299 -0.953 . . . . 0.0 113.204 -179.453 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 185' ' ' VAL . . . . . . . . . . . . . 8.1 m -63.04 -26.93 42.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 N-CA-C 112.16 0.43 . . . . 0.0 112.16 -179.225 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 186' ' ' ALA . . . . . 0.443 ' HB3' ' HA ' ' A' ' 182' ' ' PRO . . . 60.25 81.05 0.19 Allowed 'General case' 0 C--N 1.331 -0.207 0 N-CA-C 111.858 0.318 . . . . 0.0 111.858 179.48 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 187' ' ' LEU . . . . . . . . . . . . . 6.9 mt -92.8 -49.78 5.9 Favored 'General case' 0 C--N 1.332 -0.156 0 CA-C-O 120.995 0.426 . . . . 0.0 111.012 179.587 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 188' ' ' LEU . . . . . . . . . . . . . 95.2 mt -89.32 -166.7 1.66 Allowed 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 115.795 -0.639 . . . . 0.0 111.247 -179.48 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 189' ' ' THR . . . . . . . . . . . . . 74.9 m -94.08 136.13 23.95 Favored Pre-proline 0 C--N 1.328 -0.357 0 CA-C-N 115.781 -0.645 . . . . 0.0 110.626 -179.811 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 190' ' ' PRO . . . . . . . . . . . . . 2.4 Cg_endo -44.99 -38.58 13.66 Favored 'Trans proline' 0 C--N 1.35 0.61 0 C-N-CA 122.854 2.369 . . . . 0.0 112.649 -179.983 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 191' ' ' THR . . . . . . . . . . . . . 71.2 p -61.98 -42.95 99.7 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-O 120.965 0.412 . . . . 0.0 110.911 179.711 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 192' ' ' VAL . . . . . . . . . . . . . 88.8 t -71.29 -53.54 20.7 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 115.92 -0.582 . . . . 0.0 111.434 -179.816 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 193' ' ' ASP . . . . . . . . . . . . . 29.3 t70 -54.49 -52.01 63.28 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.242 -0.436 . . . . 0.0 111.442 -179.396 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 194' ' ' VAL . . . . . 0.438 ' O ' HG23 ' A' ' 198' ' ' VAL . 71.1 t -59.23 -38.22 73.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.371 -0.377 . . . . 0.0 110.614 -179.874 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 195' ' ' ALA . . . . . . . . . . . . . . . -55.22 -44.86 75.8 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.754 179.605 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 196' ' ' LEU . . . . . . . . . . . . . 95.6 mt -68.36 -35.86 78.35 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.934 179.461 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 197' ' ' ILE . . . . . 0.451 HG23 ' HD2' ' A' ' 72' ' ' ARG . 11.0 mm -59.49 -61.09 1.61 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.06 -0.518 . . . . 0.0 110.874 179.96 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 198' ' ' VAL . . . . . 0.438 HG23 ' O ' ' A' ' 194' ' ' VAL . 1.4 m -55.74 -35.0 37.83 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.462 0 CA-C-O 121.626 0.727 . . . . 0.0 109.191 178.772 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 199' ' ' TYR . . . . . . . . . . . . . 86.7 t80 -64.04 -32.5 74.07 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-N 114.56 -1.2 . . . . 0.0 110.415 179.336 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 200' ' ' LEU . . . . . . . . . . . . . 38.1 mt -71.11 -37.78 72.36 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 115.99 -0.55 . . . . 0.0 110.648 179.591 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 201' ' ' ASP . . . . . 0.532 ' HB2' ' HH ' ' A' ' 51' ' ' TYR . 7.9 m-20 -74.58 -32.98 62.55 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 115.953 -0.567 . . . . 0.0 110.161 179.63 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 202' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -72.52 -28.45 62.87 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 115.29 -0.868 . . . . 0.0 111.623 -179.527 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 203' ' ' VAL . . . . . . . . . . . . . 9.6 p -82.17 -37.78 14.99 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.18 0 N-CA-C 111.946 0.35 . . . . 0.0 111.946 -178.805 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 204' ' ' THR . . . . . 0.53 ' HG1' ' HE1' ' A' ' 171' ' ' TRP . 86.5 m -69.6 -41.87 75.16 Favored 'General case' 0 C--N 1.328 -0.337 0 C-N-CA 120.821 -0.352 . . . . 0.0 111.569 179.93 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 205' ' ' LYS . . . . . 0.611 ' HE2' ' HB3' ' A' ' 47' ' ' ALA . 59.7 mttp -76.52 -57.93 3.58 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.398 -0.365 . . . . 0.0 111.557 -178.872 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 60.4 t -69.47 -36.83 73.34 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.372 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.471 -179.503 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 207' ' ' GLY . . . . . . . . . . . . . . . -66.44 -52.76 32.87 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.615 -0.802 . . . . 0.0 112.43 -179.326 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 208' ' ' PHE . . . . . 0.426 ' O ' ' N ' ' A' ' 212' ' ' ALA . 11.3 t80 -55.21 -49.86 70.87 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-O 120.748 0.309 . . . . 0.0 110.941 179.771 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 209' ' ' GLY . . . . . 0.438 ' O ' ' HB3' ' A' ' 212' ' ' ALA . . . -63.64 -37.46 94.77 Favored Glycine 0 N--CA 1.451 -0.339 0 CA-C-N 115.632 -0.713 . . . . 0.0 113.985 -179.184 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 210' ' ' PHE . . . . . . . . . . . . . 0.6 OUTLIER -68.65 -46.66 68.57 Favored 'General case' 0 CA--C 1.512 -0.484 0 N-CA-C 108.217 -1.031 . . . . 0.0 108.217 179.272 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 211' ' ' ILE . . . . . . . . . . . . . 92.8 mt -64.9 -28.21 44.26 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.702 0 N-CA-C 107.694 -1.224 . . . . 0.0 107.694 176.656 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 212' ' ' ALA . . . . . 0.438 ' HB3' ' O ' ' A' ' 209' ' ' GLY . . . -68.29 -45.71 72.33 Favored 'General case' 0 N--CA 1.449 -0.492 0 CA-C-N 114.419 -1.264 . . . . 0.0 111.087 -179.851 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 213' ' ' LEU . . . . . . . . . . . . . 92.8 mt -70.55 -55.32 9.16 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-N 115.442 -0.799 . . . . 0.0 112.415 -178.828 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 214' ' ' ASP . . . . . . . . . . . . . 31.9 m-20 -53.11 -52.1 59.76 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.713 0.292 . . . . 0.0 111.607 -179.295 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 215' ' ' ALA . . . . . . . . . . . . . . . -62.14 -57.77 10.29 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 116.339 -0.391 . . . . 0.0 111.691 -179.438 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 216' ' ' ALA . . . . . 0.435 ' HA ' HD11 ' A' ' 219' ' ' LEU . . . -56.4 -34.85 67.11 Favored 'General case' 0 C--N 1.332 -0.188 0 CA-C-N 116.469 -0.332 . . . . 0.0 111.469 -179.537 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 217' ' ' ALA . . . . . . . . . . . . . . . -60.55 -40.7 92.55 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-O 121.048 0.452 . . . . 0.0 110.082 179.703 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 218' ' ' THR . . . . . . . . . . . . . 95.9 m -71.09 -38.5 72.4 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 115.659 -0.7 . . . . 0.0 110.71 179.331 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 219' ' ' LEU . . . . . 0.477 ' O ' ' HG2' ' A' ' 222' ' ' GLU . 87.2 mt -56.33 -43.94 79.52 Favored 'General case' 0 C--N 1.332 -0.175 0 CA-C-N 115.915 -0.584 . . . . 0.0 110.666 179.899 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 220' ' ' ARG . . . . . . . . . . . . . 7.3 ptm180 -84.45 -15.95 44.28 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.459 179.358 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 221' ' ' ALA . . . . . . . . . . . . . . . -67.84 -34.82 77.45 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 116.021 -0.536 . . . . 0.0 111.606 -179.674 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 222' ' ' GLU . . . . . 0.477 ' HG2' ' O ' ' A' ' 219' ' ' LEU . 13.1 pt-20 -67.79 -14.71 63.17 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-O 120.937 0.398 . . . . 0.0 110.541 -179.716 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 223' ' ' HIS . . . . . . . . . . . . . 77.9 m-70 -84.49 -36.2 22.42 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 115.852 -0.613 . . . . 0.0 110.761 179.617 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 224' ' ' GLY . . . . . . . . . . . . . . . 60.28 27.83 65.99 Favored Glycine 0 N--CA 1.45 -0.384 0 C-N-CA 120.884 -0.674 . . . . 0.0 112.771 179.9 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 225' ' ' GLU . . . . . . . . . . . . . 41.6 mt-10 -93.38 115.08 27.64 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.741 0.305 . . . . 0.0 110.895 -179.949 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 226' ' ' SER . . . . . . . . . . . . . 79.0 p -138.14 -56.5 0.66 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.112 179.912 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 227' ' ' LEU . . . . . . . . . . . . . 82.3 mt -81.85 158.98 23.83 Favored 'General case' 0 C--N 1.332 -0.182 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.992 -179.868 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 228' ' ' ALA . . . . . . . . . . . . . . . -97.99 154.24 17.83 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.061 179.808 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 229' ' ' GLY . . . . . . . . . . . . . . . 112.25 87.31 1.67 Allowed Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.874 -0.679 . . . . 0.0 112.432 179.987 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 230' ' ' VAL . . . . . . . . . . . . . 30.9 t -98.83 127.46 51.42 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.245 0 CA-C-O 120.741 0.305 . . . . 0.0 111.043 -179.962 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 231' ' ' ASP . . . . . . . . . . . . . 18.9 t70 -96.73 132.74 42.1 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.081 179.919 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 232' ' ' THR . . . . . . . . . . . . . 8.4 t -161.95 -34.83 0.04 OUTLIER 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.297 -0.411 . . . . 0.0 111.249 -179.911 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 233' ' ' ASP . . . . . . . . . . . . . 16.6 t70 -126.88 113.34 16.43 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.273 -0.421 . . . . 0.0 111.039 -179.876 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 234' ' ' THR . . . . . . . . . . . . . 55.6 p -140.4 151.07 63.11 Favored Pre-proline 0 C--N 1.331 -0.225 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.928 179.854 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 235' ' ' PRO . . . . . . . . . . . . . 31.3 Cg_endo -64.33 117.29 4.34 Favored 'Trans proline' 0 C--N 1.348 0.526 0 C-N-CA 122.384 2.056 . . . . 0.0 112.109 179.891 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 236' ' ' ALA . . . . . . . . . . . . . . . -137.74 122.78 19.08 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.143 -0.48 . . . . 0.0 111.198 -179.915 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 237' ' ' VAL . . . . . . . . . . . . . 7.7 p -120.31 18.78 6.19 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.238 0 CA-C-O 121.259 0.552 . . . . 0.0 110.764 179.826 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 238' ' ' ALA . . . . . . . . . . . . . . . -88.14 -4.44 58.75 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 115.858 -0.61 . . . . 0.0 110.926 179.976 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 239' ' ' ASP . . . . . . . . . . . . . 19.7 t70 58.24 91.69 0.04 OUTLIER 'General case' 0 C--N 1.332 -0.187 0 CA-C-N 115.9 -0.591 . . . . 0.0 111.002 179.904 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 240' ' ' LEU . . . . . . . . . . . . . 2.7 pt? -160.95 -12.99 0.05 OUTLIER 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.069 -0.514 . . . . 0.0 110.694 179.861 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 241' ' ' GLU . . . . . . . . . . . . . 12.1 pt-20 -70.28 -15.77 62.94 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-N 116.037 -0.528 . . . . 0.0 110.719 179.801 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 242' ' ' HIS . . . . . . . . . . . . . 66.6 t60 -67.86 -47.59 68.49 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.97 -179.988 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 243' ' ' HIS . . . . . . . . . . . . . 66.5 m80 -57.87 142.18 46.79 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.141 -179.853 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 244' ' ' HIS . . . . . . . . . . . . . 23.4 t-80 -106.67 -38.42 6.13 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.035 -0.529 . . . . 0.0 110.707 179.926 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 245' ' ' HIS . . . . . . . . . . . . . 65.9 m80 -68.96 163.8 23.7 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.691 179.785 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 246' ' ' HIS . . . . . . . . . . . . . 8.3 p80 -96.78 176.69 5.9 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.941 179.898 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 247' ' ' HIS . . . . . . . . . . . . . 8.4 m80 . . . . . 0 C--O 1.248 1.013 0 CA-C-O 118.282 -0.865 . . . . 0.0 110.88 -179.959 . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 301' ' ' RET . . . . . 0.611 H203 ' HE1' ' A' ' 171' ' ' TRP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 1' ' ' MET . . . . . 0.542 ' HE1' ' H ' ' A' ' 4' ' ' LEU . 14.0 tmm? . . . . . 0 N--CA 1.485 1.311 0 CA-C-O 120.69 0.281 . . . . 0.0 110.617 . . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 62.5 t 58.75 101.65 0.04 OUTLIER 'Isoleucine or valine' 0 C--N 1.333 -0.146 0 CA-C-N 116.122 -0.49 . . . . 0.0 111.37 179.82 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . 178.89 -27.58 0.06 OUTLIER Glycine 0 N--CA 1.45 -0.368 0 C-N-CA 120.786 -0.721 . . . . 0.0 112.582 179.938 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 4' ' ' LEU . . . . . 0.542 ' H ' ' HE1' ' A' ' 1' ' ' MET . 92.7 mt -74.04 -35.25 64.3 Favored 'General case' 0 N--CA 1.449 -0.508 0 CA-C-O 120.858 0.361 . . . . 0.0 110.94 179.88 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 5' ' ' THR . . . . . 0.453 ' HG1' ' N ' ' A' ' 6' ' ' THR . 55.1 p -54.44 -38.84 66.76 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 115.928 -0.578 . . . . 0.0 111.718 -179.587 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 6' ' ' THR . . . . . 0.578 ' HG1' HD23 ' A' ' 7' ' ' LEU . 72.0 p -54.81 -35.52 63.98 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.451 -0.34 . . . . 0.0 111.619 -179.578 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 7' ' ' LEU . . . . . 0.578 HD23 ' HG1' ' A' ' 6' ' ' THR . 3.9 mm? -60.14 -53.29 59.45 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.317 -0.401 . . . . 0.0 111.272 -179.748 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 8' ' ' PHE . . . . . 0.519 ' HB2' ' HB1' ' A' ' 55' ' ' ALA . 75.8 m-85 -64.17 -34.53 78.29 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.994 -179.645 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 9' ' ' TRP . . . . . . . . . . . . . 21.5 m95 -62.34 -46.17 89.88 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-O 121.074 0.464 . . . . 0.0 109.835 179.939 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 41.9 mt -63.11 -35.88 81.75 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 115.629 -0.714 . . . . 0.0 110.154 179.138 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -69.66 -28.85 71.71 Favored Glycine 0 N--CA 1.448 -0.545 0 CA-C-N 115.643 -0.708 . . . . 0.0 111.784 179.419 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -73.71 -30.8 63.05 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-O 120.896 0.379 . . . . 0.0 110.473 179.526 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 13' ' ' ILE . . . . . 0.402 ' O ' HG21 ' A' ' 17' ' ' VAL . 50.2 mm -68.39 -54.33 22.36 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.124 0 CA-C-N 116.058 -0.519 . . . . 0.0 110.442 179.221 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -61.42 -37.39 94.02 Favored Glycine 0 N--CA 1.448 -0.534 0 C-N-CA 120.661 -0.781 . . . . 0.0 111.744 179.43 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 15' ' ' MET . . . . . 0.518 ' SD ' ' HA ' ' A' ' 44' ' ' SER . 55.5 tpp -63.65 -44.36 94.04 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.845 0.355 . . . . 0.0 110.44 179.527 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -54.82 -42.13 71.5 Favored 'General case' 0 C--N 1.332 -0.187 0 CA-C-N 115.943 -0.572 . . . . 0.0 110.02 179.291 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . 0.402 HG21 ' O ' ' A' ' 13' ' ' ILE . 45.0 t -58.94 -44.55 91.19 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.188 0 CA-C-N 116.011 -0.54 . . . . 0.0 110.328 179.404 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -64.45 -40.44 97.74 Favored Glycine 0 C--N 1.332 0.337 0 C-N-CA 120.852 -0.689 . . . . 0.0 111.726 179.124 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 11.8 m -53.45 -48.18 69.05 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-O 120.839 0.352 . . . . 0.0 110.988 -179.943 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 97.2 mt -71.75 -36.13 70.33 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.513 -179.977 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -58.14 -38.01 75.75 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 116.528 -0.305 . . . . 0.0 111.586 -179.761 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 22' ' ' PHE . . . . . 0.408 ' HB2' HG22 ' A' ' 41' ' ' VAL . 4.0 m-85 -90.91 -28.22 18.24 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.347 -0.388 . . . . 0.0 111.394 -179.457 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -69.81 -50.8 39.43 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.961 0.41 . . . . 0.0 111.503 -179.444 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 24' ' ' TRP . . . . . . . . . . . . . 5.5 t-105 -66.19 -43.26 87.34 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 115.842 -0.617 . . . . 0.0 111.111 -179.659 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -73.82 -26.96 60.87 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.94 0.4 . . . . 0.0 110.866 179.799 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -69.6 -44.32 64.29 Favored Glycine 0 N--CA 1.452 -0.287 0 C-N-CA 120.772 -0.727 . . . . 0.0 112.066 179.743 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 40.9 mmt180 -58.7 -27.35 64.77 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-O 120.849 0.357 . . . . 0.0 110.535 179.694 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 32.5 t70 -105.42 92.36 4.16 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.003 -0.544 . . . . 0.0 110.463 179.675 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -154.38 -167.87 2.76 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.15 -179.778 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -98.92 -126.33 5.6 Favored Glycine 0 N--CA 1.451 -0.3 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.438 179.972 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 88.1 p -132.2 123.06 26.27 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-O 120.773 0.321 . . . . 0.0 110.906 179.993 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 107.76 -31.14 8.27 Favored Glycine 0 N--CA 1.451 -0.363 0 C-N-CA 120.868 -0.682 . . . . 0.0 112.472 179.976 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 16.3 mm-40 -83.57 -21.68 32.56 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 120.689 0.28 . . . . 0.0 110.994 179.929 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 34' ' ' ARG . . . . . . . . . . . . . 60.1 ttp180 -52.11 -30.5 26.54 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-N 116.158 -0.473 . . . . 0.0 111.252 -179.645 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 80.2 ttt180 -61.28 -42.55 98.83 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.871 0.367 . . . . 0.0 110.761 179.879 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 66.4 m-85 -70.75 -30.47 66.99 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.054 -0.521 . . . . 0.0 110.925 179.941 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 37' ' ' TYR . . . . . . . . . . . . . 59.2 m-85 -72.37 -56.13 5.96 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.324 -179.44 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 52.1 t -57.05 -37.4 54.94 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.189 0 CA-C-O 120.955 0.407 . . . . 0.0 110.766 -179.826 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 33.8 m -60.73 -51.01 71.19 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 115.863 -0.608 . . . . 0.0 110.628 179.521 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 40' ' ' LEU . . . . . 0.488 HD12 HD11 ' A' ' 43' ' ' ILE . 66.0 tp -60.86 -46.89 88.79 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 115.838 -0.619 . . . . 0.0 110.63 179.694 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . 0.408 HG22 ' HB2' ' A' ' 22' ' ' PHE . 90.0 t -56.7 -35.24 44.96 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.242 0 CA-C-N 115.884 -0.598 . . . . 0.0 110.041 179.289 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -61.74 -40.95 99.49 Favored Glycine 0 N--CA 1.448 -0.527 0 C-N-CA 120.673 -0.775 . . . . 0.0 111.504 179.175 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 43' ' ' ILE . . . . . 0.49 HD13 HD12 ' A' ' 83' ' ' ILE . 18.7 mt -57.46 -56.62 14.2 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.22 0 CA-C-O 120.76 0.314 . . . . 0.0 110.933 179.318 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 44' ' ' SER . . . . . 0.518 ' HA ' ' SD ' ' A' ' 15' ' ' MET . 49.7 m -58.71 -26.35 63.82 Favored 'General case' 0 C--N 1.332 -0.182 0 CA-C-N 116.315 -0.402 . . . . 0.0 111.482 -179.696 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -73.53 -53.99 7.05 Favored Glycine 0 CA--C 1.518 0.229 0 C-N-CA 120.681 -0.771 . . . . 0.0 112.879 -179.625 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 19.6 pt -61.18 -38.38 79.59 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.222 0 CA-C-O 120.871 0.367 . . . . 0.0 111.377 -179.712 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 47' ' ' ALA . . . . . 0.611 ' HB3' ' HE2' ' A' ' 205' ' ' LYS . . . -67.71 -43.21 80.57 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.814 0.34 . . . . 0.0 111.002 179.602 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -54.75 -46.71 74.36 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 115.947 -0.569 . . . . 0.0 111.754 -179.531 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 49' ' ' VAL . . . . . 0.402 ' O ' HG13 ' A' ' 53' ' ' VAL . 31.4 m -68.59 -34.19 63.89 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.241 0 CA-C-N 116.527 -0.306 . . . . 0.0 111.275 -179.595 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -66.01 -37.07 84.98 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-O 120.884 0.373 . . . . 0.0 111.005 179.638 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 51' ' ' TYR . . . . . 0.408 ' OH ' ' HB2' ' A' ' 201' ' ' ASP . 26.7 m-85 -68.75 -38.75 80.34 Favored 'General case' 0 C--N 1.327 -0.413 0 CA-C-O 121.117 0.484 . . . . 0.0 110.084 179.772 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -65.29 -45.09 85.84 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 115.635 -0.712 . . . . 0.0 111.314 179.676 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 53' ' ' VAL . . . . . 0.461 HG21 ' N ' ' A' ' 54' ' ' MET . 27.6 m -67.76 -46.5 82.36 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.139 0 CA-C-O 120.794 0.33 . . . . 0.0 110.621 179.886 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 54' ' ' MET . . . . . 0.465 ' HG2' ' HG2' ' A' ' 71' ' ' PRO . 72.0 mtm -62.27 -30.44 71.12 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 121.156 0.503 . . . . 0.0 109.854 179.111 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 55' ' ' ALA . . . . . 0.519 ' HB1' ' HB2' ' A' ' 8' ' ' PHE . . . -74.28 -30.53 62.14 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 115.601 -0.727 . . . . 0.0 111.355 179.797 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 76.3 mt -77.37 -9.74 59.03 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.457 -0.338 . . . . 0.0 111.214 -179.764 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 95.31 -11.93 68.48 Favored Glycine 0 N--CA 1.452 -0.254 0 C-N-CA 120.666 -0.778 . . . . 0.0 113.017 179.729 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 8.8 p -74.29 140.58 17.38 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-O 120.846 0.355 . . . . 0.0 110.885 -179.97 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 59' ' ' GLY . . . . . 0.463 ' HA3' ' HG3' ' A' ' 71' ' ' PRO . . . 101.29 -9.71 57.76 Favored Glycine 0 N--CA 1.45 -0.377 0 C-N-CA 120.907 -0.663 . . . . 0.0 112.286 -179.715 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 60' ' ' TRP . . . . . . . . . . . . . 15.8 m0 -76.32 118.08 18.66 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-O 120.579 0.228 . . . . 0.0 110.393 179.67 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 61' ' ' VAL . . . . . 0.469 ' HA ' ' HD3' ' A' ' 62' ' ' PRO . 7.5 p -113.26 127.63 26.61 Favored Pre-proline 0 CA--C 1.533 0.321 0 CA-C-N 116.582 -0.281 . . . . 0.0 111.716 -179.603 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 62' ' ' PRO . . . . . 0.469 ' HD3' ' HA ' ' A' ' 61' ' ' VAL . 6.8 Cg_exo -74.03 146.61 37.25 Favored 'Trans proline' 0 C--N 1.351 0.685 0 C-N-CA 122.88 2.386 . . . . 0.0 112.159 179.518 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 75.5 t -139.71 90.42 0.6 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.044 179.859 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . 59.16 -86.12 0.02 OUTLIER 'General case' 0 C--N 1.331 -0.196 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.463 179.891 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 9.7 tp10 -122.42 -19.98 6.24 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 121.011 0.434 . . . . 0.0 110.653 -179.991 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 66' ' ' ARG . . . . . . . . . . . . . 18.4 ptp180 -100.76 165.82 11.18 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 115.893 -0.594 . . . . 0.0 110.373 179.878 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 26.3 m -125.42 139.66 53.46 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.886 0.374 . . . . 0.0 111.3 -179.838 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 21.5 t -124.17 146.57 29.46 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.238 0 CA-C-N 115.972 -0.558 . . . . 0.0 110.583 179.887 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 69' ' ' PHE . . . . . . . . . . . . . 27.5 m-85 -109.37 111.05 22.39 Favored 'General case' 0 C--N 1.331 -0.206 0 CA-C-N 116.41 -0.359 . . . . 0.0 110.062 -179.629 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 70' ' ' VAL . . . . . 0.589 ' N ' ' HD2' ' A' ' 71' ' ' PRO . 47.4 t -70.02 -49.82 18.15 Favored Pre-proline 0 C--N 1.325 -0.471 0 N-CA-C 112.759 0.651 . . . . 0.0 112.759 -179.186 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 71' ' ' PRO . . . . . 0.589 ' HD2' ' N ' ' A' ' 70' ' ' VAL . 11.3 Cg_endo -54.03 -19.12 14.94 Favored 'Trans proline' 0 C--N 1.352 0.739 0 C-N-CA 122.031 1.82 . . . . 0.0 112.339 -179.616 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 72' ' ' ARG . . . . . 0.44 ' HE ' HG22 ' A' ' 197' ' ' ILE . 32.1 ttt180 -77.02 -53.49 7.74 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.596 179.605 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 73' ' ' TYR . . . . . 0.421 ' O ' HG13 ' A' ' 77' ' ' ILE . 79.9 m-85 -66.37 -39.41 89.08 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 115.816 -0.629 . . . . 0.0 110.922 -179.811 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 0.3 OUTLIER -67.4 -36.35 76.24 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-N 116.348 -0.387 . . . . 0.0 110.043 179.504 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 12.6 t70 -61.02 -37.37 82.32 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.235 -0.439 . . . . 0.0 109.951 179.253 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 76' ' ' TRP . . . . . . . . . . . . . 48.6 m0 -66.3 -36.21 82.36 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 115.927 -0.579 . . . . 0.0 110.067 179.414 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 77' ' ' ILE . . . . . 0.498 ' O ' ' HG2' ' A' ' 81' ' ' PRO . 68.3 mt -66.54 -30.07 48.55 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.364 0 CA-C-N 115.959 -0.564 . . . . 0.0 110.91 179.511 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 53.4 mt -91.91 -21.95 20.32 Favored 'General case' 0 C--N 1.328 -0.347 0 N-CA-C 112.511 0.56 . . . . 0.0 112.511 -179.644 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 79' ' ' THR . . . . . 0.459 ' HG1' ' H ' ' A' ' 80' ' ' THR . 70.0 p -100.27 -52.0 3.5 Favored 'General case' 0 N--CA 1.464 0.269 0 N-CA-C 113.619 0.97 . . . . 0.0 113.619 -177.792 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 80' ' ' THR . . . . . 0.661 ' HB ' ' HD3' ' A' ' 81' ' ' PRO . 86.3 m -51.35 -55.35 29.65 Favored Pre-proline 0 CA--C 1.532 0.271 0 N-CA-C 112.421 0.526 . . . . 0.0 112.421 -178.502 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 81' ' ' PRO . . . . . 0.661 ' HD3' ' HB ' ' A' ' 80' ' ' THR . 52.0 Cg_exo -56.49 -20.13 32.13 Favored 'Trans proline' 0 C--N 1.352 0.762 0 C-N-CA 121.542 1.495 . . . . 0.0 111.481 179.574 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 82' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -76.63 -38.2 55.08 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 115.716 -0.675 . . . . 0.0 110.223 179.552 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 83' ' ' ILE . . . . . 0.49 HD12 HD13 ' A' ' 43' ' ' ILE . 16.7 mm -66.17 -51.24 61.68 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.16 0 CA-C-N 116.004 -0.543 . . . . 0.0 110.293 179.516 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 31.0 m -61.49 -31.76 51.48 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.166 0 N-CA-C 109.71 -0.478 . . . . 0.0 109.71 178.962 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 85' ' ' TYR . . . . . . . . . . . . . 83.4 t80 -66.48 -31.94 72.99 Favored 'General case' 0 N--CA 1.454 -0.249 0 CA-C-N 115.656 -0.702 . . . . 0.0 109.569 178.763 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 86' ' ' PHE . . . . . . . . . . . . . 11.5 t80 -63.69 -50.84 67.6 Favored 'General case' 0 C--O 1.233 0.185 0 CA-C-N 115.889 -0.596 . . . . 0.0 109.793 179.179 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 3.1 mt -61.02 -35.5 77.02 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 115.786 -0.643 . . . . 0.0 109.714 179.537 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -67.08 -28.14 73.68 Favored Glycine 0 N--CA 1.45 -0.393 0 CA-C-N 115.28 -0.873 . . . . 0.0 111.865 179.49 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 50.0 mt -72.59 -37.36 68.15 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.893 0.378 . . . . 0.0 110.277 179.534 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 41.5 mt -60.4 -50.6 72.96 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 115.741 -0.663 . . . . 0.0 110.73 179.617 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . 0.446 ' HB2' ' HB2' ' A' ' 148' ' ' SER . . . -71.52 -48.57 47.98 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 115.981 -0.554 . . . . 0.0 111.374 -179.815 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 96.88 62.66 0.93 Allowed Glycine 0 N--CA 1.452 -0.271 0 C-N-CA 120.764 -0.731 . . . . 0.0 112.399 -179.902 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 93' ' ' LEU . . . . . 0.554 ' HB3' ' HB2' ' A' ' 97' ' ' GLU . 7.1 mp -77.08 175.09 9.94 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.782 0.325 . . . . 0.0 110.868 -179.958 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 94' ' ' ASP . . . . . . . . . . . . . 13.0 m-20 -91.23 172.82 8.28 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.827 179.708 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 78.5 p -60.04 -36.55 77.52 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.246 -0.434 . . . . 0.0 111.09 -179.848 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 15.9 ptm180 -73.89 -43.54 58.16 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.06 -179.965 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 97' ' ' GLU . . . . . 0.554 ' HB2' ' HB3' ' A' ' 93' ' ' LEU . 37.1 mt-10 -57.59 -46.49 83.97 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.384 -0.371 . . . . 0.0 110.764 -179.926 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 98' ' ' PHE . . . . . . . . . . . . . 21.4 m-85 -60.25 -41.29 92.9 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.361 179.53 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -58.73 -32.55 69.91 Favored Glycine 0 N--CA 1.449 -0.469 0 C-N-CA 120.687 -0.768 . . . . 0.0 112.265 179.75 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 86.7 mt -73.51 -44.54 53.6 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-O 120.747 0.308 . . . . 0.0 111.675 -179.83 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 35.3 t -68.46 -48.8 70.77 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 CA-C-N 116.318 -0.401 . . . . 0.0 111.76 -179.252 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 102' ' ' ILE . . . . . 0.513 HG22 ' HB3' ' A' ' 81' ' ' PRO . 48.2 mm -63.56 -45.87 96.5 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.379 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.868 -179.357 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 6.0 t -62.02 -33.67 74.79 Favored 'General case' 0 C--N 1.332 -0.192 0 CA-C-O 120.867 0.365 . . . . 0.0 110.759 -179.813 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 48.5 tp -60.17 -53.28 59.59 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.221 179.348 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 105' ' ' ASN . . . . . 0.571 ' N ' HD21 ' A' ' 105' ' ' ASN . 0.8 OUTLIER -56.26 -31.31 63.47 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.063 -0.517 . . . . 0.0 110.115 179.38 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 24.8 m -61.88 -38.75 89.47 Favored 'General case' 0 C--N 1.332 -0.179 0 CA-C-N 116.038 -0.528 . . . . 0.0 109.996 179.078 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 1.8 t -70.35 -41.21 78.45 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.198 0 CA-C-N 116.051 -0.522 . . . . 0.0 109.964 178.97 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 54.0 t -57.22 -47.19 84.62 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 115.367 -0.833 . . . . 0.0 111.23 179.885 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 109' ' ' MET . . . . . . . . . . . . . 21.5 mmt -69.27 -32.31 71.41 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.017 -0.538 . . . . 0.0 111.124 -179.714 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 27.8 tp -65.3 -33.28 75.6 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-O 120.964 0.411 . . . . 0.0 110.324 179.793 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -68.82 -53.84 19.24 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 115.855 -0.611 . . . . 0.0 110.743 179.465 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 112' ' ' GLY . . . . . 0.483 ' HA3' ' H22' ' A' ' 301' ' ' RET . . . -63.09 -35.62 92.33 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.652 -0.785 . . . . 0.0 112.135 179.642 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 113' ' ' PHE . . . . . 0.405 ' HZ ' HG12 ' A' ' 70' ' ' VAL . 0.7 OUTLIER -55.63 -65.31 0.61 Allowed 'General case' 0 C--N 1.33 -0.255 0 CA-C-O 121.066 0.46 . . . . 0.0 110.249 179.6 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 114' ' ' ALA . . . . . 0.558 ' HB1' HD22 ' A' ' 126' ' ' LEU . . . -66.09 -22.55 66.41 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 115.722 -0.672 . . . . 0.0 110.951 179.816 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -55.8 -48.96 68.71 Favored Glycine 0 C--N 1.333 0.392 0 C-N-CA 120.659 -0.781 . . . . 0.0 111.85 179.401 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -78.32 -15.03 59.14 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-O 120.836 0.35 . . . . 0.0 111.016 179.508 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 117' ' ' MET . . . . . . . . . . . . . 32.3 tpp -91.58 18.73 7.02 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.105 -0.498 . . . . 0.0 111.497 -179.204 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 118' ' ' VAL . . . . . 0.468 HG23 ' HB3' ' A' ' 123' ' ' ARG . 27.5 m -88.57 139.1 29.71 Favored Pre-proline 0 C--N 1.33 -0.27 0 CA-C-N 116.633 -0.258 . . . . 0.0 111.308 -179.865 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 119' ' ' PRO . . . . . . . . . . . . . 95.4 Cg_endo -89.67 -10.08 3.81 Favored 'Trans proline' 0 N--CA 1.456 -0.697 0 C-N-CA 122.699 2.266 . . . . 0.0 112.195 179.371 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -128.64 -106.71 1.3 Allowed Glycine 0 C--N 1.331 0.305 0 C-N-CA 120.848 -0.691 . . . . 0.0 112.722 -179.74 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 2.6 pp -136.93 19.52 0.85 Allowed 'Isoleucine or valine' 0 C--N 1.332 -0.185 0 CA-C-O 120.742 0.306 . . . . 0.0 111.652 -179.713 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 41.3 mt-10 -65.05 -17.71 64.68 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.311 -0.404 . . . . 0.0 110.853 179.757 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 123' ' ' ARG . . . . . 0.468 ' HB3' HG23 ' A' ' 118' ' ' VAL . 12.2 ptt180 -50.16 -42.05 50.25 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 115.736 -0.666 . . . . 0.0 112.023 -179.64 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 124' ' ' TYR . . . . . . . . . . . . . 59.0 m-85 -57.56 -32.18 66.87 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.522 -0.308 . . . . 0.0 111.511 -179.239 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 125' ' ' ALA . . . . . . . . . . . . . . . -74.2 -56.29 5.07 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-O 121.03 0.443 . . . . 0.0 111.156 -179.728 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 126' ' ' LEU . . . . . 0.558 HD22 ' HB1' ' A' ' 114' ' ' ALA . 1.1 mt -53.25 -48.83 67.92 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 115.746 -0.661 . . . . 0.0 110.494 179.96 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 127' ' ' PHE . . . . . . . . . . . . . 7.0 t80 -63.65 -35.65 81.24 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.306 -0.406 . . . . 0.0 110.483 179.396 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 128' ' ' GLY . . . . . . . . . . . . . . . -47.22 -50.73 16.21 Favored Glycine 0 C--N 1.333 0.402 0 C-N-CA 120.055 -1.069 . . . . 0.0 110.609 178.854 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 129' ' ' MET . . . . . . . . . . . . . 0.5 OUTLIER -65.31 -34.31 78.03 Favored 'General case' 0 C--N 1.329 -0.314 0 N-CA-C 109.679 -0.489 . . . . 0.0 109.679 178.293 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -57.81 -51.61 57.1 Favored Glycine 0 C--N 1.331 0.284 0 CA-C-N 115.463 -0.789 . . . . 0.0 112.597 -179.973 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -58.91 -49.47 77.66 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 120.66 0.267 . . . . 0.0 110.684 179.865 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 132' ' ' VAL . . . . . 0.411 ' O ' HG13 ' A' ' 135' ' ' ILE . 49.9 t -54.55 -39.99 48.21 Favored 'Isoleucine or valine' 0 C--O 1.233 0.228 0 CA-C-O 121.269 0.557 . . . . 0.0 109.794 179.007 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -69.98 -34.19 73.05 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 115.474 -0.784 . . . . 0.0 110.947 179.469 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 134' ' ' PHE . . . . . 0.459 ' CZ ' ' HA ' ' A' ' 172' ' ' ALA . 51.9 t80 -56.87 -58.58 7.5 Favored 'General case' 0 CA--C 1.517 -0.294 0 CA-C-N 116.341 -0.39 . . . . 0.0 110.118 179.817 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 135' ' ' ILE . . . . . 0.442 ' O ' HG23 ' A' ' 138' ' ' VAL . 0.0 OUTLIER -55.6 -34.85 36.56 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 115.799 -0.637 . . . . 0.0 109.663 179.104 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . -58.19 -36.47 82.61 Favored Glycine 0 N--CA 1.448 -0.524 0 C-N-CA 120.447 -0.882 . . . . 0.0 111.482 178.944 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 137' ' ' LEU . . . . . 0.463 HD11 HD22 ' A' ' 105' ' ' ASN . 38.3 tp -71.91 -54.18 10.82 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-O 120.615 0.245 . . . . 0.0 110.721 179.537 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 138' ' ' VAL . . . . . 0.442 HG23 ' O ' ' A' ' 135' ' ' ILE . 3.4 m -55.92 -30.32 28.09 Favored 'Isoleucine or valine' 0 C--O 1.233 0.197 0 CA-C-O 121.312 0.577 . . . . 0.0 109.712 179.351 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 139' ' ' TYR . . . . . . . . . . . . . 31.4 t80 -63.58 -47.03 83.14 Favored 'General case' 0 N--CA 1.453 -0.285 0 CA-C-N 115.31 -0.859 . . . . 0.0 110.021 178.975 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 18.2 m-85 -57.38 -35.98 70.68 Favored 'General case' 0 C--N 1.332 -0.191 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.596 179.362 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 141' ' ' LEU . . . . . . . . . . . . . 69.5 mt -59.49 -54.69 43.7 Favored 'General case' 0 C--N 1.333 -0.152 0 CA-C-N 116.262 -0.426 . . . . 0.0 110.51 179.522 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 18.6 t -70.02 -15.79 19.58 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.246 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.765 179.597 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . -68.68 -138.67 0.08 OUTLIER Glycine 0 CA--C 1.522 0.469 0 C-N-CA 121.025 -0.607 . . . . 0.0 112.779 -179.899 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 144' ' ' PRO . . . . . . . . . . . . . 19.2 Cg_endo -59.11 -23.42 68.94 Favored 'Trans proline' 0 C--N 1.349 0.587 0 C-N-CA 122.672 2.248 . . . . 0.0 112.654 -179.723 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 145' ' ' MET . . . . . 0.524 ' HB3' ' HH ' ' A' ' 160' ' ' TYR . 45.5 mtt -59.07 -28.52 66.55 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.517 -0.311 . . . . 0.0 111.28 -179.997 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 146' ' ' THR . . . . . . . . . . . . . 35.2 m -80.45 -42.9 21.81 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.913 0.387 . . . . 0.0 111.194 -179.167 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 9.1 tp10 -70.42 -34.53 72.6 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 115.964 -0.562 . . . . 0.0 111.107 -179.818 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 148' ' ' SER . . . . . 0.446 ' HB2' ' HB2' ' A' ' 91' ' ' ALA . 64.2 m -70.47 -50.85 33.75 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.054 -179.41 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 149' ' ' ALA . . . . . 0.43 ' HB2' HG22 ' A' ' 156' ' ' ILE . . . -64.79 -38.38 90.8 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.332 -179.828 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 150' ' ' SER . . . . . . . . . . . . . 100.0 p -72.15 -4.29 28.26 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.896 179.856 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 151' ' ' GLN . . . . . . . . . . . . . 24.3 mt-30 -125.46 1.54 7.66 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.168 -179.98 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -80.34 -52.54 7.57 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-O 121.013 0.435 . . . . 0.0 110.333 179.883 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 153' ' ' SER . . . . . 0.569 ' HB2' HG12 ' A' ' 156' ' ' ILE . 44.3 m -158.22 171.01 20.98 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-N 115.83 -0.623 . . . . 0.0 110.49 179.18 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 154' ' ' SER . . . . . . . . . . . . . 64.1 m -71.21 -36.82 72.01 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 121.028 0.442 . . . . 0.0 110.059 179.127 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -76.93 -41.21 23.49 Favored Glycine 0 N--CA 1.45 -0.417 0 CA-C-N 115.785 -0.643 . . . . 0.0 112.386 179.611 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 156' ' ' ILE . . . . . 0.569 HG12 ' HB2' ' A' ' 153' ' ' SER . 38.1 mm -51.76 -38.17 21.81 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.196 0 CA-C-O 120.879 0.371 . . . . 0.0 111.177 179.91 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 157' ' ' LYS . . . . . . . . . . . . . 63.1 tttm -58.93 -42.92 90.88 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 115.961 -0.563 . . . . 0.0 110.92 -179.989 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 51.0 m -71.19 -40.94 70.91 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.547 -179.732 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 159' ' ' LEU . . . . . 0.418 ' O ' ' HB2' ' A' ' 163' ' ' LEU . 2.2 mm? -63.78 -38.72 92.17 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.418 -0.355 . . . . 0.0 111.601 -179.419 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 160' ' ' TYR . . . . . 0.524 ' HH ' ' HB3' ' A' ' 145' ' ' MET . 43.5 t80 -74.2 -46.79 39.71 Favored 'General case' 0 C--N 1.327 -0.38 0 N-CA-C 112.598 0.592 . . . . 0.0 112.598 -178.533 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 161' ' ' VAL . . . . . 0.417 HG22 ' N ' ' A' ' 162' ' ' ARG . 21.2 m -57.25 -48.83 81.59 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 N-CA-C 112.395 0.517 . . . . 0.0 112.395 -178.788 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 162' ' ' ARG . . . . . 0.417 ' N ' HG22 ' A' ' 161' ' ' VAL . 27.1 ttm180 -69.04 -45.92 69.21 Favored 'General case' 0 C--N 1.329 -0.324 0 N-CA-C 111.783 0.29 . . . . 0.0 111.783 -179.302 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 163' ' ' LEU . . . . . 0.662 ' HG ' ' HB2' ' A' ' 208' ' ' PHE . 6.6 mp -61.78 -49.75 75.12 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.451 -0.34 . . . . 0.0 111.733 -179.661 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 164' ' ' ARG . . . . . . . . . . . . . 4.0 tmt_? -62.64 -45.51 92.52 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.312 -0.404 . . . . 0.0 111.749 -179.036 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 165' ' ' ASN . . . . . 0.477 ' N ' HD21 ' A' ' 165' ' ' ASN . 0.9 OUTLIER -59.49 -52.19 66.62 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.783 0.325 . . . . 0.0 111.546 -179.434 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 166' ' ' LEU . . . . . 0.508 ' O ' ' HG ' ' A' ' 170' ' ' LEU . 4.6 tt -63.88 -53.41 50.9 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-O 120.852 0.358 . . . . 0.0 111.314 -179.552 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 167' ' ' THR . . . . . 0.44 ' O ' ' HB2' ' A' ' 171' ' ' TRP . 88.3 m -54.67 -53.09 59.37 Favored 'General case' 0 C--N 1.327 -0.381 0 N-CA-C 112.581 0.585 . . . . 0.0 112.581 -178.744 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 168' ' ' VAL . . . . . . . . . . . . . 9.1 p -56.74 -40.58 71.23 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.204 0 N-CA-C 112.158 0.429 . . . . 0.0 112.158 -178.753 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 169' ' ' VAL . . . . . . . . . . . . . 51.5 t -58.26 -65.37 0.44 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 N-CA-C 111.821 0.304 . . . . 0.0 111.821 -179.487 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 170' ' ' LEU . . . . . 0.508 ' HG ' ' O ' ' A' ' 166' ' ' LEU . 0.4 OUTLIER -64.48 -28.26 69.54 Favored 'General case' 0 C--N 1.331 -0.216 0 N-CA-C 111.982 0.364 . . . . 0.0 111.982 -178.865 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 171' ' ' TRP . . . . . 0.44 ' HB2' ' O ' ' A' ' 167' ' ' THR . 5.2 m0 -71.38 -31.18 67.01 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.848 0.356 . . . . 0.0 110.742 179.488 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 172' ' ' ALA . . . . . 0.459 ' HA ' ' CZ ' ' A' ' 134' ' ' PHE . . . -73.78 -6.4 46.75 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.861 -179.727 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 173' ' ' ILE . . . . . 0.51 HG23 HD12 ' A' ' 177' ' ' ILE . 13.9 mm -86.12 -21.46 7.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 115.927 -0.579 . . . . 0.0 110.806 179.629 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 174' ' ' TYR . . . . . . . . . . . . . 14.2 m-85 -54.27 -51.24 79.5 Favored Pre-proline 0 CA--C 1.531 0.236 0 CA-C-N 116.115 -0.493 . . . . 0.0 112.109 -179.535 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 175' ' ' PRO . . . . . . . . . . . . . 89.1 Cg_exo -47.4 -29.14 9.43 Favored 'Trans proline' 0 C--N 1.352 0.728 0 C-N-CA 121.998 1.798 . . . . 0.0 112.176 179.748 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 176' ' ' PHE . . . . . 0.44 ' O ' ' HG ' ' A' ' 180' ' ' LEU . 98.3 m-85 -80.52 -50.12 10.46 Favored 'General case' 0 CA--C 1.517 -0.323 0 CA-C-N 116.057 -0.52 . . . . 0.0 111.69 179.968 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 177' ' ' ILE . . . . . 0.521 ' O ' ' HD2' ' A' ' 182' ' ' PRO . 3.1 mm -58.4 -46.47 89.36 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.533 0 CA-C-N 115.884 -0.598 . . . . 0.0 112.073 -178.227 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 178' ' ' TRP . . . . . 0.484 ' HA ' ' HG2' ' A' ' 182' ' ' PRO . 75.1 t90 -62.5 -42.45 99.51 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 121.026 0.441 . . . . 0.0 110.974 -179.986 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 179' ' ' LEU . . . . . 0.562 HD13 HG22 ' A' ' 185' ' ' VAL . 1.2 tm? -67.27 -49.51 64.04 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 115.831 -0.622 . . . . 0.0 111.369 -179.061 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 180' ' ' LEU . . . . . 0.563 HD21 HD11 ' A' ' 187' ' ' LEU . 9.9 mt -76.95 -52.29 9.65 Favored 'General case' 0 CA--C 1.535 0.374 0 N-CA-C 112.498 0.555 . . . . 0.0 112.498 -178.474 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . -64.97 -84.1 0.08 OUTLIER Glycine 0 CA--C 1.522 0.521 0 C-N-CA 120.72 -0.752 . . . . 0.0 113.425 -179.557 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 182' ' ' PRO . . . . . 0.521 ' HD2' ' O ' ' A' ' 177' ' ' ILE . 75.0 Cg_exo -44.86 -179.79 0.0 OUTLIER 'Trans proline' 0 C--N 1.351 0.671 0 C-N-CA 123.567 2.845 . . . . 0.0 113.574 179.684 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 183' ' ' PRO . . . . . . . . . . . . . 82.8 Cg_exo -50.11 5.06 0.02 OUTLIER 'Trans proline' 0 C--N 1.354 0.864 0 C-N-CA 123.196 2.597 . . . . 0.0 115.274 -179.566 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 184' ' ' GLY . . . . . 0.504 ' H ' ' C ' ' A' ' 182' ' ' PRO . . . -55.32 -70.28 1.01 Allowed Glycine 0 C--N 1.335 0.514 0 C-N-CA 119.724 -1.226 . . . . 0.0 110.899 179.236 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 185' ' ' VAL . . . . . 0.562 HG22 HD13 ' A' ' 179' ' ' LEU . 3.6 m -135.65 -5.77 0.95 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.372 0 N-CA-C 111.722 0.267 . . . . 0.0 111.722 178.559 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 186' ' ' ALA . . . . . . . . . . . . . . . 41.99 81.19 0.03 OUTLIER 'General case' 0 N--CA 1.466 0.349 0 N-CA-C 112.43 0.529 . . . . 0.0 112.43 179.372 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 187' ' ' LEU . . . . . 0.563 HD11 HD21 ' A' ' 180' ' ' LEU . 7.0 mt -92.92 -49.47 6.03 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.767 0.318 . . . . 0.0 111.548 179.871 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 188' ' ' LEU . . . . . . . . . . . . . 89.3 mt -105.8 -166.56 1.22 Allowed 'General case' 0 C--N 1.33 -0.244 0 CA-C-O 121.073 0.463 . . . . 0.0 111.515 -179.261 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 189' ' ' THR . . . . . 0.425 ' HB ' HG22 ' A' ' 192' ' ' VAL . 4.7 m -82.72 136.12 45.25 Favored Pre-proline 0 C--N 1.328 -0.339 0 CA-C-N 115.668 -0.696 . . . . 0.0 110.685 -179.615 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 190' ' ' PRO . . . . . . . . . . . . . 84.5 Cg_exo -45.76 -48.64 12.0 Favored 'Trans proline' 0 C--N 1.349 0.559 0 C-N-CA 122.628 2.219 . . . . 0.0 113.026 -179.788 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 191' ' ' THR . . . . . . . . . . . . . 3.9 t -56.8 -39.69 74.59 Favored 'General case' 0 C--N 1.33 -0.255 0 N-CA-C 111.921 0.341 . . . . 0.0 111.921 -179.492 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 192' ' ' VAL . . . . . 0.425 HG22 ' HB ' ' A' ' 189' ' ' THR . 58.6 t -67.33 -53.58 31.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-O 120.877 0.37 . . . . 0.0 111.546 -179.55 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 193' ' ' ASP . . . . . . . . . . . . . 13.5 m-20 -59.0 -43.05 91.43 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.09 -179.636 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 194' ' ' VAL . . . . . . . . . . . . . 54.3 t -60.99 -36.16 70.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.345 -0.389 . . . . 0.0 110.404 179.497 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 195' ' ' ALA . . . . . . . . . . . . . . . -58.51 -46.42 86.78 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-N 116.346 -0.388 . . . . 0.0 110.404 179.232 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 196' ' ' LEU . . . . . . . . . . . . . 90.6 mt -62.66 -38.04 88.74 Favored 'General case' 0 C--N 1.332 -0.192 0 CA-C-N 116.055 -0.52 . . . . 0.0 110.323 179.309 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 197' ' ' ILE . . . . . 0.44 HG22 ' HE ' ' A' ' 72' ' ' ARG . 20.3 mm -61.36 -57.14 13.49 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 115.947 -0.57 . . . . 0.0 110.223 179.262 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 198' ' ' VAL . . . . . . . . . . . . . 83.9 t -52.75 -34.88 20.52 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.465 0 CA-C-N 115.734 -0.666 . . . . 0.0 109.243 178.374 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 199' ' ' TYR . . . . . . . . . . . . . 62.5 t80 -69.99 -33.62 72.28 Favored 'General case' 0 C--N 1.332 -0.176 0 CA-C-N 115.388 -0.824 . . . . 0.0 110.626 179.498 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 200' ' ' LEU . . . . . 0.487 ' O ' HG11 ' A' ' 203' ' ' VAL . 31.8 mt -68.87 -44.17 73.86 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 115.919 -0.582 . . . . 0.0 111.409 -179.685 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 201' ' ' ASP . . . . . 0.408 ' HB2' ' OH ' ' A' ' 51' ' ' TYR . 11.8 m-20 -67.39 -36.05 80.52 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-O 121.293 0.568 . . . . 0.0 109.963 179.476 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 202' ' ' LEU . . . . . . . . . . . . . 3.3 mt -74.35 -28.28 61.06 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 115.232 -0.895 . . . . 0.0 112.356 -179.394 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 203' ' ' VAL . . . . . 0.487 HG11 ' O ' ' A' ' 200' ' ' LEU . 11.6 p -77.25 -36.15 23.71 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.303 0 C-N-CA 120.757 -0.377 . . . . 0.0 111.21 -178.533 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 204' ' ' THR . . . . . . . . . . . . . 90.2 m -70.7 -58.49 3.59 Favored 'General case' 0 C--N 1.327 -0.389 0 C-N-CA 120.719 -0.392 . . . . 0.0 111.068 179.316 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 205' ' ' LYS . . . . . 0.611 ' HE2' ' HB3' ' A' ' 47' ' ' ALA . 56.6 mttp -57.33 -58.02 10.09 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.242 -0.436 . . . . 0.0 111.728 -178.785 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 39.7 t -71.17 -36.3 61.94 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.431 0 CA-C-N 116.015 -0.539 . . . . 0.0 111.977 -179.061 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 207' ' ' GLY . . . . . 0.558 ' O ' HG13 ' A' ' 211' ' ' ILE . . . -58.9 -61.5 7.29 Favored Glycine 0 C--N 1.33 0.229 0 C-N-CA 120.624 -0.798 . . . . 0.0 113.816 -178.445 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 208' ' ' PHE . . . . . 0.662 ' HB2' ' HG ' ' A' ' 163' ' ' LEU . 1.0 OUTLIER -72.23 -27.47 62.54 Favored 'General case' 0 C--O 1.223 -0.333 0 CA-C-N 117.473 0.636 . . . . 0.0 111.05 -179.08 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 209' ' ' GLY . . . . . 0.508 ' O ' ' HB2' ' A' ' 212' ' ' ALA . . . -64.07 -34.2 89.3 Favored Glycine 0 N--CA 1.45 -0.369 0 N-CA-C 112.009 -0.436 . . . . 0.0 112.009 178.825 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 210' ' ' PHE . . . . . . . . . . . . . 1.2 m-85 -73.71 -48.71 30.02 Favored 'General case' 0 CA--C 1.514 -0.432 0 N-CA-C 108.21 -1.034 . . . . 0.0 108.21 178.446 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 211' ' ' ILE . . . . . 0.558 HG13 ' O ' ' A' ' 207' ' ' GLY . 5.4 mt -61.66 -28.07 43.39 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.499 0 N-CA-C 107.646 -1.242 . . . . 0.0 107.646 176.815 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 212' ' ' ALA . . . . . 0.508 ' HB2' ' O ' ' A' ' 209' ' ' GLY . . . -63.7 -41.71 98.08 Favored 'General case' 0 N--CA 1.448 -0.565 0 CA-C-N 114.384 -1.28 . . . . 0.0 110.139 179.952 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 213' ' ' LEU . . . . . . . . . . . . . 93.0 mt -70.1 -54.27 13.76 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 115.044 -0.98 . . . . 0.0 111.545 -179.729 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 214' ' ' ASP . . . . . . . . . . . . . 14.6 t70 -52.82 -54.63 31.57 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.189 -0.459 . . . . 0.0 111.605 -179.504 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 215' ' ' ALA . . . . . . . . . . . . . . . -57.53 -57.2 13.74 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.046 -0.524 . . . . 0.0 111.781 -179.476 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 216' ' ' ALA . . . . . . . . . . . . . . . -55.1 -37.38 66.77 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.375 -0.375 . . . . 0.0 111.494 -179.636 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 217' ' ' ALA . . . . . . . . . . . . . . . -62.41 -32.89 73.8 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.382 179.799 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 218' ' ' THR . . . . . . . . . . . . . 94.4 m -76.25 -41.66 48.37 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 115.806 -0.633 . . . . 0.0 110.74 179.567 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 219' ' ' LEU . . . . . . . . . . . . . 44.8 mt -61.78 -30.78 71.03 Favored 'General case' 0 C--N 1.332 -0.194 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.507 179.716 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 220' ' ' ARG . . . . . . . . . . . . . 77.1 ttt180 -83.79 -31.69 25.76 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 115.849 -0.614 . . . . 0.0 110.687 179.86 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 221' ' ' ALA . . . . . . . . . . . . . . . -72.66 -22.95 60.85 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 115.996 -0.547 . . . . 0.0 111.357 -179.88 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 222' ' ' GLU . . . . . . . . . . . . . 11.9 pt-20 -92.23 -28.58 16.93 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.415 -0.357 . . . . 0.0 110.493 -179.927 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 223' ' ' HIS . . . . . . . . . . . . . 84.3 m-70 64.29 111.61 0.03 OUTLIER 'General case' 0 C--N 1.331 -0.2 0 CA-C-N 115.794 -0.639 . . . . 0.0 111.339 179.79 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 224' ' ' GLY . . . . . . . . . . . . . . . -162.29 84.35 0.11 Allowed Glycine 0 C--N 1.33 0.21 0 C-N-CA 120.843 -0.694 . . . . 0.0 112.416 179.92 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 225' ' ' GLU . . . . . . . . . . . . . 8.8 tp10 -63.52 135.17 56.66 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.564 0.221 . . . . 0.0 110.771 -179.998 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 226' ' ' SER . . . . . . . . . . . . . 69.2 m 59.61 -86.34 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.045 -0.525 . . . . 0.0 111.236 -179.977 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 227' ' ' LEU . . . . . . . . . . . . . 27.4 tp -112.71 129.77 56.29 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.372 -0.376 . . . . 0.0 110.909 -179.918 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 228' ' ' ALA . . . . . . . . . . . . . . . -96.03 -179.29 4.63 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.262 -0.426 . . . . 0.0 110.932 179.822 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 229' ' ' GLY . . . . . . . . . . . . . . . -107.34 109.06 2.92 Favored Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.728 -0.749 . . . . 0.0 112.631 179.975 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 230' ' ' VAL . . . . . . . . . . . . . 37.0 t -71.27 136.28 26.18 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-O 120.702 0.286 . . . . 0.0 111.034 -179.866 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 231' ' ' ASP . . . . . . . . . . . . . 12.1 m-20 -76.42 111.63 12.08 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.859 179.848 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 232' ' ' THR . . . . . . . . . . . . . 72.5 p -121.68 -48.64 2.15 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.071 -0.513 . . . . 0.0 111.037 -179.975 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 233' ' ' ASP . . . . . . . . . . . . . 18.4 t70 -89.03 125.67 35.1 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.823 179.877 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 234' ' ' THR . . . . . . . . . . . . . 74.9 p -71.89 148.95 92.44 Favored Pre-proline 0 C--N 1.329 -0.322 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.1 -179.992 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 235' ' ' PRO . . . . . . . . . . . . . 55.6 Cg_endo -70.12 -39.1 6.18 Favored 'Trans proline' 0 C--N 1.348 0.543 0 C-N-CA 122.288 1.992 . . . . 0.0 111.996 179.812 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 236' ' ' ALA . . . . . . . . . . . . . . . -105.25 145.34 30.79 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.026 -0.534 . . . . 0.0 110.926 179.743 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 237' ' ' VAL . . . . . . . . . . . . . 46.2 t -118.13 117.67 55.56 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.248 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.147 -179.94 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 238' ' ' ALA . . . . . . . . . . . . . . . -125.96 -50.33 1.58 Allowed 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.359 -179.912 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 239' ' ' ASP . . . . . . . . . . . . . 15.6 m-20 57.86 100.41 0.02 OUTLIER 'General case' 0 C--N 1.332 -0.178 0 CA-C-N 116.102 -0.499 . . . . 0.0 111.088 -179.916 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 240' ' ' LEU . . . . . . . . . . . . . 81.3 mt -126.95 -8.11 6.03 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.86 179.976 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 241' ' ' GLU . . . . . . . . . . . . . 10.3 tp10 -67.27 125.45 26.1 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.861 179.981 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 242' ' ' HIS . . . . . . . . . . . . . 58.7 t-80 -85.96 114.83 23.17 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.291 -0.413 . . . . 0.0 111.02 -179.855 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 243' ' ' HIS . . . . . . . . . . . . . 8.5 p80 -137.04 147.26 46.06 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.746 179.823 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 244' ' ' HIS . . . . . . . . . . . . . 42.9 p-80 -91.11 156.9 17.55 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.918 0.39 . . . . 0.0 111.057 -179.811 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 245' ' ' HIS . . . . . . . . . . . . . 45.2 p-80 -64.38 161.73 16.37 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 115.93 -0.577 . . . . 0.0 111.223 -179.771 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 246' ' ' HIS . . . . . . . . . . . . . 96.4 m-70 -120.22 154.48 34.8 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.018 179.852 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 247' ' ' HIS . . . . . . . . . . . . . 47.2 m80 . . . . . 0 C--O 1.249 1.055 0 CA-C-O 118.19 -0.909 . . . . 0.0 111.024 -179.919 . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 301' ' ' RET . . . . . 0.483 ' H22' ' HA3' ' A' ' 112' ' ' GLY . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 1' ' ' MET . . . . . 0.546 ' H1 ' HG21 ' A' ' 5' ' ' THR . 0.0 OUTLIER . . . . . 0 N--CA 1.486 1.351 0 CA-C-O 120.807 0.337 . . . . 0.0 111.034 . . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 2' ' ' VAL . . . . . 0.441 ' N ' ' HG2' ' A' ' 1' ' ' MET . 58.6 t -141.24 -73.8 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.331 -0.225 0 CA-C-N 116.18 -0.463 . . . . 0.0 110.898 179.865 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -97.83 -9.51 54.26 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.841 -0.695 . . . . 0.0 112.354 -179.996 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 67.8 tp -74.22 -35.41 63.88 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 120.778 0.323 . . . . 0.0 110.796 179.723 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 5' ' ' THR . . . . . 0.546 HG21 ' H1 ' ' A' ' 1' ' ' MET . 69.9 p -69.62 -32.85 71.8 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.72 -179.697 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 29.0 p -54.93 -35.56 64.33 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.35 -0.386 . . . . 0.0 111.381 -179.644 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 7' ' ' LEU . . . . . . . . . . . . . 9.3 mp -59.24 -53.36 59.18 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.098 -0.501 . . . . 0.0 111.557 -179.813 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 8' ' ' PHE . . . . . 0.46 ' HB2' ' HB2' ' A' ' 55' ' ' ALA . 63.4 m-85 -59.95 -34.93 73.92 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.317 -0.402 . . . . 0.0 110.997 -179.73 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 9' ' ' TRP . . . . . . . . . . . . . 28.8 m95 -64.36 -47.61 78.62 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 116.058 -0.519 . . . . 0.0 110.357 -179.902 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 13.1 mt -58.32 -42.76 87.45 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 115.929 -0.578 . . . . 0.0 110.304 179.204 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -61.62 -34.58 89.03 Favored Glycine 0 N--CA 1.448 -0.545 0 C-N-CA 120.588 -0.815 . . . . 0.0 111.544 178.971 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -66.22 -33.15 75.1 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 120.616 0.246 . . . . 0.0 110.608 179.701 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 1.5 mt -63.21 -49.29 83.76 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.259 0 N-CA-C 109.347 -0.612 . . . . 0.0 109.347 178.987 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . 0.497 ' HA3' HD23 ' A' ' 202' ' ' LEU . . . -61.7 -24.82 64.76 Favored Glycine 0 N--CA 1.447 -0.584 0 C-N-CA 120.638 -0.791 . . . . 0.0 111.47 178.908 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 15' ' ' MET . . . . . 0.569 ' HB3' ' HB2' ' A' ' 48' ' ' ALA . 0.0 OUTLIER -77.3 -47.93 18.76 Favored 'General case' 0 C--N 1.331 -0.227 0 N-CA-C 111.763 0.283 . . . . 0.0 111.763 179.841 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 4.6 mm? -63.78 -39.22 93.72 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.778 0.323 . . . . 0.0 110.965 -179.958 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . 0.43 HG11 ' N ' ' A' ' 18' ' ' GLY . 8.5 p -68.09 -44.26 84.68 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.375 0 CA-C-O 121.388 0.613 . . . . 0.0 110.471 179.7 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . 0.43 ' N ' HG11 ' A' ' 17' ' ' VAL . . . -64.87 -49.79 61.47 Favored Glycine 0 C--N 1.319 -0.38 0 CA-C-N 114.928 -1.033 . . . . 0.0 111.349 179.135 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 19' ' ' THR . . . . . 0.474 HG23 HG11 ' A' ' 41' ' ' VAL . 94.2 m -54.11 -42.6 69.62 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-O 120.858 0.361 . . . . 0.0 111.008 179.828 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 67.6 mt -71.83 -42.96 66.36 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.061 -0.518 . . . . 0.0 111.264 179.947 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -59.02 -43.96 91.66 Favored 'General case' 0 C--N 1.329 -0.292 0 N-CA-C 111.805 0.298 . . . . 0.0 111.805 -179.797 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 22' ' ' PHE . . . . . 0.528 ' HB2' HG21 ' A' ' 41' ' ' VAL . 10.6 m-85 -75.53 -42.26 52.93 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.46 -0.337 . . . . 0.0 111.431 -179.291 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -61.79 -50.25 73.11 Favored 'General case' 0 C--N 1.33 -0.283 0 CA-C-O 120.814 0.34 . . . . 0.0 111.023 -179.845 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 24' ' ' TRP . . . . . . . . . . . . . 1.0 OUTLIER -57.92 -35.77 71.54 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.711 179.75 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -74.55 -30.17 61.64 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 120.955 0.407 . . . . 0.0 110.627 179.56 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -73.69 -38.98 49.79 Favored Glycine 0 N--CA 1.45 -0.387 0 C-N-CA 120.856 -0.687 . . . . 0.0 112.474 179.667 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 82.7 mtp180 -60.66 -41.19 94.49 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 120.879 0.371 . . . . 0.0 110.763 -179.851 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 11.4 t70 -64.51 -17.71 64.14 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.052 -0.522 . . . . 0.0 110.697 179.788 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -114.93 -178.44 3.37 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-N 116.014 -0.539 . . . . 0.0 110.915 179.816 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 164.56 59.32 0.02 OUTLIER Glycine 0 N--CA 1.452 -0.267 0 C-N-CA 120.532 -0.842 . . . . 0.0 112.869 179.89 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 46.5 t -164.07 87.55 0.5 Allowed 'General case' 0 C--N 1.327 -0.398 0 CA-C-O 120.995 0.426 . . . . 0.0 110.66 179.454 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 83.4 -22.08 7.84 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.834 -0.698 . . . . 0.0 112.192 -179.96 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 26.7 mt-10 -91.32 -20.84 21.43 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.7 0.286 . . . . 0.0 110.764 179.999 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 34' ' ' ARG . . . . . . . . . . . . . 15.8 ptp180 -51.51 -31.25 23.17 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 116.106 -0.497 . . . . 0.0 111.48 -179.652 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 89.9 mtm180 -73.51 -52.9 11.96 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.503 -0.317 . . . . 0.0 111.502 -179.7 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 73.6 m-85 -61.74 -30.53 70.83 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.247 -0.433 . . . . 0.0 111.702 -179.483 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 37' ' ' TYR . . . . . . . . . . . . . 26.1 m-85 -76.19 -55.27 5.73 Favored 'General case' 0 C--N 1.329 -0.307 0 N-CA-C 111.799 0.296 . . . . 0.0 111.799 -179.129 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 83.8 t -56.89 -36.27 49.47 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-O 120.939 0.4 . . . . 0.0 110.59 179.91 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 54.9 m -64.08 -52.11 60.85 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 115.991 -0.549 . . . . 0.0 111.116 179.718 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 40' ' ' LEU . . . . . 0.437 HD12 ' HE1' ' A' ' 208' ' ' PHE . 7.8 tp -63.3 -50.74 68.88 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.722 -179.81 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . 0.528 HG21 ' HB2' ' A' ' 22' ' ' PHE . 96.9 t -55.27 -34.84 34.38 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.356 0 CA-C-N 116.132 -0.485 . . . . 0.0 109.962 178.887 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -62.52 -37.25 94.4 Favored Glycine 0 N--CA 1.448 -0.558 0 C-N-CA 120.821 -0.704 . . . . 0.0 111.616 179.069 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 43' ' ' ILE . . . . . 0.523 HD13 HD12 ' A' ' 83' ' ' ILE . 3.8 mt -62.54 -57.95 9.77 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.158 0 CA-C-O 120.824 0.345 . . . . 0.0 110.732 179.505 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 24.6 t -59.92 -24.79 64.63 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-N 116.293 -0.412 . . . . 0.0 110.983 -179.904 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -71.99 -57.25 5.88 Favored Glycine 0 N--CA 1.452 -0.242 0 C-N-CA 120.805 -0.712 . . . . 0.0 112.427 179.825 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 15.5 pt -59.74 -37.47 71.37 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.229 0 CA-C-O 120.823 0.344 . . . . 0.0 111.007 179.888 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 47' ' ' ALA . . . . . 0.555 ' HB3' ' HE2' ' A' ' 205' ' ' LYS . . . -67.76 -39.33 84.15 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 116.316 -0.402 . . . . 0.0 111.027 179.313 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 48' ' ' ALA . . . . . 0.569 ' HB2' ' HB3' ' A' ' 15' ' ' MET . . . -57.07 -47.2 81.57 Favored 'General case' 0 C--O 1.232 0.177 0 CA-C-N 116.076 -0.511 . . . . 0.0 111.617 -179.658 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 49' ' ' VAL . . . . . 0.469 ' O ' HG13 ' A' ' 53' ' ' VAL . 29.9 m -70.66 -33.64 53.79 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-N 116.11 -0.496 . . . . 0.0 111.414 -179.359 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -62.96 -44.43 96.08 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.932 0.396 . . . . 0.0 111.286 -179.571 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 51' ' ' TYR . . . . . 0.528 ' HH ' ' HB2' ' A' ' 201' ' ' ASP . 33.3 m-85 -73.87 -36.22 64.82 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 115.829 -0.623 . . . . 0.0 110.942 -179.419 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -62.74 -45.8 91.01 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 115.841 -0.618 . . . . 0.0 111.157 -179.992 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 53' ' ' VAL . . . . . 0.554 ' HB ' HG12 ' A' ' 58' ' ' VAL . 19.7 m -73.32 -43.51 56.53 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.147 -0.478 . . . . 0.0 111.036 -179.802 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 54' ' ' MET . . . . . 0.443 ' HG3' ' HE1' ' A' ' 60' ' ' TRP . 11.4 ttp -64.94 -29.65 70.6 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.284 179.89 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 55' ' ' ALA . . . . . 0.46 ' HB2' ' HB2' ' A' ' 8' ' ' PHE . . . -65.47 -37.32 86.51 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 115.885 -0.598 . . . . 0.0 111.014 179.254 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 87.2 mt -70.85 -11.47 60.98 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.082 -0.508 . . . . 0.0 111.215 -179.781 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 104.68 17.4 14.95 Favored Glycine 0 CA--C 1.518 0.227 0 C-N-CA 120.742 -0.742 . . . . 0.0 113.296 179.487 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 58' ' ' VAL . . . . . 0.554 HG12 ' HB ' ' A' ' 53' ' ' VAL . 0.4 OUTLIER -89.46 159.36 2.89 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.231 0 CA-C-N 116.913 0.356 . . . . 0.0 110.577 179.729 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 72.44 -12.52 3.38 Favored Glycine 0 N--CA 1.45 -0.412 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.387 -179.456 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 60' ' ' TRP . . . . . 0.443 ' HE1' ' HG3' ' A' ' 54' ' ' MET . 35.1 m0 -69.79 106.68 3.2 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-O 120.663 0.268 . . . . 0.0 110.883 -179.935 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 7.5 p -116.03 128.54 25.9 Favored Pre-proline 0 CA--C 1.533 0.312 0 CA-C-N 116.406 -0.361 . . . . 0.0 111.155 179.821 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 74.0 Cg_endo -75.72 148.48 32.62 Favored 'Trans proline' 0 C--N 1.35 0.646 0 C-N-CA 122.533 2.155 . . . . 0.0 112.441 179.923 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 96.6 t -137.76 91.53 0.79 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.005 -0.543 . . . . 0.0 111.036 -179.878 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . 59.11 -88.53 0.02 OUTLIER 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 116.03 -0.532 . . . . 0.0 111.438 179.961 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 65' ' ' GLU . . . . . 0.502 ' HB2' HH11 ' A' ' 66' ' ' ARG . 11.1 mm-40 -120.54 -18.51 7.79 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-O 120.907 0.384 . . . . 0.0 110.735 179.984 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 66' ' ' ARG . . . . . 0.502 HH11 ' HB2' ' A' ' 65' ' ' GLU . 10.5 mpt_? -102.78 162.62 12.78 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 115.938 -0.574 . . . . 0.0 110.439 179.916 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 31.6 m -123.37 139.9 53.56 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.964 0.411 . . . . 0.0 111.52 -179.654 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 18.0 m -130.3 146.12 34.56 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.375 0 CA-C-N 115.932 -0.576 . . . . 0.0 110.685 179.711 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 69' ' ' PHE . . . . . . . . . . . . . 9.9 m-85 -109.1 118.03 35.71 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-O 121.048 0.452 . . . . 0.0 110.224 -179.473 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 70' ' ' VAL . . . . . 0.605 HG11 ' HD3' ' A' ' 71' ' ' PRO . 0.5 OUTLIER -67.0 -34.44 7.33 Favored Pre-proline 0 CA--C 1.541 0.6 0 N-CA-C 112.883 0.697 . . . . 0.0 112.883 -179.295 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 71' ' ' PRO . . . . . 0.605 ' HD3' HG11 ' A' ' 70' ' ' VAL . 12.2 Cg_exo -69.63 -17.75 38.01 Favored 'Trans proline' 0 C--N 1.359 1.079 0 C-N-CA 122.259 1.973 . . . . 0.0 113.059 -179.165 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 45.3 ttp180 -74.76 -55.42 5.86 Favored 'General case' 0 C--N 1.33 -0.271 0 N-CA-C 112.276 0.473 . . . . 0.0 112.276 -178.514 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 73' ' ' TYR . . . . . 0.458 ' O ' HG13 ' A' ' 77' ' ' ILE . 24.9 m-85 -71.31 -33.55 69.79 Favored 'General case' 0 C--N 1.329 -0.325 0 C-N-CA 120.764 -0.374 . . . . 0.0 110.669 -179.418 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 0.3 OUTLIER -68.95 -39.73 80.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 N-CA-C 110.072 -0.344 . . . . 0.0 110.072 179.256 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 15.4 t70 -59.98 -37.3 79.23 Favored 'General case' 0 CA--C 1.52 -0.197 0 N-CA-C 109.423 -0.584 . . . . 0.0 109.423 179.023 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 76' ' ' TRP . . . . . 0.503 ' HB3' ' SD ' ' A' ' 109' ' ' MET . 49.2 m0 -65.29 -35.49 81.17 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 115.652 -0.703 . . . . 0.0 110.427 179.521 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 77' ' ' ILE . . . . . 0.466 ' O ' ' HG2' ' A' ' 81' ' ' PRO . 78.5 mt -68.12 -30.66 48.73 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.374 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.964 179.773 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 35.2 mt -91.81 -19.55 22.43 Favored 'General case' 0 C--N 1.327 -0.371 0 N-CA-C 112.23 0.456 . . . . 0.0 112.23 -179.76 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 79' ' ' THR . . . . . 0.482 ' HB ' ' HE3' ' A' ' 205' ' ' LYS . 79.3 p -102.35 -47.6 4.44 Favored 'General case' 0 N--CA 1.464 0.238 0 N-CA-C 113.458 0.91 . . . . 0.0 113.458 -177.932 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 80' ' ' THR . . . . . 0.635 ' HB ' ' HD3' ' A' ' 81' ' ' PRO . 80.3 m -51.28 -53.4 49.53 Favored Pre-proline 0 C--N 1.329 -0.297 0 N-CA-C 112.047 0.388 . . . . 0.0 112.047 -179.019 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 81' ' ' PRO . . . . . 0.635 ' HD3' ' HB ' ' A' ' 80' ' ' THR . 50.4 Cg_exo -55.83 -22.03 35.63 Favored 'Trans proline' 0 C--N 1.351 0.691 0 C-N-CA 121.612 1.542 . . . . 0.0 111.704 179.723 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 82' ' ' LEU . . . . . 0.477 ' HB2' ' O ' ' A' ' 79' ' ' THR . 2.8 mm? -76.77 -37.1 56.49 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 115.877 -0.601 . . . . 0.0 110.745 179.807 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 83' ' ' ILE . . . . . 0.523 HD12 HD13 ' A' ' 43' ' ' ILE . 11.9 mm -65.22 -53.76 36.78 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-O 120.857 0.36 . . . . 0.0 110.469 179.67 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 21.9 m -62.63 -31.27 51.5 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.176 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.251 179.335 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 85' ' ' TYR . . . . . . . . . . . . . 82.9 t80 -67.28 -32.44 73.44 Favored 'General case' 0 C--N 1.333 -0.135 0 CA-C-N 115.999 -0.546 . . . . 0.0 110.223 179.158 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 86' ' ' PHE . . . . . . . . . . . . . 9.2 t80 -64.72 -51.96 59.6 Favored 'General case' 0 C--N 1.331 -0.196 0 CA-C-N 116.118 -0.492 . . . . 0.0 109.839 179.37 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 9.2 mp -62.95 -30.45 71.58 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 115.806 -0.634 . . . . 0.0 110.098 179.477 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -69.25 -27.31 73.83 Favored Glycine 0 N--CA 1.448 -0.523 0 C-N-CA 120.914 -0.66 . . . . 0.0 111.546 178.943 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 58.0 mt -72.05 -46.16 58.04 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 120.974 0.416 . . . . 0.0 110.4 179.701 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 98.0 mt -59.27 -37.55 77.93 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 115.844 -0.616 . . . . 0.0 111.074 179.824 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -79.86 -32.75 40.46 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.231 -0.441 . . . . 0.0 111.4 -179.877 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 78.81 51.77 5.31 Favored Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.701 -0.761 . . . . 0.0 111.937 -179.737 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 93' ' ' LEU . . . . . 0.482 HD11 ' HE1' ' A' ' 145' ' ' MET . 35.2 mt -62.21 167.16 4.24 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.892 0.377 . . . . 0.0 111.103 -179.632 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 94' ' ' ASP . . . . . . . . . . . . . 28.6 t70 -85.47 168.96 14.07 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.618 179.839 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 75.0 m -54.34 -41.52 69.16 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.45 -0.341 . . . . 0.0 110.975 -179.989 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 34.0 ttm180 -73.89 -44.1 56.36 Favored 'General case' 0 C--N 1.331 -0.197 0 CA-C-N 116.398 -0.364 . . . . 0.0 110.94 179.732 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 97' ' ' GLU . . . . . 0.534 ' HA ' HD13 ' A' ' 100' ' ' ILE . 43.7 mt-10 -53.42 -47.08 69.92 Favored 'General case' 0 C--N 1.331 -0.197 0 CA-C-N 116.128 -0.487 . . . . 0.0 111.435 -179.484 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 98' ' ' PHE . . . . . . . . . . . . . 16.9 m-85 -58.03 -49.6 76.3 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-O 120.773 0.321 . . . . 0.0 110.7 179.64 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -58.28 -26.12 58.51 Favored Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.879 -0.677 . . . . 0.0 112.644 -179.95 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 100' ' ' ILE . . . . . 0.534 HD13 ' HA ' ' A' ' 97' ' ' GLU . 94.4 mt -71.56 -52.24 27.4 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-O 120.815 0.34 . . . . 0.0 111.638 -179.71 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 43.4 t -68.21 -37.77 78.58 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.38 0 CA-C-N 116.401 -0.363 . . . . 0.0 111.669 -179.378 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 102' ' ' ILE . . . . . . . . . . . . . 49.0 mm -68.22 -47.72 76.89 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.391 -0.368 . . . . 0.0 111.48 -179.628 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 11.1 t -62.03 -31.1 71.46 Favored 'General case' 0 C--N 1.332 -0.174 0 CA-C-O 120.804 0.335 . . . . 0.0 110.723 -179.935 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 53.3 tp -64.38 -52.98 55.53 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.701 179.556 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 105' ' ' ASN . . . . . 0.611 ' N ' HD21 ' A' ' 105' ' ' ASN . 0.8 OUTLIER -61.51 -26.19 67.76 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.079 -0.51 . . . . 0.0 110.946 179.929 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 40.3 m -65.65 -54.96 20.4 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 115.995 -0.548 . . . . 0.0 111.419 -179.66 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 11.3 p -64.7 -36.41 77.45 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.232 0 CA-C-N 116.366 -0.379 . . . . 0.0 111.215 -179.724 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 70.1 t -63.46 -49.21 83.63 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.244 0 CA-C-N 116.36 -0.382 . . . . 0.0 110.839 179.67 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 109' ' ' MET . . . . . 0.503 ' SD ' ' HB3' ' A' ' 76' ' ' TRP . 7.7 tpp -63.21 -37.41 87.13 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.749 -179.978 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 22.9 tp -65.9 -30.27 70.84 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-N 115.987 -0.552 . . . . 0.0 110.259 179.782 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -65.03 -54.77 25.12 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-N 115.939 -0.573 . . . . 0.0 110.391 179.354 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . -57.82 -39.67 91.83 Favored Glycine 0 C--N 1.333 0.382 0 C-N-CA 120.576 -0.821 . . . . 0.0 111.701 179.395 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 113' ' ' PHE . . . . . . . . . . . . . 1.3 t80 -51.33 -66.03 0.45 Allowed 'General case' 0 C--N 1.332 -0.181 0 CA-C-O 121.059 0.456 . . . . 0.0 109.934 179.255 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -59.84 -29.31 68.19 Favored 'General case' 0 C--N 1.327 -0.413 0 CA-C-N 115.501 -0.772 . . . . 0.0 111.471 179.809 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -52.4 -49.62 50.79 Favored Glycine 0 C--N 1.333 0.377 0 C-N-CA 120.901 -0.666 . . . . 0.0 112.452 179.85 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -77.88 -14.71 59.47 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-O 120.8 0.333 . . . . 0.0 111.168 179.692 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 117' ' ' MET . . . . . . . . . . . . . 24.3 mmt -93.7 15.16 17.02 Favored 'General case' 0 N--CA 1.463 0.185 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.732 -179.391 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 23.3 m -82.13 144.61 51.08 Favored Pre-proline 0 C--N 1.33 -0.267 0 CA-C-O 120.568 0.223 . . . . 0.0 111.565 -179.616 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 119' ' ' PRO . . . . . . . . . . . . . 84.9 Cg_endo -91.18 -9.0 3.15 Favored 'Trans proline' 0 N--CA 1.456 -0.684 0 C-N-CA 122.758 2.305 . . . . 0.0 112.348 179.471 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -132.5 -117.09 1.81 Allowed Glycine 0 C--N 1.332 0.312 0 C-N-CA 120.748 -0.739 . . . . 0.0 113.071 -179.649 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 41.7 pt -116.13 13.72 7.74 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.151 0 CA-C-O 120.723 0.297 . . . . 0.0 111.5 -179.552 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 44.1 mt-10 -62.59 -18.46 62.19 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 116.284 -0.416 . . . . 0.0 111.349 -179.737 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 123' ' ' ARG . . . . . . . . . . . . . 20.4 ptt180 -50.43 -39.44 47.48 Favored 'General case' 0 C--N 1.332 -0.166 0 CA-C-N 116.28 -0.418 . . . . 0.0 111.7 -179.66 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 124' ' ' TYR . . . . . . . . . . . . . 59.5 m-85 -65.87 -32.38 73.86 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-O 120.748 0.308 . . . . 0.0 110.997 -179.851 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 125' ' ' ALA . . . . . . . . . . . . . . . -70.05 -47.64 61.19 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.308 -0.406 . . . . 0.0 111.179 -179.913 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 2.6 mm? -54.16 -55.6 26.24 Favored 'General case' 0 C--O 1.233 0.209 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.904 179.924 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 127' ' ' PHE . . . . . . . . . . . . . 10.0 t80 -63.73 -36.77 84.95 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.305 -0.407 . . . . 0.0 111.033 -179.553 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 128' ' ' GLY . . . . . . . . . . . . . . . -46.81 -47.24 19.03 Favored Glycine 0 C--N 1.332 0.321 0 C-N-CA 120.019 -1.086 . . . . 0.0 111.033 179.182 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 129' ' ' MET . . . . . 0.4 ' HE2' ' N ' ' A' ' 130' ' ' GLY . 0.6 OUTLIER -66.96 -40.04 87.4 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 120.978 0.418 . . . . 0.0 109.994 178.788 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 130' ' ' GLY . . . . . 0.4 ' N ' ' HE2' ' A' ' 129' ' ' MET . . . -67.62 -22.9 73.7 Favored Glycine 0 N--CA 1.45 -0.379 0 CA-C-N 115.721 -0.672 . . . . 0.0 112.809 -179.997 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 131' ' ' ALA . . . . . 0.412 ' O ' ' HB3' ' A' ' 134' ' ' PHE . . . -74.63 -53.77 8.71 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.78 0.324 . . . . 0.0 110.423 -179.991 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 16.1 t -60.2 -40.39 83.44 Favored 'Isoleucine or valine' 0 C--O 1.236 0.36 0 N-CA-C 109.085 -0.709 . . . . 0.0 109.085 178.629 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -67.0 -34.55 77.99 Favored 'General case' 0 N--CA 1.451 -0.41 0 CA-C-N 115.125 -0.943 . . . . 0.0 110.302 179.054 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 134' ' ' PHE . . . . . 0.472 ' HB2' H182 ' A' ' 301' ' ' RET . 19.4 t80 -56.47 -52.67 63.83 Favored 'General case' 0 N--CA 1.452 -0.352 0 CA-C-N 115.939 -0.573 . . . . 0.0 109.88 179.366 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 135' ' ' ILE . . . . . 0.493 ' O ' HG23 ' A' ' 138' ' ' VAL . 57.6 mt -57.06 -34.13 44.28 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.299 0 CA-C-N 115.742 -0.663 . . . . 0.0 109.857 179.189 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 136' ' ' GLY . . . . . 0.405 ' O ' ' HB3' ' A' ' 139' ' ' TYR . . . -59.99 -34.72 84.58 Favored Glycine 0 N--CA 1.448 -0.538 0 C-N-CA 120.08 -1.057 . . . . 0.0 110.843 178.418 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 137' ' ' LEU . . . . . 0.497 HD12 HD22 ' A' ' 105' ' ' ASN . 38.6 tp -71.11 -52.14 21.05 Favored 'General case' 0 N--CA 1.455 -0.223 0 CA-C-N 115.643 -0.278 . . . . 0.0 110.554 179.399 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 138' ' ' VAL . . . . . 0.493 HG23 ' O ' ' A' ' 135' ' ' ILE . 3.1 m -55.69 -33.92 34.83 Favored 'Isoleucine or valine' 0 C--O 1.233 0.211 0 N-CA-C 109.201 -0.666 . . . . 0.0 109.201 179.063 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 139' ' ' TYR . . . . . 0.405 ' HB3' ' O ' ' A' ' 136' ' ' GLY . 32.0 t80 -57.12 -45.93 83.07 Favored 'General case' 0 C--N 1.331 -0.22 0 N-CA-C 108.848 -0.797 . . . . 0.0 108.848 177.657 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 140' ' ' TYR . . . . . 0.512 ' HB3' ' SD ' ' A' ' 145' ' ' MET . 24.1 m-85 -64.53 -36.54 84.55 Favored 'General case' 0 C--N 1.331 -0.197 0 CA-C-N 115.675 -0.693 . . . . 0.0 109.99 178.422 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 141' ' ' LEU . . . . . 0.403 ' HB2' ' HA ' ' A' ' 138' ' ' VAL . 0.4 OUTLIER -54.06 -33.61 57.88 Favored 'General case' 0 C--N 1.333 -0.144 0 CA-C-N 115.874 -0.603 . . . . 0.0 110.39 179.142 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 142' ' ' VAL . . . . . 0.561 HG23 HH12 ' A' ' 164' ' ' ARG . 2.6 t -111.09 2.28 8.91 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 115.858 -0.61 . . . . 0.0 110.703 179.642 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . -74.26 -153.05 2.92 Favored Glycine 0 CA--C 1.519 0.338 0 C-N-CA 121.042 -0.599 . . . . 0.0 113.146 -179.415 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 144' ' ' PRO . . . . . . . . . . . . . 31.2 Cg_exo -59.06 -23.6 69.56 Favored 'Trans proline' 0 C--N 1.349 0.588 0 C-N-CA 122.844 2.363 . . . . 0.0 112.768 -179.697 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 145' ' ' MET . . . . . 0.512 ' SD ' ' HB3' ' A' ' 140' ' ' TYR . 80.9 mtp -57.57 -32.81 67.5 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-O 120.89 0.376 . . . . 0.0 111.088 -179.731 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 146' ' ' THR . . . . . . . . . . . . . 36.0 m -75.35 -50.04 17.18 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.087 -0.506 . . . . 0.0 111.452 -179.733 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 43.5 mt-10 -65.68 -29.44 69.99 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.319 -0.401 . . . . 0.0 111.477 -179.615 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 148' ' ' SER . . . . . . . . . . . . . 80.1 p -70.36 -50.04 43.0 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.365 -0.38 . . . . 0.0 110.795 -179.515 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 149' ' ' ALA . . . . . . . . . . . . . . . -69.46 -32.7 71.79 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.4 -179.982 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 150' ' ' SER . . . . . 0.51 ' HA ' ' HB3' ' A' ' 157' ' ' LYS . 90.8 p -68.56 -15.98 63.71 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.361 -179.529 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 151' ' ' GLN . . . . . . . . . . . . . 46.7 mt-30 -113.55 3.55 15.77 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.59 -0.277 . . . . 0.0 111.336 -179.779 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 21.2 tpp180 -75.23 -51.79 12.46 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-O 120.987 0.422 . . . . 0.0 110.536 179.924 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 153' ' ' SER . . . . . 0.625 ' HB3' HG12 ' A' ' 156' ' ' ILE . 8.7 t -157.77 172.48 18.41 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 115.794 -0.639 . . . . 0.0 110.306 179.025 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 154' ' ' SER . . . . . . . . . . . . . 48.7 m -70.01 -40.97 74.91 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.872 0.367 . . . . 0.0 110.846 179.794 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 155' ' ' GLY . . . . . 0.472 ' HA3' HD23 ' A' ' 219' ' ' LEU . . . -77.44 -34.48 40.15 Favored Glycine 0 N--CA 1.45 -0.389 0 C-N-CA 120.89 -0.671 . . . . 0.0 113.03 -179.962 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 156' ' ' ILE . . . . . 0.625 HG12 ' HB3' ' A' ' 153' ' ' SER . 39.5 mm -54.93 -46.42 76.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 N-CA-C 112.147 0.425 . . . . 0.0 112.147 -179.237 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 157' ' ' LYS . . . . . 0.51 ' HB3' ' HA ' ' A' ' 150' ' ' SER . 21.7 pttp -60.62 -39.73 89.28 Favored 'General case' 0 C--N 1.328 -0.34 0 N-CA-C 111.727 0.269 . . . . 0.0 111.727 -179.133 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 59.4 m -65.76 -48.18 72.73 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-O 120.724 0.297 . . . . 0.0 111.76 -179.387 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 159' ' ' LEU . . . . . 0.637 HD11 ' HB3' ' A' ' 215' ' ' ALA . 45.9 tp -68.08 -31.24 70.73 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.382 -0.372 . . . . 0.0 111.197 -179.714 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 160' ' ' TYR . . . . . . . . . . . . . 45.1 t80 -74.15 -47.05 38.45 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.186 -0.461 . . . . 0.0 112.028 -178.988 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 161' ' ' VAL . . . . . 0.407 HG23 ' O ' ' A' ' 157' ' ' LYS . 23.7 m -61.51 -47.34 93.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 N-CA-C 112.149 0.426 . . . . 0.0 112.149 -178.841 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 162' ' ' ARG . . . . . . . . . . . . . 27.1 tpt180 -63.24 -49.2 75.08 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.791 0.329 . . . . 0.0 111.423 -179.369 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 163' ' ' LEU . . . . . . . . . . . . . 6.9 mp -64.73 -53.61 44.53 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.922 -179.266 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 164' ' ' ARG . . . . . 0.561 HH12 HG23 ' A' ' 142' ' ' VAL . 0.9 OUTLIER -59.37 -41.32 89.05 Favored 'General case' 0 CA--C 1.53 0.199 0 CA-C-N 116.373 -0.376 . . . . 0.0 111.99 -178.554 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 165' ' ' ASN . . . . . 0.411 ' N ' ' HG3' ' A' ' 164' ' ' ARG . 0.9 OUTLIER -57.25 -51.84 67.74 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-O 120.887 0.375 . . . . 0.0 110.744 179.921 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 166' ' ' LEU . . . . . 0.481 ' O ' ' HG ' ' A' ' 170' ' ' LEU . 3.9 tt -64.25 -43.15 95.76 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-N 115.954 -0.566 . . . . 0.0 111.639 -179.377 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 167' ' ' THR . . . . . 0.479 ' HA ' HD12 ' A' ' 170' ' ' LEU . 49.2 m -56.03 -53.74 53.35 Favored 'General case' 0 C--N 1.329 -0.296 0 N-CA-C 112.629 0.603 . . . . 0.0 112.629 -178.576 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 168' ' ' VAL . . . . . . . . . . . . . 9.7 p -61.99 -39.57 84.15 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 N-CA-C 111.956 0.354 . . . . 0.0 111.956 -179.455 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 169' ' ' VAL . . . . . 0.407 HG21 ' O ' ' A' ' 165' ' ' ASN . 46.8 t -55.78 -65.27 0.39 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 N-CA-C 112.558 0.577 . . . . 0.0 112.558 -179.174 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 170' ' ' LEU . . . . . 0.481 ' HG ' ' O ' ' A' ' 166' ' ' LEU . 0.3 OUTLIER -66.71 -24.45 66.25 Favored 'General case' 0 N--CA 1.464 0.229 0 N-CA-C 111.855 0.317 . . . . 0.0 111.855 -178.745 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 171' ' ' TRP . . . . . 0.446 ' HZ3' HD21 ' A' ' 137' ' ' LEU . 9.8 m0 -73.49 -29.27 62.4 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.999 0.428 . . . . 0.0 109.847 179.245 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 172' ' ' ALA . . . . . 0.469 ' HA ' ' CZ ' ' A' ' 134' ' ' PHE . . . -74.7 -8.5 56.58 Favored 'General case' 0 N--CA 1.451 -0.382 0 CA-C-N 115.827 -0.624 . . . . 0.0 110.065 179.232 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 173' ' ' ILE . . . . . 0.62 HG22 HD12 ' A' ' 177' ' ' ILE . 44.5 mm -89.06 -22.8 6.45 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.256 0 CA-C-N 115.516 -0.765 . . . . 0.0 110.405 178.936 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 174' ' ' TYR . . . . . 0.601 ' N ' ' HD2' ' A' ' 175' ' ' PRO . 12.1 m-85 -54.87 -50.26 87.13 Favored Pre-proline 0 N--CA 1.463 0.199 0 CA-C-N 116.047 -0.524 . . . . 0.0 111.831 -179.893 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 175' ' ' PRO . . . . . 0.601 ' HD2' ' N ' ' A' ' 174' ' ' TYR . 2.0 Cg_endo -45.56 -29.31 4.98 Favored 'Trans proline' 0 C--N 1.353 0.791 0 C-N-CA 122.359 2.039 . . . . 0.0 111.768 179.275 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 176' ' ' PHE . . . . . 0.429 ' O ' ' HG ' ' A' ' 180' ' ' LEU . 99.6 m-85 -79.98 -45.7 17.98 Favored 'General case' 0 CA--C 1.516 -0.335 0 CA-C-N 115.921 -0.582 . . . . 0.0 111.078 179.396 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 177' ' ' ILE . . . . . 0.62 HD12 HG22 ' A' ' 173' ' ' ILE . 3.1 mm -58.09 -44.75 87.95 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.613 0 CA-C-N 115.787 -0.642 . . . . 0.0 112.093 -178.491 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 178' ' ' TRP . . . . . 0.41 ' HA ' ' HG2' ' A' ' 182' ' ' PRO . 72.0 t90 -69.04 -38.55 79.2 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-O 121.088 0.471 . . . . 0.0 110.64 179.951 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 179' ' ' LEU . . . . . 0.441 ' O ' HG21 ' A' ' 185' ' ' VAL . 0.4 OUTLIER -66.44 -53.64 33.2 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-N 115.557 -0.747 . . . . 0.0 111.168 -179.273 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 180' ' ' LEU . . . . . 0.513 HD12 HD11 ' A' ' 187' ' ' LEU . 8.3 mt -77.75 -52.03 9.59 Favored 'General case' 0 C--N 1.328 -0.366 0 N-CA-C 112.307 0.484 . . . . 0.0 112.307 -178.674 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 181' ' ' GLY . . . . . 0.405 ' HA3' ' OD1' ' A' ' 193' ' ' ASP . . . -58.34 -85.25 0.04 OUTLIER Glycine 0 C--N 1.336 0.552 0 C-N-CA 120.447 -0.882 . . . . 0.0 112.797 -179.739 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 182' ' ' PRO . . . . . 0.496 ' C ' ' H ' ' A' ' 184' ' ' GLY . 89.2 Cg_exo -46.1 178.55 0.0 OUTLIER 'Trans proline' 0 C--N 1.349 0.599 0 C-N-CA 123.388 2.725 . . . . 0.0 112.954 179.088 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 183' ' ' PRO . . . . . . . . . . . . . 51.5 Cg_exo -56.82 12.25 0.03 OUTLIER 'Trans proline' 0 C--N 1.351 0.667 0 C-N-CA 122.862 2.375 . . . . 0.0 114.696 -179.558 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 184' ' ' GLY . . . . . 0.496 ' H ' ' C ' ' A' ' 182' ' ' PRO . . . -54.17 -65.08 3.72 Favored Glycine 0 C--N 1.335 0.484 0 C-N-CA 119.84 -1.172 . . . . 0.0 111.06 179.149 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 185' ' ' VAL . . . . . 0.441 HG21 ' O ' ' A' ' 179' ' ' LEU . 3.4 m -135.52 -3.27 1.01 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.368 0 N-CA-C 111.574 0.213 . . . . 0.0 111.574 178.813 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 186' ' ' ALA . . . . . . . . . . . . . . . 45.5 76.49 0.09 Allowed 'General case' 0 N--CA 1.463 0.198 0 N-CA-C 112.316 0.487 . . . . 0.0 112.316 179.324 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 187' ' ' LEU . . . . . 0.513 HD11 HD12 ' A' ' 180' ' ' LEU . 4.2 mt -92.49 -49.31 6.19 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.463 -0.335 . . . . 0.0 111.267 179.683 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 188' ' ' LEU . . . . . . . . . . . . . 92.3 mt -115.48 -168.59 1.43 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 121.087 0.47 . . . . 0.0 111.586 -179.502 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 189' ' ' THR . . . . . 0.432 HG22 ' HD2' ' A' ' 190' ' ' PRO . 96.7 m -76.96 135.28 67.36 Favored Pre-proline 0 C--N 1.329 -0.318 0 CA-C-N 115.667 -0.697 . . . . 0.0 111.039 -179.681 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 190' ' ' PRO . . . . . 0.432 ' HD2' HG22 ' A' ' 189' ' ' THR . 10.2 Cg_endo -50.29 -41.7 49.85 Favored 'Trans proline' 0 C--N 1.35 0.609 0 C-N-CA 122.684 2.256 . . . . 0.0 112.185 -179.967 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 191' ' ' THR . . . . . . . . . . . . . 41.5 p -57.2 -46.49 82.82 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.763 179.525 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 192' ' ' VAL . . . . . . . . . . . . . 60.3 t -59.13 -39.75 79.3 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.725 179.584 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 193' ' ' ASP . . . . . 0.405 ' OD1' ' HA3' ' A' ' 181' ' ' GLY . 7.9 t70 -57.72 -41.89 82.72 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 115.932 -0.576 . . . . 0.0 110.646 179.672 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 194' ' ' VAL . . . . . . . . . . . . . 52.5 t -64.71 -36.06 76.53 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 115.984 -0.553 . . . . 0.0 110.918 179.814 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 195' ' ' ALA . . . . . . . . . . . . . . . -59.4 -47.62 84.75 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.451 -0.341 . . . . 0.0 111.017 179.93 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 196' ' ' LEU . . . . . . . . . . . . . 95.9 mt -67.84 -43.13 80.22 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 120.793 0.33 . . . . 0.0 110.525 179.648 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 197' ' ' ILE . . . . . . . . . . . . . 15.5 mm -57.03 -58.89 4.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.012 -0.54 . . . . 0.0 110.296 179.381 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 198' ' ' VAL . . . . . . . . . . . . . 75.2 t -52.74 -34.71 20.25 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.439 0 CA-C-N 115.773 -0.648 . . . . 0.0 109.38 178.429 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 199' ' ' TYR . . . . . . . . . . . . . 46.0 t80 -70.25 -31.44 68.83 Favored 'General case' 0 C--N 1.331 -0.205 0 CA-C-N 115.587 -0.733 . . . . 0.0 110.421 179.678 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 200' ' ' LEU . . . . . . . . . . . . . 54.4 mt -74.07 -38.45 63.92 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 115.756 -0.656 . . . . 0.0 111.365 -179.722 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 201' ' ' ASP . . . . . 0.528 ' HB2' ' HH ' ' A' ' 51' ' ' TYR . 0.9 OUTLIER -71.44 -35.1 70.79 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 121.15 0.5 . . . . 0.0 110.121 179.483 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 202' ' ' LEU . . . . . 0.497 HD23 ' HA3' ' A' ' 14' ' ' GLY . 4.3 mt -67.21 -41.9 85.01 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 115.43 -0.805 . . . . 0.0 111.721 179.596 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 203' ' ' VAL . . . . . 0.446 ' O ' ' HA3' ' A' ' 207' ' ' GLY . 7.4 p -70.19 -36.82 69.42 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-N 116.376 -0.375 . . . . 0.0 111.946 -178.479 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 204' ' ' THR . . . . . . . . . . . . . 95.1 m -68.9 -57.46 5.5 Favored 'General case' 0 C--N 1.328 -0.353 0 C-N-CA 120.308 -0.557 . . . . 0.0 111.252 179.83 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 205' ' ' LYS . . . . . 0.555 ' HE2' ' HB3' ' A' ' 47' ' ' ALA . 41.7 mttp -67.0 -59.35 3.55 Favored 'General case' 0 C--N 1.328 -0.345 0 N-CA-C 112.714 0.635 . . . . 0.0 112.714 -178.311 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 25.5 t -73.87 -37.3 47.87 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.415 0 N-CA-C 112.184 0.438 . . . . 0.0 112.184 -178.29 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 207' ' ' GLY . . . . . 0.446 ' HA3' ' O ' ' A' ' 203' ' ' VAL . . . -66.89 -57.97 8.94 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.361 -0.923 . . . . 0.0 112.434 -179.309 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 208' ' ' PHE . . . . . 0.437 ' HE1' HD12 ' A' ' 40' ' ' LEU . 0.0 OUTLIER -62.6 -29.24 70.46 Favored 'General case' 0 C--N 1.329 -0.316 0 N-CA-C 110.439 -0.208 . . . . 0.0 110.439 -179.957 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 209' ' ' GLY . . . . . 0.486 ' O ' ' HB3' ' A' ' 212' ' ' ALA . . . -70.78 -36.13 66.32 Favored Glycine 0 N--CA 1.447 -0.574 0 N-CA-C 111.137 -0.785 . . . . 0.0 111.137 178.112 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 210' ' ' PHE . . . . . . . . . . . . . 1.0 OUTLIER -70.13 -43.09 71.65 Favored 'General case' 0 CA--C 1.512 -0.519 0 N-CA-C 107.508 -1.293 . . . . 0.0 107.508 178.37 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 211' ' ' ILE . . . . . . . . . . . . . 36.6 mt -67.41 -28.45 42.25 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.728 0 N-CA-C 107.277 -1.379 . . . . 0.0 107.277 176.502 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 212' ' ' ALA . . . . . 0.486 ' HB3' ' O ' ' A' ' 209' ' ' GLY . . . -66.88 -36.42 82.26 Favored 'General case' 0 N--CA 1.448 -0.549 0 CA-C-N 114.516 -1.22 . . . . 0.0 110.141 179.646 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 213' ' ' LEU . . . . . 0.401 ' HG ' ' O ' ' A' ' 209' ' ' GLY . 92.8 mt -70.31 -52.64 21.27 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 115.086 -0.961 . . . . 0.0 111.872 -179.678 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 214' ' ' ASP . . . . . . . . . . . . . 44.7 m-20 -53.21 -50.71 64.14 Favored 'General case' 0 C--N 1.331 -0.204 0 CA-C-N 116.292 -0.413 . . . . 0.0 111.837 -178.974 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 215' ' ' ALA . . . . . 0.637 ' HB3' HD11 ' A' ' 159' ' ' LEU . . . -65.48 -57.63 7.79 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.558 -0.292 . . . . 0.0 111.726 -179.243 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 216' ' ' ALA . . . . . . . . . . . . . . . -52.12 -43.38 63.94 Favored 'General case' 0 C--N 1.332 -0.184 0 CA-C-O 120.799 0.333 . . . . 0.0 111.497 -179.488 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 217' ' ' ALA . . . . . . . . . . . . . . . -59.05 -42.11 89.49 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.098 179.69 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 218' ' ' THR . . . . . 0.489 ' HA ' ' HB1' ' A' ' 221' ' ' ALA . 78.4 m -65.78 -35.68 81.4 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 115.584 -0.734 . . . . 0.0 110.983 179.715 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 219' ' ' LEU . . . . . 0.5 ' O ' ' HG2' ' A' ' 222' ' ' GLU . 74.3 mt -57.74 -46.15 84.87 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-O 120.936 0.398 . . . . 0.0 110.246 179.822 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 220' ' ' ARG . . . . . 0.436 HH11 ' HB2' ' A' ' 219' ' ' LEU . 10.4 mpt_? -84.63 -14.13 49.54 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 115.961 -0.563 . . . . 0.0 110.798 179.178 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 221' ' ' ALA . . . . . 0.489 ' HB1' ' HA ' ' A' ' 218' ' ' THR . . . -80.4 -19.74 45.57 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 116.169 -0.469 . . . . 0.0 112.206 -179.581 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 222' ' ' GLU . . . . . 0.5 ' HG2' ' O ' ' A' ' 219' ' ' LEU . 12.9 pt-20 -81.79 -7.73 59.63 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-O 120.771 0.32 . . . . 0.0 111.052 -179.437 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 223' ' ' HIS . . . . . . . . . . . . . 23.0 p80 -146.61 -164.32 1.95 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.267 -0.424 . . . . 0.0 111.092 -179.865 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 224' ' ' GLY . . . . . . . . . . . . . . . 163.48 -35.03 0.3 Allowed Glycine 0 N--CA 1.452 -0.262 0 C-N-CA 120.978 -0.63 . . . . 0.0 112.312 -179.843 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 225' ' ' GLU . . . . . 0.533 ' HG2' ' H ' ' A' ' 227' ' ' LEU . 44.1 tt0 -118.24 131.65 56.35 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.722 0.296 . . . . 0.0 110.608 179.787 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 226' ' ' SER . . . . . . . . . . . . . 54.3 m -94.19 -3.35 51.01 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.263 -0.426 . . . . 0.0 111.231 -179.606 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 227' ' ' LEU . . . . . 0.533 ' H ' ' HG2' ' A' ' 225' ' ' GLU . 4.0 tt -86.53 125.65 33.91 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.351 -0.386 . . . . 0.0 110.814 -179.741 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 228' ' ' ALA . . . . . . . . . . . . . . . -144.46 118.74 9.56 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.198 -0.456 . . . . 0.0 111.08 179.791 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 229' ' ' GLY . . . . . . . . . . . . . . . 173.37 48.57 0.05 OUTLIER Glycine 0 CA--C 1.518 0.257 0 C-N-CA 120.806 -0.711 . . . . 0.0 112.512 179.94 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 230' ' ' VAL . . . . . . . . . . . . . 30.4 m -112.52 158.36 12.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-O 120.809 0.338 . . . . 0.0 111.381 -179.996 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 231' ' ' ASP . . . . . . . . . . . . . 24.5 t70 -134.67 99.28 4.29 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.086 -0.507 . . . . 0.0 110.704 179.739 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 232' ' ' THR . . . . . . . . . . . . . 67.8 p -122.11 -20.94 6.09 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.185 -0.462 . . . . 0.0 111.184 -179.755 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 233' ' ' ASP . . . . . . . . . . . . . 10.3 m-20 -64.02 -22.21 66.83 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.9 179.987 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 234' ' ' THR . . . . . . . . . . . . . 49.4 p -134.88 91.1 20.69 Favored Pre-proline 0 C--N 1.329 -0.319 0 CA-C-N 116.123 -0.49 . . . . 0.0 111.047 179.904 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 235' ' ' PRO . . . . . . . . . . . . . 78.1 Cg_exo -52.59 138.37 58.18 Favored 'Trans proline' 0 C--N 1.347 0.491 0 C-N-CA 122.543 2.162 . . . . 0.0 112.453 179.982 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 236' ' ' ALA . . . . . . . . . . . . . . . 61.0 173.74 0.1 Allowed 'General case' 0 C--N 1.331 -0.2 0 CA-C-N 115.985 -0.552 . . . . 0.0 111.311 179.908 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 237' ' ' VAL . . . . . . . . . . . . . 26.0 m -92.78 140.38 16.38 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.379 0 CA-C-N 116.055 -0.521 . . . . 0.0 111.329 -179.828 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 238' ' ' ALA . . . . . . . . . . . . . . . -161.67 -62.39 0.05 Allowed 'General case' 0 C--N 1.331 -0.216 0 CA-C-N 115.929 -0.578 . . . . 0.0 110.942 -179.96 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 239' ' ' ASP . . . . . . . . . . . . . 7.2 m-20 -97.62 107.36 19.84 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.255 -0.429 . . . . 0.0 110.994 179.86 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 240' ' ' LEU . . . . . . . . . . . . . 90.4 mt -116.56 107.33 14.59 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.96 179.937 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 241' ' ' GLU . . . . . . . . . . . . . 44.3 mt-10 57.28 -171.0 0.09 Allowed 'General case' 0 C--N 1.332 -0.169 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.109 -179.95 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 242' ' ' HIS . . . . . . . . . . . . . 32.0 p80 -88.34 175.35 7.68 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.839 179.841 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 243' ' ' HIS . . . . . . . . . . . . . 35.7 t-80 -70.45 123.52 21.98 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.312 -0.404 . . . . 0.0 111.115 -179.784 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 244' ' ' HIS . . . . . . . . . . . . . 52.8 t-80 -173.97 114.61 0.21 Allowed 'General case' 0 C--N 1.332 -0.186 0 CA-C-N 116.059 -0.519 . . . . 0.0 110.976 179.946 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 245' ' ' HIS . . . . . . . . . . . . . 10.9 p-80 -70.9 164.76 24.72 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.397 -0.365 . . . . 0.0 110.714 179.748 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 246' ' ' HIS . . . . . . . . . . . . . 66.1 m80 -128.0 -26.84 2.83 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.38 -0.373 . . . . 0.0 111.197 -179.772 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 247' ' ' HIS . . . . . . . . . . . . . 40.4 t-80 . . . . . 0 C--O 1.249 1.045 0 CA-C-O 118.25 -0.881 . . . . 0.0 110.686 -179.993 . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 301' ' ' RET . . . . . 0.472 H182 ' HB2' ' A' ' 134' ' ' PHE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 1' ' ' MET . . . . . 0.521 ' H3 ' ' HB3' ' A' ' 4' ' ' LEU . 71.7 mtm . . . . . 0 N--CA 1.485 1.303 0 CA-C-O 120.901 0.381 . . . . 0.0 110.994 . . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 34.5 m -74.83 -23.49 17.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.062 -0.517 . . . . 0.0 111.185 -179.957 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -111.5 -15.91 9.94 Favored Glycine 0 N--CA 1.452 -0.277 0 C-N-CA 120.793 -0.718 . . . . 0.0 112.692 -179.857 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 4' ' ' LEU . . . . . 0.521 ' HB3' ' H3 ' ' A' ' 1' ' ' MET . 56.2 tp -73.96 -35.82 64.56 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.817 0.341 . . . . 0.0 111.121 -179.913 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 60.7 p -68.08 -31.69 71.5 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.501 -179.59 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 21.3 p -52.31 -35.32 50.24 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.257 -0.429 . . . . 0.0 111.384 -179.772 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 7' ' ' LEU . . . . . . . . . . . . . 4.1 mm? -57.87 -53.75 54.74 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.26 -0.427 . . . . 0.0 111.364 -179.731 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 8' ' ' PHE . . . . . 0.536 ' HB2' ' HB3' ' A' ' 55' ' ' ALA . 63.4 m-85 -62.32 -33.29 74.39 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.31 -0.405 . . . . 0.0 110.763 -179.81 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 9' ' ' TRP . . . . . 0.457 ' O ' HG13 ' A' ' 13' ' ' ILE . 55.1 m95 -65.97 -40.83 91.59 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 116.029 -0.532 . . . . 0.0 110.101 -179.988 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 63.9 mt -66.48 -39.61 88.88 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 115.854 -0.612 . . . . 0.0 110.136 179.387 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -68.32 -28.8 73.11 Favored Glycine 0 N--CA 1.446 -0.665 0 C-N-CA 120.804 -0.712 . . . . 0.0 111.796 179.357 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -71.99 -33.87 68.46 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 120.786 0.327 . . . . 0.0 110.578 179.52 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 13' ' ' ILE . . . . . 0.457 HG13 ' O ' ' A' ' 9' ' ' TRP . 75.0 mt -64.95 -54.08 33.95 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.173 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.248 179.172 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -61.17 -39.05 96.61 Favored Glycine 0 N--CA 1.45 -0.42 0 C-N-CA 120.5 -0.857 . . . . 0.0 111.55 179.4 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 15' ' ' MET . . . . . 0.524 ' HE2' ' HD2' ' A' ' 205' ' ' LYS . 60.3 tpp -61.56 -41.44 97.37 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 120.868 0.366 . . . . 0.0 110.014 179.366 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 6.3 tt -57.53 -38.88 75.43 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 115.888 -0.596 . . . . 0.0 109.911 179.334 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 34.6 t -59.38 -46.65 92.44 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.221 0 CA-C-N 115.946 -0.57 . . . . 0.0 110.162 179.19 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -62.91 -41.96 99.77 Favored Glycine 0 N--CA 1.45 -0.375 0 C-N-CA 120.616 -0.802 . . . . 0.0 111.66 178.981 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 9.7 m -50.3 -49.19 54.36 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.698 0.285 . . . . 0.0 111.354 -179.942 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 87.5 mt -71.87 -42.09 67.25 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.694 -179.594 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -58.43 -33.42 69.67 Favored 'General case' 0 C--N 1.33 -0.265 0 N-CA-C 112.155 0.428 . . . . 0.0 112.155 -179.135 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 22' ' ' PHE . . . . . 0.418 ' HB2' HG21 ' A' ' 41' ' ' VAL . 6.8 m-85 -91.46 -37.09 13.39 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.851 0.358 . . . . 0.0 111.535 -179.526 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -64.7 -51.31 63.14 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.912 -179.231 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 24' ' ' TRP . . . . . . . . . . . . . 7.1 t-105 -63.42 -49.45 73.68 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-N 115.754 -0.657 . . . . 0.0 111.312 -179.295 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -64.63 -23.02 67.13 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 120.879 0.371 . . . . 0.0 110.793 179.906 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -73.07 -40.06 51.99 Favored Glycine 0 N--CA 1.45 -0.423 0 C-N-CA 120.807 -0.711 . . . . 0.0 112.263 179.655 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 97.9 mtt180 -71.56 -19.3 62.17 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 120.839 0.352 . . . . 0.0 110.814 179.797 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 19.2 t70 -93.08 -9.93 37.88 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.541 179.843 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -73.29 -169.52 0.65 Allowed 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 115.998 -0.546 . . . . 0.0 111.37 -179.904 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -84.31 -129.56 1.84 Allowed Glycine 0 N--CA 1.452 -0.276 0 C-N-CA 120.818 -0.706 . . . . 0.0 112.642 -179.828 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 44.0 t -125.81 -42.92 1.88 Allowed 'General case' 0 C--N 1.332 -0.191 0 CA-C-O 120.83 0.347 . . . . 0.0 111.099 -179.966 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -73.53 -45.17 30.3 Favored Glycine 0 C--N 1.332 0.316 0 C-N-CA 120.702 -0.761 . . . . 0.0 112.432 -179.998 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 7.8 mm-40 -69.35 -20.47 63.85 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-O 120.759 0.314 . . . . 0.0 110.762 179.88 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 34' ' ' ARG . . . . . . . . . . . . . 75.0 ttt180 -48.67 -29.68 4.65 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 115.972 -0.558 . . . . 0.0 111.615 -179.688 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 37.4 ttm180 -58.34 -46.53 86.06 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-O 120.818 0.342 . . . . 0.0 111.046 -179.986 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 68.1 m-85 -69.51 -29.73 67.41 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.081 -0.508 . . . . 0.0 111.388 -179.678 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 37' ' ' TYR . . . . . . . . . . . . . 63.2 m-85 -73.96 -56.1 5.35 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.413 -179.478 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 60.3 t -57.09 -38.64 61.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-O 120.984 0.421 . . . . 0.0 110.682 179.891 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 48.9 m -62.31 -49.05 77.18 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 115.858 -0.61 . . . . 0.0 110.447 179.243 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 40' ' ' LEU . . . . . 0.472 HD11 HD12 ' A' ' 43' ' ' ILE . 46.4 tp -55.56 -45.57 77.26 Favored 'General case' 0 C--O 1.236 0.346 0 CA-C-N 115.612 -0.722 . . . . 0.0 110.233 179.495 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . 0.418 HG21 ' HB2' ' A' ' 22' ' ' PHE . 60.1 t -63.17 -34.31 66.09 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.345 0 CA-C-N 115.645 -0.707 . . . . 0.0 110.172 179.283 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -59.49 -35.19 84.46 Favored Glycine 0 N--CA 1.449 -0.44 0 C-N-CA 120.69 -0.767 . . . . 0.0 111.538 179.554 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 43' ' ' ILE . . . . . 0.51 HG21 ' HE3' ' A' ' 205' ' ' LYS . 1.0 OUTLIER -68.91 -54.71 18.9 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.229 0 CA-C-O 120.797 0.332 . . . . 0.0 110.591 179.331 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 44' ' ' SER . . . . . 0.462 ' HA ' ' SD ' ' A' ' 15' ' ' MET . 32.3 t -58.74 -24.95 62.46 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.306 -179.943 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -76.16 -55.35 4.81 Favored Glycine 0 N--CA 1.45 -0.405 0 C-N-CA 120.683 -0.77 . . . . 0.0 112.747 -179.791 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 20.3 pt -59.78 -36.81 68.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-O 120.745 0.307 . . . . 0.0 111.421 -179.793 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 47' ' ' ALA . . . . . 0.638 ' HB1' ' HE2' ' A' ' 205' ' ' LYS . . . -67.89 -44.51 76.84 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-N 116.395 -0.366 . . . . 0.0 111.243 179.708 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -54.46 -48.0 72.28 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 115.918 -0.583 . . . . 0.0 111.672 -179.398 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 49' ' ' VAL . . . . . 0.417 ' O ' HG13 ' A' ' 53' ' ' VAL . 18.0 m -68.33 -33.92 63.15 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-N 116.255 -0.429 . . . . 0.0 111.371 -179.481 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -66.06 -37.5 85.99 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 120.864 0.364 . . . . 0.0 111.275 179.97 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 51' ' ' TYR . . . . . 0.43 ' OH ' ' HB2' ' A' ' 201' ' ' ASP . 29.5 m-85 -70.82 -44.0 67.45 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.458 -179.829 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -61.14 -51.92 67.06 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-N 115.53 -0.759 . . . . 0.0 111.251 179.814 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 53' ' ' VAL . . . . . 0.417 HG13 ' O ' ' A' ' 49' ' ' VAL . 33.0 m -60.88 -50.95 78.43 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.2 0 CA-C-N 116.455 -0.338 . . . . 0.0 110.869 -179.976 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 54' ' ' MET . . . . . 0.524 ' HG3' ' HE1' ' A' ' 60' ' ' TRP . 8.8 ttp -60.34 -29.2 68.74 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 121.082 0.468 . . . . 0.0 109.792 179.499 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 55' ' ' ALA . . . . . 0.536 ' HB3' ' HB2' ' A' ' 8' ' ' PHE . . . -73.17 -30.6 63.68 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 115.71 -0.677 . . . . 0.0 110.843 179.043 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 87.4 mt -78.25 0.4 25.38 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.058 -179.865 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 92.0 -22.15 33.17 Favored Glycine 0 N--CA 1.45 -0.397 0 C-N-CA 120.63 -0.795 . . . . 0.0 113.127 179.776 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 12.5 p -67.79 142.8 16.01 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.176 0 CA-C-O 120.885 0.374 . . . . 0.0 110.77 -179.966 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 97.72 -11.66 64.55 Favored Glycine 0 N--CA 1.452 -0.287 0 C-N-CA 120.88 -0.676 . . . . 0.0 112.105 -179.329 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 60' ' ' TRP . . . . . 0.524 ' HE1' ' HG3' ' A' ' 54' ' ' MET . 28.6 m0 -78.49 115.09 17.96 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.685 0.279 . . . . 0.0 110.504 179.869 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 10.7 p -118.02 125.29 28.06 Favored Pre-proline 0 CA--C 1.532 0.287 0 CA-C-N 116.518 -0.31 . . . . 0.0 111.518 -179.838 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 17.1 Cg_exo -67.75 155.53 69.58 Favored 'Trans proline' 0 C--N 1.351 0.678 0 C-N-CA 122.553 2.168 . . . . 0.0 111.965 179.652 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 93.2 t -143.09 92.15 0.47 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-N 115.989 -0.55 . . . . 0.0 111.041 179.995 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . 58.41 -85.78 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.039 -0.528 . . . . 0.0 111.63 179.801 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 37.7 mt-10 -119.72 -22.57 6.81 Favored 'General case' 0 C--N 1.332 -0.192 0 CA-C-N 116.42 -0.355 . . . . 0.0 111.141 -179.659 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 66' ' ' ARG . . . . . . . . . . . . . 32.3 mmt180 -105.94 158.06 17.05 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.683 -179.872 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 92.9 m -111.68 131.11 55.52 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.905 0.384 . . . . 0.0 111.492 -179.635 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 68' ' ' VAL . . . . . 0.414 HG21 ' HB1' ' A' ' 116' ' ' ALA . 61.8 t -113.8 146.46 18.35 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 115.899 -0.591 . . . . 0.0 110.534 179.343 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 69' ' ' PHE . . . . . . . . . . . . . 44.6 m-85 -108.89 111.97 23.96 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-N 116.174 -0.467 . . . . 0.0 110.141 -179.447 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 70' ' ' VAL . . . . . 0.621 ' N ' ' HD2' ' A' ' 71' ' ' PRO . 21.8 t -69.2 -49.62 23.48 Favored Pre-proline 0 C--N 1.324 -0.535 0 CA-C-N 116.219 -0.446 . . . . 0.0 112.202 -179.252 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 71' ' ' PRO . . . . . 0.621 ' HD2' ' N ' ' A' ' 70' ' ' VAL . 6.3 Cg_endo -48.45 -26.27 8.55 Favored 'Trans proline' 0 C--N 1.353 0.779 0 C-N-CA 122.422 2.081 . . . . 0.0 112.63 -179.524 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 55.5 ttp180 -75.23 -53.79 8.21 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-O 120.922 0.392 . . . . 0.0 111.123 -179.934 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 73' ' ' TYR . . . . . . . . . . . . . 67.4 m-85 -65.27 -47.97 74.82 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.094 -0.503 . . . . 0.0 111.3 -179.574 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 0.3 OUTLIER -59.35 -41.45 84.33 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-N 116.499 -0.319 . . . . 0.0 110.557 179.884 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 31.7 t70 -59.23 -36.53 75.61 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-O 121.023 0.44 . . . . 0.0 109.916 179.283 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 76' ' ' TRP . . . . . . . . . . . . . 47.4 m0 -66.97 -31.27 71.72 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 115.786 -0.643 . . . . 0.0 110.627 179.798 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 77' ' ' ILE . . . . . 0.461 HG12 ' HB3' ' A' ' 109' ' ' MET . 51.0 mt -73.22 -28.87 26.75 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.614 179.479 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 43.7 mt -91.75 -20.35 21.63 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.985 179.872 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 71.0 p -101.63 -52.67 3.15 Favored 'General case' 0 C--N 1.332 -0.176 0 N-CA-C 113.432 0.901 . . . . 0.0 113.432 -177.817 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 80' ' ' THR . . . . . 0.659 ' HB ' ' HD3' ' A' ' 81' ' ' PRO . 26.9 m -51.24 -55.17 30.86 Favored Pre-proline 0 C--N 1.33 -0.242 0 N-CA-C 112.327 0.491 . . . . 0.0 112.327 -178.258 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 81' ' ' PRO . . . . . 0.659 ' HD3' ' HB ' ' A' ' 80' ' ' THR . 36.0 Cg_exo -60.86 -20.41 66.41 Favored 'Trans proline' 0 C--N 1.352 0.752 0 C-N-CA 121.613 1.542 . . . . 0.0 111.459 179.74 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 82' ' ' LEU . . . . . . . . . . . . . 14.7 tp -76.79 -33.77 58.01 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 115.823 -0.626 . . . . 0.0 110.258 179.599 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 83' ' ' ILE . . . . . 0.509 HD11 HD11 ' A' ' 43' ' ' ILE . 42.2 mm -70.01 -52.54 29.83 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.149 0 CA-C-N 116.087 -0.506 . . . . 0.0 110.296 179.096 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 29.8 m -59.51 -31.79 47.5 Favored 'Isoleucine or valine' 0 CA--C 1.52 -0.193 0 N-CA-C 109.736 -0.468 . . . . 0.0 109.736 178.693 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 85' ' ' TYR . . . . . . . . . . . . . 67.7 t80 -65.69 -33.54 76.12 Favored 'General case' 0 N--CA 1.453 -0.317 0 CA-C-N 115.636 -0.711 . . . . 0.0 109.334 178.72 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 86' ' ' PHE . . . . . . . . . . . . . 4.3 t80 -60.63 -51.71 68.26 Favored 'General case' 0 C--O 1.233 0.22 0 CA-C-N 115.646 -0.707 . . . . 0.0 109.719 178.858 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 9.1 mp -61.37 -31.22 71.11 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 115.741 -0.663 . . . . 0.0 110.506 179.526 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -71.89 -28.01 69.56 Favored Glycine 0 N--CA 1.449 -0.476 0 C-N-CA 120.81 -0.71 . . . . 0.0 112.144 179.801 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 65.5 mt -71.28 -45.06 64.0 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-O 120.877 0.37 . . . . 0.0 110.591 179.838 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 69.5 mt -58.44 -51.84 68.15 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 115.988 -0.551 . . . . 0.0 110.926 179.844 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . 0.475 ' HA ' ' HA ' ' A' ' 149' ' ' ALA . . . -61.69 -36.81 81.96 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.278 -0.419 . . . . 0.0 111.427 -179.872 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 88.38 49.56 3.66 Favored Glycine 0 N--CA 1.452 -0.271 0 C-N-CA 120.826 -0.702 . . . . 0.0 112.033 -179.633 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 93' ' ' LEU . . . . . 0.495 HD13 ' HE2' ' A' ' 145' ' ' MET . 71.6 mt -67.53 178.55 1.58 Allowed 'General case' 0 C--N 1.328 -0.349 0 CA-C-O 120.917 0.389 . . . . 0.0 111.357 -179.662 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 94' ' ' ASP . . . . . . . . . . . . . 20.6 t70 -106.18 167.05 10.07 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-N 116.019 -0.537 . . . . 0.0 110.448 179.75 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 65.7 m -52.72 -34.99 55.01 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 116.46 -0.337 . . . . 0.0 111.26 -179.889 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 12.7 ptm180 -73.32 -46.79 47.39 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.381 -0.372 . . . . 0.0 111.066 -179.978 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 97' ' ' GLU . . . . . 0.454 ' HB2' ' HB3' ' A' ' 93' ' ' LEU . 45.9 mt-10 -57.74 -45.41 85.89 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.429 -0.35 . . . . 0.0 110.837 179.964 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 98' ' ' PHE . . . . . 0.466 ' O ' HG12 ' A' ' 102' ' ' ILE . 42.3 m-85 -60.18 -45.87 91.64 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.303 -0.408 . . . . 0.0 110.377 179.464 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -56.6 -30.0 58.54 Favored Glycine 0 N--CA 1.45 -0.414 0 C-N-CA 120.549 -0.834 . . . . 0.0 112.304 179.776 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 74.1 mt -73.5 -47.24 46.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 N-CA-C 112.097 0.406 . . . . 0.0 112.097 -179.761 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 1.1 p -70.52 -42.76 78.22 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-O 120.654 0.264 . . . . 0.0 111.634 -179.712 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 102' ' ' ILE . . . . . 0.466 HG12 ' O ' ' A' ' 98' ' ' PHE . 45.2 mm -62.13 -45.14 99.41 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.36 0 CA-C-N 116.426 -0.352 . . . . 0.0 111.042 -179.627 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 103' ' ' THR . . . . . 0.452 ' HA ' ' HG1' ' A' ' 106' ' ' THR . 13.6 t -66.88 -29.87 69.89 Favored 'General case' 0 C--N 1.332 -0.167 0 CA-C-O 120.817 0.341 . . . . 0.0 110.346 179.559 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 1.2 tm? -59.76 -56.06 26.51 Favored 'General case' 0 C--N 1.331 -0.206 0 N-CA-C 109.501 -0.555 . . . . 0.0 109.501 179.108 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 105' ' ' ASN . . . . . 0.606 ' N ' HD21 ' A' ' 105' ' ' ASN . 0.8 OUTLIER -57.3 -32.45 66.67 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 115.855 -0.611 . . . . 0.0 110.663 179.232 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 106' ' ' THR . . . . . 0.452 ' HG1' ' HA ' ' A' ' 103' ' ' THR . 58.0 m -57.65 -48.86 78.32 Favored 'General case' 0 C--N 1.332 -0.183 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.95 179.78 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 2.1 t -61.54 -40.85 87.94 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-O 121.149 0.5 . . . . 0.0 110.122 179.623 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 99.0 t -58.92 -43.73 89.25 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.377 0 CA-C-N 115.294 -0.867 . . . . 0.0 111.406 -179.956 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 109' ' ' MET . . . . . 0.461 ' HB3' HG12 ' A' ' 77' ' ' ILE . 15.3 mmt -70.51 -41.51 72.52 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.666 -179.332 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 32.5 tp -59.65 -31.09 69.21 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-O 120.882 0.372 . . . . 0.0 110.569 -179.872 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -70.15 -53.48 17.04 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.758 179.649 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 112' ' ' GLY . . . . . 0.443 ' HA3' ' H22' ' A' ' 301' ' ' RET . . . -59.58 -45.62 95.33 Favored Glycine 0 C--N 1.331 0.299 0 C-N-CA 120.707 -0.759 . . . . 0.0 112.301 179.751 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 113' ' ' PHE . . . . . . . . . . . . . 1.5 t80 -50.97 -60.5 3.03 Favored 'General case' 0 C--N 1.332 -0.171 0 CA-C-O 120.996 0.427 . . . . 0.0 110.116 179.488 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 114' ' ' ALA . . . . . 0.453 ' HB2' HD21 ' A' ' 126' ' ' LEU . . . -66.45 -19.81 65.89 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 115.733 -0.667 . . . . 0.0 110.6 179.451 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -59.0 -45.84 94.61 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.86 -0.686 . . . . 0.0 112.042 179.646 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 116' ' ' ALA . . . . . 0.414 ' HB1' HG21 ' A' ' 68' ' ' VAL . . . -78.16 -21.2 50.56 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.804 0.335 . . . . 0.0 111.359 179.67 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 117' ' ' MET . . . . . . . . . . . . . 24.8 mmt -83.24 19.87 1.4 Allowed 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.846 -179.253 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 118' ' ' VAL . . . . . 0.525 HG23 ' HB3' ' A' ' 123' ' ' ARG . 24.7 m -90.73 141.67 27.13 Favored Pre-proline 0 C--N 1.329 -0.294 0 CA-C-O 120.646 0.26 . . . . 0.0 111.614 -179.717 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 119' ' ' PRO . . . . . . . . . . . . . 97.3 Cg_endo -92.52 -6.75 3.05 Favored 'Trans proline' 0 N--CA 1.455 -0.774 0 C-N-CA 122.882 2.388 . . . . 0.0 112.379 179.455 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -139.41 -115.38 1.27 Allowed Glycine 0 C--N 1.332 0.314 0 C-N-CA 120.589 -0.815 . . . . 0.0 113.023 -179.586 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 38.3 pt -119.29 15.03 6.85 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.233 0 CA-C-O 120.686 0.279 . . . . 0.0 111.67 -179.345 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 10.9 mm-40 -62.11 -18.61 61.33 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.383 -0.371 . . . . 0.0 110.99 179.752 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 123' ' ' ARG . . . . . 0.525 ' HB3' HG23 ' A' ' 118' ' ' VAL . 24.2 ptt180 -54.54 -33.42 60.05 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 115.973 -0.558 . . . . 0.0 111.785 -179.751 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 124' ' ' TYR . . . . . . . . . . . . . 37.3 m-85 -65.73 -32.22 73.65 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 120.829 0.347 . . . . 0.0 111.108 -179.593 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 125' ' ' ALA . . . . . . . . . . . . . . . -72.62 -56.17 5.73 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.0 179.92 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 126' ' ' LEU . . . . . 0.453 HD21 ' HB2' ' A' ' 114' ' ' ALA . 1.3 mt -55.68 -45.44 77.77 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 115.789 -0.642 . . . . 0.0 110.488 -179.991 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 127' ' ' PHE . . . . . . . . . . . . . 7.6 t80 -67.3 -37.37 83.27 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.464 179.612 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 128' ' ' GLY . . . . . . . . . . . . . . . -47.1 -45.03 20.14 Favored Glycine 0 C--N 1.332 0.331 0 C-N-CA 120.2 -1.0 . . . . 0.0 110.748 178.866 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 129' ' ' MET . . . . . 0.407 ' HE3' ' N ' ' A' ' 130' ' ' GLY . 0.4 OUTLIER -70.95 -35.85 72.35 Favored 'General case' 0 C--N 1.328 -0.328 0 N-CA-C 109.826 -0.435 . . . . 0.0 109.826 178.578 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 130' ' ' GLY . . . . . 0.407 ' N ' ' HE3' ' A' ' 129' ' ' MET . . . -62.67 -36.38 93.19 Favored Glycine 0 C--N 1.332 0.354 0 CA-C-N 115.777 -0.647 . . . . 0.0 112.626 -179.926 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -69.66 -53.34 19.13 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.602 0.239 . . . . 0.0 110.42 179.78 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 54.5 t -55.38 -39.99 55.31 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.234 0 CA-C-O 121.376 0.608 . . . . 0.0 109.595 178.879 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -69.12 -35.29 76.26 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 115.278 -0.874 . . . . 0.0 110.51 179.316 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 134' ' ' PHE . . . . . 0.401 ' CZ ' ' HA ' ' A' ' 172' ' ' ALA . 73.5 t80 -56.94 -57.58 11.89 Favored 'General case' 0 N--CA 1.451 -0.415 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.146 179.823 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 135' ' ' ILE . . . . . 0.483 ' O ' HG22 ' A' ' 138' ' ' VAL . 0.0 OUTLIER -56.18 -32.84 35.48 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.002 -0.545 . . . . 0.0 109.61 178.761 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . -57.33 -39.15 89.9 Favored Glycine 0 N--CA 1.447 -0.58 0 C-N-CA 120.302 -0.951 . . . . 0.0 111.086 178.389 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 137' ' ' LEU . . . . . . . . . . . . . 27.8 tp -68.3 -53.84 21.58 Favored 'General case' 0 C--N 1.331 -0.197 0 CA-C-O 120.579 0.228 . . . . 0.0 110.644 179.212 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 138' ' ' VAL . . . . . 0.483 HG22 ' O ' ' A' ' 135' ' ' ILE . 3.0 m -56.15 -30.24 29.07 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.204 0 CA-C-O 121.137 0.494 . . . . 0.0 109.742 179.482 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 139' ' ' TYR . . . . . . . . . . . . . 35.2 t80 -63.7 -44.22 94.29 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 115.441 -0.8 . . . . 0.0 110.202 178.945 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 37.8 m-85 -63.04 -34.95 78.68 Favored 'General case' 0 C--N 1.331 -0.198 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.696 179.434 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 141' ' ' LEU . . . . . . . . . . . . . 89.7 mt -62.92 -51.11 68.21 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.005 -179.943 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 15.0 p -81.87 -11.01 12.31 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.358 0 CA-C-N 116.076 -0.511 . . . . 0.0 111.032 -179.874 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . -72.32 -130.31 0.12 Allowed Glycine 0 CA--C 1.521 0.44 0 C-N-CA 120.973 -0.632 . . . . 0.0 112.988 -179.68 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 144' ' ' PRO . . . . . . . . . . . . . 33.1 Cg_endo -64.34 -23.57 65.46 Favored 'Trans proline' 0 C--N 1.349 0.586 0 C-N-CA 122.549 2.166 . . . . 0.0 112.521 -179.696 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 145' ' ' MET . . . . . 0.495 ' HE2' HD13 ' A' ' 93' ' ' LEU . 45.6 mtt -54.65 -34.43 62.17 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.352 -0.385 . . . . 0.0 111.446 -179.888 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 146' ' ' THR . . . . . . . . . . . . . 53.9 p -71.62 -37.47 70.9 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 116.53 -0.304 . . . . 0.0 111.584 -179.74 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 43.4 mt-10 -71.98 -37.48 69.88 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.374 -0.376 . . . . 0.0 111.203 -179.586 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 148' ' ' SER . . . . . . . . . . . . . 66.5 m -70.35 -40.09 74.29 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.152 -0.477 . . . . 0.0 111.454 -179.684 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 149' ' ' ALA . . . . . 0.475 ' HA ' ' HA ' ' A' ' 91' ' ' ALA . . . -74.9 -48.36 25.17 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.354 -0.385 . . . . 0.0 111.832 -179.397 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 150' ' ' SER . . . . . . . . . . . . . 47.1 t -61.07 -23.04 65.17 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.358 -0.383 . . . . 0.0 111.316 -179.652 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 151' ' ' GLN . . . . . . . . . . . . . 49.1 mt-30 -108.78 13.49 24.95 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.455 -0.339 . . . . 0.0 111.209 -179.849 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 30.7 tpt180 -89.77 -52.02 5.21 Favored 'General case' 0 C--N 1.332 -0.194 0 CA-C-O 120.933 0.397 . . . . 0.0 110.616 179.751 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 153' ' ' SER . . . . . 0.586 ' HB2' HG12 ' A' ' 156' ' ' ILE . 13.2 m -157.57 172.69 18.1 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 115.852 -0.613 . . . . 0.0 110.331 179.426 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 154' ' ' SER . . . . . . . . . . . . . 94.9 p -67.75 -44.87 76.52 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.798 0.332 . . . . 0.0 110.899 179.844 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 155' ' ' GLY . . . . . 0.401 ' O ' HD23 ' A' ' 159' ' ' LEU . . . -76.7 -38.24 32.41 Favored Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 121.096 -0.573 . . . . 0.0 113.219 -179.684 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 156' ' ' ILE . . . . . 0.586 HG12 ' HB2' ' A' ' 153' ' ' SER . 36.1 mm -48.07 -37.75 7.12 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.229 0 CA-C-O 120.704 0.288 . . . . 0.0 111.404 -179.527 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 157' ' ' LYS . . . . . . . . . . . . . 87.5 tttt -64.76 -42.03 95.44 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 116.351 -0.386 . . . . 0.0 111.316 -179.93 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 85.9 p -71.28 -46.33 61.07 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.94 0.4 . . . . 0.0 111.375 -179.48 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 159' ' ' LEU . . . . . 0.518 HD22 HD11 ' A' ' 219' ' ' LEU . 4.1 mm? -61.61 -36.29 80.28 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-N 116.006 -0.543 . . . . 0.0 111.558 -179.595 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 160' ' ' TYR . . . . . . . . . . . . . 46.9 t80 -74.25 -46.86 38.84 Favored 'General case' 0 C--N 1.33 -0.274 0 N-CA-C 112.668 0.618 . . . . 0.0 112.668 -178.73 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 21.6 m -58.57 -45.23 90.49 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 N-CA-C 112.277 0.473 . . . . 0.0 112.277 -178.712 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 162' ' ' ARG . . . . . . . . . . . . . 99.9 mtt180 -68.71 -44.78 73.2 Favored 'General case' 0 C--N 1.328 -0.363 0 N-CA-C 111.781 0.289 . . . . 0.0 111.781 -179.38 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 163' ' ' LEU . . . . . 0.668 ' HG ' ' HB2' ' A' ' 208' ' ' PHE . 6.0 mp -67.37 -54.18 22.76 Favored 'General case' 0 C--N 1.328 -0.368 0 N-CA-C 112.006 0.373 . . . . 0.0 112.006 -179.199 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 164' ' ' ARG . . . . . . . . . . . . . 3.7 tmm_? -56.25 -53.12 60.95 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.348 -0.387 . . . . 0.0 111.998 -179.071 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 165' ' ' ASN . . . . . 0.487 ' N ' HD21 ' A' ' 165' ' ' ASN . 0.9 OUTLIER -54.43 -51.73 64.01 Favored 'General case' 0 C--N 1.331 -0.204 0 CA-C-O 120.788 0.327 . . . . 0.0 111.81 -179.332 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 166' ' ' LEU . . . . . 0.447 ' O ' ' HG ' ' A' ' 170' ' ' LEU . 4.5 tt -60.29 -53.33 59.0 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-N 116.357 -0.383 . . . . 0.0 111.548 -179.31 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 167' ' ' THR . . . . . . . . . . . . . 63.7 m -55.85 -52.74 62.98 Favored 'General case' 0 C--N 1.329 -0.295 0 N-CA-C 113.167 0.803 . . . . 0.0 113.167 -178.767 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 168' ' ' VAL . . . . . 0.407 HG11 ' O ' ' A' ' 165' ' ' ASN . 8.2 p -56.84 -41.23 75.48 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.209 0 N-CA-C 112.226 0.454 . . . . 0.0 112.226 -178.451 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 169' ' ' VAL . . . . . 0.417 HG22 ' O ' ' A' ' 165' ' ' ASN . 74.5 t -58.3 -63.47 0.69 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.395 0 CA-C-N 116.542 -0.299 . . . . 0.0 111.534 -179.716 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 170' ' ' LEU . . . . . 0.451 ' H ' ' HG ' ' A' ' 170' ' ' LEU . 0.8 OUTLIER -64.3 -28.26 69.59 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.551 -0.295 . . . . 0.0 111.769 -179.292 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 171' ' ' TRP . . . . . 0.486 ' NE1' H202 ' A' ' 301' ' ' RET . 4.5 m0 -71.11 -29.96 65.92 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 121.151 0.501 . . . . 0.0 110.216 179.146 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 172' ' ' ALA . . . . . 0.401 ' HA ' ' CZ ' ' A' ' 134' ' ' PHE . . . -71.49 -7.1 45.32 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 115.495 -0.775 . . . . 0.0 110.967 -179.962 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 173' ' ' ILE . . . . . 0.515 ' O ' HG12 ' A' ' 177' ' ' ILE . 16.1 mm -86.75 -23.2 6.82 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.032 -0.531 . . . . 0.0 111.243 -179.993 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 174' ' ' TYR . . . . . 0.41 ' HB2' ' HD3' ' A' ' 175' ' ' PRO . 29.0 m-85 -54.11 -49.94 87.18 Favored Pre-proline 0 N--CA 1.464 0.273 0 CA-C-N 116.409 -0.36 . . . . 0.0 111.89 -179.426 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 175' ' ' PRO . . . . . 0.41 ' HD3' ' HB2' ' A' ' 174' ' ' TYR . 71.2 Cg_exo -48.45 -31.65 18.53 Favored 'Trans proline' 0 C--N 1.351 0.663 0 C-N-CA 121.935 1.757 . . . . 0.0 112.338 179.797 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 176' ' ' PHE . . . . . 0.469 ' O ' ' HG ' ' A' ' 180' ' ' LEU . 82.0 m-85 -80.38 -50.39 10.2 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.005 -0.543 . . . . 0.0 111.882 -179.843 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 177' ' ' ILE . . . . . 0.515 HG12 ' O ' ' A' ' 173' ' ' ILE . 5.3 mm -62.12 -36.16 72.75 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.534 0 N-CA-C 112.562 0.579 . . . . 0.0 112.562 -178.016 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 178' ' ' TRP . . . . . 0.446 ' HH2' ' HB2' ' A' ' 123' ' ' ARG . 83.8 t90 -69.74 -50.18 45.98 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.738 0.304 . . . . 0.0 111.007 179.973 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 179' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -68.99 -55.06 12.03 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.262 -0.426 . . . . 0.0 111.582 -179.159 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 180' ' ' LEU . . . . . 0.571 HD23 HD12 ' A' ' 187' ' ' LEU . 43.3 mt -60.42 -46.75 88.89 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 116.501 -0.318 . . . . 0.0 111.29 -179.473 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . -56.61 177.43 0.85 Allowed Glycine 0 C--N 1.335 0.512 0 C-N-CA 120.384 -0.912 . . . . 0.0 112.715 179.636 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 182' ' ' PRO . . . . . 0.443 ' HB2' ' HD3' ' A' ' 183' ' ' PRO . 83.7 Cg_exo -47.15 -45.24 22.1 Favored 'Trans proline' 0 CA--C 1.536 0.575 0 C-N-CA 122.878 2.385 . . . . 0.0 113.697 -179.802 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 183' ' ' PRO . . . . . 0.443 ' HD3' ' HB2' ' A' ' 182' ' ' PRO . 79.7 Cg_exo -46.38 -29.95 7.66 Favored 'Trans proline' 0 C--N 1.356 0.922 0 C-N-CA 122.195 1.93 . . . . 0.0 113.171 -179.796 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 184' ' ' GLY . . . . . . . . . . . . . . . -114.5 -121.3 3.55 Favored Glycine 0 C--N 1.332 0.342 0 C-N-CA 120.335 -0.936 . . . . 0.0 113.001 -179.896 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 185' ' ' VAL . . . . . . . . . . . . . 16.6 m -64.49 -18.57 23.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 N-CA-C 112.02 0.378 . . . . 0.0 112.02 -179.46 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 186' ' ' ALA . . . . . . . . . . . . . . . 56.39 87.55 0.06 Allowed 'General case' 0 N--CA 1.463 0.209 0 CA-C-O 120.731 0.301 . . . . 0.0 111.453 179.585 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 187' ' ' LEU . . . . . 0.571 HD12 HD23 ' A' ' 180' ' ' LEU . 18.8 mt -92.05 -49.67 6.09 Favored 'General case' 0 C--N 1.332 -0.195 0 CA-C-O 120.904 0.383 . . . . 0.0 111.367 -179.867 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 188' ' ' LEU . . . . . . . . . . . . . 95.2 mt -106.79 -156.7 0.59 Allowed 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.165 -0.471 . . . . 0.0 111.027 -179.574 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 189' ' ' THR . . . . . . . . . . . . . 1.6 t -96.27 149.18 35.58 Favored Pre-proline 0 C--N 1.329 -0.304 0 CA-C-N 116.056 -0.52 . . . . 0.0 111.203 -179.686 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 190' ' ' PRO . . . . . . . . . . . . . 9.9 Cg_endo -51.42 -37.41 61.39 Favored 'Trans proline' 0 C--N 1.349 0.582 0 C-N-CA 122.75 2.3 . . . . 0.0 112.688 -179.869 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 191' ' ' THR . . . . . . . . . . . . . 70.2 p -58.93 -48.66 80.7 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.97 0.415 . . . . 0.0 110.975 179.947 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 192' ' ' VAL . . . . . . . . . . . . . 40.6 t -67.45 -48.48 77.13 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 115.882 -0.599 . . . . 0.0 111.566 -179.772 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 193' ' ' ASP . . . . . . . . . . . . . 22.4 t70 -56.45 -51.92 66.64 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.31 -0.405 . . . . 0.0 111.497 -179.586 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 194' ' ' VAL . . . . . . . . . . . . . 79.7 t -58.68 -35.86 57.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.439 -0.346 . . . . 0.0 110.898 179.929 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 195' ' ' ALA . . . . . . . . . . . . . . . -57.57 -44.88 85.62 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.4 -0.363 . . . . 0.0 110.856 179.708 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 196' ' ' LEU . . . . . . . . . . . . . 96.0 mt -68.08 -44.0 77.26 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-N 116.329 -0.396 . . . . 0.0 110.53 179.433 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 197' ' ' ILE . . . . . . . . . . . . . 18.7 mm -56.95 -59.34 3.21 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 115.986 -0.552 . . . . 0.0 110.635 179.53 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 198' ' ' VAL . . . . . . . . . . . . . 79.5 t -52.21 -34.94 18.66 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.509 0 CA-C-N 115.688 -0.687 . . . . 0.0 109.594 178.6 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 199' ' ' TYR . . . . . . . . . . . . . 48.0 t80 -70.52 -32.35 69.79 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 115.47 -0.786 . . . . 0.0 110.819 179.885 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 200' ' ' LEU . . . . . 0.426 ' O ' HG11 ' A' ' 203' ' ' VAL . 21.6 mt -69.99 -40.51 75.29 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 115.973 -0.558 . . . . 0.0 111.458 -179.673 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 201' ' ' ASP . . . . . 0.43 ' HB2' ' OH ' ' A' ' 51' ' ' TYR . 12.8 m-20 -71.83 -35.79 70.01 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-O 121.293 0.568 . . . . 0.0 109.991 179.471 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 202' ' ' LEU . . . . . . . . . . . . . 3.0 mt -69.71 -31.36 69.34 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 115.306 -0.861 . . . . 0.0 111.856 -179.734 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 203' ' ' VAL . . . . . 0.426 HG11 ' O ' ' A' ' 200' ' ' LEU . 13.1 p -76.7 -36.06 26.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 C-N-CA 121.004 -0.279 . . . . 0.0 110.911 -179.087 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 204' ' ' THR . . . . . 0.408 ' O ' ' CD1' ' A' ' 208' ' ' PHE . 53.7 m -63.8 -58.41 6.9 Favored 'General case' 0 C--N 1.33 -0.279 0 C-N-CA 120.585 -0.446 . . . . 0.0 111.389 179.376 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 205' ' ' LYS . . . . . 0.638 ' HE2' ' HB1' ' A' ' 47' ' ' ALA . 52.2 mttp -65.06 -58.31 6.39 Favored 'General case' 0 N--CA 1.464 0.231 0 N-CA-C 112.494 0.553 . . . . 0.0 112.494 -178.347 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 42.6 t -68.42 -36.81 76.4 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.475 0 N-CA-C 112.168 0.432 . . . . 0.0 112.168 -178.898 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 207' ' ' GLY . . . . . 0.534 ' O ' HG13 ' A' ' 211' ' ' ILE . . . -60.2 -60.76 8.03 Favored Glycine 0 N--CA 1.453 -0.226 0 C-N-CA 120.682 -0.771 . . . . 0.0 114.035 -178.349 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 208' ' ' PHE . . . . . 0.668 ' HB2' ' HG ' ' A' ' 163' ' ' LEU . 0.1 OUTLIER -71.55 -26.83 62.79 Favored 'General case' 0 C--O 1.224 -0.287 0 CA-C-N 117.277 0.539 . . . . 0.0 111.653 -178.643 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 209' ' ' GLY . . . . . 0.486 ' O ' ' HB2' ' A' ' 212' ' ' ALA . . . -67.6 -32.44 78.57 Favored Glycine 0 N--CA 1.449 -0.457 0 N-CA-C 111.853 -0.499 . . . . 0.0 111.853 178.966 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 210' ' ' PHE . . . . . . . . . . . . . 0.9 OUTLIER -73.21 -48.29 36.31 Favored 'General case' 0 CA--C 1.514 -0.43 0 N-CA-C 108.291 -1.003 . . . . 0.0 108.291 178.532 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 211' ' ' ILE . . . . . 0.534 HG13 ' O ' ' A' ' 207' ' ' GLY . 5.3 mt -63.48 -27.96 44.04 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.535 0 N-CA-C 107.626 -1.25 . . . . 0.0 107.626 176.715 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 212' ' ' ALA . . . . . 0.486 ' HB2' ' O ' ' A' ' 209' ' ' GLY . . . -63.72 -40.83 97.71 Favored 'General case' 0 N--CA 1.449 -0.483 0 CA-C-N 114.45 -1.25 . . . . 0.0 110.881 179.887 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 213' ' ' LEU . . . . . . . . . . . . . 97.3 mt -69.98 -55.0 10.75 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 115.273 -0.876 . . . . 0.0 112.17 -179.135 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 214' ' ' ASP . . . . . . . . . . . . . 36.2 t70 -53.81 -55.03 30.23 Favored 'General case' 0 C--O 1.234 0.27 0 CA-C-O 120.758 0.313 . . . . 0.0 111.498 -179.417 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 215' ' ' ALA . . . . . 0.422 ' O ' ' HG ' ' A' ' 219' ' ' LEU . . . -56.99 -53.06 62.29 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.306 -0.406 . . . . 0.0 111.159 -179.878 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 216' ' ' ALA . . . . . 0.457 ' HA ' HD13 ' A' ' 219' ' ' LEU . . . -58.73 -31.35 68.22 Favored 'General case' 0 C--N 1.332 -0.187 0 CA-C-N 116.443 -0.344 . . . . 0.0 111.286 -179.891 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 217' ' ' ALA . . . . . . . . . . . . . . . -61.82 -39.7 92.7 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 121.076 0.465 . . . . 0.0 109.991 179.573 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 218' ' ' THR . . . . . . . . . . . . . 97.9 m -76.02 -34.04 59.67 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 115.726 -0.67 . . . . 0.0 110.793 179.299 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 219' ' ' LEU . . . . . 0.518 HD11 HD22 ' A' ' 159' ' ' LEU . 97.3 mt -56.38 -43.07 78.88 Favored 'General case' 0 C--N 1.331 -0.202 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.665 179.723 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 220' ' ' ARG . . . . . . . . . . . . . 39.8 ptt180 -84.15 -23.93 30.42 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.0 -0.546 . . . . 0.0 110.649 179.494 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 221' ' ' ALA . . . . . . . . . . . . . . . -61.91 -35.6 78.85 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.032 -0.531 . . . . 0.0 112.007 -179.513 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 222' ' ' GLU . . . . . 0.425 ' HG2' ' O ' ' A' ' 219' ' ' LEU . 12.2 pt-20 -70.52 -18.3 62.95 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-O 120.868 0.366 . . . . 0.0 110.669 -179.444 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 223' ' ' HIS . . . . . . . . . . . . . 96.4 m-70 -88.61 -167.23 1.81 Allowed 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 115.986 -0.552 . . . . 0.0 110.62 179.701 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 224' ' ' GLY . . . . . . . . . . . . . . . -165.88 -6.15 0.03 OUTLIER Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.526 -179.858 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 225' ' ' GLU . . . . . . . . . . . . . 9.4 tp10 -92.08 103.78 16.25 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.845 0.355 . . . . 0.0 110.996 179.999 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 226' ' ' SER . . . . . . . . . . . . . 55.0 m -147.23 160.08 42.89 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.699 179.932 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 227' ' ' LEU . . . . . 0.403 HD12 ' N ' ' A' ' 227' ' ' LEU . 6.3 mp -106.12 148.53 27.73 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.288 -0.415 . . . . 0.0 111.099 -179.856 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 228' ' ' ALA . . . . . . . . . . . . . . . -134.73 168.61 18.71 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.012 -0.54 . . . . 0.0 110.801 179.759 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 229' ' ' GLY . . . . . . . . . . . . . . . 57.32 23.92 49.83 Favored Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.668 -0.777 . . . . 0.0 112.349 -179.743 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 230' ' ' VAL . . . . . . . . . . . . . 47.4 t -65.89 140.63 19.27 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.245 0 CA-C-O 120.822 0.344 . . . . 0.0 111.145 -179.965 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 231' ' ' ASP . . . . . . . . . . . . . 18.0 m-20 -93.04 104.45 16.66 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.964 -179.805 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 232' ' ' THR . . . . . . . . . . . . . 5.7 t -165.6 135.35 3.47 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.114 -0.494 . . . . 0.0 111.033 179.851 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 233' ' ' ASP . . . . . . . . . . . . . 19.9 m-20 58.45 17.66 5.04 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.836 -179.959 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 234' ' ' THR . . . . . 0.466 ' N ' ' HD2' ' A' ' 235' ' ' PRO . 88.1 m -84.11 -50.84 0.62 Allowed Pre-proline 0 CA--C 1.533 0.308 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.53 179.926 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 235' ' ' PRO . . . . . 0.466 ' HD2' ' N ' ' A' ' 234' ' ' THR . 55.2 Cg_endo -71.41 -47.3 0.52 Allowed 'Trans proline' 0 C--N 1.353 0.77 0 C-N-CA 122.016 1.81 . . . . 0.0 112.336 179.944 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 236' ' ' ALA . . . . . . . . . . . . . . . 58.23 95.71 0.03 OUTLIER 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.404 179.846 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 237' ' ' VAL . . . . . . . . . . . . . 60.5 t -82.02 120.83 34.3 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.89 179.81 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 238' ' ' ALA . . . . . . . . . . . . . . . -163.17 -48.96 0.04 OUTLIER 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 115.984 -0.553 . . . . 0.0 110.849 179.997 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 239' ' ' ASP . . . . . . . . . . . . . 10.6 m-20 -143.83 -31.87 0.45 Allowed 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.088 -0.505 . . . . 0.0 110.858 -179.919 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 240' ' ' LEU . . . . . . . . . . . . . 3.7 mm? 61.41 106.78 0.02 OUTLIER 'General case' 0 C--N 1.331 -0.199 0 CA-C-N 115.93 -0.577 . . . . 0.0 110.771 -179.825 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 241' ' ' GLU . . . . . . . . . . . . . 10.2 tp10 60.63 99.6 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.027 -0.533 . . . . 0.0 110.882 -179.822 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 242' ' ' HIS . . . . . . . . . . . . . 62.7 m80 -67.08 166.02 14.69 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.057 -179.818 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 243' ' ' HIS . . . . . . . . . . . . . 28.4 t-80 -135.89 -65.43 0.59 Allowed 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 115.988 -0.551 . . . . 0.0 110.743 179.808 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 244' ' ' HIS . . . . . . . . . . . . . 16.5 p-80 -87.89 138.22 31.65 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.757 179.81 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 245' ' ' HIS . . . . . . . . . . . . . 22.2 t60 -123.13 109.11 13.62 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.977 -179.84 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 246' ' ' HIS . . . . . . . . . . . . . 71.6 m-70 -134.33 -14.98 2.23 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.802 179.89 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 247' ' ' HIS . . . . . . . . . . . . . 51.9 t-80 . . . . . 0 C--O 1.249 1.077 0 CA-C-O 118.232 -0.89 . . . . 0.0 110.891 -179.947 . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 301' ' ' RET . . . . . 0.486 H202 ' NE1' ' A' ' 171' ' ' TRP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 1' ' ' MET . . . . . 0.512 ' HE2' ' HB2' ' A' ' 4' ' ' LEU . 12.5 tpt . . . . . 0 N--CA 1.486 1.344 0 CA-C-O 120.753 0.311 . . . . 0.0 110.766 . . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 7.3 p -125.73 -27.87 1.34 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.233 0 CA-C-N 116.289 -0.414 . . . . 0.0 111.449 -179.707 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -76.53 -0.29 67.01 Favored Glycine 0 N--CA 1.453 -0.216 0 C-N-CA 120.7 -0.762 . . . . 0.0 112.577 -179.503 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 4' ' ' LEU . . . . . 0.512 ' HB2' ' HE2' ' A' ' 1' ' ' MET . 32.0 tp -74.83 -36.46 62.41 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-O 120.779 0.323 . . . . 0.0 111.215 -179.913 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 81.5 p -59.43 -29.84 68.05 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.082 -0.508 . . . . 0.0 111.372 -179.641 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 31.3 p -53.55 -35.91 61.27 Favored 'General case' 0 C--N 1.331 -0.196 0 CA-C-N 116.231 -0.441 . . . . 0.0 111.413 -179.798 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 7' ' ' LEU . . . . . . . . . . . . . 3.9 mm? -61.15 -51.09 70.52 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 116.382 -0.372 . . . . 0.0 111.224 -179.774 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 8' ' ' PHE . . . . . . . . . . . . . 83.9 m-85 -60.33 -36.39 77.83 Favored 'General case' 0 C--N 1.331 -0.198 0 CA-C-O 120.978 0.418 . . . . 0.0 110.775 179.871 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 9' ' ' TRP . . . . . 0.433 ' O ' HG12 ' A' ' 13' ' ' ILE . 21.7 m95 -63.58 -41.9 98.34 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 115.781 -0.645 . . . . 0.0 109.897 179.827 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 87.6 mt -60.87 -45.0 96.28 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 115.549 -0.75 . . . . 0.0 110.392 179.315 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -64.42 -26.76 70.94 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.715 -0.755 . . . . 0.0 111.965 179.368 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -74.37 -30.51 62.01 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.772 0.32 . . . . 0.0 110.755 179.716 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 13' ' ' ILE . . . . . 0.433 HG12 ' O ' ' A' ' 9' ' ' TRP . 51.6 mm -69.62 -54.39 19.71 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.227 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.62 179.776 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -61.84 -34.76 89.85 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.582 -0.818 . . . . 0.0 112.033 179.64 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 15' ' ' MET . . . . . 0.506 ' SD ' ' HA ' ' A' ' 44' ' ' SER . 49.1 tpp -66.52 -45.8 78.29 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 120.778 0.323 . . . . 0.0 110.39 179.71 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -54.19 -41.46 68.62 Favored 'General case' 0 C--N 1.331 -0.206 0 CA-C-N 116.053 -0.521 . . . . 0.0 109.759 179.196 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . 0.429 HG23 ' O ' ' A' ' 13' ' ' ILE . 63.5 t -59.8 -43.21 91.29 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.187 0 CA-C-N 115.8 -0.636 . . . . 0.0 110.263 179.302 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -65.3 -40.31 96.48 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.694 -0.765 . . . . 0.0 111.58 178.95 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 15.5 m -53.79 -48.84 69.42 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.876 0.369 . . . . 0.0 110.991 -179.997 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 20' ' ' LEU . . . . . 0.401 ' O ' ' HB3' ' A' ' 24' ' ' TRP . 89.2 mt -71.61 -35.05 70.36 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.038 -0.528 . . . . 0.0 111.152 179.894 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -64.06 -34.2 77.48 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.166 -0.47 . . . . 0.0 112.252 -179.332 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 22' ' ' PHE . . . . . 0.458 ' HB2' HG22 ' A' ' 41' ' ' VAL . 4.1 m-85 -90.29 -37.81 13.82 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.67 0.271 . . . . 0.0 111.512 -179.045 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -64.85 -50.75 65.4 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 121.004 0.43 . . . . 0.0 111.731 -179.542 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 24' ' ' TRP . . . . . 0.401 ' HB3' ' O ' ' A' ' 20' ' ' LEU . 5.0 t-105 -63.42 -51.54 65.3 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 115.803 -0.635 . . . . 0.0 111.174 -179.605 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -67.07 -24.92 66.02 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.36 -0.382 . . . . 0.0 111.162 -179.842 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -71.43 -44.4 51.24 Favored Glycine 0 N--CA 1.452 -0.28 0 C-N-CA 120.88 -0.676 . . . . 0.0 112.386 179.889 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 38.5 mmt180 -63.63 -14.94 56.46 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.797 0.332 . . . . 0.0 110.873 -179.937 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 18.4 t70 -114.73 93.58 4.39 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.5 179.672 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -163.37 -168.54 1.72 Allowed 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.015 -0.539 . . . . 0.0 110.984 -179.785 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -91.06 -122.69 2.69 Favored Glycine 0 N--CA 1.45 -0.397 0 C-N-CA 120.762 -0.732 . . . . 0.0 112.522 -179.993 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 55.8 m -134.84 122.04 21.47 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.902 0.382 . . . . 0.0 110.87 -179.941 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 115.65 -42.26 1.94 Allowed Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.885 -0.674 . . . . 0.0 112.359 179.951 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 17.6 mm-40 -66.38 -20.51 66.09 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.674 0.273 . . . . 0.0 111.141 179.897 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 34' ' ' ARG . . . . . . . . . . . . . 93.0 mtt180 -48.25 -34.07 9.69 Favored 'General case' 0 C--N 1.332 -0.192 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.623 -179.491 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 82.7 mtp180 -59.01 -52.67 64.77 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-O 120.841 0.353 . . . . 0.0 111.078 -179.83 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 73.4 m-85 -61.22 -29.5 69.86 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 116.058 -0.519 . . . . 0.0 111.189 -179.953 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 37' ' ' TYR . . . . . . . . . . . . . 42.8 m-85 -73.3 -52.62 13.28 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.347 -179.758 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 91.2 t -57.03 -36.92 52.49 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.243 0 CA-C-O 121.064 0.459 . . . . 0.0 110.265 179.536 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 25.6 m -68.07 -46.08 72.03 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 115.649 -0.705 . . . . 0.0 110.467 179.35 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 15.8 tp -60.38 -45.51 93.28 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 115.628 -0.715 . . . . 0.0 110.51 179.877 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . 0.458 HG22 ' HB2' ' A' ' 22' ' ' PHE . 98.4 t -65.18 -34.02 67.66 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.476 0 CA-C-N 115.843 -0.617 . . . . 0.0 110.125 179.221 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . 0.431 ' O ' HG12 ' A' ' 46' ' ' ILE . . . -55.86 -51.57 54.43 Favored Glycine 0 N--CA 1.449 -0.485 0 CA-C-N 115.697 -0.683 . . . . 0.0 112.759 179.854 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 43' ' ' ILE . . . . . 0.599 HG21 HD21 ' A' ' 82' ' ' LEU . 10.7 pt -63.76 -48.93 84.29 Favored 'Isoleucine or valine' 0 C--O 1.231 0.12 0 CA-C-N 116.972 0.386 . . . . 0.0 111.473 -179.963 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 44' ' ' SER . . . . . 0.506 ' HA ' ' SD ' ' A' ' 15' ' ' MET . 47.8 t -60.51 -26.62 66.98 Favored 'General case' 0 CA--C 1.529 0.147 0 CA-C-O 120.968 0.413 . . . . 0.0 111.116 179.831 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -75.85 -60.44 3.16 Favored Glycine 0 CA--C 1.517 0.179 0 C-N-CA 120.966 -0.635 . . . . 0.0 113.206 -179.278 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 46' ' ' ILE . . . . . 0.431 HG12 ' O ' ' A' ' 42' ' ' GLY . 9.3 pt -57.95 -34.83 49.69 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-O 120.738 0.304 . . . . 0.0 111.339 -179.444 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 47' ' ' ALA . . . . . 0.679 ' HB2' ' HE2' ' A' ' 205' ' ' LYS . . . -67.22 -44.03 80.56 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.526 -0.306 . . . . 0.0 111.035 179.277 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -54.39 -47.07 73.12 Favored 'General case' 0 C--O 1.232 0.151 0 CA-C-N 116.273 -0.421 . . . . 0.0 111.179 -179.975 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 49' ' ' VAL . . . . . 0.421 ' O ' HG13 ' A' ' 53' ' ' VAL . 14.5 m -71.81 -34.11 50.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.292 -0.413 . . . . 0.0 111.004 179.704 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -60.07 -41.32 92.13 Favored 'General case' 0 N--CA 1.462 0.172 0 CA-C-O 121.006 0.432 . . . . 0.0 111.012 179.422 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 38.8 m-85 -73.25 -34.76 66.02 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 115.877 -0.601 . . . . 0.0 110.496 -179.883 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -66.58 -44.86 81.09 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 115.923 -0.581 . . . . 0.0 111.052 179.599 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 53' ' ' VAL . . . . . 0.45 HG21 ' N ' ' A' ' 54' ' ' MET . 31.2 m -66.61 -45.49 88.39 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.137 0 CA-C-N 116.47 -0.332 . . . . 0.0 110.87 -179.997 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 54' ' ' MET . . . . . 0.45 ' N ' HG21 ' A' ' 53' ' ' VAL . 73.1 mtm -64.27 -34.49 78.23 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-O 121.183 0.516 . . . . 0.0 109.941 179.251 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -63.61 -23.29 67.32 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 115.432 -0.804 . . . . 0.0 111.103 179.515 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 93.2 mt -94.12 -5.37 47.39 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 116.262 -0.426 . . . . 0.0 111.077 -179.864 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 98.12 19.42 23.84 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.636 -0.792 . . . . 0.0 112.935 179.743 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 59.7 t -83.61 135.4 24.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-O 120.739 0.304 . . . . 0.0 110.853 179.861 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 59' ' ' GLY . . . . . 0.515 ' HA3' ' HD3' ' A' ' 71' ' ' PRO . . . 81.03 -4.84 68.7 Favored Glycine 0 N--CA 1.45 -0.423 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.599 -179.806 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 60' ' ' TRP . . . . . . . . . . . . . 14.3 m0 -67.3 90.75 0.23 Allowed 'General case' 0 C--N 1.33 -0.248 0 CA-C-O 120.655 0.264 . . . . 0.0 110.836 179.97 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 61' ' ' VAL . . . . . 0.425 ' HA ' ' HD3' ' A' ' 62' ' ' PRO . 7.0 p -101.36 130.0 25.75 Favored Pre-proline 0 C--N 1.33 -0.277 0 CA-C-N 116.415 -0.357 . . . . 0.0 111.266 179.914 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 62' ' ' PRO . . . . . 0.425 ' HD3' ' HA ' ' A' ' 61' ' ' VAL . 7.7 Cg_exo -73.84 148.17 40.56 Favored 'Trans proline' 0 C--N 1.35 0.64 0 C-N-CA 122.966 2.444 . . . . 0.0 112.33 179.938 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 86.6 t -143.18 93.73 0.5 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.141 -0.481 . . . . 0.0 111.073 -179.956 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . 59.4 -88.31 0.02 OUTLIER 'General case' 0 C--N 1.332 -0.157 0 CA-C-N 116.129 -0.487 . . . . 0.0 111.485 179.846 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 12.6 pt-20 -123.9 -17.15 6.39 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.292 -0.413 . . . . 0.0 110.763 -179.851 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 66' ' ' ARG . . . . . . . . . . . . . 32.7 ptt180 -105.77 159.7 15.8 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 115.902 -0.59 . . . . 0.0 110.532 -179.925 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 40.0 m -119.23 138.54 52.91 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-O 120.902 0.382 . . . . 0.0 111.466 -179.646 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 68' ' ' VAL . . . . . 0.407 HG23 HG11 ' A' ' 61' ' ' VAL . 14.8 m -125.82 146.49 31.48 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.412 0 CA-C-N 115.846 -0.615 . . . . 0.0 110.732 179.666 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 69' ' ' PHE . . . . . . . . . . . . . 17.7 m-85 -108.78 115.7 30.59 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.195 -179.423 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 70' ' ' VAL . . . . . 0.564 HG11 ' HD3' ' A' ' 71' ' ' PRO . 0.3 OUTLIER -68.08 -33.47 5.01 Favored Pre-proline 0 CA--C 1.54 0.579 0 N-CA-C 112.749 0.648 . . . . 0.0 112.749 -179.24 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 71' ' ' PRO . . . . . 0.564 ' HD3' HG11 ' A' ' 70' ' ' VAL . 17.6 Cg_exo -66.39 -32.31 41.03 Favored 'Trans proline' 0 C--N 1.358 1.078 0 C-N-CA 121.781 1.654 . . . . 0.0 112.389 -178.989 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 61.8 ttp180 -65.56 -51.13 62.11 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 121.178 0.513 . . . . 0.0 109.845 179.419 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 73' ' ' TYR . . . . . . . . . . . . . 45.9 m-85 -63.67 -46.92 83.4 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 115.522 -0.763 . . . . 0.0 110.697 179.752 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 74' ' ' ILE . . . . . 0.405 ' HA ' HD13 ' A' ' 77' ' ' ILE . 0.4 OUTLIER -63.62 -34.84 70.22 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.308 -0.405 . . . . 0.0 110.175 179.64 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 28.6 t70 -58.31 -39.37 79.2 Favored 'General case' 0 C--N 1.332 -0.157 0 N-CA-C 109.497 -0.557 . . . . 0.0 109.497 179.263 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 76' ' ' TRP . . . . . 0.455 ' HA ' ' HG1' ' A' ' 79' ' ' THR . 53.1 m0 -67.44 -37.13 82.52 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 115.728 -0.669 . . . . 0.0 110.485 179.479 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 77' ' ' ILE . . . . . 0.422 ' O ' ' HG2' ' A' ' 81' ' ' PRO . 66.8 mt -59.74 -34.07 54.31 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 CA-C-N 115.971 -0.559 . . . . 0.0 110.844 179.79 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 20.0 mt -91.79 -27.03 18.26 Favored 'General case' 0 C--N 1.329 -0.313 0 N-CA-C 112.655 0.613 . . . . 0.0 112.655 -179.581 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 79' ' ' THR . . . . . 0.455 ' HG1' ' HA ' ' A' ' 76' ' ' TRP . 78.6 p -90.49 -52.74 4.76 Favored 'General case' 0 N--CA 1.464 0.267 0 N-CA-C 113.747 1.017 . . . . 0.0 113.747 -177.688 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 80' ' ' THR . . . . . 0.623 ' HB ' ' HD3' ' A' ' 81' ' ' PRO . 33.1 m -48.35 -54.06 29.1 Favored Pre-proline 0 CA--C 1.531 0.228 0 N-CA-C 112.804 0.668 . . . . 0.0 112.804 -178.126 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 81' ' ' PRO . . . . . 0.623 ' HD3' ' HB ' ' A' ' 80' ' ' THR . 49.0 Cg_exo -56.43 -27.38 67.86 Favored 'Trans proline' 0 C--N 1.351 0.702 0 C-N-CA 121.572 1.515 . . . . 0.0 111.683 -179.76 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 82' ' ' LEU . . . . . 0.599 HD21 HG21 ' A' ' 43' ' ' ILE . 12.9 tp -76.96 -32.95 57.66 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 115.882 -0.599 . . . . 0.0 110.655 -179.999 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 48.5 mm -65.95 -53.85 33.52 Favored 'Isoleucine or valine' 0 C--O 1.233 0.215 0 N-CA-C 110.05 -0.352 . . . . 0.0 110.05 179.06 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 12.6 m -60.6 -29.93 45.76 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.26 0 N-CA-C 109.253 -0.647 . . . . 0.0 109.253 178.43 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 85' ' ' TYR . . . . . . . . . . . . . 66.3 t80 -65.53 -34.34 78.02 Favored 'General case' 0 N--CA 1.455 -0.215 0 CA-C-N 115.432 -0.804 . . . . 0.0 109.252 178.354 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 86' ' ' PHE . . . . . . . . . . . . . 2.1 t80 -61.31 -51.47 68.72 Favored 'General case' 0 C--O 1.231 0.129 0 CA-C-N 115.762 -0.654 . . . . 0.0 109.623 179.217 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 7.4 mp -64.0 -31.38 72.55 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 115.801 -0.636 . . . . 0.0 110.119 179.414 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -66.6 -27.78 73.39 Favored Glycine 0 N--CA 1.449 -0.459 0 C-N-CA 120.807 -0.711 . . . . 0.0 111.742 179.322 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 88.6 mt -75.96 -44.93 37.54 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 120.81 0.338 . . . . 0.0 110.691 179.586 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 80.3 mt -54.97 -38.24 67.53 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 115.904 -0.589 . . . . 0.0 110.859 179.898 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -84.34 -54.02 5.07 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.058 -0.519 . . . . 0.0 111.079 179.953 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 100.14 65.13 0.81 Allowed Glycine 0 N--CA 1.452 -0.234 0 C-N-CA 120.887 -0.673 . . . . 0.0 112.416 179.989 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 93' ' ' LEU . . . . . 0.503 ' HB3' ' HB2' ' A' ' 97' ' ' GLU . 6.9 mp -81.51 165.63 21.02 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-O 120.795 0.331 . . . . 0.0 110.746 179.932 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 94' ' ' ASP . . . . . . . . . . . . . 9.0 m-20 -82.75 178.0 8.4 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.837 179.928 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 82.5 p -64.11 -34.47 78.11 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.07 -0.513 . . . . 0.0 111.072 -179.983 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 84.6 mtm180 -73.6 -51.27 17.42 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.279 -0.418 . . . . 0.0 111.094 -179.751 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 97' ' ' GLU . . . . . 0.503 ' HB2' ' HB3' ' A' ' 93' ' ' LEU . 20.2 mt-10 -57.39 -44.4 84.44 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.453 -0.34 . . . . 0.0 110.748 -179.842 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 98' ' ' PHE . . . . . . . . . . . . . 1.7 m-85 -57.46 -50.58 72.58 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.311 -0.404 . . . . 0.0 110.933 179.812 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -54.45 -34.8 55.21 Favored Glycine 0 N--CA 1.452 -0.278 0 C-N-CA 120.883 -0.675 . . . . 0.0 112.584 -179.966 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 96.5 mt -66.74 -43.17 90.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-O 120.89 0.376 . . . . 0.0 111.632 -179.823 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 59.6 t -69.17 -44.26 80.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.629 -179.545 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 102' ' ' ILE . . . . . . . . . . . . . 37.7 mm -65.52 -46.69 89.06 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.378 0 CA-C-N 116.405 -0.361 . . . . 0.0 111.629 -179.227 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 15.3 t -61.85 -35.93 79.74 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 120.643 0.259 . . . . 0.0 111.258 -179.588 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 29.4 tp -62.62 -46.68 87.17 Favored 'General case' 0 C--N 1.332 -0.169 0 CA-C-O 120.843 0.354 . . . . 0.0 110.761 179.781 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 105' ' ' ASN . . . . . 0.55 ' N ' HD21 ' A' ' 105' ' ' ASN . 0.9 OUTLIER -64.73 -26.18 68.25 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.69 179.697 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 53.8 m -67.1 -55.23 15.14 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.124 -0.489 . . . . 0.0 111.401 -179.927 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 7.1 p -62.43 -38.53 81.53 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.193 0 CA-C-N 116.477 -0.329 . . . . 0.0 111.103 -179.841 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 59.4 t -62.58 -44.75 99.65 Favored 'Isoleucine or valine' 0 C--O 1.234 0.269 0 CA-C-O 121.051 0.453 . . . . 0.0 110.573 179.545 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 109' ' ' MET . . . . . . . . . . . . . 7.7 tpp -67.38 -25.69 66.09 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 115.979 -0.555 . . . . 0.0 110.113 179.594 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 20.2 tp -75.93 -30.95 58.9 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 115.764 -0.653 . . . . 0.0 110.296 179.633 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -66.83 -54.23 24.6 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 115.934 -0.575 . . . . 0.0 110.72 179.662 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 112' ' ' GLY . . . . . 0.583 ' HA3' ' H22' ' A' ' 301' ' ' RET . . . -62.1 -47.55 89.1 Favored Glycine 0 C--N 1.331 0.283 0 C-N-CA 120.627 -0.797 . . . . 0.0 111.976 179.558 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 113' ' ' PHE . . . . . . . . . . . . . 3.4 t80 -50.5 -58.08 6.61 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.717 0.294 . . . . 0.0 110.68 179.362 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -71.95 -16.82 62.1 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.687 179.587 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -60.4 -48.69 84.94 Favored Glycine 0 C--N 1.331 0.295 0 C-N-CA 121.091 -0.576 . . . . 0.0 112.412 179.948 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 116' ' ' ALA . . . . . 0.432 ' HB3' ' HB3' ' A' ' 183' ' ' PRO . . . -77.83 -15.05 59.35 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-O 120.773 0.321 . . . . 0.0 111.361 179.991 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 117' ' ' MET . . . . . . . . . . . . . 25.4 mmt -90.29 14.32 13.04 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.298 -0.41 . . . . 0.0 111.6 -179.433 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 118' ' ' VAL . . . . . 0.452 HG23 ' HB3' ' A' ' 123' ' ' ARG . 26.0 m -82.16 143.72 49.44 Favored Pre-proline 0 C--N 1.331 -0.229 0 CA-C-N 116.649 -0.251 . . . . 0.0 111.196 -179.959 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 119' ' ' PRO . . . . . . . . . . . . . 67.8 Cg_endo -92.9 -1.48 3.64 Favored 'Trans proline' 0 N--CA 1.457 -0.668 0 C-N-CA 122.907 2.405 . . . . 0.0 112.416 179.551 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -138.18 -114.16 1.23 Allowed Glycine 0 C--N 1.333 0.371 0 C-N-CA 120.694 -0.765 . . . . 0.0 113.029 -179.655 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 37.0 pt -126.15 13.13 3.99 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.188 0 CA-C-O 120.781 0.324 . . . . 0.0 111.683 -179.564 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 12.2 mm-40 -61.27 -18.8 60.24 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.332 -0.395 . . . . 0.0 111.187 -179.986 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 123' ' ' ARG . . . . . 0.452 ' HB3' HG23 ' A' ' 118' ' ' VAL . 28.0 ptt180 -50.65 -38.26 45.42 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 116.0 -0.545 . . . . 0.0 111.672 -179.828 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 124' ' ' TYR . . . . . . . . . . . . . 57.5 m-85 -64.9 -33.5 76.17 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.401 -0.363 . . . . 0.0 111.241 -179.605 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 125' ' ' ALA . . . . . . . . . . . . . . . -71.98 -56.0 6.44 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 120.946 0.403 . . . . 0.0 111.204 -179.998 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 1.2 mt -52.11 -52.36 51.98 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 115.923 -0.58 . . . . 0.0 111.011 -179.871 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 127' ' ' PHE . . . . . . . . . . . . . 11.6 t80 -64.0 -37.66 88.24 Favored 'General case' 0 N--CA 1.453 -0.304 0 C-N-CA 120.778 -0.369 . . . . 0.0 110.866 179.927 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 128' ' ' GLY . . . . . . . . . . . . . . . -46.47 -44.6 16.28 Favored Glycine 0 C--N 1.332 0.349 0 C-N-CA 120.227 -0.987 . . . . 0.0 110.95 179.35 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 129' ' ' MET . . . . . . . . . . . . . 0.3 OUTLIER -70.56 -37.01 73.94 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 115.392 -0.404 . . . . 0.0 109.947 178.839 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -68.77 -26.92 74.24 Favored Glycine 0 C--N 1.331 0.3 0 CA-C-N 115.842 -0.617 . . . . 0.0 112.94 -179.872 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 131' ' ' ALA . . . . . 0.448 ' O ' ' HB3' ' A' ' 134' ' ' PHE . . . -74.66 -53.6 9.0 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.821 0.343 . . . . 0.0 110.208 179.869 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 58.0 t -58.56 -39.92 77.19 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 N-CA-C 109.09 -0.707 . . . . 0.0 109.09 178.486 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -66.87 -35.31 79.74 Favored 'General case' 0 N--CA 1.453 -0.313 0 CA-C-N 115.276 -0.875 . . . . 0.0 110.412 179.21 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 134' ' ' PHE . . . . . 0.448 ' HB3' ' O ' ' A' ' 131' ' ' ALA . 17.6 t80 -54.26 -56.63 16.49 Favored 'General case' 0 N--CA 1.455 -0.208 0 CA-C-N 116.128 -0.487 . . . . 0.0 109.889 179.425 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 135' ' ' ILE . . . . . 0.443 ' O ' HG23 ' A' ' 138' ' ' VAL . 34.7 mt -56.69 -33.4 40.26 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.323 0 CA-C-N 115.564 -0.744 . . . . 0.0 110.082 179.388 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . -59.87 -35.99 88.57 Favored Glycine 0 N--CA 1.449 -0.447 0 C-N-CA 120.241 -0.981 . . . . 0.0 111.108 178.679 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 137' ' ' LEU . . . . . 0.55 HD11 HD22 ' A' ' 105' ' ' ASN . 56.1 tp -70.86 -55.49 8.38 Favored 'General case' 0 N--CA 1.453 -0.276 0 CA-C-N 115.772 -0.214 . . . . 0.0 110.671 179.376 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 138' ' ' VAL . . . . . 0.443 HG23 ' O ' ' A' ' 135' ' ' ILE . 3.1 m -54.87 -30.3 22.83 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.222 0 N-CA-C 109.171 -0.677 . . . . 0.0 109.171 179.715 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 139' ' ' TYR . . . . . . . . . . . . . 27.1 t80 -62.49 -43.61 98.39 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 115.168 -0.923 . . . . 0.0 109.956 178.083 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 22.2 m-85 -67.48 -44.35 78.78 Favored 'General case' 0 C--O 1.232 0.151 0 CA-C-N 116.301 -0.409 . . . . 0.0 110.467 179.011 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 141' ' ' LEU . . . . . . . . . . . . . 11.0 mp -55.02 -32.57 61.94 Favored 'General case' 0 C--N 1.332 -0.183 0 CA-C-N 116.004 -0.544 . . . . 0.0 111.253 -179.719 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 10.8 p -101.44 -10.19 8.99 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-O 121.055 0.455 . . . . 0.0 110.693 179.929 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . -75.99 -135.54 0.56 Allowed Glycine 0 CA--C 1.522 0.476 0 CA-C-N 115.852 -0.613 . . . . 0.0 112.693 -179.902 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 144' ' ' PRO . . . . . . . . . . . . . 50.0 Cg_exo -53.25 -23.95 24.98 Favored 'Trans proline' 0 C--N 1.347 0.478 0 C-N-CA 122.659 2.239 . . . . 0.0 113.055 -179.688 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 145' ' ' MET . . . . . 0.553 ' HB3' ' HH ' ' A' ' 160' ' ' TYR . 41.2 mtt -57.33 -38.01 73.41 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-O 120.67 0.271 . . . . 0.0 111.549 -179.623 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 146' ' ' THR . . . . . . . . . . . . . 60.4 p -65.45 -49.06 70.55 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.443 -0.344 . . . . 0.0 111.686 -179.443 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 43.9 mt-10 -71.48 -25.4 62.26 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.422 -0.354 . . . . 0.0 111.532 -179.462 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 148' ' ' SER . . . . . . . . . . . . . 48.2 t -68.89 -46.28 68.78 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-O 120.935 0.398 . . . . 0.0 110.827 -179.574 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 149' ' ' ALA . . . . . 0.492 ' HB1' HG22 ' A' ' 156' ' ' ILE . . . -78.13 -32.14 50.25 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.028 -0.533 . . . . 0.0 111.357 -179.858 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 150' ' ' SER . . . . . . . . . . . . . 41.6 t -63.07 -14.83 53.08 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.02 -0.536 . . . . 0.0 111.555 -179.603 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 151' ' ' GLN . . . . . . . . . . . . . 9.8 pt20 -110.71 17.2 20.87 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.659 -0.246 . . . . 0.0 111.624 -179.747 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 29.7 mmt180 -98.64 -52.51 3.59 Favored 'General case' 0 C--N 1.332 -0.184 0 C-N-CA 120.856 -0.338 . . . . 0.0 110.803 179.613 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 153' ' ' SER . . . . . 0.604 ' HB3' HG12 ' A' ' 156' ' ' ILE . 21.0 t -158.1 172.2 18.84 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.792 179.007 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 154' ' ' SER . . . . . . . . . . . . . 43.3 t -71.94 -38.4 69.83 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.307 -0.406 . . . . 0.0 110.385 179.303 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -76.87 -37.68 33.02 Favored Glycine 0 N--CA 1.45 -0.384 0 C-N-CA 120.924 -0.655 . . . . 0.0 112.647 179.8 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 156' ' ' ILE . . . . . 0.604 HG12 ' HB3' ' A' ' 153' ' ' SER . 37.8 mm -52.25 -39.79 28.77 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.236 0 CA-C-O 120.724 0.297 . . . . 0.0 111.431 -179.563 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 157' ' ' LYS . . . . . . . . . . . . . 56.0 tttm -69.65 -34.59 74.22 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-N 116.318 -0.401 . . . . 0.0 111.138 -179.921 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 46.5 t -72.25 -39.96 68.06 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 120.942 0.401 . . . . 0.0 111.309 -179.208 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 159' ' ' LEU . . . . . 0.404 HD11 ' HB1' ' A' ' 215' ' ' ALA . 12.9 mt -72.58 -35.19 67.86 Favored 'General case' 0 C--N 1.326 -0.449 0 CA-C-N 116.066 -0.516 . . . . 0.0 111.315 -179.314 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 160' ' ' TYR . . . . . 0.553 ' HH ' ' HB3' ' A' ' 145' ' ' MET . 37.5 t80 -70.38 -42.36 71.83 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.648 -0.251 . . . . 0.0 111.599 -179.075 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 23.0 m -65.06 -43.91 95.87 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-O 120.719 0.295 . . . . 0.0 111.367 -179.644 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 162' ' ' ARG . . . . . . . . . . . . . 21.2 mmm180 -69.29 -46.53 66.96 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.914 0.387 . . . . 0.0 111.248 179.994 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 163' ' ' LEU . . . . . . . . . . . . . 1.3 mp -61.79 -54.8 37.33 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 115.971 -0.559 . . . . 0.0 111.702 -179.548 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 164' ' ' ARG . . . . . . . . . . . . . 25.4 ttp85 -58.09 -48.23 80.8 Favored 'General case' 0 C--N 1.331 -0.237 0 N-CA-C 112.459 0.54 . . . . 0.0 112.459 -178.843 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 165' ' ' ASN . . . . . 0.464 ' N ' HD21 ' A' ' 165' ' ' ASN . 0.9 OUTLIER -52.34 -51.38 59.1 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-O 120.942 0.401 . . . . 0.0 110.719 -179.205 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 166' ' ' LEU . . . . . 0.528 ' O ' ' HG ' ' A' ' 170' ' ' LEU . 3.6 tt -65.41 -41.48 93.58 Favored 'General case' 0 C--N 1.324 -0.515 0 CA-C-N 116.089 -0.505 . . . . 0.0 111.36 -179.895 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 167' ' ' THR . . . . . 0.401 ' O ' ' HB2' ' A' ' 171' ' ' TRP . 51.1 m -65.18 -54.11 34.69 Favored 'General case' 0 C--N 1.331 -0.232 0 N-CA-C 112.51 0.559 . . . . 0.0 112.51 -178.465 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 168' ' ' VAL . . . . . . . . . . . . . 9.1 p -54.47 -40.46 49.54 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-O 120.644 0.259 . . . . 0.0 111.67 -179.385 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 169' ' ' VAL . . . . . 0.436 HG22 ' O ' ' A' ' 165' ' ' ASN . 55.5 t -59.72 -65.11 0.49 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.486 -0.324 . . . . 0.0 111.634 -179.844 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 170' ' ' LEU . . . . . 0.528 ' HG ' ' O ' ' A' ' 166' ' ' LEU . 2.0 pp -62.79 -27.14 69.09 Favored 'General case' 0 C--N 1.33 -0.262 0 N-CA-C 112.139 0.422 . . . . 0.0 112.139 -178.806 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 171' ' ' TRP . . . . . 0.472 ' HE1' H202 ' A' ' 301' ' ' RET . 1.8 m0 -73.35 -32.48 64.56 Favored 'General case' 0 C--N 1.33 -0.245 0 C-N-CA 120.588 -0.445 . . . . 0.0 110.707 179.69 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 172' ' ' ALA . . . . . 0.409 ' HA ' ' CZ ' ' A' ' 134' ' ' PHE . . . -67.94 -7.76 31.26 Favored 'General case' 0 CA--C 1.52 -0.208 0 CA-C-O 121.345 0.593 . . . . 0.0 110.157 179.287 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 173' ' ' ILE . . . . . 0.554 ' O ' HG12 ' A' ' 177' ' ' ILE . 9.0 mm -84.15 -36.26 11.79 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.555 0 CA-C-N 114.954 -1.021 . . . . 0.0 111.501 -179.03 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 174' ' ' TYR . . . . . 0.54 ' N ' ' HD2' ' A' ' 175' ' ' PRO . 70.2 m-85 -55.56 -51.66 78.26 Favored Pre-proline 0 C--N 1.328 -0.33 0 N-CA-C 112.507 0.558 . . . . 0.0 112.507 -178.9 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 175' ' ' PRO . . . . . 0.54 ' HD2' ' N ' ' A' ' 174' ' ' TYR . 26.7 Cg_endo -60.19 -41.12 53.98 Favored 'Trans proline' 0 C--N 1.349 0.57 0 C-N-CA 122.107 1.871 . . . . 0.0 113.359 -178.776 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 176' ' ' PHE . . . . . 0.523 ' CE2' ' HA ' ' A' ' 173' ' ' ILE . 0.1 OUTLIER -79.83 -37.83 34.18 Favored 'General case' 0 C--N 1.329 -0.32 0 C-N-CA 120.609 -0.437 . . . . 0.0 112.12 -178.413 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 177' ' ' ILE . . . . . 0.554 HG12 ' O ' ' A' ' 173' ' ' ILE . 32.4 mm -63.76 -47.33 91.49 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.614 0 CA-C-O 120.873 0.368 . . . . 0.0 110.032 178.425 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 178' ' ' TRP . . . . . . . . . . . . . 60.5 t90 -52.91 -29.61 29.46 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 115.788 -0.642 . . . . 0.0 109.857 179.202 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 179' ' ' LEU . . . . . 0.404 HD13 ' O ' ' A' ' 179' ' ' LEU . 0.9 OUTLIER -72.76 -37.56 67.63 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 115.359 -0.837 . . . . 0.0 110.689 179.898 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 180' ' ' LEU . . . . . 0.415 ' HG ' ' O ' ' A' ' 176' ' ' PHE . 0.9 OUTLIER -78.31 -51.79 9.59 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.548 -0.296 . . . . 0.0 111.626 -179.399 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . -51.13 171.8 0.2 Allowed Glycine 0 C--N 1.336 0.551 0 C-N-CA 120.941 -0.647 . . . . 0.0 113.292 -179.685 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 182' ' ' PRO . . . . . 0.576 ' N ' ' HD2' ' A' ' 183' ' ' PRO . 2.5 Cg_endo -42.68 -47.81 7.59 Favored 'Trans proline' 0 C--N 1.351 0.661 0 C-N-CA 123.316 2.678 . . . . 0.0 114.015 -179.837 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 183' ' ' PRO . . . . . 0.576 ' HD2' ' N ' ' A' ' 182' ' ' PRO . 9.4 Cg_endo -50.04 -29.93 23.2 Favored 'Trans proline' 0 C--N 1.357 0.992 0 C-N-CA 122.269 1.979 . . . . 0.0 112.62 -179.754 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 184' ' ' GLY . . . . . . . . . . . . . . . -95.93 -105.08 2.12 Favored Glycine 0 N--CA 1.45 -0.368 0 C-N-CA 120.716 -0.754 . . . . 0.0 112.73 -179.904 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 185' ' ' VAL . . . . . . . . . . . . . 0.9 OUTLIER -109.4 -0.37 9.68 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-O 120.672 0.272 . . . . 0.0 111.654 -179.525 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 186' ' ' ALA . . . . . . . . . . . . . . . 55.31 84.88 0.07 Allowed 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.26 -0.427 . . . . 0.0 111.74 179.535 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 187' ' ' LEU . . . . . 0.405 ' HG ' ' HA ' ' A' ' 180' ' ' LEU . 16.4 mt -92.3 -49.44 6.16 Favored 'General case' 0 C--N 1.332 -0.162 0 CA-C-O 121.041 0.448 . . . . 0.0 110.676 179.452 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 188' ' ' LEU . . . . . . . . . . . . . 72.8 mt -102.81 -160.64 0.79 Allowed 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 115.763 -0.653 . . . . 0.0 111.282 -179.409 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 189' ' ' THR . . . . . 0.416 ' HB ' HG22 ' A' ' 192' ' ' VAL . 10.4 m -88.11 136.64 31.85 Favored Pre-proline 0 C--N 1.33 -0.249 0 CA-C-N 115.866 -0.607 . . . . 0.0 110.615 -179.805 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 190' ' ' PRO . . . . . . . . . . . . . 82.1 Cg_exo -46.58 -49.74 11.55 Favored 'Trans proline' 0 C--N 1.35 0.607 0 C-N-CA 122.614 2.209 . . . . 0.0 113.053 -179.63 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 191' ' ' THR . . . . . . . . . . . . . 7.1 t -61.4 -35.6 77.95 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.485 -0.325 . . . . 0.0 111.77 -179.478 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 192' ' ' VAL . . . . . 0.416 HG22 ' HB ' ' A' ' 189' ' ' THR . 89.3 t -71.45 -47.09 60.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-O 120.833 0.349 . . . . 0.0 111.278 -179.708 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 193' ' ' ASP . . . . . . . . . . . . . 24.4 t70 -58.93 -43.98 91.27 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.752 -179.944 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 194' ' ' VAL . . . . . . . . . . . . . 78.3 t -63.16 -37.98 80.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.929 179.787 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 195' ' ' ALA . . . . . . . . . . . . . . . -57.22 -46.56 82.83 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.484 -0.325 . . . . 0.0 111.093 179.829 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 196' ' ' LEU . . . . . 0.417 ' O ' ' HB3' ' A' ' 199' ' ' TYR . 80.8 mt -67.75 -33.44 74.87 Favored 'General case' 0 C--N 1.332 -0.188 0 CA-C-N 116.381 -0.372 . . . . 0.0 110.633 179.691 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 197' ' ' ILE . . . . . 0.494 HD12 HD12 ' A' ' 200' ' ' LEU . 21.1 mm -64.57 -50.48 75.69 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.112 179.126 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 198' ' ' VAL . . . . . . . . . . . . . 85.0 t -56.72 -34.08 42.11 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.478 0 N-CA-C 108.707 -0.849 . . . . 0.0 108.707 178.171 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 199' ' ' TYR . . . . . 0.417 ' HB3' ' O ' ' A' ' 196' ' ' LEU . 80.5 t80 -68.38 -43.72 76.69 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 114.939 -1.028 . . . . 0.0 110.167 179.544 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 200' ' ' LEU . . . . . 0.494 HD12 HD12 ' A' ' 197' ' ' ILE . 65.0 mt -56.61 -55.02 39.25 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 115.496 -0.775 . . . . 0.0 111.172 -179.667 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 201' ' ' ASP . . . . . . . . . . . . . 11.6 m-20 -64.82 -38.07 89.74 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.85 179.918 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 202' ' ' LEU . . . . . . . . . . . . . 23.5 tp -64.99 -26.05 68.12 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 115.703 -0.681 . . . . 0.0 111.393 -179.554 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 203' ' ' VAL . . . . . 0.422 HG12 HD23 ' A' ' 170' ' ' LEU . 45.0 t -82.58 -36.55 13.54 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.365 0 CA-C-N 116.635 -0.257 . . . . 0.0 111.454 -179.397 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 204' ' ' THR . . . . . . . . . . . . . 88.2 m -63.51 -49.18 74.55 Favored 'General case' 0 C--N 1.329 -0.318 0 C-N-CA 120.773 -0.371 . . . . 0.0 111.319 179.837 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 205' ' ' LYS . . . . . 0.679 ' HE2' ' HB2' ' A' ' 47' ' ' ALA . 61.0 mttp -73.32 -46.79 47.38 Favored 'General case' 0 C--N 1.326 -0.429 0 N-CA-C 111.934 0.346 . . . . 0.0 111.934 -178.926 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 94.9 t -74.14 -50.57 27.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-O 120.572 0.225 . . . . 0.0 111.398 -179.805 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 207' ' ' GLY . . . . . . . . . . . . . . . -60.0 -58.19 15.43 Favored Glycine 0 CA--C 1.519 0.292 0 C-N-CA 121.112 -0.566 . . . . 0.0 112.862 179.988 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 208' ' ' PHE . . . . . 0.443 ' O ' ' N ' ' A' ' 212' ' ' ALA . 4.3 t80 -56.27 -44.35 79.66 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.601 0.239 . . . . 0.0 110.744 179.75 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 209' ' ' GLY . . . . . 0.439 ' HA2' ' HB3' ' A' ' 212' ' ' ALA . . . -66.36 -37.7 93.0 Favored Glycine 0 C--N 1.33 0.243 0 CA-C-N 115.811 -0.631 . . . . 0.0 113.41 -179.686 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 210' ' ' PHE . . . . . . . . . . . . . 1.7 m-85 -69.14 -43.85 73.52 Favored 'General case' 0 CA--C 1.51 -0.592 0 N-CA-C 107.64 -1.244 . . . . 0.0 107.64 178.99 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 211' ' ' ILE . . . . . . . . . . . . . 79.8 mt -65.76 -29.62 47.54 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.827 0 N-CA-C 107.193 -1.41 . . . . 0.0 107.193 176.319 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 212' ' ' ALA . . . . . 0.443 ' N ' ' O ' ' A' ' 208' ' ' PHE . . . -68.94 -34.92 76.14 Favored 'General case' 0 N--CA 1.449 -0.483 0 CA-C-N 114.437 -1.256 . . . . 0.0 109.969 179.413 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 213' ' ' LEU . . . . . . . . . . . . . 57.6 mt -70.35 -55.34 9.37 Favored 'General case' 0 C--N 1.331 -0.205 0 CA-C-N 115.056 -0.975 . . . . 0.0 111.458 -179.55 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 214' ' ' ASP . . . . . . . . . . . . . 16.7 t70 -59.48 -26.88 65.63 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.284 -0.416 . . . . 0.0 110.59 179.974 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 215' ' ' ALA . . . . . 0.413 ' O ' ' HG ' ' A' ' 219' ' ' LEU . . . -71.04 -57.69 4.29 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 115.906 -0.588 . . . . 0.0 111.521 -179.911 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 216' ' ' ALA . . . . . . . . . . . . . . . -62.76 -37.49 86.84 Favored 'General case' 0 C--N 1.332 -0.187 0 CA-C-N 116.43 -0.35 . . . . 0.0 111.267 -179.702 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 217' ' ' ALA . . . . . . . . . . . . . . . -60.06 -42.98 95.66 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.312 -0.404 . . . . 0.0 110.3 179.531 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 218' ' ' THR . . . . . . . . . . . . . 98.3 m -62.43 -37.96 87.88 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 115.865 -0.607 . . . . 0.0 110.57 179.405 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 219' ' ' LEU . . . . . 0.484 ' O ' ' HG2' ' A' ' 222' ' ' GLU . 82.4 mt -56.95 -46.16 82.31 Favored 'General case' 0 C--N 1.331 -0.198 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.419 179.672 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 220' ' ' ARG . . . . . 0.446 ' HA ' ' NE2' ' A' ' 223' ' ' HIS . 8.9 mpt_? -84.52 -13.72 51.06 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.083 -0.508 . . . . 0.0 111.088 179.376 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 221' ' ' ALA . . . . . . . . . . . . . . . -81.09 -19.94 42.59 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.249 -0.432 . . . . 0.0 111.864 -179.551 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 222' ' ' GLU . . . . . 0.484 ' HG2' ' O ' ' A' ' 219' ' ' LEU . 11.6 pt-20 -79.06 -11.26 59.99 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.754 0.311 . . . . 0.0 111.154 -179.182 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 223' ' ' HIS . . . . . 0.446 ' NE2' ' HA ' ' A' ' 220' ' ' ARG . 30.9 p80 -134.43 -5.1 2.6 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.316 -0.402 . . . . 0.0 110.969 -179.975 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 224' ' ' GLY . . . . . . . . . . . . . . . -76.09 -4.12 77.31 Favored Glycine 0 C--N 1.33 0.201 0 C-N-CA 120.749 -0.739 . . . . 0.0 112.421 179.904 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 225' ' ' GLU . . . . . . . . . . . . . 12.4 pt-20 -106.58 144.2 33.59 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-O 120.749 0.309 . . . . 0.0 110.932 179.952 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 226' ' ' SER . . . . . . . . . . . . . 67.1 m 59.96 107.53 0.02 OUTLIER 'General case' 0 C--N 1.331 -0.202 0 CA-C-N 115.994 -0.548 . . . . 0.0 111.172 -179.82 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 227' ' ' LEU . . . . . 0.41 ' N ' HD13 ' A' ' 227' ' ' LEU . 6.9 mp -84.14 -35.98 23.24 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 115.996 -0.547 . . . . 0.0 110.792 -179.854 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 228' ' ' ALA . . . . . . . . . . . . . . . 51.18 30.59 5.85 Favored 'General case' 0 C--N 1.332 -0.172 0 CA-C-N 116.136 -0.484 . . . . 0.0 111.537 179.875 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 229' ' ' GLY . . . . . . . . . . . . . . . -121.16 -50.24 0.26 Allowed Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.665 -0.779 . . . . 0.0 112.747 -179.934 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 230' ' ' VAL . . . . . . . . . . . . . 44.5 t -103.11 114.0 41.47 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-O 120.68 0.276 . . . . 0.0 111.038 -179.873 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 231' ' ' ASP . . . . . . . . . . . . . 6.4 p-10 -58.8 131.49 51.09 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.82 -179.984 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 232' ' ' THR . . . . . . . . . . . . . 4.9 t -167.16 136.56 2.82 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.115 -0.493 . . . . 0.0 111.346 -179.855 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 233' ' ' ASP . . . . . . . . . . . . . 9.5 m-20 -137.08 150.66 48.18 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.001 -0.545 . . . . 0.0 110.864 179.76 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 234' ' ' THR . . . . . 0.523 ' HB ' ' HD3' ' A' ' 235' ' ' PRO . 83.4 m -77.03 -48.91 2.52 Favored Pre-proline 0 CA--C 1.533 0.301 0 CA-C-N 116.326 -0.397 . . . . 0.0 111.827 -179.867 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 235' ' ' PRO . . . . . 0.523 ' HD3' ' HB ' ' A' ' 234' ' ' THR . 71.5 Cg_exo -48.72 141.26 21.15 Favored 'Trans proline' 0 C--N 1.355 0.87 0 C-N-CA 122.3 2.0 . . . . 0.0 112.454 -179.997 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 236' ' ' ALA . . . . . . . . . . . . . . . -58.52 134.85 57.06 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-N 116.132 -0.485 . . . . 0.0 111.228 -179.87 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 237' ' ' VAL . . . . . 0.511 HG22 ' H ' ' A' ' 239' ' ' ASP . 15.0 p -105.33 148.94 9.16 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.23 0 CA-C-N 116.112 -0.495 . . . . 0.0 111.055 -179.998 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 238' ' ' ALA . . . . . . . . . . . . . . . -95.06 21.33 7.88 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.27 -0.423 . . . . 0.0 111.233 -179.991 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 239' ' ' ASP . . . . . 0.511 ' H ' HG22 ' A' ' 237' ' ' VAL . 7.1 m-20 59.11 -177.82 0.08 Allowed 'General case' 0 C--N 1.331 -0.201 0 CA-C-N 116.265 -0.425 . . . . 0.0 111.308 179.847 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 240' ' ' LEU . . . . . . . . . . . . . 3.3 mm? -108.45 130.83 55.24 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.821 179.812 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 241' ' ' GLU . . . . . . . . . . . . . 44.5 mt-10 -116.68 -26.28 7.06 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.373 -0.376 . . . . 0.0 110.849 179.746 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 242' ' ' HIS . . . . . . . . . . . . . 70.2 m80 -95.29 -40.87 9.32 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.902 179.875 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 243' ' ' HIS . . . . . . . . . . . . . 78.4 m80 -79.93 141.45 36.04 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.125 -0.488 . . . . 0.0 110.787 179.962 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 244' ' ' HIS . . . . . . . . . . . . . 2.7 p80 -113.05 168.17 9.92 Favored 'General case' 0 C--N 1.331 -0.218 0 CA-C-N 116.246 -0.434 . . . . 0.0 111.123 -179.737 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 245' ' ' HIS . . . . . . . . . . . . . 55.9 t-80 58.65 96.86 0.02 OUTLIER 'General case' 0 C--O 1.233 0.201 0 CA-C-N 115.823 -0.626 . . . . 0.0 111.078 179.844 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 246' ' ' HIS . . . . . . . . . . . . . 44.9 t-80 -157.63 149.95 22.57 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.833 -179.995 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 247' ' ' HIS . . . . . . . . . . . . . 62.2 m80 . . . . . 0 C--O 1.25 1.107 0 CA-C-O 118.341 -0.838 . . . . 0.0 110.957 -179.909 . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 301' ' ' RET . . . . . 0.583 ' H22' ' HA3' ' A' ' 112' ' ' GLY . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 87.3 mmm . . . . . 0 N--CA 1.485 1.317 0 CA-C-O 120.667 0.27 . . . . 0.0 110.997 . . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 41.8 t 56.57 89.36 0.04 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.114 179.99 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . 146.06 -37.65 1.23 Allowed Glycine 0 N--CA 1.452 -0.3 0 C-N-CA 120.846 -0.693 . . . . 0.0 112.72 -179.897 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 59.0 tp -74.44 -38.16 63.08 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.886 0.375 . . . . 0.0 110.988 -179.967 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 40.6 p -65.0 -29.57 70.5 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 115.936 -0.574 . . . . 0.0 111.442 -179.74 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 17.8 p -51.92 -35.22 44.92 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.278 -0.419 . . . . 0.0 111.561 -179.497 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 7' ' ' LEU . . . . . . . . . . . . . 4.0 mm? -58.22 -53.4 58.73 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.332 -0.395 . . . . 0.0 111.216 -179.877 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 8' ' ' PHE . . . . . 0.403 ' HB2' ' HB2' ' A' ' 55' ' ' ALA . 74.2 m-85 -61.47 -35.21 77.0 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.826 179.998 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 9' ' ' TRP . . . . . . . . . . . . . 55.2 m95 -64.74 -41.26 96.07 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 115.991 -0.55 . . . . 0.0 110.227 179.916 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 44.9 mt -62.37 -46.46 88.54 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 115.817 -0.629 . . . . 0.0 110.461 179.53 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . 0.403 ' O ' ' HG2' ' A' ' 15' ' ' MET . . . -61.99 -32.57 82.62 Favored Glycine 0 N--CA 1.45 -0.425 0 C-N-CA 120.703 -0.761 . . . . 0.0 111.817 179.369 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -67.56 -34.26 76.7 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-O 120.83 0.348 . . . . 0.0 110.707 179.852 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 65.6 mt -65.97 -46.94 86.9 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.238 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.144 179.396 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -59.83 -33.48 78.43 Favored Glycine 0 N--CA 1.45 -0.388 0 C-N-CA 120.726 -0.75 . . . . 0.0 111.712 179.208 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 15' ' ' MET . . . . . 0.643 ' HE2' ' HD2' ' A' ' 205' ' ' LYS . 24.1 mmt -70.33 -40.56 74.08 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 120.861 0.362 . . . . 0.0 110.507 179.425 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 27.9 tp -57.66 -39.31 76.77 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.047 -0.524 . . . . 0.0 110.562 179.792 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 56.1 t -67.28 -48.0 79.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.062 -0.517 . . . . 0.0 110.89 179.973 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -62.57 -49.33 74.45 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.705 -0.759 . . . . 0.0 111.86 179.507 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 38.2 m -49.65 -44.49 47.7 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-O 120.721 0.296 . . . . 0.0 111.279 -179.828 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 79.6 mt -72.14 -44.32 63.31 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.244 -0.434 . . . . 0.0 111.664 179.819 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -60.93 -29.93 69.91 Favored 'General case' 0 C--N 1.329 -0.299 0 N-CA-C 112.18 0.437 . . . . 0.0 112.18 -179.14 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 22' ' ' PHE . . . . . 0.464 ' HB2' HG23 ' A' ' 41' ' ' VAL . 8.7 m-85 -90.61 -34.57 15.42 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.757 0.313 . . . . 0.0 111.411 -179.31 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -67.58 -50.61 57.55 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 121.038 0.447 . . . . 0.0 111.319 -179.764 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 24' ' ' TRP . . . . . . . . . . . . . 4.7 t-105 -62.18 -37.16 84.19 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-N 115.698 -0.683 . . . . 0.0 111.187 -179.899 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -80.4 -21.23 42.46 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.853 0.359 . . . . 0.0 111.118 -179.994 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -73.56 -39.78 48.72 Favored Glycine 0 CA--C 1.519 0.295 0 C-N-CA 121.021 -0.609 . . . . 0.0 112.778 179.972 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 14.4 ptp180 -71.5 -4.21 25.46 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-O 120.715 0.293 . . . . 0.0 111.249 -179.665 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 23.6 t70 -134.91 87.06 2.31 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.316 -0.402 . . . . 0.0 110.658 179.871 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -165.95 -79.54 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.066 -0.515 . . . . 0.0 111.281 -179.908 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -169.04 -146.61 5.08 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.697 -179.853 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 57.8 m -117.06 -53.2 2.49 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.801 0.334 . . . . 0.0 111.125 -179.948 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -65.47 -27.69 72.79 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.811 -0.709 . . . . 0.0 112.87 -179.861 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 13.7 mm-40 -86.69 -21.47 26.65 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.663 0.268 . . . . 0.0 111.106 -179.654 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 34' ' ' ARG . . . . . . . . . . . . . 37.2 ttm180 -54.54 -29.63 51.5 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.31 -0.405 . . . . 0.0 111.416 -179.401 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 55.0 ttp180 -59.17 -40.87 86.96 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.852 0.358 . . . . 0.0 110.828 -179.899 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 63.7 m-85 -72.74 -31.21 64.78 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.123 -0.489 . . . . 0.0 110.997 -179.971 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 37' ' ' TYR . . . . . . . . . . . . . 65.9 m-85 -70.34 -54.85 10.84 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.197 -179.876 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 78.4 t -57.14 -38.99 63.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-O 120.873 0.368 . . . . 0.0 110.573 179.776 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 19.1 m -63.19 -50.48 70.14 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 115.929 -0.578 . . . . 0.0 110.79 179.405 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 40' ' ' LEU . . . . . 0.608 HD12 HD13 ' A' ' 43' ' ' ILE . 41.4 tp -56.99 -45.77 82.74 Favored 'General case' 0 C--O 1.235 0.323 0 CA-C-N 115.693 -0.685 . . . . 0.0 110.739 179.937 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . 0.464 HG23 ' HB2' ' A' ' 22' ' ' PHE . 94.3 t -62.16 -33.56 59.24 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.497 0 CA-C-N 116.103 -0.498 . . . . 0.0 109.698 179.001 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -58.17 -48.78 81.11 Favored Glycine 0 N--CA 1.45 -0.378 0 CA-C-N 115.49 -0.777 . . . . 0.0 113.135 179.888 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 43' ' ' ILE . . . . . 0.608 HD13 HD12 ' A' ' 40' ' ' LEU . 17.0 pt -64.72 -47.02 90.45 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.215 0 CA-C-N 117.213 0.506 . . . . 0.0 111.599 -179.61 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 67.9 m -61.92 -27.88 69.13 Favored 'General case' 0 C--O 1.232 0.149 0 CA-C-O 120.907 0.384 . . . . 0.0 110.945 179.496 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -79.45 -52.86 4.6 Favored Glycine 0 CA--C 1.517 0.212 0 CA-C-N 115.934 -0.575 . . . . 0.0 113.423 -179.119 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 46' ' ' ILE . . . . . 0.501 HG13 HG23 ' A' ' 79' ' ' THR . 7.2 pt -57.81 -40.22 74.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-O 121.001 0.429 . . . . 0.0 111.002 -179.613 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 47' ' ' ALA . . . . . 0.595 ' HB2' ' HE2' ' A' ' 205' ' ' LYS . . . -68.31 -42.82 78.83 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.21 179.195 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 48' ' ' ALA . . . . . 0.405 ' HB1' ' HB3' ' A' ' 15' ' ' MET . . . -54.24 -43.18 70.69 Favored 'General case' 0 C--O 1.232 0.16 0 CA-C-N 116.326 -0.397 . . . . 0.0 111.763 -179.339 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 32.5 m -73.28 -34.22 43.38 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 116.492 -0.322 . . . . 0.0 111.445 -179.572 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -64.07 -37.79 88.73 Favored 'General case' 0 C--N 1.332 -0.174 0 CA-C-O 120.897 0.379 . . . . 0.0 111.217 179.827 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 35.6 m-85 -72.18 -39.27 68.77 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 115.996 -0.547 . . . . 0.0 110.704 -179.623 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -62.82 -50.52 70.63 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 115.944 -0.571 . . . . 0.0 111.301 179.739 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 18.5 m -65.6 -43.06 94.13 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.189 0 CA-C-N 116.365 -0.379 . . . . 0.0 111.281 -179.666 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 54' ' ' MET . . . . . 0.452 ' HG3' ' HE1' ' A' ' 60' ' ' TRP . 10.9 ttp -68.55 -29.98 68.66 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.886 0.374 . . . . 0.0 110.306 179.897 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 55' ' ' ALA . . . . . 0.403 ' HB2' ' HB2' ' A' ' 8' ' ' PHE . . . -64.67 -36.86 85.65 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 115.939 -0.573 . . . . 0.0 110.939 179.328 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 86.7 mt -74.45 -1.0 19.23 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.061 -0.518 . . . . 0.0 111.245 -179.681 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 92.78 4.31 65.48 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.668 -0.777 . . . . 0.0 112.448 179.987 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 46.8 t -74.08 144.63 12.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-O 120.819 0.342 . . . . 0.0 111.187 -179.915 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 59' ' ' GLY . . . . . 0.402 ' HA3' ' HD3' ' A' ' 71' ' ' PRO . . . 76.7 5.86 84.09 Favored Glycine 0 CA--C 1.519 0.335 0 C-N-CA 120.946 -0.645 . . . . 0.0 112.815 -179.975 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 60' ' ' TRP . . . . . 0.452 ' HE1' ' HG3' ' A' ' 54' ' ' MET . 24.7 m0 -81.8 118.06 22.58 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.684 0.278 . . . . 0.0 111.076 -179.908 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 61' ' ' VAL . . . . . 0.457 HG13 ' HE1' ' A' ' 117' ' ' MET . 7.3 p -115.49 126.33 27.87 Favored Pre-proline 0 CA--C 1.533 0.313 0 CA-C-N 116.491 -0.322 . . . . 0.0 111.307 179.757 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 9.2 Cg_exo -72.13 142.69 38.52 Favored 'Trans proline' 0 C--N 1.349 0.603 0 C-N-CA 122.705 2.27 . . . . 0.0 112.081 179.739 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 98.1 t -142.36 94.33 0.57 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.064 179.968 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . 58.58 -90.14 0.03 OUTLIER 'General case' 0 C--N 1.332 -0.182 0 CA-C-N 115.973 -0.558 . . . . 0.0 111.622 179.857 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 18.5 mm-40 -117.36 -21.53 8.65 Favored 'General case' 0 C--N 1.332 -0.161 0 CA-C-N 116.39 -0.368 . . . . 0.0 111.048 -179.694 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 66' ' ' ARG . . . . . . . . . . . . . 30.7 ptt180 -107.17 158.64 16.94 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.174 -0.467 . . . . 0.0 110.629 179.911 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 60.5 m -117.76 115.24 24.62 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.386 -0.37 . . . . 0.0 111.651 -179.514 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 21.0 t -87.47 146.79 5.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 115.92 -0.582 . . . . 0.0 110.415 179.436 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 69' ' ' PHE . . . . . . . . . . . . . 26.6 m-85 -108.03 114.19 27.92 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-O 120.903 0.382 . . . . 0.0 110.096 -179.557 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 70' ' ' VAL . . . . . 0.584 ' N ' ' HD2' ' A' ' 71' ' ' PRO . 12.4 t -67.7 -48.98 41.19 Favored Pre-proline 0 C--N 1.324 -0.524 0 CA-C-N 115.921 -0.582 . . . . 0.0 112.117 -178.982 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 71' ' ' PRO . . . . . 0.584 ' HD2' ' N ' ' A' ' 70' ' ' VAL . 30.0 Cg_endo -62.64 -17.67 59.88 Favored 'Trans proline' 0 C--N 1.351 0.677 0 C-N-CA 122.166 1.91 . . . . 0.0 112.508 -179.64 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 34.2 ttp180 -69.75 -55.4 9.99 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.431 -0.349 . . . . 0.0 111.53 -179.455 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 73' ' ' TYR . . . . . 0.487 ' O ' HG13 ' A' ' 77' ' ' ILE . 74.0 m-85 -70.99 -36.39 72.47 Favored 'General case' 0 C--N 1.33 -0.264 0 C-N-CA 120.854 -0.338 . . . . 0.0 110.602 -179.577 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 0.3 OUTLIER -64.78 -41.43 92.17 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.199 0 N-CA-C 109.935 -0.394 . . . . 0.0 109.935 179.291 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 10.7 t70 -56.97 -38.1 72.51 Favored 'General case' 0 CA--C 1.518 -0.276 0 N-CA-C 109.007 -0.738 . . . . 0.0 109.007 178.531 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 76' ' ' TRP . . . . . 0.435 ' HA ' ' OG1' ' A' ' 79' ' ' THR . 44.6 m0 -66.88 -30.31 70.44 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 115.588 -0.733 . . . . 0.0 110.895 179.27 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 77' ' ' ILE . . . . . 0.522 ' O ' ' HG2' ' A' ' 81' ' ' PRO . 69.8 mt -67.13 -36.54 77.18 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.302 -0.408 . . . . 0.0 111.032 179.842 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 78' ' ' LEU . . . . . 0.55 HD13 HG22 ' A' ' 79' ' ' THR . 2.7 pp -91.59 -23.24 19.95 Favored 'General case' 0 C--N 1.326 -0.448 0 N-CA-C 112.76 0.652 . . . . 0.0 112.76 -179.871 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 79' ' ' THR . . . . . 0.55 HG22 HD13 ' A' ' 78' ' ' LEU . 40.9 p -88.05 -53.77 4.56 Favored 'General case' 0 N--CA 1.471 0.582 0 N-CA-C 113.49 0.922 . . . . 0.0 113.49 -179.011 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 80' ' ' THR . . . . . 0.614 ' HB ' ' HD3' ' A' ' 81' ' ' PRO . 18.2 m -53.69 -55.45 35.3 Favored Pre-proline 0 C--N 1.331 -0.21 0 N-CA-C 113.192 0.812 . . . . 0.0 113.192 -177.475 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 81' ' ' PRO . . . . . 0.614 ' HD3' ' HB ' ' A' ' 80' ' ' THR . 77.1 Cg_exo -53.45 -25.47 32.04 Favored 'Trans proline' 0 C--N 1.35 0.63 0 C-N-CA 121.567 1.511 . . . . 0.0 112.09 -179.842 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 82' ' ' LEU . . . . . . . . . . . . . 11.5 tp -76.69 -33.17 58.24 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.171 179.521 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 83' ' ' ILE . . . . . 0.43 HD13 HG22 ' A' ' 43' ' ' ILE . 36.6 mm -66.54 -53.37 36.32 Favored 'Isoleucine or valine' 0 C--O 1.234 0.255 0 CA-C-N 116.172 -0.467 . . . . 0.0 109.955 178.678 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 33.8 m -61.21 -30.05 47.06 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.217 0 CA-C-N 115.887 -0.597 . . . . 0.0 109.61 178.875 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 85' ' ' TYR . . . . . . . . . . . . . 85.4 t80 -67.92 -31.41 71.15 Favored 'General case' 0 N--CA 1.453 -0.285 0 CA-C-N 115.566 -0.743 . . . . 0.0 109.379 178.758 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 86' ' ' PHE . . . . . . . . . . . . . 7.6 t80 -62.51 -51.51 67.13 Favored 'General case' 0 N--CA 1.455 -0.211 0 CA-C-N 115.755 -0.657 . . . . 0.0 109.598 179.087 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 7.2 mt -61.91 -33.06 73.54 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 115.813 -0.631 . . . . 0.0 109.913 179.205 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -66.58 -27.66 73.31 Favored Glycine 0 N--CA 1.452 -0.293 0 CA-C-N 115.25 -0.886 . . . . 0.0 112.044 179.425 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 65.4 mt -74.18 -44.48 53.29 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-O 121.028 0.442 . . . . 0.0 110.749 179.826 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 78.4 mt -61.23 -31.85 71.63 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 115.823 -0.626 . . . . 0.0 111.151 -179.937 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -88.36 -38.77 14.84 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.328 -0.396 . . . . 0.0 111.788 -179.433 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 85.09 70.62 1.33 Allowed Glycine 0 CA--C 1.517 0.187 0 C-N-CA 120.701 -0.761 . . . . 0.0 112.145 -179.316 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 93' ' ' LEU . . . . . 0.463 HD13 ' HE2' ' A' ' 145' ' ' MET . 20.0 mt -87.58 169.11 12.45 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.906 0.384 . . . . 0.0 111.371 -179.447 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 94' ' ' ASP . . . . . 0.447 ' HB3' ' HG3' ' A' ' 97' ' ' GLU . 18.6 t70 -79.77 161.56 25.64 Favored 'General case' 0 C--N 1.332 -0.168 0 CA-C-N 116.027 -0.533 . . . . 0.0 110.599 179.661 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 71.0 m -55.91 -44.79 78.61 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.418 -0.356 . . . . 0.0 111.126 -179.972 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 10.2 mpt_? -68.78 -48.02 64.72 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.169 -179.804 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 97' ' ' GLU . . . . . 0.447 ' HG3' ' HB3' ' A' ' 94' ' ' ASP . 47.3 mt-10 -53.95 -38.7 65.23 Favored 'General case' 0 C--O 1.234 0.238 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.839 -179.931 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 98' ' ' PHE . . . . . 0.467 ' O ' HG12 ' A' ' 102' ' ' ILE . 5.6 m-85 -60.08 -49.96 75.58 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.392 179.4 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -59.26 -26.16 61.15 Favored Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.705 -0.759 . . . . 0.0 112.515 179.97 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 100' ' ' ILE . . . . . 0.437 HD11 ' HA ' ' A' ' 97' ' ' GLU . 97.7 mt -68.85 -50.61 52.98 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.194 0 CA-C-O 120.803 0.335 . . . . 0.0 111.527 -179.921 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 29.6 m -70.59 -36.24 64.83 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.369 0 CA-C-N 116.437 -0.347 . . . . 0.0 111.748 -179.567 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 102' ' ' ILE . . . . . 0.58 HG22 ' HB3' ' A' ' 81' ' ' PRO . 49.5 mm -67.0 -46.72 84.11 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.626 -0.261 . . . . 0.0 111.35 -179.707 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 15.3 t -63.51 -35.32 80.09 Favored 'General case' 0 C--O 1.233 0.201 0 CA-C-O 120.75 0.309 . . . . 0.0 110.954 179.925 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 104' ' ' LEU . . . . . 0.414 ' O ' HG22 ' A' ' 108' ' ' VAL . 2.8 tm? -57.52 -53.75 54.62 Favored 'General case' 0 C--N 1.331 -0.199 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.259 179.54 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 105' ' ' ASN . . . . . 0.585 HD22 HD13 ' A' ' 137' ' ' LEU . 0.8 OUTLIER -55.71 -37.93 69.06 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.498 179.527 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 44.0 m -55.19 -41.72 72.31 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-O 120.886 0.374 . . . . 0.0 110.467 179.576 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 2.1 t -64.5 -37.59 80.41 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.198 0 CA-C-O 121.38 0.61 . . . . 0.0 109.867 178.99 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . 0.414 HG22 ' O ' ' A' ' 104' ' ' LEU . 26.1 t -61.49 -50.16 81.48 Favored 'Isoleucine or valine' 0 C--O 1.236 0.361 0 CA-C-N 115.089 -0.959 . . . . 0.0 111.502 -179.91 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 109' ' ' MET . . . . . 0.459 ' HE1' HG21 ' A' ' 80' ' ' THR . 9.1 mmt -63.02 -37.14 85.99 Favored 'General case' 0 C--N 1.331 -0.2 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.872 -179.838 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 31.8 tp -62.04 -33.84 75.13 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.54 179.776 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -64.75 -52.06 58.98 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 115.988 -0.551 . . . . 0.0 110.711 179.473 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . -62.23 -39.13 97.29 Favored Glycine 0 C--N 1.331 0.252 0 C-N-CA 120.484 -0.865 . . . . 0.0 112.137 179.5 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 113' ' ' PHE . . . . . . . . . . . . . 0.5 OUTLIER -52.86 -72.69 0.05 Allowed 'General case' 0 C--N 1.33 -0.255 0 CA-C-O 121.052 0.453 . . . . 0.0 110.454 179.825 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 114' ' ' ALA . . . . . 0.474 ' HB2' HD23 ' A' ' 126' ' ' LEU . . . -65.46 -12.66 54.66 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 115.708 -0.678 . . . . 0.0 111.385 -179.899 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -66.31 -43.58 92.51 Favored Glycine 0 C--N 1.33 0.238 0 C-N-CA 120.804 -0.712 . . . . 0.0 112.69 -179.959 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -78.06 -25.73 47.89 Favored 'General case' 0 C--N 1.329 -0.29 0 N-CA-C 112.154 0.427 . . . . 0.0 112.154 -179.721 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 117' ' ' MET . . . . . 0.457 ' HE1' HG13 ' A' ' 61' ' ' VAL . 67.5 mtt -91.81 19.42 6.55 Favored 'General case' 0 C--N 1.329 -0.292 0 N-CA-C 111.868 0.321 . . . . 0.0 111.868 -179.164 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 118' ' ' VAL . . . . . 0.52 HG23 ' HB3' ' A' ' 123' ' ' ARG . 17.5 m -68.33 138.88 91.85 Favored Pre-proline 0 C--N 1.329 -0.324 0 CA-C-O 120.54 0.21 . . . . 0.0 111.169 179.862 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 119' ' ' PRO . . . . . . . . . . . . . 95.1 Cg_endo -86.6 11.56 3.25 Favored 'Trans proline' 0 C--N 1.348 0.55 0 C-N-CA 122.554 2.17 . . . . 0.0 112.339 179.922 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -164.6 -120.7 0.53 Allowed Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.86 -0.686 . . . . 0.0 112.616 -179.811 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 42.3 pt -113.89 14.04 8.22 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.219 0 CA-C-O 120.812 0.339 . . . . 0.0 111.319 -179.861 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 49.0 mt-10 -61.38 -17.53 54.49 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.081 -0.509 . . . . 0.0 111.082 179.808 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 123' ' ' ARG . . . . . 0.52 ' HB3' HG23 ' A' ' 118' ' ' VAL . 14.7 ptt180 -50.44 -29.33 10.03 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.003 -0.544 . . . . 0.0 111.769 -179.821 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 124' ' ' TYR . . . . . . . . . . . . . 33.2 m-85 -74.79 -31.93 61.87 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.46 -0.336 . . . . 0.0 111.302 -179.461 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 125' ' ' ALA . . . . . . . . . . . . . . . -73.0 -56.47 5.08 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-N 116.296 -0.411 . . . . 0.0 111.045 -179.776 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 126' ' ' LEU . . . . . 0.474 HD23 ' HB2' ' A' ' 114' ' ' ALA . 1.3 mt -54.62 -46.52 73.89 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 115.968 -0.56 . . . . 0.0 110.676 179.826 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 127' ' ' PHE . . . . . . . . . . . . . 4.9 t80 -68.22 -37.37 80.76 Favored 'General case' 0 N--CA 1.453 -0.319 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.648 179.766 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 128' ' ' GLY . . . . . . . . . . . . . . . -46.38 -44.15 15.35 Favored Glycine 0 C--N 1.333 0.387 0 C-N-CA 120.14 -1.029 . . . . 0.0 110.607 178.941 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 129' ' ' MET . . . . . 0.494 ' HE3' ' N ' ' A' ' 130' ' ' GLY . 6.0 tmm? -69.52 -41.54 75.86 Favored 'General case' 0 C--N 1.328 -0.357 0 N-CA-C 109.357 -0.608 . . . . 0.0 109.357 178.266 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 130' ' ' GLY . . . . . 0.494 ' N ' ' HE3' ' A' ' 129' ' ' MET . . . -55.49 -39.49 74.2 Favored Glycine 0 N--CA 1.452 -0.278 0 CA-C-N 115.724 -0.671 . . . . 0.0 113.044 -179.711 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -70.03 -53.12 19.03 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.699 0.285 . . . . 0.0 110.609 179.955 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 53.0 t -54.93 -39.93 51.08 Favored 'Isoleucine or valine' 0 C--O 1.233 0.215 0 CA-C-O 121.307 0.575 . . . . 0.0 109.607 178.88 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -69.25 -35.99 76.69 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 115.381 -0.827 . . . . 0.0 110.279 179.391 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 134' ' ' PHE . . . . . . . . . . . . . 47.6 t80 -58.48 -52.95 63.48 Favored 'General case' 0 N--CA 1.45 -0.43 0 CA-C-N 115.932 -0.577 . . . . 0.0 109.817 179.281 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 135' ' ' ILE . . . . . 0.461 ' O ' HG22 ' A' ' 138' ' ' VAL . 45.2 mt -58.34 -30.52 40.55 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.282 0 CA-C-N 115.699 -0.682 . . . . 0.0 109.741 178.892 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 136' ' ' GLY . . . . . 0.425 ' O ' ' HB3' ' A' ' 139' ' ' TYR . . . -59.47 -42.69 97.71 Favored Glycine 0 N--CA 1.447 -0.574 0 C-N-CA 120.42 -0.895 . . . . 0.0 111.364 178.867 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 137' ' ' LEU . . . . . 0.585 HD13 HD22 ' A' ' 105' ' ' ASN . 53.8 tp -67.24 -54.62 19.29 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.565 0.222 . . . . 0.0 110.666 179.316 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 138' ' ' VAL . . . . . 0.461 HG22 ' O ' ' A' ' 135' ' ' ILE . 3.0 m -54.71 -30.4 22.38 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.134 0 CA-C-O 121.08 0.466 . . . . 0.0 109.805 -179.672 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 139' ' ' TYR . . . . . 0.425 ' HB3' ' O ' ' A' ' 136' ' ' GLY . 20.8 t80 -61.68 -48.14 82.16 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 115.526 -0.761 . . . . 0.0 110.076 178.227 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 37.5 m-85 -63.27 -40.32 97.06 Favored 'General case' 0 C--O 1.232 0.156 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.971 179.537 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 141' ' ' LEU . . . . . . . . . . . . . 11.1 mp -54.63 -55.06 33.48 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.09 -179.824 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 10.7 p -76.95 -15.93 14.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-O 121.024 0.44 . . . . 0.0 110.985 179.911 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . -73.55 -133.34 0.22 Allowed Glycine 0 CA--C 1.522 0.528 0 C-N-CA 120.867 -0.683 . . . . 0.0 112.812 -179.883 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 144' ' ' PRO . . . . . . . . . . . . . 52.2 Cg_exo -55.5 -28.56 64.98 Favored 'Trans proline' 0 C--N 1.349 0.579 0 C-N-CA 122.746 2.297 . . . . 0.0 112.885 -179.653 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 145' ' ' MET . . . . . 0.463 ' HE2' HD13 ' A' ' 93' ' ' LEU . 43.2 mtt -56.67 -36.31 69.43 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.382 -0.372 . . . . 0.0 111.352 -179.875 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 146' ' ' THR . . . . . . . . . . . . . 24.7 m -68.09 -48.0 66.71 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.836 -179.303 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 20.0 mm-40 -71.16 -26.31 62.93 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.557 -0.292 . . . . 0.0 111.369 -179.544 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 148' ' ' SER . . . . . . . . . . . . . 47.7 t -70.71 -49.47 46.66 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.312 -0.403 . . . . 0.0 111.312 -179.557 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 149' ' ' ALA . . . . . . . . . . . . . . . -75.1 -33.87 61.67 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.074 -0.512 . . . . 0.0 111.678 -179.416 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 150' ' ' SER . . . . . . . . . . . . . 43.5 t -67.24 -12.74 60.88 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.328 -179.636 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 151' ' ' GLN . . . . . . . . . . . . . 77.7 mt-30 -119.03 12.1 12.65 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.486 -0.325 . . . . 0.0 111.42 -179.756 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 31.4 tpt180 -84.56 -51.36 6.94 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 120.81 0.338 . . . . 0.0 110.865 -179.759 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 153' ' ' SER . . . . . 0.626 ' HB3' HG12 ' A' ' 156' ' ' ILE . 18.3 t -157.69 172.46 18.48 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 116.119 -0.492 . . . . 0.0 110.715 179.41 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 154' ' ' SER . . . . . . . . . . . . . 47.0 t -68.86 -41.05 78.93 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.303 -0.408 . . . . 0.0 110.802 179.787 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -76.69 -35.79 39.49 Favored Glycine 0 N--CA 1.452 -0.259 0 C-N-CA 120.98 -0.629 . . . . 0.0 112.974 -179.909 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 156' ' ' ILE . . . . . 0.626 HG12 ' HB3' ' A' ' 153' ' ' SER . 43.1 mm -55.34 -36.82 41.99 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.237 0 CA-C-O 120.714 0.292 . . . . 0.0 111.518 -179.769 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 157' ' ' LYS . . . . . 0.618 ' HB3' ' HZ2' ' A' ' 157' ' ' LYS . 6.5 ttpm? -59.51 -53.75 54.53 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 116.415 -0.357 . . . . 0.0 111.759 -179.45 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 42.8 t -67.37 -41.01 85.75 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.445 -0.343 . . . . 0.0 111.714 -179.198 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 159' ' ' LEU . . . . . 0.449 ' O ' HD23 ' A' ' 159' ' ' LEU . 4.1 tt -67.72 -34.55 77.08 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 116.432 -0.349 . . . . 0.0 111.045 -179.554 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 160' ' ' TYR . . . . . . . . . . . . . 67.6 t80 -73.88 -45.81 48.6 Favored 'General case' 0 C--N 1.33 -0.278 0 N-CA-C 112.026 0.38 . . . . 0.0 112.026 -179.165 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 22.7 m -59.82 -43.55 92.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 N-CA-C 111.673 0.249 . . . . 0.0 111.673 -179.252 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 162' ' ' ARG . . . . . 0.454 HH22 ' HB2' ' A' ' 215' ' ' ALA . 86.8 mtm180 -68.99 -38.02 79.06 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.77 0.319 . . . . 0.0 111.218 -179.977 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 163' ' ' LEU . . . . . 0.545 ' HG ' ' HB2' ' A' ' 208' ' ' PHE . 3.4 mp -69.5 -54.17 15.51 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.643 -179.58 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 164' ' ' ARG . . . . . . . . . . . . . 4.7 tmm_? -58.71 -53.54 57.2 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.545 -179.236 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 165' ' ' ASN . . . . . 0.501 ' N ' HD21 ' A' ' 165' ' ' ASN . 0.9 OUTLIER -53.59 -52.12 60.81 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 120.876 0.37 . . . . 0.0 111.659 -179.273 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 166' ' ' LEU . . . . . 0.491 ' O ' ' HG ' ' A' ' 170' ' ' LEU . 2.1 tt -61.09 -53.33 58.46 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.065 -0.516 . . . . 0.0 111.771 -179.129 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 167' ' ' THR . . . . . 0.498 ' O ' ' HB2' ' A' ' 171' ' ' TRP . 86.0 m -55.47 -53.7 53.02 Favored 'General case' 0 C--N 1.327 -0.395 0 N-CA-C 112.8 0.667 . . . . 0.0 112.8 -178.661 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 168' ' ' VAL . . . . . . . . . . . . . 89.7 t -54.64 -44.61 70.4 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.244 0 N-CA-C 112.371 0.508 . . . . 0.0 112.371 -178.563 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 169' ' ' VAL . . . . . 0.413 HG22 ' O ' ' A' ' 165' ' ' ASN . 75.4 t -58.43 -64.79 0.5 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.421 0 N-CA-C 112.149 0.426 . . . . 0.0 112.149 -178.962 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 170' ' ' LEU . . . . . 0.491 ' HG ' ' O ' ' A' ' 166' ' ' LEU . 1.4 pp -62.3 -29.75 70.65 Favored 'General case' 0 C--N 1.33 -0.255 0 N-CA-C 112.011 0.374 . . . . 0.0 112.011 -178.863 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 171' ' ' TRP . . . . . 0.503 ' NE1' H203 ' A' ' 301' ' ' RET . 2.2 m0 -71.88 -31.2 66.21 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.861 0.362 . . . . 0.0 110.939 179.827 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 172' ' ' ALA . . . . . . . . . . . . . . . -72.18 -6.1 40.36 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.667 179.962 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 173' ' ' ILE . . . . . 0.52 HG23 HD12 ' A' ' 177' ' ' ILE . 29.0 mm -85.24 -21.28 7.91 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.188 0 CA-C-N 115.764 -0.653 . . . . 0.0 111.141 179.79 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 174' ' ' TYR . . . . . . . . . . . . . 28.0 m-85 -54.44 -50.47 84.98 Favored Pre-proline 0 N--CA 1.466 0.326 0 CA-C-N 116.437 -0.347 . . . . 0.0 111.673 -179.836 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 175' ' ' PRO . . . . . . . . . . . . . 86.7 Cg_exo -45.87 -29.9 6.32 Favored 'Trans proline' 0 C--N 1.353 0.777 0 C-N-CA 122.233 1.955 . . . . 0.0 112.358 179.844 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 176' ' ' PHE . . . . . 0.428 ' O ' ' HG ' ' A' ' 180' ' ' LEU . 92.1 m-85 -80.15 -49.3 11.88 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 115.976 -0.556 . . . . 0.0 111.699 -179.822 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 177' ' ' ILE . . . . . 0.52 HD12 HG23 ' A' ' 173' ' ' ILE . 2.9 mm -60.3 -38.0 75.93 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.528 0 CA-C-N 116.024 -0.535 . . . . 0.0 112.008 -178.459 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 178' ' ' TRP . . . . . . . . . . . . . 70.4 t90 -73.32 -44.9 58.13 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.864 0.364 . . . . 0.0 110.922 179.748 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 179' ' ' LEU . . . . . 0.42 ' O ' ' HA3' ' A' ' 184' ' ' GLY . 1.5 tm? -65.46 -54.22 31.55 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 115.998 -0.546 . . . . 0.0 111.246 -179.323 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 180' ' ' LEU . . . . . 0.428 ' HG ' ' O ' ' A' ' 176' ' ' PHE . 18.8 mt -72.46 -45.39 59.73 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.542 -0.299 . . . . 0.0 111.631 -179.267 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . -55.35 175.69 0.71 Allowed Glycine 0 C--N 1.336 0.537 0 C-N-CA 120.487 -0.863 . . . . 0.0 112.896 179.646 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 182' ' ' PRO . . . . . 0.594 ' HA ' ' HB2' ' A' ' 186' ' ' ALA . 72.2 Cg_exo -48.07 -45.34 25.64 Favored 'Trans proline' 0 CA--C 1.536 0.596 0 C-N-CA 122.983 2.455 . . . . 0.0 113.86 -179.994 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 183' ' ' PRO . . . . . 0.443 ' HD3' ' HB2' ' A' ' 182' ' ' PRO . 52.2 Cg_exo -53.96 -13.34 4.39 Favored 'Trans proline' 0 C--N 1.355 0.92 0 C-N-CA 122.056 1.837 . . . . 0.0 112.916 -179.853 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 184' ' ' GLY . . . . . 0.42 ' HA3' ' O ' ' A' ' 179' ' ' LEU . . . -115.93 -86.34 1.28 Allowed Glycine 0 N--CA 1.45 -0.414 0 C-N-CA 120.377 -0.916 . . . . 0.0 112.871 -179.779 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 185' ' ' VAL . . . . . . . . . . . . . 6.6 m -124.59 -5.06 6.48 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 N-CA-C 112.169 0.433 . . . . 0.0 112.169 -179.495 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 186' ' ' ALA . . . . . 0.594 ' HB2' ' HA ' ' A' ' 182' ' ' PRO . . . 53.41 86.59 0.04 OUTLIER 'General case' 0 N--CA 1.463 0.224 0 CA-C-N 116.479 -0.328 . . . . 0.0 111.682 179.606 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 187' ' ' LEU . . . . . . . . . . . . . 14.1 mt -92.15 -49.36 6.23 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.396 -0.366 . . . . 0.0 111.452 179.851 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 188' ' ' LEU . . . . . 0.413 HD11 ' N ' ' A' ' 188' ' ' LEU . 6.9 mp -92.93 -88.97 0.21 Allowed 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.361 -0.381 . . . . 0.0 111.272 -179.256 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 189' ' ' THR . . . . . . . . . . . . . 1.8 t -169.82 148.7 3.28 Favored Pre-proline 0 C--N 1.325 -0.483 0 CA-C-N 116.01 -0.541 . . . . 0.0 111.078 -179.55 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 190' ' ' PRO . . . . . . . . . . . . . 10.2 Cg_endo -51.99 -42.86 56.17 Favored 'Trans proline' 0 C--N 1.35 0.649 0 C-N-CA 122.798 2.332 . . . . 0.0 113.152 -179.761 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 191' ' ' THR . . . . . . . . . . . . . 5.4 t -56.4 -44.74 80.57 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-O 120.689 0.281 . . . . 0.0 111.336 -179.59 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 192' ' ' VAL . . . . . . . . . . . . . 38.5 t -70.56 -43.62 77.62 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.389 -0.369 . . . . 0.0 111.088 179.846 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 193' ' ' ASP . . . . . . . . . . . . . 11.3 t70 -55.62 -49.16 73.56 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.942 179.867 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 194' ' ' VAL . . . . . . . . . . . . . 85.9 t -63.03 -36.98 78.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.05 -179.985 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 195' ' ' ALA . . . . . . . . . . . . . . . -59.24 -48.41 81.74 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.491 -0.322 . . . . 0.0 110.979 179.827 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 196' ' ' LEU . . . . . . . . . . . . . 65.0 mt -67.91 -43.61 78.84 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.307 -0.406 . . . . 0.0 110.641 179.761 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 197' ' ' ILE . . . . . 0.424 HD11 ' HB ' ' A' ' 177' ' ' ILE . 17.6 mm -56.51 -59.78 2.59 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 115.961 -0.563 . . . . 0.0 110.444 179.435 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 198' ' ' VAL . . . . . . . . . . . . . 76.8 t -53.06 -34.69 21.5 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.496 0 CA-C-N 115.601 -0.727 . . . . 0.0 109.467 178.512 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 199' ' ' TYR . . . . . . . . . . . . . 64.9 t80 -70.24 -31.61 69.09 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 115.524 -0.762 . . . . 0.0 110.588 179.692 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 200' ' ' LEU . . . . . 0.46 ' O ' HG11 ' A' ' 203' ' ' VAL . 32.2 mt -73.23 -43.44 61.21 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 115.841 -0.618 . . . . 0.0 111.484 -179.478 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 201' ' ' ASP . . . . . . . . . . . . . 10.5 m-20 -71.94 -36.81 70.02 Favored 'General case' 0 C--N 1.327 -0.413 0 CA-C-O 121.251 0.548 . . . . 0.0 110.087 179.511 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 202' ' ' LEU . . . . . . . . . . . . . 39.5 tp -72.73 -27.78 62.25 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 115.311 -0.859 . . . . 0.0 111.779 -179.293 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 203' ' ' VAL . . . . . 0.46 HG11 ' O ' ' A' ' 200' ' ' LEU . 12.3 p -78.71 -35.94 18.96 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.215 0 C-N-CA 120.854 -0.338 . . . . 0.0 110.779 -179.087 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 204' ' ' THR . . . . . . . . . . . . . 97.2 m -66.48 -59.0 4.05 Favored 'General case' 0 C--N 1.329 -0.304 0 C-N-CA 120.598 -0.441 . . . . 0.0 110.861 179.34 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 205' ' ' LYS . . . . . 0.643 ' HD2' ' HE2' ' A' ' 15' ' ' MET . 62.7 mttp -58.76 -57.78 11.5 Favored 'General case' 0 C--N 1.331 -0.209 0 N-CA-C 112.14 0.422 . . . . 0.0 112.14 -178.675 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 49.8 t -70.55 -37.35 69.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 N-CA-C 112.324 0.49 . . . . 0.0 112.324 -178.823 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 207' ' ' GLY . . . . . 0.539 ' O ' HG13 ' A' ' 211' ' ' ILE . . . -55.76 -62.07 6.72 Favored Glycine 0 CA--C 1.518 0.242 0 C-N-CA 120.614 -0.803 . . . . 0.0 113.873 -178.608 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 208' ' ' PHE . . . . . 0.545 ' HB2' ' HG ' ' A' ' 163' ' ' LEU . 3.0 p90 -72.86 -27.63 62.03 Favored 'General case' 0 C--O 1.221 -0.416 0 CA-C-N 117.457 0.628 . . . . 0.0 110.925 -179.231 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 209' ' ' GLY . . . . . 0.494 ' O ' ' HB3' ' A' ' 212' ' ' ALA . . . -62.06 -34.78 90.12 Favored Glycine 0 N--CA 1.449 -0.447 0 N-CA-C 111.91 -0.476 . . . . 0.0 111.91 178.761 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 210' ' ' PHE . . . . . . . . . . . . . 1.2 m-85 -73.59 -48.23 34.35 Favored 'General case' 0 CA--C 1.513 -0.456 0 N-CA-C 108.153 -1.055 . . . . 0.0 108.153 178.398 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 211' ' ' ILE . . . . . 0.539 HG13 ' O ' ' A' ' 207' ' ' GLY . 4.8 mt -61.61 -27.48 42.17 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.51 0 N-CA-C 107.784 -1.191 . . . . 0.0 107.784 176.711 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 212' ' ' ALA . . . . . 0.494 ' HB3' ' O ' ' A' ' 209' ' ' GLY . . . -63.57 -41.75 98.37 Favored 'General case' 0 N--CA 1.45 -0.474 0 CA-C-N 114.478 -1.237 . . . . 0.0 110.664 -179.775 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 213' ' ' LEU . . . . . . . . . . . . . 95.3 mt -69.29 -53.04 21.75 Favored 'General case' 0 C--N 1.332 -0.162 0 CA-C-N 115.26 -0.882 . . . . 0.0 111.398 -179.68 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 214' ' ' ASP . . . . . . . . . . . . . 9.6 m-20 -55.7 -48.66 74.75 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-O 120.878 0.37 . . . . 0.0 110.746 -179.997 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 215' ' ' ALA . . . . . 0.454 ' HB2' HH22 ' A' ' 162' ' ' ARG . . . -59.44 -57.33 13.44 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 115.988 -0.551 . . . . 0.0 110.958 179.721 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 216' ' ' ALA . . . . . . . . . . . . . . . -56.36 -31.55 63.9 Favored 'General case' 0 C--N 1.332 -0.187 0 CA-C-N 116.06 -0.518 . . . . 0.0 111.065 -179.998 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 217' ' ' ALA . . . . . 0.521 ' HA ' ' HE ' ' A' ' 220' ' ' ARG . . . -62.68 -39.26 93.38 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.407 179.615 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 218' ' ' THR . . . . . . . . . . . . . 79.1 m -73.27 -37.58 66.23 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 115.81 -0.632 . . . . 0.0 111.044 179.682 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 219' ' ' LEU . . . . . 0.427 ' HG ' ' O ' ' A' ' 215' ' ' ALA . 56.0 mt -59.49 -46.88 87.55 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.873 -179.879 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 220' ' ' ARG . . . . . 0.521 ' HE ' ' HA ' ' A' ' 217' ' ' ALA . 26.5 ptt180 -77.18 -25.33 51.72 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.815 179.923 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 221' ' ' ALA . . . . . . . . . . . . . . . -59.98 -41.56 92.3 Favored 'General case' 0 C--N 1.331 -0.201 0 CA-C-N 116.061 -0.518 . . . . 0.0 111.172 -179.943 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 222' ' ' GLU . . . . . . . . . . . . . 10.2 pt-20 -86.24 -35.18 20.15 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.782 179.957 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 223' ' ' HIS . . . . . . . . . . . . . 33.6 p80 39.94 -156.63 0.01 OUTLIER 'General case' 0 N--CA 1.466 0.352 0 CA-C-N 115.755 -0.657 . . . . 0.0 111.981 -179.982 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 224' ' ' GLY . . . . . . . . . . . . . . . 158.62 134.95 1.79 Allowed Glycine 0 N--CA 1.452 -0.257 0 C-N-CA 120.886 -0.673 . . . . 0.0 112.441 -179.839 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 225' ' ' GLU . . . . . . . . . . . . . 35.6 tt0 58.89 98.66 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.256 0 CA-C-O 120.81 0.338 . . . . 0.0 110.978 -179.963 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 226' ' ' SER . . . . . . . . . . . . . 50.3 m -62.91 148.49 47.21 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.677 179.864 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 227' ' ' LEU . . . . . 0.41 HD22 ' N ' ' A' ' 227' ' ' LEU . 3.7 mm? -82.59 144.48 30.31 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.311 -0.404 . . . . 0.0 111.007 -179.831 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 228' ' ' ALA . . . . . . . . . . . . . . . -109.21 -7.69 15.24 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 115.949 -0.569 . . . . 0.0 111.021 179.875 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 229' ' ' GLY . . . . . . . . . . . . . . . 145.71 -170.22 27.02 Favored Glycine 0 C--N 1.331 0.277 0 C-N-CA 120.741 -0.742 . . . . 0.0 112.525 179.982 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 230' ' ' VAL . . . . . . . . . . . . . 19.7 t -84.26 146.02 7.35 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.242 0 CA-C-O 120.768 0.318 . . . . 0.0 110.807 179.998 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 231' ' ' ASP . . . . . . . . . . . . . 6.7 p-10 -67.6 116.86 8.8 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.825 -179.969 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 232' ' ' THR . . . . . . . . . . . . . 71.9 p -132.0 2.08 3.96 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.094 -0.503 . . . . 0.0 111.175 -179.904 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 233' ' ' ASP . . . . . . . . . . . . . 14.2 t70 -77.17 -24.45 51.47 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.961 179.956 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 234' ' ' THR . . . . . . . . . . . . . 48.0 m 57.05 87.05 0.15 Allowed Pre-proline 0 C--N 1.33 -0.247 0 CA-C-N 116.134 -0.484 . . . . 0.0 111.339 179.978 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 235' ' ' PRO . . . . . . . . . . . . . 43.3 Cg_exo -57.4 115.8 2.76 Favored 'Trans proline' 0 C--N 1.348 0.544 0 C-N-CA 122.44 2.093 . . . . 0.0 112.111 179.838 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 236' ' ' ALA . . . . . . . . . . . . . . . -146.94 124.39 11.66 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.13 -0.486 . . . . 0.0 111.251 -179.825 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 237' ' ' VAL . . . . . . . . . . . . . 51.5 t 62.25 108.13 0.04 OUTLIER 'Isoleucine or valine' 0 C--N 1.333 -0.147 0 CA-C-N 116.048 -0.524 . . . . 0.0 111.407 179.798 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 238' ' ' ALA . . . . . . . . . . . . . . . -160.13 -16.67 0.06 Allowed 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.019 -0.537 . . . . 0.0 110.972 179.869 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 239' ' ' ASP . . . . . . . . . . . . . 9.7 m-20 -144.36 -6.22 0.73 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.758 179.849 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 240' ' ' LEU . . . . . . . . . . . . . 49.5 tp -62.69 116.2 4.98 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.039 -0.528 . . . . 0.0 110.762 179.954 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 241' ' ' GLU . . . . . . . . . . . . . 38.6 tt0 -143.97 135.46 25.91 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.82 -179.94 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 242' ' ' HIS . . . . . . . . . . . . . 12.1 p80 -140.62 136.63 32.93 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.856 -179.857 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 243' ' ' HIS . . . . . . . . . . . . . 96.4 m-70 -87.83 159.08 18.55 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.125 -179.775 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 244' ' ' HIS . . . . . . . . . . . . . 36.9 m80 -105.06 158.9 16.25 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 115.989 -0.551 . . . . 0.0 110.833 179.783 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 245' ' ' HIS . . . . . . . . . . . . . 92.9 m-70 -85.16 107.73 17.37 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.803 179.98 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 246' ' ' HIS . . . . . . . . . . . . . 34.1 t-80 -76.43 -56.89 4.22 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.077 -0.511 . . . . 0.0 110.926 -179.842 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 247' ' ' HIS . . . . . . . . . . . . . 14.1 p-80 . . . . . 0 C--O 1.249 1.054 0 CA-C-O 118.098 -0.953 . . . . 0.0 111.099 179.949 . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 301' ' ' RET . . . . . 0.503 H203 ' NE1' ' A' ' 171' ' ' TRP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 75.1 mmm . . . . . 0 N--CA 1.486 1.35 0 CA-C-O 120.767 0.318 . . . . 0.0 111.042 . . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 28.2 t 56.86 86.06 0.05 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.014 -0.539 . . . . 0.0 110.95 -179.81 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . 152.08 -34.59 0.85 Allowed Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.841 -0.695 . . . . 0.0 112.506 -179.87 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 50.6 tp -73.88 -36.13 64.77 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.786 0.327 . . . . 0.0 110.948 179.87 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 73.7 p -61.39 -29.71 70.09 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.115 -0.493 . . . . 0.0 111.19 179.946 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 23.1 p -53.46 -35.42 60.51 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.09 -0.504 . . . . 0.0 111.071 -179.904 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 7' ' ' LEU . . . . . . . . . . . . . 4.1 mm? -60.25 -53.44 57.65 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.034 -0.53 . . . . 0.0 111.101 179.991 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 8' ' ' PHE . . . . . . . . . . . . . 81.4 m-85 -59.89 -37.1 78.44 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 120.964 0.412 . . . . 0.0 110.806 179.951 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 9' ' ' TRP . . . . . . . . . . . . . 35.9 m95 -63.57 -41.58 98.39 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 115.897 -0.592 . . . . 0.0 110.173 -179.972 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 38.5 mt -64.85 -49.02 72.2 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-N 115.767 -0.651 . . . . 0.0 110.159 179.244 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -57.19 -28.09 58.33 Favored Glycine 0 N--CA 1.447 -0.571 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.216 179.293 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -74.09 -38.48 63.87 Favored 'General case' 0 C--N 1.332 -0.186 0 CA-C-O 120.714 0.292 . . . . 0.0 110.79 179.636 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 63.6 mt -61.87 -54.18 38.04 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.31 -0.404 . . . . 0.0 110.436 179.475 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -60.96 -35.23 90.25 Favored Glycine 0 N--CA 1.45 -0.41 0 C-N-CA 120.591 -0.814 . . . . 0.0 111.676 179.257 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 15' ' ' MET . . . . . 0.533 ' SD ' ' HA ' ' A' ' 44' ' ' SER . 47.5 tpp -64.51 -39.98 94.79 Favored 'General case' 0 N--CA 1.454 -0.246 0 N-CA-C 110.167 -0.309 . . . . 0.0 110.167 179.343 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -59.91 -37.55 79.76 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 116.018 -0.537 . . . . 0.0 109.571 179.1 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 94.0 t -59.07 -50.5 79.53 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.172 0 CA-C-N 115.937 -0.574 . . . . 0.0 110.107 179.1 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -61.45 -45.33 96.6 Favored Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.64 -0.791 . . . . 0.0 111.726 179.163 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 32.8 m -51.7 -44.76 63.28 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-O 120.678 0.275 . . . . 0.0 111.301 -179.858 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 81.2 mt -71.59 -36.54 70.89 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.321 -0.4 . . . . 0.0 111.172 179.904 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -63.23 -33.29 75.17 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.348 -0.387 . . . . 0.0 111.338 -179.873 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 4.1 m-85 -90.86 -28.76 17.94 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.296 -0.411 . . . . 0.0 111.185 -179.472 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -71.77 -50.69 27.69 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.943 0.402 . . . . 0.0 111.118 179.919 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 24' ' ' TRP . . . . . . . . . . . . . 3.2 t-105 -64.41 -44.66 90.53 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 115.86 -0.609 . . . . 0.0 110.938 -179.946 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -77.62 -18.56 56.67 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.895 0.379 . . . . 0.0 110.915 179.776 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -73.08 -42.17 45.0 Favored Glycine 0 C--N 1.331 0.269 0 C-N-CA 120.959 -0.638 . . . . 0.0 112.383 179.947 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 94.2 mtt180 -68.17 -7.86 33.71 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-O 120.952 0.406 . . . . 0.0 110.463 179.668 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 18.6 t70 -117.21 88.98 3.01 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 115.823 -0.626 . . . . 0.0 110.496 179.729 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -165.42 -162.24 0.58 Allowed 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.141 -0.481 . . . . 0.0 111.219 -179.81 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -95.84 -131.72 6.78 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.963 -0.637 . . . . 0.0 112.631 -179.856 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 47.1 t -113.4 -63.6 1.42 Allowed 'General case' 0 C--N 1.33 -0.241 0 CA-C-O 120.812 0.339 . . . . 0.0 111.364 -179.747 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -65.44 -34.43 89.24 Favored Glycine 0 C--N 1.33 0.198 0 C-N-CA 120.802 -0.713 . . . . 0.0 112.588 -179.75 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 2.9 mp0 -68.34 -20.86 64.76 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 120.727 0.299 . . . . 0.0 110.944 -179.957 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 34' ' ' ARG . . . . . . . . . . . . . 78.9 ttt180 -57.63 -28.95 64.15 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.501 -179.619 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 27.7 tpt180 -59.17 -48.4 81.75 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.704 0.288 . . . . 0.0 111.508 -179.607 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 80.7 m-85 -64.96 -29.81 70.76 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.432 -0.349 . . . . 0.0 111.427 -179.511 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 37' ' ' TYR . . . . . . . . . . . . . 52.2 m-85 -74.31 -54.27 8.01 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.413 -0.358 . . . . 0.0 111.342 -179.521 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 83.3 t -56.93 -36.32 49.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-O 120.969 0.414 . . . . 0.0 110.372 179.747 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 53.8 m -65.78 -51.53 58.29 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 115.846 -0.616 . . . . 0.0 110.929 179.518 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 40' ' ' LEU . . . . . 0.46 HD13 HD13 ' A' ' 43' ' ' ILE . 54.2 tp -59.23 -48.12 82.79 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 115.986 -0.552 . . . . 0.0 110.802 -179.94 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 67.6 t -57.86 -34.88 49.44 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.075 -0.511 . . . . 0.0 109.976 179.058 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -62.4 -36.23 92.82 Favored Glycine 0 N--CA 1.447 -0.606 0 C-N-CA 120.738 -0.744 . . . . 0.0 111.724 179.563 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 43' ' ' ILE . . . . . 0.465 HG12 HD21 ' A' ' 82' ' ' LEU . 1.9 mt -65.25 -55.14 21.79 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.187 0 CA-C-O 120.903 0.383 . . . . 0.0 110.935 179.629 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 44' ' ' SER . . . . . 0.533 ' HA ' ' SD ' ' A' ' 15' ' ' MET . 77.9 p -59.7 -26.23 65.42 Favored 'General case' 0 C--N 1.331 -0.201 0 CA-C-N 115.92 -0.582 . . . . 0.0 111.782 -179.529 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -76.16 -54.97 4.97 Favored Glycine 0 CA--C 1.52 0.39 0 C-N-CA 120.573 -0.823 . . . . 0.0 112.858 -179.513 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 46' ' ' ILE . . . . . 0.418 ' O ' HG21 ' A' ' 49' ' ' VAL . 20.5 pt -59.25 -35.8 59.91 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.219 0 CA-C-O 120.974 0.416 . . . . 0.0 111.13 -179.935 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 47' ' ' ALA . . . . . 0.618 ' HB3' ' HE2' ' A' ' 205' ' ' LYS . . . -68.16 -45.56 73.16 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.031 179.341 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -54.83 -41.94 71.32 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 115.87 -0.605 . . . . 0.0 111.769 -179.448 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 49' ' ' VAL . . . . . 0.418 HG21 ' O ' ' A' ' 46' ' ' ILE . 19.3 m -72.42 -34.19 47.89 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-N 116.521 -0.308 . . . . 0.0 111.138 -179.519 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -67.0 -34.73 78.4 Favored 'General case' 0 C--N 1.331 -0.2 0 CA-C-O 120.872 0.368 . . . . 0.0 111.227 179.853 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 28.3 m-85 -72.44 -41.34 66.25 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.623 -179.737 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -64.04 -46.71 83.2 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 115.769 -0.65 . . . . 0.0 111.245 -179.816 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 53' ' ' VAL . . . . . 0.475 HG21 ' N ' ' A' ' 54' ' ' MET . 31.9 m -62.96 -53.61 44.39 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.159 0 CA-C-N 116.425 -0.352 . . . . 0.0 111.039 -179.903 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 54' ' ' MET . . . . . 0.475 ' N ' HG21 ' A' ' 53' ' ' VAL . 74.0 mtm -60.08 -31.1 69.7 Favored 'General case' 0 C--N 1.332 -0.182 0 CA-C-O 120.996 0.426 . . . . 0.0 110.289 179.659 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -64.9 -37.88 89.1 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 115.758 -0.655 . . . . 0.0 111.196 179.363 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 93.3 mt -71.15 -2.75 16.83 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.462 -179.586 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 93.66 -5.85 73.73 Favored Glycine 0 N--CA 1.45 -0.368 0 C-N-CA 120.597 -0.811 . . . . 0.0 112.925 179.702 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 58' ' ' VAL . . . . . 0.427 HG23 ' O ' ' A' ' 53' ' ' VAL . 1.5 m -72.64 154.2 7.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-O 120.718 0.294 . . . . 0.0 110.33 179.714 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 73.85 19.27 79.75 Favored Glycine 0 N--CA 1.45 -0.373 0 C-N-CA 120.483 -0.865 . . . . 0.0 112.188 -179.433 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 60' ' ' TRP . . . . . . . . . . . . . 22.0 m0 -99.11 99.26 10.24 Favored 'General case' 0 C--N 1.33 -0.259 0 N-CA-C 109.981 -0.377 . . . . 0.0 109.981 179.824 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 61' ' ' VAL . . . . . 0.521 ' HB ' HG23 ' A' ' 68' ' ' VAL . 61.4 t -97.95 109.51 51.75 Favored Pre-proline 0 C--N 1.324 -0.507 0 CA-C-N 115.996 -0.547 . . . . 0.0 111.542 -179.113 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 39.6 Cg_endo -66.2 135.74 41.35 Favored 'Trans proline' 0 C--N 1.35 0.639 0 C-N-CA 122.532 2.155 . . . . 0.0 112.085 179.731 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 80.9 t -137.89 95.13 1.06 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.38 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.387 -179.604 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . 58.11 -90.16 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.111 -0.495 . . . . 0.0 111.566 179.855 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 44.7 mt-10 -115.45 -24.67 8.26 Favored 'General case' 0 C--N 1.332 -0.193 0 CA-C-O 120.842 0.353 . . . . 0.0 111.157 -179.842 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 66' ' ' ARG . . . . . 0.416 ' N ' ' HD2' ' A' ' 66' ' ' ARG . 9.3 mpt_? -105.74 154.07 20.99 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.415 179.871 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 90.7 m -117.39 115.5 25.33 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.892 0.377 . . . . 0.0 111.433 -179.696 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 68' ' ' VAL . . . . . 0.521 HG23 ' HB ' ' A' ' 61' ' ' VAL . 29.0 m -83.81 146.34 6.99 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.368 0 CA-C-N 115.914 -0.584 . . . . 0.0 110.891 179.672 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 69' ' ' PHE . . . . . . . . . . . . . 64.8 m-85 -108.92 115.87 30.9 Favored 'General case' 0 N--CA 1.443 -0.794 0 CA-C-N 116.273 -0.421 . . . . 0.0 110.185 -179.377 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 70' ' ' VAL . . . . . 0.53 ' HB ' ' HD3' ' A' ' 71' ' ' PRO . 24.5 t -67.49 -49.6 40.84 Favored Pre-proline 0 C--N 1.325 -0.477 0 N-CA-C 112.616 0.599 . . . . 0.0 112.616 -178.932 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 71' ' ' PRO . . . . . 0.53 ' HD3' ' HB ' ' A' ' 70' ' ' VAL . 15.4 Cg_exo -67.08 -17.93 51.16 Favored 'Trans proline' 0 C--N 1.351 0.702 0 C-N-CA 122.315 2.01 . . . . 0.0 113.091 -178.918 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 67.2 ttt180 -66.66 -55.5 14.92 Favored 'General case' 0 C--O 1.237 0.396 0 CA-C-O 120.838 0.351 . . . . 0.0 111.626 -179.404 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 73' ' ' TYR . . . . . 0.466 ' O ' HG13 ' A' ' 77' ' ' ILE . 65.4 m-85 -71.52 -34.54 70.15 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.486 -0.324 . . . . 0.0 110.603 -179.453 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 74' ' ' ILE . . . . . 0.495 ' HA ' HD11 ' A' ' 77' ' ' ILE . 0.4 OUTLIER -66.48 -37.86 80.5 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.242 0 N-CA-C 109.833 -0.432 . . . . 0.0 109.833 179.182 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 13.8 t70 -59.14 -38.95 80.89 Favored 'General case' 0 CA--C 1.517 -0.288 0 N-CA-C 109.128 -0.693 . . . . 0.0 109.128 178.62 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 76' ' ' TRP . . . . . . . . . . . . . 51.1 m0 -65.58 -32.67 74.38 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 115.59 -0.732 . . . . 0.0 110.236 179.138 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 77' ' ' ILE . . . . . 0.495 HD11 ' HA ' ' A' ' 74' ' ' ILE . 69.0 mt -68.76 -28.61 40.55 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.25 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.078 178.984 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 34.0 mt -92.22 -20.43 21.18 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 115.772 -0.649 . . . . 0.0 112.332 179.949 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 82.1 p -103.93 -52.94 2.85 Favored 'General case' 0 N--CA 1.465 0.279 0 N-CA-C 114.025 1.12 . . . . 0.0 114.025 -177.295 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 80' ' ' THR . . . . . 0.444 ' N ' ' HD2' ' A' ' 81' ' ' PRO . 25.3 m -50.41 -54.81 30.86 Favored Pre-proline 0 C--N 1.329 -0.317 0 N-CA-C 113.016 0.747 . . . . 0.0 113.016 -178.007 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 81' ' ' PRO . . . . . 0.444 ' HD2' ' N ' ' A' ' 80' ' ' THR . 20.5 Cg_endo -59.78 -21.27 62.86 Favored 'Trans proline' 0 C--N 1.35 0.654 0 C-N-CA 121.346 1.364 . . . . 0.0 111.141 -179.655 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 82' ' ' LEU . . . . . 0.465 HD21 HG12 ' A' ' 43' ' ' ILE . 13.4 tp -77.13 -33.55 56.76 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 115.58 -0.736 . . . . 0.0 109.829 179.436 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 83' ' ' ILE . . . . . 0.46 HD13 HD12 ' A' ' 43' ' ' ILE . 35.2 mm -70.29 -53.44 23.08 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.191 0 CA-C-N 115.984 -0.553 . . . . 0.0 109.848 179.063 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 33.9 m -59.51 -30.19 43.98 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.183 0 N-CA-C 109.546 -0.539 . . . . 0.0 109.546 178.863 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 85' ' ' TYR . . . . . . . . . . . . . 68.3 t80 -69.74 -32.57 71.18 Favored 'General case' 0 N--CA 1.454 -0.26 0 CA-C-N 115.537 -0.756 . . . . 0.0 109.623 178.873 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 86' ' ' PHE . . . . . . . . . . . . . 9.9 t80 -61.33 -51.93 66.78 Favored 'General case' 0 C--O 1.232 0.149 0 CA-C-N 115.919 -0.582 . . . . 0.0 109.857 179.326 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 8.1 mp -61.01 -33.16 72.83 Favored 'General case' 0 C--N 1.332 -0.189 0 CA-C-N 115.873 -0.603 . . . . 0.0 110.08 179.374 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -67.22 -27.74 73.56 Favored Glycine 0 N--CA 1.449 -0.49 0 C-N-CA 120.836 -0.697 . . . . 0.0 111.755 179.233 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 79.3 mt -72.89 -42.95 63.08 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-O 120.924 0.392 . . . . 0.0 110.468 179.622 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 54.9 mt -59.59 -43.83 93.57 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 115.822 -0.626 . . . . 0.0 110.972 179.878 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . 0.436 ' HB2' ' HB3' ' A' ' 149' ' ' ALA . . . -74.46 -55.05 6.39 Favored 'General case' 0 C--N 1.331 -0.21 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.325 -179.886 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 103.55 51.62 0.96 Allowed Glycine 0 N--CA 1.452 -0.251 0 C-N-CA 120.843 -0.694 . . . . 0.0 112.447 179.959 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 93' ' ' LEU . . . . . 0.531 HD23 ' HB3' ' A' ' 97' ' ' GLU . 7.9 mp -65.77 170.83 4.83 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.875 0.369 . . . . 0.0 111.193 -179.884 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 94' ' ' ASP . . . . . . . . . . . . . 5.5 m-20 -85.05 164.66 18.09 Favored 'General case' 0 C--N 1.33 -0.239 0 CA-C-N 116.057 -0.519 . . . . 0.0 110.435 179.643 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 46.8 t -55.86 -34.63 65.65 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.326 -0.397 . . . . 0.0 110.97 -179.753 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 96' ' ' ARG . . . . . 0.463 ' HA ' ' NE ' ' A' ' 96' ' ' ARG . 5.6 tpm_? -73.69 -44.87 55.41 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.254 -0.43 . . . . 0.0 111.195 -179.914 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 97' ' ' GLU . . . . . 0.531 ' HB3' HD23 ' A' ' 93' ' ' LEU . 39.1 mt-10 -54.58 -47.39 73.36 Favored 'General case' 0 C--N 1.333 -0.129 0 CA-C-N 116.274 -0.421 . . . . 0.0 111.102 -179.777 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 98' ' ' PHE . . . . . 0.47 ' O ' HG12 ' A' ' 102' ' ' ILE . 41.1 m-85 -58.31 -48.85 79.19 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.859 0.362 . . . . 0.0 110.571 179.489 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -54.25 -29.89 46.67 Favored Glycine 0 N--CA 1.45 -0.383 0 C-N-CA 120.662 -0.78 . . . . 0.0 112.466 179.816 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 100' ' ' ILE . . . . . 0.481 HD12 ' HA ' ' A' ' 97' ' ' GLU . 66.6 mt -73.81 -48.32 39.99 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.229 0 N-CA-C 112.02 0.378 . . . . 0.0 112.02 -179.735 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 1.4 p -68.84 -41.76 82.34 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.246 0 N-CA-C 112.044 0.387 . . . . 0.0 112.044 -179.404 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 102' ' ' ILE . . . . . 0.47 HG12 ' O ' ' A' ' 98' ' ' PHE . 42.6 mm -64.58 -48.24 85.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.774 -0.194 . . . . 0.0 111.368 -179.358 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 14.7 t -60.95 -34.24 74.42 Favored 'General case' 0 C--N 1.332 -0.166 0 CA-C-O 120.83 0.347 . . . . 0.0 110.385 179.784 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 104' ' ' LEU . . . . . 0.448 HD23 ' HE2' ' A' ' 140' ' ' TYR . 38.0 tp -62.02 -52.92 62.02 Favored 'General case' 0 C--N 1.332 -0.174 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.251 179.296 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 105' ' ' ASN . . . . . 0.551 ' N ' HD21 ' A' ' 105' ' ' ASN . 0.8 OUTLIER -56.95 -27.4 61.13 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.765 179.524 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 30.9 m -64.9 -56.97 10.12 Favored 'General case' 0 C--N 1.332 -0.183 0 CA-C-N 116.313 -0.403 . . . . 0.0 111.481 -179.863 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 7.4 p -58.93 -36.19 60.39 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.144 0 CA-C-O 120.852 0.358 . . . . 0.0 111.087 -179.892 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 91.4 t -61.84 -49.47 84.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.099 -0.5 . . . . 0.0 111.133 179.816 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 109' ' ' MET . . . . . 0.457 ' HG2' ' O ' ' A' ' 105' ' ' ASN . 17.7 mmt -64.52 -31.51 72.75 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.244 -0.434 . . . . 0.0 111.104 179.974 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 27.7 tp -68.05 -36.18 79.45 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.247 179.675 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -62.66 -53.67 51.02 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.067 -0.515 . . . . 0.0 110.539 179.48 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 112' ' ' GLY . . . . . 0.564 ' HA3' ' H22' ' A' ' 301' ' ' RET . . . -62.23 -40.97 99.68 Favored Glycine 0 C--N 1.332 0.327 0 C-N-CA 120.638 -0.791 . . . . 0.0 111.868 179.362 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 113' ' ' PHE . . . . . 0.404 ' HZ ' HG13 ' A' ' 70' ' ' VAL . 1.4 t80 -48.88 -68.58 0.17 Allowed 'General case' 0 CA--C 1.52 -0.18 0 N-CA-C 109.858 -0.423 . . . . 0.0 109.858 179.33 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 114' ' ' ALA . . . . . 0.497 ' HA ' ' HB2' ' A' ' 117' ' ' MET . . . -67.49 -15.48 63.69 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-N 115.924 -0.58 . . . . 0.0 110.213 179.365 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 115' ' ' GLY . . . . . 0.479 ' O ' HG23 ' A' ' 118' ' ' VAL . . . -53.65 -49.81 56.25 Favored Glycine 0 C--N 1.336 0.557 0 C-N-CA 120.978 -0.629 . . . . 0.0 111.561 179.299 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 116' ' ' ALA . . . . . 0.438 ' HB3' HG12 ' A' ' 68' ' ' VAL . . . -79.36 -22.11 44.86 Favored 'General case' 0 C--N 1.321 -0.638 0 N-CA-C 111.878 0.325 . . . . 0.0 111.878 179.902 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 117' ' ' MET . . . . . 0.497 ' HB2' ' HA ' ' A' ' 114' ' ' ALA . 0.2 OUTLIER -76.67 19.45 0.27 Allowed 'General case' 0 C--N 1.328 -0.33 0 N-CA-C 112.363 0.505 . . . . 0.0 112.363 -178.84 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 118' ' ' VAL . . . . . 0.479 HG23 ' O ' ' A' ' 115' ' ' GLY . 23.3 m -123.67 138.71 30.78 Favored Pre-proline 0 C--N 1.33 -0.278 0 C-N-CA 121.131 -0.227 . . . . 0.0 111.369 179.823 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 119' ' ' PRO . . . . . . . . . . . . . 77.4 Cg_endo -96.63 23.47 0.33 Allowed 'Trans proline' 0 N--CA 1.455 -0.787 0 C-N-CA 123.19 2.593 . . . . 0.0 112.769 179.892 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -139.73 -159.16 7.87 Favored Glycine 0 C--N 1.332 0.308 0 C-N-CA 120.493 -0.86 . . . . 0.0 113.215 -179.578 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 14.3 mm -80.33 1.89 2.7 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.205 0 CA-C-O 121.136 0.493 . . . . 0.0 110.938 -179.77 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 33.6 mt-10 -59.34 -37.39 77.71 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 115.799 -0.637 . . . . 0.0 110.89 -179.991 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 123' ' ' ARG . . . . . 0.524 ' HB2' ' HH2' ' A' ' 178' ' ' TRP . 3.7 ptp180 -50.6 -32.99 20.41 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.018 -0.537 . . . . 0.0 111.654 -179.659 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 124' ' ' TYR . . . . . . . . . . . . . 91.3 m-85 -71.57 -33.2 68.88 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.385 -0.371 . . . . 0.0 111.236 -179.645 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 125' ' ' ALA . . . . . . . . . . . . . . . -70.07 -50.86 36.8 Favored 'General case' 0 C--O 1.237 0.405 0 CA-C-O 120.995 0.426 . . . . 0.0 110.047 179.194 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 8.2 mp -55.55 -54.04 48.94 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 115.695 -0.684 . . . . 0.0 110.074 179.345 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 127' ' ' PHE . . . . . . . . . . . . . 11.0 t80 -63.53 -35.73 81.44 Favored 'General case' 0 N--CA 1.452 -0.374 0 CA-C-N 115.782 -0.645 . . . . 0.0 110.611 179.958 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 128' ' ' GLY . . . . . . . . . . . . . . . -47.46 -44.48 21.87 Favored Glycine 0 C--N 1.332 0.313 0 C-N-CA 120.228 -0.987 . . . . 0.0 110.805 179.138 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 129' ' ' MET . . . . . . . . . . . . . 0.3 OUTLIER -70.51 -36.56 73.83 Favored 'General case' 0 N--CA 1.453 -0.318 0 N-CA-C 109.828 -0.434 . . . . 0.0 109.828 178.688 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -66.52 -28.56 73.81 Favored Glycine 0 C--N 1.332 0.342 0 CA-C-N 115.702 -0.681 . . . . 0.0 112.839 -179.993 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -74.67 -53.7 8.81 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-O 120.699 0.285 . . . . 0.0 110.358 179.83 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 98.4 t -57.84 -39.91 73.49 Favored 'Isoleucine or valine' 0 C--O 1.234 0.276 0 N-CA-C 109.024 -0.732 . . . . 0.0 109.024 178.433 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -67.23 -33.92 76.37 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 115.123 -0.944 . . . . 0.0 110.642 179.269 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 134' ' ' PHE . . . . . 0.442 ' HB2' H182 ' A' ' 301' ' ' RET . 74.6 t80 -56.43 -55.81 28.92 Favored 'General case' 0 N--CA 1.449 -0.484 0 CA-C-O 120.926 0.393 . . . . 0.0 109.951 179.388 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 135' ' ' ILE . . . . . 0.423 ' O ' HG21 ' A' ' 138' ' ' VAL . 40.1 mt -56.58 -33.23 39.14 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.298 0 CA-C-N 115.761 -0.654 . . . . 0.0 109.876 178.942 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . -61.44 -36.9 93.24 Favored Glycine 0 N--CA 1.447 -0.574 0 C-N-CA 120.424 -0.893 . . . . 0.0 111.456 179.067 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 137' ' ' LEU . . . . . 0.469 HD12 HD22 ' A' ' 105' ' ' ASN . 47.9 tp -72.22 -54.02 10.85 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-O 120.527 0.203 . . . . 0.0 110.633 179.657 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 138' ' ' VAL . . . . . 0.423 HG21 ' O ' ' A' ' 135' ' ' ILE . 3.4 m -56.17 -31.51 32.08 Favored 'Isoleucine or valine' 0 C--O 1.233 0.192 0 CA-C-O 121.242 0.544 . . . . 0.0 109.676 179.462 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 139' ' ' TYR . . . . . . . . . . . . . 24.9 t80 -63.41 -46.96 83.98 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 115.432 -0.804 . . . . 0.0 110.311 178.819 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 140' ' ' TYR . . . . . 0.448 ' HE2' HD23 ' A' ' 104' ' ' LEU . 17.2 m-85 -58.89 -37.98 77.84 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.626 179.638 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 141' ' ' LEU . . . . . . . . . . . . . 62.6 mt -57.61 -48.2 80.07 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.189 179.542 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 17.1 t -78.31 -12.58 13.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 115.943 -0.571 . . . . 0.0 110.658 179.654 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 143' ' ' GLY . . . . . 0.414 ' HA3' ' HD2' ' A' ' 144' ' ' PRO . . . -72.44 -134.62 0.18 Allowed Glycine 0 CA--C 1.521 0.425 0 C-N-CA 120.982 -0.627 . . . . 0.0 112.906 -179.845 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 144' ' ' PRO . . . . . 0.414 ' HD2' ' HA3' ' A' ' 143' ' ' GLY . 20.7 Cg_endo -60.43 -23.72 75.76 Favored 'Trans proline' 0 C--N 1.349 0.586 0 C-N-CA 122.647 2.231 . . . . 0.0 112.593 -179.658 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 145' ' ' MET . . . . . . . . . . . . . 55.1 mtt -59.33 -36.73 76.2 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.507 -0.315 . . . . 0.0 111.303 -179.865 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 146' ' ' THR . . . . . . . . . . . . . 86.2 m -79.63 -42.33 25.09 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.508 -0.314 . . . . 0.0 111.431 -179.154 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 8.8 tp10 -61.84 -41.46 97.83 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.243 -179.784 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 148' ' ' SER . . . . . . . . . . . . . 48.7 m -70.61 -46.32 63.59 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.263 -0.426 . . . . 0.0 111.614 -179.325 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 149' ' ' ALA . . . . . 0.436 ' HB3' ' HB2' ' A' ' 91' ' ' ALA . . . -68.33 -30.71 69.75 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.3 -0.409 . . . . 0.0 111.892 -179.206 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 150' ' ' SER . . . . . . . . . . . . . 43.3 t -72.36 -5.9 39.62 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.439 -0.346 . . . . 0.0 111.656 -179.275 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 151' ' ' GLN . . . . . . . . . . . . . 10.3 pt20 -133.55 5.79 3.74 Favored 'General case' 0 C--N 1.33 -0.251 0 N-CA-C 111.649 0.24 . . . . 0.0 111.649 -179.835 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 1.6 tmt_? -73.69 -51.88 15.15 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-O 120.994 0.426 . . . . 0.0 110.251 179.946 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 153' ' ' SER . . . . . 0.607 ' HB2' HG12 ' A' ' 156' ' ' ILE . 49.1 m -158.1 172.08 19.06 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-N 115.759 -0.655 . . . . 0.0 110.256 179.227 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 154' ' ' SER . . . . . . . . . . . . . 88.6 p -70.65 -37.67 73.76 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-O 120.883 0.373 . . . . 0.0 110.474 179.542 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -76.98 -30.26 55.95 Favored Glycine 0 N--CA 1.452 -0.276 0 C-N-CA 120.935 -0.65 . . . . 0.0 112.751 -179.914 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 156' ' ' ILE . . . . . 0.607 HG12 ' HB2' ' A' ' 153' ' ' SER . 39.1 mm -64.48 -39.21 84.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-O 120.765 0.317 . . . . 0.0 111.243 -179.988 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 157' ' ' LYS . . . . . . . . . . . . . 87.1 tttt -63.55 -41.28 98.44 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 116.306 -0.406 . . . . 0.0 111.624 -179.37 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 87.9 p -71.34 -48.33 51.02 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-O 120.956 0.408 . . . . 0.0 111.493 -179.338 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 159' ' ' LEU . . . . . 0.516 HD21 ' HB2' ' A' ' 215' ' ' ALA . 17.4 mt -66.77 -31.85 72.75 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 116.084 -0.507 . . . . 0.0 111.726 -179.269 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 160' ' ' TYR . . . . . . . . . . . . . 50.9 t80 -74.25 -46.79 39.3 Favored 'General case' 0 C--N 1.327 -0.372 0 N-CA-C 112.051 0.389 . . . . 0.0 112.051 -178.841 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 24.4 m -60.12 -44.74 95.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 N-CA-C 111.848 0.314 . . . . 0.0 111.848 -179.154 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 162' ' ' ARG . . . . . 0.445 ' HG2' HG22 ' A' ' 211' ' ' ILE . 22.3 tpp180 -68.88 -40.88 79.01 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.755 0.312 . . . . 0.0 111.638 -179.598 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 163' ' ' LEU . . . . . 0.617 ' HG ' ' HB2' ' A' ' 208' ' ' PHE . 6.3 mp -69.23 -55.14 11.45 Favored 'General case' 0 C--N 1.329 -0.323 0 N-CA-C 112.77 0.656 . . . . 0.0 112.77 -178.724 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 164' ' ' ARG . . . . . 0.413 ' HG3' ' H ' ' A' ' 165' ' ' ASN . 5.0 ppt_? -61.04 -45.5 94.5 Favored 'General case' 0 C--N 1.328 -0.339 0 N-CA-C 112.28 0.474 . . . . 0.0 112.28 -178.316 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 165' ' ' ASN . . . . . 0.413 ' H ' ' HG3' ' A' ' 164' ' ' ARG . 9.5 m-80 -59.88 -51.48 69.5 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.763 0.316 . . . . 0.0 111.28 -179.736 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 166' ' ' LEU . . . . . 0.466 ' O ' ' HG ' ' A' ' 170' ' ' LEU . 3.2 tt -61.21 -50.84 71.49 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.461 -179.511 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 167' ' ' THR . . . . . 0.444 ' O ' ' HB2' ' A' ' 171' ' ' TRP . 92.1 m -55.01 -53.32 57.31 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 115.911 -0.586 . . . . 0.0 112.514 -178.999 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 168' ' ' VAL . . . . . . . . . . . . . 85.3 t -55.16 -43.97 72.67 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.236 0 N-CA-C 112.044 0.387 . . . . 0.0 112.044 -178.803 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 169' ' ' VAL . . . . . . . . . . . . . 72.3 t -56.41 -65.05 0.42 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 N-CA-C 111.969 0.359 . . . . 0.0 111.969 -179.288 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 170' ' ' LEU . . . . . 0.466 ' HG ' ' O ' ' A' ' 166' ' ' LEU . 0.7 OUTLIER -64.76 -28.08 69.33 Favored 'General case' 0 C--N 1.331 -0.238 0 N-CA-C 112.238 0.458 . . . . 0.0 112.238 -178.852 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 171' ' ' TRP . . . . . 0.444 ' HB2' ' O ' ' A' ' 167' ' ' THR . 4.0 m0 -71.13 -30.01 65.96 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-O 121.006 0.431 . . . . 0.0 110.495 179.495 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 172' ' ' ALA . . . . . 0.427 ' HA ' ' CZ ' ' A' ' 134' ' ' PHE . . . -72.67 -6.36 43.85 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 115.917 -0.583 . . . . 0.0 111.056 -179.722 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 173' ' ' ILE . . . . . 0.492 ' O ' HG12 ' A' ' 177' ' ' ILE . 21.6 mm -87.29 -21.82 7.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 115.93 -0.577 . . . . 0.0 111.288 -179.972 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 174' ' ' TYR . . . . . 0.586 ' N ' ' HD2' ' A' ' 175' ' ' PRO . 37.0 m-85 -54.35 -51.24 79.66 Favored Pre-proline 0 CA--C 1.532 0.267 0 N-CA-C 111.955 0.354 . . . . 0.0 111.955 -179.762 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 175' ' ' PRO . . . . . 0.586 ' HD2' ' N ' ' A' ' 174' ' ' TYR . 5.3 Cg_endo -48.41 -29.57 13.76 Favored 'Trans proline' 0 C--N 1.352 0.717 0 C-N-CA 122.106 1.87 . . . . 0.0 112.299 -179.967 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 176' ' ' PHE . . . . . 0.467 ' HD2' ' HA ' ' A' ' 173' ' ' ILE . 58.9 m-85 -80.84 -49.45 11.05 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.044 -0.525 . . . . 0.0 112.053 -179.885 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 177' ' ' ILE . . . . . 0.501 ' HB ' HD13 ' A' ' 197' ' ' ILE . 4.4 mm -62.47 -34.79 66.55 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.496 0 N-CA-C 112.389 0.515 . . . . 0.0 112.389 -178.155 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 178' ' ' TRP . . . . . 0.524 ' HH2' ' HB2' ' A' ' 123' ' ' ARG . 70.0 t90 -73.71 -46.7 44.56 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-O 121.03 0.443 . . . . 0.0 110.766 179.551 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 179' ' ' LEU . . . . . 0.401 ' O ' HG21 ' A' ' 185' ' ' VAL . 1.7 tm? -69.5 -48.42 60.64 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 115.856 -0.611 . . . . 0.0 111.396 -179.172 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 180' ' ' LEU . . . . . 0.578 HD21 HD13 ' A' ' 187' ' ' LEU . 42.2 mt -75.15 -46.62 33.13 Favored 'General case' 0 C--N 1.327 -0.395 0 N-CA-C 111.911 0.338 . . . . 0.0 111.911 -179.153 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . -58.35 -179.59 1.06 Allowed Glycine 0 C--N 1.336 0.582 0 C-N-CA 120.256 -0.973 . . . . 0.0 112.383 179.767 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 182' ' ' PRO . . . . . 0.535 ' HA ' ' HB3' ' A' ' 186' ' ' ALA . 84.7 Cg_exo -47.05 -44.05 23.84 Favored 'Trans proline' 0 CA--C 1.535 0.571 0 C-N-CA 122.834 2.356 . . . . 0.0 113.94 -179.97 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 183' ' ' PRO . . . . . 0.416 ' HD3' ' HB2' ' A' ' 182' ' ' PRO . 74.7 Cg_exo -51.19 -17.71 4.12 Favored 'Trans proline' 0 C--N 1.355 0.891 0 C-N-CA 122.257 1.971 . . . . 0.0 113.456 -179.707 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 184' ' ' GLY . . . . . . . . . . . . . . . -120.51 -92.02 1.27 Allowed Glycine 0 C--N 1.332 0.343 0 C-N-CA 120.207 -0.997 . . . . 0.0 113.294 -179.743 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 185' ' ' VAL . . . . . 0.401 HG21 ' O ' ' A' ' 179' ' ' LEU . 17.8 m -106.39 -13.0 9.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 N-CA-C 112.152 0.427 . . . . 0.0 112.152 -179.004 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 186' ' ' ALA . . . . . 0.535 ' HB3' ' HA ' ' A' ' 182' ' ' PRO . . . 58.36 86.78 0.08 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.794 0.33 . . . . 0.0 111.469 179.848 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 187' ' ' LEU . . . . . 0.578 HD13 HD21 ' A' ' 180' ' ' LEU . 22.8 mt -91.79 -49.02 6.48 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 120.953 0.406 . . . . 0.0 110.968 179.909 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 188' ' ' LEU . . . . . . . . . . . . . 77.5 mt -95.87 -151.66 0.35 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 115.939 -0.573 . . . . 0.0 111.339 -179.365 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 189' ' ' THR . . . . . . . . . . . . . 29.0 m -96.96 137.45 21.31 Favored Pre-proline 0 C--N 1.331 -0.221 0 CA-C-N 115.922 -0.581 . . . . 0.0 110.852 -179.483 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 190' ' ' PRO . . . . . . . . . . . . . 82.0 Cg_exo -46.95 -29.86 8.97 Favored 'Trans proline' 0 C--N 1.349 0.577 0 C-N-CA 122.478 2.118 . . . . 0.0 112.692 179.9 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 191' ' ' THR . . . . . . . . . . . . . 76.7 p -77.4 -40.6 43.08 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.486 -0.324 . . . . 0.0 111.412 -179.948 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 192' ' ' VAL . . . . . . . . . . . . . 61.7 t -72.09 -53.27 20.47 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.289 -0.414 . . . . 0.0 111.564 -179.608 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 193' ' ' ASP . . . . . . . . . . . . . 30.7 m-20 -52.15 -48.79 64.74 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.36 -0.382 . . . . 0.0 111.015 -179.921 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 194' ' ' VAL . . . . . 0.464 ' O ' HG21 ' A' ' 198' ' ' VAL . 55.3 t -62.38 -36.38 74.41 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.645 179.724 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 195' ' ' ALA . . . . . . . . . . . . . . . -56.27 -39.84 73.28 Favored 'General case' 0 C--N 1.332 -0.155 0 CA-C-N 116.348 -0.387 . . . . 0.0 110.571 179.344 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 196' ' ' LEU . . . . . . . . . . . . . 96.4 mt -68.43 -39.62 81.49 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.018 -0.537 . . . . 0.0 110.557 179.251 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 197' ' ' ILE . . . . . 0.501 HD13 ' HB ' ' A' ' 177' ' ' ILE . 18.3 mm -60.43 -60.38 2.67 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.254 0 CA-C-N 115.856 -0.611 . . . . 0.0 111.238 179.957 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 198' ' ' VAL . . . . . 0.464 HG21 ' O ' ' A' ' 194' ' ' VAL . 3.3 m -52.98 -36.05 23.36 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.4 0 CA-C-O 121.596 0.712 . . . . 0.0 109.808 179.003 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 199' ' ' TYR . . . . . . . . . . . . . 37.1 t80 -67.97 -33.04 73.89 Favored 'General case' 0 C--N 1.321 -0.666 0 CA-C-N 114.629 -1.168 . . . . 0.0 110.849 179.858 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 200' ' ' LEU . . . . . 0.447 ' O ' HG12 ' A' ' 203' ' ' VAL . 25.5 mt -68.71 -41.85 78.52 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 121.13 0.49 . . . . 0.0 110.844 179.927 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 201' ' ' ASP . . . . . . . . . . . . . 15.8 m-20 -70.09 -33.18 71.56 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-O 121.321 0.581 . . . . 0.0 109.727 179.109 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 202' ' ' LEU . . . . . . . . . . . . . 3.1 mt -72.33 -31.14 65.41 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 115.213 -0.903 . . . . 0.0 112.014 -179.741 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 203' ' ' VAL . . . . . 0.493 ' O ' ' HA3' ' A' ' 207' ' ' GLY . 13.0 p -76.44 -35.91 27.64 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 C-N-CA 121.06 -0.256 . . . . 0.0 110.958 -178.621 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 204' ' ' THR . . . . . . . . . . . . . 88.8 m -67.66 -58.24 5.01 Favored 'General case' 0 C--N 1.326 -0.443 0 C-N-CA 120.651 -0.42 . . . . 0.0 111.289 179.498 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 205' ' ' LYS . . . . . 0.618 ' HE2' ' HB3' ' A' ' 47' ' ' ALA . 48.7 mttp -62.15 -58.49 7.59 Favored 'General case' 0 C--N 1.329 -0.303 0 N-CA-C 112.21 0.448 . . . . 0.0 112.21 -178.513 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 44.5 t -70.35 -36.22 65.96 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.48 0 CA-C-N 116.025 -0.534 . . . . 0.0 112.068 -178.836 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 207' ' ' GLY . . . . . 0.532 ' O ' HG13 ' A' ' 211' ' ' ILE . . . -58.33 -61.66 7.15 Favored Glycine 0 N--CA 1.452 -0.271 0 C-N-CA 120.634 -0.793 . . . . 0.0 113.844 -178.128 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 208' ' ' PHE . . . . . 0.617 ' HB2' ' HG ' ' A' ' 163' ' ' LEU . 0.8 OUTLIER -72.69 -27.61 62.19 Favored 'General case' 0 C--O 1.221 -0.436 0 CA-C-N 117.515 0.657 . . . . 0.0 110.854 -179.12 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 209' ' ' GLY . . . . . 0.487 ' O ' ' HB1' ' A' ' 212' ' ' ALA . . . -64.1 -31.87 82.29 Favored Glycine 0 N--CA 1.45 -0.399 0 N-CA-C 111.546 -0.622 . . . . 0.0 111.546 178.697 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 210' ' ' PHE . . . . . . . . . . . . . 0.5 OUTLIER -74.79 -47.9 28.32 Favored 'General case' 0 CA--C 1.514 -0.41 0 N-CA-C 108.425 -0.954 . . . . 0.0 108.425 178.451 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 211' ' ' ILE . . . . . 0.532 HG13 ' O ' ' A' ' 207' ' ' GLY . 4.3 mt -63.69 -27.61 43.27 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.45 0 N-CA-C 107.712 -1.218 . . . . 0.0 107.712 176.787 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 212' ' ' ALA . . . . . 0.487 ' HB1' ' O ' ' A' ' 209' ' ' GLY . . . -62.46 -46.1 90.02 Favored 'General case' 0 N--CA 1.449 -0.524 0 CA-C-N 114.469 -1.242 . . . . 0.0 110.549 -179.888 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 213' ' ' LEU . . . . . . . . . . . . . 95.8 mt -70.33 -46.03 65.01 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 115.182 -0.917 . . . . 0.0 111.864 -179.437 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 214' ' ' ASP . . . . . . . . . . . . . 19.9 t70 -56.06 -55.19 35.89 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.466 -0.334 . . . . 0.0 111.604 -179.299 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 215' ' ' ALA . . . . . 0.516 ' HB2' HD21 ' A' ' 159' ' ' LEU . . . -58.95 -53.14 61.77 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.327 -0.397 . . . . 0.0 111.406 -179.559 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 216' ' ' ALA . . . . . . . . . . . . . . . -53.14 -45.08 68.24 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.506 -179.666 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 217' ' ' ALA . . . . . . . . . . . . . . . -55.85 -39.86 72.06 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-O 121.062 0.458 . . . . 0.0 110.301 179.738 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 218' ' ' THR . . . . . . . . . . . . . 92.1 m -69.3 -34.0 74.03 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.634 -0.712 . . . . 0.0 110.861 179.48 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 219' ' ' LEU . . . . . 0.425 ' HG ' ' O ' ' A' ' 215' ' ' ALA . 75.5 mt -64.31 -39.82 94.67 Favored 'General case' 0 C--N 1.331 -0.2 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.698 179.755 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 220' ' ' ARG . . . . . . . . . . . . . 15.2 mmm180 -80.21 -27.01 38.89 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.387 179.756 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 221' ' ' ALA . . . . . . . . . . . . . . . -71.17 -26.11 62.83 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 115.986 -0.552 . . . . 0.0 111.5 -179.981 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 222' ' ' GLU . . . . . . . . . . . . . 12.7 pt-20 -92.44 -22.18 19.76 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-O 120.934 0.397 . . . . 0.0 110.385 -179.869 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 223' ' ' HIS . . . . . . . . . . . . . 46.8 m-70 61.88 -176.09 0.13 Allowed 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 115.672 -0.695 . . . . 0.0 111.235 179.871 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 224' ' ' GLY . . . . . . . . . . . . . . . 178.35 43.45 0.07 OUTLIER Glycine 0 N--CA 1.452 -0.269 0 C-N-CA 120.821 -0.704 . . . . 0.0 112.398 -179.93 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 225' ' ' GLU . . . . . . . . . . . . . 10.0 mm-40 -118.22 120.33 37.37 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 120.841 0.353 . . . . 0.0 110.833 -179.998 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 226' ' ' SER . . . . . . . . . . . . . 50.6 m -86.81 151.83 23.02 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.958 -179.929 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 227' ' ' LEU . . . . . . . . . . . . . 60.9 tp -91.22 -60.27 1.94 Allowed 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.84 -179.954 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 228' ' ' ALA . . . . . . . . . . . . . . . 56.19 178.45 0.04 OUTLIER 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 116.082 -0.508 . . . . 0.0 111.624 -179.897 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 229' ' ' GLY . . . . . . . . . . . . . . . 74.02 77.72 0.62 Allowed Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.658 -0.782 . . . . 0.0 112.621 179.901 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 230' ' ' VAL . . . . . . . . . . . . . 21.3 t -81.66 123.87 38.39 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-O 120.801 0.334 . . . . 0.0 110.861 179.768 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 231' ' ' ASP . . . . . . . . . . . . . 19.3 t70 -74.98 125.61 29.25 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.134 -179.664 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 232' ' ' THR . . . . . . . . . . . . . 9.1 t -124.45 -26.59 3.87 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.007 -0.542 . . . . 0.0 110.837 179.688 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 233' ' ' ASP . . . . . . . . . . . . . 27.1 t70 62.51 107.84 0.03 OUTLIER 'General case' 0 C--N 1.333 -0.151 0 CA-C-N 115.832 -0.622 . . . . 0.0 111.336 179.801 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 234' ' ' THR . . . . . . . . . . . . . 1.4 t -108.15 96.92 19.56 Favored Pre-proline 0 C--N 1.33 -0.282 0 CA-C-N 115.951 -0.568 . . . . 0.0 110.837 179.744 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 235' ' ' PRO . . . . . . . . . . . . . 85.9 Cg_endo -78.34 4.18 6.5 Favored 'Trans proline' 0 C--N 1.349 0.564 0 C-N-CA 122.462 2.108 . . . . 0.0 112.801 -179.696 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 236' ' ' ALA . . . . . . . . . . . . . . . -63.82 153.49 36.5 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.374 -0.375 . . . . 0.0 111.026 179.962 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 237' ' ' VAL . . . . . . . . . . . . . 13.5 p -164.3 147.57 2.61 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.249 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.914 -179.938 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 238' ' ' ALA . . . . . . . . . . . . . . . -149.1 -27.1 0.29 Allowed 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.3 -0.409 . . . . 0.0 111.294 -179.931 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 239' ' ' ASP . . . . . . . . . . . . . 15.1 m-20 -113.0 123.7 50.93 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.268 -0.424 . . . . 0.0 111.108 -179.959 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 240' ' ' LEU . . . . . . . . . . . . . 3.3 pp -125.99 -12.3 6.44 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.895 179.787 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 241' ' ' GLU . . . . . . . . . . . . . 44.6 mt-10 -73.17 134.41 44.39 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.756 179.837 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 242' ' ' HIS . . . . . . . . . . . . . 40.9 m80 -92.51 173.74 7.64 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.326 -0.397 . . . . 0.0 111.12 -179.832 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 243' ' ' HIS . . . . . . . . . . . . . 60.9 t60 -160.9 -45.85 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 115.845 -0.616 . . . . 0.0 110.568 179.821 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 244' ' ' HIS . . . . . . . . . . . . . 34.0 t-80 -107.24 -17.17 14.22 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 115.895 -0.593 . . . . 0.0 110.802 -179.989 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 245' ' ' HIS . . . . . . . . . . . . . 52.5 m-70 57.79 84.85 0.09 Allowed 'General case' 0 C--O 1.232 0.139 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.889 -179.666 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 246' ' ' HIS . . . . . . . . . . . . . 29.5 p-80 -103.55 159.49 15.55 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.018 -0.537 . . . . 0.0 110.673 -179.93 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 247' ' ' HIS . . . . . . . . . . . . . 53.3 t-80 . . . . . 0 C--O 1.249 1.059 0 CA-C-O 118.324 -0.846 . . . . 0.0 111.027 179.939 . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 301' ' ' RET . . . . . 0.564 ' H22' ' HA3' ' A' ' 112' ' ' GLY . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 51.5 mtm . . . . . 0 N--CA 1.487 1.377 0 CA-C-O 120.709 0.29 . . . . 0.0 110.942 . . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 9.4 p -175.1 -34.78 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-N 116.141 -0.481 . . . . 0.0 111.224 -179.926 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -97.29 -28.98 8.18 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.768 -0.729 . . . . 0.0 112.768 -179.866 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 32.5 tp -74.16 -35.35 64.04 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.808 0.337 . . . . 0.0 110.884 179.967 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 74.7 p -61.67 -30.56 70.81 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.132 -0.486 . . . . 0.0 111.411 -179.985 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 29.0 p -58.98 -36.12 74.36 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-O 120.783 0.325 . . . . 0.0 111.07 -179.852 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 7' ' ' LEU . . . . . . . . . . . . . 4.5 mm? -56.61 -52.06 66.28 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.861 179.862 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 8' ' ' PHE . . . . . 0.544 ' HB2' ' HB2' ' A' ' 55' ' ' ALA . 83.5 m-85 -58.1 -37.84 75.29 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.223 179.477 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 9' ' ' TRP . . . . . . . . . . . . . 15.8 m95 -63.0 -41.81 99.68 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 115.987 -0.551 . . . . 0.0 110.102 -179.987 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 84.9 mt -59.74 -43.87 94.06 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 115.617 -0.719 . . . . 0.0 110.09 179.299 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -61.36 -33.97 86.54 Favored Glycine 0 N--CA 1.448 -0.516 0 C-N-CA 120.656 -0.783 . . . . 0.0 111.554 179.168 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -66.96 -31.23 71.66 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-O 120.912 0.387 . . . . 0.0 110.376 179.447 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 75.5 mt -66.06 -47.52 84.7 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.245 0 CA-C-N 115.985 -0.552 . . . . 0.0 110.097 179.343 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -60.63 -39.43 96.54 Favored Glycine 0 N--CA 1.45 -0.409 0 C-N-CA 120.758 -0.734 . . . . 0.0 111.7 179.315 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 15' ' ' MET . . . . . 0.498 ' HE3' ' HB1' ' A' ' 47' ' ' ALA . 0.1 OUTLIER -63.54 -41.06 98.46 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 120.665 0.269 . . . . 0.0 110.575 179.422 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -55.98 -50.66 70.21 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.758 179.841 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 35.6 t -59.6 -46.4 93.19 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.389 -179.792 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -63.96 -48.5 75.32 Favored Glycine 0 C--N 1.331 0.262 0 C-N-CA 120.718 -0.753 . . . . 0.0 112.437 179.919 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 19' ' ' THR . . . . . 0.421 HG23 HG11 ' A' ' 41' ' ' VAL . 31.9 m -50.6 -44.24 56.97 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-O 120.723 0.297 . . . . 0.0 111.131 -179.774 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 95.2 mt -72.35 -40.28 67.48 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.622 179.907 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -63.19 -33.78 76.21 Favored 'General case' 0 C--N 1.331 -0.196 0 N-CA-C 112.065 0.395 . . . . 0.0 112.065 -179.294 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 22' ' ' PHE . . . . . 0.506 ' HB2' HG22 ' A' ' 41' ' ' VAL . 7.6 m-85 -86.2 -33.7 20.7 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.657 0.265 . . . . 0.0 111.658 -179.131 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -73.6 -50.7 19.85 Favored 'General case' 0 C--N 1.329 -0.297 0 N-CA-C 111.991 0.367 . . . . 0.0 111.991 -179.206 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 24' ' ' TRP . . . . . . . . . . . . . 2.7 t-105 -58.99 -46.62 87.7 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 116.029 -0.532 . . . . 0.0 111.239 -179.503 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -71.55 -21.1 61.94 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-O 120.828 0.347 . . . . 0.0 110.925 179.796 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -73.6 -37.73 52.14 Favored Glycine 0 N--CA 1.452 -0.269 0 C-N-CA 120.913 -0.66 . . . . 0.0 112.833 179.997 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 28.1 mmm180 -71.07 -39.04 72.44 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-O 120.688 0.28 . . . . 0.0 111.064 -179.761 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 30.5 t70 -78.51 -4.1 46.89 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.317 -0.402 . . . . 0.0 110.772 179.853 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -73.73 -171.93 1.16 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.177 -179.928 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -100.27 -174.44 30.07 Favored Glycine 0 N--CA 1.45 -0.386 0 C-N-CA 120.806 -0.712 . . . . 0.0 112.634 -179.856 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 75.4 p -81.37 126.7 31.93 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.827 0.346 . . . . 0.0 110.981 179.971 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 115.42 -61.94 0.37 Allowed Glycine 0 N--CA 1.451 -0.3 0 C-N-CA 120.88 -0.676 . . . . 0.0 112.562 -179.999 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 9.1 mm-40 -60.63 -21.07 62.32 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 120.698 0.285 . . . . 0.0 110.989 179.868 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 34' ' ' ARG . . . . . . . . . . . . . 38.6 ttm180 -48.44 -34.99 11.96 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-N 115.969 -0.559 . . . . 0.0 111.525 -179.758 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 70.3 mtm180 -55.1 -54.84 38.08 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.314 -0.403 . . . . 0.0 111.303 -179.986 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 82.0 m-85 -59.7 -28.7 67.53 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.097 -179.946 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 37' ' ' TYR . . . . . . . . . . . . . 52.5 m-85 -71.97 -52.42 17.18 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.3 -0.409 . . . . 0.0 111.314 -179.893 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 59.8 t -57.69 -39.26 69.3 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.219 0 CA-C-O 121.116 0.484 . . . . 0.0 110.528 179.658 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 19.6 m -62.81 -50.93 69.05 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 115.576 -0.738 . . . . 0.0 110.715 179.403 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 19.6 tp -57.57 -50.21 73.86 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 115.652 -0.704 . . . . 0.0 110.578 -179.997 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . 0.506 HG22 ' HB2' ' A' ' 22' ' ' PHE . 85.5 t -59.02 -34.9 54.39 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.235 0 CA-C-N 115.856 -0.611 . . . . 0.0 110.236 179.142 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -59.19 -39.56 94.66 Favored Glycine 0 N--CA 1.448 -0.505 0 C-N-CA 120.834 -0.698 . . . . 0.0 112.06 179.652 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 43' ' ' ILE . . . . . 0.479 HG12 HD12 ' A' ' 82' ' ' LEU . 1.2 mt -64.84 -55.59 20.15 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.193 0 CA-C-O 120.683 0.278 . . . . 0.0 110.728 179.567 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 51.3 m -57.72 -23.81 53.7 Favored 'General case' 0 C--O 1.232 0.178 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.181 -179.963 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -78.18 -56.23 3.79 Favored Glycine 0 CA--C 1.518 0.251 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.668 -179.772 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 26.6 pt -58.31 -35.4 53.49 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.215 0 CA-C-O 121.08 0.467 . . . . 0.0 110.912 179.944 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 47' ' ' ALA . . . . . 0.589 ' HB3' ' HE2' ' A' ' 205' ' ' LYS . . . -67.51 -46.74 71.99 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-N 116.031 -0.531 . . . . 0.0 111.307 179.346 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 48' ' ' ALA . . . . . 0.48 ' HB3' ' HB3' ' A' ' 15' ' ' MET . . . -54.87 -40.6 69.87 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 116.04 -0.527 . . . . 0.0 111.951 -179.485 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 25.1 m -73.08 -34.69 46.04 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 CA-C-N 116.63 -0.259 . . . . 0.0 111.516 -179.207 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -65.96 -38.18 87.93 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-O 121.145 0.498 . . . . 0.0 110.749 179.346 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 51' ' ' TYR . . . . . 0.441 ' HB3' ' O ' ' A' ' 8' ' ' PHE . 42.9 m-85 -73.09 -28.31 62.21 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-N 115.813 -0.631 . . . . 0.0 109.734 179.466 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -72.35 -38.88 68.48 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 115.419 -0.809 . . . . 0.0 110.97 179.517 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 53' ' ' VAL . . . . . 0.528 ' O ' HG22 ' A' ' 58' ' ' VAL . 33.8 m -73.95 -47.49 42.53 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.159 0 CA-C-N 116.402 -0.363 . . . . 0.0 110.78 -179.941 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 54' ' ' MET . . . . . 0.46 ' N ' HG23 ' A' ' 53' ' ' VAL . 75.0 mtm -57.75 -36.44 72.1 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-O 121.241 0.543 . . . . 0.0 109.949 179.094 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 55' ' ' ALA . . . . . 0.544 ' HB2' ' HB2' ' A' ' 8' ' ' PHE . . . -68.91 -11.69 60.86 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 115.317 -0.856 . . . . 0.0 111.705 179.876 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 47.4 mt -97.57 -4.21 38.15 Favored 'General case' 0 C--N 1.33 -0.259 0 N-CA-C 111.944 0.35 . . . . 0.0 111.944 -179.475 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 105.13 -23.0 31.77 Favored Glycine 0 CA--C 1.52 0.352 0 C-N-CA 120.373 -0.917 . . . . 0.0 114.004 179.23 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 58' ' ' VAL . . . . . 0.528 HG22 ' O ' ' A' ' 53' ' ' VAL . 16.3 m -62.05 160.41 2.21 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.128 0 CA-C-N 117.722 0.761 . . . . 0.0 109.768 179.343 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 59' ' ' GLY . . . . . 0.651 ' HA3' ' HD3' ' A' ' 71' ' ' PRO . . . 79.58 -25.56 2.86 Favored Glycine 0 N--CA 1.441 -1.033 0 C-N-CA 119.999 -1.096 . . . . 0.0 112.71 -178.844 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 60' ' ' TRP . . . . . . . . . . . . . 11.6 m0 -67.77 80.13 0.19 Allowed 'General case' 0 C--N 1.327 -0.388 0 N-CA-C 110.176 -0.305 . . . . 0.0 110.176 179.561 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 4.7 p -90.83 119.35 68.96 Favored Pre-proline 0 C--N 1.33 -0.266 0 CA-C-N 116.461 -0.336 . . . . 0.0 111.202 -179.747 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 35.8 Cg_exo -60.49 119.44 6.63 Favored 'Trans proline' 0 C--N 1.35 0.615 0 C-N-CA 122.451 2.101 . . . . 0.0 112.176 179.841 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 78.4 t -117.21 99.59 8.54 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.364 0 CA-C-N 115.931 -0.577 . . . . 0.0 110.918 179.914 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . 59.9 -85.65 0.02 OUTLIER 'General case' 0 C--N 1.332 -0.174 0 CA-C-N 116.095 -0.502 . . . . 0.0 111.254 -179.926 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 53.8 mm-40 -126.74 -26.69 3.18 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.335 179.521 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 66' ' ' ARG . . . . . . . . . . . . . 34.5 ptt180 -95.41 164.23 12.9 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 115.823 -0.626 . . . . 0.0 110.306 179.474 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 13.8 m -114.94 132.02 56.7 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.848 0.356 . . . . 0.0 111.265 -179.999 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 29.4 t -116.78 145.77 22.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.023 -0.535 . . . . 0.0 110.634 179.728 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 69' ' ' PHE . . . . . . . . . . . . . 10.8 m-85 -102.09 119.8 39.39 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-O 120.917 0.389 . . . . 0.0 110.659 -179.357 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 70' ' ' VAL . . . . . 0.58 HG22 ' HD3' ' A' ' 71' ' ' PRO . 1.2 m -69.67 -35.57 5.7 Favored Pre-proline 0 CA--C 1.544 0.727 0 N-CA-C 113.05 0.759 . . . . 0.0 113.05 -179.344 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 71' ' ' PRO . . . . . 0.651 ' HD3' ' HA3' ' A' ' 59' ' ' GLY . 8.4 Cg_exo -70.56 -19.87 31.78 Favored 'Trans proline' 0 C--N 1.358 1.055 0 C-N-CA 122.579 2.186 . . . . 0.0 112.88 -178.146 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 72' ' ' ARG . . . . . 0.428 ' NH2' ' HG3' ' A' ' 183' ' ' PRO . 38.5 ttp180 -64.72 -53.46 46.84 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-O 120.949 0.404 . . . . 0.0 110.66 -179.916 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 73' ' ' TYR . . . . . . . . . . . . . 19.6 m-85 -73.19 -37.36 66.51 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.572 -179.97 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 74' ' ' ILE . . . . . 0.437 HG22 ' HA ' ' A' ' 71' ' ' PRO . 0.4 OUTLIER -64.08 -39.86 87.0 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 N-CA-C 109.877 -0.416 . . . . 0.0 109.877 179.439 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 33.9 t70 -64.06 -34.8 78.84 Favored 'General case' 0 CA--C 1.516 -0.362 0 N-CA-C 108.882 -0.785 . . . . 0.0 108.882 178.868 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 76' ' ' TRP . . . . . 0.425 ' HB3' ' SD ' ' A' ' 109' ' ' MET . 44.5 m0 -66.42 -28.1 68.35 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 115.531 -0.759 . . . . 0.0 110.251 179.064 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 77' ' ' ILE . . . . . 0.492 ' O ' ' HG2' ' A' ' 81' ' ' PRO . 85.0 mt -75.89 -28.75 19.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-O 121.184 0.516 . . . . 0.0 109.69 178.827 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 52.0 mt -91.55 -18.32 24.27 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 115.758 -0.655 . . . . 0.0 111.446 179.183 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 76.1 p -104.22 -50.98 3.22 Favored 'General case' 0 N--CA 1.464 0.225 0 N-CA-C 113.278 0.844 . . . . 0.0 113.278 -178.084 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 80' ' ' THR . . . . . 0.658 ' HB ' ' HD3' ' A' ' 81' ' ' PRO . 40.2 m -51.98 -55.19 32.89 Favored Pre-proline 0 CA--C 1.53 0.19 0 N-CA-C 111.947 0.351 . . . . 0.0 111.947 -178.642 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 81' ' ' PRO . . . . . 0.658 ' HD3' ' HB ' ' A' ' 80' ' ' THR . 40.6 Cg_exo -58.72 -21.8 57.97 Favored 'Trans proline' 0 C--N 1.352 0.748 0 C-N-CA 121.426 1.417 . . . . 0.0 111.133 179.406 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 82' ' ' LEU . . . . . 0.479 HD12 HG12 ' A' ' 43' ' ' ILE . 0.2 OUTLIER -76.36 -43.42 40.99 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 115.555 -0.748 . . . . 0.0 109.999 179.638 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 50.4 mm -63.76 -52.38 57.9 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.192 0 CA-C-N 116.074 -0.512 . . . . 0.0 110.424 179.512 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 29.3 m -57.98 -33.79 47.11 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.202 0 N-CA-C 109.738 -0.467 . . . . 0.0 109.738 179.104 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 85' ' ' TYR . . . . . . . . . . . . . 61.6 t80 -62.1 -36.13 80.79 Favored 'General case' 0 N--CA 1.454 -0.27 0 CA-C-N 115.796 -0.638 . . . . 0.0 109.463 178.601 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 86' ' ' PHE . . . . . . . . . . . . . 13.0 t80 -59.7 -49.12 78.98 Favored 'General case' 0 C--O 1.232 0.183 0 CA-C-N 115.641 -0.709 . . . . 0.0 109.726 179.0 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 3.9 mm? -56.42 -41.8 76.96 Favored 'General case' 0 C--N 1.332 -0.176 0 CA-C-N 115.696 -0.684 . . . . 0.0 110.02 179.334 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -66.51 -27.97 73.46 Favored Glycine 0 N--CA 1.45 -0.397 0 CA-C-N 115.721 -0.672 . . . . 0.0 112.432 179.748 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 87.9 mt -71.0 -33.05 70.02 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.973 0.416 . . . . 0.0 110.516 179.814 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 95.6 mt -73.53 -30.98 63.42 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 115.884 -0.598 . . . . 0.0 111.134 179.824 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -88.47 -28.58 20.75 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.452 -0.34 . . . . 0.0 111.694 -179.603 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 80.62 58.05 2.78 Favored Glycine 0 N--CA 1.452 -0.3 0 C-N-CA 120.72 -0.752 . . . . 0.0 111.93 -179.5 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 93' ' ' LEU . . . . . 0.464 HD13 ' HE3' ' A' ' 145' ' ' MET . 94.5 mt -74.97 177.75 6.1 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.986 0.422 . . . . 0.0 111.506 -179.384 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 94' ' ' ASP . . . . . . . . . . . . . 9.9 m-20 -102.13 171.3 7.57 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-N 115.818 -0.628 . . . . 0.0 110.654 179.666 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 45.8 t -57.4 -36.91 71.91 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.292 -0.413 . . . . 0.0 111.192 -179.63 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 15.2 ptm180 -73.5 -48.12 35.75 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.467 -0.333 . . . . 0.0 111.343 -179.846 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 48.0 mt-10 -53.18 -45.69 68.65 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.303 -0.408 . . . . 0.0 111.079 -179.846 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 98' ' ' PHE . . . . . 0.45 ' O ' HG12 ' A' ' 102' ' ' ILE . 26.3 m-85 -59.25 -49.48 77.67 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.673 179.611 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -55.77 -28.02 51.25 Favored Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.811 -0.709 . . . . 0.0 112.862 -179.754 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 93.5 mt -73.77 -49.05 37.16 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 N-CA-C 111.914 0.339 . . . . 0.0 111.914 -179.641 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 33.1 m -70.58 -32.55 50.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 N-CA-C 111.962 0.356 . . . . 0.0 111.962 -179.251 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 102' ' ' ILE . . . . . 0.477 HG21 ' HB3' ' A' ' 81' ' ' PRO . 50.2 mm -74.93 -43.0 46.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.536 -0.302 . . . . 0.0 111.426 -179.573 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 14.7 t -63.52 -34.0 76.82 Favored 'General case' 0 C--O 1.232 0.134 0 CA-C-O 121.075 0.464 . . . . 0.0 110.116 179.532 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 104' ' ' LEU . . . . . 0.424 ' O ' HG23 ' A' ' 108' ' ' VAL . 42.8 tp -61.82 -57.11 13.11 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 115.796 -0.638 . . . . 0.0 110.072 179.101 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 105' ' ' ASN . . . . . 0.603 ' N ' HD21 ' A' ' 105' ' ' ASN . 0.8 OUTLIER -55.95 -25.82 45.3 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 115.967 -0.561 . . . . 0.0 110.873 179.411 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 79.0 m -64.07 -57.53 9.36 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.422 -0.353 . . . . 0.0 111.205 -179.93 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 7.1 p -62.25 -35.83 71.29 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.211 0 CA-C-N 116.394 -0.366 . . . . 0.0 110.952 179.916 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . 0.424 HG23 ' O ' ' A' ' 104' ' ' LEU . 84.6 t -62.87 -56.99 14.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-O 121.052 0.453 . . . . 0.0 110.783 179.645 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 109' ' ' MET . . . . . 0.425 ' SD ' ' HB3' ' A' ' 76' ' ' TRP . 5.5 tpp -58.07 -32.43 68.03 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 115.793 -0.639 . . . . 0.0 110.932 -179.729 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 22.4 tp -66.93 -35.97 81.19 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.243 179.663 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -62.46 -44.12 97.18 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 115.855 -0.611 . . . . 0.0 110.491 179.312 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . -64.17 -44.7 95.28 Favored Glycine 0 N--CA 1.452 -0.278 0 C-N-CA 120.751 -0.737 . . . . 0.0 112.289 179.519 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 113' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -51.04 -63.73 1.04 Allowed 'General case' 0 C--N 1.333 -0.149 0 CA-C-O 121.075 0.464 . . . . 0.0 110.347 179.765 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -67.31 -16.71 64.42 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 115.782 -0.645 . . . . 0.0 110.862 179.575 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -60.85 -47.01 93.34 Favored Glycine 0 C--N 1.332 0.35 0 C-N-CA 120.768 -0.729 . . . . 0.0 112.267 179.7 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -78.48 -22.57 47.29 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 120.666 0.27 . . . . 0.0 111.631 179.796 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 117' ' ' MET . . . . . . . . . . . . . 1.1 mpt? -87.11 18.33 3.7 Favored 'General case' 0 C--N 1.332 -0.162 0 CA-C-N 116.53 -0.304 . . . . 0.0 111.712 -179.705 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 118' ' ' VAL . . . . . 0.469 HG22 ' HB3' ' A' ' 123' ' ' ARG . 27.3 m -76.13 147.69 80.28 Favored Pre-proline 0 C--N 1.327 -0.37 0 CA-C-N 116.668 -0.242 . . . . 0.0 111.305 179.99 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 119' ' ' PRO . . . . . . . . . . . . . 67.7 Cg_endo -84.55 -15.78 6.01 Favored 'Trans proline' 0 C--N 1.347 0.476 0 C-N-CA 122.667 2.245 . . . . 0.0 112.645 -179.987 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -143.68 -110.79 0.75 Allowed Glycine 0 C--N 1.333 0.369 0 C-N-CA 120.462 -0.875 . . . . 0.0 113.282 -179.53 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 47.9 pt -111.16 11.59 8.61 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.218 0 N-CA-C 111.783 0.29 . . . . 0.0 111.783 -179.225 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 15.7 mm-40 -58.39 -19.06 32.79 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.867 0.365 . . . . 0.0 110.815 179.819 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 123' ' ' ARG . . . . . 0.469 ' HB3' HG22 ' A' ' 118' ' ' VAL . 32.0 ptt180 -53.09 -30.02 33.83 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 115.714 -0.675 . . . . 0.0 111.843 -179.817 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 124' ' ' TYR . . . . . . . . . . . . . 48.5 m-85 -75.3 -32.62 61.03 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 116.316 -0.402 . . . . 0.0 111.907 -178.985 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 125' ' ' ALA . . . . . . . . . . . . . . . -70.68 -55.65 8.23 Favored 'General case' 0 C--O 1.238 0.453 0 CA-C-O 121.121 0.486 . . . . 0.0 110.892 179.953 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 1.3 mt -55.85 -46.07 78.31 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 115.591 -0.732 . . . . 0.0 110.607 -179.613 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 127' ' ' PHE . . . . . 0.47 ' HZ ' ' HB3' ' A' ' 175' ' ' PRO . 3.0 t80 -67.29 -39.01 85.95 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.442 -0.345 . . . . 0.0 110.555 179.618 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 128' ' ' GLY . . . . . . . . . . . . . . . -46.44 -43.72 15.1 Favored Glycine 0 C--O 1.237 0.284 0 C-N-CA 120.129 -1.034 . . . . 0.0 111.09 179.356 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 129' ' ' MET . . . . . 0.414 ' HE2' ' N ' ' A' ' 130' ' ' GLY . 0.4 OUTLIER -70.92 -40.34 72.16 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 121.014 0.435 . . . . 0.0 110.263 178.999 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 130' ' ' GLY . . . . . 0.414 ' N ' ' HE2' ' A' ' 129' ' ' MET . . . -66.32 -26.4 72.62 Favored Glycine 0 N--CA 1.452 -0.254 0 CA-C-N 115.727 -0.67 . . . . 0.0 113.018 -179.691 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -75.08 -53.66 8.5 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 120.664 0.269 . . . . 0.0 110.588 179.98 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 56.2 t -59.27 -41.01 82.7 Favored 'Isoleucine or valine' 0 C--O 1.234 0.275 0 N-CA-C 109.203 -0.666 . . . . 0.0 109.203 178.7 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -67.54 -34.53 77.26 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-N 115.207 -0.906 . . . . 0.0 110.549 179.214 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 134' ' ' PHE . . . . . . . . . . . . . 39.8 t80 -55.86 -54.77 40.55 Favored 'General case' 0 N--CA 1.452 -0.344 0 CA-C-N 116.209 -0.451 . . . . 0.0 109.992 179.485 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 135' ' ' ILE . . . . . 0.462 ' HA ' HG22 ' A' ' 138' ' ' VAL . 33.1 mt -58.15 -31.89 42.97 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 CA-C-N 115.711 -0.677 . . . . 0.0 110.116 179.164 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . -59.27 -44.89 96.17 Favored Glycine 0 N--CA 1.449 -0.488 0 C-N-CA 120.401 -0.904 . . . . 0.0 112.119 179.124 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 137' ' ' LEU . . . . . 0.572 HD13 HD22 ' A' ' 105' ' ' ASN . 13.9 tp -70.76 -52.02 23.38 Favored 'General case' 0 C--N 1.33 -0.258 0 C-N-CA 121.055 -0.258 . . . . 0.0 111.173 -179.867 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 138' ' ' VAL . . . . . 0.462 HG22 ' HA ' ' A' ' 135' ' ' ILE . 4.2 m -54.53 -31.56 23.49 Favored 'Isoleucine or valine' 0 C--O 1.232 0.168 0 N-CA-C 109.604 -0.517 . . . . 0.0 109.604 -179.737 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 139' ' ' TYR . . . . . . . . . . . . . 13.9 t80 -63.69 -44.53 93.41 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 115.616 -0.72 . . . . 0.0 109.596 178.16 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 24.9 m-85 -59.01 -42.83 91.06 Favored 'General case' 0 C--O 1.233 0.189 0 CA-C-N 115.971 -0.559 . . . . 0.0 111.05 179.402 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 141' ' ' LEU . . . . . 0.487 ' HA ' ' SD ' ' A' ' 145' ' ' MET . 9.4 mp -55.59 -49.76 71.91 Favored 'General case' 0 N--CA 1.462 0.17 0 CA-C-N 116.429 -0.351 . . . . 0.0 110.994 -179.774 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 12.6 p -82.46 -10.27 11.97 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.364 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.99 -179.98 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 143' ' ' GLY . . . . . 0.472 ' O ' HG22 ' A' ' 146' ' ' THR . . . -74.99 -144.97 1.1 Allowed Glycine 0 CA--C 1.521 0.455 0 C-N-CA 121.05 -0.595 . . . . 0.0 112.889 -179.766 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 144' ' ' PRO . . . . . . . . . . . . . 78.1 Cg_exo -50.07 -23.27 9.05 Favored 'Trans proline' 0 C--N 1.348 0.537 0 C-N-CA 122.794 2.329 . . . . 0.0 112.93 -179.934 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 145' ' ' MET . . . . . 0.487 ' SD ' ' HA ' ' A' ' 141' ' ' LEU . 27.4 mtt -52.4 -43.87 65.02 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.392 -0.367 . . . . 0.0 111.636 -179.681 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 146' ' ' THR . . . . . 0.472 HG22 ' O ' ' A' ' 143' ' ' GLY . 8.3 t -76.67 -31.77 57.51 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-O 120.907 0.384 . . . . 0.0 110.862 -179.471 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 34.0 tt0 -64.5 -40.4 95.59 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 115.989 -0.55 . . . . 0.0 110.769 179.858 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 148' ' ' SER . . . . . . . . . . . . . 55.5 m -70.41 -46.88 63.1 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.75 -179.972 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 149' ' ' ALA . . . . . . . . . . . . . . . -62.38 -32.41 73.21 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 115.935 -0.575 . . . . 0.0 111.19 -179.995 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 150' ' ' SER . . . . . . . . . . . . . 48.1 t -70.56 -1.64 11.66 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.815 179.843 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 151' ' ' GLN . . . . . . . . . . . . . 48.8 mt-30 -120.18 1.64 10.83 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.121 -0.491 . . . . 0.0 111.168 -179.832 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 26.6 mmm180 -81.88 -52.45 7.08 Favored 'General case' 0 C--N 1.332 -0.171 0 CA-C-O 121.11 0.481 . . . . 0.0 110.51 179.699 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 153' ' ' SER . . . . . 0.541 ' HB2' HG12 ' A' ' 156' ' ' ILE . 25.3 m -157.41 172.31 18.81 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-N 115.599 -0.728 . . . . 0.0 110.842 179.296 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 154' ' ' SER . . . . . . . . . . . . . 81.0 p -70.41 -39.1 74.64 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.303 -0.408 . . . . 0.0 110.709 179.579 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -77.21 -39.35 27.2 Favored Glycine 0 CA--C 1.518 0.269 0 C-N-CA 121.057 -0.592 . . . . 0.0 112.905 -179.83 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 156' ' ' ILE . . . . . 0.541 HG12 ' HB2' ' A' ' 153' ' ' SER . 35.6 mm -49.73 -38.92 14.08 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.175 0 CA-C-O 120.774 0.321 . . . . 0.0 111.823 -179.616 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 157' ' ' LYS . . . . . . . . . . . . . 64.7 tttm -66.72 -37.91 85.63 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-N 116.304 -0.407 . . . . 0.0 111.363 -179.559 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 49.5 m -71.38 -37.91 71.56 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 121.003 0.43 . . . . 0.0 111.157 -178.815 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 159' ' ' LEU . . . . . 0.552 ' O ' ' HG ' ' A' ' 163' ' ' LEU . 31.3 mt -70.6 -56.79 5.66 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-N 116.043 -0.526 . . . . 0.0 111.13 -179.642 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 160' ' ' TYR . . . . . 0.432 ' OH ' ' HB3' ' A' ' 145' ' ' MET . 31.9 t80 -51.88 -41.83 62.2 Favored 'General case' 0 C--N 1.325 -0.466 0 N-CA-C 112.416 0.524 . . . . 0.0 112.416 -178.764 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 161' ' ' VAL . . . . . 0.409 HG22 ' N ' ' A' ' 162' ' ' ARG . 30.5 m -66.28 -49.07 78.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 N-CA-C 112.022 0.379 . . . . 0.0 112.022 -178.529 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 162' ' ' ARG . . . . . 0.409 ' N ' HG22 ' A' ' 161' ' ' VAL . 98.4 mtt180 -66.02 -49.38 67.94 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.768 0.318 . . . . 0.0 111.731 -179.205 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 163' ' ' LEU . . . . . 0.552 ' HG ' ' O ' ' A' ' 159' ' ' LEU . 19.7 mt -60.65 -55.43 33.32 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.635 -179.164 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 164' ' ' ARG . . . . . 0.408 ' HG3' ' N ' ' A' ' 165' ' ' ASN . 3.8 ppt_? -58.85 -38.71 79.34 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.363 -0.38 . . . . 0.0 111.959 -178.967 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 165' ' ' ASN . . . . . 0.411 ' O ' HG21 ' A' ' 169' ' ' VAL . 0.9 OUTLIER -56.6 -53.62 55.49 Favored 'General case' 0 C--O 1.237 0.408 0 CA-C-O 120.751 0.31 . . . . 0.0 111.133 -178.383 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 166' ' ' LEU . . . . . 0.462 ' O ' ' HG ' ' A' ' 170' ' ' LEU . 0.2 OUTLIER -68.01 -28.89 67.81 Favored 'General case' 0 C--N 1.326 -0.439 0 C-N-CA 120.588 -0.445 . . . . 0.0 110.267 -179.917 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 167' ' ' THR . . . . . 0.417 ' O ' ' HB2' ' A' ' 171' ' ' TRP . 21.7 m -61.19 -53.35 57.98 Favored 'General case' 0 N--CA 1.462 0.131 0 CA-C-N 116.313 -0.403 . . . . 0.0 111.259 179.743 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 168' ' ' VAL . . . . . . . . . . . . . 60.4 t -60.04 -40.64 83.79 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 115.826 -0.624 . . . . 0.0 111.799 -179.054 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 169' ' ' VAL . . . . . 0.411 HG21 ' O ' ' A' ' 165' ' ' ASN . 93.9 t -56.74 -65.5 0.39 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 C-N-CA 120.914 -0.314 . . . . 0.0 111.739 -179.69 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 170' ' ' LEU . . . . . 0.462 ' HG ' ' O ' ' A' ' 166' ' ' LEU . 1.1 pp -62.8 -33.11 74.52 Favored 'General case' 0 C--N 1.33 -0.269 0 N-CA-C 112.467 0.543 . . . . 0.0 112.467 -178.576 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 171' ' ' TRP . . . . . 0.428 ' NE1' H203 ' A' ' 301' ' ' RET . 2.2 m0 -69.01 -31.28 69.99 Favored 'General case' 0 N--CA 1.463 0.22 0 C-N-CA 120.846 -0.341 . . . . 0.0 110.844 179.644 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 172' ' ' ALA . . . . . . . . . . . . . . . -74.53 -7.08 51.93 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-O 120.909 0.385 . . . . 0.0 110.587 -179.768 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 173' ' ' ILE . . . . . 0.515 HG21 HD13 ' A' ' 177' ' ' ILE . 40.6 mm -85.48 -21.84 7.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 115.787 -0.642 . . . . 0.0 110.865 179.62 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 174' ' ' TYR . . . . . . . . . . . . . 26.9 m-85 -54.56 -50.05 87.59 Favored Pre-proline 0 N--CA 1.464 0.242 0 CA-C-N 116.33 -0.396 . . . . 0.0 111.542 -179.975 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 175' ' ' PRO . . . . . 0.47 ' HB3' ' HZ ' ' A' ' 127' ' ' PHE . 86.8 Cg_exo -46.93 -30.79 10.16 Favored 'Trans proline' 0 C--N 1.352 0.749 0 C-N-CA 122.121 1.88 . . . . 0.0 112.215 179.575 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 176' ' ' PHE . . . . . 0.466 ' HD2' ' HA ' ' A' ' 173' ' ' ILE . 76.8 m-85 -80.38 -48.81 12.35 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 115.928 -0.578 . . . . 0.0 111.65 -179.768 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 177' ' ' ILE . . . . . 0.515 HD13 HG21 ' A' ' 173' ' ' ILE . 3.4 mm -63.47 -34.24 66.25 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.516 0 CA-C-N 116.374 -0.375 . . . . 0.0 111.881 -178.5 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 178' ' ' TRP . . . . . 0.42 ' HH2' ' HB2' ' A' ' 123' ' ' ARG . 73.8 t90 -74.03 -48.78 27.7 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 121.041 0.448 . . . . 0.0 110.449 179.438 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 179' ' ' LEU . . . . . 0.471 HD11 HD22 ' A' ' 180' ' ' LEU . 1.9 tm? -63.55 -52.3 61.7 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 115.68 -0.691 . . . . 0.0 111.239 -179.395 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 180' ' ' LEU . . . . . 0.594 HD23 HD13 ' A' ' 187' ' ' LEU . 15.6 mt -76.73 -41.83 43.56 Favored 'General case' 0 C--N 1.329 -0.324 0 N-CA-C 112.076 0.398 . . . . 0.0 112.076 -178.914 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . -58.18 179.02 1.26 Allowed Glycine 0 C--N 1.334 0.456 0 C-N-CA 120.166 -1.016 . . . . 0.0 112.426 179.759 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 182' ' ' PRO . . . . . 0.429 ' HB2' ' HD3' ' A' ' 183' ' ' PRO . 72.0 Cg_exo -47.27 -45.29 22.47 Favored 'Trans proline' 0 CA--C 1.536 0.61 0 C-N-CA 122.741 2.294 . . . . 0.0 113.798 -179.856 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 183' ' ' PRO . . . . . 0.429 ' HD3' ' HB2' ' A' ' 182' ' ' PRO . 71.6 Cg_exo -49.49 -22.98 6.91 Favored 'Trans proline' 0 C--N 1.356 0.955 0 C-N-CA 122.223 1.949 . . . . 0.0 113.121 -179.786 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 184' ' ' GLY . . . . . . . . . . . . . . . -119.07 -132.99 4.58 Favored Glycine 0 N--CA 1.449 -0.448 0 C-N-CA 120.484 -0.865 . . . . 0.0 112.906 -179.824 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 185' ' ' VAL . . . . . . . . . . . . . 13.3 m -58.75 -21.02 17.93 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.396 0 N-CA-C 112.13 0.418 . . . . 0.0 112.13 -179.485 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 186' ' ' ALA . . . . . . . . . . . . . . . 55.61 87.18 0.05 Allowed 'General case' 0 N--CA 1.463 0.194 0 CA-C-O 120.74 0.305 . . . . 0.0 111.391 179.906 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 187' ' ' LEU . . . . . 0.594 HD13 HD23 ' A' ' 180' ' ' LEU . 15.8 mt -91.75 -49.54 6.21 Favored 'General case' 0 C--N 1.332 -0.195 0 CA-C-N 116.291 -0.413 . . . . 0.0 111.341 -179.713 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 188' ' ' LEU . . . . . . . . . . . . . 68.6 mt -96.85 -155.07 0.47 Allowed 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 115.923 -0.58 . . . . 0.0 110.991 -179.573 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 189' ' ' THR . . . . . 0.458 ' HG1' HG22 ' A' ' 191' ' ' THR . 1.9 t -101.6 146.74 32.76 Favored Pre-proline 0 C--N 1.328 -0.367 0 CA-C-N 116.001 -0.545 . . . . 0.0 110.817 -179.987 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 190' ' ' PRO . . . . . . . . . . . . . 86.5 Cg_exo -47.09 -45.2 21.97 Favored 'Trans proline' 0 C--N 1.348 0.502 0 C-N-CA 122.694 2.262 . . . . 0.0 113.35 -179.528 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 191' ' ' THR . . . . . 0.458 HG22 ' HG1' ' A' ' 189' ' ' THR . 5.6 t -56.58 -39.95 74.4 Favored 'General case' 0 C--N 1.329 -0.316 0 N-CA-C 112.061 0.393 . . . . 0.0 112.061 -179.338 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 192' ' ' VAL . . . . . . . . . . . . . 40.6 t -73.37 -53.82 17.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 N-CA-C 111.909 0.337 . . . . 0.0 111.909 -179.435 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 193' ' ' ASP . . . . . . . . . . . . . 19.0 m-20 -58.36 -50.11 74.84 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.516 -0.311 . . . . 0.0 111.217 -179.829 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 194' ' ' VAL . . . . . . . . . . . . . 78.0 t -59.9 -36.33 66.04 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 116.339 -0.392 . . . . 0.0 110.691 179.557 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 195' ' ' ALA . . . . . . . . . . . . . . . -56.26 -47.85 77.72 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 116.397 -0.365 . . . . 0.0 111.121 179.792 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 196' ' ' LEU . . . . . . . . . . . . . 91.6 mt -64.99 -35.39 81.02 Favored 'General case' 0 C--N 1.332 -0.177 0 CA-C-O 120.771 0.319 . . . . 0.0 110.464 179.658 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 197' ' ' ILE . . . . . 0.493 HD12 ' HB ' ' A' ' 177' ' ' ILE . 19.6 mm -61.46 -53.8 43.7 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-O 121.142 0.496 . . . . 0.0 110.022 178.972 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 198' ' ' VAL . . . . . . . . . . . . . 98.3 t -54.91 -34.32 30.81 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.47 0 CA-C-N 115.344 -0.844 . . . . 0.0 109.33 178.471 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 199' ' ' TYR . . . . . . . . . . . . . 68.8 t80 -69.35 -40.4 77.53 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 115.083 -0.962 . . . . 0.0 110.246 179.925 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 200' ' ' LEU . . . . . . . . . . . . . 38.1 mt -61.72 -41.56 97.79 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 115.74 -0.663 . . . . 0.0 111.371 -179.773 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 201' ' ' ASP . . . . . 0.412 ' HB2' ' HH ' ' A' ' 51' ' ' TYR . 0.9 OUTLIER -71.87 -40.39 68.98 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.041 -179.807 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 202' ' ' LEU . . . . . . . . . . . . . 2.7 mt -65.2 -33.71 76.66 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.119 -0.491 . . . . 0.0 111.617 -179.401 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 203' ' ' VAL . . . . . 0.521 ' O ' ' HA3' ' A' ' 207' ' ' GLY . 65.9 t -77.31 -36.07 23.4 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.384 0 CA-C-O 120.74 0.305 . . . . 0.0 111.381 -179.12 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 204' ' ' THR . . . . . 0.435 HG21 H201 ' A' ' 301' ' ' RET . 88.8 m -66.46 -58.61 4.9 Favored 'General case' 0 C--N 1.325 -0.497 0 C-N-CA 120.745 -0.382 . . . . 0.0 111.298 179.95 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 205' ' ' LYS . . . . . 0.589 ' HE2' ' HB3' ' A' ' 47' ' ' ALA . 36.1 mttp -68.13 -58.75 3.96 Favored 'General case' 0 C--N 1.328 -0.338 0 N-CA-C 112.489 0.551 . . . . 0.0 112.489 -178.348 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 17.9 t -73.46 -37.0 49.77 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.369 0 N-CA-C 112.084 0.401 . . . . 0.0 112.084 -178.281 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 207' ' ' GLY . . . . . 0.521 ' HA3' ' O ' ' A' ' 203' ' ' VAL . . . -59.35 -60.05 9.52 Favored Glycine 0 N--CA 1.452 -0.278 0 C-N-CA 120.313 -0.946 . . . . 0.0 112.502 -179.36 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 208' ' ' PHE . . . . . 0.513 ' O ' ' N ' ' A' ' 212' ' ' ALA . 1.2 m-30 -58.48 -43.76 89.09 Favored 'General case' 0 C--O 1.221 -0.402 0 CA-C-N 117.111 0.456 . . . . 0.0 110.069 179.739 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 209' ' ' GLY . . . . . 0.448 ' O ' ' HB1' ' A' ' 212' ' ' ALA . . . -53.72 -37.89 57.99 Favored Glycine 0 CA--C 1.518 0.239 0 CA-C-N 115.501 -0.772 . . . . 0.0 113.957 -179.923 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 210' ' ' PHE . . . . . . . . . . . . . 2.6 m-85 -70.01 -48.68 57.12 Favored 'General case' 0 CA--C 1.515 -0.39 0 N-CA-C 108.906 -0.775 . . . . 0.0 108.906 179.664 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 211' ' ' ILE . . . . . 0.426 HG13 ' O ' ' A' ' 207' ' ' GLY . 5.3 mt -63.87 -27.43 42.82 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.569 0 N-CA-C 107.47 -1.308 . . . . 0.0 107.47 176.629 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 212' ' ' ALA . . . . . 0.513 ' N ' ' O ' ' A' ' 208' ' ' PHE . . . -68.37 -38.61 81.56 Favored 'General case' 0 N--CA 1.449 -0.488 0 CA-C-N 114.173 -1.376 . . . . 0.0 110.481 -179.866 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 213' ' ' LEU . . . . . . . . . . . . . 52.9 mt -65.44 -54.65 25.4 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-N 115.139 -0.937 . . . . 0.0 111.093 -179.811 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 214' ' ' ASP . . . . . . . . . . . . . 15.8 m-20 -60.57 -27.05 67.4 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.367 -0.379 . . . . 0.0 110.466 179.746 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 215' ' ' ALA . . . . . 0.426 ' O ' ' HG ' ' A' ' 219' ' ' LEU . . . -68.94 -57.77 5.04 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.073 -0.512 . . . . 0.0 111.193 -179.964 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 216' ' ' ALA . . . . . . . . . . . . . . . -63.28 -31.27 72.37 Favored 'General case' 0 C--N 1.331 -0.21 0 CA-C-N 116.332 -0.395 . . . . 0.0 110.972 -179.974 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 217' ' ' ALA . . . . . . . . . . . . . . . -64.64 -37.56 87.98 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.045 -0.525 . . . . 0.0 110.433 179.73 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 218' ' ' THR . . . . . . . . . . . . . 99.1 m -69.08 -40.74 78.26 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 115.817 -0.628 . . . . 0.0 110.508 179.456 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 219' ' ' LEU . . . . . 0.426 ' HG ' ' O ' ' A' ' 215' ' ' ALA . 42.9 mt -63.93 -33.54 75.94 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.373 179.491 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 220' ' ' ARG . . . . . . . . . . . . . 58.4 ttt180 -78.7 -30.85 46.29 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 115.879 -0.601 . . . . 0.0 110.531 179.821 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 221' ' ' ALA . . . . . . . . . . . . . . . -70.45 -29.44 66.01 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.009 179.776 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 222' ' ' GLU . . . . . 0.59 ' HG3' ' H ' ' A' ' 224' ' ' GLY . 12.3 pt-20 -92.01 -21.88 20.27 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.334 179.849 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 223' ' ' HIS . . . . . . . . . . . . . 53.9 m-70 60.48 11.27 2.9 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 115.687 -0.688 . . . . 0.0 111.156 179.648 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 224' ' ' GLY . . . . . 0.59 ' H ' ' HG3' ' A' ' 222' ' ' GLU . . . 82.62 -54.86 4.96 Favored Glycine 0 N--CA 1.45 -0.389 0 C-N-CA 120.872 -0.68 . . . . 0.0 112.239 -179.835 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 225' ' ' GLU . . . . . . . . . . . . . 44.9 mt-10 -107.96 146.2 32.78 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.761 0.315 . . . . 0.0 110.509 179.719 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 226' ' ' SER . . . . . . . . . . . . . 81.7 p -139.98 125.71 19.38 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.296 -0.411 . . . . 0.0 111.005 -179.703 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 227' ' ' LEU . . . . . . . . . . . . . 4.3 pp -54.79 152.34 7.32 Favored 'General case' 0 C--N 1.331 -0.21 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.959 -179.96 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 228' ' ' ALA . . . . . . . . . . . . . . . -117.04 131.55 56.91 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.058 179.875 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 229' ' ' GLY . . . . . . . . . . . . . . . 132.89 -109.36 0.83 Allowed Glycine 0 N--CA 1.45 -0.37 0 C-N-CA 120.834 -0.698 . . . . 0.0 112.378 -179.953 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 230' ' ' VAL . . . . . . . . . . . . . 60.7 t -99.53 116.83 43.64 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.355 0 CA-C-O 120.824 0.345 . . . . 0.0 111.103 179.9 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 231' ' ' ASP . . . . . . . . . . . . . 7.5 p-10 -97.98 132.9 43.15 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.976 -179.858 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 232' ' ' THR . . . . . . . . . . . . . 4.1 t -157.24 128.53 6.84 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.15 179.852 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 233' ' ' ASP . . . . . . . . . . . . . 6.4 p-10 -167.52 156.34 9.76 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.132 -0.486 . . . . 0.0 110.807 179.971 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 234' ' ' THR . . . . . . . . . . . . . 5.4 t -127.77 142.52 44.51 Favored Pre-proline 0 C--N 1.33 -0.278 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.889 179.836 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 235' ' ' PRO . . . . . . . . . . . . . 32.4 Cg_exo -58.45 138.44 85.83 Favored 'Trans proline' 0 C--N 1.348 0.537 0 C-N-CA 122.448 2.099 . . . . 0.0 112.287 179.932 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 236' ' ' ALA . . . . . . . . . . . . . . . -159.84 106.41 1.63 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.031 -0.531 . . . . 0.0 110.87 -179.978 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 237' ' ' VAL . . . . . . . . . . . . . 46.7 t -116.53 102.75 14.07 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-N 116.085 -0.507 . . . . 0.0 111.022 -179.777 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 238' ' ' ALA . . . . . . . . . . . . . . . -164.54 124.48 1.98 Allowed 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.144 -179.987 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 239' ' ' ASP . . . . . . . . . . . . . 7.8 p-10 -76.33 149.75 36.99 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.275 -0.42 . . . . 0.0 111.037 -179.907 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 240' ' ' LEU . . . . . . . . . . . . . 88.5 mt -94.96 -36.79 11.44 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.052 -0.522 . . . . 0.0 110.928 -179.998 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 241' ' ' GLU . . . . . . . . . . . . . 11.0 tp10 59.58 94.86 0.03 OUTLIER 'General case' 0 C--N 1.333 -0.12 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.934 179.992 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 242' ' ' HIS . . . . . . . . . . . . . 27.2 p80 -148.37 144.76 27.73 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.947 179.953 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 243' ' ' HIS . . . . . . . . . . . . . 35.6 m-70 -72.99 175.57 6.52 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.877 179.861 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 244' ' ' HIS . . . . . . . . . . . . . 32.0 m80 -82.56 -56.48 3.84 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.123 -0.489 . . . . 0.0 110.761 179.711 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 245' ' ' HIS . . . . . . . . . . . . . 25.1 t60 -87.68 143.65 27.06 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.412 179.549 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 246' ' ' HIS . . . . . . . . . . . . . 12.1 t60 -60.02 -71.98 0.12 Allowed 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.343 -0.39 . . . . 0.0 111.331 -179.421 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 247' ' ' HIS . . . . . . . . . . . . . 55.7 t-80 . . . . . 0 C--O 1.25 1.081 0 CA-C-O 118.284 -0.865 . . . . 0.0 111.075 -179.754 . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 301' ' ' RET . . . . . 0.435 H201 HG21 ' A' ' 204' ' ' THR . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 86.9 mtp . . . . . 0 N--CA 1.485 1.325 0 CA-C-O 120.789 0.328 . . . . 0.0 110.823 . . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 55.4 t -132.04 -34.15 0.54 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.221 0 CA-C-N 116.178 -0.465 . . . . 0.0 111.331 -179.985 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -78.8 -31.85 42.82 Favored Glycine 0 N--CA 1.452 -0.238 0 C-N-CA 120.639 -0.791 . . . . 0.0 112.34 179.973 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 4' ' ' LEU . . . . . 0.498 HD13 HG21 ' A' ' 194' ' ' VAL . 47.6 tp -74.12 -36.95 64.23 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-O 120.849 0.356 . . . . 0.0 110.989 179.934 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 70.8 p -59.44 -31.99 69.8 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.077 -0.51 . . . . 0.0 111.665 -179.616 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 6' ' ' THR . . . . . 0.515 ' HG1' HD22 ' A' ' 7' ' ' LEU . 32.3 p -55.62 -35.45 65.9 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-O 120.844 0.354 . . . . 0.0 111.191 -179.773 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 7' ' ' LEU . . . . . 0.515 HD22 ' HG1' ' A' ' 6' ' ' THR . 4.0 mm? -58.98 -53.05 62.81 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.123 -0.49 . . . . 0.0 111.087 179.952 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 8' ' ' PHE . . . . . . . . . . . . . 73.6 m-85 -58.81 -33.11 70.01 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 116.34 -0.391 . . . . 0.0 110.817 179.932 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 9' ' ' TRP . . . . . 0.425 ' O ' HG13 ' A' ' 13' ' ' ILE . 27.8 m95 -66.35 -46.61 76.18 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 116.013 -0.54 . . . . 0.0 110.152 -179.862 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 94.1 mt -59.82 -42.07 92.7 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 115.651 -0.704 . . . . 0.0 110.347 179.377 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -63.42 -30.42 77.53 Favored Glycine 0 N--CA 1.449 -0.496 0 C-N-CA 120.712 -0.756 . . . . 0.0 111.724 179.348 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -73.19 -30.79 63.78 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.795 0.331 . . . . 0.0 110.82 179.678 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 13' ' ' ILE . . . . . 0.425 HG13 ' O ' ' A' ' 9' ' ' TRP . 67.0 mt -67.61 -54.7 21.22 Favored 'Isoleucine or valine' 0 C--O 1.233 0.206 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.399 179.473 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -62.46 -35.09 91.23 Favored Glycine 0 N--CA 1.449 -0.474 0 C-N-CA 120.716 -0.755 . . . . 0.0 111.399 179.209 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 15' ' ' MET . . . . . 0.486 ' SD ' ' HA ' ' A' ' 44' ' ' SER . 45.5 tpp -62.75 -41.96 99.45 Favored 'General case' 0 N--CA 1.453 -0.294 0 CA-C-O 120.814 0.34 . . . . 0.0 110.209 179.376 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -59.46 -37.74 78.96 Favored 'General case' 0 C--N 1.331 -0.201 0 N-CA-C 109.635 -0.505 . . . . 0.0 109.635 178.893 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 46.5 t -59.24 -43.23 89.28 Favored 'Isoleucine or valine' 0 C--O 1.232 0.176 0 CA-C-N 116.033 -0.531 . . . . 0.0 110.134 179.143 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -68.25 -42.89 81.98 Favored Glycine 0 C--N 1.331 0.291 0 C-N-CA 120.795 -0.717 . . . . 0.0 111.884 179.187 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 9.9 m -50.14 -46.24 53.74 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.698 0.285 . . . . 0.0 111.352 -179.604 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 92.7 mt -72.01 -43.17 65.46 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.271 -0.422 . . . . 0.0 111.618 -179.712 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -58.31 -33.23 69.25 Favored 'General case' 0 C--N 1.33 -0.267 0 N-CA-C 112.048 0.388 . . . . 0.0 112.048 -179.252 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 5.3 m-85 -90.57 -37.67 13.68 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 120.624 0.249 . . . . 0.0 111.495 -179.367 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -65.91 -51.18 60.83 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.874 0.369 . . . . 0.0 111.659 -179.507 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 24' ' ' TRP . . . . . . . . . . . . . 3.4 t-105 -60.44 -52.87 63.37 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-N 115.948 -0.569 . . . . 0.0 111.145 -179.66 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -68.67 -20.6 64.44 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.358 -0.383 . . . . 0.0 111.032 179.942 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -73.65 -43.75 34.99 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.855 -0.688 . . . . 0.0 112.599 179.896 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 31.2 mmt180 -62.89 -24.56 67.88 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-O 120.826 0.346 . . . . 0.0 110.997 -179.877 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 14.3 t70 -120.05 98.09 5.91 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.788 179.93 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -162.46 -78.51 0.04 OUTLIER 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.385 -0.37 . . . . 0.0 111.387 -179.872 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -150.67 -147.46 4.55 Favored Glycine 0 N--CA 1.452 -0.245 0 C-N-CA 120.66 -0.781 . . . . 0.0 112.49 -179.876 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 43.9 t -120.09 -34.33 3.72 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-O 120.775 0.321 . . . . 0.0 111.155 -179.895 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -97.47 -41.05 3.51 Favored Glycine 0 N--CA 1.452 -0.247 0 C-N-CA 120.693 -0.765 . . . . 0.0 112.569 -179.992 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 11.0 pt-20 -58.94 -20.53 53.0 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 120.644 0.259 . . . . 0.0 111.255 179.893 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 34' ' ' ARG . . . . . . . . . . . . . 74.2 mtp180 -49.2 -29.43 5.61 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.379 -179.89 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 98.9 mtt180 -60.21 -46.62 89.13 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.82 0.343 . . . . 0.0 111.057 179.899 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 52.7 m-85 -66.79 -42.66 85.62 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.176 -0.466 . . . . 0.0 111.068 -179.933 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 37' ' ' TYR . . . . . . . . . . . . . 51.9 m-85 -63.45 -51.82 64.08 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.213 -0.448 . . . . 0.0 111.449 -179.6 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 78.2 t -56.81 -36.73 50.51 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-O 121.005 0.431 . . . . 0.0 110.222 179.662 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 17.4 m -65.35 -47.85 75.05 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 115.852 -0.613 . . . . 0.0 110.257 178.976 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 48.8 tp -56.11 -45.84 79.32 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 115.665 -0.698 . . . . 0.0 110.096 179.21 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 96.5 t -60.81 -34.48 59.38 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.249 0 CA-C-N 115.698 -0.683 . . . . 0.0 109.983 179.068 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -57.03 -44.17 93.02 Favored Glycine 0 N--CA 1.447 -0.593 0 C-N-CA 120.813 -0.708 . . . . 0.0 111.834 179.599 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 43' ' ' ILE . . . . . 0.528 HG23 ' HE3' ' A' ' 205' ' ' LYS . 0.3 OUTLIER -63.1 -51.58 69.81 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.179 0 CA-C-O 120.7 0.286 . . . . 0.0 110.951 179.501 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 44' ' ' SER . . . . . 0.486 ' HA ' ' SD ' ' A' ' 15' ' ' MET . 87.5 p -60.41 -29.33 68.91 Favored 'General case' 0 C--O 1.232 0.155 0 CA-C-O 120.841 0.353 . . . . 0.0 111.305 -179.981 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -77.34 -51.31 6.16 Favored Glycine 0 CA--C 1.519 0.322 0 C-N-CA 120.668 -0.777 . . . . 0.0 113.11 -179.344 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 46' ' ' ILE . . . . . 0.623 HD12 HD11 ' A' ' 78' ' ' LEU . 12.4 pt -58.62 -37.53 65.8 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.242 0 CA-C-O 120.936 0.398 . . . . 0.0 110.979 -179.839 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 47' ' ' ALA . . . . . 0.558 ' HB1' ' HE2' ' A' ' 205' ' ' LYS . . . -67.87 -44.03 78.02 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.124 -0.489 . . . . 0.0 111.426 179.47 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -55.19 -43.25 74.22 Favored 'General case' 0 C--N 1.332 -0.194 0 CA-C-N 116.05 -0.523 . . . . 0.0 112.051 -179.326 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 35.5 m -73.2 -35.29 46.87 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.245 0 CA-C-O 120.684 0.278 . . . . 0.0 111.461 -179.541 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -63.29 -39.21 93.95 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-O 121.035 0.445 . . . . 0.0 110.965 179.955 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 24.5 m-85 -73.08 -38.96 66.23 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-N 115.817 -0.629 . . . . 0.0 110.648 -179.831 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -62.64 -45.46 92.73 Favored 'General case' 0 C--N 1.327 -0.413 0 CA-C-N 115.983 -0.553 . . . . 0.0 111.255 179.854 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 53' ' ' VAL . . . . . 0.498 HG21 ' N ' ' A' ' 54' ' ' MET . 32.3 m -66.43 -52.9 41.57 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.122 0 CA-C-N 116.504 -0.316 . . . . 0.0 111.056 -179.949 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 54' ' ' MET . . . . . 0.498 ' N ' HG21 ' A' ' 53' ' ' VAL . 76.0 mtm -58.35 -34.96 71.22 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-O 121.156 0.503 . . . . 0.0 110.134 179.508 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -63.31 -29.49 70.8 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 115.588 -0.733 . . . . 0.0 111.322 179.474 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 96.3 mt -79.23 -8.23 58.87 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.383 -0.371 . . . . 0.0 111.383 -179.633 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 98.75 -6.89 60.77 Favored Glycine 0 N--CA 1.45 -0.368 0 C-N-CA 120.531 -0.842 . . . . 0.0 113.018 179.545 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 58' ' ' VAL . . . . . 0.493 HG12 ' O ' ' A' ' 53' ' ' VAL . 3.8 p -75.26 154.4 6.3 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.235 0 CA-C-N 116.906 0.353 . . . . 0.0 110.636 179.926 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 76.3 22.77 72.62 Favored Glycine 0 N--CA 1.452 -0.261 0 C-N-CA 120.634 -0.794 . . . . 0.0 112.275 -179.408 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 60' ' ' TRP . . . . . . . . . . . . . 19.1 m0 -104.75 100.88 10.52 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-O 120.972 0.415 . . . . 0.0 110.043 179.967 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 61' ' ' VAL . . . . . 0.446 ' HB ' HG21 ' A' ' 68' ' ' VAL . 57.3 t -97.01 107.58 38.49 Favored Pre-proline 0 C--N 1.327 -0.389 0 CA-C-N 115.894 -0.594 . . . . 0.0 111.521 -179.448 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 31.3 Cg_endo -63.53 135.0 47.18 Favored 'Trans proline' 0 C--N 1.35 0.613 0 C-N-CA 122.384 2.056 . . . . 0.0 111.894 179.461 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 85.8 t -136.68 94.02 1.12 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.38 0 CA-C-N 116.109 -0.496 . . . . 0.0 111.319 -179.43 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . 57.38 -88.95 0.02 OUTLIER 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.485 179.905 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 38.0 tt0 -117.65 -22.8 7.89 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-O 120.913 0.387 . . . . 0.0 110.638 179.981 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 66' ' ' ARG . . . . . . . . . . . . . 41.5 mmt180 -102.79 157.64 16.82 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.039 -0.528 . . . . 0.0 110.225 179.747 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 26.2 m -124.14 116.43 22.73 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-O 120.869 0.366 . . . . 0.0 111.334 -179.854 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 68' ' ' VAL . . . . . 0.521 HG11 ' HA ' ' A' ' 117' ' ' MET . 24.0 m -90.77 145.53 7.31 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 115.986 -0.552 . . . . 0.0 110.84 179.664 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 69' ' ' PHE . . . . . . . . . . . . . 42.5 m-85 -109.65 111.35 22.77 Favored 'General case' 0 N--CA 1.441 -0.918 0 N-CA-C 109.879 -0.415 . . . . 0.0 109.879 -179.819 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 70' ' ' VAL . . . . . 0.563 ' N ' ' HD2' ' A' ' 71' ' ' PRO . 38.6 t -60.73 -50.11 86.66 Favored Pre-proline 0 C--N 1.326 -0.427 0 CA-C-N 116.42 -0.355 . . . . 0.0 111.903 -179.042 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 71' ' ' PRO . . . . . 0.563 ' HD2' ' N ' ' A' ' 70' ' ' VAL . 36.6 Cg_endo -64.7 -17.84 60.78 Favored 'Trans proline' 0 C--N 1.35 0.638 0 C-N-CA 122.288 1.992 . . . . 0.0 112.971 -179.343 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 37.3 ttp180 -70.95 -55.24 8.79 Favored 'General case' 0 C--O 1.235 0.321 0 C-N-CA 121.025 -0.27 . . . . 0.0 111.332 -179.492 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 73' ' ' TYR . . . . . 0.456 ' O ' HG13 ' A' ' 77' ' ' ILE . 5.7 m-85 -68.48 -34.52 76.08 Favored 'General case' 0 C--N 1.332 -0.185 0 C-N-CA 120.686 -0.406 . . . . 0.0 109.994 179.911 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 74' ' ' ILE . . . . . 0.523 ' HA ' HD11 ' A' ' 77' ' ' ILE . 0.4 OUTLIER -67.72 -36.75 77.03 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.173 0 CA-C-N 116.174 -0.467 . . . . 0.0 110.123 179.526 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 11.3 t70 -60.5 -37.61 81.68 Favored 'General case' 0 CA--C 1.518 -0.262 0 N-CA-C 109.188 -0.671 . . . . 0.0 109.188 178.749 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 76' ' ' TRP . . . . . . . . . . . . . 40.6 m0 -69.86 -28.1 65.38 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 115.638 -0.71 . . . . 0.0 110.562 179.247 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 77' ' ' ILE . . . . . 0.551 ' HA ' ' HG3' ' A' ' 109' ' ' MET . 96.3 mt -68.56 -36.27 73.89 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.34 179.596 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 78' ' ' LEU . . . . . 0.623 HD11 HD12 ' A' ' 46' ' ' ILE . 0.7 OUTLIER -90.75 -26.76 19.33 Favored 'General case' 0 C--N 1.328 -0.358 0 N-CA-C 112.81 0.671 . . . . 0.0 112.81 -179.65 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 79' ' ' THR . . . . . 0.512 HG23 HD11 ' A' ' 78' ' ' LEU . 64.8 p -84.71 -52.27 6.2 Favored 'General case' 0 C--N 1.327 -0.374 0 N-CA-C 113.71 1.004 . . . . 0.0 113.71 -178.548 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 80' ' ' THR . . . . . 0.669 ' HB ' ' HD3' ' A' ' 81' ' ' PRO . 34.0 m -53.42 -56.12 27.73 Favored Pre-proline 0 CA--C 1.533 0.314 0 N-CA-C 112.567 0.581 . . . . 0.0 112.567 -177.902 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 81' ' ' PRO . . . . . 0.669 ' HD3' ' HB ' ' A' ' 80' ' ' THR . 43.5 Cg_exo -58.33 -19.21 41.88 Favored 'Trans proline' 0 C--N 1.352 0.744 0 C-N-CA 121.728 1.618 . . . . 0.0 111.956 179.966 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 82' ' ' LEU . . . . . . . . . . . . . 16.2 tp -76.72 -35.66 57.67 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.078 179.575 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 83' ' ' ILE . . . . . 0.452 HD11 HG21 ' A' ' 43' ' ' ILE . 41.3 mm -69.57 -51.27 43.25 Favored 'Isoleucine or valine' 0 C--O 1.233 0.222 0 CA-C-N 115.926 -0.579 . . . . 0.0 110.379 179.214 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 33.0 m -60.95 -31.96 51.16 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.212 0 N-CA-C 109.505 -0.554 . . . . 0.0 109.505 179.062 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 85' ' ' TYR . . . . . 0.405 ' O ' ' HG ' ' A' ' 89' ' ' LEU . 81.3 t80 -65.42 -33.6 76.32 Favored 'General case' 0 N--CA 1.453 -0.291 0 CA-C-N 115.559 -0.746 . . . . 0.0 109.344 178.739 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 86' ' ' PHE . . . . . . . . . . . . . 3.0 t80 -61.87 -50.93 70.26 Favored 'General case' 0 C--O 1.233 0.235 0 CA-C-N 115.617 -0.719 . . . . 0.0 110.066 179.436 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 6.1 mt -62.95 -29.15 70.58 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 115.905 -0.589 . . . . 0.0 110.316 179.778 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -70.56 -28.06 71.62 Favored Glycine 0 N--CA 1.451 -0.323 0 CA-C-N 115.486 -0.779 . . . . 0.0 112.026 179.542 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 89' ' ' LEU . . . . . 0.405 ' HG ' ' O ' ' A' ' 85' ' ' TYR . 91.2 mt -74.91 -41.99 58.66 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.92 0.391 . . . . 0.0 110.772 179.744 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 97.6 mt -63.99 -36.41 83.88 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 115.959 -0.564 . . . . 0.0 111.123 179.927 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -77.19 -53.92 7.14 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.352 -0.385 . . . . 0.0 111.131 -179.854 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 107.8 52.67 0.69 Allowed Glycine 0 C--N 1.33 0.248 0 C-N-CA 120.899 -0.667 . . . . 0.0 112.213 -179.726 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 93' ' ' LEU . . . . . 0.505 HD11 ' HE2' ' A' ' 145' ' ' MET . 64.8 mt -75.82 162.24 28.33 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-O 120.909 0.385 . . . . 0.0 111.04 -179.773 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 94' ' ' ASP . . . . . . . . . . . . . 7.0 m-20 -88.86 175.14 7.58 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.707 179.881 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 65.3 m -60.44 -35.2 75.27 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.255 -179.767 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 96' ' ' ARG . . . . . 0.448 ' HG3' ' N ' ' A' ' 97' ' ' GLU . 10.5 ptp180 -73.64 -46.65 45.48 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 116.312 -0.404 . . . . 0.0 111.251 -179.842 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 97' ' ' GLU . . . . . 0.448 ' N ' ' HG3' ' A' ' 96' ' ' ARG . 42.0 mt-10 -57.02 -40.47 76.73 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.326 -0.397 . . . . 0.0 111.08 -179.68 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 98' ' ' PHE . . . . . 0.424 ' O ' HG12 ' A' ' 102' ' ' ILE . 13.5 m-85 -62.63 -50.3 71.75 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.772 179.656 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -55.29 -30.44 55.07 Favored Glycine 0 N--CA 1.452 -0.253 0 C-N-CA 120.647 -0.787 . . . . 0.0 112.695 -179.906 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 100' ' ' ILE . . . . . 0.402 ' O ' HG23 ' A' ' 103' ' ' THR . 86.8 mt -72.13 -47.78 52.52 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-O 120.864 0.364 . . . . 0.0 111.561 -179.735 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 43.2 t -67.67 -48.68 75.38 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.371 0 CA-C-N 116.289 -0.414 . . . . 0.0 111.516 -179.572 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 102' ' ' ILE . . . . . 0.424 HG12 ' O ' ' A' ' 98' ' ' PHE . 34.9 mm -59.15 -47.19 91.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.898 -179.23 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 103' ' ' THR . . . . . 0.402 HG23 ' O ' ' A' ' 100' ' ' ILE . 14.2 t -60.81 -36.26 78.58 Favored 'General case' 0 C--O 1.234 0.245 0 CA-C-O 120.772 0.32 . . . . 0.0 110.879 -179.968 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 3.0 tm? -57.01 -50.65 72.06 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-N 116.344 -0.389 . . . . 0.0 110.043 179.15 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 105' ' ' ASN . . . . . 0.404 ' O ' ' HG2' ' A' ' 109' ' ' MET . 16.6 m-80 -59.39 -31.42 69.22 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.014 -0.539 . . . . 0.0 110.674 179.368 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 41.5 m -56.92 -47.85 79.62 Favored 'General case' 0 C--O 1.232 0.177 0 CA-C-O 120.836 0.35 . . . . 0.0 110.154 179.329 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 1.9 t -61.06 -42.12 91.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 115.996 -0.547 . . . . 0.0 109.963 179.107 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 66.4 t -57.72 -45.69 86.84 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 115.171 -0.922 . . . . 0.0 111.669 -179.723 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 109' ' ' MET . . . . . 0.551 ' HG3' ' HA ' ' A' ' 77' ' ' ILE . 16.0 mmt -67.71 -44.33 77.92 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.712 -179.27 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 32.9 tp -60.64 -39.61 88.94 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-O 120.766 0.317 . . . . 0.0 110.806 -179.747 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -58.48 -54.67 44.46 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.685 179.635 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 112' ' ' GLY . . . . . 0.559 ' HA3' ' H22' ' A' ' 301' ' ' RET . . . -66.41 -32.3 81.45 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.387 179.632 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 113' ' ' PHE . . . . . . . . . . . . . 0.7 OUTLIER -52.77 -71.34 0.07 Allowed 'General case' 0 C--N 1.331 -0.202 0 CA-C-O 120.945 0.402 . . . . 0.0 110.183 179.829 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 114' ' ' ALA . . . . . 0.427 ' HB2' HD23 ' A' ' 126' ' ' LEU . . . -64.47 -22.6 67.01 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 115.796 -0.638 . . . . 0.0 110.975 179.742 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -53.57 -49.37 57.71 Favored Glycine 0 C--N 1.331 0.269 0 C-N-CA 121.025 -0.607 . . . . 0.0 112.518 179.985 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 116' ' ' ALA . . . . . 0.525 ' HB3' ' HB3' ' A' ' 183' ' ' PRO . . . -78.06 -18.14 56.15 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-O 120.742 0.306 . . . . 0.0 111.464 -179.899 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 117' ' ' MET . . . . . 0.521 ' HA ' HG11 ' A' ' 68' ' ' VAL . 33.3 ttm -99.31 19.57 15.22 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.32 -0.4 . . . . 0.0 111.556 -179.161 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 118' ' ' VAL . . . . . 0.444 HG22 ' HB3' ' A' ' 123' ' ' ARG . 25.1 m -71.34 143.33 87.89 Favored Pre-proline 0 C--N 1.33 -0.279 0 CA-C-N 116.524 -0.307 . . . . 0.0 111.514 179.993 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 119' ' ' PRO . . . . . . . . . . . . . 92.2 Cg_endo -89.49 14.89 2.09 Favored 'Trans proline' 0 N--CA 1.456 -0.677 0 C-N-CA 122.715 2.277 . . . . 0.0 112.418 179.373 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -166.07 -118.37 0.44 Allowed Glycine 0 C--N 1.334 0.421 0 C-N-CA 120.644 -0.789 . . . . 0.0 112.834 -179.668 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 2.0 pp -119.89 13.37 6.64 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.183 0 CA-C-O 120.675 0.274 . . . . 0.0 111.597 -179.595 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 43.6 mt-10 -62.62 -17.98 61.35 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.865 179.722 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 123' ' ' ARG . . . . . 0.444 ' HB3' HG22 ' A' ' 118' ' ' VAL . 3.2 ptp180 -50.28 -28.07 7.17 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 115.834 -0.621 . . . . 0.0 111.93 -179.764 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 124' ' ' TYR . . . . . . . . . . . . . 29.2 m-85 -71.42 -33.53 69.5 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.632 0.254 . . . . 0.0 111.385 -179.592 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 125' ' ' ALA . . . . . . . . . . . . . . . -74.21 -55.93 5.49 Favored 'General case' 0 C--O 1.235 0.315 0 CA-C-O 120.79 0.328 . . . . 0.0 111.184 179.918 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 126' ' ' LEU . . . . . 0.427 HD23 ' HB2' ' A' ' 114' ' ' ALA . 1.1 mp -52.16 -51.12 59.95 Favored 'General case' 0 C--N 1.332 -0.182 0 CA-C-N 116.041 -0.527 . . . . 0.0 110.313 179.79 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 127' ' ' PHE . . . . . . . . . . . . . 10.4 t80 -65.46 -30.36 71.14 Favored 'General case' 0 N--CA 1.452 -0.354 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.089 179.308 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 128' ' ' GLY . . . . . . . . . . . . . . . -48.19 -52.93 16.63 Favored Glycine 0 N--CA 1.449 -0.461 0 C-N-CA 120.196 -1.002 . . . . 0.0 110.757 178.848 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 129' ' ' MET . . . . . 0.631 ' HE2' ' HA2' ' A' ' 130' ' ' GLY . 0.0 OUTLIER -70.36 -27.24 64.18 Favored 'General case' 0 C--N 1.328 -0.367 0 N-CA-C 109.036 -0.727 . . . . 0.0 109.036 178.515 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 130' ' ' GLY . . . . . 0.631 ' HA2' ' HE2' ' A' ' 129' ' ' MET . . . -59.7 -45.27 95.99 Favored Glycine 0 C--N 1.333 0.366 0 CA-C-N 115.745 -0.661 . . . . 0.0 112.558 179.607 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -69.8 -47.53 62.5 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-O 120.738 0.304 . . . . 0.0 110.421 179.751 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 65.4 t -56.32 -44.31 79.4 Favored 'Isoleucine or valine' 0 C--O 1.235 0.293 0 CA-C-O 121.261 0.553 . . . . 0.0 109.662 178.865 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -63.25 -35.22 79.62 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 115.57 -0.741 . . . . 0.0 110.465 179.231 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 134' ' ' PHE . . . . . . . . . . . . . 72.6 t80 -56.92 -54.56 45.25 Favored 'General case' 0 N--CA 1.451 -0.375 0 CA-C-O 120.984 0.421 . . . . 0.0 110.156 179.494 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 135' ' ' ILE . . . . . 0.442 ' O ' HG23 ' A' ' 138' ' ' VAL . 39.8 mt -56.6 -31.05 33.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 115.733 -0.667 . . . . 0.0 110.198 179.285 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . -62.73 -42.41 99.69 Favored Glycine 0 N--CA 1.447 -0.607 0 C-N-CA 120.221 -0.99 . . . . 0.0 111.344 178.922 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 137' ' ' LEU . . . . . 0.422 ' HG ' HD12 ' A' ' 141' ' ' LEU . 64.9 tp -67.12 -52.64 39.29 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-O 120.464 0.174 . . . . 0.0 111.033 179.778 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 138' ' ' VAL . . . . . 0.442 HG23 ' O ' ' A' ' 135' ' ' ILE . 4.5 m -54.31 -34.43 27.87 Favored 'Isoleucine or valine' 0 CA--C 1.52 -0.177 0 N-CA-C 109.728 -0.471 . . . . 0.0 109.728 -179.642 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 139' ' ' TYR . . . . . . . . . . . . . 35.6 t80 -58.56 -46.49 86.76 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 115.785 -0.643 . . . . 0.0 109.633 178.05 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 24.6 m-85 -63.65 -40.78 97.73 Favored 'General case' 0 C--N 1.333 -0.111 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.486 179.105 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 141' ' ' LEU . . . . . 0.498 ' HA ' ' SD ' ' A' ' 145' ' ' MET . 11.2 mp -59.14 -25.64 64.04 Favored 'General case' 0 C--N 1.332 -0.186 0 CA-C-N 116.073 -0.512 . . . . 0.0 110.973 179.982 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 15.7 t -107.9 -5.18 10.5 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.254 0 CA-C-N 116.24 -0.437 . . . . 0.0 110.875 179.851 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . -75.81 -133.2 0.41 Allowed Glycine 0 CA--C 1.522 0.487 0 C-N-CA 120.874 -0.679 . . . . 0.0 112.704 179.993 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 144' ' ' PRO . . . . . . . . . . . . . 48.7 Cg_exo -55.55 -24.17 43.3 Favored 'Trans proline' 0 C--N 1.35 0.639 0 C-N-CA 122.5 2.133 . . . . 0.0 112.868 -179.732 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 145' ' ' MET . . . . . 0.505 ' HE2' HD11 ' A' ' 93' ' ' LEU . 57.5 mtt -54.15 -32.91 56.6 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 116.402 -0.363 . . . . 0.0 111.408 -179.864 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 146' ' ' THR . . . . . . . . . . . . . 79.1 p -65.9 -49.25 68.7 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.3 -0.409 . . . . 0.0 111.937 -179.407 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 14.1 mm-40 -74.89 -25.39 58.9 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.734 0.302 . . . . 0.0 111.766 -179.394 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 148' ' ' SER . . . . . . . . . . . . . 45.9 t -70.1 -45.43 66.95 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.834 0.35 . . . . 0.0 111.098 -179.623 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 149' ' ' ALA . . . . . 0.42 ' HB3' HG23 ' A' ' 156' ' ' ILE . . . -78.33 -35.14 48.06 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.119 -0.492 . . . . 0.0 111.849 -179.582 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 150' ' ' SER . . . . . 0.529 ' HA ' ' HG2' ' A' ' 157' ' ' LYS . 35.7 t -69.71 0.72 5.12 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.303 -0.408 . . . . 0.0 111.44 -179.539 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 151' ' ' GLN . . . . . . . . . . . . . 49.1 mt-30 -134.3 15.53 3.78 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.512 -0.313 . . . . 0.0 111.207 179.877 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 6.7 tpm_? -91.6 -51.89 5.04 Favored 'General case' 0 C--N 1.332 -0.195 0 CA-C-O 120.906 0.384 . . . . 0.0 110.772 179.954 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 153' ' ' SER . . . . . 0.633 ' HB3' HG12 ' A' ' 156' ' ' ILE . 24.3 t -157.76 172.6 18.2 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 115.978 -0.555 . . . . 0.0 110.746 179.256 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 154' ' ' SER . . . . . 0.5 ' HA ' ' NZ ' ' A' ' 157' ' ' LYS . 77.7 p -70.49 -40.68 73.45 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.427 -0.351 . . . . 0.0 110.859 179.727 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -77.08 -28.59 58.2 Favored Glycine 0 CA--C 1.521 0.41 0 C-N-CA 121.07 -0.585 . . . . 0.0 113.389 -179.631 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 156' ' ' ILE . . . . . 0.633 HG12 ' HB3' ' A' ' 153' ' ' SER . 33.4 mm -56.77 -37.68 54.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-O 120.678 0.275 . . . . 0.0 111.522 -179.507 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 157' ' ' LYS . . . . . 0.529 ' HG2' ' HA ' ' A' ' 150' ' ' SER . 36.7 mtmm -58.96 -41.26 87.04 Favored 'General case' 0 C--N 1.327 -0.393 0 N-CA-C 112.178 0.436 . . . . 0.0 112.178 -179.527 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 71.2 m -70.57 -48.32 55.9 Favored 'General case' 0 C--N 1.33 -0.256 0 N-CA-C 111.958 0.355 . . . . 0.0 111.958 -179.003 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 159' ' ' LEU . . . . . . . . . . . . . 3.8 mm? -67.68 -30.2 69.67 Favored 'General case' 0 C--N 1.327 -0.384 0 N-CA-C 111.789 0.292 . . . . 0.0 111.789 -179.373 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 160' ' ' TYR . . . . . . . . . . . . . 72.4 t80 -73.98 -47.41 37.48 Favored 'General case' 0 C--N 1.329 -0.3 0 N-CA-C 112.313 0.486 . . . . 0.0 112.313 -179.06 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 161' ' ' VAL . . . . . 0.409 HG21 ' N ' ' A' ' 162' ' ' ARG . 27.3 m -64.25 -43.17 97.21 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.373 0 N-CA-C 112.347 0.499 . . . . 0.0 112.347 -178.616 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 162' ' ' ARG . . . . . 0.448 ' NE ' ' HA ' ' A' ' 162' ' ' ARG . 6.7 tpm_? -68.96 -49.27 59.47 Favored 'General case' 0 C--N 1.328 -0.33 0 N-CA-C 112.001 0.371 . . . . 0.0 112.001 -178.904 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 163' ' ' LEU . . . . . . . . . . . . . 8.1 mp -67.62 -43.23 80.88 Favored 'General case' 0 C--N 1.329 -0.313 0 N-CA-C 111.928 0.344 . . . . 0.0 111.928 -179.149 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 164' ' ' ARG . . . . . . . . . . . . . 3.4 tmm_? -56.88 -50.79 71.43 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 120.695 0.283 . . . . 0.0 110.683 179.965 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 165' ' ' ASN . . . . . 0.519 ' N ' HD21 ' A' ' 165' ' ' ASN . 0.9 OUTLIER -57.29 -42.27 81.39 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.998 0.427 . . . . 0.0 110.301 179.576 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 166' ' ' LEU . . . . . 0.449 ' HB3' ' CE1' ' A' ' 208' ' ' PHE . 2.7 mt -58.7 -52.18 66.79 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 115.83 -0.623 . . . . 0.0 111.097 179.344 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 167' ' ' THR . . . . . 0.507 ' HA ' HD12 ' A' ' 170' ' ' LEU . 3.1 m -54.59 -51.86 63.95 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 115.733 -0.667 . . . . 0.0 112.442 -178.454 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 168' ' ' VAL . . . . . . . . . . . . . 59.2 t -57.26 -40.36 73.34 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.504 0 N-CA-C 112.485 0.55 . . . . 0.0 112.485 -178.894 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 169' ' ' VAL . . . . . 0.476 ' O ' HG12 ' A' ' 173' ' ' ILE . 98.2 t -68.03 -66.7 0.49 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 N-CA-C 113.499 0.926 . . . . 0.0 113.499 -177.912 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 170' ' ' LEU . . . . . 0.507 HD12 ' HA ' ' A' ' 167' ' ' THR . 0.4 OUTLIER -59.89 -33.2 71.52 Favored 'General case' 0 N--CA 1.467 0.386 0 N-CA-C 112.887 0.699 . . . . 0.0 112.887 -177.71 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 171' ' ' TRP . . . . . 0.476 ' H ' HD11 ' A' ' 170' ' ' LEU . 25.9 m0 -73.54 -30.51 63.12 Favored 'General case' 0 C--N 1.329 -0.296 0 C-N-CA 120.57 -0.452 . . . . 0.0 111.473 -179.429 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 172' ' ' ALA . . . . . . . . . . . . . . . -73.2 -7.53 51.84 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.944 0.402 . . . . 0.0 110.348 179.455 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 173' ' ' ILE . . . . . 0.534 HG22 HD13 ' A' ' 177' ' ' ILE . 31.4 mm -88.75 -24.5 6.03 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.15 0 CA-C-N 115.877 -0.601 . . . . 0.0 110.758 179.402 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 174' ' ' TYR . . . . . 0.591 ' N ' ' HD2' ' A' ' 175' ' ' PRO . 21.4 m-85 -55.11 -50.29 87.35 Favored Pre-proline 0 CA--C 1.53 0.192 0 N-CA-C 112.216 0.45 . . . . 0.0 112.216 -179.614 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 175' ' ' PRO . . . . . 0.591 ' HD2' ' N ' ' A' ' 174' ' ' TYR . 4.1 Cg_endo -47.06 -28.47 7.45 Favored 'Trans proline' 0 C--N 1.352 0.762 0 C-N-CA 122.148 1.899 . . . . 0.0 112.1 179.976 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 176' ' ' PHE . . . . . 0.5 ' O ' ' HG ' ' A' ' 180' ' ' LEU . 92.2 m-85 -80.27 -49.97 10.85 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.31 179.568 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 177' ' ' ILE . . . . . 0.534 HD13 HG22 ' A' ' 173' ' ' ILE . 2.8 mm -59.71 -37.38 70.83 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.581 0 CA-C-N 115.995 -0.548 . . . . 0.0 111.781 -178.593 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 178' ' ' TRP . . . . . . . . . . . . . 70.7 t90 -73.58 -45.38 53.57 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.915 0.388 . . . . 0.0 110.856 179.814 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 179' ' ' LEU . . . . . 0.448 ' O ' ' HA3' ' A' ' 184' ' ' GLY . 1.9 tm? -65.09 -53.12 50.29 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 115.976 -0.556 . . . . 0.0 111.417 -179.233 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 180' ' ' LEU . . . . . 0.521 HD22 HD11 ' A' ' 187' ' ' LEU . 11.1 mt -71.79 -42.96 66.46 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 116.705 -0.225 . . . . 0.0 111.515 -179.208 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . -58.54 175.41 2.56 Favored Glycine 0 C--N 1.335 0.493 0 C-N-CA 120.472 -0.87 . . . . 0.0 112.664 179.772 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 182' ' ' PRO . . . . . 0.594 ' HA ' ' HB1' ' A' ' 186' ' ' ALA . 73.1 Cg_exo -47.91 -44.27 27.72 Favored 'Trans proline' 0 C--N 1.349 0.581 0 C-N-CA 122.767 2.312 . . . . 0.0 113.38 179.791 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 183' ' ' PRO . . . . . 0.525 ' HB3' ' HB3' ' A' ' 116' ' ' ALA . 73.4 Cg_exo -52.08 -17.19 5.41 Favored 'Trans proline' 0 C--N 1.355 0.905 0 C-N-CA 122.119 1.88 . . . . 0.0 112.84 179.557 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 184' ' ' GLY . . . . . 0.448 ' HA3' ' O ' ' A' ' 179' ' ' LEU . . . -114.74 -82.79 1.08 Allowed Glycine 0 N--CA 1.45 -0.379 0 C-N-CA 120.644 -0.789 . . . . 0.0 112.942 -179.715 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 185' ' ' VAL . . . . . . . . . . . . . 8.4 m -129.71 -4.16 2.89 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.24 0 N-CA-C 112.349 0.5 . . . . 0.0 112.349 -179.376 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 186' ' ' ALA . . . . . 0.594 ' HB1' ' HA ' ' A' ' 182' ' ' PRO . . . 52.22 89.56 0.03 OUTLIER 'General case' 0 N--CA 1.464 0.241 0 CA-C-O 120.72 0.295 . . . . 0.0 111.635 179.752 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 187' ' ' LEU . . . . . 0.521 HD11 HD22 ' A' ' 180' ' ' LEU . 24.3 mt -92.24 -49.49 6.15 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.443 -0.344 . . . . 0.0 111.678 -179.81 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 188' ' ' LEU . . . . . . . . . . . . . 88.7 mt -93.27 -93.93 0.16 Allowed 'General case' 0 C--N 1.331 -0.23 0 CA-C-O 120.799 0.333 . . . . 0.0 111.23 -179.604 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 189' ' ' THR . . . . . . . . . . . . . 2.2 t -161.44 145.02 9.62 Favored Pre-proline 0 C--N 1.326 -0.418 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.957 179.979 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 190' ' ' PRO . . . . . . . . . . . . . 74.7 Cg_exo -49.15 -40.24 42.05 Favored 'Trans proline' 0 C--N 1.349 0.596 0 C-N-CA 122.747 2.298 . . . . 0.0 113.137 -179.601 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 191' ' ' THR . . . . . . . . . . . . . 38.3 p -58.97 -44.52 91.53 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.795 0.331 . . . . 0.0 111.515 -179.621 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 192' ' ' VAL . . . . . . . . . . . . . 37.2 t -72.65 -46.12 55.5 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.266 -179.947 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 193' ' ' ASP . . . . . . . . . . . . . 32.6 t70 -55.1 -44.07 74.59 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.388 -0.369 . . . . 0.0 111.006 179.844 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 194' ' ' VAL . . . . . 0.498 HG21 HD13 ' A' ' 4' ' ' LEU . 79.8 t -68.64 -36.02 72.66 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.032 179.902 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 195' ' ' ALA . . . . . . . . . . . . . . . -59.12 -46.77 87.48 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-O 120.671 0.272 . . . . 0.0 110.977 179.734 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 196' ' ' LEU . . . . . . . . . . . . . 88.3 mt -67.83 -41.02 83.68 Favored 'General case' 0 C--N 1.332 -0.192 0 CA-C-O 120.841 0.353 . . . . 0.0 110.577 179.576 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 197' ' ' ILE . . . . . . . . . . . . . 17.6 mm -59.16 -58.41 7.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.011 -0.54 . . . . 0.0 110.225 179.203 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 198' ' ' VAL . . . . . . . . . . . . . 75.7 t -52.53 -34.79 19.62 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.432 0 CA-C-N 115.633 -0.712 . . . . 0.0 109.199 178.226 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 199' ' ' TYR . . . . . . . . . . . . . 67.5 t80 -70.23 -33.39 71.6 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 115.227 -0.897 . . . . 0.0 110.811 179.965 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 200' ' ' LEU . . . . . . . . . . . . . 36.5 mt -68.65 -40.78 80.08 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.039 -0.528 . . . . 0.0 111.375 -179.597 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 201' ' ' ASP . . . . . . . . . . . . . 8.1 m-20 -71.49 -31.64 67.34 Favored 'General case' 0 C--N 1.327 -0.413 0 CA-C-O 121.117 0.484 . . . . 0.0 110.038 179.447 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 202' ' ' LEU . . . . . . . . . . . . . 3.3 mt -71.01 -33.74 70.67 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 115.546 -0.752 . . . . 0.0 111.955 -179.671 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 203' ' ' VAL . . . . . 0.501 HG13 HD23 ' A' ' 170' ' ' LEU . 7.8 p -77.1 -36.39 24.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 N-CA-C 111.593 0.22 . . . . 0.0 111.593 -178.743 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 204' ' ' THR . . . . . . . . . . . . . 57.5 m -70.58 -52.25 22.81 Favored 'General case' 0 C--N 1.327 -0.372 0 C-N-CA 120.682 -0.407 . . . . 0.0 111.6 179.735 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 205' ' ' LYS . . . . . 0.558 ' HE2' ' HB1' ' A' ' 47' ' ' ALA . 53.8 mttp -70.53 -59.12 3.02 Favored 'General case' 0 C--N 1.327 -0.385 0 N-CA-C 112.27 0.47 . . . . 0.0 112.27 -178.67 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 23.3 t -72.87 -37.82 55.4 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.357 0 CA-C-N 116.333 -0.394 . . . . 0.0 111.724 -178.814 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 207' ' ' GLY . . . . . 0.532 ' O ' HG12 ' A' ' 211' ' ' ILE . . . -62.71 -59.04 9.81 Favored Glycine 0 N--CA 1.452 -0.286 0 C-N-CA 120.353 -0.927 . . . . 0.0 112.429 -179.641 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 208' ' ' PHE . . . . . 0.473 ' O ' ' N ' ' A' ' 212' ' ' ALA . 2.2 m-30 -53.66 -49.95 66.85 Favored 'General case' 0 C--O 1.221 -0.4 0 CA-C-O 120.798 0.332 . . . . 0.0 110.112 179.992 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 209' ' ' GLY . . . . . 0.412 ' O ' ' HB3' ' A' ' 212' ' ' ALA . . . -54.19 -31.42 49.42 Favored Glycine 0 N--CA 1.449 -0.487 0 CA-C-N 115.444 -0.798 . . . . 0.0 112.456 178.927 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 210' ' ' PHE . . . . . . . . . . . . . 1.8 m-85 -72.41 -48.73 39.1 Favored 'General case' 0 C--N 1.328 -0.33 0 N-CA-C 108.764 -0.828 . . . . 0.0 108.764 178.755 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 211' ' ' ILE . . . . . 0.532 HG12 ' O ' ' A' ' 207' ' ' GLY . 0.6 OUTLIER -63.7 -27.21 42.43 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.297 0 N-CA-C 107.246 -1.39 . . . . 0.0 107.246 176.685 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 212' ' ' ALA . . . . . 0.473 ' N ' ' O ' ' A' ' 208' ' ' PHE . . . -68.03 -43.66 78.24 Favored 'General case' 0 N--CA 1.448 -0.534 0 CA-C-N 114.044 -1.434 . . . . 0.0 110.764 -179.418 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 213' ' ' LEU . . . . . . . . . . . . . 71.5 mt -70.52 -54.98 10.05 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 115.191 -0.913 . . . . 0.0 112.112 -179.19 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 214' ' ' ASP . . . . . . . . . . . . . 29.4 t70 -54.96 -54.44 42.76 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.392 -0.367 . . . . 0.0 111.858 -179.099 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 215' ' ' ALA . . . . . . . . . . . . . . . -58.44 -57.16 14.14 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 116.312 -0.404 . . . . 0.0 111.898 -179.344 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 216' ' ' ALA . . . . . 0.442 ' HA ' HD11 ' A' ' 219' ' ' LEU . . . -57.57 -33.97 68.71 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.331 -0.395 . . . . 0.0 111.682 -179.367 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 217' ' ' ALA . . . . . . . . . . . . . . . -61.06 -41.58 96.88 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.953 0.406 . . . . 0.0 110.451 179.887 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 218' ' ' THR . . . . . . . . . . . . . 95.9 m -66.9 -34.6 78.13 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 115.829 -0.623 . . . . 0.0 110.896 179.737 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 219' ' ' LEU . . . . . 0.442 HD11 ' HA ' ' A' ' 216' ' ' ALA . 87.8 mt -60.83 -45.81 93.02 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.136 -0.483 . . . . 0.0 111.126 -179.871 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 220' ' ' ARG . . . . . . . . . . . . . 11.1 mpt_? -83.45 -20.09 34.7 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.305 -0.407 . . . . 0.0 111.248 -179.806 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 221' ' ' ALA . . . . . . . . . . . . . . . -77.35 -27.21 52.61 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.415 -0.357 . . . . 0.0 111.182 179.805 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 222' ' ' GLU . . . . . . . . . . . . . 9.3 pt-20 -92.22 -27.26 17.76 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.297 -0.411 . . . . 0.0 110.505 -179.667 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 223' ' ' HIS . . . . . . . . . . . . . 81.1 m-70 62.43 -179.31 0.13 Allowed 'General case' 0 C--N 1.331 -0.223 0 CA-C-N 115.647 -0.706 . . . . 0.0 111.346 179.956 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 224' ' ' GLY . . . . . . . . . . . . . . . 165.57 15.14 0.02 OUTLIER Glycine 0 N--CA 1.452 -0.269 0 C-N-CA 120.9 -0.666 . . . . 0.0 112.45 179.978 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 225' ' ' GLU . . . . . . . . . . . . . 44.0 tt0 -75.22 139.0 42.32 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.855 0.359 . . . . 0.0 111.131 -179.815 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 226' ' ' SER . . . . . . . . . . . . . 42.1 t -139.72 2.56 2.0 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.05 -0.523 . . . . 0.0 110.725 179.852 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 227' ' ' LEU . . . . . . . . . . . . . 74.8 mt -76.1 -42.92 45.65 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.553 179.737 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 228' ' ' ALA . . . . . . . . . . . . . . . 52.7 92.98 0.02 OUTLIER 'General case' 0 C--N 1.332 -0.173 0 CA-C-N 115.826 -0.625 . . . . 0.0 111.666 179.887 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 229' ' ' GLY . . . . . . . . . . . . . . . 148.78 84.92 0.05 OUTLIER Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.929 -0.653 . . . . 0.0 112.46 179.909 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 230' ' ' VAL . . . . . . . . . . . . . 23.9 m -125.35 140.59 47.85 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.247 0 CA-C-O 120.865 0.364 . . . . 0.0 111.291 -179.905 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 231' ' ' ASP . . . . . . . . . . . . . 4.5 p-10 -93.57 112.46 24.36 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.087 -0.506 . . . . 0.0 110.833 179.894 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 232' ' ' THR . . . . . . . . . . . . . 48.3 p -143.47 -55.94 0.39 Allowed 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.081 -0.509 . . . . 0.0 111.229 -179.951 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 233' ' ' ASP . . . . . . . . . . . . . 10.3 m-20 -71.76 121.35 18.76 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.043 -179.77 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 234' ' ' THR . . . . . . . . . . . . . 81.4 p -134.79 94.72 16.33 Favored Pre-proline 0 C--N 1.329 -0.287 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.924 179.701 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 235' ' ' PRO . . . . . . . . . . . . . 73.8 Cg_endo -75.81 8.49 2.7 Favored 'Trans proline' 0 C--N 1.348 0.505 0 C-N-CA 122.426 2.084 . . . . 0.0 112.576 -179.763 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 236' ' ' ALA . . . . . . . . . . . . . . . -86.23 167.94 14.39 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.372 -0.376 . . . . 0.0 111.171 -179.884 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 237' ' ' VAL . . . . . . . . . . . . . 4.8 t -119.57 19.76 6.23 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-O 121.208 0.528 . . . . 0.0 110.573 179.984 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 238' ' ' ALA . . . . . . . . . . . . . . . 55.32 88.54 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 115.721 -0.672 . . . . 0.0 111.162 -179.899 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 239' ' ' ASP . . . . . . . . . . . . . 18.9 t70 -125.15 -28.92 3.35 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.183 -179.806 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 240' ' ' LEU . . . . . . . . . . . . . 7.1 mp -64.53 -45.32 87.66 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.414 -0.357 . . . . 0.0 111.012 -179.896 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 241' ' ' GLU . . . . . . . . . . . . . 41.4 tt0 -104.32 129.86 52.18 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.27 -0.423 . . . . 0.0 111.146 -179.754 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 242' ' ' HIS . . . . . . . . . . . . . 46.3 t-80 -146.93 155.36 42.22 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.781 -179.91 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 243' ' ' HIS . . . . . . . . . . . . . 20.6 t60 -63.8 -52.4 60.44 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.406 -0.361 . . . . 0.0 111.076 -179.9 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 244' ' ' HIS . . . . . . . . . . . . . 58.4 t-80 59.14 95.1 0.03 OUTLIER 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.735 -179.784 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 245' ' ' HIS . . . . . . . . . . . . . 78.9 m80 -60.42 138.38 58.0 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.316 -179.683 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 246' ' ' HIS . . . . . . . . . . . . . 25.8 p80 -106.65 140.17 39.94 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 116.0 -0.546 . . . . 0.0 110.747 179.76 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 247' ' ' HIS . . . . . . . . . . . . . 30.6 t60 . . . . . 0 C--O 1.249 1.031 0 CA-C-O 118.278 -0.868 . . . . 0.0 110.847 -179.868 . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 301' ' ' RET . . . . . 0.559 ' H22' ' HA3' ' A' ' 112' ' ' GLY . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 1' ' ' MET . . . . . 0.448 ' HE3' ' HB2' ' A' ' 4' ' ' LEU . 10.6 tpt . . . . . 0 N--CA 1.487 1.377 0 CA-C-O 120.71 0.291 . . . . 0.0 110.587 . . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 10.6 p -127.31 -25.68 1.37 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.395 -179.849 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -78.02 -1.58 79.91 Favored Glycine 0 N--CA 1.452 -0.28 0 C-N-CA 120.703 -0.76 . . . . 0.0 112.33 -179.997 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 4' ' ' LEU . . . . . 0.448 ' HB2' ' HE3' ' A' ' 1' ' ' MET . 49.8 tp -74.38 -35.54 63.49 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-O 120.778 0.323 . . . . 0.0 111.06 -179.974 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 69.1 p -61.06 -30.32 70.26 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.361 -179.751 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 28.0 p -54.56 -35.49 63.33 Favored 'General case' 0 C--N 1.331 -0.2 0 CA-C-N 116.278 -0.419 . . . . 0.0 111.248 -179.965 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 7' ' ' LEU . . . . . . . . . . . . . 4.0 mm? -56.65 -52.3 65.43 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 115.951 -0.568 . . . . 0.0 111.103 -179.903 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 8' ' ' PHE . . . . . 0.486 ' HB2' ' HB1' ' A' ' 55' ' ' ALA . 62.9 m-85 -64.47 -31.96 73.38 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.34 -0.391 . . . . 0.0 110.934 -179.989 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 9' ' ' TRP . . . . . . . . . . . . . 35.3 m95 -65.61 -41.69 92.47 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.173 -179.92 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 56.1 mt -67.17 -32.43 73.51 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-N 115.761 -0.654 . . . . 0.0 109.962 179.377 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -73.65 -27.72 66.74 Favored Glycine 0 N--CA 1.446 -0.67 0 CA-C-N 115.665 -0.698 . . . . 0.0 111.702 179.3 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -73.62 -33.91 64.78 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.834 0.35 . . . . 0.0 110.543 179.396 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 13' ' ' ILE . . . . . 0.428 ' O ' HG23 ' A' ' 17' ' ' VAL . 48.8 mm -68.22 -54.2 23.66 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.232 0 CA-C-N 116.002 -0.545 . . . . 0.0 110.397 179.423 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -59.18 -40.06 95.28 Favored Glycine 0 N--CA 1.45 -0.385 0 C-N-CA 120.635 -0.793 . . . . 0.0 111.48 179.221 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 15' ' ' MET . . . . . 0.509 ' SD ' ' HA ' ' A' ' 44' ' ' SER . 52.7 tpp -62.1 -43.6 98.49 Favored 'General case' 0 N--CA 1.453 -0.301 0 N-CA-C 109.99 -0.374 . . . . 0.0 109.99 179.295 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 45.4 tp -55.19 -38.18 68.02 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 115.746 -0.661 . . . . 0.0 110.222 179.184 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . 0.428 HG23 ' O ' ' A' ' 13' ' ' ILE . 44.2 t -62.13 -42.09 93.75 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.215 0 CA-C-N 115.891 -0.595 . . . . 0.0 109.971 179.243 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -66.26 -42.52 94.11 Favored Glycine 0 C--N 1.331 0.272 0 C-N-CA 120.69 -0.767 . . . . 0.0 111.58 178.928 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 7.9 m -52.09 -49.82 62.82 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.812 0.339 . . . . 0.0 111.074 179.945 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 95.0 mt -71.91 -35.6 69.73 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.435 179.926 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -62.21 -34.55 76.69 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.68 0.276 . . . . 0.0 111.648 -179.569 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 11.0 m-85 -89.95 -30.33 17.89 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.478 -0.328 . . . . 0.0 111.434 -179.442 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -72.88 -50.03 26.31 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.479 -0.328 . . . . 0.0 111.228 -179.941 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 24' ' ' TRP . . . . . . . . . . . . . 1.1 t-105 -60.66 -43.42 97.67 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.054 -0.521 . . . . 0.0 111.012 179.907 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -72.73 -25.03 61.06 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.334 -0.393 . . . . 0.0 110.907 179.927 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -74.03 -44.12 31.1 Favored Glycine 0 C--N 1.33 0.225 0 C-N-CA 121.008 -0.615 . . . . 0.0 112.469 179.695 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 85.6 mtm180 -65.89 -17.74 64.86 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.873 0.368 . . . . 0.0 110.629 179.976 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 18.4 t70 -91.82 -18.77 23.34 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.03 -0.532 . . . . 0.0 110.587 179.841 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -147.47 110.05 4.65 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.086 -0.506 . . . . 0.0 110.955 179.868 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -139.19 -122.84 2.03 Favored Glycine 0 N--CA 1.452 -0.271 0 C-N-CA 120.671 -0.776 . . . . 0.0 112.853 -179.765 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 47.9 t 62.49 -89.46 0.03 OUTLIER 'General case' 0 C--O 1.233 0.184 0 CA-C-O 120.625 0.25 . . . . 0.0 110.795 -179.566 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -93.32 -23.69 23.73 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.729 -0.748 . . . . 0.0 111.77 179.574 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 31.9 mm-40 -91.93 -20.16 21.7 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-O 120.792 0.33 . . . . 0.0 110.686 179.819 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 34' ' ' ARG . . . . . . . . . . . . . 55.4 ttp180 -47.95 -31.68 5.52 Favored 'General case' 0 C--N 1.332 -0.162 0 CA-C-N 115.974 -0.557 . . . . 0.0 111.385 -179.81 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 40.4 ttm180 -61.23 -49.46 77.02 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-O 120.856 0.36 . . . . 0.0 110.894 -179.943 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 75.9 m-85 -70.04 -37.47 75.59 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.025 -0.534 . . . . 0.0 111.568 -179.593 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 37' ' ' TYR . . . . . . . . . . . . . 35.3 m-85 -65.74 -54.75 22.95 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.318 -0.401 . . . . 0.0 111.516 -179.396 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 90.6 t -56.7 -38.18 56.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-O 120.918 0.39 . . . . 0.0 110.667 179.894 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 17.4 m -61.68 -50.95 70.42 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 115.933 -0.576 . . . . 0.0 110.616 179.346 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 40' ' ' LEU . . . . . 0.433 HD13 HD13 ' A' ' 43' ' ' ILE . 40.2 tp -59.71 -50.52 73.52 Favored 'General case' 0 C--O 1.235 0.333 0 CA-C-N 115.745 -0.661 . . . . 0.0 110.831 179.894 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 60.2 t -56.1 -34.3 38.53 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 115.834 -0.621 . . . . 0.0 110.294 179.26 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -60.94 -43.59 99.18 Favored Glycine 0 N--CA 1.45 -0.411 0 C-N-CA 120.739 -0.743 . . . . 0.0 111.826 179.597 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 43' ' ' ILE . . . . . 0.433 HD13 HD13 ' A' ' 40' ' ' LEU . 1.3 mt -58.55 -51.92 65.81 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.195 0 CA-C-O 120.792 0.329 . . . . 0.0 110.791 179.426 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 44' ' ' SER . . . . . 0.509 ' HA ' ' SD ' ' A' ' 15' ' ' MET . 44.7 m -59.66 -27.02 66.02 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.557 -179.772 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -73.79 -56.55 5.35 Favored Glycine 0 CA--C 1.519 0.33 0 C-N-CA 120.643 -0.789 . . . . 0.0 113.002 -179.588 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 24.3 pt -58.46 -35.45 54.41 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.214 0 CA-C-O 121.025 0.441 . . . . 0.0 111.295 -179.856 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 47' ' ' ALA . . . . . 0.584 ' HB3' ' HE2' ' A' ' 205' ' ' LYS . . . -66.98 -49.25 65.97 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.586 179.851 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -54.16 -44.39 71.42 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 115.983 -0.553 . . . . 0.0 111.962 -179.112 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 30.1 m -68.29 -34.24 64.99 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 C-N-CA 120.98 -0.288 . . . . 0.0 111.073 -179.731 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -67.54 -37.06 82.15 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-O 121.016 0.436 . . . . 0.0 110.939 179.264 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 38.7 m-85 -68.54 -38.76 81.11 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.028 -0.533 . . . . 0.0 110.214 -179.948 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -65.02 -50.71 65.19 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 115.804 -0.635 . . . . 0.0 111.088 179.592 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 53' ' ' VAL . . . . . 0.468 HG23 ' N ' ' A' ' 54' ' ' MET . 25.3 m -60.78 -47.9 91.16 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.109 0 CA-C-N 116.527 -0.306 . . . . 0.0 110.85 -179.939 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 54' ' ' MET . . . . . 0.478 ' HG2' ' HG2' ' A' ' 71' ' ' PRO . 74.3 mtm -62.42 -31.55 72.26 Favored 'General case' 0 C--N 1.331 -0.225 0 N-CA-C 109.607 -0.516 . . . . 0.0 109.607 179.068 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 55' ' ' ALA . . . . . 0.486 ' HB1' ' HB2' ' A' ' 8' ' ' PHE . . . -72.69 -22.49 60.9 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 115.527 -0.761 . . . . 0.0 110.981 179.583 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 81.0 mt -87.42 -5.52 58.81 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.118 179.996 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 90.15 -14.68 61.55 Favored Glycine 0 N--CA 1.45 -0.418 0 C-N-CA 120.622 -0.799 . . . . 0.0 112.911 179.765 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 9.0 p -69.5 141.64 17.01 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-O 120.85 0.357 . . . . 0.0 110.801 179.885 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 59' ' ' GLY . . . . . 0.407 ' HA3' ' HG3' ' A' ' 71' ' ' PRO . . . 92.39 -5.62 77.74 Favored Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.868 -0.682 . . . . 0.0 112.153 -179.268 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 60' ' ' TRP . . . . . . . . . . . . . 19.6 m0 -80.1 111.98 16.97 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-O 120.578 0.228 . . . . 0.0 110.785 179.919 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 61' ' ' VAL . . . . . 0.492 HG11 HG22 ' A' ' 68' ' ' VAL . 7.1 p -115.02 128.75 25.66 Favored Pre-proline 0 CA--C 1.533 0.315 0 CA-C-N 116.512 -0.313 . . . . 0.0 110.951 179.566 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 71.7 Cg_endo -76.39 156.0 36.76 Favored 'Trans proline' 0 C--N 1.35 0.629 0 C-N-CA 122.47 2.113 . . . . 0.0 112.725 -179.873 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 84.2 t -143.15 89.89 0.41 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 115.764 -0.653 . . . . 0.0 110.599 179.879 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . 58.71 -88.38 0.02 OUTLIER 'General case' 0 C--N 1.331 -0.196 0 CA-C-N 116.115 -0.493 . . . . 0.0 111.306 -179.756 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 45.5 mt-10 -120.5 -17.78 8.02 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 116.386 -0.37 . . . . 0.0 110.828 179.807 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 66' ' ' ARG . . . . . 0.455 ' HA ' ' HE ' ' A' ' 66' ' ' ARG . 3.0 mmp_? -100.29 163.5 12.37 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.25 179.672 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 85.3 m -125.83 133.91 51.82 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 121.023 0.439 . . . . 0.0 111.516 -179.673 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 68' ' ' VAL . . . . . 0.492 HG22 HG11 ' A' ' 61' ' ' VAL . 17.9 m -123.3 144.69 32.02 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-N 115.857 -0.611 . . . . 0.0 110.469 179.417 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 69' ' ' PHE . . . . . . . . . . . . . 19.4 m-85 -110.45 112.21 23.98 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.359 -0.382 . . . . 0.0 110.109 -179.217 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 70' ' ' VAL . . . . . 0.618 ' N ' ' HD2' ' A' ' 71' ' ' PRO . 28.3 t -66.02 -47.49 62.83 Favored Pre-proline 0 C--N 1.323 -0.553 0 CA-C-N 116.234 -0.439 . . . . 0.0 112.01 -179.362 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 71' ' ' PRO . . . . . 0.618 ' HD2' ' N ' ' A' ' 70' ' ' VAL . 13.9 Cg_endo -57.15 -22.22 46.9 Favored 'Trans proline' 0 C--N 1.351 0.709 0 C-N-CA 121.982 1.788 . . . . 0.0 111.773 179.518 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 60.7 ttp180 -75.91 -53.3 8.63 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.585 179.694 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 73' ' ' TYR . . . . . . . . . . . . . 69.3 m-85 -64.6 -45.76 85.56 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 115.967 -0.56 . . . . 0.0 110.709 179.912 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 0.4 OUTLIER -60.86 -36.56 72.46 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 N-CA-C 109.807 -0.442 . . . . 0.0 109.807 179.362 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 24.3 t70 -60.38 -37.97 82.44 Favored 'General case' 0 C--N 1.331 -0.209 0 N-CA-C 109.466 -0.568 . . . . 0.0 109.466 178.918 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 76' ' ' TRP . . . . . . . . . . . . . 47.4 m0 -67.08 -29.2 68.9 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 115.717 -0.674 . . . . 0.0 110.289 179.452 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 77' ' ' ILE . . . . . 0.421 ' O ' ' HG2' ' A' ' 81' ' ' PRO . 73.7 mt -72.4 -30.42 34.77 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.373 0 CA-C-N 115.838 -0.619 . . . . 0.0 110.626 179.395 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 40.2 mt -91.88 -16.69 26.33 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.209 -0.451 . . . . 0.0 111.989 -179.954 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 76.7 p -101.97 -49.02 4.06 Favored 'General case' 0 N--CA 1.464 0.262 0 N-CA-C 113.465 0.913 . . . . 0.0 113.465 -178.27 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 80' ' ' THR . . . . . 0.662 ' HB ' ' HD3' ' A' ' 81' ' ' PRO . 44.2 m -53.11 -54.46 44.2 Favored Pre-proline 0 CA--C 1.531 0.22 0 N-CA-C 112.226 0.454 . . . . 0.0 112.226 -178.338 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 81' ' ' PRO . . . . . 0.662 ' HD3' ' HB ' ' A' ' 80' ' ' THR . 34.2 Cg_exo -61.12 -19.72 64.64 Favored 'Trans proline' 0 C--N 1.352 0.735 0 C-N-CA 121.552 1.502 . . . . 0.0 111.28 179.578 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 82' ' ' LEU . . . . . . . . . . . . . 13.1 tp -76.89 -36.56 56.61 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 115.66 -0.7 . . . . 0.0 110.558 179.909 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 35.2 mm -68.02 -52.54 37.83 Favored 'Isoleucine or valine' 0 C--O 1.233 0.235 0 CA-C-N 116.308 -0.405 . . . . 0.0 110.08 179.251 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 30.9 m -59.58 -32.74 49.78 Favored 'Isoleucine or valine' 0 CA--C 1.52 -0.195 0 N-CA-C 109.482 -0.562 . . . . 0.0 109.482 178.796 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 85' ' ' TYR . . . . . . . . . . . . . 89.5 t80 -62.65 -34.63 77.46 Favored 'General case' 0 N--CA 1.454 -0.258 0 CA-C-N 115.528 -0.76 . . . . 0.0 109.163 178.595 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 86' ' ' PHE . . . . . . . . . . . . . 11.3 t80 -61.36 -51.72 67.65 Favored 'General case' 0 N--CA 1.456 -0.126 0 CA-C-N 115.561 -0.745 . . . . 0.0 109.879 179.201 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 7.6 mp -58.6 -36.43 74.0 Favored 'General case' 0 C--N 1.331 -0.202 0 CA-C-N 115.89 -0.595 . . . . 0.0 110.194 179.426 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 88' ' ' GLY . . . . . 0.441 ' HA2' HD11 ' A' ' 93' ' ' LEU . . . -64.93 -28.1 73.04 Favored Glycine 0 N--CA 1.45 -0.399 0 C-N-CA 120.916 -0.659 . . . . 0.0 112.165 179.575 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 86.5 mt -74.08 -41.25 61.97 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.902 0.382 . . . . 0.0 110.741 179.732 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 74.8 mt -58.73 -47.56 84.19 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 115.913 -0.585 . . . . 0.0 111.158 -179.756 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -74.77 -42.44 58.17 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.376 -0.375 . . . . 0.0 111.149 -179.875 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 93.06 55.96 1.54 Allowed Glycine 0 N--CA 1.45 -0.422 0 C-N-CA 120.832 -0.699 . . . . 0.0 112.466 -179.945 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 93' ' ' LEU . . . . . 0.509 HD23 ' HB3' ' A' ' 97' ' ' GLU . 9.7 mp -67.71 -176.4 0.64 Allowed 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.809 0.338 . . . . 0.0 110.908 -179.943 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 94' ' ' ASP . . . . . . . . . . . . . 10.4 m-20 -113.47 172.97 6.64 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.472 -179.929 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 45.4 t -54.03 -36.27 62.85 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.312 -0.404 . . . . 0.0 111.372 -179.759 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 96' ' ' ARG . . . . . 0.404 ' O ' HG13 ' A' ' 100' ' ' ILE . 29.3 mmm180 -73.98 -47.88 34.21 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 116.279 -0.419 . . . . 0.0 111.457 -179.85 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 97' ' ' GLU . . . . . 0.509 ' HB3' HD23 ' A' ' 93' ' ' LEU . 47.6 mt-10 -60.19 -44.59 94.96 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-O 120.912 0.387 . . . . 0.0 110.584 -179.387 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 98' ' ' PHE . . . . . 0.425 ' O ' HG12 ' A' ' 102' ' ' ILE . 12.8 m-85 -59.91 -47.95 83.66 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 115.869 -0.605 . . . . 0.0 110.514 179.325 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -55.22 -32.02 56.86 Favored Glycine 0 N--CA 1.452 -0.276 0 C-N-CA 120.799 -0.715 . . . . 0.0 112.697 179.922 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 100' ' ' ILE . . . . . 0.432 ' O ' HG23 ' A' ' 103' ' ' THR . 89.5 mt -69.51 -54.0 21.91 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.222 0 CA-C-O 120.956 0.408 . . . . 0.0 111.676 -179.894 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 17.2 t -64.7 -42.79 96.0 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.355 0 CA-C-N 116.136 -0.484 . . . . 0.0 111.933 -179.203 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 102' ' ' ILE . . . . . 0.425 HG12 ' O ' ' A' ' 98' ' ' PHE . 48.8 mm -63.67 -53.13 48.69 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-N 116.326 -0.397 . . . . 0.0 111.698 -179.325 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 103' ' ' THR . . . . . 0.432 HG23 ' O ' ' A' ' 100' ' ' ILE . 12.8 t -55.03 -35.38 64.39 Favored 'General case' 0 C--O 1.234 0.244 0 CA-C-O 120.869 0.366 . . . . 0.0 110.726 -179.909 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 104' ' ' LEU . . . . . 0.464 HD21 ' HE2' ' A' ' 140' ' ' TYR . 29.3 tp -61.08 -49.45 77.26 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.296 179.216 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 105' ' ' ASN . . . . . 0.575 ' N ' HD21 ' A' ' 105' ' ' ASN . 0.8 OUTLIER -59.1 -26.36 64.62 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.054 -0.521 . . . . 0.0 110.562 179.808 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 33.2 m -66.47 -54.16 27.22 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.276 -0.42 . . . . 0.0 111.158 179.697 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 12.8 p -66.25 -36.29 77.04 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.152 0 CA-C-N 116.486 -0.325 . . . . 0.0 111.356 -179.834 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 73.7 t -62.62 -56.86 14.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-O 120.885 0.374 . . . . 0.0 111.104 -179.949 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 109' ' ' MET . . . . . . . . . . . . . 7.1 tpp -60.48 -31.66 70.67 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.451 179.998 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 110' ' ' LEU . . . . . 0.476 ' C ' HD21 ' A' ' 110' ' ' LEU . 5.0 tt -64.19 -37.86 88.97 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-N 115.81 -0.632 . . . . 0.0 109.595 178.714 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -60.78 -50.58 72.86 Favored 'General case' 0 C--N 1.333 -0.137 0 CA-C-N 115.883 -0.598 . . . . 0.0 110.827 179.671 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . -59.38 -45.91 94.72 Favored Glycine 0 C--N 1.331 0.263 0 C-N-CA 120.687 -0.768 . . . . 0.0 112.074 179.645 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 113' ' ' PHE . . . . . . . . . . . . . 3.0 t80 -49.73 -65.66 0.53 Allowed 'General case' 0 C--N 1.333 -0.128 0 CA-C-O 120.91 0.386 . . . . 0.0 110.382 179.696 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -64.79 -17.77 64.5 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 115.901 -0.59 . . . . 0.0 110.952 179.927 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -57.24 -52.32 52.2 Favored Glycine 0 N--CA 1.45 -0.385 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.045 179.579 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -78.32 -15.06 59.11 Favored 'General case' 0 C--N 1.328 -0.351 0 N-CA-C 111.984 0.364 . . . . 0.0 111.984 179.904 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 117' ' ' MET . . . . . 0.421 ' SD ' HG21 ' A' ' 68' ' ' VAL . 26.0 mmt -80.88 19.86 0.82 Allowed 'General case' 0 N--CA 1.464 0.259 0 N-CA-C 112.182 0.438 . . . . 0.0 112.182 -178.985 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 118' ' ' VAL . . . . . 0.495 HG21 ' N ' ' A' ' 123' ' ' ARG . 17.6 m -113.24 157.74 40.16 Favored Pre-proline 0 C--N 1.328 -0.343 0 CA-C-N 116.756 -0.202 . . . . 0.0 111.208 179.819 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 119' ' ' PRO . . . . . 0.427 ' HD2' ' HB ' ' A' ' 118' ' ' VAL . 69.2 Cg_endo -73.96 -24.44 15.17 Favored 'Trans proline' 0 C--N 1.347 0.493 0 C-N-CA 122.414 2.076 . . . . 0.0 112.382 179.667 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . 152.56 151.86 5.8 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.831 179.935 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 18.9 mm 73.73 -46.94 0.17 Allowed 'Isoleucine or valine' 0 N--CA 1.466 0.334 0 C-N-CA 122.956 0.503 . . . . 0.0 111.715 -179.821 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 14.3 mm-40 -60.17 -28.25 67.78 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.103 180.0 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 123' ' ' ARG . . . . . 0.536 ' HD3' ' HA2' ' A' ' 184' ' ' GLY . 6.5 ptp180 -60.23 -29.49 68.8 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.012 -0.54 . . . . 0.0 111.03 179.896 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 124' ' ' TYR . . . . . . . . . . . . . 30.2 m-85 -69.24 -32.15 71.18 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 115.84 -0.618 . . . . 0.0 111.349 -179.707 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 125' ' ' ALA . . . . . . . . . . . . . . . -73.32 -56.41 5.11 Favored 'General case' 0 C--O 1.236 0.364 0 CA-C-O 121.05 0.452 . . . . 0.0 111.03 179.961 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 1.4 mt -56.04 -50.47 70.84 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.814 -0.63 . . . . 0.0 110.719 -179.926 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 127' ' ' PHE . . . . . 0.438 ' HZ ' ' HB3' ' A' ' 175' ' ' PRO . 9.4 t80 -65.69 -36.19 82.93 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.378 -0.374 . . . . 0.0 110.229 179.459 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 128' ' ' GLY . . . . . . . . . . . . . . . -46.29 -44.54 15.36 Favored Glycine 0 C--N 1.332 0.347 0 C-N-CA 120.171 -1.014 . . . . 0.0 110.822 178.925 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 129' ' ' MET . . . . . . . . . . . . . 0.5 OUTLIER -71.83 -36.47 70.2 Favored 'General case' 0 N--CA 1.453 -0.315 0 N-CA-C 109.833 -0.432 . . . . 0.0 109.833 178.663 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -63.13 -33.08 86.27 Favored Glycine 0 C--N 1.333 0.364 0 CA-C-N 115.794 -0.639 . . . . 0.0 112.867 -179.756 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -74.11 -53.87 9.0 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.681 0.277 . . . . 0.0 110.454 -179.99 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 44.2 t -56.91 -39.94 68.54 Favored 'Isoleucine or valine' 0 C--O 1.234 0.26 0 N-CA-C 109.344 -0.613 . . . . 0.0 109.344 178.764 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -67.4 -36.46 81.33 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 115.305 -0.862 . . . . 0.0 110.167 178.986 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 134' ' ' PHE . . . . . . . . . . . . . 84.7 t80 -56.6 -50.63 71.41 Favored 'General case' 0 N--CA 1.452 -0.335 0 CA-C-N 116.126 -0.488 . . . . 0.0 109.81 179.394 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 135' ' ' ILE . . . . . 0.444 ' O ' HG21 ' A' ' 138' ' ' VAL . 52.8 mt -59.28 -33.53 51.2 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.38 0 CA-C-N 115.67 -0.695 . . . . 0.0 110.207 179.204 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . -63.02 -41.09 99.95 Favored Glycine 0 N--CA 1.448 -0.548 0 C-N-CA 120.209 -0.996 . . . . 0.0 111.292 178.87 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 137' ' ' LEU . . . . . 0.453 HD13 HD22 ' A' ' 105' ' ' ASN . 57.9 tp -67.11 -53.94 26.07 Favored 'General case' 0 N--CA 1.454 -0.269 0 CA-C-O 120.499 0.19 . . . . 0.0 110.889 179.733 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 138' ' ' VAL . . . . . 0.444 HG21 ' O ' ' A' ' 135' ' ' ILE . 4.9 m -54.48 -33.84 27.43 Favored 'Isoleucine or valine' 0 C--O 1.233 0.205 0 CA-C-O 121.09 0.471 . . . . 0.0 109.746 -179.696 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 139' ' ' TYR . . . . . . . . . . . . . 24.2 t80 -59.8 -42.96 94.57 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 115.621 -0.718 . . . . 0.0 109.864 178.299 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 140' ' ' TYR . . . . . 0.464 ' HE2' HD21 ' A' ' 104' ' ' LEU . 25.8 m-85 -65.19 -45.74 83.59 Favored 'General case' 0 C--N 1.333 -0.142 0 CA-C-N 116.083 -0.508 . . . . 0.0 111.13 179.38 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 141' ' ' LEU . . . . . . . . . . . . . 10.6 mp -54.48 -32.65 58.2 Favored 'General case' 0 C--N 1.332 -0.171 0 CA-C-N 116.283 -0.417 . . . . 0.0 111.178 -179.745 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 11.1 p -106.84 -2.41 9.98 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-N 116.233 -0.44 . . . . 0.0 111.121 -179.812 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . -75.61 -120.61 0.13 Allowed Glycine 0 CA--C 1.522 0.469 0 C-N-CA 120.829 -0.701 . . . . 0.0 112.68 -179.848 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 144' ' ' PRO . . . . . . . . . . . . . 56.1 Cg_endo -69.64 -23.65 31.09 Favored 'Trans proline' 0 C--N 1.348 0.54 0 C-N-CA 122.489 2.126 . . . . 0.0 112.433 179.923 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 145' ' ' MET . . . . . 0.413 ' HB3' ' OH ' ' A' ' 160' ' ' TYR . 48.8 mtt -53.62 -58.85 5.7 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.103 -0.499 . . . . 0.0 111.84 -179.712 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 146' ' ' THR . . . . . . . . . . . . . 9.0 t -56.03 -32.45 64.04 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.327 -0.397 . . . . 0.0 111.888 -179.118 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 43.0 mt-10 -70.41 -41.16 73.31 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.645 -0.252 . . . . 0.0 111.329 -179.735 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 148' ' ' SER . . . . . . . . . . . . . 67.4 m -69.74 -41.81 74.76 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.432 -0.349 . . . . 0.0 111.304 -179.329 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 149' ' ' ALA . . . . . . . . . . . . . . . -70.23 -37.54 75.0 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.255 -0.429 . . . . 0.0 111.444 -179.656 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 150' ' ' SER . . . . . . . . . . . . . 75.8 m -68.2 -4.12 12.93 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.381 -0.372 . . . . 0.0 111.057 179.98 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 151' ' ' GLN . . . . . . . . . . . . . 50.4 mt-30 -117.66 4.29 12.33 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.333 -0.394 . . . . 0.0 111.043 179.876 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 7.9 tpm_? -83.81 -51.81 6.9 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 120.971 0.415 . . . . 0.0 110.617 179.863 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 153' ' ' SER . . . . . 0.527 ' HB2' HG12 ' A' ' 156' ' ' ILE . 35.3 m -157.65 172.9 17.69 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 115.768 -0.651 . . . . 0.0 110.544 179.612 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 154' ' ' SER . . . . . . . . . . . . . 66.4 p -71.86 -37.92 70.14 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-O 120.828 0.347 . . . . 0.0 110.433 179.432 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -76.63 -34.71 43.23 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 121.001 -0.619 . . . . 0.0 112.646 179.848 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 156' ' ' ILE . . . . . 0.527 HG12 ' HB2' ' A' ' 153' ' ' SER . 34.2 mm -59.52 -36.76 66.59 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-O 120.84 0.353 . . . . 0.0 111.167 179.958 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 157' ' ' LYS . . . . . . . . . . . . . 86.4 tttt -61.23 -54.99 37.25 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 116.078 -0.51 . . . . 0.0 111.524 -179.713 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 49.0 m -66.39 -38.99 88.76 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.964 -179.152 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 159' ' ' LEU . . . . . . . . . . . . . 6.4 tt -68.55 -37.05 79.6 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.725 -0.216 . . . . 0.0 111.546 -179.119 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 160' ' ' TYR . . . . . 0.413 ' OH ' ' HB3' ' A' ' 145' ' ' MET . 37.7 t80 -74.09 -47.43 36.53 Favored 'General case' 0 C--N 1.33 -0.265 0 N-CA-C 111.807 0.299 . . . . 0.0 111.807 -179.087 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 27.9 m -57.21 -41.73 78.57 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-O 120.674 0.273 . . . . 0.0 111.453 -179.332 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 162' ' ' ARG . . . . . . . . . . . . . 32.5 tpt180 -68.96 -43.92 74.01 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-O 120.867 0.365 . . . . 0.0 111.204 -179.913 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 163' ' ' LEU . . . . . 0.483 ' HG ' ' HB2' ' A' ' 208' ' ' PHE . 3.9 mp -62.41 -47.41 84.22 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 115.917 -0.583 . . . . 0.0 111.973 -179.247 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 164' ' ' ARG . . . . . 0.468 ' HG3' ' N ' ' A' ' 165' ' ' ASN . 4.5 ptt180 -67.64 -40.86 84.55 Favored 'General case' 0 C--N 1.329 -0.288 0 N-CA-C 111.829 0.307 . . . . 0.0 111.829 -178.926 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 165' ' ' ASN . . . . . 0.468 ' N ' ' HG3' ' A' ' 164' ' ' ARG . 0.9 OUTLIER -58.77 -52.07 67.28 Favored 'General case' 0 C--N 1.327 -0.372 0 N-CA-C 111.946 0.35 . . . . 0.0 111.946 -179.231 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 166' ' ' LEU . . . . . . . . . . . . . 3.0 pp -68.22 -44.29 76.09 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.707 0.289 . . . . 0.0 111.455 -179.485 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 167' ' ' THR . . . . . . . . . . . . . 71.5 m -58.48 -50.87 72.18 Favored 'General case' 0 C--N 1.331 -0.218 0 N-CA-C 112.198 0.444 . . . . 0.0 112.198 -179.402 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 168' ' ' VAL . . . . . 0.425 HG13 ' N ' ' A' ' 169' ' ' VAL . 9.2 p -61.7 -41.12 89.22 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 N-CA-C 111.713 0.264 . . . . 0.0 111.713 -179.014 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 169' ' ' VAL . . . . . 0.425 ' N ' HG13 ' A' ' 168' ' ' VAL . 55.1 t -60.98 -59.41 4.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-O 120.769 0.318 . . . . 0.0 111.175 -179.883 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 170' ' ' LEU . . . . . 0.59 HD21 HG13 ' A' ' 203' ' ' VAL . 3.9 pp -61.86 -31.63 71.91 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.358 -0.383 . . . . 0.0 110.982 -179.455 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 171' ' ' TRP . . . . . 0.439 ' HE1' ' C20' ' A' ' 301' ' ' RET . 3.4 m0 -72.07 -32.08 66.71 Favored 'General case' 0 N--CA 1.463 0.205 0 CA-C-O 120.89 0.376 . . . . 0.0 110.095 178.952 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 172' ' ' ALA . . . . . . . . . . . . . . . -69.07 -7.17 33.37 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 115.982 -0.554 . . . . 0.0 110.692 179.646 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 173' ' ' ILE . . . . . 0.488 ' O ' HG12 ' A' ' 177' ' ' ILE . 29.2 mm -88.19 -26.65 5.65 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.263 0 CA-C-N 115.939 -0.573 . . . . 0.0 110.919 179.794 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 174' ' ' TYR . . . . . 0.427 ' HB2' ' HD3' ' A' ' 175' ' ' PRO . 34.4 m-85 -53.77 -48.81 92.25 Favored Pre-proline 0 C--N 1.332 -0.163 0 CA-C-N 116.311 -0.404 . . . . 0.0 111.574 -179.737 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 175' ' ' PRO . . . . . 0.438 ' HB3' ' HZ ' ' A' ' 127' ' ' PHE . 84.8 Cg_exo -47.93 -32.39 17.69 Favored 'Trans proline' 0 C--N 1.352 0.722 0 C-N-CA 122.007 1.805 . . . . 0.0 112.199 179.558 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 176' ' ' PHE . . . . . 0.426 ' O ' ' HG ' ' A' ' 180' ' ' LEU . 81.5 m-85 -80.76 -50.59 9.67 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.059 -0.519 . . . . 0.0 111.803 -179.931 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 177' ' ' ILE . . . . . 0.488 HG12 ' O ' ' A' ' 173' ' ' ILE . 6.8 mm -62.07 -30.86 49.64 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.585 0 CA-C-N 116.104 -0.498 . . . . 0.0 112.022 -178.338 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 178' ' ' TRP . . . . . 0.426 ' HH2' ' HB2' ' A' ' 123' ' ' ARG . 73.9 t90 -73.6 -47.42 40.48 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-O 120.854 0.359 . . . . 0.0 110.662 179.714 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 179' ' ' LEU . . . . . 0.433 HD21 HD23 ' A' ' 180' ' ' LEU . 0.7 OUTLIER -70.96 -54.61 10.69 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 115.97 -0.559 . . . . 0.0 111.409 -179.287 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 180' ' ' LEU . . . . . 0.433 HD23 HD21 ' A' ' 179' ' ' LEU . 24.8 mt -64.78 -38.02 89.58 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.556 -0.293 . . . . 0.0 111.151 -179.779 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . -61.73 178.46 4.43 Favored Glycine 0 C--N 1.334 0.453 0 C-N-CA 120.086 -1.054 . . . . 0.0 112.231 179.185 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 182' ' ' PRO . . . . . 0.438 ' HB2' ' HD3' ' A' ' 183' ' ' PRO . 75.2 Cg_exo -48.02 -45.33 25.45 Favored 'Trans proline' 0 CA--C 1.534 0.507 0 C-N-CA 122.827 2.351 . . . . 0.0 113.613 179.856 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 183' ' ' PRO . . . . . 0.438 ' HD3' ' HB2' ' A' ' 182' ' ' PRO . 82.4 Cg_exo -46.65 -29.84 8.21 Favored 'Trans proline' 0 C--N 1.356 0.954 0 C-N-CA 122.14 1.894 . . . . 0.0 113.232 -179.788 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 184' ' ' GLY . . . . . 0.536 ' HA2' ' HD3' ' A' ' 123' ' ' ARG . . . -115.81 -128.19 4.28 Favored Glycine 0 N--CA 1.449 -0.453 0 C-N-CA 120.249 -0.977 . . . . 0.0 113.129 -179.663 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 185' ' ' VAL . . . . . . . . . . . . . 13.0 m -58.13 -27.33 31.65 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 N-CA-C 112.18 0.437 . . . . 0.0 112.18 -179.429 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 186' ' ' ALA . . . . . . . . . . . . . . . 59.34 82.25 0.15 Allowed 'General case' 0 C--N 1.33 -0.251 0 N-CA-C 111.983 0.364 . . . . 0.0 111.983 179.445 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 187' ' ' LEU . . . . . 0.513 ' HB2' HD11 ' A' ' 188' ' ' LEU . 8.6 mt -92.47 -49.59 6.05 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-O 121.039 0.447 . . . . 0.0 110.721 179.381 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 188' ' ' LEU . . . . . 0.513 HD11 ' HB2' ' A' ' 187' ' ' LEU . 6.9 mp -87.4 -166.38 1.56 Allowed 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 115.696 -0.684 . . . . 0.0 111.489 -179.233 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 189' ' ' THR . . . . . . . . . . . . . 10.2 m -94.39 137.43 22.71 Favored Pre-proline 0 C--N 1.33 -0.265 0 CA-C-N 115.743 -0.662 . . . . 0.0 110.498 -179.94 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 190' ' ' PRO . . . . . 0.413 ' O ' HG21 ' A' ' 194' ' ' VAL . 87.6 Cg_exo -44.31 -47.01 11.2 Favored 'Trans proline' 0 C--N 1.35 0.612 0 C-N-CA 122.661 2.241 . . . . 0.0 113.097 -179.859 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 191' ' ' THR . . . . . . . . . . . . . 6.8 t -59.27 -39.47 83.02 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 120.817 0.342 . . . . 0.0 111.28 -179.906 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 192' ' ' VAL . . . . . . . . . . . . . 58.8 t -70.58 -45.42 74.44 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.262 -0.426 . . . . 0.0 111.171 -179.952 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 193' ' ' ASP . . . . . . . . . . . . . 30.5 t70 -57.54 -43.85 84.7 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.294 -0.412 . . . . 0.0 110.678 179.937 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 194' ' ' VAL . . . . . 0.413 HG21 ' O ' ' A' ' 190' ' ' PRO . 98.1 t -64.28 -35.72 74.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 115.944 -0.571 . . . . 0.0 110.559 179.743 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 195' ' ' ALA . . . . . . . . . . . . . . . -59.19 -47.87 83.72 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 120.824 0.345 . . . . 0.0 110.793 179.551 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 196' ' ' LEU . . . . . . . . . . . . . 61.3 mt -67.83 -40.73 83.71 Favored 'General case' 0 C--N 1.332 -0.172 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.705 179.681 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 197' ' ' ILE . . . . . . . . . . . . . 14.3 mm -59.98 -58.18 8.37 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.239 0 CA-C-N 116.041 -0.527 . . . . 0.0 110.348 179.436 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 198' ' ' VAL . . . . . . . . . . . . . 64.1 t -52.28 -34.21 18.05 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.515 0 CA-C-N 115.599 -0.728 . . . . 0.0 109.311 178.469 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 199' ' ' TYR . . . . . 0.408 ' O ' HG22 ' A' ' 203' ' ' VAL . 64.9 t80 -69.32 -41.16 77.08 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 115.378 -0.828 . . . . 0.0 110.401 179.83 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 200' ' ' LEU . . . . . 0.407 HD11 HG13 ' A' ' 177' ' ' ILE . 31.4 mt -59.03 -54.81 42.91 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 115.563 -0.744 . . . . 0.0 111.524 -179.521 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 201' ' ' ASP . . . . . . . . . . . . . 10.7 m-20 -60.23 -38.64 84.04 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.322 -0.399 . . . . 0.0 110.888 -179.853 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 202' ' ' LEU . . . . . . . . . . . . . 2.0 mt -66.81 -28.43 68.37 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 115.868 -0.606 . . . . 0.0 111.409 -179.637 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 203' ' ' VAL . . . . . 0.59 HG13 HD21 ' A' ' 170' ' ' LEU . 41.3 t -79.47 -36.37 17.72 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.439 -0.346 . . . . 0.0 110.841 -179.055 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 204' ' ' THR . . . . . 0.434 ' O ' ' CD1' ' A' ' 208' ' ' PHE . 27.7 m -63.46 -58.32 7.43 Favored 'General case' 0 C--N 1.324 -0.512 0 C-N-CA 120.575 -0.45 . . . . 0.0 110.928 179.768 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 205' ' ' LYS . . . . . 0.584 ' HE2' ' HB3' ' A' ' 47' ' ' ALA . 44.2 mttp -66.32 -58.57 5.04 Favored 'General case' 0 C--N 1.331 -0.229 0 N-CA-C 112.624 0.602 . . . . 0.0 112.624 -178.254 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 43.8 t -70.83 -36.68 65.46 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.374 0 N-CA-C 112.182 0.438 . . . . 0.0 112.182 -178.444 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 207' ' ' GLY . . . . . 0.504 ' O ' HG13 ' A' ' 211' ' ' ILE . . . -61.54 -60.38 8.3 Favored Glycine 0 N--CA 1.452 -0.234 0 C-N-CA 120.58 -0.819 . . . . 0.0 113.598 -178.561 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 208' ' ' PHE . . . . . 0.483 ' HB2' ' HG ' ' A' ' 163' ' ' LEU . 0.1 OUTLIER -70.83 -26.66 63.38 Favored 'General case' 0 N--CA 1.464 0.249 0 CA-C-N 117.14 0.47 . . . . 0.0 111.515 -178.9 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 209' ' ' GLY . . . . . 0.489 ' O ' ' HB2' ' A' ' 212' ' ' ALA . . . -68.29 -32.65 76.24 Favored Glycine 0 N--CA 1.449 -0.49 0 N-CA-C 111.81 -0.516 . . . . 0.0 111.81 179.084 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 210' ' ' PHE . . . . . . . . . . . . . 0.8 OUTLIER -71.62 -48.47 47.74 Favored 'General case' 0 CA--C 1.512 -0.494 0 N-CA-C 108.053 -1.092 . . . . 0.0 108.053 178.491 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 211' ' ' ILE . . . . . 0.504 HG13 ' O ' ' A' ' 207' ' ' GLY . 4.9 mt -63.61 -27.75 43.58 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.544 0 N-CA-C 107.645 -1.243 . . . . 0.0 107.645 176.65 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 212' ' ' ALA . . . . . 0.489 ' HB2' ' O ' ' A' ' 209' ' ' GLY . . . -64.42 -40.97 96.79 Favored 'General case' 0 N--CA 1.45 -0.463 0 CA-C-N 114.583 -1.19 . . . . 0.0 110.5 179.793 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 213' ' ' LEU . . . . . . . . . . . . . 91.5 mt -70.52 -55.07 9.78 Favored 'General case' 0 N--CA 1.461 0.105 0 CA-C-N 115.489 -0.778 . . . . 0.0 111.748 -179.671 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 214' ' ' ASP . . . . . . . . . . . . . 25.1 m-20 -53.98 -49.92 67.73 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.28 -0.418 . . . . 0.0 111.648 -179.273 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 215' ' ' ALA . . . . . 0.44 ' O ' ' HG ' ' A' ' 219' ' ' LEU . . . -59.8 -57.51 12.6 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.372 -0.376 . . . . 0.0 111.48 -179.633 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 216' ' ' ALA . . . . . . . . . . . . . . . -57.66 -35.31 70.38 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.31 -0.405 . . . . 0.0 111.421 -179.703 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 217' ' ' ALA . . . . . . . . . . . . . . . -63.67 -31.75 73.02 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 121.001 0.429 . . . . 0.0 110.424 179.831 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 218' ' ' THR . . . . . . . . . . . . . 93.8 m -77.15 -46.46 23.34 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 115.759 -0.655 . . . . 0.0 110.79 179.532 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 219' ' ' LEU . . . . . 0.44 ' HG ' ' O ' ' A' ' 215' ' ' ALA . 20.4 mt -63.65 -27.72 69.42 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.585 179.753 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 220' ' ' ARG . . . . . . . . . . . . . 10.0 ttp180 -82.95 -34.24 26.53 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 115.868 -0.606 . . . . 0.0 110.708 179.887 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 221' ' ' ALA . . . . . . . . . . . . . . . -62.13 -41.43 98.24 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-N 115.975 -0.557 . . . . 0.0 111.125 -179.939 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 222' ' ' GLU . . . . . . . . . . . . . 10.7 pt-20 -85.62 -38.25 18.61 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.716 -179.922 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 223' ' ' HIS . . . . . . . . . . . . . 35.1 p80 40.06 31.06 0.08 Allowed 'General case' 0 N--CA 1.465 0.314 0 CA-C-N 115.795 -0.639 . . . . 0.0 111.872 -179.928 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 224' ' ' GLY . . . . . . . . . . . . . . . -70.26 109.25 2.78 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.375 179.817 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 225' ' ' GLU . . . . . . . . . . . . . 9.1 tp10 -113.54 150.43 32.98 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.764 0.316 . . . . 0.0 110.858 -179.8 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 226' ' ' SER . . . . . . . . . . . . . 40.7 t -104.42 -31.14 9.64 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.93 -179.972 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 227' ' ' LEU . . . . . . . . . . . . . 93.7 mt -107.85 97.61 7.31 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.934 -179.986 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 228' ' ' ALA . . . . . . . . . . . . . . . -125.25 -0.86 7.67 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.909 179.881 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 229' ' ' GLY . . . . . . . . . . . . . . . -62.03 -61.89 6.23 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.803 -0.713 . . . . 0.0 112.484 179.936 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 230' ' ' VAL . . . . . . . . . . . . . 4.1 m -143.49 145.83 21.94 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.22 0 CA-C-O 120.728 0.299 . . . . 0.0 111.329 179.979 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 231' ' ' ASP . . . . . . . . . . . . . 11.4 m-20 -86.14 80.5 8.77 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.252 179.324 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 232' ' ' THR . . . . . . . . . . . . . 41.4 p -58.68 146.59 35.87 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 115.9 -0.591 . . . . 0.0 111.408 -179.43 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 233' ' ' ASP . . . . . . . . . . . . . 10.4 m-20 -90.82 -5.77 55.17 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.031 -0.531 . . . . 0.0 110.921 -179.956 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 234' ' ' THR . . . . . . . . . . . . . 68.0 p 47.45 83.16 0.22 Allowed Pre-proline 0 CA--C 1.529 0.168 0 CA-C-N 115.916 -0.584 . . . . 0.0 111.559 -179.945 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 235' ' ' PRO . . . . . . . . . . . . . 72.4 Cg_endo -76.98 149.3 28.77 Favored 'Trans proline' 0 C--N 1.346 0.424 0 C-N-CA 122.485 2.123 . . . . 0.0 112.457 179.888 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 236' ' ' ALA . . . . . . . . . . . . . . . -75.11 140.76 43.65 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.982 179.883 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 237' ' ' VAL . . . . . 0.408 HG11 HD11 ' A' ' 240' ' ' LEU . 51.1 t -92.31 132.66 36.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.289 -0.414 . . . . 0.0 111.143 179.975 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 238' ' ' ALA . . . . . . . . . . . . . . . -88.1 -40.89 13.42 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.053 179.85 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 239' ' ' ASP . . . . . . . . . . . . . 5.0 p-10 -124.57 120.02 30.75 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.728 179.866 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 240' ' ' LEU . . . . . 0.408 HD11 HG11 ' A' ' 237' ' ' VAL . 3.9 mm? -96.01 -54.28 3.37 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.123 -0.489 . . . . 0.0 111.0 -179.771 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 241' ' ' GLU . . . . . . . . . . . . . 39.7 tt0 -147.72 -49.5 0.17 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.891 -179.924 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 242' ' ' HIS . . . . . . . . . . . . . 66.6 m80 -77.19 146.13 37.22 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.102 -0.499 . . . . 0.0 111.195 -179.781 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 243' ' ' HIS . . . . . . . . . . . . . 32.4 t-80 -112.78 109.24 18.61 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.515 179.707 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 244' ' ' HIS . . . . . . . . . . . . . 52.7 m-70 -77.49 -171.12 2.02 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.022 -179.739 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 245' ' ' HIS . . . . . . . . . . . . . 57.8 t-80 -124.31 112.67 17.27 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.918 179.979 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 246' ' ' HIS . . . . . . . . . . . . . 44.1 m-70 -124.44 115.29 20.7 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.796 179.772 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 247' ' ' HIS . . . . . . . . . . . . . 47.4 t60 . . . . . 0 C--O 1.249 1.073 0 CA-C-O 118.313 -0.851 . . . . 0.0 110.786 -179.876 . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 301' ' ' RET . . . . . 0.439 ' C20' ' HE1' ' A' ' 171' ' ' TRP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 66.5 mtm . . . . . 0 N--CA 1.485 1.287 0 CA-C-O 120.712 0.291 . . . . 0.0 110.887 . . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 28.2 m -88.66 -14.16 9.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.255 -0.429 . . . . 0.0 111.39 -179.755 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -121.75 -9.67 6.82 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.653 -0.784 . . . . 0.0 112.789 -179.88 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 49.2 tp -74.1 -35.37 64.18 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-O 120.782 0.325 . . . . 0.0 110.921 179.951 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 82.7 p -62.34 -31.63 72.29 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.447 -179.774 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 28.9 p -54.23 -35.78 62.81 Favored 'General case' 0 C--N 1.332 -0.175 0 CA-C-N 116.368 -0.378 . . . . 0.0 111.276 -179.906 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 7' ' ' LEU . . . . . . . . . . . . . 4.2 mm? -59.79 -50.73 72.66 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.202 -179.847 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 8' ' ' PHE . . . . . 0.559 ' HB2' ' HB3' ' A' ' 55' ' ' ALA . 64.2 m-85 -65.5 -34.91 79.37 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.9 -179.829 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 9' ' ' TRP . . . . . 0.4 ' O ' HG12 ' A' ' 13' ' ' ILE . 29.4 m95 -65.27 -44.77 87.0 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.292 -179.668 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 75.3 mt -60.51 -41.43 94.33 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 115.639 -0.71 . . . . 0.0 110.095 179.396 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -64.86 -34.65 90.46 Favored Glycine 0 N--CA 1.448 -0.501 0 C-N-CA 120.677 -0.773 . . . . 0.0 111.667 179.304 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -65.5 -31.32 72.33 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-O 120.849 0.357 . . . . 0.0 110.388 179.602 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 13' ' ' ILE . . . . . 0.4 HG12 ' O ' ' A' ' 9' ' ' TRP . 42.3 mm -67.72 -48.47 75.89 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 116.032 -0.531 . . . . 0.0 110.153 179.339 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -61.57 -28.12 69.2 Favored Glycine 0 N--CA 1.45 -0.386 0 C-N-CA 120.698 -0.763 . . . . 0.0 111.81 179.436 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 15' ' ' MET . . . . . 0.541 ' HE1' ' HD2' ' A' ' 205' ' ' LYS . 23.2 mmt -75.07 -39.43 60.87 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.731 0.3 . . . . 0.0 110.645 179.693 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 20.6 tp -59.09 -40.64 85.9 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.312 179.345 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 41.3 t -69.94 -45.52 76.49 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.215 0 CA-C-N 115.902 -0.59 . . . . 0.0 111.114 -179.938 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -63.84 -49.59 67.07 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.562 -0.827 . . . . 0.0 111.686 179.635 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 19' ' ' THR . . . . . 0.41 HG21 HG11 ' A' ' 41' ' ' VAL . 85.1 m -50.24 -45.23 53.92 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 115.448 -0.376 . . . . 0.0 111.014 179.767 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 77.9 mt -71.89 -39.3 69.68 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.382 179.764 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -64.1 -30.62 71.67 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.659 0.266 . . . . 0.0 111.528 -179.626 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 22' ' ' PHE . . . . . 0.518 ' HB2' HG21 ' A' ' 41' ' ' VAL . 6.3 m-85 -90.84 -31.12 16.58 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.503 -0.317 . . . . 0.0 111.113 -179.388 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -71.58 -49.78 37.27 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-O 120.907 0.384 . . . . 0.0 110.841 179.797 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 24' ' ' TRP . . . . . . . . . . . . . 1.2 t-105 -60.32 -41.61 93.85 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 115.893 -0.594 . . . . 0.0 110.72 179.797 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -73.84 -25.77 60.25 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.356 -0.384 . . . . 0.0 110.665 179.619 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -73.54 -40.44 47.13 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.907 -0.663 . . . . 0.0 112.674 179.835 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 72.2 mtp180 -72.44 -2.22 18.66 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-O 120.753 0.311 . . . . 0.0 111.068 179.965 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 19.3 t70 -107.02 -8.38 16.58 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.704 179.94 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -79.02 -174.6 4.13 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.232 -179.926 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -122.18 -170.87 13.82 Favored Glycine 0 N--CA 1.452 -0.266 0 C-N-CA 120.82 -0.705 . . . . 0.0 112.461 -179.985 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 74.8 p -68.28 113.38 5.84 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-O 120.812 0.339 . . . . 0.0 111.011 179.981 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 134.33 -54.2 0.77 Allowed Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.805 -0.712 . . . . 0.0 112.561 -179.94 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 45.8 mt-10 -85.58 -20.82 28.98 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.672 0.272 . . . . 0.0 111.05 179.953 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 34' ' ' ARG . . . . . . . . . . . . . 56.7 ttp180 -50.44 -29.51 10.45 Favored 'General case' 0 C--N 1.332 -0.175 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.339 -179.761 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 37.2 mmt180 -64.59 -43.92 92.3 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.329 -0.396 . . . . 0.0 110.953 179.981 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 64.8 m-85 -69.36 -33.76 73.56 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 116.13 -0.486 . . . . 0.0 111.44 -179.596 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 37' ' ' TYR . . . . . . . . . . . . . 54.2 m-85 -70.81 -53.01 16.93 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.533 -179.386 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 87.4 t -56.82 -36.79 50.75 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.249 0 CA-C-O 121.18 0.514 . . . . 0.0 110.21 179.509 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 40.9 m -66.76 -47.53 71.93 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 115.51 -0.768 . . . . 0.0 110.525 179.222 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 40' ' ' LEU . . . . . 0.409 ' O ' HG13 ' A' ' 43' ' ' ILE . 21.9 tp -57.1 -47.57 80.73 Favored 'General case' 0 C--O 1.235 0.3 0 CA-C-N 115.67 -0.695 . . . . 0.0 110.787 179.881 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . 0.518 HG21 ' HB2' ' A' ' 22' ' ' PHE . 94.8 t -63.05 -34.81 68.74 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-N 115.81 -0.632 . . . . 0.0 110.249 179.436 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -58.78 -39.79 94.18 Favored Glycine 0 N--CA 1.449 -0.471 0 CA-C-N 115.689 -0.687 . . . . 0.0 112.238 179.667 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 43' ' ' ILE . . . . . 0.584 HG23 ' HE3' ' A' ' 205' ' ' LYS . 0.1 OUTLIER -67.93 -50.97 54.54 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.166 0 CA-C-O 120.695 0.283 . . . . 0.0 110.984 179.851 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 50.5 m -63.59 -25.28 68.16 Favored 'General case' 0 C--N 1.331 -0.199 0 CA-C-O 120.824 0.345 . . . . 0.0 110.945 179.895 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -77.81 -52.15 5.55 Favored Glycine 0 N--CA 1.452 -0.263 0 C-N-CA 120.949 -0.643 . . . . 0.0 112.865 -179.542 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 46' ' ' ILE . . . . . 0.561 HD11 HD12 ' A' ' 78' ' ' LEU . 10.5 pt -58.32 -40.92 79.82 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.242 0 CA-C-O 120.874 0.369 . . . . 0.0 110.975 -179.75 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 47' ' ' ALA . . . . . 0.634 ' HB3' ' HE2' ' A' ' 205' ' ' LYS . . . -68.12 -40.24 82.58 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.124 179.468 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 48' ' ' ALA . . . . . 0.465 ' HB3' ' HB3' ' A' ' 15' ' ' MET . . . -54.59 -45.42 73.61 Favored 'General case' 0 C--O 1.233 0.197 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.31 -179.666 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 27.6 m -73.05 -33.9 44.0 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.257 -0.429 . . . . 0.0 111.26 -179.68 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -61.67 -37.75 85.22 Favored 'General case' 0 C--N 1.331 -0.21 0 CA-C-O 121.102 0.477 . . . . 0.0 110.576 179.256 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 51' ' ' TYR . . . . . 0.482 ' HB3' ' O ' ' A' ' 8' ' ' PHE . 29.6 m-85 -72.85 -35.63 67.28 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 115.767 -0.651 . . . . 0.0 110.266 179.682 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -66.08 -40.88 91.18 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 115.798 -0.637 . . . . 0.0 111.082 179.3 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 53' ' ' VAL . . . . . 0.411 HG23 ' N ' ' A' ' 54' ' ' MET . 27.6 m -74.1 -41.52 52.03 Favored 'Isoleucine or valine' 0 C--O 1.231 0.123 0 CA-C-N 116.47 -0.332 . . . . 0.0 111.016 179.95 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 54' ' ' MET . . . . . 0.58 ' HG2' ' HG2' ' A' ' 71' ' ' PRO . 72.0 mtm -64.93 -36.21 83.65 Favored 'General case' 0 CA--C 1.519 -0.233 0 CA-C-O 121.171 0.51 . . . . 0.0 109.831 179.128 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 55' ' ' ALA . . . . . 0.559 ' HB3' ' HB2' ' A' ' 8' ' ' PHE . . . -69.55 -16.71 63.47 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 115.489 -0.778 . . . . 0.0 111.193 179.764 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 73.5 mt -97.06 2.55 51.48 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.328 -0.396 . . . . 0.0 111.407 -179.632 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 84.75 3.23 88.28 Favored Glycine 0 N--CA 1.452 -0.258 0 C-N-CA 120.628 -0.796 . . . . 0.0 112.941 179.66 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 49.2 t -69.87 132.94 32.67 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-O 120.631 0.253 . . . . 0.0 110.907 179.875 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 59' ' ' GLY . . . . . 0.653 ' HA3' ' HD3' ' A' ' 71' ' ' PRO . . . 88.56 -13.01 63.45 Favored Glycine 0 N--CA 1.449 -0.476 0 C-N-CA 120.656 -0.783 . . . . 0.0 112.487 -179.866 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 60' ' ' TRP . . . . . . . . . . . . . 15.5 m0 -66.2 89.46 0.13 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.833 0.349 . . . . 0.0 110.7 179.901 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 61' ' ' VAL . . . . . 0.474 HG11 HG23 ' A' ' 68' ' ' VAL . 4.0 p -101.52 132.32 21.94 Favored Pre-proline 0 CA--C 1.532 0.265 0 CA-C-N 116.266 -0.424 . . . . 0.0 110.928 179.928 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 62' ' ' PRO . . . . . 0.434 ' HD3' ' HA ' ' A' ' 61' ' ' VAL . 4.6 Cg_exo -76.94 151.21 30.83 Favored 'Trans proline' 0 C--N 1.35 0.617 0 C-N-CA 122.673 2.249 . . . . 0.0 112.494 -179.763 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 73.3 t -142.32 91.84 0.5 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 115.964 -0.562 . . . . 0.0 110.804 179.774 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . 59.56 -87.43 0.02 OUTLIER 'General case' 0 N--CA 1.463 0.183 0 CA-C-N 116.097 -0.501 . . . . 0.0 111.529 179.962 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 10.3 pt-20 -124.21 -16.26 6.51 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.903 0.383 . . . . 0.0 110.673 179.972 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 66' ' ' ARG . . . . . 0.422 HH11 ' HD2' ' A' ' 66' ' ' ARG . 64.6 mtt180 -104.58 160.77 14.68 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 115.922 -0.581 . . . . 0.0 110.362 179.535 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 37.2 m -120.97 142.66 49.56 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.971 0.415 . . . . 0.0 111.473 -179.613 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 68' ' ' VAL . . . . . 0.474 HG23 HG11 ' A' ' 61' ' ' VAL . 15.3 m -131.68 145.04 35.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 115.799 -0.637 . . . . 0.0 110.552 179.609 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 69' ' ' PHE . . . . . . . . . . . . . 16.7 m-85 -109.48 115.84 30.68 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.364 -0.38 . . . . 0.0 110.365 -179.358 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 70' ' ' VAL . . . . . 0.638 HG13 ' HD3' ' A' ' 71' ' ' PRO . 0.8 OUTLIER -64.59 -36.79 19.28 Favored Pre-proline 0 CA--C 1.541 0.627 0 N-CA-C 112.701 0.63 . . . . 0.0 112.701 -179.321 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 71' ' ' PRO . . . . . 0.653 ' HD3' ' HA3' ' A' ' 59' ' ' GLY . 61.4 Cg_endo -70.52 -20.81 30.77 Favored 'Trans proline' 0 C--N 1.36 1.154 0 C-N-CA 121.934 1.756 . . . . 0.0 113.382 -179.451 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 46.6 ttp180 -73.06 -55.13 6.93 Favored 'General case' 0 C--O 1.235 0.323 0 N-CA-C 111.658 0.244 . . . . 0.0 111.658 -179.031 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 73' ' ' TYR . . . . . 0.43 ' O ' HG13 ' A' ' 77' ' ' ILE . 11.8 m-85 -65.84 -37.54 86.46 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.907 0.384 . . . . 0.0 110.022 -179.883 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 74' ' ' ILE . . . . . 0.503 ' HA ' HD13 ' A' ' 77' ' ' ILE . 0.4 OUTLIER -67.22 -41.23 86.5 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.219 0 CA-C-N 116.058 -0.519 . . . . 0.0 110.631 179.704 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 75' ' ' ASP . . . . . 0.433 ' HA ' HD22 ' A' ' 78' ' ' LEU . 17.7 t70 -55.08 -39.7 69.57 Favored 'General case' 0 CA--C 1.519 -0.245 0 N-CA-C 109.584 -0.524 . . . . 0.0 109.584 179.235 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 76' ' ' TRP . . . . . . . . . . . . . 30.7 m0 -68.44 -32.52 72.6 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 115.927 -0.579 . . . . 0.0 110.683 179.61 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 77' ' ' ILE . . . . . 0.601 ' HA ' ' HG3' ' A' ' 109' ' ' MET . 92.2 mt -60.95 -41.64 89.79 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.245 0 CA-C-N 116.104 -0.498 . . . . 0.0 111.954 -179.828 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 78' ' ' LEU . . . . . 0.561 HD12 HD11 ' A' ' 46' ' ' ILE . 0.7 OUTLIER -91.38 -30.02 16.76 Favored 'General case' 0 CA--C 1.536 0.409 0 N-CA-C 113.392 0.886 . . . . 0.0 113.392 -178.883 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 46.0 p -75.2 -53.32 9.01 Favored 'General case' 0 N--CA 1.47 0.558 0 N-CA-C 113.447 0.906 . . . . 0.0 113.447 -178.275 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 80' ' ' THR . . . . . 0.56 ' N ' ' HD2' ' A' ' 81' ' ' PRO . 7.3 m -51.47 -48.95 85.04 Favored Pre-proline 0 C--N 1.329 -0.312 0 N-CA-C 112.948 0.721 . . . . 0.0 112.948 -178.36 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 81' ' ' PRO . . . . . 0.56 ' HD2' ' N ' ' A' ' 80' ' ' THR . 23.3 Cg_endo -58.99 -26.35 81.2 Favored 'Trans proline' 0 C--N 1.351 0.659 0 C-N-CA 121.72 1.613 . . . . 0.0 111.846 -179.511 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 82' ' ' LEU . . . . . . . . . . . . . 14.1 tp -76.73 -36.5 57.12 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 115.908 -0.587 . . . . 0.0 110.557 179.991 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 83' ' ' ILE . . . . . 0.458 HD13 HD11 ' A' ' 43' ' ' ILE . 38.8 mm -67.91 -51.22 51.96 Favored 'Isoleucine or valine' 0 C--O 1.234 0.275 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.137 179.086 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 27.0 m -61.14 -31.13 49.24 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.214 0 CA-C-N 116.014 -0.539 . . . . 0.0 109.632 179.129 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 85' ' ' TYR . . . . . . . . . . . . . 58.6 t80 -65.23 -34.47 78.44 Favored 'General case' 0 N--CA 1.452 -0.332 0 CA-C-N 115.638 -0.71 . . . . 0.0 109.36 178.965 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 86' ' ' PHE . . . . . . . . . . . . . 4.2 t80 -61.39 -51.63 67.98 Favored 'General case' 0 C--O 1.231 0.131 0 CA-C-N 115.586 -0.734 . . . . 0.0 110.064 179.222 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 7.4 mt -65.05 -28.69 69.65 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 121.309 0.576 . . . . 0.0 109.772 179.66 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -72.57 -27.43 69.43 Favored Glycine 0 N--CA 1.45 -0.41 0 CA-C-N 115.2 -0.909 . . . . 0.0 111.545 179.139 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 52.8 mt -73.21 -43.35 61.42 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 121.006 0.431 . . . . 0.0 110.549 179.652 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 59.1 mt -60.14 -33.19 71.82 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 115.707 -0.679 . . . . 0.0 111.047 179.887 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . 0.524 ' HB3' ' HB2' ' A' ' 148' ' ' SER . . . -85.76 -47.97 9.25 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.514 -179.532 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 89.27 61.15 1.41 Allowed Glycine 0 N--CA 1.45 -0.378 0 C-N-CA 120.811 -0.709 . . . . 0.0 112.383 -179.742 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 93' ' ' LEU . . . . . 0.41 HD13 ' HG2' ' A' ' 145' ' ' MET . 6.5 mp -72.76 179.12 3.78 Favored 'General case' 0 C--N 1.332 -0.184 0 CA-C-O 120.753 0.311 . . . . 0.0 110.866 -179.951 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 94' ' ' ASP . . . . . . . . . . . . . 30.3 m-20 -85.5 175.3 8.9 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.883 179.948 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 48.9 m -61.69 -46.71 88.52 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.1 -179.74 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 96' ' ' ARG . . . . . 0.403 ' O ' HG13 ' A' ' 100' ' ' ILE . 80.1 ttt180 -71.94 -45.36 61.42 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.934 -179.953 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 97' ' ' GLU . . . . . 0.457 ' HA ' HD13 ' A' ' 100' ' ' ILE . 19.1 mm-40 -52.51 -46.02 66.48 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.158 -179.802 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 98' ' ' PHE . . . . . 0.451 ' O ' HG12 ' A' ' 102' ' ' ILE . 2.2 m-85 -55.33 -50.87 68.52 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.384 -0.371 . . . . 0.0 110.236 179.385 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -60.85 -30.38 72.8 Favored Glycine 0 N--CA 1.45 -0.383 0 C-N-CA 120.862 -0.685 . . . . 0.0 112.627 -179.949 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 100' ' ' ILE . . . . . 0.457 HD13 ' HA ' ' A' ' 97' ' ' GLU . 94.5 mt -64.04 -43.3 97.52 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-O 120.89 0.376 . . . . 0.0 111.393 -179.857 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 29.4 t -72.26 -41.42 66.12 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.38 0 CA-C-N 116.34 -0.391 . . . . 0.0 111.592 179.976 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 102' ' ' ILE . . . . . 0.451 HG12 ' O ' ' A' ' 98' ' ' PHE . 35.2 mm -65.38 -40.07 87.27 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 CA-C-N 116.416 -0.357 . . . . 0.0 111.65 -179.266 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 11.0 t -67.92 -40.36 83.37 Favored 'General case' 0 C--O 1.234 0.239 0 CA-C-O 120.713 0.292 . . . . 0.0 110.939 -179.958 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 104' ' ' LEU . . . . . 0.411 ' O ' HG22 ' A' ' 108' ' ' VAL . 29.2 tp -55.34 -51.54 66.4 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-N 116.349 -0.387 . . . . 0.0 110.079 179.311 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 105' ' ' ASN . . . . . 0.56 ' N ' HD21 ' A' ' 105' ' ' ASN . 0.8 OUTLIER -58.05 -37.31 74.16 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 115.855 -0.611 . . . . 0.0 110.461 179.465 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 31.0 m -54.61 -41.1 69.56 Favored 'General case' 0 C--N 1.332 -0.184 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.659 179.706 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 0.6 OUTLIER -69.24 -36.42 72.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-O 121.258 0.551 . . . . 0.0 110.0 179.245 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . 0.411 HG22 ' O ' ' A' ' 104' ' ' LEU . 60.7 t -63.87 -42.63 96.47 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 115.406 -0.816 . . . . 0.0 111.571 -179.677 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 109' ' ' MET . . . . . 0.601 ' HG3' ' HA ' ' A' ' 77' ' ' ILE . 6.9 mmt -70.07 -44.04 69.92 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.407 -0.36 . . . . 0.0 110.961 -179.624 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 21.4 tp -60.73 -32.18 71.46 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 116.349 -0.387 . . . . 0.0 110.38 179.966 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -65.27 -56.63 11.65 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.019 -0.537 . . . . 0.0 110.612 179.398 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . -60.88 -30.0 71.94 Favored Glycine 0 C--N 1.332 0.334 0 C-N-CA 120.644 -0.789 . . . . 0.0 112.117 179.655 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 113' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER -57.68 -69.0 0.19 Allowed 'General case' 0 C--N 1.33 -0.266 0 CA-C-O 121.015 0.436 . . . . 0.0 110.255 179.585 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -64.6 -29.13 70.15 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 115.79 -0.641 . . . . 0.0 111.414 -179.969 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -51.92 -51.2 41.21 Favored Glycine 0 C--N 1.332 0.324 0 C-N-CA 121.081 -0.58 . . . . 0.0 112.672 -179.888 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -77.99 -15.01 59.31 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-O 120.542 0.21 . . . . 0.0 111.553 -179.781 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 117' ' ' MET . . . . . . . . . . . . . 37.5 ttm -100.67 18.46 19.24 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-O 120.692 0.282 . . . . 0.0 111.436 -179.464 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 118' ' ' VAL . . . . . 0.487 HG12 ' N ' ' A' ' 123' ' ' ARG . 27.4 m -74.03 144.76 82.65 Favored Pre-proline 0 C--N 1.328 -0.327 0 CA-C-N 116.692 -0.231 . . . . 0.0 111.141 179.802 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 119' ' ' PRO . . . . . . . . . . . . . 97.0 Cg_endo -87.53 -10.11 5.53 Favored 'Trans proline' 0 N--CA 1.458 -0.568 0 C-N-CA 122.709 2.273 . . . . 0.0 112.484 179.756 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -136.72 -108.26 0.89 Allowed Glycine 0 C--N 1.331 0.302 0 C-N-CA 120.706 -0.759 . . . . 0.0 112.907 -179.629 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 34.3 pt -124.53 12.26 4.72 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.156 0 CA-C-O 120.652 0.263 . . . . 0.0 111.664 -179.548 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 41.7 mt-10 -58.24 -18.26 25.18 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.779 0.323 . . . . 0.0 111.03 179.722 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 123' ' ' ARG . . . . . 0.487 ' N ' HG12 ' A' ' 118' ' ' VAL . 4.9 ptm180 -50.6 -31.39 15.77 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 116.107 -0.497 . . . . 0.0 111.504 -179.868 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 124' ' ' TYR . . . . . . . . . . . . . 30.4 m-85 -70.28 -33.03 71.08 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.458 -0.337 . . . . 0.0 111.017 -179.735 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 125' ' ' ALA . . . . . . . . . . . . . . . -71.24 -50.12 36.22 Favored 'General case' 0 C--O 1.235 0.333 0 CA-C-N 116.298 -0.41 . . . . 0.0 110.942 179.687 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 3.1 mm? -53.6 -52.76 58.77 Favored 'General case' 0 C--N 1.333 -0.137 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.53 179.739 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 127' ' ' PHE . . . . . 0.437 ' HZ ' ' HB3' ' A' ' 175' ' ' PRO . 6.5 t80 -64.88 -37.21 86.87 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.316 -0.402 . . . . 0.0 111.231 -179.615 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 128' ' ' GLY . . . . . . . . . . . . . . . -46.16 -47.75 15.4 Favored Glycine 0 C--O 1.237 0.283 0 C-N-CA 119.705 -1.235 . . . . 0.0 110.517 179.192 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 129' ' ' MET . . . . . . . . . . . . . 0.5 OUTLIER -72.18 -34.91 68.79 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 115.178 -0.511 . . . . 0.0 110.101 178.665 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -62.99 -37.26 94.66 Favored Glycine 0 C--N 1.332 0.331 0 CA-C-N 115.804 -0.634 . . . . 0.0 113.347 -179.515 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -73.56 -52.61 12.9 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.788 0.294 . . . . 0.0 110.755 -179.781 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 62.2 t -55.61 -42.0 66.93 Favored 'Isoleucine or valine' 0 C--O 1.234 0.28 0 CA-C-O 121.331 0.586 . . . . 0.0 109.546 179.128 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -68.69 -37.35 79.49 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 115.342 -0.844 . . . . 0.0 110.669 179.407 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 134' ' ' PHE . . . . . . . . . . . . . 87.7 t80 -55.88 -54.78 40.44 Favored 'General case' 0 N--CA 1.452 -0.363 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.135 179.669 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 135' ' ' ILE . . . . . 0.436 ' O ' HG23 ' A' ' 138' ' ' VAL . 32.8 mt -56.38 -33.53 38.49 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.363 0 CA-C-N 115.884 -0.598 . . . . 0.0 110.126 179.303 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . -61.65 -39.64 97.67 Favored Glycine 0 N--CA 1.449 -0.484 0 C-N-CA 120.072 -1.061 . . . . 0.0 111.295 178.784 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 137' ' ' LEU . . . . . 0.536 HD12 HD22 ' A' ' 105' ' ' ASN . 31.1 tp -68.75 -54.02 18.44 Favored 'General case' 0 C--N 1.332 -0.185 0 CA-C-O 120.598 0.237 . . . . 0.0 111.173 179.933 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 138' ' ' VAL . . . . . 0.436 HG23 ' O ' ' A' ' 135' ' ' ILE . 3.3 m -55.85 -31.68 30.59 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.176 0 CA-C-O 121.182 0.515 . . . . 0.0 109.9 179.957 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 139' ' ' TYR . . . . . . . . . . . . . 21.3 t80 -66.19 -38.62 88.45 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 115.429 -0.805 . . . . 0.0 110.289 178.674 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 19.2 m-85 -65.28 -32.14 73.64 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 116.097 -0.501 . . . . 0.0 111.055 179.377 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 141' ' ' LEU . . . . . 0.461 HD22 ' SD ' ' A' ' 145' ' ' MET . 75.1 mt -69.9 -41.49 74.65 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-O 121.039 0.447 . . . . 0.0 110.351 -179.508 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 24.2 m -84.84 -10.58 11.53 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.631 0 CA-C-N 115.72 -0.673 . . . . 0.0 111.159 179.957 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . -76.91 -118.78 0.16 Allowed Glycine 0 CA--C 1.52 0.405 0 C-N-CA 120.894 -0.669 . . . . 0.0 112.986 -179.551 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 144' ' ' PRO . . . . . . . . . . . . . 55.8 Cg_endo -69.25 -30.19 25.08 Favored 'Trans proline' 0 C--N 1.349 0.6 0 C-N-CA 122.47 2.113 . . . . 0.0 112.825 -179.411 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 145' ' ' MET . . . . . 0.562 ' HB3' ' HH ' ' A' ' 160' ' ' TYR . 53.1 mtt -55.59 -31.14 61.97 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-O 120.726 0.298 . . . . 0.0 111.484 -179.664 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 146' ' ' THR . . . . . . . . . . . . . 14.3 m -71.12 -44.2 66.1 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.284 -0.416 . . . . 0.0 111.723 -179.45 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 43.6 mt-10 -75.92 -29.04 58.23 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.385 -0.371 . . . . 0.0 111.844 -179.411 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 148' ' ' SER . . . . . 0.524 ' HB2' ' HB3' ' A' ' 91' ' ' ALA . 66.2 m -70.26 -47.05 63.03 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 120.736 0.303 . . . . 0.0 111.281 -179.327 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 149' ' ' ALA . . . . . . . . . . . . . . . -72.6 -34.93 67.74 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.289 -0.414 . . . . 0.0 111.242 -179.833 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 150' ' ' SER . . . . . . . . . . . . . 47.7 t -70.42 -8.19 48.95 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.965 179.943 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 151' ' ' GLN . . . . . . . . . . . . . 47.9 mt-30 -122.32 10.04 9.85 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.262 -0.426 . . . . 0.0 111.255 -179.875 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 152' ' ' ARG . . . . . 0.58 ' HE ' HG13 ' A' ' 156' ' ' ILE . 1.2 tmm_? -85.05 -51.33 6.74 Favored 'General case' 0 C--N 1.332 -0.19 0 CA-C-O 120.979 0.418 . . . . 0.0 110.363 179.669 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 153' ' ' SER . . . . . 0.554 ' HB2' HG12 ' A' ' 156' ' ' ILE . 49.1 m -157.48 172.56 18.35 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 115.751 -0.659 . . . . 0.0 110.667 179.434 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 154' ' ' SER . . . . . . . . . . . . . 46.6 t -69.38 -42.17 75.52 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.339 -0.392 . . . . 0.0 110.76 179.754 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -77.28 -32.75 46.73 Favored Glycine 0 N--CA 1.452 -0.275 0 C-N-CA 120.948 -0.644 . . . . 0.0 113.029 -179.831 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 156' ' ' ILE . . . . . 0.58 HG13 ' HE ' ' A' ' 152' ' ' ARG . 32.2 mm -57.23 -38.65 62.72 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.199 0 CA-C-N 116.776 0.288 . . . . 0.0 111.356 -179.753 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 157' ' ' LYS . . . . . 0.44 ' O ' ' HB ' ' A' ' 161' ' ' VAL . 58.3 tttp -62.47 -43.48 98.72 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.385 -0.37 . . . . 0.0 111.372 -179.735 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 93.8 p -70.98 -48.32 53.95 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 116.102 -0.499 . . . . 0.0 111.551 -179.102 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 159' ' ' LEU . . . . . 0.432 ' O ' ' HB2' ' A' ' 163' ' ' LEU . 10.5 tt -62.08 -42.54 99.31 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.176 -179.395 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 160' ' ' TYR . . . . . 0.562 ' HH ' ' HB3' ' A' ' 145' ' ' MET . 77.6 t80 -71.59 -36.87 71.0 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 116.263 -0.426 . . . . 0.0 111.987 -179.077 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 161' ' ' VAL . . . . . 0.517 HG11 ' N ' ' A' ' 162' ' ' ARG . 1.1 t -58.4 -53.64 43.69 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.686 0 N-CA-C 111.699 0.259 . . . . 0.0 111.699 -179.181 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 162' ' ' ARG . . . . . 0.517 ' N ' HG11 ' A' ' 161' ' ' VAL . 97.3 mtt180 -69.89 -41.15 75.13 Favored 'General case' 0 C--N 1.329 -0.317 0 N-CA-C 112.04 0.385 . . . . 0.0 112.04 -179.174 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 163' ' ' LEU . . . . . 0.432 ' HB2' ' O ' ' A' ' 159' ' ' LEU . 2.7 mp -62.49 -56.14 20.93 Favored 'General case' 0 C--N 1.329 -0.314 0 N-CA-C 112.277 0.473 . . . . 0.0 112.277 -178.674 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 164' ' ' ARG . . . . . 0.438 ' NE ' ' ND2' ' A' ' 165' ' ' ASN . 5.4 ppt_? -62.42 -40.63 97.18 Favored 'General case' 0 C--N 1.328 -0.356 0 N-CA-C 112.002 0.371 . . . . 0.0 112.002 -178.361 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 165' ' ' ASN . . . . . 0.438 ' ND2' ' NE ' ' A' ' 164' ' ' ARG . 0.9 OUTLIER -54.73 -53.29 56.89 Favored 'General case' 0 C--O 1.237 0.402 0 CA-C-O 120.826 0.346 . . . . 0.0 111.557 -179.373 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 166' ' ' LEU . . . . . 0.475 ' O ' ' HG ' ' A' ' 170' ' ' LEU . 0.1 OUTLIER -67.67 -31.59 71.67 Favored 'General case' 0 C--N 1.331 -0.238 0 C-N-CA 120.847 -0.341 . . . . 0.0 111.022 -179.146 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 167' ' ' THR . . . . . 0.436 ' O ' ' HB2' ' A' ' 171' ' ' TRP . 17.7 m -59.75 -53.02 62.81 Favored 'General case' 0 C--N 1.333 -0.147 0 CA-C-O 120.842 0.353 . . . . 0.0 111.304 179.814 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 168' ' ' VAL . . . . . . . . . . . . . 58.4 t -58.97 -41.27 82.66 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.385 0 CA-C-N 115.785 -0.643 . . . . 0.0 111.749 -179.103 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 169' ' ' VAL . . . . . 0.405 HG21 ' O ' ' A' ' 165' ' ' ASN . 88.8 t -59.34 -64.87 0.51 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 N-CA-C 112.383 0.512 . . . . 0.0 112.383 -179.236 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 170' ' ' LEU . . . . . 0.475 ' HG ' ' O ' ' A' ' 166' ' ' LEU . 1.6 pp -61.04 -36.3 79.19 Favored 'General case' 0 N--CA 1.463 0.214 0 N-CA-C 112.219 0.451 . . . . 0.0 112.219 -178.67 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 171' ' ' TRP . . . . . 0.458 ' HE1' H202 ' A' ' 301' ' ' RET . 3.0 m0 -67.73 -29.4 68.62 Favored 'General case' 0 C--N 1.331 -0.231 0 C-N-CA 120.914 -0.314 . . . . 0.0 110.946 179.843 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 172' ' ' ALA . . . . . . . . . . . . . . . -73.28 -7.07 49.98 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 116.337 -0.392 . . . . 0.0 110.986 -179.938 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 173' ' ' ILE . . . . . 0.545 HG23 HD11 ' A' ' 177' ' ' ILE . 19.2 mm -87.97 -21.0 7.21 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.067 -0.515 . . . . 0.0 110.876 179.88 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 174' ' ' TYR . . . . . 0.4 ' N ' ' CD ' ' A' ' 175' ' ' PRO . 13.0 m-85 -53.67 -48.53 92.95 Favored Pre-proline 0 CA--C 1.531 0.235 0 CA-C-N 116.249 -0.432 . . . . 0.0 111.478 -179.752 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 175' ' ' PRO . . . . . 0.437 ' HB3' ' HZ ' ' A' ' 127' ' ' PHE . 92.4 Cg_exo -46.48 -31.77 10.31 Favored 'Trans proline' 0 C--N 1.352 0.756 0 C-N-CA 122.173 1.915 . . . . 0.0 112.117 179.059 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 176' ' ' PHE . . . . . 0.454 ' HD2' ' HA ' ' A' ' 173' ' ' ILE . 80.5 m-85 -80.25 -40.67 26.53 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 115.927 -0.578 . . . . 0.0 111.421 -179.893 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 177' ' ' ILE . . . . . 0.545 HD11 HG23 ' A' ' 173' ' ' ILE . 2.3 mm -65.2 -41.55 91.92 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.533 0 CA-C-N 116.346 -0.388 . . . . 0.0 111.838 -178.651 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 178' ' ' TRP . . . . . . . . . . . . . 63.9 t90 -73.65 -44.62 56.37 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.902 0.382 . . . . 0.0 111.064 -179.952 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 179' ' ' LEU . . . . . 0.433 ' O ' HG21 ' A' ' 185' ' ' VAL . 1.9 tm? -64.31 -51.86 61.36 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 115.952 -0.567 . . . . 0.0 111.451 -179.151 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 180' ' ' LEU . . . . . 0.524 HD23 HD11 ' A' ' 187' ' ' LEU . 20.7 mt -77.48 -44.98 27.04 Favored 'General case' 0 C--N 1.328 -0.336 0 N-CA-C 111.974 0.361 . . . . 0.0 111.974 -178.711 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 181' ' ' GLY . . . . . 0.4 ' C ' ' HD2' ' A' ' 183' ' ' PRO . . . -57.5 174.99 1.91 Allowed Glycine 0 C--N 1.335 0.494 0 C-N-CA 120.365 -0.921 . . . . 0.0 112.771 179.927 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 182' ' ' PRO . . . . . 0.567 ' N ' ' HD2' ' A' ' 183' ' ' PRO . 1.7 Cg_endo -44.99 -45.6 13.93 Favored 'Trans proline' 0 CA--C 1.537 0.671 0 C-N-CA 123.228 2.619 . . . . 0.0 113.84 179.615 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 183' ' ' PRO . . . . . 0.567 ' HD2' ' N ' ' A' ' 182' ' ' PRO . 18.5 Cg_endo -58.54 -4.75 1.97 Allowed 'Trans proline' 0 C--N 1.356 0.937 0 C-N-CA 121.967 1.778 . . . . 0.0 113.017 -179.762 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 184' ' ' GLY . . . . . 0.43 ' HA3' ' O ' ' A' ' 179' ' ' LEU . . . -122.09 -87.93 0.91 Allowed Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.63 -0.795 . . . . 0.0 112.636 179.94 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 185' ' ' VAL . . . . . 0.433 HG21 ' O ' ' A' ' 179' ' ' LEU . 4.3 m -123.63 -4.64 7.19 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 N-CA-C 111.658 0.244 . . . . 0.0 111.658 -179.822 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 186' ' ' ALA . . . . . 0.565 ' HB3' ' HA ' ' A' ' 182' ' ' PRO . . . 51.62 88.88 0.03 OUTLIER 'General case' 0 N--CA 1.462 0.156 0 CA-C-N 116.398 -0.364 . . . . 0.0 111.367 179.833 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 187' ' ' LEU . . . . . 0.524 HD11 HD23 ' A' ' 180' ' ' LEU . 20.2 mt -91.76 -49.4 6.29 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.396 -0.366 . . . . 0.0 111.774 -179.502 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 188' ' ' LEU . . . . . . . . . . . . . 87.5 mt -97.36 -94.3 0.22 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.462 -0.336 . . . . 0.0 111.539 -179.138 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 189' ' ' THR . . . . . . . . . . . . . 1.8 t -160.42 149.36 13.72 Favored Pre-proline 0 C--N 1.327 -0.39 0 CA-C-N 116.284 -0.416 . . . . 0.0 111.282 -179.499 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 190' ' ' PRO . . . . . . . . . . . . . 72.9 Cg_exo -50.37 -42.98 46.25 Favored 'Trans proline' 0 C--N 1.349 0.557 0 C-N-CA 122.591 2.194 . . . . 0.0 112.932 -179.853 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 191' ' ' THR . . . . . 0.457 ' HG1' ' H ' ' A' ' 192' ' ' VAL . 70.9 p -55.33 -46.55 76.35 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-O 120.77 0.319 . . . . 0.0 111.514 -179.729 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 192' ' ' VAL . . . . . 0.457 ' H ' ' HG1' ' A' ' 191' ' ' THR . 39.4 t -68.36 -50.6 55.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.626 -179.745 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 193' ' ' ASP . . . . . . . . . . . . . 30.8 t70 -55.24 -49.58 71.66 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.752 0.311 . . . . 0.0 111.284 -179.824 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 194' ' ' VAL . . . . . . . . . . . . . 76.1 t -59.62 -36.44 65.28 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.886 179.914 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 195' ' ' ALA . . . . . . . . . . . . . . . -58.71 -46.72 86.68 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.41 -0.359 . . . . 0.0 110.968 179.848 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 196' ' ' LEU . . . . . . . . . . . . . 85.3 mt -67.71 -40.17 84.3 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.348 -0.387 . . . . 0.0 110.615 179.692 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 197' ' ' ILE . . . . . . . . . . . . . 16.2 mm -59.97 -59.86 3.38 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 CA-C-N 115.988 -0.551 . . . . 0.0 110.302 179.388 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 198' ' ' VAL . . . . . . . . . . . . . 76.3 t -52.78 -34.26 19.81 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.515 0 CA-C-N 115.458 -0.792 . . . . 0.0 109.454 178.394 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 199' ' ' TYR . . . . . . . . . . . . . 65.7 t80 -70.07 -34.96 73.85 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.222 -0.899 . . . . 0.0 110.63 179.753 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 200' ' ' LEU . . . . . . . . . . . . . 28.0 mt -67.95 -39.02 83.47 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 115.845 -0.616 . . . . 0.0 111.27 -179.631 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 201' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -71.9 -32.35 67.31 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-N 116.099 -0.501 . . . . 0.0 110.776 179.804 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 202' ' ' LEU . . . . . . . . . . . . . 3.7 mt -70.91 -36.5 72.72 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.0 -0.545 . . . . 0.0 111.736 -179.556 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 203' ' ' VAL . . . . . 0.472 ' O ' ' HA3' ' A' ' 207' ' ' GLY . 11.8 p -74.62 -36.32 40.5 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.613 -0.267 . . . . 0.0 111.643 -179.008 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 204' ' ' THR . . . . . . . . . . . . . 43.7 m -67.69 -57.21 6.78 Favored 'General case' 0 C--N 1.326 -0.44 0 C-N-CA 120.84 -0.344 . . . . 0.0 111.53 -179.969 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 205' ' ' LYS . . . . . 0.634 ' HE2' ' HB3' ' A' ' 47' ' ' ALA . 60.0 mttp -69.49 -59.02 3.25 Favored 'General case' 0 C--N 1.329 -0.299 0 N-CA-C 112.549 0.574 . . . . 0.0 112.549 -178.472 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 22.1 t -72.57 -37.53 56.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 N-CA-C 112.158 0.429 . . . . 0.0 112.158 -178.473 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 207' ' ' GLY . . . . . 0.472 ' HA3' ' O ' ' A' ' 203' ' ' VAL . . . -61.51 -55.36 29.34 Favored Glycine 0 CA--C 1.517 0.195 0 C-N-CA 120.51 -0.852 . . . . 0.0 112.922 -179.464 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 208' ' ' PHE . . . . . 0.483 ' O ' ' N ' ' A' ' 212' ' ' ALA . 2.4 m-30 -61.03 -41.58 96.84 Favored 'General case' 0 C--O 1.221 -0.399 0 N-CA-C 110.026 -0.361 . . . . 0.0 110.026 -179.882 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 209' ' ' GLY . . . . . 0.474 ' O ' ' HB2' ' A' ' 212' ' ' ALA . . . -58.26 -37.57 87.4 Favored Glycine 0 N--CA 1.451 -0.33 0 CA-C-N 115.372 -0.831 . . . . 0.0 112.873 179.492 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 210' ' ' PHE . . . . . . . . . . . . . 2.7 m-85 -68.79 -49.56 57.61 Favored 'General case' 0 CA--C 1.514 -0.407 0 N-CA-C 108.548 -0.908 . . . . 0.0 108.548 179.238 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 211' ' ' ILE . . . . . . . . . . . . . 64.9 mt -63.2 -27.45 43.13 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.553 0 N-CA-C 107.61 -1.256 . . . . 0.0 107.61 176.658 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 212' ' ' ALA . . . . . 0.483 ' N ' ' O ' ' A' ' 208' ' ' PHE . . . -67.99 -38.02 82.18 Favored 'General case' 0 N--CA 1.448 -0.557 0 CA-C-N 114.488 -1.233 . . . . 0.0 110.527 -179.802 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 213' ' ' LEU . . . . . . . . . . . . . 89.2 mt -70.26 -52.52 22.43 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-N 115.373 -0.831 . . . . 0.0 111.53 -179.606 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 214' ' ' ASP . . . . . . . . . . . . . 24.5 m-20 -57.89 -52.41 65.62 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.396 -0.366 . . . . 0.0 110.954 -179.878 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 215' ' ' ALA . . . . . . . . . . . . . . . -57.25 -53.57 56.66 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.216 179.817 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 216' ' ' ALA . . . . . . . . . . . . . . . -59.98 -31.33 69.8 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-N 116.22 -0.445 . . . . 0.0 111.319 179.947 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 217' ' ' ALA . . . . . . . . . . . . . . . -62.19 -38.67 89.97 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-O 120.949 0.404 . . . . 0.0 110.281 179.651 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 218' ' ' THR . . . . . . . . . . . . . 93.5 m -72.12 -33.99 68.24 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 115.821 -0.627 . . . . 0.0 110.635 179.322 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 219' ' ' LEU . . . . . 0.463 ' O ' ' HG2' ' A' ' 222' ' ' GLU . 83.1 mt -63.2 -41.28 99.15 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 115.996 -0.547 . . . . 0.0 110.892 179.956 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 220' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -84.71 -19.88 32.05 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 116.145 -0.479 . . . . 0.0 111.162 179.682 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 221' ' ' ALA . . . . . . . . . . . . . . . -82.7 -24.81 33.47 Favored 'General case' 0 C--N 1.332 -0.181 0 N-CA-C 112.126 0.417 . . . . 0.0 112.126 -179.358 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 222' ' ' GLU . . . . . 0.463 ' HG2' ' O ' ' A' ' 219' ' ' LEU . 11.9 pt-20 -72.83 -7.8 52.5 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-O 120.782 0.325 . . . . 0.0 111.026 -179.485 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 223' ' ' HIS . . . . . . . . . . . . . 90.8 m-70 -92.83 -58.79 2.23 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.935 179.873 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 224' ' ' GLY . . . . . . . . . . . . . . . 75.79 97.12 0.14 Allowed Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.679 -0.772 . . . . 0.0 112.353 -179.822 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 225' ' ' GLU . . . . . . . . . . . . . 40.9 tt0 -55.41 118.61 4.6 Favored 'General case' 0 C--N 1.331 -0.21 0 CA-C-O 120.874 0.368 . . . . 0.0 111.075 -179.881 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 226' ' ' SER . . . . . . . . . . . . . 45.9 t -75.6 147.56 39.49 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.913 -179.968 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 227' ' ' LEU . . . . . . . . . . . . . 63.3 mt -67.86 135.4 52.48 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.781 -179.979 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 228' ' ' ALA . . . . . . . . . . . . . . . -145.33 122.92 11.77 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.254 -0.43 . . . . 0.0 111.331 -179.915 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 229' ' ' GLY . . . . . . . . . . . . . . . 68.11 -104.65 1.22 Allowed Glycine 0 N--CA 1.45 -0.368 0 C-N-CA 120.914 -0.66 . . . . 0.0 112.802 179.542 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 230' ' ' VAL . . . . . . . . . . . . . 46.1 t -77.19 111.89 14.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-O 120.852 0.358 . . . . 0.0 111.213 -179.798 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 231' ' ' ASP . . . . . . . . . . . . . 7.4 m-20 -85.66 100.73 12.17 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.861 179.964 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 232' ' ' THR . . . . . . . . . . . . . 4.8 t -158.84 140.2 13.21 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.246 -0.434 . . . . 0.0 111.342 179.989 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 233' ' ' ASP . . . . . . . . . . . . . 28.5 t70 -156.22 -52.98 0.08 Allowed 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 115.885 -0.598 . . . . 0.0 110.764 179.887 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 234' ' ' THR . . . . . . . . . . . . . 85.2 m -155.1 97.34 2.45 Favored Pre-proline 0 C--N 1.331 -0.215 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.104 179.935 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 235' ' ' PRO . . . . . . . . . . . . . 39.6 Cg_exo -57.91 -22.88 56.66 Favored 'Trans proline' 0 C--N 1.349 0.578 0 C-N-CA 122.419 2.08 . . . . 0.0 112.265 179.697 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 236' ' ' ALA . . . . . . . . . . . . . . . -73.29 173.34 9.64 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.26 -0.427 . . . . 0.0 111.104 179.941 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 237' ' ' VAL . . . . . . . . . . . . . 7.4 p -139.71 136.92 39.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.27 -179.707 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 238' ' ' ALA . . . . . . . . . . . . . . . -136.89 -64.05 0.59 Allowed 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.098 179.935 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 239' ' ' ASP . . . . . . . . . . . . . 6.4 m-20 -108.6 -179.46 3.88 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.731 179.931 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 240' ' ' LEU . . . . . 0.42 ' N ' HD21 ' A' ' 240' ' ' LEU . 3.6 mm? -107.19 121.92 45.49 Favored 'General case' 0 C--N 1.332 -0.188 0 CA-C-N 116.246 -0.433 . . . . 0.0 110.912 179.991 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 241' ' ' GLU . . . . . . . . . . . . . 41.9 mt-10 -95.28 -40.25 9.64 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.026 -0.534 . . . . 0.0 110.947 -179.9 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 242' ' ' HIS . . . . . . . . . . . . . 25.4 p-80 -87.02 166.97 14.65 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.13 -179.702 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 243' ' ' HIS . . . . . . . . . . . . . 74.3 m80 -137.1 -71.87 0.44 Allowed 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.069 -0.514 . . . . 0.0 110.584 179.874 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 244' ' ' HIS . . . . . . . . . . . . . 70.1 m80 58.26 -178.49 0.07 Allowed 'General case' 0 C--N 1.332 -0.193 0 CA-C-N 115.933 -0.576 . . . . 0.0 111.484 179.65 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 245' ' ' HIS . . . . . . . . . . . . . 26.7 p-80 -153.89 163.34 40.22 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 115.912 -0.585 . . . . 0.0 110.596 179.984 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 246' ' ' HIS . . . . . . . . . . . . . 18.0 p-80 -99.17 -27.85 13.62 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.408 -0.36 . . . . 0.0 110.941 -179.868 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 247' ' ' HIS . . . . . . . . . . . . . 59.5 t60 . . . . . 0 C--O 1.249 1.041 0 CA-C-O 118.254 -0.879 . . . . 0.0 110.889 -179.837 . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' A' A ' 301' ' ' RET . . . . . 0.458 H202 ' HE1' ' A' ' 171' ' ' TRP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 1' ' ' MET . . . . . 0.49 ' HG2' ' H ' ' A' ' 3' ' ' GLY . 58.1 ttp . . . . . 0 N--CA 1.486 1.337 0 CA-C-O 120.512 0.196 . . . . 0.0 110.808 . . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 5.2 p 45.02 23.33 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.466 0.349 0 CA-C-N 115.997 -0.547 . . . . 0.0 111.772 179.75 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 3' ' ' GLY . . . . . 0.49 ' H ' ' HG2' ' A' ' 1' ' ' MET . . . -109.32 -5.64 30.03 Favored Glycine 0 N--CA 1.45 -0.397 0 C-N-CA 120.87 -0.681 . . . . 0.0 112.224 179.855 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 60.5 tp -73.92 -35.55 64.63 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-O 120.881 0.372 . . . . 0.0 110.822 -179.982 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 64.0 p -61.59 -29.94 70.35 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 115.958 -0.565 . . . . 0.0 111.399 -179.819 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 26.9 p -55.37 -35.61 65.45 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 116.365 -0.38 . . . . 0.0 111.118 -179.725 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 7' ' ' LEU . . . . . . . . . . . . . 9.3 mp -55.98 -53.71 53.58 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.093 179.898 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 8' ' ' PHE . . . . . . . . . . . . . 65.1 m-85 -62.43 -34.23 76.37 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.716 -179.887 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 9' ' ' TRP . . . . . . . . . . . . . 37.8 m95 -64.46 -41.3 96.59 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-O 121.214 0.53 . . . . 0.0 109.896 179.69 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 86.2 mt -65.91 -31.53 72.51 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-N 115.303 -0.862 . . . . 0.0 110.052 179.227 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . 0.45 ' O ' ' HG2' ' A' ' 15' ' ' MET . . . -68.22 -34.04 79.65 Favored Glycine 0 N--CA 1.448 -0.526 0 C-N-CA 120.823 -0.703 . . . . 0.0 111.43 179.268 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -69.45 -37.18 77.23 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.839 0.352 . . . . 0.0 110.421 179.415 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 50.1 mm -62.41 -53.44 47.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 115.918 -0.583 . . . . 0.0 110.939 179.601 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -56.33 -42.03 88.24 Favored Glycine 0 C--N 1.33 0.245 0 C-N-CA 120.747 -0.74 . . . . 0.0 112.161 179.889 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 15' ' ' MET . . . . . 0.698 ' HE1' ' HD2' ' A' ' 205' ' ' LYS . 24.5 mmt -63.45 -41.87 98.64 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.737 0.303 . . . . 0.0 110.53 179.613 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 39.7 tp -54.19 -40.6 67.71 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.051 -0.522 . . . . 0.0 110.601 179.835 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 41.3 t -65.41 -49.03 80.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 115.963 -0.562 . . . . 0.0 111.067 179.955 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -63.31 -47.67 85.73 Favored Glycine 0 C--N 1.331 0.251 0 C-N-CA 120.769 -0.729 . . . . 0.0 112.219 179.724 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 19' ' ' THR . . . . . 0.431 HG21 HG13 ' A' ' 41' ' ' VAL . 24.9 m -50.32 -44.18 54.09 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-O 120.665 0.269 . . . . 0.0 111.295 -179.973 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 56.9 mt -71.43 -38.73 71.34 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 116.343 -0.39 . . . . 0.0 111.282 179.973 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -60.77 -32.18 71.5 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.242 -0.436 . . . . 0.0 111.549 -179.551 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 22' ' ' PHE . . . . . 0.511 ' HB2' HG22 ' A' ' 41' ' ' VAL . 2.8 m-85 -90.75 -34.46 15.34 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.419 -0.355 . . . . 0.0 111.209 -179.481 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -64.88 -48.49 74.06 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.245 -179.822 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 24' ' ' TRP . . . . . . . . . . . . . 3.6 t-105 -68.03 -53.63 24.34 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 115.906 -0.588 . . . . 0.0 111.25 -179.617 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -65.17 -19.52 66.02 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.862 0.363 . . . . 0.0 111.114 -179.99 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -73.63 -46.54 24.35 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.815 -0.707 . . . . 0.0 112.559 179.99 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 25.4 mmm180 -60.99 -21.86 63.94 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.878 0.37 . . . . 0.0 111.076 -179.861 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 15.6 t70 -117.19 97.63 6.02 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.924 -179.969 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -167.72 -71.42 0.03 OUTLIER 'General case' 0 C--N 1.331 -0.204 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.113 179.958 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 159.35 -166.41 34.72 Favored Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 120.826 -0.702 . . . . 0.0 112.516 -179.949 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 77.9 p -94.65 111.15 22.93 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 120.827 0.346 . . . . 0.0 111.081 -179.839 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 139.02 -50.89 0.78 Allowed Glycine 0 C--N 1.331 0.261 0 C-N-CA 120.942 -0.647 . . . . 0.0 112.523 179.832 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 45.7 mt-10 -68.98 -20.72 64.18 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.69 0.281 . . . . 0.0 111.064 -179.901 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 34' ' ' ARG . . . . . . . . . . . . . 99.9 mtt180 -49.28 -31.15 8.44 Favored 'General case' 0 C--N 1.332 -0.174 0 CA-C-N 116.123 -0.49 . . . . 0.0 111.681 -179.665 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 23.2 ttp180 -64.62 -47.89 76.91 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-O 120.805 0.336 . . . . 0.0 110.816 179.829 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 76.1 m-85 -67.12 -29.52 69.28 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.123 -0.489 . . . . 0.0 111.047 179.859 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 37' ' ' TYR . . . . . . . . . . . . . 35.5 m-85 -71.48 -52.62 17.41 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.3 -179.628 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 84.9 t -56.75 -36.61 49.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-O 121.077 0.465 . . . . 0.0 110.263 179.664 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 17.3 m -69.07 -51.12 42.15 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 115.686 -0.688 . . . . 0.0 110.865 179.392 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 11.4 tp -55.48 -50.81 68.92 Favored 'General case' 0 C--O 1.237 0.43 0 CA-C-N 115.914 -0.584 . . . . 0.0 110.707 -179.972 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . 0.511 HG22 ' HB2' ' A' ' 22' ' ' PHE . 60.0 t -62.1 -34.46 63.59 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.367 0 CA-C-N 115.675 -0.693 . . . . 0.0 110.287 179.29 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . 0.432 ' O ' HG12 ' A' ' 46' ' ' ILE . . . -60.21 -34.91 86.36 Favored Glycine 0 N--CA 1.449 -0.493 0 C-N-CA 120.864 -0.684 . . . . 0.0 112.337 179.949 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 43' ' ' ILE . . . . . 0.595 HG21 ' HE3' ' A' ' 205' ' ' LYS . 0.3 OUTLIER -71.83 -58.47 5.05 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.218 0 CA-C-O 120.752 0.311 . . . . 0.0 110.944 179.901 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 80.7 p -61.03 -20.59 62.71 Favored 'General case' 0 C--N 1.332 -0.153 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.262 -179.621 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -79.51 -57.15 3.19 Favored Glycine 0 CA--C 1.519 0.287 0 C-N-CA 120.792 -0.718 . . . . 0.0 112.94 -179.327 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 46' ' ' ILE . . . . . 0.432 HG12 ' O ' ' A' ' 42' ' ' GLY . 16.5 pt -58.36 -36.25 57.61 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.213 0 CA-C-O 120.976 0.417 . . . . 0.0 111.071 -179.994 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 47' ' ' ALA . . . . . 0.637 ' HB2' ' HE2' ' A' ' 205' ' ' LYS . . . -68.15 -45.94 72.17 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-N 116.079 -0.51 . . . . 0.0 111.314 179.518 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -54.71 -40.41 69.18 Favored 'General case' 0 C--N 1.332 -0.186 0 CA-C-N 116.271 -0.422 . . . . 0.0 111.909 -179.451 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 35.7 m -76.01 -34.11 26.36 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.384 0 CA-C-N 116.452 -0.34 . . . . 0.0 111.482 -179.318 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -65.03 -36.54 84.69 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.905 0.383 . . . . 0.0 111.033 179.718 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 38.1 m-85 -73.29 -39.8 65.06 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.021 -0.536 . . . . 0.0 110.685 -179.862 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -63.29 -46.72 85.43 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 115.92 -0.582 . . . . 0.0 111.527 179.86 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 53' ' ' VAL . . . . . 0.401 HG23 ' N ' ' A' ' 54' ' ' MET . 30.4 m -67.77 -46.14 83.04 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.19 0 CA-C-N 116.341 -0.39 . . . . 0.0 111.109 -179.78 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 54' ' ' MET . . . . . 0.437 ' HG3' ' HE1' ' A' ' 60' ' ' TRP . 13.3 ttp -64.44 -29.31 70.36 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.995 0.426 . . . . 0.0 110.294 179.834 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -64.36 -32.23 73.75 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 115.919 -0.582 . . . . 0.0 111.092 179.502 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 97.4 mt -82.85 6.26 18.97 Favored 'General case' 0 C--N 1.331 -0.204 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.197 -179.674 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 94.33 -5.25 70.97 Favored Glycine 0 N--CA 1.452 -0.265 0 C-N-CA 120.667 -0.778 . . . . 0.0 112.759 179.787 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 58.8 t -62.66 140.52 19.34 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.243 0 CA-C-O 120.701 0.286 . . . . 0.0 110.825 179.861 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 85.89 -23.64 8.91 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.615 -179.859 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 60' ' ' TRP . . . . . 0.437 ' HE1' ' HG3' ' A' ' 54' ' ' MET . 13.3 m0 -61.08 108.02 0.82 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.806 0.336 . . . . 0.0 110.722 179.909 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 7.4 p -118.67 131.58 24.23 Favored Pre-proline 0 CA--C 1.533 0.293 0 CA-C-N 116.343 -0.39 . . . . 0.0 111.469 -179.863 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 57.7 Cg_endo -71.9 147.77 50.36 Favored 'Trans proline' 0 C--N 1.35 0.637 0 C-N-CA 122.481 2.121 . . . . 0.0 112.501 179.842 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 76.8 t -141.91 99.19 0.82 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 115.92 -0.582 . . . . 0.0 111.019 -179.813 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . 58.72 -85.82 0.02 OUTLIER 'General case' 0 C--N 1.332 -0.172 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.229 -179.927 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 41.2 mt-10 -127.96 -20.39 3.84 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.319 179.723 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 66' ' ' ARG . . . . . . . . . . . . . 18.6 ptp180 -100.26 164.3 12.01 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 115.773 -0.649 . . . . 0.0 110.148 179.709 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 44.5 m -123.15 138.26 54.7 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-O 120.935 0.398 . . . . 0.0 111.213 -179.779 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 68' ' ' VAL . . . . . 0.459 HG12 ' HB3' ' A' ' 117' ' ' MET . 23.9 m -125.48 146.06 31.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.012 -0.54 . . . . 0.0 110.849 179.792 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 69' ' ' PHE . . . . . . . . . . . . . 8.5 m-85 -104.85 114.97 29.5 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.044 -179.732 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 70' ' ' VAL . . . . . 0.602 HG13 ' HD3' ' A' ' 71' ' ' PRO . 0.5 OUTLIER -66.94 -32.08 4.55 Favored Pre-proline 0 CA--C 1.54 0.58 0 N-CA-C 112.849 0.685 . . . . 0.0 112.849 -179.241 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 71' ' ' PRO . . . . . 0.602 ' HD3' HG13 ' A' ' 70' ' ' VAL . 14.5 Cg_exo -68.39 -18.04 44.07 Favored 'Trans proline' 0 C--N 1.36 1.157 0 C-N-CA 121.944 1.763 . . . . 0.0 112.704 -179.603 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 59.0 ttt180 -72.97 -55.2 6.9 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.767 0.317 . . . . 0.0 111.637 -179.224 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 73' ' ' TYR . . . . . . . . . . . . . 4.0 m-85 -71.8 -34.44 69.39 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.482 -0.326 . . . . 0.0 110.74 -179.143 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 0.4 OUTLIER -69.38 -41.2 80.75 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.192 0 CA-C-N 116.515 -0.311 . . . . 0.0 110.333 179.736 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 11.3 t70 -58.36 -37.64 75.62 Favored 'General case' 0 CA--C 1.518 -0.256 0 N-CA-C 109.427 -0.583 . . . . 0.0 109.427 178.901 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 76' ' ' TRP . . . . . 0.482 ' HB3' ' SD ' ' A' ' 109' ' ' MET . 42.6 m0 -64.97 -38.56 91.36 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 115.567 -0.742 . . . . 0.0 110.824 179.531 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 77' ' ' ILE . . . . . 0.502 ' O ' ' HG2' ' A' ' 81' ' ' PRO . 83.7 mt -66.54 -28.63 43.95 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-N 116.39 -0.368 . . . . 0.0 110.894 179.633 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 53.9 mt -91.47 -21.13 21.08 Favored 'General case' 0 C--N 1.327 -0.41 0 N-CA-C 112.044 0.387 . . . . 0.0 112.044 -179.969 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 71.5 p -102.3 -52.68 3.07 Favored 'General case' 0 CA--C 1.531 0.219 0 N-CA-C 113.425 0.898 . . . . 0.0 113.425 -178.099 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 80' ' ' THR . . . . . 0.624 ' HB ' ' HD3' ' A' ' 81' ' ' PRO . 26.2 m -50.2 -54.78 30.29 Favored Pre-proline 0 CA--C 1.532 0.283 0 N-CA-C 112.749 0.648 . . . . 0.0 112.749 -178.513 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 81' ' ' PRO . . . . . 0.624 ' HD3' ' HB ' ' A' ' 80' ' ' THR . 52.7 Cg_exo -57.1 -23.7 54.23 Favored 'Trans proline' 0 C--N 1.351 0.696 0 C-N-CA 121.513 1.475 . . . . 0.0 111.35 179.63 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 82' ' ' LEU . . . . . . . . . . . . . 16.4 tp -76.96 -32.72 57.5 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 115.445 -0.798 . . . . 0.0 109.764 179.39 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 40.4 mm -66.44 -54.38 26.63 Favored 'Isoleucine or valine' 0 C--O 1.233 0.185 0 CA-C-N 115.835 -0.62 . . . . 0.0 110.514 179.329 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 27.5 m -61.13 -31.07 49.09 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.31 0 N-CA-C 109.378 -0.601 . . . . 0.0 109.378 179.092 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 85' ' ' TYR . . . . . 0.409 ' O ' ' HG ' ' A' ' 89' ' ' LEU . 80.4 t80 -61.64 -35.58 78.33 Favored 'General case' 0 N--CA 1.453 -0.282 0 CA-C-N 115.593 -0.73 . . . . 0.0 109.155 178.338 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 86' ' ' PHE . . . . . . . . . . . . . 34.1 t80 -61.9 -49.67 75.26 Favored 'General case' 0 CA--C 1.52 -0.178 0 CA-C-N 115.78 -0.645 . . . . 0.0 109.623 179.046 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 3.9 mm? -57.71 -32.8 67.75 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 115.655 -0.702 . . . . 0.0 110.034 179.131 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -73.15 -27.43 68.37 Favored Glycine 0 N--CA 1.451 -0.305 0 CA-C-N 115.642 -0.708 . . . . 0.0 112.826 179.784 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 89' ' ' LEU . . . . . 0.409 ' HG ' ' O ' ' A' ' 85' ' ' TYR . 94.3 mt -72.39 -44.42 62.54 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.904 0.383 . . . . 0.0 111.084 -179.622 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 70.3 mt -70.49 -27.29 64.09 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 115.986 -0.552 . . . . 0.0 111.363 -179.748 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . 0.505 ' HA ' ' HB1' ' A' ' 149' ' ' ALA . . . -87.49 -52.65 5.23 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.426 -0.352 . . . . 0.0 111.239 -179.93 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 90.31 59.96 1.42 Allowed Glycine 0 N--CA 1.451 -0.361 0 C-N-CA 120.93 -0.652 . . . . 0.0 112.418 -179.966 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 93' ' ' LEU . . . . . 0.557 HD22 ' HB3' ' A' ' 97' ' ' GLU . 8.1 mp -71.28 -174.72 1.07 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.741 0.305 . . . . 0.0 110.845 -179.894 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 94' ' ' ASP . . . . . 0.444 ' HB2' ' OE2' ' A' ' 97' ' ' GLU . 12.5 m-20 -94.09 -172.16 2.75 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 121.023 0.439 . . . . 0.0 111.545 -179.446 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 43.5 m -67.8 -48.98 64.75 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 115.836 -0.62 . . . . 0.0 111.657 -179.266 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 31.9 ttm180 -73.33 -41.01 64.0 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 121.05 0.452 . . . . 0.0 110.619 -179.338 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 97' ' ' GLU . . . . . 0.557 ' HB3' HD22 ' A' ' 93' ' ' LEU . 0.3 OUTLIER -56.47 -45.83 80.72 Favored 'General case' 0 C--N 1.326 -0.449 0 CA-C-N 115.692 -0.686 . . . . 0.0 111.069 179.983 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 98' ' ' PHE . . . . . 0.429 ' O ' HG12 ' A' ' 102' ' ' ILE . 1.2 m-85 -60.79 -43.97 97.41 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.338 -0.392 . . . . 0.0 110.731 179.63 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -64.8 -29.73 76.08 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.901 -0.666 . . . . 0.0 112.639 -179.995 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 93.1 mt -68.29 -41.68 83.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-O 120.756 0.313 . . . . 0.0 111.249 -179.81 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 34.2 t -68.07 -41.16 84.12 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.411 0 CA-C-N 116.264 -0.425 . . . . 0.0 111.432 -179.573 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 102' ' ' ILE . . . . . 0.429 HG12 ' O ' ' A' ' 98' ' ' PHE . 42.0 mm -68.67 -51.36 46.64 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.447 -0.342 . . . . 0.0 111.44 -179.756 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 15.3 t -56.86 -32.21 65.59 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-O 120.916 0.389 . . . . 0.0 111.04 -179.894 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 104' ' ' LEU . . . . . 0.426 HD21 HD13 ' A' ' 137' ' ' LEU . 33.7 tp -66.06 -48.41 71.14 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.573 179.483 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 105' ' ' ASN . . . . . 0.536 ' N ' HD21 ' A' ' 105' ' ' ASN . 0.9 OUTLIER -62.52 -27.0 68.85 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.045 179.972 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 89.2 m -70.21 -53.36 17.41 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.334 -0.394 . . . . 0.0 111.419 -179.887 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 8.8 p -65.6 -37.07 79.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.296 -0.411 . . . . 0.0 111.304 -179.652 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 55.6 t -65.41 -50.16 74.33 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.249 0 CA-C-N 116.43 -0.35 . . . . 0.0 110.958 179.86 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 109' ' ' MET . . . . . 0.482 ' SD ' ' HB3' ' A' ' 76' ' ' TRP . 7.2 tpp -64.12 -33.54 75.99 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.622 -179.899 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 110' ' ' LEU . . . . . 0.478 HD22 ' C ' ' A' ' 110' ' ' LEU . 3.4 tt -63.06 -41.62 99.5 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-N 115.921 -0.581 . . . . 0.0 109.706 179.052 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -58.12 -47.83 82.08 Favored 'General case' 0 C--N 1.331 -0.203 0 CA-C-N 115.824 -0.625 . . . . 0.0 110.494 179.536 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 112' ' ' GLY . . . . . 0.564 ' HA3' ' H22' ' A' ' 301' ' ' RET . . . -68.47 -32.68 75.57 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.64 -0.791 . . . . 0.0 111.929 179.374 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 113' ' ' PHE . . . . . . . . . . . . . 0.5 OUTLIER -51.79 -68.45 0.17 Allowed 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 121.058 0.456 . . . . 0.0 109.998 179.566 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -70.48 -24.02 62.79 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 115.586 -0.733 . . . . 0.0 111.155 179.819 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -54.08 -40.86 67.68 Favored Glycine 0 C--N 1.331 0.282 0 C-N-CA 121.149 -0.548 . . . . 0.0 112.994 -179.699 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -77.81 -39.15 44.77 Favored 'General case' 0 C--N 1.328 -0.326 0 N-CA-C 112.142 0.423 . . . . 0.0 112.142 -179.429 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 117' ' ' MET . . . . . 0.459 ' HB3' HG12 ' A' ' 68' ' ' VAL . 19.3 ptp -91.4 19.74 5.84 Favored 'General case' 0 C--N 1.329 -0.324 0 N-CA-C 111.788 0.292 . . . . 0.0 111.788 -179.287 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 118' ' ' VAL . . . . . 0.502 HG23 ' HB3' ' A' ' 123' ' ' ARG . 5.0 m -54.08 149.45 18.37 Favored Pre-proline 0 C--N 1.33 -0.282 0 CA-C-N 116.598 -0.274 . . . . 0.0 111.231 179.723 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 119' ' ' PRO . . . . . . . . . . . . . 90.3 Cg_endo -87.34 3.97 6.24 Favored 'Trans proline' 0 N--CA 1.458 -0.581 0 C-N-CA 122.64 2.227 . . . . 0.0 112.236 179.622 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -168.37 -133.96 1.64 Allowed Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.786 -0.721 . . . . 0.0 112.457 -179.951 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 42.4 pt -99.18 18.01 2.77 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.246 0 CA-C-O 120.885 0.374 . . . . 0.0 111.182 -179.834 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 45.1 mt-10 -67.51 -18.46 65.05 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.274 -179.975 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 123' ' ' ARG . . . . . 0.502 ' HB3' HG23 ' A' ' 118' ' ' VAL . 20.5 ptt180 -53.07 -29.82 32.52 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 116.222 -0.444 . . . . 0.0 111.67 -179.678 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 124' ' ' TYR . . . . . . . . . . . . . 28.2 m-85 -67.48 -34.41 77.1 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.589 -0.278 . . . . 0.0 110.795 -179.858 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 125' ' ' ALA . . . . . . . . . . . . . . . -74.78 -56.08 5.16 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.17 -179.978 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 1.1 mt -52.49 -54.34 33.81 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 115.908 -0.587 . . . . 0.0 110.961 -179.86 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 127' ' ' PHE . . . . . . . . . . . . . 8.8 t80 -62.78 -36.4 82.99 Favored 'General case' 0 C--N 1.331 -0.231 0 C-N-CA 120.847 -0.341 . . . . 0.0 110.567 179.756 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 128' ' ' GLY . . . . . . . . . . . . . . . -47.31 -43.98 20.15 Favored Glycine 0 C--N 1.332 0.314 0 C-N-CA 120.136 -1.031 . . . . 0.0 111.153 179.154 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 129' ' ' MET . . . . . 0.41 ' HE2' ' N ' ' A' ' 130' ' ' GLY . 0.3 OUTLIER -71.87 -37.05 70.26 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 120.865 0.364 . . . . 0.0 110.026 178.868 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 130' ' ' GLY . . . . . 0.41 ' N ' ' HE2' ' A' ' 129' ' ' MET . . . -67.18 -28.19 73.67 Favored Glycine 0 N--CA 1.45 -0.378 0 CA-C-N 115.822 -0.626 . . . . 0.0 112.688 -179.722 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -74.81 -54.18 7.79 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.624 0.25 . . . . 0.0 110.67 -179.953 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 31.7 t -57.95 -41.17 79.55 Favored 'Isoleucine or valine' 0 C--O 1.235 0.318 0 N-CA-C 109.129 -0.693 . . . . 0.0 109.129 178.698 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -66.29 -35.8 81.32 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 115.173 -0.921 . . . . 0.0 110.106 178.929 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 134' ' ' PHE . . . . . 0.414 ' CZ ' ' HA ' ' A' ' 172' ' ' ALA . 57.9 t80 -57.48 -50.9 71.55 Favored 'General case' 0 N--CA 1.45 -0.469 0 CA-C-N 115.937 -0.574 . . . . 0.0 110.022 179.548 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 135' ' ' ILE . . . . . 0.496 ' HA ' HG22 ' A' ' 138' ' ' VAL . 60.2 mt -56.64 -33.59 40.39 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.312 0 CA-C-N 115.911 -0.586 . . . . 0.0 109.663 178.95 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . -63.21 -35.21 91.76 Favored Glycine 0 N--CA 1.447 -0.568 0 C-N-CA 120.249 -0.977 . . . . 0.0 111.205 178.507 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 137' ' ' LEU . . . . . 0.426 HD13 HD21 ' A' ' 104' ' ' LEU . 29.1 tp -73.43 -52.13 14.82 Favored 'General case' 0 C--N 1.332 -0.158 0 N-CA-C 110.422 -0.214 . . . . 0.0 110.422 179.612 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 138' ' ' VAL . . . . . 0.581 ' HA ' HD12 ' A' ' 141' ' ' LEU . 4.9 m -55.95 -30.55 28.72 Favored 'Isoleucine or valine' 0 C--O 1.234 0.28 0 N-CA-C 109.069 -0.715 . . . . 0.0 109.069 178.92 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 139' ' ' TYR . . . . . 0.413 ' O ' ' N ' ' A' ' 143' ' ' GLY . 49.8 t80 -64.82 -41.96 95.35 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 114.958 -1.019 . . . . 0.0 109.337 178.462 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 19.4 m-85 -65.02 -33.0 74.99 Favored 'General case' 0 C--N 1.333 -0.143 0 CA-C-N 116.036 -0.529 . . . . 0.0 109.791 178.577 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 141' ' ' LEU . . . . . 0.581 HD12 ' HA ' ' A' ' 138' ' ' VAL . 81.9 mt -61.21 -36.38 79.75 Favored 'General case' 0 C--O 1.232 0.149 0 CA-C-N 115.977 -0.556 . . . . 0.0 109.895 179.078 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 2.9 t -109.27 10.48 8.96 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-N 115.751 -0.659 . . . . 0.0 110.658 179.729 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 143' ' ' GLY . . . . . 0.413 ' N ' ' O ' ' A' ' 139' ' ' TYR . . . -85.52 -147.6 9.81 Favored Glycine 0 CA--C 1.519 0.291 0 C-N-CA 120.968 -0.634 . . . . 0.0 113.008 -179.511 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 144' ' ' PRO . . . . . . . . . . . . . 51.3 Cg_exo -52.98 -24.87 26.11 Favored 'Trans proline' 0 C--N 1.349 0.579 0 C-N-CA 122.716 2.278 . . . . 0.0 112.754 -179.799 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 145' ' ' MET . . . . . 0.448 ' HG2' HD11 ' A' ' 93' ' ' LEU . 55.3 mtt -53.22 -39.15 63.55 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 116.352 -0.385 . . . . 0.0 111.244 179.975 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 146' ' ' THR . . . . . . . . . . . . . 81.2 p -62.1 -51.2 68.89 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.794 -179.36 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 147' ' ' GLU . . . . . 0.452 ' O ' ' HG2' ' A' ' 151' ' ' GLN . 40.0 mt-10 -74.1 -18.06 60.86 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.394 -0.366 . . . . 0.0 111.249 -179.534 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 148' ' ' SER . . . . . . . . . . . . . 44.6 t -71.21 -47.69 55.9 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.764 0.316 . . . . 0.0 111.231 -179.807 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 149' ' ' ALA . . . . . 0.505 ' HB1' ' HA ' ' A' ' 91' ' ' ALA . . . -78.02 -31.99 50.79 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.128 -0.487 . . . . 0.0 112.242 -178.975 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 150' ' ' SER . . . . . . . . . . . . . 70.2 m -62.68 -6.67 3.79 Favored 'General case' 0 C--N 1.328 -0.337 0 N-CA-C 111.993 0.368 . . . . 0.0 111.993 -179.384 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 151' ' ' GLN . . . . . 0.452 ' HG2' ' O ' ' A' ' 147' ' ' GLU . 67.0 mm-40 -111.58 17.14 20.27 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.731 -0.213 . . . . 0.0 111.095 -179.775 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 25.6 mtp180 -101.71 -52.24 3.25 Favored 'General case' 0 C--N 1.331 -0.201 0 CA-C-O 120.832 0.349 . . . . 0.0 111.351 -179.839 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 153' ' ' SER . . . . . 0.551 ' HB3' HG12 ' A' ' 156' ' ' ILE . 31.5 t -156.83 172.27 18.93 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.959 179.691 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 154' ' ' SER . . . . . . . . . . . . . 61.4 m -73.05 -39.78 65.64 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 116.257 -0.428 . . . . 0.0 110.65 179.679 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -76.6 -28.81 58.78 Favored Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.904 -0.665 . . . . 0.0 112.7 -179.936 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 156' ' ' ILE . . . . . 0.551 HG12 ' HB3' ' A' ' 153' ' ' SER . 25.8 mm -58.37 -42.45 84.05 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.233 0 CA-C-O 120.764 0.316 . . . . 0.0 111.486 -179.96 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 157' ' ' LYS . . . . . . . . . . . . . 25.0 ttpp -63.31 -42.24 99.0 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.272 -0.422 . . . . 0.0 111.499 -179.496 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 46.5 t -65.23 -47.68 75.98 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.418 -0.355 . . . . 0.0 111.88 -179.257 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 159' ' ' LEU . . . . . 0.405 ' O ' HD11 ' A' ' 163' ' ' LEU . 4.9 tt -66.13 -34.68 78.61 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.507 -0.315 . . . . 0.0 111.241 -179.396 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 160' ' ' TYR . . . . . . . . . . . . . 58.4 t80 -73.69 -46.16 48.01 Favored 'General case' 0 C--N 1.327 -0.382 0 N-CA-C 112.365 0.506 . . . . 0.0 112.365 -178.767 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 28.8 m -59.97 -46.52 93.99 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 N-CA-C 112.171 0.434 . . . . 0.0 112.171 -178.933 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 162' ' ' ARG . . . . . . . . . . . . . 79.0 ttt180 -65.61 -46.04 80.85 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.71 0.291 . . . . 0.0 111.552 -179.331 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 163' ' ' LEU . . . . . 0.405 HD11 ' O ' ' A' ' 159' ' ' LEU . 7.8 mp -65.44 -52.02 56.13 Favored 'General case' 0 C--N 1.329 -0.317 0 N-CA-C 112.106 0.41 . . . . 0.0 112.106 -179.186 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 164' ' ' ARG . . . . . 0.425 ' HG3' ' N ' ' A' ' 165' ' ' ASN . 5.7 ppt_? -58.62 -43.34 89.62 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.598 -0.274 . . . . 0.0 111.605 -178.861 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 165' ' ' ASN . . . . . 0.425 ' N ' ' HG3' ' A' ' 164' ' ' ARG . 0.9 OUTLIER -55.97 -49.44 73.57 Favored 'General case' 0 C--N 1.331 -0.202 0 CA-C-O 121.129 0.49 . . . . 0.0 110.427 179.513 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 166' ' ' LEU . . . . . 0.482 ' O ' ' HG ' ' A' ' 170' ' ' LEU . 3.1 tt -60.15 -50.04 75.24 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 115.563 -0.744 . . . . 0.0 111.681 -179.52 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 167' ' ' THR . . . . . 0.482 ' O ' ' HB2' ' A' ' 171' ' ' TRP . 60.1 m -56.41 -54.01 50.63 Favored 'General case' 0 C--N 1.331 -0.232 0 N-CA-C 112.324 0.49 . . . . 0.0 112.324 -178.796 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 168' ' ' VAL . . . . . . . . . . . . . 45.4 t -52.27 -43.8 40.43 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.227 0 N-CA-C 112.339 0.496 . . . . 0.0 112.339 -179.764 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 169' ' ' VAL . . . . . . . . . . . . . 72.8 t -59.92 -65.75 0.44 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 N-CA-C 113.016 0.747 . . . . 0.0 113.016 -178.47 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 170' ' ' LEU . . . . . 0.482 ' HG ' ' O ' ' A' ' 166' ' ' LEU . 0.7 OUTLIER -63.08 -37.78 88.56 Favored 'General case' 0 C--N 1.33 -0.26 0 N-CA-C 112.593 0.59 . . . . 0.0 112.593 -178.163 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 171' ' ' TRP . . . . . 0.538 ' HE1' H203 ' A' ' 301' ' ' RET . 2.9 m0 -64.25 -27.58 69.15 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.832 0.349 . . . . 0.0 110.771 179.813 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 172' ' ' ALA . . . . . 0.414 ' HA ' ' CZ ' ' A' ' 134' ' ' PHE . . . -72.48 -6.93 47.19 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.948 -179.818 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 173' ' ' ILE . . . . . 0.478 ' O ' HG12 ' A' ' 177' ' ' ILE . 28.8 mm -88.4 -21.24 7.05 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 115.952 -0.567 . . . . 0.0 111.175 -179.985 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 174' ' ' TYR . . . . . 0.403 ' N ' ' CD ' ' A' ' 175' ' ' PRO . 8.7 m-85 -53.59 -48.25 93.74 Favored Pre-proline 0 N--CA 1.464 0.261 0 CA-C-N 116.339 -0.392 . . . . 0.0 111.93 -179.375 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 175' ' ' PRO . . . . . 0.403 ' CD ' ' N ' ' A' ' 174' ' ' TYR . 84.6 Cg_exo -48.43 -33.27 22.52 Favored 'Trans proline' 0 C--N 1.351 0.667 0 C-N-CA 121.854 1.703 . . . . 0.0 112.048 179.588 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 176' ' ' PHE . . . . . 0.453 ' HD2' ' HA ' ' A' ' 173' ' ' ILE . 60.9 m-85 -80.9 -50.35 9.87 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 115.873 -0.603 . . . . 0.0 111.954 -179.905 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 177' ' ' ILE . . . . . 0.478 HG12 ' O ' ' A' ' 173' ' ' ILE . 13.6 mm -60.25 -32.08 49.86 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.443 0 CA-C-N 116.279 -0.418 . . . . 0.0 112.036 -178.386 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 178' ' ' TRP . . . . . 0.445 ' HH2' ' HB2' ' A' ' 123' ' ' ARG . 82.0 t90 -73.18 -52.06 15.52 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.91 0.386 . . . . 0.0 110.81 179.928 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 179' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -68.76 -54.77 14.07 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-N 115.989 -0.55 . . . . 0.0 111.484 -179.119 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 180' ' ' LEU . . . . . 0.502 HD23 HD11 ' A' ' 187' ' ' LEU . 26.6 mt -64.06 -29.7 70.82 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.55 -0.295 . . . . 0.0 111.298 -179.37 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . -69.12 -175.79 12.24 Favored Glycine 0 N--CA 1.449 -0.44 0 C-N-CA 119.817 -1.183 . . . . 0.0 111.629 178.957 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 182' ' ' PRO . . . . . 0.512 ' HG3' ' HA ' ' A' ' 190' ' ' PRO . 82.3 Cg_exo -47.47 -43.54 27.07 Favored 'Trans proline' 0 CA--C 1.537 0.669 0 C-N-CA 122.678 2.252 . . . . 0.0 113.76 179.943 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 183' ' ' PRO . . . . . 0.417 ' CD ' ' N ' ' A' ' 182' ' ' PRO . 83.4 Cg_exo -43.07 -51.77 5.31 Favored 'Trans proline' 0 C--N 1.356 0.957 0 C-N-CA 122.491 2.127 . . . . 0.0 114.065 -179.744 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 184' ' ' GLY . . . . . . . . . . . . . . . -102.74 -123.95 5.36 Favored Glycine 0 C--N 1.335 0.515 0 C-N-CA 119.942 -1.123 . . . . 0.0 113.631 -179.063 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 185' ' ' VAL . . . . . . . . . . . . . 23.6 m -54.09 -33.33 24.49 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.405 0 N-CA-C 112.647 0.61 . . . . 0.0 112.647 -178.95 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 186' ' ' ALA . . . . . . . . . . . . . . . 58.92 83.35 0.13 Allowed 'General case' 0 N--CA 1.464 0.246 0 CA-C-O 120.675 0.274 . . . . 0.0 111.624 179.786 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 187' ' ' LEU . . . . . 0.502 HD11 HD23 ' A' ' 180' ' ' LEU . 7.7 mt -92.32 -49.92 5.91 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-O 120.902 0.382 . . . . 0.0 111.351 179.795 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 188' ' ' LEU . . . . . 0.442 HD13 ' HB2' ' A' ' 187' ' ' LEU . 7.3 mp -79.79 -164.59 0.68 Allowed 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.001 -0.545 . . . . 0.0 111.197 -179.268 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 189' ' ' THR . . . . . 0.468 ' HB ' HG23 ' A' ' 192' ' ' VAL . 20.8 m -91.08 137.46 26.46 Favored Pre-proline 0 C--N 1.329 -0.295 0 CA-C-N 115.868 -0.605 . . . . 0.0 110.634 -179.73 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 190' ' ' PRO . . . . . 0.512 ' HA ' ' HG3' ' A' ' 182' ' ' PRO . 92.3 Cg_exo -44.23 -37.24 9.87 Favored 'Trans proline' 0 C--N 1.35 0.656 0 C-N-CA 122.519 2.146 . . . . 0.0 113.278 -179.649 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 191' ' ' THR . . . . . 0.404 HG21 HG22 ' A' ' 189' ' ' THR . 6.2 t -78.52 -40.82 34.05 Favored 'General case' 0 C--N 1.33 -0.275 0 N-CA-C 111.683 0.253 . . . . 0.0 111.683 -179.616 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 192' ' ' VAL . . . . . 0.468 HG23 ' HB ' ' A' ' 189' ' ' THR . 96.9 t -62.52 -48.69 87.08 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-O 120.658 0.266 . . . . 0.0 111.463 -179.729 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 193' ' ' ASP . . . . . . . . . . . . . 21.6 m-20 -56.0 -46.58 78.7 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.397 -0.365 . . . . 0.0 111.089 -179.714 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 194' ' ' VAL . . . . . . . . . . . . . 71.0 t -59.34 -37.07 67.36 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.412 -0.358 . . . . 0.0 110.739 179.547 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 195' ' ' ALA . . . . . . . . . . . . . . . -59.32 -41.71 89.72 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.303 -0.408 . . . . 0.0 110.608 179.534 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 196' ' ' LEU . . . . . . . . . . . . . 98.1 mt -67.3 -38.4 84.95 Favored 'General case' 0 C--N 1.333 -0.143 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.197 179.248 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 197' ' ' ILE . . . . . . . . . . . . . 15.8 mm -60.57 -56.24 19.06 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.242 0 CA-C-N 115.901 -0.59 . . . . 0.0 110.248 179.122 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 198' ' ' VAL . . . . . . . . . . . . . 93.7 t -54.28 -34.58 28.01 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.516 0 CA-C-N 115.623 -0.717 . . . . 0.0 109.321 178.303 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 199' ' ' TYR . . . . . . . . . . . . . 29.7 t80 -69.83 -32.99 71.71 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 115.112 -0.949 . . . . 0.0 110.609 179.794 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 200' ' ' LEU . . . . . 0.439 ' O ' HG13 ' A' ' 203' ' ' VAL . 23.0 mt -69.86 -39.33 76.41 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 115.97 -0.559 . . . . 0.0 111.024 179.984 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 201' ' ' ASP . . . . . . . . . . . . . 15.2 m-20 -72.95 -34.6 66.64 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-O 121.204 0.526 . . . . 0.0 110.103 179.625 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 202' ' ' LEU . . . . . . . . . . . . . 3.1 mt -75.01 -27.13 59.99 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 115.514 -0.766 . . . . 0.0 111.749 -179.439 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 203' ' ' VAL . . . . . 0.439 HG13 ' O ' ' A' ' 200' ' ' LEU . 10.9 p -79.61 -36.36 17.47 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.334 0 C-N-CA 120.834 -0.347 . . . . 0.0 110.856 -178.924 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 204' ' ' THR . . . . . . . . . . . . . 96.9 m -67.87 -58.27 4.85 Favored 'General case' 0 C--N 1.328 -0.333 0 C-N-CA 120.933 -0.307 . . . . 0.0 110.902 179.212 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 205' ' ' LYS . . . . . 0.698 ' HD2' ' HE1' ' A' ' 15' ' ' MET . 60.5 mttp -60.52 -58.29 9.11 Favored 'General case' 0 C--N 1.331 -0.212 0 N-CA-C 112.067 0.395 . . . . 0.0 112.067 -178.937 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 52.8 t -67.69 -37.02 77.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 N-CA-C 111.818 0.303 . . . . 0.0 111.818 -179.303 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 207' ' ' GLY . . . . . 0.404 ' HA3' ' O ' ' A' ' 203' ' ' VAL . . . -53.55 -60.48 8.19 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.908 -0.663 . . . . 0.0 113.975 -178.818 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 208' ' ' PHE . . . . . 0.475 ' O ' ' N ' ' A' ' 212' ' ' ALA . 1.1 p90 -75.45 -26.75 58.53 Favored 'General case' 0 C--O 1.219 -0.513 0 CA-C-N 117.317 0.559 . . . . 0.0 111.778 -179.14 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 209' ' ' GLY . . . . . 0.465 ' O ' ' HB3' ' A' ' 212' ' ' ALA . . . -66.4 -35.24 89.88 Favored Glycine 0 N--CA 1.452 -0.267 0 C-N-CA 121.491 -0.385 . . . . 0.0 112.202 179.597 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 210' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER -75.75 -44.86 39.54 Favored 'General case' 0 CA--C 1.514 -0.433 0 N-CA-C 108.316 -0.994 . . . . 0.0 108.316 178.742 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 211' ' ' ILE . . . . . . . . . . . . . 44.3 mt -65.6 -27.55 41.85 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.55 0 N-CA-C 107.91 -1.144 . . . . 0.0 107.91 176.86 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 212' ' ' ALA . . . . . 0.475 ' N ' ' O ' ' A' ' 208' ' ' PHE . . . -62.37 -45.47 93.02 Favored 'General case' 0 N--CA 1.451 -0.418 0 CA-C-N 114.741 -1.118 . . . . 0.0 110.508 179.89 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 213' ' ' LEU . . . . . . . . . . . . . 93.9 mt -69.73 -54.55 13.22 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 115.151 -0.931 . . . . 0.0 111.676 -179.181 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 214' ' ' ASP . . . . . . . . . . . . . 19.5 t70 -55.21 -41.52 72.11 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.331 -0.395 . . . . 0.0 111.511 -179.608 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 215' ' ' ALA . . . . . 0.446 ' O ' ' HG ' ' A' ' 219' ' ' LEU . . . -70.25 -57.7 4.59 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.407 -0.36 . . . . 0.0 111.781 -179.419 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 216' ' ' ALA . . . . . . . . . . . . . . . -55.59 -34.92 65.26 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.5 -0.318 . . . . 0.0 111.428 -179.541 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 217' ' ' ALA . . . . . . . . . . . . . . . -67.02 -41.02 87.33 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.506 179.894 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 218' ' ' THR . . . . . . . . . . . . . 42.3 m -64.84 -37.57 88.06 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 115.775 -0.648 . . . . 0.0 110.916 179.707 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 219' ' ' LEU . . . . . 0.446 ' HG ' ' O ' ' A' ' 215' ' ' ALA . 68.9 mt -61.59 -46.25 90.64 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.851 -179.896 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 220' ' ' ARG . . . . . 0.417 ' HD2' ' N ' ' A' ' 220' ' ' ARG . 10.0 mpt_? -82.38 -14.26 55.52 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.163 -0.472 . . . . 0.0 111.086 -179.834 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 221' ' ' ALA . . . . . . . . . . . . . . . -70.67 -47.75 58.33 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.363 -0.381 . . . . 0.0 111.229 179.971 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 222' ' ' GLU . . . . . . . . . . . . . 12.3 pt-20 -91.42 -30.5 16.47 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.933 -179.737 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 223' ' ' HIS . . . . . . . . . . . . . 18.6 p80 36.92 81.9 0.02 OUTLIER 'General case' 0 N--CA 1.463 0.21 0 CA-C-N 115.898 -0.592 . . . . 0.0 111.536 -179.769 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 224' ' ' GLY . . . . . . . . . . . . . . . -99.93 54.0 0.94 Allowed Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.771 -179.682 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 225' ' ' GLU . . . . . . . . . . . . . 45.6 mt-10 -80.5 134.51 35.97 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.769 0.319 . . . . 0.0 110.68 179.726 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 226' ' ' SER . . . . . . . . . . . . . 46.0 t -69.32 -59.85 2.73 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.081 -179.737 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 227' ' ' LEU . . . . . . . . . . . . . 92.3 mt -61.53 114.54 3.31 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-O 120.88 0.372 . . . . 0.0 111.078 -179.901 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 228' ' ' ALA . . . . . . . . . . . . . . . -152.32 -0.67 0.29 Allowed 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.084 -0.507 . . . . 0.0 111.028 179.885 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 229' ' ' GLY . . . . . . . . . . . . . . . -68.03 146.26 46.07 Favored Glycine 0 N--CA 1.45 -0.369 0 C-N-CA 120.884 -0.674 . . . . 0.0 112.461 179.893 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 230' ' ' VAL . . . . . . . . . . . . . 31.1 t -84.21 132.24 32.03 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-O 120.832 0.348 . . . . 0.0 111.077 -179.845 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 231' ' ' ASP . . . . . . . . . . . . . 20.9 t70 -72.58 101.68 3.07 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.848 179.887 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 232' ' ' THR . . . . . . . . . . . . . 48.9 p -129.28 6.69 5.35 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.176 179.843 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 233' ' ' ASP . . . . . . . . . . . . . 6.1 p-10 -82.08 8.93 9.5 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.834 179.908 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 234' ' ' THR . . . . . . . . . . . . . 4.4 t -59.31 142.13 86.74 Favored Pre-proline 0 C--N 1.33 -0.282 0 CA-C-N 116.111 -0.495 . . . . 0.0 111.318 -179.957 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 235' ' ' PRO . . . . . . . . . . . . . 74.3 Cg_endo -74.81 -172.53 1.26 Allowed 'Trans proline' 0 C--N 1.347 0.492 0 C-N-CA 122.495 2.13 . . . . 0.0 112.345 179.976 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 236' ' ' ALA . . . . . . . . . . . . . . . -135.44 155.73 50.06 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.124 -0.489 . . . . 0.0 111.041 -179.987 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 237' ' ' VAL . . . . . . . . . . . . . 31.0 m -110.42 23.55 4.25 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 116.102 -0.499 . . . . 0.0 111.074 -179.931 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 238' ' ' ALA . . . . . . . . . . . . . . . -78.48 -18.57 54.64 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.22 -179.911 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 239' ' ' ASP . . . . . . . . . . . . . 15.1 m-20 64.17 157.95 0.08 Allowed 'General case' 0 N--CA 1.462 0.168 0 CA-C-N 116.156 -0.475 . . . . 0.0 111.342 179.894 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 240' ' ' LEU . . . . . . . . . . . . . 78.8 mt -103.38 -62.45 1.29 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.015 -0.539 . . . . 0.0 110.687 179.917 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 241' ' ' GLU . . . . . . . . . . . . . 12.4 pt-20 -117.9 172.96 7.04 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.775 179.91 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 242' ' ' HIS . . . . . . . . . . . . . 69.3 m-70 -100.17 -60.83 1.46 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.281 -0.418 . . . . 0.0 110.813 179.991 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 243' ' ' HIS . . . . . . . . . . . . . 6.4 p-80 -128.02 171.14 12.13 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.224 -179.752 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 244' ' ' HIS . . . . . . . . . . . . . 17.0 p80 -98.53 142.63 29.88 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 115.983 -0.553 . . . . 0.0 110.727 179.852 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 245' ' ' HIS . . . . . . . . . . . . . 48.3 t-80 -153.67 -57.27 0.12 Allowed 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.373 -0.376 . . . . 0.0 111.152 -179.783 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 246' ' ' HIS . . . . . . . . . . . . . 8.6 p80 -118.29 -14.83 9.79 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.18 -179.851 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 247' ' ' HIS . . . . . . . . . . . . . 59.5 m80 . . . . . 0 C--O 1.249 1.075 0 CA-C-O 118.215 -0.898 . . . . 0.0 111.057 -179.951 . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' A' A ' 301' ' ' RET . . . . . 0.564 ' H22' ' HA3' ' A' ' 112' ' ' GLY . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 64.2 mtm . . . . . 0 N--CA 1.485 1.291 0 CA-C-O 120.797 0.332 . . . . 0.0 110.838 . . . . . . . . . 0 0 . 1 . 021 nuclear orig full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 41.1 t -91.71 -34.83 6.47 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.242 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.118 179.962 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -88.9 -9.72 67.67 Favored Glycine 0 N--CA 1.452 -0.266 0 C-N-CA 120.867 -0.682 . . . . 0.0 112.626 -179.947 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 31.1 tp -73.95 -35.47 64.53 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-O 120.837 0.351 . . . . 0.0 110.727 -179.967 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 74.0 p -58.23 -30.99 66.94 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.079 -0.51 . . . . 0.0 111.519 -179.863 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 30.9 p -54.29 -35.71 62.88 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.377 -0.374 . . . . 0.0 111.2 -179.964 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 7' ' ' LEU . . . . . . . . . . . . . 4.1 mm? -60.22 -52.23 66.17 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.883 179.868 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 8' ' ' PHE . . . . . 0.428 ' HB2' ' HB3' ' A' ' 55' ' ' ALA . 58.2 m-85 -62.82 -30.92 71.85 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.031 -0.532 . . . . 0.0 110.909 -179.981 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 9' ' ' TRP . . . . . . . . . . . . . 21.5 m95 -67.5 -46.87 71.65 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.087 -0.506 . . . . 0.0 110.212 -179.797 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 88.9 mt -59.67 -38.44 81.49 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 115.69 -0.687 . . . . 0.0 110.343 179.411 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -65.04 -34.24 89.32 Favored Glycine 0 N--CA 1.448 -0.506 0 C-N-CA 120.679 -0.772 . . . . 0.0 111.866 179.36 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -67.91 -32.48 72.97 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-O 120.883 0.373 . . . . 0.0 110.62 179.554 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 70.2 mt -65.22 -53.42 40.8 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 115.91 -0.586 . . . . 0.0 110.624 179.611 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -64.21 -40.16 97.74 Favored Glycine 0 N--CA 1.451 -0.364 0 C-N-CA 120.6 -0.81 . . . . 0.0 112.198 179.72 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 15' ' ' MET . . . . . 0.659 ' HE3' ' HD2' ' A' ' 205' ' ' LYS . 12.5 mmt -63.14 -47.96 80.49 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.676 0.274 . . . . 0.0 110.99 179.797 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 16' ' ' LEU . . . . . 0.674 ' O ' HD22 ' A' ' 20' ' ' LEU . 50.9 tp -54.4 -55.71 25.92 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.329 -179.877 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 46.9 t -56.97 -33.36 42.05 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-O 120.958 0.409 . . . . 0.0 110.45 -179.355 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -67.26 -49.88 49.19 Favored Glycine 0 N--CA 1.452 -0.297 0 N-CA-C 111.185 -0.766 . . . . 0.0 111.185 179.483 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 19' ' ' THR . . . . . 0.608 HG23 HD23 ' A' ' 20' ' ' LEU . 1.4 m -53.39 -43.45 67.89 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 115.28 -0.46 . . . . 0.0 110.84 179.518 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 20' ' ' LEU . . . . . 0.674 HD22 ' O ' ' A' ' 16' ' ' LEU . 0.5 OUTLIER -69.79 -41.96 74.41 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-N 115.755 -0.657 . . . . 0.0 111.943 -179.559 . . . . . . . . 3 3 . 1 . 021 nuclear orig full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -59.38 -32.14 69.87 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.521 -0.309 . . . . 0.0 111.795 -179.344 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 22' ' ' PHE . . . . . 0.492 ' HB2' HG23 ' A' ' 41' ' ' VAL . 5.8 m-85 -90.96 -28.66 17.9 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.711 0.291 . . . . 0.0 111.256 -179.722 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -70.33 -50.72 36.22 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 121.007 0.432 . . . . 0.0 111.576 -179.716 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 24' ' ' TRP . . . . . . . . . . . . . 4.6 t-105 -66.06 -38.91 89.51 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 115.867 -0.606 . . . . 0.0 111.494 -179.438 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -78.67 -23.92 45.41 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-O 120.836 0.35 . . . . 0.0 110.77 179.712 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -73.53 -43.21 37.84 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 121.034 -0.603 . . . . 0.0 112.98 -179.756 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 13.4 ptp180 -61.73 -18.11 58.45 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 120.664 0.269 . . . . 0.0 111.227 -179.719 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 17.8 t70 -121.74 97.53 5.54 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 116.44 -0.345 . . . . 0.0 111.105 -179.795 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -164.69 -83.65 0.02 OUTLIER 'General case' 0 C--N 1.331 -0.239 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.167 179.623 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -148.69 -113.24 0.69 Allowed Glycine 0 N--CA 1.452 -0.283 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.441 -179.784 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 79.3 p -145.84 -44.8 0.21 Allowed 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.706 0.289 . . . . 0.0 111.115 -179.927 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -80.84 -29.82 41.23 Favored Glycine 0 C--N 1.331 0.254 0 C-N-CA 120.792 -0.718 . . . . 0.0 112.86 -179.709 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 2.7 mp0 -66.42 -20.88 66.18 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.898 0.38 . . . . 0.0 110.933 -179.846 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 34' ' ' ARG . . . . . . . . . . . . . 99.2 mtt180 -51.4 -29.54 16.06 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 115.914 -0.584 . . . . 0.0 111.679 -179.776 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 31.1 mmm180 -67.17 -44.78 78.83 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.393 -0.367 . . . . 0.0 111.42 -179.731 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 78.3 m-85 -70.54 -31.35 68.36 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.466 -0.333 . . . . 0.0 110.983 -179.946 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 37' ' ' TYR . . . . . . . . . . . . . 48.5 m-85 -72.11 -51.33 21.93 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 116.327 -0.397 . . . . 0.0 111.228 -179.757 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 10.7 p -57.27 -36.21 51.43 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-O 120.994 0.426 . . . . 0.0 109.979 179.344 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 24.0 m -66.22 -43.83 85.55 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 115.629 -0.714 . . . . 0.0 110.584 179.127 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 40' ' ' LEU . . . . . 0.576 HD13 ' HA2' ' A' ' 209' ' ' GLY . 0.3 OUTLIER -62.64 -50.51 70.92 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-O 121.585 0.707 . . . . 0.0 110.501 179.559 . . . . . . . . 3 3 . 1 . 021 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . 0.492 HG23 ' HB2' ' A' ' 22' ' ' PHE . 43.8 t -62.87 -33.49 60.64 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.626 0 CA-C-N 115.435 -0.802 . . . . 0.0 110.316 179.43 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . 0.44 ' O ' HG12 ' A' ' 46' ' ' ILE . . . -58.07 -47.79 86.93 Favored Glycine 0 N--CA 1.448 -0.527 0 CA-C-N 115.635 -0.712 . . . . 0.0 112.822 179.889 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 43' ' ' ILE . . . . . 0.56 HD12 HD23 ' A' ' 40' ' ' LEU . 9.0 pt -65.43 -51.32 65.35 Favored 'Isoleucine or valine' 0 C--O 1.233 0.201 0 CA-C-N 117.019 0.409 . . . . 0.0 111.502 -179.704 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 60.5 m -63.61 -20.47 65.69 Favored 'General case' 0 C--O 1.233 0.188 0 CA-C-O 120.92 0.39 . . . . 0.0 110.79 -179.899 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -80.61 -58.58 2.67 Favored Glycine 0 N--CA 1.452 -0.287 0 C-N-CA 121.008 -0.615 . . . . 0.0 113.103 -179.301 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 46' ' ' ILE . . . . . 0.446 ' O ' HG23 ' A' ' 49' ' ' VAL . 14.7 pt -58.19 -36.6 58.22 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.185 0 CA-C-O 120.881 0.372 . . . . 0.0 110.949 -179.758 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 47' ' ' ALA . . . . . 0.614 ' HB3' ' HE2' ' A' ' 205' ' ' LYS . . . -68.78 -42.54 77.27 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.704 178.776 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -54.39 -40.49 68.24 Favored 'General case' 0 C--O 1.232 0.181 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.329 -179.786 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 49' ' ' VAL . . . . . 0.446 HG23 ' O ' ' A' ' 46' ' ' ILE . 17.9 m -76.22 -34.1 25.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.487 -0.324 . . . . 0.0 110.98 -179.883 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -61.42 -39.96 92.7 Favored 'General case' 0 C--N 1.332 -0.165 0 CA-C-O 121.141 0.496 . . . . 0.0 110.715 179.215 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 51' ' ' TYR . . . . . 0.41 ' HB3' ' O ' ' A' ' 8' ' ' PHE . 43.5 m-85 -73.19 -35.93 66.47 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 115.651 -0.704 . . . . 0.0 110.439 179.84 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -66.68 -39.95 88.36 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 115.885 -0.598 . . . . 0.0 111.261 179.558 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 53' ' ' VAL . . . . . 0.406 HG12 ' O ' ' A' ' 49' ' ' VAL . 33.5 m -74.42 -42.44 49.79 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.173 0 CA-C-N 116.362 -0.381 . . . . 0.0 110.972 -179.785 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 54' ' ' MET . . . . . . . . . . . . . 70.7 mtm -65.27 -31.17 72.18 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 121.111 0.481 . . . . 0.0 109.852 179.118 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 55' ' ' ALA . . . . . 0.428 ' HB3' ' HB2' ' A' ' 8' ' ' PHE . . . -67.82 -18.56 64.88 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 115.544 -0.753 . . . . 0.0 111.188 179.52 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 96.5 mt -98.84 8.68 44.71 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.196 179.957 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 81.22 16.81 73.33 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.587 -0.816 . . . . 0.0 112.604 -179.993 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 58.0 t -84.53 137.19 21.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-O 120.794 0.33 . . . . 0.0 110.888 179.907 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 59' ' ' GLY . . . . . 0.48 ' HA3' ' HD3' ' A' ' 71' ' ' PRO . . . 85.08 -7.79 73.53 Favored Glycine 0 N--CA 1.449 -0.478 0 C-N-CA 120.776 -0.726 . . . . 0.0 112.476 -179.942 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 60' ' ' TRP . . . . . . . . . . . . . 12.0 m0 -65.36 99.21 0.39 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.642 0.258 . . . . 0.0 110.863 179.955 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 5.1 p -107.31 128.32 26.21 Favored Pre-proline 0 C--N 1.329 -0.298 0 CA-C-N 116.356 -0.384 . . . . 0.0 111.141 179.885 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 58.3 Cg_endo -71.68 141.11 37.1 Favored 'Trans proline' 0 C--N 1.349 0.581 0 C-N-CA 122.25 1.967 . . . . 0.0 112.039 179.817 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 61.1 t -137.39 90.77 0.77 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.356 0 CA-C-N 116.075 -0.511 . . . . 0.0 111.249 -179.621 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . 59.96 -85.49 0.02 OUTLIER 'General case' 0 C--N 1.331 -0.202 0 CA-C-N 116.0 -0.545 . . . . 0.0 111.42 179.948 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 11.6 pt-20 -121.81 -22.69 5.7 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.886 0.374 . . . . 0.0 110.937 -179.966 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 66' ' ' ARG . . . . . . . . . . . . . 84.8 mtm180 -104.72 156.78 17.69 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.041 -0.527 . . . . 0.0 110.802 -179.919 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 40.9 m -113.61 130.62 56.35 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.981 179.854 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 26.3 t -113.61 146.33 18.34 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.394 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.973 179.943 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 69' ' ' PHE . . . . . . . . . . . . . 16.8 m-85 -104.33 116.68 32.57 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 116.209 -0.451 . . . . 0.0 109.919 -179.894 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 70' ' ' VAL . . . . . 0.592 HG11 ' HD3' ' A' ' 71' ' ' PRO . 0.8 OUTLIER -66.73 -35.58 9.84 Favored Pre-proline 0 CA--C 1.541 0.612 0 N-CA-C 112.602 0.593 . . . . 0.0 112.602 -179.424 . . . . . . . . 3 3 . 1 . 021 nuclear orig full ' A' A ' 71' ' ' PRO . . . . . 0.592 ' HD3' HG11 ' A' ' 70' ' ' VAL . 9.5 Cg_exo -70.77 -22.39 27.51 Favored 'Trans proline' 0 C--N 1.36 1.138 0 C-N-CA 122.032 1.821 . . . . 0.0 112.815 -179.508 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 67.6 ttt180 -68.56 -55.63 11.0 Favored 'General case' 0 C--N 1.329 -0.323 0 N-CA-C 112.157 0.429 . . . . 0.0 112.157 -178.791 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 73' ' ' TYR . . . . . 0.503 ' O ' HG13 ' A' ' 77' ' ' ILE . 73.7 m-85 -73.53 -33.74 64.88 Favored 'General case' 0 C--N 1.328 -0.328 0 C-N-CA 120.863 -0.335 . . . . 0.0 110.892 -179.112 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 74' ' ' ILE . . . . . 0.451 ' HA ' HD12 ' A' ' 77' ' ' ILE . 0.3 OUTLIER -67.57 -41.27 85.59 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 N-CA-C 109.703 -0.48 . . . . 0.0 109.703 179.164 . . . . . . . . 3 3 . 1 . 021 nuclear orig full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 27.0 t70 -58.85 -37.54 76.7 Favored 'General case' 0 CA--C 1.519 -0.242 0 N-CA-C 109.241 -0.651 . . . . 0.0 109.241 178.703 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 76' ' ' TRP . . . . . 0.439 ' HB3' ' SD ' ' A' ' 109' ' ' MET . 48.6 m0 -66.12 -31.13 71.8 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 115.624 -0.717 . . . . 0.0 110.575 179.337 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 77' ' ' ILE . . . . . 0.503 HG13 ' O ' ' A' ' 73' ' ' TYR . 76.1 mt -69.41 -29.6 42.57 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.353 0 CA-C-O 121.036 0.446 . . . . 0.0 110.333 178.973 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 24.8 mt -91.45 -15.84 28.23 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 115.984 -0.553 . . . . 0.0 111.986 179.898 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 73.6 p -101.84 -52.6 3.15 Favored 'General case' 0 N--CA 1.464 0.225 0 N-CA-C 113.06 0.763 . . . . 0.0 113.06 -178.613 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 80' ' ' THR . . . . . 0.662 ' HB ' ' HD3' ' A' ' 81' ' ' PRO . 62.8 m -51.26 -56.26 21.79 Favored Pre-proline 0 CA--C 1.533 0.291 0 N-CA-C 112.854 0.687 . . . . 0.0 112.854 -178.287 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 81' ' ' PRO . . . . . 0.662 ' HD3' ' HB ' ' A' ' 80' ' ' THR . 52.2 Cg_exo -57.43 -25.12 64.54 Favored 'Trans proline' 0 C--N 1.353 0.766 0 C-N-CA 121.517 1.478 . . . . 0.0 111.613 -179.945 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 82' ' ' LEU . . . . . . . . . . . . . 12.3 tp -77.14 -32.96 56.75 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 115.741 -0.663 . . . . 0.0 110.393 179.838 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 83' ' ' ILE . . . . . 0.428 HG13 H202 ' A' ' 301' ' ' RET . 47.4 mm -67.56 -53.34 32.55 Favored 'Isoleucine or valine' 0 C--O 1.232 0.164 0 CA-C-N 116.377 -0.374 . . . . 0.0 110.227 179.17 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . 0.43 HG11 HD12 ' A' ' 137' ' ' LEU . 24.6 m -60.73 -29.96 46.1 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.224 0 N-CA-C 108.897 -0.779 . . . . 0.0 108.897 178.411 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 85' ' ' TYR . . . . . . . . . . . . . 93.4 t80 -65.28 -30.29 71.14 Favored 'General case' 0 N--CA 1.453 -0.297 0 CA-C-N 115.395 -0.82 . . . . 0.0 109.248 178.371 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 86' ' ' PHE . . . . . . . . . . . . . 31.6 t80 -65.44 -51.95 56.62 Favored 'General case' 0 CA--C 1.519 -0.212 0 CA-C-N 115.811 -0.631 . . . . 0.0 109.623 178.988 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 87' ' ' LEU . . . . . 0.573 HD21 HD21 ' A' ' 141' ' ' LEU . 6.0 mp -63.22 -28.85 70.32 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 115.803 -0.635 . . . . 0.0 109.854 179.117 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -68.35 -27.98 73.49 Favored Glycine 0 N--CA 1.449 -0.478 0 C-N-CA 120.707 -0.759 . . . . 0.0 111.256 178.833 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 46.4 mt -76.19 -34.33 59.31 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-O 120.963 0.411 . . . . 0.0 110.282 179.012 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 88.9 mt -79.41 -23.69 43.06 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 115.937 -0.574 . . . . 0.0 110.984 179.681 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . 0.429 ' HA ' ' HB1' ' A' ' 149' ' ' ALA . . . -88.46 -45.46 9.93 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.249 -179.903 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 91.92 57.8 1.47 Allowed Glycine 0 N--CA 1.451 -0.364 0 C-N-CA 120.802 -0.713 . . . . 0.0 112.611 -179.833 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 93' ' ' LEU . . . . . 0.423 HD21 ' HB3' ' A' ' 97' ' ' GLU . 10.6 mp -74.07 176.94 6.06 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-O 120.758 0.313 . . . . 0.0 110.779 179.836 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 94' ' ' ASP . . . . . 0.504 ' H ' ' HB2' ' A' ' 97' ' ' GLU . 5.7 m-20 -99.23 -167.0 1.41 Allowed 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.095 -179.947 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 48.8 m -67.58 -49.63 62.25 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 115.903 -0.589 . . . . 0.0 111.509 -179.542 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 96' ' ' ARG . . . . . 0.425 ' O ' HG13 ' A' ' 100' ' ' ILE . 31.4 tpt180 -74.08 -39.77 63.21 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-O 120.904 0.383 . . . . 0.0 110.601 -179.457 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 97' ' ' GLU . . . . . 0.504 ' HB2' ' H ' ' A' ' 94' ' ' ASP . 0.3 OUTLIER -55.53 -47.19 76.7 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 115.824 -0.626 . . . . 0.0 111.391 -179.757 . . . . . . . . 3 3 . 1 . 021 nuclear orig full ' A' A ' 98' ' ' PHE . . . . . 0.436 ' O ' HG12 ' A' ' 102' ' ' ILE . 3.3 m-85 -62.53 -41.53 98.92 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.487 -0.324 . . . . 0.0 110.879 179.675 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -65.47 -26.33 71.78 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.553 -0.832 . . . . 0.0 112.66 -179.777 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 100' ' ' ILE . . . . . 0.425 HG13 ' O ' ' A' ' 96' ' ' ARG . 96.5 mt -73.4 -48.82 40.41 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-O 120.688 0.28 . . . . 0.0 111.648 -179.663 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 17.0 m -64.82 -37.78 81.05 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.498 -0.319 . . . . 0.0 111.691 -179.649 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 102' ' ' ILE . . . . . 0.436 HG12 ' O ' ' A' ' 98' ' ' PHE . 49.5 mm -71.55 -49.48 46.34 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.452 -0.34 . . . . 0.0 111.41 -179.757 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 14.0 t -59.74 -30.94 69.18 Favored 'General case' 0 C--N 1.332 -0.164 0 CA-C-O 120.825 0.345 . . . . 0.0 110.938 -179.933 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 104' ' ' LEU . . . . . 0.436 HD22 ' HE2' ' A' ' 140' ' ' TYR . 46.3 tp -65.49 -54.37 29.2 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.465 179.498 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 105' ' ' ASN . . . . . 0.612 ' N ' HD21 ' A' ' 105' ' ' ASN . 0.7 OUTLIER -56.91 -26.45 59.25 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 115.996 -0.547 . . . . 0.0 110.764 179.827 . . . . . . . . 3 3 . 1 . 021 nuclear orig full ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 39.6 m -68.4 -56.76 7.38 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.13 -0.486 . . . . 0.0 111.38 -179.855 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 13.2 p -60.45 -36.66 70.98 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.16 0 CA-C-N 116.524 -0.307 . . . . 0.0 111.335 -179.779 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . 0.403 HG23 ' O ' ' A' ' 104' ' ' LEU . 93.3 t -66.36 -50.24 69.31 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-O 120.957 0.408 . . . . 0.0 111.005 179.716 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 109' ' ' MET . . . . . 0.439 ' SD ' ' HB3' ' A' ' 76' ' ' TRP . 10.0 tpp -59.95 -36.33 76.86 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 115.954 -0.566 . . . . 0.0 110.62 179.948 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 23.1 tp -65.19 -34.27 77.98 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.037 -0.528 . . . . 0.0 110.291 179.607 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -60.01 -51.28 70.32 Favored 'General case' 0 C--N 1.331 -0.218 0 CA-C-N 116.041 -0.527 . . . . 0.0 110.339 179.263 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 112' ' ' GLY . . . . . 0.527 ' HA3' ' H22' ' A' ' 301' ' ' RET . . . -62.21 -39.27 97.47 Favored Glycine 0 C--N 1.331 0.269 0 C-N-CA 120.604 -0.808 . . . . 0.0 111.911 179.245 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 113' ' ' PHE . . . . . . . . . . . . . 2.2 t80 -47.43 -68.22 0.21 Allowed 'General case' 0 C--N 1.332 -0.196 0 CA-C-O 121.063 0.459 . . . . 0.0 110.203 179.318 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 114' ' ' ALA . . . . . 0.401 ' HB2' HD22 ' A' ' 126' ' ' LEU . . . -65.12 -21.66 66.83 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 115.512 -0.767 . . . . 0.0 110.856 179.453 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -53.58 -45.03 68.3 Favored Glycine 0 C--N 1.334 0.423 0 C-N-CA 121.068 -0.587 . . . . 0.0 112.496 179.992 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -77.88 -23.59 48.73 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.721 0.295 . . . . 0.0 111.55 179.744 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 117' ' ' MET . . . . . . . . . . . . . 65.3 mtt -96.0 19.15 12.01 Favored 'General case' 0 C--N 1.331 -0.2 0 CA-C-N 116.29 -0.414 . . . . 0.0 111.613 -179.473 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 118' ' ' VAL . . . . . 0.49 HG12 ' N ' ' A' ' 123' ' ' ARG . 19.3 m -68.34 142.61 94.79 Favored Pre-proline 0 C--N 1.328 -0.338 0 CA-C-N 116.71 -0.223 . . . . 0.0 111.586 -179.902 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 119' ' ' PRO . . . . . . . . . . . . . 98.4 Cg_endo -88.0 6.09 5.11 Favored 'Trans proline' 0 N--CA 1.459 -0.513 0 C-N-CA 122.761 2.307 . . . . 0.0 112.524 179.593 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -166.09 -115.15 0.31 Allowed Glycine 0 C--N 1.332 0.327 0 C-N-CA 120.697 -0.763 . . . . 0.0 112.803 -179.814 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 43.5 pt -111.4 12.68 8.58 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.216 0 CA-C-O 120.698 0.285 . . . . 0.0 111.43 -179.634 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 11.2 mm-40 -58.83 -18.88 36.43 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.37 -0.377 . . . . 0.0 110.991 -179.993 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 123' ' ' ARG . . . . . 0.49 ' N ' HG12 ' A' ' 118' ' ' VAL . 17.5 ptt180 -53.32 -30.01 36.76 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.017 -0.538 . . . . 0.0 111.484 -179.964 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 124' ' ' TYR . . . . . . . . . . . . . 29.7 m-85 -76.5 -32.45 58.32 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.352 -0.385 . . . . 0.0 110.927 179.924 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 125' ' ' ALA . . . . . . . . . . . . . . . -72.38 -56.1 6.0 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.067 179.924 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 126' ' ' LEU . . . . . 0.401 HD22 ' HB2' ' A' ' 114' ' ' ALA . 1.5 mt -56.13 -54.08 49.43 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 115.888 -0.596 . . . . 0.0 110.829 -179.89 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 127' ' ' PHE . . . . . . . . . . . . . 11.0 t80 -64.86 -35.9 82.63 Favored 'General case' 0 N--CA 1.453 -0.306 0 C-N-CA 120.738 -0.385 . . . . 0.0 110.694 179.623 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 128' ' ' GLY . . . . . . . . . . . . . . . -47.53 -44.16 21.93 Favored Glycine 0 C--N 1.332 0.337 0 C-N-CA 120.054 -1.069 . . . . 0.0 110.825 179.111 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 129' ' ' MET . . . . . . . . . . . . . 0.2 OUTLIER -71.77 -37.24 70.5 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.991 0.424 . . . . 0.0 109.99 178.78 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -67.69 -27.59 73.59 Favored Glycine 0 N--CA 1.452 -0.29 0 CA-C-N 115.653 -0.703 . . . . 0.0 112.761 -179.852 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -75.04 -53.85 8.18 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-O 120.696 0.284 . . . . 0.0 110.48 179.944 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 45.4 t -58.54 -40.09 77.65 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.206 0 N-CA-C 109.064 -0.717 . . . . 0.0 109.064 178.546 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -69.09 -35.0 76.01 Favored 'General case' 0 N--CA 1.451 -0.389 0 CA-C-N 115.133 -0.939 . . . . 0.0 110.445 179.174 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 134' ' ' PHE . . . . . 0.434 ' CZ ' ' HA ' ' A' ' 172' ' ' ALA . 76.2 t80 -57.51 -55.27 36.95 Favored 'General case' 0 N--CA 1.451 -0.376 0 N-CA-C 109.763 -0.458 . . . . 0.0 109.763 179.492 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 135' ' ' ILE . . . . . 0.468 ' HA ' HG23 ' A' ' 138' ' ' VAL . 34.7 mt -57.25 -31.5 38.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 115.687 -0.688 . . . . 0.0 109.642 178.888 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . -65.77 -36.11 91.82 Favored Glycine 0 N--CA 1.446 -0.669 0 C-N-CA 120.386 -0.911 . . . . 0.0 111.017 178.537 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 137' ' ' LEU . . . . . 0.43 HD12 HG11 ' A' ' 84' ' ' VAL . 39.1 tp -71.47 -53.23 14.64 Favored 'General case' 0 N--CA 1.454 -0.25 0 N-CA-C 110.355 -0.239 . . . . 0.0 110.355 179.321 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 138' ' ' VAL . . . . . 0.468 HG23 ' HA ' ' A' ' 135' ' ' ILE . 5.0 m -56.36 -31.86 34.12 Favored 'Isoleucine or valine' 0 C--O 1.233 0.194 0 N-CA-C 109.08 -0.711 . . . . 0.0 109.08 178.929 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 139' ' ' TYR . . . . . . . . . . . . . 39.0 t80 -61.41 -45.82 92.74 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 115.367 -0.833 . . . . 0.0 110.127 178.54 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 140' ' ' TYR . . . . . 0.436 ' HE2' HD22 ' A' ' 104' ' ' LEU . 27.4 m-85 -60.95 -37.67 83.2 Favored 'General case' 0 C--N 1.332 -0.157 0 CA-C-N 116.29 -0.414 . . . . 0.0 110.724 179.543 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 141' ' ' LEU . . . . . 0.573 HD21 HD21 ' A' ' 87' ' ' LEU . 83.5 mt -61.92 -35.0 77.1 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.615 179.916 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 17.1 t -96.25 -4.75 10.08 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.071 -0.513 . . . . 0.0 110.546 179.581 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . -74.12 -134.36 0.29 Allowed Glycine 0 CA--C 1.52 0.398 0 C-N-CA 121.129 -0.558 . . . . 0.0 112.885 -179.809 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 144' ' ' PRO . . . . . . . . . . . . . 34.1 Cg_exo -59.91 -23.96 74.5 Favored 'Trans proline' 0 C--N 1.349 0.578 0 C-N-CA 122.752 2.301 . . . . 0.0 112.839 -179.536 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 145' ' ' MET . . . . . 0.433 ' HA ' ' HG ' ' A' ' 148' ' ' SER . 59.1 mtt -53.66 -28.69 34.66 Favored 'General case' 0 C--N 1.332 -0.179 0 CA-C-N 116.34 -0.391 . . . . 0.0 111.417 -179.854 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 146' ' ' THR . . . . . . . . . . . . . 74.9 p -70.34 -50.43 39.12 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.233 -0.44 . . . . 0.0 112.063 -179.219 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 47.4 mt-10 -73.62 -24.13 59.99 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.546 -0.297 . . . . 0.0 111.797 -179.025 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 148' ' ' SER . . . . . 0.433 ' HG ' ' HA ' ' A' ' 145' ' ' MET . 81.4 p -70.78 -49.14 49.76 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 116.444 -0.343 . . . . 0.0 111.645 -179.281 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 149' ' ' ALA . . . . . 0.429 ' HB1' ' HA ' ' A' ' 91' ' ' ALA . . . -77.98 -38.83 44.21 Favored 'General case' 0 C--N 1.329 -0.319 0 N-CA-C 112.237 0.458 . . . . 0.0 112.237 -179.026 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 150' ' ' SER . . . . . . . . . . . . . 68.4 m -60.92 -8.13 2.92 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.537 -0.302 . . . . 0.0 111.705 -179.382 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 151' ' ' GLN . . . . . . . . . . . . . 78.2 mt-30 -119.02 25.19 10.36 Favored 'General case' 0 C--N 1.329 -0.296 0 N-CA-C 111.588 0.218 . . . . 0.0 111.588 -179.812 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 49.6 mtp180 -103.25 -52.24 3.07 Favored 'General case' 0 C--N 1.331 -0.197 0 CA-C-O 120.868 0.366 . . . . 0.0 111.153 179.717 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 153' ' ' SER . . . . . 0.558 ' HB3' HG12 ' A' ' 156' ' ' ILE . 32.8 t -157.02 169.16 25.44 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-N 115.981 -0.554 . . . . 0.0 110.854 179.407 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 154' ' ' SER . . . . . . . . . . . . . 37.0 t -70.39 -35.75 73.68 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.659 179.784 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -76.71 -31.47 53.71 Favored Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.883 -0.675 . . . . 0.0 112.503 179.827 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 156' ' ' ILE . . . . . 0.558 HG12 ' HB3' ' A' ' 153' ' ' SER . 36.2 mm -61.72 -37.63 78.48 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.234 0 CA-C-O 120.651 0.262 . . . . 0.0 111.1 -179.97 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 157' ' ' LYS . . . . . . . . . . . . . 57.8 tptt -60.73 -55.49 32.59 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 116.306 -0.407 . . . . 0.0 111.871 -179.445 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 62.2 m -60.61 -45.35 94.35 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.323 -0.398 . . . . 0.0 111.885 -179.125 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 159' ' ' LEU . . . . . . . . . . . . . 8.3 tt -68.35 -32.6 72.81 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-N 116.336 -0.393 . . . . 0.0 111.499 -179.198 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 160' ' ' TYR . . . . . . . . . . . . . 79.9 t80 -73.53 -45.62 52.61 Favored 'General case' 0 C--N 1.33 -0.261 0 N-CA-C 111.858 0.318 . . . . 0.0 111.858 -179.148 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 30.0 m -62.81 -40.85 90.28 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.363 0 N-CA-C 111.772 0.286 . . . . 0.0 111.772 -179.292 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 162' ' ' ARG . . . . . . . . . . . . . 29.1 tpt180 -69.35 -45.68 68.83 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.772 0.32 . . . . 0.0 111.388 -179.632 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 163' ' ' LEU . . . . . 0.584 ' HG ' ' HB2' ' A' ' 208' ' ' PHE . 4.3 mp -69.62 -52.5 25.43 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.806 -179.294 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 164' ' ' ARG . . . . . . . . . . . . . 4.6 tmm_? -53.88 -54.01 44.6 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.393 -0.367 . . . . 0.0 111.338 -179.163 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 165' ' ' ASN . . . . . 0.523 ' N ' HD21 ' A' ' 165' ' ' ASN . 0.9 OUTLIER -56.67 -43.78 80.74 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.937 0.398 . . . . 0.0 110.441 179.715 . . . . . . . . 3 3 . 1 . 021 nuclear orig full ' A' A ' 166' ' ' LEU . . . . . 0.548 ' O ' ' HG ' ' A' ' 170' ' ' LEU . 5.6 tp -57.84 -54.53 45.92 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 115.858 -0.61 . . . . 0.0 111.067 -179.938 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 167' ' ' THR . . . . . 0.543 ' HA ' HD12 ' A' ' 170' ' ' LEU . 89.0 m -54.07 -52.25 61.52 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 115.966 -0.561 . . . . 0.0 112.21 -178.925 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 168' ' ' VAL . . . . . . . . . . . . . 94.5 t -53.92 -40.14 43.46 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.366 0 N-CA-C 112.141 0.423 . . . . 0.0 112.141 -179.172 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 169' ' ' VAL . . . . . 0.454 HG23 ' O ' ' A' ' 165' ' ' ASN . 75.2 t -65.82 -65.57 0.56 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.326 0 N-CA-C 112.346 0.498 . . . . 0.0 112.346 -178.959 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 170' ' ' LEU . . . . . 0.571 HD21 HG13 ' A' ' 203' ' ' VAL . 1.0 OUTLIER -61.66 -28.78 69.63 Favored 'General case' 0 C--N 1.33 -0.25 0 N-CA-C 112.544 0.572 . . . . 0.0 112.544 -178.428 . . . . . . . . 3 3 . 1 . 021 nuclear orig full ' A' A ' 171' ' ' TRP . . . . . 0.505 ' N ' HD11 ' A' ' 170' ' ' LEU . 4.8 m0 -74.1 -30.77 62.5 Favored 'General case' 0 C--N 1.33 -0.277 0 C-N-CA 120.538 -0.465 . . . . 0.0 110.842 179.801 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 172' ' ' ALA . . . . . 0.434 ' HA ' ' CZ ' ' A' ' 134' ' ' PHE . . . -66.51 -7.87 22.75 Favored 'General case' 0 CA--C 1.516 -0.344 0 CA-C-O 121.273 0.559 . . . . 0.0 110.026 179.163 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 173' ' ' ILE . . . . . 0.564 ' O ' HG12 ' A' ' 177' ' ' ILE . 6.6 mm -87.19 -35.81 9.02 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.624 0 CA-C-N 115.123 -0.944 . . . . 0.0 111.47 -178.966 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 174' ' ' TYR . . . . . 0.519 ' N ' ' HD2' ' A' ' 175' ' ' PRO . 55.5 m-85 -54.95 -52.09 73.86 Favored Pre-proline 0 C--N 1.329 -0.323 0 N-CA-C 112.75 0.648 . . . . 0.0 112.75 -178.91 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 175' ' ' PRO . . . . . 0.519 ' HD2' ' N ' ' A' ' 174' ' ' TYR . 28.4 Cg_endo -61.99 -39.57 49.52 Favored 'Trans proline' 0 C--N 1.348 0.539 0 C-N-CA 121.963 1.775 . . . . 0.0 113.419 -178.351 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 176' ' ' PHE . . . . . 0.509 ' CE2' ' HA ' ' A' ' 173' ' ' ILE . 0.1 OUTLIER -79.99 -38.15 32.76 Favored 'General case' 0 C--N 1.329 -0.304 0 C-N-CA 120.688 -0.405 . . . . 0.0 111.904 -178.786 . . . . . . . . 3 3 . 1 . 021 nuclear orig full ' A' A ' 177' ' ' ILE . . . . . 0.564 HG12 ' O ' ' A' ' 173' ' ' ILE . 31.7 mm -62.42 -43.58 98.36 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.477 0 N-CA-C 109.723 -0.473 . . . . 0.0 109.723 178.285 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 178' ' ' TRP . . . . . . . . . . . . . 70.3 t90 -60.87 -27.68 68.31 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 115.687 -0.688 . . . . 0.0 109.418 178.789 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 179' ' ' LEU . . . . . . . . . . . . . 1.4 tm? -74.04 -45.8 47.32 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 115.187 -0.915 . . . . 0.0 110.764 -179.963 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 180' ' ' LEU . . . . . 0.466 ' HB3' HD12 ' A' ' 187' ' ' LEU . 4.8 mt -71.33 -49.34 43.54 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.615 -0.266 . . . . 0.0 111.394 -179.372 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . -52.61 174.81 0.2 Allowed Glycine 0 C--N 1.334 0.43 0 C-N-CA 120.659 -0.781 . . . . 0.0 112.937 -179.954 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 182' ' ' PRO . . . . . 0.508 ' HA ' ' HB1' ' A' ' 186' ' ' ALA . 76.4 Cg_exo -46.93 -45.35 21.01 Favored 'Trans proline' 0 CA--C 1.536 0.602 0 C-N-CA 122.853 2.368 . . . . 0.0 113.796 -179.874 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 183' ' ' PRO . . . . . 0.452 ' HD3' ' HB2' ' A' ' 182' ' ' PRO . 79.5 Cg_exo -49.27 -23.48 6.98 Favored 'Trans proline' 0 C--N 1.355 0.908 0 C-N-CA 122.24 1.96 . . . . 0.0 113.194 -179.787 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 184' ' ' GLY . . . . . . . . . . . . . . . -108.74 -99.06 2.58 Favored Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.466 -0.873 . . . . 0.0 113.069 -179.57 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 185' ' ' VAL . . . . . . . . . . . . . 3.5 m -109.07 -5.49 10.89 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 N-CA-C 111.726 0.269 . . . . 0.0 111.726 -179.231 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 186' ' ' ALA . . . . . 0.508 ' HB1' ' HA ' ' A' ' 182' ' ' PRO . . . 55.14 87.28 0.05 OUTLIER 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.366 -0.379 . . . . 0.0 111.629 179.542 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 187' ' ' LEU . . . . . 0.466 HD12 ' HB3' ' A' ' 180' ' ' LEU . 23.5 mt -91.81 -48.97 6.5 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.332 -0.394 . . . . 0.0 110.779 179.637 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 188' ' ' LEU . . . . . . . . . . . . . 55.6 mt -106.9 -154.14 0.51 Allowed 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 115.835 -0.621 . . . . 0.0 110.642 -179.905 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 189' ' ' THR . . . . . . . . . . . . . 2.6 t -97.52 146.16 30.92 Favored Pre-proline 0 C--N 1.329 -0.315 0 CA-C-N 116.406 -0.361 . . . . 0.0 110.918 179.905 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 190' ' ' PRO . . . . . . . . . . . . . 9.6 Cg_endo -50.14 -38.46 50.58 Favored 'Trans proline' 0 C--N 1.349 0.597 0 C-N-CA 122.862 2.374 . . . . 0.0 112.769 -179.594 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 191' ' ' THR . . . . . . . . . . . . . 81.6 p -58.25 -44.34 88.27 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.911 0.386 . . . . 0.0 111.249 -179.842 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 192' ' ' VAL . . . . . . . . . . . . . 35.1 t -71.85 -43.13 69.41 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.391 0 CA-C-N 116.03 -0.532 . . . . 0.0 111.401 -179.708 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 193' ' ' ASP . . . . . . . . . . . . . 21.1 t70 -56.55 -49.01 76.07 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.403 -0.362 . . . . 0.0 111.186 -179.783 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 194' ' ' VAL . . . . . . . . . . . . . 78.2 t -64.42 -38.15 81.82 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.372 0 CA-C-N 116.262 -0.426 . . . . 0.0 111.198 -179.723 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 195' ' ' ALA . . . . . . . . . . . . . . . -54.15 -48.59 70.69 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 116.518 -0.31 . . . . 0.0 111.482 -179.802 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 196' ' ' LEU . . . . . 0.447 ' O ' ' HB3' ' A' ' 199' ' ' TYR . 94.3 mt -65.65 -39.96 91.97 Favored 'General case' 0 C--N 1.332 -0.166 0 CA-C-O 120.777 0.322 . . . . 0.0 110.814 179.884 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 197' ' ' ILE . . . . . . . . . . . . . 24.7 mm -58.73 -53.42 47.52 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.37 0 CA-C-O 121.017 0.437 . . . . 0.0 110.198 179.307 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 198' ' ' VAL . . . . . . . . . . . . . 87.6 t -55.07 -34.64 32.57 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.459 0 CA-C-N 115.582 -0.736 . . . . 0.0 109.04 178.215 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 199' ' ' TYR . . . . . 0.447 ' HB3' ' O ' ' A' ' 196' ' ' LEU . 79.7 t80 -69.73 -32.58 71.2 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 114.98 -1.009 . . . . 0.0 110.643 179.635 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 200' ' ' LEU . . . . . 0.467 HD13 HG21 ' A' ' 173' ' ' ILE . 68.2 mt -69.17 -41.04 77.74 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 115.756 -0.656 . . . . 0.0 111.697 -179.373 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 201' ' ' ASP . . . . . . . . . . . . . 9.5 m-20 -71.39 -36.31 71.34 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 121.162 0.506 . . . . 0.0 110.451 179.529 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 202' ' ' LEU . . . . . 0.406 ' O ' ' HB ' ' A' ' 206' ' ' VAL . 1.2 mm? -65.99 -33.64 76.27 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 115.462 -0.79 . . . . 0.0 111.918 -179.731 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 203' ' ' VAL . . . . . 0.571 HG13 HD21 ' A' ' 170' ' ' LEU . 9.0 p -79.07 -36.3 18.31 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 N-CA-C 111.885 0.328 . . . . 0.0 111.885 -178.241 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 204' ' ' THR . . . . . . . . . . . . . 94.1 m -64.77 -58.93 4.91 Favored 'General case' 0 C--N 1.328 -0.343 0 C-N-CA 120.082 -0.647 . . . . 0.0 111.101 179.642 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 205' ' ' LYS . . . . . 0.659 ' HD2' ' HE3' ' A' ' 15' ' ' MET . 60.1 mttp -68.35 -57.83 5.31 Favored 'General case' 0 C--N 1.33 -0.281 0 N-CA-C 112.774 0.657 . . . . 0.0 112.774 -178.028 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 206' ' ' VAL . . . . . 0.406 ' HB ' ' O ' ' A' ' 202' ' ' LEU . 19.3 t -71.16 -37.17 65.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 N-CA-C 112.02 0.378 . . . . 0.0 112.02 -178.654 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 207' ' ' GLY . . . . . 0.494 ' O ' HG13 ' A' ' 211' ' ' ILE . . . -61.75 -61.1 7.12 Favored Glycine 0 N--CA 1.452 -0.263 0 C-N-CA 120.577 -0.821 . . . . 0.0 113.72 -178.997 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 208' ' ' PHE . . . . . 0.584 ' HB2' ' HG ' ' A' ' 163' ' ' LEU . 0.1 OUTLIER -68.84 -29.95 68.38 Favored 'General case' 0 C--O 1.222 -0.362 0 CA-C-N 117.799 0.799 . . . . 0.0 110.8 -179.292 . . . . . . . . 3 3 . 1 . 021 nuclear orig full ' A' A ' 209' ' ' GLY . . . . . 0.576 ' HA2' HD13 ' A' ' 40' ' ' LEU . . . -62.07 -35.66 91.78 Favored Glycine 0 N--CA 1.45 -0.368 0 CA-C-N 116.189 -0.46 . . . . 0.0 112.418 179.4 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 210' ' ' PHE . . . . . . . . . . . . . 3.3 m-85 -72.68 -47.38 47.79 Favored 'General case' 0 CA--C 1.513 -0.461 0 N-CA-C 108.513 -0.921 . . . . 0.0 108.513 178.81 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 211' ' ' ILE . . . . . 0.494 HG13 ' O ' ' A' ' 207' ' ' GLY . 3.7 mt -62.8 -27.32 42.8 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.58 0 N-CA-C 107.192 -1.41 . . . . 0.0 107.192 176.468 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 212' ' ' ALA . . . . . 0.505 ' HB3' ' O ' ' A' ' 209' ' ' GLY . . . -67.43 -36.55 81.44 Favored 'General case' 0 N--CA 1.45 -0.468 0 CA-C-N 114.308 -1.314 . . . . 0.0 110.171 179.56 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 213' ' ' LEU . . . . . 0.424 ' HG ' ' O ' ' A' ' 209' ' ' GLY . 81.3 mt -70.17 -53.38 17.45 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 115.012 -0.994 . . . . 0.0 111.594 -179.649 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 214' ' ' ASP . . . . . . . . . . . . . 16.5 m-20 -57.44 -51.54 69.02 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.827 0.346 . . . . 0.0 111.227 -179.592 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 215' ' ' ALA . . . . . 0.436 ' O ' ' HG ' ' A' ' 219' ' ' LEU . . . -56.63 -57.25 13.19 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.226 -179.762 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 216' ' ' ALA . . . . . . . . . . . . . . . -58.4 -33.81 70.06 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.275 -0.421 . . . . 0.0 111.387 -179.741 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 217' ' ' ALA . . . . . . . . . . . . . . . -61.04 -34.68 75.25 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 121.029 0.442 . . . . 0.0 110.137 179.635 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 218' ' ' THR . . . . . . . . . . . . . 91.5 m -80.2 -34.24 37.54 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 115.716 -0.675 . . . . 0.0 110.821 179.48 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 219' ' ' LEU . . . . . 0.436 ' HG ' ' O ' ' A' ' 215' ' ' ALA . 83.6 mt -61.03 -39.01 88.16 Favored 'General case' 0 C--N 1.331 -0.202 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.721 179.845 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 220' ' ' ARG . . . . . . . . . . . . . 29.8 ptt180 -82.91 -31.12 27.96 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 116.066 -0.516 . . . . 0.0 110.639 179.875 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 221' ' ' ALA . . . . . . . . . . . . . . . -60.41 -33.06 71.95 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 116.062 -0.517 . . . . 0.0 111.279 179.936 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 222' ' ' GLU . . . . . . . . . . . . . 12.4 pt-20 -92.47 -18.49 23.14 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.057 179.955 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 223' ' ' HIS . . . . . . . . . . . . . 63.2 m-70 60.59 -179.04 0.1 Allowed 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 115.462 -0.79 . . . . 0.0 111.234 179.972 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 224' ' ' GLY . . . . . . . . . . . . . . . -176.86 -32.96 0.05 OUTLIER Glycine 0 N--CA 1.452 -0.28 0 C-N-CA 120.941 -0.647 . . . . 0.0 112.196 179.993 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 225' ' ' GLU . . . . . . . . . . . . . 12.9 pt-20 -87.82 144.67 26.48 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.783 0.325 . . . . 0.0 110.592 179.771 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 226' ' ' SER . . . . . . . . . . . . . 60.9 m -109.59 -178.71 3.62 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.287 -0.415 . . . . 0.0 111.025 -179.884 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 227' ' ' LEU . . . . . . . . . . . . . 50.3 mt -70.34 -56.44 6.71 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 115.932 -0.577 . . . . 0.0 110.898 -179.895 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 228' ' ' ALA . . . . . . . . . . . . . . . 51.92 -165.65 0.06 Allowed 'General case' 0 C--N 1.331 -0.213 0 CA-C-N 115.97 -0.559 . . . . 0.0 111.608 -179.981 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 229' ' ' GLY . . . . . . . . . . . . . . . -169.31 -54.14 0.03 OUTLIER Glycine 0 N--CA 1.452 -0.284 0 C-N-CA 120.813 -0.708 . . . . 0.0 112.386 179.994 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 230' ' ' VAL . . . . . . . . . . . . . 59.2 t -110.35 132.9 57.43 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.25 0 CA-C-O 120.828 0.347 . . . . 0.0 111.003 179.881 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 231' ' ' ASP . . . . . . . . . . . . . 18.6 t70 -100.29 120.82 40.52 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.884 -179.942 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 232' ' ' THR . . . . . . . . . . . . . 5.6 t -133.74 3.53 3.53 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.13 -0.486 . . . . 0.0 111.137 179.952 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 233' ' ' ASP . . . . . . . . . . . . . 10.9 m-20 -75.42 -178.08 3.87 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.117 -0.492 . . . . 0.0 111.007 -179.933 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 234' ' ' THR . . . . . . . . . . . . . 72.6 m -116.16 93.49 39.12 Favored Pre-proline 0 C--N 1.33 -0.269 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.029 -179.92 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 235' ' ' PRO . . . . . . . . . . . . . 38.1 Cg_endo -67.22 -54.1 0.42 Allowed 'Trans proline' 0 C--N 1.348 0.531 0 C-N-CA 122.413 2.076 . . . . 0.0 112.267 179.824 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 236' ' ' ALA . . . . . . . . . . . . . . . -122.06 131.13 53.82 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.928 179.917 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 237' ' ' VAL . . . . . . . . . . . . . 27.5 m -60.89 162.86 1.21 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.242 0 CA-C-N 116.082 -0.508 . . . . 0.0 111.198 -179.941 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 238' ' ' ALA . . . . . . . . . . . . . . . -126.99 -64.03 1.03 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.048 -0.524 . . . . 0.0 111.083 -179.985 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 239' ' ' ASP . . . . . . . . . . . . . 7.8 m-20 -95.01 118.97 32.73 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.11 -0.495 . . . . 0.0 110.94 -179.929 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 240' ' ' LEU . . . . . . . . . . . . . 62.0 tp -106.73 -46.32 4.0 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.903 179.914 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 241' ' ' GLU . . . . . . . . . . . . . 1.3 mp0 -66.82 -10.23 45.73 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 116.304 -0.407 . . . . 0.0 110.898 179.941 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 242' ' ' HIS . . . . . . . . . . . . . 18.1 t60 -131.43 102.23 5.86 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.502 179.964 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 243' ' ' HIS . . . . . . . . . . . . . 50.7 t-80 -88.59 -67.2 0.85 Allowed 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.116 -179.83 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 244' ' ' HIS . . . . . . . . . . . . . 66.5 m-70 -58.72 96.63 0.03 OUTLIER 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.947 -179.857 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 245' ' ' HIS . . . . . . . . . . . . . 2.6 p-80 -122.88 -168.83 1.82 Allowed 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.942 -179.966 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 246' ' ' HIS . . . . . . . . . . . . . 57.3 t-80 -160.53 -51.04 0.05 OUTLIER 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.729 179.836 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 247' ' ' HIS . . . . . . . . . . . . . 34.1 t-80 . . . . . 0 C--O 1.249 1.072 0 CA-C-O 118.369 -0.824 . . . . 0.0 110.839 179.909 . . . . . . . . 0 0 . 1 . 021 nuclear orig full ' A' A ' 301' ' ' RET . . . . . 0.527 ' H22' ' HA3' ' A' ' 112' ' ' GLY . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 1' ' ' MET . . . . . 0.431 ' N ' HG21 ' A' ' 5' ' ' THR . 49.5 mtm . . . . . 0 N--CA 1.486 1.329 0 CA-C-O 120.831 0.348 . . . . 0.0 110.885 . . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 60.4 t -142.85 -50.43 0.19 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.222 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.921 -179.906 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -111.53 -16.38 9.49 Favored Glycine 0 N--CA 1.452 -0.261 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.719 -179.798 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -73.74 -40.67 63.35 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.858 0.361 . . . . 0.0 110.772 -179.929 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 5' ' ' THR . . . . . 0.431 HG21 ' N ' ' A' ' 1' ' ' MET . 76.4 p -60.52 -29.49 69.15 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.329 -179.842 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 13.6 p -57.38 -36.13 70.87 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.502 -179.715 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 7' ' ' LEU . . . . . . . . . . . . . 4.1 mm? -57.56 -53.16 61.29 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-N 116.328 -0.396 . . . . 0.0 111.165 -179.839 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 8' ' ' PHE . . . . . 0.457 ' HB2' ' HB2' ' A' ' 55' ' ' ALA . 78.9 m-85 -60.91 -33.48 73.2 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 120.866 0.365 . . . . 0.0 110.752 179.901 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 9' ' ' TRP . . . . . . . . . . . . . 18.9 m95 -63.78 -45.34 90.16 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-O 121.245 0.545 . . . . 0.0 109.678 179.82 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 72.3 mt -63.45 -34.34 77.55 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-N 115.383 -0.826 . . . . 0.0 110.12 179.302 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -66.29 -37.02 92.5 Favored Glycine 0 N--CA 1.449 -0.46 0 C-N-CA 120.77 -0.728 . . . . 0.0 111.596 179.179 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -66.74 -33.18 75.06 Favored 'General case' 0 C--N 1.332 -0.17 0 CA-C-O 120.961 0.41 . . . . 0.0 110.303 179.337 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 45.0 mm -65.19 -50.79 71.99 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.212 0 CA-C-N 115.904 -0.589 . . . . 0.0 110.235 179.099 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -59.35 -31.42 69.88 Favored Glycine 0 N--CA 1.449 -0.466 0 C-N-CA 120.773 -0.727 . . . . 0.0 111.836 179.394 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 15' ' ' MET . . . . . 0.647 ' HE1' ' HD2' ' A' ' 205' ' ' LYS . 22.0 mmt -70.87 -45.61 64.11 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-O 120.686 0.279 . . . . 0.0 110.583 179.586 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 21.8 tp -54.66 -38.31 66.78 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.668 179.59 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 64.2 t -67.06 -47.54 81.76 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.191 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.03 179.927 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -64.65 -49.45 64.22 Favored Glycine 0 C--N 1.331 0.281 0 C-N-CA 120.684 -0.77 . . . . 0.0 112.17 179.679 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 22.2 m -49.56 -46.22 48.55 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-O 120.72 0.295 . . . . 0.0 111.12 -179.807 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 85.6 mt -72.22 -40.01 68.11 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-N 116.359 -0.382 . . . . 0.0 111.403 179.646 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -61.28 -30.17 70.31 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.454 -0.339 . . . . 0.0 111.817 -179.484 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 22' ' ' PHE . . . . . 0.515 ' HB2' HG21 ' A' ' 41' ' ' VAL . 13.7 m-85 -90.74 -40.43 11.84 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.735 0.302 . . . . 0.0 111.149 -179.622 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -62.75 -50.71 69.97 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.343 -179.732 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 24' ' ' TRP . . . . . . . . . . . . . 2.2 t-105 -60.96 -41.7 96.84 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 115.968 -0.56 . . . . 0.0 111.042 -179.945 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -77.72 -14.29 59.65 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.877 0.37 . . . . 0.0 110.946 179.752 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -73.53 -47.95 19.79 Favored Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.923 -0.656 . . . . 0.0 112.606 179.892 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 15.8 ptm180 -65.42 -29.95 70.7 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-O 120.889 0.376 . . . . 0.0 110.894 179.991 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 26.4 t70 -78.28 -12.52 60.01 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.059 -0.518 . . . . 0.0 110.944 179.931 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -69.8 -174.68 0.78 Allowed 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.125 179.879 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -101.25 -155.14 26.74 Favored Glycine 0 N--CA 1.452 -0.274 0 C-N-CA 120.797 -0.716 . . . . 0.0 112.451 179.931 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 78.0 p -97.18 127.42 43.13 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.808 0.337 . . . . 0.0 110.884 -179.995 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 110.96 -50.3 0.78 Allowed Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.826 -0.702 . . . . 0.0 112.593 179.969 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 12.7 mm-40 -69.34 -20.88 63.86 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-O 120.86 0.362 . . . . 0.0 110.917 179.95 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 34' ' ' ARG . . . . . . . . . . . . . 41.5 ttm180 -51.02 -29.01 11.38 Favored 'General case' 0 C--N 1.332 -0.185 0 CA-C-N 115.958 -0.564 . . . . 0.0 111.539 -179.772 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 86.4 mtm180 -61.99 -45.89 91.65 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.899 0.38 . . . . 0.0 110.917 -179.969 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 88.0 m-85 -67.55 -29.26 68.59 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.044 -0.526 . . . . 0.0 111.224 179.961 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 37' ' ' TYR . . . . . . . . . . . . . 51.7 m-85 -74.6 -54.11 8.08 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.255 -179.577 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 9.4 p -56.99 -36.6 51.18 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-O 120.949 0.405 . . . . 0.0 110.474 179.794 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 48.3 m -65.66 -51.37 60.04 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 115.901 -0.59 . . . . 0.0 110.608 179.493 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 16.6 tp -57.05 -47.24 81.43 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 115.832 -0.622 . . . . 0.0 110.624 179.702 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . 0.515 HG21 ' HB2' ' A' ' 22' ' ' PHE . 64.8 t -60.0 -34.74 57.45 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.41 0 CA-C-N 115.836 -0.62 . . . . 0.0 110.11 179.183 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -60.31 -36.2 90.3 Favored Glycine 0 N--CA 1.449 -0.448 0 C-N-CA 120.682 -0.77 . . . . 0.0 111.817 179.494 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 43' ' ' ILE . . . . . 0.542 HG22 ' HE3' ' A' ' 205' ' ' LYS . 0.8 OUTLIER -67.31 -57.27 10.38 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.139 0 CA-C-O 120.65 0.262 . . . . 0.0 110.817 179.44 . . . . . . . . 3 3 . 1 . 022 nuclear orig full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 55.6 m -57.11 -25.0 58.07 Favored 'General case' 0 C--O 1.231 0.113 0 CA-C-N 116.42 -0.354 . . . . 0.0 111.188 -179.945 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -77.33 -54.71 4.59 Favored Glycine 0 CA--C 1.518 0.267 0 C-N-CA 120.793 -0.718 . . . . 0.0 113.162 -179.504 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 25.8 pt -58.06 -40.89 78.92 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.185 0 CA-C-O 120.93 0.395 . . . . 0.0 111.01 -179.647 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 47' ' ' ALA . . . . . 0.645 ' HB2' ' HE2' ' A' ' 205' ' ' LYS . . . -67.92 -38.62 83.13 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.004 179.205 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 48' ' ' ALA . . . . . 0.415 ' HB3' ' HB3' ' A' ' 15' ' ' MET . . . -55.41 -44.56 76.29 Favored 'General case' 0 C--O 1.232 0.152 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.733 -179.708 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 30.5 m -72.56 -33.82 46.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.544 -0.298 . . . . 0.0 111.141 -179.562 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -63.37 -36.62 84.31 Favored 'General case' 0 C--N 1.331 -0.206 0 CA-C-O 120.989 0.424 . . . . 0.0 110.748 179.473 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 28.5 m-85 -73.0 -36.25 67.0 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 115.915 -0.584 . . . . 0.0 110.442 179.794 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -65.47 -42.35 92.35 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 115.979 -0.555 . . . . 0.0 110.957 179.54 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 53' ' ' VAL . . . . . 0.458 HG22 ' N ' ' A' ' 54' ' ' MET . 25.4 m -71.48 -47.33 59.17 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.188 0 CA-C-N 116.451 -0.341 . . . . 0.0 110.83 179.821 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 54' ' ' MET . . . . . 0.474 ' HG2' ' HG2' ' A' ' 71' ' ' PRO . 72.6 mtm -62.14 -31.97 72.51 Favored 'General case' 0 C--N 1.332 -0.19 0 CA-C-O 121.058 0.456 . . . . 0.0 110.007 179.439 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 55' ' ' ALA . . . . . 0.457 ' HB2' ' HB2' ' A' ' 8' ' ' PHE . . . -67.31 -32.51 73.53 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 115.701 -0.681 . . . . 0.0 111.04 179.306 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 76.3 mt -79.77 -4.4 51.82 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.28 -179.871 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 90.82 -16.09 59.12 Favored Glycine 0 CA--C 1.518 0.234 0 C-N-CA 120.539 -0.839 . . . . 0.0 113.288 179.54 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 58' ' ' VAL . . . . . 0.418 HG13 ' O ' ' A' ' 53' ' ' VAL . 13.0 p -67.4 144.37 14.6 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 117.108 0.454 . . . . 0.0 110.819 -179.884 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 94.05 -12.47 69.12 Favored Glycine 0 N--CA 1.45 -0.412 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.053 -179.461 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 60' ' ' TRP . . . . . . . . . . . . . 13.3 m0 -80.02 111.15 16.08 Favored 'General case' 0 C--N 1.331 -0.213 0 N-CA-C 110.329 -0.249 . . . . 0.0 110.329 179.703 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 6.9 p -111.29 129.56 23.93 Favored Pre-proline 0 C--N 1.329 -0.305 0 CA-C-N 116.61 -0.268 . . . . 0.0 111.201 -179.866 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 60.1 Cg_endo -71.81 152.15 57.96 Favored 'Trans proline' 0 C--N 1.35 0.618 0 C-N-CA 122.373 2.048 . . . . 0.0 112.292 179.96 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 93.7 t -143.38 94.37 0.51 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 115.929 -0.578 . . . . 0.0 110.761 -179.74 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . 58.19 -87.04 0.02 OUTLIER 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.11 -179.813 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 12.1 mm-40 -120.84 -23.19 6.0 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.288 -0.415 . . . . 0.0 110.591 179.773 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 66' ' ' ARG . . . . . . . . . . . . . 20.3 mmm180 -98.69 165.95 11.56 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.013 -0.539 . . . . 0.0 110.449 179.994 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 88.1 m -128.1 123.36 34.31 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-O 120.898 0.38 . . . . 0.0 111.173 179.947 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 68' ' ' VAL . . . . . 0.407 HG11 ' HB1' ' A' ' 116' ' ' ALA . 27.3 m -106.73 146.68 12.89 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.054 -0.521 . . . . 0.0 110.702 179.834 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 69' ' ' PHE . . . . . . . . . . . . . 21.7 m-85 -106.59 112.92 26.13 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 116.132 -0.485 . . . . 0.0 109.989 -179.511 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 70' ' ' VAL . . . . . 0.566 ' N ' ' HD2' ' A' ' 71' ' ' PRO . 15.0 t -66.31 -47.9 58.82 Favored Pre-proline 0 C--N 1.322 -0.61 0 CA-C-N 116.24 -0.436 . . . . 0.0 112.076 -179.293 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 71' ' ' PRO . . . . . 0.566 ' HD2' ' N ' ' A' ' 70' ' ' VAL . 40.5 Cg_endo -66.16 -18.07 55.67 Favored 'Trans proline' 0 C--N 1.351 0.697 0 C-N-CA 122.115 1.877 . . . . 0.0 113.274 -179.327 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 72.3 ttt180 -72.85 -55.49 6.58 Favored 'General case' 0 C--O 1.235 0.296 0 CA-C-O 120.664 0.268 . . . . 0.0 111.712 -179.434 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 73' ' ' TYR . . . . . . . . . . . . . 71.5 m-85 -70.52 -31.58 68.72 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.524 -0.307 . . . . 0.0 110.769 -179.321 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 74' ' ' ILE . . . . . 0.406 ' HA ' HD12 ' A' ' 77' ' ' ILE . 0.4 OUTLIER -69.97 -39.56 77.59 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.229 0 N-CA-C 109.793 -0.447 . . . . 0.0 109.793 179.137 . . . . . . . . 3 3 . 1 . 022 nuclear orig full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 18.8 t70 -58.55 -37.6 76.07 Favored 'General case' 0 CA--C 1.519 -0.232 0 N-CA-C 109.25 -0.648 . . . . 0.0 109.25 178.713 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 76' ' ' TRP . . . . . 0.461 ' HB3' ' SD ' ' A' ' 109' ' ' MET . 43.9 m0 -66.97 -34.99 78.97 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 115.742 -0.663 . . . . 0.0 110.194 178.926 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 77' ' ' ILE . . . . . 0.406 HD12 ' HA ' ' A' ' 74' ' ' ILE . 97.0 mt -65.43 -28.65 44.93 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 115.948 -0.569 . . . . 0.0 110.688 179.497 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 38.3 mt -91.86 -25.01 19.16 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.223 -0.444 . . . . 0.0 112.12 -179.955 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 79' ' ' THR . . . . . 0.46 ' HG1' ' H ' ' A' ' 80' ' ' THR . 67.2 p -92.69 -52.31 4.69 Favored 'General case' 0 N--CA 1.464 0.261 0 N-CA-C 113.671 0.989 . . . . 0.0 113.671 -177.74 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 80' ' ' THR . . . . . 0.46 ' H ' ' HG1' ' A' ' 79' ' ' THR . 33.4 m -49.33 -54.55 28.8 Favored Pre-proline 0 C--N 1.329 -0.314 0 N-CA-C 113.159 0.8 . . . . 0.0 113.159 -178.163 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 81' ' ' PRO . . . . . 0.427 ' HD2' ' N ' ' A' ' 80' ' ' THR . 36.6 Cg_endo -63.13 -19.11 68.02 Favored 'Trans proline' 0 C--N 1.351 0.674 0 C-N-CA 121.463 1.442 . . . . 0.0 111.376 -179.513 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 82' ' ' LEU . . . . . . . . . . . . . 14.1 tp -77.05 -33.54 57.24 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 115.643 -0.708 . . . . 0.0 110.256 179.727 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 83' ' ' ILE . . . . . 0.407 HD11 HD12 ' A' ' 43' ' ' ILE . 32.8 mm -68.89 -52.62 32.83 Favored 'Isoleucine or valine' 0 C--O 1.232 0.174 0 CA-C-N 115.98 -0.555 . . . . 0.0 109.867 179.05 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 27.9 m -61.21 -30.39 47.74 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.209 0 N-CA-C 109.513 -0.551 . . . . 0.0 109.513 178.797 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 85' ' ' TYR . . . . . . . . . . . . . 82.7 t80 -65.87 -32.91 74.69 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 115.48 -0.782 . . . . 0.0 109.347 178.741 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 86' ' ' PHE . . . . . . . . . . . . . 10.8 t80 -63.91 -51.74 63.08 Favored 'General case' 0 N--CA 1.456 -0.133 0 CA-C-N 115.681 -0.691 . . . . 0.0 109.956 179.219 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 8.8 mp -61.32 -32.66 72.53 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 115.701 -0.681 . . . . 0.0 110.457 179.67 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -68.71 -27.96 73.47 Favored Glycine 0 N--CA 1.45 -0.407 0 C-N-CA 120.731 -0.747 . . . . 0.0 111.65 179.368 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 47.5 mt -72.13 -41.8 66.77 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.87 0.367 . . . . 0.0 110.646 179.539 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 57.0 mt -65.16 -45.8 83.47 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 115.951 -0.568 . . . . 0.0 111.059 179.942 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . 0.465 ' HB3' ' HB3' ' A' ' 148' ' ' SER . . . -71.55 -55.2 8.28 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.318 -0.401 . . . . 0.0 111.167 -179.696 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 99.5 67.62 0.86 Allowed Glycine 0 CA--C 1.519 0.283 0 C-N-CA 120.812 -0.709 . . . . 0.0 112.684 179.893 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 9.2 mp -75.34 -172.74 1.85 Allowed 'General case' 0 C--N 1.33 -0.245 0 CA-C-O 120.74 0.305 . . . . 0.0 110.856 179.911 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 94' ' ' ASP . . . . . . . . . . . . . 6.7 m-20 -96.91 -173.98 2.86 Favored 'General case' 0 C--N 1.332 -0.174 0 CA-C-O 121.073 0.464 . . . . 0.0 111.266 -179.823 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 50.4 m -67.64 -51.58 48.34 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 115.78 -0.646 . . . . 0.0 111.308 -179.793 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 79.8 ttt180 -74.22 -34.86 63.82 Favored 'General case' 0 C--N 1.331 -0.197 0 CA-C-O 120.964 0.412 . . . . 0.0 110.575 -179.579 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -56.88 -45.15 82.72 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 115.687 -0.688 . . . . 0.0 111.241 -179.812 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 98' ' ' PHE . . . . . 0.418 ' O ' HG12 ' A' ' 102' ' ' ILE . 4.8 m-85 -62.17 -42.92 99.73 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.834 0.35 . . . . 0.0 110.71 179.487 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -62.6 -28.8 72.01 Favored Glycine 0 N--CA 1.45 -0.401 0 C-N-CA 120.8 -0.714 . . . . 0.0 112.682 -179.865 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 96.1 mt -72.46 -41.91 64.32 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.234 0 CA-C-O 120.873 0.368 . . . . 0.0 111.198 -179.927 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 53.8 t -67.45 -43.64 87.34 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.32 -179.932 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 102' ' ' ILE . . . . . 0.418 HG12 ' O ' ' A' ' 98' ' ' PHE . 43.0 mm -68.07 -49.59 66.49 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.63 -179.495 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 14.9 t -57.71 -33.59 68.57 Favored 'General case' 0 C--O 1.233 0.186 0 CA-C-O 120.762 0.315 . . . . 0.0 111.173 -179.701 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 41.2 tp -65.75 -48.16 72.84 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.3 -0.409 . . . . 0.0 110.545 179.601 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 105' ' ' ASN . . . . . 0.59 ' N ' HD21 ' A' ' 105' ' ' ASN . 0.8 OUTLIER -61.16 -26.08 67.45 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.766 179.758 . . . . . . . . 3 3 . 1 . 022 nuclear orig full ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 91.6 m -69.07 -57.6 5.2 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-N 116.378 -0.374 . . . . 0.0 111.425 -179.934 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 8.3 p -58.58 -37.32 64.3 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.237 0 CA-C-N 116.531 -0.304 . . . . 0.0 110.942 -179.816 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 73.9 t -66.46 -51.97 51.76 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.898 179.532 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 109' ' ' MET . . . . . 0.461 ' SD ' ' HB3' ' A' ' 76' ' ' TRP . 9.8 tpp -61.36 -32.61 72.52 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.018 -0.537 . . . . 0.0 110.387 179.753 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 10.0 mt -72.31 -30.29 64.64 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 115.848 -0.615 . . . . 0.0 109.939 179.38 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -60.06 -45.63 92.22 Favored 'General case' 0 CA--C 1.519 -0.234 0 N-CA-C 109.249 -0.649 . . . . 0.0 109.249 178.248 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 112' ' ' GLY . . . . . 0.437 ' HA3' ' H22' ' A' ' 301' ' ' RET . . . -70.26 -41.74 67.98 Favored Glycine 0 N--CA 1.449 -0.441 0 CA-C-N 115.501 -0.772 . . . . 0.0 111.19 178.392 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 113' ' ' PHE . . . . . . . . . . . . . 2.0 t80 -48.81 -65.95 0.48 Allowed 'General case' 0 CA--C 1.52 -0.186 0 N-CA-C 109.353 -0.61 . . . . 0.0 109.353 178.82 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 114' ' ' ALA . . . . . 0.484 ' HB1' HD22 ' A' ' 126' ' ' LEU . . . -64.41 -19.23 65.38 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 115.467 -0.788 . . . . 0.0 110.406 178.699 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -53.1 -51.1 48.59 Favored Glycine 0 C--N 1.335 0.488 0 C-N-CA 120.892 -0.671 . . . . 0.0 111.86 179.495 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 116' ' ' ALA . . . . . 0.407 ' HB1' HG11 ' A' ' 68' ' ' VAL . . . -78.02 -18.44 55.87 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-O 120.87 0.367 . . . . 0.0 110.948 179.279 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 117' ' ' MET . . . . . 0.464 ' HB2' ' HA ' ' A' ' 114' ' ' ALA . 22.3 mmt -81.9 18.56 1.28 Allowed 'General case' 0 C--N 1.331 -0.218 0 CA-C-N 116.015 -0.539 . . . . 0.0 111.673 -179.441 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 118' ' ' VAL . . . . . 0.432 HG11 ' N ' ' A' ' 123' ' ' ARG . 32.6 m -89.85 138.71 27.72 Favored Pre-proline 0 C--N 1.327 -0.371 0 CA-C-N 116.73 -0.213 . . . . 0.0 111.375 -179.95 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 119' ' ' PRO . . . . . . . . . . . . . 70.3 Cg_endo -89.98 -3.76 5.4 Favored 'Trans proline' 0 N--CA 1.456 -0.692 0 C-N-CA 122.73 2.286 . . . . 0.0 112.235 179.61 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -138.2 -110.83 0.97 Allowed Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.908 -179.765 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 46.8 pt -126.99 14.93 3.6 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.214 0 CA-C-O 120.738 0.304 . . . . 0.0 111.585 -179.384 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 25.6 mt-10 -61.74 -18.64 60.53 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-N 116.353 -0.385 . . . . 0.0 111.041 -179.8 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 123' ' ' ARG . . . . . 0.449 ' HB2' ' HH2' ' A' ' 178' ' ' TRP . 7.6 ptt180 -52.6 -30.12 29.5 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 115.976 -0.557 . . . . 0.0 112.085 -179.66 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 124' ' ' TYR . . . . . . . . . . . . . 50.9 m-85 -69.16 -32.44 71.79 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.794 0.331 . . . . 0.0 111.364 -179.668 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 125' ' ' ALA . . . . . . . . . . . . . . . -72.59 -56.14 5.81 Favored 'General case' 0 C--O 1.236 0.346 0 CA-C-N 116.304 -0.407 . . . . 0.0 111.296 -179.504 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 126' ' ' LEU . . . . . 0.484 HD22 ' HB1' ' A' ' 114' ' ' ALA . 1.2 mt -51.49 -45.35 62.79 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 115.839 -0.619 . . . . 0.0 110.922 -179.821 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 127' ' ' PHE . . . . . . . . . . . . . 3.6 t80 -67.65 -38.64 84.11 Favored 'General case' 0 C--N 1.33 -0.269 0 C-N-CA 120.874 -0.33 . . . . 0.0 110.394 179.581 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 128' ' ' GLY . . . . . . . . . . . . . . . -46.48 -43.1 14.56 Favored Glycine 0 C--N 1.332 0.337 0 C-N-CA 120.21 -0.995 . . . . 0.0 110.991 179.219 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 129' ' ' MET . . . . . 0.435 ' HE2' ' N ' ' A' ' 130' ' ' GLY . 0.4 OUTLIER -71.59 -41.32 69.13 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 115.383 -0.408 . . . . 0.0 110.18 179.04 . . . . . . . . 3 3 . 1 . 022 nuclear orig full ' A' A ' 130' ' ' GLY . . . . . 0.435 ' N ' ' HE2' ' A' ' 129' ' ' MET . . . -63.61 -28.98 73.34 Favored Glycine 0 C--N 1.332 0.321 0 C-N-CA 121.066 -0.588 . . . . 0.0 113.016 -179.665 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -74.69 -53.64 8.89 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.729 0.265 . . . . 0.0 110.529 -179.901 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 61.4 t -59.32 -40.47 81.52 Favored 'Isoleucine or valine' 0 C--O 1.234 0.289 0 N-CA-C 109.205 -0.665 . . . . 0.0 109.205 178.832 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -67.51 -34.08 76.38 Favored 'General case' 0 N--CA 1.452 -0.353 0 CA-C-N 115.201 -0.908 . . . . 0.0 110.48 179.175 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 134' ' ' PHE . . . . . 0.424 ' CZ ' ' HA ' ' A' ' 172' ' ' ALA . 82.2 t80 -56.04 -52.59 63.7 Favored 'General case' 0 N--CA 1.451 -0.417 0 CA-C-N 116.072 -0.513 . . . . 0.0 109.875 179.328 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 135' ' ' ILE . . . . . 0.478 ' HA ' HG23 ' A' ' 138' ' ' VAL . 53.3 mt -58.14 -34.31 49.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 115.798 -0.637 . . . . 0.0 109.855 179.094 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . -63.73 -36.62 93.56 Favored Glycine 0 C--N 1.334 0.422 0 C-N-CA 120.312 -0.947 . . . . 0.0 111.356 178.75 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 137' ' ' LEU . . . . . 0.4 HD13 HD22 ' A' ' 105' ' ' ASN . 35.1 tp -71.24 -53.56 13.95 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.7 0.286 . . . . 0.0 110.453 179.448 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 138' ' ' VAL . . . . . 0.478 HG23 ' HA ' ' A' ' 135' ' ' ILE . 5.3 m -55.98 -31.94 32.02 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.218 0 CA-C-O 121.164 0.507 . . . . 0.0 109.656 179.458 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 139' ' ' TYR . . . . . . . . . . . . . 38.6 t80 -60.82 -47.99 83.83 Favored 'General case' 0 N--CA 1.454 -0.228 0 CA-C-N 115.528 -0.76 . . . . 0.0 109.909 178.511 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 15.5 m-85 -56.5 -37.98 71.13 Favored 'General case' 0 C--N 1.334 -0.093 0 CA-C-N 116.056 -0.52 . . . . 0.0 110.81 179.22 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 141' ' ' LEU . . . . . . . . . . . . . 70.5 mt -64.28 -34.95 79.29 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.057 -0.519 . . . . 0.0 110.708 -179.853 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 13.8 t -94.29 -7.57 10.03 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.79 179.828 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . -73.89 -131.8 0.21 Allowed Glycine 0 CA--C 1.521 0.43 0 C-N-CA 120.891 -0.671 . . . . 0.0 112.673 -179.765 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 144' ' ' PRO . . . . . . . . . . . . . 28.1 Cg_endo -62.04 -23.7 75.95 Favored 'Trans proline' 0 C--N 1.347 0.478 0 C-N-CA 122.528 2.152 . . . . 0.0 112.673 -179.859 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 145' ' ' MET . . . . . . . . . . . . . 52.4 mtt -53.99 -32.02 52.78 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-O 120.661 0.267 . . . . 0.0 111.436 -179.815 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 146' ' ' THR . . . . . . . . . . . . . 73.2 p -72.06 -46.0 58.59 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.426 -0.352 . . . . 0.0 111.479 -179.693 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 42.4 mt-10 -72.7 -28.11 62.48 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.471 -179.64 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 148' ' ' SER . . . . . 0.465 ' HB3' ' HB3' ' A' ' 91' ' ' ALA . 32.6 t -70.32 -43.87 69.42 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-O 120.754 0.311 . . . . 0.0 111.105 -179.622 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 149' ' ' ALA . . . . . . . . . . . . . . . -75.11 -40.12 60.13 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.147 -0.479 . . . . 0.0 111.198 -179.838 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 150' ' ' SER . . . . . . . . . . . . . 69.0 m -63.61 -22.91 67.15 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.096 -179.909 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 151' ' ' GLN . . . . . . . . . . . . . 46.2 mt-30 -105.53 6.82 32.6 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.263 -0.426 . . . . 0.0 111.435 -179.751 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 31.9 tpt180 -84.11 -51.7 6.87 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.88 0.372 . . . . 0.0 110.542 179.646 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 153' ' ' SER . . . . . 0.545 ' HB3' HG12 ' A' ' 156' ' ' ILE . 23.1 t -157.67 169.98 23.43 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-N 115.902 -0.59 . . . . 0.0 110.449 179.091 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 154' ' ' SER . . . . . . . . . . . . . 82.7 p -71.01 -39.72 72.22 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.788 0.328 . . . . 0.0 110.5 179.555 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -77.09 -36.6 34.94 Favored Glycine 0 N--CA 1.452 -0.241 0 C-N-CA 120.864 -0.684 . . . . 0.0 112.595 179.752 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 156' ' ' ILE . . . . . 0.545 HG12 ' HB3' ' A' ' 153' ' ' SER . 28.4 mm -51.64 -38.18 21.17 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.215 0 CA-C-O 120.623 0.249 . . . . 0.0 111.438 -179.859 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 157' ' ' LYS . . . . . . . . . . . . . 63.6 tttp -60.03 -48.78 80.3 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.283 -0.417 . . . . 0.0 111.678 -179.795 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 41.3 t -63.78 -47.48 80.75 Favored 'General case' 0 C--N 1.328 -0.351 0 N-CA-C 111.96 0.355 . . . . 0.0 111.96 -179.095 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 159' ' ' LEU . . . . . 0.401 ' O ' HD22 ' A' ' 159' ' ' LEU . 1.6 tt -67.71 -31.81 72.02 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 116.494 -0.321 . . . . 0.0 111.28 -179.326 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 160' ' ' TYR . . . . . . . . . . . . . 79.9 t80 -74.05 -44.42 54.33 Favored 'General case' 0 C--N 1.329 -0.315 0 N-CA-C 111.946 0.35 . . . . 0.0 111.946 -179.218 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 161' ' ' VAL . . . . . 0.402 HG23 ' N ' ' A' ' 162' ' ' ARG . 30.4 m -62.01 -41.18 90.03 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 N-CA-C 111.691 0.256 . . . . 0.0 111.691 -179.205 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 162' ' ' ARG . . . . . 0.402 ' N ' HG23 ' A' ' 161' ' ' VAL . 94.7 mtt180 -67.87 -41.29 83.09 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-O 120.778 0.323 . . . . 0.0 111.312 -179.85 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 163' ' ' LEU . . . . . 0.594 ' HG ' ' HB2' ' A' ' 208' ' ' PHE . 7.1 mp -71.96 -54.93 8.46 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.302 -0.408 . . . . 0.0 112.064 -179.208 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 164' ' ' ARG . . . . . . . . . . . . . 4.8 tmm_? -53.97 -53.18 56.4 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.273 -0.422 . . . . 0.0 111.568 -179.408 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 165' ' ' ASN . . . . . 0.528 ' N ' HD21 ' A' ' 165' ' ' ASN . 0.9 OUTLIER -57.05 -51.75 68.02 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.4 -0.364 . . . . 0.0 111.368 -179.255 . . . . . . . . 3 3 . 1 . 022 nuclear orig full ' A' A ' 166' ' ' LEU . . . . . 0.465 ' O ' ' HG ' ' A' ' 170' ' ' LEU . 5.5 tt -58.28 -52.12 66.94 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.124 -0.489 . . . . 0.0 111.867 -179.241 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 167' ' ' THR . . . . . 0.458 ' O ' ' HB2' ' A' ' 171' ' ' TRP . 91.3 m -55.37 -53.38 56.94 Favored 'General case' 0 C--N 1.328 -0.34 0 N-CA-C 112.643 0.609 . . . . 0.0 112.643 -178.71 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 168' ' ' VAL . . . . . . . . . . . . . 96.3 t -55.21 -40.83 57.63 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.195 0 N-CA-C 112.312 0.486 . . . . 0.0 112.312 -178.558 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 169' ' ' VAL . . . . . . . . . . . . . 80.2 t -60.54 -64.66 0.57 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.39 0 N-CA-C 111.798 0.296 . . . . 0.0 111.798 -179.343 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 170' ' ' LEU . . . . . 0.465 ' HG ' ' O ' ' A' ' 166' ' ' LEU . 1.6 pp -63.98 -27.63 69.26 Favored 'General case' 0 C--N 1.33 -0.26 0 N-CA-C 112.08 0.4 . . . . 0.0 112.08 -178.781 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 171' ' ' TRP . . . . . 0.499 ' NE1' H201 ' A' ' 301' ' ' RET . 1.5 m0 -72.14 -31.14 65.71 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-O 120.926 0.393 . . . . 0.0 110.312 179.383 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 172' ' ' ALA . . . . . 0.424 ' HA ' ' CZ ' ' A' ' 134' ' ' PHE . . . -73.04 -6.19 43.87 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 115.816 -0.629 . . . . 0.0 110.615 179.94 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 173' ' ' ILE . . . . . 0.534 HG21 HD12 ' A' ' 177' ' ' ILE . 36.5 mm -87.78 -21.78 7.01 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.216 0 CA-C-N 115.838 -0.619 . . . . 0.0 111.132 179.787 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 174' ' ' TYR . . . . . . . . . . . . . 25.9 m-85 -54.57 -49.55 90.46 Favored Pre-proline 0 N--CA 1.465 0.3 0 CA-C-N 116.49 -0.323 . . . . 0.0 111.694 -179.913 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 175' ' ' PRO . . . . . 0.401 ' O ' ' HB2' ' A' ' 179' ' ' LEU . 82.7 Cg_exo -47.63 -28.37 9.13 Favored 'Trans proline' 0 C--N 1.353 0.768 0 C-N-CA 122.163 1.909 . . . . 0.0 112.259 179.912 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 176' ' ' PHE . . . . . 0.437 ' O ' ' HG ' ' A' ' 180' ' ' LEU . 95.9 m-85 -80.31 -49.61 11.31 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.026 -0.534 . . . . 0.0 111.72 -179.99 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 177' ' ' ILE . . . . . 0.534 HD12 HG21 ' A' ' 173' ' ' ILE . 2.6 mm -60.1 -45.12 96.14 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.537 0 N-CA-C 112.568 0.581 . . . . 0.0 112.568 -177.894 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 178' ' ' TRP . . . . . 0.449 ' HH2' ' HB2' ' A' ' 123' ' ' ARG . 80.5 t90 -66.63 -40.5 88.76 Favored 'General case' 0 N--CA 1.464 0.255 0 CA-C-O 121.095 0.474 . . . . 0.0 110.644 179.867 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 179' ' ' LEU . . . . . 0.529 HD11 HG22 ' A' ' 185' ' ' VAL . 0.9 OUTLIER -65.28 -52.43 54.31 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-N 115.732 -0.667 . . . . 0.0 111.272 -179.216 . . . . . . . . 3 3 . 1 . 022 nuclear orig full ' A' A ' 180' ' ' LEU . . . . . 0.478 HD22 HD12 ' A' ' 187' ' ' LEU . 9.8 mt -77.6 -52.44 9.02 Favored 'General case' 0 CA--C 1.532 0.266 0 N-CA-C 112.395 0.517 . . . . 0.0 112.395 -178.586 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . -59.89 -85.54 0.04 OUTLIER Glycine 0 C--N 1.333 0.389 0 C-N-CA 120.631 -0.795 . . . . 0.0 113.196 -179.578 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 182' ' ' PRO . . . . . 0.495 ' C ' ' H ' ' A' ' 184' ' ' GLY . 73.1 Cg_exo -45.01 178.04 0.0 OUTLIER 'Trans proline' 0 C--N 1.351 0.696 0 C-N-CA 123.368 2.712 . . . . 0.0 113.326 179.474 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 183' ' ' PRO . . . . . . . . . . . . . 62.2 Cg_exo -53.68 8.27 0.03 OUTLIER 'Trans proline' 0 C--N 1.352 0.713 0 C-N-CA 123.057 2.505 . . . . 0.0 114.991 -179.384 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 184' ' ' GLY . . . . . 0.495 ' H ' ' C ' ' A' ' 182' ' ' PRO . . . -53.69 -66.94 2.41 Favored Glycine 0 C--N 1.337 0.608 0 C-N-CA 119.795 -1.193 . . . . 0.0 110.971 179.01 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 185' ' ' VAL . . . . . 0.529 HG22 HD11 ' A' ' 179' ' ' LEU . 4.4 m -134.4 -4.61 1.21 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.389 0 CA-C-N 115.797 -0.202 . . . . 0.0 111.433 178.553 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 186' ' ' ALA . . . . . . . . . . . . . . . 43.85 79.01 0.05 OUTLIER 'General case' 0 N--CA 1.466 0.35 0 N-CA-C 112.289 0.477 . . . . 0.0 112.289 179.386 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 187' ' ' LEU . . . . . 0.478 HD12 HD22 ' A' ' 180' ' ' LEU . 4.9 mt -92.77 -49.83 5.88 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-O 120.71 0.291 . . . . 0.0 111.718 179.971 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 188' ' ' LEU . . . . . . . . . . . . . 96.0 mt -114.95 -166.45 1.11 Allowed 'General case' 0 C--N 1.331 -0.223 0 CA-C-O 120.983 0.421 . . . . 0.0 111.362 -179.169 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 189' ' ' THR . . . . . . . . . . . . . 3.0 t -85.77 148.11 47.76 Favored Pre-proline 0 C--N 1.328 -0.354 0 CA-C-N 115.826 -0.625 . . . . 0.0 111.279 -179.732 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 190' ' ' PRO . . . . . . . . . . . . . 78.2 Cg_exo -49.42 -44.59 33.98 Favored 'Trans proline' 0 C--N 1.348 0.524 0 C-N-CA 122.849 2.366 . . . . 0.0 113.503 -179.74 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 191' ' ' THR . . . . . . . . . . . . . 9.7 t -56.12 -34.51 66.14 Favored 'General case' 0 C--N 1.33 -0.276 0 N-CA-C 112.308 0.484 . . . . 0.0 112.308 -179.056 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 192' ' ' VAL . . . . . . . . . . . . . 19.1 t -72.06 -54.39 16.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 N-CA-C 111.851 0.315 . . . . 0.0 111.851 -179.204 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 193' ' ' ASP . . . . . . . . . . . . . 1.1 p30 -62.17 -46.14 90.3 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.699 0.285 . . . . 0.0 110.948 -179.735 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 194' ' ' VAL . . . . . . . . . . . . . 63.8 t -58.32 -35.94 55.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.331 -0.395 . . . . 0.0 110.44 179.4 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 195' ' ' ALA . . . . . . . . . . . . . . . -59.93 -48.25 82.45 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.281 -0.418 . . . . 0.0 111.141 179.918 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 196' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -67.88 -35.54 78.69 Favored 'General case' 0 N--CA 1.462 0.173 0 N-CA-C 109.882 -0.414 . . . . 0.0 109.882 179.543 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 197' ' ' ILE . . . . . . . . . . . . . 18.9 mm -58.43 -57.67 9.88 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.289 0 CA-C-N 115.922 -0.581 . . . . 0.0 109.776 178.949 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 198' ' ' VAL . . . . . . . . . . . . . 93.5 t -53.92 -35.27 27.56 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.44 0 N-CA-C 108.873 -0.788 . . . . 0.0 108.873 178.138 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 199' ' ' TYR . . . . . . . . . . . . . 17.7 t80 -70.76 -30.21 66.65 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 114.951 -1.022 . . . . 0.0 110.885 179.467 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 200' ' ' LEU . . . . . . . . . . . . . 34.9 mt -71.75 -44.0 64.81 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 116.048 -0.524 . . . . 0.0 111.703 -179.21 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 201' ' ' ASP . . . . . . . . . . . . . 11.9 m-20 -68.26 -35.21 77.54 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-O 121.117 0.484 . . . . 0.0 110.417 179.89 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 202' ' ' LEU . . . . . 0.433 ' O ' ' HB ' ' A' ' 206' ' ' VAL . 3.4 mt -70.89 -32.59 69.59 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 115.587 -0.733 . . . . 0.0 111.977 -179.507 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 203' ' ' VAL . . . . . 0.482 ' O ' ' HA3' ' A' ' 207' ' ' GLY . 12.5 p -78.17 -36.59 21.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 C-N-CA 121.102 -0.239 . . . . 0.0 111.376 -178.915 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 204' ' ' THR . . . . . 0.402 ' O ' ' CD1' ' A' ' 208' ' ' PHE . 45.4 m -64.73 -57.46 8.91 Favored 'General case' 0 C--N 1.325 -0.457 0 C-N-CA 120.494 -0.482 . . . . 0.0 111.134 179.655 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 205' ' ' LYS . . . . . 0.647 ' HD2' ' HE1' ' A' ' 15' ' ' MET . 47.4 mttp -70.2 -58.91 3.25 Favored 'General case' 0 C--N 1.33 -0.251 0 N-CA-C 112.791 0.663 . . . . 0.0 112.791 -178.071 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 206' ' ' VAL . . . . . 0.433 ' HB ' ' O ' ' A' ' 202' ' ' LEU . 23.3 t -70.08 -36.31 67.76 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.411 0 CA-C-N 116.454 -0.339 . . . . 0.0 111.832 -178.692 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 207' ' ' GLY . . . . . 0.484 ' O ' HG13 ' A' ' 211' ' ' ILE . . . -63.3 -60.25 7.78 Favored Glycine 0 N--CA 1.45 -0.382 0 C-N-CA 120.513 -0.851 . . . . 0.0 113.424 -178.844 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 208' ' ' PHE . . . . . 0.594 ' HB2' ' HG ' ' A' ' 163' ' ' LEU . 0.1 OUTLIER -66.47 -27.07 67.51 Favored 'General case' 0 C--O 1.225 -0.219 0 CA-C-N 117.3 0.55 . . . . 0.0 111.037 -179.136 . . . . . . . . 3 3 . 1 . 022 nuclear orig full ' A' A ' 209' ' ' GLY . . . . . 0.497 ' O ' ' HB2' ' A' ' 212' ' ' ALA . . . -69.72 -33.12 70.91 Favored Glycine 0 N--CA 1.448 -0.513 0 N-CA-C 111.683 -0.567 . . . . 0.0 111.683 178.852 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 210' ' ' PHE . . . . . . . . . . . . . 1.1 m-85 -70.85 -49.27 47.99 Favored 'General case' 0 CA--C 1.512 -0.494 0 N-CA-C 107.954 -1.128 . . . . 0.0 107.954 178.404 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 211' ' ' ILE . . . . . 0.484 HG13 ' O ' ' A' ' 207' ' ' GLY . 5.6 mt -62.59 -28.36 44.65 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.604 0 N-CA-C 107.618 -1.253 . . . . 0.0 107.618 176.572 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 212' ' ' ALA . . . . . 0.497 ' HB2' ' O ' ' A' ' 209' ' ' GLY . . . -65.05 -39.92 94.01 Favored 'General case' 0 N--CA 1.447 -0.59 0 CA-C-N 114.698 -1.137 . . . . 0.0 110.084 179.431 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 213' ' ' LEU . . . . . . . . . . . . . 88.4 mt -70.28 -53.16 18.05 Favored 'General case' 0 C--N 1.331 -0.203 0 CA-C-N 115.132 -0.94 . . . . 0.0 111.601 -179.772 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 214' ' ' ASP . . . . . . . . . . . . . 29.4 m-20 -54.01 -50.04 67.53 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.33 -0.395 . . . . 0.0 111.294 -179.38 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 215' ' ' ALA . . . . . . . . . . . . . . . -61.02 -56.42 21.26 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.289 -0.414 . . . . 0.0 111.362 -179.735 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 216' ' ' ALA . . . . . . . . . . . . . . . -56.26 -36.38 68.49 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.233 -0.439 . . . . 0.0 111.467 -179.543 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 217' ' ' ALA . . . . . . . . . . . . . . . -62.46 -40.87 98.01 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.291 -0.413 . . . . 0.0 110.392 179.765 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 218' ' ' THR . . . . . . . . . . . . . 90.9 m -65.95 -37.86 87.12 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.794 -0.639 . . . . 0.0 110.737 179.623 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 219' ' ' LEU . . . . . 0.497 ' O ' ' HG2' ' A' ' 222' ' ' GLU . 71.1 mt -57.95 -44.39 86.96 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.086 -0.506 . . . . 0.0 110.596 179.805 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 220' ' ' ARG . . . . . . . . . . . . . 7.7 mpt_? -84.05 -17.26 40.93 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.095 179.678 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 221' ' ' ALA . . . . . . . . . . . . . . . -77.27 -22.45 52.06 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.269 -0.423 . . . . 0.0 112.024 -179.458 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 222' ' ' GLU . . . . . 0.497 ' HG2' ' O ' ' A' ' 219' ' ' LEU . 11.6 pt-20 -75.4 -7.76 54.91 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-O 120.795 0.331 . . . . 0.0 111.113 -179.532 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 223' ' ' HIS . . . . . . . . . . . . . 89.8 m-70 -87.8 -16.21 34.76 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.266 -0.424 . . . . 0.0 111.056 -179.982 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 224' ' ' GLY . . . . . . . . . . . . . . . -83.52 73.72 2.63 Favored Glycine 0 N--CA 1.452 -0.234 0 C-N-CA 120.806 -0.711 . . . . 0.0 112.424 179.9 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 225' ' ' GLU . . . . . . . . . . . . . 10.0 tp10 -148.25 130.02 15.13 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 120.702 0.287 . . . . 0.0 110.939 -179.853 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 226' ' ' SER . . . . . . . . . . . . . 41.4 t 60.71 -85.95 0.02 OUTLIER 'General case' 0 C--N 1.332 -0.195 0 CA-C-N 116.035 -0.53 . . . . 0.0 111.665 179.678 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 227' ' ' LEU . . . . . . . . . . . . . 3.9 mm? -71.97 -34.13 68.72 Favored 'General case' 0 C--N 1.332 -0.185 0 CA-C-N 116.426 -0.352 . . . . 0.0 111.176 -179.441 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 228' ' ' ALA . . . . . . . . . . . . . . . 52.49 -165.85 0.06 Allowed 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.285 -0.416 . . . . 0.0 111.33 -179.8 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 229' ' ' GLY . . . . . . . . . . . . . . . -128.18 48.69 0.96 Allowed Glycine 0 C--N 1.331 0.293 0 C-N-CA 120.743 -0.741 . . . . 0.0 112.717 -179.752 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 230' ' ' VAL . . . . . . . . . . . . . 47.5 t -85.86 133.77 28.83 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.225 0 CA-C-O 120.782 0.325 . . . . 0.0 110.958 179.865 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 231' ' ' ASP . . . . . . . . . . . . . 23.8 t70 -67.6 107.48 2.54 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.313 -0.403 . . . . 0.0 110.978 179.991 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 232' ' ' THR . . . . . . . . . . . . . 8.2 t -157.6 147.66 20.55 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.039 -0.528 . . . . 0.0 110.958 179.844 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 233' ' ' ASP . . . . . . . . . . . . . 22.1 t70 58.23 90.54 0.05 OUTLIER 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.877 -179.816 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 234' ' ' THR . . . . . . . . . . . . . 4.1 t -73.29 141.05 80.15 Favored Pre-proline 0 C--N 1.33 -0.246 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.332 -179.829 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 235' ' ' PRO . . . . . . . . . . . . . 58.5 Cg_endo -71.36 -36.87 6.36 Favored 'Trans proline' 0 C--N 1.347 0.488 0 C-N-CA 122.453 2.102 . . . . 0.0 112.334 179.942 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 236' ' ' ALA . . . . . . . . . . . . . . . -76.6 164.57 25.79 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.001 179.948 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 237' ' ' VAL . . . . . . . . . . . . . 35.2 m -90.76 -178.68 0.43 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.327 -0.397 . . . . 0.0 111.166 -179.879 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 238' ' ' ALA . . . . . . . . . . . . . . . -87.07 118.3 26.37 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.263 -0.426 . . . . 0.0 111.15 -179.982 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 239' ' ' ASP . . . . . . . . . . . . . 10.9 m-20 61.05 177.5 0.11 Allowed 'General case' 0 C--N 1.332 -0.186 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.202 179.819 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 240' ' ' LEU . . . . . . . . . . . . . 95.0 mt -131.84 110.45 10.83 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 116.055 -0.52 . . . . 0.0 110.983 179.922 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 241' ' ' GLU . . . . . . . . . . . . . 39.1 tt0 -115.55 111.33 20.54 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.706 179.825 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 242' ' ' HIS . . . . . . . . . . . . . 72.4 m80 -92.68 138.83 31.15 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.983 -179.815 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 243' ' ' HIS . . . . . . . . . . . . . 45.8 t-80 -156.44 -40.35 0.08 Allowed 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.786 179.834 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 244' ' ' HIS . . . . . . . . . . . . . 47.2 m-70 -62.02 159.07 15.06 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.529 179.72 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 245' ' ' HIS . . . . . . . . . . . . . 23.5 m-70 57.95 -170.64 0.11 Allowed 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 116.295 -0.411 . . . . 0.0 110.915 -179.821 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 246' ' ' HIS . . . . . . . . . . . . . 26.2 p80 -155.37 -22.8 0.11 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.944 179.804 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 247' ' ' HIS . . . . . . . . . . . . . 60.7 t60 . . . . . 0 C--O 1.249 1.064 0 CA-C-O 118.179 -0.915 . . . . 0.0 110.886 -179.873 . . . . . . . . 0 0 . 1 . 022 nuclear orig full ' A' A ' 301' ' ' RET . . . . . 0.499 H201 ' NE1' ' A' ' 171' ' ' TRP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 85.2 mtp . . . . . 0 N--CA 1.485 1.322 0 CA-C-O 120.838 0.351 . . . . 0.0 110.807 . . . . . . . . . 0 0 . 1 . 023 nuclear orig full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 27.6 m -134.57 -31.52 0.46 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.662 -179.923 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -79.48 -20.25 69.5 Favored Glycine 0 C--N 1.33 0.242 0 C-N-CA 120.683 -0.77 . . . . 0.0 112.625 -179.925 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 59.6 tp -74.98 -38.0 61.77 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.832 0.349 . . . . 0.0 111.095 179.953 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 71.1 p -61.73 -32.59 72.82 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.096 -0.502 . . . . 0.0 111.207 -179.819 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 6' ' ' THR . . . . . 0.442 ' HG1' HD22 ' A' ' 7' ' ' LEU . 20.5 p -54.53 -35.86 63.64 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.127 -179.785 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 7' ' ' LEU . . . . . 0.442 HD22 ' HG1' ' A' ' 6' ' ' THR . 4.2 mm? -57.48 -52.86 63.66 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.809 179.836 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 8' ' ' PHE . . . . . 0.518 ' HB2' ' HB1' ' A' ' 55' ' ' ALA . 57.8 m-85 -64.87 -32.99 74.95 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 115.989 -0.551 . . . . 0.0 110.831 179.975 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 9' ' ' TRP . . . . . 0.407 ' O ' HG13 ' A' ' 13' ' ' ILE . 27.8 m95 -64.5 -44.7 90.13 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.978 0.418 . . . . 0.0 109.992 179.808 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 41.9 mt -61.8 -44.51 96.71 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 115.773 -0.649 . . . . 0.0 110.387 179.161 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -65.54 -29.22 74.67 Favored Glycine 0 N--CA 1.45 -0.433 0 C-N-CA 120.704 -0.76 . . . . 0.0 111.922 179.59 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -71.22 -33.42 69.88 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.624 0.25 . . . . 0.0 110.775 179.689 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 13' ' ' ILE . . . . . 0.407 HG13 ' O ' ' A' ' 9' ' ' TRP . 66.4 mt -66.33 -54.02 30.5 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.208 0 CA-C-O 120.9 0.381 . . . . 0.0 110.142 179.32 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -61.77 -38.07 95.34 Favored Glycine 0 N--CA 1.45 -0.432 0 C-N-CA 120.735 -0.745 . . . . 0.0 111.658 179.298 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 15' ' ' MET . . . . . . . . . . . . . 45.7 tpp -63.35 -43.51 97.5 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.794 0.331 . . . . 0.0 110.249 179.503 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -55.63 -38.96 70.2 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 115.969 -0.559 . . . . 0.0 109.834 179.23 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 98.8 t -59.91 -45.74 94.76 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.168 0 CA-C-N 115.954 -0.566 . . . . 0.0 109.926 178.955 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -62.74 -45.97 94.63 Favored Glycine 0 C--N 1.333 0.373 0 C-N-CA 120.476 -0.869 . . . . 0.0 111.448 178.801 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 23.7 m -51.86 -44.95 63.88 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 115.548 -0.326 . . . . 0.0 111.405 -179.888 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 85.4 mt -71.65 -42.98 66.9 Favored 'General case' 0 C--N 1.332 -0.184 0 CA-C-N 116.402 -0.363 . . . . 0.0 111.362 -179.921 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -56.89 -34.07 67.51 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.334 -0.393 . . . . 0.0 111.707 -179.662 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 22' ' ' PHE . . . . . 0.408 ' HB2' HG23 ' A' ' 41' ' ' VAL . 1.9 m-85 -90.96 -31.1 16.48 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.598 -0.274 . . . . 0.0 111.242 -179.418 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -68.31 -50.54 52.83 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.901 0.382 . . . . 0.0 111.543 -179.643 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 24' ' ' TRP . . . . . . . . . . . . . 5.3 t-105 -64.77 -42.27 95.24 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-N 115.898 -0.592 . . . . 0.0 111.119 -179.685 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -77.42 -18.4 57.28 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.866 0.365 . . . . 0.0 110.643 179.764 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -74.15 -48.47 15.15 Favored Glycine 0 N--CA 1.452 -0.286 0 C-N-CA 121.028 -0.606 . . . . 0.0 112.33 179.548 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 98.9 mtt180 -55.51 -38.26 68.96 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-O 120.832 0.349 . . . . 0.0 110.506 179.878 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 20.1 t70 -92.53 91.37 7.56 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 115.996 -0.547 . . . . 0.0 110.567 179.82 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -159.35 -162.62 1.07 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.122 -0.49 . . . . 0.0 111.061 -179.792 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -96.11 -113.02 2.82 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.782 -0.723 . . . . 0.0 112.668 -179.887 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 65.4 m -138.0 -56.71 0.66 Allowed 'General case' 0 C--N 1.331 -0.228 0 CA-C-O 120.773 0.32 . . . . 0.0 111.131 -179.785 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -75.2 -21.54 77.8 Favored Glycine 0 C--N 1.331 0.261 0 C-N-CA 120.905 -0.664 . . . . 0.0 112.598 -179.981 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 19.9 mm-40 -79.41 -20.65 47.06 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.82 0.343 . . . . 0.0 110.688 179.906 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 34' ' ' ARG . . . . . . . . . . . . . 52.0 ttp180 -55.11 -28.9 56.01 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.005 -0.543 . . . . 0.0 111.319 -179.784 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 31.1 mmm180 -55.04 -45.12 75.2 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.788 0.328 . . . . 0.0 111.28 -179.938 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 61.2 m-85 -69.05 -33.38 73.49 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.414 -179.528 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 37' ' ' TYR . . . . . . . . . . . . . 75.4 m-85 -72.69 -53.06 12.77 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.331 -0.395 . . . . 0.0 111.413 -179.238 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 11.5 p -56.75 -36.16 48.26 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.225 0 CA-C-O 121.092 0.472 . . . . 0.0 110.474 179.751 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 18.7 m -68.2 -46.9 69.34 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 115.714 -0.676 . . . . 0.0 110.718 179.276 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 40' ' ' LEU . . . . . 0.467 HD13 HD12 ' A' ' 43' ' ' ILE . 26.8 tp -61.18 -45.33 95.07 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 115.813 -0.631 . . . . 0.0 110.917 179.96 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . 0.408 HG23 ' HB2' ' A' ' 22' ' ' PHE . 95.7 t -62.97 -34.35 65.87 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.484 0 CA-C-N 115.988 -0.551 . . . . 0.0 110.284 179.471 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . 0.481 ' O ' HG13 ' A' ' 46' ' ' ILE . . . -58.62 -51.88 56.3 Favored Glycine 0 N--CA 1.448 -0.508 0 C-N-CA 120.902 -0.666 . . . . 0.0 112.921 -179.964 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 43' ' ' ILE . . . . . 0.526 HG21 HD22 ' A' ' 82' ' ' LEU . 18.0 pt -60.9 -49.16 85.79 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.161 0 CA-C-N 117.02 0.41 . . . . 0.0 111.566 -179.558 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 44' ' ' SER . . . . . 0.405 ' N ' HG13 ' A' ' 43' ' ' ILE . 41.0 t -61.32 -27.1 68.25 Favored 'General case' 0 C--N 1.332 -0.191 0 CA-C-O 120.889 0.375 . . . . 0.0 111.193 179.648 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -78.01 -47.59 8.35 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.803 -0.713 . . . . 0.0 113.217 -179.112 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 46' ' ' ILE . . . . . 0.481 HG13 ' O ' ' A' ' 42' ' ' GLY . 61.6 mt -59.14 -42.09 85.62 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.229 0 CA-C-O 120.846 0.355 . . . . 0.0 110.968 -179.75 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 47' ' ' ALA . . . . . 0.606 ' HB1' ' HE2' ' A' ' 205' ' ' LYS . . . -67.49 -40.83 85.25 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 116.333 -0.394 . . . . 0.0 111.084 179.336 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -54.65 -44.27 73.1 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 116.129 -0.487 . . . . 0.0 111.382 -179.771 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 49' ' ' VAL . . . . . 0.404 ' O ' HG12 ' A' ' 53' ' ' VAL . 33.3 m -75.36 -34.65 30.98 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.384 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.351 -179.742 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -62.17 -38.86 90.67 Favored 'General case' 0 C--N 1.332 -0.156 0 CA-C-O 120.965 0.412 . . . . 0.0 111.071 179.849 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 51' ' ' TYR . . . . . 0.418 ' HB3' ' O ' ' A' ' 8' ' ' PHE . 26.5 m-85 -72.77 -42.65 63.74 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 115.993 -0.549 . . . . 0.0 110.693 -179.861 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -62.5 -39.84 94.81 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 115.987 -0.551 . . . . 0.0 111.45 -179.919 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 53' ' ' VAL . . . . . 0.416 HG21 ' N ' ' A' ' 54' ' ' MET . 35.1 m -72.28 -48.71 47.19 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.16 0 CA-C-N 116.498 -0.319 . . . . 0.0 111.299 -179.679 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 54' ' ' MET . . . . . 0.435 ' HG3' ' HB2' ' A' ' 71' ' ' PRO . 74.0 mtm -61.85 -31.26 71.51 Favored 'General case' 0 C--N 1.331 -0.196 0 CA-C-O 120.979 0.419 . . . . 0.0 110.417 179.693 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 55' ' ' ALA . . . . . 0.518 ' HB1' ' HB2' ' A' ' 8' ' ' PHE . . . -70.42 -12.51 61.63 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 115.767 -0.652 . . . . 0.0 111.645 179.962 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 71.2 mt -97.71 -13.15 21.61 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 116.483 -0.326 . . . . 0.0 111.466 -179.78 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 105.18 -6.62 42.98 Favored Glycine 0 CA--C 1.52 0.353 0 C-N-CA 120.496 -0.859 . . . . 0.0 113.545 179.5 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 58' ' ' VAL . . . . . 0.41 HG22 ' O ' ' A' ' 53' ' ' VAL . 27.0 m -81.54 149.8 4.76 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.201 0 CA-C-N 117.185 0.492 . . . . 0.0 110.587 179.483 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 81.74 25.61 52.72 Favored Glycine 0 N--CA 1.45 -0.418 0 C-N-CA 120.588 -0.815 . . . . 0.0 111.768 -179.219 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 60' ' ' TRP . . . . . . . . . . . . . 17.9 m0 -104.23 95.06 5.71 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 121.101 0.477 . . . . 0.0 110.018 -179.897 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 6.0 t -91.24 124.21 62.08 Favored Pre-proline 0 C--N 1.324 -0.539 0 CA-C-N 115.712 -0.676 . . . . 0.0 111.405 -178.984 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 56.2 Cg_endo -71.81 136.42 27.72 Favored 'Trans proline' 0 C--N 1.35 0.649 0 C-N-CA 122.353 2.036 . . . . 0.0 112.345 -179.987 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 86.4 t -143.02 105.23 1.06 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.02 -0.537 . . . . 0.0 111.209 -179.573 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . 58.88 -90.08 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.295 -0.411 . . . . 0.0 111.361 179.921 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 41.2 tt0 -122.85 -25.71 4.57 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 116.306 -0.406 . . . . 0.0 110.52 179.901 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 66' ' ' ARG . . . . . . . . . . . . . 20.0 ttm180 -101.73 162.62 12.77 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 115.942 -0.572 . . . . 0.0 110.333 179.905 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 87.3 m -117.56 120.73 38.96 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-O 120.858 0.361 . . . . 0.0 111.648 -179.448 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 38.8 t -86.07 146.37 6.55 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 115.927 -0.579 . . . . 0.0 110.558 179.406 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 69' ' ' PHE . . . . . . . . . . . . . 29.8 m-85 -106.77 112.97 26.19 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 121.044 0.45 . . . . 0.0 110.177 -179.679 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 70' ' ' VAL . . . . . 0.582 HG11 ' HD3' ' A' ' 71' ' ' PRO . 0.3 OUTLIER -68.65 -33.92 4.95 Favored Pre-proline 0 CA--C 1.541 0.603 0 N-CA-C 113.217 0.821 . . . . 0.0 113.217 -179.108 . . . . . . . . 3 3 . 1 . 023 nuclear orig full ' A' A ' 71' ' ' PRO . . . . . 0.582 ' HD3' HG11 ' A' ' 70' ' ' VAL . 23.9 Cg_exo -63.71 -32.63 68.07 Favored 'Trans proline' 0 C--N 1.357 1.02 0 C-N-CA 121.766 1.644 . . . . 0.0 112.453 -179.276 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 40.0 ttm180 -69.82 -50.54 41.87 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 121.075 0.465 . . . . 0.0 110.352 179.464 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 73' ' ' TYR . . . . . 0.616 ' HH ' ' HB3' ' A' ' 116' ' ' ALA . 33.9 m-85 -65.94 -33.09 75.02 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 115.767 -0.651 . . . . 0.0 111.341 -179.706 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 0.4 OUTLIER -75.74 -38.73 37.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-O 121.02 0.438 . . . . 0.0 109.908 179.329 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 5.9 t70 -58.58 -32.77 69.26 Favored 'General case' 0 N--CA 1.455 -0.203 0 CA-C-N 115.975 -0.557 . . . . 0.0 109.965 179.294 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 76' ' ' TRP . . . . . . . . . . . . . 51.0 m0 -73.24 -46.23 51.31 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 115.914 -0.585 . . . . 0.0 110.568 179.204 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 77' ' ' ILE . . . . . 0.518 HG12 ' HB3' ' A' ' 109' ' ' MET . 88.2 mt -53.52 -29.94 17.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 115.941 -0.572 . . . . 0.0 111.253 -179.84 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 47.3 mt -91.07 -52.02 5.04 Favored 'General case' 0 CA--C 1.533 0.325 0 N-CA-C 112.521 0.563 . . . . 0.0 112.521 -179.541 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 79.7 p -71.49 -50.37 32.22 Favored 'General case' 0 N--CA 1.465 0.315 0 N-CA-C 113.931 1.085 . . . . 0.0 113.931 -177.688 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 80' ' ' THR . . . . . 0.503 HG23 ' HE2' ' A' ' 109' ' ' MET . 15.2 m -46.47 -53.32 24.75 Favored Pre-proline 0 CA--C 1.534 0.331 0 N-CA-C 112.78 0.659 . . . . 0.0 112.78 -178.173 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 81' ' ' PRO . . . . . 0.46 ' HD2' ' N ' ' A' ' 80' ' ' THR . 29.1 Cg_endo -61.99 -23.95 76.31 Favored 'Trans proline' 0 C--N 1.351 0.689 0 C-N-CA 121.639 1.559 . . . . 0.0 111.523 179.949 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 82' ' ' LEU . . . . . 0.526 HD22 HG21 ' A' ' 43' ' ' ILE . 15.6 tp -76.59 -32.62 58.23 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 115.751 -0.658 . . . . 0.0 110.156 179.507 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 83' ' ' ILE . . . . . 0.464 HG13 H203 ' A' ' 301' ' ' RET . 41.8 mm -64.71 -53.55 40.83 Favored 'Isoleucine or valine' 0 C--O 1.235 0.304 0 CA-C-N 116.181 -0.463 . . . . 0.0 109.872 178.94 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 12.6 m -61.3 -30.33 47.71 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.228 0 N-CA-C 109.297 -0.631 . . . . 0.0 109.297 178.582 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 85' ' ' TYR . . . . . . . . . . . . . 87.4 t80 -66.82 -32.61 74.0 Favored 'General case' 0 N--CA 1.453 -0.282 0 CA-C-N 115.478 -0.783 . . . . 0.0 109.371 178.585 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 86' ' ' PHE . . . . . . . . . . . . . 3.5 t80 -61.34 -51.89 66.94 Favored 'General case' 0 C--O 1.232 0.17 0 CA-C-N 115.68 -0.691 . . . . 0.0 109.767 179.259 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 7.2 mp -62.37 -31.82 72.53 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 115.741 -0.663 . . . . 0.0 110.242 179.358 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -66.27 -28.06 73.44 Favored Glycine 0 N--CA 1.45 -0.412 0 C-N-CA 120.771 -0.728 . . . . 0.0 111.615 179.365 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 92.6 mt -75.4 -38.88 59.62 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.815 0.341 . . . . 0.0 110.53 179.426 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 94.2 mt -59.96 -43.34 95.1 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.042 -0.526 . . . . 0.0 111.097 179.859 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . 0.422 ' HB1' ' HB2' ' A' ' 149' ' ' ALA . . . -82.76 -52.22 6.96 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 116.253 -0.43 . . . . 0.0 111.369 -179.798 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 100.16 68.21 0.86 Allowed Glycine 0 N--CA 1.452 -0.284 0 C-N-CA 120.81 -0.71 . . . . 0.0 112.4 -179.941 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 93' ' ' LEU . . . . . 0.536 ' HB3' ' HB2' ' A' ' 97' ' ' GLU . 8.2 mp -77.29 177.69 7.72 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.905 0.383 . . . . 0.0 111.159 -179.862 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 94' ' ' ASP . . . . . . . . . . . . . 19.7 t70 -89.66 166.96 13.29 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 115.941 -0.572 . . . . 0.0 110.808 -179.986 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 52.8 m -55.68 -38.96 70.35 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.348 -0.387 . . . . 0.0 111.177 -179.806 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 37.6 mmt180 -73.46 -44.3 58.34 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.303 -0.408 . . . . 0.0 111.13 -179.981 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 97' ' ' GLU . . . . . 0.536 ' HB2' ' HB3' ' A' ' 93' ' ' LEU . 13.2 mm-40 -55.43 -47.99 75.11 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.859 -179.969 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 98' ' ' PHE . . . . . 0.418 ' O ' HG12 ' A' ' 102' ' ' ILE . 24.3 m-85 -57.1 -47.63 80.58 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.447 179.456 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -57.27 -29.83 60.55 Favored Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.438 179.828 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 97.3 mt -73.98 -44.28 51.06 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.171 0 CA-C-O 120.93 0.395 . . . . 0.0 111.555 -179.882 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 44.7 t -67.46 -46.41 83.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.062 -0.517 . . . . 0.0 111.929 -179.247 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 102' ' ' ILE . . . . . 0.418 HG12 ' O ' ' A' ' 98' ' ' PHE . 45.4 mm -62.22 -52.49 59.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.395 -0.366 . . . . 0.0 111.722 -179.272 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 14.7 t -57.29 -35.94 70.44 Favored 'General case' 0 C--N 1.332 -0.16 0 CA-C-O 120.849 0.357 . . . . 0.0 111.174 -179.74 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 104' ' ' LEU . . . . . 0.427 HD21 ' HE2' ' A' ' 140' ' ' TYR . 50.4 tp -61.02 -46.43 90.77 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.746 179.838 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 105' ' ' ASN . . . . . 0.57 ' N ' HD21 ' A' ' 105' ' ' ASN . 0.8 OUTLIER -65.46 -26.09 67.79 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.877 179.946 . . . . . . . . 3 3 . 1 . 023 nuclear orig full ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 61.4 m -65.44 -55.35 18.49 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.292 -0.413 . . . . 0.0 111.216 -179.975 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 7.3 p -61.87 -37.35 77.96 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.184 0 CA-C-N 116.532 -0.304 . . . . 0.0 110.995 -179.734 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . 0.4 HG21 ' O ' ' A' ' 104' ' ' LEU . 53.4 t -59.58 -50.14 81.07 Favored 'Isoleucine or valine' 0 C--O 1.235 0.303 0 CA-C-O 121.002 0.429 . . . . 0.0 110.589 179.364 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 109' ' ' MET . . . . . 0.518 ' HB3' HG12 ' A' ' 77' ' ' ILE . 3.0 tpp -63.46 -30.67 71.76 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 115.946 -0.57 . . . . 0.0 110.337 179.579 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 20.1 tp -68.59 -32.69 72.77 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.104 -0.498 . . . . 0.0 109.956 179.318 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 111' ' ' ALA . . . . . 0.428 ' O ' ' HB3' ' A' ' 126' ' ' LEU . . . -63.49 -56.69 14.08 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-N 115.736 -0.666 . . . . 0.0 110.418 179.25 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 112' ' ' GLY . . . . . 0.428 ' HA3' ' H22' ' A' ' 301' ' ' RET . . . -56.59 -42.99 91.08 Favored Glycine 0 C--N 1.331 0.252 0 C-N-CA 120.646 -0.788 . . . . 0.0 112.055 179.493 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 113' ' ' PHE . . . . . . . . . . . . . 6.5 t80 -47.28 -66.84 0.34 Allowed 'General case' 0 C--N 1.331 -0.222 0 CA-C-O 121.025 0.44 . . . . 0.0 110.956 179.55 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -63.25 -30.36 71.52 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 115.865 -0.607 . . . . 0.0 111.702 -179.401 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -52.11 -43.0 55.92 Favored Glycine 0 C--N 1.33 0.239 0 C-N-CA 121.057 -0.592 . . . . 0.0 112.96 -179.614 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 116' ' ' ALA . . . . . 0.616 ' HB3' ' HH ' ' A' ' 73' ' ' TYR . . . -78.22 -27.88 47.84 Favored 'General case' 0 C--N 1.328 -0.352 0 N-CA-C 112.172 0.434 . . . . 0.0 112.172 -179.643 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 117' ' ' MET . . . . . . . . . . . . . 66.1 mtt -95.66 19.45 11.16 Favored 'General case' 0 C--N 1.33 -0.282 0 N-CA-C 111.77 0.285 . . . . 0.0 111.77 -179.191 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 118' ' ' VAL . . . . . 0.547 HG22 ' HB3' ' A' ' 123' ' ' ARG . 18.2 m -64.79 149.53 95.97 Favored Pre-proline 0 C--N 1.329 -0.296 0 CA-C-N 116.577 -0.283 . . . . 0.0 111.128 179.602 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 119' ' ' PRO . . . . . . . . . . . . . 93.9 Cg_endo -84.89 -17.83 4.68 Favored 'Trans proline' 0 N--CA 1.459 -0.517 0 C-N-CA 122.504 2.136 . . . . 0.0 112.135 179.808 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -145.41 -123.27 1.58 Allowed Glycine 0 N--CA 1.45 -0.386 0 C-N-CA 120.714 -0.755 . . . . 0.0 112.79 -179.923 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 45.1 pt -96.44 10.86 5.27 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.222 0 CA-C-O 120.714 0.293 . . . . 0.0 111.541 -179.535 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 43.6 mt-10 -59.6 -17.75 35.62 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.331 -0.395 . . . . 0.0 111.166 179.9 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 123' ' ' ARG . . . . . 0.547 ' HB3' HG22 ' A' ' 118' ' ' VAL . 19.8 ptt180 -49.69 -34.96 20.08 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 116.307 -0.406 . . . . 0.0 111.46 -179.928 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 124' ' ' TYR . . . . . . . . . . . . . 49.3 m-85 -70.98 -32.41 69.23 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.438 -0.346 . . . . 0.0 111.041 179.997 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 125' ' ' ALA . . . . . . . . . . . . . . . -68.25 -52.02 38.64 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.012 179.595 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 126' ' ' LEU . . . . . 0.428 ' HB3' ' O ' ' A' ' 111' ' ' ALA . 2.6 mm? -53.61 -56.17 19.53 Favored 'General case' 0 CA--C 1.521 -0.141 0 CA-C-N 116.09 -0.504 . . . . 0.0 110.687 179.973 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 127' ' ' PHE . . . . . 0.458 ' HZ ' ' HB3' ' A' ' 175' ' ' PRO . 9.6 t80 -67.39 -29.6 69.15 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.741 -179.91 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 128' ' ' GLY . . . . . . . . . . . . . . . -47.14 -54.49 9.73 Favored Glycine 0 N--CA 1.451 -0.36 0 C-N-CA 119.991 -1.099 . . . . 0.0 110.768 178.968 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 129' ' ' MET . . . . . 0.697 ' HE1' ' HA2' ' A' ' 130' ' ' GLY . 0.0 OUTLIER -72.21 -27.56 62.62 Favored 'General case' 0 C--N 1.328 -0.359 0 N-CA-C 109.144 -0.687 . . . . 0.0 109.144 178.624 . . . . . . . . 3 3 . 1 . 023 nuclear orig full ' A' A ' 130' ' ' GLY . . . . . 0.697 ' HA2' ' HE1' ' A' ' 129' ' ' MET . . . -61.72 -37.46 94.29 Favored Glycine 0 C--N 1.334 0.435 0 CA-C-N 115.792 -0.64 . . . . 0.0 112.288 179.541 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -74.75 -52.3 11.88 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.754 0.311 . . . . 0.0 110.457 179.696 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 42.1 t -54.88 -47.33 75.58 Favored 'Isoleucine or valine' 0 C--O 1.234 0.257 0 CA-C-O 121.243 0.544 . . . . 0.0 109.602 178.981 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -65.45 -37.08 85.82 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 115.523 -0.762 . . . . 0.0 110.915 179.245 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 134' ' ' PHE . . . . . 0.411 ' CZ ' ' HA ' ' A' ' 172' ' ' ALA . 45.9 t80 -53.27 -54.02 42.34 Favored 'General case' 0 N--CA 1.452 -0.361 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.26 179.816 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 135' ' ' ILE . . . . . 0.462 ' O ' HG22 ' A' ' 138' ' ' VAL . 42.5 mt -59.66 -32.85 50.24 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 CA-C-N 115.85 -0.614 . . . . 0.0 110.23 179.473 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 136' ' ' GLY . . . . . 0.436 ' O ' ' HB3' ' A' ' 139' ' ' TYR . . . -58.93 -40.06 94.85 Favored Glycine 0 N--CA 1.449 -0.463 0 C-N-CA 120.153 -1.023 . . . . 0.0 111.236 178.706 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 137' ' ' LEU . . . . . 0.461 HD13 HD22 ' A' ' 105' ' ' ASN . 64.0 tp -69.61 -53.37 19.11 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 115.863 -0.169 . . . . 0.0 110.806 179.541 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 138' ' ' VAL . . . . . 0.462 HG22 ' O ' ' A' ' 135' ' ' ILE . 3.3 m -54.69 -31.38 23.82 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.144 0 N-CA-C 109.333 -0.617 . . . . 0.0 109.333 -179.915 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 139' ' ' TYR . . . . . 0.436 ' HB3' ' O ' ' A' ' 136' ' ' GLY . 44.1 t80 -60.19 -46.35 90.03 Favored 'General case' 0 N--CA 1.453 -0.29 0 CA-C-N 115.544 -0.753 . . . . 0.0 109.404 178.183 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 140' ' ' TYR . . . . . 0.427 ' HE2' HD21 ' A' ' 104' ' ' LEU . 22.2 m-85 -63.86 -42.33 97.58 Favored 'General case' 0 C--N 1.333 -0.132 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.526 178.813 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 141' ' ' LEU . . . . . 0.411 ' HA ' ' SD ' ' A' ' 145' ' ' MET . 11.0 mp -57.13 -27.62 61.99 Favored 'General case' 0 C--N 1.332 -0.173 0 CA-C-N 115.948 -0.569 . . . . 0.0 111.193 -179.743 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 142' ' ' VAL . . . . . 0.413 HG21 ' O ' ' A' ' 138' ' ' VAL . 12.0 t -106.15 -7.91 10.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-O 120.992 0.425 . . . . 0.0 110.926 179.866 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . -73.84 -133.71 0.25 Allowed Glycine 0 CA--C 1.522 0.48 0 C-N-CA 120.812 -0.709 . . . . 0.0 112.814 -179.849 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 144' ' ' PRO . . . . . . . . . . . . . 51.5 Cg_exo -55.57 -23.96 42.47 Favored 'Trans proline' 0 C--N 1.349 0.555 0 C-N-CA 122.672 2.248 . . . . 0.0 113.03 -179.693 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 145' ' ' MET . . . . . 0.411 ' SD ' ' HA ' ' A' ' 141' ' ' LEU . 54.9 mtt -53.77 -27.92 31.71 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-O 120.727 0.299 . . . . 0.0 111.497 -179.583 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 146' ' ' THR . . . . . . . . . . . . . 70.5 p -79.04 -32.99 45.11 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.357 -0.383 . . . . 0.0 110.991 -179.558 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 39.7 tt0 -73.93 -40.26 63.23 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 115.861 -0.609 . . . . 0.0 111.354 -179.636 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 148' ' ' SER . . . . . . . . . . . . . 46.9 t -70.0 -42.26 73.28 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.325 -0.398 . . . . 0.0 111.327 -179.524 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 149' ' ' ALA . . . . . 0.422 ' HB2' ' HB1' ' A' ' 91' ' ' ALA . . . -70.83 -40.27 72.51 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.443 -0.344 . . . . 0.0 111.827 -179.649 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 150' ' ' SER . . . . . 0.594 ' HA ' ' HG2' ' A' ' 157' ' ' LYS . 39.2 t -69.46 -0.02 5.88 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.516 -0.311 . . . . 0.0 111.431 -179.564 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 151' ' ' GLN . . . . . . . . . . . . . 46.1 mt-30 -132.52 6.47 4.09 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.583 -0.28 . . . . 0.0 111.238 179.955 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 25.7 tpt180 -78.73 -52.41 8.43 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-O 120.94 0.4 . . . . 0.0 110.671 179.994 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 153' ' ' SER . . . . . 0.646 ' HB2' HG12 ' A' ' 156' ' ' ILE . 19.8 m -157.51 172.52 18.42 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 115.829 -0.623 . . . . 0.0 110.359 179.183 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 154' ' ' SER . . . . . 0.466 ' HA ' ' NZ ' ' A' ' 157' ' ' LYS . 49.9 m -68.68 -41.08 79.75 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.775 0.321 . . . . 0.0 110.983 179.728 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -76.78 -35.5 39.92 Favored Glycine 0 CA--C 1.519 0.343 0 C-N-CA 120.982 -0.627 . . . . 0.0 113.427 -179.537 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 156' ' ' ILE . . . . . 0.646 HG12 ' HB2' ' A' ' 153' ' ' SER . 41.8 mm -50.15 -38.48 15.06 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.217 0 N-CA-C 111.764 0.283 . . . . 0.0 111.764 -179.421 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 157' ' ' LYS . . . . . 0.594 ' HG2' ' HA ' ' A' ' 150' ' ' SER . 33.3 mtmm -59.78 -40.28 87.72 Favored 'General case' 0 C--N 1.327 -0.371 0 N-CA-C 112.034 0.383 . . . . 0.0 112.034 -179.254 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 36.5 t -72.53 -47.26 49.73 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 121.047 0.451 . . . . 0.0 111.425 -179.046 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 159' ' ' LEU . . . . . 0.43 ' O ' ' HB2' ' A' ' 163' ' ' LEU . 10.2 mt -68.67 -29.17 67.58 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-N 115.986 -0.552 . . . . 0.0 111.534 -179.108 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 160' ' ' TYR . . . . . . . . . . . . . 77.9 t80 -72.63 -46.84 52.08 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.454 -0.339 . . . . 0.0 111.629 -179.336 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 161' ' ' VAL . . . . . 0.459 HG22 ' N ' ' A' ' 162' ' ' ARG . 27.3 m -62.42 -42.79 96.98 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 N-CA-C 111.84 0.311 . . . . 0.0 111.84 -179.154 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 162' ' ' ARG . . . . . 0.459 ' N ' HG22 ' A' ' 161' ' ' VAL . 77.3 mtp180 -68.84 -48.53 63.28 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 120.647 0.26 . . . . 0.0 111.53 -179.678 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 163' ' ' LEU . . . . . 0.43 ' HB2' ' O ' ' A' ' 159' ' ' LEU . 6.8 mp -67.5 -45.08 76.88 Favored 'General case' 0 CA--C 1.531 0.24 0 CA-C-N 116.388 -0.369 . . . . 0.0 111.968 -179.01 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 164' ' ' ARG . . . . . . . . . . . . . 4.3 tmm_? -57.78 -50.97 71.46 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-O 120.635 0.255 . . . . 0.0 110.867 -179.719 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 165' ' ' ASN . . . . . 0.468 ' N ' HD21 ' A' ' 165' ' ' ASN . 0.9 OUTLIER -55.37 -41.37 72.52 Favored 'General case' 0 N--CA 1.448 -0.567 0 CA-C-N 116.352 -0.385 . . . . 0.0 110.486 179.78 . . . . . . . . 3 3 . 1 . 023 nuclear orig full ' A' A ' 166' ' ' LEU . . . . . 0.478 ' O ' ' HG ' ' A' ' 170' ' ' LEU . 3.6 mt -58.16 -53.61 56.31 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 115.944 -0.571 . . . . 0.0 110.894 179.496 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 167' ' ' THR . . . . . 0.55 ' HA ' HD11 ' A' ' 170' ' ' LEU . 13.7 m -54.39 -52.58 61.23 Favored 'General case' 0 C--N 1.331 -0.204 0 N-CA-C 112.451 0.537 . . . . 0.0 112.451 -178.431 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 168' ' ' VAL . . . . . . . . . . . . . 85.9 t -54.96 -40.57 54.12 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.483 0 N-CA-C 112.612 0.597 . . . . 0.0 112.612 -178.724 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 169' ' ' VAL . . . . . 0.443 ' O ' HG12 ' A' ' 173' ' ' ILE . 68.7 t -69.18 -67.19 0.46 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 N-CA-C 113.526 0.936 . . . . 0.0 113.526 -177.894 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 170' ' ' LEU . . . . . 0.55 HD11 ' HA ' ' A' ' 167' ' ' THR . 0.4 OUTLIER -59.18 -34.58 72.29 Favored 'General case' 0 N--CA 1.465 0.323 0 N-CA-C 112.869 0.692 . . . . 0.0 112.869 -177.7 . . . . . . . . 3 3 . 1 . 023 nuclear orig full ' A' A ' 171' ' ' TRP . . . . . 0.493 ' H ' HD13 ' A' ' 170' ' ' LEU . 16.8 m0 -73.29 -31.52 64.1 Favored 'General case' 0 C--N 1.329 -0.29 0 C-N-CA 120.607 -0.437 . . . . 0.0 111.24 -179.507 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 172' ' ' ALA . . . . . 0.411 ' HA ' ' CZ ' ' A' ' 134' ' ' PHE . . . -71.17 -7.15 44.76 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-O 120.912 0.387 . . . . 0.0 110.337 179.52 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 173' ' ' ILE . . . . . 0.53 ' O ' HG12 ' A' ' 177' ' ' ILE . 38.6 mm -88.44 -28.12 5.41 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.173 0 CA-C-N 115.896 -0.593 . . . . 0.0 111.044 179.512 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 174' ' ' TYR . . . . . 0.491 ' HD2' ' HA ' ' A' ' 171' ' ' TRP . 19.2 m-85 -54.11 -48.71 93.33 Favored Pre-proline 0 N--CA 1.467 0.392 0 CA-C-N 116.523 -0.308 . . . . 0.0 111.699 -179.512 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 175' ' ' PRO . . . . . 0.458 ' HB3' ' HZ ' ' A' ' 127' ' ' PHE . 82.5 Cg_exo -45.36 -33.29 8.73 Favored 'Trans proline' 0 C--N 1.351 0.658 0 C-N-CA 121.964 1.776 . . . . 0.0 111.857 179.467 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 176' ' ' PHE . . . . . 0.491 ' O ' ' HG ' ' A' ' 180' ' ' LEU . 96.6 m-85 -80.97 -50.6 9.5 Favored 'General case' 0 CA--C 1.518 -0.287 0 CA-C-N 115.843 -0.617 . . . . 0.0 111.792 179.937 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 177' ' ' ILE . . . . . 0.53 HG12 ' O ' ' A' ' 173' ' ' ILE . 6.6 mm -58.17 -32.49 44.5 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.517 0 CA-C-N 115.927 -0.579 . . . . 0.0 112.56 -177.494 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 178' ' ' TRP . . . . . . . . . . . . . 84.3 t90 -73.45 -32.2 64.22 Favored 'General case' 0 CA--C 1.52 -0.205 0 CA-C-O 120.884 0.373 . . . . 0.0 110.577 179.629 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 179' ' ' LEU . . . . . 0.523 ' HG ' HG22 ' A' ' 185' ' ' VAL . 17.3 tp -81.88 -55.29 4.7 Favored 'General case' 0 C--N 1.322 -0.601 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.851 -179.478 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 180' ' ' LEU . . . . . 0.491 ' HG ' ' O ' ' A' ' 176' ' ' PHE . 7.0 mt -62.04 -51.33 68.42 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.109 -0.496 . . . . 0.0 111.287 -179.479 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 181' ' ' GLY . . . . . 0.44 ' HA3' ' OD1' ' A' ' 193' ' ' ASP . . . -65.7 -84.76 0.08 OUTLIER Glycine 0 C--N 1.332 0.316 0 C-N-CA 120.338 -0.934 . . . . 0.0 111.925 179.414 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 182' ' ' PRO . . . . . 0.54 ' HB3' ' HD2' ' A' ' 183' ' ' PRO . 81.7 Cg_exo -48.25 176.98 0.02 OUTLIER 'Trans proline' 0 C--N 1.35 0.631 0 C-N-CA 122.999 2.466 . . . . 0.0 112.244 178.743 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 183' ' ' PRO . . . . . 0.54 ' HD2' ' HB3' ' A' ' 182' ' ' PRO . 19.2 Cg_endo -59.95 16.03 0.04 OUTLIER 'Trans proline' 0 C--N 1.351 0.674 0 C-N-CA 122.58 2.187 . . . . 0.0 115.142 -178.908 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 184' ' ' GLY . . . . . 0.441 ' H ' ' C ' ' A' ' 182' ' ' PRO . . . -59.51 -45.51 95.46 Favored Glycine 0 C--N 1.336 0.562 0 C-N-CA 119.48 -1.343 . . . . 0.0 110.693 178.756 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 185' ' ' VAL . . . . . 0.523 HG22 ' HG ' ' A' ' 179' ' ' LEU . 2.5 m -148.94 -35.63 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.327 -0.4 0 CA-C-N 114.867 -0.666 . . . . 0.0 110.528 178.635 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 186' ' ' ALA . . . . . . . . . . . . . . . 66.82 77.77 0.27 Allowed 'General case' 0 N--CA 1.462 0.138 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.863 178.607 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 187' ' ' LEU . . . . . 0.459 HD11 HD23 ' A' ' 180' ' ' LEU . 4.2 mt -92.67 -46.66 7.47 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.608 179.502 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 188' ' ' LEU . . . . . . . . . . . . . 97.8 mt -111.28 -166.36 1.07 Allowed 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 115.948 -0.569 . . . . 0.0 111.267 -179.808 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 189' ' ' THR . . . . . 0.427 ' HB ' HG23 ' A' ' 192' ' ' VAL . 26.8 m -81.81 136.3 48.02 Favored Pre-proline 0 C--N 1.328 -0.355 0 CA-C-N 115.822 -0.626 . . . . 0.0 110.932 -179.966 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 190' ' ' PRO . . . . . . . . . . . . . 5.6 Cg_endo -48.56 -38.99 36.95 Favored 'Trans proline' 0 C--N 1.35 0.644 0 C-N-CA 122.713 2.276 . . . . 0.0 112.08 179.611 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 191' ' ' THR . . . . . . . . . . . . . 59.5 p -58.27 -44.71 88.53 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.24 -0.437 . . . . 0.0 110.584 179.613 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 192' ' ' VAL . . . . . 0.427 HG23 ' HB ' ' A' ' 189' ' ' THR . 75.1 t -60.23 -40.38 83.5 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.229 0 CA-C-N 115.867 -0.606 . . . . 0.0 110.649 179.433 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 193' ' ' ASP . . . . . 0.44 ' OD1' ' HA3' ' A' ' 181' ' ' GLY . 3.4 t70 -56.15 -45.23 79.72 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 115.777 -0.647 . . . . 0.0 110.989 179.834 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 194' ' ' VAL . . . . . . . . . . . . . 48.4 t -63.07 -36.99 78.17 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.053 -0.521 . . . . 0.0 110.944 -179.839 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 195' ' ' ALA . . . . . . . . . . . . . . . -57.24 -47.64 80.86 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 116.393 -0.367 . . . . 0.0 110.838 179.674 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 196' ' ' LEU . . . . . . . . . . . . . 89.3 mt -68.37 -44.95 74.06 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-N 116.308 -0.406 . . . . 0.0 110.903 179.661 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 197' ' ' ILE . . . . . . . . . . . . . 20.2 mm -55.63 -58.37 4.93 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.58 179.633 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 198' ' ' VAL . . . . . . . . . . . . . 77.2 t -52.15 -35.1 18.64 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.568 0 CA-C-N 115.469 -0.787 . . . . 0.0 109.514 178.629 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 199' ' ' TYR . . . . . . . . . . . . . 42.2 t80 -70.38 -33.42 71.39 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 115.521 -0.763 . . . . 0.0 110.62 179.691 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 200' ' ' LEU . . . . . 0.408 HD11 HG13 ' A' ' 177' ' ' ILE . 51.7 mt -67.13 -42.54 84.25 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-N 115.97 -0.559 . . . . 0.0 111.135 -179.683 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 201' ' ' ASP . . . . . . . . . . . . . 8.3 m-20 -72.85 -31.65 64.91 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-O 121.083 0.468 . . . . 0.0 110.235 179.656 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 202' ' ' LEU . . . . . 0.437 ' O ' ' HB ' ' A' ' 206' ' ' VAL . 3.3 mt -70.88 -31.57 68.28 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 115.65 -0.705 . . . . 0.0 112.082 -179.476 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 203' ' ' VAL . . . . . 0.416 ' O ' ' HA3' ' A' ' 207' ' ' GLY . 7.1 p -80.82 -37.01 15.95 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-O 120.637 0.256 . . . . 0.0 111.25 -178.815 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 204' ' ' THR . . . . . 0.436 ' O ' ' HB2' ' A' ' 208' ' ' PHE . 22.2 m -70.1 -48.8 56.14 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-O 120.836 0.351 . . . . 0.0 111.406 179.945 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 205' ' ' LYS . . . . . 0.606 ' HE2' ' HB1' ' A' ' 47' ' ' ALA . 62.7 mttp -72.94 -57.65 3.9 Favored 'General case' 0 C--N 1.326 -0.429 0 N-CA-C 112.129 0.418 . . . . 0.0 112.129 -179.004 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 206' ' ' VAL . . . . . 0.437 ' HB ' ' O ' ' A' ' 202' ' ' LEU . 51.7 t -70.98 -41.89 76.99 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-O 120.631 0.253 . . . . 0.0 111.626 -179.363 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 207' ' ' GLY . . . . . 0.419 ' O ' HD12 ' A' ' 211' ' ' ILE . . . -61.2 -59.6 9.74 Favored Glycine 0 C--N 1.33 0.216 0 C-N-CA 120.631 -0.795 . . . . 0.0 112.698 -179.766 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 208' ' ' PHE . . . . . 0.48 ' O ' ' N ' ' A' ' 212' ' ' ALA . 8.1 m-85 -54.29 -47.08 72.77 Favored 'General case' 0 C--O 1.222 -0.391 0 CA-C-O 121.058 0.456 . . . . 0.0 110.202 -179.986 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 209' ' ' GLY . . . . . 0.446 ' HA2' ' HB3' ' A' ' 212' ' ' ALA . . . -56.21 -32.87 60.57 Favored Glycine 0 N--CA 1.449 -0.454 0 CA-C-N 115.004 -0.998 . . . . 0.0 113.299 179.747 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 210' ' ' PHE . . . . . . . . . . . . . 2.2 m-85 -72.03 -46.02 58.65 Favored 'General case' 0 CA--C 1.513 -0.469 0 N-CA-C 108.811 -0.811 . . . . 0.0 108.811 179.556 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 211' ' ' ILE . . . . . 0.469 HD11 HD11 ' A' ' 166' ' ' LEU . 3.3 mt -67.59 -27.3 37.87 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.658 0 N-CA-C 107.625 -1.25 . . . . 0.0 107.625 176.481 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 212' ' ' ALA . . . . . 0.48 ' N ' ' O ' ' A' ' 208' ' ' PHE . . . -68.18 -43.54 77.94 Favored 'General case' 0 N--CA 1.452 -0.371 0 CA-C-N 114.415 -1.266 . . . . 0.0 110.785 -179.712 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 213' ' ' LEU . . . . . . . . . . . . . 81.0 mt -70.1 -54.18 14.16 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 115.329 -0.85 . . . . 0.0 111.221 -179.514 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 214' ' ' ASP . . . . . . . . . . . . . 12.8 t70 -55.51 -35.36 65.53 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.801 -179.865 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 215' ' ' ALA . . . . . . . . . . . . . . . -65.65 -57.92 6.95 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.024 -0.535 . . . . 0.0 111.338 -179.916 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 216' ' ' ALA . . . . . . . . . . . . . . . -61.43 -31.09 71.02 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.112 -0.495 . . . . 0.0 111.103 -179.892 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 217' ' ' ALA . . . . . . . . . . . . . . . -62.51 -40.0 95.32 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.31 179.776 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 218' ' ' THR . . . . . . . . . . . . . 93.7 m -69.36 -38.87 78.27 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 115.94 -0.573 . . . . 0.0 110.693 179.408 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 219' ' ' LEU . . . . . . . . . . . . . 70.6 mt -59.6 -40.53 87.77 Favored 'General case' 0 C--N 1.332 -0.185 0 CA-C-N 116.097 -0.501 . . . . 0.0 110.63 179.683 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 220' ' ' ARG . . . . . . . . . . . . . 76.2 mtp180 -82.58 -18.61 40.69 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 115.963 -0.562 . . . . 0.0 110.395 179.598 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 221' ' ' ALA . . . . . . . . . . . . . . . -75.42 -26.09 58.08 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 115.865 -0.607 . . . . 0.0 111.21 179.918 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 222' ' ' GLU . . . . . . . . . . . . . 10.1 pt-20 -92.34 -23.34 19.28 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.39 -0.368 . . . . 0.0 110.381 -179.9 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 223' ' ' HIS . . . . . . . . . . . . . 79.7 m-70 59.71 100.32 0.02 OUTLIER 'General case' 0 C--N 1.331 -0.206 0 CA-C-N 115.726 -0.67 . . . . 0.0 111.118 179.885 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 224' ' ' GLY . . . . . . . . . . . . . . . -94.3 53.31 2.13 Favored Glycine 0 N--CA 1.452 -0.269 0 C-N-CA 120.767 -0.73 . . . . 0.0 112.615 -179.805 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 225' ' ' GLU . . . . . . . . . . . . . 12.1 pt-20 -124.34 148.12 47.71 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.911 0.386 . . . . 0.0 110.941 179.827 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 226' ' ' SER . . . . . . . . . . . . . 80.2 p -83.94 -175.44 5.81 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-N 116.08 -0.509 . . . . 0.0 110.803 179.895 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 227' ' ' LEU . . . . . . . . . . . . . 73.7 mt -81.39 122.26 27.26 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.944 -179.928 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 228' ' ' ALA . . . . . . . . . . . . . . . -93.72 143.84 25.95 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.161 -179.958 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 229' ' ' GLY . . . . . . . . . . . . . . . -161.32 99.78 0.18 Allowed Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.847 -0.692 . . . . 0.0 112.44 179.917 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 230' ' ' VAL . . . . . . . . . . . . . 22.1 t -99.67 137.09 28.22 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.224 0 CA-C-O 120.856 0.36 . . . . 0.0 111.105 -179.808 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 231' ' ' ASP . . . . . . . . . . . . . 5.4 m-20 -87.7 97.66 11.01 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.972 179.913 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 232' ' ' THR . . . . . . . . . . . . . 64.7 p -128.14 124.01 35.85 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.94 179.939 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 233' ' ' ASP . . . . . . . . . . . . . 17.5 t70 -87.11 -34.4 19.13 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.059 -179.857 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 234' ' ' THR . . . . . . . . . . . . . 72.6 p -99.51 117.13 64.31 Favored Pre-proline 0 C--N 1.328 -0.356 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.994 -179.999 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 235' ' ' PRO . . . . . . . . . . . . . 28.3 Cg_endo -61.88 159.22 34.45 Favored 'Trans proline' 0 C--N 1.347 0.474 0 C-N-CA 122.38 2.053 . . . . 0.0 111.991 179.879 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 236' ' ' ALA . . . . . . . . . . . . . . . -149.38 113.77 5.25 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.342 -0.39 . . . . 0.0 111.18 -179.933 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 237' ' ' VAL . . . . . . . . . . . . . 31.6 m -107.76 159.87 7.12 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.134 -0.485 . . . . 0.0 111.112 179.888 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 238' ' ' ALA . . . . . . . . . . . . . . . -76.07 -68.94 0.53 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.184 -179.989 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 239' ' ' ASP . . . . . . . . . . . . . 12.3 m-20 -97.12 148.82 22.65 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.122 -0.49 . . . . 0.0 111.043 -179.954 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 240' ' ' LEU . . . . . . . . . . . . . 71.5 mt -89.31 106.31 18.36 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.803 179.868 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 241' ' ' GLU . . . . . . . . . . . . . 18.3 mm-40 -111.96 -26.89 8.67 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.99 -179.878 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 242' ' ' HIS . . . . . . . . . . . . . 53.8 m-70 58.04 18.18 4.97 Favored 'General case' 0 C--N 1.331 -0.203 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.927 -179.948 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 243' ' ' HIS . . . . . . . . . . . . . 52.2 t-80 -113.55 -51.62 2.79 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.554 -179.993 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 244' ' ' HIS . . . . . . . . . . . . . 71.2 m80 60.13 176.7 0.09 Allowed 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 115.914 -0.584 . . . . 0.0 111.527 179.588 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 245' ' ' HIS . . . . . . . . . . . . . 85.9 m-70 -79.01 121.77 25.34 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 115.911 -0.586 . . . . 0.0 110.946 -179.934 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 246' ' ' HIS . . . . . . . . . . . . . 36.3 p-80 -99.0 176.38 5.59 Favored 'General case' 0 C--N 1.332 -0.175 0 CA-C-N 116.37 -0.377 . . . . 0.0 110.852 179.833 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 247' ' ' HIS . . . . . . . . . . . . . 23.2 t60 . . . . . 0 C--O 1.249 1.036 0 CA-C-O 118.208 -0.901 . . . . 0.0 110.922 179.881 . . . . . . . . 0 0 . 1 . 023 nuclear orig full ' A' A ' 301' ' ' RET . . . . . 0.464 H203 HG13 ' A' ' 83' ' ' ILE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 95.9 mmm . . . . . 0 N--CA 1.486 1.357 0 CA-C-O 120.888 0.375 . . . . 0.0 110.94 . . . . . . . . . 0 0 . 1 . 024 nuclear orig full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 42.2 t -126.36 -34.25 0.88 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.121 -179.903 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -86.75 -12.2 69.43 Favored Glycine 0 N--CA 1.452 -0.275 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.5 -179.813 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 67.0 tp -74.22 -36.6 63.96 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.795 0.331 . . . . 0.0 111.006 179.964 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 82.6 p -58.22 -32.96 68.81 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.531 -179.78 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 30.4 p -54.47 -34.9 62.4 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.343 -0.39 . . . . 0.0 111.109 -179.979 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 7' ' ' LEU . . . . . . . . . . . . . 4.3 mm? -58.22 -53.9 53.04 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 115.994 -0.548 . . . . 0.0 111.514 -179.732 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 8' ' ' PHE . . . . . 0.442 ' HB2' ' HB1' ' A' ' 55' ' ' ALA . 68.3 m-85 -64.22 -36.07 82.86 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.293 -0.412 . . . . 0.0 111.232 -179.484 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 9' ' ' TRP . . . . . . . . . . . . . 44.8 m95 -65.02 -48.98 71.99 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-O 121.098 0.475 . . . . 0.0 110.16 -179.675 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 79.9 mt -60.33 -38.7 84.57 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-N 115.587 -0.733 . . . . 0.0 110.532 179.685 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -65.03 -31.13 79.87 Favored Glycine 0 N--CA 1.448 -0.504 0 C-N-CA 120.647 -0.787 . . . . 0.0 111.642 179.199 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -71.13 -30.71 66.83 Favored 'General case' 0 N--CA 1.454 -0.231 0 CA-C-O 120.81 0.338 . . . . 0.0 110.56 179.393 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 71.8 mt -66.57 -54.61 24.07 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.235 0 CA-C-N 115.959 -0.564 . . . . 0.0 110.335 179.345 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -62.95 -35.56 92.22 Favored Glycine 0 N--CA 1.449 -0.455 0 C-N-CA 120.645 -0.788 . . . . 0.0 111.441 179.374 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 15' ' ' MET . . . . . 0.495 ' SD ' ' HA ' ' A' ' 44' ' ' SER . 53.1 tpp -62.9 -46.37 88.16 Favored 'General case' 0 C--N 1.329 -0.296 0 N-CA-C 110.088 -0.338 . . . . 0.0 110.088 179.358 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 16' ' ' LEU . . . . . 0.407 HD13 ' O ' ' A' ' 16' ' ' LEU . 0.8 OUTLIER -53.22 -39.99 64.16 Favored 'General case' 0 C--N 1.332 -0.187 0 CA-C-N 115.866 -0.606 . . . . 0.0 109.689 179.057 . . . . . . . . 3 3 . 1 . 024 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 70.3 t -58.98 -45.55 92.09 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.206 0 CA-C-N 116.036 -0.529 . . . . 0.0 110.177 179.156 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -63.93 -42.73 98.22 Favored Glycine 0 N--CA 1.45 -0.392 0 C-N-CA 120.749 -0.739 . . . . 0.0 111.737 179.038 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 19' ' ' THR . . . . . 0.436 ' N ' ' HG ' ' A' ' 44' ' ' SER . 11.3 m -52.74 -46.51 67.48 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-O 120.847 0.356 . . . . 0.0 111.146 -179.806 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 92.3 mt -71.8 -39.02 70.15 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.337 -179.826 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -59.8 -33.65 72.02 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.574 -0.285 . . . . 0.0 111.698 -179.615 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 22' ' ' PHE . . . . . 0.42 ' HB2' HG23 ' A' ' 41' ' ' VAL . 4.5 m-85 -90.99 -34.83 14.99 Favored 'General case' 0 C--N 1.331 -0.196 0 CA-C-O 120.727 0.299 . . . . 0.0 111.52 -179.446 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -66.53 -50.98 61.39 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 120.93 0.395 . . . . 0.0 111.539 -179.464 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 24' ' ' TRP . . . . . . . . . . . . . 5.1 t-105 -65.42 -45.11 85.16 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 115.877 -0.601 . . . . 0.0 111.176 -179.715 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -71.12 -24.02 62.2 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.854 0.359 . . . . 0.0 111.009 179.874 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -72.47 -41.23 52.39 Favored Glycine 0 N--CA 1.45 -0.371 0 C-N-CA 120.93 -0.652 . . . . 0.0 112.733 -179.866 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 99.3 mtt180 -69.16 -10.03 55.74 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.752 0.31 . . . . 0.0 110.908 -179.894 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 13.1 t70 -127.21 88.74 2.85 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.714 179.876 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -161.12 -80.91 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.199 179.921 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -162.05 -127.98 0.92 Allowed Glycine 0 N--CA 1.452 -0.248 0 C-N-CA 120.806 -0.711 . . . . 0.0 112.476 -179.96 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 89.3 p -136.78 -37.7 0.66 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.749 0.309 . . . . 0.0 110.862 -179.923 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -81.2 -36.24 21.62 Favored Glycine 0 N--CA 1.452 -0.276 0 C-N-CA 120.706 -0.759 . . . . 0.0 112.494 179.921 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 12.4 mm-40 -72.49 -21.11 61.25 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.652 0.263 . . . . 0.0 110.945 -179.922 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 34' ' ' ARG . . . . . . . . . . . . . 79.0 ttt180 -51.57 -29.36 16.88 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 116.111 -0.495 . . . . 0.0 111.468 -179.607 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 80.2 ttt180 -60.19 -48.8 80.21 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.856 0.36 . . . . 0.0 110.882 179.896 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 59.4 m-85 -67.46 -29.87 69.43 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.028 -0.533 . . . . 0.0 111.139 179.896 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 37' ' ' TYR . . . . . . . . . . . . . 43.8 m-85 -72.13 -53.0 14.05 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.071 -0.513 . . . . 0.0 111.62 -179.365 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 96.7 t -56.92 -37.39 54.05 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-O 121.103 0.477 . . . . 0.0 110.129 179.594 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 38.1 m -65.72 -46.27 79.57 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 115.662 -0.699 . . . . 0.0 110.182 179.158 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 28.2 tp -59.67 -50.17 74.91 Favored 'General case' 0 C--O 1.235 0.318 0 CA-C-N 115.771 -0.649 . . . . 0.0 110.459 179.588 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . 0.42 HG23 ' HB2' ' A' ' 22' ' ' PHE . 61.3 t -59.1 -34.63 53.88 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.254 0 CA-C-N 115.842 -0.617 . . . . 0.0 109.938 179.186 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -59.07 -39.19 94.03 Favored Glycine 0 N--CA 1.449 -0.475 0 C-N-CA 120.727 -0.749 . . . . 0.0 111.832 179.252 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 43' ' ' ILE . . . . . 0.435 ' H ' HG13 ' A' ' 43' ' ' ILE . 0.9 OUTLIER -64.96 -57.08 12.63 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.153 0 CA-C-O 120.831 0.348 . . . . 0.0 110.786 179.402 . . . . . . . . 3 3 . 1 . 024 nuclear orig full ' A' A ' 44' ' ' SER . . . . . 0.495 ' HA ' ' SD ' ' A' ' 15' ' ' MET . 40.8 t -59.72 -24.21 63.81 Favored 'General case' 0 C--N 1.332 -0.168 0 CA-C-N 116.103 -0.499 . . . . 0.0 111.56 -179.691 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -74.15 -59.55 3.89 Favored Glycine 0 CA--C 1.518 0.262 0 C-N-CA 120.72 -0.752 . . . . 0.0 113.039 -179.647 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 21.1 pt -58.72 -35.02 53.54 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.19 0 CA-C-O 120.745 0.307 . . . . 0.0 111.286 -179.876 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 47' ' ' ALA . . . . . 0.554 ' HB2' ' HE2' ' A' ' 205' ' ' LYS . . . -65.98 -45.74 80.53 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-N 116.32 -0.4 . . . . 0.0 111.058 179.833 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -54.84 -52.18 63.58 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.246 -0.434 . . . . 0.0 111.216 -179.713 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 49' ' ' VAL . . . . . 0.403 ' O ' HG13 ' A' ' 53' ' ' VAL . 34.6 m -64.35 -34.04 66.66 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.393 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.821 179.931 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -65.23 -37.93 88.81 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.367 -0.379 . . . . 0.0 110.845 179.576 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 51' ' ' TYR . . . . . 0.406 ' HB3' ' O ' ' A' ' 8' ' ' PHE . 30.3 m-85 -70.79 -29.06 65.15 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.193 179.944 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -74.5 -41.67 60.29 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-N 115.613 -0.721 . . . . 0.0 111.184 179.59 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 53' ' ' VAL . . . . . 0.425 HG22 ' N ' ' A' ' 54' ' ' MET . 20.8 m -73.25 -43.52 56.99 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.125 0 CA-C-N 116.498 -0.319 . . . . 0.0 111.008 179.883 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 54' ' ' MET . . . . . 0.425 ' N ' HG22 ' A' ' 53' ' ' VAL . 72.8 mtm -63.49 -32.46 73.92 Favored 'General case' 0 C--N 1.332 -0.183 0 CA-C-O 121.038 0.447 . . . . 0.0 110.023 179.443 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 55' ' ' ALA . . . . . 0.442 ' HB1' ' HB2' ' A' ' 8' ' ' PHE . . . -65.23 -37.06 86.07 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 115.667 -0.697 . . . . 0.0 110.712 179.349 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 93.8 mt -76.5 -13.03 60.12 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 115.869 -0.605 . . . . 0.0 110.851 179.756 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 71.53 31.21 65.7 Favored Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.782 -0.723 . . . . 0.0 112.818 179.991 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 32.3 m -79.92 19.98 0.15 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.211 0 CA-C-O 120.834 0.35 . . . . 0.0 111.557 179.869 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -159.1 14.93 0.23 Allowed Glycine 0 N--CA 1.451 -0.358 0 C-N-CA 120.795 -0.717 . . . . 0.0 112.844 179.866 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 60' ' ' TRP . . . . . . . . . . . . . 41.0 m0 -81.09 107.57 14.01 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.728 0.299 . . . . 0.0 110.633 179.862 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 4.9 p -106.38 119.33 52.19 Favored Pre-proline 0 CA--C 1.533 0.306 0 CA-C-N 116.342 -0.39 . . . . 0.0 111.572 -179.624 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 16.8 Cg_exo -67.6 133.76 30.84 Favored 'Trans proline' 0 C--N 1.351 0.659 0 C-N-CA 122.35 2.033 . . . . 0.0 111.79 179.423 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 78.2 t -132.48 100.54 4.06 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.373 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.214 -179.716 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . 59.53 -86.85 0.02 OUTLIER 'General case' 0 C--N 1.331 -0.212 0 CA-C-N 116.043 -0.526 . . . . 0.0 111.265 -179.999 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 45.1 mt-10 -122.36 -27.26 4.49 Favored 'General case' 0 C--N 1.332 -0.195 0 CA-C-N 116.362 -0.381 . . . . 0.0 110.724 179.992 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 66' ' ' ARG . . . . . 0.436 ' HD2' ' N ' ' A' ' 66' ' ' ARG . 8.1 mpt_? -104.64 140.62 37.76 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.611 179.826 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 22.3 m -98.17 113.19 25.03 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.345 -0.389 . . . . 0.0 111.113 -179.74 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 26.3 t -85.11 146.84 6.06 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.354 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.474 179.498 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 69' ' ' PHE . . . . . . . . . . . . . 19.8 m-85 -108.51 115.17 29.59 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-O 120.91 0.386 . . . . 0.0 110.111 -179.315 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 70' ' ' VAL . . . . . 0.52 ' HB ' ' HD3' ' A' ' 71' ' ' PRO . 13.4 t -68.9 -49.35 26.81 Favored Pre-proline 0 C--N 1.323 -0.557 0 CA-C-N 115.946 -0.57 . . . . 0.0 112.243 -179.006 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 71' ' ' PRO . . . . . 0.52 ' HD3' ' HB ' ' A' ' 70' ' ' VAL . 29.5 Cg_exo -61.97 -17.48 56.1 Favored 'Trans proline' 0 C--N 1.35 0.608 0 C-N-CA 122.176 1.917 . . . . 0.0 112.449 -179.525 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 51.6 ttp180 -71.34 -54.68 9.97 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.482 -0.327 . . . . 0.0 111.43 -179.727 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 73' ' ' TYR . . . . . 0.428 ' O ' HG13 ' A' ' 77' ' ' ILE . 96.2 m-85 -69.74 -31.69 69.82 Favored 'General case' 0 C--N 1.331 -0.235 0 C-N-CA 120.919 -0.313 . . . . 0.0 110.648 -179.84 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 74' ' ' ILE . . . . . 0.484 ' HA ' HD11 ' A' ' 77' ' ' ILE . 0.3 OUTLIER -69.74 -38.56 76.44 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.18 0 N-CA-C 109.672 -0.492 . . . . 0.0 109.672 178.993 . . . . . . . . 3 3 . 1 . 024 nuclear orig full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 11.4 t70 -59.08 -37.59 77.45 Favored 'General case' 0 N--CA 1.454 -0.24 0 N-CA-C 109.211 -0.663 . . . . 0.0 109.211 178.595 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 76' ' ' TRP . . . . . . . . . . . . . 53.6 m0 -67.97 -32.45 72.88 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 115.689 -0.687 . . . . 0.0 110.323 179.006 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 77' ' ' ILE . . . . . 0.484 HD11 ' HA ' ' A' ' 74' ' ' ILE . 97.6 mt -66.57 -29.37 46.29 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.362 179.232 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 48.9 mt -91.59 -19.98 22.15 Favored 'General case' 0 CA--C 1.532 0.277 0 CA-C-N 116.1 -0.5 . . . . 0.0 112.016 179.983 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 81.4 p -101.16 -52.63 3.22 Favored 'General case' 0 N--CA 1.465 0.323 0 N-CA-C 113.538 0.94 . . . . 0.0 113.538 -177.889 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 80' ' ' THR . . . . . 0.456 ' N ' ' HD2' ' A' ' 81' ' ' PRO . 61.3 m -46.69 -53.87 22.72 Favored Pre-proline 0 CA--C 1.533 0.296 0 N-CA-C 112.886 0.699 . . . . 0.0 112.886 -178.557 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 81' ' ' PRO . . . . . 0.456 ' HD2' ' N ' ' A' ' 80' ' ' THR . 35.0 Cg_endo -62.2 -22.16 73.71 Favored 'Trans proline' 0 C--N 1.35 0.622 0 C-N-CA 121.543 1.495 . . . . 0.0 111.603 -179.598 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 82' ' ' LEU . . . . . . . . . . . . . 16.2 tp -76.91 -33.31 57.77 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 115.657 -0.701 . . . . 0.0 110.234 179.674 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 28.1 mm -69.2 -53.18 26.86 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.226 0 CA-C-N 116.087 -0.506 . . . . 0.0 110.122 179.162 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 28.9 m -60.13 -31.97 49.32 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.218 0 N-CA-C 109.645 -0.502 . . . . 0.0 109.645 178.907 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 85' ' ' TYR . . . . . . . . . . . . . 79.8 t80 -65.12 -34.11 77.63 Favored 'General case' 0 N--CA 1.452 -0.366 0 CA-C-N 115.641 -0.709 . . . . 0.0 109.532 178.963 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 86' ' ' PHE . . . . . . . . . . . . . 7.9 t80 -62.62 -51.08 68.68 Favored 'General case' 0 C--N 1.333 -0.14 0 CA-C-N 115.768 -0.651 . . . . 0.0 110.247 179.404 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 9.3 mp -61.53 -36.05 79.46 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 115.992 -0.549 . . . . 0.0 110.407 179.785 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -66.33 -27.96 73.39 Favored Glycine 0 N--CA 1.45 -0.404 0 C-N-CA 120.767 -0.73 . . . . 0.0 111.875 179.282 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 75.9 mt -72.73 -40.88 65.74 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 120.994 0.426 . . . . 0.0 110.624 179.716 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 47.3 mt -58.44 -47.53 83.68 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 115.648 -0.706 . . . . 0.0 111.336 -179.644 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . 0.417 ' HB2' ' HB2' ' A' ' 149' ' ' ALA . . . -75.46 -54.52 6.9 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.635 -179.545 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 107.11 69.51 0.7 Allowed Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.854 -0.689 . . . . 0.0 112.009 -179.591 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 93' ' ' LEU . . . . . 0.524 HD21 ' HB3' ' A' ' 97' ' ' GLU . 8.5 mp -87.41 171.66 10.39 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.794 0.331 . . . . 0.0 111.131 -179.6 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 94' ' ' ASP . . . . . . . . . . . . . 8.9 m-20 -90.93 166.25 13.14 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.928 179.826 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 49.6 m -55.56 -33.02 63.49 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-N 116.312 -0.404 . . . . 0.0 111.029 -179.987 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 9.4 ptp180 -71.53 -48.05 51.25 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.842 179.88 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 97' ' ' GLU . . . . . 0.524 ' HB3' HD21 ' A' ' 93' ' ' LEU . 44.6 mt-10 -58.2 -45.14 88.16 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.923 -179.969 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 98' ' ' PHE . . . . . 0.426 ' O ' HG12 ' A' ' 102' ' ' ILE . 31.2 m-85 -59.1 -48.85 80.09 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.374 -0.375 . . . . 0.0 110.615 179.568 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -55.9 -31.07 58.07 Favored Glycine 0 N--CA 1.45 -0.381 0 C-N-CA 120.888 -0.672 . . . . 0.0 112.587 -179.775 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 98.0 mt -71.5 -44.29 71.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-O 120.798 0.332 . . . . 0.0 111.531 -179.94 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 39.7 t -68.12 -51.07 52.51 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.729 -179.344 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 102' ' ' ILE . . . . . 0.426 HG12 ' O ' ' A' ' 98' ' ' PHE . 34.0 mm -59.38 -50.0 81.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.325 -0.398 . . . . 0.0 111.771 -179.253 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 7.9 t -59.37 -36.11 75.14 Favored 'General case' 0 C--N 1.331 -0.204 0 CA-C-O 120.761 0.315 . . . . 0.0 110.911 -179.739 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 104' ' ' LEU . . . . . 0.4 ' O ' HG23 ' A' ' 108' ' ' VAL . 27.4 tp -63.03 -44.44 95.9 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.218 -0.447 . . . . 0.0 110.403 179.542 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 105' ' ' ASN . . . . . 0.574 ' N ' HD21 ' A' ' 105' ' ' ASN . 0.8 OUTLIER -63.66 -26.47 68.68 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 115.955 -0.566 . . . . 0.0 110.555 179.726 . . . . . . . . 3 3 . 1 . 024 nuclear orig full ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 84.7 m -67.15 -54.59 19.81 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 115.998 -0.546 . . . . 0.0 111.167 179.954 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 7.5 p -63.6 -36.59 76.98 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.213 0 CA-C-N 116.42 -0.354 . . . . 0.0 111.05 -179.895 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . 0.4 HG23 ' O ' ' A' ' 104' ' ' LEU . 72.3 t -65.74 -45.5 91.62 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.226 0 CA-C-N 116.386 -0.37 . . . . 0.0 110.894 179.496 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 109' ' ' MET . . . . . . . . . . . . . 8.7 tpp -65.15 -39.24 92.7 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.829 -179.82 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 29.0 tp -66.98 -30.75 70.95 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.215 179.701 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -62.5 -52.37 63.77 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 116.068 -0.515 . . . . 0.0 110.313 179.136 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 112' ' ' GLY . . . . . 0.611 ' HA3' ' H22' ' A' ' 301' ' ' RET . . . -67.62 -32.56 78.74 Favored Glycine 0 N--CA 1.45 -0.395 0 C-N-CA 120.566 -0.826 . . . . 0.0 111.649 179.127 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 113' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER -52.79 -75.89 0.03 OUTLIER 'General case' 0 C--N 1.332 -0.179 0 CA-C-O 121.008 0.432 . . . . 0.0 109.883 179.357 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -61.05 -21.43 63.62 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-N 115.619 -0.719 . . . . 0.0 110.646 179.206 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -52.57 -50.98 46.32 Favored Glycine 0 C--N 1.333 0.385 0 C-N-CA 120.905 -0.664 . . . . 0.0 112.125 179.739 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 116' ' ' ALA . . . . . 0.548 ' HB2' ' HB3' ' A' ' 183' ' ' PRO . . . -78.19 -15.7 58.58 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 121.008 0.432 . . . . 0.0 110.723 179.217 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 117' ' ' MET . . . . . . . . . . . . . 45.1 tpp -87.49 -5.95 58.58 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 115.883 -0.599 . . . . 0.0 111.502 -179.588 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 21.7 m -58.81 146.67 74.78 Favored Pre-proline 0 C--N 1.331 -0.219 0 CA-C-N 116.683 -0.235 . . . . 0.0 111.449 -179.608 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 119' ' ' PRO . . . . . . . . . . . . . 69.2 Cg_endo -90.76 -5.45 4.43 Favored 'Trans proline' 0 N--CA 1.455 -0.748 0 C-N-CA 122.912 2.408 . . . . 0.0 112.228 179.431 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -145.41 -127.99 1.98 Allowed Glycine 0 C--N 1.333 0.362 0 C-N-CA 120.867 -0.683 . . . . 0.0 112.84 -179.733 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 46.6 pt -99.16 11.56 6.21 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.212 0 CA-C-O 120.596 0.236 . . . . 0.0 111.595 -179.491 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 122' ' ' GLU . . . . . 0.436 ' O ' HD12 ' A' ' 126' ' ' LEU . 15.1 mm-40 -60.53 -21.03 62.05 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.754 0.311 . . . . 0.0 110.997 -179.914 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 123' ' ' ARG . . . . . 0.431 HH11 ' HD2' ' A' ' 123' ' ' ARG . 10.0 ptt180 -52.22 -34.47 45.91 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.027 -0.533 . . . . 0.0 111.471 -179.935 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 124' ' ' TYR . . . . . . . . . . . . . 39.6 m-85 -69.16 -32.08 71.16 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.531 -179.574 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 125' ' ' ALA . . . . . . . . . . . . . . . -72.88 -56.51 5.09 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-O 120.831 0.348 . . . . 0.0 111.098 -179.699 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 126' ' ' LEU . . . . . 0.436 HD12 ' O ' ' A' ' 122' ' ' GLU . 1.3 mp -57.26 -49.61 75.51 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.662 179.92 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 127' ' ' PHE . . . . . . . . . . . . . 7.5 t80 -66.45 -37.42 85.12 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.335 -0.393 . . . . 0.0 110.857 -179.991 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 128' ' ' GLY . . . . . . . . . . . . . . . -47.18 -46.29 21.1 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.057 -1.068 . . . . 0.0 110.904 179.045 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 129' ' ' MET . . . . . . . . . . . . . 0.3 OUTLIER -70.13 -35.77 74.31 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 115.388 -0.406 . . . . 0.0 110.041 178.848 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -68.09 -28.2 73.45 Favored Glycine 0 C--N 1.334 0.434 0 CA-C-N 115.88 -0.6 . . . . 0.0 112.94 -179.659 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -74.42 -53.65 9.15 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 120.722 0.296 . . . . 0.0 110.313 179.915 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 22.2 t -58.2 -42.69 84.04 Favored 'Isoleucine or valine' 0 C--O 1.235 0.338 0 N-CA-C 109.022 -0.733 . . . . 0.0 109.022 178.476 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -64.31 -35.27 80.32 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.264 -0.88 . . . . 0.0 110.351 179.086 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 134' ' ' PHE . . . . . . . . . . . . . 75.3 t80 -56.74 -50.67 71.54 Favored 'General case' 0 N--CA 1.453 -0.323 0 CA-C-N 116.284 -0.416 . . . . 0.0 109.901 179.447 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 135' ' ' ILE . . . . . 0.469 ' HA ' HG21 ' A' ' 138' ' ' VAL . 63.0 mt -57.44 -33.17 43.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 115.779 -0.646 . . . . 0.0 109.967 179.114 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 136' ' ' GLY . . . . . 0.433 ' O ' ' HB3' ' A' ' 139' ' ' TYR . . . -62.13 -40.62 99.19 Favored Glycine 0 N--CA 1.449 -0.478 0 C-N-CA 120.134 -1.032 . . . . 0.0 111.44 178.689 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 137' ' ' LEU . . . . . . . . . . . . . 26.8 tp -68.91 -49.91 54.01 Favored 'General case' 0 N--CA 1.455 -0.219 0 CA-C-O 120.43 0.157 . . . . 0.0 110.701 179.673 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 138' ' ' VAL . . . . . 0.516 ' HA ' HD12 ' A' ' 141' ' ' LEU . 4.7 m -58.2 -31.39 41.97 Favored 'Isoleucine or valine' 0 C--O 1.233 0.22 0 CA-C-O 121.338 0.589 . . . . 0.0 109.618 179.219 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 139' ' ' TYR . . . . . 0.433 ' HB3' ' O ' ' A' ' 136' ' ' GLY . 55.7 t80 -60.48 -43.21 97.21 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 115.34 -0.845 . . . . 0.0 109.302 178.373 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 36.7 m-85 -64.03 -32.72 74.38 Favored 'General case' 0 C--N 1.332 -0.16 0 CA-C-N 115.839 -0.619 . . . . 0.0 110.451 178.887 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 141' ' ' LEU . . . . . 0.516 HD12 ' HA ' ' A' ' 138' ' ' VAL . 95.3 mt -57.67 -47.43 82.32 Favored 'General case' 0 N--CA 1.462 0.168 0 CA-C-N 116.349 -0.387 . . . . 0.0 110.588 179.671 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 9.5 p -95.85 1.28 10.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.818 179.868 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . -75.95 -140.55 0.94 Allowed Glycine 0 CA--C 1.52 0.361 0 C-N-CA 120.99 -0.624 . . . . 0.0 112.878 -179.572 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 144' ' ' PRO . . . . . . . . . . . . . 19.5 Cg_endo -58.88 -23.92 69.9 Favored 'Trans proline' 0 C--N 1.347 0.488 0 C-N-CA 122.745 2.297 . . . . 0.0 112.685 -179.776 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 145' ' ' MET . . . . . . . . . . . . . 56.8 mtt -58.19 -33.13 68.94 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 120.806 0.336 . . . . 0.0 111.242 179.966 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 146' ' ' THR . . . . . . . . . . . . . 12.1 m -80.86 -32.35 35.05 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.385 -179.05 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 40.2 tt0 -71.8 -42.32 67.21 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-N 116.165 -0.47 . . . . 0.0 111.169 -179.743 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 148' ' ' SER . . . . . . . . . . . . . 58.2 m -70.61 -46.86 62.58 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-N 116.263 -0.426 . . . . 0.0 111.407 -179.432 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 149' ' ' ALA . . . . . 0.417 ' HB2' ' HB2' ' A' ' 91' ' ' ALA . . . -63.03 -41.33 99.49 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.309 -0.405 . . . . 0.0 111.742 -179.496 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 150' ' ' SER . . . . . . . . . . . . . 66.2 m -68.91 -0.58 5.73 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.38 -0.373 . . . . 0.0 111.501 -179.617 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 151' ' ' GLN . . . . . . . . . . . . . 44.8 mt-30 -129.09 3.69 5.26 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.628 -0.26 . . . . 0.0 111.246 179.991 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 31.0 tpt180 -76.42 -51.31 12.09 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.895 0.379 . . . . 0.0 110.651 -179.985 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 153' ' ' SER . . . . . 0.61 ' HB3' HG12 ' A' ' 156' ' ' ILE . 22.8 t -157.21 172.4 18.7 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-N 115.885 -0.598 . . . . 0.0 110.473 179.496 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 154' ' ' SER . . . . . . . . . . . . . 70.2 p -67.65 -41.22 84.18 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.382 -0.372 . . . . 0.0 110.912 179.937 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -77.07 -37.03 33.71 Favored Glycine 0 CA--C 1.519 0.305 0 C-N-CA 120.961 -0.638 . . . . 0.0 113.158 -179.657 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 156' ' ' ILE . . . . . 0.61 HG12 ' HB3' ' A' ' 153' ' ' SER . 42.4 mm -52.66 -37.22 24.19 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.186 0 CA-C-O 120.628 0.252 . . . . 0.0 111.56 -179.47 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 157' ' ' LYS . . . . . . . . . . . . . 38.3 ttpt -60.29 -53.84 52.89 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.457 -0.338 . . . . 0.0 111.555 -179.629 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 48.9 m -63.5 -44.22 94.96 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 121.008 0.432 . . . . 0.0 111.468 -179.43 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 159' ' ' LEU . . . . . . . . . . . . . 6.0 tt -63.71 -37.94 89.23 Favored 'General case' 0 C--N 1.326 -0.438 0 CA-C-N 115.993 -0.549 . . . . 0.0 110.983 -179.485 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 160' ' ' TYR . . . . . . . . . . . . . 54.1 t80 -74.4 -46.84 37.68 Favored 'General case' 0 C--N 1.329 -0.317 0 N-CA-C 112.548 0.573 . . . . 0.0 112.548 -178.796 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 161' ' ' VAL . . . . . 0.43 HG23 ' N ' ' A' ' 162' ' ' ARG . 28.2 m -56.13 -44.65 79.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 N-CA-C 111.908 0.336 . . . . 0.0 111.908 -178.685 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 162' ' ' ARG . . . . . 0.449 ' O ' HD12 ' A' ' 166' ' ' LEU . 97.8 mtt180 -68.65 -49.44 59.11 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.746 0.308 . . . . 0.0 111.475 -179.452 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 163' ' ' LEU . . . . . . . . . . . . . 6.1 mp -63.46 -51.58 65.04 Favored 'General case' 0 C--N 1.33 -0.239 0 CA-C-N 116.232 -0.44 . . . . 0.0 112.034 -179.097 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 164' ' ' ARG . . . . . 0.426 HH11 HG23 ' A' ' 168' ' ' VAL . 5.2 tmm_? -53.42 -50.32 65.46 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.411 -0.358 . . . . 0.0 111.208 -179.406 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 165' ' ' ASN . . . . . 0.474 ' N ' HD21 ' A' ' 165' ' ' ASN . 0.9 OUTLIER -53.55 -42.28 67.32 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.894 0.378 . . . . 0.0 110.609 179.898 . . . . . . . . 3 3 . 1 . 024 nuclear orig full ' A' A ' 166' ' ' LEU . . . . . 0.504 ' O ' ' HG ' ' A' ' 170' ' ' LEU . 1.4 mt -58.31 -51.24 70.61 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 115.998 -0.546 . . . . 0.0 111.205 179.54 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 167' ' ' THR . . . . . 0.536 ' HA ' HD11 ' A' ' 170' ' ' LEU . 6.0 m -53.93 -53.88 46.62 Favored 'General case' 0 C--N 1.332 -0.178 0 N-CA-C 112.299 0.481 . . . . 0.0 112.299 -178.198 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 168' ' ' VAL . . . . . 0.426 HG23 HH11 ' A' ' 164' ' ' ARG . 25.2 t -53.66 -42.51 51.29 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.525 0 N-CA-C 112.327 0.492 . . . . 0.0 112.327 -179.432 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 169' ' ' VAL . . . . . . . . . . . . . 92.4 t -68.75 -66.73 0.49 Allowed 'Isoleucine or valine' 0 CA--C 1.532 0.281 0 N-CA-C 113.789 1.033 . . . . 0.0 113.789 -177.774 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 170' ' ' LEU . . . . . 0.536 HD11 ' HA ' ' A' ' 167' ' ' THR . 0.4 OUTLIER -59.62 -33.1 71.06 Favored 'General case' 0 N--CA 1.465 0.295 0 N-CA-C 113.01 0.744 . . . . 0.0 113.01 -177.565 . . . . . . . . 3 3 . 1 . 024 nuclear orig full ' A' A ' 171' ' ' TRP . . . . . 0.494 ' H ' HD13 ' A' ' 170' ' ' LEU . 19.6 m0 -73.43 -30.9 63.53 Favored 'General case' 0 C--N 1.329 -0.315 0 C-N-CA 120.411 -0.516 . . . . 0.0 111.171 -179.509 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 172' ' ' ALA . . . . . . . . . . . . . . . -70.99 -7.28 45.09 Favored 'General case' 0 C--N 1.33 -0.275 0 C-N-CA 120.847 -0.341 . . . . 0.0 110.817 179.453 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 173' ' ' ILE . . . . . 0.463 ' O ' HG12 ' A' ' 177' ' ' ILE . 22.9 mm -88.46 -27.07 5.5 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.21 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.951 179.627 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 174' ' ' TYR . . . . . 0.45 ' HD1' ' HA ' ' A' ' 171' ' ' TRP . 29.6 m-85 -54.02 -47.7 96.28 Favored Pre-proline 0 CA--C 1.529 0.143 0 CA-C-N 116.309 -0.405 . . . . 0.0 111.943 -179.286 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 175' ' ' PRO . . . . . 0.402 ' CD ' ' N ' ' A' ' 174' ' ' TYR . 81.8 Cg_exo -47.08 -34.86 17.98 Favored 'Trans proline' 0 C--N 1.35 0.625 0 C-N-CA 121.77 1.647 . . . . 0.0 111.852 179.093 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 176' ' ' PHE . . . . . 0.495 ' O ' ' HG ' ' A' ' 180' ' ' LEU . 67.6 m-85 -80.9 -51.02 9.04 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 115.749 -0.659 . . . . 0.0 111.554 179.729 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 177' ' ' ILE . . . . . 0.463 HG12 ' O ' ' A' ' 173' ' ' ILE . 31.5 mm -58.13 -30.48 39.42 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.558 0 CA-C-N 115.742 -0.663 . . . . 0.0 111.471 -178.674 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 178' ' ' TRP . . . . . 0.41 ' O ' ' HB2' ' A' ' 183' ' ' PRO . 90.7 t90 -73.77 -59.14 2.86 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-O 121.005 0.431 . . . . 0.0 110.865 179.791 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 179' ' ' LEU . . . . . 0.491 ' HG ' HG23 ' A' ' 185' ' ' VAL . 15.4 tp -61.31 -54.72 40.3 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 115.996 -0.547 . . . . 0.0 111.711 -178.989 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 180' ' ' LEU . . . . . 0.581 HD22 HD13 ' A' ' 187' ' ' LEU . 11.6 mt -63.65 -28.68 70.07 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 116.449 -0.341 . . . . 0.0 111.744 -179.112 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 181' ' ' GLY . . . . . 0.424 ' C ' ' HD2' ' A' ' 183' ' ' PRO . . . -73.96 -173.59 28.61 Favored Glycine 0 N--CA 1.451 -0.359 0 C-N-CA 120.05 -1.071 . . . . 0.0 111.823 179.422 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 182' ' ' PRO . . . . . 0.443 ' HG2' ' HD3' ' A' ' 183' ' ' PRO . 1.3 Cg_endo -47.01 -43.19 25.06 Favored 'Trans proline' 0 CA--C 1.541 0.831 0 C-N-CA 122.856 2.371 . . . . 0.0 113.789 179.561 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 183' ' ' PRO . . . . . 0.548 ' HB3' ' HB2' ' A' ' 116' ' ' ALA . 44.2 Cg_exo -37.86 -59.22 0.55 Allowed 'Trans proline' 0 C--N 1.357 0.989 0 C-N-CA 122.819 2.346 . . . . 0.0 114.12 -179.89 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 184' ' ' GLY . . . . . . . . . . . . . . . -115.65 -107.2 2.59 Favored Glycine 0 N--CA 1.45 -0.369 0 C-N-CA 120.162 -1.018 . . . . 0.0 113.174 -179.052 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 185' ' ' VAL . . . . . 0.524 HG22 ' HA ' ' A' ' 180' ' ' LEU . 26.8 m -76.81 86.11 0.81 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.405 0 CA-C-O 121.461 0.648 . . . . 0.0 111.021 -179.492 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 186' ' ' ALA . . . . . . . . . . . . . . . -63.38 85.27 0.03 OUTLIER 'General case' 0 C--N 1.323 -0.555 0 CA-C-N 115.683 -0.69 . . . . 0.0 111.08 179.67 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 187' ' ' LEU . . . . . 0.581 HD13 HD22 ' A' ' 180' ' ' LEU . 6.2 mt -78.99 -49.21 13.09 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 116.317 -0.402 . . . . 0.0 110.9 179.843 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 188' ' ' LEU . . . . . . . . . . . . . 3.9 mm? -94.98 -157.48 0.57 Allowed 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.034 -0.53 . . . . 0.0 111.437 -179.405 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 189' ' ' THR . . . . . 0.512 ' HB ' HG21 ' A' ' 192' ' ' VAL . 32.3 m -96.12 136.32 22.16 Favored Pre-proline 0 C--N 1.331 -0.218 0 CA-C-N 115.944 -0.571 . . . . 0.0 110.96 -179.654 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 190' ' ' PRO . . . . . 0.409 ' O ' HG23 ' A' ' 194' ' ' VAL . 80.6 Cg_exo -46.64 -42.98 23.61 Favored 'Trans proline' 0 C--N 1.35 0.639 0 C-N-CA 122.61 2.207 . . . . 0.0 113.022 -179.977 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 191' ' ' THR . . . . . . . . . . . . . 75.2 p -62.19 -45.78 91.83 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-O 120.792 0.33 . . . . 0.0 111.162 -179.822 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 192' ' ' VAL . . . . . 0.512 HG21 ' HB ' ' A' ' 189' ' ' THR . 58.9 t -60.04 -44.44 94.85 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.267 -0.424 . . . . 0.0 111.031 179.922 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 193' ' ' ASP . . . . . . . . . . . . . 28.2 t70 -56.81 -43.49 81.05 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.079 -0.509 . . . . 0.0 111.074 -179.935 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 194' ' ' VAL . . . . . 0.409 HG23 ' O ' ' A' ' 190' ' ' PRO . 93.1 t -63.06 -36.03 74.17 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.354 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.867 179.765 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 195' ' ' ALA . . . . . . . . . . . . . . . -58.62 -47.15 85.34 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.081 179.809 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 196' ' ' LEU . . . . . . . . . . . . . 57.5 mt -65.74 -37.52 86.6 Favored 'General case' 0 C--N 1.332 -0.177 0 CA-C-O 120.749 0.309 . . . . 0.0 110.591 179.714 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 197' ' ' ILE . . . . . . . . . . . . . 19.7 mm -61.55 -56.99 14.16 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.114 179.28 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 198' ' ' VAL . . . . . . . . . . . . . 73.0 t -52.39 -35.26 19.79 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.43 0 CA-C-N 115.743 -0.662 . . . . 0.0 109.519 178.472 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 199' ' ' TYR . . . . . . . . . . . . . 74.5 t80 -70.09 -38.55 75.7 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 115.228 -0.897 . . . . 0.0 110.583 179.849 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 200' ' ' LEU . . . . . . . . . . . . . 38.7 mt -63.65 -44.1 94.84 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 115.752 -0.658 . . . . 0.0 111.355 -179.607 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 201' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -72.03 -37.35 69.76 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.071 -0.513 . . . . 0.0 111.212 -179.753 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 202' ' ' LEU . . . . . 0.439 ' O ' ' HB ' ' A' ' 206' ' ' VAL . 3.2 mt -68.52 -30.8 69.69 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.686 -179.452 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 203' ' ' VAL . . . . . 0.491 ' O ' ' HA3' ' A' ' 207' ' ' GLY . 42.6 t -78.98 -36.57 18.77 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.437 0 CA-C-O 120.683 0.278 . . . . 0.0 111.125 -179.449 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 204' ' ' THR . . . . . . . . . . . . . 25.8 m -70.83 -50.83 31.17 Favored 'General case' 0 C--N 1.324 -0.519 0 C-N-CA 120.747 -0.381 . . . . 0.0 111.325 179.938 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 205' ' ' LYS . . . . . 0.554 ' HE2' ' HB2' ' A' ' 47' ' ' ALA . 50.5 mttp -71.99 -58.48 3.41 Favored 'General case' 0 C--N 1.328 -0.341 0 N-CA-C 112.313 0.486 . . . . 0.0 112.313 -178.629 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 206' ' ' VAL . . . . . 0.439 ' HB ' ' O ' ' A' ' 202' ' ' LEU . 61.9 t -74.82 -37.55 42.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 N-CA-C 111.817 0.303 . . . . 0.0 111.817 -178.983 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 207' ' ' GLY . . . . . 0.491 ' HA3' ' O ' ' A' ' 203' ' ' VAL . . . -63.07 -57.48 15.51 Favored Glycine 0 N--CA 1.452 -0.244 0 C-N-CA 120.372 -0.918 . . . . 0.0 112.117 -179.767 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 208' ' ' PHE . . . . . 0.523 ' O ' ' N ' ' A' ' 212' ' ' ALA . 4.8 m-85 -55.42 -49.05 73.43 Favored 'General case' 0 C--O 1.22 -0.478 0 N-CA-C 109.865 -0.42 . . . . 0.0 109.865 179.45 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 209' ' ' GLY . . . . . 0.433 ' HA2' ' HB1' ' A' ' 212' ' ' ALA . . . -53.71 -34.81 51.11 Favored Glycine 0 N--CA 1.451 -0.315 0 CA-C-N 115.183 -0.917 . . . . 0.0 113.382 179.641 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 210' ' ' PHE . . . . . . . . . . . . . 2.1 m-85 -70.7 -48.28 55.49 Favored 'General case' 0 CA--C 1.514 -0.427 0 N-CA-C 108.775 -0.824 . . . . 0.0 108.775 179.355 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 211' ' ' ILE . . . . . 0.408 HD11 HD13 ' A' ' 166' ' ' LEU . 5.6 mt -65.48 -27.59 42.11 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.608 0 N-CA-C 107.712 -1.218 . . . . 0.0 107.712 176.698 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 212' ' ' ALA . . . . . 0.523 ' N ' ' O ' ' A' ' 208' ' ' PHE . . . -68.59 -40.13 80.63 Favored 'General case' 0 N--CA 1.448 -0.555 0 CA-C-N 114.131 -1.395 . . . . 0.0 110.332 -179.763 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 213' ' ' LEU . . . . . . . . . . . . . 74.8 mt -70.16 -50.42 40.52 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 114.974 -1.012 . . . . 0.0 111.405 -179.572 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 214' ' ' ASP . . . . . . . . . . . . . 24.0 t70 -59.05 -49.9 76.12 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.931 -179.714 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 215' ' ' ALA . . . . . . . . . . . . . . . -56.57 -55.46 33.58 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.888 179.944 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 216' ' ' ALA . . . . . . . . . . . . . . . -62.0 -30.94 71.29 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.143 -0.48 . . . . 0.0 111.32 -179.95 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 217' ' ' ALA . . . . . . . . . . . . . . . -58.28 -43.56 88.03 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-O 120.966 0.412 . . . . 0.0 110.275 179.881 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 218' ' ' THR . . . . . . . . . . . . . 89.5 m -66.51 -46.43 76.24 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 115.826 -0.625 . . . . 0.0 110.355 179.287 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 219' ' ' LEU . . . . . 0.44 ' O ' ' HG2' ' A' ' 222' ' ' GLU . 29.3 mt -60.97 -29.21 69.53 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 115.967 -0.561 . . . . 0.0 110.074 179.497 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 220' ' ' ARG . . . . . . . . . . . . . 57.9 ttp180 -84.11 -21.77 31.33 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-N 115.637 -0.71 . . . . 0.0 110.327 179.504 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 221' ' ' ALA . . . . . . . . . . . . . . . -82.72 -20.19 36.52 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 115.851 -0.613 . . . . 0.0 112.22 -179.496 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 222' ' ' GLU . . . . . 0.44 ' HG2' ' O ' ' A' ' 219' ' ' LEU . 12.3 pt-20 -81.48 -18.1 46.36 Favored 'General case' 0 C--N 1.332 -0.156 0 CA-C-O 120.731 0.3 . . . . 0.0 110.958 -179.23 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 223' ' ' HIS . . . . . . . . . . . . . 1.6 p-80 -145.73 -166.46 2.45 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.354 -0.385 . . . . 0.0 111.211 179.871 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 224' ' ' GLY . . . . . . . . . . . . . . . 66.77 22.46 71.9 Favored Glycine 0 N--CA 1.452 -0.28 0 C-N-CA 120.785 -0.722 . . . . 0.0 112.441 179.963 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 225' ' ' GLU . . . . . . . . . . . . . 12.1 mm-40 -76.14 113.34 13.57 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 120.715 0.293 . . . . 0.0 110.784 -179.965 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 226' ' ' SER . . . . . . . . . . . . . 47.9 t -123.42 -4.16 8.33 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.233 -0.439 . . . . 0.0 111.159 -179.846 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 227' ' ' LEU . . . . . . . . . . . . . 56.3 tp -126.03 -60.35 1.29 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.408 -0.36 . . . . 0.0 111.158 -179.687 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 228' ' ' ALA . . . . . . . . . . . . . . . 54.28 -168.9 0.07 Allowed 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.52 -179.727 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 229' ' ' GLY . . . . . . . . . . . . . . . -99.7 151.51 19.28 Favored Glycine 0 C--N 1.331 0.261 0 C-N-CA 120.827 -0.701 . . . . 0.0 112.452 -179.983 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 230' ' ' VAL . . . . . . . . . . . . . 17.4 m -117.6 27.41 3.48 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.191 0 CA-C-O 120.916 0.388 . . . . 0.0 111.411 -179.868 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 231' ' ' ASP . . . . . . . . . . . . . 11.9 m-20 47.47 68.19 0.69 Allowed 'General case' 0 C--N 1.326 -0.453 0 CA-C-N 115.594 -0.73 . . . . 0.0 111.169 -179.92 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 232' ' ' THR . . . . . . . . . . . . . 35.1 p -144.71 -48.13 0.25 Allowed 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.304 -179.909 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 233' ' ' ASP . . . . . . . . . . . . . 13.1 m-20 -60.5 110.91 1.39 Allowed 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.085 -0.507 . . . . 0.0 111.211 -179.733 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 234' ' ' THR . . . . . . . . . . . . . 39.0 m -99.45 131.48 24.88 Favored Pre-proline 0 C--N 1.331 -0.222 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.9 179.873 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 235' ' ' PRO . . . . . . . . . . . . . 51.1 Cg_exo -53.86 154.53 16.73 Favored 'Trans proline' 0 C--N 1.348 0.55 0 C-N-CA 122.48 2.12 . . . . 0.0 112.437 179.887 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 236' ' ' ALA . . . . . . . . . . . . . . . 61.68 103.15 0.03 OUTLIER 'General case' 0 C--N 1.332 -0.161 0 CA-C-N 116.006 -0.543 . . . . 0.0 111.465 179.66 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 237' ' ' VAL . . . . . . . . . . . . . 14.4 p -89.07 143.11 11.86 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.226 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.86 179.838 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 238' ' ' ALA . . . . . . . . . . . . . . . -104.93 -51.88 2.96 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.286 -0.416 . . . . 0.0 111.266 -179.886 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 239' ' ' ASP . . . . . . . . . . . . . 33.1 t70 -163.08 -71.23 0.05 OUTLIER 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.377 -0.374 . . . . 0.0 110.793 -179.822 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 240' ' ' LEU . . . . . . . . . . . . . 17.0 tp 56.41 17.23 2.81 Favored 'General case' 0 N--CA 1.462 0.165 0 CA-C-N 116.355 -0.384 . . . . 0.0 110.934 179.843 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 241' ' ' GLU . . . . . . . . . . . . . 9.9 tp10 -87.63 -71.14 0.58 Allowed 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.878 -179.835 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 242' ' ' HIS . . . . . . . . . . . . . 24.9 t60 57.06 91.51 0.03 OUTLIER 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 116.092 -0.503 . . . . 0.0 110.992 179.901 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 243' ' ' HIS . . . . . . . . . . . . . 54.7 t-80 -111.06 120.64 43.03 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.08 -0.509 . . . . 0.0 110.993 -179.815 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 244' ' ' HIS . . . . . . . . . . . . . 31.1 m-70 -67.6 125.35 25.91 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.726 179.921 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 245' ' ' HIS . . . . . . . . . . . . . 41.3 t60 -150.51 -60.71 0.19 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.923 -179.955 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 246' ' ' HIS . . . . . . . . . . . . . 3.0 t-160 -130.62 -62.96 0.9 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.664 -179.935 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 247' ' ' HIS . . . . . . . . . . . . . 38.0 m-70 . . . . . 0 C--O 1.249 1.052 0 CA-C-O 118.287 -0.863 . . . . 0.0 110.864 179.89 . . . . . . . . 0 0 . 1 . 024 nuclear orig full ' A' A ' 301' ' ' RET . . . . . 0.611 ' H22' ' HA3' ' A' ' 112' ' ' GLY . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 23.9 ptm . . . . . 0 N--CA 1.485 1.32 0 CA-C-O 120.754 0.311 . . . . 0.0 110.845 . . . . . . . . . 0 0 . 1 . 025 nuclear orig full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 29.9 m -140.65 10.93 0.52 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.095 -0.502 . . . . 0.0 111.153 -179.953 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -72.43 -31.47 63.25 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.673 -0.775 . . . . 0.0 112.517 -179.965 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 4' ' ' LEU . . . . . 0.516 HD23 HG21 ' A' ' 194' ' ' VAL . 85.8 mt -74.48 -38.36 62.93 Favored 'General case' 0 N--CA 1.449 -0.477 0 CA-C-O 120.723 0.297 . . . . 0.0 111.509 -179.906 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 69.2 p -54.77 -37.33 65.88 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.138 -0.483 . . . . 0.0 112.03 -179.171 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 69.2 p -56.12 -35.19 66.82 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.481 -0.327 . . . . 0.0 111.548 -179.625 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 7' ' ' LEU . . . . . . . . . . . . . 4.0 mm? -63.2 -53.47 52.67 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.429 -0.35 . . . . 0.0 111.419 -179.648 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 8' ' ' PHE . . . . . 0.488 ' HB2' ' HB3' ' A' ' 55' ' ' ALA . 65.8 m-85 -60.25 -33.06 71.78 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.332 -0.395 . . . . 0.0 110.946 -179.586 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 9' ' ' TRP . . . . . . . . . . . . . 18.3 m95 -68.71 -49.36 59.49 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.246 -179.825 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 75.9 mt -59.39 -38.81 81.46 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 115.814 -0.63 . . . . 0.0 109.825 179.134 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -67.12 -36.24 90.04 Favored Glycine 0 N--CA 1.446 -0.64 0 CA-C-N 115.473 -0.785 . . . . 0.0 111.73 179.403 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -61.98 -33.38 74.21 Favored 'General case' 0 C--O 1.232 0.18 0 CA-C-O 121.037 0.446 . . . . 0.0 109.97 179.183 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 50.7 mm -65.61 -49.92 74.85 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 115.694 -0.685 . . . . 0.0 110.266 179.115 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -58.3 -36.24 82.36 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.798 -0.715 . . . . 0.0 112.218 179.539 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 15' ' ' MET . . . . . 0.708 ' HE3' ' HD2' ' A' ' 205' ' ' LYS . 19.3 mmt -66.21 -44.6 83.41 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.74 0.305 . . . . 0.0 110.783 179.733 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -53.79 -45.43 70.72 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 115.995 -0.548 . . . . 0.0 110.742 179.809 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 49.2 t -61.12 -43.94 97.3 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.238 0 CA-C-N 116.112 -0.495 . . . . 0.0 111.149 179.943 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -66.72 -43.95 90.65 Favored Glycine 0 N--CA 1.452 -0.256 0 C-N-CA 120.699 -0.762 . . . . 0.0 112.073 179.645 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 19.2 m -52.3 -42.72 64.02 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-O 120.675 0.274 . . . . 0.0 111.341 -179.776 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 80.9 mt -71.82 -44.8 63.3 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.406 -0.361 . . . . 0.0 111.554 -179.903 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -57.01 -32.59 66.29 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.37 -0.377 . . . . 0.0 111.759 -179.405 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 22' ' ' PHE . . . . . 0.439 ' HB2' HG21 ' A' ' 41' ' ' VAL . 10.0 m-85 -90.92 -38.63 12.77 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.537 -0.301 . . . . 0.0 111.62 -179.356 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -64.03 -50.49 68.24 Favored 'General case' 0 C--N 1.332 -0.166 0 CA-C-O 120.878 0.37 . . . . 0.0 111.25 -179.685 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 24' ' ' TRP . . . . . . . . . . . . . 1.3 t-105 -59.88 -49.84 76.13 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 115.958 -0.565 . . . . 0.0 110.68 179.685 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -70.5 -17.63 62.96 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.266 -0.424 . . . . 0.0 111.033 179.88 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -73.3 -52.73 8.33 Favored Glycine 0 N--CA 1.452 -0.245 0 C-N-CA 120.822 -0.704 . . . . 0.0 112.635 -179.964 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 50.4 mtp180 -55.06 -43.05 73.5 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-O 120.861 0.363 . . . . 0.0 110.805 179.999 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 33.7 t70 -89.2 87.82 7.3 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.631 179.878 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -161.39 -170.56 2.67 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.03 -0.532 . . . . 0.0 111.061 -179.72 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -76.9 -118.04 0.16 Allowed Glycine 0 N--CA 1.45 -0.399 0 C-N-CA 120.786 -0.721 . . . . 0.0 112.551 179.797 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 46.8 t -139.3 -33.85 0.6 Allowed 'General case' 0 C--N 1.331 -0.237 0 CA-C-O 120.726 0.298 . . . . 0.0 111.076 -179.897 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -87.04 -12.18 68.61 Favored Glycine 0 N--CA 1.45 -0.373 0 C-N-CA 120.724 -0.75 . . . . 0.0 112.753 -179.792 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 43.6 mt-10 -88.43 -21.49 24.22 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.686 0.279 . . . . 0.0 110.988 -179.937 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 34' ' ' ARG . . . . . . . . . . . . . 35.7 ttp180 -49.87 -35.25 22.67 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.141 -0.481 . . . . 0.0 111.527 -179.798 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 77.6 mtm180 -61.59 -54.33 44.48 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 120.85 0.357 . . . . 0.0 111.497 -179.772 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 59.4 m-85 -62.04 -30.02 70.69 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.134 -0.484 . . . . 0.0 111.421 -179.441 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 37' ' ' TYR . . . . . . . . . . . . . 32.5 m-85 -73.76 -56.11 5.4 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.503 -179.411 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 96.0 t -56.68 -36.7 49.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-O 120.98 0.419 . . . . 0.0 110.628 179.923 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 78.3 m -63.44 -51.62 64.92 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 115.872 -0.604 . . . . 0.0 110.918 179.713 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 40' ' ' LEU . . . . . 0.515 HD11 HD12 ' A' ' 43' ' ' ILE . 51.7 tp -61.29 -45.98 92.22 Favored 'General case' 0 C--O 1.236 0.35 0 CA-C-N 115.966 -0.561 . . . . 0.0 110.722 179.989 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . 0.439 HG21 ' HB2' ' A' ' 22' ' ' PHE . 85.8 t -60.13 -34.77 58.05 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.399 0 CA-C-N 115.684 -0.689 . . . . 0.0 109.858 178.974 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -63.15 -35.39 92.02 Favored Glycine 0 N--CA 1.445 -0.724 0 C-N-CA 120.877 -0.678 . . . . 0.0 112.026 179.592 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 43' ' ' ILE . . . . . 0.604 HG23 ' HE3' ' A' ' 205' ' ' LYS . 0.8 OUTLIER -66.23 -57.75 9.28 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.126 0 C-N-CA 121.074 -0.25 . . . . 0.0 111.148 179.811 . . . . . . . . 3 3 . 1 . 025 nuclear orig full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 85.1 p -59.57 -21.56 60.48 Favored 'General case' 0 C--O 1.232 0.154 0 CA-C-N 116.485 -0.325 . . . . 0.0 111.554 -179.518 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -79.43 -56.23 3.46 Favored Glycine 0 CA--C 1.518 0.23 0 C-N-CA 120.843 -0.694 . . . . 0.0 113.063 -179.363 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 20.2 pt -58.2 -37.39 62.25 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.243 0 CA-C-O 121.138 0.494 . . . . 0.0 110.873 -179.896 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 47' ' ' ALA . . . . . 0.671 ' HB1' ' HE2' ' A' ' 205' ' ' LYS . . . -68.21 -45.26 73.82 Favored 'General case' 0 C--N 1.324 -0.525 0 CA-C-N 115.945 -0.571 . . . . 0.0 111.363 179.513 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -54.13 -42.71 69.79 Favored 'General case' 0 C--O 1.233 0.203 0 CA-C-N 116.299 -0.41 . . . . 0.0 111.807 -179.219 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 33.1 m -72.23 -34.5 49.77 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.363 0 CA-C-N 116.665 -0.243 . . . . 0.0 111.333 -179.517 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -66.9 -33.48 75.69 Favored 'General case' 0 CA--C 1.521 -0.146 0 CA-C-O 120.988 0.423 . . . . 0.0 110.73 179.402 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 3.0 m-30 -69.55 -40.72 76.66 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-N 115.909 -0.587 . . . . 0.0 110.12 179.784 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -61.44 -45.1 95.73 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 115.704 -0.68 . . . . 0.0 111.367 179.829 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 53' ' ' VAL . . . . . 0.486 HG23 ' N ' ' A' ' 54' ' ' MET . 25.3 m -67.62 -50.08 64.41 Favored 'Isoleucine or valine' 0 C--N 1.334 -0.087 0 C-N-CA 121.11 -0.236 . . . . 0.0 111.011 -179.956 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 54' ' ' MET . . . . . 0.514 ' HG2' ' HG2' ' A' ' 71' ' ' PRO . 74.7 mtm -58.04 -30.35 66.08 Favored 'General case' 0 CA--C 1.521 -0.172 0 CA-C-O 121.224 0.535 . . . . 0.0 109.866 179.336 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 55' ' ' ALA . . . . . 0.488 ' HB3' ' HB2' ' A' ' 8' ' ' PHE . . . -74.5 -33.93 62.93 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 115.414 -0.812 . . . . 0.0 111.365 179.526 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 74.8 mt -70.88 -5.19 28.78 Favored 'General case' 0 C--N 1.331 -0.203 0 CA-C-N 116.371 -0.377 . . . . 0.0 111.573 -179.416 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 98.8 -20.77 49.01 Favored Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.46 -0.876 . . . . 0.0 113.036 179.638 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 32.9 m -70.03 149.11 10.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-O 120.88 0.371 . . . . 0.0 110.826 179.805 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 59' ' ' GLY . . . . . 0.441 ' HA3' ' HG3' ' A' ' 71' ' ' PRO . . . 85.05 22.49 52.31 Favored Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.913 -0.661 . . . . 0.0 112.578 -179.47 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 60' ' ' TRP . . . . . . . . . . . . . 13.8 m0 -105.71 96.07 6.24 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-O 121.091 0.472 . . . . 0.0 109.986 -179.837 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 5.1 t -98.53 116.54 65.4 Favored Pre-proline 0 C--N 1.326 -0.435 0 CA-C-N 115.696 -0.683 . . . . 0.0 111.635 -178.87 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 57.1 Cg_endo -70.4 143.96 49.25 Favored 'Trans proline' 0 C--N 1.351 0.709 0 C-N-CA 122.437 2.092 . . . . 0.0 112.262 179.578 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 99.5 t -138.93 96.12 0.99 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.053 -0.521 . . . . 0.0 111.165 -179.88 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . 57.24 -88.1 0.02 OUTLIER 'General case' 0 C--N 1.331 -0.204 0 CA-C-N 116.189 -0.459 . . . . 0.0 111.439 179.781 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 45.7 mt-10 -121.85 -19.08 6.85 Favored 'General case' 0 C--N 1.332 -0.193 0 CA-C-N 116.433 -0.349 . . . . 0.0 110.939 179.935 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 66' ' ' ARG . . . . . . . . . . . . . 39.7 mmt180 -105.4 155.72 18.86 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.342 179.629 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 30.3 m -114.01 143.32 44.94 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-O 120.947 0.404 . . . . 0.0 111.351 -179.591 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 19.9 m -127.42 145.84 34.2 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.402 0 CA-C-N 115.83 -0.623 . . . . 0.0 110.818 179.659 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 69' ' ' PHE . . . . . . . . . . . . . 17.2 m-85 -110.73 115.6 29.84 Favored 'General case' 0 C--N 1.327 -0.38 0 N-CA-C 109.738 -0.467 . . . . 0.0 109.738 -179.63 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 70' ' ' VAL . . . . . 0.558 ' N ' ' HD2' ' A' ' 71' ' ' PRO . 59.4 t -68.43 -51.17 24.66 Favored Pre-proline 0 C--N 1.323 -0.559 0 N-CA-C 112.436 0.532 . . . . 0.0 112.436 -178.741 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 71' ' ' PRO . . . . . 0.558 ' HD2' ' N ' ' A' ' 70' ' ' VAL . 11.2 Cg_endo -54.87 -19.89 20.79 Favored 'Trans proline' 0 C--N 1.353 0.791 0 C-N-CA 122.089 1.859 . . . . 0.0 112.012 179.831 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 72' ' ' ARG . . . . . 0.419 ' NH2' HG13 ' A' ' 197' ' ' ILE . 53.1 ttt180 -74.96 -53.8 8.34 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.043 -0.526 . . . . 0.0 110.586 179.673 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 73' ' ' TYR . . . . . . . . . . . . . 75.8 m-85 -65.02 -36.91 85.91 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 115.774 -0.648 . . . . 0.0 110.704 -179.994 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 0.3 OUTLIER -70.05 -36.78 69.98 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 N-CA-C 109.744 -0.465 . . . . 0.0 109.744 179.048 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 12.3 t70 -56.52 -38.95 72.54 Favored 'General case' 0 CA--C 1.52 -0.176 0 CA-C-N 116.033 -0.531 . . . . 0.0 109.642 179.06 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 76' ' ' TRP . . . . . 0.509 ' HA ' ' HG1' ' A' ' 79' ' ' THR . 50.2 m0 -69.45 -38.54 77.84 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 115.615 -0.72 . . . . 0.0 110.624 179.418 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 92.5 mt -59.17 -28.77 39.97 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.725 179.674 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 35.4 mt -91.83 -26.91 18.29 Favored 'General case' 0 CA--C 1.533 0.293 0 N-CA-C 112.317 0.488 . . . . 0.0 112.317 -179.941 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 79' ' ' THR . . . . . 0.509 ' HG1' ' HA ' ' A' ' 76' ' ' TRP . 71.3 p -92.44 -52.24 4.75 Favored 'General case' 0 N--CA 1.466 0.342 0 N-CA-C 113.622 0.971 . . . . 0.0 113.622 -177.884 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 80' ' ' THR . . . . . 0.412 ' N ' ' HD2' ' A' ' 81' ' ' PRO . 89.0 m -47.3 -55.25 16.7 Favored Pre-proline 0 C--N 1.329 -0.325 0 N-CA-C 112.858 0.688 . . . . 0.0 112.858 -178.418 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 81' ' ' PRO . . . . . 0.412 ' HD2' ' N ' ' A' ' 80' ' ' THR . 37.2 Cg_endo -64.19 -18.99 65.42 Favored 'Trans proline' 0 C--N 1.35 0.614 0 C-N-CA 121.495 1.463 . . . . 0.0 111.232 -179.833 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 82' ' ' LEU . . . . . . . . . . . . . 18.4 tp -76.93 -33.6 57.72 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 115.529 -0.759 . . . . 0.0 110.169 179.641 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 83' ' ' ILE . . . . . 0.478 HG13 H202 ' A' ' 301' ' ' RET . 41.2 mm -70.12 -52.23 32.29 Favored 'Isoleucine or valine' 0 C--O 1.232 0.175 0 CA-C-N 116.058 -0.519 . . . . 0.0 110.101 179.203 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 27.9 m -60.61 -30.47 46.89 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.179 0 N-CA-C 109.63 -0.507 . . . . 0.0 109.63 178.795 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 85' ' ' TYR . . . . . . . . . . . . . 81.1 t80 -65.33 -35.79 82.07 Favored 'General case' 0 N--CA 1.453 -0.28 0 CA-C-N 115.542 -0.754 . . . . 0.0 109.276 178.684 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 86' ' ' PHE . . . . . . . . . . . . . 7.2 t80 -61.15 -50.13 74.41 Favored 'General case' 0 C--O 1.234 0.237 0 CA-C-N 115.633 -0.712 . . . . 0.0 109.919 179.186 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 8.8 mp -62.23 -31.84 72.44 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 115.838 -0.619 . . . . 0.0 109.861 179.384 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -68.96 -27.69 73.69 Favored Glycine 0 N--CA 1.449 -0.459 0 C-N-CA 120.856 -0.688 . . . . 0.0 111.678 179.113 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 82.7 mt -73.72 -37.36 65.17 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-O 120.948 0.404 . . . . 0.0 110.482 179.549 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 90' ' ' LEU . . . . . 0.409 HD11 HD23 ' A' ' 163' ' ' LEU . 93.6 mt -64.3 -42.67 96.26 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 115.945 -0.571 . . . . 0.0 111.144 179.9 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -80.13 -54.99 5.25 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.4 -179.654 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 95.37 67.88 1.0 Allowed Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.814 -0.708 . . . . 0.0 112.132 -179.733 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 6.6 mp -71.21 -171.13 0.55 Allowed 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.783 0.325 . . . . 0.0 111.033 -179.71 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 94' ' ' ASP . . . . . 0.414 ' HB2' ' OE2' ' A' ' 97' ' ' GLU . 5.9 m-20 -96.43 -173.41 2.76 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-N 116.246 -0.433 . . . . 0.0 111.28 -179.807 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 47.5 t -67.52 -51.26 53.04 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 115.946 -0.57 . . . . 0.0 111.624 -179.425 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 96' ' ' ARG . . . . . 0.428 ' O ' HG13 ' A' ' 100' ' ' ILE . 31.6 mmt180 -73.72 -40.07 63.83 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 120.944 0.402 . . . . 0.0 110.699 -179.505 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 97' ' ' GLU . . . . . 0.497 ' HA ' HD12 ' A' ' 100' ' ' ILE . 0.3 OUTLIER -55.48 -47.39 76.21 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 115.763 -0.653 . . . . 0.0 111.501 -179.622 . . . . . . . . 3 3 . 1 . 025 nuclear orig full ' A' A ' 98' ' ' PHE . . . . . 0.422 ' O ' HG12 ' A' ' 102' ' ' ILE . 1.2 m-85 -57.13 -45.23 83.69 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.821 0.343 . . . . 0.0 110.796 179.813 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -62.68 -30.25 76.26 Favored Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.586 -179.92 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 100' ' ' ILE . . . . . 0.497 HD12 ' HA ' ' A' ' 97' ' ' GLU . 95.5 mt -65.65 -44.79 93.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-O 120.81 0.338 . . . . 0.0 111.221 -179.939 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 56.2 t -68.64 -43.89 82.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.322 -0.399 . . . . 0.0 111.51 -179.732 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 102' ' ' ILE . . . . . 0.422 HG12 ' O ' ' A' ' 98' ' ' PHE . 48.5 mm -61.45 -51.1 76.84 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.348 -0.387 . . . . 0.0 111.189 -179.789 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 14.9 t -61.35 -29.01 69.64 Favored 'General case' 0 C--O 1.232 0.153 0 CA-C-O 120.866 0.365 . . . . 0.0 110.614 179.925 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 1.4 tm? -59.6 -52.65 64.61 Favored 'General case' 0 C--N 1.331 -0.198 0 CA-C-N 116.073 -0.512 . . . . 0.0 109.807 179.217 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 105' ' ' ASN . . . . . 0.539 ' N ' HD21 ' A' ' 105' ' ' ASN . 0.8 OUTLIER -64.33 -26.18 68.37 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 115.965 -0.561 . . . . 0.0 111.024 179.732 . . . . . . . . 3 3 . 1 . 025 nuclear orig full ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 53.7 m -63.95 -56.7 13.26 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.38 -0.373 . . . . 0.0 111.478 -179.795 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 7.2 p -62.33 -36.47 74.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.272 -0.422 . . . . 0.0 111.214 -179.851 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 81.3 t -65.59 -54.41 28.37 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.197 0 CA-C-N 116.376 -0.375 . . . . 0.0 111.01 179.817 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 109' ' ' MET . . . . . . . . . . . . . 11.2 tpp -59.58 -36.29 75.94 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.94 -179.766 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 30.2 tp -66.52 -32.94 74.6 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.309 -0.405 . . . . 0.0 110.226 179.779 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -62.02 -54.21 44.68 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 115.97 -0.559 . . . . 0.0 110.683 179.526 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 112' ' ' GLY . . . . . 0.455 ' HA3' ' H22' ' A' ' 301' ' ' RET . . . -56.87 -36.51 73.25 Favored Glycine 0 C--N 1.331 0.283 0 C-N-CA 120.605 -0.807 . . . . 0.0 112.044 179.549 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 113' ' ' PHE . . . . . . . . . . . . . 2.6 t80 -54.06 -63.67 1.07 Allowed 'General case' 0 C--N 1.332 -0.186 0 CA-C-O 120.918 0.389 . . . . 0.0 110.262 179.589 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 114' ' ' ALA . . . . . 0.4 ' O ' HG12 ' A' ' 118' ' ' VAL . . . -62.25 -28.29 69.6 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 115.88 -0.6 . . . . 0.0 111.172 179.942 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 115' ' ' GLY . . . . . 0.451 ' N ' ' HG ' ' A' ' 126' ' ' LEU . . . -52.22 -52.88 33.84 Favored Glycine 0 C--N 1.333 0.363 0 C-N-CA 121.081 -0.58 . . . . 0.0 112.729 179.971 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -77.91 -15.06 59.3 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-O 120.711 0.291 . . . . 0.0 111.535 179.84 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 117' ' ' MET . . . . . . . . . . . . . 0.5 OUTLIER -93.83 19.34 8.99 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.468 -0.333 . . . . 0.0 111.488 -179.704 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 118' ' ' VAL . . . . . 0.4 HG12 ' O ' ' A' ' 114' ' ' ALA . 33.2 m -84.55 146.74 47.73 Favored Pre-proline 0 C--N 1.331 -0.223 0 CA-C-N 116.594 -0.276 . . . . 0.0 111.335 179.86 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 119' ' ' PRO . . . . . . . . . . . . . 96.6 Cg_endo -87.91 1.92 6.64 Favored 'Trans proline' 0 N--CA 1.458 -0.593 0 C-N-CA 122.709 2.273 . . . . 0.0 112.233 179.325 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -155.55 -138.39 2.56 Favored Glycine 0 C--N 1.332 0.334 0 C-N-CA 120.806 -0.711 . . . . 0.0 112.79 -179.674 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 47.1 pt -88.55 8.72 2.64 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.193 0 CA-C-O 120.645 0.26 . . . . 0.0 111.523 -179.634 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 38.4 mt-10 -60.07 -18.55 47.61 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.423 -0.353 . . . . 0.0 111.11 -179.853 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 123' ' ' ARG . . . . . . . . . . . . . 2.6 ptp180 -52.07 -33.8 40.86 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.176 -0.465 . . . . 0.0 111.737 -179.871 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 124' ' ' TYR . . . . . . . . . . . . . 40.8 m-85 -65.01 -32.67 74.51 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.599 -0.273 . . . . 0.0 111.362 -179.659 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 125' ' ' ALA . . . . . . . . . . . . . . . -68.73 -52.96 25.05 Favored 'General case' 0 C--O 1.237 0.419 0 CA-C-O 120.79 0.328 . . . . 0.0 111.064 179.909 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 126' ' ' LEU . . . . . 0.451 ' HG ' ' N ' ' A' ' 115' ' ' GLY . 2.6 mm? -49.86 -54.32 20.17 Favored 'General case' 0 CA--C 1.52 -0.187 0 CA-C-N 116.016 -0.538 . . . . 0.0 110.61 -179.988 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 127' ' ' PHE . . . . . 0.509 ' HZ ' ' HB3' ' A' ' 175' ' ' PRO . 7.1 t80 -67.5 -31.53 71.73 Favored 'General case' 0 N--CA 1.452 -0.35 0 CA-C-N 116.285 -0.416 . . . . 0.0 111.074 -179.652 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 128' ' ' GLY . . . . . . . . . . . . . . . -46.38 -48.38 16.2 Favored Glycine 0 C--N 1.331 0.283 0 C-N-CA 119.793 -1.194 . . . . 0.0 110.737 179.07 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 129' ' ' MET . . . . . 0.501 ' HE3' ' N ' ' A' ' 130' ' ' GLY . 6.0 tmm? -70.43 -45.79 65.18 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 115.139 -0.53 . . . . 0.0 109.894 178.75 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 130' ' ' GLY . . . . . 0.501 ' N ' ' HE3' ' A' ' 129' ' ' MET . . . -57.37 -29.63 60.6 Favored Glycine 0 C--N 1.331 0.265 0 CA-C-N 115.85 -0.614 . . . . 0.0 113.174 -179.315 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -75.02 -53.65 8.55 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-O 120.702 0.287 . . . . 0.0 110.58 -179.798 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 60.0 t -57.67 -42.08 80.77 Favored 'Isoleucine or valine' 0 C--O 1.234 0.252 0 CA-C-O 121.372 0.606 . . . . 0.0 109.672 178.815 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -68.9 -33.47 73.81 Favored 'General case' 0 N--CA 1.451 -0.377 0 CA-C-N 115.272 -0.877 . . . . 0.0 110.781 179.441 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 134' ' ' PHE . . . . . . . . . . . . . 70.5 t80 -54.59 -57.42 11.51 Favored 'General case' 0 N--CA 1.451 -0.394 0 CA-C-O 121.01 0.433 . . . . 0.0 110.031 179.542 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 135' ' ' ILE . . . . . 0.429 ' O ' HG23 ' A' ' 138' ' ' VAL . 26.4 mt -57.22 -33.27 42.88 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.388 0 CA-C-N 115.728 -0.669 . . . . 0.0 109.891 178.87 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . -59.26 -39.46 94.63 Favored Glycine 0 N--CA 1.448 -0.52 0 C-N-CA 120.31 -0.948 . . . . 0.0 111.511 178.851 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 137' ' ' LEU . . . . . . . . . . . . . 54.6 tp -68.68 -55.34 11.74 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-O 120.715 0.293 . . . . 0.0 110.729 179.549 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 138' ' ' VAL . . . . . 0.429 HG23 ' O ' ' A' ' 135' ' ' ILE . 2.8 m -55.86 -32.08 31.64 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.24 0 CA-C-O 121.45 0.643 . . . . 0.0 109.478 179.747 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 139' ' ' TYR . . . . . . . . . . . . . 9.8 t80 -64.23 -36.89 85.55 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 115.28 -0.873 . . . . 0.0 109.995 178.667 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 16.1 m-85 -66.18 -53.15 40.87 Favored 'General case' 0 C--N 1.332 -0.186 0 CA-C-N 115.959 -0.564 . . . . 0.0 111.332 179.669 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 141' ' ' LEU . . . . . 0.533 HD13 HG23 ' A' ' 142' ' ' VAL . 3.0 pp -64.31 -17.12 63.36 Favored 'General case' 0 C--N 1.333 -0.148 0 CA-C-O 120.657 0.265 . . . . 0.0 111.268 -179.418 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 142' ' ' VAL . . . . . 0.533 HG23 HD13 ' A' ' 141' ' ' LEU . 47.1 t -94.93 -22.71 5.3 Favored 'Isoleucine or valine' 0 C--O 1.233 0.208 0 CA-C-O 121.054 0.454 . . . . 0.0 110.366 178.343 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . -74.25 -124.6 0.12 Allowed Glycine 0 CA--C 1.524 0.612 0 C-N-CA 121.114 -0.565 . . . . 0.0 113.485 -179.234 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 144' ' ' PRO . . . . . . . . . . . . . 46.6 Cg_endo -67.55 -23.13 43.62 Favored 'Trans proline' 0 C--N 1.35 0.642 0 C-N-CA 122.769 2.313 . . . . 0.0 113.253 -179.157 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 145' ' ' MET . . . . . 0.482 ' HB3' ' OH ' ' A' ' 160' ' ' TYR . 5.7 mtt -52.18 -57.61 9.13 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.508 -0.315 . . . . 0.0 111.658 -179.609 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 146' ' ' THR . . . . . . . . . . . . . 8.8 t -62.78 -32.2 73.32 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.488 -0.324 . . . . 0.0 111.719 -179.343 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 147' ' ' GLU . . . . . 0.414 ' HA ' ' HG ' ' A' ' 150' ' ' SER . 45.6 mt-10 -70.57 -33.9 71.61 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.425 -0.352 . . . . 0.0 111.311 -179.609 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 148' ' ' SER . . . . . . . . . . . . . 38.8 m -70.52 -49.87 43.62 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.956 0.408 . . . . 0.0 110.843 -179.889 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 149' ' ' ALA . . . . . 0.474 ' HB1' HG23 ' A' ' 156' ' ' ILE . . . -64.05 -35.23 80.06 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 115.992 -0.549 . . . . 0.0 111.757 -179.553 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 150' ' ' SER . . . . . 0.442 ' HA ' ' HB2' ' A' ' 157' ' ' LYS . 86.3 p -67.71 -5.59 16.71 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.379 -0.373 . . . . 0.0 111.232 -179.664 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 151' ' ' GLN . . . . . . . . . . . . . 78.9 mt-30 -115.3 -1.16 12.98 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.503 -0.317 . . . . 0.0 111.338 179.947 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 32.4 mmt180 -80.97 -51.63 8.33 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-O 120.843 0.354 . . . . 0.0 110.989 179.812 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 153' ' ' SER . . . . . 0.533 ' HB3' HG12 ' A' ' 156' ' ' ILE . 27.5 t -158.08 172.41 18.48 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 116.141 -0.482 . . . . 0.0 110.844 179.635 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 154' ' ' SER . . . . . . . . . . . . . 50.8 m -71.59 -40.47 69.85 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.285 -0.416 . . . . 0.0 110.455 179.327 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -76.75 -31.97 51.86 Favored Glycine 0 N--CA 1.452 -0.281 0 C-N-CA 121.013 -0.613 . . . . 0.0 112.708 179.916 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 156' ' ' ILE . . . . . 0.533 HG12 ' HB3' ' A' ' 153' ' ' SER . 29.5 mm -60.14 -38.21 76.17 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.229 0 CA-C-O 120.834 0.349 . . . . 0.0 111.131 -179.896 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 157' ' ' LYS . . . . . 0.442 ' HB2' ' HA ' ' A' ' 150' ' ' SER . 61.7 tttm -66.85 -50.87 61.14 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.327 -179.601 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 48.5 t -62.72 -39.45 94.08 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.3 -0.409 . . . . 0.0 111.549 -179.464 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 159' ' ' LEU . . . . . 0.413 ' O ' HD13 ' A' ' 163' ' ' LEU . 32.0 tp -71.11 -33.45 70.15 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.364 -0.38 . . . . 0.0 111.211 -179.477 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 160' ' ' TYR . . . . . 0.482 ' OH ' ' HB3' ' A' ' 145' ' ' MET . 48.3 t80 -73.24 -46.82 47.93 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.569 -0.287 . . . . 0.0 111.473 -179.559 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 161' ' ' VAL . . . . . 0.42 HG22 ' N ' ' A' ' 162' ' ' ARG . 27.8 m -58.52 -45.4 90.24 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 CA-C-N 116.718 -0.219 . . . . 0.0 111.531 -179.408 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 162' ' ' ARG . . . . . 0.42 ' N ' HG22 ' A' ' 161' ' ' VAL . 40.7 mmt180 -65.05 -39.71 93.69 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-O 120.854 0.359 . . . . 0.0 111.324 -179.723 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 163' ' ' LEU . . . . . 0.591 ' HG ' ' HB2' ' A' ' 208' ' ' PHE . 6.3 mp -70.2 -46.84 63.73 Favored 'General case' 0 C--N 1.328 -0.366 0 N-CA-C 112.453 0.538 . . . . 0.0 112.453 -179.149 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 164' ' ' ARG . . . . . . . . . . . . . 5.8 ppt_? -70.96 -47.71 57.44 Favored 'General case' 0 C--N 1.33 -0.262 0 N-CA-C 112.107 0.41 . . . . 0.0 112.107 -178.418 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 165' ' ' ASN . . . . . . . . . . . . . 16.2 m-80 -57.75 -49.24 77.24 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-O 120.761 0.315 . . . . 0.0 111.129 -179.847 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 166' ' ' LEU . . . . . 0.452 ' O ' ' HG ' ' A' ' 170' ' ' LEU . 5.8 tt -63.57 -52.35 61.43 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.533 -179.427 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 167' ' ' THR . . . . . . . . . . . . . 98.7 m -56.4 -53.27 59.38 Favored 'General case' 0 C--N 1.33 -0.26 0 N-CA-C 112.528 0.566 . . . . 0.0 112.528 -178.88 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 168' ' ' VAL . . . . . . . . . . . . . 72.1 t -54.08 -45.15 65.24 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.225 0 N-CA-C 112.016 0.376 . . . . 0.0 112.016 -179.127 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 169' ' ' VAL . . . . . . . . . . . . . 54.2 t -55.39 -64.45 0.47 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 N-CA-C 111.831 0.308 . . . . 0.0 111.831 -179.387 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 170' ' ' LEU . . . . . 0.452 ' HG ' ' O ' ' A' ' 166' ' ' LEU . 1.1 pp -62.67 -29.68 70.82 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.657 -0.247 . . . . 0.0 111.626 -179.39 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 171' ' ' TRP . . . . . . . . . . . . . 4.1 m0 -69.79 -32.32 70.73 Favored 'General case' 0 C--N 1.332 -0.183 0 CA-C-O 121.126 0.488 . . . . 0.0 110.184 179.207 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 172' ' ' ALA . . . . . . . . . . . . . . . -71.83 -6.5 42.12 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 115.595 -0.73 . . . . 0.0 110.996 -179.848 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 173' ' ' ILE . . . . . 0.468 ' O ' HG12 ' A' ' 177' ' ' ILE . 48.2 mm -85.41 -23.76 7.09 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.245 0 CA-C-N 115.99 -0.55 . . . . 0.0 110.736 179.647 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 174' ' ' TYR . . . . . 0.408 ' N ' ' CD ' ' A' ' 175' ' ' PRO . 20.6 m-85 -54.08 -48.48 93.95 Favored Pre-proline 0 N--CA 1.464 0.232 0 CA-C-N 116.341 -0.39 . . . . 0.0 111.203 179.791 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 175' ' ' PRO . . . . . 0.509 ' HB3' ' HZ ' ' A' ' 127' ' ' PHE . 93.3 Cg_exo -44.6 -33.2 6.51 Favored 'Trans proline' 0 C--N 1.351 0.697 0 C-N-CA 122.287 1.991 . . . . 0.0 112.097 178.894 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 176' ' ' PHE . . . . . 0.499 ' O ' ' HG ' ' A' ' 180' ' ' LEU . 93.0 m-85 -80.63 -50.32 10.1 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 115.691 -0.686 . . . . 0.0 111.851 -179.876 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 177' ' ' ILE . . . . . 0.468 HG12 ' O ' ' A' ' 173' ' ' ILE . 4.6 mm -63.78 -30.91 51.18 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.56 0 N-CA-C 112.533 0.568 . . . . 0.0 112.533 -177.966 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 178' ' ' TRP . . . . . . . . . . . . . 84.0 t90 -73.7 -45.67 50.88 Favored 'General case' 0 C--N 1.331 -0.2 0 CA-C-O 120.833 0.349 . . . . 0.0 110.904 179.904 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 179' ' ' LEU . . . . . 0.507 HD23 HD21 ' A' ' 180' ' ' LEU . 0.5 OUTLIER -73.86 -54.82 7.14 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.027 -0.533 . . . . 0.0 111.635 -179.053 . . . . . . . . 3 3 . 1 . 025 nuclear orig full ' A' A ' 180' ' ' LEU . . . . . 0.516 HD22 HD12 ' A' ' 187' ' ' LEU . 16.6 mt -62.41 -46.34 89.02 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.563 -0.29 . . . . 0.0 111.378 -179.245 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . -54.64 173.55 0.77 Allowed Glycine 0 CA--C 1.523 0.536 0 C-N-CA 120.296 -0.954 . . . . 0.0 112.514 179.707 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 182' ' ' PRO . . . . . 0.449 ' HB2' ' HD3' ' A' ' 183' ' ' PRO . 86.9 Cg_exo -45.95 -45.3 17.65 Favored 'Trans proline' 0 CA--C 1.536 0.615 0 C-N-CA 122.813 2.342 . . . . 0.0 113.801 -179.849 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 183' ' ' PRO . . . . . 0.449 ' HD3' ' HB2' ' A' ' 182' ' ' PRO . 89.0 Cg_exo -45.37 -34.24 10.09 Favored 'Trans proline' 0 C--N 1.356 0.924 0 C-N-CA 122.281 1.987 . . . . 0.0 113.429 -179.828 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 184' ' ' GLY . . . . . . . . . . . . . . . -109.68 -123.75 4.71 Favored Glycine 0 C--N 1.333 0.368 0 C-N-CA 120.299 -0.953 . . . . 0.0 113.114 -179.652 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 185' ' ' VAL . . . . . . . . . . . . . 11.2 m -62.44 -21.77 27.93 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.218 0 N-CA-C 112.252 0.464 . . . . 0.0 112.252 -179.315 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 186' ' ' ALA . . . . . . . . . . . . . . . 57.12 85.63 0.08 Allowed 'General case' 0 N--CA 1.463 0.222 0 CA-C-O 120.862 0.363 . . . . 0.0 111.761 179.693 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 187' ' ' LEU . . . . . 0.516 HD12 HD22 ' A' ' 180' ' ' LEU . 12.6 mt -92.62 -49.66 5.99 Favored 'General case' 0 C--N 1.332 -0.192 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.375 179.806 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 188' ' ' LEU . . . . . 0.513 HD12 HG12 ' A' ' 192' ' ' VAL . 79.7 mt -101.41 -159.81 0.76 Allowed 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 115.946 -0.57 . . . . 0.0 111.1 -179.333 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 189' ' ' THR . . . . . . . . . . . . . 2.0 t -96.55 147.66 33.28 Favored Pre-proline 0 C--N 1.33 -0.277 0 CA-C-N 116.089 -0.505 . . . . 0.0 111.256 -179.793 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 190' ' ' PRO . . . . . 0.41 ' O ' HG22 ' A' ' 194' ' ' VAL . 77.1 Cg_exo -47.62 -39.29 29.77 Favored 'Trans proline' 0 C--N 1.351 0.685 0 C-N-CA 122.681 2.254 . . . . 0.0 112.74 179.967 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 191' ' ' THR . . . . . 0.444 ' HG1' ' N ' ' A' ' 192' ' ' VAL . 73.7 p -57.77 -44.05 85.94 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.315 -0.402 . . . . 0.0 111.357 -179.754 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 192' ' ' VAL . . . . . 0.513 HG12 HD12 ' A' ' 188' ' ' LEU . 40.8 t -68.25 -42.64 84.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.242 -0.436 . . . . 0.0 111.146 179.933 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 193' ' ' ASP . . . . . . . . . . . . . 25.6 t70 -58.29 -50.32 74.02 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.254 -0.43 . . . . 0.0 111.176 -179.849 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 194' ' ' VAL . . . . . 0.516 HG21 HD23 ' A' ' 4' ' ' LEU . 59.6 t -60.93 -35.71 66.89 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.35 -0.386 . . . . 0.0 110.982 179.896 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 195' ' ' ALA . . . . . . . . . . . . . . . -58.39 -48.39 80.8 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.466 -0.334 . . . . 0.0 111.143 179.858 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 196' ' ' LEU . . . . . . . . . . . . . 52.7 mt -68.27 -44.99 74.34 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.327 -0.397 . . . . 0.0 110.651 179.696 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 197' ' ' ILE . . . . . 0.419 HG13 ' NH2' ' A' ' 72' ' ' ARG . 20.2 mm -56.29 -59.12 3.16 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.368 0 CA-C-N 115.805 -0.634 . . . . 0.0 110.787 179.643 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 198' ' ' VAL . . . . . . . . . . . . . 49.3 t -52.26 -35.1 19.04 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.484 0 CA-C-N 115.657 -0.701 . . . . 0.0 109.55 178.728 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 199' ' ' TYR . . . . . . . . . . . . . 48.7 t80 -70.15 -32.1 69.92 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 115.482 -0.781 . . . . 0.0 110.523 179.641 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 200' ' ' LEU . . . . . 0.419 ' O ' HG12 ' A' ' 203' ' ' VAL . 40.8 mt -70.35 -43.97 69.12 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 115.903 -0.589 . . . . 0.0 111.553 -179.609 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 201' ' ' ASP . . . . . . . . . . . . . 8.5 m-20 -70.04 -38.37 75.83 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 121.087 0.47 . . . . 0.0 110.521 -179.971 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 202' ' ' LEU . . . . . 0.449 ' O ' HG21 ' A' ' 206' ' ' VAL . 2.7 mt -70.67 -33.09 70.56 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 115.721 -0.672 . . . . 0.0 111.95 -179.389 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 203' ' ' VAL . . . . . 0.462 ' O ' ' HA3' ' A' ' 207' ' ' GLY . 13.4 p -72.47 -36.08 53.34 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.297 0 C-N-CA 120.856 -0.338 . . . . 0.0 110.848 -178.651 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 204' ' ' THR . . . . . . . . . . . . . 82.4 m -66.29 -58.32 5.61 Favored 'General case' 0 C--N 1.328 -0.328 0 C-N-CA 120.797 -0.361 . . . . 0.0 111.47 179.443 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 205' ' ' LYS . . . . . 0.708 ' HD2' ' HE3' ' A' ' 15' ' ' MET . 57.3 mttp -61.1 -60.15 4.23 Favored 'General case' 0 C--N 1.329 -0.304 0 N-CA-C 112.974 0.731 . . . . 0.0 112.974 -177.697 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 206' ' ' VAL . . . . . 0.449 HG21 ' O ' ' A' ' 202' ' ' LEU . 1.0 OUTLIER -71.1 -36.31 62.35 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.434 0 N-CA-C 112.103 0.409 . . . . 0.0 112.103 -179.471 . . . . . . . . 3 3 . 1 . 025 nuclear orig full ' A' A ' 207' ' ' GLY . . . . . 0.548 ' O ' HG13 ' A' ' 211' ' ' ILE . . . -55.91 -61.48 7.39 Favored Glycine 0 C--N 1.331 0.258 0 C-N-CA 120.534 -0.841 . . . . 0.0 113.623 -178.691 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 208' ' ' PHE . . . . . 0.591 ' HB2' ' HG ' ' A' ' 163' ' ' LEU . 0.7 OUTLIER -72.35 -29.67 64.01 Favored 'General case' 0 C--O 1.224 -0.289 0 CA-C-N 117.433 0.617 . . . . 0.0 110.465 -179.632 . . . . . . . . 3 3 . 1 . 025 nuclear orig full ' A' A ' 209' ' ' GLY . . . . . 0.482 ' O ' ' HB3' ' A' ' 212' ' ' ALA . . . -64.66 -32.08 83.03 Favored Glycine 0 N--CA 1.448 -0.514 0 CA-C-N 115.89 -0.595 . . . . 0.0 111.916 179.24 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 210' ' ' PHE . . . . . . . . . . . . . 3.3 m-85 -73.39 -47.23 43.62 Favored 'General case' 0 CA--C 1.512 -0.5 0 N-CA-C 108.242 -1.021 . . . . 0.0 108.242 178.536 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 211' ' ' ILE . . . . . 0.548 HG13 ' O ' ' A' ' 207' ' ' GLY . 4.7 mt -63.81 -27.5 42.99 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.56 0 N-CA-C 107.342 -1.355 . . . . 0.0 107.342 176.273 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 212' ' ' ALA . . . . . 0.482 ' HB3' ' O ' ' A' ' 209' ' ' GLY . . . -64.85 -39.62 93.86 Favored 'General case' 0 N--CA 1.45 -0.463 0 CA-C-N 114.335 -1.302 . . . . 0.0 110.745 179.986 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 213' ' ' LEU . . . . . . . . . . . . . 48.6 mt -67.49 -49.55 62.99 Favored 'General case' 0 C--N 1.333 -0.128 0 CA-C-N 115.511 -0.768 . . . . 0.0 111.445 -179.565 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 214' ' ' ASP . . . . . . . . . . . . . 15.9 t70 -58.62 -51.08 71.45 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.938 0.399 . . . . 0.0 110.766 -179.908 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 215' ' ' ALA . . . . . . . . . . . . . . . -60.85 -53.42 57.5 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 115.936 -0.574 . . . . 0.0 111.214 -179.901 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 216' ' ' ALA . . . . . . . . . . . . . . . -53.32 -37.02 61.91 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.128 -179.963 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 217' ' ' ALA . . . . . . . . . . . . . . . -65.4 -33.87 76.96 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.108 -0.497 . . . . 0.0 110.347 179.577 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 218' ' ' THR . . . . . . . . . . . . . 67.0 m -75.74 -40.27 55.81 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 115.742 -0.663 . . . . 0.0 110.976 179.483 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 219' ' ' LEU . . . . . . . . . . . . . 36.1 mt -68.33 -29.21 67.91 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.839 -179.816 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 220' ' ' ARG . . . . . . . . . . . . . 51.9 ttt180 -82.02 -34.99 29.3 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.077 -0.511 . . . . 0.0 110.779 179.959 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 221' ' ' ALA . . . . . . . . . . . . . . . -72.24 -23.84 61.28 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.171 -179.892 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 222' ' ' GLU . . . . . . . . . . . . . 13.1 pt-20 -91.91 -26.41 18.46 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 120.984 0.421 . . . . 0.0 110.199 179.751 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 223' ' ' HIS . . . . . . . . . . . . . 57.6 m-70 61.4 101.6 0.03 OUTLIER 'General case' 0 C--N 1.333 -0.144 0 CA-C-N 115.672 -0.694 . . . . 0.0 111.046 179.76 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 224' ' ' GLY . . . . . . . . . . . . . . . -111.81 4.76 27.51 Favored Glycine 0 C--N 1.331 0.297 0 C-N-CA 120.781 -0.724 . . . . 0.0 112.625 -179.845 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 225' ' ' GLU . . . . . . . . . . . . . 41.8 mt-10 -82.79 114.49 21.15 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.697 0.284 . . . . 0.0 110.797 179.988 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 226' ' ' SER . . . . . . . . . . . . . 71.5 p -143.28 160.16 41.01 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.342 -0.39 . . . . 0.0 110.966 179.993 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 227' ' ' LEU . . . . . . . . . . . . . 85.9 mt -100.33 -7.93 23.93 Favored 'General case' 0 C--N 1.332 -0.191 0 CA-C-N 116.088 -0.505 . . . . 0.0 110.868 179.959 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 228' ' ' ALA . . . . . . . . . . . . . . . 52.35 85.16 0.05 OUTLIER 'General case' 0 C--N 1.331 -0.212 0 CA-C-N 116.055 -0.52 . . . . 0.0 111.475 -179.934 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 229' ' ' GLY . . . . . . . . . . . . . . . 74.38 125.78 0.14 Allowed Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.869 -0.681 . . . . 0.0 112.624 -179.863 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 230' ' ' VAL . . . . . . . . . . . . . 57.6 t -72.31 131.66 34.43 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-O 120.827 0.346 . . . . 0.0 110.95 179.843 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 231' ' ' ASP . . . . . . . . . . . . . 20.3 m-20 -95.62 108.14 20.39 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.157 -179.831 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 232' ' ' THR . . . . . . . . . . . . . 6.7 t -168.51 145.82 3.95 Favored 'General case' 0 C--N 1.332 -0.193 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.206 179.802 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 233' ' ' ASP . . . . . . . . . . . . . 7.7 m-20 -78.49 -14.81 59.18 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 115.977 -0.556 . . . . 0.0 110.998 -179.936 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 234' ' ' THR . . . . . . . . . . . . . 89.8 m -105.09 107.04 57.91 Favored Pre-proline 0 C--N 1.329 -0.306 0 CA-C-N 116.252 -0.431 . . . . 0.0 111.209 -179.926 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 235' ' ' PRO . . . . . . . . . . . . . 73.3 Cg_endo -76.53 170.04 20.7 Favored 'Trans proline' 0 C--N 1.348 0.537 0 C-N-CA 122.318 2.012 . . . . 0.0 112.267 179.902 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 236' ' ' ALA . . . . . . . . . . . . . . . -85.98 143.77 27.97 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.907 179.917 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 237' ' ' VAL . . . . . . . . . . . . . 7.1 p -128.36 141.32 46.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.143 -179.909 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 238' ' ' ALA . . . . . . . . . . . . . . . -134.58 -23.25 1.64 Allowed 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.08 -0.509 . . . . 0.0 111.104 179.991 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 239' ' ' ASP . . . . . . . . . . . . . 14.6 t70 -145.11 142.21 29.47 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.961 -179.958 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 240' ' ' LEU . . . . . 0.419 ' N ' HD23 ' A' ' 240' ' ' LEU . 3.7 mm? -89.57 133.85 34.41 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 116.066 -0.515 . . . . 0.0 110.811 -179.969 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 241' ' ' GLU . . . . . . . . . . . . . 9.0 tp10 -101.72 -72.93 0.67 Allowed 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.113 -0.494 . . . . 0.0 111.087 -179.798 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 242' ' ' HIS . . . . . . . . . . . . . 43.0 m80 60.84 107.6 0.02 OUTLIER 'General case' 0 N--CA 1.462 0.16 0 CA-C-N 116.156 -0.474 . . . . 0.0 111.207 -179.674 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 243' ' ' HIS . . . . . . . . . . . . . 8.4 p80 -127.99 152.79 47.48 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.043 -0.526 . . . . 0.0 111.063 -179.922 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 244' ' ' HIS . . . . . . . . . . . . . 72.3 t60 -149.4 -24.34 0.28 Allowed 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.163 -0.472 . . . . 0.0 110.633 179.843 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 245' ' ' HIS . . . . . . . . . . . . . 62.5 m-70 -97.73 175.84 6.04 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.718 179.76 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 246' ' ' HIS . . . . . . . . . . . . . 18.9 t-80 -143.55 -41.76 0.29 Allowed 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.302 -0.408 . . . . 0.0 110.949 179.987 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 247' ' ' HIS . . . . . . . . . . . . . 47.8 m80 . . . . . 0 C--O 1.249 1.032 0 CA-C-O 118.246 -0.883 . . . . 0.0 110.884 -179.927 . . . . . . . . 0 0 . 1 . 025 nuclear orig full ' A' A ' 301' ' ' RET . . . . . 0.478 H202 HG13 ' A' ' 83' ' ' ILE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 62.8 mtm . . . . . 0 N--CA 1.484 1.275 0 CA-C-O 120.828 0.347 . . . . 0.0 110.99 . . . . . . . . . 0 0 . 1 . 026 nuclear orig full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 7.4 p -170.91 -38.18 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.249 0 CA-C-N 115.942 -0.572 . . . . 0.0 111.171 -179.982 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -103.11 -16.8 20.11 Favored Glycine 0 N--CA 1.449 -0.439 0 C-N-CA 120.646 -0.788 . . . . 0.0 112.465 -179.948 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -71.47 -37.43 71.33 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.909 0.385 . . . . 0.0 110.742 -179.971 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 65.4 p -64.19 -32.39 73.95 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.149 -179.967 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 11.8 p -57.29 -35.37 69.72 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.034 -0.53 . . . . 0.0 111.145 -179.818 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 7' ' ' LEU . . . . . . . . . . . . . 4.3 mm? -57.57 -50.94 71.47 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.295 -0.412 . . . . 0.0 111.154 179.793 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 8' ' ' PHE . . . . . 0.499 ' HB2' ' HB1' ' A' ' 55' ' ' ALA . 65.6 m-85 -65.84 -32.54 74.12 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.34 -0.391 . . . . 0.0 110.916 -179.706 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 9' ' ' TRP . . . . . 0.421 ' O ' HG13 ' A' ' 13' ' ' ILE . 23.2 m95 -67.09 -49.89 63.45 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-N 116.065 -0.516 . . . . 0.0 110.388 -179.524 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 89.5 mt -59.18 -47.05 86.74 Favored 'General case' 0 C--N 1.326 -0.45 0 CA-C-N 115.72 -0.673 . . . . 0.0 109.973 179.57 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . 0.423 ' O ' ' HG2' ' A' ' 15' ' ' MET . . . -57.67 -42.96 94.55 Favored Glycine 0 N--CA 1.445 -0.722 0 C-N-CA 120.634 -0.794 . . . . 0.0 111.363 179.062 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -56.36 -35.31 67.54 Favored 'General case' 0 C--N 1.331 -0.196 0 CA-C-O 120.939 0.4 . . . . 0.0 110.68 179.737 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 13' ' ' ILE . . . . . 0.421 HG13 ' O ' ' A' ' 9' ' ' TRP . 63.7 mt -62.32 -46.46 96.37 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 CA-C-N 116.002 -0.545 . . . . 0.0 110.082 179.334 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . 0.426 ' HA3' HD23 ' A' ' 202' ' ' LEU . . . -59.41 -40.67 96.4 Favored Glycine 0 N--CA 1.45 -0.399 0 C-N-CA 120.799 -0.715 . . . . 0.0 112.512 179.666 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 15' ' ' MET . . . . . 0.423 ' HG2' ' O ' ' A' ' 11' ' ' GLY . 13.8 mmm -62.93 -39.14 93.68 Favored 'General case' 0 C--N 1.332 -0.189 0 CA-C-O 120.824 0.345 . . . . 0.0 110.656 -179.946 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -59.11 -45.18 91.56 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.029 -0.532 . . . . 0.0 110.582 179.741 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 51.1 t -59.21 -48.63 86.26 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.2 0 CA-C-N 116.354 -0.384 . . . . 0.0 110.98 179.965 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -63.69 -48.42 77.39 Favored Glycine 0 N--CA 1.452 -0.283 0 C-N-CA 120.805 -0.712 . . . . 0.0 112.438 179.926 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 19' ' ' THR . . . . . 0.447 HG21 HG13 ' A' ' 41' ' ' VAL . 47.6 m -49.71 -41.19 42.87 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.735 0.302 . . . . 0.0 111.552 -179.445 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 78.0 mt -72.04 -41.61 67.29 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.425 -0.352 . . . . 0.0 111.393 179.841 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -62.57 -29.91 70.93 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.309 -0.405 . . . . 0.0 111.792 -179.65 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 22' ' ' PHE . . . . . 0.516 ' HB2' HG21 ' A' ' 41' ' ' VAL . 3.4 m-85 -89.99 -34.84 15.84 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.501 -0.318 . . . . 0.0 111.261 -179.256 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -70.43 -49.84 44.61 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.455 -0.339 . . . . 0.0 111.238 -179.993 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 24' ' ' TRP . . . . . . . . . . . . . 1.2 t-105 -59.46 -39.24 83.02 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.045 -0.525 . . . . 0.0 110.899 179.974 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -73.04 -24.67 60.74 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.293 -0.412 . . . . 0.0 110.992 179.938 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -67.53 -49.59 49.61 Favored Glycine 0 N--CA 1.451 -0.36 0 C-N-CA 120.722 -0.752 . . . . 0.0 112.225 179.715 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 63.1 mtm180 -60.42 -32.8 71.7 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-O 120.945 0.403 . . . . 0.0 110.768 179.707 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 9.0 t70 -72.31 -29.07 63.49 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 115.884 -0.598 . . . . 0.0 111.04 179.936 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -71.26 -174.93 1.1 Allowed 'General case' 0 C--N 1.331 -0.215 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.201 -179.857 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -91.28 -110.1 1.6 Allowed Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.861 -0.685 . . . . 0.0 112.764 -179.718 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 49.5 m -138.25 -45.49 0.51 Allowed 'General case' 0 C--N 1.331 -0.207 0 CA-C-O 120.791 0.329 . . . . 0.0 111.203 -179.747 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -57.95 -32.98 67.35 Favored Glycine 0 N--CA 1.453 -0.229 0 C-N-CA 120.842 -0.694 . . . . 0.0 112.711 -179.815 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 38.5 mt-10 -90.53 -20.74 22.31 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-O 120.807 0.336 . . . . 0.0 110.812 179.951 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 34' ' ' ARG . . . . . . . . . . . . . 38.5 ttm180 -48.37 -29.36 3.9 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 115.9 -0.591 . . . . 0.0 111.68 -179.512 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 35' ' ' ARG . . . . . 0.423 ' NE ' ' HA ' ' A' ' 35' ' ' ARG . 5.5 mmp_? -59.23 -46.6 88.04 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.808 0.337 . . . . 0.0 111.118 179.923 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 73.8 m-85 -67.63 -30.23 69.74 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.252 -179.848 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 37' ' ' TYR . . . . . . . . . . . . . 76.5 m-85 -74.13 -54.7 7.24 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.538 -179.406 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 10.5 p -56.72 -36.18 48.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-O 120.979 0.418 . . . . 0.0 110.387 179.884 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 52.5 m -68.9 -49.96 53.69 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 115.617 -0.72 . . . . 0.0 110.559 179.216 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 40' ' ' LEU . . . . . 0.414 HD11 HD13 ' A' ' 43' ' ' ILE . 22.5 tp -55.53 -50.02 71.08 Favored 'General case' 0 C--O 1.237 0.438 0 CA-C-N 115.718 -0.674 . . . . 0.0 110.374 179.651 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . 0.516 HG21 ' HB2' ' A' ' 22' ' ' PHE . 83.7 t -59.36 -34.24 53.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 115.769 -0.65 . . . . 0.0 109.94 178.912 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -58.56 -38.25 90.83 Favored Glycine 0 N--CA 1.448 -0.547 0 C-N-CA 120.71 -0.757 . . . . 0.0 111.453 179.503 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 43' ' ' ILE . . . . . 0.414 HD13 HD11 ' A' ' 40' ' ' LEU . 2.4 mt -65.21 -59.31 4.31 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.217 0 CA-C-O 120.863 0.363 . . . . 0.0 110.593 179.464 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 77.6 p -59.56 -24.67 63.91 Favored 'General case' 0 C--N 1.331 -0.218 0 CA-C-N 115.991 -0.549 . . . . 0.0 111.344 -179.666 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -75.3 -57.69 4.21 Favored Glycine 0 CA--C 1.518 0.24 0 C-N-CA 120.745 -0.74 . . . . 0.0 112.861 -179.653 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 22.6 pt -58.25 -35.27 52.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-O 120.908 0.385 . . . . 0.0 110.762 -179.896 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 47' ' ' ALA . . . . . 0.551 ' HB1' ' HE2' ' A' ' 205' ' ' LYS . . . -63.91 -49.73 71.48 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.001 -0.545 . . . . 0.0 111.07 179.764 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -54.52 -36.55 64.37 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.857 179.999 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 0.5 OUTLIER -67.04 -42.99 89.21 Favored 'Isoleucine or valine' 0 N--CA 1.432 -1.371 0 CA-C-N 116.031 -0.531 . . . . 0.0 111.486 179.797 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -67.85 -33.67 75.21 Favored 'General case' 0 C--N 1.333 -0.137 0 CA-C-N 116.43 -0.35 . . . . 0.0 111.463 179.954 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 51' ' ' TYR . . . . . 0.44 ' O ' ' HB3' ' A' ' 8' ' ' PHE . 31.5 m-85 -70.59 -36.77 73.73 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.77 -179.525 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -71.55 -42.42 67.9 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-N 115.985 -0.552 . . . . 0.0 111.531 179.985 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 53' ' ' VAL . . . . . 0.444 HG21 ' N ' ' A' ' 54' ' ' MET . 35.5 m -67.06 -50.7 61.59 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.173 0 CA-C-N 116.556 -0.293 . . . . 0.0 111.451 -179.629 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 54' ' ' MET . . . . . 0.444 ' N ' HG21 ' A' ' 53' ' ' VAL . 78.1 mtm -61.14 -32.04 71.75 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-O 121.047 0.451 . . . . 0.0 110.296 179.775 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 55' ' ' ALA . . . . . 0.499 ' HB1' ' HB2' ' A' ' 8' ' ' PHE . . . -66.44 -38.43 87.38 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 115.753 -0.658 . . . . 0.0 111.015 179.42 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 97.2 mt -71.25 -12.88 61.69 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.039 -0.528 . . . . 0.0 111.238 -179.817 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 101.05 -21.03 45.13 Favored Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.649 -0.786 . . . . 0.0 112.817 179.819 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 30.1 m -66.63 138.58 22.66 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.238 0 CA-C-O 120.872 0.367 . . . . 0.0 111.018 -179.981 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 101.8 -11.52 57.67 Favored Glycine 0 N--CA 1.45 -0.402 0 C-N-CA 120.815 -0.707 . . . . 0.0 112.413 -179.7 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 60' ' ' TRP . . . . . . . . . . . . . 22.0 m0 -78.39 117.38 19.56 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.699 0.285 . . . . 0.0 110.727 179.793 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 10.0 p -109.99 129.54 23.83 Favored Pre-proline 0 C--N 1.329 -0.295 0 CA-C-N 116.438 -0.347 . . . . 0.0 111.078 179.836 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 86.5 Cg_endo -75.96 140.61 23.08 Favored 'Trans proline' 0 C--N 1.35 0.637 0 C-N-CA 122.404 2.07 . . . . 0.0 112.111 179.897 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 81.9 t -138.94 96.13 0.99 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.041 -0.527 . . . . 0.0 110.937 -179.767 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . 58.48 -86.71 0.02 OUTLIER 'General case' 0 C--N 1.332 -0.195 0 CA-C-N 116.001 -0.545 . . . . 0.0 111.315 -179.906 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 40.8 tt0 -121.04 -26.19 5.19 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.398 -0.364 . . . . 0.0 110.781 179.959 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 66' ' ' ARG . . . . . . . . . . . . . 76.0 ttt-85 -102.11 154.55 18.89 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.576 -179.954 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 86.0 m -113.37 121.24 43.76 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 120.882 0.373 . . . . 0.0 111.57 -179.741 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 68' ' ' VAL . . . . . 0.419 HG21 ' HA ' ' A' ' 117' ' ' MET . 21.8 t -93.21 146.89 5.88 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-N 115.978 -0.555 . . . . 0.0 110.374 179.344 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 69' ' ' PHE . . . . . . . . . . . . . 30.3 m-85 -106.87 112.31 25.21 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-O 120.836 0.351 . . . . 0.0 110.152 -179.494 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 70' ' ' VAL . . . . . 0.553 ' HB ' ' HD3' ' A' ' 71' ' ' PRO . 11.2 t -68.6 -50.22 26.61 Favored Pre-proline 0 C--N 1.326 -0.45 0 CA-C-N 115.986 -0.552 . . . . 0.0 112.361 -178.85 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 71' ' ' PRO . . . . . 0.553 ' HD3' ' HB ' ' A' ' 70' ' ' VAL . 24.6 Cg_exo -63.28 -18.35 64.41 Favored 'Trans proline' 0 C--N 1.351 0.7 0 C-N-CA 122.253 1.968 . . . . 0.0 113.068 -179.455 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 70.6 ttt180 -70.69 -55.48 8.6 Favored 'General case' 0 C--O 1.235 0.316 0 CA-C-O 120.88 0.371 . . . . 0.0 111.661 -179.33 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 73' ' ' TYR . . . . . . . . . . . . . 98.8 m-85 -71.86 -33.27 68.27 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.525 -0.307 . . . . 0.0 110.72 -179.519 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 0.3 OUTLIER -65.96 -37.67 80.37 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.307 0 N-CA-C 109.446 -0.575 . . . . 0.0 109.446 179.017 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 33.1 t70 -61.65 -37.33 83.65 Favored 'General case' 0 N--CA 1.453 -0.286 0 N-CA-C 109.251 -0.648 . . . . 0.0 109.251 178.734 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 76' ' ' TRP . . . . . . . . . . . . . 45.8 m0 -66.66 -29.91 70.05 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 115.642 -0.708 . . . . 0.0 110.114 179.019 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 77' ' ' ILE . . . . . 0.435 HG12 ' HB3' ' A' ' 109' ' ' MET . 97.0 mt -71.73 -29.62 34.84 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 115.87 -0.605 . . . . 0.0 110.737 179.447 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 51.8 mt -90.43 -17.17 27.66 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 116.0 -0.546 . . . . 0.0 111.776 179.994 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 79' ' ' THR . . . . . 0.4 ' O ' HG12 ' A' ' 83' ' ' ILE . 69.7 p -102.94 -52.63 3.01 Favored 'General case' 0 C--N 1.332 -0.189 0 N-CA-C 113.311 0.856 . . . . 0.0 113.311 -178.371 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 80' ' ' THR . . . . . 0.677 ' HB ' ' HD3' ' A' ' 81' ' ' PRO . 37.4 m -50.2 -55.7 23.15 Favored Pre-proline 0 CA--C 1.533 0.292 0 N-CA-C 112.537 0.569 . . . . 0.0 112.537 -178.284 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 81' ' ' PRO . . . . . 0.677 ' HD3' ' HB ' ' A' ' 80' ' ' THR . 39.2 Cg_exo -61.06 -21.07 70.42 Favored 'Trans proline' 0 C--N 1.351 0.666 0 C-N-CA 121.55 1.5 . . . . 0.0 111.587 179.818 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 82' ' ' LEU . . . . . . . . . . . . . 14.4 tp -76.99 -33.17 57.62 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 115.811 -0.631 . . . . 0.0 110.599 179.847 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 83' ' ' ILE . . . . . 0.4 HG12 ' O ' ' A' ' 79' ' ' THR . 36.3 mm -69.92 -53.45 23.84 Favored 'Isoleucine or valine' 0 C--O 1.232 0.173 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.214 179.326 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . 0.404 HG22 ' OD1' ' A' ' 105' ' ' ASN . 34.6 m -59.61 -32.46 49.22 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.224 0 N-CA-C 109.4 -0.592 . . . . 0.0 109.4 178.637 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 85' ' ' TYR . . . . . . . . . . . . . 68.7 t80 -60.68 -43.88 97.17 Favored 'General case' 0 N--CA 1.452 -0.356 0 CA-C-N 115.455 -0.793 . . . . 0.0 109.047 178.606 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 86' ' ' PHE . . . . . . . . . . . . . 2.1 t80 -53.52 -50.25 65.84 Favored 'General case' 0 C--O 1.233 0.199 0 CA-C-N 115.632 -0.713 . . . . 0.0 109.734 179.407 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 87' ' ' LEU . . . . . 0.499 ' HA ' HD11 ' A' ' 90' ' ' LEU . 8.9 mp -59.72 -28.34 67.25 Favored 'General case' 0 C--N 1.332 -0.188 0 CA-C-N 115.785 -0.643 . . . . 0.0 110.665 179.618 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -65.28 -42.45 96.2 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.65 -0.786 . . . . 0.0 111.903 179.697 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 8.8 mp -64.5 -37.22 86.77 Favored 'General case' 0 N--CA 1.45 -0.474 0 CA-C-O 121.118 0.485 . . . . 0.0 110.504 179.387 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 90' ' ' LEU . . . . . 0.499 HD11 ' HA ' ' A' ' 87' ' ' LEU . 97.9 mt -55.32 -59.07 5.31 Favored 'General case' 0 C--N 1.326 -0.455 0 CA-C-N 115.368 -0.833 . . . . 0.0 111.162 179.905 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . 0.499 ' HB2' ' HB2' ' A' ' 149' ' ' ALA . . . -71.69 -54.82 9.1 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.085 -0.507 . . . . 0.0 111.382 -179.79 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 110.88 59.46 0.48 Allowed Glycine 0 N--CA 1.45 -0.372 0 C-N-CA 120.95 -0.643 . . . . 0.0 112.255 -179.892 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 93' ' ' LEU . . . . . 0.472 HD21 ' HB3' ' A' ' 97' ' ' GLU . 8.9 mp -77.19 169.29 18.6 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.915 0.388 . . . . 0.0 111.133 -179.722 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 94' ' ' ASP . . . . . . . . . . . . . 9.7 m-20 -91.09 163.65 14.22 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.05 -0.523 . . . . 0.0 110.704 179.827 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 80.6 p -53.96 -27.56 32.05 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.331 -0.395 . . . . 0.0 110.988 -179.926 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 80.5 mtm180 -73.07 -53.43 11.09 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.299 -0.409 . . . . 0.0 110.757 179.81 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 97' ' ' GLU . . . . . 0.472 ' HB3' HD21 ' A' ' 93' ' ' LEU . 44.9 mt-10 -57.44 -39.41 76.19 Favored 'General case' 0 C--N 1.332 -0.191 0 CA-C-N 116.122 -0.49 . . . . 0.0 111.104 -179.857 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 98' ' ' PHE . . . . . 0.426 ' O ' HG12 ' A' ' 102' ' ' ILE . 12.6 m-85 -60.29 -51.54 69.12 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.366 -0.379 . . . . 0.0 110.857 179.969 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -59.31 -28.15 64.08 Favored Glycine 0 N--CA 1.452 -0.291 0 C-N-CA 120.675 -0.774 . . . . 0.0 112.497 -179.85 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 96.3 mt -73.4 -47.05 47.4 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-O 120.823 0.344 . . . . 0.0 111.345 -179.868 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 59.4 t -67.38 -43.2 87.89 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.399 0 CA-C-N 116.235 -0.438 . . . . 0.0 111.545 -179.675 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 102' ' ' ILE . . . . . 0.426 HG12 ' O ' ' A' ' 98' ' ' PHE . 49.5 mm -64.83 -48.92 82.4 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.386 -0.37 . . . . 0.0 111.4 -179.516 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 14.0 t -60.4 -31.05 70.0 Favored 'General case' 0 C--N 1.332 -0.169 0 CA-C-O 120.811 0.339 . . . . 0.0 110.814 -179.982 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 104' ' ' LEU . . . . . 0.432 HD22 ' HE2' ' A' ' 140' ' ' TYR . 45.6 tp -61.95 -54.45 41.58 Favored 'General case' 0 C--N 1.332 -0.185 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.382 179.486 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 105' ' ' ASN . . . . . 0.507 HD22 HD13 ' A' ' 137' ' ' LEU . 4.9 m120 -61.87 -25.48 67.57 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 116.053 -0.521 . . . . 0.0 110.959 -179.986 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 52.2 m -64.27 -54.89 26.24 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.343 -0.39 . . . . 0.0 111.12 179.992 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 13.4 p -64.14 -36.37 76.75 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.205 0 CA-C-N 116.382 -0.372 . . . . 0.0 111.049 -179.989 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . 0.414 HG22 ' O ' ' A' ' 104' ' ' LEU . 96.4 t -64.13 -52.65 53.44 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.761 179.664 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 109' ' ' MET . . . . . 0.435 ' HB3' HG12 ' A' ' 77' ' ' ILE . 9.7 tpp -62.11 -26.15 68.13 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 115.872 -0.604 . . . . 0.0 110.705 -179.973 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 29.7 tp -75.69 -33.87 60.38 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.163 -0.472 . . . . 0.0 110.204 179.396 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -62.13 -54.37 42.18 Favored 'General case' 0 C--N 1.332 -0.177 0 CA-C-N 115.924 -0.58 . . . . 0.0 110.377 179.301 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . -61.75 -37.32 94.09 Favored Glycine 0 N--CA 1.45 -0.388 0 C-N-CA 120.645 -0.788 . . . . 0.0 111.652 179.435 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 113' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER -48.23 -69.88 0.11 Allowed 'General case' 0 CA--C 1.521 -0.158 0 N-CA-C 109.755 -0.461 . . . . 0.0 109.755 179.219 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -65.1 -17.79 64.76 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 115.615 -0.72 . . . . 0.0 110.271 178.875 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 115' ' ' GLY . . . . . 0.458 ' HA2' HD23 ' A' ' 126' ' ' LEU . . . -52.52 -47.99 56.15 Favored Glycine 0 C--N 1.334 0.465 0 C-N-CA 121.005 -0.617 . . . . 0.0 111.791 179.45 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -78.26 -23.1 47.46 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-O 120.666 0.27 . . . . 0.0 111.571 179.705 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 117' ' ' MET . . . . . 0.419 ' HA ' HG21 ' A' ' 68' ' ' VAL . 40.9 ttm -94.8 19.2 10.44 Favored 'General case' 0 CA--C 1.533 0.305 0 CA-C-N 116.457 -0.338 . . . . 0.0 111.859 -179.257 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 118' ' ' VAL . . . . . 0.438 HG21 ' HB3' ' A' ' 123' ' ' ARG . 21.8 m -69.17 150.88 97.28 Favored Pre-proline 0 C--N 1.331 -0.227 0 CA-C-O 120.554 0.216 . . . . 0.0 111.17 179.736 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 119' ' ' PRO . . . . . . . . . . . . . 92.9 Cg_endo -81.29 -4.96 12.66 Favored 'Trans proline' 0 C--N 1.348 0.515 0 C-N-CA 122.699 2.266 . . . . 0.0 112.364 179.846 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -158.2 -131.23 1.26 Allowed Glycine 0 C--N 1.331 0.267 0 C-N-CA 120.834 -0.698 . . . . 0.0 112.653 -179.994 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 37.9 pt -97.48 10.88 5.79 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.226 0 CA-C-O 120.877 0.37 . . . . 0.0 111.161 -179.951 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 16.4 mm-40 -59.8 -18.12 41.13 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.016 -0.538 . . . . 0.0 111.096 179.8 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 123' ' ' ARG . . . . . 0.44 ' HB2' ' HH2' ' A' ' 178' ' ' TRP . 23.0 ptt180 -50.74 -28.9 10.1 Favored 'General case' 0 C--N 1.331 -0.197 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.778 -179.884 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 124' ' ' TYR . . . . . . . . . . . . . 38.1 m-85 -69.46 -32.91 72.13 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-O 120.828 0.347 . . . . 0.0 110.975 179.965 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 125' ' ' ALA . . . . . . . . . . . . . . . -73.52 -49.94 23.99 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.094 -0.503 . . . . 0.0 111.13 179.942 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 126' ' ' LEU . . . . . 0.458 HD23 ' HA2' ' A' ' 115' ' ' GLY . 7.9 mp -53.36 -55.49 24.49 Favored 'General case' 0 C--N 1.331 -0.201 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.316 179.771 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 127' ' ' PHE . . . . . 0.423 ' HZ ' ' HB3' ' A' ' 175' ' ' PRO . 9.7 t80 -62.82 -33.9 76.18 Favored 'General case' 0 N--CA 1.452 -0.372 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.264 179.568 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 128' ' ' GLY . . . . . . . . . . . . . . . -47.97 -43.23 23.9 Favored Glycine 0 C--N 1.333 0.394 0 C-N-CA 120.167 -1.016 . . . . 0.0 110.778 178.907 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 129' ' ' MET . . . . . . . . . . . . . 0.4 OUTLIER -71.27 -38.22 71.86 Favored 'General case' 0 C--N 1.329 -0.312 0 N-CA-C 109.786 -0.45 . . . . 0.0 109.786 178.565 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -65.72 -27.49 72.73 Favored Glycine 0 N--CA 1.451 -0.313 0 CA-C-N 115.757 -0.656 . . . . 0.0 112.695 179.907 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -74.77 -53.66 8.78 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.664 0.268 . . . . 0.0 110.545 179.828 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 132' ' ' VAL . . . . . 0.507 ' O ' HG13 ' A' ' 135' ' ' ILE . 38.7 t -57.2 -39.74 69.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-O 121.567 0.699 . . . . 0.0 109.311 178.675 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -70.99 -33.97 70.93 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-N 115.15 -0.932 . . . . 0.0 110.831 179.41 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 134' ' ' PHE . . . . . 0.439 ' CZ ' ' HA ' ' A' ' 172' ' ' ALA . 35.9 t80 -55.03 -59.22 5.04 Favored 'General case' 0 N--CA 1.453 -0.281 0 CA-C-N 116.353 -0.385 . . . . 0.0 110.397 179.809 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 135' ' ' ILE . . . . . 0.507 HG13 ' O ' ' A' ' 132' ' ' VAL . 0.2 OUTLIER -55.71 -36.63 43.52 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.368 0 CA-C-N 116.012 -0.54 . . . . 0.0 109.862 179.176 . . . . . . . . 3 3 . 1 . 026 nuclear orig full ' A' A ' 136' ' ' GLY . . . . . 0.402 ' O ' ' HB3' ' A' ' 139' ' ' TYR . . . -52.77 -42.28 59.06 Favored Glycine 0 C--N 1.334 0.437 0 C-N-CA 120.396 -0.907 . . . . 0.0 111.686 178.86 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 137' ' ' LEU . . . . . 0.507 HD13 HD22 ' A' ' 105' ' ' ASN . 49.1 tp -64.52 -49.25 72.02 Favored 'General case' 0 C--N 1.33 -0.261 0 N-CA-C 110.187 -0.301 . . . . 0.0 110.187 179.161 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 138' ' ' VAL . . . . . . . . . . . . . 59.9 t -54.82 -33.12 27.4 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.928 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.238 179.847 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 139' ' ' TYR . . . . . 0.402 ' HB3' ' O ' ' A' ' 136' ' ' GLY . 18.2 t80 -63.0 -43.32 99.13 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 115.867 -0.606 . . . . 0.0 110.112 178.74 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 140' ' ' TYR . . . . . 0.432 ' HE2' HD22 ' A' ' 104' ' ' LEU . 29.1 m-85 -63.75 -44.49 93.34 Favored 'General case' 0 C--N 1.332 -0.171 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.025 179.658 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 141' ' ' LEU . . . . . 0.436 ' HA ' ' SD ' ' A' ' 145' ' ' MET . 10.4 mp -55.99 -34.37 65.69 Favored 'General case' 0 C--N 1.332 -0.191 0 CA-C-N 116.449 -0.341 . . . . 0.0 110.96 179.887 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 22.2 t -94.62 -17.3 7.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.111 179.85 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . -68.96 -140.61 0.1 OUTLIER Glycine 0 CA--C 1.521 0.441 0 C-N-CA 121.034 -0.603 . . . . 0.0 113.218 -179.789 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 144' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_exo -51.88 -23.58 16.65 Favored 'Trans proline' 0 C--N 1.35 0.614 0 C-N-CA 122.841 2.361 . . . . 0.0 113.004 -179.597 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 145' ' ' MET . . . . . 0.436 ' SD ' ' HA ' ' A' ' 141' ' ' LEU . 34.9 mtt -54.1 -35.68 62.39 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.354 -0.384 . . . . 0.0 111.734 -179.648 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 146' ' ' THR . . . . . . . . . . . . . 46.0 p -79.1 -32.1 44.5 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.83 0.347 . . . . 0.0 111.265 -179.413 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 43.3 tt0 -61.96 -48.91 78.29 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 116.114 -0.494 . . . . 0.0 111.108 -179.917 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 148' ' ' SER . . . . . . . . . . . . . 51.6 m -70.56 -44.89 66.49 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.654 -179.342 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 149' ' ' ALA . . . . . 0.499 ' HB2' ' HB2' ' A' ' 91' ' ' ALA . . . -60.31 -55.08 38.0 Favored 'General case' 0 C--N 1.329 -0.291 0 N-CA-C 112.065 0.395 . . . . 0.0 112.065 -179.256 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 150' ' ' SER . . . . . 0.464 ' HA ' ' HB3' ' A' ' 157' ' ' LYS . 67.6 m -64.03 -8.03 10.48 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.415 -0.357 . . . . 0.0 111.09 -179.681 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 151' ' ' GLN . . . . . . . . . . . . . 24.2 mt-30 -120.99 7.51 10.36 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.342 -0.39 . . . . 0.0 111.193 179.959 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 152' ' ' ARG . . . . . 0.51 ' HE ' ' HA ' ' A' ' 152' ' ' ARG . 5.3 tpm_? -85.55 -52.49 5.79 Favored 'General case' 0 C--N 1.332 -0.165 0 CA-C-O 120.841 0.353 . . . . 0.0 110.678 179.944 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 153' ' ' SER . . . . . 0.621 ' HB2' HG12 ' A' ' 156' ' ' ILE . 18.6 m -158.24 172.9 17.53 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 115.949 -0.568 . . . . 0.0 110.617 179.168 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 154' ' ' SER . . . . . . . . . . . . . 48.4 t -72.17 -40.26 68.08 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.512 179.455 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -77.45 -30.21 54.19 Favored Glycine 0 CA--C 1.518 0.274 0 C-N-CA 120.986 -0.626 . . . . 0.0 112.998 179.917 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 156' ' ' ILE . . . . . 0.621 HG12 ' HB2' ' A' ' 153' ' ' SER . 34.9 mm -58.84 -46.76 90.87 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.226 0 N-CA-C 111.974 0.361 . . . . 0.0 111.974 -179.264 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 157' ' ' LYS . . . . . 0.464 ' HB3' ' HA ' ' A' ' 150' ' ' SER . 6.5 ptpp? -60.64 -35.67 76.76 Favored 'General case' 0 C--N 1.331 -0.234 0 N-CA-C 111.588 0.218 . . . . 0.0 111.588 -179.394 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 49.0 m -66.24 -44.53 83.46 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.941 0.401 . . . . 0.0 111.236 -179.752 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 159' ' ' LEU . . . . . 0.432 HD21 ' HB1' ' A' ' 215' ' ' ALA . 5.1 mt -68.64 -37.66 79.87 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.544 -179.743 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 160' ' ' TYR . . . . . . . . . . . . . 13.8 t80 -68.55 -43.24 77.1 Favored 'General case' 0 C--N 1.327 -0.407 0 N-CA-C 112.267 0.469 . . . . 0.0 112.267 -178.705 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 24.0 m -63.78 -46.21 95.07 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 C-N-CA 120.989 -0.284 . . . . 0.0 111.717 -179.23 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 162' ' ' ARG . . . . . . . . . . . . . 24.9 tpt180 -69.25 -48.63 61.32 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.815 0.34 . . . . 0.0 111.491 -179.76 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 163' ' ' LEU . . . . . . . . . . . . . 1.5 mp -60.89 -54.8 40.62 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.089 -0.505 . . . . 0.0 111.937 -179.183 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 164' ' ' ARG . . . . . . . . . . . . . 6.1 tmm_? -55.94 -50.52 70.53 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 116.073 -0.512 . . . . 0.0 112.179 -178.498 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 165' ' ' ASN . . . . . 0.466 ' N ' HD21 ' A' ' 165' ' ' ASN . 0.9 OUTLIER -52.7 -51.52 59.97 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-O 120.662 0.268 . . . . 0.0 111.458 -179.261 . . . . . . . . 3 3 . 1 . 026 nuclear orig full ' A' A ' 166' ' ' LEU . . . . . 0.498 ' O ' ' HG ' ' A' ' 170' ' ' LEU . 3.4 tt -62.6 -52.55 62.92 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 116.385 -0.37 . . . . 0.0 111.713 -179.566 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 167' ' ' THR . . . . . . . . . . . . . 85.1 m -54.72 -53.17 58.46 Favored 'General case' 0 C--N 1.329 -0.296 0 N-CA-C 112.734 0.642 . . . . 0.0 112.734 -178.64 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 168' ' ' VAL . . . . . . . . . . . . . 81.8 t -55.53 -44.34 75.94 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 N-CA-C 112.281 0.474 . . . . 0.0 112.281 -178.723 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 169' ' ' VAL . . . . . 0.405 HG21 ' O ' ' A' ' 165' ' ' ASN . 68.8 t -57.93 -65.19 0.45 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.367 0 N-CA-C 112.409 0.522 . . . . 0.0 112.409 -179.039 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 170' ' ' LEU . . . . . 0.498 ' HG ' ' O ' ' A' ' 166' ' ' LEU . 0.7 OUTLIER -62.4 -31.68 72.4 Favored 'General case' 0 C--N 1.332 -0.195 0 N-CA-C 112.453 0.538 . . . . 0.0 112.453 -178.355 . . . . . . . . 3 3 . 1 . 026 nuclear orig full ' A' A ' 171' ' ' TRP . . . . . 0.603 ' HE1' H202 ' A' ' 301' ' ' RET . 5.8 m0 -70.12 -31.2 68.62 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-O 120.816 0.341 . . . . 0.0 110.658 179.48 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 172' ' ' ALA . . . . . 0.439 ' HA ' ' CZ ' ' A' ' 134' ' ' PHE . . . -74.21 -6.86 50.3 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.799 -179.763 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 173' ' ' ILE . . . . . 0.496 ' O ' HG12 ' A' ' 177' ' ' ILE . 34.9 mm -85.95 -21.76 7.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 115.901 -0.59 . . . . 0.0 110.383 179.43 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 174' ' ' TYR . . . . . . . . . . . . . 15.7 m-85 -54.42 -50.72 83.5 Favored Pre-proline 0 N--CA 1.463 0.222 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.744 -179.735 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 175' ' ' PRO . . . . . 0.423 ' HB3' ' HZ ' ' A' ' 127' ' ' PHE . 80.3 Cg_exo -46.13 -31.02 8.22 Favored 'Trans proline' 0 C--N 1.352 0.732 0 C-N-CA 122.131 1.887 . . . . 0.0 112.155 179.83 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 176' ' ' PHE . . . . . 0.444 ' HD2' ' HA ' ' A' ' 173' ' ' ILE . 74.4 m-85 -80.7 -49.97 10.51 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.88 -0.6 . . . . 0.0 111.826 -179.783 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 177' ' ' ILE . . . . . 0.496 HG12 ' O ' ' A' ' 173' ' ' ILE . 5.3 mm -62.82 -36.33 75.03 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.525 0 N-CA-C 112.454 0.539 . . . . 0.0 112.454 -177.958 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 178' ' ' TRP . . . . . 0.44 ' HH2' ' HB2' ' A' ' 123' ' ' ARG . 71.3 t90 -71.27 -47.55 56.29 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.827 0.346 . . . . 0.0 110.997 -179.89 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 179' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -69.84 -54.57 12.9 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.677 -179.045 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 180' ' ' LEU . . . . . 0.555 HD21 HD13 ' A' ' 187' ' ' LEU . 26.4 mt -65.06 -39.42 93.24 Favored 'General case' 0 C--N 1.328 -0.355 0 C-N-CA 121.025 -0.27 . . . . 0.0 111.469 -179.252 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . -62.26 -179.38 3.93 Favored Glycine 0 C--N 1.335 0.474 0 C-N-CA 120.031 -1.08 . . . . 0.0 112.196 179.074 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 182' ' ' PRO . . . . . . . . . . . . . 72.6 Cg_exo -48.85 -44.12 32.89 Favored 'Trans proline' 0 CA--C 1.536 0.623 0 C-N-CA 122.784 2.323 . . . . 0.0 113.87 179.896 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 183' ' ' PRO . . . . . . . . . . . . . 87.8 Cg_exo -47.62 -26.92 7.11 Favored 'Trans proline' 0 C--N 1.356 0.947 0 C-N-CA 122.279 1.986 . . . . 0.0 113.398 -179.782 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 184' ' ' GLY . . . . . . . . . . . . . . . -120.02 -125.92 3.36 Favored Glycine 0 N--CA 1.45 -0.369 0 C-N-CA 120.271 -0.966 . . . . 0.0 113.212 -179.598 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 185' ' ' VAL . . . . . . . . . . . . . 6.1 m -60.45 -27.58 40.35 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.369 0 N-CA-C 112.319 0.489 . . . . 0.0 112.319 -179.315 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 186' ' ' ALA . . . . . . . . . . . . . . . 58.23 82.79 0.13 Allowed 'General case' 0 C--N 1.331 -0.214 0 CA-C-O 120.801 0.334 . . . . 0.0 111.697 179.613 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 187' ' ' LEU . . . . . 0.555 HD13 HD21 ' A' ' 180' ' ' LEU . 8.4 mt -92.21 -49.78 6.0 Favored 'General case' 0 C--N 1.333 -0.151 0 CA-C-N 116.297 -0.411 . . . . 0.0 111.271 179.853 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 188' ' ' LEU . . . . . 0.421 ' HB3' ' H ' ' A' ' 189' ' ' THR . 4.3 mm? -91.16 -161.3 0.8 Allowed 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.002 -0.545 . . . . 0.0 111.571 -179.051 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 189' ' ' THR . . . . . 0.433 ' HB ' HG23 ' A' ' 192' ' ' VAL . 21.6 m -92.76 137.86 23.89 Favored Pre-proline 0 C--N 1.329 -0.326 0 CA-C-N 115.704 -0.68 . . . . 0.0 110.917 -179.479 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 190' ' ' PRO . . . . . . . . . . . . . 95.5 Cg_exo -44.86 -50.04 8.97 Favored 'Trans proline' 0 C--N 1.35 0.626 0 C-N-CA 122.674 2.249 . . . . 0.0 113.259 -179.951 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 191' ' ' THR . . . . . 0.425 HG21 HG23 ' A' ' 189' ' ' THR . 9.7 t -56.26 -39.79 73.18 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-O 120.668 0.271 . . . . 0.0 111.434 -179.606 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 192' ' ' VAL . . . . . 0.433 HG23 ' HB ' ' A' ' 189' ' ' THR . 72.8 t -64.71 -48.66 83.69 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.358 -0.383 . . . . 0.0 111.102 179.93 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 193' ' ' ASP . . . . . . . . . . . . . 27.0 t70 -57.12 -44.58 83.44 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.136 -0.484 . . . . 0.0 111.063 -179.875 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 194' ' ' VAL . . . . . . . . . . . . . 89.3 t -60.82 -35.86 67.42 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.247 0 CA-C-N 116.132 -0.486 . . . . 0.0 110.776 179.953 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 195' ' ' ALA . . . . . . . . . . . . . . . -60.1 -47.83 84.26 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-N 116.429 -0.35 . . . . 0.0 111.003 179.583 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 196' ' ' LEU . . . . . . . . . . . . . 86.1 mt -66.58 -42.82 86.39 Favored 'General case' 0 C--N 1.332 -0.158 0 CA-C-N 116.388 -0.369 . . . . 0.0 110.5 179.489 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 197' ' ' ILE . . . . . . . . . . . . . 15.6 mm -56.99 -59.53 3.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.077 -0.51 . . . . 0.0 110.341 179.221 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 198' ' ' VAL . . . . . . . . . . . . . 52.9 t -52.16 -34.76 18.29 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.5 0 CA-C-N 115.717 -0.674 . . . . 0.0 109.375 178.388 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 199' ' ' TYR . . . . . . . . . . . . . 57.5 t80 -69.54 -32.91 72.01 Favored 'General case' 0 C--N 1.331 -0.204 0 CA-C-N 115.462 -0.79 . . . . 0.0 110.623 -179.844 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 200' ' ' LEU . . . . . . . . . . . . . 34.6 mt -67.75 -41.55 83.21 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 115.885 -0.598 . . . . 0.0 111.081 -179.896 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 201' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -73.48 -35.02 65.63 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-O 121.147 0.499 . . . . 0.0 110.273 179.447 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 202' ' ' LEU . . . . . 0.426 HD23 ' HA3' ' A' ' 14' ' ' GLY . 1.0 OUTLIER -69.45 -28.38 66.06 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 115.495 -0.775 . . . . 0.0 111.924 -179.823 . . . . . . . . 3 3 . 1 . 026 nuclear orig full ' A' A ' 203' ' ' VAL . . . . . . . . . . . . . 9.5 p -82.44 -37.75 14.68 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.183 0 N-CA-C 111.804 0.298 . . . . 0.0 111.804 -178.831 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 204' ' ' THR . . . . . . . . . . . . . 88.9 m -67.35 -41.71 84.68 Favored 'General case' 0 C--N 1.33 -0.279 0 C-N-CA 120.798 -0.361 . . . . 0.0 111.297 179.664 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 205' ' ' LYS . . . . . 0.551 ' HE2' ' HB1' ' A' ' 47' ' ' ALA . 57.3 mttp -78.39 -51.56 9.87 Favored 'General case' 0 C--N 1.326 -0.455 0 N-CA-C 112.238 0.458 . . . . 0.0 112.238 -178.601 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 84.8 t -73.22 -37.37 52.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 N-CA-C 111.735 0.272 . . . . 0.0 111.735 -179.514 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 207' ' ' GLY . . . . . . . . . . . . . . . -71.52 -52.62 12.08 Favored Glycine 0 N--CA 1.453 -0.219 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.603 -179.654 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 208' ' ' PHE . . . . . 0.443 ' O ' ' HB1' ' A' ' 212' ' ' ALA . 10.1 t80 -59.6 -40.46 87.54 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-O 120.71 0.29 . . . . 0.0 110.477 179.648 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 209' ' ' GLY . . . . . 0.466 ' O ' ' HB3' ' A' ' 212' ' ' ALA . . . -70.18 -39.27 72.39 Favored Glycine 0 N--CA 1.451 -0.315 0 CA-C-N 115.699 -0.682 . . . . 0.0 113.302 -179.734 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 210' ' ' PHE . . . . . . . . . . . . . 1.1 m-85 -68.35 -43.0 78.41 Favored 'General case' 0 CA--C 1.508 -0.67 0 N-CA-C 107.794 -1.187 . . . . 0.0 107.794 179.099 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 211' ' ' ILE . . . . . . . . . . . . . 85.7 mt -67.49 -28.85 43.52 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.815 0 CA-C-N 114.296 -1.32 . . . . 0.0 107.548 176.688 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 212' ' ' ALA . . . . . 0.466 ' HB3' ' O ' ' A' ' 209' ' ' GLY . . . -67.0 -40.86 87.43 Favored 'General case' 0 N--CA 1.45 -0.472 0 CA-C-N 114.599 -1.182 . . . . 0.0 110.494 179.876 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 213' ' ' LEU . . . . . . . . . . . . . 91.0 mt -70.35 -52.2 24.33 Favored 'General case' 0 C--N 1.33 -0.239 0 CA-C-N 115.304 -0.862 . . . . 0.0 111.754 -179.407 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 214' ' ' ASP . . . . . . . . . . . . . 45.4 m-20 -50.04 -54.63 18.98 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.218 -0.447 . . . . 0.0 111.847 -179.277 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 215' ' ' ALA . . . . . 0.432 ' HB1' HD21 ' A' ' 159' ' ' LEU . . . -60.46 -54.49 44.87 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.432 -0.349 . . . . 0.0 111.541 -179.448 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 216' ' ' ALA . . . . . . . . . . . . . . . -55.86 -32.51 63.71 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-O 120.926 0.394 . . . . 0.0 111.317 -179.763 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 217' ' ' ALA . . . . . . . . . . . . . . . -65.57 -39.89 92.15 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.03 -0.532 . . . . 0.0 110.601 179.877 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 218' ' ' THR . . . . . . . . . . . . . 54.7 m -64.86 -44.0 91.16 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 115.993 -0.549 . . . . 0.0 110.757 179.588 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 219' ' ' LEU . . . . . . . . . . . . . 19.1 mt -68.36 -25.21 64.97 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.028 -0.533 . . . . 0.0 110.617 179.903 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 220' ' ' ARG . . . . . . . . . . . . . 62.8 ttp180 -84.28 -31.4 24.95 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 115.783 -0.644 . . . . 0.0 111.453 -179.712 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 221' ' ' ALA . . . . . . . . . . . . . . . -82.91 -20.47 35.34 Favored 'General case' 0 C--N 1.33 -0.251 0 N-CA-C 112.316 0.487 . . . . 0.0 112.316 -178.936 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 222' ' ' GLU . . . . . . . . . . . . . 10.9 pt-20 -73.71 -14.77 61.2 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-O 120.768 0.318 . . . . 0.0 111.218 -179.388 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 223' ' ' HIS . . . . . . . . . . . . . 87.4 m-70 -70.69 -34.33 71.85 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.276 -0.42 . . . . 0.0 110.75 179.847 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 224' ' ' GLY . . . . . . . . . . . . . . . -94.68 -46.82 2.85 Favored Glycine 0 C--N 1.331 0.303 0 C-N-CA 120.882 -0.675 . . . . 0.0 112.34 179.948 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 225' ' ' GLU . . . . . . . . . . . . . 9.9 mm-40 -99.55 119.77 38.59 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.764 0.316 . . . . 0.0 110.738 179.93 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 226' ' ' SER . . . . . . . . . . . . . 45.1 t -102.19 -57.64 2.03 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.291 -0.413 . . . . 0.0 111.064 -179.86 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 227' ' ' LEU . . . . . . . . . . . . . 61.5 tp -124.32 132.76 53.57 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.097 -0.501 . . . . 0.0 111.088 -179.764 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 228' ' ' ALA . . . . . . . . . . . . . . . -89.18 160.36 17.02 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.123 -0.49 . . . . 0.0 111.027 179.915 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 229' ' ' GLY . . . . . . . . . . . . . . . 112.39 73.65 0.66 Allowed Glycine 0 N--CA 1.452 -0.273 0 C-N-CA 120.76 -0.734 . . . . 0.0 112.343 -179.911 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 230' ' ' VAL . . . . . . . . . . . . . 39.9 t -85.6 140.41 15.97 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-O 120.781 0.324 . . . . 0.0 111.184 -179.915 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 231' ' ' ASP . . . . . . . . . . . . . 5.0 p-10 -113.23 109.1 18.2 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.854 179.9 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 232' ' ' THR . . . . . . . . . . . . . 4.9 t -153.24 136.25 15.52 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.016 -0.538 . . . . 0.0 110.873 179.944 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 233' ' ' ASP . . . . . . . . . . . . . 8.7 m-20 -85.49 -66.76 0.86 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.278 -0.419 . . . . 0.0 110.938 -179.876 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 234' ' ' THR . . . . . . . . . . . . . 5.2 t -105.69 143.69 27.35 Favored Pre-proline 0 C--N 1.33 -0.266 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.121 -179.904 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 235' ' ' PRO . . . . . . . . . . . . . 34.8 Cg_endo -65.08 -47.42 4.7 Favored 'Trans proline' 0 C--N 1.35 0.612 0 C-N-CA 122.383 2.056 . . . . 0.0 112.431 -179.992 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 236' ' ' ALA . . . . . . . . . . . . . . . -55.16 145.07 22.14 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.262 -0.426 . . . . 0.0 111.071 -179.85 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 237' ' ' VAL . . . . . . . . . . . . . 14.8 p -100.56 146.2 9.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.308 -179.654 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 238' ' ' ALA . . . . . . . . . . . . . . . -132.44 174.97 9.7 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 115.991 -0.55 . . . . 0.0 110.905 179.84 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 239' ' ' ASP . . . . . . . . . . . . . 3.7 p30 -76.46 175.85 8.8 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.814 -179.981 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 240' ' ' LEU . . . . . . . . . . . . . 1.2 pp -149.21 15.48 0.91 Allowed 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.084 -179.923 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 241' ' ' GLU . . . . . . . . . . . . . 8.6 tp10 -67.0 115.48 6.77 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.625 179.999 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 242' ' ' HIS . . . . . . . . . . . . . 28.1 m80 -79.05 139.19 38.2 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.29 -0.414 . . . . 0.0 111.0 -179.736 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 243' ' ' HIS . . . . . . . . . . . . . 86.9 m-70 -86.41 121.35 28.85 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.878 -179.966 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 244' ' ' HIS . . . . . . . . . . . . . 51.0 p-80 -85.64 164.78 17.5 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.888 -179.917 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 245' ' ' HIS . . . . . . . . . . . . . 83.8 m-70 -135.87 5.35 3.09 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.128 -0.487 . . . . 0.0 111.0 179.918 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 246' ' ' HIS . . . . . . . . . . . . . 55.8 t-80 -68.41 -33.18 73.77 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.739 179.975 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 247' ' ' HIS . . . . . . . . . . . . . 57.6 t60 . . . . . 0 C--O 1.25 1.09 0 CA-C-O 118.191 -0.909 . . . . 0.0 111.042 -179.901 . . . . . . . . 0 0 . 1 . 026 nuclear orig full ' A' A ' 301' ' ' RET . . . . . 0.603 H202 ' HE1' ' A' ' 171' ' ' TRP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 1' ' ' MET . . . . . 0.464 ' HG2' HG12 ' A' ' 2' ' ' VAL . 0.0 OUTLIER . . . . . 0 N--CA 1.485 1.276 0 CA-C-O 120.755 0.312 . . . . 0.0 110.992 . . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 2' ' ' VAL . . . . . 0.464 HG12 ' HG2' ' A' ' 1' ' ' MET . 7.3 p -170.37 -37.02 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.331 -0.224 0 CA-C-N 116.288 -0.415 . . . . 0.0 111.442 -179.891 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -113.46 -44.46 0.78 Allowed Glycine 0 N--CA 1.452 -0.27 0 C-N-CA 120.724 -0.75 . . . . 0.0 112.975 -179.618 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 24.7 tp -57.04 -35.21 69.04 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.828 0.347 . . . . 0.0 111.265 -179.693 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 5' ' ' THR . . . . . 0.428 HG22 ' H1 ' ' A' ' 1' ' ' MET . 74.1 p -54.87 -37.88 66.82 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 116.211 -0.45 . . . . 0.0 112.015 -179.637 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 32.1 p -53.84 -35.29 61.32 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 120.823 0.344 . . . . 0.0 111.44 -179.452 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 7' ' ' LEU . . . . . 0.422 HD21 ' O ' ' A' ' 191' ' ' THR . 9.0 mp -58.6 -53.42 58.58 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.227 -179.83 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 8' ' ' PHE . . . . . 0.462 ' HB2' ' HB2' ' A' ' 55' ' ' ALA . 69.9 m-85 -60.46 -32.47 71.42 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.002 -0.544 . . . . 0.0 110.887 -179.837 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 9' ' ' TRP . . . . . . . . . . . . . 32.2 m95 -64.4 -44.39 91.43 Favored 'General case' 0 C--N 1.327 -0.371 0 N-CA-C 109.563 -0.532 . . . . 0.0 109.563 179.612 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 78.8 mt -63.56 -36.76 84.87 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 115.472 -0.785 . . . . 0.0 110.09 179.243 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -64.22 -37.13 94.11 Favored Glycine 0 N--CA 1.448 -0.535 0 CA-C-N 115.619 -0.719 . . . . 0.0 111.806 179.332 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -65.45 -37.51 87.09 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-O 120.856 0.36 . . . . 0.0 110.337 179.634 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 50.1 mm -59.14 -50.22 80.55 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.222 0 CA-C-N 115.937 -0.574 . . . . 0.0 110.432 179.119 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -58.42 -35.09 77.78 Favored Glycine 0 N--CA 1.45 -0.411 0 C-N-CA 120.772 -0.727 . . . . 0.0 112.12 179.536 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 15' ' ' MET . . . . . 0.624 ' HE2' ' HD2' ' A' ' 205' ' ' LYS . 22.7 mmt -66.37 -43.29 86.35 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-O 120.752 0.311 . . . . 0.0 110.892 179.718 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -55.96 -43.71 77.79 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.462 179.739 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 60.6 t -60.71 -46.59 95.68 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.283 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.989 179.903 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -66.17 -49.2 59.13 Favored Glycine 0 C--N 1.33 0.246 0 C-N-CA 120.787 -0.72 . . . . 0.0 112.41 179.685 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 23.6 m -49.61 -42.94 46.08 Favored 'General case' 0 C--N 1.327 -0.39 0 C-N-CA 122.365 0.266 . . . . 0.0 111.579 -179.458 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 65.7 mt -72.38 -42.16 65.55 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.478 -0.328 . . . . 0.0 111.753 179.858 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -61.61 -30.09 70.46 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.312 -0.404 . . . . 0.0 111.577 -179.362 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 22' ' ' PHE . . . . . 0.525 ' HB2' HG23 ' A' ' 41' ' ' VAL . 6.5 m-85 -90.88 -30.76 16.74 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.41 -0.359 . . . . 0.0 111.262 -179.594 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -72.36 -50.38 27.08 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.956 0.407 . . . . 0.0 111.558 -179.548 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 24' ' ' TRP . . . . . . . . . . . . . 4.1 t-105 -62.68 -43.12 99.62 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 115.978 -0.556 . . . . 0.0 111.171 -179.72 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -80.15 -17.68 51.82 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.398 -0.365 . . . . 0.0 110.862 179.855 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -73.46 -33.79 58.13 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.876 -0.678 . . . . 0.0 112.576 179.973 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 39.7 ptt180 -84.95 13.91 5.48 Favored 'General case' 0 C--N 1.332 -0.195 0 CA-C-O 120.888 0.375 . . . . 0.0 110.887 -179.983 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 22.1 t70 -143.22 82.89 1.77 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.082 -0.508 . . . . 0.0 110.692 179.782 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -168.19 -74.51 0.02 OUTLIER 'General case' 0 C--N 1.332 -0.194 0 CA-C-N 116.111 -0.495 . . . . 0.0 111.177 -179.848 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -169.78 -155.23 9.88 Favored Glycine 0 C--N 1.331 0.295 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.627 -179.955 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 46.3 t -101.2 -62.34 1.26 Allowed 'General case' 0 C--N 1.332 -0.188 0 CA-C-O 120.819 0.343 . . . . 0.0 110.989 -179.851 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -61.02 -28.88 69.54 Favored Glycine 0 C--N 1.332 0.306 0 C-N-CA 120.796 -0.716 . . . . 0.0 112.644 -179.96 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 37.4 mt-10 -69.43 -25.69 64.24 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.742 0.306 . . . . 0.0 110.99 -179.941 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 34' ' ' ARG . . . . . . . . . . . . . 17.5 tpt180 -53.13 -28.72 27.23 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.076 -0.511 . . . . 0.0 111.478 -179.654 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 41.0 mmt180 -60.17 -43.31 95.91 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-O 120.833 0.349 . . . . 0.0 111.207 -179.843 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 82.0 m-85 -71.72 -29.73 64.87 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.294 -0.412 . . . . 0.0 111.348 -179.779 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 37' ' ' TYR . . . . . . . . . . . . . 70.0 m-85 -75.79 -54.98 6.09 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.189 -0.459 . . . . 0.0 111.182 -179.549 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 14.8 p -56.61 -36.52 48.64 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-O 121.007 0.432 . . . . 0.0 110.578 179.774 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 28.5 m -66.06 -51.07 61.54 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 115.9 -0.591 . . . . 0.0 110.82 179.457 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 40' ' ' LEU . . . . . 0.421 ' O ' HG13 ' A' ' 43' ' ' ILE . 49.3 tp -59.12 -47.77 84.07 Favored 'General case' 0 C--O 1.235 0.314 0 CA-C-N 115.922 -0.581 . . . . 0.0 110.886 179.964 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . 0.525 HG23 ' HB2' ' A' ' 22' ' ' PHE . 89.9 t -60.63 -34.73 59.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.097 179.195 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . 0.426 ' O ' HG12 ' A' ' 46' ' ' ILE . . . -60.98 -38.59 95.74 Favored Glycine 0 N--CA 1.447 -0.587 0 CA-C-N 115.712 -0.676 . . . . 0.0 112.309 179.751 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 43' ' ' ILE . . . . . 0.607 HG23 ' HE3' ' A' ' 205' ' ' LYS . 0.1 OUTLIER -66.97 -56.94 11.82 Favored 'Isoleucine or valine' 0 C--O 1.232 0.145 0 CA-C-O 120.651 0.262 . . . . 0.0 110.989 179.903 . . . . . . . . 3 3 . 1 . 027 nuclear orig full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 48.1 t -62.39 -21.31 65.26 Favored 'General case' 0 C--O 1.233 0.185 0 CA-C-O 120.833 0.349 . . . . 0.0 111.241 -179.892 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -77.06 -58.53 3.39 Favored Glycine 0 CA--C 1.519 0.305 0 C-N-CA 120.754 -0.736 . . . . 0.0 112.642 -179.758 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 46' ' ' ILE . . . . . 0.426 HG12 ' O ' ' A' ' 42' ' ' GLY . 16.1 pt -58.32 -35.87 55.63 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.157 0 CA-C-O 120.932 0.396 . . . . 0.0 110.726 179.94 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 47' ' ' ALA . . . . . 0.664 ' HB2' ' HE2' ' A' ' 205' ' ' LYS . . . -67.96 -39.89 83.29 Favored 'General case' 0 C--N 1.326 -0.45 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.771 179.056 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -54.58 -47.29 73.49 Favored 'General case' 0 C--O 1.233 0.205 0 CA-C-N 116.007 -0.542 . . . . 0.0 111.046 179.897 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 27.5 m -72.08 -34.09 49.18 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.379 0 CA-C-N 116.047 -0.524 . . . . 0.0 111.009 -179.901 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -60.1 -41.49 92.65 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-O 121.017 0.436 . . . . 0.0 110.761 179.503 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 51' ' ' TYR . . . . . 0.41 ' HB3' ' O ' ' A' ' 8' ' ' PHE . 43.8 m-85 -73.24 -31.5 64.16 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 115.899 -0.592 . . . . 0.0 110.262 -179.982 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -66.26 -43.3 86.85 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 115.887 -0.597 . . . . 0.0 110.624 179.126 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 16.5 m -75.15 -37.72 40.54 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.166 0 CA-C-N 116.277 -0.419 . . . . 0.0 111.028 179.798 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 54' ' ' MET . . . . . 0.499 ' HG2' ' HG2' ' A' ' 71' ' ' PRO . 68.5 mtm -67.22 -34.42 77.43 Favored 'General case' 0 CA--C 1.52 -0.18 0 CA-C-O 121.213 0.53 . . . . 0.0 109.776 179.215 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 55' ' ' ALA . . . . . 0.462 ' HB2' ' HB2' ' A' ' 8' ' ' PHE . . . -66.53 -19.29 65.75 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-N 115.382 -0.827 . . . . 0.0 111.124 179.481 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 87.5 mt -94.95 -3.73 48.04 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.329 -0.396 . . . . 0.0 111.01 -179.927 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 85.57 24.48 42.63 Favored Glycine 0 C--N 1.331 0.271 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.712 179.939 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 58' ' ' VAL . . . . . 0.419 ' O ' ' HG3' ' A' ' 71' ' ' PRO . 48.3 t -86.84 142.36 13.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-O 120.714 0.293 . . . . 0.0 110.829 179.882 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 59' ' ' GLY . . . . . 0.619 ' HA3' ' HD3' ' A' ' 71' ' ' PRO . . . 81.33 -3.74 76.01 Favored Glycine 0 N--CA 1.449 -0.458 0 C-N-CA 120.807 -0.711 . . . . 0.0 112.569 -179.976 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 60' ' ' TRP . . . . . . . . . . . . . 14.4 m0 -70.73 101.08 2.0 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.809 0.338 . . . . 0.0 110.646 179.853 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 61' ' ' VAL . . . . . 0.413 ' HA ' ' HD3' ' A' ' 62' ' ' PRO . 3.2 p -105.5 125.42 33.46 Favored Pre-proline 0 CA--C 1.534 0.334 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.35 -179.982 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 62' ' ' PRO . . . . . 0.413 ' HD3' ' HA ' ' A' ' 61' ' ' VAL . 8.4 Cg_exo -71.52 148.32 53.67 Favored 'Trans proline' 0 C--N 1.35 0.644 0 C-N-CA 122.617 2.211 . . . . 0.0 112.06 179.729 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 77.9 t -142.23 92.43 0.52 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-N 116.112 -0.495 . . . . 0.0 110.894 -179.932 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . 59.67 -85.99 0.02 OUTLIER 'General case' 0 C--N 1.331 -0.209 0 CA-C-N 116.158 -0.473 . . . . 0.0 111.346 -179.865 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 10.2 tp10 -121.05 -24.61 5.52 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.438 -0.346 . . . . 0.0 110.604 179.902 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 66' ' ' ARG . . . . . . . . . . . . . 80.7 mtt180 -103.54 152.96 21.1 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.132 -0.486 . . . . 0.0 110.396 -179.88 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 94.1 m -116.0 127.41 54.91 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 120.955 0.407 . . . . 0.0 111.426 -179.536 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 10.7 t -104.71 146.26 12.18 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.24 0 CA-C-N 115.941 -0.572 . . . . 0.0 110.39 179.488 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 69' ' ' PHE . . . . . . . . . . . . . 12.2 m-85 -109.81 111.76 23.38 Favored 'General case' 0 N--CA 1.452 -0.358 0 N-CA-C 109.519 -0.549 . . . . 0.0 109.519 -179.572 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 70' ' ' VAL . . . . . 0.615 ' N ' ' HD2' ' A' ' 71' ' ' PRO . 0.5 OUTLIER -66.21 -40.42 35.77 Favored Pre-proline 0 C--N 1.321 -0.654 0 N-CA-C 112.428 0.529 . . . . 0.0 112.428 -179.507 . . . . . . . . 3 3 . 1 . 027 nuclear orig full ' A' A ' 71' ' ' PRO . . . . . 0.619 ' HD3' ' HA3' ' A' ' 59' ' ' GLY . 27.1 Cg_endo -63.23 -27.04 72.2 Favored 'Trans proline' 0 C--N 1.356 0.93 0 C-N-CA 121.779 1.652 . . . . 0.0 112.821 -179.03 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 61.0 ttp180 -73.25 -52.99 11.99 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 121.0 0.428 . . . . 0.0 110.212 179.629 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 73' ' ' TYR . . . . . 0.428 ' O ' HG13 ' A' ' 77' ' ' ILE . 52.9 m-85 -66.49 -34.4 77.84 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.012 -0.54 . . . . 0.0 110.716 179.758 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 74' ' ' ILE . . . . . 0.415 ' HB ' ' O ' ' A' ' 70' ' ' VAL . 0.4 OUTLIER -72.83 -37.69 55.39 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.209 0 CA-C-N 116.282 -0.417 . . . . 0.0 110.121 179.675 . . . . . . . . 3 3 . 1 . 027 nuclear orig full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 18.2 t70 -58.02 -37.79 74.99 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-N 116.212 -0.449 . . . . 0.0 109.863 179.226 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 76' ' ' TRP . . . . . . . . . . . . . 53.3 m0 -68.69 -42.16 78.19 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 115.894 -0.594 . . . . 0.0 110.601 179.428 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 77' ' ' ILE . . . . . 0.473 ' O ' ' HG3' ' A' ' 81' ' ' PRO . 86.1 mt -58.72 -28.67 37.96 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.062 -0.517 . . . . 0.0 111.016 179.567 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 45.5 mt -92.03 -38.89 11.96 Favored 'General case' 0 CA--C 1.534 0.343 0 N-CA-C 112.551 0.574 . . . . 0.0 112.551 -179.614 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 74.8 p -82.99 -52.43 6.68 Favored 'General case' 0 N--CA 1.465 0.299 0 N-CA-C 113.929 1.085 . . . . 0.0 113.929 -177.422 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 80' ' ' THR . . . . . 0.455 ' N ' ' HD2' ' A' ' 81' ' ' PRO . 39.2 m -48.01 -54.28 25.69 Favored Pre-proline 0 C--N 1.33 -0.252 0 N-CA-C 113.089 0.774 . . . . 0.0 113.089 -178.132 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 81' ' ' PRO . . . . . 0.473 ' HG3' ' O ' ' A' ' 77' ' ' ILE . 25.1 Cg_endo -60.14 -21.09 64.57 Favored 'Trans proline' 0 C--N 1.351 0.689 0 C-N-CA 121.481 1.454 . . . . 0.0 111.397 -179.683 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 82' ' ' LEU . . . . . . . . . . . . . 17.6 tp -77.03 -32.95 57.41 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 115.633 -0.712 . . . . 0.0 110.005 179.555 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 83' ' ' ILE . . . . . 0.488 HD12 HD13 ' A' ' 43' ' ' ILE . 41.4 mm -67.9 -53.14 32.57 Favored 'Isoleucine or valine' 0 C--O 1.233 0.206 0 CA-C-N 116.059 -0.519 . . . . 0.0 109.909 178.976 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 35.9 m -60.87 -29.86 46.22 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.219 0 CA-C-N 115.97 -0.559 . . . . 0.0 109.513 178.975 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 85' ' ' TYR . . . . . . . . . . . . . 78.8 t80 -68.52 -32.8 73.01 Favored 'General case' 0 N--CA 1.453 -0.303 0 CA-C-N 115.569 -0.741 . . . . 0.0 109.623 178.792 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 86' ' ' PHE . . . . . . . . . . . . . 8.8 t80 -62.36 -51.21 68.5 Favored 'General case' 0 C--N 1.333 -0.117 0 CA-C-N 115.87 -0.605 . . . . 0.0 109.733 179.298 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 10.5 mp -61.61 -29.63 70.17 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-N 115.83 -0.623 . . . . 0.0 110.136 179.339 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -69.96 -27.85 72.56 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.899 -0.667 . . . . 0.0 111.889 179.362 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 88.1 mt -74.29 -44.57 52.17 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-O 120.994 0.426 . . . . 0.0 110.597 179.587 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 43.4 mt -63.27 -28.4 70.0 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 115.75 -0.659 . . . . 0.0 111.05 -179.976 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -88.46 -39.88 13.89 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.379 -179.628 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 88.14 59.43 1.67 Allowed Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.662 -0.78 . . . . 0.0 112.26 -179.736 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 93' ' ' LEU . . . . . 0.503 HD12 ' HE1' ' A' ' 145' ' ' MET . 45.6 mt -75.79 -175.97 3.17 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.849 0.357 . . . . 0.0 110.957 -179.883 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 94' ' ' ASP . . . . . . . . . . . . . 7.8 m-20 -109.12 171.93 7.14 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.057 -0.519 . . . . 0.0 110.709 179.847 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 66.2 m -55.07 -36.4 65.57 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.345 -179.653 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 96' ' ' ARG . . . . . 0.431 ' O ' HG13 ' A' ' 100' ' ' ILE . 38.1 ttp180 -73.26 -52.77 12.8 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.352 -0.386 . . . . 0.0 111.054 -179.687 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 47.9 mt-10 -53.14 -48.3 68.04 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.404 -0.362 . . . . 0.0 111.441 -179.48 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 98' ' ' PHE . . . . . 0.43 ' O ' HG12 ' A' ' 102' ' ' ILE . 18.1 m-85 -55.91 -52.07 65.39 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.524 -0.307 . . . . 0.0 111.112 179.921 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -57.66 -28.09 59.59 Favored Glycine 0 N--CA 1.452 -0.277 0 C-N-CA 120.771 -0.728 . . . . 0.0 112.768 -179.72 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 100' ' ' ILE . . . . . 0.431 HG13 ' O ' ' A' ' 96' ' ' ARG . 95.7 mt -72.51 -42.69 63.84 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-O 120.839 0.352 . . . . 0.0 111.279 -179.787 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 48.3 t -69.35 -48.62 66.5 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.439 0 CA-C-N 116.222 -0.444 . . . . 0.0 111.577 -179.534 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 102' ' ' ILE . . . . . 0.43 HG12 ' O ' ' A' ' 98' ' ' PHE . 34.2 mm -59.79 -48.93 85.73 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.736 -179.284 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 15.1 t -58.77 -38.34 78.27 Favored 'General case' 0 C--O 1.233 0.198 0 CA-C-O 120.707 0.289 . . . . 0.0 111.083 -179.813 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 104' ' ' LEU . . . . . 0.425 HD22 ' HE2' ' A' ' 140' ' ' TYR . 36.6 tp -58.98 -43.45 91.41 Favored 'General case' 0 C--N 1.332 -0.177 0 CA-C-O 120.986 0.422 . . . . 0.0 110.272 179.296 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 105' ' ' ASN . . . . . 0.621 ' N ' HD21 ' A' ' 105' ' ' ASN . 0.8 OUTLIER -65.87 -27.69 68.41 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-N 116.019 -0.537 . . . . 0.0 110.644 -179.981 . . . . . . . . 3 3 . 1 . 027 nuclear orig full ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 62.4 m -63.52 -57.31 10.59 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 116.372 -0.377 . . . . 0.0 111.031 -179.89 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 12.8 p -57.99 -36.35 56.01 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.184 0 CA-C-N 116.399 -0.364 . . . . 0.0 110.857 179.937 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . 0.403 HG22 ' O ' ' A' ' 104' ' ' LEU . 54.3 t -58.32 -45.39 89.4 Favored 'Isoleucine or valine' 0 C--O 1.234 0.282 0 CA-C-O 121.069 0.462 . . . . 0.0 110.675 179.351 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 109' ' ' MET . . . . . 0.445 ' HG2' ' O ' ' A' ' 105' ' ' ASN . 21.3 mmt -71.96 -31.81 66.67 Favored 'General case' 0 CA--C 1.516 -0.361 0 CA-C-N 115.921 -0.582 . . . . 0.0 110.57 179.942 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 110' ' ' LEU . . . . . 0.469 ' C ' HD23 ' A' ' 110' ' ' LEU . 4.0 tt -62.6 -34.14 76.4 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-N 115.98 -0.555 . . . . 0.0 109.54 178.854 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -67.78 -53.73 24.82 Favored 'General case' 0 C--N 1.332 -0.18 0 CA-C-N 115.761 -0.654 . . . . 0.0 110.667 179.468 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 112' ' ' GLY . . . . . 0.545 ' HA3' ' H22' ' A' ' 301' ' ' RET . . . -62.4 -38.89 97.04 Favored Glycine 0 C--N 1.332 0.309 0 C-N-CA 120.641 -0.79 . . . . 0.0 112.286 179.566 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 113' ' ' PHE . . . . . . . . . . . . . 4.3 t80 -53.61 -66.93 0.3 Allowed 'General case' 0 C--N 1.331 -0.236 0 CA-C-O 121.088 0.47 . . . . 0.0 110.194 179.718 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 114' ' ' ALA . . . . . 0.414 ' HB2' HD21 ' A' ' 126' ' ' LEU . . . -65.22 -17.67 64.68 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 115.767 -0.651 . . . . 0.0 110.491 179.287 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -58.54 -48.43 84.42 Favored Glycine 0 C--N 1.332 0.333 0 CA-C-N 115.784 -0.644 . . . . 0.0 111.914 179.42 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -78.32 -17.49 56.49 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.739 0.304 . . . . 0.0 110.988 179.322 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 117' ' ' MET . . . . . . . . . . . . . 21.1 mmt -84.95 13.9 5.49 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.098 -0.501 . . . . 0.0 111.353 -179.452 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 118' ' ' VAL . . . . . 0.473 HG21 ' HB3' ' A' ' 123' ' ' ARG . 33.6 m -81.4 139.01 48.03 Favored Pre-proline 0 C--N 1.33 -0.266 0 N-CA-C 111.838 0.31 . . . . 0.0 111.838 -179.398 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 119' ' ' PRO . . . . . . . . . . . . . 85.7 Cg_endo -92.22 -2.63 3.99 Favored 'Trans proline' 0 N--CA 1.455 -0.788 0 C-N-CA 122.91 2.407 . . . . 0.0 112.463 179.052 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -138.89 -110.34 0.91 Allowed Glycine 0 C--N 1.333 0.379 0 C-N-CA 120.675 -0.774 . . . . 0.0 112.863 -179.775 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 2.4 pp -127.07 15.29 3.56 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.192 0 N-CA-C 111.849 0.314 . . . . 0.0 111.849 -179.775 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 46.5 mt-10 -61.22 -18.54 58.83 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.906 0.384 . . . . 0.0 110.838 179.82 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 123' ' ' ARG . . . . . 0.556 ' HD2' ' HA2' ' A' ' 184' ' ' GLY . 24.4 ptt180 -51.46 -27.63 10.9 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 115.871 -0.604 . . . . 0.0 111.729 -179.92 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 124' ' ' TYR . . . . . . . . . . . . . 22.2 m-85 -75.15 -33.34 61.51 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.582 -0.281 . . . . 0.0 111.382 -179.524 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 125' ' ' ALA . . . . . . . . . . . . . . . -74.14 -56.64 4.67 Favored 'General case' 0 C--O 1.235 0.34 0 CA-C-O 120.96 0.41 . . . . 0.0 111.155 -179.933 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 126' ' ' LEU . . . . . 0.414 HD21 ' HB2' ' A' ' 114' ' ' ALA . 1.2 mt -53.48 -51.2 63.51 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.016 -0.538 . . . . 0.0 110.275 179.749 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 127' ' ' PHE . . . . . . . . . . . . . 11.0 t80 -65.29 -30.1 70.93 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.03 179.318 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 128' ' ' GLY . . . . . . . . . . . . . . . -49.02 -49.31 29.94 Favored Glycine 0 N--CA 1.45 -0.42 0 C-N-CA 120.179 -1.01 . . . . 0.0 110.581 178.703 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 129' ' ' MET . . . . . 0.596 ' HE3' ' HA2' ' A' ' 130' ' ' GLY . 0.0 OUTLIER -71.71 -27.84 63.29 Favored 'General case' 0 C--N 1.328 -0.351 0 N-CA-C 109.067 -0.716 . . . . 0.0 109.067 178.303 . . . . . . . . 3 3 . 1 . 027 nuclear orig full ' A' A ' 130' ' ' GLY . . . . . 0.596 ' HA2' ' HE3' ' A' ' 129' ' ' MET . . . -60.68 -41.23 98.88 Favored Glycine 0 C--N 1.332 0.36 0 CA-C-N 115.712 -0.676 . . . . 0.0 112.241 179.49 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -71.9 -48.99 41.71 Favored 'General case' 0 C--N 1.331 -0.21 0 CA-C-O 120.627 0.251 . . . . 0.0 110.403 179.668 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 57.2 t -55.68 -46.5 79.51 Favored 'Isoleucine or valine' 0 C--O 1.234 0.271 0 CA-C-O 121.302 0.573 . . . . 0.0 109.506 178.826 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -62.29 -38.19 88.39 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 115.397 -0.82 . . . . 0.0 110.507 178.962 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 134' ' ' PHE . . . . . 0.432 ' HB2' H182 ' A' ' 301' ' ' RET . 82.3 t80 -55.71 -53.47 56.15 Favored 'General case' 0 N--CA 1.452 -0.371 0 CA-C-N 116.058 -0.519 . . . . 0.0 110.305 179.793 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 135' ' ' ILE . . . . . 0.428 ' O ' HG23 ' A' ' 138' ' ' VAL . 47.5 mt -55.95 -32.08 32.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 115.841 -0.618 . . . . 0.0 110.193 179.573 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . -62.54 -42.6 99.68 Favored Glycine 0 N--CA 1.448 -0.522 0 C-N-CA 120.176 -1.012 . . . . 0.0 111.232 178.738 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 137' ' ' LEU . . . . . 0.561 HD12 HD22 ' A' ' 105' ' ' ASN . 61.0 tp -66.27 -54.42 25.13 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.583 0.23 . . . . 0.0 110.855 179.617 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 138' ' ' VAL . . . . . 0.428 HG23 ' O ' ' A' ' 135' ' ' ILE . 3.8 m -55.05 -31.56 25.67 Favored 'Isoleucine or valine' 0 C--O 1.232 0.184 0 N-CA-C 109.891 -0.411 . . . . 0.0 109.891 -179.7 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 139' ' ' TYR . . . . . . . . . . . . . 14.2 t80 -61.37 -42.83 99.34 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 115.871 -0.604 . . . . 0.0 109.748 178.313 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 140' ' ' TYR . . . . . 0.425 ' HE2' HD22 ' A' ' 104' ' ' LEU . 21.7 m-85 -66.95 -45.71 76.94 Favored 'General case' 0 CA--C 1.529 0.153 0 CA-C-N 116.034 -0.53 . . . . 0.0 111.096 179.262 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 141' ' ' LEU . . . . . . . . . . . . . 11.2 mp -52.4 -37.41 56.51 Favored 'General case' 0 N--CA 1.464 0.23 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.791 -179.417 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 8.6 p -104.58 -5.28 9.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-O 120.927 0.394 . . . . 0.0 111.394 -179.514 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 143' ' ' GLY . . . . . 0.419 ' HA3' ' HD2' ' A' ' 144' ' ' PRO . . . -75.51 -130.89 0.3 Allowed Glycine 0 CA--C 1.521 0.427 0 C-N-CA 120.768 -0.729 . . . . 0.0 113.009 -179.625 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 144' ' ' PRO . . . . . 0.419 ' HD2' ' HA3' ' A' ' 143' ' ' GLY . 13.2 Cg_endo -56.21 -23.47 45.46 Favored 'Trans proline' 0 C--N 1.348 0.549 0 C-N-CA 122.741 2.294 . . . . 0.0 112.658 -179.587 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 145' ' ' MET . . . . . 0.503 ' HE1' HD12 ' A' ' 93' ' ' LEU . 50.4 mtt -56.96 -29.22 63.02 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.286 -0.415 . . . . 0.0 111.696 -179.652 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 146' ' ' THR . . . . . . . . . . . . . 72.9 p -77.28 -34.65 55.62 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.837 0.351 . . . . 0.0 110.91 -179.531 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 36.9 tt0 -75.92 -32.25 59.51 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 115.989 -0.55 . . . . 0.0 111.028 -179.869 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 148' ' ' SER . . . . . . . . . . . . . 48.2 t -70.83 -47.43 59.45 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.502 -179.659 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 149' ' ' ALA . . . . . 0.43 ' HB1' HG21 ' A' ' 156' ' ' ILE . . . -70.76 -30.57 67.11 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.294 -0.412 . . . . 0.0 111.748 -179.39 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 150' ' ' SER . . . . . . . . . . . . . 78.4 p -69.12 0.0 5.29 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.38 -0.373 . . . . 0.0 111.12 -179.878 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 151' ' ' GLN . . . . . . . . . . . . . 77.0 mt-30 -121.99 9.58 9.99 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.378 -0.374 . . . . 0.0 111.494 -179.836 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 25.6 mmm180 -91.45 -53.16 4.44 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-O 121.1 0.476 . . . . 0.0 110.789 -179.994 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 153' ' ' SER . . . . . 0.646 ' HB2' HG12 ' A' ' 156' ' ' ILE . 23.5 m -158.3 172.22 18.76 Favored 'General case' 0 C--N 1.324 -0.509 0 CA-C-N 115.643 -0.708 . . . . 0.0 110.481 179.232 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 154' ' ' SER . . . . . . . . . . . . . 46.9 t -72.05 -37.08 69.76 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-O 120.977 0.418 . . . . 0.0 110.142 179.073 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -77.43 -35.38 37.32 Favored Glycine 0 N--CA 1.45 -0.423 0 CA-C-N 115.818 -0.628 . . . . 0.0 112.902 179.83 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 156' ' ' ILE . . . . . 0.646 HG12 ' HB2' ' A' ' 153' ' ' SER . 38.0 mm -52.72 -38.74 28.36 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.164 0 CA-C-O 120.687 0.28 . . . . 0.0 111.515 -179.56 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 157' ' ' LYS . . . . . . . . . . . . . 57.4 tptt -64.78 -40.53 95.41 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.434 -0.348 . . . . 0.0 111.175 -179.9 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 49.3 m -71.16 -42.73 68.74 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.415 -0.357 . . . . 0.0 111.342 -179.733 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 159' ' ' LEU . . . . . 0.481 HD23 HD12 ' A' ' 163' ' ' LEU . 4.7 tt -64.44 -40.83 96.47 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.998 -179.573 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 160' ' ' TYR . . . . . . . . . . . . . 29.0 t80 -73.29 -37.17 66.34 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.711 -179.204 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 161' ' ' VAL . . . . . 0.48 HG11 ' N ' ' A' ' 162' ' ' ARG . 1.0 OUTLIER -59.85 -50.52 79.78 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.746 0 CA-C-O 120.628 0.251 . . . . 0.0 111.623 -179.438 . . . . . . . . 3 3 . 1 . 027 nuclear orig full ' A' A ' 162' ' ' ARG . . . . . 0.48 ' N ' HG11 ' A' ' 161' ' ' VAL . 99.8 mtt180 -69.5 -34.82 74.87 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-O 120.929 0.395 . . . . 0.0 111.254 179.989 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 163' ' ' LEU . . . . . 0.647 ' HG ' ' HB2' ' A' ' 208' ' ' PHE . 1.2 mp -65.49 -55.12 19.61 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 115.945 -0.57 . . . . 0.0 112.173 -178.831 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 164' ' ' ARG . . . . . 0.411 ' HG3' ' N ' ' A' ' 165' ' ' ASN . 5.1 ppt_? -66.05 -41.22 91.13 Favored 'General case' 0 C--N 1.329 -0.286 0 N-CA-C 111.997 0.369 . . . . 0.0 111.997 -178.596 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 165' ' ' ASN . . . . . 0.411 ' N ' ' HG3' ' A' ' 164' ' ' ARG . 0.9 OUTLIER -54.35 -52.28 62.09 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-O 120.969 0.414 . . . . 0.0 111.024 -179.948 . . . . . . . . 3 3 . 1 . 027 nuclear orig full ' A' A ' 166' ' ' LEU . . . . . 0.511 ' O ' ' HG ' ' A' ' 170' ' ' LEU . 2.8 tt -64.99 -51.93 58.96 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 115.925 -0.579 . . . . 0.0 111.513 -179.377 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 167' ' ' THR . . . . . 0.44 ' O ' ' HB2' ' A' ' 171' ' ' TRP . 91.4 m -54.74 -52.81 61.37 Favored 'General case' 0 C--N 1.328 -0.357 0 N-CA-C 112.345 0.498 . . . . 0.0 112.345 -178.817 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 168' ' ' VAL . . . . . . . . . . . . . 53.0 t -54.54 -46.1 71.48 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 N-CA-C 112.22 0.452 . . . . 0.0 112.22 -179.044 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 169' ' ' VAL . . . . . . . . . . . . . 77.5 t -56.04 -65.18 0.4 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 N-CA-C 112.019 0.378 . . . . 0.0 112.019 -179.18 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 170' ' ' LEU . . . . . 0.511 ' HG ' ' O ' ' A' ' 166' ' ' LEU . 0.6 OUTLIER -63.65 -31.09 72.15 Favored 'General case' 0 C--N 1.328 -0.341 0 N-CA-C 112.43 0.53 . . . . 0.0 112.43 -178.486 . . . . . . . . 3 3 . 1 . 027 nuclear orig full ' A' A ' 171' ' ' TRP . . . . . 0.489 ' HE1' H202 ' A' ' 301' ' ' RET . 3.5 m0 -68.67 -30.87 69.65 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-O 120.941 0.4 . . . . 0.0 110.37 179.24 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 172' ' ' ALA . . . . . . . . . . . . . . . -73.03 -6.88 48.43 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 115.92 -0.582 . . . . 0.0 110.641 -179.991 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 173' ' ' ILE . . . . . 0.49 ' O ' HG12 ' A' ' 177' ' ' ILE . 29.0 mm -86.67 -22.2 7.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 115.818 -0.628 . . . . 0.0 111.203 -179.952 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 174' ' ' TYR . . . . . 0.411 ' HB2' ' HD3' ' A' ' 175' ' ' PRO . 25.5 m-85 -54.25 -49.8 88.28 Favored Pre-proline 0 N--CA 1.464 0.245 0 CA-C-N 116.514 -0.312 . . . . 0.0 111.702 -179.771 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 175' ' ' PRO . . . . . 0.411 ' HD3' ' HB2' ' A' ' 174' ' ' TYR . 79.8 Cg_exo -49.01 -30.06 17.13 Favored 'Trans proline' 0 C--N 1.349 0.591 0 C-N-CA 121.97 1.78 . . . . 0.0 112.138 179.641 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 176' ' ' PHE . . . . . 0.437 ' HD2' ' HA ' ' A' ' 173' ' ' ILE . 46.8 m-85 -80.75 -50.0 10.43 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 115.985 -0.552 . . . . 0.0 111.663 -179.897 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 177' ' ' ILE . . . . . 0.49 HG12 ' O ' ' A' ' 173' ' ' ILE . 4.2 mm -63.13 -32.64 57.03 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.501 0 N-CA-C 112.364 0.505 . . . . 0.0 112.364 -178.037 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 178' ' ' TRP . . . . . . . . . . . . . 77.7 t90 -71.95 -50.94 24.68 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.934 0.397 . . . . 0.0 110.555 179.771 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 179' ' ' LEU . . . . . 0.519 HD23 HD21 ' A' ' 180' ' ' LEU . 0.7 OUTLIER -68.95 -54.71 13.89 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.001 -0.545 . . . . 0.0 111.482 -179.341 . . . . . . . . 3 3 . 1 . 027 nuclear orig full ' A' A ' 180' ' ' LEU . . . . . 0.535 HD22 HD12 ' A' ' 187' ' ' LEU . 39.3 mt -63.54 -43.68 96.39 Favored 'General case' 0 C--N 1.329 -0.324 0 C-N-CA 121.043 -0.263 . . . . 0.0 111.025 -179.729 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . -58.04 178.26 1.38 Allowed Glycine 0 CA--C 1.521 0.462 0 C-N-CA 120.12 -1.038 . . . . 0.0 112.12 179.085 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 182' ' ' PRO . . . . . 0.416 ' HB2' ' HD3' ' A' ' 183' ' ' PRO . 74.8 Cg_exo -47.45 -44.97 24.04 Favored 'Trans proline' 0 CA--C 1.536 0.611 0 C-N-CA 122.91 2.406 . . . . 0.0 113.918 -179.886 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 183' ' ' PRO . . . . . 0.416 ' HD3' ' HB2' ' A' ' 182' ' ' PRO . 86.7 Cg_exo -46.96 -26.91 5.29 Favored 'Trans proline' 0 C--N 1.355 0.874 0 C-N-CA 122.191 1.928 . . . . 0.0 113.364 -179.665 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 184' ' ' GLY . . . . . 0.556 ' HA2' ' HD2' ' A' ' 123' ' ' ARG . . . -120.5 -129.92 3.83 Favored Glycine 0 C--N 1.333 0.368 0 C-N-CA 120.29 -0.957 . . . . 0.0 113.081 -179.685 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 185' ' ' VAL . . . . . . . . . . . . . 15.4 m -54.68 -23.67 12.03 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 N-CA-C 112.066 0.395 . . . . 0.0 112.066 -179.526 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 186' ' ' ALA . . . . . . . . . . . . . . . 55.13 86.72 0.05 Allowed 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 116.446 -0.343 . . . . 0.0 111.659 179.509 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 187' ' ' LEU . . . . . 0.535 HD12 HD22 ' A' ' 180' ' ' LEU . 12.7 mt -92.3 -49.28 6.24 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.287 -0.415 . . . . 0.0 110.904 179.905 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 188' ' ' LEU . . . . . 0.443 HD11 HG11 ' A' ' 192' ' ' VAL . 78.2 mt -98.06 -161.93 0.91 Allowed 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 115.998 -0.546 . . . . 0.0 110.832 -179.72 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 189' ' ' THR . . . . . . . . . . . . . 2.3 t -98.41 146.93 32.41 Favored Pre-proline 0 C--N 1.329 -0.288 0 CA-C-N 116.132 -0.486 . . . . 0.0 110.766 179.993 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 190' ' ' PRO . . . . . . . . . . . . . 95.8 Cg_exo -44.41 -42.51 13.87 Favored 'Trans proline' 0 C--N 1.349 0.587 0 C-N-CA 122.763 2.309 . . . . 0.0 113.374 -179.511 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 191' ' ' THR . . . . . 0.422 ' O ' HD21 ' A' ' 7' ' ' LEU . 41.6 p -59.29 -44.74 92.47 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-O 120.78 0.324 . . . . 0.0 111.707 -179.596 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 192' ' ' VAL . . . . . 0.443 HG11 HD11 ' A' ' 188' ' ' LEU . 55.3 t -70.39 -51.52 37.34 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.42 0 N-CA-C 111.858 0.318 . . . . 0.0 111.858 -179.344 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 193' ' ' ASP . . . . . . . . . . . . . 20.7 m-20 -59.11 -51.98 67.7 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 116.444 -0.344 . . . . 0.0 111.626 -179.349 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 194' ' ' VAL . . . . . . . . . . . . . 69.2 t -58.88 -35.92 58.74 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.221 0 CA-C-O 120.712 0.292 . . . . 0.0 110.907 179.885 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 195' ' ' ALA . . . . . . . . . . . . . . . -57.33 -47.7 80.88 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.329 -0.396 . . . . 0.0 110.655 179.612 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 196' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -61.85 -40.44 95.36 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.301 -0.409 . . . . 0.0 110.424 179.355 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 197' ' ' ILE . . . . . 0.436 HD11 ' HB ' ' A' ' 177' ' ' ILE . 17.0 mm -57.25 -59.3 3.35 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.32 0 CA-C-N 115.939 -0.573 . . . . 0.0 110.062 179.019 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 198' ' ' VAL . . . . . . . . . . . . . 92.9 t -52.01 -35.1 18.13 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.426 0 CA-C-N 115.473 -0.785 . . . . 0.0 109.468 178.346 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 199' ' ' TYR . . . . . . . . . . . . . 59.3 t80 -70.24 -31.01 68.23 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 115.374 -0.83 . . . . 0.0 110.725 179.873 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 200' ' ' LEU . . . . . 0.424 ' O ' HG11 ' A' ' 203' ' ' VAL . 43.4 mt -73.23 -37.49 66.38 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 115.821 -0.627 . . . . 0.0 111.383 -179.736 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 201' ' ' ASP . . . . . . . . . . . . . 16.1 m-20 -73.84 -39.37 64.06 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-O 121.043 0.449 . . . . 0.0 110.498 179.663 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 202' ' ' LEU . . . . . . . . . . . . . 2.2 mt -69.9 -28.94 66.04 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 115.735 -0.666 . . . . 0.0 111.765 -179.465 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 203' ' ' VAL . . . . . 0.431 ' O ' ' HA3' ' A' ' 207' ' ' GLY . 12.3 p -78.17 -36.43 21.2 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.331 0 C-N-CA 121.094 -0.242 . . . . 0.0 110.962 -178.979 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 204' ' ' THR . . . . . . . . . . . . . 95.6 m -64.88 -58.43 6.2 Favored 'General case' 0 C--N 1.327 -0.399 0 C-N-CA 120.563 -0.455 . . . . 0.0 110.934 179.335 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 205' ' ' LYS . . . . . 0.664 ' HE2' ' HB2' ' A' ' 47' ' ' ALA . 54.4 mttp -61.86 -58.09 9.28 Favored 'General case' 0 C--N 1.329 -0.292 0 N-CA-C 112.343 0.497 . . . . 0.0 112.343 -178.395 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 51.0 t -71.83 -37.01 60.44 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.396 0 N-CA-C 112.428 0.529 . . . . 0.0 112.428 -178.515 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 207' ' ' GLY . . . . . 0.431 ' HA3' ' O ' ' A' ' 203' ' ' VAL . . . -57.59 -60.26 9.33 Favored Glycine 0 N--CA 1.455 -0.097 0 C-N-CA 120.704 -0.76 . . . . 0.0 113.416 -178.798 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 208' ' ' PHE . . . . . 0.647 ' HB2' ' HG ' ' A' ' 163' ' ' LEU . 0.3 OUTLIER -71.67 -27.13 62.85 Favored 'General case' 0 C--O 1.223 -0.3 0 CA-C-N 117.183 0.492 . . . . 0.0 110.562 -179.713 . . . . . . . . 3 3 . 1 . 027 nuclear orig full ' A' A ' 209' ' ' GLY . . . . . 0.456 ' O ' ' HB3' ' A' ' 212' ' ' ALA . . . -65.18 -33.86 88.08 Favored Glycine 0 N--CA 1.448 -0.521 0 N-CA-C 111.718 -0.553 . . . . 0.0 111.718 178.623 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 210' ' ' PHE . . . . . . . . . . . . . 0.6 OUTLIER -73.57 -44.93 56.16 Favored 'General case' 0 CA--C 1.512 -0.502 0 N-CA-C 107.757 -1.201 . . . . 0.0 107.757 178.321 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 211' ' ' ILE . . . . . 0.4 HD12 ' HA ' ' A' ' 208' ' ' PHE . 34.5 mt -64.73 -27.65 42.99 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.653 0 N-CA-C 107.649 -1.241 . . . . 0.0 107.649 176.646 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 212' ' ' ALA . . . . . 0.489 ' N ' ' O ' ' A' ' 208' ' ' PHE . . . -64.35 -44.02 92.78 Favored 'General case' 0 N--CA 1.45 -0.452 0 CA-C-N 114.505 -1.225 . . . . 0.0 110.6 -179.859 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 213' ' ' LEU . . . . . . . . . . . . . 97.6 mt -69.67 -46.08 66.91 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 115.308 -0.86 . . . . 0.0 111.487 -179.574 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 214' ' ' ASP . . . . . . . . . . . . . 36.3 m-20 -58.11 -47.15 84.14 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-O 120.85 0.357 . . . . 0.0 110.933 -179.952 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 215' ' ' ALA . . . . . 0.404 ' O ' ' HG ' ' A' ' 219' ' ' LEU . . . -62.82 -54.05 44.9 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 115.992 -0.549 . . . . 0.0 111.239 -179.896 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 216' ' ' ALA . . . . . . . . . . . . . . . -56.36 -37.5 70.12 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-N 116.281 -0.418 . . . . 0.0 111.04 179.928 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 217' ' ' ALA . . . . . . . . . . . . . . . -63.33 -37.96 89.3 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.167 179.655 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 218' ' ' THR . . . . . . . . . . . . . 92.4 m -68.6 -39.14 81.02 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 115.677 -0.692 . . . . 0.0 110.605 179.334 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 219' ' ' LEU . . . . . 0.414 ' O ' ' HG2' ' A' ' 222' ' ' GLU . 84.4 mt -56.53 -42.15 77.98 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 115.895 -0.593 . . . . 0.0 110.272 179.798 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 220' ' ' ARG . . . . . . . . . . . . . 56.2 mtp180 -84.22 -17.9 38.32 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.065 -0.516 . . . . 0.0 110.526 179.295 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 221' ' ' ALA . . . . . . . . . . . . . . . -64.77 -37.98 89.43 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.0 -0.545 . . . . 0.0 111.555 -179.819 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 222' ' ' GLU . . . . . 0.414 ' HG2' ' O ' ' A' ' 219' ' ' LEU . 13.4 pt-20 -71.0 -8.6 54.44 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.887 0.375 . . . . 0.0 110.879 -179.896 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 223' ' ' HIS . . . . . . . . . . . . . 88.8 m-70 -97.89 8.08 45.31 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.013 -0.539 . . . . 0.0 110.807 179.823 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 224' ' ' GLY . . . . . . . . . . . . . . . -76.29 -3.56 76.99 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.848 -0.691 . . . . 0.0 112.566 -179.938 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 225' ' ' GLU . . . . . . . . . . . . . 43.3 tt0 -136.65 124.85 23.09 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.877 0.37 . . . . 0.0 110.76 179.911 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 226' ' ' SER . . . . . . . . . . . . . 63.6 p -162.65 122.31 2.3 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.883 -179.947 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 227' ' ' LEU . . . . . . . . . . . . . 7.4 mp -80.92 -19.24 44.71 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.878 -179.93 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 228' ' ' ALA . . . . . . . . . . . . . . . 53.1 22.86 2.72 Favored 'General case' 0 C--N 1.332 -0.185 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.457 -179.905 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 229' ' ' GLY . . . . . . . . . . . . . . . -134.87 -97.65 0.56 Allowed Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.872 -0.68 . . . . 0.0 112.491 -179.993 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 230' ' ' VAL . . . . . . . . . . . . . 33.9 m -93.27 150.31 3.96 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-O 120.828 0.347 . . . . 0.0 111.206 -179.903 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 231' ' ' ASP . . . . . . . . . . . . . 11.4 m-20 -95.9 93.38 7.0 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.606 179.655 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 232' ' ' THR . . . . . . . . . . . . . 7.8 t -90.99 164.69 13.89 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.329 -0.396 . . . . 0.0 111.285 -179.862 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 233' ' ' ASP . . . . . . . . . . . . . 21.0 t70 -158.06 120.81 3.81 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.04 -0.527 . . . . 0.0 110.849 -179.897 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 234' ' ' THR . . . . . . . . . . . . . 59.3 m 58.29 88.04 0.13 Allowed Pre-proline 0 C--N 1.33 -0.247 0 CA-C-N 116.047 -0.524 . . . . 0.0 111.203 -179.947 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 235' ' ' PRO . . . . . . . . . . . . . 82.5 Cg_endo -78.88 -21.85 9.29 Favored 'Trans proline' 0 C--N 1.346 0.409 0 C-N-CA 122.41 2.073 . . . . 0.0 112.282 179.757 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 236' ' ' ALA . . . . . . . . . . . . . . . -139.25 141.15 37.85 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.096 -0.502 . . . . 0.0 111.245 -179.887 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 237' ' ' VAL . . . . . . . . . . . . . 28.9 m -104.47 179.47 0.72 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.217 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.094 179.947 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 238' ' ' ALA . . . . . . . . . . . . . . . -67.95 167.33 13.95 Favored 'General case' 0 C--N 1.331 -0.199 0 CA-C-N 116.373 -0.376 . . . . 0.0 111.032 179.924 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 239' ' ' ASP . . . . . . . . . . . . . 6.8 m-20 -90.98 140.08 30.16 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.101 -0.5 . . . . 0.0 110.794 -179.996 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 240' ' ' LEU . . . . . . . . . . . . . 7.6 mp -92.18 -14.98 28.23 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.258 -0.428 . . . . 0.0 111.005 179.869 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 241' ' ' GLU . . . . . . . . . . . . . 39.9 tt0 -109.9 141.15 43.03 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.885 -179.902 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 242' ' ' HIS . . . . . . . . . . . . . 31.6 m80 -117.06 109.74 17.35 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.931 -179.823 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 243' ' ' HIS . . . . . . . . . . . . . 8.6 t-80 -141.72 -9.24 0.93 Allowed 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.803 179.83 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 244' ' ' HIS . . . . . . . . . . . . . 87.6 m-70 62.74 -82.57 0.02 OUTLIER 'General case' 0 N--CA 1.462 0.17 0 CA-C-N 115.932 -0.576 . . . . 0.0 111.506 179.762 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 245' ' ' HIS . . . . . . . . . . . . . 40.9 t60 -75.84 106.5 7.46 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-O 120.841 0.353 . . . . 0.0 111.092 -179.668 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 246' ' ' HIS . . . . . . . . . . . . . 51.6 m80 -92.17 162.06 14.48 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.055 -0.521 . . . . 0.0 110.812 179.815 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 247' ' ' HIS . . . . . . . . . . . . . 95.4 m-70 . . . . . 0 C--O 1.248 1.017 0 CA-C-O 118.265 -0.874 . . . . 0.0 110.993 179.946 . . . . . . . . 0 0 . 1 . 027 nuclear orig full ' A' A ' 301' ' ' RET . . . . . 0.545 ' H22' ' HA3' ' A' ' 112' ' ' GLY . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 85.0 mtp . . . . . 0 N--CA 1.485 1.318 0 CA-C-O 120.879 0.371 . . . . 0.0 111.096 . . . . . . . . . 0 0 . 1 . 028 nuclear orig full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 2.5 p -165.67 101.86 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 115.937 -0.574 . . . . 0.0 110.897 179.837 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . 131.42 -22.46 4.41 Favored Glycine 0 N--CA 1.45 -0.367 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.546 -179.852 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 59.5 tp -74.12 -40.69 62.5 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-O 120.823 0.344 . . . . 0.0 110.889 179.945 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 61.3 p -60.79 -29.85 69.7 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.136 179.98 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 6' ' ' THR . . . . . 0.406 ' HG1' ' N ' ' A' ' 7' ' ' LEU . 10.9 p -53.11 -35.5 59.72 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 116.043 -0.526 . . . . 0.0 111.172 -179.785 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 7' ' ' LEU . . . . . 0.406 ' N ' ' HG1' ' A' ' 6' ' ' THR . 10.0 mp -57.22 -53.59 56.36 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.297 179.961 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 8' ' ' PHE . . . . . 0.483 ' O ' ' HB3' ' A' ' 51' ' ' TYR . 65.7 m-85 -59.4 -34.63 72.68 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.006 -0.543 . . . . 0.0 110.957 -179.599 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 9' ' ' TRP . . . . . . . . . . . . . 32.0 m95 -66.71 -41.81 87.37 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-N 116.296 -0.411 . . . . 0.0 110.099 179.831 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 84.2 mt -59.64 -48.4 81.82 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 115.88 -0.6 . . . . 0.0 110.26 179.233 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -61.22 -35.28 90.65 Favored Glycine 0 N--CA 1.449 -0.461 0 C-N-CA 120.621 -0.799 . . . . 0.0 111.587 179.169 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -63.29 -30.28 71.44 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.597 0.237 . . . . 0.0 110.442 179.41 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 47.9 mm -68.58 -54.12 23.21 Favored 'Isoleucine or valine' 0 CA--C 1.52 -0.189 0 CA-C-N 116.41 -0.359 . . . . 0.0 110.309 179.057 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -53.21 -30.67 39.95 Favored Glycine 0 N--CA 1.452 -0.281 0 C-N-CA 120.689 -0.767 . . . . 0.0 111.747 179.475 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 15' ' ' MET . . . . . 0.62 ' HB3' ' HB3' ' A' ' 48' ' ' ALA . 0.0 OUTLIER -76.77 -49.54 15.67 Favored 'General case' 0 C--O 1.223 -0.33 0 CA-C-O 120.564 0.221 . . . . 0.0 110.928 179.523 . . . . . . . . 3 3 . 1 . 028 nuclear orig full ' A' A ' 16' ' ' LEU . . . . . 0.403 HD23 ' HA ' ' A' ' 16' ' ' LEU . 0.4 OUTLIER -55.67 -50.87 69.1 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-O 120.78 0.324 . . . . 0.0 110.621 179.804 . . . . . . . . 3 3 . 1 . 028 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 14.7 p -63.55 -46.31 95.35 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.377 0 CA-C-O 121.356 0.598 . . . . 0.0 110.718 179.824 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -58.97 -46.31 93.87 Favored Glycine 0 C--N 1.317 -0.484 0 CA-C-N 114.973 -1.012 . . . . 0.0 111.891 179.179 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 57.4 m -53.78 -45.06 70.55 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-O 120.707 0.289 . . . . 0.0 110.827 -179.839 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 81.7 mt -71.58 -39.68 70.42 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.273 -0.421 . . . . 0.0 110.766 179.376 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -60.42 -33.39 72.44 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.085 -0.507 . . . . 0.0 111.736 -179.767 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 22' ' ' PHE . . . . . 0.482 ' HB2' HG21 ' A' ' 41' ' ' VAL . 8.2 m-85 -91.15 -31.05 16.36 Favored 'General case' 0 N--CA 1.463 0.197 0 CA-C-O 120.753 0.311 . . . . 0.0 111.311 -179.679 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -68.72 -50.32 51.78 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.335 -179.514 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 24' ' ' TRP . . . . . . . . . . . . . 4.4 t-105 -64.18 -45.05 90.07 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-N 115.834 -0.621 . . . . 0.0 111.24 -179.595 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -74.42 -23.42 58.94 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 120.858 0.361 . . . . 0.0 110.983 179.84 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -73.65 -45.63 27.74 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.898 -0.668 . . . . 0.0 112.715 -179.794 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 27' ' ' ARG . . . . . 0.442 ' NE ' ' HA ' ' A' ' 27' ' ' ARG . 5.2 mmp_? -57.26 -26.24 60.48 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.846 0.355 . . . . 0.0 111.018 -179.998 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 24.4 t70 -105.52 96.54 6.58 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.878 179.955 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -165.2 -168.22 1.35 Allowed 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.193 -179.869 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -98.93 -158.41 29.39 Favored Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.872 -0.68 . . . . 0.0 112.298 179.736 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 47.5 t -100.31 111.51 23.79 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.88 0.371 . . . . 0.0 110.936 179.96 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 129.83 -29.05 3.83 Favored Glycine 0 C--N 1.33 0.245 0 C-N-CA 120.886 -0.673 . . . . 0.0 112.457 -179.984 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 28.7 mm-40 -86.63 -20.85 27.25 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 120.741 0.305 . . . . 0.0 110.953 -179.959 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 34' ' ' ARG . . . . . . . . . . . . . 14.7 ptm180 -48.9 -36.31 16.88 Favored 'General case' 0 C--N 1.332 -0.17 0 CA-C-N 116.076 -0.511 . . . . 0.0 111.668 -179.757 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 29.2 mmt180 -61.77 -50.47 72.22 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 120.874 0.368 . . . . 0.0 111.277 -179.686 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 46.6 m-85 -63.2 -30.58 71.7 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.044 -0.525 . . . . 0.0 111.473 -179.607 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 37' ' ' TYR . . . . . . . . . . . . . 39.1 m-85 -74.67 -55.8 5.49 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.641 -179.237 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 88.8 t -56.63 -36.85 49.81 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.205 0 CA-C-O 121.0 0.429 . . . . 0.0 110.485 179.914 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 90.7 m -63.97 -50.96 66.52 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 115.747 -0.661 . . . . 0.0 110.465 179.226 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 40' ' ' LEU . . . . . 0.453 HD12 HD12 ' A' ' 43' ' ' ILE . 40.4 tp -56.8 -50.16 73.18 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 115.549 -0.75 . . . . 0.0 110.809 -179.858 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . 0.482 HG21 ' HB2' ' A' ' 22' ' ' PHE . 69.0 t -57.76 -36.53 55.39 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 115.858 -0.61 . . . . 0.0 110.446 179.565 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -61.52 -36.1 92.08 Favored Glycine 0 N--CA 1.449 -0.493 0 C-N-CA 120.907 -0.663 . . . . 0.0 112.17 179.815 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 43' ' ' ILE . . . . . 0.519 HD11 HD12 ' A' ' 83' ' ' ILE . 2.0 mt -65.22 -56.94 13.08 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.234 0 CA-C-O 120.958 0.409 . . . . 0.0 110.802 179.713 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 32.4 t -58.26 -25.17 61.44 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 115.879 -0.601 . . . . 0.0 111.685 -179.5 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -73.83 -58.48 4.43 Favored Glycine 0 CA--C 1.517 0.191 0 C-N-CA 120.696 -0.764 . . . . 0.0 112.986 -179.576 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 46' ' ' ILE . . . . . 0.535 ' O ' HG22 ' A' ' 49' ' ' VAL . 15.8 pt -57.92 -35.87 53.63 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.221 0 CA-C-O 120.818 0.342 . . . . 0.0 110.924 -179.674 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 47' ' ' ALA . . . . . 0.628 ' HB1' ' HE2' ' A' ' 205' ' ' LYS . . . -67.04 -37.59 84.36 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.962 0.41 . . . . 0.0 110.261 178.754 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 48' ' ' ALA . . . . . 0.62 ' HB3' ' HB3' ' A' ' 15' ' ' MET . . . -60.57 -33.08 72.18 Favored 'General case' 0 C--N 1.332 -0.173 0 CA-C-N 115.736 -0.665 . . . . 0.0 111.343 179.889 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 49' ' ' VAL . . . . . 0.535 HG22 ' O ' ' A' ' 46' ' ' ILE . 1.3 m -76.54 -38.39 31.46 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.496 -0.32 . . . . 0.0 111.643 -179.425 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -62.95 -41.65 99.58 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-O 120.968 0.413 . . . . 0.0 111.393 -179.636 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 51' ' ' TYR . . . . . 0.483 ' HB3' ' O ' ' A' ' 8' ' ' PHE . 38.5 m-85 -72.74 -40.41 66.1 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-N 115.894 -0.594 . . . . 0.0 110.813 -179.283 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -63.13 -40.87 98.84 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-N 115.943 -0.571 . . . . 0.0 111.467 179.793 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 53' ' ' VAL . . . . . 0.452 HG12 ' O ' ' A' ' 49' ' ' VAL . 33.3 m -74.42 -50.56 26.47 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 N-CA-C 111.754 0.279 . . . . 0.0 111.754 -179.475 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 54' ' ' MET . . . . . 0.516 ' HG2' ' HG2' ' A' ' 71' ' ' PRO . 72.0 mtm -57.57 -30.2 65.06 Favored 'General case' 0 CA--C 1.521 -0.143 0 CA-C-O 121.013 0.435 . . . . 0.0 110.744 179.914 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -58.95 -36.97 75.7 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 115.601 -0.727 . . . . 0.0 111.643 -179.816 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 6.2 mp -87.2 4.38 42.71 Favored 'General case' 0 C--N 1.332 -0.173 0 CA-C-N 116.639 -0.255 . . . . 0.0 111.456 179.974 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 92.98 30.76 9.09 Favored Glycine 0 N--CA 1.452 -0.246 0 C-N-CA 120.674 -0.774 . . . . 0.0 113.111 179.526 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 73.7 t -88.63 130.19 38.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-O 120.71 0.29 . . . . 0.0 110.878 179.716 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 59' ' ' GLY . . . . . 0.567 ' HA3' ' HD3' ' A' ' 71' ' ' PRO . . . 87.59 -5.96 84.17 Favored Glycine 0 N--CA 1.448 -0.548 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.471 -179.815 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 60' ' ' TRP . . . . . . . . . . . . . 11.5 m0 -69.43 83.03 0.39 Allowed 'General case' 0 C--N 1.328 -0.358 0 CA-C-O 120.759 0.314 . . . . 0.0 110.59 179.835 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 6.5 p -98.99 132.25 23.94 Favored Pre-proline 0 C--N 1.33 -0.282 0 CA-C-N 116.351 -0.386 . . . . 0.0 111.298 -179.87 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 73.3 Cg_endo -75.75 148.33 32.33 Favored 'Trans proline' 0 C--N 1.35 0.612 0 C-N-CA 122.447 2.098 . . . . 0.0 112.169 179.68 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 83.7 t -141.98 97.27 0.71 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.351 -179.84 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . 57.38 -88.93 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.054 -0.521 . . . . 0.0 111.87 179.611 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 11.8 mm-40 -118.89 -20.94 7.97 Favored 'General case' 0 C--N 1.332 -0.174 0 CA-C-N 116.501 -0.318 . . . . 0.0 111.428 -179.486 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 66' ' ' ARG . . . . . . . . . . . . . 28.4 ptt180 -110.91 161.68 15.59 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.461 -0.336 . . . . 0.0 110.766 179.971 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 91.6 m -114.88 143.3 45.34 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.256 -0.429 . . . . 0.0 111.264 -179.8 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 68' ' ' VAL . . . . . 0.411 HG22 ' SD ' ' A' ' 117' ' ' MET . 30.1 m -129.14 146.51 34.14 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 115.954 -0.566 . . . . 0.0 110.924 179.943 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 69' ' ' PHE . . . . . . . . . . . . . 19.2 m-85 -106.38 117.54 34.31 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.123 -0.49 . . . . 0.0 109.833 -179.724 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 70' ' ' VAL . . . . . 0.559 HG11 ' HD3' ' A' ' 71' ' ' PRO . 1.4 p -68.77 -33.19 4.11 Favored Pre-proline 0 CA--C 1.543 0.692 0 N-CA-C 113.66 0.985 . . . . 0.0 113.66 -178.538 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 71' ' ' PRO . . . . . 0.567 ' HD3' ' HA3' ' A' ' 59' ' ' GLY . 14.2 Cg_exo -69.48 -19.11 37.87 Favored 'Trans proline' 0 C--N 1.356 0.942 0 C-N-CA 122.099 1.866 . . . . 0.0 113.46 -178.643 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 72' ' ' ARG . . . . . 0.453 ' HA ' ' HE ' ' A' ' 72' ' ' ARG . 0.9 OUTLIER -67.77 -55.27 13.7 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.917 0.389 . . . . 0.0 111.564 -179.449 . . . . . . . . 3 3 . 1 . 028 nuclear orig full ' A' A ' 73' ' ' TYR . . . . . 0.425 ' O ' HG13 ' A' ' 77' ' ' ILE . 14.2 m-85 -71.17 -33.19 69.76 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 116.081 -0.509 . . . . 0.0 111.315 -178.962 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 74' ' ' ILE . . . . . 0.401 ' HA ' HD12 ' A' ' 77' ' ' ILE . 0.3 OUTLIER -71.09 -44.93 74.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 C-N-CA 120.864 -0.334 . . . . 0.0 110.88 -179.773 . . . . . . . . 3 3 . 1 . 028 nuclear orig full ' A' A ' 75' ' ' ASP . . . . . 0.4 ' N ' ' CG2' ' A' ' 74' ' ' ILE . 37.4 t70 -58.99 -35.49 73.31 Favored 'General case' 0 N--CA 1.455 -0.183 0 N-CA-C 109.561 -0.533 . . . . 0.0 109.561 179.334 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 76' ' ' TRP . . . . . . . . . . . . . 50.2 m0 -66.0 -35.84 81.66 Favored 'General case' 0 C--N 1.332 -0.165 0 CA-C-N 116.029 -0.532 . . . . 0.0 110.129 179.141 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 77' ' ' ILE . . . . . 0.489 HG12 ' HB3' ' A' ' 109' ' ' MET . 96.4 mt -65.62 -30.78 51.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.028 -0.533 . . . . 0.0 110.718 179.378 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 69.7 mt -92.2 -20.46 21.17 Favored 'General case' 0 C--N 1.329 -0.294 0 N-CA-C 112.342 0.497 . . . . 0.0 112.342 -179.782 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 79' ' ' THR . . . . . 0.445 ' O ' ' HB2' ' A' ' 82' ' ' LEU . 62.7 p -94.39 -47.99 6.34 Favored 'General case' 0 N--CA 1.466 0.333 0 N-CA-C 112.845 0.683 . . . . 0.0 112.845 -178.406 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 80' ' ' THR . . . . . 0.571 ' N ' ' HD2' ' A' ' 81' ' ' PRO . 86.6 m -51.29 -48.72 85.07 Favored Pre-proline 0 C--N 1.328 -0.357 0 N-CA-C 112.545 0.572 . . . . 0.0 112.545 -179.319 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 81' ' ' PRO . . . . . 0.571 ' HD2' ' N ' ' A' ' 80' ' ' THR . 13.8 Cg_endo -56.02 -24.39 48.54 Favored 'Trans proline' 0 C--N 1.352 0.712 0 C-N-CA 121.536 1.491 . . . . 0.0 111.463 179.973 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 82' ' ' LEU . . . . . 0.492 HD22 HG12 ' A' ' 43' ' ' ILE . 7.2 mp -77.03 -46.03 25.14 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-N 115.707 -0.679 . . . . 0.0 110.847 179.9 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 83' ' ' ILE . . . . . 0.519 HD12 HD11 ' A' ' 43' ' ' ILE . 28.0 mm -60.8 -53.49 48.36 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.203 0 CA-C-N 116.305 -0.407 . . . . 0.0 110.527 179.655 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . 0.402 HG13 ' ND2' ' A' ' 105' ' ' ASN . 29.4 m -59.15 -35.47 57.7 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.211 0 CA-C-N 116.076 -0.511 . . . . 0.0 110.386 179.451 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 85' ' ' TYR . . . . . . . . . . . . . 72.7 t80 -65.51 -32.38 73.95 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.097 -0.501 . . . . 0.0 110.008 179.004 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 86' ' ' PHE . . . . . . . . . . . . . 1.4 t80 -61.54 -51.13 69.88 Favored 'General case' 0 C--N 1.333 -0.141 0 CA-C-N 115.963 -0.562 . . . . 0.0 109.707 179.547 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 6.9 mp -67.09 -31.57 72.15 Favored 'General case' 0 C--N 1.331 -0.2 0 CA-C-N 115.974 -0.557 . . . . 0.0 110.137 179.209 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -62.77 -28.01 70.96 Favored Glycine 0 N--CA 1.45 -0.418 0 C-N-CA 120.878 -0.677 . . . . 0.0 111.615 179.441 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 71.9 mt -78.45 -49.71 12.97 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.86 0.362 . . . . 0.0 110.536 179.411 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 96.1 mt -56.44 -32.5 64.97 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 115.994 -0.548 . . . . 0.0 110.649 179.608 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . 0.53 ' HB3' ' HB2' ' A' ' 148' ' ' SER . . . -83.67 -52.88 6.06 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 115.91 -0.587 . . . . 0.0 110.937 179.838 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 92' ' ' GLY . . . . . 0.452 ' HA3' HH21 ' A' ' 152' ' ' ARG . . . 90.68 71.82 1.23 Allowed Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.849 -0.691 . . . . 0.0 112.529 179.967 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 93' ' ' LEU . . . . . 0.495 HD13 ' HG2' ' A' ' 145' ' ' MET . 6.4 mp -84.18 -172.49 4.19 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-O 120.801 0.334 . . . . 0.0 110.912 -179.934 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 94' ' ' ASP . . . . . 0.426 ' HB2' ' OE2' ' A' ' 97' ' ' GLU . 4.6 m-20 -98.88 -172.24 2.25 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.201 -179.966 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 46.1 t -67.87 -52.91 31.09 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 115.994 -0.548 . . . . 0.0 111.527 -179.668 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 75.3 mtp180 -74.14 -35.38 64.07 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-O 120.893 0.378 . . . . 0.0 110.899 -179.358 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 97' ' ' GLU . . . . . 0.426 ' OE2' ' HB2' ' A' ' 94' ' ' ASP . 0.3 OUTLIER -60.8 -42.31 97.37 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 115.992 -0.549 . . . . 0.0 111.032 -179.873 . . . . . . . . 3 3 . 1 . 028 nuclear orig full ' A' A ' 98' ' ' PHE . . . . . . . . . . . . . 0.6 OUTLIER -61.69 -40.73 96.03 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.337 -0.392 . . . . 0.0 110.572 179.468 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -65.6 -31.55 80.4 Favored Glycine 0 N--CA 1.452 -0.27 0 C-N-CA 120.795 -0.717 . . . . 0.0 112.538 -179.932 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 96.7 mt -67.82 -43.3 86.28 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.209 0 CA-C-O 120.909 0.385 . . . . 0.0 111.239 -179.826 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 101' ' ' VAL . . . . . 0.53 HG11 ' HE3' ' A' ' 145' ' ' MET . 42.2 t -66.36 -50.49 67.27 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.358 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.367 -179.801 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 102' ' ' ILE . . . . . . . . . . . . . 48.6 mm -59.46 -49.57 83.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.59 -179.526 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 14.2 t -59.95 -29.97 68.76 Favored 'General case' 0 C--N 1.332 -0.181 0 CA-C-O 120.77 0.319 . . . . 0.0 110.903 -179.829 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -60.66 -57.0 14.56 Favored 'General case' 0 C--N 1.332 -0.178 0 CA-C-N 116.325 -0.398 . . . . 0.0 109.983 179.342 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 105' ' ' ASN . . . . . 0.402 ' ND2' HG13 ' A' ' 84' ' ' VAL . 32.7 m-80 -59.27 -26.4 64.91 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-N 116.022 -0.535 . . . . 0.0 110.782 179.533 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 76.3 m -61.49 -52.76 63.19 Favored 'General case' 0 C--N 1.332 -0.185 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.958 179.87 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 2.1 t -62.0 -37.21 77.76 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.248 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.59 179.966 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 70.3 t -60.14 -57.86 9.89 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 115.73 -0.668 . . . . 0.0 111.461 -179.898 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 109' ' ' MET . . . . . 0.489 ' HB3' HG12 ' A' ' 77' ' ' ILE . 3.7 tpp -56.91 -42.89 80.75 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.485 -179.55 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 24.1 tp -62.54 -31.0 71.71 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.318 -0.401 . . . . 0.0 110.693 -179.899 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -63.57 -55.7 21.75 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 116.038 -0.528 . . . . 0.0 110.655 179.545 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 112' ' ' GLY . . . . . 0.545 ' HA3' ' H22' ' A' ' 301' ' ' RET . . . -61.49 -36.7 92.96 Favored Glycine 0 N--CA 1.45 -0.389 0 C-N-CA 120.775 -0.726 . . . . 0.0 112.081 179.576 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 113' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER -52.25 -71.77 0.06 Allowed 'General case' 0 C--N 1.332 -0.174 0 CA-C-O 120.961 0.41 . . . . 0.0 110.195 179.619 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -63.9 -19.44 65.1 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 115.924 -0.58 . . . . 0.0 111.022 179.758 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 115' ' ' GLY . . . . . 0.454 ' HA2' HD21 ' A' ' 126' ' ' LEU . . . -54.8 -51.58 52.05 Favored Glycine 0 C--N 1.332 0.334 0 C-N-CA 120.86 -0.686 . . . . 0.0 111.841 179.611 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -78.2 -14.91 59.26 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-O 120.748 0.309 . . . . 0.0 111.227 179.659 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 117' ' ' MET . . . . . 0.411 ' SD ' HG22 ' A' ' 68' ' ' VAL . 23.5 mmt -90.59 17.07 7.93 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-N 116.358 -0.383 . . . . 0.0 111.739 -179.238 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 118' ' ' VAL . . . . . 0.4 HG21 ' HB3' ' A' ' 123' ' ' ARG . 34.4 m -81.1 144.01 53.85 Favored Pre-proline 0 C--N 1.33 -0.277 0 CA-C-O 120.505 0.193 . . . . 0.0 111.43 -179.845 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 119' ' ' PRO . . . . . . . . . . . . . 83.4 Cg_endo -82.49 -1.9 10.82 Favored 'Trans proline' 0 C--N 1.348 0.525 0 C-N-CA 122.55 2.167 . . . . 0.0 112.349 179.649 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -148.85 -129.1 1.77 Allowed Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.722 -0.751 . . . . 0.0 112.747 -179.878 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 39.8 pt -107.92 12.15 8.78 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.207 0 CA-C-O 120.676 0.274 . . . . 0.0 111.577 -179.729 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 43.9 mt-10 -60.25 -18.19 47.13 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.372 -0.376 . . . . 0.0 111.034 179.802 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 123' ' ' ARG . . . . . 0.422 ' HB2' ' HH2' ' A' ' 178' ' ' TRP . 15.7 ptt180 -50.08 -37.59 34.4 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 116.031 -0.532 . . . . 0.0 111.71 -179.578 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 124' ' ' TYR . . . . . . . . . . . . . 30.1 m-85 -58.46 -33.9 70.26 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.518 -0.31 . . . . 0.0 111.271 -179.628 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 125' ' ' ALA . . . . . . . . . . . . . . . -74.2 -49.75 22.15 Favored 'General case' 0 C--O 1.235 0.336 0 CA-C-O 120.909 0.385 . . . . 0.0 111.128 179.958 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 126' ' ' LEU . . . . . 0.454 HD21 ' HA2' ' A' ' 115' ' ' GLY . 7.4 mp -53.09 -46.46 68.66 Favored 'General case' 0 C--N 1.333 -0.144 0 CA-C-N 115.972 -0.558 . . . . 0.0 110.5 -179.928 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 127' ' ' PHE . . . . . 0.456 ' HZ ' ' HB3' ' A' ' 175' ' ' PRO . 4.8 t80 -67.23 -37.73 84.05 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.644 179.839 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 128' ' ' GLY . . . . . . . . . . . . . . . -46.38 -46.21 16.68 Favored Glycine 0 C--N 1.332 0.356 0 C-N-CA 120.193 -1.003 . . . . 0.0 110.911 179.237 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 129' ' ' MET . . . . . 0.401 ' HE3' ' N ' ' A' ' 130' ' ' GLY . 0.6 OUTLIER -68.1 -40.95 82.46 Favored 'General case' 0 C--N 1.327 -0.386 0 N-CA-C 109.749 -0.463 . . . . 0.0 109.749 178.48 . . . . . . . . 3 3 . 1 . 028 nuclear orig full ' A' A ' 130' ' ' GLY . . . . . 0.401 ' N ' ' HE3' ' A' ' 129' ' ' MET . . . -64.15 -23.15 67.73 Favored Glycine 0 N--CA 1.45 -0.411 0 CA-C-N 115.822 -0.626 . . . . 0.0 112.345 179.792 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -75.03 -53.54 8.73 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.717 0.294 . . . . 0.0 110.419 179.648 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 39.4 t -55.36 -40.33 56.77 Favored 'Isoleucine or valine' 0 C--O 1.233 0.217 0 CA-C-O 121.387 0.613 . . . . 0.0 109.638 178.799 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -69.79 -36.53 75.77 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 115.339 -0.846 . . . . 0.0 110.721 179.172 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 134' ' ' PHE . . . . . 0.443 ' CZ ' ' HA ' ' A' ' 172' ' ' ALA . 18.9 t80 -53.43 -60.06 3.79 Favored 'General case' 0 N--CA 1.454 -0.251 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.22 179.869 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 135' ' ' ILE . . . . . 0.494 ' O ' HG21 ' A' ' 138' ' ' VAL . 0.0 OUTLIER -56.11 -35.23 41.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 115.959 -0.564 . . . . 0.0 110.31 179.143 . . . . . . . . 3 3 . 1 . 028 nuclear orig full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . -57.56 -43.13 94.31 Favored Glycine 0 N--CA 1.45 -0.398 0 C-N-CA 120.226 -0.987 . . . . 0.0 111.755 179.024 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 137' ' ' LEU . . . . . 0.451 HD13 ' C ' ' A' ' 137' ' ' LEU . 1.4 tm? -63.29 -58.22 7.85 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 121.016 0.436 . . . . 0.0 110.519 179.678 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 138' ' ' VAL . . . . . 0.494 HG21 ' O ' ' A' ' 135' ' ' ILE . 2.4 m -54.22 -31.77 22.55 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.466 0 CA-C-N 115.562 -0.744 . . . . 0.0 110.213 179.68 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 139' ' ' TYR . . . . . . . . . . . . . 17.3 t80 -64.26 -34.92 79.21 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 115.885 -0.598 . . . . 0.0 110.05 179.091 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 15.4 m-85 -68.43 -48.69 63.94 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 115.989 -0.55 . . . . 0.0 111.613 179.733 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 141' ' ' LEU . . . . . . . . . . . . . 4.0 pp -68.52 -16.23 63.81 Favored 'General case' 0 CA--C 1.53 0.178 0 C-N-CA 120.974 -0.29 . . . . 0.0 111.327 -179.33 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 142' ' ' VAL . . . . . 0.422 HG23 ' O ' ' A' ' 138' ' ' VAL . 95.2 t -101.17 -18.77 6.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-O 121.079 0.466 . . . . 0.0 110.57 178.801 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . -85.26 -123.46 1.25 Allowed Glycine 0 CA--C 1.522 0.498 0 C-N-CA 120.929 -0.653 . . . . 0.0 113.145 -179.342 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 144' ' ' PRO . . . . . . . . . . . . . 69.3 Cg_exo -52.15 -35.94 64.63 Favored 'Trans proline' 0 C--N 1.35 0.634 0 C-N-CA 122.722 2.281 . . . . 0.0 113.178 -179.392 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 145' ' ' MET . . . . . 0.53 ' HE3' HG11 ' A' ' 101' ' ' VAL . 40.3 mtt -55.36 -37.72 67.87 Favored 'General case' 0 C--N 1.331 -0.206 0 CA-C-O 120.751 0.31 . . . . 0.0 111.446 -179.798 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 146' ' ' THR . . . . . . . . . . . . . 18.3 m -68.28 -41.64 80.72 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.725 -179.368 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 42.6 mt-10 -75.77 -26.32 57.26 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.403 -0.362 . . . . 0.0 111.423 -179.543 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 148' ' ' SER . . . . . 0.53 ' HB2' ' HB3' ' A' ' 91' ' ' ALA . 68.9 m -70.65 -43.67 68.7 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.372 -0.376 . . . . 0.0 111.564 -179.402 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 149' ' ' ALA . . . . . 0.43 ' HB1' ' HA ' ' A' ' 91' ' ' ALA . . . -76.04 -32.34 59.29 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.781 0.324 . . . . 0.0 111.635 -179.441 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 150' ' ' SER . . . . . . . . . . . . . 86.7 p -69.46 -1.26 8.05 Favored 'General case' 0 C--N 1.326 -0.413 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.037 179.995 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 151' ' ' GLN . . . . . . . . . . . . . 77.2 mt-30 -118.69 0.26 11.44 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.097 -0.501 . . . . 0.0 111.331 -179.838 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 152' ' ' ARG . . . . . 0.452 HH21 ' HA3' ' A' ' 92' ' ' GLY . 38.9 mmt180 -82.26 -52.62 6.77 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-O 120.833 0.349 . . . . 0.0 111.004 -179.997 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 153' ' ' SER . . . . . 0.59 ' HB3' HG12 ' A' ' 156' ' ' ILE . 35.5 t -158.36 167.64 29.15 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.749 179.241 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 154' ' ' SER . . . . . . . . . . . . . 45.9 t -70.32 -34.85 73.18 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 121.037 0.446 . . . . 0.0 110.151 179.277 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -76.91 -37.92 32.14 Favored Glycine 0 N--CA 1.45 -0.368 0 C-N-CA 120.971 -0.633 . . . . 0.0 112.264 179.618 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 156' ' ' ILE . . . . . 0.59 HG12 ' HB3' ' A' ' 153' ' ' SER . 34.2 mm -53.51 -37.75 31.28 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.178 0 CA-C-O 120.897 0.379 . . . . 0.0 111.092 179.877 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 157' ' ' LYS . . . . . . . . . . . . . 39.9 ttpt -65.49 -32.29 73.82 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 116.078 -0.51 . . . . 0.0 111.441 -179.761 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 46.0 t -72.54 -47.93 44.27 Favored 'General case' 0 C--O 1.235 0.3 0 CA-C-O 121.143 0.497 . . . . 0.0 111.006 -179.604 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 159' ' ' LEU . . . . . 0.417 ' O ' HD12 ' A' ' 163' ' ' LEU . 0.4 OUTLIER -68.63 -39.74 80.62 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 115.923 -0.58 . . . . 0.0 110.976 -179.415 . . . . . . . . 3 3 . 1 . 028 nuclear orig full ' A' A ' 160' ' ' TYR . . . . . 0.449 ' OH ' ' HB3' ' A' ' 145' ' ' MET . 37.2 t80 -62.25 -47.15 85.63 Favored 'General case' 0 C--N 1.326 -0.419 0 N-CA-C 112.086 0.402 . . . . 0.0 112.086 -178.596 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 24.9 m -61.49 -45.97 97.54 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 C-N-CA 120.909 -0.316 . . . . 0.0 111.365 -179.488 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 162' ' ' ARG . . . . . . . . . . . . . 28.1 tpt180 -68.85 -38.48 79.81 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 121.005 0.431 . . . . 0.0 111.103 -179.955 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 163' ' ' LEU . . . . . 0.417 HD12 ' O ' ' A' ' 159' ' ' LEU . 1.7 mp -64.67 -55.5 19.74 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 115.72 -0.673 . . . . 0.0 112.095 -179.23 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 164' ' ' ARG . . . . . 0.598 ' HG3' HD21 ' A' ' 165' ' ' ASN . 22.7 ptt180 -64.59 -41.72 96.05 Favored 'General case' 0 C--N 1.333 -0.15 0 N-CA-C 111.828 0.307 . . . . 0.0 111.828 -178.671 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 165' ' ' ASN . . . . . 0.598 HD21 ' HG3' ' A' ' 164' ' ' ARG . 0.9 OUTLIER -54.4 -48.37 71.67 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.91 0.386 . . . . 0.0 110.771 -179.922 . . . . . . . . 3 3 . 1 . 028 nuclear orig full ' A' A ' 166' ' ' LEU . . . . . . . . . . . . . 3.9 tt -64.06 -54.23 37.35 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 116.026 -0.533 . . . . 0.0 111.431 -179.787 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 167' ' ' THR . . . . . 0.456 ' O ' ' HB2' ' A' ' 171' ' ' TRP . 34.4 m -57.24 -54.28 48.61 Favored 'General case' 0 C--N 1.329 -0.307 0 N-CA-C 112.868 0.692 . . . . 0.0 112.868 -178.568 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 168' ' ' VAL . . . . . . . . . . . . . 9.8 p -55.58 -41.59 64.84 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.243 0 N-CA-C 112.425 0.528 . . . . 0.0 112.425 -178.694 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 169' ' ' VAL . . . . . . . . . . . . . 48.7 t -59.82 -64.62 0.56 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 C-N-CA 121.122 -0.231 . . . . 0.0 111.488 -179.628 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 170' ' ' LEU . . . . . 0.434 HD13 HG12 ' A' ' 203' ' ' VAL . 1.3 pp -62.07 -27.18 68.72 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.64 -0.254 . . . . 0.0 111.295 -179.582 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 171' ' ' TRP . . . . . 0.61 ' HE1' H202 ' A' ' 301' ' ' RET . 2.0 m0 -70.73 -36.12 73.02 Favored 'General case' 0 CA--C 1.519 -0.217 0 CA-C-O 121.099 0.476 . . . . 0.0 109.739 178.772 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 172' ' ' ALA . . . . . 0.443 ' HA ' ' CZ ' ' A' ' 134' ' ' PHE . . . -71.33 -6.85 43.08 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 115.465 -0.788 . . . . 0.0 110.877 179.573 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 173' ' ' ILE . . . . . 0.475 ' O ' HG12 ' A' ' 177' ' ' ILE . 42.1 mm -85.67 -23.29 7.13 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.191 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.943 179.571 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 174' ' ' TYR . . . . . . . . . . . . . 29.3 m-85 -53.87 -49.58 88.65 Favored Pre-proline 0 CA--C 1.53 0.201 0 CA-C-N 116.363 -0.38 . . . . 0.0 111.607 -179.72 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 175' ' ' PRO . . . . . 0.456 ' HB3' ' HZ ' ' A' ' 127' ' ' PHE . 81.2 Cg_exo -47.46 -31.62 13.82 Favored 'Trans proline' 0 C--N 1.351 0.701 0 C-N-CA 122.177 1.918 . . . . 0.0 112.228 179.446 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 176' ' ' PHE . . . . . 0.463 ' O ' ' HG ' ' A' ' 180' ' ' LEU . 75.0 m-85 -80.39 -50.04 10.66 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.02 -0.536 . . . . 0.0 111.908 -179.856 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 177' ' ' ILE . . . . . 0.475 HG12 ' O ' ' A' ' 173' ' ' ILE . 6.4 mm -62.52 -35.84 72.03 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.556 0 CA-C-N 116.091 -0.504 . . . . 0.0 112.269 -178.144 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 178' ' ' TRP . . . . . 0.422 ' HH2' ' HB2' ' A' ' 123' ' ' ARG . 68.6 t90 -73.71 -43.1 60.18 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 121.001 0.429 . . . . 0.0 110.73 179.642 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 179' ' ' LEU . . . . . 0.407 ' O ' ' HA3' ' A' ' 184' ' ' GLY . 1.6 tm? -68.71 -51.25 43.61 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 115.765 -0.652 . . . . 0.0 111.188 -179.497 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 180' ' ' LEU . . . . . 0.54 HD23 HD11 ' A' ' 187' ' ' LEU . 13.8 mt -75.22 -47.24 29.16 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-N 116.442 -0.345 . . . . 0.0 111.78 -179.223 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . -57.01 178.91 0.73 Allowed Glycine 0 C--N 1.337 0.622 0 C-N-CA 120.415 -0.898 . . . . 0.0 112.71 179.858 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 182' ' ' PRO . . . . . 0.597 ' HA ' ' HB1' ' A' ' 186' ' ' ALA . 72.9 Cg_exo -47.73 -45.27 24.46 Favored 'Trans proline' 0 CA--C 1.536 0.582 0 C-N-CA 122.848 2.365 . . . . 0.0 113.762 -179.842 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 183' ' ' PRO . . . . . 0.444 ' HD3' ' HB2' ' A' ' 182' ' ' PRO . 76.2 Cg_exo -51.83 -16.98 4.62 Favored 'Trans proline' 0 C--N 1.356 0.945 0 C-N-CA 122.173 1.916 . . . . 0.0 113.145 -179.787 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 184' ' ' GLY . . . . . 0.407 ' HA3' ' O ' ' A' ' 179' ' ' LEU . . . -115.93 -90.91 1.66 Allowed Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.463 -0.875 . . . . 0.0 113.001 -179.749 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 185' ' ' VAL . . . . . . . . . . . . . 9.4 m -116.48 -7.66 12.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 N-CA-C 111.716 0.265 . . . . 0.0 111.716 -179.43 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 186' ' ' ALA . . . . . 0.597 ' HB1' ' HA ' ' A' ' 182' ' ' PRO . . . 56.66 85.69 0.08 Allowed 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.404 -0.362 . . . . 0.0 111.717 179.567 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 187' ' ' LEU . . . . . 0.54 HD11 HD23 ' A' ' 180' ' ' LEU . 20.9 mt -91.87 -49.45 6.24 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-O 120.927 0.394 . . . . 0.0 110.713 179.567 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 188' ' ' LEU . . . . . . . . . . . . . 95.6 mt -90.23 -154.48 0.33 Allowed 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 115.883 -0.599 . . . . 0.0 110.896 -179.962 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 189' ' ' THR . . . . . . . . . . . . . 29.8 m -95.99 134.89 23.21 Favored Pre-proline 0 C--N 1.328 -0.342 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.649 -179.862 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 190' ' ' PRO . . . . . . . . . . . . . 82.3 Cg_exo -44.99 -31.31 5.31 Favored 'Trans proline' 0 C--N 1.351 0.664 0 C-N-CA 122.592 2.195 . . . . 0.0 112.884 179.999 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 191' ' ' THR . . . . . . . . . . . . . 81.5 p -76.37 -42.05 45.94 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.481 -0.327 . . . . 0.0 111.326 -179.896 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 192' ' ' VAL . . . . . . . . . . . . . 58.3 t -70.08 -48.94 59.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.312 -0.404 . . . . 0.0 111.562 -179.504 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 193' ' ' ASP . . . . . . . . . . . . . 19.3 m-20 -53.78 -46.3 70.95 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.349 -0.387 . . . . 0.0 110.965 -179.89 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 194' ' ' VAL . . . . . . . . . . . . . 69.5 t -65.36 -36.05 76.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.28 -0.418 . . . . 0.0 110.883 179.712 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 195' ' ' ALA . . . . . . . . . . . . . . . -55.0 -44.45 74.51 Favored 'General case' 0 C--N 1.331 -0.199 0 CA-C-N 116.421 -0.354 . . . . 0.0 110.843 179.783 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 196' ' ' LEU . . . . . . . . . . . . . 91.2 mt -68.07 -39.05 83.03 Favored 'General case' 0 C--N 1.332 -0.195 0 CA-C-O 120.895 0.379 . . . . 0.0 110.387 179.26 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 197' ' ' ILE . . . . . 0.446 HD13 HD13 ' A' ' 200' ' ' LEU . 13.2 mm -58.57 -56.31 17.24 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-N 115.971 -0.559 . . . . 0.0 110.083 179.091 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 198' ' ' VAL . . . . . . . . . . . . . 73.6 t -53.6 -34.46 24.09 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.509 0 CA-C-N 115.442 -0.799 . . . . 0.0 109.368 178.208 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 199' ' ' TYR . . . . . . . . . . . . . 70.0 t80 -69.92 -31.43 69.2 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 115.203 -0.908 . . . . 0.0 110.628 180.0 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 200' ' ' LEU . . . . . 0.446 HD13 HD13 ' A' ' 197' ' ' ILE . 62.5 mt -67.75 -45.53 74.7 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 115.9 -0.591 . . . . 0.0 111.299 -179.73 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 201' ' ' ASP . . . . . . . . . . . . . 7.8 m-20 -70.56 -32.61 70.1 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 121.063 0.459 . . . . 0.0 110.396 179.957 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 202' ' ' LEU . . . . . . . . . . . . . 3.9 mt -66.81 -41.99 86.64 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 115.544 -0.753 . . . . 0.0 111.882 -179.892 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 203' ' ' VAL . . . . . 0.434 HG12 HD13 ' A' ' 170' ' ' LEU . 8.2 p -71.47 -37.01 62.81 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.366 0 N-CA-C 111.883 0.327 . . . . 0.0 111.883 -178.582 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 204' ' ' THR . . . . . 0.417 ' O ' ' HB2' ' A' ' 208' ' ' PHE . 24.5 m -65.37 -47.29 76.89 Favored 'General case' 0 C--N 1.329 -0.312 0 C-N-CA 120.832 -0.347 . . . . 0.0 111.674 -179.92 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 205' ' ' LYS . . . . . 0.628 ' HE2' ' HB1' ' A' ' 47' ' ' ALA . 60.4 mttp -79.3 -57.93 3.47 Favored 'General case' 0 C--N 1.326 -0.429 0 N-CA-C 112.168 0.432 . . . . 0.0 112.168 -178.225 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 44.4 t -67.33 -37.39 78.93 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.388 0 CA-C-N 116.331 -0.395 . . . . 0.0 111.522 -179.413 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 207' ' ' GLY . . . . . . . . . . . . . . . -70.75 -53.65 11.42 Favored Glycine 0 C--N 1.331 0.278 0 C-N-CA 120.663 -0.78 . . . . 0.0 112.668 -179.622 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 208' ' ' PHE . . . . . 0.417 ' HB2' ' O ' ' A' ' 204' ' ' THR . 5.4 t80 -57.3 -42.42 81.75 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 120.872 0.368 . . . . 0.0 110.67 179.699 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 209' ' ' GLY . . . . . 0.463 ' O ' ' HB3' ' A' ' 212' ' ' ALA . . . -69.93 -38.51 75.0 Favored Glycine 0 N--CA 1.452 -0.296 0 CA-C-N 115.405 -0.816 . . . . 0.0 113.417 -179.766 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 210' ' ' PHE . . . . . . . . . . . . . 1.1 m-85 -69.43 -38.7 77.96 Favored 'General case' 0 CA--C 1.51 -0.58 0 N-CA-C 107.944 -1.132 . . . . 0.0 107.944 179.201 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 211' ' ' ILE . . . . . . . . . . . . . 82.9 mt -70.67 -28.69 35.18 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.825 0 N-CA-C 107.133 -1.432 . . . . 0.0 107.133 176.353 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 212' ' ' ALA . . . . . 0.463 ' HB3' ' O ' ' A' ' 209' ' ' GLY . . . -68.14 -37.94 81.61 Favored 'General case' 0 N--CA 1.45 -0.469 0 CA-C-N 114.394 -1.276 . . . . 0.0 110.572 179.704 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 213' ' ' LEU . . . . . . . . . . . . . 88.3 mt -70.1 -53.44 17.38 Favored 'General case' 0 C--N 1.331 -0.198 0 CA-C-N 115.28 -0.873 . . . . 0.0 111.444 -179.608 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 214' ' ' ASP . . . . . . . . . . . . . 25.6 t70 -54.15 -36.32 63.19 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.308 -0.406 . . . . 0.0 110.933 -179.764 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 215' ' ' ALA . . . . . . . . . . . . . . . -67.29 -57.27 6.97 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.026 -0.534 . . . . 0.0 111.457 -179.935 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 216' ' ' ALA . . . . . . . . . . . . . . . -58.57 -43.03 89.28 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.414 -0.357 . . . . 0.0 111.218 -179.735 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 217' ' ' ALA . . . . . . . . . . . . . . . -57.76 -36.8 72.6 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.502 179.831 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 218' ' ' THR . . . . . . . . . . . . . 90.9 m -66.01 -40.69 91.3 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 115.905 -0.589 . . . . 0.0 110.802 179.558 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 219' ' ' LEU . . . . . . . . . . . . . 27.6 mt -64.98 -35.17 80.32 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-N 116.299 -0.409 . . . . 0.0 110.53 179.745 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 220' ' ' ARG . . . . . . . . . . . . . 23.9 ttt180 -83.39 -19.04 36.78 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 115.868 -0.606 . . . . 0.0 110.635 179.931 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 221' ' ' ALA . . . . . . . . . . . . . . . -82.33 -36.92 26.45 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.156 -0.475 . . . . 0.0 111.473 179.886 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 222' ' ' GLU . . . . . . . . . . . . . 11.6 pt-20 -91.9 -39.07 11.93 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-N 116.406 -0.361 . . . . 0.0 111.184 -179.606 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 223' ' ' HIS . . . . . . . . . . . . . 1.1 m170 62.15 168.58 0.12 Allowed 'General case' 0 C--N 1.332 -0.164 0 CA-C-N 116.116 -0.493 . . . . 0.0 111.203 -179.472 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 224' ' ' GLY . . . . . . . . . . . . . . . -93.4 -4.66 64.07 Favored Glycine 0 C--N 1.33 0.223 0 C-N-CA 120.757 -0.735 . . . . 0.0 112.568 -179.942 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 225' ' ' GLU . . . . . . . . . . . . . 36.6 tt0 -94.69 146.13 24.37 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 120.777 0.322 . . . . 0.0 110.954 179.987 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 226' ' ' SER . . . . . . . . . . . . . 80.2 p -165.4 162.84 19.72 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.099 -0.5 . . . . 0.0 110.892 179.896 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 227' ' ' LEU . . . . . . . . . . . . . 52.1 tp -75.31 109.25 8.67 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.921 -179.948 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 228' ' ' ALA . . . . . . . . . . . . . . . -150.2 143.02 24.74 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.24 -179.971 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 229' ' ' GLY . . . . . . . . . . . . . . . -128.73 -129.6 3.2 Favored Glycine 0 C--N 1.331 0.257 0 C-N-CA 120.927 -0.654 . . . . 0.0 112.416 179.95 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 230' ' ' VAL . . . . . . . . . . . . . 43.7 t -109.74 129.96 63.69 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-O 120.748 0.309 . . . . 0.0 110.873 179.971 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 231' ' ' ASP . . . . . . . . . . . . . 23.8 m-20 -98.72 103.25 15.19 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.003 179.981 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 232' ' ' THR . . . . . . . . . . . . . 4.1 t -142.55 136.71 29.53 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 115.999 -0.546 . . . . 0.0 111.079 179.857 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 233' ' ' ASP . . . . . . . . . . . . . 15.1 t70 59.64 98.45 0.02 OUTLIER 'General case' 0 C--N 1.331 -0.213 0 CA-C-N 116.123 -0.49 . . . . 0.0 111.042 -179.884 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 234' ' ' THR . . . . . . . . . . . . . 57.9 m -139.1 95.95 9.23 Favored Pre-proline 0 C--N 1.329 -0.306 0 CA-C-N 116.101 -0.499 . . . . 0.0 111.017 -179.917 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 235' ' ' PRO . . . . . . . . . . . . . 38.5 Cg_exo -61.05 122.51 11.29 Favored 'Trans proline' 0 C--N 1.347 0.48 0 C-N-CA 122.533 2.155 . . . . 0.0 112.201 179.924 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 236' ' ' ALA . . . . . . . . . . . . . . . -163.7 108.39 1.03 Allowed 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.212 -179.886 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 237' ' ' VAL . . . . . . . . . . . . . 15.0 p -160.14 142.64 4.72 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.198 179.913 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 238' ' ' ALA . . . . . . . . . . . . . . . -149.99 136.73 19.27 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.952 -179.925 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 239' ' ' ASP . . . . . . . . . . . . . 10.0 m-20 60.14 103.32 0.02 OUTLIER 'General case' 0 C--N 1.332 -0.194 0 CA-C-N 116.106 -0.497 . . . . 0.0 111.162 -179.891 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 240' ' ' LEU . . . . . . . . . . . . . 54.4 tp -142.46 -27.61 0.61 Allowed 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.255 -0.429 . . . . 0.0 110.817 -179.903 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 241' ' ' GLU . . . . . . . . . . . . . 46.0 mt-10 -136.49 136.44 39.42 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.97 -179.973 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 242' ' ' HIS . . . . . . . . . . . . . 25.4 t60 -82.43 -37.0 26.1 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.785 -179.985 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 243' ' ' HIS . . . . . . . . . . . . . 42.1 m80 -104.57 127.21 52.24 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.801 -179.895 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 244' ' ' HIS . . . . . . . . . . . . . 39.2 m80 -74.6 -60.88 2.08 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.848 179.94 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 245' ' ' HIS . . . . . . . . . . . . . 63.3 m80 -67.81 170.7 7.58 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.101 -0.499 . . . . 0.0 110.688 179.952 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 246' ' ' HIS . . . . . . . . . . . . . 89.1 m-70 57.65 94.17 0.03 OUTLIER 'General case' 0 C--N 1.331 -0.213 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.907 -179.799 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 247' ' ' HIS . . . . . . . . . . . . . 47.0 t60 . . . . . 0 C--O 1.248 0.986 0 CA-C-O 118.311 -0.852 . . . . 0.0 110.816 179.976 . . . . . . . . 0 0 . 1 . 028 nuclear orig full ' A' A ' 301' ' ' RET . . . . . 0.61 H202 ' HE1' ' A' ' 171' ' ' TRP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 48.8 mtm . . . . . 0 N--CA 1.486 1.352 0 CA-C-O 120.868 0.366 . . . . 0.0 110.928 . . . . . . . . . 0 0 . 1 . 029 nuclear orig full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 11.5 t -103.54 -8.18 9.45 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-N 116.027 -0.533 . . . . 0.0 110.664 179.857 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -88.22 -38.73 7.13 Favored Glycine 0 N--CA 1.452 -0.253 0 C-N-CA 120.867 -0.683 . . . . 0.0 112.763 -179.821 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 89.1 mt -64.28 -37.42 87.42 Favored 'General case' 0 N--CA 1.45 -0.46 0 CA-C-O 120.841 0.353 . . . . 0.0 111.199 -179.945 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 5' ' ' THR . . . . . 0.438 ' HA ' ' HD2' ' A' ' 8' ' ' PHE . 78.5 p -59.79 -37.34 78.82 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.047 -0.524 . . . . 0.0 111.968 -179.6 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 20.1 p -54.24 -36.88 64.02 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.45 -0.341 . . . . 0.0 111.515 -179.441 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 7' ' ' LEU . . . . . . . . . . . . . 4.2 mm? -61.9 -53.05 61.06 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.308 -0.406 . . . . 0.0 111.344 -179.705 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 8' ' ' PHE . . . . . 0.634 ' HB2' ' HB1' ' A' ' 55' ' ' ALA . 29.2 m-85 -61.99 -27.32 68.78 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.367 -0.379 . . . . 0.0 111.223 -179.574 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 9' ' ' TRP . . . . . . . . . . . . . 19.7 m95 -69.61 -44.61 70.35 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 121.008 0.433 . . . . 0.0 110.204 179.882 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 90.2 mt -65.72 -37.12 85.53 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 115.926 -0.579 . . . . 0.0 109.997 179.181 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -66.12 -32.9 83.72 Favored Glycine 0 N--CA 1.446 -0.677 0 CA-C-N 115.597 -0.729 . . . . 0.0 111.746 179.568 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -68.44 -37.29 80.11 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.856 0.36 . . . . 0.0 110.442 179.428 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 67.7 mt -59.47 -53.57 46.45 Favored 'Isoleucine or valine' 0 C--O 1.234 0.247 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.254 179.114 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -58.26 -34.78 75.38 Favored Glycine 0 C--N 1.332 0.36 0 C-N-CA 120.652 -0.785 . . . . 0.0 111.977 179.291 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 15' ' ' MET . . . . . 0.622 ' HE2' ' HD2' ' A' ' 205' ' ' LYS . 17.3 mmt -66.17 -41.23 90.59 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-O 120.772 0.32 . . . . 0.0 110.57 179.426 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 16' ' ' LEU . . . . . 0.409 HD23 ' HA ' ' A' ' 16' ' ' LEU . 0.3 OUTLIER -57.01 -40.74 77.2 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.067 -0.515 . . . . 0.0 109.95 179.371 . . . . . . . . 3 3 . 1 . 029 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 60.5 t -60.28 -48.86 86.5 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.241 0 CA-C-N 115.856 -0.611 . . . . 0.0 110.655 179.358 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -63.34 -48.55 77.95 Favored Glycine 0 C--N 1.332 0.356 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.058 179.337 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 43.9 m -50.13 -43.26 51.74 Favored 'General case' 0 C--N 1.328 -0.366 0 C-N-CA 122.317 0.247 . . . . 0.0 111.434 -179.659 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 87.2 mt -71.51 -44.41 64.69 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.597 -0.274 . . . . 0.0 111.694 -179.781 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -61.45 -31.67 71.63 Favored 'General case' 0 C--N 1.33 -0.28 0 N-CA-C 111.866 0.321 . . . . 0.0 111.866 -179.589 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 6.9 m-85 -90.97 -35.37 14.72 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.693 0.283 . . . . 0.0 111.679 -179.32 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -66.84 -51.28 57.43 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-O 120.98 0.419 . . . . 0.0 111.781 -179.412 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 24' ' ' TRP . . . . . . . . . . . . . 7.3 t-105 -62.93 -50.68 69.87 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-N 115.804 -0.634 . . . . 0.0 110.891 -179.696 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -68.92 -19.88 64.21 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 116.364 -0.38 . . . . 0.0 110.741 179.552 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -73.32 -48.23 19.75 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.912 -0.661 . . . . 0.0 112.594 -179.961 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 78.4 mtp180 -60.5 -18.64 53.14 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 120.873 0.368 . . . . 0.0 110.688 179.877 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 33.5 t70 -109.37 98.42 7.83 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.043 -0.526 . . . . 0.0 110.639 179.811 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -166.35 -179.31 4.94 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.162 -179.836 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -68.79 -94.0 0.05 OUTLIER Glycine 0 N--CA 1.452 -0.25 0 C-N-CA 120.885 -0.674 . . . . 0.0 112.59 -179.939 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 47.4 t -158.8 -25.72 0.08 Allowed 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 120.818 0.342 . . . . 0.0 110.834 -179.948 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -90.99 -43.87 4.61 Favored Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.814 -0.708 . . . . 0.0 112.454 179.933 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 36.3 mt-10 -63.1 -21.03 65.9 Favored 'General case' 0 C--N 1.331 -0.218 0 CA-C-O 120.697 0.284 . . . . 0.0 110.946 179.993 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 34' ' ' ARG . . . . . . . . . . . . . 5.0 tmt_? -50.43 -38.2 41.98 Favored 'General case' 0 C--N 1.332 -0.169 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.202 -179.93 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 29.7 mmt180 -64.5 -44.86 89.6 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 116.343 -0.39 . . . . 0.0 111.211 -179.928 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 57.1 m-85 -66.78 -31.06 71.44 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.113 -179.989 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 37' ' ' TYR . . . . . . . . . . . . . 32.2 m-85 -70.97 -52.32 20.46 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.087 -179.687 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 85.4 t -57.04 -36.84 52.24 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-O 121.141 0.496 . . . . 0.0 110.232 179.387 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 55.4 m -62.21 -50.32 72.26 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 115.629 -0.714 . . . . 0.0 110.8 179.489 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 40' ' ' LEU . . . . . 0.616 HD12 HD12 ' A' ' 43' ' ' ILE . 44.5 tp -63.06 -44.66 95.19 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 115.644 -0.707 . . . . 0.0 110.922 179.877 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 86.8 t -62.72 -34.04 63.34 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.43 0 CA-C-N 116.043 -0.526 . . . . 0.0 110.076 179.142 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . 0.433 ' O ' HG12 ' A' ' 46' ' ' ILE . . . -60.82 -49.76 75.1 Favored Glycine 0 N--CA 1.448 -0.546 0 CA-C-N 115.461 -0.79 . . . . 0.0 113.197 -179.897 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 43' ' ' ILE . . . . . 0.616 HD12 HD12 ' A' ' 40' ' ' LEU . 22.8 pt -62.29 -48.94 86.04 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.202 0 CA-C-N 117.03 0.415 . . . . 0.0 111.993 -179.296 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 44' ' ' SER . . . . . 0.407 ' N ' HG13 ' A' ' 43' ' ' ILE . 99.0 p -59.52 -29.56 67.96 Favored 'General case' 0 C--O 1.233 0.227 0 CA-C-O 120.993 0.425 . . . . 0.0 111.016 179.961 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -77.65 -54.57 4.54 Favored Glycine 0 N--CA 1.453 -0.207 0 C-N-CA 121.075 -0.583 . . . . 0.0 113.343 -179.07 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 46' ' ' ILE . . . . . 0.446 ' O ' HG21 ' A' ' 49' ' ' VAL . 10.3 pt -58.35 -36.23 57.42 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.248 0 CA-C-O 120.758 0.313 . . . . 0.0 111.143 -179.552 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 47' ' ' ALA . . . . . 0.639 ' HB1' ' HE2' ' A' ' 205' ' ' LYS . . . -68.32 -43.06 78.42 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-O 120.939 0.4 . . . . 0.0 110.443 178.621 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -55.16 -38.17 67.94 Favored 'General case' 0 C--N 1.332 -0.193 0 CA-C-N 115.805 -0.634 . . . . 0.0 111.823 -179.795 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 49' ' ' VAL . . . . . 0.446 HG21 ' O ' ' A' ' 46' ' ' ILE . 17.5 m -76.6 -34.35 23.84 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.221 0 CA-C-O 120.611 0.244 . . . . 0.0 111.457 -179.7 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . 0.4 ' N ' HG23 ' A' ' 49' ' ' VAL . . . -63.64 -38.41 91.03 Favored 'General case' 0 CA--C 1.52 -0.179 0 CA-C-O 121.037 0.446 . . . . 0.0 111.042 179.897 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 28.5 m-85 -72.57 -42.64 64.41 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-N 115.824 -0.625 . . . . 0.0 110.482 -179.773 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -59.99 -53.48 57.37 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-N 115.734 -0.666 . . . . 0.0 110.925 179.681 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 53' ' ' VAL . . . . . 0.431 HG22 ' N ' ' A' ' 54' ' ' MET . 31.3 m -60.21 -48.67 87.16 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.234 0 CA-C-N 116.317 -0.402 . . . . 0.0 110.874 179.936 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 54' ' ' MET . . . . . 0.431 ' N ' HG22 ' A' ' 53' ' ' VAL . 7.0 ttp -60.74 -29.11 69.18 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 121.206 0.527 . . . . 0.0 109.922 179.431 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 55' ' ' ALA . . . . . 0.634 ' HB1' ' HB2' ' A' ' 8' ' ' PHE . . . -75.58 -19.23 59.4 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 115.622 -0.717 . . . . 0.0 111.528 179.62 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 96.8 mt -89.09 -0.83 57.76 Favored 'General case' 0 C--N 1.331 -0.198 0 CA-C-N 116.454 -0.339 . . . . 0.0 111.523 -179.441 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 99.94 -22.56 39.71 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.583 -0.818 . . . . 0.0 113.14 179.521 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 34.0 m -73.05 147.33 9.9 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.202 0 CA-C-N 117.008 0.404 . . . . 0.0 110.568 179.729 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 59' ' ' GLY . . . . . 0.441 ' HA3' ' HD3' ' A' ' 71' ' ' PRO . . . 90.86 13.71 58.9 Favored Glycine 0 N--CA 1.448 -0.525 0 C-N-CA 120.694 -0.765 . . . . 0.0 111.869 -178.934 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 60' ' ' TRP . . . . . . . . . . . . . 13.3 m0 -103.34 98.42 8.33 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-O 121.14 0.495 . . . . 0.0 109.891 -179.978 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 20.8 t -91.4 117.03 67.58 Favored Pre-proline 0 C--N 1.323 -0.56 0 CA-C-N 115.524 -0.762 . . . . 0.0 111.209 -178.972 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 64.8 Cg_endo -73.12 135.9 23.7 Favored 'Trans proline' 0 C--N 1.35 0.617 0 C-N-CA 122.346 2.031 . . . . 0.0 112.435 -179.928 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 46.0 t -135.18 89.05 0.82 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 115.94 -0.573 . . . . 0.0 110.718 179.696 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . 55.97 -88.7 0.02 OUTLIER 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.021 -0.536 . . . . 0.0 111.538 -179.917 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 5.2 mp0 -116.78 -19.25 9.99 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-O 121.009 0.433 . . . . 0.0 110.745 -179.866 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 66' ' ' ARG . . . . . . . . . . . . . 67.8 mtp180 -98.22 166.18 11.52 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 115.677 -0.692 . . . . 0.0 110.564 179.938 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 39.4 m -136.83 125.79 24.29 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.886 0.374 . . . . 0.0 111.381 -179.882 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 11.3 t -109.7 146.31 15.25 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.04 -0.527 . . . . 0.0 110.691 179.767 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 69' ' ' PHE . . . . . . . . . . . . . 27.5 m-85 -108.19 115.24 29.75 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.82 0.343 . . . . 0.0 110.602 -179.717 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 70' ' ' VAL . . . . . 0.603 HG12 ' HD3' ' A' ' 71' ' ' PRO . 1.4 p -69.0 -35.42 6.19 Favored Pre-proline 0 CA--C 1.542 0.651 0 N-CA-C 113.148 0.795 . . . . 0.0 113.148 -179.317 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 71' ' ' PRO . . . . . 0.603 ' HD3' HG12 ' A' ' 70' ' ' VAL . 61.2 Cg_endo -70.49 -18.19 33.74 Favored 'Trans proline' 0 C--N 1.36 1.148 0 C-N-CA 121.741 1.627 . . . . 0.0 112.574 -179.399 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 72' ' ' ARG . . . . . 0.452 ' NH2' HG13 ' A' ' 197' ' ' ILE . 72.4 ttt180 -75.9 -54.49 6.81 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.277 -0.42 . . . . 0.0 111.835 -179.026 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 73' ' ' TYR . . . . . . . . . . . . . 83.4 m-85 -73.34 -35.68 66.06 Favored 'General case' 0 C--N 1.331 -0.21 0 C-N-CA 121.085 -0.246 . . . . 0.0 111.203 -179.103 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 0.3 OUTLIER -67.17 -43.87 88.2 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.238 0 C-N-CA 120.818 -0.353 . . . . 0.0 110.354 179.72 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 20.3 t70 -59.27 -35.87 74.5 Favored 'General case' 0 N--CA 1.455 -0.188 0 N-CA-C 109.267 -0.642 . . . . 0.0 109.267 178.986 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 76' ' ' TRP . . . . . 0.482 ' HB3' ' SD ' ' A' ' 109' ' ' MET . 39.3 m0 -64.0 -36.57 84.41 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 115.702 -0.681 . . . . 0.0 110.577 179.134 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 77' ' ' ILE . . . . . 0.469 ' O ' ' HG2' ' A' ' 81' ' ' PRO . 79.5 mt -67.29 -28.95 44.16 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.239 179.5 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 81.9 mt -91.33 -14.74 30.24 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.068 -0.515 . . . . 0.0 112.023 179.868 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 79' ' ' THR . . . . . 0.404 ' O ' HG12 ' A' ' 83' ' ' ILE . 70.1 p -104.38 -53.3 2.74 Favored 'General case' 0 N--CA 1.463 0.182 0 N-CA-C 113.272 0.842 . . . . 0.0 113.272 -178.652 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 80' ' ' THR . . . . . 0.628 ' HB ' ' HD3' ' A' ' 81' ' ' PRO . 8.9 m -51.75 -55.44 29.98 Favored Pre-proline 0 C--N 1.329 -0.296 0 N-CA-C 113.014 0.746 . . . . 0.0 113.014 -178.033 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 81' ' ' PRO . . . . . 0.628 ' HD3' ' HB ' ' A' ' 80' ' ' THR . 52.7 Cg_exo -56.96 -25.58 63.35 Favored 'Trans proline' 0 C--N 1.352 0.752 0 C-N-CA 121.505 1.47 . . . . 0.0 111.77 -179.799 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 82' ' ' LEU . . . . . 0.404 HD21 HG22 ' A' ' 43' ' ' ILE . 10.9 tp -76.83 -33.16 57.96 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 115.806 -0.634 . . . . 0.0 110.577 179.961 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 83' ' ' ILE . . . . . 0.404 HG12 ' O ' ' A' ' 79' ' ' THR . 43.5 mm -65.99 -52.75 45.27 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.204 0 CA-C-O 120.883 0.373 . . . . 0.0 110.201 179.176 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 33.7 m -61.42 -30.02 47.19 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.256 0 N-CA-C 109.472 -0.566 . . . . 0.0 109.472 178.759 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 85' ' ' TYR . . . . . . . . . . . . . 68.0 t80 -67.75 -30.64 70.16 Favored 'General case' 0 N--CA 1.452 -0.329 0 CA-C-N 115.391 -0.822 . . . . 0.0 109.588 178.568 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 86' ' ' PHE . . . . . . . . . . . . . 3.3 t80 -65.14 -49.78 68.55 Favored 'General case' 0 C--O 1.232 0.172 0 CA-C-N 115.823 -0.626 . . . . 0.0 109.766 179.069 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 6.5 mt -63.87 -30.8 71.85 Favored 'General case' 0 CA--C 1.518 -0.259 0 CA-C-N 115.878 -0.601 . . . . 0.0 109.742 179.468 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -69.86 -29.08 71.18 Favored Glycine 0 N--CA 1.449 -0.455 0 CA-C-N 115.291 -0.868 . . . . 0.0 112.167 179.74 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 54.1 mt -74.04 -38.93 63.85 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-O 120.913 0.387 . . . . 0.0 110.524 179.622 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 94.6 mt -63.71 -35.82 81.81 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.002 -0.545 . . . . 0.0 110.975 179.801 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . 0.402 ' HB3' ' OG ' ' A' ' 148' ' ' SER . . . -80.97 -54.77 5.28 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.351 -179.677 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 101.51 61.56 0.77 Allowed Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.791 -0.719 . . . . 0.0 112.369 -179.668 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 93' ' ' LEU . . . . . 0.475 ' HB3' ' HB2' ' A' ' 97' ' ' GLU . 6.8 mp -80.37 178.37 8.34 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-O 120.797 0.332 . . . . 0.0 110.907 -179.771 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 94' ' ' ASP . . . . . . . . . . . . . 22.4 m-20 -96.15 168.09 10.81 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.658 179.73 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 67.8 m -55.32 -35.09 64.77 Favored 'General case' 0 C--N 1.33 -0.239 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.256 -179.899 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 27.6 tpt180 -69.33 -54.01 16.74 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.412 -0.358 . . . . 0.0 110.895 -179.815 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 97' ' ' GLU . . . . . 0.475 ' HB2' ' HB3' ' A' ' 93' ' ' LEU . 32.9 mt-10 -53.82 -49.55 68.12 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.098 -0.501 . . . . 0.0 111.184 -179.639 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 98' ' ' PHE . . . . . 0.402 ' O ' HG12 ' A' ' 102' ' ' ILE . 25.4 m-85 -55.26 -51.19 67.43 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.397 -0.365 . . . . 0.0 111.002 179.902 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -56.9 -29.89 59.44 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.858 -0.687 . . . . 0.0 112.637 -179.74 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 77.4 mt -72.85 -43.26 60.45 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-O 120.85 0.357 . . . . 0.0 111.308 -179.903 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 61.3 t -68.29 -49.8 63.41 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.355 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.702 -179.435 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 102' ' ' ILE . . . . . 0.402 HG12 ' O ' ' A' ' 98' ' ' PHE . 39.9 mm -58.11 -52.23 61.11 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 CA-C-N 116.317 -0.401 . . . . 0.0 111.584 -179.367 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 14.7 t -58.28 -34.65 70.75 Favored 'General case' 0 C--N 1.331 -0.203 0 CA-C-O 120.746 0.308 . . . . 0.0 110.82 -179.801 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 104' ' ' LEU . . . . . 0.423 HD22 ' HE2' ' A' ' 140' ' ' TYR . 30.5 tp -61.61 -45.83 92.41 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.625 179.224 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 105' ' ' ASN . . . . . 0.574 ' N ' HD21 ' A' ' 105' ' ' ASN . 0.8 OUTLIER -64.83 -26.87 68.52 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.095 -0.502 . . . . 0.0 111.117 -179.818 . . . . . . . . 3 3 . 1 . 029 nuclear orig full ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 99.3 m -66.29 -57.37 7.66 Favored 'General case' 0 C--N 1.331 -0.204 0 CA-C-N 116.548 -0.296 . . . . 0.0 111.351 179.878 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 8.8 p -58.16 -36.32 56.8 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.213 0 CA-C-N 116.383 -0.372 . . . . 0.0 110.862 -179.88 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 59.9 t -64.82 -53.3 43.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.554 179.358 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 109' ' ' MET . . . . . 0.482 ' SD ' ' HB3' ' A' ' 76' ' ' TRP . 5.7 tpp -60.89 -31.06 70.56 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 115.941 -0.572 . . . . 0.0 110.417 179.885 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 11.9 mt -74.44 -30.34 61.85 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 115.976 -0.556 . . . . 0.0 110.267 179.507 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -62.43 -42.52 99.51 Favored 'General case' 0 C--N 1.332 -0.194 0 N-CA-C 109.514 -0.55 . . . . 0.0 109.514 178.607 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . -74.42 -39.18 43.25 Favored Glycine 0 N--CA 1.449 -0.438 0 N-CA-C 111.187 -0.765 . . . . 0.0 111.187 178.748 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 113' ' ' PHE . . . . . . . . . . . . . 0.7 OUTLIER -50.66 -70.92 0.07 Allowed 'General case' 0 C--N 1.332 -0.162 0 N-CA-C 109.539 -0.541 . . . . 0.0 109.539 179.02 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 114' ' ' ALA . . . . . 0.461 ' HA ' ' HB2' ' A' ' 117' ' ' MET . . . -64.13 -21.05 66.39 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 115.387 -0.824 . . . . 0.0 110.947 179.218 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 115' ' ' GLY . . . . . 0.457 ' HA2' HD23 ' A' ' 126' ' ' LEU . . . -52.25 -49.48 50.38 Favored Glycine 0 C--N 1.335 0.508 0 C-N-CA 120.765 -0.731 . . . . 0.0 111.925 179.635 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -78.5 -18.48 54.73 Favored 'General case' 0 C--N 1.325 -0.465 0 CA-C-O 120.85 0.357 . . . . 0.0 110.983 179.392 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 117' ' ' MET . . . . . 0.461 ' HB2' ' HA ' ' A' ' 114' ' ' ALA . 19.9 mmt -84.85 3.78 36.29 Favored 'General case' 0 C--N 1.332 -0.189 0 CA-C-N 116.103 -0.499 . . . . 0.0 112.03 -179.361 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 118' ' ' VAL . . . . . 0.475 HG23 ' HB3' ' A' ' 123' ' ' ARG . 35.5 m -66.31 146.32 99.03 Favored Pre-proline 0 C--N 1.328 -0.364 0 C-N-CA 121.046 -0.262 . . . . 0.0 111.407 -179.588 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 119' ' ' PRO . . . . . . . . . . . . . 92.9 Cg_endo -86.86 -11.35 5.61 Favored 'Trans proline' 0 C--N 1.348 0.535 0 C-N-CA 122.674 2.25 . . . . 0.0 112.226 179.781 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -140.27 -124.98 2.15 Favored Glycine 0 C--N 1.331 0.281 0 C-N-CA 120.84 -0.695 . . . . 0.0 112.795 -179.907 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 2.3 pp -109.94 18.15 7.06 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.187 0 CA-C-O 120.782 0.325 . . . . 0.0 111.695 -179.564 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 42.8 mt-10 -66.47 -18.53 65.41 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.306 -0.407 . . . . 0.0 111.159 -179.9 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 123' ' ' ARG . . . . . 0.475 ' HB3' HG23 ' A' ' 118' ' ' VAL . 17.8 ptt180 -50.47 -34.61 25.52 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.825 -179.516 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 124' ' ' TYR . . . . . . . . . . . . . 29.2 m-85 -61.5 -34.13 74.96 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.766 0.317 . . . . 0.0 111.13 -179.552 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 125' ' ' ALA . . . . . . . . . . . . . . . -74.5 -49.69 21.1 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.908 179.788 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 126' ' ' LEU . . . . . 0.457 HD23 ' HA2' ' A' ' 115' ' ' GLY . 7.3 mp -53.39 -49.15 67.84 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-N 116.051 -0.522 . . . . 0.0 110.588 179.921 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 127' ' ' PHE . . . . . . . . . . . . . 5.4 t80 -67.0 -37.77 84.78 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.821 179.958 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 128' ' ' GLY . . . . . . . . . . . . . . . -46.34 -43.09 13.98 Favored Glycine 0 C--N 1.332 0.338 0 C-N-CA 120.156 -1.021 . . . . 0.0 110.817 179.097 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 129' ' ' MET . . . . . 0.427 ' HE3' ' N ' ' A' ' 130' ' ' GLY . 0.8 OUTLIER -71.81 -39.05 70.11 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.921 0.391 . . . . 0.0 109.971 178.509 . . . . . . . . 3 3 . 1 . 029 nuclear orig full ' A' A ' 130' ' ' GLY . . . . . 0.427 ' N ' ' HE3' ' A' ' 129' ' ' MET . . . -60.95 -32.88 81.57 Favored Glycine 0 C--N 1.333 0.401 0 CA-C-N 115.916 -0.584 . . . . 0.0 113.043 -179.911 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -74.84 -53.87 8.32 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-O 120.669 0.271 . . . . 0.0 110.883 179.959 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 48.2 t -56.4 -40.35 66.54 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.228 0 CA-C-O 121.478 0.656 . . . . 0.0 109.477 179.055 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -68.52 -37.82 80.35 Favored 'General case' 0 N--CA 1.451 -0.424 0 CA-C-N 115.102 -0.954 . . . . 0.0 110.408 179.24 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 134' ' ' PHE . . . . . . . . . . . . . 79.5 t80 -54.64 -51.93 63.87 Favored 'General case' 0 N--CA 1.451 -0.388 0 CA-C-N 116.09 -0.505 . . . . 0.0 109.901 179.387 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 135' ' ' ILE . . . . . 0.46 ' O ' HG21 ' A' ' 138' ' ' VAL . 56.5 mt -58.75 -33.55 49.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 115.647 -0.706 . . . . 0.0 110.046 179.068 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . -58.4 -36.35 83.55 Favored Glycine 0 N--CA 1.449 -0.449 0 C-N-CA 120.239 -0.982 . . . . 0.0 111.136 178.616 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 137' ' ' LEU . . . . . . . . . . . . . 38.4 tp -71.1 -53.15 15.64 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 115.769 -0.216 . . . . 0.0 110.805 179.494 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 138' ' ' VAL . . . . . 0.46 HG21 ' O ' ' A' ' 135' ' ' ILE . 3.3 m -55.97 -32.55 33.38 Favored 'Isoleucine or valine' 0 C--O 1.232 0.137 0 CA-C-O 121.233 0.539 . . . . 0.0 109.863 179.483 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 139' ' ' TYR . . . . . . . . . . . . . 34.4 t80 -60.3 -50.15 74.78 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 115.5 -0.773 . . . . 0.0 110.303 178.894 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 140' ' ' TYR . . . . . 0.423 ' HE2' HD22 ' A' ' 104' ' ' LEU . 22.4 m-85 -56.9 -35.41 68.96 Favored 'General case' 0 C--N 1.332 -0.152 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.741 179.64 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 141' ' ' LEU . . . . . . . . . . . . . 96.0 mt -57.73 -52.0 67.23 Favored 'General case' 0 C--N 1.332 -0.172 0 CA-C-N 116.355 -0.384 . . . . 0.0 110.504 179.602 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 10.2 t -78.48 -10.35 12.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.09 -0.505 . . . . 0.0 110.778 179.672 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . -71.58 -131.39 0.11 Allowed Glycine 0 CA--C 1.521 0.45 0 C-N-CA 120.886 -0.673 . . . . 0.0 112.677 -179.887 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 144' ' ' PRO . . . . . . . . . . . . . 44.8 Cg_endo -67.84 -24.09 40.71 Favored 'Trans proline' 0 C--N 1.348 0.542 0 C-N-CA 122.403 2.069 . . . . 0.0 112.5 -179.888 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 145' ' ' MET . . . . . . . . . . . . . 45.2 mtt -55.41 -34.62 64.57 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 120.983 0.421 . . . . 0.0 111.063 179.876 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 146' ' ' THR . . . . . . . . . . . . . 27.4 m -70.78 -45.82 64.02 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 115.991 -0.55 . . . . 0.0 112.077 -179.181 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 46.3 mt-10 -72.22 -29.51 64.03 Favored 'General case' 0 C--N 1.328 -0.345 0 N-CA-C 111.846 0.313 . . . . 0.0 111.846 -179.101 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 148' ' ' SER . . . . . 0.402 ' OG ' ' HB3' ' A' ' 91' ' ' ALA . 42.0 p -70.15 -45.04 67.6 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.551 -0.295 . . . . 0.0 111.488 -179.241 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 149' ' ' ALA . . . . . . . . . . . . . . . -77.98 -39.84 41.13 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.772 0.32 . . . . 0.0 111.79 -179.514 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 150' ' ' SER . . . . . . . . . . . . . 40.3 t -65.82 -5.09 7.9 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.284 -0.416 . . . . 0.0 111.517 -179.536 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 151' ' ' GLN . . . . . . . . . . . . . 48.4 mt-30 -127.1 17.44 7.2 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.614 -0.266 . . . . 0.0 111.232 179.876 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 25.2 tpt180 -93.82 -52.04 4.62 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-O 120.817 0.341 . . . . 0.0 111.074 179.944 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 153' ' ' SER . . . . . 0.567 ' HB3' HG12 ' A' ' 156' ' ' ILE . 23.1 t -157.38 172.57 18.35 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.581 179.466 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 154' ' ' SER . . . . . . . . . . . . . 47.6 t -70.39 -39.8 74.33 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.773 0.32 . . . . 0.0 110.949 179.961 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -76.95 -34.7 41.54 Favored Glycine 0 CA--C 1.518 0.254 0 C-N-CA 120.862 -0.685 . . . . 0.0 112.986 -179.899 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 156' ' ' ILE . . . . . 0.567 HG12 ' HB3' ' A' ' 153' ' ' SER . 38.5 mm -54.46 -38.18 40.4 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 CA-C-O 120.605 0.24 . . . . 0.0 111.492 -179.664 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 157' ' ' LYS . . . . . . . . . . . . . 27.2 ttpp -68.22 -31.98 71.87 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.41 -0.359 . . . . 0.0 111.371 -179.724 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 53.5 m -71.39 -48.5 49.56 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-O 120.898 0.38 . . . . 0.0 111.411 -179.631 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 159' ' ' LEU . . . . . 0.485 HD22 ' HB1' ' A' ' 215' ' ' ALA . 14.3 mt -71.16 -35.48 71.67 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.607 -179.637 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 160' ' ' TYR . . . . . . . . . . . . . 76.3 t80 -64.95 -44.86 88.04 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.471 -0.331 . . . . 0.0 111.874 -179.098 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 31.0 m -67.35 -46.28 84.06 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 N-CA-C 111.927 0.343 . . . . 0.0 111.927 -179.172 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 162' ' ' ARG . . . . . . . . . . . . . 78.5 mtm180 -64.78 -35.9 82.57 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.73 0.3 . . . . 0.0 111.529 -179.631 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 163' ' ' LEU . . . . . 0.553 ' HG ' ' HB2' ' A' ' 208' ' ' PHE . 7.7 mp -76.87 -51.37 11.38 Favored 'General case' 0 C--N 1.328 -0.349 0 N-CA-C 112.179 0.437 . . . . 0.0 112.179 -179.074 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 164' ' ' ARG . . . . . 0.403 ' HG3' ' N ' ' A' ' 165' ' ' ASN . 5.6 ppt_? -62.11 -41.68 98.47 Favored 'General case' 0 C--N 1.328 -0.331 0 N-CA-C 112.064 0.394 . . . . 0.0 112.064 -178.514 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 165' ' ' ASN . . . . . 0.423 ' O ' HG11 ' A' ' 168' ' ' VAL . 17.4 m-80 -69.38 -51.38 37.18 Favored 'General case' 0 C--N 1.332 -0.188 0 CA-C-O 120.696 0.284 . . . . 0.0 111.616 -179.788 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 166' ' ' LEU . . . . . 0.471 ' O ' ' HG ' ' A' ' 170' ' ' LEU . 4.2 tt -60.32 -51.33 69.97 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-O 120.844 0.354 . . . . 0.0 111.421 -179.601 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 167' ' ' THR . . . . . . . . . . . . . 88.3 m -59.91 -52.54 64.98 Favored 'General case' 0 C--N 1.329 -0.317 0 N-CA-C 112.923 0.712 . . . . 0.0 112.923 -178.826 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 168' ' ' VAL . . . . . 0.423 HG11 ' O ' ' A' ' 165' ' ' ASN . 8.9 p -54.32 -40.28 47.44 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.195 0 N-CA-C 112.297 0.48 . . . . 0.0 112.297 -178.546 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 169' ' ' VAL . . . . . 0.41 ' N ' HG13 ' A' ' 168' ' ' VAL . 79.1 t -62.03 -64.37 0.65 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-N 116.574 -0.285 . . . . 0.0 111.621 -179.721 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 170' ' ' LEU . . . . . 0.471 ' HG ' ' O ' ' A' ' 166' ' ' LEU . 1.2 pp -60.59 -30.96 70.14 Favored 'General case' 0 C--N 1.33 -0.272 0 N-CA-C 111.97 0.359 . . . . 0.0 111.97 -179.011 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 171' ' ' TRP . . . . . 0.439 ' HE1' H201 ' A' ' 301' ' ' RET . 3.2 m0 -70.32 -35.09 73.42 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-O 120.928 0.394 . . . . 0.0 110.383 179.431 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 172' ' ' ALA . . . . . . . . . . . . . . . -69.3 -7.28 35.67 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 115.844 -0.617 . . . . 0.0 110.801 -179.793 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 173' ' ' ILE . . . . . 0.545 HG22 HD12 ' A' ' 177' ' ' ILE . 43.6 mm -84.78 -23.53 7.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 115.917 -0.583 . . . . 0.0 110.736 179.536 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 174' ' ' TYR . . . . . 0.411 ' HB2' ' HD3' ' A' ' 175' ' ' PRO . 22.2 m-85 -54.41 -51.16 80.48 Favored Pre-proline 0 N--CA 1.464 0.254 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.768 -179.89 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 175' ' ' PRO . . . . . 0.411 ' HD3' ' HB2' ' A' ' 174' ' ' TYR . 87.5 Cg_exo -46.84 -29.07 7.62 Favored 'Trans proline' 0 C--N 1.352 0.752 0 C-N-CA 122.225 1.95 . . . . 0.0 112.387 -179.905 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 176' ' ' PHE . . . . . 0.478 ' O ' ' HG ' ' A' ' 180' ' ' LEU . 81.0 m-85 -80.6 -49.81 10.8 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 115.992 -0.549 . . . . 0.0 111.802 -179.893 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 177' ' ' ILE . . . . . 0.545 HD12 HG22 ' A' ' 173' ' ' ILE . 2.4 mm -61.19 -37.15 76.83 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.54 0 CA-C-N 116.201 -0.454 . . . . 0.0 112.133 -178.043 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 178' ' ' TRP . . . . . . . . . . . . . 63.8 t90 -73.45 -41.08 63.66 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-O 120.84 0.352 . . . . 0.0 110.637 179.628 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 179' ' ' LEU . . . . . 0.436 HD12 HD22 ' A' ' 180' ' ' LEU . 2.6 tm? -68.54 -54.07 19.02 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 115.97 -0.559 . . . . 0.0 111.259 -179.426 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 180' ' ' LEU . . . . . 0.478 ' HG ' ' O ' ' A' ' 176' ' ' PHE . 11.9 mt -72.58 -46.49 54.05 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.541 -0.3 . . . . 0.0 111.489 -179.408 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 181' ' ' GLY . . . . . 0.406 ' HA3' ' OD1' ' A' ' 193' ' ' ASP . . . -55.1 173.13 0.99 Allowed Glycine 0 C--N 1.336 0.557 0 C-N-CA 120.558 -0.829 . . . . 0.0 112.682 179.865 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 182' ' ' PRO . . . . . 0.628 ' HA ' ' HB2' ' A' ' 186' ' ' ALA . 82.9 Cg_exo -47.78 -44.67 26.17 Favored 'Trans proline' 0 C--N 1.347 0.49 0 C-N-CA 122.776 2.317 . . . . 0.0 113.611 179.87 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 183' ' ' PRO . . . . . 0.432 ' HD3' ' HB2' ' A' ' 182' ' ' PRO . 57.6 Cg_exo -52.65 -14.85 3.6 Favored 'Trans proline' 0 C--N 1.355 0.877 0 C-N-CA 121.982 1.788 . . . . 0.0 112.551 179.633 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 184' ' ' GLY . . . . . . . . . . . . . . . -115.08 -81.03 0.93 Allowed Glycine 0 N--CA 1.45 -0.373 0 C-N-CA 120.776 -0.726 . . . . 0.0 112.678 -179.982 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 185' ' ' VAL . . . . . . . . . . . . . 6.3 m -132.05 -2.9 1.85 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.208 0 N-CA-C 112.409 0.522 . . . . 0.0 112.409 -179.572 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 186' ' ' ALA . . . . . 0.628 ' HB2' ' HA ' ' A' ' 182' ' ' PRO . . . 53.02 87.31 0.04 OUTLIER 'General case' 0 C--N 1.331 -0.22 0 CA-C-O 120.723 0.297 . . . . 0.0 111.642 179.78 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 187' ' ' LEU . . . . . 0.428 HD13 HD23 ' A' ' 180' ' ' LEU . 18.6 mt -92.01 -49.82 6.02 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 120.838 0.351 . . . . 0.0 111.406 179.934 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 188' ' ' LEU . . . . . . . . . . . . . 38.8 mt -94.84 -89.45 0.23 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.087 -0.506 . . . . 0.0 111.412 -179.325 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 189' ' ' THR . . . . . . . . . . . . . 1.1 t -165.36 148.34 6.93 Favored Pre-proline 0 C--N 1.325 -0.461 0 CA-C-N 115.856 -0.611 . . . . 0.0 111.06 -179.56 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 190' ' ' PRO . . . . . . . . . . . . . 12.1 Cg_endo -55.83 -30.31 76.17 Favored 'Trans proline' 0 C--N 1.347 0.494 0 C-N-CA 122.513 2.142 . . . . 0.0 112.427 -179.994 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 191' ' ' THR . . . . . . . . . . . . . 77.9 p -64.56 -45.28 87.78 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 121.012 0.434 . . . . 0.0 110.686 179.682 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 192' ' ' VAL . . . . . . . . . . . . . 25.4 t -73.89 -38.47 50.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 115.81 -0.632 . . . . 0.0 111.056 179.857 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 193' ' ' ASP . . . . . 0.436 ' OD1' HG22 ' A' ' 177' ' ' ILE . 14.5 t70 -59.49 -51.51 69.56 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.9 179.8 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 194' ' ' VAL . . . . . . . . . . . . . 94.6 t -64.34 -36.37 76.96 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-N 116.02 -0.536 . . . . 0.0 111.185 -179.896 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 195' ' ' ALA . . . . . . . . . . . . . . . -57.64 -48.68 78.79 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.695 0.283 . . . . 0.0 111.092 179.92 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 196' ' ' LEU . . . . . . . . . . . . . 63.0 mt -68.44 -43.27 77.47 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 116.389 -0.369 . . . . 0.0 110.589 179.617 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 197' ' ' ILE . . . . . 0.538 HD11 ' HB ' ' A' ' 177' ' ' ILE . 17.2 mm -56.2 -59.34 2.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 115.944 -0.571 . . . . 0.0 110.56 179.416 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 198' ' ' VAL . . . . . . . . . . . . . 61.0 t -52.3 -35.39 19.63 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.505 0 CA-C-N 115.594 -0.73 . . . . 0.0 109.433 178.62 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 199' ' ' TYR . . . . . . . . . . . . . 67.3 t80 -70.58 -31.14 68.04 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 115.244 -0.889 . . . . 0.0 110.916 -179.904 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 200' ' ' LEU . . . . . 0.436 ' O ' HG13 ' A' ' 203' ' ' VAL . 37.1 mt -71.88 -40.23 69.06 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 115.902 -0.59 . . . . 0.0 111.544 -179.545 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 201' ' ' ASP . . . . . . . . . . . . . 14.7 m-20 -72.81 -34.87 67.15 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-O 121.237 0.542 . . . . 0.0 110.114 179.519 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 202' ' ' LEU . . . . . 0.459 ' HG ' ' HE1' ' A' ' 15' ' ' MET . 2.5 mt -73.01 -29.28 62.91 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 115.415 -0.811 . . . . 0.0 111.601 -179.634 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 203' ' ' VAL . . . . . 0.436 HG13 ' O ' ' A' ' 200' ' ' LEU . 12.5 p -77.6 -36.25 22.77 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.382 0 C-N-CA 121.045 -0.262 . . . . 0.0 110.669 -179.083 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 204' ' ' THR . . . . . . . . . . . . . 98.6 m -65.49 -58.79 4.97 Favored 'General case' 0 C--N 1.329 -0.307 0 C-N-CA 120.596 -0.442 . . . . 0.0 110.994 179.306 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 205' ' ' LYS . . . . . 0.639 ' HE2' ' HB1' ' A' ' 47' ' ' ALA . 61.5 mttp -63.27 -58.1 8.27 Favored 'General case' 0 C--N 1.33 -0.24 0 N-CA-C 112.461 0.541 . . . . 0.0 112.461 -178.259 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 44.6 t -69.97 -37.54 72.94 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.412 0 N-CA-C 112.235 0.458 . . . . 0.0 112.235 -178.751 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 207' ' ' GLY . . . . . 0.504 ' O ' HG13 ' A' ' 211' ' ' ILE . . . -58.22 -61.83 6.97 Favored Glycine 0 CA--C 1.52 0.365 0 C-N-CA 120.67 -0.776 . . . . 0.0 114.059 -178.486 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 208' ' ' PHE . . . . . 0.553 ' HB2' ' HG ' ' A' ' 163' ' ' LEU . 0.9 OUTLIER -73.41 -27.04 61.24 Favored 'General case' 0 C--O 1.221 -0.414 0 CA-C-N 117.47 0.635 . . . . 0.0 110.802 -179.14 . . . . . . . . 3 3 . 1 . 029 nuclear orig full ' A' A ' 209' ' ' GLY . . . . . 0.485 ' O ' ' HB3' ' A' ' 212' ' ' ALA . . . -63.19 -32.39 83.99 Favored Glycine 0 N--CA 1.447 -0.626 0 N-CA-C 111.663 -0.575 . . . . 0.0 111.663 178.616 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 210' ' ' PHE . . . . . . . . . . . . . 1.3 m-85 -75.08 -46.91 31.52 Favored 'General case' 0 CA--C 1.514 -0.439 0 N-CA-C 108.37 -0.974 . . . . 0.0 108.37 178.336 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 211' ' ' ILE . . . . . 0.504 HG13 ' O ' ' A' ' 207' ' ' GLY . 4.1 mt -63.41 -27.59 43.34 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.411 0 N-CA-C 107.473 -1.306 . . . . 0.0 107.473 176.67 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 212' ' ' ALA . . . . . 0.485 ' HB3' ' O ' ' A' ' 209' ' ' GLY . . . -63.79 -41.23 97.98 Favored 'General case' 0 N--CA 1.45 -0.461 0 CA-C-N 114.303 -1.317 . . . . 0.0 110.634 -179.772 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 213' ' ' LEU . . . . . . . . . . . . . 72.9 mt -70.12 -50.17 43.43 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 115.179 -0.919 . . . . 0.0 111.783 -179.393 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 214' ' ' ASP . . . . . . . . . . . . . 21.7 t70 -53.24 -51.83 60.94 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.331 -0.395 . . . . 0.0 111.581 -179.315 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 215' ' ' ALA . . . . . 0.485 ' HB1' HD22 ' A' ' 159' ' ' LEU . . . -64.63 -55.32 20.99 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.379 -0.373 . . . . 0.0 111.772 -179.54 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 216' ' ' ALA . . . . . 0.477 ' HA ' HD12 ' A' ' 219' ' ' LEU . . . -51.87 -37.07 50.78 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 116.414 -0.357 . . . . 0.0 111.496 -179.707 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 217' ' ' ALA . . . . . . . . . . . . . . . -63.65 -44.26 94.36 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.997 0.427 . . . . 0.0 110.06 179.577 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 218' ' ' THR . . . . . 0.405 ' HA ' ' HB1' ' A' ' 221' ' ' ALA . 54.3 m -63.67 -37.42 87.28 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 115.669 -0.696 . . . . 0.0 110.626 179.376 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 219' ' ' LEU . . . . . 0.477 HD12 ' HA ' ' A' ' 216' ' ' ALA . 93.7 mt -56.62 -50.21 72.69 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 115.951 -0.568 . . . . 0.0 110.739 179.98 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 220' ' ' ARG . . . . . . . . . . . . . 13.9 ptm180 -83.42 -10.33 58.47 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.333 -0.394 . . . . 0.0 111.006 179.831 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 221' ' ' ALA . . . . . 0.405 ' HB1' ' HA ' ' A' ' 218' ' ' THR . . . -82.68 -20.13 36.75 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.371 -0.377 . . . . 0.0 111.952 -179.958 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 222' ' ' GLU . . . . . . . . . . . . . 10.7 pt-20 -90.73 -32.04 16.32 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-O 120.648 0.261 . . . . 0.0 111.288 -179.583 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 223' ' ' HIS . . . . . . . . . . . . . 1.7 p-80 -128.99 174.24 9.71 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.724 0.297 . . . . 0.0 111.078 179.851 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 224' ' ' GLY . . . . . . . . . . . . . . . -114.32 -59.15 0.38 Allowed Glycine 0 N--CA 1.452 -0.283 0 C-N-CA 120.702 -0.761 . . . . 0.0 112.462 179.93 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 225' ' ' GLU . . . . . . . . . . . . . 9.8 tp10 58.53 99.64 0.02 OUTLIER 'General case' 0 C--N 1.332 -0.162 0 CA-C-O 120.888 0.375 . . . . 0.0 111.05 179.998 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 226' ' ' SER . . . . . . . . . . . . . 80.9 p -150.33 148.06 28.37 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.888 179.888 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 227' ' ' LEU . . . . . . . . . . . . . 97.1 mt -87.83 140.99 28.95 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.837 179.99 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 228' ' ' ALA . . . . . . . . . . . . . . . 50.76 91.07 0.02 OUTLIER 'General case' 0 C--N 1.331 -0.203 0 CA-C-N 116.079 -0.51 . . . . 0.0 111.552 -179.786 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 229' ' ' GLY . . . . . . . . . . . . . . . -117.73 134.97 11.42 Favored Glycine 0 C--N 1.332 0.311 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.593 -179.872 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 230' ' ' VAL . . . . . . . . . . . . . 28.7 m -101.73 147.75 8.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-O 120.833 0.349 . . . . 0.0 111.101 179.906 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 231' ' ' ASP . . . . . . . . . . . . . 18.5 t70 -101.46 102.79 13.63 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.061 -179.82 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 232' ' ' THR . . . . . . . . . . . . . 80.7 p -139.22 152.68 47.54 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.138 179.871 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 233' ' ' ASP . . . . . . . . . . . . . 29.2 m-20 -109.51 -58.52 2.03 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.849 179.818 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 234' ' ' THR . . . . . . . . . . . . . 85.5 m -127.95 101.89 22.55 Favored Pre-proline 0 C--N 1.329 -0.298 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.157 -179.935 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 235' ' ' PRO . . . . . . . . . . . . . 60.4 Cg_endo -72.35 163.58 38.2 Favored 'Trans proline' 0 C--N 1.349 0.576 0 C-N-CA 122.482 2.121 . . . . 0.0 112.333 179.856 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 236' ' ' ALA . . . . . 0.454 ' HB1' ' HG2' ' A' ' 241' ' ' GLU . . . -93.67 130.05 39.74 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 116.124 -0.489 . . . . 0.0 111.083 179.915 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 237' ' ' VAL . . . . . . . . . . . . . 13.4 p -90.81 145.34 7.54 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.222 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.987 -179.886 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 238' ' ' ALA . . . . . . . . . . . . . . . 60.13 -178.94 0.1 Allowed 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.258 -179.929 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 239' ' ' ASP . . . . . . . . . . . . . 4.5 p30 -107.08 -0.18 23.08 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.121 -0.491 . . . . 0.0 110.869 -179.958 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 240' ' ' LEU . . . . . . . . . . . . . 1.9 pp -86.63 -7.29 58.46 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.242 -0.436 . . . . 0.0 111.098 179.943 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 241' ' ' GLU . . . . . 0.454 ' HG2' ' HB1' ' A' ' 236' ' ' ALA . 9.3 tp10 -64.02 122.89 17.63 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.741 179.828 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 242' ' ' HIS . . . . . 0.505 ' HD1' ' HE2' ' A' ' 244' ' ' HIS . 88.7 m-70 -67.29 149.09 50.84 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.822 179.94 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 243' ' ' HIS . . . . . . . . . . . . . 26.3 p80 -148.71 -11.56 0.34 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.05 -0.523 . . . . 0.0 110.907 -179.949 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 244' ' ' HIS . . . . . 0.505 ' HE2' ' HD1' ' A' ' 242' ' ' HIS . 13.1 p80 -82.33 136.84 34.94 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.055 -0.52 . . . . 0.0 110.963 -179.941 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 245' ' ' HIS . . . . . . . . . . . . . 47.8 m80 58.81 -176.11 0.09 Allowed 'General case' 0 C--N 1.332 -0.186 0 CA-C-N 116.074 -0.512 . . . . 0.0 111.077 179.957 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 246' ' ' HIS . . . . . . . . . . . . . 36.5 m-70 -74.87 -50.11 18.12 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.057 179.978 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 247' ' ' HIS . . . . . . . . . . . . . 7.9 p80 . . . . . 0 C--O 1.248 1.021 0 CA-C-O 118.106 -0.949 . . . . 0.0 111.105 -179.847 . . . . . . . . 0 0 . 1 . 029 nuclear orig full ' A' A ' 301' ' ' RET . . . . . 0.439 H201 ' HE1' ' A' ' 171' ' ' TRP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 80.2 mtp . . . . . 0 N--CA 1.485 1.277 0 CA-C-O 120.651 0.263 . . . . 0.0 110.808 . . . . . . . . . 0 0 . 1 . 030 nuclear orig full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 30.2 m -119.64 -29.56 1.8 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.373 -0.376 . . . . 0.0 111.22 -179.876 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -84.39 -25.84 41.87 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.481 179.926 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 55.3 tp -74.26 -35.84 63.82 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.904 0.383 . . . . 0.0 110.801 179.785 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 68.3 p -64.22 -29.67 70.76 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 115.935 -0.575 . . . . 0.0 111.569 -179.74 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 6' ' ' THR . . . . . 0.54 ' HG1' HD22 ' A' ' 7' ' ' LEU . 29.9 p -52.8 -38.07 60.67 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.601 -179.52 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 7' ' ' LEU . . . . . 0.54 HD22 ' HG1' ' A' ' 6' ' ' THR . 3.4 mm? -59.4 -53.27 60.09 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.475 -0.33 . . . . 0.0 110.84 -179.798 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 8' ' ' PHE . . . . . 0.44 ' O ' ' HB3' ' A' ' 51' ' ' TYR . 73.9 m-85 -58.43 -36.2 73.28 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.594 179.879 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 9' ' ' TRP . . . . . . . . . . . . . 25.4 m95 -64.94 -41.03 95.87 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-O 121.161 0.505 . . . . 0.0 110.151 179.825 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 83.1 mt -62.35 -49.51 75.3 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 115.562 -0.744 . . . . 0.0 110.519 179.512 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -55.21 -34.81 59.19 Favored Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.683 -0.77 . . . . 0.0 111.999 179.291 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -67.86 -36.23 79.94 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-O 120.795 0.331 . . . . 0.0 110.847 179.745 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 91.1 mt -60.28 -54.16 38.79 Favored 'Isoleucine or valine' 0 C--O 1.234 0.241 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.668 179.556 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -63.02 -30.64 78.1 Favored Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 120.688 -0.768 . . . . 0.0 111.871 179.478 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 15' ' ' MET . . . . . 0.534 ' HB3' ' HB3' ' A' ' 48' ' ' ALA . 0.0 OUTLIER -64.46 -48.93 73.42 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.666 0.27 . . . . 0.0 110.835 179.656 . . . . . . . . 3 3 . 1 . 030 nuclear orig full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -57.7 -41.3 81.42 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.334 -0.393 . . . . 0.0 110.94 179.73 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 96.5 t -59.33 -42.57 87.73 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.25 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.554 179.503 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -70.44 -46.73 46.88 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.845 -0.693 . . . . 0.0 112.1 179.588 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 20.5 m -49.5 -45.39 47.03 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-O 120.78 0.324 . . . . 0.0 111.134 -179.755 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 68.3 mt -71.51 -36.74 71.17 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.099 179.618 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -64.09 -31.85 73.19 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.316 -0.402 . . . . 0.0 111.537 -179.801 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 22' ' ' PHE . . . . . 0.438 ' HB2' HG21 ' A' ' 41' ' ' VAL . 7.5 m-85 -90.28 -28.4 18.82 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-O 120.813 0.34 . . . . 0.0 110.939 -179.688 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -72.28 -50.56 26.17 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.176 -0.465 . . . . 0.0 111.288 -179.784 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 24' ' ' TRP . . . . . . . . . . . . . 5.5 t-105 -64.73 -40.07 94.7 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-N 115.73 -0.668 . . . . 0.0 111.195 -179.641 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -80.42 -22.32 41.33 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 120.855 0.36 . . . . 0.0 110.936 179.622 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -73.64 -43.65 35.43 Favored Glycine 0 C--N 1.332 0.334 0 C-N-CA 120.928 -0.653 . . . . 0.0 112.485 179.926 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 82.7 mtp180 -60.71 -20.8 61.97 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-O 120.897 0.379 . . . . 0.0 110.627 179.835 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 23.9 t70 -114.43 92.57 4.0 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.017 -0.538 . . . . 0.0 110.746 179.823 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -163.03 -171.46 2.67 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.139 -179.862 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -72.97 -121.03 0.07 OUTLIER Glycine 0 N--CA 1.452 -0.263 0 C-N-CA 120.863 -0.684 . . . . 0.0 112.487 179.983 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 50.9 m -134.06 -48.72 0.8 Allowed 'General case' 0 C--N 1.33 -0.249 0 CA-C-O 120.819 0.342 . . . . 0.0 110.844 -179.968 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -75.81 -35.95 43.77 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.809 -0.71 . . . . 0.0 112.464 179.896 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 16.7 mm-40 -65.05 -23.67 67.25 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.562 0.22 . . . . 0.0 111.167 -179.891 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 34' ' ' ARG . . . . . . . . . . . . . 52.9 ttt180 -50.85 -30.74 15.27 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.367 -0.379 . . . . 0.0 111.29 -179.716 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 79.7 ttt180 -60.13 -50.69 72.71 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.294 -0.412 . . . . 0.0 111.011 -179.838 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 73.7 m-85 -61.74 -30.47 70.8 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.091 -0.504 . . . . 0.0 111.211 -179.847 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 37' ' ' TYR . . . . . . . . . . . . . 64.0 m-85 -70.88 -54.08 12.77 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.281 -0.418 . . . . 0.0 111.141 -179.805 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 61.8 t -56.99 -38.45 60.0 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.223 0 CA-C-O 120.959 0.409 . . . . 0.0 110.654 179.86 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 20.5 m -65.39 -51.18 62.15 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 115.832 -0.622 . . . . 0.0 110.864 179.645 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 40' ' ' LEU . . . . . 0.494 HD11 HD11 ' A' ' 43' ' ' ILE . 38.0 tp -56.98 -46.84 81.95 Favored 'General case' 0 C--O 1.236 0.343 0 CA-C-N 115.894 -0.593 . . . . 0.0 110.578 179.721 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . 0.438 HG21 ' HB2' ' A' ' 22' ' ' PHE . 62.9 t -60.26 -34.28 56.76 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.326 0 CA-C-N 115.857 -0.61 . . . . 0.0 110.3 179.083 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -61.27 -39.3 97.01 Favored Glycine 0 N--CA 1.448 -0.539 0 C-N-CA 120.743 -0.742 . . . . 0.0 111.988 179.925 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 43' ' ' ILE . . . . . 0.494 HD11 HD11 ' A' ' 40' ' ' LEU . 0.7 OUTLIER -65.13 -56.59 14.87 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.223 0 CA-C-O 120.827 0.346 . . . . 0.0 110.998 179.797 . . . . . . . . 3 3 . 1 . 030 nuclear orig full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 36.3 t -57.24 -27.6 62.17 Favored 'General case' 0 C--N 1.332 -0.156 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.431 -179.747 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -76.2 -53.57 5.59 Favored Glycine 0 CA--C 1.519 0.342 0 C-N-CA 120.664 -0.779 . . . . 0.0 113.327 -179.288 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 19.7 pt -58.34 -40.03 76.5 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.168 0 CA-C-O 120.738 0.304 . . . . 0.0 111.522 -179.418 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 47' ' ' ALA . . . . . 0.669 ' HB2' ' HE2' ' A' ' 205' ' ' LYS . . . -67.44 -43.67 80.56 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-N 116.436 -0.347 . . . . 0.0 111.364 179.603 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 48' ' ' ALA . . . . . 0.534 ' HB3' ' HB3' ' A' ' 15' ' ' MET . . . -55.1 -43.76 74.32 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.079 -0.51 . . . . 0.0 111.831 -179.423 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 28.4 m -73.8 -33.89 38.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.454 -0.339 . . . . 0.0 111.503 -179.428 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -65.35 -38.54 90.39 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-O 120.927 0.394 . . . . 0.0 111.148 179.74 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 51' ' ' TYR . . . . . 0.44 ' HB3' ' O ' ' A' ' 8' ' ' PHE . 29.0 m-85 -73.06 -35.56 66.71 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 116.132 -0.486 . . . . 0.0 110.756 -179.736 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -63.9 -42.22 97.51 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.291 -0.413 . . . . 0.0 110.938 179.263 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 53' ' ' VAL . . . . . 0.416 HG21 ' N ' ' A' ' 54' ' ' MET . 21.7 m -74.87 -45.1 44.41 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.177 0 CA-C-N 116.271 -0.422 . . . . 0.0 111.42 -179.981 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 54' ' ' MET . . . . . 0.416 ' N ' HG21 ' A' ' 53' ' ' VAL . 70.6 mtm -62.74 -32.01 73.05 Favored 'General case' 0 C--N 1.332 -0.174 0 CA-C-O 120.952 0.406 . . . . 0.0 110.296 179.572 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -63.02 -18.05 62.9 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 115.772 -0.649 . . . . 0.0 111.01 179.476 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 81.8 mt -99.14 -9.16 24.15 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 115.998 -0.546 . . . . 0.0 110.933 179.771 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 73.59 31.1 61.1 Favored Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.809 -0.71 . . . . 0.0 112.96 179.784 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 32.6 m -81.24 14.5 0.45 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-O 120.907 0.384 . . . . 0.0 111.525 179.893 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -151.85 10.27 0.67 Allowed Glycine 0 N--CA 1.45 -0.389 0 C-N-CA 120.882 -0.675 . . . . 0.0 112.734 179.938 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 60' ' ' TRP . . . . . . . . . . . . . 38.4 m0 -78.33 109.52 12.54 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.631 0.253 . . . . 0.0 110.573 179.842 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 7.6 p -102.32 130.75 23.53 Favored Pre-proline 0 C--N 1.329 -0.294 0 CA-C-N 116.431 -0.35 . . . . 0.0 111.255 -179.723 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 7.8 Cg_exo -72.87 144.14 38.18 Favored 'Trans proline' 0 C--N 1.35 0.622 0 C-N-CA 122.675 2.25 . . . . 0.0 112.383 -179.851 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 85.9 t -143.85 96.29 0.53 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.201 0 CA-C-N 115.993 -0.549 . . . . 0.0 111.031 179.968 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . 60.58 -86.15 0.02 OUTLIER 'General case' 0 C--N 1.333 -0.122 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.223 -179.902 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 11.4 tp10 -124.66 -23.93 4.27 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-O 120.927 0.394 . . . . 0.0 110.38 179.793 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 66' ' ' ARG . . . . . . . . . . . . . 96.9 mtt180 -103.13 153.41 20.34 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 115.809 -0.632 . . . . 0.0 110.4 179.739 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 91.2 m -111.94 119.34 38.19 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-O 120.952 0.406 . . . . 0.0 111.671 -179.336 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 68' ' ' VAL . . . . . 0.526 HG13 ' HG3' ' A' ' 117' ' ' MET . 42.4 t -90.52 147.03 5.49 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-N 115.938 -0.574 . . . . 0.0 110.401 179.224 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 69' ' ' PHE . . . . . . . . . . . . . 21.9 m-85 -105.11 114.55 28.82 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-O 121.008 0.432 . . . . 0.0 110.247 -179.367 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 70' ' ' VAL . . . . . 0.545 ' HB ' ' HD3' ' A' ' 71' ' ' PRO . 13.6 t -68.83 -50.09 24.66 Favored Pre-proline 0 C--N 1.325 -0.486 0 CA-C-N 115.937 -0.574 . . . . 0.0 112.471 -178.856 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 71' ' ' PRO . . . . . 0.545 ' HD3' ' HB ' ' A' ' 70' ' ' VAL . 16.4 Cg_exo -66.57 -17.84 53.47 Favored 'Trans proline' 0 C--N 1.351 0.671 0 C-N-CA 122.252 1.968 . . . . 0.0 112.698 -179.304 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 72' ' ' ARG . . . . . 0.418 ' NH2' HG13 ' A' ' 197' ' ' ILE . 66.2 ttt180 -66.25 -55.31 16.76 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-O 120.866 0.365 . . . . 0.0 111.539 -179.346 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 73' ' ' TYR . . . . . 0.465 ' O ' HG13 ' A' ' 77' ' ' ILE . 77.7 m-85 -71.59 -33.76 69.31 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.38 -0.373 . . . . 0.0 110.687 -179.492 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 74' ' ' ILE . . . . . 0.404 ' HA ' HD11 ' A' ' 77' ' ' ILE . 0.4 OUTLIER -67.51 -36.84 77.55 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.2 0 N-CA-C 109.768 -0.456 . . . . 0.0 109.768 179.106 . . . . . . . . 3 3 . 1 . 030 nuclear orig full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 24.0 t70 -60.52 -38.51 84.65 Favored 'General case' 0 CA--C 1.519 -0.219 0 N-CA-C 108.959 -0.756 . . . . 0.0 108.959 178.506 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 76' ' ' TRP . . . . . . . . . . . . . 37.5 m0 -66.72 -30.86 71.2 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 115.438 -0.801 . . . . 0.0 110.468 179.193 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 77' ' ' ILE . . . . . 0.465 HG13 ' O ' ' A' ' 73' ' ' TYR . 82.3 mt -68.58 -31.11 49.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-O 121.017 0.437 . . . . 0.0 110.554 179.241 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 34.4 mt -91.51 -17.55 25.51 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.11 -0.495 . . . . 0.0 112.137 -179.889 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 72.7 p -102.32 -52.77 3.05 Favored 'General case' 0 N--CA 1.464 0.27 0 N-CA-C 113.417 0.895 . . . . 0.0 113.417 -178.238 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 80' ' ' THR . . . . . 0.668 ' HB ' ' HD3' ' A' ' 81' ' ' PRO . 49.8 m -52.39 -56.01 26.49 Favored Pre-proline 0 CA--C 1.532 0.251 0 N-CA-C 112.643 0.608 . . . . 0.0 112.643 -178.306 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 81' ' ' PRO . . . . . 0.668 ' HD3' ' HB ' ' A' ' 80' ' ' THR . 38.8 Cg_exo -58.98 -21.1 56.68 Favored 'Trans proline' 0 C--N 1.351 0.69 0 C-N-CA 121.507 1.471 . . . . 0.0 111.478 -179.942 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 82' ' ' LEU . . . . . . . . . . . . . 15.2 tp -77.03 -33.12 57.42 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 115.699 -0.682 . . . . 0.0 110.328 179.695 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 83' ' ' ILE . . . . . 0.409 HD13 HD13 ' A' ' 43' ' ' ILE . 49.1 mm -69.64 -51.86 37.36 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.166 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.232 179.25 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 35.5 m -61.1 -31.05 48.99 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.227 0 N-CA-C 109.407 -0.59 . . . . 0.0 109.407 178.706 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 85' ' ' TYR . . . . . . . . . . . . . 89.9 t80 -64.43 -34.7 78.79 Favored 'General case' 0 N--CA 1.454 -0.269 0 CA-C-N 115.472 -0.786 . . . . 0.0 109.427 178.601 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 86' ' ' PHE . . . . . . . . . . . . . 12.0 t80 -62.97 -49.6 74.06 Favored 'General case' 0 C--O 1.232 0.146 0 CA-C-N 115.765 -0.652 . . . . 0.0 110.01 179.136 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 87' ' ' LEU . . . . . 0.485 HD12 HD23 ' A' ' 141' ' ' LEU . 5.3 mt -63.59 -33.06 74.78 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 115.733 -0.667 . . . . 0.0 109.852 179.839 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -66.67 -27.52 73.28 Favored Glycine 0 N--CA 1.449 -0.474 0 CA-C-N 115.377 -0.829 . . . . 0.0 111.555 179.251 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 61.9 mt -74.58 -43.78 54.02 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.763 0.316 . . . . 0.0 111.032 179.89 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 82.6 mt -60.47 -32.34 71.31 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.123 -0.489 . . . . 0.0 111.216 -179.94 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . 0.467 ' HB1' ' HG ' ' A' ' 148' ' ' SER . . . -83.83 -54.14 5.1 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.309 -0.405 . . . . 0.0 111.424 -179.732 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 103.93 68.32 0.76 Allowed Glycine 0 N--CA 1.45 -0.369 0 C-N-CA 120.808 -0.71 . . . . 0.0 112.491 -179.706 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 93' ' ' LEU . . . . . 0.563 HD23 ' HB3' ' A' ' 97' ' ' GLU . 6.5 mp -91.23 164.77 13.77 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.712 0.291 . . . . 0.0 110.733 -179.933 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 94' ' ' ASP . . . . . . . . . . . . . 1.8 p30 -87.82 177.43 7.0 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.356 -0.384 . . . . 0.0 110.915 179.807 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 48.1 t -60.39 -32.16 71.04 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.027 -0.533 . . . . 0.0 111.881 -179.418 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 38.8 mmt180 -73.31 -53.31 11.12 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.55 -0.295 . . . . 0.0 111.62 -179.332 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 97' ' ' GLU . . . . . 0.563 ' HB3' HD23 ' A' ' 93' ' ' LEU . 44.0 mt-10 -53.3 -47.25 69.38 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.314 -0.403 . . . . 0.0 111.388 -179.671 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 98' ' ' PHE . . . . . 0.432 ' O ' HG12 ' A' ' 102' ' ' ILE . 12.6 m-85 -58.29 -49.86 75.65 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.373 -0.376 . . . . 0.0 110.876 179.975 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -54.88 -30.45 53.18 Favored Glycine 0 CA--C 1.518 0.255 0 C-N-CA 120.751 -0.737 . . . . 0.0 112.776 -179.81 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 96.3 mt -73.95 -45.53 48.72 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.214 0 CA-C-O 120.841 0.353 . . . . 0.0 111.622 -179.708 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 47.6 t -65.95 -46.74 87.52 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.411 0 CA-C-N 116.147 -0.478 . . . . 0.0 111.91 -179.161 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 102' ' ' ILE . . . . . 0.432 HG12 ' O ' ' A' ' 98' ' ' PHE . 37.6 mm -63.17 -51.77 67.19 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 N-CA-C 111.905 0.335 . . . . 0.0 111.905 -179.101 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 15.2 t -55.95 -36.72 68.1 Favored 'General case' 0 C--O 1.234 0.248 0 CA-C-O 120.869 0.366 . . . . 0.0 110.952 -179.61 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 104' ' ' LEU . . . . . 0.403 ' O ' HG23 ' A' ' 108' ' ' VAL . 29.7 tp -61.37 -47.73 84.5 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.06 -0.518 . . . . 0.0 110.683 179.464 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 105' ' ' ASN . . . . . 0.59 ' N ' HD21 ' A' ' 105' ' ' ASN . 0.8 OUTLIER -61.55 -26.33 67.87 Favored 'General case' 0 C--N 1.326 -0.438 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.745 179.848 . . . . . . . . 3 3 . 1 . 030 nuclear orig full ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 66.2 m -66.46 -57.3 7.65 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 116.374 -0.375 . . . . 0.0 111.331 -179.926 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 9.1 p -58.27 -36.57 58.51 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.142 0 CA-C-O 120.727 0.298 . . . . 0.0 111.114 -179.881 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . 0.403 HG23 ' O ' ' A' ' 104' ' ' LEU . 68.3 t -57.84 -49.58 80.52 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.372 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.519 179.513 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 109' ' ' MET . . . . . 0.439 ' HG2' ' O ' ' A' ' 105' ' ' ASN . 20.6 mmt -64.35 -30.4 71.44 Favored 'General case' 0 CA--C 1.519 -0.248 0 CA-C-N 115.868 -0.605 . . . . 0.0 110.666 179.707 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 19.4 tp -66.34 -35.61 80.8 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.069 179.555 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -64.31 -51.38 63.76 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 115.903 -0.59 . . . . 0.0 110.601 179.462 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 112' ' ' GLY . . . . . 0.427 ' HA3' ' H22' ' A' ' 301' ' ' RET . . . -66.96 -37.33 92.07 Favored Glycine 0 C--N 1.331 0.262 0 C-N-CA 120.576 -0.821 . . . . 0.0 111.861 179.478 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 113' ' ' PHE . . . . . 0.402 ' HB2' ' O ' ' A' ' 109' ' ' MET . 1.0 OUTLIER -51.02 -70.03 0.1 Allowed 'General case' 0 C--N 1.332 -0.161 0 CA-C-O 121.05 0.452 . . . . 0.0 110.02 179.541 . . . . . . . . 3 3 . 1 . 030 nuclear orig full ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -67.43 -19.89 65.43 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 115.663 -0.699 . . . . 0.0 110.748 179.407 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 115' ' ' GLY . . . . . 0.445 ' HA2' HD23 ' A' ' 126' ' ' LEU . . . -53.67 -44.43 69.09 Favored Glycine 0 C--N 1.334 0.441 0 C-N-CA 120.915 -0.659 . . . . 0.0 111.8 179.533 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -78.49 -28.46 46.4 Favored 'General case' 0 C--N 1.327 -0.41 0 N-CA-C 111.639 0.237 . . . . 0.0 111.639 179.741 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 117' ' ' MET . . . . . 0.526 ' HG3' HG13 ' A' ' 68' ' ' VAL . 62.9 mtt -86.08 11.37 11.89 Favored 'General case' 0 N--CA 1.463 0.224 0 N-CA-C 112.16 0.429 . . . . 0.0 112.16 -179.162 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 118' ' ' VAL . . . . . 0.488 HG23 ' HB3' ' A' ' 123' ' ' ARG . 29.9 m -63.64 146.06 96.99 Favored Pre-proline 0 C--N 1.327 -0.374 0 C-N-CA 121.037 -0.265 . . . . 0.0 111.081 179.845 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 119' ' ' PRO . . . . . . . . . . . . . 92.0 Cg_endo -81.99 -4.59 12.01 Favored 'Trans proline' 0 C--N 1.347 0.478 0 C-N-CA 122.534 2.156 . . . . 0.0 112.25 179.821 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -156.43 -132.1 1.46 Allowed Glycine 0 C--N 1.331 0.293 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.735 -179.982 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 2.0 pp -100.31 22.46 1.58 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-O 120.838 0.352 . . . . 0.0 111.265 -179.833 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 10.8 mm-40 -70.72 -19.27 62.76 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.846 179.942 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 123' ' ' ARG . . . . . 0.488 ' HB3' HG23 ' A' ' 118' ' ' VAL . 12.7 ptt180 -50.55 -31.0 14.42 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 115.923 -0.58 . . . . 0.0 111.907 -179.67 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 124' ' ' TYR . . . . . . . . . . . . . 40.2 m-85 -65.13 -35.61 81.65 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.675 0.274 . . . . 0.0 110.919 -179.629 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 125' ' ' ALA . . . . . . . . . . . . . . . -72.74 -51.08 20.64 Favored 'General case' 0 C--O 1.235 0.311 0 CA-C-O 120.849 0.357 . . . . 0.0 110.604 179.248 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 126' ' ' LEU . . . . . 0.445 HD23 ' HA2' ' A' ' 115' ' ' GLY . 7.0 mp -51.55 -52.39 47.52 Favored 'General case' 0 CA--C 1.52 -0.191 0 CA-C-N 116.005 -0.543 . . . . 0.0 110.135 179.488 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 127' ' ' PHE . . . . . 0.474 ' HZ ' ' HB3' ' A' ' 175' ' ' PRO . 8.7 t80 -63.93 -35.79 81.82 Favored 'General case' 0 N--CA 1.451 -0.419 0 CA-C-N 115.848 -0.615 . . . . 0.0 110.533 179.523 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 128' ' ' GLY . . . . . . . . . . . . . . . -46.22 -45.51 15.62 Favored Glycine 0 C--N 1.333 0.38 0 C-N-CA 120.195 -1.002 . . . . 0.0 110.86 179.027 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 129' ' ' MET . . . . . . . . . . . . . 0.6 OUTLIER -69.47 -39.36 77.76 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 115.319 -0.441 . . . . 0.0 109.977 178.586 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -65.15 -27.89 72.89 Favored Glycine 0 C--N 1.331 0.299 0 CA-C-N 115.783 -0.644 . . . . 0.0 112.995 -179.842 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -74.61 -54.01 8.27 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.615 0.245 . . . . 0.0 110.406 -179.964 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 47.2 t -55.83 -40.54 62.31 Favored 'Isoleucine or valine' 0 C--O 1.234 0.241 0 CA-C-O 121.459 0.647 . . . . 0.0 109.285 178.786 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -69.1 -37.8 78.61 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 115.117 -0.947 . . . . 0.0 110.613 179.41 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 134' ' ' PHE . . . . . 0.428 ' CZ ' ' HA ' ' A' ' 172' ' ' ALA . 45.3 t80 -55.45 -52.71 62.72 Favored 'General case' 0 N--CA 1.45 -0.429 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.263 179.748 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 135' ' ' ILE . . . . . . . . . . . . . 43.7 mt -59.58 -32.75 49.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 115.915 -0.584 . . . . 0.0 109.935 179.308 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . -59.43 -40.45 96.14 Favored Glycine 0 N--CA 1.448 -0.535 0 C-N-CA 120.298 -0.954 . . . . 0.0 111.45 178.926 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 137' ' ' LEU . . . . . 0.411 HD13 HD22 ' A' ' 105' ' ' ASN . 22.4 tp -65.87 -53.07 44.5 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-O 120.683 0.277 . . . . 0.0 110.616 179.617 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 138' ' ' VAL . . . . . . . . . . . . . 13.1 t -55.48 -37.48 45.39 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.836 0 CA-C-O 121.114 0.483 . . . . 0.0 110.131 179.183 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 139' ' ' TYR . . . . . . . . . . . . . 29.9 t80 -57.84 -43.22 85.71 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 115.43 -0.805 . . . . 0.0 110.738 179.024 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 28.7 m-85 -64.17 -41.6 97.07 Favored 'General case' 0 C--N 1.332 -0.156 0 CA-C-N 116.406 -0.361 . . . . 0.0 111.467 -179.978 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 141' ' ' LEU . . . . . 0.485 HD23 HD12 ' A' ' 87' ' ' LEU . 95.4 mt -56.24 -50.34 71.59 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 116.42 -0.355 . . . . 0.0 111.143 -179.761 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 142' ' ' VAL . . . . . 0.557 HG23 HH12 ' A' ' 164' ' ' ARG . 7.7 p -83.78 -9.02 11.48 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.369 0 CA-C-O 121.153 0.501 . . . . 0.0 110.59 179.956 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . -73.34 -141.18 0.5 Allowed Glycine 0 CA--C 1.521 0.452 0 C-N-CA 120.881 -0.676 . . . . 0.0 112.579 179.929 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 144' ' ' PRO . . . . . . . . . . . . . 52.2 Cg_exo -54.69 -23.24 32.09 Favored 'Trans proline' 0 C--N 1.349 0.564 0 C-N-CA 122.588 2.192 . . . . 0.0 112.75 179.971 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 145' ' ' MET . . . . . 0.574 ' HB3' ' HH ' ' A' ' 160' ' ' TYR . 37.2 mtt -52.81 -59.22 4.76 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.479 -0.328 . . . . 0.0 111.831 -179.641 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 146' ' ' THR . . . . . . . . . . . . . 11.0 t -61.04 -31.71 71.35 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.423 -0.353 . . . . 0.0 111.588 -179.476 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 29.2 mm-40 -65.13 -44.0 90.11 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 120.839 0.352 . . . . 0.0 111.223 -179.942 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 148' ' ' SER . . . . . 0.467 ' HG ' ' HB1' ' A' ' 91' ' ' ALA . 80.0 p -70.24 -42.28 72.43 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.236 -179.32 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 149' ' ' ALA . . . . . . . . . . . . . . . -65.34 -40.42 93.62 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.377 -179.747 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 150' ' ' SER . . . . . 0.454 ' HA ' ' HB2' ' A' ' 157' ' ' LYS . 83.6 p -68.21 -6.8 25.51 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.784 -179.913 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 151' ' ' GLN . . . . . . . . . . . . . 63.3 mt-30 -110.48 -7.54 14.74 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.119 -0.492 . . . . 0.0 110.914 179.883 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 78.3 ttt180 -75.06 -52.47 10.96 Favored 'General case' 0 C--N 1.332 -0.193 0 CA-C-N 116.443 -0.344 . . . . 0.0 110.831 -179.883 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 153' ' ' SER . . . . . 0.595 ' HB3' HG12 ' A' ' 156' ' ' ILE . 22.8 t -158.04 170.62 21.88 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.667 179.238 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 154' ' ' SER . . . . . . . . . . . . . 51.3 m -70.22 -37.62 75.07 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.288 -0.415 . . . . 0.0 110.392 179.382 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -77.0 -39.0 28.88 Favored Glycine 0 CA--C 1.519 0.298 0 C-N-CA 120.984 -0.627 . . . . 0.0 112.674 179.821 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 156' ' ' ILE . . . . . 0.595 HG12 ' HB3' ' A' ' 153' ' ' SER . 39.6 mm -52.88 -35.65 22.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-O 120.922 0.392 . . . . 0.0 111.315 -179.81 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 157' ' ' LYS . . . . . 0.454 ' HB2' ' HA ' ' A' ' 150' ' ' SER . 86.4 tttt -69.83 -37.23 76.13 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 115.967 -0.561 . . . . 0.0 112.028 -179.436 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 67.6 p -72.05 -45.0 62.46 Favored 'General case' 0 C--N 1.331 -0.205 0 CA-C-O 120.784 0.326 . . . . 0.0 111.601 -178.719 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 159' ' ' LEU . . . . . . . . . . . . . 10.0 mt -67.05 -46.26 74.92 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.632 -179.078 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 160' ' ' TYR . . . . . 0.574 ' HH ' ' HB3' ' A' ' 145' ' ' MET . 55.1 t80 -61.58 -37.82 85.27 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.509 -0.314 . . . . 0.0 111.26 -179.468 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 161' ' ' VAL . . . . . 0.492 HG12 ' N ' ' A' ' 162' ' ' ARG . 1.2 t -63.23 -50.49 78.86 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.747 0 CA-C-N 116.529 -0.305 . . . . 0.0 111.64 -179.487 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 162' ' ' ARG . . . . . 0.492 ' N ' HG12 ' A' ' 161' ' ' VAL . 22.9 tpp180 -69.1 -34.86 75.76 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.44 -0.345 . . . . 0.0 111.439 -179.446 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 163' ' ' LEU . . . . . 0.567 ' HG ' ' HB2' ' A' ' 208' ' ' PHE . 3.2 mp -69.5 -45.02 69.89 Favored 'General case' 0 C--N 1.328 -0.37 0 CA-C-N 116.27 -0.423 . . . . 0.0 111.604 -179.408 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 164' ' ' ARG . . . . . 0.557 HH12 HG23 ' A' ' 142' ' ' VAL . 0.1 OUTLIER -71.95 -41.07 68.23 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.557 -0.292 . . . . 0.0 111.308 -179.125 . . . . . . . . 3 3 . 1 . 030 nuclear orig full ' A' A ' 165' ' ' ASN . . . . . 0.519 HD22 ' HE ' ' A' ' 164' ' ' ARG . 0.9 OUTLIER -57.25 -50.88 71.49 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.795 0.331 . . . . 0.0 111.05 179.953 . . . . . . . . 3 3 . 1 . 030 nuclear orig full ' A' A ' 166' ' ' LEU . . . . . . . . . . . . . 3.8 tt -64.17 -54.59 31.32 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.109 -0.496 . . . . 0.0 111.548 -179.47 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 167' ' ' THR . . . . . 0.426 ' O ' ' HB2' ' A' ' 171' ' ' TRP . 76.5 m -54.81 -53.13 59.21 Favored 'General case' 0 C--N 1.33 -0.277 0 N-CA-C 112.263 0.468 . . . . 0.0 112.263 -179.158 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 168' ' ' VAL . . . . . . . . . . . . . 55.1 t -55.06 -44.93 76.45 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.218 0 N-CA-C 112.328 0.492 . . . . 0.0 112.328 -178.999 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 169' ' ' VAL . . . . . 0.403 HG23 ' O ' ' A' ' 165' ' ' ASN . 43.9 t -55.91 -64.32 0.5 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-O 120.555 0.217 . . . . 0.0 111.544 -179.362 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 170' ' ' LEU . . . . . 0.607 HD11 HG13 ' A' ' 203' ' ' VAL . 1.1 pp -63.41 -28.56 70.06 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.661 -0.245 . . . . 0.0 111.642 -179.39 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 171' ' ' TRP . . . . . 0.456 ' NE1' H202 ' A' ' 301' ' ' RET . 3.5 m0 -70.54 -32.11 69.43 Favored 'General case' 0 C--N 1.333 -0.152 0 CA-C-O 120.998 0.427 . . . . 0.0 110.413 179.418 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 172' ' ' ALA . . . . . 0.428 ' HA ' ' CZ ' ' A' ' 134' ' ' PHE . . . -72.19 -6.68 44.53 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-N 115.822 -0.626 . . . . 0.0 111.102 -179.624 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 173' ' ' ILE . . . . . 0.545 ' O ' HG12 ' A' ' 177' ' ' ILE . 23.8 mm -87.54 -22.57 6.82 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.244 0 CA-C-N 116.083 -0.508 . . . . 0.0 111.17 179.925 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 174' ' ' TYR . . . . . 0.426 ' HB2' ' HD3' ' A' ' 175' ' ' PRO . 30.9 m-85 -53.79 -49.25 90.25 Favored Pre-proline 0 N--CA 1.464 0.265 0 CA-C-N 116.567 -0.288 . . . . 0.0 111.638 -179.537 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 175' ' ' PRO . . . . . 0.474 ' HB3' ' HZ ' ' A' ' 127' ' ' PHE . 86.5 Cg_exo -47.73 -32.97 17.83 Favored 'Trans proline' 0 C--N 1.351 0.677 0 C-N-CA 122.134 1.89 . . . . 0.0 112.164 179.523 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 176' ' ' PHE . . . . . 0.497 ' O ' ' HG ' ' A' ' 180' ' ' LEU . 88.2 m-85 -80.62 -50.36 10.06 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 115.911 -0.586 . . . . 0.0 112.18 -179.531 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 177' ' ' ILE . . . . . 0.545 HG12 ' O ' ' A' ' 173' ' ' ILE . 6.2 mm -60.22 -39.58 81.09 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.548 0 N-CA-C 112.609 0.596 . . . . 0.0 112.609 -177.777 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 178' ' ' TRP . . . . . 0.482 ' HH2' ' HB2' ' A' ' 123' ' ' ARG . 78.4 t90 -67.37 -39.3 85.68 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 120.721 0.296 . . . . 0.0 111.157 -179.669 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 179' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -77.88 -52.89 8.14 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 116.462 -0.335 . . . . 0.0 111.879 -179.01 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 180' ' ' LEU . . . . . 0.552 HD21 HD12 ' A' ' 187' ' ' LEU . 39.8 mt -61.66 -51.7 67.38 Favored 'General case' 0 C--N 1.328 -0.362 0 N-CA-C 111.699 0.259 . . . . 0.0 111.699 -179.114 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 181' ' ' GLY . . . . . 0.422 ' HA3' ' OD1' ' A' ' 193' ' ' ASP . . . -57.03 179.16 0.71 Allowed Glycine 0 C--N 1.336 0.557 0 C-N-CA 120.413 -0.898 . . . . 0.0 112.92 -179.883 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 182' ' ' PRO . . . . . 0.618 ' N ' ' HD2' ' A' ' 183' ' ' PRO . 80.8 Cg_exo -44.06 -46.56 11.04 Favored 'Trans proline' 0 C--N 1.35 0.654 0 C-N-CA 122.925 2.417 . . . . 0.0 113.915 179.865 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 183' ' ' PRO . . . . . 0.618 ' HD2' ' N ' ' A' ' 182' ' ' PRO . 1.0 OUTLIER -44.28 -30.44 3.61 Favored 'Trans proline' 0 C--N 1.358 1.062 0 C-N-CA 122.497 2.131 . . . . 0.0 113.172 -179.758 . . . . . . . . 3 3 . 1 . 030 nuclear orig full ' A' A ' 184' ' ' GLY . . . . . 0.437 ' HA2' ' HD2' ' A' ' 123' ' ' ARG . . . -117.73 -120.75 3.08 Favored Glycine 0 C--N 1.332 0.326 0 C-N-CA 120.392 -0.908 . . . . 0.0 113.19 179.89 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 185' ' ' VAL . . . . . . . . . . . . . 22.6 m -64.92 -16.77 20.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 N-CA-C 112.264 0.468 . . . . 0.0 112.264 -179.405 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 186' ' ' ALA . . . . . . . . . . . . . . . 55.51 88.75 0.04 OUTLIER 'General case' 0 C--N 1.332 -0.17 0 CA-C-O 120.872 0.368 . . . . 0.0 111.266 -179.899 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 187' ' ' LEU . . . . . 0.552 HD12 HD21 ' A' ' 180' ' ' LEU . 19.5 mt -91.8 -33.06 15.12 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.391 -179.603 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 188' ' ' LEU . . . . . 0.422 ' HB2' ' H ' ' A' ' 189' ' ' THR . 0.0 OUTLIER -134.27 -162.07 1.21 Allowed 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.868 0.366 . . . . 0.0 111.501 -179.494 . . . . . . . . 3 3 . 1 . 030 nuclear orig full ' A' A ' 189' ' ' THR . . . . . 0.422 ' H ' ' HB2' ' A' ' 188' ' ' LEU . 3.2 t -86.26 147.48 44.89 Favored Pre-proline 0 C--N 1.33 -0.24 0 CA-C-N 116.045 -0.525 . . . . 0.0 111.969 -178.873 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 190' ' ' PRO . . . . . . . . . . . . . 77.8 Cg_exo -51.02 -35.93 52.27 Favored 'Trans proline' 0 C--N 1.351 0.691 0 C-N-CA 122.581 2.187 . . . . 0.0 112.665 179.708 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 191' ' ' THR . . . . . . . . . . . . . 59.5 p -57.89 -40.8 81.17 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 121.052 0.453 . . . . 0.0 110.753 179.904 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 192' ' ' VAL . . . . . . . . . . . . . 41.4 t -74.96 -52.8 17.94 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-N 115.705 -0.679 . . . . 0.0 111.484 -179.871 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 193' ' ' ASP . . . . . 0.422 ' OD1' ' HA3' ' A' ' 181' ' ' GLY . 25.4 t70 -54.94 -51.93 64.59 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-N 116.31 -0.405 . . . . 0.0 111.142 -179.716 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 194' ' ' VAL . . . . . 0.511 ' O ' HG23 ' A' ' 198' ' ' VAL . 90.8 t -61.41 -36.96 76.45 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.357 0 CA-C-N 115.927 -0.579 . . . . 0.0 111.026 -179.832 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 195' ' ' ALA . . . . . 0.449 ' HA ' HD11 ' A' ' 7' ' ' LEU . . . -52.4 -48.58 65.58 Favored 'General case' 0 C--O 1.234 0.27 0 CA-C-O 120.91 0.386 . . . . 0.0 111.006 179.723 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 196' ' ' LEU . . . . . 0.488 ' O ' ' HB3' ' A' ' 199' ' ' TYR . 98.5 mt -68.3 -39.45 82.04 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 116.432 -0.349 . . . . 0.0 110.448 179.281 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 197' ' ' ILE . . . . . 0.418 HG13 ' NH2' ' A' ' 72' ' ' ARG . 15.5 mm -55.59 -60.36 1.79 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.358 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.178 179.92 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 198' ' ' VAL . . . . . 0.511 HG23 ' O ' ' A' ' 194' ' ' VAL . 3.3 m -52.19 -35.93 20.01 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.424 0 CA-C-O 121.359 0.6 . . . . 0.0 109.902 179.08 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 199' ' ' TYR . . . . . 0.488 ' HB3' ' O ' ' A' ' 196' ' ' LEU . 69.2 t80 -62.15 -47.02 86.41 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-N 115.062 -0.972 . . . . 0.0 110.095 179.224 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 200' ' ' LEU . . . . . 0.417 HD22 ' HB ' ' A' ' 173' ' ' ILE . 5.4 mp -55.78 -38.99 70.63 Favored 'General case' 0 N--CA 1.452 -0.367 0 CA-C-N 115.973 -0.558 . . . . 0.0 111.561 179.097 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 201' ' ' ASP . . . . . . . . . . . . . 16.0 m-20 -74.19 -41.88 60.73 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 121.063 0.458 . . . . 0.0 110.683 -179.974 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 202' ' ' LEU . . . . . . . . . . . . . 2.2 mt -63.18 -33.33 75.24 Favored 'General case' 0 C--N 1.327 -0.413 0 CA-C-N 115.624 -0.716 . . . . 0.0 111.682 -179.851 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 203' ' ' VAL . . . . . 0.607 HG13 HD11 ' A' ' 170' ' ' LEU . 10.8 p -78.26 -36.29 20.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.815 -0.175 . . . . 0.0 111.329 -178.696 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 204' ' ' THR . . . . . 0.427 ' O ' ' CD1' ' A' ' 208' ' ' PHE . 55.4 m -62.47 -58.64 6.89 Favored 'General case' 0 C--N 1.328 -0.331 0 C-N-CA 120.454 -0.499 . . . . 0.0 111.315 179.761 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 205' ' ' LYS . . . . . 0.669 ' HE2' ' HB2' ' A' ' 47' ' ' ALA . 49.5 mttp -69.07 -58.18 4.43 Favored 'General case' 0 N--CA 1.464 0.241 0 N-CA-C 112.849 0.685 . . . . 0.0 112.849 -177.921 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 26.1 t -68.92 -36.34 73.58 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.444 0 CA-C-N 116.401 -0.363 . . . . 0.0 111.89 -178.706 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 207' ' ' GLY . . . . . 0.556 ' O ' HG13 ' A' ' 211' ' ' ILE . . . -61.66 -60.45 8.13 Favored Glycine 0 N--CA 1.452 -0.273 0 C-N-CA 120.698 -0.763 . . . . 0.0 113.672 -178.619 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 208' ' ' PHE . . . . . 0.567 ' HB2' ' HG ' ' A' ' 163' ' ' LEU . 0.1 OUTLIER -71.58 -25.96 62.41 Favored 'General case' 0 C--O 1.224 -0.258 0 CA-C-N 117.383 0.591 . . . . 0.0 111.319 -178.976 . . . . . . . . 3 3 . 1 . 030 nuclear orig full ' A' A ' 209' ' ' GLY . . . . . 0.471 ' O ' ' HB2' ' A' ' 212' ' ' ALA . . . -68.55 -32.4 74.89 Favored Glycine 0 N--CA 1.449 -0.464 0 N-CA-C 111.676 -0.57 . . . . 0.0 111.676 179.077 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 210' ' ' PHE . . . . . . . . . . . . . 0.8 OUTLIER -72.87 -47.39 46.41 Favored 'General case' 0 CA--C 1.514 -0.421 0 N-CA-C 108.107 -1.072 . . . . 0.0 108.107 178.505 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 211' ' ' ILE . . . . . 0.556 HG13 ' O ' ' A' ' 207' ' ' GLY . 4.6 mt -64.85 -27.73 43.14 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.544 0 N-CA-C 107.629 -1.248 . . . . 0.0 107.629 176.677 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 212' ' ' ALA . . . . . 0.471 ' HB2' ' O ' ' A' ' 209' ' ' GLY . . . -63.86 -39.86 95.2 Favored 'General case' 0 N--CA 1.451 -0.412 0 CA-C-N 114.628 -1.169 . . . . 0.0 110.381 179.794 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 213' ' ' LEU . . . . . . . . . . . . . 92.8 mt -69.72 -54.42 13.84 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 115.215 -0.902 . . . . 0.0 111.252 -179.596 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 214' ' ' ASP . . . . . . . . . . . . . 18.5 m-20 -56.57 -44.94 81.49 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.968 0.413 . . . . 0.0 110.933 -179.819 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 215' ' ' ALA . . . . . 0.485 ' O ' HD23 ' A' ' 219' ' ' LEU . . . -61.0 -58.19 9.47 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.055 -0.52 . . . . 0.0 111.004 179.969 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 216' ' ' ALA . . . . . 0.558 ' HA ' ' HG ' ' A' ' 219' ' ' LEU . . . -55.53 -30.43 60.71 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.84 179.923 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 217' ' ' ALA . . . . . . . . . . . . . . . -61.36 -41.59 97.31 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 115.874 -0.603 . . . . 0.0 109.685 179.525 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 218' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -68.28 -29.68 68.52 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 115.437 -0.801 . . . . 0.0 109.994 178.64 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 219' ' ' LEU . . . . . 0.558 ' HG ' ' HA ' ' A' ' 216' ' ' ALA . 0.2 OUTLIER -66.82 -51.79 51.47 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 115.571 -0.741 . . . . 0.0 110.875 -179.345 . . . . . . . . 3 3 . 1 . 030 nuclear orig full ' A' A ' 220' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -71.5 -18.76 62.26 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.41 179.641 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 221' ' ' ALA . . . . . . . . . . . . . . . -77.13 -32.83 56.68 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.082 -0.508 . . . . 0.0 110.796 179.314 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 222' ' ' GLU . . . . . . . . . . . . . 12.8 pt-20 -91.55 -5.1 54.61 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-N 115.975 -0.557 . . . . 0.0 110.64 179.75 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 223' ' ' HIS . . . . . . . . . . . . . 1.1 p80 -35.06 147.65 0.02 OUTLIER 'General case' 0 N--CA 1.466 0.36 0 CA-C-N 115.745 -0.661 . . . . 0.0 112.251 -179.61 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 224' ' ' GLY . . . . . . . . . . . . . . . 169.44 36.9 0.03 OUTLIER Glycine 0 CA--C 1.518 0.23 0 CA-C-N 115.739 -0.664 . . . . 0.0 112.402 179.996 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 225' ' ' GLU . . . . . . . . . . . . . 1.9 mp0 -81.69 139.81 34.7 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.792 0.33 . . . . 0.0 111.215 -179.805 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 226' ' ' SER . . . . . . . . . . . . . 75.1 m 57.74 -171.7 0.1 Allowed 'General case' 0 C--N 1.331 -0.206 0 CA-C-N 116.007 -0.542 . . . . 0.0 111.424 179.72 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 227' ' ' LEU . . . . . . . . . . . . . 50.4 tp -80.44 103.4 10.27 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.08 -0.509 . . . . 0.0 110.892 179.986 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 228' ' ' ALA . . . . . . . . . . . . . . . -142.79 82.59 1.77 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.062 179.869 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 229' ' ' GLY . . . . . . . . . . . . . . . -160.52 136.89 4.72 Favored Glycine 0 N--CA 1.45 -0.373 0 C-N-CA 120.909 -0.662 . . . . 0.0 112.406 179.888 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 230' ' ' VAL . . . . . . . . . . . . . 46.1 t -80.12 134.55 27.25 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.37 0 CA-C-O 120.839 0.352 . . . . 0.0 111.021 -179.937 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 231' ' ' ASP . . . . . . . . . . . . . 10.9 m-20 -84.84 98.75 10.48 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.832 -179.916 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 232' ' ' THR . . . . . . . . . . . . . 9.1 t -138.38 151.87 47.89 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.086 -0.506 . . . . 0.0 111.169 179.977 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 233' ' ' ASP . . . . . . . . . . . . . 6.1 m-20 -98.05 -14.28 20.59 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.912 -179.945 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 234' ' ' THR . . . . . . . . . . . . . 75.4 p -131.71 98.57 17.76 Favored Pre-proline 0 C--N 1.331 -0.238 0 CA-C-N 116.123 -0.49 . . . . 0.0 111.081 -179.965 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 235' ' ' PRO . . . . . . . . . . . . . 31.2 Cg_exo -60.55 -20.48 64.53 Favored 'Trans proline' 0 C--N 1.349 0.565 0 C-N-CA 122.585 2.19 . . . . 0.0 112.333 179.845 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 236' ' ' ALA . . . . . . . . . . . . . . . -62.19 130.48 45.6 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.117 -0.492 . . . . 0.0 111.232 179.971 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 237' ' ' VAL . . . . . . . . . . . . . 48.8 t -91.95 139.19 18.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.028 -0.533 . . . . 0.0 111.063 179.897 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 238' ' ' ALA . . . . . . . . . . . . . . . 57.83 -170.37 0.11 Allowed 'General case' 0 C--N 1.331 -0.203 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.234 -179.953 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 239' ' ' ASP . . . . . . . . . . . . . 6.1 m-20 -118.73 123.71 45.53 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.874 179.899 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 240' ' ' LEU . . . . . . . . . . . . . 8.0 mp -103.14 -37.48 7.71 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.657 179.858 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 241' ' ' GLU . . . . . . . . . . . . . 8.0 mm-40 65.27 144.13 0.03 OUTLIER 'General case' 0 N--CA 1.462 0.168 0 CA-C-N 115.836 -0.62 . . . . 0.0 111.485 179.863 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 242' ' ' HIS . . . . . . . . . . . . . 79.2 m80 -135.34 151.53 50.6 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 115.883 -0.598 . . . . 0.0 110.477 179.727 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 243' ' ' HIS . . . . . . . . . . . . . 20.6 t-80 -142.78 -50.25 0.35 Allowed 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.321 -0.4 . . . . 0.0 111.257 -179.783 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 244' ' ' HIS . . . . . . . . . . . . . 71.3 t60 -94.91 113.71 25.46 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.278 -0.419 . . . . 0.0 111.133 -179.757 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 245' ' ' HIS . . . . . . . . . . . . . 41.3 t-80 -88.24 113.21 23.63 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.771 179.814 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 246' ' ' HIS . . . . . . . . . . . . . 10.8 t-160 -93.29 140.61 29.36 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.831 -179.769 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 247' ' ' HIS . . . . . . . . . . . . . 79.9 t60 . . . . . 0 C--O 1.249 1.071 0 CA-C-O 118.258 -0.877 . . . . 0.0 110.874 -179.91 . . . . . . . . 0 0 . 1 . 030 nuclear orig full ' A' A ' 301' ' ' RET . . . . . 0.456 H202 ' NE1' ' A' ' 171' ' ' TRP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.295 0 N-CA-C 112.292 -0.323 . . . . 0.0 112.292 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 67.1 tp -72.58 -35.5 67.95 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.873 0.368 . . . . 0.0 110.833 179.967 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 74.5 p -56.38 -29.64 61.72 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 115.953 -0.567 . . . . 0.0 111.589 -179.8 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 47.5 p -52.2 -35.19 48.51 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.407 -0.36 . . . . 0.0 111.335 -179.617 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 7' ' ' LEU . . . . . . . . . . . . . 3.9 mm? -61.28 -53.02 62.12 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.312 -0.404 . . . . 0.0 111.347 -179.751 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 8' ' ' PHE . . . . . . . . . . . . . 74.7 m-85 -60.93 -32.6 72.1 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-O 121.003 0.43 . . . . 0.0 110.696 179.943 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 9' ' ' TRP . . . . . 0.407 ' O ' HG13 ' A' ' 13' ' ' ILE . 26.0 m95 -66.39 -48.65 69.4 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 115.93 -0.577 . . . . 0.0 110.077 -179.986 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 82.1 mt -57.94 -51.07 71.15 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 115.654 -0.703 . . . . 0.0 110.542 179.526 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -57.41 -35.17 70.65 Favored Glycine 0 N--CA 1.45 -0.411 0 C-N-CA 120.739 -0.743 . . . . 0.0 111.8 179.369 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -65.33 -30.82 71.7 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 120.863 0.363 . . . . 0.0 110.504 179.558 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 13' ' ' ILE . . . . . 0.407 HG13 ' O ' ' A' ' 9' ' ' TRP . 80.9 mt -66.89 -46.43 85.14 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.217 0 CA-C-N 116.062 -0.517 . . . . 0.0 110.075 179.353 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -61.84 -31.29 77.77 Favored Glycine 0 N--CA 1.45 -0.367 0 C-N-CA 120.653 -0.784 . . . . 0.0 111.862 179.329 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 15' ' ' MET . . . . . 0.533 ' HB3' ' HB2' ' A' ' 48' ' ' ALA . 0.0 OUTLIER -67.03 -46.89 73.08 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-O 120.848 0.356 . . . . 0.0 110.626 179.33 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -56.53 -40.45 75.08 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.033 -0.531 . . . . 0.0 110.483 179.547 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 84.4 t -60.36 -48.07 89.82 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.861 179.653 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -65.62 -47.27 78.73 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.775 -0.726 . . . . 0.0 112.439 179.816 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 25.2 m -49.44 -47.43 48.19 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-O 120.637 0.256 . . . . 0.0 111.433 -179.258 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 94.6 mt -71.63 -44.67 63.95 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.481 -0.327 . . . . 0.0 111.516 -179.914 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -55.14 -35.11 64.37 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.384 -0.371 . . . . 0.0 111.918 -179.436 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 22' ' ' PHE . . . . . 0.66 ' HB2' HG22 ' A' ' 41' ' ' VAL . 4.2 m-85 -91.07 -29.56 17.25 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.557 -0.292 . . . . 0.0 111.777 -179.207 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -70.31 -51.02 33.28 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.966 0.412 . . . . 0.0 111.524 -179.362 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 24' ' ' TRP . . . . . . . . . . . . . 5.8 t-105 -66.42 -50.01 64.85 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-N 115.881 -0.6 . . . . 0.0 110.999 -179.778 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.328 -0.34 0 CA-C-N 116.49 -0.323 . . . . 0.0 111.002 179.989 . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.278 0 N-CA-C 112.291 -0.324 . . . . 0.0 112.291 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 38.6 mt-10 -69.99 -20.66 63.28 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.779 0.323 . . . . 0.0 110.645 179.776 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 34' ' ' ARG . . . . . . . . . . . . . 99.8 mtt180 -49.09 -29.09 4.74 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 115.862 -0.608 . . . . 0.0 111.535 -179.862 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 21.4 mmm180 -64.3 -46.98 81.26 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-O 120.783 0.325 . . . . 0.0 111.041 179.905 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 90.2 m-85 -69.2 -32.01 71.01 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.162 179.875 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 37' ' ' TYR . . . . . 0.477 ' O ' HG23 ' A' ' 41' ' ' VAL . 43.4 m-85 -71.97 -54.75 8.99 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.085 -0.507 . . . . 0.0 111.41 -179.485 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 14.6 p -56.76 -36.34 48.91 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-O 120.972 0.415 . . . . 0.0 110.441 -179.995 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 40.9 m -64.85 -50.19 67.6 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 115.758 -0.655 . . . . 0.0 110.41 179.219 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 40' ' ' LEU . . . . . 0.654 HD12 HD11 ' A' ' 43' ' ' ILE . 57.7 tp -61.0 -38.28 85.47 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 115.573 -0.739 . . . . 0.0 110.657 179.741 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 41' ' ' VAL . . . . . 0.66 HG22 ' HB2' ' A' ' 22' ' ' PHE . 95.8 t -69.48 -34.0 59.9 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.453 0 CA-C-N 115.932 -0.576 . . . . 0.0 109.975 179.011 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -61.22 -42.31 99.75 Favored Glycine 0 N--CA 1.449 -0.483 0 CA-C-N 115.615 -0.721 . . . . 0.0 112.892 179.905 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 43' ' ' ILE . . . . . 0.654 HD11 HD12 ' A' ' 40' ' ' LEU . 38.9 pt -70.03 -44.0 78.74 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.153 0 CA-C-N 116.952 0.376 . . . . 0.0 111.31 -179.786 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 44' ' ' SER . . . . . 0.458 ' N ' HG13 ' A' ' 43' ' ' ILE . 38.7 t -66.29 -25.98 67.11 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-O 120.985 0.421 . . . . 0.0 110.713 179.461 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -79.85 -52.69 4.56 Favored Glycine 0 C--N 1.33 0.233 0 C-N-CA 121.033 -0.603 . . . . 0.0 112.907 -179.295 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 46' ' ' ILE . . . . . 0.462 ' O ' HG22 ' A' ' 49' ' ' VAL . 15.3 pt -57.88 -36.95 57.79 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.248 0 CA-C-O 121.148 0.499 . . . . 0.0 110.33 179.978 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 47' ' ' ALA . . . . . 0.757 ' HB2' ' HE2' ' A' ' 205' ' ' LYS . . . -68.2 -42.05 80.45 Favored 'General case' 0 C--N 1.326 -0.45 0 CA-C-N 115.81 -0.632 . . . . 0.0 110.78 178.716 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 48' ' ' ALA . . . . . 0.533 ' HB2' ' HB3' ' A' ' 15' ' ' MET . . . -54.48 -42.66 70.99 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 115.881 -0.599 . . . . 0.0 112.038 -179.451 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 49' ' ' VAL . . . . . 0.462 HG22 ' O ' ' A' ' 46' ' ' ILE . 31.0 m -73.42 -36.24 47.93 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.24 0 N-CA-C 111.606 0.224 . . . . 0.0 111.606 -179.437 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -62.49 -40.39 96.54 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-O 121.001 0.429 . . . . 0.0 111.285 179.792 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 4.2 m-85 -70.58 -40.2 73.42 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-N 115.997 -0.547 . . . . 0.0 110.726 -179.613 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -63.13 -42.26 99.47 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 115.882 -0.599 . . . . 0.0 111.459 179.999 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 53' ' ' VAL . . . . . 0.535 ' O ' HG22 ' A' ' 58' ' ' VAL . 33.0 m -70.28 -49.71 52.22 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.209 0 CA-C-N 116.71 -0.223 . . . . 0.0 111.057 -179.865 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 54' ' ' MET . . . . . 0.492 ' N ' HG23 ' A' ' 53' ' ' VAL . 73.1 mtm -60.75 -32.29 71.59 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-O 121.099 0.476 . . . . 0.0 109.916 179.429 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -63.26 -22.9 67.16 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 115.552 -0.749 . . . . 0.0 111.283 179.677 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 80.2 mt -89.1 -14.35 36.45 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.459 -0.337 . . . . 0.0 111.033 -179.906 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 102.53 -2.99 49.77 Favored Glycine 0 C--N 1.33 0.248 0 C-N-CA 120.689 -0.767 . . . . 0.0 113.352 179.371 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 58' ' ' VAL . . . . . 0.535 HG22 ' O ' ' A' ' 53' ' ' VAL . 15.8 m -78.63 154.25 4.97 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.166 0 CA-C-N 116.981 0.39 . . . . 0.0 111.145 -179.901 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 59' ' ' GLY . . . . . 0.438 ' HA3' ' CG ' ' A' ' 71' ' ' PRO . . . 80.69 -2.39 79.3 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.89 -0.671 . . . . 0.0 112.859 -179.943 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 60' ' ' TRP . . . . . . . . . . . . . 23.2 m0 -78.28 121.49 24.49 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 120.724 0.297 . . . . 0.0 110.503 179.718 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 7.3 p -112.8 132.25 22.37 Favored Pre-proline 0 CA--C 1.533 0.29 0 CA-C-N 116.416 -0.356 . . . . 0.0 111.343 -179.796 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 72.0 Cg_endo -77.45 145.56 23.78 Favored 'Trans proline' 0 C--N 1.35 0.638 0 C-N-CA 122.51 2.14 . . . . 0.0 112.512 179.941 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 96.6 t -142.65 94.08 0.54 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 115.872 -0.604 . . . . 0.0 110.926 -179.94 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . 57.67 -89.55 0.02 OUTLIER 'General case' 0 C--N 1.332 -0.178 0 CA-C-N 116.13 -0.486 . . . . 0.0 111.418 179.96 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 12.8 pt-20 -119.79 -19.93 7.79 Favored 'General case' 0 C--O 1.233 0.204 0 CA-C-O 120.806 0.336 . . . . 0.0 110.872 -179.987 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 66' ' ' ARG . . . . . 0.496 HH22 ' HA ' ' A' ' 183' ' ' PRO . 13.1 ptm180 -101.93 166.29 10.72 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.385 179.83 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 35.3 m -125.72 123.89 39.85 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-O 120.975 0.417 . . . . 0.0 111.462 -179.725 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 23.4 t -101.29 147.16 8.54 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.221 0 CA-C-N 115.88 -0.6 . . . . 0.0 110.284 179.41 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 69' ' ' PHE . . . . . . . . . . . . . 46.8 m-85 -106.94 112.41 25.36 Favored 'General case' 0 C--N 1.328 -0.329 0 N-CA-C 110.03 -0.359 . . . . 0.0 110.03 -179.363 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 70' ' ' VAL . . . . . 0.523 ' HB ' ' HD3' ' A' ' 71' ' ' PRO . 21.7 t -68.96 -49.89 24.04 Favored Pre-proline 0 C--N 1.327 -0.408 0 N-CA-C 112.455 0.539 . . . . 0.0 112.455 -178.891 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 71' ' ' PRO . . . . . 0.523 ' HD3' ' HB ' ' A' ' 70' ' ' VAL . 31.8 Cg_exo -58.55 -25.97 76.68 Favored 'Trans proline' 0 C--N 1.35 0.627 0 C-N-CA 121.983 1.788 . . . . 0.0 112.174 179.97 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 72' ' ' ARG . . . . . 0.406 ' HB2' ' SD ' ' A' ' 54' ' ' MET . 46.3 ttp180 -72.52 -53.27 12.52 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.975 0.417 . . . . 0.0 110.665 179.932 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 73' ' ' TYR . . . . . 0.409 ' O ' HG13 ' A' ' 77' ' ' ILE . 23.0 m-85 -65.2 -38.07 89.29 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 115.831 -0.622 . . . . 0.0 110.694 179.934 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 74' ' ' ILE . . . . . 0.444 ' O ' HD13 ' A' ' 74' ' ' ILE . 0.4 OUTLIER -70.32 -37.62 71.6 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 N-CA-C 110.008 -0.367 . . . . 0.0 110.008 179.583 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 75' ' ' ASP . . . . . 0.457 ' O ' HG23 ' A' ' 79' ' ' THR . 31.2 t70 -57.24 -38.61 74.06 Favored 'General case' 0 CA--C 1.521 -0.138 0 N-CA-C 109.453 -0.573 . . . . 0.0 109.453 178.991 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 76' ' ' TRP . . . . . . . . . . . . . 45.4 m0 -66.8 -39.72 87.85 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 115.553 -0.749 . . . . 0.0 110.27 179.375 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 77' ' ' ILE . . . . . 0.428 HD12 ' HA ' ' A' ' 74' ' ' ILE . 89.3 mt -60.49 -28.93 43.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 115.953 -0.567 . . . . 0.0 110.788 179.551 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 43.1 mt -91.97 -29.19 16.77 Favored 'General case' 0 C--N 1.33 -0.255 0 N-CA-C 112.275 0.472 . . . . 0.0 112.275 179.96 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 79' ' ' THR . . . . . 0.457 HG23 ' O ' ' A' ' 75' ' ' ASP . 66.8 p -89.38 -52.09 5.22 Favored 'General case' 0 N--CA 1.464 0.27 0 N-CA-C 113.506 0.928 . . . . 0.0 113.506 -177.725 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 80' ' ' THR . . . . . 0.447 ' N ' ' HD2' ' A' ' 81' ' ' PRO . 86.1 m -47.3 -55.03 17.47 Favored Pre-proline 0 C--N 1.328 -0.34 0 N-CA-C 112.773 0.657 . . . . 0.0 112.773 -178.683 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 81' ' ' PRO . . . . . 0.447 ' HD2' ' N ' ' A' ' 80' ' ' THR . 36.1 Cg_endo -63.2 -20.82 71.7 Favored 'Trans proline' 0 C--N 1.351 0.69 0 C-N-CA 121.55 1.5 . . . . 0.0 111.06 179.997 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 82' ' ' LEU . . . . . 0.435 ' HB3' HG22 ' A' ' 43' ' ' ILE . 0.1 OUTLIER -76.2 -34.8 59.29 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 115.364 -0.834 . . . . 0.0 109.94 179.558 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 47.9 mm -69.25 -52.74 30.28 Favored 'Isoleucine or valine' 0 CA--C 1.522 -0.126 0 CA-C-N 115.849 -0.614 . . . . 0.0 110.205 179.429 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 84' ' ' VAL . . . . . 0.429 HG22 ' HA ' ' A' ' 81' ' ' PRO . 27.7 m -59.64 -31.16 46.38 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.215 0 N-CA-C 109.614 -0.513 . . . . 0.0 109.614 178.912 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 85' ' ' TYR . . . . . . . . . . . . . 85.2 t80 -63.69 -36.54 84.19 Favored 'General case' 0 N--CA 1.454 -0.246 0 CA-C-N 115.657 -0.701 . . . . 0.0 109.188 178.457 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 86' ' ' PHE . . . . . . . . . . . . . 8.0 t80 -61.42 -44.87 96.38 Favored 'General case' 0 C--O 1.231 0.121 0 CA-C-N 115.636 -0.711 . . . . 0.0 109.457 178.87 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 3.7 mm? -61.66 -34.11 75.14 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 115.453 -0.794 . . . . 0.0 110.153 179.177 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 88' ' ' GLY . . . . . 0.516 ' HA2' HD13 ' A' ' 93' ' ' LEU . . . -69.08 -29.45 72.28 Favored Glycine 0 N--CA 1.449 -0.462 0 C-N-CA 120.812 -0.709 . . . . 0.0 112.252 179.695 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 95.9 mt -71.66 -39.48 70.29 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 121.028 0.442 . . . . 0.0 110.362 179.69 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 42.8 mt -61.14 -59.73 4.88 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 115.796 -0.638 . . . . 0.0 110.872 179.782 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 91' ' ' ALA . . . . . 0.493 ' HB2' ' HB2' ' A' ' 149' ' ' ALA . . . -70.25 -54.79 11.22 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.081 -0.509 . . . . 0.0 111.339 -179.833 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 98.85 68.77 0.91 Allowed Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.787 -0.72 . . . . 0.0 112.212 -179.861 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 93' ' ' LEU . . . . . 0.552 HD23 ' HB3' ' A' ' 97' ' ' GLU . 8.1 mp -72.0 -174.35 1.21 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.775 0.322 . . . . 0.0 110.945 -179.824 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 94' ' ' ASP . . . . . 0.452 ' HB3' ' OE2' ' A' ' 97' ' ' GLU . 10.2 t70 -97.28 -177.12 3.73 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.868 -179.73 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 77.9 p -65.58 -45.34 83.62 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.574 -179.369 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 36.2 mtp180 -74.14 -39.48 63.27 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-O 121.246 0.546 . . . . 0.0 110.438 -179.657 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 97' ' ' GLU . . . . . 0.552 ' HB3' HD23 ' A' ' 93' ' ' LEU . 0.3 OUTLIER -58.01 -44.68 87.38 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-N 115.457 -0.792 . . . . 0.0 111.039 -179.826 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 98' ' ' PHE . . . . . 0.441 ' O ' HG12 ' A' ' 102' ' ' ILE . 2.2 m-85 -61.52 -35.47 77.82 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.956 0.408 . . . . 0.0 110.502 179.543 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -70.08 -25.97 74.91 Favored Glycine 0 N--CA 1.451 -0.359 0 C-N-CA 120.7 -0.762 . . . . 0.0 112.144 179.795 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 96.4 mt -73.17 -43.71 57.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 N-CA-C 111.841 0.311 . . . . 0.0 111.841 -179.819 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 25.7 m -69.45 -39.16 78.33 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-O 120.676 0.275 . . . . 0.0 111.716 -179.389 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 102' ' ' ILE . . . . . 0.441 HG12 ' O ' ' A' ' 98' ' ' PHE . 42.0 mm -73.65 -41.0 55.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.582 -0.281 . . . . 0.0 111.621 -179.435 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 13.9 t -63.76 -35.97 82.34 Favored 'General case' 0 C--N 1.332 -0.153 0 CA-C-O 120.775 0.322 . . . . 0.0 110.884 -179.948 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 104' ' ' LEU . . . . . 0.439 ' O ' HG23 ' A' ' 108' ' ' VAL . 56.5 tp -67.52 -43.77 79.99 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.288 179.766 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 105' ' ' ASN . . . . . 0.529 ' N ' HD22 ' A' ' 105' ' ' ASN . 0.9 OUTLIER -62.72 -27.3 69.17 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.532 179.57 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 91.9 m -69.4 -52.15 29.77 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.054 -0.521 . . . . 0.0 111.502 -179.912 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 107' ' ' VAL . . . . . 0.444 HG22 ' HE2' ' A' ' 129' ' ' MET . 7.5 p -66.09 -36.35 77.23 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.214 0 CA-C-N 116.38 -0.373 . . . . 0.0 111.226 -179.976 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 108' ' ' VAL . . . . . 0.439 HG23 ' O ' ' A' ' 104' ' ' LEU . 51.0 t -62.85 -54.68 30.57 Favored 'Isoleucine or valine' 0 C--O 1.234 0.281 0 CA-C-N 116.294 -0.412 . . . . 0.0 110.866 179.746 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 109' ' ' MET . . . . . . . . . . . . . 5.6 tpp -61.66 -26.82 68.26 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.049 -0.523 . . . . 0.0 110.383 179.897 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 29.7 tp -73.05 -31.98 64.77 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.062 -0.517 . . . . 0.0 110.226 179.487 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -64.31 -51.17 64.79 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 115.926 -0.579 . . . . 0.0 110.284 179.225 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . -62.76 -44.26 97.75 Favored Glycine 0 CA--C 1.518 0.248 0 C-N-CA 120.796 -0.716 . . . . 0.0 112.42 179.539 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 113' ' ' PHE . . . . . 0.455 ' HZ ' HG13 ' A' ' 70' ' ' VAL . 0.8 OUTLIER -47.98 -61.01 2.18 Favored 'General case' 0 C--N 1.333 -0.141 0 CA-C-O 120.911 0.386 . . . . 0.0 110.397 179.592 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -69.83 -18.25 63.44 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.025 -0.534 . . . . 0.0 110.797 179.918 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -57.14 -49.06 74.98 Favored Glycine 0 C--N 1.333 0.389 0 C-N-CA 120.79 -0.719 . . . . 0.0 111.9 179.375 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -78.55 -15.51 58.48 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-O 120.782 0.325 . . . . 0.0 111.376 179.817 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 117' ' ' MET . . . . . . . . . . . . . 23.1 mmt -88.22 19.18 3.85 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 116.384 -0.371 . . . . 0.0 111.612 -179.553 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 35.7 m -84.64 141.62 38.97 Favored Pre-proline 0 C--N 1.329 -0.315 0 CA-C-O 120.57 0.224 . . . . 0.0 111.285 -179.846 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 119' ' ' PRO . . . . . . . . . . . . . 93.4 Cg_endo -87.07 -2.43 7.98 Favored 'Trans proline' 0 N--CA 1.459 -0.513 0 C-N-CA 122.77 2.314 . . . . 0.0 112.36 179.797 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -144.12 -110.05 0.7 Allowed Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.789 -0.72 . . . . 0.0 112.684 -179.911 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 42.9 pt -133.29 11.8 1.42 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.23 0 CA-C-O 120.681 0.277 . . . . 0.0 111.468 -179.646 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 46.9 mt-10 -59.24 -18.23 35.17 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.344 -0.389 . . . . 0.0 111.015 179.912 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 123' ' ' ARG . . . . . 0.524 ' HA ' HD13 ' A' ' 126' ' ' LEU . 11.1 ptt180 -50.45 -37.15 36.71 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.05 -0.523 . . . . 0.0 111.946 -179.661 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 124' ' ' TYR . . . . . . . . . . . . . 28.4 m-85 -51.19 -35.54 36.85 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.844 0.354 . . . . 0.0 111.171 -179.828 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 125' ' ' ALA . . . . . . . . . . . . . . . -74.8 -49.65 20.03 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.141 -0.481 . . . . 0.0 111.008 179.878 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 126' ' ' LEU . . . . . 0.524 HD13 ' HA ' ' A' ' 123' ' ' ARG . 6.5 mp -52.51 -55.67 20.48 Favored 'General case' 0 C--N 1.332 -0.182 0 CA-C-N 115.999 -0.546 . . . . 0.0 110.327 179.964 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 127' ' ' PHE . . . . . . . . . . . . . 10.9 t80 -64.51 -28.84 69.93 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 115.909 -0.587 . . . . 0.0 110.155 179.45 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 128' ' ' GLY . . . . . . . . . . . . . . . -49.16 -48.53 32.16 Favored Glycine 0 N--CA 1.449 -0.451 0 C-N-CA 120.121 -1.038 . . . . 0.0 110.593 178.79 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 129' ' ' MET . . . . . 0.445 ' HE3' ' HA2' ' A' ' 130' ' ' GLY . 0.0 OUTLIER -72.29 -31.72 65.98 Favored 'General case' 0 N--CA 1.452 -0.365 0 N-CA-C 109.079 -0.712 . . . . 0.0 109.079 178.467 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 130' ' ' GLY . . . . . 0.445 ' HA2' ' HE3' ' A' ' 129' ' ' MET . . . -61.52 -33.18 83.89 Favored Glycine 0 C--N 1.333 0.411 0 CA-C-N 115.749 -0.66 . . . . 0.0 112.035 179.458 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 131' ' ' ALA . . . . . 0.42 ' O ' ' HB3' ' A' ' 134' ' ' PHE . . . -74.8 -53.35 9.31 Favored 'General case' 0 N--CA 1.452 -0.326 0 CA-C-O 120.743 0.306 . . . . 0.0 110.362 179.648 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 40.8 t -55.15 -49.0 75.59 Favored 'Isoleucine or valine' 0 C--O 1.234 0.253 0 N-CA-C 109.462 -0.57 . . . . 0.0 109.462 178.783 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -59.68 -39.13 83.49 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 115.504 -0.771 . . . . 0.0 110.323 178.589 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 134' ' ' PHE . . . . . 0.459 ' CZ ' ' HA ' ' A' ' 172' ' ' ALA . 65.4 t80 -55.1 -51.13 67.37 Favored 'General case' 0 N--CA 1.451 -0.388 0 CA-C-N 115.892 -0.594 . . . . 0.0 110.367 179.68 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 135' ' ' ILE . . . . . 0.475 ' O ' HG22 ' A' ' 138' ' ' VAL . 60.2 mt -56.15 -32.05 33.31 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.238 0 CA-C-N 115.946 -0.57 . . . . 0.0 110.112 179.24 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 136' ' ' GLY . . . . . 0.402 ' O ' ' HB3' ' A' ' 139' ' ' TYR . . . -61.67 -41.24 99.56 Favored Glycine 0 N--CA 1.447 -0.598 0 C-N-CA 120.16 -1.019 . . . . 0.0 111.343 178.69 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 137' ' ' LEU . . . . . . . . . . . . . 30.0 tp -69.57 -50.71 42.08 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 115.846 -0.177 . . . . 0.0 111.09 179.935 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 138' ' ' VAL . . . . . 0.591 ' HA ' HD12 ' A' ' 141' ' ' LEU . 5.2 m -55.96 -32.62 33.53 Favored 'Isoleucine or valine' 0 C--O 1.234 0.245 0 CA-C-O 121.31 0.576 . . . . 0.0 109.754 179.478 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 139' ' ' TYR . . . . . 0.405 ' O ' ' N ' ' A' ' 143' ' ' GLY . 65.9 t80 -60.09 -48.09 83.16 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 115.353 -0.839 . . . . 0.0 109.412 178.511 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 37.0 m-85 -58.95 -35.5 73.23 Favored 'General case' 0 C--N 1.332 -0.169 0 CA-C-N 115.938 -0.573 . . . . 0.0 110.576 179.096 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 141' ' ' LEU . . . . . 0.591 HD12 ' HA ' ' A' ' 138' ' ' VAL . 95.6 mt -55.56 -46.74 77.13 Favored 'General case' 0 C--N 1.332 -0.174 0 CA-C-N 116.322 -0.399 . . . . 0.0 110.27 179.504 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 142' ' ' VAL . . . . . 0.405 HG22 ' O ' ' A' ' 142' ' ' VAL . 9.2 p -105.39 15.04 7.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 115.926 -0.579 . . . . 0.0 110.828 179.752 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 143' ' ' GLY . . . . . 0.405 ' N ' ' O ' ' A' ' 139' ' ' TYR . . . -90.86 -130.66 4.68 Favored Glycine 0 CA--C 1.52 0.393 0 C-N-CA 120.913 -0.661 . . . . 0.0 112.9 -179.627 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 144' ' ' PRO . . . . . . . . . . . . . 45.3 Cg_exo -57.23 -25.44 64.66 Favored 'Trans proline' 0 C--N 1.351 0.686 0 C-N-CA 122.585 2.19 . . . . 0.0 112.726 -179.632 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 145' ' ' MET . . . . . . . . . . . . . 60.6 mtt -56.76 -25.13 54.44 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.355 -0.384 . . . . 0.0 111.134 -179.896 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 146' ' ' THR . . . . . . . . . . . . . 78.1 p -63.83 -51.2 65.77 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.112 -0.495 . . . . 0.0 111.685 -179.786 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 43.6 mt-10 -75.56 -28.64 59.09 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.371 -0.377 . . . . 0.0 111.62 -179.252 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 148' ' ' SER . . . . . . . . . . . . . 36.8 t -70.53 -44.66 67.09 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.743 0.306 . . . . 0.0 111.208 -179.469 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 149' ' ' ALA . . . . . 0.493 ' HB2' ' HB2' ' A' ' 91' ' ' ALA . . . -77.92 -42.99 31.28 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.324 -0.398 . . . . 0.0 111.923 -179.53 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 150' ' ' SER . . . . . 0.586 ' HA ' ' HG2' ' A' ' 157' ' ' LYS . 47.5 t -63.65 -8.0 8.89 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.548 -179.504 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 151' ' ' GLN . . . . . . . . . . . . . 47.5 mt-30 -125.54 17.34 8.18 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.668 0.271 . . . . 0.0 111.279 -179.955 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 152' ' ' ARG . . . . . 0.6 ' HD2' HG13 ' A' ' 156' ' ' ILE . 3.6 tmt_? -93.24 -51.81 4.84 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-O 120.967 0.413 . . . . 0.0 110.509 179.782 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 153' ' ' SER . . . . . 0.679 ' HB3' HG12 ' A' ' 156' ' ' ILE . 20.0 t -157.42 172.41 18.63 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 115.904 -0.589 . . . . 0.0 110.451 179.304 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 154' ' ' SER . . . . . . . . . . . . . 79.0 p -71.62 -42.18 67.95 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.278 -0.419 . . . . 0.0 111.006 179.744 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -76.87 -25.72 64.04 Favored Glycine 0 C--N 1.331 0.265 0 C-N-CA 120.834 -0.698 . . . . 0.0 113.093 -179.669 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 156' ' ' ILE . . . . . 0.679 HG12 ' HB3' ' A' ' 153' ' ' SER . 27.7 mm -57.89 -38.48 66.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-O 120.551 0.215 . . . . 0.0 111.519 -179.718 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 157' ' ' LYS . . . . . 0.586 ' HG2' ' HA ' ' A' ' 150' ' ' SER . 35.8 mtmm -56.72 -39.91 74.77 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-O 120.806 0.336 . . . . 0.0 111.214 179.908 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 43.7 t -70.95 -48.1 55.28 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.569 -179.315 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 159' ' ' LEU . . . . . 0.458 ' O ' ' HB2' ' A' ' 163' ' ' LEU . 9.9 mt -68.18 -28.89 67.67 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 116.482 -0.326 . . . . 0.0 111.65 -179.609 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 160' ' ' TYR . . . . . . . . . . . . . 83.8 t80 -73.95 -45.91 47.41 Favored 'General case' 0 C--N 1.326 -0.429 0 N-CA-C 112.061 0.393 . . . . 0.0 112.061 -178.941 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 161' ' ' VAL . . . . . 0.426 HG23 ' N ' ' A' ' 162' ' ' ARG . 30.9 m -66.57 -43.89 90.34 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.419 0 N-CA-C 112.169 0.433 . . . . 0.0 112.169 -179.007 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 162' ' ' ARG . . . . . 0.426 ' N ' HG23 ' A' ' 161' ' ' VAL . 35.3 mmt180 -68.68 -41.69 78.86 Favored 'General case' 0 C--N 1.328 -0.349 0 N-CA-C 111.884 0.327 . . . . 0.0 111.884 -178.906 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 163' ' ' LEU . . . . . 0.609 ' HG ' ' HB2' ' A' ' 208' ' ' PHE . 7.7 mp -73.79 -50.06 22.38 Favored 'General case' 0 C--N 1.329 -0.326 0 N-CA-C 112.015 0.376 . . . . 0.0 112.015 -179.182 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 164' ' ' ARG . . . . . 0.465 ' HG2' ' HB3' ' A' ' 141' ' ' LEU . 6.4 tmm_? -59.45 -50.12 75.18 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.624 -0.262 . . . . 0.0 111.577 -179.139 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 165' ' ' ASN . . . . . 0.548 ' O ' HG23 ' A' ' 169' ' ' VAL . 3.9 m-20 -61.29 -51.41 69.02 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.45 -0.341 . . . . 0.0 111.524 -179.464 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 166' ' ' LEU . . . . . 0.482 ' O ' ' HG ' ' A' ' 170' ' ' LEU . 4.9 tt -60.76 -54.85 40.22 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.457 -0.338 . . . . 0.0 111.865 -179.198 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 167' ' ' THR . . . . . 0.411 ' O ' ' HB2' ' A' ' 171' ' ' TRP . 64.5 m -55.17 -54.22 45.98 Favored 'General case' 0 C--N 1.329 -0.292 0 N-CA-C 112.898 0.703 . . . . 0.0 112.898 -178.585 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 168' ' ' VAL . . . . . 0.438 ' HB ' HD13 ' A' ' 141' ' ' LEU . 9.9 p -55.1 -40.51 55.12 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.195 0 N-CA-C 112.418 0.525 . . . . 0.0 112.418 -178.924 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 169' ' ' VAL . . . . . 0.548 HG23 ' O ' ' A' ' 165' ' ' ASN . 58.5 t -60.47 -65.11 0.5 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 N-CA-C 111.874 0.324 . . . . 0.0 111.874 -179.159 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 170' ' ' LEU . . . . . 0.482 ' HG ' ' O ' ' A' ' 166' ' ' LEU . 1.0 OUTLIER -61.3 -29.2 69.72 Favored 'General case' 0 C--N 1.329 -0.283 0 C-N-CA 121.166 -0.213 . . . . 0.0 111.41 -179.273 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 171' ' ' TRP . . . . . 0.413 ' N ' HD12 ' A' ' 170' ' ' LEU . 2.8 m0 -71.03 -35.3 71.93 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-O 120.934 0.397 . . . . 0.0 110.038 178.983 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 172' ' ' ALA . . . . . 0.459 ' HA ' ' CZ ' ' A' ' 134' ' ' PHE . . . -68.32 -6.61 25.09 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 115.872 -0.604 . . . . 0.0 110.62 179.572 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 173' ' ' ILE . . . . . 0.509 HG22 HD11 ' A' ' 177' ' ' ILE . 40.4 mm -85.9 -22.19 7.39 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 115.873 -0.603 . . . . 0.0 110.798 179.515 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 174' ' ' TYR . . . . . 0.59 ' N ' ' HD2' ' A' ' 175' ' ' PRO . 12.9 m-85 -54.22 -50.81 82.57 Favored Pre-proline 0 CA--C 1.533 0.299 0 CA-C-N 116.159 -0.473 . . . . 0.0 112.109 -179.684 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 175' ' ' PRO . . . . . 0.59 ' HD2' ' N ' ' A' ' 174' ' ' TYR . 8.1 Cg_endo -50.65 -27.75 20.46 Favored 'Trans proline' 0 C--N 1.352 0.752 0 C-N-CA 122.067 1.845 . . . . 0.0 112.355 -179.797 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 176' ' ' PHE . . . . . 0.457 ' O ' ' HG ' ' A' ' 180' ' ' LEU . 49.5 m-85 -80.59 -46.43 15.71 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.291 -0.413 . . . . 0.0 111.668 -179.995 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 177' ' ' ILE . . . . . 0.509 HD11 HG22 ' A' ' 173' ' ' ILE . 3.5 mm -66.19 -36.35 77.19 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.497 0 N-CA-C 112.299 0.481 . . . . 0.0 112.299 -178.211 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 178' ' ' TRP . . . . . 0.471 ' HH2' ' HB2' ' A' ' 123' ' ' ARG . 67.8 t90 -73.94 -45.95 47.21 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-O 120.907 0.384 . . . . 0.0 110.772 179.602 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 179' ' ' LEU . . . . . 0.459 ' O ' HG22 ' A' ' 185' ' ' VAL . 2.5 tm? -67.92 -49.6 60.91 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 115.921 -0.581 . . . . 0.0 111.403 -179.077 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 180' ' ' LEU . . . . . 0.556 HD22 HD11 ' A' ' 187' ' ' LEU . 22.7 mt -77.7 -47.23 19.65 Favored 'General case' 0 C--N 1.328 -0.358 0 N-CA-C 111.812 0.301 . . . . 0.0 111.812 -179.165 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . -58.75 -178.21 0.96 Allowed Glycine 0 C--N 1.337 0.591 0 C-N-CA 120.256 -0.973 . . . . 0.0 112.772 -179.98 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 182' ' ' PRO . . . . . 0.644 ' HA ' ' HB2' ' A' ' 186' ' ' ALA . 85.7 Cg_exo -47.81 -44.32 27.14 Favored 'Trans proline' 0 CA--C 1.536 0.623 0 C-N-CA 122.967 2.445 . . . . 0.0 113.802 -179.97 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 183' ' ' PRO . . . . . 0.496 ' HA ' HH22 ' A' ' 66' ' ' ARG . 51.8 Cg_exo -55.3 -9.95 2.79 Favored 'Trans proline' 0 C--N 1.354 0.833 0 C-N-CA 122.154 1.902 . . . . 0.0 113.199 -179.736 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 184' ' ' GLY . . . . . 0.414 ' HA3' ' O ' ' A' ' 179' ' ' LEU . . . -123.21 -87.39 0.81 Allowed Glycine 0 N--CA 1.45 -0.387 0 C-N-CA 120.421 -0.895 . . . . 0.0 112.901 -179.887 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 185' ' ' VAL . . . . . 0.459 HG22 ' O ' ' A' ' 179' ' ' LEU . 8.6 m -120.43 -7.02 10.53 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-O 120.773 0.321 . . . . 0.0 111.779 -179.603 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 186' ' ' ALA . . . . . 0.644 ' HB2' ' HA ' ' A' ' 182' ' ' PRO . . . 56.18 85.36 0.07 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.116 -0.493 . . . . 0.0 111.716 179.576 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 187' ' ' LEU . . . . . 0.556 HD11 HD22 ' A' ' 180' ' ' LEU . 18.8 mt -91.78 -49.25 6.36 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.93 0.395 . . . . 0.0 110.878 179.528 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 188' ' ' LEU . . . . . 0.403 ' HB3' ' H ' ' A' ' 189' ' ' THR . 96.6 mt -90.13 -154.99 0.35 Allowed 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 115.839 -0.619 . . . . 0.0 110.947 -179.661 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 189' ' ' THR . . . . . 0.481 ' HB ' HG23 ' A' ' 192' ' ' VAL . 58.8 m -92.6 136.17 25.56 Favored Pre-proline 0 C--N 1.329 -0.326 0 CA-C-N 116.05 -0.523 . . . . 0.0 110.568 -179.719 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 190' ' ' PRO . . . . . 0.468 ' O ' HG23 ' A' ' 194' ' ' VAL . 2.2 Cg_endo -45.5 -37.69 15.23 Favored 'Trans proline' 0 C--N 1.35 0.652 0 C-N-CA 122.837 2.358 . . . . 0.0 112.776 -179.747 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 191' ' ' THR . . . . . 0.413 ' H ' HG22 ' A' ' 189' ' ' THR . 41.7 p -74.24 -45.42 48.09 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 116.487 -0.324 . . . . 0.0 111.415 -179.835 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 192' ' ' VAL . . . . . 0.481 HG23 ' HB ' ' A' ' 189' ' ' THR . 96.9 t -59.66 -52.79 56.9 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.302 -0.408 . . . . 0.0 111.415 -179.781 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 193' ' ' ASP . . . . . . . . . . . . . 25.9 t70 -54.6 -48.2 72.46 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.946 -179.761 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 194' ' ' VAL . . . . . 0.62 ' O ' HG22 ' A' ' 198' ' ' VAL . 40.6 t -55.22 -44.03 73.22 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.241 0 CA-C-N 116.376 -0.375 . . . . 0.0 110.492 179.492 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 195' ' ' ALA . . . . . . . . . . . . . . . -52.46 -42.91 64.61 Favored 'General case' 0 C--N 1.332 -0.185 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.778 179.895 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 196' ' ' LEU . . . . . . . . . . . . . 62.5 mt -67.8 -40.27 83.9 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.785 179.356 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 197' ' ' ILE . . . . . 0.42 HG12 HG21 ' A' ' 177' ' ' ILE . 12.0 mm -59.39 -60.87 1.82 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 115.766 -0.652 . . . . 0.0 111.405 -179.847 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 198' ' ' VAL . . . . . 0.62 HG22 ' O ' ' A' ' 194' ' ' VAL . 1.3 m -53.94 -34.85 26.61 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.439 0 CA-C-O 121.544 0.687 . . . . 0.0 109.566 179.053 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 199' ' ' TYR . . . . . . . . . . . . . 63.8 t80 -66.57 -33.56 75.94 Favored 'General case' 0 C--N 1.323 -0.587 0 CA-C-N 114.639 -1.164 . . . . 0.0 110.575 179.722 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 200' ' ' LEU . . . . . 0.483 ' O ' HG12 ' A' ' 203' ' ' VAL . 26.6 mt -66.67 -41.77 87.62 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.088 -0.505 . . . . 0.0 111.315 -179.897 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 201' ' ' ASP . . . . . . . . . . . . . 5.0 m-20 -74.83 -37.94 62.14 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-O 121.253 0.549 . . . . 0.0 110.044 179.499 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 202' ' ' LEU . . . . . 0.481 HD13 ' SD ' ' A' ' 15' ' ' MET . 40.5 tp -70.6 -26.79 63.67 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 115.256 -0.884 . . . . 0.0 111.559 -179.343 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 203' ' ' VAL . . . . . 0.483 HG12 ' O ' ' A' ' 200' ' ' LEU . 14.2 p -81.73 -36.7 14.59 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.13 0 CA-C-N 116.765 -0.198 . . . . 0.0 110.813 -179.141 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 204' ' ' THR . . . . . . . . . . . . . 65.8 m -63.43 -58.56 6.67 Favored 'General case' 0 C--N 1.329 -0.305 0 C-N-CA 120.713 -0.395 . . . . 0.0 110.642 179.169 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 205' ' ' LYS . . . . . 0.757 ' HE2' ' HB2' ' A' ' 47' ' ' ALA . 57.7 mttp -60.88 -58.01 10.26 Favored 'General case' 0 C--N 1.328 -0.361 0 N-CA-C 112.609 0.596 . . . . 0.0 112.609 -178.464 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 56.5 t -71.77 -37.36 62.02 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 N-CA-C 112.317 0.488 . . . . 0.0 112.317 -178.432 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 207' ' ' GLY . . . . . 0.53 ' O ' HG13 ' A' ' 211' ' ' ILE . . . -56.92 -61.67 7.24 Favored Glycine 0 CA--C 1.517 0.18 0 C-N-CA 120.665 -0.779 . . . . 0.0 113.793 -178.799 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 208' ' ' PHE . . . . . 0.609 ' HB2' ' HG ' ' A' ' 163' ' ' LEU . 0.9 OUTLIER -72.73 -27.25 61.93 Favored 'General case' 0 C--O 1.222 -0.368 0 CA-C-N 117.571 0.686 . . . . 0.0 110.771 -179.31 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 209' ' ' GLY . . . . . 0.52 ' O ' ' HB3' ' A' ' 212' ' ' ALA . . . -63.34 -32.73 85.15 Favored Glycine 0 N--CA 1.448 -0.542 0 N-CA-C 111.629 -0.588 . . . . 0.0 111.629 178.471 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 210' ' ' PHE . . . . . . . . . . . . . 0.8 OUTLIER -74.06 -47.81 34.09 Favored 'General case' 0 CA--C 1.515 -0.397 0 N-CA-C 108.221 -1.029 . . . . 0.0 108.221 178.543 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 211' ' ' ILE . . . . . 0.53 HG13 ' O ' ' A' ' 207' ' ' GLY . 4.4 mt -63.43 -27.52 43.18 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.434 0 N-CA-C 107.678 -1.23 . . . . 0.0 107.678 176.83 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 212' ' ' ALA . . . . . 0.52 ' HB3' ' O ' ' A' ' 209' ' ' GLY . . . -62.76 -40.81 98.42 Favored 'General case' 0 N--CA 1.451 -0.418 0 CA-C-N 114.447 -1.252 . . . . 0.0 110.622 -179.788 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 213' ' ' LEU . . . . . . . . . . . . . 86.4 mt -69.44 -47.29 64.54 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 115.171 -0.922 . . . . 0.0 111.44 -179.501 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 214' ' ' ASP . . . . . . . . . . . . . 14.3 t70 -56.32 -53.1 61.34 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.391 -0.368 . . . . 0.0 111.079 -179.944 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 215' ' ' ALA . . . . . . . . . . . . . . . -56.88 -56.24 24.22 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.06 -0.518 . . . . 0.0 111.341 -179.813 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 216' ' ' ALA . . . . . . . . . . . . . . . -56.78 -32.13 65.34 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.234 -179.897 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 217' ' ' ALA . . . . . . . . . . . . . . . -64.73 -34.38 78.18 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.298 -0.41 . . . . 0.0 110.197 179.793 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 218' ' ' THR . . . . . . . . . . . . . 93.0 m . . . . . 0 C--N 1.328 -0.33 0 CA-C-N 115.789 -0.641 . . . . 0.0 110.76 179.536 . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.322 0 N-CA-C 112.672 -0.171 . . . . 0.0 112.672 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 4' ' ' LEU . . . . . 0.412 ' HB2' ' HH2' ' A' ' 60' ' ' TRP . 81.9 mt -65.64 -36.65 84.32 Favored 'General case' 0 N--CA 1.45 -0.436 0 CA-C-O 120.804 0.335 . . . . 0.0 111.117 -179.844 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 67.1 p -57.21 -30.64 64.73 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.01 -0.541 . . . . 0.0 111.725 -179.651 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 27.3 p -58.8 -38.32 78.32 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 116.524 -0.307 . . . . 0.0 111.344 -179.609 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 7' ' ' LEU . . . . . . . . . . . . . 4.2 mm? -63.5 -51.45 65.49 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.106 -179.941 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 8' ' ' PHE . . . . . 0.484 ' HB2' ' HB2' ' A' ' 55' ' ' ALA . 74.1 m-85 -61.2 -33.23 73.13 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.512 179.928 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 9' ' ' TRP . . . . . 0.473 ' O ' HG13 ' A' ' 13' ' ' ILE . 9.1 m95 -66.15 -38.52 88.31 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 116.067 -0.515 . . . . 0.0 110.241 179.999 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 73.2 mt -65.7 -32.63 74.3 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 115.787 -0.642 . . . . 0.0 110.005 179.464 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -71.02 -33.64 65.31 Favored Glycine 0 N--CA 1.448 -0.517 0 C-N-CA 120.953 -0.642 . . . . 0.0 111.757 179.129 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 12' ' ' ALA . . . . . 0.456 ' O ' HD23 ' A' ' 16' ' ' LEU . . . -70.02 -32.43 70.58 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 120.889 0.376 . . . . 0.0 110.53 179.315 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 13' ' ' ILE . . . . . 0.473 HG13 ' O ' ' A' ' 9' ' ' TRP . 73.8 mt -66.95 -53.81 30.65 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.233 0 CA-C-N 116.021 -0.536 . . . . 0.0 110.577 179.721 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -64.11 -25.09 69.28 Favored Glycine 0 N--CA 1.451 -0.366 0 C-N-CA 120.657 -0.783 . . . . 0.0 112.042 179.677 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 15' ' ' MET . . . . . 0.536 ' HB3' ' HB2' ' A' ' 48' ' ' ALA . 0.0 OUTLIER -72.54 -54.47 9.11 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.559 0.219 . . . . 0.0 110.933 179.82 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 16' ' ' LEU . . . . . 0.456 HD23 ' O ' ' A' ' 12' ' ' ALA . 3.9 mm? -53.13 -45.72 68.47 Favored 'General case' 0 C--N 1.332 -0.179 0 CA-C-N 116.403 -0.362 . . . . 0.0 110.921 179.527 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 83.7 t -61.06 -40.29 85.18 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.153 0 CA-C-N 116.372 -0.376 . . . . 0.0 110.457 179.666 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -67.68 -41.73 88.81 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.859 -0.686 . . . . 0.0 111.802 179.188 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 16.3 m -51.14 -53.76 31.44 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.989 0.423 . . . . 0.0 110.711 -179.982 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 62.6 mt -71.71 -32.22 67.55 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 115.786 -0.643 . . . . 0.0 111.083 179.84 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 21' ' ' ALA . . . . . 0.46 ' O ' ' HB2' ' A' ' 25' ' ' ALA . . . -58.33 -56.67 19.13 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.793 -179.605 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 22' ' ' PHE . . . . . 0.496 ' HB2' HG22 ' A' ' 41' ' ' VAL . 4.7 m-85 -71.11 -30.75 66.91 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.409 -0.359 . . . . 0.0 111.337 -179.128 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -64.03 -51.24 65.11 Favored 'General case' 0 C--N 1.327 -0.4 0 N-CA-C 112.369 0.507 . . . . 0.0 112.369 -179.17 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 24' ' ' TRP . . . . . 0.53 ' CE3' ' HA ' ' A' ' 24' ' ' TRP . 2.4 t-105 -86.67 -26.76 24.15 Favored 'General case' 0 N--CA 1.442 -0.842 0 N-CA-C 113.326 0.861 . . . . 0.0 113.326 -177.655 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 25' ' ' ALA . . . . . 0.46 ' HB2' ' O ' ' A' ' 21' ' ' ALA . . . . . . . . 0 C--N 1.314 -0.947 0 N-CA-C 109.586 -0.524 . . . . 0.0 109.586 178.785 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.453 -0.215 0 N-CA-C 112.767 -0.133 . . . . 0.0 112.767 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 8.8 mm-40 -92.14 -23.6 19.36 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.794 0.331 . . . . 0.0 110.949 -179.964 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 34' ' ' ARG . . . . . . . . . . . . . 53.1 mtm180 -56.4 -28.34 59.04 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.156 -0.475 . . . . 0.0 111.848 -179.677 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 19.0 tpp180 -55.27 -59.05 5.33 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-O 120.744 0.307 . . . . 0.0 111.408 -179.634 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 42.3 m-85 -71.96 -34.81 69.29 Favored 'General case' 0 C--N 1.33 -0.244 0 N-CA-C 112.333 0.494 . . . . 0.0 112.333 -178.783 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 37' ' ' TYR . . . . . 0.412 ' O ' HG23 ' A' ' 41' ' ' VAL . 29.4 m-85 -70.39 -56.25 7.13 Favored 'General case' 0 N--CA 1.464 0.226 0 N-CA-C 111.619 0.229 . . . . 0.0 111.619 -179.221 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 77.9 t -56.85 -37.23 52.85 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.232 0 CA-C-O 120.8 0.333 . . . . 0.0 110.87 179.799 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 21.9 m -62.25 -51.18 68.75 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.845 179.313 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 40' ' ' LEU . . . . . 0.4 HD13 ' CE1' ' A' ' 208' ' ' PHE . 18.1 tp -59.87 -50.93 71.86 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 115.926 -0.579 . . . . 0.0 110.792 179.978 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 41' ' ' VAL . . . . . 0.496 HG22 ' HB2' ' A' ' 22' ' ' PHE . 65.3 t -58.84 -34.09 51.31 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.373 0 CA-C-N 115.775 -0.648 . . . . 0.0 109.998 179.169 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -58.76 -41.81 96.11 Favored Glycine 0 N--CA 1.448 -0.542 0 C-N-CA 120.829 -0.7 . . . . 0.0 111.657 179.429 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 43' ' ' ILE . . . . . 0.501 HD13 HD13 ' A' ' 83' ' ' ILE . 1.1 mt -61.75 -51.16 75.97 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.176 0 CA-C-O 120.847 0.356 . . . . 0.0 110.508 179.201 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 79.3 p -62.2 -23.27 66.53 Favored 'General case' 0 C--N 1.333 -0.132 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.088 179.756 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -77.55 -56.94 3.72 Favored Glycine 0 C--N 1.33 0.225 0 C-N-CA 120.832 -0.699 . . . . 0.0 112.406 179.916 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 46' ' ' ILE . . . . . 0.571 HD12 HD12 ' A' ' 78' ' ' LEU . 13.1 pt -58.49 -37.14 62.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-O 121.051 0.453 . . . . 0.0 110.721 179.77 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 47' ' ' ALA . . . . . 0.692 ' HB2' ' HE2' ' A' ' 205' ' ' LYS . . . -68.46 -41.02 80.78 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 115.97 -0.559 . . . . 0.0 110.89 179.113 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 48' ' ' ALA . . . . . 0.536 ' HB2' ' HB3' ' A' ' 15' ' ' MET . . . -55.69 -42.09 74.67 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-N 115.805 -0.634 . . . . 0.0 111.763 -179.486 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 49' ' ' VAL . . . . . 0.46 ' O ' HG13 ' A' ' 53' ' ' VAL . 8.6 m -75.56 -37.44 36.98 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.545 -0.298 . . . . 0.0 111.6 -179.516 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -60.61 -43.59 97.26 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 121.035 0.445 . . . . 0.0 111.061 179.809 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 51' ' ' TYR . . . . . 0.514 ' HE2' ' HE2' ' A' ' 15' ' ' MET . 43.3 m-85 -73.1 -32.38 64.94 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-N 115.933 -0.576 . . . . 0.0 110.484 -179.77 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -69.34 -38.97 78.41 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-N 115.897 -0.592 . . . . 0.0 111.1 179.549 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 53' ' ' VAL . . . . . 0.46 HG13 ' O ' ' A' ' 49' ' ' VAL . 33.3 m -74.62 -47.39 39.04 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.224 0 CA-C-N 116.418 -0.356 . . . . 0.0 110.573 180.0 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 54' ' ' MET . . . . . 0.454 ' N ' HG23 ' A' ' 53' ' ' VAL . 75.3 mtm -61.37 -31.77 71.67 Favored 'General case' 0 N--CA 1.455 -0.178 0 N-CA-C 109.62 -0.511 . . . . 0.0 109.62 179.058 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 55' ' ' ALA . . . . . 0.484 ' HB2' ' HB2' ' A' ' 8' ' ' PHE . . . -69.31 -22.83 63.76 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 115.588 -0.733 . . . . 0.0 110.933 179.215 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 63.8 mt -87.51 0.12 56.02 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 116.167 -0.469 . . . . 0.0 111.409 -179.797 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 90.5 -21.49 32.12 Favored Glycine 0 N--CA 1.452 -0.261 0 C-N-CA 120.564 -0.827 . . . . 0.0 113.115 179.522 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 58' ' ' VAL . . . . . 0.437 HG12 ' O ' ' A' ' 53' ' ' VAL . 13.7 p -68.36 148.7 11.68 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.215 0 CA-C-N 116.887 0.344 . . . . 0.0 110.822 179.955 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 59' ' ' GLY . . . . . 0.402 ' HA3' ' HG2' ' A' ' 71' ' ' PRO . . . 92.44 -5.06 77.37 Favored Glycine 0 N--CA 1.45 -0.403 0 C-N-CA 120.648 -0.787 . . . . 0.0 112.403 -179.573 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 60' ' ' TRP . . . . . 0.412 ' HH2' ' HB2' ' A' ' 4' ' ' LEU . 15.9 m0 -86.19 108.09 18.19 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.55 0.214 . . . . 0.0 110.954 -179.861 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 61' ' ' VAL . . . . . 0.463 HG13 HG23 ' A' ' 68' ' ' VAL . 7.5 p -111.8 128.26 25.69 Favored Pre-proline 0 CA--C 1.533 0.317 0 CA-C-N 116.52 -0.309 . . . . 0.0 111.108 179.804 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 73.8 Cg_endo -75.23 155.27 41.85 Favored 'Trans proline' 0 C--N 1.35 0.645 0 C-N-CA 122.422 2.082 . . . . 0.0 112.648 -179.679 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 80.7 t -143.21 89.73 0.4 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 115.826 -0.625 . . . . 0.0 110.858 179.929 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . 59.9 -86.86 0.02 OUTLIER 'General case' 0 C--N 1.331 -0.199 0 CA-C-N 116.065 -0.516 . . . . 0.0 111.467 179.953 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 6.2 mp0 -121.52 -19.64 6.84 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 116.286 -0.415 . . . . 0.0 110.652 179.962 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 66' ' ' ARG . . . . . . . . . . . . . 45.6 mtm180 -101.24 161.52 13.56 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 115.919 -0.582 . . . . 0.0 110.499 179.913 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 56.2 m -122.44 137.63 54.81 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.35 -0.386 . . . . 0.0 111.269 -179.804 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 68' ' ' VAL . . . . . 0.463 HG23 HG13 ' A' ' 61' ' ' VAL . 21.7 m -127.37 146.64 32.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.025 -0.534 . . . . 0.0 110.802 179.772 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 69' ' ' PHE . . . . . . . . . . . . . 23.1 m-85 -109.44 112.18 24.15 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.154 -179.261 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 70' ' ' VAL . . . . . 0.546 ' HB ' ' HD3' ' A' ' 71' ' ' PRO . 13.0 t -62.95 -49.61 80.89 Favored Pre-proline 0 C--N 1.324 -0.508 0 CA-C-N 116.227 -0.442 . . . . 0.0 112.021 -178.901 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 71' ' ' PRO . . . . . 0.546 ' HD3' ' HB ' ' A' ' 70' ' ' VAL . 38.2 Cg_exo -60.74 -18.46 55.98 Favored 'Trans proline' 0 C--N 1.35 0.616 0 C-N-CA 122.039 1.826 . . . . 0.0 112.985 -179.663 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 72' ' ' ARG . . . . . 0.478 ' NH2' HG13 ' A' ' 197' ' ' ILE . 77.5 ttt180 -76.08 -55.6 5.44 Favored 'General case' 0 C--O 1.235 0.303 0 CA-C-O 120.796 0.331 . . . . 0.0 111.86 -179.093 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 73' ' ' TYR . . . . . . . . . . . . . 27.1 m-85 -67.52 -36.15 80.49 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-O 120.817 0.342 . . . . 0.0 110.321 -179.545 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 74' ' ' ILE . . . . . 0.586 ' O ' HD23 ' A' ' 78' ' ' LEU . 0.3 OUTLIER -67.14 -43.05 88.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 N-CA-C 109.686 -0.487 . . . . 0.0 109.686 179.344 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 75' ' ' ASP . . . . . 0.403 ' HA ' HD21 ' A' ' 78' ' ' LEU . 12.0 t70 -51.95 -40.72 61.3 Favored 'General case' 0 CA--C 1.519 -0.226 0 N-CA-C 109.534 -0.543 . . . . 0.0 109.534 179.009 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 76' ' ' TRP . . . . . 0.411 ' HZ2' HG23 ' A' ' 197' ' ' ILE . 44.2 m0 -66.34 -35.5 80.51 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 115.794 -0.639 . . . . 0.0 110.825 179.425 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 77' ' ' ILE . . . . . 0.466 ' O ' ' HG2' ' A' ' 81' ' ' PRO . 88.0 mt -59.75 -40.73 83.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.094 -0.503 . . . . 0.0 112.318 -179.446 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 78' ' ' LEU . . . . . 0.586 HD23 ' O ' ' A' ' 74' ' ' ILE . 0.6 OUTLIER -91.94 -28.34 17.31 Favored 'General case' 0 CA--C 1.535 0.371 0 N-CA-C 113.038 0.755 . . . . 0.0 113.038 -179.546 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 65.3 p -79.65 -53.09 7.17 Favored 'General case' 0 N--CA 1.469 0.511 0 N-CA-C 113.468 0.914 . . . . 0.0 113.468 -178.41 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 80' ' ' THR . . . . . 0.593 ' HB ' ' HD3' ' A' ' 81' ' ' PRO . 3.8 m -50.92 -54.02 41.6 Favored Pre-proline 0 CA--C 1.533 0.291 0 N-CA-C 112.409 0.522 . . . . 0.0 112.409 -178.27 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 81' ' ' PRO . . . . . 0.593 ' HD3' ' HB ' ' A' ' 80' ' ' THR . 32.3 Cg_exo -60.08 -22.41 69.51 Favored 'Trans proline' 0 C--N 1.351 0.687 0 C-N-CA 121.869 1.712 . . . . 0.0 111.761 179.723 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 82' ' ' LEU . . . . . . . . . . . . . 15.4 tp -74.32 -33.03 63.06 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.067 -0.515 . . . . 0.0 109.921 179.647 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 83' ' ' ILE . . . . . 0.501 HD13 HD13 ' A' ' 43' ' ' ILE . 35.4 mm -68.79 -53.03 29.24 Favored 'Isoleucine or valine' 0 C--O 1.235 0.309 0 CA-C-N 115.845 -0.616 . . . . 0.0 110.037 179.04 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 84' ' ' VAL . . . . . 0.717 HG11 HD22 ' A' ' 105' ' ' ASN . 30.8 m -61.67 -30.18 47.75 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.221 0 CA-C-N 116.085 -0.507 . . . . 0.0 109.832 179.043 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 85' ' ' TYR . . . . . 0.41 ' HB2' ' O ' ' A' ' 81' ' ' PRO . 44.2 t80 -66.82 -34.68 78.35 Favored 'General case' 0 N--CA 1.454 -0.251 0 CA-C-N 115.665 -0.698 . . . . 0.0 109.386 178.724 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 86' ' ' PHE . . . . . . . . . . . . . 18.9 t80 -59.2 -51.45 69.94 Favored 'General case' 0 CA--C 1.519 -0.234 0 CA-C-N 115.735 -0.666 . . . . 0.0 109.427 178.983 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 10.5 mp -60.51 -32.29 71.32 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 115.55 -0.75 . . . . 0.0 110.04 179.28 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 88' ' ' GLY . . . . . 0.455 ' HA2' HD13 ' A' ' 93' ' ' LEU . . . -68.59 -28.21 73.32 Favored Glycine 0 N--CA 1.449 -0.438 0 C-N-CA 120.751 -0.738 . . . . 0.0 111.697 179.382 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 75.9 mt -72.49 -39.25 67.82 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-O 120.982 0.42 . . . . 0.0 110.278 179.43 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 70.5 mt -59.9 -53.1 61.86 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 115.76 -0.654 . . . . 0.0 110.603 179.569 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 91' ' ' ALA . . . . . 0.551 ' HB2' ' HB2' ' A' ' 149' ' ' ALA . . . -72.33 -52.07 17.81 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.126 -0.488 . . . . 0.0 111.062 179.89 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 97.21 57.24 1.08 Allowed Glycine 0 N--CA 1.453 -0.228 0 C-N-CA 120.817 -0.706 . . . . 0.0 112.207 -179.899 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 93' ' ' LEU . . . . . 0.592 HD23 ' HB3' ' A' ' 97' ' ' GLU . 8.9 mp -60.5 172.65 0.84 Allowed 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 121.045 0.45 . . . . 0.0 111.35 -179.704 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 94' ' ' ASP . . . . . 0.429 ' HB2' ' HG2' ' A' ' 97' ' ' GLU . 8.0 m-20 -82.63 172.55 12.82 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-N 115.904 -0.589 . . . . 0.0 110.634 179.907 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 38.3 t -56.24 -48.68 76.04 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.206 -179.839 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 99.2 mtt180 -70.4 -43.38 70.15 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.268 -0.424 . . . . 0.0 111.196 -179.835 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 97' ' ' GLU . . . . . 0.592 ' HB3' HD23 ' A' ' 93' ' ' LEU . 21.5 mm-40 -52.19 -48.0 65.26 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.991 -179.59 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 98' ' ' PHE . . . . . 0.453 ' O ' HG12 ' A' ' 102' ' ' ILE . 11.6 m-85 -57.5 -45.2 85.18 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-O 120.988 0.423 . . . . 0.0 110.19 179.177 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -62.59 -26.43 68.36 Favored Glycine 0 N--CA 1.45 -0.417 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.421 179.811 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 97.1 mt -73.28 -47.4 46.76 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.238 0 N-CA-C 111.876 0.324 . . . . 0.0 111.876 -179.632 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 26.5 m -69.19 -35.13 66.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 N-CA-C 111.9 0.333 . . . . 0.0 111.9 -179.169 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 102' ' ' ILE . . . . . 0.453 HG12 ' O ' ' A' ' 98' ' ' PHE . 48.6 mm -72.23 -47.92 51.17 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.25 0 CA-C-N 116.674 -0.239 . . . . 0.0 111.596 -179.294 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 14.4 t -60.22 -37.63 80.92 Favored 'General case' 0 C--O 1.234 0.273 0 CA-C-O 121.02 0.438 . . . . 0.0 110.879 179.895 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 104' ' ' LEU . . . . . 0.541 ' O ' HG12 ' A' ' 107' ' ' VAL . 31.3 tp -60.52 -50.15 74.68 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 115.975 -0.557 . . . . 0.0 110.512 179.648 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 105' ' ' ASN . . . . . 0.717 HD22 HG11 ' A' ' 84' ' ' VAL . 4.0 m-20 -59.27 -31.69 69.33 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.012 179.778 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 96.9 m -61.01 -57.82 11.0 Favored 'General case' 0 C--N 1.331 -0.204 0 CA-C-N 116.547 -0.297 . . . . 0.0 111.478 -179.292 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 107' ' ' VAL . . . . . 0.541 HG12 ' O ' ' A' ' 104' ' ' LEU . 14.2 p -56.4 -35.46 43.76 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.242 -0.436 . . . . 0.0 110.742 -179.912 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 108' ' ' VAL . . . . . 0.508 HG23 ' O ' ' A' ' 104' ' ' LEU . 82.1 t -61.68 -57.8 10.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.038 -0.528 . . . . 0.0 111.424 179.624 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 109' ' ' MET . . . . . 0.505 ' HG2' ' O ' ' A' ' 105' ' ' ASN . 5.4 mmt -58.39 -35.2 71.64 Favored 'General case' 0 C--N 1.333 -0.146 0 CA-C-N 116.546 -0.297 . . . . 0.0 110.928 -179.683 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 8.3 mt -68.39 -33.17 73.77 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.307 -0.406 . . . . 0.0 110.696 179.785 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -61.75 -45.0 95.8 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 121.153 0.502 . . . . 0.0 109.745 178.989 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . -73.81 -33.34 57.89 Favored Glycine 0 N--CA 1.448 -0.507 0 CA-C-N 115.595 -0.729 . . . . 0.0 111.384 179.111 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 113' ' ' PHE . . . . . 0.405 ' HD2' HD11 ' A' ' 77' ' ' ILE . 1.1 t80 -53.27 -73.53 0.04 OUTLIER 'General case' 0 N--CA 1.455 -0.186 0 CA-C-O 121.093 0.473 . . . . 0.0 109.749 179.298 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 114' ' ' ALA . . . . . 0.413 ' O ' HG13 ' A' ' 118' ' ' VAL . . . -63.1 -21.44 66.18 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 115.68 -0.691 . . . . 0.0 110.805 179.618 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 115' ' ' GLY . . . . . 0.414 ' HA2' HD22 ' A' ' 126' ' ' LEU . . . -52.57 -49.24 53.46 Favored Glycine 0 C--N 1.335 0.473 0 C-N-CA 120.785 -0.721 . . . . 0.0 112.155 179.492 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -78.38 -15.75 58.36 Favored 'General case' 0 C--N 1.326 -0.414 0 N-CA-C 111.698 0.258 . . . . 0.0 111.698 179.939 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 117' ' ' MET . . . . . 0.462 ' HG2' HG21 ' A' ' 68' ' ' VAL . 57.6 mtt -102.35 15.6 28.69 Favored 'General case' 0 C--N 1.332 -0.194 0 CA-C-O 120.687 0.279 . . . . 0.0 111.731 -179.295 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 118' ' ' VAL . . . . . 0.413 HG13 ' O ' ' A' ' 114' ' ' ALA . 19.2 m -65.62 150.26 96.33 Favored Pre-proline 0 C--N 1.329 -0.303 0 CA-C-N 116.509 -0.314 . . . . 0.0 111.213 179.9 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 119' ' ' PRO . . . . . . . . . . . . . 91.5 Cg_endo -80.97 4.48 6.94 Favored 'Trans proline' 0 C--N 1.348 0.529 0 C-N-CA 122.508 2.139 . . . . 0.0 112.501 179.68 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -170.31 -123.71 0.7 Allowed Glycine 0 C--N 1.33 0.231 0 C-N-CA 120.637 -0.792 . . . . 0.0 112.747 -179.816 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 26.2 pt -105.44 9.77 9.3 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-O 120.698 0.285 . . . . 0.0 111.467 -179.716 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 13.9 mm-40 -58.0 -19.23 29.46 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-O 120.95 0.405 . . . . 0.0 110.75 179.626 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 123' ' ' ARG . . . . . 0.503 ' HB2' ' HH2' ' A' ' 178' ' ' TRP . 23.2 ptt180 -51.5 -35.37 39.98 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 115.67 -0.695 . . . . 0.0 111.903 -179.781 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 124' ' ' TYR . . . . . . . . . . . . . 25.7 m-85 -57.29 -35.31 69.65 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.807 0.337 . . . . 0.0 110.891 -179.875 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 125' ' ' ALA . . . . . . . . . . . . . . . -74.35 -48.97 24.8 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.064 179.813 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 126' ' ' LEU . . . . . 0.414 HD22 ' HA2' ' A' ' 115' ' ' GLY . 6.9 mp -53.33 -52.48 59.02 Favored 'General case' 0 C--N 1.332 -0.158 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.787 -179.981 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 127' ' ' PHE . . . . . . . . . . . . . 6.6 t80 -64.38 -37.54 87.87 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.281 -0.418 . . . . 0.0 110.684 179.999 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 128' ' ' GLY . . . . . . . . . . . . . . . -46.42 -45.02 16.52 Favored Glycine 0 C--N 1.332 0.337 0 C-N-CA 120.118 -1.039 . . . . 0.0 110.959 179.265 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 129' ' ' MET . . . . . . . . . . . . . 0.5 OUTLIER -70.46 -38.04 74.39 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 120.868 0.366 . . . . 0.0 110.073 178.722 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -63.61 -30.81 78.73 Favored Glycine 0 C--N 1.333 0.365 0 C-N-CA 121.056 -0.592 . . . . 0.0 112.951 -179.816 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -74.48 -53.56 9.26 Favored 'General case' 0 CA--C 1.519 -0.22 0 CA-C-N 116.779 0.29 . . . . 0.0 110.369 179.94 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 43.1 t -57.42 -40.33 73.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 N-CA-C 109.251 -0.648 . . . . 0.0 109.251 178.766 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -66.09 -37.09 84.9 Favored 'General case' 0 N--CA 1.452 -0.34 0 CA-C-N 115.218 -0.901 . . . . 0.0 110.041 178.893 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 134' ' ' PHE . . . . . 0.415 ' CZ ' ' HA ' ' A' ' 172' ' ' ALA . 82.9 t80 -57.01 -50.76 71.74 Favored 'General case' 0 N--CA 1.45 -0.461 0 CA-C-N 115.919 -0.582 . . . . 0.0 109.99 179.254 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 135' ' ' ILE . . . . . 0.53 ' O ' HG22 ' A' ' 138' ' ' VAL . 57.6 mt -58.13 -30.81 40.21 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.342 0 CA-C-N 115.668 -0.696 . . . . 0.0 109.779 179.161 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 136' ' ' GLY . . . . . 0.425 ' O ' ' HB3' ' A' ' 139' ' ' TYR . . . -65.48 -38.07 94.42 Favored Glycine 0 N--CA 1.447 -0.58 0 C-N-CA 120.224 -0.988 . . . . 0.0 110.966 178.438 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 137' ' ' LEU . . . . . . . . . . . . . 29.2 tp -69.32 -46.78 66.26 Favored 'General case' 0 C--N 1.331 -0.205 0 N-CA-C 110.449 -0.204 . . . . 0.0 110.449 179.399 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 138' ' ' VAL . . . . . 0.548 ' HA ' HD12 ' A' ' 141' ' ' LEU . 4.6 m -62.13 -31.89 52.85 Favored 'Isoleucine or valine' 0 C--O 1.234 0.255 0 N-CA-C 109.029 -0.73 . . . . 0.0 109.029 178.882 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 139' ' ' TYR . . . . . 0.425 ' HB3' ' O ' ' A' ' 136' ' ' GLY . 45.6 t80 -60.99 -37.2 81.62 Favored 'General case' 0 N--CA 1.453 -0.317 0 CA-C-N 115.176 -0.92 . . . . 0.0 108.879 178.053 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 140' ' ' TYR . . . . . 0.516 ' HB3' ' SD ' ' A' ' 145' ' ' MET . 24.0 m-85 -70.25 -35.22 73.65 Favored 'General case' 0 C--N 1.332 -0.168 0 CA-C-N 115.489 -0.778 . . . . 0.0 110.122 178.478 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 141' ' ' LEU . . . . . 0.548 HD12 ' HA ' ' A' ' 138' ' ' VAL . 96.1 mt -55.55 -39.83 71.12 Favored 'General case' 0 C--O 1.232 0.149 0 CA-C-N 115.976 -0.556 . . . . 0.0 110.156 179.343 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 2.3 t -104.05 0.15 10.19 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 115.775 -0.648 . . . . 0.0 110.953 179.889 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 143' ' ' GLY . . . . . 0.416 ' O ' HG22 ' A' ' 146' ' ' THR . . . -72.89 -148.81 0.97 Allowed Glycine 0 CA--C 1.519 0.33 0 C-N-CA 120.965 -0.636 . . . . 0.0 112.876 -179.726 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 144' ' ' PRO . . . . . . . . . . . . . 31.8 Cg_endo -63.73 -23.56 69.34 Favored 'Trans proline' 0 C--N 1.347 0.497 0 C-N-CA 122.629 2.22 . . . . 0.0 112.523 -179.901 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 145' ' ' MET . . . . . 0.576 ' HG2' HD21 ' A' ' 93' ' ' LEU . 84.2 mtp -53.57 -58.37 7.4 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.451 -179.81 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 146' ' ' THR . . . . . 0.416 HG22 ' O ' ' A' ' 143' ' ' GLY . 7.4 t -60.65 -32.2 71.39 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.382 -0.372 . . . . 0.0 111.337 -179.831 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 40.5 mt-10 -66.71 -34.65 78.33 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.283 -0.417 . . . . 0.0 111.071 -179.993 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 148' ' ' SER . . . . . . . . . . . . . 47.0 t -69.58 -45.32 68.94 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.051 -179.641 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 149' ' ' ALA . . . . . 0.558 ' HB1' HG22 ' A' ' 156' ' ' ILE . . . -63.88 -38.84 92.59 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.464 -179.665 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 150' ' ' SER . . . . . 0.586 ' HA ' ' HB2' ' A' ' 157' ' ' LYS . 81.8 p -67.54 -2.53 6.73 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.295 -0.411 . . . . 0.0 111.059 -179.817 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 151' ' ' GLN . . . . . . . . . . . . . 49.4 mt-30 -119.72 -1.64 10.53 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.26 -0.427 . . . . 0.0 111.244 -179.967 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 37.7 mmt180 -81.65 -51.6 8.04 Favored 'General case' 0 C--N 1.332 -0.185 0 CA-C-O 120.945 0.403 . . . . 0.0 110.746 179.712 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 153' ' ' SER . . . . . 0.577 ' HB3' HG12 ' A' ' 156' ' ' ILE . 23.1 t -158.17 172.28 18.68 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-N 115.865 -0.607 . . . . 0.0 110.544 179.254 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 154' ' ' SER . . . . . . . . . . . . . 39.6 t -69.91 -39.87 75.92 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-O 120.871 0.367 . . . . 0.0 110.317 179.418 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -76.99 -42.39 20.02 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.943 -0.646 . . . . 0.0 112.659 179.808 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 156' ' ' ILE . . . . . 0.577 HG12 ' HB3' ' A' ' 153' ' ' SER . 36.5 mm -48.86 -37.45 9.11 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.162 0 CA-C-O 120.863 0.363 . . . . 0.0 111.495 -179.778 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 157' ' ' LYS . . . . . 0.586 ' HB2' ' HA ' ' A' ' 150' ' ' SER . 54.8 tttm -67.72 -36.36 80.46 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.277 -179.712 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 43.3 t -71.8 -42.22 67.32 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.658 -179.378 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 159' ' ' LEU . . . . . 0.414 ' O ' ' HB2' ' A' ' 163' ' ' LEU . 10.7 mp -67.42 -35.23 78.86 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.342 -0.39 . . . . 0.0 111.74 -179.372 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 160' ' ' TYR . . . . . . . . . . . . . 23.8 t80 -72.78 -46.84 51.19 Favored 'General case' 0 C--N 1.33 -0.274 0 N-CA-C 112.179 0.437 . . . . 0.0 112.179 -178.676 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 161' ' ' VAL . . . . . 0.443 HG23 ' N ' ' A' ' 162' ' ' ARG . 24.6 m -62.98 -45.95 97.55 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 N-CA-C 112.353 0.501 . . . . 0.0 112.353 -178.952 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 162' ' ' ARG . . . . . 0.443 ' N ' HG23 ' A' ' 161' ' ' VAL . 36.2 mmt180 -66.33 -42.71 87.79 Favored 'General case' 0 C--N 1.328 -0.329 0 N-CA-C 111.807 0.299 . . . . 0.0 111.807 -179.141 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 163' ' ' LEU . . . . . 0.472 ' HG ' ' HB2' ' A' ' 208' ' ' PHE . 6.1 mp -71.45 -43.86 65.87 Favored 'General case' 0 C--N 1.329 -0.297 0 N-CA-C 111.957 0.354 . . . . 0.0 111.957 -179.251 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 164' ' ' ARG . . . . . 0.459 ' HG3' ' N ' ' A' ' 165' ' ' ASN . 5.6 ppt_? -68.38 -40.71 81.29 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 120.456 0.169 . . . . 0.0 111.073 -179.374 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 165' ' ' ASN . . . . . 0.594 ' O ' HG23 ' A' ' 169' ' ' VAL . 4.9 m-20 -58.89 -48.0 82.96 Favored 'General case' 0 C--N 1.332 -0.19 0 CA-C-O 120.945 0.403 . . . . 0.0 110.558 179.35 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 166' ' ' LEU . . . . . 0.522 ' O ' ' HG ' ' A' ' 170' ' ' LEU . 4.1 tt -63.69 -48.39 77.32 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 116.109 -0.496 . . . . 0.0 111.017 -179.958 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 167' ' ' THR . . . . . 0.427 ' O ' ' HB2' ' A' ' 171' ' ' TRP . 93.0 m -57.4 -53.91 52.74 Favored 'General case' 0 C--N 1.33 -0.251 0 N-CA-C 112.426 0.528 . . . . 0.0 112.426 -178.971 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 168' ' ' VAL . . . . . 0.513 ' HB ' HD13 ' A' ' 141' ' ' LEU . 12.9 p -55.95 -40.75 64.6 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 N-CA-C 112.335 0.494 . . . . 0.0 112.335 -179.281 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 169' ' ' VAL . . . . . 0.594 HG23 ' O ' ' A' ' 165' ' ' ASN . 61.2 t -57.71 -65.8 0.39 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.389 0 N-CA-C 111.987 0.366 . . . . 0.0 111.987 -179.518 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 170' ' ' LEU . . . . . 0.522 ' HG ' ' O ' ' A' ' 166' ' ' LEU . 0.8 OUTLIER -65.18 -27.75 68.92 Favored 'General case' 0 C--N 1.331 -0.212 0 N-CA-C 112.146 0.425 . . . . 0.0 112.146 -178.813 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 171' ' ' TRP . . . . . 0.44 ' N ' HD12 ' A' ' 170' ' ' LEU . 6.9 m0 -71.77 -30.23 65.35 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.83 0.348 . . . . 0.0 110.612 179.615 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 172' ' ' ALA . . . . . 0.415 ' HA ' ' CZ ' ' A' ' 134' ' ' PHE . . . -73.7 -6.77 48.93 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.768 179.997 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 173' ' ' ILE . . . . . 0.627 HG22 HD11 ' A' ' 177' ' ' ILE . 23.6 mm -87.43 -21.63 7.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 115.93 -0.577 . . . . 0.0 110.771 179.739 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 174' ' ' TYR . . . . . 0.417 ' HB2' ' HD3' ' A' ' 175' ' ' PRO . 24.3 m-85 -54.86 -49.55 91.18 Favored Pre-proline 0 N--CA 1.464 0.228 0 CA-C-N 116.287 -0.415 . . . . 0.0 111.833 -179.796 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 175' ' ' PRO . . . . . 0.417 ' HD3' ' HB2' ' A' ' 174' ' ' TYR . 88.6 Cg_exo -47.02 -29.27 8.34 Favored 'Trans proline' 0 C--N 1.352 0.756 0 C-N-CA 122.131 1.887 . . . . 0.0 112.161 179.894 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 176' ' ' PHE . . . . . 0.444 ' O ' ' HG ' ' A' ' 180' ' ' LEU . 81.8 m-85 -80.47 -46.76 15.36 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 115.918 -0.583 . . . . 0.0 111.757 -179.965 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 177' ' ' ILE . . . . . 0.627 HD11 HG22 ' A' ' 173' ' ' ILE . 2.0 mm -64.49 -38.41 82.52 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.54 0 CA-C-N 116.166 -0.47 . . . . 0.0 112.177 -178.299 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 178' ' ' TRP . . . . . 0.503 ' HH2' ' HB2' ' A' ' 123' ' ' ARG . 60.2 t90 -73.83 -41.98 61.54 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.91 0.386 . . . . 0.0 110.779 179.67 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 179' ' ' LEU . . . . . 0.461 ' O ' HG22 ' A' ' 185' ' ' VAL . 1.7 tm? -66.27 -49.95 65.39 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.066 -0.516 . . . . 0.0 111.078 -179.622 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 180' ' ' LEU . . . . . 0.611 HD22 HD11 ' A' ' 187' ' ' LEU . 14.0 mt -78.21 -47.94 16.91 Favored 'General case' 0 C--N 1.329 -0.301 0 N-CA-C 112.038 0.384 . . . . 0.0 112.038 -179.22 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . -54.32 177.94 0.27 Allowed Glycine 0 C--N 1.337 0.6 0 C-N-CA 120.649 -0.786 . . . . 0.0 113.066 -179.701 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 182' ' ' PRO . . . . . 0.587 ' HA ' ' HB2' ' A' ' 186' ' ' ALA . 71.9 Cg_exo -48.13 -44.93 27.12 Favored 'Trans proline' 0 CA--C 1.536 0.598 0 C-N-CA 122.908 2.405 . . . . 0.0 113.764 -179.793 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 183' ' ' PRO . . . . . 0.416 ' HD3' ' HB2' ' A' ' 182' ' ' PRO . 50.6 Cg_exo -54.85 -13.68 6.6 Favored 'Trans proline' 0 C--N 1.355 0.906 0 C-N-CA 122.028 1.819 . . . . 0.0 113.017 -179.845 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 184' ' ' GLY . . . . . . . . . . . . . . . -115.5 -101.05 2.3 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.517 -0.849 . . . . 0.0 112.635 -179.776 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 185' ' ' VAL . . . . . 0.461 HG22 ' O ' ' A' ' 179' ' ' LEU . 9.0 m -105.98 -5.35 9.97 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-O 120.904 0.383 . . . . 0.0 111.305 -179.803 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 186' ' ' ALA . . . . . 0.587 ' HB2' ' HA ' ' A' ' 182' ' ' PRO . . . 55.17 85.4 0.06 Allowed 'General case' 0 C--N 1.331 -0.203 0 CA-C-N 115.991 -0.549 . . . . 0.0 111.991 179.302 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 187' ' ' LEU . . . . . 0.611 HD11 HD22 ' A' ' 180' ' ' LEU . 16.7 mt -92.21 -49.5 6.15 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.512 179.146 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 188' ' ' LEU . . . . . . . . . . . . . 95.5 mt -96.61 -160.96 0.83 Allowed 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 115.698 -0.683 . . . . 0.0 110.635 -179.944 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 189' ' ' THR . . . . . . . . . . . . . 1.9 t -99.76 146.49 31.94 Favored Pre-proline 0 C--N 1.329 -0.318 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.855 179.951 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 190' ' ' PRO . . . . . 0.44 ' O ' HG23 ' A' ' 194' ' ' VAL . 86.9 Cg_exo -46.76 -44.09 22.53 Favored 'Trans proline' 0 C--N 1.349 0.567 0 C-N-CA 122.698 2.266 . . . . 0.0 113.244 -179.417 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 191' ' ' THR . . . . . . . . . . . . . 7.9 t -58.85 -43.4 90.78 Favored 'General case' 0 C--N 1.328 -0.345 0 N-CA-C 111.899 0.333 . . . . 0.0 111.899 -179.286 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 192' ' ' VAL . . . . . . . . . . . . . 45.7 t -71.77 -50.71 36.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.633 -0.258 . . . . 0.0 111.402 -179.743 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 193' ' ' ASP . . . . . . . . . . . . . 30.5 t70 -55.23 -45.34 75.98 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.452 -0.34 . . . . 0.0 111.066 -179.848 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 194' ' ' VAL . . . . . 0.44 HG23 ' O ' ' A' ' 190' ' ' PRO . 74.6 t -64.34 -35.55 74.51 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.944 179.706 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 195' ' ' ALA . . . . . . . . . . . . . . . -56.97 -48.59 78.02 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 116.577 -0.283 . . . . 0.0 111.211 179.726 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 196' ' ' LEU . . . . . 0.412 ' O ' ' HB3' ' A' ' 199' ' ' TYR . 97.5 mt -67.76 -40.82 84.02 Favored 'General case' 0 N--CA 1.462 0.169 0 CA-C-O 120.708 0.289 . . . . 0.0 110.687 179.696 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 197' ' ' ILE . . . . . 0.489 HG12 HG21 ' A' ' 177' ' ' ILE . 11.2 mm -57.83 -60.25 2.41 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.373 179.256 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 198' ' ' VAL . . . . . 0.409 ' O ' ' HB2' ' A' ' 202' ' ' LEU . 76.3 t -52.02 -33.96 16.86 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.452 0 CA-C-N 115.486 -0.779 . . . . 0.0 109.574 178.324 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 199' ' ' TYR . . . . . 0.428 ' O ' HG23 ' A' ' 203' ' ' VAL . 68.5 t80 -69.27 -37.98 78.15 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 115.353 -0.84 . . . . 0.0 110.365 179.889 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 200' ' ' LEU . . . . . . . . . . . . . 42.0 mt -62.35 -45.71 91.97 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 115.667 -0.697 . . . . 0.0 111.212 -179.56 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 201' ' ' ASP . . . . . . . . . . . . . 7.3 m-20 -71.07 -43.64 67.38 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.114 -179.659 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 202' ' ' LEU . . . . . 0.409 ' HB2' ' O ' ' A' ' 198' ' ' VAL . 1.1 tt -59.95 -30.25 68.95 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 115.884 -0.598 . . . . 0.0 111.411 -179.476 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 203' ' ' VAL . . . . . 0.428 HG23 ' O ' ' A' ' 199' ' ' TYR . 48.5 t -81.43 -36.84 15.04 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.293 -0.412 . . . . 0.0 111.552 -178.726 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 204' ' ' THR . . . . . . . . . . . . . 71.0 m -62.46 -54.99 31.94 Favored 'General case' 0 C--N 1.328 -0.365 0 C-N-CA 120.508 -0.477 . . . . 0.0 111.009 179.497 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 205' ' ' LYS . . . . . 0.692 ' HE2' ' HB2' ' A' ' 47' ' ' ALA . 50.5 mttp -67.84 -59.13 3.53 Favored 'General case' 0 C--N 1.33 -0.245 0 N-CA-C 112.529 0.566 . . . . 0.0 112.529 -178.495 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 59.9 t -70.42 -37.55 70.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 N-CA-C 112.168 0.433 . . . . 0.0 112.168 -178.609 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 207' ' ' GLY . . . . . 0.544 ' O ' HG13 ' A' ' 211' ' ' ILE . . . -64.0 -60.66 6.96 Favored Glycine 0 N--CA 1.452 -0.254 0 C-N-CA 120.438 -0.887 . . . . 0.0 113.359 -178.866 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 208' ' ' PHE . . . . . 0.509 ' O ' ' HB2' ' A' ' 212' ' ' ALA . 0.1 OUTLIER -65.25 -26.91 68.31 Favored 'General case' 0 C--O 1.224 -0.289 0 CA-C-N 117.051 0.425 . . . . 0.0 111.064 -179.289 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 209' ' ' GLY . . . . . 0.515 ' O ' ' HB3' ' A' ' 212' ' ' ALA . . . -69.39 -32.7 71.99 Favored Glycine 0 N--CA 1.447 -0.588 0 N-CA-C 111.593 -0.603 . . . . 0.0 111.593 178.726 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 210' ' ' PHE . . . . . . . . . . . . . 2.0 m-85 -74.56 -48.28 27.74 Favored 'General case' 0 CA--C 1.513 -0.462 0 N-CA-C 108.159 -1.052 . . . . 0.0 108.159 178.343 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 211' ' ' ILE . . . . . 0.544 HG13 ' O ' ' A' ' 207' ' ' GLY . 5.5 mt -62.03 -28.63 44.77 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.594 0 N-CA-C 107.517 -1.29 . . . . 0.0 107.517 176.423 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 212' ' ' ALA . . . . . 0.515 ' HB3' ' O ' ' A' ' 209' ' ' GLY . . . -62.53 -41.14 98.68 Favored 'General case' 0 N--CA 1.447 -0.587 0 CA-C-N 114.527 -1.215 . . . . 0.0 109.915 179.394 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 213' ' ' LEU . . . . . 0.425 ' HG ' ' O ' ' A' ' 209' ' ' GLY . 74.0 mt -70.31 -46.71 63.7 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-N 115.027 -0.988 . . . . 0.0 111.712 -179.826 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 214' ' ' ASP . . . . . . . . . . . . . 10.9 t70 -51.16 -54.86 21.36 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 120.923 0.392 . . . . 0.0 111.278 -179.476 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 215' ' ' ALA . . . . . 0.409 ' HB1' HD11 ' A' ' 159' ' ' LEU . . . -58.7 -52.79 64.19 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-N 115.978 -0.555 . . . . 0.0 111.367 -179.718 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 216' ' ' ALA . . . . . . . . . . . . . . . -58.92 -33.23 70.33 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.333 -0.394 . . . . 0.0 111.619 -179.586 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 217' ' ' ALA . . . . . . . . . . . . . . . -64.05 -36.11 82.92 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 121.012 0.434 . . . . 0.0 110.36 179.893 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 218' ' ' THR . . . . . . . . . . . . . 94.1 m . . . . . 0 C--N 1.328 -0.338 0 CA-C-N 115.69 -0.686 . . . . 0.0 110.977 179.572 . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.288 0 N-CA-C 112.532 -0.227 . . . . 0.0 112.532 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 4' ' ' LEU . . . . . 0.471 ' HA ' HD23 ' A' ' 7' ' ' LEU . 70.9 mt -72.97 -36.13 67.04 Favored 'General case' 0 N--CA 1.449 -0.491 0 CA-C-O 120.878 0.371 . . . . 0.0 110.989 179.835 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 45.5 p -53.09 -37.84 62.03 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 115.877 -0.601 . . . . 0.0 111.874 -179.466 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 70.8 p -56.34 -40.54 74.61 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.438 -0.346 . . . . 0.0 111.579 -179.491 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 7' ' ' LEU . . . . . 0.471 HD23 ' HA ' ' A' ' 4' ' ' LEU . 3.4 mm? -59.85 -52.49 65.21 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 116.402 -0.363 . . . . 0.0 110.967 179.997 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 8' ' ' PHE . . . . . 0.459 ' HB2' ' HB2' ' A' ' 55' ' ' ALA . 75.8 m-85 -58.5 -32.11 68.49 Favored 'General case' 0 C--N 1.331 -0.204 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.613 -179.907 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 9' ' ' TRP . . . . . 0.416 ' O ' HG12 ' A' ' 13' ' ' ILE . 17.1 m95 -67.19 -45.63 76.33 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.036 -0.529 . . . . 0.0 109.833 179.576 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 95.1 mt -58.1 -46.82 84.89 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 115.607 -0.724 . . . . 0.0 110.15 179.305 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -60.08 -34.56 84.3 Favored Glycine 0 N--CA 1.45 -0.415 0 C-N-CA 120.746 -0.74 . . . . 0.0 111.781 179.351 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -67.67 -30.4 69.93 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.767 0.317 . . . . 0.0 110.604 179.608 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 13' ' ' ILE . . . . . 0.416 HG12 ' O ' ' A' ' 9' ' ' TRP . 50.8 mm -67.35 -52.5 41.58 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.226 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.16 179.486 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -59.93 -34.67 84.13 Favored Glycine 0 N--CA 1.448 -0.503 0 C-N-CA 120.696 -0.764 . . . . 0.0 111.641 179.105 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 15' ' ' MET . . . . . 0.557 ' HB3' ' HB2' ' A' ' 48' ' ' ALA . 18.9 mmt -66.5 -40.42 89.24 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 120.666 0.269 . . . . 0.0 110.628 179.479 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -59.69 -40.46 87.92 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.313 -0.403 . . . . 0.0 110.149 179.353 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 60.5 t -61.4 -42.76 95.02 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.201 0 CA-C-N 116.058 -0.519 . . . . 0.0 110.53 179.34 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -69.36 -46.17 57.68 Favored Glycine 0 N--CA 1.452 -0.266 0 C-N-CA 120.793 -0.718 . . . . 0.0 111.927 179.626 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 24.6 m -50.69 -49.06 58.32 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-O 120.702 0.287 . . . . 0.0 111.249 -179.82 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 96.3 mt -72.06 -44.99 62.45 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 116.305 -0.407 . . . . 0.0 111.687 -179.85 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -59.78 -31.49 69.73 Favored 'General case' 0 C--N 1.329 -0.304 0 N-CA-C 112.095 0.405 . . . . 0.0 112.095 -179.007 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 22' ' ' PHE . . . . . 0.484 ' HB2' HG22 ' A' ' 41' ' ' VAL . 12.8 m-85 -91.19 -30.71 16.51 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 120.667 0.27 . . . . 0.0 111.429 -179.329 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -72.89 -50.68 22.3 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.948 0.404 . . . . 0.0 111.341 -179.69 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 24' ' ' TRP . . . . . . . . . . . . . 3.6 t-105 -61.62 -38.51 87.91 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-N 115.784 -0.643 . . . . 0.0 111.069 -179.809 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.33 -0.28 0 CA-C-O 120.718 0.294 . . . . 0.0 111.221 179.992 . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.351 0 N-CA-C 112.19 -0.364 . . . . 0.0 112.19 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 11.8 mm-40 -89.65 -20.6 23.47 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 121.009 0.433 . . . . 0.0 110.502 179.674 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 34' ' ' ARG . . . . . . . . . . . . . 34.2 ttm180 -52.09 -29.23 20.65 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 115.66 -0.7 . . . . 0.0 111.363 -179.862 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 41.8 ttm180 -59.39 -40.54 86.92 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-O 120.759 0.314 . . . . 0.0 110.845 179.861 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 91.8 m-85 -71.04 -32.4 69.13 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.878 179.753 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 37' ' ' TYR . . . . . 0.524 ' O ' HG23 ' A' ' 41' ' ' VAL . 61.0 m-85 -70.55 -54.7 11.09 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 116.055 -0.52 . . . . 0.0 111.243 -179.743 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 11.0 p -57.17 -36.5 51.93 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-O 120.914 0.388 . . . . 0.0 110.479 179.649 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 26.3 m -65.38 -45.2 85.03 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 115.896 -0.593 . . . . 0.0 110.565 179.474 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 40' ' ' LEU . . . . . 0.649 HD12 HD11 ' A' ' 43' ' ' ILE . 51.5 tp -65.6 -38.48 89.59 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 115.949 -0.568 . . . . 0.0 110.483 179.556 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 41' ' ' VAL . . . . . 0.524 HG23 ' O ' ' A' ' 37' ' ' TYR . 97.3 t -67.34 -34.34 68.32 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.446 0 CA-C-N 115.789 -0.641 . . . . 0.0 110.253 179.429 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 42' ' ' GLY . . . . . 0.416 ' O ' HG12 ' A' ' 46' ' ' ILE . . . -64.01 -46.59 90.96 Favored Glycine 0 N--CA 1.448 -0.545 0 CA-C-N 115.76 -0.655 . . . . 0.0 112.971 179.991 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 43' ' ' ILE . . . . . 0.649 HD11 HD12 ' A' ' 40' ' ' LEU . 39.4 pt -63.04 -44.03 99.36 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.217 0 CA-C-N 116.847 0.323 . . . . 0.0 111.659 -179.558 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 44' ' ' SER . . . . . 0.466 ' N ' HG13 ' A' ' 43' ' ' ILE . 72.1 m -66.62 -27.19 67.5 Favored 'General case' 0 C--N 1.332 -0.159 0 CA-C-O 120.911 0.386 . . . . 0.0 110.808 179.604 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -78.56 -49.74 6.48 Favored Glycine 0 CA--C 1.519 0.286 0 C-N-CA 121.036 -0.602 . . . . 0.0 113.306 -179.256 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 46' ' ' ILE . . . . . 0.682 HD12 HD12 ' A' ' 78' ' ' LEU . 7.7 pt -58.09 -44.02 86.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-O 120.848 0.356 . . . . 0.0 111.04 -179.588 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 47' ' ' ALA . . . . . 0.546 ' HB2' ' HE2' ' A' ' 205' ' ' LYS . . . -67.73 -39.01 84.31 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-O 120.794 0.331 . . . . 0.0 110.578 179.077 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 48' ' ' ALA . . . . . 0.557 ' HB2' ' HB3' ' A' ' 15' ' ' MET . . . -55.0 -48.01 73.88 Favored 'General case' 0 C--N 1.332 -0.18 0 CA-C-N 116.11 -0.496 . . . . 0.0 111.579 -179.888 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 49' ' ' VAL . . . . . 0.485 HG22 ' O ' ' A' ' 46' ' ' ILE . 28.7 m -67.78 -34.28 66.69 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.473 -0.33 . . . . 0.0 111.275 -179.548 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -63.7 -37.63 88.06 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-O 120.986 0.422 . . . . 0.0 111.132 179.627 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 51' ' ' TYR . . . . . 0.412 ' O ' ' HB3' ' A' ' 8' ' ' PHE . 33.4 m-85 -72.67 -34.56 67.3 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 116.082 -0.508 . . . . 0.0 110.516 -179.766 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -68.25 -42.76 79.21 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 115.979 -0.555 . . . . 0.0 111.056 179.566 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 53' ' ' VAL . . . . . 0.414 HG23 ' N ' ' A' ' 54' ' ' MET . 33.0 m -69.62 -43.75 80.08 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.126 0 CA-C-N 116.44 -0.346 . . . . 0.0 110.876 179.978 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 54' ' ' MET . . . . . 0.567 ' HG2' ' HG2' ' A' ' 71' ' ' PRO . 74.6 mtm -65.03 -34.19 77.83 Favored 'General case' 0 CA--C 1.519 -0.222 0 N-CA-C 109.582 -0.525 . . . . 0.0 109.582 178.955 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 55' ' ' ALA . . . . . 0.459 ' HB2' ' HB2' ' A' ' 8' ' ' PHE . . . -65.97 -17.31 64.59 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.414 -0.812 . . . . 0.0 111.009 179.49 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 95.9 mt -100.08 8.61 43.81 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.339 -0.391 . . . . 0.0 111.0 179.952 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 74.26 20.91 79.55 Favored Glycine 0 N--CA 1.45 -0.371 0 C-N-CA 120.809 -0.71 . . . . 0.0 112.492 179.991 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 24.9 t -92.19 130.72 40.89 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-O 120.784 0.326 . . . . 0.0 110.903 179.884 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 94.0 0.73 65.76 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.855 -0.688 . . . . 0.0 112.753 -179.911 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 60' ' ' TRP . . . . . . . . . . . . . 13.0 m0 -75.21 111.15 10.17 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.76 0.314 . . . . 0.0 110.89 179.864 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 8.4 p -110.77 132.0 21.83 Favored Pre-proline 0 C--N 1.33 -0.271 0 CA-C-N 116.344 -0.389 . . . . 0.0 111.059 179.887 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 74.4 Cg_endo -76.25 147.18 29.13 Favored 'Trans proline' 0 C--N 1.349 0.576 0 C-N-CA 122.372 2.048 . . . . 0.0 112.229 179.742 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 93.9 t -141.51 91.98 0.55 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 115.996 -0.547 . . . . 0.0 111.181 -179.791 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . 58.04 -87.79 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.01 -0.541 . . . . 0.0 111.771 179.574 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 9.0 tp10 -118.08 -21.43 8.26 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.452 -0.34 . . . . 0.0 111.251 -179.59 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 66' ' ' ARG . . . . . . . . . . . . . 99.6 mtt180 -107.03 162.98 13.37 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.368 -0.378 . . . . 0.0 110.63 179.875 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 33.4 m -118.96 124.6 47.43 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.968 0.414 . . . . 0.0 111.455 -179.843 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 68' ' ' VAL . . . . . 0.515 HG21 ' HB3' ' A' ' 117' ' ' MET . 57.7 t -103.6 146.64 10.95 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.361 0 CA-C-N 115.815 -0.63 . . . . 0.0 110.645 179.744 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 69' ' ' PHE . . . . . . . . . . . . . 16.8 m-85 -107.79 112.19 24.72 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.399 -0.364 . . . . 0.0 110.039 -179.688 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 70' ' ' VAL . . . . . 0.607 ' N ' ' HD2' ' A' ' 71' ' ' PRO . 21.5 t -66.73 -48.83 52.13 Favored Pre-proline 0 C--N 1.323 -0.56 0 CA-C-N 116.047 -0.524 . . . . 0.0 111.953 -179.285 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 71' ' ' PRO . . . . . 0.607 ' HD2' ' N ' ' A' ' 70' ' ' VAL . 18.2 Cg_endo -59.8 -17.78 45.24 Favored 'Trans proline' 0 C--N 1.35 0.654 0 C-N-CA 122.279 1.986 . . . . 0.0 113.183 -179.64 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 72' ' ' ARG . . . . . 0.409 HH22 HG22 ' A' ' 194' ' ' VAL . 23.9 ttm180 -78.46 -55.82 4.92 Favored 'General case' 0 C--O 1.234 0.278 0 C-N-CA 120.961 -0.296 . . . . 0.0 111.621 -179.607 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 73' ' ' TYR . . . . . 0.473 ' O ' HG13 ' A' ' 77' ' ' ILE . 95.2 m-85 -70.47 -31.64 68.87 Favored 'General case' 0 C--N 1.329 -0.29 0 C-N-CA 120.89 -0.324 . . . . 0.0 110.482 -179.652 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 74' ' ' ILE . . . . . 0.55 ' HA ' HD12 ' A' ' 77' ' ' ILE . 0.3 OUTLIER -69.5 -39.29 78.36 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 N-CA-C 109.259 -0.645 . . . . 0.0 109.259 178.716 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 75' ' ' ASP . . . . . 0.443 ' O ' ' HG ' ' A' ' 78' ' ' LEU . 14.8 t70 -57.23 -37.38 72.19 Favored 'General case' 0 N--CA 1.452 -0.334 0 N-CA-C 109.113 -0.699 . . . . 0.0 109.113 178.461 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 76' ' ' TRP . . . . . 0.435 ' HA ' ' OG1' ' A' ' 79' ' ' THR . 44.7 m0 -70.26 -34.03 72.31 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 115.611 -0.722 . . . . 0.0 110.527 179.086 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 77' ' ' ILE . . . . . 0.55 HD12 ' HA ' ' A' ' 74' ' ' ILE . 94.2 mt -58.45 -38.71 71.66 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.236 0 CA-C-N 116.285 -0.416 . . . . 0.0 111.022 179.781 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 78' ' ' LEU . . . . . 0.682 HD12 HD12 ' A' ' 46' ' ' ILE . 1.1 pp -91.52 -34.12 14.9 Favored 'General case' 0 CA--C 1.536 0.41 0 N-CA-C 113.205 0.817 . . . . 0.0 113.205 -179.643 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 79' ' ' THR . . . . . 0.467 HG22 ' CD1' ' A' ' 46' ' ' ILE . 52.1 p -76.09 -52.5 10.01 Favored 'General case' 0 N--CA 1.47 0.538 0 N-CA-C 113.316 0.858 . . . . 0.0 113.316 -178.314 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 80' ' ' THR . . . . . 0.543 ' N ' ' HD2' ' A' ' 81' ' ' PRO . 3.9 m -50.76 -48.94 82.1 Favored Pre-proline 0 CA--C 1.532 0.255 0 N-CA-C 112.961 0.726 . . . . 0.0 112.961 -178.162 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 81' ' ' PRO . . . . . 0.543 ' HD2' ' N ' ' A' ' 80' ' ' THR . 28.9 Cg_endo -61.37 -25.31 79.97 Favored 'Trans proline' 0 C--N 1.352 0.717 0 C-N-CA 121.549 1.499 . . . . 0.0 111.631 -179.885 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 82' ' ' LEU . . . . . 0.506 ' HB3' HG22 ' A' ' 43' ' ' ILE . 0.1 OUTLIER -74.43 -34.76 63.3 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 115.876 -0.602 . . . . 0.0 110.23 179.698 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 49.6 mm -67.46 -53.64 30.41 Favored 'Isoleucine or valine' 0 C--O 1.234 0.253 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.029 179.165 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 84' ' ' VAL . . . . . 0.757 HG11 HD22 ' A' ' 105' ' ' ASN . 33.0 m -59.94 -30.03 44.55 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.255 0 CA-C-N 115.959 -0.564 . . . . 0.0 109.552 178.96 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 85' ' ' TYR . . . . . . . . . . . . . 89.8 t80 -67.35 -33.39 75.15 Favored 'General case' 0 N--CA 1.454 -0.275 0 CA-C-N 115.536 -0.757 . . . . 0.0 109.591 178.772 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 86' ' ' PHE . . . . . . . . . . . . . 8.3 t80 -61.81 -50.72 71.16 Favored 'General case' 0 C--O 1.234 0.259 0 CA-C-N 115.769 -0.651 . . . . 0.0 109.87 179.317 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 8.0 mp -60.91 -31.1 70.62 Favored 'General case' 0 C--N 1.332 -0.193 0 CA-C-N 115.872 -0.604 . . . . 0.0 110.232 179.617 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -70.89 -27.67 71.88 Favored Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.971 -0.633 . . . . 0.0 112.122 179.461 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 73.4 mt -71.55 -45.52 62.06 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-O 120.94 0.4 . . . . 0.0 110.514 179.934 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 90' ' ' LEU . . . . . 0.463 HD11 HD22 ' A' ' 163' ' ' LEU . 98.0 mt -54.48 -43.21 71.55 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 115.797 -0.638 . . . . 0.0 111.477 -179.918 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 91' ' ' ALA . . . . . 0.435 ' HB2' ' HB2' ' A' ' 149' ' ' ALA . . . -78.6 -54.99 5.55 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 116.488 -0.324 . . . . 0.0 111.399 -179.748 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 105.23 63.96 0.65 Allowed Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.89 -0.672 . . . . 0.0 112.331 179.98 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 93' ' ' LEU . . . . . 0.572 HD23 ' HB3' ' A' ' 97' ' ' GLU . 7.4 mp -80.69 172.62 13.52 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.794 0.33 . . . . 0.0 111.032 -179.874 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 94' ' ' ASP . . . . . . . . . . . . . 14.2 m-20 -89.19 164.9 14.78 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.099 -0.5 . . . . 0.0 110.808 179.841 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 80.7 p -53.92 -34.54 59.85 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.113 -0.494 . . . . 0.0 111.086 -179.954 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 41.5 mmt180 -72.61 -48.4 40.02 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.374 -179.631 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 97' ' ' GLU . . . . . 0.572 ' HB3' HD23 ' A' ' 93' ' ' LEU . 42.3 mt-10 -54.94 -49.23 71.86 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 116.404 -0.362 . . . . 0.0 111.134 -179.837 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 98' ' ' PHE . . . . . 0.483 ' O ' HG12 ' A' ' 102' ' ' ILE . 33.0 m-85 -55.25 -49.94 70.74 Favored 'General case' 0 C--N 1.332 -0.175 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.689 179.755 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -54.42 -32.68 52.58 Favored Glycine 0 N--CA 1.452 -0.286 0 C-N-CA 120.93 -0.652 . . . . 0.0 112.694 -179.756 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 96.4 mt -69.54 -43.07 80.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-O 120.882 0.372 . . . . 0.0 111.629 -179.684 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 61.0 t -71.87 -40.58 68.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.325 -0.398 . . . . 0.0 111.989 -179.225 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 102' ' ' ILE . . . . . 0.483 HG12 ' O ' ' A' ' 98' ' ' PHE . 38.0 mm -68.78 -41.24 82.26 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.363 0 N-CA-C 111.954 0.353 . . . . 0.0 111.954 -179.097 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 103' ' ' THR . . . . . 0.429 HG23 ' N ' ' A' ' 104' ' ' LEU . 12.4 t -64.93 -44.5 89.31 Favored 'General case' 0 C--O 1.234 0.247 0 CA-C-O 120.679 0.276 . . . . 0.0 111.314 -179.719 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 104' ' ' LEU . . . . . 0.434 ' O ' HG23 ' A' ' 108' ' ' VAL . 9.2 tt -58.47 -44.18 89.21 Favored 'General case' 0 C--N 1.332 -0.164 0 CA-C-O 120.813 0.339 . . . . 0.0 110.252 179.776 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 105' ' ' ASN . . . . . 0.757 HD22 HG11 ' A' ' 84' ' ' VAL . 5.3 m-20 -56.29 -41.63 76.21 Favored 'General case' 0 N--CA 1.455 -0.179 0 CA-C-N 116.149 -0.478 . . . . 0.0 109.857 178.852 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 85.2 m -54.71 -40.14 68.91 Favored 'General case' 0 C--N 1.332 -0.157 0 CA-C-N 116.075 -0.511 . . . . 0.0 110.269 179.508 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 107' ' ' VAL . . . . . 0.404 HG12 ' SD ' ' A' ' 129' ' ' MET . 0.9 OUTLIER -67.45 -37.4 78.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 115.843 -0.617 . . . . 0.0 110.189 179.114 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 108' ' ' VAL . . . . . 0.434 HG23 ' O ' ' A' ' 104' ' ' LEU . 64.4 t -65.72 -52.04 54.99 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-N 115.33 -0.85 . . . . 0.0 111.686 -179.471 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 109' ' ' MET . . . . . 0.55 ' HG3' ' HA ' ' A' ' 77' ' ' ILE . 5.4 mmt -61.33 -39.72 91.57 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.35 -0.386 . . . . 0.0 111.18 -179.514 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 21.6 tp -64.42 -31.59 72.87 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.339 -0.392 . . . . 0.0 110.436 179.762 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 111' ' ' ALA . . . . . 0.403 ' O ' ' HB3' ' A' ' 126' ' ' LEU . . . -62.94 -56.59 15.85 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.528 179.344 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . -60.58 -36.8 92.25 Favored Glycine 0 C--N 1.329 0.193 0 C-N-CA 120.445 -0.883 . . . . 0.0 111.813 179.483 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 113' ' ' PHE . . . . . . . . . . . . . 10.1 t80 -49.45 -63.04 1.22 Allowed 'General case' 0 C--N 1.331 -0.222 0 CA-C-O 121.119 0.485 . . . . 0.0 110.201 179.429 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 114' ' ' ALA . . . . . 0.452 ' O ' HG13 ' A' ' 118' ' ' VAL . . . -69.66 -28.1 65.6 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 115.562 -0.744 . . . . 0.0 111.189 179.591 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -52.18 -35.87 43.16 Favored Glycine 0 C--N 1.332 0.316 0 CA-C-N 116.061 -0.518 . . . . 0.0 112.785 179.907 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -78.13 -44.81 25.04 Favored 'General case' 0 C--N 1.329 -0.316 0 N-CA-C 112.132 0.419 . . . . 0.0 112.132 -179.862 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 117' ' ' MET . . . . . 0.515 ' HB3' HG21 ' A' ' 68' ' ' VAL . 15.7 ptp -85.58 19.72 2.32 Favored 'General case' 0 C--N 1.33 -0.243 0 N-CA-C 112.149 0.426 . . . . 0.0 112.149 -179.007 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 118' ' ' VAL . . . . . 0.573 HG21 ' HB3' ' A' ' 123' ' ' ARG . 8.8 m -57.87 146.34 67.89 Favored Pre-proline 0 C--N 1.328 -0.332 0 CA-C-N 116.807 -0.178 . . . . 0.0 111.253 179.618 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 119' ' ' PRO . . . . . . . . . . . . . 71.8 Cg_endo -75.56 -9.06 19.87 Favored 'Trans proline' 0 C--N 1.347 0.476 0 C-N-CA 122.574 2.183 . . . . 0.0 112.381 -179.88 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -172.35 -122.95 0.68 Allowed Glycine 0 C--N 1.331 0.277 0 C-N-CA 120.662 -0.78 . . . . 0.0 112.711 -179.98 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 50.5 pt -83.38 8.06 1.39 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.23 0 CA-C-O 120.827 0.346 . . . . 0.0 111.334 -179.915 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 122' ' ' GLU . . . . . 0.478 ' HB2' ' HB ' ' A' ' 118' ' ' VAL . 11.7 mm-40 -58.57 -19.03 34.74 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.086 179.993 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 123' ' ' ARG . . . . . 0.573 ' HB3' HG21 ' A' ' 118' ' ' VAL . 12.6 ptt180 -52.33 -30.95 30.98 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.062 -0.517 . . . . 0.0 111.494 -179.842 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 124' ' ' TYR . . . . . . . . . . . . . 24.7 m-85 -71.96 -32.54 67.37 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.378 -0.373 . . . . 0.0 111.116 -179.686 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 125' ' ' ALA . . . . . . . . . . . . . . . -68.88 -51.07 44.14 Favored 'General case' 0 C--O 1.235 0.321 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.939 179.626 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 126' ' ' LEU . . . . . 0.403 ' HB3' ' O ' ' A' ' 111' ' ' ALA . 2.9 mm? -54.99 -55.85 26.28 Favored 'General case' 0 CA--C 1.52 -0.209 0 CA-C-N 116.015 -0.539 . . . . 0.0 110.882 -179.827 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 127' ' ' PHE . . . . . 0.464 ' HZ ' ' HB3' ' A' ' 175' ' ' PRO . 7.8 t80 -65.33 -33.25 75.52 Favored 'General case' 0 N--CA 1.45 -0.435 0 CA-C-N 116.258 -0.428 . . . . 0.0 111.466 -179.065 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 128' ' ' GLY . . . . . . . . . . . . . . . -49.67 -45.3 38.89 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 119.816 -1.183 . . . . 0.0 110.623 179.009 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 129' ' ' MET . . . . . 0.404 ' SD ' HG12 ' A' ' 107' ' ' VAL . 0.6 OUTLIER -71.71 -38.89 70.46 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 115.072 -0.564 . . . . 0.0 110.356 178.881 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -67.05 -27.41 73.44 Favored Glycine 0 C--N 1.331 0.283 0 CA-C-N 115.897 -0.592 . . . . 0.0 113.002 -179.613 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -74.85 -53.23 9.46 Favored 'General case' 0 C--N 1.328 -0.348 0 N-CA-C 110.012 -0.366 . . . . 0.0 110.012 179.86 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 95.9 t -57.23 -39.83 69.86 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.234 0 CA-C-O 121.347 0.594 . . . . 0.0 109.458 178.507 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -70.39 -34.17 72.24 Favored 'General case' 0 N--CA 1.452 -0.344 0 CA-C-N 115.297 -0.865 . . . . 0.0 110.69 179.423 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 134' ' ' PHE . . . . . 0.404 ' CZ ' ' HA ' ' A' ' 172' ' ' ALA . 50.2 t80 -55.4 -60.14 3.82 Favored 'General case' 0 N--CA 1.453 -0.304 0 CA-C-O 120.985 0.422 . . . . 0.0 110.164 179.689 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 135' ' ' ILE . . . . . 0.494 ' O ' HG22 ' A' ' 138' ' ' VAL . 0.0 OUTLIER -55.75 -34.74 37.24 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 115.764 -0.653 . . . . 0.0 109.854 178.975 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 136' ' ' GLY . . . . . 0.413 ' O ' ' HB3' ' A' ' 139' ' ' TYR . . . -58.1 -41.66 94.72 Favored Glycine 0 N--CA 1.449 -0.477 0 C-N-CA 120.389 -0.91 . . . . 0.0 111.488 178.777 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 137' ' ' LEU . . . . . . . . . . . . . 45.1 tp -66.05 -56.25 12.51 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-O 120.68 0.276 . . . . 0.0 110.446 179.215 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 138' ' ' VAL . . . . . 0.517 ' O ' HG23 ' A' ' 142' ' ' VAL . 2.7 m -55.12 -30.33 23.96 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.237 0 CA-C-O 121.134 0.492 . . . . 0.0 109.813 -179.994 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 139' ' ' TYR . . . . . 0.413 ' HB3' ' O ' ' A' ' 136' ' ' GLY . 12.2 t80 -61.8 -42.33 98.87 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 115.682 -0.69 . . . . 0.0 109.804 178.566 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 29.1 m-85 -69.29 -35.22 75.79 Favored 'General case' 0 C--N 1.333 -0.15 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.494 179.064 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 141' ' ' LEU . . . . . 0.406 ' HB3' ' HD3' ' A' ' 164' ' ' ARG . 11.0 mp -62.8 -27.22 69.16 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.502 179.578 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 142' ' ' VAL . . . . . 0.619 HG22 HH11 ' A' ' 164' ' ' ARG . 12.4 t -103.88 -11.6 9.28 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.226 0 CA-C-N 116.008 -0.542 . . . . 0.0 111.103 179.964 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . -76.66 -117.24 0.15 Allowed Glycine 0 CA--C 1.523 0.566 0 C-N-CA 120.937 -0.649 . . . . 0.0 113.115 -179.702 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 144' ' ' PRO . . . . . . . . . . . . . 47.2 Cg_endo -68.35 -23.51 38.2 Favored 'Trans proline' 0 C--N 1.35 0.638 0 C-N-CA 122.67 2.246 . . . . 0.0 113.195 -179.298 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 145' ' ' MET . . . . . . . . . . . . . 58.2 mtt -65.47 -30.27 71.03 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.676 0.274 . . . . 0.0 111.403 -179.775 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 146' ' ' THR . . . . . 0.422 ' OG1' ' HA ' ' A' ' 142' ' ' VAL . 82.9 m -81.16 -32.38 33.66 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.852 0.358 . . . . 0.0 111.345 -179.31 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 38.6 tt0 -75.92 -40.65 53.82 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.119 -179.919 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 148' ' ' SER . . . . . 0.433 ' HB3' ' HB1' ' A' ' 91' ' ' ALA . 46.0 t -70.3 -45.26 66.65 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.278 -0.419 . . . . 0.0 111.242 -179.473 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 149' ' ' ALA . . . . . 0.435 ' HB2' ' HB2' ' A' ' 91' ' ' ALA . . . -65.69 -32.33 73.82 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.27 -0.423 . . . . 0.0 111.416 -179.543 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 150' ' ' SER . . . . . . . . . . . . . 80.3 p -74.47 0.45 14.64 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.283 -0.417 . . . . 0.0 111.331 -179.717 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 151' ' ' GLN . . . . . . . . . . . . . 10.3 pt20 -136.3 9.84 3.22 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.54 -0.3 . . . . 0.0 110.996 179.787 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 1.5 tmt_? -83.84 -51.81 6.89 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-O 120.833 0.349 . . . . 0.0 110.435 179.997 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 153' ' ' SER . . . . . 0.676 ' HB2' HG12 ' A' ' 156' ' ' ILE . 20.8 m -157.54 172.47 18.5 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.024 -0.535 . . . . 0.0 110.507 179.314 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 154' ' ' SER . . . . . . . . . . . . . 48.1 t -73.05 -38.32 66.53 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.378 -0.374 . . . . 0.0 110.729 179.849 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -77.36 -27.55 59.4 Favored Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.944 -0.646 . . . . 0.0 112.718 179.993 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 156' ' ' ILE . . . . . 0.676 HG12 ' HB2' ' A' ' 153' ' ' SER . 38.1 mm -62.03 -35.44 68.52 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-O 120.799 0.333 . . . . 0.0 110.923 -179.944 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 157' ' ' LYS . . . . . . . . . . . . . 91.3 mttt -58.93 -55.55 33.75 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.067 -0.515 . . . . 0.0 111.617 -179.888 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 69.0 m -70.49 -38.58 74.38 Favored 'General case' 0 N--CA 1.463 0.21 0 N-CA-C 112.256 0.465 . . . . 0.0 112.256 -178.847 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 159' ' ' LEU . . . . . . . . . . . . . 39.0 tp -69.13 -36.25 77.26 Favored 'General case' 0 C--N 1.327 -0.411 0 N-CA-C 111.74 0.274 . . . . 0.0 111.74 -179.148 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 160' ' ' TYR . . . . . . . . . . . . . 57.0 t80 -73.96 -46.11 46.05 Favored 'General case' 0 C--N 1.328 -0.366 0 N-CA-C 111.9 0.333 . . . . 0.0 111.9 -179.027 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 29.4 m -59.96 -41.73 87.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-O 120.721 0.296 . . . . 0.0 111.332 -179.634 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 162' ' ' ARG . . . . . 0.537 ' HG2' HG21 ' A' ' 211' ' ' ILE . 23.3 tpp180 -68.99 -39.89 79.11 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 120.944 0.402 . . . . 0.0 110.97 179.949 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 163' ' ' LEU . . . . . 0.54 ' HG ' ' HB2' ' A' ' 208' ' ' PHE . 4.5 mp -68.25 -44.32 75.9 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.069 -0.514 . . . . 0.0 111.668 -179.505 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 164' ' ' ARG . . . . . 0.619 HH11 HG22 ' A' ' 142' ' ' VAL . 18.4 ttp85 -72.01 -52.97 14.45 Favored 'General case' 0 C--N 1.329 -0.324 0 N-CA-C 112.125 0.417 . . . . 0.0 112.125 -179.003 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 165' ' ' ASN . . . . . 0.444 ' O ' HG23 ' A' ' 169' ' ' VAL . 4.7 m-20 -52.31 -46.31 65.93 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-O 121.056 0.455 . . . . 0.0 110.534 -179.291 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 166' ' ' LEU . . . . . 0.528 ' O ' ' HG ' ' A' ' 170' ' ' LEU . 6.8 tt -64.9 -52.08 58.45 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-N 115.809 -0.632 . . . . 0.0 111.141 179.955 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 167' ' ' THR . . . . . 0.476 ' O ' ' HB2' ' A' ' 171' ' ' TRP . 96.4 m -61.32 -54.09 48.34 Favored 'General case' 0 N--CA 1.463 0.185 0 N-CA-C 112.608 0.596 . . . . 0.0 112.608 -178.653 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 168' ' ' VAL . . . . . . . . . . . . . 94.0 t -52.2 -41.09 32.56 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.185 0 N-CA-C 112.134 0.42 . . . . 0.0 112.134 -179.284 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 169' ' ' VAL . . . . . 0.444 HG23 ' O ' ' A' ' 165' ' ' ASN . 43.9 t -61.96 -64.63 0.6 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 N-CA-C 111.965 0.357 . . . . 0.0 111.965 -179.452 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 170' ' ' LEU . . . . . 0.528 ' HG ' ' O ' ' A' ' 166' ' ' LEU . 1.3 pp -62.55 -29.37 70.52 Favored 'General case' 0 C--N 1.331 -0.206 0 N-CA-C 112.081 0.4 . . . . 0.0 112.081 -178.777 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 171' ' ' TRP . . . . . 0.476 ' HB2' ' O ' ' A' ' 167' ' ' THR . 2.7 m0 -72.87 -30.78 64.25 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.842 0.353 . . . . 0.0 110.737 179.83 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 172' ' ' ALA . . . . . 0.404 ' HA ' ' CZ ' ' A' ' 134' ' ' PHE . . . -73.65 -6.21 45.29 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-O 121.093 0.473 . . . . 0.0 110.286 179.647 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 173' ' ' ILE . . . . . 0.467 ' O ' HG12 ' A' ' 177' ' ' ILE . 44.1 mm -85.14 -20.93 8.07 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.241 0 CA-C-N 115.678 -0.692 . . . . 0.0 110.484 179.148 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 174' ' ' TYR . . . . . . . . . . . . . 13.2 m-85 -53.21 -50.07 84.4 Favored Pre-proline 0 N--CA 1.464 0.268 0 CA-C-N 116.126 -0.488 . . . . 0.0 111.18 -179.867 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 175' ' ' PRO . . . . . 0.464 ' HB3' ' HZ ' ' A' ' 127' ' ' PHE . 93.1 Cg_exo -45.17 -33.07 7.78 Favored 'Trans proline' 0 C--N 1.351 0.684 0 C-N-CA 122.252 1.968 . . . . 0.0 112.152 179.308 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 176' ' ' PHE . . . . . 0.504 ' O ' ' HG ' ' A' ' 180' ' ' LEU . 85.4 m-85 -80.82 -50.12 10.23 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 115.772 -0.649 . . . . 0.0 112.023 -179.618 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 177' ' ' ILE . . . . . 0.531 HG13 HD11 ' A' ' 200' ' ' LEU . 4.1 mm -63.42 -35.03 70.8 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.547 0 N-CA-C 112.546 0.573 . . . . 0.0 112.546 -177.867 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 178' ' ' TRP . . . . . . . . . . . . . 73.5 t90 -73.87 -52.37 13.2 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-O 120.887 0.375 . . . . 0.0 110.856 179.87 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 179' ' ' LEU . . . . . 0.487 HD23 HD23 ' A' ' 180' ' ' LEU . 0.5 OUTLIER -64.83 -54.34 32.55 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.079 -0.51 . . . . 0.0 111.677 -179.004 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 180' ' ' LEU . . . . . 0.6 HD22 HD11 ' A' ' 187' ' ' LEU . 27.9 mt -64.32 -49.09 73.09 Favored 'General case' 0 C--N 1.326 -0.448 0 C-N-CA 120.812 -0.355 . . . . 0.0 111.201 -179.529 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . -57.38 179.93 0.77 Allowed Glycine 0 C--N 1.338 0.651 0 C-N-CA 120.284 -0.96 . . . . 0.0 112.37 179.511 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 182' ' ' PRO . . . . . 0.717 ' HA ' ' HB2' ' A' ' 186' ' ' ALA . 89.0 Cg_exo -46.99 -45.04 21.89 Favored 'Trans proline' 0 CA--C 1.536 0.593 0 C-N-CA 122.969 2.446 . . . . 0.0 113.994 -179.657 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 183' ' ' PRO . . . . . 0.424 ' HD3' ' HB2' ' A' ' 182' ' ' PRO . 88.4 Cg_exo -48.14 -25.29 6.55 Favored 'Trans proline' 0 C--N 1.354 0.845 0 C-N-CA 122.303 2.002 . . . . 0.0 113.762 -179.509 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 184' ' ' GLY . . . . . 0.433 ' HA3' ' O ' ' A' ' 179' ' ' LEU . . . -112.86 -81.63 1.1 Allowed Glycine 0 C--N 1.334 0.437 0 C-N-CA 120.098 -1.049 . . . . 0.0 113.617 -179.443 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 185' ' ' VAL . . . . . . . . . . . . . 14.5 m -120.86 -8.6 10.27 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.203 0 N-CA-C 112.17 0.433 . . . . 0.0 112.17 -178.696 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 186' ' ' ALA . . . . . 0.717 ' HB2' ' HA ' ' A' ' 182' ' ' PRO . . . 57.56 85.9 0.08 Allowed 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.494 -0.321 . . . . 0.0 111.714 179.562 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 187' ' ' LEU . . . . . 0.6 HD11 HD22 ' A' ' 180' ' ' LEU . 17.9 mt -91.99 -49.33 6.28 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-O 120.963 0.411 . . . . 0.0 110.695 179.518 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 188' ' ' LEU . . . . . . . . . . . . . 86.2 mt -95.87 -158.39 0.65 Allowed 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 115.807 -0.633 . . . . 0.0 110.792 -179.766 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 189' ' ' THR . . . . . 0.511 HG22 HG22 ' A' ' 191' ' ' THR . 24.9 m -91.38 136.91 26.38 Favored Pre-proline 0 C--N 1.327 -0.378 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.566 -179.885 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 190' ' ' PRO . . . . . 0.449 ' O ' HG23 ' A' ' 194' ' ' VAL . 93.7 Cg_exo -44.35 -53.63 4.69 Favored 'Trans proline' 0 C--N 1.351 0.68 0 C-N-CA 122.559 2.172 . . . . 0.0 113.094 -179.786 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 191' ' ' THR . . . . . 0.511 HG22 HG22 ' A' ' 189' ' ' THR . 3.0 t -56.81 -36.8 70.34 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.703 0.287 . . . . 0.0 111.455 -179.721 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 192' ' ' VAL . . . . . 0.43 HG23 ' HB ' ' A' ' 189' ' ' THR . 92.7 t -70.46 -42.06 78.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.423 -0.353 . . . . 0.0 110.982 179.952 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 193' ' ' ASP . . . . . . . . . . . . . 24.8 t70 -61.6 -40.17 93.82 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.468 179.743 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 194' ' ' VAL . . . . . 0.449 HG23 ' O ' ' A' ' 190' ' ' PRO . 99.9 t -65.11 -35.88 76.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.026 -0.534 . . . . 0.0 110.229 179.323 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 195' ' ' ALA . . . . . . . . . . . . . . . -57.7 -48.4 79.66 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.846 179.48 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 196' ' ' LEU . . . . . . . . . . . . . 92.5 mt -67.9 -43.22 79.78 Favored 'General case' 0 C--N 1.332 -0.176 0 CA-C-N 116.417 -0.356 . . . . 0.0 110.816 179.634 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 197' ' ' ILE . . . . . . . . . . . . . 14.7 mm -57.86 -57.69 9.43 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.075 -0.511 . . . . 0.0 110.632 179.56 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 198' ' ' VAL . . . . . . . . . . . . . 74.7 t -55.15 -34.16 31.83 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.5 0 N-CA-C 109.078 -0.712 . . . . 0.0 109.078 178.317 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 199' ' ' TYR . . . . . . . . . . . . . 62.7 t80 -69.48 -30.66 68.59 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 115.205 -0.907 . . . . 0.0 110.62 179.843 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 200' ' ' LEU . . . . . 0.571 ' O ' HG12 ' A' ' 203' ' ' VAL . 32.1 mt -69.61 -47.69 62.63 Favored 'General case' 0 C--N 1.332 -0.153 0 CA-C-N 116.099 -0.5 . . . . 0.0 111.584 -179.56 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 201' ' ' ASP . . . . . 0.402 ' HB2' ' OH ' ' A' ' 51' ' ' TYR . 4.7 m-20 -70.62 -39.63 73.62 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-O 121.29 0.567 . . . . 0.0 110.192 179.757 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 202' ' ' LEU . . . . . . . . . . . . . 59.8 tp -71.13 -26.75 63.15 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 115.343 -0.844 . . . . 0.0 111.951 -179.292 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 203' ' ' VAL . . . . . 0.571 HG12 ' O ' ' A' ' 200' ' ' LEU . 9.3 p -79.34 -35.73 17.34 Favored 'Isoleucine or valine' 0 C--O 1.226 -0.153 0 C-N-CA 121.005 -0.278 . . . . 0.0 110.805 -179.483 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 204' ' ' THR . . . . . . . . . . . . . 95.8 m -65.71 -58.89 4.62 Favored 'General case' 0 C--N 1.329 -0.31 0 C-N-CA 120.748 -0.381 . . . . 0.0 110.797 179.33 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 205' ' ' LYS . . . . . 0.546 ' HE2' ' HB2' ' A' ' 47' ' ' ALA . 60.9 mttp -58.17 -57.29 13.53 Favored 'General case' 0 C--N 1.329 -0.296 0 N-CA-C 112.061 0.393 . . . . 0.0 112.061 -178.9 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 59.8 t -71.04 -37.35 67.15 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.365 0 N-CA-C 112.326 0.491 . . . . 0.0 112.326 -178.702 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 207' ' ' GLY . . . . . 0.531 ' O ' HG13 ' A' ' 211' ' ' ILE . . . -58.07 -61.86 6.94 Favored Glycine 0 CA--C 1.518 0.267 0 C-N-CA 120.658 -0.782 . . . . 0.0 113.966 -178.605 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 208' ' ' PHE . . . . . 0.54 ' HB2' ' HG ' ' A' ' 163' ' ' LEU . 2.1 p90 -72.93 -27.36 61.81 Favored 'General case' 0 C--O 1.222 -0.38 0 CA-C-N 117.48 0.64 . . . . 0.0 110.75 -179.308 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 209' ' ' GLY . . . . . 0.595 ' O ' ' HB3' ' A' ' 212' ' ' ALA . . . -63.34 -34.17 89.23 Favored Glycine 0 N--CA 1.449 -0.473 0 N-CA-C 111.786 -0.525 . . . . 0.0 111.786 178.65 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 210' ' ' PHE . . . . . . . . . . . . . 0.7 OUTLIER -72.75 -47.46 46.7 Favored 'General case' 0 CA--C 1.514 -0.425 0 N-CA-C 108.239 -1.023 . . . . 0.0 108.239 178.379 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 211' ' ' ILE . . . . . 0.537 HG21 ' HG2' ' A' ' 162' ' ' ARG . 4.8 mt -62.91 -27.48 43.2 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.465 0 N-CA-C 107.632 -1.248 . . . . 0.0 107.632 176.588 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 212' ' ' ALA . . . . . 0.595 ' HB3' ' O ' ' A' ' 209' ' ' GLY . . . -61.86 -41.67 98.12 Favored 'General case' 0 N--CA 1.45 -0.45 0 CA-C-N 114.436 -1.256 . . . . 0.0 110.622 -179.846 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 213' ' ' LEU . . . . . . . . . . . . . 99.1 mt -66.56 -50.39 63.29 Favored 'General case' 0 C--N 1.331 -0.202 0 CA-C-N 115.345 -0.843 . . . . 0.0 111.255 -179.872 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 214' ' ' ASP . . . . . . . . . . . . . 25.8 t70 -56.08 -54.41 45.29 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.282 -0.417 . . . . 0.0 111.152 -179.761 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 215' ' ' ALA . . . . . . . . . . . . . . . -57.44 -57.27 13.39 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.136 -0.484 . . . . 0.0 111.417 -179.865 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 216' ' ' ALA . . . . . . . . . . . . . . . -55.18 -33.48 63.04 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.353 -0.385 . . . . 0.0 111.331 -179.828 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 217' ' ' ALA . . . . . . . . . . . . . . . -61.72 -37.77 85.43 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 121.096 0.474 . . . . 0.0 110.129 179.426 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 218' ' ' THR . . . . . . . . . . . . . 98.4 m . . . . . 0 C--N 1.329 -0.288 0 CA-C-N 115.648 -0.705 . . . . 0.0 110.824 179.384 . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.307 0 N-CA-C 112.727 -0.149 . . . . 0.0 112.727 . . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 4' ' ' LEU . . . . . 0.409 ' HA ' HD23 ' A' ' 7' ' ' LEU . 82.9 mt -59.2 -35.24 73.25 Favored 'General case' 0 N--CA 1.449 -0.483 0 CA-C-O 120.812 0.339 . . . . 0.0 111.273 -179.822 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 46.4 p -61.6 -34.91 76.44 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.11 -0.495 . . . . 0.0 111.795 -179.588 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 16.4 p -56.16 -35.64 67.41 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.333 -0.394 . . . . 0.0 111.507 -179.321 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 7' ' ' LEU . . . . . 0.42 ' N ' HD22 ' A' ' 7' ' ' LEU . 3.6 mm? -61.81 -53.5 55.04 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.364 -0.38 . . . . 0.0 111.271 -179.752 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 8' ' ' PHE . . . . . 0.563 ' HB2' ' HB2' ' A' ' 55' ' ' ALA . 53.9 m-85 -59.18 -30.21 68.03 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.291 -0.413 . . . . 0.0 111.066 -179.631 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 9' ' ' TRP . . . . . . . . . . . . . 19.7 m95 -69.25 -46.76 66.5 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.345 -179.971 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 85.4 mt -62.3 -41.86 98.88 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 115.88 -0.6 . . . . 0.0 110.042 179.206 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -62.29 -33.72 86.96 Favored Glycine 0 N--CA 1.448 -0.509 0 C-N-CA 120.779 -0.724 . . . . 0.0 111.769 179.3 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -67.87 -34.48 76.76 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-O 120.84 0.352 . . . . 0.0 110.523 179.585 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 46.8 mm -62.68 -51.67 69.19 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.187 0 CA-C-N 116.029 -0.532 . . . . 0.0 110.505 179.451 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -60.18 -33.21 79.02 Favored Glycine 0 N--CA 1.449 -0.447 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.108 179.648 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 15' ' ' MET . . . . . 0.611 ' HB3' ' HB2' ' A' ' 48' ' ' ALA . 20.0 mmt -66.75 -47.05 73.44 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.624 0.25 . . . . 0.0 110.821 179.689 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -54.07 -42.14 68.95 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.301 179.583 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 79.6 t -61.26 -48.05 90.69 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-N 115.946 -0.57 . . . . 0.0 110.79 179.548 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -63.51 -46.34 92.67 Favored Glycine 0 C--N 1.331 0.272 0 C-N-CA 120.773 -0.727 . . . . 0.0 112.165 179.809 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 23.2 m -49.95 -43.19 49.86 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 120.726 0.298 . . . . 0.0 111.114 -179.644 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 81.8 mt -71.93 -47.06 55.15 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.284 -0.416 . . . . 0.0 111.446 179.905 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -57.61 -29.9 64.89 Favored 'General case' 0 C--N 1.33 -0.272 0 N-CA-C 111.982 0.364 . . . . 0.0 111.982 -179.525 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 22' ' ' PHE . . . . . 0.587 ' HB2' HG22 ' A' ' 41' ' ' VAL . 9.5 m-85 -89.42 -41.12 12.27 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.531 -0.304 . . . . 0.0 111.594 -179.097 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -65.58 -50.39 65.31 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.828 0.347 . . . . 0.0 111.38 -179.729 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 24' ' ' TRP . . . . . . . . . . . . . 1.1 t-105 -57.92 -50.3 73.81 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.078 -0.51 . . . . 0.0 111.057 179.884 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.328 -0.329 0 CA-C-N 116.284 -0.416 . . . . 0.0 111.221 -179.911 . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.258 0 N-CA-C 112.603 -0.199 . . . . 0.0 112.603 . . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 12.9 mm-40 -63.68 -24.31 67.73 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.835 0.35 . . . . 0.0 110.729 179.981 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 34' ' ' ARG . . . . . . . . . . . . . 75.6 ttt180 -50.56 -30.45 13.16 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 115.905 -0.588 . . . . 0.0 111.694 -179.77 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 88.2 mtm180 -59.24 -52.62 64.88 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.487 -0.324 . . . . 0.0 111.604 -179.677 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 86.3 m-85 -58.89 -27.58 65.36 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.51 -179.618 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 37' ' ' TYR . . . . . 0.443 ' O ' HG23 ' A' ' 41' ' ' VAL . 72.7 m-85 -77.96 -53.81 7.02 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-N 116.292 -0.413 . . . . 0.0 111.08 -179.642 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 86.6 t -56.78 -36.9 50.86 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-O 121.024 0.44 . . . . 0.0 110.292 179.634 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 99.3 m -63.06 -50.52 70.28 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 115.759 -0.655 . . . . 0.0 110.164 179.153 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 40' ' ' LEU . . . . . 0.471 HD12 HD12 ' A' ' 43' ' ' ILE . 53.7 tp -56.36 -43.46 79.18 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 115.441 -0.8 . . . . 0.0 110.252 179.44 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 41' ' ' VAL . . . . . 0.587 HG22 ' HB2' ' A' ' 22' ' ' PHE . 97.3 t -63.77 -34.35 67.52 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.253 0 CA-C-N 115.708 -0.678 . . . . 0.0 109.648 178.731 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -60.46 -35.34 88.6 Favored Glycine 0 N--CA 1.448 -0.524 0 CA-C-N 115.627 -0.715 . . . . 0.0 112.102 179.753 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 43' ' ' ILE . . . . . 0.625 HG22 ' HE3' ' A' ' 205' ' ' LYS . 0.3 OUTLIER -70.11 -57.77 7.23 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.159 0 CA-C-O 120.646 0.26 . . . . 0.0 110.796 179.704 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 67.1 m -62.89 -20.28 65.0 Favored 'General case' 0 C--O 1.232 0.153 0 CA-C-N 116.406 -0.361 . . . . 0.0 111.315 -179.732 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -77.99 -57.52 3.45 Favored Glycine 0 N--CA 1.452 -0.25 0 C-N-CA 120.778 -0.725 . . . . 0.0 112.8 -179.598 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 23.8 pt -58.87 -36.14 59.87 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.213 0 CA-C-O 120.958 0.409 . . . . 0.0 110.969 179.925 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 47' ' ' ALA . . . . . 0.587 ' HB2' ' HE2' ' A' ' 205' ' ' LYS . . . -67.63 -45.46 75.28 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.067 -0.515 . . . . 0.0 111.26 179.832 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 48' ' ' ALA . . . . . 0.611 ' HB2' ' HB3' ' A' ' 15' ' ' MET . . . -55.1 -43.81 74.36 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.106 -0.497 . . . . 0.0 111.829 -179.578 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 35.9 m -73.37 -34.17 42.6 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.353 0 CA-C-N 116.332 -0.395 . . . . 0.0 111.519 -179.325 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -65.78 -35.09 79.73 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-O 120.924 0.393 . . . . 0.0 110.869 179.925 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 26.7 m-85 -73.33 -40.03 64.78 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-N 115.96 -0.564 . . . . 0.0 110.518 179.96 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -63.84 -44.7 92.39 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 115.938 -0.574 . . . . 0.0 111.258 179.848 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 53' ' ' VAL . . . . . 0.519 HG23 ' N ' ' A' ' 54' ' ' MET . 34.2 m -68.56 -48.97 69.42 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.226 0 CA-C-N 116.404 -0.362 . . . . 0.0 110.868 179.923 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 54' ' ' MET . . . . . 0.519 ' N ' HG23 ' A' ' 53' ' ' VAL . 7.1 ttp -62.77 -30.1 71.2 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.126 179.852 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 55' ' ' ALA . . . . . 0.563 ' HB2' ' HB2' ' A' ' 8' ' ' PHE . . . -65.55 -40.04 92.39 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 115.849 -0.614 . . . . 0.0 111.023 179.336 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 95.3 mt -73.23 2.77 6.71 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.022 -0.536 . . . . 0.0 111.092 -179.864 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 90.7 7.37 66.69 Favored Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.685 -0.769 . . . . 0.0 112.592 179.942 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 41.3 t -74.46 135.85 26.5 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-O 120.864 0.364 . . . . 0.0 110.869 179.895 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 83.92 -2.55 87.4 Favored Glycine 0 N--CA 1.452 -0.286 0 C-N-CA 120.942 -0.647 . . . . 0.0 112.903 179.988 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 60' ' ' TRP . . . . . . . . . . . . . 12.0 m0 -73.74 102.32 3.95 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.56 0.219 . . . . 0.0 110.931 179.63 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 61' ' ' VAL . . . . . 0.4 ' HA ' ' HD3' ' A' ' 62' ' ' PRO . 7.6 p -115.13 124.25 30.52 Favored Pre-proline 0 CA--C 1.536 0.414 0 CA-C-N 116.559 -0.291 . . . . 0.0 111.208 179.794 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 62' ' ' PRO . . . . . 0.4 ' HD3' ' HA ' ' A' ' 61' ' ' VAL . 14.2 Cg_exo -69.47 157.3 61.44 Favored 'Trans proline' 0 C--N 1.353 0.796 0 C-N-CA 122.783 2.322 . . . . 0.0 112.744 -179.725 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 63' ' ' VAL . . . . . 0.423 HG23 HG22 ' A' ' 68' ' ' VAL . 76.5 t -144.13 94.63 0.47 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.223 0 CA-C-N 115.856 -0.611 . . . . 0.0 110.98 179.88 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . 59.51 -86.42 0.02 OUTLIER 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 116.088 -0.506 . . . . 0.0 111.503 179.789 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 11.1 tp10 -118.16 -26.88 6.22 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-N 116.526 -0.306 . . . . 0.0 111.261 -179.723 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 66' ' ' ARG . . . . . . . . . . . . . 17.4 ptp180 -107.69 153.76 22.46 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.46 -0.336 . . . . 0.0 110.443 179.903 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 60.4 m -105.88 141.52 37.15 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-O 121.047 0.451 . . . . 0.0 111.543 -179.521 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 68' ' ' VAL . . . . . 0.431 HG21 ' HG3' ' A' ' 117' ' ' MET . 33.0 m -119.89 146.37 24.77 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 115.725 -0.67 . . . . 0.0 110.367 179.537 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 69' ' ' PHE . . . . . . . . . . . . . 22.1 m-85 -109.0 112.44 24.63 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 116.318 -0.401 . . . . 0.0 110.066 -179.398 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 70' ' ' VAL . . . . . 0.481 ' HB ' ' HD3' ' A' ' 71' ' ' PRO . 3.2 t -63.78 -48.98 78.41 Favored Pre-proline 0 C--N 1.326 -0.441 0 CA-C-N 116.274 -0.421 . . . . 0.0 111.905 -179.126 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 71' ' ' PRO . . . . . 0.583 ' HA ' HG22 ' A' ' 74' ' ' ILE . 47.4 Cg_exo -56.9 -18.06 26.3 Favored 'Trans proline' 0 C--N 1.351 0.698 0 C-N-CA 122.289 1.993 . . . . 0.0 112.877 -179.606 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 68.2 ttt180 -70.95 -55.79 7.6 Favored 'General case' 0 C--O 1.236 0.362 0 CA-C-O 120.886 0.374 . . . . 0.0 111.559 -179.323 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 73' ' ' TYR . . . . . 0.458 ' O ' HG13 ' A' ' 77' ' ' ILE . 7.0 m-85 -70.64 -34.45 72.08 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.439 -0.346 . . . . 0.0 110.281 -179.497 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 74' ' ' ILE . . . . . 0.583 HG22 ' HA ' ' A' ' 71' ' ' PRO . 0.4 OUTLIER -68.01 -37.98 79.15 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.226 0 CA-C-N 116.334 -0.394 . . . . 0.0 110.013 179.322 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 75' ' ' ASP . . . . . 0.442 ' O ' HG23 ' A' ' 79' ' ' THR . 8.1 t70 -58.02 -39.56 78.65 Favored 'General case' 0 CA--C 1.518 -0.259 0 N-CA-C 109.045 -0.724 . . . . 0.0 109.045 178.806 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 76' ' ' TRP . . . . . 0.434 ' HZ2' HG23 ' A' ' 197' ' ' ILE . 39.0 m0 -67.06 -31.56 72.15 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 115.612 -0.722 . . . . 0.0 110.584 179.108 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 77' ' ' ILE . . . . . 0.544 ' HA ' ' HG3' ' A' ' 109' ' ' MET . 85.8 mt -66.71 -32.8 59.66 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.233 0 CA-C-N 116.284 -0.416 . . . . 0.0 111.035 179.468 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 21.5 mt -91.16 -17.47 26.04 Favored 'General case' 0 C--N 1.327 -0.41 0 N-CA-C 112.149 0.426 . . . . 0.0 112.149 -179.515 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 79' ' ' THR . . . . . 0.442 HG23 ' O ' ' A' ' 75' ' ' ASP . 76.9 p -103.4 -52.65 2.96 Favored 'General case' 0 CA--C 1.532 0.275 0 N-CA-C 113.784 1.031 . . . . 0.0 113.784 -177.915 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 80' ' ' THR . . . . . 0.682 ' HB ' ' HD3' ' A' ' 81' ' ' PRO . 29.4 m -51.36 -54.86 34.12 Favored Pre-proline 0 CA--C 1.531 0.246 0 N-CA-C 112.478 0.547 . . . . 0.0 112.478 -178.508 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 81' ' ' PRO . . . . . 0.682 ' HD3' ' HB ' ' A' ' 80' ' ' THR . 36.9 Cg_exo -60.51 -20.93 66.41 Favored 'Trans proline' 0 C--N 1.351 0.683 0 C-N-CA 121.575 1.516 . . . . 0.0 111.368 179.763 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 82' ' ' LEU . . . . . 0.436 HD23 HG23 ' A' ' 43' ' ' ILE . 17.3 tp -76.91 -33.34 57.77 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 115.812 -0.631 . . . . 0.0 110.302 179.751 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 48.9 mm -68.4 -52.06 40.91 Favored 'Isoleucine or valine' 0 C--O 1.233 0.221 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.055 179.109 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 84' ' ' VAL . . . . . 0.418 ' CG1' HD22 ' A' ' 105' ' ' ASN . 34.5 m -61.86 -30.0 47.56 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.142 0 N-CA-C 109.545 -0.539 . . . . 0.0 109.545 178.728 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 85' ' ' TYR . . . . . . . . . . . . . 73.4 t80 -67.63 -33.35 74.78 Favored 'General case' 0 N--CA 1.454 -0.235 0 CA-C-N 115.546 -0.752 . . . . 0.0 109.615 178.873 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 86' ' ' PHE . . . . . . . . . . . . . 5.5 t80 -61.99 -51.67 67.11 Favored 'General case' 0 C--O 1.233 0.221 0 CA-C-N 115.697 -0.683 . . . . 0.0 109.822 179.204 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 87' ' ' LEU . . . . . 0.401 ' N ' HD12 ' A' ' 87' ' ' LEU . 8.7 mp -62.43 -29.5 70.55 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 115.755 -0.657 . . . . 0.0 110.101 179.476 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -71.49 -27.76 70.74 Favored Glycine 0 N--CA 1.449 -0.455 0 C-N-CA 120.799 -0.715 . . . . 0.0 111.569 179.237 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 72.6 mt -69.92 -45.57 67.24 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-O 121.074 0.464 . . . . 0.0 109.985 179.504 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 90' ' ' LEU . . . . . 0.485 ' HB3' HG23 ' A' ' 156' ' ' ILE . 64.7 mt -60.17 -30.43 69.33 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 115.582 -0.735 . . . . 0.0 110.741 179.616 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 91' ' ' ALA . . . . . 0.458 ' HA ' ' HA ' ' A' ' 149' ' ' ALA . . . -86.32 -29.44 23.02 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.264 -179.787 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 75.03 44.69 22.93 Favored Glycine 0 N--CA 1.452 -0.258 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.146 -179.902 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 93' ' ' LEU . . . . . 0.427 ' HB3' ' HB2' ' A' ' 97' ' ' GLU . 30.1 mt -60.36 168.04 2.24 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.955 0.407 . . . . 0.0 111.206 -179.646 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 94' ' ' ASP . . . . . . . . . . . . . 5.5 m-20 -90.77 179.57 5.76 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 115.936 -0.575 . . . . 0.0 110.834 179.994 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 80.5 p -60.58 -42.83 97.48 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.906 -179.94 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 68.9 mtm180 -68.62 -49.77 56.6 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.108 -0.496 . . . . 0.0 111.027 -179.826 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 97' ' ' GLU . . . . . 0.427 ' HB2' ' HB3' ' A' ' 93' ' ' LEU . 44.9 mt-10 -54.51 -47.6 72.9 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.335 -0.393 . . . . 0.0 111.033 -179.883 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 98' ' ' PHE . . . . . 0.453 ' O ' HG12 ' A' ' 102' ' ' ILE . 11.3 m-85 -60.29 -43.62 96.09 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.416 -0.357 . . . . 0.0 110.496 179.61 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -60.63 -27.53 66.37 Favored Glycine 0 N--CA 1.451 -0.358 0 C-N-CA 120.611 -0.804 . . . . 0.0 112.414 179.746 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 96.1 mt -73.9 -47.64 42.23 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.229 0 N-CA-C 111.875 0.324 . . . . 0.0 111.875 -179.537 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 101' ' ' VAL . . . . . 0.41 HG11 ' HE3' ' A' ' 145' ' ' MET . 27.7 m -69.49 -39.01 78.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 N-CA-C 111.731 0.271 . . . . 0.0 111.731 -179.353 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 102' ' ' ILE . . . . . 0.453 HG12 ' O ' ' A' ' 98' ' ' PHE . 43.3 mm -67.67 -46.55 82.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.55 -0.296 . . . . 0.0 111.347 -179.54 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 14.7 t -62.42 -33.27 74.46 Favored 'General case' 0 C--O 1.233 0.187 0 CA-C-O 120.975 0.417 . . . . 0.0 110.404 179.643 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -58.84 -52.04 67.42 Favored 'General case' 0 C--N 1.332 -0.191 0 CA-C-N 115.995 -0.548 . . . . 0.0 109.528 179.248 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 105' ' ' ASN . . . . . 0.418 HD22 ' CG1' ' A' ' 84' ' ' VAL . 3.1 m-20 -56.72 -35.45 68.56 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 115.736 -0.666 . . . . 0.0 110.53 179.455 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 39.3 m -55.6 -50.9 68.88 Favored 'General case' 0 C--N 1.332 -0.169 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.996 179.918 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 107' ' ' VAL . . . . . 0.409 ' H ' HG23 ' A' ' 107' ' ' VAL . 0.9 OUTLIER -60.5 -39.67 81.97 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.223 0 CA-C-O 121.174 0.512 . . . . 0.0 110.39 179.6 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 81.0 t -63.66 -39.91 87.12 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-N 115.506 -0.77 . . . . 0.0 111.285 -179.821 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 109' ' ' MET . . . . . 0.544 ' HG3' ' HA ' ' A' ' 77' ' ' ILE . 28.6 mmt -67.17 -51.35 54.8 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.078 -0.51 . . . . 0.0 111.329 -179.568 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 21.1 tp -58.95 -34.73 72.09 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-N 115.96 -0.564 . . . . 0.0 110.927 -179.592 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -61.11 -57.09 13.98 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.18 -179.994 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . -67.23 -28.03 73.62 Favored Glycine 0 N--CA 1.45 -0.374 0 C-N-CA 120.724 -0.75 . . . . 0.0 112.143 179.68 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 113' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER -57.67 -75.09 0.05 OUTLIER 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 121.035 0.445 . . . . 0.0 110.132 179.817 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -61.45 -26.43 67.87 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 115.793 -0.639 . . . . 0.0 111.095 179.771 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -53.06 -50.07 52.97 Favored Glycine 0 C--N 1.331 0.28 0 C-N-CA 121.028 -0.606 . . . . 0.0 112.616 -179.974 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 116' ' ' ALA . . . . . 0.571 ' HB2' ' HB3' ' A' ' 183' ' ' PRO . . . -77.65 -16.42 58.54 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.672 0.272 . . . . 0.0 111.613 -179.739 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 117' ' ' MET . . . . . 0.431 ' HG3' HG21 ' A' ' 68' ' ' VAL . 29.7 ttm -101.85 19.22 18.69 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.407 -0.361 . . . . 0.0 111.341 -179.506 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 118' ' ' VAL . . . . . 0.58 HG21 ' HB3' ' A' ' 123' ' ' ARG . 21.4 m -70.15 145.49 93.75 Favored Pre-proline 0 C--N 1.33 -0.245 0 CA-C-N 116.432 -0.349 . . . . 0.0 111.502 179.982 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 119' ' ' PRO . . . . . . . . . . . . . 85.9 Cg_endo -93.4 15.8 1.33 Allowed 'Trans proline' 0 N--CA 1.456 -0.732 0 C-N-CA 122.997 2.465 . . . . 0.0 112.353 179.419 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -164.62 -120.38 0.52 Allowed Glycine 0 C--N 1.332 0.339 0 C-N-CA 120.66 -0.781 . . . . 0.0 112.674 -179.564 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 40.9 pt -114.68 9.84 7.74 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.232 0 CA-C-O 120.723 0.297 . . . . 0.0 111.493 -179.727 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 45.7 mt-10 -58.84 -18.08 29.48 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.304 -0.407 . . . . 0.0 110.699 179.725 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 123' ' ' ARG . . . . . 0.58 ' HB3' HG21 ' A' ' 118' ' ' VAL . 10.2 ptp180 -50.5 -33.24 20.65 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 115.794 -0.639 . . . . 0.0 111.642 -179.959 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 124' ' ' TYR . . . . . . . . . . . . . 19.3 m-85 -73.11 -32.63 65.07 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.428 -0.351 . . . . 0.0 111.513 -179.459 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 125' ' ' ALA . . . . . . . . . . . . . . . -74.32 -56.11 5.25 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.386 -0.37 . . . . 0.0 111.398 -179.492 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -55.09 -44.19 74.66 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.904 -179.931 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 127' ' ' PHE . . . . . . . . . . . . . 5.4 t80 -70.92 -37.21 72.89 Favored 'General case' 0 C--N 1.33 -0.279 0 C-N-CA 120.898 -0.321 . . . . 0.0 110.575 179.825 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 128' ' ' GLY . . . . . . . . . . . . . . . -46.79 -46.85 19.03 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.167 -1.016 . . . . 0.0 110.844 179.052 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 129' ' ' MET . . . . . . . . . . . . . 0.4 OUTLIER -69.69 -38.84 77.16 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 115.367 -0.417 . . . . 0.0 109.894 178.781 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -62.87 -29.3 73.71 Favored Glycine 0 C--N 1.333 0.38 0 CA-C-N 115.892 -0.595 . . . . 0.0 112.792 -179.893 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 131' ' ' ALA . . . . . 0.402 ' O ' ' HB3' ' A' ' 134' ' ' PHE . . . -74.29 -53.61 9.37 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 120.761 0.315 . . . . 0.0 110.317 179.871 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 28.3 t -58.03 -40.07 75.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 N-CA-C 109.321 -0.622 . . . . 0.0 109.321 178.741 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -68.64 -33.4 73.94 Favored 'General case' 0 N--CA 1.454 -0.259 0 CA-C-N 115.387 -0.824 . . . . 0.0 110.342 179.177 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 134' ' ' PHE . . . . . 0.402 ' HB3' ' O ' ' A' ' 131' ' ' ALA . 44.1 t80 -57.77 -55.14 38.7 Favored 'General case' 0 N--CA 1.452 -0.34 0 CA-C-N 116.132 -0.486 . . . . 0.0 109.752 179.239 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 135' ' ' ILE . . . . . 0.46 ' O ' HG22 ' A' ' 138' ' ' VAL . 39.2 mt -57.69 -31.87 40.97 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 115.673 -0.694 . . . . 0.0 109.86 178.861 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . -64.19 -35.31 91.81 Favored Glycine 0 N--CA 1.448 -0.515 0 C-N-CA 120.488 -0.863 . . . . 0.0 111.577 179.13 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 137' ' ' LEU . . . . . . . . . . . . . 38.9 tp -73.44 -51.13 18.3 Favored 'General case' 0 C--N 1.331 -0.205 0 CA-C-O 120.628 0.252 . . . . 0.0 110.51 179.492 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 138' ' ' VAL . . . . . 0.46 HG22 ' O ' ' A' ' 135' ' ' ILE . 4.0 m -57.37 -30.96 37.04 Favored 'Isoleucine or valine' 0 C--O 1.233 0.208 0 N-CA-C 109.376 -0.601 . . . . 0.0 109.376 179.048 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 139' ' ' TYR . . . . . . . . . . . . . 24.9 t80 -66.19 -43.34 87.12 Favored 'General case' 0 C--N 1.332 -0.196 0 CA-C-N 115.324 -0.853 . . . . 0.0 110.15 178.706 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 140' ' ' TYR . . . . . 0.435 ' HB3' ' SD ' ' A' ' 145' ' ' MET . 11.9 m-85 -53.06 -51.62 61.22 Favored 'General case' 0 C--O 1.231 0.13 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.514 179.355 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 141' ' ' LEU . . . . . . . . . . . . . 70.5 mt -53.39 -53.56 49.39 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 115.726 -0.67 . . . . 0.0 111.213 -179.788 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 17.2 t -73.42 -11.29 14.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.113 -0.494 . . . . 0.0 111.334 -179.623 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . -71.45 -140.91 0.26 Allowed Glycine 0 CA--C 1.52 0.354 0 C-N-CA 120.832 -0.699 . . . . 0.0 112.635 -179.799 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 144' ' ' PRO . . . . . . . . . . . . . 32.2 Cg_endo -62.99 -23.25 74.08 Favored 'Trans proline' 0 C--N 1.347 0.493 0 C-N-CA 122.486 2.124 . . . . 0.0 112.121 -179.991 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 145' ' ' MET . . . . . 0.435 ' SD ' ' HB3' ' A' ' 140' ' ' TYR . 82.4 mtp -57.61 -27.9 63.18 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 116.024 -0.535 . . . . 0.0 110.975 179.921 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 146' ' ' THR . . . . . . . . . . . . . 60.0 m -71.89 -40.79 68.64 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.308 -0.406 . . . . 0.0 111.042 179.82 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 2.2 mp0 -74.25 -27.57 60.83 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.008 -179.835 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 148' ' ' SER . . . . . . . . . . . . . 49.1 m -70.19 -43.16 71.33 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.388 -0.369 . . . . 0.0 111.085 -179.882 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 149' ' ' ALA . . . . . 0.458 ' HA ' ' HA ' ' A' ' 91' ' ' ALA . . . -77.84 -44.08 28.41 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.845 -179.457 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 150' ' ' SER . . . . . . . . . . . . . 66.3 m -63.72 -21.97 66.67 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.388 -0.369 . . . . 0.0 111.443 -179.451 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 151' ' ' GLN . . . . . . . . . . . . . 78.7 mt-30 -106.87 6.49 29.41 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.51 -0.314 . . . . 0.0 111.298 -179.784 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 30.2 tpt180 -82.58 -50.31 8.92 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.437 -0.347 . . . . 0.0 110.729 179.823 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 153' ' ' SER . . . . . 0.514 ' HB2' HG13 ' A' ' 156' ' ' ILE . 45.8 m -154.55 149.34 26.59 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.824 179.267 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 154' ' ' SER . . . . . . . . . . . . . 42.7 t -55.24 -40.37 70.83 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.113 -0.494 . . . . 0.0 111.055 179.947 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 155' ' ' GLY . . . . . 0.404 ' O ' ' HG ' ' A' ' 159' ' ' LEU . . . -75.01 -35.93 48.23 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.79 -0.719 . . . . 0.0 112.562 179.994 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 156' ' ' ILE . . . . . 0.514 HG13 ' HB2' ' A' ' 153' ' ' SER . 68.9 mt -60.95 -36.22 70.58 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-O 120.707 0.289 . . . . 0.0 111.307 -179.948 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 157' ' ' LYS . . . . . 0.402 ' O ' HG13 ' A' ' 161' ' ' VAL . 88.6 tttt -52.9 -45.66 67.64 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-N 116.187 -0.461 . . . . 0.0 111.499 -179.783 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 48.4 t -71.83 -37.41 70.32 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 121.003 0.43 . . . . 0.0 111.29 -179.558 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 159' ' ' LEU . . . . . 0.404 ' HG ' ' O ' ' A' ' 155' ' ' GLY . 78.0 mt -65.85 -39.18 90.52 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-N 115.936 -0.575 . . . . 0.0 111.643 -179.413 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 160' ' ' TYR . . . . . . . . . . . . . 45.5 t80 -73.94 -44.37 55.19 Favored 'General case' 0 C--N 1.327 -0.401 0 N-CA-C 112.155 0.428 . . . . 0.0 112.155 -178.647 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 161' ' ' VAL . . . . . 0.402 HG13 ' O ' ' A' ' 157' ' ' LYS . 30.8 m -59.86 -43.96 93.15 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 N-CA-C 112.226 0.454 . . . . 0.0 112.226 -178.916 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 162' ' ' ARG . . . . . 0.541 ' O ' HD12 ' A' ' 166' ' ' LEU . 93.8 mtt180 -69.16 -50.74 44.98 Favored 'General case' 0 C--N 1.33 -0.269 0 N-CA-C 112.18 0.437 . . . . 0.0 112.18 -179.134 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 163' ' ' LEU . . . . . . . . . . . . . 7.5 mp -65.71 -43.83 87.92 Favored 'General case' 0 C--N 1.33 -0.254 0 N-CA-C 111.789 0.292 . . . . 0.0 111.789 -179.06 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 164' ' ' ARG . . . . . . . . . . . . . 6.1 tmm_? -57.42 -50.98 71.26 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-N 116.56 -0.291 . . . . 0.0 111.004 -179.693 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 165' ' ' ASN . . . . . 0.486 ' O ' HG23 ' A' ' 169' ' ' VAL . 5.3 m-20 -53.04 -44.99 67.81 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-O 120.934 0.397 . . . . 0.0 110.346 179.809 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 166' ' ' LEU . . . . . 0.541 HD12 ' O ' ' A' ' 162' ' ' ARG . 1.5 mt -60.05 -48.65 80.82 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 115.931 -0.577 . . . . 0.0 111.2 179.478 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 167' ' ' THR . . . . . 0.624 ' HA ' HD11 ' A' ' 170' ' ' LEU . 12.0 m -53.68 -51.0 64.59 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.021 -0.536 . . . . 0.0 112.218 -178.265 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 168' ' ' VAL . . . . . . . . . . . . . 27.0 t -59.26 -40.6 81.66 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.566 0 N-CA-C 112.105 0.409 . . . . 0.0 112.105 -179.061 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 169' ' ' VAL . . . . . 0.486 HG23 ' O ' ' A' ' 165' ' ' ASN . 83.9 t -66.08 -66.82 0.45 Allowed 'Isoleucine or valine' 0 CA--C 1.533 0.3 0 N-CA-C 113.557 0.947 . . . . 0.0 113.557 -178.194 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 170' ' ' LEU . . . . . 0.624 HD11 ' HA ' ' A' ' 167' ' ' THR . 0.4 OUTLIER -61.66 -32.18 72.34 Favored 'General case' 0 N--CA 1.467 0.388 0 N-CA-C 112.974 0.731 . . . . 0.0 112.974 -177.529 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 171' ' ' TRP . . . . . 0.5 ' H ' HD12 ' A' ' 170' ' ' LEU . 21.4 m0 -73.53 -29.54 62.52 Favored 'General case' 0 C--N 1.329 -0.323 0 C-N-CA 120.371 -0.531 . . . . 0.0 111.087 -179.619 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 172' ' ' ALA . . . . . . . . . . . . . . . -72.24 -7.87 51.68 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-O 121.011 0.434 . . . . 0.0 110.253 179.499 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 173' ' ' ILE . . . . . 0.552 HG22 HD11 ' A' ' 177' ' ' ILE . 18.5 mm -88.92 -25.42 5.75 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.21 0 CA-C-N 115.789 -0.642 . . . . 0.0 110.939 179.528 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 174' ' ' TYR . . . . . 0.491 ' HD1' ' HA ' ' A' ' 171' ' ' TRP . 16.1 m-85 -54.62 -48.54 94.94 Favored Pre-proline 0 CA--C 1.531 0.218 0 CA-C-N 116.104 -0.498 . . . . 0.0 112.156 -179.384 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 175' ' ' PRO . . . . . . . . . . . . . 74.8 Cg_exo -47.07 -29.99 9.55 Favored 'Trans proline' 0 C--N 1.352 0.747 0 C-N-CA 121.909 1.739 . . . . 0.0 111.808 179.677 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 176' ' ' PHE . . . . . 0.497 ' O ' ' HG ' ' A' ' 180' ' ' LEU . 72.0 m-85 -80.35 -49.89 10.89 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 115.713 -0.676 . . . . 0.0 111.37 179.687 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 177' ' ' ILE . . . . . 0.552 HD11 HG22 ' A' ' 173' ' ' ILE . 3.6 mm -59.28 -36.25 62.5 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.525 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.722 -178.632 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 178' ' ' TRP . . . . . 0.407 ' O ' ' HB2' ' A' ' 183' ' ' PRO . 58.7 t90 -73.3 -51.82 16.18 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-O 121.066 0.46 . . . . 0.0 110.658 179.879 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 179' ' ' LEU . . . . . 0.563 HD13 HG22 ' A' ' 185' ' ' VAL . 1.4 tm? -61.07 -53.4 57.54 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 115.701 -0.681 . . . . 0.0 111.56 -179.159 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 180' ' ' LEU . . . . . 0.723 HD22 HD11 ' A' ' 187' ' ' LEU . 12.5 mt -74.78 -29.47 61.13 Favored 'General case' 0 C--N 1.327 -0.385 0 N-CA-C 112.2 0.444 . . . . 0.0 112.2 -178.861 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . -71.42 -177.66 27.28 Favored Glycine 0 N--CA 1.45 -0.407 0 C-N-CA 119.977 -1.106 . . . . 0.0 112.173 179.777 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 182' ' ' PRO . . . . . 0.427 ' N ' ' HD2' ' A' ' 183' ' ' PRO . 76.8 Cg_exo -47.93 -43.36 30.05 Favored 'Trans proline' 0 CA--C 1.538 0.681 0 C-N-CA 122.649 2.233 . . . . 0.0 113.386 179.527 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 183' ' ' PRO . . . . . 0.571 ' HB3' ' HB2' ' A' ' 116' ' ' ALA . 65.9 Cg_exo -41.54 -31.87 1.27 Allowed 'Trans proline' 0 C--N 1.358 1.046 0 C-N-CA 122.609 2.206 . . . . 0.0 113.601 179.824 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 184' ' ' GLY . . . . . . . . . . . . . . . -130.03 -107.65 1.24 Allowed Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.413 -0.899 . . . . 0.0 112.323 180.0 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 185' ' ' VAL . . . . . 0.563 HG22 HD13 ' A' ' 179' ' ' LEU . 27.4 m -92.41 89.87 2.96 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.44 0 CA-C-O 121.414 0.626 . . . . 0.0 110.365 179.668 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 186' ' ' ALA . . . . . . . . . . . . . . . -56.94 86.7 0.01 OUTLIER 'General case' 0 C--N 1.325 -0.491 0 CA-C-N 115.687 -0.688 . . . . 0.0 111.855 -179.448 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 187' ' ' LEU . . . . . 0.723 HD11 HD22 ' A' ' 180' ' ' LEU . 12.5 mt -74.8 -48.91 22.8 Favored 'General case' 0 C--N 1.331 -0.199 0 CA-C-O 120.985 0.422 . . . . 0.0 110.361 179.236 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 188' ' ' LEU . . . . . . . . . . . . . 63.4 mt -97.8 -147.97 0.32 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 115.775 -0.648 . . . . 0.0 110.65 -179.87 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 189' ' ' THR . . . . . . . . . . . . . 1.2 t -111.8 148.46 39.0 Favored Pre-proline 0 C--N 1.331 -0.231 0 CA-C-N 116.276 -0.42 . . . . 0.0 110.813 -179.964 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 190' ' ' PRO . . . . . 0.406 ' O ' HG23 ' A' ' 194' ' ' VAL . 7.3 Cg_endo -49.12 -42.14 39.75 Favored 'Trans proline' 0 C--N 1.349 0.57 0 C-N-CA 123.027 2.485 . . . . 0.0 113.261 -179.474 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 191' ' ' THR . . . . . . . . . . . . . 7.6 t -59.54 -40.86 88.6 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.65 0.262 . . . . 0.0 111.598 -179.341 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 192' ' ' VAL . . . . . . . . . . . . . 42.3 t -71.94 -47.92 53.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.499 -0.319 . . . . 0.0 111.398 -179.809 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 193' ' ' ASP . . . . . . . . . . . . . 30.7 t70 -57.99 -51.2 70.65 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.742 0.306 . . . . 0.0 111.038 -179.815 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 194' ' ' VAL . . . . . 0.406 HG23 ' O ' ' A' ' 190' ' ' PRO . 97.8 t -59.88 -36.15 64.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.883 179.973 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 195' ' ' ALA . . . . . . . . . . . . . . . -58.1 -46.1 86.1 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.542 -0.299 . . . . 0.0 110.942 179.697 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 196' ' ' LEU . . . . . . . . . . . . . 86.3 mt -65.69 -41.34 92.5 Favored 'General case' 0 C--N 1.332 -0.171 0 CA-C-N 116.368 -0.378 . . . . 0.0 110.404 179.596 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 197' ' ' ILE . . . . . 0.434 HG23 ' HZ2' ' A' ' 76' ' ' TRP . 19.9 mm -58.56 -58.26 7.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 115.995 -0.548 . . . . 0.0 110.239 179.366 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 198' ' ' VAL . . . . . . . . . . . . . 94.6 t -53.27 -34.52 22.39 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.416 0 CA-C-N 115.736 -0.665 . . . . 0.0 109.276 178.281 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 199' ' ' TYR . . . . . . . . . . . . . 65.4 t80 -69.7 -33.66 72.83 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 115.295 -0.866 . . . . 0.0 110.519 179.604 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 200' ' ' LEU . . . . . . . . . . . . . 40.7 mt -69.6 -39.62 77.14 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 115.855 -0.611 . . . . 0.0 111.019 -179.807 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 201' ' ' ASP . . . . . 0.455 ' HB3' ' NZ ' ' A' ' 205' ' ' LYS . 9.6 m-20 -72.86 -32.23 65.28 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.41 179.749 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 202' ' ' LEU . . . . . 0.466 ' O ' ' HB ' ' A' ' 206' ' ' VAL . 3.7 mt -73.04 -33.13 65.51 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 115.656 -0.702 . . . . 0.0 112.014 -179.376 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 203' ' ' VAL . . . . . 0.45 ' O ' ' HA3' ' A' ' 207' ' ' GLY . 7.8 p -77.9 -36.66 22.39 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-O 120.582 0.23 . . . . 0.0 111.432 -178.801 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 204' ' ' THR . . . . . . . . . . . . . 19.1 m -68.91 -53.62 20.06 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-O 120.877 0.37 . . . . 0.0 111.407 -179.956 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 205' ' ' LYS . . . . . 0.625 ' HE3' HG22 ' A' ' 43' ' ' ILE . 43.9 mttp -70.73 -58.68 3.39 Favored 'General case' 0 C--N 1.327 -0.405 0 N-CA-C 112.435 0.531 . . . . 0.0 112.435 -178.569 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 206' ' ' VAL . . . . . 0.466 ' HB ' ' O ' ' A' ' 202' ' ' LEU . 48.1 t -72.25 -37.43 58.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 N-CA-C 111.952 0.353 . . . . 0.0 111.952 -178.878 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 207' ' ' GLY . . . . . 0.514 ' O ' HG13 ' A' ' 211' ' ' ILE . . . -65.37 -59.88 7.32 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.442 -0.885 . . . . 0.0 112.516 -179.366 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 208' ' ' PHE . . . . . 0.482 ' O ' ' N ' ' A' ' 212' ' ' ALA . 2.1 m-30 -54.19 -45.17 72.1 Favored 'General case' 0 C--O 1.222 -0.388 0 N-CA-C 109.947 -0.39 . . . . 0.0 109.947 179.772 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 209' ' ' GLY . . . . . 0.498 ' HA2' ' HB3' ' A' ' 212' ' ' ALA . . . -59.07 -34.22 78.28 Favored Glycine 0 N--CA 1.448 -0.515 0 CA-C-N 115.376 -0.829 . . . . 0.0 112.821 179.43 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 210' ' ' PHE . . . . . . . . . . . . . 1.2 m-85 -70.26 -46.8 63.67 Favored 'General case' 0 CA--C 1.515 -0.369 0 N-CA-C 108.754 -0.832 . . . . 0.0 108.754 179.163 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 211' ' ' ILE . . . . . 0.514 HG13 ' O ' ' A' ' 207' ' ' GLY . 2.6 mt -67.4 -27.42 38.7 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.473 0 N-CA-C 107.416 -1.327 . . . . 0.0 107.416 176.846 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 212' ' ' ALA . . . . . 0.498 ' HB3' ' HA2' ' A' ' 209' ' ' GLY . . . -66.84 -40.09 87.83 Favored 'General case' 0 N--CA 1.449 -0.525 0 CA-C-N 114.32 -1.309 . . . . 0.0 110.214 -179.991 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 213' ' ' LEU . . . . . 0.467 ' HG ' ' O ' ' A' ' 209' ' ' GLY . 69.7 mt -70.68 -54.77 10.59 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 114.991 -1.004 . . . . 0.0 111.744 -179.555 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 214' ' ' ASP . . . . . . . . . . . . . 20.6 t70 -54.38 -47.19 72.95 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-O 120.758 0.313 . . . . 0.0 111.42 -179.464 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 215' ' ' ALA . . . . . . . . . . . . . . . -63.69 -56.17 17.8 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.309 -0.405 . . . . 0.0 111.171 -179.781 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 216' ' ' ALA . . . . . . . . . . . . . . . -56.24 -31.22 63.33 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.834 179.924 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 217' ' ' ALA . . . . . . . . . . . . . . . -65.97 -40.56 91.38 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 115.991 -0.549 . . . . 0.0 110.431 179.767 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 218' ' ' THR . . . . . . . . . . . . . 72.7 m . . . . . 0 C--N 1.329 -0.299 0 CA-C-N 115.957 -0.565 . . . . 0.0 110.437 179.41 . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.251 0 N-CA-C 112.685 -0.166 . . . . 0.0 112.685 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 96.6 mt -61.04 -35.44 76.91 Favored 'General case' 0 N--CA 1.448 -0.529 0 CA-C-O 120.758 0.313 . . . . 0.0 111.118 179.961 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 46.6 p -51.48 -36.92 46.52 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 116.013 -0.54 . . . . 0.0 111.68 -179.472 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 20.4 p -56.79 -38.94 73.23 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.209 -0.451 . . . . 0.0 111.576 -179.542 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 7' ' ' LEU . . . . . . . . . . . . . 3.9 mm? -61.81 -53.51 54.88 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.265 -0.425 . . . . 0.0 111.304 -179.716 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 8' ' ' PHE . . . . . 0.425 ' HB2' ' HB2' ' A' ' 55' ' ' ALA . 68.5 m-85 -55.43 -31.93 62.3 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.255 -0.429 . . . . 0.0 111.108 -179.607 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 9' ' ' TRP . . . . . 0.415 ' O ' HG12 ' A' ' 13' ' ' ILE . 21.7 m95 -66.01 -42.78 89.26 Favored 'General case' 0 C--N 1.326 -0.447 0 N-CA-C 109.695 -0.484 . . . . 0.0 109.695 179.694 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 84.6 mt -61.08 -38.97 88.14 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 115.62 -0.718 . . . . 0.0 110.238 179.223 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -65.84 -35.55 91.0 Favored Glycine 0 N--CA 1.449 -0.437 0 C-N-CA 120.85 -0.691 . . . . 0.0 111.865 179.349 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -65.6 -32.58 74.23 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-O 120.892 0.377 . . . . 0.0 110.672 179.585 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 13' ' ' ILE . . . . . 0.415 HG12 ' O ' ' A' ' 9' ' ' TRP . 50.5 mm -67.35 -51.03 56.94 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.245 0 CA-C-N 116.034 -0.53 . . . . 0.0 110.654 179.667 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -58.6 -31.6 67.45 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.141 179.669 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 15' ' ' MET . . . . . 0.567 ' HB3' ' HB2' ' A' ' 48' ' ' ALA . 23.9 mmt -69.89 -40.91 75.38 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-O 120.722 0.296 . . . . 0.0 110.64 179.661 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -57.47 -43.66 84.23 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.307 179.54 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 42.5 t -61.41 -49.83 82.86 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.214 0 CA-C-N 116.065 -0.516 . . . . 0.0 110.955 179.846 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -62.36 -48.27 83.59 Favored Glycine 0 C--N 1.331 0.285 0 C-N-CA 120.651 -0.785 . . . . 0.0 112.206 179.708 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 50.3 m -49.93 -41.13 45.55 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-O 120.67 0.271 . . . . 0.0 111.378 -179.754 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 52.3 mt -72.53 -46.06 56.35 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.329 -0.396 . . . . 0.0 111.41 179.903 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -60.59 -29.71 69.37 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.315 -0.402 . . . . 0.0 111.654 -179.604 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 22' ' ' PHE . . . . . 0.601 ' HB2' HG22 ' A' ' 41' ' ' VAL . 5.1 m-85 -91.23 -30.01 16.88 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.515 -0.311 . . . . 0.0 111.436 -179.56 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -72.66 -50.55 24.26 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-O 120.949 0.404 . . . . 0.0 110.997 -179.971 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 24' ' ' TRP . . . . . . . . . . . . . 2.8 t-105 -61.23 -39.49 90.48 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-N 115.737 -0.665 . . . . 0.0 110.501 179.806 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.329 -0.321 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.756 179.549 . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.257 0 N-CA-C 112.6 -0.2 . . . . 0.0 112.6 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 22.8 mm-40 -61.31 -21.14 63.7 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.757 0.313 . . . . 0.0 111.007 -179.935 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 34' ' ' ARG . . . . . . . . . . . . . 48.6 ttp180 -51.17 -29.63 14.4 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 116.043 -0.526 . . . . 0.0 111.271 -179.959 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 35' ' ' ARG . . . . . 0.439 ' CZ ' HD22 ' A' ' 89' ' ' LEU . 51.8 ttp180 -59.47 -48.19 82.58 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.326 -0.397 . . . . 0.0 111.075 -179.994 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 53.5 m-85 -64.43 -34.61 78.59 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.984 -179.922 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 37' ' ' TYR . . . . . 0.468 ' O ' HG23 ' A' ' 41' ' ' VAL . 63.6 m-85 -66.84 -54.15 25.32 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 115.993 -0.549 . . . . 0.0 111.05 -179.762 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 77.7 t -56.98 -37.05 52.67 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.242 0 CA-C-O 120.889 0.376 . . . . 0.0 110.455 179.723 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 24.2 m -66.73 -40.24 88.27 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 121.355 0.598 . . . . 0.0 110.171 179.044 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 40' ' ' LEU . . . . . 0.503 HD11 ' HA2' ' A' ' 209' ' ' GLY . 12.7 tp -65.5 -41.87 92.75 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 115.258 -0.883 . . . . 0.0 110.372 179.757 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 41' ' ' VAL . . . . . 0.601 HG22 ' HB2' ' A' ' 22' ' ' PHE . 59.7 t -69.68 -34.17 59.85 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.426 0 CA-C-N 115.561 -0.745 . . . . 0.0 110.312 179.379 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 42' ' ' GLY . . . . . 0.463 ' O ' HG12 ' A' ' 46' ' ' ILE . . . -59.26 -46.57 93.63 Favored Glycine 0 N--CA 1.448 -0.541 0 C-N-CA 120.971 -0.633 . . . . 0.0 112.554 179.999 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 43' ' ' ILE . . . . . 0.554 HG23 HD23 ' A' ' 82' ' ' LEU . 10.2 pt -65.63 -51.57 61.21 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.157 0 N-CA-C 111.729 0.27 . . . . 0.0 111.729 -179.767 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 48.1 t -63.84 -24.19 67.65 Favored 'General case' 0 C--O 1.234 0.247 0 CA-C-O 120.924 0.392 . . . . 0.0 111.396 -179.762 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -78.14 -59.05 3.02 Favored Glycine 0 CA--C 1.518 0.22 0 C-N-CA 120.92 -0.657 . . . . 0.0 113.466 -178.856 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 46' ' ' ILE . . . . . 0.498 ' O ' HG22 ' A' ' 49' ' ' VAL . 17.7 pt -57.79 -35.29 50.62 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.207 0 CA-C-O 120.751 0.31 . . . . 0.0 110.957 -179.606 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 47' ' ' ALA . . . . . 0.682 ' HB2' ' HE2' ' A' ' 205' ' ' LYS . . . -67.62 -40.12 84.7 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-O 120.841 0.353 . . . . 0.0 110.085 178.559 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 48' ' ' ALA . . . . . 0.567 ' HB2' ' HB3' ' A' ' 15' ' ' MET . . . -54.48 -43.39 71.69 Favored 'General case' 0 C--N 1.334 -0.101 0 CA-C-N 115.987 -0.551 . . . . 0.0 111.291 179.801 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 49' ' ' VAL . . . . . 0.498 HG22 ' O ' ' A' ' 46' ' ' ILE . 21.4 m -75.62 -34.36 28.88 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.221 0 CA-C-N 116.463 -0.335 . . . . 0.0 111.452 -179.82 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -59.12 -45.5 90.75 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.824 0.345 . . . . 0.0 111.392 -179.849 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 57.6 m-85 -73.16 -40.15 65.08 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 115.919 -0.582 . . . . 0.0 111.257 -179.31 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -60.64 -47.03 88.04 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 115.886 -0.597 . . . . 0.0 111.318 -179.921 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 53' ' ' VAL . . . . . 0.469 HG13 ' O ' ' A' ' 49' ' ' VAL . 16.8 m -71.89 -43.14 69.07 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.243 0 CA-C-N 116.324 -0.398 . . . . 0.0 110.969 -179.876 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 54' ' ' MET . . . . . 0.429 ' N ' HG23 ' A' ' 53' ' ' VAL . 17.0 ttp -63.71 -29.49 70.71 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 121.085 0.469 . . . . 0.0 110.101 179.509 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 55' ' ' ALA . . . . . 0.425 ' HB2' ' HB2' ' A' ' 8' ' ' PHE . . . -63.84 -36.22 83.2 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 115.63 -0.714 . . . . 0.0 111.539 179.773 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 78.6 mt -80.99 13.15 2.85 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.475 -0.33 . . . . 0.0 111.427 -179.626 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 84.39 -2.21 88.09 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.638 -0.792 . . . . 0.0 112.87 179.712 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 55.0 t -68.83 141.69 17.14 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-O 120.732 0.301 . . . . 0.0 110.768 179.777 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 59' ' ' GLY . . . . . 0.623 ' HA3' ' HD3' ' A' ' 71' ' ' PRO . . . 86.18 -16.07 45.62 Favored Glycine 0 N--CA 1.45 -0.411 0 C-N-CA 120.595 -0.812 . . . . 0.0 112.275 -179.857 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 60' ' ' TRP . . . . . . . . . . . . . 13.7 m0 -66.88 92.94 0.24 Allowed 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 120.825 0.345 . . . . 0.0 110.602 179.665 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 7.1 p -96.23 123.25 55.57 Favored Pre-proline 0 C--N 1.328 -0.347 0 CA-C-N 116.303 -0.408 . . . . 0.0 111.211 -179.832 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 46.5 Cg_endo -68.41 141.03 49.89 Favored 'Trans proline' 0 C--N 1.35 0.649 0 C-N-CA 122.403 2.068 . . . . 0.0 112.231 179.93 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 63' ' ' VAL . . . . . 0.411 HG21 ' HG3' ' A' ' 117' ' ' MET . 60.2 t -137.31 92.69 0.91 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.046 -0.525 . . . . 0.0 111.172 -179.789 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . 58.09 -88.93 0.02 OUTLIER 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 116.178 -0.465 . . . . 0.0 111.514 179.789 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 45.4 mt-10 -120.42 -17.98 8.01 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 116.486 -0.324 . . . . 0.0 110.856 179.973 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 66' ' ' ARG . . . . . . . . . . . . . 20.9 mmm180 -105.03 165.51 11.03 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 116.064 -0.516 . . . . 0.0 110.344 179.776 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 38.4 m -122.52 143.15 49.9 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-O 120.834 0.349 . . . . 0.0 111.201 -179.805 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 40.0 t -125.19 146.0 31.6 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.02 -0.537 . . . . 0.0 110.879 -179.991 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 69' ' ' PHE . . . . . . . . . . . . . 8.3 m-85 -109.31 114.32 27.9 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.371 -0.377 . . . . 0.0 110.161 179.837 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 70' ' ' VAL . . . . . 0.67 HG12 ' HD3' ' A' ' 71' ' ' PRO . 1.3 p -68.26 -35.64 7.58 Favored Pre-proline 0 CA--C 1.542 0.653 0 N-CA-C 112.945 0.72 . . . . 0.0 112.945 -179.34 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 71' ' ' PRO . . . . . 0.67 ' HD3' HG12 ' A' ' 70' ' ' VAL . 61.9 Cg_endo -71.16 -20.82 27.97 Favored 'Trans proline' 0 C--N 1.359 1.116 0 C-N-CA 121.822 1.681 . . . . 0.0 113.266 -179.352 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 66.7 ttt180 -74.23 -54.96 6.65 Favored 'General case' 0 C--N 1.329 -0.32 0 N-CA-C 112.019 0.377 . . . . 0.0 112.019 -178.993 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 73' ' ' TYR . . . . . 0.481 ' O ' HG13 ' A' ' 77' ' ' ILE . 65.9 m-85 -74.08 -32.84 63.42 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.533 -0.303 . . . . 0.0 111.526 -178.803 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 74' ' ' ILE . . . . . 0.467 ' O ' HD13 ' A' ' 74' ' ' ILE . 0.3 OUTLIER -70.23 -44.53 77.72 Favored 'Isoleucine or valine' 0 C--O 1.234 0.257 0 C-N-CA 120.615 -0.434 . . . . 0.0 110.18 179.486 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 75' ' ' ASP . . . . . 0.444 ' O ' HG23 ' A' ' 79' ' ' THR . 22.9 t70 -58.33 -35.89 72.58 Favored 'General case' 0 CA--C 1.52 -0.2 0 N-CA-C 109.094 -0.706 . . . . 0.0 109.094 178.959 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 76' ' ' TRP . . . . . 0.424 ' HA ' ' OG1' ' A' ' 79' ' ' THR . 44.7 m0 -64.95 -34.9 79.53 Favored 'General case' 0 C--N 1.332 -0.164 0 CA-C-N 115.769 -0.651 . . . . 0.0 110.228 178.801 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 77' ' ' ILE . . . . . 0.51 HG12 ' HB3' ' A' ' 109' ' ' MET . 98.0 mt -66.21 -30.42 49.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 115.981 -0.554 . . . . 0.0 110.745 179.561 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 82.0 mt -91.88 -17.89 24.58 Favored 'General case' 0 CA--C 1.532 0.257 0 N-CA-C 112.278 0.473 . . . . 0.0 112.278 179.644 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 79' ' ' THR . . . . . 0.444 HG23 ' O ' ' A' ' 75' ' ' ASP . 46.9 p -94.65 -51.65 4.64 Favored 'General case' 0 N--CA 1.465 0.319 0 N-CA-C 112.974 0.731 . . . . 0.0 112.974 -178.486 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 80' ' ' THR . . . . . 0.71 HG21 ' HE1' ' A' ' 109' ' ' MET . 27.5 m -50.25 -51.03 66.81 Favored Pre-proline 0 C--N 1.328 -0.354 0 N-CA-C 112.95 0.722 . . . . 0.0 112.95 -178.425 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 81' ' ' PRO . . . . . 0.531 ' HD2' ' N ' ' A' ' 80' ' ' THR . 19.4 Cg_endo -57.94 -23.57 60.44 Favored 'Trans proline' 0 C--N 1.352 0.732 0 C-N-CA 121.526 1.484 . . . . 0.0 111.703 -179.48 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 82' ' ' LEU . . . . . 0.554 HD23 HG23 ' A' ' 43' ' ' ILE . 3.5 mp -76.91 -38.36 53.63 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 115.923 -0.58 . . . . 0.0 110.704 179.834 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 49.9 mm -65.42 -53.44 39.82 Favored 'Isoleucine or valine' 0 C--O 1.234 0.267 0 CA-C-O 120.936 0.398 . . . . 0.0 110.221 179.371 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 26.8 m -60.68 -31.66 49.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.04 -0.527 . . . . 0.0 109.774 178.983 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 85' ' ' TYR . . . . . . . . . . . . . 87.7 t80 -67.81 -34.09 76.07 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-N 115.697 -0.683 . . . . 0.0 109.442 178.755 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 86' ' ' PHE . . . . . . . . . . . . . 1.8 t80 -58.95 -51.82 68.39 Favored 'General case' 0 C--O 1.233 0.225 0 CA-C-N 115.828 -0.624 . . . . 0.0 109.81 179.319 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 7.8 mp -63.87 -33.63 76.13 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 115.865 -0.607 . . . . 0.0 110.013 179.216 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -61.44 -28.34 69.35 Favored Glycine 0 N--CA 1.449 -0.454 0 C-N-CA 120.784 -0.722 . . . . 0.0 111.566 179.191 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 89' ' ' LEU . . . . . 0.439 HD22 ' CZ ' ' A' ' 35' ' ' ARG . 82.1 mt -79.04 -36.61 40.76 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.953 0.406 . . . . 0.0 110.165 179.325 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 97.0 mt -63.18 -37.67 88.13 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 115.821 -0.627 . . . . 0.0 111.017 179.802 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 91' ' ' ALA . . . . . 0.541 ' HB1' ' HB2' ' A' ' 148' ' ' SER . . . -87.22 -54.57 4.23 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.328 -179.837 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 103.33 70.6 0.84 Allowed Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.831 -0.699 . . . . 0.0 112.415 -179.775 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 93' ' ' LEU . . . . . 0.609 HD11 ' HG2' ' A' ' 145' ' ' MET . 7.5 mp -87.99 166.8 14.23 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.81 0.338 . . . . 0.0 111.047 -179.843 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 94' ' ' ASP . . . . . . . . . . . . . 7.9 m-20 -84.5 174.35 10.11 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.887 179.779 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 88.8 p -60.09 -35.72 75.82 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.308 -0.406 . . . . 0.0 111.004 -179.788 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 69.7 mtm180 -72.9 -48.79 34.2 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.148 -179.835 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 97' ' ' GLU . . . . . 0.593 ' HB3' HD23 ' A' ' 93' ' ' LEU . 37.5 mt-10 -56.16 -46.59 79.23 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.295 -0.412 . . . . 0.0 111.235 -179.73 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 98' ' ' PHE . . . . . 0.404 ' O ' HG12 ' A' ' 102' ' ' ILE . 6.5 m-85 -55.88 -50.59 70.23 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.366 -0.379 . . . . 0.0 111.07 -179.951 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -55.59 -34.28 60.14 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.858 -0.687 . . . . 0.0 112.637 -179.867 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 97.8 mt -66.82 -44.13 89.31 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.207 0 CA-C-O 120.773 0.32 . . . . 0.0 111.803 -179.748 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 25.0 t -68.59 -46.93 79.24 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.369 0 CA-C-N 116.263 -0.426 . . . . 0.0 111.936 -179.045 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 102' ' ' ILE . . . . . 0.404 HG12 ' O ' ' A' ' 98' ' ' PHE . 36.2 mm -63.64 -48.63 85.87 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 CA-C-N 116.283 -0.417 . . . . 0.0 111.922 -179.014 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 12.0 t -61.04 -37.2 81.75 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-O 120.761 0.315 . . . . 0.0 111.23 -179.528 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 104' ' ' LEU . . . . . 0.481 ' O ' HG23 ' A' ' 108' ' ' VAL . 10.1 tt -60.91 -42.93 99.01 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.411 179.721 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 105' ' ' ASN . . . . . 0.611 HD21 HD13 ' A' ' 137' ' ' LEU . 0.8 OUTLIER -67.68 -26.35 66.15 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.605 179.614 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 56.6 m -63.5 -53.57 49.98 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 115.941 -0.572 . . . . 0.0 111.149 179.82 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 7.8 p -63.93 -36.13 75.7 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.162 0 CA-C-N 116.336 -0.393 . . . . 0.0 111.127 179.919 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 108' ' ' VAL . . . . . 0.481 HG23 ' O ' ' A' ' 104' ' ' LEU . 79.6 t -63.3 -51.71 67.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-O 121.201 0.524 . . . . 0.0 110.604 179.44 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 109' ' ' MET . . . . . 0.71 ' HE1' HG21 ' A' ' 80' ' ' THR . 3.5 tpp -60.49 -33.73 73.02 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 115.67 -0.695 . . . . 0.0 110.422 179.759 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 20.8 tp -68.91 -33.52 73.88 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 115.9 -0.591 . . . . 0.0 110.166 179.693 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 111' ' ' ALA . . . . . 0.4 ' O ' HD13 ' A' ' 126' ' ' LEU . . . -59.7 -57.1 14.39 Favored 'General case' 0 C--N 1.332 -0.179 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.177 179.315 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . -57.31 -41.22 92.92 Favored Glycine 0 CA--C 1.518 0.233 0 C-N-CA 120.598 -0.81 . . . . 0.0 112.116 179.164 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 113' ' ' PHE . . . . . . . . . . . . . 1.5 t80 -47.16 -67.79 0.25 Allowed 'General case' 0 C--N 1.333 -0.137 0 CA-C-O 121.127 0.489 . . . . 0.0 110.081 179.473 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 114' ' ' ALA . . . . . 0.419 ' O ' HG13 ' A' ' 118' ' ' VAL . . . -64.43 -21.09 66.54 Favored 'General case' 0 C--N 1.326 -0.449 0 CA-C-N 115.512 -0.767 . . . . 0.0 110.864 179.661 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 115' ' ' GLY . . . . . 0.638 ' HA2' HD11 ' A' ' 126' ' ' LEU . . . -52.96 -49.38 55.37 Favored Glycine 0 C--N 1.333 0.375 0 C-N-CA 121.008 -0.615 . . . . 0.0 112.367 179.912 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -78.08 -15.79 58.59 Favored 'General case' 0 C--N 1.324 -0.506 0 N-CA-C 111.665 0.246 . . . . 0.0 111.665 179.742 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 117' ' ' MET . . . . . 0.411 ' HG3' HG21 ' A' ' 63' ' ' VAL . 36.1 ttm -100.94 19.89 16.49 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.497 -0.32 . . . . 0.0 111.674 -179.091 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 118' ' ' VAL . . . . . 0.444 HG21 ' HB3' ' A' ' 123' ' ' ARG . 28.3 m -74.11 147.5 85.84 Favored Pre-proline 0 C--N 1.328 -0.36 0 CA-C-N 116.559 -0.291 . . . . 0.0 111.305 179.789 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 119' ' ' PRO . . . . . . . . . . . . . 81.3 Cg_endo -88.94 -6.28 5.68 Favored 'Trans proline' 0 N--CA 1.457 -0.622 0 C-N-CA 122.688 2.259 . . . . 0.0 112.283 179.683 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -148.4 -114.69 0.78 Allowed Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.711 -0.757 . . . . 0.0 112.915 -179.783 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 44.7 pt -122.59 14.56 5.58 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 CA-C-O 120.802 0.334 . . . . 0.0 111.39 -179.51 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 36.9 mt-10 -63.4 -18.85 64.14 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.134 -179.999 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 123' ' ' ARG . . . . . 0.486 ' HA ' HD21 ' A' ' 126' ' ' LEU . 35.9 ptt180 -53.41 -32.42 49.56 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.106 -0.497 . . . . 0.0 111.925 -179.544 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 124' ' ' TYR . . . . . . . . . . . . . 91.5 m-85 -72.54 -31.41 65.27 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 116.476 -0.329 . . . . 0.0 111.466 -179.652 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 125' ' ' ALA . . . . . . . . . . . . . . . -74.51 -58.28 3.39 Favored 'General case' 0 C--O 1.237 0.44 0 CA-C-O 121.196 0.522 . . . . 0.0 111.573 -179.374 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 126' ' ' LEU . . . . . 0.638 HD11 ' HA2' ' A' ' 115' ' ' GLY . 0.7 OUTLIER -56.49 -37.24 70.1 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 115.701 -0.681 . . . . 0.0 110.511 179.789 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 127' ' ' PHE . . . . . . . . . . . . . 7.8 t80 -69.37 -42.6 74.99 Favored 'General case' 0 N--CA 1.453 -0.311 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.114 179.304 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 128' ' ' GLY . . . . . . . . . . . . . . . -48.09 -35.33 13.52 Favored Glycine 0 C--N 1.333 0.379 0 N-CA-C 110.673 -0.971 . . . . 0.0 110.673 178.746 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 129' ' ' MET . . . . . . . . . . . . . 0.2 OUTLIER -72.03 -43.67 64.63 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 115.154 -0.523 . . . . 0.0 109.877 178.619 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -67.25 -22.22 72.6 Favored Glycine 0 N--CA 1.449 -0.474 0 C-N-CA 120.869 -0.682 . . . . 0.0 112.378 179.602 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 131' ' ' ALA . . . . . 0.436 ' O ' ' HB3' ' A' ' 134' ' ' PHE . . . -74.61 -53.9 8.48 Favored 'General case' 0 CA--C 1.519 -0.234 0 CA-C-O 120.739 0.304 . . . . 0.0 110.211 179.681 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 58.1 t -58.32 -39.47 74.24 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.319 0 N-CA-C 108.535 -0.913 . . . . 0.0 108.535 178.096 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -62.77 -37.44 86.67 Favored 'General case' 0 N--CA 1.451 -0.378 0 CA-C-N 114.915 -1.039 . . . . 0.0 110.198 178.767 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 134' ' ' PHE . . . . . 0.436 ' HB3' ' O ' ' A' ' 131' ' ' ALA . 68.0 t80 -55.64 -50.09 71.11 Favored 'General case' 0 N--CA 1.453 -0.325 0 CA-C-N 116.159 -0.473 . . . . 0.0 109.88 179.364 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 135' ' ' ILE . . . . . 0.504 ' O ' HG22 ' A' ' 138' ' ' VAL . 59.0 mt -59.54 -32.45 49.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 115.667 -0.697 . . . . 0.0 110.14 179.228 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . -59.46 -41.76 97.25 Favored Glycine 0 N--CA 1.449 -0.494 0 C-N-CA 120.409 -0.901 . . . . 0.0 111.271 179.054 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 137' ' ' LEU . . . . . 0.611 HD13 HD21 ' A' ' 105' ' ' ASN . 42.7 tp -65.85 -55.61 16.17 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 120.666 0.27 . . . . 0.0 110.722 179.541 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 138' ' ' VAL . . . . . 0.637 ' HB ' HH22 ' A' ' 164' ' ' ARG . 2.5 m -54.79 -32.3 25.79 Favored 'Isoleucine or valine' 0 C--O 1.234 0.267 0 CA-C-O 121.125 0.488 . . . . 0.0 109.802 -179.506 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 139' ' ' TYR . . . . . . . . . . . . . 10.2 t80 -61.43 -42.31 98.54 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 115.654 -0.703 . . . . 0.0 109.964 178.293 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 28.1 m-85 -65.99 -42.37 89.89 Favored 'General case' 0 C--N 1.332 -0.184 0 CA-C-N 116.11 -0.496 . . . . 0.0 111.002 179.517 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 141' ' ' LEU . . . . . 0.435 ' HA ' ' SD ' ' A' ' 145' ' ' MET . 10.8 mp -56.62 -32.86 65.71 Favored 'General case' 0 N--CA 1.462 0.139 0 CA-C-N 116.356 -0.384 . . . . 0.0 110.883 -179.973 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 21.6 t -97.05 -12.75 8.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.82 179.662 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . -76.33 -123.83 0.19 Allowed Glycine 0 CA--C 1.522 0.529 0 C-N-CA 120.845 -0.693 . . . . 0.0 112.932 -179.721 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 144' ' ' PRO . . . . . . . . . . . . . 31.7 Cg_exo -58.87 -29.95 91.58 Favored 'Trans proline' 0 C--N 1.351 0.659 0 C-N-CA 122.596 2.198 . . . . 0.0 112.726 -179.672 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 145' ' ' MET . . . . . 0.609 ' HG2' HD11 ' A' ' 93' ' ' LEU . 60.1 mtt -58.7 -26.98 64.42 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.316 -0.402 . . . . 0.0 111.235 -179.893 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 146' ' ' THR . . . . . . . . . . . . . 24.0 m -81.08 -33.67 33.2 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-N 116.119 -0.491 . . . . 0.0 111.478 -179.058 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 15.0 tp10 -71.89 -43.43 65.41 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.98 -179.896 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 148' ' ' SER . . . . . 0.541 ' HB2' ' HB1' ' A' ' 91' ' ' ALA . 61.7 m -71.98 -40.15 68.79 Favored 'General case' 0 C--N 1.327 -0.405 0 N-CA-C 112.334 0.494 . . . . 0.0 112.334 -179.205 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 149' ' ' ALA . . . . . . . . . . . . . . . -76.68 -44.64 32.85 Favored 'General case' 0 C--N 1.33 -0.278 0 N-CA-C 113.395 0.887 . . . . 0.0 113.395 -177.974 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 150' ' ' SER . . . . . . . . . . . . . 54.2 m -69.12 -14.29 62.92 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.909 0.385 . . . . 0.0 110.85 -178.495 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 151' ' ' GLN . . . . . . . . . . . . . 3.0 mp0 -116.56 10.38 14.46 Favored 'General case' 0 C--N 1.324 -0.502 0 CA-C-N 115.928 -0.578 . . . . 0.0 111.494 -179.462 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 72.2 ttt180 -82.99 -51.94 7.12 Favored 'General case' 0 C--N 1.334 -0.102 0 CA-C-O 120.868 0.366 . . . . 0.0 110.943 -179.968 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 153' ' ' SER . . . . . 0.598 ' HB2' HG12 ' A' ' 156' ' ' ILE . 17.6 m -157.45 172.18 19.04 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 116.032 -0.531 . . . . 0.0 110.861 179.596 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 154' ' ' SER . . . . . . . . . . . . . 67.9 m -71.09 -37.3 72.41 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.687 179.636 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -76.82 -35.0 41.24 Favored Glycine 0 N--CA 1.452 -0.276 0 C-N-CA 120.887 -0.673 . . . . 0.0 112.568 179.908 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 156' ' ' ILE . . . . . 0.598 HG12 ' HB2' ' A' ' 153' ' ' SER . 41.4 mm -56.42 -37.72 52.51 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-O 120.887 0.375 . . . . 0.0 110.92 -179.972 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 157' ' ' LYS . . . . . . . . . . . . . 24.3 ttpp -60.98 -32.9 72.45 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.903 179.82 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 47.1 m -70.9 -45.23 64.7 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.073 -179.863 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 159' ' ' LEU . . . . . 0.487 HD22 HD21 ' A' ' 163' ' ' LEU . 11.2 mt -65.67 -36.12 82.76 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.338 -0.392 . . . . 0.0 111.07 179.931 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 160' ' ' TYR . . . . . 0.49 ' O ' ' HB3' ' A' ' 164' ' ' ARG . 57.3 t80 -65.57 -47.86 74.36 Favored 'General case' 0 C--N 1.329 -0.317 0 N-CA-C 112.206 0.447 . . . . 0.0 112.206 -178.952 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 161' ' ' VAL . . . . . 0.43 HG23 ' N ' ' A' ' 162' ' ' ARG . 17.3 m -62.17 -49.28 84.69 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 N-CA-C 112.304 0.483 . . . . 0.0 112.304 -178.608 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 162' ' ' ARG . . . . . 0.43 ' N ' HG23 ' A' ' 161' ' ' VAL . 81.9 mtt180 -68.46 -46.11 70.66 Favored 'General case' 0 C--N 1.329 -0.291 0 N-CA-C 112.076 0.398 . . . . 0.0 112.076 -179.044 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 163' ' ' LEU . . . . . 0.487 HD21 HD22 ' A' ' 159' ' ' LEU . 1.7 mp -67.67 -54.95 15.35 Favored 'General case' 0 C--N 1.328 -0.332 0 N-CA-C 112.243 0.46 . . . . 0.0 112.243 -178.62 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 164' ' ' ARG . . . . . 0.637 HH22 ' HB ' ' A' ' 138' ' ' VAL . 25.2 tpt180 -55.78 -54.89 38.91 Favored 'General case' 0 N--CA 1.465 0.292 0 N-CA-C 112.629 0.603 . . . . 0.0 112.629 -178.46 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 165' ' ' ASN . . . . . . . . . . . . . 13.8 m-80 -58.0 -49.25 77.5 Favored 'General case' 0 C--N 1.33 -0.255 0 N-CA-C 112.071 0.397 . . . . 0.0 112.071 -178.75 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 166' ' ' LEU . . . . . . . . . . . . . 4.4 tt -63.45 -55.37 24.73 Favored 'General case' 0 C--N 1.325 -0.47 0 N-CA-C 111.876 0.325 . . . . 0.0 111.876 -179.262 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 167' ' ' THR . . . . . . . . . . . . . 53.7 m -57.02 -52.92 63.34 Favored 'General case' 0 C--N 1.328 -0.368 0 N-CA-C 113.037 0.754 . . . . 0.0 113.037 -178.613 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 168' ' ' VAL . . . . . 0.451 HG12 ' O ' ' A' ' 164' ' ' ARG . 7.9 p -57.5 -41.22 78.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 N-CA-C 112.482 0.549 . . . . 0.0 112.482 -178.529 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 169' ' ' VAL . . . . . 0.463 ' CG1' ' N ' ' A' ' 170' ' ' LEU . 0.4 OUTLIER -63.72 -54.07 36.76 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.443 0 N-CA-C 111.867 0.321 . . . . 0.0 111.867 -178.76 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 170' ' ' LEU . . . . . 0.463 ' N ' ' CG1' ' A' ' 169' ' ' VAL . 3.0 pp -68.03 -31.12 70.57 Favored 'General case' 0 C--N 1.33 -0.268 0 C-N-CA 121.173 -0.211 . . . . 0.0 111.543 -178.562 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 171' ' ' TRP . . . . . 0.443 ' N ' HD12 ' A' ' 170' ' ' LEU . 3.3 m0 -72.29 -28.59 63.19 Favored 'General case' 0 C--N 1.329 -0.295 0 N-CA-C 109.952 -0.388 . . . . 0.0 109.952 178.895 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 172' ' ' ALA . . . . . . . . . . . . . . . -76.0 -6.87 53.03 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-N 115.919 -0.582 . . . . 0.0 110.554 -179.821 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 173' ' ' ILE . . . . . 0.486 ' O ' HG12 ' A' ' 177' ' ' ILE . 34.1 mm -85.86 -21.12 7.75 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.204 0 CA-C-N 115.719 -0.673 . . . . 0.0 110.853 179.41 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 174' ' ' TYR . . . . . 0.417 ' HB2' ' HD3' ' A' ' 175' ' ' PRO . 11.8 m-85 -53.76 -50.22 84.83 Favored Pre-proline 0 CA--C 1.53 0.194 0 CA-C-N 116.313 -0.403 . . . . 0.0 111.799 -179.446 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 175' ' ' PRO . . . . . 0.417 ' HD3' ' HB2' ' A' ' 174' ' ' TYR . 74.5 Cg_exo -50.42 -29.9 25.5 Favored 'Trans proline' 0 C--N 1.349 0.572 0 C-N-CA 122.191 1.927 . . . . 0.0 112.517 179.84 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 176' ' ' PHE . . . . . 0.432 ' HD2' ' HA ' ' A' ' 173' ' ' ILE . 38.9 m-85 -80.44 -50.24 10.35 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.233 -0.44 . . . . 0.0 111.846 -179.707 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 177' ' ' ILE . . . . . 0.486 HG12 ' O ' ' A' ' 173' ' ' ILE . 5.7 mm -65.65 -33.54 64.29 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.519 0 N-CA-C 112.27 0.47 . . . . 0.0 112.27 -178.229 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 178' ' ' TRP . . . . . 0.442 ' HH2' ' HB2' ' A' ' 123' ' ' ARG . 88.7 t90 -72.86 -56.53 5.08 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.873 0.368 . . . . 0.0 110.807 -179.925 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 179' ' ' LEU . . . . . 0.416 HD23 HD23 ' A' ' 180' ' ' LEU . 0.6 OUTLIER -63.04 -54.23 41.33 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 115.931 -0.577 . . . . 0.0 111.324 -179.36 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 180' ' ' LEU . . . . . 0.54 HD22 HD11 ' A' ' 187' ' ' LEU . 43.3 mt -64.67 -41.41 96.1 Favored 'General case' 0 C--N 1.331 -0.213 0 C-N-CA 120.832 -0.347 . . . . 0.0 111.068 -179.607 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . -62.6 -178.79 3.98 Favored Glycine 0 C--N 1.334 0.43 0 C-N-CA 119.952 -1.118 . . . . 0.0 112.002 179.103 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 182' ' ' PRO . . . . . 0.577 ' HA ' ' HB2' ' A' ' 186' ' ' ALA . 83.2 Cg_exo -47.84 -44.8 26.17 Favored 'Trans proline' 0 CA--C 1.536 0.58 0 C-N-CA 122.741 2.294 . . . . 0.0 113.74 179.962 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 183' ' ' PRO . . . . . 0.411 ' HD3' ' HB2' ' A' ' 182' ' ' PRO . 84.1 Cg_exo -47.04 -22.51 2.15 Favored 'Trans proline' 0 C--N 1.356 0.933 0 C-N-CA 122.209 1.939 . . . . 0.0 113.286 -179.688 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 184' ' ' GLY . . . . . . . . . . . . . . . -126.12 -124.12 2.74 Favored Glycine 0 C--N 1.333 0.367 0 C-N-CA 120.305 -0.95 . . . . 0.0 112.926 179.874 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 185' ' ' VAL . . . . . 0.41 ' CG2' ' HA ' ' A' ' 180' ' ' LEU . 19.4 m -61.28 -25.31 36.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 N-CA-C 112.281 0.474 . . . . 0.0 112.281 -179.248 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 186' ' ' ALA . . . . . 0.577 ' HB2' ' HA ' ' A' ' 182' ' ' PRO . . . 57.65 85.41 0.09 Allowed 'General case' 0 N--CA 1.465 0.318 0 CA-C-O 120.832 0.348 . . . . 0.0 111.7 179.555 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 187' ' ' LEU . . . . . 0.54 HD11 HD22 ' A' ' 180' ' ' LEU . 10.7 mt -92.88 -49.27 6.13 Favored 'General case' 0 C--N 1.332 -0.184 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.359 179.911 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 188' ' ' LEU . . . . . . . . . . . . . 53.7 mt -95.47 -161.43 0.86 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 115.988 -0.551 . . . . 0.0 111.691 -179.052 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 189' ' ' THR . . . . . . . . . . . . . 9.9 m -91.5 137.06 26.09 Favored Pre-proline 0 C--N 1.33 -0.261 0 CA-C-N 115.77 -0.65 . . . . 0.0 110.682 -179.716 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 190' ' ' PRO . . . . . . . . . . . . . 96.4 Cg_exo -44.65 -46.01 12.76 Favored 'Trans proline' 0 C--N 1.35 0.655 0 C-N-CA 122.812 2.341 . . . . 0.0 113.539 -179.735 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 191' ' ' THR . . . . . . . . . . . . . 6.7 t -59.1 -36.83 75.8 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.822 0.344 . . . . 0.0 111.329 -179.764 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 192' ' ' VAL . . . . . . . . . . . . . 58.0 t -74.79 -53.63 16.19 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.22 -0.446 . . . . 0.0 111.696 -179.591 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 193' ' ' ASP . . . . . . . . . . . . . 23.9 m-20 -56.45 -48.36 77.22 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.45 -0.341 . . . . 0.0 110.973 -179.588 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 194' ' ' VAL . . . . . . . . . . . . . 78.0 t -61.92 -36.38 73.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.432 179.602 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 195' ' ' ALA . . . . . . . . . . . . . . . -56.28 -42.34 77.33 Favored 'General case' 0 C--N 1.331 -0.197 0 CA-C-N 116.344 -0.389 . . . . 0.0 110.823 179.335 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 196' ' ' LEU . . . . . . . . . . . . . 96.1 mt -67.19 -38.86 86.09 Favored 'General case' 0 C--N 1.332 -0.174 0 CA-C-O 120.952 0.406 . . . . 0.0 110.332 179.486 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 197' ' ' ILE . . . . . . . . . . . . . 21.6 mm -59.79 -52.6 59.19 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 115.937 -0.574 . . . . 0.0 110.18 179.153 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 198' ' ' VAL . . . . . . . . . . . . . 90.8 t -57.26 -34.15 45.17 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.458 0 N-CA-C 108.908 -0.775 . . . . 0.0 108.908 178.179 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 199' ' ' TYR . . . . . . . . . . . . . 46.0 t80 -69.44 -30.3 68.19 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-N 115.115 -0.948 . . . . 0.0 110.568 179.46 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 200' ' ' LEU . . . . . 0.467 ' O ' HG12 ' A' ' 203' ' ' VAL . 48.2 mt -70.25 -42.37 72.27 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 115.944 -0.571 . . . . 0.0 111.158 -179.854 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 201' ' ' ASP . . . . . . . . . . . . . 12.3 m-20 -73.3 -34.65 65.84 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-O 121.167 0.508 . . . . 0.0 110.15 179.378 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 202' ' ' LEU . . . . . . . . . . . . . 2.5 mt -70.78 -31.33 68.07 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 115.562 -0.745 . . . . 0.0 111.795 -179.799 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 203' ' ' VAL . . . . . 0.467 HG12 ' O ' ' A' ' 200' ' ' LEU . 11.9 p -77.18 -37.1 25.42 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.235 0 C-N-CA 120.946 -0.302 . . . . 0.0 111.209 -179.143 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 204' ' ' THR . . . . . . . . . . . . . 68.0 m -65.13 -57.49 8.44 Favored 'General case' 0 C--O 1.222 -0.392 0 C-N-CA 120.76 -0.376 . . . . 0.0 111.318 179.718 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 205' ' ' LYS . . . . . 0.682 ' HE2' ' HB2' ' A' ' 47' ' ' ALA . 60.6 mttp -65.13 -55.51 18.3 Favored 'General case' 0 C--N 1.326 -0.414 0 N-CA-C 112.301 0.482 . . . . 0.0 112.301 -178.716 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 59.2 t -65.31 -47.18 88.17 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 N-CA-C 111.841 0.312 . . . . 0.0 111.841 -179.606 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 207' ' ' GLY . . . . . . . . . . . . . . . -63.94 -59.62 8.34 Favored Glycine 0 C--N 1.331 0.28 0 C-N-CA 120.708 -0.758 . . . . 0.0 112.771 -179.795 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 208' ' ' PHE . . . . . 0.42 ' O ' ' N ' ' A' ' 212' ' ' ALA . 4.1 t80 -54.71 -40.74 69.52 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.672 0.272 . . . . 0.0 110.97 179.965 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 209' ' ' GLY . . . . . 0.503 ' HA2' HD11 ' A' ' 40' ' ' LEU . . . -69.78 -38.65 76.63 Favored Glycine 0 C--N 1.329 0.189 0 CA-C-N 115.877 -0.601 . . . . 0.0 113.356 -179.558 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 210' ' ' PHE . . . . . . . . . . . . . 1.4 m-85 -69.66 -39.95 76.75 Favored 'General case' 0 CA--C 1.51 -0.571 0 N-CA-C 107.649 -1.241 . . . . 0.0 107.649 179.118 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 211' ' ' ILE . . . . . . . . . . . . . 29.9 mt -69.73 -28.6 37.84 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.87 0 CA-C-N 114.235 -1.348 . . . . 0.0 107.416 176.737 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 212' ' ' ALA . . . . . 0.461 ' HB3' ' O ' ' A' ' 209' ' ' GLY . . . -68.08 -38.8 82.78 Favored 'General case' 0 N--CA 1.447 -0.59 0 CA-C-N 114.293 -1.321 . . . . 0.0 110.637 179.856 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 213' ' ' LEU . . . . . . . . . . . . . 96.4 mt -70.6 -53.09 17.3 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 115.257 -0.883 . . . . 0.0 112.043 -179.238 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 214' ' ' ASP . . . . . . . . . . . . . 45.0 m-20 -52.09 -53.06 47.11 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.443 -0.344 . . . . 0.0 111.636 -179.428 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 215' ' ' ALA . . . . . 0.421 ' HB3' HD21 ' A' ' 159' ' ' LEU . . . -59.68 -57.36 13.26 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.344 -0.389 . . . . 0.0 111.818 -179.511 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 216' ' ' ALA . . . . . . . . . . . . . . . -58.11 -31.73 67.43 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.441 -0.345 . . . . 0.0 111.601 -179.519 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 217' ' ' ALA . . . . . . . . . . . . . . . -62.24 -42.16 99.06 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 121.015 0.436 . . . . 0.0 110.151 179.832 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 218' ' ' THR . . . . . . . . . . . . . 97.2 m . . . . . 0 C--N 1.329 -0.314 0 CA-C-N 115.827 -0.624 . . . . 0.0 110.33 179.154 . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.353 0 N-CA-C 112.384 -0.286 . . . . 0.0 112.384 . . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 59.4 tp -74.42 -35.52 63.41 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 120.844 0.355 . . . . 0.0 111.101 179.886 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 65.2 p -62.64 -30.06 71.09 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.517 -179.626 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 36.1 p -55.11 -35.46 64.68 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.44 -0.345 . . . . 0.0 111.118 -179.92 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 7' ' ' LEU . . . . . . . . . . . . . 4.2 mm? -56.65 -53.26 59.77 Favored 'General case' 0 C--N 1.331 -0.205 0 CA-C-N 116.082 -0.508 . . . . 0.0 111.052 -179.974 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 8' ' ' PHE . . . . . 0.708 ' HB2' ' HB2' ' A' ' 55' ' ' ALA . 67.9 m-85 -60.96 -36.41 79.32 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.873 -179.958 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 9' ' ' TRP . . . . . . . . . . . . . 30.4 m95 -61.4 -44.16 97.63 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.047 -179.876 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 51.8 mt -60.94 -42.65 98.59 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 115.638 -0.71 . . . . 0.0 110.239 179.246 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -62.09 -29.94 74.22 Favored Glycine 0 N--CA 1.448 -0.549 0 C-N-CA 120.69 -0.766 . . . . 0.0 111.888 179.259 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -72.58 -33.51 66.8 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-O 120.698 0.285 . . . . 0.0 110.968 179.719 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 13' ' ' ILE . . . . . 0.434 ' O ' HG23 ' A' ' 17' ' ' VAL . 83.3 mt -64.16 -54.32 32.7 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.226 0 CA-C-N 116.343 -0.39 . . . . 0.0 110.749 179.758 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -66.02 -34.15 87.59 Favored Glycine 0 N--CA 1.452 -0.291 0 C-N-CA 120.685 -0.769 . . . . 0.0 112.227 179.833 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 15' ' ' MET . . . . . 0.534 ' SD ' ' HA ' ' A' ' 44' ' ' SER . 52.7 tpp -65.69 -49.79 67.27 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.733 0.301 . . . . 0.0 110.646 179.986 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 51.0 mt -53.42 -42.23 66.84 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.506 179.382 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 17' ' ' VAL . . . . . 0.434 HG23 ' O ' ' A' ' 13' ' ' ILE . 99.5 t -58.89 -41.46 82.98 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.226 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.125 179.128 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -64.76 -40.49 97.43 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.606 -0.806 . . . . 0.0 111.49 179.029 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 3.6 m -50.97 -54.17 26.69 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.883 0.373 . . . . 0.0 111.102 179.917 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 75.2 mt -71.74 -39.72 69.88 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.061 -0.518 . . . . 0.0 111.454 -179.887 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 21' ' ' ALA . . . . . 0.567 ' O ' ' HB2' ' A' ' 25' ' ' ALA . . . -54.71 -43.88 72.95 Favored 'General case' 0 C--N 1.329 -0.316 0 N-CA-C 112.381 0.512 . . . . 0.0 112.381 -178.953 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 4.3 m-85 -84.36 -28.24 27.14 Favored 'General case' 0 C--N 1.329 -0.315 0 N-CA-C 111.889 0.329 . . . . 0.0 111.889 -178.969 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -64.98 -51.48 61.48 Favored 'General case' 0 C--N 1.326 -0.442 0 N-CA-C 112.59 0.589 . . . . 0.0 112.59 -178.965 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 24' ' ' TRP . . . . . 0.504 ' CE3' ' HA ' ' A' ' 24' ' ' TRP . 2.3 t-105 -87.1 -26.75 23.5 Favored 'General case' 0 N--CA 1.442 -0.827 0 N-CA-C 113.383 0.882 . . . . 0.0 113.383 -177.497 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 25' ' ' ALA . . . . . 0.567 ' HB2' ' O ' ' A' ' 21' ' ' ALA . . . . . . . . 0 C--N 1.318 -0.778 0 C-N-CA 120.636 -0.426 . . . . 0.0 109.947 178.896 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.306 0 N-CA-C 112.445 -0.262 . . . . 0.0 112.445 . . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 9.0 mm-40 -89.27 -20.59 23.91 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.776 0.322 . . . . 0.0 110.872 -179.957 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 34' ' ' ARG . . . . . . . . . . . . . 92.8 mtt180 -56.35 -28.7 59.86 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.129 -0.487 . . . . 0.0 111.385 -179.815 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 99.2 mtt180 -54.96 -56.46 19.44 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-O 120.863 0.363 . . . . 0.0 111.286 -179.807 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 76.1 m-85 -71.29 -40.16 71.06 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.944 -179.052 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 37' ' ' TYR . . . . . . . . . . . . . 20.7 m-85 -65.52 -56.3 13.12 Favored 'General case' 0 C--N 1.329 -0.305 0 N-CA-C 111.707 0.262 . . . . 0.0 111.707 -179.08 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 89.3 t -57.08 -37.17 53.9 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.326 0 CA-C-O 120.724 0.297 . . . . 0.0 110.935 179.981 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 15.2 m -64.36 -51.55 62.73 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 121.037 0.446 . . . . 0.0 110.748 179.33 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 40' ' ' LEU . . . . . 0.477 HD12 HD12 ' A' ' 43' ' ' ILE . 61.1 tp -59.22 -50.83 72.5 Favored 'General case' 0 C--O 1.235 0.306 0 CA-C-N 115.877 -0.601 . . . . 0.0 110.641 179.913 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 96.4 t -59.78 -34.4 55.54 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 115.974 -0.557 . . . . 0.0 109.62 178.902 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -57.22 -39.28 89.82 Favored Glycine 0 N--CA 1.447 -0.603 0 CA-C-N 115.644 -0.707 . . . . 0.0 111.767 179.407 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 43' ' ' ILE . . . . . 0.498 HG22 ' HE3' ' A' ' 205' ' ' LYS . 1.0 OUTLIER -65.65 -53.12 42.48 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.205 0 CA-C-O 120.832 0.348 . . . . 0.0 110.128 179.306 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 44' ' ' SER . . . . . 0.534 ' HA ' ' SD ' ' A' ' 15' ' ' MET . 83.0 p -61.86 -21.2 64.47 Favored 'General case' 0 C--N 1.333 -0.146 0 CA-C-N 116.104 -0.498 . . . . 0.0 111.12 179.985 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -76.25 -59.23 3.4 Favored Glycine 0 N--CA 1.452 -0.265 0 C-N-CA 120.726 -0.75 . . . . 0.0 112.662 -179.737 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 20.7 pt -61.0 -35.68 66.96 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-O 120.724 0.297 . . . . 0.0 111.425 -179.79 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 47' ' ' ALA . . . . . 0.64 ' HB2' ' HE2' ' A' ' 205' ' ' LYS . . . -67.06 -43.87 81.56 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.843 0.354 . . . . 0.0 111.065 179.478 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -54.78 -49.33 71.16 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.094 -0.503 . . . . 0.0 111.359 -179.749 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 26.9 m -67.75 -34.14 65.96 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.328 -0.396 . . . . 0.0 111.09 -179.718 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -62.75 -38.65 91.41 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-O 121.12 0.486 . . . . 0.0 110.657 179.576 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 51' ' ' TYR . . . . . 0.451 ' OH ' ' HB2' ' A' ' 201' ' ' ASP . 30.6 m-85 -72.93 -31.42 64.6 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-N 115.763 -0.653 . . . . 0.0 110.169 179.852 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -70.04 -42.52 72.8 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-N 115.749 -0.659 . . . . 0.0 111.091 179.609 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 53' ' ' VAL . . . . . 0.448 HG23 ' N ' ' A' ' 54' ' ' MET . 32.9 m -69.43 -45.5 78.48 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.197 0 CA-C-N 116.548 -0.296 . . . . 0.0 110.985 -179.848 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 54' ' ' MET . . . . . 0.448 ' N ' HG23 ' A' ' 53' ' ' VAL . 76.7 mtm -64.66 -31.06 72.12 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-O 121.034 0.445 . . . . 0.0 110.094 179.319 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 55' ' ' ALA . . . . . 0.708 ' HB2' ' HB2' ' A' ' 8' ' ' PHE . . . -74.46 -15.35 60.9 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 115.672 -0.694 . . . . 0.0 111.403 179.637 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 69.6 mt -92.1 -13.36 30.92 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.458 -0.337 . . . . 0.0 111.492 -179.697 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 104.2 -20.92 39.07 Favored Glycine 0 N--CA 1.452 -0.263 0 C-N-CA 120.52 -0.848 . . . . 0.0 113.112 179.8 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 58' ' ' VAL . . . . . 0.436 HG12 ' O ' ' A' ' 53' ' ' VAL . 11.7 p -67.08 149.61 11.52 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-N 116.861 0.331 . . . . 0.0 110.623 179.989 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 88.09 -14.47 58.92 Favored Glycine 0 N--CA 1.449 -0.471 0 C-N-CA 120.663 -0.779 . . . . 0.0 111.774 -179.155 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 60' ' ' TRP . . . . . . . . . . . . . 18.2 m0 -76.02 97.77 4.12 Favored 'General case' 0 C--N 1.331 -0.197 0 CA-C-O 120.836 0.35 . . . . 0.0 110.673 179.917 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 61' ' ' VAL . . . . . 0.511 HG13 HG23 ' A' ' 68' ' ' VAL . 5.2 p -100.32 129.26 28.41 Favored Pre-proline 0 C--N 1.328 -0.327 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.81 179.766 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 73.5 Cg_endo -73.97 146.22 36.91 Favored 'Trans proline' 0 C--N 1.35 0.619 0 C-N-CA 122.478 2.118 . . . . 0.0 112.245 -179.826 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 92.1 t -140.37 95.35 0.78 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.181 -179.67 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . 57.94 -91.42 0.03 OUTLIER 'General case' 0 C--N 1.331 -0.212 0 CA-C-N 116.123 -0.489 . . . . 0.0 111.27 -179.969 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -122.57 -11.78 8.22 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-O 120.968 0.413 . . . . 0.0 110.702 179.715 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 66' ' ' ARG . . . . . 0.451 HH22 HH12 ' A' ' 123' ' ' ARG . 16.9 ptp180 -105.52 165.6 11.03 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 115.9 -0.591 . . . . 0.0 110.364 179.454 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 61.5 m -126.33 141.51 51.88 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 120.965 0.412 . . . . 0.0 111.357 -179.842 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 68' ' ' VAL . . . . . 0.513 HG21 ' HG3' ' A' ' 117' ' ' MET . 9.1 m -133.25 146.18 32.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 115.942 -0.572 . . . . 0.0 110.669 179.575 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 69' ' ' PHE . . . . . . . . . . . . . 5.8 m-85 -107.59 118.31 36.4 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-O 121.049 0.452 . . . . 0.0 110.389 -179.056 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 70' ' ' VAL . . . . . 0.634 HG12 ' HD3' ' A' ' 71' ' ' PRO . 1.3 p -67.1 -35.32 8.63 Favored Pre-proline 0 CA--C 1.54 0.583 0 CA-C-N 115.687 -0.688 . . . . 0.0 112.829 -178.978 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 71' ' ' PRO . . . . . 0.634 ' HD3' HG12 ' A' ' 70' ' ' VAL . 8.7 Cg_exo -70.38 -18.65 33.94 Favored 'Trans proline' 0 C--N 1.356 0.948 0 C-N-CA 121.902 1.734 . . . . 0.0 112.66 -179.37 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 46.8 ttp180 -75.16 -54.3 7.36 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.55 -0.295 . . . . 0.0 111.791 -178.948 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 73' ' ' TYR . . . . . 0.414 ' O ' HG13 ' A' ' 77' ' ' ILE . 18.4 m-85 -67.66 -37.1 81.9 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.755 0.312 . . . . 0.0 110.491 -179.569 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 0.4 OUTLIER -68.39 -38.37 79.25 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.219 0 CA-C-N 116.293 -0.412 . . . . 0.0 110.139 179.526 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 19.5 t70 -59.65 -36.97 77.45 Favored 'General case' 0 CA--C 1.52 -0.199 0 N-CA-C 109.712 -0.477 . . . . 0.0 109.712 179.08 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 76' ' ' TRP . . . . . . . . . . . . . 46.0 m0 -65.03 -41.67 95.07 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 115.781 -0.645 . . . . 0.0 110.081 179.427 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 77' ' ' ILE . . . . . 0.414 HG13 ' O ' ' A' ' 73' ' ' TYR . 66.7 mt -61.79 -28.64 44.62 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.425 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.902 179.544 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 29.8 mt -90.74 -27.98 18.59 Favored 'General case' 0 CA--C 1.531 0.232 0 N-CA-C 112.481 0.549 . . . . 0.0 112.481 -179.376 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 64.6 p -91.28 -43.44 9.8 Favored 'General case' 0 C--N 1.329 -0.322 0 N-CA-C 113.002 0.741 . . . . 0.0 113.002 -178.022 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 80' ' ' THR . . . . . 0.566 ' N ' ' HD2' ' A' ' 81' ' ' PRO . 38.9 p -52.33 -45.01 94.96 Favored Pre-proline 0 C--N 1.328 -0.356 0 N-CA-C 113.072 0.767 . . . . 0.0 113.072 -179.044 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 81' ' ' PRO . . . . . 0.566 ' HD2' ' N ' ' A' ' 80' ' ' THR . 35.8 Cg_endo -62.99 -23.03 74.11 Favored 'Trans proline' 0 C--N 1.354 0.847 0 C-N-CA 121.406 1.404 . . . . 0.0 111.776 -179.78 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 82' ' ' LEU . . . . . 0.443 HD23 HG12 ' A' ' 43' ' ' ILE . 7.5 mp -76.82 -43.03 38.09 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 115.779 -0.646 . . . . 0.0 111.365 -179.494 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 83' ' ' ILE . . . . . 0.415 HD13 HD13 ' A' ' 43' ' ' ILE . 39.8 mm -63.29 -53.85 40.51 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.413 -0.358 . . . . 0.0 110.955 -179.851 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 33.5 m -60.05 -36.95 70.63 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.222 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.467 179.668 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 85' ' ' TYR . . . . . . . . . . . . . 69.8 t80 -63.48 -32.85 74.42 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.098 -0.501 . . . . 0.0 109.809 179.246 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 86' ' ' PHE . . . . . . . . . . . . . 6.0 t80 -61.64 -51.91 66.54 Favored 'General case' 0 C--O 1.233 0.193 0 CA-C-N 115.973 -0.558 . . . . 0.0 109.963 179.34 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 8.5 mp -61.06 -31.85 71.5 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 115.859 -0.61 . . . . 0.0 110.169 179.199 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -71.13 -27.87 71.2 Favored Glycine 0 N--CA 1.45 -0.392 0 C-N-CA 120.871 -0.68 . . . . 0.0 111.787 179.321 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 71.1 mt -73.13 -34.82 66.34 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-O 120.972 0.415 . . . . 0.0 110.38 179.517 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 74.8 mt -66.47 -35.66 80.82 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 115.761 -0.654 . . . . 0.0 111.303 -179.984 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -87.93 -32.33 18.96 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.589 -179.472 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 82.83 55.14 3.04 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.675 -0.774 . . . . 0.0 112.195 -179.72 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 33.8 mt -69.44 167.24 17.04 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.899 0.381 . . . . 0.0 111.128 -179.815 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 94' ' ' ASP . . . . . . . . . . . . . 18.4 t70 -86.15 168.29 14.14 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 115.987 -0.551 . . . . 0.0 110.361 179.683 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 80.8 p -57.62 -33.13 67.93 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.439 -0.346 . . . . 0.0 110.974 179.972 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 98.2 mtt180 -73.82 -53.47 10.18 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.208 179.944 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 44.0 mt-10 -53.76 -42.14 67.9 Favored 'General case' 0 C--N 1.332 -0.175 0 CA-C-N 116.362 -0.381 . . . . 0.0 110.914 -179.892 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 98' ' ' PHE . . . . . 0.423 ' O ' HG12 ' A' ' 102' ' ' ILE . 9.0 m-85 -59.91 -46.86 88.0 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.77 179.668 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -58.82 -29.59 64.87 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.816 -0.707 . . . . 0.0 112.56 -179.922 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 95.1 mt -73.51 -42.36 56.11 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.243 0 CA-C-O 120.872 0.368 . . . . 0.0 111.436 -179.847 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 42.1 t -68.61 -43.89 83.08 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.365 0 CA-C-N 116.329 -0.396 . . . . 0.0 111.208 -179.815 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 102' ' ' ILE . . . . . 0.423 HG12 ' O ' ' A' ' 98' ' ' PHE . 42.2 mm -68.53 -46.36 80.32 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.355 0 CA-C-N 116.086 -0.506 . . . . 0.0 111.688 -179.338 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 14.6 t -58.44 -35.85 72.75 Favored 'General case' 0 C--O 1.232 0.161 0 CA-C-O 120.778 0.323 . . . . 0.0 110.673 179.945 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 104' ' ' LEU . . . . . 0.443 HD22 ' HE2' ' A' ' 140' ' ' TYR . 30.1 tp -62.84 -45.99 90.03 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.036 179.124 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 105' ' ' ASN . . . . . 0.408 ' N ' HD22 ' A' ' 105' ' ' ASN . 0.9 OUTLIER -62.58 -25.75 68.24 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 115.978 -0.555 . . . . 0.0 110.712 179.354 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 24.6 m -68.57 -52.1 35.47 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.371 -0.377 . . . . 0.0 111.491 -179.803 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 10.9 p -70.24 -40.57 78.16 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.212 0 CA-C-N 116.429 -0.35 . . . . 0.0 111.888 -179.428 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 108' ' ' VAL . . . . . 0.57 ' HA ' ' HE1' ' A' ' 129' ' ' MET . 73.1 t -62.66 -58.46 7.48 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.254 0 CA-C-O 120.977 0.418 . . . . 0.0 111.458 -179.74 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 109' ' ' MET . . . . . 0.578 ' N ' ' SD ' ' A' ' 109' ' ' MET . 0.0 OUTLIER -58.39 -32.46 68.62 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 115.957 -0.565 . . . . 0.0 110.827 -179.396 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 28.4 tp -67.69 -35.29 78.54 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.296 -0.411 . . . . 0.0 110.089 179.292 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 111' ' ' ALA . . . . . 0.403 ' O ' ' HB3' ' A' ' 126' ' ' LEU . . . -60.88 -49.11 78.8 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-N 115.989 -0.551 . . . . 0.0 110.167 179.155 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . -59.82 -33.83 79.95 Favored Glycine 0 N--CA 1.45 -0.43 0 C-N-CA 120.574 -0.822 . . . . 0.0 111.716 179.271 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 113' ' ' PHE . . . . . 0.407 ' HD2' HD11 ' A' ' 77' ' ' ILE . 0.3 OUTLIER -54.71 -65.04 0.65 Allowed 'General case' 0 C--N 1.332 -0.191 0 CA-C-O 121.052 0.454 . . . . 0.0 110.226 179.326 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 114' ' ' ALA . . . . . 0.495 ' O ' HG13 ' A' ' 118' ' ' VAL . . . -66.43 -30.53 70.91 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 115.609 -0.723 . . . . 0.0 111.575 -179.64 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 115' ' ' GLY . . . . . 0.401 ' O ' HG22 ' A' ' 118' ' ' VAL . . . -52.12 -51.08 43.04 Favored Glycine 0 C--N 1.332 0.358 0 C-N-CA 121.059 -0.591 . . . . 0.0 112.988 -179.644 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 116' ' ' ALA . . . . . 0.497 ' HB2' ' HB3' ' A' ' 183' ' ' PRO . . . -78.09 -15.45 58.87 Favored 'General case' 0 C--N 1.327 -0.405 0 N-CA-C 111.829 0.307 . . . . 0.0 111.829 -179.558 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 117' ' ' MET . . . . . 0.513 ' HG3' HG21 ' A' ' 68' ' ' VAL . 35.5 ttm -106.23 17.0 24.12 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.79 0.328 . . . . 0.0 111.277 -179.425 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 118' ' ' VAL . . . . . 0.532 HG11 ' N ' ' A' ' 123' ' ' ARG . 15.9 m -63.81 148.57 94.46 Favored Pre-proline 0 C--N 1.331 -0.239 0 CA-C-N 116.414 -0.357 . . . . 0.0 111.413 179.847 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 119' ' ' PRO . . . . . . . . . . . . . 88.7 Cg_endo -82.66 -1.64 10.64 Favored 'Trans proline' 0 C--N 1.347 0.461 0 C-N-CA 122.605 2.204 . . . . 0.0 112.273 179.58 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -157.6 -121.18 0.65 Allowed Glycine 0 C--N 1.33 0.246 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.522 -179.994 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 1.9 pp -106.69 12.93 8.43 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.207 0 CA-C-O 120.866 0.365 . . . . 0.0 111.291 -179.932 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 41.9 mt-10 -59.97 -17.49 38.47 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.012 -0.54 . . . . 0.0 111.293 179.929 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 123' ' ' ARG . . . . . 0.532 ' N ' HG11 ' A' ' 118' ' ' VAL . 27.6 ptt180 -50.37 -29.66 10.52 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-N 116.118 -0.492 . . . . 0.0 111.853 -179.757 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 124' ' ' TYR . . . . . . . . . . . . . 28.9 m-85 -67.64 -33.03 74.14 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.771 0.319 . . . . 0.0 111.201 -179.783 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 125' ' ' ALA . . . . . . . . . . . . . . . -72.38 -48.54 40.84 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.254 -0.43 . . . . 0.0 111.426 -179.982 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 126' ' ' LEU . . . . . 0.417 HD13 ' HA ' ' A' ' 126' ' ' LEU . 3.3 mm? -54.6 -55.58 27.9 Favored 'General case' 0 C--N 1.331 -0.206 0 CA-C-N 116.351 -0.386 . . . . 0.0 110.987 -179.673 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 127' ' ' PHE . . . . . 0.438 ' HZ ' ' HB3' ' A' ' 175' ' ' PRO . 6.7 t80 -64.97 -39.2 93.12 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.185 -0.462 . . . . 0.0 111.456 -179.304 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 128' ' ' GLY . . . . . . . . . . . . . . . -46.44 -45.72 16.83 Favored Glycine 0 C--O 1.237 0.322 0 C-N-CA 120.228 -0.987 . . . . 0.0 111.261 179.531 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 129' ' ' MET . . . . . 0.57 ' HE1' ' HA ' ' A' ' 108' ' ' VAL . 0.3 OUTLIER -68.87 -40.18 79.41 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 115.348 -0.426 . . . . 0.0 109.907 178.986 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -68.56 -21.13 74.43 Favored Glycine 0 N--CA 1.449 -0.464 0 CA-C-N 115.701 -0.682 . . . . 0.0 112.486 179.972 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 131' ' ' ALA . . . . . 0.445 ' O ' ' HB3' ' A' ' 134' ' ' PHE . . . -75.5 -54.16 7.47 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-O 120.621 0.248 . . . . 0.0 110.596 179.886 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 46.5 t -62.94 -40.46 89.02 Favored 'Isoleucine or valine' 0 C--O 1.234 0.249 0 N-CA-C 108.839 -0.8 . . . . 0.0 108.839 178.417 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -66.82 -32.04 73.06 Favored 'General case' 0 N--CA 1.452 -0.352 0 CA-C-N 115.124 -0.943 . . . . 0.0 110.184 178.828 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 134' ' ' PHE . . . . . 0.445 ' HB3' ' O ' ' A' ' 131' ' ' ALA . 38.5 t80 -56.78 -55.61 32.14 Favored 'General case' 0 N--CA 1.452 -0.353 0 N-CA-C 109.738 -0.467 . . . . 0.0 109.738 179.402 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 135' ' ' ILE . . . . . 0.53 ' O ' HG22 ' A' ' 138' ' ' VAL . 47.9 mt -56.8 -32.71 39.19 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.407 0 CA-C-N 115.583 -0.735 . . . . 0.0 109.979 179.409 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . -59.92 -37.81 93.17 Favored Glycine 0 N--CA 1.448 -0.522 0 C-N-CA 120.113 -1.041 . . . . 0.0 110.94 178.567 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 137' ' ' LEU . . . . . . . . . . . . . 46.6 tp -71.12 -50.26 35.47 Favored 'General case' 0 N--CA 1.454 -0.247 0 CA-C-N 115.719 -0.241 . . . . 0.0 110.611 179.499 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 138' ' ' VAL . . . . . 0.649 ' HA ' HD12 ' A' ' 141' ' ' LEU . 3.7 m -57.8 -30.62 38.21 Favored 'Isoleucine or valine' 0 CA--C 1.521 -0.164 0 N-CA-C 109.23 -0.656 . . . . 0.0 109.23 179.138 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 139' ' ' TYR . . . . . . . . . . . . . 39.3 t80 -63.52 -39.8 95.37 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 115.246 -0.888 . . . . 0.0 109.173 178.205 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 140' ' ' TYR . . . . . 0.443 ' HE2' HD22 ' A' ' 104' ' ' LEU . 22.3 m-85 -65.28 -31.97 73.38 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 115.733 -0.667 . . . . 0.0 110.256 178.617 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 141' ' ' LEU . . . . . 0.649 HD12 ' HA ' ' A' ' 138' ' ' VAL . 56.8 mt -65.06 -36.71 85.22 Favored 'General case' 0 CA--C 1.519 -0.222 0 CA-C-O 121.35 0.595 . . . . 0.0 109.591 179.973 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 16.6 m -98.0 0.08 10.44 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.822 0 CA-C-N 115.112 -0.949 . . . . 0.0 111.081 -179.866 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . -81.82 -135.35 1.97 Allowed Glycine 0 CA--C 1.521 0.447 0 C-N-CA 121.035 -0.603 . . . . 0.0 113.058 -179.486 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 144' ' ' PRO . . . . . . . . . . . . . 18.3 Cg_endo -58.32 -24.85 70.06 Favored 'Trans proline' 0 C--N 1.349 0.599 0 C-N-CA 122.726 2.284 . . . . 0.0 112.527 -179.664 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 145' ' ' MET . . . . . . . . . . . . . 62.0 mtt -59.96 -25.91 65.59 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 121.14 0.495 . . . . 0.0 110.798 179.788 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 146' ' ' THR . . . . . . . . . . . . . 17.5 m -73.79 -51.2 17.2 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 115.636 -0.711 . . . . 0.0 112.364 -178.802 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 45.7 mt-10 -75.85 -28.76 58.32 Favored 'General case' 0 C--N 1.328 -0.327 0 N-CA-C 111.856 0.317 . . . . 0.0 111.856 -178.845 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 148' ' ' SER . . . . . . . . . . . . . 37.1 t -70.66 -48.09 56.64 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-O 120.746 0.307 . . . . 0.0 111.607 -179.103 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 149' ' ' ALA . . . . . . . . . . . . . . . -74.7 -44.74 48.55 Favored 'General case' 0 C--N 1.329 -0.324 0 N-CA-C 111.994 0.368 . . . . 0.0 111.994 -179.068 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 150' ' ' SER . . . . . . . . . . . . . 87.7 p -63.65 -11.83 28.73 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.647 0.261 . . . . 0.0 111.273 -179.629 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 151' ' ' GLN . . . . . . . . . . . . . 98.2 mt-30 -124.37 21.75 8.62 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.333 -0.394 . . . . 0.0 111.248 -179.702 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 28.9 tpt180 -92.02 -51.43 5.2 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.916 0.389 . . . . 0.0 110.418 179.659 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 153' ' ' SER . . . . . 0.681 ' HB3' HG12 ' A' ' 156' ' ' ILE . 32.4 t -157.43 167.76 29.29 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.09 -0.505 . . . . 0.0 110.71 179.092 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 154' ' ' SER . . . . . . . . . . . . . 44.8 t -67.65 -36.3 80.5 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-O 120.968 0.413 . . . . 0.0 110.608 179.476 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -76.97 -36.84 34.71 Favored Glycine 0 N--CA 1.451 -0.361 0 C-N-CA 120.97 -0.633 . . . . 0.0 112.887 -179.912 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 156' ' ' ILE . . . . . 0.681 HG12 ' HB3' ' A' ' 153' ' ' SER . 39.7 mm -52.83 -36.24 23.1 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.21 0 CA-C-O 120.722 0.296 . . . . 0.0 111.315 -179.922 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 157' ' ' LYS . . . . . . . . . . . . . 85.3 tttt -54.38 -49.14 70.54 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.75 -179.611 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 42.8 t -63.97 -48.43 76.47 Favored 'General case' 0 C--N 1.33 -0.245 0 N-CA-C 111.891 0.33 . . . . 0.0 111.891 -179.189 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 159' ' ' LEU . . . . . 0.526 HD23 ' O ' ' A' ' 159' ' ' LEU . 2.8 tt -67.36 -28.56 68.06 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-O 120.943 0.401 . . . . 0.0 110.673 -179.622 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 160' ' ' TYR . . . . . . . . . . . . . 25.3 t80 -73.57 -47.72 38.38 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.87 -179.245 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 31.0 m -62.46 -42.72 96.8 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.391 0 N-CA-C 112.414 0.524 . . . . 0.0 112.414 -178.565 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 162' ' ' ARG . . . . . 0.449 ' O ' HD12 ' A' ' 166' ' ' LEU . 22.3 mmm180 -68.6 -49.81 56.43 Favored 'General case' 0 C--N 1.328 -0.362 0 N-CA-C 111.746 0.276 . . . . 0.0 111.746 -178.747 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 163' ' ' LEU . . . . . 0.402 HD22 ' CD2' ' A' ' 159' ' ' LEU . 7.6 mp -70.2 -39.15 75.36 Favored 'General case' 0 C--N 1.328 -0.335 0 N-CA-C 112.195 0.443 . . . . 0.0 112.195 -178.722 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 164' ' ' ARG . . . . . 0.46 ' NH1' ' HA ' ' A' ' 141' ' ' LEU . 21.9 tpp180 -58.37 -54.37 47.75 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 120.751 0.31 . . . . 0.0 110.786 -179.783 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 165' ' ' ASN . . . . . 0.43 ' O ' HG23 ' A' ' 169' ' ' VAL . 4.5 m-20 -57.06 -37.82 72.36 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.005 -0.543 . . . . 0.0 110.18 179.812 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 166' ' ' LEU . . . . . 0.449 HD12 ' O ' ' A' ' 162' ' ' ARG . 3.6 mt -61.24 -56.3 22.22 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 115.914 -0.585 . . . . 0.0 111.562 179.877 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 167' ' ' THR . . . . . 0.508 ' HA ' HD11 ' A' ' 170' ' ' LEU . 16.7 m -54.31 -54.42 40.49 Favored 'General case' 0 C--N 1.331 -0.202 0 N-CA-C 112.198 0.444 . . . . 0.0 112.198 -177.981 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 168' ' ' VAL . . . . . 0.568 HG22 HD13 ' A' ' 141' ' ' LEU . 42.1 t -52.64 -41.75 38.66 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.603 0 N-CA-C 112.594 0.59 . . . . 0.0 112.594 -179.3 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 169' ' ' VAL . . . . . 0.517 ' O ' HG12 ' A' ' 173' ' ' ILE . 74.7 t -71.21 -68.08 0.42 Allowed 'Isoleucine or valine' 0 CA--C 1.531 0.245 0 N-CA-C 113.988 1.107 . . . . 0.0 113.988 -177.446 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 170' ' ' LEU . . . . . 0.508 HD11 ' HA ' ' A' ' 167' ' ' THR . 0.3 OUTLIER -57.61 -36.47 71.81 Favored 'General case' 0 N--CA 1.467 0.39 0 N-CA-C 112.835 0.68 . . . . 0.0 112.835 -177.382 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 171' ' ' TRP . . . . . 0.482 ' HB2' ' O ' ' A' ' 167' ' ' THR . 7.9 m0 -70.97 -34.21 71.19 Favored 'General case' 0 C--N 1.329 -0.321 0 C-N-CA 120.477 -0.489 . . . . 0.0 111.356 -179.785 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 172' ' ' ALA . . . . . 0.42 ' HA ' ' CZ ' ' A' ' 134' ' ' PHE . . . -72.4 -7.08 47.84 Favored 'General case' 0 C--N 1.332 -0.182 0 C-N-CA 120.797 -0.361 . . . . 0.0 110.862 179.848 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 173' ' ' ILE . . . . . 0.518 HG22 HD11 ' A' ' 177' ' ' ILE . 50.8 mm -87.59 -25.75 5.98 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.23 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.795 179.607 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 174' ' ' TYR . . . . . 0.42 ' HB2' ' HD3' ' A' ' 175' ' ' PRO . 38.8 m-85 -55.0 -49.02 94.5 Favored Pre-proline 0 CA--C 1.531 0.216 0 CA-C-N 116.253 -0.431 . . . . 0.0 111.684 -179.741 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 175' ' ' PRO . . . . . 0.438 ' HB3' ' HZ ' ' A' ' 127' ' ' PHE . 79.9 Cg_exo -45.8 -30.94 7.2 Favored 'Trans proline' 0 C--N 1.352 0.739 0 C-N-CA 122.169 1.913 . . . . 0.0 111.954 179.422 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 176' ' ' PHE . . . . . 0.481 ' O ' ' HG ' ' A' ' 180' ' ' LEU . 86.3 m-85 -80.08 -49.16 12.14 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 115.81 -0.632 . . . . 0.0 111.388 179.83 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 177' ' ' ILE . . . . . 0.518 HD11 HG22 ' A' ' 173' ' ' ILE . 3.8 mm -60.16 -36.94 71.23 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.551 0 N-CA-C 112.307 0.484 . . . . 0.0 112.307 -178.49 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 178' ' ' TRP . . . . . . . . . . . . . 76.5 t90 -73.35 -44.45 58.74 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.942 0.401 . . . . 0.0 110.619 -179.87 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 179' ' ' LEU . . . . . 0.488 ' O ' HG22 ' A' ' 185' ' ' VAL . 1.4 tm? -67.51 -54.3 21.27 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 115.952 -0.567 . . . . 0.0 111.155 -179.48 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 180' ' ' LEU . . . . . 0.645 HD22 HD11 ' A' ' 187' ' ' LEU . 16.5 mt -68.42 -50.3 53.78 Favored 'General case' 0 C--N 1.328 -0.327 0 N-CA-C 111.992 0.367 . . . . 0.0 111.992 -179.021 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . -54.62 176.35 0.44 Allowed Glycine 0 C--N 1.337 0.602 0 C-N-CA 120.219 -0.991 . . . . 0.0 112.861 -179.948 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 182' ' ' PRO . . . . . 0.492 ' HA ' ' HB2' ' A' ' 186' ' ' ALA . 83.8 Cg_exo -45.3 -44.77 15.88 Favored 'Trans proline' 0 C--N 1.349 0.583 0 C-N-CA 122.92 2.413 . . . . 0.0 113.599 179.692 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 183' ' ' PRO . . . . . 0.497 ' HB3' ' HB2' ' A' ' 116' ' ' ALA . 88.7 Cg_exo -46.38 -23.42 2.08 Favored 'Trans proline' 0 C--N 1.356 0.944 0 C-N-CA 122.277 1.985 . . . . 0.0 113.122 179.815 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 184' ' ' GLY . . . . . . . . . . . . . . . -123.53 -127.07 3.19 Favored Glycine 0 C--N 1.331 0.298 0 C-N-CA 120.554 -0.831 . . . . 0.0 112.797 -179.901 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 185' ' ' VAL . . . . . 0.488 HG22 ' O ' ' A' ' 179' ' ' LEU . 16.5 m -60.05 -19.9 18.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 N-CA-C 111.992 0.368 . . . . 0.0 111.992 -179.541 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 186' ' ' ALA . . . . . 0.492 ' HB2' ' HA ' ' A' ' 182' ' ' PRO . . . 57.51 87.18 0.07 Allowed 'General case' 0 C--N 1.331 -0.2 0 CA-C-O 120.712 0.291 . . . . 0.0 111.4 179.863 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 187' ' ' LEU . . . . . 0.645 HD11 HD22 ' A' ' 180' ' ' LEU . 21.2 mt -91.95 -49.59 6.15 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.299 -0.41 . . . . 0.0 111.079 -179.821 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 188' ' ' LEU . . . . . . . . . . . . . 90.5 mt -103.52 -161.65 0.85 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 115.961 -0.563 . . . . 0.0 110.983 -179.82 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 189' ' ' THR . . . . . . . . . . . . . 1.6 t -92.44 147.04 33.6 Favored Pre-proline 0 C--N 1.329 -0.298 0 CA-C-N 116.079 -0.509 . . . . 0.0 111.061 -179.83 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 190' ' ' PRO . . . . . . . . . . . . . 9.2 Cg_endo -52.58 -33.15 57.16 Favored 'Trans proline' 0 C--N 1.349 0.579 0 C-N-CA 122.772 2.315 . . . . 0.0 112.422 -179.949 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 191' ' ' THR . . . . . . . . . . . . . 80.6 p -62.73 -43.73 98.06 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.34 -0.391 . . . . 0.0 111.033 179.882 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 192' ' ' VAL . . . . . . . . . . . . . 30.3 t -71.51 -46.62 62.55 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 115.94 -0.573 . . . . 0.0 111.118 -179.857 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 193' ' ' ASP . . . . . . . . . . . . . 34.3 t70 -56.78 -51.59 68.35 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.398 -0.365 . . . . 0.0 111.139 -179.749 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 194' ' ' VAL . . . . . . . . . . . . . 76.3 t -61.06 -36.56 73.31 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.391 -0.368 . . . . 0.0 110.988 179.818 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 195' ' ' ALA . . . . . . . . . . . . . . . -56.01 -48.15 76.47 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.493 -0.321 . . . . 0.0 111.168 179.89 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 196' ' ' LEU . . . . . . . . . . . . . 72.1 mt -67.38 -41.39 85.1 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.421 -0.354 . . . . 0.0 110.713 179.83 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 197' ' ' ILE . . . . . . . . . . . . . 17.2 mm -57.13 -56.08 16.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.473 179.407 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 198' ' ' VAL . . . . . . . . . . . . . 71.5 t -52.9 -35.03 21.25 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.417 0 CA-C-N 115.509 -0.769 . . . . 0.0 109.471 178.612 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 199' ' ' TYR . . . . . . . . . . . . . 53.3 t80 -70.54 -36.31 73.62 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 115.333 -0.849 . . . . 0.0 110.594 179.661 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 200' ' ' LEU . . . . . . . . . . . . . 73.0 mt -64.44 -38.74 92.1 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 115.658 -0.701 . . . . 0.0 111.343 -179.63 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 201' ' ' ASP . . . . . 0.451 ' HB2' ' OH ' ' A' ' 51' ' ' TYR . 0.8 OUTLIER -73.6 -32.32 64.04 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-O 121.04 0.447 . . . . 0.0 110.39 179.663 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 202' ' ' LEU . . . . . 0.424 ' O ' ' HB ' ' A' ' 206' ' ' VAL . 3.7 mt -71.64 -32.52 68.02 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 115.831 -0.622 . . . . 0.0 111.92 -179.649 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 203' ' ' VAL . . . . . 0.474 ' O ' ' HA3' ' A' ' 207' ' ' GLY . 7.4 p -78.83 -37.02 19.7 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-O 120.639 0.257 . . . . 0.0 111.375 -178.927 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 204' ' ' THR . . . . . 0.402 HG21 ' HE1' ' A' ' 171' ' ' TRP . 26.2 m -72.87 -49.99 26.56 Favored 'General case' 0 C--N 1.326 -0.448 0 C-N-CA 120.728 -0.389 . . . . 0.0 111.31 179.696 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 205' ' ' LYS . . . . . 0.64 ' HE2' ' HB2' ' A' ' 47' ' ' ALA . 54.5 mttp -69.98 -59.26 3.03 Favored 'General case' 0 C--N 1.326 -0.421 0 N-CA-C 112.165 0.431 . . . . 0.0 112.165 -178.8 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 206' ' ' VAL . . . . . 0.424 ' HB ' ' O ' ' A' ' 202' ' ' LEU . 48.6 t -74.69 -37.61 43.34 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.25 0 N-CA-C 111.964 0.357 . . . . 0.0 111.964 -178.727 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 207' ' ' GLY . . . . . 0.566 ' O ' HD12 ' A' ' 211' ' ' ILE . . . -62.86 -56.63 19.88 Favored Glycine 0 N--CA 1.45 -0.379 0 C-N-CA 120.258 -0.972 . . . . 0.0 112.01 -179.405 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 208' ' ' PHE . . . . . 0.513 ' O ' ' N ' ' A' ' 212' ' ' ALA . 3.1 m-85 -53.95 -47.75 70.98 Favored 'General case' 0 C--O 1.22 -0.469 0 N-CA-C 109.896 -0.409 . . . . 0.0 109.896 179.606 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 209' ' ' GLY . . . . . 0.492 ' O ' ' HG ' ' A' ' 213' ' ' LEU . . . -53.9 -35.21 52.9 Favored Glycine 0 N--CA 1.45 -0.374 0 CA-C-N 115.091 -0.959 . . . . 0.0 113.399 179.585 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 210' ' ' PHE . . . . . . . . . . . . . 5.2 m-85 -72.46 -47.23 50.52 Favored 'General case' 0 CA--C 1.512 -0.498 0 N-CA-C 108.716 -0.846 . . . . 0.0 108.716 179.801 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 211' ' ' ILE . . . . . 0.566 HD12 ' O ' ' A' ' 207' ' ' GLY . 3.6 mt -65.05 -26.93 41.11 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.65 0 N-CA-C 107.665 -1.235 . . . . 0.0 107.665 176.444 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 212' ' ' ALA . . . . . 0.513 ' N ' ' O ' ' A' ' 208' ' ' PHE . . . -68.44 -38.66 81.37 Favored 'General case' 0 N--CA 1.45 -0.466 0 CA-C-N 114.3 -1.318 . . . . 0.0 110.422 -179.869 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 213' ' ' LEU . . . . . 0.492 ' HG ' ' O ' ' A' ' 209' ' ' GLY . 47.2 mt -69.82 -54.31 14.16 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-N 115.301 -0.863 . . . . 0.0 111.636 -179.498 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 214' ' ' ASP . . . . . . . . . . . . . 14.6 m-20 -52.21 -54.66 28.2 Favored 'General case' 0 C--O 1.234 0.26 0 CA-C-N 116.389 -0.369 . . . . 0.0 111.326 -179.514 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 215' ' ' ALA . . . . . . . . . . . . . . . -57.48 -54.87 41.92 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.357 -0.383 . . . . 0.0 111.036 179.984 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 216' ' ' ALA . . . . . . . . . . . . . . . -57.52 -30.73 65.39 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.28 179.925 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 217' ' ' ALA . . . . . . . . . . . . . . . -64.02 -38.34 90.73 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.557 -179.918 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 218' ' ' THR . . . . . . . . . . . . . 69.7 m . . . . . 0 C--N 1.33 -0.26 0 CA-C-N 115.82 -0.627 . . . . 0.0 111.247 179.855 . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.323 0 N-CA-C 112.514 -0.235 . . . . 0.0 112.514 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 55.3 tp -74.02 -36.31 64.45 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.685 0.279 . . . . 0.0 111.21 -179.88 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 82.6 p -66.3 -29.97 70.29 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.432 -0.349 . . . . 0.0 111.409 -179.693 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 22.7 p -54.22 -35.13 62.09 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.269 179.996 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 7' ' ' LEU . . . . . . . . . . . . . 3.9 mm? -57.66 -53.13 61.66 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.111 -0.495 . . . . 0.0 111.172 -179.971 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 8' ' ' PHE . . . . . 0.675 ' HB2' ' HB2' ' A' ' 55' ' ' ALA . 77.8 m-85 -59.07 -35.66 73.75 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.346 -0.388 . . . . 0.0 110.762 179.858 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 9' ' ' TRP . . . . . . . . . . . . . 47.5 m95 -64.67 -45.91 84.67 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.024 -0.534 . . . . 0.0 110.059 -179.824 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 10' ' ' LEU . . . . . 0.444 ' HA ' HD12 ' A' ' 13' ' ' ILE . 87.2 mt -61.08 -37.83 84.11 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-N 115.545 -0.752 . . . . 0.0 110.154 179.333 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -65.82 -35.46 90.9 Favored Glycine 0 N--CA 1.448 -0.53 0 C-N-CA 120.814 -0.708 . . . . 0.0 111.486 179.124 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -67.44 -31.21 71.24 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 120.977 0.418 . . . . 0.0 110.476 179.448 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 13' ' ' ILE . . . . . 0.444 HD12 ' HA ' ' A' ' 10' ' ' LEU . 88.5 mt -64.68 -54.22 32.78 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.235 0 CA-C-N 115.864 -0.607 . . . . 0.0 110.214 179.418 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -65.99 -32.45 82.6 Favored Glycine 0 N--CA 1.45 -0.377 0 C-N-CA 120.61 -0.805 . . . . 0.0 111.637 179.109 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 15' ' ' MET . . . . . 0.495 ' SD ' ' HA ' ' A' ' 44' ' ' SER . 51.3 tpp -65.83 -40.16 91.53 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-O 120.823 0.344 . . . . 0.0 110.448 179.657 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 1.6 mm? -64.02 -37.98 89.4 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-N 116.08 -0.509 . . . . 0.0 110.207 179.173 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 17' ' ' VAL . . . . . 0.442 HG23 ' O ' ' A' ' 13' ' ' ILE . 72.0 t -59.04 -42.63 86.91 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.205 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.158 179.07 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -68.8 -46.2 61.63 Favored Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.731 -0.747 . . . . 0.0 111.679 178.965 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 47.9 m -50.25 -46.66 55.08 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 120.865 0.364 . . . . 0.0 111.081 179.896 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 93.6 mt -72.19 -45.75 59.08 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.035 -0.529 . . . . 0.0 111.639 179.939 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -58.85 -30.85 68.0 Favored 'General case' 0 C--N 1.329 -0.296 0 N-CA-C 112.081 0.4 . . . . 0.0 112.081 -179.23 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 22' ' ' PHE . . . . . 0.413 ' HB2' HG22 ' A' ' 41' ' ' VAL . 13.0 m-85 -90.79 -31.36 16.54 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 120.666 0.27 . . . . 0.0 111.509 -179.252 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -71.63 -50.28 32.22 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 121.101 0.477 . . . . 0.0 111.173 -179.811 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 24' ' ' TRP . . . . . . . . . . . . . 3.1 t-105 -61.43 -43.82 98.19 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-N 115.614 -0.721 . . . . 0.0 111.329 -179.624 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.328 -0.338 0 CA-C-O 120.698 0.285 . . . . 0.0 111.057 -179.989 . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.25 0 N-CA-C 112.153 -0.379 . . . . 0.0 112.153 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 10.0 mm-40 -90.59 -20.68 22.32 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 120.752 0.311 . . . . 0.0 110.83 179.838 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 34' ' ' ARG . . . . . . . . . . . . . 54.3 mtp180 -48.43 -29.49 4.12 Favored 'General case' 0 C--N 1.333 -0.151 0 CA-C-N 115.997 -0.547 . . . . 0.0 111.547 -179.819 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 75.2 mtp180 -60.85 -48.38 82.07 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.44 -0.346 . . . . 0.0 111.023 -179.899 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 62.9 m-85 -68.66 -31.66 70.94 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.021 -0.536 . . . . 0.0 111.362 -179.678 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 37' ' ' TYR . . . . . . . . . . . . . 53.6 m-85 -69.4 -54.49 14.13 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.301 -0.409 . . . . 0.0 111.279 -179.498 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 85.3 t -57.08 -36.7 52.04 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.249 0 CA-C-O 121.011 0.434 . . . . 0.0 110.525 179.729 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 30.3 m -64.38 -49.43 71.65 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 115.789 -0.641 . . . . 0.0 110.502 179.354 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 30.5 tp -55.99 -47.73 77.17 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.718 -0.674 . . . . 0.0 110.286 179.614 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 41' ' ' VAL . . . . . 0.413 HG22 ' HB2' ' A' ' 22' ' ' PHE . 62.3 t -62.24 -34.32 63.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 115.733 -0.667 . . . . 0.0 110.016 178.95 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -57.85 -38.77 89.96 Favored Glycine 0 N--CA 1.448 -0.501 0 C-N-CA 120.859 -0.686 . . . . 0.0 112.035 179.684 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 43' ' ' ILE . . . . . 0.678 HG22 ' HE3' ' A' ' 205' ' ' LYS . 0.2 OUTLIER -68.44 -53.42 28.26 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.186 0 CA-C-O 120.825 0.345 . . . . 0.0 110.698 179.583 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 44' ' ' SER . . . . . 0.495 ' HA ' ' SD ' ' A' ' 15' ' ' MET . 45.8 m -59.11 -24.47 63.0 Favored 'General case' 0 C--N 1.333 -0.146 0 CA-C-N 116.136 -0.484 . . . . 0.0 111.466 -179.777 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -75.89 -57.16 4.19 Favored Glycine 0 CA--C 1.518 0.281 0 C-N-CA 120.766 -0.731 . . . . 0.0 113.106 -179.333 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 17.0 pt -58.17 -35.71 54.19 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-O 120.818 0.342 . . . . 0.0 111.262 -179.602 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 47' ' ' ALA . . . . . 0.694 ' HB2' ' HE2' ' A' ' 205' ' ' LYS . . . -67.73 -44.39 77.71 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-O 120.966 0.412 . . . . 0.0 110.943 179.158 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -54.38 -44.46 72.29 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 115.791 -0.641 . . . . 0.0 111.723 -179.385 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 34.2 m -71.54 -34.04 51.48 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.228 0 CA-C-N 116.532 -0.304 . . . . 0.0 111.415 -179.63 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -64.34 -37.33 87.13 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 121.046 0.45 . . . . 0.0 110.874 179.695 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 51' ' ' TYR . . . . . 0.43 ' OH ' ' HB2' ' A' ' 201' ' ' ASP . 33.2 m-85 -73.36 -36.19 66.07 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 115.946 -0.57 . . . . 0.0 110.62 179.979 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -65.99 -38.97 89.88 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 115.826 -0.625 . . . . 0.0 111.025 179.796 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 53' ' ' VAL . . . . . 0.509 ' O ' HG12 ' A' ' 58' ' ' VAL . 33.6 m -74.81 -50.35 25.9 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.194 0 CA-C-N 116.588 -0.278 . . . . 0.0 111.05 -179.887 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 54' ' ' MET . . . . . 0.504 ' N ' HG23 ' A' ' 53' ' ' VAL . 75.8 mtm -58.02 -29.69 65.51 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-O 121.009 0.433 . . . . 0.0 110.309 179.514 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 55' ' ' ALA . . . . . 0.675 ' HB2' ' HB2' ' A' ' 8' ' ' PHE . . . -73.85 -25.92 60.31 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 115.786 -0.643 . . . . 0.0 111.278 179.732 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 74.6 mt -80.28 -8.37 59.44 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.276 -0.42 . . . . 0.0 111.622 -179.625 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 102.31 -17.48 53.63 Favored Glycine 0 N--CA 1.453 -0.226 0 C-N-CA 120.438 -0.887 . . . . 0.0 113.054 179.671 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 58' ' ' VAL . . . . . 0.509 HG12 ' O ' ' A' ' 53' ' ' VAL . 12.7 p -69.43 150.86 10.21 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.957 0.379 . . . . 0.0 110.439 179.717 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 75.55 27.24 63.67 Favored Glycine 0 N--CA 1.449 -0.472 0 C-N-CA 120.723 -0.751 . . . . 0.0 111.731 -178.946 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 60' ' ' TRP . . . . . . . . . . . . . 13.8 m0 -108.7 99.15 8.55 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-O 120.947 0.403 . . . . 0.0 110.285 -179.879 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 61' ' ' VAL . . . . . 0.575 ' HB ' HG23 ' A' ' 68' ' ' VAL . 25.6 t -97.77 110.69 56.45 Favored Pre-proline 0 C--N 1.325 -0.459 0 CA-C-N 115.877 -0.601 . . . . 0.0 111.526 -179.299 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 17.2 Cg_exo -67.2 138.87 48.49 Favored 'Trans proline' 0 C--N 1.35 0.606 0 C-N-CA 122.577 2.184 . . . . 0.0 111.866 179.678 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 93.1 t -139.96 92.17 0.65 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.38 -179.694 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . 56.65 -91.7 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.117 -0.492 . . . . 0.0 111.85 179.656 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 42.9 mt-10 -115.23 -17.61 11.31 Favored 'General case' 0 C--N 1.332 -0.195 0 CA-C-O 120.837 0.351 . . . . 0.0 111.054 -179.652 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 66' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -104.81 165.56 10.99 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.285 179.77 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 91.0 m -130.09 118.81 22.08 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-N 116.295 -0.411 . . . . 0.0 111.414 -179.573 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 68' ' ' VAL . . . . . 0.575 HG23 ' HB ' ' A' ' 61' ' ' VAL . 18.5 m -100.37 141.51 17.18 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.377 0 CA-C-N 115.991 -0.55 . . . . 0.0 110.53 179.495 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 69' ' ' PHE . . . . . . . . . . . . . 24.2 m-85 -109.84 122.75 48.24 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.276 -0.42 . . . . 0.0 110.248 -179.428 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 70' ' ' VAL . . . . . 0.621 HG12 ' HD3' ' A' ' 71' ' ' PRO . 1.3 p -68.13 -35.97 8.33 Favored Pre-proline 0 CA--C 1.54 0.573 0 N-CA-C 112.549 0.574 . . . . 0.0 112.549 -179.541 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 71' ' ' PRO . . . . . 0.621 ' HD3' HG12 ' A' ' 70' ' ' VAL . 5.7 Cg_exo -71.48 -19.87 28.0 Favored 'Trans proline' 0 C--N 1.359 1.122 0 C-N-CA 121.942 1.762 . . . . 0.0 112.47 -179.729 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 56.5 ttt180 -68.68 -55.28 11.95 Favored 'General case' 0 C--O 1.236 0.378 0 CA-C-N 116.403 -0.362 . . . . 0.0 111.67 -179.181 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 73' ' ' TYR . . . . . 0.436 ' O ' HG13 ' A' ' 77' ' ' ILE . 28.2 m-85 -72.17 -30.16 64.71 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.492 -0.322 . . . . 0.0 110.655 -179.418 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 74' ' ' ILE . . . . . 0.524 HG22 ' HA ' ' A' ' 71' ' ' PRO . 0.4 OUTLIER -72.52 -38.29 59.31 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.237 0 N-CA-C 109.829 -0.434 . . . . 0.0 109.829 179.253 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 75' ' ' ASP . . . . . 0.454 ' O ' HG23 ' A' ' 79' ' ' THR . 12.9 t70 -59.11 -38.69 80.15 Favored 'General case' 0 CA--C 1.518 -0.257 0 N-CA-C 109.322 -0.621 . . . . 0.0 109.322 178.861 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 76' ' ' TRP . . . . . . . . . . . . . 45.6 m0 -65.73 -37.74 87.23 Favored 'General case' 0 C--N 1.331 -0.21 0 CA-C-N 115.702 -0.681 . . . . 0.0 110.358 179.166 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 77' ' ' ILE . . . . . 0.51 ' O ' ' HG2' ' A' ' 81' ' ' PRO . 89.5 mt -62.4 -30.67 49.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.468 178.973 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 41.7 mt -92.06 -19.81 21.96 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.07 -0.514 . . . . 0.0 112.222 -179.717 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 79' ' ' THR . . . . . 0.454 HG23 ' O ' ' A' ' 75' ' ' ASP . 73.6 p -101.28 -52.99 3.12 Favored 'General case' 0 N--CA 1.463 0.205 0 N-CA-C 113.446 0.906 . . . . 0.0 113.446 -178.033 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 80' ' ' THR . . . . . 0.849 HG22 HD21 ' A' ' 105' ' ' ASN . 59.8 m -48.74 -53.97 31.75 Favored Pre-proline 0 C--N 1.331 -0.219 0 N-CA-C 112.406 0.521 . . . . 0.0 112.406 -178.838 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 81' ' ' PRO . . . . . 0.661 ' HD3' ' HB ' ' A' ' 80' ' ' THR . 31.5 Cg_exo -59.87 -23.4 72.29 Favored 'Trans proline' 0 C--N 1.353 0.805 0 C-N-CA 121.718 1.612 . . . . 0.0 111.772 179.965 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 82' ' ' LEU . . . . . . . . . . . . . 18.4 tp -76.93 -33.11 57.74 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.043 -0.526 . . . . 0.0 110.469 179.68 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 83' ' ' ILE . . . . . 0.449 HD11 HG21 ' A' ' 43' ' ' ILE . 35.0 mm -68.26 -53.71 26.96 Favored 'Isoleucine or valine' 0 C--O 1.234 0.244 0 CA-C-N 116.367 -0.379 . . . . 0.0 110.036 179.246 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 84' ' ' VAL . . . . . 0.553 HG11 HD22 ' A' ' 105' ' ' ASN . 20.7 m -59.98 -30.98 46.65 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.23 0 N-CA-C 109.415 -0.587 . . . . 0.0 109.415 178.506 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 85' ' ' TYR . . . . . . . . . . . . . 80.8 t80 -66.38 -31.49 72.3 Favored 'General case' 0 N--CA 1.454 -0.242 0 CA-C-N 115.382 -0.827 . . . . 0.0 109.637 178.764 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 86' ' ' PHE . . . . . . . . . . . . . 14.6 t80 -64.33 -51.34 63.88 Favored 'General case' 0 C--O 1.232 0.169 0 CA-C-N 115.819 -0.628 . . . . 0.0 109.865 179.385 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 7.4 mp -60.8 -36.04 78.03 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 115.729 -0.668 . . . . 0.0 110.253 179.445 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -67.24 -27.67 73.54 Favored Glycine 0 N--CA 1.45 -0.395 0 C-N-CA 120.904 -0.665 . . . . 0.0 112.082 179.657 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 40.5 mt -71.66 -42.55 67.37 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-O 121.027 0.441 . . . . 0.0 110.421 179.801 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 90' ' ' LEU . . . . . 0.417 ' HB3' HG23 ' A' ' 156' ' ' ILE . 81.0 mt -56.13 -42.43 76.89 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 115.688 -0.687 . . . . 0.0 111.198 -179.971 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 91' ' ' ALA . . . . . 0.597 ' HB2' ' HB2' ' A' ' 149' ' ' ALA . . . -79.3 -45.99 18.59 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.311 -0.404 . . . . 0.0 111.393 -179.597 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 97.73 50.66 1.63 Allowed Glycine 0 N--CA 1.45 -0.373 0 C-N-CA 120.712 -0.756 . . . . 0.0 112.229 -179.583 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 93' ' ' LEU . . . . . 0.527 HD23 ' HB3' ' A' ' 97' ' ' GLU . 10.8 mp -61.61 171.55 1.5 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.958 0.409 . . . . 0.0 111.24 -179.891 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 94' ' ' ASP . . . . . . . . . . . . . 24.2 t70 -90.46 167.61 12.47 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 115.963 -0.562 . . . . 0.0 110.462 179.722 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 47.3 t -55.04 -35.42 64.46 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.355 -0.384 . . . . 0.0 111.107 179.983 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 5.3 mmp_? -73.83 -50.49 20.18 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.09 -0.504 . . . . 0.0 111.33 -179.858 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 97' ' ' GLU . . . . . 0.527 ' HB3' HD23 ' A' ' 93' ' ' LEU . 46.6 mt-10 -52.37 -45.2 65.66 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.34 -0.391 . . . . 0.0 111.291 -179.606 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 98' ' ' PHE . . . . . 0.416 ' O ' HG12 ' A' ' 102' ' ' ILE . 28.2 m-85 -59.55 -46.69 88.16 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.488 -0.324 . . . . 0.0 110.864 179.824 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -57.67 -28.58 60.21 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.524 -0.846 . . . . 0.0 112.466 179.848 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 79.6 mt -73.83 -48.7 38.26 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.181 0 N-CA-C 112.125 0.417 . . . . 0.0 112.125 -179.563 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 29.4 m -67.98 -41.75 84.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 N-CA-C 112.049 0.388 . . . . 0.0 112.049 -179.001 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 102' ' ' ILE . . . . . 0.482 HG23 ' HB3' ' A' ' 81' ' ' PRO . 50.9 mm -63.88 -49.35 82.22 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.675 -0.239 . . . . 0.0 111.505 -179.463 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 15.3 t -59.72 -34.75 73.33 Favored 'General case' 0 C--O 1.233 0.208 0 CA-C-O 120.951 0.405 . . . . 0.0 110.643 179.873 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 1.3 tm? -56.29 -54.08 49.67 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.008 -0.542 . . . . 0.0 109.698 179.05 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 105' ' ' ASN . . . . . 0.849 HD21 HG22 ' A' ' 80' ' ' THR . 2.8 m-20 -58.23 -34.03 69.99 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 115.591 -0.731 . . . . 0.0 110.83 179.605 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 85.4 m -56.54 -43.79 80.24 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.295 -0.411 . . . . 0.0 110.734 179.803 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 1.5 t -66.81 -42.18 88.87 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-O 121.2 0.524 . . . . 0.0 110.348 179.383 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 93.5 t -57.99 -51.17 73.99 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.386 0 CA-C-N 115.318 -0.856 . . . . 0.0 111.679 -179.722 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 109' ' ' MET . . . . . 0.61 ' HE1' HG21 ' A' ' 80' ' ' THR . 1.5 mpp? -65.22 -37.52 87.53 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.37 -179.588 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 32.4 tp -66.71 -31.5 72.2 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 116.39 -0.368 . . . . 0.0 110.58 -179.893 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -65.42 -52.56 52.5 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.394 179.487 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . -66.26 -31.43 79.07 Favored Glycine 0 N--CA 1.449 -0.434 0 C-N-CA 120.749 -0.738 . . . . 0.0 111.883 179.37 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 113' ' ' PHE . . . . . . . . . . . . . 0.4 OUTLIER -57.14 -70.69 0.12 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 121.032 0.444 . . . . 0.0 110.061 179.567 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 114' ' ' ALA . . . . . 0.505 ' HB3' HD22 ' A' ' 126' ' ' LEU . . . -64.09 -18.55 64.49 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 115.72 -0.673 . . . . 0.0 110.758 179.577 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -57.77 -53.62 43.79 Favored Glycine 0 C--N 1.332 0.314 0 C-N-CA 120.943 -0.646 . . . . 0.0 112.263 179.802 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 116' ' ' ALA . . . . . 0.547 ' HB2' ' HB3' ' A' ' 183' ' ' PRO . . . -77.48 -14.98 59.56 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.784 0.326 . . . . 0.0 111.271 179.927 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 117' ' ' MET . . . . . 0.479 ' SD ' HG21 ' A' ' 68' ' ' VAL . 17.9 mmt -86.33 13.71 7.71 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.129 -0.487 . . . . 0.0 111.589 -179.504 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 20.4 m -87.22 143.03 33.99 Favored Pre-proline 0 C--N 1.33 -0.255 0 CA-C-O 120.563 0.221 . . . . 0.0 111.371 -179.916 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 119' ' ' PRO . . . . . . . . . . . . . 68.2 Cg_endo -92.56 -2.66 3.76 Favored 'Trans proline' 0 N--CA 1.455 -0.776 0 C-N-CA 122.945 2.43 . . . . 0.0 112.267 179.441 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -132.81 -117.66 1.86 Allowed Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.779 -0.724 . . . . 0.0 112.805 -179.668 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 39.6 pt -123.26 12.97 5.31 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.234 0 CA-C-O 120.654 0.264 . . . . 0.0 111.547 -179.514 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 37.7 mt-10 -61.23 -18.65 59.4 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.375 -0.375 . . . . 0.0 110.822 179.912 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 123' ' ' ARG . . . . . 0.471 ' HB2' ' HH2' ' A' ' 178' ' ' TRP . 23.0 ptt180 -51.93 -33.79 38.92 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 115.927 -0.579 . . . . 0.0 111.615 -179.84 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 124' ' ' TYR . . . . . . . . . . . . . 59.0 m-85 -67.49 -33.3 74.81 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.459 -0.337 . . . . 0.0 111.397 -179.622 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 125' ' ' ALA . . . . . . . . . . . . . . . -72.71 -56.46 5.25 Favored 'General case' 0 C--O 1.237 0.411 0 CA-C-O 121.105 0.479 . . . . 0.0 111.073 179.835 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 126' ' ' LEU . . . . . 0.505 HD22 ' HB3' ' A' ' 114' ' ' ALA . 1.3 mt -55.24 -48.1 74.44 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 115.729 -0.669 . . . . 0.0 110.395 179.847 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 127' ' ' PHE . . . . . 0.418 ' HZ ' ' HB3' ' A' ' 175' ' ' PRO . 9.2 t80 -67.76 -30.76 70.3 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.11 -0.496 . . . . 0.0 110.334 179.316 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 128' ' ' GLY . . . . . . . . . . . . . . . -49.12 -50.58 27.76 Favored Glycine 0 N--CA 1.449 -0.441 0 C-N-CA 120.125 -1.036 . . . . 0.0 110.553 178.734 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 129' ' ' MET . . . . . 0.541 ' HE3' ' HA2' ' A' ' 130' ' ' GLY . 0.0 OUTLIER -70.84 -28.24 64.45 Favored 'General case' 0 N--CA 1.453 -0.293 0 N-CA-C 109.02 -0.733 . . . . 0.0 109.02 178.283 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 130' ' ' GLY . . . . . 0.541 ' HA2' ' HE3' ' A' ' 129' ' ' MET . . . -60.09 -41.63 98.14 Favored Glycine 0 C--N 1.335 0.48 0 CA-C-N 115.772 -0.649 . . . . 0.0 112.441 179.364 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -71.04 -49.43 44.99 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-O 120.66 0.267 . . . . 0.0 110.503 179.733 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 57.7 t -57.4 -43.72 83.07 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.217 0 CA-C-O 121.139 0.495 . . . . 0.0 109.81 179.068 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -65.86 -33.01 74.87 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 115.538 -0.756 . . . . 0.0 110.603 179.193 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 134' ' ' PHE . . . . . 0.409 ' HE1' ' HB3' ' A' ' 171' ' ' TRP . 71.6 t80 -59.02 -54.62 45.11 Favored 'General case' 0 N--CA 1.451 -0.385 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.038 179.58 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 135' ' ' ILE . . . . . 0.508 ' O ' HG22 ' A' ' 138' ' ' VAL . 38.2 mt -57.19 -30.38 34.74 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.312 0 CA-C-N 115.805 -0.634 . . . . 0.0 109.916 178.98 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . -62.88 -37.37 94.79 Favored Glycine 0 N--CA 1.447 -0.601 0 C-N-CA 120.31 -0.948 . . . . 0.0 111.301 178.877 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 137' ' ' LEU . . . . . 0.466 HD21 ' HZ3' ' A' ' 171' ' ' TRP . 21.4 tp -71.45 -51.77 22.05 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 120.582 0.23 . . . . 0.0 110.8 179.536 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 138' ' ' VAL . . . . . 0.508 HG22 ' O ' ' A' ' 135' ' ' ILE . 3.9 m -56.15 -31.9 32.92 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.213 0 CA-C-O 121.299 0.571 . . . . 0.0 109.479 179.377 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 139' ' ' TYR . . . . . . . . . . . . . 35.3 t80 -63.99 -44.67 91.96 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 115.29 -0.868 . . . . 0.0 110.136 178.882 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 140' ' ' TYR . . . . . 0.47 ' HB3' ' SD ' ' A' ' 145' ' ' MET . 23.6 m-85 -54.65 -47.01 74.04 Favored 'General case' 0 C--N 1.332 -0.167 0 CA-C-N 115.974 -0.557 . . . . 0.0 111.006 179.622 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 141' ' ' LEU . . . . . . . . . . . . . 93.2 mt -59.04 -40.81 86.23 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.252 -0.431 . . . . 0.0 111.064 -179.885 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 37.8 t -79.73 -12.46 13.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-O 121.063 0.459 . . . . 0.0 110.823 179.902 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . -70.88 -140.64 0.2 Allowed Glycine 0 CA--C 1.522 0.471 0 C-N-CA 120.989 -0.624 . . . . 0.0 112.715 -179.913 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 144' ' ' PRO . . . . . . . . . . . . . 56.6 Cg_endo -70.1 -22.77 30.07 Favored 'Trans proline' 0 C--N 1.349 0.575 0 C-N-CA 122.767 2.312 . . . . 0.0 112.894 -179.93 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 145' ' ' MET . . . . . 0.47 ' SD ' ' HB3' ' A' ' 140' ' ' TYR . 81.0 mtp -52.5 -53.48 45.4 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.281 -0.418 . . . . 0.0 111.794 -179.223 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 146' ' ' THR . . . . . . . . . . . . . 10.2 t -62.45 -32.83 73.75 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.726 0.298 . . . . 0.0 111.586 -179.53 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 45.0 mt-10 -71.35 -32.64 68.78 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.309 -0.405 . . . . 0.0 111.087 -179.837 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 148' ' ' SER . . . . . . . . . . . . . 59.6 m -70.23 -36.6 74.62 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.114 -0.494 . . . . 0.0 111.21 -179.788 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 149' ' ' ALA . . . . . 0.597 ' HB2' ' HB2' ' A' ' 91' ' ' ALA . . . -75.47 -39.46 58.64 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.265 -0.425 . . . . 0.0 111.69 -179.585 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 150' ' ' SER . . . . . . . . . . . . . 69.8 m -66.19 -4.39 7.54 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.39 -0.368 . . . . 0.0 111.217 -179.792 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 151' ' ' GLN . . . . . . . . . . . . . 47.8 mt-30 -124.59 14.53 8.77 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.389 -0.369 . . . . 0.0 111.303 -179.907 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 31.9 tpt180 -91.74 -51.55 5.18 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 120.972 0.415 . . . . 0.0 110.653 179.786 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 153' ' ' SER . . . . . 0.598 ' HB2' HG12 ' A' ' 156' ' ' ILE . 45.4 m -157.54 172.63 18.2 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 115.87 -0.604 . . . . 0.0 110.576 179.466 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 154' ' ' SER . . . . . . . . . . . . . 47.9 t -67.53 -41.84 83.69 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.393 -0.367 . . . . 0.0 110.769 179.841 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -76.69 -35.89 39.19 Favored Glycine 0 C--N 1.332 0.312 0 C-N-CA 120.85 -0.691 . . . . 0.0 112.804 -179.946 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 156' ' ' ILE . . . . . 0.598 HG12 ' HB2' ' A' ' 153' ' ' SER . 39.9 mm -56.23 -39.37 59.23 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.224 0 CA-C-O 120.729 0.299 . . . . 0.0 111.46 -179.729 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 157' ' ' LYS . . . . . 0.409 ' O ' HG13 ' A' ' 161' ' ' VAL . 62.3 tttp -61.92 -51.08 69.6 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.296 -0.411 . . . . 0.0 111.329 -179.758 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 51.4 m -64.87 -35.41 81.04 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.37 -0.377 . . . . 0.0 111.499 -179.154 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 159' ' ' LEU . . . . . 0.554 HD21 ' HB3' ' A' ' 215' ' ' ALA . 10.8 mt -68.84 -59.28 3.19 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-N 116.312 -0.403 . . . . 0.0 111.655 -179.507 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 160' ' ' TYR . . . . . . . . . . . . . 19.4 t80 -52.45 -44.97 65.82 Favored 'General case' 0 C--N 1.327 -0.374 0 N-CA-C 112.228 0.455 . . . . 0.0 112.228 -178.947 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 161' ' ' VAL . . . . . 0.475 HG23 ' N ' ' A' ' 162' ' ' ARG . 36.0 m -63.65 -45.8 96.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 N-CA-C 112.504 0.557 . . . . 0.0 112.504 -178.289 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 162' ' ' ARG . . . . . 0.595 ' O ' HD12 ' A' ' 166' ' ' LEU . 99.4 mtt180 -63.65 -49.72 72.1 Favored 'General case' 0 C--N 1.327 -0.377 0 N-CA-C 111.78 0.289 . . . . 0.0 111.78 -179.009 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 163' ' ' LEU . . . . . 0.488 ' HG ' ' O ' ' A' ' 159' ' ' LEU . 11.0 mt -67.7 -39.86 84.35 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.39 -0.368 . . . . 0.0 111.345 -178.873 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 164' ' ' ARG . . . . . . . . . . . . . 4.1 tmm_? -59.11 -47.78 84.0 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.446 -0.343 . . . . 0.0 110.756 -179.847 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 165' ' ' ASN . . . . . . . . . . . . . 5.4 m-20 -56.02 -48.74 75.39 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.303 -0.408 . . . . 0.0 110.297 179.708 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 166' ' ' LEU . . . . . 0.595 HD12 ' O ' ' A' ' 162' ' ' ARG . 1.4 mt -57.89 -45.82 85.85 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.016 -0.538 . . . . 0.0 110.763 179.364 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 167' ' ' THR . . . . . 0.656 ' HA ' HD11 ' A' ' 170' ' ' LEU . 13.9 m -54.4 -51.42 64.91 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-N 115.936 -0.574 . . . . 0.0 112.051 -178.767 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 168' ' ' VAL . . . . . . . . . . . . . 49.3 t -57.76 -40.02 73.62 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.449 0 N-CA-C 111.903 0.334 . . . . 0.0 111.903 -179.386 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 169' ' ' VAL . . . . . 0.43 ' O ' HG12 ' A' ' 173' ' ' ILE . 93.0 t -66.74 -67.69 0.39 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 N-CA-C 113.622 0.971 . . . . 0.0 113.622 -177.947 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 170' ' ' LEU . . . . . 0.656 HD11 ' HA ' ' A' ' 167' ' ' THR . 0.4 OUTLIER -61.14 -34.06 74.39 Favored 'General case' 0 N--CA 1.463 0.222 0 N-CA-C 112.899 0.703 . . . . 0.0 112.899 -177.475 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 171' ' ' TRP . . . . . 0.582 ' H ' HD12 ' A' ' 170' ' ' LEU . 26.9 m0 -72.59 -30.64 64.55 Favored 'General case' 0 C--N 1.327 -0.401 0 C-N-CA 120.612 -0.435 . . . . 0.0 111.514 -179.283 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 172' ' ' ALA . . . . . . . . . . . . . . . -73.04 -7.86 53.15 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-O 121.036 0.446 . . . . 0.0 110.474 179.916 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 173' ' ' ILE . . . . . 0.498 ' O ' HG12 ' A' ' 177' ' ' ILE . 37.3 mm -88.7 -26.05 5.66 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.222 0 CA-C-N 115.808 -0.633 . . . . 0.0 110.784 179.564 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 174' ' ' TYR . . . . . 0.448 ' HD1' ' HA ' ' A' ' 171' ' ' TRP . 24.1 m-85 -54.28 -49.02 92.75 Favored Pre-proline 0 N--CA 1.462 0.17 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.933 -179.197 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 175' ' ' PRO . . . . . 0.418 ' HB3' ' HZ ' ' A' ' 127' ' ' PHE . 82.8 Cg_exo -45.85 -32.74 9.63 Favored 'Trans proline' 0 C--N 1.351 0.675 0 C-N-CA 121.898 1.732 . . . . 0.0 111.798 179.555 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 176' ' ' PHE . . . . . 0.476 ' O ' ' HG ' ' A' ' 180' ' ' LEU . 60.1 m-85 -80.98 -50.77 9.29 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 115.692 -0.686 . . . . 0.0 111.717 -179.995 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 177' ' ' ILE . . . . . 0.498 HG12 ' O ' ' A' ' 173' ' ' ILE . 10.8 mm -58.69 -38.33 71.01 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.567 0 CA-C-N 116.015 -0.539 . . . . 0.0 111.897 -178.283 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 178' ' ' TRP . . . . . 0.471 ' HH2' ' HB2' ' A' ' 123' ' ' ARG . 83.4 t90 -65.88 -56.26 12.74 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-O 120.875 0.369 . . . . 0.0 110.894 -179.951 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 179' ' ' LEU . . . . . 0.688 ' HG ' HG22 ' A' ' 185' ' ' VAL . 34.0 tp -64.1 -55.24 23.42 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 115.971 -0.559 . . . . 0.0 112.066 -178.689 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 180' ' ' LEU . . . . . 0.698 HD22 HD11 ' A' ' 187' ' ' LEU . 10.1 mt -62.69 -28.65 70.09 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.661 -0.245 . . . . 0.0 111.283 -179.171 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . -72.18 -171.61 17.0 Favored Glycine 0 N--CA 1.45 -0.419 0 C-N-CA 119.929 -1.129 . . . . 0.0 111.922 179.157 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 182' ' ' PRO . . . . . 0.44 ' N ' ' HD2' ' A' ' 183' ' ' PRO . 71.4 Cg_exo -49.84 -43.63 40.08 Favored 'Trans proline' 0 CA--C 1.538 0.708 0 C-N-CA 122.759 2.306 . . . . 0.0 113.756 179.609 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 183' ' ' PRO . . . . . 0.547 ' HB3' ' HB2' ' A' ' 116' ' ' ALA . 60.7 Cg_exo -39.37 -55.74 1.46 Allowed 'Trans proline' 0 C--N 1.358 1.036 0 C-N-CA 122.73 2.287 . . . . 0.0 113.904 -179.414 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 184' ' ' GLY . . . . . . . . . . . . . . . -115.79 -111.91 2.78 Favored Glycine 0 N--CA 1.45 -0.387 0 C-N-CA 120.203 -0.999 . . . . 0.0 112.672 -179.551 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 185' ' ' VAL . . . . . 0.688 HG22 ' HG ' ' A' ' 179' ' ' LEU . 35.8 m -76.39 84.74 0.74 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.466 0 CA-C-O 121.467 0.651 . . . . 0.0 110.693 -179.74 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 186' ' ' ALA . . . . . . . . . . . . . . . -62.9 84.07 0.02 OUTLIER 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 115.73 -0.668 . . . . 0.0 111.361 179.999 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 187' ' ' LEU . . . . . 0.698 HD11 HD22 ' A' ' 180' ' ' LEU . 5.0 mt -77.27 -48.99 16.01 Favored 'General case' 0 C--N 1.332 -0.181 0 CA-C-O 120.964 0.411 . . . . 0.0 110.64 179.73 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 188' ' ' LEU . . . . . . . . . . . . . 83.1 mt -92.41 -162.13 0.9 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 115.811 -0.631 . . . . 0.0 111.378 -179.421 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 189' ' ' THR . . . . . . . . . . . . . 88.4 m -94.58 136.57 23.05 Favored Pre-proline 0 C--N 1.328 -0.349 0 CA-C-N 115.708 -0.678 . . . . 0.0 110.729 -179.974 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 190' ' ' PRO . . . . . 0.402 ' O ' HG23 ' A' ' 194' ' ' VAL . 80.0 Cg_exo -45.33 -43.68 16.84 Favored 'Trans proline' 0 C--N 1.35 0.609 0 C-N-CA 122.561 2.174 . . . . 0.0 112.63 179.743 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 191' ' ' THR . . . . . . . . . . . . . 82.6 p -58.72 -46.39 87.46 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.329 -0.396 . . . . 0.0 111.042 179.922 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 192' ' ' VAL . . . . . . . . . . . . . 87.6 t -63.14 -47.37 92.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.117 -0.492 . . . . 0.0 111.195 -179.983 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 193' ' ' ASP . . . . . . . . . . . . . 22.3 t70 -54.83 -48.12 73.24 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.055 -0.521 . . . . 0.0 111.311 -179.705 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 194' ' ' VAL . . . . . 0.417 ' O ' HG23 ' A' ' 198' ' ' VAL . 99.7 t -64.35 -36.12 76.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.281 -0.418 . . . . 0.0 110.887 -179.848 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 195' ' ' ALA . . . . . . . . . . . . . . . -58.2 -46.03 86.54 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.413 -0.358 . . . . 0.0 111.04 179.915 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 196' ' ' LEU . . . . . 0.416 ' O ' ' HG ' ' A' ' 200' ' ' LEU . 94.1 mt -67.01 -42.07 85.6 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.419 -0.355 . . . . 0.0 110.38 179.713 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 197' ' ' ILE . . . . . . . . . . . . . 18.7 mm -57.31 -57.83 8.46 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.231 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.398 179.256 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 198' ' ' VAL . . . . . 0.417 HG23 ' O ' ' A' ' 194' ' ' VAL . 91.0 t -52.65 -34.82 20.08 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.493 0 CA-C-N 115.598 -0.728 . . . . 0.0 109.328 178.618 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 199' ' ' TYR . . . . . . . . . . . . . 64.4 t80 -70.41 -35.36 73.39 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 115.288 -0.869 . . . . 0.0 110.73 179.704 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 200' ' ' LEU . . . . . 0.416 ' HG ' ' O ' ' A' ' 196' ' ' LEU . 73.1 mt -66.15 -41.34 90.54 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 115.762 -0.654 . . . . 0.0 111.322 -179.485 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 201' ' ' ASP . . . . . 0.43 ' HB2' ' OH ' ' A' ' 51' ' ' TYR . 9.9 m-20 -71.81 -31.83 66.97 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 116.29 -0.414 . . . . 0.0 110.482 179.879 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 202' ' ' LEU . . . . . 0.455 ' O ' ' HB ' ' A' ' 206' ' ' VAL . 3.6 mt -72.66 -34.11 67.02 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 115.831 -0.622 . . . . 0.0 111.997 -179.558 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 203' ' ' VAL . . . . . 0.472 ' O ' ' HA3' ' A' ' 207' ' ' GLY . 7.7 p -75.42 -36.68 36.34 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-O 120.609 0.242 . . . . 0.0 111.177 -179.032 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 204' ' ' THR . . . . . . . . . . . . . 25.6 m -68.41 -55.26 12.54 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-O 120.879 0.371 . . . . 0.0 111.397 179.789 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 205' ' ' LYS . . . . . 0.694 ' HE2' ' HB2' ' A' ' 47' ' ' ALA . 54.3 mttp -68.6 -58.96 3.5 Favored 'General case' 0 C--N 1.328 -0.359 0 N-CA-C 112.397 0.517 . . . . 0.0 112.397 -178.599 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 206' ' ' VAL . . . . . 0.455 ' HB ' ' O ' ' A' ' 202' ' ' LEU . 76.6 t -73.3 -38.13 53.19 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 N-CA-C 112.217 0.451 . . . . 0.0 112.217 -178.702 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 207' ' ' GLY . . . . . 0.472 ' HA3' ' O ' ' A' ' 203' ' ' VAL . . . -63.85 -59.78 8.17 Favored Glycine 0 N--CA 1.452 -0.261 0 C-N-CA 120.341 -0.933 . . . . 0.0 112.514 -179.324 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 208' ' ' PHE . . . . . 0.512 ' O ' ' N ' ' A' ' 212' ' ' ALA . 1.8 m-30 -54.53 -47.89 72.61 Favored 'General case' 0 C--O 1.221 -0.407 0 N-CA-C 109.795 -0.446 . . . . 0.0 109.795 179.515 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 209' ' ' GLY . . . . . 0.492 ' HA2' ' HB3' ' A' ' 212' ' ' ALA . . . -54.29 -35.07 54.73 Favored Glycine 0 N--CA 1.448 -0.508 0 CA-C-N 115.366 -0.834 . . . . 0.0 113.144 179.558 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 210' ' ' PHE . . . . . . . . . . . . . 1.9 m-85 -69.69 -47.67 62.41 Favored 'General case' 0 CA--C 1.515 -0.403 0 N-CA-C 108.677 -0.86 . . . . 0.0 108.677 179.334 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 211' ' ' ILE . . . . . 0.423 HG13 ' O ' ' A' ' 207' ' ' GLY . 4.0 mt -66.14 -27.47 40.9 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.486 0 N-CA-C 107.587 -1.264 . . . . 0.0 107.587 176.757 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 212' ' ' ALA . . . . . 0.512 ' N ' ' O ' ' A' ' 208' ' ' PHE . . . -67.4 -39.07 85.52 Favored 'General case' 0 N--CA 1.448 -0.536 0 CA-C-N 114.302 -1.317 . . . . 0.0 110.018 -179.768 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 213' ' ' LEU . . . . . . . . . . . . . 80.7 mt -70.21 -38.05 75.19 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 114.991 -1.004 . . . . 0.0 111.275 -179.841 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 214' ' ' ASP . . . . . . . . . . . . . 26.9 t70 -60.3 -55.09 37.87 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 116.328 -0.396 . . . . 0.0 111.016 -179.808 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 215' ' ' ALA . . . . . 0.554 ' HB3' HD21 ' A' ' 159' ' ' LEU . . . -61.05 -50.89 71.49 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.758 179.709 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 216' ' ' ALA . . . . . . . . . . . . . . . -57.45 -32.49 66.98 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.946 179.683 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 217' ' ' ALA . . . . . . . . . . . . . . . -62.72 -43.3 99.15 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-N 116.086 -0.506 . . . . 0.0 110.17 179.544 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 218' ' ' THR . . . . . . . . . . . . . 91.8 m . . . . . 0 C--N 1.331 -0.229 0 CA-C-N 115.897 -0.592 . . . . 0.0 110.472 179.267 . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.422 0 N-CA-C 112.744 -0.143 . . . . 0.0 112.744 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 52.0 tp -74.15 -35.47 64.05 Favored 'General case' 0 C--N 1.331 -0.21 0 CA-C-O 120.867 0.365 . . . . 0.0 110.752 179.928 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 64.9 p -64.15 -32.61 74.24 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.014 -0.539 . . . . 0.0 111.276 -179.99 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 15.9 p -52.87 -35.4 57.71 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.264 -179.647 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 7' ' ' LEU . . . . . 0.412 HD12 ' HA ' ' A' ' 195' ' ' ALA . 4.2 mm? -60.8 -53.34 58.52 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.242 -179.814 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 8' ' ' PHE . . . . . 0.437 ' HB2' ' HB2' ' A' ' 55' ' ' ALA . 64.0 m-85 -60.08 -32.7 71.2 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.928 0.394 . . . . 0.0 110.641 -179.986 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 9' ' ' TRP . . . . . 0.432 ' O ' HG13 ' A' ' 13' ' ' ILE . 35.8 m95 -67.08 -41.69 85.93 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 115.943 -0.571 . . . . 0.0 110.092 179.622 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 82.5 mt -61.57 -52.75 63.15 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 115.721 -0.672 . . . . 0.0 110.205 179.244 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -53.48 -36.46 53.77 Favored Glycine 0 N--CA 1.449 -0.492 0 C-N-CA 120.775 -0.726 . . . . 0.0 111.612 178.766 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -64.07 -34.68 78.58 Favored 'General case' 0 C--N 1.332 -0.191 0 CA-C-O 120.91 0.386 . . . . 0.0 110.226 179.258 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 13' ' ' ILE . . . . . 0.432 HG13 ' O ' ' A' ' 9' ' ' TRP . 80.1 mt -66.13 -48.48 81.3 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.219 0 CA-C-N 115.884 -0.598 . . . . 0.0 110.363 179.268 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -60.94 -32.96 81.81 Favored Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.662 -0.78 . . . . 0.0 111.482 179.35 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 15' ' ' MET . . . . . 0.656 ' HB3' ' HB2' ' A' ' 48' ' ' ALA . 0.0 OUTLIER -67.99 -42.68 80.39 Favored 'General case' 0 C--N 1.331 -0.218 0 CA-C-O 120.92 0.391 . . . . 0.0 110.553 179.186 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 32.4 tp -57.8 -41.41 82.09 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.029 -0.532 . . . . 0.0 110.442 179.474 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 89.4 t -64.65 -51.03 72.68 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.22 0 CA-C-N 115.824 -0.625 . . . . 0.0 111.094 179.972 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -62.03 -49.51 74.57 Favored Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.686 -0.769 . . . . 0.0 112.183 179.913 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 51.9 m -49.77 -41.58 44.58 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-O 120.752 0.31 . . . . 0.0 111.326 -179.561 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 78.1 mt -72.07 -48.59 43.05 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.272 -0.422 . . . . 0.0 111.427 179.836 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -59.5 -29.64 68.0 Favored 'General case' 0 C--N 1.329 -0.296 0 N-CA-C 112.192 0.442 . . . . 0.0 112.192 -179.284 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 8.0 m-85 -88.11 -45.57 10.04 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-O 120.661 0.267 . . . . 0.0 111.53 -179.307 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -60.7 -50.37 73.76 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.884 0.373 . . . . 0.0 111.589 -179.615 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 24' ' ' TRP . . . . . . . . . . . . . 2.0 t-105 -58.54 -44.19 89.53 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 116.007 -0.542 . . . . 0.0 111.119 -179.727 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.328 -0.351 0 CA-C-O 120.854 0.359 . . . . 0.0 110.998 -179.998 . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.246 0 N-CA-C 112.435 -0.266 . . . . 0.0 112.435 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 11.0 mm-40 -92.12 -24.64 19.05 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.841 0.353 . . . . 0.0 110.83 179.959 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 34' ' ' ARG . . . . . . . . . . . . . 78.6 mtm180 -50.48 -29.24 9.94 Favored 'General case' 0 C--N 1.332 -0.177 0 CA-C-N 115.943 -0.572 . . . . 0.0 111.575 -179.647 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 41.3 mmt180 -60.45 -46.5 89.82 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.767 0.318 . . . . 0.0 111.33 -179.904 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 76.6 m-85 -69.88 -30.58 68.06 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.282 -0.417 . . . . 0.0 111.456 -179.605 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 37' ' ' TYR . . . . . . . . . . . . . 62.8 m-85 -70.62 -55.12 9.51 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.289 -0.414 . . . . 0.0 111.302 -179.619 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 60.7 t -57.04 -37.84 57.19 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-O 120.957 0.408 . . . . 0.0 110.453 179.774 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 41.8 m -63.58 -47.98 79.29 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 115.847 -0.615 . . . . 0.0 110.316 179.209 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 27.6 tp -57.4 -48.21 79.69 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 115.52 -0.764 . . . . 0.0 110.539 179.677 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 76.3 t -60.63 -34.48 58.78 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.231 0 CA-C-N 115.717 -0.674 . . . . 0.0 110.382 179.242 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -60.03 -40.18 96.68 Favored Glycine 0 N--CA 1.449 -0.484 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.118 179.824 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 43' ' ' ILE . . . . . 0.531 HG22 ' HE3' ' A' ' 205' ' ' LYS . 0.4 OUTLIER -65.2 -53.86 35.74 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-O 120.728 0.299 . . . . 0.0 111.008 179.583 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 49.1 m -60.31 -25.75 66.0 Favored 'General case' 0 C--N 1.332 -0.181 0 CA-C-O 120.793 0.33 . . . . 0.0 111.37 -179.942 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -78.42 -51.74 5.49 Favored Glycine 0 CA--C 1.519 0.313 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.978 -179.54 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 46' ' ' ILE . . . . . 0.484 ' CD1' HG22 ' A' ' 79' ' ' THR . 21.8 pt -58.97 -38.73 75.41 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.217 0 CA-C-O 120.873 0.368 . . . . 0.0 111.035 -179.976 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 47' ' ' ALA . . . . . 0.736 ' HB2' ' HE2' ' A' ' 205' ' ' LYS . . . -67.85 -45.0 75.85 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.544 179.636 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 48' ' ' ALA . . . . . 0.656 ' HB2' ' HB3' ' A' ' 15' ' ' MET . . . -54.54 -41.58 69.9 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.069 -0.514 . . . . 0.0 112.024 -179.295 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 49' ' ' VAL . . . . . 0.417 ' O ' HG13 ' A' ' 53' ' ' VAL . 30.4 m -76.79 -34.35 22.84 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.36 0 CA-C-N 116.48 -0.327 . . . . 0.0 111.815 -179.21 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -66.92 -36.39 82.14 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 120.91 0.386 . . . . 0.0 111.101 179.922 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 3.3 m-85 -73.29 -40.09 64.83 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 115.987 -0.551 . . . . 0.0 110.452 179.951 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -62.79 -49.91 73.1 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-N 115.726 -0.67 . . . . 0.0 111.227 179.854 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 53' ' ' VAL . . . . . 0.491 ' O ' HG22 ' A' ' 58' ' ' VAL . 27.6 m -63.83 -46.02 95.48 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.218 0 CA-C-N 116.366 -0.379 . . . . 0.0 110.749 -179.975 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 54' ' ' MET . . . . . 0.5 ' HB2' ' HB2' ' A' ' 71' ' ' PRO . 11.0 ttp -64.11 -29.73 70.84 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.313 179.756 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 55' ' ' ALA . . . . . 0.437 ' HB2' ' HB2' ' A' ' 8' ' ' PHE . . . -63.0 -23.71 67.58 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 115.871 -0.604 . . . . 0.0 110.926 179.442 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 54.0 mt -94.47 -8.85 37.31 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-N 116.079 -0.51 . . . . 0.0 110.726 179.812 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 57' ' ' GLY . . . . . 0.432 ' HA2' ' CD1' ' A' ' 60' ' ' TRP . . . 75.19 30.66 58.55 Favored Glycine 0 N--CA 1.451 -0.361 0 C-N-CA 120.876 -0.678 . . . . 0.0 112.953 179.723 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 58' ' ' VAL . . . . . 0.491 HG22 ' O ' ' A' ' 53' ' ' VAL . 26.3 m -84.04 18.2 0.37 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-O 120.808 0.337 . . . . 0.0 111.504 179.992 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -152.87 6.6 0.45 Allowed Glycine 0 N--CA 1.449 -0.485 0 C-N-CA 120.751 -0.737 . . . . 0.0 112.888 179.947 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 60' ' ' TRP . . . . . 0.432 ' CD1' ' HA2' ' A' ' 57' ' ' GLY . 34.5 m0 -71.95 121.5 19.21 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-O 120.783 0.325 . . . . 0.0 110.48 179.921 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 7.5 p -114.91 128.59 25.78 Favored Pre-proline 0 CA--C 1.533 0.303 0 CA-C-N 116.263 -0.426 . . . . 0.0 111.388 -179.733 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 65.0 Cg_endo -73.95 144.01 33.73 Favored 'Trans proline' 0 C--N 1.351 0.686 0 C-N-CA 122.396 2.064 . . . . 0.0 112.107 179.719 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 59.0 t -137.83 90.42 0.72 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.384 0 CA-C-N 116.086 -0.506 . . . . 0.0 111.061 -179.645 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . 58.43 -88.05 0.02 OUTLIER 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 116.116 -0.493 . . . . 0.0 111.587 -179.996 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 45.6 mt-10 -119.19 -19.96 8.16 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-O 120.775 0.321 . . . . 0.0 110.958 179.995 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 66' ' ' ARG . . . . . . . . . . . . . 9.9 ptp180 -103.23 165.19 11.17 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.268 -0.423 . . . . 0.0 110.449 179.651 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 53.9 m -123.35 129.64 51.6 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.937 0.398 . . . . 0.0 111.472 -179.677 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 99.2 t -109.73 146.33 15.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 115.889 -0.596 . . . . 0.0 110.492 179.644 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 69' ' ' PHE . . . . . . . . . . . . . 30.3 m-85 -105.59 115.47 30.3 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 121.049 0.452 . . . . 0.0 110.484 -179.474 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 70' ' ' VAL . . . . . 0.628 HG12 ' HD3' ' A' ' 71' ' ' PRO . 0.3 OUTLIER -67.98 -36.29 9.13 Favored Pre-proline 0 CA--C 1.54 0.58 0 CA-C-N 115.863 -0.608 . . . . 0.0 112.601 -179.48 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 71' ' ' PRO . . . . . 0.628 ' HD3' HG12 ' A' ' 70' ' ' VAL . 7.7 Cg_exo -71.09 -19.12 30.28 Favored 'Trans proline' 0 C--N 1.357 1.016 0 C-N-CA 122.21 1.94 . . . . 0.0 113.308 -179.198 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 43.0 ttm180 -76.35 -55.09 5.87 Favored 'General case' 0 C--N 1.331 -0.206 0 N-CA-C 112.372 0.508 . . . . 0.0 112.372 -178.505 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 73' ' ' TYR . . . . . 0.452 ' O ' HG13 ' A' ' 77' ' ' ILE . 68.5 m-85 -71.19 -36.76 72.06 Favored 'General case' 0 C--N 1.329 -0.286 0 C-N-CA 120.841 -0.344 . . . . 0.0 110.956 -179.248 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 74' ' ' ILE . . . . . 0.432 ' O ' HD13 ' A' ' 74' ' ' ILE . 0.3 OUTLIER -64.95 -40.43 89.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 N-CA-C 109.766 -0.457 . . . . 0.0 109.766 179.309 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 75' ' ' ASP . . . . . 0.517 ' O ' HG23 ' A' ' 79' ' ' THR . 12.0 t70 -60.23 -37.51 80.55 Favored 'General case' 0 CA--C 1.518 -0.251 0 N-CA-C 109.437 -0.579 . . . . 0.0 109.437 178.772 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 76' ' ' TRP . . . . . . . . . . . . . 46.6 m0 -64.03 -31.44 72.63 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 115.899 -0.591 . . . . 0.0 110.319 179.478 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 77' ' ' ILE . . . . . 0.512 ' O ' ' HG2' ' A' ' 81' ' ' PRO . 61.8 mt -71.28 -31.72 44.79 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.478 178.963 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 25.6 mt -91.82 -15.13 28.66 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.172 -0.467 . . . . 0.0 112.165 -179.707 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 79' ' ' THR . . . . . 0.517 HG23 ' O ' ' A' ' 75' ' ' ASP . 79.8 p -104.61 -52.97 2.78 Favored 'General case' 0 N--CA 1.465 0.296 0 N-CA-C 113.614 0.968 . . . . 0.0 113.614 -177.891 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 80' ' ' THR . . . . . 0.583 ' HB ' ' HD3' ' A' ' 81' ' ' PRO . 4.5 m -52.66 -53.68 51.41 Favored Pre-proline 0 C--N 1.331 -0.237 0 N-CA-C 112.36 0.504 . . . . 0.0 112.36 -178.369 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 81' ' ' PRO . . . . . 0.583 ' HD3' ' HB ' ' A' ' 80' ' ' THR . 52.6 Cg_exo -57.01 -23.43 52.01 Favored 'Trans proline' 0 C--N 1.352 0.752 0 C-N-CA 121.612 1.541 . . . . 0.0 111.68 179.543 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 82' ' ' LEU . . . . . . . . . . . . . 18.0 tp -76.76 -33.19 58.1 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 115.926 -0.579 . . . . 0.0 110.054 179.604 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 83' ' ' ILE . . . . . 0.451 HD11 HG21 ' A' ' 43' ' ' ILE . 37.6 mm -69.36 -53.37 25.49 Favored 'Isoleucine or valine' 0 C--O 1.232 0.161 0 CA-C-N 116.007 -0.542 . . . . 0.0 110.386 179.226 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 29.0 m -59.36 -32.8 49.34 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.183 0 N-CA-C 109.8 -0.444 . . . . 0.0 109.8 179.005 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 85' ' ' TYR . . . . . . . . . . . . . 55.4 t80 -64.66 -34.57 78.6 Favored 'General case' 0 N--CA 1.454 -0.272 0 CA-C-N 115.657 -0.701 . . . . 0.0 109.561 178.801 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 86' ' ' PHE . . . . . . . . . . . . . 8.8 t80 -61.48 -51.82 67.07 Favored 'General case' 0 C--O 1.232 0.181 0 CA-C-N 115.635 -0.711 . . . . 0.0 110.232 179.507 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 7.3 mp -61.71 -31.93 72.11 Favored 'General case' 0 C--N 1.331 -0.204 0 CA-C-N 116.136 -0.483 . . . . 0.0 110.116 179.49 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -71.59 -27.57 70.89 Favored Glycine 0 N--CA 1.449 -0.44 0 CA-C-N 115.8 -0.636 . . . . 0.0 111.795 179.31 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 42.0 mt -72.07 -39.2 69.18 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.919 0.39 . . . . 0.0 110.538 179.733 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 53.6 mt -58.5 -45.8 88.01 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 115.782 -0.645 . . . . 0.0 111.106 -179.967 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 91' ' ' ALA . . . . . 0.588 ' HB2' ' HB2' ' A' ' 149' ' ' ALA . . . -79.88 -54.94 5.35 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.403 -179.728 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 102.84 65.64 0.73 Allowed Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.826 -0.702 . . . . 0.0 112.346 -179.888 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 93' ' ' LEU . . . . . 0.46 HD11 ' HG2' ' A' ' 145' ' ' MET . 8.1 mp -71.93 172.04 10.67 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.804 0.335 . . . . 0.0 111.053 179.998 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 94' ' ' ASP . . . . . 0.47 ' HB2' ' HG2' ' A' ' 97' ' ' GLU . 10.1 m-20 -78.54 174.3 11.5 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.811 179.942 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 71.4 p -61.62 -51.27 69.19 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.176 -0.466 . . . . 0.0 111.215 -179.858 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 97.8 mtt180 -65.39 -42.15 92.93 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.374 -179.66 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 97' ' ' GLU . . . . . 0.47 ' HG2' ' HB2' ' A' ' 94' ' ' ASP . 10.3 mm-40 -52.49 -50.76 62.1 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.311 -0.404 . . . . 0.0 111.163 -179.625 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 98' ' ' PHE . . . . . 0.458 ' O ' HG12 ' A' ' 102' ' ' ILE . 12.2 m-85 -56.18 -46.23 79.44 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.354 -0.385 . . . . 0.0 110.683 179.633 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -60.54 -29.67 70.09 Favored Glycine 0 N--CA 1.448 -0.505 0 C-N-CA 120.688 -0.768 . . . . 0.0 112.34 179.978 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 96.6 mt -73.87 -42.63 53.59 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.238 0 CA-C-O 120.786 0.327 . . . . 0.0 111.717 -179.853 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 39.8 t -70.61 -42.58 77.98 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 CA-C-N 116.427 -0.351 . . . . 0.0 111.519 -179.335 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 102' ' ' ILE . . . . . 0.458 HG12 ' O ' ' A' ' 98' ' ' PHE . 49.2 mm -64.92 -45.78 93.72 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.368 -0.378 . . . . 0.0 111.552 -179.548 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 13.7 t -62.22 -35.52 79.14 Favored 'General case' 0 C--O 1.233 0.211 0 CA-C-O 120.847 0.356 . . . . 0.0 110.661 179.879 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 104' ' ' LEU . . . . . 0.441 ' O ' HG23 ' A' ' 108' ' ' VAL . 29.8 tp -57.39 -53.82 53.86 Favored 'General case' 0 C--N 1.331 -0.202 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.258 179.241 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 105' ' ' ASN . . . . . 0.607 ' N ' HD22 ' A' ' 105' ' ' ASN . 0.8 OUTLIER -56.25 -36.67 68.81 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 115.952 -0.567 . . . . 0.0 110.433 179.709 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 30.6 m -54.92 -43.41 73.28 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.511 179.621 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 107' ' ' VAL . . . . . 0.454 HG12 ' SD ' ' A' ' 129' ' ' MET . 1.2 t -65.64 -39.49 85.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-O 121.274 0.559 . . . . 0.0 110.187 179.206 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 108' ' ' VAL . . . . . 0.441 HG23 ' O ' ' A' ' 104' ' ' LEU . 41.7 t -60.03 -53.16 52.4 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.38 0 CA-C-N 115.291 -0.868 . . . . 0.0 111.782 -179.728 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 109' ' ' MET . . . . . 0.449 ' HG2' ' O ' ' A' ' 105' ' ' ASN . 8.0 mmt -61.85 -41.86 98.34 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-N 116.306 -0.406 . . . . 0.0 111.257 -179.284 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 28.6 tp -60.21 -30.27 69.27 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 116.377 -0.374 . . . . 0.0 110.461 -179.906 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -66.55 -54.87 18.97 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.552 179.217 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . -60.02 -36.22 89.66 Favored Glycine 0 N--CA 1.452 -0.24 0 C-N-CA 120.497 -0.859 . . . . 0.0 111.722 179.373 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 113' ' ' PHE . . . . . . . . . . . . . 0.9 OUTLIER -56.1 -75.09 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 121.051 0.453 . . . . 0.0 110.357 179.647 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -58.44 -29.72 66.37 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 115.679 -0.691 . . . . 0.0 111.418 -179.91 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -52.3 -49.12 52.2 Favored Glycine 0 C--N 1.331 0.254 0 C-N-CA 121.075 -0.583 . . . . 0.0 112.726 -179.993 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -77.71 -16.87 58.16 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-O 120.697 0.284 . . . . 0.0 111.458 -179.976 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 117' ' ' MET . . . . . . . . . . . . . 38.3 ttm -100.95 18.08 20.57 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.352 -0.385 . . . . 0.0 111.321 -179.387 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 118' ' ' VAL . . . . . 0.479 HG21 ' HB3' ' A' ' 123' ' ' ARG . 27.1 m -70.05 148.31 96.03 Favored Pre-proline 0 C--N 1.329 -0.302 0 CA-C-N 116.451 -0.34 . . . . 0.0 111.15 179.794 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 119' ' ' PRO . . . . . . . . . . . . . 90.6 Cg_endo -83.7 -3.77 10.63 Favored 'Trans proline' 0 C--N 1.348 0.52 0 C-N-CA 122.567 2.178 . . . . 0.0 112.136 179.719 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -156.25 -141.51 3.21 Favored Glycine 0 N--CA 1.453 -0.229 0 C-N-CA 120.926 -0.654 . . . . 0.0 112.452 -179.981 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 41.0 pt -84.71 18.87 0.37 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.229 0 CA-C-O 120.845 0.355 . . . . 0.0 111.062 -179.99 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 122' ' ' GLU . . . . . 0.459 ' HB2' ' HB ' ' A' ' 118' ' ' VAL . 12.3 mm-40 -67.52 -18.01 64.88 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.0 -0.545 . . . . 0.0 111.36 -179.926 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 123' ' ' ARG . . . . . 0.479 ' HB3' HG21 ' A' ' 118' ' ' VAL . 0.0 OUTLIER -51.11 -30.2 15.56 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-N 116.424 -0.353 . . . . 0.0 111.457 -179.532 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 124' ' ' TYR . . . . . . . . . . . . . 34.6 m-85 -70.23 -32.52 70.42 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-O 120.735 0.302 . . . . 0.0 111.202 -179.717 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 125' ' ' ALA . . . . . . . . . . . . . . . -67.88 -52.2 39.33 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.268 -0.423 . . . . 0.0 110.887 179.88 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 126' ' ' LEU . . . . . 0.402 HD13 ' HA ' ' A' ' 126' ' ' LEU . 3.2 mm? -53.24 -54.44 36.07 Favored 'General case' 0 CA--C 1.521 -0.168 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.581 179.69 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 127' ' ' PHE . . . . . 0.481 ' HZ ' ' HB3' ' A' ' 175' ' ' PRO . 9.4 t80 -62.33 -35.74 80.03 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.082 -179.63 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 128' ' ' GLY . . . . . . . . . . . . . . . -47.23 -48.1 20.76 Favored Glycine 0 C--N 1.332 0.314 0 C-N-CA 119.925 -1.131 . . . . 0.0 110.287 178.718 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 129' ' ' MET . . . . . 0.454 ' SD ' HG12 ' A' ' 107' ' ' VAL . 0.4 OUTLIER -71.21 -31.41 67.55 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 115.019 -0.591 . . . . 0.0 109.697 178.379 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -60.96 -41.09 99.25 Favored Glycine 0 C--N 1.332 0.359 0 CA-C-N 115.821 -0.627 . . . . 0.0 112.753 -179.864 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -71.28 -51.92 21.75 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.644 0.259 . . . . 0.0 110.518 179.807 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 57.4 t -55.04 -39.95 52.19 Favored 'Isoleucine or valine' 0 C--O 1.233 0.226 0 CA-C-O 121.3 0.571 . . . . 0.0 109.694 178.95 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -70.77 -37.35 73.36 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 115.407 -0.815 . . . . 0.0 110.658 179.602 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 134' ' ' PHE . . . . . . . . . . . . . 43.6 t80 -56.62 -53.35 58.64 Favored 'General case' 0 N--CA 1.451 -0.386 0 CA-C-O 120.995 0.426 . . . . 0.0 109.984 179.567 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 135' ' ' ILE . . . . . . . . . . . . . 48.4 mt -58.02 -33.48 46.46 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.405 0 CA-C-N 115.787 -0.642 . . . . 0.0 109.838 179.227 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . -58.82 -40.73 95.47 Favored Glycine 0 N--CA 1.448 -0.53 0 C-N-CA 120.394 -0.908 . . . . 0.0 111.473 178.905 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 137' ' ' LEU . . . . . 0.416 HD13 HD21 ' A' ' 105' ' ' ASN . 53.5 tp -69.73 -45.04 69.05 Favored 'General case' 0 N--CA 1.455 -0.193 0 CA-C-O 120.693 0.282 . . . . 0.0 110.588 179.411 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 138' ' ' VAL . . . . . . . . . . . . . 98.8 t -56.05 -40.99 66.9 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.9 0 CA-C-O 121.222 0.534 . . . . 0.0 109.896 179.231 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 139' ' ' TYR . . . . . . . . . . . . . 29.4 t80 -59.05 -47.14 86.31 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 115.416 -0.811 . . . . 0.0 110.612 178.937 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 22.9 m-85 -54.52 -37.77 65.74 Favored 'General case' 0 C--N 1.332 -0.16 0 CA-C-N 116.39 -0.368 . . . . 0.0 110.911 179.942 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 141' ' ' LEU . . . . . 0.491 HD23 ' SD ' ' A' ' 145' ' ' MET . 79.8 mt -60.89 -50.7 72.37 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-O 120.905 0.383 . . . . 0.0 110.366 179.502 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 22.0 t -70.52 -15.21 18.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.034 -0.53 . . . . 0.0 110.723 179.531 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . -70.37 -140.24 0.16 Allowed Glycine 0 CA--C 1.521 0.461 0 C-N-CA 121.015 -0.612 . . . . 0.0 112.842 -179.88 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 144' ' ' PRO . . . . . . . . . . . . . 42.0 Cg_exo -56.64 -23.69 50.35 Favored 'Trans proline' 0 C--N 1.35 0.639 0 C-N-CA 122.641 2.227 . . . . 0.0 112.63 -179.794 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 145' ' ' MET . . . . . 0.491 ' SD ' HD23 ' A' ' 141' ' ' LEU . 54.5 mtt -57.93 -31.65 67.01 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.391 -0.368 . . . . 0.0 111.429 -179.867 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 146' ' ' THR . . . . . . . . . . . . . 25.0 m -74.11 -48.34 30.24 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.278 -0.419 . . . . 0.0 112.05 -179.061 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 45.1 mt-10 -72.92 -29.02 62.81 Favored 'General case' 0 C--N 1.329 -0.302 0 N-CA-C 111.762 0.282 . . . . 0.0 111.762 -179.157 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 148' ' ' SER . . . . . 0.408 ' HB3' ' HB1' ' A' ' 91' ' ' ALA . 46.8 t -70.76 -47.81 57.68 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.519 -0.31 . . . . 0.0 111.497 -179.179 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 149' ' ' ALA . . . . . 0.588 ' HB2' ' HB2' ' A' ' 91' ' ' ALA . . . -73.54 -43.23 60.44 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.378 -0.374 . . . . 0.0 111.865 -179.259 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 150' ' ' SER . . . . . 0.493 ' HA ' ' HB3' ' A' ' 157' ' ' LYS . 42.8 t -65.51 -8.4 19.34 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.457 -0.338 . . . . 0.0 111.286 -179.613 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 151' ' ' GLN . . . . . . . . . . . . . 46.2 mt-30 -124.89 15.73 8.59 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.454 -0.339 . . . . 0.0 111.161 179.999 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 31.3 tpt180 -90.79 -52.02 5.08 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 121.093 0.473 . . . . 0.0 110.275 179.646 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 153' ' ' SER . . . . . 0.613 ' HB2' HG12 ' A' ' 156' ' ' ILE . 24.6 m -158.02 172.69 17.98 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 115.719 -0.673 . . . . 0.0 110.473 179.228 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 154' ' ' SER . . . . . . . . . . . . . 78.3 p -70.55 -38.69 74.19 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.335 -0.393 . . . . 0.0 110.482 179.438 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -77.87 -38.01 28.22 Favored Glycine 0 N--CA 1.452 -0.265 0 C-N-CA 121.04 -0.6 . . . . 0.0 112.845 179.781 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 156' ' ' ILE . . . . . 0.613 HG12 ' HB2' ' A' ' 153' ' ' SER . 39.0 mm -53.4 -44.48 55.08 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.202 0 N-CA-C 111.917 0.34 . . . . 0.0 111.917 -179.204 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 157' ' ' LYS . . . . . 0.493 ' HB3' ' HA ' ' A' ' 150' ' ' SER . 18.9 ptpt -65.78 -30.88 71.59 Favored 'General case' 0 C--N 1.329 -0.288 0 N-CA-C 111.714 0.264 . . . . 0.0 111.714 -179.225 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 47.8 t -71.7 -48.37 47.76 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 121.076 0.465 . . . . 0.0 111.077 -179.539 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 159' ' ' LEU . . . . . 0.482 ' O ' ' HB2' ' A' ' 163' ' ' LEU . 8.4 mp -71.53 -29.81 65.19 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 115.875 -0.602 . . . . 0.0 111.313 -179.785 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 160' ' ' TYR . . . . . . . . . . . . . 92.8 t80 -70.73 -44.84 65.99 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.397 -0.365 . . . . 0.0 111.739 -179.402 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 161' ' ' VAL . . . . . 0.421 HG13 ' O ' ' A' ' 157' ' ' LYS . 28.6 m -66.05 -42.34 91.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 N-CA-C 111.624 0.231 . . . . 0.0 111.624 -179.365 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 162' ' ' ARG . . . . . . . . . . . . . 95.7 mtt180 -67.99 -44.71 75.99 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.796 0.331 . . . . 0.0 111.497 -179.808 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 163' ' ' LEU . . . . . 0.482 ' HB2' ' O ' ' A' ' 159' ' ' LEU . 4.5 mp -71.55 -54.16 11.41 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.264 -0.426 . . . . 0.0 112.039 -179.19 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 164' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -53.05 -41.64 65.01 Favored 'General case' 0 C--N 1.328 -0.353 0 N-CA-C 111.957 0.354 . . . . 0.0 111.957 -178.783 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 165' ' ' ASN . . . . . 0.505 ' O ' HG23 ' A' ' 169' ' ' VAL . 4.8 m-20 -67.03 -52.31 43.93 Favored 'General case' 0 C--N 1.329 -0.318 0 N-CA-C 112.013 0.375 . . . . 0.0 112.013 -179.114 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 166' ' ' LEU . . . . . 0.46 HD21 ' CE1' ' A' ' 208' ' ' PHE . 0.0 OUTLIER -67.45 -33.13 74.5 Favored 'General case' 0 C--N 1.329 -0.288 0 N-CA-C 111.643 0.238 . . . . 0.0 111.643 -178.871 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 167' ' ' THR . . . . . 0.451 ' O ' ' HB2' ' A' ' 171' ' ' TRP . 27.5 m -63.04 -53.83 47.72 Favored 'General case' 0 C--N 1.332 -0.195 0 N-CA-C 111.939 0.348 . . . . 0.0 111.939 -179.976 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 168' ' ' VAL . . . . . 0.426 HG12 ' O ' ' A' ' 165' ' ' ASN . 9.9 p -59.28 -40.07 80.41 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.242 0 CA-C-N 116.486 -0.325 . . . . 0.0 111.541 -178.924 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 169' ' ' VAL . . . . . 0.505 HG23 ' O ' ' A' ' 165' ' ' ASN . 74.0 t -57.14 -65.38 0.41 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.563 -0.29 . . . . 0.0 111.45 -179.767 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 170' ' ' LEU . . . . . 0.433 ' HG ' ' O ' ' A' ' 166' ' ' LEU . 2.7 pp -63.09 -29.78 71.08 Favored 'General case' 0 C--N 1.331 -0.228 0 N-CA-C 111.908 0.336 . . . . 0.0 111.908 -179.085 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 171' ' ' TRP . . . . . 0.451 ' HB2' ' O ' ' A' ' 167' ' ' THR . 2.5 m0 -72.51 -31.47 65.37 Favored 'General case' 0 C--N 1.331 -0.21 0 C-N-CA 120.797 -0.361 . . . . 0.0 110.761 179.612 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 172' ' ' ALA . . . . . . . . . . . . . . . -72.94 -6.24 43.92 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-O 121.055 0.455 . . . . 0.0 110.367 179.439 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 173' ' ' ILE . . . . . 0.61 HG22 HD11 ' A' ' 177' ' ' ILE . 37.2 mm -82.89 -25.99 8.19 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.206 0 CA-C-N 115.771 -0.649 . . . . 0.0 110.999 179.791 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 174' ' ' TYR . . . . . 0.489 ' HB2' ' HD3' ' A' ' 175' ' ' PRO . 49.9 m-85 -54.55 -50.7 83.95 Favored Pre-proline 0 N--CA 1.464 0.272 0 CA-C-N 116.353 -0.385 . . . . 0.0 111.671 -179.665 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 175' ' ' PRO . . . . . 0.489 ' HD3' ' HB2' ' A' ' 174' ' ' TYR . 97.2 Cg_exo -45.19 -30.29 4.96 Favored 'Trans proline' 0 C--N 1.35 0.647 0 C-N-CA 122.186 1.924 . . . . 0.0 112.403 179.65 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 176' ' ' PHE . . . . . 0.459 ' O ' ' HG ' ' A' ' 180' ' ' LEU . 65.8 m-85 -80.57 -49.67 11.01 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 115.979 -0.555 . . . . 0.0 111.989 -179.729 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 177' ' ' ILE . . . . . 0.61 HD11 HG22 ' A' ' 173' ' ' ILE . 2.3 mm -61.59 -37.37 77.74 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.53 0 N-CA-C 112.723 0.638 . . . . 0.0 112.723 -177.693 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 178' ' ' TRP . . . . . . . . . . . . . 63.0 t90 -72.55 -44.9 61.48 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 120.875 0.369 . . . . 0.0 110.823 179.7 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 179' ' ' LEU . . . . . 0.492 ' O ' HG22 ' A' ' 185' ' ' VAL . 2.5 tm? -67.15 -49.25 65.43 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 115.907 -0.588 . . . . 0.0 111.72 -179.0 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 180' ' ' LEU . . . . . 0.549 HD22 HD11 ' A' ' 187' ' ' LEU . 23.1 mt -77.24 -45.28 26.98 Favored 'General case' 0 C--N 1.326 -0.424 0 N-CA-C 111.982 0.364 . . . . 0.0 111.982 -178.796 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . -57.32 178.91 0.88 Allowed Glycine 0 C--N 1.334 0.47 0 C-N-CA 120.438 -0.887 . . . . 0.0 112.82 -179.878 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 182' ' ' PRO . . . . . 0.609 ' HA ' ' HB2' ' A' ' 186' ' ' ALA . 71.5 Cg_exo -47.78 -46.06 22.41 Favored 'Trans proline' 0 CA--C 1.537 0.67 0 C-N-CA 123.0 2.466 . . . . 0.0 114.177 -179.709 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 183' ' ' PRO . . . . . 0.578 ' HD2' ' N ' ' A' ' 182' ' ' PRO . 16.9 Cg_endo -57.53 -9.92 6.05 Favored 'Trans proline' 0 C--N 1.355 0.885 0 C-N-CA 122.02 1.813 . . . . 0.0 113.246 -179.409 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 184' ' ' GLY . . . . . 0.434 ' HA3' ' O ' ' A' ' 179' ' ' LEU . . . -116.23 -86.8 1.3 Allowed Glycine 0 N--CA 1.45 -0.379 0 C-N-CA 120.536 -0.84 . . . . 0.0 112.722 179.781 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 185' ' ' VAL . . . . . 0.492 HG22 ' O ' ' A' ' 179' ' ' LEU . 9.0 m -123.47 -4.1 7.18 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.246 0 CA-C-O 120.781 0.324 . . . . 0.0 111.544 -179.817 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 186' ' ' ALA . . . . . 0.609 ' HB2' ' HA ' ' A' ' 182' ' ' PRO . . . 54.56 84.83 0.06 Allowed 'General case' 0 N--CA 1.463 0.195 0 CA-C-N 116.113 -0.494 . . . . 0.0 111.828 179.557 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 187' ' ' LEU . . . . . 0.549 HD11 HD22 ' A' ' 180' ' ' LEU . 14.8 mt -92.1 -48.72 6.58 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-O 120.973 0.416 . . . . 0.0 110.906 179.509 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 188' ' ' LEU . . . . . . . . . . . . . 89.7 mt -96.82 -152.91 0.4 Allowed 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 115.883 -0.599 . . . . 0.0 111.014 -179.575 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 189' ' ' THR . . . . . 0.413 ' HB ' HG23 ' A' ' 192' ' ' VAL . 86.5 m -96.37 136.25 22.04 Favored Pre-proline 0 C--N 1.33 -0.261 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.712 -179.71 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 190' ' ' PRO . . . . . . . . . . . . . 88.7 Cg_exo -46.48 -43.07 22.75 Favored 'Trans proline' 0 C--N 1.349 0.585 0 C-N-CA 122.459 2.106 . . . . 0.0 112.855 -179.825 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 191' ' ' THR . . . . . . . . . . . . . 82.0 p -65.41 -38.64 90.57 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.376 -0.375 . . . . 0.0 111.731 -179.601 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 192' ' ' VAL . . . . . 0.413 HG23 ' HB ' ' A' ' 189' ' ' THR . 58.1 t -71.78 -53.71 19.44 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.394 -0.366 . . . . 0.0 111.415 -179.628 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 193' ' ' ASP . . . . . . . . . . . . . 26.5 t70 -54.19 -47.97 71.48 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.244 -0.435 . . . . 0.0 111.049 -179.867 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 194' ' ' VAL . . . . . 0.493 ' O ' HG22 ' A' ' 198' ' ' VAL . 46.7 t -60.13 -40.18 82.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.281 -0.418 . . . . 0.0 110.674 179.769 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 195' ' ' ALA . . . . . 0.412 ' HA ' HD12 ' A' ' 7' ' ' LEU . . . -52.86 -44.64 66.97 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.928 179.756 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 196' ' ' LEU . . . . . . . . . . . . . 94.5 mt -68.42 -36.19 78.71 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.096 179.711 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 197' ' ' ILE . . . . . 0.454 HD11 ' HB ' ' A' ' 177' ' ' ILE . 12.4 mm -61.31 -59.83 3.66 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.203 179.911 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 198' ' ' VAL . . . . . 0.493 HG22 ' O ' ' A' ' 194' ' ' VAL . 2.8 m -54.08 -35.36 28.79 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.47 0 CA-C-O 121.669 0.747 . . . . 0.0 109.523 179.307 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 199' ' ' TYR . . . . . . . . . . . . . 74.9 t80 -64.59 -41.6 96.14 Favored 'General case' 0 C--N 1.321 -0.658 0 CA-C-N 114.454 -1.248 . . . . 0.0 110.482 179.577 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 200' ' ' LEU . . . . . 0.419 ' HB3' ' CZ ' ' A' ' 174' ' ' TYR . 23.2 mt -59.04 -46.55 87.94 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 115.747 -0.66 . . . . 0.0 111.08 -179.885 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 201' ' ' ASP . . . . . . . . . . . . . 8.6 m-20 -69.95 -33.52 72.22 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 121.089 0.471 . . . . 0.0 110.426 179.709 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 202' ' ' LEU . . . . . . . . . . . . . 1.2 tt -66.54 -33.53 75.88 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 115.604 -0.725 . . . . 0.0 110.738 -179.93 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 203' ' ' VAL . . . . . 0.448 ' O ' ' HA3' ' A' ' 207' ' ' GLY . 42.3 t -76.66 -36.94 28.2 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 115.88 -0.6 . . . . 0.0 111.552 -179.007 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 204' ' ' THR . . . . . 0.473 HG23 ' CE2' ' A' ' 208' ' ' PHE . 36.5 m -64.58 -56.12 16.01 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-O 120.894 0.378 . . . . 0.0 111.679 -179.869 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 205' ' ' LYS . . . . . 0.736 ' HE2' ' HB2' ' A' ' 47' ' ' ALA . 48.9 mttp -69.03 -58.62 3.85 Favored 'General case' 0 C--N 1.326 -0.421 0 N-CA-C 112.576 0.584 . . . . 0.0 112.576 -178.351 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 48.9 t -71.57 -38.12 66.32 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 N-CA-C 112.064 0.394 . . . . 0.0 112.064 -178.515 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 207' ' ' GLY . . . . . 0.496 ' O ' HG12 ' A' ' 211' ' ' ILE . . . -63.38 -59.62 8.63 Favored Glycine 0 N--CA 1.453 -0.23 0 C-N-CA 120.579 -0.819 . . . . 0.0 112.86 -179.319 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 208' ' ' PHE . . . . . 0.509 ' O ' ' N ' ' A' ' 212' ' ' ALA . 1.8 m-30 -54.88 -47.91 73.67 Favored 'General case' 0 C--O 1.221 -0.405 0 N-CA-C 110.18 -0.304 . . . . 0.0 110.18 -179.633 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 209' ' ' GLY . . . . . 0.491 ' HA2' ' HB3' ' A' ' 212' ' ' ALA . . . -53.46 -32.36 45.27 Favored Glycine 0 N--CA 1.45 -0.432 0 CA-C-N 115.623 -0.717 . . . . 0.0 112.488 178.937 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 210' ' ' PHE . . . . . . . . . . . . . 3.0 m-85 -71.94 -45.96 59.24 Favored 'General case' 0 CA--C 1.516 -0.34 0 N-CA-C 108.694 -0.854 . . . . 0.0 108.694 178.769 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 211' ' ' ILE . . . . . 0.496 HG12 ' O ' ' A' ' 207' ' ' GLY . 2.4 mm -66.12 -27.5 41.0 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.51 0 N-CA-C 107.256 -1.387 . . . . 0.0 107.256 176.655 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 212' ' ' ALA . . . . . 0.509 ' N ' ' O ' ' A' ' 208' ' ' PHE . . . -68.67 -40.13 80.28 Favored 'General case' 0 N--CA 1.447 -0.582 0 CA-C-N 113.965 -1.471 . . . . 0.0 110.925 -179.34 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 213' ' ' LEU . . . . . . . . . . . . . 65.1 mt -70.26 -55.51 9.07 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 115.314 -0.857 . . . . 0.0 112.07 -179.164 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 214' ' ' ASP . . . . . . . . . . . . . 20.1 t70 -56.45 -50.56 71.33 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.859 0.361 . . . . 0.0 111.352 -179.429 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 215' ' ' ALA . . . . . . . . . . . . . . . -57.69 -55.39 35.49 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.467 -179.781 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 216' ' ' ALA . . . . . . . . . . . . . . . -60.59 -31.19 70.35 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.273 -0.421 . . . . 0.0 111.321 -179.697 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 217' ' ' ALA . . . . . . . . . . . . . . . -62.62 -35.82 80.82 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.342 -0.39 . . . . 0.0 110.264 179.609 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 218' ' ' THR . . . . . . . . . . . . . 86.7 m . . . . . 0 C--N 1.329 -0.285 0 CA-C-N 115.887 -0.597 . . . . 0.0 110.614 179.24 . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.299 0 N-CA-C 112.605 -0.198 . . . . 0.0 112.605 . . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 94.5 mt -56.72 -35.55 68.67 Favored 'General case' 0 N--CA 1.449 -0.514 0 CA-C-O 120.868 0.366 . . . . 0.0 111.242 -179.859 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 42.9 p -63.4 -39.01 93.34 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.08 -0.509 . . . . 0.0 111.774 -179.414 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 18.7 p -52.84 -35.33 57.22 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-N 116.484 -0.325 . . . . 0.0 111.538 -179.442 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 7' ' ' LEU . . . . . . . . . . . . . 3.8 mm? -60.62 -53.13 61.13 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.37 -0.377 . . . . 0.0 111.245 -179.755 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 8' ' ' PHE . . . . . 0.559 ' HB2' ' HB2' ' A' ' 55' ' ' ALA . 64.4 m-85 -61.67 -30.84 70.99 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.304 -0.407 . . . . 0.0 111.014 -179.726 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 9' ' ' TRP . . . . . 0.474 ' O ' HG12 ' A' ' 13' ' ' ILE . 34.9 m95 -66.79 -43.3 84.31 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 116.226 -0.443 . . . . 0.0 109.966 179.939 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 87.5 mt -65.51 -49.02 70.54 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 115.615 -0.721 . . . . 0.0 110.526 179.638 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 11' ' ' GLY . . . . . 0.4 ' O ' HD21 ' A' ' 202' ' ' LEU . . . -58.47 -32.22 68.19 Favored Glycine 0 N--CA 1.449 -0.475 0 C-N-CA 120.559 -0.829 . . . . 0.0 111.677 179.3 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -68.69 -35.43 77.18 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 120.842 0.353 . . . . 0.0 110.615 179.453 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 13' ' ' ILE . . . . . 0.474 HG12 ' O ' ' A' ' 9' ' ' TRP . 46.8 mm -64.73 -53.98 35.59 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.205 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.609 179.566 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -60.71 -32.83 80.2 Favored Glycine 0 N--CA 1.45 -0.432 0 C-N-CA 120.718 -0.753 . . . . 0.0 111.7 179.477 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 15' ' ' MET . . . . . 0.591 ' SD ' ' HA ' ' A' ' 44' ' ' SER . 54.0 tpp -64.33 -50.98 65.66 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.792 0.33 . . . . 0.0 110.619 179.896 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -52.77 -40.58 63.3 Favored 'General case' 0 C--N 1.332 -0.192 0 CA-C-N 116.021 -0.536 . . . . 0.0 110.355 179.538 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 97.6 t -59.94 -42.86 90.86 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.219 0 CA-C-N 116.034 -0.53 . . . . 0.0 110.541 179.534 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -66.12 -43.39 93.35 Favored Glycine 0 N--CA 1.452 -0.272 0 C-N-CA 120.771 -0.728 . . . . 0.0 111.74 179.067 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 17.8 m -50.28 -46.56 55.22 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 115.556 -0.322 . . . . 0.0 111.48 -179.762 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 86.0 mt -71.76 -39.85 69.71 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.316 -0.402 . . . . 0.0 111.772 -179.74 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -61.64 -31.52 71.63 Favored 'General case' 0 C--N 1.33 -0.272 0 N-CA-C 111.987 0.366 . . . . 0.0 111.987 -179.219 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 4.9 m-85 -90.75 -33.34 15.78 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-O 120.731 0.301 . . . . 0.0 111.421 -179.599 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -69.3 -50.0 50.71 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.973 0.416 . . . . 0.0 111.19 -179.824 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 24' ' ' TRP . . . . . . . . . . . . . 2.4 t-105 -61.57 -47.54 85.06 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 115.805 -0.634 . . . . 0.0 111.169 -179.842 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.331 -0.23 0 CA-C-O 120.782 0.325 . . . . 0.0 110.692 179.715 . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.517 0.201 0 N-CA-C 112.781 -0.127 . . . . 0.0 112.781 . . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 33.3 mm-40 -87.28 -20.93 26.13 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.811 0.339 . . . . 0.0 111.015 -179.85 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 34' ' ' ARG . . . . . . . . . . . . . 42.3 ttm180 -53.12 -31.96 44.94 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.596 -179.546 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 15.3 tpp180 -61.64 -44.47 96.92 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 120.836 0.351 . . . . 0.0 110.874 -179.908 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 54.9 m-85 -68.69 -31.04 69.86 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.91 179.978 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 37' ' ' TYR . . . . . 0.423 ' O ' HG23 ' A' ' 41' ' ' VAL . 44.2 m-85 -70.43 -53.6 15.81 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.219 -179.897 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 71.2 t -56.8 -36.4 49.38 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.194 0 CA-C-O 121.008 0.432 . . . . 0.0 110.265 179.615 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 24.0 m -63.89 -47.92 78.71 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 115.673 -0.694 . . . . 0.0 110.296 179.213 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 40' ' ' LEU . . . . . 0.639 HD12 HD12 ' A' ' 43' ' ' ILE . 45.5 tp -58.46 -47.79 82.88 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 115.678 -0.692 . . . . 0.0 110.153 179.493 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 41' ' ' VAL . . . . . 0.423 HG23 ' O ' ' A' ' 37' ' ' TYR . 57.6 t -60.33 -34.57 58.06 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.365 0 CA-C-N 115.645 -0.707 . . . . 0.0 109.804 178.906 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -59.97 -37.09 92.14 Favored Glycine 0 N--CA 1.448 -0.559 0 C-N-CA 120.784 -0.722 . . . . 0.0 111.591 179.479 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 43' ' ' ILE . . . . . 0.639 HD12 HD12 ' A' ' 40' ' ' LEU . 1.3 mt -65.26 -57.98 8.84 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.195 0 CA-C-O 120.833 0.349 . . . . 0.0 110.468 179.391 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 44' ' ' SER . . . . . 0.591 ' HA ' ' SD ' ' A' ' 15' ' ' MET . 64.7 m -57.51 -23.01 47.76 Favored 'General case' 0 C--N 1.332 -0.173 0 CA-C-N 116.037 -0.529 . . . . 0.0 111.71 -179.67 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -76.64 -59.17 3.32 Favored Glycine 0 CA--C 1.52 0.353 0 C-N-CA 120.638 -0.792 . . . . 0.0 112.912 -179.614 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 21.6 pt -58.42 -35.89 56.27 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.239 0 CA-C-O 120.91 0.386 . . . . 0.0 111.263 -179.796 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 47' ' ' ALA . . . . . 0.671 ' HB2' ' HE2' ' A' ' 205' ' ' LYS . . . -67.42 -45.77 75.13 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.309 179.626 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -54.42 -44.77 72.7 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.878 -179.183 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 27.0 m -73.29 -34.2 43.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 N-CA-C 111.845 0.313 . . . . 0.0 111.845 -179.363 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -65.92 -33.95 77.01 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.869 0.366 . . . . 0.0 111.266 -179.785 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 51' ' ' TYR . . . . . 0.436 ' OH ' ' HB2' ' A' ' 201' ' ' ASP . 5.3 m-85 -72.99 -47.03 48.78 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 115.987 -0.551 . . . . 0.0 110.611 -179.943 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -58.81 -44.34 90.8 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 115.652 -0.703 . . . . 0.0 111.812 -179.562 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 53' ' ' VAL . . . . . 0.545 HG23 ' N ' ' A' ' 54' ' ' MET . 34.7 m -69.96 -51.72 37.43 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.183 0 CA-C-N 116.64 -0.254 . . . . 0.0 111.429 -179.549 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 54' ' ' MET . . . . . 0.545 ' N ' HG23 ' A' ' 53' ' ' VAL . 8.3 ttp -59.14 -29.28 67.3 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 121.064 0.459 . . . . 0.0 110.287 -179.964 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 55' ' ' ALA . . . . . 0.559 ' HB2' ' HB2' ' A' ' 8' ' ' PHE . . . -67.74 -32.2 72.65 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 115.703 -0.68 . . . . 0.0 111.329 179.698 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 96.6 mt -79.93 16.66 1.12 Allowed 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.282 -0.417 . . . . 0.0 111.102 -179.875 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 81.15 -4.93 68.82 Favored Glycine 0 N--CA 1.451 -0.365 0 C-N-CA 120.501 -0.857 . . . . 0.0 112.087 -179.656 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 58' ' ' VAL . . . . . 0.426 ' HB ' ' O ' ' A' ' 53' ' ' VAL . 77.0 t -66.25 142.34 16.89 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-O 120.799 0.333 . . . . 0.0 110.779 179.698 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 87.31 -22.28 16.66 Favored Glycine 0 N--CA 1.448 -0.558 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.529 -179.703 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 60' ' ' TRP . . . . . . . . . . . . . 13.5 m0 -60.21 99.22 0.07 Allowed 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 120.745 0.307 . . . . 0.0 110.327 179.823 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 61' ' ' VAL . . . . . 0.483 ' HA ' ' HD3' ' A' ' 62' ' ' PRO . 7.7 p -98.27 129.82 29.77 Favored Pre-proline 0 C--N 1.328 -0.328 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.412 -179.593 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 62' ' ' PRO . . . . . 0.483 ' HD3' ' HA ' ' A' ' 61' ' ' VAL . 12.1 Cg_exo -71.96 136.36 27.24 Favored 'Trans proline' 0 C--N 1.349 0.588 0 C-N-CA 122.628 2.219 . . . . 0.0 112.042 179.824 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 64.6 t -132.13 89.78 1.14 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.396 0 CA-C-N 116.054 -0.521 . . . . 0.0 110.876 -179.94 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . 58.54 -84.54 0.02 OUTLIER 'General case' 0 C--N 1.333 -0.138 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.26 -179.739 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 11.3 pt-20 -124.57 -19.9 5.26 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-O 121.104 0.478 . . . . 0.0 110.351 179.724 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 66' ' ' ARG . . . . . . . . . . . . . 59.3 mtp180 -95.39 166.03 12.08 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 115.576 -0.738 . . . . 0.0 110.676 179.814 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 54.1 m -129.2 122.32 29.5 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.996 179.862 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 15.1 t -111.17 146.27 16.4 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.368 0 CA-C-N 116.082 -0.508 . . . . 0.0 110.929 -179.972 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 69' ' ' PHE . . . . . . . . . . . . . 12.0 m-85 -101.9 112.76 25.49 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.134 -0.484 . . . . 0.0 110.177 -179.803 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 70' ' ' VAL . . . . . 0.567 HG12 ' HD3' ' A' ' 71' ' ' PRO . 0.6 OUTLIER -69.31 -33.35 3.88 Favored Pre-proline 0 CA--C 1.543 0.697 0 N-CA-C 113.089 0.774 . . . . 0.0 113.089 -179.302 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 71' ' ' PRO . . . . . 0.567 ' HD3' HG12 ' A' ' 70' ' ' VAL . 11.3 Cg_exo -69.57 -22.26 33.19 Favored 'Trans proline' 0 C--N 1.357 0.985 0 C-N-CA 121.952 1.768 . . . . 0.0 112.993 -179.073 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 72' ' ' ARG . . . . . 0.483 ' HD2' HG21 ' A' ' 197' ' ' ILE . 50.5 ttp180 -68.6 -55.04 12.88 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.902 0.382 . . . . 0.0 111.663 -179.124 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 73' ' ' TYR . . . . . . . . . . . . . 61.4 m-85 -72.14 -35.06 68.98 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.417 -0.356 . . . . 0.0 110.875 -179.483 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 74' ' ' ILE . . . . . 0.53 HG22 ' HA ' ' A' ' 71' ' ' PRO . 0.3 OUTLIER -65.87 -38.45 82.2 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.189 0 N-CA-C 109.476 -0.564 . . . . 0.0 109.476 179.01 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 17.8 t70 -60.21 -37.64 80.9 Favored 'General case' 0 N--CA 1.453 -0.278 0 N-CA-C 109.147 -0.686 . . . . 0.0 109.147 178.692 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 76' ' ' TRP . . . . . 0.452 ' HZ2' HG23 ' A' ' 197' ' ' ILE . 52.1 m0 -65.7 -34.99 79.47 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 115.681 -0.69 . . . . 0.0 110.345 179.06 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 77' ' ' ILE . . . . . 0.494 HD12 ' HA ' ' A' ' 74' ' ' ILE . 77.4 mt -66.26 -31.84 55.44 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.299 -0.409 . . . . 0.0 110.5 179.504 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 22.3 mt -91.6 -21.47 20.81 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.052 -0.522 . . . . 0.0 112.097 -179.725 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 81.5 p -102.86 -53.25 2.89 Favored 'General case' 0 N--CA 1.463 0.215 0 N-CA-C 113.536 0.939 . . . . 0.0 113.536 -177.924 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 80' ' ' THR . . . . . 0.583 ' HB ' ' HD3' ' A' ' 81' ' ' PRO . 4.9 m -48.57 -53.32 36.85 Favored Pre-proline 0 CA--C 1.53 0.21 0 N-CA-C 112.32 0.489 . . . . 0.0 112.32 -178.223 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 81' ' ' PRO . . . . . 0.583 ' HD3' ' HB ' ' A' ' 80' ' ' THR . 31.6 Cg_exo -61.29 -21.41 71.67 Favored 'Trans proline' 0 C--N 1.351 0.71 0 C-N-CA 121.722 1.615 . . . . 0.0 111.857 179.631 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 82' ' ' LEU . . . . . . . . . . . . . 17.3 tp -76.64 -36.56 57.31 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-N 116.076 -0.511 . . . . 0.0 110.677 -179.983 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 1.9 mp -68.39 -51.92 42.39 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.174 0 CA-C-O 120.803 0.335 . . . . 0.0 110.157 179.094 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 26.6 m -60.18 -31.92 49.29 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.225 0 N-CA-C 109.582 -0.525 . . . . 0.0 109.582 179.026 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 85' ' ' TYR . . . . . . . . . . . . . 74.9 t80 -66.66 -31.27 71.84 Favored 'General case' 0 N--CA 1.452 -0.33 0 CA-C-N 115.698 -0.683 . . . . 0.0 109.372 178.542 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 86' ' ' PHE . . . . . . . . . . . . . 2.0 t80 -62.65 -51.81 65.79 Favored 'General case' 0 C--O 1.231 0.103 0 CA-C-N 115.743 -0.662 . . . . 0.0 109.829 179.061 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 87' ' ' LEU . . . . . 0.405 ' N ' HD12 ' A' ' 87' ' ' LEU . 8.0 mp -63.67 -29.2 70.47 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 115.658 -0.701 . . . . 0.0 110.467 179.556 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -70.53 -28.49 71.0 Favored Glycine 0 N--CA 1.449 -0.465 0 C-N-CA 120.843 -0.694 . . . . 0.0 112.007 179.559 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 79.8 mt -75.32 -42.38 54.64 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-O 120.929 0.395 . . . . 0.0 110.605 179.474 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 72.4 mt -57.71 -32.65 67.6 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 115.887 -0.597 . . . . 0.0 110.766 179.744 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 91' ' ' ALA . . . . . 0.442 ' HB1' ' HB3' ' A' ' 148' ' ' SER . . . -88.9 -34.02 17.1 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.104 -0.498 . . . . 0.0 111.208 179.891 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 84.28 53.77 3.19 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.853 -0.689 . . . . 0.0 112.401 179.926 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 55.0 mt -59.39 162.96 4.31 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 120.897 0.38 . . . . 0.0 111.109 -179.907 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 94' ' ' ASP . . . . . . . . . . . . . 18.4 m-20 -77.17 -178.37 5.02 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.069 -0.514 . . . . 0.0 110.923 179.878 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 50.8 m -63.64 -50.98 67.19 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.083 -0.508 . . . . 0.0 111.197 -179.881 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 14.2 ptm180 -73.65 -35.63 65.29 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.308 -0.405 . . . . 0.0 111.293 -179.596 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 19.9 mm-40 -54.96 -45.68 74.97 Favored 'General case' 0 C--N 1.331 -0.197 0 CA-C-N 116.56 -0.291 . . . . 0.0 110.771 -179.977 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 98' ' ' PHE . . . . . 0.493 ' O ' HG12 ' A' ' 102' ' ' ILE . 10.6 m-85 -60.86 -36.06 78.2 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-O 120.92 0.39 . . . . 0.0 110.272 179.422 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -67.19 -27.53 73.5 Favored Glycine 0 N--CA 1.449 -0.5 0 C-N-CA 120.589 -0.815 . . . . 0.0 112.225 179.511 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 97.0 mt -73.83 -44.88 51.12 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.198 0 N-CA-C 111.855 0.317 . . . . 0.0 111.855 -179.783 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 35.3 m -69.35 -40.78 80.5 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 N-CA-C 112.256 0.465 . . . . 0.0 112.256 -178.806 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 102' ' ' ILE . . . . . 0.493 HG12 ' O ' ' A' ' 98' ' ' PHE . 46.1 mm -68.53 -48.49 71.97 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.697 -0.229 . . . . 0.0 111.456 -179.501 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 14.2 t -60.42 -33.77 72.99 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-O 120.983 0.42 . . . . 0.0 110.645 179.875 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 104' ' ' LEU . . . . . 0.485 HD22 ' HE2' ' A' ' 140' ' ' TYR . 48.4 tp -60.44 -53.56 56.08 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 115.954 -0.567 . . . . 0.0 110.428 179.578 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 105' ' ' ASN . . . . . 0.611 ' N ' HD22 ' A' ' 105' ' ' ASN . 0.8 OUTLIER -61.22 -25.19 66.88 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 115.892 -0.594 . . . . 0.0 110.835 179.845 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 28.6 m -64.31 -54.13 38.02 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.258 179.961 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 107' ' ' VAL . . . . . 0.433 HG12 ' O ' ' A' ' 104' ' ' LEU . 12.5 p -64.85 -36.11 76.84 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.245 0 CA-C-N 116.504 -0.316 . . . . 0.0 111.194 -179.962 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 108' ' ' VAL . . . . . 0.401 HG23 ' O ' ' A' ' 104' ' ' LEU . 92.6 t -64.78 -52.76 50.26 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.246 0 CA-C-O 120.84 0.352 . . . . 0.0 110.89 179.743 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 109' ' ' MET . . . . . 0.547 ' HE1' HG21 ' A' ' 80' ' ' THR . 1.9 tpp -60.06 -32.13 70.65 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.06 -0.518 . . . . 0.0 110.758 179.774 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 36.4 tp -75.21 -30.17 60.52 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 115.974 -0.557 . . . . 0.0 110.261 179.46 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -60.94 -52.4 65.18 Favored 'General case' 0 C--N 1.331 -0.199 0 CA-C-N 116.081 -0.508 . . . . 0.0 110.308 179.337 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . -70.58 -38.43 68.35 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.636 -0.792 . . . . 0.0 111.851 179.268 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 113' ' ' PHE . . . . . . . . . . . . . 1.9 t80 -53.87 -63.21 1.22 Allowed 'General case' 0 C--N 1.332 -0.194 0 CA-C-O 120.849 0.356 . . . . 0.0 110.063 179.349 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 114' ' ' ALA . . . . . 0.413 ' O ' HG13 ' A' ' 118' ' ' VAL . . . -69.62 -17.43 63.52 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.135 178.949 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 115' ' ' GLY . . . . . 0.438 ' HA2' HD22 ' A' ' 126' ' ' LEU . . . -55.48 -52.62 46.69 Favored Glycine 0 C--N 1.333 0.389 0 CA-C-N 115.871 -0.604 . . . . 0.0 112.042 179.545 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 116' ' ' ALA . . . . . 0.61 ' HB2' ' HB3' ' A' ' 183' ' ' PRO . . . -77.41 -14.69 59.65 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-O 120.763 0.316 . . . . 0.0 111.192 -179.962 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 117' ' ' MET . . . . . . . . . . . . . 23.2 mmt -87.24 6.88 30.98 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.284 -0.417 . . . . 0.0 111.947 -179.413 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 118' ' ' VAL . . . . . 0.413 HG13 ' O ' ' A' ' 114' ' ' ALA . 16.5 m -80.43 145.52 59.57 Favored Pre-proline 0 C--N 1.331 -0.206 0 CA-C-O 120.498 0.19 . . . . 0.0 111.322 -179.9 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 119' ' ' PRO . . . . . . . . . . . . . 85.9 Cg_endo -85.14 -6.59 9.33 Favored 'Trans proline' 0 C--N 1.348 0.509 0 C-N-CA 122.689 2.26 . . . . 0.0 112.099 179.51 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -133.17 -143.2 4.96 Favored Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.871 -0.68 . . . . 0.0 112.615 -179.894 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 121' ' ' ILE . . . . . 0.425 ' H ' HG13 ' A' ' 121' ' ' ILE . 2.7 pp -101.31 11.46 7.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-O 120.782 0.325 . . . . 0.0 111.308 -179.908 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 9.9 mm-40 -59.47 -19.08 45.09 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.047 179.975 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 123' ' ' ARG . . . . . 0.463 ' HB2' ' HH2' ' A' ' 178' ' ' TRP . 16.4 ptt180 -52.04 -34.55 43.74 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.037 -0.529 . . . . 0.0 111.538 -179.786 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 124' ' ' TYR . . . . . . . . . . . . . 49.6 m-85 -61.18 -33.13 72.96 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-O 120.748 0.308 . . . . 0.0 110.884 -179.956 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 125' ' ' ALA . . . . . . . . . . . . . . . -72.4 -50.58 25.47 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.278 -0.419 . . . . 0.0 110.666 179.55 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 126' ' ' LEU . . . . . 0.438 HD22 ' HA2' ' A' ' 115' ' ' GLY . 7.3 mp -54.53 -54.22 44.11 Favored 'General case' 0 C--N 1.332 -0.18 0 CA-C-N 116.018 -0.537 . . . . 0.0 110.182 179.726 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 127' ' ' PHE . . . . . . . . . . . . . 8.9 t80 -63.15 -37.08 85.79 Favored 'General case' 0 N--CA 1.451 -0.409 0 CA-C-N 115.973 -0.558 . . . . 0.0 110.784 179.724 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 128' ' ' GLY . . . . . . . . . . . . . . . -46.22 -45.0 15.48 Favored Glycine 0 C--N 1.332 0.306 0 C-N-CA 120.19 -1.005 . . . . 0.0 110.918 179.109 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 129' ' ' MET . . . . . . . . . . . . . 0.4 OUTLIER -69.82 -37.74 76.34 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 115.311 -0.444 . . . . 0.0 109.85 178.646 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -61.99 -34.25 88.29 Favored Glycine 0 C--N 1.332 0.335 0 CA-C-N 115.677 -0.692 . . . . 0.0 112.942 -179.872 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -71.41 -53.77 12.95 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.697 0.284 . . . . 0.0 110.52 179.908 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 38.4 t -56.85 -39.95 68.16 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-O 121.439 0.638 . . . . 0.0 109.38 178.899 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -66.9 -35.37 79.85 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 115.151 -0.931 . . . . 0.0 110.532 179.357 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 134' ' ' PHE . . . . . . . . . . . . . 86.4 t80 -55.37 -55.27 33.53 Favored 'General case' 0 N--CA 1.452 -0.337 0 CA-C-O 121.012 0.434 . . . . 0.0 110.019 179.428 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 135' ' ' ILE . . . . . 0.429 ' O ' HG22 ' A' ' 138' ' ' VAL . 29.6 mt -56.28 -33.95 38.84 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.295 0 CA-C-N 115.761 -0.654 . . . . 0.0 109.913 179.136 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . -61.99 -40.66 99.19 Favored Glycine 0 N--CA 1.448 -0.547 0 C-N-CA 120.299 -0.953 . . . . 0.0 111.321 178.812 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 137' ' ' LEU . . . . . 0.496 HD13 HD21 ' A' ' 105' ' ' ASN . 64.8 tp -69.33 -53.1 21.3 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-O 120.532 0.205 . . . . 0.0 111.04 179.97 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 138' ' ' VAL . . . . . 0.429 HG22 ' O ' ' A' ' 135' ' ' ILE . 4.9 m -55.43 -34.62 34.87 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.167 0 N-CA-C 109.521 -0.548 . . . . 0.0 109.521 179.775 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 139' ' ' TYR . . . . . . . . . . . . . 21.4 t80 -61.58 -40.9 96.4 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 115.454 -0.794 . . . . 0.0 110.403 178.548 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 140' ' ' TYR . . . . . 0.485 ' HE2' HD22 ' A' ' 104' ' ' LEU . 20.9 m-85 -64.89 -52.17 57.97 Favored 'General case' 0 C--N 1.332 -0.189 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.673 -179.848 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 141' ' ' LEU . . . . . 0.516 HD12 ' N ' ' A' ' 142' ' ' VAL . 3.6 pp -64.27 -18.23 64.37 Favored 'General case' 0 N--CA 1.463 0.176 0 N-CA-C 111.74 0.274 . . . . 0.0 111.74 -179.271 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 142' ' ' VAL . . . . . 0.516 ' N ' HD12 ' A' ' 141' ' ' LEU . 5.2 p -109.36 -2.77 10.23 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-O 120.898 0.38 . . . . 0.0 110.924 179.866 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . -99.81 -102.51 2.44 Favored Glycine 0 CA--C 1.522 0.503 0 C-N-CA 120.767 -0.73 . . . . 0.0 113.104 -179.849 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 144' ' ' PRO . . . . . . . . . . . . . 58.2 Cg_endo -70.15 -27.87 24.07 Favored 'Trans proline' 0 C--N 1.348 0.503 0 C-N-CA 122.628 2.219 . . . . 0.0 113.285 -179.313 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 145' ' ' MET . . . . . 0.484 ' SD ' ' HA ' ' A' ' 141' ' ' LEU . 50.7 mtt -62.68 -39.07 92.78 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.669 0.271 . . . . 0.0 111.461 -179.583 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 146' ' ' THR . . . . . . . . . . . . . 67.2 p -66.21 -43.6 86.28 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.456 -0.338 . . . . 0.0 111.448 -179.524 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 39.7 mt-10 -70.45 -33.69 71.58 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.344 -0.389 . . . . 0.0 111.268 -179.651 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 148' ' ' SER . . . . . 0.442 ' HB3' ' HB1' ' A' ' 91' ' ' ALA . 48.0 t -70.34 -44.55 67.94 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.357 -0.383 . . . . 0.0 111.464 -179.485 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 149' ' ' ALA . . . . . . . . . . . . . . . -73.74 -33.94 64.54 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.339 -0.391 . . . . 0.0 111.399 -179.699 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 150' ' ' SER . . . . . 0.445 ' HB2' ' NZ ' ' A' ' 157' ' ' LYS . 81.0 p -67.33 -5.76 15.74 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 121.007 0.432 . . . . 0.0 110.657 179.783 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 151' ' ' GLN . . . . . . . . . . . . . 74.0 mt-30 -110.3 5.28 21.55 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 115.899 -0.591 . . . . 0.0 111.336 -179.812 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 31.2 ttt180 -91.8 -52.64 4.64 Favored 'General case' 0 C--N 1.331 -0.23 0 C-N-CA 120.902 -0.319 . . . . 0.0 111.213 -179.895 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 153' ' ' SER . . . . . 0.674 ' HB3' HG12 ' A' ' 156' ' ' ILE . 20.5 t -157.67 172.44 18.52 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.444 -0.344 . . . . 0.0 111.002 179.327 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 154' ' ' SER . . . . . . . . . . . . . 72.6 p -73.41 -41.7 62.98 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.705 179.576 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -72.64 -29.59 65.37 Favored Glycine 0 N--CA 1.452 -0.288 0 C-N-CA 120.804 -0.712 . . . . 0.0 112.334 179.88 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 156' ' ' ILE . . . . . 0.674 HG12 ' HB3' ' A' ' 153' ' ' SER . 34.6 mm -58.99 -38.45 73.86 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-O 120.84 0.352 . . . . 0.0 111.066 179.862 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 157' ' ' LYS . . . . . 0.445 ' NZ ' ' HB2' ' A' ' 150' ' ' SER . 21.3 ttmm -65.06 -47.86 75.82 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.129 -0.487 . . . . 0.0 111.085 179.811 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 69.1 m -60.65 -43.3 97.74 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 115.981 -0.554 . . . . 0.0 111.69 -179.042 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 159' ' ' LEU . . . . . 0.767 ' HG ' HD11 ' A' ' 163' ' ' LEU . 3.7 tp -66.5 -58.59 4.9 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-O 120.943 0.401 . . . . 0.0 110.66 -179.861 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 160' ' ' TYR . . . . . . . . . . . . . 30.1 t80 -51.14 -36.23 39.68 Favored 'General case' 0 C--N 1.326 -0.416 0 N-CA-C 113.302 0.853 . . . . 0.0 113.302 -178.13 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 161' ' ' VAL . . . . . 0.423 HG23 ' N ' ' A' ' 162' ' ' ARG . 30.7 m -73.27 -47.04 48.25 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.373 0 N-CA-C 112.159 0.429 . . . . 0.0 112.159 -177.791 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 162' ' ' ARG . . . . . 0.423 ' N ' HG23 ' A' ' 161' ' ' VAL . 24.2 ttm180 -63.68 -41.23 98.18 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-O 120.953 0.406 . . . . 0.0 111.014 -179.701 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 163' ' ' LEU . . . . . 0.767 HD11 ' HG ' ' A' ' 159' ' ' LEU . 6.6 mt -70.38 -50.34 39.76 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 115.89 -0.595 . . . . 0.0 111.712 -179.197 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 164' ' ' ARG . . . . . 0.484 ' HG3' ' N ' ' A' ' 165' ' ' ASN . 0.4 OUTLIER -58.14 -40.96 82.69 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.517 -0.31 . . . . 0.0 110.917 -178.986 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 165' ' ' ASN . . . . . 0.484 ' N ' ' HG3' ' A' ' 164' ' ' ARG . 5.3 m-20 -58.46 -51.34 70.28 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-O 120.832 0.349 . . . . 0.0 110.295 179.545 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 166' ' ' LEU . . . . . 0.513 ' O ' ' HG ' ' A' ' 170' ' ' LEU . 2.3 tt -59.39 -54.74 43.25 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 115.93 -0.577 . . . . 0.0 111.712 -179.931 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 167' ' ' THR . . . . . 0.456 ' N ' HD23 ' A' ' 166' ' ' LEU . 52.6 m -55.08 -53.03 61.12 Favored 'General case' 0 C--N 1.33 -0.245 0 N-CA-C 112.773 0.657 . . . . 0.0 112.773 -178.398 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 168' ' ' VAL . . . . . 0.417 HG23 ' O ' ' A' ' 164' ' ' ARG . 75.4 t -53.96 -42.23 53.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 N-CA-C 112.329 0.492 . . . . 0.0 112.329 -179.004 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 169' ' ' VAL . . . . . 0.479 HG23 ' O ' ' A' ' 165' ' ' ASN . 72.7 t -60.93 -64.74 0.57 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 N-CA-C 112.124 0.416 . . . . 0.0 112.124 -179.225 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 170' ' ' LEU . . . . . 0.513 ' HG ' ' O ' ' A' ' 166' ' ' LEU . 0.4 OUTLIER -61.92 -34.12 75.49 Favored 'General case' 0 N--CA 1.465 0.276 0 N-CA-C 112.354 0.502 . . . . 0.0 112.354 -178.815 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 171' ' ' TRP . . . . . 0.42 ' HA ' ' HD2' ' A' ' 174' ' ' TYR . 6.1 m0 -68.06 -29.56 68.56 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-O 120.792 0.33 . . . . 0.0 110.634 179.629 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 172' ' ' ALA . . . . . . . . . . . . . . . -73.92 -7.12 51.14 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.759 179.781 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 173' ' ' ILE . . . . . 0.49 ' O ' HG12 ' A' ' 177' ' ' ILE . 28.8 mm -87.68 -21.46 7.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 115.839 -0.619 . . . . 0.0 110.526 179.476 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 174' ' ' TYR . . . . . 0.42 ' HD2' ' HA ' ' A' ' 171' ' ' TRP . 8.2 m-85 -53.84 -48.38 93.81 Favored Pre-proline 0 CA--C 1.528 0.105 0 CA-C-N 116.055 -0.52 . . . . 0.0 111.681 -179.567 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 175' ' ' PRO . . . . . 0.403 ' CD ' ' N ' ' A' ' 174' ' ' TYR . 83.2 Cg_exo -46.65 -32.15 11.38 Favored 'Trans proline' 0 C--N 1.351 0.667 0 C-N-CA 121.831 1.687 . . . . 0.0 111.95 179.358 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 176' ' ' PHE . . . . . 0.433 ' O ' ' HG ' ' A' ' 180' ' ' LEU . 84.3 m-85 -81.1 -49.79 10.43 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 115.697 -0.683 . . . . 0.0 111.799 179.867 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 177' ' ' ILE . . . . . 0.49 HG12 ' O ' ' A' ' 173' ' ' ILE . 8.5 mm -61.01 -38.83 80.36 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.498 0 N-CA-C 112.708 0.633 . . . . 0.0 112.708 -177.896 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 178' ' ' TRP . . . . . 0.463 ' HH2' ' HB2' ' A' ' 123' ' ' ARG . 78.5 t90 -71.58 -51.88 21.05 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.79 0.328 . . . . 0.0 111.213 -179.735 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 179' ' ' LEU . . . . . 0.55 HD23 HD23 ' A' ' 180' ' ' LEU . 0.6 OUTLIER -64.55 -55.08 22.82 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.323 -0.399 . . . . 0.0 111.601 -178.997 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 180' ' ' LEU . . . . . 0.55 HD23 HD23 ' A' ' 179' ' ' LEU . 32.4 mt -65.96 -37.64 86.52 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 116.341 -0.39 . . . . 0.0 111.345 -179.332 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . -60.53 176.15 4.25 Favored Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 119.988 -1.101 . . . . 0.0 112.33 179.589 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 182' ' ' PRO . . . . . 0.555 ' HA ' ' HB2' ' A' ' 186' ' ' ALA . 88.3 Cg_exo -46.63 -44.97 20.69 Favored 'Trans proline' 0 CA--C 1.536 0.607 0 C-N-CA 122.681 2.254 . . . . 0.0 113.402 179.912 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 183' ' ' PRO . . . . . 0.61 ' HB3' ' HB2' ' A' ' 116' ' ' ALA . 97.3 Cg_exo -45.31 -35.25 11.23 Favored 'Trans proline' 0 C--N 1.356 0.926 0 C-N-CA 122.328 2.019 . . . . 0.0 113.439 179.89 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 184' ' ' GLY . . . . . . . . . . . . . . . -110.29 -123.23 4.52 Favored Glycine 0 C--N 1.332 0.344 0 C-N-CA 120.299 -0.953 . . . . 0.0 113.204 -179.453 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 185' ' ' VAL . . . . . . . . . . . . . 8.1 m -63.04 -26.93 42.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 N-CA-C 112.16 0.43 . . . . 0.0 112.16 -179.225 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 186' ' ' ALA . . . . . 0.555 ' HB2' ' HA ' ' A' ' 182' ' ' PRO . . . 60.25 81.05 0.19 Allowed 'General case' 0 C--N 1.331 -0.207 0 N-CA-C 111.858 0.318 . . . . 0.0 111.858 179.48 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 187' ' ' LEU . . . . . . . . . . . . . 6.9 mt -92.8 -49.78 5.9 Favored 'General case' 0 C--N 1.332 -0.156 0 CA-C-O 120.995 0.426 . . . . 0.0 111.012 179.587 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 188' ' ' LEU . . . . . . . . . . . . . 95.2 mt -89.32 -166.7 1.66 Allowed 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 115.795 -0.639 . . . . 0.0 111.247 -179.48 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 189' ' ' THR . . . . . 0.429 HG22 ' H ' ' A' ' 191' ' ' THR . 74.9 m -94.08 136.13 23.95 Favored Pre-proline 0 C--N 1.328 -0.357 0 CA-C-N 115.781 -0.645 . . . . 0.0 110.626 -179.811 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 190' ' ' PRO . . . . . . . . . . . . . 2.4 Cg_endo -44.99 -38.58 13.66 Favored 'Trans proline' 0 C--N 1.35 0.61 0 C-N-CA 122.854 2.369 . . . . 0.0 112.649 -179.983 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 191' ' ' THR . . . . . 0.429 ' H ' HG22 ' A' ' 189' ' ' THR . 71.2 p -61.98 -42.95 99.7 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-O 120.965 0.412 . . . . 0.0 110.911 179.711 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 192' ' ' VAL . . . . . . . . . . . . . 88.8 t -71.29 -53.54 20.7 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 115.92 -0.582 . . . . 0.0 111.434 -179.816 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 193' ' ' ASP . . . . . . . . . . . . . 29.3 t70 -54.49 -52.01 63.28 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.242 -0.436 . . . . 0.0 111.442 -179.396 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 194' ' ' VAL . . . . . 0.531 ' O ' HG22 ' A' ' 198' ' ' VAL . 71.1 t -59.23 -38.22 73.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.371 -0.377 . . . . 0.0 110.614 -179.874 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 195' ' ' ALA . . . . . . . . . . . . . . . -55.22 -44.86 75.8 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.754 179.605 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 196' ' ' LEU . . . . . . . . . . . . . 95.6 mt -68.36 -35.86 78.35 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.934 179.461 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 197' ' ' ILE . . . . . 0.483 HG21 ' HD2' ' A' ' 72' ' ' ARG . 11.0 mm -59.49 -61.09 1.61 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.06 -0.518 . . . . 0.0 110.874 179.96 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 198' ' ' VAL . . . . . 0.531 HG22 ' O ' ' A' ' 194' ' ' VAL . 1.4 m -55.74 -35.0 37.83 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.462 0 CA-C-O 121.626 0.727 . . . . 0.0 109.191 178.772 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 199' ' ' TYR . . . . . . . . . . . . . 86.7 t80 -64.04 -32.5 74.07 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-N 114.56 -1.2 . . . . 0.0 110.415 179.336 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 200' ' ' LEU . . . . . 0.444 HD11 HG13 ' A' ' 177' ' ' ILE . 38.1 mt -71.11 -37.78 72.36 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 115.99 -0.55 . . . . 0.0 110.648 179.591 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 201' ' ' ASP . . . . . 0.436 ' HB2' ' OH ' ' A' ' 51' ' ' TYR . 7.9 m-20 -74.58 -32.98 62.55 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 115.953 -0.567 . . . . 0.0 110.161 179.63 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 202' ' ' LEU . . . . . 0.4 HD21 ' O ' ' A' ' 11' ' ' GLY . 0.5 OUTLIER -72.52 -28.45 62.87 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 115.29 -0.868 . . . . 0.0 111.623 -179.527 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 203' ' ' VAL . . . . . 0.425 HG12 ' O ' ' A' ' 200' ' ' LEU . 9.6 p -82.17 -37.78 14.99 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.18 0 N-CA-C 111.946 0.35 . . . . 0.0 111.946 -178.805 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 204' ' ' THR . . . . . . . . . . . . . 86.5 m -69.6 -41.87 75.16 Favored 'General case' 0 C--N 1.328 -0.337 0 C-N-CA 120.821 -0.352 . . . . 0.0 111.569 179.93 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 205' ' ' LYS . . . . . 0.671 ' HE2' ' HB2' ' A' ' 47' ' ' ALA . 59.7 mttp -76.52 -57.93 3.58 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.398 -0.365 . . . . 0.0 111.557 -178.872 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 60.4 t -69.47 -36.83 73.34 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.372 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.471 -179.503 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 207' ' ' GLY . . . . . . . . . . . . . . . -66.44 -52.76 32.87 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.615 -0.802 . . . . 0.0 112.43 -179.326 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 208' ' ' PHE . . . . . 0.689 ' CZ ' HD13 ' A' ' 163' ' ' LEU . 11.3 t80 -55.21 -49.86 70.87 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-O 120.748 0.309 . . . . 0.0 110.941 179.771 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 209' ' ' GLY . . . . . 0.477 ' CA ' HD21 ' A' ' 40' ' ' LEU . . . -63.64 -37.46 94.77 Favored Glycine 0 N--CA 1.451 -0.339 0 CA-C-N 115.632 -0.713 . . . . 0.0 113.985 -179.184 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 210' ' ' PHE . . . . . . . . . . . . . 0.6 OUTLIER -68.65 -46.66 68.57 Favored 'General case' 0 CA--C 1.512 -0.484 0 N-CA-C 108.217 -1.031 . . . . 0.0 108.217 179.272 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 211' ' ' ILE . . . . . . . . . . . . . 92.8 mt -64.9 -28.21 44.26 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.702 0 N-CA-C 107.694 -1.224 . . . . 0.0 107.694 176.656 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 212' ' ' ALA . . . . . 0.474 ' HB3' ' HA2' ' A' ' 209' ' ' GLY . . . -68.29 -45.71 72.33 Favored 'General case' 0 N--CA 1.449 -0.492 0 CA-C-N 114.419 -1.264 . . . . 0.0 111.087 -179.851 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 213' ' ' LEU . . . . . . . . . . . . . 92.8 mt -70.55 -55.32 9.16 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-N 115.442 -0.799 . . . . 0.0 112.415 -178.828 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 214' ' ' ASP . . . . . . . . . . . . . 31.9 m-20 -53.11 -52.1 59.76 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.713 0.292 . . . . 0.0 111.607 -179.295 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 215' ' ' ALA . . . . . . . . . . . . . . . -62.14 -57.77 10.29 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 116.339 -0.391 . . . . 0.0 111.691 -179.438 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 216' ' ' ALA . . . . . . . . . . . . . . . -56.4 -34.85 67.11 Favored 'General case' 0 C--N 1.332 -0.188 0 CA-C-N 116.469 -0.332 . . . . 0.0 111.469 -179.537 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 217' ' ' ALA . . . . . . . . . . . . . . . -60.55 -40.7 92.55 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-O 121.048 0.452 . . . . 0.0 110.082 179.703 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 218' ' ' THR . . . . . . . . . . . . . 95.9 m . . . . . 0 C--N 1.33 -0.253 0 CA-C-N 115.659 -0.7 . . . . 0.0 110.71 179.331 . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.368 0 N-CA-C 112.582 -0.207 . . . . 0.0 112.582 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 4' ' ' LEU . . . . . 0.443 ' HA ' HD23 ' A' ' 7' ' ' LEU . 92.7 mt -74.04 -35.25 64.3 Favored 'General case' 0 N--CA 1.449 -0.508 0 CA-C-O 120.858 0.361 . . . . 0.0 110.94 179.88 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 55.1 p -54.44 -38.84 66.76 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 115.928 -0.578 . . . . 0.0 111.718 -179.587 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 72.0 p -54.81 -35.52 63.98 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.451 -0.34 . . . . 0.0 111.619 -179.578 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 7' ' ' LEU . . . . . 0.443 HD23 ' HA ' ' A' ' 4' ' ' LEU . 3.9 mm? -60.14 -53.29 59.45 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.317 -0.401 . . . . 0.0 111.272 -179.748 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 8' ' ' PHE . . . . . 0.604 ' HB2' ' HB2' ' A' ' 55' ' ' ALA . 75.8 m-85 -64.17 -34.53 78.29 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.994 -179.645 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 9' ' ' TRP . . . . . . . . . . . . . 21.5 m95 -62.34 -46.17 89.88 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-O 121.074 0.464 . . . . 0.0 109.835 179.939 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 41.9 mt -63.11 -35.88 81.75 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 115.629 -0.714 . . . . 0.0 110.154 179.138 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -69.66 -28.85 71.71 Favored Glycine 0 N--CA 1.448 -0.545 0 CA-C-N 115.643 -0.708 . . . . 0.0 111.784 179.419 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -73.71 -30.8 63.05 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-O 120.896 0.379 . . . . 0.0 110.473 179.526 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 13' ' ' ILE . . . . . 0.42 ' O ' HG23 ' A' ' 17' ' ' VAL . 50.2 mm -68.39 -54.33 22.36 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.124 0 CA-C-N 116.058 -0.519 . . . . 0.0 110.442 179.221 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -61.42 -37.39 94.02 Favored Glycine 0 N--CA 1.448 -0.534 0 C-N-CA 120.661 -0.781 . . . . 0.0 111.744 179.43 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 15' ' ' MET . . . . . 0.524 ' SD ' ' HA ' ' A' ' 44' ' ' SER . 55.5 tpp -63.65 -44.36 94.04 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.845 0.355 . . . . 0.0 110.44 179.527 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 16' ' ' LEU . . . . . 0.429 HD13 ' O ' ' A' ' 16' ' ' LEU . 0.4 OUTLIER -54.82 -42.13 71.5 Favored 'General case' 0 C--N 1.332 -0.187 0 CA-C-N 115.943 -0.572 . . . . 0.0 110.02 179.291 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 17' ' ' VAL . . . . . 0.42 HG23 ' O ' ' A' ' 13' ' ' ILE . 45.0 t -58.94 -44.55 91.19 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.188 0 CA-C-N 116.011 -0.54 . . . . 0.0 110.328 179.404 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -64.45 -40.44 97.74 Favored Glycine 0 C--N 1.332 0.337 0 C-N-CA 120.852 -0.689 . . . . 0.0 111.726 179.124 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 11.8 m -53.45 -48.18 69.05 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-O 120.839 0.352 . . . . 0.0 110.988 -179.943 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 97.2 mt -71.75 -36.13 70.33 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.513 -179.977 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -58.14 -38.01 75.75 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 116.528 -0.305 . . . . 0.0 111.586 -179.761 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 22' ' ' PHE . . . . . 0.606 ' HB2' HG22 ' A' ' 41' ' ' VAL . 4.0 m-85 -90.91 -28.22 18.24 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.347 -0.388 . . . . 0.0 111.394 -179.457 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -69.81 -50.8 39.43 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.961 0.41 . . . . 0.0 111.503 -179.444 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 24' ' ' TRP . . . . . . . . . . . . . 5.5 t-105 -66.19 -43.26 87.34 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 115.842 -0.617 . . . . 0.0 111.111 -179.659 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.329 -0.316 0 CA-C-O 120.94 0.4 . . . . 0.0 110.866 179.799 . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.363 0 N-CA-C 112.472 -0.251 . . . . 0.0 112.472 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 16.3 mm-40 -83.57 -21.68 32.56 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 120.689 0.28 . . . . 0.0 110.994 179.929 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 34' ' ' ARG . . . . . . . . . . . . . 60.1 ttp180 -52.11 -30.5 26.54 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-N 116.158 -0.473 . . . . 0.0 111.252 -179.645 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 80.2 ttt180 -61.28 -42.55 98.83 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.871 0.367 . . . . 0.0 110.761 179.879 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 66.4 m-85 -70.75 -30.47 66.99 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.054 -0.521 . . . . 0.0 110.925 179.941 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 37' ' ' TYR . . . . . 0.502 ' O ' HG23 ' A' ' 41' ' ' VAL . 59.2 m-85 -72.37 -56.13 5.96 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.324 -179.44 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 52.1 t -57.05 -37.4 54.94 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.189 0 CA-C-O 120.955 0.407 . . . . 0.0 110.766 -179.826 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 33.8 m -60.73 -51.01 71.19 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 115.863 -0.608 . . . . 0.0 110.628 179.521 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 40' ' ' LEU . . . . . 0.61 HD12 HD12 ' A' ' 43' ' ' ILE . 66.0 tp -60.86 -46.89 88.79 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 115.838 -0.619 . . . . 0.0 110.63 179.694 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 41' ' ' VAL . . . . . 0.606 HG22 ' HB2' ' A' ' 22' ' ' PHE . 90.0 t -56.7 -35.24 44.96 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.242 0 CA-C-N 115.884 -0.598 . . . . 0.0 110.041 179.289 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -61.74 -40.95 99.49 Favored Glycine 0 N--CA 1.448 -0.527 0 C-N-CA 120.673 -0.775 . . . . 0.0 111.504 179.175 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 43' ' ' ILE . . . . . 0.61 HD12 HD12 ' A' ' 40' ' ' LEU . 18.7 mt -57.46 -56.62 14.2 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.22 0 CA-C-O 120.76 0.314 . . . . 0.0 110.933 179.318 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 44' ' ' SER . . . . . 0.524 ' HA ' ' SD ' ' A' ' 15' ' ' MET . 49.7 m -58.71 -26.35 63.82 Favored 'General case' 0 C--N 1.332 -0.182 0 CA-C-N 116.315 -0.402 . . . . 0.0 111.482 -179.696 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -73.53 -53.99 7.05 Favored Glycine 0 CA--C 1.518 0.229 0 C-N-CA 120.681 -0.771 . . . . 0.0 112.879 -179.625 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 19.6 pt -61.18 -38.38 79.59 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.222 0 CA-C-O 120.871 0.367 . . . . 0.0 111.377 -179.712 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 47' ' ' ALA . . . . . 0.665 ' HB2' ' HE2' ' A' ' 205' ' ' LYS . . . -67.71 -43.21 80.57 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.814 0.34 . . . . 0.0 111.002 179.602 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -54.75 -46.71 74.36 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 115.947 -0.569 . . . . 0.0 111.754 -179.531 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 31.4 m -68.59 -34.19 63.89 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.241 0 CA-C-N 116.527 -0.306 . . . . 0.0 111.275 -179.595 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -66.01 -37.07 84.98 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-O 120.884 0.373 . . . . 0.0 111.005 179.638 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 51' ' ' TYR . . . . . 0.433 ' CE1' HG13 ' A' ' 198' ' ' VAL . 26.7 m-85 -68.75 -38.75 80.34 Favored 'General case' 0 C--N 1.327 -0.413 0 CA-C-O 121.117 0.484 . . . . 0.0 110.084 179.772 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -65.29 -45.09 85.84 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 115.635 -0.712 . . . . 0.0 111.314 179.676 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 53' ' ' VAL . . . . . 0.466 HG23 ' N ' ' A' ' 54' ' ' MET . 27.6 m -67.76 -46.5 82.36 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.139 0 CA-C-O 120.794 0.33 . . . . 0.0 110.621 179.886 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 54' ' ' MET . . . . . 0.498 ' HG2' ' HG2' ' A' ' 71' ' ' PRO . 72.0 mtm -62.27 -30.44 71.12 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 121.156 0.503 . . . . 0.0 109.854 179.111 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 55' ' ' ALA . . . . . 0.604 ' HB2' ' HB2' ' A' ' 8' ' ' PHE . . . -74.28 -30.53 62.14 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 115.601 -0.727 . . . . 0.0 111.355 179.797 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 76.3 mt -77.37 -9.74 59.03 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.457 -0.338 . . . . 0.0 111.214 -179.764 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 95.31 -11.93 68.48 Favored Glycine 0 N--CA 1.452 -0.254 0 C-N-CA 120.666 -0.778 . . . . 0.0 113.017 179.729 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 8.8 p -74.29 140.58 17.38 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-O 120.846 0.355 . . . . 0.0 110.885 -179.97 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 59' ' ' GLY . . . . . 0.465 ' HA3' ' HG3' ' A' ' 71' ' ' PRO . . . 101.29 -9.71 57.76 Favored Glycine 0 N--CA 1.45 -0.377 0 C-N-CA 120.907 -0.663 . . . . 0.0 112.286 -179.715 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 60' ' ' TRP . . . . . . . . . . . . . 15.8 m0 -76.32 118.08 18.66 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-O 120.579 0.228 . . . . 0.0 110.393 179.67 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 61' ' ' VAL . . . . . 0.483 ' HA ' ' HD3' ' A' ' 62' ' ' PRO . 7.5 p -113.26 127.63 26.61 Favored Pre-proline 0 CA--C 1.533 0.321 0 CA-C-N 116.582 -0.281 . . . . 0.0 111.716 -179.603 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 62' ' ' PRO . . . . . 0.483 ' HD3' ' HA ' ' A' ' 61' ' ' VAL . 6.8 Cg_exo -74.03 146.61 37.25 Favored 'Trans proline' 0 C--N 1.351 0.685 0 C-N-CA 122.88 2.386 . . . . 0.0 112.159 179.518 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 75.5 t -139.71 90.42 0.6 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.044 179.859 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . 59.16 -86.12 0.02 OUTLIER 'General case' 0 C--N 1.331 -0.196 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.463 179.891 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 9.7 tp10 -122.42 -19.98 6.24 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 121.011 0.434 . . . . 0.0 110.653 -179.991 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 66' ' ' ARG . . . . . 0.418 HH22 HH12 ' A' ' 123' ' ' ARG . 18.4 ptp180 -100.76 165.82 11.18 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 115.893 -0.594 . . . . 0.0 110.373 179.878 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 26.3 m -125.42 139.66 53.46 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.886 0.374 . . . . 0.0 111.3 -179.838 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 21.5 t -124.17 146.57 29.46 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.238 0 CA-C-N 115.972 -0.558 . . . . 0.0 110.583 179.887 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 69' ' ' PHE . . . . . . . . . . . . . 27.5 m-85 -109.37 111.05 22.39 Favored 'General case' 0 C--N 1.331 -0.206 0 CA-C-N 116.41 -0.359 . . . . 0.0 110.062 -179.629 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 70' ' ' VAL . . . . . 0.599 ' N ' ' HD2' ' A' ' 71' ' ' PRO . 47.4 t -70.02 -49.82 18.15 Favored Pre-proline 0 C--N 1.325 -0.471 0 N-CA-C 112.759 0.651 . . . . 0.0 112.759 -179.186 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 71' ' ' PRO . . . . . 0.599 ' HD2' ' N ' ' A' ' 70' ' ' VAL . 11.3 Cg_endo -54.03 -19.12 14.94 Favored 'Trans proline' 0 C--N 1.352 0.739 0 C-N-CA 122.031 1.82 . . . . 0.0 112.339 -179.616 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 72' ' ' ARG . . . . . 0.517 ' HE ' HG21 ' A' ' 197' ' ' ILE . 32.1 ttt180 -77.02 -53.49 7.74 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.596 179.605 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 73' ' ' TYR . . . . . 0.423 ' O ' HG13 ' A' ' 77' ' ' ILE . 79.9 m-85 -66.37 -39.41 89.08 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 115.816 -0.629 . . . . 0.0 110.922 -179.811 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 0.3 OUTLIER -67.4 -36.35 76.24 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-N 116.348 -0.387 . . . . 0.0 110.043 179.504 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 12.6 t70 -61.02 -37.37 82.32 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.235 -0.439 . . . . 0.0 109.951 179.253 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 76' ' ' TRP . . . . . . . . . . . . . 48.6 m0 -66.3 -36.21 82.36 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 115.927 -0.579 . . . . 0.0 110.067 179.414 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 77' ' ' ILE . . . . . 0.5 ' O ' ' HG2' ' A' ' 81' ' ' PRO . 68.3 mt -66.54 -30.07 48.55 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.364 0 CA-C-N 115.959 -0.564 . . . . 0.0 110.91 179.511 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 53.4 mt -91.91 -21.95 20.32 Favored 'General case' 0 C--N 1.328 -0.347 0 N-CA-C 112.511 0.56 . . . . 0.0 112.511 -179.644 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 79' ' ' THR . . . . . 0.401 ' HB ' ' HE3' ' A' ' 205' ' ' LYS . 70.0 p -100.27 -52.0 3.5 Favored 'General case' 0 N--CA 1.464 0.269 0 N-CA-C 113.619 0.97 . . . . 0.0 113.619 -177.792 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 80' ' ' THR . . . . . 0.675 ' HB ' ' HD3' ' A' ' 81' ' ' PRO . 86.3 m -51.35 -55.35 29.65 Favored Pre-proline 0 CA--C 1.532 0.271 0 N-CA-C 112.421 0.526 . . . . 0.0 112.421 -178.502 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 81' ' ' PRO . . . . . 0.675 ' HD3' ' HB ' ' A' ' 80' ' ' THR . 52.0 Cg_exo -56.49 -20.13 32.13 Favored 'Trans proline' 0 C--N 1.352 0.762 0 C-N-CA 121.542 1.495 . . . . 0.0 111.481 179.574 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 82' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -76.63 -38.2 55.08 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 115.716 -0.675 . . . . 0.0 110.223 179.552 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 83' ' ' ILE . . . . . 0.486 HD13 HD13 ' A' ' 43' ' ' ILE . 16.7 mm -66.17 -51.24 61.68 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.16 0 CA-C-N 116.004 -0.543 . . . . 0.0 110.293 179.516 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 31.0 m -61.49 -31.76 51.48 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.166 0 N-CA-C 109.71 -0.478 . . . . 0.0 109.71 178.962 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 85' ' ' TYR . . . . . . . . . . . . . 83.4 t80 -66.48 -31.94 72.99 Favored 'General case' 0 N--CA 1.454 -0.249 0 CA-C-N 115.656 -0.702 . . . . 0.0 109.569 178.763 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 86' ' ' PHE . . . . . . . . . . . . . 11.5 t80 -63.69 -50.84 67.6 Favored 'General case' 0 C--O 1.233 0.185 0 CA-C-N 115.889 -0.596 . . . . 0.0 109.793 179.179 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 3.1 mt -61.02 -35.5 77.02 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 115.786 -0.643 . . . . 0.0 109.714 179.537 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -67.08 -28.14 73.68 Favored Glycine 0 N--CA 1.45 -0.393 0 CA-C-N 115.28 -0.873 . . . . 0.0 111.865 179.49 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 50.0 mt -72.59 -37.36 68.15 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.893 0.378 . . . . 0.0 110.277 179.534 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 41.5 mt -60.4 -50.6 72.96 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 115.741 -0.663 . . . . 0.0 110.73 179.617 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 91' ' ' ALA . . . . . 0.498 ' HB1' ' HB2' ' A' ' 148' ' ' SER . . . -71.52 -48.57 47.98 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 115.981 -0.554 . . . . 0.0 111.374 -179.815 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 96.88 62.66 0.93 Allowed Glycine 0 N--CA 1.452 -0.271 0 C-N-CA 120.764 -0.731 . . . . 0.0 112.399 -179.902 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 93' ' ' LEU . . . . . 0.587 HD23 ' HB3' ' A' ' 97' ' ' GLU . 7.1 mp -77.08 175.09 9.94 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.782 0.325 . . . . 0.0 110.868 -179.958 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 94' ' ' ASP . . . . . . . . . . . . . 13.0 m-20 -91.23 172.82 8.28 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.827 179.708 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 78.5 p -60.04 -36.55 77.52 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.246 -0.434 . . . . 0.0 111.09 -179.848 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 15.9 ptm180 -73.89 -43.54 58.16 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.06 -179.965 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 97' ' ' GLU . . . . . 0.587 ' HB3' HD23 ' A' ' 93' ' ' LEU . 37.1 mt-10 -57.59 -46.49 83.97 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.384 -0.371 . . . . 0.0 110.764 -179.926 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 98' ' ' PHE . . . . . . . . . . . . . 21.4 m-85 -60.25 -41.29 92.9 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.361 179.53 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -58.73 -32.55 69.91 Favored Glycine 0 N--CA 1.449 -0.469 0 C-N-CA 120.687 -0.768 . . . . 0.0 112.265 179.75 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 86.7 mt -73.51 -44.54 53.6 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-O 120.747 0.308 . . . . 0.0 111.675 -179.83 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 35.3 t -68.46 -48.8 70.77 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 CA-C-N 116.318 -0.401 . . . . 0.0 111.76 -179.252 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 102' ' ' ILE . . . . . 0.558 HG23 ' HB3' ' A' ' 81' ' ' PRO . 48.2 mm -63.56 -45.87 96.5 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.379 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.868 -179.357 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 6.0 t -62.02 -33.67 74.79 Favored 'General case' 0 C--N 1.332 -0.192 0 CA-C-O 120.867 0.365 . . . . 0.0 110.759 -179.813 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 104' ' ' LEU . . . . . 0.416 HD22 ' HE2' ' A' ' 140' ' ' TYR . 48.5 tp -60.17 -53.28 59.59 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.221 179.348 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 105' ' ' ASN . . . . . 0.577 ' N ' HD22 ' A' ' 105' ' ' ASN . 0.8 OUTLIER -56.26 -31.31 63.47 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.063 -0.517 . . . . 0.0 110.115 179.38 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 24.8 m -61.88 -38.75 89.47 Favored 'General case' 0 C--N 1.332 -0.179 0 CA-C-N 116.038 -0.528 . . . . 0.0 109.996 179.078 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 107' ' ' VAL . . . . . 0.419 ' H ' HG23 ' A' ' 107' ' ' VAL . 1.8 t -70.35 -41.21 78.45 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.198 0 CA-C-N 116.051 -0.522 . . . . 0.0 109.964 178.97 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 54.0 t -57.22 -47.19 84.62 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 115.367 -0.833 . . . . 0.0 111.23 179.885 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 109' ' ' MET . . . . . 0.418 ' O ' ' HB2' ' A' ' 113' ' ' PHE . 21.5 mmt -69.27 -32.31 71.41 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.017 -0.538 . . . . 0.0 111.124 -179.714 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 27.8 tp -65.3 -33.28 75.6 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-O 120.964 0.411 . . . . 0.0 110.324 179.793 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -68.82 -53.84 19.24 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 115.855 -0.611 . . . . 0.0 110.743 179.465 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . -63.09 -35.62 92.33 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.652 -0.785 . . . . 0.0 112.135 179.642 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 113' ' ' PHE . . . . . 0.47 ' HZ ' HG13 ' A' ' 70' ' ' VAL . 0.7 OUTLIER -55.63 -65.31 0.61 Allowed 'General case' 0 C--N 1.33 -0.255 0 CA-C-O 121.066 0.46 . . . . 0.0 110.249 179.6 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 114' ' ' ALA . . . . . 0.576 ' HB3' HD22 ' A' ' 126' ' ' LEU . . . -66.09 -22.55 66.41 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 115.722 -0.672 . . . . 0.0 110.951 179.816 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -55.8 -48.96 68.71 Favored Glycine 0 C--N 1.333 0.392 0 C-N-CA 120.659 -0.781 . . . . 0.0 111.85 179.401 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -78.32 -15.03 59.14 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-O 120.836 0.35 . . . . 0.0 111.016 179.508 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 117' ' ' MET . . . . . . . . . . . . . 32.3 tpp -91.58 18.73 7.02 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.105 -0.498 . . . . 0.0 111.497 -179.204 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 118' ' ' VAL . . . . . 0.459 HG21 ' HB3' ' A' ' 123' ' ' ARG . 27.5 m -88.57 139.1 29.71 Favored Pre-proline 0 C--N 1.33 -0.27 0 CA-C-N 116.633 -0.258 . . . . 0.0 111.308 -179.865 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 119' ' ' PRO . . . . . . . . . . . . . 95.4 Cg_endo -89.67 -10.08 3.81 Favored 'Trans proline' 0 N--CA 1.456 -0.697 0 C-N-CA 122.699 2.266 . . . . 0.0 112.195 179.371 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -128.64 -106.71 1.3 Allowed Glycine 0 C--N 1.331 0.305 0 C-N-CA 120.848 -0.691 . . . . 0.0 112.722 -179.74 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 2.6 pp -136.93 19.52 0.85 Allowed 'Isoleucine or valine' 0 C--N 1.332 -0.185 0 CA-C-O 120.742 0.306 . . . . 0.0 111.652 -179.713 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 41.3 mt-10 -65.05 -17.71 64.68 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.311 -0.404 . . . . 0.0 110.853 179.757 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 123' ' ' ARG . . . . . 0.459 ' HB3' HG21 ' A' ' 118' ' ' VAL . 12.2 ptt180 -50.16 -42.05 50.25 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 115.736 -0.666 . . . . 0.0 112.023 -179.64 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 124' ' ' TYR . . . . . . . . . . . . . 59.0 m-85 -57.56 -32.18 66.87 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.522 -0.308 . . . . 0.0 111.511 -179.239 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 125' ' ' ALA . . . . . . . . . . . . . . . -74.2 -56.29 5.07 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-O 121.03 0.443 . . . . 0.0 111.156 -179.728 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 126' ' ' LEU . . . . . 0.576 HD22 ' HB3' ' A' ' 114' ' ' ALA . 1.1 mt -53.25 -48.83 67.92 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 115.746 -0.661 . . . . 0.0 110.494 179.96 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 127' ' ' PHE . . . . . . . . . . . . . 7.0 t80 -63.65 -35.65 81.24 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.306 -0.406 . . . . 0.0 110.483 179.396 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 128' ' ' GLY . . . . . . . . . . . . . . . -47.22 -50.73 16.21 Favored Glycine 0 C--N 1.333 0.402 0 C-N-CA 120.055 -1.069 . . . . 0.0 110.609 178.854 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 129' ' ' MET . . . . . . . . . . . . . 0.5 OUTLIER -65.31 -34.31 78.03 Favored 'General case' 0 C--N 1.329 -0.314 0 N-CA-C 109.679 -0.489 . . . . 0.0 109.679 178.293 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -57.81 -51.61 57.1 Favored Glycine 0 C--N 1.331 0.284 0 CA-C-N 115.463 -0.789 . . . . 0.0 112.597 -179.973 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -58.91 -49.47 77.66 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 120.66 0.267 . . . . 0.0 110.684 179.865 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 132' ' ' VAL . . . . . 0.426 ' O ' HG13 ' A' ' 135' ' ' ILE . 49.9 t -54.55 -39.99 48.21 Favored 'Isoleucine or valine' 0 C--O 1.233 0.228 0 CA-C-O 121.269 0.557 . . . . 0.0 109.794 179.007 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -69.98 -34.19 73.05 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 115.474 -0.784 . . . . 0.0 110.947 179.469 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 134' ' ' PHE . . . . . 0.457 ' CZ ' ' HA ' ' A' ' 172' ' ' ALA . 51.9 t80 -56.87 -58.58 7.5 Favored 'General case' 0 CA--C 1.517 -0.294 0 CA-C-N 116.341 -0.39 . . . . 0.0 110.118 179.817 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 135' ' ' ILE . . . . . 0.487 ' O ' HG22 ' A' ' 138' ' ' VAL . 0.0 OUTLIER -55.6 -34.85 36.56 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 115.799 -0.637 . . . . 0.0 109.663 179.104 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . -58.19 -36.47 82.61 Favored Glycine 0 N--CA 1.448 -0.524 0 C-N-CA 120.447 -0.882 . . . . 0.0 111.482 178.944 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 137' ' ' LEU . . . . . 0.536 HD13 HD21 ' A' ' 105' ' ' ASN . 38.3 tp -71.91 -54.18 10.82 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-O 120.615 0.245 . . . . 0.0 110.721 179.537 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 138' ' ' VAL . . . . . 0.487 HG22 ' O ' ' A' ' 135' ' ' ILE . 3.4 m -55.92 -30.32 28.09 Favored 'Isoleucine or valine' 0 C--O 1.233 0.197 0 CA-C-O 121.312 0.577 . . . . 0.0 109.712 179.351 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 139' ' ' TYR . . . . . . . . . . . . . 31.4 t80 -63.58 -47.03 83.14 Favored 'General case' 0 N--CA 1.453 -0.285 0 CA-C-N 115.31 -0.859 . . . . 0.0 110.021 178.975 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 140' ' ' TYR . . . . . 0.416 ' HE2' HD22 ' A' ' 104' ' ' LEU . 18.2 m-85 -57.38 -35.98 70.68 Favored 'General case' 0 C--N 1.332 -0.191 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.596 179.362 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 141' ' ' LEU . . . . . 0.445 HD13 ' HG2' ' A' ' 164' ' ' ARG . 69.5 mt -59.49 -54.69 43.7 Favored 'General case' 0 C--N 1.333 -0.152 0 CA-C-N 116.262 -0.426 . . . . 0.0 110.51 179.522 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 18.6 t -70.02 -15.79 19.58 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.246 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.765 179.597 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . -68.68 -138.67 0.08 OUTLIER Glycine 0 CA--C 1.522 0.469 0 C-N-CA 121.025 -0.607 . . . . 0.0 112.779 -179.899 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 144' ' ' PRO . . . . . . . . . . . . . 19.2 Cg_endo -59.11 -23.42 68.94 Favored 'Trans proline' 0 C--N 1.349 0.587 0 C-N-CA 122.672 2.248 . . . . 0.0 112.654 -179.723 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 145' ' ' MET . . . . . . . . . . . . . 45.5 mtt -59.07 -28.52 66.55 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.517 -0.311 . . . . 0.0 111.28 -179.997 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 146' ' ' THR . . . . . . . . . . . . . 35.2 m -80.45 -42.9 21.81 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.913 0.387 . . . . 0.0 111.194 -179.167 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 9.1 tp10 -70.42 -34.53 72.6 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 115.964 -0.562 . . . . 0.0 111.107 -179.818 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 148' ' ' SER . . . . . 0.498 ' HB2' ' HB1' ' A' ' 91' ' ' ALA . 64.2 m -70.47 -50.85 33.75 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.054 -179.41 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 149' ' ' ALA . . . . . 0.423 ' HB1' HG22 ' A' ' 156' ' ' ILE . . . -64.79 -38.38 90.8 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.332 -179.828 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 150' ' ' SER . . . . . . . . . . . . . 100.0 p -72.15 -4.29 28.26 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.896 179.856 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 151' ' ' GLN . . . . . . . . . . . . . 96.7 mt-30 -125.46 1.54 7.66 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.168 -179.98 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 152' ' ' ARG . . . . . 0.418 ' HA ' ' HE ' ' A' ' 152' ' ' ARG . 0.0 OUTLIER -80.34 -52.54 7.57 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-O 121.013 0.435 . . . . 0.0 110.333 179.883 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 153' ' ' SER . . . . . 0.606 ' HB2' HG12 ' A' ' 156' ' ' ILE . 44.3 m -158.22 171.01 20.98 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-N 115.83 -0.623 . . . . 0.0 110.49 179.18 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 154' ' ' SER . . . . . . . . . . . . . 64.1 m -71.21 -36.82 72.01 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 121.028 0.442 . . . . 0.0 110.059 179.127 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -76.93 -41.21 23.49 Favored Glycine 0 N--CA 1.45 -0.417 0 CA-C-N 115.785 -0.643 . . . . 0.0 112.386 179.611 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 156' ' ' ILE . . . . . 0.606 HG12 ' HB2' ' A' ' 153' ' ' SER . 38.1 mm -51.76 -38.17 21.81 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.196 0 CA-C-O 120.879 0.371 . . . . 0.0 111.177 179.91 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 157' ' ' LYS . . . . . . . . . . . . . 63.1 tttm -58.93 -42.92 90.88 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 115.961 -0.563 . . . . 0.0 110.92 -179.989 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 51.0 m -71.19 -40.94 70.91 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.547 -179.732 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 159' ' ' LEU . . . . . 0.417 ' O ' ' HB2' ' A' ' 163' ' ' LEU . 2.2 mm? -63.78 -38.72 92.17 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.418 -0.355 . . . . 0.0 111.601 -179.419 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 160' ' ' TYR . . . . . . . . . . . . . 43.5 t80 -74.2 -46.79 39.71 Favored 'General case' 0 C--N 1.327 -0.38 0 N-CA-C 112.598 0.592 . . . . 0.0 112.598 -178.533 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 161' ' ' VAL . . . . . 0.438 HG23 ' N ' ' A' ' 162' ' ' ARG . 21.2 m -57.25 -48.83 81.59 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 N-CA-C 112.395 0.517 . . . . 0.0 112.395 -178.788 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 162' ' ' ARG . . . . . 0.438 ' N ' HG23 ' A' ' 161' ' ' VAL . 27.1 ttm180 -69.04 -45.92 69.21 Favored 'General case' 0 C--N 1.329 -0.324 0 N-CA-C 111.783 0.29 . . . . 0.0 111.783 -179.302 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 163' ' ' LEU . . . . . 0.681 ' HG ' ' HB2' ' A' ' 208' ' ' PHE . 6.6 mp -61.78 -49.75 75.12 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.451 -0.34 . . . . 0.0 111.733 -179.661 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 164' ' ' ARG . . . . . 0.445 ' HG2' HD13 ' A' ' 141' ' ' LEU . 4.0 tmt_? -62.64 -45.51 92.52 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.312 -0.404 . . . . 0.0 111.749 -179.036 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 165' ' ' ASN . . . . . 0.523 ' O ' HG23 ' A' ' 169' ' ' VAL . 5.3 m-20 -59.49 -52.19 66.62 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.783 0.325 . . . . 0.0 111.546 -179.434 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 166' ' ' LEU . . . . . 0.511 ' O ' ' HG ' ' A' ' 170' ' ' LEU . 4.6 tt -63.88 -53.41 50.9 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-O 120.852 0.358 . . . . 0.0 111.314 -179.552 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 167' ' ' THR . . . . . 0.487 ' HA ' HD11 ' A' ' 170' ' ' LEU . 88.3 m -54.67 -53.09 59.37 Favored 'General case' 0 C--N 1.327 -0.381 0 N-CA-C 112.581 0.585 . . . . 0.0 112.581 -178.744 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 168' ' ' VAL . . . . . 0.404 HG12 ' O ' ' A' ' 165' ' ' ASN . 9.1 p -56.74 -40.58 71.23 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.204 0 N-CA-C 112.158 0.429 . . . . 0.0 112.158 -178.753 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 169' ' ' VAL . . . . . 0.523 HG23 ' O ' ' A' ' 165' ' ' ASN . 51.5 t -58.26 -65.37 0.44 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 N-CA-C 111.821 0.304 . . . . 0.0 111.821 -179.487 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 170' ' ' LEU . . . . . 0.511 ' HG ' ' O ' ' A' ' 166' ' ' LEU . 0.4 OUTLIER -64.48 -28.26 69.54 Favored 'General case' 0 C--N 1.331 -0.216 0 N-CA-C 111.982 0.364 . . . . 0.0 111.982 -178.865 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 171' ' ' TRP . . . . . 0.436 ' HB2' ' O ' ' A' ' 167' ' ' THR . 5.2 m0 -71.38 -31.18 67.01 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.848 0.356 . . . . 0.0 110.742 179.488 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 172' ' ' ALA . . . . . 0.457 ' HA ' ' CZ ' ' A' ' 134' ' ' PHE . . . -73.78 -6.4 46.75 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.861 -179.727 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 173' ' ' ILE . . . . . 0.663 HG22 HD11 ' A' ' 177' ' ' ILE . 13.9 mm -86.12 -21.46 7.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 115.927 -0.579 . . . . 0.0 110.806 179.629 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 174' ' ' TYR . . . . . . . . . . . . . 14.2 m-85 -54.27 -51.24 79.5 Favored Pre-proline 0 CA--C 1.531 0.236 0 CA-C-N 116.115 -0.493 . . . . 0.0 112.109 -179.535 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 175' ' ' PRO . . . . . . . . . . . . . 89.1 Cg_exo -47.4 -29.14 9.43 Favored 'Trans proline' 0 C--N 1.352 0.728 0 C-N-CA 121.998 1.798 . . . . 0.0 112.176 179.748 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 176' ' ' PHE . . . . . 0.459 ' O ' ' HG ' ' A' ' 180' ' ' LEU . 98.3 m-85 -80.52 -50.12 10.46 Favored 'General case' 0 CA--C 1.517 -0.323 0 CA-C-N 116.057 -0.52 . . . . 0.0 111.69 179.968 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 177' ' ' ILE . . . . . 0.663 HD11 HG22 ' A' ' 173' ' ' ILE . 3.1 mm -58.4 -46.47 89.36 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.533 0 CA-C-N 115.884 -0.598 . . . . 0.0 112.073 -178.227 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 178' ' ' TRP . . . . . 0.485 ' HA ' ' HG2' ' A' ' 182' ' ' PRO . 75.1 t90 -62.5 -42.45 99.51 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 121.026 0.441 . . . . 0.0 110.974 -179.986 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 179' ' ' LEU . . . . . 0.551 HD13 HG22 ' A' ' 185' ' ' VAL . 1.2 tm? -67.27 -49.51 64.04 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 115.831 -0.622 . . . . 0.0 111.369 -179.061 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 180' ' ' LEU . . . . . 0.653 HD22 HD11 ' A' ' 187' ' ' LEU . 9.9 mt -76.95 -52.29 9.65 Favored 'General case' 0 CA--C 1.535 0.374 0 N-CA-C 112.498 0.555 . . . . 0.0 112.498 -178.474 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . -64.97 -84.1 0.08 OUTLIER Glycine 0 CA--C 1.522 0.521 0 C-N-CA 120.72 -0.752 . . . . 0.0 113.425 -179.557 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 182' ' ' PRO . . . . . 0.557 ' HD2' ' O ' ' A' ' 177' ' ' ILE . 75.0 Cg_exo -44.86 -179.79 0.0 OUTLIER 'Trans proline' 0 C--N 1.351 0.671 0 C-N-CA 123.567 2.845 . . . . 0.0 113.574 179.684 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 183' ' ' PRO . . . . . . . . . . . . . 82.8 Cg_exo -50.11 5.06 0.02 OUTLIER 'Trans proline' 0 C--N 1.354 0.864 0 C-N-CA 123.196 2.597 . . . . 0.0 115.274 -179.566 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 184' ' ' GLY . . . . . 0.459 ' H ' ' C ' ' A' ' 182' ' ' PRO . . . -55.32 -70.28 1.01 Allowed Glycine 0 C--N 1.335 0.514 0 C-N-CA 119.724 -1.226 . . . . 0.0 110.899 179.236 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 185' ' ' VAL . . . . . 0.551 HG22 HD13 ' A' ' 179' ' ' LEU . 3.6 m -135.65 -5.77 0.95 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.372 0 N-CA-C 111.722 0.267 . . . . 0.0 111.722 178.559 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 186' ' ' ALA . . . . . . . . . . . . . . . 41.99 81.19 0.03 OUTLIER 'General case' 0 N--CA 1.466 0.349 0 N-CA-C 112.43 0.529 . . . . 0.0 112.43 179.372 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 187' ' ' LEU . . . . . 0.653 HD11 HD22 ' A' ' 180' ' ' LEU . 7.0 mt -92.92 -49.47 6.03 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.767 0.318 . . . . 0.0 111.548 179.871 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 188' ' ' LEU . . . . . . . . . . . . . 89.3 mt -105.8 -166.56 1.22 Allowed 'General case' 0 C--N 1.33 -0.244 0 CA-C-O 121.073 0.463 . . . . 0.0 111.515 -179.261 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 189' ' ' THR . . . . . 0.432 ' HB ' HG23 ' A' ' 192' ' ' VAL . 4.7 m -82.72 136.12 45.25 Favored Pre-proline 0 C--N 1.328 -0.339 0 CA-C-N 115.668 -0.696 . . . . 0.0 110.685 -179.615 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 190' ' ' PRO . . . . . 0.418 ' O ' HG23 ' A' ' 194' ' ' VAL . 84.5 Cg_exo -45.76 -48.64 12.0 Favored 'Trans proline' 0 C--N 1.349 0.559 0 C-N-CA 122.628 2.219 . . . . 0.0 113.026 -179.788 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 191' ' ' THR . . . . . 0.429 HG22 HG22 ' A' ' 189' ' ' THR . 3.9 t -56.8 -39.69 74.59 Favored 'General case' 0 C--N 1.33 -0.255 0 N-CA-C 111.921 0.341 . . . . 0.0 111.921 -179.492 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 192' ' ' VAL . . . . . 0.432 HG23 ' HB ' ' A' ' 189' ' ' THR . 58.6 t -67.33 -53.58 31.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-O 120.877 0.37 . . . . 0.0 111.546 -179.55 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 193' ' ' ASP . . . . . . . . . . . . . 13.5 m-20 -59.0 -43.05 91.43 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.09 -179.636 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 194' ' ' VAL . . . . . 0.418 HG23 ' O ' ' A' ' 190' ' ' PRO . 54.3 t -60.99 -36.16 70.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.345 -0.389 . . . . 0.0 110.404 179.497 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 195' ' ' ALA . . . . . . . . . . . . . . . -58.51 -46.42 86.78 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-N 116.346 -0.388 . . . . 0.0 110.404 179.232 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 196' ' ' LEU . . . . . . . . . . . . . 90.6 mt -62.66 -38.04 88.74 Favored 'General case' 0 C--N 1.332 -0.192 0 CA-C-N 116.055 -0.52 . . . . 0.0 110.323 179.309 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 197' ' ' ILE . . . . . 0.517 HG21 ' HE ' ' A' ' 72' ' ' ARG . 20.3 mm -61.36 -57.14 13.49 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 115.947 -0.57 . . . . 0.0 110.223 179.262 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 198' ' ' VAL . . . . . 0.433 HG13 ' CE1' ' A' ' 51' ' ' TYR . 83.9 t -52.75 -34.88 20.52 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.465 0 CA-C-N 115.734 -0.666 . . . . 0.0 109.243 178.374 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 199' ' ' TYR . . . . . . . . . . . . . 62.5 t80 -69.99 -33.62 72.28 Favored 'General case' 0 C--N 1.332 -0.176 0 CA-C-N 115.388 -0.824 . . . . 0.0 110.626 179.498 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 200' ' ' LEU . . . . . 0.573 ' O ' HG12 ' A' ' 203' ' ' VAL . 31.8 mt -68.87 -44.17 73.86 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 115.919 -0.582 . . . . 0.0 111.409 -179.685 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 201' ' ' ASP . . . . . 0.425 ' HB2' ' OH ' ' A' ' 51' ' ' TYR . 11.8 m-20 -67.39 -36.05 80.52 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-O 121.293 0.568 . . . . 0.0 109.963 179.476 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 202' ' ' LEU . . . . . . . . . . . . . 3.3 mt -74.35 -28.28 61.06 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 115.232 -0.895 . . . . 0.0 112.356 -179.394 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 203' ' ' VAL . . . . . 0.573 HG12 ' O ' ' A' ' 200' ' ' LEU . 11.6 p -77.25 -36.15 23.71 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.303 0 C-N-CA 120.757 -0.377 . . . . 0.0 111.21 -178.533 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 204' ' ' THR . . . . . . . . . . . . . 90.2 m -70.7 -58.49 3.59 Favored 'General case' 0 C--N 1.327 -0.389 0 C-N-CA 120.719 -0.392 . . . . 0.0 111.068 179.316 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 205' ' ' LYS . . . . . 0.665 ' HE2' ' HB2' ' A' ' 47' ' ' ALA . 56.6 mttp -57.33 -58.02 10.09 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.242 -0.436 . . . . 0.0 111.728 -178.785 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 39.7 t -71.17 -36.3 61.94 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.431 0 CA-C-N 116.015 -0.539 . . . . 0.0 111.977 -179.061 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 207' ' ' GLY . . . . . 0.571 ' O ' HG13 ' A' ' 211' ' ' ILE . . . -58.9 -61.5 7.29 Favored Glycine 0 C--N 1.33 0.229 0 C-N-CA 120.624 -0.798 . . . . 0.0 113.816 -178.445 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 208' ' ' PHE . . . . . 0.681 ' HB2' ' HG ' ' A' ' 163' ' ' LEU . 1.0 OUTLIER -72.23 -27.47 62.54 Favored 'General case' 0 C--O 1.223 -0.333 0 CA-C-N 117.473 0.636 . . . . 0.0 111.05 -179.08 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 209' ' ' GLY . . . . . 0.513 ' O ' ' HB3' ' A' ' 212' ' ' ALA . . . -64.07 -34.2 89.3 Favored Glycine 0 N--CA 1.45 -0.369 0 N-CA-C 112.009 -0.436 . . . . 0.0 112.009 178.825 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 210' ' ' PHE . . . . . . . . . . . . . 1.2 m-85 -73.71 -48.71 30.02 Favored 'General case' 0 CA--C 1.514 -0.432 0 N-CA-C 108.21 -1.034 . . . . 0.0 108.21 178.446 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 211' ' ' ILE . . . . . 0.571 HG13 ' O ' ' A' ' 207' ' ' GLY . 5.4 mt -61.66 -28.07 43.39 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.499 0 N-CA-C 107.646 -1.242 . . . . 0.0 107.646 176.815 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 212' ' ' ALA . . . . . 0.513 ' HB3' ' O ' ' A' ' 209' ' ' GLY . . . -63.7 -41.71 98.08 Favored 'General case' 0 N--CA 1.448 -0.565 0 CA-C-N 114.384 -1.28 . . . . 0.0 110.139 179.952 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 213' ' ' LEU . . . . . . . . . . . . . 93.0 mt -70.1 -54.27 13.76 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 115.044 -0.98 . . . . 0.0 111.545 -179.729 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 214' ' ' ASP . . . . . . . . . . . . . 14.6 t70 -52.82 -54.63 31.57 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.189 -0.459 . . . . 0.0 111.605 -179.504 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 215' ' ' ALA . . . . . . . . . . . . . . . -57.53 -57.2 13.74 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.046 -0.524 . . . . 0.0 111.781 -179.476 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 216' ' ' ALA . . . . . . . . . . . . . . . -55.1 -37.38 66.77 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.375 -0.375 . . . . 0.0 111.494 -179.636 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 217' ' ' ALA . . . . . . . . . . . . . . . -62.41 -32.89 73.8 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.382 179.799 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 218' ' ' THR . . . . . . . . . . . . . 94.4 m . . . . . 0 C--N 1.331 -0.237 0 CA-C-N 115.806 -0.633 . . . . 0.0 110.74 179.567 . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.307 0 N-CA-C 112.354 -0.299 . . . . 0.0 112.354 . . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 67.8 tp -74.22 -35.41 63.88 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 120.778 0.323 . . . . 0.0 110.796 179.723 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 69.9 p -69.62 -32.85 71.8 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.72 -179.697 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 29.0 p -54.93 -35.56 64.33 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.35 -0.386 . . . . 0.0 111.381 -179.644 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 7' ' ' LEU . . . . . . . . . . . . . 9.3 mp -59.24 -53.36 59.18 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.098 -0.501 . . . . 0.0 111.557 -179.813 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 8' ' ' PHE . . . . . 0.564 ' HB2' ' HB2' ' A' ' 55' ' ' ALA . 63.4 m-85 -59.95 -34.93 73.92 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.317 -0.402 . . . . 0.0 110.997 -179.73 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 9' ' ' TRP . . . . . . . . . . . . . 28.8 m95 -64.36 -47.61 78.62 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 116.058 -0.519 . . . . 0.0 110.357 -179.902 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 13.1 mt -58.32 -42.76 87.45 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 115.929 -0.578 . . . . 0.0 110.304 179.204 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 11' ' ' GLY . . . . . 0.433 ' HA2' HD11 ' A' ' 202' ' ' LEU . . . -61.62 -34.58 89.03 Favored Glycine 0 N--CA 1.448 -0.545 0 C-N-CA 120.588 -0.815 . . . . 0.0 111.544 178.971 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 12' ' ' ALA . . . . . 0.407 ' O ' HD23 ' A' ' 16' ' ' LEU . . . -66.22 -33.15 75.1 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 120.616 0.246 . . . . 0.0 110.608 179.701 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 1.5 mt -63.21 -49.29 83.76 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.259 0 N-CA-C 109.347 -0.612 . . . . 0.0 109.347 178.987 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 14' ' ' GLY . . . . . 0.411 ' HA3' HD21 ' A' ' 202' ' ' LEU . . . -61.7 -24.82 64.76 Favored Glycine 0 N--CA 1.447 -0.584 0 C-N-CA 120.638 -0.791 . . . . 0.0 111.47 178.908 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 15' ' ' MET . . . . . 0.677 ' HB3' ' HB2' ' A' ' 48' ' ' ALA . 0.0 OUTLIER -77.3 -47.93 18.76 Favored 'General case' 0 C--N 1.331 -0.227 0 N-CA-C 111.763 0.283 . . . . 0.0 111.763 179.841 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 16' ' ' LEU . . . . . 0.407 HD23 ' O ' ' A' ' 12' ' ' ALA . 4.6 mm? -63.78 -39.22 93.72 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.778 0.323 . . . . 0.0 110.965 -179.958 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 17' ' ' VAL . . . . . 0.454 HG13 ' N ' ' A' ' 18' ' ' GLY . 8.5 p -68.09 -44.26 84.68 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.375 0 CA-C-O 121.388 0.613 . . . . 0.0 110.471 179.7 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 18' ' ' GLY . . . . . 0.454 ' N ' HG13 ' A' ' 17' ' ' VAL . . . -64.87 -49.79 61.47 Favored Glycine 0 C--N 1.319 -0.38 0 CA-C-N 114.928 -1.033 . . . . 0.0 111.349 179.135 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 94.2 m -54.11 -42.6 69.62 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-O 120.858 0.361 . . . . 0.0 111.008 179.828 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 20' ' ' LEU . . . . . 0.409 ' O ' ' HB3' ' A' ' 24' ' ' TRP . 67.6 mt -71.83 -42.96 66.36 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.061 -0.518 . . . . 0.0 111.264 179.947 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -59.02 -43.96 91.66 Favored 'General case' 0 C--N 1.329 -0.292 0 N-CA-C 111.805 0.298 . . . . 0.0 111.805 -179.797 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 22' ' ' PHE . . . . . 0.645 ' HB2' HG22 ' A' ' 41' ' ' VAL . 10.6 m-85 -75.53 -42.26 52.93 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.46 -0.337 . . . . 0.0 111.431 -179.291 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -61.79 -50.25 73.11 Favored 'General case' 0 C--N 1.33 -0.283 0 CA-C-O 120.814 0.34 . . . . 0.0 111.023 -179.845 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 24' ' ' TRP . . . . . 0.409 ' HB3' ' O ' ' A' ' 20' ' ' LEU . 1.0 OUTLIER -57.92 -35.77 71.54 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.711 179.75 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.328 -0.346 0 CA-C-O 120.955 0.407 . . . . 0.0 110.627 179.56 . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.298 0 N-CA-C 112.192 -0.363 . . . . 0.0 112.192 . . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 26.7 mt-10 -91.32 -20.84 21.43 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.7 0.286 . . . . 0.0 110.764 179.999 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 34' ' ' ARG . . . . . . . . . . . . . 15.8 ptp180 -51.51 -31.25 23.17 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 116.106 -0.497 . . . . 0.0 111.48 -179.652 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 89.9 mtm180 -73.51 -52.9 11.96 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.503 -0.317 . . . . 0.0 111.502 -179.7 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 73.6 m-85 -61.74 -30.53 70.83 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.247 -0.433 . . . . 0.0 111.702 -179.483 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 37' ' ' TYR . . . . . 0.416 ' O ' HG23 ' A' ' 41' ' ' VAL . 26.1 m-85 -76.19 -55.27 5.73 Favored 'General case' 0 C--N 1.329 -0.307 0 N-CA-C 111.799 0.296 . . . . 0.0 111.799 -179.129 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 83.8 t -56.89 -36.27 49.47 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-O 120.939 0.4 . . . . 0.0 110.59 179.91 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 39' ' ' THR . . . . . 0.406 ' O ' HG13 ' A' ' 43' ' ' ILE . 54.9 m -64.08 -52.11 60.85 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 115.991 -0.549 . . . . 0.0 111.116 179.718 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 40' ' ' LEU . . . . . 0.458 HD13 ' CE1' ' A' ' 208' ' ' PHE . 7.8 tp -63.3 -50.74 68.88 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.722 -179.81 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 41' ' ' VAL . . . . . 0.645 HG22 ' HB2' ' A' ' 22' ' ' PHE . 96.9 t -55.27 -34.84 34.38 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.356 0 CA-C-N 116.132 -0.485 . . . . 0.0 109.962 178.887 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -62.52 -37.25 94.4 Favored Glycine 0 N--CA 1.448 -0.558 0 C-N-CA 120.821 -0.704 . . . . 0.0 111.616 179.069 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 43' ' ' ILE . . . . . 0.506 HD13 HD13 ' A' ' 83' ' ' ILE . 3.8 mt -62.54 -57.95 9.77 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.158 0 CA-C-O 120.824 0.345 . . . . 0.0 110.732 179.505 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 24.6 t -59.92 -24.79 64.63 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-N 116.293 -0.412 . . . . 0.0 110.983 -179.904 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -71.99 -57.25 5.88 Favored Glycine 0 N--CA 1.452 -0.242 0 C-N-CA 120.805 -0.712 . . . . 0.0 112.427 179.825 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 15.5 pt -59.74 -37.47 71.37 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.229 0 CA-C-O 120.823 0.344 . . . . 0.0 111.007 179.888 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 47' ' ' ALA . . . . . 0.587 ' HB2' ' HE2' ' A' ' 205' ' ' LYS . . . -67.76 -39.33 84.15 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 116.316 -0.402 . . . . 0.0 111.027 179.313 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 48' ' ' ALA . . . . . 0.677 ' HB2' ' HB3' ' A' ' 15' ' ' MET . . . -57.07 -47.2 81.57 Favored 'General case' 0 C--O 1.232 0.177 0 CA-C-N 116.076 -0.511 . . . . 0.0 111.617 -179.658 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 49' ' ' VAL . . . . . 0.454 ' O ' HG13 ' A' ' 53' ' ' VAL . 29.9 m -70.66 -33.64 53.79 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-N 116.11 -0.496 . . . . 0.0 111.414 -179.359 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -62.96 -44.43 96.08 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.932 0.396 . . . . 0.0 111.286 -179.571 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 51' ' ' TYR . . . . . 0.456 ' HE2' ' HE2' ' A' ' 15' ' ' MET . 33.3 m-85 -73.87 -36.22 64.82 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 115.829 -0.623 . . . . 0.0 110.942 -179.419 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -62.74 -45.8 91.01 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 115.841 -0.618 . . . . 0.0 111.157 -179.992 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 53' ' ' VAL . . . . . 0.504 ' HB ' HG11 ' A' ' 58' ' ' VAL . 19.7 m -73.32 -43.51 56.53 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.147 -0.478 . . . . 0.0 111.036 -179.802 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 54' ' ' MET . . . . . 0.492 ' HG3' ' HE1' ' A' ' 60' ' ' TRP . 11.4 ttp -64.94 -29.65 70.6 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.284 179.89 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 55' ' ' ALA . . . . . 0.564 ' HB2' ' HB2' ' A' ' 8' ' ' PHE . . . -65.47 -37.32 86.51 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 115.885 -0.598 . . . . 0.0 111.014 179.254 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 87.2 mt -70.85 -11.47 60.98 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.082 -0.508 . . . . 0.0 111.215 -179.781 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 104.68 17.4 14.95 Favored Glycine 0 CA--C 1.518 0.227 0 C-N-CA 120.742 -0.742 . . . . 0.0 113.296 179.487 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 58' ' ' VAL . . . . . 0.504 HG11 ' HB ' ' A' ' 53' ' ' VAL . 0.4 OUTLIER -89.46 159.36 2.89 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.231 0 CA-C-N 116.913 0.356 . . . . 0.0 110.577 179.729 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 72.44 -12.52 3.38 Favored Glycine 0 N--CA 1.45 -0.412 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.387 -179.456 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 60' ' ' TRP . . . . . 0.492 ' HE1' ' HG3' ' A' ' 54' ' ' MET . 35.1 m0 -69.79 106.68 3.2 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-O 120.663 0.268 . . . . 0.0 110.883 -179.935 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 61' ' ' VAL . . . . . 0.456 HG13 HG23 ' A' ' 68' ' ' VAL . 7.5 p -116.03 128.54 25.9 Favored Pre-proline 0 CA--C 1.533 0.312 0 CA-C-N 116.406 -0.361 . . . . 0.0 111.155 179.821 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 74.0 Cg_endo -75.72 148.48 32.62 Favored 'Trans proline' 0 C--N 1.35 0.646 0 C-N-CA 122.533 2.155 . . . . 0.0 112.441 179.923 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 96.6 t -137.76 91.53 0.79 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.005 -0.543 . . . . 0.0 111.036 -179.878 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . 59.11 -88.53 0.02 OUTLIER 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 116.03 -0.532 . . . . 0.0 111.438 179.961 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 65' ' ' GLU . . . . . 0.524 ' HB2' HH11 ' A' ' 66' ' ' ARG . 11.1 mm-40 -120.54 -18.51 7.79 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-O 120.907 0.384 . . . . 0.0 110.735 179.984 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 66' ' ' ARG . . . . . 0.524 HH11 ' HB2' ' A' ' 65' ' ' GLU . 10.5 mpt_? -102.78 162.62 12.78 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 115.938 -0.574 . . . . 0.0 110.439 179.916 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 31.6 m -123.37 139.9 53.56 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.964 0.411 . . . . 0.0 111.52 -179.654 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 68' ' ' VAL . . . . . 0.523 HG21 ' SD ' ' A' ' 117' ' ' MET . 18.0 m -130.3 146.12 34.56 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.375 0 CA-C-N 115.932 -0.576 . . . . 0.0 110.685 179.711 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 69' ' ' PHE . . . . . . . . . . . . . 9.9 m-85 -109.1 118.03 35.71 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-O 121.048 0.452 . . . . 0.0 110.224 -179.473 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 70' ' ' VAL . . . . . 0.63 HG12 ' HD3' ' A' ' 71' ' ' PRO . 0.5 OUTLIER -67.0 -34.44 7.33 Favored Pre-proline 0 CA--C 1.541 0.6 0 N-CA-C 112.883 0.697 . . . . 0.0 112.883 -179.295 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 71' ' ' PRO . . . . . 0.63 ' HD3' HG12 ' A' ' 70' ' ' VAL . 12.2 Cg_exo -69.63 -17.75 38.01 Favored 'Trans proline' 0 C--N 1.359 1.079 0 C-N-CA 122.259 1.973 . . . . 0.0 113.059 -179.165 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 45.3 ttp180 -74.76 -55.42 5.86 Favored 'General case' 0 C--N 1.33 -0.271 0 N-CA-C 112.276 0.473 . . . . 0.0 112.276 -178.514 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 73' ' ' TYR . . . . . 0.461 ' O ' HG13 ' A' ' 77' ' ' ILE . 24.9 m-85 -71.31 -33.55 69.79 Favored 'General case' 0 C--N 1.329 -0.325 0 C-N-CA 120.764 -0.374 . . . . 0.0 110.669 -179.418 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 74' ' ' ILE . . . . . 0.476 HG22 ' HA ' ' A' ' 71' ' ' PRO . 0.3 OUTLIER -68.95 -39.73 80.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 N-CA-C 110.072 -0.344 . . . . 0.0 110.072 179.256 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 15.4 t70 -59.98 -37.3 79.23 Favored 'General case' 0 CA--C 1.52 -0.197 0 N-CA-C 109.423 -0.584 . . . . 0.0 109.423 179.023 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 76' ' ' TRP . . . . . 0.523 ' HB3' ' SD ' ' A' ' 109' ' ' MET . 49.2 m0 -65.29 -35.49 81.17 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 115.652 -0.703 . . . . 0.0 110.427 179.521 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 77' ' ' ILE . . . . . 0.474 ' O ' ' HG2' ' A' ' 81' ' ' PRO . 78.5 mt -68.12 -30.66 48.73 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.374 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.964 179.773 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 35.2 mt -91.81 -19.55 22.43 Favored 'General case' 0 C--N 1.327 -0.371 0 N-CA-C 112.23 0.456 . . . . 0.0 112.23 -179.76 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 79' ' ' THR . . . . . 0.494 ' HB ' ' HE3' ' A' ' 205' ' ' LYS . 79.3 p -102.35 -47.6 4.44 Favored 'General case' 0 N--CA 1.464 0.238 0 N-CA-C 113.458 0.91 . . . . 0.0 113.458 -177.932 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 80' ' ' THR . . . . . 0.659 ' HB ' ' HD3' ' A' ' 81' ' ' PRO . 80.3 m -51.28 -53.4 49.53 Favored Pre-proline 0 C--N 1.329 -0.297 0 N-CA-C 112.047 0.388 . . . . 0.0 112.047 -179.019 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 81' ' ' PRO . . . . . 0.659 ' HD3' ' HB ' ' A' ' 80' ' ' THR . 50.4 Cg_exo -55.83 -22.03 35.63 Favored 'Trans proline' 0 C--N 1.351 0.691 0 C-N-CA 121.612 1.542 . . . . 0.0 111.704 179.723 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 82' ' ' LEU . . . . . 0.488 ' HB2' ' O ' ' A' ' 79' ' ' THR . 2.8 mm? -76.77 -37.1 56.49 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 115.877 -0.601 . . . . 0.0 110.745 179.807 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 83' ' ' ILE . . . . . 0.506 HD13 HD13 ' A' ' 43' ' ' ILE . 11.9 mm -65.22 -53.76 36.78 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-O 120.857 0.36 . . . . 0.0 110.469 179.67 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 21.9 m -62.63 -31.27 51.5 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.176 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.251 179.335 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 85' ' ' TYR . . . . . . . . . . . . . 82.9 t80 -67.28 -32.44 73.44 Favored 'General case' 0 C--N 1.333 -0.135 0 CA-C-N 115.999 -0.546 . . . . 0.0 110.223 179.158 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 86' ' ' PHE . . . . . . . . . . . . . 9.2 t80 -64.72 -51.96 59.6 Favored 'General case' 0 C--N 1.331 -0.196 0 CA-C-N 116.118 -0.492 . . . . 0.0 109.839 179.37 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 9.2 mp -62.95 -30.45 71.58 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 115.806 -0.634 . . . . 0.0 110.098 179.477 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -69.25 -27.31 73.83 Favored Glycine 0 N--CA 1.448 -0.523 0 C-N-CA 120.914 -0.66 . . . . 0.0 111.546 178.943 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 58.0 mt -72.05 -46.16 58.04 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 120.974 0.416 . . . . 0.0 110.4 179.701 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 98.0 mt -59.27 -37.55 77.93 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 115.844 -0.616 . . . . 0.0 111.074 179.824 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -79.86 -32.75 40.46 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.231 -0.441 . . . . 0.0 111.4 -179.877 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 78.81 51.77 5.31 Favored Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.701 -0.761 . . . . 0.0 111.937 -179.737 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 35.2 mt -62.21 167.16 4.24 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.892 0.377 . . . . 0.0 111.103 -179.632 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 94' ' ' ASP . . . . . . . . . . . . . 28.6 t70 -85.47 168.96 14.07 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.618 179.839 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 75.0 m -54.34 -41.52 69.16 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.45 -0.341 . . . . 0.0 110.975 -179.989 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 34.0 ttm180 -73.89 -44.1 56.36 Favored 'General case' 0 C--N 1.331 -0.197 0 CA-C-N 116.398 -0.364 . . . . 0.0 110.94 179.732 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 97' ' ' GLU . . . . . 0.558 ' HA ' HD12 ' A' ' 100' ' ' ILE . 43.7 mt-10 -53.42 -47.08 69.92 Favored 'General case' 0 C--N 1.331 -0.197 0 CA-C-N 116.128 -0.487 . . . . 0.0 111.435 -179.484 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 98' ' ' PHE . . . . . 0.421 ' O ' HG12 ' A' ' 102' ' ' ILE . 16.9 m-85 -58.03 -49.6 76.3 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-O 120.773 0.321 . . . . 0.0 110.7 179.64 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -58.28 -26.12 58.51 Favored Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.879 -0.677 . . . . 0.0 112.644 -179.95 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 100' ' ' ILE . . . . . 0.558 HD12 ' HA ' ' A' ' 97' ' ' GLU . 94.4 mt -71.56 -52.24 27.4 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-O 120.815 0.34 . . . . 0.0 111.638 -179.71 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 43.4 t -68.21 -37.77 78.58 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.38 0 CA-C-N 116.401 -0.363 . . . . 0.0 111.669 -179.378 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 102' ' ' ILE . . . . . 0.421 HG12 ' O ' ' A' ' 98' ' ' PHE . 49.0 mm -68.22 -47.72 76.89 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.391 -0.368 . . . . 0.0 111.48 -179.628 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 103' ' ' THR . . . . . 0.404 HG22 ' O ' ' A' ' 100' ' ' ILE . 11.1 t -62.03 -31.1 71.46 Favored 'General case' 0 C--N 1.332 -0.174 0 CA-C-O 120.804 0.335 . . . . 0.0 110.723 -179.935 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 104' ' ' LEU . . . . . 0.429 ' O ' HG23 ' A' ' 108' ' ' VAL . 53.3 tp -64.38 -52.98 55.53 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.701 179.556 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 105' ' ' ASN . . . . . 0.616 ' N ' HD22 ' A' ' 105' ' ' ASN . 0.8 OUTLIER -61.51 -26.19 67.76 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.079 -0.51 . . . . 0.0 110.946 179.929 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 40.3 m -65.65 -54.96 20.4 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 115.995 -0.548 . . . . 0.0 111.419 -179.66 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 11.3 p -64.7 -36.41 77.45 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.232 0 CA-C-N 116.366 -0.379 . . . . 0.0 111.215 -179.724 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 108' ' ' VAL . . . . . 0.429 HG23 ' O ' ' A' ' 104' ' ' LEU . 70.1 t -63.46 -49.21 83.63 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.244 0 CA-C-N 116.36 -0.382 . . . . 0.0 110.839 179.67 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 109' ' ' MET . . . . . 0.523 ' SD ' ' HB3' ' A' ' 76' ' ' TRP . 7.7 tpp -63.21 -37.41 87.13 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.749 -179.978 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 22.9 tp -65.9 -30.27 70.84 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-N 115.987 -0.552 . . . . 0.0 110.259 179.782 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -65.03 -54.77 25.12 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-N 115.939 -0.573 . . . . 0.0 110.391 179.354 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . -57.82 -39.67 91.83 Favored Glycine 0 C--N 1.333 0.382 0 C-N-CA 120.576 -0.821 . . . . 0.0 111.701 179.395 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 113' ' ' PHE . . . . . . . . . . . . . 1.3 t80 -51.33 -66.03 0.45 Allowed 'General case' 0 C--N 1.332 -0.181 0 CA-C-O 121.059 0.456 . . . . 0.0 109.934 179.255 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -59.84 -29.31 68.19 Favored 'General case' 0 C--N 1.327 -0.413 0 CA-C-N 115.501 -0.772 . . . . 0.0 111.471 179.809 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 115' ' ' GLY . . . . . 0.403 ' N ' ' HG ' ' A' ' 126' ' ' LEU . . . -52.4 -49.62 50.79 Favored Glycine 0 C--N 1.333 0.377 0 C-N-CA 120.901 -0.666 . . . . 0.0 112.452 179.85 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -77.88 -14.71 59.47 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-O 120.8 0.333 . . . . 0.0 111.168 179.692 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 117' ' ' MET . . . . . 0.523 ' SD ' HG21 ' A' ' 68' ' ' VAL . 24.3 mmt -93.7 15.16 17.02 Favored 'General case' 0 N--CA 1.463 0.185 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.732 -179.391 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 23.3 m -82.13 144.61 51.08 Favored Pre-proline 0 C--N 1.33 -0.267 0 CA-C-O 120.568 0.223 . . . . 0.0 111.565 -179.616 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 119' ' ' PRO . . . . . . . . . . . . . 84.9 Cg_endo -91.18 -9.0 3.15 Favored 'Trans proline' 0 N--CA 1.456 -0.684 0 C-N-CA 122.758 2.305 . . . . 0.0 112.348 179.471 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -132.5 -117.09 1.81 Allowed Glycine 0 C--N 1.332 0.312 0 C-N-CA 120.748 -0.739 . . . . 0.0 113.071 -179.649 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 41.7 pt -116.13 13.72 7.74 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.151 0 CA-C-O 120.723 0.297 . . . . 0.0 111.5 -179.552 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 44.1 mt-10 -62.59 -18.46 62.19 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 116.284 -0.416 . . . . 0.0 111.349 -179.737 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 123' ' ' ARG . . . . . . . . . . . . . 20.4 ptt180 -50.43 -39.44 47.48 Favored 'General case' 0 C--N 1.332 -0.166 0 CA-C-N 116.28 -0.418 . . . . 0.0 111.7 -179.66 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 124' ' ' TYR . . . . . . . . . . . . . 59.5 m-85 -65.87 -32.38 73.86 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-O 120.748 0.308 . . . . 0.0 110.997 -179.851 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 125' ' ' ALA . . . . . . . . . . . . . . . -70.05 -47.64 61.19 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.308 -0.406 . . . . 0.0 111.179 -179.913 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 126' ' ' LEU . . . . . 0.425 HD13 ' HA ' ' A' ' 126' ' ' LEU . 2.6 mm? -54.16 -55.6 26.24 Favored 'General case' 0 C--O 1.233 0.209 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.904 179.924 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 127' ' ' PHE . . . . . . . . . . . . . 10.0 t80 -63.73 -36.77 84.95 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.305 -0.407 . . . . 0.0 111.033 -179.553 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 128' ' ' GLY . . . . . . . . . . . . . . . -46.81 -47.24 19.03 Favored Glycine 0 C--N 1.332 0.321 0 C-N-CA 120.019 -1.086 . . . . 0.0 111.033 179.182 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 129' ' ' MET . . . . . 0.428 ' HE1' ' HA ' ' A' ' 108' ' ' VAL . 0.6 OUTLIER -66.96 -40.04 87.4 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 120.978 0.418 . . . . 0.0 109.994 178.788 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -67.62 -22.9 73.7 Favored Glycine 0 N--CA 1.45 -0.379 0 CA-C-N 115.721 -0.672 . . . . 0.0 112.809 -179.997 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 131' ' ' ALA . . . . . 0.419 ' O ' ' HB3' ' A' ' 134' ' ' PHE . . . -74.63 -53.77 8.71 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.78 0.324 . . . . 0.0 110.423 -179.991 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 16.1 t -60.2 -40.39 83.44 Favored 'Isoleucine or valine' 0 C--O 1.236 0.36 0 N-CA-C 109.085 -0.709 . . . . 0.0 109.085 178.629 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -67.0 -34.55 77.99 Favored 'General case' 0 N--CA 1.451 -0.41 0 CA-C-N 115.125 -0.943 . . . . 0.0 110.302 179.054 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 134' ' ' PHE . . . . . 0.482 ' CZ ' ' HA ' ' A' ' 172' ' ' ALA . 19.4 t80 -56.47 -52.67 63.83 Favored 'General case' 0 N--CA 1.452 -0.352 0 CA-C-N 115.939 -0.573 . . . . 0.0 109.88 179.366 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 135' ' ' ILE . . . . . 0.566 ' O ' HG22 ' A' ' 138' ' ' VAL . 57.6 mt -57.06 -34.13 44.28 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.299 0 CA-C-N 115.742 -0.663 . . . . 0.0 109.857 179.189 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 136' ' ' GLY . . . . . 0.413 ' O ' ' HB3' ' A' ' 139' ' ' TYR . . . -59.99 -34.72 84.58 Favored Glycine 0 N--CA 1.448 -0.538 0 C-N-CA 120.08 -1.057 . . . . 0.0 110.843 178.418 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 137' ' ' LEU . . . . . 0.529 HD13 HD21 ' A' ' 105' ' ' ASN . 38.6 tp -71.11 -52.14 21.05 Favored 'General case' 0 N--CA 1.455 -0.223 0 CA-C-N 115.643 -0.278 . . . . 0.0 110.554 179.399 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 138' ' ' VAL . . . . . 0.566 HG22 ' O ' ' A' ' 135' ' ' ILE . 3.1 m -55.69 -33.92 34.83 Favored 'Isoleucine or valine' 0 C--O 1.233 0.211 0 N-CA-C 109.201 -0.666 . . . . 0.0 109.201 179.063 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 139' ' ' TYR . . . . . 0.413 ' HB3' ' O ' ' A' ' 136' ' ' GLY . 32.0 t80 -57.12 -45.93 83.07 Favored 'General case' 0 C--N 1.331 -0.22 0 N-CA-C 108.848 -0.797 . . . . 0.0 108.848 177.657 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 140' ' ' TYR . . . . . 0.522 ' HB3' ' SD ' ' A' ' 145' ' ' MET . 24.1 m-85 -64.53 -36.54 84.55 Favored 'General case' 0 C--N 1.331 -0.197 0 CA-C-N 115.675 -0.693 . . . . 0.0 109.99 178.422 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 141' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -54.06 -33.61 57.88 Favored 'General case' 0 C--N 1.333 -0.144 0 CA-C-N 115.874 -0.603 . . . . 0.0 110.39 179.142 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 142' ' ' VAL . . . . . 0.568 HG22 HH12 ' A' ' 164' ' ' ARG . 2.6 t -111.09 2.28 8.91 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 115.858 -0.61 . . . . 0.0 110.703 179.642 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . -74.26 -153.05 2.92 Favored Glycine 0 CA--C 1.519 0.338 0 C-N-CA 121.042 -0.599 . . . . 0.0 113.146 -179.415 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 144' ' ' PRO . . . . . . . . . . . . . 31.2 Cg_exo -59.06 -23.6 69.56 Favored 'Trans proline' 0 C--N 1.349 0.588 0 C-N-CA 122.844 2.363 . . . . 0.0 112.768 -179.697 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 145' ' ' MET . . . . . 0.522 ' SD ' ' HB3' ' A' ' 140' ' ' TYR . 80.9 mtp -57.57 -32.81 67.5 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-O 120.89 0.376 . . . . 0.0 111.088 -179.731 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 146' ' ' THR . . . . . . . . . . . . . 36.0 m -75.35 -50.04 17.18 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.087 -0.506 . . . . 0.0 111.452 -179.733 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 43.5 mt-10 -65.68 -29.44 69.99 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.319 -0.401 . . . . 0.0 111.477 -179.615 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 148' ' ' SER . . . . . . . . . . . . . 80.1 p -70.36 -50.04 43.0 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.365 -0.38 . . . . 0.0 110.795 -179.515 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 149' ' ' ALA . . . . . . . . . . . . . . . -69.46 -32.7 71.79 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.4 -179.982 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 150' ' ' SER . . . . . 0.537 ' HA ' ' HB3' ' A' ' 157' ' ' LYS . 90.8 p -68.56 -15.98 63.71 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.361 -179.529 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 151' ' ' GLN . . . . . . . . . . . . . 46.7 mt-30 -113.55 3.55 15.77 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.59 -0.277 . . . . 0.0 111.336 -179.779 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 21.2 tpp180 -75.23 -51.79 12.46 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-O 120.987 0.422 . . . . 0.0 110.536 179.924 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 153' ' ' SER . . . . . 0.676 ' HB3' HG12 ' A' ' 156' ' ' ILE . 8.7 t -157.77 172.48 18.41 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 115.794 -0.639 . . . . 0.0 110.306 179.025 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 154' ' ' SER . . . . . . . . . . . . . 48.7 m -70.01 -40.97 74.91 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.872 0.367 . . . . 0.0 110.846 179.794 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -77.44 -34.48 40.15 Favored Glycine 0 N--CA 1.45 -0.389 0 C-N-CA 120.89 -0.671 . . . . 0.0 113.03 -179.962 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 156' ' ' ILE . . . . . 0.676 HG12 ' HB3' ' A' ' 153' ' ' SER . 39.5 mm -54.93 -46.42 76.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 N-CA-C 112.147 0.425 . . . . 0.0 112.147 -179.237 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 157' ' ' LYS . . . . . 0.537 ' HB3' ' HA ' ' A' ' 150' ' ' SER . 21.7 pttp -60.62 -39.73 89.28 Favored 'General case' 0 C--N 1.328 -0.34 0 N-CA-C 111.727 0.269 . . . . 0.0 111.727 -179.133 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 59.4 m -65.76 -48.18 72.73 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-O 120.724 0.297 . . . . 0.0 111.76 -179.387 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 159' ' ' LEU . . . . . 0.726 HD13 ' HB3' ' A' ' 215' ' ' ALA . 45.9 tp -68.08 -31.24 70.73 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.382 -0.372 . . . . 0.0 111.197 -179.714 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 160' ' ' TYR . . . . . . . . . . . . . 45.1 t80 -74.15 -47.05 38.45 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.186 -0.461 . . . . 0.0 112.028 -178.988 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 161' ' ' VAL . . . . . 0.454 HG22 ' O ' ' A' ' 157' ' ' LYS . 23.7 m -61.51 -47.34 93.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 N-CA-C 112.149 0.426 . . . . 0.0 112.149 -178.841 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 162' ' ' ARG . . . . . 0.447 ' N ' HG23 ' A' ' 161' ' ' VAL . 27.1 tpt180 -63.24 -49.2 75.08 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.791 0.329 . . . . 0.0 111.423 -179.369 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 163' ' ' LEU . . . . . 0.582 HD13 HD12 ' A' ' 159' ' ' LEU . 6.9 mp -64.73 -53.61 44.53 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.922 -179.266 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 164' ' ' ARG . . . . . 0.568 HH12 HG22 ' A' ' 142' ' ' VAL . 0.9 OUTLIER -59.37 -41.32 89.05 Favored 'General case' 0 CA--C 1.53 0.199 0 CA-C-N 116.373 -0.376 . . . . 0.0 111.99 -178.554 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 165' ' ' ASN . . . . . 0.527 ' O ' HG23 ' A' ' 169' ' ' VAL . 5.4 m-20 -57.25 -51.84 67.74 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-O 120.887 0.375 . . . . 0.0 110.744 179.921 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 166' ' ' LEU . . . . . 0.485 ' O ' ' HG ' ' A' ' 170' ' ' LEU . 3.9 tt -64.25 -43.15 95.76 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-N 115.954 -0.566 . . . . 0.0 111.639 -179.377 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 167' ' ' THR . . . . . 0.475 ' O ' HD12 ' A' ' 170' ' ' LEU . 49.2 m -56.03 -53.74 53.35 Favored 'General case' 0 C--N 1.329 -0.296 0 N-CA-C 112.629 0.603 . . . . 0.0 112.629 -178.576 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 168' ' ' VAL . . . . . . . . . . . . . 9.7 p -61.99 -39.57 84.15 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 N-CA-C 111.956 0.354 . . . . 0.0 111.956 -179.455 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 169' ' ' VAL . . . . . 0.527 HG23 ' O ' ' A' ' 165' ' ' ASN . 46.8 t -55.78 -65.27 0.39 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 N-CA-C 112.558 0.577 . . . . 0.0 112.558 -179.174 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 170' ' ' LEU . . . . . 0.485 ' HG ' ' O ' ' A' ' 166' ' ' LEU . 0.3 OUTLIER -66.71 -24.45 66.25 Favored 'General case' 0 N--CA 1.464 0.229 0 N-CA-C 111.855 0.317 . . . . 0.0 111.855 -178.745 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 171' ' ' TRP . . . . . 0.481 ' HZ3' HD21 ' A' ' 137' ' ' LEU . 9.8 m0 -73.49 -29.27 62.4 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.999 0.428 . . . . 0.0 109.847 179.245 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 172' ' ' ALA . . . . . 0.482 ' HA ' ' CZ ' ' A' ' 134' ' ' PHE . . . -74.7 -8.5 56.58 Favored 'General case' 0 N--CA 1.451 -0.382 0 CA-C-N 115.827 -0.624 . . . . 0.0 110.065 179.232 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 173' ' ' ILE . . . . . 0.7 HG22 HD11 ' A' ' 177' ' ' ILE . 44.5 mm -89.06 -22.8 6.45 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.256 0 CA-C-N 115.516 -0.765 . . . . 0.0 110.405 178.936 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 174' ' ' TYR . . . . . 0.607 ' N ' ' HD2' ' A' ' 175' ' ' PRO . 12.1 m-85 -54.87 -50.26 87.13 Favored Pre-proline 0 N--CA 1.463 0.199 0 CA-C-N 116.047 -0.524 . . . . 0.0 111.831 -179.893 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 175' ' ' PRO . . . . . 0.607 ' HD2' ' N ' ' A' ' 174' ' ' TYR . 2.0 Cg_endo -45.56 -29.31 4.98 Favored 'Trans proline' 0 C--N 1.353 0.791 0 C-N-CA 122.359 2.039 . . . . 0.0 111.768 179.275 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 176' ' ' PHE . . . . . 0.449 ' O ' ' HG ' ' A' ' 180' ' ' LEU . 99.6 m-85 -79.98 -45.7 17.98 Favored 'General case' 0 CA--C 1.516 -0.335 0 CA-C-N 115.921 -0.582 . . . . 0.0 111.078 179.396 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 177' ' ' ILE . . . . . 0.7 HD11 HG22 ' A' ' 173' ' ' ILE . 3.1 mm -58.09 -44.75 87.95 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.613 0 CA-C-N 115.787 -0.642 . . . . 0.0 112.093 -178.491 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 178' ' ' TRP . . . . . 0.407 ' HA ' ' HG2' ' A' ' 182' ' ' PRO . 72.0 t90 -69.04 -38.55 79.2 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-O 121.088 0.471 . . . . 0.0 110.64 179.951 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 179' ' ' LEU . . . . . 0.495 ' O ' HG22 ' A' ' 185' ' ' VAL . 0.4 OUTLIER -66.44 -53.64 33.2 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-N 115.557 -0.747 . . . . 0.0 111.168 -179.273 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 180' ' ' LEU . . . . . 0.523 HD13 HD12 ' A' ' 187' ' ' LEU . 8.3 mt -77.75 -52.03 9.59 Favored 'General case' 0 C--N 1.328 -0.366 0 N-CA-C 112.307 0.484 . . . . 0.0 112.307 -178.674 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 181' ' ' GLY . . . . . 0.42 ' HA3' ' OD1' ' A' ' 193' ' ' ASP . . . -58.34 -85.25 0.04 OUTLIER Glycine 0 C--N 1.336 0.552 0 C-N-CA 120.447 -0.882 . . . . 0.0 112.797 -179.739 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 182' ' ' PRO . . . . . 0.495 ' HD2' ' O ' ' A' ' 177' ' ' ILE . 89.2 Cg_exo -46.1 178.55 0.0 OUTLIER 'Trans proline' 0 C--N 1.349 0.599 0 C-N-CA 123.388 2.725 . . . . 0.0 112.954 179.088 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 183' ' ' PRO . . . . . . . . . . . . . 51.5 Cg_exo -56.82 12.25 0.03 OUTLIER 'Trans proline' 0 C--N 1.351 0.667 0 C-N-CA 122.862 2.375 . . . . 0.0 114.696 -179.558 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 184' ' ' GLY . . . . . 0.458 ' H ' ' C ' ' A' ' 182' ' ' PRO . . . -54.17 -65.08 3.72 Favored Glycine 0 C--N 1.335 0.484 0 C-N-CA 119.84 -1.172 . . . . 0.0 111.06 179.149 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 185' ' ' VAL . . . . . 0.495 HG22 ' O ' ' A' ' 179' ' ' LEU . 3.4 m -135.52 -3.27 1.01 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.368 0 N-CA-C 111.574 0.213 . . . . 0.0 111.574 178.813 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 186' ' ' ALA . . . . . . . . . . . . . . . 45.5 76.49 0.09 Allowed 'General case' 0 N--CA 1.463 0.198 0 N-CA-C 112.316 0.487 . . . . 0.0 112.316 179.324 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 187' ' ' LEU . . . . . 0.523 HD12 HD13 ' A' ' 180' ' ' LEU . 4.2 mt -92.49 -49.31 6.19 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.463 -0.335 . . . . 0.0 111.267 179.683 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 188' ' ' LEU . . . . . . . . . . . . . 92.3 mt -115.48 -168.59 1.43 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 121.087 0.47 . . . . 0.0 111.586 -179.502 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 189' ' ' THR . . . . . 0.484 ' HB ' HG23 ' A' ' 192' ' ' VAL . 96.7 m -76.96 135.28 67.36 Favored Pre-proline 0 C--N 1.329 -0.318 0 CA-C-N 115.667 -0.697 . . . . 0.0 111.039 -179.681 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 190' ' ' PRO . . . . . . . . . . . . . 10.2 Cg_endo -50.29 -41.7 49.85 Favored 'Trans proline' 0 C--N 1.35 0.609 0 C-N-CA 122.684 2.256 . . . . 0.0 112.185 -179.967 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 191' ' ' THR . . . . . 0.451 ' H ' HG22 ' A' ' 189' ' ' THR . 41.5 p -57.2 -46.49 82.82 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.763 179.525 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 192' ' ' VAL . . . . . 0.484 HG23 ' HB ' ' A' ' 189' ' ' THR . 60.3 t -59.13 -39.75 79.3 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.725 179.584 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 193' ' ' ASP . . . . . 0.425 ' OD1' HG22 ' A' ' 177' ' ' ILE . 7.9 t70 -57.72 -41.89 82.72 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 115.932 -0.576 . . . . 0.0 110.646 179.672 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 194' ' ' VAL . . . . . . . . . . . . . 52.5 t -64.71 -36.06 76.53 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 115.984 -0.553 . . . . 0.0 110.918 179.814 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 195' ' ' ALA . . . . . . . . . . . . . . . -59.4 -47.62 84.75 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.451 -0.341 . . . . 0.0 111.017 179.93 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 196' ' ' LEU . . . . . . . . . . . . . 95.9 mt -67.84 -43.13 80.22 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 120.793 0.33 . . . . 0.0 110.525 179.648 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 197' ' ' ILE . . . . . . . . . . . . . 15.5 mm -57.03 -58.89 4.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.012 -0.54 . . . . 0.0 110.296 179.381 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 198' ' ' VAL . . . . . . . . . . . . . 75.2 t -52.74 -34.71 20.25 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.439 0 CA-C-N 115.773 -0.648 . . . . 0.0 109.38 178.429 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 199' ' ' TYR . . . . . . . . . . . . . 46.0 t80 -70.25 -31.44 68.83 Favored 'General case' 0 C--N 1.331 -0.205 0 CA-C-N 115.587 -0.733 . . . . 0.0 110.421 179.678 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 200' ' ' LEU . . . . . . . . . . . . . 54.4 mt -74.07 -38.45 63.92 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 115.756 -0.656 . . . . 0.0 111.365 -179.722 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 201' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -71.44 -35.1 70.79 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 121.15 0.5 . . . . 0.0 110.121 179.483 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 202' ' ' LEU . . . . . 0.433 HD11 ' HA2' ' A' ' 11' ' ' GLY . 4.3 mt -67.21 -41.9 85.01 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 115.43 -0.805 . . . . 0.0 111.721 179.596 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 203' ' ' VAL . . . . . 0.44 ' O ' ' HA3' ' A' ' 207' ' ' GLY . 7.4 p -70.19 -36.82 69.42 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-N 116.376 -0.375 . . . . 0.0 111.946 -178.479 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 204' ' ' THR . . . . . . . . . . . . . 95.1 m -68.9 -57.46 5.5 Favored 'General case' 0 C--N 1.328 -0.353 0 C-N-CA 120.308 -0.557 . . . . 0.0 111.252 179.83 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 205' ' ' LYS . . . . . 0.587 ' HE2' ' HB2' ' A' ' 47' ' ' ALA . 41.7 mttp -67.0 -59.35 3.55 Favored 'General case' 0 C--N 1.328 -0.345 0 N-CA-C 112.714 0.635 . . . . 0.0 112.714 -178.311 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 25.5 t -73.87 -37.3 47.87 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.415 0 N-CA-C 112.184 0.438 . . . . 0.0 112.184 -178.29 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 207' ' ' GLY . . . . . 0.44 ' HA3' ' O ' ' A' ' 203' ' ' VAL . . . -66.89 -57.97 8.94 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.361 -0.923 . . . . 0.0 112.434 -179.309 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 208' ' ' PHE . . . . . 0.458 ' CE1' HD13 ' A' ' 40' ' ' LEU . 0.0 OUTLIER -62.6 -29.24 70.46 Favored 'General case' 0 C--N 1.329 -0.316 0 N-CA-C 110.439 -0.208 . . . . 0.0 110.439 -179.957 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 209' ' ' GLY . . . . . 0.501 ' O ' ' HB3' ' A' ' 212' ' ' ALA . . . -70.78 -36.13 66.32 Favored Glycine 0 N--CA 1.447 -0.574 0 N-CA-C 111.137 -0.785 . . . . 0.0 111.137 178.112 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 210' ' ' PHE . . . . . . . . . . . . . 1.0 OUTLIER -70.13 -43.09 71.65 Favored 'General case' 0 CA--C 1.512 -0.519 0 N-CA-C 107.508 -1.293 . . . . 0.0 107.508 178.37 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 211' ' ' ILE . . . . . . . . . . . . . 36.6 mt -67.41 -28.45 42.25 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.728 0 N-CA-C 107.277 -1.379 . . . . 0.0 107.277 176.502 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 212' ' ' ALA . . . . . 0.501 ' HB3' ' O ' ' A' ' 209' ' ' GLY . . . -66.88 -36.42 82.26 Favored 'General case' 0 N--CA 1.448 -0.549 0 CA-C-N 114.516 -1.22 . . . . 0.0 110.141 179.646 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 213' ' ' LEU . . . . . 0.414 ' HG ' ' O ' ' A' ' 209' ' ' GLY . 92.8 mt -70.31 -52.64 21.27 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 115.086 -0.961 . . . . 0.0 111.872 -179.678 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 214' ' ' ASP . . . . . . . . . . . . . 44.7 m-20 -53.21 -50.71 64.14 Favored 'General case' 0 C--N 1.331 -0.204 0 CA-C-N 116.292 -0.413 . . . . 0.0 111.837 -178.974 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 215' ' ' ALA . . . . . 0.726 ' HB3' HD13 ' A' ' 159' ' ' LEU . . . -65.48 -57.63 7.79 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.558 -0.292 . . . . 0.0 111.726 -179.243 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 216' ' ' ALA . . . . . . . . . . . . . . . -52.12 -43.38 63.94 Favored 'General case' 0 C--N 1.332 -0.184 0 CA-C-O 120.799 0.333 . . . . 0.0 111.497 -179.488 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 217' ' ' ALA . . . . . . . . . . . . . . . -59.05 -42.11 89.49 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.098 179.69 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 218' ' ' THR . . . . . . . . . . . . . 78.4 m . . . . . 0 C--N 1.331 -0.214 0 CA-C-N 115.584 -0.734 . . . . 0.0 110.983 179.715 . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.277 0 N-CA-C 112.692 -0.163 . . . . 0.0 112.692 . . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 56.2 tp -73.96 -35.82 64.56 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.817 0.341 . . . . 0.0 111.121 -179.913 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 60.7 p -68.08 -31.69 71.5 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.501 -179.59 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 21.3 p -52.31 -35.32 50.24 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.257 -0.429 . . . . 0.0 111.384 -179.772 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 7' ' ' LEU . . . . . . . . . . . . . 4.1 mm? -57.87 -53.75 54.74 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.26 -0.427 . . . . 0.0 111.364 -179.731 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 8' ' ' PHE . . . . . 0.68 ' HB2' ' HB2' ' A' ' 55' ' ' ALA . 63.4 m-85 -62.32 -33.29 74.39 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.31 -0.405 . . . . 0.0 110.763 -179.81 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 9' ' ' TRP . . . . . 0.465 ' O ' HG13 ' A' ' 13' ' ' ILE . 55.1 m95 -65.97 -40.83 91.59 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 116.029 -0.532 . . . . 0.0 110.101 -179.988 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 63.9 mt -66.48 -39.61 88.88 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 115.854 -0.612 . . . . 0.0 110.136 179.387 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 11' ' ' GLY . . . . . 0.425 ' HA2' HD11 ' A' ' 202' ' ' LEU . . . -68.32 -28.8 73.11 Favored Glycine 0 N--CA 1.446 -0.665 0 C-N-CA 120.804 -0.712 . . . . 0.0 111.796 179.357 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -71.99 -33.87 68.46 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 120.786 0.327 . . . . 0.0 110.578 179.52 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 13' ' ' ILE . . . . . 0.465 HG13 ' O ' ' A' ' 9' ' ' TRP . 75.0 mt -64.95 -54.08 33.95 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.173 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.248 179.172 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -61.17 -39.05 96.61 Favored Glycine 0 N--CA 1.45 -0.42 0 C-N-CA 120.5 -0.857 . . . . 0.0 111.55 179.4 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 15' ' ' MET . . . . . 0.473 ' SD ' ' HA ' ' A' ' 44' ' ' SER . 60.3 tpp -61.56 -41.44 97.37 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 120.868 0.366 . . . . 0.0 110.014 179.366 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 6.3 tt -57.53 -38.88 75.43 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 115.888 -0.596 . . . . 0.0 109.911 179.334 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 17' ' ' VAL . . . . . 0.41 HG23 ' O ' ' A' ' 13' ' ' ILE . 34.6 t -59.38 -46.65 92.44 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.221 0 CA-C-N 115.946 -0.57 . . . . 0.0 110.162 179.19 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -62.91 -41.96 99.77 Favored Glycine 0 N--CA 1.45 -0.375 0 C-N-CA 120.616 -0.802 . . . . 0.0 111.66 178.981 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 9.7 m -50.3 -49.19 54.36 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.698 0.285 . . . . 0.0 111.354 -179.942 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 87.5 mt -71.87 -42.09 67.25 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.694 -179.594 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -58.43 -33.42 69.67 Favored 'General case' 0 C--N 1.33 -0.265 0 N-CA-C 112.155 0.428 . . . . 0.0 112.155 -179.135 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 22' ' ' PHE . . . . . 0.576 ' HB2' HG22 ' A' ' 41' ' ' VAL . 6.8 m-85 -91.46 -37.09 13.39 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.851 0.358 . . . . 0.0 111.535 -179.526 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -64.7 -51.31 63.14 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.912 -179.231 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 24' ' ' TRP . . . . . . . . . . . . . 7.1 t-105 -63.42 -49.45 73.68 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-N 115.754 -0.657 . . . . 0.0 111.312 -179.295 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.328 -0.339 0 CA-C-O 120.879 0.371 . . . . 0.0 110.793 179.906 . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.264 0 N-CA-C 112.432 -0.267 . . . . 0.0 112.432 . . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 7.8 mm-40 -69.35 -20.47 63.85 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-O 120.759 0.314 . . . . 0.0 110.762 179.88 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 34' ' ' ARG . . . . . . . . . . . . . 75.0 ttt180 -48.67 -29.68 4.65 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 115.972 -0.558 . . . . 0.0 111.615 -179.688 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 37.4 ttm180 -58.34 -46.53 86.06 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-O 120.818 0.342 . . . . 0.0 111.046 -179.986 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 68.1 m-85 -69.51 -29.73 67.41 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.081 -0.508 . . . . 0.0 111.388 -179.678 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 37' ' ' TYR . . . . . 0.47 ' O ' HG23 ' A' ' 41' ' ' VAL . 63.2 m-85 -73.96 -56.1 5.35 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.413 -179.478 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 60.3 t -57.09 -38.64 61.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-O 120.984 0.421 . . . . 0.0 110.682 179.891 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 48.9 m -62.31 -49.05 77.18 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 115.858 -0.61 . . . . 0.0 110.447 179.243 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 40' ' ' LEU . . . . . 0.594 HD12 HD12 ' A' ' 43' ' ' ILE . 46.4 tp -55.56 -45.57 77.26 Favored 'General case' 0 C--O 1.236 0.346 0 CA-C-N 115.612 -0.722 . . . . 0.0 110.233 179.495 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 41' ' ' VAL . . . . . 0.576 HG22 ' HB2' ' A' ' 22' ' ' PHE . 60.1 t -63.17 -34.31 66.09 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.345 0 CA-C-N 115.645 -0.707 . . . . 0.0 110.172 179.283 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -59.49 -35.19 84.46 Favored Glycine 0 N--CA 1.449 -0.44 0 C-N-CA 120.69 -0.767 . . . . 0.0 111.538 179.554 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 43' ' ' ILE . . . . . 0.594 HD12 HD12 ' A' ' 40' ' ' LEU . 1.0 OUTLIER -68.91 -54.71 18.9 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.229 0 CA-C-O 120.797 0.332 . . . . 0.0 110.591 179.331 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 44' ' ' SER . . . . . 0.473 ' HA ' ' SD ' ' A' ' 15' ' ' MET . 32.3 t -58.74 -24.95 62.46 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.306 -179.943 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -76.16 -55.35 4.81 Favored Glycine 0 N--CA 1.45 -0.405 0 C-N-CA 120.683 -0.77 . . . . 0.0 112.747 -179.791 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 20.3 pt -59.78 -36.81 68.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-O 120.745 0.307 . . . . 0.0 111.421 -179.793 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 47' ' ' ALA . . . . . 0.764 ' HB2' ' HE2' ' A' ' 205' ' ' LYS . . . -67.89 -44.51 76.84 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-N 116.395 -0.366 . . . . 0.0 111.243 179.708 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -54.46 -48.0 72.28 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 115.918 -0.583 . . . . 0.0 111.672 -179.398 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 49' ' ' VAL . . . . . 0.415 ' O ' HG13 ' A' ' 53' ' ' VAL . 18.0 m -68.33 -33.92 63.15 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-N 116.255 -0.429 . . . . 0.0 111.371 -179.481 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -66.06 -37.5 85.99 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 120.864 0.364 . . . . 0.0 111.275 179.97 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 51' ' ' TYR . . . . . 0.447 ' OH ' ' HB2' ' A' ' 201' ' ' ASP . 29.5 m-85 -70.82 -44.0 67.45 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.458 -179.829 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -61.14 -51.92 67.06 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-N 115.53 -0.759 . . . . 0.0 111.251 179.814 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 53' ' ' VAL . . . . . 0.527 HG23 ' N ' ' A' ' 54' ' ' MET . 33.0 m -60.88 -50.95 78.43 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.2 0 CA-C-N 116.455 -0.338 . . . . 0.0 110.869 -179.976 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 54' ' ' MET . . . . . 0.57 ' HG3' ' HE1' ' A' ' 60' ' ' TRP . 8.8 ttp -60.34 -29.2 68.74 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 121.082 0.468 . . . . 0.0 109.792 179.499 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 55' ' ' ALA . . . . . 0.68 ' HB2' ' HB2' ' A' ' 8' ' ' PHE . . . -73.17 -30.6 63.68 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 115.71 -0.677 . . . . 0.0 110.843 179.043 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 87.4 mt -78.25 0.4 25.38 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.058 -179.865 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 92.0 -22.15 33.17 Favored Glycine 0 N--CA 1.45 -0.397 0 C-N-CA 120.63 -0.795 . . . . 0.0 113.127 179.776 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 58' ' ' VAL . . . . . 0.458 HG12 ' O ' ' A' ' 53' ' ' VAL . 12.5 p -67.79 142.8 16.01 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.176 0 CA-C-O 120.885 0.374 . . . . 0.0 110.77 -179.966 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 97.72 -11.66 64.55 Favored Glycine 0 N--CA 1.452 -0.287 0 C-N-CA 120.88 -0.676 . . . . 0.0 112.105 -179.329 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 60' ' ' TRP . . . . . 0.57 ' HE1' ' HG3' ' A' ' 54' ' ' MET . 28.6 m0 -78.49 115.09 17.96 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.685 0.279 . . . . 0.0 110.504 179.869 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 61' ' ' VAL . . . . . 0.402 ' HA ' ' HD3' ' A' ' 62' ' ' PRO . 10.7 p -118.02 125.29 28.06 Favored Pre-proline 0 CA--C 1.532 0.287 0 CA-C-N 116.518 -0.31 . . . . 0.0 111.518 -179.838 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 62' ' ' PRO . . . . . 0.402 ' HD3' ' HA ' ' A' ' 61' ' ' VAL . 17.1 Cg_exo -67.75 155.53 69.58 Favored 'Trans proline' 0 C--N 1.351 0.678 0 C-N-CA 122.553 2.168 . . . . 0.0 111.965 179.652 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 93.2 t -143.09 92.15 0.47 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-N 115.989 -0.55 . . . . 0.0 111.041 179.995 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . 58.41 -85.78 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.039 -0.528 . . . . 0.0 111.63 179.801 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 37.7 mt-10 -119.72 -22.57 6.81 Favored 'General case' 0 C--N 1.332 -0.192 0 CA-C-N 116.42 -0.355 . . . . 0.0 111.141 -179.659 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 66' ' ' ARG . . . . . . . . . . . . . 32.3 mmt180 -105.94 158.06 17.05 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.683 -179.872 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 92.9 m -111.68 131.11 55.52 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.905 0.384 . . . . 0.0 111.492 -179.635 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 61.8 t -113.8 146.46 18.35 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 115.899 -0.591 . . . . 0.0 110.534 179.343 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 69' ' ' PHE . . . . . . . . . . . . . 44.6 m-85 -108.89 111.97 23.96 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-N 116.174 -0.467 . . . . 0.0 110.141 -179.447 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 70' ' ' VAL . . . . . 0.63 ' N ' ' HD2' ' A' ' 71' ' ' PRO . 21.8 t -69.2 -49.62 23.48 Favored Pre-proline 0 C--N 1.324 -0.535 0 CA-C-N 116.219 -0.446 . . . . 0.0 112.202 -179.252 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 71' ' ' PRO . . . . . 0.63 ' HD2' ' N ' ' A' ' 70' ' ' VAL . 6.3 Cg_endo -48.45 -26.27 8.55 Favored 'Trans proline' 0 C--N 1.353 0.779 0 C-N-CA 122.422 2.081 . . . . 0.0 112.63 -179.524 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 55.5 ttp180 -75.23 -53.79 8.21 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-O 120.922 0.392 . . . . 0.0 111.123 -179.934 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 73' ' ' TYR . . . . . 0.441 ' OH ' ' HB2' ' A' ' 116' ' ' ALA . 67.4 m-85 -65.27 -47.97 74.82 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.094 -0.503 . . . . 0.0 111.3 -179.574 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 74' ' ' ILE . . . . . 0.48 ' O ' HD13 ' A' ' 74' ' ' ILE . 0.3 OUTLIER -59.35 -41.45 84.33 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-N 116.499 -0.319 . . . . 0.0 110.557 179.884 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 31.7 t70 -59.23 -36.53 75.61 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-O 121.023 0.44 . . . . 0.0 109.916 179.283 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 76' ' ' TRP . . . . . . . . . . . . . 47.4 m0 -66.97 -31.27 71.72 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 115.786 -0.643 . . . . 0.0 110.627 179.798 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 77' ' ' ILE . . . . . 0.485 HG12 ' HB3' ' A' ' 109' ' ' MET . 51.0 mt -73.22 -28.87 26.75 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.614 179.479 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 43.7 mt -91.75 -20.35 21.63 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.985 179.872 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 71.0 p -101.63 -52.67 3.15 Favored 'General case' 0 C--N 1.332 -0.176 0 N-CA-C 113.432 0.901 . . . . 0.0 113.432 -177.817 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 80' ' ' THR . . . . . 0.678 ' HB ' ' HD3' ' A' ' 81' ' ' PRO . 26.9 m -51.24 -55.17 30.86 Favored Pre-proline 0 C--N 1.33 -0.242 0 N-CA-C 112.327 0.491 . . . . 0.0 112.327 -178.258 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 81' ' ' PRO . . . . . 0.678 ' HD3' ' HB ' ' A' ' 80' ' ' THR . 36.0 Cg_exo -60.86 -20.41 66.41 Favored 'Trans proline' 0 C--N 1.352 0.752 0 C-N-CA 121.613 1.542 . . . . 0.0 111.459 179.74 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 82' ' ' LEU . . . . . . . . . . . . . 14.7 tp -76.79 -33.77 58.01 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 115.823 -0.626 . . . . 0.0 110.258 179.599 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 83' ' ' ILE . . . . . 0.498 HD13 HD13 ' A' ' 43' ' ' ILE . 42.2 mm -70.01 -52.54 29.83 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.149 0 CA-C-N 116.087 -0.506 . . . . 0.0 110.296 179.096 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 84' ' ' VAL . . . . . 0.57 HG11 HD22 ' A' ' 105' ' ' ASN . 29.8 m -59.51 -31.79 47.5 Favored 'Isoleucine or valine' 0 CA--C 1.52 -0.193 0 N-CA-C 109.736 -0.468 . . . . 0.0 109.736 178.693 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 85' ' ' TYR . . . . . . . . . . . . . 67.7 t80 -65.69 -33.54 76.12 Favored 'General case' 0 N--CA 1.453 -0.317 0 CA-C-N 115.636 -0.711 . . . . 0.0 109.334 178.72 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 86' ' ' PHE . . . . . . . . . . . . . 4.3 t80 -60.63 -51.71 68.26 Favored 'General case' 0 C--O 1.233 0.22 0 CA-C-N 115.646 -0.707 . . . . 0.0 109.719 178.858 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 9.1 mp -61.37 -31.22 71.11 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 115.741 -0.663 . . . . 0.0 110.506 179.526 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -71.89 -28.01 69.56 Favored Glycine 0 N--CA 1.449 -0.476 0 C-N-CA 120.81 -0.71 . . . . 0.0 112.144 179.801 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 65.5 mt -71.28 -45.06 64.0 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-O 120.877 0.37 . . . . 0.0 110.591 179.838 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 69.5 mt -58.44 -51.84 68.15 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 115.988 -0.551 . . . . 0.0 110.926 179.844 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 91' ' ' ALA . . . . . 0.464 ' HA ' ' HA ' ' A' ' 149' ' ' ALA . . . -61.69 -36.81 81.96 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.278 -0.419 . . . . 0.0 111.427 -179.872 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 88.38 49.56 3.66 Favored Glycine 0 N--CA 1.452 -0.271 0 C-N-CA 120.826 -0.702 . . . . 0.0 112.033 -179.633 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 93' ' ' LEU . . . . . 0.484 ' HB3' ' HB2' ' A' ' 97' ' ' GLU . 71.6 mt -67.53 178.55 1.58 Allowed 'General case' 0 C--N 1.328 -0.349 0 CA-C-O 120.917 0.389 . . . . 0.0 111.357 -179.662 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 94' ' ' ASP . . . . . . . . . . . . . 20.6 t70 -106.18 167.05 10.07 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-N 116.019 -0.537 . . . . 0.0 110.448 179.75 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 65.7 m -52.72 -34.99 55.01 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 116.46 -0.337 . . . . 0.0 111.26 -179.889 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 12.7 ptm180 -73.32 -46.79 47.39 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.381 -0.372 . . . . 0.0 111.066 -179.978 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 97' ' ' GLU . . . . . 0.484 ' HB2' ' HB3' ' A' ' 93' ' ' LEU . 45.9 mt-10 -57.74 -45.41 85.89 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.429 -0.35 . . . . 0.0 110.837 179.964 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 98' ' ' PHE . . . . . 0.49 ' O ' HG12 ' A' ' 102' ' ' ILE . 42.3 m-85 -60.18 -45.87 91.64 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.303 -0.408 . . . . 0.0 110.377 179.464 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -56.6 -30.0 58.54 Favored Glycine 0 N--CA 1.45 -0.414 0 C-N-CA 120.549 -0.834 . . . . 0.0 112.304 179.776 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 74.1 mt -73.5 -47.24 46.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 N-CA-C 112.097 0.406 . . . . 0.0 112.097 -179.761 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 101' ' ' VAL . . . . . 0.42 HG12 ' H ' ' A' ' 101' ' ' VAL . 1.1 p -70.52 -42.76 78.22 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-O 120.654 0.264 . . . . 0.0 111.634 -179.712 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 102' ' ' ILE . . . . . 0.49 HG12 ' O ' ' A' ' 98' ' ' PHE . 45.2 mm -62.13 -45.14 99.41 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.36 0 CA-C-N 116.426 -0.352 . . . . 0.0 111.042 -179.627 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 103' ' ' THR . . . . . 0.412 ' O ' HG23 ' A' ' 107' ' ' VAL . 13.6 t -66.88 -29.87 69.89 Favored 'General case' 0 C--N 1.332 -0.167 0 CA-C-O 120.817 0.341 . . . . 0.0 110.346 179.559 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 1.2 tm? -59.76 -56.06 26.51 Favored 'General case' 0 C--N 1.331 -0.206 0 N-CA-C 109.501 -0.555 . . . . 0.0 109.501 179.108 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 105' ' ' ASN . . . . . 0.651 HD21 HG22 ' A' ' 80' ' ' THR . 3.0 m-20 -57.3 -32.45 66.67 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 115.855 -0.611 . . . . 0.0 110.663 179.232 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 58.0 m -57.65 -48.86 78.32 Favored 'General case' 0 C--N 1.332 -0.183 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.95 179.78 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 107' ' ' VAL . . . . . 0.412 HG23 ' O ' ' A' ' 103' ' ' THR . 2.1 t -61.54 -40.85 87.94 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-O 121.149 0.5 . . . . 0.0 110.122 179.623 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 99.0 t -58.92 -43.73 89.25 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.377 0 CA-C-N 115.294 -0.867 . . . . 0.0 111.406 -179.956 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 109' ' ' MET . . . . . 0.485 ' HB3' HG12 ' A' ' 77' ' ' ILE . 15.3 mmt -70.51 -41.51 72.52 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.666 -179.332 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 32.5 tp -59.65 -31.09 69.21 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-O 120.882 0.372 . . . . 0.0 110.569 -179.872 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -70.15 -53.48 17.04 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.758 179.649 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . -59.58 -45.62 95.33 Favored Glycine 0 C--N 1.331 0.299 0 C-N-CA 120.707 -0.759 . . . . 0.0 112.301 179.751 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 113' ' ' PHE . . . . . . . . . . . . . 1.5 t80 -50.97 -60.5 3.03 Favored 'General case' 0 C--N 1.332 -0.171 0 CA-C-O 120.996 0.427 . . . . 0.0 110.116 179.488 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 114' ' ' ALA . . . . . 0.49 ' HB3' HD22 ' A' ' 126' ' ' LEU . . . -66.45 -19.81 65.89 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 115.733 -0.667 . . . . 0.0 110.6 179.451 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -59.0 -45.84 94.61 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.86 -0.686 . . . . 0.0 112.042 179.646 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 116' ' ' ALA . . . . . 0.441 ' HB2' ' OH ' ' A' ' 73' ' ' TYR . . . -78.16 -21.2 50.56 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.804 0.335 . . . . 0.0 111.359 179.67 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 117' ' ' MET . . . . . . . . . . . . . 24.8 mmt -83.24 19.87 1.4 Allowed 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.846 -179.253 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 118' ' ' VAL . . . . . 0.549 HG21 ' HB3' ' A' ' 123' ' ' ARG . 24.7 m -90.73 141.67 27.13 Favored Pre-proline 0 C--N 1.329 -0.294 0 CA-C-O 120.646 0.26 . . . . 0.0 111.614 -179.717 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 119' ' ' PRO . . . . . . . . . . . . . 97.3 Cg_endo -92.52 -6.75 3.05 Favored 'Trans proline' 0 N--CA 1.455 -0.774 0 C-N-CA 122.882 2.388 . . . . 0.0 112.379 179.455 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -139.41 -115.38 1.27 Allowed Glycine 0 C--N 1.332 0.314 0 C-N-CA 120.589 -0.815 . . . . 0.0 113.023 -179.586 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 38.3 pt -119.29 15.03 6.85 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.233 0 CA-C-O 120.686 0.279 . . . . 0.0 111.67 -179.345 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 10.9 mm-40 -62.11 -18.61 61.33 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.383 -0.371 . . . . 0.0 110.99 179.752 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 123' ' ' ARG . . . . . 0.549 ' HB3' HG21 ' A' ' 118' ' ' VAL . 24.2 ptt180 -54.54 -33.42 60.05 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 115.973 -0.558 . . . . 0.0 111.785 -179.751 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 124' ' ' TYR . . . . . . . . . . . . . 37.3 m-85 -65.73 -32.22 73.65 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 120.829 0.347 . . . . 0.0 111.108 -179.593 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 125' ' ' ALA . . . . . . . . . . . . . . . -72.62 -56.17 5.73 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.0 179.92 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 126' ' ' LEU . . . . . 0.49 HD22 ' HB3' ' A' ' 114' ' ' ALA . 1.3 mt -55.68 -45.44 77.77 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 115.789 -0.642 . . . . 0.0 110.488 -179.991 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 127' ' ' PHE . . . . . . . . . . . . . 7.6 t80 -67.3 -37.37 83.27 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.464 179.612 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 128' ' ' GLY . . . . . . . . . . . . . . . -47.1 -45.03 20.14 Favored Glycine 0 C--N 1.332 0.331 0 C-N-CA 120.2 -1.0 . . . . 0.0 110.748 178.866 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 129' ' ' MET . . . . . . . . . . . . . 0.4 OUTLIER -70.95 -35.85 72.35 Favored 'General case' 0 C--N 1.328 -0.328 0 N-CA-C 109.826 -0.435 . . . . 0.0 109.826 178.578 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -62.67 -36.38 93.19 Favored Glycine 0 C--N 1.332 0.354 0 CA-C-N 115.777 -0.647 . . . . 0.0 112.626 -179.926 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -69.66 -53.34 19.13 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.602 0.239 . . . . 0.0 110.42 179.78 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 54.5 t -55.38 -39.99 55.31 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.234 0 CA-C-O 121.376 0.608 . . . . 0.0 109.595 178.879 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -69.12 -35.29 76.26 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 115.278 -0.874 . . . . 0.0 110.51 179.316 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 134' ' ' PHE . . . . . . . . . . . . . 73.5 t80 -56.94 -57.58 11.89 Favored 'General case' 0 N--CA 1.451 -0.415 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.146 179.823 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 135' ' ' ILE . . . . . 0.555 ' O ' HG22 ' A' ' 138' ' ' VAL . 0.0 OUTLIER -56.18 -32.84 35.48 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.002 -0.545 . . . . 0.0 109.61 178.761 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 136' ' ' GLY . . . . . 0.4 ' O ' ' HB3' ' A' ' 139' ' ' TYR . . . -57.33 -39.15 89.9 Favored Glycine 0 N--CA 1.447 -0.58 0 C-N-CA 120.302 -0.951 . . . . 0.0 111.086 178.389 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 137' ' ' LEU . . . . . 0.41 HD21 ' HZ3' ' A' ' 171' ' ' TRP . 27.8 tp -68.3 -53.84 21.58 Favored 'General case' 0 C--N 1.331 -0.197 0 CA-C-O 120.579 0.228 . . . . 0.0 110.644 179.212 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 138' ' ' VAL . . . . . 0.555 HG22 ' O ' ' A' ' 135' ' ' ILE . 3.0 m -56.15 -30.24 29.07 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.204 0 CA-C-O 121.137 0.494 . . . . 0.0 109.742 179.482 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 139' ' ' TYR . . . . . 0.4 ' HB3' ' O ' ' A' ' 136' ' ' GLY . 35.2 t80 -63.7 -44.22 94.29 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 115.441 -0.8 . . . . 0.0 110.202 178.945 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 37.8 m-85 -63.04 -34.95 78.68 Favored 'General case' 0 C--N 1.331 -0.198 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.696 179.434 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 141' ' ' LEU . . . . . 0.407 HD23 ' SD ' ' A' ' 145' ' ' MET . 89.7 mt -62.92 -51.11 68.21 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.005 -179.943 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 15.0 p -81.87 -11.01 12.31 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.358 0 CA-C-N 116.076 -0.511 . . . . 0.0 111.032 -179.874 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . -72.32 -130.31 0.12 Allowed Glycine 0 CA--C 1.521 0.44 0 C-N-CA 120.973 -0.632 . . . . 0.0 112.988 -179.68 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 144' ' ' PRO . . . . . . . . . . . . . 33.1 Cg_endo -64.34 -23.57 65.46 Favored 'Trans proline' 0 C--N 1.349 0.586 0 C-N-CA 122.549 2.166 . . . . 0.0 112.521 -179.696 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 145' ' ' MET . . . . . 0.407 ' SD ' HD23 ' A' ' 141' ' ' LEU . 45.6 mtt -54.65 -34.43 62.17 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.352 -0.385 . . . . 0.0 111.446 -179.888 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 146' ' ' THR . . . . . . . . . . . . . 53.9 p -71.62 -37.47 70.9 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 116.53 -0.304 . . . . 0.0 111.584 -179.74 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 43.4 mt-10 -71.98 -37.48 69.88 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.374 -0.376 . . . . 0.0 111.203 -179.586 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 148' ' ' SER . . . . . . . . . . . . . 66.5 m -70.35 -40.09 74.29 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.152 -0.477 . . . . 0.0 111.454 -179.684 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 149' ' ' ALA . . . . . 0.464 ' HA ' ' HA ' ' A' ' 91' ' ' ALA . . . -74.9 -48.36 25.17 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.354 -0.385 . . . . 0.0 111.832 -179.397 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 150' ' ' SER . . . . . . . . . . . . . 47.1 t -61.07 -23.04 65.17 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.358 -0.383 . . . . 0.0 111.316 -179.652 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 151' ' ' GLN . . . . . . . . . . . . . 49.1 mt-30 -108.78 13.49 24.95 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.455 -0.339 . . . . 0.0 111.209 -179.849 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 30.7 tpt180 -89.77 -52.02 5.21 Favored 'General case' 0 C--N 1.332 -0.194 0 CA-C-O 120.933 0.397 . . . . 0.0 110.616 179.751 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 153' ' ' SER . . . . . 0.62 ' HB2' HG12 ' A' ' 156' ' ' ILE . 13.2 m -157.57 172.69 18.1 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 115.852 -0.613 . . . . 0.0 110.331 179.426 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 154' ' ' SER . . . . . . . . . . . . . 94.9 p -67.75 -44.87 76.52 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.798 0.332 . . . . 0.0 110.899 179.844 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 155' ' ' GLY . . . . . 0.486 ' O ' HD23 ' A' ' 159' ' ' LEU . . . -76.7 -38.24 32.41 Favored Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 121.096 -0.573 . . . . 0.0 113.219 -179.684 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 156' ' ' ILE . . . . . 0.62 HG12 ' HB2' ' A' ' 153' ' ' SER . 36.1 mm -48.07 -37.75 7.12 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.229 0 CA-C-O 120.704 0.288 . . . . 0.0 111.404 -179.527 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 157' ' ' LYS . . . . . . . . . . . . . 87.5 tttt -64.76 -42.03 95.44 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 116.351 -0.386 . . . . 0.0 111.316 -179.93 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 85.9 p -71.28 -46.33 61.07 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.94 0.4 . . . . 0.0 111.375 -179.48 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 159' ' ' LEU . . . . . 0.486 HD23 ' O ' ' A' ' 155' ' ' GLY . 4.1 mm? -61.61 -36.29 80.28 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-N 116.006 -0.543 . . . . 0.0 111.558 -179.595 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 160' ' ' TYR . . . . . . . . . . . . . 46.9 t80 -74.25 -46.86 38.84 Favored 'General case' 0 C--N 1.33 -0.274 0 N-CA-C 112.668 0.618 . . . . 0.0 112.668 -178.73 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 21.6 m -58.57 -45.23 90.49 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 N-CA-C 112.277 0.473 . . . . 0.0 112.277 -178.712 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 162' ' ' ARG . . . . . . . . . . . . . 99.9 mtt180 -68.71 -44.78 73.2 Favored 'General case' 0 C--N 1.328 -0.363 0 N-CA-C 111.781 0.289 . . . . 0.0 111.781 -179.38 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 163' ' ' LEU . . . . . 0.689 ' HG ' ' HB2' ' A' ' 208' ' ' PHE . 6.0 mp -67.37 -54.18 22.76 Favored 'General case' 0 C--N 1.328 -0.368 0 N-CA-C 112.006 0.373 . . . . 0.0 112.006 -179.199 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 164' ' ' ARG . . . . . . . . . . . . . 3.7 tmm_? -56.25 -53.12 60.95 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.348 -0.387 . . . . 0.0 111.998 -179.071 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 165' ' ' ASN . . . . . 0.57 ' O ' HG23 ' A' ' 169' ' ' VAL . 5.0 m-20 -54.43 -51.73 64.01 Favored 'General case' 0 C--N 1.331 -0.204 0 CA-C-O 120.788 0.327 . . . . 0.0 111.81 -179.332 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 166' ' ' LEU . . . . . 0.451 ' O ' ' HG ' ' A' ' 170' ' ' LEU . 4.5 tt -60.29 -53.33 59.0 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-N 116.357 -0.383 . . . . 0.0 111.548 -179.31 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 167' ' ' THR . . . . . . . . . . . . . 63.7 m -55.85 -52.74 62.98 Favored 'General case' 0 C--N 1.329 -0.295 0 N-CA-C 113.167 0.803 . . . . 0.0 113.167 -178.767 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 168' ' ' VAL . . . . . 0.426 HG12 ' O ' ' A' ' 165' ' ' ASN . 8.2 p -56.84 -41.23 75.48 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.209 0 N-CA-C 112.226 0.454 . . . . 0.0 112.226 -178.451 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 169' ' ' VAL . . . . . 0.57 HG23 ' O ' ' A' ' 165' ' ' ASN . 74.5 t -58.3 -63.47 0.69 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.395 0 CA-C-N 116.542 -0.299 . . . . 0.0 111.534 -179.716 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 170' ' ' LEU . . . . . 0.451 ' HG ' ' O ' ' A' ' 166' ' ' LEU . 0.8 OUTLIER -64.3 -28.26 69.59 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.551 -0.295 . . . . 0.0 111.769 -179.292 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 171' ' ' TRP . . . . . 0.41 ' HZ3' HD21 ' A' ' 137' ' ' LEU . 4.5 m0 -71.11 -29.96 65.92 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 121.151 0.501 . . . . 0.0 110.216 179.146 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 172' ' ' ALA . . . . . . . . . . . . . . . -71.49 -7.1 45.32 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 115.495 -0.775 . . . . 0.0 110.967 -179.962 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 173' ' ' ILE . . . . . 0.524 ' O ' HG12 ' A' ' 177' ' ' ILE . 16.1 mm -86.75 -23.2 6.82 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.032 -0.531 . . . . 0.0 111.243 -179.993 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 174' ' ' TYR . . . . . 0.452 ' HB2' ' HD3' ' A' ' 175' ' ' PRO . 29.0 m-85 -54.11 -49.94 87.18 Favored Pre-proline 0 N--CA 1.464 0.273 0 CA-C-N 116.409 -0.36 . . . . 0.0 111.89 -179.426 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 175' ' ' PRO . . . . . 0.452 ' HD3' ' HB2' ' A' ' 174' ' ' TYR . 71.2 Cg_exo -48.45 -31.65 18.53 Favored 'Trans proline' 0 C--N 1.351 0.663 0 C-N-CA 121.935 1.757 . . . . 0.0 112.338 179.797 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 176' ' ' PHE . . . . . 0.485 ' O ' ' HG ' ' A' ' 180' ' ' LEU . 82.0 m-85 -80.38 -50.39 10.2 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.005 -0.543 . . . . 0.0 111.882 -179.843 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 177' ' ' ILE . . . . . 0.524 HG12 ' O ' ' A' ' 173' ' ' ILE . 5.3 mm -62.12 -36.16 72.75 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.534 0 N-CA-C 112.562 0.579 . . . . 0.0 112.562 -178.016 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 178' ' ' TRP . . . . . 0.455 ' HH2' ' HB2' ' A' ' 123' ' ' ARG . 83.8 t90 -69.74 -50.18 45.98 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.738 0.304 . . . . 0.0 111.007 179.973 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 179' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -68.99 -55.06 12.03 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.262 -0.426 . . . . 0.0 111.582 -179.159 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 180' ' ' LEU . . . . . 0.757 HD22 HD11 ' A' ' 187' ' ' LEU . 43.3 mt -60.42 -46.75 88.89 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 116.501 -0.318 . . . . 0.0 111.29 -179.473 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . -56.61 177.43 0.85 Allowed Glycine 0 C--N 1.335 0.512 0 C-N-CA 120.384 -0.912 . . . . 0.0 112.715 179.636 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 182' ' ' PRO . . . . . 0.499 ' HA ' ' HB2' ' A' ' 186' ' ' ALA . 83.7 Cg_exo -47.15 -45.24 22.1 Favored 'Trans proline' 0 CA--C 1.536 0.575 0 C-N-CA 122.878 2.385 . . . . 0.0 113.697 -179.802 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 183' ' ' PRO . . . . . 0.423 ' HD3' ' HB2' ' A' ' 182' ' ' PRO . 79.7 Cg_exo -46.38 -29.95 7.66 Favored 'Trans proline' 0 C--N 1.356 0.922 0 C-N-CA 122.195 1.93 . . . . 0.0 113.171 -179.796 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 184' ' ' GLY . . . . . 0.409 ' HA2' ' HD2' ' A' ' 123' ' ' ARG . . . -114.5 -121.3 3.55 Favored Glycine 0 C--N 1.332 0.342 0 C-N-CA 120.335 -0.936 . . . . 0.0 113.001 -179.896 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 185' ' ' VAL . . . . . . . . . . . . . 16.6 m -64.49 -18.57 23.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 N-CA-C 112.02 0.378 . . . . 0.0 112.02 -179.46 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 186' ' ' ALA . . . . . 0.499 ' HB2' ' HA ' ' A' ' 182' ' ' PRO . . . 56.39 87.55 0.06 Allowed 'General case' 0 N--CA 1.463 0.209 0 CA-C-O 120.731 0.301 . . . . 0.0 111.453 179.585 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 187' ' ' LEU . . . . . 0.757 HD11 HD22 ' A' ' 180' ' ' LEU . 18.8 mt -92.05 -49.67 6.09 Favored 'General case' 0 C--N 1.332 -0.195 0 CA-C-O 120.904 0.383 . . . . 0.0 111.367 -179.867 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 188' ' ' LEU . . . . . . . . . . . . . 95.2 mt -106.79 -156.7 0.59 Allowed 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.165 -0.471 . . . . 0.0 111.027 -179.574 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 189' ' ' THR . . . . . . . . . . . . . 1.6 t -96.27 149.18 35.58 Favored Pre-proline 0 C--N 1.329 -0.304 0 CA-C-N 116.056 -0.52 . . . . 0.0 111.203 -179.686 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 190' ' ' PRO . . . . . 0.436 ' O ' HG23 ' A' ' 194' ' ' VAL . 9.9 Cg_endo -51.42 -37.41 61.39 Favored 'Trans proline' 0 C--N 1.349 0.582 0 C-N-CA 122.75 2.3 . . . . 0.0 112.688 -179.869 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 191' ' ' THR . . . . . . . . . . . . . 70.2 p -58.93 -48.66 80.7 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.97 0.415 . . . . 0.0 110.975 179.947 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 192' ' ' VAL . . . . . . . . . . . . . 40.6 t -67.45 -48.48 77.13 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 115.882 -0.599 . . . . 0.0 111.566 -179.772 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 193' ' ' ASP . . . . . . . . . . . . . 22.4 t70 -56.45 -51.92 66.64 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.31 -0.405 . . . . 0.0 111.497 -179.586 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 194' ' ' VAL . . . . . 0.436 HG23 ' O ' ' A' ' 190' ' ' PRO . 79.7 t -58.68 -35.86 57.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.439 -0.346 . . . . 0.0 110.898 179.929 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 195' ' ' ALA . . . . . . . . . . . . . . . -57.57 -44.88 85.62 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.4 -0.363 . . . . 0.0 110.856 179.708 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 196' ' ' LEU . . . . . . . . . . . . . 96.0 mt -68.08 -44.0 77.26 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-N 116.329 -0.396 . . . . 0.0 110.53 179.433 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 197' ' ' ILE . . . . . . . . . . . . . 18.7 mm -56.95 -59.34 3.21 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 115.986 -0.552 . . . . 0.0 110.635 179.53 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 198' ' ' VAL . . . . . . . . . . . . . 79.5 t -52.21 -34.94 18.66 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.509 0 CA-C-N 115.688 -0.687 . . . . 0.0 109.594 178.6 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 199' ' ' TYR . . . . . . . . . . . . . 48.0 t80 -70.52 -32.35 69.79 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 115.47 -0.786 . . . . 0.0 110.819 179.885 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 200' ' ' LEU . . . . . 0.552 ' O ' HG12 ' A' ' 203' ' ' VAL . 21.6 mt -69.99 -40.51 75.29 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 115.973 -0.558 . . . . 0.0 111.458 -179.673 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 201' ' ' ASP . . . . . 0.447 ' HB2' ' OH ' ' A' ' 51' ' ' TYR . 12.8 m-20 -71.83 -35.79 70.01 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-O 121.293 0.568 . . . . 0.0 109.991 179.471 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 202' ' ' LEU . . . . . 0.425 HD11 ' HA2' ' A' ' 11' ' ' GLY . 3.0 mt -69.71 -31.36 69.34 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 115.306 -0.861 . . . . 0.0 111.856 -179.734 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 203' ' ' VAL . . . . . 0.552 HG12 ' O ' ' A' ' 200' ' ' LEU . 13.1 p -76.7 -36.06 26.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 C-N-CA 121.004 -0.279 . . . . 0.0 110.911 -179.087 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 204' ' ' THR . . . . . 0.408 ' O ' ' CD1' ' A' ' 208' ' ' PHE . 53.7 m -63.8 -58.41 6.9 Favored 'General case' 0 C--N 1.33 -0.279 0 C-N-CA 120.585 -0.446 . . . . 0.0 111.389 179.376 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 205' ' ' LYS . . . . . 0.764 ' HE2' ' HB2' ' A' ' 47' ' ' ALA . 52.2 mttp -65.06 -58.31 6.39 Favored 'General case' 0 N--CA 1.464 0.231 0 N-CA-C 112.494 0.553 . . . . 0.0 112.494 -178.347 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 42.6 t -68.42 -36.81 76.4 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.475 0 N-CA-C 112.168 0.432 . . . . 0.0 112.168 -178.898 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 207' ' ' GLY . . . . . 0.546 ' O ' HG13 ' A' ' 211' ' ' ILE . . . -60.2 -60.76 8.03 Favored Glycine 0 N--CA 1.453 -0.226 0 C-N-CA 120.682 -0.771 . . . . 0.0 114.035 -178.349 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 208' ' ' PHE . . . . . 0.689 ' HB2' ' HG ' ' A' ' 163' ' ' LEU . 0.1 OUTLIER -71.55 -26.83 62.79 Favored 'General case' 0 C--O 1.224 -0.287 0 CA-C-N 117.277 0.539 . . . . 0.0 111.653 -178.643 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 209' ' ' GLY . . . . . 0.487 ' O ' ' HB3' ' A' ' 212' ' ' ALA . . . -67.6 -32.44 78.57 Favored Glycine 0 N--CA 1.449 -0.457 0 N-CA-C 111.853 -0.499 . . . . 0.0 111.853 178.966 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 210' ' ' PHE . . . . . . . . . . . . . 0.9 OUTLIER -73.21 -48.29 36.31 Favored 'General case' 0 CA--C 1.514 -0.43 0 N-CA-C 108.291 -1.003 . . . . 0.0 108.291 178.532 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 211' ' ' ILE . . . . . 0.546 HG13 ' O ' ' A' ' 207' ' ' GLY . 5.3 mt -63.48 -27.96 44.04 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.535 0 N-CA-C 107.626 -1.25 . . . . 0.0 107.626 176.715 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 212' ' ' ALA . . . . . 0.487 ' HB3' ' O ' ' A' ' 209' ' ' GLY . . . -63.72 -40.83 97.71 Favored 'General case' 0 N--CA 1.449 -0.483 0 CA-C-N 114.45 -1.25 . . . . 0.0 110.881 179.887 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 213' ' ' LEU . . . . . . . . . . . . . 97.3 mt -69.98 -55.0 10.75 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 115.273 -0.876 . . . . 0.0 112.17 -179.135 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 214' ' ' ASP . . . . . . . . . . . . . 36.2 t70 -53.81 -55.03 30.23 Favored 'General case' 0 C--O 1.234 0.27 0 CA-C-O 120.758 0.313 . . . . 0.0 111.498 -179.417 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 215' ' ' ALA . . . . . . . . . . . . . . . -56.99 -53.06 62.29 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.306 -0.406 . . . . 0.0 111.159 -179.878 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 216' ' ' ALA . . . . . . . . . . . . . . . -58.73 -31.35 68.22 Favored 'General case' 0 C--N 1.332 -0.187 0 CA-C-N 116.443 -0.344 . . . . 0.0 111.286 -179.891 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 217' ' ' ALA . . . . . . . . . . . . . . . -61.82 -39.7 92.7 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 121.076 0.465 . . . . 0.0 109.991 179.573 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 218' ' ' THR . . . . . . . . . . . . . 97.9 m . . . . . 0 C--N 1.331 -0.228 0 CA-C-N 115.726 -0.67 . . . . 0.0 110.793 179.299 . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.453 -0.216 0 N-CA-C 112.577 -0.209 . . . . 0.0 112.577 . . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 32.0 tp -74.83 -36.46 62.41 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-O 120.779 0.323 . . . . 0.0 111.215 -179.913 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 81.5 p -59.43 -29.84 68.05 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.082 -0.508 . . . . 0.0 111.372 -179.641 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 31.3 p -53.55 -35.91 61.27 Favored 'General case' 0 C--N 1.331 -0.196 0 CA-C-N 116.231 -0.441 . . . . 0.0 111.413 -179.798 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 7' ' ' LEU . . . . . . . . . . . . . 3.9 mm? -61.15 -51.09 70.52 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 116.382 -0.372 . . . . 0.0 111.224 -179.774 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 8' ' ' PHE . . . . . . . . . . . . . 83.9 m-85 -60.33 -36.39 77.83 Favored 'General case' 0 C--N 1.331 -0.198 0 CA-C-O 120.978 0.418 . . . . 0.0 110.775 179.871 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 9' ' ' TRP . . . . . 0.442 ' O ' HG12 ' A' ' 13' ' ' ILE . 21.7 m95 -63.58 -41.9 98.34 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 115.781 -0.645 . . . . 0.0 109.897 179.827 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 87.6 mt -60.87 -45.0 96.28 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 115.549 -0.75 . . . . 0.0 110.392 179.315 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -64.42 -26.76 70.94 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.715 -0.755 . . . . 0.0 111.965 179.368 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -74.37 -30.51 62.01 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.772 0.32 . . . . 0.0 110.755 179.716 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 13' ' ' ILE . . . . . 0.442 HG12 ' O ' ' A' ' 9' ' ' TRP . 51.6 mm -69.62 -54.39 19.71 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.227 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.62 179.776 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -61.84 -34.76 89.85 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.582 -0.818 . . . . 0.0 112.033 179.64 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 15' ' ' MET . . . . . 0.516 ' SD ' ' HA ' ' A' ' 44' ' ' SER . 49.1 tpp -66.52 -45.8 78.29 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 120.778 0.323 . . . . 0.0 110.39 179.71 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -54.19 -41.46 68.62 Favored 'General case' 0 C--N 1.331 -0.206 0 CA-C-N 116.053 -0.521 . . . . 0.0 109.759 179.196 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 17' ' ' VAL . . . . . 0.439 HG23 ' O ' ' A' ' 13' ' ' ILE . 63.5 t -59.8 -43.21 91.29 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.187 0 CA-C-N 115.8 -0.636 . . . . 0.0 110.263 179.302 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -65.3 -40.31 96.48 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.694 -0.765 . . . . 0.0 111.58 178.95 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 15.5 m -53.79 -48.84 69.42 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.876 0.369 . . . . 0.0 110.991 -179.997 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 20' ' ' LEU . . . . . 0.418 ' O ' ' HB3' ' A' ' 24' ' ' TRP . 89.2 mt -71.61 -35.05 70.36 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.038 -0.528 . . . . 0.0 111.152 179.894 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -64.06 -34.2 77.48 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.166 -0.47 . . . . 0.0 112.252 -179.332 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 22' ' ' PHE . . . . . 0.56 ' HB2' HG22 ' A' ' 41' ' ' VAL . 4.1 m-85 -90.29 -37.81 13.82 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.67 0.271 . . . . 0.0 111.512 -179.045 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -64.85 -50.75 65.4 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 121.004 0.43 . . . . 0.0 111.731 -179.542 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 24' ' ' TRP . . . . . 0.418 ' HB3' ' O ' ' A' ' 20' ' ' LEU . 5.0 t-105 -63.42 -51.54 65.3 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 115.803 -0.635 . . . . 0.0 111.174 -179.605 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.328 -0.336 0 CA-C-N 116.36 -0.382 . . . . 0.0 111.162 -179.842 . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.313 0 N-CA-C 112.359 -0.297 . . . . 0.0 112.359 . . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 17.6 mm-40 -66.38 -20.51 66.09 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.674 0.273 . . . . 0.0 111.141 179.897 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 34' ' ' ARG . . . . . . . . . . . . . 93.0 mtt180 -48.25 -34.07 9.69 Favored 'General case' 0 C--N 1.332 -0.192 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.623 -179.491 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 82.7 mtp180 -59.01 -52.67 64.77 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-O 120.841 0.353 . . . . 0.0 111.078 -179.83 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 73.4 m-85 -61.22 -29.5 69.86 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 116.058 -0.519 . . . . 0.0 111.189 -179.953 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 37' ' ' TYR . . . . . . . . . . . . . 42.8 m-85 -73.3 -52.62 13.28 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.347 -179.758 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 91.2 t -57.03 -36.92 52.49 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.243 0 CA-C-O 121.064 0.459 . . . . 0.0 110.265 179.536 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 25.6 m -68.07 -46.08 72.03 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 115.649 -0.705 . . . . 0.0 110.467 179.35 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 40' ' ' LEU . . . . . 0.401 HD11 ' HA2' ' A' ' 209' ' ' GLY . 15.8 tp -60.38 -45.51 93.28 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 115.628 -0.715 . . . . 0.0 110.51 179.877 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 41' ' ' VAL . . . . . 0.56 HG22 ' HB2' ' A' ' 22' ' ' PHE . 98.4 t -65.18 -34.02 67.66 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.476 0 CA-C-N 115.843 -0.617 . . . . 0.0 110.125 179.221 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 42' ' ' GLY . . . . . 0.437 ' O ' HG12 ' A' ' 46' ' ' ILE . . . -55.86 -51.57 54.43 Favored Glycine 0 N--CA 1.449 -0.485 0 CA-C-N 115.697 -0.683 . . . . 0.0 112.759 179.854 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 43' ' ' ILE . . . . . 0.737 HG23 HD23 ' A' ' 82' ' ' LEU . 10.7 pt -63.76 -48.93 84.29 Favored 'Isoleucine or valine' 0 C--O 1.231 0.12 0 CA-C-N 116.972 0.386 . . . . 0.0 111.473 -179.963 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 44' ' ' SER . . . . . 0.516 ' HA ' ' SD ' ' A' ' 15' ' ' MET . 47.8 t -60.51 -26.62 66.98 Favored 'General case' 0 CA--C 1.529 0.147 0 CA-C-O 120.968 0.413 . . . . 0.0 111.116 179.831 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -75.85 -60.44 3.16 Favored Glycine 0 CA--C 1.517 0.179 0 C-N-CA 120.966 -0.635 . . . . 0.0 113.206 -179.278 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 46' ' ' ILE . . . . . 0.484 HD11 HG22 ' A' ' 79' ' ' THR . 9.3 pt -57.95 -34.83 49.69 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-O 120.738 0.304 . . . . 0.0 111.339 -179.444 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 47' ' ' ALA . . . . . 0.69 ' HB2' ' HE2' ' A' ' 205' ' ' LYS . . . -67.22 -44.03 80.56 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.526 -0.306 . . . . 0.0 111.035 179.277 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -54.39 -47.07 73.12 Favored 'General case' 0 C--O 1.232 0.151 0 CA-C-N 116.273 -0.421 . . . . 0.0 111.179 -179.975 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 49' ' ' VAL . . . . . 0.445 ' O ' HG13 ' A' ' 53' ' ' VAL . 14.5 m -71.81 -34.11 50.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.292 -0.413 . . . . 0.0 111.004 179.704 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -60.07 -41.32 92.13 Favored 'General case' 0 N--CA 1.462 0.172 0 CA-C-O 121.006 0.432 . . . . 0.0 111.012 179.422 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 38.8 m-85 -73.25 -34.76 66.02 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 115.877 -0.601 . . . . 0.0 110.496 -179.883 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -66.58 -44.86 81.09 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 115.923 -0.581 . . . . 0.0 111.052 179.599 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 53' ' ' VAL . . . . . 0.455 HG23 ' N ' ' A' ' 54' ' ' MET . 31.2 m -66.61 -45.49 88.39 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.137 0 CA-C-N 116.47 -0.332 . . . . 0.0 110.87 -179.997 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 54' ' ' MET . . . . . 0.455 ' N ' HG23 ' A' ' 53' ' ' VAL . 73.1 mtm -64.27 -34.49 78.23 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-O 121.183 0.516 . . . . 0.0 109.941 179.251 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -63.61 -23.29 67.32 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 115.432 -0.804 . . . . 0.0 111.103 179.515 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 93.2 mt -94.12 -5.37 47.39 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 116.262 -0.426 . . . . 0.0 111.077 -179.864 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 98.12 19.42 23.84 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.636 -0.792 . . . . 0.0 112.935 179.743 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 59.7 t -83.61 135.4 24.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-O 120.739 0.304 . . . . 0.0 110.853 179.861 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 59' ' ' GLY . . . . . 0.53 ' HA3' ' HD3' ' A' ' 71' ' ' PRO . . . 81.03 -4.84 68.7 Favored Glycine 0 N--CA 1.45 -0.423 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.599 -179.806 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 60' ' ' TRP . . . . . . . . . . . . . 14.3 m0 -67.3 90.75 0.23 Allowed 'General case' 0 C--N 1.33 -0.248 0 CA-C-O 120.655 0.264 . . . . 0.0 110.836 179.97 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 61' ' ' VAL . . . . . 0.509 HG13 HG23 ' A' ' 68' ' ' VAL . 7.0 p -101.36 130.0 25.75 Favored Pre-proline 0 C--N 1.33 -0.277 0 CA-C-N 116.415 -0.357 . . . . 0.0 111.266 179.914 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 62' ' ' PRO . . . . . 0.449 ' HD3' ' HA ' ' A' ' 61' ' ' VAL . 7.7 Cg_exo -73.84 148.17 40.56 Favored 'Trans proline' 0 C--N 1.35 0.64 0 C-N-CA 122.966 2.444 . . . . 0.0 112.33 179.938 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 86.6 t -143.18 93.73 0.5 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.141 -0.481 . . . . 0.0 111.073 -179.956 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . 59.4 -88.31 0.02 OUTLIER 'General case' 0 C--N 1.332 -0.157 0 CA-C-N 116.129 -0.487 . . . . 0.0 111.485 179.846 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 12.6 pt-20 -123.9 -17.15 6.39 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.292 -0.413 . . . . 0.0 110.763 -179.851 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 66' ' ' ARG . . . . . 0.437 ' NH1' ' HA ' ' A' ' 183' ' ' PRO . 32.7 ptt180 -105.77 159.7 15.8 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 115.902 -0.59 . . . . 0.0 110.532 -179.925 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 40.0 m -119.23 138.54 52.91 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-O 120.902 0.382 . . . . 0.0 111.466 -179.646 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 68' ' ' VAL . . . . . 0.509 HG23 HG13 ' A' ' 61' ' ' VAL . 14.8 m -125.82 146.49 31.48 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.412 0 CA-C-N 115.846 -0.615 . . . . 0.0 110.732 179.666 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 69' ' ' PHE . . . . . . . . . . . . . 17.7 m-85 -108.78 115.7 30.59 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.195 -179.423 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 70' ' ' VAL . . . . . 0.55 HG12 ' HD3' ' A' ' 71' ' ' PRO . 0.3 OUTLIER -68.08 -33.47 5.01 Favored Pre-proline 0 CA--C 1.54 0.579 0 N-CA-C 112.749 0.648 . . . . 0.0 112.749 -179.24 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 71' ' ' PRO . . . . . 0.55 ' HD3' HG12 ' A' ' 70' ' ' VAL . 17.6 Cg_exo -66.39 -32.31 41.03 Favored 'Trans proline' 0 C--N 1.358 1.078 0 C-N-CA 121.781 1.654 . . . . 0.0 112.389 -178.989 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 72' ' ' ARG . . . . . 0.405 ' HD2' HG21 ' A' ' 197' ' ' ILE . 61.8 ttp180 -65.56 -51.13 62.11 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 121.178 0.513 . . . . 0.0 109.845 179.419 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 73' ' ' TYR . . . . . . . . . . . . . 45.9 m-85 -63.67 -46.92 83.4 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 115.522 -0.763 . . . . 0.0 110.697 179.752 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 0.4 OUTLIER -63.62 -34.84 70.22 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.308 -0.405 . . . . 0.0 110.175 179.64 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 75' ' ' ASP . . . . . 0.489 ' O ' HG23 ' A' ' 79' ' ' THR . 28.6 t70 -58.31 -39.37 79.2 Favored 'General case' 0 C--N 1.332 -0.157 0 N-CA-C 109.497 -0.557 . . . . 0.0 109.497 179.263 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 76' ' ' TRP . . . . . . . . . . . . . 53.1 m0 -67.44 -37.13 82.52 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 115.728 -0.669 . . . . 0.0 110.485 179.479 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 77' ' ' ILE . . . . . 0.431 ' O ' ' HG2' ' A' ' 81' ' ' PRO . 66.8 mt -59.74 -34.07 54.31 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 CA-C-N 115.971 -0.559 . . . . 0.0 110.844 179.79 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 20.0 mt -91.79 -27.03 18.26 Favored 'General case' 0 C--N 1.329 -0.313 0 N-CA-C 112.655 0.613 . . . . 0.0 112.655 -179.581 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 79' ' ' THR . . . . . 0.489 HG23 ' O ' ' A' ' 75' ' ' ASP . 78.6 p -90.49 -52.74 4.76 Favored 'General case' 0 N--CA 1.464 0.267 0 N-CA-C 113.747 1.017 . . . . 0.0 113.747 -177.688 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 80' ' ' THR . . . . . 0.642 ' HB ' ' HD3' ' A' ' 81' ' ' PRO . 33.1 m -48.35 -54.06 29.1 Favored Pre-proline 0 CA--C 1.531 0.228 0 N-CA-C 112.804 0.668 . . . . 0.0 112.804 -178.126 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 81' ' ' PRO . . . . . 0.642 ' HD3' ' HB ' ' A' ' 80' ' ' THR . 49.0 Cg_exo -56.43 -27.38 67.86 Favored 'Trans proline' 0 C--N 1.351 0.702 0 C-N-CA 121.572 1.515 . . . . 0.0 111.683 -179.76 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 82' ' ' LEU . . . . . 0.737 HD23 HG23 ' A' ' 43' ' ' ILE . 12.9 tp -76.96 -32.95 57.66 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 115.882 -0.599 . . . . 0.0 110.655 -179.999 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 48.5 mm -65.95 -53.85 33.52 Favored 'Isoleucine or valine' 0 C--O 1.233 0.215 0 N-CA-C 110.05 -0.352 . . . . 0.0 110.05 179.06 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 12.6 m -60.6 -29.93 45.76 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.26 0 N-CA-C 109.253 -0.647 . . . . 0.0 109.253 178.43 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 85' ' ' TYR . . . . . . . . . . . . . 66.3 t80 -65.53 -34.34 78.02 Favored 'General case' 0 N--CA 1.455 -0.215 0 CA-C-N 115.432 -0.804 . . . . 0.0 109.252 178.354 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 86' ' ' PHE . . . . . . . . . . . . . 2.1 t80 -61.31 -51.47 68.72 Favored 'General case' 0 C--O 1.231 0.129 0 CA-C-N 115.762 -0.654 . . . . 0.0 109.623 179.217 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 7.4 mp -64.0 -31.38 72.55 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 115.801 -0.636 . . . . 0.0 110.119 179.414 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -66.6 -27.78 73.39 Favored Glycine 0 N--CA 1.449 -0.459 0 C-N-CA 120.807 -0.711 . . . . 0.0 111.742 179.322 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 88.6 mt -75.96 -44.93 37.54 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 120.81 0.338 . . . . 0.0 110.691 179.586 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 80.3 mt -54.97 -38.24 67.53 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 115.904 -0.589 . . . . 0.0 110.859 179.898 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -84.34 -54.02 5.07 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.058 -0.519 . . . . 0.0 111.079 179.953 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 100.14 65.13 0.81 Allowed Glycine 0 N--CA 1.452 -0.234 0 C-N-CA 120.887 -0.673 . . . . 0.0 112.416 179.989 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 93' ' ' LEU . . . . . 0.532 ' HB3' ' HB2' ' A' ' 97' ' ' GLU . 6.9 mp -81.51 165.63 21.02 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-O 120.795 0.331 . . . . 0.0 110.746 179.932 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 94' ' ' ASP . . . . . . . . . . . . . 9.0 m-20 -82.75 178.0 8.4 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.837 179.928 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 82.5 p -64.11 -34.47 78.11 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.07 -0.513 . . . . 0.0 111.072 -179.983 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 84.6 mtm180 -73.6 -51.27 17.42 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.279 -0.418 . . . . 0.0 111.094 -179.751 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 97' ' ' GLU . . . . . 0.532 ' HB2' ' HB3' ' A' ' 93' ' ' LEU . 20.2 mt-10 -57.39 -44.4 84.44 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.453 -0.34 . . . . 0.0 110.748 -179.842 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 98' ' ' PHE . . . . . . . . . . . . . 1.7 m-85 -57.46 -50.58 72.58 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.311 -0.404 . . . . 0.0 110.933 179.812 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -54.45 -34.8 55.21 Favored Glycine 0 N--CA 1.452 -0.278 0 C-N-CA 120.883 -0.675 . . . . 0.0 112.584 -179.966 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 96.5 mt -66.74 -43.17 90.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-O 120.89 0.376 . . . . 0.0 111.632 -179.823 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 59.6 t -69.17 -44.26 80.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.629 -179.545 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 102' ' ' ILE . . . . . . . . . . . . . 37.7 mm -65.52 -46.69 89.06 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.378 0 CA-C-N 116.405 -0.361 . . . . 0.0 111.629 -179.227 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 15.3 t -61.85 -35.93 79.74 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 120.643 0.259 . . . . 0.0 111.258 -179.588 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 29.4 tp -62.62 -46.68 87.17 Favored 'General case' 0 C--N 1.332 -0.169 0 CA-C-O 120.843 0.354 . . . . 0.0 110.761 179.781 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 105' ' ' ASN . . . . . 0.621 HD21 HD13 ' A' ' 137' ' ' LEU . 0.9 OUTLIER -64.73 -26.18 68.25 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.69 179.697 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 53.8 m -67.1 -55.23 15.14 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.124 -0.489 . . . . 0.0 111.401 -179.927 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 7.1 p -62.43 -38.53 81.53 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.193 0 CA-C-N 116.477 -0.329 . . . . 0.0 111.103 -179.841 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 59.4 t -62.58 -44.75 99.65 Favored 'Isoleucine or valine' 0 C--O 1.234 0.269 0 CA-C-O 121.051 0.453 . . . . 0.0 110.573 179.545 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 109' ' ' MET . . . . . 0.521 ' HE1' HG21 ' A' ' 80' ' ' THR . 7.7 tpp -67.38 -25.69 66.09 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 115.979 -0.555 . . . . 0.0 110.113 179.594 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 20.2 tp -75.93 -30.95 58.9 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 115.764 -0.653 . . . . 0.0 110.296 179.633 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -66.83 -54.23 24.6 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 115.934 -0.575 . . . . 0.0 110.72 179.662 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . -62.1 -47.55 89.1 Favored Glycine 0 C--N 1.331 0.283 0 C-N-CA 120.627 -0.797 . . . . 0.0 111.976 179.558 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 113' ' ' PHE . . . . . . . . . . . . . 3.4 t80 -50.5 -58.08 6.61 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.717 0.294 . . . . 0.0 110.68 179.362 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -71.95 -16.82 62.1 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.687 179.587 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -60.4 -48.69 84.94 Favored Glycine 0 C--N 1.331 0.295 0 C-N-CA 121.091 -0.576 . . . . 0.0 112.412 179.948 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 116' ' ' ALA . . . . . 0.516 ' HB2' ' HB3' ' A' ' 183' ' ' PRO . . . -77.83 -15.05 59.35 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-O 120.773 0.321 . . . . 0.0 111.361 179.991 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 117' ' ' MET . . . . . 0.439 ' SD ' HG21 ' A' ' 68' ' ' VAL . 25.4 mmt -90.29 14.32 13.04 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.298 -0.41 . . . . 0.0 111.6 -179.433 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 118' ' ' VAL . . . . . 0.432 HG21 ' HB3' ' A' ' 123' ' ' ARG . 26.0 m -82.16 143.72 49.44 Favored Pre-proline 0 C--N 1.331 -0.229 0 CA-C-N 116.649 -0.251 . . . . 0.0 111.196 -179.959 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 119' ' ' PRO . . . . . . . . . . . . . 67.8 Cg_endo -92.9 -1.48 3.64 Favored 'Trans proline' 0 N--CA 1.457 -0.668 0 C-N-CA 122.907 2.405 . . . . 0.0 112.416 179.551 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -138.18 -114.16 1.23 Allowed Glycine 0 C--N 1.333 0.371 0 C-N-CA 120.694 -0.765 . . . . 0.0 113.029 -179.655 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 37.0 pt -126.15 13.13 3.99 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.188 0 CA-C-O 120.781 0.324 . . . . 0.0 111.683 -179.564 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 12.2 mm-40 -61.27 -18.8 60.24 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.332 -0.395 . . . . 0.0 111.187 -179.986 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 123' ' ' ARG . . . . . 0.432 ' HB3' HG21 ' A' ' 118' ' ' VAL . 28.0 ptt180 -50.65 -38.26 45.42 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 116.0 -0.545 . . . . 0.0 111.672 -179.828 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 124' ' ' TYR . . . . . . . . . . . . . 57.5 m-85 -64.9 -33.5 76.17 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.401 -0.363 . . . . 0.0 111.241 -179.605 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 125' ' ' ALA . . . . . . . . . . . . . . . -71.98 -56.0 6.44 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 120.946 0.403 . . . . 0.0 111.204 -179.998 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 1.2 mt -52.11 -52.36 51.98 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 115.923 -0.58 . . . . 0.0 111.011 -179.871 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 127' ' ' PHE . . . . . . . . . . . . . 11.6 t80 -64.0 -37.66 88.24 Favored 'General case' 0 N--CA 1.453 -0.304 0 C-N-CA 120.778 -0.369 . . . . 0.0 110.866 179.927 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 128' ' ' GLY . . . . . . . . . . . . . . . -46.47 -44.6 16.28 Favored Glycine 0 C--N 1.332 0.349 0 C-N-CA 120.227 -0.987 . . . . 0.0 110.95 179.35 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 129' ' ' MET . . . . . . . . . . . . . 0.3 OUTLIER -70.56 -37.01 73.94 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 115.392 -0.404 . . . . 0.0 109.947 178.839 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -68.77 -26.92 74.24 Favored Glycine 0 C--N 1.331 0.3 0 CA-C-N 115.842 -0.617 . . . . 0.0 112.94 -179.872 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 131' ' ' ALA . . . . . 0.456 ' O ' ' HB3' ' A' ' 134' ' ' PHE . . . -74.66 -53.6 9.0 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.821 0.343 . . . . 0.0 110.208 179.869 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 58.0 t -58.56 -39.92 77.19 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 N-CA-C 109.09 -0.707 . . . . 0.0 109.09 178.486 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -66.87 -35.31 79.74 Favored 'General case' 0 N--CA 1.453 -0.313 0 CA-C-N 115.276 -0.875 . . . . 0.0 110.412 179.21 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 134' ' ' PHE . . . . . 0.456 ' HB3' ' O ' ' A' ' 131' ' ' ALA . 17.6 t80 -54.26 -56.63 16.49 Favored 'General case' 0 N--CA 1.455 -0.208 0 CA-C-N 116.128 -0.487 . . . . 0.0 109.889 179.425 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 135' ' ' ILE . . . . . 0.479 ' O ' HG22 ' A' ' 138' ' ' VAL . 34.7 mt -56.69 -33.4 40.26 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.323 0 CA-C-N 115.564 -0.744 . . . . 0.0 110.082 179.388 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . -59.87 -35.99 88.57 Favored Glycine 0 N--CA 1.449 -0.447 0 C-N-CA 120.241 -0.981 . . . . 0.0 111.108 178.679 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 137' ' ' LEU . . . . . 0.621 HD13 HD21 ' A' ' 105' ' ' ASN . 56.1 tp -70.86 -55.49 8.38 Favored 'General case' 0 N--CA 1.453 -0.276 0 CA-C-N 115.772 -0.214 . . . . 0.0 110.671 179.376 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 138' ' ' VAL . . . . . 0.479 HG22 ' O ' ' A' ' 135' ' ' ILE . 3.1 m -54.87 -30.3 22.83 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.222 0 N-CA-C 109.171 -0.677 . . . . 0.0 109.171 179.715 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 139' ' ' TYR . . . . . . . . . . . . . 27.1 t80 -62.49 -43.61 98.39 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 115.168 -0.923 . . . . 0.0 109.956 178.083 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 22.2 m-85 -67.48 -44.35 78.78 Favored 'General case' 0 C--O 1.232 0.151 0 CA-C-N 116.301 -0.409 . . . . 0.0 110.467 179.011 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 141' ' ' LEU . . . . . 0.441 HD13 ' O ' ' A' ' 137' ' ' LEU . 11.0 mp -55.02 -32.57 61.94 Favored 'General case' 0 C--N 1.332 -0.183 0 CA-C-N 116.004 -0.544 . . . . 0.0 111.253 -179.719 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 10.8 p -101.44 -10.19 8.99 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-O 121.055 0.455 . . . . 0.0 110.693 179.929 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . -75.99 -135.54 0.56 Allowed Glycine 0 CA--C 1.522 0.476 0 CA-C-N 115.852 -0.613 . . . . 0.0 112.693 -179.902 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 144' ' ' PRO . . . . . . . . . . . . . 50.0 Cg_exo -53.25 -23.95 24.98 Favored 'Trans proline' 0 C--N 1.347 0.478 0 C-N-CA 122.659 2.239 . . . . 0.0 113.055 -179.688 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 145' ' ' MET . . . . . 0.429 ' HB3' ' OH ' ' A' ' 160' ' ' TYR . 41.2 mtt -57.33 -38.01 73.41 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-O 120.67 0.271 . . . . 0.0 111.549 -179.623 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 146' ' ' THR . . . . . . . . . . . . . 60.4 p -65.45 -49.06 70.55 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.443 -0.344 . . . . 0.0 111.686 -179.443 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 43.9 mt-10 -71.48 -25.4 62.26 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.422 -0.354 . . . . 0.0 111.532 -179.462 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 148' ' ' SER . . . . . . . . . . . . . 48.2 t -68.89 -46.28 68.78 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-O 120.935 0.398 . . . . 0.0 110.827 -179.574 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 149' ' ' ALA . . . . . 0.506 ' HB1' HG22 ' A' ' 156' ' ' ILE . . . -78.13 -32.14 50.25 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.028 -0.533 . . . . 0.0 111.357 -179.858 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 150' ' ' SER . . . . . . . . . . . . . 41.6 t -63.07 -14.83 53.08 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.02 -0.536 . . . . 0.0 111.555 -179.603 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 151' ' ' GLN . . . . . . . . . . . . . 9.8 pt20 -110.71 17.2 20.87 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.659 -0.246 . . . . 0.0 111.624 -179.747 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 29.7 mmt180 -98.64 -52.51 3.59 Favored 'General case' 0 C--N 1.332 -0.184 0 C-N-CA 120.856 -0.338 . . . . 0.0 110.803 179.613 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 153' ' ' SER . . . . . 0.654 ' HB3' HG12 ' A' ' 156' ' ' ILE . 21.0 t -158.1 172.2 18.84 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.792 179.007 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 154' ' ' SER . . . . . . . . . . . . . 43.3 t -71.94 -38.4 69.83 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.307 -0.406 . . . . 0.0 110.385 179.303 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -76.87 -37.68 33.02 Favored Glycine 0 N--CA 1.45 -0.384 0 C-N-CA 120.924 -0.655 . . . . 0.0 112.647 179.8 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 156' ' ' ILE . . . . . 0.654 HG12 ' HB3' ' A' ' 153' ' ' SER . 37.8 mm -52.25 -39.79 28.77 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.236 0 CA-C-O 120.724 0.297 . . . . 0.0 111.431 -179.563 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 157' ' ' LYS . . . . . . . . . . . . . 56.0 tttm -69.65 -34.59 74.22 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-N 116.318 -0.401 . . . . 0.0 111.138 -179.921 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 46.5 t -72.25 -39.96 68.06 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 120.942 0.401 . . . . 0.0 111.309 -179.208 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 159' ' ' LEU . . . . . 0.44 HD13 ' HB1' ' A' ' 215' ' ' ALA . 12.9 mt -72.58 -35.19 67.86 Favored 'General case' 0 C--N 1.326 -0.449 0 CA-C-N 116.066 -0.516 . . . . 0.0 111.315 -179.314 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 160' ' ' TYR . . . . . 0.429 ' OH ' ' HB3' ' A' ' 145' ' ' MET . 37.5 t80 -70.38 -42.36 71.83 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.648 -0.251 . . . . 0.0 111.599 -179.075 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 161' ' ' VAL . . . . . 0.41 HG23 ' N ' ' A' ' 162' ' ' ARG . 23.0 m -65.06 -43.91 95.87 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-O 120.719 0.295 . . . . 0.0 111.367 -179.644 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 162' ' ' ARG . . . . . 0.41 ' N ' HG23 ' A' ' 161' ' ' VAL . 21.2 mmm180 -69.29 -46.53 66.96 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.914 0.387 . . . . 0.0 111.248 179.994 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 163' ' ' LEU . . . . . . . . . . . . . 1.3 mp -61.79 -54.8 37.33 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 115.971 -0.559 . . . . 0.0 111.702 -179.548 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 164' ' ' ARG . . . . . . . . . . . . . 25.4 ttp85 -58.09 -48.23 80.8 Favored 'General case' 0 C--N 1.331 -0.237 0 N-CA-C 112.459 0.54 . . . . 0.0 112.459 -178.843 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 165' ' ' ASN . . . . . 0.491 ' O ' HG23 ' A' ' 169' ' ' VAL . 5.8 m-20 -52.34 -51.38 59.1 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-O 120.942 0.401 . . . . 0.0 110.719 -179.205 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 166' ' ' LEU . . . . . 0.529 ' O ' ' HG ' ' A' ' 170' ' ' LEU . 3.6 tt -65.41 -41.48 93.58 Favored 'General case' 0 C--N 1.324 -0.515 0 CA-C-N 116.089 -0.505 . . . . 0.0 111.36 -179.895 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 167' ' ' THR . . . . . . . . . . . . . 51.1 m -65.18 -54.11 34.69 Favored 'General case' 0 C--N 1.331 -0.232 0 N-CA-C 112.51 0.559 . . . . 0.0 112.51 -178.465 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 168' ' ' VAL . . . . . . . . . . . . . 9.1 p -54.47 -40.46 49.54 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-O 120.644 0.259 . . . . 0.0 111.67 -179.385 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 169' ' ' VAL . . . . . 0.491 HG23 ' O ' ' A' ' 165' ' ' ASN . 55.5 t -59.72 -65.11 0.49 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.486 -0.324 . . . . 0.0 111.634 -179.844 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 170' ' ' LEU . . . . . 0.529 ' HG ' ' O ' ' A' ' 166' ' ' LEU . 2.0 pp -62.79 -27.14 69.09 Favored 'General case' 0 C--N 1.33 -0.262 0 N-CA-C 112.139 0.422 . . . . 0.0 112.139 -178.806 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 171' ' ' TRP . . . . . 0.473 ' HZ3' HD21 ' A' ' 137' ' ' LEU . 1.8 m0 -73.35 -32.48 64.56 Favored 'General case' 0 C--N 1.33 -0.245 0 C-N-CA 120.588 -0.445 . . . . 0.0 110.707 179.69 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 172' ' ' ALA . . . . . 0.415 ' HA ' ' CZ ' ' A' ' 134' ' ' PHE . . . -67.94 -7.76 31.26 Favored 'General case' 0 CA--C 1.52 -0.208 0 CA-C-O 121.345 0.593 . . . . 0.0 110.157 179.287 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 173' ' ' ILE . . . . . 0.723 HG22 ' CG1' ' A' ' 177' ' ' ILE . 9.0 mm -84.15 -36.26 11.79 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.555 0 CA-C-N 114.954 -1.021 . . . . 0.0 111.501 -179.03 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 174' ' ' TYR . . . . . 0.548 ' N ' ' HD2' ' A' ' 175' ' ' PRO . 70.2 m-85 -55.56 -51.66 78.26 Favored Pre-proline 0 C--N 1.328 -0.33 0 N-CA-C 112.507 0.558 . . . . 0.0 112.507 -178.9 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 175' ' ' PRO . . . . . 0.548 ' HD2' ' N ' ' A' ' 174' ' ' TYR . 26.7 Cg_endo -60.19 -41.12 53.98 Favored 'Trans proline' 0 C--N 1.349 0.57 0 C-N-CA 122.107 1.871 . . . . 0.0 113.359 -178.776 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 176' ' ' PHE . . . . . 0.529 ' CE2' ' HA ' ' A' ' 173' ' ' ILE . 0.1 OUTLIER -79.83 -37.83 34.18 Favored 'General case' 0 C--N 1.329 -0.32 0 C-N-CA 120.609 -0.437 . . . . 0.0 112.12 -178.413 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 177' ' ' ILE . . . . . 0.723 ' CG1' HG22 ' A' ' 173' ' ' ILE . 32.4 mm -63.76 -47.33 91.49 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.614 0 CA-C-O 120.873 0.368 . . . . 0.0 110.032 178.425 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 178' ' ' TRP . . . . . . . . . . . . . 60.5 t90 -52.91 -29.61 29.46 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 115.788 -0.642 . . . . 0.0 109.857 179.202 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 179' ' ' LEU . . . . . 0.528 HD13 ' O ' ' A' ' 179' ' ' LEU . 0.9 OUTLIER -72.76 -37.56 67.63 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 115.359 -0.837 . . . . 0.0 110.689 179.898 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 180' ' ' LEU . . . . . 0.447 ' HB3' HD12 ' A' ' 187' ' ' LEU . 0.9 OUTLIER -78.31 -51.79 9.59 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.548 -0.296 . . . . 0.0 111.626 -179.399 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . -51.13 171.8 0.2 Allowed Glycine 0 C--N 1.336 0.551 0 C-N-CA 120.941 -0.647 . . . . 0.0 113.292 -179.685 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 182' ' ' PRO . . . . . 0.585 ' N ' ' HD2' ' A' ' 183' ' ' PRO . 2.5 Cg_endo -42.68 -47.81 7.59 Favored 'Trans proline' 0 C--N 1.351 0.661 0 C-N-CA 123.316 2.678 . . . . 0.0 114.015 -179.837 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 183' ' ' PRO . . . . . 0.585 ' HD2' ' N ' ' A' ' 182' ' ' PRO . 9.4 Cg_endo -50.04 -29.93 23.2 Favored 'Trans proline' 0 C--N 1.357 0.992 0 C-N-CA 122.269 1.979 . . . . 0.0 112.62 -179.754 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 184' ' ' GLY . . . . . . . . . . . . . . . -95.93 -105.08 2.12 Favored Glycine 0 N--CA 1.45 -0.368 0 C-N-CA 120.716 -0.754 . . . . 0.0 112.73 -179.904 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 185' ' ' VAL . . . . . . . . . . . . . 0.9 OUTLIER -109.4 -0.37 9.68 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-O 120.672 0.272 . . . . 0.0 111.654 -179.525 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 186' ' ' ALA . . . . . 0.49 ' HB2' ' HA ' ' A' ' 182' ' ' PRO . . . 55.31 84.88 0.07 Allowed 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.26 -0.427 . . . . 0.0 111.74 179.535 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 187' ' ' LEU . . . . . 0.447 HD12 ' HB3' ' A' ' 180' ' ' LEU . 16.4 mt -92.3 -49.44 6.16 Favored 'General case' 0 C--N 1.332 -0.162 0 CA-C-O 121.041 0.448 . . . . 0.0 110.676 179.452 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 188' ' ' LEU . . . . . . . . . . . . . 72.8 mt -102.81 -160.64 0.79 Allowed 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 115.763 -0.653 . . . . 0.0 111.282 -179.409 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 189' ' ' THR . . . . . 0.452 ' HB ' HG23 ' A' ' 192' ' ' VAL . 10.4 m -88.11 136.64 31.85 Favored Pre-proline 0 C--N 1.33 -0.249 0 CA-C-N 115.866 -0.607 . . . . 0.0 110.615 -179.805 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 190' ' ' PRO . . . . . . . . . . . . . 82.1 Cg_exo -46.58 -49.74 11.55 Favored 'Trans proline' 0 C--N 1.35 0.607 0 C-N-CA 122.614 2.209 . . . . 0.0 113.053 -179.63 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 191' ' ' THR . . . . . 0.427 HG22 HG22 ' A' ' 189' ' ' THR . 7.1 t -61.4 -35.6 77.95 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.485 -0.325 . . . . 0.0 111.77 -179.478 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 192' ' ' VAL . . . . . 0.452 HG23 ' HB ' ' A' ' 189' ' ' THR . 89.3 t -71.45 -47.09 60.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-O 120.833 0.349 . . . . 0.0 111.278 -179.708 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 193' ' ' ASP . . . . . . . . . . . . . 24.4 t70 -58.93 -43.98 91.27 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.752 -179.944 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 194' ' ' VAL . . . . . . . . . . . . . 78.3 t -63.16 -37.98 80.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.929 179.787 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 195' ' ' ALA . . . . . . . . . . . . . . . -57.22 -46.56 82.83 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.484 -0.325 . . . . 0.0 111.093 179.829 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 196' ' ' LEU . . . . . 0.426 ' O ' ' HB3' ' A' ' 199' ' ' TYR . 80.8 mt -67.75 -33.44 74.87 Favored 'General case' 0 C--N 1.332 -0.188 0 CA-C-N 116.381 -0.372 . . . . 0.0 110.633 179.691 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 197' ' ' ILE . . . . . 0.507 HD13 HD12 ' A' ' 200' ' ' LEU . 21.1 mm -64.57 -50.48 75.69 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.112 179.126 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 198' ' ' VAL . . . . . . . . . . . . . 85.0 t -56.72 -34.08 42.11 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.478 0 N-CA-C 108.707 -0.849 . . . . 0.0 108.707 178.171 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 199' ' ' TYR . . . . . 0.502 ' O ' HG23 ' A' ' 203' ' ' VAL . 80.5 t80 -68.38 -43.72 76.69 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 114.939 -1.028 . . . . 0.0 110.167 179.544 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 200' ' ' LEU . . . . . 0.507 HD12 HD13 ' A' ' 197' ' ' ILE . 65.0 mt -56.61 -55.02 39.25 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 115.496 -0.775 . . . . 0.0 111.172 -179.667 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 201' ' ' ASP . . . . . . . . . . . . . 11.6 m-20 -64.82 -38.07 89.74 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.85 179.918 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 202' ' ' LEU . . . . . . . . . . . . . 23.5 tp -64.99 -26.05 68.12 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 115.703 -0.681 . . . . 0.0 111.393 -179.554 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 203' ' ' VAL . . . . . 0.502 HG23 ' O ' ' A' ' 199' ' ' TYR . 45.0 t -82.58 -36.55 13.54 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.365 0 CA-C-N 116.635 -0.257 . . . . 0.0 111.454 -179.397 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 204' ' ' THR . . . . . 0.402 ' O ' ' HB3' ' A' ' 208' ' ' PHE . 88.2 m -63.51 -49.18 74.55 Favored 'General case' 0 C--N 1.329 -0.318 0 C-N-CA 120.773 -0.371 . . . . 0.0 111.319 179.837 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 205' ' ' LYS . . . . . 0.69 ' HE2' ' HB2' ' A' ' 47' ' ' ALA . 61.0 mttp -73.32 -46.79 47.38 Favored 'General case' 0 C--N 1.326 -0.429 0 N-CA-C 111.934 0.346 . . . . 0.0 111.934 -178.926 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 94.9 t -74.14 -50.57 27.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-O 120.572 0.225 . . . . 0.0 111.398 -179.805 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 207' ' ' GLY . . . . . . . . . . . . . . . -60.0 -58.19 15.43 Favored Glycine 0 CA--C 1.519 0.292 0 C-N-CA 121.112 -0.566 . . . . 0.0 112.862 179.988 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 208' ' ' PHE . . . . . 0.443 ' O ' ' N ' ' A' ' 212' ' ' ALA . 4.3 t80 -56.27 -44.35 79.66 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.601 0.239 . . . . 0.0 110.744 179.75 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 209' ' ' GLY . . . . . 0.491 ' HA2' ' HB3' ' A' ' 212' ' ' ALA . . . -66.36 -37.7 93.0 Favored Glycine 0 C--N 1.33 0.243 0 CA-C-N 115.811 -0.631 . . . . 0.0 113.41 -179.686 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 210' ' ' PHE . . . . . . . . . . . . . 1.7 m-85 -69.14 -43.85 73.52 Favored 'General case' 0 CA--C 1.51 -0.592 0 N-CA-C 107.64 -1.244 . . . . 0.0 107.64 178.99 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 211' ' ' ILE . . . . . . . . . . . . . 79.8 mt -65.76 -29.62 47.54 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.827 0 N-CA-C 107.193 -1.41 . . . . 0.0 107.193 176.319 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 212' ' ' ALA . . . . . 0.491 ' HB3' ' HA2' ' A' ' 209' ' ' GLY . . . -68.94 -34.92 76.14 Favored 'General case' 0 N--CA 1.449 -0.483 0 CA-C-N 114.437 -1.256 . . . . 0.0 109.969 179.413 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 213' ' ' LEU . . . . . . . . . . . . . 57.6 mt -70.35 -55.34 9.37 Favored 'General case' 0 C--N 1.331 -0.205 0 CA-C-N 115.056 -0.975 . . . . 0.0 111.458 -179.55 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 214' ' ' ASP . . . . . . . . . . . . . 16.7 t70 -59.48 -26.88 65.63 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.284 -0.416 . . . . 0.0 110.59 179.974 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 215' ' ' ALA . . . . . 0.44 ' HB1' HD13 ' A' ' 159' ' ' LEU . . . -71.04 -57.69 4.29 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 115.906 -0.588 . . . . 0.0 111.521 -179.911 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 216' ' ' ALA . . . . . . . . . . . . . . . -62.76 -37.49 86.84 Favored 'General case' 0 C--N 1.332 -0.187 0 CA-C-N 116.43 -0.35 . . . . 0.0 111.267 -179.702 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 217' ' ' ALA . . . . . . . . . . . . . . . -60.06 -42.98 95.66 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.312 -0.404 . . . . 0.0 110.3 179.531 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 218' ' ' THR . . . . . . . . . . . . . 98.3 m . . . . . 0 C--N 1.329 -0.284 0 CA-C-N 115.865 -0.607 . . . . 0.0 110.57 179.405 . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.3 0 N-CA-C 112.72 -0.152 . . . . 0.0 112.72 . . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 59.0 tp -74.44 -38.16 63.08 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.886 0.375 . . . . 0.0 110.988 -179.967 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 40.6 p -65.0 -29.57 70.5 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 115.936 -0.574 . . . . 0.0 111.442 -179.74 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 17.8 p -51.92 -35.22 44.92 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.278 -0.419 . . . . 0.0 111.561 -179.497 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 7' ' ' LEU . . . . . . . . . . . . . 4.0 mm? -58.22 -53.4 58.73 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.332 -0.395 . . . . 0.0 111.216 -179.877 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 8' ' ' PHE . . . . . 0.479 ' HB2' ' HB2' ' A' ' 55' ' ' ALA . 74.2 m-85 -61.47 -35.21 77.0 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.826 179.998 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 9' ' ' TRP . . . . . . . . . . . . . 55.2 m95 -64.74 -41.26 96.07 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 115.991 -0.55 . . . . 0.0 110.227 179.916 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 44.9 mt -62.37 -46.46 88.54 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 115.817 -0.629 . . . . 0.0 110.461 179.53 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 11' ' ' GLY . . . . . 0.419 ' O ' ' HG2' ' A' ' 15' ' ' MET . . . -61.99 -32.57 82.62 Favored Glycine 0 N--CA 1.45 -0.425 0 C-N-CA 120.703 -0.761 . . . . 0.0 111.817 179.369 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -67.56 -34.26 76.7 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-O 120.83 0.348 . . . . 0.0 110.707 179.852 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 65.6 mt -65.97 -46.94 86.9 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.238 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.144 179.396 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -59.83 -33.48 78.43 Favored Glycine 0 N--CA 1.45 -0.388 0 C-N-CA 120.726 -0.75 . . . . 0.0 111.712 179.208 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 15' ' ' MET . . . . . 0.545 ' HE3' ' CB ' ' A' ' 47' ' ' ALA . 24.1 mmt -70.33 -40.56 74.08 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 120.861 0.362 . . . . 0.0 110.507 179.425 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 27.9 tp -57.66 -39.31 76.77 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.047 -0.524 . . . . 0.0 110.562 179.792 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 56.1 t -67.28 -48.0 79.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.062 -0.517 . . . . 0.0 110.89 179.973 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -62.57 -49.33 74.45 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.705 -0.759 . . . . 0.0 111.86 179.507 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 38.2 m -49.65 -44.49 47.7 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-O 120.721 0.296 . . . . 0.0 111.279 -179.828 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 79.6 mt -72.14 -44.32 63.31 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.244 -0.434 . . . . 0.0 111.664 179.819 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -60.93 -29.93 69.91 Favored 'General case' 0 C--N 1.329 -0.299 0 N-CA-C 112.18 0.437 . . . . 0.0 112.18 -179.14 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 22' ' ' PHE . . . . . 0.644 ' HB2' HG22 ' A' ' 41' ' ' VAL . 8.7 m-85 -90.61 -34.57 15.42 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.757 0.313 . . . . 0.0 111.411 -179.31 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -67.58 -50.61 57.55 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 121.038 0.447 . . . . 0.0 111.319 -179.764 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 24' ' ' TRP . . . . . . . . . . . . . 4.7 t-105 -62.18 -37.16 84.19 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-N 115.698 -0.683 . . . . 0.0 111.187 -179.899 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.329 -0.325 0 CA-C-O 120.853 0.359 . . . . 0.0 111.118 -179.994 . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.326 0 N-CA-C 112.87 -0.092 . . . . 0.0 112.87 . . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 13.7 mm-40 -86.69 -21.47 26.65 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.663 0.268 . . . . 0.0 111.106 -179.654 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 34' ' ' ARG . . . . . . . . . . . . . 37.2 ttm180 -54.54 -29.63 51.5 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.31 -0.405 . . . . 0.0 111.416 -179.401 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 55.0 ttp180 -59.17 -40.87 86.96 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.852 0.358 . . . . 0.0 110.828 -179.899 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 63.7 m-85 -72.74 -31.21 64.78 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.123 -0.489 . . . . 0.0 110.997 -179.971 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 37' ' ' TYR . . . . . 0.467 ' O ' HG23 ' A' ' 41' ' ' VAL . 65.9 m-85 -70.34 -54.85 10.84 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.197 -179.876 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 78.4 t -57.14 -38.99 63.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-O 120.873 0.368 . . . . 0.0 110.573 179.776 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 19.1 m -63.19 -50.48 70.14 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 115.929 -0.578 . . . . 0.0 110.79 179.405 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 40' ' ' LEU . . . . . 0.691 HD12 HD11 ' A' ' 43' ' ' ILE . 41.4 tp -56.99 -45.77 82.74 Favored 'General case' 0 C--O 1.235 0.323 0 CA-C-N 115.693 -0.685 . . . . 0.0 110.739 179.937 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 41' ' ' VAL . . . . . 0.644 HG22 ' HB2' ' A' ' 22' ' ' PHE . 94.3 t -62.16 -33.56 59.24 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.497 0 CA-C-N 116.103 -0.498 . . . . 0.0 109.698 179.001 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -58.17 -48.78 81.11 Favored Glycine 0 N--CA 1.45 -0.378 0 CA-C-N 115.49 -0.777 . . . . 0.0 113.135 179.888 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 43' ' ' ILE . . . . . 0.691 HD11 HD12 ' A' ' 40' ' ' LEU . 17.0 pt -64.72 -47.02 90.45 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.215 0 CA-C-N 117.213 0.506 . . . . 0.0 111.599 -179.61 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 67.9 m -61.92 -27.88 69.13 Favored 'General case' 0 C--O 1.232 0.149 0 CA-C-O 120.907 0.384 . . . . 0.0 110.945 179.496 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -79.45 -52.86 4.6 Favored Glycine 0 CA--C 1.517 0.212 0 CA-C-N 115.934 -0.575 . . . . 0.0 113.423 -179.119 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 46' ' ' ILE . . . . . 0.504 HG13 HG22 ' A' ' 79' ' ' THR . 7.2 pt -57.81 -40.22 74.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-O 121.001 0.429 . . . . 0.0 111.002 -179.613 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 47' ' ' ALA . . . . . 0.596 ' HB2' ' HE2' ' A' ' 205' ' ' LYS . . . -68.31 -42.82 78.83 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.21 179.195 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 48' ' ' ALA . . . . . 0.453 ' HB2' ' HB3' ' A' ' 15' ' ' MET . . . -54.24 -43.18 70.69 Favored 'General case' 0 C--O 1.232 0.16 0 CA-C-N 116.326 -0.397 . . . . 0.0 111.763 -179.339 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 49' ' ' VAL . . . . . 0.443 HG22 ' O ' ' A' ' 46' ' ' ILE . 32.5 m -73.28 -34.22 43.38 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 116.492 -0.322 . . . . 0.0 111.445 -179.572 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -64.07 -37.79 88.73 Favored 'General case' 0 C--N 1.332 -0.174 0 CA-C-O 120.897 0.379 . . . . 0.0 111.217 179.827 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 35.6 m-85 -72.18 -39.27 68.77 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 115.996 -0.547 . . . . 0.0 110.704 -179.623 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -62.82 -50.52 70.63 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 115.944 -0.571 . . . . 0.0 111.301 179.739 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 53' ' ' VAL . . . . . 0.428 HG23 ' N ' ' A' ' 54' ' ' MET . 18.5 m -65.6 -43.06 94.13 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.189 0 CA-C-N 116.365 -0.379 . . . . 0.0 111.281 -179.666 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 54' ' ' MET . . . . . 0.507 ' HG3' ' HE1' ' A' ' 60' ' ' TRP . 10.9 ttp -68.55 -29.98 68.66 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.886 0.374 . . . . 0.0 110.306 179.897 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 55' ' ' ALA . . . . . 0.479 ' HB2' ' HB2' ' A' ' 8' ' ' PHE . . . -64.67 -36.86 85.65 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 115.939 -0.573 . . . . 0.0 110.939 179.328 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 86.7 mt -74.45 -1.0 19.23 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.061 -0.518 . . . . 0.0 111.245 -179.681 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 92.78 4.31 65.48 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.668 -0.777 . . . . 0.0 112.448 179.987 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 46.8 t -74.08 144.63 12.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-O 120.819 0.342 . . . . 0.0 111.187 -179.915 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 59' ' ' GLY . . . . . 0.43 ' HA3' ' HD3' ' A' ' 71' ' ' PRO . . . 76.7 5.86 84.09 Favored Glycine 0 CA--C 1.519 0.335 0 C-N-CA 120.946 -0.645 . . . . 0.0 112.815 -179.975 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 60' ' ' TRP . . . . . 0.507 ' HE1' ' HG3' ' A' ' 54' ' ' MET . 24.7 m0 -81.8 118.06 22.58 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.684 0.278 . . . . 0.0 111.076 -179.908 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 7.3 p -115.49 126.33 27.87 Favored Pre-proline 0 CA--C 1.533 0.313 0 CA-C-N 116.491 -0.322 . . . . 0.0 111.307 179.757 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 9.2 Cg_exo -72.13 142.69 38.52 Favored 'Trans proline' 0 C--N 1.349 0.603 0 C-N-CA 122.705 2.27 . . . . 0.0 112.081 179.739 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 98.1 t -142.36 94.33 0.57 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.064 179.968 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . 58.58 -90.14 0.03 OUTLIER 'General case' 0 C--N 1.332 -0.182 0 CA-C-N 115.973 -0.558 . . . . 0.0 111.622 179.857 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 18.5 mm-40 -117.36 -21.53 8.65 Favored 'General case' 0 C--N 1.332 -0.161 0 CA-C-N 116.39 -0.368 . . . . 0.0 111.048 -179.694 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 66' ' ' ARG . . . . . . . . . . . . . 30.7 ptt180 -107.17 158.64 16.94 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.174 -0.467 . . . . 0.0 110.629 179.911 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 60.5 m -117.76 115.24 24.62 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.386 -0.37 . . . . 0.0 111.651 -179.514 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 21.0 t -87.47 146.79 5.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 115.92 -0.582 . . . . 0.0 110.415 179.436 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 69' ' ' PHE . . . . . . . . . . . . . 26.6 m-85 -108.03 114.19 27.92 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-O 120.903 0.382 . . . . 0.0 110.096 -179.557 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 70' ' ' VAL . . . . . 0.595 ' N ' ' HD2' ' A' ' 71' ' ' PRO . 12.4 t -67.7 -48.98 41.19 Favored Pre-proline 0 C--N 1.324 -0.524 0 CA-C-N 115.921 -0.582 . . . . 0.0 112.117 -178.982 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 71' ' ' PRO . . . . . 0.595 ' HD2' ' N ' ' A' ' 70' ' ' VAL . 30.0 Cg_endo -62.64 -17.67 59.88 Favored 'Trans proline' 0 C--N 1.351 0.677 0 C-N-CA 122.166 1.91 . . . . 0.0 112.508 -179.64 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 34.2 ttp180 -69.75 -55.4 9.99 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.431 -0.349 . . . . 0.0 111.53 -179.455 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 73' ' ' TYR . . . . . 0.496 ' O ' HG13 ' A' ' 77' ' ' ILE . 74.0 m-85 -70.99 -36.39 72.47 Favored 'General case' 0 C--N 1.33 -0.264 0 C-N-CA 120.854 -0.338 . . . . 0.0 110.602 -179.577 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 74' ' ' ILE . . . . . 0.518 HG22 ' HA ' ' A' ' 71' ' ' PRO . 0.3 OUTLIER -64.78 -41.43 92.17 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.199 0 N-CA-C 109.935 -0.394 . . . . 0.0 109.935 179.291 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 10.7 t70 -56.97 -38.1 72.51 Favored 'General case' 0 CA--C 1.518 -0.276 0 N-CA-C 109.007 -0.738 . . . . 0.0 109.007 178.531 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 76' ' ' TRP . . . . . 0.446 ' HA ' ' OG1' ' A' ' 79' ' ' THR . 44.6 m0 -66.88 -30.31 70.44 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 115.588 -0.733 . . . . 0.0 110.895 179.27 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 77' ' ' ILE . . . . . 0.531 ' O ' ' HG2' ' A' ' 81' ' ' PRO . 69.8 mt -67.13 -36.54 77.18 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.302 -0.408 . . . . 0.0 111.032 179.842 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 78' ' ' LEU . . . . . 0.524 HD12 HG23 ' A' ' 79' ' ' THR . 2.7 pp -91.59 -23.24 19.95 Favored 'General case' 0 C--N 1.326 -0.448 0 N-CA-C 112.76 0.652 . . . . 0.0 112.76 -179.871 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 79' ' ' THR . . . . . 0.524 HG23 HD12 ' A' ' 78' ' ' LEU . 40.9 p -88.05 -53.77 4.56 Favored 'General case' 0 N--CA 1.471 0.582 0 N-CA-C 113.49 0.922 . . . . 0.0 113.49 -179.011 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 80' ' ' THR . . . . . 0.628 ' HB ' ' HD3' ' A' ' 81' ' ' PRO . 18.2 m -53.69 -55.45 35.3 Favored Pre-proline 0 C--N 1.331 -0.21 0 N-CA-C 113.192 0.812 . . . . 0.0 113.192 -177.475 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 81' ' ' PRO . . . . . 0.628 ' HD3' ' HB ' ' A' ' 80' ' ' THR . 77.1 Cg_exo -53.45 -25.47 32.04 Favored 'Trans proline' 0 C--N 1.35 0.63 0 C-N-CA 121.567 1.511 . . . . 0.0 112.09 -179.842 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 82' ' ' LEU . . . . . 0.444 HD23 HG23 ' A' ' 43' ' ' ILE . 11.5 tp -76.69 -33.17 58.24 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.171 179.521 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 83' ' ' ILE . . . . . 0.45 HD13 HG21 ' A' ' 43' ' ' ILE . 36.6 mm -66.54 -53.37 36.32 Favored 'Isoleucine or valine' 0 C--O 1.234 0.255 0 CA-C-N 116.172 -0.467 . . . . 0.0 109.955 178.678 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 33.8 m -61.21 -30.05 47.06 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.217 0 CA-C-N 115.887 -0.597 . . . . 0.0 109.61 178.875 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 85' ' ' TYR . . . . . . . . . . . . . 85.4 t80 -67.92 -31.41 71.15 Favored 'General case' 0 N--CA 1.453 -0.285 0 CA-C-N 115.566 -0.743 . . . . 0.0 109.379 178.758 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 86' ' ' PHE . . . . . . . . . . . . . 7.6 t80 -62.51 -51.51 67.13 Favored 'General case' 0 N--CA 1.455 -0.211 0 CA-C-N 115.755 -0.657 . . . . 0.0 109.598 179.087 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 7.2 mt -61.91 -33.06 73.54 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 115.813 -0.631 . . . . 0.0 109.913 179.205 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -66.58 -27.66 73.31 Favored Glycine 0 N--CA 1.452 -0.293 0 CA-C-N 115.25 -0.886 . . . . 0.0 112.044 179.425 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 65.4 mt -74.18 -44.48 53.29 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-O 121.028 0.442 . . . . 0.0 110.749 179.826 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 78.4 mt -61.23 -31.85 71.63 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 115.823 -0.626 . . . . 0.0 111.151 -179.937 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 91' ' ' ALA . . . . . 0.406 ' HB2' ' HB2' ' A' ' 149' ' ' ALA . . . -88.36 -38.77 14.84 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.328 -0.396 . . . . 0.0 111.788 -179.433 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 85.09 70.62 1.33 Allowed Glycine 0 CA--C 1.517 0.187 0 C-N-CA 120.701 -0.761 . . . . 0.0 112.145 -179.316 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 20.0 mt -87.58 169.11 12.45 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.906 0.384 . . . . 0.0 111.371 -179.447 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 94' ' ' ASP . . . . . 0.456 ' HB3' ' HG3' ' A' ' 97' ' ' GLU . 18.6 t70 -79.77 161.56 25.64 Favored 'General case' 0 C--N 1.332 -0.168 0 CA-C-N 116.027 -0.533 . . . . 0.0 110.599 179.661 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 71.0 m -55.91 -44.79 78.61 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.418 -0.356 . . . . 0.0 111.126 -179.972 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 10.2 mpt_? -68.78 -48.02 64.72 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.169 -179.804 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 97' ' ' GLU . . . . . 0.521 ' HA ' HD12 ' A' ' 100' ' ' ILE . 47.3 mt-10 -53.95 -38.7 65.23 Favored 'General case' 0 C--O 1.234 0.238 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.839 -179.931 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 98' ' ' PHE . . . . . 0.491 ' O ' HG12 ' A' ' 102' ' ' ILE . 5.6 m-85 -60.08 -49.96 75.58 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.392 179.4 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -59.26 -26.16 61.15 Favored Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.705 -0.759 . . . . 0.0 112.515 179.97 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 100' ' ' ILE . . . . . 0.521 HD12 ' HA ' ' A' ' 97' ' ' GLU . 97.7 mt -68.85 -50.61 52.98 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.194 0 CA-C-O 120.803 0.335 . . . . 0.0 111.527 -179.921 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 101' ' ' VAL . . . . . 0.43 HG11 ' HE1' ' A' ' 145' ' ' MET . 29.6 m -70.59 -36.24 64.83 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.369 0 CA-C-N 116.437 -0.347 . . . . 0.0 111.748 -179.567 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 102' ' ' ILE . . . . . 0.621 HG23 ' HB3' ' A' ' 81' ' ' PRO . 49.5 mm -67.0 -46.72 84.11 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.626 -0.261 . . . . 0.0 111.35 -179.707 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 15.3 t -63.51 -35.32 80.09 Favored 'General case' 0 C--O 1.233 0.201 0 CA-C-O 120.75 0.309 . . . . 0.0 110.954 179.925 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 104' ' ' LEU . . . . . 0.428 ' O ' HG23 ' A' ' 108' ' ' VAL . 2.8 tm? -57.52 -53.75 54.62 Favored 'General case' 0 C--N 1.331 -0.199 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.259 179.54 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 105' ' ' ASN . . . . . 0.644 HD21 HD13 ' A' ' 137' ' ' LEU . 0.8 OUTLIER -55.71 -37.93 69.06 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.498 179.527 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 44.0 m -55.19 -41.72 72.31 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-O 120.886 0.374 . . . . 0.0 110.467 179.576 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 107' ' ' VAL . . . . . 0.425 HG23 ' H ' ' A' ' 107' ' ' VAL . 2.1 t -64.5 -37.59 80.41 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.198 0 CA-C-O 121.38 0.61 . . . . 0.0 109.867 178.99 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 108' ' ' VAL . . . . . 0.428 HG23 ' O ' ' A' ' 104' ' ' LEU . 26.1 t -61.49 -50.16 81.48 Favored 'Isoleucine or valine' 0 C--O 1.236 0.361 0 CA-C-N 115.089 -0.959 . . . . 0.0 111.502 -179.91 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 109' ' ' MET . . . . . 0.517 ' HE1' HG21 ' A' ' 80' ' ' THR . 9.1 mmt -63.02 -37.14 85.99 Favored 'General case' 0 C--N 1.331 -0.2 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.872 -179.838 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 31.8 tp -62.04 -33.84 75.13 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.54 179.776 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -64.75 -52.06 58.98 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 115.988 -0.551 . . . . 0.0 110.711 179.473 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . -62.23 -39.13 97.29 Favored Glycine 0 C--N 1.331 0.252 0 C-N-CA 120.484 -0.865 . . . . 0.0 112.137 179.5 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 113' ' ' PHE . . . . . . . . . . . . . 0.5 OUTLIER -52.86 -72.69 0.05 Allowed 'General case' 0 C--N 1.33 -0.255 0 CA-C-O 121.052 0.453 . . . . 0.0 110.454 179.825 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 114' ' ' ALA . . . . . 0.456 ' HB3' HD22 ' A' ' 126' ' ' LEU . . . -65.46 -12.66 54.66 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 115.708 -0.678 . . . . 0.0 111.385 -179.899 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -66.31 -43.58 92.51 Favored Glycine 0 C--N 1.33 0.238 0 C-N-CA 120.804 -0.712 . . . . 0.0 112.69 -179.959 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -78.06 -25.73 47.89 Favored 'General case' 0 C--N 1.329 -0.29 0 N-CA-C 112.154 0.427 . . . . 0.0 112.154 -179.721 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 117' ' ' MET . . . . . . . . . . . . . 67.5 mtt -91.81 19.42 6.55 Favored 'General case' 0 C--N 1.329 -0.292 0 N-CA-C 111.868 0.321 . . . . 0.0 111.868 -179.164 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 118' ' ' VAL . . . . . 0.553 HG21 ' HB3' ' A' ' 123' ' ' ARG . 17.5 m -68.33 138.88 91.85 Favored Pre-proline 0 C--N 1.329 -0.324 0 CA-C-O 120.54 0.21 . . . . 0.0 111.169 179.862 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 119' ' ' PRO . . . . . . . . . . . . . 95.1 Cg_endo -86.6 11.56 3.25 Favored 'Trans proline' 0 C--N 1.348 0.55 0 C-N-CA 122.554 2.17 . . . . 0.0 112.339 179.922 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -164.6 -120.7 0.53 Allowed Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.86 -0.686 . . . . 0.0 112.616 -179.811 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 42.3 pt -113.89 14.04 8.22 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.219 0 CA-C-O 120.812 0.339 . . . . 0.0 111.319 -179.861 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 49.0 mt-10 -61.38 -17.53 54.49 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.081 -0.509 . . . . 0.0 111.082 179.808 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 123' ' ' ARG . . . . . 0.553 ' HB3' HG21 ' A' ' 118' ' ' VAL . 14.7 ptt180 -50.44 -29.33 10.03 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.003 -0.544 . . . . 0.0 111.769 -179.821 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 124' ' ' TYR . . . . . . . . . . . . . 33.2 m-85 -74.79 -31.93 61.87 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.46 -0.336 . . . . 0.0 111.302 -179.461 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 125' ' ' ALA . . . . . . . . . . . . . . . -73.0 -56.47 5.08 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-N 116.296 -0.411 . . . . 0.0 111.045 -179.776 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 126' ' ' LEU . . . . . 0.456 HD22 ' HB3' ' A' ' 114' ' ' ALA . 1.3 mt -54.62 -46.52 73.89 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 115.968 -0.56 . . . . 0.0 110.676 179.826 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 127' ' ' PHE . . . . . . . . . . . . . 4.9 t80 -68.22 -37.37 80.76 Favored 'General case' 0 N--CA 1.453 -0.319 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.648 179.766 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 128' ' ' GLY . . . . . . . . . . . . . . . -46.38 -44.15 15.35 Favored Glycine 0 C--N 1.333 0.387 0 C-N-CA 120.14 -1.029 . . . . 0.0 110.607 178.941 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 129' ' ' MET . . . . . 0.47 ' HE3' ' N ' ' A' ' 130' ' ' GLY . 6.0 tmm? -69.52 -41.54 75.86 Favored 'General case' 0 C--N 1.328 -0.357 0 N-CA-C 109.357 -0.608 . . . . 0.0 109.357 178.266 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 130' ' ' GLY . . . . . 0.47 ' N ' ' HE3' ' A' ' 129' ' ' MET . . . -55.49 -39.49 74.2 Favored Glycine 0 N--CA 1.452 -0.278 0 CA-C-N 115.724 -0.671 . . . . 0.0 113.044 -179.711 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -70.03 -53.12 19.03 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.699 0.285 . . . . 0.0 110.609 179.955 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 53.0 t -54.93 -39.93 51.08 Favored 'Isoleucine or valine' 0 C--O 1.233 0.215 0 CA-C-O 121.307 0.575 . . . . 0.0 109.607 178.88 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -69.25 -35.99 76.69 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 115.381 -0.827 . . . . 0.0 110.279 179.391 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 134' ' ' PHE . . . . . . . . . . . . . 47.6 t80 -58.48 -52.95 63.48 Favored 'General case' 0 N--CA 1.45 -0.43 0 CA-C-N 115.932 -0.577 . . . . 0.0 109.817 179.281 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 135' ' ' ILE . . . . . 0.497 ' O ' HG22 ' A' ' 138' ' ' VAL . 45.2 mt -58.34 -30.52 40.55 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.282 0 CA-C-N 115.699 -0.682 . . . . 0.0 109.741 178.892 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 136' ' ' GLY . . . . . 0.43 ' O ' ' HB3' ' A' ' 139' ' ' TYR . . . -59.47 -42.69 97.71 Favored Glycine 0 N--CA 1.447 -0.574 0 C-N-CA 120.42 -0.895 . . . . 0.0 111.364 178.867 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 137' ' ' LEU . . . . . 0.644 HD13 HD21 ' A' ' 105' ' ' ASN . 53.8 tp -67.24 -54.62 19.29 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.565 0.222 . . . . 0.0 110.666 179.316 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 138' ' ' VAL . . . . . 0.497 HG22 ' O ' ' A' ' 135' ' ' ILE . 3.0 m -54.71 -30.4 22.38 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.134 0 CA-C-O 121.08 0.466 . . . . 0.0 109.805 -179.672 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 139' ' ' TYR . . . . . 0.43 ' HB3' ' O ' ' A' ' 136' ' ' GLY . 20.8 t80 -61.68 -48.14 82.16 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 115.526 -0.761 . . . . 0.0 110.076 178.227 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 37.5 m-85 -63.27 -40.32 97.06 Favored 'General case' 0 C--O 1.232 0.156 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.971 179.537 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 141' ' ' LEU . . . . . 0.454 HD13 ' O ' ' A' ' 137' ' ' LEU . 11.1 mp -54.63 -55.06 33.48 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.09 -179.824 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 10.7 p -76.95 -15.93 14.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-O 121.024 0.44 . . . . 0.0 110.985 179.911 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . -73.55 -133.34 0.22 Allowed Glycine 0 CA--C 1.522 0.528 0 C-N-CA 120.867 -0.683 . . . . 0.0 112.812 -179.883 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 144' ' ' PRO . . . . . . . . . . . . . 52.2 Cg_exo -55.5 -28.56 64.98 Favored 'Trans proline' 0 C--N 1.349 0.579 0 C-N-CA 122.746 2.297 . . . . 0.0 112.885 -179.653 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 145' ' ' MET . . . . . 0.43 ' HE1' HG11 ' A' ' 101' ' ' VAL . 43.2 mtt -56.67 -36.31 69.43 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.382 -0.372 . . . . 0.0 111.352 -179.875 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 146' ' ' THR . . . . . . . . . . . . . 24.7 m -68.09 -48.0 66.71 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.836 -179.303 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 20.0 mm-40 -71.16 -26.31 62.93 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.557 -0.292 . . . . 0.0 111.369 -179.544 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 148' ' ' SER . . . . . . . . . . . . . 47.7 t -70.71 -49.47 46.66 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.312 -0.403 . . . . 0.0 111.312 -179.557 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 149' ' ' ALA . . . . . 0.406 ' HB2' ' HB2' ' A' ' 91' ' ' ALA . . . -75.1 -33.87 61.67 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.074 -0.512 . . . . 0.0 111.678 -179.416 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 150' ' ' SER . . . . . . . . . . . . . 43.5 t -67.24 -12.74 60.88 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.328 -179.636 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 151' ' ' GLN . . . . . . . . . . . . . 77.7 mt-30 -119.03 12.1 12.65 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.486 -0.325 . . . . 0.0 111.42 -179.756 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 31.4 tpt180 -84.56 -51.36 6.94 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 120.81 0.338 . . . . 0.0 110.865 -179.759 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 153' ' ' SER . . . . . 0.677 ' HB3' HG12 ' A' ' 156' ' ' ILE . 18.3 t -157.69 172.46 18.48 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 116.119 -0.492 . . . . 0.0 110.715 179.41 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 154' ' ' SER . . . . . . . . . . . . . 47.0 t -68.86 -41.05 78.93 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.303 -0.408 . . . . 0.0 110.802 179.787 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -76.69 -35.79 39.49 Favored Glycine 0 N--CA 1.452 -0.259 0 C-N-CA 120.98 -0.629 . . . . 0.0 112.974 -179.909 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 156' ' ' ILE . . . . . 0.677 HG12 ' HB3' ' A' ' 153' ' ' SER . 43.1 mm -55.34 -36.82 41.99 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.237 0 CA-C-O 120.714 0.292 . . . . 0.0 111.518 -179.769 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 157' ' ' LYS . . . . . 0.421 ' HB3' ' NZ ' ' A' ' 157' ' ' LYS . 6.5 ttpm? -59.51 -53.75 54.53 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 116.415 -0.357 . . . . 0.0 111.759 -179.45 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 42.8 t -67.37 -41.01 85.75 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.445 -0.343 . . . . 0.0 111.714 -179.198 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 159' ' ' LEU . . . . . 0.505 HD23 HD13 ' A' ' 163' ' ' LEU . 4.1 tt -67.72 -34.55 77.08 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 116.432 -0.349 . . . . 0.0 111.045 -179.554 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 160' ' ' TYR . . . . . . . . . . . . . 67.6 t80 -73.88 -45.81 48.6 Favored 'General case' 0 C--N 1.33 -0.278 0 N-CA-C 112.026 0.38 . . . . 0.0 112.026 -179.165 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 22.7 m -59.82 -43.55 92.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 N-CA-C 111.673 0.249 . . . . 0.0 111.673 -179.252 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 162' ' ' ARG . . . . . 0.514 HH22 ' HB2' ' A' ' 215' ' ' ALA . 86.8 mtm180 -68.99 -38.02 79.06 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.77 0.319 . . . . 0.0 111.218 -179.977 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 163' ' ' LEU . . . . . 0.558 ' HG ' ' HB2' ' A' ' 208' ' ' PHE . 3.4 mp -69.5 -54.17 15.51 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.643 -179.58 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 164' ' ' ARG . . . . . . . . . . . . . 4.7 tmm_? -58.71 -53.54 57.2 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.545 -179.236 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 165' ' ' ASN . . . . . 0.507 ' O ' HG23 ' A' ' 169' ' ' VAL . 4.6 m-20 -53.59 -52.12 60.81 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 120.876 0.37 . . . . 0.0 111.659 -179.273 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 166' ' ' LEU . . . . . 0.496 ' O ' ' HG ' ' A' ' 170' ' ' LEU . 2.1 tt -61.09 -53.33 58.46 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.065 -0.516 . . . . 0.0 111.771 -179.129 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 167' ' ' THR . . . . . 0.494 ' O ' ' HB2' ' A' ' 171' ' ' TRP . 86.0 m -55.47 -53.7 53.02 Favored 'General case' 0 C--N 1.327 -0.395 0 N-CA-C 112.8 0.667 . . . . 0.0 112.8 -178.661 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 168' ' ' VAL . . . . . . . . . . . . . 89.7 t -54.64 -44.61 70.4 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.244 0 N-CA-C 112.371 0.508 . . . . 0.0 112.371 -178.563 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 169' ' ' VAL . . . . . 0.507 HG23 ' O ' ' A' ' 165' ' ' ASN . 75.4 t -58.43 -64.79 0.5 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.421 0 N-CA-C 112.149 0.426 . . . . 0.0 112.149 -178.962 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 170' ' ' LEU . . . . . 0.496 ' HG ' ' O ' ' A' ' 166' ' ' LEU . 1.4 pp -62.3 -29.75 70.65 Favored 'General case' 0 C--N 1.33 -0.255 0 N-CA-C 112.011 0.374 . . . . 0.0 112.011 -178.863 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 171' ' ' TRP . . . . . 0.494 ' HB2' ' O ' ' A' ' 167' ' ' THR . 2.2 m0 -71.88 -31.2 66.21 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.861 0.362 . . . . 0.0 110.939 179.827 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 172' ' ' ALA . . . . . . . . . . . . . . . -72.18 -6.1 40.36 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.667 179.962 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 173' ' ' ILE . . . . . 0.554 HG22 HD11 ' A' ' 177' ' ' ILE . 29.0 mm -85.24 -21.28 7.91 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.188 0 CA-C-N 115.764 -0.653 . . . . 0.0 111.141 179.79 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 174' ' ' TYR . . . . . 0.445 ' HB2' ' HD3' ' A' ' 175' ' ' PRO . 28.0 m-85 -54.44 -50.47 84.98 Favored Pre-proline 0 N--CA 1.466 0.326 0 CA-C-N 116.437 -0.347 . . . . 0.0 111.673 -179.836 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 175' ' ' PRO . . . . . 0.445 ' HD3' ' HB2' ' A' ' 174' ' ' TYR . 86.7 Cg_exo -45.87 -29.9 6.32 Favored 'Trans proline' 0 C--N 1.353 0.777 0 C-N-CA 122.233 1.955 . . . . 0.0 112.358 179.844 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 176' ' ' PHE . . . . . 0.443 ' O ' ' HG ' ' A' ' 180' ' ' LEU . 92.1 m-85 -80.15 -49.3 11.88 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 115.976 -0.556 . . . . 0.0 111.699 -179.822 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 177' ' ' ILE . . . . . 0.554 HD11 HG22 ' A' ' 173' ' ' ILE . 2.9 mm -60.3 -38.0 75.93 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.528 0 CA-C-N 116.024 -0.535 . . . . 0.0 112.008 -178.459 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 178' ' ' TRP . . . . . 0.409 ' HH2' ' HB2' ' A' ' 123' ' ' ARG . 70.4 t90 -73.32 -44.9 58.13 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.864 0.364 . . . . 0.0 110.922 179.748 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 179' ' ' LEU . . . . . 0.431 ' O ' HG22 ' A' ' 185' ' ' VAL . 1.5 tm? -65.46 -54.22 31.55 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 115.998 -0.546 . . . . 0.0 111.246 -179.323 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 180' ' ' LEU . . . . . 0.5 HD22 ' CD1' ' A' ' 187' ' ' LEU . 18.8 mt -72.46 -45.39 59.73 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.542 -0.299 . . . . 0.0 111.631 -179.267 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 181' ' ' GLY . . . . . 0.405 ' HA3' ' OD1' ' A' ' 193' ' ' ASP . . . -55.35 175.69 0.71 Allowed Glycine 0 C--N 1.336 0.537 0 C-N-CA 120.487 -0.863 . . . . 0.0 112.896 179.646 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 182' ' ' PRO . . . . . 0.654 ' HA ' ' HB2' ' A' ' 186' ' ' ALA . 72.2 Cg_exo -48.07 -45.34 25.64 Favored 'Trans proline' 0 CA--C 1.536 0.596 0 C-N-CA 122.983 2.455 . . . . 0.0 113.86 -179.994 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 183' ' ' PRO . . . . . 0.424 ' HD3' ' HB2' ' A' ' 182' ' ' PRO . 52.2 Cg_exo -53.96 -13.34 4.39 Favored 'Trans proline' 0 C--N 1.355 0.92 0 C-N-CA 122.056 1.837 . . . . 0.0 112.916 -179.853 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 184' ' ' GLY . . . . . 0.423 ' HA3' ' O ' ' A' ' 179' ' ' LEU . . . -115.93 -86.34 1.28 Allowed Glycine 0 N--CA 1.45 -0.414 0 C-N-CA 120.377 -0.916 . . . . 0.0 112.871 -179.779 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 185' ' ' VAL . . . . . 0.431 HG22 ' O ' ' A' ' 179' ' ' LEU . 6.6 m -124.59 -5.06 6.48 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 N-CA-C 112.169 0.433 . . . . 0.0 112.169 -179.495 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 186' ' ' ALA . . . . . 0.654 ' HB2' ' HA ' ' A' ' 182' ' ' PRO . . . 53.41 86.59 0.04 OUTLIER 'General case' 0 N--CA 1.463 0.224 0 CA-C-N 116.479 -0.328 . . . . 0.0 111.682 179.606 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 187' ' ' LEU . . . . . 0.5 ' CD1' HD22 ' A' ' 180' ' ' LEU . 14.1 mt -92.15 -49.36 6.23 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.396 -0.366 . . . . 0.0 111.452 179.851 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 188' ' ' LEU . . . . . 0.468 ' N ' HD12 ' A' ' 188' ' ' LEU . 6.9 mp -92.93 -88.97 0.21 Allowed 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.361 -0.381 . . . . 0.0 111.272 -179.256 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 189' ' ' THR . . . . . . . . . . . . . 1.8 t -169.82 148.7 3.28 Favored Pre-proline 0 C--N 1.325 -0.483 0 CA-C-N 116.01 -0.541 . . . . 0.0 111.078 -179.55 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 190' ' ' PRO . . . . . 0.417 ' O ' HG23 ' A' ' 194' ' ' VAL . 10.2 Cg_endo -51.99 -42.86 56.17 Favored 'Trans proline' 0 C--N 1.35 0.649 0 C-N-CA 122.798 2.332 . . . . 0.0 113.152 -179.761 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 191' ' ' THR . . . . . . . . . . . . . 5.4 t -56.4 -44.74 80.57 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-O 120.689 0.281 . . . . 0.0 111.336 -179.59 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 192' ' ' VAL . . . . . . . . . . . . . 38.5 t -70.56 -43.62 77.62 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.389 -0.369 . . . . 0.0 111.088 179.846 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 193' ' ' ASP . . . . . 0.405 ' OD1' ' HA3' ' A' ' 181' ' ' GLY . 11.3 t70 -55.62 -49.16 73.56 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.942 179.867 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 194' ' ' VAL . . . . . 0.417 HG23 ' O ' ' A' ' 190' ' ' PRO . 85.9 t -63.03 -36.98 78.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.05 -179.985 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 195' ' ' ALA . . . . . . . . . . . . . . . -59.24 -48.41 81.74 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.491 -0.322 . . . . 0.0 110.979 179.827 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 196' ' ' LEU . . . . . . . . . . . . . 65.0 mt -67.91 -43.61 78.84 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.307 -0.406 . . . . 0.0 110.641 179.761 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 197' ' ' ILE . . . . . 0.415 HG12 HG21 ' A' ' 177' ' ' ILE . 17.6 mm -56.51 -59.78 2.59 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 115.961 -0.563 . . . . 0.0 110.444 179.435 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 198' ' ' VAL . . . . . . . . . . . . . 76.8 t -53.06 -34.69 21.5 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.496 0 CA-C-N 115.601 -0.727 . . . . 0.0 109.467 178.512 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 199' ' ' TYR . . . . . . . . . . . . . 64.9 t80 -70.24 -31.61 69.09 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 115.524 -0.762 . . . . 0.0 110.588 179.692 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 200' ' ' LEU . . . . . 0.537 ' O ' HG12 ' A' ' 203' ' ' VAL . 32.2 mt -73.23 -43.44 61.21 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 115.841 -0.618 . . . . 0.0 111.484 -179.478 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 201' ' ' ASP . . . . . . . . . . . . . 10.5 m-20 -71.94 -36.81 70.02 Favored 'General case' 0 C--N 1.327 -0.413 0 CA-C-O 121.251 0.548 . . . . 0.0 110.087 179.511 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 202' ' ' LEU . . . . . . . . . . . . . 39.5 tp -72.73 -27.78 62.25 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 115.311 -0.859 . . . . 0.0 111.779 -179.293 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 203' ' ' VAL . . . . . 0.537 HG12 ' O ' ' A' ' 200' ' ' LEU . 12.3 p -78.71 -35.94 18.96 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.215 0 C-N-CA 120.854 -0.338 . . . . 0.0 110.779 -179.087 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 204' ' ' THR . . . . . 0.418 ' HG1' ' HE1' ' A' ' 171' ' ' TRP . 97.2 m -66.48 -59.0 4.05 Favored 'General case' 0 C--N 1.329 -0.304 0 C-N-CA 120.598 -0.441 . . . . 0.0 110.861 179.34 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 205' ' ' LYS . . . . . 0.596 ' HE2' ' HB2' ' A' ' 47' ' ' ALA . 62.7 mttp -58.76 -57.78 11.5 Favored 'General case' 0 C--N 1.331 -0.209 0 N-CA-C 112.14 0.422 . . . . 0.0 112.14 -178.675 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 49.8 t -70.55 -37.35 69.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 N-CA-C 112.324 0.49 . . . . 0.0 112.324 -178.823 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 207' ' ' GLY . . . . . 0.553 ' O ' HG13 ' A' ' 211' ' ' ILE . . . -55.76 -62.07 6.72 Favored Glycine 0 CA--C 1.518 0.242 0 C-N-CA 120.614 -0.803 . . . . 0.0 113.873 -178.608 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 208' ' ' PHE . . . . . 0.558 ' HB2' ' HG ' ' A' ' 163' ' ' LEU . 3.0 p90 -72.86 -27.63 62.03 Favored 'General case' 0 C--O 1.221 -0.416 0 CA-C-N 117.457 0.628 . . . . 0.0 110.925 -179.231 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 209' ' ' GLY . . . . . 0.555 ' O ' ' HB3' ' A' ' 212' ' ' ALA . . . -62.06 -34.78 90.12 Favored Glycine 0 N--CA 1.449 -0.447 0 N-CA-C 111.91 -0.476 . . . . 0.0 111.91 178.761 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 210' ' ' PHE . . . . . . . . . . . . . 1.2 m-85 -73.59 -48.23 34.35 Favored 'General case' 0 CA--C 1.513 -0.456 0 N-CA-C 108.153 -1.055 . . . . 0.0 108.153 178.398 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 211' ' ' ILE . . . . . 0.553 HG13 ' O ' ' A' ' 207' ' ' GLY . 4.8 mt -61.61 -27.48 42.17 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.51 0 N-CA-C 107.784 -1.191 . . . . 0.0 107.784 176.711 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 212' ' ' ALA . . . . . 0.555 ' HB3' ' O ' ' A' ' 209' ' ' GLY . . . -63.57 -41.75 98.37 Favored 'General case' 0 N--CA 1.45 -0.474 0 CA-C-N 114.478 -1.237 . . . . 0.0 110.664 -179.775 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 213' ' ' LEU . . . . . . . . . . . . . 95.3 mt -69.29 -53.04 21.75 Favored 'General case' 0 C--N 1.332 -0.162 0 CA-C-N 115.26 -0.882 . . . . 0.0 111.398 -179.68 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 214' ' ' ASP . . . . . . . . . . . . . 9.6 m-20 -55.7 -48.66 74.75 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-O 120.878 0.37 . . . . 0.0 110.746 -179.997 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 215' ' ' ALA . . . . . 0.514 ' HB2' HH22 ' A' ' 162' ' ' ARG . . . -59.44 -57.33 13.44 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 115.988 -0.551 . . . . 0.0 110.958 179.721 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 216' ' ' ALA . . . . . . . . . . . . . . . -56.36 -31.55 63.9 Favored 'General case' 0 C--N 1.332 -0.187 0 CA-C-N 116.06 -0.518 . . . . 0.0 111.065 -179.998 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 217' ' ' ALA . . . . . . . . . . . . . . . -62.68 -39.26 93.38 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.407 179.615 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 218' ' ' THR . . . . . . . . . . . . . 79.1 m . . . . . 0 C--N 1.329 -0.296 0 CA-C-N 115.81 -0.632 . . . . 0.0 111.044 179.682 . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.303 0 N-CA-C 112.506 -0.238 . . . . 0.0 112.506 . . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 50.6 tp -73.88 -36.13 64.77 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.786 0.327 . . . . 0.0 110.948 179.87 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 73.7 p -61.39 -29.71 70.09 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.115 -0.493 . . . . 0.0 111.19 179.946 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 23.1 p -53.46 -35.42 60.51 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.09 -0.504 . . . . 0.0 111.071 -179.904 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 7' ' ' LEU . . . . . . . . . . . . . 4.1 mm? -60.25 -53.44 57.65 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.034 -0.53 . . . . 0.0 111.101 179.991 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 8' ' ' PHE . . . . . . . . . . . . . 81.4 m-85 -59.89 -37.1 78.44 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 120.964 0.412 . . . . 0.0 110.806 179.951 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 9' ' ' TRP . . . . . . . . . . . . . 35.9 m95 -63.57 -41.58 98.39 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 115.897 -0.592 . . . . 0.0 110.173 -179.972 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 38.5 mt -64.85 -49.02 72.2 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-N 115.767 -0.651 . . . . 0.0 110.159 179.244 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 11' ' ' GLY . . . . . 0.438 ' HA2' HD11 ' A' ' 202' ' ' LEU . . . -57.19 -28.09 58.33 Favored Glycine 0 N--CA 1.447 -0.571 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.216 179.293 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -74.09 -38.48 63.87 Favored 'General case' 0 C--N 1.332 -0.186 0 CA-C-O 120.714 0.292 . . . . 0.0 110.79 179.636 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 63.6 mt -61.87 -54.18 38.04 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.31 -0.404 . . . . 0.0 110.436 179.475 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -60.96 -35.23 90.25 Favored Glycine 0 N--CA 1.45 -0.41 0 C-N-CA 120.591 -0.814 . . . . 0.0 111.676 179.257 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 15' ' ' MET . . . . . 0.542 ' SD ' ' HA ' ' A' ' 44' ' ' SER . 47.5 tpp -64.51 -39.98 94.79 Favored 'General case' 0 N--CA 1.454 -0.246 0 N-CA-C 110.167 -0.309 . . . . 0.0 110.167 179.343 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 16' ' ' LEU . . . . . 0.498 HD13 ' O ' ' A' ' 16' ' ' LEU . 0.7 OUTLIER -59.91 -37.55 79.76 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 116.018 -0.537 . . . . 0.0 109.571 179.1 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 94.0 t -59.07 -50.5 79.53 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.172 0 CA-C-N 115.937 -0.574 . . . . 0.0 110.107 179.1 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -61.45 -45.33 96.6 Favored Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.64 -0.791 . . . . 0.0 111.726 179.163 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 32.8 m -51.7 -44.76 63.28 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-O 120.678 0.275 . . . . 0.0 111.301 -179.858 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 81.2 mt -71.59 -36.54 70.89 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.321 -0.4 . . . . 0.0 111.172 179.904 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -63.23 -33.29 75.17 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.348 -0.387 . . . . 0.0 111.338 -179.873 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 22' ' ' PHE . . . . . 0.512 ' HB2' HG22 ' A' ' 41' ' ' VAL . 4.1 m-85 -90.86 -28.76 17.94 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.296 -0.411 . . . . 0.0 111.185 -179.472 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -71.77 -50.69 27.69 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.943 0.402 . . . . 0.0 111.118 179.919 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 24' ' ' TRP . . . . . . . . . . . . . 3.2 t-105 -64.41 -44.66 90.53 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 115.86 -0.609 . . . . 0.0 110.938 -179.946 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.329 -0.3 0 CA-C-O 120.895 0.379 . . . . 0.0 110.915 179.776 . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.454 -0.144 0 N-CA-C 112.588 -0.205 . . . . 0.0 112.588 . . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 2.9 mp0 -68.34 -20.86 64.76 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 120.727 0.299 . . . . 0.0 110.944 -179.957 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 34' ' ' ARG . . . . . . . . . . . . . 78.9 ttt180 -57.63 -28.95 64.15 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.501 -179.619 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 27.7 tpt180 -59.17 -48.4 81.75 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.704 0.288 . . . . 0.0 111.508 -179.607 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 80.7 m-85 -64.96 -29.81 70.76 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.432 -0.349 . . . . 0.0 111.427 -179.511 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 37' ' ' TYR . . . . . 0.531 ' O ' HG23 ' A' ' 41' ' ' VAL . 52.2 m-85 -74.31 -54.27 8.01 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.413 -0.358 . . . . 0.0 111.342 -179.521 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 83.3 t -56.93 -36.32 49.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-O 120.969 0.414 . . . . 0.0 110.372 179.747 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 53.8 m -65.78 -51.53 58.29 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 115.846 -0.616 . . . . 0.0 110.929 179.518 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 40' ' ' LEU . . . . . 0.608 HD12 HD12 ' A' ' 43' ' ' ILE . 54.2 tp -59.23 -48.12 82.79 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 115.986 -0.552 . . . . 0.0 110.802 -179.94 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 41' ' ' VAL . . . . . 0.531 HG23 ' O ' ' A' ' 37' ' ' TYR . 67.6 t -57.86 -34.88 49.44 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.075 -0.511 . . . . 0.0 109.976 179.058 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -62.4 -36.23 92.82 Favored Glycine 0 N--CA 1.447 -0.606 0 C-N-CA 120.738 -0.744 . . . . 0.0 111.724 179.563 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 43' ' ' ILE . . . . . 0.608 HD12 HD12 ' A' ' 40' ' ' LEU . 1.9 mt -65.25 -55.14 21.79 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.187 0 CA-C-O 120.903 0.383 . . . . 0.0 110.935 179.629 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 44' ' ' SER . . . . . 0.542 ' HA ' ' SD ' ' A' ' 15' ' ' MET . 77.9 p -59.7 -26.23 65.42 Favored 'General case' 0 C--N 1.331 -0.201 0 CA-C-N 115.92 -0.582 . . . . 0.0 111.782 -179.529 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -76.16 -54.97 4.97 Favored Glycine 0 CA--C 1.52 0.39 0 C-N-CA 120.573 -0.823 . . . . 0.0 112.858 -179.513 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 46' ' ' ILE . . . . . 0.507 ' O ' HG22 ' A' ' 49' ' ' VAL . 20.5 pt -59.25 -35.8 59.91 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.219 0 CA-C-O 120.974 0.416 . . . . 0.0 111.13 -179.935 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 47' ' ' ALA . . . . . 0.684 ' HB2' ' HE2' ' A' ' 205' ' ' LYS . . . -68.16 -45.56 73.16 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.031 179.341 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -54.83 -41.94 71.32 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 115.87 -0.605 . . . . 0.0 111.769 -179.448 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 49' ' ' VAL . . . . . 0.507 HG22 ' O ' ' A' ' 46' ' ' ILE . 19.3 m -72.42 -34.19 47.89 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-N 116.521 -0.308 . . . . 0.0 111.138 -179.519 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -67.0 -34.73 78.4 Favored 'General case' 0 C--N 1.331 -0.2 0 CA-C-O 120.872 0.368 . . . . 0.0 111.227 179.853 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 28.3 m-85 -72.44 -41.34 66.25 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.623 -179.737 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -64.04 -46.71 83.2 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 115.769 -0.65 . . . . 0.0 111.245 -179.816 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 53' ' ' VAL . . . . . 0.623 ' O ' HG22 ' A' ' 58' ' ' VAL . 31.9 m -62.96 -53.61 44.39 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.159 0 CA-C-N 116.425 -0.352 . . . . 0.0 111.039 -179.903 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 54' ' ' MET . . . . . 0.546 ' N ' HG23 ' A' ' 53' ' ' VAL . 74.0 mtm -60.08 -31.1 69.7 Favored 'General case' 0 C--N 1.332 -0.182 0 CA-C-O 120.996 0.426 . . . . 0.0 110.289 179.659 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -64.9 -37.88 89.1 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 115.758 -0.655 . . . . 0.0 111.196 179.363 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 93.3 mt -71.15 -2.75 16.83 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.462 -179.586 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 93.66 -5.85 73.73 Favored Glycine 0 N--CA 1.45 -0.368 0 C-N-CA 120.597 -0.811 . . . . 0.0 112.925 179.702 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 58' ' ' VAL . . . . . 0.623 HG22 ' O ' ' A' ' 53' ' ' VAL . 1.5 m -72.64 154.2 7.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-O 120.718 0.294 . . . . 0.0 110.33 179.714 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 73.85 19.27 79.75 Favored Glycine 0 N--CA 1.45 -0.373 0 C-N-CA 120.483 -0.865 . . . . 0.0 112.188 -179.433 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 60' ' ' TRP . . . . . . . . . . . . . 22.0 m0 -99.11 99.26 10.24 Favored 'General case' 0 C--N 1.33 -0.259 0 N-CA-C 109.981 -0.377 . . . . 0.0 109.981 179.824 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 61' ' ' VAL . . . . . 0.563 ' HB ' HG23 ' A' ' 68' ' ' VAL . 61.4 t -97.95 109.51 51.75 Favored Pre-proline 0 C--N 1.324 -0.507 0 CA-C-N 115.996 -0.547 . . . . 0.0 111.542 -179.113 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 39.6 Cg_endo -66.2 135.74 41.35 Favored 'Trans proline' 0 C--N 1.35 0.639 0 C-N-CA 122.532 2.155 . . . . 0.0 112.085 179.731 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 80.9 t -137.89 95.13 1.06 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.38 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.387 -179.604 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . 58.11 -90.16 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.111 -0.495 . . . . 0.0 111.566 179.855 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 44.7 mt-10 -115.45 -24.67 8.26 Favored 'General case' 0 C--N 1.332 -0.193 0 CA-C-O 120.842 0.353 . . . . 0.0 111.157 -179.842 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 66' ' ' ARG . . . . . 0.424 ' HD2' ' N ' ' A' ' 66' ' ' ARG . 9.3 mpt_? -105.74 154.07 20.99 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.415 179.871 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 90.7 m -117.39 115.5 25.33 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.892 0.377 . . . . 0.0 111.433 -179.696 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 68' ' ' VAL . . . . . 0.563 HG23 ' HB ' ' A' ' 61' ' ' VAL . 29.0 m -83.81 146.34 6.99 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.368 0 CA-C-N 115.914 -0.584 . . . . 0.0 110.891 179.672 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 69' ' ' PHE . . . . . . . . . . . . . 64.8 m-85 -108.92 115.87 30.9 Favored 'General case' 0 N--CA 1.443 -0.794 0 CA-C-N 116.273 -0.421 . . . . 0.0 110.185 -179.377 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 70' ' ' VAL . . . . . 0.526 ' HB ' ' HD3' ' A' ' 71' ' ' PRO . 24.5 t -67.49 -49.6 40.84 Favored Pre-proline 0 C--N 1.325 -0.477 0 N-CA-C 112.616 0.599 . . . . 0.0 112.616 -178.932 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 71' ' ' PRO . . . . . 0.526 ' HD3' ' HB ' ' A' ' 70' ' ' VAL . 15.4 Cg_exo -67.08 -17.93 51.16 Favored 'Trans proline' 0 C--N 1.351 0.702 0 C-N-CA 122.315 2.01 . . . . 0.0 113.091 -178.918 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 67.2 ttt180 -66.66 -55.5 14.92 Favored 'General case' 0 C--O 1.237 0.396 0 CA-C-O 120.838 0.351 . . . . 0.0 111.626 -179.404 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 73' ' ' TYR . . . . . 0.475 ' O ' HG13 ' A' ' 77' ' ' ILE . 65.4 m-85 -71.52 -34.54 70.15 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.486 -0.324 . . . . 0.0 110.603 -179.453 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 74' ' ' ILE . . . . . 0.51 ' HA ' HD12 ' A' ' 77' ' ' ILE . 0.4 OUTLIER -66.48 -37.86 80.5 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.242 0 N-CA-C 109.833 -0.432 . . . . 0.0 109.833 179.182 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 13.8 t70 -59.14 -38.95 80.89 Favored 'General case' 0 CA--C 1.517 -0.288 0 N-CA-C 109.128 -0.693 . . . . 0.0 109.128 178.62 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 76' ' ' TRP . . . . . . . . . . . . . 51.1 m0 -65.58 -32.67 74.38 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 115.59 -0.732 . . . . 0.0 110.236 179.138 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 77' ' ' ILE . . . . . 0.51 HD12 ' HA ' ' A' ' 74' ' ' ILE . 69.0 mt -68.76 -28.61 40.55 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.25 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.078 178.984 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 34.0 mt -92.22 -20.43 21.18 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 115.772 -0.649 . . . . 0.0 112.332 179.949 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 82.1 p -103.93 -52.94 2.85 Favored 'General case' 0 N--CA 1.465 0.279 0 N-CA-C 114.025 1.12 . . . . 0.0 114.025 -177.295 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 80' ' ' THR . . . . . 0.456 ' N ' ' HD2' ' A' ' 81' ' ' PRO . 25.3 m -50.41 -54.81 30.86 Favored Pre-proline 0 C--N 1.329 -0.317 0 N-CA-C 113.016 0.747 . . . . 0.0 113.016 -178.007 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 81' ' ' PRO . . . . . 0.485 ' HA ' HG22 ' A' ' 84' ' ' VAL . 20.5 Cg_endo -59.78 -21.27 62.86 Favored 'Trans proline' 0 C--N 1.35 0.654 0 C-N-CA 121.346 1.364 . . . . 0.0 111.141 -179.655 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 82' ' ' LEU . . . . . 0.528 HD23 HG12 ' A' ' 43' ' ' ILE . 13.4 tp -77.13 -33.55 56.76 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 115.58 -0.736 . . . . 0.0 109.829 179.436 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 83' ' ' ILE . . . . . 0.421 HD11 HG21 ' A' ' 43' ' ' ILE . 35.2 mm -70.29 -53.44 23.08 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.191 0 CA-C-N 115.984 -0.553 . . . . 0.0 109.848 179.063 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 84' ' ' VAL . . . . . 0.736 HG11 HD22 ' A' ' 105' ' ' ASN . 33.9 m -59.51 -30.19 43.98 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.183 0 N-CA-C 109.546 -0.539 . . . . 0.0 109.546 178.863 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 85' ' ' TYR . . . . . 0.426 ' HB2' ' O ' ' A' ' 81' ' ' PRO . 68.3 t80 -69.74 -32.57 71.18 Favored 'General case' 0 N--CA 1.454 -0.26 0 CA-C-N 115.537 -0.756 . . . . 0.0 109.623 178.873 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 86' ' ' PHE . . . . . . . . . . . . . 9.9 t80 -61.33 -51.93 66.78 Favored 'General case' 0 C--O 1.232 0.149 0 CA-C-N 115.919 -0.582 . . . . 0.0 109.857 179.326 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 87' ' ' LEU . . . . . 0.402 ' N ' HD12 ' A' ' 87' ' ' LEU . 8.1 mp -61.01 -33.16 72.83 Favored 'General case' 0 C--N 1.332 -0.189 0 CA-C-N 115.873 -0.603 . . . . 0.0 110.08 179.374 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 88' ' ' GLY . . . . . 0.427 ' HA2' HD13 ' A' ' 93' ' ' LEU . . . -67.22 -27.74 73.56 Favored Glycine 0 N--CA 1.449 -0.49 0 C-N-CA 120.836 -0.697 . . . . 0.0 111.755 179.233 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 79.3 mt -72.89 -42.95 63.08 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-O 120.924 0.392 . . . . 0.0 110.468 179.622 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 54.9 mt -59.59 -43.83 93.57 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 115.822 -0.626 . . . . 0.0 110.972 179.878 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 91' ' ' ALA . . . . . 0.49 ' HB2' ' HB2' ' A' ' 149' ' ' ALA . . . -74.46 -55.05 6.39 Favored 'General case' 0 C--N 1.331 -0.21 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.325 -179.886 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 103.55 51.62 0.96 Allowed Glycine 0 N--CA 1.452 -0.251 0 C-N-CA 120.843 -0.694 . . . . 0.0 112.447 179.959 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 93' ' ' LEU . . . . . 0.601 HD23 ' HB3' ' A' ' 97' ' ' GLU . 7.9 mp -65.77 170.83 4.83 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.875 0.369 . . . . 0.0 111.193 -179.884 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 94' ' ' ASP . . . . . . . . . . . . . 5.5 m-20 -85.05 164.66 18.09 Favored 'General case' 0 C--N 1.33 -0.239 0 CA-C-N 116.057 -0.519 . . . . 0.0 110.435 179.643 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 46.8 t -55.86 -34.63 65.65 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.326 -0.397 . . . . 0.0 110.97 -179.753 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 96' ' ' ARG . . . . . 0.468 ' HA ' ' NE ' ' A' ' 96' ' ' ARG . 5.6 tpm_? -73.69 -44.87 55.41 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.254 -0.43 . . . . 0.0 111.195 -179.914 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 97' ' ' GLU . . . . . 0.601 ' HB3' HD23 ' A' ' 93' ' ' LEU . 39.1 mt-10 -54.58 -47.39 73.36 Favored 'General case' 0 C--N 1.333 -0.129 0 CA-C-N 116.274 -0.421 . . . . 0.0 111.102 -179.777 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 98' ' ' PHE . . . . . 0.491 ' O ' HG12 ' A' ' 102' ' ' ILE . 41.1 m-85 -58.31 -48.85 79.19 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.859 0.362 . . . . 0.0 110.571 179.489 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -54.25 -29.89 46.67 Favored Glycine 0 N--CA 1.45 -0.383 0 C-N-CA 120.662 -0.78 . . . . 0.0 112.466 179.816 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 100' ' ' ILE . . . . . 0.472 HD12 ' HA ' ' A' ' 97' ' ' GLU . 66.6 mt -73.81 -48.32 39.99 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.229 0 N-CA-C 112.02 0.378 . . . . 0.0 112.02 -179.735 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 101' ' ' VAL . . . . . 0.431 HG12 ' H ' ' A' ' 101' ' ' VAL . 1.4 p -68.84 -41.76 82.34 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.246 0 N-CA-C 112.044 0.387 . . . . 0.0 112.044 -179.404 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 102' ' ' ILE . . . . . 0.491 HG12 ' O ' ' A' ' 98' ' ' PHE . 42.6 mm -64.58 -48.24 85.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.774 -0.194 . . . . 0.0 111.368 -179.358 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 14.7 t -60.95 -34.24 74.42 Favored 'General case' 0 C--N 1.332 -0.166 0 CA-C-O 120.83 0.347 . . . . 0.0 110.385 179.784 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 104' ' ' LEU . . . . . 0.454 HD22 ' HE2' ' A' ' 140' ' ' TYR . 38.0 tp -62.02 -52.92 62.02 Favored 'General case' 0 C--N 1.332 -0.174 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.251 179.296 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 105' ' ' ASN . . . . . 0.736 HD22 HG11 ' A' ' 84' ' ' VAL . 4.3 m-20 -56.95 -27.4 61.13 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.765 179.524 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 30.9 m -64.9 -56.97 10.12 Favored 'General case' 0 C--N 1.332 -0.183 0 CA-C-N 116.313 -0.403 . . . . 0.0 111.481 -179.863 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 107' ' ' VAL . . . . . 0.451 HG12 ' O ' ' A' ' 104' ' ' LEU . 7.4 p -58.93 -36.19 60.39 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.144 0 CA-C-O 120.852 0.358 . . . . 0.0 111.087 -179.892 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 108' ' ' VAL . . . . . 0.452 HG23 ' O ' ' A' ' 104' ' ' LEU . 91.4 t -61.84 -49.47 84.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.099 -0.5 . . . . 0.0 111.133 179.816 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 109' ' ' MET . . . . . 0.471 ' HG2' ' O ' ' A' ' 105' ' ' ASN . 17.7 mmt -64.52 -31.51 72.75 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.244 -0.434 . . . . 0.0 111.104 179.974 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 27.7 tp -68.05 -36.18 79.45 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.247 179.675 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -62.66 -53.67 51.02 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.067 -0.515 . . . . 0.0 110.539 179.48 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . -62.23 -40.97 99.68 Favored Glycine 0 C--N 1.332 0.327 0 C-N-CA 120.638 -0.791 . . . . 0.0 111.868 179.362 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 113' ' ' PHE . . . . . . . . . . . . . 1.4 t80 -48.88 -68.58 0.17 Allowed 'General case' 0 CA--C 1.52 -0.18 0 N-CA-C 109.858 -0.423 . . . . 0.0 109.858 179.33 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 114' ' ' ALA . . . . . 0.52 ' HA ' ' HB2' ' A' ' 117' ' ' MET . . . -67.49 -15.48 63.69 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-N 115.924 -0.58 . . . . 0.0 110.213 179.365 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 115' ' ' GLY . . . . . 0.666 ' O ' HG22 ' A' ' 118' ' ' VAL . . . -53.65 -49.81 56.25 Favored Glycine 0 C--N 1.336 0.557 0 C-N-CA 120.978 -0.629 . . . . 0.0 111.561 179.299 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 116' ' ' ALA . . . . . 0.4 ' HB1' HG12 ' A' ' 68' ' ' VAL . . . -79.36 -22.11 44.86 Favored 'General case' 0 C--N 1.321 -0.638 0 N-CA-C 111.878 0.325 . . . . 0.0 111.878 179.902 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 117' ' ' MET . . . . . 0.52 ' HB2' ' HA ' ' A' ' 114' ' ' ALA . 0.2 OUTLIER -76.67 19.45 0.27 Allowed 'General case' 0 C--N 1.328 -0.33 0 N-CA-C 112.363 0.505 . . . . 0.0 112.363 -178.84 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 118' ' ' VAL . . . . . 0.666 HG22 ' O ' ' A' ' 115' ' ' GLY . 23.3 m -123.67 138.71 30.78 Favored Pre-proline 0 C--N 1.33 -0.278 0 C-N-CA 121.131 -0.227 . . . . 0.0 111.369 179.823 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 119' ' ' PRO . . . . . . . . . . . . . 77.4 Cg_endo -96.63 23.47 0.33 Allowed 'Trans proline' 0 N--CA 1.455 -0.787 0 C-N-CA 123.19 2.593 . . . . 0.0 112.769 179.892 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -139.73 -159.16 7.87 Favored Glycine 0 C--N 1.332 0.308 0 C-N-CA 120.493 -0.86 . . . . 0.0 113.215 -179.578 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 121' ' ' ILE . . . . . 0.427 HG22 ' O ' ' A' ' 121' ' ' ILE . 14.3 mm -80.33 1.89 2.7 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.205 0 CA-C-O 121.136 0.493 . . . . 0.0 110.938 -179.77 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 33.6 mt-10 -59.34 -37.39 77.71 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 115.799 -0.637 . . . . 0.0 110.89 -179.991 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 123' ' ' ARG . . . . . 0.538 ' HB2' ' HH2' ' A' ' 178' ' ' TRP . 3.7 ptp180 -50.6 -32.99 20.41 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.018 -0.537 . . . . 0.0 111.654 -179.659 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 124' ' ' TYR . . . . . . . . . . . . . 91.3 m-85 -71.57 -33.2 68.88 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.385 -0.371 . . . . 0.0 111.236 -179.645 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 125' ' ' ALA . . . . . . . . . . . . . . . -70.07 -50.86 36.8 Favored 'General case' 0 C--O 1.237 0.405 0 CA-C-O 120.995 0.426 . . . . 0.0 110.047 179.194 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 126' ' ' LEU . . . . . 0.439 HD22 ' HA2' ' A' ' 115' ' ' GLY . 8.2 mp -55.55 -54.04 48.94 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 115.695 -0.684 . . . . 0.0 110.074 179.345 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 127' ' ' PHE . . . . . . . . . . . . . 11.0 t80 -63.53 -35.73 81.44 Favored 'General case' 0 N--CA 1.452 -0.374 0 CA-C-N 115.782 -0.645 . . . . 0.0 110.611 179.958 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 128' ' ' GLY . . . . . . . . . . . . . . . -47.46 -44.48 21.87 Favored Glycine 0 C--N 1.332 0.313 0 C-N-CA 120.228 -0.987 . . . . 0.0 110.805 179.138 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 129' ' ' MET . . . . . . . . . . . . . 0.3 OUTLIER -70.51 -36.56 73.83 Favored 'General case' 0 N--CA 1.453 -0.318 0 N-CA-C 109.828 -0.434 . . . . 0.0 109.828 178.688 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -66.52 -28.56 73.81 Favored Glycine 0 C--N 1.332 0.342 0 CA-C-N 115.702 -0.681 . . . . 0.0 112.839 -179.993 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -74.67 -53.7 8.81 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-O 120.699 0.285 . . . . 0.0 110.358 179.83 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 98.4 t -57.84 -39.91 73.49 Favored 'Isoleucine or valine' 0 C--O 1.234 0.276 0 N-CA-C 109.024 -0.732 . . . . 0.0 109.024 178.433 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -67.23 -33.92 76.37 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 115.123 -0.944 . . . . 0.0 110.642 179.269 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 134' ' ' PHE . . . . . 0.425 ' CZ ' ' HA ' ' A' ' 172' ' ' ALA . 74.6 t80 -56.43 -55.81 28.92 Favored 'General case' 0 N--CA 1.449 -0.484 0 CA-C-O 120.926 0.393 . . . . 0.0 109.951 179.388 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 135' ' ' ILE . . . . . 0.421 ' O ' HG22 ' A' ' 138' ' ' VAL . 40.1 mt -56.58 -33.23 39.14 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.298 0 CA-C-N 115.761 -0.654 . . . . 0.0 109.876 178.942 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . -61.44 -36.9 93.24 Favored Glycine 0 N--CA 1.447 -0.574 0 C-N-CA 120.424 -0.893 . . . . 0.0 111.456 179.067 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 137' ' ' LEU . . . . . . . . . . . . . 47.9 tp -72.22 -54.02 10.85 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-O 120.527 0.203 . . . . 0.0 110.633 179.657 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 138' ' ' VAL . . . . . 0.421 HG22 ' O ' ' A' ' 135' ' ' ILE . 3.4 m -56.17 -31.51 32.08 Favored 'Isoleucine or valine' 0 C--O 1.233 0.192 0 CA-C-O 121.242 0.544 . . . . 0.0 109.676 179.462 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 139' ' ' TYR . . . . . . . . . . . . . 24.9 t80 -63.41 -46.96 83.98 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 115.432 -0.804 . . . . 0.0 110.311 178.819 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 140' ' ' TYR . . . . . 0.454 ' HE2' HD22 ' A' ' 104' ' ' LEU . 17.2 m-85 -58.89 -37.98 77.84 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.626 179.638 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 141' ' ' LEU . . . . . . . . . . . . . 62.6 mt -57.61 -48.2 80.07 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.189 179.542 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 17.1 t -78.31 -12.58 13.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 115.943 -0.571 . . . . 0.0 110.658 179.654 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 143' ' ' GLY . . . . . 0.43 ' HA3' ' HD2' ' A' ' 144' ' ' PRO . . . -72.44 -134.62 0.18 Allowed Glycine 0 CA--C 1.521 0.425 0 C-N-CA 120.982 -0.627 . . . . 0.0 112.906 -179.845 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 144' ' ' PRO . . . . . 0.43 ' HD2' ' HA3' ' A' ' 143' ' ' GLY . 20.7 Cg_endo -60.43 -23.72 75.76 Favored 'Trans proline' 0 C--N 1.349 0.586 0 C-N-CA 122.647 2.231 . . . . 0.0 112.593 -179.658 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 145' ' ' MET . . . . . . . . . . . . . 55.1 mtt -59.33 -36.73 76.2 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.507 -0.315 . . . . 0.0 111.303 -179.865 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 146' ' ' THR . . . . . . . . . . . . . 86.2 m -79.63 -42.33 25.09 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.508 -0.314 . . . . 0.0 111.431 -179.154 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 8.8 tp10 -61.84 -41.46 97.83 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.243 -179.784 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 148' ' ' SER . . . . . . . . . . . . . 48.7 m -70.61 -46.32 63.59 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.263 -0.426 . . . . 0.0 111.614 -179.325 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 149' ' ' ALA . . . . . 0.49 ' HB2' ' HB2' ' A' ' 91' ' ' ALA . . . -68.33 -30.71 69.75 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.3 -0.409 . . . . 0.0 111.892 -179.206 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 150' ' ' SER . . . . . . . . . . . . . 43.3 t -72.36 -5.9 39.62 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.439 -0.346 . . . . 0.0 111.656 -179.275 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 151' ' ' GLN . . . . . . . . . . . . . 10.3 pt20 -133.55 5.79 3.74 Favored 'General case' 0 C--N 1.33 -0.251 0 N-CA-C 111.649 0.24 . . . . 0.0 111.649 -179.835 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 1.6 tmt_? -73.69 -51.88 15.15 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-O 120.994 0.426 . . . . 0.0 110.251 179.946 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 153' ' ' SER . . . . . 0.637 ' HB2' HG12 ' A' ' 156' ' ' ILE . 49.1 m -158.1 172.08 19.06 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-N 115.759 -0.655 . . . . 0.0 110.256 179.227 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 154' ' ' SER . . . . . . . . . . . . . 88.6 p -70.65 -37.67 73.76 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-O 120.883 0.373 . . . . 0.0 110.474 179.542 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -76.98 -30.26 55.95 Favored Glycine 0 N--CA 1.452 -0.276 0 C-N-CA 120.935 -0.65 . . . . 0.0 112.751 -179.914 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 156' ' ' ILE . . . . . 0.637 HG12 ' HB2' ' A' ' 153' ' ' SER . 39.1 mm -64.48 -39.21 84.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-O 120.765 0.317 . . . . 0.0 111.243 -179.988 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 157' ' ' LYS . . . . . . . . . . . . . 87.1 tttt -63.55 -41.28 98.44 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 116.306 -0.406 . . . . 0.0 111.624 -179.37 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 87.9 p -71.34 -48.33 51.02 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-O 120.956 0.408 . . . . 0.0 111.493 -179.338 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 159' ' ' LEU . . . . . 0.554 HD21 ' HB3' ' A' ' 215' ' ' ALA . 17.4 mt -66.77 -31.85 72.75 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 116.084 -0.507 . . . . 0.0 111.726 -179.269 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 160' ' ' TYR . . . . . . . . . . . . . 50.9 t80 -74.25 -46.79 39.3 Favored 'General case' 0 C--N 1.327 -0.372 0 N-CA-C 112.051 0.389 . . . . 0.0 112.051 -178.841 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 24.4 m -60.12 -44.74 95.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 N-CA-C 111.848 0.314 . . . . 0.0 111.848 -179.154 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 162' ' ' ARG . . . . . 0.487 ' HG2' HG21 ' A' ' 211' ' ' ILE . 22.3 tpp180 -68.88 -40.88 79.01 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.755 0.312 . . . . 0.0 111.638 -179.598 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 163' ' ' LEU . . . . . 0.631 ' HG ' ' HB2' ' A' ' 208' ' ' PHE . 6.3 mp -69.23 -55.14 11.45 Favored 'General case' 0 C--N 1.329 -0.323 0 N-CA-C 112.77 0.656 . . . . 0.0 112.77 -178.724 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 164' ' ' ARG . . . . . 0.493 ' O ' HG23 ' A' ' 168' ' ' VAL . 5.0 ppt_? -61.04 -45.5 94.5 Favored 'General case' 0 C--N 1.328 -0.339 0 N-CA-C 112.28 0.474 . . . . 0.0 112.28 -178.316 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 165' ' ' ASN . . . . . 0.499 ' O ' HG23 ' A' ' 169' ' ' VAL . 9.5 m-80 -59.88 -51.48 69.5 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.763 0.316 . . . . 0.0 111.28 -179.736 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 166' ' ' LEU . . . . . 0.473 ' O ' ' HG ' ' A' ' 170' ' ' LEU . 3.2 tt -61.21 -50.84 71.49 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.461 -179.511 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 167' ' ' THR . . . . . 0.439 ' O ' ' HB2' ' A' ' 171' ' ' TRP . 92.1 m -55.01 -53.32 57.31 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 115.911 -0.586 . . . . 0.0 112.514 -178.999 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 168' ' ' VAL . . . . . 0.493 HG23 ' O ' ' A' ' 164' ' ' ARG . 85.3 t -55.16 -43.97 72.67 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.236 0 N-CA-C 112.044 0.387 . . . . 0.0 112.044 -178.803 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 169' ' ' VAL . . . . . 0.499 HG23 ' O ' ' A' ' 165' ' ' ASN . 72.3 t -56.41 -65.05 0.42 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 N-CA-C 111.969 0.359 . . . . 0.0 111.969 -179.288 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 170' ' ' LEU . . . . . 0.473 ' HG ' ' O ' ' A' ' 166' ' ' LEU . 0.7 OUTLIER -64.76 -28.08 69.33 Favored 'General case' 0 C--N 1.331 -0.238 0 N-CA-C 112.238 0.458 . . . . 0.0 112.238 -178.852 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 171' ' ' TRP . . . . . 0.439 ' HB2' ' O ' ' A' ' 167' ' ' THR . 4.0 m0 -71.13 -30.01 65.96 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-O 121.006 0.431 . . . . 0.0 110.495 179.495 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 172' ' ' ALA . . . . . 0.425 ' HA ' ' CZ ' ' A' ' 134' ' ' PHE . . . -72.67 -6.36 43.85 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 115.917 -0.583 . . . . 0.0 111.056 -179.722 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 173' ' ' ILE . . . . . 0.51 HG22 HD11 ' A' ' 177' ' ' ILE . 21.6 mm -87.29 -21.82 7.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 115.93 -0.577 . . . . 0.0 111.288 -179.972 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 174' ' ' TYR . . . . . 0.597 ' N ' ' HD2' ' A' ' 175' ' ' PRO . 37.0 m-85 -54.35 -51.24 79.66 Favored Pre-proline 0 CA--C 1.532 0.267 0 N-CA-C 111.955 0.354 . . . . 0.0 111.955 -179.762 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 175' ' ' PRO . . . . . 0.597 ' HD2' ' N ' ' A' ' 174' ' ' TYR . 5.3 Cg_endo -48.41 -29.57 13.76 Favored 'Trans proline' 0 C--N 1.352 0.717 0 C-N-CA 122.106 1.87 . . . . 0.0 112.299 -179.967 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 176' ' ' PHE . . . . . 0.475 ' HD2' ' HA ' ' A' ' 173' ' ' ILE . 58.9 m-85 -80.84 -49.45 11.05 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.044 -0.525 . . . . 0.0 112.053 -179.885 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 177' ' ' ILE . . . . . 0.51 HD11 HG22 ' A' ' 173' ' ' ILE . 4.4 mm -62.47 -34.79 66.55 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.496 0 N-CA-C 112.389 0.515 . . . . 0.0 112.389 -178.155 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 178' ' ' TRP . . . . . 0.538 ' HH2' ' HB2' ' A' ' 123' ' ' ARG . 70.0 t90 -73.71 -46.7 44.56 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-O 121.03 0.443 . . . . 0.0 110.766 179.551 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 179' ' ' LEU . . . . . 0.428 ' O ' HG22 ' A' ' 185' ' ' VAL . 1.7 tm? -69.5 -48.42 60.64 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 115.856 -0.611 . . . . 0.0 111.396 -179.172 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 180' ' ' LEU . . . . . 0.669 HD22 HD11 ' A' ' 187' ' ' LEU . 42.2 mt -75.15 -46.62 33.13 Favored 'General case' 0 C--N 1.327 -0.395 0 N-CA-C 111.911 0.338 . . . . 0.0 111.911 -179.153 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . -58.35 -179.59 1.06 Allowed Glycine 0 C--N 1.336 0.582 0 C-N-CA 120.256 -0.973 . . . . 0.0 112.383 179.767 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 182' ' ' PRO . . . . . 0.662 ' HA ' ' HB2' ' A' ' 186' ' ' ALA . 84.7 Cg_exo -47.05 -44.05 23.84 Favored 'Trans proline' 0 CA--C 1.535 0.571 0 C-N-CA 122.834 2.356 . . . . 0.0 113.94 -179.97 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 183' ' ' PRO . . . . . 0.407 ' CD ' ' N ' ' A' ' 182' ' ' PRO . 74.7 Cg_exo -51.19 -17.71 4.12 Favored 'Trans proline' 0 C--N 1.355 0.891 0 C-N-CA 122.257 1.971 . . . . 0.0 113.456 -179.707 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 184' ' ' GLY . . . . . . . . . . . . . . . -120.51 -92.02 1.27 Allowed Glycine 0 C--N 1.332 0.343 0 C-N-CA 120.207 -0.997 . . . . 0.0 113.294 -179.743 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 185' ' ' VAL . . . . . 0.428 HG22 ' O ' ' A' ' 179' ' ' LEU . 17.8 m -106.39 -13.0 9.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 N-CA-C 112.152 0.427 . . . . 0.0 112.152 -179.004 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 186' ' ' ALA . . . . . 0.662 ' HB2' ' HA ' ' A' ' 182' ' ' PRO . . . 58.36 86.78 0.08 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.794 0.33 . . . . 0.0 111.469 179.848 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 187' ' ' LEU . . . . . 0.669 HD11 HD22 ' A' ' 180' ' ' LEU . 22.8 mt -91.79 -49.02 6.48 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 120.953 0.406 . . . . 0.0 110.968 179.909 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 188' ' ' LEU . . . . . . . . . . . . . 77.5 mt -95.87 -151.66 0.35 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 115.939 -0.573 . . . . 0.0 111.339 -179.365 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 189' ' ' THR . . . . . 0.447 HG22 ' H ' ' A' ' 191' ' ' THR . 29.0 m -96.96 137.45 21.31 Favored Pre-proline 0 C--N 1.331 -0.221 0 CA-C-N 115.922 -0.581 . . . . 0.0 110.852 -179.483 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 190' ' ' PRO . . . . . . . . . . . . . 82.0 Cg_exo -46.95 -29.86 8.97 Favored 'Trans proline' 0 C--N 1.349 0.577 0 C-N-CA 122.478 2.118 . . . . 0.0 112.692 179.9 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 191' ' ' THR . . . . . 0.447 ' H ' HG22 ' A' ' 189' ' ' THR . 76.7 p -77.4 -40.6 43.08 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.486 -0.324 . . . . 0.0 111.412 -179.948 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 192' ' ' VAL . . . . . . . . . . . . . 61.7 t -72.09 -53.27 20.47 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.289 -0.414 . . . . 0.0 111.564 -179.608 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 193' ' ' ASP . . . . . . . . . . . . . 30.7 m-20 -52.15 -48.79 64.74 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.36 -0.382 . . . . 0.0 111.015 -179.921 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 194' ' ' VAL . . . . . 0.489 ' O ' HG22 ' A' ' 198' ' ' VAL . 55.3 t -62.38 -36.38 74.41 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.645 179.724 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 195' ' ' ALA . . . . . . . . . . . . . . . -56.27 -39.84 73.28 Favored 'General case' 0 C--N 1.332 -0.155 0 CA-C-N 116.348 -0.387 . . . . 0.0 110.571 179.344 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 196' ' ' LEU . . . . . . . . . . . . . 96.4 mt -68.43 -39.62 81.49 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.018 -0.537 . . . . 0.0 110.557 179.251 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 197' ' ' ILE . . . . . 0.407 HD11 ' HB ' ' A' ' 177' ' ' ILE . 18.3 mm -60.43 -60.38 2.67 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.254 0 CA-C-N 115.856 -0.611 . . . . 0.0 111.238 179.957 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 198' ' ' VAL . . . . . 0.489 HG22 ' O ' ' A' ' 194' ' ' VAL . 3.3 m -52.98 -36.05 23.36 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.4 0 CA-C-O 121.596 0.712 . . . . 0.0 109.808 179.003 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 199' ' ' TYR . . . . . . . . . . . . . 37.1 t80 -67.97 -33.04 73.89 Favored 'General case' 0 C--N 1.321 -0.666 0 CA-C-N 114.629 -1.168 . . . . 0.0 110.849 179.858 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 200' ' ' LEU . . . . . 0.569 ' O ' HG12 ' A' ' 203' ' ' VAL . 25.5 mt -68.71 -41.85 78.52 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 121.13 0.49 . . . . 0.0 110.844 179.927 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 201' ' ' ASP . . . . . . . . . . . . . 15.8 m-20 -70.09 -33.18 71.56 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-O 121.321 0.581 . . . . 0.0 109.727 179.109 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 202' ' ' LEU . . . . . 0.438 HD11 ' HA2' ' A' ' 11' ' ' GLY . 3.1 mt -72.33 -31.14 65.41 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 115.213 -0.903 . . . . 0.0 112.014 -179.741 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 203' ' ' VAL . . . . . 0.569 HG12 ' O ' ' A' ' 200' ' ' LEU . 13.0 p -76.44 -35.91 27.64 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 C-N-CA 121.06 -0.256 . . . . 0.0 110.958 -178.621 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 204' ' ' THR . . . . . . . . . . . . . 88.8 m -67.66 -58.24 5.01 Favored 'General case' 0 C--N 1.326 -0.443 0 C-N-CA 120.651 -0.42 . . . . 0.0 111.289 179.498 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 205' ' ' LYS . . . . . 0.684 ' HE2' ' HB2' ' A' ' 47' ' ' ALA . 48.7 mttp -62.15 -58.49 7.59 Favored 'General case' 0 C--N 1.329 -0.303 0 N-CA-C 112.21 0.448 . . . . 0.0 112.21 -178.513 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 44.5 t -70.35 -36.22 65.96 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.48 0 CA-C-N 116.025 -0.534 . . . . 0.0 112.068 -178.836 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 207' ' ' GLY . . . . . 0.548 ' O ' HG13 ' A' ' 211' ' ' ILE . . . -58.33 -61.66 7.15 Favored Glycine 0 N--CA 1.452 -0.271 0 C-N-CA 120.634 -0.793 . . . . 0.0 113.844 -178.128 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 208' ' ' PHE . . . . . 0.631 ' HB2' ' HG ' ' A' ' 163' ' ' LEU . 0.8 OUTLIER -72.69 -27.61 62.19 Favored 'General case' 0 C--O 1.221 -0.436 0 CA-C-N 117.515 0.657 . . . . 0.0 110.854 -179.12 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 209' ' ' GLY . . . . . 0.497 ' O ' ' HB3' ' A' ' 212' ' ' ALA . . . -64.1 -31.87 82.29 Favored Glycine 0 N--CA 1.45 -0.399 0 N-CA-C 111.546 -0.622 . . . . 0.0 111.546 178.697 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 210' ' ' PHE . . . . . . . . . . . . . 0.5 OUTLIER -74.79 -47.9 28.32 Favored 'General case' 0 CA--C 1.514 -0.41 0 N-CA-C 108.425 -0.954 . . . . 0.0 108.425 178.451 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 211' ' ' ILE . . . . . 0.548 HG13 ' O ' ' A' ' 207' ' ' GLY . 4.3 mt -63.69 -27.61 43.27 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.45 0 N-CA-C 107.712 -1.218 . . . . 0.0 107.712 176.787 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 212' ' ' ALA . . . . . 0.497 ' HB3' ' O ' ' A' ' 209' ' ' GLY . . . -62.46 -46.1 90.02 Favored 'General case' 0 N--CA 1.449 -0.524 0 CA-C-N 114.469 -1.242 . . . . 0.0 110.549 -179.888 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 213' ' ' LEU . . . . . . . . . . . . . 95.8 mt -70.33 -46.03 65.01 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 115.182 -0.917 . . . . 0.0 111.864 -179.437 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 214' ' ' ASP . . . . . . . . . . . . . 19.9 t70 -56.06 -55.19 35.89 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.466 -0.334 . . . . 0.0 111.604 -179.299 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 215' ' ' ALA . . . . . 0.554 ' HB3' HD21 ' A' ' 159' ' ' LEU . . . -58.95 -53.14 61.77 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.327 -0.397 . . . . 0.0 111.406 -179.559 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 216' ' ' ALA . . . . . . . . . . . . . . . -53.14 -45.08 68.24 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.506 -179.666 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 217' ' ' ALA . . . . . . . . . . . . . . . -55.85 -39.86 72.06 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-O 121.062 0.458 . . . . 0.0 110.301 179.738 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 218' ' ' THR . . . . . . . . . . . . . 92.1 m . . . . . 0 C--N 1.329 -0.306 0 CA-C-N 115.634 -0.712 . . . . 0.0 110.861 179.48 . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.33 0 N-CA-C 112.768 -0.133 . . . . 0.0 112.768 . . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 32.5 tp -74.16 -35.35 64.04 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.808 0.337 . . . . 0.0 110.884 179.967 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 74.7 p -61.67 -30.56 70.81 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.132 -0.486 . . . . 0.0 111.411 -179.985 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 29.0 p -58.98 -36.12 74.36 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-O 120.783 0.325 . . . . 0.0 111.07 -179.852 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 7' ' ' LEU . . . . . . . . . . . . . 4.5 mm? -56.61 -52.06 66.28 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.861 179.862 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 8' ' ' PHE . . . . . 0.667 ' HB2' ' HB2' ' A' ' 55' ' ' ALA . 83.5 m-85 -58.1 -37.84 75.29 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.223 179.477 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 9' ' ' TRP . . . . . . . . . . . . . 15.8 m95 -63.0 -41.81 99.68 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 115.987 -0.551 . . . . 0.0 110.102 -179.987 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 84.9 mt -59.74 -43.87 94.06 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 115.617 -0.719 . . . . 0.0 110.09 179.299 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -61.36 -33.97 86.54 Favored Glycine 0 N--CA 1.448 -0.516 0 C-N-CA 120.656 -0.783 . . . . 0.0 111.554 179.168 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -66.96 -31.23 71.66 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-O 120.912 0.387 . . . . 0.0 110.376 179.447 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 75.5 mt -66.06 -47.52 84.7 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.245 0 CA-C-N 115.985 -0.552 . . . . 0.0 110.097 179.343 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -60.63 -39.43 96.54 Favored Glycine 0 N--CA 1.45 -0.409 0 C-N-CA 120.758 -0.734 . . . . 0.0 111.7 179.315 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 15' ' ' MET . . . . . 0.592 ' HE2' ' HE2' ' A' ' 51' ' ' TYR . 0.1 OUTLIER -63.54 -41.06 98.46 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 120.665 0.269 . . . . 0.0 110.575 179.422 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -55.98 -50.66 70.21 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.758 179.841 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 35.6 t -59.6 -46.4 93.19 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.389 -179.792 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -63.96 -48.5 75.32 Favored Glycine 0 C--N 1.331 0.262 0 C-N-CA 120.718 -0.753 . . . . 0.0 112.437 179.919 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 31.9 m -50.6 -44.24 56.97 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-O 120.723 0.297 . . . . 0.0 111.131 -179.774 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 95.2 mt -72.35 -40.28 67.48 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.622 179.907 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -63.19 -33.78 76.21 Favored 'General case' 0 C--N 1.331 -0.196 0 N-CA-C 112.065 0.395 . . . . 0.0 112.065 -179.294 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 22' ' ' PHE . . . . . 0.66 ' HB2' HG22 ' A' ' 41' ' ' VAL . 7.6 m-85 -86.2 -33.7 20.7 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.657 0.265 . . . . 0.0 111.658 -179.131 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -73.6 -50.7 19.85 Favored 'General case' 0 C--N 1.329 -0.297 0 N-CA-C 111.991 0.367 . . . . 0.0 111.991 -179.206 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 24' ' ' TRP . . . . . . . . . . . . . 2.7 t-105 -58.99 -46.62 87.7 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 116.029 -0.532 . . . . 0.0 111.239 -179.503 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.328 -0.361 0 CA-C-O 120.828 0.347 . . . . 0.0 110.925 179.796 . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.3 0 N-CA-C 112.562 -0.215 . . . . 0.0 112.562 . . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 9.1 mm-40 -60.63 -21.07 62.32 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 120.698 0.285 . . . . 0.0 110.989 179.868 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 34' ' ' ARG . . . . . . . . . . . . . 38.6 ttm180 -48.44 -34.99 11.96 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-N 115.969 -0.559 . . . . 0.0 111.525 -179.758 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 70.3 mtm180 -55.1 -54.84 38.08 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.314 -0.403 . . . . 0.0 111.303 -179.986 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 82.0 m-85 -59.7 -28.7 67.53 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.097 -179.946 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 37' ' ' TYR . . . . . 0.428 ' O ' HG23 ' A' ' 41' ' ' VAL . 52.5 m-85 -71.97 -52.42 17.18 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.3 -0.409 . . . . 0.0 111.314 -179.893 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 59.8 t -57.69 -39.26 69.3 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.219 0 CA-C-O 121.116 0.484 . . . . 0.0 110.528 179.658 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 19.6 m -62.81 -50.93 69.05 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 115.576 -0.738 . . . . 0.0 110.715 179.403 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 40' ' ' LEU . . . . . 0.48 HD21 ' CA ' ' A' ' 209' ' ' GLY . 19.6 tp -57.57 -50.21 73.86 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 115.652 -0.704 . . . . 0.0 110.578 -179.997 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 41' ' ' VAL . . . . . 0.66 HG22 ' HB2' ' A' ' 22' ' ' PHE . 85.5 t -59.02 -34.9 54.39 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.235 0 CA-C-N 115.856 -0.611 . . . . 0.0 110.236 179.142 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -59.19 -39.56 94.66 Favored Glycine 0 N--CA 1.448 -0.505 0 C-N-CA 120.834 -0.698 . . . . 0.0 112.06 179.652 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 43' ' ' ILE . . . . . 0.535 HG12 HD12 ' A' ' 82' ' ' LEU . 1.2 mt -64.84 -55.59 20.15 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.193 0 CA-C-O 120.683 0.278 . . . . 0.0 110.728 179.567 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 51.3 m -57.72 -23.81 53.7 Favored 'General case' 0 C--O 1.232 0.178 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.181 -179.963 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -78.18 -56.23 3.79 Favored Glycine 0 CA--C 1.518 0.251 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.668 -179.772 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 26.6 pt -58.31 -35.4 53.49 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.215 0 CA-C-O 121.08 0.467 . . . . 0.0 110.912 179.944 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 47' ' ' ALA . . . . . 0.745 ' HB2' ' HE2' ' A' ' 205' ' ' LYS . . . -67.51 -46.74 71.99 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-N 116.031 -0.531 . . . . 0.0 111.307 179.346 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 48' ' ' ALA . . . . . 0.561 ' HB2' ' HB3' ' A' ' 15' ' ' MET . . . -54.87 -40.6 69.87 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 116.04 -0.527 . . . . 0.0 111.951 -179.485 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 25.1 m -73.08 -34.69 46.04 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 CA-C-N 116.63 -0.259 . . . . 0.0 111.516 -179.207 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 50' ' ' ALA . . . . . 0.403 ' O ' HG22 ' A' ' 53' ' ' VAL . . . -65.96 -38.18 87.93 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-O 121.145 0.498 . . . . 0.0 110.749 179.346 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 51' ' ' TYR . . . . . 0.592 ' HE2' ' HE2' ' A' ' 15' ' ' MET . 42.9 m-85 -73.09 -28.31 62.21 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-N 115.813 -0.631 . . . . 0.0 109.734 179.466 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -72.35 -38.88 68.48 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 115.419 -0.809 . . . . 0.0 110.97 179.517 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 53' ' ' VAL . . . . . 0.575 ' O ' HG22 ' A' ' 58' ' ' VAL . 33.8 m -73.95 -47.49 42.53 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.159 0 CA-C-N 116.402 -0.363 . . . . 0.0 110.78 -179.941 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 54' ' ' MET . . . . . 0.458 ' N ' HG23 ' A' ' 53' ' ' VAL . 75.0 mtm -57.75 -36.44 72.1 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-O 121.241 0.543 . . . . 0.0 109.949 179.094 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 55' ' ' ALA . . . . . 0.667 ' HB2' ' HB2' ' A' ' 8' ' ' PHE . . . -68.91 -11.69 60.86 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 115.317 -0.856 . . . . 0.0 111.705 179.876 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 47.4 mt -97.57 -4.21 38.15 Favored 'General case' 0 C--N 1.33 -0.259 0 N-CA-C 111.944 0.35 . . . . 0.0 111.944 -179.475 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 105.13 -23.0 31.77 Favored Glycine 0 CA--C 1.52 0.352 0 C-N-CA 120.373 -0.917 . . . . 0.0 114.004 179.23 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 58' ' ' VAL . . . . . 0.575 HG22 ' O ' ' A' ' 53' ' ' VAL . 16.3 m -62.05 160.41 2.21 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.128 0 CA-C-N 117.722 0.761 . . . . 0.0 109.768 179.343 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 59' ' ' GLY . . . . . 0.683 ' HA3' ' HD3' ' A' ' 71' ' ' PRO . . . 79.58 -25.56 2.86 Favored Glycine 0 N--CA 1.441 -1.033 0 C-N-CA 119.999 -1.096 . . . . 0.0 112.71 -178.844 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 60' ' ' TRP . . . . . . . . . . . . . 11.6 m0 -67.77 80.13 0.19 Allowed 'General case' 0 C--N 1.327 -0.388 0 N-CA-C 110.176 -0.305 . . . . 0.0 110.176 179.561 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 4.7 p -90.83 119.35 68.96 Favored Pre-proline 0 C--N 1.33 -0.266 0 CA-C-N 116.461 -0.336 . . . . 0.0 111.202 -179.747 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 35.8 Cg_exo -60.49 119.44 6.63 Favored 'Trans proline' 0 C--N 1.35 0.615 0 C-N-CA 122.451 2.101 . . . . 0.0 112.176 179.841 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 78.4 t -117.21 99.59 8.54 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.364 0 CA-C-N 115.931 -0.577 . . . . 0.0 110.918 179.914 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . 59.9 -85.65 0.02 OUTLIER 'General case' 0 C--N 1.332 -0.174 0 CA-C-N 116.095 -0.502 . . . . 0.0 111.254 -179.926 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 53.8 mm-40 -126.74 -26.69 3.18 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.335 179.521 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 66' ' ' ARG . . . . . . . . . . . . . 34.5 ptt180 -95.41 164.23 12.9 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 115.823 -0.626 . . . . 0.0 110.306 179.474 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 13.8 m -114.94 132.02 56.7 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.848 0.356 . . . . 0.0 111.265 -179.999 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 29.4 t -116.78 145.77 22.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.023 -0.535 . . . . 0.0 110.634 179.728 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 69' ' ' PHE . . . . . . . . . . . . . 10.8 m-85 -102.09 119.8 39.39 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-O 120.917 0.389 . . . . 0.0 110.659 -179.357 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 70' ' ' VAL . . . . . 0.632 HG13 ' O ' ' A' ' 59' ' ' GLY . 1.2 m -69.67 -35.57 5.7 Favored Pre-proline 0 CA--C 1.544 0.727 0 N-CA-C 113.05 0.759 . . . . 0.0 113.05 -179.344 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 71' ' ' PRO . . . . . 0.683 ' HD3' ' HA3' ' A' ' 59' ' ' GLY . 8.4 Cg_exo -70.56 -19.87 31.78 Favored 'Trans proline' 0 C--N 1.358 1.055 0 C-N-CA 122.579 2.186 . . . . 0.0 112.88 -178.146 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 72' ' ' ARG . . . . . 0.449 ' NH2' ' HG3' ' A' ' 183' ' ' PRO . 38.5 ttp180 -64.72 -53.46 46.84 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-O 120.949 0.404 . . . . 0.0 110.66 -179.916 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 73' ' ' TYR . . . . . . . . . . . . . 19.6 m-85 -73.19 -37.36 66.51 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.572 -179.97 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 74' ' ' ILE . . . . . 0.605 HG22 ' HA ' ' A' ' 71' ' ' PRO . 0.4 OUTLIER -64.08 -39.86 87.0 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 N-CA-C 109.877 -0.416 . . . . 0.0 109.877 179.439 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 75' ' ' ASP . . . . . 0.409 ' O ' HG23 ' A' ' 79' ' ' THR . 33.9 t70 -64.06 -34.8 78.84 Favored 'General case' 0 CA--C 1.516 -0.362 0 N-CA-C 108.882 -0.785 . . . . 0.0 108.882 178.868 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 76' ' ' TRP . . . . . 0.444 ' HB3' ' SD ' ' A' ' 109' ' ' MET . 44.5 m0 -66.42 -28.1 68.35 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 115.531 -0.759 . . . . 0.0 110.251 179.064 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 77' ' ' ILE . . . . . 0.497 ' O ' ' HG2' ' A' ' 81' ' ' PRO . 85.0 mt -75.89 -28.75 19.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-O 121.184 0.516 . . . . 0.0 109.69 178.827 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 52.0 mt -91.55 -18.32 24.27 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 115.758 -0.655 . . . . 0.0 111.446 179.183 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 79' ' ' THR . . . . . 0.409 HG23 ' O ' ' A' ' 75' ' ' ASP . 76.1 p -104.22 -50.98 3.22 Favored 'General case' 0 N--CA 1.464 0.225 0 N-CA-C 113.278 0.844 . . . . 0.0 113.278 -178.084 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 80' ' ' THR . . . . . 0.68 ' HB ' ' HD3' ' A' ' 81' ' ' PRO . 40.2 m -51.98 -55.19 32.89 Favored Pre-proline 0 CA--C 1.53 0.19 0 N-CA-C 111.947 0.351 . . . . 0.0 111.947 -178.642 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 81' ' ' PRO . . . . . 0.68 ' HD3' ' HB ' ' A' ' 80' ' ' THR . 40.6 Cg_exo -58.72 -21.8 57.97 Favored 'Trans proline' 0 C--N 1.352 0.748 0 C-N-CA 121.426 1.417 . . . . 0.0 111.133 179.406 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 82' ' ' LEU . . . . . 0.535 HD12 HG12 ' A' ' 43' ' ' ILE . 0.2 OUTLIER -76.36 -43.42 40.99 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 115.555 -0.748 . . . . 0.0 109.999 179.638 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 50.4 mm -63.76 -52.38 57.9 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.192 0 CA-C-N 116.074 -0.512 . . . . 0.0 110.424 179.512 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 29.3 m -57.98 -33.79 47.11 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.202 0 N-CA-C 109.738 -0.467 . . . . 0.0 109.738 179.104 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 85' ' ' TYR . . . . . 0.409 ' O ' ' HG ' ' A' ' 89' ' ' LEU . 61.6 t80 -62.1 -36.13 80.79 Favored 'General case' 0 N--CA 1.454 -0.27 0 CA-C-N 115.796 -0.638 . . . . 0.0 109.463 178.601 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 86' ' ' PHE . . . . . . . . . . . . . 13.0 t80 -59.7 -49.12 78.98 Favored 'General case' 0 C--O 1.232 0.183 0 CA-C-N 115.641 -0.709 . . . . 0.0 109.726 179.0 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 3.9 mm? -56.42 -41.8 76.96 Favored 'General case' 0 C--N 1.332 -0.176 0 CA-C-N 115.696 -0.684 . . . . 0.0 110.02 179.334 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -66.51 -27.97 73.46 Favored Glycine 0 N--CA 1.45 -0.397 0 CA-C-N 115.721 -0.672 . . . . 0.0 112.432 179.748 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 89' ' ' LEU . . . . . 0.409 ' HG ' ' O ' ' A' ' 85' ' ' TYR . 87.9 mt -71.0 -33.05 70.02 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.973 0.416 . . . . 0.0 110.516 179.814 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 95.6 mt -73.53 -30.98 63.42 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 115.884 -0.598 . . . . 0.0 111.134 179.824 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -88.47 -28.58 20.75 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.452 -0.34 . . . . 0.0 111.694 -179.603 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 80.62 58.05 2.78 Favored Glycine 0 N--CA 1.452 -0.3 0 C-N-CA 120.72 -0.752 . . . . 0.0 111.93 -179.5 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 94.5 mt -74.97 177.75 6.1 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.986 0.422 . . . . 0.0 111.506 -179.384 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 94' ' ' ASP . . . . . . . . . . . . . 9.9 m-20 -102.13 171.3 7.57 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-N 115.818 -0.628 . . . . 0.0 110.654 179.666 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 45.8 t -57.4 -36.91 71.91 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.292 -0.413 . . . . 0.0 111.192 -179.63 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 15.2 ptm180 -73.5 -48.12 35.75 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.467 -0.333 . . . . 0.0 111.343 -179.846 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 48.0 mt-10 -53.18 -45.69 68.65 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.303 -0.408 . . . . 0.0 111.079 -179.846 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 98' ' ' PHE . . . . . 0.472 ' O ' HG12 ' A' ' 102' ' ' ILE . 26.3 m-85 -59.25 -49.48 77.67 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.673 179.611 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -55.77 -28.02 51.25 Favored Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.811 -0.709 . . . . 0.0 112.862 -179.754 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 100' ' ' ILE . . . . . 0.424 ' O ' HG22 ' A' ' 103' ' ' THR . 93.5 mt -73.77 -49.05 37.16 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 N-CA-C 111.914 0.339 . . . . 0.0 111.914 -179.641 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 33.1 m -70.58 -32.55 50.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 N-CA-C 111.962 0.356 . . . . 0.0 111.962 -179.251 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 102' ' ' ILE . . . . . 0.504 HG23 ' HB3' ' A' ' 81' ' ' PRO . 50.2 mm -74.93 -43.0 46.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.536 -0.302 . . . . 0.0 111.426 -179.573 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 103' ' ' THR . . . . . 0.424 HG22 ' O ' ' A' ' 100' ' ' ILE . 14.7 t -63.52 -34.0 76.82 Favored 'General case' 0 C--O 1.232 0.134 0 CA-C-O 121.075 0.464 . . . . 0.0 110.116 179.532 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 104' ' ' LEU . . . . . 0.496 ' O ' HG23 ' A' ' 108' ' ' VAL . 42.8 tp -61.82 -57.11 13.11 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 115.796 -0.638 . . . . 0.0 110.072 179.101 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 105' ' ' ASN . . . . . 0.628 HD21 HD13 ' A' ' 137' ' ' LEU . 0.8 OUTLIER -55.95 -25.82 45.3 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 115.967 -0.561 . . . . 0.0 110.873 179.411 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 79.0 m -64.07 -57.53 9.36 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.422 -0.353 . . . . 0.0 111.205 -179.93 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 107' ' ' VAL . . . . . 0.416 HG12 ' O ' ' A' ' 104' ' ' LEU . 7.1 p -62.25 -35.83 71.29 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.211 0 CA-C-N 116.394 -0.366 . . . . 0.0 110.952 179.916 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 108' ' ' VAL . . . . . 0.496 HG23 ' O ' ' A' ' 104' ' ' LEU . 84.6 t -62.87 -56.99 14.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-O 121.052 0.453 . . . . 0.0 110.783 179.645 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 109' ' ' MET . . . . . 0.482 ' HE1' HG21 ' A' ' 80' ' ' THR . 5.5 tpp -58.07 -32.43 68.03 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 115.793 -0.639 . . . . 0.0 110.932 -179.729 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 22.4 tp -66.93 -35.97 81.19 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.243 179.663 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -62.46 -44.12 97.18 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 115.855 -0.611 . . . . 0.0 110.491 179.312 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . -64.17 -44.7 95.28 Favored Glycine 0 N--CA 1.452 -0.278 0 C-N-CA 120.751 -0.737 . . . . 0.0 112.289 179.519 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 113' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -51.04 -63.73 1.04 Allowed 'General case' 0 C--N 1.333 -0.149 0 CA-C-O 121.075 0.464 . . . . 0.0 110.347 179.765 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -67.31 -16.71 64.42 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 115.782 -0.645 . . . . 0.0 110.862 179.575 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -60.85 -47.01 93.34 Favored Glycine 0 C--N 1.332 0.35 0 C-N-CA 120.768 -0.729 . . . . 0.0 112.267 179.7 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 116' ' ' ALA . . . . . 0.414 ' HB2' ' HB3' ' A' ' 183' ' ' PRO . . . -78.48 -22.57 47.29 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 120.666 0.27 . . . . 0.0 111.631 179.796 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 117' ' ' MET . . . . . . . . . . . . . 1.1 mpt? -87.11 18.33 3.7 Favored 'General case' 0 C--N 1.332 -0.162 0 CA-C-N 116.53 -0.304 . . . . 0.0 111.712 -179.705 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 118' ' ' VAL . . . . . 0.5 HG21 ' HB3' ' A' ' 123' ' ' ARG . 27.3 m -76.13 147.69 80.28 Favored Pre-proline 0 C--N 1.327 -0.37 0 CA-C-N 116.668 -0.242 . . . . 0.0 111.305 179.99 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 119' ' ' PRO . . . . . . . . . . . . . 67.7 Cg_endo -84.55 -15.78 6.01 Favored 'Trans proline' 0 C--N 1.347 0.476 0 C-N-CA 122.667 2.245 . . . . 0.0 112.645 -179.987 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -143.68 -110.79 0.75 Allowed Glycine 0 C--N 1.333 0.369 0 C-N-CA 120.462 -0.875 . . . . 0.0 113.282 -179.53 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 47.9 pt -111.16 11.59 8.61 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.218 0 N-CA-C 111.783 0.29 . . . . 0.0 111.783 -179.225 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 15.7 mm-40 -58.39 -19.06 32.79 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.867 0.365 . . . . 0.0 110.815 179.819 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 123' ' ' ARG . . . . . 0.5 ' HB3' HG21 ' A' ' 118' ' ' VAL . 32.0 ptt180 -53.09 -30.02 33.83 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 115.714 -0.675 . . . . 0.0 111.843 -179.817 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 124' ' ' TYR . . . . . . . . . . . . . 48.5 m-85 -75.3 -32.62 61.03 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 116.316 -0.402 . . . . 0.0 111.907 -178.985 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 125' ' ' ALA . . . . . . . . . . . . . . . -70.68 -55.65 8.23 Favored 'General case' 0 C--O 1.238 0.453 0 CA-C-O 121.121 0.486 . . . . 0.0 110.892 179.953 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 1.3 mt -55.85 -46.07 78.31 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 115.591 -0.732 . . . . 0.0 110.607 -179.613 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 127' ' ' PHE . . . . . 0.459 ' HZ ' ' HB3' ' A' ' 175' ' ' PRO . 3.0 t80 -67.29 -39.01 85.95 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.442 -0.345 . . . . 0.0 110.555 179.618 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 128' ' ' GLY . . . . . . . . . . . . . . . -46.44 -43.72 15.1 Favored Glycine 0 C--O 1.237 0.284 0 C-N-CA 120.129 -1.034 . . . . 0.0 111.09 179.356 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 129' ' ' MET . . . . . . . . . . . . . 0.4 OUTLIER -70.92 -40.34 72.16 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 121.014 0.435 . . . . 0.0 110.263 178.999 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -66.32 -26.4 72.62 Favored Glycine 0 N--CA 1.452 -0.254 0 CA-C-N 115.727 -0.67 . . . . 0.0 113.018 -179.691 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -75.08 -53.66 8.5 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 120.664 0.269 . . . . 0.0 110.588 179.98 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 56.2 t -59.27 -41.01 82.7 Favored 'Isoleucine or valine' 0 C--O 1.234 0.275 0 N-CA-C 109.203 -0.666 . . . . 0.0 109.203 178.7 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -67.54 -34.53 77.26 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-N 115.207 -0.906 . . . . 0.0 110.549 179.214 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 134' ' ' PHE . . . . . . . . . . . . . 39.8 t80 -55.86 -54.77 40.55 Favored 'General case' 0 N--CA 1.452 -0.344 0 CA-C-N 116.209 -0.451 . . . . 0.0 109.992 179.485 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 135' ' ' ILE . . . . . 0.495 ' HA ' HG22 ' A' ' 138' ' ' VAL . 33.1 mt -58.15 -31.89 42.97 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 CA-C-N 115.711 -0.677 . . . . 0.0 110.116 179.164 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . -59.27 -44.89 96.17 Favored Glycine 0 N--CA 1.449 -0.488 0 C-N-CA 120.401 -0.904 . . . . 0.0 112.119 179.124 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 137' ' ' LEU . . . . . 0.628 HD13 HD21 ' A' ' 105' ' ' ASN . 13.9 tp -70.76 -52.02 23.38 Favored 'General case' 0 C--N 1.33 -0.258 0 C-N-CA 121.055 -0.258 . . . . 0.0 111.173 -179.867 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 138' ' ' VAL . . . . . 0.495 HG22 ' HA ' ' A' ' 135' ' ' ILE . 4.2 m -54.53 -31.56 23.49 Favored 'Isoleucine or valine' 0 C--O 1.232 0.168 0 N-CA-C 109.604 -0.517 . . . . 0.0 109.604 -179.737 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 139' ' ' TYR . . . . . . . . . . . . . 13.9 t80 -63.69 -44.53 93.41 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 115.616 -0.72 . . . . 0.0 109.596 178.16 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 24.9 m-85 -59.01 -42.83 91.06 Favored 'General case' 0 C--O 1.233 0.189 0 CA-C-N 115.971 -0.559 . . . . 0.0 111.05 179.402 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 141' ' ' LEU . . . . . 0.499 ' HA ' ' SD ' ' A' ' 145' ' ' MET . 9.4 mp -55.59 -49.76 71.91 Favored 'General case' 0 N--CA 1.462 0.17 0 CA-C-N 116.429 -0.351 . . . . 0.0 110.994 -179.774 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 12.6 p -82.46 -10.27 11.97 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.364 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.99 -179.98 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 143' ' ' GLY . . . . . 0.592 ' O ' HG22 ' A' ' 146' ' ' THR . . . -74.99 -144.97 1.1 Allowed Glycine 0 CA--C 1.521 0.455 0 C-N-CA 121.05 -0.595 . . . . 0.0 112.889 -179.766 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 144' ' ' PRO . . . . . . . . . . . . . 78.1 Cg_exo -50.07 -23.27 9.05 Favored 'Trans proline' 0 C--N 1.348 0.537 0 C-N-CA 122.794 2.329 . . . . 0.0 112.93 -179.934 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 145' ' ' MET . . . . . 0.499 ' SD ' ' HA ' ' A' ' 141' ' ' LEU . 27.4 mtt -52.4 -43.87 65.02 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.392 -0.367 . . . . 0.0 111.636 -179.681 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 146' ' ' THR . . . . . 0.592 HG22 ' O ' ' A' ' 143' ' ' GLY . 8.3 t -76.67 -31.77 57.51 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-O 120.907 0.384 . . . . 0.0 110.862 -179.471 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 34.0 tt0 -64.5 -40.4 95.59 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 115.989 -0.55 . . . . 0.0 110.769 179.858 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 148' ' ' SER . . . . . . . . . . . . . 55.5 m -70.41 -46.88 63.1 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.75 -179.972 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 149' ' ' ALA . . . . . . . . . . . . . . . -62.38 -32.41 73.21 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 115.935 -0.575 . . . . 0.0 111.19 -179.995 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 150' ' ' SER . . . . . . . . . . . . . 48.1 t -70.56 -1.64 11.66 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.815 179.843 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 151' ' ' GLN . . . . . . . . . . . . . 48.8 mt-30 -120.18 1.64 10.83 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.121 -0.491 . . . . 0.0 111.168 -179.832 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 26.6 mmm180 -81.88 -52.45 7.08 Favored 'General case' 0 C--N 1.332 -0.171 0 CA-C-O 121.11 0.481 . . . . 0.0 110.51 179.699 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 153' ' ' SER . . . . . 0.573 ' HB2' HG12 ' A' ' 156' ' ' ILE . 25.3 m -157.41 172.31 18.81 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-N 115.599 -0.728 . . . . 0.0 110.842 179.296 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 154' ' ' SER . . . . . . . . . . . . . 81.0 p -70.41 -39.1 74.64 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.303 -0.408 . . . . 0.0 110.709 179.579 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -77.21 -39.35 27.2 Favored Glycine 0 CA--C 1.518 0.269 0 C-N-CA 121.057 -0.592 . . . . 0.0 112.905 -179.83 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 156' ' ' ILE . . . . . 0.573 HG12 ' HB2' ' A' ' 153' ' ' SER . 35.6 mm -49.73 -38.92 14.08 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.175 0 CA-C-O 120.774 0.321 . . . . 0.0 111.823 -179.616 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 157' ' ' LYS . . . . . 0.434 ' O ' HG22 ' A' ' 161' ' ' VAL . 64.7 tttm -66.72 -37.91 85.63 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-N 116.304 -0.407 . . . . 0.0 111.363 -179.559 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 49.5 m -71.38 -37.91 71.56 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 121.003 0.43 . . . . 0.0 111.157 -178.815 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 159' ' ' LEU . . . . . 0.571 ' O ' ' HG ' ' A' ' 163' ' ' LEU . 31.3 mt -70.6 -56.79 5.66 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-N 116.043 -0.526 . . . . 0.0 111.13 -179.642 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 160' ' ' TYR . . . . . 0.45 ' OH ' ' HB3' ' A' ' 145' ' ' MET . 31.9 t80 -51.88 -41.83 62.2 Favored 'General case' 0 C--N 1.325 -0.466 0 N-CA-C 112.416 0.524 . . . . 0.0 112.416 -178.764 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 161' ' ' VAL . . . . . 0.468 HG23 ' N ' ' A' ' 162' ' ' ARG . 30.5 m -66.28 -49.07 78.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 N-CA-C 112.022 0.379 . . . . 0.0 112.022 -178.529 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 162' ' ' ARG . . . . . 0.468 ' N ' HG23 ' A' ' 161' ' ' VAL . 98.4 mtt180 -66.02 -49.38 67.94 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.768 0.318 . . . . 0.0 111.731 -179.205 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 163' ' ' LEU . . . . . 0.571 ' HG ' ' O ' ' A' ' 159' ' ' LEU . 19.7 mt -60.65 -55.43 33.32 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.635 -179.164 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 164' ' ' ARG . . . . . . . . . . . . . 3.8 ppt_? -58.85 -38.71 79.34 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.363 -0.38 . . . . 0.0 111.959 -178.967 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 165' ' ' ASN . . . . . 0.462 ' O ' HG23 ' A' ' 169' ' ' VAL . 5.1 m-20 -56.6 -53.62 55.49 Favored 'General case' 0 C--O 1.237 0.408 0 CA-C-O 120.751 0.31 . . . . 0.0 111.133 -178.383 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 166' ' ' LEU . . . . . 0.465 ' O ' ' HG ' ' A' ' 170' ' ' LEU . 0.2 OUTLIER -68.01 -28.89 67.81 Favored 'General case' 0 C--N 1.326 -0.439 0 C-N-CA 120.588 -0.445 . . . . 0.0 110.267 -179.917 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 167' ' ' THR . . . . . 0.412 ' O ' ' HB2' ' A' ' 171' ' ' TRP . 21.7 m -61.19 -53.35 57.98 Favored 'General case' 0 N--CA 1.462 0.131 0 CA-C-N 116.313 -0.403 . . . . 0.0 111.259 179.743 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 168' ' ' VAL . . . . . . . . . . . . . 60.4 t -60.04 -40.64 83.79 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 115.826 -0.624 . . . . 0.0 111.799 -179.054 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 169' ' ' VAL . . . . . 0.462 HG23 ' O ' ' A' ' 165' ' ' ASN . 93.9 t -56.74 -65.5 0.39 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 C-N-CA 120.914 -0.314 . . . . 0.0 111.739 -179.69 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 170' ' ' LEU . . . . . 0.465 ' HG ' ' O ' ' A' ' 166' ' ' LEU . 1.1 pp -62.8 -33.11 74.52 Favored 'General case' 0 C--N 1.33 -0.269 0 N-CA-C 112.467 0.543 . . . . 0.0 112.467 -178.576 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 171' ' ' TRP . . . . . 0.412 ' HB2' ' O ' ' A' ' 167' ' ' THR . 2.2 m0 -69.01 -31.28 69.99 Favored 'General case' 0 N--CA 1.463 0.22 0 C-N-CA 120.846 -0.341 . . . . 0.0 110.844 179.644 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 172' ' ' ALA . . . . . . . . . . . . . . . -74.53 -7.08 51.93 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-O 120.909 0.385 . . . . 0.0 110.587 -179.768 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 173' ' ' ILE . . . . . 0.527 HG22 HD11 ' A' ' 177' ' ' ILE . 40.6 mm -85.48 -21.84 7.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 115.787 -0.642 . . . . 0.0 110.865 179.62 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 174' ' ' TYR . . . . . 0.437 ' HB2' ' HD3' ' A' ' 175' ' ' PRO . 26.9 m-85 -54.56 -50.05 87.59 Favored Pre-proline 0 N--CA 1.464 0.242 0 CA-C-N 116.33 -0.396 . . . . 0.0 111.542 -179.975 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 175' ' ' PRO . . . . . 0.459 ' HB3' ' HZ ' ' A' ' 127' ' ' PHE . 86.8 Cg_exo -46.93 -30.79 10.16 Favored 'Trans proline' 0 C--N 1.352 0.749 0 C-N-CA 122.121 1.88 . . . . 0.0 112.215 179.575 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 176' ' ' PHE . . . . . 0.47 ' HD2' ' HA ' ' A' ' 173' ' ' ILE . 76.8 m-85 -80.38 -48.81 12.35 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 115.928 -0.578 . . . . 0.0 111.65 -179.768 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 177' ' ' ILE . . . . . 0.527 HD11 HG22 ' A' ' 173' ' ' ILE . 3.4 mm -63.47 -34.24 66.25 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.516 0 CA-C-N 116.374 -0.375 . . . . 0.0 111.881 -178.5 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 178' ' ' TRP . . . . . 0.431 ' HH2' ' HB2' ' A' ' 123' ' ' ARG . 73.8 t90 -74.03 -48.78 27.7 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 121.041 0.448 . . . . 0.0 110.449 179.438 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 179' ' ' LEU . . . . . 0.51 ' O ' HG22 ' A' ' 185' ' ' VAL . 1.9 tm? -63.55 -52.3 61.7 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 115.68 -0.691 . . . . 0.0 111.239 -179.395 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 180' ' ' LEU . . . . . 0.68 HD22 HD11 ' A' ' 187' ' ' LEU . 15.6 mt -76.73 -41.83 43.56 Favored 'General case' 0 C--N 1.329 -0.324 0 N-CA-C 112.076 0.398 . . . . 0.0 112.076 -178.914 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . -58.18 179.02 1.26 Allowed Glycine 0 C--N 1.334 0.456 0 C-N-CA 120.166 -1.016 . . . . 0.0 112.426 179.759 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 182' ' ' PRO . . . . . 0.451 ' HA ' ' HB2' ' A' ' 186' ' ' ALA . 72.0 Cg_exo -47.27 -45.29 22.47 Favored 'Trans proline' 0 CA--C 1.536 0.61 0 C-N-CA 122.741 2.294 . . . . 0.0 113.798 -179.856 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 183' ' ' PRO . . . . . 0.449 ' HG3' ' NH2' ' A' ' 72' ' ' ARG . 71.6 Cg_exo -49.49 -22.98 6.91 Favored 'Trans proline' 0 C--N 1.356 0.955 0 C-N-CA 122.223 1.949 . . . . 0.0 113.121 -179.786 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 184' ' ' GLY . . . . . . . . . . . . . . . -119.07 -132.99 4.58 Favored Glycine 0 N--CA 1.449 -0.448 0 C-N-CA 120.484 -0.865 . . . . 0.0 112.906 -179.824 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 185' ' ' VAL . . . . . 0.51 HG22 ' O ' ' A' ' 179' ' ' LEU . 13.3 m -58.75 -21.02 17.93 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.396 0 N-CA-C 112.13 0.418 . . . . 0.0 112.13 -179.485 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 186' ' ' ALA . . . . . 0.451 ' HB2' ' HA ' ' A' ' 182' ' ' PRO . . . 55.61 87.18 0.05 Allowed 'General case' 0 N--CA 1.463 0.194 0 CA-C-O 120.74 0.305 . . . . 0.0 111.391 179.906 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 187' ' ' LEU . . . . . 0.68 HD11 HD22 ' A' ' 180' ' ' LEU . 15.8 mt -91.75 -49.54 6.21 Favored 'General case' 0 C--N 1.332 -0.195 0 CA-C-N 116.291 -0.413 . . . . 0.0 111.341 -179.713 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 188' ' ' LEU . . . . . . . . . . . . . 68.6 mt -96.85 -155.07 0.47 Allowed 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 115.923 -0.58 . . . . 0.0 110.991 -179.573 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 189' ' ' THR . . . . . . . . . . . . . 1.9 t -101.6 146.74 32.76 Favored Pre-proline 0 C--N 1.328 -0.367 0 CA-C-N 116.001 -0.545 . . . . 0.0 110.817 -179.987 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 190' ' ' PRO . . . . . . . . . . . . . 86.5 Cg_exo -47.09 -45.2 21.97 Favored 'Trans proline' 0 C--N 1.348 0.502 0 C-N-CA 122.694 2.262 . . . . 0.0 113.35 -179.528 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 191' ' ' THR . . . . . . . . . . . . . 5.6 t -56.58 -39.95 74.4 Favored 'General case' 0 C--N 1.329 -0.316 0 N-CA-C 112.061 0.393 . . . . 0.0 112.061 -179.338 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 192' ' ' VAL . . . . . . . . . . . . . 40.6 t -73.37 -53.82 17.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 N-CA-C 111.909 0.337 . . . . 0.0 111.909 -179.435 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 193' ' ' ASP . . . . . . . . . . . . . 19.0 m-20 -58.36 -50.11 74.84 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.516 -0.311 . . . . 0.0 111.217 -179.829 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 194' ' ' VAL . . . . . . . . . . . . . 78.0 t -59.9 -36.33 66.04 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 116.339 -0.392 . . . . 0.0 110.691 179.557 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 195' ' ' ALA . . . . . . . . . . . . . . . -56.26 -47.85 77.72 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 116.397 -0.365 . . . . 0.0 111.121 179.792 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 196' ' ' LEU . . . . . . . . . . . . . 91.6 mt -64.99 -35.39 81.02 Favored 'General case' 0 C--N 1.332 -0.177 0 CA-C-O 120.771 0.319 . . . . 0.0 110.464 179.658 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 197' ' ' ILE . . . . . 0.477 HG12 HG21 ' A' ' 177' ' ' ILE . 19.6 mm -61.46 -53.8 43.7 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-O 121.142 0.496 . . . . 0.0 110.022 178.972 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 198' ' ' VAL . . . . . . . . . . . . . 98.3 t -54.91 -34.32 30.81 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.47 0 CA-C-N 115.344 -0.844 . . . . 0.0 109.33 178.471 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 199' ' ' TYR . . . . . 0.406 ' O ' HG23 ' A' ' 203' ' ' VAL . 68.8 t80 -69.35 -40.4 77.53 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 115.083 -0.962 . . . . 0.0 110.246 179.925 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 200' ' ' LEU . . . . . . . . . . . . . 38.1 mt -61.72 -41.56 97.79 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 115.74 -0.663 . . . . 0.0 111.371 -179.773 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 201' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -71.87 -40.39 68.98 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.041 -179.807 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 202' ' ' LEU . . . . . 0.403 ' O ' ' HB ' ' A' ' 206' ' ' VAL . 2.7 mt -65.2 -33.71 76.66 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.119 -0.491 . . . . 0.0 111.617 -179.401 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 203' ' ' VAL . . . . . 0.523 ' O ' ' HA3' ' A' ' 207' ' ' GLY . 65.9 t -77.31 -36.07 23.4 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.384 0 CA-C-O 120.74 0.305 . . . . 0.0 111.381 -179.12 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 204' ' ' THR . . . . . 0.42 HG23 ' CE2' ' A' ' 208' ' ' PHE . 88.8 m -66.46 -58.61 4.9 Favored 'General case' 0 C--N 1.325 -0.497 0 C-N-CA 120.745 -0.382 . . . . 0.0 111.298 179.95 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 205' ' ' LYS . . . . . 0.745 ' HE2' ' HB2' ' A' ' 47' ' ' ALA . 36.1 mttp -68.13 -58.75 3.96 Favored 'General case' 0 C--N 1.328 -0.338 0 N-CA-C 112.489 0.551 . . . . 0.0 112.489 -178.348 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 206' ' ' VAL . . . . . 0.403 ' HB ' ' O ' ' A' ' 202' ' ' LEU . 17.9 t -73.46 -37.0 49.77 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.369 0 N-CA-C 112.084 0.401 . . . . 0.0 112.084 -178.281 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 207' ' ' GLY . . . . . 0.523 ' HA3' ' O ' ' A' ' 203' ' ' VAL . . . -59.35 -60.05 9.52 Favored Glycine 0 N--CA 1.452 -0.278 0 C-N-CA 120.313 -0.946 . . . . 0.0 112.502 -179.36 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 208' ' ' PHE . . . . . 0.513 ' O ' ' N ' ' A' ' 212' ' ' ALA . 1.2 m-30 -58.48 -43.76 89.09 Favored 'General case' 0 C--O 1.221 -0.402 0 CA-C-N 117.111 0.456 . . . . 0.0 110.069 179.739 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 209' ' ' GLY . . . . . 0.487 ' O ' ' HB3' ' A' ' 212' ' ' ALA . . . -53.72 -37.89 57.99 Favored Glycine 0 CA--C 1.518 0.239 0 CA-C-N 115.501 -0.772 . . . . 0.0 113.957 -179.923 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 210' ' ' PHE . . . . . . . . . . . . . 2.6 m-85 -70.01 -48.68 57.12 Favored 'General case' 0 CA--C 1.515 -0.39 0 N-CA-C 108.906 -0.775 . . . . 0.0 108.906 179.664 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 211' ' ' ILE . . . . . 0.435 HG13 ' O ' ' A' ' 207' ' ' GLY . 5.3 mt -63.87 -27.43 42.82 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.569 0 N-CA-C 107.47 -1.308 . . . . 0.0 107.47 176.629 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 212' ' ' ALA . . . . . 0.513 ' N ' ' O ' ' A' ' 208' ' ' PHE . . . -68.37 -38.61 81.56 Favored 'General case' 0 N--CA 1.449 -0.488 0 CA-C-N 114.173 -1.376 . . . . 0.0 110.481 -179.866 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 213' ' ' LEU . . . . . . . . . . . . . 52.9 mt -65.44 -54.65 25.4 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-N 115.139 -0.937 . . . . 0.0 111.093 -179.811 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 214' ' ' ASP . . . . . . . . . . . . . 15.8 m-20 -60.57 -27.05 67.4 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.367 -0.379 . . . . 0.0 110.466 179.746 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 215' ' ' ALA . . . . . . . . . . . . . . . -68.94 -57.77 5.04 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.073 -0.512 . . . . 0.0 111.193 -179.964 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 216' ' ' ALA . . . . . . . . . . . . . . . -63.28 -31.27 72.37 Favored 'General case' 0 C--N 1.331 -0.21 0 CA-C-N 116.332 -0.395 . . . . 0.0 110.972 -179.974 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 217' ' ' ALA . . . . . . . . . . . . . . . -64.64 -37.56 87.98 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.045 -0.525 . . . . 0.0 110.433 179.73 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 218' ' ' THR . . . . . . . . . . . . . 99.1 m . . . . . 0 C--N 1.33 -0.27 0 CA-C-N 115.817 -0.628 . . . . 0.0 110.508 179.456 . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.238 0 N-CA-C 112.34 -0.304 . . . . 0.0 112.34 . . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 4' ' ' LEU . . . . . 0.514 HD11 HG21 ' A' ' 194' ' ' VAL . 47.6 tp -74.12 -36.95 64.23 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-O 120.849 0.356 . . . . 0.0 110.989 179.934 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 70.8 p -59.44 -31.99 69.8 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.077 -0.51 . . . . 0.0 111.665 -179.616 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 32.3 p -55.62 -35.45 65.9 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-O 120.844 0.354 . . . . 0.0 111.191 -179.773 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 7' ' ' LEU . . . . . . . . . . . . . 4.0 mm? -58.98 -53.05 62.81 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.123 -0.49 . . . . 0.0 111.087 179.952 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 8' ' ' PHE . . . . . 0.457 ' HB2' ' HB2' ' A' ' 55' ' ' ALA . 73.6 m-85 -58.81 -33.11 70.01 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 116.34 -0.391 . . . . 0.0 110.817 179.932 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 9' ' ' TRP . . . . . 0.433 ' O ' HG13 ' A' ' 13' ' ' ILE . 27.8 m95 -66.35 -46.61 76.18 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 116.013 -0.54 . . . . 0.0 110.152 -179.862 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 94.1 mt -59.82 -42.07 92.7 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 115.651 -0.704 . . . . 0.0 110.347 179.377 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -63.42 -30.42 77.53 Favored Glycine 0 N--CA 1.449 -0.496 0 C-N-CA 120.712 -0.756 . . . . 0.0 111.724 179.348 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -73.19 -30.79 63.78 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.795 0.331 . . . . 0.0 110.82 179.678 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 13' ' ' ILE . . . . . 0.433 HG13 ' O ' ' A' ' 9' ' ' TRP . 67.0 mt -67.61 -54.7 21.22 Favored 'Isoleucine or valine' 0 C--O 1.233 0.206 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.399 179.473 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -62.46 -35.09 91.23 Favored Glycine 0 N--CA 1.449 -0.474 0 C-N-CA 120.716 -0.755 . . . . 0.0 111.399 179.209 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 15' ' ' MET . . . . . 0.496 ' SD ' ' HA ' ' A' ' 44' ' ' SER . 45.5 tpp -62.75 -41.96 99.45 Favored 'General case' 0 N--CA 1.453 -0.294 0 CA-C-O 120.814 0.34 . . . . 0.0 110.209 179.376 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 16' ' ' LEU . . . . . 0.415 HD13 ' O ' ' A' ' 16' ' ' LEU . 0.3 OUTLIER -59.46 -37.74 78.96 Favored 'General case' 0 C--N 1.331 -0.201 0 N-CA-C 109.635 -0.505 . . . . 0.0 109.635 178.893 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 46.5 t -59.24 -43.23 89.28 Favored 'Isoleucine or valine' 0 C--O 1.232 0.176 0 CA-C-N 116.033 -0.531 . . . . 0.0 110.134 179.143 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -68.25 -42.89 81.98 Favored Glycine 0 C--N 1.331 0.291 0 C-N-CA 120.795 -0.717 . . . . 0.0 111.884 179.187 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 9.9 m -50.14 -46.24 53.74 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.698 0.285 . . . . 0.0 111.352 -179.604 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 92.7 mt -72.01 -43.17 65.46 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.271 -0.422 . . . . 0.0 111.618 -179.712 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -58.31 -33.23 69.25 Favored 'General case' 0 C--N 1.33 -0.267 0 N-CA-C 112.048 0.388 . . . . 0.0 112.048 -179.252 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 22' ' ' PHE . . . . . 0.42 ' HB2' HG22 ' A' ' 41' ' ' VAL . 5.3 m-85 -90.57 -37.67 13.68 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 120.624 0.249 . . . . 0.0 111.495 -179.367 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -65.91 -51.18 60.83 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.874 0.369 . . . . 0.0 111.659 -179.507 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 24' ' ' TRP . . . . . . . . . . . . . 3.4 t-105 -60.44 -52.87 63.37 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-N 115.948 -0.569 . . . . 0.0 111.145 -179.66 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.328 -0.363 0 CA-C-N 116.358 -0.383 . . . . 0.0 111.032 179.942 . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.247 0 N-CA-C 112.569 -0.212 . . . . 0.0 112.569 . . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 11.0 pt-20 -58.94 -20.53 53.0 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 120.644 0.259 . . . . 0.0 111.255 179.893 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 34' ' ' ARG . . . . . 0.46 ' O ' HG23 ' A' ' 38' ' ' VAL . 74.2 mtp180 -49.2 -29.43 5.61 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.379 -179.89 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 98.9 mtt180 -60.21 -46.62 89.13 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.82 0.343 . . . . 0.0 111.057 179.899 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 52.7 m-85 -66.79 -42.66 85.62 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.176 -0.466 . . . . 0.0 111.068 -179.933 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 37' ' ' TYR . . . . . 0.404 ' O ' HG23 ' A' ' 41' ' ' VAL . 51.9 m-85 -63.45 -51.82 64.08 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.213 -0.448 . . . . 0.0 111.449 -179.6 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 38' ' ' VAL . . . . . 0.46 HG23 ' O ' ' A' ' 34' ' ' ARG . 78.2 t -56.81 -36.73 50.51 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-O 121.005 0.431 . . . . 0.0 110.222 179.662 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 17.4 m -65.35 -47.85 75.05 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 115.852 -0.613 . . . . 0.0 110.257 178.976 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 48.8 tp -56.11 -45.84 79.32 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 115.665 -0.698 . . . . 0.0 110.096 179.21 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 41' ' ' VAL . . . . . 0.42 HG22 ' HB2' ' A' ' 22' ' ' PHE . 96.5 t -60.81 -34.48 59.38 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.249 0 CA-C-N 115.698 -0.683 . . . . 0.0 109.983 179.068 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -57.03 -44.17 93.02 Favored Glycine 0 N--CA 1.447 -0.593 0 C-N-CA 120.813 -0.708 . . . . 0.0 111.834 179.599 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 43' ' ' ILE . . . . . 0.551 HG22 ' HE3' ' A' ' 205' ' ' LYS . 0.3 OUTLIER -63.1 -51.58 69.81 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.179 0 CA-C-O 120.7 0.286 . . . . 0.0 110.951 179.501 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 44' ' ' SER . . . . . 0.496 ' HA ' ' SD ' ' A' ' 15' ' ' MET . 87.5 p -60.41 -29.33 68.91 Favored 'General case' 0 C--O 1.232 0.155 0 CA-C-O 120.841 0.353 . . . . 0.0 111.305 -179.981 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -77.34 -51.31 6.16 Favored Glycine 0 CA--C 1.519 0.322 0 C-N-CA 120.668 -0.777 . . . . 0.0 113.11 -179.344 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 46' ' ' ILE . . . . . 0.669 HD12 HD12 ' A' ' 78' ' ' LEU . 12.4 pt -58.62 -37.53 65.8 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.242 0 CA-C-O 120.936 0.398 . . . . 0.0 110.979 -179.839 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 47' ' ' ALA . . . . . 0.688 ' HB2' ' HE2' ' A' ' 205' ' ' LYS . . . -67.87 -44.03 78.02 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.124 -0.489 . . . . 0.0 111.426 179.47 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 48' ' ' ALA . . . . . 0.425 ' HB2' ' HG3' ' A' ' 15' ' ' MET . . . -55.19 -43.25 74.22 Favored 'General case' 0 C--N 1.332 -0.194 0 CA-C-N 116.05 -0.523 . . . . 0.0 112.051 -179.326 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 35.5 m -73.2 -35.29 46.87 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.245 0 CA-C-O 120.684 0.278 . . . . 0.0 111.461 -179.541 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -63.29 -39.21 93.95 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-O 121.035 0.445 . . . . 0.0 110.965 179.955 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 24.5 m-85 -73.08 -38.96 66.23 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-N 115.817 -0.629 . . . . 0.0 110.648 -179.831 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -62.64 -45.46 92.73 Favored 'General case' 0 C--N 1.327 -0.413 0 CA-C-N 115.983 -0.553 . . . . 0.0 111.255 179.854 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 53' ' ' VAL . . . . . 0.551 ' O ' HG12 ' A' ' 58' ' ' VAL . 32.3 m -66.43 -52.9 41.57 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.122 0 CA-C-N 116.504 -0.316 . . . . 0.0 111.056 -179.949 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 54' ' ' MET . . . . . 0.539 ' N ' HG23 ' A' ' 53' ' ' VAL . 76.0 mtm -58.35 -34.96 71.22 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-O 121.156 0.503 . . . . 0.0 110.134 179.508 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 55' ' ' ALA . . . . . 0.457 ' HB2' ' HB2' ' A' ' 8' ' ' PHE . . . -63.31 -29.49 70.8 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 115.588 -0.733 . . . . 0.0 111.322 179.474 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 96.3 mt -79.23 -8.23 58.87 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.383 -0.371 . . . . 0.0 111.383 -179.633 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 98.75 -6.89 60.77 Favored Glycine 0 N--CA 1.45 -0.368 0 C-N-CA 120.531 -0.842 . . . . 0.0 113.018 179.545 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 58' ' ' VAL . . . . . 0.551 HG12 ' O ' ' A' ' 53' ' ' VAL . 3.8 p -75.26 154.4 6.3 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.235 0 CA-C-N 116.906 0.353 . . . . 0.0 110.636 179.926 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 76.3 22.77 72.62 Favored Glycine 0 N--CA 1.452 -0.261 0 C-N-CA 120.634 -0.794 . . . . 0.0 112.275 -179.408 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 60' ' ' TRP . . . . . . . . . . . . . 19.1 m0 -104.75 100.88 10.52 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-O 120.972 0.415 . . . . 0.0 110.043 179.967 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 61' ' ' VAL . . . . . 0.485 ' HB ' HG23 ' A' ' 68' ' ' VAL . 57.3 t -97.01 107.58 38.49 Favored Pre-proline 0 C--N 1.327 -0.389 0 CA-C-N 115.894 -0.594 . . . . 0.0 111.521 -179.448 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 62' ' ' PRO . . . . . 0.424 ' HD2' ' HA ' ' A' ' 61' ' ' VAL . 31.3 Cg_endo -63.53 135.0 47.18 Favored 'Trans proline' 0 C--N 1.35 0.613 0 C-N-CA 122.384 2.056 . . . . 0.0 111.894 179.461 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 85.8 t -136.68 94.02 1.12 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.38 0 CA-C-N 116.109 -0.496 . . . . 0.0 111.319 -179.43 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . 57.38 -88.95 0.02 OUTLIER 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.485 179.905 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 38.0 tt0 -117.65 -22.8 7.89 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-O 120.913 0.387 . . . . 0.0 110.638 179.981 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 66' ' ' ARG . . . . . . . . . . . . . 41.5 mmt180 -102.79 157.64 16.82 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.039 -0.528 . . . . 0.0 110.225 179.747 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 26.2 m -124.14 116.43 22.73 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-O 120.869 0.366 . . . . 0.0 111.334 -179.854 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 68' ' ' VAL . . . . . 0.504 HG11 ' HA ' ' A' ' 117' ' ' MET . 24.0 m -90.77 145.53 7.31 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 115.986 -0.552 . . . . 0.0 110.84 179.664 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 69' ' ' PHE . . . . . . . . . . . . . 42.5 m-85 -109.65 111.35 22.77 Favored 'General case' 0 N--CA 1.441 -0.918 0 N-CA-C 109.879 -0.415 . . . . 0.0 109.879 -179.819 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 70' ' ' VAL . . . . . 0.577 ' N ' ' HD2' ' A' ' 71' ' ' PRO . 38.6 t -60.73 -50.11 86.66 Favored Pre-proline 0 C--N 1.326 -0.427 0 CA-C-N 116.42 -0.355 . . . . 0.0 111.903 -179.042 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 71' ' ' PRO . . . . . 0.577 ' HD2' ' N ' ' A' ' 70' ' ' VAL . 36.6 Cg_endo -64.7 -17.84 60.78 Favored 'Trans proline' 0 C--N 1.35 0.638 0 C-N-CA 122.288 1.992 . . . . 0.0 112.971 -179.343 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 37.3 ttp180 -70.95 -55.24 8.79 Favored 'General case' 0 C--O 1.235 0.321 0 C-N-CA 121.025 -0.27 . . . . 0.0 111.332 -179.492 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 73' ' ' TYR . . . . . 0.463 ' O ' HG13 ' A' ' 77' ' ' ILE . 5.7 m-85 -68.48 -34.52 76.08 Favored 'General case' 0 C--N 1.332 -0.185 0 C-N-CA 120.686 -0.406 . . . . 0.0 109.994 179.911 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 74' ' ' ILE . . . . . 0.524 ' HA ' HD12 ' A' ' 77' ' ' ILE . 0.4 OUTLIER -67.72 -36.75 77.03 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.173 0 CA-C-N 116.174 -0.467 . . . . 0.0 110.123 179.526 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 75' ' ' ASP . . . . . 0.43 ' O ' HG23 ' A' ' 79' ' ' THR . 11.3 t70 -60.5 -37.61 81.68 Favored 'General case' 0 CA--C 1.518 -0.262 0 N-CA-C 109.188 -0.671 . . . . 0.0 109.188 178.749 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 76' ' ' TRP . . . . . . . . . . . . . 40.6 m0 -69.86 -28.1 65.38 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 115.638 -0.71 . . . . 0.0 110.562 179.247 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 77' ' ' ILE . . . . . 0.573 ' HA ' ' HG3' ' A' ' 109' ' ' MET . 96.3 mt -68.56 -36.27 73.89 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.34 179.596 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 78' ' ' LEU . . . . . 0.669 HD12 HD12 ' A' ' 46' ' ' ILE . 0.7 OUTLIER -90.75 -26.76 19.33 Favored 'General case' 0 C--N 1.328 -0.358 0 N-CA-C 112.81 0.671 . . . . 0.0 112.81 -179.65 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 79' ' ' THR . . . . . 0.43 HG23 ' O ' ' A' ' 75' ' ' ASP . 64.8 p -84.71 -52.27 6.2 Favored 'General case' 0 C--N 1.327 -0.374 0 N-CA-C 113.71 1.004 . . . . 0.0 113.71 -178.548 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 80' ' ' THR . . . . . 0.696 ' HB ' ' HD3' ' A' ' 81' ' ' PRO . 34.0 m -53.42 -56.12 27.73 Favored Pre-proline 0 CA--C 1.533 0.314 0 N-CA-C 112.567 0.581 . . . . 0.0 112.567 -177.902 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 81' ' ' PRO . . . . . 0.696 ' HD3' ' HB ' ' A' ' 80' ' ' THR . 43.5 Cg_exo -58.33 -19.21 41.88 Favored 'Trans proline' 0 C--N 1.352 0.744 0 C-N-CA 121.728 1.618 . . . . 0.0 111.956 179.966 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 82' ' ' LEU . . . . . . . . . . . . . 16.2 tp -76.72 -35.66 57.67 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.078 179.575 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 83' ' ' ILE . . . . . 0.523 HD11 HG21 ' A' ' 43' ' ' ILE . 41.3 mm -69.57 -51.27 43.25 Favored 'Isoleucine or valine' 0 C--O 1.233 0.222 0 CA-C-N 115.926 -0.579 . . . . 0.0 110.379 179.214 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 84' ' ' VAL . . . . . 0.48 HG22 ' HA ' ' A' ' 81' ' ' PRO . 33.0 m -60.95 -31.96 51.16 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.212 0 N-CA-C 109.505 -0.554 . . . . 0.0 109.505 179.062 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 85' ' ' TYR . . . . . 0.416 ' O ' ' HG ' ' A' ' 89' ' ' LEU . 81.3 t80 -65.42 -33.6 76.32 Favored 'General case' 0 N--CA 1.453 -0.291 0 CA-C-N 115.559 -0.746 . . . . 0.0 109.344 178.739 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 86' ' ' PHE . . . . . . . . . . . . . 3.0 t80 -61.87 -50.93 70.26 Favored 'General case' 0 C--O 1.233 0.235 0 CA-C-N 115.617 -0.719 . . . . 0.0 110.066 179.436 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 6.1 mt -62.95 -29.15 70.58 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 115.905 -0.589 . . . . 0.0 110.316 179.778 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -70.56 -28.06 71.62 Favored Glycine 0 N--CA 1.451 -0.323 0 CA-C-N 115.486 -0.779 . . . . 0.0 112.026 179.542 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 89' ' ' LEU . . . . . 0.416 ' HG ' ' O ' ' A' ' 85' ' ' TYR . 91.2 mt -74.91 -41.99 58.66 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.92 0.391 . . . . 0.0 110.772 179.744 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 97.6 mt -63.99 -36.41 83.88 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 115.959 -0.564 . . . . 0.0 111.123 179.927 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -77.19 -53.92 7.14 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.352 -0.385 . . . . 0.0 111.131 -179.854 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 107.8 52.67 0.69 Allowed Glycine 0 C--N 1.33 0.248 0 C-N-CA 120.899 -0.667 . . . . 0.0 112.213 -179.726 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 64.8 mt -75.82 162.24 28.33 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-O 120.909 0.385 . . . . 0.0 111.04 -179.773 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 94' ' ' ASP . . . . . . . . . . . . . 7.0 m-20 -88.86 175.14 7.58 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.707 179.881 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 65.3 m -60.44 -35.2 75.27 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.255 -179.767 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 96' ' ' ARG . . . . . 0.456 ' HG3' ' N ' ' A' ' 97' ' ' GLU . 10.5 ptp180 -73.64 -46.65 45.48 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 116.312 -0.404 . . . . 0.0 111.251 -179.842 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 97' ' ' GLU . . . . . 0.456 ' N ' ' HG3' ' A' ' 96' ' ' ARG . 42.0 mt-10 -57.02 -40.47 76.73 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.326 -0.397 . . . . 0.0 111.08 -179.68 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 98' ' ' PHE . . . . . 0.447 ' O ' HG12 ' A' ' 102' ' ' ILE . 13.5 m-85 -62.63 -50.3 71.75 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.772 179.656 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -55.29 -30.44 55.07 Favored Glycine 0 N--CA 1.452 -0.253 0 C-N-CA 120.647 -0.787 . . . . 0.0 112.695 -179.906 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 100' ' ' ILE . . . . . 0.441 ' O ' HG22 ' A' ' 103' ' ' THR . 86.8 mt -72.13 -47.78 52.52 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-O 120.864 0.364 . . . . 0.0 111.561 -179.735 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 43.2 t -67.67 -48.68 75.38 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.371 0 CA-C-N 116.289 -0.414 . . . . 0.0 111.516 -179.572 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 102' ' ' ILE . . . . . 0.447 HG12 ' O ' ' A' ' 98' ' ' PHE . 34.9 mm -59.15 -47.19 91.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.898 -179.23 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 103' ' ' THR . . . . . 0.441 HG22 ' O ' ' A' ' 100' ' ' ILE . 14.2 t -60.81 -36.26 78.58 Favored 'General case' 0 C--O 1.234 0.245 0 CA-C-O 120.772 0.32 . . . . 0.0 110.879 -179.968 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 104' ' ' LEU . . . . . 0.434 HD12 ' HB2' ' A' ' 137' ' ' LEU . 3.0 tm? -57.01 -50.65 72.06 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-N 116.344 -0.389 . . . . 0.0 110.043 179.15 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 105' ' ' ASN . . . . . 0.414 ' O ' ' HG2' ' A' ' 109' ' ' MET . 16.6 m-80 -59.39 -31.42 69.22 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.014 -0.539 . . . . 0.0 110.674 179.368 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 41.5 m -56.92 -47.85 79.62 Favored 'General case' 0 C--O 1.232 0.177 0 CA-C-O 120.836 0.35 . . . . 0.0 110.154 179.329 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 107' ' ' VAL . . . . . 0.401 ' H ' HG23 ' A' ' 107' ' ' VAL . 1.9 t -61.06 -42.12 91.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 115.996 -0.547 . . . . 0.0 109.963 179.107 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 66.4 t -57.72 -45.69 86.84 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 115.171 -0.922 . . . . 0.0 111.669 -179.723 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 109' ' ' MET . . . . . 0.573 ' HG3' ' HA ' ' A' ' 77' ' ' ILE . 16.0 mmt -67.71 -44.33 77.92 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.712 -179.27 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 32.9 tp -60.64 -39.61 88.94 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-O 120.766 0.317 . . . . 0.0 110.806 -179.747 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -58.48 -54.67 44.46 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.685 179.635 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . -66.41 -32.3 81.45 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.387 179.632 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 113' ' ' PHE . . . . . . . . . . . . . 0.7 OUTLIER -52.77 -71.34 0.07 Allowed 'General case' 0 C--N 1.331 -0.202 0 CA-C-O 120.945 0.402 . . . . 0.0 110.183 179.829 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 114' ' ' ALA . . . . . 0.45 ' HB3' HD22 ' A' ' 126' ' ' LEU . . . -64.47 -22.6 67.01 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 115.796 -0.638 . . . . 0.0 110.975 179.742 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -53.57 -49.37 57.71 Favored Glycine 0 C--N 1.331 0.269 0 C-N-CA 121.025 -0.607 . . . . 0.0 112.518 179.985 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 116' ' ' ALA . . . . . 0.554 ' HB2' ' HB3' ' A' ' 183' ' ' PRO . . . -78.06 -18.14 56.15 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-O 120.742 0.306 . . . . 0.0 111.464 -179.899 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 117' ' ' MET . . . . . 0.504 ' HA ' HG11 ' A' ' 68' ' ' VAL . 33.3 ttm -99.31 19.57 15.22 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.32 -0.4 . . . . 0.0 111.556 -179.161 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 118' ' ' VAL . . . . . 0.453 HG21 ' HB3' ' A' ' 123' ' ' ARG . 25.1 m -71.34 143.33 87.89 Favored Pre-proline 0 C--N 1.33 -0.279 0 CA-C-N 116.524 -0.307 . . . . 0.0 111.514 179.993 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 119' ' ' PRO . . . . . . . . . . . . . 92.2 Cg_endo -89.49 14.89 2.09 Favored 'Trans proline' 0 N--CA 1.456 -0.677 0 C-N-CA 122.715 2.277 . . . . 0.0 112.418 179.373 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -166.07 -118.37 0.44 Allowed Glycine 0 C--N 1.334 0.421 0 C-N-CA 120.644 -0.789 . . . . 0.0 112.834 -179.668 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 2.0 pp -119.89 13.37 6.64 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.183 0 CA-C-O 120.675 0.274 . . . . 0.0 111.597 -179.595 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 43.6 mt-10 -62.62 -17.98 61.35 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.865 179.722 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 123' ' ' ARG . . . . . 0.453 ' HB3' HG21 ' A' ' 118' ' ' VAL . 3.2 ptp180 -50.28 -28.07 7.17 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 115.834 -0.621 . . . . 0.0 111.93 -179.764 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 124' ' ' TYR . . . . . . . . . . . . . 29.2 m-85 -71.42 -33.53 69.5 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.632 0.254 . . . . 0.0 111.385 -179.592 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 125' ' ' ALA . . . . . . . . . . . . . . . -74.21 -55.93 5.49 Favored 'General case' 0 C--O 1.235 0.315 0 CA-C-O 120.79 0.328 . . . . 0.0 111.184 179.918 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 126' ' ' LEU . . . . . 0.45 HD22 ' HB3' ' A' ' 114' ' ' ALA . 1.1 mp -52.16 -51.12 59.95 Favored 'General case' 0 C--N 1.332 -0.182 0 CA-C-N 116.041 -0.527 . . . . 0.0 110.313 179.79 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 127' ' ' PHE . . . . . . . . . . . . . 10.4 t80 -65.46 -30.36 71.14 Favored 'General case' 0 N--CA 1.452 -0.354 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.089 179.308 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 128' ' ' GLY . . . . . . . . . . . . . . . -48.19 -52.93 16.63 Favored Glycine 0 N--CA 1.449 -0.461 0 C-N-CA 120.196 -1.002 . . . . 0.0 110.757 178.848 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 129' ' ' MET . . . . . 0.549 ' HE3' ' HA2' ' A' ' 130' ' ' GLY . 0.0 OUTLIER -70.36 -27.24 64.18 Favored 'General case' 0 C--N 1.328 -0.367 0 N-CA-C 109.036 -0.727 . . . . 0.0 109.036 178.515 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 130' ' ' GLY . . . . . 0.549 ' HA2' ' HE3' ' A' ' 129' ' ' MET . . . -59.7 -45.27 95.99 Favored Glycine 0 C--N 1.333 0.366 0 CA-C-N 115.745 -0.661 . . . . 0.0 112.558 179.607 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 131' ' ' ALA . . . . . 0.403 ' O ' ' HB3' ' A' ' 134' ' ' PHE . . . -69.8 -47.53 62.5 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-O 120.738 0.304 . . . . 0.0 110.421 179.751 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 65.4 t -56.32 -44.31 79.4 Favored 'Isoleucine or valine' 0 C--O 1.235 0.293 0 CA-C-O 121.261 0.553 . . . . 0.0 109.662 178.865 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -63.25 -35.22 79.62 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 115.57 -0.741 . . . . 0.0 110.465 179.231 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 134' ' ' PHE . . . . . 0.414 ' HE1' ' HB3' ' A' ' 171' ' ' TRP . 72.6 t80 -56.92 -54.56 45.25 Favored 'General case' 0 N--CA 1.451 -0.375 0 CA-C-O 120.984 0.421 . . . . 0.0 110.156 179.494 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 135' ' ' ILE . . . . . 0.484 ' O ' HG22 ' A' ' 138' ' ' VAL . 39.8 mt -56.6 -31.05 33.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 115.733 -0.667 . . . . 0.0 110.198 179.285 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . -62.73 -42.41 99.69 Favored Glycine 0 N--CA 1.447 -0.607 0 C-N-CA 120.221 -0.99 . . . . 0.0 111.344 178.922 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 137' ' ' LEU . . . . . 0.446 ' O ' HD13 ' A' ' 141' ' ' LEU . 64.9 tp -67.12 -52.64 39.29 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-O 120.464 0.174 . . . . 0.0 111.033 179.778 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 138' ' ' VAL . . . . . 0.484 HG22 ' O ' ' A' ' 135' ' ' ILE . 4.5 m -54.31 -34.43 27.87 Favored 'Isoleucine or valine' 0 CA--C 1.52 -0.177 0 N-CA-C 109.728 -0.471 . . . . 0.0 109.728 -179.642 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 139' ' ' TYR . . . . . . . . . . . . . 35.6 t80 -58.56 -46.49 86.76 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 115.785 -0.643 . . . . 0.0 109.633 178.05 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 24.6 m-85 -63.65 -40.78 97.73 Favored 'General case' 0 C--N 1.333 -0.111 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.486 179.105 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 141' ' ' LEU . . . . . 0.507 ' HA ' ' SD ' ' A' ' 145' ' ' MET . 11.2 mp -59.14 -25.64 64.04 Favored 'General case' 0 C--N 1.332 -0.186 0 CA-C-N 116.073 -0.512 . . . . 0.0 110.973 179.982 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 142' ' ' VAL . . . . . 0.419 HG23 ' O ' ' A' ' 138' ' ' VAL . 15.7 t -107.9 -5.18 10.5 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.254 0 CA-C-N 116.24 -0.437 . . . . 0.0 110.875 179.851 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . -75.81 -133.2 0.41 Allowed Glycine 0 CA--C 1.522 0.487 0 C-N-CA 120.874 -0.679 . . . . 0.0 112.704 179.993 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 144' ' ' PRO . . . . . . . . . . . . . 48.7 Cg_exo -55.55 -24.17 43.3 Favored 'Trans proline' 0 C--N 1.35 0.639 0 C-N-CA 122.5 2.133 . . . . 0.0 112.868 -179.732 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 145' ' ' MET . . . . . 0.507 ' SD ' ' HA ' ' A' ' 141' ' ' LEU . 57.5 mtt -54.15 -32.91 56.6 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 116.402 -0.363 . . . . 0.0 111.408 -179.864 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 146' ' ' THR . . . . . . . . . . . . . 79.1 p -65.9 -49.25 68.7 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.3 -0.409 . . . . 0.0 111.937 -179.407 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 14.1 mm-40 -74.89 -25.39 58.9 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.734 0.302 . . . . 0.0 111.766 -179.394 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 148' ' ' SER . . . . . . . . . . . . . 45.9 t -70.1 -45.43 66.95 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.834 0.35 . . . . 0.0 111.098 -179.623 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 149' ' ' ALA . . . . . 0.416 ' HB1' HG22 ' A' ' 156' ' ' ILE . . . -78.33 -35.14 48.06 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.119 -0.492 . . . . 0.0 111.849 -179.582 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 150' ' ' SER . . . . . 0.559 ' HA ' ' HG2' ' A' ' 157' ' ' LYS . 35.7 t -69.71 0.72 5.12 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.303 -0.408 . . . . 0.0 111.44 -179.539 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 151' ' ' GLN . . . . . . . . . . . . . 49.1 mt-30 -134.3 15.53 3.78 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.512 -0.313 . . . . 0.0 111.207 179.877 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 152' ' ' ARG . . . . . 0.411 ' NE ' ' HA ' ' A' ' 152' ' ' ARG . 6.7 tpm_? -91.6 -51.89 5.04 Favored 'General case' 0 C--N 1.332 -0.195 0 CA-C-O 120.906 0.384 . . . . 0.0 110.772 179.954 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 153' ' ' SER . . . . . 0.679 ' HB3' HG12 ' A' ' 156' ' ' ILE . 24.3 t -157.76 172.6 18.2 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 115.978 -0.555 . . . . 0.0 110.746 179.256 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 154' ' ' SER . . . . . 0.513 ' HA ' ' NZ ' ' A' ' 157' ' ' LYS . 77.7 p -70.49 -40.68 73.45 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.427 -0.351 . . . . 0.0 110.859 179.727 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -77.08 -28.59 58.2 Favored Glycine 0 CA--C 1.521 0.41 0 C-N-CA 121.07 -0.585 . . . . 0.0 113.389 -179.631 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 156' ' ' ILE . . . . . 0.679 HG12 ' HB3' ' A' ' 153' ' ' SER . 33.4 mm -56.77 -37.68 54.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-O 120.678 0.275 . . . . 0.0 111.522 -179.507 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 157' ' ' LYS . . . . . 0.559 ' HG2' ' HA ' ' A' ' 150' ' ' SER . 36.7 mtmm -58.96 -41.26 87.04 Favored 'General case' 0 C--N 1.327 -0.393 0 N-CA-C 112.178 0.436 . . . . 0.0 112.178 -179.527 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 71.2 m -70.57 -48.32 55.9 Favored 'General case' 0 C--N 1.33 -0.256 0 N-CA-C 111.958 0.355 . . . . 0.0 111.958 -179.003 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 159' ' ' LEU . . . . . 0.402 ' O ' ' HB2' ' A' ' 163' ' ' LEU . 3.8 mm? -67.68 -30.2 69.67 Favored 'General case' 0 C--N 1.327 -0.384 0 N-CA-C 111.789 0.292 . . . . 0.0 111.789 -179.373 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 160' ' ' TYR . . . . . . . . . . . . . 72.4 t80 -73.98 -47.41 37.48 Favored 'General case' 0 C--N 1.329 -0.3 0 N-CA-C 112.313 0.486 . . . . 0.0 112.313 -179.06 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 161' ' ' VAL . . . . . 0.422 HG23 ' N ' ' A' ' 162' ' ' ARG . 27.3 m -64.25 -43.17 97.21 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.373 0 N-CA-C 112.347 0.499 . . . . 0.0 112.347 -178.616 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 162' ' ' ARG . . . . . 0.446 ' HA ' ' NE ' ' A' ' 162' ' ' ARG . 6.7 tpm_? -68.96 -49.27 59.47 Favored 'General case' 0 C--N 1.328 -0.33 0 N-CA-C 112.001 0.371 . . . . 0.0 112.001 -178.904 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 163' ' ' LEU . . . . . 0.402 ' HB2' ' O ' ' A' ' 159' ' ' LEU . 8.1 mp -67.62 -43.23 80.88 Favored 'General case' 0 C--N 1.329 -0.313 0 N-CA-C 111.928 0.344 . . . . 0.0 111.928 -179.149 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 164' ' ' ARG . . . . . . . . . . . . . 3.4 tmm_? -56.88 -50.79 71.43 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 120.695 0.283 . . . . 0.0 110.683 179.965 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 165' ' ' ASN . . . . . 0.464 ' O ' HG23 ' A' ' 169' ' ' VAL . 4.2 m-20 -57.29 -42.27 81.39 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.998 0.427 . . . . 0.0 110.301 179.576 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 166' ' ' LEU . . . . . 0.467 ' HB3' ' CE1' ' A' ' 208' ' ' PHE . 2.7 mt -58.7 -52.18 66.79 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 115.83 -0.623 . . . . 0.0 111.097 179.344 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 167' ' ' THR . . . . . 0.637 ' HA ' HD11 ' A' ' 170' ' ' LEU . 3.1 m -54.59 -51.86 63.95 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 115.733 -0.667 . . . . 0.0 112.442 -178.454 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 168' ' ' VAL . . . . . . . . . . . . . 59.2 t -57.26 -40.36 73.34 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.504 0 N-CA-C 112.485 0.55 . . . . 0.0 112.485 -178.894 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 169' ' ' VAL . . . . . 0.483 ' O ' HG12 ' A' ' 173' ' ' ILE . 98.2 t -68.03 -66.7 0.49 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 N-CA-C 113.499 0.926 . . . . 0.0 113.499 -177.912 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 170' ' ' LEU . . . . . 0.637 HD11 ' HA ' ' A' ' 167' ' ' THR . 0.4 OUTLIER -59.89 -33.2 71.52 Favored 'General case' 0 N--CA 1.467 0.386 0 N-CA-C 112.887 0.699 . . . . 0.0 112.887 -177.71 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 171' ' ' TRP . . . . . 0.543 ' H ' HD12 ' A' ' 170' ' ' LEU . 25.9 m0 -73.54 -30.51 63.12 Favored 'General case' 0 C--N 1.329 -0.296 0 C-N-CA 120.57 -0.452 . . . . 0.0 111.473 -179.429 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 172' ' ' ALA . . . . . . . . . . . . . . . -73.2 -7.53 51.84 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.944 0.402 . . . . 0.0 110.348 179.455 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 173' ' ' ILE . . . . . 0.592 HG22 HD11 ' A' ' 177' ' ' ILE . 31.4 mm -88.75 -24.5 6.03 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.15 0 CA-C-N 115.877 -0.601 . . . . 0.0 110.758 179.402 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 174' ' ' TYR . . . . . 0.598 ' N ' ' HD2' ' A' ' 175' ' ' PRO . 21.4 m-85 -55.11 -50.29 87.35 Favored Pre-proline 0 CA--C 1.53 0.192 0 N-CA-C 112.216 0.45 . . . . 0.0 112.216 -179.614 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 175' ' ' PRO . . . . . 0.598 ' HD2' ' N ' ' A' ' 174' ' ' TYR . 4.1 Cg_endo -47.06 -28.47 7.45 Favored 'Trans proline' 0 C--N 1.352 0.762 0 C-N-CA 122.148 1.899 . . . . 0.0 112.1 179.976 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 176' ' ' PHE . . . . . 0.519 ' O ' ' HG ' ' A' ' 180' ' ' LEU . 92.2 m-85 -80.27 -49.97 10.85 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.31 179.568 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 177' ' ' ILE . . . . . 0.592 HD11 HG22 ' A' ' 173' ' ' ILE . 2.8 mm -59.71 -37.38 70.83 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.581 0 CA-C-N 115.995 -0.548 . . . . 0.0 111.781 -178.593 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 178' ' ' TRP . . . . . . . . . . . . . 70.7 t90 -73.58 -45.38 53.57 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.915 0.388 . . . . 0.0 110.856 179.814 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 179' ' ' LEU . . . . . 0.451 ' O ' ' HA3' ' A' ' 184' ' ' GLY . 1.9 tm? -65.09 -53.12 50.29 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 115.976 -0.556 . . . . 0.0 111.417 -179.233 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 180' ' ' LEU . . . . . 0.604 HD22 HD11 ' A' ' 187' ' ' LEU . 11.1 mt -71.79 -42.96 66.46 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 116.705 -0.225 . . . . 0.0 111.515 -179.208 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . -58.54 175.41 2.56 Favored Glycine 0 C--N 1.335 0.493 0 C-N-CA 120.472 -0.87 . . . . 0.0 112.664 179.772 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 182' ' ' PRO . . . . . 0.714 ' HA ' ' HB2' ' A' ' 186' ' ' ALA . 73.1 Cg_exo -47.91 -44.27 27.72 Favored 'Trans proline' 0 C--N 1.349 0.581 0 C-N-CA 122.767 2.312 . . . . 0.0 113.38 179.791 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 183' ' ' PRO . . . . . 0.554 ' HB3' ' HB2' ' A' ' 116' ' ' ALA . 73.4 Cg_exo -52.08 -17.19 5.41 Favored 'Trans proline' 0 C--N 1.355 0.905 0 C-N-CA 122.119 1.88 . . . . 0.0 112.84 179.557 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 184' ' ' GLY . . . . . 0.451 ' HA3' ' O ' ' A' ' 179' ' ' LEU . . . -114.74 -82.79 1.08 Allowed Glycine 0 N--CA 1.45 -0.379 0 C-N-CA 120.644 -0.789 . . . . 0.0 112.942 -179.715 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 185' ' ' VAL . . . . . 0.409 HG22 ' O ' ' A' ' 179' ' ' LEU . 8.4 m -129.71 -4.16 2.89 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.24 0 N-CA-C 112.349 0.5 . . . . 0.0 112.349 -179.376 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 186' ' ' ALA . . . . . 0.714 ' HB2' ' HA ' ' A' ' 182' ' ' PRO . . . 52.22 89.56 0.03 OUTLIER 'General case' 0 N--CA 1.464 0.241 0 CA-C-O 120.72 0.295 . . . . 0.0 111.635 179.752 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 187' ' ' LEU . . . . . 0.604 HD11 HD22 ' A' ' 180' ' ' LEU . 24.3 mt -92.24 -49.49 6.15 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.443 -0.344 . . . . 0.0 111.678 -179.81 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 188' ' ' LEU . . . . . . . . . . . . . 88.7 mt -93.27 -93.93 0.16 Allowed 'General case' 0 C--N 1.331 -0.23 0 CA-C-O 120.799 0.333 . . . . 0.0 111.23 -179.604 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 189' ' ' THR . . . . . . . . . . . . . 2.2 t -161.44 145.02 9.62 Favored Pre-proline 0 C--N 1.326 -0.418 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.957 179.979 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 190' ' ' PRO . . . . . . . . . . . . . 74.7 Cg_exo -49.15 -40.24 42.05 Favored 'Trans proline' 0 C--N 1.349 0.596 0 C-N-CA 122.747 2.298 . . . . 0.0 113.137 -179.601 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 191' ' ' THR . . . . . . . . . . . . . 38.3 p -58.97 -44.52 91.53 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.795 0.331 . . . . 0.0 111.515 -179.621 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 192' ' ' VAL . . . . . . . . . . . . . 37.2 t -72.65 -46.12 55.5 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.266 -179.947 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 193' ' ' ASP . . . . . . . . . . . . . 32.6 t70 -55.1 -44.07 74.59 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.388 -0.369 . . . . 0.0 111.006 179.844 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 194' ' ' VAL . . . . . 0.514 HG21 HD11 ' A' ' 4' ' ' LEU . 79.8 t -68.64 -36.02 72.66 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.032 179.902 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 195' ' ' ALA . . . . . . . . . . . . . . . -59.12 -46.77 87.48 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-O 120.671 0.272 . . . . 0.0 110.977 179.734 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 196' ' ' LEU . . . . . . . . . . . . . 88.3 mt -67.83 -41.02 83.68 Favored 'General case' 0 C--N 1.332 -0.192 0 CA-C-O 120.841 0.353 . . . . 0.0 110.577 179.576 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 197' ' ' ILE . . . . . . . . . . . . . 17.6 mm -59.16 -58.41 7.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.011 -0.54 . . . . 0.0 110.225 179.203 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 198' ' ' VAL . . . . . 0.421 HG23 ' O ' ' A' ' 194' ' ' VAL . 75.7 t -52.53 -34.79 19.62 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.432 0 CA-C-N 115.633 -0.712 . . . . 0.0 109.199 178.226 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 199' ' ' TYR . . . . . . . . . . . . . 67.5 t80 -70.23 -33.39 71.6 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 115.227 -0.897 . . . . 0.0 110.811 179.965 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 200' ' ' LEU . . . . . 0.443 ' O ' HG12 ' A' ' 203' ' ' VAL . 36.5 mt -68.65 -40.78 80.08 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.039 -0.528 . . . . 0.0 111.375 -179.597 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 201' ' ' ASP . . . . . . . . . . . . . 8.1 m-20 -71.49 -31.64 67.34 Favored 'General case' 0 C--N 1.327 -0.413 0 CA-C-O 121.117 0.484 . . . . 0.0 110.038 179.447 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 202' ' ' LEU . . . . . . . . . . . . . 3.3 mt -71.01 -33.74 70.67 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 115.546 -0.752 . . . . 0.0 111.955 -179.671 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 203' ' ' VAL . . . . . 0.495 ' O ' ' HA3' ' A' ' 207' ' ' GLY . 7.8 p -77.1 -36.39 24.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 N-CA-C 111.593 0.22 . . . . 0.0 111.593 -178.743 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 204' ' ' THR . . . . . . . . . . . . . 57.5 m -70.58 -52.25 22.81 Favored 'General case' 0 C--N 1.327 -0.372 0 C-N-CA 120.682 -0.407 . . . . 0.0 111.6 179.735 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 205' ' ' LYS . . . . . 0.688 ' HE2' ' HB2' ' A' ' 47' ' ' ALA . 53.8 mttp -70.53 -59.12 3.02 Favored 'General case' 0 C--N 1.327 -0.385 0 N-CA-C 112.27 0.47 . . . . 0.0 112.27 -178.67 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 23.3 t -72.87 -37.82 55.4 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.357 0 CA-C-N 116.333 -0.394 . . . . 0.0 111.724 -178.814 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 207' ' ' GLY . . . . . 0.53 ' O ' HG12 ' A' ' 211' ' ' ILE . . . -62.71 -59.04 9.81 Favored Glycine 0 N--CA 1.452 -0.286 0 C-N-CA 120.353 -0.927 . . . . 0.0 112.429 -179.641 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 208' ' ' PHE . . . . . 0.473 ' O ' ' N ' ' A' ' 212' ' ' ALA . 2.2 m-30 -53.66 -49.95 66.85 Favored 'General case' 0 C--O 1.221 -0.4 0 CA-C-O 120.798 0.332 . . . . 0.0 110.112 179.992 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 209' ' ' GLY . . . . . 0.476 ' O ' ' HB3' ' A' ' 212' ' ' ALA . . . -54.19 -31.42 49.42 Favored Glycine 0 N--CA 1.449 -0.487 0 CA-C-N 115.444 -0.798 . . . . 0.0 112.456 178.927 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 210' ' ' PHE . . . . . . . . . . . . . 1.8 m-85 -72.41 -48.73 39.1 Favored 'General case' 0 C--N 1.328 -0.33 0 N-CA-C 108.764 -0.828 . . . . 0.0 108.764 178.755 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 211' ' ' ILE . . . . . 0.53 HG12 ' O ' ' A' ' 207' ' ' GLY . 0.6 OUTLIER -63.7 -27.21 42.43 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.297 0 N-CA-C 107.246 -1.39 . . . . 0.0 107.246 176.685 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 212' ' ' ALA . . . . . 0.476 ' HB3' ' O ' ' A' ' 209' ' ' GLY . . . -68.03 -43.66 78.24 Favored 'General case' 0 N--CA 1.448 -0.534 0 CA-C-N 114.044 -1.434 . . . . 0.0 110.764 -179.418 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 213' ' ' LEU . . . . . . . . . . . . . 71.5 mt -70.52 -54.98 10.05 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 115.191 -0.913 . . . . 0.0 112.112 -179.19 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 214' ' ' ASP . . . . . . . . . . . . . 29.4 t70 -54.96 -54.44 42.76 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.392 -0.367 . . . . 0.0 111.858 -179.099 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 215' ' ' ALA . . . . . . . . . . . . . . . -58.44 -57.16 14.14 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 116.312 -0.404 . . . . 0.0 111.898 -179.344 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 216' ' ' ALA . . . . . . . . . . . . . . . -57.57 -33.97 68.71 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.331 -0.395 . . . . 0.0 111.682 -179.367 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 217' ' ' ALA . . . . . . . . . . . . . . . -61.06 -41.58 96.88 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.953 0.406 . . . . 0.0 110.451 179.887 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 218' ' ' THR . . . . . . . . . . . . . 95.9 m . . . . . 0 C--N 1.329 -0.321 0 CA-C-N 115.829 -0.623 . . . . 0.0 110.896 179.737 . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.28 0 N-CA-C 112.33 -0.308 . . . . 0.0 112.33 . . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 49.8 tp -74.38 -35.54 63.49 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-O 120.778 0.323 . . . . 0.0 111.06 -179.974 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 69.1 p -61.06 -30.32 70.26 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.361 -179.751 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 28.0 p -54.56 -35.49 63.33 Favored 'General case' 0 C--N 1.331 -0.2 0 CA-C-N 116.278 -0.419 . . . . 0.0 111.248 -179.965 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 7' ' ' LEU . . . . . . . . . . . . . 4.0 mm? -56.65 -52.3 65.43 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 115.951 -0.568 . . . . 0.0 111.103 -179.903 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 8' ' ' PHE . . . . . 0.6 ' HB2' ' HB2' ' A' ' 55' ' ' ALA . 62.9 m-85 -64.47 -31.96 73.38 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.34 -0.391 . . . . 0.0 110.934 -179.989 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 9' ' ' TRP . . . . . 0.402 ' O ' HG12 ' A' ' 13' ' ' ILE . 35.3 m95 -65.61 -41.69 92.47 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.173 -179.92 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 56.1 mt -67.17 -32.43 73.51 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-N 115.761 -0.654 . . . . 0.0 109.962 179.377 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 11' ' ' GLY . . . . . 0.436 ' HA2' HD11 ' A' ' 202' ' ' LEU . . . -73.65 -27.72 66.74 Favored Glycine 0 N--CA 1.446 -0.67 0 CA-C-N 115.665 -0.698 . . . . 0.0 111.702 179.3 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -73.62 -33.91 64.78 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.834 0.35 . . . . 0.0 110.543 179.396 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 13' ' ' ILE . . . . . 0.439 ' O ' HG23 ' A' ' 17' ' ' VAL . 48.8 mm -68.22 -54.2 23.66 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.232 0 CA-C-N 116.002 -0.545 . . . . 0.0 110.397 179.423 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -59.18 -40.06 95.28 Favored Glycine 0 N--CA 1.45 -0.385 0 C-N-CA 120.635 -0.793 . . . . 0.0 111.48 179.221 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 15' ' ' MET . . . . . 0.516 ' SD ' ' HA ' ' A' ' 44' ' ' SER . 52.7 tpp -62.1 -43.6 98.49 Favored 'General case' 0 N--CA 1.453 -0.301 0 N-CA-C 109.99 -0.374 . . . . 0.0 109.99 179.295 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 45.4 tp -55.19 -38.18 68.02 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 115.746 -0.661 . . . . 0.0 110.222 179.184 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 17' ' ' VAL . . . . . 0.439 HG23 ' O ' ' A' ' 13' ' ' ILE . 44.2 t -62.13 -42.09 93.75 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.215 0 CA-C-N 115.891 -0.595 . . . . 0.0 109.971 179.243 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -66.26 -42.52 94.11 Favored Glycine 0 C--N 1.331 0.272 0 C-N-CA 120.69 -0.767 . . . . 0.0 111.58 178.928 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 7.9 m -52.09 -49.82 62.82 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.812 0.339 . . . . 0.0 111.074 179.945 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 20' ' ' LEU . . . . . 0.409 ' O ' ' HB3' ' A' ' 24' ' ' TRP . 95.0 mt -71.91 -35.6 69.73 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.435 179.926 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -62.21 -34.55 76.69 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.68 0.276 . . . . 0.0 111.648 -179.569 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 22' ' ' PHE . . . . . 0.543 ' HB2' HG22 ' A' ' 41' ' ' VAL . 11.0 m-85 -89.95 -30.33 17.89 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.478 -0.328 . . . . 0.0 111.434 -179.442 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -72.88 -50.03 26.31 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.479 -0.328 . . . . 0.0 111.228 -179.941 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 24' ' ' TRP . . . . . 0.409 ' HB3' ' O ' ' A' ' 20' ' ' LEU . 1.1 t-105 -60.66 -43.42 97.67 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.054 -0.521 . . . . 0.0 111.012 179.907 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.33 -0.282 0 CA-C-N 116.334 -0.393 . . . . 0.0 110.907 179.927 . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.317 0 N-CA-C 111.77 -0.532 . . . . 0.0 111.77 . . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 31.9 mm-40 -91.93 -20.16 21.7 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-O 120.792 0.33 . . . . 0.0 110.686 179.819 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 34' ' ' ARG . . . . . . . . . . . . . 55.4 ttp180 -47.95 -31.68 5.52 Favored 'General case' 0 C--N 1.332 -0.162 0 CA-C-N 115.974 -0.557 . . . . 0.0 111.385 -179.81 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 40.4 ttm180 -61.23 -49.46 77.02 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-O 120.856 0.36 . . . . 0.0 110.894 -179.943 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 75.9 m-85 -70.04 -37.47 75.59 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.025 -0.534 . . . . 0.0 111.568 -179.593 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 37' ' ' TYR . . . . . 0.539 ' O ' HG23 ' A' ' 41' ' ' VAL . 35.3 m-85 -65.74 -54.75 22.95 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.318 -0.401 . . . . 0.0 111.516 -179.396 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 90.6 t -56.7 -38.18 56.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-O 120.918 0.39 . . . . 0.0 110.667 179.894 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 17.4 m -61.68 -50.95 70.42 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 115.933 -0.576 . . . . 0.0 110.616 179.346 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 40' ' ' LEU . . . . . 0.56 HD12 HD12 ' A' ' 43' ' ' ILE . 40.2 tp -59.71 -50.52 73.52 Favored 'General case' 0 C--O 1.235 0.333 0 CA-C-N 115.745 -0.661 . . . . 0.0 110.831 179.894 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 41' ' ' VAL . . . . . 0.543 HG22 ' HB2' ' A' ' 22' ' ' PHE . 60.2 t -56.1 -34.3 38.53 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 115.834 -0.621 . . . . 0.0 110.294 179.26 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -60.94 -43.59 99.18 Favored Glycine 0 N--CA 1.45 -0.411 0 C-N-CA 120.739 -0.743 . . . . 0.0 111.826 179.597 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 43' ' ' ILE . . . . . 0.56 HD12 HD12 ' A' ' 40' ' ' LEU . 1.3 mt -58.55 -51.92 65.81 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.195 0 CA-C-O 120.792 0.329 . . . . 0.0 110.791 179.426 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 44' ' ' SER . . . . . 0.516 ' HA ' ' SD ' ' A' ' 15' ' ' MET . 44.7 m -59.66 -27.02 66.02 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.557 -179.772 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -73.79 -56.55 5.35 Favored Glycine 0 CA--C 1.519 0.33 0 C-N-CA 120.643 -0.789 . . . . 0.0 113.002 -179.588 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 24.3 pt -58.46 -35.45 54.41 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.214 0 CA-C-O 121.025 0.441 . . . . 0.0 111.295 -179.856 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 47' ' ' ALA . . . . . 0.74 ' HB2' ' HE2' ' A' ' 205' ' ' LYS . . . -66.98 -49.25 65.97 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.586 179.851 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -54.16 -44.39 71.42 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 115.983 -0.553 . . . . 0.0 111.962 -179.112 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 49' ' ' VAL . . . . . 0.406 ' O ' HG13 ' A' ' 53' ' ' VAL . 30.1 m -68.29 -34.24 64.99 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 C-N-CA 120.98 -0.288 . . . . 0.0 111.073 -179.731 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -67.54 -37.06 82.15 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-O 121.016 0.436 . . . . 0.0 110.939 179.264 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 38.7 m-85 -68.54 -38.76 81.11 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.028 -0.533 . . . . 0.0 110.214 -179.948 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -65.02 -50.71 65.19 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 115.804 -0.635 . . . . 0.0 111.088 179.592 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 53' ' ' VAL . . . . . 0.485 HG23 ' N ' ' A' ' 54' ' ' MET . 25.3 m -60.78 -47.9 91.16 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.109 0 CA-C-N 116.527 -0.306 . . . . 0.0 110.85 -179.939 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 54' ' ' MET . . . . . 0.514 ' HG2' ' HG2' ' A' ' 71' ' ' PRO . 74.3 mtm -62.42 -31.55 72.26 Favored 'General case' 0 C--N 1.331 -0.225 0 N-CA-C 109.607 -0.516 . . . . 0.0 109.607 179.068 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 55' ' ' ALA . . . . . 0.6 ' HB2' ' HB2' ' A' ' 8' ' ' PHE . . . -72.69 -22.49 60.9 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 115.527 -0.761 . . . . 0.0 110.981 179.583 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 81.0 mt -87.42 -5.52 58.81 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.118 179.996 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 90.15 -14.68 61.55 Favored Glycine 0 N--CA 1.45 -0.418 0 C-N-CA 120.622 -0.799 . . . . 0.0 112.911 179.765 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 58' ' ' VAL . . . . . 0.424 HG12 ' O ' ' A' ' 53' ' ' VAL . 9.0 p -69.5 141.64 17.01 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-O 120.85 0.357 . . . . 0.0 110.801 179.885 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 59' ' ' GLY . . . . . 0.411 ' HA3' ' HG3' ' A' ' 71' ' ' PRO . . . 92.39 -5.62 77.74 Favored Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.868 -0.682 . . . . 0.0 112.153 -179.268 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 60' ' ' TRP . . . . . . . . . . . . . 19.6 m0 -80.1 111.98 16.97 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-O 120.578 0.228 . . . . 0.0 110.785 179.919 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 61' ' ' VAL . . . . . 0.569 HG13 HG23 ' A' ' 68' ' ' VAL . 7.1 p -115.02 128.75 25.66 Favored Pre-proline 0 CA--C 1.533 0.315 0 CA-C-N 116.512 -0.313 . . . . 0.0 110.951 179.566 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 71.7 Cg_endo -76.39 156.0 36.76 Favored 'Trans proline' 0 C--N 1.35 0.629 0 C-N-CA 122.47 2.113 . . . . 0.0 112.725 -179.873 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 84.2 t -143.15 89.89 0.41 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 115.764 -0.653 . . . . 0.0 110.599 179.879 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . 58.71 -88.38 0.02 OUTLIER 'General case' 0 C--N 1.331 -0.196 0 CA-C-N 116.115 -0.493 . . . . 0.0 111.306 -179.756 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 45.5 mt-10 -120.5 -17.78 8.02 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 116.386 -0.37 . . . . 0.0 110.828 179.807 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 66' ' ' ARG . . . . . 0.468 ' HA ' ' HE ' ' A' ' 66' ' ' ARG . 3.0 mmp_? -100.29 163.5 12.37 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.25 179.672 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 85.3 m -125.83 133.91 51.82 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 121.023 0.439 . . . . 0.0 111.516 -179.673 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 68' ' ' VAL . . . . . 0.569 HG23 HG13 ' A' ' 61' ' ' VAL . 17.9 m -123.3 144.69 32.02 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-N 115.857 -0.611 . . . . 0.0 110.469 179.417 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 69' ' ' PHE . . . . . . . . . . . . . 19.4 m-85 -110.45 112.21 23.98 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.359 -0.382 . . . . 0.0 110.109 -179.217 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 70' ' ' VAL . . . . . 0.63 ' N ' ' HD2' ' A' ' 71' ' ' PRO . 28.3 t -66.02 -47.49 62.83 Favored Pre-proline 0 C--N 1.323 -0.553 0 CA-C-N 116.234 -0.439 . . . . 0.0 112.01 -179.362 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 71' ' ' PRO . . . . . 0.63 ' HD2' ' N ' ' A' ' 70' ' ' VAL . 13.9 Cg_endo -57.15 -22.22 46.9 Favored 'Trans proline' 0 C--N 1.351 0.709 0 C-N-CA 121.982 1.788 . . . . 0.0 111.773 179.518 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 60.7 ttp180 -75.91 -53.3 8.63 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.585 179.694 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 73' ' ' TYR . . . . . . . . . . . . . 69.3 m-85 -64.6 -45.76 85.56 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 115.967 -0.56 . . . . 0.0 110.709 179.912 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 0.4 OUTLIER -60.86 -36.56 72.46 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 N-CA-C 109.807 -0.442 . . . . 0.0 109.807 179.362 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 75' ' ' ASP . . . . . 0.415 ' O ' HG23 ' A' ' 79' ' ' THR . 24.3 t70 -60.38 -37.97 82.44 Favored 'General case' 0 C--N 1.331 -0.209 0 N-CA-C 109.466 -0.568 . . . . 0.0 109.466 178.918 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 76' ' ' TRP . . . . . . . . . . . . . 47.4 m0 -67.08 -29.2 68.9 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 115.717 -0.674 . . . . 0.0 110.289 179.452 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 77' ' ' ILE . . . . . 0.426 ' O ' ' HG2' ' A' ' 81' ' ' PRO . 73.7 mt -72.4 -30.42 34.77 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.373 0 CA-C-N 115.838 -0.619 . . . . 0.0 110.626 179.395 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 40.2 mt -91.88 -16.69 26.33 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.209 -0.451 . . . . 0.0 111.989 -179.954 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 79' ' ' THR . . . . . 0.415 HG23 ' O ' ' A' ' 75' ' ' ASP . 76.7 p -101.97 -49.02 4.06 Favored 'General case' 0 N--CA 1.464 0.262 0 N-CA-C 113.465 0.913 . . . . 0.0 113.465 -178.27 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 80' ' ' THR . . . . . 0.679 ' HB ' ' HD3' ' A' ' 81' ' ' PRO . 44.2 m -53.11 -54.46 44.2 Favored Pre-proline 0 CA--C 1.531 0.22 0 N-CA-C 112.226 0.454 . . . . 0.0 112.226 -178.338 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 81' ' ' PRO . . . . . 0.679 ' HD3' ' HB ' ' A' ' 80' ' ' THR . 34.2 Cg_exo -61.12 -19.72 64.64 Favored 'Trans proline' 0 C--N 1.352 0.735 0 C-N-CA 121.552 1.502 . . . . 0.0 111.28 179.578 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 82' ' ' LEU . . . . . . . . . . . . . 13.1 tp -76.89 -36.56 56.61 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 115.66 -0.7 . . . . 0.0 110.558 179.909 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 35.2 mm -68.02 -52.54 37.83 Favored 'Isoleucine or valine' 0 C--O 1.233 0.235 0 CA-C-N 116.308 -0.405 . . . . 0.0 110.08 179.251 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 30.9 m -59.58 -32.74 49.78 Favored 'Isoleucine or valine' 0 CA--C 1.52 -0.195 0 N-CA-C 109.482 -0.562 . . . . 0.0 109.482 178.796 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 85' ' ' TYR . . . . . . . . . . . . . 89.5 t80 -62.65 -34.63 77.46 Favored 'General case' 0 N--CA 1.454 -0.258 0 CA-C-N 115.528 -0.76 . . . . 0.0 109.163 178.595 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 86' ' ' PHE . . . . . . . . . . . . . 11.3 t80 -61.36 -51.72 67.65 Favored 'General case' 0 N--CA 1.456 -0.126 0 CA-C-N 115.561 -0.745 . . . . 0.0 109.879 179.201 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 7.6 mp -58.6 -36.43 74.0 Favored 'General case' 0 C--N 1.331 -0.202 0 CA-C-N 115.89 -0.595 . . . . 0.0 110.194 179.426 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 88' ' ' GLY . . . . . 0.475 ' HA2' HD13 ' A' ' 93' ' ' LEU . . . -64.93 -28.1 73.04 Favored Glycine 0 N--CA 1.45 -0.399 0 C-N-CA 120.916 -0.659 . . . . 0.0 112.165 179.575 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 86.5 mt -74.08 -41.25 61.97 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.902 0.382 . . . . 0.0 110.741 179.732 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 74.8 mt -58.73 -47.56 84.19 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 115.913 -0.585 . . . . 0.0 111.158 -179.756 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -74.77 -42.44 58.17 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.376 -0.375 . . . . 0.0 111.149 -179.875 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 93.06 55.96 1.54 Allowed Glycine 0 N--CA 1.45 -0.422 0 C-N-CA 120.832 -0.699 . . . . 0.0 112.466 -179.945 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 93' ' ' LEU . . . . . 0.565 HD23 ' HB3' ' A' ' 97' ' ' GLU . 9.7 mp -67.71 -176.4 0.64 Allowed 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.809 0.338 . . . . 0.0 110.908 -179.943 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 94' ' ' ASP . . . . . . . . . . . . . 10.4 m-20 -113.47 172.97 6.64 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.472 -179.929 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 45.4 t -54.03 -36.27 62.85 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.312 -0.404 . . . . 0.0 111.372 -179.759 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 96' ' ' ARG . . . . . 0.402 ' O ' HG13 ' A' ' 100' ' ' ILE . 29.3 mmm180 -73.98 -47.88 34.21 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 116.279 -0.419 . . . . 0.0 111.457 -179.85 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 97' ' ' GLU . . . . . 0.565 ' HB3' HD23 ' A' ' 93' ' ' LEU . 47.6 mt-10 -60.19 -44.59 94.96 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-O 120.912 0.387 . . . . 0.0 110.584 -179.387 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 98' ' ' PHE . . . . . 0.448 ' O ' HG12 ' A' ' 102' ' ' ILE . 12.8 m-85 -59.91 -47.95 83.66 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 115.869 -0.605 . . . . 0.0 110.514 179.325 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -55.22 -32.02 56.86 Favored Glycine 0 N--CA 1.452 -0.276 0 C-N-CA 120.799 -0.715 . . . . 0.0 112.697 179.922 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 100' ' ' ILE . . . . . 0.451 ' O ' HG22 ' A' ' 103' ' ' THR . 89.5 mt -69.51 -54.0 21.91 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.222 0 CA-C-O 120.956 0.408 . . . . 0.0 111.676 -179.894 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 17.2 t -64.7 -42.79 96.0 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.355 0 CA-C-N 116.136 -0.484 . . . . 0.0 111.933 -179.203 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 102' ' ' ILE . . . . . 0.448 HG12 ' O ' ' A' ' 98' ' ' PHE . 48.8 mm -63.67 -53.13 48.69 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-N 116.326 -0.397 . . . . 0.0 111.698 -179.325 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 103' ' ' THR . . . . . 0.451 HG22 ' O ' ' A' ' 100' ' ' ILE . 12.8 t -55.03 -35.38 64.39 Favored 'General case' 0 C--O 1.234 0.244 0 CA-C-O 120.869 0.366 . . . . 0.0 110.726 -179.909 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 104' ' ' LEU . . . . . 0.48 HD22 ' HE2' ' A' ' 140' ' ' TYR . 29.3 tp -61.08 -49.45 77.26 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.296 179.216 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 105' ' ' ASN . . . . . 0.58 ' N ' HD22 ' A' ' 105' ' ' ASN . 0.8 OUTLIER -59.1 -26.36 64.62 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.054 -0.521 . . . . 0.0 110.562 179.808 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 33.2 m -66.47 -54.16 27.22 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.276 -0.42 . . . . 0.0 111.158 179.697 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 12.8 p -66.25 -36.29 77.04 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.152 0 CA-C-N 116.486 -0.325 . . . . 0.0 111.356 -179.834 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 108' ' ' VAL . . . . . 0.412 HG23 ' O ' ' A' ' 104' ' ' LEU . 73.7 t -62.62 -56.86 14.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-O 120.885 0.374 . . . . 0.0 111.104 -179.949 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 109' ' ' MET . . . . . 0.442 ' HE1' HG21 ' A' ' 80' ' ' THR . 7.1 tpp -60.48 -31.66 70.67 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.451 179.998 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 110' ' ' LEU . . . . . 0.491 HD23 ' C ' ' A' ' 110' ' ' LEU . 5.0 tt -64.19 -37.86 88.97 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-N 115.81 -0.632 . . . . 0.0 109.595 178.714 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -60.78 -50.58 72.86 Favored 'General case' 0 C--N 1.333 -0.137 0 CA-C-N 115.883 -0.598 . . . . 0.0 110.827 179.671 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . -59.38 -45.91 94.72 Favored Glycine 0 C--N 1.331 0.263 0 C-N-CA 120.687 -0.768 . . . . 0.0 112.074 179.645 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 113' ' ' PHE . . . . . . . . . . . . . 3.0 t80 -49.73 -65.66 0.53 Allowed 'General case' 0 C--N 1.333 -0.128 0 CA-C-O 120.91 0.386 . . . . 0.0 110.382 179.696 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -64.79 -17.77 64.5 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 115.901 -0.59 . . . . 0.0 110.952 179.927 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 115' ' ' GLY . . . . . 0.506 ' O ' HG22 ' A' ' 118' ' ' VAL . . . -57.24 -52.32 52.2 Favored Glycine 0 N--CA 1.45 -0.385 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.045 179.579 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -78.32 -15.06 59.11 Favored 'General case' 0 C--N 1.328 -0.351 0 N-CA-C 111.984 0.364 . . . . 0.0 111.984 179.904 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 117' ' ' MET . . . . . 0.501 ' SD ' HG21 ' A' ' 68' ' ' VAL . 26.0 mmt -80.88 19.86 0.82 Allowed 'General case' 0 N--CA 1.464 0.259 0 N-CA-C 112.182 0.438 . . . . 0.0 112.182 -178.985 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 118' ' ' VAL . . . . . 0.524 HG21 ' N ' ' A' ' 123' ' ' ARG . 17.6 m -113.24 157.74 40.16 Favored Pre-proline 0 C--N 1.328 -0.343 0 CA-C-N 116.756 -0.202 . . . . 0.0 111.208 179.819 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 119' ' ' PRO . . . . . 0.435 ' HD2' ' HB ' ' A' ' 118' ' ' VAL . 69.2 Cg_endo -73.96 -24.44 15.17 Favored 'Trans proline' 0 C--N 1.347 0.493 0 C-N-CA 122.414 2.076 . . . . 0.0 112.382 179.667 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . 152.56 151.86 5.8 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.831 179.935 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 18.9 mm 73.73 -46.94 0.17 Allowed 'Isoleucine or valine' 0 N--CA 1.466 0.334 0 C-N-CA 122.956 0.503 . . . . 0.0 111.715 -179.821 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 14.3 mm-40 -60.17 -28.25 67.78 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.103 180.0 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 123' ' ' ARG . . . . . 0.564 ' HD3' ' HA2' ' A' ' 184' ' ' GLY . 6.5 ptp180 -60.23 -29.49 68.8 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.012 -0.54 . . . . 0.0 111.03 179.896 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 124' ' ' TYR . . . . . . . . . . . . . 30.2 m-85 -69.24 -32.15 71.18 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 115.84 -0.618 . . . . 0.0 111.349 -179.707 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 125' ' ' ALA . . . . . . . . . . . . . . . -73.32 -56.41 5.11 Favored 'General case' 0 C--O 1.236 0.364 0 CA-C-O 121.05 0.452 . . . . 0.0 111.03 179.961 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 1.4 mt -56.04 -50.47 70.84 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.814 -0.63 . . . . 0.0 110.719 -179.926 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 127' ' ' PHE . . . . . 0.429 ' HZ ' ' HB3' ' A' ' 175' ' ' PRO . 9.4 t80 -65.69 -36.19 82.93 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.378 -0.374 . . . . 0.0 110.229 179.459 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 128' ' ' GLY . . . . . . . . . . . . . . . -46.29 -44.54 15.36 Favored Glycine 0 C--N 1.332 0.347 0 C-N-CA 120.171 -1.014 . . . . 0.0 110.822 178.925 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 129' ' ' MET . . . . . . . . . . . . . 0.5 OUTLIER -71.83 -36.47 70.2 Favored 'General case' 0 N--CA 1.453 -0.315 0 N-CA-C 109.833 -0.432 . . . . 0.0 109.833 178.663 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -63.13 -33.08 86.27 Favored Glycine 0 C--N 1.333 0.364 0 CA-C-N 115.794 -0.639 . . . . 0.0 112.867 -179.756 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -74.11 -53.87 9.0 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.681 0.277 . . . . 0.0 110.454 -179.99 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 44.2 t -56.91 -39.94 68.54 Favored 'Isoleucine or valine' 0 C--O 1.234 0.26 0 N-CA-C 109.344 -0.613 . . . . 0.0 109.344 178.764 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -67.4 -36.46 81.33 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 115.305 -0.862 . . . . 0.0 110.167 178.986 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 134' ' ' PHE . . . . . . . . . . . . . 84.7 t80 -56.6 -50.63 71.41 Favored 'General case' 0 N--CA 1.452 -0.335 0 CA-C-N 116.126 -0.488 . . . . 0.0 109.81 179.394 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 135' ' ' ILE . . . . . 0.485 ' O ' HG22 ' A' ' 138' ' ' VAL . 52.8 mt -59.28 -33.53 51.2 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.38 0 CA-C-N 115.67 -0.695 . . . . 0.0 110.207 179.204 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . -63.02 -41.09 99.95 Favored Glycine 0 N--CA 1.448 -0.548 0 C-N-CA 120.209 -0.996 . . . . 0.0 111.292 178.87 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 137' ' ' LEU . . . . . 0.478 HD13 HD21 ' A' ' 105' ' ' ASN . 57.9 tp -67.11 -53.94 26.07 Favored 'General case' 0 N--CA 1.454 -0.269 0 CA-C-O 120.499 0.19 . . . . 0.0 110.889 179.733 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 138' ' ' VAL . . . . . 0.485 HG22 ' O ' ' A' ' 135' ' ' ILE . 4.9 m -54.48 -33.84 27.43 Favored 'Isoleucine or valine' 0 C--O 1.233 0.205 0 CA-C-O 121.09 0.471 . . . . 0.0 109.746 -179.696 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 139' ' ' TYR . . . . . . . . . . . . . 24.2 t80 -59.8 -42.96 94.57 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 115.621 -0.718 . . . . 0.0 109.864 178.299 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 140' ' ' TYR . . . . . 0.48 ' HE2' HD22 ' A' ' 104' ' ' LEU . 25.8 m-85 -65.19 -45.74 83.59 Favored 'General case' 0 C--N 1.333 -0.142 0 CA-C-N 116.083 -0.508 . . . . 0.0 111.13 179.38 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 141' ' ' LEU . . . . . . . . . . . . . 10.6 mp -54.48 -32.65 58.2 Favored 'General case' 0 C--N 1.332 -0.171 0 CA-C-N 116.283 -0.417 . . . . 0.0 111.178 -179.745 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 142' ' ' VAL . . . . . 0.417 HG22 ' O ' ' A' ' 142' ' ' VAL . 11.1 p -106.84 -2.41 9.98 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-N 116.233 -0.44 . . . . 0.0 111.121 -179.812 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . -75.61 -120.61 0.13 Allowed Glycine 0 CA--C 1.522 0.469 0 C-N-CA 120.829 -0.701 . . . . 0.0 112.68 -179.848 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 144' ' ' PRO . . . . . . . . . . . . . 56.1 Cg_endo -69.64 -23.65 31.09 Favored 'Trans proline' 0 C--N 1.348 0.54 0 C-N-CA 122.489 2.126 . . . . 0.0 112.433 179.923 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 145' ' ' MET . . . . . 0.433 ' HB3' ' OH ' ' A' ' 160' ' ' TYR . 48.8 mtt -53.62 -58.85 5.7 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.103 -0.499 . . . . 0.0 111.84 -179.712 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 146' ' ' THR . . . . . . . . . . . . . 9.0 t -56.03 -32.45 64.04 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.327 -0.397 . . . . 0.0 111.888 -179.118 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 43.0 mt-10 -70.41 -41.16 73.31 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.645 -0.252 . . . . 0.0 111.329 -179.735 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 148' ' ' SER . . . . . . . . . . . . . 67.4 m -69.74 -41.81 74.76 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.432 -0.349 . . . . 0.0 111.304 -179.329 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 149' ' ' ALA . . . . . . . . . . . . . . . -70.23 -37.54 75.0 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.255 -0.429 . . . . 0.0 111.444 -179.656 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 150' ' ' SER . . . . . . . . . . . . . 75.8 m -68.2 -4.12 12.93 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.381 -0.372 . . . . 0.0 111.057 179.98 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 151' ' ' GLN . . . . . . . . . . . . . 50.4 mt-30 -117.66 4.29 12.33 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.333 -0.394 . . . . 0.0 111.043 179.876 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 7.9 tpm_? -83.81 -51.81 6.9 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 120.971 0.415 . . . . 0.0 110.617 179.863 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 153' ' ' SER . . . . . 0.565 ' HB2' HG12 ' A' ' 156' ' ' ILE . 35.3 m -157.65 172.9 17.69 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 115.768 -0.651 . . . . 0.0 110.544 179.612 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 154' ' ' SER . . . . . . . . . . . . . 66.4 p -71.86 -37.92 70.14 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-O 120.828 0.347 . . . . 0.0 110.433 179.432 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -76.63 -34.71 43.23 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 121.001 -0.619 . . . . 0.0 112.646 179.848 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 156' ' ' ILE . . . . . 0.565 HG12 ' HB2' ' A' ' 153' ' ' SER . 34.2 mm -59.52 -36.76 66.59 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-O 120.84 0.353 . . . . 0.0 111.167 179.958 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 157' ' ' LYS . . . . . . . . . . . . . 86.4 tttt -61.23 -54.99 37.25 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 116.078 -0.51 . . . . 0.0 111.524 -179.713 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 49.0 m -66.39 -38.99 88.76 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.964 -179.152 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 159' ' ' LEU . . . . . . . . . . . . . 6.4 tt -68.55 -37.05 79.6 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.725 -0.216 . . . . 0.0 111.546 -179.119 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 160' ' ' TYR . . . . . 0.433 ' OH ' ' HB3' ' A' ' 145' ' ' MET . 37.7 t80 -74.09 -47.43 36.53 Favored 'General case' 0 C--N 1.33 -0.265 0 N-CA-C 111.807 0.299 . . . . 0.0 111.807 -179.087 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 27.9 m -57.21 -41.73 78.57 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-O 120.674 0.273 . . . . 0.0 111.453 -179.332 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 162' ' ' ARG . . . . . 0.405 ' O ' HD23 ' A' ' 166' ' ' LEU . 32.5 tpt180 -68.96 -43.92 74.01 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-O 120.867 0.365 . . . . 0.0 111.204 -179.913 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 163' ' ' LEU . . . . . 0.496 ' HG ' ' HB2' ' A' ' 208' ' ' PHE . 3.9 mp -62.41 -47.41 84.22 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 115.917 -0.583 . . . . 0.0 111.973 -179.247 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 164' ' ' ARG . . . . . 0.462 ' HG3' ' N ' ' A' ' 165' ' ' ASN . 4.5 ptt180 -67.64 -40.86 84.55 Favored 'General case' 0 C--N 1.329 -0.288 0 N-CA-C 111.829 0.307 . . . . 0.0 111.829 -178.926 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 165' ' ' ASN . . . . . 0.501 ' O ' HG23 ' A' ' 169' ' ' VAL . 5.5 m-20 -58.77 -52.07 67.28 Favored 'General case' 0 C--N 1.327 -0.372 0 N-CA-C 111.946 0.35 . . . . 0.0 111.946 -179.231 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 166' ' ' LEU . . . . . 0.405 HD23 ' O ' ' A' ' 162' ' ' ARG . 3.0 pp -68.22 -44.29 76.09 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.707 0.289 . . . . 0.0 111.455 -179.485 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 167' ' ' THR . . . . . . . . . . . . . 71.5 m -58.48 -50.87 72.18 Favored 'General case' 0 C--N 1.331 -0.218 0 N-CA-C 112.198 0.444 . . . . 0.0 112.198 -179.402 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 168' ' ' VAL . . . . . 0.409 HG13 ' N ' ' A' ' 169' ' ' VAL . 9.2 p -61.7 -41.12 89.22 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 N-CA-C 111.713 0.264 . . . . 0.0 111.713 -179.014 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 169' ' ' VAL . . . . . 0.501 HG23 ' O ' ' A' ' 165' ' ' ASN . 55.1 t -60.98 -59.41 4.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-O 120.769 0.318 . . . . 0.0 111.175 -179.883 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 170' ' ' LEU . . . . . 0.577 HD22 HG12 ' A' ' 203' ' ' VAL . 3.9 pp -61.86 -31.63 71.91 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.358 -0.383 . . . . 0.0 110.982 -179.455 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 171' ' ' TRP . . . . . 0.425 ' HD1' HD12 ' A' ' 170' ' ' LEU . 3.4 m0 -72.07 -32.08 66.71 Favored 'General case' 0 N--CA 1.463 0.205 0 CA-C-O 120.89 0.376 . . . . 0.0 110.095 178.952 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 172' ' ' ALA . . . . . . . . . . . . . . . -69.07 -7.17 33.37 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 115.982 -0.554 . . . . 0.0 110.692 179.646 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 173' ' ' ILE . . . . . 0.494 ' O ' HG12 ' A' ' 177' ' ' ILE . 29.2 mm -88.19 -26.65 5.65 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.263 0 CA-C-N 115.939 -0.573 . . . . 0.0 110.919 179.794 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 174' ' ' TYR . . . . . 0.465 ' HB2' ' HD3' ' A' ' 175' ' ' PRO . 34.4 m-85 -53.77 -48.81 92.25 Favored Pre-proline 0 C--N 1.332 -0.163 0 CA-C-N 116.311 -0.404 . . . . 0.0 111.574 -179.737 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 175' ' ' PRO . . . . . 0.465 ' HD3' ' HB2' ' A' ' 174' ' ' TYR . 84.8 Cg_exo -47.93 -32.39 17.69 Favored 'Trans proline' 0 C--N 1.352 0.722 0 C-N-CA 122.007 1.805 . . . . 0.0 112.199 179.558 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 176' ' ' PHE . . . . . 0.439 ' O ' ' HG ' ' A' ' 180' ' ' LEU . 81.5 m-85 -80.76 -50.59 9.67 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.059 -0.519 . . . . 0.0 111.803 -179.931 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 177' ' ' ILE . . . . . 0.494 HG12 ' O ' ' A' ' 173' ' ' ILE . 6.8 mm -62.07 -30.86 49.64 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.585 0 CA-C-N 116.104 -0.498 . . . . 0.0 112.022 -178.338 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 178' ' ' TRP . . . . . 0.435 ' HH2' ' HB2' ' A' ' 123' ' ' ARG . 73.9 t90 -73.6 -47.42 40.48 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-O 120.854 0.359 . . . . 0.0 110.662 179.714 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 179' ' ' LEU . . . . . 0.56 HD23 HD23 ' A' ' 180' ' ' LEU . 0.7 OUTLIER -70.96 -54.61 10.69 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 115.97 -0.559 . . . . 0.0 111.409 -179.287 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 180' ' ' LEU . . . . . 0.56 HD23 HD23 ' A' ' 179' ' ' LEU . 24.8 mt -64.78 -38.02 89.58 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.556 -0.293 . . . . 0.0 111.151 -179.779 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . -61.73 178.46 4.43 Favored Glycine 0 C--N 1.334 0.453 0 C-N-CA 120.086 -1.054 . . . . 0.0 112.231 179.185 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 182' ' ' PRO . . . . . 0.525 ' HA ' ' HB2' ' A' ' 186' ' ' ALA . 75.2 Cg_exo -48.02 -45.33 25.45 Favored 'Trans proline' 0 CA--C 1.534 0.507 0 C-N-CA 122.827 2.351 . . . . 0.0 113.613 179.856 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 183' ' ' PRO . . . . . 0.416 ' HD3' ' HB2' ' A' ' 182' ' ' PRO . 82.4 Cg_exo -46.65 -29.84 8.21 Favored 'Trans proline' 0 C--N 1.356 0.954 0 C-N-CA 122.14 1.894 . . . . 0.0 113.232 -179.788 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 184' ' ' GLY . . . . . 0.564 ' HA2' ' HD3' ' A' ' 123' ' ' ARG . . . -115.81 -128.19 4.28 Favored Glycine 0 N--CA 1.449 -0.453 0 C-N-CA 120.249 -0.977 . . . . 0.0 113.129 -179.663 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 185' ' ' VAL . . . . . . . . . . . . . 13.0 m -58.13 -27.33 31.65 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 N-CA-C 112.18 0.437 . . . . 0.0 112.18 -179.429 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 186' ' ' ALA . . . . . 0.525 ' HB2' ' HA ' ' A' ' 182' ' ' PRO . . . 59.34 82.25 0.15 Allowed 'General case' 0 C--N 1.33 -0.251 0 N-CA-C 111.983 0.364 . . . . 0.0 111.983 179.445 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 187' ' ' LEU . . . . . 0.56 ' HB2' HD12 ' A' ' 188' ' ' LEU . 8.6 mt -92.47 -49.59 6.05 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-O 121.039 0.447 . . . . 0.0 110.721 179.381 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 188' ' ' LEU . . . . . 0.56 HD12 ' HB2' ' A' ' 187' ' ' LEU . 6.9 mp -87.4 -166.38 1.56 Allowed 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 115.696 -0.684 . . . . 0.0 111.489 -179.233 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 189' ' ' THR . . . . . . . . . . . . . 10.2 m -94.39 137.43 22.71 Favored Pre-proline 0 C--N 1.33 -0.265 0 CA-C-N 115.743 -0.662 . . . . 0.0 110.498 -179.94 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 190' ' ' PRO . . . . . 0.473 ' O ' HG23 ' A' ' 194' ' ' VAL . 87.6 Cg_exo -44.31 -47.01 11.2 Favored 'Trans proline' 0 C--N 1.35 0.612 0 C-N-CA 122.661 2.241 . . . . 0.0 113.097 -179.859 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 191' ' ' THR . . . . . . . . . . . . . 6.8 t -59.27 -39.47 83.02 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 120.817 0.342 . . . . 0.0 111.28 -179.906 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 192' ' ' VAL . . . . . . . . . . . . . 58.8 t -70.58 -45.42 74.44 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.262 -0.426 . . . . 0.0 111.171 -179.952 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 193' ' ' ASP . . . . . . . . . . . . . 30.5 t70 -57.54 -43.85 84.7 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.294 -0.412 . . . . 0.0 110.678 179.937 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 194' ' ' VAL . . . . . 0.473 HG23 ' O ' ' A' ' 190' ' ' PRO . 98.1 t -64.28 -35.72 74.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 115.944 -0.571 . . . . 0.0 110.559 179.743 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 195' ' ' ALA . . . . . . . . . . . . . . . -59.19 -47.87 83.72 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 120.824 0.345 . . . . 0.0 110.793 179.551 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 196' ' ' LEU . . . . . . . . . . . . . 61.3 mt -67.83 -40.73 83.71 Favored 'General case' 0 C--N 1.332 -0.172 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.705 179.681 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 197' ' ' ILE . . . . . . . . . . . . . 14.3 mm -59.98 -58.18 8.37 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.239 0 CA-C-N 116.041 -0.527 . . . . 0.0 110.348 179.436 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 198' ' ' VAL . . . . . . . . . . . . . 64.1 t -52.28 -34.21 18.05 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.515 0 CA-C-N 115.599 -0.728 . . . . 0.0 109.311 178.469 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 199' ' ' TYR . . . . . 0.479 ' O ' HG23 ' A' ' 203' ' ' VAL . 64.9 t80 -69.32 -41.16 77.08 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 115.378 -0.828 . . . . 0.0 110.401 179.83 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 200' ' ' LEU . . . . . 0.438 HD11 HG13 ' A' ' 177' ' ' ILE . 31.4 mt -59.03 -54.81 42.91 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 115.563 -0.744 . . . . 0.0 111.524 -179.521 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 201' ' ' ASP . . . . . . . . . . . . . 10.7 m-20 -60.23 -38.64 84.04 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.322 -0.399 . . . . 0.0 110.888 -179.853 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 202' ' ' LEU . . . . . 0.436 HD11 ' HA2' ' A' ' 11' ' ' GLY . 2.0 mt -66.81 -28.43 68.37 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 115.868 -0.606 . . . . 0.0 111.409 -179.637 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 203' ' ' VAL . . . . . 0.577 HG12 HD22 ' A' ' 170' ' ' LEU . 41.3 t -79.47 -36.37 17.72 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.439 -0.346 . . . . 0.0 110.841 -179.055 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 204' ' ' THR . . . . . 0.434 ' O ' ' CD1' ' A' ' 208' ' ' PHE . 27.7 m -63.46 -58.32 7.43 Favored 'General case' 0 C--N 1.324 -0.512 0 C-N-CA 120.575 -0.45 . . . . 0.0 110.928 179.768 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 205' ' ' LYS . . . . . 0.74 ' HE2' ' HB2' ' A' ' 47' ' ' ALA . 44.2 mttp -66.32 -58.57 5.04 Favored 'General case' 0 C--N 1.331 -0.229 0 N-CA-C 112.624 0.602 . . . . 0.0 112.624 -178.254 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 43.8 t -70.83 -36.68 65.46 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.374 0 N-CA-C 112.182 0.438 . . . . 0.0 112.182 -178.444 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 207' ' ' GLY . . . . . 0.518 ' O ' HG13 ' A' ' 211' ' ' ILE . . . -61.54 -60.38 8.3 Favored Glycine 0 N--CA 1.452 -0.234 0 C-N-CA 120.58 -0.819 . . . . 0.0 113.598 -178.561 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 208' ' ' PHE . . . . . 0.496 ' HB2' ' HG ' ' A' ' 163' ' ' LEU . 0.1 OUTLIER -70.83 -26.66 63.38 Favored 'General case' 0 N--CA 1.464 0.249 0 CA-C-N 117.14 0.47 . . . . 0.0 111.515 -178.9 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 209' ' ' GLY . . . . . 0.508 ' O ' ' HB3' ' A' ' 212' ' ' ALA . . . -68.29 -32.65 76.24 Favored Glycine 0 N--CA 1.449 -0.49 0 N-CA-C 111.81 -0.516 . . . . 0.0 111.81 179.084 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 210' ' ' PHE . . . . . . . . . . . . . 0.8 OUTLIER -71.62 -48.47 47.74 Favored 'General case' 0 CA--C 1.512 -0.494 0 N-CA-C 108.053 -1.092 . . . . 0.0 108.053 178.491 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 211' ' ' ILE . . . . . 0.518 HG13 ' O ' ' A' ' 207' ' ' GLY . 4.9 mt -63.61 -27.75 43.58 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.544 0 N-CA-C 107.645 -1.243 . . . . 0.0 107.645 176.65 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 212' ' ' ALA . . . . . 0.508 ' HB3' ' O ' ' A' ' 209' ' ' GLY . . . -64.42 -40.97 96.79 Favored 'General case' 0 N--CA 1.45 -0.463 0 CA-C-N 114.583 -1.19 . . . . 0.0 110.5 179.793 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 213' ' ' LEU . . . . . . . . . . . . . 91.5 mt -70.52 -55.07 9.78 Favored 'General case' 0 N--CA 1.461 0.105 0 CA-C-N 115.489 -0.778 . . . . 0.0 111.748 -179.671 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 214' ' ' ASP . . . . . . . . . . . . . 25.1 m-20 -53.98 -49.92 67.73 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.28 -0.418 . . . . 0.0 111.648 -179.273 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 215' ' ' ALA . . . . . . . . . . . . . . . -59.8 -57.51 12.6 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.372 -0.376 . . . . 0.0 111.48 -179.633 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 216' ' ' ALA . . . . . . . . . . . . . . . -57.66 -35.31 70.38 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.31 -0.405 . . . . 0.0 111.421 -179.703 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 217' ' ' ALA . . . . . . . . . . . . . . . -63.67 -31.75 73.02 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 121.001 0.429 . . . . 0.0 110.424 179.831 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 218' ' ' THR . . . . . . . . . . . . . 93.8 m . . . . . 0 C--N 1.33 -0.256 0 CA-C-N 115.759 -0.655 . . . . 0.0 110.79 179.532 . . . . . . . . 0 0 . 1 . 019 nuclear build core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.342 0 N-CA-C 112.789 -0.124 . . . . 0.0 112.789 . . . . . . . . . 0 0 . 1 . 019 nuclear build core ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 49.2 tp -74.1 -35.37 64.18 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-O 120.782 0.325 . . . . 0.0 110.921 179.951 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 82.7 p -62.34 -31.63 72.29 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.447 -179.774 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 28.9 p -54.23 -35.78 62.81 Favored 'General case' 0 C--N 1.332 -0.175 0 CA-C-N 116.368 -0.378 . . . . 0.0 111.276 -179.906 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 7' ' ' LEU . . . . . . . . . . . . . 4.2 mm? -59.79 -50.73 72.66 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.202 -179.847 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 8' ' ' PHE . . . . . 0.664 ' HB2' ' HB2' ' A' ' 55' ' ' ALA . 64.2 m-85 -65.5 -34.91 79.37 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.9 -179.829 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 9' ' ' TRP . . . . . 0.416 ' O ' HG12 ' A' ' 13' ' ' ILE . 29.4 m95 -65.27 -44.77 87.0 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.292 -179.668 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 75.3 mt -60.51 -41.43 94.33 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 115.639 -0.71 . . . . 0.0 110.095 179.396 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -64.86 -34.65 90.46 Favored Glycine 0 N--CA 1.448 -0.501 0 C-N-CA 120.677 -0.773 . . . . 0.0 111.667 179.304 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -65.5 -31.32 72.33 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-O 120.849 0.357 . . . . 0.0 110.388 179.602 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 13' ' ' ILE . . . . . 0.416 HG12 ' O ' ' A' ' 9' ' ' TRP . 42.3 mm -67.72 -48.47 75.89 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 116.032 -0.531 . . . . 0.0 110.153 179.339 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -61.57 -28.12 69.2 Favored Glycine 0 N--CA 1.45 -0.386 0 C-N-CA 120.698 -0.763 . . . . 0.0 111.81 179.436 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 15' ' ' MET . . . . . 0.56 ' HE3' ' CB ' ' A' ' 47' ' ' ALA . 23.2 mmt -75.07 -39.43 60.87 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.731 0.3 . . . . 0.0 110.645 179.693 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 20.6 tp -59.09 -40.64 85.9 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.312 179.345 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 41.3 t -69.94 -45.52 76.49 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.215 0 CA-C-N 115.902 -0.59 . . . . 0.0 111.114 -179.938 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -63.84 -49.59 67.07 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.562 -0.827 . . . . 0.0 111.686 179.635 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 85.1 m -50.24 -45.23 53.92 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 115.448 -0.376 . . . . 0.0 111.014 179.767 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 77.9 mt -71.89 -39.3 69.68 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.382 179.764 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -64.1 -30.62 71.67 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.659 0.266 . . . . 0.0 111.528 -179.626 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 22' ' ' PHE . . . . . 0.575 ' HB2' HG22 ' A' ' 41' ' ' VAL . 6.3 m-85 -90.84 -31.12 16.58 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.503 -0.317 . . . . 0.0 111.113 -179.388 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -71.58 -49.78 37.27 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-O 120.907 0.384 . . . . 0.0 110.841 179.797 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 24' ' ' TRP . . . . . . . . . . . . . 1.2 t-105 -60.32 -41.61 93.85 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 115.893 -0.594 . . . . 0.0 110.72 179.797 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.328 -0.341 0 CA-C-N 116.356 -0.384 . . . . 0.0 110.665 179.619 . . . . . . . . 0 0 . 1 . 019 nuclear build core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.342 0 N-CA-C 112.561 -0.216 . . . . 0.0 112.561 . . . . . . . . . 0 0 . 1 . 019 nuclear build core ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 45.8 mt-10 -85.58 -20.82 28.98 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.672 0.272 . . . . 0.0 111.05 179.953 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 34' ' ' ARG . . . . . 0.455 ' O ' HG23 ' A' ' 38' ' ' VAL . 56.7 ttp180 -50.44 -29.51 10.45 Favored 'General case' 0 C--N 1.332 -0.175 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.339 -179.761 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 37.2 mmt180 -64.59 -43.92 92.3 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.329 -0.396 . . . . 0.0 110.953 179.981 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 64.8 m-85 -69.36 -33.76 73.56 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 116.13 -0.486 . . . . 0.0 111.44 -179.596 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 37' ' ' TYR . . . . . . . . . . . . . 54.2 m-85 -70.81 -53.01 16.93 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.533 -179.386 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 38' ' ' VAL . . . . . 0.455 HG23 ' O ' ' A' ' 34' ' ' ARG . 87.4 t -56.82 -36.79 50.75 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.249 0 CA-C-O 121.18 0.514 . . . . 0.0 110.21 179.509 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 40.9 m -66.76 -47.53 71.93 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 115.51 -0.768 . . . . 0.0 110.525 179.222 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 40' ' ' LEU . . . . . 0.405 ' O ' HG13 ' A' ' 43' ' ' ILE . 21.9 tp -57.1 -47.57 80.73 Favored 'General case' 0 C--O 1.235 0.3 0 CA-C-N 115.67 -0.695 . . . . 0.0 110.787 179.881 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 41' ' ' VAL . . . . . 0.575 HG22 ' HB2' ' A' ' 22' ' ' PHE . 94.8 t -63.05 -34.81 68.74 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-N 115.81 -0.632 . . . . 0.0 110.249 179.436 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -58.78 -39.79 94.18 Favored Glycine 0 N--CA 1.449 -0.471 0 CA-C-N 115.689 -0.687 . . . . 0.0 112.238 179.667 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 43' ' ' ILE . . . . . 0.609 HG22 ' HE3' ' A' ' 205' ' ' LYS . 0.1 OUTLIER -67.93 -50.97 54.54 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.166 0 CA-C-O 120.695 0.283 . . . . 0.0 110.984 179.851 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 50.5 m -63.59 -25.28 68.16 Favored 'General case' 0 C--N 1.331 -0.199 0 CA-C-O 120.824 0.345 . . . . 0.0 110.945 179.895 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -77.81 -52.15 5.55 Favored Glycine 0 N--CA 1.452 -0.263 0 C-N-CA 120.949 -0.643 . . . . 0.0 112.865 -179.542 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 46' ' ' ILE . . . . . 0.72 HD12 HD12 ' A' ' 78' ' ' LEU . 10.5 pt -58.32 -40.92 79.82 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.242 0 CA-C-O 120.874 0.369 . . . . 0.0 110.975 -179.75 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 47' ' ' ALA . . . . . 0.669 ' HB2' ' HE2' ' A' ' 205' ' ' LYS . . . -68.12 -40.24 82.58 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.124 179.468 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 48' ' ' ALA . . . . . 0.528 ' HB2' ' HB3' ' A' ' 15' ' ' MET . . . -54.59 -45.42 73.61 Favored 'General case' 0 C--O 1.233 0.197 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.31 -179.666 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 27.6 m -73.05 -33.9 44.0 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.257 -0.429 . . . . 0.0 111.26 -179.68 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -61.67 -37.75 85.22 Favored 'General case' 0 C--N 1.331 -0.21 0 CA-C-O 121.102 0.477 . . . . 0.0 110.576 179.256 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 51' ' ' TYR . . . . . 0.487 ' HB3' ' O ' ' A' ' 8' ' ' PHE . 29.6 m-85 -72.85 -35.63 67.28 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 115.767 -0.651 . . . . 0.0 110.266 179.682 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -66.08 -40.88 91.18 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 115.798 -0.637 . . . . 0.0 111.082 179.3 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 27.6 m -74.1 -41.52 52.03 Favored 'Isoleucine or valine' 0 C--O 1.231 0.123 0 CA-C-N 116.47 -0.332 . . . . 0.0 111.016 179.95 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 54' ' ' MET . . . . . 0.623 ' HG2' ' HG2' ' A' ' 71' ' ' PRO . 72.0 mtm -64.93 -36.21 83.65 Favored 'General case' 0 CA--C 1.519 -0.233 0 CA-C-O 121.171 0.51 . . . . 0.0 109.831 179.128 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 55' ' ' ALA . . . . . 0.664 ' HB2' ' HB2' ' A' ' 8' ' ' PHE . . . -69.55 -16.71 63.47 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 115.489 -0.778 . . . . 0.0 111.193 179.764 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 73.5 mt -97.06 2.55 51.48 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.328 -0.396 . . . . 0.0 111.407 -179.632 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 84.75 3.23 88.28 Favored Glycine 0 N--CA 1.452 -0.258 0 C-N-CA 120.628 -0.796 . . . . 0.0 112.941 179.66 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 49.2 t -69.87 132.94 32.67 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-O 120.631 0.253 . . . . 0.0 110.907 179.875 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 59' ' ' GLY . . . . . 0.695 ' HA3' ' HD3' ' A' ' 71' ' ' PRO . . . 88.56 -13.01 63.45 Favored Glycine 0 N--CA 1.449 -0.476 0 C-N-CA 120.656 -0.783 . . . . 0.0 112.487 -179.866 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 60' ' ' TRP . . . . . . . . . . . . . 15.5 m0 -66.2 89.46 0.13 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.833 0.349 . . . . 0.0 110.7 179.901 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 61' ' ' VAL . . . . . 0.523 HG13 HG23 ' A' ' 68' ' ' VAL . 4.0 p -101.52 132.32 21.94 Favored Pre-proline 0 CA--C 1.532 0.265 0 CA-C-N 116.266 -0.424 . . . . 0.0 110.928 179.928 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 62' ' ' PRO . . . . . 0.452 ' HD3' ' HA ' ' A' ' 61' ' ' VAL . 4.6 Cg_exo -76.94 151.21 30.83 Favored 'Trans proline' 0 C--N 1.35 0.617 0 C-N-CA 122.673 2.249 . . . . 0.0 112.494 -179.763 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 73.3 t -142.32 91.84 0.5 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 115.964 -0.562 . . . . 0.0 110.804 179.774 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . 59.56 -87.43 0.02 OUTLIER 'General case' 0 N--CA 1.463 0.183 0 CA-C-N 116.097 -0.501 . . . . 0.0 111.529 179.962 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 10.3 pt-20 -124.21 -16.26 6.51 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.903 0.383 . . . . 0.0 110.673 179.972 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 66' ' ' ARG . . . . . 0.431 HH11 ' HD2' ' A' ' 66' ' ' ARG . 64.6 mtt180 -104.58 160.77 14.68 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 115.922 -0.581 . . . . 0.0 110.362 179.535 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 37.2 m -120.97 142.66 49.56 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.971 0.415 . . . . 0.0 111.473 -179.613 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 68' ' ' VAL . . . . . 0.523 HG23 HG13 ' A' ' 61' ' ' VAL . 15.3 m -131.68 145.04 35.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 115.799 -0.637 . . . . 0.0 110.552 179.609 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 69' ' ' PHE . . . . . 0.406 ' C ' ' HD2' ' A' ' 71' ' ' PRO . 16.7 m-85 -109.48 115.84 30.68 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.364 -0.38 . . . . 0.0 110.365 -179.358 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 70' ' ' VAL . . . . . 0.741 HG12 ' HD3' ' A' ' 71' ' ' PRO . 0.8 OUTLIER -64.59 -36.79 19.28 Favored Pre-proline 0 CA--C 1.541 0.627 0 N-CA-C 112.701 0.63 . . . . 0.0 112.701 -179.321 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 71' ' ' PRO . . . . . 0.741 ' HD3' HG12 ' A' ' 70' ' ' VAL . 61.4 Cg_endo -70.52 -20.81 30.77 Favored 'Trans proline' 0 C--N 1.36 1.154 0 C-N-CA 121.934 1.756 . . . . 0.0 113.382 -179.451 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 46.6 ttp180 -73.06 -55.13 6.93 Favored 'General case' 0 C--O 1.235 0.323 0 N-CA-C 111.658 0.244 . . . . 0.0 111.658 -179.031 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 73' ' ' TYR . . . . . 0.431 ' O ' HG13 ' A' ' 77' ' ' ILE . 11.8 m-85 -65.84 -37.54 86.46 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.907 0.384 . . . . 0.0 110.022 -179.883 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 74' ' ' ILE . . . . . 0.529 ' HA ' HD12 ' A' ' 77' ' ' ILE . 0.4 OUTLIER -67.22 -41.23 86.5 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.219 0 CA-C-N 116.058 -0.519 . . . . 0.0 110.631 179.704 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 75' ' ' ASP . . . . . 0.433 ' O ' HG23 ' A' ' 79' ' ' THR . 17.7 t70 -55.08 -39.7 69.57 Favored 'General case' 0 CA--C 1.519 -0.245 0 N-CA-C 109.584 -0.524 . . . . 0.0 109.584 179.235 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 76' ' ' TRP . . . . . 0.485 ' HZ2' HG23 ' A' ' 197' ' ' ILE . 30.7 m0 -68.44 -32.52 72.6 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 115.927 -0.579 . . . . 0.0 110.683 179.61 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 77' ' ' ILE . . . . . 0.629 ' HA ' ' HG3' ' A' ' 109' ' ' MET . 92.2 mt -60.95 -41.64 89.79 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.245 0 CA-C-N 116.104 -0.498 . . . . 0.0 111.954 -179.828 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 78' ' ' LEU . . . . . 0.72 HD12 HD12 ' A' ' 46' ' ' ILE . 0.7 OUTLIER -91.38 -30.02 16.76 Favored 'General case' 0 CA--C 1.536 0.409 0 N-CA-C 113.392 0.886 . . . . 0.0 113.392 -178.883 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 79' ' ' THR . . . . . 0.438 HG22 ' CD1' ' A' ' 46' ' ' ILE . 46.0 p -75.2 -53.32 9.01 Favored 'General case' 0 N--CA 1.47 0.558 0 N-CA-C 113.447 0.906 . . . . 0.0 113.447 -178.275 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 80' ' ' THR . . . . . 0.617 HG21 ' HE1' ' A' ' 109' ' ' MET . 7.3 m -51.47 -48.95 85.04 Favored Pre-proline 0 C--N 1.329 -0.312 0 N-CA-C 112.948 0.721 . . . . 0.0 112.948 -178.36 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 81' ' ' PRO . . . . . 0.569 ' HD2' ' N ' ' A' ' 80' ' ' THR . 23.3 Cg_endo -58.99 -26.35 81.2 Favored 'Trans proline' 0 C--N 1.351 0.659 0 C-N-CA 121.72 1.613 . . . . 0.0 111.846 -179.511 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 82' ' ' LEU . . . . . . . . . . . . . 14.1 tp -76.73 -36.5 57.12 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 115.908 -0.587 . . . . 0.0 110.557 179.991 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 83' ' ' ILE . . . . . 0.518 HD13 HD13 ' A' ' 43' ' ' ILE . 38.8 mm -67.91 -51.22 51.96 Favored 'Isoleucine or valine' 0 C--O 1.234 0.275 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.137 179.086 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 84' ' ' VAL . . . . . 0.765 HG11 HD22 ' A' ' 105' ' ' ASN . 27.0 m -61.14 -31.13 49.24 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.214 0 CA-C-N 116.014 -0.539 . . . . 0.0 109.632 179.129 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 85' ' ' TYR . . . . . 0.408 ' HB2' ' O ' ' A' ' 81' ' ' PRO . 58.6 t80 -65.23 -34.47 78.44 Favored 'General case' 0 N--CA 1.452 -0.332 0 CA-C-N 115.638 -0.71 . . . . 0.0 109.36 178.965 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 86' ' ' PHE . . . . . . . . . . . . . 4.2 t80 -61.39 -51.63 67.98 Favored 'General case' 0 C--O 1.231 0.131 0 CA-C-N 115.586 -0.734 . . . . 0.0 110.064 179.222 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 7.4 mt -65.05 -28.69 69.65 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 121.309 0.576 . . . . 0.0 109.772 179.66 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -72.57 -27.43 69.43 Favored Glycine 0 N--CA 1.45 -0.41 0 CA-C-N 115.2 -0.909 . . . . 0.0 111.545 179.139 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 52.8 mt -73.21 -43.35 61.42 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 121.006 0.431 . . . . 0.0 110.549 179.652 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 59.1 mt -60.14 -33.19 71.82 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 115.707 -0.679 . . . . 0.0 111.047 179.887 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 91' ' ' ALA . . . . . 0.566 ' HB1' ' HB2' ' A' ' 148' ' ' SER . . . -85.76 -47.97 9.25 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.514 -179.532 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 89.27 61.15 1.41 Allowed Glycine 0 N--CA 1.45 -0.378 0 C-N-CA 120.811 -0.709 . . . . 0.0 112.383 -179.742 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 93' ' ' LEU . . . . . 0.442 HD11 ' HG2' ' A' ' 145' ' ' MET . 6.5 mp -72.76 179.12 3.78 Favored 'General case' 0 C--N 1.332 -0.184 0 CA-C-O 120.753 0.311 . . . . 0.0 110.866 -179.951 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 94' ' ' ASP . . . . . . . . . . . . . 30.3 m-20 -85.5 175.3 8.9 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.883 179.948 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 48.9 m -61.69 -46.71 88.52 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.1 -179.74 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 96' ' ' ARG . . . . . 0.404 ' O ' HG13 ' A' ' 100' ' ' ILE . 80.1 ttt180 -71.94 -45.36 61.42 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.934 -179.953 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 97' ' ' GLU . . . . . 0.482 ' HA ' HD12 ' A' ' 100' ' ' ILE . 19.1 mm-40 -52.51 -46.02 66.48 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.158 -179.802 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 98' ' ' PHE . . . . . 0.474 ' O ' HG12 ' A' ' 102' ' ' ILE . 2.2 m-85 -55.33 -50.87 68.52 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.384 -0.371 . . . . 0.0 110.236 179.385 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -60.85 -30.38 72.8 Favored Glycine 0 N--CA 1.45 -0.383 0 C-N-CA 120.862 -0.685 . . . . 0.0 112.627 -179.949 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 100' ' ' ILE . . . . . 0.482 HD12 ' HA ' ' A' ' 97' ' ' GLU . 94.5 mt -64.04 -43.3 97.52 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-O 120.89 0.376 . . . . 0.0 111.393 -179.857 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 29.4 t -72.26 -41.42 66.12 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.38 0 CA-C-N 116.34 -0.391 . . . . 0.0 111.592 179.976 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 102' ' ' ILE . . . . . 0.474 HG12 ' O ' ' A' ' 98' ' ' PHE . 35.2 mm -65.38 -40.07 87.27 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 CA-C-N 116.416 -0.357 . . . . 0.0 111.65 -179.266 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 11.0 t -67.92 -40.36 83.37 Favored 'General case' 0 C--O 1.234 0.239 0 CA-C-O 120.713 0.292 . . . . 0.0 110.939 -179.958 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 104' ' ' LEU . . . . . 0.426 HD22 ' HE2' ' A' ' 140' ' ' TYR . 29.2 tp -55.34 -51.54 66.4 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-N 116.349 -0.387 . . . . 0.0 110.079 179.311 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 105' ' ' ASN . . . . . 0.765 HD22 HG11 ' A' ' 84' ' ' VAL . 4.1 m-20 -58.05 -37.31 74.16 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 115.855 -0.611 . . . . 0.0 110.461 179.465 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 31.0 m -54.61 -41.1 69.56 Favored 'General case' 0 C--N 1.332 -0.184 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.659 179.706 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 0.6 OUTLIER -69.24 -36.42 72.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-O 121.258 0.551 . . . . 0.0 110.0 179.245 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 108' ' ' VAL . . . . . 0.426 HG23 ' O ' ' A' ' 104' ' ' LEU . 60.7 t -63.87 -42.63 96.47 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 115.406 -0.816 . . . . 0.0 111.571 -179.677 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 109' ' ' MET . . . . . 0.629 ' HG3' ' HA ' ' A' ' 77' ' ' ILE . 6.9 mmt -70.07 -44.04 69.92 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.407 -0.36 . . . . 0.0 110.961 -179.624 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 21.4 tp -60.73 -32.18 71.46 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 116.349 -0.387 . . . . 0.0 110.38 179.966 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -65.27 -56.63 11.65 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.019 -0.537 . . . . 0.0 110.612 179.398 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . -60.88 -30.0 71.94 Favored Glycine 0 C--N 1.332 0.334 0 C-N-CA 120.644 -0.789 . . . . 0.0 112.117 179.655 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 113' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER -57.68 -69.0 0.19 Allowed 'General case' 0 C--N 1.33 -0.266 0 CA-C-O 121.015 0.436 . . . . 0.0 110.255 179.585 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 114' ' ' ALA . . . . . 0.446 ' O ' HG13 ' A' ' 118' ' ' VAL . . . -64.6 -29.13 70.15 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 115.79 -0.641 . . . . 0.0 111.414 -179.969 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -51.92 -51.2 41.21 Favored Glycine 0 C--N 1.332 0.324 0 C-N-CA 121.081 -0.58 . . . . 0.0 112.672 -179.888 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -77.99 -15.01 59.31 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-O 120.542 0.21 . . . . 0.0 111.553 -179.781 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 117' ' ' MET . . . . . 0.45 ' HE2' HG21 ' A' ' 68' ' ' VAL . 37.5 ttm -100.67 18.46 19.24 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-O 120.692 0.282 . . . . 0.0 111.436 -179.464 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 118' ' ' VAL . . . . . 0.506 HG11 ' N ' ' A' ' 123' ' ' ARG . 27.4 m -74.03 144.76 82.65 Favored Pre-proline 0 C--N 1.328 -0.327 0 CA-C-N 116.692 -0.231 . . . . 0.0 111.141 179.802 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 119' ' ' PRO . . . . . . . . . . . . . 97.0 Cg_endo -87.53 -10.11 5.53 Favored 'Trans proline' 0 N--CA 1.458 -0.568 0 C-N-CA 122.709 2.273 . . . . 0.0 112.484 179.756 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -136.72 -108.26 0.89 Allowed Glycine 0 C--N 1.331 0.302 0 C-N-CA 120.706 -0.759 . . . . 0.0 112.907 -179.629 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 34.3 pt -124.53 12.26 4.72 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.156 0 CA-C-O 120.652 0.263 . . . . 0.0 111.664 -179.548 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 41.7 mt-10 -58.24 -18.26 25.18 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.779 0.323 . . . . 0.0 111.03 179.722 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 123' ' ' ARG . . . . . 0.506 ' N ' HG11 ' A' ' 118' ' ' VAL . 4.9 ptm180 -50.6 -31.39 15.77 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 116.107 -0.497 . . . . 0.0 111.504 -179.868 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 124' ' ' TYR . . . . . . . . . . . . . 30.4 m-85 -70.28 -33.03 71.08 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.458 -0.337 . . . . 0.0 111.017 -179.735 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 125' ' ' ALA . . . . . . . . . . . . . . . -71.24 -50.12 36.22 Favored 'General case' 0 C--O 1.235 0.333 0 CA-C-N 116.298 -0.41 . . . . 0.0 110.942 179.687 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 3.1 mm? -53.6 -52.76 58.77 Favored 'General case' 0 C--N 1.333 -0.137 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.53 179.739 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 127' ' ' PHE . . . . . 0.433 ' HZ ' ' HB3' ' A' ' 175' ' ' PRO . 6.5 t80 -64.88 -37.21 86.87 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.316 -0.402 . . . . 0.0 111.231 -179.615 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 128' ' ' GLY . . . . . . . . . . . . . . . -46.16 -47.75 15.4 Favored Glycine 0 C--O 1.237 0.283 0 C-N-CA 119.705 -1.235 . . . . 0.0 110.517 179.192 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 129' ' ' MET . . . . . . . . . . . . . 0.5 OUTLIER -72.18 -34.91 68.79 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 115.178 -0.511 . . . . 0.0 110.101 178.665 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -62.99 -37.26 94.66 Favored Glycine 0 C--N 1.332 0.331 0 CA-C-N 115.804 -0.634 . . . . 0.0 113.347 -179.515 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -73.56 -52.61 12.9 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.788 0.294 . . . . 0.0 110.755 -179.781 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 62.2 t -55.61 -42.0 66.93 Favored 'Isoleucine or valine' 0 C--O 1.234 0.28 0 CA-C-O 121.331 0.586 . . . . 0.0 109.546 179.128 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -68.69 -37.35 79.49 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 115.342 -0.844 . . . . 0.0 110.669 179.407 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 134' ' ' PHE . . . . . . . . . . . . . 87.7 t80 -55.88 -54.78 40.44 Favored 'General case' 0 N--CA 1.452 -0.363 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.135 179.669 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 135' ' ' ILE . . . . . 0.425 ' O ' HG22 ' A' ' 138' ' ' VAL . 32.8 mt -56.38 -33.53 38.49 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.363 0 CA-C-N 115.884 -0.598 . . . . 0.0 110.126 179.303 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . -61.65 -39.64 97.67 Favored Glycine 0 N--CA 1.449 -0.484 0 C-N-CA 120.072 -1.061 . . . . 0.0 111.295 178.784 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 137' ' ' LEU . . . . . . . . . . . . . 31.1 tp -68.75 -54.02 18.44 Favored 'General case' 0 C--N 1.332 -0.185 0 CA-C-O 120.598 0.237 . . . . 0.0 111.173 179.933 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 138' ' ' VAL . . . . . 0.425 HG22 ' O ' ' A' ' 135' ' ' ILE . 3.3 m -55.85 -31.68 30.59 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.176 0 CA-C-O 121.182 0.515 . . . . 0.0 109.9 179.957 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 139' ' ' TYR . . . . . . . . . . . . . 21.3 t80 -66.19 -38.62 88.45 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 115.429 -0.805 . . . . 0.0 110.289 178.674 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 140' ' ' TYR . . . . . 0.426 ' HE2' HD22 ' A' ' 104' ' ' LEU . 19.2 m-85 -65.28 -32.14 73.64 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 116.097 -0.501 . . . . 0.0 111.055 179.377 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 141' ' ' LEU . . . . . 0.49 HD23 ' SD ' ' A' ' 145' ' ' MET . 75.1 mt -69.9 -41.49 74.65 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-O 121.039 0.447 . . . . 0.0 110.351 -179.508 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 24.2 m -84.84 -10.58 11.53 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.631 0 CA-C-N 115.72 -0.673 . . . . 0.0 111.159 179.957 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . -76.91 -118.78 0.16 Allowed Glycine 0 CA--C 1.52 0.405 0 C-N-CA 120.894 -0.669 . . . . 0.0 112.986 -179.551 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 144' ' ' PRO . . . . . . . . . . . . . 55.8 Cg_endo -69.25 -30.19 25.08 Favored 'Trans proline' 0 C--N 1.349 0.6 0 C-N-CA 122.47 2.113 . . . . 0.0 112.825 -179.411 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 145' ' ' MET . . . . . 0.49 ' SD ' HD23 ' A' ' 141' ' ' LEU . 53.1 mtt -55.59 -31.14 61.97 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-O 120.726 0.298 . . . . 0.0 111.484 -179.664 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 146' ' ' THR . . . . . . . . . . . . . 14.3 m -71.12 -44.2 66.1 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.284 -0.416 . . . . 0.0 111.723 -179.45 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 43.6 mt-10 -75.92 -29.04 58.23 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.385 -0.371 . . . . 0.0 111.844 -179.411 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 148' ' ' SER . . . . . 0.566 ' HB2' ' HB1' ' A' ' 91' ' ' ALA . 66.2 m -70.26 -47.05 63.03 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 120.736 0.303 . . . . 0.0 111.281 -179.327 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 149' ' ' ALA . . . . . . . . . . . . . . . -72.6 -34.93 67.74 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.289 -0.414 . . . . 0.0 111.242 -179.833 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 150' ' ' SER . . . . . . . . . . . . . 47.7 t -70.42 -8.19 48.95 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.965 179.943 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 151' ' ' GLN . . . . . . . . . . . . . 47.9 mt-30 -122.32 10.04 9.85 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.262 -0.426 . . . . 0.0 111.255 -179.875 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 152' ' ' ARG . . . . . 0.635 ' HE ' HG13 ' A' ' 156' ' ' ILE . 1.2 tmm_? -85.05 -51.33 6.74 Favored 'General case' 0 C--N 1.332 -0.19 0 CA-C-O 120.979 0.418 . . . . 0.0 110.363 179.669 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 153' ' ' SER . . . . . 0.594 ' HB2' HG12 ' A' ' 156' ' ' ILE . 49.1 m -157.48 172.56 18.35 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 115.751 -0.659 . . . . 0.0 110.667 179.434 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 154' ' ' SER . . . . . . . . . . . . . 46.6 t -69.38 -42.17 75.52 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.339 -0.392 . . . . 0.0 110.76 179.754 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -77.28 -32.75 46.73 Favored Glycine 0 N--CA 1.452 -0.275 0 C-N-CA 120.948 -0.644 . . . . 0.0 113.029 -179.831 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 156' ' ' ILE . . . . . 0.635 HG13 ' HE ' ' A' ' 152' ' ' ARG . 32.2 mm -57.23 -38.65 62.72 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.199 0 CA-C-N 116.776 0.288 . . . . 0.0 111.356 -179.753 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 157' ' ' LYS . . . . . 0.435 ' O ' ' HB ' ' A' ' 161' ' ' VAL . 58.3 tttp -62.47 -43.48 98.72 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.385 -0.37 . . . . 0.0 111.372 -179.735 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 93.8 p -70.98 -48.32 53.95 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 116.102 -0.499 . . . . 0.0 111.551 -179.102 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 159' ' ' LEU . . . . . 0.436 ' O ' ' HB2' ' A' ' 163' ' ' LEU . 10.5 tt -62.08 -42.54 99.31 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.176 -179.395 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 160' ' ' TYR . . . . . . . . . . . . . 77.6 t80 -71.59 -36.87 71.0 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 116.263 -0.426 . . . . 0.0 111.987 -179.077 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 161' ' ' VAL . . . . . 0.538 HG12 ' N ' ' A' ' 162' ' ' ARG . 1.1 t -58.4 -53.64 43.69 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.686 0 N-CA-C 111.699 0.259 . . . . 0.0 111.699 -179.181 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 162' ' ' ARG . . . . . 0.538 ' N ' HG12 ' A' ' 161' ' ' VAL . 97.3 mtt180 -69.89 -41.15 75.13 Favored 'General case' 0 C--N 1.329 -0.317 0 N-CA-C 112.04 0.385 . . . . 0.0 112.04 -179.174 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 163' ' ' LEU . . . . . 0.45 ' O ' HD23 ' A' ' 166' ' ' LEU . 2.7 mp -62.49 -56.14 20.93 Favored 'General case' 0 C--N 1.329 -0.314 0 N-CA-C 112.277 0.473 . . . . 0.0 112.277 -178.674 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 164' ' ' ARG . . . . . . . . . . . . . 5.4 ppt_? -62.42 -40.63 97.18 Favored 'General case' 0 C--N 1.328 -0.356 0 N-CA-C 112.002 0.371 . . . . 0.0 112.002 -178.361 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 165' ' ' ASN . . . . . 0.448 ' O ' HG23 ' A' ' 169' ' ' VAL . 5.0 m-20 -54.73 -53.29 56.89 Favored 'General case' 0 C--O 1.237 0.402 0 CA-C-O 120.826 0.346 . . . . 0.0 111.557 -179.373 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 166' ' ' LEU . . . . . 0.48 ' O ' ' HG ' ' A' ' 170' ' ' LEU . 0.1 OUTLIER -67.67 -31.59 71.67 Favored 'General case' 0 C--N 1.331 -0.238 0 C-N-CA 120.847 -0.341 . . . . 0.0 111.022 -179.146 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 167' ' ' THR . . . . . 0.428 ' O ' ' HB2' ' A' ' 171' ' ' TRP . 17.7 m -59.75 -53.02 62.81 Favored 'General case' 0 C--N 1.333 -0.147 0 CA-C-O 120.842 0.353 . . . . 0.0 111.304 179.814 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 168' ' ' VAL . . . . . . . . . . . . . 58.4 t -58.97 -41.27 82.66 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.385 0 CA-C-N 115.785 -0.643 . . . . 0.0 111.749 -179.103 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 169' ' ' VAL . . . . . 0.448 HG23 ' O ' ' A' ' 165' ' ' ASN . 88.8 t -59.34 -64.87 0.51 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 N-CA-C 112.383 0.512 . . . . 0.0 112.383 -179.236 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 170' ' ' LEU . . . . . 0.48 ' HG ' ' O ' ' A' ' 166' ' ' LEU . 1.6 pp -61.04 -36.3 79.19 Favored 'General case' 0 N--CA 1.463 0.214 0 N-CA-C 112.219 0.451 . . . . 0.0 112.219 -178.67 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 171' ' ' TRP . . . . . 0.428 ' HB2' ' O ' ' A' ' 167' ' ' THR . 3.0 m0 -67.73 -29.4 68.62 Favored 'General case' 0 C--N 1.331 -0.231 0 C-N-CA 120.914 -0.314 . . . . 0.0 110.946 179.843 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 172' ' ' ALA . . . . . . . . . . . . . . . -73.28 -7.07 49.98 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 116.337 -0.392 . . . . 0.0 110.986 -179.938 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 173' ' ' ILE . . . . . 0.686 HG22 HD11 ' A' ' 177' ' ' ILE . 19.2 mm -87.97 -21.0 7.21 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.067 -0.515 . . . . 0.0 110.876 179.88 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 174' ' ' TYR . . . . . 0.409 ' HD2' ' HA ' ' A' ' 171' ' ' TRP . 13.0 m-85 -53.67 -48.53 92.95 Favored Pre-proline 0 CA--C 1.531 0.235 0 CA-C-N 116.249 -0.432 . . . . 0.0 111.478 -179.752 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 175' ' ' PRO . . . . . 0.433 ' HB3' ' HZ ' ' A' ' 127' ' ' PHE . 92.4 Cg_exo -46.48 -31.77 10.31 Favored 'Trans proline' 0 C--N 1.352 0.756 0 C-N-CA 122.173 1.915 . . . . 0.0 112.117 179.059 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 176' ' ' PHE . . . . . 0.466 ' O ' ' HG ' ' A' ' 180' ' ' LEU . 80.5 m-85 -80.25 -40.67 26.53 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 115.927 -0.578 . . . . 0.0 111.421 -179.893 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 177' ' ' ILE . . . . . 0.686 HD11 HG22 ' A' ' 173' ' ' ILE . 2.3 mm -65.2 -41.55 91.92 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.533 0 CA-C-N 116.346 -0.388 . . . . 0.0 111.838 -178.651 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 178' ' ' TRP . . . . . . . . . . . . . 63.9 t90 -73.65 -44.62 56.37 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.902 0.382 . . . . 0.0 111.064 -179.952 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 179' ' ' LEU . . . . . 0.535 ' O ' HG22 ' A' ' 185' ' ' VAL . 1.9 tm? -64.31 -51.86 61.36 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 115.952 -0.567 . . . . 0.0 111.451 -179.151 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 180' ' ' LEU . . . . . 0.712 HD22 HD11 ' A' ' 187' ' ' LEU . 20.7 mt -77.48 -44.98 27.04 Favored 'General case' 0 C--N 1.328 -0.336 0 N-CA-C 111.974 0.361 . . . . 0.0 111.974 -178.711 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 181' ' ' GLY . . . . . 0.412 ' HA3' ' OD1' ' A' ' 193' ' ' ASP . . . -57.5 174.99 1.91 Allowed Glycine 0 C--N 1.335 0.494 0 C-N-CA 120.365 -0.921 . . . . 0.0 112.771 179.927 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 182' ' ' PRO . . . . . 0.648 ' HA ' ' HB2' ' A' ' 186' ' ' ALA . 1.7 Cg_endo -44.99 -45.6 13.93 Favored 'Trans proline' 0 CA--C 1.537 0.671 0 C-N-CA 123.228 2.619 . . . . 0.0 113.84 179.615 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 183' ' ' PRO . . . . . 0.578 ' HD2' ' N ' ' A' ' 182' ' ' PRO . 18.5 Cg_endo -58.54 -4.75 1.97 Allowed 'Trans proline' 0 C--N 1.356 0.937 0 C-N-CA 121.967 1.778 . . . . 0.0 113.017 -179.762 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 184' ' ' GLY . . . . . 0.434 ' HA3' ' O ' ' A' ' 179' ' ' LEU . . . -122.09 -87.93 0.91 Allowed Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.63 -0.795 . . . . 0.0 112.636 179.94 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 185' ' ' VAL . . . . . 0.535 HG22 ' O ' ' A' ' 179' ' ' LEU . 4.3 m -123.63 -4.64 7.19 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 N-CA-C 111.658 0.244 . . . . 0.0 111.658 -179.822 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 186' ' ' ALA . . . . . 0.648 ' HB2' ' HA ' ' A' ' 182' ' ' PRO . . . 51.62 88.88 0.03 OUTLIER 'General case' 0 N--CA 1.462 0.156 0 CA-C-N 116.398 -0.364 . . . . 0.0 111.367 179.833 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 187' ' ' LEU . . . . . 0.712 HD11 HD22 ' A' ' 180' ' ' LEU . 20.2 mt -91.76 -49.4 6.29 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.396 -0.366 . . . . 0.0 111.774 -179.502 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 188' ' ' LEU . . . . . . . . . . . . . 87.5 mt -97.36 -94.3 0.22 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.462 -0.336 . . . . 0.0 111.539 -179.138 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 189' ' ' THR . . . . . . . . . . . . . 1.8 t -160.42 149.36 13.72 Favored Pre-proline 0 C--N 1.327 -0.39 0 CA-C-N 116.284 -0.416 . . . . 0.0 111.282 -179.499 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 190' ' ' PRO . . . . . 0.437 ' O ' HG23 ' A' ' 194' ' ' VAL . 72.9 Cg_exo -50.37 -42.98 46.25 Favored 'Trans proline' 0 C--N 1.349 0.557 0 C-N-CA 122.591 2.194 . . . . 0.0 112.932 -179.853 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 191' ' ' THR . . . . . . . . . . . . . 70.9 p -55.33 -46.55 76.35 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-O 120.77 0.319 . . . . 0.0 111.514 -179.729 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 192' ' ' VAL . . . . . . . . . . . . . 39.4 t -68.36 -50.6 55.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.626 -179.745 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 193' ' ' ASP . . . . . 0.428 ' OD1' HG22 ' A' ' 177' ' ' ILE . 30.8 t70 -55.24 -49.58 71.66 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.752 0.311 . . . . 0.0 111.284 -179.824 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 194' ' ' VAL . . . . . 0.437 HG23 ' O ' ' A' ' 190' ' ' PRO . 76.1 t -59.62 -36.44 65.28 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.886 179.914 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 195' ' ' ALA . . . . . . . . . . . . . . . -58.71 -46.72 86.68 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.41 -0.359 . . . . 0.0 110.968 179.848 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 196' ' ' LEU . . . . . . . . . . . . . 85.3 mt -67.71 -40.17 84.3 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.348 -0.387 . . . . 0.0 110.615 179.692 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 197' ' ' ILE . . . . . 0.485 HG23 ' HZ2' ' A' ' 76' ' ' TRP . 16.2 mm -59.97 -59.86 3.38 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 CA-C-N 115.988 -0.551 . . . . 0.0 110.302 179.388 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 198' ' ' VAL . . . . . . . . . . . . . 76.3 t -52.78 -34.26 19.81 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.515 0 CA-C-N 115.458 -0.792 . . . . 0.0 109.454 178.394 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 199' ' ' TYR . . . . . . . . . . . . . 65.7 t80 -70.07 -34.96 73.85 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.222 -0.899 . . . . 0.0 110.63 179.753 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 200' ' ' LEU . . . . . 0.468 ' O ' HG12 ' A' ' 203' ' ' VAL . 28.0 mt -67.95 -39.02 83.47 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 115.845 -0.616 . . . . 0.0 111.27 -179.631 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 201' ' ' ASP . . . . . 0.403 ' HB2' ' OH ' ' A' ' 51' ' ' TYR . 0.9 OUTLIER -71.9 -32.35 67.31 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-N 116.099 -0.501 . . . . 0.0 110.776 179.804 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 202' ' ' LEU . . . . . . . . . . . . . 3.7 mt -70.91 -36.5 72.72 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.0 -0.545 . . . . 0.0 111.736 -179.556 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 203' ' ' VAL . . . . . 0.473 ' O ' ' HA3' ' A' ' 207' ' ' GLY . 11.8 p -74.62 -36.32 40.5 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.613 -0.267 . . . . 0.0 111.643 -179.008 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 204' ' ' THR . . . . . 0.462 HG23 ' CE2' ' A' ' 208' ' ' PHE . 43.7 m -67.69 -57.21 6.78 Favored 'General case' 0 C--N 1.326 -0.44 0 C-N-CA 120.84 -0.344 . . . . 0.0 111.53 -179.969 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 205' ' ' LYS . . . . . 0.669 ' HE2' ' HB2' ' A' ' 47' ' ' ALA . 60.0 mttp -69.49 -59.02 3.25 Favored 'General case' 0 C--N 1.329 -0.299 0 N-CA-C 112.549 0.574 . . . . 0.0 112.549 -178.472 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 22.1 t -72.57 -37.53 56.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 N-CA-C 112.158 0.429 . . . . 0.0 112.158 -178.473 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 207' ' ' GLY . . . . . 0.473 ' HA3' ' O ' ' A' ' 203' ' ' VAL . . . -61.51 -55.36 29.34 Favored Glycine 0 CA--C 1.517 0.195 0 C-N-CA 120.51 -0.852 . . . . 0.0 112.922 -179.464 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 208' ' ' PHE . . . . . 0.483 ' O ' ' N ' ' A' ' 212' ' ' ALA . 2.4 m-30 -61.03 -41.58 96.84 Favored 'General case' 0 C--O 1.221 -0.399 0 N-CA-C 110.026 -0.361 . . . . 0.0 110.026 -179.882 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 209' ' ' GLY . . . . . 0.499 ' O ' ' HB3' ' A' ' 212' ' ' ALA . . . -58.26 -37.57 87.4 Favored Glycine 0 N--CA 1.451 -0.33 0 CA-C-N 115.372 -0.831 . . . . 0.0 112.873 179.492 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 210' ' ' PHE . . . . . . . . . . . . . 2.7 m-85 -68.79 -49.56 57.61 Favored 'General case' 0 CA--C 1.514 -0.407 0 N-CA-C 108.548 -0.908 . . . . 0.0 108.548 179.238 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 211' ' ' ILE . . . . . . . . . . . . . 64.9 mt -63.2 -27.45 43.13 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.553 0 N-CA-C 107.61 -1.256 . . . . 0.0 107.61 176.658 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 212' ' ' ALA . . . . . 0.499 ' HB3' ' O ' ' A' ' 209' ' ' GLY . . . -67.99 -38.02 82.18 Favored 'General case' 0 N--CA 1.448 -0.557 0 CA-C-N 114.488 -1.233 . . . . 0.0 110.527 -179.802 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 213' ' ' LEU . . . . . 0.411 ' HG ' ' O ' ' A' ' 209' ' ' GLY . 89.2 mt -70.26 -52.52 22.43 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-N 115.373 -0.831 . . . . 0.0 111.53 -179.606 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 214' ' ' ASP . . . . . . . . . . . . . 24.5 m-20 -57.89 -52.41 65.62 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.396 -0.366 . . . . 0.0 110.954 -179.878 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 215' ' ' ALA . . . . . . . . . . . . . . . -57.25 -53.57 56.66 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.216 179.817 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 216' ' ' ALA . . . . . . . . . . . . . . . -59.98 -31.33 69.8 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-N 116.22 -0.445 . . . . 0.0 111.319 179.947 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 217' ' ' ALA . . . . . . . . . . . . . . . -62.19 -38.67 89.97 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-O 120.949 0.404 . . . . 0.0 110.281 179.651 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 218' ' ' THR . . . . . . . . . . . . . 93.5 m . . . . . 0 C--N 1.33 -0.264 0 CA-C-N 115.821 -0.627 . . . . 0.0 110.635 179.322 . . . . . . . . 0 0 . 1 . 020 nuclear build core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.397 0 N-CA-C 112.224 -0.35 . . . . 0.0 112.224 . . . . . . . . . 0 0 . 1 . 020 nuclear build core ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 60.5 tp -73.92 -35.55 64.63 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-O 120.881 0.372 . . . . 0.0 110.822 -179.982 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 64.0 p -61.59 -29.94 70.35 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 115.958 -0.565 . . . . 0.0 111.399 -179.819 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 26.9 p -55.37 -35.61 65.45 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 116.365 -0.38 . . . . 0.0 111.118 -179.725 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 7' ' ' LEU . . . . . . . . . . . . . 9.3 mp -55.98 -53.71 53.58 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.093 179.898 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 8' ' ' PHE . . . . . 0.507 ' HB2' ' HB2' ' A' ' 55' ' ' ALA . 65.1 m-85 -62.43 -34.23 76.37 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.716 -179.887 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 9' ' ' TRP . . . . . . . . . . . . . 37.8 m95 -64.46 -41.3 96.59 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-O 121.214 0.53 . . . . 0.0 109.896 179.69 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 86.2 mt -65.91 -31.53 72.51 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-N 115.303 -0.862 . . . . 0.0 110.052 179.227 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 11' ' ' GLY . . . . . 0.464 ' O ' ' HG2' ' A' ' 15' ' ' MET . . . -68.22 -34.04 79.65 Favored Glycine 0 N--CA 1.448 -0.526 0 C-N-CA 120.823 -0.703 . . . . 0.0 111.43 179.268 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -69.45 -37.18 77.23 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.839 0.352 . . . . 0.0 110.421 179.415 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 50.1 mm -62.41 -53.44 47.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 115.918 -0.583 . . . . 0.0 110.939 179.601 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -56.33 -42.03 88.24 Favored Glycine 0 C--N 1.33 0.245 0 C-N-CA 120.747 -0.74 . . . . 0.0 112.161 179.889 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 15' ' ' MET . . . . . 0.464 ' HG2' ' O ' ' A' ' 11' ' ' GLY . 24.5 mmt -63.45 -41.87 98.64 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.737 0.303 . . . . 0.0 110.53 179.613 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 39.7 tp -54.19 -40.6 67.71 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.051 -0.522 . . . . 0.0 110.601 179.835 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 41.3 t -65.41 -49.03 80.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 115.963 -0.562 . . . . 0.0 111.067 179.955 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -63.31 -47.67 85.73 Favored Glycine 0 C--N 1.331 0.251 0 C-N-CA 120.769 -0.729 . . . . 0.0 112.219 179.724 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 24.9 m -50.32 -44.18 54.09 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-O 120.665 0.269 . . . . 0.0 111.295 -179.973 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 56.9 mt -71.43 -38.73 71.34 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 116.343 -0.39 . . . . 0.0 111.282 179.973 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -60.77 -32.18 71.5 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.242 -0.436 . . . . 0.0 111.549 -179.551 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 22' ' ' PHE . . . . . 0.629 ' HB2' HG22 ' A' ' 41' ' ' VAL . 2.8 m-85 -90.75 -34.46 15.34 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.419 -0.355 . . . . 0.0 111.209 -179.481 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -64.88 -48.49 74.06 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.245 -179.822 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 24' ' ' TRP . . . . . . . . . . . . . 3.6 t-105 -68.03 -53.63 24.34 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 115.906 -0.588 . . . . 0.0 111.25 -179.617 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.329 -0.315 0 CA-C-O 120.862 0.363 . . . . 0.0 111.114 -179.99 . . . . . . . . 0 0 . 1 . 020 nuclear build core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.453 -0.216 0 N-CA-C 112.523 -0.231 . . . . 0.0 112.523 . . . . . . . . . 0 0 . 1 . 020 nuclear build core ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 45.7 mt-10 -68.98 -20.72 64.18 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.69 0.281 . . . . 0.0 111.064 -179.901 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 34' ' ' ARG . . . . . 0.444 ' O ' HG23 ' A' ' 38' ' ' VAL . 99.9 mtt180 -49.28 -31.15 8.44 Favored 'General case' 0 C--N 1.332 -0.174 0 CA-C-N 116.123 -0.49 . . . . 0.0 111.681 -179.665 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 23.2 ttp180 -64.62 -47.89 76.91 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-O 120.805 0.336 . . . . 0.0 110.816 179.829 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 76.1 m-85 -67.12 -29.52 69.28 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.123 -0.489 . . . . 0.0 111.047 179.859 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 37' ' ' TYR . . . . . 0.447 ' O ' HG23 ' A' ' 41' ' ' VAL . 35.5 m-85 -71.48 -52.62 17.41 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.3 -179.628 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 38' ' ' VAL . . . . . 0.444 HG23 ' O ' ' A' ' 34' ' ' ARG . 84.9 t -56.75 -36.61 49.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-O 121.077 0.465 . . . . 0.0 110.263 179.664 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 17.3 m -69.07 -51.12 42.15 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 115.686 -0.688 . . . . 0.0 110.865 179.392 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 40' ' ' LEU . . . . . 0.408 HD23 ' CG ' ' A' ' 22' ' ' PHE . 11.4 tp -55.48 -50.81 68.92 Favored 'General case' 0 C--O 1.237 0.43 0 CA-C-N 115.914 -0.584 . . . . 0.0 110.707 -179.972 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 41' ' ' VAL . . . . . 0.629 HG22 ' HB2' ' A' ' 22' ' ' PHE . 60.0 t -62.1 -34.46 63.59 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.367 0 CA-C-N 115.675 -0.693 . . . . 0.0 110.287 179.29 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 42' ' ' GLY . . . . . 0.427 ' O ' HG12 ' A' ' 46' ' ' ILE . . . -60.21 -34.91 86.36 Favored Glycine 0 N--CA 1.449 -0.493 0 C-N-CA 120.864 -0.684 . . . . 0.0 112.337 179.949 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 43' ' ' ILE . . . . . 0.667 HG22 ' HE3' ' A' ' 205' ' ' LYS . 0.3 OUTLIER -71.83 -58.47 5.05 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.218 0 CA-C-O 120.752 0.311 . . . . 0.0 110.944 179.901 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 80.7 p -61.03 -20.59 62.71 Favored 'General case' 0 C--N 1.332 -0.153 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.262 -179.621 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -79.51 -57.15 3.19 Favored Glycine 0 CA--C 1.519 0.287 0 C-N-CA 120.792 -0.718 . . . . 0.0 112.94 -179.327 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 46' ' ' ILE . . . . . 0.427 HG12 ' O ' ' A' ' 42' ' ' GLY . 16.5 pt -58.36 -36.25 57.61 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.213 0 CA-C-O 120.976 0.417 . . . . 0.0 111.071 -179.994 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 47' ' ' ALA . . . . . 0.663 ' HB2' ' HE2' ' A' ' 205' ' ' LYS . . . -68.15 -45.94 72.17 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-N 116.079 -0.51 . . . . 0.0 111.314 179.518 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 48' ' ' ALA . . . . . 0.429 ' HB2' ' HB3' ' A' ' 15' ' ' MET . . . -54.71 -40.41 69.18 Favored 'General case' 0 C--N 1.332 -0.186 0 CA-C-N 116.271 -0.422 . . . . 0.0 111.909 -179.451 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 35.7 m -76.01 -34.11 26.36 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.384 0 CA-C-N 116.452 -0.34 . . . . 0.0 111.482 -179.318 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -65.03 -36.54 84.69 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.905 0.383 . . . . 0.0 111.033 179.718 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 38.1 m-85 -73.29 -39.8 65.06 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.021 -0.536 . . . . 0.0 110.685 -179.862 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -63.29 -46.72 85.43 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 115.92 -0.582 . . . . 0.0 111.527 179.86 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 53' ' ' VAL . . . . . 0.464 HG23 ' N ' ' A' ' 54' ' ' MET . 30.4 m -67.77 -46.14 83.04 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.19 0 CA-C-N 116.341 -0.39 . . . . 0.0 111.109 -179.78 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 54' ' ' MET . . . . . 0.483 ' HG3' ' HE1' ' A' ' 60' ' ' TRP . 13.3 ttp -64.44 -29.31 70.36 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.995 0.426 . . . . 0.0 110.294 179.834 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 55' ' ' ALA . . . . . 0.507 ' HB2' ' HB2' ' A' ' 8' ' ' PHE . . . -64.36 -32.23 73.75 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 115.919 -0.582 . . . . 0.0 111.092 179.502 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 97.4 mt -82.85 6.26 18.97 Favored 'General case' 0 C--N 1.331 -0.204 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.197 -179.674 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 94.33 -5.25 70.97 Favored Glycine 0 N--CA 1.452 -0.265 0 C-N-CA 120.667 -0.778 . . . . 0.0 112.759 179.787 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 58.8 t -62.66 140.52 19.34 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.243 0 CA-C-O 120.701 0.286 . . . . 0.0 110.825 179.861 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 85.89 -23.64 8.91 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.615 -179.859 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 60' ' ' TRP . . . . . 0.483 ' HE1' ' HG3' ' A' ' 54' ' ' MET . 13.3 m0 -61.08 108.02 0.82 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.806 0.336 . . . . 0.0 110.722 179.909 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 7.4 p -118.67 131.58 24.23 Favored Pre-proline 0 CA--C 1.533 0.293 0 CA-C-N 116.343 -0.39 . . . . 0.0 111.469 -179.863 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 57.7 Cg_endo -71.9 147.77 50.36 Favored 'Trans proline' 0 C--N 1.35 0.637 0 C-N-CA 122.481 2.121 . . . . 0.0 112.501 179.842 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 76.8 t -141.91 99.19 0.82 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 115.92 -0.582 . . . . 0.0 111.019 -179.813 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . 58.72 -85.82 0.02 OUTLIER 'General case' 0 C--N 1.332 -0.172 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.229 -179.927 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 41.2 mt-10 -127.96 -20.39 3.84 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.319 179.723 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 66' ' ' ARG . . . . . . . . . . . . . 18.6 ptp180 -100.26 164.3 12.01 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 115.773 -0.649 . . . . 0.0 110.148 179.709 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 44.5 m -123.15 138.26 54.7 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-O 120.935 0.398 . . . . 0.0 111.213 -179.779 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 68' ' ' VAL . . . . . 0.485 HG11 ' HB3' ' A' ' 117' ' ' MET . 23.9 m -125.48 146.06 31.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.012 -0.54 . . . . 0.0 110.849 179.792 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 69' ' ' PHE . . . . . . . . . . . . . 8.5 m-85 -104.85 114.97 29.5 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.044 -179.732 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 70' ' ' VAL . . . . . 0.561 HG12 ' HD3' ' A' ' 71' ' ' PRO . 0.5 OUTLIER -66.94 -32.08 4.55 Favored Pre-proline 0 CA--C 1.54 0.58 0 N-CA-C 112.849 0.685 . . . . 0.0 112.849 -179.241 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 71' ' ' PRO . . . . . 0.561 ' HD3' HG12 ' A' ' 70' ' ' VAL . 14.5 Cg_exo -68.39 -18.04 44.07 Favored 'Trans proline' 0 C--N 1.36 1.157 0 C-N-CA 121.944 1.763 . . . . 0.0 112.704 -179.603 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 59.0 ttt180 -72.97 -55.2 6.9 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.767 0.317 . . . . 0.0 111.637 -179.224 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 73' ' ' TYR . . . . . . . . . . . . . 4.0 m-85 -71.8 -34.44 69.39 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.482 -0.326 . . . . 0.0 110.74 -179.143 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 74' ' ' ILE . . . . . 0.531 HG22 ' HA ' ' A' ' 71' ' ' PRO . 0.4 OUTLIER -69.38 -41.2 80.75 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.192 0 CA-C-N 116.515 -0.311 . . . . 0.0 110.333 179.736 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 11.3 t70 -58.36 -37.64 75.62 Favored 'General case' 0 CA--C 1.518 -0.256 0 N-CA-C 109.427 -0.583 . . . . 0.0 109.427 178.901 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 76' ' ' TRP . . . . . 0.499 ' HB3' ' SD ' ' A' ' 109' ' ' MET . 42.6 m0 -64.97 -38.56 91.36 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 115.567 -0.742 . . . . 0.0 110.824 179.531 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 77' ' ' ILE . . . . . 0.512 ' O ' ' HG2' ' A' ' 81' ' ' PRO . 83.7 mt -66.54 -28.63 43.95 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-N 116.39 -0.368 . . . . 0.0 110.894 179.633 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 53.9 mt -91.47 -21.13 21.08 Favored 'General case' 0 C--N 1.327 -0.41 0 N-CA-C 112.044 0.387 . . . . 0.0 112.044 -179.969 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 71.5 p -102.3 -52.68 3.07 Favored 'General case' 0 CA--C 1.531 0.219 0 N-CA-C 113.425 0.898 . . . . 0.0 113.425 -178.099 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 80' ' ' THR . . . . . 0.643 ' HB ' ' HD3' ' A' ' 81' ' ' PRO . 26.2 m -50.2 -54.78 30.29 Favored Pre-proline 0 CA--C 1.532 0.283 0 N-CA-C 112.749 0.648 . . . . 0.0 112.749 -178.513 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 81' ' ' PRO . . . . . 0.643 ' HD3' ' HB ' ' A' ' 80' ' ' THR . 52.7 Cg_exo -57.1 -23.7 54.23 Favored 'Trans proline' 0 C--N 1.351 0.696 0 C-N-CA 121.513 1.475 . . . . 0.0 111.35 179.63 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 82' ' ' LEU . . . . . . . . . . . . . 16.4 tp -76.96 -32.72 57.5 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 115.445 -0.798 . . . . 0.0 109.764 179.39 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 83' ' ' ILE . . . . . 0.456 HG23 ' HE2' ' A' ' 208' ' ' PHE . 40.4 mm -66.44 -54.38 26.63 Favored 'Isoleucine or valine' 0 C--O 1.233 0.185 0 CA-C-N 115.835 -0.62 . . . . 0.0 110.514 179.329 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 27.5 m -61.13 -31.07 49.09 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.31 0 N-CA-C 109.378 -0.601 . . . . 0.0 109.378 179.092 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 85' ' ' TYR . . . . . 0.422 ' O ' ' HG ' ' A' ' 89' ' ' LEU . 80.4 t80 -61.64 -35.58 78.33 Favored 'General case' 0 N--CA 1.453 -0.282 0 CA-C-N 115.593 -0.73 . . . . 0.0 109.155 178.338 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 86' ' ' PHE . . . . . . . . . . . . . 34.1 t80 -61.9 -49.67 75.26 Favored 'General case' 0 CA--C 1.52 -0.178 0 CA-C-N 115.78 -0.645 . . . . 0.0 109.623 179.046 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 3.9 mm? -57.71 -32.8 67.75 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 115.655 -0.702 . . . . 0.0 110.034 179.131 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -73.15 -27.43 68.37 Favored Glycine 0 N--CA 1.451 -0.305 0 CA-C-N 115.642 -0.708 . . . . 0.0 112.826 179.784 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 89' ' ' LEU . . . . . 0.422 ' HG ' ' O ' ' A' ' 85' ' ' TYR . 94.3 mt -72.39 -44.42 62.54 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.904 0.383 . . . . 0.0 111.084 -179.622 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 70.3 mt -70.49 -27.29 64.09 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 115.986 -0.552 . . . . 0.0 111.363 -179.748 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 91' ' ' ALA . . . . . 0.659 ' HA ' ' HB2' ' A' ' 149' ' ' ALA . . . -87.49 -52.65 5.23 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.426 -0.352 . . . . 0.0 111.239 -179.93 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 90.31 59.96 1.42 Allowed Glycine 0 N--CA 1.451 -0.361 0 C-N-CA 120.93 -0.652 . . . . 0.0 112.418 -179.966 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 93' ' ' LEU . . . . . 0.593 HD23 ' HB3' ' A' ' 97' ' ' GLU . 8.1 mp -71.28 -174.72 1.07 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.741 0.305 . . . . 0.0 110.845 -179.894 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 94' ' ' ASP . . . . . 0.451 ' HB2' ' OE2' ' A' ' 97' ' ' GLU . 12.5 m-20 -94.09 -172.16 2.75 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 121.023 0.439 . . . . 0.0 111.545 -179.446 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 43.5 m -67.8 -48.98 64.75 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 115.836 -0.62 . . . . 0.0 111.657 -179.266 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 31.9 ttm180 -73.33 -41.01 64.0 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 121.05 0.452 . . . . 0.0 110.619 -179.338 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 97' ' ' GLU . . . . . 0.593 ' HB3' HD23 ' A' ' 93' ' ' LEU . 0.3 OUTLIER -56.47 -45.83 80.72 Favored 'General case' 0 C--N 1.326 -0.449 0 CA-C-N 115.692 -0.686 . . . . 0.0 111.069 179.983 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 98' ' ' PHE . . . . . 0.448 ' O ' HG12 ' A' ' 102' ' ' ILE . 1.2 m-85 -60.79 -43.97 97.41 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.338 -0.392 . . . . 0.0 110.731 179.63 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -64.8 -29.73 76.08 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.901 -0.666 . . . . 0.0 112.639 -179.995 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 93.1 mt -68.29 -41.68 83.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-O 120.756 0.313 . . . . 0.0 111.249 -179.81 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 34.2 t -68.07 -41.16 84.12 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.411 0 CA-C-N 116.264 -0.425 . . . . 0.0 111.432 -179.573 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 102' ' ' ILE . . . . . 0.448 HG12 ' O ' ' A' ' 98' ' ' PHE . 42.0 mm -68.67 -51.36 46.64 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.447 -0.342 . . . . 0.0 111.44 -179.756 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 15.3 t -56.86 -32.21 65.59 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-O 120.916 0.389 . . . . 0.0 111.04 -179.894 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 104' ' ' LEU . . . . . 0.475 HD23 HD13 ' A' ' 137' ' ' LEU . 33.7 tp -66.06 -48.41 71.14 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.573 179.483 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 105' ' ' ASN . . . . . 0.542 ' N ' HD22 ' A' ' 105' ' ' ASN . 0.9 OUTLIER -62.52 -27.0 68.85 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.045 179.972 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 89.2 m -70.21 -53.36 17.41 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.334 -0.394 . . . . 0.0 111.419 -179.887 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 8.8 p -65.6 -37.07 79.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.296 -0.411 . . . . 0.0 111.304 -179.652 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 55.6 t -65.41 -50.16 74.33 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.249 0 CA-C-N 116.43 -0.35 . . . . 0.0 110.958 179.86 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 109' ' ' MET . . . . . 0.626 ' HE1' HG21 ' A' ' 80' ' ' THR . 7.2 tpp -64.12 -33.54 75.99 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.622 -179.899 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 110' ' ' LEU . . . . . 0.472 HD23 ' C ' ' A' ' 110' ' ' LEU . 3.4 tt -63.06 -41.62 99.5 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-N 115.921 -0.581 . . . . 0.0 109.706 179.052 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -58.12 -47.83 82.08 Favored 'General case' 0 C--N 1.331 -0.203 0 CA-C-N 115.824 -0.625 . . . . 0.0 110.494 179.536 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . -68.47 -32.68 75.57 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.64 -0.791 . . . . 0.0 111.929 179.374 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 113' ' ' PHE . . . . . . . . . . . . . 0.5 OUTLIER -51.79 -68.45 0.17 Allowed 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 121.058 0.456 . . . . 0.0 109.998 179.566 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 114' ' ' ALA . . . . . 0.456 ' O ' HG13 ' A' ' 118' ' ' VAL . . . -70.48 -24.02 62.79 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 115.586 -0.733 . . . . 0.0 111.155 179.819 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -54.08 -40.86 67.68 Favored Glycine 0 C--N 1.331 0.282 0 C-N-CA 121.149 -0.548 . . . . 0.0 112.994 -179.699 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -77.81 -39.15 44.77 Favored 'General case' 0 C--N 1.328 -0.326 0 N-CA-C 112.142 0.423 . . . . 0.0 112.142 -179.429 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 117' ' ' MET . . . . . 0.485 ' HB3' HG11 ' A' ' 68' ' ' VAL . 19.3 ptp -91.4 19.74 5.84 Favored 'General case' 0 C--N 1.329 -0.324 0 N-CA-C 111.788 0.292 . . . . 0.0 111.788 -179.287 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 118' ' ' VAL . . . . . 0.544 HG21 ' HB3' ' A' ' 123' ' ' ARG . 5.0 m -54.08 149.45 18.37 Favored Pre-proline 0 C--N 1.33 -0.282 0 CA-C-N 116.598 -0.274 . . . . 0.0 111.231 179.723 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 119' ' ' PRO . . . . . . . . . . . . . 90.3 Cg_endo -87.34 3.97 6.24 Favored 'Trans proline' 0 N--CA 1.458 -0.581 0 C-N-CA 122.64 2.227 . . . . 0.0 112.236 179.622 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -168.37 -133.96 1.64 Allowed Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.786 -0.721 . . . . 0.0 112.457 -179.951 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 42.4 pt -99.18 18.01 2.77 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.246 0 CA-C-O 120.885 0.374 . . . . 0.0 111.182 -179.834 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 45.1 mt-10 -67.51 -18.46 65.05 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.274 -179.975 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 123' ' ' ARG . . . . . 0.544 ' HB3' HG21 ' A' ' 118' ' ' VAL . 20.5 ptt180 -53.07 -29.82 32.52 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 116.222 -0.444 . . . . 0.0 111.67 -179.678 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 124' ' ' TYR . . . . . . . . . . . . . 28.2 m-85 -67.48 -34.41 77.1 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.589 -0.278 . . . . 0.0 110.795 -179.858 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 125' ' ' ALA . . . . . . . . . . . . . . . -74.78 -56.08 5.16 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.17 -179.978 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 1.1 mt -52.49 -54.34 33.81 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 115.908 -0.587 . . . . 0.0 110.961 -179.86 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 127' ' ' PHE . . . . . . . . . . . . . 8.8 t80 -62.78 -36.4 82.99 Favored 'General case' 0 C--N 1.331 -0.231 0 C-N-CA 120.847 -0.341 . . . . 0.0 110.567 179.756 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 128' ' ' GLY . . . . . . . . . . . . . . . -47.31 -43.98 20.15 Favored Glycine 0 C--N 1.332 0.314 0 C-N-CA 120.136 -1.031 . . . . 0.0 111.153 179.154 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 129' ' ' MET . . . . . . . . . . . . . 0.3 OUTLIER -71.87 -37.05 70.26 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 120.865 0.364 . . . . 0.0 110.026 178.868 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -67.18 -28.19 73.67 Favored Glycine 0 N--CA 1.45 -0.378 0 CA-C-N 115.822 -0.626 . . . . 0.0 112.688 -179.722 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -74.81 -54.18 7.79 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.624 0.25 . . . . 0.0 110.67 -179.953 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 31.7 t -57.95 -41.17 79.55 Favored 'Isoleucine or valine' 0 C--O 1.235 0.318 0 N-CA-C 109.129 -0.693 . . . . 0.0 109.129 178.698 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -66.29 -35.8 81.32 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 115.173 -0.921 . . . . 0.0 110.106 178.929 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 134' ' ' PHE . . . . . 0.418 ' CZ ' ' HA ' ' A' ' 172' ' ' ALA . 57.9 t80 -57.48 -50.9 71.55 Favored 'General case' 0 N--CA 1.45 -0.469 0 CA-C-N 115.937 -0.574 . . . . 0.0 110.022 179.548 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 135' ' ' ILE . . . . . 0.451 ' O ' HG22 ' A' ' 138' ' ' VAL . 60.2 mt -56.64 -33.59 40.39 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.312 0 CA-C-N 115.911 -0.586 . . . . 0.0 109.663 178.95 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . -63.21 -35.21 91.76 Favored Glycine 0 N--CA 1.447 -0.568 0 C-N-CA 120.249 -0.977 . . . . 0.0 111.205 178.507 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 137' ' ' LEU . . . . . 0.475 HD13 HD23 ' A' ' 104' ' ' LEU . 29.1 tp -73.43 -52.13 14.82 Favored 'General case' 0 C--N 1.332 -0.158 0 N-CA-C 110.422 -0.214 . . . . 0.0 110.422 179.612 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 138' ' ' VAL . . . . . 0.791 ' HA ' HD12 ' A' ' 141' ' ' LEU . 4.9 m -55.95 -30.55 28.72 Favored 'Isoleucine or valine' 0 C--O 1.234 0.28 0 N-CA-C 109.069 -0.715 . . . . 0.0 109.069 178.92 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 139' ' ' TYR . . . . . 0.413 ' O ' ' N ' ' A' ' 143' ' ' GLY . 49.8 t80 -64.82 -41.96 95.35 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 114.958 -1.019 . . . . 0.0 109.337 178.462 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 19.4 m-85 -65.02 -33.0 74.99 Favored 'General case' 0 C--N 1.333 -0.143 0 CA-C-N 116.036 -0.529 . . . . 0.0 109.791 178.577 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 141' ' ' LEU . . . . . 0.791 HD12 ' HA ' ' A' ' 138' ' ' VAL . 81.9 mt -61.21 -36.38 79.75 Favored 'General case' 0 C--O 1.232 0.149 0 CA-C-N 115.977 -0.556 . . . . 0.0 109.895 179.078 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 142' ' ' VAL . . . . . 0.404 HG22 ' NH1' ' A' ' 164' ' ' ARG . 2.9 t -109.27 10.48 8.96 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-N 115.751 -0.659 . . . . 0.0 110.658 179.729 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 143' ' ' GLY . . . . . 0.413 ' N ' ' O ' ' A' ' 139' ' ' TYR . . . -85.52 -147.6 9.81 Favored Glycine 0 CA--C 1.519 0.291 0 C-N-CA 120.968 -0.634 . . . . 0.0 113.008 -179.511 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 144' ' ' PRO . . . . . . . . . . . . . 51.3 Cg_exo -52.98 -24.87 26.11 Favored 'Trans proline' 0 C--N 1.349 0.579 0 C-N-CA 122.716 2.278 . . . . 0.0 112.754 -179.799 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 145' ' ' MET . . . . . 0.464 ' HG2' HD11 ' A' ' 93' ' ' LEU . 55.3 mtt -53.22 -39.15 63.55 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 116.352 -0.385 . . . . 0.0 111.244 179.975 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 146' ' ' THR . . . . . . . . . . . . . 81.2 p -62.1 -51.2 68.89 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.794 -179.36 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 147' ' ' GLU . . . . . 0.479 ' O ' ' HG2' ' A' ' 151' ' ' GLN . 40.0 mt-10 -74.1 -18.06 60.86 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.394 -0.366 . . . . 0.0 111.249 -179.534 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 148' ' ' SER . . . . . . . . . . . . . 44.6 t -71.21 -47.69 55.9 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.764 0.316 . . . . 0.0 111.231 -179.807 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 149' ' ' ALA . . . . . 0.659 ' HB2' ' HA ' ' A' ' 91' ' ' ALA . . . -78.02 -31.99 50.79 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.128 -0.487 . . . . 0.0 112.242 -178.975 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 150' ' ' SER . . . . . . . . . . . . . 70.2 m -62.68 -6.67 3.79 Favored 'General case' 0 C--N 1.328 -0.337 0 N-CA-C 111.993 0.368 . . . . 0.0 111.993 -179.384 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 151' ' ' GLN . . . . . 0.479 ' HG2' ' O ' ' A' ' 147' ' ' GLU . 67.0 mm-40 -111.58 17.14 20.27 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.731 -0.213 . . . . 0.0 111.095 -179.775 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 25.6 mtp180 -101.71 -52.24 3.25 Favored 'General case' 0 C--N 1.331 -0.201 0 CA-C-O 120.832 0.349 . . . . 0.0 111.351 -179.839 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 153' ' ' SER . . . . . 0.594 ' HB3' HG12 ' A' ' 156' ' ' ILE . 31.5 t -156.83 172.27 18.93 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.959 179.691 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 154' ' ' SER . . . . . . . . . . . . . 61.4 m -73.05 -39.78 65.64 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 116.257 -0.428 . . . . 0.0 110.65 179.679 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -76.6 -28.81 58.78 Favored Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.904 -0.665 . . . . 0.0 112.7 -179.936 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 156' ' ' ILE . . . . . 0.594 HG12 ' HB3' ' A' ' 153' ' ' SER . 25.8 mm -58.37 -42.45 84.05 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.233 0 CA-C-O 120.764 0.316 . . . . 0.0 111.486 -179.96 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 157' ' ' LYS . . . . . 0.422 ' O ' HG13 ' A' ' 161' ' ' VAL . 25.0 ttpp -63.31 -42.24 99.0 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.272 -0.422 . . . . 0.0 111.499 -179.496 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 46.5 t -65.23 -47.68 75.98 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.418 -0.355 . . . . 0.0 111.88 -179.257 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 159' ' ' LEU . . . . . 0.501 ' O ' HD13 ' A' ' 163' ' ' LEU . 4.9 tt -66.13 -34.68 78.61 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.507 -0.315 . . . . 0.0 111.241 -179.396 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 160' ' ' TYR . . . . . . . . . . . . . 58.4 t80 -73.69 -46.16 48.01 Favored 'General case' 0 C--N 1.327 -0.382 0 N-CA-C 112.365 0.506 . . . . 0.0 112.365 -178.767 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 161' ' ' VAL . . . . . 0.442 HG23 ' N ' ' A' ' 162' ' ' ARG . 28.8 m -59.97 -46.52 93.99 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 N-CA-C 112.171 0.434 . . . . 0.0 112.171 -178.933 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 162' ' ' ARG . . . . . 0.442 ' N ' HG23 ' A' ' 161' ' ' VAL . 79.0 ttt180 -65.61 -46.04 80.85 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.71 0.291 . . . . 0.0 111.552 -179.331 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 163' ' ' LEU . . . . . 0.501 HD13 ' O ' ' A' ' 159' ' ' LEU . 7.8 mp -65.44 -52.02 56.13 Favored 'General case' 0 C--N 1.329 -0.317 0 N-CA-C 112.106 0.41 . . . . 0.0 112.106 -179.186 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 164' ' ' ARG . . . . . 0.602 ' O ' HG23 ' A' ' 168' ' ' VAL . 5.7 ppt_? -58.62 -43.34 89.62 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.598 -0.274 . . . . 0.0 111.605 -178.861 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 165' ' ' ASN . . . . . 0.471 ' O ' HG23 ' A' ' 169' ' ' VAL . 4.7 m-20 -55.97 -49.44 73.57 Favored 'General case' 0 C--N 1.331 -0.202 0 CA-C-O 121.129 0.49 . . . . 0.0 110.427 179.513 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 166' ' ' LEU . . . . . 0.485 ' O ' ' HG ' ' A' ' 170' ' ' LEU . 3.1 tt -60.15 -50.04 75.24 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 115.563 -0.744 . . . . 0.0 111.681 -179.52 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 167' ' ' THR . . . . . 0.479 ' O ' ' HB2' ' A' ' 171' ' ' TRP . 60.1 m -56.41 -54.01 50.63 Favored 'General case' 0 C--N 1.331 -0.232 0 N-CA-C 112.324 0.49 . . . . 0.0 112.324 -178.796 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 168' ' ' VAL . . . . . 0.644 HG22 HD13 ' A' ' 141' ' ' LEU . 45.4 t -52.27 -43.8 40.43 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.227 0 N-CA-C 112.339 0.496 . . . . 0.0 112.339 -179.764 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 169' ' ' VAL . . . . . 0.471 HG23 ' O ' ' A' ' 165' ' ' ASN . 72.8 t -59.92 -65.75 0.44 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 N-CA-C 113.016 0.747 . . . . 0.0 113.016 -178.47 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 170' ' ' LEU . . . . . 0.485 ' HG ' ' O ' ' A' ' 166' ' ' LEU . 0.7 OUTLIER -63.08 -37.78 88.56 Favored 'General case' 0 C--N 1.33 -0.26 0 N-CA-C 112.593 0.59 . . . . 0.0 112.593 -178.163 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 171' ' ' TRP . . . . . 0.479 ' HB2' ' O ' ' A' ' 167' ' ' THR . 2.9 m0 -64.25 -27.58 69.15 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.832 0.349 . . . . 0.0 110.771 179.813 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 172' ' ' ALA . . . . . 0.418 ' HA ' ' CZ ' ' A' ' 134' ' ' PHE . . . -72.48 -6.93 47.19 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.948 -179.818 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 173' ' ' ILE . . . . . 0.492 ' O ' HG12 ' A' ' 177' ' ' ILE . 28.8 mm -88.4 -21.24 7.05 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 115.952 -0.567 . . . . 0.0 111.175 -179.985 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 174' ' ' TYR . . . . . 0.403 ' N ' ' CD ' ' A' ' 175' ' ' PRO . 8.7 m-85 -53.59 -48.25 93.74 Favored Pre-proline 0 N--CA 1.464 0.261 0 CA-C-N 116.339 -0.392 . . . . 0.0 111.93 -179.375 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 175' ' ' PRO . . . . . 0.403 ' CD ' ' N ' ' A' ' 174' ' ' TYR . 84.6 Cg_exo -48.43 -33.27 22.52 Favored 'Trans proline' 0 C--N 1.351 0.667 0 C-N-CA 121.854 1.703 . . . . 0.0 112.048 179.588 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 176' ' ' PHE . . . . . 0.465 ' HD2' ' HA ' ' A' ' 173' ' ' ILE . 60.9 m-85 -80.9 -50.35 9.87 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 115.873 -0.603 . . . . 0.0 111.954 -179.905 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 177' ' ' ILE . . . . . 0.507 HG13 HD11 ' A' ' 200' ' ' LEU . 13.6 mm -60.25 -32.08 49.86 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.443 0 CA-C-N 116.279 -0.418 . . . . 0.0 112.036 -178.386 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 178' ' ' TRP . . . . . 0.458 ' HH2' ' HB2' ' A' ' 123' ' ' ARG . 82.0 t90 -73.18 -52.06 15.52 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.91 0.386 . . . . 0.0 110.81 179.928 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 179' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -68.76 -54.77 14.07 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-N 115.989 -0.55 . . . . 0.0 111.484 -179.119 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 180' ' ' LEU . . . . . 0.542 HD22 HD11 ' A' ' 187' ' ' LEU . 26.6 mt -64.06 -29.7 70.82 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.55 -0.295 . . . . 0.0 111.298 -179.37 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . -69.12 -175.79 12.24 Favored Glycine 0 N--CA 1.449 -0.44 0 C-N-CA 119.817 -1.183 . . . . 0.0 111.629 178.957 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 182' ' ' PRO . . . . . 0.502 ' HG3' ' HA ' ' A' ' 190' ' ' PRO . 82.3 Cg_exo -47.47 -43.54 27.07 Favored 'Trans proline' 0 CA--C 1.537 0.669 0 C-N-CA 122.678 2.252 . . . . 0.0 113.76 179.943 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 183' ' ' PRO . . . . . 0.424 ' HB2' ' O ' ' A' ' 178' ' ' TRP . 83.4 Cg_exo -43.07 -51.77 5.31 Favored 'Trans proline' 0 C--N 1.356 0.957 0 C-N-CA 122.491 2.127 . . . . 0.0 114.065 -179.744 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 184' ' ' GLY . . . . . . . . . . . . . . . -102.74 -123.95 5.36 Favored Glycine 0 C--N 1.335 0.515 0 C-N-CA 119.942 -1.123 . . . . 0.0 113.631 -179.063 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 185' ' ' VAL . . . . . 0.406 ' CG2' HD21 ' A' ' 187' ' ' LEU . 23.6 m -54.09 -33.33 24.49 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.405 0 N-CA-C 112.647 0.61 . . . . 0.0 112.647 -178.95 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 186' ' ' ALA . . . . . 0.421 ' HB2' ' HA ' ' A' ' 182' ' ' PRO . . . 58.92 83.35 0.13 Allowed 'General case' 0 N--CA 1.464 0.246 0 CA-C-O 120.675 0.274 . . . . 0.0 111.624 179.786 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 187' ' ' LEU . . . . . 0.542 HD11 HD22 ' A' ' 180' ' ' LEU . 7.7 mt -92.32 -49.92 5.91 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-O 120.902 0.382 . . . . 0.0 111.351 179.795 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 188' ' ' LEU . . . . . 0.463 HD12 ' HB2' ' A' ' 187' ' ' LEU . 7.3 mp -79.79 -164.59 0.68 Allowed 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.001 -0.545 . . . . 0.0 111.197 -179.268 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 189' ' ' THR . . . . . 0.497 ' HB ' HG23 ' A' ' 192' ' ' VAL . 20.8 m -91.08 137.46 26.46 Favored Pre-proline 0 C--N 1.329 -0.295 0 CA-C-N 115.868 -0.605 . . . . 0.0 110.634 -179.73 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 190' ' ' PRO . . . . . 0.502 ' HA ' ' HG3' ' A' ' 182' ' ' PRO . 92.3 Cg_exo -44.23 -37.24 9.87 Favored 'Trans proline' 0 C--N 1.35 0.656 0 C-N-CA 122.519 2.146 . . . . 0.0 113.278 -179.649 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 191' ' ' THR . . . . . 0.433 HG22 HG22 ' A' ' 189' ' ' THR . 6.2 t -78.52 -40.82 34.05 Favored 'General case' 0 C--N 1.33 -0.275 0 N-CA-C 111.683 0.253 . . . . 0.0 111.683 -179.616 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 192' ' ' VAL . . . . . 0.497 HG23 ' HB ' ' A' ' 189' ' ' THR . 96.9 t -62.52 -48.69 87.08 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-O 120.658 0.266 . . . . 0.0 111.463 -179.729 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 193' ' ' ASP . . . . . . . . . . . . . 21.6 m-20 -56.0 -46.58 78.7 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.397 -0.365 . . . . 0.0 111.089 -179.714 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 194' ' ' VAL . . . . . 0.429 HG23 ' O ' ' A' ' 190' ' ' PRO . 71.0 t -59.34 -37.07 67.36 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.412 -0.358 . . . . 0.0 110.739 179.547 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 195' ' ' ALA . . . . . . . . . . . . . . . -59.32 -41.71 89.72 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.303 -0.408 . . . . 0.0 110.608 179.534 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 196' ' ' LEU . . . . . . . . . . . . . 98.1 mt -67.3 -38.4 84.95 Favored 'General case' 0 C--N 1.333 -0.143 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.197 179.248 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 197' ' ' ILE . . . . . 0.445 HG23 ' HZ2' ' A' ' 76' ' ' TRP . 15.8 mm -60.57 -56.24 19.06 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.242 0 CA-C-N 115.901 -0.59 . . . . 0.0 110.248 179.122 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 198' ' ' VAL . . . . . . . . . . . . . 93.7 t -54.28 -34.58 28.01 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.516 0 CA-C-N 115.623 -0.717 . . . . 0.0 109.321 178.303 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 199' ' ' TYR . . . . . . . . . . . . . 29.7 t80 -69.83 -32.99 71.71 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 115.112 -0.949 . . . . 0.0 110.609 179.794 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 200' ' ' LEU . . . . . 0.516 ' O ' HG12 ' A' ' 203' ' ' VAL . 23.0 mt -69.86 -39.33 76.41 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 115.97 -0.559 . . . . 0.0 111.024 179.984 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 201' ' ' ASP . . . . . . . . . . . . . 15.2 m-20 -72.95 -34.6 66.64 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-O 121.204 0.526 . . . . 0.0 110.103 179.625 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 202' ' ' LEU . . . . . . . . . . . . . 3.1 mt -75.01 -27.13 59.99 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 115.514 -0.766 . . . . 0.0 111.749 -179.439 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 203' ' ' VAL . . . . . 0.516 HG12 ' O ' ' A' ' 200' ' ' LEU . 10.9 p -79.61 -36.36 17.47 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.334 0 C-N-CA 120.834 -0.347 . . . . 0.0 110.856 -178.924 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 204' ' ' THR . . . . . . . . . . . . . 96.9 m -67.87 -58.27 4.85 Favored 'General case' 0 C--N 1.328 -0.333 0 C-N-CA 120.933 -0.307 . . . . 0.0 110.902 179.212 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 205' ' ' LYS . . . . . 0.667 ' HE3' HG22 ' A' ' 43' ' ' ILE . 60.5 mttp -60.52 -58.29 9.11 Favored 'General case' 0 C--N 1.331 -0.212 0 N-CA-C 112.067 0.395 . . . . 0.0 112.067 -178.937 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 52.8 t -67.69 -37.02 77.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 N-CA-C 111.818 0.303 . . . . 0.0 111.818 -179.303 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 207' ' ' GLY . . . . . 0.407 ' HA3' ' O ' ' A' ' 203' ' ' VAL . . . -53.55 -60.48 8.19 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.908 -0.663 . . . . 0.0 113.975 -178.818 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 208' ' ' PHE . . . . . 0.506 ' O ' ' HB2' ' A' ' 212' ' ' ALA . 1.1 p90 -75.45 -26.75 58.53 Favored 'General case' 0 C--O 1.219 -0.513 0 CA-C-N 117.317 0.559 . . . . 0.0 111.778 -179.14 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 209' ' ' GLY . . . . . 0.45 ' O ' ' HB3' ' A' ' 212' ' ' ALA . . . -66.4 -35.24 89.88 Favored Glycine 0 N--CA 1.452 -0.267 0 C-N-CA 121.491 -0.385 . . . . 0.0 112.202 179.597 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 210' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER -75.75 -44.86 39.54 Favored 'General case' 0 CA--C 1.514 -0.433 0 N-CA-C 108.316 -0.994 . . . . 0.0 108.316 178.742 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 211' ' ' ILE . . . . . . . . . . . . . 44.3 mt -65.6 -27.55 41.85 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.55 0 N-CA-C 107.91 -1.144 . . . . 0.0 107.91 176.86 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 212' ' ' ALA . . . . . 0.506 ' HB2' ' O ' ' A' ' 208' ' ' PHE . . . -62.37 -45.47 93.02 Favored 'General case' 0 N--CA 1.451 -0.418 0 CA-C-N 114.741 -1.118 . . . . 0.0 110.508 179.89 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 213' ' ' LEU . . . . . . . . . . . . . 93.9 mt -69.73 -54.55 13.22 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 115.151 -0.931 . . . . 0.0 111.676 -179.181 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 214' ' ' ASP . . . . . . . . . . . . . 19.5 t70 -55.21 -41.52 72.11 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.331 -0.395 . . . . 0.0 111.511 -179.608 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 215' ' ' ALA . . . . . . . . . . . . . . . -70.25 -57.7 4.59 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.407 -0.36 . . . . 0.0 111.781 -179.419 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 216' ' ' ALA . . . . . . . . . . . . . . . -55.59 -34.92 65.26 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.5 -0.318 . . . . 0.0 111.428 -179.541 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 217' ' ' ALA . . . . . . . . . . . . . . . -67.02 -41.02 87.33 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.506 179.894 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 218' ' ' THR . . . . . . . . . . . . . 42.3 m . . . . . 0 C--N 1.33 -0.28 0 CA-C-N 115.775 -0.648 . . . . 0.0 110.916 179.707 . . . . . . . . 0 0 . 1 . 021 nuclear build core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.266 0 N-CA-C 112.626 -0.189 . . . . 0.0 112.626 . . . . . . . . . 0 0 . 1 . 021 nuclear build core ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 31.1 tp -73.95 -35.47 64.53 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-O 120.837 0.351 . . . . 0.0 110.727 -179.967 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 74.0 p -58.23 -30.99 66.94 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.079 -0.51 . . . . 0.0 111.519 -179.863 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 30.9 p -54.29 -35.71 62.88 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.377 -0.374 . . . . 0.0 111.2 -179.964 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 7' ' ' LEU . . . . . . . . . . . . . 4.1 mm? -60.22 -52.23 66.17 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.883 179.868 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 8' ' ' PHE . . . . . 0.542 ' HB2' ' HB2' ' A' ' 55' ' ' ALA . 58.2 m-85 -62.82 -30.92 71.85 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.031 -0.532 . . . . 0.0 110.909 -179.981 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 9' ' ' TRP . . . . . . . . . . . . . 21.5 m95 -67.5 -46.87 71.65 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.087 -0.506 . . . . 0.0 110.212 -179.797 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 88.9 mt -59.67 -38.44 81.49 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 115.69 -0.687 . . . . 0.0 110.343 179.411 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -65.04 -34.24 89.32 Favored Glycine 0 N--CA 1.448 -0.506 0 C-N-CA 120.679 -0.772 . . . . 0.0 111.866 179.36 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -67.91 -32.48 72.97 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-O 120.883 0.373 . . . . 0.0 110.62 179.554 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 70.2 mt -65.22 -53.42 40.8 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 115.91 -0.586 . . . . 0.0 110.624 179.611 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -64.21 -40.16 97.74 Favored Glycine 0 N--CA 1.451 -0.364 0 C-N-CA 120.6 -0.81 . . . . 0.0 112.198 179.72 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 15' ' ' MET . . . . . 0.513 ' HE3' ' HD2' ' A' ' 205' ' ' LYS . 12.5 mmt -63.14 -47.96 80.49 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.676 0.274 . . . . 0.0 110.99 179.797 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 16' ' ' LEU . . . . . 0.706 ' O ' HD23 ' A' ' 20' ' ' LEU . 50.9 tp -54.4 -55.71 25.92 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.329 -179.877 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 46.9 t -56.97 -33.36 42.05 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-O 120.958 0.409 . . . . 0.0 110.45 -179.355 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -67.26 -49.88 49.19 Favored Glycine 0 N--CA 1.452 -0.297 0 N-CA-C 111.185 -0.766 . . . . 0.0 111.185 179.483 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 19' ' ' THR . . . . . 0.538 HG22 HD22 ' A' ' 20' ' ' LEU . 1.4 m -53.39 -43.45 67.89 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 115.28 -0.46 . . . . 0.0 110.84 179.518 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 20' ' ' LEU . . . . . 0.706 HD23 ' O ' ' A' ' 16' ' ' LEU . 0.5 OUTLIER -69.79 -41.96 74.41 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-N 115.755 -0.657 . . . . 0.0 111.943 -179.559 . . . . . . . . 3 3 . 1 . 021 nuclear build core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -59.38 -32.14 69.87 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.521 -0.309 . . . . 0.0 111.795 -179.344 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 22' ' ' PHE . . . . . 0.756 ' HB2' HG22 ' A' ' 41' ' ' VAL . 5.8 m-85 -90.96 -28.66 17.9 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.711 0.291 . . . . 0.0 111.256 -179.722 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -70.33 -50.72 36.22 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 121.007 0.432 . . . . 0.0 111.576 -179.716 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 24' ' ' TRP . . . . . . . . . . . . . 4.6 t-105 -66.06 -38.91 89.51 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 115.867 -0.606 . . . . 0.0 111.494 -179.438 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.33 -0.256 0 CA-C-O 120.836 0.35 . . . . 0.0 110.77 179.712 . . . . . . . . 0 0 . 1 . 021 nuclear build core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.453 -0.209 0 N-CA-C 112.86 -0.096 . . . . 0.0 112.86 . . . . . . . . . 0 0 . 1 . 021 nuclear build core ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 2.7 mp0 -66.42 -20.88 66.18 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.898 0.38 . . . . 0.0 110.933 -179.846 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 34' ' ' ARG . . . . . . . . . . . . . 99.2 mtt180 -51.4 -29.54 16.06 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 115.914 -0.584 . . . . 0.0 111.679 -179.776 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 31.1 mmm180 -67.17 -44.78 78.83 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.393 -0.367 . . . . 0.0 111.42 -179.731 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 78.3 m-85 -70.54 -31.35 68.36 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.466 -0.333 . . . . 0.0 110.983 -179.946 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 37' ' ' TYR . . . . . 0.446 ' O ' HG23 ' A' ' 41' ' ' VAL . 48.5 m-85 -72.11 -51.33 21.93 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 116.327 -0.397 . . . . 0.0 111.228 -179.757 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 10.7 p -57.27 -36.21 51.43 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-O 120.994 0.426 . . . . 0.0 109.979 179.344 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 24.0 m -66.22 -43.83 85.55 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 115.629 -0.714 . . . . 0.0 110.584 179.127 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 40' ' ' LEU . . . . . 0.589 HD11 ' HA2' ' A' ' 209' ' ' GLY . 0.3 OUTLIER -62.64 -50.51 70.92 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-O 121.585 0.707 . . . . 0.0 110.501 179.559 . . . . . . . . 3 3 . 1 . 021 nuclear build core ' A' A ' 41' ' ' VAL . . . . . 0.756 HG22 ' HB2' ' A' ' 22' ' ' PHE . 43.8 t -62.87 -33.49 60.64 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.626 0 CA-C-N 115.435 -0.802 . . . . 0.0 110.316 179.43 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 42' ' ' GLY . . . . . 0.442 ' O ' HG12 ' A' ' 46' ' ' ILE . . . -58.07 -47.79 86.93 Favored Glycine 0 N--CA 1.448 -0.527 0 CA-C-N 115.635 -0.712 . . . . 0.0 112.822 179.889 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 43' ' ' ILE . . . . . 0.572 HG23 HD23 ' A' ' 82' ' ' LEU . 9.0 pt -65.43 -51.32 65.35 Favored 'Isoleucine or valine' 0 C--O 1.233 0.201 0 CA-C-N 117.019 0.409 . . . . 0.0 111.502 -179.704 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 60.5 m -63.61 -20.47 65.69 Favored 'General case' 0 C--O 1.233 0.188 0 CA-C-O 120.92 0.39 . . . . 0.0 110.79 -179.899 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -80.61 -58.58 2.67 Favored Glycine 0 N--CA 1.452 -0.287 0 C-N-CA 121.008 -0.615 . . . . 0.0 113.103 -179.301 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 46' ' ' ILE . . . . . 0.536 ' O ' HG22 ' A' ' 49' ' ' VAL . 14.7 pt -58.19 -36.6 58.22 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.185 0 CA-C-O 120.881 0.372 . . . . 0.0 110.949 -179.758 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 47' ' ' ALA . . . . . 0.647 ' HB2' ' HE2' ' A' ' 205' ' ' LYS . . . -68.78 -42.54 77.27 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.704 178.776 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -54.39 -40.49 68.24 Favored 'General case' 0 C--O 1.232 0.181 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.329 -179.786 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 49' ' ' VAL . . . . . 0.536 HG22 ' O ' ' A' ' 46' ' ' ILE . 17.9 m -76.22 -34.1 25.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.487 -0.324 . . . . 0.0 110.98 -179.883 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -61.42 -39.96 92.7 Favored 'General case' 0 C--N 1.332 -0.165 0 CA-C-O 121.141 0.496 . . . . 0.0 110.715 179.215 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 51' ' ' TYR . . . . . 0.445 ' HE2' ' HE2' ' A' ' 15' ' ' MET . 43.5 m-85 -73.19 -35.93 66.47 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 115.651 -0.704 . . . . 0.0 110.439 179.84 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -66.68 -39.95 88.36 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 115.885 -0.598 . . . . 0.0 111.261 179.558 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 53' ' ' VAL . . . . . 0.402 HG13 ' O ' ' A' ' 49' ' ' VAL . 33.5 m -74.42 -42.44 49.79 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.173 0 CA-C-N 116.362 -0.381 . . . . 0.0 110.972 -179.785 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 54' ' ' MET . . . . . . . . . . . . . 70.7 mtm -65.27 -31.17 72.18 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 121.111 0.481 . . . . 0.0 109.852 179.118 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 55' ' ' ALA . . . . . 0.542 ' HB2' ' HB2' ' A' ' 8' ' ' PHE . . . -67.82 -18.56 64.88 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 115.544 -0.753 . . . . 0.0 111.188 179.52 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 96.5 mt -98.84 8.68 44.71 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.196 179.957 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 81.22 16.81 73.33 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.587 -0.816 . . . . 0.0 112.604 -179.993 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 58.0 t -84.53 137.19 21.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-O 120.794 0.33 . . . . 0.0 110.888 179.907 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 59' ' ' GLY . . . . . 0.484 ' HA3' ' HD3' ' A' ' 71' ' ' PRO . . . 85.08 -7.79 73.53 Favored Glycine 0 N--CA 1.449 -0.478 0 C-N-CA 120.776 -0.726 . . . . 0.0 112.476 -179.942 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 60' ' ' TRP . . . . . . . . . . . . . 12.0 m0 -65.36 99.21 0.39 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.642 0.258 . . . . 0.0 110.863 179.955 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 5.1 p -107.31 128.32 26.21 Favored Pre-proline 0 C--N 1.329 -0.298 0 CA-C-N 116.356 -0.384 . . . . 0.0 111.141 179.885 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 58.3 Cg_endo -71.68 141.11 37.1 Favored 'Trans proline' 0 C--N 1.349 0.581 0 C-N-CA 122.25 1.967 . . . . 0.0 112.039 179.817 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 61.1 t -137.39 90.77 0.77 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.356 0 CA-C-N 116.075 -0.511 . . . . 0.0 111.249 -179.621 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . 59.96 -85.49 0.02 OUTLIER 'General case' 0 C--N 1.331 -0.202 0 CA-C-N 116.0 -0.545 . . . . 0.0 111.42 179.948 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 65' ' ' GLU . . . . . 0.413 ' HG3' ' HG3' ' A' ' 66' ' ' ARG . 11.6 pt-20 -121.81 -22.69 5.7 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.886 0.374 . . . . 0.0 110.937 -179.966 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 66' ' ' ARG . . . . . 0.413 ' HG3' ' HG3' ' A' ' 65' ' ' GLU . 84.8 mtm180 -104.72 156.78 17.69 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.041 -0.527 . . . . 0.0 110.802 -179.919 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 40.9 m -113.61 130.62 56.35 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.981 179.854 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 26.3 t -113.61 146.33 18.34 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.394 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.973 179.943 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 69' ' ' PHE . . . . . . . . . . . . . 16.8 m-85 -104.33 116.68 32.57 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 116.209 -0.451 . . . . 0.0 109.919 -179.894 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 70' ' ' VAL . . . . . 0.641 HG12 ' HD3' ' A' ' 71' ' ' PRO . 0.8 OUTLIER -66.73 -35.58 9.84 Favored Pre-proline 0 CA--C 1.541 0.612 0 N-CA-C 112.602 0.593 . . . . 0.0 112.602 -179.424 . . . . . . . . 3 3 . 1 . 021 nuclear build core ' A' A ' 71' ' ' PRO . . . . . 0.641 ' HD3' HG12 ' A' ' 70' ' ' VAL . 9.5 Cg_exo -70.77 -22.39 27.51 Favored 'Trans proline' 0 C--N 1.36 1.138 0 C-N-CA 122.032 1.821 . . . . 0.0 112.815 -179.508 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 67.6 ttt180 -68.56 -55.63 11.0 Favored 'General case' 0 C--N 1.329 -0.323 0 N-CA-C 112.157 0.429 . . . . 0.0 112.157 -178.791 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 73' ' ' TYR . . . . . 0.509 ' O ' HG13 ' A' ' 77' ' ' ILE . 73.7 m-85 -73.53 -33.74 64.88 Favored 'General case' 0 C--N 1.328 -0.328 0 C-N-CA 120.863 -0.335 . . . . 0.0 110.892 -179.112 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 74' ' ' ILE . . . . . 0.53 HG22 ' HA ' ' A' ' 71' ' ' PRO . 0.3 OUTLIER -67.57 -41.27 85.59 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 N-CA-C 109.703 -0.48 . . . . 0.0 109.703 179.164 . . . . . . . . 3 3 . 1 . 021 nuclear build core ' A' A ' 75' ' ' ASP . . . . . 0.457 ' O ' HG23 ' A' ' 79' ' ' THR . 27.0 t70 -58.85 -37.54 76.7 Favored 'General case' 0 CA--C 1.519 -0.242 0 N-CA-C 109.241 -0.651 . . . . 0.0 109.241 178.703 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 76' ' ' TRP . . . . . 0.46 ' HB3' ' SD ' ' A' ' 109' ' ' MET . 48.6 m0 -66.12 -31.13 71.8 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 115.624 -0.717 . . . . 0.0 110.575 179.337 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 77' ' ' ILE . . . . . 0.509 HG13 ' O ' ' A' ' 73' ' ' TYR . 76.1 mt -69.41 -29.6 42.57 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.353 0 CA-C-O 121.036 0.446 . . . . 0.0 110.333 178.973 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 24.8 mt -91.45 -15.84 28.23 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 115.984 -0.553 . . . . 0.0 111.986 179.898 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 79' ' ' THR . . . . . 0.457 HG23 ' O ' ' A' ' 75' ' ' ASP . 73.6 p -101.84 -52.6 3.15 Favored 'General case' 0 N--CA 1.464 0.225 0 N-CA-C 113.06 0.763 . . . . 0.0 113.06 -178.613 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 80' ' ' THR . . . . . 0.694 ' HB ' ' HD3' ' A' ' 81' ' ' PRO . 62.8 m -51.26 -56.26 21.79 Favored Pre-proline 0 CA--C 1.533 0.291 0 N-CA-C 112.854 0.687 . . . . 0.0 112.854 -178.287 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 81' ' ' PRO . . . . . 0.694 ' HD3' ' HB ' ' A' ' 80' ' ' THR . 52.2 Cg_exo -57.43 -25.12 64.54 Favored 'Trans proline' 0 C--N 1.353 0.766 0 C-N-CA 121.517 1.478 . . . . 0.0 111.613 -179.945 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 82' ' ' LEU . . . . . 0.572 HD23 HG23 ' A' ' 43' ' ' ILE . 12.3 tp -77.14 -32.96 56.75 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 115.741 -0.663 . . . . 0.0 110.393 179.838 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 47.4 mm -67.56 -53.34 32.55 Favored 'Isoleucine or valine' 0 C--O 1.232 0.164 0 CA-C-N 116.377 -0.374 . . . . 0.0 110.227 179.17 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 24.6 m -60.73 -29.96 46.1 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.224 0 N-CA-C 108.897 -0.779 . . . . 0.0 108.897 178.411 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 85' ' ' TYR . . . . . . . . . . . . . 93.4 t80 -65.28 -30.29 71.14 Favored 'General case' 0 N--CA 1.453 -0.297 0 CA-C-N 115.395 -0.82 . . . . 0.0 109.248 178.371 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 86' ' ' PHE . . . . . . . . . . . . . 31.6 t80 -65.44 -51.95 56.62 Favored 'General case' 0 CA--C 1.519 -0.212 0 CA-C-N 115.811 -0.631 . . . . 0.0 109.623 178.988 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 87' ' ' LEU . . . . . 0.639 HD22 HD22 ' A' ' 141' ' ' LEU . 6.0 mp -63.22 -28.85 70.32 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 115.803 -0.635 . . . . 0.0 109.854 179.117 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -68.35 -27.98 73.49 Favored Glycine 0 N--CA 1.449 -0.478 0 C-N-CA 120.707 -0.759 . . . . 0.0 111.256 178.833 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 46.4 mt -76.19 -34.33 59.31 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-O 120.963 0.411 . . . . 0.0 110.282 179.012 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 88.9 mt -79.41 -23.69 43.06 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 115.937 -0.574 . . . . 0.0 110.984 179.681 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 91' ' ' ALA . . . . . 0.46 ' HA ' ' HB2' ' A' ' 149' ' ' ALA . . . -88.46 -45.46 9.93 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.249 -179.903 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 91.92 57.8 1.47 Allowed Glycine 0 N--CA 1.451 -0.364 0 C-N-CA 120.802 -0.713 . . . . 0.0 112.611 -179.833 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 93' ' ' LEU . . . . . 0.496 HD23 ' HB3' ' A' ' 97' ' ' GLU . 10.6 mp -74.07 176.94 6.06 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-O 120.758 0.313 . . . . 0.0 110.779 179.836 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 94' ' ' ASP . . . . . 0.557 ' H ' ' HB2' ' A' ' 97' ' ' GLU . 5.7 m-20 -99.23 -167.0 1.41 Allowed 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.095 -179.947 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 48.8 m -67.58 -49.63 62.25 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 115.903 -0.589 . . . . 0.0 111.509 -179.542 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 96' ' ' ARG . . . . . 0.424 ' O ' HG13 ' A' ' 100' ' ' ILE . 31.4 tpt180 -74.08 -39.77 63.21 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-O 120.904 0.383 . . . . 0.0 110.601 -179.457 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 97' ' ' GLU . . . . . 0.557 ' HB2' ' H ' ' A' ' 94' ' ' ASP . 0.3 OUTLIER -55.53 -47.19 76.7 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 115.824 -0.626 . . . . 0.0 111.391 -179.757 . . . . . . . . 3 3 . 1 . 021 nuclear build core ' A' A ' 98' ' ' PHE . . . . . 0.459 ' O ' HG12 ' A' ' 102' ' ' ILE . 3.3 m-85 -62.53 -41.53 98.92 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.487 -0.324 . . . . 0.0 110.879 179.675 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -65.47 -26.33 71.78 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.553 -0.832 . . . . 0.0 112.66 -179.777 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 100' ' ' ILE . . . . . 0.424 HG13 ' O ' ' A' ' 96' ' ' ARG . 96.5 mt -73.4 -48.82 40.41 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-O 120.688 0.28 . . . . 0.0 111.648 -179.663 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 17.0 m -64.82 -37.78 81.05 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.498 -0.319 . . . . 0.0 111.691 -179.649 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 102' ' ' ILE . . . . . 0.459 HG12 ' O ' ' A' ' 98' ' ' PHE . 49.5 mm -71.55 -49.48 46.34 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.452 -0.34 . . . . 0.0 111.41 -179.757 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 14.0 t -59.74 -30.94 69.18 Favored 'General case' 0 C--N 1.332 -0.164 0 CA-C-O 120.825 0.345 . . . . 0.0 110.938 -179.933 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 104' ' ' LEU . . . . . 0.458 ' O ' HG12 ' A' ' 107' ' ' VAL . 46.3 tp -65.49 -54.37 29.2 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.465 179.498 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 105' ' ' ASN . . . . . 0.634 ' N ' HD22 ' A' ' 105' ' ' ASN . 0.7 OUTLIER -56.91 -26.45 59.25 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 115.996 -0.547 . . . . 0.0 110.764 179.827 . . . . . . . . 3 3 . 1 . 021 nuclear build core ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 39.6 m -68.4 -56.76 7.38 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.13 -0.486 . . . . 0.0 111.38 -179.855 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 107' ' ' VAL . . . . . 0.458 HG12 ' O ' ' A' ' 104' ' ' LEU . 13.2 p -60.45 -36.66 70.98 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.16 0 CA-C-N 116.524 -0.307 . . . . 0.0 111.335 -179.779 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 93.3 t -66.36 -50.24 69.31 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-O 120.957 0.408 . . . . 0.0 111.005 179.716 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 109' ' ' MET . . . . . 0.46 ' SD ' ' HB3' ' A' ' 76' ' ' TRP . 10.0 tpp -59.95 -36.33 76.86 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 115.954 -0.566 . . . . 0.0 110.62 179.948 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 23.1 tp -65.19 -34.27 77.98 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.037 -0.528 . . . . 0.0 110.291 179.607 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -60.01 -51.28 70.32 Favored 'General case' 0 C--N 1.331 -0.218 0 CA-C-N 116.041 -0.527 . . . . 0.0 110.339 179.263 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . -62.21 -39.27 97.47 Favored Glycine 0 C--N 1.331 0.269 0 C-N-CA 120.604 -0.808 . . . . 0.0 111.911 179.245 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 113' ' ' PHE . . . . . . . . . . . . . 2.2 t80 -47.43 -68.22 0.21 Allowed 'General case' 0 C--N 1.332 -0.196 0 CA-C-O 121.063 0.459 . . . . 0.0 110.203 179.318 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -65.12 -21.66 66.83 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 115.512 -0.767 . . . . 0.0 110.856 179.453 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -53.58 -45.03 68.3 Favored Glycine 0 C--N 1.334 0.423 0 C-N-CA 121.068 -0.587 . . . . 0.0 112.496 179.992 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -77.88 -23.59 48.73 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.721 0.295 . . . . 0.0 111.55 179.744 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 117' ' ' MET . . . . . . . . . . . . . 65.3 mtt -96.0 19.15 12.01 Favored 'General case' 0 C--N 1.331 -0.2 0 CA-C-N 116.29 -0.414 . . . . 0.0 111.613 -179.473 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 118' ' ' VAL . . . . . 0.494 HG11 ' N ' ' A' ' 123' ' ' ARG . 19.3 m -68.34 142.61 94.79 Favored Pre-proline 0 C--N 1.328 -0.338 0 CA-C-N 116.71 -0.223 . . . . 0.0 111.586 -179.902 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 119' ' ' PRO . . . . . . . . . . . . . 98.4 Cg_endo -88.0 6.09 5.11 Favored 'Trans proline' 0 N--CA 1.459 -0.513 0 C-N-CA 122.761 2.307 . . . . 0.0 112.524 179.593 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -166.09 -115.15 0.31 Allowed Glycine 0 C--N 1.332 0.327 0 C-N-CA 120.697 -0.763 . . . . 0.0 112.803 -179.814 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 43.5 pt -111.4 12.68 8.58 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.216 0 CA-C-O 120.698 0.285 . . . . 0.0 111.43 -179.634 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 11.2 mm-40 -58.83 -18.88 36.43 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.37 -0.377 . . . . 0.0 110.991 -179.993 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 123' ' ' ARG . . . . . 0.494 ' N ' HG11 ' A' ' 118' ' ' VAL . 17.5 ptt180 -53.32 -30.01 36.76 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.017 -0.538 . . . . 0.0 111.484 -179.964 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 124' ' ' TYR . . . . . . . . . . . . . 29.7 m-85 -76.5 -32.45 58.32 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.352 -0.385 . . . . 0.0 110.927 179.924 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 125' ' ' ALA . . . . . . . . . . . . . . . -72.38 -56.1 6.0 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.067 179.924 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 1.5 mt -56.13 -54.08 49.43 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 115.888 -0.596 . . . . 0.0 110.829 -179.89 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 127' ' ' PHE . . . . . . . . . . . . . 11.0 t80 -64.86 -35.9 82.63 Favored 'General case' 0 N--CA 1.453 -0.306 0 C-N-CA 120.738 -0.385 . . . . 0.0 110.694 179.623 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 128' ' ' GLY . . . . . . . . . . . . . . . -47.53 -44.16 21.93 Favored Glycine 0 C--N 1.332 0.337 0 C-N-CA 120.054 -1.069 . . . . 0.0 110.825 179.111 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 129' ' ' MET . . . . . . . . . . . . . 0.2 OUTLIER -71.77 -37.24 70.5 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.991 0.424 . . . . 0.0 109.99 178.78 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -67.69 -27.59 73.59 Favored Glycine 0 N--CA 1.452 -0.29 0 CA-C-N 115.653 -0.703 . . . . 0.0 112.761 -179.852 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -75.04 -53.85 8.18 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-O 120.696 0.284 . . . . 0.0 110.48 179.944 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 45.4 t -58.54 -40.09 77.65 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.206 0 N-CA-C 109.064 -0.717 . . . . 0.0 109.064 178.546 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -69.09 -35.0 76.01 Favored 'General case' 0 N--CA 1.451 -0.389 0 CA-C-N 115.133 -0.939 . . . . 0.0 110.445 179.174 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 134' ' ' PHE . . . . . 0.442 ' CZ ' ' HA ' ' A' ' 172' ' ' ALA . 76.2 t80 -57.51 -55.27 36.95 Favored 'General case' 0 N--CA 1.451 -0.376 0 N-CA-C 109.763 -0.458 . . . . 0.0 109.763 179.492 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 135' ' ' ILE . . . . . 0.458 ' HA ' HG22 ' A' ' 138' ' ' VAL . 34.7 mt -57.25 -31.5 38.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 115.687 -0.688 . . . . 0.0 109.642 178.888 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . -65.77 -36.11 91.82 Favored Glycine 0 N--CA 1.446 -0.669 0 C-N-CA 120.386 -0.911 . . . . 0.0 111.017 178.537 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 137' ' ' LEU . . . . . 0.454 HD13 HD21 ' A' ' 105' ' ' ASN . 39.1 tp -71.47 -53.23 14.64 Favored 'General case' 0 N--CA 1.454 -0.25 0 N-CA-C 110.355 -0.239 . . . . 0.0 110.355 179.321 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 138' ' ' VAL . . . . . 0.458 HG22 ' HA ' ' A' ' 135' ' ' ILE . 5.0 m -56.36 -31.86 34.12 Favored 'Isoleucine or valine' 0 C--O 1.233 0.194 0 N-CA-C 109.08 -0.711 . . . . 0.0 109.08 178.929 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 139' ' ' TYR . . . . . . . . . . . . . 39.0 t80 -61.41 -45.82 92.74 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 115.367 -0.833 . . . . 0.0 110.127 178.54 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 140' ' ' TYR . . . . . 0.445 ' HE2' HD22 ' A' ' 104' ' ' LEU . 27.4 m-85 -60.95 -37.67 83.2 Favored 'General case' 0 C--N 1.332 -0.157 0 CA-C-N 116.29 -0.414 . . . . 0.0 110.724 179.543 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 141' ' ' LEU . . . . . 0.639 HD22 HD22 ' A' ' 87' ' ' LEU . 83.5 mt -61.92 -35.0 77.1 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.615 179.916 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 17.1 t -96.25 -4.75 10.08 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.071 -0.513 . . . . 0.0 110.546 179.581 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . -74.12 -134.36 0.29 Allowed Glycine 0 CA--C 1.52 0.398 0 C-N-CA 121.129 -0.558 . . . . 0.0 112.885 -179.809 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 144' ' ' PRO . . . . . . . . . . . . . 34.1 Cg_exo -59.91 -23.96 74.5 Favored 'Trans proline' 0 C--N 1.349 0.578 0 C-N-CA 122.752 2.301 . . . . 0.0 112.839 -179.536 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 145' ' ' MET . . . . . . . . . . . . . 59.1 mtt -53.66 -28.69 34.66 Favored 'General case' 0 C--N 1.332 -0.179 0 CA-C-N 116.34 -0.391 . . . . 0.0 111.417 -179.854 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 146' ' ' THR . . . . . . . . . . . . . 74.9 p -70.34 -50.43 39.12 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.233 -0.44 . . . . 0.0 112.063 -179.219 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 47.4 mt-10 -73.62 -24.13 59.99 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.546 -0.297 . . . . 0.0 111.797 -179.025 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 148' ' ' SER . . . . . . . . . . . . . 81.4 p -70.78 -49.14 49.76 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 116.444 -0.343 . . . . 0.0 111.645 -179.281 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 149' ' ' ALA . . . . . 0.46 ' HB2' ' HA ' ' A' ' 91' ' ' ALA . . . -77.98 -38.83 44.21 Favored 'General case' 0 C--N 1.329 -0.319 0 N-CA-C 112.237 0.458 . . . . 0.0 112.237 -179.026 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 150' ' ' SER . . . . . . . . . . . . . 68.4 m -60.92 -8.13 2.92 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.537 -0.302 . . . . 0.0 111.705 -179.382 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 151' ' ' GLN . . . . . . . . . . . . . 78.2 mt-30 -119.02 25.19 10.36 Favored 'General case' 0 C--N 1.329 -0.296 0 N-CA-C 111.588 0.218 . . . . 0.0 111.588 -179.812 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 49.6 mtp180 -103.25 -52.24 3.07 Favored 'General case' 0 C--N 1.331 -0.197 0 CA-C-O 120.868 0.366 . . . . 0.0 111.153 179.717 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 153' ' ' SER . . . . . 0.605 ' HB3' HG12 ' A' ' 156' ' ' ILE . 32.8 t -157.02 169.16 25.44 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-N 115.981 -0.554 . . . . 0.0 110.854 179.407 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 154' ' ' SER . . . . . . . . . . . . . 37.0 t -70.39 -35.75 73.68 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.659 179.784 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -76.71 -31.47 53.71 Favored Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.883 -0.675 . . . . 0.0 112.503 179.827 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 156' ' ' ILE . . . . . 0.605 HG12 ' HB3' ' A' ' 153' ' ' SER . 36.2 mm -61.72 -37.63 78.48 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.234 0 CA-C-O 120.651 0.262 . . . . 0.0 111.1 -179.97 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 157' ' ' LYS . . . . . . . . . . . . . 57.8 tptt -60.73 -55.49 32.59 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 116.306 -0.407 . . . . 0.0 111.871 -179.445 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 62.2 m -60.61 -45.35 94.35 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.323 -0.398 . . . . 0.0 111.885 -179.125 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 159' ' ' LEU . . . . . . . . . . . . . 8.3 tt -68.35 -32.6 72.81 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-N 116.336 -0.393 . . . . 0.0 111.499 -179.198 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 160' ' ' TYR . . . . . . . . . . . . . 79.9 t80 -73.53 -45.62 52.61 Favored 'General case' 0 C--N 1.33 -0.261 0 N-CA-C 111.858 0.318 . . . . 0.0 111.858 -179.148 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 30.0 m -62.81 -40.85 90.28 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.363 0 N-CA-C 111.772 0.286 . . . . 0.0 111.772 -179.292 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 162' ' ' ARG . . . . . 0.405 ' HG2' HG21 ' A' ' 211' ' ' ILE . 29.1 tpt180 -69.35 -45.68 68.83 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.772 0.32 . . . . 0.0 111.388 -179.632 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 163' ' ' LEU . . . . . 0.588 ' HG ' ' HB2' ' A' ' 208' ' ' PHE . 4.3 mp -69.62 -52.5 25.43 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.806 -179.294 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 164' ' ' ARG . . . . . . . . . . . . . 4.6 tmm_? -53.88 -54.01 44.6 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.393 -0.367 . . . . 0.0 111.338 -179.163 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 165' ' ' ASN . . . . . 0.41 ' O ' HG23 ' A' ' 169' ' ' VAL . 4.7 m-20 -56.67 -43.78 80.74 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.937 0.398 . . . . 0.0 110.441 179.715 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 166' ' ' LEU . . . . . 0.552 ' O ' ' HG ' ' A' ' 170' ' ' LEU . 5.6 tp -57.84 -54.53 45.92 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 115.858 -0.61 . . . . 0.0 111.067 -179.938 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 167' ' ' THR . . . . . 0.641 ' HA ' HD11 ' A' ' 170' ' ' LEU . 89.0 m -54.07 -52.25 61.52 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 115.966 -0.561 . . . . 0.0 112.21 -178.925 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 168' ' ' VAL . . . . . . . . . . . . . 94.5 t -53.92 -40.14 43.46 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.366 0 N-CA-C 112.141 0.423 . . . . 0.0 112.141 -179.172 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 169' ' ' VAL . . . . . 0.41 HG23 ' O ' ' A' ' 165' ' ' ASN . 75.2 t -65.82 -65.57 0.56 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.326 0 N-CA-C 112.346 0.498 . . . . 0.0 112.346 -178.959 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 170' ' ' LEU . . . . . 0.718 HD22 HG13 ' A' ' 203' ' ' VAL . 1.0 OUTLIER -61.66 -28.78 69.63 Favored 'General case' 0 C--N 1.33 -0.25 0 N-CA-C 112.544 0.572 . . . . 0.0 112.544 -178.428 . . . . . . . . 3 3 . 1 . 021 nuclear build core ' A' A ' 171' ' ' TRP . . . . . 0.562 ' N ' HD12 ' A' ' 170' ' ' LEU . 4.8 m0 -74.1 -30.77 62.5 Favored 'General case' 0 C--N 1.33 -0.277 0 C-N-CA 120.538 -0.465 . . . . 0.0 110.842 179.801 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 172' ' ' ALA . . . . . 0.442 ' HA ' ' CZ ' ' A' ' 134' ' ' PHE . . . -66.51 -7.87 22.75 Favored 'General case' 0 CA--C 1.516 -0.344 0 CA-C-O 121.273 0.559 . . . . 0.0 110.026 179.163 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 173' ' ' ILE . . . . . 0.718 HG22 ' CG1' ' A' ' 177' ' ' ILE . 6.6 mm -87.19 -35.81 9.02 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.624 0 CA-C-N 115.123 -0.944 . . . . 0.0 111.47 -178.966 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 174' ' ' TYR . . . . . 0.531 ' N ' ' HD2' ' A' ' 175' ' ' PRO . 55.5 m-85 -54.95 -52.09 73.86 Favored Pre-proline 0 C--N 1.329 -0.323 0 N-CA-C 112.75 0.648 . . . . 0.0 112.75 -178.91 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 175' ' ' PRO . . . . . 0.531 ' HD2' ' N ' ' A' ' 174' ' ' TYR . 28.4 Cg_endo -61.99 -39.57 49.52 Favored 'Trans proline' 0 C--N 1.348 0.539 0 C-N-CA 121.963 1.775 . . . . 0.0 113.419 -178.351 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 176' ' ' PHE . . . . . 0.519 ' CE2' ' HA ' ' A' ' 173' ' ' ILE . 0.1 OUTLIER -79.99 -38.15 32.76 Favored 'General case' 0 C--N 1.329 -0.304 0 C-N-CA 120.688 -0.405 . . . . 0.0 111.904 -178.786 . . . . . . . . 3 3 . 1 . 021 nuclear build core ' A' A ' 177' ' ' ILE . . . . . 0.718 ' CG1' HG22 ' A' ' 173' ' ' ILE . 31.7 mm -62.42 -43.58 98.36 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.477 0 N-CA-C 109.723 -0.473 . . . . 0.0 109.723 178.285 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 178' ' ' TRP . . . . . . . . . . . . . 70.3 t90 -60.87 -27.68 68.31 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 115.687 -0.688 . . . . 0.0 109.418 178.789 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 179' ' ' LEU . . . . . 0.422 HD13 ' O ' ' A' ' 179' ' ' LEU . 1.4 tm? -74.04 -45.8 47.32 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 115.187 -0.915 . . . . 0.0 110.764 -179.963 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 180' ' ' LEU . . . . . 0.478 ' HG ' ' O ' ' A' ' 176' ' ' PHE . 4.8 mt -71.33 -49.34 43.54 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.615 -0.266 . . . . 0.0 111.394 -179.372 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . -52.61 174.81 0.2 Allowed Glycine 0 C--N 1.334 0.43 0 C-N-CA 120.659 -0.781 . . . . 0.0 112.937 -179.954 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 182' ' ' PRO . . . . . 0.613 ' HA ' ' HB2' ' A' ' 186' ' ' ALA . 76.4 Cg_exo -46.93 -45.35 21.01 Favored 'Trans proline' 0 CA--C 1.536 0.602 0 C-N-CA 122.853 2.368 . . . . 0.0 113.796 -179.874 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 183' ' ' PRO . . . . . 0.431 ' HD3' ' HB2' ' A' ' 182' ' ' PRO . 79.5 Cg_exo -49.27 -23.48 6.98 Favored 'Trans proline' 0 C--N 1.355 0.908 0 C-N-CA 122.24 1.96 . . . . 0.0 113.194 -179.787 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 184' ' ' GLY . . . . . . . . . . . . . . . -108.74 -99.06 2.58 Favored Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.466 -0.873 . . . . 0.0 113.069 -179.57 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 185' ' ' VAL . . . . . . . . . . . . . 3.5 m -109.07 -5.49 10.89 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 N-CA-C 111.726 0.269 . . . . 0.0 111.726 -179.231 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 186' ' ' ALA . . . . . 0.613 ' HB2' ' HA ' ' A' ' 182' ' ' PRO . . . 55.14 87.28 0.05 OUTLIER 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.366 -0.379 . . . . 0.0 111.629 179.542 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 187' ' ' LEU . . . . . 0.454 HD12 ' HB3' ' A' ' 180' ' ' LEU . 23.5 mt -91.81 -48.97 6.5 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.332 -0.394 . . . . 0.0 110.779 179.637 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 188' ' ' LEU . . . . . . . . . . . . . 55.6 mt -106.9 -154.14 0.51 Allowed 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 115.835 -0.621 . . . . 0.0 110.642 -179.905 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 189' ' ' THR . . . . . . . . . . . . . 2.6 t -97.52 146.16 30.92 Favored Pre-proline 0 C--N 1.329 -0.315 0 CA-C-N 116.406 -0.361 . . . . 0.0 110.918 179.905 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 190' ' ' PRO . . . . . 0.403 ' O ' HG23 ' A' ' 194' ' ' VAL . 9.6 Cg_endo -50.14 -38.46 50.58 Favored 'Trans proline' 0 C--N 1.349 0.597 0 C-N-CA 122.862 2.374 . . . . 0.0 112.769 -179.594 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 191' ' ' THR . . . . . . . . . . . . . 81.6 p -58.25 -44.34 88.27 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.911 0.386 . . . . 0.0 111.249 -179.842 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 192' ' ' VAL . . . . . . . . . . . . . 35.1 t -71.85 -43.13 69.41 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.391 0 CA-C-N 116.03 -0.532 . . . . 0.0 111.401 -179.708 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 193' ' ' ASP . . . . . . . . . . . . . 21.1 t70 -56.55 -49.01 76.07 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.403 -0.362 . . . . 0.0 111.186 -179.783 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 194' ' ' VAL . . . . . 0.501 ' O ' HG23 ' A' ' 198' ' ' VAL . 78.2 t -64.42 -38.15 81.82 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.372 0 CA-C-N 116.262 -0.426 . . . . 0.0 111.198 -179.723 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 195' ' ' ALA . . . . . . . . . . . . . . . -54.15 -48.59 70.69 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 116.518 -0.31 . . . . 0.0 111.482 -179.802 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 196' ' ' LEU . . . . . 0.455 ' O ' ' HB3' ' A' ' 199' ' ' TYR . 94.3 mt -65.65 -39.96 91.97 Favored 'General case' 0 C--N 1.332 -0.166 0 CA-C-O 120.777 0.322 . . . . 0.0 110.814 179.884 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 197' ' ' ILE . . . . . 0.423 HD13 HD12 ' A' ' 200' ' ' LEU . 24.7 mm -58.73 -53.42 47.52 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.37 0 CA-C-O 121.017 0.437 . . . . 0.0 110.198 179.307 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 198' ' ' VAL . . . . . 0.501 HG23 ' O ' ' A' ' 194' ' ' VAL . 87.6 t -55.07 -34.64 32.57 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.459 0 CA-C-N 115.582 -0.736 . . . . 0.0 109.04 178.215 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 199' ' ' TYR . . . . . 0.455 ' HB3' ' O ' ' A' ' 196' ' ' LEU . 79.7 t80 -69.73 -32.58 71.2 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 114.98 -1.009 . . . . 0.0 110.643 179.635 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 200' ' ' LEU . . . . . 0.423 HD12 HD13 ' A' ' 197' ' ' ILE . 68.2 mt -69.17 -41.04 77.74 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 115.756 -0.656 . . . . 0.0 111.697 -179.373 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 201' ' ' ASP . . . . . . . . . . . . . 9.5 m-20 -71.39 -36.31 71.34 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 121.162 0.506 . . . . 0.0 110.451 179.529 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 202' ' ' LEU . . . . . 0.41 ' O ' ' HB ' ' A' ' 206' ' ' VAL . 1.2 mm? -65.99 -33.64 76.27 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 115.462 -0.79 . . . . 0.0 111.918 -179.731 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 203' ' ' VAL . . . . . 0.718 HG13 HD22 ' A' ' 170' ' ' LEU . 9.0 p -79.07 -36.3 18.31 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 N-CA-C 111.885 0.328 . . . . 0.0 111.885 -178.241 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 204' ' ' THR . . . . . 0.429 ' OG1' HD13 ' A' ' 170' ' ' LEU . 94.1 m -64.77 -58.93 4.91 Favored 'General case' 0 C--N 1.328 -0.343 0 C-N-CA 120.082 -0.647 . . . . 0.0 111.101 179.642 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 205' ' ' LYS . . . . . 0.647 ' HE2' ' HB2' ' A' ' 47' ' ' ALA . 60.1 mttp -68.35 -57.83 5.31 Favored 'General case' 0 C--N 1.33 -0.281 0 N-CA-C 112.774 0.657 . . . . 0.0 112.774 -178.028 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 206' ' ' VAL . . . . . 0.41 ' HB ' ' O ' ' A' ' 202' ' ' LEU . 19.3 t -71.16 -37.17 65.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 N-CA-C 112.02 0.378 . . . . 0.0 112.02 -178.654 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 207' ' ' GLY . . . . . 0.511 ' O ' HG13 ' A' ' 211' ' ' ILE . . . -61.75 -61.1 7.12 Favored Glycine 0 N--CA 1.452 -0.263 0 C-N-CA 120.577 -0.821 . . . . 0.0 113.72 -178.997 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 208' ' ' PHE . . . . . 0.588 ' HB2' ' HG ' ' A' ' 163' ' ' LEU . 0.1 OUTLIER -68.84 -29.95 68.38 Favored 'General case' 0 C--O 1.222 -0.362 0 CA-C-N 117.799 0.799 . . . . 0.0 110.8 -179.292 . . . . . . . . 3 3 . 1 . 021 nuclear build core ' A' A ' 209' ' ' GLY . . . . . 0.589 ' HA2' HD11 ' A' ' 40' ' ' LEU . . . -62.07 -35.66 91.78 Favored Glycine 0 N--CA 1.45 -0.368 0 CA-C-N 116.189 -0.46 . . . . 0.0 112.418 179.4 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 210' ' ' PHE . . . . . . . . . . . . . 3.3 m-85 -72.68 -47.38 47.79 Favored 'General case' 0 CA--C 1.513 -0.461 0 N-CA-C 108.513 -0.921 . . . . 0.0 108.513 178.81 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 211' ' ' ILE . . . . . 0.511 HG13 ' O ' ' A' ' 207' ' ' GLY . 3.7 mt -62.8 -27.32 42.8 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.58 0 N-CA-C 107.192 -1.41 . . . . 0.0 107.192 176.468 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 212' ' ' ALA . . . . . 0.531 ' HB3' ' O ' ' A' ' 209' ' ' GLY . . . -67.43 -36.55 81.44 Favored 'General case' 0 N--CA 1.45 -0.468 0 CA-C-N 114.308 -1.314 . . . . 0.0 110.171 179.56 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 213' ' ' LEU . . . . . 0.437 ' HG ' ' O ' ' A' ' 209' ' ' GLY . 81.3 mt -70.17 -53.38 17.45 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 115.012 -0.994 . . . . 0.0 111.594 -179.649 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 214' ' ' ASP . . . . . . . . . . . . . 16.5 m-20 -57.44 -51.54 69.02 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.827 0.346 . . . . 0.0 111.227 -179.592 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 215' ' ' ALA . . . . . . . . . . . . . . . -56.63 -57.25 13.19 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.226 -179.762 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 216' ' ' ALA . . . . . . . . . . . . . . . -58.4 -33.81 70.06 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.275 -0.421 . . . . 0.0 111.387 -179.741 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 217' ' ' ALA . . . . . . . . . . . . . . . -61.04 -34.68 75.25 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 121.029 0.442 . . . . 0.0 110.137 179.635 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 218' ' ' THR . . . . . . . . . . . . . 91.5 m . . . . . 0 C--N 1.331 -0.231 0 CA-C-N 115.716 -0.675 . . . . 0.0 110.821 179.48 . . . . . . . . 0 0 . 1 . 022 nuclear build core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.261 0 N-CA-C 112.719 -0.152 . . . . 0.0 112.719 . . . . . . . . . 0 0 . 1 . 022 nuclear build core ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -73.74 -40.67 63.35 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.858 0.361 . . . . 0.0 110.772 -179.929 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 76.4 p -60.52 -29.49 69.15 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.329 -179.842 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 13.6 p -57.38 -36.13 70.87 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.502 -179.715 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 7' ' ' LEU . . . . . . . . . . . . . 4.1 mm? -57.56 -53.16 61.29 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-N 116.328 -0.396 . . . . 0.0 111.165 -179.839 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 8' ' ' PHE . . . . . 0.516 ' HB2' ' HB2' ' A' ' 55' ' ' ALA . 78.9 m-85 -60.91 -33.48 73.2 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 120.866 0.365 . . . . 0.0 110.752 179.901 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 9' ' ' TRP . . . . . . . . . . . . . 18.9 m95 -63.78 -45.34 90.16 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-O 121.245 0.545 . . . . 0.0 109.678 179.82 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 72.3 mt -63.45 -34.34 77.55 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-N 115.383 -0.826 . . . . 0.0 110.12 179.302 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -66.29 -37.02 92.5 Favored Glycine 0 N--CA 1.449 -0.46 0 C-N-CA 120.77 -0.728 . . . . 0.0 111.596 179.179 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -66.74 -33.18 75.06 Favored 'General case' 0 C--N 1.332 -0.17 0 CA-C-O 120.961 0.41 . . . . 0.0 110.303 179.337 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 45.0 mm -65.19 -50.79 71.99 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.212 0 CA-C-N 115.904 -0.589 . . . . 0.0 110.235 179.099 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -59.35 -31.42 69.88 Favored Glycine 0 N--CA 1.449 -0.466 0 C-N-CA 120.773 -0.727 . . . . 0.0 111.836 179.394 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 15' ' ' MET . . . . . 0.45 ' HB3' ' HB2' ' A' ' 48' ' ' ALA . 22.0 mmt -70.87 -45.61 64.11 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-O 120.686 0.279 . . . . 0.0 110.583 179.586 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 21.8 tp -54.66 -38.31 66.78 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.668 179.59 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 64.2 t -67.06 -47.54 81.76 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.191 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.03 179.927 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -64.65 -49.45 64.22 Favored Glycine 0 C--N 1.331 0.281 0 C-N-CA 120.684 -0.77 . . . . 0.0 112.17 179.679 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 22.2 m -49.56 -46.22 48.55 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-O 120.72 0.295 . . . . 0.0 111.12 -179.807 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 85.6 mt -72.22 -40.01 68.11 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-N 116.359 -0.382 . . . . 0.0 111.403 179.646 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -61.28 -30.17 70.31 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.454 -0.339 . . . . 0.0 111.817 -179.484 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 22' ' ' PHE . . . . . 0.692 ' HB2' HG22 ' A' ' 41' ' ' VAL . 13.7 m-85 -90.74 -40.43 11.84 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.735 0.302 . . . . 0.0 111.149 -179.622 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -62.75 -50.71 69.97 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.343 -179.732 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 24' ' ' TRP . . . . . . . . . . . . . 2.2 t-105 -60.96 -41.7 96.84 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 115.968 -0.56 . . . . 0.0 111.042 -179.945 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.329 -0.302 0 CA-C-O 120.877 0.37 . . . . 0.0 110.946 179.752 . . . . . . . . 0 0 . 1 . 022 nuclear build core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.305 0 N-CA-C 112.593 -0.203 . . . . 0.0 112.593 . . . . . . . . . 0 0 . 1 . 022 nuclear build core ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 12.7 mm-40 -69.34 -20.88 63.86 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-O 120.86 0.362 . . . . 0.0 110.917 179.95 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 34' ' ' ARG . . . . . . . . . . . . . 41.5 ttm180 -51.02 -29.01 11.38 Favored 'General case' 0 C--N 1.332 -0.185 0 CA-C-N 115.958 -0.564 . . . . 0.0 111.539 -179.772 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 86.4 mtm180 -61.99 -45.89 91.65 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.899 0.38 . . . . 0.0 110.917 -179.969 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 88.0 m-85 -67.55 -29.26 68.59 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.044 -0.526 . . . . 0.0 111.224 179.961 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 37' ' ' TYR . . . . . 0.528 ' O ' HG23 ' A' ' 41' ' ' VAL . 51.7 m-85 -74.6 -54.11 8.08 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.255 -179.577 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 9.4 p -56.99 -36.6 51.18 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-O 120.949 0.405 . . . . 0.0 110.474 179.794 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 48.3 m -65.66 -51.37 60.04 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 115.901 -0.59 . . . . 0.0 110.608 179.493 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 40' ' ' LEU . . . . . 0.453 HD13 ' CE1' ' A' ' 208' ' ' PHE . 16.6 tp -57.05 -47.24 81.43 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 115.832 -0.622 . . . . 0.0 110.624 179.702 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 41' ' ' VAL . . . . . 0.692 HG22 ' HB2' ' A' ' 22' ' ' PHE . 64.8 t -60.0 -34.74 57.45 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.41 0 CA-C-N 115.836 -0.62 . . . . 0.0 110.11 179.183 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -60.31 -36.2 90.3 Favored Glycine 0 N--CA 1.449 -0.448 0 C-N-CA 120.682 -0.77 . . . . 0.0 111.817 179.494 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 43' ' ' ILE . . . . . 0.675 HG22 ' HE3' ' A' ' 205' ' ' LYS . 0.8 OUTLIER -67.31 -57.27 10.38 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.139 0 CA-C-O 120.65 0.262 . . . . 0.0 110.817 179.44 . . . . . . . . 3 3 . 1 . 022 nuclear build core ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 55.6 m -57.11 -25.0 58.07 Favored 'General case' 0 C--O 1.231 0.113 0 CA-C-N 116.42 -0.354 . . . . 0.0 111.188 -179.945 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -77.33 -54.71 4.59 Favored Glycine 0 CA--C 1.518 0.267 0 C-N-CA 120.793 -0.718 . . . . 0.0 113.162 -179.504 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 46' ' ' ILE . . . . . 0.41 ' O ' HG22 ' A' ' 49' ' ' VAL . 25.8 pt -58.06 -40.89 78.92 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.185 0 CA-C-O 120.93 0.395 . . . . 0.0 111.01 -179.647 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 47' ' ' ALA . . . . . 0.66 ' HB2' ' HE2' ' A' ' 205' ' ' LYS . . . -67.92 -38.62 83.13 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.004 179.205 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 48' ' ' ALA . . . . . 0.45 ' HB2' ' HB3' ' A' ' 15' ' ' MET . . . -55.41 -44.56 76.29 Favored 'General case' 0 C--O 1.232 0.152 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.733 -179.708 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 49' ' ' VAL . . . . . 0.41 HG22 ' O ' ' A' ' 46' ' ' ILE . 30.5 m -72.56 -33.82 46.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.544 -0.298 . . . . 0.0 111.141 -179.562 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -63.37 -36.62 84.31 Favored 'General case' 0 C--N 1.331 -0.206 0 CA-C-O 120.989 0.424 . . . . 0.0 110.748 179.473 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 28.5 m-85 -73.0 -36.25 67.0 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 115.915 -0.584 . . . . 0.0 110.442 179.794 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -65.47 -42.35 92.35 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 115.979 -0.555 . . . . 0.0 110.957 179.54 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 53' ' ' VAL . . . . . 0.506 ' O ' HG12 ' A' ' 58' ' ' VAL . 25.4 m -71.48 -47.33 59.17 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.188 0 CA-C-N 116.451 -0.341 . . . . 0.0 110.83 179.821 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 54' ' ' MET . . . . . 0.517 ' HG2' ' HG2' ' A' ' 71' ' ' PRO . 72.6 mtm -62.14 -31.97 72.51 Favored 'General case' 0 C--N 1.332 -0.19 0 CA-C-O 121.058 0.456 . . . . 0.0 110.007 179.439 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 55' ' ' ALA . . . . . 0.516 ' HB2' ' HB2' ' A' ' 8' ' ' PHE . . . -67.31 -32.51 73.53 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 115.701 -0.681 . . . . 0.0 111.04 179.306 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 76.3 mt -79.77 -4.4 51.82 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.28 -179.871 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 90.82 -16.09 59.12 Favored Glycine 0 CA--C 1.518 0.234 0 C-N-CA 120.539 -0.839 . . . . 0.0 113.288 179.54 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 58' ' ' VAL . . . . . 0.506 HG12 ' O ' ' A' ' 53' ' ' VAL . 13.0 p -67.4 144.37 14.6 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 117.108 0.454 . . . . 0.0 110.819 -179.884 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 94.05 -12.47 69.12 Favored Glycine 0 N--CA 1.45 -0.412 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.053 -179.461 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 60' ' ' TRP . . . . . . . . . . . . . 13.3 m0 -80.02 111.15 16.08 Favored 'General case' 0 C--N 1.331 -0.213 0 N-CA-C 110.329 -0.249 . . . . 0.0 110.329 179.703 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 6.9 p -111.29 129.56 23.93 Favored Pre-proline 0 C--N 1.329 -0.305 0 CA-C-N 116.61 -0.268 . . . . 0.0 111.201 -179.866 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 60.1 Cg_endo -71.81 152.15 57.96 Favored 'Trans proline' 0 C--N 1.35 0.618 0 C-N-CA 122.373 2.048 . . . . 0.0 112.292 179.96 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 93.7 t -143.38 94.37 0.51 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 115.929 -0.578 . . . . 0.0 110.761 -179.74 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . 58.19 -87.04 0.02 OUTLIER 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.11 -179.813 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 12.1 mm-40 -120.84 -23.19 6.0 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.288 -0.415 . . . . 0.0 110.591 179.773 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 66' ' ' ARG . . . . . . . . . . . . . 20.3 mmm180 -98.69 165.95 11.56 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.013 -0.539 . . . . 0.0 110.449 179.994 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 88.1 m -128.1 123.36 34.31 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-O 120.898 0.38 . . . . 0.0 111.173 179.947 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 68' ' ' VAL . . . . . 0.494 HG21 ' SD ' ' A' ' 117' ' ' MET . 27.3 m -106.73 146.68 12.89 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.054 -0.521 . . . . 0.0 110.702 179.834 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 69' ' ' PHE . . . . . . . . . . . . . 21.7 m-85 -106.59 112.92 26.13 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 116.132 -0.485 . . . . 0.0 109.989 -179.511 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 70' ' ' VAL . . . . . 0.58 ' N ' ' HD2' ' A' ' 71' ' ' PRO . 15.0 t -66.31 -47.9 58.82 Favored Pre-proline 0 C--N 1.322 -0.61 0 CA-C-N 116.24 -0.436 . . . . 0.0 112.076 -179.293 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 71' ' ' PRO . . . . . 0.58 ' HD2' ' N ' ' A' ' 70' ' ' VAL . 40.5 Cg_endo -66.16 -18.07 55.67 Favored 'Trans proline' 0 C--N 1.351 0.697 0 C-N-CA 122.115 1.877 . . . . 0.0 113.274 -179.327 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 72.3 ttt180 -72.85 -55.49 6.58 Favored 'General case' 0 C--O 1.235 0.296 0 CA-C-O 120.664 0.268 . . . . 0.0 111.712 -179.434 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 73' ' ' TYR . . . . . . . . . . . . . 71.5 m-85 -70.52 -31.58 68.72 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.524 -0.307 . . . . 0.0 110.769 -179.321 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 74' ' ' ILE . . . . . 0.46 HG22 ' HA ' ' A' ' 71' ' ' PRO . 0.4 OUTLIER -69.97 -39.56 77.59 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.229 0 N-CA-C 109.793 -0.447 . . . . 0.0 109.793 179.137 . . . . . . . . 3 3 . 1 . 022 nuclear build core ' A' A ' 75' ' ' ASP . . . . . 0.473 ' O ' HG23 ' A' ' 79' ' ' THR . 18.8 t70 -58.55 -37.6 76.07 Favored 'General case' 0 CA--C 1.519 -0.232 0 N-CA-C 109.25 -0.648 . . . . 0.0 109.25 178.713 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 76' ' ' TRP . . . . . 0.482 ' HB3' ' SD ' ' A' ' 109' ' ' MET . 43.9 m0 -66.97 -34.99 78.97 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 115.742 -0.663 . . . . 0.0 110.194 178.926 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 77' ' ' ILE . . . . . 0.425 HD12 ' HA ' ' A' ' 74' ' ' ILE . 97.0 mt -65.43 -28.65 44.93 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 115.948 -0.569 . . . . 0.0 110.688 179.497 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 38.3 mt -91.86 -25.01 19.16 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.223 -0.444 . . . . 0.0 112.12 -179.955 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 79' ' ' THR . . . . . 0.473 HG23 ' O ' ' A' ' 75' ' ' ASP . 67.2 p -92.69 -52.31 4.69 Favored 'General case' 0 N--CA 1.464 0.261 0 N-CA-C 113.671 0.989 . . . . 0.0 113.671 -177.74 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 80' ' ' THR . . . . . 0.442 ' N ' ' HD2' ' A' ' 81' ' ' PRO . 33.4 m -49.33 -54.55 28.8 Favored Pre-proline 0 C--N 1.329 -0.314 0 N-CA-C 113.159 0.8 . . . . 0.0 113.159 -178.163 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 81' ' ' PRO . . . . . 0.442 ' HD2' ' N ' ' A' ' 80' ' ' THR . 36.6 Cg_endo -63.13 -19.11 68.02 Favored 'Trans proline' 0 C--N 1.351 0.674 0 C-N-CA 121.463 1.442 . . . . 0.0 111.376 -179.513 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 82' ' ' LEU . . . . . . . . . . . . . 14.1 tp -77.05 -33.54 57.24 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 115.643 -0.708 . . . . 0.0 110.256 179.727 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 83' ' ' ILE . . . . . 0.428 HD11 HG21 ' A' ' 43' ' ' ILE . 32.8 mm -68.89 -52.62 32.83 Favored 'Isoleucine or valine' 0 C--O 1.232 0.174 0 CA-C-N 115.98 -0.555 . . . . 0.0 109.867 179.05 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 84' ' ' VAL . . . . . 0.433 HG22 ' HA ' ' A' ' 81' ' ' PRO . 27.9 m -61.21 -30.39 47.74 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.209 0 N-CA-C 109.513 -0.551 . . . . 0.0 109.513 178.797 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 85' ' ' TYR . . . . . 0.4 ' HB2' ' O ' ' A' ' 81' ' ' PRO . 82.7 t80 -65.87 -32.91 74.69 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 115.48 -0.782 . . . . 0.0 109.347 178.741 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 86' ' ' PHE . . . . . 0.418 ' HE2' ' HB2' ' A' ' 40' ' ' LEU . 10.8 t80 -63.91 -51.74 63.08 Favored 'General case' 0 N--CA 1.456 -0.133 0 CA-C-N 115.681 -0.691 . . . . 0.0 109.956 179.219 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 8.8 mp -61.32 -32.66 72.53 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 115.701 -0.681 . . . . 0.0 110.457 179.67 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -68.71 -27.96 73.47 Favored Glycine 0 N--CA 1.45 -0.407 0 C-N-CA 120.731 -0.747 . . . . 0.0 111.65 179.368 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 47.5 mt -72.13 -41.8 66.77 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.87 0.367 . . . . 0.0 110.646 179.539 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 57.0 mt -65.16 -45.8 83.47 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 115.951 -0.568 . . . . 0.0 111.059 179.942 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 91' ' ' ALA . . . . . 0.466 ' HB1' ' HB3' ' A' ' 148' ' ' SER . . . -71.55 -55.2 8.28 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.318 -0.401 . . . . 0.0 111.167 -179.696 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 99.5 67.62 0.86 Allowed Glycine 0 CA--C 1.519 0.283 0 C-N-CA 120.812 -0.709 . . . . 0.0 112.684 179.893 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 9.2 mp -75.34 -172.74 1.85 Allowed 'General case' 0 C--N 1.33 -0.245 0 CA-C-O 120.74 0.305 . . . . 0.0 110.856 179.911 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 94' ' ' ASP . . . . . 0.474 ' H ' ' HB2' ' A' ' 97' ' ' GLU . 6.7 m-20 -96.91 -173.98 2.86 Favored 'General case' 0 C--N 1.332 -0.174 0 CA-C-O 121.073 0.464 . . . . 0.0 111.266 -179.823 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 50.4 m -67.64 -51.58 48.34 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 115.78 -0.646 . . . . 0.0 111.308 -179.793 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 79.8 ttt180 -74.22 -34.86 63.82 Favored 'General case' 0 C--N 1.331 -0.197 0 CA-C-O 120.964 0.412 . . . . 0.0 110.575 -179.579 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 97' ' ' GLU . . . . . 0.474 ' HB2' ' H ' ' A' ' 94' ' ' ASP . 0.3 OUTLIER -56.88 -45.15 82.72 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 115.687 -0.688 . . . . 0.0 111.241 -179.812 . . . . . . . . 3 3 . 1 . 022 nuclear build core ' A' A ' 98' ' ' PHE . . . . . 0.443 ' O ' HG12 ' A' ' 102' ' ' ILE . 4.8 m-85 -62.17 -42.92 99.73 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.834 0.35 . . . . 0.0 110.71 179.487 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -62.6 -28.8 72.01 Favored Glycine 0 N--CA 1.45 -0.401 0 C-N-CA 120.8 -0.714 . . . . 0.0 112.682 -179.865 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 96.1 mt -72.46 -41.91 64.32 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.234 0 CA-C-O 120.873 0.368 . . . . 0.0 111.198 -179.927 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 53.8 t -67.45 -43.64 87.34 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.32 -179.932 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 102' ' ' ILE . . . . . 0.443 HG12 ' O ' ' A' ' 98' ' ' PHE . 43.0 mm -68.07 -49.59 66.49 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.63 -179.495 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 14.9 t -57.71 -33.59 68.57 Favored 'General case' 0 C--O 1.233 0.186 0 CA-C-O 120.762 0.315 . . . . 0.0 111.173 -179.701 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 41.2 tp -65.75 -48.16 72.84 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.3 -0.409 . . . . 0.0 110.545 179.601 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 105' ' ' ASN . . . . . 0.597 ' N ' HD22 ' A' ' 105' ' ' ASN . 0.8 OUTLIER -61.16 -26.08 67.45 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.766 179.758 . . . . . . . . 3 3 . 1 . 022 nuclear build core ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 91.6 m -69.07 -57.6 5.2 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-N 116.378 -0.374 . . . . 0.0 111.425 -179.934 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 8.3 p -58.58 -37.32 64.3 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.237 0 CA-C-N 116.531 -0.304 . . . . 0.0 110.942 -179.816 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 73.9 t -66.46 -51.97 51.76 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.898 179.532 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 109' ' ' MET . . . . . 0.482 ' SD ' ' HB3' ' A' ' 76' ' ' TRP . 9.8 tpp -61.36 -32.61 72.52 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.018 -0.537 . . . . 0.0 110.387 179.753 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 10.0 mt -72.31 -30.29 64.64 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 115.848 -0.615 . . . . 0.0 109.939 179.38 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -60.06 -45.63 92.22 Favored 'General case' 0 CA--C 1.519 -0.234 0 N-CA-C 109.249 -0.649 . . . . 0.0 109.249 178.248 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . -70.26 -41.74 67.98 Favored Glycine 0 N--CA 1.449 -0.441 0 CA-C-N 115.501 -0.772 . . . . 0.0 111.19 178.392 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 113' ' ' PHE . . . . . . . . . . . . . 2.0 t80 -48.81 -65.95 0.48 Allowed 'General case' 0 CA--C 1.52 -0.186 0 N-CA-C 109.353 -0.61 . . . . 0.0 109.353 178.82 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 114' ' ' ALA . . . . . 0.504 ' HB3' HD22 ' A' ' 126' ' ' LEU . . . -64.41 -19.23 65.38 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 115.467 -0.788 . . . . 0.0 110.406 178.699 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -53.1 -51.1 48.59 Favored Glycine 0 C--N 1.335 0.488 0 C-N-CA 120.892 -0.671 . . . . 0.0 111.86 179.495 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 116' ' ' ALA . . . . . 0.455 ' HB1' HG12 ' A' ' 68' ' ' VAL . . . -78.02 -18.44 55.87 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-O 120.87 0.367 . . . . 0.0 110.948 179.279 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 117' ' ' MET . . . . . 0.494 ' SD ' HG21 ' A' ' 68' ' ' VAL . 22.3 mmt -81.9 18.56 1.28 Allowed 'General case' 0 C--N 1.331 -0.218 0 CA-C-N 116.015 -0.539 . . . . 0.0 111.673 -179.441 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 118' ' ' VAL . . . . . 0.441 HG11 ' N ' ' A' ' 123' ' ' ARG . 32.6 m -89.85 138.71 27.72 Favored Pre-proline 0 C--N 1.327 -0.371 0 CA-C-N 116.73 -0.213 . . . . 0.0 111.375 -179.95 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 119' ' ' PRO . . . . . . . . . . . . . 70.3 Cg_endo -89.98 -3.76 5.4 Favored 'Trans proline' 0 N--CA 1.456 -0.692 0 C-N-CA 122.73 2.286 . . . . 0.0 112.235 179.61 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -138.2 -110.83 0.97 Allowed Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.908 -179.765 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 46.8 pt -126.99 14.93 3.6 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.214 0 CA-C-O 120.738 0.304 . . . . 0.0 111.585 -179.384 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 25.6 mt-10 -61.74 -18.64 60.53 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-N 116.353 -0.385 . . . . 0.0 111.041 -179.8 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 123' ' ' ARG . . . . . 0.464 ' HB2' ' HH2' ' A' ' 178' ' ' TRP . 7.6 ptt180 -52.6 -30.12 29.5 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 115.976 -0.557 . . . . 0.0 112.085 -179.66 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 124' ' ' TYR . . . . . . . . . . . . . 50.9 m-85 -69.16 -32.44 71.79 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.794 0.331 . . . . 0.0 111.364 -179.668 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 125' ' ' ALA . . . . . . . . . . . . . . . -72.59 -56.14 5.81 Favored 'General case' 0 C--O 1.236 0.346 0 CA-C-N 116.304 -0.407 . . . . 0.0 111.296 -179.504 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 126' ' ' LEU . . . . . 0.504 HD22 ' HB3' ' A' ' 114' ' ' ALA . 1.2 mt -51.49 -45.35 62.79 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 115.839 -0.619 . . . . 0.0 110.922 -179.821 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 127' ' ' PHE . . . . . . . . . . . . . 3.6 t80 -67.65 -38.64 84.11 Favored 'General case' 0 C--N 1.33 -0.269 0 C-N-CA 120.874 -0.33 . . . . 0.0 110.394 179.581 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 128' ' ' GLY . . . . . . . . . . . . . . . -46.48 -43.1 14.56 Favored Glycine 0 C--N 1.332 0.337 0 C-N-CA 120.21 -0.995 . . . . 0.0 110.991 179.219 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 129' ' ' MET . . . . . . . . . . . . . 0.4 OUTLIER -71.59 -41.32 69.13 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 115.383 -0.408 . . . . 0.0 110.18 179.04 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -63.61 -28.98 73.34 Favored Glycine 0 C--N 1.332 0.321 0 C-N-CA 121.066 -0.588 . . . . 0.0 113.016 -179.665 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -74.69 -53.64 8.89 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.729 0.265 . . . . 0.0 110.529 -179.901 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 61.4 t -59.32 -40.47 81.52 Favored 'Isoleucine or valine' 0 C--O 1.234 0.289 0 N-CA-C 109.205 -0.665 . . . . 0.0 109.205 178.832 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -67.51 -34.08 76.38 Favored 'General case' 0 N--CA 1.452 -0.353 0 CA-C-N 115.201 -0.908 . . . . 0.0 110.48 179.175 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 134' ' ' PHE . . . . . 0.421 ' CZ ' ' HA ' ' A' ' 172' ' ' ALA . 82.2 t80 -56.04 -52.59 63.7 Favored 'General case' 0 N--CA 1.451 -0.417 0 CA-C-N 116.072 -0.513 . . . . 0.0 109.875 179.328 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 135' ' ' ILE . . . . . 0.457 ' HA ' HG22 ' A' ' 138' ' ' VAL . 53.3 mt -58.14 -34.31 49.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 115.798 -0.637 . . . . 0.0 109.855 179.094 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . -63.73 -36.62 93.56 Favored Glycine 0 C--N 1.334 0.422 0 C-N-CA 120.312 -0.947 . . . . 0.0 111.356 178.75 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 137' ' ' LEU . . . . . 0.426 HD13 HD21 ' A' ' 105' ' ' ASN . 35.1 tp -71.24 -53.56 13.95 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.7 0.286 . . . . 0.0 110.453 179.448 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 138' ' ' VAL . . . . . 0.457 HG22 ' HA ' ' A' ' 135' ' ' ILE . 5.3 m -55.98 -31.94 32.02 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.218 0 CA-C-O 121.164 0.507 . . . . 0.0 109.656 179.458 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 139' ' ' TYR . . . . . . . . . . . . . 38.6 t80 -60.82 -47.99 83.83 Favored 'General case' 0 N--CA 1.454 -0.228 0 CA-C-N 115.528 -0.76 . . . . 0.0 109.909 178.511 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 15.5 m-85 -56.5 -37.98 71.13 Favored 'General case' 0 C--N 1.334 -0.093 0 CA-C-N 116.056 -0.52 . . . . 0.0 110.81 179.22 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 141' ' ' LEU . . . . . . . . . . . . . 70.5 mt -64.28 -34.95 79.29 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.057 -0.519 . . . . 0.0 110.708 -179.853 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 13.8 t -94.29 -7.57 10.03 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.79 179.828 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . -73.89 -131.8 0.21 Allowed Glycine 0 CA--C 1.521 0.43 0 C-N-CA 120.891 -0.671 . . . . 0.0 112.673 -179.765 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 144' ' ' PRO . . . . . . . . . . . . . 28.1 Cg_endo -62.04 -23.7 75.95 Favored 'Trans proline' 0 C--N 1.347 0.478 0 C-N-CA 122.528 2.152 . . . . 0.0 112.673 -179.859 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 145' ' ' MET . . . . . . . . . . . . . 52.4 mtt -53.99 -32.02 52.78 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-O 120.661 0.267 . . . . 0.0 111.436 -179.815 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 146' ' ' THR . . . . . . . . . . . . . 73.2 p -72.06 -46.0 58.59 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.426 -0.352 . . . . 0.0 111.479 -179.693 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 42.4 mt-10 -72.7 -28.11 62.48 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.471 -179.64 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 148' ' ' SER . . . . . 0.466 ' HB3' ' HB1' ' A' ' 91' ' ' ALA . 32.6 t -70.32 -43.87 69.42 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-O 120.754 0.311 . . . . 0.0 111.105 -179.622 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 149' ' ' ALA . . . . . . . . . . . . . . . -75.11 -40.12 60.13 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.147 -0.479 . . . . 0.0 111.198 -179.838 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 150' ' ' SER . . . . . . . . . . . . . 69.0 m -63.61 -22.91 67.15 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.096 -179.909 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 151' ' ' GLN . . . . . . . . . . . . . 46.2 mt-30 -105.53 6.82 32.6 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.263 -0.426 . . . . 0.0 111.435 -179.751 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 31.9 tpt180 -84.11 -51.7 6.87 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.88 0.372 . . . . 0.0 110.542 179.646 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 153' ' ' SER . . . . . 0.596 ' HB3' HG12 ' A' ' 156' ' ' ILE . 23.1 t -157.67 169.98 23.43 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-N 115.902 -0.59 . . . . 0.0 110.449 179.091 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 154' ' ' SER . . . . . . . . . . . . . 82.7 p -71.01 -39.72 72.22 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.788 0.328 . . . . 0.0 110.5 179.555 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -77.09 -36.6 34.94 Favored Glycine 0 N--CA 1.452 -0.241 0 C-N-CA 120.864 -0.684 . . . . 0.0 112.595 179.752 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 156' ' ' ILE . . . . . 0.596 HG12 ' HB3' ' A' ' 153' ' ' SER . 28.4 mm -51.64 -38.18 21.17 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.215 0 CA-C-O 120.623 0.249 . . . . 0.0 111.438 -179.859 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 157' ' ' LYS . . . . . 0.414 ' O ' HG13 ' A' ' 161' ' ' VAL . 63.6 tttp -60.03 -48.78 80.3 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.283 -0.417 . . . . 0.0 111.678 -179.795 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 41.3 t -63.78 -47.48 80.75 Favored 'General case' 0 C--N 1.328 -0.351 0 N-CA-C 111.96 0.355 . . . . 0.0 111.96 -179.095 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 159' ' ' LEU . . . . . 0.528 HD23 HD13 ' A' ' 163' ' ' LEU . 1.6 tt -67.71 -31.81 72.02 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 116.494 -0.321 . . . . 0.0 111.28 -179.326 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 160' ' ' TYR . . . . . . . . . . . . . 79.9 t80 -74.05 -44.42 54.33 Favored 'General case' 0 C--N 1.329 -0.315 0 N-CA-C 111.946 0.35 . . . . 0.0 111.946 -179.218 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 161' ' ' VAL . . . . . 0.414 HG13 ' O ' ' A' ' 157' ' ' LYS . 30.4 m -62.01 -41.18 90.03 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 N-CA-C 111.691 0.256 . . . . 0.0 111.691 -179.205 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 162' ' ' ARG . . . . . . . . . . . . . 94.7 mtt180 -67.87 -41.29 83.09 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-O 120.778 0.323 . . . . 0.0 111.312 -179.85 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 163' ' ' LEU . . . . . 0.601 ' HG ' ' HB2' ' A' ' 208' ' ' PHE . 7.1 mp -71.96 -54.93 8.46 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.302 -0.408 . . . . 0.0 112.064 -179.208 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 164' ' ' ARG . . . . . 0.434 ' O ' HG23 ' A' ' 168' ' ' VAL . 4.8 tmm_? -53.97 -53.18 56.4 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.273 -0.422 . . . . 0.0 111.568 -179.408 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 165' ' ' ASN . . . . . 0.485 ' O ' HG23 ' A' ' 169' ' ' VAL . 4.1 m-20 -57.05 -51.75 68.02 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.4 -0.364 . . . . 0.0 111.368 -179.255 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 166' ' ' LEU . . . . . 0.472 ' O ' ' HG ' ' A' ' 170' ' ' LEU . 5.5 tt -58.28 -52.12 66.94 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.124 -0.489 . . . . 0.0 111.867 -179.241 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 167' ' ' THR . . . . . 0.453 ' O ' ' HB2' ' A' ' 171' ' ' TRP . 91.3 m -55.37 -53.38 56.94 Favored 'General case' 0 C--N 1.328 -0.34 0 N-CA-C 112.643 0.609 . . . . 0.0 112.643 -178.71 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 168' ' ' VAL . . . . . 0.434 HG23 ' O ' ' A' ' 164' ' ' ARG . 96.3 t -55.21 -40.83 57.63 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.195 0 N-CA-C 112.312 0.486 . . . . 0.0 112.312 -178.558 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 169' ' ' VAL . . . . . 0.485 HG23 ' O ' ' A' ' 165' ' ' ASN . 80.2 t -60.54 -64.66 0.57 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.39 0 N-CA-C 111.798 0.296 . . . . 0.0 111.798 -179.343 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 170' ' ' LEU . . . . . 0.489 HD12 ' N ' ' A' ' 171' ' ' TRP . 1.6 pp -63.98 -27.63 69.26 Favored 'General case' 0 C--N 1.33 -0.26 0 N-CA-C 112.08 0.4 . . . . 0.0 112.08 -178.781 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 171' ' ' TRP . . . . . 0.489 ' N ' HD12 ' A' ' 170' ' ' LEU . 1.5 m0 -72.14 -31.14 65.71 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-O 120.926 0.393 . . . . 0.0 110.312 179.383 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 172' ' ' ALA . . . . . 0.421 ' HA ' ' CZ ' ' A' ' 134' ' ' PHE . . . -73.04 -6.19 43.87 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 115.816 -0.629 . . . . 0.0 110.615 179.94 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 173' ' ' ILE . . . . . 0.602 HG22 HD11 ' A' ' 177' ' ' ILE . 36.5 mm -87.78 -21.78 7.01 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.216 0 CA-C-N 115.838 -0.619 . . . . 0.0 111.132 179.787 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 174' ' ' TYR . . . . . 0.437 ' HB2' ' HD3' ' A' ' 175' ' ' PRO . 25.9 m-85 -54.57 -49.55 90.46 Favored Pre-proline 0 N--CA 1.465 0.3 0 CA-C-N 116.49 -0.323 . . . . 0.0 111.694 -179.913 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 175' ' ' PRO . . . . . 0.437 ' HD3' ' HB2' ' A' ' 174' ' ' TYR . 82.7 Cg_exo -47.63 -28.37 9.13 Favored 'Trans proline' 0 C--N 1.353 0.768 0 C-N-CA 122.163 1.909 . . . . 0.0 112.259 179.912 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 176' ' ' PHE . . . . . 0.457 ' O ' ' HG ' ' A' ' 180' ' ' LEU . 95.9 m-85 -80.31 -49.61 11.31 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.026 -0.534 . . . . 0.0 111.72 -179.99 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 177' ' ' ILE . . . . . 0.602 HD11 HG22 ' A' ' 173' ' ' ILE . 2.6 mm -60.1 -45.12 96.14 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.537 0 N-CA-C 112.568 0.581 . . . . 0.0 112.568 -177.894 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 178' ' ' TRP . . . . . 0.464 ' HH2' ' HB2' ' A' ' 123' ' ' ARG . 80.5 t90 -66.63 -40.5 88.76 Favored 'General case' 0 N--CA 1.464 0.255 0 CA-C-O 121.095 0.474 . . . . 0.0 110.644 179.867 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 179' ' ' LEU . . . . . 0.544 ' O ' HG22 ' A' ' 185' ' ' VAL . 0.9 OUTLIER -65.28 -52.43 54.31 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-N 115.732 -0.667 . . . . 0.0 111.272 -179.216 . . . . . . . . 3 3 . 1 . 022 nuclear build core ' A' A ' 180' ' ' LEU . . . . . 0.551 HD22 HD11 ' A' ' 187' ' ' LEU . 9.8 mt -77.6 -52.44 9.02 Favored 'General case' 0 CA--C 1.532 0.266 0 N-CA-C 112.395 0.517 . . . . 0.0 112.395 -178.586 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . -59.89 -85.54 0.04 OUTLIER Glycine 0 C--N 1.333 0.389 0 C-N-CA 120.631 -0.795 . . . . 0.0 113.196 -179.578 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 182' ' ' PRO . . . . . 0.49 ' HD2' ' O ' ' A' ' 177' ' ' ILE . 73.1 Cg_exo -45.01 178.04 0.0 OUTLIER 'Trans proline' 0 C--N 1.351 0.696 0 C-N-CA 123.368 2.712 . . . . 0.0 113.326 179.474 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 183' ' ' PRO . . . . . . . . . . . . . 62.2 Cg_exo -53.68 8.27 0.03 OUTLIER 'Trans proline' 0 C--N 1.352 0.713 0 C-N-CA 123.057 2.505 . . . . 0.0 114.991 -179.384 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 184' ' ' GLY . . . . . 0.45 ' H ' ' C ' ' A' ' 182' ' ' PRO . . . -53.69 -66.94 2.41 Favored Glycine 0 C--N 1.337 0.608 0 C-N-CA 119.795 -1.193 . . . . 0.0 110.971 179.01 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 185' ' ' VAL . . . . . 0.544 HG22 ' O ' ' A' ' 179' ' ' LEU . 4.4 m -134.4 -4.61 1.21 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.389 0 CA-C-N 115.797 -0.202 . . . . 0.0 111.433 178.553 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 186' ' ' ALA . . . . . . . . . . . . . . . 43.85 79.01 0.05 OUTLIER 'General case' 0 N--CA 1.466 0.35 0 N-CA-C 112.289 0.477 . . . . 0.0 112.289 179.386 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 187' ' ' LEU . . . . . 0.551 HD11 HD22 ' A' ' 180' ' ' LEU . 4.9 mt -92.77 -49.83 5.88 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-O 120.71 0.291 . . . . 0.0 111.718 179.971 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 188' ' ' LEU . . . . . 0.414 HD13 HG11 ' A' ' 192' ' ' VAL . 96.0 mt -114.95 -166.45 1.11 Allowed 'General case' 0 C--N 1.331 -0.223 0 CA-C-O 120.983 0.421 . . . . 0.0 111.362 -179.169 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 189' ' ' THR . . . . . . . . . . . . . 3.0 t -85.77 148.11 47.76 Favored Pre-proline 0 C--N 1.328 -0.354 0 CA-C-N 115.826 -0.625 . . . . 0.0 111.279 -179.732 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 190' ' ' PRO . . . . . . . . . . . . . 78.2 Cg_exo -49.42 -44.59 33.98 Favored 'Trans proline' 0 C--N 1.348 0.524 0 C-N-CA 122.849 2.366 . . . . 0.0 113.503 -179.74 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 191' ' ' THR . . . . . . . . . . . . . 9.7 t -56.12 -34.51 66.14 Favored 'General case' 0 C--N 1.33 -0.276 0 N-CA-C 112.308 0.484 . . . . 0.0 112.308 -179.056 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 192' ' ' VAL . . . . . 0.414 HG11 HD13 ' A' ' 188' ' ' LEU . 19.1 t -72.06 -54.39 16.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 N-CA-C 111.851 0.315 . . . . 0.0 111.851 -179.204 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 193' ' ' ASP . . . . . . . . . . . . . 1.1 p30 -62.17 -46.14 90.3 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.699 0.285 . . . . 0.0 110.948 -179.735 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 194' ' ' VAL . . . . . 0.433 ' O ' HG23 ' A' ' 198' ' ' VAL . 63.8 t -58.32 -35.94 55.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.331 -0.395 . . . . 0.0 110.44 179.4 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 195' ' ' ALA . . . . . . . . . . . . . . . -59.93 -48.25 82.45 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.281 -0.418 . . . . 0.0 111.141 179.918 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 196' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -67.88 -35.54 78.69 Favored 'General case' 0 N--CA 1.462 0.173 0 N-CA-C 109.882 -0.414 . . . . 0.0 109.882 179.543 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 197' ' ' ILE . . . . . . . . . . . . . 18.9 mm -58.43 -57.67 9.88 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.289 0 CA-C-N 115.922 -0.581 . . . . 0.0 109.776 178.949 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 198' ' ' VAL . . . . . 0.433 HG23 ' O ' ' A' ' 194' ' ' VAL . 93.5 t -53.92 -35.27 27.56 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.44 0 N-CA-C 108.873 -0.788 . . . . 0.0 108.873 178.138 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 199' ' ' TYR . . . . . . . . . . . . . 17.7 t80 -70.76 -30.21 66.65 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 114.951 -1.022 . . . . 0.0 110.885 179.467 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 200' ' ' LEU . . . . . 0.521 HD11 HG13 ' A' ' 177' ' ' ILE . 34.9 mt -71.75 -44.0 64.81 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 116.048 -0.524 . . . . 0.0 111.703 -179.21 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 201' ' ' ASP . . . . . . . . . . . . . 11.9 m-20 -68.26 -35.21 77.54 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-O 121.117 0.484 . . . . 0.0 110.417 179.89 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 202' ' ' LEU . . . . . 0.439 ' O ' ' HB ' ' A' ' 206' ' ' VAL . 3.4 mt -70.89 -32.59 69.59 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 115.587 -0.733 . . . . 0.0 111.977 -179.507 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 203' ' ' VAL . . . . . 0.484 ' O ' ' HA3' ' A' ' 207' ' ' GLY . 12.5 p -78.17 -36.59 21.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 C-N-CA 121.102 -0.239 . . . . 0.0 111.376 -178.915 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 204' ' ' THR . . . . . 0.402 ' O ' ' CD1' ' A' ' 208' ' ' PHE . 45.4 m -64.73 -57.46 8.91 Favored 'General case' 0 C--N 1.325 -0.457 0 C-N-CA 120.494 -0.482 . . . . 0.0 111.134 179.655 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 205' ' ' LYS . . . . . 0.675 ' HE3' HG22 ' A' ' 43' ' ' ILE . 47.4 mttp -70.2 -58.91 3.25 Favored 'General case' 0 C--N 1.33 -0.251 0 N-CA-C 112.791 0.663 . . . . 0.0 112.791 -178.071 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 206' ' ' VAL . . . . . 0.439 ' HB ' ' O ' ' A' ' 202' ' ' LEU . 23.3 t -70.08 -36.31 67.76 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.411 0 CA-C-N 116.454 -0.339 . . . . 0.0 111.832 -178.692 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 207' ' ' GLY . . . . . 0.496 ' O ' HG13 ' A' ' 211' ' ' ILE . . . -63.3 -60.25 7.78 Favored Glycine 0 N--CA 1.45 -0.382 0 C-N-CA 120.513 -0.851 . . . . 0.0 113.424 -178.844 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 208' ' ' PHE . . . . . 0.601 ' HB2' ' HG ' ' A' ' 163' ' ' LEU . 0.1 OUTLIER -66.47 -27.07 67.51 Favored 'General case' 0 C--O 1.225 -0.219 0 CA-C-N 117.3 0.55 . . . . 0.0 111.037 -179.136 . . . . . . . . 3 3 . 1 . 022 nuclear build core ' A' A ' 209' ' ' GLY . . . . . 0.506 ' O ' ' HB3' ' A' ' 212' ' ' ALA . . . -69.72 -33.12 70.91 Favored Glycine 0 N--CA 1.448 -0.513 0 N-CA-C 111.683 -0.567 . . . . 0.0 111.683 178.852 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 210' ' ' PHE . . . . . . . . . . . . . 1.1 m-85 -70.85 -49.27 47.99 Favored 'General case' 0 CA--C 1.512 -0.494 0 N-CA-C 107.954 -1.128 . . . . 0.0 107.954 178.404 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 211' ' ' ILE . . . . . 0.496 HG13 ' O ' ' A' ' 207' ' ' GLY . 5.6 mt -62.59 -28.36 44.65 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.604 0 N-CA-C 107.618 -1.253 . . . . 0.0 107.618 176.572 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 212' ' ' ALA . . . . . 0.506 ' HB3' ' O ' ' A' ' 209' ' ' GLY . . . -65.05 -39.92 94.01 Favored 'General case' 0 N--CA 1.447 -0.59 0 CA-C-N 114.698 -1.137 . . . . 0.0 110.084 179.431 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 213' ' ' LEU . . . . . 0.41 ' HG ' ' O ' ' A' ' 209' ' ' GLY . 88.4 mt -70.28 -53.16 18.05 Favored 'General case' 0 C--N 1.331 -0.203 0 CA-C-N 115.132 -0.94 . . . . 0.0 111.601 -179.772 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 214' ' ' ASP . . . . . . . . . . . . . 29.4 m-20 -54.01 -50.04 67.53 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.33 -0.395 . . . . 0.0 111.294 -179.38 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 215' ' ' ALA . . . . . . . . . . . . . . . -61.02 -56.42 21.26 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.289 -0.414 . . . . 0.0 111.362 -179.735 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 216' ' ' ALA . . . . . . . . . . . . . . . -56.26 -36.38 68.49 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.233 -0.439 . . . . 0.0 111.467 -179.543 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 217' ' ' ALA . . . . . . . . . . . . . . . -62.46 -40.87 98.01 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.291 -0.413 . . . . 0.0 110.392 179.765 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 218' ' ' THR . . . . . . . . . . . . . 90.9 m . . . . . 0 C--N 1.329 -0.306 0 CA-C-N 115.794 -0.639 . . . . 0.0 110.737 179.623 . . . . . . . . 0 0 . 1 . 023 nuclear build core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.235 0 N-CA-C 112.625 -0.19 . . . . 0.0 112.625 . . . . . . . . . 0 0 . 1 . 023 nuclear build core ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 59.6 tp -74.98 -38.0 61.77 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.832 0.349 . . . . 0.0 111.095 179.953 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 71.1 p -61.73 -32.59 72.82 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.096 -0.502 . . . . 0.0 111.207 -179.819 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 20.5 p -54.53 -35.86 63.64 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.127 -179.785 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 7' ' ' LEU . . . . . . . . . . . . . 4.2 mm? -57.48 -52.86 63.66 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.809 179.836 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 8' ' ' PHE . . . . . 0.689 ' HB2' ' HB2' ' A' ' 55' ' ' ALA . 57.8 m-85 -64.87 -32.99 74.95 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 115.989 -0.551 . . . . 0.0 110.831 179.975 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 9' ' ' TRP . . . . . 0.413 ' O ' HG13 ' A' ' 13' ' ' ILE . 27.8 m95 -64.5 -44.7 90.13 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.978 0.418 . . . . 0.0 109.992 179.808 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 41.9 mt -61.8 -44.51 96.71 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 115.773 -0.649 . . . . 0.0 110.387 179.161 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -65.54 -29.22 74.67 Favored Glycine 0 N--CA 1.45 -0.433 0 C-N-CA 120.704 -0.76 . . . . 0.0 111.922 179.59 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -71.22 -33.42 69.88 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.624 0.25 . . . . 0.0 110.775 179.689 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 13' ' ' ILE . . . . . 0.413 HG13 ' O ' ' A' ' 9' ' ' TRP . 66.4 mt -66.33 -54.02 30.5 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.208 0 CA-C-O 120.9 0.381 . . . . 0.0 110.142 179.32 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -61.77 -38.07 95.34 Favored Glycine 0 N--CA 1.45 -0.432 0 C-N-CA 120.735 -0.745 . . . . 0.0 111.658 179.298 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 15' ' ' MET . . . . . 0.4 ' HG3' ' HB2' ' A' ' 48' ' ' ALA . 45.7 tpp -63.35 -43.51 97.5 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.794 0.331 . . . . 0.0 110.249 179.503 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -55.63 -38.96 70.2 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 115.969 -0.559 . . . . 0.0 109.834 179.23 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 98.8 t -59.91 -45.74 94.76 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.168 0 CA-C-N 115.954 -0.566 . . . . 0.0 109.926 178.955 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -62.74 -45.97 94.63 Favored Glycine 0 C--N 1.333 0.373 0 C-N-CA 120.476 -0.869 . . . . 0.0 111.448 178.801 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 23.7 m -51.86 -44.95 63.88 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 115.548 -0.326 . . . . 0.0 111.405 -179.888 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 85.4 mt -71.65 -42.98 66.9 Favored 'General case' 0 C--N 1.332 -0.184 0 CA-C-N 116.402 -0.363 . . . . 0.0 111.362 -179.921 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -56.89 -34.07 67.51 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.334 -0.393 . . . . 0.0 111.707 -179.662 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 22' ' ' PHE . . . . . 0.467 ' HB2' HG22 ' A' ' 41' ' ' VAL . 1.9 m-85 -90.96 -31.1 16.48 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.598 -0.274 . . . . 0.0 111.242 -179.418 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -68.31 -50.54 52.83 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.901 0.382 . . . . 0.0 111.543 -179.643 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 24' ' ' TRP . . . . . . . . . . . . . 5.3 t-105 -64.77 -42.27 95.24 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-N 115.898 -0.592 . . . . 0.0 111.119 -179.685 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.329 -0.312 0 CA-C-O 120.866 0.365 . . . . 0.0 110.643 179.764 . . . . . . . . 0 0 . 1 . 023 nuclear build core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.249 0 N-CA-C 112.598 -0.201 . . . . 0.0 112.598 . . . . . . . . . 0 0 . 1 . 023 nuclear build core ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 19.9 mm-40 -79.41 -20.65 47.06 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.82 0.343 . . . . 0.0 110.688 179.906 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 34' ' ' ARG . . . . . . . . . . . . . 52.0 ttp180 -55.11 -28.9 56.01 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.005 -0.543 . . . . 0.0 111.319 -179.784 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 31.1 mmm180 -55.04 -45.12 75.2 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.788 0.328 . . . . 0.0 111.28 -179.938 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 61.2 m-85 -69.05 -33.38 73.49 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.414 -179.528 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 37' ' ' TYR . . . . . . . . . . . . . 75.4 m-85 -72.69 -53.06 12.77 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.331 -0.395 . . . . 0.0 111.413 -179.238 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 11.5 p -56.75 -36.16 48.26 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.225 0 CA-C-O 121.092 0.472 . . . . 0.0 110.474 179.751 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 18.7 m -68.2 -46.9 69.34 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 115.714 -0.676 . . . . 0.0 110.718 179.276 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 40' ' ' LEU . . . . . 0.606 HD12 HD11 ' A' ' 43' ' ' ILE . 26.8 tp -61.18 -45.33 95.07 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 115.813 -0.631 . . . . 0.0 110.917 179.96 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 41' ' ' VAL . . . . . 0.467 HG22 ' HB2' ' A' ' 22' ' ' PHE . 95.7 t -62.97 -34.35 65.87 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.484 0 CA-C-N 115.988 -0.551 . . . . 0.0 110.284 179.471 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 42' ' ' GLY . . . . . 0.482 ' O ' HG13 ' A' ' 46' ' ' ILE . . . -58.62 -51.88 56.3 Favored Glycine 0 N--CA 1.448 -0.508 0 C-N-CA 120.902 -0.666 . . . . 0.0 112.921 -179.964 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 43' ' ' ILE . . . . . 0.731 HG23 HD23 ' A' ' 82' ' ' LEU . 18.0 pt -60.9 -49.16 85.79 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.161 0 CA-C-N 117.02 0.41 . . . . 0.0 111.566 -179.558 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 44' ' ' SER . . . . . 0.423 ' N ' HG13 ' A' ' 43' ' ' ILE . 41.0 t -61.32 -27.1 68.25 Favored 'General case' 0 C--N 1.332 -0.191 0 CA-C-O 120.889 0.375 . . . . 0.0 111.193 179.648 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -78.01 -47.59 8.35 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.803 -0.713 . . . . 0.0 113.217 -179.112 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 46' ' ' ILE . . . . . 0.482 HG13 ' O ' ' A' ' 42' ' ' GLY . 61.6 mt -59.14 -42.09 85.62 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.229 0 CA-C-O 120.846 0.355 . . . . 0.0 110.968 -179.75 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 47' ' ' ALA . . . . . 0.631 ' HB2' ' HE2' ' A' ' 205' ' ' LYS . . . -67.49 -40.83 85.25 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 116.333 -0.394 . . . . 0.0 111.084 179.336 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 48' ' ' ALA . . . . . 0.4 ' HB2' ' HG3' ' A' ' 15' ' ' MET . . . -54.65 -44.27 73.1 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 116.129 -0.487 . . . . 0.0 111.382 -179.771 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 49' ' ' VAL . . . . . 0.418 HG22 ' O ' ' A' ' 46' ' ' ILE . 33.3 m -75.36 -34.65 30.98 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.384 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.351 -179.742 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -62.17 -38.86 90.67 Favored 'General case' 0 C--N 1.332 -0.156 0 CA-C-O 120.965 0.412 . . . . 0.0 111.071 179.849 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 51' ' ' TYR . . . . . 0.426 ' HB3' ' O ' ' A' ' 8' ' ' PHE . 26.5 m-85 -72.77 -42.65 63.74 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 115.993 -0.549 . . . . 0.0 110.693 -179.861 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -62.5 -39.84 94.81 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 115.987 -0.551 . . . . 0.0 111.45 -179.919 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 53' ' ' VAL . . . . . 0.473 HG23 ' N ' ' A' ' 54' ' ' MET . 35.1 m -72.28 -48.71 47.19 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.16 0 CA-C-N 116.498 -0.319 . . . . 0.0 111.299 -179.679 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 54' ' ' MET . . . . . 0.48 ' HG3' ' HB2' ' A' ' 71' ' ' PRO . 74.0 mtm -61.85 -31.26 71.51 Favored 'General case' 0 C--N 1.331 -0.196 0 CA-C-O 120.979 0.419 . . . . 0.0 110.417 179.693 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 55' ' ' ALA . . . . . 0.689 ' HB2' ' HB2' ' A' ' 8' ' ' PHE . . . -70.42 -12.51 61.63 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 115.767 -0.652 . . . . 0.0 111.645 179.962 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 71.2 mt -97.71 -13.15 21.61 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 116.483 -0.326 . . . . 0.0 111.466 -179.78 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 105.18 -6.62 42.98 Favored Glycine 0 CA--C 1.52 0.353 0 C-N-CA 120.496 -0.859 . . . . 0.0 113.545 179.5 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 58' ' ' VAL . . . . . 0.46 HG22 ' O ' ' A' ' 53' ' ' VAL . 27.0 m -81.54 149.8 4.76 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.201 0 CA-C-N 117.185 0.492 . . . . 0.0 110.587 179.483 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 81.74 25.61 52.72 Favored Glycine 0 N--CA 1.45 -0.418 0 C-N-CA 120.588 -0.815 . . . . 0.0 111.768 -179.219 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 60' ' ' TRP . . . . . . . . . . . . . 17.9 m0 -104.23 95.06 5.71 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 121.101 0.477 . . . . 0.0 110.018 -179.897 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 6.0 t -91.24 124.21 62.08 Favored Pre-proline 0 C--N 1.324 -0.539 0 CA-C-N 115.712 -0.676 . . . . 0.0 111.405 -178.984 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 56.2 Cg_endo -71.81 136.42 27.72 Favored 'Trans proline' 0 C--N 1.35 0.649 0 C-N-CA 122.353 2.036 . . . . 0.0 112.345 -179.987 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 86.4 t -143.02 105.23 1.06 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.02 -0.537 . . . . 0.0 111.209 -179.573 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . 58.88 -90.08 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.295 -0.411 . . . . 0.0 111.361 179.921 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 41.2 tt0 -122.85 -25.71 4.57 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 116.306 -0.406 . . . . 0.0 110.52 179.901 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 66' ' ' ARG . . . . . . . . . . . . . 20.0 ttm180 -101.73 162.62 12.77 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 115.942 -0.572 . . . . 0.0 110.333 179.905 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 87.3 m -117.56 120.73 38.96 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-O 120.858 0.361 . . . . 0.0 111.648 -179.448 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 38.8 t -86.07 146.37 6.55 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 115.927 -0.579 . . . . 0.0 110.558 179.406 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 69' ' ' PHE . . . . . . . . . . . . . 29.8 m-85 -106.77 112.97 26.19 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 121.044 0.45 . . . . 0.0 110.177 -179.679 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 70' ' ' VAL . . . . . 0.561 HG12 ' HD3' ' A' ' 71' ' ' PRO . 0.3 OUTLIER -68.65 -33.92 4.95 Favored Pre-proline 0 CA--C 1.541 0.603 0 N-CA-C 113.217 0.821 . . . . 0.0 113.217 -179.108 . . . . . . . . 3 3 . 1 . 023 nuclear build core ' A' A ' 71' ' ' PRO . . . . . 0.561 ' HD3' HG12 ' A' ' 70' ' ' VAL . 23.9 Cg_exo -63.71 -32.63 68.07 Favored 'Trans proline' 0 C--N 1.357 1.02 0 C-N-CA 121.766 1.644 . . . . 0.0 112.453 -179.276 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 40.0 ttm180 -69.82 -50.54 41.87 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 121.075 0.465 . . . . 0.0 110.352 179.464 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 73' ' ' TYR . . . . . 0.469 ' O ' HG13 ' A' ' 77' ' ' ILE . 33.9 m-85 -65.94 -33.09 75.02 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 115.767 -0.651 . . . . 0.0 111.341 -179.706 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 74' ' ' ILE . . . . . 0.432 ' O ' HD13 ' A' ' 74' ' ' ILE . 0.4 OUTLIER -75.74 -38.73 37.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-O 121.02 0.438 . . . . 0.0 109.908 179.329 . . . . . . . . 3 3 . 1 . 023 nuclear build core ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 5.9 t70 -58.58 -32.77 69.26 Favored 'General case' 0 N--CA 1.455 -0.203 0 CA-C-N 115.975 -0.557 . . . . 0.0 109.965 179.294 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 76' ' ' TRP . . . . . 0.41 ' HB3' ' SD ' ' A' ' 109' ' ' MET . 51.0 m0 -73.24 -46.23 51.31 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 115.914 -0.585 . . . . 0.0 110.568 179.204 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 77' ' ' ILE . . . . . 0.538 HG12 ' HB3' ' A' ' 109' ' ' MET . 88.2 mt -53.52 -29.94 17.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 115.941 -0.572 . . . . 0.0 111.253 -179.84 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 47.3 mt -91.07 -52.02 5.04 Favored 'General case' 0 CA--C 1.533 0.325 0 N-CA-C 112.521 0.563 . . . . 0.0 112.521 -179.541 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 79.7 p -71.49 -50.37 32.22 Favored 'General case' 0 N--CA 1.465 0.315 0 N-CA-C 113.931 1.085 . . . . 0.0 113.931 -177.688 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 80' ' ' THR . . . . . 0.705 HG21 ' HE1' ' A' ' 109' ' ' MET . 15.2 m -46.47 -53.32 24.75 Favored Pre-proline 0 CA--C 1.534 0.331 0 N-CA-C 112.78 0.659 . . . . 0.0 112.78 -178.173 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 81' ' ' PRO . . . . . 0.475 ' HD2' ' N ' ' A' ' 80' ' ' THR . 29.1 Cg_endo -61.99 -23.95 76.31 Favored 'Trans proline' 0 C--N 1.351 0.689 0 C-N-CA 121.639 1.559 . . . . 0.0 111.523 179.949 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 82' ' ' LEU . . . . . 0.731 HD23 HG23 ' A' ' 43' ' ' ILE . 15.6 tp -76.59 -32.62 58.23 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 115.751 -0.658 . . . . 0.0 110.156 179.507 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 41.8 mm -64.71 -53.55 40.83 Favored 'Isoleucine or valine' 0 C--O 1.235 0.304 0 CA-C-N 116.181 -0.463 . . . . 0.0 109.872 178.94 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 84' ' ' VAL . . . . . 0.568 HG11 HD22 ' A' ' 105' ' ' ASN . 12.6 m -61.3 -30.33 47.71 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.228 0 N-CA-C 109.297 -0.631 . . . . 0.0 109.297 178.582 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 85' ' ' TYR . . . . . . . . . . . . . 87.4 t80 -66.82 -32.61 74.0 Favored 'General case' 0 N--CA 1.453 -0.282 0 CA-C-N 115.478 -0.783 . . . . 0.0 109.371 178.585 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 86' ' ' PHE . . . . . . . . . . . . . 3.5 t80 -61.34 -51.89 66.94 Favored 'General case' 0 C--O 1.232 0.17 0 CA-C-N 115.68 -0.691 . . . . 0.0 109.767 179.259 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 7.2 mp -62.37 -31.82 72.53 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 115.741 -0.663 . . . . 0.0 110.242 179.358 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -66.27 -28.06 73.44 Favored Glycine 0 N--CA 1.45 -0.412 0 C-N-CA 120.771 -0.728 . . . . 0.0 111.615 179.365 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 92.6 mt -75.4 -38.88 59.62 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.815 0.341 . . . . 0.0 110.53 179.426 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 94.2 mt -59.96 -43.34 95.1 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.042 -0.526 . . . . 0.0 111.097 179.859 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 91' ' ' ALA . . . . . 0.497 ' HB2' ' HB2' ' A' ' 149' ' ' ALA . . . -82.76 -52.22 6.96 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 116.253 -0.43 . . . . 0.0 111.369 -179.798 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 100.16 68.21 0.86 Allowed Glycine 0 N--CA 1.452 -0.284 0 C-N-CA 120.81 -0.71 . . . . 0.0 112.4 -179.941 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 93' ' ' LEU . . . . . 0.57 ' HB3' ' HB2' ' A' ' 97' ' ' GLU . 8.2 mp -77.29 177.69 7.72 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.905 0.383 . . . . 0.0 111.159 -179.862 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 94' ' ' ASP . . . . . . . . . . . . . 19.7 t70 -89.66 166.96 13.29 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 115.941 -0.572 . . . . 0.0 110.808 -179.986 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 52.8 m -55.68 -38.96 70.35 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.348 -0.387 . . . . 0.0 111.177 -179.806 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 37.6 mmt180 -73.46 -44.3 58.34 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.303 -0.408 . . . . 0.0 111.13 -179.981 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 97' ' ' GLU . . . . . 0.57 ' HB2' ' HB3' ' A' ' 93' ' ' LEU . 13.2 mm-40 -55.43 -47.99 75.11 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.859 -179.969 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 98' ' ' PHE . . . . . 0.436 ' O ' HG12 ' A' ' 102' ' ' ILE . 24.3 m-85 -57.1 -47.63 80.58 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.447 179.456 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -57.27 -29.83 60.55 Favored Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.438 179.828 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 97.3 mt -73.98 -44.28 51.06 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.171 0 CA-C-O 120.93 0.395 . . . . 0.0 111.555 -179.882 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 44.7 t -67.46 -46.41 83.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.062 -0.517 . . . . 0.0 111.929 -179.247 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 102' ' ' ILE . . . . . 0.436 HG12 ' O ' ' A' ' 98' ' ' PHE . 45.4 mm -62.22 -52.49 59.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.395 -0.366 . . . . 0.0 111.722 -179.272 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 14.7 t -57.29 -35.94 70.44 Favored 'General case' 0 C--N 1.332 -0.16 0 CA-C-O 120.849 0.357 . . . . 0.0 111.174 -179.74 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 104' ' ' LEU . . . . . 0.446 HD22 ' HE2' ' A' ' 140' ' ' TYR . 50.4 tp -61.02 -46.43 90.77 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.746 179.838 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 105' ' ' ASN . . . . . 0.568 HD22 HG11 ' A' ' 84' ' ' VAL . 2.9 m-20 -65.46 -26.09 67.79 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.877 179.946 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 61.4 m -65.44 -55.35 18.49 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.292 -0.413 . . . . 0.0 111.216 -179.975 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 7.3 p -61.87 -37.35 77.96 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.184 0 CA-C-N 116.532 -0.304 . . . . 0.0 110.995 -179.734 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 108' ' ' VAL . . . . . 0.432 HG23 ' O ' ' A' ' 104' ' ' LEU . 53.4 t -59.58 -50.14 81.07 Favored 'Isoleucine or valine' 0 C--O 1.235 0.303 0 CA-C-O 121.002 0.429 . . . . 0.0 110.589 179.364 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 109' ' ' MET . . . . . 0.705 ' HE1' HG21 ' A' ' 80' ' ' THR . 3.0 tpp -63.46 -30.67 71.76 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 115.946 -0.57 . . . . 0.0 110.337 179.579 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 20.1 tp -68.59 -32.69 72.77 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.104 -0.498 . . . . 0.0 109.956 179.318 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 111' ' ' ALA . . . . . 0.437 ' O ' ' HB3' ' A' ' 126' ' ' LEU . . . -63.49 -56.69 14.08 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-N 115.736 -0.666 . . . . 0.0 110.418 179.25 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . -56.59 -42.99 91.08 Favored Glycine 0 C--N 1.331 0.252 0 C-N-CA 120.646 -0.788 . . . . 0.0 112.055 179.493 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 113' ' ' PHE . . . . . . . . . . . . . 6.5 t80 -47.28 -66.84 0.34 Allowed 'General case' 0 C--N 1.331 -0.222 0 CA-C-O 121.025 0.44 . . . . 0.0 110.956 179.55 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -63.25 -30.36 71.52 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 115.865 -0.607 . . . . 0.0 111.702 -179.401 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -52.11 -43.0 55.92 Favored Glycine 0 C--N 1.33 0.239 0 C-N-CA 121.057 -0.592 . . . . 0.0 112.96 -179.614 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -78.22 -27.88 47.84 Favored 'General case' 0 C--N 1.328 -0.352 0 N-CA-C 112.172 0.434 . . . . 0.0 112.172 -179.643 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 117' ' ' MET . . . . . . . . . . . . . 66.1 mtt -95.66 19.45 11.16 Favored 'General case' 0 C--N 1.33 -0.282 0 N-CA-C 111.77 0.285 . . . . 0.0 111.77 -179.191 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 118' ' ' VAL . . . . . 0.578 HG21 ' HB3' ' A' ' 123' ' ' ARG . 18.2 m -64.79 149.53 95.97 Favored Pre-proline 0 C--N 1.329 -0.296 0 CA-C-N 116.577 -0.283 . . . . 0.0 111.128 179.602 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 119' ' ' PRO . . . . . . . . . . . . . 93.9 Cg_endo -84.89 -17.83 4.68 Favored 'Trans proline' 0 N--CA 1.459 -0.517 0 C-N-CA 122.504 2.136 . . . . 0.0 112.135 179.808 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -145.41 -123.27 1.58 Allowed Glycine 0 N--CA 1.45 -0.386 0 C-N-CA 120.714 -0.755 . . . . 0.0 112.79 -179.923 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 45.1 pt -96.44 10.86 5.27 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.222 0 CA-C-O 120.714 0.293 . . . . 0.0 111.541 -179.535 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 43.6 mt-10 -59.6 -17.75 35.62 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.331 -0.395 . . . . 0.0 111.166 179.9 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 123' ' ' ARG . . . . . 0.578 ' HB3' HG21 ' A' ' 118' ' ' VAL . 19.8 ptt180 -49.69 -34.96 20.08 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 116.307 -0.406 . . . . 0.0 111.46 -179.928 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 124' ' ' TYR . . . . . . . . . . . . . 49.3 m-85 -70.98 -32.41 69.23 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.438 -0.346 . . . . 0.0 111.041 179.997 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 125' ' ' ALA . . . . . . . . . . . . . . . -68.25 -52.02 38.64 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.012 179.595 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 126' ' ' LEU . . . . . 0.437 ' HB3' ' O ' ' A' ' 111' ' ' ALA . 2.6 mm? -53.61 -56.17 19.53 Favored 'General case' 0 CA--C 1.521 -0.141 0 CA-C-N 116.09 -0.504 . . . . 0.0 110.687 179.973 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 127' ' ' PHE . . . . . 0.449 ' HZ ' ' HB3' ' A' ' 175' ' ' PRO . 9.6 t80 -67.39 -29.6 69.15 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.741 -179.91 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 128' ' ' GLY . . . . . . . . . . . . . . . -47.14 -54.49 9.73 Favored Glycine 0 N--CA 1.451 -0.36 0 C-N-CA 119.991 -1.099 . . . . 0.0 110.768 178.968 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 129' ' ' MET . . . . . 0.435 ' HE3' ' HB3' ' A' ' 133' ' ' ALA . 0.0 OUTLIER -72.21 -27.56 62.62 Favored 'General case' 0 C--N 1.328 -0.359 0 N-CA-C 109.144 -0.687 . . . . 0.0 109.144 178.624 . . . . . . . . 3 3 . 1 . 023 nuclear build core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -61.72 -37.46 94.29 Favored Glycine 0 C--N 1.334 0.435 0 CA-C-N 115.792 -0.64 . . . . 0.0 112.288 179.541 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -74.75 -52.3 11.88 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.754 0.311 . . . . 0.0 110.457 179.696 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 42.1 t -54.88 -47.33 75.58 Favored 'Isoleucine or valine' 0 C--O 1.234 0.257 0 CA-C-O 121.243 0.544 . . . . 0.0 109.602 178.981 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 133' ' ' ALA . . . . . 0.435 ' HB3' ' HE3' ' A' ' 129' ' ' MET . . . -65.45 -37.08 85.82 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 115.523 -0.762 . . . . 0.0 110.915 179.245 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 134' ' ' PHE . . . . . 0.411 ' CZ ' ' HA ' ' A' ' 172' ' ' ALA . 45.9 t80 -53.27 -54.02 42.34 Favored 'General case' 0 N--CA 1.452 -0.361 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.26 179.816 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 135' ' ' ILE . . . . . 0.51 ' O ' HG22 ' A' ' 138' ' ' VAL . 42.5 mt -59.66 -32.85 50.24 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 CA-C-N 115.85 -0.614 . . . . 0.0 110.23 179.473 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 136' ' ' GLY . . . . . 0.445 ' O ' ' HB3' ' A' ' 139' ' ' TYR . . . -58.93 -40.06 94.85 Favored Glycine 0 N--CA 1.449 -0.463 0 C-N-CA 120.153 -1.023 . . . . 0.0 111.236 178.706 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 137' ' ' LEU . . . . . 0.483 ' O ' HD13 ' A' ' 141' ' ' LEU . 64.0 tp -69.61 -53.37 19.11 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 115.863 -0.169 . . . . 0.0 110.806 179.541 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 138' ' ' VAL . . . . . 0.51 HG22 ' O ' ' A' ' 135' ' ' ILE . 3.3 m -54.69 -31.38 23.82 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.144 0 N-CA-C 109.333 -0.617 . . . . 0.0 109.333 -179.915 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 139' ' ' TYR . . . . . 0.445 ' HB3' ' O ' ' A' ' 136' ' ' GLY . 44.1 t80 -60.19 -46.35 90.03 Favored 'General case' 0 N--CA 1.453 -0.29 0 CA-C-N 115.544 -0.753 . . . . 0.0 109.404 178.183 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 140' ' ' TYR . . . . . 0.446 ' HE2' HD22 ' A' ' 104' ' ' LEU . 22.2 m-85 -63.86 -42.33 97.58 Favored 'General case' 0 C--N 1.333 -0.132 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.526 178.813 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 141' ' ' LEU . . . . . 0.483 HD13 ' O ' ' A' ' 137' ' ' LEU . 11.0 mp -57.13 -27.62 61.99 Favored 'General case' 0 C--N 1.332 -0.173 0 CA-C-N 115.948 -0.569 . . . . 0.0 111.193 -179.743 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 142' ' ' VAL . . . . . 0.47 HG23 ' O ' ' A' ' 138' ' ' VAL . 12.0 t -106.15 -7.91 10.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-O 120.992 0.425 . . . . 0.0 110.926 179.866 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . -73.84 -133.71 0.25 Allowed Glycine 0 CA--C 1.522 0.48 0 C-N-CA 120.812 -0.709 . . . . 0.0 112.814 -179.849 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 144' ' ' PRO . . . . . . . . . . . . . 51.5 Cg_exo -55.57 -23.96 42.47 Favored 'Trans proline' 0 C--N 1.349 0.555 0 C-N-CA 122.672 2.248 . . . . 0.0 113.03 -179.693 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 145' ' ' MET . . . . . 0.422 ' SD ' ' HA ' ' A' ' 141' ' ' LEU . 54.9 mtt -53.77 -27.92 31.71 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-O 120.727 0.299 . . . . 0.0 111.497 -179.583 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 146' ' ' THR . . . . . . . . . . . . . 70.5 p -79.04 -32.99 45.11 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.357 -0.383 . . . . 0.0 110.991 -179.558 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 39.7 tt0 -73.93 -40.26 63.23 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 115.861 -0.609 . . . . 0.0 111.354 -179.636 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 148' ' ' SER . . . . . . . . . . . . . 46.9 t -70.0 -42.26 73.28 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.325 -0.398 . . . . 0.0 111.327 -179.524 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 149' ' ' ALA . . . . . 0.497 ' HB2' ' HB2' ' A' ' 91' ' ' ALA . . . -70.83 -40.27 72.51 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.443 -0.344 . . . . 0.0 111.827 -179.649 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 150' ' ' SER . . . . . 0.604 ' HA ' ' HG2' ' A' ' 157' ' ' LYS . 39.2 t -69.46 -0.02 5.88 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.516 -0.311 . . . . 0.0 111.431 -179.564 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 151' ' ' GLN . . . . . . . . . . . . . 46.1 mt-30 -132.52 6.47 4.09 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.583 -0.28 . . . . 0.0 111.238 179.955 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 25.7 tpt180 -78.73 -52.41 8.43 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-O 120.94 0.4 . . . . 0.0 110.671 179.994 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 153' ' ' SER . . . . . 0.682 ' HB2' HG12 ' A' ' 156' ' ' ILE . 19.8 m -157.51 172.52 18.42 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 115.829 -0.623 . . . . 0.0 110.359 179.183 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 154' ' ' SER . . . . . 0.476 ' HA ' ' NZ ' ' A' ' 157' ' ' LYS . 49.9 m -68.68 -41.08 79.75 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.775 0.321 . . . . 0.0 110.983 179.728 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -76.78 -35.5 39.92 Favored Glycine 0 CA--C 1.519 0.343 0 C-N-CA 120.982 -0.627 . . . . 0.0 113.427 -179.537 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 156' ' ' ILE . . . . . 0.682 HG12 ' HB2' ' A' ' 153' ' ' SER . 41.8 mm -50.15 -38.48 15.06 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.217 0 N-CA-C 111.764 0.283 . . . . 0.0 111.764 -179.421 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 157' ' ' LYS . . . . . 0.604 ' HG2' ' HA ' ' A' ' 150' ' ' SER . 33.3 mtmm -59.78 -40.28 87.72 Favored 'General case' 0 C--N 1.327 -0.371 0 N-CA-C 112.034 0.383 . . . . 0.0 112.034 -179.254 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 36.5 t -72.53 -47.26 49.73 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 121.047 0.451 . . . . 0.0 111.425 -179.046 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 159' ' ' LEU . . . . . 0.432 ' O ' ' HB2' ' A' ' 163' ' ' LEU . 10.2 mt -68.67 -29.17 67.58 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-N 115.986 -0.552 . . . . 0.0 111.534 -179.108 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 160' ' ' TYR . . . . . . . . . . . . . 77.9 t80 -72.63 -46.84 52.08 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.454 -0.339 . . . . 0.0 111.629 -179.336 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 161' ' ' VAL . . . . . 0.409 HG23 ' N ' ' A' ' 162' ' ' ARG . 27.3 m -62.42 -42.79 96.98 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 N-CA-C 111.84 0.311 . . . . 0.0 111.84 -179.154 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 162' ' ' ARG . . . . . 0.409 ' N ' HG23 ' A' ' 161' ' ' VAL . 77.3 mtp180 -68.84 -48.53 63.28 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 120.647 0.26 . . . . 0.0 111.53 -179.678 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 163' ' ' LEU . . . . . 0.432 ' HB2' ' O ' ' A' ' 159' ' ' LEU . 6.8 mp -67.5 -45.08 76.88 Favored 'General case' 0 CA--C 1.531 0.24 0 CA-C-N 116.388 -0.369 . . . . 0.0 111.968 -179.01 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 164' ' ' ARG . . . . . . . . . . . . . 4.3 tmm_? -57.78 -50.97 71.46 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-O 120.635 0.255 . . . . 0.0 110.867 -179.719 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 165' ' ' ASN . . . . . 0.526 ' O ' HG23 ' A' ' 169' ' ' VAL . 4.6 m-20 -55.37 -41.37 72.52 Favored 'General case' 0 N--CA 1.448 -0.567 0 CA-C-N 116.352 -0.385 . . . . 0.0 110.486 179.78 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 166' ' ' LEU . . . . . 0.479 ' O ' ' HG ' ' A' ' 170' ' ' LEU . 3.6 mt -58.16 -53.61 56.31 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 115.944 -0.571 . . . . 0.0 110.894 179.496 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 167' ' ' THR . . . . . 0.661 ' HA ' HD11 ' A' ' 170' ' ' LEU . 13.7 m -54.39 -52.58 61.23 Favored 'General case' 0 C--N 1.331 -0.204 0 N-CA-C 112.451 0.537 . . . . 0.0 112.451 -178.431 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 168' ' ' VAL . . . . . . . . . . . . . 85.9 t -54.96 -40.57 54.12 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.483 0 N-CA-C 112.612 0.597 . . . . 0.0 112.612 -178.724 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 169' ' ' VAL . . . . . 0.526 HG23 ' O ' ' A' ' 165' ' ' ASN . 68.7 t -69.18 -67.19 0.46 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 N-CA-C 113.526 0.936 . . . . 0.0 113.526 -177.894 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 170' ' ' LEU . . . . . 0.661 HD11 ' HA ' ' A' ' 167' ' ' THR . 0.4 OUTLIER -59.18 -34.58 72.29 Favored 'General case' 0 N--CA 1.465 0.323 0 N-CA-C 112.869 0.692 . . . . 0.0 112.869 -177.7 . . . . . . . . 3 3 . 1 . 023 nuclear build core ' A' A ' 171' ' ' TRP . . . . . 0.537 ' H ' HD12 ' A' ' 170' ' ' LEU . 16.8 m0 -73.29 -31.52 64.1 Favored 'General case' 0 C--N 1.329 -0.29 0 C-N-CA 120.607 -0.437 . . . . 0.0 111.24 -179.507 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 172' ' ' ALA . . . . . 0.411 ' HA ' ' CZ ' ' A' ' 134' ' ' PHE . . . -71.17 -7.15 44.76 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-O 120.912 0.387 . . . . 0.0 110.337 179.52 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 173' ' ' ILE . . . . . 0.537 ' O ' HG12 ' A' ' 177' ' ' ILE . 38.6 mm -88.44 -28.12 5.41 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.173 0 CA-C-N 115.896 -0.593 . . . . 0.0 111.044 179.512 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 174' ' ' TYR . . . . . 0.505 ' HD2' ' HA ' ' A' ' 171' ' ' TRP . 19.2 m-85 -54.11 -48.71 93.33 Favored Pre-proline 0 N--CA 1.467 0.392 0 CA-C-N 116.523 -0.308 . . . . 0.0 111.699 -179.512 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 175' ' ' PRO . . . . . 0.449 ' HB3' ' HZ ' ' A' ' 127' ' ' PHE . 82.5 Cg_exo -45.36 -33.29 8.73 Favored 'Trans proline' 0 C--N 1.351 0.658 0 C-N-CA 121.964 1.776 . . . . 0.0 111.857 179.467 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 176' ' ' PHE . . . . . 0.512 ' O ' ' HG ' ' A' ' 180' ' ' LEU . 96.6 m-85 -80.97 -50.6 9.5 Favored 'General case' 0 CA--C 1.518 -0.287 0 CA-C-N 115.843 -0.617 . . . . 0.0 111.792 179.937 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 177' ' ' ILE . . . . . 0.537 HG12 ' O ' ' A' ' 173' ' ' ILE . 6.6 mm -58.17 -32.49 44.5 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.517 0 CA-C-N 115.927 -0.579 . . . . 0.0 112.56 -177.494 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 178' ' ' TRP . . . . . . . . . . . . . 84.3 t90 -73.45 -32.2 64.22 Favored 'General case' 0 CA--C 1.52 -0.205 0 CA-C-O 120.884 0.373 . . . . 0.0 110.577 179.629 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 179' ' ' LEU . . . . . 0.651 ' HG ' HG22 ' A' ' 185' ' ' VAL . 17.3 tp -81.88 -55.29 4.7 Favored 'General case' 0 C--N 1.322 -0.601 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.851 -179.478 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 180' ' ' LEU . . . . . 0.625 HD22 HD11 ' A' ' 187' ' ' LEU . 7.0 mt -62.04 -51.33 68.42 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.109 -0.496 . . . . 0.0 111.287 -179.479 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 181' ' ' GLY . . . . . 0.452 ' HA3' ' OD1' ' A' ' 193' ' ' ASP . . . -65.7 -84.76 0.08 OUTLIER Glycine 0 C--N 1.332 0.316 0 C-N-CA 120.338 -0.934 . . . . 0.0 111.925 179.414 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 182' ' ' PRO . . . . . 0.541 ' HB3' ' HD2' ' A' ' 183' ' ' PRO . 81.7 Cg_exo -48.25 176.98 0.02 OUTLIER 'Trans proline' 0 C--N 1.35 0.631 0 C-N-CA 122.999 2.466 . . . . 0.0 112.244 178.743 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 183' ' ' PRO . . . . . 0.541 ' HD2' ' HB3' ' A' ' 182' ' ' PRO . 19.2 Cg_endo -59.95 16.03 0.04 OUTLIER 'Trans proline' 0 C--N 1.351 0.674 0 C-N-CA 122.58 2.187 . . . . 0.0 115.142 -178.908 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 184' ' ' GLY . . . . . 0.508 ' HA3' HD12 ' A' ' 179' ' ' LEU . . . -59.51 -45.51 95.46 Favored Glycine 0 C--N 1.336 0.562 0 C-N-CA 119.48 -1.343 . . . . 0.0 110.693 178.756 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 185' ' ' VAL . . . . . 0.651 HG22 ' HG ' ' A' ' 179' ' ' LEU . 2.5 m -148.94 -35.63 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.327 -0.4 0 CA-C-N 114.867 -0.666 . . . . 0.0 110.528 178.635 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 186' ' ' ALA . . . . . . . . . . . . . . . 66.82 77.77 0.27 Allowed 'General case' 0 N--CA 1.462 0.138 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.863 178.607 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 187' ' ' LEU . . . . . 0.625 HD11 HD22 ' A' ' 180' ' ' LEU . 4.2 mt -92.67 -46.66 7.47 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.608 179.502 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 188' ' ' LEU . . . . . . . . . . . . . 97.8 mt -111.28 -166.36 1.07 Allowed 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 115.948 -0.569 . . . . 0.0 111.267 -179.808 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 189' ' ' THR . . . . . 0.449 ' HB ' HG23 ' A' ' 192' ' ' VAL . 26.8 m -81.81 136.3 48.02 Favored Pre-proline 0 C--N 1.328 -0.355 0 CA-C-N 115.822 -0.626 . . . . 0.0 110.932 -179.966 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 190' ' ' PRO . . . . . . . . . . . . . 5.6 Cg_endo -48.56 -38.99 36.95 Favored 'Trans proline' 0 C--N 1.35 0.644 0 C-N-CA 122.713 2.276 . . . . 0.0 112.08 179.611 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 191' ' ' THR . . . . . . . . . . . . . 59.5 p -58.27 -44.71 88.53 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.24 -0.437 . . . . 0.0 110.584 179.613 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 192' ' ' VAL . . . . . 0.449 HG23 ' HB ' ' A' ' 189' ' ' THR . 75.1 t -60.23 -40.38 83.5 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.229 0 CA-C-N 115.867 -0.606 . . . . 0.0 110.649 179.433 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 193' ' ' ASP . . . . . 0.487 ' OD1' HG22 ' A' ' 177' ' ' ILE . 3.4 t70 -56.15 -45.23 79.72 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 115.777 -0.647 . . . . 0.0 110.989 179.834 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 194' ' ' VAL . . . . . . . . . . . . . 48.4 t -63.07 -36.99 78.17 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.053 -0.521 . . . . 0.0 110.944 -179.839 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 195' ' ' ALA . . . . . . . . . . . . . . . -57.24 -47.64 80.86 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 116.393 -0.367 . . . . 0.0 110.838 179.674 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 196' ' ' LEU . . . . . . . . . . . . . 89.3 mt -68.37 -44.95 74.06 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-N 116.308 -0.406 . . . . 0.0 110.903 179.661 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 197' ' ' ILE . . . . . . . . . . . . . 20.2 mm -55.63 -58.37 4.93 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.58 179.633 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 198' ' ' VAL . . . . . . . . . . . . . 77.2 t -52.15 -35.1 18.64 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.568 0 CA-C-N 115.469 -0.787 . . . . 0.0 109.514 178.629 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 199' ' ' TYR . . . . . . . . . . . . . 42.2 t80 -70.38 -33.42 71.39 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 115.521 -0.763 . . . . 0.0 110.62 179.691 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 200' ' ' LEU . . . . . 0.449 HD11 HG13 ' A' ' 177' ' ' ILE . 51.7 mt -67.13 -42.54 84.25 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-N 115.97 -0.559 . . . . 0.0 111.135 -179.683 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 201' ' ' ASP . . . . . . . . . . . . . 8.3 m-20 -72.85 -31.65 64.91 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-O 121.083 0.468 . . . . 0.0 110.235 179.656 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 202' ' ' LEU . . . . . 0.442 ' O ' ' HB ' ' A' ' 206' ' ' VAL . 3.3 mt -70.88 -31.57 68.28 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 115.65 -0.705 . . . . 0.0 112.082 -179.476 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 203' ' ' VAL . . . . . 0.496 HG13 HD22 ' A' ' 170' ' ' LEU . 7.1 p -80.82 -37.01 15.95 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-O 120.637 0.256 . . . . 0.0 111.25 -178.815 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 204' ' ' THR . . . . . 0.426 ' O ' ' HB2' ' A' ' 208' ' ' PHE . 22.2 m -70.1 -48.8 56.14 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-O 120.836 0.351 . . . . 0.0 111.406 179.945 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 205' ' ' LYS . . . . . 0.631 ' HE2' ' HB2' ' A' ' 47' ' ' ALA . 62.7 mttp -72.94 -57.65 3.9 Favored 'General case' 0 C--N 1.326 -0.429 0 N-CA-C 112.129 0.418 . . . . 0.0 112.129 -179.004 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 206' ' ' VAL . . . . . 0.442 ' HB ' ' O ' ' A' ' 202' ' ' LEU . 51.7 t -70.98 -41.89 76.99 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-O 120.631 0.253 . . . . 0.0 111.626 -179.363 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 207' ' ' GLY . . . . . 0.49 ' O ' HD12 ' A' ' 211' ' ' ILE . . . -61.2 -59.6 9.74 Favored Glycine 0 C--N 1.33 0.216 0 C-N-CA 120.631 -0.795 . . . . 0.0 112.698 -179.766 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 208' ' ' PHE . . . . . 0.48 ' O ' ' N ' ' A' ' 212' ' ' ALA . 8.1 m-85 -54.29 -47.08 72.77 Favored 'General case' 0 C--O 1.222 -0.391 0 CA-C-O 121.058 0.456 . . . . 0.0 110.202 -179.986 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 209' ' ' GLY . . . . . 0.519 ' HA2' ' HB3' ' A' ' 212' ' ' ALA . . . -56.21 -32.87 60.57 Favored Glycine 0 N--CA 1.449 -0.454 0 CA-C-N 115.004 -0.998 . . . . 0.0 113.299 179.747 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 210' ' ' PHE . . . . . . . . . . . . . 2.2 m-85 -72.03 -46.02 58.65 Favored 'General case' 0 CA--C 1.513 -0.469 0 N-CA-C 108.811 -0.811 . . . . 0.0 108.811 179.556 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 211' ' ' ILE . . . . . 0.49 HD12 ' O ' ' A' ' 207' ' ' GLY . 3.3 mt -67.59 -27.3 37.87 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.658 0 N-CA-C 107.625 -1.25 . . . . 0.0 107.625 176.481 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 212' ' ' ALA . . . . . 0.519 ' HB3' ' HA2' ' A' ' 209' ' ' GLY . . . -68.18 -43.54 77.94 Favored 'General case' 0 N--CA 1.452 -0.371 0 CA-C-N 114.415 -1.266 . . . . 0.0 110.785 -179.712 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 213' ' ' LEU . . . . . 0.4 ' HG ' ' O ' ' A' ' 209' ' ' GLY . 81.0 mt -70.1 -54.18 14.16 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 115.329 -0.85 . . . . 0.0 111.221 -179.514 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 214' ' ' ASP . . . . . . . . . . . . . 12.8 t70 -55.51 -35.36 65.53 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.801 -179.865 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 215' ' ' ALA . . . . . . . . . . . . . . . -65.65 -57.92 6.95 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.024 -0.535 . . . . 0.0 111.338 -179.916 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 216' ' ' ALA . . . . . . . . . . . . . . . -61.43 -31.09 71.02 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.112 -0.495 . . . . 0.0 111.103 -179.892 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 217' ' ' ALA . . . . . . . . . . . . . . . -62.51 -40.0 95.32 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.31 179.776 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 218' ' ' THR . . . . . . . . . . . . . 93.7 m . . . . . 0 C--N 1.33 -0.256 0 CA-C-N 115.94 -0.573 . . . . 0.0 110.693 179.408 . . . . . . . . 0 0 . 1 . 024 nuclear build core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.275 0 N-CA-C 112.5 -0.24 . . . . 0.0 112.5 . . . . . . . . . 0 0 . 1 . 024 nuclear build core ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 67.0 tp -74.22 -36.6 63.96 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.795 0.331 . . . . 0.0 111.006 179.964 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 82.6 p -58.22 -32.96 68.81 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.531 -179.78 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 30.4 p -54.47 -34.9 62.4 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.343 -0.39 . . . . 0.0 111.109 -179.979 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 7' ' ' LEU . . . . . . . . . . . . . 4.3 mm? -58.22 -53.9 53.04 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 115.994 -0.548 . . . . 0.0 111.514 -179.732 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 8' ' ' PHE . . . . . 0.518 ' HB2' ' HB2' ' A' ' 55' ' ' ALA . 68.3 m-85 -64.22 -36.07 82.86 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.293 -0.412 . . . . 0.0 111.232 -179.484 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 9' ' ' TRP . . . . . . . . . . . . . 44.8 m95 -65.02 -48.98 71.99 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-O 121.098 0.475 . . . . 0.0 110.16 -179.675 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 79.9 mt -60.33 -38.7 84.57 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-N 115.587 -0.733 . . . . 0.0 110.532 179.685 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -65.03 -31.13 79.87 Favored Glycine 0 N--CA 1.448 -0.504 0 C-N-CA 120.647 -0.787 . . . . 0.0 111.642 179.199 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -71.13 -30.71 66.83 Favored 'General case' 0 N--CA 1.454 -0.231 0 CA-C-O 120.81 0.338 . . . . 0.0 110.56 179.393 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 71.8 mt -66.57 -54.61 24.07 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.235 0 CA-C-N 115.959 -0.564 . . . . 0.0 110.335 179.345 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -62.95 -35.56 92.22 Favored Glycine 0 N--CA 1.449 -0.455 0 C-N-CA 120.645 -0.788 . . . . 0.0 111.441 179.374 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 15' ' ' MET . . . . . 0.503 ' SD ' ' HA ' ' A' ' 44' ' ' SER . 53.1 tpp -62.9 -46.37 88.16 Favored 'General case' 0 C--N 1.329 -0.296 0 N-CA-C 110.088 -0.338 . . . . 0.0 110.088 179.358 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 16' ' ' LEU . . . . . 0.463 HD13 ' O ' ' A' ' 16' ' ' LEU . 0.8 OUTLIER -53.22 -39.99 64.16 Favored 'General case' 0 C--N 1.332 -0.187 0 CA-C-N 115.866 -0.606 . . . . 0.0 109.689 179.057 . . . . . . . . 3 3 . 1 . 024 nuclear build core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 70.3 t -58.98 -45.55 92.09 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.206 0 CA-C-N 116.036 -0.529 . . . . 0.0 110.177 179.156 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -63.93 -42.73 98.22 Favored Glycine 0 N--CA 1.45 -0.392 0 C-N-CA 120.749 -0.739 . . . . 0.0 111.737 179.038 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 11.3 m -52.74 -46.51 67.48 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-O 120.847 0.356 . . . . 0.0 111.146 -179.806 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 92.3 mt -71.8 -39.02 70.15 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.337 -179.826 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -59.8 -33.65 72.02 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.574 -0.285 . . . . 0.0 111.698 -179.615 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 22' ' ' PHE . . . . . 0.52 ' HB2' HG22 ' A' ' 41' ' ' VAL . 4.5 m-85 -90.99 -34.83 14.99 Favored 'General case' 0 C--N 1.331 -0.196 0 CA-C-O 120.727 0.299 . . . . 0.0 111.52 -179.446 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -66.53 -50.98 61.39 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 120.93 0.395 . . . . 0.0 111.539 -179.464 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 24' ' ' TRP . . . . . . . . . . . . . 5.1 t-105 -65.42 -45.11 85.16 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 115.877 -0.601 . . . . 0.0 111.176 -179.715 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.328 -0.327 0 CA-C-O 120.854 0.359 . . . . 0.0 111.009 179.874 . . . . . . . . 0 0 . 1 . 024 nuclear build core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.276 0 N-CA-C 112.494 -0.242 . . . . 0.0 112.494 . . . . . . . . . 0 0 . 1 . 024 nuclear build core ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 12.4 mm-40 -72.49 -21.11 61.25 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.652 0.263 . . . . 0.0 110.945 -179.922 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 34' ' ' ARG . . . . . 0.411 ' O ' HG23 ' A' ' 38' ' ' VAL . 79.0 ttt180 -51.57 -29.36 16.88 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 116.111 -0.495 . . . . 0.0 111.468 -179.607 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 80.2 ttt180 -60.19 -48.8 80.21 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.856 0.36 . . . . 0.0 110.882 179.896 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 59.4 m-85 -67.46 -29.87 69.43 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.028 -0.533 . . . . 0.0 111.139 179.896 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 37' ' ' TYR . . . . . 0.426 ' O ' HG23 ' A' ' 41' ' ' VAL . 43.8 m-85 -72.13 -53.0 14.05 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.071 -0.513 . . . . 0.0 111.62 -179.365 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 38' ' ' VAL . . . . . 0.411 HG23 ' O ' ' A' ' 34' ' ' ARG . 96.7 t -56.92 -37.39 54.05 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-O 121.103 0.477 . . . . 0.0 110.129 179.594 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 38.1 m -65.72 -46.27 79.57 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 115.662 -0.699 . . . . 0.0 110.182 179.158 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 40' ' ' LEU . . . . . 0.475 HD12 HD12 ' A' ' 43' ' ' ILE . 28.2 tp -59.67 -50.17 74.91 Favored 'General case' 0 C--O 1.235 0.318 0 CA-C-N 115.771 -0.649 . . . . 0.0 110.459 179.588 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 41' ' ' VAL . . . . . 0.52 HG22 ' HB2' ' A' ' 22' ' ' PHE . 61.3 t -59.1 -34.63 53.88 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.254 0 CA-C-N 115.842 -0.617 . . . . 0.0 109.938 179.186 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -59.07 -39.19 94.03 Favored Glycine 0 N--CA 1.449 -0.475 0 C-N-CA 120.727 -0.749 . . . . 0.0 111.832 179.252 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 43' ' ' ILE . . . . . 0.475 HD12 HD12 ' A' ' 40' ' ' LEU . 0.9 OUTLIER -64.96 -57.08 12.63 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.153 0 CA-C-O 120.831 0.348 . . . . 0.0 110.786 179.402 . . . . . . . . 3 3 . 1 . 024 nuclear build core ' A' A ' 44' ' ' SER . . . . . 0.503 ' HA ' ' SD ' ' A' ' 15' ' ' MET . 40.8 t -59.72 -24.21 63.81 Favored 'General case' 0 C--N 1.332 -0.168 0 CA-C-N 116.103 -0.499 . . . . 0.0 111.56 -179.691 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -74.15 -59.55 3.89 Favored Glycine 0 CA--C 1.518 0.262 0 C-N-CA 120.72 -0.752 . . . . 0.0 113.039 -179.647 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 46' ' ' ILE . . . . . 0.409 HD11 HG22 ' A' ' 79' ' ' THR . 21.1 pt -58.72 -35.02 53.54 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.19 0 CA-C-O 120.745 0.307 . . . . 0.0 111.286 -179.876 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 47' ' ' ALA . . . . . 0.619 ' HB2' ' HE2' ' A' ' 205' ' ' LYS . . . -65.98 -45.74 80.53 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-N 116.32 -0.4 . . . . 0.0 111.058 179.833 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -54.84 -52.18 63.58 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.246 -0.434 . . . . 0.0 111.216 -179.713 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 49' ' ' VAL . . . . . 0.41 ' O ' HG13 ' A' ' 53' ' ' VAL . 34.6 m -64.35 -34.04 66.66 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.393 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.821 179.931 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -65.23 -37.93 88.81 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.367 -0.379 . . . . 0.0 110.845 179.576 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 51' ' ' TYR . . . . . 0.416 ' OH ' ' HB2' ' A' ' 201' ' ' ASP . 30.3 m-85 -70.79 -29.06 65.15 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.193 179.944 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -74.5 -41.67 60.29 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-N 115.613 -0.721 . . . . 0.0 111.184 179.59 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 53' ' ' VAL . . . . . 0.425 HG23 ' N ' ' A' ' 54' ' ' MET . 20.8 m -73.25 -43.52 56.99 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.125 0 CA-C-N 116.498 -0.319 . . . . 0.0 111.008 179.883 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 54' ' ' MET . . . . . 0.448 ' HG2' ' HB2' ' A' ' 71' ' ' PRO . 72.8 mtm -63.49 -32.46 73.92 Favored 'General case' 0 C--N 1.332 -0.183 0 CA-C-O 121.038 0.447 . . . . 0.0 110.023 179.443 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 55' ' ' ALA . . . . . 0.518 ' HB2' ' HB2' ' A' ' 8' ' ' PHE . . . -65.23 -37.06 86.07 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 115.667 -0.697 . . . . 0.0 110.712 179.349 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 93.8 mt -76.5 -13.03 60.12 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 115.869 -0.605 . . . . 0.0 110.851 179.756 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 71.53 31.21 65.7 Favored Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.782 -0.723 . . . . 0.0 112.818 179.991 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 32.3 m -79.92 19.98 0.15 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.211 0 CA-C-O 120.834 0.35 . . . . 0.0 111.557 179.869 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -159.1 14.93 0.23 Allowed Glycine 0 N--CA 1.451 -0.358 0 C-N-CA 120.795 -0.717 . . . . 0.0 112.844 179.866 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 60' ' ' TRP . . . . . . . . . . . . . 41.0 m0 -81.09 107.57 14.01 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.728 0.299 . . . . 0.0 110.633 179.862 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 61' ' ' VAL . . . . . 0.42 ' HA ' ' HD3' ' A' ' 62' ' ' PRO . 4.9 p -106.38 119.33 52.19 Favored Pre-proline 0 CA--C 1.533 0.306 0 CA-C-N 116.342 -0.39 . . . . 0.0 111.572 -179.624 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 62' ' ' PRO . . . . . 0.42 ' HD3' ' HA ' ' A' ' 61' ' ' VAL . 16.8 Cg_exo -67.6 133.76 30.84 Favored 'Trans proline' 0 C--N 1.351 0.659 0 C-N-CA 122.35 2.033 . . . . 0.0 111.79 179.423 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 78.2 t -132.48 100.54 4.06 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.373 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.214 -179.716 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . 59.53 -86.85 0.02 OUTLIER 'General case' 0 C--N 1.331 -0.212 0 CA-C-N 116.043 -0.526 . . . . 0.0 111.265 -179.999 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 45.1 mt-10 -122.36 -27.26 4.49 Favored 'General case' 0 C--N 1.332 -0.195 0 CA-C-N 116.362 -0.381 . . . . 0.0 110.724 179.992 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 66' ' ' ARG . . . . . 0.444 ' HD2' ' N ' ' A' ' 66' ' ' ARG . 8.1 mpt_? -104.64 140.62 37.76 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.611 179.826 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 22.3 m -98.17 113.19 25.03 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.345 -0.389 . . . . 0.0 111.113 -179.74 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 26.3 t -85.11 146.84 6.06 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.354 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.474 179.498 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 69' ' ' PHE . . . . . . . . . . . . . 19.8 m-85 -108.51 115.17 29.59 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-O 120.91 0.386 . . . . 0.0 110.111 -179.315 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 70' ' ' VAL . . . . . 0.521 ' HB ' ' HD3' ' A' ' 71' ' ' PRO . 13.4 t -68.9 -49.35 26.81 Favored Pre-proline 0 C--N 1.323 -0.557 0 CA-C-N 115.946 -0.57 . . . . 0.0 112.243 -179.006 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 71' ' ' PRO . . . . . 0.521 ' HD3' ' HB ' ' A' ' 70' ' ' VAL . 29.5 Cg_exo -61.97 -17.48 56.1 Favored 'Trans proline' 0 C--N 1.35 0.608 0 C-N-CA 122.176 1.917 . . . . 0.0 112.449 -179.525 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 51.6 ttp180 -71.34 -54.68 9.97 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.482 -0.327 . . . . 0.0 111.43 -179.727 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 73' ' ' TYR . . . . . 0.431 ' O ' HG13 ' A' ' 77' ' ' ILE . 96.2 m-85 -69.74 -31.69 69.82 Favored 'General case' 0 C--N 1.331 -0.235 0 C-N-CA 120.919 -0.313 . . . . 0.0 110.648 -179.84 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 74' ' ' ILE . . . . . 0.477 ' HA ' HD12 ' A' ' 77' ' ' ILE . 0.3 OUTLIER -69.74 -38.56 76.44 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.18 0 N-CA-C 109.672 -0.492 . . . . 0.0 109.672 178.993 . . . . . . . . 3 3 . 1 . 024 nuclear build core ' A' A ' 75' ' ' ASP . . . . . 0.473 ' O ' HG23 ' A' ' 79' ' ' THR . 11.4 t70 -59.08 -37.59 77.45 Favored 'General case' 0 N--CA 1.454 -0.24 0 N-CA-C 109.211 -0.663 . . . . 0.0 109.211 178.595 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 76' ' ' TRP . . . . . . . . . . . . . 53.6 m0 -67.97 -32.45 72.88 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 115.689 -0.687 . . . . 0.0 110.323 179.006 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 77' ' ' ILE . . . . . 0.477 HD12 ' HA ' ' A' ' 74' ' ' ILE . 97.6 mt -66.57 -29.37 46.29 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.362 179.232 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 48.9 mt -91.59 -19.98 22.15 Favored 'General case' 0 CA--C 1.532 0.277 0 CA-C-N 116.1 -0.5 . . . . 0.0 112.016 179.983 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 79' ' ' THR . . . . . 0.473 HG23 ' O ' ' A' ' 75' ' ' ASP . 81.4 p -101.16 -52.63 3.22 Favored 'General case' 0 N--CA 1.465 0.323 0 N-CA-C 113.538 0.94 . . . . 0.0 113.538 -177.889 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 80' ' ' THR . . . . . 0.467 HG21 ' HE1' ' A' ' 109' ' ' MET . 61.3 m -46.69 -53.87 22.72 Favored Pre-proline 0 CA--C 1.533 0.296 0 N-CA-C 112.886 0.699 . . . . 0.0 112.886 -178.557 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 81' ' ' PRO . . . . . 0.465 ' HD2' ' N ' ' A' ' 80' ' ' THR . 35.0 Cg_endo -62.2 -22.16 73.71 Favored 'Trans proline' 0 C--N 1.35 0.622 0 C-N-CA 121.543 1.495 . . . . 0.0 111.603 -179.598 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 82' ' ' LEU . . . . . . . . . . . . . 16.2 tp -76.91 -33.31 57.77 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 115.657 -0.701 . . . . 0.0 110.234 179.674 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 28.1 mm -69.2 -53.18 26.86 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.226 0 CA-C-N 116.087 -0.506 . . . . 0.0 110.122 179.162 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 84' ' ' VAL . . . . . 0.416 HG13 ' HH2' ' A' ' 171' ' ' TRP . 28.9 m -60.13 -31.97 49.32 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.218 0 N-CA-C 109.645 -0.502 . . . . 0.0 109.645 178.907 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 85' ' ' TYR . . . . . 0.405 ' O ' ' HG ' ' A' ' 89' ' ' LEU . 79.8 t80 -65.12 -34.11 77.63 Favored 'General case' 0 N--CA 1.452 -0.366 0 CA-C-N 115.641 -0.709 . . . . 0.0 109.532 178.963 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 86' ' ' PHE . . . . . . . . . . . . . 7.9 t80 -62.62 -51.08 68.68 Favored 'General case' 0 C--N 1.333 -0.14 0 CA-C-N 115.768 -0.651 . . . . 0.0 110.247 179.404 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 9.3 mp -61.53 -36.05 79.46 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 115.992 -0.549 . . . . 0.0 110.407 179.785 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -66.33 -27.96 73.39 Favored Glycine 0 N--CA 1.45 -0.404 0 C-N-CA 120.767 -0.73 . . . . 0.0 111.875 179.282 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 89' ' ' LEU . . . . . 0.405 ' HG ' ' O ' ' A' ' 85' ' ' TYR . 75.9 mt -72.73 -40.88 65.74 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 120.994 0.426 . . . . 0.0 110.624 179.716 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 47.3 mt -58.44 -47.53 83.68 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 115.648 -0.706 . . . . 0.0 111.336 -179.644 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 91' ' ' ALA . . . . . 0.423 ' HB2' ' HB2' ' A' ' 149' ' ' ALA . . . -75.46 -54.52 6.9 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.635 -179.545 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 107.11 69.51 0.7 Allowed Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.854 -0.689 . . . . 0.0 112.009 -179.591 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 93' ' ' LEU . . . . . 0.544 HD23 ' HB3' ' A' ' 97' ' ' GLU . 8.5 mp -87.41 171.66 10.39 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.794 0.331 . . . . 0.0 111.131 -179.6 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 94' ' ' ASP . . . . . . . . . . . . . 8.9 m-20 -90.93 166.25 13.14 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.928 179.826 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 49.6 m -55.56 -33.02 63.49 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-N 116.312 -0.404 . . . . 0.0 111.029 -179.987 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 9.4 ptp180 -71.53 -48.05 51.25 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.842 179.88 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 97' ' ' GLU . . . . . 0.544 ' HB3' HD23 ' A' ' 93' ' ' LEU . 44.6 mt-10 -58.2 -45.14 88.16 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.923 -179.969 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 98' ' ' PHE . . . . . 0.443 ' O ' HG12 ' A' ' 102' ' ' ILE . 31.2 m-85 -59.1 -48.85 80.09 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.374 -0.375 . . . . 0.0 110.615 179.568 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -55.9 -31.07 58.07 Favored Glycine 0 N--CA 1.45 -0.381 0 C-N-CA 120.888 -0.672 . . . . 0.0 112.587 -179.775 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 98.0 mt -71.5 -44.29 71.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-O 120.798 0.332 . . . . 0.0 111.531 -179.94 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 39.7 t -68.12 -51.07 52.51 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.729 -179.344 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 102' ' ' ILE . . . . . 0.443 HG12 ' O ' ' A' ' 98' ' ' PHE . 34.0 mm -59.38 -50.0 81.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.325 -0.398 . . . . 0.0 111.771 -179.253 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 7.9 t -59.37 -36.11 75.14 Favored 'General case' 0 C--N 1.331 -0.204 0 CA-C-O 120.761 0.315 . . . . 0.0 110.911 -179.739 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 104' ' ' LEU . . . . . 0.457 ' O ' HG23 ' A' ' 108' ' ' VAL . 27.4 tp -63.03 -44.44 95.9 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.218 -0.447 . . . . 0.0 110.403 179.542 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 105' ' ' ASN . . . . . 0.578 ' N ' HD22 ' A' ' 105' ' ' ASN . 0.8 OUTLIER -63.66 -26.47 68.68 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 115.955 -0.566 . . . . 0.0 110.555 179.726 . . . . . . . . 3 3 . 1 . 024 nuclear build core ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 84.7 m -67.15 -54.59 19.81 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 115.998 -0.546 . . . . 0.0 111.167 179.954 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 7.5 p -63.6 -36.59 76.98 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.213 0 CA-C-N 116.42 -0.354 . . . . 0.0 111.05 -179.895 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 108' ' ' VAL . . . . . 0.457 HG23 ' O ' ' A' ' 104' ' ' LEU . 72.3 t -65.74 -45.5 91.62 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.226 0 CA-C-N 116.386 -0.37 . . . . 0.0 110.894 179.496 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 109' ' ' MET . . . . . 0.467 ' HE1' HG21 ' A' ' 80' ' ' THR . 8.7 tpp -65.15 -39.24 92.7 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.829 -179.82 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 29.0 tp -66.98 -30.75 70.95 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.215 179.701 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -62.5 -52.37 63.77 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 116.068 -0.515 . . . . 0.0 110.313 179.136 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . -67.62 -32.56 78.74 Favored Glycine 0 N--CA 1.45 -0.395 0 C-N-CA 120.566 -0.826 . . . . 0.0 111.649 179.127 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 113' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER -52.79 -75.89 0.03 OUTLIER 'General case' 0 C--N 1.332 -0.179 0 CA-C-O 121.008 0.432 . . . . 0.0 109.883 179.357 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 114' ' ' ALA . . . . . 0.431 ' HB3' HD22 ' A' ' 126' ' ' LEU . . . -61.05 -21.43 63.62 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-N 115.619 -0.719 . . . . 0.0 110.646 179.206 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -52.57 -50.98 46.32 Favored Glycine 0 C--N 1.333 0.385 0 C-N-CA 120.905 -0.664 . . . . 0.0 112.125 179.739 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 116' ' ' ALA . . . . . 0.574 ' HB2' ' HB3' ' A' ' 183' ' ' PRO . . . -78.19 -15.7 58.58 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 121.008 0.432 . . . . 0.0 110.723 179.217 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 117' ' ' MET . . . . . 0.419 ' HB3' ' HA ' ' A' ' 114' ' ' ALA . 45.1 tpp -87.49 -5.95 58.58 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 115.883 -0.599 . . . . 0.0 111.502 -179.588 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 118' ' ' VAL . . . . . 0.406 HG11 ' N ' ' A' ' 123' ' ' ARG . 21.7 m -58.81 146.67 74.78 Favored Pre-proline 0 C--N 1.331 -0.219 0 CA-C-N 116.683 -0.235 . . . . 0.0 111.449 -179.608 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 119' ' ' PRO . . . . . . . . . . . . . 69.2 Cg_endo -90.76 -5.45 4.43 Favored 'Trans proline' 0 N--CA 1.455 -0.748 0 C-N-CA 122.912 2.408 . . . . 0.0 112.228 179.431 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -145.41 -127.99 1.98 Allowed Glycine 0 C--N 1.333 0.362 0 C-N-CA 120.867 -0.683 . . . . 0.0 112.84 -179.733 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 46.6 pt -99.16 11.56 6.21 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.212 0 CA-C-O 120.596 0.236 . . . . 0.0 111.595 -179.491 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 122' ' ' GLU . . . . . 0.47 ' O ' HD12 ' A' ' 126' ' ' LEU . 15.1 mm-40 -60.53 -21.03 62.05 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.754 0.311 . . . . 0.0 110.997 -179.914 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 123' ' ' ARG . . . . . 0.439 HH11 ' HD2' ' A' ' 123' ' ' ARG . 10.0 ptt180 -52.22 -34.47 45.91 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.027 -0.533 . . . . 0.0 111.471 -179.935 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 124' ' ' TYR . . . . . . . . . . . . . 39.6 m-85 -69.16 -32.08 71.16 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.531 -179.574 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 125' ' ' ALA . . . . . . . . . . . . . . . -72.88 -56.51 5.09 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-O 120.831 0.348 . . . . 0.0 111.098 -179.699 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 126' ' ' LEU . . . . . 0.47 HD12 ' O ' ' A' ' 122' ' ' GLU . 1.3 mp -57.26 -49.61 75.51 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.662 179.92 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 127' ' ' PHE . . . . . . . . . . . . . 7.5 t80 -66.45 -37.42 85.12 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.335 -0.393 . . . . 0.0 110.857 -179.991 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 128' ' ' GLY . . . . . . . . . . . . . . . -47.18 -46.29 21.1 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.057 -1.068 . . . . 0.0 110.904 179.045 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 129' ' ' MET . . . . . . . . . . . . . 0.3 OUTLIER -70.13 -35.77 74.31 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 115.388 -0.406 . . . . 0.0 110.041 178.848 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -68.09 -28.2 73.45 Favored Glycine 0 C--N 1.334 0.434 0 CA-C-N 115.88 -0.6 . . . . 0.0 112.94 -179.659 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -74.42 -53.65 9.15 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 120.722 0.296 . . . . 0.0 110.313 179.915 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 22.2 t -58.2 -42.69 84.04 Favored 'Isoleucine or valine' 0 C--O 1.235 0.338 0 N-CA-C 109.022 -0.733 . . . . 0.0 109.022 178.476 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -64.31 -35.27 80.32 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.264 -0.88 . . . . 0.0 110.351 179.086 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 134' ' ' PHE . . . . . . . . . . . . . 75.3 t80 -56.74 -50.67 71.54 Favored 'General case' 0 N--CA 1.453 -0.323 0 CA-C-N 116.284 -0.416 . . . . 0.0 109.901 179.447 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 135' ' ' ILE . . . . . 0.479 ' O ' HG22 ' A' ' 138' ' ' VAL . 63.0 mt -57.44 -33.17 43.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 115.779 -0.646 . . . . 0.0 109.967 179.114 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 136' ' ' GLY . . . . . 0.446 ' O ' ' HB3' ' A' ' 139' ' ' TYR . . . -62.13 -40.62 99.19 Favored Glycine 0 N--CA 1.449 -0.478 0 C-N-CA 120.134 -1.032 . . . . 0.0 111.44 178.689 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 137' ' ' LEU . . . . . . . . . . . . . 26.8 tp -68.91 -49.91 54.01 Favored 'General case' 0 N--CA 1.455 -0.219 0 CA-C-O 120.43 0.157 . . . . 0.0 110.701 179.673 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 138' ' ' VAL . . . . . 0.554 ' HA ' HD12 ' A' ' 141' ' ' LEU . 4.7 m -58.2 -31.39 41.97 Favored 'Isoleucine or valine' 0 C--O 1.233 0.22 0 CA-C-O 121.338 0.589 . . . . 0.0 109.618 179.219 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 139' ' ' TYR . . . . . 0.446 ' HB3' ' O ' ' A' ' 136' ' ' GLY . 55.7 t80 -60.48 -43.21 97.21 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 115.34 -0.845 . . . . 0.0 109.302 178.373 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 36.7 m-85 -64.03 -32.72 74.38 Favored 'General case' 0 C--N 1.332 -0.16 0 CA-C-N 115.839 -0.619 . . . . 0.0 110.451 178.887 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 141' ' ' LEU . . . . . 0.554 HD12 ' HA ' ' A' ' 138' ' ' VAL . 95.3 mt -57.67 -47.43 82.32 Favored 'General case' 0 N--CA 1.462 0.168 0 CA-C-N 116.349 -0.387 . . . . 0.0 110.588 179.671 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 9.5 p -95.85 1.28 10.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.818 179.868 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 143' ' ' GLY . . . . . 0.4 ' HA3' ' HD2' ' A' ' 144' ' ' PRO . . . -75.95 -140.55 0.94 Allowed Glycine 0 CA--C 1.52 0.361 0 C-N-CA 120.99 -0.624 . . . . 0.0 112.878 -179.572 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 144' ' ' PRO . . . . . 0.4 ' HD2' ' HA3' ' A' ' 143' ' ' GLY . 19.5 Cg_endo -58.88 -23.92 69.9 Favored 'Trans proline' 0 C--N 1.347 0.488 0 C-N-CA 122.745 2.297 . . . . 0.0 112.685 -179.776 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 145' ' ' MET . . . . . . . . . . . . . 56.8 mtt -58.19 -33.13 68.94 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 120.806 0.336 . . . . 0.0 111.242 179.966 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 146' ' ' THR . . . . . . . . . . . . . 12.1 m -80.86 -32.35 35.05 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.385 -179.05 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 40.2 tt0 -71.8 -42.32 67.21 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-N 116.165 -0.47 . . . . 0.0 111.169 -179.743 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 148' ' ' SER . . . . . . . . . . . . . 58.2 m -70.61 -46.86 62.58 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-N 116.263 -0.426 . . . . 0.0 111.407 -179.432 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 149' ' ' ALA . . . . . 0.423 ' HB2' ' HB2' ' A' ' 91' ' ' ALA . . . -63.03 -41.33 99.49 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.309 -0.405 . . . . 0.0 111.742 -179.496 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 150' ' ' SER . . . . . . . . . . . . . 66.2 m -68.91 -0.58 5.73 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.38 -0.373 . . . . 0.0 111.501 -179.617 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 151' ' ' GLN . . . . . . . . . . . . . 44.8 mt-30 -129.09 3.69 5.26 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.628 -0.26 . . . . 0.0 111.246 179.991 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 31.0 tpt180 -76.42 -51.31 12.09 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.895 0.379 . . . . 0.0 110.651 -179.985 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 153' ' ' SER . . . . . 0.658 ' HB3' HG12 ' A' ' 156' ' ' ILE . 22.8 t -157.21 172.4 18.7 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-N 115.885 -0.598 . . . . 0.0 110.473 179.496 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 154' ' ' SER . . . . . . . . . . . . . 70.2 p -67.65 -41.22 84.18 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.382 -0.372 . . . . 0.0 110.912 179.937 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -77.07 -37.03 33.71 Favored Glycine 0 CA--C 1.519 0.305 0 C-N-CA 120.961 -0.638 . . . . 0.0 113.158 -179.657 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 156' ' ' ILE . . . . . 0.658 HG12 ' HB3' ' A' ' 153' ' ' SER . 42.4 mm -52.66 -37.22 24.19 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.186 0 CA-C-O 120.628 0.252 . . . . 0.0 111.56 -179.47 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 157' ' ' LYS . . . . . 0.44 ' O ' HG13 ' A' ' 161' ' ' VAL . 38.3 ttpt -60.29 -53.84 52.89 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.457 -0.338 . . . . 0.0 111.555 -179.629 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 48.9 m -63.5 -44.22 94.96 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 121.008 0.432 . . . . 0.0 111.468 -179.43 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 159' ' ' LEU . . . . . 0.422 HD23 ' O ' ' A' ' 159' ' ' LEU . 6.0 tt -63.71 -37.94 89.23 Favored 'General case' 0 C--N 1.326 -0.438 0 CA-C-N 115.993 -0.549 . . . . 0.0 110.983 -179.485 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 160' ' ' TYR . . . . . . . . . . . . . 54.1 t80 -74.4 -46.84 37.68 Favored 'General case' 0 C--N 1.329 -0.317 0 N-CA-C 112.548 0.573 . . . . 0.0 112.548 -178.796 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 161' ' ' VAL . . . . . 0.44 HG13 ' O ' ' A' ' 157' ' ' LYS . 28.2 m -56.13 -44.65 79.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 N-CA-C 111.908 0.336 . . . . 0.0 111.908 -178.685 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 162' ' ' ARG . . . . . 0.467 ' O ' HD12 ' A' ' 166' ' ' LEU . 97.8 mtt180 -68.65 -49.44 59.11 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.746 0.308 . . . . 0.0 111.475 -179.452 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 163' ' ' LEU . . . . . . . . . . . . . 6.1 mp -63.46 -51.58 65.04 Favored 'General case' 0 C--N 1.33 -0.239 0 CA-C-N 116.232 -0.44 . . . . 0.0 112.034 -179.097 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 164' ' ' ARG . . . . . 0.433 HH11 HG21 ' A' ' 168' ' ' VAL . 5.2 tmm_? -53.42 -50.32 65.46 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.411 -0.358 . . . . 0.0 111.208 -179.406 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 165' ' ' ASN . . . . . 0.413 ' O ' HG23 ' A' ' 169' ' ' VAL . 5.1 m-20 -53.55 -42.28 67.32 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.894 0.378 . . . . 0.0 110.609 179.898 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 166' ' ' LEU . . . . . 0.504 ' O ' ' HG ' ' A' ' 170' ' ' LEU . 1.4 mt -58.31 -51.24 70.61 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 115.998 -0.546 . . . . 0.0 111.205 179.54 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 167' ' ' THR . . . . . 0.645 ' HA ' HD11 ' A' ' 170' ' ' LEU . 6.0 m -53.93 -53.88 46.62 Favored 'General case' 0 C--N 1.332 -0.178 0 N-CA-C 112.299 0.481 . . . . 0.0 112.299 -178.198 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 168' ' ' VAL . . . . . 0.433 HG21 HH11 ' A' ' 164' ' ' ARG . 25.2 t -53.66 -42.51 51.29 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.525 0 N-CA-C 112.327 0.492 . . . . 0.0 112.327 -179.432 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 169' ' ' VAL . . . . . 0.413 HG23 ' O ' ' A' ' 165' ' ' ASN . 92.4 t -68.75 -66.73 0.49 Allowed 'Isoleucine or valine' 0 CA--C 1.532 0.281 0 N-CA-C 113.789 1.033 . . . . 0.0 113.789 -177.774 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 170' ' ' LEU . . . . . 0.645 HD11 ' HA ' ' A' ' 167' ' ' THR . 0.4 OUTLIER -59.62 -33.1 71.06 Favored 'General case' 0 N--CA 1.465 0.295 0 N-CA-C 113.01 0.744 . . . . 0.0 113.01 -177.565 . . . . . . . . 3 3 . 1 . 024 nuclear build core ' A' A ' 171' ' ' TRP . . . . . 0.554 ' H ' HD12 ' A' ' 170' ' ' LEU . 19.6 m0 -73.43 -30.9 63.53 Favored 'General case' 0 C--N 1.329 -0.315 0 C-N-CA 120.411 -0.516 . . . . 0.0 111.171 -179.509 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 172' ' ' ALA . . . . . . . . . . . . . . . -70.99 -7.28 45.09 Favored 'General case' 0 C--N 1.33 -0.275 0 C-N-CA 120.847 -0.341 . . . . 0.0 110.817 179.453 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 173' ' ' ILE . . . . . 0.478 ' O ' HG12 ' A' ' 177' ' ' ILE . 22.9 mm -88.46 -27.07 5.5 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.21 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.951 179.627 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 174' ' ' TYR . . . . . 0.459 ' HD1' ' HA ' ' A' ' 171' ' ' TRP . 29.6 m-85 -54.02 -47.7 96.28 Favored Pre-proline 0 CA--C 1.529 0.143 0 CA-C-N 116.309 -0.405 . . . . 0.0 111.943 -179.286 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 175' ' ' PRO . . . . . 0.402 ' CD ' ' N ' ' A' ' 174' ' ' TYR . 81.8 Cg_exo -47.08 -34.86 17.98 Favored 'Trans proline' 0 C--N 1.35 0.625 0 C-N-CA 121.77 1.647 . . . . 0.0 111.852 179.093 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 176' ' ' PHE . . . . . 0.515 ' O ' ' HG ' ' A' ' 180' ' ' LEU . 67.6 m-85 -80.9 -51.02 9.04 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 115.749 -0.659 . . . . 0.0 111.554 179.729 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 177' ' ' ILE . . . . . 0.478 HG12 ' O ' ' A' ' 173' ' ' ILE . 31.5 mm -58.13 -30.48 39.42 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.558 0 CA-C-N 115.742 -0.663 . . . . 0.0 111.471 -178.674 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 178' ' ' TRP . . . . . 0.423 ' O ' ' HB2' ' A' ' 183' ' ' PRO . 90.7 t90 -73.77 -59.14 2.86 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-O 121.005 0.431 . . . . 0.0 110.865 179.791 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 179' ' ' LEU . . . . . 0.634 ' HG ' HG22 ' A' ' 185' ' ' VAL . 15.4 tp -61.31 -54.72 40.3 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 115.996 -0.547 . . . . 0.0 111.711 -178.989 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 180' ' ' LEU . . . . . 0.677 HD22 HD11 ' A' ' 187' ' ' LEU . 11.6 mt -63.65 -28.68 70.07 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 116.449 -0.341 . . . . 0.0 111.744 -179.112 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 181' ' ' GLY . . . . . 0.432 ' C ' ' HD2' ' A' ' 183' ' ' PRO . . . -73.96 -173.59 28.61 Favored Glycine 0 N--CA 1.451 -0.359 0 C-N-CA 120.05 -1.071 . . . . 0.0 111.823 179.422 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 182' ' ' PRO . . . . . 0.457 ' HG2' ' HD3' ' A' ' 183' ' ' PRO . 1.3 Cg_endo -47.01 -43.19 25.06 Favored 'Trans proline' 0 CA--C 1.541 0.831 0 C-N-CA 122.856 2.371 . . . . 0.0 113.789 179.561 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 183' ' ' PRO . . . . . 0.574 ' HB3' ' HB2' ' A' ' 116' ' ' ALA . 44.2 Cg_exo -37.86 -59.22 0.55 Allowed 'Trans proline' 0 C--N 1.357 0.989 0 C-N-CA 122.819 2.346 . . . . 0.0 114.12 -179.89 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 184' ' ' GLY . . . . . . . . . . . . . . . -115.65 -107.2 2.59 Favored Glycine 0 N--CA 1.45 -0.369 0 C-N-CA 120.162 -1.018 . . . . 0.0 113.174 -179.052 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 185' ' ' VAL . . . . . 0.667 HG23 ' HA ' ' A' ' 180' ' ' LEU . 26.8 m -76.81 86.11 0.81 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.405 0 CA-C-O 121.461 0.648 . . . . 0.0 111.021 -179.492 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 186' ' ' ALA . . . . . . . . . . . . . . . -63.38 85.27 0.03 OUTLIER 'General case' 0 C--N 1.323 -0.555 0 CA-C-N 115.683 -0.69 . . . . 0.0 111.08 179.67 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 187' ' ' LEU . . . . . 0.677 HD11 HD22 ' A' ' 180' ' ' LEU . 6.2 mt -78.99 -49.21 13.09 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 116.317 -0.402 . . . . 0.0 110.9 179.843 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 188' ' ' LEU . . . . . 0.484 ' HB3' ' H ' ' A' ' 189' ' ' THR . 3.9 mm? -94.98 -157.48 0.57 Allowed 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.034 -0.53 . . . . 0.0 111.437 -179.405 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 189' ' ' THR . . . . . 0.508 ' HB ' HG23 ' A' ' 192' ' ' VAL . 32.3 m -96.12 136.32 22.16 Favored Pre-proline 0 C--N 1.331 -0.218 0 CA-C-N 115.944 -0.571 . . . . 0.0 110.96 -179.654 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 190' ' ' PRO . . . . . 0.458 ' O ' HG23 ' A' ' 194' ' ' VAL . 80.6 Cg_exo -46.64 -42.98 23.61 Favored 'Trans proline' 0 C--N 1.35 0.639 0 C-N-CA 122.61 2.207 . . . . 0.0 113.022 -179.977 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 191' ' ' THR . . . . . . . . . . . . . 75.2 p -62.19 -45.78 91.83 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-O 120.792 0.33 . . . . 0.0 111.162 -179.822 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 192' ' ' VAL . . . . . 0.508 HG23 ' HB ' ' A' ' 189' ' ' THR . 58.9 t -60.04 -44.44 94.85 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.267 -0.424 . . . . 0.0 111.031 179.922 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 193' ' ' ASP . . . . . . . . . . . . . 28.2 t70 -56.81 -43.49 81.05 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.079 -0.509 . . . . 0.0 111.074 -179.935 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 194' ' ' VAL . . . . . 0.458 HG23 ' O ' ' A' ' 190' ' ' PRO . 93.1 t -63.06 -36.03 74.17 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.354 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.867 179.765 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 195' ' ' ALA . . . . . . . . . . . . . . . -58.62 -47.15 85.34 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.081 179.809 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 196' ' ' LEU . . . . . . . . . . . . . 57.5 mt -65.74 -37.52 86.6 Favored 'General case' 0 C--N 1.332 -0.177 0 CA-C-O 120.749 0.309 . . . . 0.0 110.591 179.714 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 197' ' ' ILE . . . . . . . . . . . . . 19.7 mm -61.55 -56.99 14.16 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.114 179.28 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 198' ' ' VAL . . . . . . . . . . . . . 73.0 t -52.39 -35.26 19.79 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.43 0 CA-C-N 115.743 -0.662 . . . . 0.0 109.519 178.472 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 199' ' ' TYR . . . . . . . . . . . . . 74.5 t80 -70.09 -38.55 75.7 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 115.228 -0.897 . . . . 0.0 110.583 179.849 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 200' ' ' LEU . . . . . . . . . . . . . 38.7 mt -63.65 -44.1 94.84 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 115.752 -0.658 . . . . 0.0 111.355 -179.607 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 201' ' ' ASP . . . . . 0.416 ' HB2' ' OH ' ' A' ' 51' ' ' TYR . 0.7 OUTLIER -72.03 -37.35 69.76 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.071 -0.513 . . . . 0.0 111.212 -179.753 . . . . . . . . 3 3 . 1 . 024 nuclear build core ' A' A ' 202' ' ' LEU . . . . . 0.445 ' O ' ' HB ' ' A' ' 206' ' ' VAL . 3.2 mt -68.52 -30.8 69.69 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.686 -179.452 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 203' ' ' VAL . . . . . 0.491 ' O ' ' HA3' ' A' ' 207' ' ' GLY . 42.6 t -78.98 -36.57 18.77 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.437 0 CA-C-O 120.683 0.278 . . . . 0.0 111.125 -179.449 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 204' ' ' THR . . . . . . . . . . . . . 25.8 m -70.83 -50.83 31.17 Favored 'General case' 0 C--N 1.324 -0.519 0 C-N-CA 120.747 -0.381 . . . . 0.0 111.325 179.938 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 205' ' ' LYS . . . . . 0.619 ' HE2' ' HB2' ' A' ' 47' ' ' ALA . 50.5 mttp -71.99 -58.48 3.41 Favored 'General case' 0 C--N 1.328 -0.341 0 N-CA-C 112.313 0.486 . . . . 0.0 112.313 -178.629 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 206' ' ' VAL . . . . . 0.445 ' HB ' ' O ' ' A' ' 202' ' ' LEU . 61.9 t -74.82 -37.55 42.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 N-CA-C 111.817 0.303 . . . . 0.0 111.817 -178.983 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 207' ' ' GLY . . . . . 0.491 ' HA3' ' O ' ' A' ' 203' ' ' VAL . . . -63.07 -57.48 15.51 Favored Glycine 0 N--CA 1.452 -0.244 0 C-N-CA 120.372 -0.918 . . . . 0.0 112.117 -179.767 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 208' ' ' PHE . . . . . 0.523 ' O ' ' N ' ' A' ' 212' ' ' ALA . 4.8 m-85 -55.42 -49.05 73.43 Favored 'General case' 0 C--O 1.22 -0.478 0 N-CA-C 109.865 -0.42 . . . . 0.0 109.865 179.45 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 209' ' ' GLY . . . . . 0.519 ' HA2' ' HB3' ' A' ' 212' ' ' ALA . . . -53.71 -34.81 51.11 Favored Glycine 0 N--CA 1.451 -0.315 0 CA-C-N 115.183 -0.917 . . . . 0.0 113.382 179.641 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 210' ' ' PHE . . . . . . . . . . . . . 2.1 m-85 -70.7 -48.28 55.49 Favored 'General case' 0 CA--C 1.514 -0.427 0 N-CA-C 108.775 -0.824 . . . . 0.0 108.775 179.355 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 211' ' ' ILE . . . . . 0.483 HD13 HD11 ' A' ' 166' ' ' LEU . 5.6 mt -65.48 -27.59 42.11 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.608 0 N-CA-C 107.712 -1.218 . . . . 0.0 107.712 176.698 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 212' ' ' ALA . . . . . 0.523 ' N ' ' O ' ' A' ' 208' ' ' PHE . . . -68.59 -40.13 80.63 Favored 'General case' 0 N--CA 1.448 -0.555 0 CA-C-N 114.131 -1.395 . . . . 0.0 110.332 -179.763 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 213' ' ' LEU . . . . . 0.408 ' HG ' ' O ' ' A' ' 209' ' ' GLY . 74.8 mt -70.16 -50.42 40.52 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 114.974 -1.012 . . . . 0.0 111.405 -179.572 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 214' ' ' ASP . . . . . . . . . . . . . 24.0 t70 -59.05 -49.9 76.12 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.931 -179.714 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 215' ' ' ALA . . . . . . . . . . . . . . . -56.57 -55.46 33.58 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.888 179.944 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 216' ' ' ALA . . . . . . . . . . . . . . . -62.0 -30.94 71.29 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.143 -0.48 . . . . 0.0 111.32 -179.95 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 217' ' ' ALA . . . . . . . . . . . . . . . -58.28 -43.56 88.03 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-O 120.966 0.412 . . . . 0.0 110.275 179.881 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 218' ' ' THR . . . . . . . . . . . . . 89.5 m . . . . . 0 C--N 1.33 -0.275 0 CA-C-N 115.826 -0.625 . . . . 0.0 110.355 179.287 . . . . . . . . 0 0 . 1 . 025 nuclear build core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.301 0 N-CA-C 112.517 -0.233 . . . . 0.0 112.517 . . . . . . . . . 0 0 . 1 . 025 nuclear build core ' A' A ' 4' ' ' LEU . . . . . 0.504 HD22 HG21 ' A' ' 194' ' ' VAL . 85.8 mt -74.48 -38.36 62.93 Favored 'General case' 0 N--CA 1.449 -0.477 0 CA-C-O 120.723 0.297 . . . . 0.0 111.509 -179.906 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 69.2 p -54.77 -37.33 65.88 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.138 -0.483 . . . . 0.0 112.03 -179.171 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 69.2 p -56.12 -35.19 66.82 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.481 -0.327 . . . . 0.0 111.548 -179.625 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 7' ' ' LEU . . . . . . . . . . . . . 4.0 mm? -63.2 -53.47 52.67 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.429 -0.35 . . . . 0.0 111.419 -179.648 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 8' ' ' PHE . . . . . 0.673 ' HB2' ' HB2' ' A' ' 55' ' ' ALA . 65.8 m-85 -60.25 -33.06 71.78 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.332 -0.395 . . . . 0.0 110.946 -179.586 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 9' ' ' TRP . . . . . . . . . . . . . 18.3 m95 -68.71 -49.36 59.49 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.246 -179.825 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 75.9 mt -59.39 -38.81 81.46 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 115.814 -0.63 . . . . 0.0 109.825 179.134 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -67.12 -36.24 90.04 Favored Glycine 0 N--CA 1.446 -0.64 0 CA-C-N 115.473 -0.785 . . . . 0.0 111.73 179.403 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -61.98 -33.38 74.21 Favored 'General case' 0 C--O 1.232 0.18 0 CA-C-O 121.037 0.446 . . . . 0.0 109.97 179.183 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 50.7 mm -65.61 -49.92 74.85 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 115.694 -0.685 . . . . 0.0 110.266 179.115 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -58.3 -36.24 82.36 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.798 -0.715 . . . . 0.0 112.218 179.539 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 15' ' ' MET . . . . . . . . . . . . . 19.3 mmt -66.21 -44.6 83.41 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.74 0.305 . . . . 0.0 110.783 179.733 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 16' ' ' LEU . . . . . 0.4 HD13 ' O ' ' A' ' 16' ' ' LEU . 0.5 OUTLIER -53.79 -45.43 70.72 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 115.995 -0.548 . . . . 0.0 110.742 179.809 . . . . . . . . 3 3 . 1 . 025 nuclear build core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 49.2 t -61.12 -43.94 97.3 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.238 0 CA-C-N 116.112 -0.495 . . . . 0.0 111.149 179.943 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -66.72 -43.95 90.65 Favored Glycine 0 N--CA 1.452 -0.256 0 C-N-CA 120.699 -0.762 . . . . 0.0 112.073 179.645 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 19.2 m -52.3 -42.72 64.02 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-O 120.675 0.274 . . . . 0.0 111.341 -179.776 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 80.9 mt -71.82 -44.8 63.3 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.406 -0.361 . . . . 0.0 111.554 -179.903 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -57.01 -32.59 66.29 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.37 -0.377 . . . . 0.0 111.759 -179.405 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 22' ' ' PHE . . . . . 0.623 ' HB2' HG22 ' A' ' 41' ' ' VAL . 10.0 m-85 -90.92 -38.63 12.77 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.537 -0.301 . . . . 0.0 111.62 -179.356 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -64.03 -50.49 68.24 Favored 'General case' 0 C--N 1.332 -0.166 0 CA-C-O 120.878 0.37 . . . . 0.0 111.25 -179.685 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 24' ' ' TRP . . . . . . . . . . . . . 1.3 t-105 -59.88 -49.84 76.13 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 115.958 -0.565 . . . . 0.0 110.68 179.685 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.329 -0.313 0 CA-C-N 116.266 -0.424 . . . . 0.0 111.033 179.88 . . . . . . . . 0 0 . 1 . 025 nuclear build core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.373 0 N-CA-C 112.753 -0.139 . . . . 0.0 112.753 . . . . . . . . . 0 0 . 1 . 025 nuclear build core ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 43.6 mt-10 -88.43 -21.49 24.22 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.686 0.279 . . . . 0.0 110.988 -179.937 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 34' ' ' ARG . . . . . 0.432 ' O ' HG23 ' A' ' 38' ' ' VAL . 35.7 ttp180 -49.87 -35.25 22.67 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.141 -0.481 . . . . 0.0 111.527 -179.798 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 77.6 mtm180 -61.59 -54.33 44.48 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 120.85 0.357 . . . . 0.0 111.497 -179.772 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 59.4 m-85 -62.04 -30.02 70.69 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.134 -0.484 . . . . 0.0 111.421 -179.441 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 37' ' ' TYR . . . . . 0.526 ' O ' HG23 ' A' ' 41' ' ' VAL . 32.5 m-85 -73.76 -56.11 5.4 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.503 -179.411 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 38' ' ' VAL . . . . . 0.432 HG23 ' O ' ' A' ' 34' ' ' ARG . 96.0 t -56.68 -36.7 49.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-O 120.98 0.419 . . . . 0.0 110.628 179.923 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 78.3 m -63.44 -51.62 64.92 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 115.872 -0.604 . . . . 0.0 110.918 179.713 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 40' ' ' LEU . . . . . 0.603 HD12 HD12 ' A' ' 43' ' ' ILE . 51.7 tp -61.29 -45.98 92.22 Favored 'General case' 0 C--O 1.236 0.35 0 CA-C-N 115.966 -0.561 . . . . 0.0 110.722 179.989 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 41' ' ' VAL . . . . . 0.623 HG22 ' HB2' ' A' ' 22' ' ' PHE . 85.8 t -60.13 -34.77 58.05 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.399 0 CA-C-N 115.684 -0.689 . . . . 0.0 109.858 178.974 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -63.15 -35.39 92.02 Favored Glycine 0 N--CA 1.445 -0.724 0 C-N-CA 120.877 -0.678 . . . . 0.0 112.026 179.592 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 43' ' ' ILE . . . . . 0.662 HG22 ' HE3' ' A' ' 205' ' ' LYS . 0.8 OUTLIER -66.23 -57.75 9.28 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.126 0 C-N-CA 121.074 -0.25 . . . . 0.0 111.148 179.811 . . . . . . . . 3 3 . 1 . 025 nuclear build core ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 85.1 p -59.57 -21.56 60.48 Favored 'General case' 0 C--O 1.232 0.154 0 CA-C-N 116.485 -0.325 . . . . 0.0 111.554 -179.518 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -79.43 -56.23 3.46 Favored Glycine 0 CA--C 1.518 0.23 0 C-N-CA 120.843 -0.694 . . . . 0.0 113.063 -179.363 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 46' ' ' ILE . . . . . 0.431 ' O ' HG22 ' A' ' 49' ' ' VAL . 20.2 pt -58.2 -37.39 62.25 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.243 0 CA-C-O 121.138 0.494 . . . . 0.0 110.873 -179.896 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 47' ' ' ALA . . . . . 0.713 ' HB2' ' HE2' ' A' ' 205' ' ' LYS . . . -68.21 -45.26 73.82 Favored 'General case' 0 C--N 1.324 -0.525 0 CA-C-N 115.945 -0.571 . . . . 0.0 111.363 179.513 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -54.13 -42.71 69.79 Favored 'General case' 0 C--O 1.233 0.203 0 CA-C-N 116.299 -0.41 . . . . 0.0 111.807 -179.219 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 49' ' ' VAL . . . . . 0.431 HG22 ' O ' ' A' ' 46' ' ' ILE . 33.1 m -72.23 -34.5 49.77 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.363 0 CA-C-N 116.665 -0.243 . . . . 0.0 111.333 -179.517 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -66.9 -33.48 75.69 Favored 'General case' 0 CA--C 1.521 -0.146 0 CA-C-O 120.988 0.423 . . . . 0.0 110.73 179.402 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 3.0 m-30 -69.55 -40.72 76.66 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-N 115.909 -0.587 . . . . 0.0 110.12 179.784 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -61.44 -45.1 95.73 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 115.704 -0.68 . . . . 0.0 111.367 179.829 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 53' ' ' VAL . . . . . 0.502 HG23 ' N ' ' A' ' 54' ' ' MET . 25.3 m -67.62 -50.08 64.41 Favored 'Isoleucine or valine' 0 C--N 1.334 -0.087 0 C-N-CA 121.11 -0.236 . . . . 0.0 111.011 -179.956 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 54' ' ' MET . . . . . 0.541 ' HG2' ' HG2' ' A' ' 71' ' ' PRO . 74.7 mtm -58.04 -30.35 66.08 Favored 'General case' 0 CA--C 1.521 -0.172 0 CA-C-O 121.224 0.535 . . . . 0.0 109.866 179.336 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 55' ' ' ALA . . . . . 0.673 ' HB2' ' HB2' ' A' ' 8' ' ' PHE . . . -74.5 -33.93 62.93 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 115.414 -0.812 . . . . 0.0 111.365 179.526 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 74.8 mt -70.88 -5.19 28.78 Favored 'General case' 0 C--N 1.331 -0.203 0 CA-C-N 116.371 -0.377 . . . . 0.0 111.573 -179.416 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 98.8 -20.77 49.01 Favored Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.46 -0.876 . . . . 0.0 113.036 179.638 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 58' ' ' VAL . . . . . 0.428 HG22 ' O ' ' A' ' 53' ' ' VAL . 32.9 m -70.03 149.11 10.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-O 120.88 0.371 . . . . 0.0 110.826 179.805 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 59' ' ' GLY . . . . . 0.472 ' HA3' ' HG3' ' A' ' 71' ' ' PRO . . . 85.05 22.49 52.31 Favored Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.913 -0.661 . . . . 0.0 112.578 -179.47 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 60' ' ' TRP . . . . . . . . . . . . . 13.8 m0 -105.71 96.07 6.24 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-O 121.091 0.472 . . . . 0.0 109.986 -179.837 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 5.1 t -98.53 116.54 65.4 Favored Pre-proline 0 C--N 1.326 -0.435 0 CA-C-N 115.696 -0.683 . . . . 0.0 111.635 -178.87 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 57.1 Cg_endo -70.4 143.96 49.25 Favored 'Trans proline' 0 C--N 1.351 0.709 0 C-N-CA 122.437 2.092 . . . . 0.0 112.262 179.578 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 99.5 t -138.93 96.12 0.99 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.053 -0.521 . . . . 0.0 111.165 -179.88 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . 57.24 -88.1 0.02 OUTLIER 'General case' 0 C--N 1.331 -0.204 0 CA-C-N 116.189 -0.459 . . . . 0.0 111.439 179.781 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 45.7 mt-10 -121.85 -19.08 6.85 Favored 'General case' 0 C--N 1.332 -0.193 0 CA-C-N 116.433 -0.349 . . . . 0.0 110.939 179.935 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 66' ' ' ARG . . . . . . . . . . . . . 39.7 mmt180 -105.4 155.72 18.86 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.342 179.629 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 30.3 m -114.01 143.32 44.94 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-O 120.947 0.404 . . . . 0.0 111.351 -179.591 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 19.9 m -127.42 145.84 34.2 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.402 0 CA-C-N 115.83 -0.623 . . . . 0.0 110.818 179.659 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 69' ' ' PHE . . . . . . . . . . . . . 17.2 m-85 -110.73 115.6 29.84 Favored 'General case' 0 C--N 1.327 -0.38 0 N-CA-C 109.738 -0.467 . . . . 0.0 109.738 -179.63 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 70' ' ' VAL . . . . . 0.566 ' N ' ' HD2' ' A' ' 71' ' ' PRO . 59.4 t -68.43 -51.17 24.66 Favored Pre-proline 0 C--N 1.323 -0.559 0 N-CA-C 112.436 0.532 . . . . 0.0 112.436 -178.741 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 71' ' ' PRO . . . . . 0.566 ' HD2' ' N ' ' A' ' 70' ' ' VAL . 11.2 Cg_endo -54.87 -19.89 20.79 Favored 'Trans proline' 0 C--N 1.353 0.791 0 C-N-CA 122.089 1.859 . . . . 0.0 112.012 179.831 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 72' ' ' ARG . . . . . 0.412 ' NH2' HG13 ' A' ' 197' ' ' ILE . 53.1 ttt180 -74.96 -53.8 8.34 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.043 -0.526 . . . . 0.0 110.586 179.673 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 73' ' ' TYR . . . . . 0.4 ' O ' HG13 ' A' ' 77' ' ' ILE . 75.8 m-85 -65.02 -36.91 85.91 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 115.774 -0.648 . . . . 0.0 110.704 -179.994 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 0.3 OUTLIER -70.05 -36.78 69.98 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 N-CA-C 109.744 -0.465 . . . . 0.0 109.744 179.048 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 75' ' ' ASP . . . . . 0.401 ' O ' HG23 ' A' ' 79' ' ' THR . 12.3 t70 -56.52 -38.95 72.54 Favored 'General case' 0 CA--C 1.52 -0.176 0 CA-C-N 116.033 -0.531 . . . . 0.0 109.642 179.06 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 76' ' ' TRP . . . . . . . . . . . . . 50.2 m0 -69.45 -38.54 77.84 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 115.615 -0.72 . . . . 0.0 110.624 179.418 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 77' ' ' ILE . . . . . 0.4 HG13 ' O ' ' A' ' 73' ' ' TYR . 92.5 mt -59.17 -28.77 39.97 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.725 179.674 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 35.4 mt -91.83 -26.91 18.29 Favored 'General case' 0 CA--C 1.533 0.293 0 N-CA-C 112.317 0.488 . . . . 0.0 112.317 -179.941 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 79' ' ' THR . . . . . 0.413 HG22 HD11 ' A' ' 46' ' ' ILE . 71.3 p -92.44 -52.24 4.75 Favored 'General case' 0 N--CA 1.466 0.342 0 N-CA-C 113.622 0.971 . . . . 0.0 113.622 -177.884 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 80' ' ' THR . . . . . 0.425 ' N ' ' HD2' ' A' ' 81' ' ' PRO . 89.0 m -47.3 -55.25 16.7 Favored Pre-proline 0 C--N 1.329 -0.325 0 N-CA-C 112.858 0.688 . . . . 0.0 112.858 -178.418 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 81' ' ' PRO . . . . . 0.437 ' HA ' HG22 ' A' ' 84' ' ' VAL . 37.2 Cg_endo -64.19 -18.99 65.42 Favored 'Trans proline' 0 C--N 1.35 0.614 0 C-N-CA 121.495 1.463 . . . . 0.0 111.232 -179.833 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 82' ' ' LEU . . . . . . . . . . . . . 18.4 tp -76.93 -33.6 57.72 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 115.529 -0.759 . . . . 0.0 110.169 179.641 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 83' ' ' ILE . . . . . 0.414 HD13 HD13 ' A' ' 43' ' ' ILE . 41.2 mm -70.12 -52.23 32.29 Favored 'Isoleucine or valine' 0 C--O 1.232 0.175 0 CA-C-N 116.058 -0.519 . . . . 0.0 110.101 179.203 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 84' ' ' VAL . . . . . 0.437 HG22 ' HA ' ' A' ' 81' ' ' PRO . 27.9 m -60.61 -30.47 46.89 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.179 0 N-CA-C 109.63 -0.507 . . . . 0.0 109.63 178.795 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 85' ' ' TYR . . . . . . . . . . . . . 81.1 t80 -65.33 -35.79 82.07 Favored 'General case' 0 N--CA 1.453 -0.28 0 CA-C-N 115.542 -0.754 . . . . 0.0 109.276 178.684 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 86' ' ' PHE . . . . . . . . . . . . . 7.2 t80 -61.15 -50.13 74.41 Favored 'General case' 0 C--O 1.234 0.237 0 CA-C-N 115.633 -0.712 . . . . 0.0 109.919 179.186 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 8.8 mp -62.23 -31.84 72.44 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 115.838 -0.619 . . . . 0.0 109.861 179.384 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -68.96 -27.69 73.69 Favored Glycine 0 N--CA 1.449 -0.459 0 C-N-CA 120.856 -0.688 . . . . 0.0 111.678 179.113 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 82.7 mt -73.72 -37.36 65.17 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-O 120.948 0.404 . . . . 0.0 110.482 179.549 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 90' ' ' LEU . . . . . 0.437 HD11 HD22 ' A' ' 163' ' ' LEU . 93.6 mt -64.3 -42.67 96.26 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 115.945 -0.571 . . . . 0.0 111.144 179.9 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -80.13 -54.99 5.25 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.4 -179.654 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 95.37 67.88 1.0 Allowed Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.814 -0.708 . . . . 0.0 112.132 -179.733 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 93' ' ' LEU . . . . . 0.426 ' N ' HD12 ' A' ' 93' ' ' LEU . 6.6 mp -71.21 -171.13 0.55 Allowed 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.783 0.325 . . . . 0.0 111.033 -179.71 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 94' ' ' ASP . . . . . 0.419 ' HB2' ' OE2' ' A' ' 97' ' ' GLU . 5.9 m-20 -96.43 -173.41 2.76 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-N 116.246 -0.433 . . . . 0.0 111.28 -179.807 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 47.5 t -67.52 -51.26 53.04 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 115.946 -0.57 . . . . 0.0 111.624 -179.425 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 96' ' ' ARG . . . . . 0.425 ' O ' HG13 ' A' ' 100' ' ' ILE . 31.6 mmt180 -73.72 -40.07 63.83 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 120.944 0.402 . . . . 0.0 110.699 -179.505 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 97' ' ' GLU . . . . . 0.54 ' HA ' HD12 ' A' ' 100' ' ' ILE . 0.3 OUTLIER -55.48 -47.39 76.21 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 115.763 -0.653 . . . . 0.0 111.501 -179.622 . . . . . . . . 3 3 . 1 . 025 nuclear build core ' A' A ' 98' ' ' PHE . . . . . 0.444 ' O ' HG12 ' A' ' 102' ' ' ILE . 1.2 m-85 -57.13 -45.23 83.69 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.821 0.343 . . . . 0.0 110.796 179.813 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -62.68 -30.25 76.26 Favored Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.586 -179.92 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 100' ' ' ILE . . . . . 0.54 HD12 ' HA ' ' A' ' 97' ' ' GLU . 95.5 mt -65.65 -44.79 93.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-O 120.81 0.338 . . . . 0.0 111.221 -179.939 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 101' ' ' VAL . . . . . 0.431 HG21 ' CE ' ' A' ' 145' ' ' MET . 56.2 t -68.64 -43.89 82.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.322 -0.399 . . . . 0.0 111.51 -179.732 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 102' ' ' ILE . . . . . 0.444 HG12 ' O ' ' A' ' 98' ' ' PHE . 48.5 mm -61.45 -51.1 76.84 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.348 -0.387 . . . . 0.0 111.189 -179.789 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 14.9 t -61.35 -29.01 69.64 Favored 'General case' 0 C--O 1.232 0.153 0 CA-C-O 120.866 0.365 . . . . 0.0 110.614 179.925 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 104' ' ' LEU . . . . . 0.458 ' O ' HG23 ' A' ' 108' ' ' VAL . 1.4 tm? -59.6 -52.65 64.61 Favored 'General case' 0 C--N 1.331 -0.198 0 CA-C-N 116.073 -0.512 . . . . 0.0 109.807 179.217 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 105' ' ' ASN . . . . . 0.569 ' N ' HD22 ' A' ' 105' ' ' ASN . 0.8 OUTLIER -64.33 -26.18 68.37 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 115.965 -0.561 . . . . 0.0 111.024 179.732 . . . . . . . . 3 3 . 1 . 025 nuclear build core ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 53.7 m -63.95 -56.7 13.26 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.38 -0.373 . . . . 0.0 111.478 -179.795 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 7.2 p -62.33 -36.47 74.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.272 -0.422 . . . . 0.0 111.214 -179.851 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 108' ' ' VAL . . . . . 0.458 HG23 ' O ' ' A' ' 104' ' ' LEU . 81.3 t -65.59 -54.41 28.37 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.197 0 CA-C-N 116.376 -0.375 . . . . 0.0 111.01 179.817 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 109' ' ' MET . . . . . . . . . . . . . 11.2 tpp -59.58 -36.29 75.94 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.94 -179.766 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 30.2 tp -66.52 -32.94 74.6 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.309 -0.405 . . . . 0.0 110.226 179.779 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -62.02 -54.21 44.68 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 115.97 -0.559 . . . . 0.0 110.683 179.526 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . -56.87 -36.51 73.25 Favored Glycine 0 C--N 1.331 0.283 0 C-N-CA 120.605 -0.807 . . . . 0.0 112.044 179.549 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 113' ' ' PHE . . . . . . . . . . . . . 2.6 t80 -54.06 -63.67 1.07 Allowed 'General case' 0 C--N 1.332 -0.186 0 CA-C-O 120.918 0.389 . . . . 0.0 110.262 179.589 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 114' ' ' ALA . . . . . 0.447 ' O ' HG13 ' A' ' 118' ' ' VAL . . . -62.25 -28.29 69.6 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 115.88 -0.6 . . . . 0.0 111.172 179.942 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 115' ' ' GLY . . . . . 0.465 ' N ' ' HG ' ' A' ' 126' ' ' LEU . . . -52.22 -52.88 33.84 Favored Glycine 0 C--N 1.333 0.363 0 C-N-CA 121.081 -0.58 . . . . 0.0 112.729 179.971 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -77.91 -15.06 59.3 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-O 120.711 0.291 . . . . 0.0 111.535 179.84 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 117' ' ' MET . . . . . . . . . . . . . 0.5 OUTLIER -93.83 19.34 8.99 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.468 -0.333 . . . . 0.0 111.488 -179.704 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 118' ' ' VAL . . . . . 0.447 HG13 ' O ' ' A' ' 114' ' ' ALA . 33.2 m -84.55 146.74 47.73 Favored Pre-proline 0 C--N 1.331 -0.223 0 CA-C-N 116.594 -0.276 . . . . 0.0 111.335 179.86 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 119' ' ' PRO . . . . . . . . . . . . . 96.6 Cg_endo -87.91 1.92 6.64 Favored 'Trans proline' 0 N--CA 1.458 -0.593 0 C-N-CA 122.709 2.273 . . . . 0.0 112.233 179.325 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -155.55 -138.39 2.56 Favored Glycine 0 C--N 1.332 0.334 0 C-N-CA 120.806 -0.711 . . . . 0.0 112.79 -179.674 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 47.1 pt -88.55 8.72 2.64 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.193 0 CA-C-O 120.645 0.26 . . . . 0.0 111.523 -179.634 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 38.4 mt-10 -60.07 -18.55 47.61 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.423 -0.353 . . . . 0.0 111.11 -179.853 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 123' ' ' ARG . . . . . 0.4 ' HB2' ' HH2' ' A' ' 178' ' ' TRP . 2.6 ptp180 -52.07 -33.8 40.86 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.176 -0.465 . . . . 0.0 111.737 -179.871 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 124' ' ' TYR . . . . . . . . . . . . . 40.8 m-85 -65.01 -32.67 74.51 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.599 -0.273 . . . . 0.0 111.362 -179.659 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 125' ' ' ALA . . . . . . . . . . . . . . . -68.73 -52.96 25.05 Favored 'General case' 0 C--O 1.237 0.419 0 CA-C-O 120.79 0.328 . . . . 0.0 111.064 179.909 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 126' ' ' LEU . . . . . 0.465 ' HG ' ' N ' ' A' ' 115' ' ' GLY . 2.6 mm? -49.86 -54.32 20.17 Favored 'General case' 0 CA--C 1.52 -0.187 0 CA-C-N 116.016 -0.538 . . . . 0.0 110.61 -179.988 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 127' ' ' PHE . . . . . 0.505 ' HZ ' ' HB3' ' A' ' 175' ' ' PRO . 7.1 t80 -67.5 -31.53 71.73 Favored 'General case' 0 N--CA 1.452 -0.35 0 CA-C-N 116.285 -0.416 . . . . 0.0 111.074 -179.652 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 128' ' ' GLY . . . . . . . . . . . . . . . -46.38 -48.38 16.2 Favored Glycine 0 C--N 1.331 0.283 0 C-N-CA 119.793 -1.194 . . . . 0.0 110.737 179.07 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 129' ' ' MET . . . . . 0.491 ' HE3' ' N ' ' A' ' 130' ' ' GLY . 6.0 tmm? -70.43 -45.79 65.18 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 115.139 -0.53 . . . . 0.0 109.894 178.75 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 130' ' ' GLY . . . . . 0.491 ' N ' ' HE3' ' A' ' 129' ' ' MET . . . -57.37 -29.63 60.6 Favored Glycine 0 C--N 1.331 0.265 0 CA-C-N 115.85 -0.614 . . . . 0.0 113.174 -179.315 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -75.02 -53.65 8.55 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-O 120.702 0.287 . . . . 0.0 110.58 -179.798 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 60.0 t -57.67 -42.08 80.77 Favored 'Isoleucine or valine' 0 C--O 1.234 0.252 0 CA-C-O 121.372 0.606 . . . . 0.0 109.672 178.815 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -68.9 -33.47 73.81 Favored 'General case' 0 N--CA 1.451 -0.377 0 CA-C-N 115.272 -0.877 . . . . 0.0 110.781 179.441 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 134' ' ' PHE . . . . . . . . . . . . . 70.5 t80 -54.59 -57.42 11.51 Favored 'General case' 0 N--CA 1.451 -0.394 0 CA-C-O 121.01 0.433 . . . . 0.0 110.031 179.542 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 135' ' ' ILE . . . . . 0.457 ' O ' HG22 ' A' ' 138' ' ' VAL . 26.4 mt -57.22 -33.27 42.88 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.388 0 CA-C-N 115.728 -0.669 . . . . 0.0 109.891 178.87 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . -59.26 -39.46 94.63 Favored Glycine 0 N--CA 1.448 -0.52 0 C-N-CA 120.31 -0.948 . . . . 0.0 111.511 178.851 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 137' ' ' LEU . . . . . . . . . . . . . 54.6 tp -68.68 -55.34 11.74 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-O 120.715 0.293 . . . . 0.0 110.729 179.549 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 138' ' ' VAL . . . . . 0.457 HG22 ' O ' ' A' ' 135' ' ' ILE . 2.8 m -55.86 -32.08 31.64 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.24 0 CA-C-O 121.45 0.643 . . . . 0.0 109.478 179.747 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 139' ' ' TYR . . . . . . . . . . . . . 9.8 t80 -64.23 -36.89 85.55 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 115.28 -0.873 . . . . 0.0 109.995 178.667 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 16.1 m-85 -66.18 -53.15 40.87 Favored 'General case' 0 C--N 1.332 -0.186 0 CA-C-N 115.959 -0.564 . . . . 0.0 111.332 179.669 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 141' ' ' LEU . . . . . 0.644 HD12 HG23 ' A' ' 142' ' ' VAL . 3.0 pp -64.31 -17.12 63.36 Favored 'General case' 0 C--N 1.333 -0.148 0 CA-C-O 120.657 0.265 . . . . 0.0 111.268 -179.418 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 142' ' ' VAL . . . . . 0.644 HG23 HD12 ' A' ' 141' ' ' LEU . 47.1 t -94.93 -22.71 5.3 Favored 'Isoleucine or valine' 0 C--O 1.233 0.208 0 CA-C-O 121.054 0.454 . . . . 0.0 110.366 178.343 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . -74.25 -124.6 0.12 Allowed Glycine 0 CA--C 1.524 0.612 0 C-N-CA 121.114 -0.565 . . . . 0.0 113.485 -179.234 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 144' ' ' PRO . . . . . . . . . . . . . 46.6 Cg_endo -67.55 -23.13 43.62 Favored 'Trans proline' 0 C--N 1.35 0.642 0 C-N-CA 122.769 2.313 . . . . 0.0 113.253 -179.157 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 145' ' ' MET . . . . . 0.493 ' HB3' ' OH ' ' A' ' 160' ' ' TYR . 5.7 mtt -52.18 -57.61 9.13 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.508 -0.315 . . . . 0.0 111.658 -179.609 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 146' ' ' THR . . . . . . . . . . . . . 8.8 t -62.78 -32.2 73.32 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.488 -0.324 . . . . 0.0 111.719 -179.343 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 45.6 mt-10 -70.57 -33.9 71.61 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.425 -0.352 . . . . 0.0 111.311 -179.609 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 148' ' ' SER . . . . . . . . . . . . . 38.8 m -70.52 -49.87 43.62 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.956 0.408 . . . . 0.0 110.843 -179.889 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 149' ' ' ALA . . . . . 0.498 ' HB1' HG22 ' A' ' 156' ' ' ILE . . . -64.05 -35.23 80.06 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 115.992 -0.549 . . . . 0.0 111.757 -179.553 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 150' ' ' SER . . . . . 0.444 ' HA ' ' HB2' ' A' ' 157' ' ' LYS . 86.3 p -67.71 -5.59 16.71 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.379 -0.373 . . . . 0.0 111.232 -179.664 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 151' ' ' GLN . . . . . . . . . . . . . 78.9 mt-30 -115.3 -1.16 12.98 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.503 -0.317 . . . . 0.0 111.338 179.947 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 32.4 mmt180 -80.97 -51.63 8.33 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-O 120.843 0.354 . . . . 0.0 110.989 179.812 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 153' ' ' SER . . . . . 0.58 ' HB3' HG12 ' A' ' 156' ' ' ILE . 27.5 t -158.08 172.41 18.48 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 116.141 -0.482 . . . . 0.0 110.844 179.635 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 154' ' ' SER . . . . . . . . . . . . . 50.8 m -71.59 -40.47 69.85 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.285 -0.416 . . . . 0.0 110.455 179.327 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -76.75 -31.97 51.86 Favored Glycine 0 N--CA 1.452 -0.281 0 C-N-CA 121.013 -0.613 . . . . 0.0 112.708 179.916 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 156' ' ' ILE . . . . . 0.58 HG12 ' HB3' ' A' ' 153' ' ' SER . 29.5 mm -60.14 -38.21 76.17 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.229 0 CA-C-O 120.834 0.349 . . . . 0.0 111.131 -179.896 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 157' ' ' LYS . . . . . 0.444 ' HB2' ' HA ' ' A' ' 150' ' ' SER . 61.7 tttm -66.85 -50.87 61.14 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.327 -179.601 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 48.5 t -62.72 -39.45 94.08 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.3 -0.409 . . . . 0.0 111.549 -179.464 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 159' ' ' LEU . . . . . 0.456 ' O ' HD13 ' A' ' 163' ' ' LEU . 32.0 tp -71.11 -33.45 70.15 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.364 -0.38 . . . . 0.0 111.211 -179.477 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 160' ' ' TYR . . . . . 0.493 ' OH ' ' HB3' ' A' ' 145' ' ' MET . 48.3 t80 -73.24 -46.82 47.93 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.569 -0.287 . . . . 0.0 111.473 -179.559 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 161' ' ' VAL . . . . . 0.429 HG23 ' N ' ' A' ' 162' ' ' ARG . 27.8 m -58.52 -45.4 90.24 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 CA-C-N 116.718 -0.219 . . . . 0.0 111.531 -179.408 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 162' ' ' ARG . . . . . 0.429 ' N ' HG23 ' A' ' 161' ' ' VAL . 40.7 mmt180 -65.05 -39.71 93.69 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-O 120.854 0.359 . . . . 0.0 111.324 -179.723 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 163' ' ' LEU . . . . . 0.605 ' HG ' ' HB2' ' A' ' 208' ' ' PHE . 6.3 mp -70.2 -46.84 63.73 Favored 'General case' 0 C--N 1.328 -0.366 0 N-CA-C 112.453 0.538 . . . . 0.0 112.453 -179.149 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 164' ' ' ARG . . . . . 0.427 ' O ' HG23 ' A' ' 168' ' ' VAL . 5.8 ppt_? -70.96 -47.71 57.44 Favored 'General case' 0 C--N 1.33 -0.262 0 N-CA-C 112.107 0.41 . . . . 0.0 112.107 -178.418 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 165' ' ' ASN . . . . . 0.472 ' O ' HG23 ' A' ' 169' ' ' VAL . 5.1 m120 -57.75 -49.24 77.24 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-O 120.761 0.315 . . . . 0.0 111.129 -179.847 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 166' ' ' LEU . . . . . 0.458 ' O ' ' HG ' ' A' ' 170' ' ' LEU . 5.8 tt -63.57 -52.35 61.43 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.533 -179.427 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 167' ' ' THR . . . . . . . . . . . . . 98.7 m -56.4 -53.27 59.38 Favored 'General case' 0 C--N 1.33 -0.26 0 N-CA-C 112.528 0.566 . . . . 0.0 112.528 -178.88 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 168' ' ' VAL . . . . . 0.427 HG23 ' O ' ' A' ' 164' ' ' ARG . 72.1 t -54.08 -45.15 65.24 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.225 0 N-CA-C 112.016 0.376 . . . . 0.0 112.016 -179.127 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 169' ' ' VAL . . . . . 0.472 HG23 ' O ' ' A' ' 165' ' ' ASN . 54.2 t -55.39 -64.45 0.47 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 N-CA-C 111.831 0.308 . . . . 0.0 111.831 -179.387 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 170' ' ' LEU . . . . . 0.458 ' HG ' ' O ' ' A' ' 166' ' ' LEU . 1.1 pp -62.67 -29.68 70.82 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.657 -0.247 . . . . 0.0 111.626 -179.39 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 171' ' ' TRP . . . . . . . . . . . . . 4.1 m0 -69.79 -32.32 70.73 Favored 'General case' 0 C--N 1.332 -0.183 0 CA-C-O 121.126 0.488 . . . . 0.0 110.184 179.207 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 172' ' ' ALA . . . . . 0.401 ' C ' ' HD2' ' A' ' 175' ' ' PRO . . . -71.83 -6.5 42.12 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 115.595 -0.73 . . . . 0.0 110.996 -179.848 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 173' ' ' ILE . . . . . 0.475 ' O ' HG12 ' A' ' 177' ' ' ILE . 48.2 mm -85.41 -23.76 7.09 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.245 0 CA-C-N 115.99 -0.55 . . . . 0.0 110.736 179.647 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 174' ' ' TYR . . . . . 0.408 ' N ' ' CD ' ' A' ' 175' ' ' PRO . 20.6 m-85 -54.08 -48.48 93.95 Favored Pre-proline 0 N--CA 1.464 0.232 0 CA-C-N 116.341 -0.39 . . . . 0.0 111.203 179.791 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 175' ' ' PRO . . . . . 0.505 ' HB3' ' HZ ' ' A' ' 127' ' ' PHE . 93.3 Cg_exo -44.6 -33.2 6.51 Favored 'Trans proline' 0 C--N 1.351 0.697 0 C-N-CA 122.287 1.991 . . . . 0.0 112.097 178.894 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 176' ' ' PHE . . . . . 0.517 ' O ' ' HG ' ' A' ' 180' ' ' LEU . 93.0 m-85 -80.63 -50.32 10.1 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 115.691 -0.686 . . . . 0.0 111.851 -179.876 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 177' ' ' ILE . . . . . 0.475 HG12 ' O ' ' A' ' 173' ' ' ILE . 4.6 mm -63.78 -30.91 51.18 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.56 0 N-CA-C 112.533 0.568 . . . . 0.0 112.533 -177.966 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 178' ' ' TRP . . . . . 0.4 ' HH2' ' HB2' ' A' ' 123' ' ' ARG . 84.0 t90 -73.7 -45.67 50.88 Favored 'General case' 0 C--N 1.331 -0.2 0 CA-C-O 120.833 0.349 . . . . 0.0 110.904 179.904 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 179' ' ' LEU . . . . . 0.527 HD23 HD23 ' A' ' 180' ' ' LEU . 0.5 OUTLIER -73.86 -54.82 7.14 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.027 -0.533 . . . . 0.0 111.635 -179.053 . . . . . . . . 3 3 . 1 . 025 nuclear build core ' A' A ' 180' ' ' LEU . . . . . 0.629 HD22 HD11 ' A' ' 187' ' ' LEU . 16.6 mt -62.41 -46.34 89.02 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.563 -0.29 . . . . 0.0 111.378 -179.245 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . -54.64 173.55 0.77 Allowed Glycine 0 CA--C 1.523 0.536 0 C-N-CA 120.296 -0.954 . . . . 0.0 112.514 179.707 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 182' ' ' PRO . . . . . 0.501 ' HA ' ' HB2' ' A' ' 186' ' ' ALA . 86.9 Cg_exo -45.95 -45.3 17.65 Favored 'Trans proline' 0 CA--C 1.536 0.615 0 C-N-CA 122.813 2.342 . . . . 0.0 113.801 -179.849 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 183' ' ' PRO . . . . . 0.434 ' HD3' ' HB2' ' A' ' 182' ' ' PRO . 89.0 Cg_exo -45.37 -34.24 10.09 Favored 'Trans proline' 0 C--N 1.356 0.924 0 C-N-CA 122.281 1.987 . . . . 0.0 113.429 -179.828 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 184' ' ' GLY . . . . . . . . . . . . . . . -109.68 -123.75 4.71 Favored Glycine 0 C--N 1.333 0.368 0 C-N-CA 120.299 -0.953 . . . . 0.0 113.114 -179.652 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 185' ' ' VAL . . . . . . . . . . . . . 11.2 m -62.44 -21.77 27.93 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.218 0 N-CA-C 112.252 0.464 . . . . 0.0 112.252 -179.315 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 186' ' ' ALA . . . . . 0.501 ' HB2' ' HA ' ' A' ' 182' ' ' PRO . . . 57.12 85.63 0.08 Allowed 'General case' 0 N--CA 1.463 0.222 0 CA-C-O 120.862 0.363 . . . . 0.0 111.761 179.693 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 187' ' ' LEU . . . . . 0.629 HD11 HD22 ' A' ' 180' ' ' LEU . 12.6 mt -92.62 -49.66 5.99 Favored 'General case' 0 C--N 1.332 -0.192 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.375 179.806 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 188' ' ' LEU . . . . . 0.588 HD13 HG11 ' A' ' 192' ' ' VAL . 79.7 mt -101.41 -159.81 0.76 Allowed 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 115.946 -0.57 . . . . 0.0 111.1 -179.333 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 189' ' ' THR . . . . . . . . . . . . . 2.0 t -96.55 147.66 33.28 Favored Pre-proline 0 C--N 1.33 -0.277 0 CA-C-N 116.089 -0.505 . . . . 0.0 111.256 -179.793 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 190' ' ' PRO . . . . . 0.435 ' O ' HG23 ' A' ' 194' ' ' VAL . 77.1 Cg_exo -47.62 -39.29 29.77 Favored 'Trans proline' 0 C--N 1.351 0.685 0 C-N-CA 122.681 2.254 . . . . 0.0 112.74 179.967 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 191' ' ' THR . . . . . . . . . . . . . 73.7 p -57.77 -44.05 85.94 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.315 -0.402 . . . . 0.0 111.357 -179.754 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 192' ' ' VAL . . . . . 0.588 HG11 HD13 ' A' ' 188' ' ' LEU . 40.8 t -68.25 -42.64 84.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.242 -0.436 . . . . 0.0 111.146 179.933 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 193' ' ' ASP . . . . . . . . . . . . . 25.6 t70 -58.29 -50.32 74.02 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.254 -0.43 . . . . 0.0 111.176 -179.849 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 194' ' ' VAL . . . . . 0.504 HG21 HD22 ' A' ' 4' ' ' LEU . 59.6 t -60.93 -35.71 66.89 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.35 -0.386 . . . . 0.0 110.982 179.896 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 195' ' ' ALA . . . . . . . . . . . . . . . -58.39 -48.39 80.8 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.466 -0.334 . . . . 0.0 111.143 179.858 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 196' ' ' LEU . . . . . . . . . . . . . 52.7 mt -68.27 -44.99 74.34 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.327 -0.397 . . . . 0.0 110.651 179.696 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 197' ' ' ILE . . . . . 0.412 HG13 ' NH2' ' A' ' 72' ' ' ARG . 20.2 mm -56.29 -59.12 3.16 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.368 0 CA-C-N 115.805 -0.634 . . . . 0.0 110.787 179.643 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 198' ' ' VAL . . . . . . . . . . . . . 49.3 t -52.26 -35.1 19.04 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.484 0 CA-C-N 115.657 -0.701 . . . . 0.0 109.55 178.728 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 199' ' ' TYR . . . . . . . . . . . . . 48.7 t80 -70.15 -32.1 69.92 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 115.482 -0.781 . . . . 0.0 110.523 179.641 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 200' ' ' LEU . . . . . 0.511 ' O ' HG12 ' A' ' 203' ' ' VAL . 40.8 mt -70.35 -43.97 69.12 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 115.903 -0.589 . . . . 0.0 111.553 -179.609 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 201' ' ' ASP . . . . . . . . . . . . . 8.5 m-20 -70.04 -38.37 75.83 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 121.087 0.47 . . . . 0.0 110.521 -179.971 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 202' ' ' LEU . . . . . 0.573 ' O ' HG22 ' A' ' 206' ' ' VAL . 2.7 mt -70.67 -33.09 70.56 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 115.721 -0.672 . . . . 0.0 111.95 -179.389 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 203' ' ' VAL . . . . . 0.511 HG12 ' O ' ' A' ' 200' ' ' LEU . 13.4 p -72.47 -36.08 53.34 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.297 0 C-N-CA 120.856 -0.338 . . . . 0.0 110.848 -178.651 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 204' ' ' THR . . . . . . . . . . . . . 82.4 m -66.29 -58.32 5.61 Favored 'General case' 0 C--N 1.328 -0.328 0 C-N-CA 120.797 -0.361 . . . . 0.0 111.47 179.443 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 205' ' ' LYS . . . . . 0.713 ' HE2' ' HB2' ' A' ' 47' ' ' ALA . 57.3 mttp -61.1 -60.15 4.23 Favored 'General case' 0 C--N 1.329 -0.304 0 N-CA-C 112.974 0.731 . . . . 0.0 112.974 -177.697 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 206' ' ' VAL . . . . . 0.573 HG22 ' O ' ' A' ' 202' ' ' LEU . 1.0 OUTLIER -71.1 -36.31 62.35 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.434 0 N-CA-C 112.103 0.409 . . . . 0.0 112.103 -179.471 . . . . . . . . 3 3 . 1 . 025 nuclear build core ' A' A ' 207' ' ' GLY . . . . . 0.564 ' O ' HG13 ' A' ' 211' ' ' ILE . . . -55.91 -61.48 7.39 Favored Glycine 0 C--N 1.331 0.258 0 C-N-CA 120.534 -0.841 . . . . 0.0 113.623 -178.691 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 208' ' ' PHE . . . . . 0.605 ' HB2' ' HG ' ' A' ' 163' ' ' LEU . 0.7 OUTLIER -72.35 -29.67 64.01 Favored 'General case' 0 C--O 1.224 -0.289 0 CA-C-N 117.433 0.617 . . . . 0.0 110.465 -179.632 . . . . . . . . 3 3 . 1 . 025 nuclear build core ' A' A ' 209' ' ' GLY . . . . . 0.53 ' O ' ' HB3' ' A' ' 212' ' ' ALA . . . -64.66 -32.08 83.03 Favored Glycine 0 N--CA 1.448 -0.514 0 CA-C-N 115.89 -0.595 . . . . 0.0 111.916 179.24 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 210' ' ' PHE . . . . . . . . . . . . . 3.3 m-85 -73.39 -47.23 43.62 Favored 'General case' 0 CA--C 1.512 -0.5 0 N-CA-C 108.242 -1.021 . . . . 0.0 108.242 178.536 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 211' ' ' ILE . . . . . 0.564 HG13 ' O ' ' A' ' 207' ' ' GLY . 4.7 mt -63.81 -27.5 42.99 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.56 0 N-CA-C 107.342 -1.355 . . . . 0.0 107.342 176.273 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 212' ' ' ALA . . . . . 0.53 ' HB3' ' O ' ' A' ' 209' ' ' GLY . . . -64.85 -39.62 93.86 Favored 'General case' 0 N--CA 1.45 -0.463 0 CA-C-N 114.335 -1.302 . . . . 0.0 110.745 179.986 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 213' ' ' LEU . . . . . . . . . . . . . 48.6 mt -67.49 -49.55 62.99 Favored 'General case' 0 C--N 1.333 -0.128 0 CA-C-N 115.511 -0.768 . . . . 0.0 111.445 -179.565 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 214' ' ' ASP . . . . . . . . . . . . . 15.9 t70 -58.62 -51.08 71.45 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.938 0.399 . . . . 0.0 110.766 -179.908 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 215' ' ' ALA . . . . . . . . . . . . . . . -60.85 -53.42 57.5 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 115.936 -0.574 . . . . 0.0 111.214 -179.901 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 216' ' ' ALA . . . . . . . . . . . . . . . -53.32 -37.02 61.91 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.128 -179.963 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 217' ' ' ALA . . . . . . . . . . . . . . . -65.4 -33.87 76.96 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.108 -0.497 . . . . 0.0 110.347 179.577 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 218' ' ' THR . . . . . . . . . . . . . 67.0 m . . . . . 0 C--N 1.33 -0.263 0 CA-C-N 115.742 -0.663 . . . . 0.0 110.976 179.483 . . . . . . . . 0 0 . 1 . 026 nuclear build core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.449 -0.439 0 N-CA-C 112.465 -0.254 . . . . 0.0 112.465 . . . . . . . . . 0 0 . 1 . 026 nuclear build core ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -71.47 -37.43 71.33 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.909 0.385 . . . . 0.0 110.742 -179.971 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 65.4 p -64.19 -32.39 73.95 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.149 -179.967 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 11.8 p -57.29 -35.37 69.72 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.034 -0.53 . . . . 0.0 111.145 -179.818 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 7' ' ' LEU . . . . . . . . . . . . . 4.3 mm? -57.57 -50.94 71.47 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.295 -0.412 . . . . 0.0 111.154 179.793 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 8' ' ' PHE . . . . . 0.593 ' HB2' ' HB2' ' A' ' 55' ' ' ALA . 65.6 m-85 -65.84 -32.54 74.12 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.34 -0.391 . . . . 0.0 110.916 -179.706 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 9' ' ' TRP . . . . . 0.428 ' O ' HG13 ' A' ' 13' ' ' ILE . 23.2 m95 -67.09 -49.89 63.45 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-N 116.065 -0.516 . . . . 0.0 110.388 -179.524 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 89.5 mt -59.18 -47.05 86.74 Favored 'General case' 0 C--N 1.326 -0.45 0 CA-C-N 115.72 -0.673 . . . . 0.0 109.973 179.57 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 11' ' ' GLY . . . . . 0.422 ' O ' ' HG2' ' A' ' 15' ' ' MET . . . -57.67 -42.96 94.55 Favored Glycine 0 N--CA 1.445 -0.722 0 C-N-CA 120.634 -0.794 . . . . 0.0 111.363 179.062 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -56.36 -35.31 67.54 Favored 'General case' 0 C--N 1.331 -0.196 0 CA-C-O 120.939 0.4 . . . . 0.0 110.68 179.737 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 13' ' ' ILE . . . . . 0.428 HG13 ' O ' ' A' ' 9' ' ' TRP . 63.7 mt -62.32 -46.46 96.37 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 CA-C-N 116.002 -0.545 . . . . 0.0 110.082 179.334 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -59.41 -40.67 96.4 Favored Glycine 0 N--CA 1.45 -0.399 0 C-N-CA 120.799 -0.715 . . . . 0.0 112.512 179.666 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 15' ' ' MET . . . . . 0.422 ' HG2' ' O ' ' A' ' 11' ' ' GLY . 13.8 mmm -62.93 -39.14 93.68 Favored 'General case' 0 C--N 1.332 -0.189 0 CA-C-O 120.824 0.345 . . . . 0.0 110.656 -179.946 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 16' ' ' LEU . . . . . 0.427 HD13 ' O ' ' A' ' 16' ' ' LEU . 0.5 OUTLIER -59.11 -45.18 91.56 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.029 -0.532 . . . . 0.0 110.582 179.741 . . . . . . . . 3 3 . 1 . 026 nuclear build core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 51.1 t -59.21 -48.63 86.26 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.2 0 CA-C-N 116.354 -0.384 . . . . 0.0 110.98 179.965 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -63.69 -48.42 77.39 Favored Glycine 0 N--CA 1.452 -0.283 0 C-N-CA 120.805 -0.712 . . . . 0.0 112.438 179.926 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 47.6 m -49.71 -41.19 42.87 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.735 0.302 . . . . 0.0 111.552 -179.445 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 78.0 mt -72.04 -41.61 67.29 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.425 -0.352 . . . . 0.0 111.393 179.841 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -62.57 -29.91 70.93 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.309 -0.405 . . . . 0.0 111.792 -179.65 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 22' ' ' PHE . . . . . 0.632 ' HB2' HG22 ' A' ' 41' ' ' VAL . 3.4 m-85 -89.99 -34.84 15.84 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.501 -0.318 . . . . 0.0 111.261 -179.256 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -70.43 -49.84 44.61 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.455 -0.339 . . . . 0.0 111.238 -179.993 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 24' ' ' TRP . . . . . . . . . . . . . 1.2 t-105 -59.46 -39.24 83.02 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.045 -0.525 . . . . 0.0 110.899 179.974 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.328 -0.342 0 CA-C-N 116.293 -0.412 . . . . 0.0 110.992 179.938 . . . . . . . . 0 0 . 1 . 026 nuclear build core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.453 -0.229 0 N-CA-C 112.711 -0.156 . . . . 0.0 112.711 . . . . . . . . . 0 0 . 1 . 026 nuclear build core ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 38.5 mt-10 -90.53 -20.74 22.31 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-O 120.807 0.336 . . . . 0.0 110.812 179.951 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 34' ' ' ARG . . . . . . . . . . . . . 38.5 ttm180 -48.37 -29.36 3.9 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 115.9 -0.591 . . . . 0.0 111.68 -179.512 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 35' ' ' ARG . . . . . 0.424 ' NE ' ' HA ' ' A' ' 35' ' ' ARG . 5.5 mmp_? -59.23 -46.6 88.04 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.808 0.337 . . . . 0.0 111.118 179.923 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 73.8 m-85 -67.63 -30.23 69.74 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.252 -179.848 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 37' ' ' TYR . . . . . 0.429 ' O ' HG23 ' A' ' 41' ' ' VAL . 76.5 m-85 -74.13 -54.7 7.24 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.538 -179.406 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 10.5 p -56.72 -36.18 48.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-O 120.979 0.418 . . . . 0.0 110.387 179.884 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 52.5 m -68.9 -49.96 53.69 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 115.617 -0.72 . . . . 0.0 110.559 179.216 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 40' ' ' LEU . . . . . 0.499 HD12 HD12 ' A' ' 43' ' ' ILE . 22.5 tp -55.53 -50.02 71.08 Favored 'General case' 0 C--O 1.237 0.438 0 CA-C-N 115.718 -0.674 . . . . 0.0 110.374 179.651 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 41' ' ' VAL . . . . . 0.632 HG22 ' HB2' ' A' ' 22' ' ' PHE . 83.7 t -59.36 -34.24 53.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 115.769 -0.65 . . . . 0.0 109.94 178.912 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -58.56 -38.25 90.83 Favored Glycine 0 N--CA 1.448 -0.547 0 C-N-CA 120.71 -0.757 . . . . 0.0 111.453 179.503 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 43' ' ' ILE . . . . . 0.499 HD12 HD12 ' A' ' 40' ' ' LEU . 2.4 mt -65.21 -59.31 4.31 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.217 0 CA-C-O 120.863 0.363 . . . . 0.0 110.593 179.464 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 77.6 p -59.56 -24.67 63.91 Favored 'General case' 0 C--N 1.331 -0.218 0 CA-C-N 115.991 -0.549 . . . . 0.0 111.344 -179.666 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -75.3 -57.69 4.21 Favored Glycine 0 CA--C 1.518 0.24 0 C-N-CA 120.745 -0.74 . . . . 0.0 112.861 -179.653 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 22.6 pt -58.25 -35.27 52.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-O 120.908 0.385 . . . . 0.0 110.762 -179.896 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 47' ' ' ALA . . . . . 0.71 ' HB2' ' HE2' ' A' ' 205' ' ' LYS . . . -63.91 -49.73 71.48 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.001 -0.545 . . . . 0.0 111.07 179.764 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -54.52 -36.55 64.37 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.857 179.999 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 0.5 OUTLIER -67.04 -42.99 89.21 Favored 'Isoleucine or valine' 0 N--CA 1.432 -1.371 0 CA-C-N 116.031 -0.531 . . . . 0.0 111.486 179.797 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 50' ' ' ALA . . . . . 0.435 ' HA ' HG22 ' A' ' 53' ' ' VAL . . . -67.85 -33.67 75.21 Favored 'General case' 0 C--N 1.333 -0.137 0 CA-C-N 116.43 -0.35 . . . . 0.0 111.463 179.954 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 51' ' ' TYR . . . . . 0.461 ' O ' ' HB3' ' A' ' 8' ' ' PHE . 31.5 m-85 -70.59 -36.77 73.73 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.77 -179.525 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -71.55 -42.42 67.9 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-N 115.985 -0.552 . . . . 0.0 111.531 179.985 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 53' ' ' VAL . . . . . 0.508 HG23 ' N ' ' A' ' 54' ' ' MET . 35.5 m -67.06 -50.7 61.59 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.173 0 CA-C-N 116.556 -0.293 . . . . 0.0 111.451 -179.629 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 54' ' ' MET . . . . . 0.508 ' N ' HG23 ' A' ' 53' ' ' VAL . 78.1 mtm -61.14 -32.04 71.75 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-O 121.047 0.451 . . . . 0.0 110.296 179.775 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 55' ' ' ALA . . . . . 0.593 ' HB2' ' HB2' ' A' ' 8' ' ' PHE . . . -66.44 -38.43 87.38 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 115.753 -0.658 . . . . 0.0 111.015 179.42 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 97.2 mt -71.25 -12.88 61.69 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.039 -0.528 . . . . 0.0 111.238 -179.817 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 101.05 -21.03 45.13 Favored Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.649 -0.786 . . . . 0.0 112.817 179.819 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 30.1 m -66.63 138.58 22.66 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.238 0 CA-C-O 120.872 0.367 . . . . 0.0 111.018 -179.981 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 101.8 -11.52 57.67 Favored Glycine 0 N--CA 1.45 -0.402 0 C-N-CA 120.815 -0.707 . . . . 0.0 112.413 -179.7 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 60' ' ' TRP . . . . . . . . . . . . . 22.0 m0 -78.39 117.38 19.56 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.699 0.285 . . . . 0.0 110.727 179.793 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 10.0 p -109.99 129.54 23.83 Favored Pre-proline 0 C--N 1.329 -0.295 0 CA-C-N 116.438 -0.347 . . . . 0.0 111.078 179.836 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 86.5 Cg_endo -75.96 140.61 23.08 Favored 'Trans proline' 0 C--N 1.35 0.637 0 C-N-CA 122.404 2.07 . . . . 0.0 112.111 179.897 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 81.9 t -138.94 96.13 0.99 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.041 -0.527 . . . . 0.0 110.937 -179.767 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . 58.48 -86.71 0.02 OUTLIER 'General case' 0 C--N 1.332 -0.195 0 CA-C-N 116.001 -0.545 . . . . 0.0 111.315 -179.906 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 40.8 tt0 -121.04 -26.19 5.19 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.398 -0.364 . . . . 0.0 110.781 179.959 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 66' ' ' ARG . . . . . . . . . . . . . 76.0 ttt-85 -102.11 154.55 18.89 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.576 -179.954 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 86.0 m -113.37 121.24 43.76 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 120.882 0.373 . . . . 0.0 111.57 -179.741 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 68' ' ' VAL . . . . . 0.417 HG21 ' HA ' ' A' ' 117' ' ' MET . 21.8 t -93.21 146.89 5.88 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-N 115.978 -0.555 . . . . 0.0 110.374 179.344 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 69' ' ' PHE . . . . . . . . . . . . . 30.3 m-85 -106.87 112.31 25.21 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-O 120.836 0.351 . . . . 0.0 110.152 -179.494 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 70' ' ' VAL . . . . . 0.561 ' HB ' ' HD3' ' A' ' 71' ' ' PRO . 11.2 t -68.6 -50.22 26.61 Favored Pre-proline 0 C--N 1.326 -0.45 0 CA-C-N 115.986 -0.552 . . . . 0.0 112.361 -178.85 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 71' ' ' PRO . . . . . 0.561 ' HD3' ' HB ' ' A' ' 70' ' ' VAL . 24.6 Cg_exo -63.28 -18.35 64.41 Favored 'Trans proline' 0 C--N 1.351 0.7 0 C-N-CA 122.253 1.968 . . . . 0.0 113.068 -179.455 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 70.6 ttt180 -70.69 -55.48 8.6 Favored 'General case' 0 C--O 1.235 0.316 0 CA-C-O 120.88 0.371 . . . . 0.0 111.661 -179.33 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 73' ' ' TYR . . . . . . . . . . . . . 98.8 m-85 -71.86 -33.27 68.27 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.525 -0.307 . . . . 0.0 110.72 -179.519 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 74' ' ' ILE . . . . . 0.489 HG22 ' HA ' ' A' ' 71' ' ' PRO . 0.3 OUTLIER -65.96 -37.67 80.37 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.307 0 N-CA-C 109.446 -0.575 . . . . 0.0 109.446 179.017 . . . . . . . . 3 3 . 1 . 026 nuclear build core ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 33.1 t70 -61.65 -37.33 83.65 Favored 'General case' 0 N--CA 1.453 -0.286 0 N-CA-C 109.251 -0.648 . . . . 0.0 109.251 178.734 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 76' ' ' TRP . . . . . . . . . . . . . 45.8 m0 -66.66 -29.91 70.05 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 115.642 -0.708 . . . . 0.0 110.114 179.019 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 77' ' ' ILE . . . . . 0.463 HG12 ' HB3' ' A' ' 109' ' ' MET . 97.0 mt -71.73 -29.62 34.84 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 115.87 -0.605 . . . . 0.0 110.737 179.447 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 51.8 mt -90.43 -17.17 27.66 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 116.0 -0.546 . . . . 0.0 111.776 179.994 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 79' ' ' THR . . . . . 0.409 ' O ' HG12 ' A' ' 83' ' ' ILE . 69.7 p -102.94 -52.63 3.01 Favored 'General case' 0 C--N 1.332 -0.189 0 N-CA-C 113.311 0.856 . . . . 0.0 113.311 -178.371 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 80' ' ' THR . . . . . 0.697 ' HB ' ' HD3' ' A' ' 81' ' ' PRO . 37.4 m -50.2 -55.7 23.15 Favored Pre-proline 0 CA--C 1.533 0.292 0 N-CA-C 112.537 0.569 . . . . 0.0 112.537 -178.284 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 81' ' ' PRO . . . . . 0.697 ' HD3' ' HB ' ' A' ' 80' ' ' THR . 39.2 Cg_exo -61.06 -21.07 70.42 Favored 'Trans proline' 0 C--N 1.351 0.666 0 C-N-CA 121.55 1.5 . . . . 0.0 111.587 179.818 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 82' ' ' LEU . . . . . . . . . . . . . 14.4 tp -76.99 -33.17 57.62 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 115.811 -0.631 . . . . 0.0 110.599 179.847 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 83' ' ' ILE . . . . . 0.409 HG12 ' O ' ' A' ' 79' ' ' THR . 36.3 mm -69.92 -53.45 23.84 Favored 'Isoleucine or valine' 0 C--O 1.232 0.173 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.214 179.326 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 84' ' ' VAL . . . . . 0.615 HG21 ' ND2' ' A' ' 105' ' ' ASN . 34.6 m -59.61 -32.46 49.22 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.224 0 N-CA-C 109.4 -0.592 . . . . 0.0 109.4 178.637 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 85' ' ' TYR . . . . . . . . . . . . . 68.7 t80 -60.68 -43.88 97.17 Favored 'General case' 0 N--CA 1.452 -0.356 0 CA-C-N 115.455 -0.793 . . . . 0.0 109.047 178.606 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 86' ' ' PHE . . . . . . . . . . . . . 2.1 t80 -53.52 -50.25 65.84 Favored 'General case' 0 C--O 1.233 0.199 0 CA-C-N 115.632 -0.713 . . . . 0.0 109.734 179.407 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 87' ' ' LEU . . . . . 0.568 ' HA ' HD12 ' A' ' 90' ' ' LEU . 8.9 mp -59.72 -28.34 67.25 Favored 'General case' 0 C--N 1.332 -0.188 0 CA-C-N 115.785 -0.643 . . . . 0.0 110.665 179.618 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -65.28 -42.45 96.2 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.65 -0.786 . . . . 0.0 111.903 179.697 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 89' ' ' LEU . . . . . 0.423 ' N ' HD12 ' A' ' 89' ' ' LEU . 8.8 mp -64.5 -37.22 86.77 Favored 'General case' 0 N--CA 1.45 -0.474 0 CA-C-O 121.118 0.485 . . . . 0.0 110.504 179.387 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 90' ' ' LEU . . . . . 0.568 HD12 ' HA ' ' A' ' 87' ' ' LEU . 97.9 mt -55.32 -59.07 5.31 Favored 'General case' 0 C--N 1.326 -0.455 0 CA-C-N 115.368 -0.833 . . . . 0.0 111.162 179.905 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 91' ' ' ALA . . . . . 0.564 ' HB2' ' HB2' ' A' ' 149' ' ' ALA . . . -71.69 -54.82 9.1 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.085 -0.507 . . . . 0.0 111.382 -179.79 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 110.88 59.46 0.48 Allowed Glycine 0 N--CA 1.45 -0.372 0 C-N-CA 120.95 -0.643 . . . . 0.0 112.255 -179.892 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 93' ' ' LEU . . . . . 0.501 HD23 ' HB3' ' A' ' 97' ' ' GLU . 8.9 mp -77.19 169.29 18.6 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.915 0.388 . . . . 0.0 111.133 -179.722 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 94' ' ' ASP . . . . . . . . . . . . . 9.7 m-20 -91.09 163.65 14.22 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.05 -0.523 . . . . 0.0 110.704 179.827 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 80.6 p -53.96 -27.56 32.05 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.331 -0.395 . . . . 0.0 110.988 -179.926 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 80.5 mtm180 -73.07 -53.43 11.09 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.299 -0.409 . . . . 0.0 110.757 179.81 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 97' ' ' GLU . . . . . 0.501 ' HB3' HD23 ' A' ' 93' ' ' LEU . 44.9 mt-10 -57.44 -39.41 76.19 Favored 'General case' 0 C--N 1.332 -0.191 0 CA-C-N 116.122 -0.49 . . . . 0.0 111.104 -179.857 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 98' ' ' PHE . . . . . 0.45 ' O ' HG12 ' A' ' 102' ' ' ILE . 12.6 m-85 -60.29 -51.54 69.12 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.366 -0.379 . . . . 0.0 110.857 179.969 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -59.31 -28.15 64.08 Favored Glycine 0 N--CA 1.452 -0.291 0 C-N-CA 120.675 -0.774 . . . . 0.0 112.497 -179.85 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 96.3 mt -73.4 -47.05 47.4 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-O 120.823 0.344 . . . . 0.0 111.345 -179.868 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 59.4 t -67.38 -43.2 87.89 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.399 0 CA-C-N 116.235 -0.438 . . . . 0.0 111.545 -179.675 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 102' ' ' ILE . . . . . 0.45 HG12 ' O ' ' A' ' 98' ' ' PHE . 49.5 mm -64.83 -48.92 82.4 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.386 -0.37 . . . . 0.0 111.4 -179.516 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 14.0 t -60.4 -31.05 70.0 Favored 'General case' 0 C--N 1.332 -0.169 0 CA-C-O 120.811 0.339 . . . . 0.0 110.814 -179.982 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 104' ' ' LEU . . . . . 0.499 ' O ' HG23 ' A' ' 108' ' ' VAL . 45.6 tp -61.95 -54.45 41.58 Favored 'General case' 0 C--N 1.332 -0.185 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.382 179.486 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 105' ' ' ASN . . . . . 0.615 ' ND2' HG21 ' A' ' 84' ' ' VAL . 16.0 m-20 -61.87 -25.48 67.57 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 116.053 -0.521 . . . . 0.0 110.959 -179.986 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 52.2 m -64.27 -54.89 26.24 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.343 -0.39 . . . . 0.0 111.12 179.992 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 107' ' ' VAL . . . . . 0.438 HG12 ' O ' ' A' ' 104' ' ' LEU . 13.4 p -64.14 -36.37 76.75 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.205 0 CA-C-N 116.382 -0.372 . . . . 0.0 111.049 -179.989 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 108' ' ' VAL . . . . . 0.499 HG23 ' O ' ' A' ' 104' ' ' LEU . 96.4 t -64.13 -52.65 53.44 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.761 179.664 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 109' ' ' MET . . . . . 0.463 ' HB3' HG12 ' A' ' 77' ' ' ILE . 9.7 tpp -62.11 -26.15 68.13 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 115.872 -0.604 . . . . 0.0 110.705 -179.973 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 29.7 tp -75.69 -33.87 60.38 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.163 -0.472 . . . . 0.0 110.204 179.396 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -62.13 -54.37 42.18 Favored 'General case' 0 C--N 1.332 -0.177 0 CA-C-N 115.924 -0.58 . . . . 0.0 110.377 179.301 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . -61.75 -37.32 94.09 Favored Glycine 0 N--CA 1.45 -0.388 0 C-N-CA 120.645 -0.788 . . . . 0.0 111.652 179.435 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 113' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER -48.23 -69.88 0.11 Allowed 'General case' 0 CA--C 1.521 -0.158 0 N-CA-C 109.755 -0.461 . . . . 0.0 109.755 179.219 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 114' ' ' ALA . . . . . 0.403 ' O ' HG13 ' A' ' 118' ' ' VAL . . . -65.1 -17.79 64.76 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 115.615 -0.72 . . . . 0.0 110.271 178.875 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 115' ' ' GLY . . . . . 0.528 ' HA2' HD22 ' A' ' 126' ' ' LEU . . . -52.52 -47.99 56.15 Favored Glycine 0 C--N 1.334 0.465 0 C-N-CA 121.005 -0.617 . . . . 0.0 111.791 179.45 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -78.26 -23.1 47.46 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-O 120.666 0.27 . . . . 0.0 111.571 179.705 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 117' ' ' MET . . . . . 0.417 ' HA ' HG21 ' A' ' 68' ' ' VAL . 40.9 ttm -94.8 19.2 10.44 Favored 'General case' 0 CA--C 1.533 0.305 0 CA-C-N 116.457 -0.338 . . . . 0.0 111.859 -179.257 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 118' ' ' VAL . . . . . 0.45 HG21 ' HB3' ' A' ' 123' ' ' ARG . 21.8 m -69.17 150.88 97.28 Favored Pre-proline 0 C--N 1.331 -0.227 0 CA-C-O 120.554 0.216 . . . . 0.0 111.17 179.736 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 119' ' ' PRO . . . . . . . . . . . . . 92.9 Cg_endo -81.29 -4.96 12.66 Favored 'Trans proline' 0 C--N 1.348 0.515 0 C-N-CA 122.699 2.266 . . . . 0.0 112.364 179.846 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -158.2 -131.23 1.26 Allowed Glycine 0 C--N 1.331 0.267 0 C-N-CA 120.834 -0.698 . . . . 0.0 112.653 -179.994 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 37.9 pt -97.48 10.88 5.79 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.226 0 CA-C-O 120.877 0.37 . . . . 0.0 111.161 -179.951 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 16.4 mm-40 -59.8 -18.12 41.13 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.016 -0.538 . . . . 0.0 111.096 179.8 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 123' ' ' ARG . . . . . 0.45 ' HB3' HG21 ' A' ' 118' ' ' VAL . 23.0 ptt180 -50.74 -28.9 10.1 Favored 'General case' 0 C--N 1.331 -0.197 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.778 -179.884 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 124' ' ' TYR . . . . . . . . . . . . . 38.1 m-85 -69.46 -32.91 72.13 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-O 120.828 0.347 . . . . 0.0 110.975 179.965 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 125' ' ' ALA . . . . . . . . . . . . . . . -73.52 -49.94 23.99 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.094 -0.503 . . . . 0.0 111.13 179.942 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 126' ' ' LEU . . . . . 0.528 HD22 ' HA2' ' A' ' 115' ' ' GLY . 7.9 mp -53.36 -55.49 24.49 Favored 'General case' 0 C--N 1.331 -0.201 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.316 179.771 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 127' ' ' PHE . . . . . 0.407 ' HZ ' ' HB3' ' A' ' 175' ' ' PRO . 9.7 t80 -62.82 -33.9 76.18 Favored 'General case' 0 N--CA 1.452 -0.372 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.264 179.568 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 128' ' ' GLY . . . . . . . . . . . . . . . -47.97 -43.23 23.9 Favored Glycine 0 C--N 1.333 0.394 0 C-N-CA 120.167 -1.016 . . . . 0.0 110.778 178.907 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 129' ' ' MET . . . . . 0.421 ' HE1' ' HA ' ' A' ' 108' ' ' VAL . 0.4 OUTLIER -71.27 -38.22 71.86 Favored 'General case' 0 C--N 1.329 -0.312 0 N-CA-C 109.786 -0.45 . . . . 0.0 109.786 178.565 . . . . . . . . 3 3 . 1 . 026 nuclear build core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -65.72 -27.49 72.73 Favored Glycine 0 N--CA 1.451 -0.313 0 CA-C-N 115.757 -0.656 . . . . 0.0 112.695 179.907 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -74.77 -53.66 8.78 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.664 0.268 . . . . 0.0 110.545 179.828 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 132' ' ' VAL . . . . . 0.526 ' O ' HG13 ' A' ' 135' ' ' ILE . 38.7 t -57.2 -39.74 69.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-O 121.567 0.699 . . . . 0.0 109.311 178.675 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -70.99 -33.97 70.93 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-N 115.15 -0.932 . . . . 0.0 110.831 179.41 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 134' ' ' PHE . . . . . 0.437 ' CZ ' ' HA ' ' A' ' 172' ' ' ALA . 35.9 t80 -55.03 -59.22 5.04 Favored 'General case' 0 N--CA 1.453 -0.281 0 CA-C-N 116.353 -0.385 . . . . 0.0 110.397 179.809 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 135' ' ' ILE . . . . . 0.526 HG13 ' O ' ' A' ' 132' ' ' VAL . 0.2 OUTLIER -55.71 -36.63 43.52 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.368 0 CA-C-N 116.012 -0.54 . . . . 0.0 109.862 179.176 . . . . . . . . 3 3 . 1 . 026 nuclear build core ' A' A ' 136' ' ' GLY . . . . . 0.413 ' O ' ' HB3' ' A' ' 139' ' ' TYR . . . -52.77 -42.28 59.06 Favored Glycine 0 C--N 1.334 0.437 0 C-N-CA 120.396 -0.907 . . . . 0.0 111.686 178.86 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 137' ' ' LEU . . . . . . . . . . . . . 49.1 tp -64.52 -49.25 72.02 Favored 'General case' 0 C--N 1.33 -0.261 0 N-CA-C 110.187 -0.301 . . . . 0.0 110.187 179.161 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 138' ' ' VAL . . . . . . . . . . . . . 59.9 t -54.82 -33.12 27.4 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.928 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.238 179.847 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 139' ' ' TYR . . . . . 0.413 ' HB3' ' O ' ' A' ' 136' ' ' GLY . 18.2 t80 -63.0 -43.32 99.13 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 115.867 -0.606 . . . . 0.0 110.112 178.74 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 140' ' ' TYR . . . . . 0.472 ' HE2' HD22 ' A' ' 104' ' ' LEU . 29.1 m-85 -63.75 -44.49 93.34 Favored 'General case' 0 C--N 1.332 -0.171 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.025 179.658 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 141' ' ' LEU . . . . . 0.445 ' HA ' ' SD ' ' A' ' 145' ' ' MET . 10.4 mp -55.99 -34.37 65.69 Favored 'General case' 0 C--N 1.332 -0.191 0 CA-C-N 116.449 -0.341 . . . . 0.0 110.96 179.887 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 22.2 t -94.62 -17.3 7.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.111 179.85 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . -68.96 -140.61 0.1 OUTLIER Glycine 0 CA--C 1.521 0.441 0 C-N-CA 121.034 -0.603 . . . . 0.0 113.218 -179.789 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 144' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_exo -51.88 -23.58 16.65 Favored 'Trans proline' 0 C--N 1.35 0.614 0 C-N-CA 122.841 2.361 . . . . 0.0 113.004 -179.597 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 145' ' ' MET . . . . . 0.445 ' SD ' ' HA ' ' A' ' 141' ' ' LEU . 34.9 mtt -54.1 -35.68 62.39 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.354 -0.384 . . . . 0.0 111.734 -179.648 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 146' ' ' THR . . . . . . . . . . . . . 46.0 p -79.1 -32.1 44.5 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.83 0.347 . . . . 0.0 111.265 -179.413 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 43.3 tt0 -61.96 -48.91 78.29 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 116.114 -0.494 . . . . 0.0 111.108 -179.917 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 148' ' ' SER . . . . . . . . . . . . . 51.6 m -70.56 -44.89 66.49 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.654 -179.342 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 149' ' ' ALA . . . . . 0.564 ' HB2' ' HB2' ' A' ' 91' ' ' ALA . . . -60.31 -55.08 38.0 Favored 'General case' 0 C--N 1.329 -0.291 0 N-CA-C 112.065 0.395 . . . . 0.0 112.065 -179.256 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 150' ' ' SER . . . . . 0.489 ' HA ' ' HB3' ' A' ' 157' ' ' LYS . 67.6 m -64.03 -8.03 10.48 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.415 -0.357 . . . . 0.0 111.09 -179.681 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 151' ' ' GLN . . . . . . . . . . . . . 98.8 mt-30 -120.99 7.51 10.36 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.342 -0.39 . . . . 0.0 111.193 179.959 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 152' ' ' ARG . . . . . 0.534 ' HA ' ' HE ' ' A' ' 152' ' ' ARG . 5.3 tpm_? -85.55 -52.49 5.79 Favored 'General case' 0 C--N 1.332 -0.165 0 CA-C-O 120.841 0.353 . . . . 0.0 110.678 179.944 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 153' ' ' SER . . . . . 0.653 ' HB2' HG12 ' A' ' 156' ' ' ILE . 18.6 m -158.24 172.9 17.53 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 115.949 -0.568 . . . . 0.0 110.617 179.168 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 154' ' ' SER . . . . . . . . . . . . . 48.4 t -72.17 -40.26 68.08 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.512 179.455 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -77.45 -30.21 54.19 Favored Glycine 0 CA--C 1.518 0.274 0 C-N-CA 120.986 -0.626 . . . . 0.0 112.998 179.917 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 156' ' ' ILE . . . . . 0.653 HG12 ' HB2' ' A' ' 153' ' ' SER . 34.9 mm -58.84 -46.76 90.87 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.226 0 N-CA-C 111.974 0.361 . . . . 0.0 111.974 -179.264 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 157' ' ' LYS . . . . . 0.489 ' HB3' ' HA ' ' A' ' 150' ' ' SER . 6.5 ptpp? -60.64 -35.67 76.76 Favored 'General case' 0 C--N 1.331 -0.234 0 N-CA-C 111.588 0.218 . . . . 0.0 111.588 -179.394 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 49.0 m -66.24 -44.53 83.46 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.941 0.401 . . . . 0.0 111.236 -179.752 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 159' ' ' LEU . . . . . 0.459 HD21 ' HB3' ' A' ' 215' ' ' ALA . 5.1 mt -68.64 -37.66 79.87 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.544 -179.743 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 160' ' ' TYR . . . . . 0.406 ' OH ' ' HB3' ' A' ' 145' ' ' MET . 13.8 t80 -68.55 -43.24 77.1 Favored 'General case' 0 C--N 1.327 -0.407 0 N-CA-C 112.267 0.469 . . . . 0.0 112.267 -178.705 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 161' ' ' VAL . . . . . 0.415 HG23 ' N ' ' A' ' 162' ' ' ARG . 24.0 m -63.78 -46.21 95.07 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 C-N-CA 120.989 -0.284 . . . . 0.0 111.717 -179.23 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 162' ' ' ARG . . . . . 0.415 ' N ' HG23 ' A' ' 161' ' ' VAL . 24.9 tpt180 -69.25 -48.63 61.32 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.815 0.34 . . . . 0.0 111.491 -179.76 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 163' ' ' LEU . . . . . . . . . . . . . 1.5 mp -60.89 -54.8 40.62 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.089 -0.505 . . . . 0.0 111.937 -179.183 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 164' ' ' ARG . . . . . . . . . . . . . 6.1 tmm_? -55.94 -50.52 70.53 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 116.073 -0.512 . . . . 0.0 112.179 -178.498 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 165' ' ' ASN . . . . . 0.507 ' O ' HG23 ' A' ' 169' ' ' VAL . 4.9 m-20 -52.7 -51.52 59.97 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-O 120.662 0.268 . . . . 0.0 111.458 -179.261 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 166' ' ' LEU . . . . . 0.503 ' O ' ' HG ' ' A' ' 170' ' ' LEU . 3.4 tt -62.6 -52.55 62.92 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 116.385 -0.37 . . . . 0.0 111.713 -179.566 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 167' ' ' THR . . . . . . . . . . . . . 85.1 m -54.72 -53.17 58.46 Favored 'General case' 0 C--N 1.329 -0.296 0 N-CA-C 112.734 0.642 . . . . 0.0 112.734 -178.64 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 168' ' ' VAL . . . . . . . . . . . . . 81.8 t -55.53 -44.34 75.94 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 N-CA-C 112.281 0.474 . . . . 0.0 112.281 -178.723 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 169' ' ' VAL . . . . . 0.507 HG23 ' O ' ' A' ' 165' ' ' ASN . 68.8 t -57.93 -65.19 0.45 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.367 0 N-CA-C 112.409 0.522 . . . . 0.0 112.409 -179.039 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 170' ' ' LEU . . . . . 0.503 ' HG ' ' O ' ' A' ' 166' ' ' LEU . 0.7 OUTLIER -62.4 -31.68 72.4 Favored 'General case' 0 C--N 1.332 -0.195 0 N-CA-C 112.453 0.538 . . . . 0.0 112.453 -178.355 . . . . . . . . 3 3 . 1 . 026 nuclear build core ' A' A ' 171' ' ' TRP . . . . . . . . . . . . . 5.8 m0 -70.12 -31.2 68.62 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-O 120.816 0.341 . . . . 0.0 110.658 179.48 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 172' ' ' ALA . . . . . 0.437 ' HA ' ' CZ ' ' A' ' 134' ' ' PHE . . . -74.21 -6.86 50.3 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.799 -179.763 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 173' ' ' ILE . . . . . 0.504 ' O ' HG12 ' A' ' 177' ' ' ILE . 34.9 mm -85.95 -21.76 7.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 115.901 -0.59 . . . . 0.0 110.383 179.43 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 174' ' ' TYR . . . . . . . . . . . . . 15.7 m-85 -54.42 -50.72 83.5 Favored Pre-proline 0 N--CA 1.463 0.222 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.744 -179.735 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 175' ' ' PRO . . . . . 0.407 ' HB3' ' HZ ' ' A' ' 127' ' ' PHE . 80.3 Cg_exo -46.13 -31.02 8.22 Favored 'Trans proline' 0 C--N 1.352 0.732 0 C-N-CA 122.131 1.887 . . . . 0.0 112.155 179.83 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 176' ' ' PHE . . . . . 0.455 ' O ' ' HG ' ' A' ' 180' ' ' LEU . 74.4 m-85 -80.7 -49.97 10.51 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.88 -0.6 . . . . 0.0 111.826 -179.783 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 177' ' ' ILE . . . . . 0.504 HG12 ' O ' ' A' ' 173' ' ' ILE . 5.3 mm -62.82 -36.33 75.03 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.525 0 N-CA-C 112.454 0.539 . . . . 0.0 112.454 -177.958 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 178' ' ' TRP . . . . . 0.449 ' HH2' ' HB2' ' A' ' 123' ' ' ARG . 71.3 t90 -71.27 -47.55 56.29 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.827 0.346 . . . . 0.0 110.997 -179.89 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 179' ' ' LEU . . . . . 0.441 HD23 HD23 ' A' ' 180' ' ' LEU . 0.5 OUTLIER -69.84 -54.57 12.9 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.677 -179.045 . . . . . . . . 3 3 . 1 . 026 nuclear build core ' A' A ' 180' ' ' LEU . . . . . 0.597 HD22 HD11 ' A' ' 187' ' ' LEU . 26.4 mt -65.06 -39.42 93.24 Favored 'General case' 0 C--N 1.328 -0.355 0 C-N-CA 121.025 -0.27 . . . . 0.0 111.469 -179.252 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . -62.26 -179.38 3.93 Favored Glycine 0 C--N 1.335 0.474 0 C-N-CA 120.031 -1.08 . . . . 0.0 112.196 179.074 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 182' ' ' PRO . . . . . 0.561 ' HA ' ' HB2' ' A' ' 186' ' ' ALA . 72.6 Cg_exo -48.85 -44.12 32.89 Favored 'Trans proline' 0 CA--C 1.536 0.623 0 C-N-CA 122.784 2.323 . . . . 0.0 113.87 179.896 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 183' ' ' PRO . . . . . . . . . . . . . 87.8 Cg_exo -47.62 -26.92 7.11 Favored 'Trans proline' 0 C--N 1.356 0.947 0 C-N-CA 122.279 1.986 . . . . 0.0 113.398 -179.782 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 184' ' ' GLY . . . . . . . . . . . . . . . -120.02 -125.92 3.36 Favored Glycine 0 N--CA 1.45 -0.369 0 C-N-CA 120.271 -0.966 . . . . 0.0 113.212 -179.598 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 185' ' ' VAL . . . . . . . . . . . . . 6.1 m -60.45 -27.58 40.35 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.369 0 N-CA-C 112.319 0.489 . . . . 0.0 112.319 -179.315 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 186' ' ' ALA . . . . . 0.561 ' HB2' ' HA ' ' A' ' 182' ' ' PRO . . . 58.23 82.79 0.13 Allowed 'General case' 0 C--N 1.331 -0.214 0 CA-C-O 120.801 0.334 . . . . 0.0 111.697 179.613 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 187' ' ' LEU . . . . . 0.597 HD11 HD22 ' A' ' 180' ' ' LEU . 8.4 mt -92.21 -49.78 6.0 Favored 'General case' 0 C--N 1.333 -0.151 0 CA-C-N 116.297 -0.411 . . . . 0.0 111.271 179.853 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 188' ' ' LEU . . . . . 0.471 ' HB3' ' H ' ' A' ' 189' ' ' THR . 4.3 mm? -91.16 -161.3 0.8 Allowed 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.002 -0.545 . . . . 0.0 111.571 -179.051 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 189' ' ' THR . . . . . 0.471 ' H ' ' HB3' ' A' ' 188' ' ' LEU . 21.6 m -92.76 137.86 23.89 Favored Pre-proline 0 C--N 1.329 -0.326 0 CA-C-N 115.704 -0.68 . . . . 0.0 110.917 -179.479 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 190' ' ' PRO . . . . . 0.456 ' O ' HG23 ' A' ' 194' ' ' VAL . 95.5 Cg_exo -44.86 -50.04 8.97 Favored 'Trans proline' 0 C--N 1.35 0.626 0 C-N-CA 122.674 2.249 . . . . 0.0 113.259 -179.951 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 191' ' ' THR . . . . . 0.419 HG22 HG22 ' A' ' 189' ' ' THR . 9.7 t -56.26 -39.79 73.18 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-O 120.668 0.271 . . . . 0.0 111.434 -179.606 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 192' ' ' VAL . . . . . 0.454 HG23 ' HB ' ' A' ' 189' ' ' THR . 72.8 t -64.71 -48.66 83.69 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.358 -0.383 . . . . 0.0 111.102 179.93 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 193' ' ' ASP . . . . . . . . . . . . . 27.0 t70 -57.12 -44.58 83.44 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.136 -0.484 . . . . 0.0 111.063 -179.875 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 194' ' ' VAL . . . . . 0.456 HG23 ' O ' ' A' ' 190' ' ' PRO . 89.3 t -60.82 -35.86 67.42 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.247 0 CA-C-N 116.132 -0.486 . . . . 0.0 110.776 179.953 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 195' ' ' ALA . . . . . . . . . . . . . . . -60.1 -47.83 84.26 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-N 116.429 -0.35 . . . . 0.0 111.003 179.583 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 196' ' ' LEU . . . . . . . . . . . . . 86.1 mt -66.58 -42.82 86.39 Favored 'General case' 0 C--N 1.332 -0.158 0 CA-C-N 116.388 -0.369 . . . . 0.0 110.5 179.489 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 197' ' ' ILE . . . . . . . . . . . . . 15.6 mm -56.99 -59.53 3.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.077 -0.51 . . . . 0.0 110.341 179.221 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 198' ' ' VAL . . . . . . . . . . . . . 52.9 t -52.16 -34.76 18.29 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.5 0 CA-C-N 115.717 -0.674 . . . . 0.0 109.375 178.388 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 199' ' ' TYR . . . . . . . . . . . . . 57.5 t80 -69.54 -32.91 72.01 Favored 'General case' 0 C--N 1.331 -0.204 0 CA-C-N 115.462 -0.79 . . . . 0.0 110.623 -179.844 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 200' ' ' LEU . . . . . 0.446 ' O ' HG12 ' A' ' 203' ' ' VAL . 34.6 mt -67.75 -41.55 83.21 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 115.885 -0.598 . . . . 0.0 111.081 -179.896 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 201' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -73.48 -35.02 65.63 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-O 121.147 0.499 . . . . 0.0 110.273 179.447 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 202' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -69.45 -28.38 66.06 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 115.495 -0.775 . . . . 0.0 111.924 -179.823 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 203' ' ' VAL . . . . . 0.446 HG12 ' O ' ' A' ' 200' ' ' LEU . 9.5 p -82.44 -37.75 14.68 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.183 0 N-CA-C 111.804 0.298 . . . . 0.0 111.804 -178.831 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 204' ' ' THR . . . . . . . . . . . . . 88.9 m -67.35 -41.71 84.68 Favored 'General case' 0 C--N 1.33 -0.279 0 C-N-CA 120.798 -0.361 . . . . 0.0 111.297 179.664 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 205' ' ' LYS . . . . . 0.71 ' HE2' ' HB2' ' A' ' 47' ' ' ALA . 57.3 mttp -78.39 -51.56 9.87 Favored 'General case' 0 C--N 1.326 -0.455 0 N-CA-C 112.238 0.458 . . . . 0.0 112.238 -178.601 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 84.8 t -73.22 -37.37 52.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 N-CA-C 111.735 0.272 . . . . 0.0 111.735 -179.514 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 207' ' ' GLY . . . . . . . . . . . . . . . -71.52 -52.62 12.08 Favored Glycine 0 N--CA 1.453 -0.219 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.603 -179.654 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 208' ' ' PHE . . . . . 0.446 ' O ' ' HB2' ' A' ' 212' ' ' ALA . 10.1 t80 -59.6 -40.46 87.54 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-O 120.71 0.29 . . . . 0.0 110.477 179.648 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 209' ' ' GLY . . . . . 0.476 ' O ' ' HB3' ' A' ' 212' ' ' ALA . . . -70.18 -39.27 72.39 Favored Glycine 0 N--CA 1.451 -0.315 0 CA-C-N 115.699 -0.682 . . . . 0.0 113.302 -179.734 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 210' ' ' PHE . . . . . . . . . . . . . 1.1 m-85 -68.35 -43.0 78.41 Favored 'General case' 0 CA--C 1.508 -0.67 0 N-CA-C 107.794 -1.187 . . . . 0.0 107.794 179.099 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 211' ' ' ILE . . . . . . . . . . . . . 85.7 mt -67.49 -28.85 43.52 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.815 0 CA-C-N 114.296 -1.32 . . . . 0.0 107.548 176.688 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 212' ' ' ALA . . . . . 0.476 ' HB3' ' O ' ' A' ' 209' ' ' GLY . . . -67.0 -40.86 87.43 Favored 'General case' 0 N--CA 1.45 -0.472 0 CA-C-N 114.599 -1.182 . . . . 0.0 110.494 179.876 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 213' ' ' LEU . . . . . . . . . . . . . 91.0 mt -70.35 -52.2 24.33 Favored 'General case' 0 C--N 1.33 -0.239 0 CA-C-N 115.304 -0.862 . . . . 0.0 111.754 -179.407 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 214' ' ' ASP . . . . . . . . . . . . . 45.4 m-20 -50.04 -54.63 18.98 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.218 -0.447 . . . . 0.0 111.847 -179.277 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 215' ' ' ALA . . . . . 0.459 ' HB3' HD21 ' A' ' 159' ' ' LEU . . . -60.46 -54.49 44.87 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.432 -0.349 . . . . 0.0 111.541 -179.448 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 216' ' ' ALA . . . . . . . . . . . . . . . -55.86 -32.51 63.71 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-O 120.926 0.394 . . . . 0.0 111.317 -179.763 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 217' ' ' ALA . . . . . . . . . . . . . . . -65.57 -39.89 92.15 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.03 -0.532 . . . . 0.0 110.601 179.877 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 218' ' ' THR . . . . . . . . . . . . . 54.7 m . . . . . 0 C--N 1.329 -0.296 0 CA-C-N 115.993 -0.549 . . . . 0.0 110.757 179.588 . . . . . . . . 0 0 . 1 . 027 nuclear build core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.27 0 CA-C-O 120.464 -0.075 . . . . 0.0 112.975 . . . . . . . . . 0 0 . 1 . 027 nuclear build core ' A' A ' 4' ' ' LEU . . . . . 0.453 HD12 HD22 ' A' ' 7' ' ' LEU . 24.7 tp -57.04 -35.21 69.04 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.828 0.347 . . . . 0.0 111.265 -179.693 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 74.1 p -54.87 -37.88 66.82 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 116.211 -0.45 . . . . 0.0 112.015 -179.637 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 32.1 p -53.84 -35.29 61.32 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 120.823 0.344 . . . . 0.0 111.44 -179.452 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 7' ' ' LEU . . . . . 0.48 HD21 ' O ' ' A' ' 191' ' ' THR . 9.0 mp -58.6 -53.42 58.58 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.227 -179.83 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 8' ' ' PHE . . . . . 0.543 ' HB2' ' HB2' ' A' ' 55' ' ' ALA . 69.9 m-85 -60.46 -32.47 71.42 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.002 -0.544 . . . . 0.0 110.887 -179.837 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 9' ' ' TRP . . . . . . . . . . . . . 32.2 m95 -64.4 -44.39 91.43 Favored 'General case' 0 C--N 1.327 -0.371 0 N-CA-C 109.563 -0.532 . . . . 0.0 109.563 179.612 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 78.8 mt -63.56 -36.76 84.87 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 115.472 -0.785 . . . . 0.0 110.09 179.243 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -64.22 -37.13 94.11 Favored Glycine 0 N--CA 1.448 -0.535 0 CA-C-N 115.619 -0.719 . . . . 0.0 111.806 179.332 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -65.45 -37.51 87.09 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-O 120.856 0.36 . . . . 0.0 110.337 179.634 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 50.1 mm -59.14 -50.22 80.55 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.222 0 CA-C-N 115.937 -0.574 . . . . 0.0 110.432 179.119 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -58.42 -35.09 77.78 Favored Glycine 0 N--CA 1.45 -0.411 0 C-N-CA 120.772 -0.727 . . . . 0.0 112.12 179.536 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 15' ' ' MET . . . . . 0.451 ' HE3' ' CB ' ' A' ' 47' ' ' ALA . 22.7 mmt -66.37 -43.29 86.35 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-O 120.752 0.311 . . . . 0.0 110.892 179.718 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -55.96 -43.71 77.79 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.462 179.739 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 60.6 t -60.71 -46.59 95.68 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.283 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.989 179.903 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -66.17 -49.2 59.13 Favored Glycine 0 C--N 1.33 0.246 0 C-N-CA 120.787 -0.72 . . . . 0.0 112.41 179.685 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 23.6 m -49.61 -42.94 46.08 Favored 'General case' 0 C--N 1.327 -0.39 0 C-N-CA 122.365 0.266 . . . . 0.0 111.579 -179.458 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 65.7 mt -72.38 -42.16 65.55 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.478 -0.328 . . . . 0.0 111.753 179.858 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -61.61 -30.09 70.46 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.312 -0.404 . . . . 0.0 111.577 -179.362 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 22' ' ' PHE . . . . . 0.699 ' HB2' HG22 ' A' ' 41' ' ' VAL . 6.5 m-85 -90.88 -30.76 16.74 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.41 -0.359 . . . . 0.0 111.262 -179.594 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -72.36 -50.38 27.08 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.956 0.407 . . . . 0.0 111.558 -179.548 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 24' ' ' TRP . . . . . . . . . . . . . 4.1 t-105 -62.68 -43.12 99.62 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 115.978 -0.556 . . . . 0.0 111.171 -179.72 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.329 -0.289 0 CA-C-N 116.398 -0.365 . . . . 0.0 110.862 179.855 . . . . . . . . 0 0 . 1 . 027 nuclear build core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.518 0.253 0 N-CA-C 112.644 -0.183 . . . . 0.0 112.644 . . . . . . . . . 0 0 . 1 . 027 nuclear build core ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 37.4 mt-10 -69.43 -25.69 64.24 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.742 0.306 . . . . 0.0 110.99 -179.941 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 34' ' ' ARG . . . . . . . . . . . . . 17.5 tpt180 -53.13 -28.72 27.23 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.076 -0.511 . . . . 0.0 111.478 -179.654 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 41.0 mmt180 -60.17 -43.31 95.91 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-O 120.833 0.349 . . . . 0.0 111.207 -179.843 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 82.0 m-85 -71.72 -29.73 64.87 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.294 -0.412 . . . . 0.0 111.348 -179.779 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 37' ' ' TYR . . . . . 0.467 ' O ' HG23 ' A' ' 41' ' ' VAL . 70.0 m-85 -75.79 -54.98 6.09 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.189 -0.459 . . . . 0.0 111.182 -179.549 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 14.8 p -56.61 -36.52 48.64 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-O 121.007 0.432 . . . . 0.0 110.578 179.774 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 28.5 m -66.06 -51.07 61.54 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 115.9 -0.591 . . . . 0.0 110.82 179.457 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 40' ' ' LEU . . . . . 0.459 HD12 HD12 ' A' ' 43' ' ' ILE . 49.3 tp -59.12 -47.77 84.07 Favored 'General case' 0 C--O 1.235 0.314 0 CA-C-N 115.922 -0.581 . . . . 0.0 110.886 179.964 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 41' ' ' VAL . . . . . 0.699 HG22 ' HB2' ' A' ' 22' ' ' PHE . 89.9 t -60.63 -34.73 59.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.097 179.195 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 42' ' ' GLY . . . . . 0.428 ' O ' HG12 ' A' ' 46' ' ' ILE . . . -60.98 -38.59 95.74 Favored Glycine 0 N--CA 1.447 -0.587 0 CA-C-N 115.712 -0.676 . . . . 0.0 112.309 179.751 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 43' ' ' ILE . . . . . 0.76 HG22 ' HE3' ' A' ' 205' ' ' LYS . 0.1 OUTLIER -66.97 -56.94 11.82 Favored 'Isoleucine or valine' 0 C--O 1.232 0.145 0 CA-C-O 120.651 0.262 . . . . 0.0 110.989 179.903 . . . . . . . . 3 3 . 1 . 027 nuclear build core ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 48.1 t -62.39 -21.31 65.26 Favored 'General case' 0 C--O 1.233 0.185 0 CA-C-O 120.833 0.349 . . . . 0.0 111.241 -179.892 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -77.06 -58.53 3.39 Favored Glycine 0 CA--C 1.519 0.305 0 C-N-CA 120.754 -0.736 . . . . 0.0 112.642 -179.758 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 46' ' ' ILE . . . . . 0.428 HG12 ' O ' ' A' ' 42' ' ' GLY . 16.1 pt -58.32 -35.87 55.63 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.157 0 CA-C-O 120.932 0.396 . . . . 0.0 110.726 179.94 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 47' ' ' ALA . . . . . 0.687 ' HB2' ' HE2' ' A' ' 205' ' ' LYS . . . -67.96 -39.89 83.29 Favored 'General case' 0 C--N 1.326 -0.45 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.771 179.056 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 48' ' ' ALA . . . . . 0.438 ' HB2' ' HB3' ' A' ' 15' ' ' MET . . . -54.58 -47.29 73.49 Favored 'General case' 0 C--O 1.233 0.205 0 CA-C-N 116.007 -0.542 . . . . 0.0 111.046 179.897 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 27.5 m -72.08 -34.09 49.18 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.379 0 CA-C-N 116.047 -0.524 . . . . 0.0 111.009 -179.901 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -60.1 -41.49 92.65 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-O 121.017 0.436 . . . . 0.0 110.761 179.503 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 51' ' ' TYR . . . . . 0.421 ' HB3' ' O ' ' A' ' 8' ' ' PHE . 43.8 m-85 -73.24 -31.5 64.16 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 115.899 -0.592 . . . . 0.0 110.262 -179.982 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -66.26 -43.3 86.85 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 115.887 -0.597 . . . . 0.0 110.624 179.126 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 16.5 m -75.15 -37.72 40.54 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.166 0 CA-C-N 116.277 -0.419 . . . . 0.0 111.028 179.798 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 54' ' ' MET . . . . . 0.531 ' HG2' ' HG2' ' A' ' 71' ' ' PRO . 68.5 mtm -67.22 -34.42 77.43 Favored 'General case' 0 CA--C 1.52 -0.18 0 CA-C-O 121.213 0.53 . . . . 0.0 109.776 179.215 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 55' ' ' ALA . . . . . 0.543 ' HB2' ' HB2' ' A' ' 8' ' ' PHE . . . -66.53 -19.29 65.75 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-N 115.382 -0.827 . . . . 0.0 111.124 179.481 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 87.5 mt -94.95 -3.73 48.04 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.329 -0.396 . . . . 0.0 111.01 -179.927 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 85.57 24.48 42.63 Favored Glycine 0 C--N 1.331 0.271 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.712 179.939 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 58' ' ' VAL . . . . . 0.441 ' O ' ' HG3' ' A' ' 71' ' ' PRO . 48.3 t -86.84 142.36 13.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-O 120.714 0.293 . . . . 0.0 110.829 179.882 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 59' ' ' GLY . . . . . 0.638 ' HA3' ' HD3' ' A' ' 71' ' ' PRO . . . 81.33 -3.74 76.01 Favored Glycine 0 N--CA 1.449 -0.458 0 C-N-CA 120.807 -0.711 . . . . 0.0 112.569 -179.976 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 60' ' ' TRP . . . . . . . . . . . . . 14.4 m0 -70.73 101.08 2.0 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.809 0.338 . . . . 0.0 110.646 179.853 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 61' ' ' VAL . . . . . 0.422 ' HA ' ' HD3' ' A' ' 62' ' ' PRO . 3.2 p -105.5 125.42 33.46 Favored Pre-proline 0 CA--C 1.534 0.334 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.35 -179.982 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 62' ' ' PRO . . . . . 0.422 ' HD3' ' HA ' ' A' ' 61' ' ' VAL . 8.4 Cg_exo -71.52 148.32 53.67 Favored 'Trans proline' 0 C--N 1.35 0.644 0 C-N-CA 122.617 2.211 . . . . 0.0 112.06 179.729 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 77.9 t -142.23 92.43 0.52 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-N 116.112 -0.495 . . . . 0.0 110.894 -179.932 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . 59.67 -85.99 0.02 OUTLIER 'General case' 0 C--N 1.331 -0.209 0 CA-C-N 116.158 -0.473 . . . . 0.0 111.346 -179.865 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 10.2 tp10 -121.05 -24.61 5.52 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.438 -0.346 . . . . 0.0 110.604 179.902 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 66' ' ' ARG . . . . . . . . . . . . . 80.7 mtt180 -103.54 152.96 21.1 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.132 -0.486 . . . . 0.0 110.396 -179.88 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 94.1 m -116.0 127.41 54.91 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 120.955 0.407 . . . . 0.0 111.426 -179.536 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 10.7 t -104.71 146.26 12.18 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.24 0 CA-C-N 115.941 -0.572 . . . . 0.0 110.39 179.488 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 69' ' ' PHE . . . . . . . . . . . . . 12.2 m-85 -109.81 111.76 23.38 Favored 'General case' 0 N--CA 1.452 -0.358 0 N-CA-C 109.519 -0.549 . . . . 0.0 109.519 -179.572 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 70' ' ' VAL . . . . . 0.64 ' N ' ' HD2' ' A' ' 71' ' ' PRO . 0.5 OUTLIER -66.21 -40.42 35.77 Favored Pre-proline 0 C--N 1.321 -0.654 0 N-CA-C 112.428 0.529 . . . . 0.0 112.428 -179.507 . . . . . . . . 3 3 . 1 . 027 nuclear build core ' A' A ' 71' ' ' PRO . . . . . 0.64 ' HD2' ' N ' ' A' ' 70' ' ' VAL . 27.1 Cg_endo -63.23 -27.04 72.2 Favored 'Trans proline' 0 C--N 1.356 0.93 0 C-N-CA 121.779 1.652 . . . . 0.0 112.821 -179.03 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 61.0 ttp180 -73.25 -52.99 11.99 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 121.0 0.428 . . . . 0.0 110.212 179.629 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 73' ' ' TYR . . . . . 0.425 ' O ' HG13 ' A' ' 77' ' ' ILE . 52.9 m-85 -66.49 -34.4 77.84 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.012 -0.54 . . . . 0.0 110.716 179.758 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 74' ' ' ILE . . . . . 0.427 ' HB ' ' O ' ' A' ' 70' ' ' VAL . 0.4 OUTLIER -72.83 -37.69 55.39 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.209 0 CA-C-N 116.282 -0.417 . . . . 0.0 110.121 179.675 . . . . . . . . 3 3 . 1 . 027 nuclear build core ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 18.2 t70 -58.02 -37.79 74.99 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-N 116.212 -0.449 . . . . 0.0 109.863 179.226 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 76' ' ' TRP . . . . . . . . . . . . . 53.3 m0 -68.69 -42.16 78.19 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 115.894 -0.594 . . . . 0.0 110.601 179.428 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 77' ' ' ILE . . . . . 0.495 ' O ' ' HG3' ' A' ' 81' ' ' PRO . 86.1 mt -58.72 -28.67 37.96 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.062 -0.517 . . . . 0.0 111.016 179.567 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 45.5 mt -92.03 -38.89 11.96 Favored 'General case' 0 CA--C 1.534 0.343 0 N-CA-C 112.551 0.574 . . . . 0.0 112.551 -179.614 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 79' ' ' THR . . . . . 0.428 HG22 HD11 ' A' ' 46' ' ' ILE . 74.8 p -82.99 -52.43 6.68 Favored 'General case' 0 N--CA 1.465 0.299 0 N-CA-C 113.929 1.085 . . . . 0.0 113.929 -177.422 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 80' ' ' THR . . . . . 0.466 ' N ' ' HD2' ' A' ' 81' ' ' PRO . 39.2 m -48.01 -54.28 25.69 Favored Pre-proline 0 C--N 1.33 -0.252 0 N-CA-C 113.089 0.774 . . . . 0.0 113.089 -178.132 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 81' ' ' PRO . . . . . 0.495 ' HG3' ' O ' ' A' ' 77' ' ' ILE . 25.1 Cg_endo -60.14 -21.09 64.57 Favored 'Trans proline' 0 C--N 1.351 0.689 0 C-N-CA 121.481 1.454 . . . . 0.0 111.397 -179.683 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 82' ' ' LEU . . . . . . . . . . . . . 17.6 tp -77.03 -32.95 57.41 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 115.633 -0.712 . . . . 0.0 110.005 179.555 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 83' ' ' ILE . . . . . 0.517 HD13 HD13 ' A' ' 43' ' ' ILE . 41.4 mm -67.9 -53.14 32.57 Favored 'Isoleucine or valine' 0 C--O 1.233 0.206 0 CA-C-N 116.059 -0.519 . . . . 0.0 109.909 178.976 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 35.9 m -60.87 -29.86 46.22 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.219 0 CA-C-N 115.97 -0.559 . . . . 0.0 109.513 178.975 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 85' ' ' TYR . . . . . . . . . . . . . 78.8 t80 -68.52 -32.8 73.01 Favored 'General case' 0 N--CA 1.453 -0.303 0 CA-C-N 115.569 -0.741 . . . . 0.0 109.623 178.792 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 86' ' ' PHE . . . . . . . . . . . . . 8.8 t80 -62.36 -51.21 68.5 Favored 'General case' 0 C--N 1.333 -0.117 0 CA-C-N 115.87 -0.605 . . . . 0.0 109.733 179.298 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 10.5 mp -61.61 -29.63 70.17 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-N 115.83 -0.623 . . . . 0.0 110.136 179.339 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -69.96 -27.85 72.56 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.899 -0.667 . . . . 0.0 111.889 179.362 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 88.1 mt -74.29 -44.57 52.17 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-O 120.994 0.426 . . . . 0.0 110.597 179.587 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 43.4 mt -63.27 -28.4 70.0 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 115.75 -0.659 . . . . 0.0 111.05 -179.976 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -88.46 -39.88 13.89 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.379 -179.628 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 88.14 59.43 1.67 Allowed Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.662 -0.78 . . . . 0.0 112.26 -179.736 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 93' ' ' LEU . . . . . 0.417 ' HB3' ' HB2' ' A' ' 97' ' ' GLU . 45.6 mt -75.79 -175.97 3.17 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.849 0.357 . . . . 0.0 110.957 -179.883 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 94' ' ' ASP . . . . . . . . . . . . . 7.8 m-20 -109.12 171.93 7.14 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.057 -0.519 . . . . 0.0 110.709 179.847 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 66.2 m -55.07 -36.4 65.57 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.345 -179.653 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 96' ' ' ARG . . . . . 0.425 ' O ' HG13 ' A' ' 100' ' ' ILE . 38.1 ttp180 -73.26 -52.77 12.8 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.352 -0.386 . . . . 0.0 111.054 -179.687 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 97' ' ' GLU . . . . . 0.417 ' HB2' ' HB3' ' A' ' 93' ' ' LEU . 47.9 mt-10 -53.14 -48.3 68.04 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.404 -0.362 . . . . 0.0 111.441 -179.48 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 98' ' ' PHE . . . . . 0.451 ' O ' HG12 ' A' ' 102' ' ' ILE . 18.1 m-85 -55.91 -52.07 65.39 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.524 -0.307 . . . . 0.0 111.112 179.921 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -57.66 -28.09 59.59 Favored Glycine 0 N--CA 1.452 -0.277 0 C-N-CA 120.771 -0.728 . . . . 0.0 112.768 -179.72 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 100' ' ' ILE . . . . . 0.425 HG13 ' O ' ' A' ' 96' ' ' ARG . 95.7 mt -72.51 -42.69 63.84 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-O 120.839 0.352 . . . . 0.0 111.279 -179.787 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 48.3 t -69.35 -48.62 66.5 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.439 0 CA-C-N 116.222 -0.444 . . . . 0.0 111.577 -179.534 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 102' ' ' ILE . . . . . 0.451 HG12 ' O ' ' A' ' 98' ' ' PHE . 34.2 mm -59.79 -48.93 85.73 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.736 -179.284 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 15.1 t -58.77 -38.34 78.27 Favored 'General case' 0 C--O 1.233 0.198 0 CA-C-O 120.707 0.289 . . . . 0.0 111.083 -179.813 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 104' ' ' LEU . . . . . 0.474 ' O ' HG23 ' A' ' 108' ' ' VAL . 36.6 tp -58.98 -43.45 91.41 Favored 'General case' 0 C--N 1.332 -0.177 0 CA-C-O 120.986 0.422 . . . . 0.0 110.272 179.296 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 105' ' ' ASN . . . . . 0.676 HD21 HD13 ' A' ' 137' ' ' LEU . 0.8 OUTLIER -65.87 -27.69 68.41 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-N 116.019 -0.537 . . . . 0.0 110.644 -179.981 . . . . . . . . 3 3 . 1 . 027 nuclear build core ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 62.4 m -63.52 -57.31 10.59 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 116.372 -0.377 . . . . 0.0 111.031 -179.89 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 107' ' ' VAL . . . . . 0.423 HG12 ' O ' ' A' ' 104' ' ' LEU . 12.8 p -57.99 -36.35 56.01 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.184 0 CA-C-N 116.399 -0.364 . . . . 0.0 110.857 179.937 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 108' ' ' VAL . . . . . 0.474 HG23 ' O ' ' A' ' 104' ' ' LEU . 54.3 t -58.32 -45.39 89.4 Favored 'Isoleucine or valine' 0 C--O 1.234 0.282 0 CA-C-O 121.069 0.462 . . . . 0.0 110.675 179.351 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 109' ' ' MET . . . . . 0.456 ' HG2' ' O ' ' A' ' 105' ' ' ASN . 21.3 mmt -71.96 -31.81 66.67 Favored 'General case' 0 CA--C 1.516 -0.361 0 CA-C-N 115.921 -0.582 . . . . 0.0 110.57 179.942 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 110' ' ' LEU . . . . . 0.456 HD23 ' C ' ' A' ' 110' ' ' LEU . 4.0 tt -62.6 -34.14 76.4 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-N 115.98 -0.555 . . . . 0.0 109.54 178.854 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -67.78 -53.73 24.82 Favored 'General case' 0 C--N 1.332 -0.18 0 CA-C-N 115.761 -0.654 . . . . 0.0 110.667 179.468 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . -62.4 -38.89 97.04 Favored Glycine 0 C--N 1.332 0.309 0 C-N-CA 120.641 -0.79 . . . . 0.0 112.286 179.566 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 113' ' ' PHE . . . . . . . . . . . . . 4.3 t80 -53.61 -66.93 0.3 Allowed 'General case' 0 C--N 1.331 -0.236 0 CA-C-O 121.088 0.47 . . . . 0.0 110.194 179.718 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 114' ' ' ALA . . . . . 0.408 ' HB3' HD22 ' A' ' 126' ' ' LEU . . . -65.22 -17.67 64.68 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 115.767 -0.651 . . . . 0.0 110.491 179.287 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -58.54 -48.43 84.42 Favored Glycine 0 C--N 1.332 0.333 0 CA-C-N 115.784 -0.644 . . . . 0.0 111.914 179.42 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -78.32 -17.49 56.49 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.739 0.304 . . . . 0.0 110.988 179.322 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 117' ' ' MET . . . . . . . . . . . . . 21.1 mmt -84.95 13.9 5.49 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.098 -0.501 . . . . 0.0 111.353 -179.452 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 118' ' ' VAL . . . . . 0.466 HG21 ' HB3' ' A' ' 123' ' ' ARG . 33.6 m -81.4 139.01 48.03 Favored Pre-proline 0 C--N 1.33 -0.266 0 N-CA-C 111.838 0.31 . . . . 0.0 111.838 -179.398 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 119' ' ' PRO . . . . . . . . . . . . . 85.7 Cg_endo -92.22 -2.63 3.99 Favored 'Trans proline' 0 N--CA 1.455 -0.788 0 C-N-CA 122.91 2.407 . . . . 0.0 112.463 179.052 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -138.89 -110.34 0.91 Allowed Glycine 0 C--N 1.333 0.379 0 C-N-CA 120.675 -0.774 . . . . 0.0 112.863 -179.775 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 2.4 pp -127.07 15.29 3.56 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.192 0 N-CA-C 111.849 0.314 . . . . 0.0 111.849 -179.775 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 46.5 mt-10 -61.22 -18.54 58.83 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.906 0.384 . . . . 0.0 110.838 179.82 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 123' ' ' ARG . . . . . 0.582 ' HD2' ' HA2' ' A' ' 184' ' ' GLY . 24.4 ptt180 -51.46 -27.63 10.9 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 115.871 -0.604 . . . . 0.0 111.729 -179.92 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 124' ' ' TYR . . . . . . . . . . . . . 22.2 m-85 -75.15 -33.34 61.51 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.582 -0.281 . . . . 0.0 111.382 -179.524 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 125' ' ' ALA . . . . . . . . . . . . . . . -74.14 -56.64 4.67 Favored 'General case' 0 C--O 1.235 0.34 0 CA-C-O 120.96 0.41 . . . . 0.0 111.155 -179.933 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 126' ' ' LEU . . . . . 0.408 HD22 ' HB3' ' A' ' 114' ' ' ALA . 1.2 mt -53.48 -51.2 63.51 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.016 -0.538 . . . . 0.0 110.275 179.749 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 127' ' ' PHE . . . . . . . . . . . . . 11.0 t80 -65.29 -30.1 70.93 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.03 179.318 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 128' ' ' GLY . . . . . . . . . . . . . . . -49.02 -49.31 29.94 Favored Glycine 0 N--CA 1.45 -0.42 0 C-N-CA 120.179 -1.01 . . . . 0.0 110.581 178.703 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 129' ' ' MET . . . . . 0.479 ' HE3' ' HA2' ' A' ' 130' ' ' GLY . 0.0 OUTLIER -71.71 -27.84 63.29 Favored 'General case' 0 C--N 1.328 -0.351 0 N-CA-C 109.067 -0.716 . . . . 0.0 109.067 178.303 . . . . . . . . 3 3 . 1 . 027 nuclear build core ' A' A ' 130' ' ' GLY . . . . . 0.479 ' HA2' ' HE3' ' A' ' 129' ' ' MET . . . -60.68 -41.23 98.88 Favored Glycine 0 C--N 1.332 0.36 0 CA-C-N 115.712 -0.676 . . . . 0.0 112.241 179.49 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -71.9 -48.99 41.71 Favored 'General case' 0 C--N 1.331 -0.21 0 CA-C-O 120.627 0.251 . . . . 0.0 110.403 179.668 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 57.2 t -55.68 -46.5 79.51 Favored 'Isoleucine or valine' 0 C--O 1.234 0.271 0 CA-C-O 121.302 0.573 . . . . 0.0 109.506 178.826 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -62.29 -38.19 88.39 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 115.397 -0.82 . . . . 0.0 110.507 178.962 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 134' ' ' PHE . . . . . . . . . . . . . 82.3 t80 -55.71 -53.47 56.15 Favored 'General case' 0 N--CA 1.452 -0.371 0 CA-C-N 116.058 -0.519 . . . . 0.0 110.305 179.793 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 135' ' ' ILE . . . . . 0.434 ' O ' HG22 ' A' ' 138' ' ' VAL . 47.5 mt -55.95 -32.08 32.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 115.841 -0.618 . . . . 0.0 110.193 179.573 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . -62.54 -42.6 99.68 Favored Glycine 0 N--CA 1.448 -0.522 0 C-N-CA 120.176 -1.012 . . . . 0.0 111.232 178.738 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 137' ' ' LEU . . . . . 0.676 HD13 HD21 ' A' ' 105' ' ' ASN . 61.0 tp -66.27 -54.42 25.13 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.583 0.23 . . . . 0.0 110.855 179.617 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 138' ' ' VAL . . . . . 0.434 HG22 ' O ' ' A' ' 135' ' ' ILE . 3.8 m -55.05 -31.56 25.67 Favored 'Isoleucine or valine' 0 C--O 1.232 0.184 0 N-CA-C 109.891 -0.411 . . . . 0.0 109.891 -179.7 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 139' ' ' TYR . . . . . . . . . . . . . 14.2 t80 -61.37 -42.83 99.34 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 115.871 -0.604 . . . . 0.0 109.748 178.313 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 140' ' ' TYR . . . . . 0.437 ' HE2' HD22 ' A' ' 104' ' ' LEU . 21.7 m-85 -66.95 -45.71 76.94 Favored 'General case' 0 CA--C 1.529 0.153 0 CA-C-N 116.034 -0.53 . . . . 0.0 111.096 179.262 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 141' ' ' LEU . . . . . . . . . . . . . 11.2 mp -52.4 -37.41 56.51 Favored 'General case' 0 N--CA 1.464 0.23 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.791 -179.417 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 8.6 p -104.58 -5.28 9.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-O 120.927 0.394 . . . . 0.0 111.394 -179.514 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 143' ' ' GLY . . . . . 0.434 ' HA3' ' HD2' ' A' ' 144' ' ' PRO . . . -75.51 -130.89 0.3 Allowed Glycine 0 CA--C 1.521 0.427 0 C-N-CA 120.768 -0.729 . . . . 0.0 113.009 -179.625 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 144' ' ' PRO . . . . . 0.434 ' HD2' ' HA3' ' A' ' 143' ' ' GLY . 13.2 Cg_endo -56.21 -23.47 45.46 Favored 'Trans proline' 0 C--N 1.348 0.549 0 C-N-CA 122.741 2.294 . . . . 0.0 112.658 -179.587 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 145' ' ' MET . . . . . . . . . . . . . 50.4 mtt -56.96 -29.22 63.02 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.286 -0.415 . . . . 0.0 111.696 -179.652 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 146' ' ' THR . . . . . . . . . . . . . 72.9 p -77.28 -34.65 55.62 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.837 0.351 . . . . 0.0 110.91 -179.531 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 36.9 tt0 -75.92 -32.25 59.51 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 115.989 -0.55 . . . . 0.0 111.028 -179.869 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 148' ' ' SER . . . . . . . . . . . . . 48.2 t -70.83 -47.43 59.45 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.502 -179.659 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 149' ' ' ALA . . . . . 0.432 ' HB1' HG22 ' A' ' 156' ' ' ILE . . . -70.76 -30.57 67.11 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.294 -0.412 . . . . 0.0 111.748 -179.39 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 150' ' ' SER . . . . . 0.412 ' HB3' ' HD3' ' A' ' 157' ' ' LYS . 78.4 p -69.12 0.0 5.29 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.38 -0.373 . . . . 0.0 111.12 -179.878 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 151' ' ' GLN . . . . . . . . . . . . . 77.0 mt-30 -121.99 9.58 9.99 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.378 -0.374 . . . . 0.0 111.494 -179.836 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 25.6 mmm180 -91.45 -53.16 4.44 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-O 121.1 0.476 . . . . 0.0 110.789 -179.994 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 153' ' ' SER . . . . . 0.675 ' HB2' HG12 ' A' ' 156' ' ' ILE . 23.5 m -158.3 172.22 18.76 Favored 'General case' 0 C--N 1.324 -0.509 0 CA-C-N 115.643 -0.708 . . . . 0.0 110.481 179.232 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 154' ' ' SER . . . . . . . . . . . . . 46.9 t -72.05 -37.08 69.76 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-O 120.977 0.418 . . . . 0.0 110.142 179.073 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -77.43 -35.38 37.32 Favored Glycine 0 N--CA 1.45 -0.423 0 CA-C-N 115.818 -0.628 . . . . 0.0 112.902 179.83 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 156' ' ' ILE . . . . . 0.675 HG12 ' HB2' ' A' ' 153' ' ' SER . 38.0 mm -52.72 -38.74 28.36 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.164 0 CA-C-O 120.687 0.28 . . . . 0.0 111.515 -179.56 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 157' ' ' LYS . . . . . 0.412 ' HD3' ' HB3' ' A' ' 150' ' ' SER . 57.4 tptt -64.78 -40.53 95.41 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.434 -0.348 . . . . 0.0 111.175 -179.9 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 49.3 m -71.16 -42.73 68.74 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.415 -0.357 . . . . 0.0 111.342 -179.733 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 159' ' ' LEU . . . . . 0.474 HD23 HD13 ' A' ' 163' ' ' LEU . 4.7 tt -64.44 -40.83 96.47 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.998 -179.573 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 160' ' ' TYR . . . . . . . . . . . . . 29.0 t80 -73.29 -37.17 66.34 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.711 -179.204 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 161' ' ' VAL . . . . . 0.492 HG12 ' N ' ' A' ' 162' ' ' ARG . 1.0 OUTLIER -59.85 -50.52 79.78 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.746 0 CA-C-O 120.628 0.251 . . . . 0.0 111.623 -179.438 . . . . . . . . 3 3 . 1 . 027 nuclear build core ' A' A ' 162' ' ' ARG . . . . . 0.492 ' N ' HG12 ' A' ' 161' ' ' VAL . 99.8 mtt180 -69.5 -34.82 74.87 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-O 120.929 0.395 . . . . 0.0 111.254 179.989 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 163' ' ' LEU . . . . . 0.661 ' HG ' ' HB2' ' A' ' 208' ' ' PHE . 1.2 mp -65.49 -55.12 19.61 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 115.945 -0.57 . . . . 0.0 112.173 -178.831 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 164' ' ' ARG . . . . . . . . . . . . . 5.1 ppt_? -66.05 -41.22 91.13 Favored 'General case' 0 C--N 1.329 -0.286 0 N-CA-C 111.997 0.369 . . . . 0.0 111.997 -178.596 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 165' ' ' ASN . . . . . 0.489 ' O ' HG23 ' A' ' 169' ' ' VAL . 5.1 m-20 -54.35 -52.28 62.09 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-O 120.969 0.414 . . . . 0.0 111.024 -179.948 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 166' ' ' LEU . . . . . 0.516 ' O ' ' HG ' ' A' ' 170' ' ' LEU . 2.8 tt -64.99 -51.93 58.96 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 115.925 -0.579 . . . . 0.0 111.513 -179.377 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 167' ' ' THR . . . . . 0.431 ' O ' ' HB2' ' A' ' 171' ' ' TRP . 91.4 m -54.74 -52.81 61.37 Favored 'General case' 0 C--N 1.328 -0.357 0 N-CA-C 112.345 0.498 . . . . 0.0 112.345 -178.817 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 168' ' ' VAL . . . . . . . . . . . . . 53.0 t -54.54 -46.1 71.48 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 N-CA-C 112.22 0.452 . . . . 0.0 112.22 -179.044 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 169' ' ' VAL . . . . . 0.489 HG23 ' O ' ' A' ' 165' ' ' ASN . 77.5 t -56.04 -65.18 0.4 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 N-CA-C 112.019 0.378 . . . . 0.0 112.019 -179.18 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 170' ' ' LEU . . . . . 0.516 ' HG ' ' O ' ' A' ' 166' ' ' LEU . 0.6 OUTLIER -63.65 -31.09 72.15 Favored 'General case' 0 C--N 1.328 -0.341 0 N-CA-C 112.43 0.53 . . . . 0.0 112.43 -178.486 . . . . . . . . 3 3 . 1 . 027 nuclear build core ' A' A ' 171' ' ' TRP . . . . . 0.431 ' HB2' ' O ' ' A' ' 167' ' ' THR . 3.5 m0 -68.67 -30.87 69.65 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-O 120.941 0.4 . . . . 0.0 110.37 179.24 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 172' ' ' ALA . . . . . . . . . . . . . . . -73.03 -6.88 48.43 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 115.92 -0.582 . . . . 0.0 110.641 -179.991 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 173' ' ' ILE . . . . . 0.513 HG22 HD11 ' A' ' 177' ' ' ILE . 29.0 mm -86.67 -22.2 7.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 115.818 -0.628 . . . . 0.0 111.203 -179.952 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 174' ' ' TYR . . . . . 0.453 ' HB2' ' HD3' ' A' ' 175' ' ' PRO . 25.5 m-85 -54.25 -49.8 88.28 Favored Pre-proline 0 N--CA 1.464 0.245 0 CA-C-N 116.514 -0.312 . . . . 0.0 111.702 -179.771 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 175' ' ' PRO . . . . . 0.453 ' HD3' ' HB2' ' A' ' 174' ' ' TYR . 79.8 Cg_exo -49.01 -30.06 17.13 Favored 'Trans proline' 0 C--N 1.349 0.591 0 C-N-CA 121.97 1.78 . . . . 0.0 112.138 179.641 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 176' ' ' PHE . . . . . 0.45 ' O ' ' HG ' ' A' ' 180' ' ' LEU . 46.8 m-85 -80.75 -50.0 10.43 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 115.985 -0.552 . . . . 0.0 111.663 -179.897 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 177' ' ' ILE . . . . . 0.513 HD11 HG22 ' A' ' 173' ' ' ILE . 4.2 mm -63.13 -32.64 57.03 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.501 0 N-CA-C 112.364 0.505 . . . . 0.0 112.364 -178.037 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 178' ' ' TRP . . . . . . . . . . . . . 77.7 t90 -71.95 -50.94 24.68 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.934 0.397 . . . . 0.0 110.555 179.771 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 179' ' ' LEU . . . . . 0.625 HD23 HD23 ' A' ' 180' ' ' LEU . 0.7 OUTLIER -68.95 -54.71 13.89 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.001 -0.545 . . . . 0.0 111.482 -179.341 . . . . . . . . 3 3 . 1 . 027 nuclear build core ' A' A ' 180' ' ' LEU . . . . . 0.674 HD22 HD11 ' A' ' 187' ' ' LEU . 39.3 mt -63.54 -43.68 96.39 Favored 'General case' 0 C--N 1.329 -0.324 0 C-N-CA 121.043 -0.263 . . . . 0.0 111.025 -179.729 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . -58.04 178.26 1.38 Allowed Glycine 0 CA--C 1.521 0.462 0 C-N-CA 120.12 -1.038 . . . . 0.0 112.12 179.085 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 182' ' ' PRO . . . . . 0.492 ' HA ' ' HB2' ' A' ' 186' ' ' ALA . 74.8 Cg_exo -47.45 -44.97 24.04 Favored 'Trans proline' 0 CA--C 1.536 0.611 0 C-N-CA 122.91 2.406 . . . . 0.0 113.918 -179.886 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 183' ' ' PRO . . . . . . . . . . . . . 86.7 Cg_exo -46.96 -26.91 5.29 Favored 'Trans proline' 0 C--N 1.355 0.874 0 C-N-CA 122.191 1.928 . . . . 0.0 113.364 -179.665 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 184' ' ' GLY . . . . . 0.582 ' HA2' ' HD2' ' A' ' 123' ' ' ARG . . . -120.5 -129.92 3.83 Favored Glycine 0 C--N 1.333 0.368 0 C-N-CA 120.29 -0.957 . . . . 0.0 113.081 -179.685 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 185' ' ' VAL . . . . . . . . . . . . . 15.4 m -54.68 -23.67 12.03 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 N-CA-C 112.066 0.395 . . . . 0.0 112.066 -179.526 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 186' ' ' ALA . . . . . 0.492 ' HB2' ' HA ' ' A' ' 182' ' ' PRO . . . 55.13 86.72 0.05 Allowed 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 116.446 -0.343 . . . . 0.0 111.659 179.509 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 187' ' ' LEU . . . . . 0.674 HD11 HD22 ' A' ' 180' ' ' LEU . 12.7 mt -92.3 -49.28 6.24 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.287 -0.415 . . . . 0.0 110.904 179.905 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 188' ' ' LEU . . . . . 0.521 HD13 HG11 ' A' ' 192' ' ' VAL . 78.2 mt -98.06 -161.93 0.91 Allowed 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 115.998 -0.546 . . . . 0.0 110.832 -179.72 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 189' ' ' THR . . . . . . . . . . . . . 2.3 t -98.41 146.93 32.41 Favored Pre-proline 0 C--N 1.329 -0.288 0 CA-C-N 116.132 -0.486 . . . . 0.0 110.766 179.993 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 190' ' ' PRO . . . . . . . . . . . . . 95.8 Cg_exo -44.41 -42.51 13.87 Favored 'Trans proline' 0 C--N 1.349 0.587 0 C-N-CA 122.763 2.309 . . . . 0.0 113.374 -179.511 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 191' ' ' THR . . . . . 0.48 ' O ' HD21 ' A' ' 7' ' ' LEU . 41.6 p -59.29 -44.74 92.47 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-O 120.78 0.324 . . . . 0.0 111.707 -179.596 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 192' ' ' VAL . . . . . 0.521 HG11 HD13 ' A' ' 188' ' ' LEU . 55.3 t -70.39 -51.52 37.34 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.42 0 N-CA-C 111.858 0.318 . . . . 0.0 111.858 -179.344 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 193' ' ' ASP . . . . . . . . . . . . . 20.7 m-20 -59.11 -51.98 67.7 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 116.444 -0.344 . . . . 0.0 111.626 -179.349 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 194' ' ' VAL . . . . . . . . . . . . . 69.2 t -58.88 -35.92 58.74 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.221 0 CA-C-O 120.712 0.292 . . . . 0.0 110.907 179.885 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 195' ' ' ALA . . . . . . . . . . . . . . . -57.33 -47.7 80.88 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.329 -0.396 . . . . 0.0 110.655 179.612 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 196' ' ' LEU . . . . . 0.402 HD23 ' N ' ' A' ' 196' ' ' LEU . 0.3 OUTLIER -61.85 -40.44 95.36 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.301 -0.409 . . . . 0.0 110.424 179.355 . . . . . . . . 3 3 . 1 . 027 nuclear build core ' A' A ' 197' ' ' ILE . . . . . . . . . . . . . 17.0 mm -57.25 -59.3 3.35 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.32 0 CA-C-N 115.939 -0.573 . . . . 0.0 110.062 179.019 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 198' ' ' VAL . . . . . . . . . . . . . 92.9 t -52.01 -35.1 18.13 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.426 0 CA-C-N 115.473 -0.785 . . . . 0.0 109.468 178.346 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 199' ' ' TYR . . . . . . . . . . . . . 59.3 t80 -70.24 -31.01 68.23 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 115.374 -0.83 . . . . 0.0 110.725 179.873 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 200' ' ' LEU . . . . . 0.496 ' O ' HG12 ' A' ' 203' ' ' VAL . 43.4 mt -73.23 -37.49 66.38 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 115.821 -0.627 . . . . 0.0 111.383 -179.736 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 201' ' ' ASP . . . . . . . . . . . . . 16.1 m-20 -73.84 -39.37 64.06 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-O 121.043 0.449 . . . . 0.0 110.498 179.663 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 202' ' ' LEU . . . . . . . . . . . . . 2.2 mt -69.9 -28.94 66.04 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 115.735 -0.666 . . . . 0.0 111.765 -179.465 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 203' ' ' VAL . . . . . 0.496 HG12 ' O ' ' A' ' 200' ' ' LEU . 12.3 p -78.17 -36.43 21.2 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.331 0 C-N-CA 121.094 -0.242 . . . . 0.0 110.962 -178.979 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 204' ' ' THR . . . . . . . . . . . . . 95.6 m -64.88 -58.43 6.2 Favored 'General case' 0 C--N 1.327 -0.399 0 C-N-CA 120.563 -0.455 . . . . 0.0 110.934 179.335 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 205' ' ' LYS . . . . . 0.76 ' HE3' HG22 ' A' ' 43' ' ' ILE . 54.4 mttp -61.86 -58.09 9.28 Favored 'General case' 0 C--N 1.329 -0.292 0 N-CA-C 112.343 0.497 . . . . 0.0 112.343 -178.395 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 51.0 t -71.83 -37.01 60.44 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.396 0 N-CA-C 112.428 0.529 . . . . 0.0 112.428 -178.515 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 207' ' ' GLY . . . . . 0.433 ' HA3' ' O ' ' A' ' 203' ' ' VAL . . . -57.59 -60.26 9.33 Favored Glycine 0 N--CA 1.455 -0.097 0 C-N-CA 120.704 -0.76 . . . . 0.0 113.416 -178.798 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 208' ' ' PHE . . . . . 0.661 ' HB2' ' HG ' ' A' ' 163' ' ' LEU . 0.3 OUTLIER -71.67 -27.13 62.85 Favored 'General case' 0 C--O 1.223 -0.3 0 CA-C-N 117.183 0.492 . . . . 0.0 110.562 -179.713 . . . . . . . . 3 3 . 1 . 027 nuclear build core ' A' A ' 209' ' ' GLY . . . . . 0.51 ' O ' ' HB3' ' A' ' 212' ' ' ALA . . . -65.18 -33.86 88.08 Favored Glycine 0 N--CA 1.448 -0.521 0 N-CA-C 111.718 -0.553 . . . . 0.0 111.718 178.623 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 210' ' ' PHE . . . . . . . . . . . . . 0.6 OUTLIER -73.57 -44.93 56.16 Favored 'General case' 0 CA--C 1.512 -0.502 0 N-CA-C 107.757 -1.201 . . . . 0.0 107.757 178.321 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 211' ' ' ILE . . . . . 0.416 HD12 ' HA ' ' A' ' 208' ' ' PHE . 34.5 mt -64.73 -27.65 42.99 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.653 0 N-CA-C 107.649 -1.241 . . . . 0.0 107.649 176.646 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 212' ' ' ALA . . . . . 0.51 ' HB3' ' O ' ' A' ' 209' ' ' GLY . . . -64.35 -44.02 92.78 Favored 'General case' 0 N--CA 1.45 -0.452 0 CA-C-N 114.505 -1.225 . . . . 0.0 110.6 -179.859 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 213' ' ' LEU . . . . . . . . . . . . . 97.6 mt -69.67 -46.08 66.91 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 115.308 -0.86 . . . . 0.0 111.487 -179.574 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 214' ' ' ASP . . . . . . . . . . . . . 36.3 m-20 -58.11 -47.15 84.14 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-O 120.85 0.357 . . . . 0.0 110.933 -179.952 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 215' ' ' ALA . . . . . . . . . . . . . . . -62.82 -54.05 44.9 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 115.992 -0.549 . . . . 0.0 111.239 -179.896 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 216' ' ' ALA . . . . . . . . . . . . . . . -56.36 -37.5 70.12 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-N 116.281 -0.418 . . . . 0.0 111.04 179.928 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 217' ' ' ALA . . . . . . . . . . . . . . . -63.33 -37.96 89.3 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.167 179.655 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 218' ' ' THR . . . . . . . . . . . . . 92.4 m . . . . . 0 C--N 1.328 -0.336 0 CA-C-N 115.677 -0.692 . . . . 0.0 110.605 179.334 . . . . . . . . 0 0 . 1 . 028 nuclear build core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.367 0 N-CA-C 112.546 -0.222 . . . . 0.0 112.546 . . . . . . . . . 0 0 . 1 . 028 nuclear build core ' A' A ' 4' ' ' LEU . . . . . 0.463 HD13 HG22 ' A' ' 191' ' ' THR . 59.5 tp -74.12 -40.69 62.5 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-O 120.823 0.344 . . . . 0.0 110.889 179.945 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 61.3 p -60.79 -29.85 69.7 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.136 179.98 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 10.9 p -53.11 -35.5 59.72 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 116.043 -0.526 . . . . 0.0 111.172 -179.785 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 7' ' ' LEU . . . . . . . . . . . . . 10.0 mp -57.22 -53.59 56.36 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.297 179.961 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 8' ' ' PHE . . . . . 0.49 ' O ' ' HB3' ' A' ' 51' ' ' TYR . 65.7 m-85 -59.4 -34.63 72.68 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.006 -0.543 . . . . 0.0 110.957 -179.599 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 9' ' ' TRP . . . . . 0.404 ' O ' HG12 ' A' ' 13' ' ' ILE . 32.0 m95 -66.71 -41.81 87.37 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-N 116.296 -0.411 . . . . 0.0 110.099 179.831 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 84.2 mt -59.64 -48.4 81.82 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 115.88 -0.6 . . . . 0.0 110.26 179.233 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 11' ' ' GLY . . . . . 0.489 ' HA2' HD11 ' A' ' 202' ' ' LEU . . . -61.22 -35.28 90.65 Favored Glycine 0 N--CA 1.449 -0.461 0 C-N-CA 120.621 -0.799 . . . . 0.0 111.587 179.169 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -63.29 -30.28 71.44 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.597 0.237 . . . . 0.0 110.442 179.41 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 13' ' ' ILE . . . . . 0.404 HG12 ' O ' ' A' ' 9' ' ' TRP . 47.9 mm -68.58 -54.12 23.21 Favored 'Isoleucine or valine' 0 CA--C 1.52 -0.189 0 CA-C-N 116.41 -0.359 . . . . 0.0 110.309 179.057 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -53.21 -30.67 39.95 Favored Glycine 0 N--CA 1.452 -0.281 0 C-N-CA 120.689 -0.767 . . . . 0.0 111.747 179.475 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 15' ' ' MET . . . . . 0.718 ' HB3' ' HB2' ' A' ' 48' ' ' ALA . 0.0 OUTLIER -76.77 -49.54 15.67 Favored 'General case' 0 C--O 1.223 -0.33 0 CA-C-O 120.564 0.221 . . . . 0.0 110.928 179.523 . . . . . . . . 3 3 . 1 . 028 nuclear build core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -55.67 -50.87 69.1 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-O 120.78 0.324 . . . . 0.0 110.621 179.804 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 17' ' ' VAL . . . . . 0.481 HG13 ' N ' ' A' ' 18' ' ' GLY . 14.7 p -63.55 -46.31 95.35 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.377 0 CA-C-O 121.356 0.598 . . . . 0.0 110.718 179.824 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 18' ' ' GLY . . . . . 0.481 ' N ' HG13 ' A' ' 17' ' ' VAL . . . -58.97 -46.31 93.87 Favored Glycine 0 C--N 1.317 -0.484 0 CA-C-N 114.973 -1.012 . . . . 0.0 111.891 179.179 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 57.4 m -53.78 -45.06 70.55 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-O 120.707 0.289 . . . . 0.0 110.827 -179.839 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 81.7 mt -71.58 -39.68 70.42 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.273 -0.421 . . . . 0.0 110.766 179.376 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -60.42 -33.39 72.44 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.085 -0.507 . . . . 0.0 111.736 -179.767 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 22' ' ' PHE . . . . . 0.586 ' HB2' HG22 ' A' ' 41' ' ' VAL . 8.2 m-85 -91.15 -31.05 16.36 Favored 'General case' 0 N--CA 1.463 0.197 0 CA-C-O 120.753 0.311 . . . . 0.0 111.311 -179.679 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -68.72 -50.32 51.78 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.335 -179.514 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 24' ' ' TRP . . . . . . . . . . . . . 4.4 t-105 -64.18 -45.05 90.07 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-N 115.834 -0.621 . . . . 0.0 111.24 -179.595 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.33 -0.258 0 CA-C-O 120.858 0.361 . . . . 0.0 110.983 179.84 . . . . . . . . 0 0 . 1 . 028 nuclear build core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.24 0 N-CA-C 112.457 -0.257 . . . . 0.0 112.457 . . . . . . . . . 0 0 . 1 . 028 nuclear build core ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 28.7 mm-40 -86.63 -20.85 27.25 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 120.741 0.305 . . . . 0.0 110.953 -179.959 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 34' ' ' ARG . . . . . . . . . . . . . 14.7 ptm180 -48.9 -36.31 16.88 Favored 'General case' 0 C--N 1.332 -0.17 0 CA-C-N 116.076 -0.511 . . . . 0.0 111.668 -179.757 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 29.2 mmt180 -61.77 -50.47 72.22 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 120.874 0.368 . . . . 0.0 111.277 -179.686 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 46.6 m-85 -63.2 -30.58 71.7 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.044 -0.525 . . . . 0.0 111.473 -179.607 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 37' ' ' TYR . . . . . 0.431 ' O ' HG23 ' A' ' 41' ' ' VAL . 39.1 m-85 -74.67 -55.8 5.49 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.641 -179.237 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 88.8 t -56.63 -36.85 49.81 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.205 0 CA-C-O 121.0 0.429 . . . . 0.0 110.485 179.914 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 90.7 m -63.97 -50.96 66.52 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 115.747 -0.661 . . . . 0.0 110.465 179.226 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 40' ' ' LEU . . . . . 0.529 HD12 HD12 ' A' ' 43' ' ' ILE . 40.4 tp -56.8 -50.16 73.18 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 115.549 -0.75 . . . . 0.0 110.809 -179.858 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 41' ' ' VAL . . . . . 0.586 HG22 ' HB2' ' A' ' 22' ' ' PHE . 69.0 t -57.76 -36.53 55.39 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 115.858 -0.61 . . . . 0.0 110.446 179.565 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -61.52 -36.1 92.08 Favored Glycine 0 N--CA 1.449 -0.493 0 C-N-CA 120.907 -0.663 . . . . 0.0 112.17 179.815 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 43' ' ' ILE . . . . . 0.572 HG12 HD23 ' A' ' 82' ' ' LEU . 2.0 mt -65.22 -56.94 13.08 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.234 0 CA-C-O 120.958 0.409 . . . . 0.0 110.802 179.713 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 32.4 t -58.26 -25.17 61.44 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 115.879 -0.601 . . . . 0.0 111.685 -179.5 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -73.83 -58.48 4.43 Favored Glycine 0 CA--C 1.517 0.191 0 C-N-CA 120.696 -0.764 . . . . 0.0 112.986 -179.576 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 46' ' ' ILE . . . . . 0.644 ' O ' HG22 ' A' ' 49' ' ' VAL . 15.8 pt -57.92 -35.87 53.63 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.221 0 CA-C-O 120.818 0.342 . . . . 0.0 110.924 -179.674 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 47' ' ' ALA . . . . . 0.67 ' HB2' ' HE2' ' A' ' 205' ' ' LYS . . . -67.04 -37.59 84.36 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.962 0.41 . . . . 0.0 110.261 178.754 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 48' ' ' ALA . . . . . 0.718 ' HB2' ' HB3' ' A' ' 15' ' ' MET . . . -60.57 -33.08 72.18 Favored 'General case' 0 C--N 1.332 -0.173 0 CA-C-N 115.736 -0.665 . . . . 0.0 111.343 179.889 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 49' ' ' VAL . . . . . 0.644 HG22 ' O ' ' A' ' 46' ' ' ILE . 1.3 m -76.54 -38.39 31.46 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.496 -0.32 . . . . 0.0 111.643 -179.425 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -62.95 -41.65 99.58 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-O 120.968 0.413 . . . . 0.0 111.393 -179.636 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 51' ' ' TYR . . . . . 0.595 ' HE2' ' HE2' ' A' ' 15' ' ' MET . 38.5 m-85 -72.74 -40.41 66.1 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-N 115.894 -0.594 . . . . 0.0 110.813 -179.283 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -63.13 -40.87 98.84 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-N 115.943 -0.571 . . . . 0.0 111.467 179.793 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 53' ' ' VAL . . . . . 0.515 HG23 ' N ' ' A' ' 54' ' ' MET . 33.3 m -74.42 -50.56 26.47 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 N-CA-C 111.754 0.279 . . . . 0.0 111.754 -179.475 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 54' ' ' MET . . . . . 0.534 ' HG2' ' HG2' ' A' ' 71' ' ' PRO . 72.0 mtm -57.57 -30.2 65.06 Favored 'General case' 0 CA--C 1.521 -0.143 0 CA-C-O 121.013 0.435 . . . . 0.0 110.744 179.914 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -58.95 -36.97 75.7 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 115.601 -0.727 . . . . 0.0 111.643 -179.816 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 6.2 mp -87.2 4.38 42.71 Favored 'General case' 0 C--N 1.332 -0.173 0 CA-C-N 116.639 -0.255 . . . . 0.0 111.456 179.974 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 92.98 30.76 9.09 Favored Glycine 0 N--CA 1.452 -0.246 0 C-N-CA 120.674 -0.774 . . . . 0.0 113.111 179.526 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 73.7 t -88.63 130.19 38.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-O 120.71 0.29 . . . . 0.0 110.878 179.716 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 59' ' ' GLY . . . . . 0.581 ' HA3' ' HD3' ' A' ' 71' ' ' PRO . . . 87.59 -5.96 84.17 Favored Glycine 0 N--CA 1.448 -0.548 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.471 -179.815 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 60' ' ' TRP . . . . . . . . . . . . . 11.5 m0 -69.43 83.03 0.39 Allowed 'General case' 0 C--N 1.328 -0.358 0 CA-C-O 120.759 0.314 . . . . 0.0 110.59 179.835 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 6.5 p -98.99 132.25 23.94 Favored Pre-proline 0 C--N 1.33 -0.282 0 CA-C-N 116.351 -0.386 . . . . 0.0 111.298 -179.87 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 73.3 Cg_endo -75.75 148.33 32.33 Favored 'Trans proline' 0 C--N 1.35 0.612 0 C-N-CA 122.447 2.098 . . . . 0.0 112.169 179.68 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 83.7 t -141.98 97.27 0.71 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.351 -179.84 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . 57.38 -88.93 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.054 -0.521 . . . . 0.0 111.87 179.611 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 11.8 mm-40 -118.89 -20.94 7.97 Favored 'General case' 0 C--N 1.332 -0.174 0 CA-C-N 116.501 -0.318 . . . . 0.0 111.428 -179.486 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 66' ' ' ARG . . . . . . . . . . . . . 28.4 ptt180 -110.91 161.68 15.59 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.461 -0.336 . . . . 0.0 110.766 179.971 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 91.6 m -114.88 143.3 45.34 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.256 -0.429 . . . . 0.0 111.264 -179.8 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 68' ' ' VAL . . . . . 0.559 HG21 ' SD ' ' A' ' 117' ' ' MET . 30.1 m -129.14 146.51 34.14 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 115.954 -0.566 . . . . 0.0 110.924 179.943 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 69' ' ' PHE . . . . . . . . . . . . . 19.2 m-85 -106.38 117.54 34.31 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.123 -0.49 . . . . 0.0 109.833 -179.724 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 70' ' ' VAL . . . . . 0.561 HG12 ' HD3' ' A' ' 71' ' ' PRO . 1.4 p -68.77 -33.19 4.11 Favored Pre-proline 0 CA--C 1.543 0.692 0 N-CA-C 113.66 0.985 . . . . 0.0 113.66 -178.538 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 71' ' ' PRO . . . . . 0.581 ' HD3' ' HA3' ' A' ' 59' ' ' GLY . 14.2 Cg_exo -69.48 -19.11 37.87 Favored 'Trans proline' 0 C--N 1.356 0.942 0 C-N-CA 122.099 1.866 . . . . 0.0 113.46 -178.643 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 72' ' ' ARG . . . . . 0.469 ' HE ' ' HA ' ' A' ' 72' ' ' ARG . 0.9 OUTLIER -67.77 -55.27 13.7 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.917 0.389 . . . . 0.0 111.564 -179.449 . . . . . . . . 3 3 . 1 . 028 nuclear build core ' A' A ' 73' ' ' TYR . . . . . 0.42 ' O ' HG13 ' A' ' 77' ' ' ILE . 14.2 m-85 -71.17 -33.19 69.76 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 116.081 -0.509 . . . . 0.0 111.315 -178.962 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 74' ' ' ILE . . . . . 0.541 HG22 ' HA ' ' A' ' 71' ' ' PRO . 0.3 OUTLIER -71.09 -44.93 74.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 C-N-CA 120.864 -0.334 . . . . 0.0 110.88 -179.773 . . . . . . . . 3 3 . 1 . 028 nuclear build core ' A' A ' 75' ' ' ASP . . . . . 0.492 ' O ' HG23 ' A' ' 79' ' ' THR . 37.4 t70 -58.99 -35.49 73.31 Favored 'General case' 0 N--CA 1.455 -0.183 0 N-CA-C 109.561 -0.533 . . . . 0.0 109.561 179.334 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 76' ' ' TRP . . . . . . . . . . . . . 50.2 m0 -66.0 -35.84 81.66 Favored 'General case' 0 C--N 1.332 -0.165 0 CA-C-N 116.029 -0.532 . . . . 0.0 110.129 179.141 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 77' ' ' ILE . . . . . 0.512 HG12 ' HB3' ' A' ' 109' ' ' MET . 96.4 mt -65.62 -30.78 51.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.028 -0.533 . . . . 0.0 110.718 179.378 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 69.7 mt -92.2 -20.46 21.17 Favored 'General case' 0 C--N 1.329 -0.294 0 N-CA-C 112.342 0.497 . . . . 0.0 112.342 -179.782 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 79' ' ' THR . . . . . 0.492 HG23 ' O ' ' A' ' 75' ' ' ASP . 62.7 p -94.39 -47.99 6.34 Favored 'General case' 0 N--CA 1.466 0.333 0 N-CA-C 112.845 0.683 . . . . 0.0 112.845 -178.406 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 80' ' ' THR . . . . . 0.582 ' N ' ' HD2' ' A' ' 81' ' ' PRO . 86.6 m -51.29 -48.72 85.07 Favored Pre-proline 0 C--N 1.328 -0.357 0 N-CA-C 112.545 0.572 . . . . 0.0 112.545 -179.319 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 81' ' ' PRO . . . . . 0.582 ' HD2' ' N ' ' A' ' 80' ' ' THR . 13.8 Cg_endo -56.02 -24.39 48.54 Favored 'Trans proline' 0 C--N 1.352 0.712 0 C-N-CA 121.536 1.491 . . . . 0.0 111.463 179.973 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 82' ' ' LEU . . . . . 0.572 HD23 HG12 ' A' ' 43' ' ' ILE . 7.2 mp -77.03 -46.03 25.14 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-N 115.707 -0.679 . . . . 0.0 110.847 179.9 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 83' ' ' ILE . . . . . 0.556 HD13 HD13 ' A' ' 43' ' ' ILE . 28.0 mm -60.8 -53.49 48.36 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.203 0 CA-C-N 116.305 -0.407 . . . . 0.0 110.527 179.655 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 84' ' ' VAL . . . . . 0.413 HG11 ' ND2' ' A' ' 105' ' ' ASN . 29.4 m -59.15 -35.47 57.7 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.211 0 CA-C-N 116.076 -0.511 . . . . 0.0 110.386 179.451 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 85' ' ' TYR . . . . . . . . . . . . . 72.7 t80 -65.51 -32.38 73.95 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.097 -0.501 . . . . 0.0 110.008 179.004 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 86' ' ' PHE . . . . . . . . . . . . . 1.4 t80 -61.54 -51.13 69.88 Favored 'General case' 0 C--N 1.333 -0.141 0 CA-C-N 115.963 -0.562 . . . . 0.0 109.707 179.547 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 6.9 mp -67.09 -31.57 72.15 Favored 'General case' 0 C--N 1.331 -0.2 0 CA-C-N 115.974 -0.557 . . . . 0.0 110.137 179.209 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -62.77 -28.01 70.96 Favored Glycine 0 N--CA 1.45 -0.418 0 C-N-CA 120.878 -0.677 . . . . 0.0 111.615 179.441 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 71.9 mt -78.45 -49.71 12.97 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.86 0.362 . . . . 0.0 110.536 179.411 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 96.1 mt -56.44 -32.5 64.97 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 115.994 -0.548 . . . . 0.0 110.649 179.608 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 91' ' ' ALA . . . . . 0.55 ' HB1' ' HB2' ' A' ' 148' ' ' SER . . . -83.67 -52.88 6.06 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 115.91 -0.587 . . . . 0.0 110.937 179.838 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 92' ' ' GLY . . . . . 0.462 ' HA3' HH21 ' A' ' 152' ' ' ARG . . . 90.68 71.82 1.23 Allowed Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.849 -0.691 . . . . 0.0 112.529 179.967 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 93' ' ' LEU . . . . . 0.551 HD11 ' HG2' ' A' ' 145' ' ' MET . 6.4 mp -84.18 -172.49 4.19 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-O 120.801 0.334 . . . . 0.0 110.912 -179.934 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 94' ' ' ASP . . . . . 0.453 ' H ' ' HB2' ' A' ' 97' ' ' GLU . 4.6 m-20 -98.88 -172.24 2.25 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.201 -179.966 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 46.1 t -67.87 -52.91 31.09 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 115.994 -0.548 . . . . 0.0 111.527 -179.668 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 75.3 mtp180 -74.14 -35.38 64.07 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-O 120.893 0.378 . . . . 0.0 110.899 -179.358 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 97' ' ' GLU . . . . . 0.453 ' HB2' ' H ' ' A' ' 94' ' ' ASP . 0.3 OUTLIER -60.8 -42.31 97.37 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 115.992 -0.549 . . . . 0.0 111.032 -179.873 . . . . . . . . 3 3 . 1 . 028 nuclear build core ' A' A ' 98' ' ' PHE . . . . . . . . . . . . . 0.6 OUTLIER -61.69 -40.73 96.03 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.337 -0.392 . . . . 0.0 110.572 179.468 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -65.6 -31.55 80.4 Favored Glycine 0 N--CA 1.452 -0.27 0 C-N-CA 120.795 -0.717 . . . . 0.0 112.538 -179.932 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 96.7 mt -67.82 -43.3 86.28 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.209 0 CA-C-O 120.909 0.385 . . . . 0.0 111.239 -179.826 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 101' ' ' VAL . . . . . 0.671 HG21 ' HE3' ' A' ' 145' ' ' MET . 42.2 t -66.36 -50.49 67.27 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.358 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.367 -179.801 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 102' ' ' ILE . . . . . . . . . . . . . 48.6 mm -59.46 -49.57 83.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.59 -179.526 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 14.2 t -59.95 -29.97 68.76 Favored 'General case' 0 C--N 1.332 -0.181 0 CA-C-O 120.77 0.319 . . . . 0.0 110.903 -179.829 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -60.66 -57.0 14.56 Favored 'General case' 0 C--N 1.332 -0.178 0 CA-C-N 116.325 -0.398 . . . . 0.0 109.983 179.342 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 105' ' ' ASN . . . . . 0.413 ' ND2' HG11 ' A' ' 84' ' ' VAL . 32.7 m-80 -59.27 -26.4 64.91 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-N 116.022 -0.535 . . . . 0.0 110.782 179.533 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 76.3 m -61.49 -52.76 63.19 Favored 'General case' 0 C--N 1.332 -0.185 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.958 179.87 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 107' ' ' VAL . . . . . 0.424 HG23 ' H ' ' A' ' 107' ' ' VAL . 2.1 t -62.0 -37.21 77.76 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.248 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.59 179.966 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 70.3 t -60.14 -57.86 9.89 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 115.73 -0.668 . . . . 0.0 111.461 -179.898 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 109' ' ' MET . . . . . 0.512 ' HB3' HG12 ' A' ' 77' ' ' ILE . 3.7 tpp -56.91 -42.89 80.75 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.485 -179.55 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 24.1 tp -62.54 -31.0 71.71 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.318 -0.401 . . . . 0.0 110.693 -179.899 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -63.57 -55.7 21.75 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 116.038 -0.528 . . . . 0.0 110.655 179.545 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . -61.49 -36.7 92.96 Favored Glycine 0 N--CA 1.45 -0.389 0 C-N-CA 120.775 -0.726 . . . . 0.0 112.081 179.576 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 113' ' ' PHE . . . . . 0.417 ' O ' ' HG2' ' A' ' 117' ' ' MET . 0.3 OUTLIER -52.25 -71.77 0.06 Allowed 'General case' 0 C--N 1.332 -0.174 0 CA-C-O 120.961 0.41 . . . . 0.0 110.195 179.619 . . . . . . . . 3 3 . 1 . 028 nuclear build core ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -63.9 -19.44 65.1 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 115.924 -0.58 . . . . 0.0 111.022 179.758 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 115' ' ' GLY . . . . . 0.495 ' HA2' HD22 ' A' ' 126' ' ' LEU . . . -54.8 -51.58 52.05 Favored Glycine 0 C--N 1.332 0.334 0 C-N-CA 120.86 -0.686 . . . . 0.0 111.841 179.611 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -78.2 -14.91 59.26 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-O 120.748 0.309 . . . . 0.0 111.227 179.659 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 117' ' ' MET . . . . . 0.559 ' SD ' HG21 ' A' ' 68' ' ' VAL . 23.5 mmt -90.59 17.07 7.93 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-N 116.358 -0.383 . . . . 0.0 111.739 -179.238 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 118' ' ' VAL . . . . . 0.426 HG21 ' HB3' ' A' ' 123' ' ' ARG . 34.4 m -81.1 144.01 53.85 Favored Pre-proline 0 C--N 1.33 -0.277 0 CA-C-O 120.505 0.193 . . . . 0.0 111.43 -179.845 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 119' ' ' PRO . . . . . . . . . . . . . 83.4 Cg_endo -82.49 -1.9 10.82 Favored 'Trans proline' 0 C--N 1.348 0.525 0 C-N-CA 122.55 2.167 . . . . 0.0 112.349 179.649 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -148.85 -129.1 1.77 Allowed Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.722 -0.751 . . . . 0.0 112.747 -179.878 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 39.8 pt -107.92 12.15 8.78 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.207 0 CA-C-O 120.676 0.274 . . . . 0.0 111.577 -179.729 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 43.9 mt-10 -60.25 -18.19 47.13 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.372 -0.376 . . . . 0.0 111.034 179.802 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 123' ' ' ARG . . . . . 0.432 ' HB2' ' HH2' ' A' ' 178' ' ' TRP . 15.7 ptt180 -50.08 -37.59 34.4 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 116.031 -0.532 . . . . 0.0 111.71 -179.578 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 124' ' ' TYR . . . . . . . . . . . . . 30.1 m-85 -58.46 -33.9 70.26 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.518 -0.31 . . . . 0.0 111.271 -179.628 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 125' ' ' ALA . . . . . . . . . . . . . . . -74.2 -49.75 22.15 Favored 'General case' 0 C--O 1.235 0.336 0 CA-C-O 120.909 0.385 . . . . 0.0 111.128 179.958 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 126' ' ' LEU . . . . . 0.495 HD22 ' HA2' ' A' ' 115' ' ' GLY . 7.4 mp -53.09 -46.46 68.66 Favored 'General case' 0 C--N 1.333 -0.144 0 CA-C-N 115.972 -0.558 . . . . 0.0 110.5 -179.928 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 127' ' ' PHE . . . . . 0.449 ' HZ ' ' HB3' ' A' ' 175' ' ' PRO . 4.8 t80 -67.23 -37.73 84.05 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.644 179.839 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 128' ' ' GLY . . . . . . . . . . . . . . . -46.38 -46.21 16.68 Favored Glycine 0 C--N 1.332 0.356 0 C-N-CA 120.193 -1.003 . . . . 0.0 110.911 179.237 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 129' ' ' MET . . . . . . . . . . . . . 0.6 OUTLIER -68.1 -40.95 82.46 Favored 'General case' 0 C--N 1.327 -0.386 0 N-CA-C 109.749 -0.463 . . . . 0.0 109.749 178.48 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -64.15 -23.15 67.73 Favored Glycine 0 N--CA 1.45 -0.411 0 CA-C-N 115.822 -0.626 . . . . 0.0 112.345 179.792 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 131' ' ' ALA . . . . . 0.4 ' O ' ' HB3' ' A' ' 134' ' ' PHE . . . -75.03 -53.54 8.73 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.717 0.294 . . . . 0.0 110.419 179.648 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 39.4 t -55.36 -40.33 56.77 Favored 'Isoleucine or valine' 0 C--O 1.233 0.217 0 CA-C-O 121.387 0.613 . . . . 0.0 109.638 178.799 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -69.79 -36.53 75.77 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 115.339 -0.846 . . . . 0.0 110.721 179.172 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 134' ' ' PHE . . . . . 0.442 ' CZ ' ' HA ' ' A' ' 172' ' ' ALA . 18.9 t80 -53.43 -60.06 3.79 Favored 'General case' 0 N--CA 1.454 -0.251 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.22 179.869 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 135' ' ' ILE . . . . . 0.526 ' O ' HG22 ' A' ' 138' ' ' VAL . 0.0 OUTLIER -56.11 -35.23 41.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 115.959 -0.564 . . . . 0.0 110.31 179.143 . . . . . . . . 3 3 . 1 . 028 nuclear build core ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . -57.56 -43.13 94.31 Favored Glycine 0 N--CA 1.45 -0.398 0 C-N-CA 120.226 -0.987 . . . . 0.0 111.755 179.024 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 137' ' ' LEU . . . . . 0.569 HD13 ' N ' ' A' ' 138' ' ' VAL . 1.4 tm? -63.29 -58.22 7.85 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 121.016 0.436 . . . . 0.0 110.519 179.678 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 138' ' ' VAL . . . . . 0.569 ' N ' HD13 ' A' ' 137' ' ' LEU . 2.4 m -54.22 -31.77 22.55 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.466 0 CA-C-N 115.562 -0.744 . . . . 0.0 110.213 179.68 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 139' ' ' TYR . . . . . . . . . . . . . 17.3 t80 -64.26 -34.92 79.21 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 115.885 -0.598 . . . . 0.0 110.05 179.091 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 15.4 m-85 -68.43 -48.69 63.94 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 115.989 -0.55 . . . . 0.0 111.613 179.733 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 141' ' ' LEU . . . . . 0.517 HD12 HG23 ' A' ' 142' ' ' VAL . 4.0 pp -68.52 -16.23 63.81 Favored 'General case' 0 CA--C 1.53 0.178 0 C-N-CA 120.974 -0.29 . . . . 0.0 111.327 -179.33 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 142' ' ' VAL . . . . . 0.517 HG23 HD12 ' A' ' 141' ' ' LEU . 95.2 t -101.17 -18.77 6.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-O 121.079 0.466 . . . . 0.0 110.57 178.801 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . -85.26 -123.46 1.25 Allowed Glycine 0 CA--C 1.522 0.498 0 C-N-CA 120.929 -0.653 . . . . 0.0 113.145 -179.342 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 144' ' ' PRO . . . . . . . . . . . . . 69.3 Cg_exo -52.15 -35.94 64.63 Favored 'Trans proline' 0 C--N 1.35 0.634 0 C-N-CA 122.722 2.281 . . . . 0.0 113.178 -179.392 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 145' ' ' MET . . . . . 0.671 ' HE3' HG21 ' A' ' 101' ' ' VAL . 40.3 mtt -55.36 -37.72 67.87 Favored 'General case' 0 C--N 1.331 -0.206 0 CA-C-O 120.751 0.31 . . . . 0.0 111.446 -179.798 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 146' ' ' THR . . . . . . . . . . . . . 18.3 m -68.28 -41.64 80.72 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.725 -179.368 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 42.6 mt-10 -75.77 -26.32 57.26 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.403 -0.362 . . . . 0.0 111.423 -179.543 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 148' ' ' SER . . . . . 0.55 ' HB2' ' HB1' ' A' ' 91' ' ' ALA . 68.9 m -70.65 -43.67 68.7 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.372 -0.376 . . . . 0.0 111.564 -179.402 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 149' ' ' ALA . . . . . 0.43 ' HB2' ' HA ' ' A' ' 91' ' ' ALA . . . -76.04 -32.34 59.29 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.781 0.324 . . . . 0.0 111.635 -179.441 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 150' ' ' SER . . . . . . . . . . . . . 86.7 p -69.46 -1.26 8.05 Favored 'General case' 0 C--N 1.326 -0.413 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.037 179.995 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 151' ' ' GLN . . . . . . . . . . . . . 77.2 mt-30 -118.69 0.26 11.44 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.097 -0.501 . . . . 0.0 111.331 -179.838 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 152' ' ' ARG . . . . . 0.462 HH21 ' HA3' ' A' ' 92' ' ' GLY . 38.9 mmt180 -82.26 -52.62 6.77 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-O 120.833 0.349 . . . . 0.0 111.004 -179.997 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 153' ' ' SER . . . . . 0.634 ' HB3' HG12 ' A' ' 156' ' ' ILE . 35.5 t -158.36 167.64 29.15 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.749 179.241 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 154' ' ' SER . . . . . . . . . . . . . 45.9 t -70.32 -34.85 73.18 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 121.037 0.446 . . . . 0.0 110.151 179.277 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -76.91 -37.92 32.14 Favored Glycine 0 N--CA 1.45 -0.368 0 C-N-CA 120.971 -0.633 . . . . 0.0 112.264 179.618 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 156' ' ' ILE . . . . . 0.634 HG12 ' HB3' ' A' ' 153' ' ' SER . 34.2 mm -53.51 -37.75 31.28 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.178 0 CA-C-O 120.897 0.379 . . . . 0.0 111.092 179.877 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 157' ' ' LYS . . . . . . . . . . . . . 39.9 ttpt -65.49 -32.29 73.82 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 116.078 -0.51 . . . . 0.0 111.441 -179.761 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 46.0 t -72.54 -47.93 44.27 Favored 'General case' 0 C--O 1.235 0.3 0 CA-C-O 121.143 0.497 . . . . 0.0 111.006 -179.604 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 159' ' ' LEU . . . . . 0.528 HD13 ' HB1' ' A' ' 215' ' ' ALA . 0.4 OUTLIER -68.63 -39.74 80.62 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 115.923 -0.58 . . . . 0.0 110.976 -179.415 . . . . . . . . 3 3 . 1 . 028 nuclear build core ' A' A ' 160' ' ' TYR . . . . . 0.47 ' OH ' ' HB3' ' A' ' 145' ' ' MET . 37.2 t80 -62.25 -47.15 85.63 Favored 'General case' 0 C--N 1.326 -0.419 0 N-CA-C 112.086 0.402 . . . . 0.0 112.086 -178.596 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 161' ' ' VAL . . . . . 0.412 HG23 ' N ' ' A' ' 162' ' ' ARG . 24.9 m -61.49 -45.97 97.54 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 C-N-CA 120.909 -0.316 . . . . 0.0 111.365 -179.488 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 162' ' ' ARG . . . . . 0.412 ' N ' HG23 ' A' ' 161' ' ' VAL . 28.1 tpt180 -68.85 -38.48 79.81 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 121.005 0.431 . . . . 0.0 111.103 -179.955 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 163' ' ' LEU . . . . . 0.416 HD13 ' O ' ' A' ' 159' ' ' LEU . 1.7 mp -64.67 -55.5 19.74 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 115.72 -0.673 . . . . 0.0 112.095 -179.23 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 164' ' ' ARG . . . . . 0.54 ' HG3' ' N ' ' A' ' 165' ' ' ASN . 22.7 ptt180 -64.59 -41.72 96.05 Favored 'General case' 0 C--N 1.333 -0.15 0 N-CA-C 111.828 0.307 . . . . 0.0 111.828 -178.671 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 165' ' ' ASN . . . . . 0.54 ' N ' ' HG3' ' A' ' 164' ' ' ARG . 5.7 m-20 -54.4 -48.37 71.67 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.91 0.386 . . . . 0.0 110.771 -179.922 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 166' ' ' LEU . . . . . . . . . . . . . 3.9 tt -64.06 -54.23 37.35 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 116.026 -0.533 . . . . 0.0 111.431 -179.787 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 167' ' ' THR . . . . . 0.446 ' O ' ' HB2' ' A' ' 171' ' ' TRP . 34.4 m -57.24 -54.28 48.61 Favored 'General case' 0 C--N 1.329 -0.307 0 N-CA-C 112.868 0.692 . . . . 0.0 112.868 -178.568 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 168' ' ' VAL . . . . . 0.404 HG13 ' N ' ' A' ' 169' ' ' VAL . 9.8 p -55.58 -41.59 64.84 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.243 0 N-CA-C 112.425 0.528 . . . . 0.0 112.425 -178.694 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 169' ' ' VAL . . . . . 0.501 HG23 ' O ' ' A' ' 165' ' ' ASN . 48.7 t -59.82 -64.62 0.56 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 C-N-CA 121.122 -0.231 . . . . 0.0 111.488 -179.628 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 170' ' ' LEU . . . . . 0.526 HD12 ' HD1' ' A' ' 171' ' ' TRP . 1.3 pp -62.07 -27.18 68.72 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.64 -0.254 . . . . 0.0 111.295 -179.582 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 171' ' ' TRP . . . . . 0.526 ' HD1' HD12 ' A' ' 170' ' ' LEU . 2.0 m0 -70.73 -36.12 73.02 Favored 'General case' 0 CA--C 1.519 -0.217 0 CA-C-O 121.099 0.476 . . . . 0.0 109.739 178.772 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 172' ' ' ALA . . . . . 0.442 ' HA ' ' CZ ' ' A' ' 134' ' ' PHE . . . -71.33 -6.85 43.08 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 115.465 -0.788 . . . . 0.0 110.877 179.573 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 173' ' ' ILE . . . . . 0.483 ' O ' HG12 ' A' ' 177' ' ' ILE . 42.1 mm -85.67 -23.29 7.13 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.191 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.943 179.571 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 174' ' ' TYR . . . . . 0.43 ' HB2' ' HD3' ' A' ' 175' ' ' PRO . 29.3 m-85 -53.87 -49.58 88.65 Favored Pre-proline 0 CA--C 1.53 0.201 0 CA-C-N 116.363 -0.38 . . . . 0.0 111.607 -179.72 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 175' ' ' PRO . . . . . 0.449 ' HB3' ' HZ ' ' A' ' 127' ' ' PHE . 81.2 Cg_exo -47.46 -31.62 13.82 Favored 'Trans proline' 0 C--N 1.351 0.701 0 C-N-CA 122.177 1.918 . . . . 0.0 112.228 179.446 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 176' ' ' PHE . . . . . 0.482 ' O ' ' HG ' ' A' ' 180' ' ' LEU . 75.0 m-85 -80.39 -50.04 10.66 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.02 -0.536 . . . . 0.0 111.908 -179.856 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 177' ' ' ILE . . . . . 0.483 HG12 ' O ' ' A' ' 173' ' ' ILE . 6.4 mm -62.52 -35.84 72.03 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.556 0 CA-C-N 116.091 -0.504 . . . . 0.0 112.269 -178.144 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 178' ' ' TRP . . . . . 0.432 ' HH2' ' HB2' ' A' ' 123' ' ' ARG . 68.6 t90 -73.71 -43.1 60.18 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 121.001 0.429 . . . . 0.0 110.73 179.642 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 179' ' ' LEU . . . . . 0.441 ' O ' HG22 ' A' ' 185' ' ' VAL . 1.6 tm? -68.71 -51.25 43.61 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 115.765 -0.652 . . . . 0.0 111.188 -179.497 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 180' ' ' LEU . . . . . 0.589 HD22 HD11 ' A' ' 187' ' ' LEU . 13.8 mt -75.22 -47.24 29.16 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-N 116.442 -0.345 . . . . 0.0 111.78 -179.223 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . -57.01 178.91 0.73 Allowed Glycine 0 C--N 1.337 0.622 0 C-N-CA 120.415 -0.898 . . . . 0.0 112.71 179.858 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 182' ' ' PRO . . . . . 0.694 ' HA ' ' HB2' ' A' ' 186' ' ' ALA . 72.9 Cg_exo -47.73 -45.27 24.46 Favored 'Trans proline' 0 CA--C 1.536 0.582 0 C-N-CA 122.848 2.365 . . . . 0.0 113.762 -179.842 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 183' ' ' PRO . . . . . 0.427 ' HD3' ' HB2' ' A' ' 182' ' ' PRO . 76.2 Cg_exo -51.83 -16.98 4.62 Favored 'Trans proline' 0 C--N 1.356 0.945 0 C-N-CA 122.173 1.916 . . . . 0.0 113.145 -179.787 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 184' ' ' GLY . . . . . 0.409 ' HA3' ' O ' ' A' ' 179' ' ' LEU . . . -115.93 -90.91 1.66 Allowed Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.463 -0.875 . . . . 0.0 113.001 -179.749 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 185' ' ' VAL . . . . . 0.441 HG22 ' O ' ' A' ' 179' ' ' LEU . 9.4 m -116.48 -7.66 12.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 N-CA-C 111.716 0.265 . . . . 0.0 111.716 -179.43 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 186' ' ' ALA . . . . . 0.694 ' HB2' ' HA ' ' A' ' 182' ' ' PRO . . . 56.66 85.69 0.08 Allowed 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.404 -0.362 . . . . 0.0 111.717 179.567 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 187' ' ' LEU . . . . . 0.589 HD11 HD22 ' A' ' 180' ' ' LEU . 20.9 mt -91.87 -49.45 6.24 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-O 120.927 0.394 . . . . 0.0 110.713 179.567 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 188' ' ' LEU . . . . . 0.428 ' HB3' ' H ' ' A' ' 189' ' ' THR . 95.6 mt -90.23 -154.48 0.33 Allowed 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 115.883 -0.599 . . . . 0.0 110.896 -179.962 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 189' ' ' THR . . . . . 0.428 ' H ' ' HB3' ' A' ' 188' ' ' LEU . 29.8 m -95.99 134.89 23.21 Favored Pre-proline 0 C--N 1.328 -0.342 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.649 -179.862 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 190' ' ' PRO . . . . . 0.407 ' O ' HG23 ' A' ' 194' ' ' VAL . 82.3 Cg_exo -44.99 -31.31 5.31 Favored 'Trans proline' 0 C--N 1.351 0.664 0 C-N-CA 122.592 2.195 . . . . 0.0 112.884 179.999 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 191' ' ' THR . . . . . 0.463 HG22 HD13 ' A' ' 4' ' ' LEU . 81.5 p -76.37 -42.05 45.94 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.481 -0.327 . . . . 0.0 111.326 -179.896 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 192' ' ' VAL . . . . . . . . . . . . . 58.3 t -70.08 -48.94 59.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.312 -0.404 . . . . 0.0 111.562 -179.504 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 193' ' ' ASP . . . . . . . . . . . . . 19.3 m-20 -53.78 -46.3 70.95 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.349 -0.387 . . . . 0.0 110.965 -179.89 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 194' ' ' VAL . . . . . 0.407 HG23 ' O ' ' A' ' 190' ' ' PRO . 69.5 t -65.36 -36.05 76.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.28 -0.418 . . . . 0.0 110.883 179.712 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 195' ' ' ALA . . . . . . . . . . . . . . . -55.0 -44.45 74.51 Favored 'General case' 0 C--N 1.331 -0.199 0 CA-C-N 116.421 -0.354 . . . . 0.0 110.843 179.783 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 196' ' ' LEU . . . . . . . . . . . . . 91.2 mt -68.07 -39.05 83.03 Favored 'General case' 0 C--N 1.332 -0.195 0 CA-C-O 120.895 0.379 . . . . 0.0 110.387 179.26 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 197' ' ' ILE . . . . . 0.449 HG12 HG21 ' A' ' 177' ' ' ILE . 13.2 mm -58.57 -56.31 17.24 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-N 115.971 -0.559 . . . . 0.0 110.083 179.091 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 198' ' ' VAL . . . . . . . . . . . . . 73.6 t -53.6 -34.46 24.09 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.509 0 CA-C-N 115.442 -0.799 . . . . 0.0 109.368 178.208 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 199' ' ' TYR . . . . . . . . . . . . . 70.0 t80 -69.92 -31.43 69.2 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 115.203 -0.908 . . . . 0.0 110.628 180.0 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 200' ' ' LEU . . . . . 0.446 HD12 HD13 ' A' ' 197' ' ' ILE . 62.5 mt -67.75 -45.53 74.7 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 115.9 -0.591 . . . . 0.0 111.299 -179.73 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 201' ' ' ASP . . . . . . . . . . . . . 7.8 m-20 -70.56 -32.61 70.1 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 121.063 0.459 . . . . 0.0 110.396 179.957 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 202' ' ' LEU . . . . . 0.489 HD11 ' HA2' ' A' ' 11' ' ' GLY . 3.9 mt -66.81 -41.99 86.64 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 115.544 -0.753 . . . . 0.0 111.882 -179.892 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 203' ' ' VAL . . . . . 0.406 ' CG1' HD22 ' A' ' 170' ' ' LEU . 8.2 p -71.47 -37.01 62.81 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.366 0 N-CA-C 111.883 0.327 . . . . 0.0 111.883 -178.582 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 204' ' ' THR . . . . . 0.439 ' O ' ' HB2' ' A' ' 208' ' ' PHE . 24.5 m -65.37 -47.29 76.89 Favored 'General case' 0 C--N 1.329 -0.312 0 C-N-CA 120.832 -0.347 . . . . 0.0 111.674 -179.92 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 205' ' ' LYS . . . . . 0.67 ' HE2' ' HB2' ' A' ' 47' ' ' ALA . 60.4 mttp -79.3 -57.93 3.47 Favored 'General case' 0 C--N 1.326 -0.429 0 N-CA-C 112.168 0.432 . . . . 0.0 112.168 -178.225 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 44.4 t -67.33 -37.39 78.93 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.388 0 CA-C-N 116.331 -0.395 . . . . 0.0 111.522 -179.413 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 207' ' ' GLY . . . . . . . . . . . . . . . -70.75 -53.65 11.42 Favored Glycine 0 C--N 1.331 0.278 0 C-N-CA 120.663 -0.78 . . . . 0.0 112.668 -179.622 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 208' ' ' PHE . . . . . 0.439 ' HB2' ' O ' ' A' ' 204' ' ' THR . 5.4 t80 -57.3 -42.42 81.75 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 120.872 0.368 . . . . 0.0 110.67 179.699 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 209' ' ' GLY . . . . . 0.487 ' O ' ' HB3' ' A' ' 212' ' ' ALA . . . -69.93 -38.51 75.0 Favored Glycine 0 N--CA 1.452 -0.296 0 CA-C-N 115.405 -0.816 . . . . 0.0 113.417 -179.766 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 210' ' ' PHE . . . . . . . . . . . . . 1.1 m-85 -69.43 -38.7 77.96 Favored 'General case' 0 CA--C 1.51 -0.58 0 N-CA-C 107.944 -1.132 . . . . 0.0 107.944 179.201 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 211' ' ' ILE . . . . . . . . . . . . . 82.9 mt -70.67 -28.69 35.18 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.825 0 N-CA-C 107.133 -1.432 . . . . 0.0 107.133 176.353 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 212' ' ' ALA . . . . . 0.487 ' HB3' ' O ' ' A' ' 209' ' ' GLY . . . -68.14 -37.94 81.61 Favored 'General case' 0 N--CA 1.45 -0.469 0 CA-C-N 114.394 -1.276 . . . . 0.0 110.572 179.704 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 213' ' ' LEU . . . . . . . . . . . . . 88.3 mt -70.1 -53.44 17.38 Favored 'General case' 0 C--N 1.331 -0.198 0 CA-C-N 115.28 -0.873 . . . . 0.0 111.444 -179.608 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 214' ' ' ASP . . . . . . . . . . . . . 25.6 t70 -54.15 -36.32 63.19 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.308 -0.406 . . . . 0.0 110.933 -179.764 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 215' ' ' ALA . . . . . 0.528 ' HB1' HD13 ' A' ' 159' ' ' LEU . . . -67.29 -57.27 6.97 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.026 -0.534 . . . . 0.0 111.457 -179.935 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 216' ' ' ALA . . . . . . . . . . . . . . . -58.57 -43.03 89.28 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.414 -0.357 . . . . 0.0 111.218 -179.735 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 217' ' ' ALA . . . . . . . . . . . . . . . -57.76 -36.8 72.6 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.502 179.831 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 218' ' ' THR . . . . . . . . . . . . . 90.9 m . . . . . 0 C--N 1.33 -0.268 0 CA-C-N 115.905 -0.589 . . . . 0.0 110.802 179.558 . . . . . . . . 0 0 . 1 . 029 nuclear build core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.253 0 N-CA-C 112.763 -0.135 . . . . 0.0 112.763 . . . . . . . . . 0 0 . 1 . 029 nuclear build core ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 89.1 mt -64.28 -37.42 87.42 Favored 'General case' 0 N--CA 1.45 -0.46 0 CA-C-O 120.841 0.353 . . . . 0.0 111.199 -179.945 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 5' ' ' THR . . . . . 0.46 ' HA ' ' HD2' ' A' ' 8' ' ' PHE . 78.5 p -59.79 -37.34 78.82 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.047 -0.524 . . . . 0.0 111.968 -179.6 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 20.1 p -54.24 -36.88 64.02 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.45 -0.341 . . . . 0.0 111.515 -179.441 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 7' ' ' LEU . . . . . . . . . . . . . 4.2 mm? -61.9 -53.05 61.06 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.308 -0.406 . . . . 0.0 111.344 -179.705 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 8' ' ' PHE . . . . . 0.721 ' HB2' ' HB2' ' A' ' 55' ' ' ALA . 29.2 m-85 -61.99 -27.32 68.78 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.367 -0.379 . . . . 0.0 111.223 -179.574 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 9' ' ' TRP . . . . . . . . . . . . . 19.7 m95 -69.61 -44.61 70.35 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 121.008 0.433 . . . . 0.0 110.204 179.882 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 90.2 mt -65.72 -37.12 85.53 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 115.926 -0.579 . . . . 0.0 109.997 179.181 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 11' ' ' GLY . . . . . 0.415 ' HA2' HD11 ' A' ' 202' ' ' LEU . . . -66.12 -32.9 83.72 Favored Glycine 0 N--CA 1.446 -0.677 0 CA-C-N 115.597 -0.729 . . . . 0.0 111.746 179.568 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -68.44 -37.29 80.11 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.856 0.36 . . . . 0.0 110.442 179.428 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 67.7 mt -59.47 -53.57 46.45 Favored 'Isoleucine or valine' 0 C--O 1.234 0.247 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.254 179.114 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -58.26 -34.78 75.38 Favored Glycine 0 C--N 1.332 0.36 0 C-N-CA 120.652 -0.785 . . . . 0.0 111.977 179.291 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 15' ' ' MET . . . . . 0.497 ' HE3' ' CB ' ' A' ' 47' ' ' ALA . 17.3 mmt -66.17 -41.23 90.59 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-O 120.772 0.32 . . . . 0.0 110.57 179.426 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 16' ' ' LEU . . . . . 0.429 HD22 ' HA ' ' A' ' 16' ' ' LEU . 0.3 OUTLIER -57.01 -40.74 77.2 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.067 -0.515 . . . . 0.0 109.95 179.371 . . . . . . . . 3 3 . 1 . 029 nuclear build core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 60.5 t -60.28 -48.86 86.5 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.241 0 CA-C-N 115.856 -0.611 . . . . 0.0 110.655 179.358 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -63.34 -48.55 77.95 Favored Glycine 0 C--N 1.332 0.356 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.058 179.337 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 43.9 m -50.13 -43.26 51.74 Favored 'General case' 0 C--N 1.328 -0.366 0 C-N-CA 122.317 0.247 . . . . 0.0 111.434 -179.659 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 87.2 mt -71.51 -44.41 64.69 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.597 -0.274 . . . . 0.0 111.694 -179.781 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -61.45 -31.67 71.63 Favored 'General case' 0 C--N 1.33 -0.28 0 N-CA-C 111.866 0.321 . . . . 0.0 111.866 -179.589 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 22' ' ' PHE . . . . . 0.511 ' HB2' HG22 ' A' ' 41' ' ' VAL . 6.9 m-85 -90.97 -35.37 14.72 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.693 0.283 . . . . 0.0 111.679 -179.32 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -66.84 -51.28 57.43 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-O 120.98 0.419 . . . . 0.0 111.781 -179.412 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 24' ' ' TRP . . . . . . . . . . . . . 7.3 t-105 -62.93 -50.68 69.87 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-N 115.804 -0.634 . . . . 0.0 110.891 -179.696 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.327 -0.379 0 CA-C-N 116.364 -0.38 . . . . 0.0 110.741 179.552 . . . . . . . . 0 0 . 1 . 029 nuclear build core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.343 0 N-CA-C 112.454 -0.258 . . . . 0.0 112.454 . . . . . . . . . 0 0 . 1 . 029 nuclear build core ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 36.3 mt-10 -63.1 -21.03 65.9 Favored 'General case' 0 C--N 1.331 -0.218 0 CA-C-O 120.697 0.284 . . . . 0.0 110.946 179.993 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 34' ' ' ARG . . . . . . . . . . . . . 5.0 tmt_? -50.43 -38.2 41.98 Favored 'General case' 0 C--N 1.332 -0.169 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.202 -179.93 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 29.7 mmt180 -64.5 -44.86 89.6 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 116.343 -0.39 . . . . 0.0 111.211 -179.928 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 57.1 m-85 -66.78 -31.06 71.44 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.113 -179.989 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 37' ' ' TYR . . . . . 0.519 ' O ' HG23 ' A' ' 41' ' ' VAL . 32.2 m-85 -70.97 -52.32 20.46 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.087 -179.687 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 85.4 t -57.04 -36.84 52.24 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-O 121.141 0.496 . . . . 0.0 110.232 179.387 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 55.4 m -62.21 -50.32 72.26 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 115.629 -0.714 . . . . 0.0 110.8 179.489 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 40' ' ' LEU . . . . . 0.722 HD12 HD11 ' A' ' 43' ' ' ILE . 44.5 tp -63.06 -44.66 95.19 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 115.644 -0.707 . . . . 0.0 110.922 179.877 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 41' ' ' VAL . . . . . 0.519 HG23 ' O ' ' A' ' 37' ' ' TYR . 86.8 t -62.72 -34.04 63.34 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.43 0 CA-C-N 116.043 -0.526 . . . . 0.0 110.076 179.142 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 42' ' ' GLY . . . . . 0.433 ' O ' HG12 ' A' ' 46' ' ' ILE . . . -60.82 -49.76 75.1 Favored Glycine 0 N--CA 1.448 -0.546 0 CA-C-N 115.461 -0.79 . . . . 0.0 113.197 -179.897 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 43' ' ' ILE . . . . . 0.722 HD11 HD12 ' A' ' 40' ' ' LEU . 22.8 pt -62.29 -48.94 86.04 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.202 0 CA-C-N 117.03 0.415 . . . . 0.0 111.993 -179.296 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 44' ' ' SER . . . . . 0.426 ' N ' HG13 ' A' ' 43' ' ' ILE . 99.0 p -59.52 -29.56 67.96 Favored 'General case' 0 C--O 1.233 0.227 0 CA-C-O 120.993 0.425 . . . . 0.0 111.016 179.961 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -77.65 -54.57 4.54 Favored Glycine 0 N--CA 1.453 -0.207 0 C-N-CA 121.075 -0.583 . . . . 0.0 113.343 -179.07 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 46' ' ' ILE . . . . . 0.587 ' O ' HG22 ' A' ' 49' ' ' VAL . 10.3 pt -58.35 -36.23 57.42 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.248 0 CA-C-O 120.758 0.313 . . . . 0.0 111.143 -179.552 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 47' ' ' ALA . . . . . 0.73 ' HB2' ' HE2' ' A' ' 205' ' ' LYS . . . -68.32 -43.06 78.42 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-O 120.939 0.4 . . . . 0.0 110.443 178.621 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -55.16 -38.17 67.94 Favored 'General case' 0 C--N 1.332 -0.193 0 CA-C-N 115.805 -0.634 . . . . 0.0 111.823 -179.795 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 49' ' ' VAL . . . . . 0.587 HG22 ' O ' ' A' ' 46' ' ' ILE . 17.5 m -76.6 -34.35 23.84 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.221 0 CA-C-O 120.611 0.244 . . . . 0.0 111.457 -179.7 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -63.64 -38.41 91.03 Favored 'General case' 0 CA--C 1.52 -0.179 0 CA-C-O 121.037 0.446 . . . . 0.0 111.042 179.897 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 28.5 m-85 -72.57 -42.64 64.41 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-N 115.824 -0.625 . . . . 0.0 110.482 -179.773 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -59.99 -53.48 57.37 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-N 115.734 -0.666 . . . . 0.0 110.925 179.681 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 53' ' ' VAL . . . . . 0.507 HG23 ' N ' ' A' ' 54' ' ' MET . 31.3 m -60.21 -48.67 87.16 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.234 0 CA-C-N 116.317 -0.402 . . . . 0.0 110.874 179.936 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 54' ' ' MET . . . . . 0.507 ' N ' HG23 ' A' ' 53' ' ' VAL . 7.0 ttp -60.74 -29.11 69.18 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 121.206 0.527 . . . . 0.0 109.922 179.431 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 55' ' ' ALA . . . . . 0.721 ' HB2' ' HB2' ' A' ' 8' ' ' PHE . . . -75.58 -19.23 59.4 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 115.622 -0.717 . . . . 0.0 111.528 179.62 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 96.8 mt -89.09 -0.83 57.76 Favored 'General case' 0 C--N 1.331 -0.198 0 CA-C-N 116.454 -0.339 . . . . 0.0 111.523 -179.441 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 99.94 -22.56 39.71 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.583 -0.818 . . . . 0.0 113.14 179.521 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 58' ' ' VAL . . . . . 0.432 HG22 ' O ' ' A' ' 53' ' ' VAL . 34.0 m -73.05 147.33 9.9 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.202 0 CA-C-N 117.008 0.404 . . . . 0.0 110.568 179.729 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 59' ' ' GLY . . . . . 0.456 ' HA3' ' HD3' ' A' ' 71' ' ' PRO . . . 90.86 13.71 58.9 Favored Glycine 0 N--CA 1.448 -0.525 0 C-N-CA 120.694 -0.765 . . . . 0.0 111.869 -178.934 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 60' ' ' TRP . . . . . . . . . . . . . 13.3 m0 -103.34 98.42 8.33 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-O 121.14 0.495 . . . . 0.0 109.891 -179.978 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 20.8 t -91.4 117.03 67.58 Favored Pre-proline 0 C--N 1.323 -0.56 0 CA-C-N 115.524 -0.762 . . . . 0.0 111.209 -178.972 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 64.8 Cg_endo -73.12 135.9 23.7 Favored 'Trans proline' 0 C--N 1.35 0.617 0 C-N-CA 122.346 2.031 . . . . 0.0 112.435 -179.928 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 46.0 t -135.18 89.05 0.82 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 115.94 -0.573 . . . . 0.0 110.718 179.696 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . 55.97 -88.7 0.02 OUTLIER 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.021 -0.536 . . . . 0.0 111.538 -179.917 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 5.2 mp0 -116.78 -19.25 9.99 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-O 121.009 0.433 . . . . 0.0 110.745 -179.866 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 66' ' ' ARG . . . . . . . . . . . . . 67.8 mtp180 -98.22 166.18 11.52 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 115.677 -0.692 . . . . 0.0 110.564 179.938 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 39.4 m -136.83 125.79 24.29 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.886 0.374 . . . . 0.0 111.381 -179.882 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 11.3 t -109.7 146.31 15.25 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.04 -0.527 . . . . 0.0 110.691 179.767 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 69' ' ' PHE . . . . . 0.405 ' HA ' ' O ' ' A' ' 59' ' ' GLY . 27.5 m-85 -108.19 115.24 29.75 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.82 0.343 . . . . 0.0 110.602 -179.717 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 70' ' ' VAL . . . . . 0.668 HG12 ' HD3' ' A' ' 71' ' ' PRO . 1.4 p -69.0 -35.42 6.19 Favored Pre-proline 0 CA--C 1.542 0.651 0 N-CA-C 113.148 0.795 . . . . 0.0 113.148 -179.317 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 71' ' ' PRO . . . . . 0.668 ' HD3' HG12 ' A' ' 70' ' ' VAL . 61.2 Cg_endo -70.49 -18.19 33.74 Favored 'Trans proline' 0 C--N 1.36 1.148 0 C-N-CA 121.741 1.627 . . . . 0.0 112.574 -179.399 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 72' ' ' ARG . . . . . 0.448 ' NH2' HG13 ' A' ' 197' ' ' ILE . 72.4 ttt180 -75.9 -54.49 6.81 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.277 -0.42 . . . . 0.0 111.835 -179.026 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 73' ' ' TYR . . . . . . . . . . . . . 83.4 m-85 -73.34 -35.68 66.06 Favored 'General case' 0 C--N 1.331 -0.21 0 C-N-CA 121.085 -0.246 . . . . 0.0 111.203 -179.103 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 74' ' ' ILE . . . . . 0.437 ' O ' HD13 ' A' ' 74' ' ' ILE . 0.3 OUTLIER -67.17 -43.87 88.2 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.238 0 C-N-CA 120.818 -0.353 . . . . 0.0 110.354 179.72 . . . . . . . . 3 3 . 1 . 029 nuclear build core ' A' A ' 75' ' ' ASP . . . . . 0.508 ' O ' HG23 ' A' ' 79' ' ' THR . 20.3 t70 -59.27 -35.87 74.5 Favored 'General case' 0 N--CA 1.455 -0.188 0 N-CA-C 109.267 -0.642 . . . . 0.0 109.267 178.986 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 76' ' ' TRP . . . . . 0.5 ' HB3' ' SD ' ' A' ' 109' ' ' MET . 39.3 m0 -64.0 -36.57 84.41 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 115.702 -0.681 . . . . 0.0 110.577 179.134 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 77' ' ' ILE . . . . . 0.472 ' O ' ' HG2' ' A' ' 81' ' ' PRO . 79.5 mt -67.29 -28.95 44.16 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.239 179.5 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 81.9 mt -91.33 -14.74 30.24 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.068 -0.515 . . . . 0.0 112.023 179.868 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 79' ' ' THR . . . . . 0.508 HG23 ' O ' ' A' ' 75' ' ' ASP . 70.1 p -104.38 -53.3 2.74 Favored 'General case' 0 N--CA 1.463 0.182 0 N-CA-C 113.272 0.842 . . . . 0.0 113.272 -178.652 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 80' ' ' THR . . . . . 0.641 ' HB ' ' HD3' ' A' ' 81' ' ' PRO . 8.9 m -51.75 -55.44 29.98 Favored Pre-proline 0 C--N 1.329 -0.296 0 N-CA-C 113.014 0.746 . . . . 0.0 113.014 -178.033 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 81' ' ' PRO . . . . . 0.641 ' HD3' ' HB ' ' A' ' 80' ' ' THR . 52.7 Cg_exo -56.96 -25.58 63.35 Favored 'Trans proline' 0 C--N 1.352 0.752 0 C-N-CA 121.505 1.47 . . . . 0.0 111.77 -179.799 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 82' ' ' LEU . . . . . 0.477 HD23 HG23 ' A' ' 43' ' ' ILE . 10.9 tp -76.83 -33.16 57.96 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 115.806 -0.634 . . . . 0.0 110.577 179.961 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 83' ' ' ILE . . . . . 0.413 HG12 ' O ' ' A' ' 79' ' ' THR . 43.5 mm -65.99 -52.75 45.27 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.204 0 CA-C-O 120.883 0.373 . . . . 0.0 110.201 179.176 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 33.7 m -61.42 -30.02 47.19 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.256 0 N-CA-C 109.472 -0.566 . . . . 0.0 109.472 178.759 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 85' ' ' TYR . . . . . . . . . . . . . 68.0 t80 -67.75 -30.64 70.16 Favored 'General case' 0 N--CA 1.452 -0.329 0 CA-C-N 115.391 -0.822 . . . . 0.0 109.588 178.568 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 86' ' ' PHE . . . . . . . . . . . . . 3.3 t80 -65.14 -49.78 68.55 Favored 'General case' 0 C--O 1.232 0.172 0 CA-C-N 115.823 -0.626 . . . . 0.0 109.766 179.069 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 6.5 mt -63.87 -30.8 71.85 Favored 'General case' 0 CA--C 1.518 -0.259 0 CA-C-N 115.878 -0.601 . . . . 0.0 109.742 179.468 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -69.86 -29.08 71.18 Favored Glycine 0 N--CA 1.449 -0.455 0 CA-C-N 115.291 -0.868 . . . . 0.0 112.167 179.74 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 54.1 mt -74.04 -38.93 63.85 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-O 120.913 0.387 . . . . 0.0 110.524 179.622 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 94.6 mt -63.71 -35.82 81.81 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.002 -0.545 . . . . 0.0 110.975 179.801 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 91' ' ' ALA . . . . . 0.425 ' HB1' ' OG ' ' A' ' 148' ' ' SER . . . -80.97 -54.77 5.28 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.351 -179.677 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 101.51 61.56 0.77 Allowed Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.791 -0.719 . . . . 0.0 112.369 -179.668 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 93' ' ' LEU . . . . . 0.505 ' HB3' ' HB2' ' A' ' 97' ' ' GLU . 6.8 mp -80.37 178.37 8.34 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-O 120.797 0.332 . . . . 0.0 110.907 -179.771 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 94' ' ' ASP . . . . . . . . . . . . . 22.4 m-20 -96.15 168.09 10.81 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.658 179.73 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 67.8 m -55.32 -35.09 64.77 Favored 'General case' 0 C--N 1.33 -0.239 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.256 -179.899 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 27.6 tpt180 -69.33 -54.01 16.74 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.412 -0.358 . . . . 0.0 110.895 -179.815 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 97' ' ' GLU . . . . . 0.505 ' HB2' ' HB3' ' A' ' 93' ' ' LEU . 32.9 mt-10 -53.82 -49.55 68.12 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.098 -0.501 . . . . 0.0 111.184 -179.639 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 98' ' ' PHE . . . . . 0.42 ' O ' HG12 ' A' ' 102' ' ' ILE . 25.4 m-85 -55.26 -51.19 67.43 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.397 -0.365 . . . . 0.0 111.002 179.902 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -56.9 -29.89 59.44 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.858 -0.687 . . . . 0.0 112.637 -179.74 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 100' ' ' ILE . . . . . 0.41 HD12 ' HA ' ' A' ' 97' ' ' GLU . 77.4 mt -72.85 -43.26 60.45 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-O 120.85 0.357 . . . . 0.0 111.308 -179.903 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 61.3 t -68.29 -49.8 63.41 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.355 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.702 -179.435 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 102' ' ' ILE . . . . . 0.42 HG12 ' O ' ' A' ' 98' ' ' PHE . 39.9 mm -58.11 -52.23 61.11 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 CA-C-N 116.317 -0.401 . . . . 0.0 111.584 -179.367 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 14.7 t -58.28 -34.65 70.75 Favored 'General case' 0 C--N 1.331 -0.203 0 CA-C-O 120.746 0.308 . . . . 0.0 110.82 -179.801 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 104' ' ' LEU . . . . . 0.47 HD22 ' HE2' ' A' ' 140' ' ' TYR . 30.5 tp -61.61 -45.83 92.41 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.625 179.224 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 105' ' ' ASN . . . . . 0.579 ' N ' HD22 ' A' ' 105' ' ' ASN . 0.8 OUTLIER -64.83 -26.87 68.52 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.095 -0.502 . . . . 0.0 111.117 -179.818 . . . . . . . . 3 3 . 1 . 029 nuclear build core ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 99.3 m -66.29 -57.37 7.66 Favored 'General case' 0 C--N 1.331 -0.204 0 CA-C-N 116.548 -0.296 . . . . 0.0 111.351 179.878 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 8.8 p -58.16 -36.32 56.8 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.213 0 CA-C-N 116.383 -0.372 . . . . 0.0 110.862 -179.88 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 108' ' ' VAL . . . . . 0.423 HG23 ' O ' ' A' ' 104' ' ' LEU . 59.9 t -64.82 -53.3 43.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.554 179.358 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 109' ' ' MET . . . . . 0.563 ' HE1' HG21 ' A' ' 80' ' ' THR . 5.7 tpp -60.89 -31.06 70.56 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 115.941 -0.572 . . . . 0.0 110.417 179.885 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 11.9 mt -74.44 -30.34 61.85 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 115.976 -0.556 . . . . 0.0 110.267 179.507 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -62.43 -42.52 99.51 Favored 'General case' 0 C--N 1.332 -0.194 0 N-CA-C 109.514 -0.55 . . . . 0.0 109.514 178.607 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . -74.42 -39.18 43.25 Favored Glycine 0 N--CA 1.449 -0.438 0 N-CA-C 111.187 -0.765 . . . . 0.0 111.187 178.748 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 113' ' ' PHE . . . . . . . . . . . . . 0.7 OUTLIER -50.66 -70.92 0.07 Allowed 'General case' 0 C--N 1.332 -0.162 0 N-CA-C 109.539 -0.541 . . . . 0.0 109.539 179.02 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 114' ' ' ALA . . . . . 0.479 ' HA ' ' HB2' ' A' ' 117' ' ' MET . . . -64.13 -21.05 66.39 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 115.387 -0.824 . . . . 0.0 110.947 179.218 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 115' ' ' GLY . . . . . 0.52 ' HA2' HD22 ' A' ' 126' ' ' LEU . . . -52.25 -49.48 50.38 Favored Glycine 0 C--N 1.335 0.508 0 C-N-CA 120.765 -0.731 . . . . 0.0 111.925 179.635 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -78.5 -18.48 54.73 Favored 'General case' 0 C--N 1.325 -0.465 0 CA-C-O 120.85 0.357 . . . . 0.0 110.983 179.392 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 117' ' ' MET . . . . . 0.479 ' HB2' ' HA ' ' A' ' 114' ' ' ALA . 19.9 mmt -84.85 3.78 36.29 Favored 'General case' 0 C--N 1.332 -0.189 0 CA-C-N 116.103 -0.499 . . . . 0.0 112.03 -179.361 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 118' ' ' VAL . . . . . 0.493 HG21 ' HB3' ' A' ' 123' ' ' ARG . 35.5 m -66.31 146.32 99.03 Favored Pre-proline 0 C--N 1.328 -0.364 0 C-N-CA 121.046 -0.262 . . . . 0.0 111.407 -179.588 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 119' ' ' PRO . . . . . . . . . . . . . 92.9 Cg_endo -86.86 -11.35 5.61 Favored 'Trans proline' 0 C--N 1.348 0.535 0 C-N-CA 122.674 2.25 . . . . 0.0 112.226 179.781 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -140.27 -124.98 2.15 Favored Glycine 0 C--N 1.331 0.281 0 C-N-CA 120.84 -0.695 . . . . 0.0 112.795 -179.907 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 2.3 pp -109.94 18.15 7.06 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.187 0 CA-C-O 120.782 0.325 . . . . 0.0 111.695 -179.564 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 42.8 mt-10 -66.47 -18.53 65.41 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.306 -0.407 . . . . 0.0 111.159 -179.9 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 123' ' ' ARG . . . . . 0.493 ' HB3' HG21 ' A' ' 118' ' ' VAL . 17.8 ptt180 -50.47 -34.61 25.52 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.825 -179.516 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 124' ' ' TYR . . . . . . . . . . . . . 29.2 m-85 -61.5 -34.13 74.96 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.766 0.317 . . . . 0.0 111.13 -179.552 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 125' ' ' ALA . . . . . . . . . . . . . . . -74.5 -49.69 21.1 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.908 179.788 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 126' ' ' LEU . . . . . 0.52 HD22 ' HA2' ' A' ' 115' ' ' GLY . 7.3 mp -53.39 -49.15 67.84 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-N 116.051 -0.522 . . . . 0.0 110.588 179.921 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 127' ' ' PHE . . . . . . . . . . . . . 5.4 t80 -67.0 -37.77 84.78 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.821 179.958 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 128' ' ' GLY . . . . . . . . . . . . . . . -46.34 -43.09 13.98 Favored Glycine 0 C--N 1.332 0.338 0 C-N-CA 120.156 -1.021 . . . . 0.0 110.817 179.097 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 129' ' ' MET . . . . . . . . . . . . . 0.8 OUTLIER -71.81 -39.05 70.11 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.921 0.391 . . . . 0.0 109.971 178.509 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -60.95 -32.88 81.57 Favored Glycine 0 C--N 1.333 0.401 0 CA-C-N 115.916 -0.584 . . . . 0.0 113.043 -179.911 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -74.84 -53.87 8.32 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-O 120.669 0.271 . . . . 0.0 110.883 179.959 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 48.2 t -56.4 -40.35 66.54 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.228 0 CA-C-O 121.478 0.656 . . . . 0.0 109.477 179.055 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -68.52 -37.82 80.35 Favored 'General case' 0 N--CA 1.451 -0.424 0 CA-C-N 115.102 -0.954 . . . . 0.0 110.408 179.24 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 134' ' ' PHE . . . . . . . . . . . . . 79.5 t80 -54.64 -51.93 63.87 Favored 'General case' 0 N--CA 1.451 -0.388 0 CA-C-N 116.09 -0.505 . . . . 0.0 109.901 179.387 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 135' ' ' ILE . . . . . 0.523 ' O ' HG22 ' A' ' 138' ' ' VAL . 56.5 mt -58.75 -33.55 49.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 115.647 -0.706 . . . . 0.0 110.046 179.068 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . -58.4 -36.35 83.55 Favored Glycine 0 N--CA 1.449 -0.449 0 C-N-CA 120.239 -0.982 . . . . 0.0 111.136 178.616 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 137' ' ' LEU . . . . . . . . . . . . . 38.4 tp -71.1 -53.15 15.64 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 115.769 -0.216 . . . . 0.0 110.805 179.494 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 138' ' ' VAL . . . . . 0.523 HG22 ' O ' ' A' ' 135' ' ' ILE . 3.3 m -55.97 -32.55 33.38 Favored 'Isoleucine or valine' 0 C--O 1.232 0.137 0 CA-C-O 121.233 0.539 . . . . 0.0 109.863 179.483 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 139' ' ' TYR . . . . . . . . . . . . . 34.4 t80 -60.3 -50.15 74.78 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 115.5 -0.773 . . . . 0.0 110.303 178.894 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 140' ' ' TYR . . . . . 0.47 ' HE2' HD22 ' A' ' 104' ' ' LEU . 22.4 m-85 -56.9 -35.41 68.96 Favored 'General case' 0 C--N 1.332 -0.152 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.741 179.64 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 141' ' ' LEU . . . . . . . . . . . . . 96.0 mt -57.73 -52.0 67.23 Favored 'General case' 0 C--N 1.332 -0.172 0 CA-C-N 116.355 -0.384 . . . . 0.0 110.504 179.602 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 10.2 t -78.48 -10.35 12.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.09 -0.505 . . . . 0.0 110.778 179.672 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . -71.58 -131.39 0.11 Allowed Glycine 0 CA--C 1.521 0.45 0 C-N-CA 120.886 -0.673 . . . . 0.0 112.677 -179.887 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 144' ' ' PRO . . . . . . . . . . . . . 44.8 Cg_endo -67.84 -24.09 40.71 Favored 'Trans proline' 0 C--N 1.348 0.542 0 C-N-CA 122.403 2.069 . . . . 0.0 112.5 -179.888 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 145' ' ' MET . . . . . . . . . . . . . 45.2 mtt -55.41 -34.62 64.57 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 120.983 0.421 . . . . 0.0 111.063 179.876 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 146' ' ' THR . . . . . . . . . . . . . 27.4 m -70.78 -45.82 64.02 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 115.991 -0.55 . . . . 0.0 112.077 -179.181 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 46.3 mt-10 -72.22 -29.51 64.03 Favored 'General case' 0 C--N 1.328 -0.345 0 N-CA-C 111.846 0.313 . . . . 0.0 111.846 -179.101 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 148' ' ' SER . . . . . 0.425 ' OG ' ' HB1' ' A' ' 91' ' ' ALA . 42.0 p -70.15 -45.04 67.6 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.551 -0.295 . . . . 0.0 111.488 -179.241 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 149' ' ' ALA . . . . . . . . . . . . . . . -77.98 -39.84 41.13 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.772 0.32 . . . . 0.0 111.79 -179.514 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 150' ' ' SER . . . . . . . . . . . . . 40.3 t -65.82 -5.09 7.9 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.284 -0.416 . . . . 0.0 111.517 -179.536 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 151' ' ' GLN . . . . . . . . . . . . . 48.4 mt-30 -127.1 17.44 7.2 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.614 -0.266 . . . . 0.0 111.232 179.876 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 25.2 tpt180 -93.82 -52.04 4.62 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-O 120.817 0.341 . . . . 0.0 111.074 179.944 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 153' ' ' SER . . . . . 0.611 ' HB3' HG12 ' A' ' 156' ' ' ILE . 23.1 t -157.38 172.57 18.35 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.581 179.466 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 154' ' ' SER . . . . . . . . . . . . . 47.6 t -70.39 -39.8 74.33 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.773 0.32 . . . . 0.0 110.949 179.961 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -76.95 -34.7 41.54 Favored Glycine 0 CA--C 1.518 0.254 0 C-N-CA 120.862 -0.685 . . . . 0.0 112.986 -179.899 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 156' ' ' ILE . . . . . 0.611 HG12 ' HB3' ' A' ' 153' ' ' SER . 38.5 mm -54.46 -38.18 40.4 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 CA-C-O 120.605 0.24 . . . . 0.0 111.492 -179.664 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 157' ' ' LYS . . . . . 0.435 ' O ' HG22 ' A' ' 161' ' ' VAL . 27.2 ttpp -68.22 -31.98 71.87 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.41 -0.359 . . . . 0.0 111.371 -179.724 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 53.5 m -71.39 -48.5 49.56 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-O 120.898 0.38 . . . . 0.0 111.411 -179.631 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 159' ' ' LEU . . . . . 0.524 HD21 ' HB3' ' A' ' 215' ' ' ALA . 14.3 mt -71.16 -35.48 71.67 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.607 -179.637 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 160' ' ' TYR . . . . . . . . . . . . . 76.3 t80 -64.95 -44.86 88.04 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.471 -0.331 . . . . 0.0 111.874 -179.098 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 161' ' ' VAL . . . . . 0.435 HG22 ' O ' ' A' ' 157' ' ' LYS . 31.0 m -67.35 -46.28 84.06 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 N-CA-C 111.927 0.343 . . . . 0.0 111.927 -179.172 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 162' ' ' ARG . . . . . 0.433 ' N ' HG23 ' A' ' 161' ' ' VAL . 78.5 mtm180 -64.78 -35.9 82.57 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.73 0.3 . . . . 0.0 111.529 -179.631 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 163' ' ' LEU . . . . . 0.56 ' HG ' ' HB2' ' A' ' 208' ' ' PHE . 7.7 mp -76.87 -51.37 11.38 Favored 'General case' 0 C--N 1.328 -0.349 0 N-CA-C 112.179 0.437 . . . . 0.0 112.179 -179.074 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 164' ' ' ARG . . . . . . . . . . . . . 5.6 ppt_? -62.11 -41.68 98.47 Favored 'General case' 0 C--N 1.328 -0.331 0 N-CA-C 112.064 0.394 . . . . 0.0 112.064 -178.514 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 165' ' ' ASN . . . . . 0.463 ' O ' HG23 ' A' ' 169' ' ' VAL . 6.6 m120 -69.38 -51.38 37.18 Favored 'General case' 0 C--N 1.332 -0.188 0 CA-C-O 120.696 0.284 . . . . 0.0 111.616 -179.788 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 166' ' ' LEU . . . . . 0.476 ' O ' ' HG ' ' A' ' 170' ' ' LEU . 4.2 tt -60.32 -51.33 69.97 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-O 120.844 0.354 . . . . 0.0 111.421 -179.601 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 167' ' ' THR . . . . . . . . . . . . . 88.3 m -59.91 -52.54 64.98 Favored 'General case' 0 C--N 1.329 -0.317 0 N-CA-C 112.923 0.712 . . . . 0.0 112.923 -178.826 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 168' ' ' VAL . . . . . 0.454 HG12 ' O ' ' A' ' 165' ' ' ASN . 8.9 p -54.32 -40.28 47.44 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.195 0 N-CA-C 112.297 0.48 . . . . 0.0 112.297 -178.546 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 169' ' ' VAL . . . . . 0.463 HG23 ' O ' ' A' ' 165' ' ' ASN . 79.1 t -62.03 -64.37 0.65 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-N 116.574 -0.285 . . . . 0.0 111.621 -179.721 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 170' ' ' LEU . . . . . 0.476 ' HG ' ' O ' ' A' ' 166' ' ' LEU . 1.2 pp -60.59 -30.96 70.14 Favored 'General case' 0 C--N 1.33 -0.272 0 N-CA-C 111.97 0.359 . . . . 0.0 111.97 -179.011 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 171' ' ' TRP . . . . . 0.414 ' N ' HD12 ' A' ' 170' ' ' LEU . 3.2 m0 -70.32 -35.09 73.42 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-O 120.928 0.394 . . . . 0.0 110.383 179.431 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 172' ' ' ALA . . . . . . . . . . . . . . . -69.3 -7.28 35.67 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 115.844 -0.617 . . . . 0.0 110.801 -179.793 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 173' ' ' ILE . . . . . 0.624 HG22 HD11 ' A' ' 177' ' ' ILE . 43.6 mm -84.78 -23.53 7.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 115.917 -0.583 . . . . 0.0 110.736 179.536 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 174' ' ' TYR . . . . . 0.457 ' HB2' ' HD3' ' A' ' 175' ' ' PRO . 22.2 m-85 -54.41 -51.16 80.48 Favored Pre-proline 0 N--CA 1.464 0.254 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.768 -179.89 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 175' ' ' PRO . . . . . 0.457 ' HD3' ' HB2' ' A' ' 174' ' ' TYR . 87.5 Cg_exo -46.84 -29.07 7.62 Favored 'Trans proline' 0 C--N 1.352 0.752 0 C-N-CA 122.225 1.95 . . . . 0.0 112.387 -179.905 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 176' ' ' PHE . . . . . 0.5 ' O ' ' HG ' ' A' ' 180' ' ' LEU . 81.0 m-85 -80.6 -49.81 10.8 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 115.992 -0.549 . . . . 0.0 111.802 -179.893 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 177' ' ' ILE . . . . . 0.624 HD11 HG22 ' A' ' 173' ' ' ILE . 2.4 mm -61.19 -37.15 76.83 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.54 0 CA-C-N 116.201 -0.454 . . . . 0.0 112.133 -178.043 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 178' ' ' TRP . . . . . . . . . . . . . 63.8 t90 -73.45 -41.08 63.66 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-O 120.84 0.352 . . . . 0.0 110.637 179.628 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 179' ' ' LEU . . . . . 0.479 ' O ' HG22 ' A' ' 185' ' ' VAL . 2.6 tm? -68.54 -54.07 19.02 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 115.97 -0.559 . . . . 0.0 111.259 -179.426 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 180' ' ' LEU . . . . . 0.584 HD22 HD11 ' A' ' 187' ' ' LEU . 11.9 mt -72.58 -46.49 54.05 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.541 -0.3 . . . . 0.0 111.489 -179.408 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 181' ' ' GLY . . . . . 0.424 ' HA3' ' OD1' ' A' ' 193' ' ' ASP . . . -55.1 173.13 0.99 Allowed Glycine 0 C--N 1.336 0.557 0 C-N-CA 120.558 -0.829 . . . . 0.0 112.682 179.865 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 182' ' ' PRO . . . . . 0.659 ' HA ' ' HB2' ' A' ' 186' ' ' ALA . 82.9 Cg_exo -47.78 -44.67 26.17 Favored 'Trans proline' 0 C--N 1.347 0.49 0 C-N-CA 122.776 2.317 . . . . 0.0 113.611 179.87 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 183' ' ' PRO . . . . . 0.419 ' HD3' ' HB2' ' A' ' 182' ' ' PRO . 57.6 Cg_exo -52.65 -14.85 3.6 Favored 'Trans proline' 0 C--N 1.355 0.877 0 C-N-CA 121.982 1.788 . . . . 0.0 112.551 179.633 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 184' ' ' GLY . . . . . 0.401 ' HA3' ' O ' ' A' ' 179' ' ' LEU . . . -115.08 -81.03 0.93 Allowed Glycine 0 N--CA 1.45 -0.373 0 C-N-CA 120.776 -0.726 . . . . 0.0 112.678 -179.982 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 185' ' ' VAL . . . . . 0.479 HG22 ' O ' ' A' ' 179' ' ' LEU . 6.3 m -132.05 -2.9 1.85 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.208 0 N-CA-C 112.409 0.522 . . . . 0.0 112.409 -179.572 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 186' ' ' ALA . . . . . 0.659 ' HB2' ' HA ' ' A' ' 182' ' ' PRO . . . 53.02 87.31 0.04 OUTLIER 'General case' 0 C--N 1.331 -0.22 0 CA-C-O 120.723 0.297 . . . . 0.0 111.642 179.78 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 187' ' ' LEU . . . . . 0.584 HD11 HD22 ' A' ' 180' ' ' LEU . 18.6 mt -92.01 -49.82 6.02 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 120.838 0.351 . . . . 0.0 111.406 179.934 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 188' ' ' LEU . . . . . . . . . . . . . 38.8 mt -94.84 -89.45 0.23 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.087 -0.506 . . . . 0.0 111.412 -179.325 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 189' ' ' THR . . . . . . . . . . . . . 1.1 t -165.36 148.34 6.93 Favored Pre-proline 0 C--N 1.325 -0.461 0 CA-C-N 115.856 -0.611 . . . . 0.0 111.06 -179.56 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 190' ' ' PRO . . . . . . . . . . . . . 12.1 Cg_endo -55.83 -30.31 76.17 Favored 'Trans proline' 0 C--N 1.347 0.494 0 C-N-CA 122.513 2.142 . . . . 0.0 112.427 -179.994 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 191' ' ' THR . . . . . . . . . . . . . 77.9 p -64.56 -45.28 87.78 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 121.012 0.434 . . . . 0.0 110.686 179.682 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 192' ' ' VAL . . . . . . . . . . . . . 25.4 t -73.89 -38.47 50.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 115.81 -0.632 . . . . 0.0 111.056 179.857 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 193' ' ' ASP . . . . . 0.478 ' OD1' HG22 ' A' ' 177' ' ' ILE . 14.5 t70 -59.49 -51.51 69.56 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.9 179.8 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 194' ' ' VAL . . . . . . . . . . . . . 94.6 t -64.34 -36.37 76.96 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-N 116.02 -0.536 . . . . 0.0 111.185 -179.896 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 195' ' ' ALA . . . . . . . . . . . . . . . -57.64 -48.68 78.79 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.695 0.283 . . . . 0.0 111.092 179.92 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 196' ' ' LEU . . . . . . . . . . . . . 63.0 mt -68.44 -43.27 77.47 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 116.389 -0.369 . . . . 0.0 110.589 179.617 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 197' ' ' ILE . . . . . 0.499 HG12 HG21 ' A' ' 177' ' ' ILE . 17.2 mm -56.2 -59.34 2.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 115.944 -0.571 . . . . 0.0 110.56 179.416 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 198' ' ' VAL . . . . . . . . . . . . . 61.0 t -52.3 -35.39 19.63 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.505 0 CA-C-N 115.594 -0.73 . . . . 0.0 109.433 178.62 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 199' ' ' TYR . . . . . . . . . . . . . 67.3 t80 -70.58 -31.14 68.04 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 115.244 -0.889 . . . . 0.0 110.916 -179.904 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 200' ' ' LEU . . . . . 0.536 ' O ' HG12 ' A' ' 203' ' ' VAL . 37.1 mt -71.88 -40.23 69.06 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 115.902 -0.59 . . . . 0.0 111.544 -179.545 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 201' ' ' ASP . . . . . . . . . . . . . 14.7 m-20 -72.81 -34.87 67.15 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-O 121.237 0.542 . . . . 0.0 110.114 179.519 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 202' ' ' LEU . . . . . 0.415 HD11 ' HA2' ' A' ' 11' ' ' GLY . 2.5 mt -73.01 -29.28 62.91 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 115.415 -0.811 . . . . 0.0 111.601 -179.634 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 203' ' ' VAL . . . . . 0.536 HG12 ' O ' ' A' ' 200' ' ' LEU . 12.5 p -77.6 -36.25 22.77 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.382 0 C-N-CA 121.045 -0.262 . . . . 0.0 110.669 -179.083 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 204' ' ' THR . . . . . . . . . . . . . 98.6 m -65.49 -58.79 4.97 Favored 'General case' 0 C--N 1.329 -0.307 0 C-N-CA 120.596 -0.442 . . . . 0.0 110.994 179.306 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 205' ' ' LYS . . . . . 0.73 ' HE2' ' HB2' ' A' ' 47' ' ' ALA . 61.5 mttp -63.27 -58.1 8.27 Favored 'General case' 0 C--N 1.33 -0.24 0 N-CA-C 112.461 0.541 . . . . 0.0 112.461 -178.259 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 44.6 t -69.97 -37.54 72.94 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.412 0 N-CA-C 112.235 0.458 . . . . 0.0 112.235 -178.751 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 207' ' ' GLY . . . . . 0.52 ' O ' HG13 ' A' ' 211' ' ' ILE . . . -58.22 -61.83 6.97 Favored Glycine 0 CA--C 1.52 0.365 0 C-N-CA 120.67 -0.776 . . . . 0.0 114.059 -178.486 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 208' ' ' PHE . . . . . 0.56 ' HB2' ' HG ' ' A' ' 163' ' ' LEU . 0.9 OUTLIER -73.41 -27.04 61.24 Favored 'General case' 0 C--O 1.221 -0.414 0 CA-C-N 117.47 0.635 . . . . 0.0 110.802 -179.14 . . . . . . . . 3 3 . 1 . 029 nuclear build core ' A' A ' 209' ' ' GLY . . . . . 0.502 ' O ' ' HB3' ' A' ' 212' ' ' ALA . . . -63.19 -32.39 83.99 Favored Glycine 0 N--CA 1.447 -0.626 0 N-CA-C 111.663 -0.575 . . . . 0.0 111.663 178.616 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 210' ' ' PHE . . . . . . . . . . . . . 1.3 m-85 -75.08 -46.91 31.52 Favored 'General case' 0 CA--C 1.514 -0.439 0 N-CA-C 108.37 -0.974 . . . . 0.0 108.37 178.336 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 211' ' ' ILE . . . . . 0.52 HG13 ' O ' ' A' ' 207' ' ' GLY . 4.1 mt -63.41 -27.59 43.34 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.411 0 N-CA-C 107.473 -1.306 . . . . 0.0 107.473 176.67 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 212' ' ' ALA . . . . . 0.502 ' HB3' ' O ' ' A' ' 209' ' ' GLY . . . -63.79 -41.23 97.98 Favored 'General case' 0 N--CA 1.45 -0.461 0 CA-C-N 114.303 -1.317 . . . . 0.0 110.634 -179.772 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 213' ' ' LEU . . . . . . . . . . . . . 72.9 mt -70.12 -50.17 43.43 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 115.179 -0.919 . . . . 0.0 111.783 -179.393 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 214' ' ' ASP . . . . . . . . . . . . . 21.7 t70 -53.24 -51.83 60.94 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.331 -0.395 . . . . 0.0 111.581 -179.315 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 215' ' ' ALA . . . . . 0.524 ' HB3' HD21 ' A' ' 159' ' ' LEU . . . -64.63 -55.32 20.99 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.379 -0.373 . . . . 0.0 111.772 -179.54 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 216' ' ' ALA . . . . . . . . . . . . . . . -51.87 -37.07 50.78 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 116.414 -0.357 . . . . 0.0 111.496 -179.707 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 217' ' ' ALA . . . . . . . . . . . . . . . -63.65 -44.26 94.36 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.997 0.427 . . . . 0.0 110.06 179.577 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 218' ' ' THR . . . . . . . . . . . . . 54.3 m . . . . . 0 C--N 1.33 -0.258 0 CA-C-N 115.669 -0.696 . . . . 0.0 110.626 179.376 . . . . . . . . 0 0 . 1 . 030 nuclear build core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.338 0 N-CA-C 112.481 -0.248 . . . . 0.0 112.481 . . . . . . . . . 0 0 . 1 . 030 nuclear build core ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 55.3 tp -74.26 -35.84 63.82 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.904 0.383 . . . . 0.0 110.801 179.785 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 68.3 p -64.22 -29.67 70.76 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 115.935 -0.575 . . . . 0.0 111.569 -179.74 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 29.9 p -52.8 -38.07 60.67 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.601 -179.52 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 7' ' ' LEU . . . . . 0.498 HD12 ' HA ' ' A' ' 195' ' ' ALA . 3.4 mm? -59.4 -53.27 60.09 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.475 -0.33 . . . . 0.0 110.84 -179.798 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 8' ' ' PHE . . . . . 0.444 ' O ' ' HB3' ' A' ' 51' ' ' TYR . 73.9 m-85 -58.43 -36.2 73.28 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.594 179.879 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 9' ' ' TRP . . . . . . . . . . . . . 25.4 m95 -64.94 -41.03 95.87 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-O 121.161 0.505 . . . . 0.0 110.151 179.825 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 83.1 mt -62.35 -49.51 75.3 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 115.562 -0.744 . . . . 0.0 110.519 179.512 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -55.21 -34.81 59.19 Favored Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.683 -0.77 . . . . 0.0 111.999 179.291 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -67.86 -36.23 79.94 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-O 120.795 0.331 . . . . 0.0 110.847 179.745 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 91.1 mt -60.28 -54.16 38.79 Favored 'Isoleucine or valine' 0 C--O 1.234 0.241 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.668 179.556 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -63.02 -30.64 78.1 Favored Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 120.688 -0.768 . . . . 0.0 111.871 179.478 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 15' ' ' MET . . . . . 0.617 ' HB3' ' HB2' ' A' ' 48' ' ' ALA . 0.0 OUTLIER -64.46 -48.93 73.42 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.666 0.27 . . . . 0.0 110.835 179.656 . . . . . . . . 3 3 . 1 . 030 nuclear build core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -57.7 -41.3 81.42 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.334 -0.393 . . . . 0.0 110.94 179.73 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 96.5 t -59.33 -42.57 87.73 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.25 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.554 179.503 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -70.44 -46.73 46.88 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.845 -0.693 . . . . 0.0 112.1 179.588 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 20.5 m -49.5 -45.39 47.03 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-O 120.78 0.324 . . . . 0.0 111.134 -179.755 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 68.3 mt -71.51 -36.74 71.17 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.099 179.618 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -64.09 -31.85 73.19 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.316 -0.402 . . . . 0.0 111.537 -179.801 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 22' ' ' PHE . . . . . 0.714 ' HB2' HG22 ' A' ' 41' ' ' VAL . 7.5 m-85 -90.28 -28.4 18.82 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-O 120.813 0.34 . . . . 0.0 110.939 -179.688 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -72.28 -50.56 26.17 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.176 -0.465 . . . . 0.0 111.288 -179.784 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 24' ' ' TRP . . . . . . . . . . . . . 5.5 t-105 -64.73 -40.07 94.7 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-N 115.73 -0.668 . . . . 0.0 111.195 -179.641 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.33 -0.258 0 CA-C-O 120.855 0.36 . . . . 0.0 110.936 179.622 . . . . . . . . 0 0 . 1 . 030 nuclear build core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.338 0 N-CA-C 112.464 -0.254 . . . . 0.0 112.464 . . . . . . . . . 0 0 . 1 . 030 nuclear build core ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 16.7 mm-40 -65.05 -23.67 67.25 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.562 0.22 . . . . 0.0 111.167 -179.891 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 34' ' ' ARG . . . . . . . . . . . . . 52.9 ttt180 -50.85 -30.74 15.27 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.367 -0.379 . . . . 0.0 111.29 -179.716 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 79.7 ttt180 -60.13 -50.69 72.71 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.294 -0.412 . . . . 0.0 111.011 -179.838 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 73.7 m-85 -61.74 -30.47 70.8 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.091 -0.504 . . . . 0.0 111.211 -179.847 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 37' ' ' TYR . . . . . 0.595 ' O ' HG23 ' A' ' 41' ' ' VAL . 64.0 m-85 -70.88 -54.08 12.77 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.281 -0.418 . . . . 0.0 111.141 -179.805 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 61.8 t -56.99 -38.45 60.0 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.223 0 CA-C-O 120.959 0.409 . . . . 0.0 110.654 179.86 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 20.5 m -65.39 -51.18 62.15 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 115.832 -0.622 . . . . 0.0 110.864 179.645 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 40' ' ' LEU . . . . . 0.561 HD12 HD12 ' A' ' 43' ' ' ILE . 38.0 tp -56.98 -46.84 81.95 Favored 'General case' 0 C--O 1.236 0.343 0 CA-C-N 115.894 -0.593 . . . . 0.0 110.578 179.721 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 41' ' ' VAL . . . . . 0.714 HG22 ' HB2' ' A' ' 22' ' ' PHE . 62.9 t -60.26 -34.28 56.76 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.326 0 CA-C-N 115.857 -0.61 . . . . 0.0 110.3 179.083 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -61.27 -39.3 97.01 Favored Glycine 0 N--CA 1.448 -0.539 0 C-N-CA 120.743 -0.742 . . . . 0.0 111.988 179.925 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 43' ' ' ILE . . . . . 0.561 HD12 HD12 ' A' ' 40' ' ' LEU . 0.7 OUTLIER -65.13 -56.59 14.87 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.223 0 CA-C-O 120.827 0.346 . . . . 0.0 110.998 179.797 . . . . . . . . 3 3 . 1 . 030 nuclear build core ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 36.3 t -57.24 -27.6 62.17 Favored 'General case' 0 C--N 1.332 -0.156 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.431 -179.747 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -76.2 -53.57 5.59 Favored Glycine 0 CA--C 1.519 0.342 0 C-N-CA 120.664 -0.779 . . . . 0.0 113.327 -179.288 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 19.7 pt -58.34 -40.03 76.5 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.168 0 CA-C-O 120.738 0.304 . . . . 0.0 111.522 -179.418 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 47' ' ' ALA . . . . . 0.695 ' HB2' ' HE2' ' A' ' 205' ' ' LYS . . . -67.44 -43.67 80.56 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-N 116.436 -0.347 . . . . 0.0 111.364 179.603 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 48' ' ' ALA . . . . . 0.617 ' HB2' ' HB3' ' A' ' 15' ' ' MET . . . -55.1 -43.76 74.32 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.079 -0.51 . . . . 0.0 111.831 -179.423 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 28.4 m -73.8 -33.89 38.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.454 -0.339 . . . . 0.0 111.503 -179.428 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -65.35 -38.54 90.39 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-O 120.927 0.394 . . . . 0.0 111.148 179.74 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 51' ' ' TYR . . . . . 0.557 ' HE2' ' HE2' ' A' ' 15' ' ' MET . 29.0 m-85 -73.06 -35.56 66.71 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 116.132 -0.486 . . . . 0.0 110.756 -179.736 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -63.9 -42.22 97.51 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.291 -0.413 . . . . 0.0 110.938 179.263 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 53' ' ' VAL . . . . . 0.429 HG23 ' N ' ' A' ' 54' ' ' MET . 21.7 m -74.87 -45.1 44.41 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.177 0 CA-C-N 116.271 -0.422 . . . . 0.0 111.42 -179.981 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 54' ' ' MET . . . . . 0.429 ' N ' HG23 ' A' ' 53' ' ' VAL . 70.6 mtm -62.74 -32.01 73.05 Favored 'General case' 0 C--N 1.332 -0.174 0 CA-C-O 120.952 0.406 . . . . 0.0 110.296 179.572 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -63.02 -18.05 62.9 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 115.772 -0.649 . . . . 0.0 111.01 179.476 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 81.8 mt -99.14 -9.16 24.15 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 115.998 -0.546 . . . . 0.0 110.933 179.771 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 73.59 31.1 61.1 Favored Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.809 -0.71 . . . . 0.0 112.96 179.784 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 58' ' ' VAL . . . . . 0.418 HG22 ' O ' ' A' ' 53' ' ' VAL . 32.6 m -81.24 14.5 0.45 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-O 120.907 0.384 . . . . 0.0 111.525 179.893 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -151.85 10.27 0.67 Allowed Glycine 0 N--CA 1.45 -0.389 0 C-N-CA 120.882 -0.675 . . . . 0.0 112.734 179.938 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 60' ' ' TRP . . . . . . . . . . . . . 38.4 m0 -78.33 109.52 12.54 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.631 0.253 . . . . 0.0 110.573 179.842 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 7.6 p -102.32 130.75 23.53 Favored Pre-proline 0 C--N 1.329 -0.294 0 CA-C-N 116.431 -0.35 . . . . 0.0 111.255 -179.723 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 7.8 Cg_exo -72.87 144.14 38.18 Favored 'Trans proline' 0 C--N 1.35 0.622 0 C-N-CA 122.675 2.25 . . . . 0.0 112.383 -179.851 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 85.9 t -143.85 96.29 0.53 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.201 0 CA-C-N 115.993 -0.549 . . . . 0.0 111.031 179.968 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . 60.58 -86.15 0.02 OUTLIER 'General case' 0 C--N 1.333 -0.122 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.223 -179.902 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 11.4 tp10 -124.66 -23.93 4.27 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-O 120.927 0.394 . . . . 0.0 110.38 179.793 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 66' ' ' ARG . . . . . . . . . . . . . 96.9 mtt180 -103.13 153.41 20.34 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 115.809 -0.632 . . . . 0.0 110.4 179.739 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 91.2 m -111.94 119.34 38.19 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-O 120.952 0.406 . . . . 0.0 111.671 -179.336 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 68' ' ' VAL . . . . . 0.582 HG11 ' HG3' ' A' ' 117' ' ' MET . 42.4 t -90.52 147.03 5.49 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-N 115.938 -0.574 . . . . 0.0 110.401 179.224 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 69' ' ' PHE . . . . . . . . . . . . . 21.9 m-85 -105.11 114.55 28.82 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-O 121.008 0.432 . . . . 0.0 110.247 -179.367 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 70' ' ' VAL . . . . . 0.54 ' HB ' ' HD3' ' A' ' 71' ' ' PRO . 13.6 t -68.83 -50.09 24.66 Favored Pre-proline 0 C--N 1.325 -0.486 0 CA-C-N 115.937 -0.574 . . . . 0.0 112.471 -178.856 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 71' ' ' PRO . . . . . 0.54 ' HD3' ' HB ' ' A' ' 70' ' ' VAL . 16.4 Cg_exo -66.57 -17.84 53.47 Favored 'Trans proline' 0 C--N 1.351 0.671 0 C-N-CA 122.252 1.968 . . . . 0.0 112.698 -179.304 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 72' ' ' ARG . . . . . 0.417 ' NH2' HG13 ' A' ' 197' ' ' ILE . 66.2 ttt180 -66.25 -55.31 16.76 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-O 120.866 0.365 . . . . 0.0 111.539 -179.346 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 73' ' ' TYR . . . . . 0.473 ' O ' HG13 ' A' ' 77' ' ' ILE . 77.7 m-85 -71.59 -33.76 69.31 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.38 -0.373 . . . . 0.0 110.687 -179.492 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 74' ' ' ILE . . . . . 0.487 ' HA ' HD12 ' A' ' 77' ' ' ILE . 0.4 OUTLIER -67.51 -36.84 77.55 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.2 0 N-CA-C 109.768 -0.456 . . . . 0.0 109.768 179.106 . . . . . . . . 3 3 . 1 . 030 nuclear build core ' A' A ' 75' ' ' ASP . . . . . 0.402 ' O ' HG23 ' A' ' 79' ' ' THR . 24.0 t70 -60.52 -38.51 84.65 Favored 'General case' 0 CA--C 1.519 -0.219 0 N-CA-C 108.959 -0.756 . . . . 0.0 108.959 178.506 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 76' ' ' TRP . . . . . . . . . . . . . 37.5 m0 -66.72 -30.86 71.2 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 115.438 -0.801 . . . . 0.0 110.468 179.193 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 77' ' ' ILE . . . . . 0.487 HD12 ' HA ' ' A' ' 74' ' ' ILE . 82.3 mt -68.58 -31.11 49.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-O 121.017 0.437 . . . . 0.0 110.554 179.241 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 34.4 mt -91.51 -17.55 25.51 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.11 -0.495 . . . . 0.0 112.137 -179.889 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 79' ' ' THR . . . . . 0.402 HG23 ' O ' ' A' ' 75' ' ' ASP . 72.7 p -102.32 -52.77 3.05 Favored 'General case' 0 N--CA 1.464 0.27 0 N-CA-C 113.417 0.895 . . . . 0.0 113.417 -178.238 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 80' ' ' THR . . . . . 0.695 ' HB ' ' HD3' ' A' ' 81' ' ' PRO . 49.8 m -52.39 -56.01 26.49 Favored Pre-proline 0 CA--C 1.532 0.251 0 N-CA-C 112.643 0.608 . . . . 0.0 112.643 -178.306 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 81' ' ' PRO . . . . . 0.695 ' HD3' ' HB ' ' A' ' 80' ' ' THR . 38.8 Cg_exo -58.98 -21.1 56.68 Favored 'Trans proline' 0 C--N 1.351 0.69 0 C-N-CA 121.507 1.471 . . . . 0.0 111.478 -179.942 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 82' ' ' LEU . . . . . . . . . . . . . 15.2 tp -77.03 -33.12 57.42 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 115.699 -0.682 . . . . 0.0 110.328 179.695 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 83' ' ' ILE . . . . . 0.427 HD11 HG21 ' A' ' 43' ' ' ILE . 49.1 mm -69.64 -51.86 37.36 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.166 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.232 179.25 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 84' ' ' VAL . . . . . 0.528 HG11 HD22 ' A' ' 105' ' ' ASN . 35.5 m -61.1 -31.05 48.99 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.227 0 N-CA-C 109.407 -0.59 . . . . 0.0 109.407 178.706 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 85' ' ' TYR . . . . . . . . . . . . . 89.9 t80 -64.43 -34.7 78.79 Favored 'General case' 0 N--CA 1.454 -0.269 0 CA-C-N 115.472 -0.786 . . . . 0.0 109.427 178.601 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 86' ' ' PHE . . . . . . . . . . . . . 12.0 t80 -62.97 -49.6 74.06 Favored 'General case' 0 C--O 1.232 0.146 0 CA-C-N 115.765 -0.652 . . . . 0.0 110.01 179.136 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 87' ' ' LEU . . . . . 0.562 HD12 HD22 ' A' ' 141' ' ' LEU . 5.3 mt -63.59 -33.06 74.78 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 115.733 -0.667 . . . . 0.0 109.852 179.839 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -66.67 -27.52 73.28 Favored Glycine 0 N--CA 1.449 -0.474 0 CA-C-N 115.377 -0.829 . . . . 0.0 111.555 179.251 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 61.9 mt -74.58 -43.78 54.02 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.763 0.316 . . . . 0.0 111.032 179.89 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 82.6 mt -60.47 -32.34 71.31 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.123 -0.489 . . . . 0.0 111.216 -179.94 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -83.83 -54.14 5.1 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.309 -0.405 . . . . 0.0 111.424 -179.732 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 103.93 68.32 0.76 Allowed Glycine 0 N--CA 1.45 -0.369 0 C-N-CA 120.808 -0.71 . . . . 0.0 112.491 -179.706 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 93' ' ' LEU . . . . . 0.577 HD23 ' HB3' ' A' ' 97' ' ' GLU . 6.5 mp -91.23 164.77 13.77 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.712 0.291 . . . . 0.0 110.733 -179.933 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 94' ' ' ASP . . . . . . . . . . . . . 1.8 p30 -87.82 177.43 7.0 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.356 -0.384 . . . . 0.0 110.915 179.807 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 48.1 t -60.39 -32.16 71.04 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.027 -0.533 . . . . 0.0 111.881 -179.418 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 38.8 mmt180 -73.31 -53.31 11.12 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.55 -0.295 . . . . 0.0 111.62 -179.332 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 97' ' ' GLU . . . . . 0.577 ' HB3' HD23 ' A' ' 93' ' ' LEU . 44.0 mt-10 -53.3 -47.25 69.38 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.314 -0.403 . . . . 0.0 111.388 -179.671 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 98' ' ' PHE . . . . . 0.45 ' O ' HG12 ' A' ' 102' ' ' ILE . 12.6 m-85 -58.29 -49.86 75.65 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.373 -0.376 . . . . 0.0 110.876 179.975 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -54.88 -30.45 53.18 Favored Glycine 0 CA--C 1.518 0.255 0 C-N-CA 120.751 -0.737 . . . . 0.0 112.776 -179.81 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 96.3 mt -73.95 -45.53 48.72 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.214 0 CA-C-O 120.841 0.353 . . . . 0.0 111.622 -179.708 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 47.6 t -65.95 -46.74 87.52 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.411 0 CA-C-N 116.147 -0.478 . . . . 0.0 111.91 -179.161 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 102' ' ' ILE . . . . . 0.45 HG12 ' O ' ' A' ' 98' ' ' PHE . 37.6 mm -63.17 -51.77 67.19 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 N-CA-C 111.905 0.335 . . . . 0.0 111.905 -179.101 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 15.2 t -55.95 -36.72 68.1 Favored 'General case' 0 C--O 1.234 0.248 0 CA-C-O 120.869 0.366 . . . . 0.0 110.952 -179.61 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 104' ' ' LEU . . . . . 0.49 ' O ' HG23 ' A' ' 108' ' ' VAL . 29.7 tp -61.37 -47.73 84.5 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.06 -0.518 . . . . 0.0 110.683 179.464 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 105' ' ' ASN . . . . . 0.528 HD22 HG11 ' A' ' 84' ' ' VAL . 3.5 m-20 -61.55 -26.33 67.87 Favored 'General case' 0 C--N 1.326 -0.438 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.745 179.848 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 66.2 m -66.46 -57.3 7.65 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 116.374 -0.375 . . . . 0.0 111.331 -179.926 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 107' ' ' VAL . . . . . 0.404 HG12 ' O ' ' A' ' 104' ' ' LEU . 9.1 p -58.27 -36.57 58.51 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.142 0 CA-C-O 120.727 0.298 . . . . 0.0 111.114 -179.881 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 108' ' ' VAL . . . . . 0.49 HG23 ' O ' ' A' ' 104' ' ' LEU . 68.3 t -57.84 -49.58 80.52 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.372 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.519 179.513 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 109' ' ' MET . . . . . 0.453 ' HG2' ' O ' ' A' ' 105' ' ' ASN . 20.6 mmt -64.35 -30.4 71.44 Favored 'General case' 0 CA--C 1.519 -0.248 0 CA-C-N 115.868 -0.605 . . . . 0.0 110.666 179.707 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 19.4 tp -66.34 -35.61 80.8 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.069 179.555 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -64.31 -51.38 63.76 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 115.903 -0.59 . . . . 0.0 110.601 179.462 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . -66.96 -37.33 92.07 Favored Glycine 0 C--N 1.331 0.262 0 C-N-CA 120.576 -0.821 . . . . 0.0 111.861 179.478 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 113' ' ' PHE . . . . . 0.424 ' HB2' ' O ' ' A' ' 109' ' ' MET . 1.0 OUTLIER -51.02 -70.03 0.1 Allowed 'General case' 0 C--N 1.332 -0.161 0 CA-C-O 121.05 0.452 . . . . 0.0 110.02 179.541 . . . . . . . . 3 3 . 1 . 030 nuclear build core ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -67.43 -19.89 65.43 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 115.663 -0.699 . . . . 0.0 110.748 179.407 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 115' ' ' GLY . . . . . 0.479 ' HA2' HD22 ' A' ' 126' ' ' LEU . . . -53.67 -44.43 69.09 Favored Glycine 0 C--N 1.334 0.441 0 C-N-CA 120.915 -0.659 . . . . 0.0 111.8 179.533 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -78.49 -28.46 46.4 Favored 'General case' 0 C--N 1.327 -0.41 0 N-CA-C 111.639 0.237 . . . . 0.0 111.639 179.741 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 117' ' ' MET . . . . . 0.582 ' HG3' HG11 ' A' ' 68' ' ' VAL . 62.9 mtt -86.08 11.37 11.89 Favored 'General case' 0 N--CA 1.463 0.224 0 N-CA-C 112.16 0.429 . . . . 0.0 112.16 -179.162 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 118' ' ' VAL . . . . . 0.495 HG21 ' HB3' ' A' ' 123' ' ' ARG . 29.9 m -63.64 146.06 96.99 Favored Pre-proline 0 C--N 1.327 -0.374 0 C-N-CA 121.037 -0.265 . . . . 0.0 111.081 179.845 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 119' ' ' PRO . . . . . . . . . . . . . 92.0 Cg_endo -81.99 -4.59 12.01 Favored 'Trans proline' 0 C--N 1.347 0.478 0 C-N-CA 122.534 2.156 . . . . 0.0 112.25 179.821 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -156.43 -132.1 1.46 Allowed Glycine 0 C--N 1.331 0.293 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.735 -179.982 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 2.0 pp -100.31 22.46 1.58 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-O 120.838 0.352 . . . . 0.0 111.265 -179.833 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 10.8 mm-40 -70.72 -19.27 62.76 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.846 179.942 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 123' ' ' ARG . . . . . 0.495 ' HB3' HG21 ' A' ' 118' ' ' VAL . 12.7 ptt180 -50.55 -31.0 14.42 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 115.923 -0.58 . . . . 0.0 111.907 -179.67 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 124' ' ' TYR . . . . . . . . . . . . . 40.2 m-85 -65.13 -35.61 81.65 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.675 0.274 . . . . 0.0 110.919 -179.629 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 125' ' ' ALA . . . . . . . . . . . . . . . -72.74 -51.08 20.64 Favored 'General case' 0 C--O 1.235 0.311 0 CA-C-O 120.849 0.357 . . . . 0.0 110.604 179.248 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 126' ' ' LEU . . . . . 0.479 HD22 ' HA2' ' A' ' 115' ' ' GLY . 7.0 mp -51.55 -52.39 47.52 Favored 'General case' 0 CA--C 1.52 -0.191 0 CA-C-N 116.005 -0.543 . . . . 0.0 110.135 179.488 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 127' ' ' PHE . . . . . 0.464 ' HZ ' ' HB3' ' A' ' 175' ' ' PRO . 8.7 t80 -63.93 -35.79 81.82 Favored 'General case' 0 N--CA 1.451 -0.419 0 CA-C-N 115.848 -0.615 . . . . 0.0 110.533 179.523 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 128' ' ' GLY . . . . . . . . . . . . . . . -46.22 -45.51 15.62 Favored Glycine 0 C--N 1.333 0.38 0 C-N-CA 120.195 -1.002 . . . . 0.0 110.86 179.027 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 129' ' ' MET . . . . . . . . . . . . . 0.6 OUTLIER -69.47 -39.36 77.76 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 115.319 -0.441 . . . . 0.0 109.977 178.586 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -65.15 -27.89 72.89 Favored Glycine 0 C--N 1.331 0.299 0 CA-C-N 115.783 -0.644 . . . . 0.0 112.995 -179.842 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -74.61 -54.01 8.27 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.615 0.245 . . . . 0.0 110.406 -179.964 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 47.2 t -55.83 -40.54 62.31 Favored 'Isoleucine or valine' 0 C--O 1.234 0.241 0 CA-C-O 121.459 0.647 . . . . 0.0 109.285 178.786 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -69.1 -37.8 78.61 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 115.117 -0.947 . . . . 0.0 110.613 179.41 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 134' ' ' PHE . . . . . 0.428 ' CZ ' ' HA ' ' A' ' 172' ' ' ALA . 45.3 t80 -55.45 -52.71 62.72 Favored 'General case' 0 N--CA 1.45 -0.429 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.263 179.748 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 135' ' ' ILE . . . . . . . . . . . . . 43.7 mt -59.58 -32.75 49.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 115.915 -0.584 . . . . 0.0 109.935 179.308 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . -59.43 -40.45 96.14 Favored Glycine 0 N--CA 1.448 -0.535 0 C-N-CA 120.298 -0.954 . . . . 0.0 111.45 178.926 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 137' ' ' LEU . . . . . . . . . . . . . 22.4 tp -65.87 -53.07 44.5 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-O 120.683 0.277 . . . . 0.0 110.616 179.617 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 138' ' ' VAL . . . . . . . . . . . . . 13.1 t -55.48 -37.48 45.39 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.836 0 CA-C-O 121.114 0.483 . . . . 0.0 110.131 179.183 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 139' ' ' TYR . . . . . . . . . . . . . 29.9 t80 -57.84 -43.22 85.71 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 115.43 -0.805 . . . . 0.0 110.738 179.024 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 28.7 m-85 -64.17 -41.6 97.07 Favored 'General case' 0 C--N 1.332 -0.156 0 CA-C-N 116.406 -0.361 . . . . 0.0 111.467 -179.978 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 141' ' ' LEU . . . . . 0.562 HD22 HD12 ' A' ' 87' ' ' LEU . 95.4 mt -56.24 -50.34 71.59 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 116.42 -0.355 . . . . 0.0 111.143 -179.761 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 142' ' ' VAL . . . . . 0.558 HG23 HH12 ' A' ' 164' ' ' ARG . 7.7 p -83.78 -9.02 11.48 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.369 0 CA-C-O 121.153 0.501 . . . . 0.0 110.59 179.956 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 143' ' ' GLY . . . . . 0.426 ' O ' HG22 ' A' ' 146' ' ' THR . . . -73.34 -141.18 0.5 Allowed Glycine 0 CA--C 1.521 0.452 0 C-N-CA 120.881 -0.676 . . . . 0.0 112.579 179.929 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 144' ' ' PRO . . . . . . . . . . . . . 52.2 Cg_exo -54.69 -23.24 32.09 Favored 'Trans proline' 0 C--N 1.349 0.564 0 C-N-CA 122.588 2.192 . . . . 0.0 112.75 179.971 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 145' ' ' MET . . . . . . . . . . . . . 37.2 mtt -52.81 -59.22 4.76 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.479 -0.328 . . . . 0.0 111.831 -179.641 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 146' ' ' THR . . . . . 0.426 HG22 ' O ' ' A' ' 143' ' ' GLY . 11.0 t -61.04 -31.71 71.35 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.423 -0.353 . . . . 0.0 111.588 -179.476 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 29.2 mm-40 -65.13 -44.0 90.11 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 120.839 0.352 . . . . 0.0 111.223 -179.942 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 148' ' ' SER . . . . . . . . . . . . . 80.0 p -70.24 -42.28 72.43 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.236 -179.32 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 149' ' ' ALA . . . . . . . . . . . . . . . -65.34 -40.42 93.62 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.377 -179.747 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 150' ' ' SER . . . . . 0.464 ' HA ' ' HB2' ' A' ' 157' ' ' LYS . 83.6 p -68.21 -6.8 25.51 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.784 -179.913 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 151' ' ' GLN . . . . . . . . . . . . . 63.3 mt-30 -110.48 -7.54 14.74 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.119 -0.492 . . . . 0.0 110.914 179.883 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 78.3 ttt180 -75.06 -52.47 10.96 Favored 'General case' 0 C--N 1.332 -0.193 0 CA-C-N 116.443 -0.344 . . . . 0.0 110.831 -179.883 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 153' ' ' SER . . . . . 0.643 ' HB3' HG12 ' A' ' 156' ' ' ILE . 22.8 t -158.04 170.62 21.88 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.667 179.238 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 154' ' ' SER . . . . . . . . . . . . . 51.3 m -70.22 -37.62 75.07 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.288 -0.415 . . . . 0.0 110.392 179.382 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -77.0 -39.0 28.88 Favored Glycine 0 CA--C 1.519 0.298 0 C-N-CA 120.984 -0.627 . . . . 0.0 112.674 179.821 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 156' ' ' ILE . . . . . 0.643 HG12 ' HB3' ' A' ' 153' ' ' SER . 39.6 mm -52.88 -35.65 22.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-O 120.922 0.392 . . . . 0.0 111.315 -179.81 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 157' ' ' LYS . . . . . 0.464 ' HB2' ' HA ' ' A' ' 150' ' ' SER . 86.4 tttt -69.83 -37.23 76.13 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 115.967 -0.561 . . . . 0.0 112.028 -179.436 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 67.6 p -72.05 -45.0 62.46 Favored 'General case' 0 C--N 1.331 -0.205 0 CA-C-O 120.784 0.326 . . . . 0.0 111.601 -178.719 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 159' ' ' LEU . . . . . . . . . . . . . 10.0 mt -67.05 -46.26 74.92 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.632 -179.078 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 160' ' ' TYR . . . . . . . . . . . . . 55.1 t80 -61.58 -37.82 85.27 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.509 -0.314 . . . . 0.0 111.26 -179.468 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 161' ' ' VAL . . . . . 0.515 HG12 ' N ' ' A' ' 162' ' ' ARG . 1.2 t -63.23 -50.49 78.86 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.747 0 CA-C-N 116.529 -0.305 . . . . 0.0 111.64 -179.487 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 162' ' ' ARG . . . . . 0.515 ' N ' HG12 ' A' ' 161' ' ' VAL . 22.9 tpp180 -69.1 -34.86 75.76 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.44 -0.345 . . . . 0.0 111.439 -179.446 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 163' ' ' LEU . . . . . 0.576 ' HG ' ' HB2' ' A' ' 208' ' ' PHE . 3.2 mp -69.5 -45.02 69.89 Favored 'General case' 0 C--N 1.328 -0.37 0 CA-C-N 116.27 -0.423 . . . . 0.0 111.604 -179.408 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 164' ' ' ARG . . . . . 0.558 HH12 HG23 ' A' ' 142' ' ' VAL . 0.1 OUTLIER -71.95 -41.07 68.23 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.557 -0.292 . . . . 0.0 111.308 -179.125 . . . . . . . . 3 3 . 1 . 030 nuclear build core ' A' A ' 165' ' ' ASN . . . . . 0.487 ' N ' ' HG3' ' A' ' 164' ' ' ARG . 5.7 m-20 -57.25 -50.88 71.49 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.795 0.331 . . . . 0.0 111.05 179.953 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 166' ' ' LEU . . . . . . . . . . . . . 3.8 tt -64.17 -54.59 31.32 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.109 -0.496 . . . . 0.0 111.548 -179.47 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 167' ' ' THR . . . . . 0.416 ' O ' ' HB2' ' A' ' 171' ' ' TRP . 76.5 m -54.81 -53.13 59.21 Favored 'General case' 0 C--N 1.33 -0.277 0 N-CA-C 112.263 0.468 . . . . 0.0 112.263 -179.158 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 168' ' ' VAL . . . . . . . . . . . . . 55.1 t -55.06 -44.93 76.45 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.218 0 N-CA-C 112.328 0.492 . . . . 0.0 112.328 -178.999 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 169' ' ' VAL . . . . . 0.48 HG23 ' O ' ' A' ' 165' ' ' ASN . 43.9 t -55.91 -64.32 0.5 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-O 120.555 0.217 . . . . 0.0 111.544 -179.362 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 170' ' ' LEU . . . . . 0.555 HD12 ' HD1' ' A' ' 171' ' ' TRP . 1.1 pp -63.41 -28.56 70.06 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.661 -0.245 . . . . 0.0 111.642 -179.39 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 171' ' ' TRP . . . . . 0.555 ' HD1' HD12 ' A' ' 170' ' ' LEU . 3.5 m0 -70.54 -32.11 69.43 Favored 'General case' 0 C--N 1.333 -0.152 0 CA-C-O 120.998 0.427 . . . . 0.0 110.413 179.418 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 172' ' ' ALA . . . . . 0.428 ' HA ' ' CZ ' ' A' ' 134' ' ' PHE . . . -72.19 -6.68 44.53 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-N 115.822 -0.626 . . . . 0.0 111.102 -179.624 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 173' ' ' ILE . . . . . 0.555 ' O ' HG12 ' A' ' 177' ' ' ILE . 23.8 mm -87.54 -22.57 6.82 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.244 0 CA-C-N 116.083 -0.508 . . . . 0.0 111.17 179.925 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 174' ' ' TYR . . . . . 0.465 ' HB2' ' HD3' ' A' ' 175' ' ' PRO . 30.9 m-85 -53.79 -49.25 90.25 Favored Pre-proline 0 N--CA 1.464 0.265 0 CA-C-N 116.567 -0.288 . . . . 0.0 111.638 -179.537 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 175' ' ' PRO . . . . . 0.465 ' HD3' ' HB2' ' A' ' 174' ' ' TYR . 86.5 Cg_exo -47.73 -32.97 17.83 Favored 'Trans proline' 0 C--N 1.351 0.677 0 C-N-CA 122.134 1.89 . . . . 0.0 112.164 179.523 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 176' ' ' PHE . . . . . 0.518 ' O ' ' HG ' ' A' ' 180' ' ' LEU . 88.2 m-85 -80.62 -50.36 10.06 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 115.911 -0.586 . . . . 0.0 112.18 -179.531 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 177' ' ' ILE . . . . . 0.555 HG12 ' O ' ' A' ' 173' ' ' ILE . 6.2 mm -60.22 -39.58 81.09 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.548 0 N-CA-C 112.609 0.596 . . . . 0.0 112.609 -177.777 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 178' ' ' TRP . . . . . 0.492 ' HH2' ' HB2' ' A' ' 123' ' ' ARG . 78.4 t90 -67.37 -39.3 85.68 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 120.721 0.296 . . . . 0.0 111.157 -179.669 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 179' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -77.88 -52.89 8.14 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 116.462 -0.335 . . . . 0.0 111.879 -179.01 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 180' ' ' LEU . . . . . 0.717 HD22 HD11 ' A' ' 187' ' ' LEU . 39.8 mt -61.66 -51.7 67.38 Favored 'General case' 0 C--N 1.328 -0.362 0 N-CA-C 111.699 0.259 . . . . 0.0 111.699 -179.114 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 181' ' ' GLY . . . . . 0.437 ' HA3' ' OD1' ' A' ' 193' ' ' ASP . . . -57.03 179.16 0.71 Allowed Glycine 0 C--N 1.336 0.557 0 C-N-CA 120.413 -0.898 . . . . 0.0 112.92 -179.883 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 182' ' ' PRO . . . . . 0.628 ' N ' ' HD2' ' A' ' 183' ' ' PRO . 80.8 Cg_exo -44.06 -46.56 11.04 Favored 'Trans proline' 0 C--N 1.35 0.654 0 C-N-CA 122.925 2.417 . . . . 0.0 113.915 179.865 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 183' ' ' PRO . . . . . 0.628 ' HD2' ' N ' ' A' ' 182' ' ' PRO . 1.0 OUTLIER -44.28 -30.44 3.61 Favored 'Trans proline' 0 C--N 1.358 1.062 0 C-N-CA 122.497 2.131 . . . . 0.0 113.172 -179.758 . . . . . . . . 3 3 . 1 . 030 nuclear build core ' A' A ' 184' ' ' GLY . . . . . 0.451 ' HA2' ' HD2' ' A' ' 123' ' ' ARG . . . -117.73 -120.75 3.08 Favored Glycine 0 C--N 1.332 0.326 0 C-N-CA 120.392 -0.908 . . . . 0.0 113.19 179.89 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 185' ' ' VAL . . . . . . . . . . . . . 22.6 m -64.92 -16.77 20.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 N-CA-C 112.264 0.468 . . . . 0.0 112.264 -179.405 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 186' ' ' ALA . . . . . 0.487 ' HB2' ' HA ' ' A' ' 182' ' ' PRO . . . 55.51 88.75 0.04 OUTLIER 'General case' 0 C--N 1.332 -0.17 0 CA-C-O 120.872 0.368 . . . . 0.0 111.266 -179.899 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 187' ' ' LEU . . . . . 0.717 HD11 HD22 ' A' ' 180' ' ' LEU . 19.5 mt -91.8 -33.06 15.12 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.391 -179.603 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 188' ' ' LEU . . . . . 0.58 HD13 ' N ' ' A' ' 188' ' ' LEU . 0.0 OUTLIER -134.27 -162.07 1.21 Allowed 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.868 0.366 . . . . 0.0 111.501 -179.494 . . . . . . . . 3 3 . 1 . 030 nuclear build core ' A' A ' 189' ' ' THR . . . . . . . . . . . . . 3.2 t -86.26 147.48 44.89 Favored Pre-proline 0 C--N 1.33 -0.24 0 CA-C-N 116.045 -0.525 . . . . 0.0 111.969 -178.873 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 190' ' ' PRO . . . . . . . . . . . . . 77.8 Cg_exo -51.02 -35.93 52.27 Favored 'Trans proline' 0 C--N 1.351 0.691 0 C-N-CA 122.581 2.187 . . . . 0.0 112.665 179.708 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 191' ' ' THR . . . . . . . . . . . . . 59.5 p -57.89 -40.8 81.17 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 121.052 0.453 . . . . 0.0 110.753 179.904 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 192' ' ' VAL . . . . . . . . . . . . . 41.4 t -74.96 -52.8 17.94 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-N 115.705 -0.679 . . . . 0.0 111.484 -179.871 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 193' ' ' ASP . . . . . 0.437 ' OD1' ' HA3' ' A' ' 181' ' ' GLY . 25.4 t70 -54.94 -51.93 64.59 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-N 116.31 -0.405 . . . . 0.0 111.142 -179.716 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 194' ' ' VAL . . . . . 0.549 ' O ' HG22 ' A' ' 198' ' ' VAL . 90.8 t -61.41 -36.96 76.45 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.357 0 CA-C-N 115.927 -0.579 . . . . 0.0 111.026 -179.832 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 195' ' ' ALA . . . . . 0.498 ' HA ' HD12 ' A' ' 7' ' ' LEU . . . -52.4 -48.58 65.58 Favored 'General case' 0 C--O 1.234 0.27 0 CA-C-O 120.91 0.386 . . . . 0.0 111.006 179.723 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 196' ' ' LEU . . . . . 0.5 ' O ' ' HB3' ' A' ' 199' ' ' TYR . 98.5 mt -68.3 -39.45 82.04 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 116.432 -0.349 . . . . 0.0 110.448 179.281 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 197' ' ' ILE . . . . . 0.417 HG13 ' NH2' ' A' ' 72' ' ' ARG . 15.5 mm -55.59 -60.36 1.79 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.358 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.178 179.92 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 198' ' ' VAL . . . . . 0.549 HG22 ' O ' ' A' ' 194' ' ' VAL . 3.3 m -52.19 -35.93 20.01 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.424 0 CA-C-O 121.359 0.6 . . . . 0.0 109.902 179.08 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 199' ' ' TYR . . . . . 0.5 ' HB3' ' O ' ' A' ' 196' ' ' LEU . 69.2 t80 -62.15 -47.02 86.41 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-N 115.062 -0.972 . . . . 0.0 110.095 179.224 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 200' ' ' LEU . . . . . 0.504 HD21 ' HB ' ' A' ' 173' ' ' ILE . 5.4 mp -55.78 -38.99 70.63 Favored 'General case' 0 N--CA 1.452 -0.367 0 CA-C-N 115.973 -0.558 . . . . 0.0 111.561 179.097 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 201' ' ' ASP . . . . . . . . . . . . . 16.0 m-20 -74.19 -41.88 60.73 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 121.063 0.458 . . . . 0.0 110.683 -179.974 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 202' ' ' LEU . . . . . 0.402 ' O ' ' HB ' ' A' ' 206' ' ' VAL . 2.2 mt -63.18 -33.33 75.24 Favored 'General case' 0 C--N 1.327 -0.413 0 CA-C-N 115.624 -0.716 . . . . 0.0 111.682 -179.851 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 203' ' ' VAL . . . . . 0.494 HG13 HD13 ' A' ' 170' ' ' LEU . 10.8 p -78.26 -36.29 20.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.815 -0.175 . . . . 0.0 111.329 -178.696 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 204' ' ' THR . . . . . 0.427 ' O ' ' CD1' ' A' ' 208' ' ' PHE . 55.4 m -62.47 -58.64 6.89 Favored 'General case' 0 C--N 1.328 -0.331 0 C-N-CA 120.454 -0.499 . . . . 0.0 111.315 179.761 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 205' ' ' LYS . . . . . 0.695 ' HE2' ' HB2' ' A' ' 47' ' ' ALA . 49.5 mttp -69.07 -58.18 4.43 Favored 'General case' 0 N--CA 1.464 0.241 0 N-CA-C 112.849 0.685 . . . . 0.0 112.849 -177.921 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 206' ' ' VAL . . . . . 0.402 ' HB ' ' O ' ' A' ' 202' ' ' LEU . 26.1 t -68.92 -36.34 73.58 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.444 0 CA-C-N 116.401 -0.363 . . . . 0.0 111.89 -178.706 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 207' ' ' GLY . . . . . 0.569 ' O ' HG13 ' A' ' 211' ' ' ILE . . . -61.66 -60.45 8.13 Favored Glycine 0 N--CA 1.452 -0.273 0 C-N-CA 120.698 -0.763 . . . . 0.0 113.672 -178.619 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 208' ' ' PHE . . . . . 0.576 ' HB2' ' HG ' ' A' ' 163' ' ' LEU . 0.1 OUTLIER -71.58 -25.96 62.41 Favored 'General case' 0 C--O 1.224 -0.258 0 CA-C-N 117.383 0.591 . . . . 0.0 111.319 -178.976 . . . . . . . . 3 3 . 1 . 030 nuclear build core ' A' A ' 209' ' ' GLY . . . . . 0.473 ' O ' ' HB3' ' A' ' 212' ' ' ALA . . . -68.55 -32.4 74.89 Favored Glycine 0 N--CA 1.449 -0.464 0 N-CA-C 111.676 -0.57 . . . . 0.0 111.676 179.077 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 210' ' ' PHE . . . . . . . . . . . . . 0.8 OUTLIER -72.87 -47.39 46.41 Favored 'General case' 0 CA--C 1.514 -0.421 0 N-CA-C 108.107 -1.072 . . . . 0.0 108.107 178.505 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 211' ' ' ILE . . . . . 0.569 HG13 ' O ' ' A' ' 207' ' ' GLY . 4.6 mt -64.85 -27.73 43.14 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.544 0 N-CA-C 107.629 -1.248 . . . . 0.0 107.629 176.677 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 212' ' ' ALA . . . . . 0.473 ' HB3' ' O ' ' A' ' 209' ' ' GLY . . . -63.86 -39.86 95.2 Favored 'General case' 0 N--CA 1.451 -0.412 0 CA-C-N 114.628 -1.169 . . . . 0.0 110.381 179.794 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 213' ' ' LEU . . . . . 0.406 ' HG ' ' O ' ' A' ' 209' ' ' GLY . 92.8 mt -69.72 -54.42 13.84 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 115.215 -0.902 . . . . 0.0 111.252 -179.596 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 214' ' ' ASP . . . . . . . . . . . . . 18.5 m-20 -56.57 -44.94 81.49 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.968 0.413 . . . . 0.0 110.933 -179.819 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 215' ' ' ALA . . . . . . . . . . . . . . . -61.0 -58.19 9.47 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.055 -0.52 . . . . 0.0 111.004 179.969 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 216' ' ' ALA . . . . . . . . . . . . . . . -55.53 -30.43 60.71 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.84 179.923 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 217' ' ' ALA . . . . . . . . . . . . . . . -61.36 -41.59 97.31 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 115.874 -0.603 . . . . 0.0 109.685 179.525 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 218' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER . . . . . 0 C--N 1.329 -0.293 0 CA-C-N 115.437 -0.801 . . . . 0.0 109.994 178.64 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 70.2 mtm . . . . . 0 N--CA 1.486 1.329 0 CA-C-O 120.723 0.297 . . . . 0.0 110.822 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 13.4 p -96.38 -29.65 3.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.268 -0.423 . . . . 0.0 110.931 179.927 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -90.73 -15.43 56.6 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.869 -0.682 . . . . 0.0 112.292 179.802 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 67.1 tp -72.58 -35.5 67.95 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.873 0.368 . . . . 0.0 110.833 179.967 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 74.5 p -56.38 -29.64 61.72 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 115.953 -0.567 . . . . 0.0 111.589 -179.8 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 47.5 p -52.2 -35.19 48.51 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.407 -0.36 . . . . 0.0 111.335 -179.617 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 7' ' ' LEU . . . . . . . . . . . . . 3.9 mm? -61.28 -53.02 62.12 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.312 -0.404 . . . . 0.0 111.347 -179.751 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 8' ' ' PHE . . . . . . . . . . . . . 74.7 m-85 -60.93 -32.6 72.1 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-O 121.003 0.43 . . . . 0.0 110.696 179.943 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 9' ' ' TRP . . . . . 0.407 ' O ' HG13 ' A' ' 13' ' ' ILE . 26.0 m95 -66.39 -48.65 69.4 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 115.93 -0.577 . . . . 0.0 110.077 -179.986 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 82.1 mt -57.94 -51.07 71.15 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 115.654 -0.703 . . . . 0.0 110.542 179.526 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -57.41 -35.17 70.65 Favored Glycine 0 N--CA 1.45 -0.411 0 C-N-CA 120.739 -0.743 . . . . 0.0 111.8 179.369 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -65.33 -30.82 71.7 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 120.863 0.363 . . . . 0.0 110.504 179.558 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 13' ' ' ILE . . . . . 0.407 HG13 ' O ' ' A' ' 9' ' ' TRP . 80.9 mt -66.89 -46.43 85.14 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.217 0 CA-C-N 116.062 -0.517 . . . . 0.0 110.075 179.353 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -61.84 -31.29 77.77 Favored Glycine 0 N--CA 1.45 -0.367 0 C-N-CA 120.653 -0.784 . . . . 0.0 111.862 179.329 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 15' ' ' MET . . . . . 0.533 ' HB3' ' HB2' ' A' ' 48' ' ' ALA . 0.0 OUTLIER -67.03 -46.89 73.08 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-O 120.848 0.356 . . . . 0.0 110.626 179.33 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -56.53 -40.45 75.08 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.033 -0.531 . . . . 0.0 110.483 179.547 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 84.4 t -60.36 -48.07 89.82 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.861 179.653 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -65.62 -47.27 78.73 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.775 -0.726 . . . . 0.0 112.439 179.816 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 25.2 m -49.44 -47.43 48.19 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-O 120.637 0.256 . . . . 0.0 111.433 -179.258 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 94.6 mt -71.63 -44.67 63.95 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.481 -0.327 . . . . 0.0 111.516 -179.914 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -55.14 -35.11 64.37 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.384 -0.371 . . . . 0.0 111.918 -179.436 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 22' ' ' PHE . . . . . 0.66 ' HB2' HG22 ' A' ' 41' ' ' VAL . 4.2 m-85 -91.07 -29.56 17.25 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.557 -0.292 . . . . 0.0 111.777 -179.207 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -70.31 -51.02 33.28 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.966 0.412 . . . . 0.0 111.524 -179.362 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 24' ' ' TRP . . . . . . . . . . . . . 5.8 t-105 -66.42 -50.01 64.85 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-N 115.881 -0.6 . . . . 0.0 110.999 -179.778 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -68.07 -25.4 65.33 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.49 -0.323 . . . . 0.0 111.002 179.989 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -72.76 -41.66 49.1 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.821 -0.704 . . . . 0.0 112.512 -179.969 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 96.5 mtt180 -65.94 -25.69 67.25 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.875 0.369 . . . . 0.0 110.725 179.799 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 19.5 t70 -82.92 -10.37 58.85 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 115.969 -0.56 . . . . 0.0 110.92 179.953 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -70.42 179.96 2.29 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.176 -0.465 . . . . 0.0 111.308 -179.813 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -96.96 -157.17 30.94 Favored Glycine 0 N--CA 1.451 -0.359 0 C-N-CA 120.914 -0.66 . . . . 0.0 112.242 179.953 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 37.1 t -95.22 120.05 34.77 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.781 0.324 . . . . 0.0 110.738 179.82 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 125.18 -49.52 0.91 Allowed Glycine 0 N--CA 1.452 -0.278 0 C-N-CA 120.902 -0.666 . . . . 0.0 112.291 -179.647 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 38.6 mt-10 -69.99 -20.66 63.28 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.779 0.323 . . . . 0.0 110.645 179.776 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 34' ' ' ARG . . . . . . . . . . . . . 99.8 mtt180 -49.09 -29.09 4.74 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 115.862 -0.608 . . . . 0.0 111.535 -179.862 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 21.4 mmm180 -64.3 -46.98 81.26 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-O 120.783 0.325 . . . . 0.0 111.041 179.905 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 90.2 m-85 -69.2 -32.01 71.01 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.162 179.875 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 37' ' ' TYR . . . . . 0.477 ' O ' HG23 ' A' ' 41' ' ' VAL . 43.4 m-85 -71.97 -54.75 8.99 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.085 -0.507 . . . . 0.0 111.41 -179.485 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 14.6 p -56.76 -36.34 48.91 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-O 120.972 0.415 . . . . 0.0 110.441 -179.995 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 40.9 m -64.85 -50.19 67.6 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 115.758 -0.655 . . . . 0.0 110.41 179.219 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 40' ' ' LEU . . . . . 0.654 HD12 HD11 ' A' ' 43' ' ' ILE . 57.7 tp -61.0 -38.28 85.47 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 115.573 -0.739 . . . . 0.0 110.657 179.741 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 41' ' ' VAL . . . . . 0.66 HG22 ' HB2' ' A' ' 22' ' ' PHE . 95.8 t -69.48 -34.0 59.9 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.453 0 CA-C-N 115.932 -0.576 . . . . 0.0 109.975 179.011 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -61.22 -42.31 99.75 Favored Glycine 0 N--CA 1.449 -0.483 0 CA-C-N 115.615 -0.721 . . . . 0.0 112.892 179.905 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 43' ' ' ILE . . . . . 0.654 HD11 HD12 ' A' ' 40' ' ' LEU . 38.9 pt -70.03 -44.0 78.74 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.153 0 CA-C-N 116.952 0.376 . . . . 0.0 111.31 -179.786 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 44' ' ' SER . . . . . 0.458 ' N ' HG13 ' A' ' 43' ' ' ILE . 38.7 t -66.29 -25.98 67.11 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-O 120.985 0.421 . . . . 0.0 110.713 179.461 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -79.85 -52.69 4.56 Favored Glycine 0 C--N 1.33 0.233 0 C-N-CA 121.033 -0.603 . . . . 0.0 112.907 -179.295 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 46' ' ' ILE . . . . . 0.462 ' O ' HG22 ' A' ' 49' ' ' VAL . 15.3 pt -57.88 -36.95 57.79 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.248 0 CA-C-O 121.148 0.499 . . . . 0.0 110.33 179.978 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 47' ' ' ALA . . . . . 0.757 ' HB2' ' HE2' ' A' ' 205' ' ' LYS . . . -68.2 -42.05 80.45 Favored 'General case' 0 C--N 1.326 -0.45 0 CA-C-N 115.81 -0.632 . . . . 0.0 110.78 178.716 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 48' ' ' ALA . . . . . 0.533 ' HB2' ' HB3' ' A' ' 15' ' ' MET . . . -54.48 -42.66 70.99 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 115.881 -0.599 . . . . 0.0 112.038 -179.451 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 49' ' ' VAL . . . . . 0.462 HG22 ' O ' ' A' ' 46' ' ' ILE . 31.0 m -73.42 -36.24 47.93 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.24 0 N-CA-C 111.606 0.224 . . . . 0.0 111.606 -179.437 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -62.49 -40.39 96.54 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-O 121.001 0.429 . . . . 0.0 111.285 179.792 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 4.2 m-85 -70.58 -40.2 73.42 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-N 115.997 -0.547 . . . . 0.0 110.726 -179.613 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -63.13 -42.26 99.47 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 115.882 -0.599 . . . . 0.0 111.459 179.999 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 53' ' ' VAL . . . . . 0.535 ' O ' HG22 ' A' ' 58' ' ' VAL . 33.0 m -70.28 -49.71 52.22 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.209 0 CA-C-N 116.71 -0.223 . . . . 0.0 111.057 -179.865 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 54' ' ' MET . . . . . 0.492 ' N ' HG23 ' A' ' 53' ' ' VAL . 73.1 mtm -60.75 -32.29 71.59 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-O 121.099 0.476 . . . . 0.0 109.916 179.429 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -63.26 -22.9 67.16 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 115.552 -0.749 . . . . 0.0 111.283 179.677 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 80.2 mt -89.1 -14.35 36.45 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.459 -0.337 . . . . 0.0 111.033 -179.906 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 102.53 -2.99 49.77 Favored Glycine 0 C--N 1.33 0.248 0 C-N-CA 120.689 -0.767 . . . . 0.0 113.352 179.371 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 58' ' ' VAL . . . . . 0.535 HG22 ' O ' ' A' ' 53' ' ' VAL . 15.8 m -78.63 154.25 4.97 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.166 0 CA-C-N 116.981 0.39 . . . . 0.0 111.145 -179.901 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 59' ' ' GLY . . . . . 0.438 ' HA3' ' CG ' ' A' ' 71' ' ' PRO . . . 80.69 -2.39 79.3 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.89 -0.671 . . . . 0.0 112.859 -179.943 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 60' ' ' TRP . . . . . . . . . . . . . 23.2 m0 -78.28 121.49 24.49 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 120.724 0.297 . . . . 0.0 110.503 179.718 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 7.3 p -112.8 132.25 22.37 Favored Pre-proline 0 CA--C 1.533 0.29 0 CA-C-N 116.416 -0.356 . . . . 0.0 111.343 -179.796 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 72.0 Cg_endo -77.45 145.56 23.78 Favored 'Trans proline' 0 C--N 1.35 0.638 0 C-N-CA 122.51 2.14 . . . . 0.0 112.512 179.941 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 96.6 t -142.65 94.08 0.54 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 115.872 -0.604 . . . . 0.0 110.926 -179.94 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . 57.67 -89.55 0.02 OUTLIER 'General case' 0 C--N 1.332 -0.178 0 CA-C-N 116.13 -0.486 . . . . 0.0 111.418 179.96 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 12.8 pt-20 -119.79 -19.93 7.79 Favored 'General case' 0 C--O 1.233 0.204 0 CA-C-O 120.806 0.336 . . . . 0.0 110.872 -179.987 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 66' ' ' ARG . . . . . 0.496 HH22 ' HA ' ' A' ' 183' ' ' PRO . 13.1 ptm180 -101.93 166.29 10.72 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.385 179.83 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 35.3 m -125.72 123.89 39.85 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-O 120.975 0.417 . . . . 0.0 111.462 -179.725 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 23.4 t -101.29 147.16 8.54 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.221 0 CA-C-N 115.88 -0.6 . . . . 0.0 110.284 179.41 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 69' ' ' PHE . . . . . . . . . . . . . 46.8 m-85 -106.94 112.41 25.36 Favored 'General case' 0 C--N 1.328 -0.329 0 N-CA-C 110.03 -0.359 . . . . 0.0 110.03 -179.363 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 70' ' ' VAL . . . . . 0.523 ' HB ' ' HD3' ' A' ' 71' ' ' PRO . 21.7 t -68.96 -49.89 24.04 Favored Pre-proline 0 C--N 1.327 -0.408 0 N-CA-C 112.455 0.539 . . . . 0.0 112.455 -178.891 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 71' ' ' PRO . . . . . 0.523 ' HD3' ' HB ' ' A' ' 70' ' ' VAL . 31.8 Cg_exo -58.55 -25.97 76.68 Favored 'Trans proline' 0 C--N 1.35 0.627 0 C-N-CA 121.983 1.788 . . . . 0.0 112.174 179.97 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 72' ' ' ARG . . . . . 0.406 ' HB2' ' SD ' ' A' ' 54' ' ' MET . 46.3 ttp180 -72.52 -53.27 12.52 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.975 0.417 . . . . 0.0 110.665 179.932 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 73' ' ' TYR . . . . . 0.409 ' O ' HG13 ' A' ' 77' ' ' ILE . 23.0 m-85 -65.2 -38.07 89.29 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 115.831 -0.622 . . . . 0.0 110.694 179.934 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 74' ' ' ILE . . . . . 0.444 ' O ' HD13 ' A' ' 74' ' ' ILE . 0.4 OUTLIER -70.32 -37.62 71.6 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 N-CA-C 110.008 -0.367 . . . . 0.0 110.008 179.583 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 75' ' ' ASP . . . . . 0.457 ' O ' HG23 ' A' ' 79' ' ' THR . 31.2 t70 -57.24 -38.61 74.06 Favored 'General case' 0 CA--C 1.521 -0.138 0 N-CA-C 109.453 -0.573 . . . . 0.0 109.453 178.991 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 76' ' ' TRP . . . . . . . . . . . . . 45.4 m0 -66.8 -39.72 87.85 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 115.553 -0.749 . . . . 0.0 110.27 179.375 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 77' ' ' ILE . . . . . 0.428 HD12 ' HA ' ' A' ' 74' ' ' ILE . 89.3 mt -60.49 -28.93 43.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 115.953 -0.567 . . . . 0.0 110.788 179.551 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 43.1 mt -91.97 -29.19 16.77 Favored 'General case' 0 C--N 1.33 -0.255 0 N-CA-C 112.275 0.472 . . . . 0.0 112.275 179.96 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 79' ' ' THR . . . . . 0.457 HG23 ' O ' ' A' ' 75' ' ' ASP . 66.8 p -89.38 -52.09 5.22 Favored 'General case' 0 N--CA 1.464 0.27 0 N-CA-C 113.506 0.928 . . . . 0.0 113.506 -177.725 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 80' ' ' THR . . . . . 0.447 ' N ' ' HD2' ' A' ' 81' ' ' PRO . 86.1 m -47.3 -55.03 17.47 Favored Pre-proline 0 C--N 1.328 -0.34 0 N-CA-C 112.773 0.657 . . . . 0.0 112.773 -178.683 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 81' ' ' PRO . . . . . 0.447 ' HD2' ' N ' ' A' ' 80' ' ' THR . 36.1 Cg_endo -63.2 -20.82 71.7 Favored 'Trans proline' 0 C--N 1.351 0.69 0 C-N-CA 121.55 1.5 . . . . 0.0 111.06 179.997 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 82' ' ' LEU . . . . . 0.435 ' HB3' HG22 ' A' ' 43' ' ' ILE . 0.1 OUTLIER -76.2 -34.8 59.29 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 115.364 -0.834 . . . . 0.0 109.94 179.558 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 47.9 mm -69.25 -52.74 30.28 Favored 'Isoleucine or valine' 0 CA--C 1.522 -0.126 0 CA-C-N 115.849 -0.614 . . . . 0.0 110.205 179.429 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 84' ' ' VAL . . . . . 0.429 HG22 ' HA ' ' A' ' 81' ' ' PRO . 27.7 m -59.64 -31.16 46.38 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.215 0 N-CA-C 109.614 -0.513 . . . . 0.0 109.614 178.912 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 85' ' ' TYR . . . . . . . . . . . . . 85.2 t80 -63.69 -36.54 84.19 Favored 'General case' 0 N--CA 1.454 -0.246 0 CA-C-N 115.657 -0.701 . . . . 0.0 109.188 178.457 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 86' ' ' PHE . . . . . . . . . . . . . 8.0 t80 -61.42 -44.87 96.38 Favored 'General case' 0 C--O 1.231 0.121 0 CA-C-N 115.636 -0.711 . . . . 0.0 109.457 178.87 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 3.7 mm? -61.66 -34.11 75.14 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 115.453 -0.794 . . . . 0.0 110.153 179.177 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 88' ' ' GLY . . . . . 0.516 ' HA2' HD13 ' A' ' 93' ' ' LEU . . . -69.08 -29.45 72.28 Favored Glycine 0 N--CA 1.449 -0.462 0 C-N-CA 120.812 -0.709 . . . . 0.0 112.252 179.695 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 95.9 mt -71.66 -39.48 70.29 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 121.028 0.442 . . . . 0.0 110.362 179.69 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 42.8 mt -61.14 -59.73 4.88 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 115.796 -0.638 . . . . 0.0 110.872 179.782 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 91' ' ' ALA . . . . . 0.493 ' HB2' ' HB2' ' A' ' 149' ' ' ALA . . . -70.25 -54.79 11.22 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.081 -0.509 . . . . 0.0 111.339 -179.833 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 98.85 68.77 0.91 Allowed Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.787 -0.72 . . . . 0.0 112.212 -179.861 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 93' ' ' LEU . . . . . 0.552 HD23 ' HB3' ' A' ' 97' ' ' GLU . 8.1 mp -72.0 -174.35 1.21 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.775 0.322 . . . . 0.0 110.945 -179.824 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 94' ' ' ASP . . . . . 0.452 ' HB3' ' OE2' ' A' ' 97' ' ' GLU . 10.2 t70 -97.28 -177.12 3.73 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.868 -179.73 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 77.9 p -65.58 -45.34 83.62 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.574 -179.369 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 36.2 mtp180 -74.14 -39.48 63.27 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-O 121.246 0.546 . . . . 0.0 110.438 -179.657 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 97' ' ' GLU . . . . . 0.552 ' HB3' HD23 ' A' ' 93' ' ' LEU . 0.3 OUTLIER -58.01 -44.68 87.38 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-N 115.457 -0.792 . . . . 0.0 111.039 -179.826 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 98' ' ' PHE . . . . . 0.441 ' O ' HG12 ' A' ' 102' ' ' ILE . 2.2 m-85 -61.52 -35.47 77.82 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.956 0.408 . . . . 0.0 110.502 179.543 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -70.08 -25.97 74.91 Favored Glycine 0 N--CA 1.451 -0.359 0 C-N-CA 120.7 -0.762 . . . . 0.0 112.144 179.795 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 96.4 mt -73.17 -43.71 57.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 N-CA-C 111.841 0.311 . . . . 0.0 111.841 -179.819 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 25.7 m -69.45 -39.16 78.33 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-O 120.676 0.275 . . . . 0.0 111.716 -179.389 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 102' ' ' ILE . . . . . 0.441 HG12 ' O ' ' A' ' 98' ' ' PHE . 42.0 mm -73.65 -41.0 55.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.582 -0.281 . . . . 0.0 111.621 -179.435 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 13.9 t -63.76 -35.97 82.34 Favored 'General case' 0 C--N 1.332 -0.153 0 CA-C-O 120.775 0.322 . . . . 0.0 110.884 -179.948 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 104' ' ' LEU . . . . . 0.439 ' O ' HG23 ' A' ' 108' ' ' VAL . 56.5 tp -67.52 -43.77 79.99 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.288 179.766 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 105' ' ' ASN . . . . . 0.529 ' N ' HD22 ' A' ' 105' ' ' ASN . 0.9 OUTLIER -62.72 -27.3 69.17 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.532 179.57 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 91.9 m -69.4 -52.15 29.77 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.054 -0.521 . . . . 0.0 111.502 -179.912 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 107' ' ' VAL . . . . . 0.444 HG22 ' HE2' ' A' ' 129' ' ' MET . 7.5 p -66.09 -36.35 77.23 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.214 0 CA-C-N 116.38 -0.373 . . . . 0.0 111.226 -179.976 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 108' ' ' VAL . . . . . 0.439 HG23 ' O ' ' A' ' 104' ' ' LEU . 51.0 t -62.85 -54.68 30.57 Favored 'Isoleucine or valine' 0 C--O 1.234 0.281 0 CA-C-N 116.294 -0.412 . . . . 0.0 110.866 179.746 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 109' ' ' MET . . . . . . . . . . . . . 5.6 tpp -61.66 -26.82 68.26 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.049 -0.523 . . . . 0.0 110.383 179.897 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 29.7 tp -73.05 -31.98 64.77 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.062 -0.517 . . . . 0.0 110.226 179.487 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -64.31 -51.17 64.79 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 115.926 -0.579 . . . . 0.0 110.284 179.225 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 112' ' ' GLY . . . . . 0.629 ' HA3' ' H21' ' A' ' 301' ' ' RET . . . -62.76 -44.26 97.75 Favored Glycine 0 CA--C 1.518 0.248 0 C-N-CA 120.796 -0.716 . . . . 0.0 112.42 179.539 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 113' ' ' PHE . . . . . 0.455 ' HZ ' HG13 ' A' ' 70' ' ' VAL . 0.8 OUTLIER -47.98 -61.01 2.18 Favored 'General case' 0 C--N 1.333 -0.141 0 CA-C-O 120.911 0.386 . . . . 0.0 110.397 179.592 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -69.83 -18.25 63.44 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.025 -0.534 . . . . 0.0 110.797 179.918 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -57.14 -49.06 74.98 Favored Glycine 0 C--N 1.333 0.389 0 C-N-CA 120.79 -0.719 . . . . 0.0 111.9 179.375 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -78.55 -15.51 58.48 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-O 120.782 0.325 . . . . 0.0 111.376 179.817 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 117' ' ' MET . . . . . . . . . . . . . 23.1 mmt -88.22 19.18 3.85 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 116.384 -0.371 . . . . 0.0 111.612 -179.553 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 35.7 m -84.64 141.62 38.97 Favored Pre-proline 0 C--N 1.329 -0.315 0 CA-C-O 120.57 0.224 . . . . 0.0 111.285 -179.846 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 119' ' ' PRO . . . . . . . . . . . . . 93.4 Cg_endo -87.07 -2.43 7.98 Favored 'Trans proline' 0 N--CA 1.459 -0.513 0 C-N-CA 122.77 2.314 . . . . 0.0 112.36 179.797 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -144.12 -110.05 0.7 Allowed Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.789 -0.72 . . . . 0.0 112.684 -179.911 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 42.9 pt -133.29 11.8 1.42 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.23 0 CA-C-O 120.681 0.277 . . . . 0.0 111.468 -179.646 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 46.9 mt-10 -59.24 -18.23 35.17 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.344 -0.389 . . . . 0.0 111.015 179.912 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 123' ' ' ARG . . . . . 0.524 ' HA ' HD13 ' A' ' 126' ' ' LEU . 11.1 ptt180 -50.45 -37.15 36.71 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.05 -0.523 . . . . 0.0 111.946 -179.661 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 124' ' ' TYR . . . . . . . . . . . . . 28.4 m-85 -51.19 -35.54 36.85 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.844 0.354 . . . . 0.0 111.171 -179.828 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 125' ' ' ALA . . . . . . . . . . . . . . . -74.8 -49.65 20.03 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.141 -0.481 . . . . 0.0 111.008 179.878 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 126' ' ' LEU . . . . . 0.524 HD13 ' HA ' ' A' ' 123' ' ' ARG . 6.5 mp -52.51 -55.67 20.48 Favored 'General case' 0 C--N 1.332 -0.182 0 CA-C-N 115.999 -0.546 . . . . 0.0 110.327 179.964 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 127' ' ' PHE . . . . . 0.427 ' CE1' ' H42' ' A' ' 301' ' ' RET . 10.9 t80 -64.51 -28.84 69.93 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 115.909 -0.587 . . . . 0.0 110.155 179.45 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 128' ' ' GLY . . . . . . . . . . . . . . . -49.16 -48.53 32.16 Favored Glycine 0 N--CA 1.449 -0.451 0 C-N-CA 120.121 -1.038 . . . . 0.0 110.593 178.79 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 129' ' ' MET . . . . . 0.445 ' HE3' ' HA2' ' A' ' 130' ' ' GLY . 0.0 OUTLIER -72.29 -31.72 65.98 Favored 'General case' 0 N--CA 1.452 -0.365 0 N-CA-C 109.079 -0.712 . . . . 0.0 109.079 178.467 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 130' ' ' GLY . . . . . 0.445 ' HA2' ' HE3' ' A' ' 129' ' ' MET . . . -61.52 -33.18 83.89 Favored Glycine 0 C--N 1.333 0.411 0 CA-C-N 115.749 -0.66 . . . . 0.0 112.035 179.458 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 131' ' ' ALA . . . . . 0.42 ' O ' ' HB3' ' A' ' 134' ' ' PHE . . . -74.8 -53.35 9.31 Favored 'General case' 0 N--CA 1.452 -0.326 0 CA-C-O 120.743 0.306 . . . . 0.0 110.362 179.648 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 40.8 t -55.15 -49.0 75.59 Favored 'Isoleucine or valine' 0 C--O 1.234 0.253 0 N-CA-C 109.462 -0.57 . . . . 0.0 109.462 178.783 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -59.68 -39.13 83.49 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 115.504 -0.771 . . . . 0.0 110.323 178.589 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 134' ' ' PHE . . . . . 0.459 ' CZ ' ' HA ' ' A' ' 172' ' ' ALA . 65.4 t80 -55.1 -51.13 67.37 Favored 'General case' 0 N--CA 1.451 -0.388 0 CA-C-N 115.892 -0.594 . . . . 0.0 110.367 179.68 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 135' ' ' ILE . . . . . 0.475 ' O ' HG22 ' A' ' 138' ' ' VAL . 60.2 mt -56.15 -32.05 33.31 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.238 0 CA-C-N 115.946 -0.57 . . . . 0.0 110.112 179.24 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 136' ' ' GLY . . . . . 0.402 ' O ' ' HB3' ' A' ' 139' ' ' TYR . . . -61.67 -41.24 99.56 Favored Glycine 0 N--CA 1.447 -0.598 0 C-N-CA 120.16 -1.019 . . . . 0.0 111.343 178.69 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 137' ' ' LEU . . . . . . . . . . . . . 30.0 tp -69.57 -50.71 42.08 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 115.846 -0.177 . . . . 0.0 111.09 179.935 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 138' ' ' VAL . . . . . 0.591 ' HA ' HD12 ' A' ' 141' ' ' LEU . 5.2 m -55.96 -32.62 33.53 Favored 'Isoleucine or valine' 0 C--O 1.234 0.245 0 CA-C-O 121.31 0.576 . . . . 0.0 109.754 179.478 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 139' ' ' TYR . . . . . 0.405 ' O ' ' N ' ' A' ' 143' ' ' GLY . 65.9 t80 -60.09 -48.09 83.16 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 115.353 -0.839 . . . . 0.0 109.412 178.511 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 37.0 m-85 -58.95 -35.5 73.23 Favored 'General case' 0 C--N 1.332 -0.169 0 CA-C-N 115.938 -0.573 . . . . 0.0 110.576 179.096 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 141' ' ' LEU . . . . . 0.591 HD12 ' HA ' ' A' ' 138' ' ' VAL . 95.6 mt -55.56 -46.74 77.13 Favored 'General case' 0 C--N 1.332 -0.174 0 CA-C-N 116.322 -0.399 . . . . 0.0 110.27 179.504 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 142' ' ' VAL . . . . . 0.405 HG22 ' O ' ' A' ' 142' ' ' VAL . 9.2 p -105.39 15.04 7.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 115.926 -0.579 . . . . 0.0 110.828 179.752 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 143' ' ' GLY . . . . . 0.405 ' N ' ' O ' ' A' ' 139' ' ' TYR . . . -90.86 -130.66 4.68 Favored Glycine 0 CA--C 1.52 0.393 0 C-N-CA 120.913 -0.661 . . . . 0.0 112.9 -179.627 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 144' ' ' PRO . . . . . . . . . . . . . 45.3 Cg_exo -57.23 -25.44 64.66 Favored 'Trans proline' 0 C--N 1.351 0.686 0 C-N-CA 122.585 2.19 . . . . 0.0 112.726 -179.632 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 145' ' ' MET . . . . . . . . . . . . . 60.6 mtt -56.76 -25.13 54.44 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.355 -0.384 . . . . 0.0 111.134 -179.896 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 146' ' ' THR . . . . . . . . . . . . . 78.1 p -63.83 -51.2 65.77 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.112 -0.495 . . . . 0.0 111.685 -179.786 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 43.6 mt-10 -75.56 -28.64 59.09 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.371 -0.377 . . . . 0.0 111.62 -179.252 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 148' ' ' SER . . . . . . . . . . . . . 36.8 t -70.53 -44.66 67.09 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.743 0.306 . . . . 0.0 111.208 -179.469 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 149' ' ' ALA . . . . . 0.493 ' HB2' ' HB2' ' A' ' 91' ' ' ALA . . . -77.92 -42.99 31.28 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.324 -0.398 . . . . 0.0 111.923 -179.53 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 150' ' ' SER . . . . . 0.586 ' HA ' ' HG2' ' A' ' 157' ' ' LYS . 47.5 t -63.65 -8.0 8.89 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.548 -179.504 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 151' ' ' GLN . . . . . . . . . . . . . 47.5 mt-30 -125.54 17.34 8.18 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.668 0.271 . . . . 0.0 111.279 -179.955 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 152' ' ' ARG . . . . . 0.6 ' HD2' HG13 ' A' ' 156' ' ' ILE . 3.6 tmt_? -93.24 -51.81 4.84 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-O 120.967 0.413 . . . . 0.0 110.509 179.782 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 153' ' ' SER . . . . . 0.679 ' HB3' HG12 ' A' ' 156' ' ' ILE . 20.0 t -157.42 172.41 18.63 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 115.904 -0.589 . . . . 0.0 110.451 179.304 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 154' ' ' SER . . . . . . . . . . . . . 79.0 p -71.62 -42.18 67.95 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.278 -0.419 . . . . 0.0 111.006 179.744 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -76.87 -25.72 64.04 Favored Glycine 0 C--N 1.331 0.265 0 C-N-CA 120.834 -0.698 . . . . 0.0 113.093 -179.669 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 156' ' ' ILE . . . . . 0.679 HG12 ' HB3' ' A' ' 153' ' ' SER . 27.7 mm -57.89 -38.48 66.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-O 120.551 0.215 . . . . 0.0 111.519 -179.718 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 157' ' ' LYS . . . . . 0.586 ' HG2' ' HA ' ' A' ' 150' ' ' SER . 35.8 mtmm -56.72 -39.91 74.77 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-O 120.806 0.336 . . . . 0.0 111.214 179.908 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 43.7 t -70.95 -48.1 55.28 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.569 -179.315 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 159' ' ' LEU . . . . . 0.458 ' O ' ' HB2' ' A' ' 163' ' ' LEU . 9.9 mt -68.18 -28.89 67.67 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 116.482 -0.326 . . . . 0.0 111.65 -179.609 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 160' ' ' TYR . . . . . . . . . . . . . 83.8 t80 -73.95 -45.91 47.41 Favored 'General case' 0 C--N 1.326 -0.429 0 N-CA-C 112.061 0.393 . . . . 0.0 112.061 -178.941 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 161' ' ' VAL . . . . . 0.426 HG23 ' N ' ' A' ' 162' ' ' ARG . 30.9 m -66.57 -43.89 90.34 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.419 0 N-CA-C 112.169 0.433 . . . . 0.0 112.169 -179.007 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 162' ' ' ARG . . . . . 0.426 ' N ' HG23 ' A' ' 161' ' ' VAL . 35.3 mmt180 -68.68 -41.69 78.86 Favored 'General case' 0 C--N 1.328 -0.349 0 N-CA-C 111.884 0.327 . . . . 0.0 111.884 -178.906 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 163' ' ' LEU . . . . . 0.609 ' HG ' ' HB2' ' A' ' 208' ' ' PHE . 7.7 mp -73.79 -50.06 22.38 Favored 'General case' 0 C--N 1.329 -0.326 0 N-CA-C 112.015 0.376 . . . . 0.0 112.015 -179.182 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 164' ' ' ARG . . . . . 0.465 ' HG2' ' HB3' ' A' ' 141' ' ' LEU . 6.4 tmm_? -59.45 -50.12 75.18 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.624 -0.262 . . . . 0.0 111.577 -179.139 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 165' ' ' ASN . . . . . 0.548 ' O ' HG23 ' A' ' 169' ' ' VAL . 3.9 m-20 -61.29 -51.41 69.02 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.45 -0.341 . . . . 0.0 111.524 -179.464 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 166' ' ' LEU . . . . . 0.482 ' O ' ' HG ' ' A' ' 170' ' ' LEU . 4.9 tt -60.76 -54.85 40.22 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.457 -0.338 . . . . 0.0 111.865 -179.198 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 167' ' ' THR . . . . . 0.411 ' O ' ' HB2' ' A' ' 171' ' ' TRP . 64.5 m -55.17 -54.22 45.98 Favored 'General case' 0 C--N 1.329 -0.292 0 N-CA-C 112.898 0.703 . . . . 0.0 112.898 -178.585 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 168' ' ' VAL . . . . . 0.438 ' HB ' HD13 ' A' ' 141' ' ' LEU . 9.9 p -55.1 -40.51 55.12 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.195 0 N-CA-C 112.418 0.525 . . . . 0.0 112.418 -178.924 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 169' ' ' VAL . . . . . 0.548 HG23 ' O ' ' A' ' 165' ' ' ASN . 58.5 t -60.47 -65.11 0.5 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 N-CA-C 111.874 0.324 . . . . 0.0 111.874 -179.159 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 170' ' ' LEU . . . . . 0.482 ' HG ' ' O ' ' A' ' 166' ' ' LEU . 1.0 OUTLIER -61.3 -29.2 69.72 Favored 'General case' 0 C--N 1.329 -0.283 0 C-N-CA 121.166 -0.213 . . . . 0.0 111.41 -179.273 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 171' ' ' TRP . . . . . 0.766 ' HE1' H203 ' A' ' 301' ' ' RET . 2.8 m0 -71.03 -35.3 71.93 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-O 120.934 0.397 . . . . 0.0 110.038 178.983 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 172' ' ' ALA . . . . . 0.459 ' HA ' ' CZ ' ' A' ' 134' ' ' PHE . . . -68.32 -6.61 25.09 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 115.872 -0.604 . . . . 0.0 110.62 179.572 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 173' ' ' ILE . . . . . 0.509 HG22 HD11 ' A' ' 177' ' ' ILE . 40.4 mm -85.9 -22.19 7.39 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 115.873 -0.603 . . . . 0.0 110.798 179.515 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 174' ' ' TYR . . . . . 0.59 ' N ' ' HD2' ' A' ' 175' ' ' PRO . 12.9 m-85 -54.22 -50.81 82.57 Favored Pre-proline 0 CA--C 1.533 0.299 0 CA-C-N 116.159 -0.473 . . . . 0.0 112.109 -179.684 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 175' ' ' PRO . . . . . 0.59 ' HD2' ' N ' ' A' ' 174' ' ' TYR . 8.1 Cg_endo -50.65 -27.75 20.46 Favored 'Trans proline' 0 C--N 1.352 0.752 0 C-N-CA 122.067 1.845 . . . . 0.0 112.355 -179.797 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 176' ' ' PHE . . . . . 0.457 ' O ' ' HG ' ' A' ' 180' ' ' LEU . 49.5 m-85 -80.59 -46.43 15.71 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.291 -0.413 . . . . 0.0 111.668 -179.995 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 177' ' ' ILE . . . . . 0.509 HD11 HG22 ' A' ' 173' ' ' ILE . 3.5 mm -66.19 -36.35 77.19 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.497 0 N-CA-C 112.299 0.481 . . . . 0.0 112.299 -178.211 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 178' ' ' TRP . . . . . 0.471 ' HH2' ' HB2' ' A' ' 123' ' ' ARG . 67.8 t90 -73.94 -45.95 47.21 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-O 120.907 0.384 . . . . 0.0 110.772 179.602 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 179' ' ' LEU . . . . . 0.459 ' O ' HG22 ' A' ' 185' ' ' VAL . 2.5 tm? -67.92 -49.6 60.91 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 115.921 -0.581 . . . . 0.0 111.403 -179.077 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 180' ' ' LEU . . . . . 0.556 HD22 HD11 ' A' ' 187' ' ' LEU . 22.7 mt -77.7 -47.23 19.65 Favored 'General case' 0 C--N 1.328 -0.358 0 N-CA-C 111.812 0.301 . . . . 0.0 111.812 -179.165 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . -58.75 -178.21 0.96 Allowed Glycine 0 C--N 1.337 0.591 0 C-N-CA 120.256 -0.973 . . . . 0.0 112.772 -179.98 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 182' ' ' PRO . . . . . 0.644 ' HA ' ' HB2' ' A' ' 186' ' ' ALA . 85.7 Cg_exo -47.81 -44.32 27.14 Favored 'Trans proline' 0 CA--C 1.536 0.623 0 C-N-CA 122.967 2.445 . . . . 0.0 113.802 -179.97 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 183' ' ' PRO . . . . . 0.496 ' HA ' HH22 ' A' ' 66' ' ' ARG . 51.8 Cg_exo -55.3 -9.95 2.79 Favored 'Trans proline' 0 C--N 1.354 0.833 0 C-N-CA 122.154 1.902 . . . . 0.0 113.199 -179.736 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 184' ' ' GLY . . . . . 0.414 ' HA3' ' O ' ' A' ' 179' ' ' LEU . . . -123.21 -87.39 0.81 Allowed Glycine 0 N--CA 1.45 -0.387 0 C-N-CA 120.421 -0.895 . . . . 0.0 112.901 -179.887 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 185' ' ' VAL . . . . . 0.459 HG22 ' O ' ' A' ' 179' ' ' LEU . 8.6 m -120.43 -7.02 10.53 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-O 120.773 0.321 . . . . 0.0 111.779 -179.603 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 186' ' ' ALA . . . . . 0.644 ' HB2' ' HA ' ' A' ' 182' ' ' PRO . . . 56.18 85.36 0.07 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.116 -0.493 . . . . 0.0 111.716 179.576 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 187' ' ' LEU . . . . . 0.556 HD11 HD22 ' A' ' 180' ' ' LEU . 18.8 mt -91.78 -49.25 6.36 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.93 0.395 . . . . 0.0 110.878 179.528 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 188' ' ' LEU . . . . . 0.403 ' HB3' ' H ' ' A' ' 189' ' ' THR . 96.6 mt -90.13 -154.99 0.35 Allowed 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 115.839 -0.619 . . . . 0.0 110.947 -179.661 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 189' ' ' THR . . . . . 0.481 ' HB ' HG23 ' A' ' 192' ' ' VAL . 58.8 m -92.6 136.17 25.56 Favored Pre-proline 0 C--N 1.329 -0.326 0 CA-C-N 116.05 -0.523 . . . . 0.0 110.568 -179.719 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 190' ' ' PRO . . . . . 0.468 ' O ' HG23 ' A' ' 194' ' ' VAL . 2.2 Cg_endo -45.5 -37.69 15.23 Favored 'Trans proline' 0 C--N 1.35 0.652 0 C-N-CA 122.837 2.358 . . . . 0.0 112.776 -179.747 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 191' ' ' THR . . . . . 0.413 ' H ' HG22 ' A' ' 189' ' ' THR . 41.7 p -74.24 -45.42 48.09 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 116.487 -0.324 . . . . 0.0 111.415 -179.835 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 192' ' ' VAL . . . . . 0.481 HG23 ' HB ' ' A' ' 189' ' ' THR . 96.9 t -59.66 -52.79 56.9 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.302 -0.408 . . . . 0.0 111.415 -179.781 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 193' ' ' ASP . . . . . . . . . . . . . 25.9 t70 -54.6 -48.2 72.46 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.946 -179.761 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 194' ' ' VAL . . . . . 0.62 ' O ' HG22 ' A' ' 198' ' ' VAL . 40.6 t -55.22 -44.03 73.22 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.241 0 CA-C-N 116.376 -0.375 . . . . 0.0 110.492 179.492 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 195' ' ' ALA . . . . . . . . . . . . . . . -52.46 -42.91 64.61 Favored 'General case' 0 C--N 1.332 -0.185 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.778 179.895 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 196' ' ' LEU . . . . . . . . . . . . . 62.5 mt -67.8 -40.27 83.9 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.785 179.356 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 197' ' ' ILE . . . . . 0.42 HG12 HG21 ' A' ' 177' ' ' ILE . 12.0 mm -59.39 -60.87 1.82 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 115.766 -0.652 . . . . 0.0 111.405 -179.847 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 198' ' ' VAL . . . . . 0.62 HG22 ' O ' ' A' ' 194' ' ' VAL . 1.3 m -53.94 -34.85 26.61 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.439 0 CA-C-O 121.544 0.687 . . . . 0.0 109.566 179.053 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 199' ' ' TYR . . . . . . . . . . . . . 63.8 t80 -66.57 -33.56 75.94 Favored 'General case' 0 C--N 1.323 -0.587 0 CA-C-N 114.639 -1.164 . . . . 0.0 110.575 179.722 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 200' ' ' LEU . . . . . 0.483 ' O ' HG12 ' A' ' 203' ' ' VAL . 26.6 mt -66.67 -41.77 87.62 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.088 -0.505 . . . . 0.0 111.315 -179.897 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 201' ' ' ASP . . . . . . . . . . . . . 5.0 m-20 -74.83 -37.94 62.14 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-O 121.253 0.549 . . . . 0.0 110.044 179.499 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 202' ' ' LEU . . . . . 0.481 HD13 ' SD ' ' A' ' 15' ' ' MET . 40.5 tp -70.6 -26.79 63.67 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 115.256 -0.884 . . . . 0.0 111.559 -179.343 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 203' ' ' VAL . . . . . 0.483 HG12 ' O ' ' A' ' 200' ' ' LEU . 14.2 p -81.73 -36.7 14.59 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.13 0 CA-C-N 116.765 -0.198 . . . . 0.0 110.813 -179.141 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 204' ' ' THR . . . . . . . . . . . . . 65.8 m -63.43 -58.56 6.67 Favored 'General case' 0 C--N 1.329 -0.305 0 C-N-CA 120.713 -0.395 . . . . 0.0 110.642 179.169 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 205' ' ' LYS . . . . . 0.757 ' HE2' ' HB2' ' A' ' 47' ' ' ALA . 57.7 mttp -60.88 -58.01 10.26 Favored 'General case' 0 C--N 1.328 -0.361 0 N-CA-C 112.609 0.596 . . . . 0.0 112.609 -178.464 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 56.5 t -71.77 -37.36 62.02 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 N-CA-C 112.317 0.488 . . . . 0.0 112.317 -178.432 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 207' ' ' GLY . . . . . 0.53 ' O ' HG13 ' A' ' 211' ' ' ILE . . . -56.92 -61.67 7.24 Favored Glycine 0 CA--C 1.517 0.18 0 C-N-CA 120.665 -0.779 . . . . 0.0 113.793 -178.799 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 208' ' ' PHE . . . . . 0.609 ' HB2' ' HG ' ' A' ' 163' ' ' LEU . 0.9 OUTLIER -72.73 -27.25 61.93 Favored 'General case' 0 C--O 1.222 -0.368 0 CA-C-N 117.571 0.686 . . . . 0.0 110.771 -179.31 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 209' ' ' GLY . . . . . 0.52 ' O ' ' HB3' ' A' ' 212' ' ' ALA . . . -63.34 -32.73 85.15 Favored Glycine 0 N--CA 1.448 -0.542 0 N-CA-C 111.629 -0.588 . . . . 0.0 111.629 178.471 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 210' ' ' PHE . . . . . . . . . . . . . 0.8 OUTLIER -74.06 -47.81 34.09 Favored 'General case' 0 CA--C 1.515 -0.397 0 N-CA-C 108.221 -1.029 . . . . 0.0 108.221 178.543 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 211' ' ' ILE . . . . . 0.53 HG13 ' O ' ' A' ' 207' ' ' GLY . 4.4 mt -63.43 -27.52 43.18 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.434 0 N-CA-C 107.678 -1.23 . . . . 0.0 107.678 176.83 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 212' ' ' ALA . . . . . 0.52 ' HB3' ' O ' ' A' ' 209' ' ' GLY . . . -62.76 -40.81 98.42 Favored 'General case' 0 N--CA 1.451 -0.418 0 CA-C-N 114.447 -1.252 . . . . 0.0 110.622 -179.788 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 213' ' ' LEU . . . . . . . . . . . . . 86.4 mt -69.44 -47.29 64.54 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 115.171 -0.922 . . . . 0.0 111.44 -179.501 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 214' ' ' ASP . . . . . . . . . . . . . 14.3 t70 -56.32 -53.1 61.34 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.391 -0.368 . . . . 0.0 111.079 -179.944 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 215' ' ' ALA . . . . . . . . . . . . . . . -56.88 -56.24 24.22 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.06 -0.518 . . . . 0.0 111.341 -179.813 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 216' ' ' ALA . . . . . . . . . . . . . . . -56.78 -32.13 65.34 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.234 -179.897 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 217' ' ' ALA . . . . . . . . . . . . . . . -64.73 -34.38 78.18 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.298 -0.41 . . . . 0.0 110.197 179.793 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 218' ' ' THR . . . . . . . . . . . . . 93.0 m -76.17 -32.61 59.13 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 115.789 -0.641 . . . . 0.0 110.76 179.536 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 219' ' ' LEU . . . . . 0.474 ' O ' ' HG2' ' A' ' 222' ' ' GLU . 69.4 mt -62.23 -41.16 98.16 Favored 'General case' 0 C--N 1.333 -0.15 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.697 -179.999 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 220' ' ' ARG . . . . . . . . . . . . . 35.9 ptt180 -83.89 -24.53 30.76 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.044 -0.525 . . . . 0.0 111.012 179.841 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 221' ' ' ALA . . . . . . . . . . . . . . . -77.24 -19.2 56.94 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.074 -0.512 . . . . 0.0 112.227 -179.38 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 222' ' ' GLU . . . . . 0.474 ' HG2' ' O ' ' A' ' 219' ' ' LEU . 10.2 pt-20 -70.1 -10.91 60.28 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-O 120.811 0.339 . . . . 0.0 110.722 -178.918 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 223' ' ' HIS . . . . . . . . . . . . . 1.6 p-80 -150.05 5.69 0.58 Allowed 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.058 -0.519 . . . . 0.0 111.285 -179.744 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 224' ' ' GLY . . . . . . . . . . . . . . . 60.46 82.49 0.07 OUTLIER Glycine 0 N--CA 1.452 -0.272 0 C-N-CA 120.659 -0.782 . . . . 0.0 112.368 -179.969 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 225' ' ' GLU . . . . . . . . . . . . . 25.8 mm-40 65.19 147.07 0.03 OUTLIER 'General case' 0 N--CA 1.463 0.182 0 CA-C-O 121.026 0.441 . . . . 0.0 111.411 -179.975 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 226' ' ' SER . . . . . . . . . . . . . 60.6 m -61.08 146.07 48.65 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 115.939 -0.573 . . . . 0.0 110.936 179.974 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 227' ' ' LEU . . . . . . . . . . . . . 93.5 mt -76.34 162.53 27.81 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.761 179.989 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 228' ' ' ALA . . . . . . . . . . . . . . . -155.19 -179.71 8.34 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.2 -0.454 . . . . 0.0 111.028 179.856 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 229' ' ' GLY . . . . . . . . . . . . . . . -73.44 160.89 53.99 Favored Glycine 0 N--CA 1.45 -0.388 0 C-N-CA 120.709 -0.758 . . . . 0.0 112.548 179.9 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 230' ' ' VAL . . . . . . . . . . . . . 21.7 m -128.21 149.02 32.71 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.229 0 CA-C-O 120.738 0.304 . . . . 0.0 111.038 179.948 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 231' ' ' ASP . . . . . . . . . . . . . 22.3 t70 -101.35 109.81 21.72 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.75 179.911 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 232' ' ' THR . . . . . . . . . . . . . 3.6 t -152.61 122.41 6.94 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.29 -179.785 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 233' ' ' ASP . . . . . . . . . . . . . 5.3 p-10 -101.76 135.41 43.35 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.017 -0.538 . . . . 0.0 110.598 179.668 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 234' ' ' THR . . . . . . . . . . . . . 51.2 m 58.37 89.32 0.11 Allowed Pre-proline 0 C--N 1.331 -0.222 0 CA-C-N 116.324 -0.398 . . . . 0.0 111.0 179.97 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 235' ' ' PRO . . . . . . . . . . . . . 31.5 Cg_endo -63.28 172.64 4.98 Favored 'Trans proline' 0 C--N 1.347 0.5 0 C-N-CA 122.636 2.224 . . . . 0.0 112.387 179.972 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 236' ' ' ALA . . . . . . . . . . . . . . . -96.82 119.02 34.52 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.944 -179.984 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 237' ' ' VAL . . . . . . . . . . . . . 27.3 m -81.66 148.86 5.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.262 179.957 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 238' ' ' ALA . . . . . . . . . . . . . . . -140.83 -31.95 0.59 Allowed 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.925 179.97 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 239' ' ' ASP . . . . . . . . . . . . . 5.5 p-10 -136.82 139.62 41.87 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.659 179.866 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 240' ' ' LEU . . . . . . . . . . . . . 61.1 tp -151.22 -36.01 0.14 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.306 -0.406 . . . . 0.0 111.068 -179.738 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 241' ' ' GLU . . . . . . . . . . . . . 10.7 tp10 63.98 112.94 0.03 OUTLIER 'General case' 0 C--N 1.332 -0.155 0 CA-C-N 116.176 -0.466 . . . . 0.0 111.126 179.935 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 242' ' ' HIS . . . . . . . . . . . . . 85.1 m-70 -81.45 146.72 30.1 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.123 -179.674 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 243' ' ' HIS . . . . . . . . . . . . . 36.5 t-80 -109.15 -18.18 13.69 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 115.945 -0.571 . . . . 0.0 110.622 179.924 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 244' ' ' HIS . . . . . . . . . . . . . 44.4 m80 -99.95 119.98 39.09 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.025 -0.534 . . . . 0.0 110.87 179.989 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 245' ' ' HIS . . . . . . . . . . . . . 60.1 t-80 -136.37 -40.9 0.64 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.68 179.865 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 246' ' ' HIS . . . . . . . . . . . . . 62.2 t-80 -131.87 116.11 16.77 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.068 -0.515 . . . . 0.0 110.862 -179.867 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 247' ' ' HIS . . . . . . . . . . . . . 58.5 t-80 . . . . . 0 C--O 1.249 1.03 0 CA-C-O 118.208 -0.901 . . . . 0.0 110.848 179.933 . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 301' ' ' RET . . . . . 0.766 H203 ' HE1' ' A' ' 171' ' ' TRP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 93.8 mmm . . . . . 0 N--CA 1.486 1.358 0 CA-C-O 120.828 0.347 . . . . 0.0 110.834 . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 8.3 p -113.15 -11.46 11.97 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.087 -179.858 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -86.81 -42.81 6.26 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.839 -0.696 . . . . 0.0 112.672 179.994 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 4' ' ' LEU . . . . . 0.412 ' HB2' ' HH2' ' A' ' 60' ' ' TRP . 81.9 mt -65.64 -36.65 84.32 Favored 'General case' 0 N--CA 1.45 -0.436 0 CA-C-O 120.804 0.335 . . . . 0.0 111.117 -179.844 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 67.1 p -57.21 -30.64 64.73 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.01 -0.541 . . . . 0.0 111.725 -179.651 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 27.3 p -58.8 -38.32 78.32 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 116.524 -0.307 . . . . 0.0 111.344 -179.609 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 7' ' ' LEU . . . . . . . . . . . . . 4.2 mm? -63.5 -51.45 65.49 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.106 -179.941 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 8' ' ' PHE . . . . . 0.484 ' HB2' ' HB2' ' A' ' 55' ' ' ALA . 74.1 m-85 -61.2 -33.23 73.13 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.512 179.928 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 9' ' ' TRP . . . . . 0.473 ' O ' HG13 ' A' ' 13' ' ' ILE . 9.1 m95 -66.15 -38.52 88.31 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 116.067 -0.515 . . . . 0.0 110.241 179.999 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 73.2 mt -65.7 -32.63 74.3 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 115.787 -0.642 . . . . 0.0 110.005 179.464 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -71.02 -33.64 65.31 Favored Glycine 0 N--CA 1.448 -0.517 0 C-N-CA 120.953 -0.642 . . . . 0.0 111.757 179.129 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 12' ' ' ALA . . . . . 0.456 ' O ' HD23 ' A' ' 16' ' ' LEU . . . -70.02 -32.43 70.58 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 120.889 0.376 . . . . 0.0 110.53 179.315 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 13' ' ' ILE . . . . . 0.473 HG13 ' O ' ' A' ' 9' ' ' TRP . 73.8 mt -66.95 -53.81 30.65 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.233 0 CA-C-N 116.021 -0.536 . . . . 0.0 110.577 179.721 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -64.11 -25.09 69.28 Favored Glycine 0 N--CA 1.451 -0.366 0 C-N-CA 120.657 -0.783 . . . . 0.0 112.042 179.677 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 15' ' ' MET . . . . . 0.536 ' HB3' ' HB2' ' A' ' 48' ' ' ALA . 0.0 OUTLIER -72.54 -54.47 9.11 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.559 0.219 . . . . 0.0 110.933 179.82 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 16' ' ' LEU . . . . . 0.456 HD23 ' O ' ' A' ' 12' ' ' ALA . 3.9 mm? -53.13 -45.72 68.47 Favored 'General case' 0 C--N 1.332 -0.179 0 CA-C-N 116.403 -0.362 . . . . 0.0 110.921 179.527 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 83.7 t -61.06 -40.29 85.18 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.153 0 CA-C-N 116.372 -0.376 . . . . 0.0 110.457 179.666 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -67.68 -41.73 88.81 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.859 -0.686 . . . . 0.0 111.802 179.188 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 16.3 m -51.14 -53.76 31.44 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.989 0.423 . . . . 0.0 110.711 -179.982 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 62.6 mt -71.71 -32.22 67.55 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 115.786 -0.643 . . . . 0.0 111.083 179.84 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 21' ' ' ALA . . . . . 0.46 ' O ' ' HB2' ' A' ' 25' ' ' ALA . . . -58.33 -56.67 19.13 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.793 -179.605 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 22' ' ' PHE . . . . . 0.496 ' HB2' HG22 ' A' ' 41' ' ' VAL . 4.7 m-85 -71.11 -30.75 66.91 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.409 -0.359 . . . . 0.0 111.337 -179.128 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -64.03 -51.24 65.11 Favored 'General case' 0 C--N 1.327 -0.4 0 N-CA-C 112.369 0.507 . . . . 0.0 112.369 -179.17 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 24' ' ' TRP . . . . . 0.53 ' CE3' ' HA ' ' A' ' 24' ' ' TRP . 2.4 t-105 -86.67 -26.76 24.15 Favored 'General case' 0 N--CA 1.442 -0.842 0 N-CA-C 113.326 0.861 . . . . 0.0 113.326 -177.655 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 25' ' ' ALA . . . . . 0.46 ' HB2' ' O ' ' A' ' 21' ' ' ALA . . . -46.86 -48.61 21.02 Favored 'General case' 0 C--N 1.314 -0.947 0 N-CA-C 109.586 -0.524 . . . . 0.0 109.586 178.785 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -74.35 -21.29 79.09 Favored Glycine 0 N--CA 1.45 -0.426 0 N-CA-C 110.039 -1.224 . . . . 0.0 110.039 177.354 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 27' ' ' ARG . . . . . 0.47 ' HA ' ' CE3' ' A' ' 24' ' ' TRP . 19.0 mtt180 59.88 77.49 0.31 Allowed 'General case' 0 CA--C 1.516 -0.34 0 CA-C-N 114.676 -0.762 . . . . 0.0 111.855 179.357 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 20.2 t70 50.97 86.76 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 115.638 -0.71 . . . . 0.0 111.046 178.975 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -76.01 158.57 31.75 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.4 -179.601 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -72.58 -79.13 0.48 Allowed Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.877 -0.677 . . . . 0.0 112.515 -179.967 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 31' ' ' SER . . . . . 0.422 ' HA ' ' HE ' ' A' ' 34' ' ' ARG . 44.3 t -156.63 -55.22 0.08 Allowed 'General case' 0 C--N 1.331 -0.239 0 CA-C-O 120.644 0.259 . . . . 0.0 111.183 -179.904 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -56.11 -28.39 53.84 Favored Glycine 0 C--N 1.33 0.231 0 C-N-CA 120.823 -0.703 . . . . 0.0 112.767 -179.97 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 8.8 mm-40 -92.14 -23.6 19.36 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.794 0.331 . . . . 0.0 110.949 -179.964 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 34' ' ' ARG . . . . . 0.422 ' HE ' ' HA ' ' A' ' 31' ' ' SER . 53.1 mtm180 -56.4 -28.34 59.04 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.156 -0.475 . . . . 0.0 111.848 -179.677 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 19.0 tpp180 -55.27 -59.05 5.33 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-O 120.744 0.307 . . . . 0.0 111.408 -179.634 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 42.3 m-85 -71.96 -34.81 69.29 Favored 'General case' 0 C--N 1.33 -0.244 0 N-CA-C 112.333 0.494 . . . . 0.0 112.333 -178.783 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 37' ' ' TYR . . . . . 0.412 ' O ' HG23 ' A' ' 41' ' ' VAL . 29.4 m-85 -70.39 -56.25 7.13 Favored 'General case' 0 N--CA 1.464 0.226 0 N-CA-C 111.619 0.229 . . . . 0.0 111.619 -179.221 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 77.9 t -56.85 -37.23 52.85 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.232 0 CA-C-O 120.8 0.333 . . . . 0.0 110.87 179.799 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 21.9 m -62.25 -51.18 68.75 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.845 179.313 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 40' ' ' LEU . . . . . 0.4 HD13 ' CE1' ' A' ' 208' ' ' PHE . 18.1 tp -59.87 -50.93 71.86 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 115.926 -0.579 . . . . 0.0 110.792 179.978 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 41' ' ' VAL . . . . . 0.496 HG22 ' HB2' ' A' ' 22' ' ' PHE . 65.3 t -58.84 -34.09 51.31 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.373 0 CA-C-N 115.775 -0.648 . . . . 0.0 109.998 179.169 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -58.76 -41.81 96.11 Favored Glycine 0 N--CA 1.448 -0.542 0 C-N-CA 120.829 -0.7 . . . . 0.0 111.657 179.429 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 43' ' ' ILE . . . . . 0.501 HD13 HD13 ' A' ' 83' ' ' ILE . 1.1 mt -61.75 -51.16 75.97 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.176 0 CA-C-O 120.847 0.356 . . . . 0.0 110.508 179.201 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 79.3 p -62.2 -23.27 66.53 Favored 'General case' 0 C--N 1.333 -0.132 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.088 179.756 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -77.55 -56.94 3.72 Favored Glycine 0 C--N 1.33 0.225 0 C-N-CA 120.832 -0.699 . . . . 0.0 112.406 179.916 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 46' ' ' ILE . . . . . 0.571 HD12 HD12 ' A' ' 78' ' ' LEU . 13.1 pt -58.49 -37.14 62.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-O 121.051 0.453 . . . . 0.0 110.721 179.77 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 47' ' ' ALA . . . . . 0.692 ' HB2' ' HE2' ' A' ' 205' ' ' LYS . . . -68.46 -41.02 80.78 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 115.97 -0.559 . . . . 0.0 110.89 179.113 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 48' ' ' ALA . . . . . 0.536 ' HB2' ' HB3' ' A' ' 15' ' ' MET . . . -55.69 -42.09 74.67 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-N 115.805 -0.634 . . . . 0.0 111.763 -179.486 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 49' ' ' VAL . . . . . 0.46 ' O ' HG13 ' A' ' 53' ' ' VAL . 8.6 m -75.56 -37.44 36.98 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.545 -0.298 . . . . 0.0 111.6 -179.516 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -60.61 -43.59 97.26 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 121.035 0.445 . . . . 0.0 111.061 179.809 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 51' ' ' TYR . . . . . 0.514 ' HE2' ' HE2' ' A' ' 15' ' ' MET . 43.3 m-85 -73.1 -32.38 64.94 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-N 115.933 -0.576 . . . . 0.0 110.484 -179.77 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -69.34 -38.97 78.41 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-N 115.897 -0.592 . . . . 0.0 111.1 179.549 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 53' ' ' VAL . . . . . 0.46 HG13 ' O ' ' A' ' 49' ' ' VAL . 33.3 m -74.62 -47.39 39.04 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.224 0 CA-C-N 116.418 -0.356 . . . . 0.0 110.573 180.0 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 54' ' ' MET . . . . . 0.454 ' N ' HG23 ' A' ' 53' ' ' VAL . 75.3 mtm -61.37 -31.77 71.67 Favored 'General case' 0 N--CA 1.455 -0.178 0 N-CA-C 109.62 -0.511 . . . . 0.0 109.62 179.058 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 55' ' ' ALA . . . . . 0.484 ' HB2' ' HB2' ' A' ' 8' ' ' PHE . . . -69.31 -22.83 63.76 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 115.588 -0.733 . . . . 0.0 110.933 179.215 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 63.8 mt -87.51 0.12 56.02 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 116.167 -0.469 . . . . 0.0 111.409 -179.797 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 90.5 -21.49 32.12 Favored Glycine 0 N--CA 1.452 -0.261 0 C-N-CA 120.564 -0.827 . . . . 0.0 113.115 179.522 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 58' ' ' VAL . . . . . 0.437 HG12 ' O ' ' A' ' 53' ' ' VAL . 13.7 p -68.36 148.7 11.68 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.215 0 CA-C-N 116.887 0.344 . . . . 0.0 110.822 179.955 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 59' ' ' GLY . . . . . 0.402 ' HA3' ' HG2' ' A' ' 71' ' ' PRO . . . 92.44 -5.06 77.37 Favored Glycine 0 N--CA 1.45 -0.403 0 C-N-CA 120.648 -0.787 . . . . 0.0 112.403 -179.573 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 60' ' ' TRP . . . . . 0.412 ' HH2' ' HB2' ' A' ' 4' ' ' LEU . 15.9 m0 -86.19 108.09 18.19 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.55 0.214 . . . . 0.0 110.954 -179.861 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 61' ' ' VAL . . . . . 0.463 HG13 HG23 ' A' ' 68' ' ' VAL . 7.5 p -111.8 128.26 25.69 Favored Pre-proline 0 CA--C 1.533 0.317 0 CA-C-N 116.52 -0.309 . . . . 0.0 111.108 179.804 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 73.8 Cg_endo -75.23 155.27 41.85 Favored 'Trans proline' 0 C--N 1.35 0.645 0 C-N-CA 122.422 2.082 . . . . 0.0 112.648 -179.679 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 80.7 t -143.21 89.73 0.4 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 115.826 -0.625 . . . . 0.0 110.858 179.929 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . 59.9 -86.86 0.02 OUTLIER 'General case' 0 C--N 1.331 -0.199 0 CA-C-N 116.065 -0.516 . . . . 0.0 111.467 179.953 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 6.2 mp0 -121.52 -19.64 6.84 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 116.286 -0.415 . . . . 0.0 110.652 179.962 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 66' ' ' ARG . . . . . . . . . . . . . 45.6 mtm180 -101.24 161.52 13.56 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 115.919 -0.582 . . . . 0.0 110.499 179.913 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 56.2 m -122.44 137.63 54.81 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.35 -0.386 . . . . 0.0 111.269 -179.804 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 68' ' ' VAL . . . . . 0.463 HG23 HG13 ' A' ' 61' ' ' VAL . 21.7 m -127.37 146.64 32.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.025 -0.534 . . . . 0.0 110.802 179.772 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 69' ' ' PHE . . . . . . . . . . . . . 23.1 m-85 -109.44 112.18 24.15 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.154 -179.261 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 70' ' ' VAL . . . . . 0.546 ' HB ' ' HD3' ' A' ' 71' ' ' PRO . 13.0 t -62.95 -49.61 80.89 Favored Pre-proline 0 C--N 1.324 -0.508 0 CA-C-N 116.227 -0.442 . . . . 0.0 112.021 -178.901 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 71' ' ' PRO . . . . . 0.546 ' HD3' ' HB ' ' A' ' 70' ' ' VAL . 38.2 Cg_exo -60.74 -18.46 55.98 Favored 'Trans proline' 0 C--N 1.35 0.616 0 C-N-CA 122.039 1.826 . . . . 0.0 112.985 -179.663 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 72' ' ' ARG . . . . . 0.478 ' NH2' HG13 ' A' ' 197' ' ' ILE . 77.5 ttt180 -76.08 -55.6 5.44 Favored 'General case' 0 C--O 1.235 0.303 0 CA-C-O 120.796 0.331 . . . . 0.0 111.86 -179.093 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 73' ' ' TYR . . . . . . . . . . . . . 27.1 m-85 -67.52 -36.15 80.49 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-O 120.817 0.342 . . . . 0.0 110.321 -179.545 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 74' ' ' ILE . . . . . 0.586 ' O ' HD23 ' A' ' 78' ' ' LEU . 0.3 OUTLIER -67.14 -43.05 88.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 N-CA-C 109.686 -0.487 . . . . 0.0 109.686 179.344 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 75' ' ' ASP . . . . . 0.403 ' HA ' HD21 ' A' ' 78' ' ' LEU . 12.0 t70 -51.95 -40.72 61.3 Favored 'General case' 0 CA--C 1.519 -0.226 0 N-CA-C 109.534 -0.543 . . . . 0.0 109.534 179.009 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 76' ' ' TRP . . . . . 0.411 ' HZ2' HG23 ' A' ' 197' ' ' ILE . 44.2 m0 -66.34 -35.5 80.51 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 115.794 -0.639 . . . . 0.0 110.825 179.425 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 77' ' ' ILE . . . . . 0.466 ' O ' ' HG2' ' A' ' 81' ' ' PRO . 88.0 mt -59.75 -40.73 83.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.094 -0.503 . . . . 0.0 112.318 -179.446 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 78' ' ' LEU . . . . . 0.586 HD23 ' O ' ' A' ' 74' ' ' ILE . 0.6 OUTLIER -91.94 -28.34 17.31 Favored 'General case' 0 CA--C 1.535 0.371 0 N-CA-C 113.038 0.755 . . . . 0.0 113.038 -179.546 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 65.3 p -79.65 -53.09 7.17 Favored 'General case' 0 N--CA 1.469 0.511 0 N-CA-C 113.468 0.914 . . . . 0.0 113.468 -178.41 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 80' ' ' THR . . . . . 0.593 ' HB ' ' HD3' ' A' ' 81' ' ' PRO . 3.8 m -50.92 -54.02 41.6 Favored Pre-proline 0 CA--C 1.533 0.291 0 N-CA-C 112.409 0.522 . . . . 0.0 112.409 -178.27 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 81' ' ' PRO . . . . . 0.593 ' HD3' ' HB ' ' A' ' 80' ' ' THR . 32.3 Cg_exo -60.08 -22.41 69.51 Favored 'Trans proline' 0 C--N 1.351 0.687 0 C-N-CA 121.869 1.712 . . . . 0.0 111.761 179.723 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 82' ' ' LEU . . . . . . . . . . . . . 15.4 tp -74.32 -33.03 63.06 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.067 -0.515 . . . . 0.0 109.921 179.647 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 83' ' ' ILE . . . . . 0.501 HD13 HD13 ' A' ' 43' ' ' ILE . 35.4 mm -68.79 -53.03 29.24 Favored 'Isoleucine or valine' 0 C--O 1.235 0.309 0 CA-C-N 115.845 -0.616 . . . . 0.0 110.037 179.04 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 84' ' ' VAL . . . . . 0.717 HG11 HD22 ' A' ' 105' ' ' ASN . 30.8 m -61.67 -30.18 47.75 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.221 0 CA-C-N 116.085 -0.507 . . . . 0.0 109.832 179.043 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 85' ' ' TYR . . . . . 0.41 ' HB2' ' O ' ' A' ' 81' ' ' PRO . 44.2 t80 -66.82 -34.68 78.35 Favored 'General case' 0 N--CA 1.454 -0.251 0 CA-C-N 115.665 -0.698 . . . . 0.0 109.386 178.724 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 86' ' ' PHE . . . . . . . . . . . . . 18.9 t80 -59.2 -51.45 69.94 Favored 'General case' 0 CA--C 1.519 -0.234 0 CA-C-N 115.735 -0.666 . . . . 0.0 109.427 178.983 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 10.5 mp -60.51 -32.29 71.32 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 115.55 -0.75 . . . . 0.0 110.04 179.28 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 88' ' ' GLY . . . . . 0.455 ' HA2' HD13 ' A' ' 93' ' ' LEU . . . -68.59 -28.21 73.32 Favored Glycine 0 N--CA 1.449 -0.438 0 C-N-CA 120.751 -0.738 . . . . 0.0 111.697 179.382 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 75.9 mt -72.49 -39.25 67.82 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-O 120.982 0.42 . . . . 0.0 110.278 179.43 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 70.5 mt -59.9 -53.1 61.86 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 115.76 -0.654 . . . . 0.0 110.603 179.569 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 91' ' ' ALA . . . . . 0.551 ' HB2' ' HB2' ' A' ' 149' ' ' ALA . . . -72.33 -52.07 17.81 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.126 -0.488 . . . . 0.0 111.062 179.89 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 97.21 57.24 1.08 Allowed Glycine 0 N--CA 1.453 -0.228 0 C-N-CA 120.817 -0.706 . . . . 0.0 112.207 -179.899 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 93' ' ' LEU . . . . . 0.592 HD23 ' HB3' ' A' ' 97' ' ' GLU . 8.9 mp -60.5 172.65 0.84 Allowed 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 121.045 0.45 . . . . 0.0 111.35 -179.704 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 94' ' ' ASP . . . . . 0.429 ' HB2' ' HG2' ' A' ' 97' ' ' GLU . 8.0 m-20 -82.63 172.55 12.82 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-N 115.904 -0.589 . . . . 0.0 110.634 179.907 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 38.3 t -56.24 -48.68 76.04 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.206 -179.839 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 99.2 mtt180 -70.4 -43.38 70.15 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.268 -0.424 . . . . 0.0 111.196 -179.835 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 97' ' ' GLU . . . . . 0.592 ' HB3' HD23 ' A' ' 93' ' ' LEU . 21.5 mm-40 -52.19 -48.0 65.26 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.991 -179.59 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 98' ' ' PHE . . . . . 0.453 ' O ' HG12 ' A' ' 102' ' ' ILE . 11.6 m-85 -57.5 -45.2 85.18 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-O 120.988 0.423 . . . . 0.0 110.19 179.177 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -62.59 -26.43 68.36 Favored Glycine 0 N--CA 1.45 -0.417 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.421 179.811 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 97.1 mt -73.28 -47.4 46.76 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.238 0 N-CA-C 111.876 0.324 . . . . 0.0 111.876 -179.632 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 26.5 m -69.19 -35.13 66.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 N-CA-C 111.9 0.333 . . . . 0.0 111.9 -179.169 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 102' ' ' ILE . . . . . 0.453 HG12 ' O ' ' A' ' 98' ' ' PHE . 48.6 mm -72.23 -47.92 51.17 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.25 0 CA-C-N 116.674 -0.239 . . . . 0.0 111.596 -179.294 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 14.4 t -60.22 -37.63 80.92 Favored 'General case' 0 C--O 1.234 0.273 0 CA-C-O 121.02 0.438 . . . . 0.0 110.879 179.895 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 104' ' ' LEU . . . . . 0.541 ' O ' HG12 ' A' ' 107' ' ' VAL . 31.3 tp -60.52 -50.15 74.68 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 115.975 -0.557 . . . . 0.0 110.512 179.648 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 105' ' ' ASN . . . . . 0.717 HD22 HG11 ' A' ' 84' ' ' VAL . 4.0 m-20 -59.27 -31.69 69.33 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.012 179.778 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 96.9 m -61.01 -57.82 11.0 Favored 'General case' 0 C--N 1.331 -0.204 0 CA-C-N 116.547 -0.297 . . . . 0.0 111.478 -179.292 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 107' ' ' VAL . . . . . 0.541 HG12 ' O ' ' A' ' 104' ' ' LEU . 14.2 p -56.4 -35.46 43.76 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.242 -0.436 . . . . 0.0 110.742 -179.912 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 108' ' ' VAL . . . . . 0.508 HG23 ' O ' ' A' ' 104' ' ' LEU . 82.1 t -61.68 -57.8 10.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.038 -0.528 . . . . 0.0 111.424 179.624 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 109' ' ' MET . . . . . 0.505 ' HG2' ' O ' ' A' ' 105' ' ' ASN . 5.4 mmt -58.39 -35.2 71.64 Favored 'General case' 0 C--N 1.333 -0.146 0 CA-C-N 116.546 -0.297 . . . . 0.0 110.928 -179.683 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 8.3 mt -68.39 -33.17 73.77 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.307 -0.406 . . . . 0.0 110.696 179.785 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -61.75 -45.0 95.8 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 121.153 0.502 . . . . 0.0 109.745 178.989 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 112' ' ' GLY . . . . . 0.562 ' HA3' ' H21' ' A' ' 301' ' ' RET . . . -73.81 -33.34 57.89 Favored Glycine 0 N--CA 1.448 -0.507 0 CA-C-N 115.595 -0.729 . . . . 0.0 111.384 179.111 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 113' ' ' PHE . . . . . 0.405 ' HD2' HD11 ' A' ' 77' ' ' ILE . 1.1 t80 -53.27 -73.53 0.04 OUTLIER 'General case' 0 N--CA 1.455 -0.186 0 CA-C-O 121.093 0.473 . . . . 0.0 109.749 179.298 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 114' ' ' ALA . . . . . 0.413 ' O ' HG13 ' A' ' 118' ' ' VAL . . . -63.1 -21.44 66.18 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 115.68 -0.691 . . . . 0.0 110.805 179.618 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 115' ' ' GLY . . . . . 0.414 ' HA2' HD22 ' A' ' 126' ' ' LEU . . . -52.57 -49.24 53.46 Favored Glycine 0 C--N 1.335 0.473 0 C-N-CA 120.785 -0.721 . . . . 0.0 112.155 179.492 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -78.38 -15.75 58.36 Favored 'General case' 0 C--N 1.326 -0.414 0 N-CA-C 111.698 0.258 . . . . 0.0 111.698 179.939 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 117' ' ' MET . . . . . 0.462 ' HG2' HG21 ' A' ' 68' ' ' VAL . 57.6 mtt -102.35 15.6 28.69 Favored 'General case' 0 C--N 1.332 -0.194 0 CA-C-O 120.687 0.279 . . . . 0.0 111.731 -179.295 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 118' ' ' VAL . . . . . 0.413 HG13 ' O ' ' A' ' 114' ' ' ALA . 19.2 m -65.62 150.26 96.33 Favored Pre-proline 0 C--N 1.329 -0.303 0 CA-C-N 116.509 -0.314 . . . . 0.0 111.213 179.9 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 119' ' ' PRO . . . . . . . . . . . . . 91.5 Cg_endo -80.97 4.48 6.94 Favored 'Trans proline' 0 C--N 1.348 0.529 0 C-N-CA 122.508 2.139 . . . . 0.0 112.501 179.68 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -170.31 -123.71 0.7 Allowed Glycine 0 C--N 1.33 0.231 0 C-N-CA 120.637 -0.792 . . . . 0.0 112.747 -179.816 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 26.2 pt -105.44 9.77 9.3 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-O 120.698 0.285 . . . . 0.0 111.467 -179.716 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 13.9 mm-40 -58.0 -19.23 29.46 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-O 120.95 0.405 . . . . 0.0 110.75 179.626 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 123' ' ' ARG . . . . . 0.503 ' HB2' ' HH2' ' A' ' 178' ' ' TRP . 23.2 ptt180 -51.5 -35.37 39.98 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 115.67 -0.695 . . . . 0.0 111.903 -179.781 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 124' ' ' TYR . . . . . . . . . . . . . 25.7 m-85 -57.29 -35.31 69.65 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.807 0.337 . . . . 0.0 110.891 -179.875 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 125' ' ' ALA . . . . . . . . . . . . . . . -74.35 -48.97 24.8 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.064 179.813 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 126' ' ' LEU . . . . . 0.414 HD22 ' HA2' ' A' ' 115' ' ' GLY . 6.9 mp -53.33 -52.48 59.02 Favored 'General case' 0 C--N 1.332 -0.158 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.787 -179.981 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 127' ' ' PHE . . . . . 0.458 ' CE1' ' H42' ' A' ' 301' ' ' RET . 6.6 t80 -64.38 -37.54 87.87 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.281 -0.418 . . . . 0.0 110.684 179.999 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 128' ' ' GLY . . . . . . . . . . . . . . . -46.42 -45.02 16.52 Favored Glycine 0 C--N 1.332 0.337 0 C-N-CA 120.118 -1.039 . . . . 0.0 110.959 179.265 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 129' ' ' MET . . . . . . . . . . . . . 0.5 OUTLIER -70.46 -38.04 74.39 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 120.868 0.366 . . . . 0.0 110.073 178.722 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -63.61 -30.81 78.73 Favored Glycine 0 C--N 1.333 0.365 0 C-N-CA 121.056 -0.592 . . . . 0.0 112.951 -179.816 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -74.48 -53.56 9.26 Favored 'General case' 0 CA--C 1.519 -0.22 0 CA-C-N 116.779 0.29 . . . . 0.0 110.369 179.94 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 43.1 t -57.42 -40.33 73.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 N-CA-C 109.251 -0.648 . . . . 0.0 109.251 178.766 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -66.09 -37.09 84.9 Favored 'General case' 0 N--CA 1.452 -0.34 0 CA-C-N 115.218 -0.901 . . . . 0.0 110.041 178.893 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 134' ' ' PHE . . . . . 0.415 ' CZ ' ' HA ' ' A' ' 172' ' ' ALA . 82.9 t80 -57.01 -50.76 71.74 Favored 'General case' 0 N--CA 1.45 -0.461 0 CA-C-N 115.919 -0.582 . . . . 0.0 109.99 179.254 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 135' ' ' ILE . . . . . 0.53 ' O ' HG22 ' A' ' 138' ' ' VAL . 57.6 mt -58.13 -30.81 40.21 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.342 0 CA-C-N 115.668 -0.696 . . . . 0.0 109.779 179.161 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 136' ' ' GLY . . . . . 0.425 ' O ' ' HB3' ' A' ' 139' ' ' TYR . . . -65.48 -38.07 94.42 Favored Glycine 0 N--CA 1.447 -0.58 0 C-N-CA 120.224 -0.988 . . . . 0.0 110.966 178.438 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 137' ' ' LEU . . . . . . . . . . . . . 29.2 tp -69.32 -46.78 66.26 Favored 'General case' 0 C--N 1.331 -0.205 0 N-CA-C 110.449 -0.204 . . . . 0.0 110.449 179.399 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 138' ' ' VAL . . . . . 0.548 ' HA ' HD12 ' A' ' 141' ' ' LEU . 4.6 m -62.13 -31.89 52.85 Favored 'Isoleucine or valine' 0 C--O 1.234 0.255 0 N-CA-C 109.029 -0.73 . . . . 0.0 109.029 178.882 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 139' ' ' TYR . . . . . 0.425 ' HB3' ' O ' ' A' ' 136' ' ' GLY . 45.6 t80 -60.99 -37.2 81.62 Favored 'General case' 0 N--CA 1.453 -0.317 0 CA-C-N 115.176 -0.92 . . . . 0.0 108.879 178.053 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 140' ' ' TYR . . . . . 0.516 ' HB3' ' SD ' ' A' ' 145' ' ' MET . 24.0 m-85 -70.25 -35.22 73.65 Favored 'General case' 0 C--N 1.332 -0.168 0 CA-C-N 115.489 -0.778 . . . . 0.0 110.122 178.478 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 141' ' ' LEU . . . . . 0.548 HD12 ' HA ' ' A' ' 138' ' ' VAL . 96.1 mt -55.55 -39.83 71.12 Favored 'General case' 0 C--O 1.232 0.149 0 CA-C-N 115.976 -0.556 . . . . 0.0 110.156 179.343 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 2.3 t -104.05 0.15 10.19 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 115.775 -0.648 . . . . 0.0 110.953 179.889 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 143' ' ' GLY . . . . . 0.416 ' O ' HG22 ' A' ' 146' ' ' THR . . . -72.89 -148.81 0.97 Allowed Glycine 0 CA--C 1.519 0.33 0 C-N-CA 120.965 -0.636 . . . . 0.0 112.876 -179.726 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 144' ' ' PRO . . . . . . . . . . . . . 31.8 Cg_endo -63.73 -23.56 69.34 Favored 'Trans proline' 0 C--N 1.347 0.497 0 C-N-CA 122.629 2.22 . . . . 0.0 112.523 -179.901 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 145' ' ' MET . . . . . 0.576 ' HG2' HD21 ' A' ' 93' ' ' LEU . 84.2 mtp -53.57 -58.37 7.4 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.451 -179.81 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 146' ' ' THR . . . . . 0.416 HG22 ' O ' ' A' ' 143' ' ' GLY . 7.4 t -60.65 -32.2 71.39 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.382 -0.372 . . . . 0.0 111.337 -179.831 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 40.5 mt-10 -66.71 -34.65 78.33 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.283 -0.417 . . . . 0.0 111.071 -179.993 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 148' ' ' SER . . . . . . . . . . . . . 47.0 t -69.58 -45.32 68.94 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.051 -179.641 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 149' ' ' ALA . . . . . 0.558 ' HB1' HG22 ' A' ' 156' ' ' ILE . . . -63.88 -38.84 92.59 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.464 -179.665 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 150' ' ' SER . . . . . 0.586 ' HA ' ' HB2' ' A' ' 157' ' ' LYS . 81.8 p -67.54 -2.53 6.73 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.295 -0.411 . . . . 0.0 111.059 -179.817 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 151' ' ' GLN . . . . . . . . . . . . . 49.4 mt-30 -119.72 -1.64 10.53 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.26 -0.427 . . . . 0.0 111.244 -179.967 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 37.7 mmt180 -81.65 -51.6 8.04 Favored 'General case' 0 C--N 1.332 -0.185 0 CA-C-O 120.945 0.403 . . . . 0.0 110.746 179.712 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 153' ' ' SER . . . . . 0.577 ' HB3' HG12 ' A' ' 156' ' ' ILE . 23.1 t -158.17 172.28 18.68 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-N 115.865 -0.607 . . . . 0.0 110.544 179.254 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 154' ' ' SER . . . . . . . . . . . . . 39.6 t -69.91 -39.87 75.92 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-O 120.871 0.367 . . . . 0.0 110.317 179.418 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -76.99 -42.39 20.02 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.943 -0.646 . . . . 0.0 112.659 179.808 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 156' ' ' ILE . . . . . 0.577 HG12 ' HB3' ' A' ' 153' ' ' SER . 36.5 mm -48.86 -37.45 9.11 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.162 0 CA-C-O 120.863 0.363 . . . . 0.0 111.495 -179.778 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 157' ' ' LYS . . . . . 0.586 ' HB2' ' HA ' ' A' ' 150' ' ' SER . 54.8 tttm -67.72 -36.36 80.46 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.277 -179.712 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 43.3 t -71.8 -42.22 67.32 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.658 -179.378 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 159' ' ' LEU . . . . . 0.414 ' O ' ' HB2' ' A' ' 163' ' ' LEU . 10.7 mp -67.42 -35.23 78.86 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.342 -0.39 . . . . 0.0 111.74 -179.372 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 160' ' ' TYR . . . . . . . . . . . . . 23.8 t80 -72.78 -46.84 51.19 Favored 'General case' 0 C--N 1.33 -0.274 0 N-CA-C 112.179 0.437 . . . . 0.0 112.179 -178.676 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 161' ' ' VAL . . . . . 0.443 HG23 ' N ' ' A' ' 162' ' ' ARG . 24.6 m -62.98 -45.95 97.55 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 N-CA-C 112.353 0.501 . . . . 0.0 112.353 -178.952 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 162' ' ' ARG . . . . . 0.443 ' N ' HG23 ' A' ' 161' ' ' VAL . 36.2 mmt180 -66.33 -42.71 87.79 Favored 'General case' 0 C--N 1.328 -0.329 0 N-CA-C 111.807 0.299 . . . . 0.0 111.807 -179.141 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 163' ' ' LEU . . . . . 0.472 ' HG ' ' HB2' ' A' ' 208' ' ' PHE . 6.1 mp -71.45 -43.86 65.87 Favored 'General case' 0 C--N 1.329 -0.297 0 N-CA-C 111.957 0.354 . . . . 0.0 111.957 -179.251 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 164' ' ' ARG . . . . . 0.459 ' HG3' ' N ' ' A' ' 165' ' ' ASN . 5.6 ppt_? -68.38 -40.71 81.29 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 120.456 0.169 . . . . 0.0 111.073 -179.374 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 165' ' ' ASN . . . . . 0.594 ' O ' HG23 ' A' ' 169' ' ' VAL . 4.9 m-20 -58.89 -48.0 82.96 Favored 'General case' 0 C--N 1.332 -0.19 0 CA-C-O 120.945 0.403 . . . . 0.0 110.558 179.35 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 166' ' ' LEU . . . . . 0.522 ' O ' ' HG ' ' A' ' 170' ' ' LEU . 4.1 tt -63.69 -48.39 77.32 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 116.109 -0.496 . . . . 0.0 111.017 -179.958 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 167' ' ' THR . . . . . 0.427 ' O ' ' HB2' ' A' ' 171' ' ' TRP . 93.0 m -57.4 -53.91 52.74 Favored 'General case' 0 C--N 1.33 -0.251 0 N-CA-C 112.426 0.528 . . . . 0.0 112.426 -178.971 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 168' ' ' VAL . . . . . 0.513 ' HB ' HD13 ' A' ' 141' ' ' LEU . 12.9 p -55.95 -40.75 64.6 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 N-CA-C 112.335 0.494 . . . . 0.0 112.335 -179.281 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 169' ' ' VAL . . . . . 0.594 HG23 ' O ' ' A' ' 165' ' ' ASN . 61.2 t -57.71 -65.8 0.39 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.389 0 N-CA-C 111.987 0.366 . . . . 0.0 111.987 -179.518 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 170' ' ' LEU . . . . . 0.522 ' HG ' ' O ' ' A' ' 166' ' ' LEU . 0.8 OUTLIER -65.18 -27.75 68.92 Favored 'General case' 0 C--N 1.331 -0.212 0 N-CA-C 112.146 0.425 . . . . 0.0 112.146 -178.813 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 171' ' ' TRP . . . . . 0.73 ' HE1' H203 ' A' ' 301' ' ' RET . 6.9 m0 -71.77 -30.23 65.35 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.83 0.348 . . . . 0.0 110.612 179.615 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 172' ' ' ALA . . . . . 0.415 ' HA ' ' CZ ' ' A' ' 134' ' ' PHE . . . -73.7 -6.77 48.93 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.768 179.997 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 173' ' ' ILE . . . . . 0.627 HG22 HD11 ' A' ' 177' ' ' ILE . 23.6 mm -87.43 -21.63 7.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 115.93 -0.577 . . . . 0.0 110.771 179.739 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 174' ' ' TYR . . . . . 0.417 ' HB2' ' HD3' ' A' ' 175' ' ' PRO . 24.3 m-85 -54.86 -49.55 91.18 Favored Pre-proline 0 N--CA 1.464 0.228 0 CA-C-N 116.287 -0.415 . . . . 0.0 111.833 -179.796 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 175' ' ' PRO . . . . . 0.417 ' HD3' ' HB2' ' A' ' 174' ' ' TYR . 88.6 Cg_exo -47.02 -29.27 8.34 Favored 'Trans proline' 0 C--N 1.352 0.756 0 C-N-CA 122.131 1.887 . . . . 0.0 112.161 179.894 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 176' ' ' PHE . . . . . 0.444 ' O ' ' HG ' ' A' ' 180' ' ' LEU . 81.8 m-85 -80.47 -46.76 15.36 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 115.918 -0.583 . . . . 0.0 111.757 -179.965 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 177' ' ' ILE . . . . . 0.627 HD11 HG22 ' A' ' 173' ' ' ILE . 2.0 mm -64.49 -38.41 82.52 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.54 0 CA-C-N 116.166 -0.47 . . . . 0.0 112.177 -178.299 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 178' ' ' TRP . . . . . 0.503 ' HH2' ' HB2' ' A' ' 123' ' ' ARG . 60.2 t90 -73.83 -41.98 61.54 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.91 0.386 . . . . 0.0 110.779 179.67 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 179' ' ' LEU . . . . . 0.461 ' O ' HG22 ' A' ' 185' ' ' VAL . 1.7 tm? -66.27 -49.95 65.39 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.066 -0.516 . . . . 0.0 111.078 -179.622 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 180' ' ' LEU . . . . . 0.611 HD22 HD11 ' A' ' 187' ' ' LEU . 14.0 mt -78.21 -47.94 16.91 Favored 'General case' 0 C--N 1.329 -0.301 0 N-CA-C 112.038 0.384 . . . . 0.0 112.038 -179.22 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . -54.32 177.94 0.27 Allowed Glycine 0 C--N 1.337 0.6 0 C-N-CA 120.649 -0.786 . . . . 0.0 113.066 -179.701 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 182' ' ' PRO . . . . . 0.587 ' HA ' ' HB2' ' A' ' 186' ' ' ALA . 71.9 Cg_exo -48.13 -44.93 27.12 Favored 'Trans proline' 0 CA--C 1.536 0.598 0 C-N-CA 122.908 2.405 . . . . 0.0 113.764 -179.793 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 183' ' ' PRO . . . . . 0.416 ' HD3' ' HB2' ' A' ' 182' ' ' PRO . 50.6 Cg_exo -54.85 -13.68 6.6 Favored 'Trans proline' 0 C--N 1.355 0.906 0 C-N-CA 122.028 1.819 . . . . 0.0 113.017 -179.845 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 184' ' ' GLY . . . . . . . . . . . . . . . -115.5 -101.05 2.3 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.517 -0.849 . . . . 0.0 112.635 -179.776 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 185' ' ' VAL . . . . . 0.461 HG22 ' O ' ' A' ' 179' ' ' LEU . 9.0 m -105.98 -5.35 9.97 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-O 120.904 0.383 . . . . 0.0 111.305 -179.803 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 186' ' ' ALA . . . . . 0.587 ' HB2' ' HA ' ' A' ' 182' ' ' PRO . . . 55.17 85.4 0.06 Allowed 'General case' 0 C--N 1.331 -0.203 0 CA-C-N 115.991 -0.549 . . . . 0.0 111.991 179.302 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 187' ' ' LEU . . . . . 0.611 HD11 HD22 ' A' ' 180' ' ' LEU . 16.7 mt -92.21 -49.5 6.15 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.512 179.146 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 188' ' ' LEU . . . . . . . . . . . . . 95.5 mt -96.61 -160.96 0.83 Allowed 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 115.698 -0.683 . . . . 0.0 110.635 -179.944 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 189' ' ' THR . . . . . . . . . . . . . 1.9 t -99.76 146.49 31.94 Favored Pre-proline 0 C--N 1.329 -0.318 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.855 179.951 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 190' ' ' PRO . . . . . 0.44 ' O ' HG23 ' A' ' 194' ' ' VAL . 86.9 Cg_exo -46.76 -44.09 22.53 Favored 'Trans proline' 0 C--N 1.349 0.567 0 C-N-CA 122.698 2.266 . . . . 0.0 113.244 -179.417 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 191' ' ' THR . . . . . . . . . . . . . 7.9 t -58.85 -43.4 90.78 Favored 'General case' 0 C--N 1.328 -0.345 0 N-CA-C 111.899 0.333 . . . . 0.0 111.899 -179.286 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 192' ' ' VAL . . . . . . . . . . . . . 45.7 t -71.77 -50.71 36.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.633 -0.258 . . . . 0.0 111.402 -179.743 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 193' ' ' ASP . . . . . . . . . . . . . 30.5 t70 -55.23 -45.34 75.98 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.452 -0.34 . . . . 0.0 111.066 -179.848 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 194' ' ' VAL . . . . . 0.44 HG23 ' O ' ' A' ' 190' ' ' PRO . 74.6 t -64.34 -35.55 74.51 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.944 179.706 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 195' ' ' ALA . . . . . . . . . . . . . . . -56.97 -48.59 78.02 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 116.577 -0.283 . . . . 0.0 111.211 179.726 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 196' ' ' LEU . . . . . 0.412 ' O ' ' HB3' ' A' ' 199' ' ' TYR . 97.5 mt -67.76 -40.82 84.02 Favored 'General case' 0 N--CA 1.462 0.169 0 CA-C-O 120.708 0.289 . . . . 0.0 110.687 179.696 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 197' ' ' ILE . . . . . 0.489 HG12 HG21 ' A' ' 177' ' ' ILE . 11.2 mm -57.83 -60.25 2.41 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.373 179.256 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 198' ' ' VAL . . . . . 0.409 ' O ' ' HB2' ' A' ' 202' ' ' LEU . 76.3 t -52.02 -33.96 16.86 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.452 0 CA-C-N 115.486 -0.779 . . . . 0.0 109.574 178.324 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 199' ' ' TYR . . . . . 0.428 ' O ' HG23 ' A' ' 203' ' ' VAL . 68.5 t80 -69.27 -37.98 78.15 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 115.353 -0.84 . . . . 0.0 110.365 179.889 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 200' ' ' LEU . . . . . . . . . . . . . 42.0 mt -62.35 -45.71 91.97 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 115.667 -0.697 . . . . 0.0 111.212 -179.56 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 201' ' ' ASP . . . . . . . . . . . . . 7.3 m-20 -71.07 -43.64 67.38 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.114 -179.659 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 202' ' ' LEU . . . . . 0.409 ' HB2' ' O ' ' A' ' 198' ' ' VAL . 1.1 tt -59.95 -30.25 68.95 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 115.884 -0.598 . . . . 0.0 111.411 -179.476 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 203' ' ' VAL . . . . . 0.428 HG23 ' O ' ' A' ' 199' ' ' TYR . 48.5 t -81.43 -36.84 15.04 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.293 -0.412 . . . . 0.0 111.552 -178.726 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 204' ' ' THR . . . . . . . . . . . . . 71.0 m -62.46 -54.99 31.94 Favored 'General case' 0 C--N 1.328 -0.365 0 C-N-CA 120.508 -0.477 . . . . 0.0 111.009 179.497 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 205' ' ' LYS . . . . . 0.692 ' HE2' ' HB2' ' A' ' 47' ' ' ALA . 50.5 mttp -67.84 -59.13 3.53 Favored 'General case' 0 C--N 1.33 -0.245 0 N-CA-C 112.529 0.566 . . . . 0.0 112.529 -178.495 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 59.9 t -70.42 -37.55 70.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 N-CA-C 112.168 0.433 . . . . 0.0 112.168 -178.609 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 207' ' ' GLY . . . . . 0.544 ' O ' HG13 ' A' ' 211' ' ' ILE . . . -64.0 -60.66 6.96 Favored Glycine 0 N--CA 1.452 -0.254 0 C-N-CA 120.438 -0.887 . . . . 0.0 113.359 -178.866 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 208' ' ' PHE . . . . . 0.509 ' O ' ' HB2' ' A' ' 212' ' ' ALA . 0.1 OUTLIER -65.25 -26.91 68.31 Favored 'General case' 0 C--O 1.224 -0.289 0 CA-C-N 117.051 0.425 . . . . 0.0 111.064 -179.289 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 209' ' ' GLY . . . . . 0.515 ' O ' ' HB3' ' A' ' 212' ' ' ALA . . . -69.39 -32.7 71.99 Favored Glycine 0 N--CA 1.447 -0.588 0 N-CA-C 111.593 -0.603 . . . . 0.0 111.593 178.726 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 210' ' ' PHE . . . . . . . . . . . . . 2.0 m-85 -74.56 -48.28 27.74 Favored 'General case' 0 CA--C 1.513 -0.462 0 N-CA-C 108.159 -1.052 . . . . 0.0 108.159 178.343 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 211' ' ' ILE . . . . . 0.544 HG13 ' O ' ' A' ' 207' ' ' GLY . 5.5 mt -62.03 -28.63 44.77 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.594 0 N-CA-C 107.517 -1.29 . . . . 0.0 107.517 176.423 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 212' ' ' ALA . . . . . 0.515 ' HB3' ' O ' ' A' ' 209' ' ' GLY . . . -62.53 -41.14 98.68 Favored 'General case' 0 N--CA 1.447 -0.587 0 CA-C-N 114.527 -1.215 . . . . 0.0 109.915 179.394 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 213' ' ' LEU . . . . . 0.425 ' HG ' ' O ' ' A' ' 209' ' ' GLY . 74.0 mt -70.31 -46.71 63.7 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-N 115.027 -0.988 . . . . 0.0 111.712 -179.826 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 214' ' ' ASP . . . . . . . . . . . . . 10.9 t70 -51.16 -54.86 21.36 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 120.923 0.392 . . . . 0.0 111.278 -179.476 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 215' ' ' ALA . . . . . 0.412 ' O ' ' HG ' ' A' ' 219' ' ' LEU . . . -58.7 -52.79 64.19 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-N 115.978 -0.555 . . . . 0.0 111.367 -179.718 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 216' ' ' ALA . . . . . . . . . . . . . . . -58.92 -33.23 70.33 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.333 -0.394 . . . . 0.0 111.619 -179.586 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 217' ' ' ALA . . . . . . . . . . . . . . . -64.05 -36.11 82.92 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 121.012 0.434 . . . . 0.0 110.36 179.893 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 218' ' ' THR . . . . . . . . . . . . . 94.1 m -72.09 -38.79 69.3 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 115.69 -0.686 . . . . 0.0 110.977 179.572 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 219' ' ' LEU . . . . . 0.412 ' HG ' ' O ' ' A' ' 215' ' ' ALA . 54.3 mt -63.85 -33.7 76.27 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.163 -0.472 . . . . 0.0 111.018 -179.883 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 220' ' ' ARG . . . . . . . . . . . . . 45.9 mtp180 -83.64 -30.21 27.05 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.884 179.802 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 221' ' ' ALA . . . . . . . . . . . . . . . -72.24 -24.01 61.31 Favored 'General case' 0 C--N 1.331 -0.203 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.233 -179.992 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 222' ' ' GLU . . . . . . . . . . . . . 10.0 pt-20 -92.25 -26.66 18.05 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.987 0.422 . . . . 0.0 110.32 179.967 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 223' ' ' HIS . . . . . . . . . . . . . 77.5 m-70 62.17 -176.24 0.13 Allowed 'General case' 0 C--N 1.331 -0.206 0 CA-C-N 115.532 -0.758 . . . . 0.0 111.222 179.999 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 224' ' ' GLY . . . . . . . . . . . . . . . -159.95 129.1 2.11 Favored Glycine 0 N--CA 1.45 -0.372 0 C-N-CA 120.637 -0.792 . . . . 0.0 112.685 -179.904 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 225' ' ' GLU . . . . . . . . . . . . . 44.5 mt-10 59.93 101.41 0.02 OUTLIER 'General case' 0 C--N 1.331 -0.2 0 CA-C-O 120.976 0.417 . . . . 0.0 111.178 179.908 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 226' ' ' SER . . . . . . . . . . . . . 63.3 m -96.9 149.63 21.66 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 115.979 -0.555 . . . . 0.0 110.865 179.983 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 227' ' ' LEU . . . . . . . . . . . . . 71.6 mt -73.53 127.49 32.88 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.968 179.981 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 228' ' ' ALA . . . . . . . . . . . . . . . -105.79 -43.2 4.95 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.1 179.966 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 229' ' ' GLY . . . . . . . . . . . . . . . 170.62 -118.79 0.77 Allowed Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.681 -0.771 . . . . 0.0 112.726 -179.874 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 230' ' ' VAL . . . . . . . . . . . . . 50.8 t -72.27 140.71 17.59 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.197 0 CA-C-O 120.875 0.369 . . . . 0.0 111.213 -179.825 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 231' ' ' ASP . . . . . . . . . . . . . 6.0 p-10 -83.7 104.79 14.09 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.779 179.99 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 232' ' ' THR . . . . . . . . . . . . . 82.6 p -132.2 15.23 4.63 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.257 -179.867 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 233' ' ' ASP . . . . . . . . . . . . . 4.4 p30 -79.9 2.73 22.22 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.386 -0.37 . . . . 0.0 110.893 179.96 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 234' ' ' THR . . . . . . . . . . . . . 74.1 p -114.41 150.61 44.09 Favored Pre-proline 0 C--N 1.33 -0.254 0 CA-C-N 116.284 -0.416 . . . . 0.0 111.071 -179.998 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 235' ' ' PRO . . . . . . . . . . . . . 60.2 Cg_endo -72.19 -55.31 0.12 Allowed 'Trans proline' 0 C--N 1.347 0.456 0 C-N-CA 122.488 2.125 . . . . 0.0 112.605 -179.693 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 236' ' ' ALA . . . . . . . . . . . . . . . -82.12 173.47 12.12 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.353 -0.385 . . . . 0.0 111.464 -179.801 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 237' ' ' VAL . . . . . . . . . . . . . 11.5 p -144.09 141.15 24.85 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 115.948 -0.569 . . . . 0.0 110.855 179.939 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 238' ' ' ALA . . . . . . . . . . . . . . . -116.35 160.81 19.97 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.373 -0.376 . . . . 0.0 111.248 -179.791 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 239' ' ' ASP . . . . . . . . . . . . . 5.4 m-20 -94.01 164.06 13.24 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.854 -179.969 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 240' ' ' LEU . . . . . 0.435 HD23 ' N ' ' A' ' 240' ' ' LEU . 2.4 pt? -155.26 4.14 0.2 Allowed 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.381 -0.372 . . . . 0.0 110.972 179.899 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 241' ' ' GLU . . . . . . . . . . . . . 43.9 mt-10 -126.18 129.6 49.32 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.736 179.953 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 242' ' ' HIS . . . . . . . . . . . . . 69.2 m80 -85.45 171.75 11.55 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.158 -179.646 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 243' ' ' HIS . . . . . . . . . . . . . 42.8 m80 62.01 109.04 0.02 OUTLIER 'General case' 0 C--N 1.332 -0.169 0 CA-C-N 115.895 -0.593 . . . . 0.0 111.408 179.79 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 244' ' ' HIS . . . . . . . . . . . . . 69.2 m80 -116.05 5.26 13.83 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.027 -0.533 . . . . 0.0 110.795 179.899 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 245' ' ' HIS . . . . . . . . . . . . . 61.4 m80 61.39 102.04 0.03 OUTLIER 'General case' 0 N--CA 1.462 0.163 0 CA-C-N 116.027 -0.533 . . . . 0.0 110.913 -179.914 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 246' ' ' HIS . . . . . . . . . . . . . 8.3 p80 -147.02 -178.56 6.27 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.266 -0.424 . . . . 0.0 110.971 -179.804 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 247' ' ' HIS . . . . . . . . . . . . . 58.6 t-80 . . . . . 0 C--O 1.249 1.046 0 CA-C-O 118.34 -0.838 . . . . 0.0 110.968 -179.931 . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 301' ' ' RET . . . . . 0.73 H203 ' HE1' ' A' ' 171' ' ' TRP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 1' ' ' MET . . . . . 0.665 ' HG2' ' H ' ' A' ' 3' ' ' GLY . 54.6 ttp . . . . . 0 N--CA 1.486 1.343 0 CA-C-O 120.794 0.33 . . . . 0.0 110.726 . . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 32.7 m -97.5 -7.25 9.37 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-N 116.268 -0.424 . . . . 0.0 111.389 -179.783 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 3' ' ' GLY . . . . . 0.665 ' H ' ' HG2' ' A' ' 1' ' ' MET . . . -72.43 -14.0 77.29 Favored Glycine 0 N--CA 1.452 -0.288 0 C-N-CA 120.814 -0.708 . . . . 0.0 112.532 -179.824 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 4' ' ' LEU . . . . . 0.471 ' HA ' HD23 ' A' ' 7' ' ' LEU . 70.9 mt -72.97 -36.13 67.04 Favored 'General case' 0 N--CA 1.449 -0.491 0 CA-C-O 120.878 0.371 . . . . 0.0 110.989 179.835 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 45.5 p -53.09 -37.84 62.03 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 115.877 -0.601 . . . . 0.0 111.874 -179.466 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 70.8 p -56.34 -40.54 74.61 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.438 -0.346 . . . . 0.0 111.579 -179.491 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 7' ' ' LEU . . . . . 0.471 HD23 ' HA ' ' A' ' 4' ' ' LEU . 3.4 mm? -59.85 -52.49 65.21 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 116.402 -0.363 . . . . 0.0 110.967 179.997 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 8' ' ' PHE . . . . . 0.459 ' HB2' ' HB2' ' A' ' 55' ' ' ALA . 75.8 m-85 -58.5 -32.11 68.49 Favored 'General case' 0 C--N 1.331 -0.204 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.613 -179.907 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 9' ' ' TRP . . . . . 0.416 ' O ' HG12 ' A' ' 13' ' ' ILE . 17.1 m95 -67.19 -45.63 76.33 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.036 -0.529 . . . . 0.0 109.833 179.576 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 95.1 mt -58.1 -46.82 84.89 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 115.607 -0.724 . . . . 0.0 110.15 179.305 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -60.08 -34.56 84.3 Favored Glycine 0 N--CA 1.45 -0.415 0 C-N-CA 120.746 -0.74 . . . . 0.0 111.781 179.351 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -67.67 -30.4 69.93 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.767 0.317 . . . . 0.0 110.604 179.608 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 13' ' ' ILE . . . . . 0.416 HG12 ' O ' ' A' ' 9' ' ' TRP . 50.8 mm -67.35 -52.5 41.58 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.226 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.16 179.486 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -59.93 -34.67 84.13 Favored Glycine 0 N--CA 1.448 -0.503 0 C-N-CA 120.696 -0.764 . . . . 0.0 111.641 179.105 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 15' ' ' MET . . . . . 0.557 ' HB3' ' HB2' ' A' ' 48' ' ' ALA . 18.9 mmt -66.5 -40.42 89.24 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 120.666 0.269 . . . . 0.0 110.628 179.479 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -59.69 -40.46 87.92 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.313 -0.403 . . . . 0.0 110.149 179.353 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 60.5 t -61.4 -42.76 95.02 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.201 0 CA-C-N 116.058 -0.519 . . . . 0.0 110.53 179.34 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -69.36 -46.17 57.68 Favored Glycine 0 N--CA 1.452 -0.266 0 C-N-CA 120.793 -0.718 . . . . 0.0 111.927 179.626 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 24.6 m -50.69 -49.06 58.32 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-O 120.702 0.287 . . . . 0.0 111.249 -179.82 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 96.3 mt -72.06 -44.99 62.45 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 116.305 -0.407 . . . . 0.0 111.687 -179.85 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -59.78 -31.49 69.73 Favored 'General case' 0 C--N 1.329 -0.304 0 N-CA-C 112.095 0.405 . . . . 0.0 112.095 -179.007 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 22' ' ' PHE . . . . . 0.484 ' HB2' HG22 ' A' ' 41' ' ' VAL . 12.8 m-85 -91.19 -30.71 16.51 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 120.667 0.27 . . . . 0.0 111.429 -179.329 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -72.89 -50.68 22.3 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.948 0.404 . . . . 0.0 111.341 -179.69 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 24' ' ' TRP . . . . . . . . . . . . . 3.6 t-105 -61.62 -38.51 87.91 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-N 115.784 -0.643 . . . . 0.0 111.069 -179.809 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -80.63 -24.19 39.22 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.718 0.294 . . . . 0.0 111.221 179.992 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -73.05 -43.03 41.94 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.722 -0.752 . . . . 0.0 112.577 179.976 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 12.2 ptp180 -66.98 -18.26 65.3 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 120.759 0.314 . . . . 0.0 111.085 -179.953 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 31.3 t70 -97.0 17.66 16.46 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-O 121.057 0.456 . . . . 0.0 110.686 -179.659 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -99.33 176.3 5.57 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 115.935 -0.575 . . . . 0.0 111.176 -179.914 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -104.63 167.08 15.21 Favored Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.805 -0.712 . . . . 0.0 112.419 -179.991 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 73.4 m -64.36 120.49 12.33 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 120.9 0.381 . . . . 0.0 110.772 -179.953 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 128.11 -50.19 0.9 Allowed Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.959 -0.638 . . . . 0.0 112.19 -179.78 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 11.8 mm-40 -89.65 -20.6 23.47 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 121.009 0.433 . . . . 0.0 110.502 179.674 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 34' ' ' ARG . . . . . . . . . . . . . 34.2 ttm180 -52.09 -29.23 20.65 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 115.66 -0.7 . . . . 0.0 111.363 -179.862 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 41.8 ttm180 -59.39 -40.54 86.92 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-O 120.759 0.314 . . . . 0.0 110.845 179.861 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 91.8 m-85 -71.04 -32.4 69.13 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.878 179.753 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 37' ' ' TYR . . . . . 0.524 ' O ' HG23 ' A' ' 41' ' ' VAL . 61.0 m-85 -70.55 -54.7 11.09 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 116.055 -0.52 . . . . 0.0 111.243 -179.743 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 11.0 p -57.17 -36.5 51.93 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-O 120.914 0.388 . . . . 0.0 110.479 179.649 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 26.3 m -65.38 -45.2 85.03 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 115.896 -0.593 . . . . 0.0 110.565 179.474 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 40' ' ' LEU . . . . . 0.649 HD12 HD11 ' A' ' 43' ' ' ILE . 51.5 tp -65.6 -38.48 89.59 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 115.949 -0.568 . . . . 0.0 110.483 179.556 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 41' ' ' VAL . . . . . 0.524 HG23 ' O ' ' A' ' 37' ' ' TYR . 97.3 t -67.34 -34.34 68.32 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.446 0 CA-C-N 115.789 -0.641 . . . . 0.0 110.253 179.429 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 42' ' ' GLY . . . . . 0.416 ' O ' HG12 ' A' ' 46' ' ' ILE . . . -64.01 -46.59 90.96 Favored Glycine 0 N--CA 1.448 -0.545 0 CA-C-N 115.76 -0.655 . . . . 0.0 112.971 179.991 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 43' ' ' ILE . . . . . 0.649 HD11 HD12 ' A' ' 40' ' ' LEU . 39.4 pt -63.04 -44.03 99.36 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.217 0 CA-C-N 116.847 0.323 . . . . 0.0 111.659 -179.558 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 44' ' ' SER . . . . . 0.466 ' N ' HG13 ' A' ' 43' ' ' ILE . 72.1 m -66.62 -27.19 67.5 Favored 'General case' 0 C--N 1.332 -0.159 0 CA-C-O 120.911 0.386 . . . . 0.0 110.808 179.604 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -78.56 -49.74 6.48 Favored Glycine 0 CA--C 1.519 0.286 0 C-N-CA 121.036 -0.602 . . . . 0.0 113.306 -179.256 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 46' ' ' ILE . . . . . 0.682 HD12 HD12 ' A' ' 78' ' ' LEU . 7.7 pt -58.09 -44.02 86.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-O 120.848 0.356 . . . . 0.0 111.04 -179.588 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 47' ' ' ALA . . . . . 0.546 ' HB2' ' HE2' ' A' ' 205' ' ' LYS . . . -67.73 -39.01 84.31 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-O 120.794 0.331 . . . . 0.0 110.578 179.077 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 48' ' ' ALA . . . . . 0.557 ' HB2' ' HB3' ' A' ' 15' ' ' MET . . . -55.0 -48.01 73.88 Favored 'General case' 0 C--N 1.332 -0.18 0 CA-C-N 116.11 -0.496 . . . . 0.0 111.579 -179.888 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 49' ' ' VAL . . . . . 0.485 HG22 ' O ' ' A' ' 46' ' ' ILE . 28.7 m -67.78 -34.28 66.69 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.473 -0.33 . . . . 0.0 111.275 -179.548 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -63.7 -37.63 88.06 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-O 120.986 0.422 . . . . 0.0 111.132 179.627 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 51' ' ' TYR . . . . . 0.412 ' O ' ' HB3' ' A' ' 8' ' ' PHE . 33.4 m-85 -72.67 -34.56 67.3 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 116.082 -0.508 . . . . 0.0 110.516 -179.766 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -68.25 -42.76 79.21 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 115.979 -0.555 . . . . 0.0 111.056 179.566 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 53' ' ' VAL . . . . . 0.414 HG23 ' N ' ' A' ' 54' ' ' MET . 33.0 m -69.62 -43.75 80.08 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.126 0 CA-C-N 116.44 -0.346 . . . . 0.0 110.876 179.978 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 54' ' ' MET . . . . . 0.567 ' HG2' ' HG2' ' A' ' 71' ' ' PRO . 74.6 mtm -65.03 -34.19 77.83 Favored 'General case' 0 CA--C 1.519 -0.222 0 N-CA-C 109.582 -0.525 . . . . 0.0 109.582 178.955 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 55' ' ' ALA . . . . . 0.459 ' HB2' ' HB2' ' A' ' 8' ' ' PHE . . . -65.97 -17.31 64.59 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.414 -0.812 . . . . 0.0 111.009 179.49 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 95.9 mt -100.08 8.61 43.81 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.339 -0.391 . . . . 0.0 111.0 179.952 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 74.26 20.91 79.55 Favored Glycine 0 N--CA 1.45 -0.371 0 C-N-CA 120.809 -0.71 . . . . 0.0 112.492 179.991 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 24.9 t -92.19 130.72 40.89 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-O 120.784 0.326 . . . . 0.0 110.903 179.884 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 94.0 0.73 65.76 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.855 -0.688 . . . . 0.0 112.753 -179.911 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 60' ' ' TRP . . . . . . . . . . . . . 13.0 m0 -75.21 111.15 10.17 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.76 0.314 . . . . 0.0 110.89 179.864 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 8.4 p -110.77 132.0 21.83 Favored Pre-proline 0 C--N 1.33 -0.271 0 CA-C-N 116.344 -0.389 . . . . 0.0 111.059 179.887 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 74.4 Cg_endo -76.25 147.18 29.13 Favored 'Trans proline' 0 C--N 1.349 0.576 0 C-N-CA 122.372 2.048 . . . . 0.0 112.229 179.742 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 93.9 t -141.51 91.98 0.55 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 115.996 -0.547 . . . . 0.0 111.181 -179.791 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . 58.04 -87.79 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.01 -0.541 . . . . 0.0 111.771 179.574 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 9.0 tp10 -118.08 -21.43 8.26 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.452 -0.34 . . . . 0.0 111.251 -179.59 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 66' ' ' ARG . . . . . . . . . . . . . 99.6 mtt180 -107.03 162.98 13.37 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.368 -0.378 . . . . 0.0 110.63 179.875 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 33.4 m -118.96 124.6 47.43 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.968 0.414 . . . . 0.0 111.455 -179.843 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 68' ' ' VAL . . . . . 0.515 HG21 ' HB3' ' A' ' 117' ' ' MET . 57.7 t -103.6 146.64 10.95 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.361 0 CA-C-N 115.815 -0.63 . . . . 0.0 110.645 179.744 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 69' ' ' PHE . . . . . . . . . . . . . 16.8 m-85 -107.79 112.19 24.72 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.399 -0.364 . . . . 0.0 110.039 -179.688 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 70' ' ' VAL . . . . . 0.607 ' N ' ' HD2' ' A' ' 71' ' ' PRO . 21.5 t -66.73 -48.83 52.13 Favored Pre-proline 0 C--N 1.323 -0.56 0 CA-C-N 116.047 -0.524 . . . . 0.0 111.953 -179.285 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 71' ' ' PRO . . . . . 0.607 ' HD2' ' N ' ' A' ' 70' ' ' VAL . 18.2 Cg_endo -59.8 -17.78 45.24 Favored 'Trans proline' 0 C--N 1.35 0.654 0 C-N-CA 122.279 1.986 . . . . 0.0 113.183 -179.64 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 72' ' ' ARG . . . . . 0.409 HH22 HG22 ' A' ' 194' ' ' VAL . 23.9 ttm180 -78.46 -55.82 4.92 Favored 'General case' 0 C--O 1.234 0.278 0 C-N-CA 120.961 -0.296 . . . . 0.0 111.621 -179.607 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 73' ' ' TYR . . . . . 0.473 ' O ' HG13 ' A' ' 77' ' ' ILE . 95.2 m-85 -70.47 -31.64 68.87 Favored 'General case' 0 C--N 1.329 -0.29 0 C-N-CA 120.89 -0.324 . . . . 0.0 110.482 -179.652 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 74' ' ' ILE . . . . . 0.55 ' HA ' HD12 ' A' ' 77' ' ' ILE . 0.3 OUTLIER -69.5 -39.29 78.36 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 N-CA-C 109.259 -0.645 . . . . 0.0 109.259 178.716 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 75' ' ' ASP . . . . . 0.443 ' O ' ' HG ' ' A' ' 78' ' ' LEU . 14.8 t70 -57.23 -37.38 72.19 Favored 'General case' 0 N--CA 1.452 -0.334 0 N-CA-C 109.113 -0.699 . . . . 0.0 109.113 178.461 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 76' ' ' TRP . . . . . 0.435 ' HA ' ' OG1' ' A' ' 79' ' ' THR . 44.7 m0 -70.26 -34.03 72.31 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 115.611 -0.722 . . . . 0.0 110.527 179.086 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 77' ' ' ILE . . . . . 0.55 HD12 ' HA ' ' A' ' 74' ' ' ILE . 94.2 mt -58.45 -38.71 71.66 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.236 0 CA-C-N 116.285 -0.416 . . . . 0.0 111.022 179.781 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 78' ' ' LEU . . . . . 0.682 HD12 HD12 ' A' ' 46' ' ' ILE . 1.1 pp -91.52 -34.12 14.9 Favored 'General case' 0 CA--C 1.536 0.41 0 N-CA-C 113.205 0.817 . . . . 0.0 113.205 -179.643 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 79' ' ' THR . . . . . 0.467 HG22 ' CD1' ' A' ' 46' ' ' ILE . 52.1 p -76.09 -52.5 10.01 Favored 'General case' 0 N--CA 1.47 0.538 0 N-CA-C 113.316 0.858 . . . . 0.0 113.316 -178.314 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 80' ' ' THR . . . . . 0.543 ' N ' ' HD2' ' A' ' 81' ' ' PRO . 3.9 m -50.76 -48.94 82.1 Favored Pre-proline 0 CA--C 1.532 0.255 0 N-CA-C 112.961 0.726 . . . . 0.0 112.961 -178.162 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 81' ' ' PRO . . . . . 0.543 ' HD2' ' N ' ' A' ' 80' ' ' THR . 28.9 Cg_endo -61.37 -25.31 79.97 Favored 'Trans proline' 0 C--N 1.352 0.717 0 C-N-CA 121.549 1.499 . . . . 0.0 111.631 -179.885 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 82' ' ' LEU . . . . . 0.506 ' HB3' HG22 ' A' ' 43' ' ' ILE . 0.1 OUTLIER -74.43 -34.76 63.3 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 115.876 -0.602 . . . . 0.0 110.23 179.698 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 49.6 mm -67.46 -53.64 30.41 Favored 'Isoleucine or valine' 0 C--O 1.234 0.253 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.029 179.165 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 84' ' ' VAL . . . . . 0.757 HG11 HD22 ' A' ' 105' ' ' ASN . 33.0 m -59.94 -30.03 44.55 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.255 0 CA-C-N 115.959 -0.564 . . . . 0.0 109.552 178.96 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 85' ' ' TYR . . . . . . . . . . . . . 89.8 t80 -67.35 -33.39 75.15 Favored 'General case' 0 N--CA 1.454 -0.275 0 CA-C-N 115.536 -0.757 . . . . 0.0 109.591 178.772 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 86' ' ' PHE . . . . . . . . . . . . . 8.3 t80 -61.81 -50.72 71.16 Favored 'General case' 0 C--O 1.234 0.259 0 CA-C-N 115.769 -0.651 . . . . 0.0 109.87 179.317 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 8.0 mp -60.91 -31.1 70.62 Favored 'General case' 0 C--N 1.332 -0.193 0 CA-C-N 115.872 -0.604 . . . . 0.0 110.232 179.617 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -70.89 -27.67 71.88 Favored Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.971 -0.633 . . . . 0.0 112.122 179.461 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 73.4 mt -71.55 -45.52 62.06 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-O 120.94 0.4 . . . . 0.0 110.514 179.934 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 90' ' ' LEU . . . . . 0.463 HD11 HD22 ' A' ' 163' ' ' LEU . 98.0 mt -54.48 -43.21 71.55 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 115.797 -0.638 . . . . 0.0 111.477 -179.918 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 91' ' ' ALA . . . . . 0.435 ' HB2' ' HB2' ' A' ' 149' ' ' ALA . . . -78.6 -54.99 5.55 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 116.488 -0.324 . . . . 0.0 111.399 -179.748 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 105.23 63.96 0.65 Allowed Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.89 -0.672 . . . . 0.0 112.331 179.98 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 93' ' ' LEU . . . . . 0.572 HD23 ' HB3' ' A' ' 97' ' ' GLU . 7.4 mp -80.69 172.62 13.52 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.794 0.33 . . . . 0.0 111.032 -179.874 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 94' ' ' ASP . . . . . . . . . . . . . 14.2 m-20 -89.19 164.9 14.78 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.099 -0.5 . . . . 0.0 110.808 179.841 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 80.7 p -53.92 -34.54 59.85 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.113 -0.494 . . . . 0.0 111.086 -179.954 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 41.5 mmt180 -72.61 -48.4 40.02 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.374 -179.631 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 97' ' ' GLU . . . . . 0.572 ' HB3' HD23 ' A' ' 93' ' ' LEU . 42.3 mt-10 -54.94 -49.23 71.86 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 116.404 -0.362 . . . . 0.0 111.134 -179.837 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 98' ' ' PHE . . . . . 0.483 ' O ' HG12 ' A' ' 102' ' ' ILE . 33.0 m-85 -55.25 -49.94 70.74 Favored 'General case' 0 C--N 1.332 -0.175 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.689 179.755 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -54.42 -32.68 52.58 Favored Glycine 0 N--CA 1.452 -0.286 0 C-N-CA 120.93 -0.652 . . . . 0.0 112.694 -179.756 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 96.4 mt -69.54 -43.07 80.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-O 120.882 0.372 . . . . 0.0 111.629 -179.684 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 61.0 t -71.87 -40.58 68.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.325 -0.398 . . . . 0.0 111.989 -179.225 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 102' ' ' ILE . . . . . 0.483 HG12 ' O ' ' A' ' 98' ' ' PHE . 38.0 mm -68.78 -41.24 82.26 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.363 0 N-CA-C 111.954 0.353 . . . . 0.0 111.954 -179.097 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 103' ' ' THR . . . . . 0.429 HG23 ' N ' ' A' ' 104' ' ' LEU . 12.4 t -64.93 -44.5 89.31 Favored 'General case' 0 C--O 1.234 0.247 0 CA-C-O 120.679 0.276 . . . . 0.0 111.314 -179.719 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 104' ' ' LEU . . . . . 0.434 ' O ' HG23 ' A' ' 108' ' ' VAL . 9.2 tt -58.47 -44.18 89.21 Favored 'General case' 0 C--N 1.332 -0.164 0 CA-C-O 120.813 0.339 . . . . 0.0 110.252 179.776 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 105' ' ' ASN . . . . . 0.757 HD22 HG11 ' A' ' 84' ' ' VAL . 5.3 m-20 -56.29 -41.63 76.21 Favored 'General case' 0 N--CA 1.455 -0.179 0 CA-C-N 116.149 -0.478 . . . . 0.0 109.857 178.852 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 85.2 m -54.71 -40.14 68.91 Favored 'General case' 0 C--N 1.332 -0.157 0 CA-C-N 116.075 -0.511 . . . . 0.0 110.269 179.508 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 107' ' ' VAL . . . . . 0.404 HG12 ' SD ' ' A' ' 129' ' ' MET . 0.9 OUTLIER -67.45 -37.4 78.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 115.843 -0.617 . . . . 0.0 110.189 179.114 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 108' ' ' VAL . . . . . 0.439 HG12 H173 ' A' ' 301' ' ' RET . 64.4 t -65.72 -52.04 54.99 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-N 115.33 -0.85 . . . . 0.0 111.686 -179.471 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 109' ' ' MET . . . . . 0.55 ' HG3' ' HA ' ' A' ' 77' ' ' ILE . 5.4 mmt -61.33 -39.72 91.57 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.35 -0.386 . . . . 0.0 111.18 -179.514 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 21.6 tp -64.42 -31.59 72.87 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.339 -0.392 . . . . 0.0 110.436 179.762 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 111' ' ' ALA . . . . . 0.403 ' O ' ' HB3' ' A' ' 126' ' ' LEU . . . -62.94 -56.59 15.85 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.528 179.344 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . -60.58 -36.8 92.25 Favored Glycine 0 C--N 1.329 0.193 0 C-N-CA 120.445 -0.883 . . . . 0.0 111.813 179.483 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 113' ' ' PHE . . . . . . . . . . . . . 10.1 t80 -49.45 -63.04 1.22 Allowed 'General case' 0 C--N 1.331 -0.222 0 CA-C-O 121.119 0.485 . . . . 0.0 110.201 179.429 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 114' ' ' ALA . . . . . 0.452 ' O ' HG13 ' A' ' 118' ' ' VAL . . . -69.66 -28.1 65.6 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 115.562 -0.744 . . . . 0.0 111.189 179.591 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -52.18 -35.87 43.16 Favored Glycine 0 C--N 1.332 0.316 0 CA-C-N 116.061 -0.518 . . . . 0.0 112.785 179.907 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -78.13 -44.81 25.04 Favored 'General case' 0 C--N 1.329 -0.316 0 N-CA-C 112.132 0.419 . . . . 0.0 112.132 -179.862 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 117' ' ' MET . . . . . 0.515 ' HB3' HG21 ' A' ' 68' ' ' VAL . 15.7 ptp -85.58 19.72 2.32 Favored 'General case' 0 C--N 1.33 -0.243 0 N-CA-C 112.149 0.426 . . . . 0.0 112.149 -179.007 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 118' ' ' VAL . . . . . 0.573 HG21 ' HB3' ' A' ' 123' ' ' ARG . 8.8 m -57.87 146.34 67.89 Favored Pre-proline 0 C--N 1.328 -0.332 0 CA-C-N 116.807 -0.178 . . . . 0.0 111.253 179.618 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 119' ' ' PRO . . . . . . . . . . . . . 71.8 Cg_endo -75.56 -9.06 19.87 Favored 'Trans proline' 0 C--N 1.347 0.476 0 C-N-CA 122.574 2.183 . . . . 0.0 112.381 -179.88 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -172.35 -122.95 0.68 Allowed Glycine 0 C--N 1.331 0.277 0 C-N-CA 120.662 -0.78 . . . . 0.0 112.711 -179.98 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 50.5 pt -83.38 8.06 1.39 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.23 0 CA-C-O 120.827 0.346 . . . . 0.0 111.334 -179.915 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 122' ' ' GLU . . . . . 0.478 ' HB2' ' HB ' ' A' ' 118' ' ' VAL . 11.7 mm-40 -58.57 -19.03 34.74 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.086 179.993 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 123' ' ' ARG . . . . . 0.573 ' HB3' HG21 ' A' ' 118' ' ' VAL . 12.6 ptt180 -52.33 -30.95 30.98 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.062 -0.517 . . . . 0.0 111.494 -179.842 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 124' ' ' TYR . . . . . . . . . . . . . 24.7 m-85 -71.96 -32.54 67.37 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.378 -0.373 . . . . 0.0 111.116 -179.686 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 125' ' ' ALA . . . . . . . . . . . . . . . -68.88 -51.07 44.14 Favored 'General case' 0 C--O 1.235 0.321 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.939 179.626 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 126' ' ' LEU . . . . . 0.403 ' HB3' ' O ' ' A' ' 111' ' ' ALA . 2.9 mm? -54.99 -55.85 26.28 Favored 'General case' 0 CA--C 1.52 -0.209 0 CA-C-N 116.015 -0.539 . . . . 0.0 110.882 -179.827 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 127' ' ' PHE . . . . . 0.464 ' HZ ' ' HB3' ' A' ' 175' ' ' PRO . 7.8 t80 -65.33 -33.25 75.52 Favored 'General case' 0 N--CA 1.45 -0.435 0 CA-C-N 116.258 -0.428 . . . . 0.0 111.466 -179.065 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 128' ' ' GLY . . . . . . . . . . . . . . . -49.67 -45.3 38.89 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 119.816 -1.183 . . . . 0.0 110.623 179.009 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 129' ' ' MET . . . . . 0.404 ' SD ' HG12 ' A' ' 107' ' ' VAL . 0.6 OUTLIER -71.71 -38.89 70.46 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 115.072 -0.564 . . . . 0.0 110.356 178.881 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -67.05 -27.41 73.44 Favored Glycine 0 C--N 1.331 0.283 0 CA-C-N 115.897 -0.592 . . . . 0.0 113.002 -179.613 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -74.85 -53.23 9.46 Favored 'General case' 0 C--N 1.328 -0.348 0 N-CA-C 110.012 -0.366 . . . . 0.0 110.012 179.86 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 95.9 t -57.23 -39.83 69.86 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.234 0 CA-C-O 121.347 0.594 . . . . 0.0 109.458 178.507 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -70.39 -34.17 72.24 Favored 'General case' 0 N--CA 1.452 -0.344 0 CA-C-N 115.297 -0.865 . . . . 0.0 110.69 179.423 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 134' ' ' PHE . . . . . 0.46 ' HB2' H182 ' A' ' 301' ' ' RET . 50.2 t80 -55.4 -60.14 3.82 Favored 'General case' 0 N--CA 1.453 -0.304 0 CA-C-O 120.985 0.422 . . . . 0.0 110.164 179.689 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 135' ' ' ILE . . . . . 0.494 ' O ' HG22 ' A' ' 138' ' ' VAL . 0.0 OUTLIER -55.75 -34.74 37.24 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 115.764 -0.653 . . . . 0.0 109.854 178.975 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 136' ' ' GLY . . . . . 0.413 ' O ' ' HB3' ' A' ' 139' ' ' TYR . . . -58.1 -41.66 94.72 Favored Glycine 0 N--CA 1.449 -0.477 0 C-N-CA 120.389 -0.91 . . . . 0.0 111.488 178.777 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 137' ' ' LEU . . . . . . . . . . . . . 45.1 tp -66.05 -56.25 12.51 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-O 120.68 0.276 . . . . 0.0 110.446 179.215 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 138' ' ' VAL . . . . . 0.517 ' O ' HG23 ' A' ' 142' ' ' VAL . 2.7 m -55.12 -30.33 23.96 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.237 0 CA-C-O 121.134 0.492 . . . . 0.0 109.813 -179.994 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 139' ' ' TYR . . . . . 0.413 ' HB3' ' O ' ' A' ' 136' ' ' GLY . 12.2 t80 -61.8 -42.33 98.87 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 115.682 -0.69 . . . . 0.0 109.804 178.566 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 29.1 m-85 -69.29 -35.22 75.79 Favored 'General case' 0 C--N 1.333 -0.15 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.494 179.064 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 141' ' ' LEU . . . . . 0.406 ' HB3' ' HD3' ' A' ' 164' ' ' ARG . 11.0 mp -62.8 -27.22 69.16 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.502 179.578 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 142' ' ' VAL . . . . . 0.619 HG22 HH11 ' A' ' 164' ' ' ARG . 12.4 t -103.88 -11.6 9.28 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.226 0 CA-C-N 116.008 -0.542 . . . . 0.0 111.103 179.964 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . -76.66 -117.24 0.15 Allowed Glycine 0 CA--C 1.523 0.566 0 C-N-CA 120.937 -0.649 . . . . 0.0 113.115 -179.702 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 144' ' ' PRO . . . . . . . . . . . . . 47.2 Cg_endo -68.35 -23.51 38.2 Favored 'Trans proline' 0 C--N 1.35 0.638 0 C-N-CA 122.67 2.246 . . . . 0.0 113.195 -179.298 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 145' ' ' MET . . . . . . . . . . . . . 58.2 mtt -65.47 -30.27 71.03 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.676 0.274 . . . . 0.0 111.403 -179.775 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 146' ' ' THR . . . . . 0.422 ' OG1' ' HA ' ' A' ' 142' ' ' VAL . 82.9 m -81.16 -32.38 33.66 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.852 0.358 . . . . 0.0 111.345 -179.31 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 38.6 tt0 -75.92 -40.65 53.82 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.119 -179.919 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 148' ' ' SER . . . . . 0.433 ' HB3' ' HB1' ' A' ' 91' ' ' ALA . 46.0 t -70.3 -45.26 66.65 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.278 -0.419 . . . . 0.0 111.242 -179.473 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 149' ' ' ALA . . . . . 0.435 ' HB2' ' HB2' ' A' ' 91' ' ' ALA . . . -65.69 -32.33 73.82 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.27 -0.423 . . . . 0.0 111.416 -179.543 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 150' ' ' SER . . . . . . . . . . . . . 80.3 p -74.47 0.45 14.64 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.283 -0.417 . . . . 0.0 111.331 -179.717 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 151' ' ' GLN . . . . . . . . . . . . . 10.3 pt20 -136.3 9.84 3.22 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.54 -0.3 . . . . 0.0 110.996 179.787 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 1.5 tmt_? -83.84 -51.81 6.89 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-O 120.833 0.349 . . . . 0.0 110.435 179.997 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 153' ' ' SER . . . . . 0.676 ' HB2' HG12 ' A' ' 156' ' ' ILE . 20.8 m -157.54 172.47 18.5 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.024 -0.535 . . . . 0.0 110.507 179.314 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 154' ' ' SER . . . . . . . . . . . . . 48.1 t -73.05 -38.32 66.53 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.378 -0.374 . . . . 0.0 110.729 179.849 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -77.36 -27.55 59.4 Favored Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.944 -0.646 . . . . 0.0 112.718 179.993 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 156' ' ' ILE . . . . . 0.676 HG12 ' HB2' ' A' ' 153' ' ' SER . 38.1 mm -62.03 -35.44 68.52 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-O 120.799 0.333 . . . . 0.0 110.923 -179.944 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 157' ' ' LYS . . . . . . . . . . . . . 91.3 mttt -58.93 -55.55 33.75 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.067 -0.515 . . . . 0.0 111.617 -179.888 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 69.0 m -70.49 -38.58 74.38 Favored 'General case' 0 N--CA 1.463 0.21 0 N-CA-C 112.256 0.465 . . . . 0.0 112.256 -178.847 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 159' ' ' LEU . . . . . . . . . . . . . 39.0 tp -69.13 -36.25 77.26 Favored 'General case' 0 C--N 1.327 -0.411 0 N-CA-C 111.74 0.274 . . . . 0.0 111.74 -179.148 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 160' ' ' TYR . . . . . . . . . . . . . 57.0 t80 -73.96 -46.11 46.05 Favored 'General case' 0 C--N 1.328 -0.366 0 N-CA-C 111.9 0.333 . . . . 0.0 111.9 -179.027 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 29.4 m -59.96 -41.73 87.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-O 120.721 0.296 . . . . 0.0 111.332 -179.634 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 162' ' ' ARG . . . . . 0.537 ' HG2' HG21 ' A' ' 211' ' ' ILE . 23.3 tpp180 -68.99 -39.89 79.11 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 120.944 0.402 . . . . 0.0 110.97 179.949 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 163' ' ' LEU . . . . . 0.54 ' HG ' ' HB2' ' A' ' 208' ' ' PHE . 4.5 mp -68.25 -44.32 75.9 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.069 -0.514 . . . . 0.0 111.668 -179.505 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 164' ' ' ARG . . . . . 0.619 HH11 HG22 ' A' ' 142' ' ' VAL . 18.4 ttp85 -72.01 -52.97 14.45 Favored 'General case' 0 C--N 1.329 -0.324 0 N-CA-C 112.125 0.417 . . . . 0.0 112.125 -179.003 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 165' ' ' ASN . . . . . 0.444 ' O ' HG23 ' A' ' 169' ' ' VAL . 4.7 m-20 -52.31 -46.31 65.93 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-O 121.056 0.455 . . . . 0.0 110.534 -179.291 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 166' ' ' LEU . . . . . 0.528 ' O ' ' HG ' ' A' ' 170' ' ' LEU . 6.8 tt -64.9 -52.08 58.45 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-N 115.809 -0.632 . . . . 0.0 111.141 179.955 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 167' ' ' THR . . . . . 0.476 ' O ' ' HB2' ' A' ' 171' ' ' TRP . 96.4 m -61.32 -54.09 48.34 Favored 'General case' 0 N--CA 1.463 0.185 0 N-CA-C 112.608 0.596 . . . . 0.0 112.608 -178.653 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 168' ' ' VAL . . . . . . . . . . . . . 94.0 t -52.2 -41.09 32.56 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.185 0 N-CA-C 112.134 0.42 . . . . 0.0 112.134 -179.284 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 169' ' ' VAL . . . . . 0.444 HG23 ' O ' ' A' ' 165' ' ' ASN . 43.9 t -61.96 -64.63 0.6 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 N-CA-C 111.965 0.357 . . . . 0.0 111.965 -179.452 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 170' ' ' LEU . . . . . 0.528 ' HG ' ' O ' ' A' ' 166' ' ' LEU . 1.3 pp -62.55 -29.37 70.52 Favored 'General case' 0 C--N 1.331 -0.206 0 N-CA-C 112.081 0.4 . . . . 0.0 112.081 -178.777 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 171' ' ' TRP . . . . . 0.624 ' HZ2' H202 ' A' ' 301' ' ' RET . 2.7 m0 -72.87 -30.78 64.25 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.842 0.353 . . . . 0.0 110.737 179.83 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 172' ' ' ALA . . . . . 0.404 ' HA ' ' CZ ' ' A' ' 134' ' ' PHE . . . -73.65 -6.21 45.29 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-O 121.093 0.473 . . . . 0.0 110.286 179.647 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 173' ' ' ILE . . . . . 0.467 ' O ' HG12 ' A' ' 177' ' ' ILE . 44.1 mm -85.14 -20.93 8.07 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.241 0 CA-C-N 115.678 -0.692 . . . . 0.0 110.484 179.148 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 174' ' ' TYR . . . . . . . . . . . . . 13.2 m-85 -53.21 -50.07 84.4 Favored Pre-proline 0 N--CA 1.464 0.268 0 CA-C-N 116.126 -0.488 . . . . 0.0 111.18 -179.867 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 175' ' ' PRO . . . . . 0.464 ' HB3' ' HZ ' ' A' ' 127' ' ' PHE . 93.1 Cg_exo -45.17 -33.07 7.78 Favored 'Trans proline' 0 C--N 1.351 0.684 0 C-N-CA 122.252 1.968 . . . . 0.0 112.152 179.308 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 176' ' ' PHE . . . . . 0.504 ' O ' ' HG ' ' A' ' 180' ' ' LEU . 85.4 m-85 -80.82 -50.12 10.23 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 115.772 -0.649 . . . . 0.0 112.023 -179.618 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 177' ' ' ILE . . . . . 0.531 HG13 HD11 ' A' ' 200' ' ' LEU . 4.1 mm -63.42 -35.03 70.8 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.547 0 N-CA-C 112.546 0.573 . . . . 0.0 112.546 -177.867 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 178' ' ' TRP . . . . . . . . . . . . . 73.5 t90 -73.87 -52.37 13.2 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-O 120.887 0.375 . . . . 0.0 110.856 179.87 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 179' ' ' LEU . . . . . 0.487 HD23 HD23 ' A' ' 180' ' ' LEU . 0.5 OUTLIER -64.83 -54.34 32.55 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.079 -0.51 . . . . 0.0 111.677 -179.004 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 180' ' ' LEU . . . . . 0.6 HD22 HD11 ' A' ' 187' ' ' LEU . 27.9 mt -64.32 -49.09 73.09 Favored 'General case' 0 C--N 1.326 -0.448 0 C-N-CA 120.812 -0.355 . . . . 0.0 111.201 -179.529 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . -57.38 179.93 0.77 Allowed Glycine 0 C--N 1.338 0.651 0 C-N-CA 120.284 -0.96 . . . . 0.0 112.37 179.511 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 182' ' ' PRO . . . . . 0.717 ' HA ' ' HB2' ' A' ' 186' ' ' ALA . 89.0 Cg_exo -46.99 -45.04 21.89 Favored 'Trans proline' 0 CA--C 1.536 0.593 0 C-N-CA 122.969 2.446 . . . . 0.0 113.994 -179.657 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 183' ' ' PRO . . . . . 0.424 ' HD3' ' HB2' ' A' ' 182' ' ' PRO . 88.4 Cg_exo -48.14 -25.29 6.55 Favored 'Trans proline' 0 C--N 1.354 0.845 0 C-N-CA 122.303 2.002 . . . . 0.0 113.762 -179.509 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 184' ' ' GLY . . . . . 0.433 ' HA3' ' O ' ' A' ' 179' ' ' LEU . . . -112.86 -81.63 1.1 Allowed Glycine 0 C--N 1.334 0.437 0 C-N-CA 120.098 -1.049 . . . . 0.0 113.617 -179.443 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 185' ' ' VAL . . . . . . . . . . . . . 14.5 m -120.86 -8.6 10.27 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.203 0 N-CA-C 112.17 0.433 . . . . 0.0 112.17 -178.696 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 186' ' ' ALA . . . . . 0.717 ' HB2' ' HA ' ' A' ' 182' ' ' PRO . . . 57.56 85.9 0.08 Allowed 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.494 -0.321 . . . . 0.0 111.714 179.562 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 187' ' ' LEU . . . . . 0.6 HD11 HD22 ' A' ' 180' ' ' LEU . 17.9 mt -91.99 -49.33 6.28 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-O 120.963 0.411 . . . . 0.0 110.695 179.518 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 188' ' ' LEU . . . . . . . . . . . . . 86.2 mt -95.87 -158.39 0.65 Allowed 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 115.807 -0.633 . . . . 0.0 110.792 -179.766 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 189' ' ' THR . . . . . 0.511 HG22 HG22 ' A' ' 191' ' ' THR . 24.9 m -91.38 136.91 26.38 Favored Pre-proline 0 C--N 1.327 -0.378 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.566 -179.885 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 190' ' ' PRO . . . . . 0.449 ' O ' HG23 ' A' ' 194' ' ' VAL . 93.7 Cg_exo -44.35 -53.63 4.69 Favored 'Trans proline' 0 C--N 1.351 0.68 0 C-N-CA 122.559 2.172 . . . . 0.0 113.094 -179.786 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 191' ' ' THR . . . . . 0.511 HG22 HG22 ' A' ' 189' ' ' THR . 3.0 t -56.81 -36.8 70.34 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.703 0.287 . . . . 0.0 111.455 -179.721 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 192' ' ' VAL . . . . . 0.43 HG23 ' HB ' ' A' ' 189' ' ' THR . 92.7 t -70.46 -42.06 78.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.423 -0.353 . . . . 0.0 110.982 179.952 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 193' ' ' ASP . . . . . . . . . . . . . 24.8 t70 -61.6 -40.17 93.82 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.468 179.743 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 194' ' ' VAL . . . . . 0.449 HG23 ' O ' ' A' ' 190' ' ' PRO . 99.9 t -65.11 -35.88 76.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.026 -0.534 . . . . 0.0 110.229 179.323 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 195' ' ' ALA . . . . . . . . . . . . . . . -57.7 -48.4 79.66 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.846 179.48 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 196' ' ' LEU . . . . . . . . . . . . . 92.5 mt -67.9 -43.22 79.78 Favored 'General case' 0 C--N 1.332 -0.176 0 CA-C-N 116.417 -0.356 . . . . 0.0 110.816 179.634 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 197' ' ' ILE . . . . . . . . . . . . . 14.7 mm -57.86 -57.69 9.43 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.075 -0.511 . . . . 0.0 110.632 179.56 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 198' ' ' VAL . . . . . . . . . . . . . 74.7 t -55.15 -34.16 31.83 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.5 0 N-CA-C 109.078 -0.712 . . . . 0.0 109.078 178.317 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 199' ' ' TYR . . . . . . . . . . . . . 62.7 t80 -69.48 -30.66 68.59 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 115.205 -0.907 . . . . 0.0 110.62 179.843 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 200' ' ' LEU . . . . . 0.571 ' O ' HG12 ' A' ' 203' ' ' VAL . 32.1 mt -69.61 -47.69 62.63 Favored 'General case' 0 C--N 1.332 -0.153 0 CA-C-N 116.099 -0.5 . . . . 0.0 111.584 -179.56 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 201' ' ' ASP . . . . . 0.402 ' HB2' ' OH ' ' A' ' 51' ' ' TYR . 4.7 m-20 -70.62 -39.63 73.62 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-O 121.29 0.567 . . . . 0.0 110.192 179.757 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 202' ' ' LEU . . . . . . . . . . . . . 59.8 tp -71.13 -26.75 63.15 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 115.343 -0.844 . . . . 0.0 111.951 -179.292 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 203' ' ' VAL . . . . . 0.571 HG12 ' O ' ' A' ' 200' ' ' LEU . 9.3 p -79.34 -35.73 17.34 Favored 'Isoleucine or valine' 0 C--O 1.226 -0.153 0 C-N-CA 121.005 -0.278 . . . . 0.0 110.805 -179.483 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 204' ' ' THR . . . . . . . . . . . . . 95.8 m -65.71 -58.89 4.62 Favored 'General case' 0 C--N 1.329 -0.31 0 C-N-CA 120.748 -0.381 . . . . 0.0 110.797 179.33 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 205' ' ' LYS . . . . . 0.546 ' HE2' ' HB2' ' A' ' 47' ' ' ALA . 60.9 mttp -58.17 -57.29 13.53 Favored 'General case' 0 C--N 1.329 -0.296 0 N-CA-C 112.061 0.393 . . . . 0.0 112.061 -178.9 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 59.8 t -71.04 -37.35 67.15 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.365 0 N-CA-C 112.326 0.491 . . . . 0.0 112.326 -178.702 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 207' ' ' GLY . . . . . 0.531 ' O ' HG13 ' A' ' 211' ' ' ILE . . . -58.07 -61.86 6.94 Favored Glycine 0 CA--C 1.518 0.267 0 C-N-CA 120.658 -0.782 . . . . 0.0 113.966 -178.605 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 208' ' ' PHE . . . . . 0.54 ' HB2' ' HG ' ' A' ' 163' ' ' LEU . 2.1 p90 -72.93 -27.36 61.81 Favored 'General case' 0 C--O 1.222 -0.38 0 CA-C-N 117.48 0.64 . . . . 0.0 110.75 -179.308 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 209' ' ' GLY . . . . . 0.595 ' O ' ' HB3' ' A' ' 212' ' ' ALA . . . -63.34 -34.17 89.23 Favored Glycine 0 N--CA 1.449 -0.473 0 N-CA-C 111.786 -0.525 . . . . 0.0 111.786 178.65 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 210' ' ' PHE . . . . . . . . . . . . . 0.7 OUTLIER -72.75 -47.46 46.7 Favored 'General case' 0 CA--C 1.514 -0.425 0 N-CA-C 108.239 -1.023 . . . . 0.0 108.239 178.379 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 211' ' ' ILE . . . . . 0.537 HG21 ' HG2' ' A' ' 162' ' ' ARG . 4.8 mt -62.91 -27.48 43.2 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.465 0 N-CA-C 107.632 -1.248 . . . . 0.0 107.632 176.588 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 212' ' ' ALA . . . . . 0.595 ' HB3' ' O ' ' A' ' 209' ' ' GLY . . . -61.86 -41.67 98.12 Favored 'General case' 0 N--CA 1.45 -0.45 0 CA-C-N 114.436 -1.256 . . . . 0.0 110.622 -179.846 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 213' ' ' LEU . . . . . . . . . . . . . 99.1 mt -66.56 -50.39 63.29 Favored 'General case' 0 C--N 1.331 -0.202 0 CA-C-N 115.345 -0.843 . . . . 0.0 111.255 -179.872 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 214' ' ' ASP . . . . . . . . . . . . . 25.8 t70 -56.08 -54.41 45.29 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.282 -0.417 . . . . 0.0 111.152 -179.761 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 215' ' ' ALA . . . . . 0.414 ' O ' ' HG ' ' A' ' 219' ' ' LEU . . . -57.44 -57.27 13.39 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.136 -0.484 . . . . 0.0 111.417 -179.865 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 216' ' ' ALA . . . . . . . . . . . . . . . -55.18 -33.48 63.04 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.353 -0.385 . . . . 0.0 111.331 -179.828 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 217' ' ' ALA . . . . . . . . . . . . . . . -61.72 -37.77 85.43 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 121.096 0.474 . . . . 0.0 110.129 179.426 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 218' ' ' THR . . . . . . . . . . . . . 98.4 m -76.92 -35.0 57.65 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 115.648 -0.705 . . . . 0.0 110.824 179.384 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 219' ' ' LEU . . . . . 0.414 ' HG ' ' O ' ' A' ' 215' ' ' ALA . 81.3 mt -60.1 -39.6 86.74 Favored 'General case' 0 C--N 1.332 -0.17 0 CA-C-O 120.926 0.393 . . . . 0.0 110.529 179.666 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 220' ' ' ARG . . . . . . . . . . . . . 8.6 ptm180 -83.52 -24.25 31.75 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.396 179.485 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 221' ' ' ALA . . . . . . . . . . . . . . . -75.51 -24.93 56.87 Favored 'General case' 0 C--N 1.331 -0.204 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.179 179.798 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 222' ' ' GLU . . . . . . . . . . . . . 9.7 pt-20 -92.13 -24.16 19.2 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 121.084 0.469 . . . . 0.0 110.101 179.882 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 223' ' ' HIS . . . . . . . . . . . . . 57.6 m-70 64.83 164.76 0.15 Allowed 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 115.338 -0.846 . . . . 0.0 111.244 179.91 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 224' ' ' GLY . . . . . . . . . . . . . . . -93.08 72.83 1.34 Allowed Glycine 0 N--CA 1.452 -0.283 0 C-N-CA 120.846 -0.693 . . . . 0.0 112.518 -179.887 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 225' ' ' GLU . . . . . . . . . . . . . 8.3 tp10 -96.3 141.48 29.59 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-O 120.782 0.325 . . . . 0.0 110.767 179.85 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 226' ' ' SER . . . . . . . . . . . . . 42.8 m -73.17 175.4 6.81 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.242 -0.436 . . . . 0.0 110.809 -179.987 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 227' ' ' LEU . . . . . . . . . . . . . 4.1 mm? -94.47 134.13 37.33 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.082 -0.508 . . . . 0.0 110.704 179.903 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 228' ' ' ALA . . . . . . . . . . . . . . . -97.56 8.99 43.63 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.193 179.996 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 229' ' ' GLY . . . . . . . . . . . . . . . -82.96 -56.46 2.73 Favored Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.567 -179.977 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 230' ' ' VAL . . . . . . . . . . . . . 16.3 m -117.84 174.1 4.22 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-O 120.835 0.35 . . . . 0.0 111.283 -179.891 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 231' ' ' ASP . . . . . . . . . . . . . 5.8 m-20 -132.88 102.89 5.81 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.107 -0.497 . . . . 0.0 111.049 -179.947 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 232' ' ' THR . . . . . . . . . . . . . 8.4 t -132.78 -32.4 1.26 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.145 -0.48 . . . . 0.0 111.017 179.597 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 233' ' ' ASP . . . . . . . . . . . . . 3.7 p30 -128.64 152.73 48.03 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.717 179.679 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 234' ' ' THR . . . . . . . . . . . . . 69.1 p -96.46 143.04 25.43 Favored Pre-proline 0 C--N 1.33 -0.279 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.973 179.965 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 235' ' ' PRO . . . . . . . . . . . . . 32.5 Cg_exo -60.64 166.65 9.55 Favored 'Trans proline' 0 C--N 1.347 0.475 0 C-N-CA 122.435 2.09 . . . . 0.0 112.243 179.945 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 236' ' ' ALA . . . . . . . . . . . . . . . -70.68 171.12 10.95 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.095 179.844 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 237' ' ' VAL . . . . . . . . . . . . . 61.0 t 64.1 120.76 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.332 -0.155 0 CA-C-N 116.01 -0.541 . . . . 0.0 111.433 179.873 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 238' ' ' ALA . . . . . . . . . . . . . . . -54.81 144.13 23.47 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 115.971 -0.559 . . . . 0.0 111.211 -179.867 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 239' ' ' ASP . . . . . . . . . . . . . 8.5 m-20 -67.58 114.76 6.49 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.98 -179.801 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 240' ' ' LEU . . . . . . . . . . . . . 96.0 mt -82.95 118.15 23.28 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.036 -0.529 . . . . 0.0 110.776 179.874 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 241' ' ' GLU . . . . . . . . . . . . . 39.6 tt0 -108.9 -32.07 7.42 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.112 -179.813 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 242' ' ' HIS . . . . . . . . . . . . . 19.5 p80 -69.11 -15.81 63.52 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.363 -0.381 . . . . 0.0 110.934 -179.884 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 243' ' ' HIS . . . . . . . . . . . . . 60.1 t-80 -169.29 111.83 0.5 Allowed 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.302 -0.408 . . . . 0.0 110.952 -179.998 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 244' ' ' HIS . . . . . . . . . . . . . 15.9 t-80 -110.11 -49.44 3.07 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.829 179.788 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 245' ' ' HIS . . . . . . . . . . . . . 19.0 t60 -124.47 141.09 52.35 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.752 179.921 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 246' ' ' HIS . . . . . . . . . . . . . 60.1 m80 -61.32 107.63 0.8 Allowed 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.92 179.926 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 247' ' ' HIS . . . . . . . . . . . . . 8.7 p80 . . . . . 0 C--O 1.248 1.008 0 CA-C-O 118.097 -0.954 . . . . 0.0 110.964 -179.98 . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 301' ' ' RET . . . . . 0.624 H202 ' HZ2' ' A' ' 171' ' ' TRP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 94.2 mmm . . . . . 0 N--CA 1.486 1.353 0 CA-C-O 120.818 0.342 . . . . 0.0 111.004 . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 14.7 p -117.6 -15.26 9.21 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.22 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.98 -179.957 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -81.42 -44.22 8.09 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.727 -179.717 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 4' ' ' LEU . . . . . 0.409 ' HA ' HD23 ' A' ' 7' ' ' LEU . 82.9 mt -59.2 -35.24 73.25 Favored 'General case' 0 N--CA 1.449 -0.483 0 CA-C-O 120.812 0.339 . . . . 0.0 111.273 -179.822 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 46.4 p -61.6 -34.91 76.44 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.11 -0.495 . . . . 0.0 111.795 -179.588 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 16.4 p -56.16 -35.64 67.41 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.333 -0.394 . . . . 0.0 111.507 -179.321 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 7' ' ' LEU . . . . . 0.42 ' N ' HD22 ' A' ' 7' ' ' LEU . 3.6 mm? -61.81 -53.5 55.04 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.364 -0.38 . . . . 0.0 111.271 -179.752 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 8' ' ' PHE . . . . . 0.563 ' HB2' ' HB2' ' A' ' 55' ' ' ALA . 53.9 m-85 -59.18 -30.21 68.03 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.291 -0.413 . . . . 0.0 111.066 -179.631 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 9' ' ' TRP . . . . . . . . . . . . . 19.7 m95 -69.25 -46.76 66.5 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.345 -179.971 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 85.4 mt -62.3 -41.86 98.88 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 115.88 -0.6 . . . . 0.0 110.042 179.206 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -62.29 -33.72 86.96 Favored Glycine 0 N--CA 1.448 -0.509 0 C-N-CA 120.779 -0.724 . . . . 0.0 111.769 179.3 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -67.87 -34.48 76.76 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-O 120.84 0.352 . . . . 0.0 110.523 179.585 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 46.8 mm -62.68 -51.67 69.19 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.187 0 CA-C-N 116.029 -0.532 . . . . 0.0 110.505 179.451 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -60.18 -33.21 79.02 Favored Glycine 0 N--CA 1.449 -0.447 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.108 179.648 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 15' ' ' MET . . . . . 0.611 ' HB3' ' HB2' ' A' ' 48' ' ' ALA . 20.0 mmt -66.75 -47.05 73.44 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.624 0.25 . . . . 0.0 110.821 179.689 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -54.07 -42.14 68.95 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.301 179.583 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 79.6 t -61.26 -48.05 90.69 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-N 115.946 -0.57 . . . . 0.0 110.79 179.548 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -63.51 -46.34 92.67 Favored Glycine 0 C--N 1.331 0.272 0 C-N-CA 120.773 -0.727 . . . . 0.0 112.165 179.809 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 23.2 m -49.95 -43.19 49.86 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 120.726 0.298 . . . . 0.0 111.114 -179.644 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 81.8 mt -71.93 -47.06 55.15 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.284 -0.416 . . . . 0.0 111.446 179.905 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -57.61 -29.9 64.89 Favored 'General case' 0 C--N 1.33 -0.272 0 N-CA-C 111.982 0.364 . . . . 0.0 111.982 -179.525 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 22' ' ' PHE . . . . . 0.587 ' HB2' HG22 ' A' ' 41' ' ' VAL . 9.5 m-85 -89.42 -41.12 12.27 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.531 -0.304 . . . . 0.0 111.594 -179.097 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -65.58 -50.39 65.31 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.828 0.347 . . . . 0.0 111.38 -179.729 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 24' ' ' TRP . . . . . . . . . . . . . 1.1 t-105 -57.92 -50.3 73.81 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.078 -0.51 . . . . 0.0 111.057 179.884 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -69.66 -23.46 63.47 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.284 -0.416 . . . . 0.0 111.221 -179.911 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -73.42 -42.65 40.71 Favored Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.808 -0.71 . . . . 0.0 112.651 179.92 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 18.5 mmm180 -61.42 -22.16 64.76 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-O 120.799 0.333 . . . . 0.0 110.991 -179.989 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 13.7 t70 -116.6 97.3 5.92 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.074 -0.512 . . . . 0.0 110.702 179.974 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -160.92 -66.26 0.06 Allowed 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.134 -179.833 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 160.5 -138.66 5.63 Favored Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.865 -0.683 . . . . 0.0 112.449 -179.937 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 58.1 m -119.98 125.89 49.49 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.808 0.337 . . . . 0.0 110.824 179.987 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 105.41 -53.48 0.65 Allowed Glycine 0 N--CA 1.452 -0.258 0 C-N-CA 120.875 -0.679 . . . . 0.0 112.603 179.925 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 12.9 mm-40 -63.68 -24.31 67.73 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.835 0.35 . . . . 0.0 110.729 179.981 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 34' ' ' ARG . . . . . . . . . . . . . 75.6 ttt180 -50.56 -30.45 13.16 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 115.905 -0.588 . . . . 0.0 111.694 -179.77 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 88.2 mtm180 -59.24 -52.62 64.88 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.487 -0.324 . . . . 0.0 111.604 -179.677 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 86.3 m-85 -58.89 -27.58 65.36 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.51 -179.618 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 37' ' ' TYR . . . . . 0.443 ' O ' HG23 ' A' ' 41' ' ' VAL . 72.7 m-85 -77.96 -53.81 7.02 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-N 116.292 -0.413 . . . . 0.0 111.08 -179.642 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 86.6 t -56.78 -36.9 50.86 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-O 121.024 0.44 . . . . 0.0 110.292 179.634 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 99.3 m -63.06 -50.52 70.28 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 115.759 -0.655 . . . . 0.0 110.164 179.153 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 40' ' ' LEU . . . . . 0.471 HD12 HD12 ' A' ' 43' ' ' ILE . 53.7 tp -56.36 -43.46 79.18 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 115.441 -0.8 . . . . 0.0 110.252 179.44 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 41' ' ' VAL . . . . . 0.587 HG22 ' HB2' ' A' ' 22' ' ' PHE . 97.3 t -63.77 -34.35 67.52 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.253 0 CA-C-N 115.708 -0.678 . . . . 0.0 109.648 178.731 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -60.46 -35.34 88.6 Favored Glycine 0 N--CA 1.448 -0.524 0 CA-C-N 115.627 -0.715 . . . . 0.0 112.102 179.753 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 43' ' ' ILE . . . . . 0.625 HG22 ' HE3' ' A' ' 205' ' ' LYS . 0.3 OUTLIER -70.11 -57.77 7.23 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.159 0 CA-C-O 120.646 0.26 . . . . 0.0 110.796 179.704 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 67.1 m -62.89 -20.28 65.0 Favored 'General case' 0 C--O 1.232 0.153 0 CA-C-N 116.406 -0.361 . . . . 0.0 111.315 -179.732 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -77.99 -57.52 3.45 Favored Glycine 0 N--CA 1.452 -0.25 0 C-N-CA 120.778 -0.725 . . . . 0.0 112.8 -179.598 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 23.8 pt -58.87 -36.14 59.87 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.213 0 CA-C-O 120.958 0.409 . . . . 0.0 110.969 179.925 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 47' ' ' ALA . . . . . 0.587 ' HB2' ' HE2' ' A' ' 205' ' ' LYS . . . -67.63 -45.46 75.28 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.067 -0.515 . . . . 0.0 111.26 179.832 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 48' ' ' ALA . . . . . 0.611 ' HB2' ' HB3' ' A' ' 15' ' ' MET . . . -55.1 -43.81 74.36 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.106 -0.497 . . . . 0.0 111.829 -179.578 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 35.9 m -73.37 -34.17 42.6 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.353 0 CA-C-N 116.332 -0.395 . . . . 0.0 111.519 -179.325 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -65.78 -35.09 79.73 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-O 120.924 0.393 . . . . 0.0 110.869 179.925 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 26.7 m-85 -73.33 -40.03 64.78 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-N 115.96 -0.564 . . . . 0.0 110.518 179.96 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -63.84 -44.7 92.39 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 115.938 -0.574 . . . . 0.0 111.258 179.848 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 53' ' ' VAL . . . . . 0.519 HG23 ' N ' ' A' ' 54' ' ' MET . 34.2 m -68.56 -48.97 69.42 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.226 0 CA-C-N 116.404 -0.362 . . . . 0.0 110.868 179.923 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 54' ' ' MET . . . . . 0.519 ' N ' HG23 ' A' ' 53' ' ' VAL . 7.1 ttp -62.77 -30.1 71.2 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.126 179.852 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 55' ' ' ALA . . . . . 0.563 ' HB2' ' HB2' ' A' ' 8' ' ' PHE . . . -65.55 -40.04 92.39 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 115.849 -0.614 . . . . 0.0 111.023 179.336 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 95.3 mt -73.23 2.77 6.71 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.022 -0.536 . . . . 0.0 111.092 -179.864 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 90.7 7.37 66.69 Favored Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.685 -0.769 . . . . 0.0 112.592 179.942 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 41.3 t -74.46 135.85 26.5 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-O 120.864 0.364 . . . . 0.0 110.869 179.895 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 83.92 -2.55 87.4 Favored Glycine 0 N--CA 1.452 -0.286 0 C-N-CA 120.942 -0.647 . . . . 0.0 112.903 179.988 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 60' ' ' TRP . . . . . . . . . . . . . 12.0 m0 -73.74 102.32 3.95 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.56 0.219 . . . . 0.0 110.931 179.63 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 61' ' ' VAL . . . . . 0.4 ' HA ' ' HD3' ' A' ' 62' ' ' PRO . 7.6 p -115.13 124.25 30.52 Favored Pre-proline 0 CA--C 1.536 0.414 0 CA-C-N 116.559 -0.291 . . . . 0.0 111.208 179.794 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 62' ' ' PRO . . . . . 0.4 ' HD3' ' HA ' ' A' ' 61' ' ' VAL . 14.2 Cg_exo -69.47 157.3 61.44 Favored 'Trans proline' 0 C--N 1.353 0.796 0 C-N-CA 122.783 2.322 . . . . 0.0 112.744 -179.725 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.423 HG23 HG22 ' A' ' 68' ' ' VAL . 76.5 t -144.13 94.63 0.47 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.223 0 CA-C-N 115.856 -0.611 . . . . 0.0 110.98 179.88 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . 59.51 -86.42 0.02 OUTLIER 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 116.088 -0.506 . . . . 0.0 111.503 179.789 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 11.1 tp10 -118.16 -26.88 6.22 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-N 116.526 -0.306 . . . . 0.0 111.261 -179.723 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 66' ' ' ARG . . . . . . . . . . . . . 17.4 ptp180 -107.69 153.76 22.46 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.46 -0.336 . . . . 0.0 110.443 179.903 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 60.4 m -105.88 141.52 37.15 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-O 121.047 0.451 . . . . 0.0 111.543 -179.521 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 68' ' ' VAL . . . . . 0.431 HG21 ' HG3' ' A' ' 117' ' ' MET . 33.0 m -119.89 146.37 24.77 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 115.725 -0.67 . . . . 0.0 110.367 179.537 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 69' ' ' PHE . . . . . . . . . . . . . 22.1 m-85 -109.0 112.44 24.63 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 116.318 -0.401 . . . . 0.0 110.066 -179.398 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 70' ' ' VAL . . . . . 0.481 ' HB ' ' HD3' ' A' ' 71' ' ' PRO . 3.2 t -63.78 -48.98 78.41 Favored Pre-proline 0 C--N 1.326 -0.441 0 CA-C-N 116.274 -0.421 . . . . 0.0 111.905 -179.126 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 71' ' ' PRO . . . . . 0.583 ' HA ' HG22 ' A' ' 74' ' ' ILE . 47.4 Cg_exo -56.9 -18.06 26.3 Favored 'Trans proline' 0 C--N 1.351 0.698 0 C-N-CA 122.289 1.993 . . . . 0.0 112.877 -179.606 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 68.2 ttt180 -70.95 -55.79 7.6 Favored 'General case' 0 C--O 1.236 0.362 0 CA-C-O 120.886 0.374 . . . . 0.0 111.559 -179.323 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 73' ' ' TYR . . . . . 0.458 ' O ' HG13 ' A' ' 77' ' ' ILE . 7.0 m-85 -70.64 -34.45 72.08 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.439 -0.346 . . . . 0.0 110.281 -179.497 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 74' ' ' ILE . . . . . 0.583 HG22 ' HA ' ' A' ' 71' ' ' PRO . 0.4 OUTLIER -68.01 -37.98 79.15 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.226 0 CA-C-N 116.334 -0.394 . . . . 0.0 110.013 179.322 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 75' ' ' ASP . . . . . 0.442 ' O ' HG23 ' A' ' 79' ' ' THR . 8.1 t70 -58.02 -39.56 78.65 Favored 'General case' 0 CA--C 1.518 -0.259 0 N-CA-C 109.045 -0.724 . . . . 0.0 109.045 178.806 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 76' ' ' TRP . . . . . 0.434 ' HZ2' HG23 ' A' ' 197' ' ' ILE . 39.0 m0 -67.06 -31.56 72.15 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 115.612 -0.722 . . . . 0.0 110.584 179.108 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 77' ' ' ILE . . . . . 0.544 ' HA ' ' HG3' ' A' ' 109' ' ' MET . 85.8 mt -66.71 -32.8 59.66 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.233 0 CA-C-N 116.284 -0.416 . . . . 0.0 111.035 179.468 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 21.5 mt -91.16 -17.47 26.04 Favored 'General case' 0 C--N 1.327 -0.41 0 N-CA-C 112.149 0.426 . . . . 0.0 112.149 -179.515 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 79' ' ' THR . . . . . 0.442 HG23 ' O ' ' A' ' 75' ' ' ASP . 76.9 p -103.4 -52.65 2.96 Favored 'General case' 0 CA--C 1.532 0.275 0 N-CA-C 113.784 1.031 . . . . 0.0 113.784 -177.915 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 80' ' ' THR . . . . . 0.682 ' HB ' ' HD3' ' A' ' 81' ' ' PRO . 29.4 m -51.36 -54.86 34.12 Favored Pre-proline 0 CA--C 1.531 0.246 0 N-CA-C 112.478 0.547 . . . . 0.0 112.478 -178.508 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 81' ' ' PRO . . . . . 0.682 ' HD3' ' HB ' ' A' ' 80' ' ' THR . 36.9 Cg_exo -60.51 -20.93 66.41 Favored 'Trans proline' 0 C--N 1.351 0.683 0 C-N-CA 121.575 1.516 . . . . 0.0 111.368 179.763 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 82' ' ' LEU . . . . . 0.436 HD23 HG23 ' A' ' 43' ' ' ILE . 17.3 tp -76.91 -33.34 57.77 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 115.812 -0.631 . . . . 0.0 110.302 179.751 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 48.9 mm -68.4 -52.06 40.91 Favored 'Isoleucine or valine' 0 C--O 1.233 0.221 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.055 179.109 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 84' ' ' VAL . . . . . 0.418 ' CG1' HD22 ' A' ' 105' ' ' ASN . 34.5 m -61.86 -30.0 47.56 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.142 0 N-CA-C 109.545 -0.539 . . . . 0.0 109.545 178.728 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 85' ' ' TYR . . . . . . . . . . . . . 73.4 t80 -67.63 -33.35 74.78 Favored 'General case' 0 N--CA 1.454 -0.235 0 CA-C-N 115.546 -0.752 . . . . 0.0 109.615 178.873 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 86' ' ' PHE . . . . . . . . . . . . . 5.5 t80 -61.99 -51.67 67.11 Favored 'General case' 0 C--O 1.233 0.221 0 CA-C-N 115.697 -0.683 . . . . 0.0 109.822 179.204 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 87' ' ' LEU . . . . . 0.401 ' N ' HD12 ' A' ' 87' ' ' LEU . 8.7 mp -62.43 -29.5 70.55 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 115.755 -0.657 . . . . 0.0 110.101 179.476 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -71.49 -27.76 70.74 Favored Glycine 0 N--CA 1.449 -0.455 0 C-N-CA 120.799 -0.715 . . . . 0.0 111.569 179.237 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 72.6 mt -69.92 -45.57 67.24 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-O 121.074 0.464 . . . . 0.0 109.985 179.504 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 90' ' ' LEU . . . . . 0.485 ' HB3' HG23 ' A' ' 156' ' ' ILE . 64.7 mt -60.17 -30.43 69.33 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 115.582 -0.735 . . . . 0.0 110.741 179.616 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 91' ' ' ALA . . . . . 0.458 ' HA ' ' HA ' ' A' ' 149' ' ' ALA . . . -86.32 -29.44 23.02 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.264 -179.787 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 75.03 44.69 22.93 Favored Glycine 0 N--CA 1.452 -0.258 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.146 -179.902 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 93' ' ' LEU . . . . . 0.427 ' HB3' ' HB2' ' A' ' 97' ' ' GLU . 30.1 mt -60.36 168.04 2.24 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.955 0.407 . . . . 0.0 111.206 -179.646 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 94' ' ' ASP . . . . . . . . . . . . . 5.5 m-20 -90.77 179.57 5.76 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 115.936 -0.575 . . . . 0.0 110.834 179.994 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 80.5 p -60.58 -42.83 97.48 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.906 -179.94 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 68.9 mtm180 -68.62 -49.77 56.6 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.108 -0.496 . . . . 0.0 111.027 -179.826 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 97' ' ' GLU . . . . . 0.427 ' HB2' ' HB3' ' A' ' 93' ' ' LEU . 44.9 mt-10 -54.51 -47.6 72.9 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.335 -0.393 . . . . 0.0 111.033 -179.883 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 98' ' ' PHE . . . . . 0.453 ' O ' HG12 ' A' ' 102' ' ' ILE . 11.3 m-85 -60.29 -43.62 96.09 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.416 -0.357 . . . . 0.0 110.496 179.61 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -60.63 -27.53 66.37 Favored Glycine 0 N--CA 1.451 -0.358 0 C-N-CA 120.611 -0.804 . . . . 0.0 112.414 179.746 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 96.1 mt -73.9 -47.64 42.23 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.229 0 N-CA-C 111.875 0.324 . . . . 0.0 111.875 -179.537 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 101' ' ' VAL . . . . . 0.41 HG11 ' HE3' ' A' ' 145' ' ' MET . 27.7 m -69.49 -39.01 78.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 N-CA-C 111.731 0.271 . . . . 0.0 111.731 -179.353 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 102' ' ' ILE . . . . . 0.453 HG12 ' O ' ' A' ' 98' ' ' PHE . 43.3 mm -67.67 -46.55 82.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.55 -0.296 . . . . 0.0 111.347 -179.54 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 14.7 t -62.42 -33.27 74.46 Favored 'General case' 0 C--O 1.233 0.187 0 CA-C-O 120.975 0.417 . . . . 0.0 110.404 179.643 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -58.84 -52.04 67.42 Favored 'General case' 0 C--N 1.332 -0.191 0 CA-C-N 115.995 -0.548 . . . . 0.0 109.528 179.248 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 105' ' ' ASN . . . . . 0.418 HD22 ' CG1' ' A' ' 84' ' ' VAL . 3.1 m-20 -56.72 -35.45 68.56 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 115.736 -0.666 . . . . 0.0 110.53 179.455 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 39.3 m -55.6 -50.9 68.88 Favored 'General case' 0 C--N 1.332 -0.169 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.996 179.918 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 107' ' ' VAL . . . . . 0.409 ' H ' HG23 ' A' ' 107' ' ' VAL . 0.9 OUTLIER -60.5 -39.67 81.97 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.223 0 CA-C-O 121.174 0.512 . . . . 0.0 110.39 179.6 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 81.0 t -63.66 -39.91 87.12 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-N 115.506 -0.77 . . . . 0.0 111.285 -179.821 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 109' ' ' MET . . . . . 0.544 ' HG3' ' HA ' ' A' ' 77' ' ' ILE . 28.6 mmt -67.17 -51.35 54.8 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.078 -0.51 . . . . 0.0 111.329 -179.568 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 21.1 tp -58.95 -34.73 72.09 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-N 115.96 -0.564 . . . . 0.0 110.927 -179.592 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -61.11 -57.09 13.98 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.18 -179.994 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 112' ' ' GLY . . . . . 0.584 ' HA3' ' H21' ' A' ' 301' ' ' RET . . . -67.23 -28.03 73.62 Favored Glycine 0 N--CA 1.45 -0.374 0 C-N-CA 120.724 -0.75 . . . . 0.0 112.143 179.68 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 113' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER -57.67 -75.09 0.05 OUTLIER 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 121.035 0.445 . . . . 0.0 110.132 179.817 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -61.45 -26.43 67.87 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 115.793 -0.639 . . . . 0.0 111.095 179.771 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -53.06 -50.07 52.97 Favored Glycine 0 C--N 1.331 0.28 0 C-N-CA 121.028 -0.606 . . . . 0.0 112.616 -179.974 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 116' ' ' ALA . . . . . 0.571 ' HB2' ' HB3' ' A' ' 183' ' ' PRO . . . -77.65 -16.42 58.54 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.672 0.272 . . . . 0.0 111.613 -179.739 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 117' ' ' MET . . . . . 0.431 ' HG3' HG21 ' A' ' 68' ' ' VAL . 29.7 ttm -101.85 19.22 18.69 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.407 -0.361 . . . . 0.0 111.341 -179.506 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 118' ' ' VAL . . . . . 0.58 HG21 ' HB3' ' A' ' 123' ' ' ARG . 21.4 m -70.15 145.49 93.75 Favored Pre-proline 0 C--N 1.33 -0.245 0 CA-C-N 116.432 -0.349 . . . . 0.0 111.502 179.982 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 119' ' ' PRO . . . . . . . . . . . . . 85.9 Cg_endo -93.4 15.8 1.33 Allowed 'Trans proline' 0 N--CA 1.456 -0.732 0 C-N-CA 122.997 2.465 . . . . 0.0 112.353 179.419 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -164.62 -120.38 0.52 Allowed Glycine 0 C--N 1.332 0.339 0 C-N-CA 120.66 -0.781 . . . . 0.0 112.674 -179.564 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 40.9 pt -114.68 9.84 7.74 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.232 0 CA-C-O 120.723 0.297 . . . . 0.0 111.493 -179.727 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 45.7 mt-10 -58.84 -18.08 29.48 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.304 -0.407 . . . . 0.0 110.699 179.725 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 123' ' ' ARG . . . . . 0.58 ' HB3' HG21 ' A' ' 118' ' ' VAL . 10.2 ptp180 -50.5 -33.24 20.65 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 115.794 -0.639 . . . . 0.0 111.642 -179.959 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 124' ' ' TYR . . . . . . . . . . . . . 19.3 m-85 -73.11 -32.63 65.07 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.428 -0.351 . . . . 0.0 111.513 -179.459 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 125' ' ' ALA . . . . . . . . . . . . . . . -74.32 -56.11 5.25 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.386 -0.37 . . . . 0.0 111.398 -179.492 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -55.09 -44.19 74.66 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.904 -179.931 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 127' ' ' PHE . . . . . 0.439 ' CE1' ' H42' ' A' ' 301' ' ' RET . 5.4 t80 -70.92 -37.21 72.89 Favored 'General case' 0 C--N 1.33 -0.279 0 C-N-CA 120.898 -0.321 . . . . 0.0 110.575 179.825 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 128' ' ' GLY . . . . . . . . . . . . . . . -46.79 -46.85 19.03 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.167 -1.016 . . . . 0.0 110.844 179.052 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 129' ' ' MET . . . . . . . . . . . . . 0.4 OUTLIER -69.69 -38.84 77.16 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 115.367 -0.417 . . . . 0.0 109.894 178.781 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -62.87 -29.3 73.71 Favored Glycine 0 C--N 1.333 0.38 0 CA-C-N 115.892 -0.595 . . . . 0.0 112.792 -179.893 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 131' ' ' ALA . . . . . 0.402 ' O ' ' HB3' ' A' ' 134' ' ' PHE . . . -74.29 -53.61 9.37 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 120.761 0.315 . . . . 0.0 110.317 179.871 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 28.3 t -58.03 -40.07 75.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 N-CA-C 109.321 -0.622 . . . . 0.0 109.321 178.741 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -68.64 -33.4 73.94 Favored 'General case' 0 N--CA 1.454 -0.259 0 CA-C-N 115.387 -0.824 . . . . 0.0 110.342 179.177 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 134' ' ' PHE . . . . . 0.402 ' HB3' ' O ' ' A' ' 131' ' ' ALA . 44.1 t80 -57.77 -55.14 38.7 Favored 'General case' 0 N--CA 1.452 -0.34 0 CA-C-N 116.132 -0.486 . . . . 0.0 109.752 179.239 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 135' ' ' ILE . . . . . 0.46 ' O ' HG22 ' A' ' 138' ' ' VAL . 39.2 mt -57.69 -31.87 40.97 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 115.673 -0.694 . . . . 0.0 109.86 178.861 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . -64.19 -35.31 91.81 Favored Glycine 0 N--CA 1.448 -0.515 0 C-N-CA 120.488 -0.863 . . . . 0.0 111.577 179.13 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 137' ' ' LEU . . . . . . . . . . . . . 38.9 tp -73.44 -51.13 18.3 Favored 'General case' 0 C--N 1.331 -0.205 0 CA-C-O 120.628 0.252 . . . . 0.0 110.51 179.492 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 138' ' ' VAL . . . . . 0.46 HG22 ' O ' ' A' ' 135' ' ' ILE . 4.0 m -57.37 -30.96 37.04 Favored 'Isoleucine or valine' 0 C--O 1.233 0.208 0 N-CA-C 109.376 -0.601 . . . . 0.0 109.376 179.048 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 139' ' ' TYR . . . . . . . . . . . . . 24.9 t80 -66.19 -43.34 87.12 Favored 'General case' 0 C--N 1.332 -0.196 0 CA-C-N 115.324 -0.853 . . . . 0.0 110.15 178.706 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 140' ' ' TYR . . . . . 0.435 ' HB3' ' SD ' ' A' ' 145' ' ' MET . 11.9 m-85 -53.06 -51.62 61.22 Favored 'General case' 0 C--O 1.231 0.13 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.514 179.355 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 141' ' ' LEU . . . . . . . . . . . . . 70.5 mt -53.39 -53.56 49.39 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 115.726 -0.67 . . . . 0.0 111.213 -179.788 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 17.2 t -73.42 -11.29 14.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.113 -0.494 . . . . 0.0 111.334 -179.623 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . -71.45 -140.91 0.26 Allowed Glycine 0 CA--C 1.52 0.354 0 C-N-CA 120.832 -0.699 . . . . 0.0 112.635 -179.799 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 144' ' ' PRO . . . . . . . . . . . . . 32.2 Cg_endo -62.99 -23.25 74.08 Favored 'Trans proline' 0 C--N 1.347 0.493 0 C-N-CA 122.486 2.124 . . . . 0.0 112.121 -179.991 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 145' ' ' MET . . . . . 0.435 ' SD ' ' HB3' ' A' ' 140' ' ' TYR . 82.4 mtp -57.61 -27.9 63.18 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 116.024 -0.535 . . . . 0.0 110.975 179.921 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 146' ' ' THR . . . . . . . . . . . . . 60.0 m -71.89 -40.79 68.64 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.308 -0.406 . . . . 0.0 111.042 179.82 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 2.2 mp0 -74.25 -27.57 60.83 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.008 -179.835 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 148' ' ' SER . . . . . . . . . . . . . 49.1 m -70.19 -43.16 71.33 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.388 -0.369 . . . . 0.0 111.085 -179.882 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 149' ' ' ALA . . . . . 0.458 ' HA ' ' HA ' ' A' ' 91' ' ' ALA . . . -77.84 -44.08 28.41 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.845 -179.457 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 150' ' ' SER . . . . . . . . . . . . . 66.3 m -63.72 -21.97 66.67 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.388 -0.369 . . . . 0.0 111.443 -179.451 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 151' ' ' GLN . . . . . . . . . . . . . 78.7 mt-30 -106.87 6.49 29.41 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.51 -0.314 . . . . 0.0 111.298 -179.784 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 30.2 tpt180 -82.58 -50.31 8.92 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.437 -0.347 . . . . 0.0 110.729 179.823 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 153' ' ' SER . . . . . 0.514 ' HB2' HG13 ' A' ' 156' ' ' ILE . 45.8 m -154.55 149.34 26.59 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.824 179.267 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 154' ' ' SER . . . . . . . . . . . . . 42.7 t -55.24 -40.37 70.83 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.113 -0.494 . . . . 0.0 111.055 179.947 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 155' ' ' GLY . . . . . 0.404 ' O ' ' HG ' ' A' ' 159' ' ' LEU . . . -75.01 -35.93 48.23 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.79 -0.719 . . . . 0.0 112.562 179.994 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 156' ' ' ILE . . . . . 0.514 HG13 ' HB2' ' A' ' 153' ' ' SER . 68.9 mt -60.95 -36.22 70.58 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-O 120.707 0.289 . . . . 0.0 111.307 -179.948 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 157' ' ' LYS . . . . . 0.402 ' O ' HG13 ' A' ' 161' ' ' VAL . 88.6 tttt -52.9 -45.66 67.64 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-N 116.187 -0.461 . . . . 0.0 111.499 -179.783 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 48.4 t -71.83 -37.41 70.32 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 121.003 0.43 . . . . 0.0 111.29 -179.558 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 159' ' ' LEU . . . . . 0.404 ' HG ' ' O ' ' A' ' 155' ' ' GLY . 78.0 mt -65.85 -39.18 90.52 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-N 115.936 -0.575 . . . . 0.0 111.643 -179.413 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 160' ' ' TYR . . . . . . . . . . . . . 45.5 t80 -73.94 -44.37 55.19 Favored 'General case' 0 C--N 1.327 -0.401 0 N-CA-C 112.155 0.428 . . . . 0.0 112.155 -178.647 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 161' ' ' VAL . . . . . 0.402 HG13 ' O ' ' A' ' 157' ' ' LYS . 30.8 m -59.86 -43.96 93.15 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 N-CA-C 112.226 0.454 . . . . 0.0 112.226 -178.916 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 162' ' ' ARG . . . . . 0.541 ' O ' HD12 ' A' ' 166' ' ' LEU . 93.8 mtt180 -69.16 -50.74 44.98 Favored 'General case' 0 C--N 1.33 -0.269 0 N-CA-C 112.18 0.437 . . . . 0.0 112.18 -179.134 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 163' ' ' LEU . . . . . . . . . . . . . 7.5 mp -65.71 -43.83 87.92 Favored 'General case' 0 C--N 1.33 -0.254 0 N-CA-C 111.789 0.292 . . . . 0.0 111.789 -179.06 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 164' ' ' ARG . . . . . . . . . . . . . 6.1 tmm_? -57.42 -50.98 71.26 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-N 116.56 -0.291 . . . . 0.0 111.004 -179.693 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 165' ' ' ASN . . . . . 0.486 ' O ' HG23 ' A' ' 169' ' ' VAL . 5.3 m-20 -53.04 -44.99 67.81 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-O 120.934 0.397 . . . . 0.0 110.346 179.809 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 166' ' ' LEU . . . . . 0.541 HD12 ' O ' ' A' ' 162' ' ' ARG . 1.5 mt -60.05 -48.65 80.82 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 115.931 -0.577 . . . . 0.0 111.2 179.478 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 167' ' ' THR . . . . . 0.624 ' HA ' HD11 ' A' ' 170' ' ' LEU . 12.0 m -53.68 -51.0 64.59 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.021 -0.536 . . . . 0.0 112.218 -178.265 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 168' ' ' VAL . . . . . . . . . . . . . 27.0 t -59.26 -40.6 81.66 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.566 0 N-CA-C 112.105 0.409 . . . . 0.0 112.105 -179.061 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 169' ' ' VAL . . . . . 0.486 HG23 ' O ' ' A' ' 165' ' ' ASN . 83.9 t -66.08 -66.82 0.45 Allowed 'Isoleucine or valine' 0 CA--C 1.533 0.3 0 N-CA-C 113.557 0.947 . . . . 0.0 113.557 -178.194 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 170' ' ' LEU . . . . . 0.624 HD11 ' HA ' ' A' ' 167' ' ' THR . 0.4 OUTLIER -61.66 -32.18 72.34 Favored 'General case' 0 N--CA 1.467 0.388 0 N-CA-C 112.974 0.731 . . . . 0.0 112.974 -177.529 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 171' ' ' TRP . . . . . 0.695 ' HE1' H203 ' A' ' 301' ' ' RET . 21.4 m0 -73.53 -29.54 62.52 Favored 'General case' 0 C--N 1.329 -0.323 0 C-N-CA 120.371 -0.531 . . . . 0.0 111.087 -179.619 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 172' ' ' ALA . . . . . . . . . . . . . . . -72.24 -7.87 51.68 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-O 121.011 0.434 . . . . 0.0 110.253 179.499 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 173' ' ' ILE . . . . . 0.552 HG22 HD11 ' A' ' 177' ' ' ILE . 18.5 mm -88.92 -25.42 5.75 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.21 0 CA-C-N 115.789 -0.642 . . . . 0.0 110.939 179.528 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 174' ' ' TYR . . . . . 0.491 ' HD1' ' HA ' ' A' ' 171' ' ' TRP . 16.1 m-85 -54.62 -48.54 94.94 Favored Pre-proline 0 CA--C 1.531 0.218 0 CA-C-N 116.104 -0.498 . . . . 0.0 112.156 -179.384 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 175' ' ' PRO . . . . . . . . . . . . . 74.8 Cg_exo -47.07 -29.99 9.55 Favored 'Trans proline' 0 C--N 1.352 0.747 0 C-N-CA 121.909 1.739 . . . . 0.0 111.808 179.677 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 176' ' ' PHE . . . . . 0.497 ' O ' ' HG ' ' A' ' 180' ' ' LEU . 72.0 m-85 -80.35 -49.89 10.89 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 115.713 -0.676 . . . . 0.0 111.37 179.687 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 177' ' ' ILE . . . . . 0.552 HD11 HG22 ' A' ' 173' ' ' ILE . 3.6 mm -59.28 -36.25 62.5 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.525 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.722 -178.632 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 178' ' ' TRP . . . . . 0.407 ' O ' ' HB2' ' A' ' 183' ' ' PRO . 58.7 t90 -73.3 -51.82 16.18 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-O 121.066 0.46 . . . . 0.0 110.658 179.879 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 179' ' ' LEU . . . . . 0.563 HD13 HG22 ' A' ' 185' ' ' VAL . 1.4 tm? -61.07 -53.4 57.54 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 115.701 -0.681 . . . . 0.0 111.56 -179.159 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 180' ' ' LEU . . . . . 0.723 HD22 HD11 ' A' ' 187' ' ' LEU . 12.5 mt -74.78 -29.47 61.13 Favored 'General case' 0 C--N 1.327 -0.385 0 N-CA-C 112.2 0.444 . . . . 0.0 112.2 -178.861 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . -71.42 -177.66 27.28 Favored Glycine 0 N--CA 1.45 -0.407 0 C-N-CA 119.977 -1.106 . . . . 0.0 112.173 179.777 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 182' ' ' PRO . . . . . 0.427 ' N ' ' HD2' ' A' ' 183' ' ' PRO . 76.8 Cg_exo -47.93 -43.36 30.05 Favored 'Trans proline' 0 CA--C 1.538 0.681 0 C-N-CA 122.649 2.233 . . . . 0.0 113.386 179.527 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 183' ' ' PRO . . . . . 0.571 ' HB3' ' HB2' ' A' ' 116' ' ' ALA . 65.9 Cg_exo -41.54 -31.87 1.27 Allowed 'Trans proline' 0 C--N 1.358 1.046 0 C-N-CA 122.609 2.206 . . . . 0.0 113.601 179.824 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 184' ' ' GLY . . . . . . . . . . . . . . . -130.03 -107.65 1.24 Allowed Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.413 -0.899 . . . . 0.0 112.323 180.0 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 185' ' ' VAL . . . . . 0.563 HG22 HD13 ' A' ' 179' ' ' LEU . 27.4 m -92.41 89.87 2.96 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.44 0 CA-C-O 121.414 0.626 . . . . 0.0 110.365 179.668 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 186' ' ' ALA . . . . . . . . . . . . . . . -56.94 86.7 0.01 OUTLIER 'General case' 0 C--N 1.325 -0.491 0 CA-C-N 115.687 -0.688 . . . . 0.0 111.855 -179.448 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 187' ' ' LEU . . . . . 0.723 HD11 HD22 ' A' ' 180' ' ' LEU . 12.5 mt -74.8 -48.91 22.8 Favored 'General case' 0 C--N 1.331 -0.199 0 CA-C-O 120.985 0.422 . . . . 0.0 110.361 179.236 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 188' ' ' LEU . . . . . . . . . . . . . 63.4 mt -97.8 -147.97 0.32 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 115.775 -0.648 . . . . 0.0 110.65 -179.87 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 189' ' ' THR . . . . . . . . . . . . . 1.2 t -111.8 148.46 39.0 Favored Pre-proline 0 C--N 1.331 -0.231 0 CA-C-N 116.276 -0.42 . . . . 0.0 110.813 -179.964 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 190' ' ' PRO . . . . . 0.406 ' O ' HG23 ' A' ' 194' ' ' VAL . 7.3 Cg_endo -49.12 -42.14 39.75 Favored 'Trans proline' 0 C--N 1.349 0.57 0 C-N-CA 123.027 2.485 . . . . 0.0 113.261 -179.474 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 191' ' ' THR . . . . . . . . . . . . . 7.6 t -59.54 -40.86 88.6 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.65 0.262 . . . . 0.0 111.598 -179.341 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 192' ' ' VAL . . . . . . . . . . . . . 42.3 t -71.94 -47.92 53.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.499 -0.319 . . . . 0.0 111.398 -179.809 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 193' ' ' ASP . . . . . . . . . . . . . 30.7 t70 -57.99 -51.2 70.65 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.742 0.306 . . . . 0.0 111.038 -179.815 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 194' ' ' VAL . . . . . 0.406 HG23 ' O ' ' A' ' 190' ' ' PRO . 97.8 t -59.88 -36.15 64.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.883 179.973 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 195' ' ' ALA . . . . . . . . . . . . . . . -58.1 -46.1 86.1 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.542 -0.299 . . . . 0.0 110.942 179.697 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 196' ' ' LEU . . . . . . . . . . . . . 86.3 mt -65.69 -41.34 92.5 Favored 'General case' 0 C--N 1.332 -0.171 0 CA-C-N 116.368 -0.378 . . . . 0.0 110.404 179.596 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 197' ' ' ILE . . . . . 0.434 HG23 ' HZ2' ' A' ' 76' ' ' TRP . 19.9 mm -58.56 -58.26 7.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 115.995 -0.548 . . . . 0.0 110.239 179.366 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 198' ' ' VAL . . . . . . . . . . . . . 94.6 t -53.27 -34.52 22.39 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.416 0 CA-C-N 115.736 -0.665 . . . . 0.0 109.276 178.281 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 199' ' ' TYR . . . . . . . . . . . . . 65.4 t80 -69.7 -33.66 72.83 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 115.295 -0.866 . . . . 0.0 110.519 179.604 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 200' ' ' LEU . . . . . . . . . . . . . 40.7 mt -69.6 -39.62 77.14 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 115.855 -0.611 . . . . 0.0 111.019 -179.807 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 201' ' ' ASP . . . . . 0.455 ' HB3' ' NZ ' ' A' ' 205' ' ' LYS . 9.6 m-20 -72.86 -32.23 65.28 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.41 179.749 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 202' ' ' LEU . . . . . 0.466 ' O ' ' HB ' ' A' ' 206' ' ' VAL . 3.7 mt -73.04 -33.13 65.51 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 115.656 -0.702 . . . . 0.0 112.014 -179.376 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 203' ' ' VAL . . . . . 0.45 ' O ' ' HA3' ' A' ' 207' ' ' GLY . 7.8 p -77.9 -36.66 22.39 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-O 120.582 0.23 . . . . 0.0 111.432 -178.801 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 204' ' ' THR . . . . . . . . . . . . . 19.1 m -68.91 -53.62 20.06 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-O 120.877 0.37 . . . . 0.0 111.407 -179.956 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 205' ' ' LYS . . . . . 0.625 ' HE3' HG22 ' A' ' 43' ' ' ILE . 43.9 mttp -70.73 -58.68 3.39 Favored 'General case' 0 C--N 1.327 -0.405 0 N-CA-C 112.435 0.531 . . . . 0.0 112.435 -178.569 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 206' ' ' VAL . . . . . 0.466 ' HB ' ' O ' ' A' ' 202' ' ' LEU . 48.1 t -72.25 -37.43 58.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 N-CA-C 111.952 0.353 . . . . 0.0 111.952 -178.878 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 207' ' ' GLY . . . . . 0.514 ' O ' HG13 ' A' ' 211' ' ' ILE . . . -65.37 -59.88 7.32 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.442 -0.885 . . . . 0.0 112.516 -179.366 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 208' ' ' PHE . . . . . 0.482 ' O ' ' N ' ' A' ' 212' ' ' ALA . 2.1 m-30 -54.19 -45.17 72.1 Favored 'General case' 0 C--O 1.222 -0.388 0 N-CA-C 109.947 -0.39 . . . . 0.0 109.947 179.772 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 209' ' ' GLY . . . . . 0.498 ' HA2' ' HB3' ' A' ' 212' ' ' ALA . . . -59.07 -34.22 78.28 Favored Glycine 0 N--CA 1.448 -0.515 0 CA-C-N 115.376 -0.829 . . . . 0.0 112.821 179.43 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 210' ' ' PHE . . . . . . . . . . . . . 1.2 m-85 -70.26 -46.8 63.67 Favored 'General case' 0 CA--C 1.515 -0.369 0 N-CA-C 108.754 -0.832 . . . . 0.0 108.754 179.163 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 211' ' ' ILE . . . . . 0.514 HG13 ' O ' ' A' ' 207' ' ' GLY . 2.6 mt -67.4 -27.42 38.7 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.473 0 N-CA-C 107.416 -1.327 . . . . 0.0 107.416 176.846 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 212' ' ' ALA . . . . . 0.498 ' HB3' ' HA2' ' A' ' 209' ' ' GLY . . . -66.84 -40.09 87.83 Favored 'General case' 0 N--CA 1.449 -0.525 0 CA-C-N 114.32 -1.309 . . . . 0.0 110.214 -179.991 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 213' ' ' LEU . . . . . 0.467 ' HG ' ' O ' ' A' ' 209' ' ' GLY . 69.7 mt -70.68 -54.77 10.59 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 114.991 -1.004 . . . . 0.0 111.744 -179.555 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 214' ' ' ASP . . . . . . . . . . . . . 20.6 t70 -54.38 -47.19 72.95 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-O 120.758 0.313 . . . . 0.0 111.42 -179.464 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 215' ' ' ALA . . . . . . . . . . . . . . . -63.69 -56.17 17.8 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.309 -0.405 . . . . 0.0 111.171 -179.781 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 216' ' ' ALA . . . . . . . . . . . . . . . -56.24 -31.22 63.33 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.834 179.924 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 217' ' ' ALA . . . . . . . . . . . . . . . -65.97 -40.56 91.38 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 115.991 -0.549 . . . . 0.0 110.431 179.767 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 218' ' ' THR . . . . . . . . . . . . . 72.7 m -62.93 -36.88 84.86 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 115.957 -0.565 . . . . 0.0 110.437 179.41 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 219' ' ' LEU . . . . . . . . . . . . . 43.1 mt -69.93 -32.78 71.23 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 115.891 -0.595 . . . . 0.0 110.606 179.732 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 220' ' ' ARG . . . . . . . . . . . . . 91.4 mtm180 -83.29 -23.2 32.73 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 116.064 -0.517 . . . . 0.0 111.021 179.952 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 221' ' ' ALA . . . . . . . . . . . . . . . -82.33 -28.32 31.69 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.378 -0.374 . . . . 0.0 111.288 -179.791 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 222' ' ' GLU . . . . . . . . . . . . . 10.6 pt-20 -91.76 -30.74 16.08 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.296 179.998 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 223' ' ' HIS . . . . . . . . . . . . . 56.4 m-70 64.82 131.34 0.02 OUTLIER 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 115.525 -0.761 . . . . 0.0 111.215 -179.981 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 224' ' ' GLY . . . . . . . . . . . . . . . -99.81 10.93 60.81 Favored Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.804 -0.712 . . . . 0.0 112.283 179.827 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 225' ' ' GLU . . . . . . . . . . . . . 12.6 pt-20 -167.9 157.73 10.15 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-O 120.926 0.393 . . . . 0.0 111.051 -179.903 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 226' ' ' SER . . . . . . . . . . . . . 30.8 p -143.16 -30.02 0.52 Allowed 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 115.898 -0.592 . . . . 0.0 110.577 179.639 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 227' ' ' LEU . . . . . . . . . . . . . 2.3 pt? -60.53 152.05 26.98 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 115.949 -0.569 . . . . 0.0 110.72 179.684 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 228' ' ' ALA . . . . . . . . . . . . . . . -91.51 -45.89 8.27 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.348 -0.387 . . . . 0.0 110.974 179.812 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 229' ' ' GLY . . . . . . . . . . . . . . . -157.67 -122.56 0.71 Allowed Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.802 -0.713 . . . . 0.0 112.336 179.944 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 230' ' ' VAL . . . . . . . . . . . . . 46.8 t -128.15 140.25 49.69 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-O 120.749 0.309 . . . . 0.0 110.87 179.826 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 231' ' ' ASP . . . . . . . . . . . . . 4.0 p-10 -92.01 121.92 34.04 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.015 -179.846 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 232' ' ' THR . . . . . . . . . . . . . 9.5 t -110.1 8.52 23.93 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 115.974 -0.557 . . . . 0.0 110.896 -179.952 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 233' ' ' ASP . . . . . . . . . . . . . 24.1 t70 -79.1 -27.81 42.97 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.105 -0.498 . . . . 0.0 111.0 -179.931 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 234' ' ' THR . . . . . . . . . . . . . 8.1 t -72.69 141.5 82.46 Favored Pre-proline 0 C--N 1.329 -0.309 0 CA-C-N 116.321 -0.4 . . . . 0.0 111.029 -179.934 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 235' ' ' PRO . . . . . . . . . . . . . 70.3 Cg_endo -74.68 108.26 2.66 Favored 'Trans proline' 0 C--N 1.348 0.518 0 C-N-CA 122.324 2.016 . . . . 0.0 112.518 179.843 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 236' ' ' ALA . . . . . . . . . . . . . . . -107.75 113.08 26.08 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.09 -0.505 . . . . 0.0 110.831 179.771 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 237' ' ' VAL . . . . . . . . . . . . . 35.0 m -100.62 150.37 5.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.256 -0.429 . . . . 0.0 111.426 -179.698 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 238' ' ' ALA . . . . . . . . . . . . . . . 59.38 99.58 0.02 OUTLIER 'General case' 0 C--N 1.333 -0.138 0 CA-C-N 115.876 -0.602 . . . . 0.0 111.479 179.973 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 239' ' ' ASP . . . . . . . . . . . . . 10.7 m-20 -143.04 -3.55 0.96 Allowed 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.868 179.871 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 240' ' ' LEU . . . . . . . . . . . . . 84.5 mt -91.3 3.74 54.12 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 116.264 -0.425 . . . . 0.0 110.921 179.855 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 241' ' ' GLU . . . . . . . . . . . . . 15.4 mm-40 58.34 21.56 8.44 Favored 'General case' 0 C--N 1.332 -0.176 0 CA-C-N 116.038 -0.528 . . . . 0.0 111.263 179.826 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 242' ' ' HIS . . . . . . . . . . . . . 59.4 t60 -137.83 118.77 14.27 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.851 0.358 . . . . 0.0 111.018 -179.953 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 243' ' ' HIS . . . . . . . . . . . . . 32.6 t60 -80.38 125.16 29.57 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.705 179.89 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 244' ' ' HIS . . . . . . . . . . . . . 64.1 m-70 -87.11 120.63 28.58 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.888 -179.969 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 245' ' ' HIS . . . . . . . . . . . . . 76.7 t60 -92.64 -62.24 1.43 Allowed 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.296 -0.411 . . . . 0.0 110.923 179.978 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 246' ' ' HIS . . . . . . . . . . . . . 31.0 p80 -89.83 138.31 31.6 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.999 -179.972 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 247' ' ' HIS . . . . . . . . . . . . . 57.2 m-70 . . . . . 0 C--O 1.249 1.028 0 CA-C-O 118.274 -0.869 . . . . 0.0 110.729 179.815 . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 301' ' ' RET . . . . . 0.695 H203 ' HE1' ' A' ' 171' ' ' TRP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 83.5 mtp . . . . . 0 N--CA 1.486 1.33 0 CA-C-O 120.842 0.353 . . . . 0.0 111.011 . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 36.0 m -133.19 7.49 1.42 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.25 0 CA-C-N 116.071 -0.513 . . . . 0.0 111.049 179.941 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -104.84 -59.18 0.66 Allowed Glycine 0 C--N 1.331 0.286 0 C-N-CA 120.784 -0.722 . . . . 0.0 112.685 -179.897 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 96.6 mt -61.04 -35.44 76.91 Favored 'General case' 0 N--CA 1.448 -0.529 0 CA-C-O 120.758 0.313 . . . . 0.0 111.118 179.961 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 46.6 p -51.48 -36.92 46.52 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 116.013 -0.54 . . . . 0.0 111.68 -179.472 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 20.4 p -56.79 -38.94 73.23 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.209 -0.451 . . . . 0.0 111.576 -179.542 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 7' ' ' LEU . . . . . . . . . . . . . 3.9 mm? -61.81 -53.51 54.88 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.265 -0.425 . . . . 0.0 111.304 -179.716 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 8' ' ' PHE . . . . . 0.425 ' HB2' ' HB2' ' A' ' 55' ' ' ALA . 68.5 m-85 -55.43 -31.93 62.3 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.255 -0.429 . . . . 0.0 111.108 -179.607 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 9' ' ' TRP . . . . . 0.415 ' O ' HG12 ' A' ' 13' ' ' ILE . 21.7 m95 -66.01 -42.78 89.26 Favored 'General case' 0 C--N 1.326 -0.447 0 N-CA-C 109.695 -0.484 . . . . 0.0 109.695 179.694 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 84.6 mt -61.08 -38.97 88.14 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 115.62 -0.718 . . . . 0.0 110.238 179.223 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -65.84 -35.55 91.0 Favored Glycine 0 N--CA 1.449 -0.437 0 C-N-CA 120.85 -0.691 . . . . 0.0 111.865 179.349 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -65.6 -32.58 74.23 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-O 120.892 0.377 . . . . 0.0 110.672 179.585 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 13' ' ' ILE . . . . . 0.415 HG12 ' O ' ' A' ' 9' ' ' TRP . 50.5 mm -67.35 -51.03 56.94 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.245 0 CA-C-N 116.034 -0.53 . . . . 0.0 110.654 179.667 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -58.6 -31.6 67.45 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.141 179.669 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 15' ' ' MET . . . . . 0.567 ' HB3' ' HB2' ' A' ' 48' ' ' ALA . 23.9 mmt -69.89 -40.91 75.38 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-O 120.722 0.296 . . . . 0.0 110.64 179.661 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -57.47 -43.66 84.23 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.307 179.54 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 42.5 t -61.41 -49.83 82.86 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.214 0 CA-C-N 116.065 -0.516 . . . . 0.0 110.955 179.846 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -62.36 -48.27 83.59 Favored Glycine 0 C--N 1.331 0.285 0 C-N-CA 120.651 -0.785 . . . . 0.0 112.206 179.708 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 50.3 m -49.93 -41.13 45.55 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-O 120.67 0.271 . . . . 0.0 111.378 -179.754 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 52.3 mt -72.53 -46.06 56.35 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.329 -0.396 . . . . 0.0 111.41 179.903 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -60.59 -29.71 69.37 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.315 -0.402 . . . . 0.0 111.654 -179.604 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 22' ' ' PHE . . . . . 0.601 ' HB2' HG22 ' A' ' 41' ' ' VAL . 5.1 m-85 -91.23 -30.01 16.88 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.515 -0.311 . . . . 0.0 111.436 -179.56 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -72.66 -50.55 24.26 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-O 120.949 0.404 . . . . 0.0 110.997 -179.971 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 24' ' ' TRP . . . . . . . . . . . . . 2.8 t-105 -61.23 -39.49 90.48 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-N 115.737 -0.665 . . . . 0.0 110.501 179.806 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -80.69 -20.05 43.82 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.756 179.549 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -73.51 -46.85 23.87 Favored Glycine 0 C--N 1.331 0.271 0 C-N-CA 121.065 -0.588 . . . . 0.0 112.644 179.919 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 15.7 ptp180 -61.0 -20.16 62.15 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-O 120.804 0.335 . . . . 0.0 110.921 179.951 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 18.4 t70 -105.18 84.46 2.12 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.683 179.796 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -129.05 -175.15 3.47 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.032 -179.891 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -126.3 48.86 0.94 Allowed Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.701 -0.761 . . . . 0.0 112.671 -179.777 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 44.4 t 55.91 90.57 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.874 0.368 . . . . 0.0 111.171 179.871 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 137.68 -65.3 0.55 Allowed Glycine 0 N--CA 1.452 -0.257 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.6 179.684 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 22.8 mm-40 -61.31 -21.14 63.7 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.757 0.313 . . . . 0.0 111.007 -179.935 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 34' ' ' ARG . . . . . . . . . . . . . 48.6 ttp180 -51.17 -29.63 14.4 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 116.043 -0.526 . . . . 0.0 111.271 -179.959 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 35' ' ' ARG . . . . . 0.439 ' CZ ' HD22 ' A' ' 89' ' ' LEU . 51.8 ttp180 -59.47 -48.19 82.58 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.326 -0.397 . . . . 0.0 111.075 -179.994 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 53.5 m-85 -64.43 -34.61 78.59 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.984 -179.922 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 37' ' ' TYR . . . . . 0.468 ' O ' HG23 ' A' ' 41' ' ' VAL . 63.6 m-85 -66.84 -54.15 25.32 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 115.993 -0.549 . . . . 0.0 111.05 -179.762 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 77.7 t -56.98 -37.05 52.67 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.242 0 CA-C-O 120.889 0.376 . . . . 0.0 110.455 179.723 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 24.2 m -66.73 -40.24 88.27 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 121.355 0.598 . . . . 0.0 110.171 179.044 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 40' ' ' LEU . . . . . 0.503 HD11 ' HA2' ' A' ' 209' ' ' GLY . 12.7 tp -65.5 -41.87 92.75 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 115.258 -0.883 . . . . 0.0 110.372 179.757 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 41' ' ' VAL . . . . . 0.601 HG22 ' HB2' ' A' ' 22' ' ' PHE . 59.7 t -69.68 -34.17 59.85 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.426 0 CA-C-N 115.561 -0.745 . . . . 0.0 110.312 179.379 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 42' ' ' GLY . . . . . 0.463 ' O ' HG12 ' A' ' 46' ' ' ILE . . . -59.26 -46.57 93.63 Favored Glycine 0 N--CA 1.448 -0.541 0 C-N-CA 120.971 -0.633 . . . . 0.0 112.554 179.999 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 43' ' ' ILE . . . . . 0.554 HG23 HD23 ' A' ' 82' ' ' LEU . 10.2 pt -65.63 -51.57 61.21 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.157 0 N-CA-C 111.729 0.27 . . . . 0.0 111.729 -179.767 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 48.1 t -63.84 -24.19 67.65 Favored 'General case' 0 C--O 1.234 0.247 0 CA-C-O 120.924 0.392 . . . . 0.0 111.396 -179.762 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -78.14 -59.05 3.02 Favored Glycine 0 CA--C 1.518 0.22 0 C-N-CA 120.92 -0.657 . . . . 0.0 113.466 -178.856 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 46' ' ' ILE . . . . . 0.498 ' O ' HG22 ' A' ' 49' ' ' VAL . 17.7 pt -57.79 -35.29 50.62 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.207 0 CA-C-O 120.751 0.31 . . . . 0.0 110.957 -179.606 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 47' ' ' ALA . . . . . 0.682 ' HB2' ' HE2' ' A' ' 205' ' ' LYS . . . -67.62 -40.12 84.7 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-O 120.841 0.353 . . . . 0.0 110.085 178.559 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 48' ' ' ALA . . . . . 0.567 ' HB2' ' HB3' ' A' ' 15' ' ' MET . . . -54.48 -43.39 71.69 Favored 'General case' 0 C--N 1.334 -0.101 0 CA-C-N 115.987 -0.551 . . . . 0.0 111.291 179.801 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 49' ' ' VAL . . . . . 0.498 HG22 ' O ' ' A' ' 46' ' ' ILE . 21.4 m -75.62 -34.36 28.88 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.221 0 CA-C-N 116.463 -0.335 . . . . 0.0 111.452 -179.82 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -59.12 -45.5 90.75 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.824 0.345 . . . . 0.0 111.392 -179.849 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 57.6 m-85 -73.16 -40.15 65.08 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 115.919 -0.582 . . . . 0.0 111.257 -179.31 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -60.64 -47.03 88.04 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 115.886 -0.597 . . . . 0.0 111.318 -179.921 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 53' ' ' VAL . . . . . 0.469 HG13 ' O ' ' A' ' 49' ' ' VAL . 16.8 m -71.89 -43.14 69.07 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.243 0 CA-C-N 116.324 -0.398 . . . . 0.0 110.969 -179.876 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 54' ' ' MET . . . . . 0.429 ' N ' HG23 ' A' ' 53' ' ' VAL . 17.0 ttp -63.71 -29.49 70.71 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 121.085 0.469 . . . . 0.0 110.101 179.509 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 55' ' ' ALA . . . . . 0.425 ' HB2' ' HB2' ' A' ' 8' ' ' PHE . . . -63.84 -36.22 83.2 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 115.63 -0.714 . . . . 0.0 111.539 179.773 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 78.6 mt -80.99 13.15 2.85 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.475 -0.33 . . . . 0.0 111.427 -179.626 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 84.39 -2.21 88.09 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.638 -0.792 . . . . 0.0 112.87 179.712 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 55.0 t -68.83 141.69 17.14 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-O 120.732 0.301 . . . . 0.0 110.768 179.777 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 59' ' ' GLY . . . . . 0.623 ' HA3' ' HD3' ' A' ' 71' ' ' PRO . . . 86.18 -16.07 45.62 Favored Glycine 0 N--CA 1.45 -0.411 0 C-N-CA 120.595 -0.812 . . . . 0.0 112.275 -179.857 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 60' ' ' TRP . . . . . . . . . . . . . 13.7 m0 -66.88 92.94 0.24 Allowed 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 120.825 0.345 . . . . 0.0 110.602 179.665 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 7.1 p -96.23 123.25 55.57 Favored Pre-proline 0 C--N 1.328 -0.347 0 CA-C-N 116.303 -0.408 . . . . 0.0 111.211 -179.832 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 46.5 Cg_endo -68.41 141.03 49.89 Favored 'Trans proline' 0 C--N 1.35 0.649 0 C-N-CA 122.403 2.068 . . . . 0.0 112.231 179.93 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.411 HG21 ' HG3' ' A' ' 117' ' ' MET . 60.2 t -137.31 92.69 0.91 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.046 -0.525 . . . . 0.0 111.172 -179.789 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . 58.09 -88.93 0.02 OUTLIER 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 116.178 -0.465 . . . . 0.0 111.514 179.789 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 45.4 mt-10 -120.42 -17.98 8.01 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 116.486 -0.324 . . . . 0.0 110.856 179.973 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 66' ' ' ARG . . . . . . . . . . . . . 20.9 mmm180 -105.03 165.51 11.03 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 116.064 -0.516 . . . . 0.0 110.344 179.776 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 38.4 m -122.52 143.15 49.9 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-O 120.834 0.349 . . . . 0.0 111.201 -179.805 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 40.0 t -125.19 146.0 31.6 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.02 -0.537 . . . . 0.0 110.879 -179.991 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 69' ' ' PHE . . . . . . . . . . . . . 8.3 m-85 -109.31 114.32 27.9 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.371 -0.377 . . . . 0.0 110.161 179.837 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 70' ' ' VAL . . . . . 0.67 HG12 ' HD3' ' A' ' 71' ' ' PRO . 1.3 p -68.26 -35.64 7.58 Favored Pre-proline 0 CA--C 1.542 0.653 0 N-CA-C 112.945 0.72 . . . . 0.0 112.945 -179.34 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 71' ' ' PRO . . . . . 0.67 ' HD3' HG12 ' A' ' 70' ' ' VAL . 61.9 Cg_endo -71.16 -20.82 27.97 Favored 'Trans proline' 0 C--N 1.359 1.116 0 C-N-CA 121.822 1.681 . . . . 0.0 113.266 -179.352 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 66.7 ttt180 -74.23 -54.96 6.65 Favored 'General case' 0 C--N 1.329 -0.32 0 N-CA-C 112.019 0.377 . . . . 0.0 112.019 -178.993 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 73' ' ' TYR . . . . . 0.481 ' O ' HG13 ' A' ' 77' ' ' ILE . 65.9 m-85 -74.08 -32.84 63.42 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.533 -0.303 . . . . 0.0 111.526 -178.803 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 74' ' ' ILE . . . . . 0.467 ' O ' HD13 ' A' ' 74' ' ' ILE . 0.3 OUTLIER -70.23 -44.53 77.72 Favored 'Isoleucine or valine' 0 C--O 1.234 0.257 0 C-N-CA 120.615 -0.434 . . . . 0.0 110.18 179.486 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 75' ' ' ASP . . . . . 0.444 ' O ' HG23 ' A' ' 79' ' ' THR . 22.9 t70 -58.33 -35.89 72.58 Favored 'General case' 0 CA--C 1.52 -0.2 0 N-CA-C 109.094 -0.706 . . . . 0.0 109.094 178.959 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 76' ' ' TRP . . . . . 0.424 ' HA ' ' OG1' ' A' ' 79' ' ' THR . 44.7 m0 -64.95 -34.9 79.53 Favored 'General case' 0 C--N 1.332 -0.164 0 CA-C-N 115.769 -0.651 . . . . 0.0 110.228 178.801 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 77' ' ' ILE . . . . . 0.51 HG12 ' HB3' ' A' ' 109' ' ' MET . 98.0 mt -66.21 -30.42 49.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 115.981 -0.554 . . . . 0.0 110.745 179.561 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 82.0 mt -91.88 -17.89 24.58 Favored 'General case' 0 CA--C 1.532 0.257 0 N-CA-C 112.278 0.473 . . . . 0.0 112.278 179.644 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 79' ' ' THR . . . . . 0.444 HG23 ' O ' ' A' ' 75' ' ' ASP . 46.9 p -94.65 -51.65 4.64 Favored 'General case' 0 N--CA 1.465 0.319 0 N-CA-C 112.974 0.731 . . . . 0.0 112.974 -178.486 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 80' ' ' THR . . . . . 0.71 HG21 ' HE1' ' A' ' 109' ' ' MET . 27.5 m -50.25 -51.03 66.81 Favored Pre-proline 0 C--N 1.328 -0.354 0 N-CA-C 112.95 0.722 . . . . 0.0 112.95 -178.425 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 81' ' ' PRO . . . . . 0.531 ' HD2' ' N ' ' A' ' 80' ' ' THR . 19.4 Cg_endo -57.94 -23.57 60.44 Favored 'Trans proline' 0 C--N 1.352 0.732 0 C-N-CA 121.526 1.484 . . . . 0.0 111.703 -179.48 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 82' ' ' LEU . . . . . 0.554 HD23 HG23 ' A' ' 43' ' ' ILE . 3.5 mp -76.91 -38.36 53.63 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 115.923 -0.58 . . . . 0.0 110.704 179.834 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 49.9 mm -65.42 -53.44 39.82 Favored 'Isoleucine or valine' 0 C--O 1.234 0.267 0 CA-C-O 120.936 0.398 . . . . 0.0 110.221 179.371 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 26.8 m -60.68 -31.66 49.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.04 -0.527 . . . . 0.0 109.774 178.983 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 85' ' ' TYR . . . . . . . . . . . . . 87.7 t80 -67.81 -34.09 76.07 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-N 115.697 -0.683 . . . . 0.0 109.442 178.755 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 86' ' ' PHE . . . . . . . . . . . . . 1.8 t80 -58.95 -51.82 68.39 Favored 'General case' 0 C--O 1.233 0.225 0 CA-C-N 115.828 -0.624 . . . . 0.0 109.81 179.319 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 7.8 mp -63.87 -33.63 76.13 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 115.865 -0.607 . . . . 0.0 110.013 179.216 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -61.44 -28.34 69.35 Favored Glycine 0 N--CA 1.449 -0.454 0 C-N-CA 120.784 -0.722 . . . . 0.0 111.566 179.191 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 89' ' ' LEU . . . . . 0.439 HD22 ' CZ ' ' A' ' 35' ' ' ARG . 82.1 mt -79.04 -36.61 40.76 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.953 0.406 . . . . 0.0 110.165 179.325 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 97.0 mt -63.18 -37.67 88.13 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 115.821 -0.627 . . . . 0.0 111.017 179.802 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 91' ' ' ALA . . . . . 0.541 ' HB1' ' HB2' ' A' ' 148' ' ' SER . . . -87.22 -54.57 4.23 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.328 -179.837 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 103.33 70.6 0.84 Allowed Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.831 -0.699 . . . . 0.0 112.415 -179.775 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 93' ' ' LEU . . . . . 0.609 HD11 ' HG2' ' A' ' 145' ' ' MET . 7.5 mp -87.99 166.8 14.23 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.81 0.338 . . . . 0.0 111.047 -179.843 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 94' ' ' ASP . . . . . . . . . . . . . 7.9 m-20 -84.5 174.35 10.11 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.887 179.779 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 88.8 p -60.09 -35.72 75.82 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.308 -0.406 . . . . 0.0 111.004 -179.788 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 69.7 mtm180 -72.9 -48.79 34.2 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.148 -179.835 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 97' ' ' GLU . . . . . 0.593 ' HB3' HD23 ' A' ' 93' ' ' LEU . 37.5 mt-10 -56.16 -46.59 79.23 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.295 -0.412 . . . . 0.0 111.235 -179.73 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 98' ' ' PHE . . . . . 0.404 ' O ' HG12 ' A' ' 102' ' ' ILE . 6.5 m-85 -55.88 -50.59 70.23 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.366 -0.379 . . . . 0.0 111.07 -179.951 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -55.59 -34.28 60.14 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.858 -0.687 . . . . 0.0 112.637 -179.867 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 97.8 mt -66.82 -44.13 89.31 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.207 0 CA-C-O 120.773 0.32 . . . . 0.0 111.803 -179.748 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 25.0 t -68.59 -46.93 79.24 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.369 0 CA-C-N 116.263 -0.426 . . . . 0.0 111.936 -179.045 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 102' ' ' ILE . . . . . 0.404 HG12 ' O ' ' A' ' 98' ' ' PHE . 36.2 mm -63.64 -48.63 85.87 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 CA-C-N 116.283 -0.417 . . . . 0.0 111.922 -179.014 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 12.0 t -61.04 -37.2 81.75 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-O 120.761 0.315 . . . . 0.0 111.23 -179.528 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 104' ' ' LEU . . . . . 0.481 ' O ' HG23 ' A' ' 108' ' ' VAL . 10.1 tt -60.91 -42.93 99.01 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.411 179.721 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 105' ' ' ASN . . . . . 0.611 HD21 HD13 ' A' ' 137' ' ' LEU . 0.8 OUTLIER -67.68 -26.35 66.15 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.605 179.614 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 56.6 m -63.5 -53.57 49.98 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 115.941 -0.572 . . . . 0.0 111.149 179.82 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 7.8 p -63.93 -36.13 75.7 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.162 0 CA-C-N 116.336 -0.393 . . . . 0.0 111.127 179.919 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 108' ' ' VAL . . . . . 0.481 HG23 ' O ' ' A' ' 104' ' ' LEU . 79.6 t -63.3 -51.71 67.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-O 121.201 0.524 . . . . 0.0 110.604 179.44 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 109' ' ' MET . . . . . 0.71 ' HE1' HG21 ' A' ' 80' ' ' THR . 3.5 tpp -60.49 -33.73 73.02 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 115.67 -0.695 . . . . 0.0 110.422 179.759 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 20.8 tp -68.91 -33.52 73.88 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 115.9 -0.591 . . . . 0.0 110.166 179.693 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 111' ' ' ALA . . . . . 0.4 ' O ' HD13 ' A' ' 126' ' ' LEU . . . -59.7 -57.1 14.39 Favored 'General case' 0 C--N 1.332 -0.179 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.177 179.315 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 112' ' ' GLY . . . . . 0.697 ' HA3' ' H21' ' A' ' 301' ' ' RET . . . -57.31 -41.22 92.92 Favored Glycine 0 CA--C 1.518 0.233 0 C-N-CA 120.598 -0.81 . . . . 0.0 112.116 179.164 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 113' ' ' PHE . . . . . . . . . . . . . 1.5 t80 -47.16 -67.79 0.25 Allowed 'General case' 0 C--N 1.333 -0.137 0 CA-C-O 121.127 0.489 . . . . 0.0 110.081 179.473 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 114' ' ' ALA . . . . . 0.419 ' O ' HG13 ' A' ' 118' ' ' VAL . . . -64.43 -21.09 66.54 Favored 'General case' 0 C--N 1.326 -0.449 0 CA-C-N 115.512 -0.767 . . . . 0.0 110.864 179.661 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 115' ' ' GLY . . . . . 0.638 ' HA2' HD11 ' A' ' 126' ' ' LEU . . . -52.96 -49.38 55.37 Favored Glycine 0 C--N 1.333 0.375 0 C-N-CA 121.008 -0.615 . . . . 0.0 112.367 179.912 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -78.08 -15.79 58.59 Favored 'General case' 0 C--N 1.324 -0.506 0 N-CA-C 111.665 0.246 . . . . 0.0 111.665 179.742 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 117' ' ' MET . . . . . 0.411 ' HG3' HG21 ' A' ' 63' ' ' VAL . 36.1 ttm -100.94 19.89 16.49 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.497 -0.32 . . . . 0.0 111.674 -179.091 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 118' ' ' VAL . . . . . 0.444 HG21 ' HB3' ' A' ' 123' ' ' ARG . 28.3 m -74.11 147.5 85.84 Favored Pre-proline 0 C--N 1.328 -0.36 0 CA-C-N 116.559 -0.291 . . . . 0.0 111.305 179.789 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 119' ' ' PRO . . . . . . . . . . . . . 81.3 Cg_endo -88.94 -6.28 5.68 Favored 'Trans proline' 0 N--CA 1.457 -0.622 0 C-N-CA 122.688 2.259 . . . . 0.0 112.283 179.683 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -148.4 -114.69 0.78 Allowed Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.711 -0.757 . . . . 0.0 112.915 -179.783 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 44.7 pt -122.59 14.56 5.58 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 CA-C-O 120.802 0.334 . . . . 0.0 111.39 -179.51 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 36.9 mt-10 -63.4 -18.85 64.14 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.134 -179.999 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 123' ' ' ARG . . . . . 0.486 ' HA ' HD21 ' A' ' 126' ' ' LEU . 35.9 ptt180 -53.41 -32.42 49.56 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.106 -0.497 . . . . 0.0 111.925 -179.544 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 124' ' ' TYR . . . . . . . . . . . . . 91.5 m-85 -72.54 -31.41 65.27 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 116.476 -0.329 . . . . 0.0 111.466 -179.652 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 125' ' ' ALA . . . . . . . . . . . . . . . -74.51 -58.28 3.39 Favored 'General case' 0 C--O 1.237 0.44 0 CA-C-O 121.196 0.522 . . . . 0.0 111.573 -179.374 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 126' ' ' LEU . . . . . 0.638 HD11 ' HA2' ' A' ' 115' ' ' GLY . 0.7 OUTLIER -56.49 -37.24 70.1 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 115.701 -0.681 . . . . 0.0 110.511 179.789 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 127' ' ' PHE . . . . . 0.477 ' HE1' ' H42' ' A' ' 301' ' ' RET . 7.8 t80 -69.37 -42.6 74.99 Favored 'General case' 0 N--CA 1.453 -0.311 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.114 179.304 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 128' ' ' GLY . . . . . . . . . . . . . . . -48.09 -35.33 13.52 Favored Glycine 0 C--N 1.333 0.379 0 N-CA-C 110.673 -0.971 . . . . 0.0 110.673 178.746 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 129' ' ' MET . . . . . . . . . . . . . 0.2 OUTLIER -72.03 -43.67 64.63 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 115.154 -0.523 . . . . 0.0 109.877 178.619 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -67.25 -22.22 72.6 Favored Glycine 0 N--CA 1.449 -0.474 0 C-N-CA 120.869 -0.682 . . . . 0.0 112.378 179.602 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 131' ' ' ALA . . . . . 0.436 ' O ' ' HB3' ' A' ' 134' ' ' PHE . . . -74.61 -53.9 8.48 Favored 'General case' 0 CA--C 1.519 -0.234 0 CA-C-O 120.739 0.304 . . . . 0.0 110.211 179.681 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 58.1 t -58.32 -39.47 74.24 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.319 0 N-CA-C 108.535 -0.913 . . . . 0.0 108.535 178.096 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -62.77 -37.44 86.67 Favored 'General case' 0 N--CA 1.451 -0.378 0 CA-C-N 114.915 -1.039 . . . . 0.0 110.198 178.767 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 134' ' ' PHE . . . . . 0.436 ' HB3' ' O ' ' A' ' 131' ' ' ALA . 68.0 t80 -55.64 -50.09 71.11 Favored 'General case' 0 N--CA 1.453 -0.325 0 CA-C-N 116.159 -0.473 . . . . 0.0 109.88 179.364 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 135' ' ' ILE . . . . . 0.504 ' O ' HG22 ' A' ' 138' ' ' VAL . 59.0 mt -59.54 -32.45 49.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 115.667 -0.697 . . . . 0.0 110.14 179.228 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . -59.46 -41.76 97.25 Favored Glycine 0 N--CA 1.449 -0.494 0 C-N-CA 120.409 -0.901 . . . . 0.0 111.271 179.054 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 137' ' ' LEU . . . . . 0.611 HD13 HD21 ' A' ' 105' ' ' ASN . 42.7 tp -65.85 -55.61 16.17 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 120.666 0.27 . . . . 0.0 110.722 179.541 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 138' ' ' VAL . . . . . 0.637 ' HB ' HH22 ' A' ' 164' ' ' ARG . 2.5 m -54.79 -32.3 25.79 Favored 'Isoleucine or valine' 0 C--O 1.234 0.267 0 CA-C-O 121.125 0.488 . . . . 0.0 109.802 -179.506 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 139' ' ' TYR . . . . . . . . . . . . . 10.2 t80 -61.43 -42.31 98.54 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 115.654 -0.703 . . . . 0.0 109.964 178.293 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 28.1 m-85 -65.99 -42.37 89.89 Favored 'General case' 0 C--N 1.332 -0.184 0 CA-C-N 116.11 -0.496 . . . . 0.0 111.002 179.517 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 141' ' ' LEU . . . . . 0.435 ' HA ' ' SD ' ' A' ' 145' ' ' MET . 10.8 mp -56.62 -32.86 65.71 Favored 'General case' 0 N--CA 1.462 0.139 0 CA-C-N 116.356 -0.384 . . . . 0.0 110.883 -179.973 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 21.6 t -97.05 -12.75 8.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.82 179.662 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . -76.33 -123.83 0.19 Allowed Glycine 0 CA--C 1.522 0.529 0 C-N-CA 120.845 -0.693 . . . . 0.0 112.932 -179.721 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 144' ' ' PRO . . . . . . . . . . . . . 31.7 Cg_exo -58.87 -29.95 91.58 Favored 'Trans proline' 0 C--N 1.351 0.659 0 C-N-CA 122.596 2.198 . . . . 0.0 112.726 -179.672 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 145' ' ' MET . . . . . 0.609 ' HG2' HD11 ' A' ' 93' ' ' LEU . 60.1 mtt -58.7 -26.98 64.42 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.316 -0.402 . . . . 0.0 111.235 -179.893 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 146' ' ' THR . . . . . . . . . . . . . 24.0 m -81.08 -33.67 33.2 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-N 116.119 -0.491 . . . . 0.0 111.478 -179.058 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 15.0 tp10 -71.89 -43.43 65.41 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.98 -179.896 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 148' ' ' SER . . . . . 0.541 ' HB2' ' HB1' ' A' ' 91' ' ' ALA . 61.7 m -71.98 -40.15 68.79 Favored 'General case' 0 C--N 1.327 -0.405 0 N-CA-C 112.334 0.494 . . . . 0.0 112.334 -179.205 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 149' ' ' ALA . . . . . . . . . . . . . . . -76.68 -44.64 32.85 Favored 'General case' 0 C--N 1.33 -0.278 0 N-CA-C 113.395 0.887 . . . . 0.0 113.395 -177.974 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 150' ' ' SER . . . . . . . . . . . . . 54.2 m -69.12 -14.29 62.92 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.909 0.385 . . . . 0.0 110.85 -178.495 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 151' ' ' GLN . . . . . . . . . . . . . 3.0 mp0 -116.56 10.38 14.46 Favored 'General case' 0 C--N 1.324 -0.502 0 CA-C-N 115.928 -0.578 . . . . 0.0 111.494 -179.462 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 72.2 ttt180 -82.99 -51.94 7.12 Favored 'General case' 0 C--N 1.334 -0.102 0 CA-C-O 120.868 0.366 . . . . 0.0 110.943 -179.968 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 153' ' ' SER . . . . . 0.598 ' HB2' HG12 ' A' ' 156' ' ' ILE . 17.6 m -157.45 172.18 19.04 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 116.032 -0.531 . . . . 0.0 110.861 179.596 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 154' ' ' SER . . . . . . . . . . . . . 67.9 m -71.09 -37.3 72.41 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.687 179.636 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -76.82 -35.0 41.24 Favored Glycine 0 N--CA 1.452 -0.276 0 C-N-CA 120.887 -0.673 . . . . 0.0 112.568 179.908 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 156' ' ' ILE . . . . . 0.598 HG12 ' HB2' ' A' ' 153' ' ' SER . 41.4 mm -56.42 -37.72 52.51 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-O 120.887 0.375 . . . . 0.0 110.92 -179.972 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 157' ' ' LYS . . . . . . . . . . . . . 24.3 ttpp -60.98 -32.9 72.45 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.903 179.82 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 47.1 m -70.9 -45.23 64.7 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.073 -179.863 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 159' ' ' LEU . . . . . 0.487 HD22 HD21 ' A' ' 163' ' ' LEU . 11.2 mt -65.67 -36.12 82.76 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.338 -0.392 . . . . 0.0 111.07 179.931 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 160' ' ' TYR . . . . . 0.49 ' O ' ' HB3' ' A' ' 164' ' ' ARG . 57.3 t80 -65.57 -47.86 74.36 Favored 'General case' 0 C--N 1.329 -0.317 0 N-CA-C 112.206 0.447 . . . . 0.0 112.206 -178.952 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 161' ' ' VAL . . . . . 0.43 HG23 ' N ' ' A' ' 162' ' ' ARG . 17.3 m -62.17 -49.28 84.69 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 N-CA-C 112.304 0.483 . . . . 0.0 112.304 -178.608 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 162' ' ' ARG . . . . . 0.43 ' N ' HG23 ' A' ' 161' ' ' VAL . 81.9 mtt180 -68.46 -46.11 70.66 Favored 'General case' 0 C--N 1.329 -0.291 0 N-CA-C 112.076 0.398 . . . . 0.0 112.076 -179.044 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 163' ' ' LEU . . . . . 0.487 HD21 HD22 ' A' ' 159' ' ' LEU . 1.7 mp -67.67 -54.95 15.35 Favored 'General case' 0 C--N 1.328 -0.332 0 N-CA-C 112.243 0.46 . . . . 0.0 112.243 -178.62 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 164' ' ' ARG . . . . . 0.637 HH22 ' HB ' ' A' ' 138' ' ' VAL . 25.2 tpt180 -55.78 -54.89 38.91 Favored 'General case' 0 N--CA 1.465 0.292 0 N-CA-C 112.629 0.603 . . . . 0.0 112.629 -178.46 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 165' ' ' ASN . . . . . . . . . . . . . 13.8 m-80 -58.0 -49.25 77.5 Favored 'General case' 0 C--N 1.33 -0.255 0 N-CA-C 112.071 0.397 . . . . 0.0 112.071 -178.75 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 166' ' ' LEU . . . . . . . . . . . . . 4.4 tt -63.45 -55.37 24.73 Favored 'General case' 0 C--N 1.325 -0.47 0 N-CA-C 111.876 0.325 . . . . 0.0 111.876 -179.262 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 167' ' ' THR . . . . . . . . . . . . . 53.7 m -57.02 -52.92 63.34 Favored 'General case' 0 C--N 1.328 -0.368 0 N-CA-C 113.037 0.754 . . . . 0.0 113.037 -178.613 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 168' ' ' VAL . . . . . 0.451 HG12 ' O ' ' A' ' 164' ' ' ARG . 7.9 p -57.5 -41.22 78.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 N-CA-C 112.482 0.549 . . . . 0.0 112.482 -178.529 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 169' ' ' VAL . . . . . 0.463 ' CG1' ' N ' ' A' ' 170' ' ' LEU . 0.4 OUTLIER -63.72 -54.07 36.76 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.443 0 N-CA-C 111.867 0.321 . . . . 0.0 111.867 -178.76 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 170' ' ' LEU . . . . . 0.463 ' N ' ' CG1' ' A' ' 169' ' ' VAL . 3.0 pp -68.03 -31.12 70.57 Favored 'General case' 0 C--N 1.33 -0.268 0 C-N-CA 121.173 -0.211 . . . . 0.0 111.543 -178.562 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 171' ' ' TRP . . . . . 0.768 ' HE1' H203 ' A' ' 301' ' ' RET . 3.3 m0 -72.29 -28.59 63.19 Favored 'General case' 0 C--N 1.329 -0.295 0 N-CA-C 109.952 -0.388 . . . . 0.0 109.952 178.895 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 172' ' ' ALA . . . . . . . . . . . . . . . -76.0 -6.87 53.03 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-N 115.919 -0.582 . . . . 0.0 110.554 -179.821 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 173' ' ' ILE . . . . . 0.486 ' O ' HG12 ' A' ' 177' ' ' ILE . 34.1 mm -85.86 -21.12 7.75 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.204 0 CA-C-N 115.719 -0.673 . . . . 0.0 110.853 179.41 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 174' ' ' TYR . . . . . 0.417 ' HB2' ' HD3' ' A' ' 175' ' ' PRO . 11.8 m-85 -53.76 -50.22 84.83 Favored Pre-proline 0 CA--C 1.53 0.194 0 CA-C-N 116.313 -0.403 . . . . 0.0 111.799 -179.446 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 175' ' ' PRO . . . . . 0.417 ' HD3' ' HB2' ' A' ' 174' ' ' TYR . 74.5 Cg_exo -50.42 -29.9 25.5 Favored 'Trans proline' 0 C--N 1.349 0.572 0 C-N-CA 122.191 1.927 . . . . 0.0 112.517 179.84 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 176' ' ' PHE . . . . . 0.432 ' HD2' ' HA ' ' A' ' 173' ' ' ILE . 38.9 m-85 -80.44 -50.24 10.35 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.233 -0.44 . . . . 0.0 111.846 -179.707 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 177' ' ' ILE . . . . . 0.486 HG12 ' O ' ' A' ' 173' ' ' ILE . 5.7 mm -65.65 -33.54 64.29 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.519 0 N-CA-C 112.27 0.47 . . . . 0.0 112.27 -178.229 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 178' ' ' TRP . . . . . 0.442 ' HH2' ' HB2' ' A' ' 123' ' ' ARG . 88.7 t90 -72.86 -56.53 5.08 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.873 0.368 . . . . 0.0 110.807 -179.925 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 179' ' ' LEU . . . . . 0.416 HD23 HD23 ' A' ' 180' ' ' LEU . 0.6 OUTLIER -63.04 -54.23 41.33 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 115.931 -0.577 . . . . 0.0 111.324 -179.36 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 180' ' ' LEU . . . . . 0.54 HD22 HD11 ' A' ' 187' ' ' LEU . 43.3 mt -64.67 -41.41 96.1 Favored 'General case' 0 C--N 1.331 -0.213 0 C-N-CA 120.832 -0.347 . . . . 0.0 111.068 -179.607 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . -62.6 -178.79 3.98 Favored Glycine 0 C--N 1.334 0.43 0 C-N-CA 119.952 -1.118 . . . . 0.0 112.002 179.103 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 182' ' ' PRO . . . . . 0.577 ' HA ' ' HB2' ' A' ' 186' ' ' ALA . 83.2 Cg_exo -47.84 -44.8 26.17 Favored 'Trans proline' 0 CA--C 1.536 0.58 0 C-N-CA 122.741 2.294 . . . . 0.0 113.74 179.962 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 183' ' ' PRO . . . . . 0.411 ' HD3' ' HB2' ' A' ' 182' ' ' PRO . 84.1 Cg_exo -47.04 -22.51 2.15 Favored 'Trans proline' 0 C--N 1.356 0.933 0 C-N-CA 122.209 1.939 . . . . 0.0 113.286 -179.688 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 184' ' ' GLY . . . . . . . . . . . . . . . -126.12 -124.12 2.74 Favored Glycine 0 C--N 1.333 0.367 0 C-N-CA 120.305 -0.95 . . . . 0.0 112.926 179.874 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 185' ' ' VAL . . . . . 0.41 ' CG2' ' HA ' ' A' ' 180' ' ' LEU . 19.4 m -61.28 -25.31 36.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 N-CA-C 112.281 0.474 . . . . 0.0 112.281 -179.248 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 186' ' ' ALA . . . . . 0.577 ' HB2' ' HA ' ' A' ' 182' ' ' PRO . . . 57.65 85.41 0.09 Allowed 'General case' 0 N--CA 1.465 0.318 0 CA-C-O 120.832 0.348 . . . . 0.0 111.7 179.555 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 187' ' ' LEU . . . . . 0.54 HD11 HD22 ' A' ' 180' ' ' LEU . 10.7 mt -92.88 -49.27 6.13 Favored 'General case' 0 C--N 1.332 -0.184 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.359 179.911 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 188' ' ' LEU . . . . . . . . . . . . . 53.7 mt -95.47 -161.43 0.86 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 115.988 -0.551 . . . . 0.0 111.691 -179.052 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 189' ' ' THR . . . . . . . . . . . . . 9.9 m -91.5 137.06 26.09 Favored Pre-proline 0 C--N 1.33 -0.261 0 CA-C-N 115.77 -0.65 . . . . 0.0 110.682 -179.716 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 190' ' ' PRO . . . . . . . . . . . . . 96.4 Cg_exo -44.65 -46.01 12.76 Favored 'Trans proline' 0 C--N 1.35 0.655 0 C-N-CA 122.812 2.341 . . . . 0.0 113.539 -179.735 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 191' ' ' THR . . . . . . . . . . . . . 6.7 t -59.1 -36.83 75.8 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.822 0.344 . . . . 0.0 111.329 -179.764 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 192' ' ' VAL . . . . . . . . . . . . . 58.0 t -74.79 -53.63 16.19 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.22 -0.446 . . . . 0.0 111.696 -179.591 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 193' ' ' ASP . . . . . . . . . . . . . 23.9 m-20 -56.45 -48.36 77.22 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.45 -0.341 . . . . 0.0 110.973 -179.588 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 194' ' ' VAL . . . . . . . . . . . . . 78.0 t -61.92 -36.38 73.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.432 179.602 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 195' ' ' ALA . . . . . . . . . . . . . . . -56.28 -42.34 77.33 Favored 'General case' 0 C--N 1.331 -0.197 0 CA-C-N 116.344 -0.389 . . . . 0.0 110.823 179.335 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 196' ' ' LEU . . . . . . . . . . . . . 96.1 mt -67.19 -38.86 86.09 Favored 'General case' 0 C--N 1.332 -0.174 0 CA-C-O 120.952 0.406 . . . . 0.0 110.332 179.486 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 197' ' ' ILE . . . . . . . . . . . . . 21.6 mm -59.79 -52.6 59.19 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 115.937 -0.574 . . . . 0.0 110.18 179.153 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 198' ' ' VAL . . . . . . . . . . . . . 90.8 t -57.26 -34.15 45.17 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.458 0 N-CA-C 108.908 -0.775 . . . . 0.0 108.908 178.179 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 199' ' ' TYR . . . . . . . . . . . . . 46.0 t80 -69.44 -30.3 68.19 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-N 115.115 -0.948 . . . . 0.0 110.568 179.46 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 200' ' ' LEU . . . . . 0.467 ' O ' HG12 ' A' ' 203' ' ' VAL . 48.2 mt -70.25 -42.37 72.27 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 115.944 -0.571 . . . . 0.0 111.158 -179.854 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 201' ' ' ASP . . . . . . . . . . . . . 12.3 m-20 -73.3 -34.65 65.84 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-O 121.167 0.508 . . . . 0.0 110.15 179.378 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 202' ' ' LEU . . . . . . . . . . . . . 2.5 mt -70.78 -31.33 68.07 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 115.562 -0.745 . . . . 0.0 111.795 -179.799 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 203' ' ' VAL . . . . . 0.467 HG12 ' O ' ' A' ' 200' ' ' LEU . 11.9 p -77.18 -37.1 25.42 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.235 0 C-N-CA 120.946 -0.302 . . . . 0.0 111.209 -179.143 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 204' ' ' THR . . . . . . . . . . . . . 68.0 m -65.13 -57.49 8.44 Favored 'General case' 0 C--O 1.222 -0.392 0 C-N-CA 120.76 -0.376 . . . . 0.0 111.318 179.718 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 205' ' ' LYS . . . . . 0.682 ' HE2' ' HB2' ' A' ' 47' ' ' ALA . 60.6 mttp -65.13 -55.51 18.3 Favored 'General case' 0 C--N 1.326 -0.414 0 N-CA-C 112.301 0.482 . . . . 0.0 112.301 -178.716 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 59.2 t -65.31 -47.18 88.17 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 N-CA-C 111.841 0.312 . . . . 0.0 111.841 -179.606 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 207' ' ' GLY . . . . . . . . . . . . . . . -63.94 -59.62 8.34 Favored Glycine 0 C--N 1.331 0.28 0 C-N-CA 120.708 -0.758 . . . . 0.0 112.771 -179.795 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 208' ' ' PHE . . . . . 0.42 ' O ' ' N ' ' A' ' 212' ' ' ALA . 4.1 t80 -54.71 -40.74 69.52 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.672 0.272 . . . . 0.0 110.97 179.965 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 209' ' ' GLY . . . . . 0.503 ' HA2' HD11 ' A' ' 40' ' ' LEU . . . -69.78 -38.65 76.63 Favored Glycine 0 C--N 1.329 0.189 0 CA-C-N 115.877 -0.601 . . . . 0.0 113.356 -179.558 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 210' ' ' PHE . . . . . . . . . . . . . 1.4 m-85 -69.66 -39.95 76.75 Favored 'General case' 0 CA--C 1.51 -0.571 0 N-CA-C 107.649 -1.241 . . . . 0.0 107.649 179.118 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 211' ' ' ILE . . . . . . . . . . . . . 29.9 mt -69.73 -28.6 37.84 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.87 0 CA-C-N 114.235 -1.348 . . . . 0.0 107.416 176.737 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 212' ' ' ALA . . . . . 0.461 ' HB3' ' O ' ' A' ' 209' ' ' GLY . . . -68.08 -38.8 82.78 Favored 'General case' 0 N--CA 1.447 -0.59 0 CA-C-N 114.293 -1.321 . . . . 0.0 110.637 179.856 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 213' ' ' LEU . . . . . . . . . . . . . 96.4 mt -70.6 -53.09 17.3 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 115.257 -0.883 . . . . 0.0 112.043 -179.238 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 214' ' ' ASP . . . . . . . . . . . . . 45.0 m-20 -52.09 -53.06 47.11 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.443 -0.344 . . . . 0.0 111.636 -179.428 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 215' ' ' ALA . . . . . 0.421 ' HB3' HD21 ' A' ' 159' ' ' LEU . . . -59.68 -57.36 13.26 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.344 -0.389 . . . . 0.0 111.818 -179.511 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 216' ' ' ALA . . . . . . . . . . . . . . . -58.11 -31.73 67.43 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.441 -0.345 . . . . 0.0 111.601 -179.519 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 217' ' ' ALA . . . . . . . . . . . . . . . -62.24 -42.16 99.06 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 121.015 0.436 . . . . 0.0 110.151 179.832 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 218' ' ' THR . . . . . . . . . . . . . 97.2 m -67.44 -39.2 85.41 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 115.827 -0.624 . . . . 0.0 110.33 179.154 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 219' ' ' LEU . . . . . 0.491 ' O ' ' HG2' ' A' ' 222' ' ' GLU . 82.9 mt -58.77 -41.88 87.64 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 115.784 -0.644 . . . . 0.0 110.669 179.733 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 220' ' ' ARG . . . . . . . . . . . . . 36.0 ptt180 -83.96 -14.12 51.66 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.213 -0.448 . . . . 0.0 110.587 179.435 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 221' ' ' ALA . . . . . . . . . . . . . . . -82.55 -20.21 37.05 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.13 -0.486 . . . . 0.0 111.931 -179.57 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 222' ' ' GLU . . . . . 0.491 ' HG2' ' O ' ' A' ' 219' ' ' LEU . 11.4 pt-20 -67.17 -28.39 68.07 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-O 121.058 0.456 . . . . 0.0 110.352 -179.732 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 223' ' ' HIS . . . . . . . . . . . . . 78.2 m80 -66.76 -24.82 66.26 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 115.68 -0.691 . . . . 0.0 110.908 -179.924 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 224' ' ' GLY . . . . . . . . . . . . . . . 73.04 -124.78 9.28 Favored Glycine 0 N--CA 1.452 -0.235 0 C-N-CA 120.85 -0.69 . . . . 0.0 112.458 179.91 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 225' ' ' GLU . . . . . . . . . . . . . 8.9 tp10 -163.95 148.81 10.42 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.83 0.348 . . . . 0.0 110.912 179.977 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 226' ' ' SER . . . . . . . . . . . . . 50.5 m -109.15 -32.17 7.32 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.889 179.966 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 227' ' ' LEU . . . . . . . . . . . . . 53.5 tp -61.36 143.2 56.19 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.067 -0.515 . . . . 0.0 110.884 179.903 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 228' ' ' ALA . . . . . . . . . . . . . . . -88.11 135.98 33.18 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.964 179.858 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 229' ' ' GLY . . . . . . . . . . . . . . . 139.21 138.68 3.69 Favored Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.807 -0.711 . . . . 0.0 112.302 -179.738 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 230' ' ' VAL . . . . . . . . . . . . . 5.6 m -119.8 29.74 2.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-O 120.874 0.369 . . . . 0.0 111.364 -179.911 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 231' ' ' ASP . . . . . . . . . . . . . 5.7 m-20 49.0 67.96 0.79 Allowed 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 115.695 -0.684 . . . . 0.0 110.832 -179.846 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 232' ' ' THR . . . . . . . . . . . . . 38.6 p -139.12 -65.46 0.48 Allowed 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.273 -0.422 . . . . 0.0 111.429 -179.538 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 233' ' ' ASP . . . . . . . . . . . . . 17.1 m-20 -88.79 -78.35 0.34 Allowed 'General case' 0 C--N 1.33 -0.239 0 CA-C-N 116.33 -0.396 . . . . 0.0 111.242 -179.631 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 234' ' ' THR . . . . . . . . . . . . . 81.9 p -140.87 146.07 42.36 Favored Pre-proline 0 C--N 1.33 -0.275 0 CA-C-N 116.363 -0.38 . . . . 0.0 111.021 -179.797 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 235' ' ' PRO . . . . . . . . . . . . . 58.5 Cg_endo -71.94 153.1 58.16 Favored 'Trans proline' 0 C--N 1.348 0.544 0 C-N-CA 122.298 1.998 . . . . 0.0 112.096 179.801 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 236' ' ' ALA . . . . . 0.546 ' O ' HG12 ' A' ' 237' ' ' VAL . . . 63.16 109.81 0.03 OUTLIER 'General case' 0 C--N 1.333 -0.139 0 CA-C-N 116.095 -0.502 . . . . 0.0 111.211 -179.893 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 237' ' ' VAL . . . . . 0.563 HG22 ' H ' ' A' ' 238' ' ' ALA . 0.5 OUTLIER 52.23 176.94 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.466 0.328 0 CA-C-N 115.882 -0.599 . . . . 0.0 111.606 -179.905 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 238' ' ' ALA . . . . . 0.563 ' H ' HG22 ' A' ' 237' ' ' VAL . . . -149.32 0.2 0.5 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.349 -0.387 . . . . 0.0 111.135 179.903 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 239' ' ' ASP . . . . . . . . . . . . . 7.8 m-20 59.89 98.1 0.03 OUTLIER 'General case' 0 C--N 1.332 -0.185 0 CA-C-N 116.019 -0.537 . . . . 0.0 111.411 179.78 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 240' ' ' LEU . . . . . . . . . . . . . 7.5 mp -111.96 104.74 13.03 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.08 -0.509 . . . . 0.0 110.692 179.717 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 241' ' ' GLU . . . . . . . . . . . . . 2.2 mp0 -96.38 0.73 50.99 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 116.293 -0.412 . . . . 0.0 110.921 179.986 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 242' ' ' HIS . . . . . . . . . . . . . 14.6 t-80 -88.37 118.85 28.28 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.299 -0.41 . . . . 0.0 110.855 179.936 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 243' ' ' HIS . . . . . . . . . . . . . 18.4 p-80 -85.71 171.17 11.83 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.041 -179.982 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 244' ' ' HIS . . . . . . . . . . . . . 56.1 t-80 -138.52 97.15 3.29 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 115.977 -0.556 . . . . 0.0 110.812 179.997 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 245' ' ' HIS . . . . . . . . . . . . . 58.8 m-70 60.05 106.0 0.02 OUTLIER 'General case' 0 C--N 1.331 -0.218 0 CA-C-N 116.115 -0.493 . . . . 0.0 111.32 -179.942 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 246' ' ' HIS . . . . . . . . . . . . . 12.4 p-80 -106.68 -14.19 15.08 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.067 -0.515 . . . . 0.0 110.8 179.771 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 247' ' ' HIS . . . . . . . . . . . . . 82.0 m-70 . . . . . 0 C--O 1.248 1.006 0 CA-C-O 118.218 -0.896 . . . . 0.0 110.946 -179.942 . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 301' ' ' RET . . . . . 0.768 H203 ' HE1' ' A' ' 171' ' ' TRP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 59.9 ttp . . . . . 0 N--CA 1.486 1.348 0 CA-C-O 120.678 0.275 . . . . 0.0 110.865 . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 42.1 t 62.47 103.77 0.04 OUTLIER 'Isoleucine or valine' 0 C--N 1.332 -0.195 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.332 179.807 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . 145.07 -37.72 1.31 Allowed Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.846 -0.692 . . . . 0.0 112.384 179.976 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 59.4 tp -74.42 -35.52 63.41 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 120.844 0.355 . . . . 0.0 111.101 179.886 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 65.2 p -62.64 -30.06 71.09 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.517 -179.626 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 36.1 p -55.11 -35.46 64.68 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.44 -0.345 . . . . 0.0 111.118 -179.92 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 7' ' ' LEU . . . . . . . . . . . . . 4.2 mm? -56.65 -53.26 59.77 Favored 'General case' 0 C--N 1.331 -0.205 0 CA-C-N 116.082 -0.508 . . . . 0.0 111.052 -179.974 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 8' ' ' PHE . . . . . 0.708 ' HB2' ' HB2' ' A' ' 55' ' ' ALA . 67.9 m-85 -60.96 -36.41 79.32 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.873 -179.958 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 9' ' ' TRP . . . . . . . . . . . . . 30.4 m95 -61.4 -44.16 97.63 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.047 -179.876 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 51.8 mt -60.94 -42.65 98.59 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 115.638 -0.71 . . . . 0.0 110.239 179.246 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -62.09 -29.94 74.22 Favored Glycine 0 N--CA 1.448 -0.549 0 C-N-CA 120.69 -0.766 . . . . 0.0 111.888 179.259 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -72.58 -33.51 66.8 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-O 120.698 0.285 . . . . 0.0 110.968 179.719 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 13' ' ' ILE . . . . . 0.434 ' O ' HG23 ' A' ' 17' ' ' VAL . 83.3 mt -64.16 -54.32 32.7 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.226 0 CA-C-N 116.343 -0.39 . . . . 0.0 110.749 179.758 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -66.02 -34.15 87.59 Favored Glycine 0 N--CA 1.452 -0.291 0 C-N-CA 120.685 -0.769 . . . . 0.0 112.227 179.833 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 15' ' ' MET . . . . . 0.534 ' SD ' ' HA ' ' A' ' 44' ' ' SER . 52.7 tpp -65.69 -49.79 67.27 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.733 0.301 . . . . 0.0 110.646 179.986 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 51.0 mt -53.42 -42.23 66.84 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.506 179.382 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 17' ' ' VAL . . . . . 0.434 HG23 ' O ' ' A' ' 13' ' ' ILE . 99.5 t -58.89 -41.46 82.98 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.226 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.125 179.128 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -64.76 -40.49 97.43 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.606 -0.806 . . . . 0.0 111.49 179.029 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 3.6 m -50.97 -54.17 26.69 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.883 0.373 . . . . 0.0 111.102 179.917 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 75.2 mt -71.74 -39.72 69.88 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.061 -0.518 . . . . 0.0 111.454 -179.887 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 21' ' ' ALA . . . . . 0.567 ' O ' ' HB2' ' A' ' 25' ' ' ALA . . . -54.71 -43.88 72.95 Favored 'General case' 0 C--N 1.329 -0.316 0 N-CA-C 112.381 0.512 . . . . 0.0 112.381 -178.953 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 4.3 m-85 -84.36 -28.24 27.14 Favored 'General case' 0 C--N 1.329 -0.315 0 N-CA-C 111.889 0.329 . . . . 0.0 111.889 -178.969 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -64.98 -51.48 61.48 Favored 'General case' 0 C--N 1.326 -0.442 0 N-CA-C 112.59 0.589 . . . . 0.0 112.59 -178.965 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 24' ' ' TRP . . . . . 0.504 ' CE3' ' HA ' ' A' ' 24' ' ' TRP . 2.3 t-105 -87.1 -26.75 23.5 Favored 'General case' 0 N--CA 1.442 -0.827 0 N-CA-C 113.383 0.882 . . . . 0.0 113.383 -177.497 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 25' ' ' ALA . . . . . 0.567 ' HB2' ' O ' ' A' ' 21' ' ' ALA . . . -47.28 -48.25 24.91 Favored 'General case' 0 C--N 1.318 -0.778 0 C-N-CA 120.636 -0.426 . . . . 0.0 109.947 178.896 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -70.34 -23.85 77.12 Favored Glycine 0 N--CA 1.449 -0.454 0 N-CA-C 109.427 -1.469 . . . . 0.0 109.427 177.478 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 27' ' ' ARG . . . . . 0.491 ' HG3' ' O ' ' A' ' 24' ' ' TRP . 16.0 mtm180 59.37 73.41 0.48 Allowed 'General case' 0 CA--C 1.512 -0.505 0 CA-C-N 114.384 -0.908 . . . . 0.0 111.859 178.63 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 28' ' ' ASP . . . . . 0.401 ' HB3' ' O ' ' A' ' 27' ' ' ARG . 4.4 t70 65.52 -71.34 0.08 Allowed 'General case' 0 N--CA 1.453 -0.319 0 CA-C-N 115.406 -0.815 . . . . 0.0 111.53 178.721 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . 64.41 -176.24 0.17 Allowed 'General case' 0 C--N 1.333 -0.133 0 CA-C-O 120.93 0.395 . . . . 0.0 111.317 179.234 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -82.9 -99.55 0.51 Allowed Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.809 -0.71 . . . . 0.0 112.768 -179.779 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 61.6 m -149.45 -27.57 0.27 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.646 0.26 . . . . 0.0 111.123 -179.653 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -63.98 -32.81 85.42 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.683 -0.77 . . . . 0.0 112.445 -179.988 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 9.0 mm-40 -89.27 -20.59 23.91 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.776 0.322 . . . . 0.0 110.872 -179.957 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 34' ' ' ARG . . . . . . . . . . . . . 92.8 mtt180 -56.35 -28.7 59.86 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.129 -0.487 . . . . 0.0 111.385 -179.815 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 99.2 mtt180 -54.96 -56.46 19.44 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-O 120.863 0.363 . . . . 0.0 111.286 -179.807 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 76.1 m-85 -71.29 -40.16 71.06 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.944 -179.052 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 37' ' ' TYR . . . . . . . . . . . . . 20.7 m-85 -65.52 -56.3 13.12 Favored 'General case' 0 C--N 1.329 -0.305 0 N-CA-C 111.707 0.262 . . . . 0.0 111.707 -179.08 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 89.3 t -57.08 -37.17 53.9 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.326 0 CA-C-O 120.724 0.297 . . . . 0.0 110.935 179.981 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 15.2 m -64.36 -51.55 62.73 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 121.037 0.446 . . . . 0.0 110.748 179.33 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 40' ' ' LEU . . . . . 0.477 HD12 HD12 ' A' ' 43' ' ' ILE . 61.1 tp -59.22 -50.83 72.5 Favored 'General case' 0 C--O 1.235 0.306 0 CA-C-N 115.877 -0.601 . . . . 0.0 110.641 179.913 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 96.4 t -59.78 -34.4 55.54 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 115.974 -0.557 . . . . 0.0 109.62 178.902 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -57.22 -39.28 89.82 Favored Glycine 0 N--CA 1.447 -0.603 0 CA-C-N 115.644 -0.707 . . . . 0.0 111.767 179.407 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 43' ' ' ILE . . . . . 0.498 HG22 ' HE3' ' A' ' 205' ' ' LYS . 1.0 OUTLIER -65.65 -53.12 42.48 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.205 0 CA-C-O 120.832 0.348 . . . . 0.0 110.128 179.306 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 44' ' ' SER . . . . . 0.534 ' HA ' ' SD ' ' A' ' 15' ' ' MET . 83.0 p -61.86 -21.2 64.47 Favored 'General case' 0 C--N 1.333 -0.146 0 CA-C-N 116.104 -0.498 . . . . 0.0 111.12 179.985 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -76.25 -59.23 3.4 Favored Glycine 0 N--CA 1.452 -0.265 0 C-N-CA 120.726 -0.75 . . . . 0.0 112.662 -179.737 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 20.7 pt -61.0 -35.68 66.96 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-O 120.724 0.297 . . . . 0.0 111.425 -179.79 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 47' ' ' ALA . . . . . 0.64 ' HB2' ' HE2' ' A' ' 205' ' ' LYS . . . -67.06 -43.87 81.56 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.843 0.354 . . . . 0.0 111.065 179.478 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -54.78 -49.33 71.16 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.094 -0.503 . . . . 0.0 111.359 -179.749 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 26.9 m -67.75 -34.14 65.96 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.328 -0.396 . . . . 0.0 111.09 -179.718 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -62.75 -38.65 91.41 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-O 121.12 0.486 . . . . 0.0 110.657 179.576 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 51' ' ' TYR . . . . . 0.451 ' OH ' ' HB2' ' A' ' 201' ' ' ASP . 30.6 m-85 -72.93 -31.42 64.6 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-N 115.763 -0.653 . . . . 0.0 110.169 179.852 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -70.04 -42.52 72.8 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-N 115.749 -0.659 . . . . 0.0 111.091 179.609 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 53' ' ' VAL . . . . . 0.448 HG23 ' N ' ' A' ' 54' ' ' MET . 32.9 m -69.43 -45.5 78.48 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.197 0 CA-C-N 116.548 -0.296 . . . . 0.0 110.985 -179.848 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 54' ' ' MET . . . . . 0.448 ' N ' HG23 ' A' ' 53' ' ' VAL . 76.7 mtm -64.66 -31.06 72.12 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-O 121.034 0.445 . . . . 0.0 110.094 179.319 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 55' ' ' ALA . . . . . 0.708 ' HB2' ' HB2' ' A' ' 8' ' ' PHE . . . -74.46 -15.35 60.9 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 115.672 -0.694 . . . . 0.0 111.403 179.637 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 69.6 mt -92.1 -13.36 30.92 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.458 -0.337 . . . . 0.0 111.492 -179.697 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 104.2 -20.92 39.07 Favored Glycine 0 N--CA 1.452 -0.263 0 C-N-CA 120.52 -0.848 . . . . 0.0 113.112 179.8 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 58' ' ' VAL . . . . . 0.436 HG12 ' O ' ' A' ' 53' ' ' VAL . 11.7 p -67.08 149.61 11.52 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-N 116.861 0.331 . . . . 0.0 110.623 179.989 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 88.09 -14.47 58.92 Favored Glycine 0 N--CA 1.449 -0.471 0 C-N-CA 120.663 -0.779 . . . . 0.0 111.774 -179.155 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 60' ' ' TRP . . . . . . . . . . . . . 18.2 m0 -76.02 97.77 4.12 Favored 'General case' 0 C--N 1.331 -0.197 0 CA-C-O 120.836 0.35 . . . . 0.0 110.673 179.917 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 61' ' ' VAL . . . . . 0.511 HG13 HG23 ' A' ' 68' ' ' VAL . 5.2 p -100.32 129.26 28.41 Favored Pre-proline 0 C--N 1.328 -0.327 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.81 179.766 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 73.5 Cg_endo -73.97 146.22 36.91 Favored 'Trans proline' 0 C--N 1.35 0.619 0 C-N-CA 122.478 2.118 . . . . 0.0 112.245 -179.826 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 92.1 t -140.37 95.35 0.78 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.181 -179.67 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . 57.94 -91.42 0.03 OUTLIER 'General case' 0 C--N 1.331 -0.212 0 CA-C-N 116.123 -0.489 . . . . 0.0 111.27 -179.969 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -122.57 -11.78 8.22 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-O 120.968 0.413 . . . . 0.0 110.702 179.715 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 66' ' ' ARG . . . . . 0.451 HH22 HH12 ' A' ' 123' ' ' ARG . 16.9 ptp180 -105.52 165.6 11.03 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 115.9 -0.591 . . . . 0.0 110.364 179.454 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 61.5 m -126.33 141.51 51.88 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 120.965 0.412 . . . . 0.0 111.357 -179.842 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 68' ' ' VAL . . . . . 0.513 HG21 ' HG3' ' A' ' 117' ' ' MET . 9.1 m -133.25 146.18 32.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 115.942 -0.572 . . . . 0.0 110.669 179.575 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 69' ' ' PHE . . . . . . . . . . . . . 5.8 m-85 -107.59 118.31 36.4 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-O 121.049 0.452 . . . . 0.0 110.389 -179.056 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 70' ' ' VAL . . . . . 0.634 HG12 ' HD3' ' A' ' 71' ' ' PRO . 1.3 p -67.1 -35.32 8.63 Favored Pre-proline 0 CA--C 1.54 0.583 0 CA-C-N 115.687 -0.688 . . . . 0.0 112.829 -178.978 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 71' ' ' PRO . . . . . 0.634 ' HD3' HG12 ' A' ' 70' ' ' VAL . 8.7 Cg_exo -70.38 -18.65 33.94 Favored 'Trans proline' 0 C--N 1.356 0.948 0 C-N-CA 121.902 1.734 . . . . 0.0 112.66 -179.37 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 46.8 ttp180 -75.16 -54.3 7.36 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.55 -0.295 . . . . 0.0 111.791 -178.948 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 73' ' ' TYR . . . . . 0.414 ' O ' HG13 ' A' ' 77' ' ' ILE . 18.4 m-85 -67.66 -37.1 81.9 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.755 0.312 . . . . 0.0 110.491 -179.569 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 0.4 OUTLIER -68.39 -38.37 79.25 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.219 0 CA-C-N 116.293 -0.412 . . . . 0.0 110.139 179.526 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 19.5 t70 -59.65 -36.97 77.45 Favored 'General case' 0 CA--C 1.52 -0.199 0 N-CA-C 109.712 -0.477 . . . . 0.0 109.712 179.08 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 76' ' ' TRP . . . . . . . . . . . . . 46.0 m0 -65.03 -41.67 95.07 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 115.781 -0.645 . . . . 0.0 110.081 179.427 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 77' ' ' ILE . . . . . 0.414 HG13 ' O ' ' A' ' 73' ' ' TYR . 66.7 mt -61.79 -28.64 44.62 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.425 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.902 179.544 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 29.8 mt -90.74 -27.98 18.59 Favored 'General case' 0 CA--C 1.531 0.232 0 N-CA-C 112.481 0.549 . . . . 0.0 112.481 -179.376 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 64.6 p -91.28 -43.44 9.8 Favored 'General case' 0 C--N 1.329 -0.322 0 N-CA-C 113.002 0.741 . . . . 0.0 113.002 -178.022 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 80' ' ' THR . . . . . 0.566 ' N ' ' HD2' ' A' ' 81' ' ' PRO . 38.9 p -52.33 -45.01 94.96 Favored Pre-proline 0 C--N 1.328 -0.356 0 N-CA-C 113.072 0.767 . . . . 0.0 113.072 -179.044 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 81' ' ' PRO . . . . . 0.566 ' HD2' ' N ' ' A' ' 80' ' ' THR . 35.8 Cg_endo -62.99 -23.03 74.11 Favored 'Trans proline' 0 C--N 1.354 0.847 0 C-N-CA 121.406 1.404 . . . . 0.0 111.776 -179.78 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 82' ' ' LEU . . . . . 0.443 HD23 HG12 ' A' ' 43' ' ' ILE . 7.5 mp -76.82 -43.03 38.09 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 115.779 -0.646 . . . . 0.0 111.365 -179.494 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 83' ' ' ILE . . . . . 0.415 HD13 HD13 ' A' ' 43' ' ' ILE . 39.8 mm -63.29 -53.85 40.51 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.413 -0.358 . . . . 0.0 110.955 -179.851 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 33.5 m -60.05 -36.95 70.63 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.222 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.467 179.668 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 85' ' ' TYR . . . . . . . . . . . . . 69.8 t80 -63.48 -32.85 74.42 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.098 -0.501 . . . . 0.0 109.809 179.246 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 86' ' ' PHE . . . . . . . . . . . . . 6.0 t80 -61.64 -51.91 66.54 Favored 'General case' 0 C--O 1.233 0.193 0 CA-C-N 115.973 -0.558 . . . . 0.0 109.963 179.34 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 8.5 mp -61.06 -31.85 71.5 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 115.859 -0.61 . . . . 0.0 110.169 179.199 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -71.13 -27.87 71.2 Favored Glycine 0 N--CA 1.45 -0.392 0 C-N-CA 120.871 -0.68 . . . . 0.0 111.787 179.321 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 71.1 mt -73.13 -34.82 66.34 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-O 120.972 0.415 . . . . 0.0 110.38 179.517 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 74.8 mt -66.47 -35.66 80.82 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 115.761 -0.654 . . . . 0.0 111.303 -179.984 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -87.93 -32.33 18.96 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.589 -179.472 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 82.83 55.14 3.04 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.675 -0.774 . . . . 0.0 112.195 -179.72 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 33.8 mt -69.44 167.24 17.04 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.899 0.381 . . . . 0.0 111.128 -179.815 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 94' ' ' ASP . . . . . . . . . . . . . 18.4 t70 -86.15 168.29 14.14 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 115.987 -0.551 . . . . 0.0 110.361 179.683 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 80.8 p -57.62 -33.13 67.93 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.439 -0.346 . . . . 0.0 110.974 179.972 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 98.2 mtt180 -73.82 -53.47 10.18 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.208 179.944 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 44.0 mt-10 -53.76 -42.14 67.9 Favored 'General case' 0 C--N 1.332 -0.175 0 CA-C-N 116.362 -0.381 . . . . 0.0 110.914 -179.892 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 98' ' ' PHE . . . . . 0.423 ' O ' HG12 ' A' ' 102' ' ' ILE . 9.0 m-85 -59.91 -46.86 88.0 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.77 179.668 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -58.82 -29.59 64.87 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.816 -0.707 . . . . 0.0 112.56 -179.922 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 95.1 mt -73.51 -42.36 56.11 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.243 0 CA-C-O 120.872 0.368 . . . . 0.0 111.436 -179.847 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 42.1 t -68.61 -43.89 83.08 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.365 0 CA-C-N 116.329 -0.396 . . . . 0.0 111.208 -179.815 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 102' ' ' ILE . . . . . 0.423 HG12 ' O ' ' A' ' 98' ' ' PHE . 42.2 mm -68.53 -46.36 80.32 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.355 0 CA-C-N 116.086 -0.506 . . . . 0.0 111.688 -179.338 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 14.6 t -58.44 -35.85 72.75 Favored 'General case' 0 C--O 1.232 0.161 0 CA-C-O 120.778 0.323 . . . . 0.0 110.673 179.945 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 104' ' ' LEU . . . . . 0.443 HD22 ' HE2' ' A' ' 140' ' ' TYR . 30.1 tp -62.84 -45.99 90.03 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.036 179.124 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 105' ' ' ASN . . . . . 0.408 ' N ' HD22 ' A' ' 105' ' ' ASN . 0.9 OUTLIER -62.58 -25.75 68.24 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 115.978 -0.555 . . . . 0.0 110.712 179.354 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 24.6 m -68.57 -52.1 35.47 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.371 -0.377 . . . . 0.0 111.491 -179.803 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 10.9 p -70.24 -40.57 78.16 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.212 0 CA-C-N 116.429 -0.35 . . . . 0.0 111.888 -179.428 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 108' ' ' VAL . . . . . 0.57 ' HA ' ' HE1' ' A' ' 129' ' ' MET . 73.1 t -62.66 -58.46 7.48 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.254 0 CA-C-O 120.977 0.418 . . . . 0.0 111.458 -179.74 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 109' ' ' MET . . . . . 0.578 ' N ' ' SD ' ' A' ' 109' ' ' MET . 0.0 OUTLIER -58.39 -32.46 68.62 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 115.957 -0.565 . . . . 0.0 110.827 -179.396 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 28.4 tp -67.69 -35.29 78.54 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.296 -0.411 . . . . 0.0 110.089 179.292 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 111' ' ' ALA . . . . . 0.403 ' O ' ' HB3' ' A' ' 126' ' ' LEU . . . -60.88 -49.11 78.8 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-N 115.989 -0.551 . . . . 0.0 110.167 179.155 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 112' ' ' GLY . . . . . 0.502 ' HA3' ' H21' ' A' ' 301' ' ' RET . . . -59.82 -33.83 79.95 Favored Glycine 0 N--CA 1.45 -0.43 0 C-N-CA 120.574 -0.822 . . . . 0.0 111.716 179.271 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 113' ' ' PHE . . . . . 0.407 ' HD2' HD11 ' A' ' 77' ' ' ILE . 0.3 OUTLIER -54.71 -65.04 0.65 Allowed 'General case' 0 C--N 1.332 -0.191 0 CA-C-O 121.052 0.454 . . . . 0.0 110.226 179.326 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 114' ' ' ALA . . . . . 0.495 ' O ' HG13 ' A' ' 118' ' ' VAL . . . -66.43 -30.53 70.91 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 115.609 -0.723 . . . . 0.0 111.575 -179.64 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 115' ' ' GLY . . . . . 0.401 ' O ' HG22 ' A' ' 118' ' ' VAL . . . -52.12 -51.08 43.04 Favored Glycine 0 C--N 1.332 0.358 0 C-N-CA 121.059 -0.591 . . . . 0.0 112.988 -179.644 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 116' ' ' ALA . . . . . 0.497 ' HB2' ' HB3' ' A' ' 183' ' ' PRO . . . -78.09 -15.45 58.87 Favored 'General case' 0 C--N 1.327 -0.405 0 N-CA-C 111.829 0.307 . . . . 0.0 111.829 -179.558 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 117' ' ' MET . . . . . 0.513 ' HG3' HG21 ' A' ' 68' ' ' VAL . 35.5 ttm -106.23 17.0 24.12 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.79 0.328 . . . . 0.0 111.277 -179.425 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 118' ' ' VAL . . . . . 0.532 HG11 ' N ' ' A' ' 123' ' ' ARG . 15.9 m -63.81 148.57 94.46 Favored Pre-proline 0 C--N 1.331 -0.239 0 CA-C-N 116.414 -0.357 . . . . 0.0 111.413 179.847 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 119' ' ' PRO . . . . . . . . . . . . . 88.7 Cg_endo -82.66 -1.64 10.64 Favored 'Trans proline' 0 C--N 1.347 0.461 0 C-N-CA 122.605 2.204 . . . . 0.0 112.273 179.58 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -157.6 -121.18 0.65 Allowed Glycine 0 C--N 1.33 0.246 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.522 -179.994 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 1.9 pp -106.69 12.93 8.43 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.207 0 CA-C-O 120.866 0.365 . . . . 0.0 111.291 -179.932 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 41.9 mt-10 -59.97 -17.49 38.47 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.012 -0.54 . . . . 0.0 111.293 179.929 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 123' ' ' ARG . . . . . 0.532 ' N ' HG11 ' A' ' 118' ' ' VAL . 27.6 ptt180 -50.37 -29.66 10.52 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-N 116.118 -0.492 . . . . 0.0 111.853 -179.757 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 124' ' ' TYR . . . . . . . . . . . . . 28.9 m-85 -67.64 -33.03 74.14 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.771 0.319 . . . . 0.0 111.201 -179.783 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 125' ' ' ALA . . . . . . . . . . . . . . . -72.38 -48.54 40.84 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.254 -0.43 . . . . 0.0 111.426 -179.982 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 126' ' ' LEU . . . . . 0.417 HD13 ' HA ' ' A' ' 126' ' ' LEU . 3.3 mm? -54.6 -55.58 27.9 Favored 'General case' 0 C--N 1.331 -0.206 0 CA-C-N 116.351 -0.386 . . . . 0.0 110.987 -179.673 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 127' ' ' PHE . . . . . 0.438 ' HZ ' ' HB3' ' A' ' 175' ' ' PRO . 6.7 t80 -64.97 -39.2 93.12 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.185 -0.462 . . . . 0.0 111.456 -179.304 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 128' ' ' GLY . . . . . . . . . . . . . . . -46.44 -45.72 16.83 Favored Glycine 0 C--O 1.237 0.322 0 C-N-CA 120.228 -0.987 . . . . 0.0 111.261 179.531 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 129' ' ' MET . . . . . 0.57 ' HE1' ' HA ' ' A' ' 108' ' ' VAL . 0.3 OUTLIER -68.87 -40.18 79.41 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 115.348 -0.426 . . . . 0.0 109.907 178.986 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -68.56 -21.13 74.43 Favored Glycine 0 N--CA 1.449 -0.464 0 CA-C-N 115.701 -0.682 . . . . 0.0 112.486 179.972 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 131' ' ' ALA . . . . . 0.445 ' O ' ' HB3' ' A' ' 134' ' ' PHE . . . -75.5 -54.16 7.47 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-O 120.621 0.248 . . . . 0.0 110.596 179.886 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 46.5 t -62.94 -40.46 89.02 Favored 'Isoleucine or valine' 0 C--O 1.234 0.249 0 N-CA-C 108.839 -0.8 . . . . 0.0 108.839 178.417 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -66.82 -32.04 73.06 Favored 'General case' 0 N--CA 1.452 -0.352 0 CA-C-N 115.124 -0.943 . . . . 0.0 110.184 178.828 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 134' ' ' PHE . . . . . 0.445 ' HB3' ' O ' ' A' ' 131' ' ' ALA . 38.5 t80 -56.78 -55.61 32.14 Favored 'General case' 0 N--CA 1.452 -0.353 0 N-CA-C 109.738 -0.467 . . . . 0.0 109.738 179.402 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 135' ' ' ILE . . . . . 0.53 ' O ' HG22 ' A' ' 138' ' ' VAL . 47.9 mt -56.8 -32.71 39.19 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.407 0 CA-C-N 115.583 -0.735 . . . . 0.0 109.979 179.409 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . -59.92 -37.81 93.17 Favored Glycine 0 N--CA 1.448 -0.522 0 C-N-CA 120.113 -1.041 . . . . 0.0 110.94 178.567 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 137' ' ' LEU . . . . . . . . . . . . . 46.6 tp -71.12 -50.26 35.47 Favored 'General case' 0 N--CA 1.454 -0.247 0 CA-C-N 115.719 -0.241 . . . . 0.0 110.611 179.499 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 138' ' ' VAL . . . . . 0.649 ' HA ' HD12 ' A' ' 141' ' ' LEU . 3.7 m -57.8 -30.62 38.21 Favored 'Isoleucine or valine' 0 CA--C 1.521 -0.164 0 N-CA-C 109.23 -0.656 . . . . 0.0 109.23 179.138 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 139' ' ' TYR . . . . . . . . . . . . . 39.3 t80 -63.52 -39.8 95.37 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 115.246 -0.888 . . . . 0.0 109.173 178.205 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 140' ' ' TYR . . . . . 0.443 ' HE2' HD22 ' A' ' 104' ' ' LEU . 22.3 m-85 -65.28 -31.97 73.38 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 115.733 -0.667 . . . . 0.0 110.256 178.617 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 141' ' ' LEU . . . . . 0.649 HD12 ' HA ' ' A' ' 138' ' ' VAL . 56.8 mt -65.06 -36.71 85.22 Favored 'General case' 0 CA--C 1.519 -0.222 0 CA-C-O 121.35 0.595 . . . . 0.0 109.591 179.973 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 16.6 m -98.0 0.08 10.44 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.822 0 CA-C-N 115.112 -0.949 . . . . 0.0 111.081 -179.866 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . -81.82 -135.35 1.97 Allowed Glycine 0 CA--C 1.521 0.447 0 C-N-CA 121.035 -0.603 . . . . 0.0 113.058 -179.486 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 144' ' ' PRO . . . . . . . . . . . . . 18.3 Cg_endo -58.32 -24.85 70.06 Favored 'Trans proline' 0 C--N 1.349 0.599 0 C-N-CA 122.726 2.284 . . . . 0.0 112.527 -179.664 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 145' ' ' MET . . . . . . . . . . . . . 62.0 mtt -59.96 -25.91 65.59 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 121.14 0.495 . . . . 0.0 110.798 179.788 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 146' ' ' THR . . . . . . . . . . . . . 17.5 m -73.79 -51.2 17.2 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 115.636 -0.711 . . . . 0.0 112.364 -178.802 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 45.7 mt-10 -75.85 -28.76 58.32 Favored 'General case' 0 C--N 1.328 -0.327 0 N-CA-C 111.856 0.317 . . . . 0.0 111.856 -178.845 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 148' ' ' SER . . . . . . . . . . . . . 37.1 t -70.66 -48.09 56.64 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-O 120.746 0.307 . . . . 0.0 111.607 -179.103 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 149' ' ' ALA . . . . . . . . . . . . . . . -74.7 -44.74 48.55 Favored 'General case' 0 C--N 1.329 -0.324 0 N-CA-C 111.994 0.368 . . . . 0.0 111.994 -179.068 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 150' ' ' SER . . . . . . . . . . . . . 87.7 p -63.65 -11.83 28.73 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.647 0.261 . . . . 0.0 111.273 -179.629 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 151' ' ' GLN . . . . . . . . . . . . . 98.2 mt-30 -124.37 21.75 8.62 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.333 -0.394 . . . . 0.0 111.248 -179.702 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 28.9 tpt180 -92.02 -51.43 5.2 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.916 0.389 . . . . 0.0 110.418 179.659 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 153' ' ' SER . . . . . 0.681 ' HB3' HG12 ' A' ' 156' ' ' ILE . 32.4 t -157.43 167.76 29.29 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.09 -0.505 . . . . 0.0 110.71 179.092 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 154' ' ' SER . . . . . . . . . . . . . 44.8 t -67.65 -36.3 80.5 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-O 120.968 0.413 . . . . 0.0 110.608 179.476 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -76.97 -36.84 34.71 Favored Glycine 0 N--CA 1.451 -0.361 0 C-N-CA 120.97 -0.633 . . . . 0.0 112.887 -179.912 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 156' ' ' ILE . . . . . 0.681 HG12 ' HB3' ' A' ' 153' ' ' SER . 39.7 mm -52.83 -36.24 23.1 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.21 0 CA-C-O 120.722 0.296 . . . . 0.0 111.315 -179.922 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 157' ' ' LYS . . . . . . . . . . . . . 85.3 tttt -54.38 -49.14 70.54 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.75 -179.611 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 42.8 t -63.97 -48.43 76.47 Favored 'General case' 0 C--N 1.33 -0.245 0 N-CA-C 111.891 0.33 . . . . 0.0 111.891 -179.189 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 159' ' ' LEU . . . . . 0.526 HD23 ' O ' ' A' ' 159' ' ' LEU . 2.8 tt -67.36 -28.56 68.06 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-O 120.943 0.401 . . . . 0.0 110.673 -179.622 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 160' ' ' TYR . . . . . . . . . . . . . 25.3 t80 -73.57 -47.72 38.38 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.87 -179.245 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 31.0 m -62.46 -42.72 96.8 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.391 0 N-CA-C 112.414 0.524 . . . . 0.0 112.414 -178.565 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 162' ' ' ARG . . . . . 0.449 ' O ' HD12 ' A' ' 166' ' ' LEU . 22.3 mmm180 -68.6 -49.81 56.43 Favored 'General case' 0 C--N 1.328 -0.362 0 N-CA-C 111.746 0.276 . . . . 0.0 111.746 -178.747 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 163' ' ' LEU . . . . . 0.402 HD22 ' CD2' ' A' ' 159' ' ' LEU . 7.6 mp -70.2 -39.15 75.36 Favored 'General case' 0 C--N 1.328 -0.335 0 N-CA-C 112.195 0.443 . . . . 0.0 112.195 -178.722 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 164' ' ' ARG . . . . . 0.46 ' NH1' ' HA ' ' A' ' 141' ' ' LEU . 21.9 tpp180 -58.37 -54.37 47.75 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 120.751 0.31 . . . . 0.0 110.786 -179.783 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 165' ' ' ASN . . . . . 0.43 ' O ' HG23 ' A' ' 169' ' ' VAL . 4.5 m-20 -57.06 -37.82 72.36 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.005 -0.543 . . . . 0.0 110.18 179.812 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 166' ' ' LEU . . . . . 0.449 HD12 ' O ' ' A' ' 162' ' ' ARG . 3.6 mt -61.24 -56.3 22.22 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 115.914 -0.585 . . . . 0.0 111.562 179.877 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 167' ' ' THR . . . . . 0.508 ' HA ' HD11 ' A' ' 170' ' ' LEU . 16.7 m -54.31 -54.42 40.49 Favored 'General case' 0 C--N 1.331 -0.202 0 N-CA-C 112.198 0.444 . . . . 0.0 112.198 -177.981 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 168' ' ' VAL . . . . . 0.568 HG22 HD13 ' A' ' 141' ' ' LEU . 42.1 t -52.64 -41.75 38.66 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.603 0 N-CA-C 112.594 0.59 . . . . 0.0 112.594 -179.3 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 169' ' ' VAL . . . . . 0.517 ' O ' HG12 ' A' ' 173' ' ' ILE . 74.7 t -71.21 -68.08 0.42 Allowed 'Isoleucine or valine' 0 CA--C 1.531 0.245 0 N-CA-C 113.988 1.107 . . . . 0.0 113.988 -177.446 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 170' ' ' LEU . . . . . 0.508 HD11 ' HA ' ' A' ' 167' ' ' THR . 0.3 OUTLIER -57.61 -36.47 71.81 Favored 'General case' 0 N--CA 1.467 0.39 0 N-CA-C 112.835 0.68 . . . . 0.0 112.835 -177.382 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 171' ' ' TRP . . . . . 0.482 ' HB2' ' O ' ' A' ' 167' ' ' THR . 7.9 m0 -70.97 -34.21 71.19 Favored 'General case' 0 C--N 1.329 -0.321 0 C-N-CA 120.477 -0.489 . . . . 0.0 111.356 -179.785 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 172' ' ' ALA . . . . . 0.42 ' HA ' ' CZ ' ' A' ' 134' ' ' PHE . . . -72.4 -7.08 47.84 Favored 'General case' 0 C--N 1.332 -0.182 0 C-N-CA 120.797 -0.361 . . . . 0.0 110.862 179.848 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 173' ' ' ILE . . . . . 0.518 HG22 HD11 ' A' ' 177' ' ' ILE . 50.8 mm -87.59 -25.75 5.98 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.23 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.795 179.607 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 174' ' ' TYR . . . . . 0.42 ' HB2' ' HD3' ' A' ' 175' ' ' PRO . 38.8 m-85 -55.0 -49.02 94.5 Favored Pre-proline 0 CA--C 1.531 0.216 0 CA-C-N 116.253 -0.431 . . . . 0.0 111.684 -179.741 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 175' ' ' PRO . . . . . 0.438 ' HB3' ' HZ ' ' A' ' 127' ' ' PHE . 79.9 Cg_exo -45.8 -30.94 7.2 Favored 'Trans proline' 0 C--N 1.352 0.739 0 C-N-CA 122.169 1.913 . . . . 0.0 111.954 179.422 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 176' ' ' PHE . . . . . 0.481 ' O ' ' HG ' ' A' ' 180' ' ' LEU . 86.3 m-85 -80.08 -49.16 12.14 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 115.81 -0.632 . . . . 0.0 111.388 179.83 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 177' ' ' ILE . . . . . 0.518 HD11 HG22 ' A' ' 173' ' ' ILE . 3.8 mm -60.16 -36.94 71.23 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.551 0 N-CA-C 112.307 0.484 . . . . 0.0 112.307 -178.49 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 178' ' ' TRP . . . . . . . . . . . . . 76.5 t90 -73.35 -44.45 58.74 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.942 0.401 . . . . 0.0 110.619 -179.87 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 179' ' ' LEU . . . . . 0.488 ' O ' HG22 ' A' ' 185' ' ' VAL . 1.4 tm? -67.51 -54.3 21.27 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 115.952 -0.567 . . . . 0.0 111.155 -179.48 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 180' ' ' LEU . . . . . 0.645 HD22 HD11 ' A' ' 187' ' ' LEU . 16.5 mt -68.42 -50.3 53.78 Favored 'General case' 0 C--N 1.328 -0.327 0 N-CA-C 111.992 0.367 . . . . 0.0 111.992 -179.021 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . -54.62 176.35 0.44 Allowed Glycine 0 C--N 1.337 0.602 0 C-N-CA 120.219 -0.991 . . . . 0.0 112.861 -179.948 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 182' ' ' PRO . . . . . 0.492 ' HA ' ' HB2' ' A' ' 186' ' ' ALA . 83.8 Cg_exo -45.3 -44.77 15.88 Favored 'Trans proline' 0 C--N 1.349 0.583 0 C-N-CA 122.92 2.413 . . . . 0.0 113.599 179.692 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 183' ' ' PRO . . . . . 0.497 ' HB3' ' HB2' ' A' ' 116' ' ' ALA . 88.7 Cg_exo -46.38 -23.42 2.08 Favored 'Trans proline' 0 C--N 1.356 0.944 0 C-N-CA 122.277 1.985 . . . . 0.0 113.122 179.815 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 184' ' ' GLY . . . . . . . . . . . . . . . -123.53 -127.07 3.19 Favored Glycine 0 C--N 1.331 0.298 0 C-N-CA 120.554 -0.831 . . . . 0.0 112.797 -179.901 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 185' ' ' VAL . . . . . 0.488 HG22 ' O ' ' A' ' 179' ' ' LEU . 16.5 m -60.05 -19.9 18.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 N-CA-C 111.992 0.368 . . . . 0.0 111.992 -179.541 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 186' ' ' ALA . . . . . 0.492 ' HB2' ' HA ' ' A' ' 182' ' ' PRO . . . 57.51 87.18 0.07 Allowed 'General case' 0 C--N 1.331 -0.2 0 CA-C-O 120.712 0.291 . . . . 0.0 111.4 179.863 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 187' ' ' LEU . . . . . 0.645 HD11 HD22 ' A' ' 180' ' ' LEU . 21.2 mt -91.95 -49.59 6.15 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.299 -0.41 . . . . 0.0 111.079 -179.821 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 188' ' ' LEU . . . . . . . . . . . . . 90.5 mt -103.52 -161.65 0.85 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 115.961 -0.563 . . . . 0.0 110.983 -179.82 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 189' ' ' THR . . . . . . . . . . . . . 1.6 t -92.44 147.04 33.6 Favored Pre-proline 0 C--N 1.329 -0.298 0 CA-C-N 116.079 -0.509 . . . . 0.0 111.061 -179.83 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 190' ' ' PRO . . . . . . . . . . . . . 9.2 Cg_endo -52.58 -33.15 57.16 Favored 'Trans proline' 0 C--N 1.349 0.579 0 C-N-CA 122.772 2.315 . . . . 0.0 112.422 -179.949 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 191' ' ' THR . . . . . . . . . . . . . 80.6 p -62.73 -43.73 98.06 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.34 -0.391 . . . . 0.0 111.033 179.882 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 192' ' ' VAL . . . . . . . . . . . . . 30.3 t -71.51 -46.62 62.55 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 115.94 -0.573 . . . . 0.0 111.118 -179.857 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 193' ' ' ASP . . . . . . . . . . . . . 34.3 t70 -56.78 -51.59 68.35 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.398 -0.365 . . . . 0.0 111.139 -179.749 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 194' ' ' VAL . . . . . . . . . . . . . 76.3 t -61.06 -36.56 73.31 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.391 -0.368 . . . . 0.0 110.988 179.818 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 195' ' ' ALA . . . . . . . . . . . . . . . -56.01 -48.15 76.47 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.493 -0.321 . . . . 0.0 111.168 179.89 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 196' ' ' LEU . . . . . . . . . . . . . 72.1 mt -67.38 -41.39 85.1 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.421 -0.354 . . . . 0.0 110.713 179.83 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 197' ' ' ILE . . . . . . . . . . . . . 17.2 mm -57.13 -56.08 16.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.473 179.407 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 198' ' ' VAL . . . . . . . . . . . . . 71.5 t -52.9 -35.03 21.25 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.417 0 CA-C-N 115.509 -0.769 . . . . 0.0 109.471 178.612 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 199' ' ' TYR . . . . . . . . . . . . . 53.3 t80 -70.54 -36.31 73.62 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 115.333 -0.849 . . . . 0.0 110.594 179.661 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 200' ' ' LEU . . . . . . . . . . . . . 73.0 mt -64.44 -38.74 92.1 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 115.658 -0.701 . . . . 0.0 111.343 -179.63 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 201' ' ' ASP . . . . . 0.451 ' HB2' ' OH ' ' A' ' 51' ' ' TYR . 0.8 OUTLIER -73.6 -32.32 64.04 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-O 121.04 0.447 . . . . 0.0 110.39 179.663 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 202' ' ' LEU . . . . . 0.424 ' O ' ' HB ' ' A' ' 206' ' ' VAL . 3.7 mt -71.64 -32.52 68.02 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 115.831 -0.622 . . . . 0.0 111.92 -179.649 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 203' ' ' VAL . . . . . 0.474 ' O ' ' HA3' ' A' ' 207' ' ' GLY . 7.4 p -78.83 -37.02 19.7 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-O 120.639 0.257 . . . . 0.0 111.375 -178.927 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 204' ' ' THR . . . . . 0.402 HG21 ' HE1' ' A' ' 171' ' ' TRP . 26.2 m -72.87 -49.99 26.56 Favored 'General case' 0 C--N 1.326 -0.448 0 C-N-CA 120.728 -0.389 . . . . 0.0 111.31 179.696 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 205' ' ' LYS . . . . . 0.64 ' HE2' ' HB2' ' A' ' 47' ' ' ALA . 54.5 mttp -69.98 -59.26 3.03 Favored 'General case' 0 C--N 1.326 -0.421 0 N-CA-C 112.165 0.431 . . . . 0.0 112.165 -178.8 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 206' ' ' VAL . . . . . 0.424 ' HB ' ' O ' ' A' ' 202' ' ' LEU . 48.6 t -74.69 -37.61 43.34 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.25 0 N-CA-C 111.964 0.357 . . . . 0.0 111.964 -178.727 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 207' ' ' GLY . . . . . 0.566 ' O ' HD12 ' A' ' 211' ' ' ILE . . . -62.86 -56.63 19.88 Favored Glycine 0 N--CA 1.45 -0.379 0 C-N-CA 120.258 -0.972 . . . . 0.0 112.01 -179.405 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 208' ' ' PHE . . . . . 0.513 ' O ' ' N ' ' A' ' 212' ' ' ALA . 3.1 m-85 -53.95 -47.75 70.98 Favored 'General case' 0 C--O 1.22 -0.469 0 N-CA-C 109.896 -0.409 . . . . 0.0 109.896 179.606 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 209' ' ' GLY . . . . . 0.492 ' O ' ' HG ' ' A' ' 213' ' ' LEU . . . -53.9 -35.21 52.9 Favored Glycine 0 N--CA 1.45 -0.374 0 CA-C-N 115.091 -0.959 . . . . 0.0 113.399 179.585 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 210' ' ' PHE . . . . . . . . . . . . . 5.2 m-85 -72.46 -47.23 50.52 Favored 'General case' 0 CA--C 1.512 -0.498 0 N-CA-C 108.716 -0.846 . . . . 0.0 108.716 179.801 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 211' ' ' ILE . . . . . 0.566 HD12 ' O ' ' A' ' 207' ' ' GLY . 3.6 mt -65.05 -26.93 41.11 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.65 0 N-CA-C 107.665 -1.235 . . . . 0.0 107.665 176.444 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 212' ' ' ALA . . . . . 0.513 ' N ' ' O ' ' A' ' 208' ' ' PHE . . . -68.44 -38.66 81.37 Favored 'General case' 0 N--CA 1.45 -0.466 0 CA-C-N 114.3 -1.318 . . . . 0.0 110.422 -179.869 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 213' ' ' LEU . . . . . 0.492 ' HG ' ' O ' ' A' ' 209' ' ' GLY . 47.2 mt -69.82 -54.31 14.16 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-N 115.301 -0.863 . . . . 0.0 111.636 -179.498 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 214' ' ' ASP . . . . . . . . . . . . . 14.6 m-20 -52.21 -54.66 28.2 Favored 'General case' 0 C--O 1.234 0.26 0 CA-C-N 116.389 -0.369 . . . . 0.0 111.326 -179.514 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 215' ' ' ALA . . . . . . . . . . . . . . . -57.48 -54.87 41.92 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.357 -0.383 . . . . 0.0 111.036 179.984 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 216' ' ' ALA . . . . . . . . . . . . . . . -57.52 -30.73 65.39 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.28 179.925 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 217' ' ' ALA . . . . . . . . . . . . . . . -64.02 -38.34 90.73 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.557 -179.918 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 218' ' ' THR . . . . . . . . . . . . . 69.7 m -72.75 -49.09 33.16 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 115.82 -0.627 . . . . 0.0 111.247 179.855 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 219' ' ' LEU . . . . . . . . . . . . . 25.4 mt -56.82 -29.07 62.41 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.955 -179.784 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 220' ' ' ARG . . . . . . . . . . . . . 79.3 ttt180 -83.82 -36.22 23.65 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.059 -0.518 . . . . 0.0 110.978 179.904 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 221' ' ' ALA . . . . . . . . . . . . . . . -62.76 -27.08 69.04 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.278 -0.419 . . . . 0.0 111.41 -179.837 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 222' ' ' GLU . . . . . 0.6 ' HG3' ' H ' ' A' ' 224' ' ' GLY . 11.0 pt-20 -92.0 -21.97 20.24 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 121.04 0.447 . . . . 0.0 110.398 -179.947 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 223' ' ' HIS . . . . . . . . . . . . . 65.7 m-70 59.21 19.06 7.1 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 115.649 -0.705 . . . . 0.0 111.245 179.551 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 224' ' ' GLY . . . . . 0.6 ' H ' ' HG3' ' A' ' 222' ' ' GLU . . . 88.58 45.41 4.93 Favored Glycine 0 N--CA 1.452 -0.272 0 C-N-CA 120.716 -0.754 . . . . 0.0 112.319 -179.929 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 225' ' ' GLU . . . . . . . . . . . . . 8.8 tp10 -121.82 144.91 48.55 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-O 120.827 0.346 . . . . 0.0 110.936 -179.957 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 226' ' ' SER . . . . . . . . . . . . . 31.6 t -136.89 -63.42 0.61 Allowed 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.287 -0.415 . . . . 0.0 111.154 -179.753 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 227' ' ' LEU . . . . . 0.51 ' HG ' ' H ' ' A' ' 229' ' ' GLY . 44.2 tp -103.98 119.79 39.67 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.266 -0.424 . . . . 0.0 111.077 -179.737 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 228' ' ' ALA . . . . . . . . . . . . . . . -92.02 3.97 54.08 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.021 179.815 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 229' ' ' GLY . . . . . 0.51 ' H ' ' HG ' ' A' ' 227' ' ' LEU . . . -71.96 -172.52 17.61 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.853 -0.689 . . . . 0.0 112.56 -179.967 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 230' ' ' VAL . . . . . . . . . . . . . 4.9 p -158.19 125.42 0.58 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-O 120.869 0.366 . . . . 0.0 111.017 -179.945 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 231' ' ' ASP . . . . . . . . . . . . . 11.8 m-20 -100.36 91.31 4.66 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.679 179.881 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 232' ' ' THR . . . . . . . . . . . . . 8.7 t -126.19 152.09 46.48 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.143 -0.481 . . . . 0.0 111.035 -179.912 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 233' ' ' ASP . . . . . . . . . . . . . 17.5 m-20 65.14 134.19 0.02 OUTLIER 'General case' 0 C--N 1.333 -0.143 0 CA-C-N 116.029 -0.532 . . . . 0.0 111.226 179.979 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 234' ' ' THR . . . . . . . . . . . . . 70.4 p -65.94 154.42 89.39 Favored Pre-proline 0 C--N 1.329 -0.306 0 CA-C-N 116.076 -0.511 . . . . 0.0 111.097 179.977 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 235' ' ' PRO . . . . . . . . . . . . . 73.5 Cg_endo -74.97 10.53 1.68 Allowed 'Trans proline' 0 C--N 1.348 0.527 0 C-N-CA 122.456 2.104 . . . . 0.0 112.529 -179.957 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 236' ' ' ALA . . . . . . . . . . . . . . . -101.49 106.95 18.12 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.309 -0.405 . . . . 0.0 111.287 -179.943 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 237' ' ' VAL . . . . . . . . . . . . . 22.2 t -116.52 121.3 67.31 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.192 0 CA-C-N 116.18 -0.463 . . . . 0.0 111.061 179.931 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 238' ' ' ALA . . . . . . . . . . . . . . . -81.0 -67.97 0.73 Allowed 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.217 179.98 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 239' ' ' ASP . . . . . . . . . . . . . 14.7 t70 -147.49 104.73 3.65 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.77 -179.996 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 240' ' ' LEU . . . . . . . . . . . . . 49.1 tp -114.77 -29.03 6.88 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.923 -179.829 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 241' ' ' GLU . . . . . . . . . . . . . 10.9 mm-40 -72.64 134.85 45.31 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.897 -179.98 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 242' ' ' HIS . . . . . . . . . . . . . 84.6 t60 -139.19 -45.34 0.46 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.599 179.834 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 243' ' ' HIS . . . . . . . . . . . . . 72.2 m80 -88.82 179.64 6.17 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.049 -0.523 . . . . 0.0 110.669 179.766 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 244' ' ' HIS . . . . . . . . . . . . . 95.5 m-70 -103.31 162.93 12.59 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.299 -0.409 . . . . 0.0 111.06 179.953 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 245' ' ' HIS . . . . . . . . . . . . . 65.5 m-70 60.91 -87.22 0.02 OUTLIER 'General case' 0 C--N 1.331 -0.206 0 CA-C-N 115.842 -0.617 . . . . 0.0 111.06 179.899 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 246' ' ' HIS . . . . . . . . . . . . . 56.6 m80 -102.66 168.61 9.15 Favored 'General case' 0 C--N 1.332 -0.172 0 CA-C-N 116.331 -0.395 . . . . 0.0 110.886 -179.903 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 247' ' ' HIS . . . . . . . . . . . . . 68.9 m-70 . . . . . 0 C--O 1.25 1.115 0 CA-C-O 118.314 -0.85 . . . . 0.0 111.057 179.938 . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 301' ' ' RET . . . . . 0.502 ' H21' ' HA3' ' A' ' 112' ' ' GLY . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 96.7 mmm . . . . . 0 N--CA 1.486 1.333 0 CA-C-O 120.773 0.321 . . . . 0.0 110.919 . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 42.9 t -119.74 -32.99 1.56 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.976 179.82 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -82.06 -23.94 56.11 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.798 -0.715 . . . . 0.0 112.514 -179.961 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 55.3 tp -74.02 -36.31 64.45 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.685 0.279 . . . . 0.0 111.21 -179.88 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 82.6 p -66.3 -29.97 70.29 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.432 -0.349 . . . . 0.0 111.409 -179.693 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 22.7 p -54.22 -35.13 62.09 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.269 179.996 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 7' ' ' LEU . . . . . . . . . . . . . 3.9 mm? -57.66 -53.13 61.66 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.111 -0.495 . . . . 0.0 111.172 -179.971 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 8' ' ' PHE . . . . . 0.675 ' HB2' ' HB2' ' A' ' 55' ' ' ALA . 77.8 m-85 -59.07 -35.66 73.75 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.346 -0.388 . . . . 0.0 110.762 179.858 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 9' ' ' TRP . . . . . . . . . . . . . 47.5 m95 -64.67 -45.91 84.67 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.024 -0.534 . . . . 0.0 110.059 -179.824 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 10' ' ' LEU . . . . . 0.444 ' HA ' HD12 ' A' ' 13' ' ' ILE . 87.2 mt -61.08 -37.83 84.11 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-N 115.545 -0.752 . . . . 0.0 110.154 179.333 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -65.82 -35.46 90.9 Favored Glycine 0 N--CA 1.448 -0.53 0 C-N-CA 120.814 -0.708 . . . . 0.0 111.486 179.124 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -67.44 -31.21 71.24 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 120.977 0.418 . . . . 0.0 110.476 179.448 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 13' ' ' ILE . . . . . 0.444 HD12 ' HA ' ' A' ' 10' ' ' LEU . 88.5 mt -64.68 -54.22 32.78 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.235 0 CA-C-N 115.864 -0.607 . . . . 0.0 110.214 179.418 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -65.99 -32.45 82.6 Favored Glycine 0 N--CA 1.45 -0.377 0 C-N-CA 120.61 -0.805 . . . . 0.0 111.637 179.109 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 15' ' ' MET . . . . . 0.495 ' SD ' ' HA ' ' A' ' 44' ' ' SER . 51.3 tpp -65.83 -40.16 91.53 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-O 120.823 0.344 . . . . 0.0 110.448 179.657 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 1.6 mm? -64.02 -37.98 89.4 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-N 116.08 -0.509 . . . . 0.0 110.207 179.173 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 17' ' ' VAL . . . . . 0.442 HG23 ' O ' ' A' ' 13' ' ' ILE . 72.0 t -59.04 -42.63 86.91 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.205 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.158 179.07 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -68.8 -46.2 61.63 Favored Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.731 -0.747 . . . . 0.0 111.679 178.965 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 47.9 m -50.25 -46.66 55.08 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 120.865 0.364 . . . . 0.0 111.081 179.896 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 93.6 mt -72.19 -45.75 59.08 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.035 -0.529 . . . . 0.0 111.639 179.939 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -58.85 -30.85 68.0 Favored 'General case' 0 C--N 1.329 -0.296 0 N-CA-C 112.081 0.4 . . . . 0.0 112.081 -179.23 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 22' ' ' PHE . . . . . 0.413 ' HB2' HG22 ' A' ' 41' ' ' VAL . 13.0 m-85 -90.79 -31.36 16.54 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 120.666 0.27 . . . . 0.0 111.509 -179.252 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -71.63 -50.28 32.22 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 121.101 0.477 . . . . 0.0 111.173 -179.811 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 24' ' ' TRP . . . . . . . . . . . . . 3.1 t-105 -61.43 -43.82 98.19 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-N 115.614 -0.721 . . . . 0.0 111.329 -179.624 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -66.26 -25.3 66.81 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.698 0.285 . . . . 0.0 111.057 -179.989 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -71.07 -41.02 61.35 Favored Glycine 0 N--CA 1.452 -0.253 0 C-N-CA 120.817 -0.706 . . . . 0.0 112.503 -179.893 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 99.0 mtt180 -68.03 -26.96 66.14 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.838 0.352 . . . . 0.0 110.996 -179.99 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 23.9 t70 -94.3 9.17 39.2 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.046 -0.524 . . . . 0.0 110.86 -179.742 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -87.6 -177.77 5.95 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.201 -179.99 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -96.99 -149.23 25.27 Favored Glycine 0 N--CA 1.452 -0.254 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.643 -179.911 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 59.4 m -109.2 127.96 54.65 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.861 0.362 . . . . 0.0 110.797 179.966 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 112.66 -32.35 6.27 Favored Glycine 0 N--CA 1.452 -0.25 0 C-N-CA 120.873 -0.68 . . . . 0.0 112.153 -179.962 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 10.0 mm-40 -90.59 -20.68 22.32 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 120.752 0.311 . . . . 0.0 110.83 179.838 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 34' ' ' ARG . . . . . . . . . . . . . 54.3 mtp180 -48.43 -29.49 4.12 Favored 'General case' 0 C--N 1.333 -0.151 0 CA-C-N 115.997 -0.547 . . . . 0.0 111.547 -179.819 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 75.2 mtp180 -60.85 -48.38 82.07 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.44 -0.346 . . . . 0.0 111.023 -179.899 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 62.9 m-85 -68.66 -31.66 70.94 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.021 -0.536 . . . . 0.0 111.362 -179.678 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 37' ' ' TYR . . . . . . . . . . . . . 53.6 m-85 -69.4 -54.49 14.13 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.301 -0.409 . . . . 0.0 111.279 -179.498 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 85.3 t -57.08 -36.7 52.04 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.249 0 CA-C-O 121.011 0.434 . . . . 0.0 110.525 179.729 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 30.3 m -64.38 -49.43 71.65 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 115.789 -0.641 . . . . 0.0 110.502 179.354 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 30.5 tp -55.99 -47.73 77.17 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.718 -0.674 . . . . 0.0 110.286 179.614 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 41' ' ' VAL . . . . . 0.413 HG22 ' HB2' ' A' ' 22' ' ' PHE . 62.3 t -62.24 -34.32 63.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 115.733 -0.667 . . . . 0.0 110.016 178.95 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -57.85 -38.77 89.96 Favored Glycine 0 N--CA 1.448 -0.501 0 C-N-CA 120.859 -0.686 . . . . 0.0 112.035 179.684 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 43' ' ' ILE . . . . . 0.678 HG22 ' HE3' ' A' ' 205' ' ' LYS . 0.2 OUTLIER -68.44 -53.42 28.26 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.186 0 CA-C-O 120.825 0.345 . . . . 0.0 110.698 179.583 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 44' ' ' SER . . . . . 0.495 ' HA ' ' SD ' ' A' ' 15' ' ' MET . 45.8 m -59.11 -24.47 63.0 Favored 'General case' 0 C--N 1.333 -0.146 0 CA-C-N 116.136 -0.484 . . . . 0.0 111.466 -179.777 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -75.89 -57.16 4.19 Favored Glycine 0 CA--C 1.518 0.281 0 C-N-CA 120.766 -0.731 . . . . 0.0 113.106 -179.333 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 17.0 pt -58.17 -35.71 54.19 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-O 120.818 0.342 . . . . 0.0 111.262 -179.602 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 47' ' ' ALA . . . . . 0.694 ' HB2' ' HE2' ' A' ' 205' ' ' LYS . . . -67.73 -44.39 77.71 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-O 120.966 0.412 . . . . 0.0 110.943 179.158 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -54.38 -44.46 72.29 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 115.791 -0.641 . . . . 0.0 111.723 -179.385 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 34.2 m -71.54 -34.04 51.48 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.228 0 CA-C-N 116.532 -0.304 . . . . 0.0 111.415 -179.63 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -64.34 -37.33 87.13 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 121.046 0.45 . . . . 0.0 110.874 179.695 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 51' ' ' TYR . . . . . 0.43 ' OH ' ' HB2' ' A' ' 201' ' ' ASP . 33.2 m-85 -73.36 -36.19 66.07 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 115.946 -0.57 . . . . 0.0 110.62 179.979 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -65.99 -38.97 89.88 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 115.826 -0.625 . . . . 0.0 111.025 179.796 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 53' ' ' VAL . . . . . 0.509 ' O ' HG12 ' A' ' 58' ' ' VAL . 33.6 m -74.81 -50.35 25.9 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.194 0 CA-C-N 116.588 -0.278 . . . . 0.0 111.05 -179.887 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 54' ' ' MET . . . . . 0.504 ' N ' HG23 ' A' ' 53' ' ' VAL . 75.8 mtm -58.02 -29.69 65.51 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-O 121.009 0.433 . . . . 0.0 110.309 179.514 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 55' ' ' ALA . . . . . 0.675 ' HB2' ' HB2' ' A' ' 8' ' ' PHE . . . -73.85 -25.92 60.31 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 115.786 -0.643 . . . . 0.0 111.278 179.732 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 74.6 mt -80.28 -8.37 59.44 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.276 -0.42 . . . . 0.0 111.622 -179.625 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 102.31 -17.48 53.63 Favored Glycine 0 N--CA 1.453 -0.226 0 C-N-CA 120.438 -0.887 . . . . 0.0 113.054 179.671 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 58' ' ' VAL . . . . . 0.509 HG12 ' O ' ' A' ' 53' ' ' VAL . 12.7 p -69.43 150.86 10.21 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.957 0.379 . . . . 0.0 110.439 179.717 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 75.55 27.24 63.67 Favored Glycine 0 N--CA 1.449 -0.472 0 C-N-CA 120.723 -0.751 . . . . 0.0 111.731 -178.946 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 60' ' ' TRP . . . . . . . . . . . . . 13.8 m0 -108.7 99.15 8.55 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-O 120.947 0.403 . . . . 0.0 110.285 -179.879 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 61' ' ' VAL . . . . . 0.575 ' HB ' HG23 ' A' ' 68' ' ' VAL . 25.6 t -97.77 110.69 56.45 Favored Pre-proline 0 C--N 1.325 -0.459 0 CA-C-N 115.877 -0.601 . . . . 0.0 111.526 -179.299 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 17.2 Cg_exo -67.2 138.87 48.49 Favored 'Trans proline' 0 C--N 1.35 0.606 0 C-N-CA 122.577 2.184 . . . . 0.0 111.866 179.678 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 93.1 t -139.96 92.17 0.65 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.38 -179.694 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . 56.65 -91.7 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.117 -0.492 . . . . 0.0 111.85 179.656 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 42.9 mt-10 -115.23 -17.61 11.31 Favored 'General case' 0 C--N 1.332 -0.195 0 CA-C-O 120.837 0.351 . . . . 0.0 111.054 -179.652 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 66' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -104.81 165.56 10.99 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.285 179.77 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 91.0 m -130.09 118.81 22.08 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-N 116.295 -0.411 . . . . 0.0 111.414 -179.573 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 68' ' ' VAL . . . . . 0.575 HG23 ' HB ' ' A' ' 61' ' ' VAL . 18.5 m -100.37 141.51 17.18 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.377 0 CA-C-N 115.991 -0.55 . . . . 0.0 110.53 179.495 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 69' ' ' PHE . . . . . . . . . . . . . 24.2 m-85 -109.84 122.75 48.24 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.276 -0.42 . . . . 0.0 110.248 -179.428 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 70' ' ' VAL . . . . . 0.621 HG12 ' HD3' ' A' ' 71' ' ' PRO . 1.3 p -68.13 -35.97 8.33 Favored Pre-proline 0 CA--C 1.54 0.573 0 N-CA-C 112.549 0.574 . . . . 0.0 112.549 -179.541 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 71' ' ' PRO . . . . . 0.621 ' HD3' HG12 ' A' ' 70' ' ' VAL . 5.7 Cg_exo -71.48 -19.87 28.0 Favored 'Trans proline' 0 C--N 1.359 1.122 0 C-N-CA 121.942 1.762 . . . . 0.0 112.47 -179.729 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 56.5 ttt180 -68.68 -55.28 11.95 Favored 'General case' 0 C--O 1.236 0.378 0 CA-C-N 116.403 -0.362 . . . . 0.0 111.67 -179.181 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 73' ' ' TYR . . . . . 0.436 ' O ' HG13 ' A' ' 77' ' ' ILE . 28.2 m-85 -72.17 -30.16 64.71 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.492 -0.322 . . . . 0.0 110.655 -179.418 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 74' ' ' ILE . . . . . 0.524 HG22 ' HA ' ' A' ' 71' ' ' PRO . 0.4 OUTLIER -72.52 -38.29 59.31 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.237 0 N-CA-C 109.829 -0.434 . . . . 0.0 109.829 179.253 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 75' ' ' ASP . . . . . 0.454 ' O ' HG23 ' A' ' 79' ' ' THR . 12.9 t70 -59.11 -38.69 80.15 Favored 'General case' 0 CA--C 1.518 -0.257 0 N-CA-C 109.322 -0.621 . . . . 0.0 109.322 178.861 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 76' ' ' TRP . . . . . 0.412 ' CD1' ' H12' ' A' ' 301' ' ' RET . 45.6 m0 -65.73 -37.74 87.23 Favored 'General case' 0 C--N 1.331 -0.21 0 CA-C-N 115.702 -0.681 . . . . 0.0 110.358 179.166 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 77' ' ' ILE . . . . . 0.51 ' O ' ' HG2' ' A' ' 81' ' ' PRO . 89.5 mt -62.4 -30.67 49.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.468 178.973 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 41.7 mt -92.06 -19.81 21.96 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.07 -0.514 . . . . 0.0 112.222 -179.717 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 79' ' ' THR . . . . . 0.454 HG23 ' O ' ' A' ' 75' ' ' ASP . 73.6 p -101.28 -52.99 3.12 Favored 'General case' 0 N--CA 1.463 0.205 0 N-CA-C 113.446 0.906 . . . . 0.0 113.446 -178.033 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 80' ' ' THR . . . . . 0.849 HG22 HD21 ' A' ' 105' ' ' ASN . 59.8 m -48.74 -53.97 31.75 Favored Pre-proline 0 C--N 1.331 -0.219 0 N-CA-C 112.406 0.521 . . . . 0.0 112.406 -178.838 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 81' ' ' PRO . . . . . 0.661 ' HD3' ' HB ' ' A' ' 80' ' ' THR . 31.5 Cg_exo -59.87 -23.4 72.29 Favored 'Trans proline' 0 C--N 1.353 0.805 0 C-N-CA 121.718 1.612 . . . . 0.0 111.772 179.965 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 82' ' ' LEU . . . . . . . . . . . . . 18.4 tp -76.93 -33.11 57.74 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.043 -0.526 . . . . 0.0 110.469 179.68 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 83' ' ' ILE . . . . . 0.449 HD11 HG21 ' A' ' 43' ' ' ILE . 35.0 mm -68.26 -53.71 26.96 Favored 'Isoleucine or valine' 0 C--O 1.234 0.244 0 CA-C-N 116.367 -0.379 . . . . 0.0 110.036 179.246 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 84' ' ' VAL . . . . . 0.553 HG11 HD22 ' A' ' 105' ' ' ASN . 20.7 m -59.98 -30.98 46.65 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.23 0 N-CA-C 109.415 -0.587 . . . . 0.0 109.415 178.506 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 85' ' ' TYR . . . . . . . . . . . . . 80.8 t80 -66.38 -31.49 72.3 Favored 'General case' 0 N--CA 1.454 -0.242 0 CA-C-N 115.382 -0.827 . . . . 0.0 109.637 178.764 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 86' ' ' PHE . . . . . . . . . . . . . 14.6 t80 -64.33 -51.34 63.88 Favored 'General case' 0 C--O 1.232 0.169 0 CA-C-N 115.819 -0.628 . . . . 0.0 109.865 179.385 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 7.4 mp -60.8 -36.04 78.03 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 115.729 -0.668 . . . . 0.0 110.253 179.445 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -67.24 -27.67 73.54 Favored Glycine 0 N--CA 1.45 -0.395 0 C-N-CA 120.904 -0.665 . . . . 0.0 112.082 179.657 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 40.5 mt -71.66 -42.55 67.37 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-O 121.027 0.441 . . . . 0.0 110.421 179.801 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 90' ' ' LEU . . . . . 0.417 ' HB3' HG23 ' A' ' 156' ' ' ILE . 81.0 mt -56.13 -42.43 76.89 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 115.688 -0.687 . . . . 0.0 111.198 -179.971 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 91' ' ' ALA . . . . . 0.597 ' HB2' ' HB2' ' A' ' 149' ' ' ALA . . . -79.3 -45.99 18.59 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.311 -0.404 . . . . 0.0 111.393 -179.597 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 97.73 50.66 1.63 Allowed Glycine 0 N--CA 1.45 -0.373 0 C-N-CA 120.712 -0.756 . . . . 0.0 112.229 -179.583 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 93' ' ' LEU . . . . . 0.527 HD23 ' HB3' ' A' ' 97' ' ' GLU . 10.8 mp -61.61 171.55 1.5 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.958 0.409 . . . . 0.0 111.24 -179.891 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 94' ' ' ASP . . . . . . . . . . . . . 24.2 t70 -90.46 167.61 12.47 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 115.963 -0.562 . . . . 0.0 110.462 179.722 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 47.3 t -55.04 -35.42 64.46 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.355 -0.384 . . . . 0.0 111.107 179.983 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 5.3 mmp_? -73.83 -50.49 20.18 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.09 -0.504 . . . . 0.0 111.33 -179.858 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 97' ' ' GLU . . . . . 0.527 ' HB3' HD23 ' A' ' 93' ' ' LEU . 46.6 mt-10 -52.37 -45.2 65.66 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.34 -0.391 . . . . 0.0 111.291 -179.606 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 98' ' ' PHE . . . . . 0.416 ' O ' HG12 ' A' ' 102' ' ' ILE . 28.2 m-85 -59.55 -46.69 88.16 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.488 -0.324 . . . . 0.0 110.864 179.824 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -57.67 -28.58 60.21 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.524 -0.846 . . . . 0.0 112.466 179.848 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 79.6 mt -73.83 -48.7 38.26 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.181 0 N-CA-C 112.125 0.417 . . . . 0.0 112.125 -179.563 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 29.4 m -67.98 -41.75 84.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 N-CA-C 112.049 0.388 . . . . 0.0 112.049 -179.001 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 102' ' ' ILE . . . . . 0.482 HG23 ' HB3' ' A' ' 81' ' ' PRO . 50.9 mm -63.88 -49.35 82.22 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.675 -0.239 . . . . 0.0 111.505 -179.463 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 15.3 t -59.72 -34.75 73.33 Favored 'General case' 0 C--O 1.233 0.208 0 CA-C-O 120.951 0.405 . . . . 0.0 110.643 179.873 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 1.3 tm? -56.29 -54.08 49.67 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.008 -0.542 . . . . 0.0 109.698 179.05 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 105' ' ' ASN . . . . . 0.849 HD21 HG22 ' A' ' 80' ' ' THR . 2.8 m-20 -58.23 -34.03 69.99 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 115.591 -0.731 . . . . 0.0 110.83 179.605 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 85.4 m -56.54 -43.79 80.24 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.295 -0.411 . . . . 0.0 110.734 179.803 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 1.5 t -66.81 -42.18 88.87 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-O 121.2 0.524 . . . . 0.0 110.348 179.383 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 93.5 t -57.99 -51.17 73.99 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.386 0 CA-C-N 115.318 -0.856 . . . . 0.0 111.679 -179.722 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 109' ' ' MET . . . . . 0.61 ' HE1' HG21 ' A' ' 80' ' ' THR . 1.5 mpp? -65.22 -37.52 87.53 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.37 -179.588 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 32.4 tp -66.71 -31.5 72.2 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 116.39 -0.368 . . . . 0.0 110.58 -179.893 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -65.42 -52.56 52.5 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.394 179.487 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 112' ' ' GLY . . . . . 0.622 ' HA3' ' H21' ' A' ' 301' ' ' RET . . . -66.26 -31.43 79.07 Favored Glycine 0 N--CA 1.449 -0.434 0 C-N-CA 120.749 -0.738 . . . . 0.0 111.883 179.37 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 113' ' ' PHE . . . . . . . . . . . . . 0.4 OUTLIER -57.14 -70.69 0.12 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 121.032 0.444 . . . . 0.0 110.061 179.567 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 114' ' ' ALA . . . . . 0.505 ' HB3' HD22 ' A' ' 126' ' ' LEU . . . -64.09 -18.55 64.49 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 115.72 -0.673 . . . . 0.0 110.758 179.577 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -57.77 -53.62 43.79 Favored Glycine 0 C--N 1.332 0.314 0 C-N-CA 120.943 -0.646 . . . . 0.0 112.263 179.802 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 116' ' ' ALA . . . . . 0.547 ' HB2' ' HB3' ' A' ' 183' ' ' PRO . . . -77.48 -14.98 59.56 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.784 0.326 . . . . 0.0 111.271 179.927 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 117' ' ' MET . . . . . 0.479 ' SD ' HG21 ' A' ' 68' ' ' VAL . 17.9 mmt -86.33 13.71 7.71 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.129 -0.487 . . . . 0.0 111.589 -179.504 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 20.4 m -87.22 143.03 33.99 Favored Pre-proline 0 C--N 1.33 -0.255 0 CA-C-O 120.563 0.221 . . . . 0.0 111.371 -179.916 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 119' ' ' PRO . . . . . . . . . . . . . 68.2 Cg_endo -92.56 -2.66 3.76 Favored 'Trans proline' 0 N--CA 1.455 -0.776 0 C-N-CA 122.945 2.43 . . . . 0.0 112.267 179.441 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -132.81 -117.66 1.86 Allowed Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.779 -0.724 . . . . 0.0 112.805 -179.668 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 39.6 pt -123.26 12.97 5.31 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.234 0 CA-C-O 120.654 0.264 . . . . 0.0 111.547 -179.514 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 37.7 mt-10 -61.23 -18.65 59.4 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.375 -0.375 . . . . 0.0 110.822 179.912 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 123' ' ' ARG . . . . . 0.471 ' HB2' ' HH2' ' A' ' 178' ' ' TRP . 23.0 ptt180 -51.93 -33.79 38.92 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 115.927 -0.579 . . . . 0.0 111.615 -179.84 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 124' ' ' TYR . . . . . . . . . . . . . 59.0 m-85 -67.49 -33.3 74.81 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.459 -0.337 . . . . 0.0 111.397 -179.622 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 125' ' ' ALA . . . . . . . . . . . . . . . -72.71 -56.46 5.25 Favored 'General case' 0 C--O 1.237 0.411 0 CA-C-O 121.105 0.479 . . . . 0.0 111.073 179.835 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 126' ' ' LEU . . . . . 0.505 HD22 ' HB3' ' A' ' 114' ' ' ALA . 1.3 mt -55.24 -48.1 74.44 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 115.729 -0.669 . . . . 0.0 110.395 179.847 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 127' ' ' PHE . . . . . 0.418 ' HZ ' ' HB3' ' A' ' 175' ' ' PRO . 9.2 t80 -67.76 -30.76 70.3 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.11 -0.496 . . . . 0.0 110.334 179.316 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 128' ' ' GLY . . . . . . . . . . . . . . . -49.12 -50.58 27.76 Favored Glycine 0 N--CA 1.449 -0.441 0 C-N-CA 120.125 -1.036 . . . . 0.0 110.553 178.734 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 129' ' ' MET . . . . . 0.541 ' HE3' ' HA2' ' A' ' 130' ' ' GLY . 0.0 OUTLIER -70.84 -28.24 64.45 Favored 'General case' 0 N--CA 1.453 -0.293 0 N-CA-C 109.02 -0.733 . . . . 0.0 109.02 178.283 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 130' ' ' GLY . . . . . 0.541 ' HA2' ' HE3' ' A' ' 129' ' ' MET . . . -60.09 -41.63 98.14 Favored Glycine 0 C--N 1.335 0.48 0 CA-C-N 115.772 -0.649 . . . . 0.0 112.441 179.364 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -71.04 -49.43 44.99 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-O 120.66 0.267 . . . . 0.0 110.503 179.733 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 57.7 t -57.4 -43.72 83.07 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.217 0 CA-C-O 121.139 0.495 . . . . 0.0 109.81 179.068 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -65.86 -33.01 74.87 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 115.538 -0.756 . . . . 0.0 110.603 179.193 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 134' ' ' PHE . . . . . 0.409 ' HE1' ' HB3' ' A' ' 171' ' ' TRP . 71.6 t80 -59.02 -54.62 45.11 Favored 'General case' 0 N--CA 1.451 -0.385 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.038 179.58 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 135' ' ' ILE . . . . . 0.508 ' O ' HG22 ' A' ' 138' ' ' VAL . 38.2 mt -57.19 -30.38 34.74 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.312 0 CA-C-N 115.805 -0.634 . . . . 0.0 109.916 178.98 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . -62.88 -37.37 94.79 Favored Glycine 0 N--CA 1.447 -0.601 0 C-N-CA 120.31 -0.948 . . . . 0.0 111.301 178.877 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 137' ' ' LEU . . . . . 0.466 HD21 ' HZ3' ' A' ' 171' ' ' TRP . 21.4 tp -71.45 -51.77 22.05 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 120.582 0.23 . . . . 0.0 110.8 179.536 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 138' ' ' VAL . . . . . 0.508 HG22 ' O ' ' A' ' 135' ' ' ILE . 3.9 m -56.15 -31.9 32.92 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.213 0 CA-C-O 121.299 0.571 . . . . 0.0 109.479 179.377 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 139' ' ' TYR . . . . . . . . . . . . . 35.3 t80 -63.99 -44.67 91.96 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 115.29 -0.868 . . . . 0.0 110.136 178.882 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 140' ' ' TYR . . . . . 0.47 ' HB3' ' SD ' ' A' ' 145' ' ' MET . 23.6 m-85 -54.65 -47.01 74.04 Favored 'General case' 0 C--N 1.332 -0.167 0 CA-C-N 115.974 -0.557 . . . . 0.0 111.006 179.622 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 141' ' ' LEU . . . . . . . . . . . . . 93.2 mt -59.04 -40.81 86.23 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.252 -0.431 . . . . 0.0 111.064 -179.885 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 37.8 t -79.73 -12.46 13.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-O 121.063 0.459 . . . . 0.0 110.823 179.902 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . -70.88 -140.64 0.2 Allowed Glycine 0 CA--C 1.522 0.471 0 C-N-CA 120.989 -0.624 . . . . 0.0 112.715 -179.913 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 144' ' ' PRO . . . . . . . . . . . . . 56.6 Cg_endo -70.1 -22.77 30.07 Favored 'Trans proline' 0 C--N 1.349 0.575 0 C-N-CA 122.767 2.312 . . . . 0.0 112.894 -179.93 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 145' ' ' MET . . . . . 0.47 ' SD ' ' HB3' ' A' ' 140' ' ' TYR . 81.0 mtp -52.5 -53.48 45.4 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.281 -0.418 . . . . 0.0 111.794 -179.223 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 146' ' ' THR . . . . . . . . . . . . . 10.2 t -62.45 -32.83 73.75 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.726 0.298 . . . . 0.0 111.586 -179.53 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 45.0 mt-10 -71.35 -32.64 68.78 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.309 -0.405 . . . . 0.0 111.087 -179.837 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 148' ' ' SER . . . . . . . . . . . . . 59.6 m -70.23 -36.6 74.62 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.114 -0.494 . . . . 0.0 111.21 -179.788 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 149' ' ' ALA . . . . . 0.597 ' HB2' ' HB2' ' A' ' 91' ' ' ALA . . . -75.47 -39.46 58.64 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.265 -0.425 . . . . 0.0 111.69 -179.585 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 150' ' ' SER . . . . . . . . . . . . . 69.8 m -66.19 -4.39 7.54 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.39 -0.368 . . . . 0.0 111.217 -179.792 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 151' ' ' GLN . . . . . . . . . . . . . 47.8 mt-30 -124.59 14.53 8.77 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.389 -0.369 . . . . 0.0 111.303 -179.907 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 31.9 tpt180 -91.74 -51.55 5.18 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 120.972 0.415 . . . . 0.0 110.653 179.786 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 153' ' ' SER . . . . . 0.598 ' HB2' HG12 ' A' ' 156' ' ' ILE . 45.4 m -157.54 172.63 18.2 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 115.87 -0.604 . . . . 0.0 110.576 179.466 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 154' ' ' SER . . . . . . . . . . . . . 47.9 t -67.53 -41.84 83.69 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.393 -0.367 . . . . 0.0 110.769 179.841 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -76.69 -35.89 39.19 Favored Glycine 0 C--N 1.332 0.312 0 C-N-CA 120.85 -0.691 . . . . 0.0 112.804 -179.946 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 156' ' ' ILE . . . . . 0.598 HG12 ' HB2' ' A' ' 153' ' ' SER . 39.9 mm -56.23 -39.37 59.23 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.224 0 CA-C-O 120.729 0.299 . . . . 0.0 111.46 -179.729 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 157' ' ' LYS . . . . . 0.409 ' O ' HG13 ' A' ' 161' ' ' VAL . 62.3 tttp -61.92 -51.08 69.6 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.296 -0.411 . . . . 0.0 111.329 -179.758 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 51.4 m -64.87 -35.41 81.04 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.37 -0.377 . . . . 0.0 111.499 -179.154 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 159' ' ' LEU . . . . . 0.554 HD21 ' HB3' ' A' ' 215' ' ' ALA . 10.8 mt -68.84 -59.28 3.19 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-N 116.312 -0.403 . . . . 0.0 111.655 -179.507 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 160' ' ' TYR . . . . . . . . . . . . . 19.4 t80 -52.45 -44.97 65.82 Favored 'General case' 0 C--N 1.327 -0.374 0 N-CA-C 112.228 0.455 . . . . 0.0 112.228 -178.947 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 161' ' ' VAL . . . . . 0.475 HG23 ' N ' ' A' ' 162' ' ' ARG . 36.0 m -63.65 -45.8 96.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 N-CA-C 112.504 0.557 . . . . 0.0 112.504 -178.289 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 162' ' ' ARG . . . . . 0.595 ' O ' HD12 ' A' ' 166' ' ' LEU . 99.4 mtt180 -63.65 -49.72 72.1 Favored 'General case' 0 C--N 1.327 -0.377 0 N-CA-C 111.78 0.289 . . . . 0.0 111.78 -179.009 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 163' ' ' LEU . . . . . 0.488 ' HG ' ' O ' ' A' ' 159' ' ' LEU . 11.0 mt -67.7 -39.86 84.35 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.39 -0.368 . . . . 0.0 111.345 -178.873 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 164' ' ' ARG . . . . . . . . . . . . . 4.1 tmm_? -59.11 -47.78 84.0 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.446 -0.343 . . . . 0.0 110.756 -179.847 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 165' ' ' ASN . . . . . . . . . . . . . 5.4 m-20 -56.02 -48.74 75.39 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.303 -0.408 . . . . 0.0 110.297 179.708 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 166' ' ' LEU . . . . . 0.595 HD12 ' O ' ' A' ' 162' ' ' ARG . 1.4 mt -57.89 -45.82 85.85 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.016 -0.538 . . . . 0.0 110.763 179.364 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 167' ' ' THR . . . . . 0.656 ' HA ' HD11 ' A' ' 170' ' ' LEU . 13.9 m -54.4 -51.42 64.91 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-N 115.936 -0.574 . . . . 0.0 112.051 -178.767 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 168' ' ' VAL . . . . . . . . . . . . . 49.3 t -57.76 -40.02 73.62 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.449 0 N-CA-C 111.903 0.334 . . . . 0.0 111.903 -179.386 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 169' ' ' VAL . . . . . 0.43 ' O ' HG12 ' A' ' 173' ' ' ILE . 93.0 t -66.74 -67.69 0.39 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 N-CA-C 113.622 0.971 . . . . 0.0 113.622 -177.947 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 170' ' ' LEU . . . . . 0.656 HD11 ' HA ' ' A' ' 167' ' ' THR . 0.4 OUTLIER -61.14 -34.06 74.39 Favored 'General case' 0 N--CA 1.463 0.222 0 N-CA-C 112.899 0.703 . . . . 0.0 112.899 -177.475 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 171' ' ' TRP . . . . . 0.818 ' HE1' H203 ' A' ' 301' ' ' RET . 26.9 m0 -72.59 -30.64 64.55 Favored 'General case' 0 C--N 1.327 -0.401 0 C-N-CA 120.612 -0.435 . . . . 0.0 111.514 -179.283 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 172' ' ' ALA . . . . . . . . . . . . . . . -73.04 -7.86 53.15 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-O 121.036 0.446 . . . . 0.0 110.474 179.916 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 173' ' ' ILE . . . . . 0.498 ' O ' HG12 ' A' ' 177' ' ' ILE . 37.3 mm -88.7 -26.05 5.66 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.222 0 CA-C-N 115.808 -0.633 . . . . 0.0 110.784 179.564 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 174' ' ' TYR . . . . . 0.448 ' HD1' ' HA ' ' A' ' 171' ' ' TRP . 24.1 m-85 -54.28 -49.02 92.75 Favored Pre-proline 0 N--CA 1.462 0.17 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.933 -179.197 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 175' ' ' PRO . . . . . 0.418 ' HB3' ' HZ ' ' A' ' 127' ' ' PHE . 82.8 Cg_exo -45.85 -32.74 9.63 Favored 'Trans proline' 0 C--N 1.351 0.675 0 C-N-CA 121.898 1.732 . . . . 0.0 111.798 179.555 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 176' ' ' PHE . . . . . 0.476 ' O ' ' HG ' ' A' ' 180' ' ' LEU . 60.1 m-85 -80.98 -50.77 9.29 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 115.692 -0.686 . . . . 0.0 111.717 -179.995 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 177' ' ' ILE . . . . . 0.498 HG12 ' O ' ' A' ' 173' ' ' ILE . 10.8 mm -58.69 -38.33 71.01 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.567 0 CA-C-N 116.015 -0.539 . . . . 0.0 111.897 -178.283 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 178' ' ' TRP . . . . . 0.471 ' HH2' ' HB2' ' A' ' 123' ' ' ARG . 83.4 t90 -65.88 -56.26 12.74 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-O 120.875 0.369 . . . . 0.0 110.894 -179.951 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 179' ' ' LEU . . . . . 0.688 ' HG ' HG22 ' A' ' 185' ' ' VAL . 34.0 tp -64.1 -55.24 23.42 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 115.971 -0.559 . . . . 0.0 112.066 -178.689 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 180' ' ' LEU . . . . . 0.698 HD22 HD11 ' A' ' 187' ' ' LEU . 10.1 mt -62.69 -28.65 70.09 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.661 -0.245 . . . . 0.0 111.283 -179.171 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . -72.18 -171.61 17.0 Favored Glycine 0 N--CA 1.45 -0.419 0 C-N-CA 119.929 -1.129 . . . . 0.0 111.922 179.157 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 182' ' ' PRO . . . . . 0.44 ' N ' ' HD2' ' A' ' 183' ' ' PRO . 71.4 Cg_exo -49.84 -43.63 40.08 Favored 'Trans proline' 0 CA--C 1.538 0.708 0 C-N-CA 122.759 2.306 . . . . 0.0 113.756 179.609 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 183' ' ' PRO . . . . . 0.547 ' HB3' ' HB2' ' A' ' 116' ' ' ALA . 60.7 Cg_exo -39.37 -55.74 1.46 Allowed 'Trans proline' 0 C--N 1.358 1.036 0 C-N-CA 122.73 2.287 . . . . 0.0 113.904 -179.414 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 184' ' ' GLY . . . . . . . . . . . . . . . -115.79 -111.91 2.78 Favored Glycine 0 N--CA 1.45 -0.387 0 C-N-CA 120.203 -0.999 . . . . 0.0 112.672 -179.551 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 185' ' ' VAL . . . . . 0.688 HG22 ' HG ' ' A' ' 179' ' ' LEU . 35.8 m -76.39 84.74 0.74 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.466 0 CA-C-O 121.467 0.651 . . . . 0.0 110.693 -179.74 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 186' ' ' ALA . . . . . . . . . . . . . . . -62.9 84.07 0.02 OUTLIER 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 115.73 -0.668 . . . . 0.0 111.361 179.999 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 187' ' ' LEU . . . . . 0.698 HD11 HD22 ' A' ' 180' ' ' LEU . 5.0 mt -77.27 -48.99 16.01 Favored 'General case' 0 C--N 1.332 -0.181 0 CA-C-O 120.964 0.411 . . . . 0.0 110.64 179.73 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 188' ' ' LEU . . . . . . . . . . . . . 83.1 mt -92.41 -162.13 0.9 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 115.811 -0.631 . . . . 0.0 111.378 -179.421 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 189' ' ' THR . . . . . . . . . . . . . 88.4 m -94.58 136.57 23.05 Favored Pre-proline 0 C--N 1.328 -0.349 0 CA-C-N 115.708 -0.678 . . . . 0.0 110.729 -179.974 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 190' ' ' PRO . . . . . 0.402 ' O ' HG23 ' A' ' 194' ' ' VAL . 80.0 Cg_exo -45.33 -43.68 16.84 Favored 'Trans proline' 0 C--N 1.35 0.609 0 C-N-CA 122.561 2.174 . . . . 0.0 112.63 179.743 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 191' ' ' THR . . . . . . . . . . . . . 82.6 p -58.72 -46.39 87.46 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.329 -0.396 . . . . 0.0 111.042 179.922 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 192' ' ' VAL . . . . . . . . . . . . . 87.6 t -63.14 -47.37 92.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.117 -0.492 . . . . 0.0 111.195 -179.983 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 193' ' ' ASP . . . . . . . . . . . . . 22.3 t70 -54.83 -48.12 73.24 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.055 -0.521 . . . . 0.0 111.311 -179.705 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 194' ' ' VAL . . . . . 0.417 ' O ' HG23 ' A' ' 198' ' ' VAL . 99.7 t -64.35 -36.12 76.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.281 -0.418 . . . . 0.0 110.887 -179.848 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 195' ' ' ALA . . . . . . . . . . . . . . . -58.2 -46.03 86.54 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.413 -0.358 . . . . 0.0 111.04 179.915 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 196' ' ' LEU . . . . . 0.416 ' O ' ' HG ' ' A' ' 200' ' ' LEU . 94.1 mt -67.01 -42.07 85.6 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.419 -0.355 . . . . 0.0 110.38 179.713 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 197' ' ' ILE . . . . . . . . . . . . . 18.7 mm -57.31 -57.83 8.46 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.231 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.398 179.256 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 198' ' ' VAL . . . . . 0.417 HG23 ' O ' ' A' ' 194' ' ' VAL . 91.0 t -52.65 -34.82 20.08 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.493 0 CA-C-N 115.598 -0.728 . . . . 0.0 109.328 178.618 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 199' ' ' TYR . . . . . . . . . . . . . 64.4 t80 -70.41 -35.36 73.39 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 115.288 -0.869 . . . . 0.0 110.73 179.704 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 200' ' ' LEU . . . . . 0.416 ' HG ' ' O ' ' A' ' 196' ' ' LEU . 73.1 mt -66.15 -41.34 90.54 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 115.762 -0.654 . . . . 0.0 111.322 -179.485 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 201' ' ' ASP . . . . . 0.43 ' HB2' ' OH ' ' A' ' 51' ' ' TYR . 9.9 m-20 -71.81 -31.83 66.97 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 116.29 -0.414 . . . . 0.0 110.482 179.879 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 202' ' ' LEU . . . . . 0.455 ' O ' ' HB ' ' A' ' 206' ' ' VAL . 3.6 mt -72.66 -34.11 67.02 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 115.831 -0.622 . . . . 0.0 111.997 -179.558 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 203' ' ' VAL . . . . . 0.472 ' O ' ' HA3' ' A' ' 207' ' ' GLY . 7.7 p -75.42 -36.68 36.34 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-O 120.609 0.242 . . . . 0.0 111.177 -179.032 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 204' ' ' THR . . . . . . . . . . . . . 25.6 m -68.41 -55.26 12.54 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-O 120.879 0.371 . . . . 0.0 111.397 179.789 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 205' ' ' LYS . . . . . 0.694 ' HE2' ' HB2' ' A' ' 47' ' ' ALA . 54.3 mttp -68.6 -58.96 3.5 Favored 'General case' 0 C--N 1.328 -0.359 0 N-CA-C 112.397 0.517 . . . . 0.0 112.397 -178.599 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 206' ' ' VAL . . . . . 0.455 ' HB ' ' O ' ' A' ' 202' ' ' LEU . 76.6 t -73.3 -38.13 53.19 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 N-CA-C 112.217 0.451 . . . . 0.0 112.217 -178.702 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 207' ' ' GLY . . . . . 0.472 ' HA3' ' O ' ' A' ' 203' ' ' VAL . . . -63.85 -59.78 8.17 Favored Glycine 0 N--CA 1.452 -0.261 0 C-N-CA 120.341 -0.933 . . . . 0.0 112.514 -179.324 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 208' ' ' PHE . . . . . 0.512 ' O ' ' N ' ' A' ' 212' ' ' ALA . 1.8 m-30 -54.53 -47.89 72.61 Favored 'General case' 0 C--O 1.221 -0.407 0 N-CA-C 109.795 -0.446 . . . . 0.0 109.795 179.515 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 209' ' ' GLY . . . . . 0.492 ' HA2' ' HB3' ' A' ' 212' ' ' ALA . . . -54.29 -35.07 54.73 Favored Glycine 0 N--CA 1.448 -0.508 0 CA-C-N 115.366 -0.834 . . . . 0.0 113.144 179.558 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 210' ' ' PHE . . . . . . . . . . . . . 1.9 m-85 -69.69 -47.67 62.41 Favored 'General case' 0 CA--C 1.515 -0.403 0 N-CA-C 108.677 -0.86 . . . . 0.0 108.677 179.334 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 211' ' ' ILE . . . . . 0.423 HG13 ' O ' ' A' ' 207' ' ' GLY . 4.0 mt -66.14 -27.47 40.9 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.486 0 N-CA-C 107.587 -1.264 . . . . 0.0 107.587 176.757 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 212' ' ' ALA . . . . . 0.512 ' N ' ' O ' ' A' ' 208' ' ' PHE . . . -67.4 -39.07 85.52 Favored 'General case' 0 N--CA 1.448 -0.536 0 CA-C-N 114.302 -1.317 . . . . 0.0 110.018 -179.768 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 213' ' ' LEU . . . . . . . . . . . . . 80.7 mt -70.21 -38.05 75.19 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 114.991 -1.004 . . . . 0.0 111.275 -179.841 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 214' ' ' ASP . . . . . . . . . . . . . 26.9 t70 -60.3 -55.09 37.87 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 116.328 -0.396 . . . . 0.0 111.016 -179.808 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 215' ' ' ALA . . . . . 0.554 ' HB3' HD21 ' A' ' 159' ' ' LEU . . . -61.05 -50.89 71.49 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.758 179.709 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 216' ' ' ALA . . . . . . . . . . . . . . . -57.45 -32.49 66.98 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.946 179.683 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 217' ' ' ALA . . . . . . . . . . . . . . . -62.72 -43.3 99.15 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-N 116.086 -0.506 . . . . 0.0 110.17 179.544 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 218' ' ' THR . . . . . . . . . . . . . 91.8 m -64.88 -46.99 79.46 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 115.897 -0.592 . . . . 0.0 110.472 179.267 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 219' ' ' LEU . . . . . 0.421 ' HG ' ' O ' ' A' ' 215' ' ' ALA . 30.1 mt -61.58 -26.46 67.98 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-O 121.302 0.573 . . . . 0.0 109.944 179.273 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 220' ' ' ARG . . . . . . . . . . . . . 56.7 ttp180 -84.49 -26.6 28.03 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 115.305 -0.861 . . . . 0.0 110.933 179.614 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 221' ' ' ALA . . . . . . . . . . . . . . . -82.64 -26.83 31.82 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.093 -0.503 . . . . 0.0 112.05 -179.191 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 222' ' ' GLU . . . . . 0.402 ' HG2' ' O ' ' A' ' 219' ' ' LEU . 11.0 pt-20 -68.81 -15.62 63.56 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.862 0.363 . . . . 0.0 110.741 -179.486 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 223' ' ' HIS . . . . . . . . . . . . . 28.3 m80 -73.38 -68.6 0.49 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.049 -0.523 . . . . 0.0 111.038 179.855 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 224' ' ' GLY . . . . . . . . . . . . . . . 90.89 -42.52 2.87 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.847 -0.692 . . . . 0.0 112.441 -179.864 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 225' ' ' GLU . . . . . . . . . . . . . 1.6 mp0 -60.1 134.38 57.0 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 120.919 0.39 . . . . 0.0 111.046 -179.825 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 226' ' ' SER . . . . . . . . . . . . . 24.7 m -124.12 170.32 10.82 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.808 -179.931 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 227' ' ' LEU . . . . . 0.438 ' N ' HD12 ' A' ' 227' ' ' LEU . 7.4 mp -91.04 129.22 37.06 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.307 -0.406 . . . . 0.0 110.563 179.688 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 228' ' ' ALA . . . . . . . . . . . . . . . -145.75 144.9 30.61 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.426 -0.352 . . . . 0.0 111.056 179.934 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 229' ' ' GLY . . . . . . . . . . . . . . . 167.98 179.07 40.33 Favored Glycine 0 N--CA 1.45 -0.411 0 C-N-CA 120.623 -0.799 . . . . 0.0 112.603 -179.946 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 230' ' ' VAL . . . . . . . . . . . . . 6.8 p -156.18 139.88 7.9 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-O 120.848 0.356 . . . . 0.0 110.772 -179.997 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 231' ' ' ASP . . . . . . . . . . . . . 17.9 t70 -96.49 93.72 6.97 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.032 -179.799 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 232' ' ' THR . . . . . . . . . . . . . 10.1 t -122.29 -31.53 3.81 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.104 -0.498 . . . . 0.0 111.112 179.957 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 233' ' ' ASP . . . . . . . . . . . . . 21.7 t70 -150.66 -68.07 0.19 Allowed 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.304 -0.407 . . . . 0.0 110.941 179.996 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 234' ' ' THR . . . . . . . . . . . . . 5.1 t -133.66 142.77 45.06 Favored Pre-proline 0 C--N 1.328 -0.348 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.039 179.924 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 235' ' ' PRO . . . . . . . . . . . . . 37.4 Cg_endo -66.14 151.55 83.39 Favored 'Trans proline' 0 C--N 1.348 0.508 0 C-N-CA 122.402 2.068 . . . . 0.0 112.234 179.984 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 236' ' ' ALA . . . . . . . . . . . . . . . 60.02 97.93 0.03 OUTLIER 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 116.057 -0.519 . . . . 0.0 111.345 179.99 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 237' ' ' VAL . . . . . . . . . . . . . 80.1 t -91.36 111.5 23.97 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-N 116.107 -0.497 . . . . 0.0 111.104 179.924 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 238' ' ' ALA . . . . . 0.429 ' H ' ' H ' ' A' ' 239' ' ' ASP . . . -155.39 -12.53 0.11 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.087 -0.506 . . . . 0.0 111.072 179.928 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 239' ' ' ASP . . . . . 0.429 ' H ' ' H ' ' A' ' 238' ' ' ALA . 16.3 m-20 58.62 96.33 0.03 OUTLIER 'General case' 0 N--CA 1.463 0.176 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.854 -179.821 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 240' ' ' LEU . . . . . . . . . . . . . 61.9 mt -115.24 0.6 13.57 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.233 -0.44 . . . . 0.0 111.243 -179.748 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 241' ' ' GLU . . . . . . . . . . . . . 1.5 mp0 -81.99 162.63 22.58 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.424 -0.353 . . . . 0.0 110.667 179.768 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 242' ' ' HIS . . . . . . . . . . . . . 63.4 t60 -143.59 -44.44 0.28 Allowed 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.377 -0.374 . . . . 0.0 110.932 -179.881 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 243' ' ' HIS . . . . . . . . . . . . . 43.3 m80 -66.18 121.49 15.31 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.774 -179.974 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 244' ' ' HIS . . . . . . . . . . . . . 54.8 t-80 -134.44 114.01 12.44 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.287 -0.415 . . . . 0.0 110.973 179.938 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 245' ' ' HIS . . . . . . . . . . . . . 47.8 m80 -107.64 147.76 30.24 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.894 -179.94 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 246' ' ' HIS . . . . . . . . . . . . . 93.5 m-70 -93.77 -36.7 12.15 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.901 -179.967 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 247' ' ' HIS . . . . . . . . . . . . . 7.2 m80 . . . . . 0 C--O 1.25 1.11 0 CA-C-O 118.193 -0.908 . . . . 0.0 110.892 -179.962 . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 301' ' ' RET . . . . . 0.818 H203 ' HE1' ' A' ' 171' ' ' TRP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 2.7 mpp? . . . . . 0 N--CA 1.486 1.375 0 CA-C-O 120.905 0.383 . . . . 0.0 110.867 . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 16.2 m -138.64 -39.95 0.31 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 115.971 -0.559 . . . . 0.0 111.251 -179.948 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -106.76 -13.37 22.21 Favored Glycine 0 N--CA 1.45 -0.422 0 C-N-CA 120.785 -0.721 . . . . 0.0 112.744 -179.989 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 52.0 tp -74.15 -35.47 64.05 Favored 'General case' 0 C--N 1.331 -0.21 0 CA-C-O 120.867 0.365 . . . . 0.0 110.752 179.928 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 64.9 p -64.15 -32.61 74.24 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.014 -0.539 . . . . 0.0 111.276 -179.99 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 15.9 p -52.87 -35.4 57.71 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.264 -179.647 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 7' ' ' LEU . . . . . 0.412 HD12 ' HA ' ' A' ' 195' ' ' ALA . 4.2 mm? -60.8 -53.34 58.52 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.242 -179.814 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 8' ' ' PHE . . . . . 0.437 ' HB2' ' HB2' ' A' ' 55' ' ' ALA . 64.0 m-85 -60.08 -32.7 71.2 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.928 0.394 . . . . 0.0 110.641 -179.986 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 9' ' ' TRP . . . . . 0.432 ' O ' HG13 ' A' ' 13' ' ' ILE . 35.8 m95 -67.08 -41.69 85.93 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 115.943 -0.571 . . . . 0.0 110.092 179.622 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 82.5 mt -61.57 -52.75 63.15 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 115.721 -0.672 . . . . 0.0 110.205 179.244 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -53.48 -36.46 53.77 Favored Glycine 0 N--CA 1.449 -0.492 0 C-N-CA 120.775 -0.726 . . . . 0.0 111.612 178.766 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -64.07 -34.68 78.58 Favored 'General case' 0 C--N 1.332 -0.191 0 CA-C-O 120.91 0.386 . . . . 0.0 110.226 179.258 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 13' ' ' ILE . . . . . 0.432 HG13 ' O ' ' A' ' 9' ' ' TRP . 80.1 mt -66.13 -48.48 81.3 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.219 0 CA-C-N 115.884 -0.598 . . . . 0.0 110.363 179.268 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -60.94 -32.96 81.81 Favored Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.662 -0.78 . . . . 0.0 111.482 179.35 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 15' ' ' MET . . . . . 0.656 ' HB3' ' HB2' ' A' ' 48' ' ' ALA . 0.0 OUTLIER -67.99 -42.68 80.39 Favored 'General case' 0 C--N 1.331 -0.218 0 CA-C-O 120.92 0.391 . . . . 0.0 110.553 179.186 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 32.4 tp -57.8 -41.41 82.09 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.029 -0.532 . . . . 0.0 110.442 179.474 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 89.4 t -64.65 -51.03 72.68 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.22 0 CA-C-N 115.824 -0.625 . . . . 0.0 111.094 179.972 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -62.03 -49.51 74.57 Favored Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.686 -0.769 . . . . 0.0 112.183 179.913 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 51.9 m -49.77 -41.58 44.58 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-O 120.752 0.31 . . . . 0.0 111.326 -179.561 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 78.1 mt -72.07 -48.59 43.05 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.272 -0.422 . . . . 0.0 111.427 179.836 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -59.5 -29.64 68.0 Favored 'General case' 0 C--N 1.329 -0.296 0 N-CA-C 112.192 0.442 . . . . 0.0 112.192 -179.284 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 8.0 m-85 -88.11 -45.57 10.04 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-O 120.661 0.267 . . . . 0.0 111.53 -179.307 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -60.7 -50.37 73.76 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.884 0.373 . . . . 0.0 111.589 -179.615 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 24' ' ' TRP . . . . . . . . . . . . . 2.0 t-105 -58.54 -44.19 89.53 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 116.007 -0.542 . . . . 0.0 111.119 -179.727 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -74.98 -18.26 60.4 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-O 120.854 0.359 . . . . 0.0 110.998 -179.998 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -73.81 -48.31 17.16 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.849 -0.691 . . . . 0.0 112.493 179.923 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 21.4 mmm180 -57.98 -30.57 66.14 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-O 120.838 0.352 . . . . 0.0 110.908 -179.926 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 25.4 t70 -102.05 91.84 4.51 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.067 -0.515 . . . . 0.0 110.799 -179.958 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -169.96 -176.46 2.32 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.058 -0.519 . . . . 0.0 111.081 -179.962 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -92.04 177.54 39.93 Favored Glycine 0 N--CA 1.452 -0.275 0 C-N-CA 120.784 -0.722 . . . . 0.0 112.444 179.795 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 78.2 p -80.84 127.32 32.4 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.784 0.325 . . . . 0.0 111.057 -179.947 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 115.66 -27.95 8.06 Favored Glycine 0 N--CA 1.452 -0.246 0 C-N-CA 120.847 -0.692 . . . . 0.0 112.435 179.916 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 11.0 mm-40 -92.12 -24.64 19.05 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.841 0.353 . . . . 0.0 110.83 179.959 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 34' ' ' ARG . . . . . . . . . . . . . 78.6 mtm180 -50.48 -29.24 9.94 Favored 'General case' 0 C--N 1.332 -0.177 0 CA-C-N 115.943 -0.572 . . . . 0.0 111.575 -179.647 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 41.3 mmt180 -60.45 -46.5 89.82 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.767 0.318 . . . . 0.0 111.33 -179.904 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 76.6 m-85 -69.88 -30.58 68.06 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.282 -0.417 . . . . 0.0 111.456 -179.605 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 37' ' ' TYR . . . . . . . . . . . . . 62.8 m-85 -70.62 -55.12 9.51 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.289 -0.414 . . . . 0.0 111.302 -179.619 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 60.7 t -57.04 -37.84 57.19 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-O 120.957 0.408 . . . . 0.0 110.453 179.774 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 41.8 m -63.58 -47.98 79.29 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 115.847 -0.615 . . . . 0.0 110.316 179.209 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 27.6 tp -57.4 -48.21 79.69 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 115.52 -0.764 . . . . 0.0 110.539 179.677 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 76.3 t -60.63 -34.48 58.78 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.231 0 CA-C-N 115.717 -0.674 . . . . 0.0 110.382 179.242 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -60.03 -40.18 96.68 Favored Glycine 0 N--CA 1.449 -0.484 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.118 179.824 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 43' ' ' ILE . . . . . 0.531 HG22 ' HE3' ' A' ' 205' ' ' LYS . 0.4 OUTLIER -65.2 -53.86 35.74 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-O 120.728 0.299 . . . . 0.0 111.008 179.583 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 49.1 m -60.31 -25.75 66.0 Favored 'General case' 0 C--N 1.332 -0.181 0 CA-C-O 120.793 0.33 . . . . 0.0 111.37 -179.942 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -78.42 -51.74 5.49 Favored Glycine 0 CA--C 1.519 0.313 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.978 -179.54 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 46' ' ' ILE . . . . . 0.484 ' CD1' HG22 ' A' ' 79' ' ' THR . 21.8 pt -58.97 -38.73 75.41 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.217 0 CA-C-O 120.873 0.368 . . . . 0.0 111.035 -179.976 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 47' ' ' ALA . . . . . 0.736 ' HB2' ' HE2' ' A' ' 205' ' ' LYS . . . -67.85 -45.0 75.85 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.544 179.636 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 48' ' ' ALA . . . . . 0.656 ' HB2' ' HB3' ' A' ' 15' ' ' MET . . . -54.54 -41.58 69.9 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.069 -0.514 . . . . 0.0 112.024 -179.295 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 49' ' ' VAL . . . . . 0.417 ' O ' HG13 ' A' ' 53' ' ' VAL . 30.4 m -76.79 -34.35 22.84 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.36 0 CA-C-N 116.48 -0.327 . . . . 0.0 111.815 -179.21 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -66.92 -36.39 82.14 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 120.91 0.386 . . . . 0.0 111.101 179.922 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 3.3 m-85 -73.29 -40.09 64.83 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 115.987 -0.551 . . . . 0.0 110.452 179.951 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -62.79 -49.91 73.1 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-N 115.726 -0.67 . . . . 0.0 111.227 179.854 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 53' ' ' VAL . . . . . 0.491 ' O ' HG22 ' A' ' 58' ' ' VAL . 27.6 m -63.83 -46.02 95.48 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.218 0 CA-C-N 116.366 -0.379 . . . . 0.0 110.749 -179.975 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 54' ' ' MET . . . . . 0.5 ' HB2' ' HB2' ' A' ' 71' ' ' PRO . 11.0 ttp -64.11 -29.73 70.84 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.313 179.756 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 55' ' ' ALA . . . . . 0.437 ' HB2' ' HB2' ' A' ' 8' ' ' PHE . . . -63.0 -23.71 67.58 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 115.871 -0.604 . . . . 0.0 110.926 179.442 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 54.0 mt -94.47 -8.85 37.31 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-N 116.079 -0.51 . . . . 0.0 110.726 179.812 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 57' ' ' GLY . . . . . 0.432 ' HA2' ' CD1' ' A' ' 60' ' ' TRP . . . 75.19 30.66 58.55 Favored Glycine 0 N--CA 1.451 -0.361 0 C-N-CA 120.876 -0.678 . . . . 0.0 112.953 179.723 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 58' ' ' VAL . . . . . 0.491 HG22 ' O ' ' A' ' 53' ' ' VAL . 26.3 m -84.04 18.2 0.37 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-O 120.808 0.337 . . . . 0.0 111.504 179.992 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -152.87 6.6 0.45 Allowed Glycine 0 N--CA 1.449 -0.485 0 C-N-CA 120.751 -0.737 . . . . 0.0 112.888 179.947 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 60' ' ' TRP . . . . . 0.432 ' CD1' ' HA2' ' A' ' 57' ' ' GLY . 34.5 m0 -71.95 121.5 19.21 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-O 120.783 0.325 . . . . 0.0 110.48 179.921 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 7.5 p -114.91 128.59 25.78 Favored Pre-proline 0 CA--C 1.533 0.303 0 CA-C-N 116.263 -0.426 . . . . 0.0 111.388 -179.733 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 65.0 Cg_endo -73.95 144.01 33.73 Favored 'Trans proline' 0 C--N 1.351 0.686 0 C-N-CA 122.396 2.064 . . . . 0.0 112.107 179.719 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 59.0 t -137.83 90.42 0.72 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.384 0 CA-C-N 116.086 -0.506 . . . . 0.0 111.061 -179.645 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . 58.43 -88.05 0.02 OUTLIER 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 116.116 -0.493 . . . . 0.0 111.587 -179.996 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 45.6 mt-10 -119.19 -19.96 8.16 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-O 120.775 0.321 . . . . 0.0 110.958 179.995 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 66' ' ' ARG . . . . . . . . . . . . . 9.9 ptp180 -103.23 165.19 11.17 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.268 -0.423 . . . . 0.0 110.449 179.651 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 53.9 m -123.35 129.64 51.6 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.937 0.398 . . . . 0.0 111.472 -179.677 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 99.2 t -109.73 146.33 15.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 115.889 -0.596 . . . . 0.0 110.492 179.644 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 69' ' ' PHE . . . . . . . . . . . . . 30.3 m-85 -105.59 115.47 30.3 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 121.049 0.452 . . . . 0.0 110.484 -179.474 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 70' ' ' VAL . . . . . 0.628 HG12 ' HD3' ' A' ' 71' ' ' PRO . 0.3 OUTLIER -67.98 -36.29 9.13 Favored Pre-proline 0 CA--C 1.54 0.58 0 CA-C-N 115.863 -0.608 . . . . 0.0 112.601 -179.48 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 71' ' ' PRO . . . . . 0.628 ' HD3' HG12 ' A' ' 70' ' ' VAL . 7.7 Cg_exo -71.09 -19.12 30.28 Favored 'Trans proline' 0 C--N 1.357 1.016 0 C-N-CA 122.21 1.94 . . . . 0.0 113.308 -179.198 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 43.0 ttm180 -76.35 -55.09 5.87 Favored 'General case' 0 C--N 1.331 -0.206 0 N-CA-C 112.372 0.508 . . . . 0.0 112.372 -178.505 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 73' ' ' TYR . . . . . 0.452 ' O ' HG13 ' A' ' 77' ' ' ILE . 68.5 m-85 -71.19 -36.76 72.06 Favored 'General case' 0 C--N 1.329 -0.286 0 C-N-CA 120.841 -0.344 . . . . 0.0 110.956 -179.248 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 74' ' ' ILE . . . . . 0.432 ' O ' HD13 ' A' ' 74' ' ' ILE . 0.3 OUTLIER -64.95 -40.43 89.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 N-CA-C 109.766 -0.457 . . . . 0.0 109.766 179.309 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 75' ' ' ASP . . . . . 0.517 ' O ' HG23 ' A' ' 79' ' ' THR . 12.0 t70 -60.23 -37.51 80.55 Favored 'General case' 0 CA--C 1.518 -0.251 0 N-CA-C 109.437 -0.579 . . . . 0.0 109.437 178.772 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 76' ' ' TRP . . . . . . . . . . . . . 46.6 m0 -64.03 -31.44 72.63 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 115.899 -0.591 . . . . 0.0 110.319 179.478 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 77' ' ' ILE . . . . . 0.512 ' O ' ' HG2' ' A' ' 81' ' ' PRO . 61.8 mt -71.28 -31.72 44.79 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.478 178.963 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 25.6 mt -91.82 -15.13 28.66 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.172 -0.467 . . . . 0.0 112.165 -179.707 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 79' ' ' THR . . . . . 0.517 HG23 ' O ' ' A' ' 75' ' ' ASP . 79.8 p -104.61 -52.97 2.78 Favored 'General case' 0 N--CA 1.465 0.296 0 N-CA-C 113.614 0.968 . . . . 0.0 113.614 -177.891 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 80' ' ' THR . . . . . 0.583 ' HB ' ' HD3' ' A' ' 81' ' ' PRO . 4.5 m -52.66 -53.68 51.41 Favored Pre-proline 0 C--N 1.331 -0.237 0 N-CA-C 112.36 0.504 . . . . 0.0 112.36 -178.369 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 81' ' ' PRO . . . . . 0.583 ' HD3' ' HB ' ' A' ' 80' ' ' THR . 52.6 Cg_exo -57.01 -23.43 52.01 Favored 'Trans proline' 0 C--N 1.352 0.752 0 C-N-CA 121.612 1.541 . . . . 0.0 111.68 179.543 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 82' ' ' LEU . . . . . . . . . . . . . 18.0 tp -76.76 -33.19 58.1 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 115.926 -0.579 . . . . 0.0 110.054 179.604 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 83' ' ' ILE . . . . . 0.451 HD11 HG21 ' A' ' 43' ' ' ILE . 37.6 mm -69.36 -53.37 25.49 Favored 'Isoleucine or valine' 0 C--O 1.232 0.161 0 CA-C-N 116.007 -0.542 . . . . 0.0 110.386 179.226 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 29.0 m -59.36 -32.8 49.34 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.183 0 N-CA-C 109.8 -0.444 . . . . 0.0 109.8 179.005 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 85' ' ' TYR . . . . . . . . . . . . . 55.4 t80 -64.66 -34.57 78.6 Favored 'General case' 0 N--CA 1.454 -0.272 0 CA-C-N 115.657 -0.701 . . . . 0.0 109.561 178.801 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 86' ' ' PHE . . . . . . . . . . . . . 8.8 t80 -61.48 -51.82 67.07 Favored 'General case' 0 C--O 1.232 0.181 0 CA-C-N 115.635 -0.711 . . . . 0.0 110.232 179.507 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 7.3 mp -61.71 -31.93 72.11 Favored 'General case' 0 C--N 1.331 -0.204 0 CA-C-N 116.136 -0.483 . . . . 0.0 110.116 179.49 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -71.59 -27.57 70.89 Favored Glycine 0 N--CA 1.449 -0.44 0 CA-C-N 115.8 -0.636 . . . . 0.0 111.795 179.31 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 42.0 mt -72.07 -39.2 69.18 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.919 0.39 . . . . 0.0 110.538 179.733 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 53.6 mt -58.5 -45.8 88.01 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 115.782 -0.645 . . . . 0.0 111.106 -179.967 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 91' ' ' ALA . . . . . 0.588 ' HB2' ' HB2' ' A' ' 149' ' ' ALA . . . -79.88 -54.94 5.35 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.403 -179.728 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 102.84 65.64 0.73 Allowed Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.826 -0.702 . . . . 0.0 112.346 -179.888 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 93' ' ' LEU . . . . . 0.46 HD11 ' HG2' ' A' ' 145' ' ' MET . 8.1 mp -71.93 172.04 10.67 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.804 0.335 . . . . 0.0 111.053 179.998 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 94' ' ' ASP . . . . . 0.47 ' HB2' ' HG2' ' A' ' 97' ' ' GLU . 10.1 m-20 -78.54 174.3 11.5 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.811 179.942 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 71.4 p -61.62 -51.27 69.19 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.176 -0.466 . . . . 0.0 111.215 -179.858 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 97.8 mtt180 -65.39 -42.15 92.93 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.374 -179.66 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 97' ' ' GLU . . . . . 0.47 ' HG2' ' HB2' ' A' ' 94' ' ' ASP . 10.3 mm-40 -52.49 -50.76 62.1 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.311 -0.404 . . . . 0.0 111.163 -179.625 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 98' ' ' PHE . . . . . 0.458 ' O ' HG12 ' A' ' 102' ' ' ILE . 12.2 m-85 -56.18 -46.23 79.44 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.354 -0.385 . . . . 0.0 110.683 179.633 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -60.54 -29.67 70.09 Favored Glycine 0 N--CA 1.448 -0.505 0 C-N-CA 120.688 -0.768 . . . . 0.0 112.34 179.978 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 96.6 mt -73.87 -42.63 53.59 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.238 0 CA-C-O 120.786 0.327 . . . . 0.0 111.717 -179.853 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 39.8 t -70.61 -42.58 77.98 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 CA-C-N 116.427 -0.351 . . . . 0.0 111.519 -179.335 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 102' ' ' ILE . . . . . 0.458 HG12 ' O ' ' A' ' 98' ' ' PHE . 49.2 mm -64.92 -45.78 93.72 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.368 -0.378 . . . . 0.0 111.552 -179.548 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 13.7 t -62.22 -35.52 79.14 Favored 'General case' 0 C--O 1.233 0.211 0 CA-C-O 120.847 0.356 . . . . 0.0 110.661 179.879 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 104' ' ' LEU . . . . . 0.441 ' O ' HG23 ' A' ' 108' ' ' VAL . 29.8 tp -57.39 -53.82 53.86 Favored 'General case' 0 C--N 1.331 -0.202 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.258 179.241 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 105' ' ' ASN . . . . . 0.607 ' N ' HD22 ' A' ' 105' ' ' ASN . 0.8 OUTLIER -56.25 -36.67 68.81 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 115.952 -0.567 . . . . 0.0 110.433 179.709 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 30.6 m -54.92 -43.41 73.28 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.511 179.621 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 107' ' ' VAL . . . . . 0.454 HG12 ' SD ' ' A' ' 129' ' ' MET . 1.2 t -65.64 -39.49 85.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-O 121.274 0.559 . . . . 0.0 110.187 179.206 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 108' ' ' VAL . . . . . 0.441 HG23 ' O ' ' A' ' 104' ' ' LEU . 41.7 t -60.03 -53.16 52.4 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.38 0 CA-C-N 115.291 -0.868 . . . . 0.0 111.782 -179.728 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 109' ' ' MET . . . . . 0.449 ' HG2' ' O ' ' A' ' 105' ' ' ASN . 8.0 mmt -61.85 -41.86 98.34 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-N 116.306 -0.406 . . . . 0.0 111.257 -179.284 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 28.6 tp -60.21 -30.27 69.27 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 116.377 -0.374 . . . . 0.0 110.461 -179.906 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -66.55 -54.87 18.97 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.552 179.217 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . -60.02 -36.22 89.66 Favored Glycine 0 N--CA 1.452 -0.24 0 C-N-CA 120.497 -0.859 . . . . 0.0 111.722 179.373 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 113' ' ' PHE . . . . . . . . . . . . . 0.9 OUTLIER -56.1 -75.09 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 121.051 0.453 . . . . 0.0 110.357 179.647 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -58.44 -29.72 66.37 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 115.679 -0.691 . . . . 0.0 111.418 -179.91 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -52.3 -49.12 52.2 Favored Glycine 0 C--N 1.331 0.254 0 C-N-CA 121.075 -0.583 . . . . 0.0 112.726 -179.993 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -77.71 -16.87 58.16 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-O 120.697 0.284 . . . . 0.0 111.458 -179.976 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 117' ' ' MET . . . . . . . . . . . . . 38.3 ttm -100.95 18.08 20.57 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.352 -0.385 . . . . 0.0 111.321 -179.387 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 118' ' ' VAL . . . . . 0.479 HG21 ' HB3' ' A' ' 123' ' ' ARG . 27.1 m -70.05 148.31 96.03 Favored Pre-proline 0 C--N 1.329 -0.302 0 CA-C-N 116.451 -0.34 . . . . 0.0 111.15 179.794 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 119' ' ' PRO . . . . . . . . . . . . . 90.6 Cg_endo -83.7 -3.77 10.63 Favored 'Trans proline' 0 C--N 1.348 0.52 0 C-N-CA 122.567 2.178 . . . . 0.0 112.136 179.719 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -156.25 -141.51 3.21 Favored Glycine 0 N--CA 1.453 -0.229 0 C-N-CA 120.926 -0.654 . . . . 0.0 112.452 -179.981 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 41.0 pt -84.71 18.87 0.37 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.229 0 CA-C-O 120.845 0.355 . . . . 0.0 111.062 -179.99 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 122' ' ' GLU . . . . . 0.459 ' HB2' ' HB ' ' A' ' 118' ' ' VAL . 12.3 mm-40 -67.52 -18.01 64.88 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.0 -0.545 . . . . 0.0 111.36 -179.926 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 123' ' ' ARG . . . . . 0.479 ' HB3' HG21 ' A' ' 118' ' ' VAL . 0.0 OUTLIER -51.11 -30.2 15.56 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-N 116.424 -0.353 . . . . 0.0 111.457 -179.532 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 124' ' ' TYR . . . . . . . . . . . . . 34.6 m-85 -70.23 -32.52 70.42 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-O 120.735 0.302 . . . . 0.0 111.202 -179.717 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 125' ' ' ALA . . . . . . . . . . . . . . . -67.88 -52.2 39.33 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.268 -0.423 . . . . 0.0 110.887 179.88 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 126' ' ' LEU . . . . . 0.402 HD13 ' HA ' ' A' ' 126' ' ' LEU . 3.2 mm? -53.24 -54.44 36.07 Favored 'General case' 0 CA--C 1.521 -0.168 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.581 179.69 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 127' ' ' PHE . . . . . 0.481 ' HZ ' ' HB3' ' A' ' 175' ' ' PRO . 9.4 t80 -62.33 -35.74 80.03 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.082 -179.63 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 128' ' ' GLY . . . . . . . . . . . . . . . -47.23 -48.1 20.76 Favored Glycine 0 C--N 1.332 0.314 0 C-N-CA 119.925 -1.131 . . . . 0.0 110.287 178.718 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 129' ' ' MET . . . . . 0.454 ' SD ' HG12 ' A' ' 107' ' ' VAL . 0.4 OUTLIER -71.21 -31.41 67.55 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 115.019 -0.591 . . . . 0.0 109.697 178.379 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -60.96 -41.09 99.25 Favored Glycine 0 C--N 1.332 0.359 0 CA-C-N 115.821 -0.627 . . . . 0.0 112.753 -179.864 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -71.28 -51.92 21.75 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.644 0.259 . . . . 0.0 110.518 179.807 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 57.4 t -55.04 -39.95 52.19 Favored 'Isoleucine or valine' 0 C--O 1.233 0.226 0 CA-C-O 121.3 0.571 . . . . 0.0 109.694 178.95 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -70.77 -37.35 73.36 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 115.407 -0.815 . . . . 0.0 110.658 179.602 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 134' ' ' PHE . . . . . . . . . . . . . 43.6 t80 -56.62 -53.35 58.64 Favored 'General case' 0 N--CA 1.451 -0.386 0 CA-C-O 120.995 0.426 . . . . 0.0 109.984 179.567 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 135' ' ' ILE . . . . . . . . . . . . . 48.4 mt -58.02 -33.48 46.46 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.405 0 CA-C-N 115.787 -0.642 . . . . 0.0 109.838 179.227 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . -58.82 -40.73 95.47 Favored Glycine 0 N--CA 1.448 -0.53 0 C-N-CA 120.394 -0.908 . . . . 0.0 111.473 178.905 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 137' ' ' LEU . . . . . 0.416 HD13 HD21 ' A' ' 105' ' ' ASN . 53.5 tp -69.73 -45.04 69.05 Favored 'General case' 0 N--CA 1.455 -0.193 0 CA-C-O 120.693 0.282 . . . . 0.0 110.588 179.411 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 138' ' ' VAL . . . . . . . . . . . . . 98.8 t -56.05 -40.99 66.9 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.9 0 CA-C-O 121.222 0.534 . . . . 0.0 109.896 179.231 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 139' ' ' TYR . . . . . . . . . . . . . 29.4 t80 -59.05 -47.14 86.31 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 115.416 -0.811 . . . . 0.0 110.612 178.937 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 22.9 m-85 -54.52 -37.77 65.74 Favored 'General case' 0 C--N 1.332 -0.16 0 CA-C-N 116.39 -0.368 . . . . 0.0 110.911 179.942 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 141' ' ' LEU . . . . . 0.491 HD23 ' SD ' ' A' ' 145' ' ' MET . 79.8 mt -60.89 -50.7 72.37 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-O 120.905 0.383 . . . . 0.0 110.366 179.502 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 22.0 t -70.52 -15.21 18.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.034 -0.53 . . . . 0.0 110.723 179.531 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . -70.37 -140.24 0.16 Allowed Glycine 0 CA--C 1.521 0.461 0 C-N-CA 121.015 -0.612 . . . . 0.0 112.842 -179.88 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 144' ' ' PRO . . . . . . . . . . . . . 42.0 Cg_exo -56.64 -23.69 50.35 Favored 'Trans proline' 0 C--N 1.35 0.639 0 C-N-CA 122.641 2.227 . . . . 0.0 112.63 -179.794 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 145' ' ' MET . . . . . 0.491 ' SD ' HD23 ' A' ' 141' ' ' LEU . 54.5 mtt -57.93 -31.65 67.01 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.391 -0.368 . . . . 0.0 111.429 -179.867 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 146' ' ' THR . . . . . . . . . . . . . 25.0 m -74.11 -48.34 30.24 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.278 -0.419 . . . . 0.0 112.05 -179.061 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 45.1 mt-10 -72.92 -29.02 62.81 Favored 'General case' 0 C--N 1.329 -0.302 0 N-CA-C 111.762 0.282 . . . . 0.0 111.762 -179.157 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 148' ' ' SER . . . . . 0.408 ' HB3' ' HB1' ' A' ' 91' ' ' ALA . 46.8 t -70.76 -47.81 57.68 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.519 -0.31 . . . . 0.0 111.497 -179.179 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 149' ' ' ALA . . . . . 0.588 ' HB2' ' HB2' ' A' ' 91' ' ' ALA . . . -73.54 -43.23 60.44 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.378 -0.374 . . . . 0.0 111.865 -179.259 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 150' ' ' SER . . . . . 0.493 ' HA ' ' HB3' ' A' ' 157' ' ' LYS . 42.8 t -65.51 -8.4 19.34 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.457 -0.338 . . . . 0.0 111.286 -179.613 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 151' ' ' GLN . . . . . . . . . . . . . 46.2 mt-30 -124.89 15.73 8.59 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.454 -0.339 . . . . 0.0 111.161 179.999 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 31.3 tpt180 -90.79 -52.02 5.08 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 121.093 0.473 . . . . 0.0 110.275 179.646 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 153' ' ' SER . . . . . 0.613 ' HB2' HG12 ' A' ' 156' ' ' ILE . 24.6 m -158.02 172.69 17.98 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 115.719 -0.673 . . . . 0.0 110.473 179.228 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 154' ' ' SER . . . . . . . . . . . . . 78.3 p -70.55 -38.69 74.19 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.335 -0.393 . . . . 0.0 110.482 179.438 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -77.87 -38.01 28.22 Favored Glycine 0 N--CA 1.452 -0.265 0 C-N-CA 121.04 -0.6 . . . . 0.0 112.845 179.781 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 156' ' ' ILE . . . . . 0.613 HG12 ' HB2' ' A' ' 153' ' ' SER . 39.0 mm -53.4 -44.48 55.08 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.202 0 N-CA-C 111.917 0.34 . . . . 0.0 111.917 -179.204 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 157' ' ' LYS . . . . . 0.493 ' HB3' ' HA ' ' A' ' 150' ' ' SER . 18.9 ptpt -65.78 -30.88 71.59 Favored 'General case' 0 C--N 1.329 -0.288 0 N-CA-C 111.714 0.264 . . . . 0.0 111.714 -179.225 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 47.8 t -71.7 -48.37 47.76 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 121.076 0.465 . . . . 0.0 111.077 -179.539 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 159' ' ' LEU . . . . . 0.482 ' O ' ' HB2' ' A' ' 163' ' ' LEU . 8.4 mp -71.53 -29.81 65.19 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 115.875 -0.602 . . . . 0.0 111.313 -179.785 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 160' ' ' TYR . . . . . . . . . . . . . 92.8 t80 -70.73 -44.84 65.99 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.397 -0.365 . . . . 0.0 111.739 -179.402 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 161' ' ' VAL . . . . . 0.421 HG13 ' O ' ' A' ' 157' ' ' LYS . 28.6 m -66.05 -42.34 91.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 N-CA-C 111.624 0.231 . . . . 0.0 111.624 -179.365 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 162' ' ' ARG . . . . . . . . . . . . . 95.7 mtt180 -67.99 -44.71 75.99 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.796 0.331 . . . . 0.0 111.497 -179.808 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 163' ' ' LEU . . . . . 0.482 ' HB2' ' O ' ' A' ' 159' ' ' LEU . 4.5 mp -71.55 -54.16 11.41 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.264 -0.426 . . . . 0.0 112.039 -179.19 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 164' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -53.05 -41.64 65.01 Favored 'General case' 0 C--N 1.328 -0.353 0 N-CA-C 111.957 0.354 . . . . 0.0 111.957 -178.783 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 165' ' ' ASN . . . . . 0.505 ' O ' HG23 ' A' ' 169' ' ' VAL . 4.8 m-20 -67.03 -52.31 43.93 Favored 'General case' 0 C--N 1.329 -0.318 0 N-CA-C 112.013 0.375 . . . . 0.0 112.013 -179.114 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 166' ' ' LEU . . . . . 0.46 HD21 ' CE1' ' A' ' 208' ' ' PHE . 0.0 OUTLIER -67.45 -33.13 74.5 Favored 'General case' 0 C--N 1.329 -0.288 0 N-CA-C 111.643 0.238 . . . . 0.0 111.643 -178.871 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 167' ' ' THR . . . . . 0.451 ' O ' ' HB2' ' A' ' 171' ' ' TRP . 27.5 m -63.04 -53.83 47.72 Favored 'General case' 0 C--N 1.332 -0.195 0 N-CA-C 111.939 0.348 . . . . 0.0 111.939 -179.976 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 168' ' ' VAL . . . . . 0.426 HG12 ' O ' ' A' ' 165' ' ' ASN . 9.9 p -59.28 -40.07 80.41 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.242 0 CA-C-N 116.486 -0.325 . . . . 0.0 111.541 -178.924 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 169' ' ' VAL . . . . . 0.505 HG23 ' O ' ' A' ' 165' ' ' ASN . 74.0 t -57.14 -65.38 0.41 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.563 -0.29 . . . . 0.0 111.45 -179.767 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 170' ' ' LEU . . . . . 0.433 ' HG ' ' O ' ' A' ' 166' ' ' LEU . 2.7 pp -63.09 -29.78 71.08 Favored 'General case' 0 C--N 1.331 -0.228 0 N-CA-C 111.908 0.336 . . . . 0.0 111.908 -179.085 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 171' ' ' TRP . . . . . 0.77 ' HE1' H203 ' A' ' 301' ' ' RET . 2.5 m0 -72.51 -31.47 65.37 Favored 'General case' 0 C--N 1.331 -0.21 0 C-N-CA 120.797 -0.361 . . . . 0.0 110.761 179.612 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 172' ' ' ALA . . . . . . . . . . . . . . . -72.94 -6.24 43.92 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-O 121.055 0.455 . . . . 0.0 110.367 179.439 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 173' ' ' ILE . . . . . 0.61 HG22 HD11 ' A' ' 177' ' ' ILE . 37.2 mm -82.89 -25.99 8.19 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.206 0 CA-C-N 115.771 -0.649 . . . . 0.0 110.999 179.791 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 174' ' ' TYR . . . . . 0.489 ' HB2' ' HD3' ' A' ' 175' ' ' PRO . 49.9 m-85 -54.55 -50.7 83.95 Favored Pre-proline 0 N--CA 1.464 0.272 0 CA-C-N 116.353 -0.385 . . . . 0.0 111.671 -179.665 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 175' ' ' PRO . . . . . 0.489 ' HD3' ' HB2' ' A' ' 174' ' ' TYR . 97.2 Cg_exo -45.19 -30.29 4.96 Favored 'Trans proline' 0 C--N 1.35 0.647 0 C-N-CA 122.186 1.924 . . . . 0.0 112.403 179.65 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 176' ' ' PHE . . . . . 0.459 ' O ' ' HG ' ' A' ' 180' ' ' LEU . 65.8 m-85 -80.57 -49.67 11.01 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 115.979 -0.555 . . . . 0.0 111.989 -179.729 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 177' ' ' ILE . . . . . 0.61 HD11 HG22 ' A' ' 173' ' ' ILE . 2.3 mm -61.59 -37.37 77.74 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.53 0 N-CA-C 112.723 0.638 . . . . 0.0 112.723 -177.693 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 178' ' ' TRP . . . . . . . . . . . . . 63.0 t90 -72.55 -44.9 61.48 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 120.875 0.369 . . . . 0.0 110.823 179.7 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 179' ' ' LEU . . . . . 0.492 ' O ' HG22 ' A' ' 185' ' ' VAL . 2.5 tm? -67.15 -49.25 65.43 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 115.907 -0.588 . . . . 0.0 111.72 -179.0 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 180' ' ' LEU . . . . . 0.549 HD22 HD11 ' A' ' 187' ' ' LEU . 23.1 mt -77.24 -45.28 26.98 Favored 'General case' 0 C--N 1.326 -0.424 0 N-CA-C 111.982 0.364 . . . . 0.0 111.982 -178.796 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . -57.32 178.91 0.88 Allowed Glycine 0 C--N 1.334 0.47 0 C-N-CA 120.438 -0.887 . . . . 0.0 112.82 -179.878 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 182' ' ' PRO . . . . . 0.609 ' HA ' ' HB2' ' A' ' 186' ' ' ALA . 71.5 Cg_exo -47.78 -46.06 22.41 Favored 'Trans proline' 0 CA--C 1.537 0.67 0 C-N-CA 123.0 2.466 . . . . 0.0 114.177 -179.709 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 183' ' ' PRO . . . . . 0.578 ' HD2' ' N ' ' A' ' 182' ' ' PRO . 16.9 Cg_endo -57.53 -9.92 6.05 Favored 'Trans proline' 0 C--N 1.355 0.885 0 C-N-CA 122.02 1.813 . . . . 0.0 113.246 -179.409 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 184' ' ' GLY . . . . . 0.434 ' HA3' ' O ' ' A' ' 179' ' ' LEU . . . -116.23 -86.8 1.3 Allowed Glycine 0 N--CA 1.45 -0.379 0 C-N-CA 120.536 -0.84 . . . . 0.0 112.722 179.781 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 185' ' ' VAL . . . . . 0.492 HG22 ' O ' ' A' ' 179' ' ' LEU . 9.0 m -123.47 -4.1 7.18 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.246 0 CA-C-O 120.781 0.324 . . . . 0.0 111.544 -179.817 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 186' ' ' ALA . . . . . 0.609 ' HB2' ' HA ' ' A' ' 182' ' ' PRO . . . 54.56 84.83 0.06 Allowed 'General case' 0 N--CA 1.463 0.195 0 CA-C-N 116.113 -0.494 . . . . 0.0 111.828 179.557 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 187' ' ' LEU . . . . . 0.549 HD11 HD22 ' A' ' 180' ' ' LEU . 14.8 mt -92.1 -48.72 6.58 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-O 120.973 0.416 . . . . 0.0 110.906 179.509 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 188' ' ' LEU . . . . . . . . . . . . . 89.7 mt -96.82 -152.91 0.4 Allowed 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 115.883 -0.599 . . . . 0.0 111.014 -179.575 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 189' ' ' THR . . . . . 0.413 ' HB ' HG23 ' A' ' 192' ' ' VAL . 86.5 m -96.37 136.25 22.04 Favored Pre-proline 0 C--N 1.33 -0.261 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.712 -179.71 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 190' ' ' PRO . . . . . . . . . . . . . 88.7 Cg_exo -46.48 -43.07 22.75 Favored 'Trans proline' 0 C--N 1.349 0.585 0 C-N-CA 122.459 2.106 . . . . 0.0 112.855 -179.825 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 191' ' ' THR . . . . . . . . . . . . . 82.0 p -65.41 -38.64 90.57 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.376 -0.375 . . . . 0.0 111.731 -179.601 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 192' ' ' VAL . . . . . 0.413 HG23 ' HB ' ' A' ' 189' ' ' THR . 58.1 t -71.78 -53.71 19.44 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.394 -0.366 . . . . 0.0 111.415 -179.628 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 193' ' ' ASP . . . . . . . . . . . . . 26.5 t70 -54.19 -47.97 71.48 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.244 -0.435 . . . . 0.0 111.049 -179.867 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 194' ' ' VAL . . . . . 0.493 ' O ' HG22 ' A' ' 198' ' ' VAL . 46.7 t -60.13 -40.18 82.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.281 -0.418 . . . . 0.0 110.674 179.769 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 195' ' ' ALA . . . . . 0.412 ' HA ' HD12 ' A' ' 7' ' ' LEU . . . -52.86 -44.64 66.97 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.928 179.756 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 196' ' ' LEU . . . . . . . . . . . . . 94.5 mt -68.42 -36.19 78.71 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.096 179.711 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 197' ' ' ILE . . . . . 0.454 HD11 ' HB ' ' A' ' 177' ' ' ILE . 12.4 mm -61.31 -59.83 3.66 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.203 179.911 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 198' ' ' VAL . . . . . 0.493 HG22 ' O ' ' A' ' 194' ' ' VAL . 2.8 m -54.08 -35.36 28.79 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.47 0 CA-C-O 121.669 0.747 . . . . 0.0 109.523 179.307 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 199' ' ' TYR . . . . . . . . . . . . . 74.9 t80 -64.59 -41.6 96.14 Favored 'General case' 0 C--N 1.321 -0.658 0 CA-C-N 114.454 -1.248 . . . . 0.0 110.482 179.577 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 200' ' ' LEU . . . . . 0.419 ' HB3' ' CZ ' ' A' ' 174' ' ' TYR . 23.2 mt -59.04 -46.55 87.94 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 115.747 -0.66 . . . . 0.0 111.08 -179.885 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 201' ' ' ASP . . . . . . . . . . . . . 8.6 m-20 -69.95 -33.52 72.22 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 121.089 0.471 . . . . 0.0 110.426 179.709 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 202' ' ' LEU . . . . . . . . . . . . . 1.2 tt -66.54 -33.53 75.88 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 115.604 -0.725 . . . . 0.0 110.738 -179.93 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 203' ' ' VAL . . . . . 0.448 ' O ' ' HA3' ' A' ' 207' ' ' GLY . 42.3 t -76.66 -36.94 28.2 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 115.88 -0.6 . . . . 0.0 111.552 -179.007 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 204' ' ' THR . . . . . 0.473 HG23 ' CE2' ' A' ' 208' ' ' PHE . 36.5 m -64.58 -56.12 16.01 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-O 120.894 0.378 . . . . 0.0 111.679 -179.869 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 205' ' ' LYS . . . . . 0.736 ' HE2' ' HB2' ' A' ' 47' ' ' ALA . 48.9 mttp -69.03 -58.62 3.85 Favored 'General case' 0 C--N 1.326 -0.421 0 N-CA-C 112.576 0.584 . . . . 0.0 112.576 -178.351 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 48.9 t -71.57 -38.12 66.32 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 N-CA-C 112.064 0.394 . . . . 0.0 112.064 -178.515 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 207' ' ' GLY . . . . . 0.496 ' O ' HG12 ' A' ' 211' ' ' ILE . . . -63.38 -59.62 8.63 Favored Glycine 0 N--CA 1.453 -0.23 0 C-N-CA 120.579 -0.819 . . . . 0.0 112.86 -179.319 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 208' ' ' PHE . . . . . 0.509 ' O ' ' N ' ' A' ' 212' ' ' ALA . 1.8 m-30 -54.88 -47.91 73.67 Favored 'General case' 0 C--O 1.221 -0.405 0 N-CA-C 110.18 -0.304 . . . . 0.0 110.18 -179.633 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 209' ' ' GLY . . . . . 0.491 ' HA2' ' HB3' ' A' ' 212' ' ' ALA . . . -53.46 -32.36 45.27 Favored Glycine 0 N--CA 1.45 -0.432 0 CA-C-N 115.623 -0.717 . . . . 0.0 112.488 178.937 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 210' ' ' PHE . . . . . . . . . . . . . 3.0 m-85 -71.94 -45.96 59.24 Favored 'General case' 0 CA--C 1.516 -0.34 0 N-CA-C 108.694 -0.854 . . . . 0.0 108.694 178.769 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 211' ' ' ILE . . . . . 0.496 HG12 ' O ' ' A' ' 207' ' ' GLY . 2.4 mm -66.12 -27.5 41.0 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.51 0 N-CA-C 107.256 -1.387 . . . . 0.0 107.256 176.655 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 212' ' ' ALA . . . . . 0.509 ' N ' ' O ' ' A' ' 208' ' ' PHE . . . -68.67 -40.13 80.28 Favored 'General case' 0 N--CA 1.447 -0.582 0 CA-C-N 113.965 -1.471 . . . . 0.0 110.925 -179.34 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 213' ' ' LEU . . . . . . . . . . . . . 65.1 mt -70.26 -55.51 9.07 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 115.314 -0.857 . . . . 0.0 112.07 -179.164 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 214' ' ' ASP . . . . . . . . . . . . . 20.1 t70 -56.45 -50.56 71.33 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.859 0.361 . . . . 0.0 111.352 -179.429 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 215' ' ' ALA . . . . . . . . . . . . . . . -57.69 -55.39 35.49 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.467 -179.781 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 216' ' ' ALA . . . . . 0.475 ' HA ' HD12 ' A' ' 219' ' ' LEU . . . -60.59 -31.19 70.35 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.273 -0.421 . . . . 0.0 111.321 -179.697 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 217' ' ' ALA . . . . . . . . . . . . . . . -62.62 -35.82 80.82 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.342 -0.39 . . . . 0.0 110.264 179.609 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 218' ' ' THR . . . . . . . . . . . . . 86.7 m -75.68 -34.19 60.43 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 115.887 -0.597 . . . . 0.0 110.614 179.24 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 219' ' ' LEU . . . . . 0.475 HD12 ' HA ' ' A' ' 216' ' ' ALA . 81.9 mt -61.97 -38.18 87.58 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 116.051 -0.522 . . . . 0.0 110.686 179.672 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 220' ' ' ARG . . . . . . . . . . . . . 87.3 mtm180 -84.49 -26.81 27.89 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 115.938 -0.574 . . . . 0.0 111.021 179.773 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 221' ' ' ALA . . . . . . . . . . . . . . . -77.53 -19.8 55.19 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.121 -0.49 . . . . 0.0 112.091 -179.342 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 222' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -70.04 -12.56 61.7 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-O 120.862 0.363 . . . . 0.0 110.862 -179.339 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 223' ' ' HIS . . . . . . . . . . . . . 94.2 m-70 -75.79 -68.62 0.55 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.072 -0.513 . . . . 0.0 111.13 -179.984 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 224' ' ' GLY . . . . . . . . . . . . . . . 157.84 19.6 0.03 OUTLIER Glycine 0 C--N 1.331 0.271 0 C-N-CA 120.675 -0.774 . . . . 0.0 112.637 179.938 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 225' ' ' GLU . . . . . . . . . . . . . 29.9 mm-40 -68.12 116.72 9.06 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 120.837 0.351 . . . . 0.0 110.943 -179.966 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 226' ' ' SER . . . . . . . . . . . . . 70.1 m -115.56 143.33 45.49 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.904 179.993 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 227' ' ' LEU . . . . . 0.411 HD22 ' N ' ' A' ' 227' ' ' LEU . 3.6 mm? -101.22 -15.61 17.27 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.801 179.974 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 228' ' ' ALA . . . . . . . . . . . . . . . 52.78 26.92 4.86 Favored 'General case' 0 C--N 1.332 -0.181 0 CA-C-N 116.1 -0.5 . . . . 0.0 111.467 -179.95 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 229' ' ' GLY . . . . . . . . . . . . . . . 176.4 160.1 23.09 Favored Glycine 0 N--CA 1.453 -0.224 0 C-N-CA 120.866 -0.683 . . . . 0.0 112.45 179.916 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 230' ' ' VAL . . . . . . . . . . . . . 27.7 m -128.41 147.09 32.97 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.239 0 CA-C-O 120.871 0.367 . . . . 0.0 111.387 -179.897 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 231' ' ' ASP . . . . . . . . . . . . . 4.8 m-20 -104.8 95.75 6.1 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.086 -0.506 . . . . 0.0 110.81 179.868 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 232' ' ' THR . . . . . . . . . . . . . 79.7 p -120.95 120.55 35.8 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.122 -0.49 . . . . 0.0 111.088 -179.858 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 233' ' ' ASP . . . . . . . . . . . . . 5.0 p-10 -106.59 -47.86 3.67 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.873 -179.996 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 234' ' ' THR . . . . . . . . . . . . . 80.5 p -129.28 151.24 77.47 Favored Pre-proline 0 C--N 1.329 -0.293 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.969 179.866 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 235' ' ' PRO . . . . . . . . . . . . . 46.9 Cg_exo -56.02 133.93 61.02 Favored 'Trans proline' 0 C--N 1.347 0.494 0 C-N-CA 122.496 2.131 . . . . 0.0 112.363 -179.885 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 236' ' ' ALA . . . . . . . . . . . . . . . -78.55 121.07 24.14 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.029 -0.532 . . . . 0.0 111.028 179.918 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 237' ' ' VAL . . . . . . . . . . . . . 13.0 p -82.95 149.86 4.46 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.988 -179.893 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 238' ' ' ALA . . . . . . . . . . . . . . . -117.16 -56.15 2.27 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.077 179.995 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 239' ' ' ASP . . . . . . . . . . . . . 4.0 p30 -109.24 129.94 55.5 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.953 -179.942 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 240' ' ' LEU . . . . . . . . . . . . . 1.1 tm? -86.83 115.98 24.61 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.522 -179.944 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 241' ' ' GLU . . . . . . . . . . . . . 15.5 mm-40 -118.36 150.7 39.07 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.134 -0.484 . . . . 0.0 110.877 179.917 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 242' ' ' HIS . . . . . . . . . . . . . 24.6 p-80 -85.88 173.04 10.27 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.887 -179.974 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 243' ' ' HIS . . . . . . . . . . . . . 29.0 t-80 -84.63 138.48 32.67 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.895 -179.855 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 244' ' ' HIS . . . . . . . . . . . . . 99.4 m-70 -100.72 165.99 11.1 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.198 -0.456 . . . . 0.0 111.076 -179.91 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 245' ' ' HIS . . . . . . . . . . . . . 58.4 m80 -77.23 106.4 8.94 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.894 179.849 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 246' ' ' HIS . . . . . . . . . . . . . 68.3 m80 -105.15 156.0 18.5 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.01 -0.541 . . . . 0.0 110.861 179.944 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 247' ' ' HIS . . . . . . . . . . . . . 50.9 t-80 . . . . . 0 C--O 1.249 1.05 0 CA-C-O 118.334 -0.841 . . . . 0.0 110.844 -179.952 . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 301' ' ' RET . . . . . 0.77 H203 ' HE1' ' A' ' 171' ' ' TRP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 1' ' ' MET . . . . . 0.483 ' HG2' ' N ' ' A' ' 2' ' ' VAL . 0.0 OUTLIER . . . . . 0 N--CA 1.486 1.348 0 CA-C-O 120.818 0.342 . . . . 0.0 111.213 . . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 2' ' ' VAL . . . . . 0.483 ' N ' ' HG2' ' A' ' 1' ' ' MET . 8.8 p -154.2 17.16 0.05 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-O 121.02 0.438 . . . . 0.0 110.871 -179.888 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -155.41 -53.8 0.01 OUTLIER Glycine 0 C--N 1.332 0.331 0 C-N-CA 120.705 -0.759 . . . . 0.0 112.605 -179.76 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 94.5 mt -56.72 -35.55 68.67 Favored 'General case' 0 N--CA 1.449 -0.514 0 CA-C-O 120.868 0.366 . . . . 0.0 111.242 -179.859 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 42.9 p -63.4 -39.01 93.34 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.08 -0.509 . . . . 0.0 111.774 -179.414 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 18.7 p -52.84 -35.33 57.22 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-N 116.484 -0.325 . . . . 0.0 111.538 -179.442 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 7' ' ' LEU . . . . . . . . . . . . . 3.8 mm? -60.62 -53.13 61.13 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.37 -0.377 . . . . 0.0 111.245 -179.755 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 8' ' ' PHE . . . . . 0.559 ' HB2' ' HB2' ' A' ' 55' ' ' ALA . 64.4 m-85 -61.67 -30.84 70.99 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.304 -0.407 . . . . 0.0 111.014 -179.726 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 9' ' ' TRP . . . . . 0.474 ' O ' HG12 ' A' ' 13' ' ' ILE . 34.9 m95 -66.79 -43.3 84.31 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 116.226 -0.443 . . . . 0.0 109.966 179.939 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 87.5 mt -65.51 -49.02 70.54 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 115.615 -0.721 . . . . 0.0 110.526 179.638 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 11' ' ' GLY . . . . . 0.4 ' O ' HD21 ' A' ' 202' ' ' LEU . . . -58.47 -32.22 68.19 Favored Glycine 0 N--CA 1.449 -0.475 0 C-N-CA 120.559 -0.829 . . . . 0.0 111.677 179.3 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -68.69 -35.43 77.18 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 120.842 0.353 . . . . 0.0 110.615 179.453 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 13' ' ' ILE . . . . . 0.474 HG12 ' O ' ' A' ' 9' ' ' TRP . 46.8 mm -64.73 -53.98 35.59 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.205 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.609 179.566 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -60.71 -32.83 80.2 Favored Glycine 0 N--CA 1.45 -0.432 0 C-N-CA 120.718 -0.753 . . . . 0.0 111.7 179.477 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 15' ' ' MET . . . . . 0.591 ' SD ' ' HA ' ' A' ' 44' ' ' SER . 54.0 tpp -64.33 -50.98 65.66 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.792 0.33 . . . . 0.0 110.619 179.896 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -52.77 -40.58 63.3 Favored 'General case' 0 C--N 1.332 -0.192 0 CA-C-N 116.021 -0.536 . . . . 0.0 110.355 179.538 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 97.6 t -59.94 -42.86 90.86 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.219 0 CA-C-N 116.034 -0.53 . . . . 0.0 110.541 179.534 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -66.12 -43.39 93.35 Favored Glycine 0 N--CA 1.452 -0.272 0 C-N-CA 120.771 -0.728 . . . . 0.0 111.74 179.067 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 17.8 m -50.28 -46.56 55.22 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 115.556 -0.322 . . . . 0.0 111.48 -179.762 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 86.0 mt -71.76 -39.85 69.71 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.316 -0.402 . . . . 0.0 111.772 -179.74 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -61.64 -31.52 71.63 Favored 'General case' 0 C--N 1.33 -0.272 0 N-CA-C 111.987 0.366 . . . . 0.0 111.987 -179.219 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 4.9 m-85 -90.75 -33.34 15.78 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-O 120.731 0.301 . . . . 0.0 111.421 -179.599 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -69.3 -50.0 50.71 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.973 0.416 . . . . 0.0 111.19 -179.824 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 24' ' ' TRP . . . . . . . . . . . . . 2.4 t-105 -61.57 -47.54 85.06 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 115.805 -0.634 . . . . 0.0 111.169 -179.842 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -75.12 -19.44 59.91 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-O 120.782 0.325 . . . . 0.0 110.692 179.715 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -73.44 -45.77 28.45 Favored Glycine 0 N--CA 1.453 -0.22 0 C-N-CA 120.932 -0.651 . . . . 0.0 112.497 179.806 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 99.4 mtt180 -59.96 -26.41 65.98 Favored 'General case' 0 C--N 1.33 -0.239 0 CA-C-O 120.843 0.354 . . . . 0.0 111.038 -179.91 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 17.8 t70 -106.81 99.28 8.86 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.775 179.873 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -163.36 -167.91 1.57 Allowed 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.043 -179.772 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -89.64 -133.54 5.07 Favored Glycine 0 N--CA 1.45 -0.415 0 C-N-CA 120.751 -0.738 . . . . 0.0 112.445 179.94 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 32.0 t -127.0 125.84 42.14 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.822 0.344 . . . . 0.0 110.982 -179.932 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 106.1 -24.83 25.45 Favored Glycine 0 C--N 1.331 0.255 0 C-N-CA 120.78 -0.724 . . . . 0.0 112.781 179.553 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 33.3 mm-40 -87.28 -20.93 26.13 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.811 0.339 . . . . 0.0 111.015 -179.85 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 34' ' ' ARG . . . . . . . . . . . . . 42.3 ttm180 -53.12 -31.96 44.94 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.596 -179.546 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 15.3 tpp180 -61.64 -44.47 96.92 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 120.836 0.351 . . . . 0.0 110.874 -179.908 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 54.9 m-85 -68.69 -31.04 69.86 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.91 179.978 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 37' ' ' TYR . . . . . 0.423 ' O ' HG23 ' A' ' 41' ' ' VAL . 44.2 m-85 -70.43 -53.6 15.81 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.219 -179.897 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 71.2 t -56.8 -36.4 49.38 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.194 0 CA-C-O 121.008 0.432 . . . . 0.0 110.265 179.615 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 24.0 m -63.89 -47.92 78.71 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 115.673 -0.694 . . . . 0.0 110.296 179.213 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 40' ' ' LEU . . . . . 0.639 HD12 HD12 ' A' ' 43' ' ' ILE . 45.5 tp -58.46 -47.79 82.88 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 115.678 -0.692 . . . . 0.0 110.153 179.493 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 41' ' ' VAL . . . . . 0.423 HG23 ' O ' ' A' ' 37' ' ' TYR . 57.6 t -60.33 -34.57 58.06 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.365 0 CA-C-N 115.645 -0.707 . . . . 0.0 109.804 178.906 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -59.97 -37.09 92.14 Favored Glycine 0 N--CA 1.448 -0.559 0 C-N-CA 120.784 -0.722 . . . . 0.0 111.591 179.479 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 43' ' ' ILE . . . . . 0.639 HD12 HD12 ' A' ' 40' ' ' LEU . 1.3 mt -65.26 -57.98 8.84 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.195 0 CA-C-O 120.833 0.349 . . . . 0.0 110.468 179.391 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 44' ' ' SER . . . . . 0.591 ' HA ' ' SD ' ' A' ' 15' ' ' MET . 64.7 m -57.51 -23.01 47.76 Favored 'General case' 0 C--N 1.332 -0.173 0 CA-C-N 116.037 -0.529 . . . . 0.0 111.71 -179.67 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -76.64 -59.17 3.32 Favored Glycine 0 CA--C 1.52 0.353 0 C-N-CA 120.638 -0.792 . . . . 0.0 112.912 -179.614 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 21.6 pt -58.42 -35.89 56.27 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.239 0 CA-C-O 120.91 0.386 . . . . 0.0 111.263 -179.796 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 47' ' ' ALA . . . . . 0.671 ' HB2' ' HE2' ' A' ' 205' ' ' LYS . . . -67.42 -45.77 75.13 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.309 179.626 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -54.42 -44.77 72.7 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.878 -179.183 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 27.0 m -73.29 -34.2 43.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 N-CA-C 111.845 0.313 . . . . 0.0 111.845 -179.363 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -65.92 -33.95 77.01 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.869 0.366 . . . . 0.0 111.266 -179.785 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 51' ' ' TYR . . . . . 0.436 ' OH ' ' HB2' ' A' ' 201' ' ' ASP . 5.3 m-85 -72.99 -47.03 48.78 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 115.987 -0.551 . . . . 0.0 110.611 -179.943 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -58.81 -44.34 90.8 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 115.652 -0.703 . . . . 0.0 111.812 -179.562 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 53' ' ' VAL . . . . . 0.545 HG23 ' N ' ' A' ' 54' ' ' MET . 34.7 m -69.96 -51.72 37.43 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.183 0 CA-C-N 116.64 -0.254 . . . . 0.0 111.429 -179.549 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 54' ' ' MET . . . . . 0.545 ' N ' HG23 ' A' ' 53' ' ' VAL . 8.3 ttp -59.14 -29.28 67.3 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 121.064 0.459 . . . . 0.0 110.287 -179.964 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 55' ' ' ALA . . . . . 0.559 ' HB2' ' HB2' ' A' ' 8' ' ' PHE . . . -67.74 -32.2 72.65 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 115.703 -0.68 . . . . 0.0 111.329 179.698 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 96.6 mt -79.93 16.66 1.12 Allowed 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.282 -0.417 . . . . 0.0 111.102 -179.875 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 81.15 -4.93 68.82 Favored Glycine 0 N--CA 1.451 -0.365 0 C-N-CA 120.501 -0.857 . . . . 0.0 112.087 -179.656 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 58' ' ' VAL . . . . . 0.426 ' HB ' ' O ' ' A' ' 53' ' ' VAL . 77.0 t -66.25 142.34 16.89 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-O 120.799 0.333 . . . . 0.0 110.779 179.698 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 87.31 -22.28 16.66 Favored Glycine 0 N--CA 1.448 -0.558 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.529 -179.703 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 60' ' ' TRP . . . . . . . . . . . . . 13.5 m0 -60.21 99.22 0.07 Allowed 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 120.745 0.307 . . . . 0.0 110.327 179.823 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 61' ' ' VAL . . . . . 0.483 ' HA ' ' HD3' ' A' ' 62' ' ' PRO . 7.7 p -98.27 129.82 29.77 Favored Pre-proline 0 C--N 1.328 -0.328 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.412 -179.593 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 62' ' ' PRO . . . . . 0.483 ' HD3' ' HA ' ' A' ' 61' ' ' VAL . 12.1 Cg_exo -71.96 136.36 27.24 Favored 'Trans proline' 0 C--N 1.349 0.588 0 C-N-CA 122.628 2.219 . . . . 0.0 112.042 179.824 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 64.6 t -132.13 89.78 1.14 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.396 0 CA-C-N 116.054 -0.521 . . . . 0.0 110.876 -179.94 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . 58.54 -84.54 0.02 OUTLIER 'General case' 0 C--N 1.333 -0.138 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.26 -179.739 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 11.3 pt-20 -124.57 -19.9 5.26 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-O 121.104 0.478 . . . . 0.0 110.351 179.724 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 66' ' ' ARG . . . . . . . . . . . . . 59.3 mtp180 -95.39 166.03 12.08 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 115.576 -0.738 . . . . 0.0 110.676 179.814 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 54.1 m -129.2 122.32 29.5 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.996 179.862 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 15.1 t -111.17 146.27 16.4 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.368 0 CA-C-N 116.082 -0.508 . . . . 0.0 110.929 -179.972 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 69' ' ' PHE . . . . . . . . . . . . . 12.0 m-85 -101.9 112.76 25.49 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.134 -0.484 . . . . 0.0 110.177 -179.803 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 70' ' ' VAL . . . . . 0.567 HG12 ' HD3' ' A' ' 71' ' ' PRO . 0.6 OUTLIER -69.31 -33.35 3.88 Favored Pre-proline 0 CA--C 1.543 0.697 0 N-CA-C 113.089 0.774 . . . . 0.0 113.089 -179.302 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 71' ' ' PRO . . . . . 0.567 ' HD3' HG12 ' A' ' 70' ' ' VAL . 11.3 Cg_exo -69.57 -22.26 33.19 Favored 'Trans proline' 0 C--N 1.357 0.985 0 C-N-CA 121.952 1.768 . . . . 0.0 112.993 -179.073 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 72' ' ' ARG . . . . . 0.483 ' HD2' HG21 ' A' ' 197' ' ' ILE . 50.5 ttp180 -68.6 -55.04 12.88 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.902 0.382 . . . . 0.0 111.663 -179.124 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 73' ' ' TYR . . . . . . . . . . . . . 61.4 m-85 -72.14 -35.06 68.98 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.417 -0.356 . . . . 0.0 110.875 -179.483 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 74' ' ' ILE . . . . . 0.53 HG22 ' HA ' ' A' ' 71' ' ' PRO . 0.3 OUTLIER -65.87 -38.45 82.2 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.189 0 N-CA-C 109.476 -0.564 . . . . 0.0 109.476 179.01 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 17.8 t70 -60.21 -37.64 80.9 Favored 'General case' 0 N--CA 1.453 -0.278 0 N-CA-C 109.147 -0.686 . . . . 0.0 109.147 178.692 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 76' ' ' TRP . . . . . 0.452 ' HZ2' HG23 ' A' ' 197' ' ' ILE . 52.1 m0 -65.7 -34.99 79.47 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 115.681 -0.69 . . . . 0.0 110.345 179.06 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 77' ' ' ILE . . . . . 0.494 HD12 ' HA ' ' A' ' 74' ' ' ILE . 77.4 mt -66.26 -31.84 55.44 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.299 -0.409 . . . . 0.0 110.5 179.504 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 22.3 mt -91.6 -21.47 20.81 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.052 -0.522 . . . . 0.0 112.097 -179.725 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 81.5 p -102.86 -53.25 2.89 Favored 'General case' 0 N--CA 1.463 0.215 0 N-CA-C 113.536 0.939 . . . . 0.0 113.536 -177.924 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 80' ' ' THR . . . . . 0.583 ' HB ' ' HD3' ' A' ' 81' ' ' PRO . 4.9 m -48.57 -53.32 36.85 Favored Pre-proline 0 CA--C 1.53 0.21 0 N-CA-C 112.32 0.489 . . . . 0.0 112.32 -178.223 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 81' ' ' PRO . . . . . 0.583 ' HD3' ' HB ' ' A' ' 80' ' ' THR . 31.6 Cg_exo -61.29 -21.41 71.67 Favored 'Trans proline' 0 C--N 1.351 0.71 0 C-N-CA 121.722 1.615 . . . . 0.0 111.857 179.631 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 82' ' ' LEU . . . . . . . . . . . . . 17.3 tp -76.64 -36.56 57.31 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-N 116.076 -0.511 . . . . 0.0 110.677 -179.983 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 1.9 mp -68.39 -51.92 42.39 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.174 0 CA-C-O 120.803 0.335 . . . . 0.0 110.157 179.094 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 26.6 m -60.18 -31.92 49.29 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.225 0 N-CA-C 109.582 -0.525 . . . . 0.0 109.582 179.026 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 85' ' ' TYR . . . . . . . . . . . . . 74.9 t80 -66.66 -31.27 71.84 Favored 'General case' 0 N--CA 1.452 -0.33 0 CA-C-N 115.698 -0.683 . . . . 0.0 109.372 178.542 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 86' ' ' PHE . . . . . . . . . . . . . 2.0 t80 -62.65 -51.81 65.79 Favored 'General case' 0 C--O 1.231 0.103 0 CA-C-N 115.743 -0.662 . . . . 0.0 109.829 179.061 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 87' ' ' LEU . . . . . 0.405 ' N ' HD12 ' A' ' 87' ' ' LEU . 8.0 mp -63.67 -29.2 70.47 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 115.658 -0.701 . . . . 0.0 110.467 179.556 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -70.53 -28.49 71.0 Favored Glycine 0 N--CA 1.449 -0.465 0 C-N-CA 120.843 -0.694 . . . . 0.0 112.007 179.559 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 79.8 mt -75.32 -42.38 54.64 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-O 120.929 0.395 . . . . 0.0 110.605 179.474 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 72.4 mt -57.71 -32.65 67.6 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 115.887 -0.597 . . . . 0.0 110.766 179.744 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 91' ' ' ALA . . . . . 0.442 ' HB1' ' HB3' ' A' ' 148' ' ' SER . . . -88.9 -34.02 17.1 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.104 -0.498 . . . . 0.0 111.208 179.891 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 84.28 53.77 3.19 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.853 -0.689 . . . . 0.0 112.401 179.926 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 55.0 mt -59.39 162.96 4.31 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 120.897 0.38 . . . . 0.0 111.109 -179.907 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 94' ' ' ASP . . . . . . . . . . . . . 18.4 m-20 -77.17 -178.37 5.02 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.069 -0.514 . . . . 0.0 110.923 179.878 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 50.8 m -63.64 -50.98 67.19 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.083 -0.508 . . . . 0.0 111.197 -179.881 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 14.2 ptm180 -73.65 -35.63 65.29 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.308 -0.405 . . . . 0.0 111.293 -179.596 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 19.9 mm-40 -54.96 -45.68 74.97 Favored 'General case' 0 C--N 1.331 -0.197 0 CA-C-N 116.56 -0.291 . . . . 0.0 110.771 -179.977 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 98' ' ' PHE . . . . . 0.493 ' O ' HG12 ' A' ' 102' ' ' ILE . 10.6 m-85 -60.86 -36.06 78.2 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-O 120.92 0.39 . . . . 0.0 110.272 179.422 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -67.19 -27.53 73.5 Favored Glycine 0 N--CA 1.449 -0.5 0 C-N-CA 120.589 -0.815 . . . . 0.0 112.225 179.511 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 97.0 mt -73.83 -44.88 51.12 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.198 0 N-CA-C 111.855 0.317 . . . . 0.0 111.855 -179.783 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 35.3 m -69.35 -40.78 80.5 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 N-CA-C 112.256 0.465 . . . . 0.0 112.256 -178.806 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 102' ' ' ILE . . . . . 0.493 HG12 ' O ' ' A' ' 98' ' ' PHE . 46.1 mm -68.53 -48.49 71.97 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.697 -0.229 . . . . 0.0 111.456 -179.501 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 14.2 t -60.42 -33.77 72.99 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-O 120.983 0.42 . . . . 0.0 110.645 179.875 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 104' ' ' LEU . . . . . 0.485 HD22 ' HE2' ' A' ' 140' ' ' TYR . 48.4 tp -60.44 -53.56 56.08 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 115.954 -0.567 . . . . 0.0 110.428 179.578 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 105' ' ' ASN . . . . . 0.611 ' N ' HD22 ' A' ' 105' ' ' ASN . 0.8 OUTLIER -61.22 -25.19 66.88 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 115.892 -0.594 . . . . 0.0 110.835 179.845 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 28.6 m -64.31 -54.13 38.02 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.258 179.961 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 107' ' ' VAL . . . . . 0.433 HG12 ' O ' ' A' ' 104' ' ' LEU . 12.5 p -64.85 -36.11 76.84 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.245 0 CA-C-N 116.504 -0.316 . . . . 0.0 111.194 -179.962 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 108' ' ' VAL . . . . . 0.401 HG23 ' O ' ' A' ' 104' ' ' LEU . 92.6 t -64.78 -52.76 50.26 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.246 0 CA-C-O 120.84 0.352 . . . . 0.0 110.89 179.743 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 109' ' ' MET . . . . . 0.547 ' HE1' HG21 ' A' ' 80' ' ' THR . 1.9 tpp -60.06 -32.13 70.65 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.06 -0.518 . . . . 0.0 110.758 179.774 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 36.4 tp -75.21 -30.17 60.52 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 115.974 -0.557 . . . . 0.0 110.261 179.46 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -60.94 -52.4 65.18 Favored 'General case' 0 C--N 1.331 -0.199 0 CA-C-N 116.081 -0.508 . . . . 0.0 110.308 179.337 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 112' ' ' GLY . . . . . 0.681 ' HA3' ' H21' ' A' ' 301' ' ' RET . . . -70.58 -38.43 68.35 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.636 -0.792 . . . . 0.0 111.851 179.268 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 113' ' ' PHE . . . . . . . . . . . . . 1.9 t80 -53.87 -63.21 1.22 Allowed 'General case' 0 C--N 1.332 -0.194 0 CA-C-O 120.849 0.356 . . . . 0.0 110.063 179.349 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 114' ' ' ALA . . . . . 0.413 ' O ' HG13 ' A' ' 118' ' ' VAL . . . -69.62 -17.43 63.52 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.135 178.949 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 115' ' ' GLY . . . . . 0.438 ' HA2' HD22 ' A' ' 126' ' ' LEU . . . -55.48 -52.62 46.69 Favored Glycine 0 C--N 1.333 0.389 0 CA-C-N 115.871 -0.604 . . . . 0.0 112.042 179.545 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 116' ' ' ALA . . . . . 0.61 ' HB2' ' HB3' ' A' ' 183' ' ' PRO . . . -77.41 -14.69 59.65 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-O 120.763 0.316 . . . . 0.0 111.192 -179.962 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 117' ' ' MET . . . . . . . . . . . . . 23.2 mmt -87.24 6.88 30.98 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.284 -0.417 . . . . 0.0 111.947 -179.413 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 118' ' ' VAL . . . . . 0.413 HG13 ' O ' ' A' ' 114' ' ' ALA . 16.5 m -80.43 145.52 59.57 Favored Pre-proline 0 C--N 1.331 -0.206 0 CA-C-O 120.498 0.19 . . . . 0.0 111.322 -179.9 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 119' ' ' PRO . . . . . . . . . . . . . 85.9 Cg_endo -85.14 -6.59 9.33 Favored 'Trans proline' 0 C--N 1.348 0.509 0 C-N-CA 122.689 2.26 . . . . 0.0 112.099 179.51 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -133.17 -143.2 4.96 Favored Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.871 -0.68 . . . . 0.0 112.615 -179.894 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 121' ' ' ILE . . . . . 0.425 ' H ' HG13 ' A' ' 121' ' ' ILE . 2.7 pp -101.31 11.46 7.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-O 120.782 0.325 . . . . 0.0 111.308 -179.908 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 9.9 mm-40 -59.47 -19.08 45.09 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.047 179.975 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 123' ' ' ARG . . . . . 0.463 ' HB2' ' HH2' ' A' ' 178' ' ' TRP . 16.4 ptt180 -52.04 -34.55 43.74 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.037 -0.529 . . . . 0.0 111.538 -179.786 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 124' ' ' TYR . . . . . . . . . . . . . 49.6 m-85 -61.18 -33.13 72.96 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-O 120.748 0.308 . . . . 0.0 110.884 -179.956 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 125' ' ' ALA . . . . . . . . . . . . . . . -72.4 -50.58 25.47 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.278 -0.419 . . . . 0.0 110.666 179.55 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 126' ' ' LEU . . . . . 0.438 HD22 ' HA2' ' A' ' 115' ' ' GLY . 7.3 mp -54.53 -54.22 44.11 Favored 'General case' 0 C--N 1.332 -0.18 0 CA-C-N 116.018 -0.537 . . . . 0.0 110.182 179.726 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 127' ' ' PHE . . . . . 0.422 ' HE1' ' H42' ' A' ' 301' ' ' RET . 8.9 t80 -63.15 -37.08 85.79 Favored 'General case' 0 N--CA 1.451 -0.409 0 CA-C-N 115.973 -0.558 . . . . 0.0 110.784 179.724 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 128' ' ' GLY . . . . . . . . . . . . . . . -46.22 -45.0 15.48 Favored Glycine 0 C--N 1.332 0.306 0 C-N-CA 120.19 -1.005 . . . . 0.0 110.918 179.109 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 129' ' ' MET . . . . . . . . . . . . . 0.4 OUTLIER -69.82 -37.74 76.34 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 115.311 -0.444 . . . . 0.0 109.85 178.646 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -61.99 -34.25 88.29 Favored Glycine 0 C--N 1.332 0.335 0 CA-C-N 115.677 -0.692 . . . . 0.0 112.942 -179.872 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -71.41 -53.77 12.95 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.697 0.284 . . . . 0.0 110.52 179.908 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 38.4 t -56.85 -39.95 68.16 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-O 121.439 0.638 . . . . 0.0 109.38 178.899 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -66.9 -35.37 79.85 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 115.151 -0.931 . . . . 0.0 110.532 179.357 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 134' ' ' PHE . . . . . . . . . . . . . 86.4 t80 -55.37 -55.27 33.53 Favored 'General case' 0 N--CA 1.452 -0.337 0 CA-C-O 121.012 0.434 . . . . 0.0 110.019 179.428 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 135' ' ' ILE . . . . . 0.429 ' O ' HG22 ' A' ' 138' ' ' VAL . 29.6 mt -56.28 -33.95 38.84 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.295 0 CA-C-N 115.761 -0.654 . . . . 0.0 109.913 179.136 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . -61.99 -40.66 99.19 Favored Glycine 0 N--CA 1.448 -0.547 0 C-N-CA 120.299 -0.953 . . . . 0.0 111.321 178.812 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 137' ' ' LEU . . . . . 0.496 HD13 HD21 ' A' ' 105' ' ' ASN . 64.8 tp -69.33 -53.1 21.3 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-O 120.532 0.205 . . . . 0.0 111.04 179.97 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 138' ' ' VAL . . . . . 0.429 HG22 ' O ' ' A' ' 135' ' ' ILE . 4.9 m -55.43 -34.62 34.87 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.167 0 N-CA-C 109.521 -0.548 . . . . 0.0 109.521 179.775 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 139' ' ' TYR . . . . . . . . . . . . . 21.4 t80 -61.58 -40.9 96.4 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 115.454 -0.794 . . . . 0.0 110.403 178.548 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 140' ' ' TYR . . . . . 0.485 ' HE2' HD22 ' A' ' 104' ' ' LEU . 20.9 m-85 -64.89 -52.17 57.97 Favored 'General case' 0 C--N 1.332 -0.189 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.673 -179.848 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 141' ' ' LEU . . . . . 0.516 HD12 ' N ' ' A' ' 142' ' ' VAL . 3.6 pp -64.27 -18.23 64.37 Favored 'General case' 0 N--CA 1.463 0.176 0 N-CA-C 111.74 0.274 . . . . 0.0 111.74 -179.271 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 142' ' ' VAL . . . . . 0.516 ' N ' HD12 ' A' ' 141' ' ' LEU . 5.2 p -109.36 -2.77 10.23 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-O 120.898 0.38 . . . . 0.0 110.924 179.866 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . -99.81 -102.51 2.44 Favored Glycine 0 CA--C 1.522 0.503 0 C-N-CA 120.767 -0.73 . . . . 0.0 113.104 -179.849 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 144' ' ' PRO . . . . . . . . . . . . . 58.2 Cg_endo -70.15 -27.87 24.07 Favored 'Trans proline' 0 C--N 1.348 0.503 0 C-N-CA 122.628 2.219 . . . . 0.0 113.285 -179.313 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 145' ' ' MET . . . . . 0.484 ' SD ' ' HA ' ' A' ' 141' ' ' LEU . 50.7 mtt -62.68 -39.07 92.78 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.669 0.271 . . . . 0.0 111.461 -179.583 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 146' ' ' THR . . . . . . . . . . . . . 67.2 p -66.21 -43.6 86.28 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.456 -0.338 . . . . 0.0 111.448 -179.524 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 39.7 mt-10 -70.45 -33.69 71.58 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.344 -0.389 . . . . 0.0 111.268 -179.651 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 148' ' ' SER . . . . . 0.442 ' HB3' ' HB1' ' A' ' 91' ' ' ALA . 48.0 t -70.34 -44.55 67.94 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.357 -0.383 . . . . 0.0 111.464 -179.485 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 149' ' ' ALA . . . . . . . . . . . . . . . -73.74 -33.94 64.54 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.339 -0.391 . . . . 0.0 111.399 -179.699 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 150' ' ' SER . . . . . 0.445 ' HB2' ' NZ ' ' A' ' 157' ' ' LYS . 81.0 p -67.33 -5.76 15.74 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 121.007 0.432 . . . . 0.0 110.657 179.783 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 151' ' ' GLN . . . . . . . . . . . . . 74.0 mt-30 -110.3 5.28 21.55 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 115.899 -0.591 . . . . 0.0 111.336 -179.812 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 31.2 ttt180 -91.8 -52.64 4.64 Favored 'General case' 0 C--N 1.331 -0.23 0 C-N-CA 120.902 -0.319 . . . . 0.0 111.213 -179.895 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 153' ' ' SER . . . . . 0.674 ' HB3' HG12 ' A' ' 156' ' ' ILE . 20.5 t -157.67 172.44 18.52 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.444 -0.344 . . . . 0.0 111.002 179.327 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 154' ' ' SER . . . . . . . . . . . . . 72.6 p -73.41 -41.7 62.98 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.705 179.576 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -72.64 -29.59 65.37 Favored Glycine 0 N--CA 1.452 -0.288 0 C-N-CA 120.804 -0.712 . . . . 0.0 112.334 179.88 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 156' ' ' ILE . . . . . 0.674 HG12 ' HB3' ' A' ' 153' ' ' SER . 34.6 mm -58.99 -38.45 73.86 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-O 120.84 0.352 . . . . 0.0 111.066 179.862 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 157' ' ' LYS . . . . . 0.445 ' NZ ' ' HB2' ' A' ' 150' ' ' SER . 21.3 ttmm -65.06 -47.86 75.82 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.129 -0.487 . . . . 0.0 111.085 179.811 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 69.1 m -60.65 -43.3 97.74 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 115.981 -0.554 . . . . 0.0 111.69 -179.042 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 159' ' ' LEU . . . . . 0.767 ' HG ' HD11 ' A' ' 163' ' ' LEU . 3.7 tp -66.5 -58.59 4.9 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-O 120.943 0.401 . . . . 0.0 110.66 -179.861 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 160' ' ' TYR . . . . . . . . . . . . . 30.1 t80 -51.14 -36.23 39.68 Favored 'General case' 0 C--N 1.326 -0.416 0 N-CA-C 113.302 0.853 . . . . 0.0 113.302 -178.13 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 161' ' ' VAL . . . . . 0.423 HG23 ' N ' ' A' ' 162' ' ' ARG . 30.7 m -73.27 -47.04 48.25 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.373 0 N-CA-C 112.159 0.429 . . . . 0.0 112.159 -177.791 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 162' ' ' ARG . . . . . 0.423 ' N ' HG23 ' A' ' 161' ' ' VAL . 24.2 ttm180 -63.68 -41.23 98.18 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-O 120.953 0.406 . . . . 0.0 111.014 -179.701 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 163' ' ' LEU . . . . . 0.767 HD11 ' HG ' ' A' ' 159' ' ' LEU . 6.6 mt -70.38 -50.34 39.76 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 115.89 -0.595 . . . . 0.0 111.712 -179.197 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 164' ' ' ARG . . . . . 0.484 ' HG3' ' N ' ' A' ' 165' ' ' ASN . 0.4 OUTLIER -58.14 -40.96 82.69 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.517 -0.31 . . . . 0.0 110.917 -178.986 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 165' ' ' ASN . . . . . 0.484 ' N ' ' HG3' ' A' ' 164' ' ' ARG . 5.3 m-20 -58.46 -51.34 70.28 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-O 120.832 0.349 . . . . 0.0 110.295 179.545 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 166' ' ' LEU . . . . . 0.513 ' O ' ' HG ' ' A' ' 170' ' ' LEU . 2.3 tt -59.39 -54.74 43.25 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 115.93 -0.577 . . . . 0.0 111.712 -179.931 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 167' ' ' THR . . . . . 0.456 ' N ' HD23 ' A' ' 166' ' ' LEU . 52.6 m -55.08 -53.03 61.12 Favored 'General case' 0 C--N 1.33 -0.245 0 N-CA-C 112.773 0.657 . . . . 0.0 112.773 -178.398 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 168' ' ' VAL . . . . . 0.417 HG23 ' O ' ' A' ' 164' ' ' ARG . 75.4 t -53.96 -42.23 53.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 N-CA-C 112.329 0.492 . . . . 0.0 112.329 -179.004 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 169' ' ' VAL . . . . . 0.479 HG23 ' O ' ' A' ' 165' ' ' ASN . 72.7 t -60.93 -64.74 0.57 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 N-CA-C 112.124 0.416 . . . . 0.0 112.124 -179.225 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 170' ' ' LEU . . . . . 0.513 ' HG ' ' O ' ' A' ' 166' ' ' LEU . 0.4 OUTLIER -61.92 -34.12 75.49 Favored 'General case' 0 N--CA 1.465 0.276 0 N-CA-C 112.354 0.502 . . . . 0.0 112.354 -178.815 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 171' ' ' TRP . . . . . 0.69 ' HE1' H203 ' A' ' 301' ' ' RET . 6.1 m0 -68.06 -29.56 68.56 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-O 120.792 0.33 . . . . 0.0 110.634 179.629 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 172' ' ' ALA . . . . . . . . . . . . . . . -73.92 -7.12 51.14 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.759 179.781 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 173' ' ' ILE . . . . . 0.49 ' O ' HG12 ' A' ' 177' ' ' ILE . 28.8 mm -87.68 -21.46 7.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 115.839 -0.619 . . . . 0.0 110.526 179.476 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 174' ' ' TYR . . . . . 0.42 ' HD2' ' HA ' ' A' ' 171' ' ' TRP . 8.2 m-85 -53.84 -48.38 93.81 Favored Pre-proline 0 CA--C 1.528 0.105 0 CA-C-N 116.055 -0.52 . . . . 0.0 111.681 -179.567 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 175' ' ' PRO . . . . . 0.403 ' CD ' ' N ' ' A' ' 174' ' ' TYR . 83.2 Cg_exo -46.65 -32.15 11.38 Favored 'Trans proline' 0 C--N 1.351 0.667 0 C-N-CA 121.831 1.687 . . . . 0.0 111.95 179.358 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 176' ' ' PHE . . . . . 0.433 ' O ' ' HG ' ' A' ' 180' ' ' LEU . 84.3 m-85 -81.1 -49.79 10.43 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 115.697 -0.683 . . . . 0.0 111.799 179.867 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 177' ' ' ILE . . . . . 0.49 HG12 ' O ' ' A' ' 173' ' ' ILE . 8.5 mm -61.01 -38.83 80.36 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.498 0 N-CA-C 112.708 0.633 . . . . 0.0 112.708 -177.896 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 178' ' ' TRP . . . . . 0.463 ' HH2' ' HB2' ' A' ' 123' ' ' ARG . 78.5 t90 -71.58 -51.88 21.05 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.79 0.328 . . . . 0.0 111.213 -179.735 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 179' ' ' LEU . . . . . 0.55 HD23 HD23 ' A' ' 180' ' ' LEU . 0.6 OUTLIER -64.55 -55.08 22.82 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.323 -0.399 . . . . 0.0 111.601 -178.997 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 180' ' ' LEU . . . . . 0.55 HD23 HD23 ' A' ' 179' ' ' LEU . 32.4 mt -65.96 -37.64 86.52 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 116.341 -0.39 . . . . 0.0 111.345 -179.332 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . -60.53 176.15 4.25 Favored Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 119.988 -1.101 . . . . 0.0 112.33 179.589 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 182' ' ' PRO . . . . . 0.555 ' HA ' ' HB2' ' A' ' 186' ' ' ALA . 88.3 Cg_exo -46.63 -44.97 20.69 Favored 'Trans proline' 0 CA--C 1.536 0.607 0 C-N-CA 122.681 2.254 . . . . 0.0 113.402 179.912 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 183' ' ' PRO . . . . . 0.61 ' HB3' ' HB2' ' A' ' 116' ' ' ALA . 97.3 Cg_exo -45.31 -35.25 11.23 Favored 'Trans proline' 0 C--N 1.356 0.926 0 C-N-CA 122.328 2.019 . . . . 0.0 113.439 179.89 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 184' ' ' GLY . . . . . . . . . . . . . . . -110.29 -123.23 4.52 Favored Glycine 0 C--N 1.332 0.344 0 C-N-CA 120.299 -0.953 . . . . 0.0 113.204 -179.453 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 185' ' ' VAL . . . . . . . . . . . . . 8.1 m -63.04 -26.93 42.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 N-CA-C 112.16 0.43 . . . . 0.0 112.16 -179.225 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 186' ' ' ALA . . . . . 0.555 ' HB2' ' HA ' ' A' ' 182' ' ' PRO . . . 60.25 81.05 0.19 Allowed 'General case' 0 C--N 1.331 -0.207 0 N-CA-C 111.858 0.318 . . . . 0.0 111.858 179.48 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 187' ' ' LEU . . . . . . . . . . . . . 6.9 mt -92.8 -49.78 5.9 Favored 'General case' 0 C--N 1.332 -0.156 0 CA-C-O 120.995 0.426 . . . . 0.0 111.012 179.587 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 188' ' ' LEU . . . . . . . . . . . . . 95.2 mt -89.32 -166.7 1.66 Allowed 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 115.795 -0.639 . . . . 0.0 111.247 -179.48 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 189' ' ' THR . . . . . 0.429 HG22 ' H ' ' A' ' 191' ' ' THR . 74.9 m -94.08 136.13 23.95 Favored Pre-proline 0 C--N 1.328 -0.357 0 CA-C-N 115.781 -0.645 . . . . 0.0 110.626 -179.811 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 190' ' ' PRO . . . . . . . . . . . . . 2.4 Cg_endo -44.99 -38.58 13.66 Favored 'Trans proline' 0 C--N 1.35 0.61 0 C-N-CA 122.854 2.369 . . . . 0.0 112.649 -179.983 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 191' ' ' THR . . . . . 0.429 ' H ' HG22 ' A' ' 189' ' ' THR . 71.2 p -61.98 -42.95 99.7 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-O 120.965 0.412 . . . . 0.0 110.911 179.711 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 192' ' ' VAL . . . . . . . . . . . . . 88.8 t -71.29 -53.54 20.7 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 115.92 -0.582 . . . . 0.0 111.434 -179.816 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 193' ' ' ASP . . . . . . . . . . . . . 29.3 t70 -54.49 -52.01 63.28 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.242 -0.436 . . . . 0.0 111.442 -179.396 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 194' ' ' VAL . . . . . 0.531 ' O ' HG22 ' A' ' 198' ' ' VAL . 71.1 t -59.23 -38.22 73.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.371 -0.377 . . . . 0.0 110.614 -179.874 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 195' ' ' ALA . . . . . . . . . . . . . . . -55.22 -44.86 75.8 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.754 179.605 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 196' ' ' LEU . . . . . . . . . . . . . 95.6 mt -68.36 -35.86 78.35 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.934 179.461 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 197' ' ' ILE . . . . . 0.483 HG21 ' HD2' ' A' ' 72' ' ' ARG . 11.0 mm -59.49 -61.09 1.61 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.06 -0.518 . . . . 0.0 110.874 179.96 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 198' ' ' VAL . . . . . 0.531 HG22 ' O ' ' A' ' 194' ' ' VAL . 1.4 m -55.74 -35.0 37.83 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.462 0 CA-C-O 121.626 0.727 . . . . 0.0 109.191 178.772 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 199' ' ' TYR . . . . . . . . . . . . . 86.7 t80 -64.04 -32.5 74.07 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-N 114.56 -1.2 . . . . 0.0 110.415 179.336 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 200' ' ' LEU . . . . . 0.444 HD11 HG13 ' A' ' 177' ' ' ILE . 38.1 mt -71.11 -37.78 72.36 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 115.99 -0.55 . . . . 0.0 110.648 179.591 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 201' ' ' ASP . . . . . 0.436 ' HB2' ' OH ' ' A' ' 51' ' ' TYR . 7.9 m-20 -74.58 -32.98 62.55 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 115.953 -0.567 . . . . 0.0 110.161 179.63 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 202' ' ' LEU . . . . . 0.4 HD21 ' O ' ' A' ' 11' ' ' GLY . 0.5 OUTLIER -72.52 -28.45 62.87 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 115.29 -0.868 . . . . 0.0 111.623 -179.527 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 203' ' ' VAL . . . . . 0.425 HG12 ' O ' ' A' ' 200' ' ' LEU . 9.6 p -82.17 -37.78 14.99 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.18 0 N-CA-C 111.946 0.35 . . . . 0.0 111.946 -178.805 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 204' ' ' THR . . . . . . . . . . . . . 86.5 m -69.6 -41.87 75.16 Favored 'General case' 0 C--N 1.328 -0.337 0 C-N-CA 120.821 -0.352 . . . . 0.0 111.569 179.93 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 205' ' ' LYS . . . . . 0.671 ' HE2' ' HB2' ' A' ' 47' ' ' ALA . 59.7 mttp -76.52 -57.93 3.58 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.398 -0.365 . . . . 0.0 111.557 -178.872 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 60.4 t -69.47 -36.83 73.34 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.372 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.471 -179.503 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 207' ' ' GLY . . . . . . . . . . . . . . . -66.44 -52.76 32.87 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.615 -0.802 . . . . 0.0 112.43 -179.326 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 208' ' ' PHE . . . . . 0.689 ' CZ ' HD13 ' A' ' 163' ' ' LEU . 11.3 t80 -55.21 -49.86 70.87 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-O 120.748 0.309 . . . . 0.0 110.941 179.771 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 209' ' ' GLY . . . . . 0.477 ' CA ' HD21 ' A' ' 40' ' ' LEU . . . -63.64 -37.46 94.77 Favored Glycine 0 N--CA 1.451 -0.339 0 CA-C-N 115.632 -0.713 . . . . 0.0 113.985 -179.184 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 210' ' ' PHE . . . . . . . . . . . . . 0.6 OUTLIER -68.65 -46.66 68.57 Favored 'General case' 0 CA--C 1.512 -0.484 0 N-CA-C 108.217 -1.031 . . . . 0.0 108.217 179.272 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 211' ' ' ILE . . . . . . . . . . . . . 92.8 mt -64.9 -28.21 44.26 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.702 0 N-CA-C 107.694 -1.224 . . . . 0.0 107.694 176.656 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 212' ' ' ALA . . . . . 0.474 ' HB3' ' HA2' ' A' ' 209' ' ' GLY . . . -68.29 -45.71 72.33 Favored 'General case' 0 N--CA 1.449 -0.492 0 CA-C-N 114.419 -1.264 . . . . 0.0 111.087 -179.851 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 213' ' ' LEU . . . . . . . . . . . . . 92.8 mt -70.55 -55.32 9.16 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-N 115.442 -0.799 . . . . 0.0 112.415 -178.828 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 214' ' ' ASP . . . . . . . . . . . . . 31.9 m-20 -53.11 -52.1 59.76 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.713 0.292 . . . . 0.0 111.607 -179.295 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 215' ' ' ALA . . . . . 0.401 ' O ' ' HG ' ' A' ' 219' ' ' LEU . . . -62.14 -57.77 10.29 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 116.339 -0.391 . . . . 0.0 111.691 -179.438 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 216' ' ' ALA . . . . . 0.424 ' HA ' HD12 ' A' ' 219' ' ' LEU . . . -56.4 -34.85 67.11 Favored 'General case' 0 C--N 1.332 -0.188 0 CA-C-N 116.469 -0.332 . . . . 0.0 111.469 -179.537 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 217' ' ' ALA . . . . . . . . . . . . . . . -60.55 -40.7 92.55 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-O 121.048 0.452 . . . . 0.0 110.082 179.703 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 218' ' ' THR . . . . . . . . . . . . . 95.9 m -71.09 -38.5 72.4 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 115.659 -0.7 . . . . 0.0 110.71 179.331 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 219' ' ' LEU . . . . . 0.491 ' O ' ' HG2' ' A' ' 222' ' ' GLU . 87.2 mt -56.33 -43.94 79.52 Favored 'General case' 0 C--N 1.332 -0.175 0 CA-C-N 115.915 -0.584 . . . . 0.0 110.666 179.899 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 220' ' ' ARG . . . . . . . . . . . . . 7.3 ptm180 -84.45 -15.95 44.28 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.459 179.358 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 221' ' ' ALA . . . . . . . . . . . . . . . -67.84 -34.82 77.45 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 116.021 -0.536 . . . . 0.0 111.606 -179.674 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 222' ' ' GLU . . . . . 0.491 ' HG2' ' O ' ' A' ' 219' ' ' LEU . 13.1 pt-20 -67.79 -14.71 63.17 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-O 120.937 0.398 . . . . 0.0 110.541 -179.716 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 223' ' ' HIS . . . . . 0.407 ' HB3' ' HG3' ' A' ' 225' ' ' GLU . 74.0 m80 -84.49 -36.2 22.42 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 115.852 -0.613 . . . . 0.0 110.761 179.617 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 224' ' ' GLY . . . . . . . . . . . . . . . 60.28 27.83 65.99 Favored Glycine 0 N--CA 1.45 -0.384 0 C-N-CA 120.884 -0.674 . . . . 0.0 112.771 179.9 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 225' ' ' GLU . . . . . 0.407 ' HG3' ' HB3' ' A' ' 223' ' ' HIS . 41.6 mt-10 -93.38 115.08 27.64 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.741 0.305 . . . . 0.0 110.895 -179.949 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 226' ' ' SER . . . . . . . . . . . . . 79.0 p -138.14 -56.5 0.66 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.112 179.912 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 227' ' ' LEU . . . . . . . . . . . . . 82.3 mt -81.85 158.98 23.83 Favored 'General case' 0 C--N 1.332 -0.182 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.992 -179.868 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 228' ' ' ALA . . . . . . . . . . . . . . . -97.99 154.24 17.83 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.061 179.808 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 229' ' ' GLY . . . . . . . . . . . . . . . 112.25 87.31 1.67 Allowed Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.874 -0.679 . . . . 0.0 112.432 179.987 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 230' ' ' VAL . . . . . . . . . . . . . 30.9 t -98.83 127.46 51.42 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.245 0 CA-C-O 120.741 0.305 . . . . 0.0 111.043 -179.962 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 231' ' ' ASP . . . . . . . . . . . . . 18.9 t70 -96.73 132.74 42.1 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.081 179.919 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 232' ' ' THR . . . . . . . . . . . . . 8.4 t -161.95 -34.83 0.04 OUTLIER 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.297 -0.411 . . . . 0.0 111.249 -179.911 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 233' ' ' ASP . . . . . . . . . . . . . 16.6 t70 -126.88 113.34 16.43 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.273 -0.421 . . . . 0.0 111.039 -179.876 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 234' ' ' THR . . . . . . . . . . . . . 55.6 p -140.4 151.07 63.11 Favored Pre-proline 0 C--N 1.331 -0.225 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.928 179.854 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 235' ' ' PRO . . . . . . . . . . . . . 31.3 Cg_endo -64.33 117.29 4.34 Favored 'Trans proline' 0 C--N 1.348 0.526 0 C-N-CA 122.384 2.056 . . . . 0.0 112.109 179.891 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 236' ' ' ALA . . . . . . . . . . . . . . . -137.74 122.78 19.08 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.143 -0.48 . . . . 0.0 111.198 -179.915 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 237' ' ' VAL . . . . . . . . . . . . . 7.7 p -120.31 18.78 6.19 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.238 0 CA-C-O 121.259 0.552 . . . . 0.0 110.764 179.826 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 238' ' ' ALA . . . . . . . . . . . . . . . -88.14 -4.44 58.75 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 115.858 -0.61 . . . . 0.0 110.926 179.976 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 239' ' ' ASP . . . . . . . . . . . . . 19.7 t70 58.24 91.69 0.04 OUTLIER 'General case' 0 C--N 1.332 -0.187 0 CA-C-N 115.9 -0.591 . . . . 0.0 111.002 179.904 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 240' ' ' LEU . . . . . 0.44 ' H ' ' H ' ' A' ' 241' ' ' GLU . 2.7 pt? -160.95 -12.99 0.05 OUTLIER 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.069 -0.514 . . . . 0.0 110.694 179.861 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 241' ' ' GLU . . . . . 0.44 ' H ' ' H ' ' A' ' 240' ' ' LEU . 12.1 pt-20 -70.28 -15.77 62.94 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-N 116.037 -0.528 . . . . 0.0 110.719 179.801 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 242' ' ' HIS . . . . . . . . . . . . . 66.6 t60 -67.86 -47.59 68.49 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.97 -179.988 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 243' ' ' HIS . . . . . . . . . . . . . 66.5 m80 -57.87 142.18 46.79 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.141 -179.853 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 244' ' ' HIS . . . . . . . . . . . . . 23.4 t-80 -106.67 -38.42 6.13 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.035 -0.529 . . . . 0.0 110.707 179.926 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 245' ' ' HIS . . . . . . . . . . . . . 65.9 m80 -68.96 163.8 23.7 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.691 179.785 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 246' ' ' HIS . . . . . . . . . . . . . 8.3 p80 -96.78 176.69 5.9 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.941 179.898 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 247' ' ' HIS . . . . . . . . . . . . . 8.4 m80 . . . . . 0 C--O 1.248 1.013 0 CA-C-O 118.282 -0.865 . . . . 0.0 110.88 -179.959 . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 301' ' ' RET . . . . . 0.69 H203 ' HE1' ' A' ' 171' ' ' TRP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 1' ' ' MET . . . . . 0.57 ' HE1' ' H ' ' A' ' 4' ' ' LEU . 14.0 tmm? . . . . . 0 N--CA 1.485 1.311 0 CA-C-O 120.69 0.281 . . . . 0.0 110.617 . . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 62.5 t 58.75 101.65 0.04 OUTLIER 'Isoleucine or valine' 0 C--N 1.333 -0.146 0 CA-C-N 116.122 -0.49 . . . . 0.0 111.37 179.82 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . 178.89 -27.58 0.06 OUTLIER Glycine 0 N--CA 1.45 -0.368 0 C-N-CA 120.786 -0.721 . . . . 0.0 112.582 179.938 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 4' ' ' LEU . . . . . 0.57 ' H ' ' HE1' ' A' ' 1' ' ' MET . 92.7 mt -74.04 -35.25 64.3 Favored 'General case' 0 N--CA 1.449 -0.508 0 CA-C-O 120.858 0.361 . . . . 0.0 110.94 179.88 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 55.1 p -54.44 -38.84 66.76 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 115.928 -0.578 . . . . 0.0 111.718 -179.587 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 72.0 p -54.81 -35.52 63.98 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.451 -0.34 . . . . 0.0 111.619 -179.578 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 7' ' ' LEU . . . . . 0.443 HD23 ' HA ' ' A' ' 4' ' ' LEU . 3.9 mm? -60.14 -53.29 59.45 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.317 -0.401 . . . . 0.0 111.272 -179.748 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 8' ' ' PHE . . . . . 0.604 ' HB2' ' HB2' ' A' ' 55' ' ' ALA . 75.8 m-85 -64.17 -34.53 78.29 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.994 -179.645 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 9' ' ' TRP . . . . . . . . . . . . . 21.5 m95 -62.34 -46.17 89.88 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-O 121.074 0.464 . . . . 0.0 109.835 179.939 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 41.9 mt -63.11 -35.88 81.75 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 115.629 -0.714 . . . . 0.0 110.154 179.138 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -69.66 -28.85 71.71 Favored Glycine 0 N--CA 1.448 -0.545 0 CA-C-N 115.643 -0.708 . . . . 0.0 111.784 179.419 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -73.71 -30.8 63.05 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-O 120.896 0.379 . . . . 0.0 110.473 179.526 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 13' ' ' ILE . . . . . 0.42 ' O ' HG23 ' A' ' 17' ' ' VAL . 50.2 mm -68.39 -54.33 22.36 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.124 0 CA-C-N 116.058 -0.519 . . . . 0.0 110.442 179.221 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -61.42 -37.39 94.02 Favored Glycine 0 N--CA 1.448 -0.534 0 C-N-CA 120.661 -0.781 . . . . 0.0 111.744 179.43 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 15' ' ' MET . . . . . 0.524 ' SD ' ' HA ' ' A' ' 44' ' ' SER . 55.5 tpp -63.65 -44.36 94.04 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.845 0.355 . . . . 0.0 110.44 179.527 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 16' ' ' LEU . . . . . 0.429 HD13 ' O ' ' A' ' 16' ' ' LEU . 0.4 OUTLIER -54.82 -42.13 71.5 Favored 'General case' 0 C--N 1.332 -0.187 0 CA-C-N 115.943 -0.572 . . . . 0.0 110.02 179.291 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 17' ' ' VAL . . . . . 0.42 HG23 ' O ' ' A' ' 13' ' ' ILE . 45.0 t -58.94 -44.55 91.19 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.188 0 CA-C-N 116.011 -0.54 . . . . 0.0 110.328 179.404 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -64.45 -40.44 97.74 Favored Glycine 0 C--N 1.332 0.337 0 C-N-CA 120.852 -0.689 . . . . 0.0 111.726 179.124 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 11.8 m -53.45 -48.18 69.05 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-O 120.839 0.352 . . . . 0.0 110.988 -179.943 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 97.2 mt -71.75 -36.13 70.33 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.513 -179.977 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -58.14 -38.01 75.75 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 116.528 -0.305 . . . . 0.0 111.586 -179.761 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 22' ' ' PHE . . . . . 0.606 ' HB2' HG22 ' A' ' 41' ' ' VAL . 4.0 m-85 -90.91 -28.22 18.24 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.347 -0.388 . . . . 0.0 111.394 -179.457 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -69.81 -50.8 39.43 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.961 0.41 . . . . 0.0 111.503 -179.444 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 24' ' ' TRP . . . . . . . . . . . . . 5.5 t-105 -66.19 -43.26 87.34 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 115.842 -0.617 . . . . 0.0 111.111 -179.659 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -73.82 -26.96 60.87 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.94 0.4 . . . . 0.0 110.866 179.799 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -69.6 -44.32 64.29 Favored Glycine 0 N--CA 1.452 -0.287 0 C-N-CA 120.772 -0.727 . . . . 0.0 112.066 179.743 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 40.9 mmt180 -58.7 -27.35 64.77 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-O 120.849 0.357 . . . . 0.0 110.535 179.694 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 32.5 t70 -105.42 92.36 4.16 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.003 -0.544 . . . . 0.0 110.463 179.675 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 29' ' ' ALA . . . . . 0.411 ' HA ' ' NH1' ' A' ' 220' ' ' ARG . . . -154.38 -167.87 2.76 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.15 -179.778 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -98.92 -126.33 5.6 Favored Glycine 0 N--CA 1.451 -0.3 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.438 179.972 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 88.1 p -132.2 123.06 26.27 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-O 120.773 0.321 . . . . 0.0 110.906 179.993 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 107.76 -31.14 8.27 Favored Glycine 0 N--CA 1.451 -0.363 0 C-N-CA 120.868 -0.682 . . . . 0.0 112.472 179.976 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 16.3 mm-40 -83.57 -21.68 32.56 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 120.689 0.28 . . . . 0.0 110.994 179.929 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 34' ' ' ARG . . . . . . . . . . . . . 60.1 ttp180 -52.11 -30.5 26.54 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-N 116.158 -0.473 . . . . 0.0 111.252 -179.645 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 80.2 ttt180 -61.28 -42.55 98.83 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.871 0.367 . . . . 0.0 110.761 179.879 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 66.4 m-85 -70.75 -30.47 66.99 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.054 -0.521 . . . . 0.0 110.925 179.941 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 37' ' ' TYR . . . . . 0.502 ' O ' HG23 ' A' ' 41' ' ' VAL . 59.2 m-85 -72.37 -56.13 5.96 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.324 -179.44 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 52.1 t -57.05 -37.4 54.94 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.189 0 CA-C-O 120.955 0.407 . . . . 0.0 110.766 -179.826 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 33.8 m -60.73 -51.01 71.19 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 115.863 -0.608 . . . . 0.0 110.628 179.521 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 40' ' ' LEU . . . . . 0.61 HD12 HD12 ' A' ' 43' ' ' ILE . 66.0 tp -60.86 -46.89 88.79 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 115.838 -0.619 . . . . 0.0 110.63 179.694 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 41' ' ' VAL . . . . . 0.606 HG22 ' HB2' ' A' ' 22' ' ' PHE . 90.0 t -56.7 -35.24 44.96 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.242 0 CA-C-N 115.884 -0.598 . . . . 0.0 110.041 179.289 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -61.74 -40.95 99.49 Favored Glycine 0 N--CA 1.448 -0.527 0 C-N-CA 120.673 -0.775 . . . . 0.0 111.504 179.175 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 43' ' ' ILE . . . . . 0.61 HD12 HD12 ' A' ' 40' ' ' LEU . 18.7 mt -57.46 -56.62 14.2 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.22 0 CA-C-O 120.76 0.314 . . . . 0.0 110.933 179.318 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 44' ' ' SER . . . . . 0.524 ' HA ' ' SD ' ' A' ' 15' ' ' MET . 49.7 m -58.71 -26.35 63.82 Favored 'General case' 0 C--N 1.332 -0.182 0 CA-C-N 116.315 -0.402 . . . . 0.0 111.482 -179.696 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -73.53 -53.99 7.05 Favored Glycine 0 CA--C 1.518 0.229 0 C-N-CA 120.681 -0.771 . . . . 0.0 112.879 -179.625 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 19.6 pt -61.18 -38.38 79.59 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.222 0 CA-C-O 120.871 0.367 . . . . 0.0 111.377 -179.712 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 47' ' ' ALA . . . . . 0.665 ' HB2' ' HE2' ' A' ' 205' ' ' LYS . . . -67.71 -43.21 80.57 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.814 0.34 . . . . 0.0 111.002 179.602 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -54.75 -46.71 74.36 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 115.947 -0.569 . . . . 0.0 111.754 -179.531 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 31.4 m -68.59 -34.19 63.89 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.241 0 CA-C-N 116.527 -0.306 . . . . 0.0 111.275 -179.595 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -66.01 -37.07 84.98 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-O 120.884 0.373 . . . . 0.0 111.005 179.638 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 51' ' ' TYR . . . . . 0.433 ' CE1' HG13 ' A' ' 198' ' ' VAL . 26.7 m-85 -68.75 -38.75 80.34 Favored 'General case' 0 C--N 1.327 -0.413 0 CA-C-O 121.117 0.484 . . . . 0.0 110.084 179.772 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -65.29 -45.09 85.84 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 115.635 -0.712 . . . . 0.0 111.314 179.676 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 53' ' ' VAL . . . . . 0.466 HG23 ' N ' ' A' ' 54' ' ' MET . 27.6 m -67.76 -46.5 82.36 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.139 0 CA-C-O 120.794 0.33 . . . . 0.0 110.621 179.886 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 54' ' ' MET . . . . . 0.498 ' HG2' ' HG2' ' A' ' 71' ' ' PRO . 72.0 mtm -62.27 -30.44 71.12 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 121.156 0.503 . . . . 0.0 109.854 179.111 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 55' ' ' ALA . . . . . 0.604 ' HB2' ' HB2' ' A' ' 8' ' ' PHE . . . -74.28 -30.53 62.14 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 115.601 -0.727 . . . . 0.0 111.355 179.797 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 76.3 mt -77.37 -9.74 59.03 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.457 -0.338 . . . . 0.0 111.214 -179.764 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 95.31 -11.93 68.48 Favored Glycine 0 N--CA 1.452 -0.254 0 C-N-CA 120.666 -0.778 . . . . 0.0 113.017 179.729 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 8.8 p -74.29 140.58 17.38 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-O 120.846 0.355 . . . . 0.0 110.885 -179.97 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 59' ' ' GLY . . . . . 0.465 ' HA3' ' HG3' ' A' ' 71' ' ' PRO . . . 101.29 -9.71 57.76 Favored Glycine 0 N--CA 1.45 -0.377 0 C-N-CA 120.907 -0.663 . . . . 0.0 112.286 -179.715 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 60' ' ' TRP . . . . . . . . . . . . . 15.8 m0 -76.32 118.08 18.66 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-O 120.579 0.228 . . . . 0.0 110.393 179.67 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 61' ' ' VAL . . . . . 0.483 ' HA ' ' HD3' ' A' ' 62' ' ' PRO . 7.5 p -113.26 127.63 26.61 Favored Pre-proline 0 CA--C 1.533 0.321 0 CA-C-N 116.582 -0.281 . . . . 0.0 111.716 -179.603 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 62' ' ' PRO . . . . . 0.483 ' HD3' ' HA ' ' A' ' 61' ' ' VAL . 6.8 Cg_exo -74.03 146.61 37.25 Favored 'Trans proline' 0 C--N 1.351 0.685 0 C-N-CA 122.88 2.386 . . . . 0.0 112.159 179.518 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 75.5 t -139.71 90.42 0.6 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.044 179.859 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . 59.16 -86.12 0.02 OUTLIER 'General case' 0 C--N 1.331 -0.196 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.463 179.891 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 9.7 tp10 -122.42 -19.98 6.24 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 121.011 0.434 . . . . 0.0 110.653 -179.991 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 66' ' ' ARG . . . . . 0.418 HH22 HH12 ' A' ' 123' ' ' ARG . 18.4 ptp180 -100.76 165.82 11.18 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 115.893 -0.594 . . . . 0.0 110.373 179.878 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 26.3 m -125.42 139.66 53.46 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.886 0.374 . . . . 0.0 111.3 -179.838 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 21.5 t -124.17 146.57 29.46 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.238 0 CA-C-N 115.972 -0.558 . . . . 0.0 110.583 179.887 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 69' ' ' PHE . . . . . . . . . . . . . 27.5 m-85 -109.37 111.05 22.39 Favored 'General case' 0 C--N 1.331 -0.206 0 CA-C-N 116.41 -0.359 . . . . 0.0 110.062 -179.629 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 70' ' ' VAL . . . . . 0.599 ' N ' ' HD2' ' A' ' 71' ' ' PRO . 47.4 t -70.02 -49.82 18.15 Favored Pre-proline 0 C--N 1.325 -0.471 0 N-CA-C 112.759 0.651 . . . . 0.0 112.759 -179.186 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 71' ' ' PRO . . . . . 0.599 ' HD2' ' N ' ' A' ' 70' ' ' VAL . 11.3 Cg_endo -54.03 -19.12 14.94 Favored 'Trans proline' 0 C--N 1.352 0.739 0 C-N-CA 122.031 1.82 . . . . 0.0 112.339 -179.616 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 72' ' ' ARG . . . . . 0.517 ' HE ' HG21 ' A' ' 197' ' ' ILE . 32.1 ttt180 -77.02 -53.49 7.74 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.596 179.605 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 73' ' ' TYR . . . . . 0.423 ' O ' HG13 ' A' ' 77' ' ' ILE . 79.9 m-85 -66.37 -39.41 89.08 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 115.816 -0.629 . . . . 0.0 110.922 -179.811 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 0.3 OUTLIER -67.4 -36.35 76.24 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-N 116.348 -0.387 . . . . 0.0 110.043 179.504 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 12.6 t70 -61.02 -37.37 82.32 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.235 -0.439 . . . . 0.0 109.951 179.253 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 76' ' ' TRP . . . . . . . . . . . . . 48.6 m0 -66.3 -36.21 82.36 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 115.927 -0.579 . . . . 0.0 110.067 179.414 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 77' ' ' ILE . . . . . 0.5 ' O ' ' HG2' ' A' ' 81' ' ' PRO . 68.3 mt -66.54 -30.07 48.55 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.364 0 CA-C-N 115.959 -0.564 . . . . 0.0 110.91 179.511 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 53.4 mt -91.91 -21.95 20.32 Favored 'General case' 0 C--N 1.328 -0.347 0 N-CA-C 112.511 0.56 . . . . 0.0 112.511 -179.644 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 79' ' ' THR . . . . . 0.401 ' HB ' ' HE3' ' A' ' 205' ' ' LYS . 70.0 p -100.27 -52.0 3.5 Favored 'General case' 0 N--CA 1.464 0.269 0 N-CA-C 113.619 0.97 . . . . 0.0 113.619 -177.792 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 80' ' ' THR . . . . . 0.675 ' HB ' ' HD3' ' A' ' 81' ' ' PRO . 86.3 m -51.35 -55.35 29.65 Favored Pre-proline 0 CA--C 1.532 0.271 0 N-CA-C 112.421 0.526 . . . . 0.0 112.421 -178.502 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 81' ' ' PRO . . . . . 0.675 ' HD3' ' HB ' ' A' ' 80' ' ' THR . 52.0 Cg_exo -56.49 -20.13 32.13 Favored 'Trans proline' 0 C--N 1.352 0.762 0 C-N-CA 121.542 1.495 . . . . 0.0 111.481 179.574 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 82' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -76.63 -38.2 55.08 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 115.716 -0.675 . . . . 0.0 110.223 179.552 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 83' ' ' ILE . . . . . 0.486 HD13 HD13 ' A' ' 43' ' ' ILE . 16.7 mm -66.17 -51.24 61.68 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.16 0 CA-C-N 116.004 -0.543 . . . . 0.0 110.293 179.516 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 31.0 m -61.49 -31.76 51.48 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.166 0 N-CA-C 109.71 -0.478 . . . . 0.0 109.71 178.962 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 85' ' ' TYR . . . . . . . . . . . . . 83.4 t80 -66.48 -31.94 72.99 Favored 'General case' 0 N--CA 1.454 -0.249 0 CA-C-N 115.656 -0.702 . . . . 0.0 109.569 178.763 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 86' ' ' PHE . . . . . . . . . . . . . 11.5 t80 -63.69 -50.84 67.6 Favored 'General case' 0 C--O 1.233 0.185 0 CA-C-N 115.889 -0.596 . . . . 0.0 109.793 179.179 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 3.1 mt -61.02 -35.5 77.02 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 115.786 -0.643 . . . . 0.0 109.714 179.537 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -67.08 -28.14 73.68 Favored Glycine 0 N--CA 1.45 -0.393 0 CA-C-N 115.28 -0.873 . . . . 0.0 111.865 179.49 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 50.0 mt -72.59 -37.36 68.15 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.893 0.378 . . . . 0.0 110.277 179.534 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 41.5 mt -60.4 -50.6 72.96 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 115.741 -0.663 . . . . 0.0 110.73 179.617 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 91' ' ' ALA . . . . . 0.498 ' HB1' ' HB2' ' A' ' 148' ' ' SER . . . -71.52 -48.57 47.98 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 115.981 -0.554 . . . . 0.0 111.374 -179.815 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 96.88 62.66 0.93 Allowed Glycine 0 N--CA 1.452 -0.271 0 C-N-CA 120.764 -0.731 . . . . 0.0 112.399 -179.902 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 93' ' ' LEU . . . . . 0.587 HD23 ' HB3' ' A' ' 97' ' ' GLU . 7.1 mp -77.08 175.09 9.94 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.782 0.325 . . . . 0.0 110.868 -179.958 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 94' ' ' ASP . . . . . . . . . . . . . 13.0 m-20 -91.23 172.82 8.28 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.827 179.708 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 78.5 p -60.04 -36.55 77.52 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.246 -0.434 . . . . 0.0 111.09 -179.848 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 15.9 ptm180 -73.89 -43.54 58.16 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.06 -179.965 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 97' ' ' GLU . . . . . 0.587 ' HB3' HD23 ' A' ' 93' ' ' LEU . 37.1 mt-10 -57.59 -46.49 83.97 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.384 -0.371 . . . . 0.0 110.764 -179.926 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 98' ' ' PHE . . . . . . . . . . . . . 21.4 m-85 -60.25 -41.29 92.9 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.361 179.53 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -58.73 -32.55 69.91 Favored Glycine 0 N--CA 1.449 -0.469 0 C-N-CA 120.687 -0.768 . . . . 0.0 112.265 179.75 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 86.7 mt -73.51 -44.54 53.6 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-O 120.747 0.308 . . . . 0.0 111.675 -179.83 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 35.3 t -68.46 -48.8 70.77 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 CA-C-N 116.318 -0.401 . . . . 0.0 111.76 -179.252 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 102' ' ' ILE . . . . . 0.558 HG23 ' HB3' ' A' ' 81' ' ' PRO . 48.2 mm -63.56 -45.87 96.5 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.379 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.868 -179.357 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 6.0 t -62.02 -33.67 74.79 Favored 'General case' 0 C--N 1.332 -0.192 0 CA-C-O 120.867 0.365 . . . . 0.0 110.759 -179.813 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 104' ' ' LEU . . . . . 0.416 HD22 ' HE2' ' A' ' 140' ' ' TYR . 48.5 tp -60.17 -53.28 59.59 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.221 179.348 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 105' ' ' ASN . . . . . 0.577 ' N ' HD22 ' A' ' 105' ' ' ASN . 0.8 OUTLIER -56.26 -31.31 63.47 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.063 -0.517 . . . . 0.0 110.115 179.38 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 24.8 m -61.88 -38.75 89.47 Favored 'General case' 0 C--N 1.332 -0.179 0 CA-C-N 116.038 -0.528 . . . . 0.0 109.996 179.078 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 107' ' ' VAL . . . . . 0.419 ' H ' HG23 ' A' ' 107' ' ' VAL . 1.8 t -70.35 -41.21 78.45 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.198 0 CA-C-N 116.051 -0.522 . . . . 0.0 109.964 178.97 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 54.0 t -57.22 -47.19 84.62 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 115.367 -0.833 . . . . 0.0 111.23 179.885 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 109' ' ' MET . . . . . 0.418 ' O ' ' HB2' ' A' ' 113' ' ' PHE . 21.5 mmt -69.27 -32.31 71.41 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.017 -0.538 . . . . 0.0 111.124 -179.714 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 27.8 tp -65.3 -33.28 75.6 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-O 120.964 0.411 . . . . 0.0 110.324 179.793 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -68.82 -53.84 19.24 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 115.855 -0.611 . . . . 0.0 110.743 179.465 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 112' ' ' GLY . . . . . 0.59 ' HA3' ' H21' ' A' ' 301' ' ' RET . . . -63.09 -35.62 92.33 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.652 -0.785 . . . . 0.0 112.135 179.642 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 113' ' ' PHE . . . . . 0.47 ' HZ ' HG13 ' A' ' 70' ' ' VAL . 0.7 OUTLIER -55.63 -65.31 0.61 Allowed 'General case' 0 C--N 1.33 -0.255 0 CA-C-O 121.066 0.46 . . . . 0.0 110.249 179.6 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 114' ' ' ALA . . . . . 0.576 ' HB3' HD22 ' A' ' 126' ' ' LEU . . . -66.09 -22.55 66.41 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 115.722 -0.672 . . . . 0.0 110.951 179.816 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -55.8 -48.96 68.71 Favored Glycine 0 C--N 1.333 0.392 0 C-N-CA 120.659 -0.781 . . . . 0.0 111.85 179.401 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -78.32 -15.03 59.14 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-O 120.836 0.35 . . . . 0.0 111.016 179.508 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 117' ' ' MET . . . . . . . . . . . . . 32.3 tpp -91.58 18.73 7.02 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.105 -0.498 . . . . 0.0 111.497 -179.204 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 118' ' ' VAL . . . . . 0.459 HG21 ' HB3' ' A' ' 123' ' ' ARG . 27.5 m -88.57 139.1 29.71 Favored Pre-proline 0 C--N 1.33 -0.27 0 CA-C-N 116.633 -0.258 . . . . 0.0 111.308 -179.865 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 119' ' ' PRO . . . . . . . . . . . . . 95.4 Cg_endo -89.67 -10.08 3.81 Favored 'Trans proline' 0 N--CA 1.456 -0.697 0 C-N-CA 122.699 2.266 . . . . 0.0 112.195 179.371 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -128.64 -106.71 1.3 Allowed Glycine 0 C--N 1.331 0.305 0 C-N-CA 120.848 -0.691 . . . . 0.0 112.722 -179.74 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 2.6 pp -136.93 19.52 0.85 Allowed 'Isoleucine or valine' 0 C--N 1.332 -0.185 0 CA-C-O 120.742 0.306 . . . . 0.0 111.652 -179.713 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 41.3 mt-10 -65.05 -17.71 64.68 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.311 -0.404 . . . . 0.0 110.853 179.757 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 123' ' ' ARG . . . . . 0.459 ' HB3' HG21 ' A' ' 118' ' ' VAL . 12.2 ptt180 -50.16 -42.05 50.25 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 115.736 -0.666 . . . . 0.0 112.023 -179.64 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 124' ' ' TYR . . . . . . . . . . . . . 59.0 m-85 -57.56 -32.18 66.87 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.522 -0.308 . . . . 0.0 111.511 -179.239 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 125' ' ' ALA . . . . . . . . . . . . . . . -74.2 -56.29 5.07 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-O 121.03 0.443 . . . . 0.0 111.156 -179.728 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 126' ' ' LEU . . . . . 0.576 HD22 ' HB3' ' A' ' 114' ' ' ALA . 1.1 mt -53.25 -48.83 67.92 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 115.746 -0.661 . . . . 0.0 110.494 179.96 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 127' ' ' PHE . . . . . 0.429 ' HE1' ' H42' ' A' ' 301' ' ' RET . 7.0 t80 -63.65 -35.65 81.24 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.306 -0.406 . . . . 0.0 110.483 179.396 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 128' ' ' GLY . . . . . . . . . . . . . . . -47.22 -50.73 16.21 Favored Glycine 0 C--N 1.333 0.402 0 C-N-CA 120.055 -1.069 . . . . 0.0 110.609 178.854 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 129' ' ' MET . . . . . . . . . . . . . 0.5 OUTLIER -65.31 -34.31 78.03 Favored 'General case' 0 C--N 1.329 -0.314 0 N-CA-C 109.679 -0.489 . . . . 0.0 109.679 178.293 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -57.81 -51.61 57.1 Favored Glycine 0 C--N 1.331 0.284 0 CA-C-N 115.463 -0.789 . . . . 0.0 112.597 -179.973 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -58.91 -49.47 77.66 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 120.66 0.267 . . . . 0.0 110.684 179.865 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 132' ' ' VAL . . . . . 0.426 ' O ' HG13 ' A' ' 135' ' ' ILE . 49.9 t -54.55 -39.99 48.21 Favored 'Isoleucine or valine' 0 C--O 1.233 0.228 0 CA-C-O 121.269 0.557 . . . . 0.0 109.794 179.007 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -69.98 -34.19 73.05 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 115.474 -0.784 . . . . 0.0 110.947 179.469 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 134' ' ' PHE . . . . . 0.457 ' CZ ' ' HA ' ' A' ' 172' ' ' ALA . 51.9 t80 -56.87 -58.58 7.5 Favored 'General case' 0 CA--C 1.517 -0.294 0 CA-C-N 116.341 -0.39 . . . . 0.0 110.118 179.817 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 135' ' ' ILE . . . . . 0.487 ' O ' HG22 ' A' ' 138' ' ' VAL . 0.0 OUTLIER -55.6 -34.85 36.56 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 115.799 -0.637 . . . . 0.0 109.663 179.104 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . -58.19 -36.47 82.61 Favored Glycine 0 N--CA 1.448 -0.524 0 C-N-CA 120.447 -0.882 . . . . 0.0 111.482 178.944 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 137' ' ' LEU . . . . . 0.536 HD13 HD21 ' A' ' 105' ' ' ASN . 38.3 tp -71.91 -54.18 10.82 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-O 120.615 0.245 . . . . 0.0 110.721 179.537 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 138' ' ' VAL . . . . . 0.487 HG22 ' O ' ' A' ' 135' ' ' ILE . 3.4 m -55.92 -30.32 28.09 Favored 'Isoleucine or valine' 0 C--O 1.233 0.197 0 CA-C-O 121.312 0.577 . . . . 0.0 109.712 179.351 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 139' ' ' TYR . . . . . . . . . . . . . 31.4 t80 -63.58 -47.03 83.14 Favored 'General case' 0 N--CA 1.453 -0.285 0 CA-C-N 115.31 -0.859 . . . . 0.0 110.021 178.975 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 140' ' ' TYR . . . . . 0.416 ' HE2' HD22 ' A' ' 104' ' ' LEU . 18.2 m-85 -57.38 -35.98 70.68 Favored 'General case' 0 C--N 1.332 -0.191 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.596 179.362 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 141' ' ' LEU . . . . . 0.445 HD13 ' HG2' ' A' ' 164' ' ' ARG . 69.5 mt -59.49 -54.69 43.7 Favored 'General case' 0 C--N 1.333 -0.152 0 CA-C-N 116.262 -0.426 . . . . 0.0 110.51 179.522 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 18.6 t -70.02 -15.79 19.58 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.246 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.765 179.597 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . -68.68 -138.67 0.08 OUTLIER Glycine 0 CA--C 1.522 0.469 0 C-N-CA 121.025 -0.607 . . . . 0.0 112.779 -179.899 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 144' ' ' PRO . . . . . . . . . . . . . 19.2 Cg_endo -59.11 -23.42 68.94 Favored 'Trans proline' 0 C--N 1.349 0.587 0 C-N-CA 122.672 2.248 . . . . 0.0 112.654 -179.723 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 145' ' ' MET . . . . . . . . . . . . . 45.5 mtt -59.07 -28.52 66.55 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.517 -0.311 . . . . 0.0 111.28 -179.997 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 146' ' ' THR . . . . . . . . . . . . . 35.2 m -80.45 -42.9 21.81 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.913 0.387 . . . . 0.0 111.194 -179.167 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 9.1 tp10 -70.42 -34.53 72.6 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 115.964 -0.562 . . . . 0.0 111.107 -179.818 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 148' ' ' SER . . . . . 0.498 ' HB2' ' HB1' ' A' ' 91' ' ' ALA . 64.2 m -70.47 -50.85 33.75 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.054 -179.41 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 149' ' ' ALA . . . . . 0.423 ' HB1' HG22 ' A' ' 156' ' ' ILE . . . -64.79 -38.38 90.8 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.332 -179.828 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 150' ' ' SER . . . . . . . . . . . . . 100.0 p -72.15 -4.29 28.26 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.896 179.856 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 151' ' ' GLN . . . . . . . . . . . . . 96.7 mt-30 -125.46 1.54 7.66 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.168 -179.98 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 152' ' ' ARG . . . . . 0.418 ' HA ' ' HE ' ' A' ' 152' ' ' ARG . 0.0 OUTLIER -80.34 -52.54 7.57 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-O 121.013 0.435 . . . . 0.0 110.333 179.883 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 153' ' ' SER . . . . . 0.606 ' HB2' HG12 ' A' ' 156' ' ' ILE . 44.3 m -158.22 171.01 20.98 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-N 115.83 -0.623 . . . . 0.0 110.49 179.18 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 154' ' ' SER . . . . . . . . . . . . . 64.1 m -71.21 -36.82 72.01 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 121.028 0.442 . . . . 0.0 110.059 179.127 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -76.93 -41.21 23.49 Favored Glycine 0 N--CA 1.45 -0.417 0 CA-C-N 115.785 -0.643 . . . . 0.0 112.386 179.611 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 156' ' ' ILE . . . . . 0.606 HG12 ' HB2' ' A' ' 153' ' ' SER . 38.1 mm -51.76 -38.17 21.81 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.196 0 CA-C-O 120.879 0.371 . . . . 0.0 111.177 179.91 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 157' ' ' LYS . . . . . . . . . . . . . 63.1 tttm -58.93 -42.92 90.88 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 115.961 -0.563 . . . . 0.0 110.92 -179.989 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 51.0 m -71.19 -40.94 70.91 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.547 -179.732 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 159' ' ' LEU . . . . . 0.417 ' O ' ' HB2' ' A' ' 163' ' ' LEU . 2.2 mm? -63.78 -38.72 92.17 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.418 -0.355 . . . . 0.0 111.601 -179.419 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 160' ' ' TYR . . . . . . . . . . . . . 43.5 t80 -74.2 -46.79 39.71 Favored 'General case' 0 C--N 1.327 -0.38 0 N-CA-C 112.598 0.592 . . . . 0.0 112.598 -178.533 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 161' ' ' VAL . . . . . 0.438 HG23 ' N ' ' A' ' 162' ' ' ARG . 21.2 m -57.25 -48.83 81.59 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 N-CA-C 112.395 0.517 . . . . 0.0 112.395 -178.788 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 162' ' ' ARG . . . . . 0.438 ' N ' HG23 ' A' ' 161' ' ' VAL . 27.1 ttm180 -69.04 -45.92 69.21 Favored 'General case' 0 C--N 1.329 -0.324 0 N-CA-C 111.783 0.29 . . . . 0.0 111.783 -179.302 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 163' ' ' LEU . . . . . 0.681 ' HG ' ' HB2' ' A' ' 208' ' ' PHE . 6.6 mp -61.78 -49.75 75.12 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.451 -0.34 . . . . 0.0 111.733 -179.661 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 164' ' ' ARG . . . . . 0.445 ' HG2' HD13 ' A' ' 141' ' ' LEU . 4.0 tmt_? -62.64 -45.51 92.52 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.312 -0.404 . . . . 0.0 111.749 -179.036 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 165' ' ' ASN . . . . . 0.523 ' O ' HG23 ' A' ' 169' ' ' VAL . 5.3 m-20 -59.49 -52.19 66.62 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.783 0.325 . . . . 0.0 111.546 -179.434 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 166' ' ' LEU . . . . . 0.511 ' O ' ' HG ' ' A' ' 170' ' ' LEU . 4.6 tt -63.88 -53.41 50.9 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-O 120.852 0.358 . . . . 0.0 111.314 -179.552 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 167' ' ' THR . . . . . 0.487 ' HA ' HD11 ' A' ' 170' ' ' LEU . 88.3 m -54.67 -53.09 59.37 Favored 'General case' 0 C--N 1.327 -0.381 0 N-CA-C 112.581 0.585 . . . . 0.0 112.581 -178.744 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 168' ' ' VAL . . . . . 0.404 HG12 ' O ' ' A' ' 165' ' ' ASN . 9.1 p -56.74 -40.58 71.23 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.204 0 N-CA-C 112.158 0.429 . . . . 0.0 112.158 -178.753 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 169' ' ' VAL . . . . . 0.523 HG23 ' O ' ' A' ' 165' ' ' ASN . 51.5 t -58.26 -65.37 0.44 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 N-CA-C 111.821 0.304 . . . . 0.0 111.821 -179.487 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 170' ' ' LEU . . . . . 0.511 ' HG ' ' O ' ' A' ' 166' ' ' LEU . 0.4 OUTLIER -64.48 -28.26 69.54 Favored 'General case' 0 C--N 1.331 -0.216 0 N-CA-C 111.982 0.364 . . . . 0.0 111.982 -178.865 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 171' ' ' TRP . . . . . 0.436 ' HB2' ' O ' ' A' ' 167' ' ' THR . 5.2 m0 -71.38 -31.18 67.01 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.848 0.356 . . . . 0.0 110.742 179.488 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 172' ' ' ALA . . . . . 0.457 ' HA ' ' CZ ' ' A' ' 134' ' ' PHE . . . -73.78 -6.4 46.75 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.861 -179.727 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 173' ' ' ILE . . . . . 0.663 HG22 HD11 ' A' ' 177' ' ' ILE . 13.9 mm -86.12 -21.46 7.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 115.927 -0.579 . . . . 0.0 110.806 179.629 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 174' ' ' TYR . . . . . . . . . . . . . 14.2 m-85 -54.27 -51.24 79.5 Favored Pre-proline 0 CA--C 1.531 0.236 0 CA-C-N 116.115 -0.493 . . . . 0.0 112.109 -179.535 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 175' ' ' PRO . . . . . . . . . . . . . 89.1 Cg_exo -47.4 -29.14 9.43 Favored 'Trans proline' 0 C--N 1.352 0.728 0 C-N-CA 121.998 1.798 . . . . 0.0 112.176 179.748 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 176' ' ' PHE . . . . . 0.459 ' O ' ' HG ' ' A' ' 180' ' ' LEU . 98.3 m-85 -80.52 -50.12 10.46 Favored 'General case' 0 CA--C 1.517 -0.323 0 CA-C-N 116.057 -0.52 . . . . 0.0 111.69 179.968 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 177' ' ' ILE . . . . . 0.663 HD11 HG22 ' A' ' 173' ' ' ILE . 3.1 mm -58.4 -46.47 89.36 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.533 0 CA-C-N 115.884 -0.598 . . . . 0.0 112.073 -178.227 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 178' ' ' TRP . . . . . 0.485 ' HA ' ' HG2' ' A' ' 182' ' ' PRO . 75.1 t90 -62.5 -42.45 99.51 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 121.026 0.441 . . . . 0.0 110.974 -179.986 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 179' ' ' LEU . . . . . 0.551 HD13 HG22 ' A' ' 185' ' ' VAL . 1.2 tm? -67.27 -49.51 64.04 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 115.831 -0.622 . . . . 0.0 111.369 -179.061 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 180' ' ' LEU . . . . . 0.653 HD22 HD11 ' A' ' 187' ' ' LEU . 9.9 mt -76.95 -52.29 9.65 Favored 'General case' 0 CA--C 1.535 0.374 0 N-CA-C 112.498 0.555 . . . . 0.0 112.498 -178.474 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . -64.97 -84.1 0.08 OUTLIER Glycine 0 CA--C 1.522 0.521 0 C-N-CA 120.72 -0.752 . . . . 0.0 113.425 -179.557 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 182' ' ' PRO . . . . . 0.557 ' HD2' ' O ' ' A' ' 177' ' ' ILE . 75.0 Cg_exo -44.86 -179.79 0.0 OUTLIER 'Trans proline' 0 C--N 1.351 0.671 0 C-N-CA 123.567 2.845 . . . . 0.0 113.574 179.684 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 183' ' ' PRO . . . . . . . . . . . . . 82.8 Cg_exo -50.11 5.06 0.02 OUTLIER 'Trans proline' 0 C--N 1.354 0.864 0 C-N-CA 123.196 2.597 . . . . 0.0 115.274 -179.566 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 184' ' ' GLY . . . . . 0.459 ' H ' ' C ' ' A' ' 182' ' ' PRO . . . -55.32 -70.28 1.01 Allowed Glycine 0 C--N 1.335 0.514 0 C-N-CA 119.724 -1.226 . . . . 0.0 110.899 179.236 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 185' ' ' VAL . . . . . 0.551 HG22 HD13 ' A' ' 179' ' ' LEU . 3.6 m -135.65 -5.77 0.95 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.372 0 N-CA-C 111.722 0.267 . . . . 0.0 111.722 178.559 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 186' ' ' ALA . . . . . . . . . . . . . . . 41.99 81.19 0.03 OUTLIER 'General case' 0 N--CA 1.466 0.349 0 N-CA-C 112.43 0.529 . . . . 0.0 112.43 179.372 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 187' ' ' LEU . . . . . 0.653 HD11 HD22 ' A' ' 180' ' ' LEU . 7.0 mt -92.92 -49.47 6.03 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.767 0.318 . . . . 0.0 111.548 179.871 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 188' ' ' LEU . . . . . . . . . . . . . 89.3 mt -105.8 -166.56 1.22 Allowed 'General case' 0 C--N 1.33 -0.244 0 CA-C-O 121.073 0.463 . . . . 0.0 111.515 -179.261 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 189' ' ' THR . . . . . 0.432 ' HB ' HG23 ' A' ' 192' ' ' VAL . 4.7 m -82.72 136.12 45.25 Favored Pre-proline 0 C--N 1.328 -0.339 0 CA-C-N 115.668 -0.696 . . . . 0.0 110.685 -179.615 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 190' ' ' PRO . . . . . 0.418 ' O ' HG23 ' A' ' 194' ' ' VAL . 84.5 Cg_exo -45.76 -48.64 12.0 Favored 'Trans proline' 0 C--N 1.349 0.559 0 C-N-CA 122.628 2.219 . . . . 0.0 113.026 -179.788 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 191' ' ' THR . . . . . 0.429 HG22 HG22 ' A' ' 189' ' ' THR . 3.9 t -56.8 -39.69 74.59 Favored 'General case' 0 C--N 1.33 -0.255 0 N-CA-C 111.921 0.341 . . . . 0.0 111.921 -179.492 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 192' ' ' VAL . . . . . 0.432 HG23 ' HB ' ' A' ' 189' ' ' THR . 58.6 t -67.33 -53.58 31.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-O 120.877 0.37 . . . . 0.0 111.546 -179.55 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 193' ' ' ASP . . . . . . . . . . . . . 13.5 m-20 -59.0 -43.05 91.43 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.09 -179.636 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 194' ' ' VAL . . . . . 0.418 HG23 ' O ' ' A' ' 190' ' ' PRO . 54.3 t -60.99 -36.16 70.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.345 -0.389 . . . . 0.0 110.404 179.497 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 195' ' ' ALA . . . . . . . . . . . . . . . -58.51 -46.42 86.78 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-N 116.346 -0.388 . . . . 0.0 110.404 179.232 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 196' ' ' LEU . . . . . . . . . . . . . 90.6 mt -62.66 -38.04 88.74 Favored 'General case' 0 C--N 1.332 -0.192 0 CA-C-N 116.055 -0.52 . . . . 0.0 110.323 179.309 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 197' ' ' ILE . . . . . 0.517 HG21 ' HE ' ' A' ' 72' ' ' ARG . 20.3 mm -61.36 -57.14 13.49 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 115.947 -0.57 . . . . 0.0 110.223 179.262 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 198' ' ' VAL . . . . . 0.433 HG13 ' CE1' ' A' ' 51' ' ' TYR . 83.9 t -52.75 -34.88 20.52 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.465 0 CA-C-N 115.734 -0.666 . . . . 0.0 109.243 178.374 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 199' ' ' TYR . . . . . . . . . . . . . 62.5 t80 -69.99 -33.62 72.28 Favored 'General case' 0 C--N 1.332 -0.176 0 CA-C-N 115.388 -0.824 . . . . 0.0 110.626 179.498 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 200' ' ' LEU . . . . . 0.573 ' O ' HG12 ' A' ' 203' ' ' VAL . 31.8 mt -68.87 -44.17 73.86 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 115.919 -0.582 . . . . 0.0 111.409 -179.685 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 201' ' ' ASP . . . . . 0.425 ' HB2' ' OH ' ' A' ' 51' ' ' TYR . 11.8 m-20 -67.39 -36.05 80.52 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-O 121.293 0.568 . . . . 0.0 109.963 179.476 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 202' ' ' LEU . . . . . . . . . . . . . 3.3 mt -74.35 -28.28 61.06 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 115.232 -0.895 . . . . 0.0 112.356 -179.394 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 203' ' ' VAL . . . . . 0.573 HG12 ' O ' ' A' ' 200' ' ' LEU . 11.6 p -77.25 -36.15 23.71 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.303 0 C-N-CA 120.757 -0.377 . . . . 0.0 111.21 -178.533 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 204' ' ' THR . . . . . . . . . . . . . 90.2 m -70.7 -58.49 3.59 Favored 'General case' 0 C--N 1.327 -0.389 0 C-N-CA 120.719 -0.392 . . . . 0.0 111.068 179.316 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 205' ' ' LYS . . . . . 0.665 ' HE2' ' HB2' ' A' ' 47' ' ' ALA . 56.6 mttp -57.33 -58.02 10.09 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.242 -0.436 . . . . 0.0 111.728 -178.785 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 39.7 t -71.17 -36.3 61.94 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.431 0 CA-C-N 116.015 -0.539 . . . . 0.0 111.977 -179.061 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 207' ' ' GLY . . . . . 0.571 ' O ' HG13 ' A' ' 211' ' ' ILE . . . -58.9 -61.5 7.29 Favored Glycine 0 C--N 1.33 0.229 0 C-N-CA 120.624 -0.798 . . . . 0.0 113.816 -178.445 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 208' ' ' PHE . . . . . 0.681 ' HB2' ' HG ' ' A' ' 163' ' ' LEU . 1.0 OUTLIER -72.23 -27.47 62.54 Favored 'General case' 0 C--O 1.223 -0.333 0 CA-C-N 117.473 0.636 . . . . 0.0 111.05 -179.08 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 209' ' ' GLY . . . . . 0.513 ' O ' ' HB3' ' A' ' 212' ' ' ALA . . . -64.07 -34.2 89.3 Favored Glycine 0 N--CA 1.45 -0.369 0 N-CA-C 112.009 -0.436 . . . . 0.0 112.009 178.825 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 210' ' ' PHE . . . . . . . . . . . . . 1.2 m-85 -73.71 -48.71 30.02 Favored 'General case' 0 CA--C 1.514 -0.432 0 N-CA-C 108.21 -1.034 . . . . 0.0 108.21 178.446 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 211' ' ' ILE . . . . . 0.571 HG13 ' O ' ' A' ' 207' ' ' GLY . 5.4 mt -61.66 -28.07 43.39 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.499 0 N-CA-C 107.646 -1.242 . . . . 0.0 107.646 176.815 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 212' ' ' ALA . . . . . 0.513 ' HB3' ' O ' ' A' ' 209' ' ' GLY . . . -63.7 -41.71 98.08 Favored 'General case' 0 N--CA 1.448 -0.565 0 CA-C-N 114.384 -1.28 . . . . 0.0 110.139 179.952 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 213' ' ' LEU . . . . . . . . . . . . . 93.0 mt -70.1 -54.27 13.76 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 115.044 -0.98 . . . . 0.0 111.545 -179.729 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 214' ' ' ASP . . . . . . . . . . . . . 14.6 t70 -52.82 -54.63 31.57 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.189 -0.459 . . . . 0.0 111.605 -179.504 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 215' ' ' ALA . . . . . 0.405 ' O ' ' HG ' ' A' ' 219' ' ' LEU . . . -57.53 -57.2 13.74 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.046 -0.524 . . . . 0.0 111.781 -179.476 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 216' ' ' ALA . . . . . . . . . . . . . . . -55.1 -37.38 66.77 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.375 -0.375 . . . . 0.0 111.494 -179.636 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 217' ' ' ALA . . . . . . . . . . . . . . . -62.41 -32.89 73.8 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.382 179.799 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 218' ' ' THR . . . . . . . . . . . . . 94.4 m -76.25 -41.66 48.37 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 115.806 -0.633 . . . . 0.0 110.74 179.567 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 219' ' ' LEU . . . . . 0.405 ' HG ' ' O ' ' A' ' 215' ' ' ALA . 44.8 mt -61.78 -30.78 71.03 Favored 'General case' 0 C--N 1.332 -0.194 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.507 179.716 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 220' ' ' ARG . . . . . 0.411 ' NH1' ' HA ' ' A' ' 29' ' ' ALA . 77.1 ttt180 -83.79 -31.69 25.76 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 115.849 -0.614 . . . . 0.0 110.687 179.86 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 221' ' ' ALA . . . . . . . . . . . . . . . -72.66 -22.95 60.85 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 115.996 -0.547 . . . . 0.0 111.357 -179.88 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 222' ' ' GLU . . . . . . . . . . . . . 11.9 pt-20 -92.23 -28.58 16.93 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.415 -0.357 . . . . 0.0 110.493 -179.927 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 223' ' ' HIS . . . . . . . . . . . . . 84.3 m-70 64.29 111.61 0.03 OUTLIER 'General case' 0 C--N 1.331 -0.2 0 CA-C-N 115.794 -0.639 . . . . 0.0 111.339 179.79 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 224' ' ' GLY . . . . . . . . . . . . . . . -162.29 84.35 0.11 Allowed Glycine 0 C--N 1.33 0.21 0 C-N-CA 120.843 -0.694 . . . . 0.0 112.416 179.92 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 225' ' ' GLU . . . . . . . . . . . . . 8.8 tp10 -63.52 135.17 56.66 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.564 0.221 . . . . 0.0 110.771 -179.998 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 226' ' ' SER . . . . . . . . . . . . . 69.2 m 59.61 -86.34 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.045 -0.525 . . . . 0.0 111.236 -179.977 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 227' ' ' LEU . . . . . . . . . . . . . 27.4 tp -112.71 129.77 56.29 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.372 -0.376 . . . . 0.0 110.909 -179.918 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 228' ' ' ALA . . . . . . . . . . . . . . . -96.03 -179.29 4.63 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.262 -0.426 . . . . 0.0 110.932 179.822 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 229' ' ' GLY . . . . . . . . . . . . . . . -107.34 109.06 2.92 Favored Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.728 -0.749 . . . . 0.0 112.631 179.975 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 230' ' ' VAL . . . . . . . . . . . . . 37.0 t -71.27 136.28 26.18 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-O 120.702 0.286 . . . . 0.0 111.034 -179.866 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 231' ' ' ASP . . . . . . . . . . . . . 12.1 m-20 -76.42 111.63 12.08 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.859 179.848 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 232' ' ' THR . . . . . . . . . . . . . 72.5 p -121.68 -48.64 2.15 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.071 -0.513 . . . . 0.0 111.037 -179.975 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 233' ' ' ASP . . . . . . . . . . . . . 18.4 t70 -89.03 125.67 35.1 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.823 179.877 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 234' ' ' THR . . . . . . . . . . . . . 74.9 p -71.89 148.95 92.44 Favored Pre-proline 0 C--N 1.329 -0.322 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.1 -179.992 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 235' ' ' PRO . . . . . . . . . . . . . 55.6 Cg_endo -70.12 -39.1 6.18 Favored 'Trans proline' 0 C--N 1.348 0.543 0 C-N-CA 122.288 1.992 . . . . 0.0 111.996 179.812 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 236' ' ' ALA . . . . . . . . . . . . . . . -105.25 145.34 30.79 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.026 -0.534 . . . . 0.0 110.926 179.743 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 237' ' ' VAL . . . . . . . . . . . . . 46.2 t -118.13 117.67 55.56 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.248 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.147 -179.94 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 238' ' ' ALA . . . . . . . . . . . . . . . -125.96 -50.33 1.58 Allowed 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.359 -179.912 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 239' ' ' ASP . . . . . . . . . . . . . 15.6 m-20 57.86 100.41 0.02 OUTLIER 'General case' 0 C--N 1.332 -0.178 0 CA-C-N 116.102 -0.499 . . . . 0.0 111.088 -179.916 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 240' ' ' LEU . . . . . . . . . . . . . 81.3 mt -126.95 -8.11 6.03 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.86 179.976 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 241' ' ' GLU . . . . . . . . . . . . . 10.3 tp10 -67.27 125.45 26.1 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.861 179.981 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 242' ' ' HIS . . . . . . . . . . . . . 58.7 t-80 -85.96 114.83 23.17 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.291 -0.413 . . . . 0.0 111.02 -179.855 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 243' ' ' HIS . . . . . . . . . . . . . 8.5 p80 -137.04 147.26 46.06 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.746 179.823 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 244' ' ' HIS . . . . . . . . . . . . . 42.9 p-80 -91.11 156.9 17.55 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.918 0.39 . . . . 0.0 111.057 -179.811 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 245' ' ' HIS . . . . . . . . . . . . . 45.2 p-80 -64.38 161.73 16.37 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 115.93 -0.577 . . . . 0.0 111.223 -179.771 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 246' ' ' HIS . . . . . . . . . . . . . 96.4 m-70 -120.22 154.48 34.8 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.018 179.852 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 247' ' ' HIS . . . . . . . . . . . . . 47.2 m80 . . . . . 0 C--O 1.249 1.055 0 CA-C-O 118.19 -0.909 . . . . 0.0 111.024 -179.919 . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 301' ' ' RET . . . . . 0.59 ' H21' ' HA3' ' A' ' 112' ' ' GLY . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 1' ' ' MET . . . . . 0.431 ' HG2' ' N ' ' A' ' 2' ' ' VAL . 0.0 OUTLIER . . . . . 0 N--CA 1.486 1.351 0 CA-C-O 120.807 0.337 . . . . 0.0 111.034 . . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 2' ' ' VAL . . . . . 0.431 ' N ' ' HG2' ' A' ' 1' ' ' MET . 58.6 t -141.24 -73.8 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.331 -0.225 0 CA-C-N 116.18 -0.463 . . . . 0.0 110.898 179.865 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -97.83 -9.51 54.26 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.841 -0.695 . . . . 0.0 112.354 -179.996 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 67.8 tp -74.22 -35.41 63.88 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 120.778 0.323 . . . . 0.0 110.796 179.723 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 69.9 p -69.62 -32.85 71.8 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.72 -179.697 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 29.0 p -54.93 -35.56 64.33 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.35 -0.386 . . . . 0.0 111.381 -179.644 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 7' ' ' LEU . . . . . . . . . . . . . 9.3 mp -59.24 -53.36 59.18 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.098 -0.501 . . . . 0.0 111.557 -179.813 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 8' ' ' PHE . . . . . 0.564 ' HB2' ' HB2' ' A' ' 55' ' ' ALA . 63.4 m-85 -59.95 -34.93 73.92 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.317 -0.402 . . . . 0.0 110.997 -179.73 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 9' ' ' TRP . . . . . . . . . . . . . 28.8 m95 -64.36 -47.61 78.62 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 116.058 -0.519 . . . . 0.0 110.357 -179.902 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 13.1 mt -58.32 -42.76 87.45 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 115.929 -0.578 . . . . 0.0 110.304 179.204 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 11' ' ' GLY . . . . . 0.433 ' HA2' HD11 ' A' ' 202' ' ' LEU . . . -61.62 -34.58 89.03 Favored Glycine 0 N--CA 1.448 -0.545 0 C-N-CA 120.588 -0.815 . . . . 0.0 111.544 178.971 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 12' ' ' ALA . . . . . 0.407 ' O ' HD23 ' A' ' 16' ' ' LEU . . . -66.22 -33.15 75.1 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 120.616 0.246 . . . . 0.0 110.608 179.701 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 1.5 mt -63.21 -49.29 83.76 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.259 0 N-CA-C 109.347 -0.612 . . . . 0.0 109.347 178.987 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 14' ' ' GLY . . . . . 0.411 ' HA3' HD21 ' A' ' 202' ' ' LEU . . . -61.7 -24.82 64.76 Favored Glycine 0 N--CA 1.447 -0.584 0 C-N-CA 120.638 -0.791 . . . . 0.0 111.47 178.908 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 15' ' ' MET . . . . . 0.677 ' HB3' ' HB2' ' A' ' 48' ' ' ALA . 0.0 OUTLIER -77.3 -47.93 18.76 Favored 'General case' 0 C--N 1.331 -0.227 0 N-CA-C 111.763 0.283 . . . . 0.0 111.763 179.841 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 16' ' ' LEU . . . . . 0.407 HD23 ' O ' ' A' ' 12' ' ' ALA . 4.6 mm? -63.78 -39.22 93.72 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.778 0.323 . . . . 0.0 110.965 -179.958 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 17' ' ' VAL . . . . . 0.454 HG13 ' N ' ' A' ' 18' ' ' GLY . 8.5 p -68.09 -44.26 84.68 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.375 0 CA-C-O 121.388 0.613 . . . . 0.0 110.471 179.7 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 18' ' ' GLY . . . . . 0.454 ' N ' HG13 ' A' ' 17' ' ' VAL . . . -64.87 -49.79 61.47 Favored Glycine 0 C--N 1.319 -0.38 0 CA-C-N 114.928 -1.033 . . . . 0.0 111.349 179.135 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 94.2 m -54.11 -42.6 69.62 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-O 120.858 0.361 . . . . 0.0 111.008 179.828 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 20' ' ' LEU . . . . . 0.409 ' O ' ' HB3' ' A' ' 24' ' ' TRP . 67.6 mt -71.83 -42.96 66.36 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.061 -0.518 . . . . 0.0 111.264 179.947 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -59.02 -43.96 91.66 Favored 'General case' 0 C--N 1.329 -0.292 0 N-CA-C 111.805 0.298 . . . . 0.0 111.805 -179.797 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 22' ' ' PHE . . . . . 0.645 ' HB2' HG22 ' A' ' 41' ' ' VAL . 10.6 m-85 -75.53 -42.26 52.93 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.46 -0.337 . . . . 0.0 111.431 -179.291 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -61.79 -50.25 73.11 Favored 'General case' 0 C--N 1.33 -0.283 0 CA-C-O 120.814 0.34 . . . . 0.0 111.023 -179.845 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 24' ' ' TRP . . . . . 0.409 ' HB3' ' O ' ' A' ' 20' ' ' LEU . 1.0 OUTLIER -57.92 -35.77 71.54 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.711 179.75 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -74.55 -30.17 61.64 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 120.955 0.407 . . . . 0.0 110.627 179.56 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -73.69 -38.98 49.79 Favored Glycine 0 N--CA 1.45 -0.387 0 C-N-CA 120.856 -0.687 . . . . 0.0 112.474 179.667 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 82.7 mtp180 -60.66 -41.19 94.49 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 120.879 0.371 . . . . 0.0 110.763 -179.851 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 11.4 t70 -64.51 -17.71 64.14 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.052 -0.522 . . . . 0.0 110.697 179.788 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -114.93 -178.44 3.37 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-N 116.014 -0.539 . . . . 0.0 110.915 179.816 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 164.56 59.32 0.02 OUTLIER Glycine 0 N--CA 1.452 -0.267 0 C-N-CA 120.532 -0.842 . . . . 0.0 112.869 179.89 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 46.5 t -164.07 87.55 0.5 Allowed 'General case' 0 C--N 1.327 -0.398 0 CA-C-O 120.995 0.426 . . . . 0.0 110.66 179.454 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 83.4 -22.08 7.84 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.834 -0.698 . . . . 0.0 112.192 -179.96 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 26.7 mt-10 -91.32 -20.84 21.43 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.7 0.286 . . . . 0.0 110.764 179.999 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 34' ' ' ARG . . . . . . . . . . . . . 15.8 ptp180 -51.51 -31.25 23.17 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 116.106 -0.497 . . . . 0.0 111.48 -179.652 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 89.9 mtm180 -73.51 -52.9 11.96 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.503 -0.317 . . . . 0.0 111.502 -179.7 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 73.6 m-85 -61.74 -30.53 70.83 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.247 -0.433 . . . . 0.0 111.702 -179.483 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 37' ' ' TYR . . . . . 0.416 ' O ' HG23 ' A' ' 41' ' ' VAL . 26.1 m-85 -76.19 -55.27 5.73 Favored 'General case' 0 C--N 1.329 -0.307 0 N-CA-C 111.799 0.296 . . . . 0.0 111.799 -179.129 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 83.8 t -56.89 -36.27 49.47 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-O 120.939 0.4 . . . . 0.0 110.59 179.91 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 39' ' ' THR . . . . . 0.406 ' O ' HG13 ' A' ' 43' ' ' ILE . 54.9 m -64.08 -52.11 60.85 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 115.991 -0.549 . . . . 0.0 111.116 179.718 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 40' ' ' LEU . . . . . 0.458 HD13 ' CE1' ' A' ' 208' ' ' PHE . 7.8 tp -63.3 -50.74 68.88 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.722 -179.81 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 41' ' ' VAL . . . . . 0.645 HG22 ' HB2' ' A' ' 22' ' ' PHE . 96.9 t -55.27 -34.84 34.38 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.356 0 CA-C-N 116.132 -0.485 . . . . 0.0 109.962 178.887 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -62.52 -37.25 94.4 Favored Glycine 0 N--CA 1.448 -0.558 0 C-N-CA 120.821 -0.704 . . . . 0.0 111.616 179.069 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 43' ' ' ILE . . . . . 0.506 HD13 HD13 ' A' ' 83' ' ' ILE . 3.8 mt -62.54 -57.95 9.77 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.158 0 CA-C-O 120.824 0.345 . . . . 0.0 110.732 179.505 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 24.6 t -59.92 -24.79 64.63 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-N 116.293 -0.412 . . . . 0.0 110.983 -179.904 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -71.99 -57.25 5.88 Favored Glycine 0 N--CA 1.452 -0.242 0 C-N-CA 120.805 -0.712 . . . . 0.0 112.427 179.825 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 15.5 pt -59.74 -37.47 71.37 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.229 0 CA-C-O 120.823 0.344 . . . . 0.0 111.007 179.888 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 47' ' ' ALA . . . . . 0.587 ' HB2' ' HE2' ' A' ' 205' ' ' LYS . . . -67.76 -39.33 84.15 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 116.316 -0.402 . . . . 0.0 111.027 179.313 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 48' ' ' ALA . . . . . 0.677 ' HB2' ' HB3' ' A' ' 15' ' ' MET . . . -57.07 -47.2 81.57 Favored 'General case' 0 C--O 1.232 0.177 0 CA-C-N 116.076 -0.511 . . . . 0.0 111.617 -179.658 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 49' ' ' VAL . . . . . 0.454 ' O ' HG13 ' A' ' 53' ' ' VAL . 29.9 m -70.66 -33.64 53.79 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-N 116.11 -0.496 . . . . 0.0 111.414 -179.359 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -62.96 -44.43 96.08 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.932 0.396 . . . . 0.0 111.286 -179.571 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 51' ' ' TYR . . . . . 0.456 ' HE2' ' HE2' ' A' ' 15' ' ' MET . 33.3 m-85 -73.87 -36.22 64.82 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 115.829 -0.623 . . . . 0.0 110.942 -179.419 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -62.74 -45.8 91.01 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 115.841 -0.618 . . . . 0.0 111.157 -179.992 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 53' ' ' VAL . . . . . 0.504 ' HB ' HG11 ' A' ' 58' ' ' VAL . 19.7 m -73.32 -43.51 56.53 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.147 -0.478 . . . . 0.0 111.036 -179.802 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 54' ' ' MET . . . . . 0.492 ' HG3' ' HE1' ' A' ' 60' ' ' TRP . 11.4 ttp -64.94 -29.65 70.6 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.284 179.89 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 55' ' ' ALA . . . . . 0.564 ' HB2' ' HB2' ' A' ' 8' ' ' PHE . . . -65.47 -37.32 86.51 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 115.885 -0.598 . . . . 0.0 111.014 179.254 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 87.2 mt -70.85 -11.47 60.98 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.082 -0.508 . . . . 0.0 111.215 -179.781 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 104.68 17.4 14.95 Favored Glycine 0 CA--C 1.518 0.227 0 C-N-CA 120.742 -0.742 . . . . 0.0 113.296 179.487 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 58' ' ' VAL . . . . . 0.504 HG11 ' HB ' ' A' ' 53' ' ' VAL . 0.4 OUTLIER -89.46 159.36 2.89 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.231 0 CA-C-N 116.913 0.356 . . . . 0.0 110.577 179.729 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 72.44 -12.52 3.38 Favored Glycine 0 N--CA 1.45 -0.412 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.387 -179.456 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 60' ' ' TRP . . . . . 0.492 ' HE1' ' HG3' ' A' ' 54' ' ' MET . 35.1 m0 -69.79 106.68 3.2 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-O 120.663 0.268 . . . . 0.0 110.883 -179.935 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 61' ' ' VAL . . . . . 0.456 HG13 HG23 ' A' ' 68' ' ' VAL . 7.5 p -116.03 128.54 25.9 Favored Pre-proline 0 CA--C 1.533 0.312 0 CA-C-N 116.406 -0.361 . . . . 0.0 111.155 179.821 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 74.0 Cg_endo -75.72 148.48 32.62 Favored 'Trans proline' 0 C--N 1.35 0.646 0 C-N-CA 122.533 2.155 . . . . 0.0 112.441 179.923 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 96.6 t -137.76 91.53 0.79 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.005 -0.543 . . . . 0.0 111.036 -179.878 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . 59.11 -88.53 0.02 OUTLIER 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 116.03 -0.532 . . . . 0.0 111.438 179.961 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 65' ' ' GLU . . . . . 0.524 ' HB2' HH11 ' A' ' 66' ' ' ARG . 11.1 mm-40 -120.54 -18.51 7.79 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-O 120.907 0.384 . . . . 0.0 110.735 179.984 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 66' ' ' ARG . . . . . 0.524 HH11 ' HB2' ' A' ' 65' ' ' GLU . 10.5 mpt_? -102.78 162.62 12.78 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 115.938 -0.574 . . . . 0.0 110.439 179.916 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 31.6 m -123.37 139.9 53.56 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.964 0.411 . . . . 0.0 111.52 -179.654 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 68' ' ' VAL . . . . . 0.523 HG21 ' SD ' ' A' ' 117' ' ' MET . 18.0 m -130.3 146.12 34.56 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.375 0 CA-C-N 115.932 -0.576 . . . . 0.0 110.685 179.711 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 69' ' ' PHE . . . . . . . . . . . . . 9.9 m-85 -109.1 118.03 35.71 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-O 121.048 0.452 . . . . 0.0 110.224 -179.473 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 70' ' ' VAL . . . . . 0.63 HG12 ' HD3' ' A' ' 71' ' ' PRO . 0.5 OUTLIER -67.0 -34.44 7.33 Favored Pre-proline 0 CA--C 1.541 0.6 0 N-CA-C 112.883 0.697 . . . . 0.0 112.883 -179.295 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 71' ' ' PRO . . . . . 0.63 ' HD3' HG12 ' A' ' 70' ' ' VAL . 12.2 Cg_exo -69.63 -17.75 38.01 Favored 'Trans proline' 0 C--N 1.359 1.079 0 C-N-CA 122.259 1.973 . . . . 0.0 113.059 -179.165 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 45.3 ttp180 -74.76 -55.42 5.86 Favored 'General case' 0 C--N 1.33 -0.271 0 N-CA-C 112.276 0.473 . . . . 0.0 112.276 -178.514 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 73' ' ' TYR . . . . . 0.461 ' O ' HG13 ' A' ' 77' ' ' ILE . 24.9 m-85 -71.31 -33.55 69.79 Favored 'General case' 0 C--N 1.329 -0.325 0 C-N-CA 120.764 -0.374 . . . . 0.0 110.669 -179.418 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 74' ' ' ILE . . . . . 0.476 HG22 ' HA ' ' A' ' 71' ' ' PRO . 0.3 OUTLIER -68.95 -39.73 80.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 N-CA-C 110.072 -0.344 . . . . 0.0 110.072 179.256 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 15.4 t70 -59.98 -37.3 79.23 Favored 'General case' 0 CA--C 1.52 -0.197 0 N-CA-C 109.423 -0.584 . . . . 0.0 109.423 179.023 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 76' ' ' TRP . . . . . 0.523 ' HB3' ' SD ' ' A' ' 109' ' ' MET . 49.2 m0 -65.29 -35.49 81.17 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 115.652 -0.703 . . . . 0.0 110.427 179.521 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 77' ' ' ILE . . . . . 0.474 ' O ' ' HG2' ' A' ' 81' ' ' PRO . 78.5 mt -68.12 -30.66 48.73 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.374 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.964 179.773 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 35.2 mt -91.81 -19.55 22.43 Favored 'General case' 0 C--N 1.327 -0.371 0 N-CA-C 112.23 0.456 . . . . 0.0 112.23 -179.76 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 79' ' ' THR . . . . . 0.494 ' HB ' ' HE3' ' A' ' 205' ' ' LYS . 79.3 p -102.35 -47.6 4.44 Favored 'General case' 0 N--CA 1.464 0.238 0 N-CA-C 113.458 0.91 . . . . 0.0 113.458 -177.932 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 80' ' ' THR . . . . . 0.659 ' HB ' ' HD3' ' A' ' 81' ' ' PRO . 80.3 m -51.28 -53.4 49.53 Favored Pre-proline 0 C--N 1.329 -0.297 0 N-CA-C 112.047 0.388 . . . . 0.0 112.047 -179.019 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 81' ' ' PRO . . . . . 0.659 ' HD3' ' HB ' ' A' ' 80' ' ' THR . 50.4 Cg_exo -55.83 -22.03 35.63 Favored 'Trans proline' 0 C--N 1.351 0.691 0 C-N-CA 121.612 1.542 . . . . 0.0 111.704 179.723 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 82' ' ' LEU . . . . . 0.488 ' HB2' ' O ' ' A' ' 79' ' ' THR . 2.8 mm? -76.77 -37.1 56.49 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 115.877 -0.601 . . . . 0.0 110.745 179.807 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 83' ' ' ILE . . . . . 0.506 HD13 HD13 ' A' ' 43' ' ' ILE . 11.9 mm -65.22 -53.76 36.78 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-O 120.857 0.36 . . . . 0.0 110.469 179.67 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 21.9 m -62.63 -31.27 51.5 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.176 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.251 179.335 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 85' ' ' TYR . . . . . . . . . . . . . 82.9 t80 -67.28 -32.44 73.44 Favored 'General case' 0 C--N 1.333 -0.135 0 CA-C-N 115.999 -0.546 . . . . 0.0 110.223 179.158 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 86' ' ' PHE . . . . . . . . . . . . . 9.2 t80 -64.72 -51.96 59.6 Favored 'General case' 0 C--N 1.331 -0.196 0 CA-C-N 116.118 -0.492 . . . . 0.0 109.839 179.37 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 9.2 mp -62.95 -30.45 71.58 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 115.806 -0.634 . . . . 0.0 110.098 179.477 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -69.25 -27.31 73.83 Favored Glycine 0 N--CA 1.448 -0.523 0 C-N-CA 120.914 -0.66 . . . . 0.0 111.546 178.943 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 58.0 mt -72.05 -46.16 58.04 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 120.974 0.416 . . . . 0.0 110.4 179.701 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 98.0 mt -59.27 -37.55 77.93 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 115.844 -0.616 . . . . 0.0 111.074 179.824 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -79.86 -32.75 40.46 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.231 -0.441 . . . . 0.0 111.4 -179.877 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 78.81 51.77 5.31 Favored Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.701 -0.761 . . . . 0.0 111.937 -179.737 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 35.2 mt -62.21 167.16 4.24 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.892 0.377 . . . . 0.0 111.103 -179.632 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 94' ' ' ASP . . . . . . . . . . . . . 28.6 t70 -85.47 168.96 14.07 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.618 179.839 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 75.0 m -54.34 -41.52 69.16 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.45 -0.341 . . . . 0.0 110.975 -179.989 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 34.0 ttm180 -73.89 -44.1 56.36 Favored 'General case' 0 C--N 1.331 -0.197 0 CA-C-N 116.398 -0.364 . . . . 0.0 110.94 179.732 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 97' ' ' GLU . . . . . 0.558 ' HA ' HD12 ' A' ' 100' ' ' ILE . 43.7 mt-10 -53.42 -47.08 69.92 Favored 'General case' 0 C--N 1.331 -0.197 0 CA-C-N 116.128 -0.487 . . . . 0.0 111.435 -179.484 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 98' ' ' PHE . . . . . 0.421 ' O ' HG12 ' A' ' 102' ' ' ILE . 16.9 m-85 -58.03 -49.6 76.3 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-O 120.773 0.321 . . . . 0.0 110.7 179.64 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -58.28 -26.12 58.51 Favored Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.879 -0.677 . . . . 0.0 112.644 -179.95 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 100' ' ' ILE . . . . . 0.558 HD12 ' HA ' ' A' ' 97' ' ' GLU . 94.4 mt -71.56 -52.24 27.4 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-O 120.815 0.34 . . . . 0.0 111.638 -179.71 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 43.4 t -68.21 -37.77 78.58 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.38 0 CA-C-N 116.401 -0.363 . . . . 0.0 111.669 -179.378 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 102' ' ' ILE . . . . . 0.421 HG12 ' O ' ' A' ' 98' ' ' PHE . 49.0 mm -68.22 -47.72 76.89 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.391 -0.368 . . . . 0.0 111.48 -179.628 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 103' ' ' THR . . . . . 0.404 HG22 ' O ' ' A' ' 100' ' ' ILE . 11.1 t -62.03 -31.1 71.46 Favored 'General case' 0 C--N 1.332 -0.174 0 CA-C-O 120.804 0.335 . . . . 0.0 110.723 -179.935 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 104' ' ' LEU . . . . . 0.429 ' O ' HG23 ' A' ' 108' ' ' VAL . 53.3 tp -64.38 -52.98 55.53 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.701 179.556 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 105' ' ' ASN . . . . . 0.616 ' N ' HD22 ' A' ' 105' ' ' ASN . 0.8 OUTLIER -61.51 -26.19 67.76 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.079 -0.51 . . . . 0.0 110.946 179.929 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 40.3 m -65.65 -54.96 20.4 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 115.995 -0.548 . . . . 0.0 111.419 -179.66 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 11.3 p -64.7 -36.41 77.45 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.232 0 CA-C-N 116.366 -0.379 . . . . 0.0 111.215 -179.724 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 108' ' ' VAL . . . . . 0.429 HG23 ' O ' ' A' ' 104' ' ' LEU . 70.1 t -63.46 -49.21 83.63 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.244 0 CA-C-N 116.36 -0.382 . . . . 0.0 110.839 179.67 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 109' ' ' MET . . . . . 0.523 ' SD ' ' HB3' ' A' ' 76' ' ' TRP . 7.7 tpp -63.21 -37.41 87.13 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.749 -179.978 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 22.9 tp -65.9 -30.27 70.84 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-N 115.987 -0.552 . . . . 0.0 110.259 179.782 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -65.03 -54.77 25.12 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-N 115.939 -0.573 . . . . 0.0 110.391 179.354 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 112' ' ' GLY . . . . . 0.455 ' HA3' ' H21' ' A' ' 301' ' ' RET . . . -57.82 -39.67 91.83 Favored Glycine 0 C--N 1.333 0.382 0 C-N-CA 120.576 -0.821 . . . . 0.0 111.701 179.395 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 113' ' ' PHE . . . . . . . . . . . . . 1.3 t80 -51.33 -66.03 0.45 Allowed 'General case' 0 C--N 1.332 -0.181 0 CA-C-O 121.059 0.456 . . . . 0.0 109.934 179.255 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -59.84 -29.31 68.19 Favored 'General case' 0 C--N 1.327 -0.413 0 CA-C-N 115.501 -0.772 . . . . 0.0 111.471 179.809 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 115' ' ' GLY . . . . . 0.403 ' N ' ' HG ' ' A' ' 126' ' ' LEU . . . -52.4 -49.62 50.79 Favored Glycine 0 C--N 1.333 0.377 0 C-N-CA 120.901 -0.666 . . . . 0.0 112.452 179.85 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -77.88 -14.71 59.47 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-O 120.8 0.333 . . . . 0.0 111.168 179.692 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 117' ' ' MET . . . . . 0.523 ' SD ' HG21 ' A' ' 68' ' ' VAL . 24.3 mmt -93.7 15.16 17.02 Favored 'General case' 0 N--CA 1.463 0.185 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.732 -179.391 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 23.3 m -82.13 144.61 51.08 Favored Pre-proline 0 C--N 1.33 -0.267 0 CA-C-O 120.568 0.223 . . . . 0.0 111.565 -179.616 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 119' ' ' PRO . . . . . . . . . . . . . 84.9 Cg_endo -91.18 -9.0 3.15 Favored 'Trans proline' 0 N--CA 1.456 -0.684 0 C-N-CA 122.758 2.305 . . . . 0.0 112.348 179.471 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -132.5 -117.09 1.81 Allowed Glycine 0 C--N 1.332 0.312 0 C-N-CA 120.748 -0.739 . . . . 0.0 113.071 -179.649 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 41.7 pt -116.13 13.72 7.74 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.151 0 CA-C-O 120.723 0.297 . . . . 0.0 111.5 -179.552 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 44.1 mt-10 -62.59 -18.46 62.19 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 116.284 -0.416 . . . . 0.0 111.349 -179.737 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 123' ' ' ARG . . . . . . . . . . . . . 20.4 ptt180 -50.43 -39.44 47.48 Favored 'General case' 0 C--N 1.332 -0.166 0 CA-C-N 116.28 -0.418 . . . . 0.0 111.7 -179.66 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 124' ' ' TYR . . . . . . . . . . . . . 59.5 m-85 -65.87 -32.38 73.86 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-O 120.748 0.308 . . . . 0.0 110.997 -179.851 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 125' ' ' ALA . . . . . . . . . . . . . . . -70.05 -47.64 61.19 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.308 -0.406 . . . . 0.0 111.179 -179.913 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 126' ' ' LEU . . . . . 0.425 HD13 ' HA ' ' A' ' 126' ' ' LEU . 2.6 mm? -54.16 -55.6 26.24 Favored 'General case' 0 C--O 1.233 0.209 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.904 179.924 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 127' ' ' PHE . . . . . . . . . . . . . 10.0 t80 -63.73 -36.77 84.95 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.305 -0.407 . . . . 0.0 111.033 -179.553 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 128' ' ' GLY . . . . . . . . . . . . . . . -46.81 -47.24 19.03 Favored Glycine 0 C--N 1.332 0.321 0 C-N-CA 120.019 -1.086 . . . . 0.0 111.033 179.182 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 129' ' ' MET . . . . . 0.428 ' HE1' ' HA ' ' A' ' 108' ' ' VAL . 0.6 OUTLIER -66.96 -40.04 87.4 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 120.978 0.418 . . . . 0.0 109.994 178.788 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -67.62 -22.9 73.7 Favored Glycine 0 N--CA 1.45 -0.379 0 CA-C-N 115.721 -0.672 . . . . 0.0 112.809 -179.997 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 131' ' ' ALA . . . . . 0.419 ' O ' ' HB3' ' A' ' 134' ' ' PHE . . . -74.63 -53.77 8.71 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.78 0.324 . . . . 0.0 110.423 -179.991 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 16.1 t -60.2 -40.39 83.44 Favored 'Isoleucine or valine' 0 C--O 1.236 0.36 0 N-CA-C 109.085 -0.709 . . . . 0.0 109.085 178.629 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -67.0 -34.55 77.99 Favored 'General case' 0 N--CA 1.451 -0.41 0 CA-C-N 115.125 -0.943 . . . . 0.0 110.302 179.054 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 134' ' ' PHE . . . . . 0.482 ' CZ ' ' HA ' ' A' ' 172' ' ' ALA . 19.4 t80 -56.47 -52.67 63.83 Favored 'General case' 0 N--CA 1.452 -0.352 0 CA-C-N 115.939 -0.573 . . . . 0.0 109.88 179.366 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 135' ' ' ILE . . . . . 0.566 ' O ' HG22 ' A' ' 138' ' ' VAL . 57.6 mt -57.06 -34.13 44.28 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.299 0 CA-C-N 115.742 -0.663 . . . . 0.0 109.857 179.189 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 136' ' ' GLY . . . . . 0.413 ' O ' ' HB3' ' A' ' 139' ' ' TYR . . . -59.99 -34.72 84.58 Favored Glycine 0 N--CA 1.448 -0.538 0 C-N-CA 120.08 -1.057 . . . . 0.0 110.843 178.418 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 137' ' ' LEU . . . . . 0.529 HD13 HD21 ' A' ' 105' ' ' ASN . 38.6 tp -71.11 -52.14 21.05 Favored 'General case' 0 N--CA 1.455 -0.223 0 CA-C-N 115.643 -0.278 . . . . 0.0 110.554 179.399 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 138' ' ' VAL . . . . . 0.566 HG22 ' O ' ' A' ' 135' ' ' ILE . 3.1 m -55.69 -33.92 34.83 Favored 'Isoleucine or valine' 0 C--O 1.233 0.211 0 N-CA-C 109.201 -0.666 . . . . 0.0 109.201 179.063 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 139' ' ' TYR . . . . . 0.413 ' HB3' ' O ' ' A' ' 136' ' ' GLY . 32.0 t80 -57.12 -45.93 83.07 Favored 'General case' 0 C--N 1.331 -0.22 0 N-CA-C 108.848 -0.797 . . . . 0.0 108.848 177.657 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 140' ' ' TYR . . . . . 0.522 ' HB3' ' SD ' ' A' ' 145' ' ' MET . 24.1 m-85 -64.53 -36.54 84.55 Favored 'General case' 0 C--N 1.331 -0.197 0 CA-C-N 115.675 -0.693 . . . . 0.0 109.99 178.422 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 141' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -54.06 -33.61 57.88 Favored 'General case' 0 C--N 1.333 -0.144 0 CA-C-N 115.874 -0.603 . . . . 0.0 110.39 179.142 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 142' ' ' VAL . . . . . 0.568 HG22 HH12 ' A' ' 164' ' ' ARG . 2.6 t -111.09 2.28 8.91 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 115.858 -0.61 . . . . 0.0 110.703 179.642 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . -74.26 -153.05 2.92 Favored Glycine 0 CA--C 1.519 0.338 0 C-N-CA 121.042 -0.599 . . . . 0.0 113.146 -179.415 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 144' ' ' PRO . . . . . . . . . . . . . 31.2 Cg_exo -59.06 -23.6 69.56 Favored 'Trans proline' 0 C--N 1.349 0.588 0 C-N-CA 122.844 2.363 . . . . 0.0 112.768 -179.697 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 145' ' ' MET . . . . . 0.522 ' SD ' ' HB3' ' A' ' 140' ' ' TYR . 80.9 mtp -57.57 -32.81 67.5 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-O 120.89 0.376 . . . . 0.0 111.088 -179.731 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 146' ' ' THR . . . . . . . . . . . . . 36.0 m -75.35 -50.04 17.18 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.087 -0.506 . . . . 0.0 111.452 -179.733 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 43.5 mt-10 -65.68 -29.44 69.99 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.319 -0.401 . . . . 0.0 111.477 -179.615 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 148' ' ' SER . . . . . . . . . . . . . 80.1 p -70.36 -50.04 43.0 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.365 -0.38 . . . . 0.0 110.795 -179.515 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 149' ' ' ALA . . . . . . . . . . . . . . . -69.46 -32.7 71.79 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.4 -179.982 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 150' ' ' SER . . . . . 0.537 ' HA ' ' HB3' ' A' ' 157' ' ' LYS . 90.8 p -68.56 -15.98 63.71 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.361 -179.529 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 151' ' ' GLN . . . . . . . . . . . . . 46.7 mt-30 -113.55 3.55 15.77 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.59 -0.277 . . . . 0.0 111.336 -179.779 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 21.2 tpp180 -75.23 -51.79 12.46 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-O 120.987 0.422 . . . . 0.0 110.536 179.924 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 153' ' ' SER . . . . . 0.676 ' HB3' HG12 ' A' ' 156' ' ' ILE . 8.7 t -157.77 172.48 18.41 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 115.794 -0.639 . . . . 0.0 110.306 179.025 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 154' ' ' SER . . . . . . . . . . . . . 48.7 m -70.01 -40.97 74.91 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.872 0.367 . . . . 0.0 110.846 179.794 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 155' ' ' GLY . . . . . 0.494 ' HA3' HD22 ' A' ' 219' ' ' LEU . . . -77.44 -34.48 40.15 Favored Glycine 0 N--CA 1.45 -0.389 0 C-N-CA 120.89 -0.671 . . . . 0.0 113.03 -179.962 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 156' ' ' ILE . . . . . 0.676 HG12 ' HB3' ' A' ' 153' ' ' SER . 39.5 mm -54.93 -46.42 76.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 N-CA-C 112.147 0.425 . . . . 0.0 112.147 -179.237 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 157' ' ' LYS . . . . . 0.537 ' HB3' ' HA ' ' A' ' 150' ' ' SER . 21.7 pttp -60.62 -39.73 89.28 Favored 'General case' 0 C--N 1.328 -0.34 0 N-CA-C 111.727 0.269 . . . . 0.0 111.727 -179.133 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 59.4 m -65.76 -48.18 72.73 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-O 120.724 0.297 . . . . 0.0 111.76 -179.387 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 159' ' ' LEU . . . . . 0.726 HD13 ' HB3' ' A' ' 215' ' ' ALA . 45.9 tp -68.08 -31.24 70.73 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.382 -0.372 . . . . 0.0 111.197 -179.714 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 160' ' ' TYR . . . . . . . . . . . . . 45.1 t80 -74.15 -47.05 38.45 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.186 -0.461 . . . . 0.0 112.028 -178.988 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 161' ' ' VAL . . . . . 0.454 HG22 ' O ' ' A' ' 157' ' ' LYS . 23.7 m -61.51 -47.34 93.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 N-CA-C 112.149 0.426 . . . . 0.0 112.149 -178.841 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 162' ' ' ARG . . . . . 0.447 ' N ' HG23 ' A' ' 161' ' ' VAL . 27.1 tpt180 -63.24 -49.2 75.08 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.791 0.329 . . . . 0.0 111.423 -179.369 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 163' ' ' LEU . . . . . 0.582 HD13 HD12 ' A' ' 159' ' ' LEU . 6.9 mp -64.73 -53.61 44.53 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.922 -179.266 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 164' ' ' ARG . . . . . 0.568 HH12 HG22 ' A' ' 142' ' ' VAL . 0.9 OUTLIER -59.37 -41.32 89.05 Favored 'General case' 0 CA--C 1.53 0.199 0 CA-C-N 116.373 -0.376 . . . . 0.0 111.99 -178.554 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 165' ' ' ASN . . . . . 0.527 ' O ' HG23 ' A' ' 169' ' ' VAL . 5.4 m-20 -57.25 -51.84 67.74 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-O 120.887 0.375 . . . . 0.0 110.744 179.921 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 166' ' ' LEU . . . . . 0.485 ' O ' ' HG ' ' A' ' 170' ' ' LEU . 3.9 tt -64.25 -43.15 95.76 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-N 115.954 -0.566 . . . . 0.0 111.639 -179.377 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 167' ' ' THR . . . . . 0.475 ' O ' HD12 ' A' ' 170' ' ' LEU . 49.2 m -56.03 -53.74 53.35 Favored 'General case' 0 C--N 1.329 -0.296 0 N-CA-C 112.629 0.603 . . . . 0.0 112.629 -178.576 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 168' ' ' VAL . . . . . . . . . . . . . 9.7 p -61.99 -39.57 84.15 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 N-CA-C 111.956 0.354 . . . . 0.0 111.956 -179.455 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 169' ' ' VAL . . . . . 0.527 HG23 ' O ' ' A' ' 165' ' ' ASN . 46.8 t -55.78 -65.27 0.39 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 N-CA-C 112.558 0.577 . . . . 0.0 112.558 -179.174 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 170' ' ' LEU . . . . . 0.485 ' HG ' ' O ' ' A' ' 166' ' ' LEU . 0.3 OUTLIER -66.71 -24.45 66.25 Favored 'General case' 0 N--CA 1.464 0.229 0 N-CA-C 111.855 0.317 . . . . 0.0 111.855 -178.745 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 171' ' ' TRP . . . . . 0.556 ' HE1' H203 ' A' ' 301' ' ' RET . 9.8 m0 -73.49 -29.27 62.4 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.999 0.428 . . . . 0.0 109.847 179.245 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 172' ' ' ALA . . . . . 0.482 ' HA ' ' CZ ' ' A' ' 134' ' ' PHE . . . -74.7 -8.5 56.58 Favored 'General case' 0 N--CA 1.451 -0.382 0 CA-C-N 115.827 -0.624 . . . . 0.0 110.065 179.232 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 173' ' ' ILE . . . . . 0.7 HG22 HD11 ' A' ' 177' ' ' ILE . 44.5 mm -89.06 -22.8 6.45 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.256 0 CA-C-N 115.516 -0.765 . . . . 0.0 110.405 178.936 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 174' ' ' TYR . . . . . 0.607 ' N ' ' HD2' ' A' ' 175' ' ' PRO . 12.1 m-85 -54.87 -50.26 87.13 Favored Pre-proline 0 N--CA 1.463 0.199 0 CA-C-N 116.047 -0.524 . . . . 0.0 111.831 -179.893 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 175' ' ' PRO . . . . . 0.607 ' HD2' ' N ' ' A' ' 174' ' ' TYR . 2.0 Cg_endo -45.56 -29.31 4.98 Favored 'Trans proline' 0 C--N 1.353 0.791 0 C-N-CA 122.359 2.039 . . . . 0.0 111.768 179.275 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 176' ' ' PHE . . . . . 0.449 ' O ' ' HG ' ' A' ' 180' ' ' LEU . 99.6 m-85 -79.98 -45.7 17.98 Favored 'General case' 0 CA--C 1.516 -0.335 0 CA-C-N 115.921 -0.582 . . . . 0.0 111.078 179.396 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 177' ' ' ILE . . . . . 0.7 HD11 HG22 ' A' ' 173' ' ' ILE . 3.1 mm -58.09 -44.75 87.95 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.613 0 CA-C-N 115.787 -0.642 . . . . 0.0 112.093 -178.491 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 178' ' ' TRP . . . . . 0.407 ' HA ' ' HG2' ' A' ' 182' ' ' PRO . 72.0 t90 -69.04 -38.55 79.2 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-O 121.088 0.471 . . . . 0.0 110.64 179.951 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 179' ' ' LEU . . . . . 0.495 ' O ' HG22 ' A' ' 185' ' ' VAL . 0.4 OUTLIER -66.44 -53.64 33.2 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-N 115.557 -0.747 . . . . 0.0 111.168 -179.273 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 180' ' ' LEU . . . . . 0.523 HD13 HD12 ' A' ' 187' ' ' LEU . 8.3 mt -77.75 -52.03 9.59 Favored 'General case' 0 C--N 1.328 -0.366 0 N-CA-C 112.307 0.484 . . . . 0.0 112.307 -178.674 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 181' ' ' GLY . . . . . 0.42 ' HA3' ' OD1' ' A' ' 193' ' ' ASP . . . -58.34 -85.25 0.04 OUTLIER Glycine 0 C--N 1.336 0.552 0 C-N-CA 120.447 -0.882 . . . . 0.0 112.797 -179.739 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 182' ' ' PRO . . . . . 0.495 ' HD2' ' O ' ' A' ' 177' ' ' ILE . 89.2 Cg_exo -46.1 178.55 0.0 OUTLIER 'Trans proline' 0 C--N 1.349 0.599 0 C-N-CA 123.388 2.725 . . . . 0.0 112.954 179.088 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 183' ' ' PRO . . . . . . . . . . . . . 51.5 Cg_exo -56.82 12.25 0.03 OUTLIER 'Trans proline' 0 C--N 1.351 0.667 0 C-N-CA 122.862 2.375 . . . . 0.0 114.696 -179.558 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 184' ' ' GLY . . . . . 0.458 ' H ' ' C ' ' A' ' 182' ' ' PRO . . . -54.17 -65.08 3.72 Favored Glycine 0 C--N 1.335 0.484 0 C-N-CA 119.84 -1.172 . . . . 0.0 111.06 179.149 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 185' ' ' VAL . . . . . 0.495 HG22 ' O ' ' A' ' 179' ' ' LEU . 3.4 m -135.52 -3.27 1.01 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.368 0 N-CA-C 111.574 0.213 . . . . 0.0 111.574 178.813 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 186' ' ' ALA . . . . . . . . . . . . . . . 45.5 76.49 0.09 Allowed 'General case' 0 N--CA 1.463 0.198 0 N-CA-C 112.316 0.487 . . . . 0.0 112.316 179.324 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 187' ' ' LEU . . . . . 0.523 HD12 HD13 ' A' ' 180' ' ' LEU . 4.2 mt -92.49 -49.31 6.19 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.463 -0.335 . . . . 0.0 111.267 179.683 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 188' ' ' LEU . . . . . . . . . . . . . 92.3 mt -115.48 -168.59 1.43 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 121.087 0.47 . . . . 0.0 111.586 -179.502 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 189' ' ' THR . . . . . 0.484 ' HB ' HG23 ' A' ' 192' ' ' VAL . 96.7 m -76.96 135.28 67.36 Favored Pre-proline 0 C--N 1.329 -0.318 0 CA-C-N 115.667 -0.697 . . . . 0.0 111.039 -179.681 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 190' ' ' PRO . . . . . . . . . . . . . 10.2 Cg_endo -50.29 -41.7 49.85 Favored 'Trans proline' 0 C--N 1.35 0.609 0 C-N-CA 122.684 2.256 . . . . 0.0 112.185 -179.967 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 191' ' ' THR . . . . . 0.451 ' H ' HG22 ' A' ' 189' ' ' THR . 41.5 p -57.2 -46.49 82.82 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.763 179.525 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 192' ' ' VAL . . . . . 0.484 HG23 ' HB ' ' A' ' 189' ' ' THR . 60.3 t -59.13 -39.75 79.3 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.725 179.584 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 193' ' ' ASP . . . . . 0.425 ' OD1' HG22 ' A' ' 177' ' ' ILE . 7.9 t70 -57.72 -41.89 82.72 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 115.932 -0.576 . . . . 0.0 110.646 179.672 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 194' ' ' VAL . . . . . . . . . . . . . 52.5 t -64.71 -36.06 76.53 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 115.984 -0.553 . . . . 0.0 110.918 179.814 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 195' ' ' ALA . . . . . . . . . . . . . . . -59.4 -47.62 84.75 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.451 -0.341 . . . . 0.0 111.017 179.93 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 196' ' ' LEU . . . . . . . . . . . . . 95.9 mt -67.84 -43.13 80.22 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 120.793 0.33 . . . . 0.0 110.525 179.648 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 197' ' ' ILE . . . . . . . . . . . . . 15.5 mm -57.03 -58.89 4.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.012 -0.54 . . . . 0.0 110.296 179.381 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 198' ' ' VAL . . . . . . . . . . . . . 75.2 t -52.74 -34.71 20.25 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.439 0 CA-C-N 115.773 -0.648 . . . . 0.0 109.38 178.429 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 199' ' ' TYR . . . . . . . . . . . . . 46.0 t80 -70.25 -31.44 68.83 Favored 'General case' 0 C--N 1.331 -0.205 0 CA-C-N 115.587 -0.733 . . . . 0.0 110.421 179.678 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 200' ' ' LEU . . . . . . . . . . . . . 54.4 mt -74.07 -38.45 63.92 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 115.756 -0.656 . . . . 0.0 111.365 -179.722 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 201' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -71.44 -35.1 70.79 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 121.15 0.5 . . . . 0.0 110.121 179.483 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 202' ' ' LEU . . . . . 0.433 HD11 ' HA2' ' A' ' 11' ' ' GLY . 4.3 mt -67.21 -41.9 85.01 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 115.43 -0.805 . . . . 0.0 111.721 179.596 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 203' ' ' VAL . . . . . 0.44 ' O ' ' HA3' ' A' ' 207' ' ' GLY . 7.4 p -70.19 -36.82 69.42 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-N 116.376 -0.375 . . . . 0.0 111.946 -178.479 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 204' ' ' THR . . . . . . . . . . . . . 95.1 m -68.9 -57.46 5.5 Favored 'General case' 0 C--N 1.328 -0.353 0 C-N-CA 120.308 -0.557 . . . . 0.0 111.252 179.83 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 205' ' ' LYS . . . . . 0.587 ' HE2' ' HB2' ' A' ' 47' ' ' ALA . 41.7 mttp -67.0 -59.35 3.55 Favored 'General case' 0 C--N 1.328 -0.345 0 N-CA-C 112.714 0.635 . . . . 0.0 112.714 -178.311 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 25.5 t -73.87 -37.3 47.87 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.415 0 N-CA-C 112.184 0.438 . . . . 0.0 112.184 -178.29 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 207' ' ' GLY . . . . . 0.44 ' HA3' ' O ' ' A' ' 203' ' ' VAL . . . -66.89 -57.97 8.94 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.361 -0.923 . . . . 0.0 112.434 -179.309 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 208' ' ' PHE . . . . . 0.458 ' CE1' HD13 ' A' ' 40' ' ' LEU . 0.0 OUTLIER -62.6 -29.24 70.46 Favored 'General case' 0 C--N 1.329 -0.316 0 N-CA-C 110.439 -0.208 . . . . 0.0 110.439 -179.957 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 209' ' ' GLY . . . . . 0.501 ' O ' ' HB3' ' A' ' 212' ' ' ALA . . . -70.78 -36.13 66.32 Favored Glycine 0 N--CA 1.447 -0.574 0 N-CA-C 111.137 -0.785 . . . . 0.0 111.137 178.112 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 210' ' ' PHE . . . . . . . . . . . . . 1.0 OUTLIER -70.13 -43.09 71.65 Favored 'General case' 0 CA--C 1.512 -0.519 0 N-CA-C 107.508 -1.293 . . . . 0.0 107.508 178.37 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 211' ' ' ILE . . . . . . . . . . . . . 36.6 mt -67.41 -28.45 42.25 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.728 0 N-CA-C 107.277 -1.379 . . . . 0.0 107.277 176.502 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 212' ' ' ALA . . . . . 0.501 ' HB3' ' O ' ' A' ' 209' ' ' GLY . . . -66.88 -36.42 82.26 Favored 'General case' 0 N--CA 1.448 -0.549 0 CA-C-N 114.516 -1.22 . . . . 0.0 110.141 179.646 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 213' ' ' LEU . . . . . 0.414 ' HG ' ' O ' ' A' ' 209' ' ' GLY . 92.8 mt -70.31 -52.64 21.27 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 115.086 -0.961 . . . . 0.0 111.872 -179.678 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 214' ' ' ASP . . . . . . . . . . . . . 44.7 m-20 -53.21 -50.71 64.14 Favored 'General case' 0 C--N 1.331 -0.204 0 CA-C-N 116.292 -0.413 . . . . 0.0 111.837 -178.974 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 215' ' ' ALA . . . . . 0.726 ' HB3' HD13 ' A' ' 159' ' ' LEU . . . -65.48 -57.63 7.79 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.558 -0.292 . . . . 0.0 111.726 -179.243 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 216' ' ' ALA . . . . . . . . . . . . . . . -52.12 -43.38 63.94 Favored 'General case' 0 C--N 1.332 -0.184 0 CA-C-O 120.799 0.333 . . . . 0.0 111.497 -179.488 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 217' ' ' ALA . . . . . . . . . . . . . . . -59.05 -42.11 89.49 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.098 179.69 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 218' ' ' THR . . . . . 0.536 ' HA ' ' HB3' ' A' ' 221' ' ' ALA . 78.4 m -65.78 -35.68 81.4 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 115.584 -0.734 . . . . 0.0 110.983 179.715 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 219' ' ' LEU . . . . . 0.514 ' O ' ' HG2' ' A' ' 222' ' ' GLU . 74.3 mt -57.74 -46.15 84.87 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-O 120.936 0.398 . . . . 0.0 110.246 179.822 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 220' ' ' ARG . . . . . 0.47 HH11 ' HB2' ' A' ' 219' ' ' LEU . 10.4 mpt_? -84.63 -14.13 49.54 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 115.961 -0.563 . . . . 0.0 110.798 179.178 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 221' ' ' ALA . . . . . 0.536 ' HB3' ' HA ' ' A' ' 218' ' ' THR . . . -80.4 -19.74 45.57 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 116.169 -0.469 . . . . 0.0 112.206 -179.581 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 222' ' ' GLU . . . . . 0.514 ' HG2' ' O ' ' A' ' 219' ' ' LEU . 12.9 pt-20 -81.79 -7.73 59.63 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-O 120.771 0.32 . . . . 0.0 111.052 -179.437 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 223' ' ' HIS . . . . . . . . . . . . . 23.0 p80 -146.61 -164.32 1.95 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.267 -0.424 . . . . 0.0 111.092 -179.865 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 224' ' ' GLY . . . . . . . . . . . . . . . 163.48 -35.03 0.3 Allowed Glycine 0 N--CA 1.452 -0.262 0 C-N-CA 120.978 -0.63 . . . . 0.0 112.312 -179.843 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 225' ' ' GLU . . . . . 0.617 ' HG2' ' H ' ' A' ' 227' ' ' LEU . 44.1 tt0 -118.24 131.65 56.35 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.722 0.296 . . . . 0.0 110.608 179.787 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 226' ' ' SER . . . . . . . . . . . . . 54.3 m -94.19 -3.35 51.01 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.263 -0.426 . . . . 0.0 111.231 -179.606 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 227' ' ' LEU . . . . . 0.617 ' H ' ' HG2' ' A' ' 225' ' ' GLU . 4.0 tt -86.53 125.65 33.91 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.351 -0.386 . . . . 0.0 110.814 -179.741 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 228' ' ' ALA . . . . . 0.438 ' N ' HD23 ' A' ' 227' ' ' LEU . . . -144.46 118.74 9.56 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.198 -0.456 . . . . 0.0 111.08 179.791 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 229' ' ' GLY . . . . . . . . . . . . . . . 173.37 48.57 0.05 OUTLIER Glycine 0 CA--C 1.518 0.257 0 C-N-CA 120.806 -0.711 . . . . 0.0 112.512 179.94 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 230' ' ' VAL . . . . . . . . . . . . . 30.4 m -112.52 158.36 12.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-O 120.809 0.338 . . . . 0.0 111.381 -179.996 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 231' ' ' ASP . . . . . . . . . . . . . 24.5 t70 -134.67 99.28 4.29 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.086 -0.507 . . . . 0.0 110.704 179.739 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 232' ' ' THR . . . . . . . . . . . . . 67.8 p -122.11 -20.94 6.09 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.185 -0.462 . . . . 0.0 111.184 -179.755 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 233' ' ' ASP . . . . . . . . . . . . . 10.3 m-20 -64.02 -22.21 66.83 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.9 179.987 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 234' ' ' THR . . . . . . . . . . . . . 49.4 p -134.88 91.1 20.69 Favored Pre-proline 0 C--N 1.329 -0.319 0 CA-C-N 116.123 -0.49 . . . . 0.0 111.047 179.904 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 235' ' ' PRO . . . . . . . . . . . . . 78.1 Cg_exo -52.59 138.37 58.18 Favored 'Trans proline' 0 C--N 1.347 0.491 0 C-N-CA 122.543 2.162 . . . . 0.0 112.453 179.982 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 236' ' ' ALA . . . . . . . . . . . . . . . 61.0 173.74 0.1 Allowed 'General case' 0 C--N 1.331 -0.2 0 CA-C-N 115.985 -0.552 . . . . 0.0 111.311 179.908 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 237' ' ' VAL . . . . . . . . . . . . . 26.0 m -92.78 140.38 16.38 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.379 0 CA-C-N 116.055 -0.521 . . . . 0.0 111.329 -179.828 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 238' ' ' ALA . . . . . . . . . . . . . . . -161.67 -62.39 0.05 Allowed 'General case' 0 C--N 1.331 -0.216 0 CA-C-N 115.929 -0.578 . . . . 0.0 110.942 -179.96 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 239' ' ' ASP . . . . . . . . . . . . . 7.2 m-20 -97.62 107.36 19.84 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.255 -0.429 . . . . 0.0 110.994 179.86 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 240' ' ' LEU . . . . . . . . . . . . . 90.4 mt -116.56 107.33 14.59 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.96 179.937 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 241' ' ' GLU . . . . . . . . . . . . . 44.3 mt-10 57.28 -171.0 0.09 Allowed 'General case' 0 C--N 1.332 -0.169 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.109 -179.95 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 242' ' ' HIS . . . . . . . . . . . . . 32.0 p80 -88.34 175.35 7.68 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.839 179.841 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 243' ' ' HIS . . . . . . . . . . . . . 35.7 t-80 -70.45 123.52 21.98 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.312 -0.404 . . . . 0.0 111.115 -179.784 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 244' ' ' HIS . . . . . . . . . . . . . 52.8 t-80 -173.97 114.61 0.21 Allowed 'General case' 0 C--N 1.332 -0.186 0 CA-C-N 116.059 -0.519 . . . . 0.0 110.976 179.946 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 245' ' ' HIS . . . . . . . . . . . . . 10.9 p-80 -70.9 164.76 24.72 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.397 -0.365 . . . . 0.0 110.714 179.748 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 246' ' ' HIS . . . . . . . . . . . . . 66.1 m80 -128.0 -26.84 2.83 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.38 -0.373 . . . . 0.0 111.197 -179.772 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 247' ' ' HIS . . . . . . . . . . . . . 40.4 t-80 . . . . . 0 C--O 1.249 1.045 0 CA-C-O 118.25 -0.881 . . . . 0.0 110.686 -179.993 . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 301' ' ' RET . . . . . 0.556 H203 ' HE1' ' A' ' 171' ' ' TRP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 71.7 mtm . . . . . 0 N--CA 1.485 1.303 0 CA-C-O 120.901 0.381 . . . . 0.0 110.994 . . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 34.5 m -74.83 -23.49 17.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.062 -0.517 . . . . 0.0 111.185 -179.957 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -111.5 -15.91 9.94 Favored Glycine 0 N--CA 1.452 -0.277 0 C-N-CA 120.793 -0.718 . . . . 0.0 112.692 -179.857 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 56.2 tp -73.96 -35.82 64.56 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.817 0.341 . . . . 0.0 111.121 -179.913 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 60.7 p -68.08 -31.69 71.5 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.501 -179.59 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 21.3 p -52.31 -35.32 50.24 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.257 -0.429 . . . . 0.0 111.384 -179.772 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 7' ' ' LEU . . . . . . . . . . . . . 4.1 mm? -57.87 -53.75 54.74 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.26 -0.427 . . . . 0.0 111.364 -179.731 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 8' ' ' PHE . . . . . 0.68 ' HB2' ' HB2' ' A' ' 55' ' ' ALA . 63.4 m-85 -62.32 -33.29 74.39 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.31 -0.405 . . . . 0.0 110.763 -179.81 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 9' ' ' TRP . . . . . 0.465 ' O ' HG13 ' A' ' 13' ' ' ILE . 55.1 m95 -65.97 -40.83 91.59 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 116.029 -0.532 . . . . 0.0 110.101 -179.988 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 63.9 mt -66.48 -39.61 88.88 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 115.854 -0.612 . . . . 0.0 110.136 179.387 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 11' ' ' GLY . . . . . 0.425 ' HA2' HD11 ' A' ' 202' ' ' LEU . . . -68.32 -28.8 73.11 Favored Glycine 0 N--CA 1.446 -0.665 0 C-N-CA 120.804 -0.712 . . . . 0.0 111.796 179.357 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -71.99 -33.87 68.46 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 120.786 0.327 . . . . 0.0 110.578 179.52 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 13' ' ' ILE . . . . . 0.465 HG13 ' O ' ' A' ' 9' ' ' TRP . 75.0 mt -64.95 -54.08 33.95 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.173 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.248 179.172 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -61.17 -39.05 96.61 Favored Glycine 0 N--CA 1.45 -0.42 0 C-N-CA 120.5 -0.857 . . . . 0.0 111.55 179.4 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 15' ' ' MET . . . . . 0.473 ' SD ' ' HA ' ' A' ' 44' ' ' SER . 60.3 tpp -61.56 -41.44 97.37 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 120.868 0.366 . . . . 0.0 110.014 179.366 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 6.3 tt -57.53 -38.88 75.43 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 115.888 -0.596 . . . . 0.0 109.911 179.334 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 17' ' ' VAL . . . . . 0.41 HG23 ' O ' ' A' ' 13' ' ' ILE . 34.6 t -59.38 -46.65 92.44 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.221 0 CA-C-N 115.946 -0.57 . . . . 0.0 110.162 179.19 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -62.91 -41.96 99.77 Favored Glycine 0 N--CA 1.45 -0.375 0 C-N-CA 120.616 -0.802 . . . . 0.0 111.66 178.981 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 9.7 m -50.3 -49.19 54.36 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.698 0.285 . . . . 0.0 111.354 -179.942 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 87.5 mt -71.87 -42.09 67.25 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.694 -179.594 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -58.43 -33.42 69.67 Favored 'General case' 0 C--N 1.33 -0.265 0 N-CA-C 112.155 0.428 . . . . 0.0 112.155 -179.135 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 22' ' ' PHE . . . . . 0.576 ' HB2' HG22 ' A' ' 41' ' ' VAL . 6.8 m-85 -91.46 -37.09 13.39 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.851 0.358 . . . . 0.0 111.535 -179.526 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -64.7 -51.31 63.14 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.912 -179.231 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 24' ' ' TRP . . . . . . . . . . . . . 7.1 t-105 -63.42 -49.45 73.68 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-N 115.754 -0.657 . . . . 0.0 111.312 -179.295 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -64.63 -23.02 67.13 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 120.879 0.371 . . . . 0.0 110.793 179.906 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -73.07 -40.06 51.99 Favored Glycine 0 N--CA 1.45 -0.423 0 C-N-CA 120.807 -0.711 . . . . 0.0 112.263 179.655 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 97.9 mtt180 -71.56 -19.3 62.17 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 120.839 0.352 . . . . 0.0 110.814 179.797 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 19.2 t70 -93.08 -9.93 37.88 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.541 179.843 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -73.29 -169.52 0.65 Allowed 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 115.998 -0.546 . . . . 0.0 111.37 -179.904 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -84.31 -129.56 1.84 Allowed Glycine 0 N--CA 1.452 -0.276 0 C-N-CA 120.818 -0.706 . . . . 0.0 112.642 -179.828 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 44.0 t -125.81 -42.92 1.88 Allowed 'General case' 0 C--N 1.332 -0.191 0 CA-C-O 120.83 0.347 . . . . 0.0 111.099 -179.966 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -73.53 -45.17 30.3 Favored Glycine 0 C--N 1.332 0.316 0 C-N-CA 120.702 -0.761 . . . . 0.0 112.432 -179.998 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 7.8 mm-40 -69.35 -20.47 63.85 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-O 120.759 0.314 . . . . 0.0 110.762 179.88 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 34' ' ' ARG . . . . . . . . . . . . . 75.0 ttt180 -48.67 -29.68 4.65 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 115.972 -0.558 . . . . 0.0 111.615 -179.688 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 37.4 ttm180 -58.34 -46.53 86.06 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-O 120.818 0.342 . . . . 0.0 111.046 -179.986 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 68.1 m-85 -69.51 -29.73 67.41 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.081 -0.508 . . . . 0.0 111.388 -179.678 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 37' ' ' TYR . . . . . 0.47 ' O ' HG23 ' A' ' 41' ' ' VAL . 63.2 m-85 -73.96 -56.1 5.35 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.413 -179.478 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 60.3 t -57.09 -38.64 61.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-O 120.984 0.421 . . . . 0.0 110.682 179.891 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 48.9 m -62.31 -49.05 77.18 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 115.858 -0.61 . . . . 0.0 110.447 179.243 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 40' ' ' LEU . . . . . 0.594 HD12 HD12 ' A' ' 43' ' ' ILE . 46.4 tp -55.56 -45.57 77.26 Favored 'General case' 0 C--O 1.236 0.346 0 CA-C-N 115.612 -0.722 . . . . 0.0 110.233 179.495 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 41' ' ' VAL . . . . . 0.576 HG22 ' HB2' ' A' ' 22' ' ' PHE . 60.1 t -63.17 -34.31 66.09 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.345 0 CA-C-N 115.645 -0.707 . . . . 0.0 110.172 179.283 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -59.49 -35.19 84.46 Favored Glycine 0 N--CA 1.449 -0.44 0 C-N-CA 120.69 -0.767 . . . . 0.0 111.538 179.554 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 43' ' ' ILE . . . . . 0.594 HD12 HD12 ' A' ' 40' ' ' LEU . 1.0 OUTLIER -68.91 -54.71 18.9 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.229 0 CA-C-O 120.797 0.332 . . . . 0.0 110.591 179.331 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 44' ' ' SER . . . . . 0.473 ' HA ' ' SD ' ' A' ' 15' ' ' MET . 32.3 t -58.74 -24.95 62.46 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.306 -179.943 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -76.16 -55.35 4.81 Favored Glycine 0 N--CA 1.45 -0.405 0 C-N-CA 120.683 -0.77 . . . . 0.0 112.747 -179.791 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 20.3 pt -59.78 -36.81 68.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-O 120.745 0.307 . . . . 0.0 111.421 -179.793 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 47' ' ' ALA . . . . . 0.764 ' HB2' ' HE2' ' A' ' 205' ' ' LYS . . . -67.89 -44.51 76.84 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-N 116.395 -0.366 . . . . 0.0 111.243 179.708 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -54.46 -48.0 72.28 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 115.918 -0.583 . . . . 0.0 111.672 -179.398 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 49' ' ' VAL . . . . . 0.415 ' O ' HG13 ' A' ' 53' ' ' VAL . 18.0 m -68.33 -33.92 63.15 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-N 116.255 -0.429 . . . . 0.0 111.371 -179.481 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -66.06 -37.5 85.99 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 120.864 0.364 . . . . 0.0 111.275 179.97 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 51' ' ' TYR . . . . . 0.447 ' OH ' ' HB2' ' A' ' 201' ' ' ASP . 29.5 m-85 -70.82 -44.0 67.45 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.458 -179.829 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -61.14 -51.92 67.06 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-N 115.53 -0.759 . . . . 0.0 111.251 179.814 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 53' ' ' VAL . . . . . 0.527 HG23 ' N ' ' A' ' 54' ' ' MET . 33.0 m -60.88 -50.95 78.43 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.2 0 CA-C-N 116.455 -0.338 . . . . 0.0 110.869 -179.976 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 54' ' ' MET . . . . . 0.57 ' HG3' ' HE1' ' A' ' 60' ' ' TRP . 8.8 ttp -60.34 -29.2 68.74 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 121.082 0.468 . . . . 0.0 109.792 179.499 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 55' ' ' ALA . . . . . 0.68 ' HB2' ' HB2' ' A' ' 8' ' ' PHE . . . -73.17 -30.6 63.68 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 115.71 -0.677 . . . . 0.0 110.843 179.043 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 87.4 mt -78.25 0.4 25.38 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.058 -179.865 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 92.0 -22.15 33.17 Favored Glycine 0 N--CA 1.45 -0.397 0 C-N-CA 120.63 -0.795 . . . . 0.0 113.127 179.776 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 58' ' ' VAL . . . . . 0.458 HG12 ' O ' ' A' ' 53' ' ' VAL . 12.5 p -67.79 142.8 16.01 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.176 0 CA-C-O 120.885 0.374 . . . . 0.0 110.77 -179.966 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 97.72 -11.66 64.55 Favored Glycine 0 N--CA 1.452 -0.287 0 C-N-CA 120.88 -0.676 . . . . 0.0 112.105 -179.329 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 60' ' ' TRP . . . . . 0.57 ' HE1' ' HG3' ' A' ' 54' ' ' MET . 28.6 m0 -78.49 115.09 17.96 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.685 0.279 . . . . 0.0 110.504 179.869 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 61' ' ' VAL . . . . . 0.402 ' HA ' ' HD3' ' A' ' 62' ' ' PRO . 10.7 p -118.02 125.29 28.06 Favored Pre-proline 0 CA--C 1.532 0.287 0 CA-C-N 116.518 -0.31 . . . . 0.0 111.518 -179.838 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 62' ' ' PRO . . . . . 0.402 ' HD3' ' HA ' ' A' ' 61' ' ' VAL . 17.1 Cg_exo -67.75 155.53 69.58 Favored 'Trans proline' 0 C--N 1.351 0.678 0 C-N-CA 122.553 2.168 . . . . 0.0 111.965 179.652 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 93.2 t -143.09 92.15 0.47 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-N 115.989 -0.55 . . . . 0.0 111.041 179.995 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . 58.41 -85.78 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.039 -0.528 . . . . 0.0 111.63 179.801 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 37.7 mt-10 -119.72 -22.57 6.81 Favored 'General case' 0 C--N 1.332 -0.192 0 CA-C-N 116.42 -0.355 . . . . 0.0 111.141 -179.659 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 66' ' ' ARG . . . . . . . . . . . . . 32.3 mmt180 -105.94 158.06 17.05 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.683 -179.872 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 92.9 m -111.68 131.11 55.52 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.905 0.384 . . . . 0.0 111.492 -179.635 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 61.8 t -113.8 146.46 18.35 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 115.899 -0.591 . . . . 0.0 110.534 179.343 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 69' ' ' PHE . . . . . . . . . . . . . 44.6 m-85 -108.89 111.97 23.96 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-N 116.174 -0.467 . . . . 0.0 110.141 -179.447 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 70' ' ' VAL . . . . . 0.63 ' N ' ' HD2' ' A' ' 71' ' ' PRO . 21.8 t -69.2 -49.62 23.48 Favored Pre-proline 0 C--N 1.324 -0.535 0 CA-C-N 116.219 -0.446 . . . . 0.0 112.202 -179.252 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 71' ' ' PRO . . . . . 0.63 ' HD2' ' N ' ' A' ' 70' ' ' VAL . 6.3 Cg_endo -48.45 -26.27 8.55 Favored 'Trans proline' 0 C--N 1.353 0.779 0 C-N-CA 122.422 2.081 . . . . 0.0 112.63 -179.524 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 55.5 ttp180 -75.23 -53.79 8.21 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-O 120.922 0.392 . . . . 0.0 111.123 -179.934 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 73' ' ' TYR . . . . . 0.441 ' OH ' ' HB2' ' A' ' 116' ' ' ALA . 67.4 m-85 -65.27 -47.97 74.82 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.094 -0.503 . . . . 0.0 111.3 -179.574 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 74' ' ' ILE . . . . . 0.48 ' O ' HD13 ' A' ' 74' ' ' ILE . 0.3 OUTLIER -59.35 -41.45 84.33 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-N 116.499 -0.319 . . . . 0.0 110.557 179.884 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 31.7 t70 -59.23 -36.53 75.61 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-O 121.023 0.44 . . . . 0.0 109.916 179.283 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 76' ' ' TRP . . . . . . . . . . . . . 47.4 m0 -66.97 -31.27 71.72 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 115.786 -0.643 . . . . 0.0 110.627 179.798 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 77' ' ' ILE . . . . . 0.485 HG12 ' HB3' ' A' ' 109' ' ' MET . 51.0 mt -73.22 -28.87 26.75 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.614 179.479 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 43.7 mt -91.75 -20.35 21.63 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.985 179.872 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 71.0 p -101.63 -52.67 3.15 Favored 'General case' 0 C--N 1.332 -0.176 0 N-CA-C 113.432 0.901 . . . . 0.0 113.432 -177.817 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 80' ' ' THR . . . . . 0.678 ' HB ' ' HD3' ' A' ' 81' ' ' PRO . 26.9 m -51.24 -55.17 30.86 Favored Pre-proline 0 C--N 1.33 -0.242 0 N-CA-C 112.327 0.491 . . . . 0.0 112.327 -178.258 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 81' ' ' PRO . . . . . 0.678 ' HD3' ' HB ' ' A' ' 80' ' ' THR . 36.0 Cg_exo -60.86 -20.41 66.41 Favored 'Trans proline' 0 C--N 1.352 0.752 0 C-N-CA 121.613 1.542 . . . . 0.0 111.459 179.74 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 82' ' ' LEU . . . . . . . . . . . . . 14.7 tp -76.79 -33.77 58.01 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 115.823 -0.626 . . . . 0.0 110.258 179.599 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 83' ' ' ILE . . . . . 0.498 HD13 HD13 ' A' ' 43' ' ' ILE . 42.2 mm -70.01 -52.54 29.83 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.149 0 CA-C-N 116.087 -0.506 . . . . 0.0 110.296 179.096 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 84' ' ' VAL . . . . . 0.57 HG11 HD22 ' A' ' 105' ' ' ASN . 29.8 m -59.51 -31.79 47.5 Favored 'Isoleucine or valine' 0 CA--C 1.52 -0.193 0 N-CA-C 109.736 -0.468 . . . . 0.0 109.736 178.693 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 85' ' ' TYR . . . . . . . . . . . . . 67.7 t80 -65.69 -33.54 76.12 Favored 'General case' 0 N--CA 1.453 -0.317 0 CA-C-N 115.636 -0.711 . . . . 0.0 109.334 178.72 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 86' ' ' PHE . . . . . . . . . . . . . 4.3 t80 -60.63 -51.71 68.26 Favored 'General case' 0 C--O 1.233 0.22 0 CA-C-N 115.646 -0.707 . . . . 0.0 109.719 178.858 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 9.1 mp -61.37 -31.22 71.11 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 115.741 -0.663 . . . . 0.0 110.506 179.526 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -71.89 -28.01 69.56 Favored Glycine 0 N--CA 1.449 -0.476 0 C-N-CA 120.81 -0.71 . . . . 0.0 112.144 179.801 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 65.5 mt -71.28 -45.06 64.0 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-O 120.877 0.37 . . . . 0.0 110.591 179.838 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 69.5 mt -58.44 -51.84 68.15 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 115.988 -0.551 . . . . 0.0 110.926 179.844 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 91' ' ' ALA . . . . . 0.464 ' HA ' ' HA ' ' A' ' 149' ' ' ALA . . . -61.69 -36.81 81.96 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.278 -0.419 . . . . 0.0 111.427 -179.872 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 88.38 49.56 3.66 Favored Glycine 0 N--CA 1.452 -0.271 0 C-N-CA 120.826 -0.702 . . . . 0.0 112.033 -179.633 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 93' ' ' LEU . . . . . 0.484 ' HB3' ' HB2' ' A' ' 97' ' ' GLU . 71.6 mt -67.53 178.55 1.58 Allowed 'General case' 0 C--N 1.328 -0.349 0 CA-C-O 120.917 0.389 . . . . 0.0 111.357 -179.662 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 94' ' ' ASP . . . . . . . . . . . . . 20.6 t70 -106.18 167.05 10.07 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-N 116.019 -0.537 . . . . 0.0 110.448 179.75 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 65.7 m -52.72 -34.99 55.01 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 116.46 -0.337 . . . . 0.0 111.26 -179.889 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 12.7 ptm180 -73.32 -46.79 47.39 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.381 -0.372 . . . . 0.0 111.066 -179.978 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 97' ' ' GLU . . . . . 0.484 ' HB2' ' HB3' ' A' ' 93' ' ' LEU . 45.9 mt-10 -57.74 -45.41 85.89 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.429 -0.35 . . . . 0.0 110.837 179.964 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 98' ' ' PHE . . . . . 0.49 ' O ' HG12 ' A' ' 102' ' ' ILE . 42.3 m-85 -60.18 -45.87 91.64 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.303 -0.408 . . . . 0.0 110.377 179.464 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -56.6 -30.0 58.54 Favored Glycine 0 N--CA 1.45 -0.414 0 C-N-CA 120.549 -0.834 . . . . 0.0 112.304 179.776 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 74.1 mt -73.5 -47.24 46.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 N-CA-C 112.097 0.406 . . . . 0.0 112.097 -179.761 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 101' ' ' VAL . . . . . 0.42 HG12 ' H ' ' A' ' 101' ' ' VAL . 1.1 p -70.52 -42.76 78.22 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-O 120.654 0.264 . . . . 0.0 111.634 -179.712 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 102' ' ' ILE . . . . . 0.49 HG12 ' O ' ' A' ' 98' ' ' PHE . 45.2 mm -62.13 -45.14 99.41 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.36 0 CA-C-N 116.426 -0.352 . . . . 0.0 111.042 -179.627 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 103' ' ' THR . . . . . 0.412 ' O ' HG23 ' A' ' 107' ' ' VAL . 13.6 t -66.88 -29.87 69.89 Favored 'General case' 0 C--N 1.332 -0.167 0 CA-C-O 120.817 0.341 . . . . 0.0 110.346 179.559 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 1.2 tm? -59.76 -56.06 26.51 Favored 'General case' 0 C--N 1.331 -0.206 0 N-CA-C 109.501 -0.555 . . . . 0.0 109.501 179.108 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 105' ' ' ASN . . . . . 0.651 HD21 HG22 ' A' ' 80' ' ' THR . 3.0 m-20 -57.3 -32.45 66.67 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 115.855 -0.611 . . . . 0.0 110.663 179.232 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 58.0 m -57.65 -48.86 78.32 Favored 'General case' 0 C--N 1.332 -0.183 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.95 179.78 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 107' ' ' VAL . . . . . 0.412 HG23 ' O ' ' A' ' 103' ' ' THR . 2.1 t -61.54 -40.85 87.94 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-O 121.149 0.5 . . . . 0.0 110.122 179.623 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 99.0 t -58.92 -43.73 89.25 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.377 0 CA-C-N 115.294 -0.867 . . . . 0.0 111.406 -179.956 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 109' ' ' MET . . . . . 0.485 ' HB3' HG12 ' A' ' 77' ' ' ILE . 15.3 mmt -70.51 -41.51 72.52 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.666 -179.332 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 32.5 tp -59.65 -31.09 69.21 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-O 120.882 0.372 . . . . 0.0 110.569 -179.872 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -70.15 -53.48 17.04 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.758 179.649 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 112' ' ' GLY . . . . . 0.541 ' HA3' ' H21' ' A' ' 301' ' ' RET . . . -59.58 -45.62 95.33 Favored Glycine 0 C--N 1.331 0.299 0 C-N-CA 120.707 -0.759 . . . . 0.0 112.301 179.751 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 113' ' ' PHE . . . . . . . . . . . . . 1.5 t80 -50.97 -60.5 3.03 Favored 'General case' 0 C--N 1.332 -0.171 0 CA-C-O 120.996 0.427 . . . . 0.0 110.116 179.488 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 114' ' ' ALA . . . . . 0.49 ' HB3' HD22 ' A' ' 126' ' ' LEU . . . -66.45 -19.81 65.89 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 115.733 -0.667 . . . . 0.0 110.6 179.451 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -59.0 -45.84 94.61 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.86 -0.686 . . . . 0.0 112.042 179.646 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 116' ' ' ALA . . . . . 0.441 ' HB2' ' OH ' ' A' ' 73' ' ' TYR . . . -78.16 -21.2 50.56 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.804 0.335 . . . . 0.0 111.359 179.67 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 117' ' ' MET . . . . . . . . . . . . . 24.8 mmt -83.24 19.87 1.4 Allowed 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.846 -179.253 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 118' ' ' VAL . . . . . 0.549 HG21 ' HB3' ' A' ' 123' ' ' ARG . 24.7 m -90.73 141.67 27.13 Favored Pre-proline 0 C--N 1.329 -0.294 0 CA-C-O 120.646 0.26 . . . . 0.0 111.614 -179.717 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 119' ' ' PRO . . . . . . . . . . . . . 97.3 Cg_endo -92.52 -6.75 3.05 Favored 'Trans proline' 0 N--CA 1.455 -0.774 0 C-N-CA 122.882 2.388 . . . . 0.0 112.379 179.455 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -139.41 -115.38 1.27 Allowed Glycine 0 C--N 1.332 0.314 0 C-N-CA 120.589 -0.815 . . . . 0.0 113.023 -179.586 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 38.3 pt -119.29 15.03 6.85 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.233 0 CA-C-O 120.686 0.279 . . . . 0.0 111.67 -179.345 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 10.9 mm-40 -62.11 -18.61 61.33 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.383 -0.371 . . . . 0.0 110.99 179.752 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 123' ' ' ARG . . . . . 0.549 ' HB3' HG21 ' A' ' 118' ' ' VAL . 24.2 ptt180 -54.54 -33.42 60.05 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 115.973 -0.558 . . . . 0.0 111.785 -179.751 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 124' ' ' TYR . . . . . . . . . . . . . 37.3 m-85 -65.73 -32.22 73.65 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 120.829 0.347 . . . . 0.0 111.108 -179.593 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 125' ' ' ALA . . . . . . . . . . . . . . . -72.62 -56.17 5.73 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.0 179.92 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 126' ' ' LEU . . . . . 0.49 HD22 ' HB3' ' A' ' 114' ' ' ALA . 1.3 mt -55.68 -45.44 77.77 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 115.789 -0.642 . . . . 0.0 110.488 -179.991 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 127' ' ' PHE . . . . . 0.437 ' CE1' ' H42' ' A' ' 301' ' ' RET . 7.6 t80 -67.3 -37.37 83.27 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.464 179.612 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 128' ' ' GLY . . . . . . . . . . . . . . . -47.1 -45.03 20.14 Favored Glycine 0 C--N 1.332 0.331 0 C-N-CA 120.2 -1.0 . . . . 0.0 110.748 178.866 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 129' ' ' MET . . . . . . . . . . . . . 0.4 OUTLIER -70.95 -35.85 72.35 Favored 'General case' 0 C--N 1.328 -0.328 0 N-CA-C 109.826 -0.435 . . . . 0.0 109.826 178.578 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -62.67 -36.38 93.19 Favored Glycine 0 C--N 1.332 0.354 0 CA-C-N 115.777 -0.647 . . . . 0.0 112.626 -179.926 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -69.66 -53.34 19.13 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.602 0.239 . . . . 0.0 110.42 179.78 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 54.5 t -55.38 -39.99 55.31 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.234 0 CA-C-O 121.376 0.608 . . . . 0.0 109.595 178.879 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -69.12 -35.29 76.26 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 115.278 -0.874 . . . . 0.0 110.51 179.316 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 134' ' ' PHE . . . . . . . . . . . . . 73.5 t80 -56.94 -57.58 11.89 Favored 'General case' 0 N--CA 1.451 -0.415 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.146 179.823 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 135' ' ' ILE . . . . . 0.555 ' O ' HG22 ' A' ' 138' ' ' VAL . 0.0 OUTLIER -56.18 -32.84 35.48 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.002 -0.545 . . . . 0.0 109.61 178.761 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 136' ' ' GLY . . . . . 0.4 ' O ' ' HB3' ' A' ' 139' ' ' TYR . . . -57.33 -39.15 89.9 Favored Glycine 0 N--CA 1.447 -0.58 0 C-N-CA 120.302 -0.951 . . . . 0.0 111.086 178.389 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 137' ' ' LEU . . . . . 0.41 HD21 ' HZ3' ' A' ' 171' ' ' TRP . 27.8 tp -68.3 -53.84 21.58 Favored 'General case' 0 C--N 1.331 -0.197 0 CA-C-O 120.579 0.228 . . . . 0.0 110.644 179.212 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 138' ' ' VAL . . . . . 0.555 HG22 ' O ' ' A' ' 135' ' ' ILE . 3.0 m -56.15 -30.24 29.07 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.204 0 CA-C-O 121.137 0.494 . . . . 0.0 109.742 179.482 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 139' ' ' TYR . . . . . 0.4 ' HB3' ' O ' ' A' ' 136' ' ' GLY . 35.2 t80 -63.7 -44.22 94.29 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 115.441 -0.8 . . . . 0.0 110.202 178.945 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 37.8 m-85 -63.04 -34.95 78.68 Favored 'General case' 0 C--N 1.331 -0.198 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.696 179.434 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 141' ' ' LEU . . . . . 0.407 HD23 ' SD ' ' A' ' 145' ' ' MET . 89.7 mt -62.92 -51.11 68.21 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.005 -179.943 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 15.0 p -81.87 -11.01 12.31 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.358 0 CA-C-N 116.076 -0.511 . . . . 0.0 111.032 -179.874 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . -72.32 -130.31 0.12 Allowed Glycine 0 CA--C 1.521 0.44 0 C-N-CA 120.973 -0.632 . . . . 0.0 112.988 -179.68 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 144' ' ' PRO . . . . . . . . . . . . . 33.1 Cg_endo -64.34 -23.57 65.46 Favored 'Trans proline' 0 C--N 1.349 0.586 0 C-N-CA 122.549 2.166 . . . . 0.0 112.521 -179.696 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 145' ' ' MET . . . . . 0.407 ' SD ' HD23 ' A' ' 141' ' ' LEU . 45.6 mtt -54.65 -34.43 62.17 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.352 -0.385 . . . . 0.0 111.446 -179.888 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 146' ' ' THR . . . . . . . . . . . . . 53.9 p -71.62 -37.47 70.9 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 116.53 -0.304 . . . . 0.0 111.584 -179.74 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 43.4 mt-10 -71.98 -37.48 69.88 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.374 -0.376 . . . . 0.0 111.203 -179.586 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 148' ' ' SER . . . . . . . . . . . . . 66.5 m -70.35 -40.09 74.29 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.152 -0.477 . . . . 0.0 111.454 -179.684 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 149' ' ' ALA . . . . . 0.464 ' HA ' ' HA ' ' A' ' 91' ' ' ALA . . . -74.9 -48.36 25.17 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.354 -0.385 . . . . 0.0 111.832 -179.397 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 150' ' ' SER . . . . . . . . . . . . . 47.1 t -61.07 -23.04 65.17 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.358 -0.383 . . . . 0.0 111.316 -179.652 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 151' ' ' GLN . . . . . . . . . . . . . 49.1 mt-30 -108.78 13.49 24.95 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.455 -0.339 . . . . 0.0 111.209 -179.849 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 30.7 tpt180 -89.77 -52.02 5.21 Favored 'General case' 0 C--N 1.332 -0.194 0 CA-C-O 120.933 0.397 . . . . 0.0 110.616 179.751 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 153' ' ' SER . . . . . 0.62 ' HB2' HG12 ' A' ' 156' ' ' ILE . 13.2 m -157.57 172.69 18.1 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 115.852 -0.613 . . . . 0.0 110.331 179.426 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 154' ' ' SER . . . . . . . . . . . . . 94.9 p -67.75 -44.87 76.52 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.798 0.332 . . . . 0.0 110.899 179.844 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 155' ' ' GLY . . . . . 0.486 ' O ' HD23 ' A' ' 159' ' ' LEU . . . -76.7 -38.24 32.41 Favored Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 121.096 -0.573 . . . . 0.0 113.219 -179.684 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 156' ' ' ILE . . . . . 0.62 HG12 ' HB2' ' A' ' 153' ' ' SER . 36.1 mm -48.07 -37.75 7.12 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.229 0 CA-C-O 120.704 0.288 . . . . 0.0 111.404 -179.527 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 157' ' ' LYS . . . . . . . . . . . . . 87.5 tttt -64.76 -42.03 95.44 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 116.351 -0.386 . . . . 0.0 111.316 -179.93 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 85.9 p -71.28 -46.33 61.07 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.94 0.4 . . . . 0.0 111.375 -179.48 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 159' ' ' LEU . . . . . 0.646 HD21 HD11 ' A' ' 219' ' ' LEU . 4.1 mm? -61.61 -36.29 80.28 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-N 116.006 -0.543 . . . . 0.0 111.558 -179.595 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 160' ' ' TYR . . . . . . . . . . . . . 46.9 t80 -74.25 -46.86 38.84 Favored 'General case' 0 C--N 1.33 -0.274 0 N-CA-C 112.668 0.618 . . . . 0.0 112.668 -178.73 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 21.6 m -58.57 -45.23 90.49 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 N-CA-C 112.277 0.473 . . . . 0.0 112.277 -178.712 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 162' ' ' ARG . . . . . . . . . . . . . 99.9 mtt180 -68.71 -44.78 73.2 Favored 'General case' 0 C--N 1.328 -0.363 0 N-CA-C 111.781 0.289 . . . . 0.0 111.781 -179.38 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 163' ' ' LEU . . . . . 0.689 ' HG ' ' HB2' ' A' ' 208' ' ' PHE . 6.0 mp -67.37 -54.18 22.76 Favored 'General case' 0 C--N 1.328 -0.368 0 N-CA-C 112.006 0.373 . . . . 0.0 112.006 -179.199 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 164' ' ' ARG . . . . . . . . . . . . . 3.7 tmm_? -56.25 -53.12 60.95 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.348 -0.387 . . . . 0.0 111.998 -179.071 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 165' ' ' ASN . . . . . 0.57 ' O ' HG23 ' A' ' 169' ' ' VAL . 5.0 m-20 -54.43 -51.73 64.01 Favored 'General case' 0 C--N 1.331 -0.204 0 CA-C-O 120.788 0.327 . . . . 0.0 111.81 -179.332 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 166' ' ' LEU . . . . . 0.451 ' O ' ' HG ' ' A' ' 170' ' ' LEU . 4.5 tt -60.29 -53.33 59.0 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-N 116.357 -0.383 . . . . 0.0 111.548 -179.31 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 167' ' ' THR . . . . . . . . . . . . . 63.7 m -55.85 -52.74 62.98 Favored 'General case' 0 C--N 1.329 -0.295 0 N-CA-C 113.167 0.803 . . . . 0.0 113.167 -178.767 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 168' ' ' VAL . . . . . 0.426 HG12 ' O ' ' A' ' 165' ' ' ASN . 8.2 p -56.84 -41.23 75.48 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.209 0 N-CA-C 112.226 0.454 . . . . 0.0 112.226 -178.451 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 169' ' ' VAL . . . . . 0.57 HG23 ' O ' ' A' ' 165' ' ' ASN . 74.5 t -58.3 -63.47 0.69 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.395 0 CA-C-N 116.542 -0.299 . . . . 0.0 111.534 -179.716 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 170' ' ' LEU . . . . . 0.451 ' HG ' ' O ' ' A' ' 166' ' ' LEU . 0.8 OUTLIER -64.3 -28.26 69.59 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.551 -0.295 . . . . 0.0 111.769 -179.292 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 171' ' ' TRP . . . . . 0.657 ' HE1' H203 ' A' ' 301' ' ' RET . 4.5 m0 -71.11 -29.96 65.92 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 121.151 0.501 . . . . 0.0 110.216 179.146 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 172' ' ' ALA . . . . . . . . . . . . . . . -71.49 -7.1 45.32 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 115.495 -0.775 . . . . 0.0 110.967 -179.962 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 173' ' ' ILE . . . . . 0.524 ' O ' HG12 ' A' ' 177' ' ' ILE . 16.1 mm -86.75 -23.2 6.82 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.032 -0.531 . . . . 0.0 111.243 -179.993 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 174' ' ' TYR . . . . . 0.452 ' HB2' ' HD3' ' A' ' 175' ' ' PRO . 29.0 m-85 -54.11 -49.94 87.18 Favored Pre-proline 0 N--CA 1.464 0.273 0 CA-C-N 116.409 -0.36 . . . . 0.0 111.89 -179.426 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 175' ' ' PRO . . . . . 0.452 ' HD3' ' HB2' ' A' ' 174' ' ' TYR . 71.2 Cg_exo -48.45 -31.65 18.53 Favored 'Trans proline' 0 C--N 1.351 0.663 0 C-N-CA 121.935 1.757 . . . . 0.0 112.338 179.797 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 176' ' ' PHE . . . . . 0.485 ' O ' ' HG ' ' A' ' 180' ' ' LEU . 82.0 m-85 -80.38 -50.39 10.2 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.005 -0.543 . . . . 0.0 111.882 -179.843 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 177' ' ' ILE . . . . . 0.524 HG12 ' O ' ' A' ' 173' ' ' ILE . 5.3 mm -62.12 -36.16 72.75 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.534 0 N-CA-C 112.562 0.579 . . . . 0.0 112.562 -178.016 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 178' ' ' TRP . . . . . 0.455 ' HH2' ' HB2' ' A' ' 123' ' ' ARG . 83.8 t90 -69.74 -50.18 45.98 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.738 0.304 . . . . 0.0 111.007 179.973 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 179' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -68.99 -55.06 12.03 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.262 -0.426 . . . . 0.0 111.582 -179.159 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 180' ' ' LEU . . . . . 0.757 HD22 HD11 ' A' ' 187' ' ' LEU . 43.3 mt -60.42 -46.75 88.89 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 116.501 -0.318 . . . . 0.0 111.29 -179.473 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . -56.61 177.43 0.85 Allowed Glycine 0 C--N 1.335 0.512 0 C-N-CA 120.384 -0.912 . . . . 0.0 112.715 179.636 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 182' ' ' PRO . . . . . 0.499 ' HA ' ' HB2' ' A' ' 186' ' ' ALA . 83.7 Cg_exo -47.15 -45.24 22.1 Favored 'Trans proline' 0 CA--C 1.536 0.575 0 C-N-CA 122.878 2.385 . . . . 0.0 113.697 -179.802 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 183' ' ' PRO . . . . . 0.423 ' HD3' ' HB2' ' A' ' 182' ' ' PRO . 79.7 Cg_exo -46.38 -29.95 7.66 Favored 'Trans proline' 0 C--N 1.356 0.922 0 C-N-CA 122.195 1.93 . . . . 0.0 113.171 -179.796 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 184' ' ' GLY . . . . . 0.409 ' HA2' ' HD2' ' A' ' 123' ' ' ARG . . . -114.5 -121.3 3.55 Favored Glycine 0 C--N 1.332 0.342 0 C-N-CA 120.335 -0.936 . . . . 0.0 113.001 -179.896 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 185' ' ' VAL . . . . . . . . . . . . . 16.6 m -64.49 -18.57 23.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 N-CA-C 112.02 0.378 . . . . 0.0 112.02 -179.46 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 186' ' ' ALA . . . . . 0.499 ' HB2' ' HA ' ' A' ' 182' ' ' PRO . . . 56.39 87.55 0.06 Allowed 'General case' 0 N--CA 1.463 0.209 0 CA-C-O 120.731 0.301 . . . . 0.0 111.453 179.585 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 187' ' ' LEU . . . . . 0.757 HD11 HD22 ' A' ' 180' ' ' LEU . 18.8 mt -92.05 -49.67 6.09 Favored 'General case' 0 C--N 1.332 -0.195 0 CA-C-O 120.904 0.383 . . . . 0.0 111.367 -179.867 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 188' ' ' LEU . . . . . . . . . . . . . 95.2 mt -106.79 -156.7 0.59 Allowed 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.165 -0.471 . . . . 0.0 111.027 -179.574 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 189' ' ' THR . . . . . . . . . . . . . 1.6 t -96.27 149.18 35.58 Favored Pre-proline 0 C--N 1.329 -0.304 0 CA-C-N 116.056 -0.52 . . . . 0.0 111.203 -179.686 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 190' ' ' PRO . . . . . 0.436 ' O ' HG23 ' A' ' 194' ' ' VAL . 9.9 Cg_endo -51.42 -37.41 61.39 Favored 'Trans proline' 0 C--N 1.349 0.582 0 C-N-CA 122.75 2.3 . . . . 0.0 112.688 -179.869 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 191' ' ' THR . . . . . . . . . . . . . 70.2 p -58.93 -48.66 80.7 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.97 0.415 . . . . 0.0 110.975 179.947 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 192' ' ' VAL . . . . . . . . . . . . . 40.6 t -67.45 -48.48 77.13 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 115.882 -0.599 . . . . 0.0 111.566 -179.772 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 193' ' ' ASP . . . . . . . . . . . . . 22.4 t70 -56.45 -51.92 66.64 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.31 -0.405 . . . . 0.0 111.497 -179.586 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 194' ' ' VAL . . . . . 0.436 HG23 ' O ' ' A' ' 190' ' ' PRO . 79.7 t -58.68 -35.86 57.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.439 -0.346 . . . . 0.0 110.898 179.929 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 195' ' ' ALA . . . . . . . . . . . . . . . -57.57 -44.88 85.62 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.4 -0.363 . . . . 0.0 110.856 179.708 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 196' ' ' LEU . . . . . . . . . . . . . 96.0 mt -68.08 -44.0 77.26 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-N 116.329 -0.396 . . . . 0.0 110.53 179.433 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 197' ' ' ILE . . . . . . . . . . . . . 18.7 mm -56.95 -59.34 3.21 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 115.986 -0.552 . . . . 0.0 110.635 179.53 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 198' ' ' VAL . . . . . . . . . . . . . 79.5 t -52.21 -34.94 18.66 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.509 0 CA-C-N 115.688 -0.687 . . . . 0.0 109.594 178.6 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 199' ' ' TYR . . . . . . . . . . . . . 48.0 t80 -70.52 -32.35 69.79 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 115.47 -0.786 . . . . 0.0 110.819 179.885 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 200' ' ' LEU . . . . . 0.552 ' O ' HG12 ' A' ' 203' ' ' VAL . 21.6 mt -69.99 -40.51 75.29 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 115.973 -0.558 . . . . 0.0 111.458 -179.673 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 201' ' ' ASP . . . . . 0.447 ' HB2' ' OH ' ' A' ' 51' ' ' TYR . 12.8 m-20 -71.83 -35.79 70.01 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-O 121.293 0.568 . . . . 0.0 109.991 179.471 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 202' ' ' LEU . . . . . 0.425 HD11 ' HA2' ' A' ' 11' ' ' GLY . 3.0 mt -69.71 -31.36 69.34 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 115.306 -0.861 . . . . 0.0 111.856 -179.734 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 203' ' ' VAL . . . . . 0.552 HG12 ' O ' ' A' ' 200' ' ' LEU . 13.1 p -76.7 -36.06 26.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 C-N-CA 121.004 -0.279 . . . . 0.0 110.911 -179.087 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 204' ' ' THR . . . . . 0.408 ' O ' ' CD1' ' A' ' 208' ' ' PHE . 53.7 m -63.8 -58.41 6.9 Favored 'General case' 0 C--N 1.33 -0.279 0 C-N-CA 120.585 -0.446 . . . . 0.0 111.389 179.376 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 205' ' ' LYS . . . . . 0.764 ' HE2' ' HB2' ' A' ' 47' ' ' ALA . 52.2 mttp -65.06 -58.31 6.39 Favored 'General case' 0 N--CA 1.464 0.231 0 N-CA-C 112.494 0.553 . . . . 0.0 112.494 -178.347 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 42.6 t -68.42 -36.81 76.4 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.475 0 N-CA-C 112.168 0.432 . . . . 0.0 112.168 -178.898 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 207' ' ' GLY . . . . . 0.546 ' O ' HG13 ' A' ' 211' ' ' ILE . . . -60.2 -60.76 8.03 Favored Glycine 0 N--CA 1.453 -0.226 0 C-N-CA 120.682 -0.771 . . . . 0.0 114.035 -178.349 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 208' ' ' PHE . . . . . 0.689 ' HB2' ' HG ' ' A' ' 163' ' ' LEU . 0.1 OUTLIER -71.55 -26.83 62.79 Favored 'General case' 0 C--O 1.224 -0.287 0 CA-C-N 117.277 0.539 . . . . 0.0 111.653 -178.643 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 209' ' ' GLY . . . . . 0.487 ' O ' ' HB3' ' A' ' 212' ' ' ALA . . . -67.6 -32.44 78.57 Favored Glycine 0 N--CA 1.449 -0.457 0 N-CA-C 111.853 -0.499 . . . . 0.0 111.853 178.966 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 210' ' ' PHE . . . . . . . . . . . . . 0.9 OUTLIER -73.21 -48.29 36.31 Favored 'General case' 0 CA--C 1.514 -0.43 0 N-CA-C 108.291 -1.003 . . . . 0.0 108.291 178.532 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 211' ' ' ILE . . . . . 0.546 HG13 ' O ' ' A' ' 207' ' ' GLY . 5.3 mt -63.48 -27.96 44.04 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.535 0 N-CA-C 107.626 -1.25 . . . . 0.0 107.626 176.715 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 212' ' ' ALA . . . . . 0.487 ' HB3' ' O ' ' A' ' 209' ' ' GLY . . . -63.72 -40.83 97.71 Favored 'General case' 0 N--CA 1.449 -0.483 0 CA-C-N 114.45 -1.25 . . . . 0.0 110.881 179.887 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 213' ' ' LEU . . . . . . . . . . . . . 97.3 mt -69.98 -55.0 10.75 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 115.273 -0.876 . . . . 0.0 112.17 -179.135 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 214' ' ' ASP . . . . . . . . . . . . . 36.2 t70 -53.81 -55.03 30.23 Favored 'General case' 0 C--O 1.234 0.27 0 CA-C-O 120.758 0.313 . . . . 0.0 111.498 -179.417 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 215' ' ' ALA . . . . . 0.435 ' O ' ' HG ' ' A' ' 219' ' ' LEU . . . -56.99 -53.06 62.29 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.306 -0.406 . . . . 0.0 111.159 -179.878 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 216' ' ' ALA . . . . . 0.622 ' HA ' HD12 ' A' ' 219' ' ' LEU . . . -58.73 -31.35 68.22 Favored 'General case' 0 C--N 1.332 -0.187 0 CA-C-N 116.443 -0.344 . . . . 0.0 111.286 -179.891 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 217' ' ' ALA . . . . . . . . . . . . . . . -61.82 -39.7 92.7 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 121.076 0.465 . . . . 0.0 109.991 179.573 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 218' ' ' THR . . . . . . . . . . . . . 97.9 m -76.02 -34.04 59.67 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 115.726 -0.67 . . . . 0.0 110.793 179.299 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 219' ' ' LEU . . . . . 0.646 HD11 HD21 ' A' ' 159' ' ' LEU . 97.3 mt -56.38 -43.07 78.88 Favored 'General case' 0 C--N 1.331 -0.202 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.665 179.723 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 220' ' ' ARG . . . . . . . . . . . . . 39.8 ptt180 -84.15 -23.93 30.42 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.0 -0.546 . . . . 0.0 110.649 179.494 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 221' ' ' ALA . . . . . . . . . . . . . . . -61.91 -35.6 78.85 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.032 -0.531 . . . . 0.0 112.007 -179.513 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 222' ' ' GLU . . . . . 0.444 ' HG2' ' O ' ' A' ' 219' ' ' LEU . 12.2 pt-20 -70.52 -18.3 62.95 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-O 120.868 0.366 . . . . 0.0 110.669 -179.444 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 223' ' ' HIS . . . . . . . . . . . . . 49.6 m80 -88.61 -167.23 1.81 Allowed 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 115.986 -0.552 . . . . 0.0 110.62 179.701 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 224' ' ' GLY . . . . . 0.417 ' H ' ' H ' ' A' ' 225' ' ' GLU . . . -165.88 -6.15 0.03 OUTLIER Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.526 -179.858 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 225' ' ' GLU . . . . . 0.417 ' H ' ' H ' ' A' ' 224' ' ' GLY . 9.4 tp10 -92.08 103.78 16.25 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.845 0.355 . . . . 0.0 110.996 179.999 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 226' ' ' SER . . . . . . . . . . . . . 55.0 m -147.23 160.08 42.89 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.699 179.932 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 227' ' ' LEU . . . . . 0.425 ' N ' HD12 ' A' ' 227' ' ' LEU . 6.3 mp -106.12 148.53 27.73 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.288 -0.415 . . . . 0.0 111.099 -179.856 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 228' ' ' ALA . . . . . . . . . . . . . . . -134.73 168.61 18.71 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.012 -0.54 . . . . 0.0 110.801 179.759 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 229' ' ' GLY . . . . . . . . . . . . . . . 57.32 23.92 49.83 Favored Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.668 -0.777 . . . . 0.0 112.349 -179.743 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 230' ' ' VAL . . . . . . . . . . . . . 47.4 t -65.89 140.63 19.27 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.245 0 CA-C-O 120.822 0.344 . . . . 0.0 111.145 -179.965 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 231' ' ' ASP . . . . . . . . . . . . . 18.0 m-20 -93.04 104.45 16.66 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.964 -179.805 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 232' ' ' THR . . . . . . . . . . . . . 5.7 t -165.6 135.35 3.47 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.114 -0.494 . . . . 0.0 111.033 179.851 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 233' ' ' ASP . . . . . . . . . . . . . 19.9 m-20 58.45 17.66 5.04 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.836 -179.959 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 234' ' ' THR . . . . . 0.483 ' N ' ' HD2' ' A' ' 235' ' ' PRO . 88.1 m -84.11 -50.84 0.62 Allowed Pre-proline 0 CA--C 1.533 0.308 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.53 179.926 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 235' ' ' PRO . . . . . 0.483 ' HD2' ' N ' ' A' ' 234' ' ' THR . 55.2 Cg_endo -71.41 -47.3 0.52 Allowed 'Trans proline' 0 C--N 1.353 0.77 0 C-N-CA 122.016 1.81 . . . . 0.0 112.336 179.944 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 236' ' ' ALA . . . . . . . . . . . . . . . 58.23 95.71 0.03 OUTLIER 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.404 179.846 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 237' ' ' VAL . . . . . . . . . . . . . 60.5 t -82.02 120.83 34.3 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.89 179.81 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 238' ' ' ALA . . . . . . . . . . . . . . . -163.17 -48.96 0.04 OUTLIER 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 115.984 -0.553 . . . . 0.0 110.849 179.997 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 239' ' ' ASP . . . . . . . . . . . . . 10.6 m-20 -143.83 -31.87 0.45 Allowed 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.088 -0.505 . . . . 0.0 110.858 -179.919 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 240' ' ' LEU . . . . . 0.434 ' N ' HD22 ' A' ' 240' ' ' LEU . 3.7 mm? 61.41 106.78 0.02 OUTLIER 'General case' 0 C--N 1.331 -0.199 0 CA-C-N 115.93 -0.577 . . . . 0.0 110.771 -179.825 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 241' ' ' GLU . . . . . . . . . . . . . 10.2 tp10 60.63 99.6 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.027 -0.533 . . . . 0.0 110.882 -179.822 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 242' ' ' HIS . . . . . . . . . . . . . 62.7 m80 -67.08 166.02 14.69 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.057 -179.818 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 243' ' ' HIS . . . . . . . . . . . . . 28.4 t-80 -135.89 -65.43 0.59 Allowed 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 115.988 -0.551 . . . . 0.0 110.743 179.808 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 244' ' ' HIS . . . . . . . . . . . . . 16.5 p-80 -87.89 138.22 31.65 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.757 179.81 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 245' ' ' HIS . . . . . . . . . . . . . 22.2 t60 -123.13 109.11 13.62 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.977 -179.84 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 246' ' ' HIS . . . . . . . . . . . . . 71.6 m-70 -134.33 -14.98 2.23 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.802 179.89 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 247' ' ' HIS . . . . . . . . . . . . . 51.9 t-80 . . . . . 0 C--O 1.249 1.077 0 CA-C-O 118.232 -0.89 . . . . 0.0 110.891 -179.947 . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 301' ' ' RET . . . . . 0.657 H203 ' HE1' ' A' ' 171' ' ' TRP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 12.5 tpt . . . . . 0 N--CA 1.486 1.344 0 CA-C-O 120.753 0.311 . . . . 0.0 110.766 . . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 7.3 p -125.73 -27.87 1.34 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.233 0 CA-C-N 116.289 -0.414 . . . . 0.0 111.449 -179.707 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -76.53 -0.29 67.01 Favored Glycine 0 N--CA 1.453 -0.216 0 C-N-CA 120.7 -0.762 . . . . 0.0 112.577 -179.503 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 32.0 tp -74.83 -36.46 62.41 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-O 120.779 0.323 . . . . 0.0 111.215 -179.913 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 81.5 p -59.43 -29.84 68.05 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.082 -0.508 . . . . 0.0 111.372 -179.641 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 31.3 p -53.55 -35.91 61.27 Favored 'General case' 0 C--N 1.331 -0.196 0 CA-C-N 116.231 -0.441 . . . . 0.0 111.413 -179.798 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 7' ' ' LEU . . . . . . . . . . . . . 3.9 mm? -61.15 -51.09 70.52 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 116.382 -0.372 . . . . 0.0 111.224 -179.774 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 8' ' ' PHE . . . . . . . . . . . . . 83.9 m-85 -60.33 -36.39 77.83 Favored 'General case' 0 C--N 1.331 -0.198 0 CA-C-O 120.978 0.418 . . . . 0.0 110.775 179.871 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 9' ' ' TRP . . . . . 0.442 ' O ' HG12 ' A' ' 13' ' ' ILE . 21.7 m95 -63.58 -41.9 98.34 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 115.781 -0.645 . . . . 0.0 109.897 179.827 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 87.6 mt -60.87 -45.0 96.28 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 115.549 -0.75 . . . . 0.0 110.392 179.315 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -64.42 -26.76 70.94 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.715 -0.755 . . . . 0.0 111.965 179.368 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -74.37 -30.51 62.01 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.772 0.32 . . . . 0.0 110.755 179.716 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 13' ' ' ILE . . . . . 0.442 HG12 ' O ' ' A' ' 9' ' ' TRP . 51.6 mm -69.62 -54.39 19.71 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.227 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.62 179.776 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -61.84 -34.76 89.85 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.582 -0.818 . . . . 0.0 112.033 179.64 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 15' ' ' MET . . . . . 0.516 ' SD ' ' HA ' ' A' ' 44' ' ' SER . 49.1 tpp -66.52 -45.8 78.29 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 120.778 0.323 . . . . 0.0 110.39 179.71 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -54.19 -41.46 68.62 Favored 'General case' 0 C--N 1.331 -0.206 0 CA-C-N 116.053 -0.521 . . . . 0.0 109.759 179.196 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 17' ' ' VAL . . . . . 0.439 HG23 ' O ' ' A' ' 13' ' ' ILE . 63.5 t -59.8 -43.21 91.29 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.187 0 CA-C-N 115.8 -0.636 . . . . 0.0 110.263 179.302 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -65.3 -40.31 96.48 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.694 -0.765 . . . . 0.0 111.58 178.95 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 15.5 m -53.79 -48.84 69.42 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.876 0.369 . . . . 0.0 110.991 -179.997 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 20' ' ' LEU . . . . . 0.418 ' O ' ' HB3' ' A' ' 24' ' ' TRP . 89.2 mt -71.61 -35.05 70.36 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.038 -0.528 . . . . 0.0 111.152 179.894 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -64.06 -34.2 77.48 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.166 -0.47 . . . . 0.0 112.252 -179.332 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 22' ' ' PHE . . . . . 0.56 ' HB2' HG22 ' A' ' 41' ' ' VAL . 4.1 m-85 -90.29 -37.81 13.82 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.67 0.271 . . . . 0.0 111.512 -179.045 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -64.85 -50.75 65.4 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 121.004 0.43 . . . . 0.0 111.731 -179.542 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 24' ' ' TRP . . . . . 0.418 ' HB3' ' O ' ' A' ' 20' ' ' LEU . 5.0 t-105 -63.42 -51.54 65.3 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 115.803 -0.635 . . . . 0.0 111.174 -179.605 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -67.07 -24.92 66.02 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.36 -0.382 . . . . 0.0 111.162 -179.842 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -71.43 -44.4 51.24 Favored Glycine 0 N--CA 1.452 -0.28 0 C-N-CA 120.88 -0.676 . . . . 0.0 112.386 179.889 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 38.5 mmt180 -63.63 -14.94 56.46 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.797 0.332 . . . . 0.0 110.873 -179.937 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 18.4 t70 -114.73 93.58 4.39 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.5 179.672 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -163.37 -168.54 1.72 Allowed 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.015 -0.539 . . . . 0.0 110.984 -179.785 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -91.06 -122.69 2.69 Favored Glycine 0 N--CA 1.45 -0.397 0 C-N-CA 120.762 -0.732 . . . . 0.0 112.522 -179.993 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 55.8 m -134.84 122.04 21.47 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.902 0.382 . . . . 0.0 110.87 -179.941 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 115.65 -42.26 1.94 Allowed Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.885 -0.674 . . . . 0.0 112.359 179.951 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 17.6 mm-40 -66.38 -20.51 66.09 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.674 0.273 . . . . 0.0 111.141 179.897 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 34' ' ' ARG . . . . . . . . . . . . . 93.0 mtt180 -48.25 -34.07 9.69 Favored 'General case' 0 C--N 1.332 -0.192 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.623 -179.491 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 82.7 mtp180 -59.01 -52.67 64.77 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-O 120.841 0.353 . . . . 0.0 111.078 -179.83 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 73.4 m-85 -61.22 -29.5 69.86 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 116.058 -0.519 . . . . 0.0 111.189 -179.953 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 37' ' ' TYR . . . . . . . . . . . . . 42.8 m-85 -73.3 -52.62 13.28 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.347 -179.758 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 91.2 t -57.03 -36.92 52.49 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.243 0 CA-C-O 121.064 0.459 . . . . 0.0 110.265 179.536 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 25.6 m -68.07 -46.08 72.03 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 115.649 -0.705 . . . . 0.0 110.467 179.35 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 40' ' ' LEU . . . . . 0.401 HD11 ' HA2' ' A' ' 209' ' ' GLY . 15.8 tp -60.38 -45.51 93.28 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 115.628 -0.715 . . . . 0.0 110.51 179.877 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 41' ' ' VAL . . . . . 0.56 HG22 ' HB2' ' A' ' 22' ' ' PHE . 98.4 t -65.18 -34.02 67.66 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.476 0 CA-C-N 115.843 -0.617 . . . . 0.0 110.125 179.221 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 42' ' ' GLY . . . . . 0.437 ' O ' HG12 ' A' ' 46' ' ' ILE . . . -55.86 -51.57 54.43 Favored Glycine 0 N--CA 1.449 -0.485 0 CA-C-N 115.697 -0.683 . . . . 0.0 112.759 179.854 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 43' ' ' ILE . . . . . 0.737 HG23 HD23 ' A' ' 82' ' ' LEU . 10.7 pt -63.76 -48.93 84.29 Favored 'Isoleucine or valine' 0 C--O 1.231 0.12 0 CA-C-N 116.972 0.386 . . . . 0.0 111.473 -179.963 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 44' ' ' SER . . . . . 0.516 ' HA ' ' SD ' ' A' ' 15' ' ' MET . 47.8 t -60.51 -26.62 66.98 Favored 'General case' 0 CA--C 1.529 0.147 0 CA-C-O 120.968 0.413 . . . . 0.0 111.116 179.831 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -75.85 -60.44 3.16 Favored Glycine 0 CA--C 1.517 0.179 0 C-N-CA 120.966 -0.635 . . . . 0.0 113.206 -179.278 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 46' ' ' ILE . . . . . 0.484 HD11 HG22 ' A' ' 79' ' ' THR . 9.3 pt -57.95 -34.83 49.69 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-O 120.738 0.304 . . . . 0.0 111.339 -179.444 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 47' ' ' ALA . . . . . 0.69 ' HB2' ' HE2' ' A' ' 205' ' ' LYS . . . -67.22 -44.03 80.56 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.526 -0.306 . . . . 0.0 111.035 179.277 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -54.39 -47.07 73.12 Favored 'General case' 0 C--O 1.232 0.151 0 CA-C-N 116.273 -0.421 . . . . 0.0 111.179 -179.975 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 49' ' ' VAL . . . . . 0.445 ' O ' HG13 ' A' ' 53' ' ' VAL . 14.5 m -71.81 -34.11 50.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.292 -0.413 . . . . 0.0 111.004 179.704 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -60.07 -41.32 92.13 Favored 'General case' 0 N--CA 1.462 0.172 0 CA-C-O 121.006 0.432 . . . . 0.0 111.012 179.422 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 38.8 m-85 -73.25 -34.76 66.02 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 115.877 -0.601 . . . . 0.0 110.496 -179.883 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -66.58 -44.86 81.09 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 115.923 -0.581 . . . . 0.0 111.052 179.599 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 53' ' ' VAL . . . . . 0.455 HG23 ' N ' ' A' ' 54' ' ' MET . 31.2 m -66.61 -45.49 88.39 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.137 0 CA-C-N 116.47 -0.332 . . . . 0.0 110.87 -179.997 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 54' ' ' MET . . . . . 0.455 ' N ' HG23 ' A' ' 53' ' ' VAL . 73.1 mtm -64.27 -34.49 78.23 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-O 121.183 0.516 . . . . 0.0 109.941 179.251 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -63.61 -23.29 67.32 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 115.432 -0.804 . . . . 0.0 111.103 179.515 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 93.2 mt -94.12 -5.37 47.39 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 116.262 -0.426 . . . . 0.0 111.077 -179.864 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 98.12 19.42 23.84 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.636 -0.792 . . . . 0.0 112.935 179.743 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 59.7 t -83.61 135.4 24.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-O 120.739 0.304 . . . . 0.0 110.853 179.861 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 59' ' ' GLY . . . . . 0.53 ' HA3' ' HD3' ' A' ' 71' ' ' PRO . . . 81.03 -4.84 68.7 Favored Glycine 0 N--CA 1.45 -0.423 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.599 -179.806 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 60' ' ' TRP . . . . . . . . . . . . . 14.3 m0 -67.3 90.75 0.23 Allowed 'General case' 0 C--N 1.33 -0.248 0 CA-C-O 120.655 0.264 . . . . 0.0 110.836 179.97 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 61' ' ' VAL . . . . . 0.509 HG13 HG23 ' A' ' 68' ' ' VAL . 7.0 p -101.36 130.0 25.75 Favored Pre-proline 0 C--N 1.33 -0.277 0 CA-C-N 116.415 -0.357 . . . . 0.0 111.266 179.914 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 62' ' ' PRO . . . . . 0.449 ' HD3' ' HA ' ' A' ' 61' ' ' VAL . 7.7 Cg_exo -73.84 148.17 40.56 Favored 'Trans proline' 0 C--N 1.35 0.64 0 C-N-CA 122.966 2.444 . . . . 0.0 112.33 179.938 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 86.6 t -143.18 93.73 0.5 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.141 -0.481 . . . . 0.0 111.073 -179.956 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . 59.4 -88.31 0.02 OUTLIER 'General case' 0 C--N 1.332 -0.157 0 CA-C-N 116.129 -0.487 . . . . 0.0 111.485 179.846 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 12.6 pt-20 -123.9 -17.15 6.39 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.292 -0.413 . . . . 0.0 110.763 -179.851 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 66' ' ' ARG . . . . . 0.437 ' NH1' ' HA ' ' A' ' 183' ' ' PRO . 32.7 ptt180 -105.77 159.7 15.8 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 115.902 -0.59 . . . . 0.0 110.532 -179.925 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 40.0 m -119.23 138.54 52.91 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-O 120.902 0.382 . . . . 0.0 111.466 -179.646 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 68' ' ' VAL . . . . . 0.509 HG23 HG13 ' A' ' 61' ' ' VAL . 14.8 m -125.82 146.49 31.48 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.412 0 CA-C-N 115.846 -0.615 . . . . 0.0 110.732 179.666 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 69' ' ' PHE . . . . . . . . . . . . . 17.7 m-85 -108.78 115.7 30.59 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.195 -179.423 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 70' ' ' VAL . . . . . 0.55 HG12 ' HD3' ' A' ' 71' ' ' PRO . 0.3 OUTLIER -68.08 -33.47 5.01 Favored Pre-proline 0 CA--C 1.54 0.579 0 N-CA-C 112.749 0.648 . . . . 0.0 112.749 -179.24 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 71' ' ' PRO . . . . . 0.55 ' HD3' HG12 ' A' ' 70' ' ' VAL . 17.6 Cg_exo -66.39 -32.31 41.03 Favored 'Trans proline' 0 C--N 1.358 1.078 0 C-N-CA 121.781 1.654 . . . . 0.0 112.389 -178.989 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 72' ' ' ARG . . . . . 0.405 ' HD2' HG21 ' A' ' 197' ' ' ILE . 61.8 ttp180 -65.56 -51.13 62.11 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 121.178 0.513 . . . . 0.0 109.845 179.419 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 73' ' ' TYR . . . . . . . . . . . . . 45.9 m-85 -63.67 -46.92 83.4 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 115.522 -0.763 . . . . 0.0 110.697 179.752 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 0.4 OUTLIER -63.62 -34.84 70.22 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.308 -0.405 . . . . 0.0 110.175 179.64 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 75' ' ' ASP . . . . . 0.489 ' O ' HG23 ' A' ' 79' ' ' THR . 28.6 t70 -58.31 -39.37 79.2 Favored 'General case' 0 C--N 1.332 -0.157 0 N-CA-C 109.497 -0.557 . . . . 0.0 109.497 179.263 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 76' ' ' TRP . . . . . . . . . . . . . 53.1 m0 -67.44 -37.13 82.52 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 115.728 -0.669 . . . . 0.0 110.485 179.479 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 77' ' ' ILE . . . . . 0.431 ' O ' ' HG2' ' A' ' 81' ' ' PRO . 66.8 mt -59.74 -34.07 54.31 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 CA-C-N 115.971 -0.559 . . . . 0.0 110.844 179.79 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 20.0 mt -91.79 -27.03 18.26 Favored 'General case' 0 C--N 1.329 -0.313 0 N-CA-C 112.655 0.613 . . . . 0.0 112.655 -179.581 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 79' ' ' THR . . . . . 0.489 HG23 ' O ' ' A' ' 75' ' ' ASP . 78.6 p -90.49 -52.74 4.76 Favored 'General case' 0 N--CA 1.464 0.267 0 N-CA-C 113.747 1.017 . . . . 0.0 113.747 -177.688 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 80' ' ' THR . . . . . 0.642 ' HB ' ' HD3' ' A' ' 81' ' ' PRO . 33.1 m -48.35 -54.06 29.1 Favored Pre-proline 0 CA--C 1.531 0.228 0 N-CA-C 112.804 0.668 . . . . 0.0 112.804 -178.126 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 81' ' ' PRO . . . . . 0.642 ' HD3' ' HB ' ' A' ' 80' ' ' THR . 49.0 Cg_exo -56.43 -27.38 67.86 Favored 'Trans proline' 0 C--N 1.351 0.702 0 C-N-CA 121.572 1.515 . . . . 0.0 111.683 -179.76 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 82' ' ' LEU . . . . . 0.737 HD23 HG23 ' A' ' 43' ' ' ILE . 12.9 tp -76.96 -32.95 57.66 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 115.882 -0.599 . . . . 0.0 110.655 -179.999 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 48.5 mm -65.95 -53.85 33.52 Favored 'Isoleucine or valine' 0 C--O 1.233 0.215 0 N-CA-C 110.05 -0.352 . . . . 0.0 110.05 179.06 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 12.6 m -60.6 -29.93 45.76 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.26 0 N-CA-C 109.253 -0.647 . . . . 0.0 109.253 178.43 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 85' ' ' TYR . . . . . . . . . . . . . 66.3 t80 -65.53 -34.34 78.02 Favored 'General case' 0 N--CA 1.455 -0.215 0 CA-C-N 115.432 -0.804 . . . . 0.0 109.252 178.354 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 86' ' ' PHE . . . . . . . . . . . . . 2.1 t80 -61.31 -51.47 68.72 Favored 'General case' 0 C--O 1.231 0.129 0 CA-C-N 115.762 -0.654 . . . . 0.0 109.623 179.217 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 7.4 mp -64.0 -31.38 72.55 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 115.801 -0.636 . . . . 0.0 110.119 179.414 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -66.6 -27.78 73.39 Favored Glycine 0 N--CA 1.449 -0.459 0 C-N-CA 120.807 -0.711 . . . . 0.0 111.742 179.322 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 88.6 mt -75.96 -44.93 37.54 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 120.81 0.338 . . . . 0.0 110.691 179.586 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 80.3 mt -54.97 -38.24 67.53 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 115.904 -0.589 . . . . 0.0 110.859 179.898 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -84.34 -54.02 5.07 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.058 -0.519 . . . . 0.0 111.079 179.953 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 100.14 65.13 0.81 Allowed Glycine 0 N--CA 1.452 -0.234 0 C-N-CA 120.887 -0.673 . . . . 0.0 112.416 179.989 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 93' ' ' LEU . . . . . 0.532 ' HB3' ' HB2' ' A' ' 97' ' ' GLU . 6.9 mp -81.51 165.63 21.02 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-O 120.795 0.331 . . . . 0.0 110.746 179.932 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 94' ' ' ASP . . . . . . . . . . . . . 9.0 m-20 -82.75 178.0 8.4 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.837 179.928 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 82.5 p -64.11 -34.47 78.11 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.07 -0.513 . . . . 0.0 111.072 -179.983 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 84.6 mtm180 -73.6 -51.27 17.42 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.279 -0.418 . . . . 0.0 111.094 -179.751 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 97' ' ' GLU . . . . . 0.532 ' HB2' ' HB3' ' A' ' 93' ' ' LEU . 20.2 mt-10 -57.39 -44.4 84.44 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.453 -0.34 . . . . 0.0 110.748 -179.842 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 98' ' ' PHE . . . . . . . . . . . . . 1.7 m-85 -57.46 -50.58 72.58 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.311 -0.404 . . . . 0.0 110.933 179.812 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -54.45 -34.8 55.21 Favored Glycine 0 N--CA 1.452 -0.278 0 C-N-CA 120.883 -0.675 . . . . 0.0 112.584 -179.966 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 96.5 mt -66.74 -43.17 90.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-O 120.89 0.376 . . . . 0.0 111.632 -179.823 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 59.6 t -69.17 -44.26 80.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.629 -179.545 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 102' ' ' ILE . . . . . . . . . . . . . 37.7 mm -65.52 -46.69 89.06 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.378 0 CA-C-N 116.405 -0.361 . . . . 0.0 111.629 -179.227 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 15.3 t -61.85 -35.93 79.74 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 120.643 0.259 . . . . 0.0 111.258 -179.588 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 29.4 tp -62.62 -46.68 87.17 Favored 'General case' 0 C--N 1.332 -0.169 0 CA-C-O 120.843 0.354 . . . . 0.0 110.761 179.781 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 105' ' ' ASN . . . . . 0.621 HD21 HD13 ' A' ' 137' ' ' LEU . 0.9 OUTLIER -64.73 -26.18 68.25 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.69 179.697 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 53.8 m -67.1 -55.23 15.14 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.124 -0.489 . . . . 0.0 111.401 -179.927 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 7.1 p -62.43 -38.53 81.53 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.193 0 CA-C-N 116.477 -0.329 . . . . 0.0 111.103 -179.841 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 59.4 t -62.58 -44.75 99.65 Favored 'Isoleucine or valine' 0 C--O 1.234 0.269 0 CA-C-O 121.051 0.453 . . . . 0.0 110.573 179.545 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 109' ' ' MET . . . . . 0.521 ' HE1' HG21 ' A' ' 80' ' ' THR . 7.7 tpp -67.38 -25.69 66.09 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 115.979 -0.555 . . . . 0.0 110.113 179.594 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 20.2 tp -75.93 -30.95 58.9 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 115.764 -0.653 . . . . 0.0 110.296 179.633 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -66.83 -54.23 24.6 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 115.934 -0.575 . . . . 0.0 110.72 179.662 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 112' ' ' GLY . . . . . 0.684 ' HA3' ' H21' ' A' ' 301' ' ' RET . . . -62.1 -47.55 89.1 Favored Glycine 0 C--N 1.331 0.283 0 C-N-CA 120.627 -0.797 . . . . 0.0 111.976 179.558 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 113' ' ' PHE . . . . . . . . . . . . . 3.4 t80 -50.5 -58.08 6.61 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.717 0.294 . . . . 0.0 110.68 179.362 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -71.95 -16.82 62.1 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.687 179.587 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -60.4 -48.69 84.94 Favored Glycine 0 C--N 1.331 0.295 0 C-N-CA 121.091 -0.576 . . . . 0.0 112.412 179.948 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 116' ' ' ALA . . . . . 0.516 ' HB2' ' HB3' ' A' ' 183' ' ' PRO . . . -77.83 -15.05 59.35 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-O 120.773 0.321 . . . . 0.0 111.361 179.991 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 117' ' ' MET . . . . . 0.439 ' SD ' HG21 ' A' ' 68' ' ' VAL . 25.4 mmt -90.29 14.32 13.04 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.298 -0.41 . . . . 0.0 111.6 -179.433 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 118' ' ' VAL . . . . . 0.432 HG21 ' HB3' ' A' ' 123' ' ' ARG . 26.0 m -82.16 143.72 49.44 Favored Pre-proline 0 C--N 1.331 -0.229 0 CA-C-N 116.649 -0.251 . . . . 0.0 111.196 -179.959 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 119' ' ' PRO . . . . . . . . . . . . . 67.8 Cg_endo -92.9 -1.48 3.64 Favored 'Trans proline' 0 N--CA 1.457 -0.668 0 C-N-CA 122.907 2.405 . . . . 0.0 112.416 179.551 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -138.18 -114.16 1.23 Allowed Glycine 0 C--N 1.333 0.371 0 C-N-CA 120.694 -0.765 . . . . 0.0 113.029 -179.655 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 37.0 pt -126.15 13.13 3.99 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.188 0 CA-C-O 120.781 0.324 . . . . 0.0 111.683 -179.564 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 12.2 mm-40 -61.27 -18.8 60.24 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.332 -0.395 . . . . 0.0 111.187 -179.986 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 123' ' ' ARG . . . . . 0.432 ' HB3' HG21 ' A' ' 118' ' ' VAL . 28.0 ptt180 -50.65 -38.26 45.42 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 116.0 -0.545 . . . . 0.0 111.672 -179.828 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 124' ' ' TYR . . . . . . . . . . . . . 57.5 m-85 -64.9 -33.5 76.17 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.401 -0.363 . . . . 0.0 111.241 -179.605 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 125' ' ' ALA . . . . . . . . . . . . . . . -71.98 -56.0 6.44 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 120.946 0.403 . . . . 0.0 111.204 -179.998 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 1.2 mt -52.11 -52.36 51.98 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 115.923 -0.58 . . . . 0.0 111.011 -179.871 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 127' ' ' PHE . . . . . . . . . . . . . 11.6 t80 -64.0 -37.66 88.24 Favored 'General case' 0 N--CA 1.453 -0.304 0 C-N-CA 120.778 -0.369 . . . . 0.0 110.866 179.927 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 128' ' ' GLY . . . . . . . . . . . . . . . -46.47 -44.6 16.28 Favored Glycine 0 C--N 1.332 0.349 0 C-N-CA 120.227 -0.987 . . . . 0.0 110.95 179.35 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 129' ' ' MET . . . . . . . . . . . . . 0.3 OUTLIER -70.56 -37.01 73.94 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 115.392 -0.404 . . . . 0.0 109.947 178.839 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -68.77 -26.92 74.24 Favored Glycine 0 C--N 1.331 0.3 0 CA-C-N 115.842 -0.617 . . . . 0.0 112.94 -179.872 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 131' ' ' ALA . . . . . 0.456 ' O ' ' HB3' ' A' ' 134' ' ' PHE . . . -74.66 -53.6 9.0 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.821 0.343 . . . . 0.0 110.208 179.869 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 58.0 t -58.56 -39.92 77.19 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 N-CA-C 109.09 -0.707 . . . . 0.0 109.09 178.486 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -66.87 -35.31 79.74 Favored 'General case' 0 N--CA 1.453 -0.313 0 CA-C-N 115.276 -0.875 . . . . 0.0 110.412 179.21 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 134' ' ' PHE . . . . . 0.456 ' HB3' ' O ' ' A' ' 131' ' ' ALA . 17.6 t80 -54.26 -56.63 16.49 Favored 'General case' 0 N--CA 1.455 -0.208 0 CA-C-N 116.128 -0.487 . . . . 0.0 109.889 179.425 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 135' ' ' ILE . . . . . 0.479 ' O ' HG22 ' A' ' 138' ' ' VAL . 34.7 mt -56.69 -33.4 40.26 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.323 0 CA-C-N 115.564 -0.744 . . . . 0.0 110.082 179.388 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . -59.87 -35.99 88.57 Favored Glycine 0 N--CA 1.449 -0.447 0 C-N-CA 120.241 -0.981 . . . . 0.0 111.108 178.679 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 137' ' ' LEU . . . . . 0.621 HD13 HD21 ' A' ' 105' ' ' ASN . 56.1 tp -70.86 -55.49 8.38 Favored 'General case' 0 N--CA 1.453 -0.276 0 CA-C-N 115.772 -0.214 . . . . 0.0 110.671 179.376 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 138' ' ' VAL . . . . . 0.479 HG22 ' O ' ' A' ' 135' ' ' ILE . 3.1 m -54.87 -30.3 22.83 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.222 0 N-CA-C 109.171 -0.677 . . . . 0.0 109.171 179.715 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 139' ' ' TYR . . . . . . . . . . . . . 27.1 t80 -62.49 -43.61 98.39 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 115.168 -0.923 . . . . 0.0 109.956 178.083 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 22.2 m-85 -67.48 -44.35 78.78 Favored 'General case' 0 C--O 1.232 0.151 0 CA-C-N 116.301 -0.409 . . . . 0.0 110.467 179.011 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 141' ' ' LEU . . . . . 0.441 HD13 ' O ' ' A' ' 137' ' ' LEU . 11.0 mp -55.02 -32.57 61.94 Favored 'General case' 0 C--N 1.332 -0.183 0 CA-C-N 116.004 -0.544 . . . . 0.0 111.253 -179.719 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 10.8 p -101.44 -10.19 8.99 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-O 121.055 0.455 . . . . 0.0 110.693 179.929 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . -75.99 -135.54 0.56 Allowed Glycine 0 CA--C 1.522 0.476 0 CA-C-N 115.852 -0.613 . . . . 0.0 112.693 -179.902 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 144' ' ' PRO . . . . . . . . . . . . . 50.0 Cg_exo -53.25 -23.95 24.98 Favored 'Trans proline' 0 C--N 1.347 0.478 0 C-N-CA 122.659 2.239 . . . . 0.0 113.055 -179.688 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 145' ' ' MET . . . . . 0.429 ' HB3' ' OH ' ' A' ' 160' ' ' TYR . 41.2 mtt -57.33 -38.01 73.41 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-O 120.67 0.271 . . . . 0.0 111.549 -179.623 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 146' ' ' THR . . . . . . . . . . . . . 60.4 p -65.45 -49.06 70.55 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.443 -0.344 . . . . 0.0 111.686 -179.443 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 43.9 mt-10 -71.48 -25.4 62.26 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.422 -0.354 . . . . 0.0 111.532 -179.462 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 148' ' ' SER . . . . . . . . . . . . . 48.2 t -68.89 -46.28 68.78 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-O 120.935 0.398 . . . . 0.0 110.827 -179.574 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 149' ' ' ALA . . . . . 0.506 ' HB1' HG22 ' A' ' 156' ' ' ILE . . . -78.13 -32.14 50.25 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.028 -0.533 . . . . 0.0 111.357 -179.858 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 150' ' ' SER . . . . . . . . . . . . . 41.6 t -63.07 -14.83 53.08 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.02 -0.536 . . . . 0.0 111.555 -179.603 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 151' ' ' GLN . . . . . . . . . . . . . 9.8 pt20 -110.71 17.2 20.87 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.659 -0.246 . . . . 0.0 111.624 -179.747 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 29.7 mmt180 -98.64 -52.51 3.59 Favored 'General case' 0 C--N 1.332 -0.184 0 C-N-CA 120.856 -0.338 . . . . 0.0 110.803 179.613 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 153' ' ' SER . . . . . 0.654 ' HB3' HG12 ' A' ' 156' ' ' ILE . 21.0 t -158.1 172.2 18.84 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.792 179.007 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 154' ' ' SER . . . . . . . . . . . . . 43.3 t -71.94 -38.4 69.83 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.307 -0.406 . . . . 0.0 110.385 179.303 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -76.87 -37.68 33.02 Favored Glycine 0 N--CA 1.45 -0.384 0 C-N-CA 120.924 -0.655 . . . . 0.0 112.647 179.8 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 156' ' ' ILE . . . . . 0.654 HG12 ' HB3' ' A' ' 153' ' ' SER . 37.8 mm -52.25 -39.79 28.77 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.236 0 CA-C-O 120.724 0.297 . . . . 0.0 111.431 -179.563 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 157' ' ' LYS . . . . . . . . . . . . . 56.0 tttm -69.65 -34.59 74.22 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-N 116.318 -0.401 . . . . 0.0 111.138 -179.921 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 46.5 t -72.25 -39.96 68.06 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 120.942 0.401 . . . . 0.0 111.309 -179.208 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 159' ' ' LEU . . . . . 0.44 HD13 ' HB1' ' A' ' 215' ' ' ALA . 12.9 mt -72.58 -35.19 67.86 Favored 'General case' 0 C--N 1.326 -0.449 0 CA-C-N 116.066 -0.516 . . . . 0.0 111.315 -179.314 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 160' ' ' TYR . . . . . 0.429 ' OH ' ' HB3' ' A' ' 145' ' ' MET . 37.5 t80 -70.38 -42.36 71.83 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.648 -0.251 . . . . 0.0 111.599 -179.075 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 161' ' ' VAL . . . . . 0.41 HG23 ' N ' ' A' ' 162' ' ' ARG . 23.0 m -65.06 -43.91 95.87 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-O 120.719 0.295 . . . . 0.0 111.367 -179.644 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 162' ' ' ARG . . . . . 0.41 ' N ' HG23 ' A' ' 161' ' ' VAL . 21.2 mmm180 -69.29 -46.53 66.96 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.914 0.387 . . . . 0.0 111.248 179.994 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 163' ' ' LEU . . . . . . . . . . . . . 1.3 mp -61.79 -54.8 37.33 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 115.971 -0.559 . . . . 0.0 111.702 -179.548 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 164' ' ' ARG . . . . . . . . . . . . . 25.4 ttp85 -58.09 -48.23 80.8 Favored 'General case' 0 C--N 1.331 -0.237 0 N-CA-C 112.459 0.54 . . . . 0.0 112.459 -178.843 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 165' ' ' ASN . . . . . 0.491 ' O ' HG23 ' A' ' 169' ' ' VAL . 5.8 m-20 -52.34 -51.38 59.1 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-O 120.942 0.401 . . . . 0.0 110.719 -179.205 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 166' ' ' LEU . . . . . 0.529 ' O ' ' HG ' ' A' ' 170' ' ' LEU . 3.6 tt -65.41 -41.48 93.58 Favored 'General case' 0 C--N 1.324 -0.515 0 CA-C-N 116.089 -0.505 . . . . 0.0 111.36 -179.895 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 167' ' ' THR . . . . . . . . . . . . . 51.1 m -65.18 -54.11 34.69 Favored 'General case' 0 C--N 1.331 -0.232 0 N-CA-C 112.51 0.559 . . . . 0.0 112.51 -178.465 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 168' ' ' VAL . . . . . . . . . . . . . 9.1 p -54.47 -40.46 49.54 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-O 120.644 0.259 . . . . 0.0 111.67 -179.385 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 169' ' ' VAL . . . . . 0.491 HG23 ' O ' ' A' ' 165' ' ' ASN . 55.5 t -59.72 -65.11 0.49 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.486 -0.324 . . . . 0.0 111.634 -179.844 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 170' ' ' LEU . . . . . 0.529 ' HG ' ' O ' ' A' ' 166' ' ' LEU . 2.0 pp -62.79 -27.14 69.09 Favored 'General case' 0 C--N 1.33 -0.262 0 N-CA-C 112.139 0.422 . . . . 0.0 112.139 -178.806 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 171' ' ' TRP . . . . . 0.736 ' HE1' H203 ' A' ' 301' ' ' RET . 1.8 m0 -73.35 -32.48 64.56 Favored 'General case' 0 C--N 1.33 -0.245 0 C-N-CA 120.588 -0.445 . . . . 0.0 110.707 179.69 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 172' ' ' ALA . . . . . 0.415 ' HA ' ' CZ ' ' A' ' 134' ' ' PHE . . . -67.94 -7.76 31.26 Favored 'General case' 0 CA--C 1.52 -0.208 0 CA-C-O 121.345 0.593 . . . . 0.0 110.157 179.287 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 173' ' ' ILE . . . . . 0.723 HG22 ' CG1' ' A' ' 177' ' ' ILE . 9.0 mm -84.15 -36.26 11.79 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.555 0 CA-C-N 114.954 -1.021 . . . . 0.0 111.501 -179.03 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 174' ' ' TYR . . . . . 0.548 ' N ' ' HD2' ' A' ' 175' ' ' PRO . 70.2 m-85 -55.56 -51.66 78.26 Favored Pre-proline 0 C--N 1.328 -0.33 0 N-CA-C 112.507 0.558 . . . . 0.0 112.507 -178.9 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 175' ' ' PRO . . . . . 0.548 ' HD2' ' N ' ' A' ' 174' ' ' TYR . 26.7 Cg_endo -60.19 -41.12 53.98 Favored 'Trans proline' 0 C--N 1.349 0.57 0 C-N-CA 122.107 1.871 . . . . 0.0 113.359 -178.776 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 176' ' ' PHE . . . . . 0.529 ' CE2' ' HA ' ' A' ' 173' ' ' ILE . 0.1 OUTLIER -79.83 -37.83 34.18 Favored 'General case' 0 C--N 1.329 -0.32 0 C-N-CA 120.609 -0.437 . . . . 0.0 112.12 -178.413 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 177' ' ' ILE . . . . . 0.723 ' CG1' HG22 ' A' ' 173' ' ' ILE . 32.4 mm -63.76 -47.33 91.49 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.614 0 CA-C-O 120.873 0.368 . . . . 0.0 110.032 178.425 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 178' ' ' TRP . . . . . . . . . . . . . 60.5 t90 -52.91 -29.61 29.46 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 115.788 -0.642 . . . . 0.0 109.857 179.202 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 179' ' ' LEU . . . . . 0.528 HD13 ' O ' ' A' ' 179' ' ' LEU . 0.9 OUTLIER -72.76 -37.56 67.63 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 115.359 -0.837 . . . . 0.0 110.689 179.898 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 180' ' ' LEU . . . . . 0.447 ' HB3' HD12 ' A' ' 187' ' ' LEU . 0.9 OUTLIER -78.31 -51.79 9.59 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.548 -0.296 . . . . 0.0 111.626 -179.399 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . -51.13 171.8 0.2 Allowed Glycine 0 C--N 1.336 0.551 0 C-N-CA 120.941 -0.647 . . . . 0.0 113.292 -179.685 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 182' ' ' PRO . . . . . 0.585 ' N ' ' HD2' ' A' ' 183' ' ' PRO . 2.5 Cg_endo -42.68 -47.81 7.59 Favored 'Trans proline' 0 C--N 1.351 0.661 0 C-N-CA 123.316 2.678 . . . . 0.0 114.015 -179.837 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 183' ' ' PRO . . . . . 0.585 ' HD2' ' N ' ' A' ' 182' ' ' PRO . 9.4 Cg_endo -50.04 -29.93 23.2 Favored 'Trans proline' 0 C--N 1.357 0.992 0 C-N-CA 122.269 1.979 . . . . 0.0 112.62 -179.754 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 184' ' ' GLY . . . . . . . . . . . . . . . -95.93 -105.08 2.12 Favored Glycine 0 N--CA 1.45 -0.368 0 C-N-CA 120.716 -0.754 . . . . 0.0 112.73 -179.904 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 185' ' ' VAL . . . . . . . . . . . . . 0.9 OUTLIER -109.4 -0.37 9.68 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-O 120.672 0.272 . . . . 0.0 111.654 -179.525 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 186' ' ' ALA . . . . . 0.49 ' HB2' ' HA ' ' A' ' 182' ' ' PRO . . . 55.31 84.88 0.07 Allowed 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.26 -0.427 . . . . 0.0 111.74 179.535 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 187' ' ' LEU . . . . . 0.447 HD12 ' HB3' ' A' ' 180' ' ' LEU . 16.4 mt -92.3 -49.44 6.16 Favored 'General case' 0 C--N 1.332 -0.162 0 CA-C-O 121.041 0.448 . . . . 0.0 110.676 179.452 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 188' ' ' LEU . . . . . . . . . . . . . 72.8 mt -102.81 -160.64 0.79 Allowed 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 115.763 -0.653 . . . . 0.0 111.282 -179.409 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 189' ' ' THR . . . . . 0.452 ' HB ' HG23 ' A' ' 192' ' ' VAL . 10.4 m -88.11 136.64 31.85 Favored Pre-proline 0 C--N 1.33 -0.249 0 CA-C-N 115.866 -0.607 . . . . 0.0 110.615 -179.805 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 190' ' ' PRO . . . . . . . . . . . . . 82.1 Cg_exo -46.58 -49.74 11.55 Favored 'Trans proline' 0 C--N 1.35 0.607 0 C-N-CA 122.614 2.209 . . . . 0.0 113.053 -179.63 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 191' ' ' THR . . . . . 0.427 HG22 HG22 ' A' ' 189' ' ' THR . 7.1 t -61.4 -35.6 77.95 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.485 -0.325 . . . . 0.0 111.77 -179.478 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 192' ' ' VAL . . . . . 0.452 HG23 ' HB ' ' A' ' 189' ' ' THR . 89.3 t -71.45 -47.09 60.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-O 120.833 0.349 . . . . 0.0 111.278 -179.708 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 193' ' ' ASP . . . . . . . . . . . . . 24.4 t70 -58.93 -43.98 91.27 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.752 -179.944 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 194' ' ' VAL . . . . . . . . . . . . . 78.3 t -63.16 -37.98 80.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.929 179.787 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 195' ' ' ALA . . . . . . . . . . . . . . . -57.22 -46.56 82.83 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.484 -0.325 . . . . 0.0 111.093 179.829 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 196' ' ' LEU . . . . . 0.426 ' O ' ' HB3' ' A' ' 199' ' ' TYR . 80.8 mt -67.75 -33.44 74.87 Favored 'General case' 0 C--N 1.332 -0.188 0 CA-C-N 116.381 -0.372 . . . . 0.0 110.633 179.691 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 197' ' ' ILE . . . . . 0.507 HD13 HD12 ' A' ' 200' ' ' LEU . 21.1 mm -64.57 -50.48 75.69 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.112 179.126 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 198' ' ' VAL . . . . . . . . . . . . . 85.0 t -56.72 -34.08 42.11 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.478 0 N-CA-C 108.707 -0.849 . . . . 0.0 108.707 178.171 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 199' ' ' TYR . . . . . 0.502 ' O ' HG23 ' A' ' 203' ' ' VAL . 80.5 t80 -68.38 -43.72 76.69 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 114.939 -1.028 . . . . 0.0 110.167 179.544 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 200' ' ' LEU . . . . . 0.507 HD12 HD13 ' A' ' 197' ' ' ILE . 65.0 mt -56.61 -55.02 39.25 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 115.496 -0.775 . . . . 0.0 111.172 -179.667 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 201' ' ' ASP . . . . . . . . . . . . . 11.6 m-20 -64.82 -38.07 89.74 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.85 179.918 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 202' ' ' LEU . . . . . . . . . . . . . 23.5 tp -64.99 -26.05 68.12 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 115.703 -0.681 . . . . 0.0 111.393 -179.554 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 203' ' ' VAL . . . . . 0.502 HG23 ' O ' ' A' ' 199' ' ' TYR . 45.0 t -82.58 -36.55 13.54 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.365 0 CA-C-N 116.635 -0.257 . . . . 0.0 111.454 -179.397 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 204' ' ' THR . . . . . 0.402 ' O ' ' HB3' ' A' ' 208' ' ' PHE . 88.2 m -63.51 -49.18 74.55 Favored 'General case' 0 C--N 1.329 -0.318 0 C-N-CA 120.773 -0.371 . . . . 0.0 111.319 179.837 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 205' ' ' LYS . . . . . 0.69 ' HE2' ' HB2' ' A' ' 47' ' ' ALA . 61.0 mttp -73.32 -46.79 47.38 Favored 'General case' 0 C--N 1.326 -0.429 0 N-CA-C 111.934 0.346 . . . . 0.0 111.934 -178.926 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 94.9 t -74.14 -50.57 27.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-O 120.572 0.225 . . . . 0.0 111.398 -179.805 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 207' ' ' GLY . . . . . . . . . . . . . . . -60.0 -58.19 15.43 Favored Glycine 0 CA--C 1.519 0.292 0 C-N-CA 121.112 -0.566 . . . . 0.0 112.862 179.988 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 208' ' ' PHE . . . . . 0.443 ' O ' ' N ' ' A' ' 212' ' ' ALA . 4.3 t80 -56.27 -44.35 79.66 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.601 0.239 . . . . 0.0 110.744 179.75 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 209' ' ' GLY . . . . . 0.491 ' HA2' ' HB3' ' A' ' 212' ' ' ALA . . . -66.36 -37.7 93.0 Favored Glycine 0 C--N 1.33 0.243 0 CA-C-N 115.811 -0.631 . . . . 0.0 113.41 -179.686 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 210' ' ' PHE . . . . . . . . . . . . . 1.7 m-85 -69.14 -43.85 73.52 Favored 'General case' 0 CA--C 1.51 -0.592 0 N-CA-C 107.64 -1.244 . . . . 0.0 107.64 178.99 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 211' ' ' ILE . . . . . . . . . . . . . 79.8 mt -65.76 -29.62 47.54 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.827 0 N-CA-C 107.193 -1.41 . . . . 0.0 107.193 176.319 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 212' ' ' ALA . . . . . 0.491 ' HB3' ' HA2' ' A' ' 209' ' ' GLY . . . -68.94 -34.92 76.14 Favored 'General case' 0 N--CA 1.449 -0.483 0 CA-C-N 114.437 -1.256 . . . . 0.0 109.969 179.413 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 213' ' ' LEU . . . . . . . . . . . . . 57.6 mt -70.35 -55.34 9.37 Favored 'General case' 0 C--N 1.331 -0.205 0 CA-C-N 115.056 -0.975 . . . . 0.0 111.458 -179.55 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 214' ' ' ASP . . . . . . . . . . . . . 16.7 t70 -59.48 -26.88 65.63 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.284 -0.416 . . . . 0.0 110.59 179.974 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 215' ' ' ALA . . . . . 0.44 ' HB1' HD13 ' A' ' 159' ' ' LEU . . . -71.04 -57.69 4.29 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 115.906 -0.588 . . . . 0.0 111.521 -179.911 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 216' ' ' ALA . . . . . . . . . . . . . . . -62.76 -37.49 86.84 Favored 'General case' 0 C--N 1.332 -0.187 0 CA-C-N 116.43 -0.35 . . . . 0.0 111.267 -179.702 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 217' ' ' ALA . . . . . . . . . . . . . . . -60.06 -42.98 95.66 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.312 -0.404 . . . . 0.0 110.3 179.531 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 218' ' ' THR . . . . . 0.451 ' HA ' ' HB3' ' A' ' 221' ' ' ALA . 98.3 m -62.43 -37.96 87.88 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 115.865 -0.607 . . . . 0.0 110.57 179.405 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 219' ' ' LEU . . . . . 0.494 ' O ' ' HG2' ' A' ' 222' ' ' GLU . 82.4 mt -56.95 -46.16 82.31 Favored 'General case' 0 C--N 1.331 -0.198 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.419 179.672 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 220' ' ' ARG . . . . . 0.459 ' HA ' ' NE2' ' A' ' 223' ' ' HIS . 8.9 mpt_? -84.52 -13.72 51.06 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.083 -0.508 . . . . 0.0 111.088 179.376 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 221' ' ' ALA . . . . . 0.451 ' HB3' ' HA ' ' A' ' 218' ' ' THR . . . -81.09 -19.94 42.59 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.249 -0.432 . . . . 0.0 111.864 -179.551 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 222' ' ' GLU . . . . . 0.494 ' HG2' ' O ' ' A' ' 219' ' ' LEU . 11.6 pt-20 -79.06 -11.26 59.99 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.754 0.311 . . . . 0.0 111.154 -179.182 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 223' ' ' HIS . . . . . 0.459 ' NE2' ' HA ' ' A' ' 220' ' ' ARG . 30.9 p80 -134.43 -5.1 2.6 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.316 -0.402 . . . . 0.0 110.969 -179.975 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 224' ' ' GLY . . . . . . . . . . . . . . . -76.09 -4.12 77.31 Favored Glycine 0 C--N 1.33 0.201 0 C-N-CA 120.749 -0.739 . . . . 0.0 112.421 179.904 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 225' ' ' GLU . . . . . . . . . . . . . 12.4 pt-20 -106.58 144.2 33.59 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-O 120.749 0.309 . . . . 0.0 110.932 179.952 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 226' ' ' SER . . . . . . . . . . . . . 67.1 m 59.96 107.53 0.02 OUTLIER 'General case' 0 C--N 1.331 -0.202 0 CA-C-N 115.994 -0.548 . . . . 0.0 111.172 -179.82 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 227' ' ' LEU . . . . . 0.457 ' N ' HD12 ' A' ' 227' ' ' LEU . 6.9 mp -84.14 -35.98 23.24 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 115.996 -0.547 . . . . 0.0 110.792 -179.854 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 228' ' ' ALA . . . . . . . . . . . . . . . 51.18 30.59 5.85 Favored 'General case' 0 C--N 1.332 -0.172 0 CA-C-N 116.136 -0.484 . . . . 0.0 111.537 179.875 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 229' ' ' GLY . . . . . . . . . . . . . . . -121.16 -50.24 0.26 Allowed Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.665 -0.779 . . . . 0.0 112.747 -179.934 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 230' ' ' VAL . . . . . . . . . . . . . 44.5 t -103.11 114.0 41.47 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-O 120.68 0.276 . . . . 0.0 111.038 -179.873 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 231' ' ' ASP . . . . . . . . . . . . . 6.4 p-10 -58.8 131.49 51.09 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.82 -179.984 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 232' ' ' THR . . . . . . . . . . . . . 4.9 t -167.16 136.56 2.82 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.115 -0.493 . . . . 0.0 111.346 -179.855 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 233' ' ' ASP . . . . . . . . . . . . . 9.5 m-20 -137.08 150.66 48.18 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.001 -0.545 . . . . 0.0 110.864 179.76 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 234' ' ' THR . . . . . 0.541 ' HB ' ' HD3' ' A' ' 235' ' ' PRO . 83.4 m -77.03 -48.91 2.52 Favored Pre-proline 0 CA--C 1.533 0.301 0 CA-C-N 116.326 -0.397 . . . . 0.0 111.827 -179.867 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 235' ' ' PRO . . . . . 0.541 ' HD3' ' HB ' ' A' ' 234' ' ' THR . 71.5 Cg_exo -48.72 141.26 21.15 Favored 'Trans proline' 0 C--N 1.355 0.87 0 C-N-CA 122.3 2.0 . . . . 0.0 112.454 -179.997 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 236' ' ' ALA . . . . . . . . . . . . . . . -58.52 134.85 57.06 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-N 116.132 -0.485 . . . . 0.0 111.228 -179.87 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 237' ' ' VAL . . . . . 0.558 HG22 ' H ' ' A' ' 239' ' ' ASP . 15.0 p -105.33 148.94 9.16 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.23 0 CA-C-N 116.112 -0.495 . . . . 0.0 111.055 -179.998 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 238' ' ' ALA . . . . . . . . . . . . . . . -95.06 21.33 7.88 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.27 -0.423 . . . . 0.0 111.233 -179.991 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 239' ' ' ASP . . . . . 0.558 ' H ' HG22 ' A' ' 237' ' ' VAL . 7.1 m-20 59.11 -177.82 0.08 Allowed 'General case' 0 C--N 1.331 -0.201 0 CA-C-N 116.265 -0.425 . . . . 0.0 111.308 179.847 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 240' ' ' LEU . . . . . 0.456 ' N ' HD22 ' A' ' 240' ' ' LEU . 3.3 mm? -108.45 130.83 55.24 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.821 179.812 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 241' ' ' GLU . . . . . . . . . . . . . 44.5 mt-10 -116.68 -26.28 7.06 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.373 -0.376 . . . . 0.0 110.849 179.746 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 242' ' ' HIS . . . . . . . . . . . . . 70.2 m80 -95.29 -40.87 9.32 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.902 179.875 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 243' ' ' HIS . . . . . . . . . . . . . 78.4 m80 -79.93 141.45 36.04 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.125 -0.488 . . . . 0.0 110.787 179.962 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 244' ' ' HIS . . . . . . . . . . . . . 13.6 p-80 -113.05 168.17 9.92 Favored 'General case' 0 C--N 1.331 -0.218 0 CA-C-N 116.246 -0.434 . . . . 0.0 111.123 -179.737 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 245' ' ' HIS . . . . . . . . . . . . . 55.9 t-80 58.65 96.86 0.02 OUTLIER 'General case' 0 C--O 1.233 0.201 0 CA-C-N 115.823 -0.626 . . . . 0.0 111.078 179.844 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 246' ' ' HIS . . . . . . . . . . . . . 44.9 t-80 -157.63 149.95 22.57 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.833 -179.995 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 247' ' ' HIS . . . . . . . . . . . . . 62.2 m80 . . . . . 0 C--O 1.25 1.107 0 CA-C-O 118.341 -0.838 . . . . 0.0 110.957 -179.909 . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 301' ' ' RET . . . . . 0.736 H203 ' HE1' ' A' ' 171' ' ' TRP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 87.3 mmm . . . . . 0 N--CA 1.485 1.317 0 CA-C-O 120.667 0.27 . . . . 0.0 110.997 . . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 41.8 t 56.57 89.36 0.04 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.114 179.99 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . 146.06 -37.65 1.23 Allowed Glycine 0 N--CA 1.452 -0.3 0 C-N-CA 120.846 -0.693 . . . . 0.0 112.72 -179.897 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 59.0 tp -74.44 -38.16 63.08 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.886 0.375 . . . . 0.0 110.988 -179.967 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 40.6 p -65.0 -29.57 70.5 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 115.936 -0.574 . . . . 0.0 111.442 -179.74 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 17.8 p -51.92 -35.22 44.92 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.278 -0.419 . . . . 0.0 111.561 -179.497 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 7' ' ' LEU . . . . . . . . . . . . . 4.0 mm? -58.22 -53.4 58.73 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.332 -0.395 . . . . 0.0 111.216 -179.877 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 8' ' ' PHE . . . . . 0.479 ' HB2' ' HB2' ' A' ' 55' ' ' ALA . 74.2 m-85 -61.47 -35.21 77.0 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.826 179.998 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 9' ' ' TRP . . . . . . . . . . . . . 55.2 m95 -64.74 -41.26 96.07 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 115.991 -0.55 . . . . 0.0 110.227 179.916 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 44.9 mt -62.37 -46.46 88.54 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 115.817 -0.629 . . . . 0.0 110.461 179.53 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 11' ' ' GLY . . . . . 0.419 ' O ' ' HG2' ' A' ' 15' ' ' MET . . . -61.99 -32.57 82.62 Favored Glycine 0 N--CA 1.45 -0.425 0 C-N-CA 120.703 -0.761 . . . . 0.0 111.817 179.369 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -67.56 -34.26 76.7 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-O 120.83 0.348 . . . . 0.0 110.707 179.852 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 65.6 mt -65.97 -46.94 86.9 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.238 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.144 179.396 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -59.83 -33.48 78.43 Favored Glycine 0 N--CA 1.45 -0.388 0 C-N-CA 120.726 -0.75 . . . . 0.0 111.712 179.208 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 15' ' ' MET . . . . . 0.545 ' HE3' ' CB ' ' A' ' 47' ' ' ALA . 24.1 mmt -70.33 -40.56 74.08 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 120.861 0.362 . . . . 0.0 110.507 179.425 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 27.9 tp -57.66 -39.31 76.77 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.047 -0.524 . . . . 0.0 110.562 179.792 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 56.1 t -67.28 -48.0 79.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.062 -0.517 . . . . 0.0 110.89 179.973 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -62.57 -49.33 74.45 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.705 -0.759 . . . . 0.0 111.86 179.507 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 38.2 m -49.65 -44.49 47.7 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-O 120.721 0.296 . . . . 0.0 111.279 -179.828 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 79.6 mt -72.14 -44.32 63.31 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.244 -0.434 . . . . 0.0 111.664 179.819 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -60.93 -29.93 69.91 Favored 'General case' 0 C--N 1.329 -0.299 0 N-CA-C 112.18 0.437 . . . . 0.0 112.18 -179.14 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 22' ' ' PHE . . . . . 0.644 ' HB2' HG22 ' A' ' 41' ' ' VAL . 8.7 m-85 -90.61 -34.57 15.42 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.757 0.313 . . . . 0.0 111.411 -179.31 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -67.58 -50.61 57.55 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 121.038 0.447 . . . . 0.0 111.319 -179.764 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 24' ' ' TRP . . . . . . . . . . . . . 4.7 t-105 -62.18 -37.16 84.19 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-N 115.698 -0.683 . . . . 0.0 111.187 -179.899 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -80.4 -21.23 42.46 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.853 0.359 . . . . 0.0 111.118 -179.994 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -73.56 -39.78 48.72 Favored Glycine 0 CA--C 1.519 0.295 0 C-N-CA 121.021 -0.609 . . . . 0.0 112.778 179.972 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 14.4 ptp180 -71.5 -4.21 25.46 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-O 120.715 0.293 . . . . 0.0 111.249 -179.665 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 23.6 t70 -134.91 87.06 2.31 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.316 -0.402 . . . . 0.0 110.658 179.871 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -165.95 -79.54 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.066 -0.515 . . . . 0.0 111.281 -179.908 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -169.04 -146.61 5.08 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.697 -179.853 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 57.8 m -117.06 -53.2 2.49 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.801 0.334 . . . . 0.0 111.125 -179.948 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -65.47 -27.69 72.79 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.811 -0.709 . . . . 0.0 112.87 -179.861 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 13.7 mm-40 -86.69 -21.47 26.65 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.663 0.268 . . . . 0.0 111.106 -179.654 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 34' ' ' ARG . . . . . . . . . . . . . 37.2 ttm180 -54.54 -29.63 51.5 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.31 -0.405 . . . . 0.0 111.416 -179.401 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 55.0 ttp180 -59.17 -40.87 86.96 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.852 0.358 . . . . 0.0 110.828 -179.899 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 63.7 m-85 -72.74 -31.21 64.78 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.123 -0.489 . . . . 0.0 110.997 -179.971 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 37' ' ' TYR . . . . . 0.467 ' O ' HG23 ' A' ' 41' ' ' VAL . 65.9 m-85 -70.34 -54.85 10.84 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.197 -179.876 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 78.4 t -57.14 -38.99 63.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-O 120.873 0.368 . . . . 0.0 110.573 179.776 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 19.1 m -63.19 -50.48 70.14 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 115.929 -0.578 . . . . 0.0 110.79 179.405 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 40' ' ' LEU . . . . . 0.691 HD12 HD11 ' A' ' 43' ' ' ILE . 41.4 tp -56.99 -45.77 82.74 Favored 'General case' 0 C--O 1.235 0.323 0 CA-C-N 115.693 -0.685 . . . . 0.0 110.739 179.937 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 41' ' ' VAL . . . . . 0.644 HG22 ' HB2' ' A' ' 22' ' ' PHE . 94.3 t -62.16 -33.56 59.24 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.497 0 CA-C-N 116.103 -0.498 . . . . 0.0 109.698 179.001 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -58.17 -48.78 81.11 Favored Glycine 0 N--CA 1.45 -0.378 0 CA-C-N 115.49 -0.777 . . . . 0.0 113.135 179.888 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 43' ' ' ILE . . . . . 0.691 HD11 HD12 ' A' ' 40' ' ' LEU . 17.0 pt -64.72 -47.02 90.45 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.215 0 CA-C-N 117.213 0.506 . . . . 0.0 111.599 -179.61 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 67.9 m -61.92 -27.88 69.13 Favored 'General case' 0 C--O 1.232 0.149 0 CA-C-O 120.907 0.384 . . . . 0.0 110.945 179.496 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -79.45 -52.86 4.6 Favored Glycine 0 CA--C 1.517 0.212 0 CA-C-N 115.934 -0.575 . . . . 0.0 113.423 -179.119 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 46' ' ' ILE . . . . . 0.504 HG13 HG22 ' A' ' 79' ' ' THR . 7.2 pt -57.81 -40.22 74.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-O 121.001 0.429 . . . . 0.0 111.002 -179.613 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 47' ' ' ALA . . . . . 0.596 ' HB2' ' HE2' ' A' ' 205' ' ' LYS . . . -68.31 -42.82 78.83 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.21 179.195 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 48' ' ' ALA . . . . . 0.453 ' HB2' ' HB3' ' A' ' 15' ' ' MET . . . -54.24 -43.18 70.69 Favored 'General case' 0 C--O 1.232 0.16 0 CA-C-N 116.326 -0.397 . . . . 0.0 111.763 -179.339 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 49' ' ' VAL . . . . . 0.443 HG22 ' O ' ' A' ' 46' ' ' ILE . 32.5 m -73.28 -34.22 43.38 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 116.492 -0.322 . . . . 0.0 111.445 -179.572 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -64.07 -37.79 88.73 Favored 'General case' 0 C--N 1.332 -0.174 0 CA-C-O 120.897 0.379 . . . . 0.0 111.217 179.827 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 35.6 m-85 -72.18 -39.27 68.77 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 115.996 -0.547 . . . . 0.0 110.704 -179.623 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -62.82 -50.52 70.63 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 115.944 -0.571 . . . . 0.0 111.301 179.739 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 53' ' ' VAL . . . . . 0.428 HG23 ' N ' ' A' ' 54' ' ' MET . 18.5 m -65.6 -43.06 94.13 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.189 0 CA-C-N 116.365 -0.379 . . . . 0.0 111.281 -179.666 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 54' ' ' MET . . . . . 0.507 ' HG3' ' HE1' ' A' ' 60' ' ' TRP . 10.9 ttp -68.55 -29.98 68.66 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.886 0.374 . . . . 0.0 110.306 179.897 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 55' ' ' ALA . . . . . 0.479 ' HB2' ' HB2' ' A' ' 8' ' ' PHE . . . -64.67 -36.86 85.65 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 115.939 -0.573 . . . . 0.0 110.939 179.328 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 86.7 mt -74.45 -1.0 19.23 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.061 -0.518 . . . . 0.0 111.245 -179.681 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 92.78 4.31 65.48 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.668 -0.777 . . . . 0.0 112.448 179.987 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 46.8 t -74.08 144.63 12.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-O 120.819 0.342 . . . . 0.0 111.187 -179.915 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 59' ' ' GLY . . . . . 0.43 ' HA3' ' HD3' ' A' ' 71' ' ' PRO . . . 76.7 5.86 84.09 Favored Glycine 0 CA--C 1.519 0.335 0 C-N-CA 120.946 -0.645 . . . . 0.0 112.815 -179.975 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 60' ' ' TRP . . . . . 0.507 ' HE1' ' HG3' ' A' ' 54' ' ' MET . 24.7 m0 -81.8 118.06 22.58 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.684 0.278 . . . . 0.0 111.076 -179.908 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 7.3 p -115.49 126.33 27.87 Favored Pre-proline 0 CA--C 1.533 0.313 0 CA-C-N 116.491 -0.322 . . . . 0.0 111.307 179.757 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 9.2 Cg_exo -72.13 142.69 38.52 Favored 'Trans proline' 0 C--N 1.349 0.603 0 C-N-CA 122.705 2.27 . . . . 0.0 112.081 179.739 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 98.1 t -142.36 94.33 0.57 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.064 179.968 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . 58.58 -90.14 0.03 OUTLIER 'General case' 0 C--N 1.332 -0.182 0 CA-C-N 115.973 -0.558 . . . . 0.0 111.622 179.857 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 18.5 mm-40 -117.36 -21.53 8.65 Favored 'General case' 0 C--N 1.332 -0.161 0 CA-C-N 116.39 -0.368 . . . . 0.0 111.048 -179.694 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 66' ' ' ARG . . . . . . . . . . . . . 30.7 ptt180 -107.17 158.64 16.94 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.174 -0.467 . . . . 0.0 110.629 179.911 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 60.5 m -117.76 115.24 24.62 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.386 -0.37 . . . . 0.0 111.651 -179.514 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 21.0 t -87.47 146.79 5.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 115.92 -0.582 . . . . 0.0 110.415 179.436 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 69' ' ' PHE . . . . . . . . . . . . . 26.6 m-85 -108.03 114.19 27.92 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-O 120.903 0.382 . . . . 0.0 110.096 -179.557 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 70' ' ' VAL . . . . . 0.595 ' N ' ' HD2' ' A' ' 71' ' ' PRO . 12.4 t -67.7 -48.98 41.19 Favored Pre-proline 0 C--N 1.324 -0.524 0 CA-C-N 115.921 -0.582 . . . . 0.0 112.117 -178.982 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 71' ' ' PRO . . . . . 0.595 ' HD2' ' N ' ' A' ' 70' ' ' VAL . 30.0 Cg_endo -62.64 -17.67 59.88 Favored 'Trans proline' 0 C--N 1.351 0.677 0 C-N-CA 122.166 1.91 . . . . 0.0 112.508 -179.64 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 34.2 ttp180 -69.75 -55.4 9.99 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.431 -0.349 . . . . 0.0 111.53 -179.455 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 73' ' ' TYR . . . . . 0.496 ' O ' HG13 ' A' ' 77' ' ' ILE . 74.0 m-85 -70.99 -36.39 72.47 Favored 'General case' 0 C--N 1.33 -0.264 0 C-N-CA 120.854 -0.338 . . . . 0.0 110.602 -179.577 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 74' ' ' ILE . . . . . 0.518 HG22 ' HA ' ' A' ' 71' ' ' PRO . 0.3 OUTLIER -64.78 -41.43 92.17 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.199 0 N-CA-C 109.935 -0.394 . . . . 0.0 109.935 179.291 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 10.7 t70 -56.97 -38.1 72.51 Favored 'General case' 0 CA--C 1.518 -0.276 0 N-CA-C 109.007 -0.738 . . . . 0.0 109.007 178.531 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 76' ' ' TRP . . . . . 0.446 ' HA ' ' OG1' ' A' ' 79' ' ' THR . 44.6 m0 -66.88 -30.31 70.44 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 115.588 -0.733 . . . . 0.0 110.895 179.27 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 77' ' ' ILE . . . . . 0.531 ' O ' ' HG2' ' A' ' 81' ' ' PRO . 69.8 mt -67.13 -36.54 77.18 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.302 -0.408 . . . . 0.0 111.032 179.842 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 78' ' ' LEU . . . . . 0.524 HD12 HG23 ' A' ' 79' ' ' THR . 2.7 pp -91.59 -23.24 19.95 Favored 'General case' 0 C--N 1.326 -0.448 0 N-CA-C 112.76 0.652 . . . . 0.0 112.76 -179.871 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 79' ' ' THR . . . . . 0.524 HG23 HD12 ' A' ' 78' ' ' LEU . 40.9 p -88.05 -53.77 4.56 Favored 'General case' 0 N--CA 1.471 0.582 0 N-CA-C 113.49 0.922 . . . . 0.0 113.49 -179.011 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 80' ' ' THR . . . . . 0.628 ' HB ' ' HD3' ' A' ' 81' ' ' PRO . 18.2 m -53.69 -55.45 35.3 Favored Pre-proline 0 C--N 1.331 -0.21 0 N-CA-C 113.192 0.812 . . . . 0.0 113.192 -177.475 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 81' ' ' PRO . . . . . 0.628 ' HD3' ' HB ' ' A' ' 80' ' ' THR . 77.1 Cg_exo -53.45 -25.47 32.04 Favored 'Trans proline' 0 C--N 1.35 0.63 0 C-N-CA 121.567 1.511 . . . . 0.0 112.09 -179.842 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 82' ' ' LEU . . . . . 0.444 HD23 HG23 ' A' ' 43' ' ' ILE . 11.5 tp -76.69 -33.17 58.24 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.171 179.521 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 83' ' ' ILE . . . . . 0.45 HD13 HG21 ' A' ' 43' ' ' ILE . 36.6 mm -66.54 -53.37 36.32 Favored 'Isoleucine or valine' 0 C--O 1.234 0.255 0 CA-C-N 116.172 -0.467 . . . . 0.0 109.955 178.678 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 33.8 m -61.21 -30.05 47.06 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.217 0 CA-C-N 115.887 -0.597 . . . . 0.0 109.61 178.875 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 85' ' ' TYR . . . . . . . . . . . . . 85.4 t80 -67.92 -31.41 71.15 Favored 'General case' 0 N--CA 1.453 -0.285 0 CA-C-N 115.566 -0.743 . . . . 0.0 109.379 178.758 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 86' ' ' PHE . . . . . . . . . . . . . 7.6 t80 -62.51 -51.51 67.13 Favored 'General case' 0 N--CA 1.455 -0.211 0 CA-C-N 115.755 -0.657 . . . . 0.0 109.598 179.087 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 7.2 mt -61.91 -33.06 73.54 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 115.813 -0.631 . . . . 0.0 109.913 179.205 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -66.58 -27.66 73.31 Favored Glycine 0 N--CA 1.452 -0.293 0 CA-C-N 115.25 -0.886 . . . . 0.0 112.044 179.425 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 65.4 mt -74.18 -44.48 53.29 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-O 121.028 0.442 . . . . 0.0 110.749 179.826 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 78.4 mt -61.23 -31.85 71.63 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 115.823 -0.626 . . . . 0.0 111.151 -179.937 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 91' ' ' ALA . . . . . 0.406 ' HB2' ' HB2' ' A' ' 149' ' ' ALA . . . -88.36 -38.77 14.84 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.328 -0.396 . . . . 0.0 111.788 -179.433 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 85.09 70.62 1.33 Allowed Glycine 0 CA--C 1.517 0.187 0 C-N-CA 120.701 -0.761 . . . . 0.0 112.145 -179.316 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 20.0 mt -87.58 169.11 12.45 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.906 0.384 . . . . 0.0 111.371 -179.447 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 94' ' ' ASP . . . . . 0.456 ' HB3' ' HG3' ' A' ' 97' ' ' GLU . 18.6 t70 -79.77 161.56 25.64 Favored 'General case' 0 C--N 1.332 -0.168 0 CA-C-N 116.027 -0.533 . . . . 0.0 110.599 179.661 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 71.0 m -55.91 -44.79 78.61 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.418 -0.356 . . . . 0.0 111.126 -179.972 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 10.2 mpt_? -68.78 -48.02 64.72 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.169 -179.804 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 97' ' ' GLU . . . . . 0.521 ' HA ' HD12 ' A' ' 100' ' ' ILE . 47.3 mt-10 -53.95 -38.7 65.23 Favored 'General case' 0 C--O 1.234 0.238 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.839 -179.931 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 98' ' ' PHE . . . . . 0.491 ' O ' HG12 ' A' ' 102' ' ' ILE . 5.6 m-85 -60.08 -49.96 75.58 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.392 179.4 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -59.26 -26.16 61.15 Favored Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.705 -0.759 . . . . 0.0 112.515 179.97 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 100' ' ' ILE . . . . . 0.521 HD12 ' HA ' ' A' ' 97' ' ' GLU . 97.7 mt -68.85 -50.61 52.98 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.194 0 CA-C-O 120.803 0.335 . . . . 0.0 111.527 -179.921 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 101' ' ' VAL . . . . . 0.43 HG11 ' HE1' ' A' ' 145' ' ' MET . 29.6 m -70.59 -36.24 64.83 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.369 0 CA-C-N 116.437 -0.347 . . . . 0.0 111.748 -179.567 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 102' ' ' ILE . . . . . 0.621 HG23 ' HB3' ' A' ' 81' ' ' PRO . 49.5 mm -67.0 -46.72 84.11 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.626 -0.261 . . . . 0.0 111.35 -179.707 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 15.3 t -63.51 -35.32 80.09 Favored 'General case' 0 C--O 1.233 0.201 0 CA-C-O 120.75 0.309 . . . . 0.0 110.954 179.925 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 104' ' ' LEU . . . . . 0.428 ' O ' HG23 ' A' ' 108' ' ' VAL . 2.8 tm? -57.52 -53.75 54.62 Favored 'General case' 0 C--N 1.331 -0.199 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.259 179.54 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 105' ' ' ASN . . . . . 0.644 HD21 HD13 ' A' ' 137' ' ' LEU . 0.8 OUTLIER -55.71 -37.93 69.06 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.498 179.527 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 44.0 m -55.19 -41.72 72.31 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-O 120.886 0.374 . . . . 0.0 110.467 179.576 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 107' ' ' VAL . . . . . 0.425 HG23 ' H ' ' A' ' 107' ' ' VAL . 2.1 t -64.5 -37.59 80.41 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.198 0 CA-C-O 121.38 0.61 . . . . 0.0 109.867 178.99 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 108' ' ' VAL . . . . . 0.428 HG23 ' O ' ' A' ' 104' ' ' LEU . 26.1 t -61.49 -50.16 81.48 Favored 'Isoleucine or valine' 0 C--O 1.236 0.361 0 CA-C-N 115.089 -0.959 . . . . 0.0 111.502 -179.91 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 109' ' ' MET . . . . . 0.517 ' HE1' HG21 ' A' ' 80' ' ' THR . 9.1 mmt -63.02 -37.14 85.99 Favored 'General case' 0 C--N 1.331 -0.2 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.872 -179.838 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 31.8 tp -62.04 -33.84 75.13 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.54 179.776 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -64.75 -52.06 58.98 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 115.988 -0.551 . . . . 0.0 110.711 179.473 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . -62.23 -39.13 97.29 Favored Glycine 0 C--N 1.331 0.252 0 C-N-CA 120.484 -0.865 . . . . 0.0 112.137 179.5 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 113' ' ' PHE . . . . . . . . . . . . . 0.5 OUTLIER -52.86 -72.69 0.05 Allowed 'General case' 0 C--N 1.33 -0.255 0 CA-C-O 121.052 0.453 . . . . 0.0 110.454 179.825 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 114' ' ' ALA . . . . . 0.456 ' HB3' HD22 ' A' ' 126' ' ' LEU . . . -65.46 -12.66 54.66 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 115.708 -0.678 . . . . 0.0 111.385 -179.899 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -66.31 -43.58 92.51 Favored Glycine 0 C--N 1.33 0.238 0 C-N-CA 120.804 -0.712 . . . . 0.0 112.69 -179.959 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -78.06 -25.73 47.89 Favored 'General case' 0 C--N 1.329 -0.29 0 N-CA-C 112.154 0.427 . . . . 0.0 112.154 -179.721 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 117' ' ' MET . . . . . . . . . . . . . 67.5 mtt -91.81 19.42 6.55 Favored 'General case' 0 C--N 1.329 -0.292 0 N-CA-C 111.868 0.321 . . . . 0.0 111.868 -179.164 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 118' ' ' VAL . . . . . 0.553 HG21 ' HB3' ' A' ' 123' ' ' ARG . 17.5 m -68.33 138.88 91.85 Favored Pre-proline 0 C--N 1.329 -0.324 0 CA-C-O 120.54 0.21 . . . . 0.0 111.169 179.862 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 119' ' ' PRO . . . . . . . . . . . . . 95.1 Cg_endo -86.6 11.56 3.25 Favored 'Trans proline' 0 C--N 1.348 0.55 0 C-N-CA 122.554 2.17 . . . . 0.0 112.339 179.922 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -164.6 -120.7 0.53 Allowed Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.86 -0.686 . . . . 0.0 112.616 -179.811 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 42.3 pt -113.89 14.04 8.22 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.219 0 CA-C-O 120.812 0.339 . . . . 0.0 111.319 -179.861 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 49.0 mt-10 -61.38 -17.53 54.49 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.081 -0.509 . . . . 0.0 111.082 179.808 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 123' ' ' ARG . . . . . 0.553 ' HB3' HG21 ' A' ' 118' ' ' VAL . 14.7 ptt180 -50.44 -29.33 10.03 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.003 -0.544 . . . . 0.0 111.769 -179.821 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 124' ' ' TYR . . . . . . . . . . . . . 33.2 m-85 -74.79 -31.93 61.87 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.46 -0.336 . . . . 0.0 111.302 -179.461 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 125' ' ' ALA . . . . . . . . . . . . . . . -73.0 -56.47 5.08 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-N 116.296 -0.411 . . . . 0.0 111.045 -179.776 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 126' ' ' LEU . . . . . 0.456 HD22 ' HB3' ' A' ' 114' ' ' ALA . 1.3 mt -54.62 -46.52 73.89 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 115.968 -0.56 . . . . 0.0 110.676 179.826 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 127' ' ' PHE . . . . . . . . . . . . . 4.9 t80 -68.22 -37.37 80.76 Favored 'General case' 0 N--CA 1.453 -0.319 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.648 179.766 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 128' ' ' GLY . . . . . . . . . . . . . . . -46.38 -44.15 15.35 Favored Glycine 0 C--N 1.333 0.387 0 C-N-CA 120.14 -1.029 . . . . 0.0 110.607 178.941 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 129' ' ' MET . . . . . 0.47 ' HE3' ' N ' ' A' ' 130' ' ' GLY . 6.0 tmm? -69.52 -41.54 75.86 Favored 'General case' 0 C--N 1.328 -0.357 0 N-CA-C 109.357 -0.608 . . . . 0.0 109.357 178.266 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 130' ' ' GLY . . . . . 0.47 ' N ' ' HE3' ' A' ' 129' ' ' MET . . . -55.49 -39.49 74.2 Favored Glycine 0 N--CA 1.452 -0.278 0 CA-C-N 115.724 -0.671 . . . . 0.0 113.044 -179.711 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -70.03 -53.12 19.03 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.699 0.285 . . . . 0.0 110.609 179.955 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 53.0 t -54.93 -39.93 51.08 Favored 'Isoleucine or valine' 0 C--O 1.233 0.215 0 CA-C-O 121.307 0.575 . . . . 0.0 109.607 178.88 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -69.25 -35.99 76.69 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 115.381 -0.827 . . . . 0.0 110.279 179.391 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 134' ' ' PHE . . . . . 0.489 ' HB2' H182 ' A' ' 301' ' ' RET . 47.6 t80 -58.48 -52.95 63.48 Favored 'General case' 0 N--CA 1.45 -0.43 0 CA-C-N 115.932 -0.577 . . . . 0.0 109.817 179.281 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 135' ' ' ILE . . . . . 0.497 ' O ' HG22 ' A' ' 138' ' ' VAL . 45.2 mt -58.34 -30.52 40.55 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.282 0 CA-C-N 115.699 -0.682 . . . . 0.0 109.741 178.892 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 136' ' ' GLY . . . . . 0.43 ' O ' ' HB3' ' A' ' 139' ' ' TYR . . . -59.47 -42.69 97.71 Favored Glycine 0 N--CA 1.447 -0.574 0 C-N-CA 120.42 -0.895 . . . . 0.0 111.364 178.867 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 137' ' ' LEU . . . . . 0.644 HD13 HD21 ' A' ' 105' ' ' ASN . 53.8 tp -67.24 -54.62 19.29 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.565 0.222 . . . . 0.0 110.666 179.316 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 138' ' ' VAL . . . . . 0.497 HG22 ' O ' ' A' ' 135' ' ' ILE . 3.0 m -54.71 -30.4 22.38 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.134 0 CA-C-O 121.08 0.466 . . . . 0.0 109.805 -179.672 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 139' ' ' TYR . . . . . 0.43 ' HB3' ' O ' ' A' ' 136' ' ' GLY . 20.8 t80 -61.68 -48.14 82.16 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 115.526 -0.761 . . . . 0.0 110.076 178.227 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 37.5 m-85 -63.27 -40.32 97.06 Favored 'General case' 0 C--O 1.232 0.156 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.971 179.537 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 141' ' ' LEU . . . . . 0.454 HD13 ' O ' ' A' ' 137' ' ' LEU . 11.1 mp -54.63 -55.06 33.48 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.09 -179.824 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 10.7 p -76.95 -15.93 14.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-O 121.024 0.44 . . . . 0.0 110.985 179.911 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . -73.55 -133.34 0.22 Allowed Glycine 0 CA--C 1.522 0.528 0 C-N-CA 120.867 -0.683 . . . . 0.0 112.812 -179.883 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 144' ' ' PRO . . . . . . . . . . . . . 52.2 Cg_exo -55.5 -28.56 64.98 Favored 'Trans proline' 0 C--N 1.349 0.579 0 C-N-CA 122.746 2.297 . . . . 0.0 112.885 -179.653 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 145' ' ' MET . . . . . 0.43 ' HE1' HG11 ' A' ' 101' ' ' VAL . 43.2 mtt -56.67 -36.31 69.43 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.382 -0.372 . . . . 0.0 111.352 -179.875 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 146' ' ' THR . . . . . . . . . . . . . 24.7 m -68.09 -48.0 66.71 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.836 -179.303 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 20.0 mm-40 -71.16 -26.31 62.93 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.557 -0.292 . . . . 0.0 111.369 -179.544 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 148' ' ' SER . . . . . . . . . . . . . 47.7 t -70.71 -49.47 46.66 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.312 -0.403 . . . . 0.0 111.312 -179.557 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 149' ' ' ALA . . . . . 0.406 ' HB2' ' HB2' ' A' ' 91' ' ' ALA . . . -75.1 -33.87 61.67 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.074 -0.512 . . . . 0.0 111.678 -179.416 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 150' ' ' SER . . . . . . . . . . . . . 43.5 t -67.24 -12.74 60.88 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.328 -179.636 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 151' ' ' GLN . . . . . . . . . . . . . 77.7 mt-30 -119.03 12.1 12.65 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.486 -0.325 . . . . 0.0 111.42 -179.756 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 31.4 tpt180 -84.56 -51.36 6.94 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 120.81 0.338 . . . . 0.0 110.865 -179.759 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 153' ' ' SER . . . . . 0.677 ' HB3' HG12 ' A' ' 156' ' ' ILE . 18.3 t -157.69 172.46 18.48 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 116.119 -0.492 . . . . 0.0 110.715 179.41 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 154' ' ' SER . . . . . . . . . . . . . 47.0 t -68.86 -41.05 78.93 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.303 -0.408 . . . . 0.0 110.802 179.787 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -76.69 -35.79 39.49 Favored Glycine 0 N--CA 1.452 -0.259 0 C-N-CA 120.98 -0.629 . . . . 0.0 112.974 -179.909 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 156' ' ' ILE . . . . . 0.677 HG12 ' HB3' ' A' ' 153' ' ' SER . 43.1 mm -55.34 -36.82 41.99 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.237 0 CA-C-O 120.714 0.292 . . . . 0.0 111.518 -179.769 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 157' ' ' LYS . . . . . 0.421 ' HB3' ' NZ ' ' A' ' 157' ' ' LYS . 6.5 ttpm? -59.51 -53.75 54.53 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 116.415 -0.357 . . . . 0.0 111.759 -179.45 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 42.8 t -67.37 -41.01 85.75 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.445 -0.343 . . . . 0.0 111.714 -179.198 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 159' ' ' LEU . . . . . 0.505 HD23 HD13 ' A' ' 163' ' ' LEU . 4.1 tt -67.72 -34.55 77.08 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 116.432 -0.349 . . . . 0.0 111.045 -179.554 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 160' ' ' TYR . . . . . . . . . . . . . 67.6 t80 -73.88 -45.81 48.6 Favored 'General case' 0 C--N 1.33 -0.278 0 N-CA-C 112.026 0.38 . . . . 0.0 112.026 -179.165 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 22.7 m -59.82 -43.55 92.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 N-CA-C 111.673 0.249 . . . . 0.0 111.673 -179.252 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 162' ' ' ARG . . . . . 0.514 HH22 ' HB2' ' A' ' 215' ' ' ALA . 86.8 mtm180 -68.99 -38.02 79.06 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.77 0.319 . . . . 0.0 111.218 -179.977 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 163' ' ' LEU . . . . . 0.558 ' HG ' ' HB2' ' A' ' 208' ' ' PHE . 3.4 mp -69.5 -54.17 15.51 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.643 -179.58 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 164' ' ' ARG . . . . . . . . . . . . . 4.7 tmm_? -58.71 -53.54 57.2 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.545 -179.236 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 165' ' ' ASN . . . . . 0.507 ' O ' HG23 ' A' ' 169' ' ' VAL . 4.6 m-20 -53.59 -52.12 60.81 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 120.876 0.37 . . . . 0.0 111.659 -179.273 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 166' ' ' LEU . . . . . 0.496 ' O ' ' HG ' ' A' ' 170' ' ' LEU . 2.1 tt -61.09 -53.33 58.46 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.065 -0.516 . . . . 0.0 111.771 -179.129 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 167' ' ' THR . . . . . 0.494 ' O ' ' HB2' ' A' ' 171' ' ' TRP . 86.0 m -55.47 -53.7 53.02 Favored 'General case' 0 C--N 1.327 -0.395 0 N-CA-C 112.8 0.667 . . . . 0.0 112.8 -178.661 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 168' ' ' VAL . . . . . . . . . . . . . 89.7 t -54.64 -44.61 70.4 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.244 0 N-CA-C 112.371 0.508 . . . . 0.0 112.371 -178.563 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 169' ' ' VAL . . . . . 0.507 HG23 ' O ' ' A' ' 165' ' ' ASN . 75.4 t -58.43 -64.79 0.5 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.421 0 N-CA-C 112.149 0.426 . . . . 0.0 112.149 -178.962 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 170' ' ' LEU . . . . . 0.496 ' HG ' ' O ' ' A' ' 166' ' ' LEU . 1.4 pp -62.3 -29.75 70.65 Favored 'General case' 0 C--N 1.33 -0.255 0 N-CA-C 112.011 0.374 . . . . 0.0 112.011 -178.863 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 171' ' ' TRP . . . . . 0.616 ' HE1' H203 ' A' ' 301' ' ' RET . 2.2 m0 -71.88 -31.2 66.21 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.861 0.362 . . . . 0.0 110.939 179.827 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 172' ' ' ALA . . . . . . . . . . . . . . . -72.18 -6.1 40.36 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.667 179.962 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 173' ' ' ILE . . . . . 0.554 HG22 HD11 ' A' ' 177' ' ' ILE . 29.0 mm -85.24 -21.28 7.91 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.188 0 CA-C-N 115.764 -0.653 . . . . 0.0 111.141 179.79 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 174' ' ' TYR . . . . . 0.445 ' HB2' ' HD3' ' A' ' 175' ' ' PRO . 28.0 m-85 -54.44 -50.47 84.98 Favored Pre-proline 0 N--CA 1.466 0.326 0 CA-C-N 116.437 -0.347 . . . . 0.0 111.673 -179.836 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 175' ' ' PRO . . . . . 0.445 ' HD3' ' HB2' ' A' ' 174' ' ' TYR . 86.7 Cg_exo -45.87 -29.9 6.32 Favored 'Trans proline' 0 C--N 1.353 0.777 0 C-N-CA 122.233 1.955 . . . . 0.0 112.358 179.844 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 176' ' ' PHE . . . . . 0.443 ' O ' ' HG ' ' A' ' 180' ' ' LEU . 92.1 m-85 -80.15 -49.3 11.88 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 115.976 -0.556 . . . . 0.0 111.699 -179.822 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 177' ' ' ILE . . . . . 0.554 HD11 HG22 ' A' ' 173' ' ' ILE . 2.9 mm -60.3 -38.0 75.93 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.528 0 CA-C-N 116.024 -0.535 . . . . 0.0 112.008 -178.459 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 178' ' ' TRP . . . . . 0.409 ' HH2' ' HB2' ' A' ' 123' ' ' ARG . 70.4 t90 -73.32 -44.9 58.13 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.864 0.364 . . . . 0.0 110.922 179.748 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 179' ' ' LEU . . . . . 0.431 ' O ' HG22 ' A' ' 185' ' ' VAL . 1.5 tm? -65.46 -54.22 31.55 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 115.998 -0.546 . . . . 0.0 111.246 -179.323 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 180' ' ' LEU . . . . . 0.5 HD22 ' CD1' ' A' ' 187' ' ' LEU . 18.8 mt -72.46 -45.39 59.73 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.542 -0.299 . . . . 0.0 111.631 -179.267 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 181' ' ' GLY . . . . . 0.405 ' HA3' ' OD1' ' A' ' 193' ' ' ASP . . . -55.35 175.69 0.71 Allowed Glycine 0 C--N 1.336 0.537 0 C-N-CA 120.487 -0.863 . . . . 0.0 112.896 179.646 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 182' ' ' PRO . . . . . 0.654 ' HA ' ' HB2' ' A' ' 186' ' ' ALA . 72.2 Cg_exo -48.07 -45.34 25.64 Favored 'Trans proline' 0 CA--C 1.536 0.596 0 C-N-CA 122.983 2.455 . . . . 0.0 113.86 -179.994 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 183' ' ' PRO . . . . . 0.424 ' HD3' ' HB2' ' A' ' 182' ' ' PRO . 52.2 Cg_exo -53.96 -13.34 4.39 Favored 'Trans proline' 0 C--N 1.355 0.92 0 C-N-CA 122.056 1.837 . . . . 0.0 112.916 -179.853 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 184' ' ' GLY . . . . . 0.423 ' HA3' ' O ' ' A' ' 179' ' ' LEU . . . -115.93 -86.34 1.28 Allowed Glycine 0 N--CA 1.45 -0.414 0 C-N-CA 120.377 -0.916 . . . . 0.0 112.871 -179.779 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 185' ' ' VAL . . . . . 0.431 HG22 ' O ' ' A' ' 179' ' ' LEU . 6.6 m -124.59 -5.06 6.48 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 N-CA-C 112.169 0.433 . . . . 0.0 112.169 -179.495 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 186' ' ' ALA . . . . . 0.654 ' HB2' ' HA ' ' A' ' 182' ' ' PRO . . . 53.41 86.59 0.04 OUTLIER 'General case' 0 N--CA 1.463 0.224 0 CA-C-N 116.479 -0.328 . . . . 0.0 111.682 179.606 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 187' ' ' LEU . . . . . 0.5 ' CD1' HD22 ' A' ' 180' ' ' LEU . 14.1 mt -92.15 -49.36 6.23 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.396 -0.366 . . . . 0.0 111.452 179.851 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 188' ' ' LEU . . . . . 0.468 ' N ' HD12 ' A' ' 188' ' ' LEU . 6.9 mp -92.93 -88.97 0.21 Allowed 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.361 -0.381 . . . . 0.0 111.272 -179.256 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 189' ' ' THR . . . . . . . . . . . . . 1.8 t -169.82 148.7 3.28 Favored Pre-proline 0 C--N 1.325 -0.483 0 CA-C-N 116.01 -0.541 . . . . 0.0 111.078 -179.55 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 190' ' ' PRO . . . . . 0.417 ' O ' HG23 ' A' ' 194' ' ' VAL . 10.2 Cg_endo -51.99 -42.86 56.17 Favored 'Trans proline' 0 C--N 1.35 0.649 0 C-N-CA 122.798 2.332 . . . . 0.0 113.152 -179.761 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 191' ' ' THR . . . . . . . . . . . . . 5.4 t -56.4 -44.74 80.57 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-O 120.689 0.281 . . . . 0.0 111.336 -179.59 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 192' ' ' VAL . . . . . . . . . . . . . 38.5 t -70.56 -43.62 77.62 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.389 -0.369 . . . . 0.0 111.088 179.846 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 193' ' ' ASP . . . . . 0.405 ' OD1' ' HA3' ' A' ' 181' ' ' GLY . 11.3 t70 -55.62 -49.16 73.56 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.942 179.867 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 194' ' ' VAL . . . . . 0.417 HG23 ' O ' ' A' ' 190' ' ' PRO . 85.9 t -63.03 -36.98 78.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.05 -179.985 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 195' ' ' ALA . . . . . . . . . . . . . . . -59.24 -48.41 81.74 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.491 -0.322 . . . . 0.0 110.979 179.827 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 196' ' ' LEU . . . . . . . . . . . . . 65.0 mt -67.91 -43.61 78.84 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.307 -0.406 . . . . 0.0 110.641 179.761 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 197' ' ' ILE . . . . . 0.415 HG12 HG21 ' A' ' 177' ' ' ILE . 17.6 mm -56.51 -59.78 2.59 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 115.961 -0.563 . . . . 0.0 110.444 179.435 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 198' ' ' VAL . . . . . . . . . . . . . 76.8 t -53.06 -34.69 21.5 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.496 0 CA-C-N 115.601 -0.727 . . . . 0.0 109.467 178.512 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 199' ' ' TYR . . . . . . . . . . . . . 64.9 t80 -70.24 -31.61 69.09 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 115.524 -0.762 . . . . 0.0 110.588 179.692 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 200' ' ' LEU . . . . . 0.537 ' O ' HG12 ' A' ' 203' ' ' VAL . 32.2 mt -73.23 -43.44 61.21 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 115.841 -0.618 . . . . 0.0 111.484 -179.478 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 201' ' ' ASP . . . . . . . . . . . . . 10.5 m-20 -71.94 -36.81 70.02 Favored 'General case' 0 C--N 1.327 -0.413 0 CA-C-O 121.251 0.548 . . . . 0.0 110.087 179.511 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 202' ' ' LEU . . . . . . . . . . . . . 39.5 tp -72.73 -27.78 62.25 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 115.311 -0.859 . . . . 0.0 111.779 -179.293 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 203' ' ' VAL . . . . . 0.537 HG12 ' O ' ' A' ' 200' ' ' LEU . 12.3 p -78.71 -35.94 18.96 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.215 0 C-N-CA 120.854 -0.338 . . . . 0.0 110.779 -179.087 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 204' ' ' THR . . . . . 0.418 ' HG1' ' HE1' ' A' ' 171' ' ' TRP . 97.2 m -66.48 -59.0 4.05 Favored 'General case' 0 C--N 1.329 -0.304 0 C-N-CA 120.598 -0.441 . . . . 0.0 110.861 179.34 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 205' ' ' LYS . . . . . 0.596 ' HE2' ' HB2' ' A' ' 47' ' ' ALA . 62.7 mttp -58.76 -57.78 11.5 Favored 'General case' 0 C--N 1.331 -0.209 0 N-CA-C 112.14 0.422 . . . . 0.0 112.14 -178.675 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 49.8 t -70.55 -37.35 69.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 N-CA-C 112.324 0.49 . . . . 0.0 112.324 -178.823 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 207' ' ' GLY . . . . . 0.553 ' O ' HG13 ' A' ' 211' ' ' ILE . . . -55.76 -62.07 6.72 Favored Glycine 0 CA--C 1.518 0.242 0 C-N-CA 120.614 -0.803 . . . . 0.0 113.873 -178.608 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 208' ' ' PHE . . . . . 0.558 ' HB2' ' HG ' ' A' ' 163' ' ' LEU . 3.0 p90 -72.86 -27.63 62.03 Favored 'General case' 0 C--O 1.221 -0.416 0 CA-C-N 117.457 0.628 . . . . 0.0 110.925 -179.231 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 209' ' ' GLY . . . . . 0.555 ' O ' ' HB3' ' A' ' 212' ' ' ALA . . . -62.06 -34.78 90.12 Favored Glycine 0 N--CA 1.449 -0.447 0 N-CA-C 111.91 -0.476 . . . . 0.0 111.91 178.761 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 210' ' ' PHE . . . . . . . . . . . . . 1.2 m-85 -73.59 -48.23 34.35 Favored 'General case' 0 CA--C 1.513 -0.456 0 N-CA-C 108.153 -1.055 . . . . 0.0 108.153 178.398 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 211' ' ' ILE . . . . . 0.553 HG13 ' O ' ' A' ' 207' ' ' GLY . 4.8 mt -61.61 -27.48 42.17 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.51 0 N-CA-C 107.784 -1.191 . . . . 0.0 107.784 176.711 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 212' ' ' ALA . . . . . 0.555 ' HB3' ' O ' ' A' ' 209' ' ' GLY . . . -63.57 -41.75 98.37 Favored 'General case' 0 N--CA 1.45 -0.474 0 CA-C-N 114.478 -1.237 . . . . 0.0 110.664 -179.775 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 213' ' ' LEU . . . . . . . . . . . . . 95.3 mt -69.29 -53.04 21.75 Favored 'General case' 0 C--N 1.332 -0.162 0 CA-C-N 115.26 -0.882 . . . . 0.0 111.398 -179.68 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 214' ' ' ASP . . . . . . . . . . . . . 9.6 m-20 -55.7 -48.66 74.75 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-O 120.878 0.37 . . . . 0.0 110.746 -179.997 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 215' ' ' ALA . . . . . 0.514 ' HB2' HH22 ' A' ' 162' ' ' ARG . . . -59.44 -57.33 13.44 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 115.988 -0.551 . . . . 0.0 110.958 179.721 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 216' ' ' ALA . . . . . 0.415 ' HA ' HD12 ' A' ' 219' ' ' LEU . . . -56.36 -31.55 63.9 Favored 'General case' 0 C--N 1.332 -0.187 0 CA-C-N 116.06 -0.518 . . . . 0.0 111.065 -179.998 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 217' ' ' ALA . . . . . 0.559 ' HA ' ' HE ' ' A' ' 220' ' ' ARG . . . -62.68 -39.26 93.38 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.407 179.615 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 218' ' ' THR . . . . . . . . . . . . . 79.1 m -73.27 -37.58 66.23 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 115.81 -0.632 . . . . 0.0 111.044 179.682 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 219' ' ' LEU . . . . . 0.438 ' HG ' ' O ' ' A' ' 215' ' ' ALA . 56.0 mt -59.49 -46.88 87.55 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.873 -179.879 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 220' ' ' ARG . . . . . 0.559 ' HE ' ' HA ' ' A' ' 217' ' ' ALA . 26.5 ptt180 -77.18 -25.33 51.72 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.815 179.923 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 221' ' ' ALA . . . . . . . . . . . . . . . -59.98 -41.56 92.3 Favored 'General case' 0 C--N 1.331 -0.201 0 CA-C-N 116.061 -0.518 . . . . 0.0 111.172 -179.943 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 222' ' ' GLU . . . . . . . . . . . . . 10.2 pt-20 -86.24 -35.18 20.15 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.782 179.957 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 223' ' ' HIS . . . . . . . . . . . . . 33.6 p80 39.94 -156.63 0.01 OUTLIER 'General case' 0 N--CA 1.466 0.352 0 CA-C-N 115.755 -0.657 . . . . 0.0 111.981 -179.982 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 224' ' ' GLY . . . . . . . . . . . . . . . 158.62 134.95 1.79 Allowed Glycine 0 N--CA 1.452 -0.257 0 C-N-CA 120.886 -0.673 . . . . 0.0 112.441 -179.839 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 225' ' ' GLU . . . . . . . . . . . . . 35.6 tt0 58.89 98.66 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.256 0 CA-C-O 120.81 0.338 . . . . 0.0 110.978 -179.963 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 226' ' ' SER . . . . . . . . . . . . . 50.3 m -62.91 148.49 47.21 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.677 179.864 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 227' ' ' LEU . . . . . 0.409 HD22 ' N ' ' A' ' 227' ' ' LEU . 3.7 mm? -82.59 144.48 30.31 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.311 -0.404 . . . . 0.0 111.007 -179.831 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 228' ' ' ALA . . . . . . . . . . . . . . . -109.21 -7.69 15.24 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 115.949 -0.569 . . . . 0.0 111.021 179.875 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 229' ' ' GLY . . . . . . . . . . . . . . . 145.71 -170.22 27.02 Favored Glycine 0 C--N 1.331 0.277 0 C-N-CA 120.741 -0.742 . . . . 0.0 112.525 179.982 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 230' ' ' VAL . . . . . . . . . . . . . 19.7 t -84.26 146.02 7.35 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.242 0 CA-C-O 120.768 0.318 . . . . 0.0 110.807 179.998 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 231' ' ' ASP . . . . . . . . . . . . . 6.7 p-10 -67.6 116.86 8.8 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.825 -179.969 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 232' ' ' THR . . . . . . . . . . . . . 71.9 p -132.0 2.08 3.96 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.094 -0.503 . . . . 0.0 111.175 -179.904 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 233' ' ' ASP . . . . . . . . . . . . . 14.2 t70 -77.17 -24.45 51.47 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.961 179.956 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 234' ' ' THR . . . . . . . . . . . . . 48.0 m 57.05 87.05 0.15 Allowed Pre-proline 0 C--N 1.33 -0.247 0 CA-C-N 116.134 -0.484 . . . . 0.0 111.339 179.978 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 235' ' ' PRO . . . . . . . . . . . . . 43.3 Cg_exo -57.4 115.8 2.76 Favored 'Trans proline' 0 C--N 1.348 0.544 0 C-N-CA 122.44 2.093 . . . . 0.0 112.111 179.838 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 236' ' ' ALA . . . . . . . . . . . . . . . -146.94 124.39 11.66 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.13 -0.486 . . . . 0.0 111.251 -179.825 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 237' ' ' VAL . . . . . . . . . . . . . 51.5 t 62.25 108.13 0.04 OUTLIER 'Isoleucine or valine' 0 C--N 1.333 -0.147 0 CA-C-N 116.048 -0.524 . . . . 0.0 111.407 179.798 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 238' ' ' ALA . . . . . . . . . . . . . . . -160.13 -16.67 0.06 Allowed 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.019 -0.537 . . . . 0.0 110.972 179.869 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 239' ' ' ASP . . . . . . . . . . . . . 9.7 m-20 -144.36 -6.22 0.73 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.758 179.849 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 240' ' ' LEU . . . . . . . . . . . . . 49.5 tp -62.69 116.2 4.98 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.039 -0.528 . . . . 0.0 110.762 179.954 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 241' ' ' GLU . . . . . . . . . . . . . 38.6 tt0 -143.97 135.46 25.91 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.82 -179.94 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 242' ' ' HIS . . . . . . . . . . . . . 12.1 p80 -140.62 136.63 32.93 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.856 -179.857 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 243' ' ' HIS . . . . . . . . . . . . . 96.4 m-70 -87.83 159.08 18.55 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.125 -179.775 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 244' ' ' HIS . . . . . . . . . . . . . 36.9 m80 -105.06 158.9 16.25 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 115.989 -0.551 . . . . 0.0 110.833 179.783 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 245' ' ' HIS . . . . . . . . . . . . . 92.9 m-70 -85.16 107.73 17.37 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.803 179.98 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 246' ' ' HIS . . . . . . . . . . . . . 34.1 t-80 -76.43 -56.89 4.22 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.077 -0.511 . . . . 0.0 110.926 -179.842 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 247' ' ' HIS . . . . . . . . . . . . . 14.1 p-80 . . . . . 0 C--O 1.249 1.054 0 CA-C-O 118.098 -0.953 . . . . 0.0 111.099 179.949 . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 301' ' ' RET . . . . . 0.616 H203 ' HE1' ' A' ' 171' ' ' TRP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 75.1 mmm . . . . . 0 N--CA 1.486 1.35 0 CA-C-O 120.767 0.318 . . . . 0.0 111.042 . . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 28.2 t 56.86 86.06 0.05 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.014 -0.539 . . . . 0.0 110.95 -179.81 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . 152.08 -34.59 0.85 Allowed Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.841 -0.695 . . . . 0.0 112.506 -179.87 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 50.6 tp -73.88 -36.13 64.77 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.786 0.327 . . . . 0.0 110.948 179.87 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 73.7 p -61.39 -29.71 70.09 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.115 -0.493 . . . . 0.0 111.19 179.946 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 23.1 p -53.46 -35.42 60.51 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.09 -0.504 . . . . 0.0 111.071 -179.904 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 7' ' ' LEU . . . . . . . . . . . . . 4.1 mm? -60.25 -53.44 57.65 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.034 -0.53 . . . . 0.0 111.101 179.991 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 8' ' ' PHE . . . . . . . . . . . . . 81.4 m-85 -59.89 -37.1 78.44 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 120.964 0.412 . . . . 0.0 110.806 179.951 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 9' ' ' TRP . . . . . . . . . . . . . 35.9 m95 -63.57 -41.58 98.39 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 115.897 -0.592 . . . . 0.0 110.173 -179.972 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 38.5 mt -64.85 -49.02 72.2 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-N 115.767 -0.651 . . . . 0.0 110.159 179.244 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 11' ' ' GLY . . . . . 0.438 ' HA2' HD11 ' A' ' 202' ' ' LEU . . . -57.19 -28.09 58.33 Favored Glycine 0 N--CA 1.447 -0.571 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.216 179.293 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -74.09 -38.48 63.87 Favored 'General case' 0 C--N 1.332 -0.186 0 CA-C-O 120.714 0.292 . . . . 0.0 110.79 179.636 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 63.6 mt -61.87 -54.18 38.04 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.31 -0.404 . . . . 0.0 110.436 179.475 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -60.96 -35.23 90.25 Favored Glycine 0 N--CA 1.45 -0.41 0 C-N-CA 120.591 -0.814 . . . . 0.0 111.676 179.257 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 15' ' ' MET . . . . . 0.542 ' SD ' ' HA ' ' A' ' 44' ' ' SER . 47.5 tpp -64.51 -39.98 94.79 Favored 'General case' 0 N--CA 1.454 -0.246 0 N-CA-C 110.167 -0.309 . . . . 0.0 110.167 179.343 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 16' ' ' LEU . . . . . 0.498 HD13 ' O ' ' A' ' 16' ' ' LEU . 0.7 OUTLIER -59.91 -37.55 79.76 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 116.018 -0.537 . . . . 0.0 109.571 179.1 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 94.0 t -59.07 -50.5 79.53 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.172 0 CA-C-N 115.937 -0.574 . . . . 0.0 110.107 179.1 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -61.45 -45.33 96.6 Favored Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.64 -0.791 . . . . 0.0 111.726 179.163 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 32.8 m -51.7 -44.76 63.28 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-O 120.678 0.275 . . . . 0.0 111.301 -179.858 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 81.2 mt -71.59 -36.54 70.89 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.321 -0.4 . . . . 0.0 111.172 179.904 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -63.23 -33.29 75.17 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.348 -0.387 . . . . 0.0 111.338 -179.873 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 22' ' ' PHE . . . . . 0.512 ' HB2' HG22 ' A' ' 41' ' ' VAL . 4.1 m-85 -90.86 -28.76 17.94 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.296 -0.411 . . . . 0.0 111.185 -179.472 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -71.77 -50.69 27.69 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.943 0.402 . . . . 0.0 111.118 179.919 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 24' ' ' TRP . . . . . . . . . . . . . 3.2 t-105 -64.41 -44.66 90.53 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 115.86 -0.609 . . . . 0.0 110.938 -179.946 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -77.62 -18.56 56.67 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.895 0.379 . . . . 0.0 110.915 179.776 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -73.08 -42.17 45.0 Favored Glycine 0 C--N 1.331 0.269 0 C-N-CA 120.959 -0.638 . . . . 0.0 112.383 179.947 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 94.2 mtt180 -68.17 -7.86 33.71 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-O 120.952 0.406 . . . . 0.0 110.463 179.668 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 18.6 t70 -117.21 88.98 3.01 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 115.823 -0.626 . . . . 0.0 110.496 179.729 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -165.42 -162.24 0.58 Allowed 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.141 -0.481 . . . . 0.0 111.219 -179.81 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -95.84 -131.72 6.78 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.963 -0.637 . . . . 0.0 112.631 -179.856 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 47.1 t -113.4 -63.6 1.42 Allowed 'General case' 0 C--N 1.33 -0.241 0 CA-C-O 120.812 0.339 . . . . 0.0 111.364 -179.747 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -65.44 -34.43 89.24 Favored Glycine 0 C--N 1.33 0.198 0 C-N-CA 120.802 -0.713 . . . . 0.0 112.588 -179.75 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 2.9 mp0 -68.34 -20.86 64.76 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 120.727 0.299 . . . . 0.0 110.944 -179.957 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 34' ' ' ARG . . . . . . . . . . . . . 78.9 ttt180 -57.63 -28.95 64.15 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.501 -179.619 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 27.7 tpt180 -59.17 -48.4 81.75 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.704 0.288 . . . . 0.0 111.508 -179.607 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 80.7 m-85 -64.96 -29.81 70.76 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.432 -0.349 . . . . 0.0 111.427 -179.511 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 37' ' ' TYR . . . . . 0.531 ' O ' HG23 ' A' ' 41' ' ' VAL . 52.2 m-85 -74.31 -54.27 8.01 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.413 -0.358 . . . . 0.0 111.342 -179.521 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 83.3 t -56.93 -36.32 49.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-O 120.969 0.414 . . . . 0.0 110.372 179.747 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 53.8 m -65.78 -51.53 58.29 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 115.846 -0.616 . . . . 0.0 110.929 179.518 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 40' ' ' LEU . . . . . 0.608 HD12 HD12 ' A' ' 43' ' ' ILE . 54.2 tp -59.23 -48.12 82.79 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 115.986 -0.552 . . . . 0.0 110.802 -179.94 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 41' ' ' VAL . . . . . 0.531 HG23 ' O ' ' A' ' 37' ' ' TYR . 67.6 t -57.86 -34.88 49.44 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.075 -0.511 . . . . 0.0 109.976 179.058 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -62.4 -36.23 92.82 Favored Glycine 0 N--CA 1.447 -0.606 0 C-N-CA 120.738 -0.744 . . . . 0.0 111.724 179.563 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 43' ' ' ILE . . . . . 0.608 HD12 HD12 ' A' ' 40' ' ' LEU . 1.9 mt -65.25 -55.14 21.79 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.187 0 CA-C-O 120.903 0.383 . . . . 0.0 110.935 179.629 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 44' ' ' SER . . . . . 0.542 ' HA ' ' SD ' ' A' ' 15' ' ' MET . 77.9 p -59.7 -26.23 65.42 Favored 'General case' 0 C--N 1.331 -0.201 0 CA-C-N 115.92 -0.582 . . . . 0.0 111.782 -179.529 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -76.16 -54.97 4.97 Favored Glycine 0 CA--C 1.52 0.39 0 C-N-CA 120.573 -0.823 . . . . 0.0 112.858 -179.513 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 46' ' ' ILE . . . . . 0.507 ' O ' HG22 ' A' ' 49' ' ' VAL . 20.5 pt -59.25 -35.8 59.91 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.219 0 CA-C-O 120.974 0.416 . . . . 0.0 111.13 -179.935 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 47' ' ' ALA . . . . . 0.684 ' HB2' ' HE2' ' A' ' 205' ' ' LYS . . . -68.16 -45.56 73.16 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.031 179.341 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -54.83 -41.94 71.32 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 115.87 -0.605 . . . . 0.0 111.769 -179.448 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 49' ' ' VAL . . . . . 0.507 HG22 ' O ' ' A' ' 46' ' ' ILE . 19.3 m -72.42 -34.19 47.89 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-N 116.521 -0.308 . . . . 0.0 111.138 -179.519 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -67.0 -34.73 78.4 Favored 'General case' 0 C--N 1.331 -0.2 0 CA-C-O 120.872 0.368 . . . . 0.0 111.227 179.853 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 28.3 m-85 -72.44 -41.34 66.25 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.623 -179.737 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -64.04 -46.71 83.2 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 115.769 -0.65 . . . . 0.0 111.245 -179.816 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 53' ' ' VAL . . . . . 0.623 ' O ' HG22 ' A' ' 58' ' ' VAL . 31.9 m -62.96 -53.61 44.39 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.159 0 CA-C-N 116.425 -0.352 . . . . 0.0 111.039 -179.903 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 54' ' ' MET . . . . . 0.546 ' N ' HG23 ' A' ' 53' ' ' VAL . 74.0 mtm -60.08 -31.1 69.7 Favored 'General case' 0 C--N 1.332 -0.182 0 CA-C-O 120.996 0.426 . . . . 0.0 110.289 179.659 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -64.9 -37.88 89.1 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 115.758 -0.655 . . . . 0.0 111.196 179.363 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 93.3 mt -71.15 -2.75 16.83 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.462 -179.586 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 93.66 -5.85 73.73 Favored Glycine 0 N--CA 1.45 -0.368 0 C-N-CA 120.597 -0.811 . . . . 0.0 112.925 179.702 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 58' ' ' VAL . . . . . 0.623 HG22 ' O ' ' A' ' 53' ' ' VAL . 1.5 m -72.64 154.2 7.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-O 120.718 0.294 . . . . 0.0 110.33 179.714 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 73.85 19.27 79.75 Favored Glycine 0 N--CA 1.45 -0.373 0 C-N-CA 120.483 -0.865 . . . . 0.0 112.188 -179.433 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 60' ' ' TRP . . . . . . . . . . . . . 22.0 m0 -99.11 99.26 10.24 Favored 'General case' 0 C--N 1.33 -0.259 0 N-CA-C 109.981 -0.377 . . . . 0.0 109.981 179.824 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 61' ' ' VAL . . . . . 0.563 ' HB ' HG23 ' A' ' 68' ' ' VAL . 61.4 t -97.95 109.51 51.75 Favored Pre-proline 0 C--N 1.324 -0.507 0 CA-C-N 115.996 -0.547 . . . . 0.0 111.542 -179.113 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 39.6 Cg_endo -66.2 135.74 41.35 Favored 'Trans proline' 0 C--N 1.35 0.639 0 C-N-CA 122.532 2.155 . . . . 0.0 112.085 179.731 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 80.9 t -137.89 95.13 1.06 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.38 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.387 -179.604 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . 58.11 -90.16 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.111 -0.495 . . . . 0.0 111.566 179.855 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 44.7 mt-10 -115.45 -24.67 8.26 Favored 'General case' 0 C--N 1.332 -0.193 0 CA-C-O 120.842 0.353 . . . . 0.0 111.157 -179.842 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 66' ' ' ARG . . . . . 0.424 ' HD2' ' N ' ' A' ' 66' ' ' ARG . 9.3 mpt_? -105.74 154.07 20.99 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.415 179.871 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 90.7 m -117.39 115.5 25.33 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.892 0.377 . . . . 0.0 111.433 -179.696 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 68' ' ' VAL . . . . . 0.563 HG23 ' HB ' ' A' ' 61' ' ' VAL . 29.0 m -83.81 146.34 6.99 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.368 0 CA-C-N 115.914 -0.584 . . . . 0.0 110.891 179.672 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 69' ' ' PHE . . . . . . . . . . . . . 64.8 m-85 -108.92 115.87 30.9 Favored 'General case' 0 N--CA 1.443 -0.794 0 CA-C-N 116.273 -0.421 . . . . 0.0 110.185 -179.377 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 70' ' ' VAL . . . . . 0.526 ' HB ' ' HD3' ' A' ' 71' ' ' PRO . 24.5 t -67.49 -49.6 40.84 Favored Pre-proline 0 C--N 1.325 -0.477 0 N-CA-C 112.616 0.599 . . . . 0.0 112.616 -178.932 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 71' ' ' PRO . . . . . 0.526 ' HD3' ' HB ' ' A' ' 70' ' ' VAL . 15.4 Cg_exo -67.08 -17.93 51.16 Favored 'Trans proline' 0 C--N 1.351 0.702 0 C-N-CA 122.315 2.01 . . . . 0.0 113.091 -178.918 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 67.2 ttt180 -66.66 -55.5 14.92 Favored 'General case' 0 C--O 1.237 0.396 0 CA-C-O 120.838 0.351 . . . . 0.0 111.626 -179.404 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 73' ' ' TYR . . . . . 0.475 ' O ' HG13 ' A' ' 77' ' ' ILE . 65.4 m-85 -71.52 -34.54 70.15 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.486 -0.324 . . . . 0.0 110.603 -179.453 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 74' ' ' ILE . . . . . 0.51 ' HA ' HD12 ' A' ' 77' ' ' ILE . 0.4 OUTLIER -66.48 -37.86 80.5 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.242 0 N-CA-C 109.833 -0.432 . . . . 0.0 109.833 179.182 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 13.8 t70 -59.14 -38.95 80.89 Favored 'General case' 0 CA--C 1.517 -0.288 0 N-CA-C 109.128 -0.693 . . . . 0.0 109.128 178.62 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 76' ' ' TRP . . . . . . . . . . . . . 51.1 m0 -65.58 -32.67 74.38 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 115.59 -0.732 . . . . 0.0 110.236 179.138 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 77' ' ' ILE . . . . . 0.51 HD12 ' HA ' ' A' ' 74' ' ' ILE . 69.0 mt -68.76 -28.61 40.55 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.25 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.078 178.984 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 34.0 mt -92.22 -20.43 21.18 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 115.772 -0.649 . . . . 0.0 112.332 179.949 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 82.1 p -103.93 -52.94 2.85 Favored 'General case' 0 N--CA 1.465 0.279 0 N-CA-C 114.025 1.12 . . . . 0.0 114.025 -177.295 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 80' ' ' THR . . . . . 0.456 ' N ' ' HD2' ' A' ' 81' ' ' PRO . 25.3 m -50.41 -54.81 30.86 Favored Pre-proline 0 C--N 1.329 -0.317 0 N-CA-C 113.016 0.747 . . . . 0.0 113.016 -178.007 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 81' ' ' PRO . . . . . 0.485 ' HA ' HG22 ' A' ' 84' ' ' VAL . 20.5 Cg_endo -59.78 -21.27 62.86 Favored 'Trans proline' 0 C--N 1.35 0.654 0 C-N-CA 121.346 1.364 . . . . 0.0 111.141 -179.655 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 82' ' ' LEU . . . . . 0.528 HD23 HG12 ' A' ' 43' ' ' ILE . 13.4 tp -77.13 -33.55 56.76 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 115.58 -0.736 . . . . 0.0 109.829 179.436 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 83' ' ' ILE . . . . . 0.421 HD11 HG21 ' A' ' 43' ' ' ILE . 35.2 mm -70.29 -53.44 23.08 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.191 0 CA-C-N 115.984 -0.553 . . . . 0.0 109.848 179.063 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 84' ' ' VAL . . . . . 0.736 HG11 HD22 ' A' ' 105' ' ' ASN . 33.9 m -59.51 -30.19 43.98 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.183 0 N-CA-C 109.546 -0.539 . . . . 0.0 109.546 178.863 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 85' ' ' TYR . . . . . 0.426 ' HB2' ' O ' ' A' ' 81' ' ' PRO . 68.3 t80 -69.74 -32.57 71.18 Favored 'General case' 0 N--CA 1.454 -0.26 0 CA-C-N 115.537 -0.756 . . . . 0.0 109.623 178.873 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 86' ' ' PHE . . . . . . . . . . . . . 9.9 t80 -61.33 -51.93 66.78 Favored 'General case' 0 C--O 1.232 0.149 0 CA-C-N 115.919 -0.582 . . . . 0.0 109.857 179.326 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 87' ' ' LEU . . . . . 0.402 ' N ' HD12 ' A' ' 87' ' ' LEU . 8.1 mp -61.01 -33.16 72.83 Favored 'General case' 0 C--N 1.332 -0.189 0 CA-C-N 115.873 -0.603 . . . . 0.0 110.08 179.374 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 88' ' ' GLY . . . . . 0.427 ' HA2' HD13 ' A' ' 93' ' ' LEU . . . -67.22 -27.74 73.56 Favored Glycine 0 N--CA 1.449 -0.49 0 C-N-CA 120.836 -0.697 . . . . 0.0 111.755 179.233 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 79.3 mt -72.89 -42.95 63.08 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-O 120.924 0.392 . . . . 0.0 110.468 179.622 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 54.9 mt -59.59 -43.83 93.57 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 115.822 -0.626 . . . . 0.0 110.972 179.878 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 91' ' ' ALA . . . . . 0.49 ' HB2' ' HB2' ' A' ' 149' ' ' ALA . . . -74.46 -55.05 6.39 Favored 'General case' 0 C--N 1.331 -0.21 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.325 -179.886 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 103.55 51.62 0.96 Allowed Glycine 0 N--CA 1.452 -0.251 0 C-N-CA 120.843 -0.694 . . . . 0.0 112.447 179.959 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 93' ' ' LEU . . . . . 0.601 HD23 ' HB3' ' A' ' 97' ' ' GLU . 7.9 mp -65.77 170.83 4.83 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.875 0.369 . . . . 0.0 111.193 -179.884 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 94' ' ' ASP . . . . . . . . . . . . . 5.5 m-20 -85.05 164.66 18.09 Favored 'General case' 0 C--N 1.33 -0.239 0 CA-C-N 116.057 -0.519 . . . . 0.0 110.435 179.643 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 46.8 t -55.86 -34.63 65.65 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.326 -0.397 . . . . 0.0 110.97 -179.753 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 96' ' ' ARG . . . . . 0.468 ' HA ' ' NE ' ' A' ' 96' ' ' ARG . 5.6 tpm_? -73.69 -44.87 55.41 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.254 -0.43 . . . . 0.0 111.195 -179.914 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 97' ' ' GLU . . . . . 0.601 ' HB3' HD23 ' A' ' 93' ' ' LEU . 39.1 mt-10 -54.58 -47.39 73.36 Favored 'General case' 0 C--N 1.333 -0.129 0 CA-C-N 116.274 -0.421 . . . . 0.0 111.102 -179.777 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 98' ' ' PHE . . . . . 0.491 ' O ' HG12 ' A' ' 102' ' ' ILE . 41.1 m-85 -58.31 -48.85 79.19 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.859 0.362 . . . . 0.0 110.571 179.489 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -54.25 -29.89 46.67 Favored Glycine 0 N--CA 1.45 -0.383 0 C-N-CA 120.662 -0.78 . . . . 0.0 112.466 179.816 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 100' ' ' ILE . . . . . 0.472 HD12 ' HA ' ' A' ' 97' ' ' GLU . 66.6 mt -73.81 -48.32 39.99 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.229 0 N-CA-C 112.02 0.378 . . . . 0.0 112.02 -179.735 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 101' ' ' VAL . . . . . 0.431 HG12 ' H ' ' A' ' 101' ' ' VAL . 1.4 p -68.84 -41.76 82.34 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.246 0 N-CA-C 112.044 0.387 . . . . 0.0 112.044 -179.404 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 102' ' ' ILE . . . . . 0.491 HG12 ' O ' ' A' ' 98' ' ' PHE . 42.6 mm -64.58 -48.24 85.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.774 -0.194 . . . . 0.0 111.368 -179.358 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 14.7 t -60.95 -34.24 74.42 Favored 'General case' 0 C--N 1.332 -0.166 0 CA-C-O 120.83 0.347 . . . . 0.0 110.385 179.784 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 104' ' ' LEU . . . . . 0.454 HD22 ' HE2' ' A' ' 140' ' ' TYR . 38.0 tp -62.02 -52.92 62.02 Favored 'General case' 0 C--N 1.332 -0.174 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.251 179.296 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 105' ' ' ASN . . . . . 0.736 HD22 HG11 ' A' ' 84' ' ' VAL . 4.3 m-20 -56.95 -27.4 61.13 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.765 179.524 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 30.9 m -64.9 -56.97 10.12 Favored 'General case' 0 C--N 1.332 -0.183 0 CA-C-N 116.313 -0.403 . . . . 0.0 111.481 -179.863 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 107' ' ' VAL . . . . . 0.451 HG12 ' O ' ' A' ' 104' ' ' LEU . 7.4 p -58.93 -36.19 60.39 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.144 0 CA-C-O 120.852 0.358 . . . . 0.0 111.087 -179.892 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 108' ' ' VAL . . . . . 0.452 HG23 ' O ' ' A' ' 104' ' ' LEU . 91.4 t -61.84 -49.47 84.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.099 -0.5 . . . . 0.0 111.133 179.816 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 109' ' ' MET . . . . . 0.471 ' HG2' ' O ' ' A' ' 105' ' ' ASN . 17.7 mmt -64.52 -31.51 72.75 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.244 -0.434 . . . . 0.0 111.104 179.974 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 27.7 tp -68.05 -36.18 79.45 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.247 179.675 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -62.66 -53.67 51.02 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.067 -0.515 . . . . 0.0 110.539 179.48 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 112' ' ' GLY . . . . . 0.673 ' HA3' ' H21' ' A' ' 301' ' ' RET . . . -62.23 -40.97 99.68 Favored Glycine 0 C--N 1.332 0.327 0 C-N-CA 120.638 -0.791 . . . . 0.0 111.868 179.362 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 113' ' ' PHE . . . . . . . . . . . . . 1.4 t80 -48.88 -68.58 0.17 Allowed 'General case' 0 CA--C 1.52 -0.18 0 N-CA-C 109.858 -0.423 . . . . 0.0 109.858 179.33 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 114' ' ' ALA . . . . . 0.52 ' HA ' ' HB2' ' A' ' 117' ' ' MET . . . -67.49 -15.48 63.69 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-N 115.924 -0.58 . . . . 0.0 110.213 179.365 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 115' ' ' GLY . . . . . 0.666 ' O ' HG22 ' A' ' 118' ' ' VAL . . . -53.65 -49.81 56.25 Favored Glycine 0 C--N 1.336 0.557 0 C-N-CA 120.978 -0.629 . . . . 0.0 111.561 179.299 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 116' ' ' ALA . . . . . 0.4 ' HB1' HG12 ' A' ' 68' ' ' VAL . . . -79.36 -22.11 44.86 Favored 'General case' 0 C--N 1.321 -0.638 0 N-CA-C 111.878 0.325 . . . . 0.0 111.878 179.902 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 117' ' ' MET . . . . . 0.52 ' HB2' ' HA ' ' A' ' 114' ' ' ALA . 0.2 OUTLIER -76.67 19.45 0.27 Allowed 'General case' 0 C--N 1.328 -0.33 0 N-CA-C 112.363 0.505 . . . . 0.0 112.363 -178.84 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 118' ' ' VAL . . . . . 0.666 HG22 ' O ' ' A' ' 115' ' ' GLY . 23.3 m -123.67 138.71 30.78 Favored Pre-proline 0 C--N 1.33 -0.278 0 C-N-CA 121.131 -0.227 . . . . 0.0 111.369 179.823 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 119' ' ' PRO . . . . . . . . . . . . . 77.4 Cg_endo -96.63 23.47 0.33 Allowed 'Trans proline' 0 N--CA 1.455 -0.787 0 C-N-CA 123.19 2.593 . . . . 0.0 112.769 179.892 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -139.73 -159.16 7.87 Favored Glycine 0 C--N 1.332 0.308 0 C-N-CA 120.493 -0.86 . . . . 0.0 113.215 -179.578 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 121' ' ' ILE . . . . . 0.427 HG22 ' O ' ' A' ' 121' ' ' ILE . 14.3 mm -80.33 1.89 2.7 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.205 0 CA-C-O 121.136 0.493 . . . . 0.0 110.938 -179.77 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 33.6 mt-10 -59.34 -37.39 77.71 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 115.799 -0.637 . . . . 0.0 110.89 -179.991 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 123' ' ' ARG . . . . . 0.538 ' HB2' ' HH2' ' A' ' 178' ' ' TRP . 3.7 ptp180 -50.6 -32.99 20.41 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.018 -0.537 . . . . 0.0 111.654 -179.659 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 124' ' ' TYR . . . . . . . . . . . . . 91.3 m-85 -71.57 -33.2 68.88 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.385 -0.371 . . . . 0.0 111.236 -179.645 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 125' ' ' ALA . . . . . . . . . . . . . . . -70.07 -50.86 36.8 Favored 'General case' 0 C--O 1.237 0.405 0 CA-C-O 120.995 0.426 . . . . 0.0 110.047 179.194 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 126' ' ' LEU . . . . . 0.439 HD22 ' HA2' ' A' ' 115' ' ' GLY . 8.2 mp -55.55 -54.04 48.94 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 115.695 -0.684 . . . . 0.0 110.074 179.345 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 127' ' ' PHE . . . . . 0.407 ' CE1' ' H42' ' A' ' 301' ' ' RET . 11.0 t80 -63.53 -35.73 81.44 Favored 'General case' 0 N--CA 1.452 -0.374 0 CA-C-N 115.782 -0.645 . . . . 0.0 110.611 179.958 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 128' ' ' GLY . . . . . . . . . . . . . . . -47.46 -44.48 21.87 Favored Glycine 0 C--N 1.332 0.313 0 C-N-CA 120.228 -0.987 . . . . 0.0 110.805 179.138 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 129' ' ' MET . . . . . . . . . . . . . 0.3 OUTLIER -70.51 -36.56 73.83 Favored 'General case' 0 N--CA 1.453 -0.318 0 N-CA-C 109.828 -0.434 . . . . 0.0 109.828 178.688 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -66.52 -28.56 73.81 Favored Glycine 0 C--N 1.332 0.342 0 CA-C-N 115.702 -0.681 . . . . 0.0 112.839 -179.993 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -74.67 -53.7 8.81 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-O 120.699 0.285 . . . . 0.0 110.358 179.83 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 98.4 t -57.84 -39.91 73.49 Favored 'Isoleucine or valine' 0 C--O 1.234 0.276 0 N-CA-C 109.024 -0.732 . . . . 0.0 109.024 178.433 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -67.23 -33.92 76.37 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 115.123 -0.944 . . . . 0.0 110.642 179.269 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 134' ' ' PHE . . . . . 0.425 ' CZ ' ' HA ' ' A' ' 172' ' ' ALA . 74.6 t80 -56.43 -55.81 28.92 Favored 'General case' 0 N--CA 1.449 -0.484 0 CA-C-O 120.926 0.393 . . . . 0.0 109.951 179.388 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 135' ' ' ILE . . . . . 0.421 ' O ' HG22 ' A' ' 138' ' ' VAL . 40.1 mt -56.58 -33.23 39.14 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.298 0 CA-C-N 115.761 -0.654 . . . . 0.0 109.876 178.942 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . -61.44 -36.9 93.24 Favored Glycine 0 N--CA 1.447 -0.574 0 C-N-CA 120.424 -0.893 . . . . 0.0 111.456 179.067 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 137' ' ' LEU . . . . . . . . . . . . . 47.9 tp -72.22 -54.02 10.85 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-O 120.527 0.203 . . . . 0.0 110.633 179.657 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 138' ' ' VAL . . . . . 0.421 HG22 ' O ' ' A' ' 135' ' ' ILE . 3.4 m -56.17 -31.51 32.08 Favored 'Isoleucine or valine' 0 C--O 1.233 0.192 0 CA-C-O 121.242 0.544 . . . . 0.0 109.676 179.462 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 139' ' ' TYR . . . . . . . . . . . . . 24.9 t80 -63.41 -46.96 83.98 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 115.432 -0.804 . . . . 0.0 110.311 178.819 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 140' ' ' TYR . . . . . 0.454 ' HE2' HD22 ' A' ' 104' ' ' LEU . 17.2 m-85 -58.89 -37.98 77.84 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.626 179.638 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 141' ' ' LEU . . . . . . . . . . . . . 62.6 mt -57.61 -48.2 80.07 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.189 179.542 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 17.1 t -78.31 -12.58 13.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 115.943 -0.571 . . . . 0.0 110.658 179.654 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 143' ' ' GLY . . . . . 0.43 ' HA3' ' HD2' ' A' ' 144' ' ' PRO . . . -72.44 -134.62 0.18 Allowed Glycine 0 CA--C 1.521 0.425 0 C-N-CA 120.982 -0.627 . . . . 0.0 112.906 -179.845 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 144' ' ' PRO . . . . . 0.43 ' HD2' ' HA3' ' A' ' 143' ' ' GLY . 20.7 Cg_endo -60.43 -23.72 75.76 Favored 'Trans proline' 0 C--N 1.349 0.586 0 C-N-CA 122.647 2.231 . . . . 0.0 112.593 -179.658 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 145' ' ' MET . . . . . . . . . . . . . 55.1 mtt -59.33 -36.73 76.2 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.507 -0.315 . . . . 0.0 111.303 -179.865 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 146' ' ' THR . . . . . . . . . . . . . 86.2 m -79.63 -42.33 25.09 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.508 -0.314 . . . . 0.0 111.431 -179.154 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 8.8 tp10 -61.84 -41.46 97.83 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.243 -179.784 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 148' ' ' SER . . . . . . . . . . . . . 48.7 m -70.61 -46.32 63.59 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.263 -0.426 . . . . 0.0 111.614 -179.325 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 149' ' ' ALA . . . . . 0.49 ' HB2' ' HB2' ' A' ' 91' ' ' ALA . . . -68.33 -30.71 69.75 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.3 -0.409 . . . . 0.0 111.892 -179.206 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 150' ' ' SER . . . . . . . . . . . . . 43.3 t -72.36 -5.9 39.62 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.439 -0.346 . . . . 0.0 111.656 -179.275 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 151' ' ' GLN . . . . . . . . . . . . . 10.3 pt20 -133.55 5.79 3.74 Favored 'General case' 0 C--N 1.33 -0.251 0 N-CA-C 111.649 0.24 . . . . 0.0 111.649 -179.835 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 1.6 tmt_? -73.69 -51.88 15.15 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-O 120.994 0.426 . . . . 0.0 110.251 179.946 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 153' ' ' SER . . . . . 0.637 ' HB2' HG12 ' A' ' 156' ' ' ILE . 49.1 m -158.1 172.08 19.06 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-N 115.759 -0.655 . . . . 0.0 110.256 179.227 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 154' ' ' SER . . . . . . . . . . . . . 88.6 p -70.65 -37.67 73.76 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-O 120.883 0.373 . . . . 0.0 110.474 179.542 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -76.98 -30.26 55.95 Favored Glycine 0 N--CA 1.452 -0.276 0 C-N-CA 120.935 -0.65 . . . . 0.0 112.751 -179.914 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 156' ' ' ILE . . . . . 0.637 HG12 ' HB2' ' A' ' 153' ' ' SER . 39.1 mm -64.48 -39.21 84.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-O 120.765 0.317 . . . . 0.0 111.243 -179.988 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 157' ' ' LYS . . . . . . . . . . . . . 87.1 tttt -63.55 -41.28 98.44 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 116.306 -0.406 . . . . 0.0 111.624 -179.37 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 87.9 p -71.34 -48.33 51.02 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-O 120.956 0.408 . . . . 0.0 111.493 -179.338 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 159' ' ' LEU . . . . . 0.554 HD21 ' HB3' ' A' ' 215' ' ' ALA . 17.4 mt -66.77 -31.85 72.75 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 116.084 -0.507 . . . . 0.0 111.726 -179.269 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 160' ' ' TYR . . . . . . . . . . . . . 50.9 t80 -74.25 -46.79 39.3 Favored 'General case' 0 C--N 1.327 -0.372 0 N-CA-C 112.051 0.389 . . . . 0.0 112.051 -178.841 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 24.4 m -60.12 -44.74 95.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 N-CA-C 111.848 0.314 . . . . 0.0 111.848 -179.154 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 162' ' ' ARG . . . . . 0.487 ' HG2' HG21 ' A' ' 211' ' ' ILE . 22.3 tpp180 -68.88 -40.88 79.01 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.755 0.312 . . . . 0.0 111.638 -179.598 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 163' ' ' LEU . . . . . 0.631 ' HG ' ' HB2' ' A' ' 208' ' ' PHE . 6.3 mp -69.23 -55.14 11.45 Favored 'General case' 0 C--N 1.329 -0.323 0 N-CA-C 112.77 0.656 . . . . 0.0 112.77 -178.724 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 164' ' ' ARG . . . . . 0.493 ' O ' HG23 ' A' ' 168' ' ' VAL . 5.0 ppt_? -61.04 -45.5 94.5 Favored 'General case' 0 C--N 1.328 -0.339 0 N-CA-C 112.28 0.474 . . . . 0.0 112.28 -178.316 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 165' ' ' ASN . . . . . 0.499 ' O ' HG23 ' A' ' 169' ' ' VAL . 9.5 m-80 -59.88 -51.48 69.5 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.763 0.316 . . . . 0.0 111.28 -179.736 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 166' ' ' LEU . . . . . 0.473 ' O ' ' HG ' ' A' ' 170' ' ' LEU . 3.2 tt -61.21 -50.84 71.49 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.461 -179.511 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 167' ' ' THR . . . . . 0.439 ' O ' ' HB2' ' A' ' 171' ' ' TRP . 92.1 m -55.01 -53.32 57.31 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 115.911 -0.586 . . . . 0.0 112.514 -178.999 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 168' ' ' VAL . . . . . 0.493 HG23 ' O ' ' A' ' 164' ' ' ARG . 85.3 t -55.16 -43.97 72.67 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.236 0 N-CA-C 112.044 0.387 . . . . 0.0 112.044 -178.803 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 169' ' ' VAL . . . . . 0.499 HG23 ' O ' ' A' ' 165' ' ' ASN . 72.3 t -56.41 -65.05 0.42 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 N-CA-C 111.969 0.359 . . . . 0.0 111.969 -179.288 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 170' ' ' LEU . . . . . 0.473 ' HG ' ' O ' ' A' ' 166' ' ' LEU . 0.7 OUTLIER -64.76 -28.08 69.33 Favored 'General case' 0 C--N 1.331 -0.238 0 N-CA-C 112.238 0.458 . . . . 0.0 112.238 -178.852 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 171' ' ' TRP . . . . . 0.645 ' HE1' H203 ' A' ' 301' ' ' RET . 4.0 m0 -71.13 -30.01 65.96 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-O 121.006 0.431 . . . . 0.0 110.495 179.495 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 172' ' ' ALA . . . . . 0.425 ' HA ' ' CZ ' ' A' ' 134' ' ' PHE . . . -72.67 -6.36 43.85 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 115.917 -0.583 . . . . 0.0 111.056 -179.722 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 173' ' ' ILE . . . . . 0.51 HG22 HD11 ' A' ' 177' ' ' ILE . 21.6 mm -87.29 -21.82 7.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 115.93 -0.577 . . . . 0.0 111.288 -179.972 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 174' ' ' TYR . . . . . 0.597 ' N ' ' HD2' ' A' ' 175' ' ' PRO . 37.0 m-85 -54.35 -51.24 79.66 Favored Pre-proline 0 CA--C 1.532 0.267 0 N-CA-C 111.955 0.354 . . . . 0.0 111.955 -179.762 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 175' ' ' PRO . . . . . 0.597 ' HD2' ' N ' ' A' ' 174' ' ' TYR . 5.3 Cg_endo -48.41 -29.57 13.76 Favored 'Trans proline' 0 C--N 1.352 0.717 0 C-N-CA 122.106 1.87 . . . . 0.0 112.299 -179.967 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 176' ' ' PHE . . . . . 0.475 ' HD2' ' HA ' ' A' ' 173' ' ' ILE . 58.9 m-85 -80.84 -49.45 11.05 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.044 -0.525 . . . . 0.0 112.053 -179.885 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 177' ' ' ILE . . . . . 0.51 HD11 HG22 ' A' ' 173' ' ' ILE . 4.4 mm -62.47 -34.79 66.55 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.496 0 N-CA-C 112.389 0.515 . . . . 0.0 112.389 -178.155 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 178' ' ' TRP . . . . . 0.538 ' HH2' ' HB2' ' A' ' 123' ' ' ARG . 70.0 t90 -73.71 -46.7 44.56 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-O 121.03 0.443 . . . . 0.0 110.766 179.551 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 179' ' ' LEU . . . . . 0.428 ' O ' HG22 ' A' ' 185' ' ' VAL . 1.7 tm? -69.5 -48.42 60.64 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 115.856 -0.611 . . . . 0.0 111.396 -179.172 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 180' ' ' LEU . . . . . 0.669 HD22 HD11 ' A' ' 187' ' ' LEU . 42.2 mt -75.15 -46.62 33.13 Favored 'General case' 0 C--N 1.327 -0.395 0 N-CA-C 111.911 0.338 . . . . 0.0 111.911 -179.153 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . -58.35 -179.59 1.06 Allowed Glycine 0 C--N 1.336 0.582 0 C-N-CA 120.256 -0.973 . . . . 0.0 112.383 179.767 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 182' ' ' PRO . . . . . 0.662 ' HA ' ' HB2' ' A' ' 186' ' ' ALA . 84.7 Cg_exo -47.05 -44.05 23.84 Favored 'Trans proline' 0 CA--C 1.535 0.571 0 C-N-CA 122.834 2.356 . . . . 0.0 113.94 -179.97 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 183' ' ' PRO . . . . . 0.407 ' CD ' ' N ' ' A' ' 182' ' ' PRO . 74.7 Cg_exo -51.19 -17.71 4.12 Favored 'Trans proline' 0 C--N 1.355 0.891 0 C-N-CA 122.257 1.971 . . . . 0.0 113.456 -179.707 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 184' ' ' GLY . . . . . . . . . . . . . . . -120.51 -92.02 1.27 Allowed Glycine 0 C--N 1.332 0.343 0 C-N-CA 120.207 -0.997 . . . . 0.0 113.294 -179.743 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 185' ' ' VAL . . . . . 0.428 HG22 ' O ' ' A' ' 179' ' ' LEU . 17.8 m -106.39 -13.0 9.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 N-CA-C 112.152 0.427 . . . . 0.0 112.152 -179.004 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 186' ' ' ALA . . . . . 0.662 ' HB2' ' HA ' ' A' ' 182' ' ' PRO . . . 58.36 86.78 0.08 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.794 0.33 . . . . 0.0 111.469 179.848 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 187' ' ' LEU . . . . . 0.669 HD11 HD22 ' A' ' 180' ' ' LEU . 22.8 mt -91.79 -49.02 6.48 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 120.953 0.406 . . . . 0.0 110.968 179.909 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 188' ' ' LEU . . . . . . . . . . . . . 77.5 mt -95.87 -151.66 0.35 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 115.939 -0.573 . . . . 0.0 111.339 -179.365 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 189' ' ' THR . . . . . 0.447 HG22 ' H ' ' A' ' 191' ' ' THR . 29.0 m -96.96 137.45 21.31 Favored Pre-proline 0 C--N 1.331 -0.221 0 CA-C-N 115.922 -0.581 . . . . 0.0 110.852 -179.483 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 190' ' ' PRO . . . . . . . . . . . . . 82.0 Cg_exo -46.95 -29.86 8.97 Favored 'Trans proline' 0 C--N 1.349 0.577 0 C-N-CA 122.478 2.118 . . . . 0.0 112.692 179.9 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 191' ' ' THR . . . . . 0.447 ' H ' HG22 ' A' ' 189' ' ' THR . 76.7 p -77.4 -40.6 43.08 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.486 -0.324 . . . . 0.0 111.412 -179.948 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 192' ' ' VAL . . . . . . . . . . . . . 61.7 t -72.09 -53.27 20.47 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.289 -0.414 . . . . 0.0 111.564 -179.608 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 193' ' ' ASP . . . . . . . . . . . . . 30.7 m-20 -52.15 -48.79 64.74 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.36 -0.382 . . . . 0.0 111.015 -179.921 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 194' ' ' VAL . . . . . 0.489 ' O ' HG22 ' A' ' 198' ' ' VAL . 55.3 t -62.38 -36.38 74.41 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.645 179.724 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 195' ' ' ALA . . . . . . . . . . . . . . . -56.27 -39.84 73.28 Favored 'General case' 0 C--N 1.332 -0.155 0 CA-C-N 116.348 -0.387 . . . . 0.0 110.571 179.344 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 196' ' ' LEU . . . . . . . . . . . . . 96.4 mt -68.43 -39.62 81.49 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.018 -0.537 . . . . 0.0 110.557 179.251 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 197' ' ' ILE . . . . . 0.407 HD11 ' HB ' ' A' ' 177' ' ' ILE . 18.3 mm -60.43 -60.38 2.67 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.254 0 CA-C-N 115.856 -0.611 . . . . 0.0 111.238 179.957 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 198' ' ' VAL . . . . . 0.489 HG22 ' O ' ' A' ' 194' ' ' VAL . 3.3 m -52.98 -36.05 23.36 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.4 0 CA-C-O 121.596 0.712 . . . . 0.0 109.808 179.003 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 199' ' ' TYR . . . . . . . . . . . . . 37.1 t80 -67.97 -33.04 73.89 Favored 'General case' 0 C--N 1.321 -0.666 0 CA-C-N 114.629 -1.168 . . . . 0.0 110.849 179.858 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 200' ' ' LEU . . . . . 0.569 ' O ' HG12 ' A' ' 203' ' ' VAL . 25.5 mt -68.71 -41.85 78.52 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 121.13 0.49 . . . . 0.0 110.844 179.927 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 201' ' ' ASP . . . . . . . . . . . . . 15.8 m-20 -70.09 -33.18 71.56 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-O 121.321 0.581 . . . . 0.0 109.727 179.109 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 202' ' ' LEU . . . . . 0.438 HD11 ' HA2' ' A' ' 11' ' ' GLY . 3.1 mt -72.33 -31.14 65.41 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 115.213 -0.903 . . . . 0.0 112.014 -179.741 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 203' ' ' VAL . . . . . 0.569 HG12 ' O ' ' A' ' 200' ' ' LEU . 13.0 p -76.44 -35.91 27.64 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 C-N-CA 121.06 -0.256 . . . . 0.0 110.958 -178.621 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 204' ' ' THR . . . . . . . . . . . . . 88.8 m -67.66 -58.24 5.01 Favored 'General case' 0 C--N 1.326 -0.443 0 C-N-CA 120.651 -0.42 . . . . 0.0 111.289 179.498 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 205' ' ' LYS . . . . . 0.684 ' HE2' ' HB2' ' A' ' 47' ' ' ALA . 48.7 mttp -62.15 -58.49 7.59 Favored 'General case' 0 C--N 1.329 -0.303 0 N-CA-C 112.21 0.448 . . . . 0.0 112.21 -178.513 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 44.5 t -70.35 -36.22 65.96 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.48 0 CA-C-N 116.025 -0.534 . . . . 0.0 112.068 -178.836 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 207' ' ' GLY . . . . . 0.548 ' O ' HG13 ' A' ' 211' ' ' ILE . . . -58.33 -61.66 7.15 Favored Glycine 0 N--CA 1.452 -0.271 0 C-N-CA 120.634 -0.793 . . . . 0.0 113.844 -178.128 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 208' ' ' PHE . . . . . 0.631 ' HB2' ' HG ' ' A' ' 163' ' ' LEU . 0.8 OUTLIER -72.69 -27.61 62.19 Favored 'General case' 0 C--O 1.221 -0.436 0 CA-C-N 117.515 0.657 . . . . 0.0 110.854 -179.12 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 209' ' ' GLY . . . . . 0.497 ' O ' ' HB3' ' A' ' 212' ' ' ALA . . . -64.1 -31.87 82.29 Favored Glycine 0 N--CA 1.45 -0.399 0 N-CA-C 111.546 -0.622 . . . . 0.0 111.546 178.697 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 210' ' ' PHE . . . . . . . . . . . . . 0.5 OUTLIER -74.79 -47.9 28.32 Favored 'General case' 0 CA--C 1.514 -0.41 0 N-CA-C 108.425 -0.954 . . . . 0.0 108.425 178.451 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 211' ' ' ILE . . . . . 0.548 HG13 ' O ' ' A' ' 207' ' ' GLY . 4.3 mt -63.69 -27.61 43.27 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.45 0 N-CA-C 107.712 -1.218 . . . . 0.0 107.712 176.787 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 212' ' ' ALA . . . . . 0.497 ' HB3' ' O ' ' A' ' 209' ' ' GLY . . . -62.46 -46.1 90.02 Favored 'General case' 0 N--CA 1.449 -0.524 0 CA-C-N 114.469 -1.242 . . . . 0.0 110.549 -179.888 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 213' ' ' LEU . . . . . . . . . . . . . 95.8 mt -70.33 -46.03 65.01 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 115.182 -0.917 . . . . 0.0 111.864 -179.437 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 214' ' ' ASP . . . . . . . . . . . . . 19.9 t70 -56.06 -55.19 35.89 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.466 -0.334 . . . . 0.0 111.604 -179.299 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 215' ' ' ALA . . . . . 0.554 ' HB3' HD21 ' A' ' 159' ' ' LEU . . . -58.95 -53.14 61.77 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.327 -0.397 . . . . 0.0 111.406 -179.559 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 216' ' ' ALA . . . . . . . . . . . . . . . -53.14 -45.08 68.24 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.506 -179.666 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 217' ' ' ALA . . . . . . . . . . . . . . . -55.85 -39.86 72.06 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-O 121.062 0.458 . . . . 0.0 110.301 179.738 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 218' ' ' THR . . . . . . . . . . . . . 92.1 m -69.3 -34.0 74.03 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.634 -0.712 . . . . 0.0 110.861 179.48 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 219' ' ' LEU . . . . . 0.438 ' HG ' ' O ' ' A' ' 215' ' ' ALA . 75.5 mt -64.31 -39.82 94.67 Favored 'General case' 0 C--N 1.331 -0.2 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.698 179.755 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 220' ' ' ARG . . . . . . . . . . . . . 15.2 mmm180 -80.21 -27.01 38.89 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.387 179.756 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 221' ' ' ALA . . . . . . . . . . . . . . . -71.17 -26.11 62.83 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 115.986 -0.552 . . . . 0.0 111.5 -179.981 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 222' ' ' GLU . . . . . . . . . . . . . 12.7 pt-20 -92.44 -22.18 19.76 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-O 120.934 0.397 . . . . 0.0 110.385 -179.869 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 223' ' ' HIS . . . . . . . . . . . . . 46.8 m-70 61.88 -176.09 0.13 Allowed 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 115.672 -0.695 . . . . 0.0 111.235 179.871 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 224' ' ' GLY . . . . . . . . . . . . . . . 178.35 43.45 0.07 OUTLIER Glycine 0 N--CA 1.452 -0.269 0 C-N-CA 120.821 -0.704 . . . . 0.0 112.398 -179.93 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 225' ' ' GLU . . . . . . . . . . . . . 10.0 mm-40 -118.22 120.33 37.37 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 120.841 0.353 . . . . 0.0 110.833 -179.998 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 226' ' ' SER . . . . . . . . . . . . . 50.6 m -86.81 151.83 23.02 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.958 -179.929 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 227' ' ' LEU . . . . . . . . . . . . . 60.9 tp -91.22 -60.27 1.94 Allowed 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.84 -179.954 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 228' ' ' ALA . . . . . . . . . . . . . . . 56.19 178.45 0.04 OUTLIER 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 116.082 -0.508 . . . . 0.0 111.624 -179.897 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 229' ' ' GLY . . . . . . . . . . . . . . . 74.02 77.72 0.62 Allowed Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.658 -0.782 . . . . 0.0 112.621 179.901 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 230' ' ' VAL . . . . . . . . . . . . . 21.3 t -81.66 123.87 38.39 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-O 120.801 0.334 . . . . 0.0 110.861 179.768 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 231' ' ' ASP . . . . . . . . . . . . . 19.3 t70 -74.98 125.61 29.25 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.134 -179.664 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 232' ' ' THR . . . . . . . . . . . . . 9.1 t -124.45 -26.59 3.87 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.007 -0.542 . . . . 0.0 110.837 179.688 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 233' ' ' ASP . . . . . . . . . . . . . 27.1 t70 62.51 107.84 0.03 OUTLIER 'General case' 0 C--N 1.333 -0.151 0 CA-C-N 115.832 -0.622 . . . . 0.0 111.336 179.801 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 234' ' ' THR . . . . . . . . . . . . . 1.4 t -108.15 96.92 19.56 Favored Pre-proline 0 C--N 1.33 -0.282 0 CA-C-N 115.951 -0.568 . . . . 0.0 110.837 179.744 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 235' ' ' PRO . . . . . . . . . . . . . 85.9 Cg_endo -78.34 4.18 6.5 Favored 'Trans proline' 0 C--N 1.349 0.564 0 C-N-CA 122.462 2.108 . . . . 0.0 112.801 -179.696 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 236' ' ' ALA . . . . . . . . . . . . . . . -63.82 153.49 36.5 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.374 -0.375 . . . . 0.0 111.026 179.962 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 237' ' ' VAL . . . . . . . . . . . . . 13.5 p -164.3 147.57 2.61 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.249 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.914 -179.938 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 238' ' ' ALA . . . . . . . . . . . . . . . -149.1 -27.1 0.29 Allowed 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.3 -0.409 . . . . 0.0 111.294 -179.931 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 239' ' ' ASP . . . . . . . . . . . . . 15.1 m-20 -113.0 123.7 50.93 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.268 -0.424 . . . . 0.0 111.108 -179.959 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 240' ' ' LEU . . . . . . . . . . . . . 3.3 pp -125.99 -12.3 6.44 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.895 179.787 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 241' ' ' GLU . . . . . . . . . . . . . 44.6 mt-10 -73.17 134.41 44.39 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.756 179.837 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 242' ' ' HIS . . . . . . . . . . . . . 40.9 m80 -92.51 173.74 7.64 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.326 -0.397 . . . . 0.0 111.12 -179.832 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 243' ' ' HIS . . . . . . . . . . . . . 60.9 t60 -160.9 -45.85 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 115.845 -0.616 . . . . 0.0 110.568 179.821 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 244' ' ' HIS . . . . . . . . . . . . . 34.0 t-80 -107.24 -17.17 14.22 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 115.895 -0.593 . . . . 0.0 110.802 -179.989 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 245' ' ' HIS . . . . . . . . . . . . . 52.5 m-70 57.79 84.85 0.09 Allowed 'General case' 0 C--O 1.232 0.139 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.889 -179.666 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 246' ' ' HIS . . . . . . . . . . . . . 29.5 p-80 -103.55 159.49 15.55 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.018 -0.537 . . . . 0.0 110.673 -179.93 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 247' ' ' HIS . . . . . . . . . . . . . 53.3 t-80 . . . . . 0 C--O 1.249 1.059 0 CA-C-O 118.324 -0.846 . . . . 0.0 111.027 179.939 . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 301' ' ' RET . . . . . 0.673 ' H21' ' HA3' ' A' ' 112' ' ' GLY . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 51.5 mtm . . . . . 0 N--CA 1.487 1.377 0 CA-C-O 120.709 0.29 . . . . 0.0 110.942 . . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 9.4 p -175.1 -34.78 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-N 116.141 -0.481 . . . . 0.0 111.224 -179.926 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -97.29 -28.98 8.18 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.768 -0.729 . . . . 0.0 112.768 -179.866 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 32.5 tp -74.16 -35.35 64.04 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.808 0.337 . . . . 0.0 110.884 179.967 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 74.7 p -61.67 -30.56 70.81 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.132 -0.486 . . . . 0.0 111.411 -179.985 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 29.0 p -58.98 -36.12 74.36 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-O 120.783 0.325 . . . . 0.0 111.07 -179.852 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 7' ' ' LEU . . . . . . . . . . . . . 4.5 mm? -56.61 -52.06 66.28 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.861 179.862 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 8' ' ' PHE . . . . . 0.667 ' HB2' ' HB2' ' A' ' 55' ' ' ALA . 83.5 m-85 -58.1 -37.84 75.29 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.223 179.477 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 9' ' ' TRP . . . . . . . . . . . . . 15.8 m95 -63.0 -41.81 99.68 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 115.987 -0.551 . . . . 0.0 110.102 -179.987 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 84.9 mt -59.74 -43.87 94.06 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 115.617 -0.719 . . . . 0.0 110.09 179.299 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -61.36 -33.97 86.54 Favored Glycine 0 N--CA 1.448 -0.516 0 C-N-CA 120.656 -0.783 . . . . 0.0 111.554 179.168 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -66.96 -31.23 71.66 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-O 120.912 0.387 . . . . 0.0 110.376 179.447 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 75.5 mt -66.06 -47.52 84.7 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.245 0 CA-C-N 115.985 -0.552 . . . . 0.0 110.097 179.343 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -60.63 -39.43 96.54 Favored Glycine 0 N--CA 1.45 -0.409 0 C-N-CA 120.758 -0.734 . . . . 0.0 111.7 179.315 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 15' ' ' MET . . . . . 0.592 ' HE2' ' HE2' ' A' ' 51' ' ' TYR . 0.1 OUTLIER -63.54 -41.06 98.46 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 120.665 0.269 . . . . 0.0 110.575 179.422 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -55.98 -50.66 70.21 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.758 179.841 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 35.6 t -59.6 -46.4 93.19 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.389 -179.792 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -63.96 -48.5 75.32 Favored Glycine 0 C--N 1.331 0.262 0 C-N-CA 120.718 -0.753 . . . . 0.0 112.437 179.919 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 31.9 m -50.6 -44.24 56.97 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-O 120.723 0.297 . . . . 0.0 111.131 -179.774 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 95.2 mt -72.35 -40.28 67.48 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.622 179.907 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -63.19 -33.78 76.21 Favored 'General case' 0 C--N 1.331 -0.196 0 N-CA-C 112.065 0.395 . . . . 0.0 112.065 -179.294 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 22' ' ' PHE . . . . . 0.66 ' HB2' HG22 ' A' ' 41' ' ' VAL . 7.6 m-85 -86.2 -33.7 20.7 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.657 0.265 . . . . 0.0 111.658 -179.131 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -73.6 -50.7 19.85 Favored 'General case' 0 C--N 1.329 -0.297 0 N-CA-C 111.991 0.367 . . . . 0.0 111.991 -179.206 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 24' ' ' TRP . . . . . . . . . . . . . 2.7 t-105 -58.99 -46.62 87.7 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 116.029 -0.532 . . . . 0.0 111.239 -179.503 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -71.55 -21.1 61.94 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-O 120.828 0.347 . . . . 0.0 110.925 179.796 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -73.6 -37.73 52.14 Favored Glycine 0 N--CA 1.452 -0.269 0 C-N-CA 120.913 -0.66 . . . . 0.0 112.833 179.997 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 28.1 mmm180 -71.07 -39.04 72.44 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-O 120.688 0.28 . . . . 0.0 111.064 -179.761 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 30.5 t70 -78.51 -4.1 46.89 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.317 -0.402 . . . . 0.0 110.772 179.853 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -73.73 -171.93 1.16 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.177 -179.928 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -100.27 -174.44 30.07 Favored Glycine 0 N--CA 1.45 -0.386 0 C-N-CA 120.806 -0.712 . . . . 0.0 112.634 -179.856 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 75.4 p -81.37 126.7 31.93 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.827 0.346 . . . . 0.0 110.981 179.971 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 115.42 -61.94 0.37 Allowed Glycine 0 N--CA 1.451 -0.3 0 C-N-CA 120.88 -0.676 . . . . 0.0 112.562 -179.999 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 9.1 mm-40 -60.63 -21.07 62.32 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 120.698 0.285 . . . . 0.0 110.989 179.868 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 34' ' ' ARG . . . . . . . . . . . . . 38.6 ttm180 -48.44 -34.99 11.96 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-N 115.969 -0.559 . . . . 0.0 111.525 -179.758 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 70.3 mtm180 -55.1 -54.84 38.08 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.314 -0.403 . . . . 0.0 111.303 -179.986 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 82.0 m-85 -59.7 -28.7 67.53 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.097 -179.946 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 37' ' ' TYR . . . . . 0.428 ' O ' HG23 ' A' ' 41' ' ' VAL . 52.5 m-85 -71.97 -52.42 17.18 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.3 -0.409 . . . . 0.0 111.314 -179.893 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 59.8 t -57.69 -39.26 69.3 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.219 0 CA-C-O 121.116 0.484 . . . . 0.0 110.528 179.658 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 19.6 m -62.81 -50.93 69.05 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 115.576 -0.738 . . . . 0.0 110.715 179.403 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 40' ' ' LEU . . . . . 0.48 HD21 ' CA ' ' A' ' 209' ' ' GLY . 19.6 tp -57.57 -50.21 73.86 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 115.652 -0.704 . . . . 0.0 110.578 -179.997 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 41' ' ' VAL . . . . . 0.66 HG22 ' HB2' ' A' ' 22' ' ' PHE . 85.5 t -59.02 -34.9 54.39 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.235 0 CA-C-N 115.856 -0.611 . . . . 0.0 110.236 179.142 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -59.19 -39.56 94.66 Favored Glycine 0 N--CA 1.448 -0.505 0 C-N-CA 120.834 -0.698 . . . . 0.0 112.06 179.652 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 43' ' ' ILE . . . . . 0.535 HG12 HD12 ' A' ' 82' ' ' LEU . 1.2 mt -64.84 -55.59 20.15 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.193 0 CA-C-O 120.683 0.278 . . . . 0.0 110.728 179.567 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 51.3 m -57.72 -23.81 53.7 Favored 'General case' 0 C--O 1.232 0.178 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.181 -179.963 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -78.18 -56.23 3.79 Favored Glycine 0 CA--C 1.518 0.251 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.668 -179.772 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 26.6 pt -58.31 -35.4 53.49 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.215 0 CA-C-O 121.08 0.467 . . . . 0.0 110.912 179.944 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 47' ' ' ALA . . . . . 0.745 ' HB2' ' HE2' ' A' ' 205' ' ' LYS . . . -67.51 -46.74 71.99 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-N 116.031 -0.531 . . . . 0.0 111.307 179.346 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 48' ' ' ALA . . . . . 0.561 ' HB2' ' HB3' ' A' ' 15' ' ' MET . . . -54.87 -40.6 69.87 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 116.04 -0.527 . . . . 0.0 111.951 -179.485 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 25.1 m -73.08 -34.69 46.04 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 CA-C-N 116.63 -0.259 . . . . 0.0 111.516 -179.207 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 50' ' ' ALA . . . . . 0.403 ' O ' HG22 ' A' ' 53' ' ' VAL . . . -65.96 -38.18 87.93 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-O 121.145 0.498 . . . . 0.0 110.749 179.346 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 51' ' ' TYR . . . . . 0.592 ' HE2' ' HE2' ' A' ' 15' ' ' MET . 42.9 m-85 -73.09 -28.31 62.21 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-N 115.813 -0.631 . . . . 0.0 109.734 179.466 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -72.35 -38.88 68.48 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 115.419 -0.809 . . . . 0.0 110.97 179.517 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 53' ' ' VAL . . . . . 0.575 ' O ' HG22 ' A' ' 58' ' ' VAL . 33.8 m -73.95 -47.49 42.53 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.159 0 CA-C-N 116.402 -0.363 . . . . 0.0 110.78 -179.941 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 54' ' ' MET . . . . . 0.458 ' N ' HG23 ' A' ' 53' ' ' VAL . 75.0 mtm -57.75 -36.44 72.1 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-O 121.241 0.543 . . . . 0.0 109.949 179.094 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 55' ' ' ALA . . . . . 0.667 ' HB2' ' HB2' ' A' ' 8' ' ' PHE . . . -68.91 -11.69 60.86 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 115.317 -0.856 . . . . 0.0 111.705 179.876 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 47.4 mt -97.57 -4.21 38.15 Favored 'General case' 0 C--N 1.33 -0.259 0 N-CA-C 111.944 0.35 . . . . 0.0 111.944 -179.475 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 105.13 -23.0 31.77 Favored Glycine 0 CA--C 1.52 0.352 0 C-N-CA 120.373 -0.917 . . . . 0.0 114.004 179.23 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 58' ' ' VAL . . . . . 0.575 HG22 ' O ' ' A' ' 53' ' ' VAL . 16.3 m -62.05 160.41 2.21 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.128 0 CA-C-N 117.722 0.761 . . . . 0.0 109.768 179.343 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 59' ' ' GLY . . . . . 0.683 ' HA3' ' HD3' ' A' ' 71' ' ' PRO . . . 79.58 -25.56 2.86 Favored Glycine 0 N--CA 1.441 -1.033 0 C-N-CA 119.999 -1.096 . . . . 0.0 112.71 -178.844 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 60' ' ' TRP . . . . . . . . . . . . . 11.6 m0 -67.77 80.13 0.19 Allowed 'General case' 0 C--N 1.327 -0.388 0 N-CA-C 110.176 -0.305 . . . . 0.0 110.176 179.561 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 4.7 p -90.83 119.35 68.96 Favored Pre-proline 0 C--N 1.33 -0.266 0 CA-C-N 116.461 -0.336 . . . . 0.0 111.202 -179.747 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 35.8 Cg_exo -60.49 119.44 6.63 Favored 'Trans proline' 0 C--N 1.35 0.615 0 C-N-CA 122.451 2.101 . . . . 0.0 112.176 179.841 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 78.4 t -117.21 99.59 8.54 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.364 0 CA-C-N 115.931 -0.577 . . . . 0.0 110.918 179.914 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . 59.9 -85.65 0.02 OUTLIER 'General case' 0 C--N 1.332 -0.174 0 CA-C-N 116.095 -0.502 . . . . 0.0 111.254 -179.926 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 53.8 mm-40 -126.74 -26.69 3.18 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.335 179.521 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 66' ' ' ARG . . . . . . . . . . . . . 34.5 ptt180 -95.41 164.23 12.9 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 115.823 -0.626 . . . . 0.0 110.306 179.474 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 13.8 m -114.94 132.02 56.7 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.848 0.356 . . . . 0.0 111.265 -179.999 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 29.4 t -116.78 145.77 22.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.023 -0.535 . . . . 0.0 110.634 179.728 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 69' ' ' PHE . . . . . . . . . . . . . 10.8 m-85 -102.09 119.8 39.39 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-O 120.917 0.389 . . . . 0.0 110.659 -179.357 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 70' ' ' VAL . . . . . 0.632 HG13 ' O ' ' A' ' 59' ' ' GLY . 1.2 m -69.67 -35.57 5.7 Favored Pre-proline 0 CA--C 1.544 0.727 0 N-CA-C 113.05 0.759 . . . . 0.0 113.05 -179.344 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 71' ' ' PRO . . . . . 0.683 ' HD3' ' HA3' ' A' ' 59' ' ' GLY . 8.4 Cg_exo -70.56 -19.87 31.78 Favored 'Trans proline' 0 C--N 1.358 1.055 0 C-N-CA 122.579 2.186 . . . . 0.0 112.88 -178.146 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 72' ' ' ARG . . . . . 0.449 ' NH2' ' HG3' ' A' ' 183' ' ' PRO . 38.5 ttp180 -64.72 -53.46 46.84 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-O 120.949 0.404 . . . . 0.0 110.66 -179.916 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 73' ' ' TYR . . . . . . . . . . . . . 19.6 m-85 -73.19 -37.36 66.51 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.572 -179.97 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 74' ' ' ILE . . . . . 0.605 HG22 ' HA ' ' A' ' 71' ' ' PRO . 0.4 OUTLIER -64.08 -39.86 87.0 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 N-CA-C 109.877 -0.416 . . . . 0.0 109.877 179.439 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 75' ' ' ASP . . . . . 0.409 ' O ' HG23 ' A' ' 79' ' ' THR . 33.9 t70 -64.06 -34.8 78.84 Favored 'General case' 0 CA--C 1.516 -0.362 0 N-CA-C 108.882 -0.785 . . . . 0.0 108.882 178.868 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 76' ' ' TRP . . . . . 0.444 ' HB3' ' SD ' ' A' ' 109' ' ' MET . 44.5 m0 -66.42 -28.1 68.35 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 115.531 -0.759 . . . . 0.0 110.251 179.064 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 77' ' ' ILE . . . . . 0.497 ' O ' ' HG2' ' A' ' 81' ' ' PRO . 85.0 mt -75.89 -28.75 19.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-O 121.184 0.516 . . . . 0.0 109.69 178.827 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 52.0 mt -91.55 -18.32 24.27 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 115.758 -0.655 . . . . 0.0 111.446 179.183 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 79' ' ' THR . . . . . 0.409 HG23 ' O ' ' A' ' 75' ' ' ASP . 76.1 p -104.22 -50.98 3.22 Favored 'General case' 0 N--CA 1.464 0.225 0 N-CA-C 113.278 0.844 . . . . 0.0 113.278 -178.084 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 80' ' ' THR . . . . . 0.68 ' HB ' ' HD3' ' A' ' 81' ' ' PRO . 40.2 m -51.98 -55.19 32.89 Favored Pre-proline 0 CA--C 1.53 0.19 0 N-CA-C 111.947 0.351 . . . . 0.0 111.947 -178.642 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 81' ' ' PRO . . . . . 0.68 ' HD3' ' HB ' ' A' ' 80' ' ' THR . 40.6 Cg_exo -58.72 -21.8 57.97 Favored 'Trans proline' 0 C--N 1.352 0.748 0 C-N-CA 121.426 1.417 . . . . 0.0 111.133 179.406 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 82' ' ' LEU . . . . . 0.535 HD12 HG12 ' A' ' 43' ' ' ILE . 0.2 OUTLIER -76.36 -43.42 40.99 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 115.555 -0.748 . . . . 0.0 109.999 179.638 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 50.4 mm -63.76 -52.38 57.9 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.192 0 CA-C-N 116.074 -0.512 . . . . 0.0 110.424 179.512 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 29.3 m -57.98 -33.79 47.11 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.202 0 N-CA-C 109.738 -0.467 . . . . 0.0 109.738 179.104 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 85' ' ' TYR . . . . . 0.409 ' O ' ' HG ' ' A' ' 89' ' ' LEU . 61.6 t80 -62.1 -36.13 80.79 Favored 'General case' 0 N--CA 1.454 -0.27 0 CA-C-N 115.796 -0.638 . . . . 0.0 109.463 178.601 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 86' ' ' PHE . . . . . . . . . . . . . 13.0 t80 -59.7 -49.12 78.98 Favored 'General case' 0 C--O 1.232 0.183 0 CA-C-N 115.641 -0.709 . . . . 0.0 109.726 179.0 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 3.9 mm? -56.42 -41.8 76.96 Favored 'General case' 0 C--N 1.332 -0.176 0 CA-C-N 115.696 -0.684 . . . . 0.0 110.02 179.334 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -66.51 -27.97 73.46 Favored Glycine 0 N--CA 1.45 -0.397 0 CA-C-N 115.721 -0.672 . . . . 0.0 112.432 179.748 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 89' ' ' LEU . . . . . 0.409 ' HG ' ' O ' ' A' ' 85' ' ' TYR . 87.9 mt -71.0 -33.05 70.02 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.973 0.416 . . . . 0.0 110.516 179.814 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 95.6 mt -73.53 -30.98 63.42 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 115.884 -0.598 . . . . 0.0 111.134 179.824 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -88.47 -28.58 20.75 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.452 -0.34 . . . . 0.0 111.694 -179.603 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 80.62 58.05 2.78 Favored Glycine 0 N--CA 1.452 -0.3 0 C-N-CA 120.72 -0.752 . . . . 0.0 111.93 -179.5 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 94.5 mt -74.97 177.75 6.1 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.986 0.422 . . . . 0.0 111.506 -179.384 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 94' ' ' ASP . . . . . . . . . . . . . 9.9 m-20 -102.13 171.3 7.57 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-N 115.818 -0.628 . . . . 0.0 110.654 179.666 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 45.8 t -57.4 -36.91 71.91 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.292 -0.413 . . . . 0.0 111.192 -179.63 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 15.2 ptm180 -73.5 -48.12 35.75 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.467 -0.333 . . . . 0.0 111.343 -179.846 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 48.0 mt-10 -53.18 -45.69 68.65 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.303 -0.408 . . . . 0.0 111.079 -179.846 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 98' ' ' PHE . . . . . 0.472 ' O ' HG12 ' A' ' 102' ' ' ILE . 26.3 m-85 -59.25 -49.48 77.67 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.673 179.611 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -55.77 -28.02 51.25 Favored Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.811 -0.709 . . . . 0.0 112.862 -179.754 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 100' ' ' ILE . . . . . 0.424 ' O ' HG22 ' A' ' 103' ' ' THR . 93.5 mt -73.77 -49.05 37.16 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 N-CA-C 111.914 0.339 . . . . 0.0 111.914 -179.641 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 33.1 m -70.58 -32.55 50.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 N-CA-C 111.962 0.356 . . . . 0.0 111.962 -179.251 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 102' ' ' ILE . . . . . 0.504 HG23 ' HB3' ' A' ' 81' ' ' PRO . 50.2 mm -74.93 -43.0 46.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.536 -0.302 . . . . 0.0 111.426 -179.573 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 103' ' ' THR . . . . . 0.424 HG22 ' O ' ' A' ' 100' ' ' ILE . 14.7 t -63.52 -34.0 76.82 Favored 'General case' 0 C--O 1.232 0.134 0 CA-C-O 121.075 0.464 . . . . 0.0 110.116 179.532 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 104' ' ' LEU . . . . . 0.496 ' O ' HG23 ' A' ' 108' ' ' VAL . 42.8 tp -61.82 -57.11 13.11 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 115.796 -0.638 . . . . 0.0 110.072 179.101 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 105' ' ' ASN . . . . . 0.628 HD21 HD13 ' A' ' 137' ' ' LEU . 0.8 OUTLIER -55.95 -25.82 45.3 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 115.967 -0.561 . . . . 0.0 110.873 179.411 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 79.0 m -64.07 -57.53 9.36 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.422 -0.353 . . . . 0.0 111.205 -179.93 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 107' ' ' VAL . . . . . 0.416 HG12 ' O ' ' A' ' 104' ' ' LEU . 7.1 p -62.25 -35.83 71.29 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.211 0 CA-C-N 116.394 -0.366 . . . . 0.0 110.952 179.916 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 108' ' ' VAL . . . . . 0.496 HG23 ' O ' ' A' ' 104' ' ' LEU . 84.6 t -62.87 -56.99 14.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-O 121.052 0.453 . . . . 0.0 110.783 179.645 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 109' ' ' MET . . . . . 0.482 ' HE1' HG21 ' A' ' 80' ' ' THR . 5.5 tpp -58.07 -32.43 68.03 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 115.793 -0.639 . . . . 0.0 110.932 -179.729 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 22.4 tp -66.93 -35.97 81.19 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.243 179.663 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -62.46 -44.12 97.18 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 115.855 -0.611 . . . . 0.0 110.491 179.312 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . -64.17 -44.7 95.28 Favored Glycine 0 N--CA 1.452 -0.278 0 C-N-CA 120.751 -0.737 . . . . 0.0 112.289 179.519 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 113' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -51.04 -63.73 1.04 Allowed 'General case' 0 C--N 1.333 -0.149 0 CA-C-O 121.075 0.464 . . . . 0.0 110.347 179.765 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -67.31 -16.71 64.42 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 115.782 -0.645 . . . . 0.0 110.862 179.575 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -60.85 -47.01 93.34 Favored Glycine 0 C--N 1.332 0.35 0 C-N-CA 120.768 -0.729 . . . . 0.0 112.267 179.7 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 116' ' ' ALA . . . . . 0.414 ' HB2' ' HB3' ' A' ' 183' ' ' PRO . . . -78.48 -22.57 47.29 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 120.666 0.27 . . . . 0.0 111.631 179.796 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 117' ' ' MET . . . . . . . . . . . . . 1.1 mpt? -87.11 18.33 3.7 Favored 'General case' 0 C--N 1.332 -0.162 0 CA-C-N 116.53 -0.304 . . . . 0.0 111.712 -179.705 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 118' ' ' VAL . . . . . 0.5 HG21 ' HB3' ' A' ' 123' ' ' ARG . 27.3 m -76.13 147.69 80.28 Favored Pre-proline 0 C--N 1.327 -0.37 0 CA-C-N 116.668 -0.242 . . . . 0.0 111.305 179.99 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 119' ' ' PRO . . . . . . . . . . . . . 67.7 Cg_endo -84.55 -15.78 6.01 Favored 'Trans proline' 0 C--N 1.347 0.476 0 C-N-CA 122.667 2.245 . . . . 0.0 112.645 -179.987 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -143.68 -110.79 0.75 Allowed Glycine 0 C--N 1.333 0.369 0 C-N-CA 120.462 -0.875 . . . . 0.0 113.282 -179.53 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 47.9 pt -111.16 11.59 8.61 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.218 0 N-CA-C 111.783 0.29 . . . . 0.0 111.783 -179.225 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 15.7 mm-40 -58.39 -19.06 32.79 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.867 0.365 . . . . 0.0 110.815 179.819 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 123' ' ' ARG . . . . . 0.5 ' HB3' HG21 ' A' ' 118' ' ' VAL . 32.0 ptt180 -53.09 -30.02 33.83 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 115.714 -0.675 . . . . 0.0 111.843 -179.817 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 124' ' ' TYR . . . . . . . . . . . . . 48.5 m-85 -75.3 -32.62 61.03 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 116.316 -0.402 . . . . 0.0 111.907 -178.985 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 125' ' ' ALA . . . . . . . . . . . . . . . -70.68 -55.65 8.23 Favored 'General case' 0 C--O 1.238 0.453 0 CA-C-O 121.121 0.486 . . . . 0.0 110.892 179.953 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 1.3 mt -55.85 -46.07 78.31 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 115.591 -0.732 . . . . 0.0 110.607 -179.613 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 127' ' ' PHE . . . . . 0.459 ' HZ ' ' HB3' ' A' ' 175' ' ' PRO . 3.0 t80 -67.29 -39.01 85.95 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.442 -0.345 . . . . 0.0 110.555 179.618 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 128' ' ' GLY . . . . . . . . . . . . . . . -46.44 -43.72 15.1 Favored Glycine 0 C--O 1.237 0.284 0 C-N-CA 120.129 -1.034 . . . . 0.0 111.09 179.356 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 129' ' ' MET . . . . . . . . . . . . . 0.4 OUTLIER -70.92 -40.34 72.16 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 121.014 0.435 . . . . 0.0 110.263 178.999 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -66.32 -26.4 72.62 Favored Glycine 0 N--CA 1.452 -0.254 0 CA-C-N 115.727 -0.67 . . . . 0.0 113.018 -179.691 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -75.08 -53.66 8.5 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 120.664 0.269 . . . . 0.0 110.588 179.98 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 56.2 t -59.27 -41.01 82.7 Favored 'Isoleucine or valine' 0 C--O 1.234 0.275 0 N-CA-C 109.203 -0.666 . . . . 0.0 109.203 178.7 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -67.54 -34.53 77.26 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-N 115.207 -0.906 . . . . 0.0 110.549 179.214 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 134' ' ' PHE . . . . . . . . . . . . . 39.8 t80 -55.86 -54.77 40.55 Favored 'General case' 0 N--CA 1.452 -0.344 0 CA-C-N 116.209 -0.451 . . . . 0.0 109.992 179.485 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 135' ' ' ILE . . . . . 0.495 ' HA ' HG22 ' A' ' 138' ' ' VAL . 33.1 mt -58.15 -31.89 42.97 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 CA-C-N 115.711 -0.677 . . . . 0.0 110.116 179.164 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . -59.27 -44.89 96.17 Favored Glycine 0 N--CA 1.449 -0.488 0 C-N-CA 120.401 -0.904 . . . . 0.0 112.119 179.124 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 137' ' ' LEU . . . . . 0.628 HD13 HD21 ' A' ' 105' ' ' ASN . 13.9 tp -70.76 -52.02 23.38 Favored 'General case' 0 C--N 1.33 -0.258 0 C-N-CA 121.055 -0.258 . . . . 0.0 111.173 -179.867 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 138' ' ' VAL . . . . . 0.495 HG22 ' HA ' ' A' ' 135' ' ' ILE . 4.2 m -54.53 -31.56 23.49 Favored 'Isoleucine or valine' 0 C--O 1.232 0.168 0 N-CA-C 109.604 -0.517 . . . . 0.0 109.604 -179.737 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 139' ' ' TYR . . . . . . . . . . . . . 13.9 t80 -63.69 -44.53 93.41 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 115.616 -0.72 . . . . 0.0 109.596 178.16 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 24.9 m-85 -59.01 -42.83 91.06 Favored 'General case' 0 C--O 1.233 0.189 0 CA-C-N 115.971 -0.559 . . . . 0.0 111.05 179.402 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 141' ' ' LEU . . . . . 0.499 ' HA ' ' SD ' ' A' ' 145' ' ' MET . 9.4 mp -55.59 -49.76 71.91 Favored 'General case' 0 N--CA 1.462 0.17 0 CA-C-N 116.429 -0.351 . . . . 0.0 110.994 -179.774 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 12.6 p -82.46 -10.27 11.97 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.364 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.99 -179.98 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 143' ' ' GLY . . . . . 0.592 ' O ' HG22 ' A' ' 146' ' ' THR . . . -74.99 -144.97 1.1 Allowed Glycine 0 CA--C 1.521 0.455 0 C-N-CA 121.05 -0.595 . . . . 0.0 112.889 -179.766 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 144' ' ' PRO . . . . . . . . . . . . . 78.1 Cg_exo -50.07 -23.27 9.05 Favored 'Trans proline' 0 C--N 1.348 0.537 0 C-N-CA 122.794 2.329 . . . . 0.0 112.93 -179.934 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 145' ' ' MET . . . . . 0.499 ' SD ' ' HA ' ' A' ' 141' ' ' LEU . 27.4 mtt -52.4 -43.87 65.02 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.392 -0.367 . . . . 0.0 111.636 -179.681 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 146' ' ' THR . . . . . 0.592 HG22 ' O ' ' A' ' 143' ' ' GLY . 8.3 t -76.67 -31.77 57.51 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-O 120.907 0.384 . . . . 0.0 110.862 -179.471 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 34.0 tt0 -64.5 -40.4 95.59 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 115.989 -0.55 . . . . 0.0 110.769 179.858 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 148' ' ' SER . . . . . . . . . . . . . 55.5 m -70.41 -46.88 63.1 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.75 -179.972 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 149' ' ' ALA . . . . . . . . . . . . . . . -62.38 -32.41 73.21 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 115.935 -0.575 . . . . 0.0 111.19 -179.995 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 150' ' ' SER . . . . . . . . . . . . . 48.1 t -70.56 -1.64 11.66 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.815 179.843 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 151' ' ' GLN . . . . . . . . . . . . . 48.8 mt-30 -120.18 1.64 10.83 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.121 -0.491 . . . . 0.0 111.168 -179.832 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 26.6 mmm180 -81.88 -52.45 7.08 Favored 'General case' 0 C--N 1.332 -0.171 0 CA-C-O 121.11 0.481 . . . . 0.0 110.51 179.699 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 153' ' ' SER . . . . . 0.573 ' HB2' HG12 ' A' ' 156' ' ' ILE . 25.3 m -157.41 172.31 18.81 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-N 115.599 -0.728 . . . . 0.0 110.842 179.296 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 154' ' ' SER . . . . . . . . . . . . . 81.0 p -70.41 -39.1 74.64 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.303 -0.408 . . . . 0.0 110.709 179.579 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -77.21 -39.35 27.2 Favored Glycine 0 CA--C 1.518 0.269 0 C-N-CA 121.057 -0.592 . . . . 0.0 112.905 -179.83 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 156' ' ' ILE . . . . . 0.573 HG12 ' HB2' ' A' ' 153' ' ' SER . 35.6 mm -49.73 -38.92 14.08 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.175 0 CA-C-O 120.774 0.321 . . . . 0.0 111.823 -179.616 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 157' ' ' LYS . . . . . 0.434 ' O ' HG22 ' A' ' 161' ' ' VAL . 64.7 tttm -66.72 -37.91 85.63 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-N 116.304 -0.407 . . . . 0.0 111.363 -179.559 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 49.5 m -71.38 -37.91 71.56 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 121.003 0.43 . . . . 0.0 111.157 -178.815 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 159' ' ' LEU . . . . . 0.571 ' O ' ' HG ' ' A' ' 163' ' ' LEU . 31.3 mt -70.6 -56.79 5.66 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-N 116.043 -0.526 . . . . 0.0 111.13 -179.642 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 160' ' ' TYR . . . . . 0.45 ' OH ' ' HB3' ' A' ' 145' ' ' MET . 31.9 t80 -51.88 -41.83 62.2 Favored 'General case' 0 C--N 1.325 -0.466 0 N-CA-C 112.416 0.524 . . . . 0.0 112.416 -178.764 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 161' ' ' VAL . . . . . 0.468 HG23 ' N ' ' A' ' 162' ' ' ARG . 30.5 m -66.28 -49.07 78.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 N-CA-C 112.022 0.379 . . . . 0.0 112.022 -178.529 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 162' ' ' ARG . . . . . 0.468 ' N ' HG23 ' A' ' 161' ' ' VAL . 98.4 mtt180 -66.02 -49.38 67.94 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.768 0.318 . . . . 0.0 111.731 -179.205 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 163' ' ' LEU . . . . . 0.571 ' HG ' ' O ' ' A' ' 159' ' ' LEU . 19.7 mt -60.65 -55.43 33.32 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.635 -179.164 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 164' ' ' ARG . . . . . . . . . . . . . 3.8 ppt_? -58.85 -38.71 79.34 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.363 -0.38 . . . . 0.0 111.959 -178.967 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 165' ' ' ASN . . . . . 0.462 ' O ' HG23 ' A' ' 169' ' ' VAL . 5.1 m-20 -56.6 -53.62 55.49 Favored 'General case' 0 C--O 1.237 0.408 0 CA-C-O 120.751 0.31 . . . . 0.0 111.133 -178.383 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 166' ' ' LEU . . . . . 0.465 ' O ' ' HG ' ' A' ' 170' ' ' LEU . 0.2 OUTLIER -68.01 -28.89 67.81 Favored 'General case' 0 C--N 1.326 -0.439 0 C-N-CA 120.588 -0.445 . . . . 0.0 110.267 -179.917 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 167' ' ' THR . . . . . 0.412 ' O ' ' HB2' ' A' ' 171' ' ' TRP . 21.7 m -61.19 -53.35 57.98 Favored 'General case' 0 N--CA 1.462 0.131 0 CA-C-N 116.313 -0.403 . . . . 0.0 111.259 179.743 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 168' ' ' VAL . . . . . . . . . . . . . 60.4 t -60.04 -40.64 83.79 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 115.826 -0.624 . . . . 0.0 111.799 -179.054 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 169' ' ' VAL . . . . . 0.462 HG23 ' O ' ' A' ' 165' ' ' ASN . 93.9 t -56.74 -65.5 0.39 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 C-N-CA 120.914 -0.314 . . . . 0.0 111.739 -179.69 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 170' ' ' LEU . . . . . 0.465 ' HG ' ' O ' ' A' ' 166' ' ' LEU . 1.1 pp -62.8 -33.11 74.52 Favored 'General case' 0 C--N 1.33 -0.269 0 N-CA-C 112.467 0.543 . . . . 0.0 112.467 -178.576 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 171' ' ' TRP . . . . . 0.801 ' HE1' H203 ' A' ' 301' ' ' RET . 2.2 m0 -69.01 -31.28 69.99 Favored 'General case' 0 N--CA 1.463 0.22 0 C-N-CA 120.846 -0.341 . . . . 0.0 110.844 179.644 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 172' ' ' ALA . . . . . . . . . . . . . . . -74.53 -7.08 51.93 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-O 120.909 0.385 . . . . 0.0 110.587 -179.768 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 173' ' ' ILE . . . . . 0.527 HG22 HD11 ' A' ' 177' ' ' ILE . 40.6 mm -85.48 -21.84 7.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 115.787 -0.642 . . . . 0.0 110.865 179.62 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 174' ' ' TYR . . . . . 0.437 ' HB2' ' HD3' ' A' ' 175' ' ' PRO . 26.9 m-85 -54.56 -50.05 87.59 Favored Pre-proline 0 N--CA 1.464 0.242 0 CA-C-N 116.33 -0.396 . . . . 0.0 111.542 -179.975 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 175' ' ' PRO . . . . . 0.459 ' HB3' ' HZ ' ' A' ' 127' ' ' PHE . 86.8 Cg_exo -46.93 -30.79 10.16 Favored 'Trans proline' 0 C--N 1.352 0.749 0 C-N-CA 122.121 1.88 . . . . 0.0 112.215 179.575 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 176' ' ' PHE . . . . . 0.47 ' HD2' ' HA ' ' A' ' 173' ' ' ILE . 76.8 m-85 -80.38 -48.81 12.35 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 115.928 -0.578 . . . . 0.0 111.65 -179.768 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 177' ' ' ILE . . . . . 0.527 HD11 HG22 ' A' ' 173' ' ' ILE . 3.4 mm -63.47 -34.24 66.25 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.516 0 CA-C-N 116.374 -0.375 . . . . 0.0 111.881 -178.5 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 178' ' ' TRP . . . . . 0.431 ' HH2' ' HB2' ' A' ' 123' ' ' ARG . 73.8 t90 -74.03 -48.78 27.7 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 121.041 0.448 . . . . 0.0 110.449 179.438 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 179' ' ' LEU . . . . . 0.51 ' O ' HG22 ' A' ' 185' ' ' VAL . 1.9 tm? -63.55 -52.3 61.7 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 115.68 -0.691 . . . . 0.0 111.239 -179.395 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 180' ' ' LEU . . . . . 0.68 HD22 HD11 ' A' ' 187' ' ' LEU . 15.6 mt -76.73 -41.83 43.56 Favored 'General case' 0 C--N 1.329 -0.324 0 N-CA-C 112.076 0.398 . . . . 0.0 112.076 -178.914 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . -58.18 179.02 1.26 Allowed Glycine 0 C--N 1.334 0.456 0 C-N-CA 120.166 -1.016 . . . . 0.0 112.426 179.759 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 182' ' ' PRO . . . . . 0.451 ' HA ' ' HB2' ' A' ' 186' ' ' ALA . 72.0 Cg_exo -47.27 -45.29 22.47 Favored 'Trans proline' 0 CA--C 1.536 0.61 0 C-N-CA 122.741 2.294 . . . . 0.0 113.798 -179.856 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 183' ' ' PRO . . . . . 0.449 ' HG3' ' NH2' ' A' ' 72' ' ' ARG . 71.6 Cg_exo -49.49 -22.98 6.91 Favored 'Trans proline' 0 C--N 1.356 0.955 0 C-N-CA 122.223 1.949 . . . . 0.0 113.121 -179.786 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 184' ' ' GLY . . . . . . . . . . . . . . . -119.07 -132.99 4.58 Favored Glycine 0 N--CA 1.449 -0.448 0 C-N-CA 120.484 -0.865 . . . . 0.0 112.906 -179.824 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 185' ' ' VAL . . . . . 0.51 HG22 ' O ' ' A' ' 179' ' ' LEU . 13.3 m -58.75 -21.02 17.93 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.396 0 N-CA-C 112.13 0.418 . . . . 0.0 112.13 -179.485 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 186' ' ' ALA . . . . . 0.451 ' HB2' ' HA ' ' A' ' 182' ' ' PRO . . . 55.61 87.18 0.05 Allowed 'General case' 0 N--CA 1.463 0.194 0 CA-C-O 120.74 0.305 . . . . 0.0 111.391 179.906 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 187' ' ' LEU . . . . . 0.68 HD11 HD22 ' A' ' 180' ' ' LEU . 15.8 mt -91.75 -49.54 6.21 Favored 'General case' 0 C--N 1.332 -0.195 0 CA-C-N 116.291 -0.413 . . . . 0.0 111.341 -179.713 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 188' ' ' LEU . . . . . . . . . . . . . 68.6 mt -96.85 -155.07 0.47 Allowed 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 115.923 -0.58 . . . . 0.0 110.991 -179.573 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 189' ' ' THR . . . . . . . . . . . . . 1.9 t -101.6 146.74 32.76 Favored Pre-proline 0 C--N 1.328 -0.367 0 CA-C-N 116.001 -0.545 . . . . 0.0 110.817 -179.987 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 190' ' ' PRO . . . . . . . . . . . . . 86.5 Cg_exo -47.09 -45.2 21.97 Favored 'Trans proline' 0 C--N 1.348 0.502 0 C-N-CA 122.694 2.262 . . . . 0.0 113.35 -179.528 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 191' ' ' THR . . . . . . . . . . . . . 5.6 t -56.58 -39.95 74.4 Favored 'General case' 0 C--N 1.329 -0.316 0 N-CA-C 112.061 0.393 . . . . 0.0 112.061 -179.338 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 192' ' ' VAL . . . . . . . . . . . . . 40.6 t -73.37 -53.82 17.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 N-CA-C 111.909 0.337 . . . . 0.0 111.909 -179.435 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 193' ' ' ASP . . . . . . . . . . . . . 19.0 m-20 -58.36 -50.11 74.84 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.516 -0.311 . . . . 0.0 111.217 -179.829 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 194' ' ' VAL . . . . . . . . . . . . . 78.0 t -59.9 -36.33 66.04 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 116.339 -0.392 . . . . 0.0 110.691 179.557 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 195' ' ' ALA . . . . . . . . . . . . . . . -56.26 -47.85 77.72 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 116.397 -0.365 . . . . 0.0 111.121 179.792 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 196' ' ' LEU . . . . . . . . . . . . . 91.6 mt -64.99 -35.39 81.02 Favored 'General case' 0 C--N 1.332 -0.177 0 CA-C-O 120.771 0.319 . . . . 0.0 110.464 179.658 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 197' ' ' ILE . . . . . 0.477 HG12 HG21 ' A' ' 177' ' ' ILE . 19.6 mm -61.46 -53.8 43.7 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-O 121.142 0.496 . . . . 0.0 110.022 178.972 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 198' ' ' VAL . . . . . . . . . . . . . 98.3 t -54.91 -34.32 30.81 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.47 0 CA-C-N 115.344 -0.844 . . . . 0.0 109.33 178.471 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 199' ' ' TYR . . . . . 0.406 ' O ' HG23 ' A' ' 203' ' ' VAL . 68.8 t80 -69.35 -40.4 77.53 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 115.083 -0.962 . . . . 0.0 110.246 179.925 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 200' ' ' LEU . . . . . . . . . . . . . 38.1 mt -61.72 -41.56 97.79 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 115.74 -0.663 . . . . 0.0 111.371 -179.773 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 201' ' ' ASP . . . . . 0.459 ' OD2' ' H14' ' A' ' 301' ' ' RET . 0.9 OUTLIER -71.87 -40.39 68.98 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.041 -179.807 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 202' ' ' LEU . . . . . 0.403 ' O ' ' HB ' ' A' ' 206' ' ' VAL . 2.7 mt -65.2 -33.71 76.66 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.119 -0.491 . . . . 0.0 111.617 -179.401 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 203' ' ' VAL . . . . . 0.523 ' O ' ' HA3' ' A' ' 207' ' ' GLY . 65.9 t -77.31 -36.07 23.4 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.384 0 CA-C-O 120.74 0.305 . . . . 0.0 111.381 -179.12 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 204' ' ' THR . . . . . 0.42 HG23 ' CE2' ' A' ' 208' ' ' PHE . 88.8 m -66.46 -58.61 4.9 Favored 'General case' 0 C--N 1.325 -0.497 0 C-N-CA 120.745 -0.382 . . . . 0.0 111.298 179.95 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 205' ' ' LYS . . . . . 0.745 ' HE2' ' HB2' ' A' ' 47' ' ' ALA . 36.1 mttp -68.13 -58.75 3.96 Favored 'General case' 0 C--N 1.328 -0.338 0 N-CA-C 112.489 0.551 . . . . 0.0 112.489 -178.348 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 206' ' ' VAL . . . . . 0.403 ' HB ' ' O ' ' A' ' 202' ' ' LEU . 17.9 t -73.46 -37.0 49.77 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.369 0 N-CA-C 112.084 0.401 . . . . 0.0 112.084 -178.281 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 207' ' ' GLY . . . . . 0.523 ' HA3' ' O ' ' A' ' 203' ' ' VAL . . . -59.35 -60.05 9.52 Favored Glycine 0 N--CA 1.452 -0.278 0 C-N-CA 120.313 -0.946 . . . . 0.0 112.502 -179.36 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 208' ' ' PHE . . . . . 0.513 ' O ' ' N ' ' A' ' 212' ' ' ALA . 1.2 m-30 -58.48 -43.76 89.09 Favored 'General case' 0 C--O 1.221 -0.402 0 CA-C-N 117.111 0.456 . . . . 0.0 110.069 179.739 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 209' ' ' GLY . . . . . 0.487 ' O ' ' HB3' ' A' ' 212' ' ' ALA . . . -53.72 -37.89 57.99 Favored Glycine 0 CA--C 1.518 0.239 0 CA-C-N 115.501 -0.772 . . . . 0.0 113.957 -179.923 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 210' ' ' PHE . . . . . . . . . . . . . 2.6 m-85 -70.01 -48.68 57.12 Favored 'General case' 0 CA--C 1.515 -0.39 0 N-CA-C 108.906 -0.775 . . . . 0.0 108.906 179.664 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 211' ' ' ILE . . . . . 0.435 HG13 ' O ' ' A' ' 207' ' ' GLY . 5.3 mt -63.87 -27.43 42.82 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.569 0 N-CA-C 107.47 -1.308 . . . . 0.0 107.47 176.629 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 212' ' ' ALA . . . . . 0.513 ' N ' ' O ' ' A' ' 208' ' ' PHE . . . -68.37 -38.61 81.56 Favored 'General case' 0 N--CA 1.449 -0.488 0 CA-C-N 114.173 -1.376 . . . . 0.0 110.481 -179.866 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 213' ' ' LEU . . . . . . . . . . . . . 52.9 mt -65.44 -54.65 25.4 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-N 115.139 -0.937 . . . . 0.0 111.093 -179.811 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 214' ' ' ASP . . . . . . . . . . . . . 15.8 m-20 -60.57 -27.05 67.4 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.367 -0.379 . . . . 0.0 110.466 179.746 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 215' ' ' ALA . . . . . 0.437 ' O ' ' HG ' ' A' ' 219' ' ' LEU . . . -68.94 -57.77 5.04 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.073 -0.512 . . . . 0.0 111.193 -179.964 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 216' ' ' ALA . . . . . . . . . . . . . . . -63.28 -31.27 72.37 Favored 'General case' 0 C--N 1.331 -0.21 0 CA-C-N 116.332 -0.395 . . . . 0.0 110.972 -179.974 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 217' ' ' ALA . . . . . . . . . . . . . . . -64.64 -37.56 87.98 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.045 -0.525 . . . . 0.0 110.433 179.73 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 218' ' ' THR . . . . . . . . . . . . . 99.1 m -69.08 -40.74 78.26 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 115.817 -0.628 . . . . 0.0 110.508 179.456 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 219' ' ' LEU . . . . . 0.437 ' HG ' ' O ' ' A' ' 215' ' ' ALA . 42.9 mt -63.93 -33.54 75.94 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.373 179.491 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 220' ' ' ARG . . . . . . . . . . . . . 58.4 ttt180 -78.7 -30.85 46.29 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 115.879 -0.601 . . . . 0.0 110.531 179.821 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 221' ' ' ALA . . . . . . . . . . . . . . . -70.45 -29.44 66.01 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.009 179.776 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 222' ' ' GLU . . . . . 0.672 ' HG3' ' H ' ' A' ' 224' ' ' GLY . 12.3 pt-20 -92.01 -21.88 20.27 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.334 179.849 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 223' ' ' HIS . . . . . . . . . . . . . 53.9 m-70 60.48 11.27 2.9 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 115.687 -0.688 . . . . 0.0 111.156 179.648 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 224' ' ' GLY . . . . . 0.672 ' H ' ' HG3' ' A' ' 222' ' ' GLU . . . 82.62 -54.86 4.96 Favored Glycine 0 N--CA 1.45 -0.389 0 C-N-CA 120.872 -0.68 . . . . 0.0 112.239 -179.835 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 225' ' ' GLU . . . . . . . . . . . . . 44.9 mt-10 -107.96 146.2 32.78 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.761 0.315 . . . . 0.0 110.509 179.719 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 226' ' ' SER . . . . . . . . . . . . . 81.7 p -139.98 125.71 19.38 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.296 -0.411 . . . . 0.0 111.005 -179.703 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 227' ' ' LEU . . . . . . . . . . . . . 4.3 pp -54.79 152.34 7.32 Favored 'General case' 0 C--N 1.331 -0.21 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.959 -179.96 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 228' ' ' ALA . . . . . . . . . . . . . . . -117.04 131.55 56.91 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.058 179.875 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 229' ' ' GLY . . . . . . . . . . . . . . . 132.89 -109.36 0.83 Allowed Glycine 0 N--CA 1.45 -0.37 0 C-N-CA 120.834 -0.698 . . . . 0.0 112.378 -179.953 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 230' ' ' VAL . . . . . . . . . . . . . 60.7 t -99.53 116.83 43.64 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.355 0 CA-C-O 120.824 0.345 . . . . 0.0 111.103 179.9 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 231' ' ' ASP . . . . . . . . . . . . . 7.5 p-10 -97.98 132.9 43.15 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.976 -179.858 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 232' ' ' THR . . . . . . . . . . . . . 4.1 t -157.24 128.53 6.84 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.15 179.852 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 233' ' ' ASP . . . . . . . . . . . . . 6.4 p-10 -167.52 156.34 9.76 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.132 -0.486 . . . . 0.0 110.807 179.971 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 234' ' ' THR . . . . . 0.4 ' HA ' ' HD3' ' A' ' 235' ' ' PRO . 5.4 t -127.77 142.52 44.51 Favored Pre-proline 0 C--N 1.33 -0.278 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.889 179.836 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 235' ' ' PRO . . . . . 0.4 ' HD3' ' HA ' ' A' ' 234' ' ' THR . 32.4 Cg_exo -58.45 138.44 85.83 Favored 'Trans proline' 0 C--N 1.348 0.537 0 C-N-CA 122.448 2.099 . . . . 0.0 112.287 179.932 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 236' ' ' ALA . . . . . . . . . . . . . . . -159.84 106.41 1.63 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.031 -0.531 . . . . 0.0 110.87 -179.978 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 237' ' ' VAL . . . . . . . . . . . . . 46.7 t -116.53 102.75 14.07 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-N 116.085 -0.507 . . . . 0.0 111.022 -179.777 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 238' ' ' ALA . . . . . . . . . . . . . . . -164.54 124.48 1.98 Allowed 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.144 -179.987 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 239' ' ' ASP . . . . . . . . . . . . . 7.8 p-10 -76.33 149.75 36.99 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.275 -0.42 . . . . 0.0 111.037 -179.907 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 240' ' ' LEU . . . . . . . . . . . . . 88.5 mt -94.96 -36.79 11.44 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.052 -0.522 . . . . 0.0 110.928 -179.998 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 241' ' ' GLU . . . . . . . . . . . . . 11.0 tp10 59.58 94.86 0.03 OUTLIER 'General case' 0 C--N 1.333 -0.12 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.934 179.992 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 242' ' ' HIS . . . . . . . . . . . . . 27.2 p80 -148.37 144.76 27.73 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.947 179.953 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 243' ' ' HIS . . . . . . . . . . . . . 35.6 m-70 -72.99 175.57 6.52 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.877 179.861 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 244' ' ' HIS . . . . . . . . . . . . . 32.0 m80 -82.56 -56.48 3.84 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.123 -0.489 . . . . 0.0 110.761 179.711 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 245' ' ' HIS . . . . . . . . . . . . . 62.6 t-80 -87.68 143.65 27.06 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.412 179.549 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 246' ' ' HIS . . . . . . . . . . . . . 12.1 t60 -60.02 -71.98 0.12 Allowed 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.343 -0.39 . . . . 0.0 111.331 -179.421 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 247' ' ' HIS . . . . . . . . . . . . . 55.7 t-80 . . . . . 0 C--O 1.25 1.081 0 CA-C-O 118.284 -0.865 . . . . 0.0 111.075 -179.754 . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 301' ' ' RET . . . . . 0.801 H203 ' HE1' ' A' ' 171' ' ' TRP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 86.9 mtp . . . . . 0 N--CA 1.485 1.325 0 CA-C-O 120.789 0.328 . . . . 0.0 110.823 . . . . . . . . . 0 0 . 1 . 017 nuclear build full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 55.4 t -132.04 -34.15 0.54 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.221 0 CA-C-N 116.178 -0.465 . . . . 0.0 111.331 -179.985 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -78.8 -31.85 42.82 Favored Glycine 0 N--CA 1.452 -0.238 0 C-N-CA 120.639 -0.791 . . . . 0.0 112.34 179.973 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 4' ' ' LEU . . . . . 0.514 HD11 HG21 ' A' ' 194' ' ' VAL . 47.6 tp -74.12 -36.95 64.23 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-O 120.849 0.356 . . . . 0.0 110.989 179.934 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 70.8 p -59.44 -31.99 69.8 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.077 -0.51 . . . . 0.0 111.665 -179.616 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 32.3 p -55.62 -35.45 65.9 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-O 120.844 0.354 . . . . 0.0 111.191 -179.773 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 7' ' ' LEU . . . . . . . . . . . . . 4.0 mm? -58.98 -53.05 62.81 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.123 -0.49 . . . . 0.0 111.087 179.952 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 8' ' ' PHE . . . . . 0.457 ' HB2' ' HB2' ' A' ' 55' ' ' ALA . 73.6 m-85 -58.81 -33.11 70.01 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 116.34 -0.391 . . . . 0.0 110.817 179.932 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 9' ' ' TRP . . . . . 0.433 ' O ' HG13 ' A' ' 13' ' ' ILE . 27.8 m95 -66.35 -46.61 76.18 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 116.013 -0.54 . . . . 0.0 110.152 -179.862 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 94.1 mt -59.82 -42.07 92.7 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 115.651 -0.704 . . . . 0.0 110.347 179.377 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -63.42 -30.42 77.53 Favored Glycine 0 N--CA 1.449 -0.496 0 C-N-CA 120.712 -0.756 . . . . 0.0 111.724 179.348 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -73.19 -30.79 63.78 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.795 0.331 . . . . 0.0 110.82 179.678 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 13' ' ' ILE . . . . . 0.433 HG13 ' O ' ' A' ' 9' ' ' TRP . 67.0 mt -67.61 -54.7 21.22 Favored 'Isoleucine or valine' 0 C--O 1.233 0.206 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.399 179.473 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -62.46 -35.09 91.23 Favored Glycine 0 N--CA 1.449 -0.474 0 C-N-CA 120.716 -0.755 . . . . 0.0 111.399 179.209 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 15' ' ' MET . . . . . 0.496 ' SD ' ' HA ' ' A' ' 44' ' ' SER . 45.5 tpp -62.75 -41.96 99.45 Favored 'General case' 0 N--CA 1.453 -0.294 0 CA-C-O 120.814 0.34 . . . . 0.0 110.209 179.376 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 16' ' ' LEU . . . . . 0.415 HD13 ' O ' ' A' ' 16' ' ' LEU . 0.3 OUTLIER -59.46 -37.74 78.96 Favored 'General case' 0 C--N 1.331 -0.201 0 N-CA-C 109.635 -0.505 . . . . 0.0 109.635 178.893 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 46.5 t -59.24 -43.23 89.28 Favored 'Isoleucine or valine' 0 C--O 1.232 0.176 0 CA-C-N 116.033 -0.531 . . . . 0.0 110.134 179.143 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -68.25 -42.89 81.98 Favored Glycine 0 C--N 1.331 0.291 0 C-N-CA 120.795 -0.717 . . . . 0.0 111.884 179.187 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 9.9 m -50.14 -46.24 53.74 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.698 0.285 . . . . 0.0 111.352 -179.604 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 92.7 mt -72.01 -43.17 65.46 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.271 -0.422 . . . . 0.0 111.618 -179.712 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -58.31 -33.23 69.25 Favored 'General case' 0 C--N 1.33 -0.267 0 N-CA-C 112.048 0.388 . . . . 0.0 112.048 -179.252 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 22' ' ' PHE . . . . . 0.42 ' HB2' HG22 ' A' ' 41' ' ' VAL . 5.3 m-85 -90.57 -37.67 13.68 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 120.624 0.249 . . . . 0.0 111.495 -179.367 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -65.91 -51.18 60.83 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.874 0.369 . . . . 0.0 111.659 -179.507 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 24' ' ' TRP . . . . . . . . . . . . . 3.4 t-105 -60.44 -52.87 63.37 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-N 115.948 -0.569 . . . . 0.0 111.145 -179.66 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -68.67 -20.6 64.44 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.358 -0.383 . . . . 0.0 111.032 179.942 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -73.65 -43.75 34.99 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.855 -0.688 . . . . 0.0 112.599 179.896 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 31.2 mmt180 -62.89 -24.56 67.88 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-O 120.826 0.346 . . . . 0.0 110.997 -179.877 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 14.3 t70 -120.05 98.09 5.91 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.788 179.93 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 29' ' ' ALA . . . . . 0.4 ' HB1' ' OE1' ' A' ' 33' ' ' GLU . . . -162.46 -78.51 0.04 OUTLIER 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.385 -0.37 . . . . 0.0 111.387 -179.872 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -150.67 -147.46 4.55 Favored Glycine 0 N--CA 1.452 -0.245 0 C-N-CA 120.66 -0.781 . . . . 0.0 112.49 -179.876 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 43.9 t -120.09 -34.33 3.72 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-O 120.775 0.321 . . . . 0.0 111.155 -179.895 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -97.47 -41.05 3.51 Favored Glycine 0 N--CA 1.452 -0.247 0 C-N-CA 120.693 -0.765 . . . . 0.0 112.569 -179.992 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 33' ' ' GLU . . . . . 0.4 ' OE1' ' HB1' ' A' ' 29' ' ' ALA . 11.0 pt-20 -58.94 -20.53 53.0 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 120.644 0.259 . . . . 0.0 111.255 179.893 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 34' ' ' ARG . . . . . 0.46 ' O ' HG23 ' A' ' 38' ' ' VAL . 74.2 mtp180 -49.2 -29.43 5.61 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.379 -179.89 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 98.9 mtt180 -60.21 -46.62 89.13 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.82 0.343 . . . . 0.0 111.057 179.899 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 52.7 m-85 -66.79 -42.66 85.62 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.176 -0.466 . . . . 0.0 111.068 -179.933 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 37' ' ' TYR . . . . . 0.404 ' O ' HG23 ' A' ' 41' ' ' VAL . 51.9 m-85 -63.45 -51.82 64.08 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.213 -0.448 . . . . 0.0 111.449 -179.6 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 38' ' ' VAL . . . . . 0.46 HG23 ' O ' ' A' ' 34' ' ' ARG . 78.2 t -56.81 -36.73 50.51 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-O 121.005 0.431 . . . . 0.0 110.222 179.662 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 17.4 m -65.35 -47.85 75.05 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 115.852 -0.613 . . . . 0.0 110.257 178.976 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 48.8 tp -56.11 -45.84 79.32 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 115.665 -0.698 . . . . 0.0 110.096 179.21 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 41' ' ' VAL . . . . . 0.42 HG22 ' HB2' ' A' ' 22' ' ' PHE . 96.5 t -60.81 -34.48 59.38 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.249 0 CA-C-N 115.698 -0.683 . . . . 0.0 109.983 179.068 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -57.03 -44.17 93.02 Favored Glycine 0 N--CA 1.447 -0.593 0 C-N-CA 120.813 -0.708 . . . . 0.0 111.834 179.599 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 43' ' ' ILE . . . . . 0.551 HG22 ' HE3' ' A' ' 205' ' ' LYS . 0.3 OUTLIER -63.1 -51.58 69.81 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.179 0 CA-C-O 120.7 0.286 . . . . 0.0 110.951 179.501 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 44' ' ' SER . . . . . 0.496 ' HA ' ' SD ' ' A' ' 15' ' ' MET . 87.5 p -60.41 -29.33 68.91 Favored 'General case' 0 C--O 1.232 0.155 0 CA-C-O 120.841 0.353 . . . . 0.0 111.305 -179.981 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -77.34 -51.31 6.16 Favored Glycine 0 CA--C 1.519 0.322 0 C-N-CA 120.668 -0.777 . . . . 0.0 113.11 -179.344 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 46' ' ' ILE . . . . . 0.669 HD12 HD12 ' A' ' 78' ' ' LEU . 12.4 pt -58.62 -37.53 65.8 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.242 0 CA-C-O 120.936 0.398 . . . . 0.0 110.979 -179.839 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 47' ' ' ALA . . . . . 0.688 ' HB2' ' HE2' ' A' ' 205' ' ' LYS . . . -67.87 -44.03 78.02 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.124 -0.489 . . . . 0.0 111.426 179.47 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 48' ' ' ALA . . . . . 0.425 ' HB2' ' HG3' ' A' ' 15' ' ' MET . . . -55.19 -43.25 74.22 Favored 'General case' 0 C--N 1.332 -0.194 0 CA-C-N 116.05 -0.523 . . . . 0.0 112.051 -179.326 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 35.5 m -73.2 -35.29 46.87 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.245 0 CA-C-O 120.684 0.278 . . . . 0.0 111.461 -179.541 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -63.29 -39.21 93.95 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-O 121.035 0.445 . . . . 0.0 110.965 179.955 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 24.5 m-85 -73.08 -38.96 66.23 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-N 115.817 -0.629 . . . . 0.0 110.648 -179.831 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -62.64 -45.46 92.73 Favored 'General case' 0 C--N 1.327 -0.413 0 CA-C-N 115.983 -0.553 . . . . 0.0 111.255 179.854 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 53' ' ' VAL . . . . . 0.551 ' O ' HG12 ' A' ' 58' ' ' VAL . 32.3 m -66.43 -52.9 41.57 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.122 0 CA-C-N 116.504 -0.316 . . . . 0.0 111.056 -179.949 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 54' ' ' MET . . . . . 0.539 ' N ' HG23 ' A' ' 53' ' ' VAL . 76.0 mtm -58.35 -34.96 71.22 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-O 121.156 0.503 . . . . 0.0 110.134 179.508 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 55' ' ' ALA . . . . . 0.457 ' HB2' ' HB2' ' A' ' 8' ' ' PHE . . . -63.31 -29.49 70.8 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 115.588 -0.733 . . . . 0.0 111.322 179.474 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 96.3 mt -79.23 -8.23 58.87 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.383 -0.371 . . . . 0.0 111.383 -179.633 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 98.75 -6.89 60.77 Favored Glycine 0 N--CA 1.45 -0.368 0 C-N-CA 120.531 -0.842 . . . . 0.0 113.018 179.545 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 58' ' ' VAL . . . . . 0.551 HG12 ' O ' ' A' ' 53' ' ' VAL . 3.8 p -75.26 154.4 6.3 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.235 0 CA-C-N 116.906 0.353 . . . . 0.0 110.636 179.926 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 76.3 22.77 72.62 Favored Glycine 0 N--CA 1.452 -0.261 0 C-N-CA 120.634 -0.794 . . . . 0.0 112.275 -179.408 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 60' ' ' TRP . . . . . . . . . . . . . 19.1 m0 -104.75 100.88 10.52 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-O 120.972 0.415 . . . . 0.0 110.043 179.967 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 61' ' ' VAL . . . . . 0.485 ' HB ' HG23 ' A' ' 68' ' ' VAL . 57.3 t -97.01 107.58 38.49 Favored Pre-proline 0 C--N 1.327 -0.389 0 CA-C-N 115.894 -0.594 . . . . 0.0 111.521 -179.448 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 62' ' ' PRO . . . . . 0.424 ' HD2' ' HA ' ' A' ' 61' ' ' VAL . 31.3 Cg_endo -63.53 135.0 47.18 Favored 'Trans proline' 0 C--N 1.35 0.613 0 C-N-CA 122.384 2.056 . . . . 0.0 111.894 179.461 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 85.8 t -136.68 94.02 1.12 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.38 0 CA-C-N 116.109 -0.496 . . . . 0.0 111.319 -179.43 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . 57.38 -88.95 0.02 OUTLIER 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.485 179.905 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 38.0 tt0 -117.65 -22.8 7.89 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-O 120.913 0.387 . . . . 0.0 110.638 179.981 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 66' ' ' ARG . . . . . . . . . . . . . 41.5 mmt180 -102.79 157.64 16.82 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.039 -0.528 . . . . 0.0 110.225 179.747 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 26.2 m -124.14 116.43 22.73 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-O 120.869 0.366 . . . . 0.0 111.334 -179.854 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 68' ' ' VAL . . . . . 0.504 HG11 ' HA ' ' A' ' 117' ' ' MET . 24.0 m -90.77 145.53 7.31 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 115.986 -0.552 . . . . 0.0 110.84 179.664 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 69' ' ' PHE . . . . . . . . . . . . . 42.5 m-85 -109.65 111.35 22.77 Favored 'General case' 0 N--CA 1.441 -0.918 0 N-CA-C 109.879 -0.415 . . . . 0.0 109.879 -179.819 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 70' ' ' VAL . . . . . 0.577 ' N ' ' HD2' ' A' ' 71' ' ' PRO . 38.6 t -60.73 -50.11 86.66 Favored Pre-proline 0 C--N 1.326 -0.427 0 CA-C-N 116.42 -0.355 . . . . 0.0 111.903 -179.042 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 71' ' ' PRO . . . . . 0.577 ' HD2' ' N ' ' A' ' 70' ' ' VAL . 36.6 Cg_endo -64.7 -17.84 60.78 Favored 'Trans proline' 0 C--N 1.35 0.638 0 C-N-CA 122.288 1.992 . . . . 0.0 112.971 -179.343 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 37.3 ttp180 -70.95 -55.24 8.79 Favored 'General case' 0 C--O 1.235 0.321 0 C-N-CA 121.025 -0.27 . . . . 0.0 111.332 -179.492 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 73' ' ' TYR . . . . . 0.463 ' O ' HG13 ' A' ' 77' ' ' ILE . 5.7 m-85 -68.48 -34.52 76.08 Favored 'General case' 0 C--N 1.332 -0.185 0 C-N-CA 120.686 -0.406 . . . . 0.0 109.994 179.911 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 74' ' ' ILE . . . . . 0.524 ' HA ' HD12 ' A' ' 77' ' ' ILE . 0.4 OUTLIER -67.72 -36.75 77.03 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.173 0 CA-C-N 116.174 -0.467 . . . . 0.0 110.123 179.526 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 75' ' ' ASP . . . . . 0.43 ' O ' HG23 ' A' ' 79' ' ' THR . 11.3 t70 -60.5 -37.61 81.68 Favored 'General case' 0 CA--C 1.518 -0.262 0 N-CA-C 109.188 -0.671 . . . . 0.0 109.188 178.749 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 76' ' ' TRP . . . . . . . . . . . . . 40.6 m0 -69.86 -28.1 65.38 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 115.638 -0.71 . . . . 0.0 110.562 179.247 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 77' ' ' ILE . . . . . 0.573 ' HA ' ' HG3' ' A' ' 109' ' ' MET . 96.3 mt -68.56 -36.27 73.89 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.34 179.596 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 78' ' ' LEU . . . . . 0.669 HD12 HD12 ' A' ' 46' ' ' ILE . 0.7 OUTLIER -90.75 -26.76 19.33 Favored 'General case' 0 C--N 1.328 -0.358 0 N-CA-C 112.81 0.671 . . . . 0.0 112.81 -179.65 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 79' ' ' THR . . . . . 0.43 HG23 ' O ' ' A' ' 75' ' ' ASP . 64.8 p -84.71 -52.27 6.2 Favored 'General case' 0 C--N 1.327 -0.374 0 N-CA-C 113.71 1.004 . . . . 0.0 113.71 -178.548 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 80' ' ' THR . . . . . 0.696 ' HB ' ' HD3' ' A' ' 81' ' ' PRO . 34.0 m -53.42 -56.12 27.73 Favored Pre-proline 0 CA--C 1.533 0.314 0 N-CA-C 112.567 0.581 . . . . 0.0 112.567 -177.902 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 81' ' ' PRO . . . . . 0.696 ' HD3' ' HB ' ' A' ' 80' ' ' THR . 43.5 Cg_exo -58.33 -19.21 41.88 Favored 'Trans proline' 0 C--N 1.352 0.744 0 C-N-CA 121.728 1.618 . . . . 0.0 111.956 179.966 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 82' ' ' LEU . . . . . . . . . . . . . 16.2 tp -76.72 -35.66 57.67 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.078 179.575 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 83' ' ' ILE . . . . . 0.523 HD11 HG21 ' A' ' 43' ' ' ILE . 41.3 mm -69.57 -51.27 43.25 Favored 'Isoleucine or valine' 0 C--O 1.233 0.222 0 CA-C-N 115.926 -0.579 . . . . 0.0 110.379 179.214 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 84' ' ' VAL . . . . . 0.48 HG22 ' HA ' ' A' ' 81' ' ' PRO . 33.0 m -60.95 -31.96 51.16 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.212 0 N-CA-C 109.505 -0.554 . . . . 0.0 109.505 179.062 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 85' ' ' TYR . . . . . 0.416 ' O ' ' HG ' ' A' ' 89' ' ' LEU . 81.3 t80 -65.42 -33.6 76.32 Favored 'General case' 0 N--CA 1.453 -0.291 0 CA-C-N 115.559 -0.746 . . . . 0.0 109.344 178.739 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 86' ' ' PHE . . . . . . . . . . . . . 3.0 t80 -61.87 -50.93 70.26 Favored 'General case' 0 C--O 1.233 0.235 0 CA-C-N 115.617 -0.719 . . . . 0.0 110.066 179.436 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 6.1 mt -62.95 -29.15 70.58 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 115.905 -0.589 . . . . 0.0 110.316 179.778 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -70.56 -28.06 71.62 Favored Glycine 0 N--CA 1.451 -0.323 0 CA-C-N 115.486 -0.779 . . . . 0.0 112.026 179.542 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 89' ' ' LEU . . . . . 0.416 ' HG ' ' O ' ' A' ' 85' ' ' TYR . 91.2 mt -74.91 -41.99 58.66 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.92 0.391 . . . . 0.0 110.772 179.744 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 97.6 mt -63.99 -36.41 83.88 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 115.959 -0.564 . . . . 0.0 111.123 179.927 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -77.19 -53.92 7.14 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.352 -0.385 . . . . 0.0 111.131 -179.854 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 107.8 52.67 0.69 Allowed Glycine 0 C--N 1.33 0.248 0 C-N-CA 120.899 -0.667 . . . . 0.0 112.213 -179.726 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 64.8 mt -75.82 162.24 28.33 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-O 120.909 0.385 . . . . 0.0 111.04 -179.773 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 94' ' ' ASP . . . . . . . . . . . . . 7.0 m-20 -88.86 175.14 7.58 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.707 179.881 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 65.3 m -60.44 -35.2 75.27 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.255 -179.767 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 96' ' ' ARG . . . . . 0.456 ' HG3' ' N ' ' A' ' 97' ' ' GLU . 10.5 ptp180 -73.64 -46.65 45.48 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 116.312 -0.404 . . . . 0.0 111.251 -179.842 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 97' ' ' GLU . . . . . 0.456 ' N ' ' HG3' ' A' ' 96' ' ' ARG . 42.0 mt-10 -57.02 -40.47 76.73 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.326 -0.397 . . . . 0.0 111.08 -179.68 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 98' ' ' PHE . . . . . 0.447 ' O ' HG12 ' A' ' 102' ' ' ILE . 13.5 m-85 -62.63 -50.3 71.75 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.772 179.656 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -55.29 -30.44 55.07 Favored Glycine 0 N--CA 1.452 -0.253 0 C-N-CA 120.647 -0.787 . . . . 0.0 112.695 -179.906 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 100' ' ' ILE . . . . . 0.441 ' O ' HG22 ' A' ' 103' ' ' THR . 86.8 mt -72.13 -47.78 52.52 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-O 120.864 0.364 . . . . 0.0 111.561 -179.735 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 43.2 t -67.67 -48.68 75.38 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.371 0 CA-C-N 116.289 -0.414 . . . . 0.0 111.516 -179.572 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 102' ' ' ILE . . . . . 0.447 HG12 ' O ' ' A' ' 98' ' ' PHE . 34.9 mm -59.15 -47.19 91.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.898 -179.23 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 103' ' ' THR . . . . . 0.441 HG22 ' O ' ' A' ' 100' ' ' ILE . 14.2 t -60.81 -36.26 78.58 Favored 'General case' 0 C--O 1.234 0.245 0 CA-C-O 120.772 0.32 . . . . 0.0 110.879 -179.968 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 104' ' ' LEU . . . . . 0.434 HD12 ' HB2' ' A' ' 137' ' ' LEU . 3.0 tm? -57.01 -50.65 72.06 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-N 116.344 -0.389 . . . . 0.0 110.043 179.15 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 105' ' ' ASN . . . . . 0.414 ' O ' ' HG2' ' A' ' 109' ' ' MET . 16.6 m-80 -59.39 -31.42 69.22 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.014 -0.539 . . . . 0.0 110.674 179.368 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 41.5 m -56.92 -47.85 79.62 Favored 'General case' 0 C--O 1.232 0.177 0 CA-C-O 120.836 0.35 . . . . 0.0 110.154 179.329 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 107' ' ' VAL . . . . . 0.401 ' H ' HG23 ' A' ' 107' ' ' VAL . 1.9 t -61.06 -42.12 91.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 115.996 -0.547 . . . . 0.0 109.963 179.107 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 66.4 t -57.72 -45.69 86.84 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 115.171 -0.922 . . . . 0.0 111.669 -179.723 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 109' ' ' MET . . . . . 0.573 ' HG3' ' HA ' ' A' ' 77' ' ' ILE . 16.0 mmt -67.71 -44.33 77.92 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.712 -179.27 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 32.9 tp -60.64 -39.61 88.94 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-O 120.766 0.317 . . . . 0.0 110.806 -179.747 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -58.48 -54.67 44.46 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.685 179.635 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 112' ' ' GLY . . . . . 0.659 ' HA3' ' H21' ' A' ' 301' ' ' RET . . . -66.41 -32.3 81.45 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.387 179.632 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 113' ' ' PHE . . . . . . . . . . . . . 0.7 OUTLIER -52.77 -71.34 0.07 Allowed 'General case' 0 C--N 1.331 -0.202 0 CA-C-O 120.945 0.402 . . . . 0.0 110.183 179.829 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 114' ' ' ALA . . . . . 0.45 ' HB3' HD22 ' A' ' 126' ' ' LEU . . . -64.47 -22.6 67.01 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 115.796 -0.638 . . . . 0.0 110.975 179.742 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -53.57 -49.37 57.71 Favored Glycine 0 C--N 1.331 0.269 0 C-N-CA 121.025 -0.607 . . . . 0.0 112.518 179.985 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 116' ' ' ALA . . . . . 0.554 ' HB2' ' HB3' ' A' ' 183' ' ' PRO . . . -78.06 -18.14 56.15 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-O 120.742 0.306 . . . . 0.0 111.464 -179.899 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 117' ' ' MET . . . . . 0.504 ' HA ' HG11 ' A' ' 68' ' ' VAL . 33.3 ttm -99.31 19.57 15.22 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.32 -0.4 . . . . 0.0 111.556 -179.161 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 118' ' ' VAL . . . . . 0.453 HG21 ' HB3' ' A' ' 123' ' ' ARG . 25.1 m -71.34 143.33 87.89 Favored Pre-proline 0 C--N 1.33 -0.279 0 CA-C-N 116.524 -0.307 . . . . 0.0 111.514 179.993 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 119' ' ' PRO . . . . . . . . . . . . . 92.2 Cg_endo -89.49 14.89 2.09 Favored 'Trans proline' 0 N--CA 1.456 -0.677 0 C-N-CA 122.715 2.277 . . . . 0.0 112.418 179.373 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -166.07 -118.37 0.44 Allowed Glycine 0 C--N 1.334 0.421 0 C-N-CA 120.644 -0.789 . . . . 0.0 112.834 -179.668 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 2.0 pp -119.89 13.37 6.64 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.183 0 CA-C-O 120.675 0.274 . . . . 0.0 111.597 -179.595 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 43.6 mt-10 -62.62 -17.98 61.35 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.865 179.722 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 123' ' ' ARG . . . . . 0.453 ' HB3' HG21 ' A' ' 118' ' ' VAL . 3.2 ptp180 -50.28 -28.07 7.17 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 115.834 -0.621 . . . . 0.0 111.93 -179.764 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 124' ' ' TYR . . . . . . . . . . . . . 29.2 m-85 -71.42 -33.53 69.5 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.632 0.254 . . . . 0.0 111.385 -179.592 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 125' ' ' ALA . . . . . . . . . . . . . . . -74.21 -55.93 5.49 Favored 'General case' 0 C--O 1.235 0.315 0 CA-C-O 120.79 0.328 . . . . 0.0 111.184 179.918 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 126' ' ' LEU . . . . . 0.45 HD22 ' HB3' ' A' ' 114' ' ' ALA . 1.1 mp -52.16 -51.12 59.95 Favored 'General case' 0 C--N 1.332 -0.182 0 CA-C-N 116.041 -0.527 . . . . 0.0 110.313 179.79 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 127' ' ' PHE . . . . . 0.463 ' HE1' ' H42' ' A' ' 301' ' ' RET . 10.4 t80 -65.46 -30.36 71.14 Favored 'General case' 0 N--CA 1.452 -0.354 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.089 179.308 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 128' ' ' GLY . . . . . . . . . . . . . . . -48.19 -52.93 16.63 Favored Glycine 0 N--CA 1.449 -0.461 0 C-N-CA 120.196 -1.002 . . . . 0.0 110.757 178.848 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 129' ' ' MET . . . . . 0.549 ' HE3' ' HA2' ' A' ' 130' ' ' GLY . 0.0 OUTLIER -70.36 -27.24 64.18 Favored 'General case' 0 C--N 1.328 -0.367 0 N-CA-C 109.036 -0.727 . . . . 0.0 109.036 178.515 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 130' ' ' GLY . . . . . 0.549 ' HA2' ' HE3' ' A' ' 129' ' ' MET . . . -59.7 -45.27 95.99 Favored Glycine 0 C--N 1.333 0.366 0 CA-C-N 115.745 -0.661 . . . . 0.0 112.558 179.607 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 131' ' ' ALA . . . . . 0.403 ' O ' ' HB3' ' A' ' 134' ' ' PHE . . . -69.8 -47.53 62.5 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-O 120.738 0.304 . . . . 0.0 110.421 179.751 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 65.4 t -56.32 -44.31 79.4 Favored 'Isoleucine or valine' 0 C--O 1.235 0.293 0 CA-C-O 121.261 0.553 . . . . 0.0 109.662 178.865 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -63.25 -35.22 79.62 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 115.57 -0.741 . . . . 0.0 110.465 179.231 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 134' ' ' PHE . . . . . 0.414 ' HE1' ' HB3' ' A' ' 171' ' ' TRP . 72.6 t80 -56.92 -54.56 45.25 Favored 'General case' 0 N--CA 1.451 -0.375 0 CA-C-O 120.984 0.421 . . . . 0.0 110.156 179.494 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 135' ' ' ILE . . . . . 0.484 ' O ' HG22 ' A' ' 138' ' ' VAL . 39.8 mt -56.6 -31.05 33.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 115.733 -0.667 . . . . 0.0 110.198 179.285 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . -62.73 -42.41 99.69 Favored Glycine 0 N--CA 1.447 -0.607 0 C-N-CA 120.221 -0.99 . . . . 0.0 111.344 178.922 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 137' ' ' LEU . . . . . 0.446 ' O ' HD13 ' A' ' 141' ' ' LEU . 64.9 tp -67.12 -52.64 39.29 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-O 120.464 0.174 . . . . 0.0 111.033 179.778 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 138' ' ' VAL . . . . . 0.484 HG22 ' O ' ' A' ' 135' ' ' ILE . 4.5 m -54.31 -34.43 27.87 Favored 'Isoleucine or valine' 0 CA--C 1.52 -0.177 0 N-CA-C 109.728 -0.471 . . . . 0.0 109.728 -179.642 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 139' ' ' TYR . . . . . . . . . . . . . 35.6 t80 -58.56 -46.49 86.76 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 115.785 -0.643 . . . . 0.0 109.633 178.05 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 24.6 m-85 -63.65 -40.78 97.73 Favored 'General case' 0 C--N 1.333 -0.111 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.486 179.105 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 141' ' ' LEU . . . . . 0.507 ' HA ' ' SD ' ' A' ' 145' ' ' MET . 11.2 mp -59.14 -25.64 64.04 Favored 'General case' 0 C--N 1.332 -0.186 0 CA-C-N 116.073 -0.512 . . . . 0.0 110.973 179.982 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 142' ' ' VAL . . . . . 0.419 HG23 ' O ' ' A' ' 138' ' ' VAL . 15.7 t -107.9 -5.18 10.5 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.254 0 CA-C-N 116.24 -0.437 . . . . 0.0 110.875 179.851 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . -75.81 -133.2 0.41 Allowed Glycine 0 CA--C 1.522 0.487 0 C-N-CA 120.874 -0.679 . . . . 0.0 112.704 179.993 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 144' ' ' PRO . . . . . . . . . . . . . 48.7 Cg_exo -55.55 -24.17 43.3 Favored 'Trans proline' 0 C--N 1.35 0.639 0 C-N-CA 122.5 2.133 . . . . 0.0 112.868 -179.732 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 145' ' ' MET . . . . . 0.507 ' SD ' ' HA ' ' A' ' 141' ' ' LEU . 57.5 mtt -54.15 -32.91 56.6 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 116.402 -0.363 . . . . 0.0 111.408 -179.864 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 146' ' ' THR . . . . . . . . . . . . . 79.1 p -65.9 -49.25 68.7 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.3 -0.409 . . . . 0.0 111.937 -179.407 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 14.1 mm-40 -74.89 -25.39 58.9 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.734 0.302 . . . . 0.0 111.766 -179.394 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 148' ' ' SER . . . . . . . . . . . . . 45.9 t -70.1 -45.43 66.95 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.834 0.35 . . . . 0.0 111.098 -179.623 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 149' ' ' ALA . . . . . 0.416 ' HB1' HG22 ' A' ' 156' ' ' ILE . . . -78.33 -35.14 48.06 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.119 -0.492 . . . . 0.0 111.849 -179.582 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 150' ' ' SER . . . . . 0.559 ' HA ' ' HG2' ' A' ' 157' ' ' LYS . 35.7 t -69.71 0.72 5.12 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.303 -0.408 . . . . 0.0 111.44 -179.539 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 151' ' ' GLN . . . . . . . . . . . . . 49.1 mt-30 -134.3 15.53 3.78 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.512 -0.313 . . . . 0.0 111.207 179.877 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 152' ' ' ARG . . . . . 0.411 ' NE ' ' HA ' ' A' ' 152' ' ' ARG . 6.7 tpm_? -91.6 -51.89 5.04 Favored 'General case' 0 C--N 1.332 -0.195 0 CA-C-O 120.906 0.384 . . . . 0.0 110.772 179.954 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 153' ' ' SER . . . . . 0.679 ' HB3' HG12 ' A' ' 156' ' ' ILE . 24.3 t -157.76 172.6 18.2 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 115.978 -0.555 . . . . 0.0 110.746 179.256 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 154' ' ' SER . . . . . 0.513 ' HA ' ' NZ ' ' A' ' 157' ' ' LYS . 77.7 p -70.49 -40.68 73.45 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.427 -0.351 . . . . 0.0 110.859 179.727 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -77.08 -28.59 58.2 Favored Glycine 0 CA--C 1.521 0.41 0 C-N-CA 121.07 -0.585 . . . . 0.0 113.389 -179.631 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 156' ' ' ILE . . . . . 0.679 HG12 ' HB3' ' A' ' 153' ' ' SER . 33.4 mm -56.77 -37.68 54.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-O 120.678 0.275 . . . . 0.0 111.522 -179.507 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 157' ' ' LYS . . . . . 0.559 ' HG2' ' HA ' ' A' ' 150' ' ' SER . 36.7 mtmm -58.96 -41.26 87.04 Favored 'General case' 0 C--N 1.327 -0.393 0 N-CA-C 112.178 0.436 . . . . 0.0 112.178 -179.527 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 71.2 m -70.57 -48.32 55.9 Favored 'General case' 0 C--N 1.33 -0.256 0 N-CA-C 111.958 0.355 . . . . 0.0 111.958 -179.003 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 159' ' ' LEU . . . . . 0.402 ' O ' ' HB2' ' A' ' 163' ' ' LEU . 3.8 mm? -67.68 -30.2 69.67 Favored 'General case' 0 C--N 1.327 -0.384 0 N-CA-C 111.789 0.292 . . . . 0.0 111.789 -179.373 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 160' ' ' TYR . . . . . . . . . . . . . 72.4 t80 -73.98 -47.41 37.48 Favored 'General case' 0 C--N 1.329 -0.3 0 N-CA-C 112.313 0.486 . . . . 0.0 112.313 -179.06 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 161' ' ' VAL . . . . . 0.422 HG23 ' N ' ' A' ' 162' ' ' ARG . 27.3 m -64.25 -43.17 97.21 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.373 0 N-CA-C 112.347 0.499 . . . . 0.0 112.347 -178.616 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 162' ' ' ARG . . . . . 0.446 ' HA ' ' NE ' ' A' ' 162' ' ' ARG . 6.7 tpm_? -68.96 -49.27 59.47 Favored 'General case' 0 C--N 1.328 -0.33 0 N-CA-C 112.001 0.371 . . . . 0.0 112.001 -178.904 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 163' ' ' LEU . . . . . 0.402 ' HB2' ' O ' ' A' ' 159' ' ' LEU . 8.1 mp -67.62 -43.23 80.88 Favored 'General case' 0 C--N 1.329 -0.313 0 N-CA-C 111.928 0.344 . . . . 0.0 111.928 -179.149 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 164' ' ' ARG . . . . . . . . . . . . . 3.4 tmm_? -56.88 -50.79 71.43 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 120.695 0.283 . . . . 0.0 110.683 179.965 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 165' ' ' ASN . . . . . 0.464 ' O ' HG23 ' A' ' 169' ' ' VAL . 4.2 m-20 -57.29 -42.27 81.39 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.998 0.427 . . . . 0.0 110.301 179.576 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 166' ' ' LEU . . . . . 0.467 ' HB3' ' CE1' ' A' ' 208' ' ' PHE . 2.7 mt -58.7 -52.18 66.79 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 115.83 -0.623 . . . . 0.0 111.097 179.344 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 167' ' ' THR . . . . . 0.637 ' HA ' HD11 ' A' ' 170' ' ' LEU . 3.1 m -54.59 -51.86 63.95 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 115.733 -0.667 . . . . 0.0 112.442 -178.454 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 168' ' ' VAL . . . . . . . . . . . . . 59.2 t -57.26 -40.36 73.34 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.504 0 N-CA-C 112.485 0.55 . . . . 0.0 112.485 -178.894 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 169' ' ' VAL . . . . . 0.483 ' O ' HG12 ' A' ' 173' ' ' ILE . 98.2 t -68.03 -66.7 0.49 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 N-CA-C 113.499 0.926 . . . . 0.0 113.499 -177.912 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 170' ' ' LEU . . . . . 0.637 HD11 ' HA ' ' A' ' 167' ' ' THR . 0.4 OUTLIER -59.89 -33.2 71.52 Favored 'General case' 0 N--CA 1.467 0.386 0 N-CA-C 112.887 0.699 . . . . 0.0 112.887 -177.71 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 171' ' ' TRP . . . . . 0.721 ' HE1' H203 ' A' ' 301' ' ' RET . 25.9 m0 -73.54 -30.51 63.12 Favored 'General case' 0 C--N 1.329 -0.296 0 C-N-CA 120.57 -0.452 . . . . 0.0 111.473 -179.429 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 172' ' ' ALA . . . . . . . . . . . . . . . -73.2 -7.53 51.84 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.944 0.402 . . . . 0.0 110.348 179.455 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 173' ' ' ILE . . . . . 0.592 HG22 HD11 ' A' ' 177' ' ' ILE . 31.4 mm -88.75 -24.5 6.03 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.15 0 CA-C-N 115.877 -0.601 . . . . 0.0 110.758 179.402 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 174' ' ' TYR . . . . . 0.598 ' N ' ' HD2' ' A' ' 175' ' ' PRO . 21.4 m-85 -55.11 -50.29 87.35 Favored Pre-proline 0 CA--C 1.53 0.192 0 N-CA-C 112.216 0.45 . . . . 0.0 112.216 -179.614 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 175' ' ' PRO . . . . . 0.598 ' HD2' ' N ' ' A' ' 174' ' ' TYR . 4.1 Cg_endo -47.06 -28.47 7.45 Favored 'Trans proline' 0 C--N 1.352 0.762 0 C-N-CA 122.148 1.899 . . . . 0.0 112.1 179.976 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 176' ' ' PHE . . . . . 0.519 ' O ' ' HG ' ' A' ' 180' ' ' LEU . 92.2 m-85 -80.27 -49.97 10.85 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.31 179.568 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 177' ' ' ILE . . . . . 0.592 HD11 HG22 ' A' ' 173' ' ' ILE . 2.8 mm -59.71 -37.38 70.83 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.581 0 CA-C-N 115.995 -0.548 . . . . 0.0 111.781 -178.593 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 178' ' ' TRP . . . . . . . . . . . . . 70.7 t90 -73.58 -45.38 53.57 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.915 0.388 . . . . 0.0 110.856 179.814 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 179' ' ' LEU . . . . . 0.451 ' O ' ' HA3' ' A' ' 184' ' ' GLY . 1.9 tm? -65.09 -53.12 50.29 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 115.976 -0.556 . . . . 0.0 111.417 -179.233 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 180' ' ' LEU . . . . . 0.604 HD22 HD11 ' A' ' 187' ' ' LEU . 11.1 mt -71.79 -42.96 66.46 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 116.705 -0.225 . . . . 0.0 111.515 -179.208 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . -58.54 175.41 2.56 Favored Glycine 0 C--N 1.335 0.493 0 C-N-CA 120.472 -0.87 . . . . 0.0 112.664 179.772 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 182' ' ' PRO . . . . . 0.714 ' HA ' ' HB2' ' A' ' 186' ' ' ALA . 73.1 Cg_exo -47.91 -44.27 27.72 Favored 'Trans proline' 0 C--N 1.349 0.581 0 C-N-CA 122.767 2.312 . . . . 0.0 113.38 179.791 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 183' ' ' PRO . . . . . 0.554 ' HB3' ' HB2' ' A' ' 116' ' ' ALA . 73.4 Cg_exo -52.08 -17.19 5.41 Favored 'Trans proline' 0 C--N 1.355 0.905 0 C-N-CA 122.119 1.88 . . . . 0.0 112.84 179.557 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 184' ' ' GLY . . . . . 0.451 ' HA3' ' O ' ' A' ' 179' ' ' LEU . . . -114.74 -82.79 1.08 Allowed Glycine 0 N--CA 1.45 -0.379 0 C-N-CA 120.644 -0.789 . . . . 0.0 112.942 -179.715 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 185' ' ' VAL . . . . . 0.409 HG22 ' O ' ' A' ' 179' ' ' LEU . 8.4 m -129.71 -4.16 2.89 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.24 0 N-CA-C 112.349 0.5 . . . . 0.0 112.349 -179.376 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 186' ' ' ALA . . . . . 0.714 ' HB2' ' HA ' ' A' ' 182' ' ' PRO . . . 52.22 89.56 0.03 OUTLIER 'General case' 0 N--CA 1.464 0.241 0 CA-C-O 120.72 0.295 . . . . 0.0 111.635 179.752 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 187' ' ' LEU . . . . . 0.604 HD11 HD22 ' A' ' 180' ' ' LEU . 24.3 mt -92.24 -49.49 6.15 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.443 -0.344 . . . . 0.0 111.678 -179.81 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 188' ' ' LEU . . . . . . . . . . . . . 88.7 mt -93.27 -93.93 0.16 Allowed 'General case' 0 C--N 1.331 -0.23 0 CA-C-O 120.799 0.333 . . . . 0.0 111.23 -179.604 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 189' ' ' THR . . . . . . . . . . . . . 2.2 t -161.44 145.02 9.62 Favored Pre-proline 0 C--N 1.326 -0.418 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.957 179.979 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 190' ' ' PRO . . . . . . . . . . . . . 74.7 Cg_exo -49.15 -40.24 42.05 Favored 'Trans proline' 0 C--N 1.349 0.596 0 C-N-CA 122.747 2.298 . . . . 0.0 113.137 -179.601 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 191' ' ' THR . . . . . . . . . . . . . 38.3 p -58.97 -44.52 91.53 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.795 0.331 . . . . 0.0 111.515 -179.621 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 192' ' ' VAL . . . . . . . . . . . . . 37.2 t -72.65 -46.12 55.5 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.266 -179.947 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 193' ' ' ASP . . . . . . . . . . . . . 32.6 t70 -55.1 -44.07 74.59 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.388 -0.369 . . . . 0.0 111.006 179.844 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 194' ' ' VAL . . . . . 0.514 HG21 HD11 ' A' ' 4' ' ' LEU . 79.8 t -68.64 -36.02 72.66 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.032 179.902 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 195' ' ' ALA . . . . . . . . . . . . . . . -59.12 -46.77 87.48 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-O 120.671 0.272 . . . . 0.0 110.977 179.734 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 196' ' ' LEU . . . . . . . . . . . . . 88.3 mt -67.83 -41.02 83.68 Favored 'General case' 0 C--N 1.332 -0.192 0 CA-C-O 120.841 0.353 . . . . 0.0 110.577 179.576 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 197' ' ' ILE . . . . . . . . . . . . . 17.6 mm -59.16 -58.41 7.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.011 -0.54 . . . . 0.0 110.225 179.203 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 198' ' ' VAL . . . . . 0.421 HG23 ' O ' ' A' ' 194' ' ' VAL . 75.7 t -52.53 -34.79 19.62 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.432 0 CA-C-N 115.633 -0.712 . . . . 0.0 109.199 178.226 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 199' ' ' TYR . . . . . . . . . . . . . 67.5 t80 -70.23 -33.39 71.6 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 115.227 -0.897 . . . . 0.0 110.811 179.965 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 200' ' ' LEU . . . . . 0.443 ' O ' HG12 ' A' ' 203' ' ' VAL . 36.5 mt -68.65 -40.78 80.08 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.039 -0.528 . . . . 0.0 111.375 -179.597 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 201' ' ' ASP . . . . . . . . . . . . . 8.1 m-20 -71.49 -31.64 67.34 Favored 'General case' 0 C--N 1.327 -0.413 0 CA-C-O 121.117 0.484 . . . . 0.0 110.038 179.447 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 202' ' ' LEU . . . . . . . . . . . . . 3.3 mt -71.01 -33.74 70.67 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 115.546 -0.752 . . . . 0.0 111.955 -179.671 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 203' ' ' VAL . . . . . 0.495 ' O ' ' HA3' ' A' ' 207' ' ' GLY . 7.8 p -77.1 -36.39 24.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 N-CA-C 111.593 0.22 . . . . 0.0 111.593 -178.743 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 204' ' ' THR . . . . . . . . . . . . . 57.5 m -70.58 -52.25 22.81 Favored 'General case' 0 C--N 1.327 -0.372 0 C-N-CA 120.682 -0.407 . . . . 0.0 111.6 179.735 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 205' ' ' LYS . . . . . 0.688 ' HE2' ' HB2' ' A' ' 47' ' ' ALA . 53.8 mttp -70.53 -59.12 3.02 Favored 'General case' 0 C--N 1.327 -0.385 0 N-CA-C 112.27 0.47 . . . . 0.0 112.27 -178.67 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 23.3 t -72.87 -37.82 55.4 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.357 0 CA-C-N 116.333 -0.394 . . . . 0.0 111.724 -178.814 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 207' ' ' GLY . . . . . 0.53 ' O ' HG12 ' A' ' 211' ' ' ILE . . . -62.71 -59.04 9.81 Favored Glycine 0 N--CA 1.452 -0.286 0 C-N-CA 120.353 -0.927 . . . . 0.0 112.429 -179.641 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 208' ' ' PHE . . . . . 0.473 ' O ' ' N ' ' A' ' 212' ' ' ALA . 2.2 m-30 -53.66 -49.95 66.85 Favored 'General case' 0 C--O 1.221 -0.4 0 CA-C-O 120.798 0.332 . . . . 0.0 110.112 179.992 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 209' ' ' GLY . . . . . 0.476 ' O ' ' HB3' ' A' ' 212' ' ' ALA . . . -54.19 -31.42 49.42 Favored Glycine 0 N--CA 1.449 -0.487 0 CA-C-N 115.444 -0.798 . . . . 0.0 112.456 178.927 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 210' ' ' PHE . . . . . . . . . . . . . 1.8 m-85 -72.41 -48.73 39.1 Favored 'General case' 0 C--N 1.328 -0.33 0 N-CA-C 108.764 -0.828 . . . . 0.0 108.764 178.755 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 211' ' ' ILE . . . . . 0.53 HG12 ' O ' ' A' ' 207' ' ' GLY . 0.6 OUTLIER -63.7 -27.21 42.43 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.297 0 N-CA-C 107.246 -1.39 . . . . 0.0 107.246 176.685 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 212' ' ' ALA . . . . . 0.476 ' HB3' ' O ' ' A' ' 209' ' ' GLY . . . -68.03 -43.66 78.24 Favored 'General case' 0 N--CA 1.448 -0.534 0 CA-C-N 114.044 -1.434 . . . . 0.0 110.764 -179.418 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 213' ' ' LEU . . . . . . . . . . . . . 71.5 mt -70.52 -54.98 10.05 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 115.191 -0.913 . . . . 0.0 112.112 -179.19 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 214' ' ' ASP . . . . . . . . . . . . . 29.4 t70 -54.96 -54.44 42.76 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.392 -0.367 . . . . 0.0 111.858 -179.099 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 215' ' ' ALA . . . . . . . . . . . . . . . -58.44 -57.16 14.14 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 116.312 -0.404 . . . . 0.0 111.898 -179.344 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 216' ' ' ALA . . . . . 0.413 ' HA ' HD12 ' A' ' 219' ' ' LEU . . . -57.57 -33.97 68.71 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.331 -0.395 . . . . 0.0 111.682 -179.367 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 217' ' ' ALA . . . . . . . . . . . . . . . -61.06 -41.58 96.88 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.953 0.406 . . . . 0.0 110.451 179.887 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 218' ' ' THR . . . . . . . . . . . . . 95.9 m -66.9 -34.6 78.13 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 115.829 -0.623 . . . . 0.0 110.896 179.737 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 219' ' ' LEU . . . . . 0.413 HD12 ' HA ' ' A' ' 216' ' ' ALA . 87.8 mt -60.83 -45.81 93.02 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.136 -0.483 . . . . 0.0 111.126 -179.871 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 220' ' ' ARG . . . . . . . . . . . . . 11.1 mpt_? -83.45 -20.09 34.7 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.305 -0.407 . . . . 0.0 111.248 -179.806 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 221' ' ' ALA . . . . . . . . . . . . . . . -77.35 -27.21 52.61 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.415 -0.357 . . . . 0.0 111.182 179.805 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 222' ' ' GLU . . . . . . . . . . . . . 9.3 pt-20 -92.22 -27.26 17.76 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.297 -0.411 . . . . 0.0 110.505 -179.667 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 223' ' ' HIS . . . . . . . . . . . . . 81.1 m-70 62.43 -179.31 0.13 Allowed 'General case' 0 C--N 1.331 -0.223 0 CA-C-N 115.647 -0.706 . . . . 0.0 111.346 179.956 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 224' ' ' GLY . . . . . . . . . . . . . . . 165.57 15.14 0.02 OUTLIER Glycine 0 N--CA 1.452 -0.269 0 C-N-CA 120.9 -0.666 . . . . 0.0 112.45 179.978 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 225' ' ' GLU . . . . . . . . . . . . . 44.0 tt0 -75.22 139.0 42.32 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.855 0.359 . . . . 0.0 111.131 -179.815 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 226' ' ' SER . . . . . . . . . . . . . 42.1 t -139.72 2.56 2.0 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.05 -0.523 . . . . 0.0 110.725 179.852 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 227' ' ' LEU . . . . . . . . . . . . . 74.8 mt -76.1 -42.92 45.65 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.553 179.737 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 228' ' ' ALA . . . . . . . . . . . . . . . 52.7 92.98 0.02 OUTLIER 'General case' 0 C--N 1.332 -0.173 0 CA-C-N 115.826 -0.625 . . . . 0.0 111.666 179.887 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 229' ' ' GLY . . . . . . . . . . . . . . . 148.78 84.92 0.05 OUTLIER Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.929 -0.653 . . . . 0.0 112.46 179.909 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 230' ' ' VAL . . . . . . . . . . . . . 23.9 m -125.35 140.59 47.85 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.247 0 CA-C-O 120.865 0.364 . . . . 0.0 111.291 -179.905 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 231' ' ' ASP . . . . . . . . . . . . . 4.5 p-10 -93.57 112.46 24.36 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.087 -0.506 . . . . 0.0 110.833 179.894 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 232' ' ' THR . . . . . . . . . . . . . 48.3 p -143.47 -55.94 0.39 Allowed 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.081 -0.509 . . . . 0.0 111.229 -179.951 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 233' ' ' ASP . . . . . . . . . . . . . 10.3 m-20 -71.76 121.35 18.76 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.043 -179.77 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 234' ' ' THR . . . . . . . . . . . . . 81.4 p -134.79 94.72 16.33 Favored Pre-proline 0 C--N 1.329 -0.287 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.924 179.701 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 235' ' ' PRO . . . . . . . . . . . . . 73.8 Cg_endo -75.81 8.49 2.7 Favored 'Trans proline' 0 C--N 1.348 0.505 0 C-N-CA 122.426 2.084 . . . . 0.0 112.576 -179.763 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 236' ' ' ALA . . . . . . . . . . . . . . . -86.23 167.94 14.39 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.372 -0.376 . . . . 0.0 111.171 -179.884 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 237' ' ' VAL . . . . . 0.447 ' O ' HG12 ' A' ' 237' ' ' VAL . 4.8 t -119.57 19.76 6.23 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-O 121.208 0.528 . . . . 0.0 110.573 179.984 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 238' ' ' ALA . . . . . . . . . . . . . . . 55.32 88.54 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 115.721 -0.672 . . . . 0.0 111.162 -179.899 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 239' ' ' ASP . . . . . . . . . . . . . 18.9 t70 -125.15 -28.92 3.35 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.183 -179.806 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 240' ' ' LEU . . . . . 0.409 HD12 ' N ' ' A' ' 240' ' ' LEU . 7.1 mp -64.53 -45.32 87.66 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.414 -0.357 . . . . 0.0 111.012 -179.896 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 241' ' ' GLU . . . . . . . . . . . . . 41.4 tt0 -104.32 129.86 52.18 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.27 -0.423 . . . . 0.0 111.146 -179.754 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 242' ' ' HIS . . . . . . . . . . . . . 46.3 t-80 -146.93 155.36 42.22 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.781 -179.91 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 243' ' ' HIS . . . . . . . . . . . . . 20.6 t60 -63.8 -52.4 60.44 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.406 -0.361 . . . . 0.0 111.076 -179.9 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 244' ' ' HIS . . . . . . . . . . . . . 58.4 t-80 59.14 95.1 0.03 OUTLIER 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.735 -179.784 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 245' ' ' HIS . . . . . . . . . . . . . 78.9 m80 -60.42 138.38 58.0 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.316 -179.683 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 246' ' ' HIS . . . . . . . . . . . . . 25.8 p80 -106.65 140.17 39.94 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 116.0 -0.546 . . . . 0.0 110.747 179.76 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 247' ' ' HIS . . . . . . . . . . . . . 30.6 t60 . . . . . 0 C--O 1.249 1.031 0 CA-C-O 118.278 -0.868 . . . . 0.0 110.847 -179.868 . . . . . . . . 0 0 . 1 . 017 nuclear build full ' A' A ' 301' ' ' RET . . . . . 0.721 H203 ' HE1' ' A' ' 171' ' ' TRP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 10.6 tpt . . . . . 0 N--CA 1.487 1.377 0 CA-C-O 120.71 0.291 . . . . 0.0 110.587 . . . . . . . . . 0 0 . 1 . 018 nuclear build full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 10.6 p -127.31 -25.68 1.37 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.395 -179.849 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -78.02 -1.58 79.91 Favored Glycine 0 N--CA 1.452 -0.28 0 C-N-CA 120.703 -0.76 . . . . 0.0 112.33 -179.997 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 49.8 tp -74.38 -35.54 63.49 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-O 120.778 0.323 . . . . 0.0 111.06 -179.974 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 69.1 p -61.06 -30.32 70.26 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.361 -179.751 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 28.0 p -54.56 -35.49 63.33 Favored 'General case' 0 C--N 1.331 -0.2 0 CA-C-N 116.278 -0.419 . . . . 0.0 111.248 -179.965 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 7' ' ' LEU . . . . . . . . . . . . . 4.0 mm? -56.65 -52.3 65.43 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 115.951 -0.568 . . . . 0.0 111.103 -179.903 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 8' ' ' PHE . . . . . 0.6 ' HB2' ' HB2' ' A' ' 55' ' ' ALA . 62.9 m-85 -64.47 -31.96 73.38 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.34 -0.391 . . . . 0.0 110.934 -179.989 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 9' ' ' TRP . . . . . 0.402 ' O ' HG12 ' A' ' 13' ' ' ILE . 35.3 m95 -65.61 -41.69 92.47 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.173 -179.92 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 56.1 mt -67.17 -32.43 73.51 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-N 115.761 -0.654 . . . . 0.0 109.962 179.377 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 11' ' ' GLY . . . . . 0.436 ' HA2' HD11 ' A' ' 202' ' ' LEU . . . -73.65 -27.72 66.74 Favored Glycine 0 N--CA 1.446 -0.67 0 CA-C-N 115.665 -0.698 . . . . 0.0 111.702 179.3 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -73.62 -33.91 64.78 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.834 0.35 . . . . 0.0 110.543 179.396 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 13' ' ' ILE . . . . . 0.439 ' O ' HG23 ' A' ' 17' ' ' VAL . 48.8 mm -68.22 -54.2 23.66 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.232 0 CA-C-N 116.002 -0.545 . . . . 0.0 110.397 179.423 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -59.18 -40.06 95.28 Favored Glycine 0 N--CA 1.45 -0.385 0 C-N-CA 120.635 -0.793 . . . . 0.0 111.48 179.221 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 15' ' ' MET . . . . . 0.516 ' SD ' ' HA ' ' A' ' 44' ' ' SER . 52.7 tpp -62.1 -43.6 98.49 Favored 'General case' 0 N--CA 1.453 -0.301 0 N-CA-C 109.99 -0.374 . . . . 0.0 109.99 179.295 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 45.4 tp -55.19 -38.18 68.02 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 115.746 -0.661 . . . . 0.0 110.222 179.184 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 17' ' ' VAL . . . . . 0.439 HG23 ' O ' ' A' ' 13' ' ' ILE . 44.2 t -62.13 -42.09 93.75 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.215 0 CA-C-N 115.891 -0.595 . . . . 0.0 109.971 179.243 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -66.26 -42.52 94.11 Favored Glycine 0 C--N 1.331 0.272 0 C-N-CA 120.69 -0.767 . . . . 0.0 111.58 178.928 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 7.9 m -52.09 -49.82 62.82 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.812 0.339 . . . . 0.0 111.074 179.945 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 20' ' ' LEU . . . . . 0.409 ' O ' ' HB3' ' A' ' 24' ' ' TRP . 95.0 mt -71.91 -35.6 69.73 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.435 179.926 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -62.21 -34.55 76.69 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.68 0.276 . . . . 0.0 111.648 -179.569 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 22' ' ' PHE . . . . . 0.543 ' HB2' HG22 ' A' ' 41' ' ' VAL . 11.0 m-85 -89.95 -30.33 17.89 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.478 -0.328 . . . . 0.0 111.434 -179.442 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -72.88 -50.03 26.31 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.479 -0.328 . . . . 0.0 111.228 -179.941 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 24' ' ' TRP . . . . . 0.409 ' HB3' ' O ' ' A' ' 20' ' ' LEU . 1.1 t-105 -60.66 -43.42 97.67 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.054 -0.521 . . . . 0.0 111.012 179.907 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -72.73 -25.03 61.06 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.334 -0.393 . . . . 0.0 110.907 179.927 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -74.03 -44.12 31.1 Favored Glycine 0 C--N 1.33 0.225 0 C-N-CA 121.008 -0.615 . . . . 0.0 112.469 179.695 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 85.6 mtm180 -65.89 -17.74 64.86 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.873 0.368 . . . . 0.0 110.629 179.976 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 18.4 t70 -91.82 -18.77 23.34 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.03 -0.532 . . . . 0.0 110.587 179.841 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -147.47 110.05 4.65 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.086 -0.506 . . . . 0.0 110.955 179.868 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -139.19 -122.84 2.03 Favored Glycine 0 N--CA 1.452 -0.271 0 C-N-CA 120.671 -0.776 . . . . 0.0 112.853 -179.765 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 47.9 t 62.49 -89.46 0.03 OUTLIER 'General case' 0 C--O 1.233 0.184 0 CA-C-O 120.625 0.25 . . . . 0.0 110.795 -179.566 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -93.32 -23.69 23.73 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.729 -0.748 . . . . 0.0 111.77 179.574 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 31.9 mm-40 -91.93 -20.16 21.7 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-O 120.792 0.33 . . . . 0.0 110.686 179.819 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 34' ' ' ARG . . . . . . . . . . . . . 55.4 ttp180 -47.95 -31.68 5.52 Favored 'General case' 0 C--N 1.332 -0.162 0 CA-C-N 115.974 -0.557 . . . . 0.0 111.385 -179.81 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 40.4 ttm180 -61.23 -49.46 77.02 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-O 120.856 0.36 . . . . 0.0 110.894 -179.943 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 75.9 m-85 -70.04 -37.47 75.59 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.025 -0.534 . . . . 0.0 111.568 -179.593 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 37' ' ' TYR . . . . . 0.539 ' O ' HG23 ' A' ' 41' ' ' VAL . 35.3 m-85 -65.74 -54.75 22.95 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.318 -0.401 . . . . 0.0 111.516 -179.396 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 90.6 t -56.7 -38.18 56.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-O 120.918 0.39 . . . . 0.0 110.667 179.894 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 17.4 m -61.68 -50.95 70.42 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 115.933 -0.576 . . . . 0.0 110.616 179.346 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 40' ' ' LEU . . . . . 0.56 HD12 HD12 ' A' ' 43' ' ' ILE . 40.2 tp -59.71 -50.52 73.52 Favored 'General case' 0 C--O 1.235 0.333 0 CA-C-N 115.745 -0.661 . . . . 0.0 110.831 179.894 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 41' ' ' VAL . . . . . 0.543 HG22 ' HB2' ' A' ' 22' ' ' PHE . 60.2 t -56.1 -34.3 38.53 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 115.834 -0.621 . . . . 0.0 110.294 179.26 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -60.94 -43.59 99.18 Favored Glycine 0 N--CA 1.45 -0.411 0 C-N-CA 120.739 -0.743 . . . . 0.0 111.826 179.597 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 43' ' ' ILE . . . . . 0.56 HD12 HD12 ' A' ' 40' ' ' LEU . 1.3 mt -58.55 -51.92 65.81 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.195 0 CA-C-O 120.792 0.329 . . . . 0.0 110.791 179.426 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 44' ' ' SER . . . . . 0.516 ' HA ' ' SD ' ' A' ' 15' ' ' MET . 44.7 m -59.66 -27.02 66.02 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.557 -179.772 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -73.79 -56.55 5.35 Favored Glycine 0 CA--C 1.519 0.33 0 C-N-CA 120.643 -0.789 . . . . 0.0 113.002 -179.588 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 24.3 pt -58.46 -35.45 54.41 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.214 0 CA-C-O 121.025 0.441 . . . . 0.0 111.295 -179.856 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 47' ' ' ALA . . . . . 0.74 ' HB2' ' HE2' ' A' ' 205' ' ' LYS . . . -66.98 -49.25 65.97 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.586 179.851 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -54.16 -44.39 71.42 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 115.983 -0.553 . . . . 0.0 111.962 -179.112 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 49' ' ' VAL . . . . . 0.406 ' O ' HG13 ' A' ' 53' ' ' VAL . 30.1 m -68.29 -34.24 64.99 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 C-N-CA 120.98 -0.288 . . . . 0.0 111.073 -179.731 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -67.54 -37.06 82.15 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-O 121.016 0.436 . . . . 0.0 110.939 179.264 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 38.7 m-85 -68.54 -38.76 81.11 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.028 -0.533 . . . . 0.0 110.214 -179.948 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -65.02 -50.71 65.19 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 115.804 -0.635 . . . . 0.0 111.088 179.592 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 53' ' ' VAL . . . . . 0.485 HG23 ' N ' ' A' ' 54' ' ' MET . 25.3 m -60.78 -47.9 91.16 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.109 0 CA-C-N 116.527 -0.306 . . . . 0.0 110.85 -179.939 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 54' ' ' MET . . . . . 0.514 ' HG2' ' HG2' ' A' ' 71' ' ' PRO . 74.3 mtm -62.42 -31.55 72.26 Favored 'General case' 0 C--N 1.331 -0.225 0 N-CA-C 109.607 -0.516 . . . . 0.0 109.607 179.068 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 55' ' ' ALA . . . . . 0.6 ' HB2' ' HB2' ' A' ' 8' ' ' PHE . . . -72.69 -22.49 60.9 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 115.527 -0.761 . . . . 0.0 110.981 179.583 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 81.0 mt -87.42 -5.52 58.81 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.118 179.996 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 90.15 -14.68 61.55 Favored Glycine 0 N--CA 1.45 -0.418 0 C-N-CA 120.622 -0.799 . . . . 0.0 112.911 179.765 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 58' ' ' VAL . . . . . 0.424 HG12 ' O ' ' A' ' 53' ' ' VAL . 9.0 p -69.5 141.64 17.01 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-O 120.85 0.357 . . . . 0.0 110.801 179.885 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 59' ' ' GLY . . . . . 0.411 ' HA3' ' HG3' ' A' ' 71' ' ' PRO . . . 92.39 -5.62 77.74 Favored Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.868 -0.682 . . . . 0.0 112.153 -179.268 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 60' ' ' TRP . . . . . . . . . . . . . 19.6 m0 -80.1 111.98 16.97 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-O 120.578 0.228 . . . . 0.0 110.785 179.919 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 61' ' ' VAL . . . . . 0.569 HG13 HG23 ' A' ' 68' ' ' VAL . 7.1 p -115.02 128.75 25.66 Favored Pre-proline 0 CA--C 1.533 0.315 0 CA-C-N 116.512 -0.313 . . . . 0.0 110.951 179.566 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 71.7 Cg_endo -76.39 156.0 36.76 Favored 'Trans proline' 0 C--N 1.35 0.629 0 C-N-CA 122.47 2.113 . . . . 0.0 112.725 -179.873 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 84.2 t -143.15 89.89 0.41 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 115.764 -0.653 . . . . 0.0 110.599 179.879 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . 58.71 -88.38 0.02 OUTLIER 'General case' 0 C--N 1.331 -0.196 0 CA-C-N 116.115 -0.493 . . . . 0.0 111.306 -179.756 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 45.5 mt-10 -120.5 -17.78 8.02 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 116.386 -0.37 . . . . 0.0 110.828 179.807 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 66' ' ' ARG . . . . . 0.468 ' HA ' ' HE ' ' A' ' 66' ' ' ARG . 3.0 mmp_? -100.29 163.5 12.37 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.25 179.672 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 85.3 m -125.83 133.91 51.82 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 121.023 0.439 . . . . 0.0 111.516 -179.673 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 68' ' ' VAL . . . . . 0.569 HG23 HG13 ' A' ' 61' ' ' VAL . 17.9 m -123.3 144.69 32.02 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-N 115.857 -0.611 . . . . 0.0 110.469 179.417 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 69' ' ' PHE . . . . . . . . . . . . . 19.4 m-85 -110.45 112.21 23.98 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.359 -0.382 . . . . 0.0 110.109 -179.217 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 70' ' ' VAL . . . . . 0.63 ' N ' ' HD2' ' A' ' 71' ' ' PRO . 28.3 t -66.02 -47.49 62.83 Favored Pre-proline 0 C--N 1.323 -0.553 0 CA-C-N 116.234 -0.439 . . . . 0.0 112.01 -179.362 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 71' ' ' PRO . . . . . 0.63 ' HD2' ' N ' ' A' ' 70' ' ' VAL . 13.9 Cg_endo -57.15 -22.22 46.9 Favored 'Trans proline' 0 C--N 1.351 0.709 0 C-N-CA 121.982 1.788 . . . . 0.0 111.773 179.518 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 60.7 ttp180 -75.91 -53.3 8.63 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.585 179.694 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 73' ' ' TYR . . . . . . . . . . . . . 69.3 m-85 -64.6 -45.76 85.56 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 115.967 -0.56 . . . . 0.0 110.709 179.912 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 0.4 OUTLIER -60.86 -36.56 72.46 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 N-CA-C 109.807 -0.442 . . . . 0.0 109.807 179.362 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 75' ' ' ASP . . . . . 0.415 ' O ' HG23 ' A' ' 79' ' ' THR . 24.3 t70 -60.38 -37.97 82.44 Favored 'General case' 0 C--N 1.331 -0.209 0 N-CA-C 109.466 -0.568 . . . . 0.0 109.466 178.918 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 76' ' ' TRP . . . . . . . . . . . . . 47.4 m0 -67.08 -29.2 68.9 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 115.717 -0.674 . . . . 0.0 110.289 179.452 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 77' ' ' ILE . . . . . 0.426 ' O ' ' HG2' ' A' ' 81' ' ' PRO . 73.7 mt -72.4 -30.42 34.77 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.373 0 CA-C-N 115.838 -0.619 . . . . 0.0 110.626 179.395 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 40.2 mt -91.88 -16.69 26.33 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.209 -0.451 . . . . 0.0 111.989 -179.954 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 79' ' ' THR . . . . . 0.415 HG23 ' O ' ' A' ' 75' ' ' ASP . 76.7 p -101.97 -49.02 4.06 Favored 'General case' 0 N--CA 1.464 0.262 0 N-CA-C 113.465 0.913 . . . . 0.0 113.465 -178.27 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 80' ' ' THR . . . . . 0.679 ' HB ' ' HD3' ' A' ' 81' ' ' PRO . 44.2 m -53.11 -54.46 44.2 Favored Pre-proline 0 CA--C 1.531 0.22 0 N-CA-C 112.226 0.454 . . . . 0.0 112.226 -178.338 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 81' ' ' PRO . . . . . 0.679 ' HD3' ' HB ' ' A' ' 80' ' ' THR . 34.2 Cg_exo -61.12 -19.72 64.64 Favored 'Trans proline' 0 C--N 1.352 0.735 0 C-N-CA 121.552 1.502 . . . . 0.0 111.28 179.578 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 82' ' ' LEU . . . . . . . . . . . . . 13.1 tp -76.89 -36.56 56.61 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 115.66 -0.7 . . . . 0.0 110.558 179.909 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 35.2 mm -68.02 -52.54 37.83 Favored 'Isoleucine or valine' 0 C--O 1.233 0.235 0 CA-C-N 116.308 -0.405 . . . . 0.0 110.08 179.251 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 30.9 m -59.58 -32.74 49.78 Favored 'Isoleucine or valine' 0 CA--C 1.52 -0.195 0 N-CA-C 109.482 -0.562 . . . . 0.0 109.482 178.796 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 85' ' ' TYR . . . . . . . . . . . . . 89.5 t80 -62.65 -34.63 77.46 Favored 'General case' 0 N--CA 1.454 -0.258 0 CA-C-N 115.528 -0.76 . . . . 0.0 109.163 178.595 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 86' ' ' PHE . . . . . . . . . . . . . 11.3 t80 -61.36 -51.72 67.65 Favored 'General case' 0 N--CA 1.456 -0.126 0 CA-C-N 115.561 -0.745 . . . . 0.0 109.879 179.201 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 7.6 mp -58.6 -36.43 74.0 Favored 'General case' 0 C--N 1.331 -0.202 0 CA-C-N 115.89 -0.595 . . . . 0.0 110.194 179.426 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 88' ' ' GLY . . . . . 0.475 ' HA2' HD13 ' A' ' 93' ' ' LEU . . . -64.93 -28.1 73.04 Favored Glycine 0 N--CA 1.45 -0.399 0 C-N-CA 120.916 -0.659 . . . . 0.0 112.165 179.575 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 86.5 mt -74.08 -41.25 61.97 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.902 0.382 . . . . 0.0 110.741 179.732 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 74.8 mt -58.73 -47.56 84.19 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 115.913 -0.585 . . . . 0.0 111.158 -179.756 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -74.77 -42.44 58.17 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.376 -0.375 . . . . 0.0 111.149 -179.875 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 93.06 55.96 1.54 Allowed Glycine 0 N--CA 1.45 -0.422 0 C-N-CA 120.832 -0.699 . . . . 0.0 112.466 -179.945 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 93' ' ' LEU . . . . . 0.565 HD23 ' HB3' ' A' ' 97' ' ' GLU . 9.7 mp -67.71 -176.4 0.64 Allowed 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.809 0.338 . . . . 0.0 110.908 -179.943 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 94' ' ' ASP . . . . . . . . . . . . . 10.4 m-20 -113.47 172.97 6.64 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.472 -179.929 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 45.4 t -54.03 -36.27 62.85 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.312 -0.404 . . . . 0.0 111.372 -179.759 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 96' ' ' ARG . . . . . 0.402 ' O ' HG13 ' A' ' 100' ' ' ILE . 29.3 mmm180 -73.98 -47.88 34.21 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 116.279 -0.419 . . . . 0.0 111.457 -179.85 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 97' ' ' GLU . . . . . 0.565 ' HB3' HD23 ' A' ' 93' ' ' LEU . 47.6 mt-10 -60.19 -44.59 94.96 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-O 120.912 0.387 . . . . 0.0 110.584 -179.387 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 98' ' ' PHE . . . . . 0.448 ' O ' HG12 ' A' ' 102' ' ' ILE . 12.8 m-85 -59.91 -47.95 83.66 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 115.869 -0.605 . . . . 0.0 110.514 179.325 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -55.22 -32.02 56.86 Favored Glycine 0 N--CA 1.452 -0.276 0 C-N-CA 120.799 -0.715 . . . . 0.0 112.697 179.922 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 100' ' ' ILE . . . . . 0.451 ' O ' HG22 ' A' ' 103' ' ' THR . 89.5 mt -69.51 -54.0 21.91 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.222 0 CA-C-O 120.956 0.408 . . . . 0.0 111.676 -179.894 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 17.2 t -64.7 -42.79 96.0 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.355 0 CA-C-N 116.136 -0.484 . . . . 0.0 111.933 -179.203 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 102' ' ' ILE . . . . . 0.448 HG12 ' O ' ' A' ' 98' ' ' PHE . 48.8 mm -63.67 -53.13 48.69 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-N 116.326 -0.397 . . . . 0.0 111.698 -179.325 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 103' ' ' THR . . . . . 0.451 HG22 ' O ' ' A' ' 100' ' ' ILE . 12.8 t -55.03 -35.38 64.39 Favored 'General case' 0 C--O 1.234 0.244 0 CA-C-O 120.869 0.366 . . . . 0.0 110.726 -179.909 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 104' ' ' LEU . . . . . 0.48 HD22 ' HE2' ' A' ' 140' ' ' TYR . 29.3 tp -61.08 -49.45 77.26 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.296 179.216 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 105' ' ' ASN . . . . . 0.58 ' N ' HD22 ' A' ' 105' ' ' ASN . 0.8 OUTLIER -59.1 -26.36 64.62 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.054 -0.521 . . . . 0.0 110.562 179.808 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 33.2 m -66.47 -54.16 27.22 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.276 -0.42 . . . . 0.0 111.158 179.697 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 12.8 p -66.25 -36.29 77.04 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.152 0 CA-C-N 116.486 -0.325 . . . . 0.0 111.356 -179.834 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 108' ' ' VAL . . . . . 0.412 HG23 ' O ' ' A' ' 104' ' ' LEU . 73.7 t -62.62 -56.86 14.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-O 120.885 0.374 . . . . 0.0 111.104 -179.949 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 109' ' ' MET . . . . . 0.442 ' HE1' HG21 ' A' ' 80' ' ' THR . 7.1 tpp -60.48 -31.66 70.67 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.451 179.998 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 110' ' ' LEU . . . . . 0.491 HD23 ' C ' ' A' ' 110' ' ' LEU . 5.0 tt -64.19 -37.86 88.97 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-N 115.81 -0.632 . . . . 0.0 109.595 178.714 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -60.78 -50.58 72.86 Favored 'General case' 0 C--N 1.333 -0.137 0 CA-C-N 115.883 -0.598 . . . . 0.0 110.827 179.671 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . -59.38 -45.91 94.72 Favored Glycine 0 C--N 1.331 0.263 0 C-N-CA 120.687 -0.768 . . . . 0.0 112.074 179.645 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 113' ' ' PHE . . . . . . . . . . . . . 3.0 t80 -49.73 -65.66 0.53 Allowed 'General case' 0 C--N 1.333 -0.128 0 CA-C-O 120.91 0.386 . . . . 0.0 110.382 179.696 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -64.79 -17.77 64.5 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 115.901 -0.59 . . . . 0.0 110.952 179.927 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 115' ' ' GLY . . . . . 0.506 ' O ' HG22 ' A' ' 118' ' ' VAL . . . -57.24 -52.32 52.2 Favored Glycine 0 N--CA 1.45 -0.385 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.045 179.579 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -78.32 -15.06 59.11 Favored 'General case' 0 C--N 1.328 -0.351 0 N-CA-C 111.984 0.364 . . . . 0.0 111.984 179.904 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 117' ' ' MET . . . . . 0.501 ' SD ' HG21 ' A' ' 68' ' ' VAL . 26.0 mmt -80.88 19.86 0.82 Allowed 'General case' 0 N--CA 1.464 0.259 0 N-CA-C 112.182 0.438 . . . . 0.0 112.182 -178.985 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 118' ' ' VAL . . . . . 0.524 HG21 ' N ' ' A' ' 123' ' ' ARG . 17.6 m -113.24 157.74 40.16 Favored Pre-proline 0 C--N 1.328 -0.343 0 CA-C-N 116.756 -0.202 . . . . 0.0 111.208 179.819 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 119' ' ' PRO . . . . . 0.435 ' HD2' ' HB ' ' A' ' 118' ' ' VAL . 69.2 Cg_endo -73.96 -24.44 15.17 Favored 'Trans proline' 0 C--N 1.347 0.493 0 C-N-CA 122.414 2.076 . . . . 0.0 112.382 179.667 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . 152.56 151.86 5.8 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.831 179.935 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 18.9 mm 73.73 -46.94 0.17 Allowed 'Isoleucine or valine' 0 N--CA 1.466 0.334 0 C-N-CA 122.956 0.503 . . . . 0.0 111.715 -179.821 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 14.3 mm-40 -60.17 -28.25 67.78 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.103 180.0 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 123' ' ' ARG . . . . . 0.564 ' HD3' ' HA2' ' A' ' 184' ' ' GLY . 6.5 ptp180 -60.23 -29.49 68.8 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.012 -0.54 . . . . 0.0 111.03 179.896 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 124' ' ' TYR . . . . . . . . . . . . . 30.2 m-85 -69.24 -32.15 71.18 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 115.84 -0.618 . . . . 0.0 111.349 -179.707 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 125' ' ' ALA . . . . . . . . . . . . . . . -73.32 -56.41 5.11 Favored 'General case' 0 C--O 1.236 0.364 0 CA-C-O 121.05 0.452 . . . . 0.0 111.03 179.961 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 1.4 mt -56.04 -50.47 70.84 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.814 -0.63 . . . . 0.0 110.719 -179.926 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 127' ' ' PHE . . . . . 0.429 ' HZ ' ' HB3' ' A' ' 175' ' ' PRO . 9.4 t80 -65.69 -36.19 82.93 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.378 -0.374 . . . . 0.0 110.229 179.459 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 128' ' ' GLY . . . . . . . . . . . . . . . -46.29 -44.54 15.36 Favored Glycine 0 C--N 1.332 0.347 0 C-N-CA 120.171 -1.014 . . . . 0.0 110.822 178.925 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 129' ' ' MET . . . . . . . . . . . . . 0.5 OUTLIER -71.83 -36.47 70.2 Favored 'General case' 0 N--CA 1.453 -0.315 0 N-CA-C 109.833 -0.432 . . . . 0.0 109.833 178.663 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -63.13 -33.08 86.27 Favored Glycine 0 C--N 1.333 0.364 0 CA-C-N 115.794 -0.639 . . . . 0.0 112.867 -179.756 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -74.11 -53.87 9.0 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.681 0.277 . . . . 0.0 110.454 -179.99 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 44.2 t -56.91 -39.94 68.54 Favored 'Isoleucine or valine' 0 C--O 1.234 0.26 0 N-CA-C 109.344 -0.613 . . . . 0.0 109.344 178.764 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -67.4 -36.46 81.33 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 115.305 -0.862 . . . . 0.0 110.167 178.986 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 134' ' ' PHE . . . . . . . . . . . . . 84.7 t80 -56.6 -50.63 71.41 Favored 'General case' 0 N--CA 1.452 -0.335 0 CA-C-N 116.126 -0.488 . . . . 0.0 109.81 179.394 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 135' ' ' ILE . . . . . 0.485 ' O ' HG22 ' A' ' 138' ' ' VAL . 52.8 mt -59.28 -33.53 51.2 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.38 0 CA-C-N 115.67 -0.695 . . . . 0.0 110.207 179.204 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . -63.02 -41.09 99.95 Favored Glycine 0 N--CA 1.448 -0.548 0 C-N-CA 120.209 -0.996 . . . . 0.0 111.292 178.87 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 137' ' ' LEU . . . . . 0.478 HD13 HD21 ' A' ' 105' ' ' ASN . 57.9 tp -67.11 -53.94 26.07 Favored 'General case' 0 N--CA 1.454 -0.269 0 CA-C-O 120.499 0.19 . . . . 0.0 110.889 179.733 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 138' ' ' VAL . . . . . 0.485 HG22 ' O ' ' A' ' 135' ' ' ILE . 4.9 m -54.48 -33.84 27.43 Favored 'Isoleucine or valine' 0 C--O 1.233 0.205 0 CA-C-O 121.09 0.471 . . . . 0.0 109.746 -179.696 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 139' ' ' TYR . . . . . . . . . . . . . 24.2 t80 -59.8 -42.96 94.57 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 115.621 -0.718 . . . . 0.0 109.864 178.299 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 140' ' ' TYR . . . . . 0.48 ' HE2' HD22 ' A' ' 104' ' ' LEU . 25.8 m-85 -65.19 -45.74 83.59 Favored 'General case' 0 C--N 1.333 -0.142 0 CA-C-N 116.083 -0.508 . . . . 0.0 111.13 179.38 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 141' ' ' LEU . . . . . . . . . . . . . 10.6 mp -54.48 -32.65 58.2 Favored 'General case' 0 C--N 1.332 -0.171 0 CA-C-N 116.283 -0.417 . . . . 0.0 111.178 -179.745 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 142' ' ' VAL . . . . . 0.417 HG22 ' O ' ' A' ' 142' ' ' VAL . 11.1 p -106.84 -2.41 9.98 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-N 116.233 -0.44 . . . . 0.0 111.121 -179.812 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . -75.61 -120.61 0.13 Allowed Glycine 0 CA--C 1.522 0.469 0 C-N-CA 120.829 -0.701 . . . . 0.0 112.68 -179.848 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 144' ' ' PRO . . . . . . . . . . . . . 56.1 Cg_endo -69.64 -23.65 31.09 Favored 'Trans proline' 0 C--N 1.348 0.54 0 C-N-CA 122.489 2.126 . . . . 0.0 112.433 179.923 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 145' ' ' MET . . . . . 0.433 ' HB3' ' OH ' ' A' ' 160' ' ' TYR . 48.8 mtt -53.62 -58.85 5.7 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.103 -0.499 . . . . 0.0 111.84 -179.712 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 146' ' ' THR . . . . . . . . . . . . . 9.0 t -56.03 -32.45 64.04 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.327 -0.397 . . . . 0.0 111.888 -179.118 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 43.0 mt-10 -70.41 -41.16 73.31 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.645 -0.252 . . . . 0.0 111.329 -179.735 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 148' ' ' SER . . . . . . . . . . . . . 67.4 m -69.74 -41.81 74.76 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.432 -0.349 . . . . 0.0 111.304 -179.329 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 149' ' ' ALA . . . . . . . . . . . . . . . -70.23 -37.54 75.0 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.255 -0.429 . . . . 0.0 111.444 -179.656 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 150' ' ' SER . . . . . . . . . . . . . 75.8 m -68.2 -4.12 12.93 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.381 -0.372 . . . . 0.0 111.057 179.98 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 151' ' ' GLN . . . . . . . . . . . . . 50.4 mt-30 -117.66 4.29 12.33 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.333 -0.394 . . . . 0.0 111.043 179.876 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 7.9 tpm_? -83.81 -51.81 6.9 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 120.971 0.415 . . . . 0.0 110.617 179.863 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 153' ' ' SER . . . . . 0.565 ' HB2' HG12 ' A' ' 156' ' ' ILE . 35.3 m -157.65 172.9 17.69 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 115.768 -0.651 . . . . 0.0 110.544 179.612 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 154' ' ' SER . . . . . . . . . . . . . 66.4 p -71.86 -37.92 70.14 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-O 120.828 0.347 . . . . 0.0 110.433 179.432 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -76.63 -34.71 43.23 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 121.001 -0.619 . . . . 0.0 112.646 179.848 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 156' ' ' ILE . . . . . 0.565 HG12 ' HB2' ' A' ' 153' ' ' SER . 34.2 mm -59.52 -36.76 66.59 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-O 120.84 0.353 . . . . 0.0 111.167 179.958 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 157' ' ' LYS . . . . . . . . . . . . . 86.4 tttt -61.23 -54.99 37.25 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 116.078 -0.51 . . . . 0.0 111.524 -179.713 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 49.0 m -66.39 -38.99 88.76 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.964 -179.152 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 159' ' ' LEU . . . . . . . . . . . . . 6.4 tt -68.55 -37.05 79.6 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.725 -0.216 . . . . 0.0 111.546 -179.119 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 160' ' ' TYR . . . . . 0.433 ' OH ' ' HB3' ' A' ' 145' ' ' MET . 37.7 t80 -74.09 -47.43 36.53 Favored 'General case' 0 C--N 1.33 -0.265 0 N-CA-C 111.807 0.299 . . . . 0.0 111.807 -179.087 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 27.9 m -57.21 -41.73 78.57 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-O 120.674 0.273 . . . . 0.0 111.453 -179.332 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 162' ' ' ARG . . . . . 0.405 ' O ' HD23 ' A' ' 166' ' ' LEU . 32.5 tpt180 -68.96 -43.92 74.01 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-O 120.867 0.365 . . . . 0.0 111.204 -179.913 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 163' ' ' LEU . . . . . 0.496 ' HG ' ' HB2' ' A' ' 208' ' ' PHE . 3.9 mp -62.41 -47.41 84.22 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 115.917 -0.583 . . . . 0.0 111.973 -179.247 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 164' ' ' ARG . . . . . 0.462 ' HG3' ' N ' ' A' ' 165' ' ' ASN . 4.5 ptt180 -67.64 -40.86 84.55 Favored 'General case' 0 C--N 1.329 -0.288 0 N-CA-C 111.829 0.307 . . . . 0.0 111.829 -178.926 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 165' ' ' ASN . . . . . 0.501 ' O ' HG23 ' A' ' 169' ' ' VAL . 5.5 m-20 -58.77 -52.07 67.28 Favored 'General case' 0 C--N 1.327 -0.372 0 N-CA-C 111.946 0.35 . . . . 0.0 111.946 -179.231 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 166' ' ' LEU . . . . . 0.405 HD23 ' O ' ' A' ' 162' ' ' ARG . 3.0 pp -68.22 -44.29 76.09 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.707 0.289 . . . . 0.0 111.455 -179.485 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 167' ' ' THR . . . . . . . . . . . . . 71.5 m -58.48 -50.87 72.18 Favored 'General case' 0 C--N 1.331 -0.218 0 N-CA-C 112.198 0.444 . . . . 0.0 112.198 -179.402 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 168' ' ' VAL . . . . . 0.409 HG13 ' N ' ' A' ' 169' ' ' VAL . 9.2 p -61.7 -41.12 89.22 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 N-CA-C 111.713 0.264 . . . . 0.0 111.713 -179.014 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 169' ' ' VAL . . . . . 0.501 HG23 ' O ' ' A' ' 165' ' ' ASN . 55.1 t -60.98 -59.41 4.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-O 120.769 0.318 . . . . 0.0 111.175 -179.883 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 170' ' ' LEU . . . . . 0.577 HD22 HG12 ' A' ' 203' ' ' VAL . 3.9 pp -61.86 -31.63 71.91 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.358 -0.383 . . . . 0.0 110.982 -179.455 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 171' ' ' TRP . . . . . 0.925 ' HE1' H203 ' A' ' 301' ' ' RET . 3.4 m0 -72.07 -32.08 66.71 Favored 'General case' 0 N--CA 1.463 0.205 0 CA-C-O 120.89 0.376 . . . . 0.0 110.095 178.952 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 172' ' ' ALA . . . . . . . . . . . . . . . -69.07 -7.17 33.37 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 115.982 -0.554 . . . . 0.0 110.692 179.646 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 173' ' ' ILE . . . . . 0.494 ' O ' HG12 ' A' ' 177' ' ' ILE . 29.2 mm -88.19 -26.65 5.65 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.263 0 CA-C-N 115.939 -0.573 . . . . 0.0 110.919 179.794 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 174' ' ' TYR . . . . . 0.465 ' HB2' ' HD3' ' A' ' 175' ' ' PRO . 34.4 m-85 -53.77 -48.81 92.25 Favored Pre-proline 0 C--N 1.332 -0.163 0 CA-C-N 116.311 -0.404 . . . . 0.0 111.574 -179.737 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 175' ' ' PRO . . . . . 0.465 ' HD3' ' HB2' ' A' ' 174' ' ' TYR . 84.8 Cg_exo -47.93 -32.39 17.69 Favored 'Trans proline' 0 C--N 1.352 0.722 0 C-N-CA 122.007 1.805 . . . . 0.0 112.199 179.558 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 176' ' ' PHE . . . . . 0.439 ' O ' ' HG ' ' A' ' 180' ' ' LEU . 81.5 m-85 -80.76 -50.59 9.67 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.059 -0.519 . . . . 0.0 111.803 -179.931 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 177' ' ' ILE . . . . . 0.494 HG12 ' O ' ' A' ' 173' ' ' ILE . 6.8 mm -62.07 -30.86 49.64 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.585 0 CA-C-N 116.104 -0.498 . . . . 0.0 112.022 -178.338 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 178' ' ' TRP . . . . . 0.435 ' HH2' ' HB2' ' A' ' 123' ' ' ARG . 73.9 t90 -73.6 -47.42 40.48 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-O 120.854 0.359 . . . . 0.0 110.662 179.714 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 179' ' ' LEU . . . . . 0.56 HD23 HD23 ' A' ' 180' ' ' LEU . 0.7 OUTLIER -70.96 -54.61 10.69 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 115.97 -0.559 . . . . 0.0 111.409 -179.287 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 180' ' ' LEU . . . . . 0.56 HD23 HD23 ' A' ' 179' ' ' LEU . 24.8 mt -64.78 -38.02 89.58 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.556 -0.293 . . . . 0.0 111.151 -179.779 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . -61.73 178.46 4.43 Favored Glycine 0 C--N 1.334 0.453 0 C-N-CA 120.086 -1.054 . . . . 0.0 112.231 179.185 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 182' ' ' PRO . . . . . 0.525 ' HA ' ' HB2' ' A' ' 186' ' ' ALA . 75.2 Cg_exo -48.02 -45.33 25.45 Favored 'Trans proline' 0 CA--C 1.534 0.507 0 C-N-CA 122.827 2.351 . . . . 0.0 113.613 179.856 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 183' ' ' PRO . . . . . 0.416 ' HD3' ' HB2' ' A' ' 182' ' ' PRO . 82.4 Cg_exo -46.65 -29.84 8.21 Favored 'Trans proline' 0 C--N 1.356 0.954 0 C-N-CA 122.14 1.894 . . . . 0.0 113.232 -179.788 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 184' ' ' GLY . . . . . 0.564 ' HA2' ' HD3' ' A' ' 123' ' ' ARG . . . -115.81 -128.19 4.28 Favored Glycine 0 N--CA 1.449 -0.453 0 C-N-CA 120.249 -0.977 . . . . 0.0 113.129 -179.663 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 185' ' ' VAL . . . . . . . . . . . . . 13.0 m -58.13 -27.33 31.65 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 N-CA-C 112.18 0.437 . . . . 0.0 112.18 -179.429 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 186' ' ' ALA . . . . . 0.525 ' HB2' ' HA ' ' A' ' 182' ' ' PRO . . . 59.34 82.25 0.15 Allowed 'General case' 0 C--N 1.33 -0.251 0 N-CA-C 111.983 0.364 . . . . 0.0 111.983 179.445 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 187' ' ' LEU . . . . . 0.56 ' HB2' HD12 ' A' ' 188' ' ' LEU . 8.6 mt -92.47 -49.59 6.05 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-O 121.039 0.447 . . . . 0.0 110.721 179.381 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 188' ' ' LEU . . . . . 0.56 HD12 ' HB2' ' A' ' 187' ' ' LEU . 6.9 mp -87.4 -166.38 1.56 Allowed 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 115.696 -0.684 . . . . 0.0 111.489 -179.233 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 189' ' ' THR . . . . . . . . . . . . . 10.2 m -94.39 137.43 22.71 Favored Pre-proline 0 C--N 1.33 -0.265 0 CA-C-N 115.743 -0.662 . . . . 0.0 110.498 -179.94 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 190' ' ' PRO . . . . . 0.473 ' O ' HG23 ' A' ' 194' ' ' VAL . 87.6 Cg_exo -44.31 -47.01 11.2 Favored 'Trans proline' 0 C--N 1.35 0.612 0 C-N-CA 122.661 2.241 . . . . 0.0 113.097 -179.859 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 191' ' ' THR . . . . . . . . . . . . . 6.8 t -59.27 -39.47 83.02 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 120.817 0.342 . . . . 0.0 111.28 -179.906 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 192' ' ' VAL . . . . . . . . . . . . . 58.8 t -70.58 -45.42 74.44 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.262 -0.426 . . . . 0.0 111.171 -179.952 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 193' ' ' ASP . . . . . . . . . . . . . 30.5 t70 -57.54 -43.85 84.7 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.294 -0.412 . . . . 0.0 110.678 179.937 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 194' ' ' VAL . . . . . 0.473 HG23 ' O ' ' A' ' 190' ' ' PRO . 98.1 t -64.28 -35.72 74.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 115.944 -0.571 . . . . 0.0 110.559 179.743 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 195' ' ' ALA . . . . . . . . . . . . . . . -59.19 -47.87 83.72 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 120.824 0.345 . . . . 0.0 110.793 179.551 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 196' ' ' LEU . . . . . . . . . . . . . 61.3 mt -67.83 -40.73 83.71 Favored 'General case' 0 C--N 1.332 -0.172 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.705 179.681 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 197' ' ' ILE . . . . . . . . . . . . . 14.3 mm -59.98 -58.18 8.37 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.239 0 CA-C-N 116.041 -0.527 . . . . 0.0 110.348 179.436 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 198' ' ' VAL . . . . . . . . . . . . . 64.1 t -52.28 -34.21 18.05 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.515 0 CA-C-N 115.599 -0.728 . . . . 0.0 109.311 178.469 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 199' ' ' TYR . . . . . 0.479 ' O ' HG23 ' A' ' 203' ' ' VAL . 64.9 t80 -69.32 -41.16 77.08 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 115.378 -0.828 . . . . 0.0 110.401 179.83 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 200' ' ' LEU . . . . . 0.438 HD11 HG13 ' A' ' 177' ' ' ILE . 31.4 mt -59.03 -54.81 42.91 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 115.563 -0.744 . . . . 0.0 111.524 -179.521 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 201' ' ' ASP . . . . . . . . . . . . . 10.7 m-20 -60.23 -38.64 84.04 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.322 -0.399 . . . . 0.0 110.888 -179.853 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 202' ' ' LEU . . . . . 0.436 HD11 ' HA2' ' A' ' 11' ' ' GLY . 2.0 mt -66.81 -28.43 68.37 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 115.868 -0.606 . . . . 0.0 111.409 -179.637 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 203' ' ' VAL . . . . . 0.577 HG12 HD22 ' A' ' 170' ' ' LEU . 41.3 t -79.47 -36.37 17.72 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.439 -0.346 . . . . 0.0 110.841 -179.055 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 204' ' ' THR . . . . . 0.434 ' O ' ' CD1' ' A' ' 208' ' ' PHE . 27.7 m -63.46 -58.32 7.43 Favored 'General case' 0 C--N 1.324 -0.512 0 C-N-CA 120.575 -0.45 . . . . 0.0 110.928 179.768 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 205' ' ' LYS . . . . . 0.74 ' HE2' ' HB2' ' A' ' 47' ' ' ALA . 44.2 mttp -66.32 -58.57 5.04 Favored 'General case' 0 C--N 1.331 -0.229 0 N-CA-C 112.624 0.602 . . . . 0.0 112.624 -178.254 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 43.8 t -70.83 -36.68 65.46 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.374 0 N-CA-C 112.182 0.438 . . . . 0.0 112.182 -178.444 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 207' ' ' GLY . . . . . 0.518 ' O ' HG13 ' A' ' 211' ' ' ILE . . . -61.54 -60.38 8.3 Favored Glycine 0 N--CA 1.452 -0.234 0 C-N-CA 120.58 -0.819 . . . . 0.0 113.598 -178.561 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 208' ' ' PHE . . . . . 0.496 ' HB2' ' HG ' ' A' ' 163' ' ' LEU . 0.1 OUTLIER -70.83 -26.66 63.38 Favored 'General case' 0 N--CA 1.464 0.249 0 CA-C-N 117.14 0.47 . . . . 0.0 111.515 -178.9 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 209' ' ' GLY . . . . . 0.508 ' O ' ' HB3' ' A' ' 212' ' ' ALA . . . -68.29 -32.65 76.24 Favored Glycine 0 N--CA 1.449 -0.49 0 N-CA-C 111.81 -0.516 . . . . 0.0 111.81 179.084 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 210' ' ' PHE . . . . . . . . . . . . . 0.8 OUTLIER -71.62 -48.47 47.74 Favored 'General case' 0 CA--C 1.512 -0.494 0 N-CA-C 108.053 -1.092 . . . . 0.0 108.053 178.491 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 211' ' ' ILE . . . . . 0.518 HG13 ' O ' ' A' ' 207' ' ' GLY . 4.9 mt -63.61 -27.75 43.58 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.544 0 N-CA-C 107.645 -1.243 . . . . 0.0 107.645 176.65 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 212' ' ' ALA . . . . . 0.508 ' HB3' ' O ' ' A' ' 209' ' ' GLY . . . -64.42 -40.97 96.79 Favored 'General case' 0 N--CA 1.45 -0.463 0 CA-C-N 114.583 -1.19 . . . . 0.0 110.5 179.793 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 213' ' ' LEU . . . . . . . . . . . . . 91.5 mt -70.52 -55.07 9.78 Favored 'General case' 0 N--CA 1.461 0.105 0 CA-C-N 115.489 -0.778 . . . . 0.0 111.748 -179.671 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 214' ' ' ASP . . . . . . . . . . . . . 25.1 m-20 -53.98 -49.92 67.73 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.28 -0.418 . . . . 0.0 111.648 -179.273 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 215' ' ' ALA . . . . . 0.45 ' O ' ' HG ' ' A' ' 219' ' ' LEU . . . -59.8 -57.51 12.6 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.372 -0.376 . . . . 0.0 111.48 -179.633 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 216' ' ' ALA . . . . . . . . . . . . . . . -57.66 -35.31 70.38 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.31 -0.405 . . . . 0.0 111.421 -179.703 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 217' ' ' ALA . . . . . . . . . . . . . . . -63.67 -31.75 73.02 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 121.001 0.429 . . . . 0.0 110.424 179.831 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 218' ' ' THR . . . . . . . . . . . . . 93.8 m -77.15 -46.46 23.34 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 115.759 -0.655 . . . . 0.0 110.79 179.532 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 219' ' ' LEU . . . . . 0.45 ' HG ' ' O ' ' A' ' 215' ' ' ALA . 20.4 mt -63.65 -27.72 69.42 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.585 179.753 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 220' ' ' ARG . . . . . 0.402 HH11 ' HD2' ' A' ' 220' ' ' ARG . 10.0 ttp180 -82.95 -34.24 26.53 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 115.868 -0.606 . . . . 0.0 110.708 179.887 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 221' ' ' ALA . . . . . . . . . . . . . . . -62.13 -41.43 98.24 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-N 115.975 -0.557 . . . . 0.0 111.125 -179.939 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 222' ' ' GLU . . . . . . . . . . . . . 10.7 pt-20 -85.62 -38.25 18.61 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.716 -179.922 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 223' ' ' HIS . . . . . . . . . . . . . 35.1 p80 40.06 31.06 0.08 Allowed 'General case' 0 N--CA 1.465 0.314 0 CA-C-N 115.795 -0.639 . . . . 0.0 111.872 -179.928 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 224' ' ' GLY . . . . . . . . . . . . . . . -70.26 109.25 2.78 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.375 179.817 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 225' ' ' GLU . . . . . . . . . . . . . 9.1 tp10 -113.54 150.43 32.98 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.764 0.316 . . . . 0.0 110.858 -179.8 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 226' ' ' SER . . . . . . . . . . . . . 40.7 t -104.42 -31.14 9.64 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.93 -179.972 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 227' ' ' LEU . . . . . . . . . . . . . 93.7 mt -107.85 97.61 7.31 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.934 -179.986 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 228' ' ' ALA . . . . . . . . . . . . . . . -125.25 -0.86 7.67 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.909 179.881 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 229' ' ' GLY . . . . . . . . . . . . . . . -62.03 -61.89 6.23 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.803 -0.713 . . . . 0.0 112.484 179.936 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 230' ' ' VAL . . . . . . . . . . . . . 4.1 m -143.49 145.83 21.94 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.22 0 CA-C-O 120.728 0.299 . . . . 0.0 111.329 179.979 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 231' ' ' ASP . . . . . . . . . . . . . 11.4 m-20 -86.14 80.5 8.77 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.252 179.324 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 232' ' ' THR . . . . . . . . . . . . . 41.4 p -58.68 146.59 35.87 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 115.9 -0.591 . . . . 0.0 111.408 -179.43 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 233' ' ' ASP . . . . . . . . . . . . . 10.4 m-20 -90.82 -5.77 55.17 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.031 -0.531 . . . . 0.0 110.921 -179.956 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 234' ' ' THR . . . . . . . . . . . . . 68.0 p 47.45 83.16 0.22 Allowed Pre-proline 0 CA--C 1.529 0.168 0 CA-C-N 115.916 -0.584 . . . . 0.0 111.559 -179.945 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 235' ' ' PRO . . . . . . . . . . . . . 72.4 Cg_endo -76.98 149.3 28.77 Favored 'Trans proline' 0 C--N 1.346 0.424 0 C-N-CA 122.485 2.123 . . . . 0.0 112.457 179.888 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 236' ' ' ALA . . . . . . . . . . . . . . . -75.11 140.76 43.65 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.982 179.883 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 237' ' ' VAL . . . . . 0.476 HG11 HD13 ' A' ' 240' ' ' LEU . 51.1 t -92.31 132.66 36.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.289 -0.414 . . . . 0.0 111.143 179.975 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 238' ' ' ALA . . . . . . . . . . . . . . . -88.1 -40.89 13.42 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.053 179.85 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 239' ' ' ASP . . . . . . . . . . . . . 5.0 p-10 -124.57 120.02 30.75 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.728 179.866 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 240' ' ' LEU . . . . . 0.476 HD13 HG11 ' A' ' 237' ' ' VAL . 3.9 mm? -96.01 -54.28 3.37 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.123 -0.489 . . . . 0.0 111.0 -179.771 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 241' ' ' GLU . . . . . . . . . . . . . 39.7 tt0 -147.72 -49.5 0.17 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.891 -179.924 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 242' ' ' HIS . . . . . . . . . . . . . 66.6 m80 -77.19 146.13 37.22 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.102 -0.499 . . . . 0.0 111.195 -179.781 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 243' ' ' HIS . . . . . . . . . . . . . 32.4 t-80 -112.78 109.24 18.61 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.515 179.707 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 244' ' ' HIS . . . . . . . . . . . . . 52.7 m-70 -77.49 -171.12 2.02 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.022 -179.739 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 245' ' ' HIS . . . . . . . . . . . . . 57.8 t-80 -124.31 112.67 17.27 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.918 179.979 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 246' ' ' HIS . . . . . . . . . . . . . 44.1 m-70 -124.44 115.29 20.7 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.796 179.772 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 247' ' ' HIS . . . . . . . . . . . . . 47.4 t60 . . . . . 0 C--O 1.249 1.073 0 CA-C-O 118.313 -0.851 . . . . 0.0 110.786 -179.876 . . . . . . . . 0 0 . 1 . 018 nuclear build full ' A' A ' 301' ' ' RET . . . . . 0.925 H203 ' HE1' ' A' ' 171' ' ' TRP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 66.5 mtm . . . . . 0 N--CA 1.485 1.287 0 CA-C-O 120.712 0.291 . . . . 0.0 110.887 . . . . . . . . . 0 0 . 1 . 019 nuclear build full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 28.2 m -88.66 -14.16 9.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.255 -0.429 . . . . 0.0 111.39 -179.755 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -121.75 -9.67 6.82 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.653 -0.784 . . . . 0.0 112.789 -179.88 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 49.2 tp -74.1 -35.37 64.18 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-O 120.782 0.325 . . . . 0.0 110.921 179.951 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 82.7 p -62.34 -31.63 72.29 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.447 -179.774 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 28.9 p -54.23 -35.78 62.81 Favored 'General case' 0 C--N 1.332 -0.175 0 CA-C-N 116.368 -0.378 . . . . 0.0 111.276 -179.906 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 7' ' ' LEU . . . . . . . . . . . . . 4.2 mm? -59.79 -50.73 72.66 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.202 -179.847 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 8' ' ' PHE . . . . . 0.664 ' HB2' ' HB2' ' A' ' 55' ' ' ALA . 64.2 m-85 -65.5 -34.91 79.37 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.9 -179.829 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 9' ' ' TRP . . . . . 0.416 ' O ' HG12 ' A' ' 13' ' ' ILE . 29.4 m95 -65.27 -44.77 87.0 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.292 -179.668 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 75.3 mt -60.51 -41.43 94.33 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 115.639 -0.71 . . . . 0.0 110.095 179.396 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -64.86 -34.65 90.46 Favored Glycine 0 N--CA 1.448 -0.501 0 C-N-CA 120.677 -0.773 . . . . 0.0 111.667 179.304 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -65.5 -31.32 72.33 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-O 120.849 0.357 . . . . 0.0 110.388 179.602 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 13' ' ' ILE . . . . . 0.416 HG12 ' O ' ' A' ' 9' ' ' TRP . 42.3 mm -67.72 -48.47 75.89 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 116.032 -0.531 . . . . 0.0 110.153 179.339 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -61.57 -28.12 69.2 Favored Glycine 0 N--CA 1.45 -0.386 0 C-N-CA 120.698 -0.763 . . . . 0.0 111.81 179.436 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 15' ' ' MET . . . . . 0.56 ' HE3' ' CB ' ' A' ' 47' ' ' ALA . 23.2 mmt -75.07 -39.43 60.87 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.731 0.3 . . . . 0.0 110.645 179.693 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 20.6 tp -59.09 -40.64 85.9 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.312 179.345 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 41.3 t -69.94 -45.52 76.49 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.215 0 CA-C-N 115.902 -0.59 . . . . 0.0 111.114 -179.938 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -63.84 -49.59 67.07 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.562 -0.827 . . . . 0.0 111.686 179.635 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 85.1 m -50.24 -45.23 53.92 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 115.448 -0.376 . . . . 0.0 111.014 179.767 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 77.9 mt -71.89 -39.3 69.68 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.382 179.764 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -64.1 -30.62 71.67 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.659 0.266 . . . . 0.0 111.528 -179.626 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 22' ' ' PHE . . . . . 0.575 ' HB2' HG22 ' A' ' 41' ' ' VAL . 6.3 m-85 -90.84 -31.12 16.58 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.503 -0.317 . . . . 0.0 111.113 -179.388 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -71.58 -49.78 37.27 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-O 120.907 0.384 . . . . 0.0 110.841 179.797 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 24' ' ' TRP . . . . . . . . . . . . . 1.2 t-105 -60.32 -41.61 93.85 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 115.893 -0.594 . . . . 0.0 110.72 179.797 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -73.84 -25.77 60.25 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.356 -0.384 . . . . 0.0 110.665 179.619 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -73.54 -40.44 47.13 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.907 -0.663 . . . . 0.0 112.674 179.835 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 72.2 mtp180 -72.44 -2.22 18.66 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-O 120.753 0.311 . . . . 0.0 111.068 179.965 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 19.3 t70 -107.02 -8.38 16.58 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.704 179.94 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -79.02 -174.6 4.13 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.232 -179.926 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -122.18 -170.87 13.82 Favored Glycine 0 N--CA 1.452 -0.266 0 C-N-CA 120.82 -0.705 . . . . 0.0 112.461 -179.985 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 74.8 p -68.28 113.38 5.84 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-O 120.812 0.339 . . . . 0.0 111.011 179.981 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 134.33 -54.2 0.77 Allowed Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.805 -0.712 . . . . 0.0 112.561 -179.94 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 45.8 mt-10 -85.58 -20.82 28.98 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.672 0.272 . . . . 0.0 111.05 179.953 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 34' ' ' ARG . . . . . 0.455 ' O ' HG23 ' A' ' 38' ' ' VAL . 56.7 ttp180 -50.44 -29.51 10.45 Favored 'General case' 0 C--N 1.332 -0.175 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.339 -179.761 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 37.2 mmt180 -64.59 -43.92 92.3 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.329 -0.396 . . . . 0.0 110.953 179.981 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 64.8 m-85 -69.36 -33.76 73.56 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 116.13 -0.486 . . . . 0.0 111.44 -179.596 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 37' ' ' TYR . . . . . . . . . . . . . 54.2 m-85 -70.81 -53.01 16.93 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.533 -179.386 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 38' ' ' VAL . . . . . 0.455 HG23 ' O ' ' A' ' 34' ' ' ARG . 87.4 t -56.82 -36.79 50.75 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.249 0 CA-C-O 121.18 0.514 . . . . 0.0 110.21 179.509 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 40.9 m -66.76 -47.53 71.93 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 115.51 -0.768 . . . . 0.0 110.525 179.222 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 40' ' ' LEU . . . . . 0.405 ' O ' HG13 ' A' ' 43' ' ' ILE . 21.9 tp -57.1 -47.57 80.73 Favored 'General case' 0 C--O 1.235 0.3 0 CA-C-N 115.67 -0.695 . . . . 0.0 110.787 179.881 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 41' ' ' VAL . . . . . 0.575 HG22 ' HB2' ' A' ' 22' ' ' PHE . 94.8 t -63.05 -34.81 68.74 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-N 115.81 -0.632 . . . . 0.0 110.249 179.436 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -58.78 -39.79 94.18 Favored Glycine 0 N--CA 1.449 -0.471 0 CA-C-N 115.689 -0.687 . . . . 0.0 112.238 179.667 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 43' ' ' ILE . . . . . 0.609 HG22 ' HE3' ' A' ' 205' ' ' LYS . 0.1 OUTLIER -67.93 -50.97 54.54 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.166 0 CA-C-O 120.695 0.283 . . . . 0.0 110.984 179.851 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 50.5 m -63.59 -25.28 68.16 Favored 'General case' 0 C--N 1.331 -0.199 0 CA-C-O 120.824 0.345 . . . . 0.0 110.945 179.895 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -77.81 -52.15 5.55 Favored Glycine 0 N--CA 1.452 -0.263 0 C-N-CA 120.949 -0.643 . . . . 0.0 112.865 -179.542 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 46' ' ' ILE . . . . . 0.72 HD12 HD12 ' A' ' 78' ' ' LEU . 10.5 pt -58.32 -40.92 79.82 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.242 0 CA-C-O 120.874 0.369 . . . . 0.0 110.975 -179.75 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 47' ' ' ALA . . . . . 0.669 ' HB2' ' HE2' ' A' ' 205' ' ' LYS . . . -68.12 -40.24 82.58 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.124 179.468 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 48' ' ' ALA . . . . . 0.528 ' HB2' ' HB3' ' A' ' 15' ' ' MET . . . -54.59 -45.42 73.61 Favored 'General case' 0 C--O 1.233 0.197 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.31 -179.666 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 27.6 m -73.05 -33.9 44.0 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.257 -0.429 . . . . 0.0 111.26 -179.68 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -61.67 -37.75 85.22 Favored 'General case' 0 C--N 1.331 -0.21 0 CA-C-O 121.102 0.477 . . . . 0.0 110.576 179.256 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 51' ' ' TYR . . . . . 0.487 ' HB3' ' O ' ' A' ' 8' ' ' PHE . 29.6 m-85 -72.85 -35.63 67.28 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 115.767 -0.651 . . . . 0.0 110.266 179.682 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -66.08 -40.88 91.18 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 115.798 -0.637 . . . . 0.0 111.082 179.3 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 27.6 m -74.1 -41.52 52.03 Favored 'Isoleucine or valine' 0 C--O 1.231 0.123 0 CA-C-N 116.47 -0.332 . . . . 0.0 111.016 179.95 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 54' ' ' MET . . . . . 0.623 ' HG2' ' HG2' ' A' ' 71' ' ' PRO . 72.0 mtm -64.93 -36.21 83.65 Favored 'General case' 0 CA--C 1.519 -0.233 0 CA-C-O 121.171 0.51 . . . . 0.0 109.831 179.128 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 55' ' ' ALA . . . . . 0.664 ' HB2' ' HB2' ' A' ' 8' ' ' PHE . . . -69.55 -16.71 63.47 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 115.489 -0.778 . . . . 0.0 111.193 179.764 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 73.5 mt -97.06 2.55 51.48 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.328 -0.396 . . . . 0.0 111.407 -179.632 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 84.75 3.23 88.28 Favored Glycine 0 N--CA 1.452 -0.258 0 C-N-CA 120.628 -0.796 . . . . 0.0 112.941 179.66 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 49.2 t -69.87 132.94 32.67 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-O 120.631 0.253 . . . . 0.0 110.907 179.875 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 59' ' ' GLY . . . . . 0.695 ' HA3' ' HD3' ' A' ' 71' ' ' PRO . . . 88.56 -13.01 63.45 Favored Glycine 0 N--CA 1.449 -0.476 0 C-N-CA 120.656 -0.783 . . . . 0.0 112.487 -179.866 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 60' ' ' TRP . . . . . . . . . . . . . 15.5 m0 -66.2 89.46 0.13 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.833 0.349 . . . . 0.0 110.7 179.901 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 61' ' ' VAL . . . . . 0.523 HG13 HG23 ' A' ' 68' ' ' VAL . 4.0 p -101.52 132.32 21.94 Favored Pre-proline 0 CA--C 1.532 0.265 0 CA-C-N 116.266 -0.424 . . . . 0.0 110.928 179.928 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 62' ' ' PRO . . . . . 0.452 ' HD3' ' HA ' ' A' ' 61' ' ' VAL . 4.6 Cg_exo -76.94 151.21 30.83 Favored 'Trans proline' 0 C--N 1.35 0.617 0 C-N-CA 122.673 2.249 . . . . 0.0 112.494 -179.763 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 73.3 t -142.32 91.84 0.5 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 115.964 -0.562 . . . . 0.0 110.804 179.774 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . 59.56 -87.43 0.02 OUTLIER 'General case' 0 N--CA 1.463 0.183 0 CA-C-N 116.097 -0.501 . . . . 0.0 111.529 179.962 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 10.3 pt-20 -124.21 -16.26 6.51 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.903 0.383 . . . . 0.0 110.673 179.972 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 66' ' ' ARG . . . . . 0.431 HH11 ' HD2' ' A' ' 66' ' ' ARG . 64.6 mtt180 -104.58 160.77 14.68 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 115.922 -0.581 . . . . 0.0 110.362 179.535 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 37.2 m -120.97 142.66 49.56 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.971 0.415 . . . . 0.0 111.473 -179.613 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 68' ' ' VAL . . . . . 0.523 HG23 HG13 ' A' ' 61' ' ' VAL . 15.3 m -131.68 145.04 35.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 115.799 -0.637 . . . . 0.0 110.552 179.609 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 69' ' ' PHE . . . . . 0.406 ' C ' ' HD2' ' A' ' 71' ' ' PRO . 16.7 m-85 -109.48 115.84 30.68 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.364 -0.38 . . . . 0.0 110.365 -179.358 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 70' ' ' VAL . . . . . 0.741 HG12 ' HD3' ' A' ' 71' ' ' PRO . 0.8 OUTLIER -64.59 -36.79 19.28 Favored Pre-proline 0 CA--C 1.541 0.627 0 N-CA-C 112.701 0.63 . . . . 0.0 112.701 -179.321 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 71' ' ' PRO . . . . . 0.741 ' HD3' HG12 ' A' ' 70' ' ' VAL . 61.4 Cg_endo -70.52 -20.81 30.77 Favored 'Trans proline' 0 C--N 1.36 1.154 0 C-N-CA 121.934 1.756 . . . . 0.0 113.382 -179.451 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 46.6 ttp180 -73.06 -55.13 6.93 Favored 'General case' 0 C--O 1.235 0.323 0 N-CA-C 111.658 0.244 . . . . 0.0 111.658 -179.031 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 73' ' ' TYR . . . . . 0.431 ' O ' HG13 ' A' ' 77' ' ' ILE . 11.8 m-85 -65.84 -37.54 86.46 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.907 0.384 . . . . 0.0 110.022 -179.883 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 74' ' ' ILE . . . . . 0.529 ' HA ' HD12 ' A' ' 77' ' ' ILE . 0.4 OUTLIER -67.22 -41.23 86.5 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.219 0 CA-C-N 116.058 -0.519 . . . . 0.0 110.631 179.704 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 75' ' ' ASP . . . . . 0.433 ' O ' HG23 ' A' ' 79' ' ' THR . 17.7 t70 -55.08 -39.7 69.57 Favored 'General case' 0 CA--C 1.519 -0.245 0 N-CA-C 109.584 -0.524 . . . . 0.0 109.584 179.235 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 76' ' ' TRP . . . . . 0.485 ' HZ2' HG23 ' A' ' 197' ' ' ILE . 30.7 m0 -68.44 -32.52 72.6 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 115.927 -0.579 . . . . 0.0 110.683 179.61 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 77' ' ' ILE . . . . . 0.629 ' HA ' ' HG3' ' A' ' 109' ' ' MET . 92.2 mt -60.95 -41.64 89.79 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.245 0 CA-C-N 116.104 -0.498 . . . . 0.0 111.954 -179.828 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 78' ' ' LEU . . . . . 0.72 HD12 HD12 ' A' ' 46' ' ' ILE . 0.7 OUTLIER -91.38 -30.02 16.76 Favored 'General case' 0 CA--C 1.536 0.409 0 N-CA-C 113.392 0.886 . . . . 0.0 113.392 -178.883 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 79' ' ' THR . . . . . 0.438 HG22 ' CD1' ' A' ' 46' ' ' ILE . 46.0 p -75.2 -53.32 9.01 Favored 'General case' 0 N--CA 1.47 0.558 0 N-CA-C 113.447 0.906 . . . . 0.0 113.447 -178.275 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 80' ' ' THR . . . . . 0.617 HG21 ' HE1' ' A' ' 109' ' ' MET . 7.3 m -51.47 -48.95 85.04 Favored Pre-proline 0 C--N 1.329 -0.312 0 N-CA-C 112.948 0.721 . . . . 0.0 112.948 -178.36 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 81' ' ' PRO . . . . . 0.569 ' HD2' ' N ' ' A' ' 80' ' ' THR . 23.3 Cg_endo -58.99 -26.35 81.2 Favored 'Trans proline' 0 C--N 1.351 0.659 0 C-N-CA 121.72 1.613 . . . . 0.0 111.846 -179.511 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 82' ' ' LEU . . . . . . . . . . . . . 14.1 tp -76.73 -36.5 57.12 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 115.908 -0.587 . . . . 0.0 110.557 179.991 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 83' ' ' ILE . . . . . 0.518 HD13 HD13 ' A' ' 43' ' ' ILE . 38.8 mm -67.91 -51.22 51.96 Favored 'Isoleucine or valine' 0 C--O 1.234 0.275 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.137 179.086 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 84' ' ' VAL . . . . . 0.765 HG11 HD22 ' A' ' 105' ' ' ASN . 27.0 m -61.14 -31.13 49.24 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.214 0 CA-C-N 116.014 -0.539 . . . . 0.0 109.632 179.129 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 85' ' ' TYR . . . . . 0.408 ' HB2' ' O ' ' A' ' 81' ' ' PRO . 58.6 t80 -65.23 -34.47 78.44 Favored 'General case' 0 N--CA 1.452 -0.332 0 CA-C-N 115.638 -0.71 . . . . 0.0 109.36 178.965 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 86' ' ' PHE . . . . . . . . . . . . . 4.2 t80 -61.39 -51.63 67.98 Favored 'General case' 0 C--O 1.231 0.131 0 CA-C-N 115.586 -0.734 . . . . 0.0 110.064 179.222 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 7.4 mt -65.05 -28.69 69.65 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 121.309 0.576 . . . . 0.0 109.772 179.66 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -72.57 -27.43 69.43 Favored Glycine 0 N--CA 1.45 -0.41 0 CA-C-N 115.2 -0.909 . . . . 0.0 111.545 179.139 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 52.8 mt -73.21 -43.35 61.42 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 121.006 0.431 . . . . 0.0 110.549 179.652 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 59.1 mt -60.14 -33.19 71.82 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 115.707 -0.679 . . . . 0.0 111.047 179.887 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 91' ' ' ALA . . . . . 0.566 ' HB1' ' HB2' ' A' ' 148' ' ' SER . . . -85.76 -47.97 9.25 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.514 -179.532 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 89.27 61.15 1.41 Allowed Glycine 0 N--CA 1.45 -0.378 0 C-N-CA 120.811 -0.709 . . . . 0.0 112.383 -179.742 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 93' ' ' LEU . . . . . 0.442 HD11 ' HG2' ' A' ' 145' ' ' MET . 6.5 mp -72.76 179.12 3.78 Favored 'General case' 0 C--N 1.332 -0.184 0 CA-C-O 120.753 0.311 . . . . 0.0 110.866 -179.951 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 94' ' ' ASP . . . . . . . . . . . . . 30.3 m-20 -85.5 175.3 8.9 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.883 179.948 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 48.9 m -61.69 -46.71 88.52 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.1 -179.74 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 96' ' ' ARG . . . . . 0.404 ' O ' HG13 ' A' ' 100' ' ' ILE . 80.1 ttt180 -71.94 -45.36 61.42 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.934 -179.953 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 97' ' ' GLU . . . . . 0.482 ' HA ' HD12 ' A' ' 100' ' ' ILE . 19.1 mm-40 -52.51 -46.02 66.48 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.158 -179.802 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 98' ' ' PHE . . . . . 0.474 ' O ' HG12 ' A' ' 102' ' ' ILE . 2.2 m-85 -55.33 -50.87 68.52 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.384 -0.371 . . . . 0.0 110.236 179.385 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -60.85 -30.38 72.8 Favored Glycine 0 N--CA 1.45 -0.383 0 C-N-CA 120.862 -0.685 . . . . 0.0 112.627 -179.949 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 100' ' ' ILE . . . . . 0.482 HD12 ' HA ' ' A' ' 97' ' ' GLU . 94.5 mt -64.04 -43.3 97.52 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-O 120.89 0.376 . . . . 0.0 111.393 -179.857 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 29.4 t -72.26 -41.42 66.12 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.38 0 CA-C-N 116.34 -0.391 . . . . 0.0 111.592 179.976 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 102' ' ' ILE . . . . . 0.474 HG12 ' O ' ' A' ' 98' ' ' PHE . 35.2 mm -65.38 -40.07 87.27 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 CA-C-N 116.416 -0.357 . . . . 0.0 111.65 -179.266 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 11.0 t -67.92 -40.36 83.37 Favored 'General case' 0 C--O 1.234 0.239 0 CA-C-O 120.713 0.292 . . . . 0.0 110.939 -179.958 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 104' ' ' LEU . . . . . 0.426 HD22 ' HE2' ' A' ' 140' ' ' TYR . 29.2 tp -55.34 -51.54 66.4 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-N 116.349 -0.387 . . . . 0.0 110.079 179.311 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 105' ' ' ASN . . . . . 0.765 HD22 HG11 ' A' ' 84' ' ' VAL . 4.1 m-20 -58.05 -37.31 74.16 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 115.855 -0.611 . . . . 0.0 110.461 179.465 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 31.0 m -54.61 -41.1 69.56 Favored 'General case' 0 C--N 1.332 -0.184 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.659 179.706 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 0.6 OUTLIER -69.24 -36.42 72.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-O 121.258 0.551 . . . . 0.0 110.0 179.245 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 108' ' ' VAL . . . . . 0.426 HG23 ' O ' ' A' ' 104' ' ' LEU . 60.7 t -63.87 -42.63 96.47 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 115.406 -0.816 . . . . 0.0 111.571 -179.677 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 109' ' ' MET . . . . . 0.629 ' HG3' ' HA ' ' A' ' 77' ' ' ILE . 6.9 mmt -70.07 -44.04 69.92 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.407 -0.36 . . . . 0.0 110.961 -179.624 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 21.4 tp -60.73 -32.18 71.46 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 116.349 -0.387 . . . . 0.0 110.38 179.966 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -65.27 -56.63 11.65 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.019 -0.537 . . . . 0.0 110.612 179.398 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . -60.88 -30.0 71.94 Favored Glycine 0 C--N 1.332 0.334 0 C-N-CA 120.644 -0.789 . . . . 0.0 112.117 179.655 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 113' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER -57.68 -69.0 0.19 Allowed 'General case' 0 C--N 1.33 -0.266 0 CA-C-O 121.015 0.436 . . . . 0.0 110.255 179.585 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 114' ' ' ALA . . . . . 0.446 ' O ' HG13 ' A' ' 118' ' ' VAL . . . -64.6 -29.13 70.15 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 115.79 -0.641 . . . . 0.0 111.414 -179.969 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -51.92 -51.2 41.21 Favored Glycine 0 C--N 1.332 0.324 0 C-N-CA 121.081 -0.58 . . . . 0.0 112.672 -179.888 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -77.99 -15.01 59.31 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-O 120.542 0.21 . . . . 0.0 111.553 -179.781 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 117' ' ' MET . . . . . 0.45 ' HE2' HG21 ' A' ' 68' ' ' VAL . 37.5 ttm -100.67 18.46 19.24 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-O 120.692 0.282 . . . . 0.0 111.436 -179.464 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 118' ' ' VAL . . . . . 0.506 HG11 ' N ' ' A' ' 123' ' ' ARG . 27.4 m -74.03 144.76 82.65 Favored Pre-proline 0 C--N 1.328 -0.327 0 CA-C-N 116.692 -0.231 . . . . 0.0 111.141 179.802 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 119' ' ' PRO . . . . . . . . . . . . . 97.0 Cg_endo -87.53 -10.11 5.53 Favored 'Trans proline' 0 N--CA 1.458 -0.568 0 C-N-CA 122.709 2.273 . . . . 0.0 112.484 179.756 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -136.72 -108.26 0.89 Allowed Glycine 0 C--N 1.331 0.302 0 C-N-CA 120.706 -0.759 . . . . 0.0 112.907 -179.629 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 34.3 pt -124.53 12.26 4.72 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.156 0 CA-C-O 120.652 0.263 . . . . 0.0 111.664 -179.548 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 41.7 mt-10 -58.24 -18.26 25.18 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.779 0.323 . . . . 0.0 111.03 179.722 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 123' ' ' ARG . . . . . 0.506 ' N ' HG11 ' A' ' 118' ' ' VAL . 4.9 ptm180 -50.6 -31.39 15.77 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 116.107 -0.497 . . . . 0.0 111.504 -179.868 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 124' ' ' TYR . . . . . . . . . . . . . 30.4 m-85 -70.28 -33.03 71.08 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.458 -0.337 . . . . 0.0 111.017 -179.735 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 125' ' ' ALA . . . . . . . . . . . . . . . -71.24 -50.12 36.22 Favored 'General case' 0 C--O 1.235 0.333 0 CA-C-N 116.298 -0.41 . . . . 0.0 110.942 179.687 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 3.1 mm? -53.6 -52.76 58.77 Favored 'General case' 0 C--N 1.333 -0.137 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.53 179.739 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 127' ' ' PHE . . . . . 0.433 ' HZ ' ' HB3' ' A' ' 175' ' ' PRO . 6.5 t80 -64.88 -37.21 86.87 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.316 -0.402 . . . . 0.0 111.231 -179.615 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 128' ' ' GLY . . . . . . . . . . . . . . . -46.16 -47.75 15.4 Favored Glycine 0 C--O 1.237 0.283 0 C-N-CA 119.705 -1.235 . . . . 0.0 110.517 179.192 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 129' ' ' MET . . . . . . . . . . . . . 0.5 OUTLIER -72.18 -34.91 68.79 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 115.178 -0.511 . . . . 0.0 110.101 178.665 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -62.99 -37.26 94.66 Favored Glycine 0 C--N 1.332 0.331 0 CA-C-N 115.804 -0.634 . . . . 0.0 113.347 -179.515 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -73.56 -52.61 12.9 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.788 0.294 . . . . 0.0 110.755 -179.781 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 62.2 t -55.61 -42.0 66.93 Favored 'Isoleucine or valine' 0 C--O 1.234 0.28 0 CA-C-O 121.331 0.586 . . . . 0.0 109.546 179.128 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -68.69 -37.35 79.49 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 115.342 -0.844 . . . . 0.0 110.669 179.407 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 134' ' ' PHE . . . . . . . . . . . . . 87.7 t80 -55.88 -54.78 40.44 Favored 'General case' 0 N--CA 1.452 -0.363 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.135 179.669 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 135' ' ' ILE . . . . . 0.425 ' O ' HG22 ' A' ' 138' ' ' VAL . 32.8 mt -56.38 -33.53 38.49 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.363 0 CA-C-N 115.884 -0.598 . . . . 0.0 110.126 179.303 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . -61.65 -39.64 97.67 Favored Glycine 0 N--CA 1.449 -0.484 0 C-N-CA 120.072 -1.061 . . . . 0.0 111.295 178.784 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 137' ' ' LEU . . . . . . . . . . . . . 31.1 tp -68.75 -54.02 18.44 Favored 'General case' 0 C--N 1.332 -0.185 0 CA-C-O 120.598 0.237 . . . . 0.0 111.173 179.933 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 138' ' ' VAL . . . . . 0.425 HG22 ' O ' ' A' ' 135' ' ' ILE . 3.3 m -55.85 -31.68 30.59 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.176 0 CA-C-O 121.182 0.515 . . . . 0.0 109.9 179.957 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 139' ' ' TYR . . . . . . . . . . . . . 21.3 t80 -66.19 -38.62 88.45 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 115.429 -0.805 . . . . 0.0 110.289 178.674 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 140' ' ' TYR . . . . . 0.426 ' HE2' HD22 ' A' ' 104' ' ' LEU . 19.2 m-85 -65.28 -32.14 73.64 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 116.097 -0.501 . . . . 0.0 111.055 179.377 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 141' ' ' LEU . . . . . 0.49 HD23 ' SD ' ' A' ' 145' ' ' MET . 75.1 mt -69.9 -41.49 74.65 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-O 121.039 0.447 . . . . 0.0 110.351 -179.508 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 24.2 m -84.84 -10.58 11.53 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.631 0 CA-C-N 115.72 -0.673 . . . . 0.0 111.159 179.957 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . -76.91 -118.78 0.16 Allowed Glycine 0 CA--C 1.52 0.405 0 C-N-CA 120.894 -0.669 . . . . 0.0 112.986 -179.551 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 144' ' ' PRO . . . . . . . . . . . . . 55.8 Cg_endo -69.25 -30.19 25.08 Favored 'Trans proline' 0 C--N 1.349 0.6 0 C-N-CA 122.47 2.113 . . . . 0.0 112.825 -179.411 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 145' ' ' MET . . . . . 0.49 ' SD ' HD23 ' A' ' 141' ' ' LEU . 53.1 mtt -55.59 -31.14 61.97 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-O 120.726 0.298 . . . . 0.0 111.484 -179.664 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 146' ' ' THR . . . . . . . . . . . . . 14.3 m -71.12 -44.2 66.1 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.284 -0.416 . . . . 0.0 111.723 -179.45 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 43.6 mt-10 -75.92 -29.04 58.23 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.385 -0.371 . . . . 0.0 111.844 -179.411 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 148' ' ' SER . . . . . 0.566 ' HB2' ' HB1' ' A' ' 91' ' ' ALA . 66.2 m -70.26 -47.05 63.03 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 120.736 0.303 . . . . 0.0 111.281 -179.327 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 149' ' ' ALA . . . . . . . . . . . . . . . -72.6 -34.93 67.74 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.289 -0.414 . . . . 0.0 111.242 -179.833 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 150' ' ' SER . . . . . . . . . . . . . 47.7 t -70.42 -8.19 48.95 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.965 179.943 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 151' ' ' GLN . . . . . . . . . . . . . 47.9 mt-30 -122.32 10.04 9.85 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.262 -0.426 . . . . 0.0 111.255 -179.875 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 152' ' ' ARG . . . . . 0.635 ' HE ' HG13 ' A' ' 156' ' ' ILE . 1.2 tmm_? -85.05 -51.33 6.74 Favored 'General case' 0 C--N 1.332 -0.19 0 CA-C-O 120.979 0.418 . . . . 0.0 110.363 179.669 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 153' ' ' SER . . . . . 0.594 ' HB2' HG12 ' A' ' 156' ' ' ILE . 49.1 m -157.48 172.56 18.35 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 115.751 -0.659 . . . . 0.0 110.667 179.434 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 154' ' ' SER . . . . . . . . . . . . . 46.6 t -69.38 -42.17 75.52 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.339 -0.392 . . . . 0.0 110.76 179.754 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -77.28 -32.75 46.73 Favored Glycine 0 N--CA 1.452 -0.275 0 C-N-CA 120.948 -0.644 . . . . 0.0 113.029 -179.831 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 156' ' ' ILE . . . . . 0.635 HG13 ' HE ' ' A' ' 152' ' ' ARG . 32.2 mm -57.23 -38.65 62.72 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.199 0 CA-C-N 116.776 0.288 . . . . 0.0 111.356 -179.753 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 157' ' ' LYS . . . . . 0.435 ' O ' ' HB ' ' A' ' 161' ' ' VAL . 58.3 tttp -62.47 -43.48 98.72 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.385 -0.37 . . . . 0.0 111.372 -179.735 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 93.8 p -70.98 -48.32 53.95 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 116.102 -0.499 . . . . 0.0 111.551 -179.102 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 159' ' ' LEU . . . . . 0.436 ' O ' ' HB2' ' A' ' 163' ' ' LEU . 10.5 tt -62.08 -42.54 99.31 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.176 -179.395 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 160' ' ' TYR . . . . . . . . . . . . . 77.6 t80 -71.59 -36.87 71.0 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 116.263 -0.426 . . . . 0.0 111.987 -179.077 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 161' ' ' VAL . . . . . 0.538 HG12 ' N ' ' A' ' 162' ' ' ARG . 1.1 t -58.4 -53.64 43.69 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.686 0 N-CA-C 111.699 0.259 . . . . 0.0 111.699 -179.181 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 162' ' ' ARG . . . . . 0.538 ' N ' HG12 ' A' ' 161' ' ' VAL . 97.3 mtt180 -69.89 -41.15 75.13 Favored 'General case' 0 C--N 1.329 -0.317 0 N-CA-C 112.04 0.385 . . . . 0.0 112.04 -179.174 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 163' ' ' LEU . . . . . 0.45 ' O ' HD23 ' A' ' 166' ' ' LEU . 2.7 mp -62.49 -56.14 20.93 Favored 'General case' 0 C--N 1.329 -0.314 0 N-CA-C 112.277 0.473 . . . . 0.0 112.277 -178.674 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 164' ' ' ARG . . . . . . . . . . . . . 5.4 ppt_? -62.42 -40.63 97.18 Favored 'General case' 0 C--N 1.328 -0.356 0 N-CA-C 112.002 0.371 . . . . 0.0 112.002 -178.361 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 165' ' ' ASN . . . . . 0.448 ' O ' HG23 ' A' ' 169' ' ' VAL . 5.0 m-20 -54.73 -53.29 56.89 Favored 'General case' 0 C--O 1.237 0.402 0 CA-C-O 120.826 0.346 . . . . 0.0 111.557 -179.373 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 166' ' ' LEU . . . . . 0.48 ' O ' ' HG ' ' A' ' 170' ' ' LEU . 0.1 OUTLIER -67.67 -31.59 71.67 Favored 'General case' 0 C--N 1.331 -0.238 0 C-N-CA 120.847 -0.341 . . . . 0.0 111.022 -179.146 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 167' ' ' THR . . . . . 0.428 ' O ' ' HB2' ' A' ' 171' ' ' TRP . 17.7 m -59.75 -53.02 62.81 Favored 'General case' 0 C--N 1.333 -0.147 0 CA-C-O 120.842 0.353 . . . . 0.0 111.304 179.814 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 168' ' ' VAL . . . . . . . . . . . . . 58.4 t -58.97 -41.27 82.66 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.385 0 CA-C-N 115.785 -0.643 . . . . 0.0 111.749 -179.103 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 169' ' ' VAL . . . . . 0.448 HG23 ' O ' ' A' ' 165' ' ' ASN . 88.8 t -59.34 -64.87 0.51 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 N-CA-C 112.383 0.512 . . . . 0.0 112.383 -179.236 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 170' ' ' LEU . . . . . 0.48 ' HG ' ' O ' ' A' ' 166' ' ' LEU . 1.6 pp -61.04 -36.3 79.19 Favored 'General case' 0 N--CA 1.463 0.214 0 N-CA-C 112.219 0.451 . . . . 0.0 112.219 -178.67 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 171' ' ' TRP . . . . . 0.716 ' HE1' H203 ' A' ' 301' ' ' RET . 3.0 m0 -67.73 -29.4 68.62 Favored 'General case' 0 C--N 1.331 -0.231 0 C-N-CA 120.914 -0.314 . . . . 0.0 110.946 179.843 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 172' ' ' ALA . . . . . . . . . . . . . . . -73.28 -7.07 49.98 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 116.337 -0.392 . . . . 0.0 110.986 -179.938 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 173' ' ' ILE . . . . . 0.686 HG22 HD11 ' A' ' 177' ' ' ILE . 19.2 mm -87.97 -21.0 7.21 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.067 -0.515 . . . . 0.0 110.876 179.88 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 174' ' ' TYR . . . . . 0.409 ' HD2' ' HA ' ' A' ' 171' ' ' TRP . 13.0 m-85 -53.67 -48.53 92.95 Favored Pre-proline 0 CA--C 1.531 0.235 0 CA-C-N 116.249 -0.432 . . . . 0.0 111.478 -179.752 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 175' ' ' PRO . . . . . 0.433 ' HB3' ' HZ ' ' A' ' 127' ' ' PHE . 92.4 Cg_exo -46.48 -31.77 10.31 Favored 'Trans proline' 0 C--N 1.352 0.756 0 C-N-CA 122.173 1.915 . . . . 0.0 112.117 179.059 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 176' ' ' PHE . . . . . 0.466 ' O ' ' HG ' ' A' ' 180' ' ' LEU . 80.5 m-85 -80.25 -40.67 26.53 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 115.927 -0.578 . . . . 0.0 111.421 -179.893 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 177' ' ' ILE . . . . . 0.686 HD11 HG22 ' A' ' 173' ' ' ILE . 2.3 mm -65.2 -41.55 91.92 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.533 0 CA-C-N 116.346 -0.388 . . . . 0.0 111.838 -178.651 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 178' ' ' TRP . . . . . . . . . . . . . 63.9 t90 -73.65 -44.62 56.37 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.902 0.382 . . . . 0.0 111.064 -179.952 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 179' ' ' LEU . . . . . 0.535 ' O ' HG22 ' A' ' 185' ' ' VAL . 1.9 tm? -64.31 -51.86 61.36 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 115.952 -0.567 . . . . 0.0 111.451 -179.151 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 180' ' ' LEU . . . . . 0.712 HD22 HD11 ' A' ' 187' ' ' LEU . 20.7 mt -77.48 -44.98 27.04 Favored 'General case' 0 C--N 1.328 -0.336 0 N-CA-C 111.974 0.361 . . . . 0.0 111.974 -178.711 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 181' ' ' GLY . . . . . 0.412 ' HA3' ' OD1' ' A' ' 193' ' ' ASP . . . -57.5 174.99 1.91 Allowed Glycine 0 C--N 1.335 0.494 0 C-N-CA 120.365 -0.921 . . . . 0.0 112.771 179.927 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 182' ' ' PRO . . . . . 0.648 ' HA ' ' HB2' ' A' ' 186' ' ' ALA . 1.7 Cg_endo -44.99 -45.6 13.93 Favored 'Trans proline' 0 CA--C 1.537 0.671 0 C-N-CA 123.228 2.619 . . . . 0.0 113.84 179.615 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 183' ' ' PRO . . . . . 0.578 ' HD2' ' N ' ' A' ' 182' ' ' PRO . 18.5 Cg_endo -58.54 -4.75 1.97 Allowed 'Trans proline' 0 C--N 1.356 0.937 0 C-N-CA 121.967 1.778 . . . . 0.0 113.017 -179.762 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 184' ' ' GLY . . . . . 0.434 ' HA3' ' O ' ' A' ' 179' ' ' LEU . . . -122.09 -87.93 0.91 Allowed Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.63 -0.795 . . . . 0.0 112.636 179.94 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 185' ' ' VAL . . . . . 0.535 HG22 ' O ' ' A' ' 179' ' ' LEU . 4.3 m -123.63 -4.64 7.19 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 N-CA-C 111.658 0.244 . . . . 0.0 111.658 -179.822 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 186' ' ' ALA . . . . . 0.648 ' HB2' ' HA ' ' A' ' 182' ' ' PRO . . . 51.62 88.88 0.03 OUTLIER 'General case' 0 N--CA 1.462 0.156 0 CA-C-N 116.398 -0.364 . . . . 0.0 111.367 179.833 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 187' ' ' LEU . . . . . 0.712 HD11 HD22 ' A' ' 180' ' ' LEU . 20.2 mt -91.76 -49.4 6.29 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.396 -0.366 . . . . 0.0 111.774 -179.502 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 188' ' ' LEU . . . . . . . . . . . . . 87.5 mt -97.36 -94.3 0.22 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.462 -0.336 . . . . 0.0 111.539 -179.138 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 189' ' ' THR . . . . . . . . . . . . . 1.8 t -160.42 149.36 13.72 Favored Pre-proline 0 C--N 1.327 -0.39 0 CA-C-N 116.284 -0.416 . . . . 0.0 111.282 -179.499 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 190' ' ' PRO . . . . . 0.437 ' O ' HG23 ' A' ' 194' ' ' VAL . 72.9 Cg_exo -50.37 -42.98 46.25 Favored 'Trans proline' 0 C--N 1.349 0.557 0 C-N-CA 122.591 2.194 . . . . 0.0 112.932 -179.853 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 191' ' ' THR . . . . . . . . . . . . . 70.9 p -55.33 -46.55 76.35 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-O 120.77 0.319 . . . . 0.0 111.514 -179.729 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 192' ' ' VAL . . . . . . . . . . . . . 39.4 t -68.36 -50.6 55.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.626 -179.745 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 193' ' ' ASP . . . . . 0.428 ' OD1' HG22 ' A' ' 177' ' ' ILE . 30.8 t70 -55.24 -49.58 71.66 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.752 0.311 . . . . 0.0 111.284 -179.824 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 194' ' ' VAL . . . . . 0.437 HG23 ' O ' ' A' ' 190' ' ' PRO . 76.1 t -59.62 -36.44 65.28 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.886 179.914 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 195' ' ' ALA . . . . . . . . . . . . . . . -58.71 -46.72 86.68 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.41 -0.359 . . . . 0.0 110.968 179.848 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 196' ' ' LEU . . . . . . . . . . . . . 85.3 mt -67.71 -40.17 84.3 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.348 -0.387 . . . . 0.0 110.615 179.692 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 197' ' ' ILE . . . . . 0.485 HG23 ' HZ2' ' A' ' 76' ' ' TRP . 16.2 mm -59.97 -59.86 3.38 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 CA-C-N 115.988 -0.551 . . . . 0.0 110.302 179.388 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 198' ' ' VAL . . . . . . . . . . . . . 76.3 t -52.78 -34.26 19.81 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.515 0 CA-C-N 115.458 -0.792 . . . . 0.0 109.454 178.394 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 199' ' ' TYR . . . . . . . . . . . . . 65.7 t80 -70.07 -34.96 73.85 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.222 -0.899 . . . . 0.0 110.63 179.753 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 200' ' ' LEU . . . . . 0.468 ' O ' HG12 ' A' ' 203' ' ' VAL . 28.0 mt -67.95 -39.02 83.47 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 115.845 -0.616 . . . . 0.0 111.27 -179.631 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 201' ' ' ASP . . . . . 0.403 ' HB2' ' OH ' ' A' ' 51' ' ' TYR . 0.9 OUTLIER -71.9 -32.35 67.31 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-N 116.099 -0.501 . . . . 0.0 110.776 179.804 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 202' ' ' LEU . . . . . . . . . . . . . 3.7 mt -70.91 -36.5 72.72 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.0 -0.545 . . . . 0.0 111.736 -179.556 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 203' ' ' VAL . . . . . 0.473 ' O ' ' HA3' ' A' ' 207' ' ' GLY . 11.8 p -74.62 -36.32 40.5 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.613 -0.267 . . . . 0.0 111.643 -179.008 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 204' ' ' THR . . . . . 0.462 HG23 ' CE2' ' A' ' 208' ' ' PHE . 43.7 m -67.69 -57.21 6.78 Favored 'General case' 0 C--N 1.326 -0.44 0 C-N-CA 120.84 -0.344 . . . . 0.0 111.53 -179.969 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 205' ' ' LYS . . . . . 0.669 ' HE2' ' HB2' ' A' ' 47' ' ' ALA . 60.0 mttp -69.49 -59.02 3.25 Favored 'General case' 0 C--N 1.329 -0.299 0 N-CA-C 112.549 0.574 . . . . 0.0 112.549 -178.472 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 22.1 t -72.57 -37.53 56.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 N-CA-C 112.158 0.429 . . . . 0.0 112.158 -178.473 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 207' ' ' GLY . . . . . 0.473 ' HA3' ' O ' ' A' ' 203' ' ' VAL . . . -61.51 -55.36 29.34 Favored Glycine 0 CA--C 1.517 0.195 0 C-N-CA 120.51 -0.852 . . . . 0.0 112.922 -179.464 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 208' ' ' PHE . . . . . 0.483 ' O ' ' N ' ' A' ' 212' ' ' ALA . 2.4 m-30 -61.03 -41.58 96.84 Favored 'General case' 0 C--O 1.221 -0.399 0 N-CA-C 110.026 -0.361 . . . . 0.0 110.026 -179.882 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 209' ' ' GLY . . . . . 0.499 ' O ' ' HB3' ' A' ' 212' ' ' ALA . . . -58.26 -37.57 87.4 Favored Glycine 0 N--CA 1.451 -0.33 0 CA-C-N 115.372 -0.831 . . . . 0.0 112.873 179.492 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 210' ' ' PHE . . . . . . . . . . . . . 2.7 m-85 -68.79 -49.56 57.61 Favored 'General case' 0 CA--C 1.514 -0.407 0 N-CA-C 108.548 -0.908 . . . . 0.0 108.548 179.238 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 211' ' ' ILE . . . . . . . . . . . . . 64.9 mt -63.2 -27.45 43.13 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.553 0 N-CA-C 107.61 -1.256 . . . . 0.0 107.61 176.658 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 212' ' ' ALA . . . . . 0.499 ' HB3' ' O ' ' A' ' 209' ' ' GLY . . . -67.99 -38.02 82.18 Favored 'General case' 0 N--CA 1.448 -0.557 0 CA-C-N 114.488 -1.233 . . . . 0.0 110.527 -179.802 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 213' ' ' LEU . . . . . 0.411 ' HG ' ' O ' ' A' ' 209' ' ' GLY . 89.2 mt -70.26 -52.52 22.43 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-N 115.373 -0.831 . . . . 0.0 111.53 -179.606 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 214' ' ' ASP . . . . . . . . . . . . . 24.5 m-20 -57.89 -52.41 65.62 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.396 -0.366 . . . . 0.0 110.954 -179.878 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 215' ' ' ALA . . . . . . . . . . . . . . . -57.25 -53.57 56.66 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.216 179.817 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 216' ' ' ALA . . . . . . . . . . . . . . . -59.98 -31.33 69.8 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-N 116.22 -0.445 . . . . 0.0 111.319 179.947 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 217' ' ' ALA . . . . . . . . . . . . . . . -62.19 -38.67 89.97 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-O 120.949 0.404 . . . . 0.0 110.281 179.651 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 218' ' ' THR . . . . . . . . . . . . . 93.5 m -72.12 -33.99 68.24 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 115.821 -0.627 . . . . 0.0 110.635 179.322 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 219' ' ' LEU . . . . . 0.484 ' O ' ' HG2' ' A' ' 222' ' ' GLU . 83.1 mt -63.2 -41.28 99.15 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 115.996 -0.547 . . . . 0.0 110.892 179.956 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 220' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -84.71 -19.88 32.05 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 116.145 -0.479 . . . . 0.0 111.162 179.682 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 221' ' ' ALA . . . . . . . . . . . . . . . -82.7 -24.81 33.47 Favored 'General case' 0 C--N 1.332 -0.181 0 N-CA-C 112.126 0.417 . . . . 0.0 112.126 -179.358 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 222' ' ' GLU . . . . . 0.484 ' HG2' ' O ' ' A' ' 219' ' ' LEU . 11.9 pt-20 -72.83 -7.8 52.5 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-O 120.782 0.325 . . . . 0.0 111.026 -179.485 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 223' ' ' HIS . . . . . . . . . . . . . 90.8 m-70 -92.83 -58.79 2.23 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.935 179.873 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 224' ' ' GLY . . . . . . . . . . . . . . . 75.79 97.12 0.14 Allowed Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.679 -0.772 . . . . 0.0 112.353 -179.822 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 225' ' ' GLU . . . . . . . . . . . . . 40.9 tt0 -55.41 118.61 4.6 Favored 'General case' 0 C--N 1.331 -0.21 0 CA-C-O 120.874 0.368 . . . . 0.0 111.075 -179.881 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 226' ' ' SER . . . . . . . . . . . . . 45.9 t -75.6 147.56 39.49 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.913 -179.968 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 227' ' ' LEU . . . . . . . . . . . . . 63.3 mt -67.86 135.4 52.48 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.781 -179.979 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 228' ' ' ALA . . . . . . . . . . . . . . . -145.33 122.92 11.77 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.254 -0.43 . . . . 0.0 111.331 -179.915 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 229' ' ' GLY . . . . . . . . . . . . . . . 68.11 -104.65 1.22 Allowed Glycine 0 N--CA 1.45 -0.368 0 C-N-CA 120.914 -0.66 . . . . 0.0 112.802 179.542 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 230' ' ' VAL . . . . . . . . . . . . . 46.1 t -77.19 111.89 14.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-O 120.852 0.358 . . . . 0.0 111.213 -179.798 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 231' ' ' ASP . . . . . . . . . . . . . 7.4 m-20 -85.66 100.73 12.17 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.861 179.964 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 232' ' ' THR . . . . . . . . . . . . . 4.8 t -158.84 140.2 13.21 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.246 -0.434 . . . . 0.0 111.342 179.989 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 233' ' ' ASP . . . . . . . . . . . . . 28.5 t70 -156.22 -52.98 0.08 Allowed 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 115.885 -0.598 . . . . 0.0 110.764 179.887 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 234' ' ' THR . . . . . . . . . . . . . 85.2 m -155.1 97.34 2.45 Favored Pre-proline 0 C--N 1.331 -0.215 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.104 179.935 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 235' ' ' PRO . . . . . . . . . . . . . 39.6 Cg_exo -57.91 -22.88 56.66 Favored 'Trans proline' 0 C--N 1.349 0.578 0 C-N-CA 122.419 2.08 . . . . 0.0 112.265 179.697 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 236' ' ' ALA . . . . . . . . . . . . . . . -73.29 173.34 9.64 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.26 -0.427 . . . . 0.0 111.104 179.941 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 237' ' ' VAL . . . . . . . . . . . . . 7.4 p -139.71 136.92 39.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.27 -179.707 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 238' ' ' ALA . . . . . . . . . . . . . . . -136.89 -64.05 0.59 Allowed 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.098 179.935 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 239' ' ' ASP . . . . . . . . . . . . . 6.4 m-20 -108.6 -179.46 3.88 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.731 179.931 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 240' ' ' LEU . . . . . 0.417 ' N ' HD22 ' A' ' 240' ' ' LEU . 3.6 mm? -107.19 121.92 45.49 Favored 'General case' 0 C--N 1.332 -0.188 0 CA-C-N 116.246 -0.433 . . . . 0.0 110.912 179.991 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 241' ' ' GLU . . . . . . . . . . . . . 41.9 mt-10 -95.28 -40.25 9.64 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.026 -0.534 . . . . 0.0 110.947 -179.9 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 242' ' ' HIS . . . . . . . . . . . . . 25.4 p-80 -87.02 166.97 14.65 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.13 -179.702 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 243' ' ' HIS . . . . . . . . . . . . . 74.3 m80 -137.1 -71.87 0.44 Allowed 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.069 -0.514 . . . . 0.0 110.584 179.874 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 244' ' ' HIS . . . . . . . . . . . . . 70.1 m80 58.26 -178.49 0.07 Allowed 'General case' 0 C--N 1.332 -0.193 0 CA-C-N 115.933 -0.576 . . . . 0.0 111.484 179.65 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 245' ' ' HIS . . . . . . . . . . . . . 26.7 p-80 -153.89 163.34 40.22 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 115.912 -0.585 . . . . 0.0 110.596 179.984 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 246' ' ' HIS . . . . . . . . . . . . . 18.0 p-80 -99.17 -27.85 13.62 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.408 -0.36 . . . . 0.0 110.941 -179.868 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 247' ' ' HIS . . . . . . . . . . . . . 59.5 t60 . . . . . 0 C--O 1.249 1.041 0 CA-C-O 118.254 -0.879 . . . . 0.0 110.889 -179.837 . . . . . . . . 0 0 . 1 . 019 nuclear build full ' A' A ' 301' ' ' RET . . . . . 0.716 H203 ' HE1' ' A' ' 171' ' ' TRP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 1' ' ' MET . . . . . 0.559 ' HG2' ' H ' ' A' ' 3' ' ' GLY . 58.1 ttp . . . . . 0 N--CA 1.486 1.337 0 CA-C-O 120.512 0.196 . . . . 0.0 110.808 . . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 2' ' ' VAL . . . . . 0.443 HG12 ' O ' ' A' ' 1' ' ' MET . 5.2 p 45.02 23.33 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.466 0.349 0 CA-C-N 115.997 -0.547 . . . . 0.0 111.772 179.75 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 3' ' ' GLY . . . . . 0.559 ' H ' ' HG2' ' A' ' 1' ' ' MET . . . -109.32 -5.64 30.03 Favored Glycine 0 N--CA 1.45 -0.397 0 C-N-CA 120.87 -0.681 . . . . 0.0 112.224 179.855 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 60.5 tp -73.92 -35.55 64.63 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-O 120.881 0.372 . . . . 0.0 110.822 -179.982 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 64.0 p -61.59 -29.94 70.35 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 115.958 -0.565 . . . . 0.0 111.399 -179.819 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 26.9 p -55.37 -35.61 65.45 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 116.365 -0.38 . . . . 0.0 111.118 -179.725 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 7' ' ' LEU . . . . . . . . . . . . . 9.3 mp -55.98 -53.71 53.58 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.093 179.898 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 8' ' ' PHE . . . . . 0.507 ' HB2' ' HB2' ' A' ' 55' ' ' ALA . 65.1 m-85 -62.43 -34.23 76.37 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.716 -179.887 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 9' ' ' TRP . . . . . . . . . . . . . 37.8 m95 -64.46 -41.3 96.59 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-O 121.214 0.53 . . . . 0.0 109.896 179.69 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 86.2 mt -65.91 -31.53 72.51 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-N 115.303 -0.862 . . . . 0.0 110.052 179.227 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 11' ' ' GLY . . . . . 0.464 ' O ' ' HG2' ' A' ' 15' ' ' MET . . . -68.22 -34.04 79.65 Favored Glycine 0 N--CA 1.448 -0.526 0 C-N-CA 120.823 -0.703 . . . . 0.0 111.43 179.268 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -69.45 -37.18 77.23 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.839 0.352 . . . . 0.0 110.421 179.415 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 50.1 mm -62.41 -53.44 47.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 115.918 -0.583 . . . . 0.0 110.939 179.601 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -56.33 -42.03 88.24 Favored Glycine 0 C--N 1.33 0.245 0 C-N-CA 120.747 -0.74 . . . . 0.0 112.161 179.889 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 15' ' ' MET . . . . . 0.464 ' HG2' ' O ' ' A' ' 11' ' ' GLY . 24.5 mmt -63.45 -41.87 98.64 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.737 0.303 . . . . 0.0 110.53 179.613 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 39.7 tp -54.19 -40.6 67.71 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.051 -0.522 . . . . 0.0 110.601 179.835 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 41.3 t -65.41 -49.03 80.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 115.963 -0.562 . . . . 0.0 111.067 179.955 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -63.31 -47.67 85.73 Favored Glycine 0 C--N 1.331 0.251 0 C-N-CA 120.769 -0.729 . . . . 0.0 112.219 179.724 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 24.9 m -50.32 -44.18 54.09 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-O 120.665 0.269 . . . . 0.0 111.295 -179.973 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 56.9 mt -71.43 -38.73 71.34 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 116.343 -0.39 . . . . 0.0 111.282 179.973 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -60.77 -32.18 71.5 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.242 -0.436 . . . . 0.0 111.549 -179.551 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 22' ' ' PHE . . . . . 0.629 ' HB2' HG22 ' A' ' 41' ' ' VAL . 2.8 m-85 -90.75 -34.46 15.34 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.419 -0.355 . . . . 0.0 111.209 -179.481 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -64.88 -48.49 74.06 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.245 -179.822 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 24' ' ' TRP . . . . . . . . . . . . . 3.6 t-105 -68.03 -53.63 24.34 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 115.906 -0.588 . . . . 0.0 111.25 -179.617 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -65.17 -19.52 66.02 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.862 0.363 . . . . 0.0 111.114 -179.99 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -73.63 -46.54 24.35 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.815 -0.707 . . . . 0.0 112.559 179.99 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 25.4 mmm180 -60.99 -21.86 63.94 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.878 0.37 . . . . 0.0 111.076 -179.861 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 15.6 t70 -117.19 97.63 6.02 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.924 -179.969 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -167.72 -71.42 0.03 OUTLIER 'General case' 0 C--N 1.331 -0.204 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.113 179.958 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 159.35 -166.41 34.72 Favored Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 120.826 -0.702 . . . . 0.0 112.516 -179.949 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 77.9 p -94.65 111.15 22.93 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 120.827 0.346 . . . . 0.0 111.081 -179.839 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 139.02 -50.89 0.78 Allowed Glycine 0 C--N 1.331 0.261 0 C-N-CA 120.942 -0.647 . . . . 0.0 112.523 179.832 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 45.7 mt-10 -68.98 -20.72 64.18 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.69 0.281 . . . . 0.0 111.064 -179.901 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 34' ' ' ARG . . . . . 0.444 ' O ' HG23 ' A' ' 38' ' ' VAL . 99.9 mtt180 -49.28 -31.15 8.44 Favored 'General case' 0 C--N 1.332 -0.174 0 CA-C-N 116.123 -0.49 . . . . 0.0 111.681 -179.665 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 23.2 ttp180 -64.62 -47.89 76.91 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-O 120.805 0.336 . . . . 0.0 110.816 179.829 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 76.1 m-85 -67.12 -29.52 69.28 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.123 -0.489 . . . . 0.0 111.047 179.859 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 37' ' ' TYR . . . . . 0.447 ' O ' HG23 ' A' ' 41' ' ' VAL . 35.5 m-85 -71.48 -52.62 17.41 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.3 -179.628 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 38' ' ' VAL . . . . . 0.444 HG23 ' O ' ' A' ' 34' ' ' ARG . 84.9 t -56.75 -36.61 49.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-O 121.077 0.465 . . . . 0.0 110.263 179.664 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 17.3 m -69.07 -51.12 42.15 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 115.686 -0.688 . . . . 0.0 110.865 179.392 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 40' ' ' LEU . . . . . 0.408 HD23 ' CG ' ' A' ' 22' ' ' PHE . 11.4 tp -55.48 -50.81 68.92 Favored 'General case' 0 C--O 1.237 0.43 0 CA-C-N 115.914 -0.584 . . . . 0.0 110.707 -179.972 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 41' ' ' VAL . . . . . 0.629 HG22 ' HB2' ' A' ' 22' ' ' PHE . 60.0 t -62.1 -34.46 63.59 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.367 0 CA-C-N 115.675 -0.693 . . . . 0.0 110.287 179.29 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 42' ' ' GLY . . . . . 0.427 ' O ' HG12 ' A' ' 46' ' ' ILE . . . -60.21 -34.91 86.36 Favored Glycine 0 N--CA 1.449 -0.493 0 C-N-CA 120.864 -0.684 . . . . 0.0 112.337 179.949 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 43' ' ' ILE . . . . . 0.667 HG22 ' HE3' ' A' ' 205' ' ' LYS . 0.3 OUTLIER -71.83 -58.47 5.05 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.218 0 CA-C-O 120.752 0.311 . . . . 0.0 110.944 179.901 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 80.7 p -61.03 -20.59 62.71 Favored 'General case' 0 C--N 1.332 -0.153 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.262 -179.621 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -79.51 -57.15 3.19 Favored Glycine 0 CA--C 1.519 0.287 0 C-N-CA 120.792 -0.718 . . . . 0.0 112.94 -179.327 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 46' ' ' ILE . . . . . 0.427 HG12 ' O ' ' A' ' 42' ' ' GLY . 16.5 pt -58.36 -36.25 57.61 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.213 0 CA-C-O 120.976 0.417 . . . . 0.0 111.071 -179.994 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 47' ' ' ALA . . . . . 0.663 ' HB2' ' HE2' ' A' ' 205' ' ' LYS . . . -68.15 -45.94 72.17 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-N 116.079 -0.51 . . . . 0.0 111.314 179.518 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 48' ' ' ALA . . . . . 0.429 ' HB2' ' HB3' ' A' ' 15' ' ' MET . . . -54.71 -40.41 69.18 Favored 'General case' 0 C--N 1.332 -0.186 0 CA-C-N 116.271 -0.422 . . . . 0.0 111.909 -179.451 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 35.7 m -76.01 -34.11 26.36 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.384 0 CA-C-N 116.452 -0.34 . . . . 0.0 111.482 -179.318 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -65.03 -36.54 84.69 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.905 0.383 . . . . 0.0 111.033 179.718 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 38.1 m-85 -73.29 -39.8 65.06 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.021 -0.536 . . . . 0.0 110.685 -179.862 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -63.29 -46.72 85.43 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 115.92 -0.582 . . . . 0.0 111.527 179.86 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 53' ' ' VAL . . . . . 0.464 HG23 ' N ' ' A' ' 54' ' ' MET . 30.4 m -67.77 -46.14 83.04 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.19 0 CA-C-N 116.341 -0.39 . . . . 0.0 111.109 -179.78 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 54' ' ' MET . . . . . 0.483 ' HG3' ' HE1' ' A' ' 60' ' ' TRP . 13.3 ttp -64.44 -29.31 70.36 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.995 0.426 . . . . 0.0 110.294 179.834 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 55' ' ' ALA . . . . . 0.507 ' HB2' ' HB2' ' A' ' 8' ' ' PHE . . . -64.36 -32.23 73.75 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 115.919 -0.582 . . . . 0.0 111.092 179.502 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 97.4 mt -82.85 6.26 18.97 Favored 'General case' 0 C--N 1.331 -0.204 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.197 -179.674 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 94.33 -5.25 70.97 Favored Glycine 0 N--CA 1.452 -0.265 0 C-N-CA 120.667 -0.778 . . . . 0.0 112.759 179.787 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 58.8 t -62.66 140.52 19.34 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.243 0 CA-C-O 120.701 0.286 . . . . 0.0 110.825 179.861 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 85.89 -23.64 8.91 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.615 -179.859 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 60' ' ' TRP . . . . . 0.483 ' HE1' ' HG3' ' A' ' 54' ' ' MET . 13.3 m0 -61.08 108.02 0.82 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.806 0.336 . . . . 0.0 110.722 179.909 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 7.4 p -118.67 131.58 24.23 Favored Pre-proline 0 CA--C 1.533 0.293 0 CA-C-N 116.343 -0.39 . . . . 0.0 111.469 -179.863 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 57.7 Cg_endo -71.9 147.77 50.36 Favored 'Trans proline' 0 C--N 1.35 0.637 0 C-N-CA 122.481 2.121 . . . . 0.0 112.501 179.842 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 76.8 t -141.91 99.19 0.82 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 115.92 -0.582 . . . . 0.0 111.019 -179.813 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . 58.72 -85.82 0.02 OUTLIER 'General case' 0 C--N 1.332 -0.172 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.229 -179.927 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 41.2 mt-10 -127.96 -20.39 3.84 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.319 179.723 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 66' ' ' ARG . . . . . . . . . . . . . 18.6 ptp180 -100.26 164.3 12.01 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 115.773 -0.649 . . . . 0.0 110.148 179.709 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 44.5 m -123.15 138.26 54.7 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-O 120.935 0.398 . . . . 0.0 111.213 -179.779 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 68' ' ' VAL . . . . . 0.485 HG11 ' HB3' ' A' ' 117' ' ' MET . 23.9 m -125.48 146.06 31.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.012 -0.54 . . . . 0.0 110.849 179.792 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 69' ' ' PHE . . . . . . . . . . . . . 8.5 m-85 -104.85 114.97 29.5 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.044 -179.732 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 70' ' ' VAL . . . . . 0.561 HG12 ' HD3' ' A' ' 71' ' ' PRO . 0.5 OUTLIER -66.94 -32.08 4.55 Favored Pre-proline 0 CA--C 1.54 0.58 0 N-CA-C 112.849 0.685 . . . . 0.0 112.849 -179.241 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 71' ' ' PRO . . . . . 0.561 ' HD3' HG12 ' A' ' 70' ' ' VAL . 14.5 Cg_exo -68.39 -18.04 44.07 Favored 'Trans proline' 0 C--N 1.36 1.157 0 C-N-CA 121.944 1.763 . . . . 0.0 112.704 -179.603 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 59.0 ttt180 -72.97 -55.2 6.9 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.767 0.317 . . . . 0.0 111.637 -179.224 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 73' ' ' TYR . . . . . . . . . . . . . 4.0 m-85 -71.8 -34.44 69.39 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.482 -0.326 . . . . 0.0 110.74 -179.143 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 74' ' ' ILE . . . . . 0.531 HG22 ' HA ' ' A' ' 71' ' ' PRO . 0.4 OUTLIER -69.38 -41.2 80.75 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.192 0 CA-C-N 116.515 -0.311 . . . . 0.0 110.333 179.736 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 11.3 t70 -58.36 -37.64 75.62 Favored 'General case' 0 CA--C 1.518 -0.256 0 N-CA-C 109.427 -0.583 . . . . 0.0 109.427 178.901 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 76' ' ' TRP . . . . . 0.499 ' HB3' ' SD ' ' A' ' 109' ' ' MET . 42.6 m0 -64.97 -38.56 91.36 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 115.567 -0.742 . . . . 0.0 110.824 179.531 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 77' ' ' ILE . . . . . 0.512 ' O ' ' HG2' ' A' ' 81' ' ' PRO . 83.7 mt -66.54 -28.63 43.95 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-N 116.39 -0.368 . . . . 0.0 110.894 179.633 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 53.9 mt -91.47 -21.13 21.08 Favored 'General case' 0 C--N 1.327 -0.41 0 N-CA-C 112.044 0.387 . . . . 0.0 112.044 -179.969 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 71.5 p -102.3 -52.68 3.07 Favored 'General case' 0 CA--C 1.531 0.219 0 N-CA-C 113.425 0.898 . . . . 0.0 113.425 -178.099 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 80' ' ' THR . . . . . 0.643 ' HB ' ' HD3' ' A' ' 81' ' ' PRO . 26.2 m -50.2 -54.78 30.29 Favored Pre-proline 0 CA--C 1.532 0.283 0 N-CA-C 112.749 0.648 . . . . 0.0 112.749 -178.513 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 81' ' ' PRO . . . . . 0.643 ' HD3' ' HB ' ' A' ' 80' ' ' THR . 52.7 Cg_exo -57.1 -23.7 54.23 Favored 'Trans proline' 0 C--N 1.351 0.696 0 C-N-CA 121.513 1.475 . . . . 0.0 111.35 179.63 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 82' ' ' LEU . . . . . . . . . . . . . 16.4 tp -76.96 -32.72 57.5 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 115.445 -0.798 . . . . 0.0 109.764 179.39 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 83' ' ' ILE . . . . . 0.456 HG23 ' HE2' ' A' ' 208' ' ' PHE . 40.4 mm -66.44 -54.38 26.63 Favored 'Isoleucine or valine' 0 C--O 1.233 0.185 0 CA-C-N 115.835 -0.62 . . . . 0.0 110.514 179.329 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 27.5 m -61.13 -31.07 49.09 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.31 0 N-CA-C 109.378 -0.601 . . . . 0.0 109.378 179.092 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 85' ' ' TYR . . . . . 0.422 ' O ' ' HG ' ' A' ' 89' ' ' LEU . 80.4 t80 -61.64 -35.58 78.33 Favored 'General case' 0 N--CA 1.453 -0.282 0 CA-C-N 115.593 -0.73 . . . . 0.0 109.155 178.338 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 86' ' ' PHE . . . . . . . . . . . . . 34.1 t80 -61.9 -49.67 75.26 Favored 'General case' 0 CA--C 1.52 -0.178 0 CA-C-N 115.78 -0.645 . . . . 0.0 109.623 179.046 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 3.9 mm? -57.71 -32.8 67.75 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 115.655 -0.702 . . . . 0.0 110.034 179.131 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -73.15 -27.43 68.37 Favored Glycine 0 N--CA 1.451 -0.305 0 CA-C-N 115.642 -0.708 . . . . 0.0 112.826 179.784 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 89' ' ' LEU . . . . . 0.422 ' HG ' ' O ' ' A' ' 85' ' ' TYR . 94.3 mt -72.39 -44.42 62.54 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.904 0.383 . . . . 0.0 111.084 -179.622 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 70.3 mt -70.49 -27.29 64.09 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 115.986 -0.552 . . . . 0.0 111.363 -179.748 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 91' ' ' ALA . . . . . 0.659 ' HA ' ' HB2' ' A' ' 149' ' ' ALA . . . -87.49 -52.65 5.23 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.426 -0.352 . . . . 0.0 111.239 -179.93 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 90.31 59.96 1.42 Allowed Glycine 0 N--CA 1.451 -0.361 0 C-N-CA 120.93 -0.652 . . . . 0.0 112.418 -179.966 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 93' ' ' LEU . . . . . 0.593 HD23 ' HB3' ' A' ' 97' ' ' GLU . 8.1 mp -71.28 -174.72 1.07 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.741 0.305 . . . . 0.0 110.845 -179.894 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 94' ' ' ASP . . . . . 0.451 ' HB2' ' OE2' ' A' ' 97' ' ' GLU . 12.5 m-20 -94.09 -172.16 2.75 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 121.023 0.439 . . . . 0.0 111.545 -179.446 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 43.5 m -67.8 -48.98 64.75 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 115.836 -0.62 . . . . 0.0 111.657 -179.266 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 31.9 ttm180 -73.33 -41.01 64.0 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 121.05 0.452 . . . . 0.0 110.619 -179.338 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 97' ' ' GLU . . . . . 0.593 ' HB3' HD23 ' A' ' 93' ' ' LEU . 0.3 OUTLIER -56.47 -45.83 80.72 Favored 'General case' 0 C--N 1.326 -0.449 0 CA-C-N 115.692 -0.686 . . . . 0.0 111.069 179.983 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 98' ' ' PHE . . . . . 0.448 ' O ' HG12 ' A' ' 102' ' ' ILE . 1.2 m-85 -60.79 -43.97 97.41 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.338 -0.392 . . . . 0.0 110.731 179.63 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -64.8 -29.73 76.08 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.901 -0.666 . . . . 0.0 112.639 -179.995 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 93.1 mt -68.29 -41.68 83.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-O 120.756 0.313 . . . . 0.0 111.249 -179.81 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 34.2 t -68.07 -41.16 84.12 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.411 0 CA-C-N 116.264 -0.425 . . . . 0.0 111.432 -179.573 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 102' ' ' ILE . . . . . 0.448 HG12 ' O ' ' A' ' 98' ' ' PHE . 42.0 mm -68.67 -51.36 46.64 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.447 -0.342 . . . . 0.0 111.44 -179.756 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 15.3 t -56.86 -32.21 65.59 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-O 120.916 0.389 . . . . 0.0 111.04 -179.894 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 104' ' ' LEU . . . . . 0.475 HD23 HD13 ' A' ' 137' ' ' LEU . 33.7 tp -66.06 -48.41 71.14 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.573 179.483 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 105' ' ' ASN . . . . . 0.542 ' N ' HD22 ' A' ' 105' ' ' ASN . 0.9 OUTLIER -62.52 -27.0 68.85 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.045 179.972 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 89.2 m -70.21 -53.36 17.41 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.334 -0.394 . . . . 0.0 111.419 -179.887 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 8.8 p -65.6 -37.07 79.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.296 -0.411 . . . . 0.0 111.304 -179.652 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 55.6 t -65.41 -50.16 74.33 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.249 0 CA-C-N 116.43 -0.35 . . . . 0.0 110.958 179.86 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 109' ' ' MET . . . . . 0.626 ' HE1' HG21 ' A' ' 80' ' ' THR . 7.2 tpp -64.12 -33.54 75.99 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.622 -179.899 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 110' ' ' LEU . . . . . 0.472 HD23 ' C ' ' A' ' 110' ' ' LEU . 3.4 tt -63.06 -41.62 99.5 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-N 115.921 -0.581 . . . . 0.0 109.706 179.052 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -58.12 -47.83 82.08 Favored 'General case' 0 C--N 1.331 -0.203 0 CA-C-N 115.824 -0.625 . . . . 0.0 110.494 179.536 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 112' ' ' GLY . . . . . 0.652 ' HA3' ' H21' ' A' ' 301' ' ' RET . . . -68.47 -32.68 75.57 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.64 -0.791 . . . . 0.0 111.929 179.374 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 113' ' ' PHE . . . . . . . . . . . . . 0.5 OUTLIER -51.79 -68.45 0.17 Allowed 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 121.058 0.456 . . . . 0.0 109.998 179.566 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 114' ' ' ALA . . . . . 0.456 ' O ' HG13 ' A' ' 118' ' ' VAL . . . -70.48 -24.02 62.79 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 115.586 -0.733 . . . . 0.0 111.155 179.819 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -54.08 -40.86 67.68 Favored Glycine 0 C--N 1.331 0.282 0 C-N-CA 121.149 -0.548 . . . . 0.0 112.994 -179.699 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -77.81 -39.15 44.77 Favored 'General case' 0 C--N 1.328 -0.326 0 N-CA-C 112.142 0.423 . . . . 0.0 112.142 -179.429 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 117' ' ' MET . . . . . 0.485 ' HB3' HG11 ' A' ' 68' ' ' VAL . 19.3 ptp -91.4 19.74 5.84 Favored 'General case' 0 C--N 1.329 -0.324 0 N-CA-C 111.788 0.292 . . . . 0.0 111.788 -179.287 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 118' ' ' VAL . . . . . 0.544 HG21 ' HB3' ' A' ' 123' ' ' ARG . 5.0 m -54.08 149.45 18.37 Favored Pre-proline 0 C--N 1.33 -0.282 0 CA-C-N 116.598 -0.274 . . . . 0.0 111.231 179.723 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 119' ' ' PRO . . . . . . . . . . . . . 90.3 Cg_endo -87.34 3.97 6.24 Favored 'Trans proline' 0 N--CA 1.458 -0.581 0 C-N-CA 122.64 2.227 . . . . 0.0 112.236 179.622 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -168.37 -133.96 1.64 Allowed Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.786 -0.721 . . . . 0.0 112.457 -179.951 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 42.4 pt -99.18 18.01 2.77 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.246 0 CA-C-O 120.885 0.374 . . . . 0.0 111.182 -179.834 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 45.1 mt-10 -67.51 -18.46 65.05 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.274 -179.975 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 123' ' ' ARG . . . . . 0.544 ' HB3' HG21 ' A' ' 118' ' ' VAL . 20.5 ptt180 -53.07 -29.82 32.52 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 116.222 -0.444 . . . . 0.0 111.67 -179.678 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 124' ' ' TYR . . . . . . . . . . . . . 28.2 m-85 -67.48 -34.41 77.1 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.589 -0.278 . . . . 0.0 110.795 -179.858 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 125' ' ' ALA . . . . . . . . . . . . . . . -74.78 -56.08 5.16 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.17 -179.978 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 1.1 mt -52.49 -54.34 33.81 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 115.908 -0.587 . . . . 0.0 110.961 -179.86 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 127' ' ' PHE . . . . . 0.417 ' CE1' ' H42' ' A' ' 301' ' ' RET . 8.8 t80 -62.78 -36.4 82.99 Favored 'General case' 0 C--N 1.331 -0.231 0 C-N-CA 120.847 -0.341 . . . . 0.0 110.567 179.756 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 128' ' ' GLY . . . . . . . . . . . . . . . -47.31 -43.98 20.15 Favored Glycine 0 C--N 1.332 0.314 0 C-N-CA 120.136 -1.031 . . . . 0.0 111.153 179.154 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 129' ' ' MET . . . . . . . . . . . . . 0.3 OUTLIER -71.87 -37.05 70.26 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 120.865 0.364 . . . . 0.0 110.026 178.868 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -67.18 -28.19 73.67 Favored Glycine 0 N--CA 1.45 -0.378 0 CA-C-N 115.822 -0.626 . . . . 0.0 112.688 -179.722 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -74.81 -54.18 7.79 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.624 0.25 . . . . 0.0 110.67 -179.953 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 31.7 t -57.95 -41.17 79.55 Favored 'Isoleucine or valine' 0 C--O 1.235 0.318 0 N-CA-C 109.129 -0.693 . . . . 0.0 109.129 178.698 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -66.29 -35.8 81.32 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 115.173 -0.921 . . . . 0.0 110.106 178.929 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 134' ' ' PHE . . . . . 0.418 ' CZ ' ' HA ' ' A' ' 172' ' ' ALA . 57.9 t80 -57.48 -50.9 71.55 Favored 'General case' 0 N--CA 1.45 -0.469 0 CA-C-N 115.937 -0.574 . . . . 0.0 110.022 179.548 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 135' ' ' ILE . . . . . 0.451 ' O ' HG22 ' A' ' 138' ' ' VAL . 60.2 mt -56.64 -33.59 40.39 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.312 0 CA-C-N 115.911 -0.586 . . . . 0.0 109.663 178.95 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . -63.21 -35.21 91.76 Favored Glycine 0 N--CA 1.447 -0.568 0 C-N-CA 120.249 -0.977 . . . . 0.0 111.205 178.507 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 137' ' ' LEU . . . . . 0.475 HD13 HD23 ' A' ' 104' ' ' LEU . 29.1 tp -73.43 -52.13 14.82 Favored 'General case' 0 C--N 1.332 -0.158 0 N-CA-C 110.422 -0.214 . . . . 0.0 110.422 179.612 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 138' ' ' VAL . . . . . 0.791 ' HA ' HD12 ' A' ' 141' ' ' LEU . 4.9 m -55.95 -30.55 28.72 Favored 'Isoleucine or valine' 0 C--O 1.234 0.28 0 N-CA-C 109.069 -0.715 . . . . 0.0 109.069 178.92 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 139' ' ' TYR . . . . . 0.413 ' O ' ' N ' ' A' ' 143' ' ' GLY . 49.8 t80 -64.82 -41.96 95.35 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 114.958 -1.019 . . . . 0.0 109.337 178.462 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 19.4 m-85 -65.02 -33.0 74.99 Favored 'General case' 0 C--N 1.333 -0.143 0 CA-C-N 116.036 -0.529 . . . . 0.0 109.791 178.577 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 141' ' ' LEU . . . . . 0.791 HD12 ' HA ' ' A' ' 138' ' ' VAL . 81.9 mt -61.21 -36.38 79.75 Favored 'General case' 0 C--O 1.232 0.149 0 CA-C-N 115.977 -0.556 . . . . 0.0 109.895 179.078 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 142' ' ' VAL . . . . . 0.404 HG22 ' NH1' ' A' ' 164' ' ' ARG . 2.9 t -109.27 10.48 8.96 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-N 115.751 -0.659 . . . . 0.0 110.658 179.729 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 143' ' ' GLY . . . . . 0.413 ' N ' ' O ' ' A' ' 139' ' ' TYR . . . -85.52 -147.6 9.81 Favored Glycine 0 CA--C 1.519 0.291 0 C-N-CA 120.968 -0.634 . . . . 0.0 113.008 -179.511 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 144' ' ' PRO . . . . . . . . . . . . . 51.3 Cg_exo -52.98 -24.87 26.11 Favored 'Trans proline' 0 C--N 1.349 0.579 0 C-N-CA 122.716 2.278 . . . . 0.0 112.754 -179.799 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 145' ' ' MET . . . . . 0.464 ' HG2' HD11 ' A' ' 93' ' ' LEU . 55.3 mtt -53.22 -39.15 63.55 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 116.352 -0.385 . . . . 0.0 111.244 179.975 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 146' ' ' THR . . . . . . . . . . . . . 81.2 p -62.1 -51.2 68.89 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.794 -179.36 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 147' ' ' GLU . . . . . 0.479 ' O ' ' HG2' ' A' ' 151' ' ' GLN . 40.0 mt-10 -74.1 -18.06 60.86 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.394 -0.366 . . . . 0.0 111.249 -179.534 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 148' ' ' SER . . . . . . . . . . . . . 44.6 t -71.21 -47.69 55.9 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.764 0.316 . . . . 0.0 111.231 -179.807 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 149' ' ' ALA . . . . . 0.659 ' HB2' ' HA ' ' A' ' 91' ' ' ALA . . . -78.02 -31.99 50.79 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.128 -0.487 . . . . 0.0 112.242 -178.975 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 150' ' ' SER . . . . . . . . . . . . . 70.2 m -62.68 -6.67 3.79 Favored 'General case' 0 C--N 1.328 -0.337 0 N-CA-C 111.993 0.368 . . . . 0.0 111.993 -179.384 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 151' ' ' GLN . . . . . 0.479 ' HG2' ' O ' ' A' ' 147' ' ' GLU . 67.0 mm-40 -111.58 17.14 20.27 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.731 -0.213 . . . . 0.0 111.095 -179.775 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 25.6 mtp180 -101.71 -52.24 3.25 Favored 'General case' 0 C--N 1.331 -0.201 0 CA-C-O 120.832 0.349 . . . . 0.0 111.351 -179.839 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 153' ' ' SER . . . . . 0.594 ' HB3' HG12 ' A' ' 156' ' ' ILE . 31.5 t -156.83 172.27 18.93 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.959 179.691 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 154' ' ' SER . . . . . . . . . . . . . 61.4 m -73.05 -39.78 65.64 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 116.257 -0.428 . . . . 0.0 110.65 179.679 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -76.6 -28.81 58.78 Favored Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.904 -0.665 . . . . 0.0 112.7 -179.936 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 156' ' ' ILE . . . . . 0.594 HG12 ' HB3' ' A' ' 153' ' ' SER . 25.8 mm -58.37 -42.45 84.05 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.233 0 CA-C-O 120.764 0.316 . . . . 0.0 111.486 -179.96 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 157' ' ' LYS . . . . . 0.422 ' O ' HG13 ' A' ' 161' ' ' VAL . 25.0 ttpp -63.31 -42.24 99.0 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.272 -0.422 . . . . 0.0 111.499 -179.496 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 46.5 t -65.23 -47.68 75.98 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.418 -0.355 . . . . 0.0 111.88 -179.257 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 159' ' ' LEU . . . . . 0.501 ' O ' HD13 ' A' ' 163' ' ' LEU . 4.9 tt -66.13 -34.68 78.61 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.507 -0.315 . . . . 0.0 111.241 -179.396 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 160' ' ' TYR . . . . . . . . . . . . . 58.4 t80 -73.69 -46.16 48.01 Favored 'General case' 0 C--N 1.327 -0.382 0 N-CA-C 112.365 0.506 . . . . 0.0 112.365 -178.767 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 161' ' ' VAL . . . . . 0.442 HG23 ' N ' ' A' ' 162' ' ' ARG . 28.8 m -59.97 -46.52 93.99 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 N-CA-C 112.171 0.434 . . . . 0.0 112.171 -178.933 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 162' ' ' ARG . . . . . 0.442 ' N ' HG23 ' A' ' 161' ' ' VAL . 79.0 ttt180 -65.61 -46.04 80.85 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.71 0.291 . . . . 0.0 111.552 -179.331 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 163' ' ' LEU . . . . . 0.501 HD13 ' O ' ' A' ' 159' ' ' LEU . 7.8 mp -65.44 -52.02 56.13 Favored 'General case' 0 C--N 1.329 -0.317 0 N-CA-C 112.106 0.41 . . . . 0.0 112.106 -179.186 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 164' ' ' ARG . . . . . 0.602 ' O ' HG23 ' A' ' 168' ' ' VAL . 5.7 ppt_? -58.62 -43.34 89.62 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.598 -0.274 . . . . 0.0 111.605 -178.861 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 165' ' ' ASN . . . . . 0.471 ' O ' HG23 ' A' ' 169' ' ' VAL . 4.7 m-20 -55.97 -49.44 73.57 Favored 'General case' 0 C--N 1.331 -0.202 0 CA-C-O 121.129 0.49 . . . . 0.0 110.427 179.513 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 166' ' ' LEU . . . . . 0.485 ' O ' ' HG ' ' A' ' 170' ' ' LEU . 3.1 tt -60.15 -50.04 75.24 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 115.563 -0.744 . . . . 0.0 111.681 -179.52 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 167' ' ' THR . . . . . 0.479 ' O ' ' HB2' ' A' ' 171' ' ' TRP . 60.1 m -56.41 -54.01 50.63 Favored 'General case' 0 C--N 1.331 -0.232 0 N-CA-C 112.324 0.49 . . . . 0.0 112.324 -178.796 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 168' ' ' VAL . . . . . 0.644 HG22 HD13 ' A' ' 141' ' ' LEU . 45.4 t -52.27 -43.8 40.43 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.227 0 N-CA-C 112.339 0.496 . . . . 0.0 112.339 -179.764 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 169' ' ' VAL . . . . . 0.471 HG23 ' O ' ' A' ' 165' ' ' ASN . 72.8 t -59.92 -65.75 0.44 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 N-CA-C 113.016 0.747 . . . . 0.0 113.016 -178.47 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 170' ' ' LEU . . . . . 0.485 ' HG ' ' O ' ' A' ' 166' ' ' LEU . 0.7 OUTLIER -63.08 -37.78 88.56 Favored 'General case' 0 C--N 1.33 -0.26 0 N-CA-C 112.593 0.59 . . . . 0.0 112.593 -178.163 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 171' ' ' TRP . . . . . 0.657 ' HE1' H203 ' A' ' 301' ' ' RET . 2.9 m0 -64.25 -27.58 69.15 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.832 0.349 . . . . 0.0 110.771 179.813 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 172' ' ' ALA . . . . . 0.418 ' HA ' ' CZ ' ' A' ' 134' ' ' PHE . . . -72.48 -6.93 47.19 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.948 -179.818 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 173' ' ' ILE . . . . . 0.492 ' O ' HG12 ' A' ' 177' ' ' ILE . 28.8 mm -88.4 -21.24 7.05 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 115.952 -0.567 . . . . 0.0 111.175 -179.985 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 174' ' ' TYR . . . . . 0.403 ' N ' ' CD ' ' A' ' 175' ' ' PRO . 8.7 m-85 -53.59 -48.25 93.74 Favored Pre-proline 0 N--CA 1.464 0.261 0 CA-C-N 116.339 -0.392 . . . . 0.0 111.93 -179.375 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 175' ' ' PRO . . . . . 0.403 ' CD ' ' N ' ' A' ' 174' ' ' TYR . 84.6 Cg_exo -48.43 -33.27 22.52 Favored 'Trans proline' 0 C--N 1.351 0.667 0 C-N-CA 121.854 1.703 . . . . 0.0 112.048 179.588 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 176' ' ' PHE . . . . . 0.465 ' HD2' ' HA ' ' A' ' 173' ' ' ILE . 60.9 m-85 -80.9 -50.35 9.87 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 115.873 -0.603 . . . . 0.0 111.954 -179.905 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 177' ' ' ILE . . . . . 0.507 HG13 HD11 ' A' ' 200' ' ' LEU . 13.6 mm -60.25 -32.08 49.86 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.443 0 CA-C-N 116.279 -0.418 . . . . 0.0 112.036 -178.386 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 178' ' ' TRP . . . . . 0.458 ' HH2' ' HB2' ' A' ' 123' ' ' ARG . 82.0 t90 -73.18 -52.06 15.52 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.91 0.386 . . . . 0.0 110.81 179.928 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 179' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -68.76 -54.77 14.07 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-N 115.989 -0.55 . . . . 0.0 111.484 -179.119 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 180' ' ' LEU . . . . . 0.542 HD22 HD11 ' A' ' 187' ' ' LEU . 26.6 mt -64.06 -29.7 70.82 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.55 -0.295 . . . . 0.0 111.298 -179.37 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . -69.12 -175.79 12.24 Favored Glycine 0 N--CA 1.449 -0.44 0 C-N-CA 119.817 -1.183 . . . . 0.0 111.629 178.957 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 182' ' ' PRO . . . . . 0.502 ' HG3' ' HA ' ' A' ' 190' ' ' PRO . 82.3 Cg_exo -47.47 -43.54 27.07 Favored 'Trans proline' 0 CA--C 1.537 0.669 0 C-N-CA 122.678 2.252 . . . . 0.0 113.76 179.943 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 183' ' ' PRO . . . . . 0.424 ' HB2' ' O ' ' A' ' 178' ' ' TRP . 83.4 Cg_exo -43.07 -51.77 5.31 Favored 'Trans proline' 0 C--N 1.356 0.957 0 C-N-CA 122.491 2.127 . . . . 0.0 114.065 -179.744 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 184' ' ' GLY . . . . . . . . . . . . . . . -102.74 -123.95 5.36 Favored Glycine 0 C--N 1.335 0.515 0 C-N-CA 119.942 -1.123 . . . . 0.0 113.631 -179.063 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 185' ' ' VAL . . . . . 0.406 ' CG2' HD21 ' A' ' 187' ' ' LEU . 23.6 m -54.09 -33.33 24.49 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.405 0 N-CA-C 112.647 0.61 . . . . 0.0 112.647 -178.95 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 186' ' ' ALA . . . . . 0.421 ' HB2' ' HA ' ' A' ' 182' ' ' PRO . . . 58.92 83.35 0.13 Allowed 'General case' 0 N--CA 1.464 0.246 0 CA-C-O 120.675 0.274 . . . . 0.0 111.624 179.786 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 187' ' ' LEU . . . . . 0.542 HD11 HD22 ' A' ' 180' ' ' LEU . 7.7 mt -92.32 -49.92 5.91 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-O 120.902 0.382 . . . . 0.0 111.351 179.795 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 188' ' ' LEU . . . . . 0.463 HD12 ' HB2' ' A' ' 187' ' ' LEU . 7.3 mp -79.79 -164.59 0.68 Allowed 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.001 -0.545 . . . . 0.0 111.197 -179.268 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 189' ' ' THR . . . . . 0.497 ' HB ' HG23 ' A' ' 192' ' ' VAL . 20.8 m -91.08 137.46 26.46 Favored Pre-proline 0 C--N 1.329 -0.295 0 CA-C-N 115.868 -0.605 . . . . 0.0 110.634 -179.73 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 190' ' ' PRO . . . . . 0.502 ' HA ' ' HG3' ' A' ' 182' ' ' PRO . 92.3 Cg_exo -44.23 -37.24 9.87 Favored 'Trans proline' 0 C--N 1.35 0.656 0 C-N-CA 122.519 2.146 . . . . 0.0 113.278 -179.649 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 191' ' ' THR . . . . . 0.433 HG22 HG22 ' A' ' 189' ' ' THR . 6.2 t -78.52 -40.82 34.05 Favored 'General case' 0 C--N 1.33 -0.275 0 N-CA-C 111.683 0.253 . . . . 0.0 111.683 -179.616 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 192' ' ' VAL . . . . . 0.497 HG23 ' HB ' ' A' ' 189' ' ' THR . 96.9 t -62.52 -48.69 87.08 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-O 120.658 0.266 . . . . 0.0 111.463 -179.729 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 193' ' ' ASP . . . . . . . . . . . . . 21.6 m-20 -56.0 -46.58 78.7 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.397 -0.365 . . . . 0.0 111.089 -179.714 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 194' ' ' VAL . . . . . 0.429 HG23 ' O ' ' A' ' 190' ' ' PRO . 71.0 t -59.34 -37.07 67.36 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.412 -0.358 . . . . 0.0 110.739 179.547 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 195' ' ' ALA . . . . . . . . . . . . . . . -59.32 -41.71 89.72 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.303 -0.408 . . . . 0.0 110.608 179.534 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 196' ' ' LEU . . . . . . . . . . . . . 98.1 mt -67.3 -38.4 84.95 Favored 'General case' 0 C--N 1.333 -0.143 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.197 179.248 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 197' ' ' ILE . . . . . 0.445 HG23 ' HZ2' ' A' ' 76' ' ' TRP . 15.8 mm -60.57 -56.24 19.06 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.242 0 CA-C-N 115.901 -0.59 . . . . 0.0 110.248 179.122 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 198' ' ' VAL . . . . . . . . . . . . . 93.7 t -54.28 -34.58 28.01 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.516 0 CA-C-N 115.623 -0.717 . . . . 0.0 109.321 178.303 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 199' ' ' TYR . . . . . . . . . . . . . 29.7 t80 -69.83 -32.99 71.71 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 115.112 -0.949 . . . . 0.0 110.609 179.794 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 200' ' ' LEU . . . . . 0.516 ' O ' HG12 ' A' ' 203' ' ' VAL . 23.0 mt -69.86 -39.33 76.41 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 115.97 -0.559 . . . . 0.0 111.024 179.984 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 201' ' ' ASP . . . . . . . . . . . . . 15.2 m-20 -72.95 -34.6 66.64 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-O 121.204 0.526 . . . . 0.0 110.103 179.625 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 202' ' ' LEU . . . . . . . . . . . . . 3.1 mt -75.01 -27.13 59.99 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 115.514 -0.766 . . . . 0.0 111.749 -179.439 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 203' ' ' VAL . . . . . 0.516 HG12 ' O ' ' A' ' 200' ' ' LEU . 10.9 p -79.61 -36.36 17.47 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.334 0 C-N-CA 120.834 -0.347 . . . . 0.0 110.856 -178.924 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 204' ' ' THR . . . . . . . . . . . . . 96.9 m -67.87 -58.27 4.85 Favored 'General case' 0 C--N 1.328 -0.333 0 C-N-CA 120.933 -0.307 . . . . 0.0 110.902 179.212 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 205' ' ' LYS . . . . . 0.667 ' HE3' HG22 ' A' ' 43' ' ' ILE . 60.5 mttp -60.52 -58.29 9.11 Favored 'General case' 0 C--N 1.331 -0.212 0 N-CA-C 112.067 0.395 . . . . 0.0 112.067 -178.937 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 52.8 t -67.69 -37.02 77.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 N-CA-C 111.818 0.303 . . . . 0.0 111.818 -179.303 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 207' ' ' GLY . . . . . 0.407 ' HA3' ' O ' ' A' ' 203' ' ' VAL . . . -53.55 -60.48 8.19 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.908 -0.663 . . . . 0.0 113.975 -178.818 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 208' ' ' PHE . . . . . 0.506 ' O ' ' HB2' ' A' ' 212' ' ' ALA . 1.1 p90 -75.45 -26.75 58.53 Favored 'General case' 0 C--O 1.219 -0.513 0 CA-C-N 117.317 0.559 . . . . 0.0 111.778 -179.14 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 209' ' ' GLY . . . . . 0.45 ' O ' ' HB3' ' A' ' 212' ' ' ALA . . . -66.4 -35.24 89.88 Favored Glycine 0 N--CA 1.452 -0.267 0 C-N-CA 121.491 -0.385 . . . . 0.0 112.202 179.597 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 210' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER -75.75 -44.86 39.54 Favored 'General case' 0 CA--C 1.514 -0.433 0 N-CA-C 108.316 -0.994 . . . . 0.0 108.316 178.742 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 211' ' ' ILE . . . . . . . . . . . . . 44.3 mt -65.6 -27.55 41.85 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.55 0 N-CA-C 107.91 -1.144 . . . . 0.0 107.91 176.86 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 212' ' ' ALA . . . . . 0.506 ' HB2' ' O ' ' A' ' 208' ' ' PHE . . . -62.37 -45.47 93.02 Favored 'General case' 0 N--CA 1.451 -0.418 0 CA-C-N 114.741 -1.118 . . . . 0.0 110.508 179.89 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 213' ' ' LEU . . . . . . . . . . . . . 93.9 mt -69.73 -54.55 13.22 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 115.151 -0.931 . . . . 0.0 111.676 -179.181 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 214' ' ' ASP . . . . . . . . . . . . . 19.5 t70 -55.21 -41.52 72.11 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.331 -0.395 . . . . 0.0 111.511 -179.608 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 215' ' ' ALA . . . . . 0.459 ' O ' ' HG ' ' A' ' 219' ' ' LEU . . . -70.25 -57.7 4.59 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.407 -0.36 . . . . 0.0 111.781 -179.419 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 216' ' ' ALA . . . . . . . . . . . . . . . -55.59 -34.92 65.26 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.5 -0.318 . . . . 0.0 111.428 -179.541 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 217' ' ' ALA . . . . . . . . . . . . . . . -67.02 -41.02 87.33 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.506 179.894 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 218' ' ' THR . . . . . . . . . . . . . 42.3 m -64.84 -37.57 88.06 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 115.775 -0.648 . . . . 0.0 110.916 179.707 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 219' ' ' LEU . . . . . 0.459 ' HG ' ' O ' ' A' ' 215' ' ' ALA . 68.9 mt -61.59 -46.25 90.64 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.851 -179.896 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 220' ' ' ARG . . . . . 0.427 ' HD2' ' N ' ' A' ' 220' ' ' ARG . 10.0 mpt_? -82.38 -14.26 55.52 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.163 -0.472 . . . . 0.0 111.086 -179.834 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 221' ' ' ALA . . . . . . . . . . . . . . . -70.67 -47.75 58.33 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.363 -0.381 . . . . 0.0 111.229 179.971 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 222' ' ' GLU . . . . . . . . . . . . . 12.3 pt-20 -91.42 -30.5 16.47 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.933 -179.737 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 223' ' ' HIS . . . . . . . . . . . . . 18.6 p80 36.92 81.9 0.02 OUTLIER 'General case' 0 N--CA 1.463 0.21 0 CA-C-N 115.898 -0.592 . . . . 0.0 111.536 -179.769 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 224' ' ' GLY . . . . . . . . . . . . . . . -99.93 54.0 0.94 Allowed Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.771 -179.682 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 225' ' ' GLU . . . . . . . . . . . . . 45.6 mt-10 -80.5 134.51 35.97 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.769 0.319 . . . . 0.0 110.68 179.726 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 226' ' ' SER . . . . . . . . . . . . . 46.0 t -69.32 -59.85 2.73 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.081 -179.737 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 227' ' ' LEU . . . . . . . . . . . . . 92.3 mt -61.53 114.54 3.31 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-O 120.88 0.372 . . . . 0.0 111.078 -179.901 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 228' ' ' ALA . . . . . . . . . . . . . . . -152.32 -0.67 0.29 Allowed 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.084 -0.507 . . . . 0.0 111.028 179.885 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 229' ' ' GLY . . . . . . . . . . . . . . . -68.03 146.26 46.07 Favored Glycine 0 N--CA 1.45 -0.369 0 C-N-CA 120.884 -0.674 . . . . 0.0 112.461 179.893 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 230' ' ' VAL . . . . . . . . . . . . . 31.1 t -84.21 132.24 32.03 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-O 120.832 0.348 . . . . 0.0 111.077 -179.845 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 231' ' ' ASP . . . . . . . . . . . . . 20.9 t70 -72.58 101.68 3.07 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.848 179.887 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 232' ' ' THR . . . . . . . . . . . . . 48.9 p -129.28 6.69 5.35 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.176 179.843 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 233' ' ' ASP . . . . . . . . . . . . . 6.1 p-10 -82.08 8.93 9.5 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.834 179.908 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 234' ' ' THR . . . . . . . . . . . . . 4.4 t -59.31 142.13 86.74 Favored Pre-proline 0 C--N 1.33 -0.282 0 CA-C-N 116.111 -0.495 . . . . 0.0 111.318 -179.957 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 235' ' ' PRO . . . . . . . . . . . . . 74.3 Cg_endo -74.81 -172.53 1.26 Allowed 'Trans proline' 0 C--N 1.347 0.492 0 C-N-CA 122.495 2.13 . . . . 0.0 112.345 179.976 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 236' ' ' ALA . . . . . . . . . . . . . . . -135.44 155.73 50.06 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.124 -0.489 . . . . 0.0 111.041 -179.987 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 237' ' ' VAL . . . . . . . . . . . . . 31.0 m -110.42 23.55 4.25 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 116.102 -0.499 . . . . 0.0 111.074 -179.931 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 238' ' ' ALA . . . . . . . . . . . . . . . -78.48 -18.57 54.64 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.22 -179.911 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 239' ' ' ASP . . . . . . . . . . . . . 15.1 m-20 64.17 157.95 0.08 Allowed 'General case' 0 N--CA 1.462 0.168 0 CA-C-N 116.156 -0.475 . . . . 0.0 111.342 179.894 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 240' ' ' LEU . . . . . . . . . . . . . 78.8 mt -103.38 -62.45 1.29 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.015 -0.539 . . . . 0.0 110.687 179.917 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 241' ' ' GLU . . . . . . . . . . . . . 12.4 pt-20 -117.9 172.96 7.04 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.775 179.91 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 242' ' ' HIS . . . . . . . . . . . . . 69.3 m-70 -100.17 -60.83 1.46 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.281 -0.418 . . . . 0.0 110.813 179.991 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 243' ' ' HIS . . . . . . . . . . . . . 6.4 p-80 -128.02 171.14 12.13 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.224 -179.752 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 244' ' ' HIS . . . . . . . . . . . . . 17.0 p80 -98.53 142.63 29.88 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 115.983 -0.553 . . . . 0.0 110.727 179.852 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 245' ' ' HIS . . . . . . . . . . . . . 48.3 t-80 -153.67 -57.27 0.12 Allowed 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.373 -0.376 . . . . 0.0 111.152 -179.783 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 246' ' ' HIS . . . . . . . . . . . . . 37.6 p-80 -118.29 -14.83 9.79 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.18 -179.851 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 247' ' ' HIS . . . . . . . . . . . . . 59.5 m80 . . . . . 0 C--O 1.249 1.075 0 CA-C-O 118.215 -0.898 . . . . 0.0 111.057 -179.951 . . . . . . . . 0 0 . 1 . 020 nuclear build full ' A' A ' 301' ' ' RET . . . . . 0.657 H203 ' HE1' ' A' ' 171' ' ' TRP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 64.2 mtm . . . . . 0 N--CA 1.485 1.291 0 CA-C-O 120.797 0.332 . . . . 0.0 110.838 . . . . . . . . . 0 0 . 1 . 021 nuclear build full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 41.1 t -91.71 -34.83 6.47 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.242 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.118 179.962 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -88.9 -9.72 67.67 Favored Glycine 0 N--CA 1.452 -0.266 0 C-N-CA 120.867 -0.682 . . . . 0.0 112.626 -179.947 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 31.1 tp -73.95 -35.47 64.53 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-O 120.837 0.351 . . . . 0.0 110.727 -179.967 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 74.0 p -58.23 -30.99 66.94 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.079 -0.51 . . . . 0.0 111.519 -179.863 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 30.9 p -54.29 -35.71 62.88 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.377 -0.374 . . . . 0.0 111.2 -179.964 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 7' ' ' LEU . . . . . . . . . . . . . 4.1 mm? -60.22 -52.23 66.17 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.883 179.868 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 8' ' ' PHE . . . . . 0.542 ' HB2' ' HB2' ' A' ' 55' ' ' ALA . 58.2 m-85 -62.82 -30.92 71.85 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.031 -0.532 . . . . 0.0 110.909 -179.981 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 9' ' ' TRP . . . . . . . . . . . . . 21.5 m95 -67.5 -46.87 71.65 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.087 -0.506 . . . . 0.0 110.212 -179.797 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 88.9 mt -59.67 -38.44 81.49 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 115.69 -0.687 . . . . 0.0 110.343 179.411 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -65.04 -34.24 89.32 Favored Glycine 0 N--CA 1.448 -0.506 0 C-N-CA 120.679 -0.772 . . . . 0.0 111.866 179.36 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -67.91 -32.48 72.97 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-O 120.883 0.373 . . . . 0.0 110.62 179.554 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 70.2 mt -65.22 -53.42 40.8 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 115.91 -0.586 . . . . 0.0 110.624 179.611 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -64.21 -40.16 97.74 Favored Glycine 0 N--CA 1.451 -0.364 0 C-N-CA 120.6 -0.81 . . . . 0.0 112.198 179.72 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 15' ' ' MET . . . . . 0.513 ' HE3' ' HD2' ' A' ' 205' ' ' LYS . 12.5 mmt -63.14 -47.96 80.49 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.676 0.274 . . . . 0.0 110.99 179.797 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 16' ' ' LEU . . . . . 0.706 ' O ' HD23 ' A' ' 20' ' ' LEU . 50.9 tp -54.4 -55.71 25.92 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.329 -179.877 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 46.9 t -56.97 -33.36 42.05 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-O 120.958 0.409 . . . . 0.0 110.45 -179.355 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -67.26 -49.88 49.19 Favored Glycine 0 N--CA 1.452 -0.297 0 N-CA-C 111.185 -0.766 . . . . 0.0 111.185 179.483 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 19' ' ' THR . . . . . 0.538 HG22 HD22 ' A' ' 20' ' ' LEU . 1.4 m -53.39 -43.45 67.89 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 115.28 -0.46 . . . . 0.0 110.84 179.518 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 20' ' ' LEU . . . . . 0.706 HD23 ' O ' ' A' ' 16' ' ' LEU . 0.5 OUTLIER -69.79 -41.96 74.41 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-N 115.755 -0.657 . . . . 0.0 111.943 -179.559 . . . . . . . . 3 3 . 1 . 021 nuclear build full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -59.38 -32.14 69.87 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.521 -0.309 . . . . 0.0 111.795 -179.344 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 22' ' ' PHE . . . . . 0.756 ' HB2' HG22 ' A' ' 41' ' ' VAL . 5.8 m-85 -90.96 -28.66 17.9 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.711 0.291 . . . . 0.0 111.256 -179.722 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -70.33 -50.72 36.22 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 121.007 0.432 . . . . 0.0 111.576 -179.716 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 24' ' ' TRP . . . . . . . . . . . . . 4.6 t-105 -66.06 -38.91 89.51 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 115.867 -0.606 . . . . 0.0 111.494 -179.438 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -78.67 -23.92 45.41 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-O 120.836 0.35 . . . . 0.0 110.77 179.712 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -73.53 -43.21 37.84 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 121.034 -0.603 . . . . 0.0 112.98 -179.756 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 13.4 ptp180 -61.73 -18.11 58.45 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 120.664 0.269 . . . . 0.0 111.227 -179.719 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 17.8 t70 -121.74 97.53 5.54 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 116.44 -0.345 . . . . 0.0 111.105 -179.795 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -164.69 -83.65 0.02 OUTLIER 'General case' 0 C--N 1.331 -0.239 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.167 179.623 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -148.69 -113.24 0.69 Allowed Glycine 0 N--CA 1.452 -0.283 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.441 -179.784 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 79.3 p -145.84 -44.8 0.21 Allowed 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.706 0.289 . . . . 0.0 111.115 -179.927 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -80.84 -29.82 41.23 Favored Glycine 0 C--N 1.331 0.254 0 C-N-CA 120.792 -0.718 . . . . 0.0 112.86 -179.709 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 2.7 mp0 -66.42 -20.88 66.18 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.898 0.38 . . . . 0.0 110.933 -179.846 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 34' ' ' ARG . . . . . . . . . . . . . 99.2 mtt180 -51.4 -29.54 16.06 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 115.914 -0.584 . . . . 0.0 111.679 -179.776 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 31.1 mmm180 -67.17 -44.78 78.83 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.393 -0.367 . . . . 0.0 111.42 -179.731 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 78.3 m-85 -70.54 -31.35 68.36 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.466 -0.333 . . . . 0.0 110.983 -179.946 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 37' ' ' TYR . . . . . 0.446 ' O ' HG23 ' A' ' 41' ' ' VAL . 48.5 m-85 -72.11 -51.33 21.93 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 116.327 -0.397 . . . . 0.0 111.228 -179.757 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 10.7 p -57.27 -36.21 51.43 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-O 120.994 0.426 . . . . 0.0 109.979 179.344 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 24.0 m -66.22 -43.83 85.55 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 115.629 -0.714 . . . . 0.0 110.584 179.127 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 40' ' ' LEU . . . . . 0.589 HD11 ' HA2' ' A' ' 209' ' ' GLY . 0.3 OUTLIER -62.64 -50.51 70.92 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-O 121.585 0.707 . . . . 0.0 110.501 179.559 . . . . . . . . 3 3 . 1 . 021 nuclear build full ' A' A ' 41' ' ' VAL . . . . . 0.756 HG22 ' HB2' ' A' ' 22' ' ' PHE . 43.8 t -62.87 -33.49 60.64 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.626 0 CA-C-N 115.435 -0.802 . . . . 0.0 110.316 179.43 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 42' ' ' GLY . . . . . 0.442 ' O ' HG12 ' A' ' 46' ' ' ILE . . . -58.07 -47.79 86.93 Favored Glycine 0 N--CA 1.448 -0.527 0 CA-C-N 115.635 -0.712 . . . . 0.0 112.822 179.889 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 43' ' ' ILE . . . . . 0.572 HG23 HD23 ' A' ' 82' ' ' LEU . 9.0 pt -65.43 -51.32 65.35 Favored 'Isoleucine or valine' 0 C--O 1.233 0.201 0 CA-C-N 117.019 0.409 . . . . 0.0 111.502 -179.704 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 60.5 m -63.61 -20.47 65.69 Favored 'General case' 0 C--O 1.233 0.188 0 CA-C-O 120.92 0.39 . . . . 0.0 110.79 -179.899 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -80.61 -58.58 2.67 Favored Glycine 0 N--CA 1.452 -0.287 0 C-N-CA 121.008 -0.615 . . . . 0.0 113.103 -179.301 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 46' ' ' ILE . . . . . 0.536 ' O ' HG22 ' A' ' 49' ' ' VAL . 14.7 pt -58.19 -36.6 58.22 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.185 0 CA-C-O 120.881 0.372 . . . . 0.0 110.949 -179.758 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 47' ' ' ALA . . . . . 0.647 ' HB2' ' HE2' ' A' ' 205' ' ' LYS . . . -68.78 -42.54 77.27 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.704 178.776 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -54.39 -40.49 68.24 Favored 'General case' 0 C--O 1.232 0.181 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.329 -179.786 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 49' ' ' VAL . . . . . 0.536 HG22 ' O ' ' A' ' 46' ' ' ILE . 17.9 m -76.22 -34.1 25.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.487 -0.324 . . . . 0.0 110.98 -179.883 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -61.42 -39.96 92.7 Favored 'General case' 0 C--N 1.332 -0.165 0 CA-C-O 121.141 0.496 . . . . 0.0 110.715 179.215 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 51' ' ' TYR . . . . . 0.445 ' HE2' ' HE2' ' A' ' 15' ' ' MET . 43.5 m-85 -73.19 -35.93 66.47 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 115.651 -0.704 . . . . 0.0 110.439 179.84 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -66.68 -39.95 88.36 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 115.885 -0.598 . . . . 0.0 111.261 179.558 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 53' ' ' VAL . . . . . 0.402 HG13 ' O ' ' A' ' 49' ' ' VAL . 33.5 m -74.42 -42.44 49.79 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.173 0 CA-C-N 116.362 -0.381 . . . . 0.0 110.972 -179.785 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 54' ' ' MET . . . . . . . . . . . . . 70.7 mtm -65.27 -31.17 72.18 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 121.111 0.481 . . . . 0.0 109.852 179.118 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 55' ' ' ALA . . . . . 0.542 ' HB2' ' HB2' ' A' ' 8' ' ' PHE . . . -67.82 -18.56 64.88 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 115.544 -0.753 . . . . 0.0 111.188 179.52 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 96.5 mt -98.84 8.68 44.71 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.196 179.957 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 81.22 16.81 73.33 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.587 -0.816 . . . . 0.0 112.604 -179.993 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 58.0 t -84.53 137.19 21.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-O 120.794 0.33 . . . . 0.0 110.888 179.907 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 59' ' ' GLY . . . . . 0.484 ' HA3' ' HD3' ' A' ' 71' ' ' PRO . . . 85.08 -7.79 73.53 Favored Glycine 0 N--CA 1.449 -0.478 0 C-N-CA 120.776 -0.726 . . . . 0.0 112.476 -179.942 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 60' ' ' TRP . . . . . . . . . . . . . 12.0 m0 -65.36 99.21 0.39 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.642 0.258 . . . . 0.0 110.863 179.955 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 5.1 p -107.31 128.32 26.21 Favored Pre-proline 0 C--N 1.329 -0.298 0 CA-C-N 116.356 -0.384 . . . . 0.0 111.141 179.885 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 58.3 Cg_endo -71.68 141.11 37.1 Favored 'Trans proline' 0 C--N 1.349 0.581 0 C-N-CA 122.25 1.967 . . . . 0.0 112.039 179.817 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 61.1 t -137.39 90.77 0.77 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.356 0 CA-C-N 116.075 -0.511 . . . . 0.0 111.249 -179.621 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . 59.96 -85.49 0.02 OUTLIER 'General case' 0 C--N 1.331 -0.202 0 CA-C-N 116.0 -0.545 . . . . 0.0 111.42 179.948 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 65' ' ' GLU . . . . . 0.413 ' HG3' ' HG3' ' A' ' 66' ' ' ARG . 11.6 pt-20 -121.81 -22.69 5.7 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.886 0.374 . . . . 0.0 110.937 -179.966 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 66' ' ' ARG . . . . . 0.413 ' HG3' ' HG3' ' A' ' 65' ' ' GLU . 84.8 mtm180 -104.72 156.78 17.69 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.041 -0.527 . . . . 0.0 110.802 -179.919 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 40.9 m -113.61 130.62 56.35 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.981 179.854 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 26.3 t -113.61 146.33 18.34 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.394 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.973 179.943 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 69' ' ' PHE . . . . . . . . . . . . . 16.8 m-85 -104.33 116.68 32.57 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 116.209 -0.451 . . . . 0.0 109.919 -179.894 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 70' ' ' VAL . . . . . 0.641 HG12 ' HD3' ' A' ' 71' ' ' PRO . 0.8 OUTLIER -66.73 -35.58 9.84 Favored Pre-proline 0 CA--C 1.541 0.612 0 N-CA-C 112.602 0.593 . . . . 0.0 112.602 -179.424 . . . . . . . . 3 3 . 1 . 021 nuclear build full ' A' A ' 71' ' ' PRO . . . . . 0.641 ' HD3' HG12 ' A' ' 70' ' ' VAL . 9.5 Cg_exo -70.77 -22.39 27.51 Favored 'Trans proline' 0 C--N 1.36 1.138 0 C-N-CA 122.032 1.821 . . . . 0.0 112.815 -179.508 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 67.6 ttt180 -68.56 -55.63 11.0 Favored 'General case' 0 C--N 1.329 -0.323 0 N-CA-C 112.157 0.429 . . . . 0.0 112.157 -178.791 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 73' ' ' TYR . . . . . 0.509 ' O ' HG13 ' A' ' 77' ' ' ILE . 73.7 m-85 -73.53 -33.74 64.88 Favored 'General case' 0 C--N 1.328 -0.328 0 C-N-CA 120.863 -0.335 . . . . 0.0 110.892 -179.112 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 74' ' ' ILE . . . . . 0.53 HG22 ' HA ' ' A' ' 71' ' ' PRO . 0.3 OUTLIER -67.57 -41.27 85.59 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 N-CA-C 109.703 -0.48 . . . . 0.0 109.703 179.164 . . . . . . . . 3 3 . 1 . 021 nuclear build full ' A' A ' 75' ' ' ASP . . . . . 0.457 ' O ' HG23 ' A' ' 79' ' ' THR . 27.0 t70 -58.85 -37.54 76.7 Favored 'General case' 0 CA--C 1.519 -0.242 0 N-CA-C 109.241 -0.651 . . . . 0.0 109.241 178.703 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 76' ' ' TRP . . . . . 0.46 ' HB3' ' SD ' ' A' ' 109' ' ' MET . 48.6 m0 -66.12 -31.13 71.8 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 115.624 -0.717 . . . . 0.0 110.575 179.337 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 77' ' ' ILE . . . . . 0.509 HG13 ' O ' ' A' ' 73' ' ' TYR . 76.1 mt -69.41 -29.6 42.57 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.353 0 CA-C-O 121.036 0.446 . . . . 0.0 110.333 178.973 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 24.8 mt -91.45 -15.84 28.23 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 115.984 -0.553 . . . . 0.0 111.986 179.898 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 79' ' ' THR . . . . . 0.457 HG23 ' O ' ' A' ' 75' ' ' ASP . 73.6 p -101.84 -52.6 3.15 Favored 'General case' 0 N--CA 1.464 0.225 0 N-CA-C 113.06 0.763 . . . . 0.0 113.06 -178.613 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 80' ' ' THR . . . . . 0.694 ' HB ' ' HD3' ' A' ' 81' ' ' PRO . 62.8 m -51.26 -56.26 21.79 Favored Pre-proline 0 CA--C 1.533 0.291 0 N-CA-C 112.854 0.687 . . . . 0.0 112.854 -178.287 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 81' ' ' PRO . . . . . 0.694 ' HD3' ' HB ' ' A' ' 80' ' ' THR . 52.2 Cg_exo -57.43 -25.12 64.54 Favored 'Trans proline' 0 C--N 1.353 0.766 0 C-N-CA 121.517 1.478 . . . . 0.0 111.613 -179.945 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 82' ' ' LEU . . . . . 0.572 HD23 HG23 ' A' ' 43' ' ' ILE . 12.3 tp -77.14 -32.96 56.75 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 115.741 -0.663 . . . . 0.0 110.393 179.838 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 47.4 mm -67.56 -53.34 32.55 Favored 'Isoleucine or valine' 0 C--O 1.232 0.164 0 CA-C-N 116.377 -0.374 . . . . 0.0 110.227 179.17 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 24.6 m -60.73 -29.96 46.1 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.224 0 N-CA-C 108.897 -0.779 . . . . 0.0 108.897 178.411 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 85' ' ' TYR . . . . . . . . . . . . . 93.4 t80 -65.28 -30.29 71.14 Favored 'General case' 0 N--CA 1.453 -0.297 0 CA-C-N 115.395 -0.82 . . . . 0.0 109.248 178.371 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 86' ' ' PHE . . . . . . . . . . . . . 31.6 t80 -65.44 -51.95 56.62 Favored 'General case' 0 CA--C 1.519 -0.212 0 CA-C-N 115.811 -0.631 . . . . 0.0 109.623 178.988 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 87' ' ' LEU . . . . . 0.639 HD22 HD22 ' A' ' 141' ' ' LEU . 6.0 mp -63.22 -28.85 70.32 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 115.803 -0.635 . . . . 0.0 109.854 179.117 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -68.35 -27.98 73.49 Favored Glycine 0 N--CA 1.449 -0.478 0 C-N-CA 120.707 -0.759 . . . . 0.0 111.256 178.833 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 46.4 mt -76.19 -34.33 59.31 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-O 120.963 0.411 . . . . 0.0 110.282 179.012 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 88.9 mt -79.41 -23.69 43.06 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 115.937 -0.574 . . . . 0.0 110.984 179.681 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 91' ' ' ALA . . . . . 0.46 ' HA ' ' HB2' ' A' ' 149' ' ' ALA . . . -88.46 -45.46 9.93 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.249 -179.903 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 91.92 57.8 1.47 Allowed Glycine 0 N--CA 1.451 -0.364 0 C-N-CA 120.802 -0.713 . . . . 0.0 112.611 -179.833 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 93' ' ' LEU . . . . . 0.496 HD23 ' HB3' ' A' ' 97' ' ' GLU . 10.6 mp -74.07 176.94 6.06 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-O 120.758 0.313 . . . . 0.0 110.779 179.836 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 94' ' ' ASP . . . . . 0.557 ' H ' ' HB2' ' A' ' 97' ' ' GLU . 5.7 m-20 -99.23 -167.0 1.41 Allowed 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.095 -179.947 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 48.8 m -67.58 -49.63 62.25 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 115.903 -0.589 . . . . 0.0 111.509 -179.542 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 96' ' ' ARG . . . . . 0.424 ' O ' HG13 ' A' ' 100' ' ' ILE . 31.4 tpt180 -74.08 -39.77 63.21 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-O 120.904 0.383 . . . . 0.0 110.601 -179.457 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 97' ' ' GLU . . . . . 0.557 ' HB2' ' H ' ' A' ' 94' ' ' ASP . 0.3 OUTLIER -55.53 -47.19 76.7 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 115.824 -0.626 . . . . 0.0 111.391 -179.757 . . . . . . . . 3 3 . 1 . 021 nuclear build full ' A' A ' 98' ' ' PHE . . . . . 0.459 ' O ' HG12 ' A' ' 102' ' ' ILE . 3.3 m-85 -62.53 -41.53 98.92 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.487 -0.324 . . . . 0.0 110.879 179.675 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -65.47 -26.33 71.78 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.553 -0.832 . . . . 0.0 112.66 -179.777 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 100' ' ' ILE . . . . . 0.424 HG13 ' O ' ' A' ' 96' ' ' ARG . 96.5 mt -73.4 -48.82 40.41 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-O 120.688 0.28 . . . . 0.0 111.648 -179.663 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 17.0 m -64.82 -37.78 81.05 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.498 -0.319 . . . . 0.0 111.691 -179.649 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 102' ' ' ILE . . . . . 0.459 HG12 ' O ' ' A' ' 98' ' ' PHE . 49.5 mm -71.55 -49.48 46.34 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.452 -0.34 . . . . 0.0 111.41 -179.757 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 14.0 t -59.74 -30.94 69.18 Favored 'General case' 0 C--N 1.332 -0.164 0 CA-C-O 120.825 0.345 . . . . 0.0 110.938 -179.933 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 104' ' ' LEU . . . . . 0.458 ' O ' HG12 ' A' ' 107' ' ' VAL . 46.3 tp -65.49 -54.37 29.2 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.465 179.498 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 105' ' ' ASN . . . . . 0.634 ' N ' HD22 ' A' ' 105' ' ' ASN . 0.7 OUTLIER -56.91 -26.45 59.25 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 115.996 -0.547 . . . . 0.0 110.764 179.827 . . . . . . . . 3 3 . 1 . 021 nuclear build full ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 39.6 m -68.4 -56.76 7.38 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.13 -0.486 . . . . 0.0 111.38 -179.855 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 107' ' ' VAL . . . . . 0.458 HG12 ' O ' ' A' ' 104' ' ' LEU . 13.2 p -60.45 -36.66 70.98 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.16 0 CA-C-N 116.524 -0.307 . . . . 0.0 111.335 -179.779 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 108' ' ' VAL . . . . . 0.418 ' CG1' H182 ' A' ' 301' ' ' RET . 93.3 t -66.36 -50.24 69.31 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-O 120.957 0.408 . . . . 0.0 111.005 179.716 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 109' ' ' MET . . . . . 0.46 ' SD ' ' HB3' ' A' ' 76' ' ' TRP . 10.0 tpp -59.95 -36.33 76.86 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 115.954 -0.566 . . . . 0.0 110.62 179.948 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 23.1 tp -65.19 -34.27 77.98 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.037 -0.528 . . . . 0.0 110.291 179.607 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -60.01 -51.28 70.32 Favored 'General case' 0 C--N 1.331 -0.218 0 CA-C-N 116.041 -0.527 . . . . 0.0 110.339 179.263 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 112' ' ' GLY . . . . . 0.628 ' HA3' ' H21' ' A' ' 301' ' ' RET . . . -62.21 -39.27 97.47 Favored Glycine 0 C--N 1.331 0.269 0 C-N-CA 120.604 -0.808 . . . . 0.0 111.911 179.245 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 113' ' ' PHE . . . . . . . . . . . . . 2.2 t80 -47.43 -68.22 0.21 Allowed 'General case' 0 C--N 1.332 -0.196 0 CA-C-O 121.063 0.459 . . . . 0.0 110.203 179.318 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -65.12 -21.66 66.83 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 115.512 -0.767 . . . . 0.0 110.856 179.453 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -53.58 -45.03 68.3 Favored Glycine 0 C--N 1.334 0.423 0 C-N-CA 121.068 -0.587 . . . . 0.0 112.496 179.992 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -77.88 -23.59 48.73 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.721 0.295 . . . . 0.0 111.55 179.744 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 117' ' ' MET . . . . . . . . . . . . . 65.3 mtt -96.0 19.15 12.01 Favored 'General case' 0 C--N 1.331 -0.2 0 CA-C-N 116.29 -0.414 . . . . 0.0 111.613 -179.473 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 118' ' ' VAL . . . . . 0.494 HG11 ' N ' ' A' ' 123' ' ' ARG . 19.3 m -68.34 142.61 94.79 Favored Pre-proline 0 C--N 1.328 -0.338 0 CA-C-N 116.71 -0.223 . . . . 0.0 111.586 -179.902 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 119' ' ' PRO . . . . . . . . . . . . . 98.4 Cg_endo -88.0 6.09 5.11 Favored 'Trans proline' 0 N--CA 1.459 -0.513 0 C-N-CA 122.761 2.307 . . . . 0.0 112.524 179.593 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -166.09 -115.15 0.31 Allowed Glycine 0 C--N 1.332 0.327 0 C-N-CA 120.697 -0.763 . . . . 0.0 112.803 -179.814 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 43.5 pt -111.4 12.68 8.58 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.216 0 CA-C-O 120.698 0.285 . . . . 0.0 111.43 -179.634 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 11.2 mm-40 -58.83 -18.88 36.43 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.37 -0.377 . . . . 0.0 110.991 -179.993 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 123' ' ' ARG . . . . . 0.494 ' N ' HG11 ' A' ' 118' ' ' VAL . 17.5 ptt180 -53.32 -30.01 36.76 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.017 -0.538 . . . . 0.0 111.484 -179.964 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 124' ' ' TYR . . . . . . . . . . . . . 29.7 m-85 -76.5 -32.45 58.32 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.352 -0.385 . . . . 0.0 110.927 179.924 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 125' ' ' ALA . . . . . . . . . . . . . . . -72.38 -56.1 6.0 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.067 179.924 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 1.5 mt -56.13 -54.08 49.43 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 115.888 -0.596 . . . . 0.0 110.829 -179.89 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 127' ' ' PHE . . . . . 0.403 ' CE1' ' H42' ' A' ' 301' ' ' RET . 11.0 t80 -64.86 -35.9 82.63 Favored 'General case' 0 N--CA 1.453 -0.306 0 C-N-CA 120.738 -0.385 . . . . 0.0 110.694 179.623 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 128' ' ' GLY . . . . . . . . . . . . . . . -47.53 -44.16 21.93 Favored Glycine 0 C--N 1.332 0.337 0 C-N-CA 120.054 -1.069 . . . . 0.0 110.825 179.111 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 129' ' ' MET . . . . . . . . . . . . . 0.2 OUTLIER -71.77 -37.24 70.5 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.991 0.424 . . . . 0.0 109.99 178.78 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -67.69 -27.59 73.59 Favored Glycine 0 N--CA 1.452 -0.29 0 CA-C-N 115.653 -0.703 . . . . 0.0 112.761 -179.852 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -75.04 -53.85 8.18 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-O 120.696 0.284 . . . . 0.0 110.48 179.944 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 45.4 t -58.54 -40.09 77.65 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.206 0 N-CA-C 109.064 -0.717 . . . . 0.0 109.064 178.546 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -69.09 -35.0 76.01 Favored 'General case' 0 N--CA 1.451 -0.389 0 CA-C-N 115.133 -0.939 . . . . 0.0 110.445 179.174 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 134' ' ' PHE . . . . . 0.442 ' CZ ' ' HA ' ' A' ' 172' ' ' ALA . 76.2 t80 -57.51 -55.27 36.95 Favored 'General case' 0 N--CA 1.451 -0.376 0 N-CA-C 109.763 -0.458 . . . . 0.0 109.763 179.492 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 135' ' ' ILE . . . . . 0.458 ' HA ' HG22 ' A' ' 138' ' ' VAL . 34.7 mt -57.25 -31.5 38.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 115.687 -0.688 . . . . 0.0 109.642 178.888 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . -65.77 -36.11 91.82 Favored Glycine 0 N--CA 1.446 -0.669 0 C-N-CA 120.386 -0.911 . . . . 0.0 111.017 178.537 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 137' ' ' LEU . . . . . 0.454 HD13 HD21 ' A' ' 105' ' ' ASN . 39.1 tp -71.47 -53.23 14.64 Favored 'General case' 0 N--CA 1.454 -0.25 0 N-CA-C 110.355 -0.239 . . . . 0.0 110.355 179.321 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 138' ' ' VAL . . . . . 0.458 HG22 ' HA ' ' A' ' 135' ' ' ILE . 5.0 m -56.36 -31.86 34.12 Favored 'Isoleucine or valine' 0 C--O 1.233 0.194 0 N-CA-C 109.08 -0.711 . . . . 0.0 109.08 178.929 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 139' ' ' TYR . . . . . . . . . . . . . 39.0 t80 -61.41 -45.82 92.74 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 115.367 -0.833 . . . . 0.0 110.127 178.54 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 140' ' ' TYR . . . . . 0.445 ' HE2' HD22 ' A' ' 104' ' ' LEU . 27.4 m-85 -60.95 -37.67 83.2 Favored 'General case' 0 C--N 1.332 -0.157 0 CA-C-N 116.29 -0.414 . . . . 0.0 110.724 179.543 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 141' ' ' LEU . . . . . 0.639 HD22 HD22 ' A' ' 87' ' ' LEU . 83.5 mt -61.92 -35.0 77.1 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.615 179.916 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 17.1 t -96.25 -4.75 10.08 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.071 -0.513 . . . . 0.0 110.546 179.581 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . -74.12 -134.36 0.29 Allowed Glycine 0 CA--C 1.52 0.398 0 C-N-CA 121.129 -0.558 . . . . 0.0 112.885 -179.809 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 144' ' ' PRO . . . . . . . . . . . . . 34.1 Cg_exo -59.91 -23.96 74.5 Favored 'Trans proline' 0 C--N 1.349 0.578 0 C-N-CA 122.752 2.301 . . . . 0.0 112.839 -179.536 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 145' ' ' MET . . . . . . . . . . . . . 59.1 mtt -53.66 -28.69 34.66 Favored 'General case' 0 C--N 1.332 -0.179 0 CA-C-N 116.34 -0.391 . . . . 0.0 111.417 -179.854 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 146' ' ' THR . . . . . . . . . . . . . 74.9 p -70.34 -50.43 39.12 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.233 -0.44 . . . . 0.0 112.063 -179.219 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 47.4 mt-10 -73.62 -24.13 59.99 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.546 -0.297 . . . . 0.0 111.797 -179.025 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 148' ' ' SER . . . . . . . . . . . . . 81.4 p -70.78 -49.14 49.76 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 116.444 -0.343 . . . . 0.0 111.645 -179.281 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 149' ' ' ALA . . . . . 0.46 ' HB2' ' HA ' ' A' ' 91' ' ' ALA . . . -77.98 -38.83 44.21 Favored 'General case' 0 C--N 1.329 -0.319 0 N-CA-C 112.237 0.458 . . . . 0.0 112.237 -179.026 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 150' ' ' SER . . . . . . . . . . . . . 68.4 m -60.92 -8.13 2.92 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.537 -0.302 . . . . 0.0 111.705 -179.382 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 151' ' ' GLN . . . . . . . . . . . . . 78.2 mt-30 -119.02 25.19 10.36 Favored 'General case' 0 C--N 1.329 -0.296 0 N-CA-C 111.588 0.218 . . . . 0.0 111.588 -179.812 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 49.6 mtp180 -103.25 -52.24 3.07 Favored 'General case' 0 C--N 1.331 -0.197 0 CA-C-O 120.868 0.366 . . . . 0.0 111.153 179.717 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 153' ' ' SER . . . . . 0.605 ' HB3' HG12 ' A' ' 156' ' ' ILE . 32.8 t -157.02 169.16 25.44 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-N 115.981 -0.554 . . . . 0.0 110.854 179.407 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 154' ' ' SER . . . . . . . . . . . . . 37.0 t -70.39 -35.75 73.68 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.659 179.784 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -76.71 -31.47 53.71 Favored Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.883 -0.675 . . . . 0.0 112.503 179.827 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 156' ' ' ILE . . . . . 0.605 HG12 ' HB3' ' A' ' 153' ' ' SER . 36.2 mm -61.72 -37.63 78.48 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.234 0 CA-C-O 120.651 0.262 . . . . 0.0 111.1 -179.97 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 157' ' ' LYS . . . . . . . . . . . . . 57.8 tptt -60.73 -55.49 32.59 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 116.306 -0.407 . . . . 0.0 111.871 -179.445 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 62.2 m -60.61 -45.35 94.35 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.323 -0.398 . . . . 0.0 111.885 -179.125 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 159' ' ' LEU . . . . . . . . . . . . . 8.3 tt -68.35 -32.6 72.81 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-N 116.336 -0.393 . . . . 0.0 111.499 -179.198 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 160' ' ' TYR . . . . . . . . . . . . . 79.9 t80 -73.53 -45.62 52.61 Favored 'General case' 0 C--N 1.33 -0.261 0 N-CA-C 111.858 0.318 . . . . 0.0 111.858 -179.148 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 30.0 m -62.81 -40.85 90.28 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.363 0 N-CA-C 111.772 0.286 . . . . 0.0 111.772 -179.292 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 162' ' ' ARG . . . . . 0.405 ' HG2' HG21 ' A' ' 211' ' ' ILE . 29.1 tpt180 -69.35 -45.68 68.83 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.772 0.32 . . . . 0.0 111.388 -179.632 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 163' ' ' LEU . . . . . 0.588 ' HG ' ' HB2' ' A' ' 208' ' ' PHE . 4.3 mp -69.62 -52.5 25.43 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.806 -179.294 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 164' ' ' ARG . . . . . . . . . . . . . 4.6 tmm_? -53.88 -54.01 44.6 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.393 -0.367 . . . . 0.0 111.338 -179.163 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 165' ' ' ASN . . . . . 0.41 ' O ' HG23 ' A' ' 169' ' ' VAL . 4.7 m-20 -56.67 -43.78 80.74 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.937 0.398 . . . . 0.0 110.441 179.715 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 166' ' ' LEU . . . . . 0.552 ' O ' ' HG ' ' A' ' 170' ' ' LEU . 5.6 tp -57.84 -54.53 45.92 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 115.858 -0.61 . . . . 0.0 111.067 -179.938 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 167' ' ' THR . . . . . 0.641 ' HA ' HD11 ' A' ' 170' ' ' LEU . 89.0 m -54.07 -52.25 61.52 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 115.966 -0.561 . . . . 0.0 112.21 -178.925 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 168' ' ' VAL . . . . . . . . . . . . . 94.5 t -53.92 -40.14 43.46 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.366 0 N-CA-C 112.141 0.423 . . . . 0.0 112.141 -179.172 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 169' ' ' VAL . . . . . 0.41 HG23 ' O ' ' A' ' 165' ' ' ASN . 75.2 t -65.82 -65.57 0.56 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.326 0 N-CA-C 112.346 0.498 . . . . 0.0 112.346 -178.959 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 170' ' ' LEU . . . . . 0.718 HD22 HG13 ' A' ' 203' ' ' VAL . 1.0 OUTLIER -61.66 -28.78 69.63 Favored 'General case' 0 C--N 1.33 -0.25 0 N-CA-C 112.544 0.572 . . . . 0.0 112.544 -178.428 . . . . . . . . 3 3 . 1 . 021 nuclear build full ' A' A ' 171' ' ' TRP . . . . . 0.766 ' HE1' H203 ' A' ' 301' ' ' RET . 4.8 m0 -74.1 -30.77 62.5 Favored 'General case' 0 C--N 1.33 -0.277 0 C-N-CA 120.538 -0.465 . . . . 0.0 110.842 179.801 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 172' ' ' ALA . . . . . 0.442 ' HA ' ' CZ ' ' A' ' 134' ' ' PHE . . . -66.51 -7.87 22.75 Favored 'General case' 0 CA--C 1.516 -0.344 0 CA-C-O 121.273 0.559 . . . . 0.0 110.026 179.163 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 173' ' ' ILE . . . . . 0.718 HG22 ' CG1' ' A' ' 177' ' ' ILE . 6.6 mm -87.19 -35.81 9.02 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.624 0 CA-C-N 115.123 -0.944 . . . . 0.0 111.47 -178.966 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 174' ' ' TYR . . . . . 0.531 ' N ' ' HD2' ' A' ' 175' ' ' PRO . 55.5 m-85 -54.95 -52.09 73.86 Favored Pre-proline 0 C--N 1.329 -0.323 0 N-CA-C 112.75 0.648 . . . . 0.0 112.75 -178.91 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 175' ' ' PRO . . . . . 0.531 ' HD2' ' N ' ' A' ' 174' ' ' TYR . 28.4 Cg_endo -61.99 -39.57 49.52 Favored 'Trans proline' 0 C--N 1.348 0.539 0 C-N-CA 121.963 1.775 . . . . 0.0 113.419 -178.351 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 176' ' ' PHE . . . . . 0.519 ' CE2' ' HA ' ' A' ' 173' ' ' ILE . 0.1 OUTLIER -79.99 -38.15 32.76 Favored 'General case' 0 C--N 1.329 -0.304 0 C-N-CA 120.688 -0.405 . . . . 0.0 111.904 -178.786 . . . . . . . . 3 3 . 1 . 021 nuclear build full ' A' A ' 177' ' ' ILE . . . . . 0.718 ' CG1' HG22 ' A' ' 173' ' ' ILE . 31.7 mm -62.42 -43.58 98.36 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.477 0 N-CA-C 109.723 -0.473 . . . . 0.0 109.723 178.285 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 178' ' ' TRP . . . . . . . . . . . . . 70.3 t90 -60.87 -27.68 68.31 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 115.687 -0.688 . . . . 0.0 109.418 178.789 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 179' ' ' LEU . . . . . 0.422 HD13 ' O ' ' A' ' 179' ' ' LEU . 1.4 tm? -74.04 -45.8 47.32 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 115.187 -0.915 . . . . 0.0 110.764 -179.963 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 180' ' ' LEU . . . . . 0.478 ' HG ' ' O ' ' A' ' 176' ' ' PHE . 4.8 mt -71.33 -49.34 43.54 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.615 -0.266 . . . . 0.0 111.394 -179.372 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . -52.61 174.81 0.2 Allowed Glycine 0 C--N 1.334 0.43 0 C-N-CA 120.659 -0.781 . . . . 0.0 112.937 -179.954 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 182' ' ' PRO . . . . . 0.613 ' HA ' ' HB2' ' A' ' 186' ' ' ALA . 76.4 Cg_exo -46.93 -45.35 21.01 Favored 'Trans proline' 0 CA--C 1.536 0.602 0 C-N-CA 122.853 2.368 . . . . 0.0 113.796 -179.874 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 183' ' ' PRO . . . . . 0.431 ' HD3' ' HB2' ' A' ' 182' ' ' PRO . 79.5 Cg_exo -49.27 -23.48 6.98 Favored 'Trans proline' 0 C--N 1.355 0.908 0 C-N-CA 122.24 1.96 . . . . 0.0 113.194 -179.787 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 184' ' ' GLY . . . . . . . . . . . . . . . -108.74 -99.06 2.58 Favored Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.466 -0.873 . . . . 0.0 113.069 -179.57 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 185' ' ' VAL . . . . . . . . . . . . . 3.5 m -109.07 -5.49 10.89 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 N-CA-C 111.726 0.269 . . . . 0.0 111.726 -179.231 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 186' ' ' ALA . . . . . 0.613 ' HB2' ' HA ' ' A' ' 182' ' ' PRO . . . 55.14 87.28 0.05 OUTLIER 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.366 -0.379 . . . . 0.0 111.629 179.542 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 187' ' ' LEU . . . . . 0.454 HD12 ' HB3' ' A' ' 180' ' ' LEU . 23.5 mt -91.81 -48.97 6.5 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.332 -0.394 . . . . 0.0 110.779 179.637 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 188' ' ' LEU . . . . . . . . . . . . . 55.6 mt -106.9 -154.14 0.51 Allowed 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 115.835 -0.621 . . . . 0.0 110.642 -179.905 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 189' ' ' THR . . . . . . . . . . . . . 2.6 t -97.52 146.16 30.92 Favored Pre-proline 0 C--N 1.329 -0.315 0 CA-C-N 116.406 -0.361 . . . . 0.0 110.918 179.905 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 190' ' ' PRO . . . . . 0.403 ' O ' HG23 ' A' ' 194' ' ' VAL . 9.6 Cg_endo -50.14 -38.46 50.58 Favored 'Trans proline' 0 C--N 1.349 0.597 0 C-N-CA 122.862 2.374 . . . . 0.0 112.769 -179.594 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 191' ' ' THR . . . . . . . . . . . . . 81.6 p -58.25 -44.34 88.27 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.911 0.386 . . . . 0.0 111.249 -179.842 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 192' ' ' VAL . . . . . . . . . . . . . 35.1 t -71.85 -43.13 69.41 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.391 0 CA-C-N 116.03 -0.532 . . . . 0.0 111.401 -179.708 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 193' ' ' ASP . . . . . . . . . . . . . 21.1 t70 -56.55 -49.01 76.07 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.403 -0.362 . . . . 0.0 111.186 -179.783 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 194' ' ' VAL . . . . . 0.501 ' O ' HG23 ' A' ' 198' ' ' VAL . 78.2 t -64.42 -38.15 81.82 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.372 0 CA-C-N 116.262 -0.426 . . . . 0.0 111.198 -179.723 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 195' ' ' ALA . . . . . . . . . . . . . . . -54.15 -48.59 70.69 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 116.518 -0.31 . . . . 0.0 111.482 -179.802 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 196' ' ' LEU . . . . . 0.455 ' O ' ' HB3' ' A' ' 199' ' ' TYR . 94.3 mt -65.65 -39.96 91.97 Favored 'General case' 0 C--N 1.332 -0.166 0 CA-C-O 120.777 0.322 . . . . 0.0 110.814 179.884 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 197' ' ' ILE . . . . . 0.423 HD13 HD12 ' A' ' 200' ' ' LEU . 24.7 mm -58.73 -53.42 47.52 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.37 0 CA-C-O 121.017 0.437 . . . . 0.0 110.198 179.307 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 198' ' ' VAL . . . . . 0.501 HG23 ' O ' ' A' ' 194' ' ' VAL . 87.6 t -55.07 -34.64 32.57 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.459 0 CA-C-N 115.582 -0.736 . . . . 0.0 109.04 178.215 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 199' ' ' TYR . . . . . 0.455 ' HB3' ' O ' ' A' ' 196' ' ' LEU . 79.7 t80 -69.73 -32.58 71.2 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 114.98 -1.009 . . . . 0.0 110.643 179.635 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 200' ' ' LEU . . . . . 0.423 HD12 HD13 ' A' ' 197' ' ' ILE . 68.2 mt -69.17 -41.04 77.74 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 115.756 -0.656 . . . . 0.0 111.697 -179.373 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 201' ' ' ASP . . . . . . . . . . . . . 9.5 m-20 -71.39 -36.31 71.34 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 121.162 0.506 . . . . 0.0 110.451 179.529 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 202' ' ' LEU . . . . . 0.41 ' O ' ' HB ' ' A' ' 206' ' ' VAL . 1.2 mm? -65.99 -33.64 76.27 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 115.462 -0.79 . . . . 0.0 111.918 -179.731 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 203' ' ' VAL . . . . . 0.718 HG13 HD22 ' A' ' 170' ' ' LEU . 9.0 p -79.07 -36.3 18.31 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 N-CA-C 111.885 0.328 . . . . 0.0 111.885 -178.241 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 204' ' ' THR . . . . . 0.429 ' OG1' HD13 ' A' ' 170' ' ' LEU . 94.1 m -64.77 -58.93 4.91 Favored 'General case' 0 C--N 1.328 -0.343 0 C-N-CA 120.082 -0.647 . . . . 0.0 111.101 179.642 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 205' ' ' LYS . . . . . 0.647 ' HE2' ' HB2' ' A' ' 47' ' ' ALA . 60.1 mttp -68.35 -57.83 5.31 Favored 'General case' 0 C--N 1.33 -0.281 0 N-CA-C 112.774 0.657 . . . . 0.0 112.774 -178.028 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 206' ' ' VAL . . . . . 0.41 ' HB ' ' O ' ' A' ' 202' ' ' LEU . 19.3 t -71.16 -37.17 65.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 N-CA-C 112.02 0.378 . . . . 0.0 112.02 -178.654 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 207' ' ' GLY . . . . . 0.511 ' O ' HG13 ' A' ' 211' ' ' ILE . . . -61.75 -61.1 7.12 Favored Glycine 0 N--CA 1.452 -0.263 0 C-N-CA 120.577 -0.821 . . . . 0.0 113.72 -178.997 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 208' ' ' PHE . . . . . 0.588 ' HB2' ' HG ' ' A' ' 163' ' ' LEU . 0.1 OUTLIER -68.84 -29.95 68.38 Favored 'General case' 0 C--O 1.222 -0.362 0 CA-C-N 117.799 0.799 . . . . 0.0 110.8 -179.292 . . . . . . . . 3 3 . 1 . 021 nuclear build full ' A' A ' 209' ' ' GLY . . . . . 0.589 ' HA2' HD11 ' A' ' 40' ' ' LEU . . . -62.07 -35.66 91.78 Favored Glycine 0 N--CA 1.45 -0.368 0 CA-C-N 116.189 -0.46 . . . . 0.0 112.418 179.4 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 210' ' ' PHE . . . . . . . . . . . . . 3.3 m-85 -72.68 -47.38 47.79 Favored 'General case' 0 CA--C 1.513 -0.461 0 N-CA-C 108.513 -0.921 . . . . 0.0 108.513 178.81 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 211' ' ' ILE . . . . . 0.511 HG13 ' O ' ' A' ' 207' ' ' GLY . 3.7 mt -62.8 -27.32 42.8 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.58 0 N-CA-C 107.192 -1.41 . . . . 0.0 107.192 176.468 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 212' ' ' ALA . . . . . 0.531 ' HB3' ' O ' ' A' ' 209' ' ' GLY . . . -67.43 -36.55 81.44 Favored 'General case' 0 N--CA 1.45 -0.468 0 CA-C-N 114.308 -1.314 . . . . 0.0 110.171 179.56 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 213' ' ' LEU . . . . . 0.437 ' HG ' ' O ' ' A' ' 209' ' ' GLY . 81.3 mt -70.17 -53.38 17.45 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 115.012 -0.994 . . . . 0.0 111.594 -179.649 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 214' ' ' ASP . . . . . . . . . . . . . 16.5 m-20 -57.44 -51.54 69.02 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.827 0.346 . . . . 0.0 111.227 -179.592 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 215' ' ' ALA . . . . . 0.448 ' O ' ' HG ' ' A' ' 219' ' ' LEU . . . -56.63 -57.25 13.19 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.226 -179.762 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 216' ' ' ALA . . . . . . . . . . . . . . . -58.4 -33.81 70.06 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.275 -0.421 . . . . 0.0 111.387 -179.741 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 217' ' ' ALA . . . . . . . . . . . . . . . -61.04 -34.68 75.25 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 121.029 0.442 . . . . 0.0 110.137 179.635 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 218' ' ' THR . . . . . . . . . . . . . 91.5 m -80.2 -34.24 37.54 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 115.716 -0.675 . . . . 0.0 110.821 179.48 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 219' ' ' LEU . . . . . 0.448 ' HG ' ' O ' ' A' ' 215' ' ' ALA . 83.6 mt -61.03 -39.01 88.16 Favored 'General case' 0 C--N 1.331 -0.202 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.721 179.845 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 220' ' ' ARG . . . . . . . . . . . . . 29.8 ptt180 -82.91 -31.12 27.96 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 116.066 -0.516 . . . . 0.0 110.639 179.875 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 221' ' ' ALA . . . . . . . . . . . . . . . -60.41 -33.06 71.95 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 116.062 -0.517 . . . . 0.0 111.279 179.936 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 222' ' ' GLU . . . . . . . . . . . . . 12.4 pt-20 -92.47 -18.49 23.14 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.057 179.955 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 223' ' ' HIS . . . . . . . . . . . . . 63.2 m-70 60.59 -179.04 0.1 Allowed 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 115.462 -0.79 . . . . 0.0 111.234 179.972 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 224' ' ' GLY . . . . . . . . . . . . . . . -176.86 -32.96 0.05 OUTLIER Glycine 0 N--CA 1.452 -0.28 0 C-N-CA 120.941 -0.647 . . . . 0.0 112.196 179.993 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 225' ' ' GLU . . . . . . . . . . . . . 12.9 pt-20 -87.82 144.67 26.48 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.783 0.325 . . . . 0.0 110.592 179.771 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 226' ' ' SER . . . . . . . . . . . . . 60.9 m -109.59 -178.71 3.62 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.287 -0.415 . . . . 0.0 111.025 -179.884 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 227' ' ' LEU . . . . . . . . . . . . . 50.3 mt -70.34 -56.44 6.71 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 115.932 -0.577 . . . . 0.0 110.898 -179.895 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 228' ' ' ALA . . . . . . . . . . . . . . . 51.92 -165.65 0.06 Allowed 'General case' 0 C--N 1.331 -0.213 0 CA-C-N 115.97 -0.559 . . . . 0.0 111.608 -179.981 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 229' ' ' GLY . . . . . . . . . . . . . . . -169.31 -54.14 0.03 OUTLIER Glycine 0 N--CA 1.452 -0.284 0 C-N-CA 120.813 -0.708 . . . . 0.0 112.386 179.994 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 230' ' ' VAL . . . . . . . . . . . . . 59.2 t -110.35 132.9 57.43 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.25 0 CA-C-O 120.828 0.347 . . . . 0.0 111.003 179.881 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 231' ' ' ASP . . . . . . . . . . . . . 18.6 t70 -100.29 120.82 40.52 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.884 -179.942 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 232' ' ' THR . . . . . . . . . . . . . 5.6 t -133.74 3.53 3.53 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.13 -0.486 . . . . 0.0 111.137 179.952 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 233' ' ' ASP . . . . . . . . . . . . . 10.9 m-20 -75.42 -178.08 3.87 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.117 -0.492 . . . . 0.0 111.007 -179.933 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 234' ' ' THR . . . . . . . . . . . . . 72.6 m -116.16 93.49 39.12 Favored Pre-proline 0 C--N 1.33 -0.269 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.029 -179.92 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 235' ' ' PRO . . . . . . . . . . . . . 38.1 Cg_endo -67.22 -54.1 0.42 Allowed 'Trans proline' 0 C--N 1.348 0.531 0 C-N-CA 122.413 2.076 . . . . 0.0 112.267 179.824 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 236' ' ' ALA . . . . . . . . . . . . . . . -122.06 131.13 53.82 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.928 179.917 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 237' ' ' VAL . . . . . . . . . . . . . 27.5 m -60.89 162.86 1.21 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.242 0 CA-C-N 116.082 -0.508 . . . . 0.0 111.198 -179.941 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 238' ' ' ALA . . . . . . . . . . . . . . . -126.99 -64.03 1.03 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.048 -0.524 . . . . 0.0 111.083 -179.985 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 239' ' ' ASP . . . . . . . . . . . . . 7.8 m-20 -95.01 118.97 32.73 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.11 -0.495 . . . . 0.0 110.94 -179.929 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 240' ' ' LEU . . . . . . . . . . . . . 62.0 tp -106.73 -46.32 4.0 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.903 179.914 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 241' ' ' GLU . . . . . . . . . . . . . 1.3 mp0 -66.82 -10.23 45.73 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 116.304 -0.407 . . . . 0.0 110.898 179.941 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 242' ' ' HIS . . . . . . . . . . . . . 18.1 t60 -131.43 102.23 5.86 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.502 179.964 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 243' ' ' HIS . . . . . . . . . . . . . 50.7 t-80 -88.59 -67.2 0.85 Allowed 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.116 -179.83 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 244' ' ' HIS . . . . . . . . . . . . . 66.5 m-70 -58.72 96.63 0.03 OUTLIER 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.947 -179.857 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 245' ' ' HIS . . . . . . . . . . . . . 2.6 p-80 -122.88 -168.83 1.82 Allowed 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.942 -179.966 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 246' ' ' HIS . . . . . . . . . . . . . 57.3 t-80 -160.53 -51.04 0.05 OUTLIER 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.729 179.836 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 247' ' ' HIS . . . . . . . . . . . . . 34.1 t-80 . . . . . 0 C--O 1.249 1.072 0 CA-C-O 118.369 -0.824 . . . . 0.0 110.839 179.909 . . . . . . . . 0 0 . 1 . 021 nuclear build full ' A' A ' 301' ' ' RET . . . . . 0.766 H203 ' HE1' ' A' ' 171' ' ' TRP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 1' ' ' MET . . . . . 0.472 ' N ' HG23 ' A' ' 5' ' ' THR . 49.5 mtm . . . . . 0 N--CA 1.486 1.329 0 CA-C-O 120.831 0.348 . . . . 0.0 110.885 . . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 60.4 t -142.85 -50.43 0.19 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.222 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.921 -179.906 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -111.53 -16.38 9.49 Favored Glycine 0 N--CA 1.452 -0.261 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.719 -179.798 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -73.74 -40.67 63.35 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.858 0.361 . . . . 0.0 110.772 -179.929 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 5' ' ' THR . . . . . 0.472 HG23 ' N ' ' A' ' 1' ' ' MET . 76.4 p -60.52 -29.49 69.15 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.329 -179.842 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 13.6 p -57.38 -36.13 70.87 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.502 -179.715 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 7' ' ' LEU . . . . . . . . . . . . . 4.1 mm? -57.56 -53.16 61.29 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-N 116.328 -0.396 . . . . 0.0 111.165 -179.839 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 8' ' ' PHE . . . . . 0.516 ' HB2' ' HB2' ' A' ' 55' ' ' ALA . 78.9 m-85 -60.91 -33.48 73.2 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 120.866 0.365 . . . . 0.0 110.752 179.901 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 9' ' ' TRP . . . . . . . . . . . . . 18.9 m95 -63.78 -45.34 90.16 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-O 121.245 0.545 . . . . 0.0 109.678 179.82 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 72.3 mt -63.45 -34.34 77.55 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-N 115.383 -0.826 . . . . 0.0 110.12 179.302 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -66.29 -37.02 92.5 Favored Glycine 0 N--CA 1.449 -0.46 0 C-N-CA 120.77 -0.728 . . . . 0.0 111.596 179.179 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -66.74 -33.18 75.06 Favored 'General case' 0 C--N 1.332 -0.17 0 CA-C-O 120.961 0.41 . . . . 0.0 110.303 179.337 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 45.0 mm -65.19 -50.79 71.99 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.212 0 CA-C-N 115.904 -0.589 . . . . 0.0 110.235 179.099 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -59.35 -31.42 69.88 Favored Glycine 0 N--CA 1.449 -0.466 0 C-N-CA 120.773 -0.727 . . . . 0.0 111.836 179.394 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 15' ' ' MET . . . . . 0.45 ' HB3' ' HB2' ' A' ' 48' ' ' ALA . 22.0 mmt -70.87 -45.61 64.11 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-O 120.686 0.279 . . . . 0.0 110.583 179.586 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 21.8 tp -54.66 -38.31 66.78 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.668 179.59 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 64.2 t -67.06 -47.54 81.76 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.191 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.03 179.927 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -64.65 -49.45 64.22 Favored Glycine 0 C--N 1.331 0.281 0 C-N-CA 120.684 -0.77 . . . . 0.0 112.17 179.679 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 22.2 m -49.56 -46.22 48.55 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-O 120.72 0.295 . . . . 0.0 111.12 -179.807 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 85.6 mt -72.22 -40.01 68.11 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-N 116.359 -0.382 . . . . 0.0 111.403 179.646 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -61.28 -30.17 70.31 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.454 -0.339 . . . . 0.0 111.817 -179.484 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 22' ' ' PHE . . . . . 0.692 ' HB2' HG22 ' A' ' 41' ' ' VAL . 13.7 m-85 -90.74 -40.43 11.84 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.735 0.302 . . . . 0.0 111.149 -179.622 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -62.75 -50.71 69.97 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.343 -179.732 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 24' ' ' TRP . . . . . . . . . . . . . 2.2 t-105 -60.96 -41.7 96.84 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 115.968 -0.56 . . . . 0.0 111.042 -179.945 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -77.72 -14.29 59.65 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.877 0.37 . . . . 0.0 110.946 179.752 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -73.53 -47.95 19.79 Favored Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.923 -0.656 . . . . 0.0 112.606 179.892 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 15.8 ptm180 -65.42 -29.95 70.7 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-O 120.889 0.376 . . . . 0.0 110.894 179.991 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 26.4 t70 -78.28 -12.52 60.01 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.059 -0.518 . . . . 0.0 110.944 179.931 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -69.8 -174.68 0.78 Allowed 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.125 179.879 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -101.25 -155.14 26.74 Favored Glycine 0 N--CA 1.452 -0.274 0 C-N-CA 120.797 -0.716 . . . . 0.0 112.451 179.931 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 78.0 p -97.18 127.42 43.13 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.808 0.337 . . . . 0.0 110.884 -179.995 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 110.96 -50.3 0.78 Allowed Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.826 -0.702 . . . . 0.0 112.593 179.969 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 12.7 mm-40 -69.34 -20.88 63.86 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-O 120.86 0.362 . . . . 0.0 110.917 179.95 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 34' ' ' ARG . . . . . . . . . . . . . 41.5 ttm180 -51.02 -29.01 11.38 Favored 'General case' 0 C--N 1.332 -0.185 0 CA-C-N 115.958 -0.564 . . . . 0.0 111.539 -179.772 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 86.4 mtm180 -61.99 -45.89 91.65 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.899 0.38 . . . . 0.0 110.917 -179.969 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 88.0 m-85 -67.55 -29.26 68.59 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.044 -0.526 . . . . 0.0 111.224 179.961 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 37' ' ' TYR . . . . . 0.528 ' O ' HG23 ' A' ' 41' ' ' VAL . 51.7 m-85 -74.6 -54.11 8.08 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.255 -179.577 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 9.4 p -56.99 -36.6 51.18 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-O 120.949 0.405 . . . . 0.0 110.474 179.794 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 48.3 m -65.66 -51.37 60.04 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 115.901 -0.59 . . . . 0.0 110.608 179.493 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 40' ' ' LEU . . . . . 0.453 HD13 ' CE1' ' A' ' 208' ' ' PHE . 16.6 tp -57.05 -47.24 81.43 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 115.832 -0.622 . . . . 0.0 110.624 179.702 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 41' ' ' VAL . . . . . 0.692 HG22 ' HB2' ' A' ' 22' ' ' PHE . 64.8 t -60.0 -34.74 57.45 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.41 0 CA-C-N 115.836 -0.62 . . . . 0.0 110.11 179.183 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -60.31 -36.2 90.3 Favored Glycine 0 N--CA 1.449 -0.448 0 C-N-CA 120.682 -0.77 . . . . 0.0 111.817 179.494 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 43' ' ' ILE . . . . . 0.675 HG22 ' HE3' ' A' ' 205' ' ' LYS . 0.8 OUTLIER -67.31 -57.27 10.38 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.139 0 CA-C-O 120.65 0.262 . . . . 0.0 110.817 179.44 . . . . . . . . 3 3 . 1 . 022 nuclear build full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 55.6 m -57.11 -25.0 58.07 Favored 'General case' 0 C--O 1.231 0.113 0 CA-C-N 116.42 -0.354 . . . . 0.0 111.188 -179.945 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -77.33 -54.71 4.59 Favored Glycine 0 CA--C 1.518 0.267 0 C-N-CA 120.793 -0.718 . . . . 0.0 113.162 -179.504 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 46' ' ' ILE . . . . . 0.41 ' O ' HG22 ' A' ' 49' ' ' VAL . 25.8 pt -58.06 -40.89 78.92 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.185 0 CA-C-O 120.93 0.395 . . . . 0.0 111.01 -179.647 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 47' ' ' ALA . . . . . 0.66 ' HB2' ' HE2' ' A' ' 205' ' ' LYS . . . -67.92 -38.62 83.13 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.004 179.205 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 48' ' ' ALA . . . . . 0.45 ' HB2' ' HB3' ' A' ' 15' ' ' MET . . . -55.41 -44.56 76.29 Favored 'General case' 0 C--O 1.232 0.152 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.733 -179.708 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 49' ' ' VAL . . . . . 0.41 HG22 ' O ' ' A' ' 46' ' ' ILE . 30.5 m -72.56 -33.82 46.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.544 -0.298 . . . . 0.0 111.141 -179.562 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -63.37 -36.62 84.31 Favored 'General case' 0 C--N 1.331 -0.206 0 CA-C-O 120.989 0.424 . . . . 0.0 110.748 179.473 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 28.5 m-85 -73.0 -36.25 67.0 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 115.915 -0.584 . . . . 0.0 110.442 179.794 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -65.47 -42.35 92.35 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 115.979 -0.555 . . . . 0.0 110.957 179.54 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 53' ' ' VAL . . . . . 0.506 ' O ' HG12 ' A' ' 58' ' ' VAL . 25.4 m -71.48 -47.33 59.17 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.188 0 CA-C-N 116.451 -0.341 . . . . 0.0 110.83 179.821 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 54' ' ' MET . . . . . 0.517 ' HG2' ' HG2' ' A' ' 71' ' ' PRO . 72.6 mtm -62.14 -31.97 72.51 Favored 'General case' 0 C--N 1.332 -0.19 0 CA-C-O 121.058 0.456 . . . . 0.0 110.007 179.439 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 55' ' ' ALA . . . . . 0.516 ' HB2' ' HB2' ' A' ' 8' ' ' PHE . . . -67.31 -32.51 73.53 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 115.701 -0.681 . . . . 0.0 111.04 179.306 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 76.3 mt -79.77 -4.4 51.82 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.28 -179.871 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 90.82 -16.09 59.12 Favored Glycine 0 CA--C 1.518 0.234 0 C-N-CA 120.539 -0.839 . . . . 0.0 113.288 179.54 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 58' ' ' VAL . . . . . 0.506 HG12 ' O ' ' A' ' 53' ' ' VAL . 13.0 p -67.4 144.37 14.6 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 117.108 0.454 . . . . 0.0 110.819 -179.884 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 94.05 -12.47 69.12 Favored Glycine 0 N--CA 1.45 -0.412 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.053 -179.461 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 60' ' ' TRP . . . . . . . . . . . . . 13.3 m0 -80.02 111.15 16.08 Favored 'General case' 0 C--N 1.331 -0.213 0 N-CA-C 110.329 -0.249 . . . . 0.0 110.329 179.703 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 6.9 p -111.29 129.56 23.93 Favored Pre-proline 0 C--N 1.329 -0.305 0 CA-C-N 116.61 -0.268 . . . . 0.0 111.201 -179.866 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 60.1 Cg_endo -71.81 152.15 57.96 Favored 'Trans proline' 0 C--N 1.35 0.618 0 C-N-CA 122.373 2.048 . . . . 0.0 112.292 179.96 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 93.7 t -143.38 94.37 0.51 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 115.929 -0.578 . . . . 0.0 110.761 -179.74 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . 58.19 -87.04 0.02 OUTLIER 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.11 -179.813 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 12.1 mm-40 -120.84 -23.19 6.0 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.288 -0.415 . . . . 0.0 110.591 179.773 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 66' ' ' ARG . . . . . . . . . . . . . 20.3 mmm180 -98.69 165.95 11.56 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.013 -0.539 . . . . 0.0 110.449 179.994 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 88.1 m -128.1 123.36 34.31 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-O 120.898 0.38 . . . . 0.0 111.173 179.947 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 68' ' ' VAL . . . . . 0.494 HG21 ' SD ' ' A' ' 117' ' ' MET . 27.3 m -106.73 146.68 12.89 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.054 -0.521 . . . . 0.0 110.702 179.834 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 69' ' ' PHE . . . . . . . . . . . . . 21.7 m-85 -106.59 112.92 26.13 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 116.132 -0.485 . . . . 0.0 109.989 -179.511 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 70' ' ' VAL . . . . . 0.58 ' N ' ' HD2' ' A' ' 71' ' ' PRO . 15.0 t -66.31 -47.9 58.82 Favored Pre-proline 0 C--N 1.322 -0.61 0 CA-C-N 116.24 -0.436 . . . . 0.0 112.076 -179.293 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 71' ' ' PRO . . . . . 0.58 ' HD2' ' N ' ' A' ' 70' ' ' VAL . 40.5 Cg_endo -66.16 -18.07 55.67 Favored 'Trans proline' 0 C--N 1.351 0.697 0 C-N-CA 122.115 1.877 . . . . 0.0 113.274 -179.327 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 72.3 ttt180 -72.85 -55.49 6.58 Favored 'General case' 0 C--O 1.235 0.296 0 CA-C-O 120.664 0.268 . . . . 0.0 111.712 -179.434 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 73' ' ' TYR . . . . . . . . . . . . . 71.5 m-85 -70.52 -31.58 68.72 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.524 -0.307 . . . . 0.0 110.769 -179.321 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 74' ' ' ILE . . . . . 0.46 HG22 ' HA ' ' A' ' 71' ' ' PRO . 0.4 OUTLIER -69.97 -39.56 77.59 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.229 0 N-CA-C 109.793 -0.447 . . . . 0.0 109.793 179.137 . . . . . . . . 3 3 . 1 . 022 nuclear build full ' A' A ' 75' ' ' ASP . . . . . 0.473 ' O ' HG23 ' A' ' 79' ' ' THR . 18.8 t70 -58.55 -37.6 76.07 Favored 'General case' 0 CA--C 1.519 -0.232 0 N-CA-C 109.25 -0.648 . . . . 0.0 109.25 178.713 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 76' ' ' TRP . . . . . 0.482 ' HB3' ' SD ' ' A' ' 109' ' ' MET . 43.9 m0 -66.97 -34.99 78.97 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 115.742 -0.663 . . . . 0.0 110.194 178.926 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 77' ' ' ILE . . . . . 0.425 HD12 ' HA ' ' A' ' 74' ' ' ILE . 97.0 mt -65.43 -28.65 44.93 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 115.948 -0.569 . . . . 0.0 110.688 179.497 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 38.3 mt -91.86 -25.01 19.16 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.223 -0.444 . . . . 0.0 112.12 -179.955 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 79' ' ' THR . . . . . 0.473 HG23 ' O ' ' A' ' 75' ' ' ASP . 67.2 p -92.69 -52.31 4.69 Favored 'General case' 0 N--CA 1.464 0.261 0 N-CA-C 113.671 0.989 . . . . 0.0 113.671 -177.74 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 80' ' ' THR . . . . . 0.442 ' N ' ' HD2' ' A' ' 81' ' ' PRO . 33.4 m -49.33 -54.55 28.8 Favored Pre-proline 0 C--N 1.329 -0.314 0 N-CA-C 113.159 0.8 . . . . 0.0 113.159 -178.163 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 81' ' ' PRO . . . . . 0.442 ' HD2' ' N ' ' A' ' 80' ' ' THR . 36.6 Cg_endo -63.13 -19.11 68.02 Favored 'Trans proline' 0 C--N 1.351 0.674 0 C-N-CA 121.463 1.442 . . . . 0.0 111.376 -179.513 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 82' ' ' LEU . . . . . . . . . . . . . 14.1 tp -77.05 -33.54 57.24 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 115.643 -0.708 . . . . 0.0 110.256 179.727 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 83' ' ' ILE . . . . . 0.428 HD11 HG21 ' A' ' 43' ' ' ILE . 32.8 mm -68.89 -52.62 32.83 Favored 'Isoleucine or valine' 0 C--O 1.232 0.174 0 CA-C-N 115.98 -0.555 . . . . 0.0 109.867 179.05 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 84' ' ' VAL . . . . . 0.433 HG22 ' HA ' ' A' ' 81' ' ' PRO . 27.9 m -61.21 -30.39 47.74 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.209 0 N-CA-C 109.513 -0.551 . . . . 0.0 109.513 178.797 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 85' ' ' TYR . . . . . 0.4 ' HB2' ' O ' ' A' ' 81' ' ' PRO . 82.7 t80 -65.87 -32.91 74.69 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 115.48 -0.782 . . . . 0.0 109.347 178.741 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 86' ' ' PHE . . . . . 0.418 ' HE2' ' HB2' ' A' ' 40' ' ' LEU . 10.8 t80 -63.91 -51.74 63.08 Favored 'General case' 0 N--CA 1.456 -0.133 0 CA-C-N 115.681 -0.691 . . . . 0.0 109.956 179.219 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 8.8 mp -61.32 -32.66 72.53 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 115.701 -0.681 . . . . 0.0 110.457 179.67 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -68.71 -27.96 73.47 Favored Glycine 0 N--CA 1.45 -0.407 0 C-N-CA 120.731 -0.747 . . . . 0.0 111.65 179.368 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 47.5 mt -72.13 -41.8 66.77 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.87 0.367 . . . . 0.0 110.646 179.539 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 57.0 mt -65.16 -45.8 83.47 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 115.951 -0.568 . . . . 0.0 111.059 179.942 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 91' ' ' ALA . . . . . 0.466 ' HB1' ' HB3' ' A' ' 148' ' ' SER . . . -71.55 -55.2 8.28 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.318 -0.401 . . . . 0.0 111.167 -179.696 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 99.5 67.62 0.86 Allowed Glycine 0 CA--C 1.519 0.283 0 C-N-CA 120.812 -0.709 . . . . 0.0 112.684 179.893 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 9.2 mp -75.34 -172.74 1.85 Allowed 'General case' 0 C--N 1.33 -0.245 0 CA-C-O 120.74 0.305 . . . . 0.0 110.856 179.911 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 94' ' ' ASP . . . . . 0.474 ' H ' ' HB2' ' A' ' 97' ' ' GLU . 6.7 m-20 -96.91 -173.98 2.86 Favored 'General case' 0 C--N 1.332 -0.174 0 CA-C-O 121.073 0.464 . . . . 0.0 111.266 -179.823 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 50.4 m -67.64 -51.58 48.34 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 115.78 -0.646 . . . . 0.0 111.308 -179.793 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 79.8 ttt180 -74.22 -34.86 63.82 Favored 'General case' 0 C--N 1.331 -0.197 0 CA-C-O 120.964 0.412 . . . . 0.0 110.575 -179.579 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 97' ' ' GLU . . . . . 0.474 ' HB2' ' H ' ' A' ' 94' ' ' ASP . 0.3 OUTLIER -56.88 -45.15 82.72 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 115.687 -0.688 . . . . 0.0 111.241 -179.812 . . . . . . . . 3 3 . 1 . 022 nuclear build full ' A' A ' 98' ' ' PHE . . . . . 0.443 ' O ' HG12 ' A' ' 102' ' ' ILE . 4.8 m-85 -62.17 -42.92 99.73 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.834 0.35 . . . . 0.0 110.71 179.487 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -62.6 -28.8 72.01 Favored Glycine 0 N--CA 1.45 -0.401 0 C-N-CA 120.8 -0.714 . . . . 0.0 112.682 -179.865 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 96.1 mt -72.46 -41.91 64.32 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.234 0 CA-C-O 120.873 0.368 . . . . 0.0 111.198 -179.927 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 53.8 t -67.45 -43.64 87.34 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.32 -179.932 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 102' ' ' ILE . . . . . 0.443 HG12 ' O ' ' A' ' 98' ' ' PHE . 43.0 mm -68.07 -49.59 66.49 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.63 -179.495 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 14.9 t -57.71 -33.59 68.57 Favored 'General case' 0 C--O 1.233 0.186 0 CA-C-O 120.762 0.315 . . . . 0.0 111.173 -179.701 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 41.2 tp -65.75 -48.16 72.84 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.3 -0.409 . . . . 0.0 110.545 179.601 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 105' ' ' ASN . . . . . 0.597 ' N ' HD22 ' A' ' 105' ' ' ASN . 0.8 OUTLIER -61.16 -26.08 67.45 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.766 179.758 . . . . . . . . 3 3 . 1 . 022 nuclear build full ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 91.6 m -69.07 -57.6 5.2 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-N 116.378 -0.374 . . . . 0.0 111.425 -179.934 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 8.3 p -58.58 -37.32 64.3 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.237 0 CA-C-N 116.531 -0.304 . . . . 0.0 110.942 -179.816 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 73.9 t -66.46 -51.97 51.76 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.898 179.532 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 109' ' ' MET . . . . . 0.482 ' SD ' ' HB3' ' A' ' 76' ' ' TRP . 9.8 tpp -61.36 -32.61 72.52 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.018 -0.537 . . . . 0.0 110.387 179.753 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 10.0 mt -72.31 -30.29 64.64 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 115.848 -0.615 . . . . 0.0 109.939 179.38 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -60.06 -45.63 92.22 Favored 'General case' 0 CA--C 1.519 -0.234 0 N-CA-C 109.249 -0.649 . . . . 0.0 109.249 178.248 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 112' ' ' GLY . . . . . 0.542 ' HA3' ' H21' ' A' ' 301' ' ' RET . . . -70.26 -41.74 67.98 Favored Glycine 0 N--CA 1.449 -0.441 0 CA-C-N 115.501 -0.772 . . . . 0.0 111.19 178.392 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 113' ' ' PHE . . . . . . . . . . . . . 2.0 t80 -48.81 -65.95 0.48 Allowed 'General case' 0 CA--C 1.52 -0.186 0 N-CA-C 109.353 -0.61 . . . . 0.0 109.353 178.82 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 114' ' ' ALA . . . . . 0.504 ' HB3' HD22 ' A' ' 126' ' ' LEU . . . -64.41 -19.23 65.38 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 115.467 -0.788 . . . . 0.0 110.406 178.699 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -53.1 -51.1 48.59 Favored Glycine 0 C--N 1.335 0.488 0 C-N-CA 120.892 -0.671 . . . . 0.0 111.86 179.495 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 116' ' ' ALA . . . . . 0.455 ' HB1' HG12 ' A' ' 68' ' ' VAL . . . -78.02 -18.44 55.87 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-O 120.87 0.367 . . . . 0.0 110.948 179.279 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 117' ' ' MET . . . . . 0.494 ' SD ' HG21 ' A' ' 68' ' ' VAL . 22.3 mmt -81.9 18.56 1.28 Allowed 'General case' 0 C--N 1.331 -0.218 0 CA-C-N 116.015 -0.539 . . . . 0.0 111.673 -179.441 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 118' ' ' VAL . . . . . 0.441 HG11 ' N ' ' A' ' 123' ' ' ARG . 32.6 m -89.85 138.71 27.72 Favored Pre-proline 0 C--N 1.327 -0.371 0 CA-C-N 116.73 -0.213 . . . . 0.0 111.375 -179.95 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 119' ' ' PRO . . . . . . . . . . . . . 70.3 Cg_endo -89.98 -3.76 5.4 Favored 'Trans proline' 0 N--CA 1.456 -0.692 0 C-N-CA 122.73 2.286 . . . . 0.0 112.235 179.61 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -138.2 -110.83 0.97 Allowed Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.908 -179.765 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 46.8 pt -126.99 14.93 3.6 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.214 0 CA-C-O 120.738 0.304 . . . . 0.0 111.585 -179.384 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 25.6 mt-10 -61.74 -18.64 60.53 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-N 116.353 -0.385 . . . . 0.0 111.041 -179.8 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 123' ' ' ARG . . . . . 0.464 ' HB2' ' HH2' ' A' ' 178' ' ' TRP . 7.6 ptt180 -52.6 -30.12 29.5 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 115.976 -0.557 . . . . 0.0 112.085 -179.66 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 124' ' ' TYR . . . . . . . . . . . . . 50.9 m-85 -69.16 -32.44 71.79 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.794 0.331 . . . . 0.0 111.364 -179.668 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 125' ' ' ALA . . . . . . . . . . . . . . . -72.59 -56.14 5.81 Favored 'General case' 0 C--O 1.236 0.346 0 CA-C-N 116.304 -0.407 . . . . 0.0 111.296 -179.504 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 126' ' ' LEU . . . . . 0.504 HD22 ' HB3' ' A' ' 114' ' ' ALA . 1.2 mt -51.49 -45.35 62.79 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 115.839 -0.619 . . . . 0.0 110.922 -179.821 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 127' ' ' PHE . . . . . . . . . . . . . 3.6 t80 -67.65 -38.64 84.11 Favored 'General case' 0 C--N 1.33 -0.269 0 C-N-CA 120.874 -0.33 . . . . 0.0 110.394 179.581 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 128' ' ' GLY . . . . . . . . . . . . . . . -46.48 -43.1 14.56 Favored Glycine 0 C--N 1.332 0.337 0 C-N-CA 120.21 -0.995 . . . . 0.0 110.991 179.219 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 129' ' ' MET . . . . . . . . . . . . . 0.4 OUTLIER -71.59 -41.32 69.13 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 115.383 -0.408 . . . . 0.0 110.18 179.04 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -63.61 -28.98 73.34 Favored Glycine 0 C--N 1.332 0.321 0 C-N-CA 121.066 -0.588 . . . . 0.0 113.016 -179.665 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -74.69 -53.64 8.89 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.729 0.265 . . . . 0.0 110.529 -179.901 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 61.4 t -59.32 -40.47 81.52 Favored 'Isoleucine or valine' 0 C--O 1.234 0.289 0 N-CA-C 109.205 -0.665 . . . . 0.0 109.205 178.832 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -67.51 -34.08 76.38 Favored 'General case' 0 N--CA 1.452 -0.353 0 CA-C-N 115.201 -0.908 . . . . 0.0 110.48 179.175 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 134' ' ' PHE . . . . . 0.421 ' CZ ' ' HA ' ' A' ' 172' ' ' ALA . 82.2 t80 -56.04 -52.59 63.7 Favored 'General case' 0 N--CA 1.451 -0.417 0 CA-C-N 116.072 -0.513 . . . . 0.0 109.875 179.328 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 135' ' ' ILE . . . . . 0.457 ' HA ' HG22 ' A' ' 138' ' ' VAL . 53.3 mt -58.14 -34.31 49.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 115.798 -0.637 . . . . 0.0 109.855 179.094 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . -63.73 -36.62 93.56 Favored Glycine 0 C--N 1.334 0.422 0 C-N-CA 120.312 -0.947 . . . . 0.0 111.356 178.75 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 137' ' ' LEU . . . . . 0.426 HD13 HD21 ' A' ' 105' ' ' ASN . 35.1 tp -71.24 -53.56 13.95 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.7 0.286 . . . . 0.0 110.453 179.448 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 138' ' ' VAL . . . . . 0.457 HG22 ' HA ' ' A' ' 135' ' ' ILE . 5.3 m -55.98 -31.94 32.02 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.218 0 CA-C-O 121.164 0.507 . . . . 0.0 109.656 179.458 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 139' ' ' TYR . . . . . . . . . . . . . 38.6 t80 -60.82 -47.99 83.83 Favored 'General case' 0 N--CA 1.454 -0.228 0 CA-C-N 115.528 -0.76 . . . . 0.0 109.909 178.511 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 15.5 m-85 -56.5 -37.98 71.13 Favored 'General case' 0 C--N 1.334 -0.093 0 CA-C-N 116.056 -0.52 . . . . 0.0 110.81 179.22 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 141' ' ' LEU . . . . . . . . . . . . . 70.5 mt -64.28 -34.95 79.29 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.057 -0.519 . . . . 0.0 110.708 -179.853 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 13.8 t -94.29 -7.57 10.03 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.79 179.828 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . -73.89 -131.8 0.21 Allowed Glycine 0 CA--C 1.521 0.43 0 C-N-CA 120.891 -0.671 . . . . 0.0 112.673 -179.765 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 144' ' ' PRO . . . . . . . . . . . . . 28.1 Cg_endo -62.04 -23.7 75.95 Favored 'Trans proline' 0 C--N 1.347 0.478 0 C-N-CA 122.528 2.152 . . . . 0.0 112.673 -179.859 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 145' ' ' MET . . . . . . . . . . . . . 52.4 mtt -53.99 -32.02 52.78 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-O 120.661 0.267 . . . . 0.0 111.436 -179.815 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 146' ' ' THR . . . . . . . . . . . . . 73.2 p -72.06 -46.0 58.59 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.426 -0.352 . . . . 0.0 111.479 -179.693 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 42.4 mt-10 -72.7 -28.11 62.48 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.471 -179.64 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 148' ' ' SER . . . . . 0.466 ' HB3' ' HB1' ' A' ' 91' ' ' ALA . 32.6 t -70.32 -43.87 69.42 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-O 120.754 0.311 . . . . 0.0 111.105 -179.622 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 149' ' ' ALA . . . . . . . . . . . . . . . -75.11 -40.12 60.13 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.147 -0.479 . . . . 0.0 111.198 -179.838 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 150' ' ' SER . . . . . . . . . . . . . 69.0 m -63.61 -22.91 67.15 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.096 -179.909 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 151' ' ' GLN . . . . . . . . . . . . . 46.2 mt-30 -105.53 6.82 32.6 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.263 -0.426 . . . . 0.0 111.435 -179.751 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 31.9 tpt180 -84.11 -51.7 6.87 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.88 0.372 . . . . 0.0 110.542 179.646 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 153' ' ' SER . . . . . 0.596 ' HB3' HG12 ' A' ' 156' ' ' ILE . 23.1 t -157.67 169.98 23.43 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-N 115.902 -0.59 . . . . 0.0 110.449 179.091 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 154' ' ' SER . . . . . . . . . . . . . 82.7 p -71.01 -39.72 72.22 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.788 0.328 . . . . 0.0 110.5 179.555 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -77.09 -36.6 34.94 Favored Glycine 0 N--CA 1.452 -0.241 0 C-N-CA 120.864 -0.684 . . . . 0.0 112.595 179.752 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 156' ' ' ILE . . . . . 0.596 HG12 ' HB3' ' A' ' 153' ' ' SER . 28.4 mm -51.64 -38.18 21.17 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.215 0 CA-C-O 120.623 0.249 . . . . 0.0 111.438 -179.859 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 157' ' ' LYS . . . . . 0.414 ' O ' HG13 ' A' ' 161' ' ' VAL . 63.6 tttp -60.03 -48.78 80.3 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.283 -0.417 . . . . 0.0 111.678 -179.795 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 41.3 t -63.78 -47.48 80.75 Favored 'General case' 0 C--N 1.328 -0.351 0 N-CA-C 111.96 0.355 . . . . 0.0 111.96 -179.095 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 159' ' ' LEU . . . . . 0.528 HD23 HD13 ' A' ' 163' ' ' LEU . 1.6 tt -67.71 -31.81 72.02 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 116.494 -0.321 . . . . 0.0 111.28 -179.326 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 160' ' ' TYR . . . . . . . . . . . . . 79.9 t80 -74.05 -44.42 54.33 Favored 'General case' 0 C--N 1.329 -0.315 0 N-CA-C 111.946 0.35 . . . . 0.0 111.946 -179.218 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 161' ' ' VAL . . . . . 0.414 HG13 ' O ' ' A' ' 157' ' ' LYS . 30.4 m -62.01 -41.18 90.03 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 N-CA-C 111.691 0.256 . . . . 0.0 111.691 -179.205 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 162' ' ' ARG . . . . . . . . . . . . . 94.7 mtt180 -67.87 -41.29 83.09 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-O 120.778 0.323 . . . . 0.0 111.312 -179.85 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 163' ' ' LEU . . . . . 0.601 ' HG ' ' HB2' ' A' ' 208' ' ' PHE . 7.1 mp -71.96 -54.93 8.46 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.302 -0.408 . . . . 0.0 112.064 -179.208 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 164' ' ' ARG . . . . . 0.434 ' O ' HG23 ' A' ' 168' ' ' VAL . 4.8 tmm_? -53.97 -53.18 56.4 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.273 -0.422 . . . . 0.0 111.568 -179.408 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 165' ' ' ASN . . . . . 0.485 ' O ' HG23 ' A' ' 169' ' ' VAL . 4.1 m-20 -57.05 -51.75 68.02 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.4 -0.364 . . . . 0.0 111.368 -179.255 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 166' ' ' LEU . . . . . 0.472 ' O ' ' HG ' ' A' ' 170' ' ' LEU . 5.5 tt -58.28 -52.12 66.94 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.124 -0.489 . . . . 0.0 111.867 -179.241 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 167' ' ' THR . . . . . 0.453 ' O ' ' HB2' ' A' ' 171' ' ' TRP . 91.3 m -55.37 -53.38 56.94 Favored 'General case' 0 C--N 1.328 -0.34 0 N-CA-C 112.643 0.609 . . . . 0.0 112.643 -178.71 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 168' ' ' VAL . . . . . 0.434 HG23 ' O ' ' A' ' 164' ' ' ARG . 96.3 t -55.21 -40.83 57.63 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.195 0 N-CA-C 112.312 0.486 . . . . 0.0 112.312 -178.558 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 169' ' ' VAL . . . . . 0.485 HG23 ' O ' ' A' ' 165' ' ' ASN . 80.2 t -60.54 -64.66 0.57 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.39 0 N-CA-C 111.798 0.296 . . . . 0.0 111.798 -179.343 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 170' ' ' LEU . . . . . 0.489 HD12 ' N ' ' A' ' 171' ' ' TRP . 1.6 pp -63.98 -27.63 69.26 Favored 'General case' 0 C--N 1.33 -0.26 0 N-CA-C 112.08 0.4 . . . . 0.0 112.08 -178.781 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 171' ' ' TRP . . . . . 0.686 ' HE1' H203 ' A' ' 301' ' ' RET . 1.5 m0 -72.14 -31.14 65.71 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-O 120.926 0.393 . . . . 0.0 110.312 179.383 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 172' ' ' ALA . . . . . 0.421 ' HA ' ' CZ ' ' A' ' 134' ' ' PHE . . . -73.04 -6.19 43.87 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 115.816 -0.629 . . . . 0.0 110.615 179.94 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 173' ' ' ILE . . . . . 0.602 HG22 HD11 ' A' ' 177' ' ' ILE . 36.5 mm -87.78 -21.78 7.01 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.216 0 CA-C-N 115.838 -0.619 . . . . 0.0 111.132 179.787 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 174' ' ' TYR . . . . . 0.437 ' HB2' ' HD3' ' A' ' 175' ' ' PRO . 25.9 m-85 -54.57 -49.55 90.46 Favored Pre-proline 0 N--CA 1.465 0.3 0 CA-C-N 116.49 -0.323 . . . . 0.0 111.694 -179.913 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 175' ' ' PRO . . . . . 0.437 ' HD3' ' HB2' ' A' ' 174' ' ' TYR . 82.7 Cg_exo -47.63 -28.37 9.13 Favored 'Trans proline' 0 C--N 1.353 0.768 0 C-N-CA 122.163 1.909 . . . . 0.0 112.259 179.912 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 176' ' ' PHE . . . . . 0.457 ' O ' ' HG ' ' A' ' 180' ' ' LEU . 95.9 m-85 -80.31 -49.61 11.31 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.026 -0.534 . . . . 0.0 111.72 -179.99 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 177' ' ' ILE . . . . . 0.602 HD11 HG22 ' A' ' 173' ' ' ILE . 2.6 mm -60.1 -45.12 96.14 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.537 0 N-CA-C 112.568 0.581 . . . . 0.0 112.568 -177.894 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 178' ' ' TRP . . . . . 0.464 ' HH2' ' HB2' ' A' ' 123' ' ' ARG . 80.5 t90 -66.63 -40.5 88.76 Favored 'General case' 0 N--CA 1.464 0.255 0 CA-C-O 121.095 0.474 . . . . 0.0 110.644 179.867 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 179' ' ' LEU . . . . . 0.544 ' O ' HG22 ' A' ' 185' ' ' VAL . 0.9 OUTLIER -65.28 -52.43 54.31 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-N 115.732 -0.667 . . . . 0.0 111.272 -179.216 . . . . . . . . 3 3 . 1 . 022 nuclear build full ' A' A ' 180' ' ' LEU . . . . . 0.551 HD22 HD11 ' A' ' 187' ' ' LEU . 9.8 mt -77.6 -52.44 9.02 Favored 'General case' 0 CA--C 1.532 0.266 0 N-CA-C 112.395 0.517 . . . . 0.0 112.395 -178.586 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . -59.89 -85.54 0.04 OUTLIER Glycine 0 C--N 1.333 0.389 0 C-N-CA 120.631 -0.795 . . . . 0.0 113.196 -179.578 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 182' ' ' PRO . . . . . 0.49 ' HD2' ' O ' ' A' ' 177' ' ' ILE . 73.1 Cg_exo -45.01 178.04 0.0 OUTLIER 'Trans proline' 0 C--N 1.351 0.696 0 C-N-CA 123.368 2.712 . . . . 0.0 113.326 179.474 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 183' ' ' PRO . . . . . . . . . . . . . 62.2 Cg_exo -53.68 8.27 0.03 OUTLIER 'Trans proline' 0 C--N 1.352 0.713 0 C-N-CA 123.057 2.505 . . . . 0.0 114.991 -179.384 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 184' ' ' GLY . . . . . 0.45 ' H ' ' C ' ' A' ' 182' ' ' PRO . . . -53.69 -66.94 2.41 Favored Glycine 0 C--N 1.337 0.608 0 C-N-CA 119.795 -1.193 . . . . 0.0 110.971 179.01 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 185' ' ' VAL . . . . . 0.544 HG22 ' O ' ' A' ' 179' ' ' LEU . 4.4 m -134.4 -4.61 1.21 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.389 0 CA-C-N 115.797 -0.202 . . . . 0.0 111.433 178.553 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 186' ' ' ALA . . . . . . . . . . . . . . . 43.85 79.01 0.05 OUTLIER 'General case' 0 N--CA 1.466 0.35 0 N-CA-C 112.289 0.477 . . . . 0.0 112.289 179.386 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 187' ' ' LEU . . . . . 0.551 HD11 HD22 ' A' ' 180' ' ' LEU . 4.9 mt -92.77 -49.83 5.88 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-O 120.71 0.291 . . . . 0.0 111.718 179.971 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 188' ' ' LEU . . . . . 0.414 HD13 HG11 ' A' ' 192' ' ' VAL . 96.0 mt -114.95 -166.45 1.11 Allowed 'General case' 0 C--N 1.331 -0.223 0 CA-C-O 120.983 0.421 . . . . 0.0 111.362 -179.169 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 189' ' ' THR . . . . . . . . . . . . . 3.0 t -85.77 148.11 47.76 Favored Pre-proline 0 C--N 1.328 -0.354 0 CA-C-N 115.826 -0.625 . . . . 0.0 111.279 -179.732 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 190' ' ' PRO . . . . . . . . . . . . . 78.2 Cg_exo -49.42 -44.59 33.98 Favored 'Trans proline' 0 C--N 1.348 0.524 0 C-N-CA 122.849 2.366 . . . . 0.0 113.503 -179.74 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 191' ' ' THR . . . . . . . . . . . . . 9.7 t -56.12 -34.51 66.14 Favored 'General case' 0 C--N 1.33 -0.276 0 N-CA-C 112.308 0.484 . . . . 0.0 112.308 -179.056 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 192' ' ' VAL . . . . . 0.414 HG11 HD13 ' A' ' 188' ' ' LEU . 19.1 t -72.06 -54.39 16.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 N-CA-C 111.851 0.315 . . . . 0.0 111.851 -179.204 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 193' ' ' ASP . . . . . . . . . . . . . 1.1 p30 -62.17 -46.14 90.3 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.699 0.285 . . . . 0.0 110.948 -179.735 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 194' ' ' VAL . . . . . 0.433 ' O ' HG23 ' A' ' 198' ' ' VAL . 63.8 t -58.32 -35.94 55.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.331 -0.395 . . . . 0.0 110.44 179.4 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 195' ' ' ALA . . . . . . . . . . . . . . . -59.93 -48.25 82.45 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.281 -0.418 . . . . 0.0 111.141 179.918 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 196' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -67.88 -35.54 78.69 Favored 'General case' 0 N--CA 1.462 0.173 0 N-CA-C 109.882 -0.414 . . . . 0.0 109.882 179.543 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 197' ' ' ILE . . . . . . . . . . . . . 18.9 mm -58.43 -57.67 9.88 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.289 0 CA-C-N 115.922 -0.581 . . . . 0.0 109.776 178.949 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 198' ' ' VAL . . . . . 0.433 HG23 ' O ' ' A' ' 194' ' ' VAL . 93.5 t -53.92 -35.27 27.56 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.44 0 N-CA-C 108.873 -0.788 . . . . 0.0 108.873 178.138 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 199' ' ' TYR . . . . . . . . . . . . . 17.7 t80 -70.76 -30.21 66.65 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 114.951 -1.022 . . . . 0.0 110.885 179.467 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 200' ' ' LEU . . . . . 0.521 HD11 HG13 ' A' ' 177' ' ' ILE . 34.9 mt -71.75 -44.0 64.81 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 116.048 -0.524 . . . . 0.0 111.703 -179.21 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 201' ' ' ASP . . . . . . . . . . . . . 11.9 m-20 -68.26 -35.21 77.54 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-O 121.117 0.484 . . . . 0.0 110.417 179.89 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 202' ' ' LEU . . . . . 0.439 ' O ' ' HB ' ' A' ' 206' ' ' VAL . 3.4 mt -70.89 -32.59 69.59 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 115.587 -0.733 . . . . 0.0 111.977 -179.507 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 203' ' ' VAL . . . . . 0.484 ' O ' ' HA3' ' A' ' 207' ' ' GLY . 12.5 p -78.17 -36.59 21.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 C-N-CA 121.102 -0.239 . . . . 0.0 111.376 -178.915 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 204' ' ' THR . . . . . 0.402 ' O ' ' CD1' ' A' ' 208' ' ' PHE . 45.4 m -64.73 -57.46 8.91 Favored 'General case' 0 C--N 1.325 -0.457 0 C-N-CA 120.494 -0.482 . . . . 0.0 111.134 179.655 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 205' ' ' LYS . . . . . 0.675 ' HE3' HG22 ' A' ' 43' ' ' ILE . 47.4 mttp -70.2 -58.91 3.25 Favored 'General case' 0 C--N 1.33 -0.251 0 N-CA-C 112.791 0.663 . . . . 0.0 112.791 -178.071 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 206' ' ' VAL . . . . . 0.439 ' HB ' ' O ' ' A' ' 202' ' ' LEU . 23.3 t -70.08 -36.31 67.76 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.411 0 CA-C-N 116.454 -0.339 . . . . 0.0 111.832 -178.692 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 207' ' ' GLY . . . . . 0.496 ' O ' HG13 ' A' ' 211' ' ' ILE . . . -63.3 -60.25 7.78 Favored Glycine 0 N--CA 1.45 -0.382 0 C-N-CA 120.513 -0.851 . . . . 0.0 113.424 -178.844 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 208' ' ' PHE . . . . . 0.601 ' HB2' ' HG ' ' A' ' 163' ' ' LEU . 0.1 OUTLIER -66.47 -27.07 67.51 Favored 'General case' 0 C--O 1.225 -0.219 0 CA-C-N 117.3 0.55 . . . . 0.0 111.037 -179.136 . . . . . . . . 3 3 . 1 . 022 nuclear build full ' A' A ' 209' ' ' GLY . . . . . 0.506 ' O ' ' HB3' ' A' ' 212' ' ' ALA . . . -69.72 -33.12 70.91 Favored Glycine 0 N--CA 1.448 -0.513 0 N-CA-C 111.683 -0.567 . . . . 0.0 111.683 178.852 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 210' ' ' PHE . . . . . . . . . . . . . 1.1 m-85 -70.85 -49.27 47.99 Favored 'General case' 0 CA--C 1.512 -0.494 0 N-CA-C 107.954 -1.128 . . . . 0.0 107.954 178.404 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 211' ' ' ILE . . . . . 0.496 HG13 ' O ' ' A' ' 207' ' ' GLY . 5.6 mt -62.59 -28.36 44.65 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.604 0 N-CA-C 107.618 -1.253 . . . . 0.0 107.618 176.572 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 212' ' ' ALA . . . . . 0.506 ' HB3' ' O ' ' A' ' 209' ' ' GLY . . . -65.05 -39.92 94.01 Favored 'General case' 0 N--CA 1.447 -0.59 0 CA-C-N 114.698 -1.137 . . . . 0.0 110.084 179.431 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 213' ' ' LEU . . . . . 0.41 ' HG ' ' O ' ' A' ' 209' ' ' GLY . 88.4 mt -70.28 -53.16 18.05 Favored 'General case' 0 C--N 1.331 -0.203 0 CA-C-N 115.132 -0.94 . . . . 0.0 111.601 -179.772 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 214' ' ' ASP . . . . . . . . . . . . . 29.4 m-20 -54.01 -50.04 67.53 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.33 -0.395 . . . . 0.0 111.294 -179.38 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 215' ' ' ALA . . . . . . . . . . . . . . . -61.02 -56.42 21.26 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.289 -0.414 . . . . 0.0 111.362 -179.735 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 216' ' ' ALA . . . . . . . . . . . . . . . -56.26 -36.38 68.49 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.233 -0.439 . . . . 0.0 111.467 -179.543 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 217' ' ' ALA . . . . . . . . . . . . . . . -62.46 -40.87 98.01 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.291 -0.413 . . . . 0.0 110.392 179.765 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 218' ' ' THR . . . . . . . . . . . . . 90.9 m -65.95 -37.86 87.12 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.794 -0.639 . . . . 0.0 110.737 179.623 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 219' ' ' LEU . . . . . 0.504 ' O ' ' HG2' ' A' ' 222' ' ' GLU . 71.1 mt -57.95 -44.39 86.96 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.086 -0.506 . . . . 0.0 110.596 179.805 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 220' ' ' ARG . . . . . . . . . . . . . 7.7 mpt_? -84.05 -17.26 40.93 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.095 179.678 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 221' ' ' ALA . . . . . . . . . . . . . . . -77.27 -22.45 52.06 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.269 -0.423 . . . . 0.0 112.024 -179.458 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 222' ' ' GLU . . . . . 0.504 ' HG2' ' O ' ' A' ' 219' ' ' LEU . 11.6 pt-20 -75.4 -7.76 54.91 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-O 120.795 0.331 . . . . 0.0 111.113 -179.532 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 223' ' ' HIS . . . . . . . . . . . . . 78.5 m80 -87.8 -16.21 34.76 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.266 -0.424 . . . . 0.0 111.056 -179.982 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 224' ' ' GLY . . . . . . . . . . . . . . . -83.52 73.72 2.63 Favored Glycine 0 N--CA 1.452 -0.234 0 C-N-CA 120.806 -0.711 . . . . 0.0 112.424 179.9 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 225' ' ' GLU . . . . . . . . . . . . . 10.0 tp10 -148.25 130.02 15.13 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 120.702 0.287 . . . . 0.0 110.939 -179.853 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 226' ' ' SER . . . . . . . . . . . . . 41.4 t 60.71 -85.95 0.02 OUTLIER 'General case' 0 C--N 1.332 -0.195 0 CA-C-N 116.035 -0.53 . . . . 0.0 111.665 179.678 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 227' ' ' LEU . . . . . . . . . . . . . 3.9 mm? -71.97 -34.13 68.72 Favored 'General case' 0 C--N 1.332 -0.185 0 CA-C-N 116.426 -0.352 . . . . 0.0 111.176 -179.441 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 228' ' ' ALA . . . . . . . . . . . . . . . 52.49 -165.85 0.06 Allowed 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.285 -0.416 . . . . 0.0 111.33 -179.8 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 229' ' ' GLY . . . . . . . . . . . . . . . -128.18 48.69 0.96 Allowed Glycine 0 C--N 1.331 0.293 0 C-N-CA 120.743 -0.741 . . . . 0.0 112.717 -179.752 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 230' ' ' VAL . . . . . . . . . . . . . 47.5 t -85.86 133.77 28.83 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.225 0 CA-C-O 120.782 0.325 . . . . 0.0 110.958 179.865 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 231' ' ' ASP . . . . . . . . . . . . . 23.8 t70 -67.6 107.48 2.54 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.313 -0.403 . . . . 0.0 110.978 179.991 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 232' ' ' THR . . . . . . . . . . . . . 8.2 t -157.6 147.66 20.55 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.039 -0.528 . . . . 0.0 110.958 179.844 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 233' ' ' ASP . . . . . . . . . . . . . 22.1 t70 58.23 90.54 0.05 OUTLIER 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.877 -179.816 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 234' ' ' THR . . . . . . . . . . . . . 4.1 t -73.29 141.05 80.15 Favored Pre-proline 0 C--N 1.33 -0.246 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.332 -179.829 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 235' ' ' PRO . . . . . . . . . . . . . 58.5 Cg_endo -71.36 -36.87 6.36 Favored 'Trans proline' 0 C--N 1.347 0.488 0 C-N-CA 122.453 2.102 . . . . 0.0 112.334 179.942 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 236' ' ' ALA . . . . . . . . . . . . . . . -76.6 164.57 25.79 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.001 179.948 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 237' ' ' VAL . . . . . . . . . . . . . 35.2 m -90.76 -178.68 0.43 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.327 -0.397 . . . . 0.0 111.166 -179.879 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 238' ' ' ALA . . . . . . . . . . . . . . . -87.07 118.3 26.37 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.263 -0.426 . . . . 0.0 111.15 -179.982 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 239' ' ' ASP . . . . . . . . . . . . . 10.9 m-20 61.05 177.5 0.11 Allowed 'General case' 0 C--N 1.332 -0.186 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.202 179.819 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 240' ' ' LEU . . . . . . . . . . . . . 95.0 mt -131.84 110.45 10.83 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 116.055 -0.52 . . . . 0.0 110.983 179.922 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 241' ' ' GLU . . . . . . . . . . . . . 39.1 tt0 -115.55 111.33 20.54 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.706 179.825 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 242' ' ' HIS . . . . . . . . . . . . . 72.4 m80 -92.68 138.83 31.15 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.983 -179.815 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 243' ' ' HIS . . . . . . . . . . . . . 45.8 t-80 -156.44 -40.35 0.08 Allowed 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.786 179.834 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 244' ' ' HIS . . . . . . . . . . . . . 47.2 m-70 -62.02 159.07 15.06 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.529 179.72 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 245' ' ' HIS . . . . . . . . . . . . . 28.7 m80 57.95 -170.64 0.11 Allowed 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 116.295 -0.411 . . . . 0.0 110.915 -179.821 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 246' ' ' HIS . . . . . . . . . . . . . 26.2 p80 -155.37 -22.8 0.11 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.944 179.804 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 247' ' ' HIS . . . . . . . . . . . . . 60.7 t60 . . . . . 0 C--O 1.249 1.064 0 CA-C-O 118.179 -0.915 . . . . 0.0 110.886 -179.873 . . . . . . . . 0 0 . 1 . 022 nuclear build full ' A' A ' 301' ' ' RET . . . . . 0.686 H203 ' HE1' ' A' ' 171' ' ' TRP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 85.2 mtp . . . . . 0 N--CA 1.485 1.322 0 CA-C-O 120.838 0.351 . . . . 0.0 110.807 . . . . . . . . . 0 0 . 1 . 023 nuclear build full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 27.6 m -134.57 -31.52 0.46 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.662 -179.923 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -79.48 -20.25 69.5 Favored Glycine 0 C--N 1.33 0.242 0 C-N-CA 120.683 -0.77 . . . . 0.0 112.625 -179.925 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 59.6 tp -74.98 -38.0 61.77 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.832 0.349 . . . . 0.0 111.095 179.953 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 71.1 p -61.73 -32.59 72.82 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.096 -0.502 . . . . 0.0 111.207 -179.819 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 20.5 p -54.53 -35.86 63.64 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.127 -179.785 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 7' ' ' LEU . . . . . . . . . . . . . 4.2 mm? -57.48 -52.86 63.66 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.809 179.836 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 8' ' ' PHE . . . . . 0.689 ' HB2' ' HB2' ' A' ' 55' ' ' ALA . 57.8 m-85 -64.87 -32.99 74.95 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 115.989 -0.551 . . . . 0.0 110.831 179.975 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 9' ' ' TRP . . . . . 0.413 ' O ' HG13 ' A' ' 13' ' ' ILE . 27.8 m95 -64.5 -44.7 90.13 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.978 0.418 . . . . 0.0 109.992 179.808 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 41.9 mt -61.8 -44.51 96.71 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 115.773 -0.649 . . . . 0.0 110.387 179.161 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -65.54 -29.22 74.67 Favored Glycine 0 N--CA 1.45 -0.433 0 C-N-CA 120.704 -0.76 . . . . 0.0 111.922 179.59 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -71.22 -33.42 69.88 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.624 0.25 . . . . 0.0 110.775 179.689 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 13' ' ' ILE . . . . . 0.413 HG13 ' O ' ' A' ' 9' ' ' TRP . 66.4 mt -66.33 -54.02 30.5 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.208 0 CA-C-O 120.9 0.381 . . . . 0.0 110.142 179.32 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -61.77 -38.07 95.34 Favored Glycine 0 N--CA 1.45 -0.432 0 C-N-CA 120.735 -0.745 . . . . 0.0 111.658 179.298 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 15' ' ' MET . . . . . 0.4 ' HG3' ' HB2' ' A' ' 48' ' ' ALA . 45.7 tpp -63.35 -43.51 97.5 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.794 0.331 . . . . 0.0 110.249 179.503 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -55.63 -38.96 70.2 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 115.969 -0.559 . . . . 0.0 109.834 179.23 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 98.8 t -59.91 -45.74 94.76 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.168 0 CA-C-N 115.954 -0.566 . . . . 0.0 109.926 178.955 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -62.74 -45.97 94.63 Favored Glycine 0 C--N 1.333 0.373 0 C-N-CA 120.476 -0.869 . . . . 0.0 111.448 178.801 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 23.7 m -51.86 -44.95 63.88 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 115.548 -0.326 . . . . 0.0 111.405 -179.888 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 85.4 mt -71.65 -42.98 66.9 Favored 'General case' 0 C--N 1.332 -0.184 0 CA-C-N 116.402 -0.363 . . . . 0.0 111.362 -179.921 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -56.89 -34.07 67.51 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.334 -0.393 . . . . 0.0 111.707 -179.662 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 22' ' ' PHE . . . . . 0.467 ' HB2' HG22 ' A' ' 41' ' ' VAL . 1.9 m-85 -90.96 -31.1 16.48 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.598 -0.274 . . . . 0.0 111.242 -179.418 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -68.31 -50.54 52.83 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.901 0.382 . . . . 0.0 111.543 -179.643 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 24' ' ' TRP . . . . . . . . . . . . . 5.3 t-105 -64.77 -42.27 95.24 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-N 115.898 -0.592 . . . . 0.0 111.119 -179.685 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -77.42 -18.4 57.28 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.866 0.365 . . . . 0.0 110.643 179.764 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -74.15 -48.47 15.15 Favored Glycine 0 N--CA 1.452 -0.286 0 C-N-CA 121.028 -0.606 . . . . 0.0 112.33 179.548 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 98.9 mtt180 -55.51 -38.26 68.96 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-O 120.832 0.349 . . . . 0.0 110.506 179.878 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 20.1 t70 -92.53 91.37 7.56 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 115.996 -0.547 . . . . 0.0 110.567 179.82 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -159.35 -162.62 1.07 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.122 -0.49 . . . . 0.0 111.061 -179.792 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -96.11 -113.02 2.82 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.782 -0.723 . . . . 0.0 112.668 -179.887 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 65.4 m -138.0 -56.71 0.66 Allowed 'General case' 0 C--N 1.331 -0.228 0 CA-C-O 120.773 0.32 . . . . 0.0 111.131 -179.785 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -75.2 -21.54 77.8 Favored Glycine 0 C--N 1.331 0.261 0 C-N-CA 120.905 -0.664 . . . . 0.0 112.598 -179.981 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 19.9 mm-40 -79.41 -20.65 47.06 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.82 0.343 . . . . 0.0 110.688 179.906 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 34' ' ' ARG . . . . . . . . . . . . . 52.0 ttp180 -55.11 -28.9 56.01 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.005 -0.543 . . . . 0.0 111.319 -179.784 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 31.1 mmm180 -55.04 -45.12 75.2 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.788 0.328 . . . . 0.0 111.28 -179.938 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 61.2 m-85 -69.05 -33.38 73.49 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.414 -179.528 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 37' ' ' TYR . . . . . . . . . . . . . 75.4 m-85 -72.69 -53.06 12.77 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.331 -0.395 . . . . 0.0 111.413 -179.238 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 11.5 p -56.75 -36.16 48.26 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.225 0 CA-C-O 121.092 0.472 . . . . 0.0 110.474 179.751 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 18.7 m -68.2 -46.9 69.34 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 115.714 -0.676 . . . . 0.0 110.718 179.276 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 40' ' ' LEU . . . . . 0.606 HD12 HD11 ' A' ' 43' ' ' ILE . 26.8 tp -61.18 -45.33 95.07 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 115.813 -0.631 . . . . 0.0 110.917 179.96 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 41' ' ' VAL . . . . . 0.467 HG22 ' HB2' ' A' ' 22' ' ' PHE . 95.7 t -62.97 -34.35 65.87 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.484 0 CA-C-N 115.988 -0.551 . . . . 0.0 110.284 179.471 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 42' ' ' GLY . . . . . 0.482 ' O ' HG13 ' A' ' 46' ' ' ILE . . . -58.62 -51.88 56.3 Favored Glycine 0 N--CA 1.448 -0.508 0 C-N-CA 120.902 -0.666 . . . . 0.0 112.921 -179.964 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 43' ' ' ILE . . . . . 0.731 HG23 HD23 ' A' ' 82' ' ' LEU . 18.0 pt -60.9 -49.16 85.79 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.161 0 CA-C-N 117.02 0.41 . . . . 0.0 111.566 -179.558 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 44' ' ' SER . . . . . 0.423 ' N ' HG13 ' A' ' 43' ' ' ILE . 41.0 t -61.32 -27.1 68.25 Favored 'General case' 0 C--N 1.332 -0.191 0 CA-C-O 120.889 0.375 . . . . 0.0 111.193 179.648 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -78.01 -47.59 8.35 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.803 -0.713 . . . . 0.0 113.217 -179.112 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 46' ' ' ILE . . . . . 0.482 HG13 ' O ' ' A' ' 42' ' ' GLY . 61.6 mt -59.14 -42.09 85.62 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.229 0 CA-C-O 120.846 0.355 . . . . 0.0 110.968 -179.75 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 47' ' ' ALA . . . . . 0.631 ' HB2' ' HE2' ' A' ' 205' ' ' LYS . . . -67.49 -40.83 85.25 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 116.333 -0.394 . . . . 0.0 111.084 179.336 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 48' ' ' ALA . . . . . 0.4 ' HB2' ' HG3' ' A' ' 15' ' ' MET . . . -54.65 -44.27 73.1 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 116.129 -0.487 . . . . 0.0 111.382 -179.771 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 49' ' ' VAL . . . . . 0.418 HG22 ' O ' ' A' ' 46' ' ' ILE . 33.3 m -75.36 -34.65 30.98 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.384 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.351 -179.742 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -62.17 -38.86 90.67 Favored 'General case' 0 C--N 1.332 -0.156 0 CA-C-O 120.965 0.412 . . . . 0.0 111.071 179.849 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 51' ' ' TYR . . . . . 0.426 ' HB3' ' O ' ' A' ' 8' ' ' PHE . 26.5 m-85 -72.77 -42.65 63.74 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 115.993 -0.549 . . . . 0.0 110.693 -179.861 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -62.5 -39.84 94.81 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 115.987 -0.551 . . . . 0.0 111.45 -179.919 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 53' ' ' VAL . . . . . 0.473 HG23 ' N ' ' A' ' 54' ' ' MET . 35.1 m -72.28 -48.71 47.19 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.16 0 CA-C-N 116.498 -0.319 . . . . 0.0 111.299 -179.679 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 54' ' ' MET . . . . . 0.48 ' HG3' ' HB2' ' A' ' 71' ' ' PRO . 74.0 mtm -61.85 -31.26 71.51 Favored 'General case' 0 C--N 1.331 -0.196 0 CA-C-O 120.979 0.419 . . . . 0.0 110.417 179.693 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 55' ' ' ALA . . . . . 0.689 ' HB2' ' HB2' ' A' ' 8' ' ' PHE . . . -70.42 -12.51 61.63 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 115.767 -0.652 . . . . 0.0 111.645 179.962 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 71.2 mt -97.71 -13.15 21.61 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 116.483 -0.326 . . . . 0.0 111.466 -179.78 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 105.18 -6.62 42.98 Favored Glycine 0 CA--C 1.52 0.353 0 C-N-CA 120.496 -0.859 . . . . 0.0 113.545 179.5 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 58' ' ' VAL . . . . . 0.46 HG22 ' O ' ' A' ' 53' ' ' VAL . 27.0 m -81.54 149.8 4.76 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.201 0 CA-C-N 117.185 0.492 . . . . 0.0 110.587 179.483 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 81.74 25.61 52.72 Favored Glycine 0 N--CA 1.45 -0.418 0 C-N-CA 120.588 -0.815 . . . . 0.0 111.768 -179.219 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 60' ' ' TRP . . . . . . . . . . . . . 17.9 m0 -104.23 95.06 5.71 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 121.101 0.477 . . . . 0.0 110.018 -179.897 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 6.0 t -91.24 124.21 62.08 Favored Pre-proline 0 C--N 1.324 -0.539 0 CA-C-N 115.712 -0.676 . . . . 0.0 111.405 -178.984 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 56.2 Cg_endo -71.81 136.42 27.72 Favored 'Trans proline' 0 C--N 1.35 0.649 0 C-N-CA 122.353 2.036 . . . . 0.0 112.345 -179.987 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 86.4 t -143.02 105.23 1.06 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.02 -0.537 . . . . 0.0 111.209 -179.573 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . 58.88 -90.08 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.295 -0.411 . . . . 0.0 111.361 179.921 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 41.2 tt0 -122.85 -25.71 4.57 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 116.306 -0.406 . . . . 0.0 110.52 179.901 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 66' ' ' ARG . . . . . . . . . . . . . 20.0 ttm180 -101.73 162.62 12.77 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 115.942 -0.572 . . . . 0.0 110.333 179.905 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 87.3 m -117.56 120.73 38.96 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-O 120.858 0.361 . . . . 0.0 111.648 -179.448 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 38.8 t -86.07 146.37 6.55 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 115.927 -0.579 . . . . 0.0 110.558 179.406 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 69' ' ' PHE . . . . . . . . . . . . . 29.8 m-85 -106.77 112.97 26.19 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 121.044 0.45 . . . . 0.0 110.177 -179.679 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 70' ' ' VAL . . . . . 0.561 HG12 ' HD3' ' A' ' 71' ' ' PRO . 0.3 OUTLIER -68.65 -33.92 4.95 Favored Pre-proline 0 CA--C 1.541 0.603 0 N-CA-C 113.217 0.821 . . . . 0.0 113.217 -179.108 . . . . . . . . 3 3 . 1 . 023 nuclear build full ' A' A ' 71' ' ' PRO . . . . . 0.561 ' HD3' HG12 ' A' ' 70' ' ' VAL . 23.9 Cg_exo -63.71 -32.63 68.07 Favored 'Trans proline' 0 C--N 1.357 1.02 0 C-N-CA 121.766 1.644 . . . . 0.0 112.453 -179.276 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 40.0 ttm180 -69.82 -50.54 41.87 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 121.075 0.465 . . . . 0.0 110.352 179.464 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 73' ' ' TYR . . . . . 0.469 ' O ' HG13 ' A' ' 77' ' ' ILE . 33.9 m-85 -65.94 -33.09 75.02 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 115.767 -0.651 . . . . 0.0 111.341 -179.706 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 74' ' ' ILE . . . . . 0.432 ' O ' HD13 ' A' ' 74' ' ' ILE . 0.4 OUTLIER -75.74 -38.73 37.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-O 121.02 0.438 . . . . 0.0 109.908 179.329 . . . . . . . . 3 3 . 1 . 023 nuclear build full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 5.9 t70 -58.58 -32.77 69.26 Favored 'General case' 0 N--CA 1.455 -0.203 0 CA-C-N 115.975 -0.557 . . . . 0.0 109.965 179.294 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 76' ' ' TRP . . . . . 0.41 ' HB3' ' SD ' ' A' ' 109' ' ' MET . 51.0 m0 -73.24 -46.23 51.31 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 115.914 -0.585 . . . . 0.0 110.568 179.204 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 77' ' ' ILE . . . . . 0.538 HG12 ' HB3' ' A' ' 109' ' ' MET . 88.2 mt -53.52 -29.94 17.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 115.941 -0.572 . . . . 0.0 111.253 -179.84 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 47.3 mt -91.07 -52.02 5.04 Favored 'General case' 0 CA--C 1.533 0.325 0 N-CA-C 112.521 0.563 . . . . 0.0 112.521 -179.541 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 79.7 p -71.49 -50.37 32.22 Favored 'General case' 0 N--CA 1.465 0.315 0 N-CA-C 113.931 1.085 . . . . 0.0 113.931 -177.688 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 80' ' ' THR . . . . . 0.705 HG21 ' HE1' ' A' ' 109' ' ' MET . 15.2 m -46.47 -53.32 24.75 Favored Pre-proline 0 CA--C 1.534 0.331 0 N-CA-C 112.78 0.659 . . . . 0.0 112.78 -178.173 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 81' ' ' PRO . . . . . 0.475 ' HD2' ' N ' ' A' ' 80' ' ' THR . 29.1 Cg_endo -61.99 -23.95 76.31 Favored 'Trans proline' 0 C--N 1.351 0.689 0 C-N-CA 121.639 1.559 . . . . 0.0 111.523 179.949 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 82' ' ' LEU . . . . . 0.731 HD23 HG23 ' A' ' 43' ' ' ILE . 15.6 tp -76.59 -32.62 58.23 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 115.751 -0.658 . . . . 0.0 110.156 179.507 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 41.8 mm -64.71 -53.55 40.83 Favored 'Isoleucine or valine' 0 C--O 1.235 0.304 0 CA-C-N 116.181 -0.463 . . . . 0.0 109.872 178.94 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 84' ' ' VAL . . . . . 0.568 HG11 HD22 ' A' ' 105' ' ' ASN . 12.6 m -61.3 -30.33 47.71 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.228 0 N-CA-C 109.297 -0.631 . . . . 0.0 109.297 178.582 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 85' ' ' TYR . . . . . . . . . . . . . 87.4 t80 -66.82 -32.61 74.0 Favored 'General case' 0 N--CA 1.453 -0.282 0 CA-C-N 115.478 -0.783 . . . . 0.0 109.371 178.585 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 86' ' ' PHE . . . . . . . . . . . . . 3.5 t80 -61.34 -51.89 66.94 Favored 'General case' 0 C--O 1.232 0.17 0 CA-C-N 115.68 -0.691 . . . . 0.0 109.767 179.259 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 7.2 mp -62.37 -31.82 72.53 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 115.741 -0.663 . . . . 0.0 110.242 179.358 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -66.27 -28.06 73.44 Favored Glycine 0 N--CA 1.45 -0.412 0 C-N-CA 120.771 -0.728 . . . . 0.0 111.615 179.365 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 92.6 mt -75.4 -38.88 59.62 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.815 0.341 . . . . 0.0 110.53 179.426 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 94.2 mt -59.96 -43.34 95.1 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.042 -0.526 . . . . 0.0 111.097 179.859 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 91' ' ' ALA . . . . . 0.497 ' HB2' ' HB2' ' A' ' 149' ' ' ALA . . . -82.76 -52.22 6.96 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 116.253 -0.43 . . . . 0.0 111.369 -179.798 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 100.16 68.21 0.86 Allowed Glycine 0 N--CA 1.452 -0.284 0 C-N-CA 120.81 -0.71 . . . . 0.0 112.4 -179.941 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 93' ' ' LEU . . . . . 0.57 ' HB3' ' HB2' ' A' ' 97' ' ' GLU . 8.2 mp -77.29 177.69 7.72 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.905 0.383 . . . . 0.0 111.159 -179.862 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 94' ' ' ASP . . . . . . . . . . . . . 19.7 t70 -89.66 166.96 13.29 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 115.941 -0.572 . . . . 0.0 110.808 -179.986 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 52.8 m -55.68 -38.96 70.35 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.348 -0.387 . . . . 0.0 111.177 -179.806 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 37.6 mmt180 -73.46 -44.3 58.34 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.303 -0.408 . . . . 0.0 111.13 -179.981 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 97' ' ' GLU . . . . . 0.57 ' HB2' ' HB3' ' A' ' 93' ' ' LEU . 13.2 mm-40 -55.43 -47.99 75.11 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.859 -179.969 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 98' ' ' PHE . . . . . 0.436 ' O ' HG12 ' A' ' 102' ' ' ILE . 24.3 m-85 -57.1 -47.63 80.58 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.447 179.456 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -57.27 -29.83 60.55 Favored Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.438 179.828 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 97.3 mt -73.98 -44.28 51.06 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.171 0 CA-C-O 120.93 0.395 . . . . 0.0 111.555 -179.882 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 44.7 t -67.46 -46.41 83.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.062 -0.517 . . . . 0.0 111.929 -179.247 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 102' ' ' ILE . . . . . 0.436 HG12 ' O ' ' A' ' 98' ' ' PHE . 45.4 mm -62.22 -52.49 59.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.395 -0.366 . . . . 0.0 111.722 -179.272 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 14.7 t -57.29 -35.94 70.44 Favored 'General case' 0 C--N 1.332 -0.16 0 CA-C-O 120.849 0.357 . . . . 0.0 111.174 -179.74 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 104' ' ' LEU . . . . . 0.446 HD22 ' HE2' ' A' ' 140' ' ' TYR . 50.4 tp -61.02 -46.43 90.77 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.746 179.838 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 105' ' ' ASN . . . . . 0.568 HD22 HG11 ' A' ' 84' ' ' VAL . 2.9 m-20 -65.46 -26.09 67.79 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.877 179.946 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 61.4 m -65.44 -55.35 18.49 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.292 -0.413 . . . . 0.0 111.216 -179.975 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 7.3 p -61.87 -37.35 77.96 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.184 0 CA-C-N 116.532 -0.304 . . . . 0.0 110.995 -179.734 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 108' ' ' VAL . . . . . 0.432 HG23 ' O ' ' A' ' 104' ' ' LEU . 53.4 t -59.58 -50.14 81.07 Favored 'Isoleucine or valine' 0 C--O 1.235 0.303 0 CA-C-O 121.002 0.429 . . . . 0.0 110.589 179.364 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 109' ' ' MET . . . . . 0.705 ' HE1' HG21 ' A' ' 80' ' ' THR . 3.0 tpp -63.46 -30.67 71.76 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 115.946 -0.57 . . . . 0.0 110.337 179.579 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 20.1 tp -68.59 -32.69 72.77 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.104 -0.498 . . . . 0.0 109.956 179.318 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 111' ' ' ALA . . . . . 0.437 ' O ' ' HB3' ' A' ' 126' ' ' LEU . . . -63.49 -56.69 14.08 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-N 115.736 -0.666 . . . . 0.0 110.418 179.25 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 112' ' ' GLY . . . . . 0.53 ' HA3' ' H21' ' A' ' 301' ' ' RET . . . -56.59 -42.99 91.08 Favored Glycine 0 C--N 1.331 0.252 0 C-N-CA 120.646 -0.788 . . . . 0.0 112.055 179.493 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 113' ' ' PHE . . . . . . . . . . . . . 6.5 t80 -47.28 -66.84 0.34 Allowed 'General case' 0 C--N 1.331 -0.222 0 CA-C-O 121.025 0.44 . . . . 0.0 110.956 179.55 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -63.25 -30.36 71.52 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 115.865 -0.607 . . . . 0.0 111.702 -179.401 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -52.11 -43.0 55.92 Favored Glycine 0 C--N 1.33 0.239 0 C-N-CA 121.057 -0.592 . . . . 0.0 112.96 -179.614 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -78.22 -27.88 47.84 Favored 'General case' 0 C--N 1.328 -0.352 0 N-CA-C 112.172 0.434 . . . . 0.0 112.172 -179.643 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 117' ' ' MET . . . . . . . . . . . . . 66.1 mtt -95.66 19.45 11.16 Favored 'General case' 0 C--N 1.33 -0.282 0 N-CA-C 111.77 0.285 . . . . 0.0 111.77 -179.191 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 118' ' ' VAL . . . . . 0.578 HG21 ' HB3' ' A' ' 123' ' ' ARG . 18.2 m -64.79 149.53 95.97 Favored Pre-proline 0 C--N 1.329 -0.296 0 CA-C-N 116.577 -0.283 . . . . 0.0 111.128 179.602 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 119' ' ' PRO . . . . . . . . . . . . . 93.9 Cg_endo -84.89 -17.83 4.68 Favored 'Trans proline' 0 N--CA 1.459 -0.517 0 C-N-CA 122.504 2.136 . . . . 0.0 112.135 179.808 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -145.41 -123.27 1.58 Allowed Glycine 0 N--CA 1.45 -0.386 0 C-N-CA 120.714 -0.755 . . . . 0.0 112.79 -179.923 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 45.1 pt -96.44 10.86 5.27 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.222 0 CA-C-O 120.714 0.293 . . . . 0.0 111.541 -179.535 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 43.6 mt-10 -59.6 -17.75 35.62 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.331 -0.395 . . . . 0.0 111.166 179.9 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 123' ' ' ARG . . . . . 0.578 ' HB3' HG21 ' A' ' 118' ' ' VAL . 19.8 ptt180 -49.69 -34.96 20.08 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 116.307 -0.406 . . . . 0.0 111.46 -179.928 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 124' ' ' TYR . . . . . . . . . . . . . 49.3 m-85 -70.98 -32.41 69.23 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.438 -0.346 . . . . 0.0 111.041 179.997 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 125' ' ' ALA . . . . . . . . . . . . . . . -68.25 -52.02 38.64 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.012 179.595 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 126' ' ' LEU . . . . . 0.437 ' HB3' ' O ' ' A' ' 111' ' ' ALA . 2.6 mm? -53.61 -56.17 19.53 Favored 'General case' 0 CA--C 1.521 -0.141 0 CA-C-N 116.09 -0.504 . . . . 0.0 110.687 179.973 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 127' ' ' PHE . . . . . 0.449 ' HZ ' ' HB3' ' A' ' 175' ' ' PRO . 9.6 t80 -67.39 -29.6 69.15 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.741 -179.91 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 128' ' ' GLY . . . . . . . . . . . . . . . -47.14 -54.49 9.73 Favored Glycine 0 N--CA 1.451 -0.36 0 C-N-CA 119.991 -1.099 . . . . 0.0 110.768 178.968 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 129' ' ' MET . . . . . 0.435 ' HE3' ' HB3' ' A' ' 133' ' ' ALA . 0.0 OUTLIER -72.21 -27.56 62.62 Favored 'General case' 0 C--N 1.328 -0.359 0 N-CA-C 109.144 -0.687 . . . . 0.0 109.144 178.624 . . . . . . . . 3 3 . 1 . 023 nuclear build full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -61.72 -37.46 94.29 Favored Glycine 0 C--N 1.334 0.435 0 CA-C-N 115.792 -0.64 . . . . 0.0 112.288 179.541 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -74.75 -52.3 11.88 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.754 0.311 . . . . 0.0 110.457 179.696 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 42.1 t -54.88 -47.33 75.58 Favored 'Isoleucine or valine' 0 C--O 1.234 0.257 0 CA-C-O 121.243 0.544 . . . . 0.0 109.602 178.981 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 133' ' ' ALA . . . . . 0.435 ' HB3' ' HE3' ' A' ' 129' ' ' MET . . . -65.45 -37.08 85.82 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 115.523 -0.762 . . . . 0.0 110.915 179.245 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 134' ' ' PHE . . . . . 0.411 ' CZ ' ' HA ' ' A' ' 172' ' ' ALA . 45.9 t80 -53.27 -54.02 42.34 Favored 'General case' 0 N--CA 1.452 -0.361 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.26 179.816 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 135' ' ' ILE . . . . . 0.51 ' O ' HG22 ' A' ' 138' ' ' VAL . 42.5 mt -59.66 -32.85 50.24 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 CA-C-N 115.85 -0.614 . . . . 0.0 110.23 179.473 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 136' ' ' GLY . . . . . 0.445 ' O ' ' HB3' ' A' ' 139' ' ' TYR . . . -58.93 -40.06 94.85 Favored Glycine 0 N--CA 1.449 -0.463 0 C-N-CA 120.153 -1.023 . . . . 0.0 111.236 178.706 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 137' ' ' LEU . . . . . 0.483 ' O ' HD13 ' A' ' 141' ' ' LEU . 64.0 tp -69.61 -53.37 19.11 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 115.863 -0.169 . . . . 0.0 110.806 179.541 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 138' ' ' VAL . . . . . 0.51 HG22 ' O ' ' A' ' 135' ' ' ILE . 3.3 m -54.69 -31.38 23.82 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.144 0 N-CA-C 109.333 -0.617 . . . . 0.0 109.333 -179.915 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 139' ' ' TYR . . . . . 0.445 ' HB3' ' O ' ' A' ' 136' ' ' GLY . 44.1 t80 -60.19 -46.35 90.03 Favored 'General case' 0 N--CA 1.453 -0.29 0 CA-C-N 115.544 -0.753 . . . . 0.0 109.404 178.183 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 140' ' ' TYR . . . . . 0.446 ' HE2' HD22 ' A' ' 104' ' ' LEU . 22.2 m-85 -63.86 -42.33 97.58 Favored 'General case' 0 C--N 1.333 -0.132 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.526 178.813 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 141' ' ' LEU . . . . . 0.483 HD13 ' O ' ' A' ' 137' ' ' LEU . 11.0 mp -57.13 -27.62 61.99 Favored 'General case' 0 C--N 1.332 -0.173 0 CA-C-N 115.948 -0.569 . . . . 0.0 111.193 -179.743 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 142' ' ' VAL . . . . . 0.47 HG23 ' O ' ' A' ' 138' ' ' VAL . 12.0 t -106.15 -7.91 10.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-O 120.992 0.425 . . . . 0.0 110.926 179.866 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . -73.84 -133.71 0.25 Allowed Glycine 0 CA--C 1.522 0.48 0 C-N-CA 120.812 -0.709 . . . . 0.0 112.814 -179.849 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 144' ' ' PRO . . . . . . . . . . . . . 51.5 Cg_exo -55.57 -23.96 42.47 Favored 'Trans proline' 0 C--N 1.349 0.555 0 C-N-CA 122.672 2.248 . . . . 0.0 113.03 -179.693 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 145' ' ' MET . . . . . 0.422 ' SD ' ' HA ' ' A' ' 141' ' ' LEU . 54.9 mtt -53.77 -27.92 31.71 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-O 120.727 0.299 . . . . 0.0 111.497 -179.583 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 146' ' ' THR . . . . . . . . . . . . . 70.5 p -79.04 -32.99 45.11 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.357 -0.383 . . . . 0.0 110.991 -179.558 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 39.7 tt0 -73.93 -40.26 63.23 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 115.861 -0.609 . . . . 0.0 111.354 -179.636 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 148' ' ' SER . . . . . . . . . . . . . 46.9 t -70.0 -42.26 73.28 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.325 -0.398 . . . . 0.0 111.327 -179.524 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 149' ' ' ALA . . . . . 0.497 ' HB2' ' HB2' ' A' ' 91' ' ' ALA . . . -70.83 -40.27 72.51 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.443 -0.344 . . . . 0.0 111.827 -179.649 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 150' ' ' SER . . . . . 0.604 ' HA ' ' HG2' ' A' ' 157' ' ' LYS . 39.2 t -69.46 -0.02 5.88 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.516 -0.311 . . . . 0.0 111.431 -179.564 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 151' ' ' GLN . . . . . . . . . . . . . 46.1 mt-30 -132.52 6.47 4.09 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.583 -0.28 . . . . 0.0 111.238 179.955 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 25.7 tpt180 -78.73 -52.41 8.43 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-O 120.94 0.4 . . . . 0.0 110.671 179.994 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 153' ' ' SER . . . . . 0.682 ' HB2' HG12 ' A' ' 156' ' ' ILE . 19.8 m -157.51 172.52 18.42 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 115.829 -0.623 . . . . 0.0 110.359 179.183 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 154' ' ' SER . . . . . 0.476 ' HA ' ' NZ ' ' A' ' 157' ' ' LYS . 49.9 m -68.68 -41.08 79.75 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.775 0.321 . . . . 0.0 110.983 179.728 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -76.78 -35.5 39.92 Favored Glycine 0 CA--C 1.519 0.343 0 C-N-CA 120.982 -0.627 . . . . 0.0 113.427 -179.537 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 156' ' ' ILE . . . . . 0.682 HG12 ' HB2' ' A' ' 153' ' ' SER . 41.8 mm -50.15 -38.48 15.06 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.217 0 N-CA-C 111.764 0.283 . . . . 0.0 111.764 -179.421 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 157' ' ' LYS . . . . . 0.604 ' HG2' ' HA ' ' A' ' 150' ' ' SER . 33.3 mtmm -59.78 -40.28 87.72 Favored 'General case' 0 C--N 1.327 -0.371 0 N-CA-C 112.034 0.383 . . . . 0.0 112.034 -179.254 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 36.5 t -72.53 -47.26 49.73 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 121.047 0.451 . . . . 0.0 111.425 -179.046 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 159' ' ' LEU . . . . . 0.432 ' O ' ' HB2' ' A' ' 163' ' ' LEU . 10.2 mt -68.67 -29.17 67.58 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-N 115.986 -0.552 . . . . 0.0 111.534 -179.108 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 160' ' ' TYR . . . . . . . . . . . . . 77.9 t80 -72.63 -46.84 52.08 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.454 -0.339 . . . . 0.0 111.629 -179.336 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 161' ' ' VAL . . . . . 0.409 HG23 ' N ' ' A' ' 162' ' ' ARG . 27.3 m -62.42 -42.79 96.98 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 N-CA-C 111.84 0.311 . . . . 0.0 111.84 -179.154 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 162' ' ' ARG . . . . . 0.409 ' N ' HG23 ' A' ' 161' ' ' VAL . 77.3 mtp180 -68.84 -48.53 63.28 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 120.647 0.26 . . . . 0.0 111.53 -179.678 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 163' ' ' LEU . . . . . 0.432 ' HB2' ' O ' ' A' ' 159' ' ' LEU . 6.8 mp -67.5 -45.08 76.88 Favored 'General case' 0 CA--C 1.531 0.24 0 CA-C-N 116.388 -0.369 . . . . 0.0 111.968 -179.01 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 164' ' ' ARG . . . . . . . . . . . . . 4.3 tmm_? -57.78 -50.97 71.46 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-O 120.635 0.255 . . . . 0.0 110.867 -179.719 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 165' ' ' ASN . . . . . 0.526 ' O ' HG23 ' A' ' 169' ' ' VAL . 4.6 m-20 -55.37 -41.37 72.52 Favored 'General case' 0 N--CA 1.448 -0.567 0 CA-C-N 116.352 -0.385 . . . . 0.0 110.486 179.78 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 166' ' ' LEU . . . . . 0.479 ' O ' ' HG ' ' A' ' 170' ' ' LEU . 3.6 mt -58.16 -53.61 56.31 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 115.944 -0.571 . . . . 0.0 110.894 179.496 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 167' ' ' THR . . . . . 0.661 ' HA ' HD11 ' A' ' 170' ' ' LEU . 13.7 m -54.39 -52.58 61.23 Favored 'General case' 0 C--N 1.331 -0.204 0 N-CA-C 112.451 0.537 . . . . 0.0 112.451 -178.431 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 168' ' ' VAL . . . . . . . . . . . . . 85.9 t -54.96 -40.57 54.12 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.483 0 N-CA-C 112.612 0.597 . . . . 0.0 112.612 -178.724 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 169' ' ' VAL . . . . . 0.526 HG23 ' O ' ' A' ' 165' ' ' ASN . 68.7 t -69.18 -67.19 0.46 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 N-CA-C 113.526 0.936 . . . . 0.0 113.526 -177.894 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 170' ' ' LEU . . . . . 0.661 HD11 ' HA ' ' A' ' 167' ' ' THR . 0.4 OUTLIER -59.18 -34.58 72.29 Favored 'General case' 0 N--CA 1.465 0.323 0 N-CA-C 112.869 0.692 . . . . 0.0 112.869 -177.7 . . . . . . . . 3 3 . 1 . 023 nuclear build full ' A' A ' 171' ' ' TRP . . . . . 0.749 ' HE1' H203 ' A' ' 301' ' ' RET . 16.8 m0 -73.29 -31.52 64.1 Favored 'General case' 0 C--N 1.329 -0.29 0 C-N-CA 120.607 -0.437 . . . . 0.0 111.24 -179.507 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 172' ' ' ALA . . . . . 0.411 ' HA ' ' CZ ' ' A' ' 134' ' ' PHE . . . -71.17 -7.15 44.76 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-O 120.912 0.387 . . . . 0.0 110.337 179.52 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 173' ' ' ILE . . . . . 0.537 ' O ' HG12 ' A' ' 177' ' ' ILE . 38.6 mm -88.44 -28.12 5.41 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.173 0 CA-C-N 115.896 -0.593 . . . . 0.0 111.044 179.512 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 174' ' ' TYR . . . . . 0.505 ' HD2' ' HA ' ' A' ' 171' ' ' TRP . 19.2 m-85 -54.11 -48.71 93.33 Favored Pre-proline 0 N--CA 1.467 0.392 0 CA-C-N 116.523 -0.308 . . . . 0.0 111.699 -179.512 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 175' ' ' PRO . . . . . 0.449 ' HB3' ' HZ ' ' A' ' 127' ' ' PHE . 82.5 Cg_exo -45.36 -33.29 8.73 Favored 'Trans proline' 0 C--N 1.351 0.658 0 C-N-CA 121.964 1.776 . . . . 0.0 111.857 179.467 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 176' ' ' PHE . . . . . 0.512 ' O ' ' HG ' ' A' ' 180' ' ' LEU . 96.6 m-85 -80.97 -50.6 9.5 Favored 'General case' 0 CA--C 1.518 -0.287 0 CA-C-N 115.843 -0.617 . . . . 0.0 111.792 179.937 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 177' ' ' ILE . . . . . 0.537 HG12 ' O ' ' A' ' 173' ' ' ILE . 6.6 mm -58.17 -32.49 44.5 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.517 0 CA-C-N 115.927 -0.579 . . . . 0.0 112.56 -177.494 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 178' ' ' TRP . . . . . . . . . . . . . 84.3 t90 -73.45 -32.2 64.22 Favored 'General case' 0 CA--C 1.52 -0.205 0 CA-C-O 120.884 0.373 . . . . 0.0 110.577 179.629 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 179' ' ' LEU . . . . . 0.651 ' HG ' HG22 ' A' ' 185' ' ' VAL . 17.3 tp -81.88 -55.29 4.7 Favored 'General case' 0 C--N 1.322 -0.601 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.851 -179.478 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 180' ' ' LEU . . . . . 0.625 HD22 HD11 ' A' ' 187' ' ' LEU . 7.0 mt -62.04 -51.33 68.42 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.109 -0.496 . . . . 0.0 111.287 -179.479 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 181' ' ' GLY . . . . . 0.452 ' HA3' ' OD1' ' A' ' 193' ' ' ASP . . . -65.7 -84.76 0.08 OUTLIER Glycine 0 C--N 1.332 0.316 0 C-N-CA 120.338 -0.934 . . . . 0.0 111.925 179.414 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 182' ' ' PRO . . . . . 0.541 ' HB3' ' HD2' ' A' ' 183' ' ' PRO . 81.7 Cg_exo -48.25 176.98 0.02 OUTLIER 'Trans proline' 0 C--N 1.35 0.631 0 C-N-CA 122.999 2.466 . . . . 0.0 112.244 178.743 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 183' ' ' PRO . . . . . 0.541 ' HD2' ' HB3' ' A' ' 182' ' ' PRO . 19.2 Cg_endo -59.95 16.03 0.04 OUTLIER 'Trans proline' 0 C--N 1.351 0.674 0 C-N-CA 122.58 2.187 . . . . 0.0 115.142 -178.908 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 184' ' ' GLY . . . . . 0.508 ' HA3' HD12 ' A' ' 179' ' ' LEU . . . -59.51 -45.51 95.46 Favored Glycine 0 C--N 1.336 0.562 0 C-N-CA 119.48 -1.343 . . . . 0.0 110.693 178.756 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 185' ' ' VAL . . . . . 0.651 HG22 ' HG ' ' A' ' 179' ' ' LEU . 2.5 m -148.94 -35.63 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.327 -0.4 0 CA-C-N 114.867 -0.666 . . . . 0.0 110.528 178.635 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 186' ' ' ALA . . . . . . . . . . . . . . . 66.82 77.77 0.27 Allowed 'General case' 0 N--CA 1.462 0.138 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.863 178.607 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 187' ' ' LEU . . . . . 0.625 HD11 HD22 ' A' ' 180' ' ' LEU . 4.2 mt -92.67 -46.66 7.47 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.608 179.502 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 188' ' ' LEU . . . . . . . . . . . . . 97.8 mt -111.28 -166.36 1.07 Allowed 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 115.948 -0.569 . . . . 0.0 111.267 -179.808 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 189' ' ' THR . . . . . 0.449 ' HB ' HG23 ' A' ' 192' ' ' VAL . 26.8 m -81.81 136.3 48.02 Favored Pre-proline 0 C--N 1.328 -0.355 0 CA-C-N 115.822 -0.626 . . . . 0.0 110.932 -179.966 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 190' ' ' PRO . . . . . . . . . . . . . 5.6 Cg_endo -48.56 -38.99 36.95 Favored 'Trans proline' 0 C--N 1.35 0.644 0 C-N-CA 122.713 2.276 . . . . 0.0 112.08 179.611 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 191' ' ' THR . . . . . . . . . . . . . 59.5 p -58.27 -44.71 88.53 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.24 -0.437 . . . . 0.0 110.584 179.613 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 192' ' ' VAL . . . . . 0.449 HG23 ' HB ' ' A' ' 189' ' ' THR . 75.1 t -60.23 -40.38 83.5 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.229 0 CA-C-N 115.867 -0.606 . . . . 0.0 110.649 179.433 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 193' ' ' ASP . . . . . 0.487 ' OD1' HG22 ' A' ' 177' ' ' ILE . 3.4 t70 -56.15 -45.23 79.72 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 115.777 -0.647 . . . . 0.0 110.989 179.834 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 194' ' ' VAL . . . . . . . . . . . . . 48.4 t -63.07 -36.99 78.17 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.053 -0.521 . . . . 0.0 110.944 -179.839 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 195' ' ' ALA . . . . . . . . . . . . . . . -57.24 -47.64 80.86 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 116.393 -0.367 . . . . 0.0 110.838 179.674 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 196' ' ' LEU . . . . . . . . . . . . . 89.3 mt -68.37 -44.95 74.06 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-N 116.308 -0.406 . . . . 0.0 110.903 179.661 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 197' ' ' ILE . . . . . . . . . . . . . 20.2 mm -55.63 -58.37 4.93 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.58 179.633 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 198' ' ' VAL . . . . . . . . . . . . . 77.2 t -52.15 -35.1 18.64 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.568 0 CA-C-N 115.469 -0.787 . . . . 0.0 109.514 178.629 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 199' ' ' TYR . . . . . . . . . . . . . 42.2 t80 -70.38 -33.42 71.39 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 115.521 -0.763 . . . . 0.0 110.62 179.691 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 200' ' ' LEU . . . . . 0.449 HD11 HG13 ' A' ' 177' ' ' ILE . 51.7 mt -67.13 -42.54 84.25 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-N 115.97 -0.559 . . . . 0.0 111.135 -179.683 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 201' ' ' ASP . . . . . . . . . . . . . 8.3 m-20 -72.85 -31.65 64.91 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-O 121.083 0.468 . . . . 0.0 110.235 179.656 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 202' ' ' LEU . . . . . 0.442 ' O ' ' HB ' ' A' ' 206' ' ' VAL . 3.3 mt -70.88 -31.57 68.28 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 115.65 -0.705 . . . . 0.0 112.082 -179.476 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 203' ' ' VAL . . . . . 0.496 HG13 HD22 ' A' ' 170' ' ' LEU . 7.1 p -80.82 -37.01 15.95 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-O 120.637 0.256 . . . . 0.0 111.25 -178.815 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 204' ' ' THR . . . . . 0.426 ' O ' ' HB2' ' A' ' 208' ' ' PHE . 22.2 m -70.1 -48.8 56.14 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-O 120.836 0.351 . . . . 0.0 111.406 179.945 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 205' ' ' LYS . . . . . 0.631 ' HE2' ' HB2' ' A' ' 47' ' ' ALA . 62.7 mttp -72.94 -57.65 3.9 Favored 'General case' 0 C--N 1.326 -0.429 0 N-CA-C 112.129 0.418 . . . . 0.0 112.129 -179.004 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 206' ' ' VAL . . . . . 0.442 ' HB ' ' O ' ' A' ' 202' ' ' LEU . 51.7 t -70.98 -41.89 76.99 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-O 120.631 0.253 . . . . 0.0 111.626 -179.363 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 207' ' ' GLY . . . . . 0.49 ' O ' HD12 ' A' ' 211' ' ' ILE . . . -61.2 -59.6 9.74 Favored Glycine 0 C--N 1.33 0.216 0 C-N-CA 120.631 -0.795 . . . . 0.0 112.698 -179.766 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 208' ' ' PHE . . . . . 0.48 ' O ' ' N ' ' A' ' 212' ' ' ALA . 8.1 m-85 -54.29 -47.08 72.77 Favored 'General case' 0 C--O 1.222 -0.391 0 CA-C-O 121.058 0.456 . . . . 0.0 110.202 -179.986 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 209' ' ' GLY . . . . . 0.519 ' HA2' ' HB3' ' A' ' 212' ' ' ALA . . . -56.21 -32.87 60.57 Favored Glycine 0 N--CA 1.449 -0.454 0 CA-C-N 115.004 -0.998 . . . . 0.0 113.299 179.747 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 210' ' ' PHE . . . . . . . . . . . . . 2.2 m-85 -72.03 -46.02 58.65 Favored 'General case' 0 CA--C 1.513 -0.469 0 N-CA-C 108.811 -0.811 . . . . 0.0 108.811 179.556 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 211' ' ' ILE . . . . . 0.49 HD12 ' O ' ' A' ' 207' ' ' GLY . 3.3 mt -67.59 -27.3 37.87 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.658 0 N-CA-C 107.625 -1.25 . . . . 0.0 107.625 176.481 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 212' ' ' ALA . . . . . 0.519 ' HB3' ' HA2' ' A' ' 209' ' ' GLY . . . -68.18 -43.54 77.94 Favored 'General case' 0 N--CA 1.452 -0.371 0 CA-C-N 114.415 -1.266 . . . . 0.0 110.785 -179.712 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 213' ' ' LEU . . . . . 0.4 ' HG ' ' O ' ' A' ' 209' ' ' GLY . 81.0 mt -70.1 -54.18 14.16 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 115.329 -0.85 . . . . 0.0 111.221 -179.514 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 214' ' ' ASP . . . . . . . . . . . . . 12.8 t70 -55.51 -35.36 65.53 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.801 -179.865 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 215' ' ' ALA . . . . . . . . . . . . . . . -65.65 -57.92 6.95 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.024 -0.535 . . . . 0.0 111.338 -179.916 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 216' ' ' ALA . . . . . . . . . . . . . . . -61.43 -31.09 71.02 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.112 -0.495 . . . . 0.0 111.103 -179.892 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 217' ' ' ALA . . . . . . . . . . . . . . . -62.51 -40.0 95.32 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.31 179.776 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 218' ' ' THR . . . . . . . . . . . . . 93.7 m -69.36 -38.87 78.27 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 115.94 -0.573 . . . . 0.0 110.693 179.408 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 219' ' ' LEU . . . . . . . . . . . . . 70.6 mt -59.6 -40.53 87.77 Favored 'General case' 0 C--N 1.332 -0.185 0 CA-C-N 116.097 -0.501 . . . . 0.0 110.63 179.683 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 220' ' ' ARG . . . . . . . . . . . . . 76.2 mtp180 -82.58 -18.61 40.69 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 115.963 -0.562 . . . . 0.0 110.395 179.598 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 221' ' ' ALA . . . . . . . . . . . . . . . -75.42 -26.09 58.08 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 115.865 -0.607 . . . . 0.0 111.21 179.918 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 222' ' ' GLU . . . . . . . . . . . . . 10.1 pt-20 -92.34 -23.34 19.28 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.39 -0.368 . . . . 0.0 110.381 -179.9 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 223' ' ' HIS . . . . . . . . . . . . . 79.7 m-70 59.71 100.32 0.02 OUTLIER 'General case' 0 C--N 1.331 -0.206 0 CA-C-N 115.726 -0.67 . . . . 0.0 111.118 179.885 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 224' ' ' GLY . . . . . . . . . . . . . . . -94.3 53.31 2.13 Favored Glycine 0 N--CA 1.452 -0.269 0 C-N-CA 120.767 -0.73 . . . . 0.0 112.615 -179.805 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 225' ' ' GLU . . . . . . . . . . . . . 12.1 pt-20 -124.34 148.12 47.71 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.911 0.386 . . . . 0.0 110.941 179.827 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 226' ' ' SER . . . . . . . . . . . . . 80.2 p -83.94 -175.44 5.81 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-N 116.08 -0.509 . . . . 0.0 110.803 179.895 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 227' ' ' LEU . . . . . . . . . . . . . 73.7 mt -81.39 122.26 27.26 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.944 -179.928 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 228' ' ' ALA . . . . . . . . . . . . . . . -93.72 143.84 25.95 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.161 -179.958 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 229' ' ' GLY . . . . . . . . . . . . . . . -161.32 99.78 0.18 Allowed Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.847 -0.692 . . . . 0.0 112.44 179.917 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 230' ' ' VAL . . . . . . . . . . . . . 22.1 t -99.67 137.09 28.22 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.224 0 CA-C-O 120.856 0.36 . . . . 0.0 111.105 -179.808 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 231' ' ' ASP . . . . . . . . . . . . . 5.4 m-20 -87.7 97.66 11.01 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.972 179.913 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 232' ' ' THR . . . . . . . . . . . . . 64.7 p -128.14 124.01 35.85 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.94 179.939 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 233' ' ' ASP . . . . . . . . . . . . . 17.5 t70 -87.11 -34.4 19.13 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.059 -179.857 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 234' ' ' THR . . . . . . . . . . . . . 72.6 p -99.51 117.13 64.31 Favored Pre-proline 0 C--N 1.328 -0.356 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.994 -179.999 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 235' ' ' PRO . . . . . . . . . . . . . 28.3 Cg_endo -61.88 159.22 34.45 Favored 'Trans proline' 0 C--N 1.347 0.474 0 C-N-CA 122.38 2.053 . . . . 0.0 111.991 179.879 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 236' ' ' ALA . . . . . . . . . . . . . . . -149.38 113.77 5.25 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.342 -0.39 . . . . 0.0 111.18 -179.933 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 237' ' ' VAL . . . . . . . . . . . . . 31.6 m -107.76 159.87 7.12 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.134 -0.485 . . . . 0.0 111.112 179.888 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 238' ' ' ALA . . . . . . . . . . . . . . . -76.07 -68.94 0.53 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.184 -179.989 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 239' ' ' ASP . . . . . . . . . . . . . 12.3 m-20 -97.12 148.82 22.65 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.122 -0.49 . . . . 0.0 111.043 -179.954 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 240' ' ' LEU . . . . . . . . . . . . . 71.5 mt -89.31 106.31 18.36 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.803 179.868 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 241' ' ' GLU . . . . . . . . . . . . . 18.3 mm-40 -111.96 -26.89 8.67 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.99 -179.878 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 242' ' ' HIS . . . . . . . . . . . . . 53.8 m-70 58.04 18.18 4.97 Favored 'General case' 0 C--N 1.331 -0.203 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.927 -179.948 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 243' ' ' HIS . . . . . . . . . . . . . 52.2 t-80 -113.55 -51.62 2.79 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.554 -179.993 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 244' ' ' HIS . . . . . . . . . . . . . 71.2 m80 60.13 176.7 0.09 Allowed 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 115.914 -0.584 . . . . 0.0 111.527 179.588 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 245' ' ' HIS . . . . . . . . . . . . . 85.9 m-70 -79.01 121.77 25.34 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 115.911 -0.586 . . . . 0.0 110.946 -179.934 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 246' ' ' HIS . . . . . . . . . . . . . 36.3 p-80 -99.0 176.38 5.59 Favored 'General case' 0 C--N 1.332 -0.175 0 CA-C-N 116.37 -0.377 . . . . 0.0 110.852 179.833 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 247' ' ' HIS . . . . . . . . . . . . . 23.2 t60 . . . . . 0 C--O 1.249 1.036 0 CA-C-O 118.208 -0.901 . . . . 0.0 110.922 179.881 . . . . . . . . 0 0 . 1 . 023 nuclear build full ' A' A ' 301' ' ' RET . . . . . 0.749 H203 ' HE1' ' A' ' 171' ' ' TRP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 95.9 mmm . . . . . 0 N--CA 1.486 1.357 0 CA-C-O 120.888 0.375 . . . . 0.0 110.94 . . . . . . . . . 0 0 . 1 . 024 nuclear build full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 42.2 t -126.36 -34.25 0.88 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.121 -179.903 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -86.75 -12.2 69.43 Favored Glycine 0 N--CA 1.452 -0.275 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.5 -179.813 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 67.0 tp -74.22 -36.6 63.96 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.795 0.331 . . . . 0.0 111.006 179.964 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 82.6 p -58.22 -32.96 68.81 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.531 -179.78 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 30.4 p -54.47 -34.9 62.4 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.343 -0.39 . . . . 0.0 111.109 -179.979 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 7' ' ' LEU . . . . . . . . . . . . . 4.3 mm? -58.22 -53.9 53.04 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 115.994 -0.548 . . . . 0.0 111.514 -179.732 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 8' ' ' PHE . . . . . 0.518 ' HB2' ' HB2' ' A' ' 55' ' ' ALA . 68.3 m-85 -64.22 -36.07 82.86 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.293 -0.412 . . . . 0.0 111.232 -179.484 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 9' ' ' TRP . . . . . . . . . . . . . 44.8 m95 -65.02 -48.98 71.99 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-O 121.098 0.475 . . . . 0.0 110.16 -179.675 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 79.9 mt -60.33 -38.7 84.57 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-N 115.587 -0.733 . . . . 0.0 110.532 179.685 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -65.03 -31.13 79.87 Favored Glycine 0 N--CA 1.448 -0.504 0 C-N-CA 120.647 -0.787 . . . . 0.0 111.642 179.199 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -71.13 -30.71 66.83 Favored 'General case' 0 N--CA 1.454 -0.231 0 CA-C-O 120.81 0.338 . . . . 0.0 110.56 179.393 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 71.8 mt -66.57 -54.61 24.07 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.235 0 CA-C-N 115.959 -0.564 . . . . 0.0 110.335 179.345 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -62.95 -35.56 92.22 Favored Glycine 0 N--CA 1.449 -0.455 0 C-N-CA 120.645 -0.788 . . . . 0.0 111.441 179.374 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 15' ' ' MET . . . . . 0.503 ' SD ' ' HA ' ' A' ' 44' ' ' SER . 53.1 tpp -62.9 -46.37 88.16 Favored 'General case' 0 C--N 1.329 -0.296 0 N-CA-C 110.088 -0.338 . . . . 0.0 110.088 179.358 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 16' ' ' LEU . . . . . 0.463 HD13 ' O ' ' A' ' 16' ' ' LEU . 0.8 OUTLIER -53.22 -39.99 64.16 Favored 'General case' 0 C--N 1.332 -0.187 0 CA-C-N 115.866 -0.606 . . . . 0.0 109.689 179.057 . . . . . . . . 3 3 . 1 . 024 nuclear build full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 70.3 t -58.98 -45.55 92.09 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.206 0 CA-C-N 116.036 -0.529 . . . . 0.0 110.177 179.156 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -63.93 -42.73 98.22 Favored Glycine 0 N--CA 1.45 -0.392 0 C-N-CA 120.749 -0.739 . . . . 0.0 111.737 179.038 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 11.3 m -52.74 -46.51 67.48 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-O 120.847 0.356 . . . . 0.0 111.146 -179.806 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 92.3 mt -71.8 -39.02 70.15 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.337 -179.826 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -59.8 -33.65 72.02 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.574 -0.285 . . . . 0.0 111.698 -179.615 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 22' ' ' PHE . . . . . 0.52 ' HB2' HG22 ' A' ' 41' ' ' VAL . 4.5 m-85 -90.99 -34.83 14.99 Favored 'General case' 0 C--N 1.331 -0.196 0 CA-C-O 120.727 0.299 . . . . 0.0 111.52 -179.446 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -66.53 -50.98 61.39 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 120.93 0.395 . . . . 0.0 111.539 -179.464 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 24' ' ' TRP . . . . . . . . . . . . . 5.1 t-105 -65.42 -45.11 85.16 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 115.877 -0.601 . . . . 0.0 111.176 -179.715 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -71.12 -24.02 62.2 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.854 0.359 . . . . 0.0 111.009 179.874 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -72.47 -41.23 52.39 Favored Glycine 0 N--CA 1.45 -0.371 0 C-N-CA 120.93 -0.652 . . . . 0.0 112.733 -179.866 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 99.3 mtt180 -69.16 -10.03 55.74 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.752 0.31 . . . . 0.0 110.908 -179.894 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 13.1 t70 -127.21 88.74 2.85 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.714 179.876 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -161.12 -80.91 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.199 179.921 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -162.05 -127.98 0.92 Allowed Glycine 0 N--CA 1.452 -0.248 0 C-N-CA 120.806 -0.711 . . . . 0.0 112.476 -179.96 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 89.3 p -136.78 -37.7 0.66 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.749 0.309 . . . . 0.0 110.862 -179.923 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -81.2 -36.24 21.62 Favored Glycine 0 N--CA 1.452 -0.276 0 C-N-CA 120.706 -0.759 . . . . 0.0 112.494 179.921 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 12.4 mm-40 -72.49 -21.11 61.25 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.652 0.263 . . . . 0.0 110.945 -179.922 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 34' ' ' ARG . . . . . 0.411 ' O ' HG23 ' A' ' 38' ' ' VAL . 79.0 ttt180 -51.57 -29.36 16.88 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 116.111 -0.495 . . . . 0.0 111.468 -179.607 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 80.2 ttt180 -60.19 -48.8 80.21 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.856 0.36 . . . . 0.0 110.882 179.896 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 59.4 m-85 -67.46 -29.87 69.43 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.028 -0.533 . . . . 0.0 111.139 179.896 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 37' ' ' TYR . . . . . 0.426 ' O ' HG23 ' A' ' 41' ' ' VAL . 43.8 m-85 -72.13 -53.0 14.05 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.071 -0.513 . . . . 0.0 111.62 -179.365 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 38' ' ' VAL . . . . . 0.411 HG23 ' O ' ' A' ' 34' ' ' ARG . 96.7 t -56.92 -37.39 54.05 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-O 121.103 0.477 . . . . 0.0 110.129 179.594 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 38.1 m -65.72 -46.27 79.57 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 115.662 -0.699 . . . . 0.0 110.182 179.158 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 40' ' ' LEU . . . . . 0.475 HD12 HD12 ' A' ' 43' ' ' ILE . 28.2 tp -59.67 -50.17 74.91 Favored 'General case' 0 C--O 1.235 0.318 0 CA-C-N 115.771 -0.649 . . . . 0.0 110.459 179.588 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 41' ' ' VAL . . . . . 0.52 HG22 ' HB2' ' A' ' 22' ' ' PHE . 61.3 t -59.1 -34.63 53.88 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.254 0 CA-C-N 115.842 -0.617 . . . . 0.0 109.938 179.186 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -59.07 -39.19 94.03 Favored Glycine 0 N--CA 1.449 -0.475 0 C-N-CA 120.727 -0.749 . . . . 0.0 111.832 179.252 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 43' ' ' ILE . . . . . 0.475 HD12 HD12 ' A' ' 40' ' ' LEU . 0.9 OUTLIER -64.96 -57.08 12.63 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.153 0 CA-C-O 120.831 0.348 . . . . 0.0 110.786 179.402 . . . . . . . . 3 3 . 1 . 024 nuclear build full ' A' A ' 44' ' ' SER . . . . . 0.503 ' HA ' ' SD ' ' A' ' 15' ' ' MET . 40.8 t -59.72 -24.21 63.81 Favored 'General case' 0 C--N 1.332 -0.168 0 CA-C-N 116.103 -0.499 . . . . 0.0 111.56 -179.691 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -74.15 -59.55 3.89 Favored Glycine 0 CA--C 1.518 0.262 0 C-N-CA 120.72 -0.752 . . . . 0.0 113.039 -179.647 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 46' ' ' ILE . . . . . 0.409 HD11 HG22 ' A' ' 79' ' ' THR . 21.1 pt -58.72 -35.02 53.54 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.19 0 CA-C-O 120.745 0.307 . . . . 0.0 111.286 -179.876 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 47' ' ' ALA . . . . . 0.619 ' HB2' ' HE2' ' A' ' 205' ' ' LYS . . . -65.98 -45.74 80.53 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-N 116.32 -0.4 . . . . 0.0 111.058 179.833 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -54.84 -52.18 63.58 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.246 -0.434 . . . . 0.0 111.216 -179.713 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 49' ' ' VAL . . . . . 0.41 ' O ' HG13 ' A' ' 53' ' ' VAL . 34.6 m -64.35 -34.04 66.66 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.393 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.821 179.931 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -65.23 -37.93 88.81 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.367 -0.379 . . . . 0.0 110.845 179.576 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 51' ' ' TYR . . . . . 0.416 ' OH ' ' HB2' ' A' ' 201' ' ' ASP . 30.3 m-85 -70.79 -29.06 65.15 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.193 179.944 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -74.5 -41.67 60.29 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-N 115.613 -0.721 . . . . 0.0 111.184 179.59 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 53' ' ' VAL . . . . . 0.425 HG23 ' N ' ' A' ' 54' ' ' MET . 20.8 m -73.25 -43.52 56.99 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.125 0 CA-C-N 116.498 -0.319 . . . . 0.0 111.008 179.883 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 54' ' ' MET . . . . . 0.448 ' HG2' ' HB2' ' A' ' 71' ' ' PRO . 72.8 mtm -63.49 -32.46 73.92 Favored 'General case' 0 C--N 1.332 -0.183 0 CA-C-O 121.038 0.447 . . . . 0.0 110.023 179.443 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 55' ' ' ALA . . . . . 0.518 ' HB2' ' HB2' ' A' ' 8' ' ' PHE . . . -65.23 -37.06 86.07 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 115.667 -0.697 . . . . 0.0 110.712 179.349 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 93.8 mt -76.5 -13.03 60.12 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 115.869 -0.605 . . . . 0.0 110.851 179.756 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 71.53 31.21 65.7 Favored Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.782 -0.723 . . . . 0.0 112.818 179.991 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 32.3 m -79.92 19.98 0.15 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.211 0 CA-C-O 120.834 0.35 . . . . 0.0 111.557 179.869 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -159.1 14.93 0.23 Allowed Glycine 0 N--CA 1.451 -0.358 0 C-N-CA 120.795 -0.717 . . . . 0.0 112.844 179.866 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 60' ' ' TRP . . . . . . . . . . . . . 41.0 m0 -81.09 107.57 14.01 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.728 0.299 . . . . 0.0 110.633 179.862 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 61' ' ' VAL . . . . . 0.42 ' HA ' ' HD3' ' A' ' 62' ' ' PRO . 4.9 p -106.38 119.33 52.19 Favored Pre-proline 0 CA--C 1.533 0.306 0 CA-C-N 116.342 -0.39 . . . . 0.0 111.572 -179.624 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 62' ' ' PRO . . . . . 0.42 ' HD3' ' HA ' ' A' ' 61' ' ' VAL . 16.8 Cg_exo -67.6 133.76 30.84 Favored 'Trans proline' 0 C--N 1.351 0.659 0 C-N-CA 122.35 2.033 . . . . 0.0 111.79 179.423 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 78.2 t -132.48 100.54 4.06 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.373 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.214 -179.716 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . 59.53 -86.85 0.02 OUTLIER 'General case' 0 C--N 1.331 -0.212 0 CA-C-N 116.043 -0.526 . . . . 0.0 111.265 -179.999 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 45.1 mt-10 -122.36 -27.26 4.49 Favored 'General case' 0 C--N 1.332 -0.195 0 CA-C-N 116.362 -0.381 . . . . 0.0 110.724 179.992 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 66' ' ' ARG . . . . . 0.444 ' HD2' ' N ' ' A' ' 66' ' ' ARG . 8.1 mpt_? -104.64 140.62 37.76 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.611 179.826 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 22.3 m -98.17 113.19 25.03 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.345 -0.389 . . . . 0.0 111.113 -179.74 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 26.3 t -85.11 146.84 6.06 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.354 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.474 179.498 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 69' ' ' PHE . . . . . . . . . . . . . 19.8 m-85 -108.51 115.17 29.59 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-O 120.91 0.386 . . . . 0.0 110.111 -179.315 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 70' ' ' VAL . . . . . 0.521 ' HB ' ' HD3' ' A' ' 71' ' ' PRO . 13.4 t -68.9 -49.35 26.81 Favored Pre-proline 0 C--N 1.323 -0.557 0 CA-C-N 115.946 -0.57 . . . . 0.0 112.243 -179.006 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 71' ' ' PRO . . . . . 0.521 ' HD3' ' HB ' ' A' ' 70' ' ' VAL . 29.5 Cg_exo -61.97 -17.48 56.1 Favored 'Trans proline' 0 C--N 1.35 0.608 0 C-N-CA 122.176 1.917 . . . . 0.0 112.449 -179.525 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 51.6 ttp180 -71.34 -54.68 9.97 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.482 -0.327 . . . . 0.0 111.43 -179.727 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 73' ' ' TYR . . . . . 0.431 ' O ' HG13 ' A' ' 77' ' ' ILE . 96.2 m-85 -69.74 -31.69 69.82 Favored 'General case' 0 C--N 1.331 -0.235 0 C-N-CA 120.919 -0.313 . . . . 0.0 110.648 -179.84 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 74' ' ' ILE . . . . . 0.477 ' HA ' HD12 ' A' ' 77' ' ' ILE . 0.3 OUTLIER -69.74 -38.56 76.44 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.18 0 N-CA-C 109.672 -0.492 . . . . 0.0 109.672 178.993 . . . . . . . . 3 3 . 1 . 024 nuclear build full ' A' A ' 75' ' ' ASP . . . . . 0.473 ' O ' HG23 ' A' ' 79' ' ' THR . 11.4 t70 -59.08 -37.59 77.45 Favored 'General case' 0 N--CA 1.454 -0.24 0 N-CA-C 109.211 -0.663 . . . . 0.0 109.211 178.595 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 76' ' ' TRP . . . . . . . . . . . . . 53.6 m0 -67.97 -32.45 72.88 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 115.689 -0.687 . . . . 0.0 110.323 179.006 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 77' ' ' ILE . . . . . 0.477 HD12 ' HA ' ' A' ' 74' ' ' ILE . 97.6 mt -66.57 -29.37 46.29 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.362 179.232 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 48.9 mt -91.59 -19.98 22.15 Favored 'General case' 0 CA--C 1.532 0.277 0 CA-C-N 116.1 -0.5 . . . . 0.0 112.016 179.983 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 79' ' ' THR . . . . . 0.473 HG23 ' O ' ' A' ' 75' ' ' ASP . 81.4 p -101.16 -52.63 3.22 Favored 'General case' 0 N--CA 1.465 0.323 0 N-CA-C 113.538 0.94 . . . . 0.0 113.538 -177.889 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 80' ' ' THR . . . . . 0.467 HG21 ' HE1' ' A' ' 109' ' ' MET . 61.3 m -46.69 -53.87 22.72 Favored Pre-proline 0 CA--C 1.533 0.296 0 N-CA-C 112.886 0.699 . . . . 0.0 112.886 -178.557 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 81' ' ' PRO . . . . . 0.465 ' HD2' ' N ' ' A' ' 80' ' ' THR . 35.0 Cg_endo -62.2 -22.16 73.71 Favored 'Trans proline' 0 C--N 1.35 0.622 0 C-N-CA 121.543 1.495 . . . . 0.0 111.603 -179.598 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 82' ' ' LEU . . . . . . . . . . . . . 16.2 tp -76.91 -33.31 57.77 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 115.657 -0.701 . . . . 0.0 110.234 179.674 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 28.1 mm -69.2 -53.18 26.86 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.226 0 CA-C-N 116.087 -0.506 . . . . 0.0 110.122 179.162 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 84' ' ' VAL . . . . . 0.416 HG13 ' HH2' ' A' ' 171' ' ' TRP . 28.9 m -60.13 -31.97 49.32 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.218 0 N-CA-C 109.645 -0.502 . . . . 0.0 109.645 178.907 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 85' ' ' TYR . . . . . 0.405 ' O ' ' HG ' ' A' ' 89' ' ' LEU . 79.8 t80 -65.12 -34.11 77.63 Favored 'General case' 0 N--CA 1.452 -0.366 0 CA-C-N 115.641 -0.709 . . . . 0.0 109.532 178.963 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 86' ' ' PHE . . . . . . . . . . . . . 7.9 t80 -62.62 -51.08 68.68 Favored 'General case' 0 C--N 1.333 -0.14 0 CA-C-N 115.768 -0.651 . . . . 0.0 110.247 179.404 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 9.3 mp -61.53 -36.05 79.46 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 115.992 -0.549 . . . . 0.0 110.407 179.785 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -66.33 -27.96 73.39 Favored Glycine 0 N--CA 1.45 -0.404 0 C-N-CA 120.767 -0.73 . . . . 0.0 111.875 179.282 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 89' ' ' LEU . . . . . 0.405 ' HG ' ' O ' ' A' ' 85' ' ' TYR . 75.9 mt -72.73 -40.88 65.74 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 120.994 0.426 . . . . 0.0 110.624 179.716 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 47.3 mt -58.44 -47.53 83.68 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 115.648 -0.706 . . . . 0.0 111.336 -179.644 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 91' ' ' ALA . . . . . 0.423 ' HB2' ' HB2' ' A' ' 149' ' ' ALA . . . -75.46 -54.52 6.9 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.635 -179.545 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 107.11 69.51 0.7 Allowed Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.854 -0.689 . . . . 0.0 112.009 -179.591 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 93' ' ' LEU . . . . . 0.544 HD23 ' HB3' ' A' ' 97' ' ' GLU . 8.5 mp -87.41 171.66 10.39 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.794 0.331 . . . . 0.0 111.131 -179.6 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 94' ' ' ASP . . . . . . . . . . . . . 8.9 m-20 -90.93 166.25 13.14 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.928 179.826 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 49.6 m -55.56 -33.02 63.49 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-N 116.312 -0.404 . . . . 0.0 111.029 -179.987 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 9.4 ptp180 -71.53 -48.05 51.25 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.842 179.88 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 97' ' ' GLU . . . . . 0.544 ' HB3' HD23 ' A' ' 93' ' ' LEU . 44.6 mt-10 -58.2 -45.14 88.16 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.923 -179.969 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 98' ' ' PHE . . . . . 0.443 ' O ' HG12 ' A' ' 102' ' ' ILE . 31.2 m-85 -59.1 -48.85 80.09 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.374 -0.375 . . . . 0.0 110.615 179.568 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -55.9 -31.07 58.07 Favored Glycine 0 N--CA 1.45 -0.381 0 C-N-CA 120.888 -0.672 . . . . 0.0 112.587 -179.775 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 98.0 mt -71.5 -44.29 71.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-O 120.798 0.332 . . . . 0.0 111.531 -179.94 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 39.7 t -68.12 -51.07 52.51 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.729 -179.344 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 102' ' ' ILE . . . . . 0.443 HG12 ' O ' ' A' ' 98' ' ' PHE . 34.0 mm -59.38 -50.0 81.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.325 -0.398 . . . . 0.0 111.771 -179.253 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 7.9 t -59.37 -36.11 75.14 Favored 'General case' 0 C--N 1.331 -0.204 0 CA-C-O 120.761 0.315 . . . . 0.0 110.911 -179.739 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 104' ' ' LEU . . . . . 0.457 ' O ' HG23 ' A' ' 108' ' ' VAL . 27.4 tp -63.03 -44.44 95.9 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.218 -0.447 . . . . 0.0 110.403 179.542 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 105' ' ' ASN . . . . . 0.578 ' N ' HD22 ' A' ' 105' ' ' ASN . 0.8 OUTLIER -63.66 -26.47 68.68 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 115.955 -0.566 . . . . 0.0 110.555 179.726 . . . . . . . . 3 3 . 1 . 024 nuclear build full ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 84.7 m -67.15 -54.59 19.81 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 115.998 -0.546 . . . . 0.0 111.167 179.954 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 7.5 p -63.6 -36.59 76.98 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.213 0 CA-C-N 116.42 -0.354 . . . . 0.0 111.05 -179.895 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 108' ' ' VAL . . . . . 0.457 HG23 ' O ' ' A' ' 104' ' ' LEU . 72.3 t -65.74 -45.5 91.62 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.226 0 CA-C-N 116.386 -0.37 . . . . 0.0 110.894 179.496 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 109' ' ' MET . . . . . 0.467 ' HE1' HG21 ' A' ' 80' ' ' THR . 8.7 tpp -65.15 -39.24 92.7 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.829 -179.82 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 29.0 tp -66.98 -30.75 70.95 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.215 179.701 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -62.5 -52.37 63.77 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 116.068 -0.515 . . . . 0.0 110.313 179.136 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 112' ' ' GLY . . . . . 0.712 ' HA3' ' H21' ' A' ' 301' ' ' RET . . . -67.62 -32.56 78.74 Favored Glycine 0 N--CA 1.45 -0.395 0 C-N-CA 120.566 -0.826 . . . . 0.0 111.649 179.127 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 113' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER -52.79 -75.89 0.03 OUTLIER 'General case' 0 C--N 1.332 -0.179 0 CA-C-O 121.008 0.432 . . . . 0.0 109.883 179.357 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 114' ' ' ALA . . . . . 0.431 ' HB3' HD22 ' A' ' 126' ' ' LEU . . . -61.05 -21.43 63.62 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-N 115.619 -0.719 . . . . 0.0 110.646 179.206 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -52.57 -50.98 46.32 Favored Glycine 0 C--N 1.333 0.385 0 C-N-CA 120.905 -0.664 . . . . 0.0 112.125 179.739 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 116' ' ' ALA . . . . . 0.574 ' HB2' ' HB3' ' A' ' 183' ' ' PRO . . . -78.19 -15.7 58.58 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 121.008 0.432 . . . . 0.0 110.723 179.217 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 117' ' ' MET . . . . . 0.419 ' HB3' ' HA ' ' A' ' 114' ' ' ALA . 45.1 tpp -87.49 -5.95 58.58 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 115.883 -0.599 . . . . 0.0 111.502 -179.588 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 118' ' ' VAL . . . . . 0.406 HG11 ' N ' ' A' ' 123' ' ' ARG . 21.7 m -58.81 146.67 74.78 Favored Pre-proline 0 C--N 1.331 -0.219 0 CA-C-N 116.683 -0.235 . . . . 0.0 111.449 -179.608 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 119' ' ' PRO . . . . . . . . . . . . . 69.2 Cg_endo -90.76 -5.45 4.43 Favored 'Trans proline' 0 N--CA 1.455 -0.748 0 C-N-CA 122.912 2.408 . . . . 0.0 112.228 179.431 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -145.41 -127.99 1.98 Allowed Glycine 0 C--N 1.333 0.362 0 C-N-CA 120.867 -0.683 . . . . 0.0 112.84 -179.733 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 46.6 pt -99.16 11.56 6.21 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.212 0 CA-C-O 120.596 0.236 . . . . 0.0 111.595 -179.491 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 122' ' ' GLU . . . . . 0.47 ' O ' HD12 ' A' ' 126' ' ' LEU . 15.1 mm-40 -60.53 -21.03 62.05 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.754 0.311 . . . . 0.0 110.997 -179.914 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 123' ' ' ARG . . . . . 0.439 HH11 ' HD2' ' A' ' 123' ' ' ARG . 10.0 ptt180 -52.22 -34.47 45.91 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.027 -0.533 . . . . 0.0 111.471 -179.935 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 124' ' ' TYR . . . . . . . . . . . . . 39.6 m-85 -69.16 -32.08 71.16 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.531 -179.574 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 125' ' ' ALA . . . . . . . . . . . . . . . -72.88 -56.51 5.09 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-O 120.831 0.348 . . . . 0.0 111.098 -179.699 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 126' ' ' LEU . . . . . 0.47 HD12 ' O ' ' A' ' 122' ' ' GLU . 1.3 mp -57.26 -49.61 75.51 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.662 179.92 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 127' ' ' PHE . . . . . . . . . . . . . 7.5 t80 -66.45 -37.42 85.12 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.335 -0.393 . . . . 0.0 110.857 -179.991 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 128' ' ' GLY . . . . . . . . . . . . . . . -47.18 -46.29 21.1 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.057 -1.068 . . . . 0.0 110.904 179.045 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 129' ' ' MET . . . . . . . . . . . . . 0.3 OUTLIER -70.13 -35.77 74.31 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 115.388 -0.406 . . . . 0.0 110.041 178.848 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -68.09 -28.2 73.45 Favored Glycine 0 C--N 1.334 0.434 0 CA-C-N 115.88 -0.6 . . . . 0.0 112.94 -179.659 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -74.42 -53.65 9.15 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 120.722 0.296 . . . . 0.0 110.313 179.915 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 22.2 t -58.2 -42.69 84.04 Favored 'Isoleucine or valine' 0 C--O 1.235 0.338 0 N-CA-C 109.022 -0.733 . . . . 0.0 109.022 178.476 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -64.31 -35.27 80.32 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.264 -0.88 . . . . 0.0 110.351 179.086 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 134' ' ' PHE . . . . . . . . . . . . . 75.3 t80 -56.74 -50.67 71.54 Favored 'General case' 0 N--CA 1.453 -0.323 0 CA-C-N 116.284 -0.416 . . . . 0.0 109.901 179.447 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 135' ' ' ILE . . . . . 0.479 ' O ' HG22 ' A' ' 138' ' ' VAL . 63.0 mt -57.44 -33.17 43.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 115.779 -0.646 . . . . 0.0 109.967 179.114 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 136' ' ' GLY . . . . . 0.446 ' O ' ' HB3' ' A' ' 139' ' ' TYR . . . -62.13 -40.62 99.19 Favored Glycine 0 N--CA 1.449 -0.478 0 C-N-CA 120.134 -1.032 . . . . 0.0 111.44 178.689 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 137' ' ' LEU . . . . . . . . . . . . . 26.8 tp -68.91 -49.91 54.01 Favored 'General case' 0 N--CA 1.455 -0.219 0 CA-C-O 120.43 0.157 . . . . 0.0 110.701 179.673 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 138' ' ' VAL . . . . . 0.554 ' HA ' HD12 ' A' ' 141' ' ' LEU . 4.7 m -58.2 -31.39 41.97 Favored 'Isoleucine or valine' 0 C--O 1.233 0.22 0 CA-C-O 121.338 0.589 . . . . 0.0 109.618 179.219 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 139' ' ' TYR . . . . . 0.446 ' HB3' ' O ' ' A' ' 136' ' ' GLY . 55.7 t80 -60.48 -43.21 97.21 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 115.34 -0.845 . . . . 0.0 109.302 178.373 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 36.7 m-85 -64.03 -32.72 74.38 Favored 'General case' 0 C--N 1.332 -0.16 0 CA-C-N 115.839 -0.619 . . . . 0.0 110.451 178.887 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 141' ' ' LEU . . . . . 0.554 HD12 ' HA ' ' A' ' 138' ' ' VAL . 95.3 mt -57.67 -47.43 82.32 Favored 'General case' 0 N--CA 1.462 0.168 0 CA-C-N 116.349 -0.387 . . . . 0.0 110.588 179.671 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 9.5 p -95.85 1.28 10.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.818 179.868 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 143' ' ' GLY . . . . . 0.4 ' HA3' ' HD2' ' A' ' 144' ' ' PRO . . . -75.95 -140.55 0.94 Allowed Glycine 0 CA--C 1.52 0.361 0 C-N-CA 120.99 -0.624 . . . . 0.0 112.878 -179.572 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 144' ' ' PRO . . . . . 0.4 ' HD2' ' HA3' ' A' ' 143' ' ' GLY . 19.5 Cg_endo -58.88 -23.92 69.9 Favored 'Trans proline' 0 C--N 1.347 0.488 0 C-N-CA 122.745 2.297 . . . . 0.0 112.685 -179.776 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 145' ' ' MET . . . . . . . . . . . . . 56.8 mtt -58.19 -33.13 68.94 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 120.806 0.336 . . . . 0.0 111.242 179.966 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 146' ' ' THR . . . . . . . . . . . . . 12.1 m -80.86 -32.35 35.05 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.385 -179.05 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 40.2 tt0 -71.8 -42.32 67.21 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-N 116.165 -0.47 . . . . 0.0 111.169 -179.743 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 148' ' ' SER . . . . . . . . . . . . . 58.2 m -70.61 -46.86 62.58 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-N 116.263 -0.426 . . . . 0.0 111.407 -179.432 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 149' ' ' ALA . . . . . 0.423 ' HB2' ' HB2' ' A' ' 91' ' ' ALA . . . -63.03 -41.33 99.49 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.309 -0.405 . . . . 0.0 111.742 -179.496 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 150' ' ' SER . . . . . . . . . . . . . 66.2 m -68.91 -0.58 5.73 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.38 -0.373 . . . . 0.0 111.501 -179.617 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 151' ' ' GLN . . . . . . . . . . . . . 44.8 mt-30 -129.09 3.69 5.26 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.628 -0.26 . . . . 0.0 111.246 179.991 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 31.0 tpt180 -76.42 -51.31 12.09 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.895 0.379 . . . . 0.0 110.651 -179.985 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 153' ' ' SER . . . . . 0.658 ' HB3' HG12 ' A' ' 156' ' ' ILE . 22.8 t -157.21 172.4 18.7 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-N 115.885 -0.598 . . . . 0.0 110.473 179.496 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 154' ' ' SER . . . . . . . . . . . . . 70.2 p -67.65 -41.22 84.18 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.382 -0.372 . . . . 0.0 110.912 179.937 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -77.07 -37.03 33.71 Favored Glycine 0 CA--C 1.519 0.305 0 C-N-CA 120.961 -0.638 . . . . 0.0 113.158 -179.657 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 156' ' ' ILE . . . . . 0.658 HG12 ' HB3' ' A' ' 153' ' ' SER . 42.4 mm -52.66 -37.22 24.19 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.186 0 CA-C-O 120.628 0.252 . . . . 0.0 111.56 -179.47 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 157' ' ' LYS . . . . . 0.44 ' O ' HG13 ' A' ' 161' ' ' VAL . 38.3 ttpt -60.29 -53.84 52.89 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.457 -0.338 . . . . 0.0 111.555 -179.629 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 48.9 m -63.5 -44.22 94.96 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 121.008 0.432 . . . . 0.0 111.468 -179.43 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 159' ' ' LEU . . . . . 0.422 HD23 ' O ' ' A' ' 159' ' ' LEU . 6.0 tt -63.71 -37.94 89.23 Favored 'General case' 0 C--N 1.326 -0.438 0 CA-C-N 115.993 -0.549 . . . . 0.0 110.983 -179.485 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 160' ' ' TYR . . . . . . . . . . . . . 54.1 t80 -74.4 -46.84 37.68 Favored 'General case' 0 C--N 1.329 -0.317 0 N-CA-C 112.548 0.573 . . . . 0.0 112.548 -178.796 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 161' ' ' VAL . . . . . 0.44 HG13 ' O ' ' A' ' 157' ' ' LYS . 28.2 m -56.13 -44.65 79.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 N-CA-C 111.908 0.336 . . . . 0.0 111.908 -178.685 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 162' ' ' ARG . . . . . 0.467 ' O ' HD12 ' A' ' 166' ' ' LEU . 97.8 mtt180 -68.65 -49.44 59.11 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.746 0.308 . . . . 0.0 111.475 -179.452 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 163' ' ' LEU . . . . . . . . . . . . . 6.1 mp -63.46 -51.58 65.04 Favored 'General case' 0 C--N 1.33 -0.239 0 CA-C-N 116.232 -0.44 . . . . 0.0 112.034 -179.097 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 164' ' ' ARG . . . . . 0.433 HH11 HG21 ' A' ' 168' ' ' VAL . 5.2 tmm_? -53.42 -50.32 65.46 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.411 -0.358 . . . . 0.0 111.208 -179.406 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 165' ' ' ASN . . . . . 0.413 ' O ' HG23 ' A' ' 169' ' ' VAL . 5.1 m-20 -53.55 -42.28 67.32 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.894 0.378 . . . . 0.0 110.609 179.898 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 166' ' ' LEU . . . . . 0.504 ' O ' ' HG ' ' A' ' 170' ' ' LEU . 1.4 mt -58.31 -51.24 70.61 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 115.998 -0.546 . . . . 0.0 111.205 179.54 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 167' ' ' THR . . . . . 0.645 ' HA ' HD11 ' A' ' 170' ' ' LEU . 6.0 m -53.93 -53.88 46.62 Favored 'General case' 0 C--N 1.332 -0.178 0 N-CA-C 112.299 0.481 . . . . 0.0 112.299 -178.198 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 168' ' ' VAL . . . . . 0.433 HG21 HH11 ' A' ' 164' ' ' ARG . 25.2 t -53.66 -42.51 51.29 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.525 0 N-CA-C 112.327 0.492 . . . . 0.0 112.327 -179.432 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 169' ' ' VAL . . . . . 0.413 HG23 ' O ' ' A' ' 165' ' ' ASN . 92.4 t -68.75 -66.73 0.49 Allowed 'Isoleucine or valine' 0 CA--C 1.532 0.281 0 N-CA-C 113.789 1.033 . . . . 0.0 113.789 -177.774 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 170' ' ' LEU . . . . . 0.645 HD11 ' HA ' ' A' ' 167' ' ' THR . 0.4 OUTLIER -59.62 -33.1 71.06 Favored 'General case' 0 N--CA 1.465 0.295 0 N-CA-C 113.01 0.744 . . . . 0.0 113.01 -177.565 . . . . . . . . 3 3 . 1 . 024 nuclear build full ' A' A ' 171' ' ' TRP . . . . . 0.773 ' HE1' H203 ' A' ' 301' ' ' RET . 19.6 m0 -73.43 -30.9 63.53 Favored 'General case' 0 C--N 1.329 -0.315 0 C-N-CA 120.411 -0.516 . . . . 0.0 111.171 -179.509 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 172' ' ' ALA . . . . . . . . . . . . . . . -70.99 -7.28 45.09 Favored 'General case' 0 C--N 1.33 -0.275 0 C-N-CA 120.847 -0.341 . . . . 0.0 110.817 179.453 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 173' ' ' ILE . . . . . 0.478 ' O ' HG12 ' A' ' 177' ' ' ILE . 22.9 mm -88.46 -27.07 5.5 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.21 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.951 179.627 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 174' ' ' TYR . . . . . 0.459 ' HD1' ' HA ' ' A' ' 171' ' ' TRP . 29.6 m-85 -54.02 -47.7 96.28 Favored Pre-proline 0 CA--C 1.529 0.143 0 CA-C-N 116.309 -0.405 . . . . 0.0 111.943 -179.286 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 175' ' ' PRO . . . . . 0.402 ' CD ' ' N ' ' A' ' 174' ' ' TYR . 81.8 Cg_exo -47.08 -34.86 17.98 Favored 'Trans proline' 0 C--N 1.35 0.625 0 C-N-CA 121.77 1.647 . . . . 0.0 111.852 179.093 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 176' ' ' PHE . . . . . 0.515 ' O ' ' HG ' ' A' ' 180' ' ' LEU . 67.6 m-85 -80.9 -51.02 9.04 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 115.749 -0.659 . . . . 0.0 111.554 179.729 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 177' ' ' ILE . . . . . 0.478 HG12 ' O ' ' A' ' 173' ' ' ILE . 31.5 mm -58.13 -30.48 39.42 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.558 0 CA-C-N 115.742 -0.663 . . . . 0.0 111.471 -178.674 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 178' ' ' TRP . . . . . 0.423 ' O ' ' HB2' ' A' ' 183' ' ' PRO . 90.7 t90 -73.77 -59.14 2.86 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-O 121.005 0.431 . . . . 0.0 110.865 179.791 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 179' ' ' LEU . . . . . 0.634 ' HG ' HG22 ' A' ' 185' ' ' VAL . 15.4 tp -61.31 -54.72 40.3 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 115.996 -0.547 . . . . 0.0 111.711 -178.989 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 180' ' ' LEU . . . . . 0.677 HD22 HD11 ' A' ' 187' ' ' LEU . 11.6 mt -63.65 -28.68 70.07 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 116.449 -0.341 . . . . 0.0 111.744 -179.112 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 181' ' ' GLY . . . . . 0.432 ' C ' ' HD2' ' A' ' 183' ' ' PRO . . . -73.96 -173.59 28.61 Favored Glycine 0 N--CA 1.451 -0.359 0 C-N-CA 120.05 -1.071 . . . . 0.0 111.823 179.422 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 182' ' ' PRO . . . . . 0.457 ' HG2' ' HD3' ' A' ' 183' ' ' PRO . 1.3 Cg_endo -47.01 -43.19 25.06 Favored 'Trans proline' 0 CA--C 1.541 0.831 0 C-N-CA 122.856 2.371 . . . . 0.0 113.789 179.561 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 183' ' ' PRO . . . . . 0.574 ' HB3' ' HB2' ' A' ' 116' ' ' ALA . 44.2 Cg_exo -37.86 -59.22 0.55 Allowed 'Trans proline' 0 C--N 1.357 0.989 0 C-N-CA 122.819 2.346 . . . . 0.0 114.12 -179.89 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 184' ' ' GLY . . . . . . . . . . . . . . . -115.65 -107.2 2.59 Favored Glycine 0 N--CA 1.45 -0.369 0 C-N-CA 120.162 -1.018 . . . . 0.0 113.174 -179.052 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 185' ' ' VAL . . . . . 0.667 HG23 ' HA ' ' A' ' 180' ' ' LEU . 26.8 m -76.81 86.11 0.81 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.405 0 CA-C-O 121.461 0.648 . . . . 0.0 111.021 -179.492 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 186' ' ' ALA . . . . . . . . . . . . . . . -63.38 85.27 0.03 OUTLIER 'General case' 0 C--N 1.323 -0.555 0 CA-C-N 115.683 -0.69 . . . . 0.0 111.08 179.67 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 187' ' ' LEU . . . . . 0.677 HD11 HD22 ' A' ' 180' ' ' LEU . 6.2 mt -78.99 -49.21 13.09 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 116.317 -0.402 . . . . 0.0 110.9 179.843 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 188' ' ' LEU . . . . . 0.484 ' HB3' ' H ' ' A' ' 189' ' ' THR . 3.9 mm? -94.98 -157.48 0.57 Allowed 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.034 -0.53 . . . . 0.0 111.437 -179.405 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 189' ' ' THR . . . . . 0.508 ' HB ' HG23 ' A' ' 192' ' ' VAL . 32.3 m -96.12 136.32 22.16 Favored Pre-proline 0 C--N 1.331 -0.218 0 CA-C-N 115.944 -0.571 . . . . 0.0 110.96 -179.654 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 190' ' ' PRO . . . . . 0.458 ' O ' HG23 ' A' ' 194' ' ' VAL . 80.6 Cg_exo -46.64 -42.98 23.61 Favored 'Trans proline' 0 C--N 1.35 0.639 0 C-N-CA 122.61 2.207 . . . . 0.0 113.022 -179.977 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 191' ' ' THR . . . . . . . . . . . . . 75.2 p -62.19 -45.78 91.83 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-O 120.792 0.33 . . . . 0.0 111.162 -179.822 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 192' ' ' VAL . . . . . 0.508 HG23 ' HB ' ' A' ' 189' ' ' THR . 58.9 t -60.04 -44.44 94.85 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.267 -0.424 . . . . 0.0 111.031 179.922 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 193' ' ' ASP . . . . . . . . . . . . . 28.2 t70 -56.81 -43.49 81.05 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.079 -0.509 . . . . 0.0 111.074 -179.935 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 194' ' ' VAL . . . . . 0.458 HG23 ' O ' ' A' ' 190' ' ' PRO . 93.1 t -63.06 -36.03 74.17 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.354 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.867 179.765 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 195' ' ' ALA . . . . . . . . . . . . . . . -58.62 -47.15 85.34 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.081 179.809 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 196' ' ' LEU . . . . . . . . . . . . . 57.5 mt -65.74 -37.52 86.6 Favored 'General case' 0 C--N 1.332 -0.177 0 CA-C-O 120.749 0.309 . . . . 0.0 110.591 179.714 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 197' ' ' ILE . . . . . . . . . . . . . 19.7 mm -61.55 -56.99 14.16 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.114 179.28 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 198' ' ' VAL . . . . . . . . . . . . . 73.0 t -52.39 -35.26 19.79 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.43 0 CA-C-N 115.743 -0.662 . . . . 0.0 109.519 178.472 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 199' ' ' TYR . . . . . . . . . . . . . 74.5 t80 -70.09 -38.55 75.7 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 115.228 -0.897 . . . . 0.0 110.583 179.849 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 200' ' ' LEU . . . . . . . . . . . . . 38.7 mt -63.65 -44.1 94.84 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 115.752 -0.658 . . . . 0.0 111.355 -179.607 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 201' ' ' ASP . . . . . 0.416 ' HB2' ' OH ' ' A' ' 51' ' ' TYR . 0.7 OUTLIER -72.03 -37.35 69.76 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.071 -0.513 . . . . 0.0 111.212 -179.753 . . . . . . . . 3 3 . 1 . 024 nuclear build full ' A' A ' 202' ' ' LEU . . . . . 0.445 ' O ' ' HB ' ' A' ' 206' ' ' VAL . 3.2 mt -68.52 -30.8 69.69 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.686 -179.452 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 203' ' ' VAL . . . . . 0.491 ' O ' ' HA3' ' A' ' 207' ' ' GLY . 42.6 t -78.98 -36.57 18.77 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.437 0 CA-C-O 120.683 0.278 . . . . 0.0 111.125 -179.449 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 204' ' ' THR . . . . . . . . . . . . . 25.8 m -70.83 -50.83 31.17 Favored 'General case' 0 C--N 1.324 -0.519 0 C-N-CA 120.747 -0.381 . . . . 0.0 111.325 179.938 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 205' ' ' LYS . . . . . 0.619 ' HE2' ' HB2' ' A' ' 47' ' ' ALA . 50.5 mttp -71.99 -58.48 3.41 Favored 'General case' 0 C--N 1.328 -0.341 0 N-CA-C 112.313 0.486 . . . . 0.0 112.313 -178.629 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 206' ' ' VAL . . . . . 0.445 ' HB ' ' O ' ' A' ' 202' ' ' LEU . 61.9 t -74.82 -37.55 42.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 N-CA-C 111.817 0.303 . . . . 0.0 111.817 -178.983 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 207' ' ' GLY . . . . . 0.491 ' HA3' ' O ' ' A' ' 203' ' ' VAL . . . -63.07 -57.48 15.51 Favored Glycine 0 N--CA 1.452 -0.244 0 C-N-CA 120.372 -0.918 . . . . 0.0 112.117 -179.767 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 208' ' ' PHE . . . . . 0.523 ' O ' ' N ' ' A' ' 212' ' ' ALA . 4.8 m-85 -55.42 -49.05 73.43 Favored 'General case' 0 C--O 1.22 -0.478 0 N-CA-C 109.865 -0.42 . . . . 0.0 109.865 179.45 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 209' ' ' GLY . . . . . 0.519 ' HA2' ' HB3' ' A' ' 212' ' ' ALA . . . -53.71 -34.81 51.11 Favored Glycine 0 N--CA 1.451 -0.315 0 CA-C-N 115.183 -0.917 . . . . 0.0 113.382 179.641 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 210' ' ' PHE . . . . . . . . . . . . . 2.1 m-85 -70.7 -48.28 55.49 Favored 'General case' 0 CA--C 1.514 -0.427 0 N-CA-C 108.775 -0.824 . . . . 0.0 108.775 179.355 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 211' ' ' ILE . . . . . 0.483 HD13 HD11 ' A' ' 166' ' ' LEU . 5.6 mt -65.48 -27.59 42.11 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.608 0 N-CA-C 107.712 -1.218 . . . . 0.0 107.712 176.698 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 212' ' ' ALA . . . . . 0.523 ' N ' ' O ' ' A' ' 208' ' ' PHE . . . -68.59 -40.13 80.63 Favored 'General case' 0 N--CA 1.448 -0.555 0 CA-C-N 114.131 -1.395 . . . . 0.0 110.332 -179.763 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 213' ' ' LEU . . . . . 0.408 ' HG ' ' O ' ' A' ' 209' ' ' GLY . 74.8 mt -70.16 -50.42 40.52 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 114.974 -1.012 . . . . 0.0 111.405 -179.572 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 214' ' ' ASP . . . . . . . . . . . . . 24.0 t70 -59.05 -49.9 76.12 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.931 -179.714 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 215' ' ' ALA . . . . . . . . . . . . . . . -56.57 -55.46 33.58 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.888 179.944 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 216' ' ' ALA . . . . . . . . . . . . . . . -62.0 -30.94 71.29 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.143 -0.48 . . . . 0.0 111.32 -179.95 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 217' ' ' ALA . . . . . . . . . . . . . . . -58.28 -43.56 88.03 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-O 120.966 0.412 . . . . 0.0 110.275 179.881 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 218' ' ' THR . . . . . . . . . . . . . 89.5 m -66.51 -46.43 76.24 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 115.826 -0.625 . . . . 0.0 110.355 179.287 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 219' ' ' LEU . . . . . 0.463 ' O ' ' HG2' ' A' ' 222' ' ' GLU . 29.3 mt -60.97 -29.21 69.53 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 115.967 -0.561 . . . . 0.0 110.074 179.497 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 220' ' ' ARG . . . . . . . . . . . . . 57.9 ttp180 -84.11 -21.77 31.33 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-N 115.637 -0.71 . . . . 0.0 110.327 179.504 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 221' ' ' ALA . . . . . . . . . . . . . . . -82.72 -20.19 36.52 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 115.851 -0.613 . . . . 0.0 112.22 -179.496 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 222' ' ' GLU . . . . . 0.463 ' HG2' ' O ' ' A' ' 219' ' ' LEU . 12.3 pt-20 -81.48 -18.1 46.36 Favored 'General case' 0 C--N 1.332 -0.156 0 CA-C-O 120.731 0.3 . . . . 0.0 110.958 -179.23 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 223' ' ' HIS . . . . . . . . . . . . . 1.6 p-80 -145.73 -166.46 2.45 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.354 -0.385 . . . . 0.0 111.211 179.871 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 224' ' ' GLY . . . . . . . . . . . . . . . 66.77 22.46 71.9 Favored Glycine 0 N--CA 1.452 -0.28 0 C-N-CA 120.785 -0.722 . . . . 0.0 112.441 179.963 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 225' ' ' GLU . . . . . . . . . . . . . 12.1 mm-40 -76.14 113.34 13.57 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 120.715 0.293 . . . . 0.0 110.784 -179.965 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 226' ' ' SER . . . . . . . . . . . . . 47.9 t -123.42 -4.16 8.33 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.233 -0.439 . . . . 0.0 111.159 -179.846 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 227' ' ' LEU . . . . . . . . . . . . . 56.3 tp -126.03 -60.35 1.29 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.408 -0.36 . . . . 0.0 111.158 -179.687 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 228' ' ' ALA . . . . . . . . . . . . . . . 54.28 -168.9 0.07 Allowed 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.52 -179.727 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 229' ' ' GLY . . . . . . . . . . . . . . . -99.7 151.51 19.28 Favored Glycine 0 C--N 1.331 0.261 0 C-N-CA 120.827 -0.701 . . . . 0.0 112.452 -179.983 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 230' ' ' VAL . . . . . . . . . . . . . 17.4 m -117.6 27.41 3.48 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.191 0 CA-C-O 120.916 0.388 . . . . 0.0 111.411 -179.868 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 231' ' ' ASP . . . . . . . . . . . . . 11.9 m-20 47.47 68.19 0.69 Allowed 'General case' 0 C--N 1.326 -0.453 0 CA-C-N 115.594 -0.73 . . . . 0.0 111.169 -179.92 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 232' ' ' THR . . . . . . . . . . . . . 35.1 p -144.71 -48.13 0.25 Allowed 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.304 -179.909 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 233' ' ' ASP . . . . . . . . . . . . . 13.1 m-20 -60.5 110.91 1.39 Allowed 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.085 -0.507 . . . . 0.0 111.211 -179.733 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 234' ' ' THR . . . . . . . . . . . . . 39.0 m -99.45 131.48 24.88 Favored Pre-proline 0 C--N 1.331 -0.222 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.9 179.873 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 235' ' ' PRO . . . . . . . . . . . . . 51.1 Cg_exo -53.86 154.53 16.73 Favored 'Trans proline' 0 C--N 1.348 0.55 0 C-N-CA 122.48 2.12 . . . . 0.0 112.437 179.887 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 236' ' ' ALA . . . . . . . . . . . . . . . 61.68 103.15 0.03 OUTLIER 'General case' 0 C--N 1.332 -0.161 0 CA-C-N 116.006 -0.543 . . . . 0.0 111.465 179.66 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 237' ' ' VAL . . . . . . . . . . . . . 14.4 p -89.07 143.11 11.86 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.226 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.86 179.838 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 238' ' ' ALA . . . . . . . . . . . . . . . -104.93 -51.88 2.96 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.286 -0.416 . . . . 0.0 111.266 -179.886 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 239' ' ' ASP . . . . . . . . . . . . . 33.1 t70 -163.08 -71.23 0.05 OUTLIER 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.377 -0.374 . . . . 0.0 110.793 -179.822 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 240' ' ' LEU . . . . . . . . . . . . . 17.0 tp 56.41 17.23 2.81 Favored 'General case' 0 N--CA 1.462 0.165 0 CA-C-N 116.355 -0.384 . . . . 0.0 110.934 179.843 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 241' ' ' GLU . . . . . . . . . . . . . 9.9 tp10 -87.63 -71.14 0.58 Allowed 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.878 -179.835 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 242' ' ' HIS . . . . . . . . . . . . . 24.9 t60 57.06 91.51 0.03 OUTLIER 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 116.092 -0.503 . . . . 0.0 110.992 179.901 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 243' ' ' HIS . . . . . . . . . . . . . 54.7 t-80 -111.06 120.64 43.03 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.08 -0.509 . . . . 0.0 110.993 -179.815 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 244' ' ' HIS . . . . . . . . . . . . . 31.1 m-70 -67.6 125.35 25.91 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.726 179.921 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 245' ' ' HIS . . . . . . . . . . . . . 59.1 t-80 -150.51 -60.71 0.19 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.923 -179.955 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 246' ' ' HIS . . . . . . . . . . . . . 3.0 t-160 -130.62 -62.96 0.9 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.664 -179.935 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 247' ' ' HIS . . . . . . . . . . . . . 38.0 m-70 . . . . . 0 C--O 1.249 1.052 0 CA-C-O 118.287 -0.863 . . . . 0.0 110.864 179.89 . . . . . . . . 0 0 . 1 . 024 nuclear build full ' A' A ' 301' ' ' RET . . . . . 0.773 H203 ' HE1' ' A' ' 171' ' ' TRP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 23.9 ptm . . . . . 0 N--CA 1.485 1.32 0 CA-C-O 120.754 0.311 . . . . 0.0 110.845 . . . . . . . . . 0 0 . 1 . 025 nuclear build full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 29.9 m -140.65 10.93 0.52 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.095 -0.502 . . . . 0.0 111.153 -179.953 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -72.43 -31.47 63.25 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.673 -0.775 . . . . 0.0 112.517 -179.965 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 4' ' ' LEU . . . . . 0.504 HD22 HG21 ' A' ' 194' ' ' VAL . 85.8 mt -74.48 -38.36 62.93 Favored 'General case' 0 N--CA 1.449 -0.477 0 CA-C-O 120.723 0.297 . . . . 0.0 111.509 -179.906 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 69.2 p -54.77 -37.33 65.88 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.138 -0.483 . . . . 0.0 112.03 -179.171 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 69.2 p -56.12 -35.19 66.82 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.481 -0.327 . . . . 0.0 111.548 -179.625 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 7' ' ' LEU . . . . . . . . . . . . . 4.0 mm? -63.2 -53.47 52.67 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.429 -0.35 . . . . 0.0 111.419 -179.648 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 8' ' ' PHE . . . . . 0.673 ' HB2' ' HB2' ' A' ' 55' ' ' ALA . 65.8 m-85 -60.25 -33.06 71.78 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.332 -0.395 . . . . 0.0 110.946 -179.586 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 9' ' ' TRP . . . . . . . . . . . . . 18.3 m95 -68.71 -49.36 59.49 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.246 -179.825 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 75.9 mt -59.39 -38.81 81.46 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 115.814 -0.63 . . . . 0.0 109.825 179.134 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -67.12 -36.24 90.04 Favored Glycine 0 N--CA 1.446 -0.64 0 CA-C-N 115.473 -0.785 . . . . 0.0 111.73 179.403 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -61.98 -33.38 74.21 Favored 'General case' 0 C--O 1.232 0.18 0 CA-C-O 121.037 0.446 . . . . 0.0 109.97 179.183 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 50.7 mm -65.61 -49.92 74.85 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 115.694 -0.685 . . . . 0.0 110.266 179.115 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -58.3 -36.24 82.36 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.798 -0.715 . . . . 0.0 112.218 179.539 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 15' ' ' MET . . . . . . . . . . . . . 19.3 mmt -66.21 -44.6 83.41 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.74 0.305 . . . . 0.0 110.783 179.733 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 16' ' ' LEU . . . . . 0.4 HD13 ' O ' ' A' ' 16' ' ' LEU . 0.5 OUTLIER -53.79 -45.43 70.72 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 115.995 -0.548 . . . . 0.0 110.742 179.809 . . . . . . . . 3 3 . 1 . 025 nuclear build full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 49.2 t -61.12 -43.94 97.3 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.238 0 CA-C-N 116.112 -0.495 . . . . 0.0 111.149 179.943 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -66.72 -43.95 90.65 Favored Glycine 0 N--CA 1.452 -0.256 0 C-N-CA 120.699 -0.762 . . . . 0.0 112.073 179.645 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 19.2 m -52.3 -42.72 64.02 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-O 120.675 0.274 . . . . 0.0 111.341 -179.776 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 80.9 mt -71.82 -44.8 63.3 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.406 -0.361 . . . . 0.0 111.554 -179.903 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -57.01 -32.59 66.29 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.37 -0.377 . . . . 0.0 111.759 -179.405 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 22' ' ' PHE . . . . . 0.623 ' HB2' HG22 ' A' ' 41' ' ' VAL . 10.0 m-85 -90.92 -38.63 12.77 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.537 -0.301 . . . . 0.0 111.62 -179.356 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -64.03 -50.49 68.24 Favored 'General case' 0 C--N 1.332 -0.166 0 CA-C-O 120.878 0.37 . . . . 0.0 111.25 -179.685 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 24' ' ' TRP . . . . . . . . . . . . . 1.3 t-105 -59.88 -49.84 76.13 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 115.958 -0.565 . . . . 0.0 110.68 179.685 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -70.5 -17.63 62.96 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.266 -0.424 . . . . 0.0 111.033 179.88 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -73.3 -52.73 8.33 Favored Glycine 0 N--CA 1.452 -0.245 0 C-N-CA 120.822 -0.704 . . . . 0.0 112.635 -179.964 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 50.4 mtp180 -55.06 -43.05 73.5 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-O 120.861 0.363 . . . . 0.0 110.805 179.999 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 33.7 t70 -89.2 87.82 7.3 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.631 179.878 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -161.39 -170.56 2.67 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.03 -0.532 . . . . 0.0 111.061 -179.72 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -76.9 -118.04 0.16 Allowed Glycine 0 N--CA 1.45 -0.399 0 C-N-CA 120.786 -0.721 . . . . 0.0 112.551 179.797 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 46.8 t -139.3 -33.85 0.6 Allowed 'General case' 0 C--N 1.331 -0.237 0 CA-C-O 120.726 0.298 . . . . 0.0 111.076 -179.897 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -87.04 -12.18 68.61 Favored Glycine 0 N--CA 1.45 -0.373 0 C-N-CA 120.724 -0.75 . . . . 0.0 112.753 -179.792 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 43.6 mt-10 -88.43 -21.49 24.22 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.686 0.279 . . . . 0.0 110.988 -179.937 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 34' ' ' ARG . . . . . 0.432 ' O ' HG23 ' A' ' 38' ' ' VAL . 35.7 ttp180 -49.87 -35.25 22.67 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.141 -0.481 . . . . 0.0 111.527 -179.798 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 77.6 mtm180 -61.59 -54.33 44.48 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 120.85 0.357 . . . . 0.0 111.497 -179.772 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 59.4 m-85 -62.04 -30.02 70.69 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.134 -0.484 . . . . 0.0 111.421 -179.441 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 37' ' ' TYR . . . . . 0.526 ' O ' HG23 ' A' ' 41' ' ' VAL . 32.5 m-85 -73.76 -56.11 5.4 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.503 -179.411 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 38' ' ' VAL . . . . . 0.432 HG23 ' O ' ' A' ' 34' ' ' ARG . 96.0 t -56.68 -36.7 49.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-O 120.98 0.419 . . . . 0.0 110.628 179.923 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 78.3 m -63.44 -51.62 64.92 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 115.872 -0.604 . . . . 0.0 110.918 179.713 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 40' ' ' LEU . . . . . 0.603 HD12 HD12 ' A' ' 43' ' ' ILE . 51.7 tp -61.29 -45.98 92.22 Favored 'General case' 0 C--O 1.236 0.35 0 CA-C-N 115.966 -0.561 . . . . 0.0 110.722 179.989 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 41' ' ' VAL . . . . . 0.623 HG22 ' HB2' ' A' ' 22' ' ' PHE . 85.8 t -60.13 -34.77 58.05 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.399 0 CA-C-N 115.684 -0.689 . . . . 0.0 109.858 178.974 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -63.15 -35.39 92.02 Favored Glycine 0 N--CA 1.445 -0.724 0 C-N-CA 120.877 -0.678 . . . . 0.0 112.026 179.592 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 43' ' ' ILE . . . . . 0.662 HG22 ' HE3' ' A' ' 205' ' ' LYS . 0.8 OUTLIER -66.23 -57.75 9.28 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.126 0 C-N-CA 121.074 -0.25 . . . . 0.0 111.148 179.811 . . . . . . . . 3 3 . 1 . 025 nuclear build full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 85.1 p -59.57 -21.56 60.48 Favored 'General case' 0 C--O 1.232 0.154 0 CA-C-N 116.485 -0.325 . . . . 0.0 111.554 -179.518 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -79.43 -56.23 3.46 Favored Glycine 0 CA--C 1.518 0.23 0 C-N-CA 120.843 -0.694 . . . . 0.0 113.063 -179.363 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 46' ' ' ILE . . . . . 0.431 ' O ' HG22 ' A' ' 49' ' ' VAL . 20.2 pt -58.2 -37.39 62.25 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.243 0 CA-C-O 121.138 0.494 . . . . 0.0 110.873 -179.896 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 47' ' ' ALA . . . . . 0.713 ' HB2' ' HE2' ' A' ' 205' ' ' LYS . . . -68.21 -45.26 73.82 Favored 'General case' 0 C--N 1.324 -0.525 0 CA-C-N 115.945 -0.571 . . . . 0.0 111.363 179.513 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -54.13 -42.71 69.79 Favored 'General case' 0 C--O 1.233 0.203 0 CA-C-N 116.299 -0.41 . . . . 0.0 111.807 -179.219 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 49' ' ' VAL . . . . . 0.431 HG22 ' O ' ' A' ' 46' ' ' ILE . 33.1 m -72.23 -34.5 49.77 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.363 0 CA-C-N 116.665 -0.243 . . . . 0.0 111.333 -179.517 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -66.9 -33.48 75.69 Favored 'General case' 0 CA--C 1.521 -0.146 0 CA-C-O 120.988 0.423 . . . . 0.0 110.73 179.402 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 3.0 m-30 -69.55 -40.72 76.66 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-N 115.909 -0.587 . . . . 0.0 110.12 179.784 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -61.44 -45.1 95.73 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 115.704 -0.68 . . . . 0.0 111.367 179.829 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 53' ' ' VAL . . . . . 0.502 HG23 ' N ' ' A' ' 54' ' ' MET . 25.3 m -67.62 -50.08 64.41 Favored 'Isoleucine or valine' 0 C--N 1.334 -0.087 0 C-N-CA 121.11 -0.236 . . . . 0.0 111.011 -179.956 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 54' ' ' MET . . . . . 0.541 ' HG2' ' HG2' ' A' ' 71' ' ' PRO . 74.7 mtm -58.04 -30.35 66.08 Favored 'General case' 0 CA--C 1.521 -0.172 0 CA-C-O 121.224 0.535 . . . . 0.0 109.866 179.336 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 55' ' ' ALA . . . . . 0.673 ' HB2' ' HB2' ' A' ' 8' ' ' PHE . . . -74.5 -33.93 62.93 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 115.414 -0.812 . . . . 0.0 111.365 179.526 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 74.8 mt -70.88 -5.19 28.78 Favored 'General case' 0 C--N 1.331 -0.203 0 CA-C-N 116.371 -0.377 . . . . 0.0 111.573 -179.416 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 98.8 -20.77 49.01 Favored Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.46 -0.876 . . . . 0.0 113.036 179.638 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 58' ' ' VAL . . . . . 0.428 HG22 ' O ' ' A' ' 53' ' ' VAL . 32.9 m -70.03 149.11 10.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-O 120.88 0.371 . . . . 0.0 110.826 179.805 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 59' ' ' GLY . . . . . 0.472 ' HA3' ' HG3' ' A' ' 71' ' ' PRO . . . 85.05 22.49 52.31 Favored Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.913 -0.661 . . . . 0.0 112.578 -179.47 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 60' ' ' TRP . . . . . . . . . . . . . 13.8 m0 -105.71 96.07 6.24 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-O 121.091 0.472 . . . . 0.0 109.986 -179.837 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 5.1 t -98.53 116.54 65.4 Favored Pre-proline 0 C--N 1.326 -0.435 0 CA-C-N 115.696 -0.683 . . . . 0.0 111.635 -178.87 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 57.1 Cg_endo -70.4 143.96 49.25 Favored 'Trans proline' 0 C--N 1.351 0.709 0 C-N-CA 122.437 2.092 . . . . 0.0 112.262 179.578 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 99.5 t -138.93 96.12 0.99 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.053 -0.521 . . . . 0.0 111.165 -179.88 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . 57.24 -88.1 0.02 OUTLIER 'General case' 0 C--N 1.331 -0.204 0 CA-C-N 116.189 -0.459 . . . . 0.0 111.439 179.781 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 45.7 mt-10 -121.85 -19.08 6.85 Favored 'General case' 0 C--N 1.332 -0.193 0 CA-C-N 116.433 -0.349 . . . . 0.0 110.939 179.935 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 66' ' ' ARG . . . . . . . . . . . . . 39.7 mmt180 -105.4 155.72 18.86 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.342 179.629 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 30.3 m -114.01 143.32 44.94 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-O 120.947 0.404 . . . . 0.0 111.351 -179.591 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 19.9 m -127.42 145.84 34.2 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.402 0 CA-C-N 115.83 -0.623 . . . . 0.0 110.818 179.659 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 69' ' ' PHE . . . . . . . . . . . . . 17.2 m-85 -110.73 115.6 29.84 Favored 'General case' 0 C--N 1.327 -0.38 0 N-CA-C 109.738 -0.467 . . . . 0.0 109.738 -179.63 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 70' ' ' VAL . . . . . 0.566 ' N ' ' HD2' ' A' ' 71' ' ' PRO . 59.4 t -68.43 -51.17 24.66 Favored Pre-proline 0 C--N 1.323 -0.559 0 N-CA-C 112.436 0.532 . . . . 0.0 112.436 -178.741 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 71' ' ' PRO . . . . . 0.566 ' HD2' ' N ' ' A' ' 70' ' ' VAL . 11.2 Cg_endo -54.87 -19.89 20.79 Favored 'Trans proline' 0 C--N 1.353 0.791 0 C-N-CA 122.089 1.859 . . . . 0.0 112.012 179.831 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 72' ' ' ARG . . . . . 0.412 ' NH2' HG13 ' A' ' 197' ' ' ILE . 53.1 ttt180 -74.96 -53.8 8.34 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.043 -0.526 . . . . 0.0 110.586 179.673 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 73' ' ' TYR . . . . . 0.4 ' O ' HG13 ' A' ' 77' ' ' ILE . 75.8 m-85 -65.02 -36.91 85.91 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 115.774 -0.648 . . . . 0.0 110.704 -179.994 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 0.3 OUTLIER -70.05 -36.78 69.98 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 N-CA-C 109.744 -0.465 . . . . 0.0 109.744 179.048 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 75' ' ' ASP . . . . . 0.401 ' O ' HG23 ' A' ' 79' ' ' THR . 12.3 t70 -56.52 -38.95 72.54 Favored 'General case' 0 CA--C 1.52 -0.176 0 CA-C-N 116.033 -0.531 . . . . 0.0 109.642 179.06 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 76' ' ' TRP . . . . . . . . . . . . . 50.2 m0 -69.45 -38.54 77.84 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 115.615 -0.72 . . . . 0.0 110.624 179.418 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 77' ' ' ILE . . . . . 0.4 HG13 ' O ' ' A' ' 73' ' ' TYR . 92.5 mt -59.17 -28.77 39.97 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.725 179.674 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 35.4 mt -91.83 -26.91 18.29 Favored 'General case' 0 CA--C 1.533 0.293 0 N-CA-C 112.317 0.488 . . . . 0.0 112.317 -179.941 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 79' ' ' THR . . . . . 0.413 HG22 HD11 ' A' ' 46' ' ' ILE . 71.3 p -92.44 -52.24 4.75 Favored 'General case' 0 N--CA 1.466 0.342 0 N-CA-C 113.622 0.971 . . . . 0.0 113.622 -177.884 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 80' ' ' THR . . . . . 0.425 ' N ' ' HD2' ' A' ' 81' ' ' PRO . 89.0 m -47.3 -55.25 16.7 Favored Pre-proline 0 C--N 1.329 -0.325 0 N-CA-C 112.858 0.688 . . . . 0.0 112.858 -178.418 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 81' ' ' PRO . . . . . 0.437 ' HA ' HG22 ' A' ' 84' ' ' VAL . 37.2 Cg_endo -64.19 -18.99 65.42 Favored 'Trans proline' 0 C--N 1.35 0.614 0 C-N-CA 121.495 1.463 . . . . 0.0 111.232 -179.833 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 82' ' ' LEU . . . . . . . . . . . . . 18.4 tp -76.93 -33.6 57.72 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 115.529 -0.759 . . . . 0.0 110.169 179.641 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 83' ' ' ILE . . . . . 0.414 HD13 HD13 ' A' ' 43' ' ' ILE . 41.2 mm -70.12 -52.23 32.29 Favored 'Isoleucine or valine' 0 C--O 1.232 0.175 0 CA-C-N 116.058 -0.519 . . . . 0.0 110.101 179.203 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 84' ' ' VAL . . . . . 0.437 HG22 ' HA ' ' A' ' 81' ' ' PRO . 27.9 m -60.61 -30.47 46.89 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.179 0 N-CA-C 109.63 -0.507 . . . . 0.0 109.63 178.795 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 85' ' ' TYR . . . . . . . . . . . . . 81.1 t80 -65.33 -35.79 82.07 Favored 'General case' 0 N--CA 1.453 -0.28 0 CA-C-N 115.542 -0.754 . . . . 0.0 109.276 178.684 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 86' ' ' PHE . . . . . . . . . . . . . 7.2 t80 -61.15 -50.13 74.41 Favored 'General case' 0 C--O 1.234 0.237 0 CA-C-N 115.633 -0.712 . . . . 0.0 109.919 179.186 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 8.8 mp -62.23 -31.84 72.44 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 115.838 -0.619 . . . . 0.0 109.861 179.384 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -68.96 -27.69 73.69 Favored Glycine 0 N--CA 1.449 -0.459 0 C-N-CA 120.856 -0.688 . . . . 0.0 111.678 179.113 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 82.7 mt -73.72 -37.36 65.17 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-O 120.948 0.404 . . . . 0.0 110.482 179.549 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 90' ' ' LEU . . . . . 0.437 HD11 HD22 ' A' ' 163' ' ' LEU . 93.6 mt -64.3 -42.67 96.26 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 115.945 -0.571 . . . . 0.0 111.144 179.9 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -80.13 -54.99 5.25 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.4 -179.654 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 95.37 67.88 1.0 Allowed Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.814 -0.708 . . . . 0.0 112.132 -179.733 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 93' ' ' LEU . . . . . 0.426 ' N ' HD12 ' A' ' 93' ' ' LEU . 6.6 mp -71.21 -171.13 0.55 Allowed 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.783 0.325 . . . . 0.0 111.033 -179.71 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 94' ' ' ASP . . . . . 0.419 ' HB2' ' OE2' ' A' ' 97' ' ' GLU . 5.9 m-20 -96.43 -173.41 2.76 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-N 116.246 -0.433 . . . . 0.0 111.28 -179.807 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 47.5 t -67.52 -51.26 53.04 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 115.946 -0.57 . . . . 0.0 111.624 -179.425 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 96' ' ' ARG . . . . . 0.425 ' O ' HG13 ' A' ' 100' ' ' ILE . 31.6 mmt180 -73.72 -40.07 63.83 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 120.944 0.402 . . . . 0.0 110.699 -179.505 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 97' ' ' GLU . . . . . 0.54 ' HA ' HD12 ' A' ' 100' ' ' ILE . 0.3 OUTLIER -55.48 -47.39 76.21 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 115.763 -0.653 . . . . 0.0 111.501 -179.622 . . . . . . . . 3 3 . 1 . 025 nuclear build full ' A' A ' 98' ' ' PHE . . . . . 0.444 ' O ' HG12 ' A' ' 102' ' ' ILE . 1.2 m-85 -57.13 -45.23 83.69 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.821 0.343 . . . . 0.0 110.796 179.813 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -62.68 -30.25 76.26 Favored Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.586 -179.92 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 100' ' ' ILE . . . . . 0.54 HD12 ' HA ' ' A' ' 97' ' ' GLU . 95.5 mt -65.65 -44.79 93.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-O 120.81 0.338 . . . . 0.0 111.221 -179.939 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 101' ' ' VAL . . . . . 0.431 HG21 ' CE ' ' A' ' 145' ' ' MET . 56.2 t -68.64 -43.89 82.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.322 -0.399 . . . . 0.0 111.51 -179.732 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 102' ' ' ILE . . . . . 0.444 HG12 ' O ' ' A' ' 98' ' ' PHE . 48.5 mm -61.45 -51.1 76.84 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.348 -0.387 . . . . 0.0 111.189 -179.789 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 14.9 t -61.35 -29.01 69.64 Favored 'General case' 0 C--O 1.232 0.153 0 CA-C-O 120.866 0.365 . . . . 0.0 110.614 179.925 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 104' ' ' LEU . . . . . 0.458 ' O ' HG23 ' A' ' 108' ' ' VAL . 1.4 tm? -59.6 -52.65 64.61 Favored 'General case' 0 C--N 1.331 -0.198 0 CA-C-N 116.073 -0.512 . . . . 0.0 109.807 179.217 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 105' ' ' ASN . . . . . 0.569 ' N ' HD22 ' A' ' 105' ' ' ASN . 0.8 OUTLIER -64.33 -26.18 68.37 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 115.965 -0.561 . . . . 0.0 111.024 179.732 . . . . . . . . 3 3 . 1 . 025 nuclear build full ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 53.7 m -63.95 -56.7 13.26 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.38 -0.373 . . . . 0.0 111.478 -179.795 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 7.2 p -62.33 -36.47 74.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.272 -0.422 . . . . 0.0 111.214 -179.851 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 108' ' ' VAL . . . . . 0.458 HG23 ' O ' ' A' ' 104' ' ' LEU . 81.3 t -65.59 -54.41 28.37 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.197 0 CA-C-N 116.376 -0.375 . . . . 0.0 111.01 179.817 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 109' ' ' MET . . . . . . . . . . . . . 11.2 tpp -59.58 -36.29 75.94 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.94 -179.766 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 30.2 tp -66.52 -32.94 74.6 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.309 -0.405 . . . . 0.0 110.226 179.779 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -62.02 -54.21 44.68 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 115.97 -0.559 . . . . 0.0 110.683 179.526 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 112' ' ' GLY . . . . . 0.555 ' HA3' ' H21' ' A' ' 301' ' ' RET . . . -56.87 -36.51 73.25 Favored Glycine 0 C--N 1.331 0.283 0 C-N-CA 120.605 -0.807 . . . . 0.0 112.044 179.549 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 113' ' ' PHE . . . . . . . . . . . . . 2.6 t80 -54.06 -63.67 1.07 Allowed 'General case' 0 C--N 1.332 -0.186 0 CA-C-O 120.918 0.389 . . . . 0.0 110.262 179.589 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 114' ' ' ALA . . . . . 0.447 ' O ' HG13 ' A' ' 118' ' ' VAL . . . -62.25 -28.29 69.6 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 115.88 -0.6 . . . . 0.0 111.172 179.942 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 115' ' ' GLY . . . . . 0.465 ' N ' ' HG ' ' A' ' 126' ' ' LEU . . . -52.22 -52.88 33.84 Favored Glycine 0 C--N 1.333 0.363 0 C-N-CA 121.081 -0.58 . . . . 0.0 112.729 179.971 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -77.91 -15.06 59.3 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-O 120.711 0.291 . . . . 0.0 111.535 179.84 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 117' ' ' MET . . . . . . . . . . . . . 0.5 OUTLIER -93.83 19.34 8.99 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.468 -0.333 . . . . 0.0 111.488 -179.704 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 118' ' ' VAL . . . . . 0.447 HG13 ' O ' ' A' ' 114' ' ' ALA . 33.2 m -84.55 146.74 47.73 Favored Pre-proline 0 C--N 1.331 -0.223 0 CA-C-N 116.594 -0.276 . . . . 0.0 111.335 179.86 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 119' ' ' PRO . . . . . . . . . . . . . 96.6 Cg_endo -87.91 1.92 6.64 Favored 'Trans proline' 0 N--CA 1.458 -0.593 0 C-N-CA 122.709 2.273 . . . . 0.0 112.233 179.325 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -155.55 -138.39 2.56 Favored Glycine 0 C--N 1.332 0.334 0 C-N-CA 120.806 -0.711 . . . . 0.0 112.79 -179.674 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 47.1 pt -88.55 8.72 2.64 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.193 0 CA-C-O 120.645 0.26 . . . . 0.0 111.523 -179.634 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 38.4 mt-10 -60.07 -18.55 47.61 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.423 -0.353 . . . . 0.0 111.11 -179.853 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 123' ' ' ARG . . . . . 0.4 ' HB2' ' HH2' ' A' ' 178' ' ' TRP . 2.6 ptp180 -52.07 -33.8 40.86 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.176 -0.465 . . . . 0.0 111.737 -179.871 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 124' ' ' TYR . . . . . . . . . . . . . 40.8 m-85 -65.01 -32.67 74.51 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.599 -0.273 . . . . 0.0 111.362 -179.659 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 125' ' ' ALA . . . . . . . . . . . . . . . -68.73 -52.96 25.05 Favored 'General case' 0 C--O 1.237 0.419 0 CA-C-O 120.79 0.328 . . . . 0.0 111.064 179.909 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 126' ' ' LEU . . . . . 0.465 ' HG ' ' N ' ' A' ' 115' ' ' GLY . 2.6 mm? -49.86 -54.32 20.17 Favored 'General case' 0 CA--C 1.52 -0.187 0 CA-C-N 116.016 -0.538 . . . . 0.0 110.61 -179.988 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 127' ' ' PHE . . . . . 0.505 ' HZ ' ' HB3' ' A' ' 175' ' ' PRO . 7.1 t80 -67.5 -31.53 71.73 Favored 'General case' 0 N--CA 1.452 -0.35 0 CA-C-N 116.285 -0.416 . . . . 0.0 111.074 -179.652 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 128' ' ' GLY . . . . . . . . . . . . . . . -46.38 -48.38 16.2 Favored Glycine 0 C--N 1.331 0.283 0 C-N-CA 119.793 -1.194 . . . . 0.0 110.737 179.07 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 129' ' ' MET . . . . . 0.491 ' HE3' ' N ' ' A' ' 130' ' ' GLY . 6.0 tmm? -70.43 -45.79 65.18 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 115.139 -0.53 . . . . 0.0 109.894 178.75 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 130' ' ' GLY . . . . . 0.491 ' N ' ' HE3' ' A' ' 129' ' ' MET . . . -57.37 -29.63 60.6 Favored Glycine 0 C--N 1.331 0.265 0 CA-C-N 115.85 -0.614 . . . . 0.0 113.174 -179.315 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -75.02 -53.65 8.55 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-O 120.702 0.287 . . . . 0.0 110.58 -179.798 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 60.0 t -57.67 -42.08 80.77 Favored 'Isoleucine or valine' 0 C--O 1.234 0.252 0 CA-C-O 121.372 0.606 . . . . 0.0 109.672 178.815 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -68.9 -33.47 73.81 Favored 'General case' 0 N--CA 1.451 -0.377 0 CA-C-N 115.272 -0.877 . . . . 0.0 110.781 179.441 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 134' ' ' PHE . . . . . . . . . . . . . 70.5 t80 -54.59 -57.42 11.51 Favored 'General case' 0 N--CA 1.451 -0.394 0 CA-C-O 121.01 0.433 . . . . 0.0 110.031 179.542 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 135' ' ' ILE . . . . . 0.457 ' O ' HG22 ' A' ' 138' ' ' VAL . 26.4 mt -57.22 -33.27 42.88 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.388 0 CA-C-N 115.728 -0.669 . . . . 0.0 109.891 178.87 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . -59.26 -39.46 94.63 Favored Glycine 0 N--CA 1.448 -0.52 0 C-N-CA 120.31 -0.948 . . . . 0.0 111.511 178.851 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 137' ' ' LEU . . . . . . . . . . . . . 54.6 tp -68.68 -55.34 11.74 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-O 120.715 0.293 . . . . 0.0 110.729 179.549 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 138' ' ' VAL . . . . . 0.457 HG22 ' O ' ' A' ' 135' ' ' ILE . 2.8 m -55.86 -32.08 31.64 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.24 0 CA-C-O 121.45 0.643 . . . . 0.0 109.478 179.747 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 139' ' ' TYR . . . . . . . . . . . . . 9.8 t80 -64.23 -36.89 85.55 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 115.28 -0.873 . . . . 0.0 109.995 178.667 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 16.1 m-85 -66.18 -53.15 40.87 Favored 'General case' 0 C--N 1.332 -0.186 0 CA-C-N 115.959 -0.564 . . . . 0.0 111.332 179.669 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 141' ' ' LEU . . . . . 0.644 HD12 HG23 ' A' ' 142' ' ' VAL . 3.0 pp -64.31 -17.12 63.36 Favored 'General case' 0 C--N 1.333 -0.148 0 CA-C-O 120.657 0.265 . . . . 0.0 111.268 -179.418 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 142' ' ' VAL . . . . . 0.644 HG23 HD12 ' A' ' 141' ' ' LEU . 47.1 t -94.93 -22.71 5.3 Favored 'Isoleucine or valine' 0 C--O 1.233 0.208 0 CA-C-O 121.054 0.454 . . . . 0.0 110.366 178.343 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . -74.25 -124.6 0.12 Allowed Glycine 0 CA--C 1.524 0.612 0 C-N-CA 121.114 -0.565 . . . . 0.0 113.485 -179.234 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 144' ' ' PRO . . . . . . . . . . . . . 46.6 Cg_endo -67.55 -23.13 43.62 Favored 'Trans proline' 0 C--N 1.35 0.642 0 C-N-CA 122.769 2.313 . . . . 0.0 113.253 -179.157 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 145' ' ' MET . . . . . 0.493 ' HB3' ' OH ' ' A' ' 160' ' ' TYR . 5.7 mtt -52.18 -57.61 9.13 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.508 -0.315 . . . . 0.0 111.658 -179.609 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 146' ' ' THR . . . . . . . . . . . . . 8.8 t -62.78 -32.2 73.32 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.488 -0.324 . . . . 0.0 111.719 -179.343 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 45.6 mt-10 -70.57 -33.9 71.61 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.425 -0.352 . . . . 0.0 111.311 -179.609 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 148' ' ' SER . . . . . . . . . . . . . 38.8 m -70.52 -49.87 43.62 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.956 0.408 . . . . 0.0 110.843 -179.889 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 149' ' ' ALA . . . . . 0.498 ' HB1' HG22 ' A' ' 156' ' ' ILE . . . -64.05 -35.23 80.06 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 115.992 -0.549 . . . . 0.0 111.757 -179.553 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 150' ' ' SER . . . . . 0.444 ' HA ' ' HB2' ' A' ' 157' ' ' LYS . 86.3 p -67.71 -5.59 16.71 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.379 -0.373 . . . . 0.0 111.232 -179.664 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 151' ' ' GLN . . . . . . . . . . . . . 78.9 mt-30 -115.3 -1.16 12.98 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.503 -0.317 . . . . 0.0 111.338 179.947 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 32.4 mmt180 -80.97 -51.63 8.33 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-O 120.843 0.354 . . . . 0.0 110.989 179.812 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 153' ' ' SER . . . . . 0.58 ' HB3' HG12 ' A' ' 156' ' ' ILE . 27.5 t -158.08 172.41 18.48 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 116.141 -0.482 . . . . 0.0 110.844 179.635 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 154' ' ' SER . . . . . . . . . . . . . 50.8 m -71.59 -40.47 69.85 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.285 -0.416 . . . . 0.0 110.455 179.327 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -76.75 -31.97 51.86 Favored Glycine 0 N--CA 1.452 -0.281 0 C-N-CA 121.013 -0.613 . . . . 0.0 112.708 179.916 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 156' ' ' ILE . . . . . 0.58 HG12 ' HB3' ' A' ' 153' ' ' SER . 29.5 mm -60.14 -38.21 76.17 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.229 0 CA-C-O 120.834 0.349 . . . . 0.0 111.131 -179.896 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 157' ' ' LYS . . . . . 0.444 ' HB2' ' HA ' ' A' ' 150' ' ' SER . 61.7 tttm -66.85 -50.87 61.14 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.327 -179.601 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 48.5 t -62.72 -39.45 94.08 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.3 -0.409 . . . . 0.0 111.549 -179.464 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 159' ' ' LEU . . . . . 0.456 ' O ' HD13 ' A' ' 163' ' ' LEU . 32.0 tp -71.11 -33.45 70.15 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.364 -0.38 . . . . 0.0 111.211 -179.477 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 160' ' ' TYR . . . . . 0.493 ' OH ' ' HB3' ' A' ' 145' ' ' MET . 48.3 t80 -73.24 -46.82 47.93 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.569 -0.287 . . . . 0.0 111.473 -179.559 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 161' ' ' VAL . . . . . 0.429 HG23 ' N ' ' A' ' 162' ' ' ARG . 27.8 m -58.52 -45.4 90.24 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 CA-C-N 116.718 -0.219 . . . . 0.0 111.531 -179.408 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 162' ' ' ARG . . . . . 0.429 ' N ' HG23 ' A' ' 161' ' ' VAL . 40.7 mmt180 -65.05 -39.71 93.69 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-O 120.854 0.359 . . . . 0.0 111.324 -179.723 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 163' ' ' LEU . . . . . 0.605 ' HG ' ' HB2' ' A' ' 208' ' ' PHE . 6.3 mp -70.2 -46.84 63.73 Favored 'General case' 0 C--N 1.328 -0.366 0 N-CA-C 112.453 0.538 . . . . 0.0 112.453 -179.149 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 164' ' ' ARG . . . . . 0.427 ' O ' HG23 ' A' ' 168' ' ' VAL . 5.8 ppt_? -70.96 -47.71 57.44 Favored 'General case' 0 C--N 1.33 -0.262 0 N-CA-C 112.107 0.41 . . . . 0.0 112.107 -178.418 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 165' ' ' ASN . . . . . 0.472 ' O ' HG23 ' A' ' 169' ' ' VAL . 5.1 m120 -57.75 -49.24 77.24 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-O 120.761 0.315 . . . . 0.0 111.129 -179.847 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 166' ' ' LEU . . . . . 0.458 ' O ' ' HG ' ' A' ' 170' ' ' LEU . 5.8 tt -63.57 -52.35 61.43 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.533 -179.427 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 167' ' ' THR . . . . . . . . . . . . . 98.7 m -56.4 -53.27 59.38 Favored 'General case' 0 C--N 1.33 -0.26 0 N-CA-C 112.528 0.566 . . . . 0.0 112.528 -178.88 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 168' ' ' VAL . . . . . 0.427 HG23 ' O ' ' A' ' 164' ' ' ARG . 72.1 t -54.08 -45.15 65.24 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.225 0 N-CA-C 112.016 0.376 . . . . 0.0 112.016 -179.127 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 169' ' ' VAL . . . . . 0.472 HG23 ' O ' ' A' ' 165' ' ' ASN . 54.2 t -55.39 -64.45 0.47 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 N-CA-C 111.831 0.308 . . . . 0.0 111.831 -179.387 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 170' ' ' LEU . . . . . 0.458 ' HG ' ' O ' ' A' ' 166' ' ' LEU . 1.1 pp -62.67 -29.68 70.82 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.657 -0.247 . . . . 0.0 111.626 -179.39 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 171' ' ' TRP . . . . . 0.818 ' HE1' H203 ' A' ' 301' ' ' RET . 4.1 m0 -69.79 -32.32 70.73 Favored 'General case' 0 C--N 1.332 -0.183 0 CA-C-O 121.126 0.488 . . . . 0.0 110.184 179.207 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 172' ' ' ALA . . . . . 0.401 ' C ' ' HD2' ' A' ' 175' ' ' PRO . . . -71.83 -6.5 42.12 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 115.595 -0.73 . . . . 0.0 110.996 -179.848 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 173' ' ' ILE . . . . . 0.475 ' O ' HG12 ' A' ' 177' ' ' ILE . 48.2 mm -85.41 -23.76 7.09 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.245 0 CA-C-N 115.99 -0.55 . . . . 0.0 110.736 179.647 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 174' ' ' TYR . . . . . 0.408 ' N ' ' CD ' ' A' ' 175' ' ' PRO . 20.6 m-85 -54.08 -48.48 93.95 Favored Pre-proline 0 N--CA 1.464 0.232 0 CA-C-N 116.341 -0.39 . . . . 0.0 111.203 179.791 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 175' ' ' PRO . . . . . 0.505 ' HB3' ' HZ ' ' A' ' 127' ' ' PHE . 93.3 Cg_exo -44.6 -33.2 6.51 Favored 'Trans proline' 0 C--N 1.351 0.697 0 C-N-CA 122.287 1.991 . . . . 0.0 112.097 178.894 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 176' ' ' PHE . . . . . 0.517 ' O ' ' HG ' ' A' ' 180' ' ' LEU . 93.0 m-85 -80.63 -50.32 10.1 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 115.691 -0.686 . . . . 0.0 111.851 -179.876 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 177' ' ' ILE . . . . . 0.475 HG12 ' O ' ' A' ' 173' ' ' ILE . 4.6 mm -63.78 -30.91 51.18 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.56 0 N-CA-C 112.533 0.568 . . . . 0.0 112.533 -177.966 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 178' ' ' TRP . . . . . 0.4 ' HH2' ' HB2' ' A' ' 123' ' ' ARG . 84.0 t90 -73.7 -45.67 50.88 Favored 'General case' 0 C--N 1.331 -0.2 0 CA-C-O 120.833 0.349 . . . . 0.0 110.904 179.904 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 179' ' ' LEU . . . . . 0.527 HD23 HD23 ' A' ' 180' ' ' LEU . 0.5 OUTLIER -73.86 -54.82 7.14 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.027 -0.533 . . . . 0.0 111.635 -179.053 . . . . . . . . 3 3 . 1 . 025 nuclear build full ' A' A ' 180' ' ' LEU . . . . . 0.629 HD22 HD11 ' A' ' 187' ' ' LEU . 16.6 mt -62.41 -46.34 89.02 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.563 -0.29 . . . . 0.0 111.378 -179.245 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . -54.64 173.55 0.77 Allowed Glycine 0 CA--C 1.523 0.536 0 C-N-CA 120.296 -0.954 . . . . 0.0 112.514 179.707 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 182' ' ' PRO . . . . . 0.501 ' HA ' ' HB2' ' A' ' 186' ' ' ALA . 86.9 Cg_exo -45.95 -45.3 17.65 Favored 'Trans proline' 0 CA--C 1.536 0.615 0 C-N-CA 122.813 2.342 . . . . 0.0 113.801 -179.849 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 183' ' ' PRO . . . . . 0.434 ' HD3' ' HB2' ' A' ' 182' ' ' PRO . 89.0 Cg_exo -45.37 -34.24 10.09 Favored 'Trans proline' 0 C--N 1.356 0.924 0 C-N-CA 122.281 1.987 . . . . 0.0 113.429 -179.828 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 184' ' ' GLY . . . . . . . . . . . . . . . -109.68 -123.75 4.71 Favored Glycine 0 C--N 1.333 0.368 0 C-N-CA 120.299 -0.953 . . . . 0.0 113.114 -179.652 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 185' ' ' VAL . . . . . . . . . . . . . 11.2 m -62.44 -21.77 27.93 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.218 0 N-CA-C 112.252 0.464 . . . . 0.0 112.252 -179.315 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 186' ' ' ALA . . . . . 0.501 ' HB2' ' HA ' ' A' ' 182' ' ' PRO . . . 57.12 85.63 0.08 Allowed 'General case' 0 N--CA 1.463 0.222 0 CA-C-O 120.862 0.363 . . . . 0.0 111.761 179.693 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 187' ' ' LEU . . . . . 0.629 HD11 HD22 ' A' ' 180' ' ' LEU . 12.6 mt -92.62 -49.66 5.99 Favored 'General case' 0 C--N 1.332 -0.192 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.375 179.806 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 188' ' ' LEU . . . . . 0.588 HD13 HG11 ' A' ' 192' ' ' VAL . 79.7 mt -101.41 -159.81 0.76 Allowed 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 115.946 -0.57 . . . . 0.0 111.1 -179.333 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 189' ' ' THR . . . . . . . . . . . . . 2.0 t -96.55 147.66 33.28 Favored Pre-proline 0 C--N 1.33 -0.277 0 CA-C-N 116.089 -0.505 . . . . 0.0 111.256 -179.793 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 190' ' ' PRO . . . . . 0.435 ' O ' HG23 ' A' ' 194' ' ' VAL . 77.1 Cg_exo -47.62 -39.29 29.77 Favored 'Trans proline' 0 C--N 1.351 0.685 0 C-N-CA 122.681 2.254 . . . . 0.0 112.74 179.967 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 191' ' ' THR . . . . . . . . . . . . . 73.7 p -57.77 -44.05 85.94 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.315 -0.402 . . . . 0.0 111.357 -179.754 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 192' ' ' VAL . . . . . 0.588 HG11 HD13 ' A' ' 188' ' ' LEU . 40.8 t -68.25 -42.64 84.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.242 -0.436 . . . . 0.0 111.146 179.933 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 193' ' ' ASP . . . . . . . . . . . . . 25.6 t70 -58.29 -50.32 74.02 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.254 -0.43 . . . . 0.0 111.176 -179.849 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 194' ' ' VAL . . . . . 0.504 HG21 HD22 ' A' ' 4' ' ' LEU . 59.6 t -60.93 -35.71 66.89 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.35 -0.386 . . . . 0.0 110.982 179.896 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 195' ' ' ALA . . . . . . . . . . . . . . . -58.39 -48.39 80.8 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.466 -0.334 . . . . 0.0 111.143 179.858 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 196' ' ' LEU . . . . . . . . . . . . . 52.7 mt -68.27 -44.99 74.34 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.327 -0.397 . . . . 0.0 110.651 179.696 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 197' ' ' ILE . . . . . 0.412 HG13 ' NH2' ' A' ' 72' ' ' ARG . 20.2 mm -56.29 -59.12 3.16 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.368 0 CA-C-N 115.805 -0.634 . . . . 0.0 110.787 179.643 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 198' ' ' VAL . . . . . . . . . . . . . 49.3 t -52.26 -35.1 19.04 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.484 0 CA-C-N 115.657 -0.701 . . . . 0.0 109.55 178.728 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 199' ' ' TYR . . . . . . . . . . . . . 48.7 t80 -70.15 -32.1 69.92 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 115.482 -0.781 . . . . 0.0 110.523 179.641 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 200' ' ' LEU . . . . . 0.511 ' O ' HG12 ' A' ' 203' ' ' VAL . 40.8 mt -70.35 -43.97 69.12 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 115.903 -0.589 . . . . 0.0 111.553 -179.609 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 201' ' ' ASP . . . . . . . . . . . . . 8.5 m-20 -70.04 -38.37 75.83 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 121.087 0.47 . . . . 0.0 110.521 -179.971 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 202' ' ' LEU . . . . . 0.573 ' O ' HG22 ' A' ' 206' ' ' VAL . 2.7 mt -70.67 -33.09 70.56 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 115.721 -0.672 . . . . 0.0 111.95 -179.389 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 203' ' ' VAL . . . . . 0.511 HG12 ' O ' ' A' ' 200' ' ' LEU . 13.4 p -72.47 -36.08 53.34 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.297 0 C-N-CA 120.856 -0.338 . . . . 0.0 110.848 -178.651 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 204' ' ' THR . . . . . . . . . . . . . 82.4 m -66.29 -58.32 5.61 Favored 'General case' 0 C--N 1.328 -0.328 0 C-N-CA 120.797 -0.361 . . . . 0.0 111.47 179.443 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 205' ' ' LYS . . . . . 0.713 ' HE2' ' HB2' ' A' ' 47' ' ' ALA . 57.3 mttp -61.1 -60.15 4.23 Favored 'General case' 0 C--N 1.329 -0.304 0 N-CA-C 112.974 0.731 . . . . 0.0 112.974 -177.697 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 206' ' ' VAL . . . . . 0.573 HG22 ' O ' ' A' ' 202' ' ' LEU . 1.0 OUTLIER -71.1 -36.31 62.35 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.434 0 N-CA-C 112.103 0.409 . . . . 0.0 112.103 -179.471 . . . . . . . . 3 3 . 1 . 025 nuclear build full ' A' A ' 207' ' ' GLY . . . . . 0.564 ' O ' HG13 ' A' ' 211' ' ' ILE . . . -55.91 -61.48 7.39 Favored Glycine 0 C--N 1.331 0.258 0 C-N-CA 120.534 -0.841 . . . . 0.0 113.623 -178.691 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 208' ' ' PHE . . . . . 0.605 ' HB2' ' HG ' ' A' ' 163' ' ' LEU . 0.7 OUTLIER -72.35 -29.67 64.01 Favored 'General case' 0 C--O 1.224 -0.289 0 CA-C-N 117.433 0.617 . . . . 0.0 110.465 -179.632 . . . . . . . . 3 3 . 1 . 025 nuclear build full ' A' A ' 209' ' ' GLY . . . . . 0.53 ' O ' ' HB3' ' A' ' 212' ' ' ALA . . . -64.66 -32.08 83.03 Favored Glycine 0 N--CA 1.448 -0.514 0 CA-C-N 115.89 -0.595 . . . . 0.0 111.916 179.24 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 210' ' ' PHE . . . . . . . . . . . . . 3.3 m-85 -73.39 -47.23 43.62 Favored 'General case' 0 CA--C 1.512 -0.5 0 N-CA-C 108.242 -1.021 . . . . 0.0 108.242 178.536 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 211' ' ' ILE . . . . . 0.564 HG13 ' O ' ' A' ' 207' ' ' GLY . 4.7 mt -63.81 -27.5 42.99 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.56 0 N-CA-C 107.342 -1.355 . . . . 0.0 107.342 176.273 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 212' ' ' ALA . . . . . 0.53 ' HB3' ' O ' ' A' ' 209' ' ' GLY . . . -64.85 -39.62 93.86 Favored 'General case' 0 N--CA 1.45 -0.463 0 CA-C-N 114.335 -1.302 . . . . 0.0 110.745 179.986 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 213' ' ' LEU . . . . . . . . . . . . . 48.6 mt -67.49 -49.55 62.99 Favored 'General case' 0 C--N 1.333 -0.128 0 CA-C-N 115.511 -0.768 . . . . 0.0 111.445 -179.565 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 214' ' ' ASP . . . . . . . . . . . . . 15.9 t70 -58.62 -51.08 71.45 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.938 0.399 . . . . 0.0 110.766 -179.908 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 215' ' ' ALA . . . . . 0.402 ' O ' ' HG ' ' A' ' 219' ' ' LEU . . . -60.85 -53.42 57.5 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 115.936 -0.574 . . . . 0.0 111.214 -179.901 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 216' ' ' ALA . . . . . . . . . . . . . . . -53.32 -37.02 61.91 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.128 -179.963 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 217' ' ' ALA . . . . . . . . . . . . . . . -65.4 -33.87 76.96 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.108 -0.497 . . . . 0.0 110.347 179.577 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 218' ' ' THR . . . . . . . . . . . . . 67.0 m -75.74 -40.27 55.81 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 115.742 -0.663 . . . . 0.0 110.976 179.483 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 219' ' ' LEU . . . . . 0.402 ' HG ' ' O ' ' A' ' 215' ' ' ALA . 36.1 mt -68.33 -29.21 67.91 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.839 -179.816 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 220' ' ' ARG . . . . . . . . . . . . . 51.9 ttt180 -82.02 -34.99 29.3 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.077 -0.511 . . . . 0.0 110.779 179.959 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 221' ' ' ALA . . . . . . . . . . . . . . . -72.24 -23.84 61.28 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.171 -179.892 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 222' ' ' GLU . . . . . . . . . . . . . 13.1 pt-20 -91.91 -26.41 18.46 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 120.984 0.421 . . . . 0.0 110.199 179.751 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 223' ' ' HIS . . . . . . . . . . . . . 57.6 m-70 61.4 101.6 0.03 OUTLIER 'General case' 0 C--N 1.333 -0.144 0 CA-C-N 115.672 -0.694 . . . . 0.0 111.046 179.76 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 224' ' ' GLY . . . . . . . . . . . . . . . -111.81 4.76 27.51 Favored Glycine 0 C--N 1.331 0.297 0 C-N-CA 120.781 -0.724 . . . . 0.0 112.625 -179.845 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 225' ' ' GLU . . . . . . . . . . . . . 41.8 mt-10 -82.79 114.49 21.15 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.697 0.284 . . . . 0.0 110.797 179.988 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 226' ' ' SER . . . . . . . . . . . . . 71.5 p -143.28 160.16 41.01 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.342 -0.39 . . . . 0.0 110.966 179.993 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 227' ' ' LEU . . . . . . . . . . . . . 85.9 mt -100.33 -7.93 23.93 Favored 'General case' 0 C--N 1.332 -0.191 0 CA-C-N 116.088 -0.505 . . . . 0.0 110.868 179.959 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 228' ' ' ALA . . . . . . . . . . . . . . . 52.35 85.16 0.05 OUTLIER 'General case' 0 C--N 1.331 -0.212 0 CA-C-N 116.055 -0.52 . . . . 0.0 111.475 -179.934 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 229' ' ' GLY . . . . . . . . . . . . . . . 74.38 125.78 0.14 Allowed Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.869 -0.681 . . . . 0.0 112.624 -179.863 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 230' ' ' VAL . . . . . . . . . . . . . 57.6 t -72.31 131.66 34.43 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-O 120.827 0.346 . . . . 0.0 110.95 179.843 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 231' ' ' ASP . . . . . . . . . . . . . 20.3 m-20 -95.62 108.14 20.39 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.157 -179.831 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 232' ' ' THR . . . . . . . . . . . . . 6.7 t -168.51 145.82 3.95 Favored 'General case' 0 C--N 1.332 -0.193 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.206 179.802 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 233' ' ' ASP . . . . . . . . . . . . . 7.7 m-20 -78.49 -14.81 59.18 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 115.977 -0.556 . . . . 0.0 110.998 -179.936 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 234' ' ' THR . . . . . . . . . . . . . 89.8 m -105.09 107.04 57.91 Favored Pre-proline 0 C--N 1.329 -0.306 0 CA-C-N 116.252 -0.431 . . . . 0.0 111.209 -179.926 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 235' ' ' PRO . . . . . . . . . . . . . 73.3 Cg_endo -76.53 170.04 20.7 Favored 'Trans proline' 0 C--N 1.348 0.537 0 C-N-CA 122.318 2.012 . . . . 0.0 112.267 179.902 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 236' ' ' ALA . . . . . . . . . . . . . . . -85.98 143.77 27.97 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.907 179.917 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 237' ' ' VAL . . . . . . . . . . . . . 7.1 p -128.36 141.32 46.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.143 -179.909 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 238' ' ' ALA . . . . . . . . . . . . . . . -134.58 -23.25 1.64 Allowed 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.08 -0.509 . . . . 0.0 111.104 179.991 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 239' ' ' ASP . . . . . . . . . . . . . 14.6 t70 -145.11 142.21 29.47 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.961 -179.958 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 240' ' ' LEU . . . . . 0.436 ' N ' HD22 ' A' ' 240' ' ' LEU . 3.7 mm? -89.57 133.85 34.41 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 116.066 -0.515 . . . . 0.0 110.811 -179.969 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 241' ' ' GLU . . . . . . . . . . . . . 9.0 tp10 -101.72 -72.93 0.67 Allowed 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.113 -0.494 . . . . 0.0 111.087 -179.798 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 242' ' ' HIS . . . . . . . . . . . . . 43.0 m80 60.84 107.6 0.02 OUTLIER 'General case' 0 N--CA 1.462 0.16 0 CA-C-N 116.156 -0.474 . . . . 0.0 111.207 -179.674 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 243' ' ' HIS . . . . . . . . . . . . . 8.4 p80 -127.99 152.79 47.48 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.043 -0.526 . . . . 0.0 111.063 -179.922 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 244' ' ' HIS . . . . . . . . . . . . . 72.3 t60 -149.4 -24.34 0.28 Allowed 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.163 -0.472 . . . . 0.0 110.633 179.843 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 245' ' ' HIS . . . . . . . . . . . . . 62.5 m-70 -97.73 175.84 6.04 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.718 179.76 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 246' ' ' HIS . . . . . . . . . . . . . 18.9 t-80 -143.55 -41.76 0.29 Allowed 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.302 -0.408 . . . . 0.0 110.949 179.987 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 247' ' ' HIS . . . . . . . . . . . . . 47.8 m80 . . . . . 0 C--O 1.249 1.032 0 CA-C-O 118.246 -0.883 . . . . 0.0 110.884 -179.927 . . . . . . . . 0 0 . 1 . 025 nuclear build full ' A' A ' 301' ' ' RET . . . . . 0.818 H203 ' HE1' ' A' ' 171' ' ' TRP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 62.8 mtm . . . . . 0 N--CA 1.484 1.275 0 CA-C-O 120.828 0.347 . . . . 0.0 110.99 . . . . . . . . . 0 0 . 1 . 026 nuclear build full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 7.4 p -170.91 -38.18 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.249 0 CA-C-N 115.942 -0.572 . . . . 0.0 111.171 -179.982 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -103.11 -16.8 20.11 Favored Glycine 0 N--CA 1.449 -0.439 0 C-N-CA 120.646 -0.788 . . . . 0.0 112.465 -179.948 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -71.47 -37.43 71.33 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.909 0.385 . . . . 0.0 110.742 -179.971 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 65.4 p -64.19 -32.39 73.95 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.149 -179.967 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 11.8 p -57.29 -35.37 69.72 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.034 -0.53 . . . . 0.0 111.145 -179.818 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 7' ' ' LEU . . . . . . . . . . . . . 4.3 mm? -57.57 -50.94 71.47 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.295 -0.412 . . . . 0.0 111.154 179.793 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 8' ' ' PHE . . . . . 0.593 ' HB2' ' HB2' ' A' ' 55' ' ' ALA . 65.6 m-85 -65.84 -32.54 74.12 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.34 -0.391 . . . . 0.0 110.916 -179.706 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 9' ' ' TRP . . . . . 0.428 ' O ' HG13 ' A' ' 13' ' ' ILE . 23.2 m95 -67.09 -49.89 63.45 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-N 116.065 -0.516 . . . . 0.0 110.388 -179.524 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 89.5 mt -59.18 -47.05 86.74 Favored 'General case' 0 C--N 1.326 -0.45 0 CA-C-N 115.72 -0.673 . . . . 0.0 109.973 179.57 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 11' ' ' GLY . . . . . 0.422 ' O ' ' HG2' ' A' ' 15' ' ' MET . . . -57.67 -42.96 94.55 Favored Glycine 0 N--CA 1.445 -0.722 0 C-N-CA 120.634 -0.794 . . . . 0.0 111.363 179.062 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -56.36 -35.31 67.54 Favored 'General case' 0 C--N 1.331 -0.196 0 CA-C-O 120.939 0.4 . . . . 0.0 110.68 179.737 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 13' ' ' ILE . . . . . 0.428 HG13 ' O ' ' A' ' 9' ' ' TRP . 63.7 mt -62.32 -46.46 96.37 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 CA-C-N 116.002 -0.545 . . . . 0.0 110.082 179.334 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -59.41 -40.67 96.4 Favored Glycine 0 N--CA 1.45 -0.399 0 C-N-CA 120.799 -0.715 . . . . 0.0 112.512 179.666 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 15' ' ' MET . . . . . 0.422 ' HG2' ' O ' ' A' ' 11' ' ' GLY . 13.8 mmm -62.93 -39.14 93.68 Favored 'General case' 0 C--N 1.332 -0.189 0 CA-C-O 120.824 0.345 . . . . 0.0 110.656 -179.946 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 16' ' ' LEU . . . . . 0.427 HD13 ' O ' ' A' ' 16' ' ' LEU . 0.5 OUTLIER -59.11 -45.18 91.56 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.029 -0.532 . . . . 0.0 110.582 179.741 . . . . . . . . 3 3 . 1 . 026 nuclear build full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 51.1 t -59.21 -48.63 86.26 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.2 0 CA-C-N 116.354 -0.384 . . . . 0.0 110.98 179.965 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -63.69 -48.42 77.39 Favored Glycine 0 N--CA 1.452 -0.283 0 C-N-CA 120.805 -0.712 . . . . 0.0 112.438 179.926 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 47.6 m -49.71 -41.19 42.87 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.735 0.302 . . . . 0.0 111.552 -179.445 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 78.0 mt -72.04 -41.61 67.29 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.425 -0.352 . . . . 0.0 111.393 179.841 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -62.57 -29.91 70.93 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.309 -0.405 . . . . 0.0 111.792 -179.65 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 22' ' ' PHE . . . . . 0.632 ' HB2' HG22 ' A' ' 41' ' ' VAL . 3.4 m-85 -89.99 -34.84 15.84 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.501 -0.318 . . . . 0.0 111.261 -179.256 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -70.43 -49.84 44.61 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.455 -0.339 . . . . 0.0 111.238 -179.993 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 24' ' ' TRP . . . . . . . . . . . . . 1.2 t-105 -59.46 -39.24 83.02 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.045 -0.525 . . . . 0.0 110.899 179.974 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -73.04 -24.67 60.74 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.293 -0.412 . . . . 0.0 110.992 179.938 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -67.53 -49.59 49.61 Favored Glycine 0 N--CA 1.451 -0.36 0 C-N-CA 120.722 -0.752 . . . . 0.0 112.225 179.715 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 63.1 mtm180 -60.42 -32.8 71.7 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-O 120.945 0.403 . . . . 0.0 110.768 179.707 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 9.0 t70 -72.31 -29.07 63.49 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 115.884 -0.598 . . . . 0.0 111.04 179.936 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -71.26 -174.93 1.1 Allowed 'General case' 0 C--N 1.331 -0.215 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.201 -179.857 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -91.28 -110.1 1.6 Allowed Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.861 -0.685 . . . . 0.0 112.764 -179.718 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 49.5 m -138.25 -45.49 0.51 Allowed 'General case' 0 C--N 1.331 -0.207 0 CA-C-O 120.791 0.329 . . . . 0.0 111.203 -179.747 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -57.95 -32.98 67.35 Favored Glycine 0 N--CA 1.453 -0.229 0 C-N-CA 120.842 -0.694 . . . . 0.0 112.711 -179.815 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 38.5 mt-10 -90.53 -20.74 22.31 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-O 120.807 0.336 . . . . 0.0 110.812 179.951 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 34' ' ' ARG . . . . . . . . . . . . . 38.5 ttm180 -48.37 -29.36 3.9 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 115.9 -0.591 . . . . 0.0 111.68 -179.512 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 35' ' ' ARG . . . . . 0.424 ' NE ' ' HA ' ' A' ' 35' ' ' ARG . 5.5 mmp_? -59.23 -46.6 88.04 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.808 0.337 . . . . 0.0 111.118 179.923 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 73.8 m-85 -67.63 -30.23 69.74 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.252 -179.848 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 37' ' ' TYR . . . . . 0.429 ' O ' HG23 ' A' ' 41' ' ' VAL . 76.5 m-85 -74.13 -54.7 7.24 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.538 -179.406 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 10.5 p -56.72 -36.18 48.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-O 120.979 0.418 . . . . 0.0 110.387 179.884 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 52.5 m -68.9 -49.96 53.69 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 115.617 -0.72 . . . . 0.0 110.559 179.216 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 40' ' ' LEU . . . . . 0.499 HD12 HD12 ' A' ' 43' ' ' ILE . 22.5 tp -55.53 -50.02 71.08 Favored 'General case' 0 C--O 1.237 0.438 0 CA-C-N 115.718 -0.674 . . . . 0.0 110.374 179.651 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 41' ' ' VAL . . . . . 0.632 HG22 ' HB2' ' A' ' 22' ' ' PHE . 83.7 t -59.36 -34.24 53.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 115.769 -0.65 . . . . 0.0 109.94 178.912 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -58.56 -38.25 90.83 Favored Glycine 0 N--CA 1.448 -0.547 0 C-N-CA 120.71 -0.757 . . . . 0.0 111.453 179.503 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 43' ' ' ILE . . . . . 0.499 HD12 HD12 ' A' ' 40' ' ' LEU . 2.4 mt -65.21 -59.31 4.31 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.217 0 CA-C-O 120.863 0.363 . . . . 0.0 110.593 179.464 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 77.6 p -59.56 -24.67 63.91 Favored 'General case' 0 C--N 1.331 -0.218 0 CA-C-N 115.991 -0.549 . . . . 0.0 111.344 -179.666 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -75.3 -57.69 4.21 Favored Glycine 0 CA--C 1.518 0.24 0 C-N-CA 120.745 -0.74 . . . . 0.0 112.861 -179.653 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 22.6 pt -58.25 -35.27 52.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-O 120.908 0.385 . . . . 0.0 110.762 -179.896 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 47' ' ' ALA . . . . . 0.71 ' HB2' ' HE2' ' A' ' 205' ' ' LYS . . . -63.91 -49.73 71.48 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.001 -0.545 . . . . 0.0 111.07 179.764 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -54.52 -36.55 64.37 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.857 179.999 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 0.5 OUTLIER -67.04 -42.99 89.21 Favored 'Isoleucine or valine' 0 N--CA 1.432 -1.371 0 CA-C-N 116.031 -0.531 . . . . 0.0 111.486 179.797 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 50' ' ' ALA . . . . . 0.435 ' HA ' HG22 ' A' ' 53' ' ' VAL . . . -67.85 -33.67 75.21 Favored 'General case' 0 C--N 1.333 -0.137 0 CA-C-N 116.43 -0.35 . . . . 0.0 111.463 179.954 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 51' ' ' TYR . . . . . 0.461 ' O ' ' HB3' ' A' ' 8' ' ' PHE . 31.5 m-85 -70.59 -36.77 73.73 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.77 -179.525 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -71.55 -42.42 67.9 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-N 115.985 -0.552 . . . . 0.0 111.531 179.985 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 53' ' ' VAL . . . . . 0.508 HG23 ' N ' ' A' ' 54' ' ' MET . 35.5 m -67.06 -50.7 61.59 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.173 0 CA-C-N 116.556 -0.293 . . . . 0.0 111.451 -179.629 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 54' ' ' MET . . . . . 0.508 ' N ' HG23 ' A' ' 53' ' ' VAL . 78.1 mtm -61.14 -32.04 71.75 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-O 121.047 0.451 . . . . 0.0 110.296 179.775 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 55' ' ' ALA . . . . . 0.593 ' HB2' ' HB2' ' A' ' 8' ' ' PHE . . . -66.44 -38.43 87.38 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 115.753 -0.658 . . . . 0.0 111.015 179.42 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 97.2 mt -71.25 -12.88 61.69 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.039 -0.528 . . . . 0.0 111.238 -179.817 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 101.05 -21.03 45.13 Favored Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.649 -0.786 . . . . 0.0 112.817 179.819 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 30.1 m -66.63 138.58 22.66 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.238 0 CA-C-O 120.872 0.367 . . . . 0.0 111.018 -179.981 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 101.8 -11.52 57.67 Favored Glycine 0 N--CA 1.45 -0.402 0 C-N-CA 120.815 -0.707 . . . . 0.0 112.413 -179.7 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 60' ' ' TRP . . . . . . . . . . . . . 22.0 m0 -78.39 117.38 19.56 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.699 0.285 . . . . 0.0 110.727 179.793 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 10.0 p -109.99 129.54 23.83 Favored Pre-proline 0 C--N 1.329 -0.295 0 CA-C-N 116.438 -0.347 . . . . 0.0 111.078 179.836 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 86.5 Cg_endo -75.96 140.61 23.08 Favored 'Trans proline' 0 C--N 1.35 0.637 0 C-N-CA 122.404 2.07 . . . . 0.0 112.111 179.897 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 81.9 t -138.94 96.13 0.99 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.041 -0.527 . . . . 0.0 110.937 -179.767 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . 58.48 -86.71 0.02 OUTLIER 'General case' 0 C--N 1.332 -0.195 0 CA-C-N 116.001 -0.545 . . . . 0.0 111.315 -179.906 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 40.8 tt0 -121.04 -26.19 5.19 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.398 -0.364 . . . . 0.0 110.781 179.959 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 66' ' ' ARG . . . . . . . . . . . . . 76.0 ttt-85 -102.11 154.55 18.89 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.576 -179.954 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 86.0 m -113.37 121.24 43.76 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 120.882 0.373 . . . . 0.0 111.57 -179.741 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 68' ' ' VAL . . . . . 0.417 HG21 ' HA ' ' A' ' 117' ' ' MET . 21.8 t -93.21 146.89 5.88 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-N 115.978 -0.555 . . . . 0.0 110.374 179.344 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 69' ' ' PHE . . . . . . . . . . . . . 30.3 m-85 -106.87 112.31 25.21 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-O 120.836 0.351 . . . . 0.0 110.152 -179.494 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 70' ' ' VAL . . . . . 0.561 ' HB ' ' HD3' ' A' ' 71' ' ' PRO . 11.2 t -68.6 -50.22 26.61 Favored Pre-proline 0 C--N 1.326 -0.45 0 CA-C-N 115.986 -0.552 . . . . 0.0 112.361 -178.85 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 71' ' ' PRO . . . . . 0.561 ' HD3' ' HB ' ' A' ' 70' ' ' VAL . 24.6 Cg_exo -63.28 -18.35 64.41 Favored 'Trans proline' 0 C--N 1.351 0.7 0 C-N-CA 122.253 1.968 . . . . 0.0 113.068 -179.455 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 70.6 ttt180 -70.69 -55.48 8.6 Favored 'General case' 0 C--O 1.235 0.316 0 CA-C-O 120.88 0.371 . . . . 0.0 111.661 -179.33 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 73' ' ' TYR . . . . . . . . . . . . . 98.8 m-85 -71.86 -33.27 68.27 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.525 -0.307 . . . . 0.0 110.72 -179.519 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 74' ' ' ILE . . . . . 0.489 HG22 ' HA ' ' A' ' 71' ' ' PRO . 0.3 OUTLIER -65.96 -37.67 80.37 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.307 0 N-CA-C 109.446 -0.575 . . . . 0.0 109.446 179.017 . . . . . . . . 3 3 . 1 . 026 nuclear build full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 33.1 t70 -61.65 -37.33 83.65 Favored 'General case' 0 N--CA 1.453 -0.286 0 N-CA-C 109.251 -0.648 . . . . 0.0 109.251 178.734 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 76' ' ' TRP . . . . . . . . . . . . . 45.8 m0 -66.66 -29.91 70.05 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 115.642 -0.708 . . . . 0.0 110.114 179.019 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 77' ' ' ILE . . . . . 0.463 HG12 ' HB3' ' A' ' 109' ' ' MET . 97.0 mt -71.73 -29.62 34.84 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 115.87 -0.605 . . . . 0.0 110.737 179.447 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 51.8 mt -90.43 -17.17 27.66 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 116.0 -0.546 . . . . 0.0 111.776 179.994 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 79' ' ' THR . . . . . 0.409 ' O ' HG12 ' A' ' 83' ' ' ILE . 69.7 p -102.94 -52.63 3.01 Favored 'General case' 0 C--N 1.332 -0.189 0 N-CA-C 113.311 0.856 . . . . 0.0 113.311 -178.371 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 80' ' ' THR . . . . . 0.697 ' HB ' ' HD3' ' A' ' 81' ' ' PRO . 37.4 m -50.2 -55.7 23.15 Favored Pre-proline 0 CA--C 1.533 0.292 0 N-CA-C 112.537 0.569 . . . . 0.0 112.537 -178.284 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 81' ' ' PRO . . . . . 0.697 ' HD3' ' HB ' ' A' ' 80' ' ' THR . 39.2 Cg_exo -61.06 -21.07 70.42 Favored 'Trans proline' 0 C--N 1.351 0.666 0 C-N-CA 121.55 1.5 . . . . 0.0 111.587 179.818 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 82' ' ' LEU . . . . . . . . . . . . . 14.4 tp -76.99 -33.17 57.62 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 115.811 -0.631 . . . . 0.0 110.599 179.847 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 83' ' ' ILE . . . . . 0.409 HG12 ' O ' ' A' ' 79' ' ' THR . 36.3 mm -69.92 -53.45 23.84 Favored 'Isoleucine or valine' 0 C--O 1.232 0.173 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.214 179.326 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 84' ' ' VAL . . . . . 0.615 HG21 ' ND2' ' A' ' 105' ' ' ASN . 34.6 m -59.61 -32.46 49.22 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.224 0 N-CA-C 109.4 -0.592 . . . . 0.0 109.4 178.637 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 85' ' ' TYR . . . . . . . . . . . . . 68.7 t80 -60.68 -43.88 97.17 Favored 'General case' 0 N--CA 1.452 -0.356 0 CA-C-N 115.455 -0.793 . . . . 0.0 109.047 178.606 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 86' ' ' PHE . . . . . . . . . . . . . 2.1 t80 -53.52 -50.25 65.84 Favored 'General case' 0 C--O 1.233 0.199 0 CA-C-N 115.632 -0.713 . . . . 0.0 109.734 179.407 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 87' ' ' LEU . . . . . 0.568 ' HA ' HD12 ' A' ' 90' ' ' LEU . 8.9 mp -59.72 -28.34 67.25 Favored 'General case' 0 C--N 1.332 -0.188 0 CA-C-N 115.785 -0.643 . . . . 0.0 110.665 179.618 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -65.28 -42.45 96.2 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.65 -0.786 . . . . 0.0 111.903 179.697 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 89' ' ' LEU . . . . . 0.423 ' N ' HD12 ' A' ' 89' ' ' LEU . 8.8 mp -64.5 -37.22 86.77 Favored 'General case' 0 N--CA 1.45 -0.474 0 CA-C-O 121.118 0.485 . . . . 0.0 110.504 179.387 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 90' ' ' LEU . . . . . 0.568 HD12 ' HA ' ' A' ' 87' ' ' LEU . 97.9 mt -55.32 -59.07 5.31 Favored 'General case' 0 C--N 1.326 -0.455 0 CA-C-N 115.368 -0.833 . . . . 0.0 111.162 179.905 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 91' ' ' ALA . . . . . 0.564 ' HB2' ' HB2' ' A' ' 149' ' ' ALA . . . -71.69 -54.82 9.1 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.085 -0.507 . . . . 0.0 111.382 -179.79 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 110.88 59.46 0.48 Allowed Glycine 0 N--CA 1.45 -0.372 0 C-N-CA 120.95 -0.643 . . . . 0.0 112.255 -179.892 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 93' ' ' LEU . . . . . 0.501 HD23 ' HB3' ' A' ' 97' ' ' GLU . 8.9 mp -77.19 169.29 18.6 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.915 0.388 . . . . 0.0 111.133 -179.722 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 94' ' ' ASP . . . . . . . . . . . . . 9.7 m-20 -91.09 163.65 14.22 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.05 -0.523 . . . . 0.0 110.704 179.827 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 80.6 p -53.96 -27.56 32.05 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.331 -0.395 . . . . 0.0 110.988 -179.926 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 80.5 mtm180 -73.07 -53.43 11.09 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.299 -0.409 . . . . 0.0 110.757 179.81 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 97' ' ' GLU . . . . . 0.501 ' HB3' HD23 ' A' ' 93' ' ' LEU . 44.9 mt-10 -57.44 -39.41 76.19 Favored 'General case' 0 C--N 1.332 -0.191 0 CA-C-N 116.122 -0.49 . . . . 0.0 111.104 -179.857 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 98' ' ' PHE . . . . . 0.45 ' O ' HG12 ' A' ' 102' ' ' ILE . 12.6 m-85 -60.29 -51.54 69.12 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.366 -0.379 . . . . 0.0 110.857 179.969 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -59.31 -28.15 64.08 Favored Glycine 0 N--CA 1.452 -0.291 0 C-N-CA 120.675 -0.774 . . . . 0.0 112.497 -179.85 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 96.3 mt -73.4 -47.05 47.4 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-O 120.823 0.344 . . . . 0.0 111.345 -179.868 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 59.4 t -67.38 -43.2 87.89 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.399 0 CA-C-N 116.235 -0.438 . . . . 0.0 111.545 -179.675 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 102' ' ' ILE . . . . . 0.45 HG12 ' O ' ' A' ' 98' ' ' PHE . 49.5 mm -64.83 -48.92 82.4 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.386 -0.37 . . . . 0.0 111.4 -179.516 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 14.0 t -60.4 -31.05 70.0 Favored 'General case' 0 C--N 1.332 -0.169 0 CA-C-O 120.811 0.339 . . . . 0.0 110.814 -179.982 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 104' ' ' LEU . . . . . 0.499 ' O ' HG23 ' A' ' 108' ' ' VAL . 45.6 tp -61.95 -54.45 41.58 Favored 'General case' 0 C--N 1.332 -0.185 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.382 179.486 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 105' ' ' ASN . . . . . 0.615 ' ND2' HG21 ' A' ' 84' ' ' VAL . 16.0 m-20 -61.87 -25.48 67.57 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 116.053 -0.521 . . . . 0.0 110.959 -179.986 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 52.2 m -64.27 -54.89 26.24 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.343 -0.39 . . . . 0.0 111.12 179.992 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 107' ' ' VAL . . . . . 0.438 HG12 ' O ' ' A' ' 104' ' ' LEU . 13.4 p -64.14 -36.37 76.75 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.205 0 CA-C-N 116.382 -0.372 . . . . 0.0 111.049 -179.989 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 108' ' ' VAL . . . . . 0.499 HG23 ' O ' ' A' ' 104' ' ' LEU . 96.4 t -64.13 -52.65 53.44 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.761 179.664 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 109' ' ' MET . . . . . 0.463 ' HB3' HG12 ' A' ' 77' ' ' ILE . 9.7 tpp -62.11 -26.15 68.13 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 115.872 -0.604 . . . . 0.0 110.705 -179.973 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 29.7 tp -75.69 -33.87 60.38 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.163 -0.472 . . . . 0.0 110.204 179.396 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -62.13 -54.37 42.18 Favored 'General case' 0 C--N 1.332 -0.177 0 CA-C-N 115.924 -0.58 . . . . 0.0 110.377 179.301 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 112' ' ' GLY . . . . . 0.401 ' HA3' ' H21' ' A' ' 301' ' ' RET . . . -61.75 -37.32 94.09 Favored Glycine 0 N--CA 1.45 -0.388 0 C-N-CA 120.645 -0.788 . . . . 0.0 111.652 179.435 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 113' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER -48.23 -69.88 0.11 Allowed 'General case' 0 CA--C 1.521 -0.158 0 N-CA-C 109.755 -0.461 . . . . 0.0 109.755 179.219 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 114' ' ' ALA . . . . . 0.403 ' O ' HG13 ' A' ' 118' ' ' VAL . . . -65.1 -17.79 64.76 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 115.615 -0.72 . . . . 0.0 110.271 178.875 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 115' ' ' GLY . . . . . 0.528 ' HA2' HD22 ' A' ' 126' ' ' LEU . . . -52.52 -47.99 56.15 Favored Glycine 0 C--N 1.334 0.465 0 C-N-CA 121.005 -0.617 . . . . 0.0 111.791 179.45 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -78.26 -23.1 47.46 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-O 120.666 0.27 . . . . 0.0 111.571 179.705 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 117' ' ' MET . . . . . 0.417 ' HA ' HG21 ' A' ' 68' ' ' VAL . 40.9 ttm -94.8 19.2 10.44 Favored 'General case' 0 CA--C 1.533 0.305 0 CA-C-N 116.457 -0.338 . . . . 0.0 111.859 -179.257 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 118' ' ' VAL . . . . . 0.45 HG21 ' HB3' ' A' ' 123' ' ' ARG . 21.8 m -69.17 150.88 97.28 Favored Pre-proline 0 C--N 1.331 -0.227 0 CA-C-O 120.554 0.216 . . . . 0.0 111.17 179.736 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 119' ' ' PRO . . . . . . . . . . . . . 92.9 Cg_endo -81.29 -4.96 12.66 Favored 'Trans proline' 0 C--N 1.348 0.515 0 C-N-CA 122.699 2.266 . . . . 0.0 112.364 179.846 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -158.2 -131.23 1.26 Allowed Glycine 0 C--N 1.331 0.267 0 C-N-CA 120.834 -0.698 . . . . 0.0 112.653 -179.994 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 37.9 pt -97.48 10.88 5.79 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.226 0 CA-C-O 120.877 0.37 . . . . 0.0 111.161 -179.951 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 16.4 mm-40 -59.8 -18.12 41.13 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.016 -0.538 . . . . 0.0 111.096 179.8 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 123' ' ' ARG . . . . . 0.45 ' HB3' HG21 ' A' ' 118' ' ' VAL . 23.0 ptt180 -50.74 -28.9 10.1 Favored 'General case' 0 C--N 1.331 -0.197 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.778 -179.884 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 124' ' ' TYR . . . . . . . . . . . . . 38.1 m-85 -69.46 -32.91 72.13 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-O 120.828 0.347 . . . . 0.0 110.975 179.965 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 125' ' ' ALA . . . . . . . . . . . . . . . -73.52 -49.94 23.99 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.094 -0.503 . . . . 0.0 111.13 179.942 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 126' ' ' LEU . . . . . 0.528 HD22 ' HA2' ' A' ' 115' ' ' GLY . 7.9 mp -53.36 -55.49 24.49 Favored 'General case' 0 C--N 1.331 -0.201 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.316 179.771 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 127' ' ' PHE . . . . . 0.439 ' HE1' ' H42' ' A' ' 301' ' ' RET . 9.7 t80 -62.82 -33.9 76.18 Favored 'General case' 0 N--CA 1.452 -0.372 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.264 179.568 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 128' ' ' GLY . . . . . . . . . . . . . . . -47.97 -43.23 23.9 Favored Glycine 0 C--N 1.333 0.394 0 C-N-CA 120.167 -1.016 . . . . 0.0 110.778 178.907 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 129' ' ' MET . . . . . 0.421 ' HE1' ' HA ' ' A' ' 108' ' ' VAL . 0.4 OUTLIER -71.27 -38.22 71.86 Favored 'General case' 0 C--N 1.329 -0.312 0 N-CA-C 109.786 -0.45 . . . . 0.0 109.786 178.565 . . . . . . . . 3 3 . 1 . 026 nuclear build full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -65.72 -27.49 72.73 Favored Glycine 0 N--CA 1.451 -0.313 0 CA-C-N 115.757 -0.656 . . . . 0.0 112.695 179.907 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -74.77 -53.66 8.78 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.664 0.268 . . . . 0.0 110.545 179.828 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 132' ' ' VAL . . . . . 0.526 ' O ' HG13 ' A' ' 135' ' ' ILE . 38.7 t -57.2 -39.74 69.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-O 121.567 0.699 . . . . 0.0 109.311 178.675 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -70.99 -33.97 70.93 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-N 115.15 -0.932 . . . . 0.0 110.831 179.41 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 134' ' ' PHE . . . . . 0.437 ' CZ ' ' HA ' ' A' ' 172' ' ' ALA . 35.9 t80 -55.03 -59.22 5.04 Favored 'General case' 0 N--CA 1.453 -0.281 0 CA-C-N 116.353 -0.385 . . . . 0.0 110.397 179.809 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 135' ' ' ILE . . . . . 0.526 HG13 ' O ' ' A' ' 132' ' ' VAL . 0.2 OUTLIER -55.71 -36.63 43.52 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.368 0 CA-C-N 116.012 -0.54 . . . . 0.0 109.862 179.176 . . . . . . . . 3 3 . 1 . 026 nuclear build full ' A' A ' 136' ' ' GLY . . . . . 0.413 ' O ' ' HB3' ' A' ' 139' ' ' TYR . . . -52.77 -42.28 59.06 Favored Glycine 0 C--N 1.334 0.437 0 C-N-CA 120.396 -0.907 . . . . 0.0 111.686 178.86 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 137' ' ' LEU . . . . . . . . . . . . . 49.1 tp -64.52 -49.25 72.02 Favored 'General case' 0 C--N 1.33 -0.261 0 N-CA-C 110.187 -0.301 . . . . 0.0 110.187 179.161 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 138' ' ' VAL . . . . . . . . . . . . . 59.9 t -54.82 -33.12 27.4 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.928 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.238 179.847 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 139' ' ' TYR . . . . . 0.413 ' HB3' ' O ' ' A' ' 136' ' ' GLY . 18.2 t80 -63.0 -43.32 99.13 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 115.867 -0.606 . . . . 0.0 110.112 178.74 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 140' ' ' TYR . . . . . 0.472 ' HE2' HD22 ' A' ' 104' ' ' LEU . 29.1 m-85 -63.75 -44.49 93.34 Favored 'General case' 0 C--N 1.332 -0.171 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.025 179.658 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 141' ' ' LEU . . . . . 0.445 ' HA ' ' SD ' ' A' ' 145' ' ' MET . 10.4 mp -55.99 -34.37 65.69 Favored 'General case' 0 C--N 1.332 -0.191 0 CA-C-N 116.449 -0.341 . . . . 0.0 110.96 179.887 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 22.2 t -94.62 -17.3 7.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.111 179.85 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . -68.96 -140.61 0.1 OUTLIER Glycine 0 CA--C 1.521 0.441 0 C-N-CA 121.034 -0.603 . . . . 0.0 113.218 -179.789 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 144' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_exo -51.88 -23.58 16.65 Favored 'Trans proline' 0 C--N 1.35 0.614 0 C-N-CA 122.841 2.361 . . . . 0.0 113.004 -179.597 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 145' ' ' MET . . . . . 0.445 ' SD ' ' HA ' ' A' ' 141' ' ' LEU . 34.9 mtt -54.1 -35.68 62.39 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.354 -0.384 . . . . 0.0 111.734 -179.648 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 146' ' ' THR . . . . . . . . . . . . . 46.0 p -79.1 -32.1 44.5 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.83 0.347 . . . . 0.0 111.265 -179.413 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 43.3 tt0 -61.96 -48.91 78.29 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 116.114 -0.494 . . . . 0.0 111.108 -179.917 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 148' ' ' SER . . . . . . . . . . . . . 51.6 m -70.56 -44.89 66.49 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.654 -179.342 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 149' ' ' ALA . . . . . 0.564 ' HB2' ' HB2' ' A' ' 91' ' ' ALA . . . -60.31 -55.08 38.0 Favored 'General case' 0 C--N 1.329 -0.291 0 N-CA-C 112.065 0.395 . . . . 0.0 112.065 -179.256 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 150' ' ' SER . . . . . 0.489 ' HA ' ' HB3' ' A' ' 157' ' ' LYS . 67.6 m -64.03 -8.03 10.48 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.415 -0.357 . . . . 0.0 111.09 -179.681 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 151' ' ' GLN . . . . . . . . . . . . . 98.8 mt-30 -120.99 7.51 10.36 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.342 -0.39 . . . . 0.0 111.193 179.959 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 152' ' ' ARG . . . . . 0.534 ' HA ' ' HE ' ' A' ' 152' ' ' ARG . 5.3 tpm_? -85.55 -52.49 5.79 Favored 'General case' 0 C--N 1.332 -0.165 0 CA-C-O 120.841 0.353 . . . . 0.0 110.678 179.944 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 153' ' ' SER . . . . . 0.653 ' HB2' HG12 ' A' ' 156' ' ' ILE . 18.6 m -158.24 172.9 17.53 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 115.949 -0.568 . . . . 0.0 110.617 179.168 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 154' ' ' SER . . . . . . . . . . . . . 48.4 t -72.17 -40.26 68.08 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.512 179.455 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -77.45 -30.21 54.19 Favored Glycine 0 CA--C 1.518 0.274 0 C-N-CA 120.986 -0.626 . . . . 0.0 112.998 179.917 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 156' ' ' ILE . . . . . 0.653 HG12 ' HB2' ' A' ' 153' ' ' SER . 34.9 mm -58.84 -46.76 90.87 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.226 0 N-CA-C 111.974 0.361 . . . . 0.0 111.974 -179.264 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 157' ' ' LYS . . . . . 0.489 ' HB3' ' HA ' ' A' ' 150' ' ' SER . 6.5 ptpp? -60.64 -35.67 76.76 Favored 'General case' 0 C--N 1.331 -0.234 0 N-CA-C 111.588 0.218 . . . . 0.0 111.588 -179.394 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 49.0 m -66.24 -44.53 83.46 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.941 0.401 . . . . 0.0 111.236 -179.752 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 159' ' ' LEU . . . . . 0.459 HD21 ' HB3' ' A' ' 215' ' ' ALA . 5.1 mt -68.64 -37.66 79.87 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.544 -179.743 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 160' ' ' TYR . . . . . 0.406 ' OH ' ' HB3' ' A' ' 145' ' ' MET . 13.8 t80 -68.55 -43.24 77.1 Favored 'General case' 0 C--N 1.327 -0.407 0 N-CA-C 112.267 0.469 . . . . 0.0 112.267 -178.705 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 161' ' ' VAL . . . . . 0.415 HG23 ' N ' ' A' ' 162' ' ' ARG . 24.0 m -63.78 -46.21 95.07 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 C-N-CA 120.989 -0.284 . . . . 0.0 111.717 -179.23 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 162' ' ' ARG . . . . . 0.415 ' N ' HG23 ' A' ' 161' ' ' VAL . 24.9 tpt180 -69.25 -48.63 61.32 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.815 0.34 . . . . 0.0 111.491 -179.76 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 163' ' ' LEU . . . . . . . . . . . . . 1.5 mp -60.89 -54.8 40.62 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.089 -0.505 . . . . 0.0 111.937 -179.183 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 164' ' ' ARG . . . . . . . . . . . . . 6.1 tmm_? -55.94 -50.52 70.53 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 116.073 -0.512 . . . . 0.0 112.179 -178.498 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 165' ' ' ASN . . . . . 0.507 ' O ' HG23 ' A' ' 169' ' ' VAL . 4.9 m-20 -52.7 -51.52 59.97 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-O 120.662 0.268 . . . . 0.0 111.458 -179.261 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 166' ' ' LEU . . . . . 0.503 ' O ' ' HG ' ' A' ' 170' ' ' LEU . 3.4 tt -62.6 -52.55 62.92 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 116.385 -0.37 . . . . 0.0 111.713 -179.566 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 167' ' ' THR . . . . . . . . . . . . . 85.1 m -54.72 -53.17 58.46 Favored 'General case' 0 C--N 1.329 -0.296 0 N-CA-C 112.734 0.642 . . . . 0.0 112.734 -178.64 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 168' ' ' VAL . . . . . . . . . . . . . 81.8 t -55.53 -44.34 75.94 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 N-CA-C 112.281 0.474 . . . . 0.0 112.281 -178.723 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 169' ' ' VAL . . . . . 0.507 HG23 ' O ' ' A' ' 165' ' ' ASN . 68.8 t -57.93 -65.19 0.45 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.367 0 N-CA-C 112.409 0.522 . . . . 0.0 112.409 -179.039 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 170' ' ' LEU . . . . . 0.503 ' HG ' ' O ' ' A' ' 166' ' ' LEU . 0.7 OUTLIER -62.4 -31.68 72.4 Favored 'General case' 0 C--N 1.332 -0.195 0 N-CA-C 112.453 0.538 . . . . 0.0 112.453 -178.355 . . . . . . . . 3 3 . 1 . 026 nuclear build full ' A' A ' 171' ' ' TRP . . . . . 0.779 ' HE1' H203 ' A' ' 301' ' ' RET . 5.8 m0 -70.12 -31.2 68.62 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-O 120.816 0.341 . . . . 0.0 110.658 179.48 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 172' ' ' ALA . . . . . 0.437 ' HA ' ' CZ ' ' A' ' 134' ' ' PHE . . . -74.21 -6.86 50.3 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.799 -179.763 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 173' ' ' ILE . . . . . 0.504 ' O ' HG12 ' A' ' 177' ' ' ILE . 34.9 mm -85.95 -21.76 7.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 115.901 -0.59 . . . . 0.0 110.383 179.43 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 174' ' ' TYR . . . . . . . . . . . . . 15.7 m-85 -54.42 -50.72 83.5 Favored Pre-proline 0 N--CA 1.463 0.222 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.744 -179.735 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 175' ' ' PRO . . . . . 0.407 ' HB3' ' HZ ' ' A' ' 127' ' ' PHE . 80.3 Cg_exo -46.13 -31.02 8.22 Favored 'Trans proline' 0 C--N 1.352 0.732 0 C-N-CA 122.131 1.887 . . . . 0.0 112.155 179.83 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 176' ' ' PHE . . . . . 0.455 ' O ' ' HG ' ' A' ' 180' ' ' LEU . 74.4 m-85 -80.7 -49.97 10.51 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.88 -0.6 . . . . 0.0 111.826 -179.783 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 177' ' ' ILE . . . . . 0.504 HG12 ' O ' ' A' ' 173' ' ' ILE . 5.3 mm -62.82 -36.33 75.03 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.525 0 N-CA-C 112.454 0.539 . . . . 0.0 112.454 -177.958 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 178' ' ' TRP . . . . . 0.449 ' HH2' ' HB2' ' A' ' 123' ' ' ARG . 71.3 t90 -71.27 -47.55 56.29 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.827 0.346 . . . . 0.0 110.997 -179.89 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 179' ' ' LEU . . . . . 0.441 HD23 HD23 ' A' ' 180' ' ' LEU . 0.5 OUTLIER -69.84 -54.57 12.9 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.677 -179.045 . . . . . . . . 3 3 . 1 . 026 nuclear build full ' A' A ' 180' ' ' LEU . . . . . 0.597 HD22 HD11 ' A' ' 187' ' ' LEU . 26.4 mt -65.06 -39.42 93.24 Favored 'General case' 0 C--N 1.328 -0.355 0 C-N-CA 121.025 -0.27 . . . . 0.0 111.469 -179.252 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . -62.26 -179.38 3.93 Favored Glycine 0 C--N 1.335 0.474 0 C-N-CA 120.031 -1.08 . . . . 0.0 112.196 179.074 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 182' ' ' PRO . . . . . 0.561 ' HA ' ' HB2' ' A' ' 186' ' ' ALA . 72.6 Cg_exo -48.85 -44.12 32.89 Favored 'Trans proline' 0 CA--C 1.536 0.623 0 C-N-CA 122.784 2.323 . . . . 0.0 113.87 179.896 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 183' ' ' PRO . . . . . . . . . . . . . 87.8 Cg_exo -47.62 -26.92 7.11 Favored 'Trans proline' 0 C--N 1.356 0.947 0 C-N-CA 122.279 1.986 . . . . 0.0 113.398 -179.782 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 184' ' ' GLY . . . . . . . . . . . . . . . -120.02 -125.92 3.36 Favored Glycine 0 N--CA 1.45 -0.369 0 C-N-CA 120.271 -0.966 . . . . 0.0 113.212 -179.598 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 185' ' ' VAL . . . . . . . . . . . . . 6.1 m -60.45 -27.58 40.35 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.369 0 N-CA-C 112.319 0.489 . . . . 0.0 112.319 -179.315 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 186' ' ' ALA . . . . . 0.561 ' HB2' ' HA ' ' A' ' 182' ' ' PRO . . . 58.23 82.79 0.13 Allowed 'General case' 0 C--N 1.331 -0.214 0 CA-C-O 120.801 0.334 . . . . 0.0 111.697 179.613 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 187' ' ' LEU . . . . . 0.597 HD11 HD22 ' A' ' 180' ' ' LEU . 8.4 mt -92.21 -49.78 6.0 Favored 'General case' 0 C--N 1.333 -0.151 0 CA-C-N 116.297 -0.411 . . . . 0.0 111.271 179.853 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 188' ' ' LEU . . . . . 0.471 ' HB3' ' H ' ' A' ' 189' ' ' THR . 4.3 mm? -91.16 -161.3 0.8 Allowed 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.002 -0.545 . . . . 0.0 111.571 -179.051 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 189' ' ' THR . . . . . 0.471 ' H ' ' HB3' ' A' ' 188' ' ' LEU . 21.6 m -92.76 137.86 23.89 Favored Pre-proline 0 C--N 1.329 -0.326 0 CA-C-N 115.704 -0.68 . . . . 0.0 110.917 -179.479 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 190' ' ' PRO . . . . . 0.456 ' O ' HG23 ' A' ' 194' ' ' VAL . 95.5 Cg_exo -44.86 -50.04 8.97 Favored 'Trans proline' 0 C--N 1.35 0.626 0 C-N-CA 122.674 2.249 . . . . 0.0 113.259 -179.951 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 191' ' ' THR . . . . . 0.419 HG22 HG22 ' A' ' 189' ' ' THR . 9.7 t -56.26 -39.79 73.18 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-O 120.668 0.271 . . . . 0.0 111.434 -179.606 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 192' ' ' VAL . . . . . 0.454 HG23 ' HB ' ' A' ' 189' ' ' THR . 72.8 t -64.71 -48.66 83.69 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.358 -0.383 . . . . 0.0 111.102 179.93 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 193' ' ' ASP . . . . . . . . . . . . . 27.0 t70 -57.12 -44.58 83.44 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.136 -0.484 . . . . 0.0 111.063 -179.875 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 194' ' ' VAL . . . . . 0.456 HG23 ' O ' ' A' ' 190' ' ' PRO . 89.3 t -60.82 -35.86 67.42 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.247 0 CA-C-N 116.132 -0.486 . . . . 0.0 110.776 179.953 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 195' ' ' ALA . . . . . . . . . . . . . . . -60.1 -47.83 84.26 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-N 116.429 -0.35 . . . . 0.0 111.003 179.583 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 196' ' ' LEU . . . . . . . . . . . . . 86.1 mt -66.58 -42.82 86.39 Favored 'General case' 0 C--N 1.332 -0.158 0 CA-C-N 116.388 -0.369 . . . . 0.0 110.5 179.489 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 197' ' ' ILE . . . . . . . . . . . . . 15.6 mm -56.99 -59.53 3.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.077 -0.51 . . . . 0.0 110.341 179.221 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 198' ' ' VAL . . . . . . . . . . . . . 52.9 t -52.16 -34.76 18.29 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.5 0 CA-C-N 115.717 -0.674 . . . . 0.0 109.375 178.388 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 199' ' ' TYR . . . . . . . . . . . . . 57.5 t80 -69.54 -32.91 72.01 Favored 'General case' 0 C--N 1.331 -0.204 0 CA-C-N 115.462 -0.79 . . . . 0.0 110.623 -179.844 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 200' ' ' LEU . . . . . 0.446 ' O ' HG12 ' A' ' 203' ' ' VAL . 34.6 mt -67.75 -41.55 83.21 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 115.885 -0.598 . . . . 0.0 111.081 -179.896 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 201' ' ' ASP . . . . . 0.452 ' OD2' ' H14' ' A' ' 301' ' ' RET . 1.0 OUTLIER -73.48 -35.02 65.63 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-O 121.147 0.499 . . . . 0.0 110.273 179.447 . . . . . . . . 3 3 . 1 . 026 nuclear build full ' A' A ' 202' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -69.45 -28.38 66.06 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 115.495 -0.775 . . . . 0.0 111.924 -179.823 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 203' ' ' VAL . . . . . 0.446 HG12 ' O ' ' A' ' 200' ' ' LEU . 9.5 p -82.44 -37.75 14.68 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.183 0 N-CA-C 111.804 0.298 . . . . 0.0 111.804 -178.831 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 204' ' ' THR . . . . . . . . . . . . . 88.9 m -67.35 -41.71 84.68 Favored 'General case' 0 C--N 1.33 -0.279 0 C-N-CA 120.798 -0.361 . . . . 0.0 111.297 179.664 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 205' ' ' LYS . . . . . 0.71 ' HE2' ' HB2' ' A' ' 47' ' ' ALA . 57.3 mttp -78.39 -51.56 9.87 Favored 'General case' 0 C--N 1.326 -0.455 0 N-CA-C 112.238 0.458 . . . . 0.0 112.238 -178.601 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 84.8 t -73.22 -37.37 52.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 N-CA-C 111.735 0.272 . . . . 0.0 111.735 -179.514 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 207' ' ' GLY . . . . . . . . . . . . . . . -71.52 -52.62 12.08 Favored Glycine 0 N--CA 1.453 -0.219 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.603 -179.654 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 208' ' ' PHE . . . . . 0.446 ' O ' ' HB2' ' A' ' 212' ' ' ALA . 10.1 t80 -59.6 -40.46 87.54 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-O 120.71 0.29 . . . . 0.0 110.477 179.648 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 209' ' ' GLY . . . . . 0.476 ' O ' ' HB3' ' A' ' 212' ' ' ALA . . . -70.18 -39.27 72.39 Favored Glycine 0 N--CA 1.451 -0.315 0 CA-C-N 115.699 -0.682 . . . . 0.0 113.302 -179.734 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 210' ' ' PHE . . . . . . . . . . . . . 1.1 m-85 -68.35 -43.0 78.41 Favored 'General case' 0 CA--C 1.508 -0.67 0 N-CA-C 107.794 -1.187 . . . . 0.0 107.794 179.099 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 211' ' ' ILE . . . . . . . . . . . . . 85.7 mt -67.49 -28.85 43.52 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.815 0 CA-C-N 114.296 -1.32 . . . . 0.0 107.548 176.688 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 212' ' ' ALA . . . . . 0.476 ' HB3' ' O ' ' A' ' 209' ' ' GLY . . . -67.0 -40.86 87.43 Favored 'General case' 0 N--CA 1.45 -0.472 0 CA-C-N 114.599 -1.182 . . . . 0.0 110.494 179.876 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 213' ' ' LEU . . . . . . . . . . . . . 91.0 mt -70.35 -52.2 24.33 Favored 'General case' 0 C--N 1.33 -0.239 0 CA-C-N 115.304 -0.862 . . . . 0.0 111.754 -179.407 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 214' ' ' ASP . . . . . . . . . . . . . 45.4 m-20 -50.04 -54.63 18.98 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.218 -0.447 . . . . 0.0 111.847 -179.277 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 215' ' ' ALA . . . . . 0.459 ' HB3' HD21 ' A' ' 159' ' ' LEU . . . -60.46 -54.49 44.87 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.432 -0.349 . . . . 0.0 111.541 -179.448 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 216' ' ' ALA . . . . . . . . . . . . . . . -55.86 -32.51 63.71 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-O 120.926 0.394 . . . . 0.0 111.317 -179.763 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 217' ' ' ALA . . . . . . . . . . . . . . . -65.57 -39.89 92.15 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.03 -0.532 . . . . 0.0 110.601 179.877 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 218' ' ' THR . . . . . . . . . . . . . 54.7 m -64.86 -44.0 91.16 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 115.993 -0.549 . . . . 0.0 110.757 179.588 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 219' ' ' LEU . . . . . . . . . . . . . 19.1 mt -68.36 -25.21 64.97 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.028 -0.533 . . . . 0.0 110.617 179.903 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 220' ' ' ARG . . . . . . . . . . . . . 62.8 ttp180 -84.28 -31.4 24.95 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 115.783 -0.644 . . . . 0.0 111.453 -179.712 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 221' ' ' ALA . . . . . . . . . . . . . . . -82.91 -20.47 35.34 Favored 'General case' 0 C--N 1.33 -0.251 0 N-CA-C 112.316 0.487 . . . . 0.0 112.316 -178.936 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 222' ' ' GLU . . . . . . . . . . . . . 10.9 pt-20 -73.71 -14.77 61.2 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-O 120.768 0.318 . . . . 0.0 111.218 -179.388 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 223' ' ' HIS . . . . . . . . . . . . . 37.2 m80 -70.69 -34.33 71.85 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.276 -0.42 . . . . 0.0 110.75 179.847 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 224' ' ' GLY . . . . . . . . . . . . . . . -94.68 -46.82 2.85 Favored Glycine 0 C--N 1.331 0.303 0 C-N-CA 120.882 -0.675 . . . . 0.0 112.34 179.948 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 225' ' ' GLU . . . . . . . . . . . . . 9.9 mm-40 -99.55 119.77 38.59 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.764 0.316 . . . . 0.0 110.738 179.93 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 226' ' ' SER . . . . . . . . . . . . . 45.1 t -102.19 -57.64 2.03 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.291 -0.413 . . . . 0.0 111.064 -179.86 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 227' ' ' LEU . . . . . . . . . . . . . 61.5 tp -124.32 132.76 53.57 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.097 -0.501 . . . . 0.0 111.088 -179.764 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 228' ' ' ALA . . . . . . . . . . . . . . . -89.18 160.36 17.02 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.123 -0.49 . . . . 0.0 111.027 179.915 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 229' ' ' GLY . . . . . . . . . . . . . . . 112.39 73.65 0.66 Allowed Glycine 0 N--CA 1.452 -0.273 0 C-N-CA 120.76 -0.734 . . . . 0.0 112.343 -179.911 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 230' ' ' VAL . . . . . . . . . . . . . 39.9 t -85.6 140.41 15.97 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-O 120.781 0.324 . . . . 0.0 111.184 -179.915 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 231' ' ' ASP . . . . . . . . . . . . . 5.0 p-10 -113.23 109.1 18.2 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.854 179.9 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 232' ' ' THR . . . . . . . . . . . . . 4.9 t -153.24 136.25 15.52 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.016 -0.538 . . . . 0.0 110.873 179.944 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 233' ' ' ASP . . . . . . . . . . . . . 8.7 m-20 -85.49 -66.76 0.86 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.278 -0.419 . . . . 0.0 110.938 -179.876 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 234' ' ' THR . . . . . . . . . . . . . 5.2 t -105.69 143.69 27.35 Favored Pre-proline 0 C--N 1.33 -0.266 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.121 -179.904 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 235' ' ' PRO . . . . . . . . . . . . . 34.8 Cg_endo -65.08 -47.42 4.7 Favored 'Trans proline' 0 C--N 1.35 0.612 0 C-N-CA 122.383 2.056 . . . . 0.0 112.431 -179.992 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 236' ' ' ALA . . . . . . . . . . . . . . . -55.16 145.07 22.14 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.262 -0.426 . . . . 0.0 111.071 -179.85 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 237' ' ' VAL . . . . . . . . . . . . . 14.8 p -100.56 146.2 9.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.308 -179.654 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 238' ' ' ALA . . . . . . . . . . . . . . . -132.44 174.97 9.7 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 115.991 -0.55 . . . . 0.0 110.905 179.84 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 239' ' ' ASP . . . . . . . . . . . . . 3.7 p30 -76.46 175.85 8.8 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.814 -179.981 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 240' ' ' LEU . . . . . . . . . . . . . 1.2 pp -149.21 15.48 0.91 Allowed 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.084 -179.923 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 241' ' ' GLU . . . . . . . . . . . . . 8.6 tp10 -67.0 115.48 6.77 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.625 179.999 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 242' ' ' HIS . . . . . . . . . . . . . 28.1 m80 -79.05 139.19 38.2 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.29 -0.414 . . . . 0.0 111.0 -179.736 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 243' ' ' HIS . . . . . . . . . . . . . 86.9 m-70 -86.41 121.35 28.85 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.878 -179.966 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 244' ' ' HIS . . . . . . . . . . . . . 51.0 p-80 -85.64 164.78 17.5 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.888 -179.917 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 245' ' ' HIS . . . . . . . . . . . . . 83.8 m-70 -135.87 5.35 3.09 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.128 -0.487 . . . . 0.0 111.0 179.918 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 246' ' ' HIS . . . . . . . . . . . . . 55.8 t-80 -68.41 -33.18 73.77 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.739 179.975 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 247' ' ' HIS . . . . . . . . . . . . . 57.6 t60 . . . . . 0 C--O 1.25 1.09 0 CA-C-O 118.191 -0.909 . . . . 0.0 111.042 -179.901 . . . . . . . . 0 0 . 1 . 026 nuclear build full ' A' A ' 301' ' ' RET . . . . . 0.779 H203 ' HE1' ' A' ' 171' ' ' TRP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 1' ' ' MET . . . . . 0.501 ' HG2' HG12 ' A' ' 2' ' ' VAL . 0.0 OUTLIER . . . . . 0 N--CA 1.485 1.276 0 CA-C-O 120.755 0.312 . . . . 0.0 110.992 . . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 2' ' ' VAL . . . . . 0.501 HG12 ' HG2' ' A' ' 1' ' ' MET . 7.3 p -170.37 -37.02 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.331 -0.224 0 CA-C-N 116.288 -0.415 . . . . 0.0 111.442 -179.891 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -113.46 -44.46 0.78 Allowed Glycine 0 N--CA 1.452 -0.27 0 C-N-CA 120.724 -0.75 . . . . 0.0 112.975 -179.618 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 4' ' ' LEU . . . . . 0.453 HD12 HD22 ' A' ' 7' ' ' LEU . 24.7 tp -57.04 -35.21 69.04 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.828 0.347 . . . . 0.0 111.265 -179.693 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 74.1 p -54.87 -37.88 66.82 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 116.211 -0.45 . . . . 0.0 112.015 -179.637 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 32.1 p -53.84 -35.29 61.32 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 120.823 0.344 . . . . 0.0 111.44 -179.452 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 7' ' ' LEU . . . . . 0.48 HD21 ' O ' ' A' ' 191' ' ' THR . 9.0 mp -58.6 -53.42 58.58 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.227 -179.83 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 8' ' ' PHE . . . . . 0.543 ' HB2' ' HB2' ' A' ' 55' ' ' ALA . 69.9 m-85 -60.46 -32.47 71.42 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.002 -0.544 . . . . 0.0 110.887 -179.837 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 9' ' ' TRP . . . . . . . . . . . . . 32.2 m95 -64.4 -44.39 91.43 Favored 'General case' 0 C--N 1.327 -0.371 0 N-CA-C 109.563 -0.532 . . . . 0.0 109.563 179.612 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 78.8 mt -63.56 -36.76 84.87 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 115.472 -0.785 . . . . 0.0 110.09 179.243 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -64.22 -37.13 94.11 Favored Glycine 0 N--CA 1.448 -0.535 0 CA-C-N 115.619 -0.719 . . . . 0.0 111.806 179.332 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -65.45 -37.51 87.09 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-O 120.856 0.36 . . . . 0.0 110.337 179.634 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 50.1 mm -59.14 -50.22 80.55 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.222 0 CA-C-N 115.937 -0.574 . . . . 0.0 110.432 179.119 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -58.42 -35.09 77.78 Favored Glycine 0 N--CA 1.45 -0.411 0 C-N-CA 120.772 -0.727 . . . . 0.0 112.12 179.536 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 15' ' ' MET . . . . . 0.451 ' HE3' ' CB ' ' A' ' 47' ' ' ALA . 22.7 mmt -66.37 -43.29 86.35 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-O 120.752 0.311 . . . . 0.0 110.892 179.718 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -55.96 -43.71 77.79 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.462 179.739 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 60.6 t -60.71 -46.59 95.68 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.283 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.989 179.903 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -66.17 -49.2 59.13 Favored Glycine 0 C--N 1.33 0.246 0 C-N-CA 120.787 -0.72 . . . . 0.0 112.41 179.685 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 23.6 m -49.61 -42.94 46.08 Favored 'General case' 0 C--N 1.327 -0.39 0 C-N-CA 122.365 0.266 . . . . 0.0 111.579 -179.458 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 65.7 mt -72.38 -42.16 65.55 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.478 -0.328 . . . . 0.0 111.753 179.858 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -61.61 -30.09 70.46 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.312 -0.404 . . . . 0.0 111.577 -179.362 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 22' ' ' PHE . . . . . 0.699 ' HB2' HG22 ' A' ' 41' ' ' VAL . 6.5 m-85 -90.88 -30.76 16.74 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.41 -0.359 . . . . 0.0 111.262 -179.594 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -72.36 -50.38 27.08 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.956 0.407 . . . . 0.0 111.558 -179.548 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 24' ' ' TRP . . . . . . . . . . . . . 4.1 t-105 -62.68 -43.12 99.62 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 115.978 -0.556 . . . . 0.0 111.171 -179.72 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -80.15 -17.68 51.82 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.398 -0.365 . . . . 0.0 110.862 179.855 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -73.46 -33.79 58.13 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.876 -0.678 . . . . 0.0 112.576 179.973 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 39.7 ptt180 -84.95 13.91 5.48 Favored 'General case' 0 C--N 1.332 -0.195 0 CA-C-O 120.888 0.375 . . . . 0.0 110.887 -179.983 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 22.1 t70 -143.22 82.89 1.77 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.082 -0.508 . . . . 0.0 110.692 179.782 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -168.19 -74.51 0.02 OUTLIER 'General case' 0 C--N 1.332 -0.194 0 CA-C-N 116.111 -0.495 . . . . 0.0 111.177 -179.848 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -169.78 -155.23 9.88 Favored Glycine 0 C--N 1.331 0.295 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.627 -179.955 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 46.3 t -101.2 -62.34 1.26 Allowed 'General case' 0 C--N 1.332 -0.188 0 CA-C-O 120.819 0.343 . . . . 0.0 110.989 -179.851 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -61.02 -28.88 69.54 Favored Glycine 0 C--N 1.332 0.306 0 C-N-CA 120.796 -0.716 . . . . 0.0 112.644 -179.96 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 37.4 mt-10 -69.43 -25.69 64.24 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.742 0.306 . . . . 0.0 110.99 -179.941 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 34' ' ' ARG . . . . . . . . . . . . . 17.5 tpt180 -53.13 -28.72 27.23 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.076 -0.511 . . . . 0.0 111.478 -179.654 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 41.0 mmt180 -60.17 -43.31 95.91 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-O 120.833 0.349 . . . . 0.0 111.207 -179.843 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 82.0 m-85 -71.72 -29.73 64.87 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.294 -0.412 . . . . 0.0 111.348 -179.779 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 37' ' ' TYR . . . . . 0.467 ' O ' HG23 ' A' ' 41' ' ' VAL . 70.0 m-85 -75.79 -54.98 6.09 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.189 -0.459 . . . . 0.0 111.182 -179.549 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 14.8 p -56.61 -36.52 48.64 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-O 121.007 0.432 . . . . 0.0 110.578 179.774 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 28.5 m -66.06 -51.07 61.54 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 115.9 -0.591 . . . . 0.0 110.82 179.457 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 40' ' ' LEU . . . . . 0.459 HD12 HD12 ' A' ' 43' ' ' ILE . 49.3 tp -59.12 -47.77 84.07 Favored 'General case' 0 C--O 1.235 0.314 0 CA-C-N 115.922 -0.581 . . . . 0.0 110.886 179.964 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 41' ' ' VAL . . . . . 0.699 HG22 ' HB2' ' A' ' 22' ' ' PHE . 89.9 t -60.63 -34.73 59.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.097 179.195 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 42' ' ' GLY . . . . . 0.428 ' O ' HG12 ' A' ' 46' ' ' ILE . . . -60.98 -38.59 95.74 Favored Glycine 0 N--CA 1.447 -0.587 0 CA-C-N 115.712 -0.676 . . . . 0.0 112.309 179.751 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 43' ' ' ILE . . . . . 0.76 HG22 ' HE3' ' A' ' 205' ' ' LYS . 0.1 OUTLIER -66.97 -56.94 11.82 Favored 'Isoleucine or valine' 0 C--O 1.232 0.145 0 CA-C-O 120.651 0.262 . . . . 0.0 110.989 179.903 . . . . . . . . 3 3 . 1 . 027 nuclear build full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 48.1 t -62.39 -21.31 65.26 Favored 'General case' 0 C--O 1.233 0.185 0 CA-C-O 120.833 0.349 . . . . 0.0 111.241 -179.892 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -77.06 -58.53 3.39 Favored Glycine 0 CA--C 1.519 0.305 0 C-N-CA 120.754 -0.736 . . . . 0.0 112.642 -179.758 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 46' ' ' ILE . . . . . 0.428 HG12 ' O ' ' A' ' 42' ' ' GLY . 16.1 pt -58.32 -35.87 55.63 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.157 0 CA-C-O 120.932 0.396 . . . . 0.0 110.726 179.94 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 47' ' ' ALA . . . . . 0.687 ' HB2' ' HE2' ' A' ' 205' ' ' LYS . . . -67.96 -39.89 83.29 Favored 'General case' 0 C--N 1.326 -0.45 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.771 179.056 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 48' ' ' ALA . . . . . 0.438 ' HB2' ' HB3' ' A' ' 15' ' ' MET . . . -54.58 -47.29 73.49 Favored 'General case' 0 C--O 1.233 0.205 0 CA-C-N 116.007 -0.542 . . . . 0.0 111.046 179.897 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 27.5 m -72.08 -34.09 49.18 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.379 0 CA-C-N 116.047 -0.524 . . . . 0.0 111.009 -179.901 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -60.1 -41.49 92.65 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-O 121.017 0.436 . . . . 0.0 110.761 179.503 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 51' ' ' TYR . . . . . 0.421 ' HB3' ' O ' ' A' ' 8' ' ' PHE . 43.8 m-85 -73.24 -31.5 64.16 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 115.899 -0.592 . . . . 0.0 110.262 -179.982 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -66.26 -43.3 86.85 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 115.887 -0.597 . . . . 0.0 110.624 179.126 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 16.5 m -75.15 -37.72 40.54 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.166 0 CA-C-N 116.277 -0.419 . . . . 0.0 111.028 179.798 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 54' ' ' MET . . . . . 0.531 ' HG2' ' HG2' ' A' ' 71' ' ' PRO . 68.5 mtm -67.22 -34.42 77.43 Favored 'General case' 0 CA--C 1.52 -0.18 0 CA-C-O 121.213 0.53 . . . . 0.0 109.776 179.215 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 55' ' ' ALA . . . . . 0.543 ' HB2' ' HB2' ' A' ' 8' ' ' PHE . . . -66.53 -19.29 65.75 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-N 115.382 -0.827 . . . . 0.0 111.124 179.481 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 87.5 mt -94.95 -3.73 48.04 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.329 -0.396 . . . . 0.0 111.01 -179.927 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 85.57 24.48 42.63 Favored Glycine 0 C--N 1.331 0.271 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.712 179.939 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 58' ' ' VAL . . . . . 0.441 ' O ' ' HG3' ' A' ' 71' ' ' PRO . 48.3 t -86.84 142.36 13.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-O 120.714 0.293 . . . . 0.0 110.829 179.882 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 59' ' ' GLY . . . . . 0.638 ' HA3' ' HD3' ' A' ' 71' ' ' PRO . . . 81.33 -3.74 76.01 Favored Glycine 0 N--CA 1.449 -0.458 0 C-N-CA 120.807 -0.711 . . . . 0.0 112.569 -179.976 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 60' ' ' TRP . . . . . . . . . . . . . 14.4 m0 -70.73 101.08 2.0 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.809 0.338 . . . . 0.0 110.646 179.853 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 61' ' ' VAL . . . . . 0.422 ' HA ' ' HD3' ' A' ' 62' ' ' PRO . 3.2 p -105.5 125.42 33.46 Favored Pre-proline 0 CA--C 1.534 0.334 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.35 -179.982 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 62' ' ' PRO . . . . . 0.422 ' HD3' ' HA ' ' A' ' 61' ' ' VAL . 8.4 Cg_exo -71.52 148.32 53.67 Favored 'Trans proline' 0 C--N 1.35 0.644 0 C-N-CA 122.617 2.211 . . . . 0.0 112.06 179.729 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 77.9 t -142.23 92.43 0.52 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-N 116.112 -0.495 . . . . 0.0 110.894 -179.932 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . 59.67 -85.99 0.02 OUTLIER 'General case' 0 C--N 1.331 -0.209 0 CA-C-N 116.158 -0.473 . . . . 0.0 111.346 -179.865 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 10.2 tp10 -121.05 -24.61 5.52 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.438 -0.346 . . . . 0.0 110.604 179.902 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 66' ' ' ARG . . . . . . . . . . . . . 80.7 mtt180 -103.54 152.96 21.1 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.132 -0.486 . . . . 0.0 110.396 -179.88 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 94.1 m -116.0 127.41 54.91 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 120.955 0.407 . . . . 0.0 111.426 -179.536 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 10.7 t -104.71 146.26 12.18 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.24 0 CA-C-N 115.941 -0.572 . . . . 0.0 110.39 179.488 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 69' ' ' PHE . . . . . . . . . . . . . 12.2 m-85 -109.81 111.76 23.38 Favored 'General case' 0 N--CA 1.452 -0.358 0 N-CA-C 109.519 -0.549 . . . . 0.0 109.519 -179.572 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 70' ' ' VAL . . . . . 0.64 ' N ' ' HD2' ' A' ' 71' ' ' PRO . 0.5 OUTLIER -66.21 -40.42 35.77 Favored Pre-proline 0 C--N 1.321 -0.654 0 N-CA-C 112.428 0.529 . . . . 0.0 112.428 -179.507 . . . . . . . . 3 3 . 1 . 027 nuclear build full ' A' A ' 71' ' ' PRO . . . . . 0.64 ' HD2' ' N ' ' A' ' 70' ' ' VAL . 27.1 Cg_endo -63.23 -27.04 72.2 Favored 'Trans proline' 0 C--N 1.356 0.93 0 C-N-CA 121.779 1.652 . . . . 0.0 112.821 -179.03 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 61.0 ttp180 -73.25 -52.99 11.99 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 121.0 0.428 . . . . 0.0 110.212 179.629 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 73' ' ' TYR . . . . . 0.425 ' O ' HG13 ' A' ' 77' ' ' ILE . 52.9 m-85 -66.49 -34.4 77.84 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.012 -0.54 . . . . 0.0 110.716 179.758 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 74' ' ' ILE . . . . . 0.427 ' HB ' ' O ' ' A' ' 70' ' ' VAL . 0.4 OUTLIER -72.83 -37.69 55.39 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.209 0 CA-C-N 116.282 -0.417 . . . . 0.0 110.121 179.675 . . . . . . . . 3 3 . 1 . 027 nuclear build full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 18.2 t70 -58.02 -37.79 74.99 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-N 116.212 -0.449 . . . . 0.0 109.863 179.226 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 76' ' ' TRP . . . . . . . . . . . . . 53.3 m0 -68.69 -42.16 78.19 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 115.894 -0.594 . . . . 0.0 110.601 179.428 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 77' ' ' ILE . . . . . 0.495 ' O ' ' HG3' ' A' ' 81' ' ' PRO . 86.1 mt -58.72 -28.67 37.96 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.062 -0.517 . . . . 0.0 111.016 179.567 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 45.5 mt -92.03 -38.89 11.96 Favored 'General case' 0 CA--C 1.534 0.343 0 N-CA-C 112.551 0.574 . . . . 0.0 112.551 -179.614 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 79' ' ' THR . . . . . 0.428 HG22 HD11 ' A' ' 46' ' ' ILE . 74.8 p -82.99 -52.43 6.68 Favored 'General case' 0 N--CA 1.465 0.299 0 N-CA-C 113.929 1.085 . . . . 0.0 113.929 -177.422 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 80' ' ' THR . . . . . 0.466 ' N ' ' HD2' ' A' ' 81' ' ' PRO . 39.2 m -48.01 -54.28 25.69 Favored Pre-proline 0 C--N 1.33 -0.252 0 N-CA-C 113.089 0.774 . . . . 0.0 113.089 -178.132 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 81' ' ' PRO . . . . . 0.495 ' HG3' ' O ' ' A' ' 77' ' ' ILE . 25.1 Cg_endo -60.14 -21.09 64.57 Favored 'Trans proline' 0 C--N 1.351 0.689 0 C-N-CA 121.481 1.454 . . . . 0.0 111.397 -179.683 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 82' ' ' LEU . . . . . . . . . . . . . 17.6 tp -77.03 -32.95 57.41 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 115.633 -0.712 . . . . 0.0 110.005 179.555 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 83' ' ' ILE . . . . . 0.517 HD13 HD13 ' A' ' 43' ' ' ILE . 41.4 mm -67.9 -53.14 32.57 Favored 'Isoleucine or valine' 0 C--O 1.233 0.206 0 CA-C-N 116.059 -0.519 . . . . 0.0 109.909 178.976 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 35.9 m -60.87 -29.86 46.22 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.219 0 CA-C-N 115.97 -0.559 . . . . 0.0 109.513 178.975 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 85' ' ' TYR . . . . . . . . . . . . . 78.8 t80 -68.52 -32.8 73.01 Favored 'General case' 0 N--CA 1.453 -0.303 0 CA-C-N 115.569 -0.741 . . . . 0.0 109.623 178.792 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 86' ' ' PHE . . . . . . . . . . . . . 8.8 t80 -62.36 -51.21 68.5 Favored 'General case' 0 C--N 1.333 -0.117 0 CA-C-N 115.87 -0.605 . . . . 0.0 109.733 179.298 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 10.5 mp -61.61 -29.63 70.17 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-N 115.83 -0.623 . . . . 0.0 110.136 179.339 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -69.96 -27.85 72.56 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.899 -0.667 . . . . 0.0 111.889 179.362 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 88.1 mt -74.29 -44.57 52.17 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-O 120.994 0.426 . . . . 0.0 110.597 179.587 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 43.4 mt -63.27 -28.4 70.0 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 115.75 -0.659 . . . . 0.0 111.05 -179.976 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -88.46 -39.88 13.89 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.379 -179.628 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 88.14 59.43 1.67 Allowed Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.662 -0.78 . . . . 0.0 112.26 -179.736 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 93' ' ' LEU . . . . . 0.417 ' HB3' ' HB2' ' A' ' 97' ' ' GLU . 45.6 mt -75.79 -175.97 3.17 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.849 0.357 . . . . 0.0 110.957 -179.883 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 94' ' ' ASP . . . . . . . . . . . . . 7.8 m-20 -109.12 171.93 7.14 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.057 -0.519 . . . . 0.0 110.709 179.847 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 66.2 m -55.07 -36.4 65.57 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.345 -179.653 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 96' ' ' ARG . . . . . 0.425 ' O ' HG13 ' A' ' 100' ' ' ILE . 38.1 ttp180 -73.26 -52.77 12.8 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.352 -0.386 . . . . 0.0 111.054 -179.687 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 97' ' ' GLU . . . . . 0.417 ' HB2' ' HB3' ' A' ' 93' ' ' LEU . 47.9 mt-10 -53.14 -48.3 68.04 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.404 -0.362 . . . . 0.0 111.441 -179.48 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 98' ' ' PHE . . . . . 0.451 ' O ' HG12 ' A' ' 102' ' ' ILE . 18.1 m-85 -55.91 -52.07 65.39 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.524 -0.307 . . . . 0.0 111.112 179.921 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -57.66 -28.09 59.59 Favored Glycine 0 N--CA 1.452 -0.277 0 C-N-CA 120.771 -0.728 . . . . 0.0 112.768 -179.72 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 100' ' ' ILE . . . . . 0.425 HG13 ' O ' ' A' ' 96' ' ' ARG . 95.7 mt -72.51 -42.69 63.84 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-O 120.839 0.352 . . . . 0.0 111.279 -179.787 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 48.3 t -69.35 -48.62 66.5 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.439 0 CA-C-N 116.222 -0.444 . . . . 0.0 111.577 -179.534 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 102' ' ' ILE . . . . . 0.451 HG12 ' O ' ' A' ' 98' ' ' PHE . 34.2 mm -59.79 -48.93 85.73 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.736 -179.284 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 15.1 t -58.77 -38.34 78.27 Favored 'General case' 0 C--O 1.233 0.198 0 CA-C-O 120.707 0.289 . . . . 0.0 111.083 -179.813 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 104' ' ' LEU . . . . . 0.474 ' O ' HG23 ' A' ' 108' ' ' VAL . 36.6 tp -58.98 -43.45 91.41 Favored 'General case' 0 C--N 1.332 -0.177 0 CA-C-O 120.986 0.422 . . . . 0.0 110.272 179.296 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 105' ' ' ASN . . . . . 0.676 HD21 HD13 ' A' ' 137' ' ' LEU . 0.8 OUTLIER -65.87 -27.69 68.41 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-N 116.019 -0.537 . . . . 0.0 110.644 -179.981 . . . . . . . . 3 3 . 1 . 027 nuclear build full ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 62.4 m -63.52 -57.31 10.59 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 116.372 -0.377 . . . . 0.0 111.031 -179.89 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 107' ' ' VAL . . . . . 0.423 HG12 ' O ' ' A' ' 104' ' ' LEU . 12.8 p -57.99 -36.35 56.01 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.184 0 CA-C-N 116.399 -0.364 . . . . 0.0 110.857 179.937 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 108' ' ' VAL . . . . . 0.474 HG23 ' O ' ' A' ' 104' ' ' LEU . 54.3 t -58.32 -45.39 89.4 Favored 'Isoleucine or valine' 0 C--O 1.234 0.282 0 CA-C-O 121.069 0.462 . . . . 0.0 110.675 179.351 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 109' ' ' MET . . . . . 0.456 ' HG2' ' O ' ' A' ' 105' ' ' ASN . 21.3 mmt -71.96 -31.81 66.67 Favored 'General case' 0 CA--C 1.516 -0.361 0 CA-C-N 115.921 -0.582 . . . . 0.0 110.57 179.942 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 110' ' ' LEU . . . . . 0.456 HD23 ' C ' ' A' ' 110' ' ' LEU . 4.0 tt -62.6 -34.14 76.4 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-N 115.98 -0.555 . . . . 0.0 109.54 178.854 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -67.78 -53.73 24.82 Favored 'General case' 0 C--N 1.332 -0.18 0 CA-C-N 115.761 -0.654 . . . . 0.0 110.667 179.468 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 112' ' ' GLY . . . . . 0.652 ' HA3' ' H21' ' A' ' 301' ' ' RET . . . -62.4 -38.89 97.04 Favored Glycine 0 C--N 1.332 0.309 0 C-N-CA 120.641 -0.79 . . . . 0.0 112.286 179.566 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 113' ' ' PHE . . . . . . . . . . . . . 4.3 t80 -53.61 -66.93 0.3 Allowed 'General case' 0 C--N 1.331 -0.236 0 CA-C-O 121.088 0.47 . . . . 0.0 110.194 179.718 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 114' ' ' ALA . . . . . 0.408 ' HB3' HD22 ' A' ' 126' ' ' LEU . . . -65.22 -17.67 64.68 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 115.767 -0.651 . . . . 0.0 110.491 179.287 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -58.54 -48.43 84.42 Favored Glycine 0 C--N 1.332 0.333 0 CA-C-N 115.784 -0.644 . . . . 0.0 111.914 179.42 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -78.32 -17.49 56.49 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.739 0.304 . . . . 0.0 110.988 179.322 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 117' ' ' MET . . . . . . . . . . . . . 21.1 mmt -84.95 13.9 5.49 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.098 -0.501 . . . . 0.0 111.353 -179.452 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 118' ' ' VAL . . . . . 0.466 HG21 ' HB3' ' A' ' 123' ' ' ARG . 33.6 m -81.4 139.01 48.03 Favored Pre-proline 0 C--N 1.33 -0.266 0 N-CA-C 111.838 0.31 . . . . 0.0 111.838 -179.398 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 119' ' ' PRO . . . . . . . . . . . . . 85.7 Cg_endo -92.22 -2.63 3.99 Favored 'Trans proline' 0 N--CA 1.455 -0.788 0 C-N-CA 122.91 2.407 . . . . 0.0 112.463 179.052 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -138.89 -110.34 0.91 Allowed Glycine 0 C--N 1.333 0.379 0 C-N-CA 120.675 -0.774 . . . . 0.0 112.863 -179.775 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 2.4 pp -127.07 15.29 3.56 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.192 0 N-CA-C 111.849 0.314 . . . . 0.0 111.849 -179.775 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 46.5 mt-10 -61.22 -18.54 58.83 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.906 0.384 . . . . 0.0 110.838 179.82 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 123' ' ' ARG . . . . . 0.582 ' HD2' ' HA2' ' A' ' 184' ' ' GLY . 24.4 ptt180 -51.46 -27.63 10.9 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 115.871 -0.604 . . . . 0.0 111.729 -179.92 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 124' ' ' TYR . . . . . . . . . . . . . 22.2 m-85 -75.15 -33.34 61.51 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.582 -0.281 . . . . 0.0 111.382 -179.524 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 125' ' ' ALA . . . . . . . . . . . . . . . -74.14 -56.64 4.67 Favored 'General case' 0 C--O 1.235 0.34 0 CA-C-O 120.96 0.41 . . . . 0.0 111.155 -179.933 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 126' ' ' LEU . . . . . 0.408 HD22 ' HB3' ' A' ' 114' ' ' ALA . 1.2 mt -53.48 -51.2 63.51 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.016 -0.538 . . . . 0.0 110.275 179.749 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 127' ' ' PHE . . . . . . . . . . . . . 11.0 t80 -65.29 -30.1 70.93 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.03 179.318 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 128' ' ' GLY . . . . . . . . . . . . . . . -49.02 -49.31 29.94 Favored Glycine 0 N--CA 1.45 -0.42 0 C-N-CA 120.179 -1.01 . . . . 0.0 110.581 178.703 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 129' ' ' MET . . . . . 0.479 ' HE3' ' HA2' ' A' ' 130' ' ' GLY . 0.0 OUTLIER -71.71 -27.84 63.29 Favored 'General case' 0 C--N 1.328 -0.351 0 N-CA-C 109.067 -0.716 . . . . 0.0 109.067 178.303 . . . . . . . . 3 3 . 1 . 027 nuclear build full ' A' A ' 130' ' ' GLY . . . . . 0.479 ' HA2' ' HE3' ' A' ' 129' ' ' MET . . . -60.68 -41.23 98.88 Favored Glycine 0 C--N 1.332 0.36 0 CA-C-N 115.712 -0.676 . . . . 0.0 112.241 179.49 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -71.9 -48.99 41.71 Favored 'General case' 0 C--N 1.331 -0.21 0 CA-C-O 120.627 0.251 . . . . 0.0 110.403 179.668 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 57.2 t -55.68 -46.5 79.51 Favored 'Isoleucine or valine' 0 C--O 1.234 0.271 0 CA-C-O 121.302 0.573 . . . . 0.0 109.506 178.826 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -62.29 -38.19 88.39 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 115.397 -0.82 . . . . 0.0 110.507 178.962 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 134' ' ' PHE . . . . . . . . . . . . . 82.3 t80 -55.71 -53.47 56.15 Favored 'General case' 0 N--CA 1.452 -0.371 0 CA-C-N 116.058 -0.519 . . . . 0.0 110.305 179.793 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 135' ' ' ILE . . . . . 0.434 ' O ' HG22 ' A' ' 138' ' ' VAL . 47.5 mt -55.95 -32.08 32.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 115.841 -0.618 . . . . 0.0 110.193 179.573 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . -62.54 -42.6 99.68 Favored Glycine 0 N--CA 1.448 -0.522 0 C-N-CA 120.176 -1.012 . . . . 0.0 111.232 178.738 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 137' ' ' LEU . . . . . 0.676 HD13 HD21 ' A' ' 105' ' ' ASN . 61.0 tp -66.27 -54.42 25.13 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.583 0.23 . . . . 0.0 110.855 179.617 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 138' ' ' VAL . . . . . 0.434 HG22 ' O ' ' A' ' 135' ' ' ILE . 3.8 m -55.05 -31.56 25.67 Favored 'Isoleucine or valine' 0 C--O 1.232 0.184 0 N-CA-C 109.891 -0.411 . . . . 0.0 109.891 -179.7 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 139' ' ' TYR . . . . . . . . . . . . . 14.2 t80 -61.37 -42.83 99.34 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 115.871 -0.604 . . . . 0.0 109.748 178.313 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 140' ' ' TYR . . . . . 0.437 ' HE2' HD22 ' A' ' 104' ' ' LEU . 21.7 m-85 -66.95 -45.71 76.94 Favored 'General case' 0 CA--C 1.529 0.153 0 CA-C-N 116.034 -0.53 . . . . 0.0 111.096 179.262 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 141' ' ' LEU . . . . . . . . . . . . . 11.2 mp -52.4 -37.41 56.51 Favored 'General case' 0 N--CA 1.464 0.23 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.791 -179.417 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 8.6 p -104.58 -5.28 9.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-O 120.927 0.394 . . . . 0.0 111.394 -179.514 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 143' ' ' GLY . . . . . 0.434 ' HA3' ' HD2' ' A' ' 144' ' ' PRO . . . -75.51 -130.89 0.3 Allowed Glycine 0 CA--C 1.521 0.427 0 C-N-CA 120.768 -0.729 . . . . 0.0 113.009 -179.625 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 144' ' ' PRO . . . . . 0.434 ' HD2' ' HA3' ' A' ' 143' ' ' GLY . 13.2 Cg_endo -56.21 -23.47 45.46 Favored 'Trans proline' 0 C--N 1.348 0.549 0 C-N-CA 122.741 2.294 . . . . 0.0 112.658 -179.587 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 145' ' ' MET . . . . . . . . . . . . . 50.4 mtt -56.96 -29.22 63.02 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.286 -0.415 . . . . 0.0 111.696 -179.652 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 146' ' ' THR . . . . . . . . . . . . . 72.9 p -77.28 -34.65 55.62 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.837 0.351 . . . . 0.0 110.91 -179.531 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 36.9 tt0 -75.92 -32.25 59.51 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 115.989 -0.55 . . . . 0.0 111.028 -179.869 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 148' ' ' SER . . . . . . . . . . . . . 48.2 t -70.83 -47.43 59.45 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.502 -179.659 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 149' ' ' ALA . . . . . 0.432 ' HB1' HG22 ' A' ' 156' ' ' ILE . . . -70.76 -30.57 67.11 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.294 -0.412 . . . . 0.0 111.748 -179.39 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 150' ' ' SER . . . . . 0.412 ' HB3' ' HD3' ' A' ' 157' ' ' LYS . 78.4 p -69.12 0.0 5.29 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.38 -0.373 . . . . 0.0 111.12 -179.878 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 151' ' ' GLN . . . . . . . . . . . . . 77.0 mt-30 -121.99 9.58 9.99 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.378 -0.374 . . . . 0.0 111.494 -179.836 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 25.6 mmm180 -91.45 -53.16 4.44 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-O 121.1 0.476 . . . . 0.0 110.789 -179.994 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 153' ' ' SER . . . . . 0.675 ' HB2' HG12 ' A' ' 156' ' ' ILE . 23.5 m -158.3 172.22 18.76 Favored 'General case' 0 C--N 1.324 -0.509 0 CA-C-N 115.643 -0.708 . . . . 0.0 110.481 179.232 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 154' ' ' SER . . . . . . . . . . . . . 46.9 t -72.05 -37.08 69.76 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-O 120.977 0.418 . . . . 0.0 110.142 179.073 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -77.43 -35.38 37.32 Favored Glycine 0 N--CA 1.45 -0.423 0 CA-C-N 115.818 -0.628 . . . . 0.0 112.902 179.83 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 156' ' ' ILE . . . . . 0.675 HG12 ' HB2' ' A' ' 153' ' ' SER . 38.0 mm -52.72 -38.74 28.36 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.164 0 CA-C-O 120.687 0.28 . . . . 0.0 111.515 -179.56 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 157' ' ' LYS . . . . . 0.412 ' HD3' ' HB3' ' A' ' 150' ' ' SER . 57.4 tptt -64.78 -40.53 95.41 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.434 -0.348 . . . . 0.0 111.175 -179.9 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 49.3 m -71.16 -42.73 68.74 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.415 -0.357 . . . . 0.0 111.342 -179.733 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 159' ' ' LEU . . . . . 0.474 HD23 HD13 ' A' ' 163' ' ' LEU . 4.7 tt -64.44 -40.83 96.47 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.998 -179.573 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 160' ' ' TYR . . . . . . . . . . . . . 29.0 t80 -73.29 -37.17 66.34 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.711 -179.204 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 161' ' ' VAL . . . . . 0.492 HG12 ' N ' ' A' ' 162' ' ' ARG . 1.0 OUTLIER -59.85 -50.52 79.78 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.746 0 CA-C-O 120.628 0.251 . . . . 0.0 111.623 -179.438 . . . . . . . . 3 3 . 1 . 027 nuclear build full ' A' A ' 162' ' ' ARG . . . . . 0.492 ' N ' HG12 ' A' ' 161' ' ' VAL . 99.8 mtt180 -69.5 -34.82 74.87 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-O 120.929 0.395 . . . . 0.0 111.254 179.989 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 163' ' ' LEU . . . . . 0.661 ' HG ' ' HB2' ' A' ' 208' ' ' PHE . 1.2 mp -65.49 -55.12 19.61 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 115.945 -0.57 . . . . 0.0 112.173 -178.831 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 164' ' ' ARG . . . . . . . . . . . . . 5.1 ppt_? -66.05 -41.22 91.13 Favored 'General case' 0 C--N 1.329 -0.286 0 N-CA-C 111.997 0.369 . . . . 0.0 111.997 -178.596 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 165' ' ' ASN . . . . . 0.489 ' O ' HG23 ' A' ' 169' ' ' VAL . 5.1 m-20 -54.35 -52.28 62.09 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-O 120.969 0.414 . . . . 0.0 111.024 -179.948 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 166' ' ' LEU . . . . . 0.516 ' O ' ' HG ' ' A' ' 170' ' ' LEU . 2.8 tt -64.99 -51.93 58.96 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 115.925 -0.579 . . . . 0.0 111.513 -179.377 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 167' ' ' THR . . . . . 0.431 ' O ' ' HB2' ' A' ' 171' ' ' TRP . 91.4 m -54.74 -52.81 61.37 Favored 'General case' 0 C--N 1.328 -0.357 0 N-CA-C 112.345 0.498 . . . . 0.0 112.345 -178.817 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 168' ' ' VAL . . . . . . . . . . . . . 53.0 t -54.54 -46.1 71.48 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 N-CA-C 112.22 0.452 . . . . 0.0 112.22 -179.044 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 169' ' ' VAL . . . . . 0.489 HG23 ' O ' ' A' ' 165' ' ' ASN . 77.5 t -56.04 -65.18 0.4 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 N-CA-C 112.019 0.378 . . . . 0.0 112.019 -179.18 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 170' ' ' LEU . . . . . 0.516 ' HG ' ' O ' ' A' ' 166' ' ' LEU . 0.6 OUTLIER -63.65 -31.09 72.15 Favored 'General case' 0 C--N 1.328 -0.341 0 N-CA-C 112.43 0.53 . . . . 0.0 112.43 -178.486 . . . . . . . . 3 3 . 1 . 027 nuclear build full ' A' A ' 171' ' ' TRP . . . . . 0.608 ' HE1' H203 ' A' ' 301' ' ' RET . 3.5 m0 -68.67 -30.87 69.65 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-O 120.941 0.4 . . . . 0.0 110.37 179.24 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 172' ' ' ALA . . . . . . . . . . . . . . . -73.03 -6.88 48.43 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 115.92 -0.582 . . . . 0.0 110.641 -179.991 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 173' ' ' ILE . . . . . 0.513 HG22 HD11 ' A' ' 177' ' ' ILE . 29.0 mm -86.67 -22.2 7.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 115.818 -0.628 . . . . 0.0 111.203 -179.952 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 174' ' ' TYR . . . . . 0.453 ' HB2' ' HD3' ' A' ' 175' ' ' PRO . 25.5 m-85 -54.25 -49.8 88.28 Favored Pre-proline 0 N--CA 1.464 0.245 0 CA-C-N 116.514 -0.312 . . . . 0.0 111.702 -179.771 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 175' ' ' PRO . . . . . 0.453 ' HD3' ' HB2' ' A' ' 174' ' ' TYR . 79.8 Cg_exo -49.01 -30.06 17.13 Favored 'Trans proline' 0 C--N 1.349 0.591 0 C-N-CA 121.97 1.78 . . . . 0.0 112.138 179.641 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 176' ' ' PHE . . . . . 0.45 ' O ' ' HG ' ' A' ' 180' ' ' LEU . 46.8 m-85 -80.75 -50.0 10.43 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 115.985 -0.552 . . . . 0.0 111.663 -179.897 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 177' ' ' ILE . . . . . 0.513 HD11 HG22 ' A' ' 173' ' ' ILE . 4.2 mm -63.13 -32.64 57.03 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.501 0 N-CA-C 112.364 0.505 . . . . 0.0 112.364 -178.037 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 178' ' ' TRP . . . . . . . . . . . . . 77.7 t90 -71.95 -50.94 24.68 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.934 0.397 . . . . 0.0 110.555 179.771 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 179' ' ' LEU . . . . . 0.625 HD23 HD23 ' A' ' 180' ' ' LEU . 0.7 OUTLIER -68.95 -54.71 13.89 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.001 -0.545 . . . . 0.0 111.482 -179.341 . . . . . . . . 3 3 . 1 . 027 nuclear build full ' A' A ' 180' ' ' LEU . . . . . 0.674 HD22 HD11 ' A' ' 187' ' ' LEU . 39.3 mt -63.54 -43.68 96.39 Favored 'General case' 0 C--N 1.329 -0.324 0 C-N-CA 121.043 -0.263 . . . . 0.0 111.025 -179.729 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . -58.04 178.26 1.38 Allowed Glycine 0 CA--C 1.521 0.462 0 C-N-CA 120.12 -1.038 . . . . 0.0 112.12 179.085 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 182' ' ' PRO . . . . . 0.492 ' HA ' ' HB2' ' A' ' 186' ' ' ALA . 74.8 Cg_exo -47.45 -44.97 24.04 Favored 'Trans proline' 0 CA--C 1.536 0.611 0 C-N-CA 122.91 2.406 . . . . 0.0 113.918 -179.886 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 183' ' ' PRO . . . . . . . . . . . . . 86.7 Cg_exo -46.96 -26.91 5.29 Favored 'Trans proline' 0 C--N 1.355 0.874 0 C-N-CA 122.191 1.928 . . . . 0.0 113.364 -179.665 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 184' ' ' GLY . . . . . 0.582 ' HA2' ' HD2' ' A' ' 123' ' ' ARG . . . -120.5 -129.92 3.83 Favored Glycine 0 C--N 1.333 0.368 0 C-N-CA 120.29 -0.957 . . . . 0.0 113.081 -179.685 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 185' ' ' VAL . . . . . . . . . . . . . 15.4 m -54.68 -23.67 12.03 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 N-CA-C 112.066 0.395 . . . . 0.0 112.066 -179.526 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 186' ' ' ALA . . . . . 0.492 ' HB2' ' HA ' ' A' ' 182' ' ' PRO . . . 55.13 86.72 0.05 Allowed 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 116.446 -0.343 . . . . 0.0 111.659 179.509 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 187' ' ' LEU . . . . . 0.674 HD11 HD22 ' A' ' 180' ' ' LEU . 12.7 mt -92.3 -49.28 6.24 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.287 -0.415 . . . . 0.0 110.904 179.905 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 188' ' ' LEU . . . . . 0.521 HD13 HG11 ' A' ' 192' ' ' VAL . 78.2 mt -98.06 -161.93 0.91 Allowed 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 115.998 -0.546 . . . . 0.0 110.832 -179.72 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 189' ' ' THR . . . . . . . . . . . . . 2.3 t -98.41 146.93 32.41 Favored Pre-proline 0 C--N 1.329 -0.288 0 CA-C-N 116.132 -0.486 . . . . 0.0 110.766 179.993 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 190' ' ' PRO . . . . . . . . . . . . . 95.8 Cg_exo -44.41 -42.51 13.87 Favored 'Trans proline' 0 C--N 1.349 0.587 0 C-N-CA 122.763 2.309 . . . . 0.0 113.374 -179.511 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 191' ' ' THR . . . . . 0.48 ' O ' HD21 ' A' ' 7' ' ' LEU . 41.6 p -59.29 -44.74 92.47 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-O 120.78 0.324 . . . . 0.0 111.707 -179.596 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 192' ' ' VAL . . . . . 0.521 HG11 HD13 ' A' ' 188' ' ' LEU . 55.3 t -70.39 -51.52 37.34 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.42 0 N-CA-C 111.858 0.318 . . . . 0.0 111.858 -179.344 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 193' ' ' ASP . . . . . . . . . . . . . 20.7 m-20 -59.11 -51.98 67.7 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 116.444 -0.344 . . . . 0.0 111.626 -179.349 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 194' ' ' VAL . . . . . . . . . . . . . 69.2 t -58.88 -35.92 58.74 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.221 0 CA-C-O 120.712 0.292 . . . . 0.0 110.907 179.885 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 195' ' ' ALA . . . . . . . . . . . . . . . -57.33 -47.7 80.88 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.329 -0.396 . . . . 0.0 110.655 179.612 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 196' ' ' LEU . . . . . 0.402 HD23 ' N ' ' A' ' 196' ' ' LEU . 0.3 OUTLIER -61.85 -40.44 95.36 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.301 -0.409 . . . . 0.0 110.424 179.355 . . . . . . . . 3 3 . 1 . 027 nuclear build full ' A' A ' 197' ' ' ILE . . . . . . . . . . . . . 17.0 mm -57.25 -59.3 3.35 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.32 0 CA-C-N 115.939 -0.573 . . . . 0.0 110.062 179.019 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 198' ' ' VAL . . . . . . . . . . . . . 92.9 t -52.01 -35.1 18.13 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.426 0 CA-C-N 115.473 -0.785 . . . . 0.0 109.468 178.346 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 199' ' ' TYR . . . . . . . . . . . . . 59.3 t80 -70.24 -31.01 68.23 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 115.374 -0.83 . . . . 0.0 110.725 179.873 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 200' ' ' LEU . . . . . 0.496 ' O ' HG12 ' A' ' 203' ' ' VAL . 43.4 mt -73.23 -37.49 66.38 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 115.821 -0.627 . . . . 0.0 111.383 -179.736 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 201' ' ' ASP . . . . . . . . . . . . . 16.1 m-20 -73.84 -39.37 64.06 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-O 121.043 0.449 . . . . 0.0 110.498 179.663 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 202' ' ' LEU . . . . . . . . . . . . . 2.2 mt -69.9 -28.94 66.04 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 115.735 -0.666 . . . . 0.0 111.765 -179.465 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 203' ' ' VAL . . . . . 0.496 HG12 ' O ' ' A' ' 200' ' ' LEU . 12.3 p -78.17 -36.43 21.2 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.331 0 C-N-CA 121.094 -0.242 . . . . 0.0 110.962 -178.979 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 204' ' ' THR . . . . . . . . . . . . . 95.6 m -64.88 -58.43 6.2 Favored 'General case' 0 C--N 1.327 -0.399 0 C-N-CA 120.563 -0.455 . . . . 0.0 110.934 179.335 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 205' ' ' LYS . . . . . 0.76 ' HE3' HG22 ' A' ' 43' ' ' ILE . 54.4 mttp -61.86 -58.09 9.28 Favored 'General case' 0 C--N 1.329 -0.292 0 N-CA-C 112.343 0.497 . . . . 0.0 112.343 -178.395 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 51.0 t -71.83 -37.01 60.44 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.396 0 N-CA-C 112.428 0.529 . . . . 0.0 112.428 -178.515 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 207' ' ' GLY . . . . . 0.433 ' HA3' ' O ' ' A' ' 203' ' ' VAL . . . -57.59 -60.26 9.33 Favored Glycine 0 N--CA 1.455 -0.097 0 C-N-CA 120.704 -0.76 . . . . 0.0 113.416 -178.798 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 208' ' ' PHE . . . . . 0.661 ' HB2' ' HG ' ' A' ' 163' ' ' LEU . 0.3 OUTLIER -71.67 -27.13 62.85 Favored 'General case' 0 C--O 1.223 -0.3 0 CA-C-N 117.183 0.492 . . . . 0.0 110.562 -179.713 . . . . . . . . 3 3 . 1 . 027 nuclear build full ' A' A ' 209' ' ' GLY . . . . . 0.51 ' O ' ' HB3' ' A' ' 212' ' ' ALA . . . -65.18 -33.86 88.08 Favored Glycine 0 N--CA 1.448 -0.521 0 N-CA-C 111.718 -0.553 . . . . 0.0 111.718 178.623 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 210' ' ' PHE . . . . . . . . . . . . . 0.6 OUTLIER -73.57 -44.93 56.16 Favored 'General case' 0 CA--C 1.512 -0.502 0 N-CA-C 107.757 -1.201 . . . . 0.0 107.757 178.321 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 211' ' ' ILE . . . . . 0.416 HD12 ' HA ' ' A' ' 208' ' ' PHE . 34.5 mt -64.73 -27.65 42.99 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.653 0 N-CA-C 107.649 -1.241 . . . . 0.0 107.649 176.646 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 212' ' ' ALA . . . . . 0.51 ' HB3' ' O ' ' A' ' 209' ' ' GLY . . . -64.35 -44.02 92.78 Favored 'General case' 0 N--CA 1.45 -0.452 0 CA-C-N 114.505 -1.225 . . . . 0.0 110.6 -179.859 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 213' ' ' LEU . . . . . . . . . . . . . 97.6 mt -69.67 -46.08 66.91 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 115.308 -0.86 . . . . 0.0 111.487 -179.574 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 214' ' ' ASP . . . . . . . . . . . . . 36.3 m-20 -58.11 -47.15 84.14 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-O 120.85 0.357 . . . . 0.0 110.933 -179.952 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 215' ' ' ALA . . . . . 0.416 ' O ' ' HG ' ' A' ' 219' ' ' LEU . . . -62.82 -54.05 44.9 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 115.992 -0.549 . . . . 0.0 111.239 -179.896 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 216' ' ' ALA . . . . . . . . . . . . . . . -56.36 -37.5 70.12 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-N 116.281 -0.418 . . . . 0.0 111.04 179.928 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 217' ' ' ALA . . . . . . . . . . . . . . . -63.33 -37.96 89.3 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.167 179.655 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 218' ' ' THR . . . . . . . . . . . . . 92.4 m -68.6 -39.14 81.02 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 115.677 -0.692 . . . . 0.0 110.605 179.334 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 219' ' ' LEU . . . . . 0.434 ' O ' ' HG2' ' A' ' 222' ' ' GLU . 84.4 mt -56.53 -42.15 77.98 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 115.895 -0.593 . . . . 0.0 110.272 179.798 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 220' ' ' ARG . . . . . . . . . . . . . 56.2 mtp180 -84.22 -17.9 38.32 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.065 -0.516 . . . . 0.0 110.526 179.295 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 221' ' ' ALA . . . . . . . . . . . . . . . -64.77 -37.98 89.43 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.0 -0.545 . . . . 0.0 111.555 -179.819 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 222' ' ' GLU . . . . . 0.434 ' HG2' ' O ' ' A' ' 219' ' ' LEU . 13.4 pt-20 -71.0 -8.6 54.44 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.887 0.375 . . . . 0.0 110.879 -179.896 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 223' ' ' HIS . . . . . . . . . . . . . 52.5 m80 -97.89 8.08 45.31 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.013 -0.539 . . . . 0.0 110.807 179.823 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 224' ' ' GLY . . . . . . . . . . . . . . . -76.29 -3.56 76.99 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.848 -0.691 . . . . 0.0 112.566 -179.938 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 225' ' ' GLU . . . . . . . . . . . . . 43.3 tt0 -136.65 124.85 23.09 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.877 0.37 . . . . 0.0 110.76 179.911 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 226' ' ' SER . . . . . . . . . . . . . 63.6 p -162.65 122.31 2.3 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.883 -179.947 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 227' ' ' LEU . . . . . 0.415 ' N ' HD12 ' A' ' 227' ' ' LEU . 7.4 mp -80.92 -19.24 44.71 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.878 -179.93 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 228' ' ' ALA . . . . . . . . . . . . . . . 53.1 22.86 2.72 Favored 'General case' 0 C--N 1.332 -0.185 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.457 -179.905 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 229' ' ' GLY . . . . . . . . . . . . . . . -134.87 -97.65 0.56 Allowed Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.872 -0.68 . . . . 0.0 112.491 -179.993 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 230' ' ' VAL . . . . . . . . . . . . . 33.9 m -93.27 150.31 3.96 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-O 120.828 0.347 . . . . 0.0 111.206 -179.903 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 231' ' ' ASP . . . . . . . . . . . . . 11.4 m-20 -95.9 93.38 7.0 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.606 179.655 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 232' ' ' THR . . . . . . . . . . . . . 7.8 t -90.99 164.69 13.89 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.329 -0.396 . . . . 0.0 111.285 -179.862 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 233' ' ' ASP . . . . . . . . . . . . . 21.0 t70 -158.06 120.81 3.81 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.04 -0.527 . . . . 0.0 110.849 -179.897 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 234' ' ' THR . . . . . . . . . . . . . 59.3 m 58.29 88.04 0.13 Allowed Pre-proline 0 C--N 1.33 -0.247 0 CA-C-N 116.047 -0.524 . . . . 0.0 111.203 -179.947 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 235' ' ' PRO . . . . . . . . . . . . . 82.5 Cg_endo -78.88 -21.85 9.29 Favored 'Trans proline' 0 C--N 1.346 0.409 0 C-N-CA 122.41 2.073 . . . . 0.0 112.282 179.757 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 236' ' ' ALA . . . . . . . . . . . . . . . -139.25 141.15 37.85 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.096 -0.502 . . . . 0.0 111.245 -179.887 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 237' ' ' VAL . . . . . . . . . . . . . 28.9 m -104.47 179.47 0.72 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.217 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.094 179.947 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 238' ' ' ALA . . . . . . . . . . . . . . . -67.95 167.33 13.95 Favored 'General case' 0 C--N 1.331 -0.199 0 CA-C-N 116.373 -0.376 . . . . 0.0 111.032 179.924 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 239' ' ' ASP . . . . . . . . . . . . . 6.8 m-20 -90.98 140.08 30.16 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.101 -0.5 . . . . 0.0 110.794 -179.996 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 240' ' ' LEU . . . . . . . . . . . . . 7.6 mp -92.18 -14.98 28.23 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.258 -0.428 . . . . 0.0 111.005 179.869 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 241' ' ' GLU . . . . . . . . . . . . . 39.9 tt0 -109.9 141.15 43.03 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.885 -179.902 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 242' ' ' HIS . . . . . . . . . . . . . 31.6 m80 -117.06 109.74 17.35 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.931 -179.823 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 243' ' ' HIS . . . . . . . . . . . . . 8.6 t-80 -141.72 -9.24 0.93 Allowed 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.803 179.83 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 244' ' ' HIS . . . . . . . . . . . . . 87.6 m-70 62.74 -82.57 0.02 OUTLIER 'General case' 0 N--CA 1.462 0.17 0 CA-C-N 115.932 -0.576 . . . . 0.0 111.506 179.762 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 245' ' ' HIS . . . . . . . . . . . . . 40.9 t60 -75.84 106.5 7.46 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-O 120.841 0.353 . . . . 0.0 111.092 -179.668 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 246' ' ' HIS . . . . . . . . . . . . . 51.6 m80 -92.17 162.06 14.48 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.055 -0.521 . . . . 0.0 110.812 179.815 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 247' ' ' HIS . . . . . . . . . . . . . 95.4 m-70 . . . . . 0 C--O 1.248 1.017 0 CA-C-O 118.265 -0.874 . . . . 0.0 110.993 179.946 . . . . . . . . 0 0 . 1 . 027 nuclear build full ' A' A ' 301' ' ' RET . . . . . 0.652 ' H21' ' HA3' ' A' ' 112' ' ' GLY . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 85.0 mtp . . . . . 0 N--CA 1.485 1.318 0 CA-C-O 120.879 0.371 . . . . 0.0 111.096 . . . . . . . . . 0 0 . 1 . 028 nuclear build full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 2.5 p -165.67 101.86 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 115.937 -0.574 . . . . 0.0 110.897 179.837 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . 131.42 -22.46 4.41 Favored Glycine 0 N--CA 1.45 -0.367 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.546 -179.852 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 4' ' ' LEU . . . . . 0.463 HD13 HG22 ' A' ' 191' ' ' THR . 59.5 tp -74.12 -40.69 62.5 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-O 120.823 0.344 . . . . 0.0 110.889 179.945 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 61.3 p -60.79 -29.85 69.7 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.136 179.98 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 10.9 p -53.11 -35.5 59.72 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 116.043 -0.526 . . . . 0.0 111.172 -179.785 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 7' ' ' LEU . . . . . . . . . . . . . 10.0 mp -57.22 -53.59 56.36 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.297 179.961 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 8' ' ' PHE . . . . . 0.49 ' O ' ' HB3' ' A' ' 51' ' ' TYR . 65.7 m-85 -59.4 -34.63 72.68 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.006 -0.543 . . . . 0.0 110.957 -179.599 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 9' ' ' TRP . . . . . 0.404 ' O ' HG12 ' A' ' 13' ' ' ILE . 32.0 m95 -66.71 -41.81 87.37 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-N 116.296 -0.411 . . . . 0.0 110.099 179.831 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 84.2 mt -59.64 -48.4 81.82 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 115.88 -0.6 . . . . 0.0 110.26 179.233 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 11' ' ' GLY . . . . . 0.489 ' HA2' HD11 ' A' ' 202' ' ' LEU . . . -61.22 -35.28 90.65 Favored Glycine 0 N--CA 1.449 -0.461 0 C-N-CA 120.621 -0.799 . . . . 0.0 111.587 179.169 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -63.29 -30.28 71.44 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.597 0.237 . . . . 0.0 110.442 179.41 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 13' ' ' ILE . . . . . 0.404 HG12 ' O ' ' A' ' 9' ' ' TRP . 47.9 mm -68.58 -54.12 23.21 Favored 'Isoleucine or valine' 0 CA--C 1.52 -0.189 0 CA-C-N 116.41 -0.359 . . . . 0.0 110.309 179.057 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -53.21 -30.67 39.95 Favored Glycine 0 N--CA 1.452 -0.281 0 C-N-CA 120.689 -0.767 . . . . 0.0 111.747 179.475 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 15' ' ' MET . . . . . 0.718 ' HB3' ' HB2' ' A' ' 48' ' ' ALA . 0.0 OUTLIER -76.77 -49.54 15.67 Favored 'General case' 0 C--O 1.223 -0.33 0 CA-C-O 120.564 0.221 . . . . 0.0 110.928 179.523 . . . . . . . . 3 3 . 1 . 028 nuclear build full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -55.67 -50.87 69.1 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-O 120.78 0.324 . . . . 0.0 110.621 179.804 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 17' ' ' VAL . . . . . 0.481 HG13 ' N ' ' A' ' 18' ' ' GLY . 14.7 p -63.55 -46.31 95.35 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.377 0 CA-C-O 121.356 0.598 . . . . 0.0 110.718 179.824 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 18' ' ' GLY . . . . . 0.481 ' N ' HG13 ' A' ' 17' ' ' VAL . . . -58.97 -46.31 93.87 Favored Glycine 0 C--N 1.317 -0.484 0 CA-C-N 114.973 -1.012 . . . . 0.0 111.891 179.179 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 57.4 m -53.78 -45.06 70.55 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-O 120.707 0.289 . . . . 0.0 110.827 -179.839 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 81.7 mt -71.58 -39.68 70.42 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.273 -0.421 . . . . 0.0 110.766 179.376 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -60.42 -33.39 72.44 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.085 -0.507 . . . . 0.0 111.736 -179.767 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 22' ' ' PHE . . . . . 0.586 ' HB2' HG22 ' A' ' 41' ' ' VAL . 8.2 m-85 -91.15 -31.05 16.36 Favored 'General case' 0 N--CA 1.463 0.197 0 CA-C-O 120.753 0.311 . . . . 0.0 111.311 -179.679 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -68.72 -50.32 51.78 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.335 -179.514 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 24' ' ' TRP . . . . . . . . . . . . . 4.4 t-105 -64.18 -45.05 90.07 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-N 115.834 -0.621 . . . . 0.0 111.24 -179.595 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -74.42 -23.42 58.94 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 120.858 0.361 . . . . 0.0 110.983 179.84 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -73.65 -45.63 27.74 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.898 -0.668 . . . . 0.0 112.715 -179.794 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 27' ' ' ARG . . . . . 0.442 ' HA ' ' NE ' ' A' ' 27' ' ' ARG . 5.2 mmp_? -57.26 -26.24 60.48 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.846 0.355 . . . . 0.0 111.018 -179.998 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 24.4 t70 -105.52 96.54 6.58 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.878 179.955 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -165.2 -168.22 1.35 Allowed 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.193 -179.869 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -98.93 -158.41 29.39 Favored Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.872 -0.68 . . . . 0.0 112.298 179.736 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 47.5 t -100.31 111.51 23.79 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.88 0.371 . . . . 0.0 110.936 179.96 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 129.83 -29.05 3.83 Favored Glycine 0 C--N 1.33 0.245 0 C-N-CA 120.886 -0.673 . . . . 0.0 112.457 -179.984 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 28.7 mm-40 -86.63 -20.85 27.25 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 120.741 0.305 . . . . 0.0 110.953 -179.959 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 34' ' ' ARG . . . . . . . . . . . . . 14.7 ptm180 -48.9 -36.31 16.88 Favored 'General case' 0 C--N 1.332 -0.17 0 CA-C-N 116.076 -0.511 . . . . 0.0 111.668 -179.757 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 29.2 mmt180 -61.77 -50.47 72.22 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 120.874 0.368 . . . . 0.0 111.277 -179.686 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 46.6 m-85 -63.2 -30.58 71.7 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.044 -0.525 . . . . 0.0 111.473 -179.607 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 37' ' ' TYR . . . . . 0.431 ' O ' HG23 ' A' ' 41' ' ' VAL . 39.1 m-85 -74.67 -55.8 5.49 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.641 -179.237 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 88.8 t -56.63 -36.85 49.81 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.205 0 CA-C-O 121.0 0.429 . . . . 0.0 110.485 179.914 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 90.7 m -63.97 -50.96 66.52 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 115.747 -0.661 . . . . 0.0 110.465 179.226 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 40' ' ' LEU . . . . . 0.529 HD12 HD12 ' A' ' 43' ' ' ILE . 40.4 tp -56.8 -50.16 73.18 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 115.549 -0.75 . . . . 0.0 110.809 -179.858 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 41' ' ' VAL . . . . . 0.586 HG22 ' HB2' ' A' ' 22' ' ' PHE . 69.0 t -57.76 -36.53 55.39 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 115.858 -0.61 . . . . 0.0 110.446 179.565 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -61.52 -36.1 92.08 Favored Glycine 0 N--CA 1.449 -0.493 0 C-N-CA 120.907 -0.663 . . . . 0.0 112.17 179.815 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 43' ' ' ILE . . . . . 0.572 HG12 HD23 ' A' ' 82' ' ' LEU . 2.0 mt -65.22 -56.94 13.08 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.234 0 CA-C-O 120.958 0.409 . . . . 0.0 110.802 179.713 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 32.4 t -58.26 -25.17 61.44 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 115.879 -0.601 . . . . 0.0 111.685 -179.5 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -73.83 -58.48 4.43 Favored Glycine 0 CA--C 1.517 0.191 0 C-N-CA 120.696 -0.764 . . . . 0.0 112.986 -179.576 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 46' ' ' ILE . . . . . 0.644 ' O ' HG22 ' A' ' 49' ' ' VAL . 15.8 pt -57.92 -35.87 53.63 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.221 0 CA-C-O 120.818 0.342 . . . . 0.0 110.924 -179.674 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 47' ' ' ALA . . . . . 0.67 ' HB2' ' HE2' ' A' ' 205' ' ' LYS . . . -67.04 -37.59 84.36 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.962 0.41 . . . . 0.0 110.261 178.754 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 48' ' ' ALA . . . . . 0.718 ' HB2' ' HB3' ' A' ' 15' ' ' MET . . . -60.57 -33.08 72.18 Favored 'General case' 0 C--N 1.332 -0.173 0 CA-C-N 115.736 -0.665 . . . . 0.0 111.343 179.889 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 49' ' ' VAL . . . . . 0.644 HG22 ' O ' ' A' ' 46' ' ' ILE . 1.3 m -76.54 -38.39 31.46 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.496 -0.32 . . . . 0.0 111.643 -179.425 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -62.95 -41.65 99.58 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-O 120.968 0.413 . . . . 0.0 111.393 -179.636 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 51' ' ' TYR . . . . . 0.595 ' HE2' ' HE2' ' A' ' 15' ' ' MET . 38.5 m-85 -72.74 -40.41 66.1 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-N 115.894 -0.594 . . . . 0.0 110.813 -179.283 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -63.13 -40.87 98.84 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-N 115.943 -0.571 . . . . 0.0 111.467 179.793 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 53' ' ' VAL . . . . . 0.515 HG23 ' N ' ' A' ' 54' ' ' MET . 33.3 m -74.42 -50.56 26.47 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 N-CA-C 111.754 0.279 . . . . 0.0 111.754 -179.475 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 54' ' ' MET . . . . . 0.534 ' HG2' ' HG2' ' A' ' 71' ' ' PRO . 72.0 mtm -57.57 -30.2 65.06 Favored 'General case' 0 CA--C 1.521 -0.143 0 CA-C-O 121.013 0.435 . . . . 0.0 110.744 179.914 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -58.95 -36.97 75.7 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 115.601 -0.727 . . . . 0.0 111.643 -179.816 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 6.2 mp -87.2 4.38 42.71 Favored 'General case' 0 C--N 1.332 -0.173 0 CA-C-N 116.639 -0.255 . . . . 0.0 111.456 179.974 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 92.98 30.76 9.09 Favored Glycine 0 N--CA 1.452 -0.246 0 C-N-CA 120.674 -0.774 . . . . 0.0 113.111 179.526 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 73.7 t -88.63 130.19 38.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-O 120.71 0.29 . . . . 0.0 110.878 179.716 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 59' ' ' GLY . . . . . 0.581 ' HA3' ' HD3' ' A' ' 71' ' ' PRO . . . 87.59 -5.96 84.17 Favored Glycine 0 N--CA 1.448 -0.548 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.471 -179.815 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 60' ' ' TRP . . . . . . . . . . . . . 11.5 m0 -69.43 83.03 0.39 Allowed 'General case' 0 C--N 1.328 -0.358 0 CA-C-O 120.759 0.314 . . . . 0.0 110.59 179.835 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 6.5 p -98.99 132.25 23.94 Favored Pre-proline 0 C--N 1.33 -0.282 0 CA-C-N 116.351 -0.386 . . . . 0.0 111.298 -179.87 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 73.3 Cg_endo -75.75 148.33 32.33 Favored 'Trans proline' 0 C--N 1.35 0.612 0 C-N-CA 122.447 2.098 . . . . 0.0 112.169 179.68 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 83.7 t -141.98 97.27 0.71 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.351 -179.84 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . 57.38 -88.93 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.054 -0.521 . . . . 0.0 111.87 179.611 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 11.8 mm-40 -118.89 -20.94 7.97 Favored 'General case' 0 C--N 1.332 -0.174 0 CA-C-N 116.501 -0.318 . . . . 0.0 111.428 -179.486 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 66' ' ' ARG . . . . . . . . . . . . . 28.4 ptt180 -110.91 161.68 15.59 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.461 -0.336 . . . . 0.0 110.766 179.971 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 91.6 m -114.88 143.3 45.34 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.256 -0.429 . . . . 0.0 111.264 -179.8 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 68' ' ' VAL . . . . . 0.559 HG21 ' SD ' ' A' ' 117' ' ' MET . 30.1 m -129.14 146.51 34.14 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 115.954 -0.566 . . . . 0.0 110.924 179.943 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 69' ' ' PHE . . . . . . . . . . . . . 19.2 m-85 -106.38 117.54 34.31 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.123 -0.49 . . . . 0.0 109.833 -179.724 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 70' ' ' VAL . . . . . 0.561 HG12 ' HD3' ' A' ' 71' ' ' PRO . 1.4 p -68.77 -33.19 4.11 Favored Pre-proline 0 CA--C 1.543 0.692 0 N-CA-C 113.66 0.985 . . . . 0.0 113.66 -178.538 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 71' ' ' PRO . . . . . 0.581 ' HD3' ' HA3' ' A' ' 59' ' ' GLY . 14.2 Cg_exo -69.48 -19.11 37.87 Favored 'Trans proline' 0 C--N 1.356 0.942 0 C-N-CA 122.099 1.866 . . . . 0.0 113.46 -178.643 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 72' ' ' ARG . . . . . 0.469 ' HE ' ' HA ' ' A' ' 72' ' ' ARG . 0.9 OUTLIER -67.77 -55.27 13.7 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.917 0.389 . . . . 0.0 111.564 -179.449 . . . . . . . . 3 3 . 1 . 028 nuclear build full ' A' A ' 73' ' ' TYR . . . . . 0.42 ' O ' HG13 ' A' ' 77' ' ' ILE . 14.2 m-85 -71.17 -33.19 69.76 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 116.081 -0.509 . . . . 0.0 111.315 -178.962 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 74' ' ' ILE . . . . . 0.541 HG22 ' HA ' ' A' ' 71' ' ' PRO . 0.3 OUTLIER -71.09 -44.93 74.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 C-N-CA 120.864 -0.334 . . . . 0.0 110.88 -179.773 . . . . . . . . 3 3 . 1 . 028 nuclear build full ' A' A ' 75' ' ' ASP . . . . . 0.492 ' O ' HG23 ' A' ' 79' ' ' THR . 37.4 t70 -58.99 -35.49 73.31 Favored 'General case' 0 N--CA 1.455 -0.183 0 N-CA-C 109.561 -0.533 . . . . 0.0 109.561 179.334 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 76' ' ' TRP . . . . . . . . . . . . . 50.2 m0 -66.0 -35.84 81.66 Favored 'General case' 0 C--N 1.332 -0.165 0 CA-C-N 116.029 -0.532 . . . . 0.0 110.129 179.141 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 77' ' ' ILE . . . . . 0.512 HG12 ' HB3' ' A' ' 109' ' ' MET . 96.4 mt -65.62 -30.78 51.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.028 -0.533 . . . . 0.0 110.718 179.378 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 69.7 mt -92.2 -20.46 21.17 Favored 'General case' 0 C--N 1.329 -0.294 0 N-CA-C 112.342 0.497 . . . . 0.0 112.342 -179.782 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 79' ' ' THR . . . . . 0.492 HG23 ' O ' ' A' ' 75' ' ' ASP . 62.7 p -94.39 -47.99 6.34 Favored 'General case' 0 N--CA 1.466 0.333 0 N-CA-C 112.845 0.683 . . . . 0.0 112.845 -178.406 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 80' ' ' THR . . . . . 0.582 ' N ' ' HD2' ' A' ' 81' ' ' PRO . 86.6 m -51.29 -48.72 85.07 Favored Pre-proline 0 C--N 1.328 -0.357 0 N-CA-C 112.545 0.572 . . . . 0.0 112.545 -179.319 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 81' ' ' PRO . . . . . 0.582 ' HD2' ' N ' ' A' ' 80' ' ' THR . 13.8 Cg_endo -56.02 -24.39 48.54 Favored 'Trans proline' 0 C--N 1.352 0.712 0 C-N-CA 121.536 1.491 . . . . 0.0 111.463 179.973 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 82' ' ' LEU . . . . . 0.572 HD23 HG12 ' A' ' 43' ' ' ILE . 7.2 mp -77.03 -46.03 25.14 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-N 115.707 -0.679 . . . . 0.0 110.847 179.9 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 83' ' ' ILE . . . . . 0.556 HD13 HD13 ' A' ' 43' ' ' ILE . 28.0 mm -60.8 -53.49 48.36 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.203 0 CA-C-N 116.305 -0.407 . . . . 0.0 110.527 179.655 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 84' ' ' VAL . . . . . 0.413 HG11 ' ND2' ' A' ' 105' ' ' ASN . 29.4 m -59.15 -35.47 57.7 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.211 0 CA-C-N 116.076 -0.511 . . . . 0.0 110.386 179.451 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 85' ' ' TYR . . . . . . . . . . . . . 72.7 t80 -65.51 -32.38 73.95 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.097 -0.501 . . . . 0.0 110.008 179.004 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 86' ' ' PHE . . . . . . . . . . . . . 1.4 t80 -61.54 -51.13 69.88 Favored 'General case' 0 C--N 1.333 -0.141 0 CA-C-N 115.963 -0.562 . . . . 0.0 109.707 179.547 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 6.9 mp -67.09 -31.57 72.15 Favored 'General case' 0 C--N 1.331 -0.2 0 CA-C-N 115.974 -0.557 . . . . 0.0 110.137 179.209 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -62.77 -28.01 70.96 Favored Glycine 0 N--CA 1.45 -0.418 0 C-N-CA 120.878 -0.677 . . . . 0.0 111.615 179.441 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 71.9 mt -78.45 -49.71 12.97 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.86 0.362 . . . . 0.0 110.536 179.411 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 96.1 mt -56.44 -32.5 64.97 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 115.994 -0.548 . . . . 0.0 110.649 179.608 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 91' ' ' ALA . . . . . 0.55 ' HB1' ' HB2' ' A' ' 148' ' ' SER . . . -83.67 -52.88 6.06 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 115.91 -0.587 . . . . 0.0 110.937 179.838 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 92' ' ' GLY . . . . . 0.462 ' HA3' HH21 ' A' ' 152' ' ' ARG . . . 90.68 71.82 1.23 Allowed Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.849 -0.691 . . . . 0.0 112.529 179.967 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 93' ' ' LEU . . . . . 0.551 HD11 ' HG2' ' A' ' 145' ' ' MET . 6.4 mp -84.18 -172.49 4.19 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-O 120.801 0.334 . . . . 0.0 110.912 -179.934 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 94' ' ' ASP . . . . . 0.453 ' H ' ' HB2' ' A' ' 97' ' ' GLU . 4.6 m-20 -98.88 -172.24 2.25 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.201 -179.966 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 46.1 t -67.87 -52.91 31.09 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 115.994 -0.548 . . . . 0.0 111.527 -179.668 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 75.3 mtp180 -74.14 -35.38 64.07 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-O 120.893 0.378 . . . . 0.0 110.899 -179.358 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 97' ' ' GLU . . . . . 0.453 ' HB2' ' H ' ' A' ' 94' ' ' ASP . 0.3 OUTLIER -60.8 -42.31 97.37 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 115.992 -0.549 . . . . 0.0 111.032 -179.873 . . . . . . . . 3 3 . 1 . 028 nuclear build full ' A' A ' 98' ' ' PHE . . . . . . . . . . . . . 0.6 OUTLIER -61.69 -40.73 96.03 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.337 -0.392 . . . . 0.0 110.572 179.468 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -65.6 -31.55 80.4 Favored Glycine 0 N--CA 1.452 -0.27 0 C-N-CA 120.795 -0.717 . . . . 0.0 112.538 -179.932 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 96.7 mt -67.82 -43.3 86.28 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.209 0 CA-C-O 120.909 0.385 . . . . 0.0 111.239 -179.826 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 101' ' ' VAL . . . . . 0.671 HG21 ' HE3' ' A' ' 145' ' ' MET . 42.2 t -66.36 -50.49 67.27 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.358 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.367 -179.801 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 102' ' ' ILE . . . . . . . . . . . . . 48.6 mm -59.46 -49.57 83.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.59 -179.526 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 14.2 t -59.95 -29.97 68.76 Favored 'General case' 0 C--N 1.332 -0.181 0 CA-C-O 120.77 0.319 . . . . 0.0 110.903 -179.829 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -60.66 -57.0 14.56 Favored 'General case' 0 C--N 1.332 -0.178 0 CA-C-N 116.325 -0.398 . . . . 0.0 109.983 179.342 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 105' ' ' ASN . . . . . 0.413 ' ND2' HG11 ' A' ' 84' ' ' VAL . 32.7 m-80 -59.27 -26.4 64.91 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-N 116.022 -0.535 . . . . 0.0 110.782 179.533 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 76.3 m -61.49 -52.76 63.19 Favored 'General case' 0 C--N 1.332 -0.185 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.958 179.87 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 107' ' ' VAL . . . . . 0.424 HG23 ' H ' ' A' ' 107' ' ' VAL . 2.1 t -62.0 -37.21 77.76 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.248 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.59 179.966 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 70.3 t -60.14 -57.86 9.89 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 115.73 -0.668 . . . . 0.0 111.461 -179.898 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 109' ' ' MET . . . . . 0.512 ' HB3' HG12 ' A' ' 77' ' ' ILE . 3.7 tpp -56.91 -42.89 80.75 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.485 -179.55 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 24.1 tp -62.54 -31.0 71.71 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.318 -0.401 . . . . 0.0 110.693 -179.899 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -63.57 -55.7 21.75 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 116.038 -0.528 . . . . 0.0 110.655 179.545 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 112' ' ' GLY . . . . . 0.646 ' HA3' ' H21' ' A' ' 301' ' ' RET . . . -61.49 -36.7 92.96 Favored Glycine 0 N--CA 1.45 -0.389 0 C-N-CA 120.775 -0.726 . . . . 0.0 112.081 179.576 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 113' ' ' PHE . . . . . 0.417 ' O ' ' HG2' ' A' ' 117' ' ' MET . 0.3 OUTLIER -52.25 -71.77 0.06 Allowed 'General case' 0 C--N 1.332 -0.174 0 CA-C-O 120.961 0.41 . . . . 0.0 110.195 179.619 . . . . . . . . 3 3 . 1 . 028 nuclear build full ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -63.9 -19.44 65.1 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 115.924 -0.58 . . . . 0.0 111.022 179.758 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 115' ' ' GLY . . . . . 0.495 ' HA2' HD22 ' A' ' 126' ' ' LEU . . . -54.8 -51.58 52.05 Favored Glycine 0 C--N 1.332 0.334 0 C-N-CA 120.86 -0.686 . . . . 0.0 111.841 179.611 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -78.2 -14.91 59.26 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-O 120.748 0.309 . . . . 0.0 111.227 179.659 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 117' ' ' MET . . . . . 0.559 ' SD ' HG21 ' A' ' 68' ' ' VAL . 23.5 mmt -90.59 17.07 7.93 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-N 116.358 -0.383 . . . . 0.0 111.739 -179.238 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 118' ' ' VAL . . . . . 0.426 HG21 ' HB3' ' A' ' 123' ' ' ARG . 34.4 m -81.1 144.01 53.85 Favored Pre-proline 0 C--N 1.33 -0.277 0 CA-C-O 120.505 0.193 . . . . 0.0 111.43 -179.845 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 119' ' ' PRO . . . . . . . . . . . . . 83.4 Cg_endo -82.49 -1.9 10.82 Favored 'Trans proline' 0 C--N 1.348 0.525 0 C-N-CA 122.55 2.167 . . . . 0.0 112.349 179.649 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -148.85 -129.1 1.77 Allowed Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.722 -0.751 . . . . 0.0 112.747 -179.878 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 39.8 pt -107.92 12.15 8.78 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.207 0 CA-C-O 120.676 0.274 . . . . 0.0 111.577 -179.729 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 43.9 mt-10 -60.25 -18.19 47.13 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.372 -0.376 . . . . 0.0 111.034 179.802 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 123' ' ' ARG . . . . . 0.432 ' HB2' ' HH2' ' A' ' 178' ' ' TRP . 15.7 ptt180 -50.08 -37.59 34.4 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 116.031 -0.532 . . . . 0.0 111.71 -179.578 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 124' ' ' TYR . . . . . . . . . . . . . 30.1 m-85 -58.46 -33.9 70.26 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.518 -0.31 . . . . 0.0 111.271 -179.628 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 125' ' ' ALA . . . . . . . . . . . . . . . -74.2 -49.75 22.15 Favored 'General case' 0 C--O 1.235 0.336 0 CA-C-O 120.909 0.385 . . . . 0.0 111.128 179.958 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 126' ' ' LEU . . . . . 0.495 HD22 ' HA2' ' A' ' 115' ' ' GLY . 7.4 mp -53.09 -46.46 68.66 Favored 'General case' 0 C--N 1.333 -0.144 0 CA-C-N 115.972 -0.558 . . . . 0.0 110.5 -179.928 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 127' ' ' PHE . . . . . 0.449 ' HZ ' ' HB3' ' A' ' 175' ' ' PRO . 4.8 t80 -67.23 -37.73 84.05 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.644 179.839 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 128' ' ' GLY . . . . . . . . . . . . . . . -46.38 -46.21 16.68 Favored Glycine 0 C--N 1.332 0.356 0 C-N-CA 120.193 -1.003 . . . . 0.0 110.911 179.237 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 129' ' ' MET . . . . . . . . . . . . . 0.6 OUTLIER -68.1 -40.95 82.46 Favored 'General case' 0 C--N 1.327 -0.386 0 N-CA-C 109.749 -0.463 . . . . 0.0 109.749 178.48 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -64.15 -23.15 67.73 Favored Glycine 0 N--CA 1.45 -0.411 0 CA-C-N 115.822 -0.626 . . . . 0.0 112.345 179.792 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 131' ' ' ALA . . . . . 0.4 ' O ' ' HB3' ' A' ' 134' ' ' PHE . . . -75.03 -53.54 8.73 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.717 0.294 . . . . 0.0 110.419 179.648 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 39.4 t -55.36 -40.33 56.77 Favored 'Isoleucine or valine' 0 C--O 1.233 0.217 0 CA-C-O 121.387 0.613 . . . . 0.0 109.638 178.799 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -69.79 -36.53 75.77 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 115.339 -0.846 . . . . 0.0 110.721 179.172 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 134' ' ' PHE . . . . . 0.442 ' CZ ' ' HA ' ' A' ' 172' ' ' ALA . 18.9 t80 -53.43 -60.06 3.79 Favored 'General case' 0 N--CA 1.454 -0.251 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.22 179.869 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 135' ' ' ILE . . . . . 0.526 ' O ' HG22 ' A' ' 138' ' ' VAL . 0.0 OUTLIER -56.11 -35.23 41.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 115.959 -0.564 . . . . 0.0 110.31 179.143 . . . . . . . . 3 3 . 1 . 028 nuclear build full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . -57.56 -43.13 94.31 Favored Glycine 0 N--CA 1.45 -0.398 0 C-N-CA 120.226 -0.987 . . . . 0.0 111.755 179.024 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 137' ' ' LEU . . . . . 0.569 HD13 ' N ' ' A' ' 138' ' ' VAL . 1.4 tm? -63.29 -58.22 7.85 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 121.016 0.436 . . . . 0.0 110.519 179.678 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 138' ' ' VAL . . . . . 0.569 ' N ' HD13 ' A' ' 137' ' ' LEU . 2.4 m -54.22 -31.77 22.55 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.466 0 CA-C-N 115.562 -0.744 . . . . 0.0 110.213 179.68 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 139' ' ' TYR . . . . . . . . . . . . . 17.3 t80 -64.26 -34.92 79.21 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 115.885 -0.598 . . . . 0.0 110.05 179.091 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 15.4 m-85 -68.43 -48.69 63.94 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 115.989 -0.55 . . . . 0.0 111.613 179.733 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 141' ' ' LEU . . . . . 0.517 HD12 HG23 ' A' ' 142' ' ' VAL . 4.0 pp -68.52 -16.23 63.81 Favored 'General case' 0 CA--C 1.53 0.178 0 C-N-CA 120.974 -0.29 . . . . 0.0 111.327 -179.33 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 142' ' ' VAL . . . . . 0.517 HG23 HD12 ' A' ' 141' ' ' LEU . 95.2 t -101.17 -18.77 6.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-O 121.079 0.466 . . . . 0.0 110.57 178.801 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . -85.26 -123.46 1.25 Allowed Glycine 0 CA--C 1.522 0.498 0 C-N-CA 120.929 -0.653 . . . . 0.0 113.145 -179.342 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 144' ' ' PRO . . . . . . . . . . . . . 69.3 Cg_exo -52.15 -35.94 64.63 Favored 'Trans proline' 0 C--N 1.35 0.634 0 C-N-CA 122.722 2.281 . . . . 0.0 113.178 -179.392 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 145' ' ' MET . . . . . 0.671 ' HE3' HG21 ' A' ' 101' ' ' VAL . 40.3 mtt -55.36 -37.72 67.87 Favored 'General case' 0 C--N 1.331 -0.206 0 CA-C-O 120.751 0.31 . . . . 0.0 111.446 -179.798 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 146' ' ' THR . . . . . . . . . . . . . 18.3 m -68.28 -41.64 80.72 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.725 -179.368 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 42.6 mt-10 -75.77 -26.32 57.26 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.403 -0.362 . . . . 0.0 111.423 -179.543 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 148' ' ' SER . . . . . 0.55 ' HB2' ' HB1' ' A' ' 91' ' ' ALA . 68.9 m -70.65 -43.67 68.7 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.372 -0.376 . . . . 0.0 111.564 -179.402 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 149' ' ' ALA . . . . . 0.43 ' HB2' ' HA ' ' A' ' 91' ' ' ALA . . . -76.04 -32.34 59.29 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.781 0.324 . . . . 0.0 111.635 -179.441 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 150' ' ' SER . . . . . . . . . . . . . 86.7 p -69.46 -1.26 8.05 Favored 'General case' 0 C--N 1.326 -0.413 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.037 179.995 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 151' ' ' GLN . . . . . . . . . . . . . 77.2 mt-30 -118.69 0.26 11.44 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.097 -0.501 . . . . 0.0 111.331 -179.838 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 152' ' ' ARG . . . . . 0.462 HH21 ' HA3' ' A' ' 92' ' ' GLY . 38.9 mmt180 -82.26 -52.62 6.77 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-O 120.833 0.349 . . . . 0.0 111.004 -179.997 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 153' ' ' SER . . . . . 0.634 ' HB3' HG12 ' A' ' 156' ' ' ILE . 35.5 t -158.36 167.64 29.15 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.749 179.241 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 154' ' ' SER . . . . . . . . . . . . . 45.9 t -70.32 -34.85 73.18 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 121.037 0.446 . . . . 0.0 110.151 179.277 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -76.91 -37.92 32.14 Favored Glycine 0 N--CA 1.45 -0.368 0 C-N-CA 120.971 -0.633 . . . . 0.0 112.264 179.618 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 156' ' ' ILE . . . . . 0.634 HG12 ' HB3' ' A' ' 153' ' ' SER . 34.2 mm -53.51 -37.75 31.28 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.178 0 CA-C-O 120.897 0.379 . . . . 0.0 111.092 179.877 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 157' ' ' LYS . . . . . . . . . . . . . 39.9 ttpt -65.49 -32.29 73.82 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 116.078 -0.51 . . . . 0.0 111.441 -179.761 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 46.0 t -72.54 -47.93 44.27 Favored 'General case' 0 C--O 1.235 0.3 0 CA-C-O 121.143 0.497 . . . . 0.0 111.006 -179.604 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 159' ' ' LEU . . . . . 0.528 HD13 ' HB1' ' A' ' 215' ' ' ALA . 0.4 OUTLIER -68.63 -39.74 80.62 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 115.923 -0.58 . . . . 0.0 110.976 -179.415 . . . . . . . . 3 3 . 1 . 028 nuclear build full ' A' A ' 160' ' ' TYR . . . . . 0.47 ' OH ' ' HB3' ' A' ' 145' ' ' MET . 37.2 t80 -62.25 -47.15 85.63 Favored 'General case' 0 C--N 1.326 -0.419 0 N-CA-C 112.086 0.402 . . . . 0.0 112.086 -178.596 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 161' ' ' VAL . . . . . 0.412 HG23 ' N ' ' A' ' 162' ' ' ARG . 24.9 m -61.49 -45.97 97.54 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 C-N-CA 120.909 -0.316 . . . . 0.0 111.365 -179.488 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 162' ' ' ARG . . . . . 0.412 ' N ' HG23 ' A' ' 161' ' ' VAL . 28.1 tpt180 -68.85 -38.48 79.81 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 121.005 0.431 . . . . 0.0 111.103 -179.955 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 163' ' ' LEU . . . . . 0.416 HD13 ' O ' ' A' ' 159' ' ' LEU . 1.7 mp -64.67 -55.5 19.74 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 115.72 -0.673 . . . . 0.0 112.095 -179.23 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 164' ' ' ARG . . . . . 0.54 ' HG3' ' N ' ' A' ' 165' ' ' ASN . 22.7 ptt180 -64.59 -41.72 96.05 Favored 'General case' 0 C--N 1.333 -0.15 0 N-CA-C 111.828 0.307 . . . . 0.0 111.828 -178.671 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 165' ' ' ASN . . . . . 0.54 ' N ' ' HG3' ' A' ' 164' ' ' ARG . 5.7 m-20 -54.4 -48.37 71.67 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.91 0.386 . . . . 0.0 110.771 -179.922 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 166' ' ' LEU . . . . . . . . . . . . . 3.9 tt -64.06 -54.23 37.35 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 116.026 -0.533 . . . . 0.0 111.431 -179.787 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 167' ' ' THR . . . . . 0.446 ' O ' ' HB2' ' A' ' 171' ' ' TRP . 34.4 m -57.24 -54.28 48.61 Favored 'General case' 0 C--N 1.329 -0.307 0 N-CA-C 112.868 0.692 . . . . 0.0 112.868 -178.568 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 168' ' ' VAL . . . . . 0.404 HG13 ' N ' ' A' ' 169' ' ' VAL . 9.8 p -55.58 -41.59 64.84 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.243 0 N-CA-C 112.425 0.528 . . . . 0.0 112.425 -178.694 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 169' ' ' VAL . . . . . 0.501 HG23 ' O ' ' A' ' 165' ' ' ASN . 48.7 t -59.82 -64.62 0.56 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 C-N-CA 121.122 -0.231 . . . . 0.0 111.488 -179.628 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 170' ' ' LEU . . . . . 0.526 HD12 ' HD1' ' A' ' 171' ' ' TRP . 1.3 pp -62.07 -27.18 68.72 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.64 -0.254 . . . . 0.0 111.295 -179.582 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 171' ' ' TRP . . . . . 0.691 ' HE1' H203 ' A' ' 301' ' ' RET . 2.0 m0 -70.73 -36.12 73.02 Favored 'General case' 0 CA--C 1.519 -0.217 0 CA-C-O 121.099 0.476 . . . . 0.0 109.739 178.772 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 172' ' ' ALA . . . . . 0.442 ' HA ' ' CZ ' ' A' ' 134' ' ' PHE . . . -71.33 -6.85 43.08 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 115.465 -0.788 . . . . 0.0 110.877 179.573 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 173' ' ' ILE . . . . . 0.483 ' O ' HG12 ' A' ' 177' ' ' ILE . 42.1 mm -85.67 -23.29 7.13 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.191 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.943 179.571 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 174' ' ' TYR . . . . . 0.43 ' HB2' ' HD3' ' A' ' 175' ' ' PRO . 29.3 m-85 -53.87 -49.58 88.65 Favored Pre-proline 0 CA--C 1.53 0.201 0 CA-C-N 116.363 -0.38 . . . . 0.0 111.607 -179.72 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 175' ' ' PRO . . . . . 0.449 ' HB3' ' HZ ' ' A' ' 127' ' ' PHE . 81.2 Cg_exo -47.46 -31.62 13.82 Favored 'Trans proline' 0 C--N 1.351 0.701 0 C-N-CA 122.177 1.918 . . . . 0.0 112.228 179.446 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 176' ' ' PHE . . . . . 0.482 ' O ' ' HG ' ' A' ' 180' ' ' LEU . 75.0 m-85 -80.39 -50.04 10.66 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.02 -0.536 . . . . 0.0 111.908 -179.856 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 177' ' ' ILE . . . . . 0.483 HG12 ' O ' ' A' ' 173' ' ' ILE . 6.4 mm -62.52 -35.84 72.03 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.556 0 CA-C-N 116.091 -0.504 . . . . 0.0 112.269 -178.144 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 178' ' ' TRP . . . . . 0.432 ' HH2' ' HB2' ' A' ' 123' ' ' ARG . 68.6 t90 -73.71 -43.1 60.18 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 121.001 0.429 . . . . 0.0 110.73 179.642 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 179' ' ' LEU . . . . . 0.441 ' O ' HG22 ' A' ' 185' ' ' VAL . 1.6 tm? -68.71 -51.25 43.61 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 115.765 -0.652 . . . . 0.0 111.188 -179.497 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 180' ' ' LEU . . . . . 0.589 HD22 HD11 ' A' ' 187' ' ' LEU . 13.8 mt -75.22 -47.24 29.16 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-N 116.442 -0.345 . . . . 0.0 111.78 -179.223 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . -57.01 178.91 0.73 Allowed Glycine 0 C--N 1.337 0.622 0 C-N-CA 120.415 -0.898 . . . . 0.0 112.71 179.858 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 182' ' ' PRO . . . . . 0.694 ' HA ' ' HB2' ' A' ' 186' ' ' ALA . 72.9 Cg_exo -47.73 -45.27 24.46 Favored 'Trans proline' 0 CA--C 1.536 0.582 0 C-N-CA 122.848 2.365 . . . . 0.0 113.762 -179.842 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 183' ' ' PRO . . . . . 0.427 ' HD3' ' HB2' ' A' ' 182' ' ' PRO . 76.2 Cg_exo -51.83 -16.98 4.62 Favored 'Trans proline' 0 C--N 1.356 0.945 0 C-N-CA 122.173 1.916 . . . . 0.0 113.145 -179.787 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 184' ' ' GLY . . . . . 0.409 ' HA3' ' O ' ' A' ' 179' ' ' LEU . . . -115.93 -90.91 1.66 Allowed Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.463 -0.875 . . . . 0.0 113.001 -179.749 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 185' ' ' VAL . . . . . 0.441 HG22 ' O ' ' A' ' 179' ' ' LEU . 9.4 m -116.48 -7.66 12.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 N-CA-C 111.716 0.265 . . . . 0.0 111.716 -179.43 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 186' ' ' ALA . . . . . 0.694 ' HB2' ' HA ' ' A' ' 182' ' ' PRO . . . 56.66 85.69 0.08 Allowed 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.404 -0.362 . . . . 0.0 111.717 179.567 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 187' ' ' LEU . . . . . 0.589 HD11 HD22 ' A' ' 180' ' ' LEU . 20.9 mt -91.87 -49.45 6.24 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-O 120.927 0.394 . . . . 0.0 110.713 179.567 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 188' ' ' LEU . . . . . 0.428 ' HB3' ' H ' ' A' ' 189' ' ' THR . 95.6 mt -90.23 -154.48 0.33 Allowed 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 115.883 -0.599 . . . . 0.0 110.896 -179.962 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 189' ' ' THR . . . . . 0.428 ' H ' ' HB3' ' A' ' 188' ' ' LEU . 29.8 m -95.99 134.89 23.21 Favored Pre-proline 0 C--N 1.328 -0.342 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.649 -179.862 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 190' ' ' PRO . . . . . 0.407 ' O ' HG23 ' A' ' 194' ' ' VAL . 82.3 Cg_exo -44.99 -31.31 5.31 Favored 'Trans proline' 0 C--N 1.351 0.664 0 C-N-CA 122.592 2.195 . . . . 0.0 112.884 179.999 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 191' ' ' THR . . . . . 0.463 HG22 HD13 ' A' ' 4' ' ' LEU . 81.5 p -76.37 -42.05 45.94 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.481 -0.327 . . . . 0.0 111.326 -179.896 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 192' ' ' VAL . . . . . . . . . . . . . 58.3 t -70.08 -48.94 59.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.312 -0.404 . . . . 0.0 111.562 -179.504 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 193' ' ' ASP . . . . . . . . . . . . . 19.3 m-20 -53.78 -46.3 70.95 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.349 -0.387 . . . . 0.0 110.965 -179.89 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 194' ' ' VAL . . . . . 0.407 HG23 ' O ' ' A' ' 190' ' ' PRO . 69.5 t -65.36 -36.05 76.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.28 -0.418 . . . . 0.0 110.883 179.712 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 195' ' ' ALA . . . . . . . . . . . . . . . -55.0 -44.45 74.51 Favored 'General case' 0 C--N 1.331 -0.199 0 CA-C-N 116.421 -0.354 . . . . 0.0 110.843 179.783 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 196' ' ' LEU . . . . . . . . . . . . . 91.2 mt -68.07 -39.05 83.03 Favored 'General case' 0 C--N 1.332 -0.195 0 CA-C-O 120.895 0.379 . . . . 0.0 110.387 179.26 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 197' ' ' ILE . . . . . 0.449 HG12 HG21 ' A' ' 177' ' ' ILE . 13.2 mm -58.57 -56.31 17.24 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-N 115.971 -0.559 . . . . 0.0 110.083 179.091 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 198' ' ' VAL . . . . . . . . . . . . . 73.6 t -53.6 -34.46 24.09 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.509 0 CA-C-N 115.442 -0.799 . . . . 0.0 109.368 178.208 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 199' ' ' TYR . . . . . . . . . . . . . 70.0 t80 -69.92 -31.43 69.2 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 115.203 -0.908 . . . . 0.0 110.628 180.0 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 200' ' ' LEU . . . . . 0.446 HD12 HD13 ' A' ' 197' ' ' ILE . 62.5 mt -67.75 -45.53 74.7 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 115.9 -0.591 . . . . 0.0 111.299 -179.73 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 201' ' ' ASP . . . . . . . . . . . . . 7.8 m-20 -70.56 -32.61 70.1 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 121.063 0.459 . . . . 0.0 110.396 179.957 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 202' ' ' LEU . . . . . 0.489 HD11 ' HA2' ' A' ' 11' ' ' GLY . 3.9 mt -66.81 -41.99 86.64 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 115.544 -0.753 . . . . 0.0 111.882 -179.892 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 203' ' ' VAL . . . . . 0.406 ' CG1' HD22 ' A' ' 170' ' ' LEU . 8.2 p -71.47 -37.01 62.81 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.366 0 N-CA-C 111.883 0.327 . . . . 0.0 111.883 -178.582 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 204' ' ' THR . . . . . 0.439 ' O ' ' HB2' ' A' ' 208' ' ' PHE . 24.5 m -65.37 -47.29 76.89 Favored 'General case' 0 C--N 1.329 -0.312 0 C-N-CA 120.832 -0.347 . . . . 0.0 111.674 -179.92 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 205' ' ' LYS . . . . . 0.67 ' HE2' ' HB2' ' A' ' 47' ' ' ALA . 60.4 mttp -79.3 -57.93 3.47 Favored 'General case' 0 C--N 1.326 -0.429 0 N-CA-C 112.168 0.432 . . . . 0.0 112.168 -178.225 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 44.4 t -67.33 -37.39 78.93 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.388 0 CA-C-N 116.331 -0.395 . . . . 0.0 111.522 -179.413 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 207' ' ' GLY . . . . . . . . . . . . . . . -70.75 -53.65 11.42 Favored Glycine 0 C--N 1.331 0.278 0 C-N-CA 120.663 -0.78 . . . . 0.0 112.668 -179.622 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 208' ' ' PHE . . . . . 0.439 ' HB2' ' O ' ' A' ' 204' ' ' THR . 5.4 t80 -57.3 -42.42 81.75 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 120.872 0.368 . . . . 0.0 110.67 179.699 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 209' ' ' GLY . . . . . 0.487 ' O ' ' HB3' ' A' ' 212' ' ' ALA . . . -69.93 -38.51 75.0 Favored Glycine 0 N--CA 1.452 -0.296 0 CA-C-N 115.405 -0.816 . . . . 0.0 113.417 -179.766 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 210' ' ' PHE . . . . . . . . . . . . . 1.1 m-85 -69.43 -38.7 77.96 Favored 'General case' 0 CA--C 1.51 -0.58 0 N-CA-C 107.944 -1.132 . . . . 0.0 107.944 179.201 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 211' ' ' ILE . . . . . . . . . . . . . 82.9 mt -70.67 -28.69 35.18 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.825 0 N-CA-C 107.133 -1.432 . . . . 0.0 107.133 176.353 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 212' ' ' ALA . . . . . 0.487 ' HB3' ' O ' ' A' ' 209' ' ' GLY . . . -68.14 -37.94 81.61 Favored 'General case' 0 N--CA 1.45 -0.469 0 CA-C-N 114.394 -1.276 . . . . 0.0 110.572 179.704 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 213' ' ' LEU . . . . . . . . . . . . . 88.3 mt -70.1 -53.44 17.38 Favored 'General case' 0 C--N 1.331 -0.198 0 CA-C-N 115.28 -0.873 . . . . 0.0 111.444 -179.608 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 214' ' ' ASP . . . . . . . . . . . . . 25.6 t70 -54.15 -36.32 63.19 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.308 -0.406 . . . . 0.0 110.933 -179.764 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 215' ' ' ALA . . . . . 0.528 ' HB1' HD13 ' A' ' 159' ' ' LEU . . . -67.29 -57.27 6.97 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.026 -0.534 . . . . 0.0 111.457 -179.935 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 216' ' ' ALA . . . . . . . . . . . . . . . -58.57 -43.03 89.28 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.414 -0.357 . . . . 0.0 111.218 -179.735 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 217' ' ' ALA . . . . . . . . . . . . . . . -57.76 -36.8 72.6 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.502 179.831 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 218' ' ' THR . . . . . . . . . . . . . 90.9 m -66.01 -40.69 91.3 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 115.905 -0.589 . . . . 0.0 110.802 179.558 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 219' ' ' LEU . . . . . . . . . . . . . 27.6 mt -64.98 -35.17 80.32 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-N 116.299 -0.409 . . . . 0.0 110.53 179.745 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 220' ' ' ARG . . . . . 0.403 HH11 ' HD2' ' A' ' 220' ' ' ARG . 23.9 ttt180 -83.39 -19.04 36.78 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 115.868 -0.606 . . . . 0.0 110.635 179.931 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 221' ' ' ALA . . . . . . . . . . . . . . . -82.33 -36.92 26.45 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.156 -0.475 . . . . 0.0 111.473 179.886 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 222' ' ' GLU . . . . . . . . . . . . . 11.6 pt-20 -91.9 -39.07 11.93 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-N 116.406 -0.361 . . . . 0.0 111.184 -179.606 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 223' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER 62.15 168.58 0.12 Allowed 'General case' 0 C--N 1.332 -0.164 0 CA-C-N 116.116 -0.493 . . . . 0.0 111.203 -179.472 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 224' ' ' GLY . . . . . . . . . . . . . . . -93.4 -4.66 64.07 Favored Glycine 0 C--N 1.33 0.223 0 C-N-CA 120.757 -0.735 . . . . 0.0 112.568 -179.942 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 225' ' ' GLU . . . . . . . . . . . . . 36.6 tt0 -94.69 146.13 24.37 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 120.777 0.322 . . . . 0.0 110.954 179.987 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 226' ' ' SER . . . . . . . . . . . . . 80.2 p -165.4 162.84 19.72 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.099 -0.5 . . . . 0.0 110.892 179.896 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 227' ' ' LEU . . . . . . . . . . . . . 52.1 tp -75.31 109.25 8.67 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.921 -179.948 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 228' ' ' ALA . . . . . . . . . . . . . . . -150.2 143.02 24.74 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.24 -179.971 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 229' ' ' GLY . . . . . . . . . . . . . . . -128.73 -129.6 3.2 Favored Glycine 0 C--N 1.331 0.257 0 C-N-CA 120.927 -0.654 . . . . 0.0 112.416 179.95 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 230' ' ' VAL . . . . . . . . . . . . . 43.7 t -109.74 129.96 63.69 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-O 120.748 0.309 . . . . 0.0 110.873 179.971 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 231' ' ' ASP . . . . . . . . . . . . . 23.8 m-20 -98.72 103.25 15.19 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.003 179.981 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 232' ' ' THR . . . . . . . . . . . . . 4.1 t -142.55 136.71 29.53 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 115.999 -0.546 . . . . 0.0 111.079 179.857 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 233' ' ' ASP . . . . . . . . . . . . . 15.1 t70 59.64 98.45 0.02 OUTLIER 'General case' 0 C--N 1.331 -0.213 0 CA-C-N 116.123 -0.49 . . . . 0.0 111.042 -179.884 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 234' ' ' THR . . . . . . . . . . . . . 57.9 m -139.1 95.95 9.23 Favored Pre-proline 0 C--N 1.329 -0.306 0 CA-C-N 116.101 -0.499 . . . . 0.0 111.017 -179.917 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 235' ' ' PRO . . . . . . . . . . . . . 38.5 Cg_exo -61.05 122.51 11.29 Favored 'Trans proline' 0 C--N 1.347 0.48 0 C-N-CA 122.533 2.155 . . . . 0.0 112.201 179.924 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 236' ' ' ALA . . . . . . . . . . . . . . . -163.7 108.39 1.03 Allowed 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.212 -179.886 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 237' ' ' VAL . . . . . . . . . . . . . 15.0 p -160.14 142.64 4.72 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.198 179.913 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 238' ' ' ALA . . . . . . . . . . . . . . . -149.99 136.73 19.27 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.952 -179.925 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 239' ' ' ASP . . . . . . . . . . . . . 10.0 m-20 60.14 103.32 0.02 OUTLIER 'General case' 0 C--N 1.332 -0.194 0 CA-C-N 116.106 -0.497 . . . . 0.0 111.162 -179.891 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 240' ' ' LEU . . . . . . . . . . . . . 54.4 tp -142.46 -27.61 0.61 Allowed 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.255 -0.429 . . . . 0.0 110.817 -179.903 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 241' ' ' GLU . . . . . . . . . . . . . 46.0 mt-10 -136.49 136.44 39.42 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.97 -179.973 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 242' ' ' HIS . . . . . . . . . . . . . 25.4 t60 -82.43 -37.0 26.1 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.785 -179.985 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 243' ' ' HIS . . . . . . . . . . . . . 42.1 m80 -104.57 127.21 52.24 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.801 -179.895 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 244' ' ' HIS . . . . . . . . . . . . . 39.2 m80 -74.6 -60.88 2.08 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.848 179.94 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 245' ' ' HIS . . . . . . . . . . . . . 63.3 m80 -67.81 170.7 7.58 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.101 -0.499 . . . . 0.0 110.688 179.952 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 246' ' ' HIS . . . . . . . . . . . . . 89.1 m-70 57.65 94.17 0.03 OUTLIER 'General case' 0 C--N 1.331 -0.213 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.907 -179.799 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 247' ' ' HIS . . . . . . . . . . . . . 47.0 t60 . . . . . 0 C--O 1.248 0.986 0 CA-C-O 118.311 -0.852 . . . . 0.0 110.816 179.976 . . . . . . . . 0 0 . 1 . 028 nuclear build full ' A' A ' 301' ' ' RET . . . . . 0.691 H203 ' HE1' ' A' ' 171' ' ' TRP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 48.8 mtm . . . . . 0 N--CA 1.486 1.352 0 CA-C-O 120.868 0.366 . . . . 0.0 110.928 . . . . . . . . . 0 0 . 1 . 029 nuclear build full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 11.5 t -103.54 -8.18 9.45 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-N 116.027 -0.533 . . . . 0.0 110.664 179.857 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -88.22 -38.73 7.13 Favored Glycine 0 N--CA 1.452 -0.253 0 C-N-CA 120.867 -0.683 . . . . 0.0 112.763 -179.821 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 89.1 mt -64.28 -37.42 87.42 Favored 'General case' 0 N--CA 1.45 -0.46 0 CA-C-O 120.841 0.353 . . . . 0.0 111.199 -179.945 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 5' ' ' THR . . . . . 0.46 ' HA ' ' HD2' ' A' ' 8' ' ' PHE . 78.5 p -59.79 -37.34 78.82 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.047 -0.524 . . . . 0.0 111.968 -179.6 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 20.1 p -54.24 -36.88 64.02 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.45 -0.341 . . . . 0.0 111.515 -179.441 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 7' ' ' LEU . . . . . . . . . . . . . 4.2 mm? -61.9 -53.05 61.06 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.308 -0.406 . . . . 0.0 111.344 -179.705 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 8' ' ' PHE . . . . . 0.721 ' HB2' ' HB2' ' A' ' 55' ' ' ALA . 29.2 m-85 -61.99 -27.32 68.78 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.367 -0.379 . . . . 0.0 111.223 -179.574 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 9' ' ' TRP . . . . . . . . . . . . . 19.7 m95 -69.61 -44.61 70.35 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 121.008 0.433 . . . . 0.0 110.204 179.882 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 90.2 mt -65.72 -37.12 85.53 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 115.926 -0.579 . . . . 0.0 109.997 179.181 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 11' ' ' GLY . . . . . 0.415 ' HA2' HD11 ' A' ' 202' ' ' LEU . . . -66.12 -32.9 83.72 Favored Glycine 0 N--CA 1.446 -0.677 0 CA-C-N 115.597 -0.729 . . . . 0.0 111.746 179.568 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -68.44 -37.29 80.11 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.856 0.36 . . . . 0.0 110.442 179.428 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 67.7 mt -59.47 -53.57 46.45 Favored 'Isoleucine or valine' 0 C--O 1.234 0.247 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.254 179.114 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -58.26 -34.78 75.38 Favored Glycine 0 C--N 1.332 0.36 0 C-N-CA 120.652 -0.785 . . . . 0.0 111.977 179.291 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 15' ' ' MET . . . . . 0.497 ' HE3' ' CB ' ' A' ' 47' ' ' ALA . 17.3 mmt -66.17 -41.23 90.59 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-O 120.772 0.32 . . . . 0.0 110.57 179.426 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 16' ' ' LEU . . . . . 0.429 HD22 ' HA ' ' A' ' 16' ' ' LEU . 0.3 OUTLIER -57.01 -40.74 77.2 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.067 -0.515 . . . . 0.0 109.95 179.371 . . . . . . . . 3 3 . 1 . 029 nuclear build full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 60.5 t -60.28 -48.86 86.5 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.241 0 CA-C-N 115.856 -0.611 . . . . 0.0 110.655 179.358 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -63.34 -48.55 77.95 Favored Glycine 0 C--N 1.332 0.356 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.058 179.337 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 43.9 m -50.13 -43.26 51.74 Favored 'General case' 0 C--N 1.328 -0.366 0 C-N-CA 122.317 0.247 . . . . 0.0 111.434 -179.659 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 87.2 mt -71.51 -44.41 64.69 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.597 -0.274 . . . . 0.0 111.694 -179.781 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -61.45 -31.67 71.63 Favored 'General case' 0 C--N 1.33 -0.28 0 N-CA-C 111.866 0.321 . . . . 0.0 111.866 -179.589 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 22' ' ' PHE . . . . . 0.511 ' HB2' HG22 ' A' ' 41' ' ' VAL . 6.9 m-85 -90.97 -35.37 14.72 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.693 0.283 . . . . 0.0 111.679 -179.32 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -66.84 -51.28 57.43 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-O 120.98 0.419 . . . . 0.0 111.781 -179.412 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 24' ' ' TRP . . . . . . . . . . . . . 7.3 t-105 -62.93 -50.68 69.87 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-N 115.804 -0.634 . . . . 0.0 110.891 -179.696 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -68.92 -19.88 64.21 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 116.364 -0.38 . . . . 0.0 110.741 179.552 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -73.32 -48.23 19.75 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.912 -0.661 . . . . 0.0 112.594 -179.961 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 78.4 mtp180 -60.5 -18.64 53.14 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 120.873 0.368 . . . . 0.0 110.688 179.877 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 33.5 t70 -109.37 98.42 7.83 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.043 -0.526 . . . . 0.0 110.639 179.811 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -166.35 -179.31 4.94 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.162 -179.836 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -68.79 -94.0 0.05 OUTLIER Glycine 0 N--CA 1.452 -0.25 0 C-N-CA 120.885 -0.674 . . . . 0.0 112.59 -179.939 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 47.4 t -158.8 -25.72 0.08 Allowed 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 120.818 0.342 . . . . 0.0 110.834 -179.948 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -90.99 -43.87 4.61 Favored Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.814 -0.708 . . . . 0.0 112.454 179.933 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 36.3 mt-10 -63.1 -21.03 65.9 Favored 'General case' 0 C--N 1.331 -0.218 0 CA-C-O 120.697 0.284 . . . . 0.0 110.946 179.993 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 34' ' ' ARG . . . . . . . . . . . . . 5.0 tmt_? -50.43 -38.2 41.98 Favored 'General case' 0 C--N 1.332 -0.169 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.202 -179.93 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 29.7 mmt180 -64.5 -44.86 89.6 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 116.343 -0.39 . . . . 0.0 111.211 -179.928 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 57.1 m-85 -66.78 -31.06 71.44 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.113 -179.989 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 37' ' ' TYR . . . . . 0.519 ' O ' HG23 ' A' ' 41' ' ' VAL . 32.2 m-85 -70.97 -52.32 20.46 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.087 -179.687 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 85.4 t -57.04 -36.84 52.24 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-O 121.141 0.496 . . . . 0.0 110.232 179.387 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 55.4 m -62.21 -50.32 72.26 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 115.629 -0.714 . . . . 0.0 110.8 179.489 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 40' ' ' LEU . . . . . 0.722 HD12 HD11 ' A' ' 43' ' ' ILE . 44.5 tp -63.06 -44.66 95.19 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 115.644 -0.707 . . . . 0.0 110.922 179.877 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 41' ' ' VAL . . . . . 0.519 HG23 ' O ' ' A' ' 37' ' ' TYR . 86.8 t -62.72 -34.04 63.34 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.43 0 CA-C-N 116.043 -0.526 . . . . 0.0 110.076 179.142 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 42' ' ' GLY . . . . . 0.433 ' O ' HG12 ' A' ' 46' ' ' ILE . . . -60.82 -49.76 75.1 Favored Glycine 0 N--CA 1.448 -0.546 0 CA-C-N 115.461 -0.79 . . . . 0.0 113.197 -179.897 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 43' ' ' ILE . . . . . 0.722 HD11 HD12 ' A' ' 40' ' ' LEU . 22.8 pt -62.29 -48.94 86.04 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.202 0 CA-C-N 117.03 0.415 . . . . 0.0 111.993 -179.296 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 44' ' ' SER . . . . . 0.426 ' N ' HG13 ' A' ' 43' ' ' ILE . 99.0 p -59.52 -29.56 67.96 Favored 'General case' 0 C--O 1.233 0.227 0 CA-C-O 120.993 0.425 . . . . 0.0 111.016 179.961 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -77.65 -54.57 4.54 Favored Glycine 0 N--CA 1.453 -0.207 0 C-N-CA 121.075 -0.583 . . . . 0.0 113.343 -179.07 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 46' ' ' ILE . . . . . 0.587 ' O ' HG22 ' A' ' 49' ' ' VAL . 10.3 pt -58.35 -36.23 57.42 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.248 0 CA-C-O 120.758 0.313 . . . . 0.0 111.143 -179.552 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 47' ' ' ALA . . . . . 0.73 ' HB2' ' HE2' ' A' ' 205' ' ' LYS . . . -68.32 -43.06 78.42 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-O 120.939 0.4 . . . . 0.0 110.443 178.621 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -55.16 -38.17 67.94 Favored 'General case' 0 C--N 1.332 -0.193 0 CA-C-N 115.805 -0.634 . . . . 0.0 111.823 -179.795 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 49' ' ' VAL . . . . . 0.587 HG22 ' O ' ' A' ' 46' ' ' ILE . 17.5 m -76.6 -34.35 23.84 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.221 0 CA-C-O 120.611 0.244 . . . . 0.0 111.457 -179.7 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -63.64 -38.41 91.03 Favored 'General case' 0 CA--C 1.52 -0.179 0 CA-C-O 121.037 0.446 . . . . 0.0 111.042 179.897 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 28.5 m-85 -72.57 -42.64 64.41 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-N 115.824 -0.625 . . . . 0.0 110.482 -179.773 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -59.99 -53.48 57.37 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-N 115.734 -0.666 . . . . 0.0 110.925 179.681 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 53' ' ' VAL . . . . . 0.507 HG23 ' N ' ' A' ' 54' ' ' MET . 31.3 m -60.21 -48.67 87.16 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.234 0 CA-C-N 116.317 -0.402 . . . . 0.0 110.874 179.936 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 54' ' ' MET . . . . . 0.507 ' N ' HG23 ' A' ' 53' ' ' VAL . 7.0 ttp -60.74 -29.11 69.18 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 121.206 0.527 . . . . 0.0 109.922 179.431 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 55' ' ' ALA . . . . . 0.721 ' HB2' ' HB2' ' A' ' 8' ' ' PHE . . . -75.58 -19.23 59.4 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 115.622 -0.717 . . . . 0.0 111.528 179.62 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 96.8 mt -89.09 -0.83 57.76 Favored 'General case' 0 C--N 1.331 -0.198 0 CA-C-N 116.454 -0.339 . . . . 0.0 111.523 -179.441 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 99.94 -22.56 39.71 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.583 -0.818 . . . . 0.0 113.14 179.521 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 58' ' ' VAL . . . . . 0.432 HG22 ' O ' ' A' ' 53' ' ' VAL . 34.0 m -73.05 147.33 9.9 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.202 0 CA-C-N 117.008 0.404 . . . . 0.0 110.568 179.729 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 59' ' ' GLY . . . . . 0.456 ' HA3' ' HD3' ' A' ' 71' ' ' PRO . . . 90.86 13.71 58.9 Favored Glycine 0 N--CA 1.448 -0.525 0 C-N-CA 120.694 -0.765 . . . . 0.0 111.869 -178.934 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 60' ' ' TRP . . . . . . . . . . . . . 13.3 m0 -103.34 98.42 8.33 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-O 121.14 0.495 . . . . 0.0 109.891 -179.978 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 20.8 t -91.4 117.03 67.58 Favored Pre-proline 0 C--N 1.323 -0.56 0 CA-C-N 115.524 -0.762 . . . . 0.0 111.209 -178.972 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 64.8 Cg_endo -73.12 135.9 23.7 Favored 'Trans proline' 0 C--N 1.35 0.617 0 C-N-CA 122.346 2.031 . . . . 0.0 112.435 -179.928 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 46.0 t -135.18 89.05 0.82 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 115.94 -0.573 . . . . 0.0 110.718 179.696 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . 55.97 -88.7 0.02 OUTLIER 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.021 -0.536 . . . . 0.0 111.538 -179.917 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 5.2 mp0 -116.78 -19.25 9.99 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-O 121.009 0.433 . . . . 0.0 110.745 -179.866 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 66' ' ' ARG . . . . . . . . . . . . . 67.8 mtp180 -98.22 166.18 11.52 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 115.677 -0.692 . . . . 0.0 110.564 179.938 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 39.4 m -136.83 125.79 24.29 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.886 0.374 . . . . 0.0 111.381 -179.882 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 11.3 t -109.7 146.31 15.25 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.04 -0.527 . . . . 0.0 110.691 179.767 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 69' ' ' PHE . . . . . 0.405 ' HA ' ' O ' ' A' ' 59' ' ' GLY . 27.5 m-85 -108.19 115.24 29.75 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.82 0.343 . . . . 0.0 110.602 -179.717 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 70' ' ' VAL . . . . . 0.668 HG12 ' HD3' ' A' ' 71' ' ' PRO . 1.4 p -69.0 -35.42 6.19 Favored Pre-proline 0 CA--C 1.542 0.651 0 N-CA-C 113.148 0.795 . . . . 0.0 113.148 -179.317 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 71' ' ' PRO . . . . . 0.668 ' HD3' HG12 ' A' ' 70' ' ' VAL . 61.2 Cg_endo -70.49 -18.19 33.74 Favored 'Trans proline' 0 C--N 1.36 1.148 0 C-N-CA 121.741 1.627 . . . . 0.0 112.574 -179.399 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 72' ' ' ARG . . . . . 0.448 ' NH2' HG13 ' A' ' 197' ' ' ILE . 72.4 ttt180 -75.9 -54.49 6.81 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.277 -0.42 . . . . 0.0 111.835 -179.026 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 73' ' ' TYR . . . . . . . . . . . . . 83.4 m-85 -73.34 -35.68 66.06 Favored 'General case' 0 C--N 1.331 -0.21 0 C-N-CA 121.085 -0.246 . . . . 0.0 111.203 -179.103 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 74' ' ' ILE . . . . . 0.437 ' O ' HD13 ' A' ' 74' ' ' ILE . 0.3 OUTLIER -67.17 -43.87 88.2 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.238 0 C-N-CA 120.818 -0.353 . . . . 0.0 110.354 179.72 . . . . . . . . 3 3 . 1 . 029 nuclear build full ' A' A ' 75' ' ' ASP . . . . . 0.508 ' O ' HG23 ' A' ' 79' ' ' THR . 20.3 t70 -59.27 -35.87 74.5 Favored 'General case' 0 N--CA 1.455 -0.188 0 N-CA-C 109.267 -0.642 . . . . 0.0 109.267 178.986 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 76' ' ' TRP . . . . . 0.5 ' HB3' ' SD ' ' A' ' 109' ' ' MET . 39.3 m0 -64.0 -36.57 84.41 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 115.702 -0.681 . . . . 0.0 110.577 179.134 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 77' ' ' ILE . . . . . 0.472 ' O ' ' HG2' ' A' ' 81' ' ' PRO . 79.5 mt -67.29 -28.95 44.16 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.239 179.5 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 81.9 mt -91.33 -14.74 30.24 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.068 -0.515 . . . . 0.0 112.023 179.868 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 79' ' ' THR . . . . . 0.508 HG23 ' O ' ' A' ' 75' ' ' ASP . 70.1 p -104.38 -53.3 2.74 Favored 'General case' 0 N--CA 1.463 0.182 0 N-CA-C 113.272 0.842 . . . . 0.0 113.272 -178.652 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 80' ' ' THR . . . . . 0.641 ' HB ' ' HD3' ' A' ' 81' ' ' PRO . 8.9 m -51.75 -55.44 29.98 Favored Pre-proline 0 C--N 1.329 -0.296 0 N-CA-C 113.014 0.746 . . . . 0.0 113.014 -178.033 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 81' ' ' PRO . . . . . 0.641 ' HD3' ' HB ' ' A' ' 80' ' ' THR . 52.7 Cg_exo -56.96 -25.58 63.35 Favored 'Trans proline' 0 C--N 1.352 0.752 0 C-N-CA 121.505 1.47 . . . . 0.0 111.77 -179.799 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 82' ' ' LEU . . . . . 0.477 HD23 HG23 ' A' ' 43' ' ' ILE . 10.9 tp -76.83 -33.16 57.96 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 115.806 -0.634 . . . . 0.0 110.577 179.961 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 83' ' ' ILE . . . . . 0.413 HG12 ' O ' ' A' ' 79' ' ' THR . 43.5 mm -65.99 -52.75 45.27 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.204 0 CA-C-O 120.883 0.373 . . . . 0.0 110.201 179.176 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 33.7 m -61.42 -30.02 47.19 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.256 0 N-CA-C 109.472 -0.566 . . . . 0.0 109.472 178.759 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 85' ' ' TYR . . . . . . . . . . . . . 68.0 t80 -67.75 -30.64 70.16 Favored 'General case' 0 N--CA 1.452 -0.329 0 CA-C-N 115.391 -0.822 . . . . 0.0 109.588 178.568 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 86' ' ' PHE . . . . . . . . . . . . . 3.3 t80 -65.14 -49.78 68.55 Favored 'General case' 0 C--O 1.232 0.172 0 CA-C-N 115.823 -0.626 . . . . 0.0 109.766 179.069 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 6.5 mt -63.87 -30.8 71.85 Favored 'General case' 0 CA--C 1.518 -0.259 0 CA-C-N 115.878 -0.601 . . . . 0.0 109.742 179.468 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -69.86 -29.08 71.18 Favored Glycine 0 N--CA 1.449 -0.455 0 CA-C-N 115.291 -0.868 . . . . 0.0 112.167 179.74 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 54.1 mt -74.04 -38.93 63.85 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-O 120.913 0.387 . . . . 0.0 110.524 179.622 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 94.6 mt -63.71 -35.82 81.81 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.002 -0.545 . . . . 0.0 110.975 179.801 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 91' ' ' ALA . . . . . 0.425 ' HB1' ' OG ' ' A' ' 148' ' ' SER . . . -80.97 -54.77 5.28 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.351 -179.677 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 101.51 61.56 0.77 Allowed Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.791 -0.719 . . . . 0.0 112.369 -179.668 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 93' ' ' LEU . . . . . 0.505 ' HB3' ' HB2' ' A' ' 97' ' ' GLU . 6.8 mp -80.37 178.37 8.34 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-O 120.797 0.332 . . . . 0.0 110.907 -179.771 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 94' ' ' ASP . . . . . . . . . . . . . 22.4 m-20 -96.15 168.09 10.81 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.658 179.73 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 67.8 m -55.32 -35.09 64.77 Favored 'General case' 0 C--N 1.33 -0.239 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.256 -179.899 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 27.6 tpt180 -69.33 -54.01 16.74 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.412 -0.358 . . . . 0.0 110.895 -179.815 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 97' ' ' GLU . . . . . 0.505 ' HB2' ' HB3' ' A' ' 93' ' ' LEU . 32.9 mt-10 -53.82 -49.55 68.12 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.098 -0.501 . . . . 0.0 111.184 -179.639 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 98' ' ' PHE . . . . . 0.42 ' O ' HG12 ' A' ' 102' ' ' ILE . 25.4 m-85 -55.26 -51.19 67.43 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.397 -0.365 . . . . 0.0 111.002 179.902 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -56.9 -29.89 59.44 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.858 -0.687 . . . . 0.0 112.637 -179.74 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 100' ' ' ILE . . . . . 0.41 HD12 ' HA ' ' A' ' 97' ' ' GLU . 77.4 mt -72.85 -43.26 60.45 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-O 120.85 0.357 . . . . 0.0 111.308 -179.903 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 61.3 t -68.29 -49.8 63.41 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.355 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.702 -179.435 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 102' ' ' ILE . . . . . 0.42 HG12 ' O ' ' A' ' 98' ' ' PHE . 39.9 mm -58.11 -52.23 61.11 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 CA-C-N 116.317 -0.401 . . . . 0.0 111.584 -179.367 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 14.7 t -58.28 -34.65 70.75 Favored 'General case' 0 C--N 1.331 -0.203 0 CA-C-O 120.746 0.308 . . . . 0.0 110.82 -179.801 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 104' ' ' LEU . . . . . 0.47 HD22 ' HE2' ' A' ' 140' ' ' TYR . 30.5 tp -61.61 -45.83 92.41 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.625 179.224 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 105' ' ' ASN . . . . . 0.579 ' N ' HD22 ' A' ' 105' ' ' ASN . 0.8 OUTLIER -64.83 -26.87 68.52 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.095 -0.502 . . . . 0.0 111.117 -179.818 . . . . . . . . 3 3 . 1 . 029 nuclear build full ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 99.3 m -66.29 -57.37 7.66 Favored 'General case' 0 C--N 1.331 -0.204 0 CA-C-N 116.548 -0.296 . . . . 0.0 111.351 179.878 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 8.8 p -58.16 -36.32 56.8 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.213 0 CA-C-N 116.383 -0.372 . . . . 0.0 110.862 -179.88 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 108' ' ' VAL . . . . . 0.423 HG23 ' O ' ' A' ' 104' ' ' LEU . 59.9 t -64.82 -53.3 43.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.554 179.358 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 109' ' ' MET . . . . . 0.563 ' HE1' HG21 ' A' ' 80' ' ' THR . 5.7 tpp -60.89 -31.06 70.56 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 115.941 -0.572 . . . . 0.0 110.417 179.885 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 11.9 mt -74.44 -30.34 61.85 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 115.976 -0.556 . . . . 0.0 110.267 179.507 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -62.43 -42.52 99.51 Favored 'General case' 0 C--N 1.332 -0.194 0 N-CA-C 109.514 -0.55 . . . . 0.0 109.514 178.607 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 112' ' ' GLY . . . . . 0.419 ' HA3' ' H21' ' A' ' 301' ' ' RET . . . -74.42 -39.18 43.25 Favored Glycine 0 N--CA 1.449 -0.438 0 N-CA-C 111.187 -0.765 . . . . 0.0 111.187 178.748 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 113' ' ' PHE . . . . . . . . . . . . . 0.7 OUTLIER -50.66 -70.92 0.07 Allowed 'General case' 0 C--N 1.332 -0.162 0 N-CA-C 109.539 -0.541 . . . . 0.0 109.539 179.02 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 114' ' ' ALA . . . . . 0.479 ' HA ' ' HB2' ' A' ' 117' ' ' MET . . . -64.13 -21.05 66.39 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 115.387 -0.824 . . . . 0.0 110.947 179.218 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 115' ' ' GLY . . . . . 0.52 ' HA2' HD22 ' A' ' 126' ' ' LEU . . . -52.25 -49.48 50.38 Favored Glycine 0 C--N 1.335 0.508 0 C-N-CA 120.765 -0.731 . . . . 0.0 111.925 179.635 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -78.5 -18.48 54.73 Favored 'General case' 0 C--N 1.325 -0.465 0 CA-C-O 120.85 0.357 . . . . 0.0 110.983 179.392 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 117' ' ' MET . . . . . 0.479 ' HB2' ' HA ' ' A' ' 114' ' ' ALA . 19.9 mmt -84.85 3.78 36.29 Favored 'General case' 0 C--N 1.332 -0.189 0 CA-C-N 116.103 -0.499 . . . . 0.0 112.03 -179.361 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 118' ' ' VAL . . . . . 0.493 HG21 ' HB3' ' A' ' 123' ' ' ARG . 35.5 m -66.31 146.32 99.03 Favored Pre-proline 0 C--N 1.328 -0.364 0 C-N-CA 121.046 -0.262 . . . . 0.0 111.407 -179.588 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 119' ' ' PRO . . . . . . . . . . . . . 92.9 Cg_endo -86.86 -11.35 5.61 Favored 'Trans proline' 0 C--N 1.348 0.535 0 C-N-CA 122.674 2.25 . . . . 0.0 112.226 179.781 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -140.27 -124.98 2.15 Favored Glycine 0 C--N 1.331 0.281 0 C-N-CA 120.84 -0.695 . . . . 0.0 112.795 -179.907 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 2.3 pp -109.94 18.15 7.06 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.187 0 CA-C-O 120.782 0.325 . . . . 0.0 111.695 -179.564 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 42.8 mt-10 -66.47 -18.53 65.41 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.306 -0.407 . . . . 0.0 111.159 -179.9 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 123' ' ' ARG . . . . . 0.493 ' HB3' HG21 ' A' ' 118' ' ' VAL . 17.8 ptt180 -50.47 -34.61 25.52 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.825 -179.516 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 124' ' ' TYR . . . . . . . . . . . . . 29.2 m-85 -61.5 -34.13 74.96 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.766 0.317 . . . . 0.0 111.13 -179.552 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 125' ' ' ALA . . . . . . . . . . . . . . . -74.5 -49.69 21.1 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.908 179.788 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 126' ' ' LEU . . . . . 0.52 HD22 ' HA2' ' A' ' 115' ' ' GLY . 7.3 mp -53.39 -49.15 67.84 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-N 116.051 -0.522 . . . . 0.0 110.588 179.921 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 127' ' ' PHE . . . . . . . . . . . . . 5.4 t80 -67.0 -37.77 84.78 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.821 179.958 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 128' ' ' GLY . . . . . . . . . . . . . . . -46.34 -43.09 13.98 Favored Glycine 0 C--N 1.332 0.338 0 C-N-CA 120.156 -1.021 . . . . 0.0 110.817 179.097 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 129' ' ' MET . . . . . . . . . . . . . 0.8 OUTLIER -71.81 -39.05 70.11 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.921 0.391 . . . . 0.0 109.971 178.509 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -60.95 -32.88 81.57 Favored Glycine 0 C--N 1.333 0.401 0 CA-C-N 115.916 -0.584 . . . . 0.0 113.043 -179.911 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -74.84 -53.87 8.32 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-O 120.669 0.271 . . . . 0.0 110.883 179.959 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 48.2 t -56.4 -40.35 66.54 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.228 0 CA-C-O 121.478 0.656 . . . . 0.0 109.477 179.055 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -68.52 -37.82 80.35 Favored 'General case' 0 N--CA 1.451 -0.424 0 CA-C-N 115.102 -0.954 . . . . 0.0 110.408 179.24 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 134' ' ' PHE . . . . . . . . . . . . . 79.5 t80 -54.64 -51.93 63.87 Favored 'General case' 0 N--CA 1.451 -0.388 0 CA-C-N 116.09 -0.505 . . . . 0.0 109.901 179.387 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 135' ' ' ILE . . . . . 0.523 ' O ' HG22 ' A' ' 138' ' ' VAL . 56.5 mt -58.75 -33.55 49.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 115.647 -0.706 . . . . 0.0 110.046 179.068 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . -58.4 -36.35 83.55 Favored Glycine 0 N--CA 1.449 -0.449 0 C-N-CA 120.239 -0.982 . . . . 0.0 111.136 178.616 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 137' ' ' LEU . . . . . . . . . . . . . 38.4 tp -71.1 -53.15 15.64 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 115.769 -0.216 . . . . 0.0 110.805 179.494 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 138' ' ' VAL . . . . . 0.523 HG22 ' O ' ' A' ' 135' ' ' ILE . 3.3 m -55.97 -32.55 33.38 Favored 'Isoleucine or valine' 0 C--O 1.232 0.137 0 CA-C-O 121.233 0.539 . . . . 0.0 109.863 179.483 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 139' ' ' TYR . . . . . . . . . . . . . 34.4 t80 -60.3 -50.15 74.78 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 115.5 -0.773 . . . . 0.0 110.303 178.894 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 140' ' ' TYR . . . . . 0.47 ' HE2' HD22 ' A' ' 104' ' ' LEU . 22.4 m-85 -56.9 -35.41 68.96 Favored 'General case' 0 C--N 1.332 -0.152 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.741 179.64 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 141' ' ' LEU . . . . . . . . . . . . . 96.0 mt -57.73 -52.0 67.23 Favored 'General case' 0 C--N 1.332 -0.172 0 CA-C-N 116.355 -0.384 . . . . 0.0 110.504 179.602 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 10.2 t -78.48 -10.35 12.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.09 -0.505 . . . . 0.0 110.778 179.672 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . -71.58 -131.39 0.11 Allowed Glycine 0 CA--C 1.521 0.45 0 C-N-CA 120.886 -0.673 . . . . 0.0 112.677 -179.887 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 144' ' ' PRO . . . . . . . . . . . . . 44.8 Cg_endo -67.84 -24.09 40.71 Favored 'Trans proline' 0 C--N 1.348 0.542 0 C-N-CA 122.403 2.069 . . . . 0.0 112.5 -179.888 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 145' ' ' MET . . . . . . . . . . . . . 45.2 mtt -55.41 -34.62 64.57 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 120.983 0.421 . . . . 0.0 111.063 179.876 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 146' ' ' THR . . . . . . . . . . . . . 27.4 m -70.78 -45.82 64.02 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 115.991 -0.55 . . . . 0.0 112.077 -179.181 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 46.3 mt-10 -72.22 -29.51 64.03 Favored 'General case' 0 C--N 1.328 -0.345 0 N-CA-C 111.846 0.313 . . . . 0.0 111.846 -179.101 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 148' ' ' SER . . . . . 0.425 ' OG ' ' HB1' ' A' ' 91' ' ' ALA . 42.0 p -70.15 -45.04 67.6 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.551 -0.295 . . . . 0.0 111.488 -179.241 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 149' ' ' ALA . . . . . . . . . . . . . . . -77.98 -39.84 41.13 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.772 0.32 . . . . 0.0 111.79 -179.514 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 150' ' ' SER . . . . . . . . . . . . . 40.3 t -65.82 -5.09 7.9 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.284 -0.416 . . . . 0.0 111.517 -179.536 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 151' ' ' GLN . . . . . . . . . . . . . 48.4 mt-30 -127.1 17.44 7.2 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.614 -0.266 . . . . 0.0 111.232 179.876 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 25.2 tpt180 -93.82 -52.04 4.62 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-O 120.817 0.341 . . . . 0.0 111.074 179.944 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 153' ' ' SER . . . . . 0.611 ' HB3' HG12 ' A' ' 156' ' ' ILE . 23.1 t -157.38 172.57 18.35 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.581 179.466 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 154' ' ' SER . . . . . . . . . . . . . 47.6 t -70.39 -39.8 74.33 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.773 0.32 . . . . 0.0 110.949 179.961 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -76.95 -34.7 41.54 Favored Glycine 0 CA--C 1.518 0.254 0 C-N-CA 120.862 -0.685 . . . . 0.0 112.986 -179.899 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 156' ' ' ILE . . . . . 0.611 HG12 ' HB3' ' A' ' 153' ' ' SER . 38.5 mm -54.46 -38.18 40.4 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 CA-C-O 120.605 0.24 . . . . 0.0 111.492 -179.664 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 157' ' ' LYS . . . . . 0.435 ' O ' HG22 ' A' ' 161' ' ' VAL . 27.2 ttpp -68.22 -31.98 71.87 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.41 -0.359 . . . . 0.0 111.371 -179.724 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 53.5 m -71.39 -48.5 49.56 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-O 120.898 0.38 . . . . 0.0 111.411 -179.631 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 159' ' ' LEU . . . . . 0.524 HD21 ' HB3' ' A' ' 215' ' ' ALA . 14.3 mt -71.16 -35.48 71.67 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.607 -179.637 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 160' ' ' TYR . . . . . . . . . . . . . 76.3 t80 -64.95 -44.86 88.04 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.471 -0.331 . . . . 0.0 111.874 -179.098 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 161' ' ' VAL . . . . . 0.435 HG22 ' O ' ' A' ' 157' ' ' LYS . 31.0 m -67.35 -46.28 84.06 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 N-CA-C 111.927 0.343 . . . . 0.0 111.927 -179.172 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 162' ' ' ARG . . . . . 0.433 ' N ' HG23 ' A' ' 161' ' ' VAL . 78.5 mtm180 -64.78 -35.9 82.57 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.73 0.3 . . . . 0.0 111.529 -179.631 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 163' ' ' LEU . . . . . 0.56 ' HG ' ' HB2' ' A' ' 208' ' ' PHE . 7.7 mp -76.87 -51.37 11.38 Favored 'General case' 0 C--N 1.328 -0.349 0 N-CA-C 112.179 0.437 . . . . 0.0 112.179 -179.074 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 164' ' ' ARG . . . . . . . . . . . . . 5.6 ppt_? -62.11 -41.68 98.47 Favored 'General case' 0 C--N 1.328 -0.331 0 N-CA-C 112.064 0.394 . . . . 0.0 112.064 -178.514 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 165' ' ' ASN . . . . . 0.463 ' O ' HG23 ' A' ' 169' ' ' VAL . 6.6 m120 -69.38 -51.38 37.18 Favored 'General case' 0 C--N 1.332 -0.188 0 CA-C-O 120.696 0.284 . . . . 0.0 111.616 -179.788 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 166' ' ' LEU . . . . . 0.476 ' O ' ' HG ' ' A' ' 170' ' ' LEU . 4.2 tt -60.32 -51.33 69.97 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-O 120.844 0.354 . . . . 0.0 111.421 -179.601 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 167' ' ' THR . . . . . . . . . . . . . 88.3 m -59.91 -52.54 64.98 Favored 'General case' 0 C--N 1.329 -0.317 0 N-CA-C 112.923 0.712 . . . . 0.0 112.923 -178.826 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 168' ' ' VAL . . . . . 0.454 HG12 ' O ' ' A' ' 165' ' ' ASN . 8.9 p -54.32 -40.28 47.44 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.195 0 N-CA-C 112.297 0.48 . . . . 0.0 112.297 -178.546 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 169' ' ' VAL . . . . . 0.463 HG23 ' O ' ' A' ' 165' ' ' ASN . 79.1 t -62.03 -64.37 0.65 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-N 116.574 -0.285 . . . . 0.0 111.621 -179.721 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 170' ' ' LEU . . . . . 0.476 ' HG ' ' O ' ' A' ' 166' ' ' LEU . 1.2 pp -60.59 -30.96 70.14 Favored 'General case' 0 C--N 1.33 -0.272 0 N-CA-C 111.97 0.359 . . . . 0.0 111.97 -179.011 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 171' ' ' TRP . . . . . 0.796 ' HE1' H203 ' A' ' 301' ' ' RET . 3.2 m0 -70.32 -35.09 73.42 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-O 120.928 0.394 . . . . 0.0 110.383 179.431 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 172' ' ' ALA . . . . . . . . . . . . . . . -69.3 -7.28 35.67 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 115.844 -0.617 . . . . 0.0 110.801 -179.793 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 173' ' ' ILE . . . . . 0.624 HG22 HD11 ' A' ' 177' ' ' ILE . 43.6 mm -84.78 -23.53 7.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 115.917 -0.583 . . . . 0.0 110.736 179.536 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 174' ' ' TYR . . . . . 0.457 ' HB2' ' HD3' ' A' ' 175' ' ' PRO . 22.2 m-85 -54.41 -51.16 80.48 Favored Pre-proline 0 N--CA 1.464 0.254 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.768 -179.89 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 175' ' ' PRO . . . . . 0.457 ' HD3' ' HB2' ' A' ' 174' ' ' TYR . 87.5 Cg_exo -46.84 -29.07 7.62 Favored 'Trans proline' 0 C--N 1.352 0.752 0 C-N-CA 122.225 1.95 . . . . 0.0 112.387 -179.905 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 176' ' ' PHE . . . . . 0.5 ' O ' ' HG ' ' A' ' 180' ' ' LEU . 81.0 m-85 -80.6 -49.81 10.8 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 115.992 -0.549 . . . . 0.0 111.802 -179.893 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 177' ' ' ILE . . . . . 0.624 HD11 HG22 ' A' ' 173' ' ' ILE . 2.4 mm -61.19 -37.15 76.83 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.54 0 CA-C-N 116.201 -0.454 . . . . 0.0 112.133 -178.043 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 178' ' ' TRP . . . . . . . . . . . . . 63.8 t90 -73.45 -41.08 63.66 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-O 120.84 0.352 . . . . 0.0 110.637 179.628 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 179' ' ' LEU . . . . . 0.479 ' O ' HG22 ' A' ' 185' ' ' VAL . 2.6 tm? -68.54 -54.07 19.02 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 115.97 -0.559 . . . . 0.0 111.259 -179.426 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 180' ' ' LEU . . . . . 0.584 HD22 HD11 ' A' ' 187' ' ' LEU . 11.9 mt -72.58 -46.49 54.05 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.541 -0.3 . . . . 0.0 111.489 -179.408 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 181' ' ' GLY . . . . . 0.424 ' HA3' ' OD1' ' A' ' 193' ' ' ASP . . . -55.1 173.13 0.99 Allowed Glycine 0 C--N 1.336 0.557 0 C-N-CA 120.558 -0.829 . . . . 0.0 112.682 179.865 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 182' ' ' PRO . . . . . 0.659 ' HA ' ' HB2' ' A' ' 186' ' ' ALA . 82.9 Cg_exo -47.78 -44.67 26.17 Favored 'Trans proline' 0 C--N 1.347 0.49 0 C-N-CA 122.776 2.317 . . . . 0.0 113.611 179.87 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 183' ' ' PRO . . . . . 0.419 ' HD3' ' HB2' ' A' ' 182' ' ' PRO . 57.6 Cg_exo -52.65 -14.85 3.6 Favored 'Trans proline' 0 C--N 1.355 0.877 0 C-N-CA 121.982 1.788 . . . . 0.0 112.551 179.633 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 184' ' ' GLY . . . . . 0.401 ' HA3' ' O ' ' A' ' 179' ' ' LEU . . . -115.08 -81.03 0.93 Allowed Glycine 0 N--CA 1.45 -0.373 0 C-N-CA 120.776 -0.726 . . . . 0.0 112.678 -179.982 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 185' ' ' VAL . . . . . 0.479 HG22 ' O ' ' A' ' 179' ' ' LEU . 6.3 m -132.05 -2.9 1.85 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.208 0 N-CA-C 112.409 0.522 . . . . 0.0 112.409 -179.572 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 186' ' ' ALA . . . . . 0.659 ' HB2' ' HA ' ' A' ' 182' ' ' PRO . . . 53.02 87.31 0.04 OUTLIER 'General case' 0 C--N 1.331 -0.22 0 CA-C-O 120.723 0.297 . . . . 0.0 111.642 179.78 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 187' ' ' LEU . . . . . 0.584 HD11 HD22 ' A' ' 180' ' ' LEU . 18.6 mt -92.01 -49.82 6.02 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 120.838 0.351 . . . . 0.0 111.406 179.934 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 188' ' ' LEU . . . . . . . . . . . . . 38.8 mt -94.84 -89.45 0.23 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.087 -0.506 . . . . 0.0 111.412 -179.325 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 189' ' ' THR . . . . . . . . . . . . . 1.1 t -165.36 148.34 6.93 Favored Pre-proline 0 C--N 1.325 -0.461 0 CA-C-N 115.856 -0.611 . . . . 0.0 111.06 -179.56 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 190' ' ' PRO . . . . . . . . . . . . . 12.1 Cg_endo -55.83 -30.31 76.17 Favored 'Trans proline' 0 C--N 1.347 0.494 0 C-N-CA 122.513 2.142 . . . . 0.0 112.427 -179.994 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 191' ' ' THR . . . . . . . . . . . . . 77.9 p -64.56 -45.28 87.78 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 121.012 0.434 . . . . 0.0 110.686 179.682 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 192' ' ' VAL . . . . . . . . . . . . . 25.4 t -73.89 -38.47 50.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 115.81 -0.632 . . . . 0.0 111.056 179.857 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 193' ' ' ASP . . . . . 0.478 ' OD1' HG22 ' A' ' 177' ' ' ILE . 14.5 t70 -59.49 -51.51 69.56 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.9 179.8 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 194' ' ' VAL . . . . . . . . . . . . . 94.6 t -64.34 -36.37 76.96 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-N 116.02 -0.536 . . . . 0.0 111.185 -179.896 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 195' ' ' ALA . . . . . . . . . . . . . . . -57.64 -48.68 78.79 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.695 0.283 . . . . 0.0 111.092 179.92 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 196' ' ' LEU . . . . . . . . . . . . . 63.0 mt -68.44 -43.27 77.47 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 116.389 -0.369 . . . . 0.0 110.589 179.617 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 197' ' ' ILE . . . . . 0.499 HG12 HG21 ' A' ' 177' ' ' ILE . 17.2 mm -56.2 -59.34 2.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 115.944 -0.571 . . . . 0.0 110.56 179.416 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 198' ' ' VAL . . . . . . . . . . . . . 61.0 t -52.3 -35.39 19.63 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.505 0 CA-C-N 115.594 -0.73 . . . . 0.0 109.433 178.62 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 199' ' ' TYR . . . . . . . . . . . . . 67.3 t80 -70.58 -31.14 68.04 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 115.244 -0.889 . . . . 0.0 110.916 -179.904 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 200' ' ' LEU . . . . . 0.536 ' O ' HG12 ' A' ' 203' ' ' VAL . 37.1 mt -71.88 -40.23 69.06 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 115.902 -0.59 . . . . 0.0 111.544 -179.545 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 201' ' ' ASP . . . . . . . . . . . . . 14.7 m-20 -72.81 -34.87 67.15 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-O 121.237 0.542 . . . . 0.0 110.114 179.519 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 202' ' ' LEU . . . . . 0.415 HD11 ' HA2' ' A' ' 11' ' ' GLY . 2.5 mt -73.01 -29.28 62.91 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 115.415 -0.811 . . . . 0.0 111.601 -179.634 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 203' ' ' VAL . . . . . 0.536 HG12 ' O ' ' A' ' 200' ' ' LEU . 12.5 p -77.6 -36.25 22.77 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.382 0 C-N-CA 121.045 -0.262 . . . . 0.0 110.669 -179.083 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 204' ' ' THR . . . . . . . . . . . . . 98.6 m -65.49 -58.79 4.97 Favored 'General case' 0 C--N 1.329 -0.307 0 C-N-CA 120.596 -0.442 . . . . 0.0 110.994 179.306 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 205' ' ' LYS . . . . . 0.73 ' HE2' ' HB2' ' A' ' 47' ' ' ALA . 61.5 mttp -63.27 -58.1 8.27 Favored 'General case' 0 C--N 1.33 -0.24 0 N-CA-C 112.461 0.541 . . . . 0.0 112.461 -178.259 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 44.6 t -69.97 -37.54 72.94 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.412 0 N-CA-C 112.235 0.458 . . . . 0.0 112.235 -178.751 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 207' ' ' GLY . . . . . 0.52 ' O ' HG13 ' A' ' 211' ' ' ILE . . . -58.22 -61.83 6.97 Favored Glycine 0 CA--C 1.52 0.365 0 C-N-CA 120.67 -0.776 . . . . 0.0 114.059 -178.486 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 208' ' ' PHE . . . . . 0.56 ' HB2' ' HG ' ' A' ' 163' ' ' LEU . 0.9 OUTLIER -73.41 -27.04 61.24 Favored 'General case' 0 C--O 1.221 -0.414 0 CA-C-N 117.47 0.635 . . . . 0.0 110.802 -179.14 . . . . . . . . 3 3 . 1 . 029 nuclear build full ' A' A ' 209' ' ' GLY . . . . . 0.502 ' O ' ' HB3' ' A' ' 212' ' ' ALA . . . -63.19 -32.39 83.99 Favored Glycine 0 N--CA 1.447 -0.626 0 N-CA-C 111.663 -0.575 . . . . 0.0 111.663 178.616 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 210' ' ' PHE . . . . . . . . . . . . . 1.3 m-85 -75.08 -46.91 31.52 Favored 'General case' 0 CA--C 1.514 -0.439 0 N-CA-C 108.37 -0.974 . . . . 0.0 108.37 178.336 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 211' ' ' ILE . . . . . 0.52 HG13 ' O ' ' A' ' 207' ' ' GLY . 4.1 mt -63.41 -27.59 43.34 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.411 0 N-CA-C 107.473 -1.306 . . . . 0.0 107.473 176.67 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 212' ' ' ALA . . . . . 0.502 ' HB3' ' O ' ' A' ' 209' ' ' GLY . . . -63.79 -41.23 97.98 Favored 'General case' 0 N--CA 1.45 -0.461 0 CA-C-N 114.303 -1.317 . . . . 0.0 110.634 -179.772 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 213' ' ' LEU . . . . . . . . . . . . . 72.9 mt -70.12 -50.17 43.43 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 115.179 -0.919 . . . . 0.0 111.783 -179.393 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 214' ' ' ASP . . . . . . . . . . . . . 21.7 t70 -53.24 -51.83 60.94 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.331 -0.395 . . . . 0.0 111.581 -179.315 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 215' ' ' ALA . . . . . 0.524 ' HB3' HD21 ' A' ' 159' ' ' LEU . . . -64.63 -55.32 20.99 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.379 -0.373 . . . . 0.0 111.772 -179.54 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 216' ' ' ALA . . . . . 0.466 ' HA ' HD12 ' A' ' 219' ' ' LEU . . . -51.87 -37.07 50.78 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 116.414 -0.357 . . . . 0.0 111.496 -179.707 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 217' ' ' ALA . . . . . . . . . . . . . . . -63.65 -44.26 94.36 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.997 0.427 . . . . 0.0 110.06 179.577 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 218' ' ' THR . . . . . 0.424 ' HA ' ' HB3' ' A' ' 221' ' ' ALA . 54.3 m -63.67 -37.42 87.28 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 115.669 -0.696 . . . . 0.0 110.626 179.376 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 219' ' ' LEU . . . . . 0.466 HD12 ' HA ' ' A' ' 216' ' ' ALA . 93.7 mt -56.62 -50.21 72.69 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 115.951 -0.568 . . . . 0.0 110.739 179.98 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 220' ' ' ARG . . . . . . . . . . . . . 13.9 ptm180 -83.42 -10.33 58.47 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.333 -0.394 . . . . 0.0 111.006 179.831 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 221' ' ' ALA . . . . . 0.424 ' HB3' ' HA ' ' A' ' 218' ' ' THR . . . -82.68 -20.13 36.75 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.371 -0.377 . . . . 0.0 111.952 -179.958 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 222' ' ' GLU . . . . . . . . . . . . . 10.7 pt-20 -90.73 -32.04 16.32 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-O 120.648 0.261 . . . . 0.0 111.288 -179.583 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 223' ' ' HIS . . . . . . . . . . . . . 1.7 p-80 -128.99 174.24 9.71 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.724 0.297 . . . . 0.0 111.078 179.851 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 224' ' ' GLY . . . . . . . . . . . . . . . -114.32 -59.15 0.38 Allowed Glycine 0 N--CA 1.452 -0.283 0 C-N-CA 120.702 -0.761 . . . . 0.0 112.462 179.93 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 225' ' ' GLU . . . . . . . . . . . . . 9.8 tp10 58.53 99.64 0.02 OUTLIER 'General case' 0 C--N 1.332 -0.162 0 CA-C-O 120.888 0.375 . . . . 0.0 111.05 179.998 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 226' ' ' SER . . . . . . . . . . . . . 80.9 p -150.33 148.06 28.37 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.888 179.888 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 227' ' ' LEU . . . . . . . . . . . . . 97.1 mt -87.83 140.99 28.95 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.837 179.99 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 228' ' ' ALA . . . . . . . . . . . . . . . 50.76 91.07 0.02 OUTLIER 'General case' 0 C--N 1.331 -0.203 0 CA-C-N 116.079 -0.51 . . . . 0.0 111.552 -179.786 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 229' ' ' GLY . . . . . . . . . . . . . . . -117.73 134.97 11.42 Favored Glycine 0 C--N 1.332 0.311 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.593 -179.872 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 230' ' ' VAL . . . . . . . . . . . . . 28.7 m -101.73 147.75 8.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-O 120.833 0.349 . . . . 0.0 111.101 179.906 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 231' ' ' ASP . . . . . . . . . . . . . 18.5 t70 -101.46 102.79 13.63 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.061 -179.82 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 232' ' ' THR . . . . . . . . . . . . . 80.7 p -139.22 152.68 47.54 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.138 179.871 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 233' ' ' ASP . . . . . . . . . . . . . 29.2 m-20 -109.51 -58.52 2.03 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.849 179.818 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 234' ' ' THR . . . . . . . . . . . . . 85.5 m -127.95 101.89 22.55 Favored Pre-proline 0 C--N 1.329 -0.298 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.157 -179.935 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 235' ' ' PRO . . . . . . . . . . . . . 60.4 Cg_endo -72.35 163.58 38.2 Favored 'Trans proline' 0 C--N 1.349 0.576 0 C-N-CA 122.482 2.121 . . . . 0.0 112.333 179.856 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 236' ' ' ALA . . . . . 0.405 ' HB1' ' HG2' ' A' ' 241' ' ' GLU . . . -93.67 130.05 39.74 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 116.124 -0.489 . . . . 0.0 111.083 179.915 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 237' ' ' VAL . . . . . . . . . . . . . 13.4 p -90.81 145.34 7.54 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.222 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.987 -179.886 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 238' ' ' ALA . . . . . . . . . . . . . . . 60.13 -178.94 0.1 Allowed 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.258 -179.929 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 239' ' ' ASP . . . . . . . . . . . . . 4.5 p30 -107.08 -0.18 23.08 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.121 -0.491 . . . . 0.0 110.869 -179.958 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 240' ' ' LEU . . . . . 0.419 ' H ' ' HG ' ' A' ' 240' ' ' LEU . 1.9 pp -86.63 -7.29 58.46 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.242 -0.436 . . . . 0.0 111.098 179.943 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 241' ' ' GLU . . . . . 0.405 ' HG2' ' HB1' ' A' ' 236' ' ' ALA . 9.3 tp10 -64.02 122.89 17.63 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.741 179.828 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 242' ' ' HIS . . . . . . . . . . . . . 88.7 m-70 -67.29 149.09 50.84 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.822 179.94 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 243' ' ' HIS . . . . . . . . . . . . . 26.3 p80 -148.71 -11.56 0.34 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.05 -0.523 . . . . 0.0 110.907 -179.949 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 244' ' ' HIS . . . . . . . . . . . . . 13.1 p80 -82.33 136.84 34.94 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.055 -0.52 . . . . 0.0 110.963 -179.941 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 245' ' ' HIS . . . . . . . . . . . . . 47.8 m80 58.81 -176.11 0.09 Allowed 'General case' 0 C--N 1.332 -0.186 0 CA-C-N 116.074 -0.512 . . . . 0.0 111.077 179.957 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 246' ' ' HIS . . . . . . . . . . . . . 36.5 m-70 -74.87 -50.11 18.12 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.057 179.978 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 247' ' ' HIS . . . . . . . . . . . . . 7.9 p80 . . . . . 0 C--O 1.248 1.021 0 CA-C-O 118.106 -0.949 . . . . 0.0 111.105 -179.847 . . . . . . . . 0 0 . 1 . 029 nuclear build full ' A' A ' 301' ' ' RET . . . . . 0.796 H203 ' HE1' ' A' ' 171' ' ' TRP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 80.2 mtp . . . . . 0 N--CA 1.485 1.277 0 CA-C-O 120.651 0.263 . . . . 0.0 110.808 . . . . . . . . . 0 0 . 1 . 030 nuclear build full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 30.2 m -119.64 -29.56 1.8 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.373 -0.376 . . . . 0.0 111.22 -179.876 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -84.39 -25.84 41.87 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.481 179.926 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 55.3 tp -74.26 -35.84 63.82 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.904 0.383 . . . . 0.0 110.801 179.785 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 68.3 p -64.22 -29.67 70.76 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 115.935 -0.575 . . . . 0.0 111.569 -179.74 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 29.9 p -52.8 -38.07 60.67 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.601 -179.52 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 7' ' ' LEU . . . . . 0.498 HD12 ' HA ' ' A' ' 195' ' ' ALA . 3.4 mm? -59.4 -53.27 60.09 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.475 -0.33 . . . . 0.0 110.84 -179.798 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 8' ' ' PHE . . . . . 0.444 ' O ' ' HB3' ' A' ' 51' ' ' TYR . 73.9 m-85 -58.43 -36.2 73.28 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.594 179.879 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 9' ' ' TRP . . . . . . . . . . . . . 25.4 m95 -64.94 -41.03 95.87 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-O 121.161 0.505 . . . . 0.0 110.151 179.825 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 83.1 mt -62.35 -49.51 75.3 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 115.562 -0.744 . . . . 0.0 110.519 179.512 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -55.21 -34.81 59.19 Favored Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.683 -0.77 . . . . 0.0 111.999 179.291 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -67.86 -36.23 79.94 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-O 120.795 0.331 . . . . 0.0 110.847 179.745 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 91.1 mt -60.28 -54.16 38.79 Favored 'Isoleucine or valine' 0 C--O 1.234 0.241 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.668 179.556 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -63.02 -30.64 78.1 Favored Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 120.688 -0.768 . . . . 0.0 111.871 179.478 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 15' ' ' MET . . . . . 0.617 ' HB3' ' HB2' ' A' ' 48' ' ' ALA . 0.0 OUTLIER -64.46 -48.93 73.42 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.666 0.27 . . . . 0.0 110.835 179.656 . . . . . . . . 3 3 . 1 . 030 nuclear build full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -57.7 -41.3 81.42 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.334 -0.393 . . . . 0.0 110.94 179.73 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 96.5 t -59.33 -42.57 87.73 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.25 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.554 179.503 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -70.44 -46.73 46.88 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.845 -0.693 . . . . 0.0 112.1 179.588 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 20.5 m -49.5 -45.39 47.03 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-O 120.78 0.324 . . . . 0.0 111.134 -179.755 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 68.3 mt -71.51 -36.74 71.17 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.099 179.618 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -64.09 -31.85 73.19 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.316 -0.402 . . . . 0.0 111.537 -179.801 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 22' ' ' PHE . . . . . 0.714 ' HB2' HG22 ' A' ' 41' ' ' VAL . 7.5 m-85 -90.28 -28.4 18.82 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-O 120.813 0.34 . . . . 0.0 110.939 -179.688 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -72.28 -50.56 26.17 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.176 -0.465 . . . . 0.0 111.288 -179.784 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 24' ' ' TRP . . . . . . . . . . . . . 5.5 t-105 -64.73 -40.07 94.7 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-N 115.73 -0.668 . . . . 0.0 111.195 -179.641 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -80.42 -22.32 41.33 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 120.855 0.36 . . . . 0.0 110.936 179.622 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -73.64 -43.65 35.43 Favored Glycine 0 C--N 1.332 0.334 0 C-N-CA 120.928 -0.653 . . . . 0.0 112.485 179.926 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 82.7 mtp180 -60.71 -20.8 61.97 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-O 120.897 0.379 . . . . 0.0 110.627 179.835 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 23.9 t70 -114.43 92.57 4.0 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.017 -0.538 . . . . 0.0 110.746 179.823 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -163.03 -171.46 2.67 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.139 -179.862 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -72.97 -121.03 0.07 OUTLIER Glycine 0 N--CA 1.452 -0.263 0 C-N-CA 120.863 -0.684 . . . . 0.0 112.487 179.983 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 50.9 m -134.06 -48.72 0.8 Allowed 'General case' 0 C--N 1.33 -0.249 0 CA-C-O 120.819 0.342 . . . . 0.0 110.844 -179.968 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -75.81 -35.95 43.77 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.809 -0.71 . . . . 0.0 112.464 179.896 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 16.7 mm-40 -65.05 -23.67 67.25 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.562 0.22 . . . . 0.0 111.167 -179.891 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 34' ' ' ARG . . . . . . . . . . . . . 52.9 ttt180 -50.85 -30.74 15.27 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.367 -0.379 . . . . 0.0 111.29 -179.716 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 79.7 ttt180 -60.13 -50.69 72.71 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.294 -0.412 . . . . 0.0 111.011 -179.838 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 73.7 m-85 -61.74 -30.47 70.8 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.091 -0.504 . . . . 0.0 111.211 -179.847 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 37' ' ' TYR . . . . . 0.595 ' O ' HG23 ' A' ' 41' ' ' VAL . 64.0 m-85 -70.88 -54.08 12.77 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.281 -0.418 . . . . 0.0 111.141 -179.805 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 61.8 t -56.99 -38.45 60.0 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.223 0 CA-C-O 120.959 0.409 . . . . 0.0 110.654 179.86 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 20.5 m -65.39 -51.18 62.15 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 115.832 -0.622 . . . . 0.0 110.864 179.645 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 40' ' ' LEU . . . . . 0.561 HD12 HD12 ' A' ' 43' ' ' ILE . 38.0 tp -56.98 -46.84 81.95 Favored 'General case' 0 C--O 1.236 0.343 0 CA-C-N 115.894 -0.593 . . . . 0.0 110.578 179.721 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 41' ' ' VAL . . . . . 0.714 HG22 ' HB2' ' A' ' 22' ' ' PHE . 62.9 t -60.26 -34.28 56.76 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.326 0 CA-C-N 115.857 -0.61 . . . . 0.0 110.3 179.083 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -61.27 -39.3 97.01 Favored Glycine 0 N--CA 1.448 -0.539 0 C-N-CA 120.743 -0.742 . . . . 0.0 111.988 179.925 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 43' ' ' ILE . . . . . 0.561 HD12 HD12 ' A' ' 40' ' ' LEU . 0.7 OUTLIER -65.13 -56.59 14.87 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.223 0 CA-C-O 120.827 0.346 . . . . 0.0 110.998 179.797 . . . . . . . . 3 3 . 1 . 030 nuclear build full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 36.3 t -57.24 -27.6 62.17 Favored 'General case' 0 C--N 1.332 -0.156 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.431 -179.747 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -76.2 -53.57 5.59 Favored Glycine 0 CA--C 1.519 0.342 0 C-N-CA 120.664 -0.779 . . . . 0.0 113.327 -179.288 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 19.7 pt -58.34 -40.03 76.5 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.168 0 CA-C-O 120.738 0.304 . . . . 0.0 111.522 -179.418 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 47' ' ' ALA . . . . . 0.695 ' HB2' ' HE2' ' A' ' 205' ' ' LYS . . . -67.44 -43.67 80.56 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-N 116.436 -0.347 . . . . 0.0 111.364 179.603 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 48' ' ' ALA . . . . . 0.617 ' HB2' ' HB3' ' A' ' 15' ' ' MET . . . -55.1 -43.76 74.32 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.079 -0.51 . . . . 0.0 111.831 -179.423 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 28.4 m -73.8 -33.89 38.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.454 -0.339 . . . . 0.0 111.503 -179.428 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -65.35 -38.54 90.39 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-O 120.927 0.394 . . . . 0.0 111.148 179.74 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 51' ' ' TYR . . . . . 0.557 ' HE2' ' HE2' ' A' ' 15' ' ' MET . 29.0 m-85 -73.06 -35.56 66.71 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 116.132 -0.486 . . . . 0.0 110.756 -179.736 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -63.9 -42.22 97.51 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.291 -0.413 . . . . 0.0 110.938 179.263 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 53' ' ' VAL . . . . . 0.429 HG23 ' N ' ' A' ' 54' ' ' MET . 21.7 m -74.87 -45.1 44.41 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.177 0 CA-C-N 116.271 -0.422 . . . . 0.0 111.42 -179.981 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 54' ' ' MET . . . . . 0.429 ' N ' HG23 ' A' ' 53' ' ' VAL . 70.6 mtm -62.74 -32.01 73.05 Favored 'General case' 0 C--N 1.332 -0.174 0 CA-C-O 120.952 0.406 . . . . 0.0 110.296 179.572 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -63.02 -18.05 62.9 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 115.772 -0.649 . . . . 0.0 111.01 179.476 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 81.8 mt -99.14 -9.16 24.15 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 115.998 -0.546 . . . . 0.0 110.933 179.771 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 73.59 31.1 61.1 Favored Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.809 -0.71 . . . . 0.0 112.96 179.784 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 58' ' ' VAL . . . . . 0.418 HG22 ' O ' ' A' ' 53' ' ' VAL . 32.6 m -81.24 14.5 0.45 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-O 120.907 0.384 . . . . 0.0 111.525 179.893 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -151.85 10.27 0.67 Allowed Glycine 0 N--CA 1.45 -0.389 0 C-N-CA 120.882 -0.675 . . . . 0.0 112.734 179.938 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 60' ' ' TRP . . . . . . . . . . . . . 38.4 m0 -78.33 109.52 12.54 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.631 0.253 . . . . 0.0 110.573 179.842 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 7.6 p -102.32 130.75 23.53 Favored Pre-proline 0 C--N 1.329 -0.294 0 CA-C-N 116.431 -0.35 . . . . 0.0 111.255 -179.723 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 7.8 Cg_exo -72.87 144.14 38.18 Favored 'Trans proline' 0 C--N 1.35 0.622 0 C-N-CA 122.675 2.25 . . . . 0.0 112.383 -179.851 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 85.9 t -143.85 96.29 0.53 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.201 0 CA-C-N 115.993 -0.549 . . . . 0.0 111.031 179.968 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . 60.58 -86.15 0.02 OUTLIER 'General case' 0 C--N 1.333 -0.122 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.223 -179.902 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 11.4 tp10 -124.66 -23.93 4.27 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-O 120.927 0.394 . . . . 0.0 110.38 179.793 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 66' ' ' ARG . . . . . . . . . . . . . 96.9 mtt180 -103.13 153.41 20.34 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 115.809 -0.632 . . . . 0.0 110.4 179.739 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 91.2 m -111.94 119.34 38.19 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-O 120.952 0.406 . . . . 0.0 111.671 -179.336 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 68' ' ' VAL . . . . . 0.582 HG11 ' HG3' ' A' ' 117' ' ' MET . 42.4 t -90.52 147.03 5.49 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-N 115.938 -0.574 . . . . 0.0 110.401 179.224 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 69' ' ' PHE . . . . . . . . . . . . . 21.9 m-85 -105.11 114.55 28.82 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-O 121.008 0.432 . . . . 0.0 110.247 -179.367 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 70' ' ' VAL . . . . . 0.54 ' HB ' ' HD3' ' A' ' 71' ' ' PRO . 13.6 t -68.83 -50.09 24.66 Favored Pre-proline 0 C--N 1.325 -0.486 0 CA-C-N 115.937 -0.574 . . . . 0.0 112.471 -178.856 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 71' ' ' PRO . . . . . 0.54 ' HD3' ' HB ' ' A' ' 70' ' ' VAL . 16.4 Cg_exo -66.57 -17.84 53.47 Favored 'Trans proline' 0 C--N 1.351 0.671 0 C-N-CA 122.252 1.968 . . . . 0.0 112.698 -179.304 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 72' ' ' ARG . . . . . 0.417 ' NH2' HG13 ' A' ' 197' ' ' ILE . 66.2 ttt180 -66.25 -55.31 16.76 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-O 120.866 0.365 . . . . 0.0 111.539 -179.346 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 73' ' ' TYR . . . . . 0.473 ' O ' HG13 ' A' ' 77' ' ' ILE . 77.7 m-85 -71.59 -33.76 69.31 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.38 -0.373 . . . . 0.0 110.687 -179.492 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 74' ' ' ILE . . . . . 0.487 ' HA ' HD12 ' A' ' 77' ' ' ILE . 0.4 OUTLIER -67.51 -36.84 77.55 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.2 0 N-CA-C 109.768 -0.456 . . . . 0.0 109.768 179.106 . . . . . . . . 3 3 . 1 . 030 nuclear build full ' A' A ' 75' ' ' ASP . . . . . 0.402 ' O ' HG23 ' A' ' 79' ' ' THR . 24.0 t70 -60.52 -38.51 84.65 Favored 'General case' 0 CA--C 1.519 -0.219 0 N-CA-C 108.959 -0.756 . . . . 0.0 108.959 178.506 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 76' ' ' TRP . . . . . . . . . . . . . 37.5 m0 -66.72 -30.86 71.2 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 115.438 -0.801 . . . . 0.0 110.468 179.193 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 77' ' ' ILE . . . . . 0.487 HD12 ' HA ' ' A' ' 74' ' ' ILE . 82.3 mt -68.58 -31.11 49.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-O 121.017 0.437 . . . . 0.0 110.554 179.241 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 34.4 mt -91.51 -17.55 25.51 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.11 -0.495 . . . . 0.0 112.137 -179.889 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 79' ' ' THR . . . . . 0.402 HG23 ' O ' ' A' ' 75' ' ' ASP . 72.7 p -102.32 -52.77 3.05 Favored 'General case' 0 N--CA 1.464 0.27 0 N-CA-C 113.417 0.895 . . . . 0.0 113.417 -178.238 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 80' ' ' THR . . . . . 0.695 ' HB ' ' HD3' ' A' ' 81' ' ' PRO . 49.8 m -52.39 -56.01 26.49 Favored Pre-proline 0 CA--C 1.532 0.251 0 N-CA-C 112.643 0.608 . . . . 0.0 112.643 -178.306 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 81' ' ' PRO . . . . . 0.695 ' HD3' ' HB ' ' A' ' 80' ' ' THR . 38.8 Cg_exo -58.98 -21.1 56.68 Favored 'Trans proline' 0 C--N 1.351 0.69 0 C-N-CA 121.507 1.471 . . . . 0.0 111.478 -179.942 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 82' ' ' LEU . . . . . . . . . . . . . 15.2 tp -77.03 -33.12 57.42 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 115.699 -0.682 . . . . 0.0 110.328 179.695 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 83' ' ' ILE . . . . . 0.427 HD11 HG21 ' A' ' 43' ' ' ILE . 49.1 mm -69.64 -51.86 37.36 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.166 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.232 179.25 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 84' ' ' VAL . . . . . 0.528 HG11 HD22 ' A' ' 105' ' ' ASN . 35.5 m -61.1 -31.05 48.99 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.227 0 N-CA-C 109.407 -0.59 . . . . 0.0 109.407 178.706 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 85' ' ' TYR . . . . . . . . . . . . . 89.9 t80 -64.43 -34.7 78.79 Favored 'General case' 0 N--CA 1.454 -0.269 0 CA-C-N 115.472 -0.786 . . . . 0.0 109.427 178.601 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 86' ' ' PHE . . . . . . . . . . . . . 12.0 t80 -62.97 -49.6 74.06 Favored 'General case' 0 C--O 1.232 0.146 0 CA-C-N 115.765 -0.652 . . . . 0.0 110.01 179.136 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 87' ' ' LEU . . . . . 0.562 HD12 HD22 ' A' ' 141' ' ' LEU . 5.3 mt -63.59 -33.06 74.78 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 115.733 -0.667 . . . . 0.0 109.852 179.839 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -66.67 -27.52 73.28 Favored Glycine 0 N--CA 1.449 -0.474 0 CA-C-N 115.377 -0.829 . . . . 0.0 111.555 179.251 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 61.9 mt -74.58 -43.78 54.02 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.763 0.316 . . . . 0.0 111.032 179.89 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 82.6 mt -60.47 -32.34 71.31 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.123 -0.489 . . . . 0.0 111.216 -179.94 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -83.83 -54.14 5.1 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.309 -0.405 . . . . 0.0 111.424 -179.732 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 103.93 68.32 0.76 Allowed Glycine 0 N--CA 1.45 -0.369 0 C-N-CA 120.808 -0.71 . . . . 0.0 112.491 -179.706 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 93' ' ' LEU . . . . . 0.577 HD23 ' HB3' ' A' ' 97' ' ' GLU . 6.5 mp -91.23 164.77 13.77 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.712 0.291 . . . . 0.0 110.733 -179.933 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 94' ' ' ASP . . . . . . . . . . . . . 1.8 p30 -87.82 177.43 7.0 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.356 -0.384 . . . . 0.0 110.915 179.807 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 48.1 t -60.39 -32.16 71.04 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.027 -0.533 . . . . 0.0 111.881 -179.418 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 38.8 mmt180 -73.31 -53.31 11.12 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.55 -0.295 . . . . 0.0 111.62 -179.332 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 97' ' ' GLU . . . . . 0.577 ' HB3' HD23 ' A' ' 93' ' ' LEU . 44.0 mt-10 -53.3 -47.25 69.38 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.314 -0.403 . . . . 0.0 111.388 -179.671 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 98' ' ' PHE . . . . . 0.45 ' O ' HG12 ' A' ' 102' ' ' ILE . 12.6 m-85 -58.29 -49.86 75.65 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.373 -0.376 . . . . 0.0 110.876 179.975 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -54.88 -30.45 53.18 Favored Glycine 0 CA--C 1.518 0.255 0 C-N-CA 120.751 -0.737 . . . . 0.0 112.776 -179.81 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 96.3 mt -73.95 -45.53 48.72 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.214 0 CA-C-O 120.841 0.353 . . . . 0.0 111.622 -179.708 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 47.6 t -65.95 -46.74 87.52 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.411 0 CA-C-N 116.147 -0.478 . . . . 0.0 111.91 -179.161 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 102' ' ' ILE . . . . . 0.45 HG12 ' O ' ' A' ' 98' ' ' PHE . 37.6 mm -63.17 -51.77 67.19 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 N-CA-C 111.905 0.335 . . . . 0.0 111.905 -179.101 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 15.2 t -55.95 -36.72 68.1 Favored 'General case' 0 C--O 1.234 0.248 0 CA-C-O 120.869 0.366 . . . . 0.0 110.952 -179.61 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 104' ' ' LEU . . . . . 0.49 ' O ' HG23 ' A' ' 108' ' ' VAL . 29.7 tp -61.37 -47.73 84.5 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.06 -0.518 . . . . 0.0 110.683 179.464 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 105' ' ' ASN . . . . . 0.528 HD22 HG11 ' A' ' 84' ' ' VAL . 3.5 m-20 -61.55 -26.33 67.87 Favored 'General case' 0 C--N 1.326 -0.438 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.745 179.848 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 66.2 m -66.46 -57.3 7.65 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 116.374 -0.375 . . . . 0.0 111.331 -179.926 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 107' ' ' VAL . . . . . 0.404 HG12 ' O ' ' A' ' 104' ' ' LEU . 9.1 p -58.27 -36.57 58.51 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.142 0 CA-C-O 120.727 0.298 . . . . 0.0 111.114 -179.881 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 108' ' ' VAL . . . . . 0.49 HG23 ' O ' ' A' ' 104' ' ' LEU . 68.3 t -57.84 -49.58 80.52 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.372 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.519 179.513 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 109' ' ' MET . . . . . 0.453 ' HG2' ' O ' ' A' ' 105' ' ' ASN . 20.6 mmt -64.35 -30.4 71.44 Favored 'General case' 0 CA--C 1.519 -0.248 0 CA-C-N 115.868 -0.605 . . . . 0.0 110.666 179.707 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 19.4 tp -66.34 -35.61 80.8 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.069 179.555 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -64.31 -51.38 63.76 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 115.903 -0.59 . . . . 0.0 110.601 179.462 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 112' ' ' GLY . . . . . 0.513 ' HA3' ' H21' ' A' ' 301' ' ' RET . . . -66.96 -37.33 92.07 Favored Glycine 0 C--N 1.331 0.262 0 C-N-CA 120.576 -0.821 . . . . 0.0 111.861 179.478 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 113' ' ' PHE . . . . . 0.424 ' HB2' ' O ' ' A' ' 109' ' ' MET . 1.0 OUTLIER -51.02 -70.03 0.1 Allowed 'General case' 0 C--N 1.332 -0.161 0 CA-C-O 121.05 0.452 . . . . 0.0 110.02 179.541 . . . . . . . . 3 3 . 1 . 030 nuclear build full ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -67.43 -19.89 65.43 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 115.663 -0.699 . . . . 0.0 110.748 179.407 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 115' ' ' GLY . . . . . 0.479 ' HA2' HD22 ' A' ' 126' ' ' LEU . . . -53.67 -44.43 69.09 Favored Glycine 0 C--N 1.334 0.441 0 C-N-CA 120.915 -0.659 . . . . 0.0 111.8 179.533 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -78.49 -28.46 46.4 Favored 'General case' 0 C--N 1.327 -0.41 0 N-CA-C 111.639 0.237 . . . . 0.0 111.639 179.741 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 117' ' ' MET . . . . . 0.582 ' HG3' HG11 ' A' ' 68' ' ' VAL . 62.9 mtt -86.08 11.37 11.89 Favored 'General case' 0 N--CA 1.463 0.224 0 N-CA-C 112.16 0.429 . . . . 0.0 112.16 -179.162 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 118' ' ' VAL . . . . . 0.495 HG21 ' HB3' ' A' ' 123' ' ' ARG . 29.9 m -63.64 146.06 96.99 Favored Pre-proline 0 C--N 1.327 -0.374 0 C-N-CA 121.037 -0.265 . . . . 0.0 111.081 179.845 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 119' ' ' PRO . . . . . . . . . . . . . 92.0 Cg_endo -81.99 -4.59 12.01 Favored 'Trans proline' 0 C--N 1.347 0.478 0 C-N-CA 122.534 2.156 . . . . 0.0 112.25 179.821 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -156.43 -132.1 1.46 Allowed Glycine 0 C--N 1.331 0.293 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.735 -179.982 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 2.0 pp -100.31 22.46 1.58 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-O 120.838 0.352 . . . . 0.0 111.265 -179.833 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 10.8 mm-40 -70.72 -19.27 62.76 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.846 179.942 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 123' ' ' ARG . . . . . 0.495 ' HB3' HG21 ' A' ' 118' ' ' VAL . 12.7 ptt180 -50.55 -31.0 14.42 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 115.923 -0.58 . . . . 0.0 111.907 -179.67 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 124' ' ' TYR . . . . . . . . . . . . . 40.2 m-85 -65.13 -35.61 81.65 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.675 0.274 . . . . 0.0 110.919 -179.629 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 125' ' ' ALA . . . . . . . . . . . . . . . -72.74 -51.08 20.64 Favored 'General case' 0 C--O 1.235 0.311 0 CA-C-O 120.849 0.357 . . . . 0.0 110.604 179.248 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 126' ' ' LEU . . . . . 0.479 HD22 ' HA2' ' A' ' 115' ' ' GLY . 7.0 mp -51.55 -52.39 47.52 Favored 'General case' 0 CA--C 1.52 -0.191 0 CA-C-N 116.005 -0.543 . . . . 0.0 110.135 179.488 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 127' ' ' PHE . . . . . 0.464 ' HZ ' ' HB3' ' A' ' 175' ' ' PRO . 8.7 t80 -63.93 -35.79 81.82 Favored 'General case' 0 N--CA 1.451 -0.419 0 CA-C-N 115.848 -0.615 . . . . 0.0 110.533 179.523 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 128' ' ' GLY . . . . . . . . . . . . . . . -46.22 -45.51 15.62 Favored Glycine 0 C--N 1.333 0.38 0 C-N-CA 120.195 -1.002 . . . . 0.0 110.86 179.027 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 129' ' ' MET . . . . . . . . . . . . . 0.6 OUTLIER -69.47 -39.36 77.76 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 115.319 -0.441 . . . . 0.0 109.977 178.586 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -65.15 -27.89 72.89 Favored Glycine 0 C--N 1.331 0.299 0 CA-C-N 115.783 -0.644 . . . . 0.0 112.995 -179.842 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -74.61 -54.01 8.27 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.615 0.245 . . . . 0.0 110.406 -179.964 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 47.2 t -55.83 -40.54 62.31 Favored 'Isoleucine or valine' 0 C--O 1.234 0.241 0 CA-C-O 121.459 0.647 . . . . 0.0 109.285 178.786 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -69.1 -37.8 78.61 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 115.117 -0.947 . . . . 0.0 110.613 179.41 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 134' ' ' PHE . . . . . 0.428 ' CZ ' ' HA ' ' A' ' 172' ' ' ALA . 45.3 t80 -55.45 -52.71 62.72 Favored 'General case' 0 N--CA 1.45 -0.429 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.263 179.748 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 135' ' ' ILE . . . . . . . . . . . . . 43.7 mt -59.58 -32.75 49.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 115.915 -0.584 . . . . 0.0 109.935 179.308 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . -59.43 -40.45 96.14 Favored Glycine 0 N--CA 1.448 -0.535 0 C-N-CA 120.298 -0.954 . . . . 0.0 111.45 178.926 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 137' ' ' LEU . . . . . . . . . . . . . 22.4 tp -65.87 -53.07 44.5 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-O 120.683 0.277 . . . . 0.0 110.616 179.617 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 138' ' ' VAL . . . . . . . . . . . . . 13.1 t -55.48 -37.48 45.39 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.836 0 CA-C-O 121.114 0.483 . . . . 0.0 110.131 179.183 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 139' ' ' TYR . . . . . . . . . . . . . 29.9 t80 -57.84 -43.22 85.71 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 115.43 -0.805 . . . . 0.0 110.738 179.024 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 28.7 m-85 -64.17 -41.6 97.07 Favored 'General case' 0 C--N 1.332 -0.156 0 CA-C-N 116.406 -0.361 . . . . 0.0 111.467 -179.978 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 141' ' ' LEU . . . . . 0.562 HD22 HD12 ' A' ' 87' ' ' LEU . 95.4 mt -56.24 -50.34 71.59 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 116.42 -0.355 . . . . 0.0 111.143 -179.761 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 142' ' ' VAL . . . . . 0.558 HG23 HH12 ' A' ' 164' ' ' ARG . 7.7 p -83.78 -9.02 11.48 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.369 0 CA-C-O 121.153 0.501 . . . . 0.0 110.59 179.956 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 143' ' ' GLY . . . . . 0.426 ' O ' HG22 ' A' ' 146' ' ' THR . . . -73.34 -141.18 0.5 Allowed Glycine 0 CA--C 1.521 0.452 0 C-N-CA 120.881 -0.676 . . . . 0.0 112.579 179.929 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 144' ' ' PRO . . . . . . . . . . . . . 52.2 Cg_exo -54.69 -23.24 32.09 Favored 'Trans proline' 0 C--N 1.349 0.564 0 C-N-CA 122.588 2.192 . . . . 0.0 112.75 179.971 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 145' ' ' MET . . . . . . . . . . . . . 37.2 mtt -52.81 -59.22 4.76 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.479 -0.328 . . . . 0.0 111.831 -179.641 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 146' ' ' THR . . . . . 0.426 HG22 ' O ' ' A' ' 143' ' ' GLY . 11.0 t -61.04 -31.71 71.35 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.423 -0.353 . . . . 0.0 111.588 -179.476 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 29.2 mm-40 -65.13 -44.0 90.11 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 120.839 0.352 . . . . 0.0 111.223 -179.942 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 148' ' ' SER . . . . . . . . . . . . . 80.0 p -70.24 -42.28 72.43 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.236 -179.32 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 149' ' ' ALA . . . . . . . . . . . . . . . -65.34 -40.42 93.62 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.377 -179.747 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 150' ' ' SER . . . . . 0.464 ' HA ' ' HB2' ' A' ' 157' ' ' LYS . 83.6 p -68.21 -6.8 25.51 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.784 -179.913 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 151' ' ' GLN . . . . . . . . . . . . . 63.3 mt-30 -110.48 -7.54 14.74 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.119 -0.492 . . . . 0.0 110.914 179.883 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 78.3 ttt180 -75.06 -52.47 10.96 Favored 'General case' 0 C--N 1.332 -0.193 0 CA-C-N 116.443 -0.344 . . . . 0.0 110.831 -179.883 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 153' ' ' SER . . . . . 0.643 ' HB3' HG12 ' A' ' 156' ' ' ILE . 22.8 t -158.04 170.62 21.88 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.667 179.238 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 154' ' ' SER . . . . . . . . . . . . . 51.3 m -70.22 -37.62 75.07 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.288 -0.415 . . . . 0.0 110.392 179.382 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -77.0 -39.0 28.88 Favored Glycine 0 CA--C 1.519 0.298 0 C-N-CA 120.984 -0.627 . . . . 0.0 112.674 179.821 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 156' ' ' ILE . . . . . 0.643 HG12 ' HB3' ' A' ' 153' ' ' SER . 39.6 mm -52.88 -35.65 22.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-O 120.922 0.392 . . . . 0.0 111.315 -179.81 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 157' ' ' LYS . . . . . 0.464 ' HB2' ' HA ' ' A' ' 150' ' ' SER . 86.4 tttt -69.83 -37.23 76.13 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 115.967 -0.561 . . . . 0.0 112.028 -179.436 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 67.6 p -72.05 -45.0 62.46 Favored 'General case' 0 C--N 1.331 -0.205 0 CA-C-O 120.784 0.326 . . . . 0.0 111.601 -178.719 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 159' ' ' LEU . . . . . . . . . . . . . 10.0 mt -67.05 -46.26 74.92 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.632 -179.078 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 160' ' ' TYR . . . . . . . . . . . . . 55.1 t80 -61.58 -37.82 85.27 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.509 -0.314 . . . . 0.0 111.26 -179.468 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 161' ' ' VAL . . . . . 0.515 HG12 ' N ' ' A' ' 162' ' ' ARG . 1.2 t -63.23 -50.49 78.86 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.747 0 CA-C-N 116.529 -0.305 . . . . 0.0 111.64 -179.487 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 162' ' ' ARG . . . . . 0.515 ' N ' HG12 ' A' ' 161' ' ' VAL . 22.9 tpp180 -69.1 -34.86 75.76 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.44 -0.345 . . . . 0.0 111.439 -179.446 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 163' ' ' LEU . . . . . 0.576 ' HG ' ' HB2' ' A' ' 208' ' ' PHE . 3.2 mp -69.5 -45.02 69.89 Favored 'General case' 0 C--N 1.328 -0.37 0 CA-C-N 116.27 -0.423 . . . . 0.0 111.604 -179.408 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 164' ' ' ARG . . . . . 0.558 HH12 HG23 ' A' ' 142' ' ' VAL . 0.1 OUTLIER -71.95 -41.07 68.23 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.557 -0.292 . . . . 0.0 111.308 -179.125 . . . . . . . . 3 3 . 1 . 030 nuclear build full ' A' A ' 165' ' ' ASN . . . . . 0.487 ' N ' ' HG3' ' A' ' 164' ' ' ARG . 5.7 m-20 -57.25 -50.88 71.49 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.795 0.331 . . . . 0.0 111.05 179.953 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 166' ' ' LEU . . . . . . . . . . . . . 3.8 tt -64.17 -54.59 31.32 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.109 -0.496 . . . . 0.0 111.548 -179.47 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 167' ' ' THR . . . . . 0.416 ' O ' ' HB2' ' A' ' 171' ' ' TRP . 76.5 m -54.81 -53.13 59.21 Favored 'General case' 0 C--N 1.33 -0.277 0 N-CA-C 112.263 0.468 . . . . 0.0 112.263 -179.158 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 168' ' ' VAL . . . . . . . . . . . . . 55.1 t -55.06 -44.93 76.45 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.218 0 N-CA-C 112.328 0.492 . . . . 0.0 112.328 -178.999 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 169' ' ' VAL . . . . . 0.48 HG23 ' O ' ' A' ' 165' ' ' ASN . 43.9 t -55.91 -64.32 0.5 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-O 120.555 0.217 . . . . 0.0 111.544 -179.362 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 170' ' ' LEU . . . . . 0.555 HD12 ' HD1' ' A' ' 171' ' ' TRP . 1.1 pp -63.41 -28.56 70.06 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.661 -0.245 . . . . 0.0 111.642 -179.39 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 171' ' ' TRP . . . . . 0.645 ' HE1' H203 ' A' ' 301' ' ' RET . 3.5 m0 -70.54 -32.11 69.43 Favored 'General case' 0 C--N 1.333 -0.152 0 CA-C-O 120.998 0.427 . . . . 0.0 110.413 179.418 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 172' ' ' ALA . . . . . 0.428 ' HA ' ' CZ ' ' A' ' 134' ' ' PHE . . . -72.19 -6.68 44.53 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-N 115.822 -0.626 . . . . 0.0 111.102 -179.624 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 173' ' ' ILE . . . . . 0.555 ' O ' HG12 ' A' ' 177' ' ' ILE . 23.8 mm -87.54 -22.57 6.82 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.244 0 CA-C-N 116.083 -0.508 . . . . 0.0 111.17 179.925 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 174' ' ' TYR . . . . . 0.465 ' HB2' ' HD3' ' A' ' 175' ' ' PRO . 30.9 m-85 -53.79 -49.25 90.25 Favored Pre-proline 0 N--CA 1.464 0.265 0 CA-C-N 116.567 -0.288 . . . . 0.0 111.638 -179.537 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 175' ' ' PRO . . . . . 0.465 ' HD3' ' HB2' ' A' ' 174' ' ' TYR . 86.5 Cg_exo -47.73 -32.97 17.83 Favored 'Trans proline' 0 C--N 1.351 0.677 0 C-N-CA 122.134 1.89 . . . . 0.0 112.164 179.523 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 176' ' ' PHE . . . . . 0.518 ' O ' ' HG ' ' A' ' 180' ' ' LEU . 88.2 m-85 -80.62 -50.36 10.06 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 115.911 -0.586 . . . . 0.0 112.18 -179.531 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 177' ' ' ILE . . . . . 0.555 HG12 ' O ' ' A' ' 173' ' ' ILE . 6.2 mm -60.22 -39.58 81.09 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.548 0 N-CA-C 112.609 0.596 . . . . 0.0 112.609 -177.777 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 178' ' ' TRP . . . . . 0.492 ' HH2' ' HB2' ' A' ' 123' ' ' ARG . 78.4 t90 -67.37 -39.3 85.68 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 120.721 0.296 . . . . 0.0 111.157 -179.669 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 179' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -77.88 -52.89 8.14 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 116.462 -0.335 . . . . 0.0 111.879 -179.01 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 180' ' ' LEU . . . . . 0.717 HD22 HD11 ' A' ' 187' ' ' LEU . 39.8 mt -61.66 -51.7 67.38 Favored 'General case' 0 C--N 1.328 -0.362 0 N-CA-C 111.699 0.259 . . . . 0.0 111.699 -179.114 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 181' ' ' GLY . . . . . 0.437 ' HA3' ' OD1' ' A' ' 193' ' ' ASP . . . -57.03 179.16 0.71 Allowed Glycine 0 C--N 1.336 0.557 0 C-N-CA 120.413 -0.898 . . . . 0.0 112.92 -179.883 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 182' ' ' PRO . . . . . 0.628 ' N ' ' HD2' ' A' ' 183' ' ' PRO . 80.8 Cg_exo -44.06 -46.56 11.04 Favored 'Trans proline' 0 C--N 1.35 0.654 0 C-N-CA 122.925 2.417 . . . . 0.0 113.915 179.865 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 183' ' ' PRO . . . . . 0.628 ' HD2' ' N ' ' A' ' 182' ' ' PRO . 1.0 OUTLIER -44.28 -30.44 3.61 Favored 'Trans proline' 0 C--N 1.358 1.062 0 C-N-CA 122.497 2.131 . . . . 0.0 113.172 -179.758 . . . . . . . . 3 3 . 1 . 030 nuclear build full ' A' A ' 184' ' ' GLY . . . . . 0.451 ' HA2' ' HD2' ' A' ' 123' ' ' ARG . . . -117.73 -120.75 3.08 Favored Glycine 0 C--N 1.332 0.326 0 C-N-CA 120.392 -0.908 . . . . 0.0 113.19 179.89 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 185' ' ' VAL . . . . . . . . . . . . . 22.6 m -64.92 -16.77 20.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 N-CA-C 112.264 0.468 . . . . 0.0 112.264 -179.405 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 186' ' ' ALA . . . . . 0.487 ' HB2' ' HA ' ' A' ' 182' ' ' PRO . . . 55.51 88.75 0.04 OUTLIER 'General case' 0 C--N 1.332 -0.17 0 CA-C-O 120.872 0.368 . . . . 0.0 111.266 -179.899 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 187' ' ' LEU . . . . . 0.717 HD11 HD22 ' A' ' 180' ' ' LEU . 19.5 mt -91.8 -33.06 15.12 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.391 -179.603 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 188' ' ' LEU . . . . . 0.58 HD13 ' N ' ' A' ' 188' ' ' LEU . 0.0 OUTLIER -134.27 -162.07 1.21 Allowed 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.868 0.366 . . . . 0.0 111.501 -179.494 . . . . . . . . 3 3 . 1 . 030 nuclear build full ' A' A ' 189' ' ' THR . . . . . . . . . . . . . 3.2 t -86.26 147.48 44.89 Favored Pre-proline 0 C--N 1.33 -0.24 0 CA-C-N 116.045 -0.525 . . . . 0.0 111.969 -178.873 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 190' ' ' PRO . . . . . . . . . . . . . 77.8 Cg_exo -51.02 -35.93 52.27 Favored 'Trans proline' 0 C--N 1.351 0.691 0 C-N-CA 122.581 2.187 . . . . 0.0 112.665 179.708 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 191' ' ' THR . . . . . . . . . . . . . 59.5 p -57.89 -40.8 81.17 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 121.052 0.453 . . . . 0.0 110.753 179.904 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 192' ' ' VAL . . . . . . . . . . . . . 41.4 t -74.96 -52.8 17.94 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-N 115.705 -0.679 . . . . 0.0 111.484 -179.871 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 193' ' ' ASP . . . . . 0.437 ' OD1' ' HA3' ' A' ' 181' ' ' GLY . 25.4 t70 -54.94 -51.93 64.59 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-N 116.31 -0.405 . . . . 0.0 111.142 -179.716 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 194' ' ' VAL . . . . . 0.549 ' O ' HG22 ' A' ' 198' ' ' VAL . 90.8 t -61.41 -36.96 76.45 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.357 0 CA-C-N 115.927 -0.579 . . . . 0.0 111.026 -179.832 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 195' ' ' ALA . . . . . 0.498 ' HA ' HD12 ' A' ' 7' ' ' LEU . . . -52.4 -48.58 65.58 Favored 'General case' 0 C--O 1.234 0.27 0 CA-C-O 120.91 0.386 . . . . 0.0 111.006 179.723 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 196' ' ' LEU . . . . . 0.5 ' O ' ' HB3' ' A' ' 199' ' ' TYR . 98.5 mt -68.3 -39.45 82.04 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 116.432 -0.349 . . . . 0.0 110.448 179.281 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 197' ' ' ILE . . . . . 0.417 HG13 ' NH2' ' A' ' 72' ' ' ARG . 15.5 mm -55.59 -60.36 1.79 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.358 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.178 179.92 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 198' ' ' VAL . . . . . 0.549 HG22 ' O ' ' A' ' 194' ' ' VAL . 3.3 m -52.19 -35.93 20.01 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.424 0 CA-C-O 121.359 0.6 . . . . 0.0 109.902 179.08 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 199' ' ' TYR . . . . . 0.5 ' HB3' ' O ' ' A' ' 196' ' ' LEU . 69.2 t80 -62.15 -47.02 86.41 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-N 115.062 -0.972 . . . . 0.0 110.095 179.224 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 200' ' ' LEU . . . . . 0.504 HD21 ' HB ' ' A' ' 173' ' ' ILE . 5.4 mp -55.78 -38.99 70.63 Favored 'General case' 0 N--CA 1.452 -0.367 0 CA-C-N 115.973 -0.558 . . . . 0.0 111.561 179.097 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 201' ' ' ASP . . . . . . . . . . . . . 16.0 m-20 -74.19 -41.88 60.73 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 121.063 0.458 . . . . 0.0 110.683 -179.974 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 202' ' ' LEU . . . . . 0.402 ' O ' ' HB ' ' A' ' 206' ' ' VAL . 2.2 mt -63.18 -33.33 75.24 Favored 'General case' 0 C--N 1.327 -0.413 0 CA-C-N 115.624 -0.716 . . . . 0.0 111.682 -179.851 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 203' ' ' VAL . . . . . 0.494 HG13 HD13 ' A' ' 170' ' ' LEU . 10.8 p -78.26 -36.29 20.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.815 -0.175 . . . . 0.0 111.329 -178.696 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 204' ' ' THR . . . . . 0.427 ' O ' ' CD1' ' A' ' 208' ' ' PHE . 55.4 m -62.47 -58.64 6.89 Favored 'General case' 0 C--N 1.328 -0.331 0 C-N-CA 120.454 -0.499 . . . . 0.0 111.315 179.761 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 205' ' ' LYS . . . . . 0.695 ' HE2' ' HB2' ' A' ' 47' ' ' ALA . 49.5 mttp -69.07 -58.18 4.43 Favored 'General case' 0 N--CA 1.464 0.241 0 N-CA-C 112.849 0.685 . . . . 0.0 112.849 -177.921 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 206' ' ' VAL . . . . . 0.402 ' HB ' ' O ' ' A' ' 202' ' ' LEU . 26.1 t -68.92 -36.34 73.58 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.444 0 CA-C-N 116.401 -0.363 . . . . 0.0 111.89 -178.706 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 207' ' ' GLY . . . . . 0.569 ' O ' HG13 ' A' ' 211' ' ' ILE . . . -61.66 -60.45 8.13 Favored Glycine 0 N--CA 1.452 -0.273 0 C-N-CA 120.698 -0.763 . . . . 0.0 113.672 -178.619 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 208' ' ' PHE . . . . . 0.576 ' HB2' ' HG ' ' A' ' 163' ' ' LEU . 0.1 OUTLIER -71.58 -25.96 62.41 Favored 'General case' 0 C--O 1.224 -0.258 0 CA-C-N 117.383 0.591 . . . . 0.0 111.319 -178.976 . . . . . . . . 3 3 . 1 . 030 nuclear build full ' A' A ' 209' ' ' GLY . . . . . 0.473 ' O ' ' HB3' ' A' ' 212' ' ' ALA . . . -68.55 -32.4 74.89 Favored Glycine 0 N--CA 1.449 -0.464 0 N-CA-C 111.676 -0.57 . . . . 0.0 111.676 179.077 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 210' ' ' PHE . . . . . . . . . . . . . 0.8 OUTLIER -72.87 -47.39 46.41 Favored 'General case' 0 CA--C 1.514 -0.421 0 N-CA-C 108.107 -1.072 . . . . 0.0 108.107 178.505 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 211' ' ' ILE . . . . . 0.569 HG13 ' O ' ' A' ' 207' ' ' GLY . 4.6 mt -64.85 -27.73 43.14 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.544 0 N-CA-C 107.629 -1.248 . . . . 0.0 107.629 176.677 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 212' ' ' ALA . . . . . 0.473 ' HB3' ' O ' ' A' ' 209' ' ' GLY . . . -63.86 -39.86 95.2 Favored 'General case' 0 N--CA 1.451 -0.412 0 CA-C-N 114.628 -1.169 . . . . 0.0 110.381 179.794 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 213' ' ' LEU . . . . . 0.406 ' HG ' ' O ' ' A' ' 209' ' ' GLY . 92.8 mt -69.72 -54.42 13.84 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 115.215 -0.902 . . . . 0.0 111.252 -179.596 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 214' ' ' ASP . . . . . . . . . . . . . 18.5 m-20 -56.57 -44.94 81.49 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.968 0.413 . . . . 0.0 110.933 -179.819 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 215' ' ' ALA . . . . . 0.446 ' O ' HD23 ' A' ' 219' ' ' LEU . . . -61.0 -58.19 9.47 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.055 -0.52 . . . . 0.0 111.004 179.969 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 216' ' ' ALA . . . . . 0.598 ' HA ' ' HG ' ' A' ' 219' ' ' LEU . . . -55.53 -30.43 60.71 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.84 179.923 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 217' ' ' ALA . . . . . . . . . . . . . . . -61.36 -41.59 97.31 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 115.874 -0.603 . . . . 0.0 109.685 179.525 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 218' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -68.28 -29.68 68.52 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 115.437 -0.801 . . . . 0.0 109.994 178.64 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 219' ' ' LEU . . . . . 0.598 ' HG ' ' HA ' ' A' ' 216' ' ' ALA . 0.2 OUTLIER -66.82 -51.79 51.47 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 115.571 -0.741 . . . . 0.0 110.875 -179.345 . . . . . . . . 3 3 . 1 . 030 nuclear build full ' A' A ' 220' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -71.5 -18.76 62.26 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.41 179.641 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 221' ' ' ALA . . . . . . . . . . . . . . . -77.13 -32.83 56.68 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.082 -0.508 . . . . 0.0 110.796 179.314 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 222' ' ' GLU . . . . . . . . . . . . . 12.8 pt-20 -91.55 -5.1 54.61 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-N 115.975 -0.557 . . . . 0.0 110.64 179.75 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 223' ' ' HIS . . . . . . . . . . . . . 1.1 p80 -35.06 147.65 0.02 OUTLIER 'General case' 0 N--CA 1.466 0.36 0 CA-C-N 115.745 -0.661 . . . . 0.0 112.251 -179.61 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 224' ' ' GLY . . . . . . . . . . . . . . . 169.44 36.9 0.03 OUTLIER Glycine 0 CA--C 1.518 0.23 0 CA-C-N 115.739 -0.664 . . . . 0.0 112.402 179.996 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 225' ' ' GLU . . . . . . . . . . . . . 1.9 mp0 -81.69 139.81 34.7 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.792 0.33 . . . . 0.0 111.215 -179.805 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 226' ' ' SER . . . . . . . . . . . . . 75.1 m 57.74 -171.7 0.1 Allowed 'General case' 0 C--N 1.331 -0.206 0 CA-C-N 116.007 -0.542 . . . . 0.0 111.424 179.72 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 227' ' ' LEU . . . . . . . . . . . . . 50.4 tp -80.44 103.4 10.27 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.08 -0.509 . . . . 0.0 110.892 179.986 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 228' ' ' ALA . . . . . . . . . . . . . . . -142.79 82.59 1.77 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.062 179.869 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 229' ' ' GLY . . . . . . . . . . . . . . . -160.52 136.89 4.72 Favored Glycine 0 N--CA 1.45 -0.373 0 C-N-CA 120.909 -0.662 . . . . 0.0 112.406 179.888 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 230' ' ' VAL . . . . . . . . . . . . . 46.1 t -80.12 134.55 27.25 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.37 0 CA-C-O 120.839 0.352 . . . . 0.0 111.021 -179.937 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 231' ' ' ASP . . . . . . . . . . . . . 10.9 m-20 -84.84 98.75 10.48 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.832 -179.916 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 232' ' ' THR . . . . . . . . . . . . . 9.1 t -138.38 151.87 47.89 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.086 -0.506 . . . . 0.0 111.169 179.977 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 233' ' ' ASP . . . . . . . . . . . . . 6.1 m-20 -98.05 -14.28 20.59 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.912 -179.945 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 234' ' ' THR . . . . . . . . . . . . . 75.4 p -131.71 98.57 17.76 Favored Pre-proline 0 C--N 1.331 -0.238 0 CA-C-N 116.123 -0.49 . . . . 0.0 111.081 -179.965 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 235' ' ' PRO . . . . . . . . . . . . . 31.2 Cg_exo -60.55 -20.48 64.53 Favored 'Trans proline' 0 C--N 1.349 0.565 0 C-N-CA 122.585 2.19 . . . . 0.0 112.333 179.845 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 236' ' ' ALA . . . . . . . . . . . . . . . -62.19 130.48 45.6 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.117 -0.492 . . . . 0.0 111.232 179.971 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 237' ' ' VAL . . . . . . . . . . . . . 48.8 t -91.95 139.19 18.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.028 -0.533 . . . . 0.0 111.063 179.897 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 238' ' ' ALA . . . . . . . . . . . . . . . 57.83 -170.37 0.11 Allowed 'General case' 0 C--N 1.331 -0.203 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.234 -179.953 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 239' ' ' ASP . . . . . . . . . . . . . 6.1 m-20 -118.73 123.71 45.53 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.874 179.899 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 240' ' ' LEU . . . . . 0.407 ' N ' HD12 ' A' ' 240' ' ' LEU . 8.0 mp -103.14 -37.48 7.71 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.657 179.858 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 241' ' ' GLU . . . . . . . . . . . . . 8.0 mm-40 65.27 144.13 0.03 OUTLIER 'General case' 0 N--CA 1.462 0.168 0 CA-C-N 115.836 -0.62 . . . . 0.0 111.485 179.863 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 242' ' ' HIS . . . . . . . . . . . . . 79.2 m80 -135.34 151.53 50.6 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 115.883 -0.598 . . . . 0.0 110.477 179.727 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 243' ' ' HIS . . . . . . . . . . . . . 20.6 t-80 -142.78 -50.25 0.35 Allowed 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.321 -0.4 . . . . 0.0 111.257 -179.783 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 244' ' ' HIS . . . . . . . . . . . . . 71.3 t60 -94.91 113.71 25.46 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.278 -0.419 . . . . 0.0 111.133 -179.757 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 245' ' ' HIS . . . . . . . . . . . . . 41.3 t-80 -88.24 113.21 23.63 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.771 179.814 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 246' ' ' HIS . . . . . . . . . . . . . 10.8 t-160 -93.29 140.61 29.36 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.831 -179.769 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 247' ' ' HIS . . . . . . . . . . . . . 79.9 t60 . . . . . 0 C--O 1.249 1.071 0 CA-C-O 118.258 -0.877 . . . . 0.0 110.874 -179.91 . . . . . . . . 0 0 . 1 . 030 nuclear build full ' A' A ' 301' ' ' RET . . . . . 0.645 H203 ' HE1' ' A' ' 171' ' ' TRP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.295 0 N-CA-C 112.292 -0.323 . . . . 0.0 112.292 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 67.1 tp -72.58 -35.5 67.95 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.873 0.368 . . . . 0.0 110.833 179.967 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 74.5 p -56.38 -29.64 61.72 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 115.953 -0.567 . . . . 0.0 111.589 -179.8 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 47.5 p -52.2 -35.19 48.51 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.407 -0.36 . . . . 0.0 111.335 -179.617 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 7' ' ' LEU . . . . . . . . . . . . . 3.9 mm? -61.28 -53.02 62.12 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.312 -0.404 . . . . 0.0 111.347 -179.751 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 8' ' ' PHE . . . . . . . . . . . . . 74.7 m-85 -60.93 -32.6 72.1 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-O 121.003 0.43 . . . . 0.0 110.696 179.943 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 9' ' ' TRP . . . . . 0.407 ' O ' HG13 ' A' ' 13' ' ' ILE . 26.0 m95 -66.39 -48.65 69.4 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 115.93 -0.577 . . . . 0.0 110.077 -179.986 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 82.1 mt -57.94 -51.07 71.15 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 115.654 -0.703 . . . . 0.0 110.542 179.526 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -57.41 -35.17 70.65 Favored Glycine 0 N--CA 1.45 -0.411 0 C-N-CA 120.739 -0.743 . . . . 0.0 111.8 179.369 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -65.33 -30.82 71.7 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 120.863 0.363 . . . . 0.0 110.504 179.558 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 13' ' ' ILE . . . . . 0.407 HG13 ' O ' ' A' ' 9' ' ' TRP . 80.9 mt -66.89 -46.43 85.14 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.217 0 CA-C-N 116.062 -0.517 . . . . 0.0 110.075 179.353 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -61.84 -31.29 77.77 Favored Glycine 0 N--CA 1.45 -0.367 0 C-N-CA 120.653 -0.784 . . . . 0.0 111.862 179.329 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 15' ' ' MET . . . . . 0.533 ' HB3' ' HB2' ' A' ' 48' ' ' ALA . 0.0 OUTLIER -67.03 -46.89 73.08 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-O 120.848 0.356 . . . . 0.0 110.626 179.33 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -56.53 -40.45 75.08 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.033 -0.531 . . . . 0.0 110.483 179.547 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 84.4 t -60.36 -48.07 89.82 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.861 179.653 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -65.62 -47.27 78.73 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.775 -0.726 . . . . 0.0 112.439 179.816 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 25.2 m -49.44 -47.43 48.19 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-O 120.637 0.256 . . . . 0.0 111.433 -179.258 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 94.6 mt -71.63 -44.67 63.95 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.481 -0.327 . . . . 0.0 111.516 -179.914 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -55.14 -35.11 64.37 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.384 -0.371 . . . . 0.0 111.918 -179.436 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 22' ' ' PHE . . . . . 0.66 ' HB2' HG22 ' A' ' 41' ' ' VAL . 4.2 m-85 -91.07 -29.56 17.25 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.557 -0.292 . . . . 0.0 111.777 -179.207 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -70.31 -51.02 33.28 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.966 0.412 . . . . 0.0 111.524 -179.362 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 24' ' ' TRP . . . . . . . . . . . . . 5.8 t-105 -66.42 -50.01 64.85 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-N 115.881 -0.6 . . . . 0.0 110.999 -179.778 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.328 -0.34 0 CA-C-N 116.49 -0.323 . . . . 0.0 111.002 179.989 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.278 0 N-CA-C 112.291 -0.324 . . . . 0.0 112.291 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 38.6 mt-10 -69.99 -20.66 63.28 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.779 0.323 . . . . 0.0 110.645 179.776 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 34' ' ' ARG . . . . . . . . . . . . . 99.8 mtt180 -49.09 -29.09 4.74 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 115.862 -0.608 . . . . 0.0 111.535 -179.862 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 21.4 mmm180 -64.3 -46.98 81.26 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-O 120.783 0.325 . . . . 0.0 111.041 179.905 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 90.2 m-85 -69.2 -32.01 71.01 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.162 179.875 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 37' ' ' TYR . . . . . 0.477 ' O ' HG23 ' A' ' 41' ' ' VAL . 43.4 m-85 -71.97 -54.75 8.99 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.085 -0.507 . . . . 0.0 111.41 -179.485 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 14.6 p -56.76 -36.34 48.91 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-O 120.972 0.415 . . . . 0.0 110.441 -179.995 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 40.9 m -64.85 -50.19 67.6 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 115.758 -0.655 . . . . 0.0 110.41 179.219 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 40' ' ' LEU . . . . . 0.654 HD12 HD11 ' A' ' 43' ' ' ILE . 57.7 tp -61.0 -38.28 85.47 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 115.573 -0.739 . . . . 0.0 110.657 179.741 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . 0.66 HG22 ' HB2' ' A' ' 22' ' ' PHE . 95.8 t -69.48 -34.0 59.9 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.453 0 CA-C-N 115.932 -0.576 . . . . 0.0 109.975 179.011 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -61.22 -42.31 99.75 Favored Glycine 0 N--CA 1.449 -0.483 0 CA-C-N 115.615 -0.721 . . . . 0.0 112.892 179.905 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 43' ' ' ILE . . . . . 0.654 HD11 HD12 ' A' ' 40' ' ' LEU . 38.9 pt -70.03 -44.0 78.74 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.153 0 CA-C-N 116.952 0.376 . . . . 0.0 111.31 -179.786 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 44' ' ' SER . . . . . 0.458 ' N ' HG13 ' A' ' 43' ' ' ILE . 38.7 t -66.29 -25.98 67.11 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-O 120.985 0.421 . . . . 0.0 110.713 179.461 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -79.85 -52.69 4.56 Favored Glycine 0 C--N 1.33 0.233 0 C-N-CA 121.033 -0.603 . . . . 0.0 112.907 -179.295 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 46' ' ' ILE . . . . . 0.462 ' O ' HG22 ' A' ' 49' ' ' VAL . 15.3 pt -57.88 -36.95 57.79 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.248 0 CA-C-O 121.148 0.499 . . . . 0.0 110.33 179.978 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 47' ' ' ALA . . . . . 0.757 ' HB2' ' HE2' ' A' ' 205' ' ' LYS . . . -68.2 -42.05 80.45 Favored 'General case' 0 C--N 1.326 -0.45 0 CA-C-N 115.81 -0.632 . . . . 0.0 110.78 178.716 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 48' ' ' ALA . . . . . 0.533 ' HB2' ' HB3' ' A' ' 15' ' ' MET . . . -54.48 -42.66 70.99 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 115.881 -0.599 . . . . 0.0 112.038 -179.451 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 49' ' ' VAL . . . . . 0.462 HG22 ' O ' ' A' ' 46' ' ' ILE . 31.0 m -73.42 -36.24 47.93 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.24 0 N-CA-C 111.606 0.224 . . . . 0.0 111.606 -179.437 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -62.49 -40.39 96.54 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-O 121.001 0.429 . . . . 0.0 111.285 179.792 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 4.2 m-85 -70.58 -40.2 73.42 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-N 115.997 -0.547 . . . . 0.0 110.726 -179.613 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -63.13 -42.26 99.47 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 115.882 -0.599 . . . . 0.0 111.459 179.999 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 53' ' ' VAL . . . . . 0.535 ' O ' HG22 ' A' ' 58' ' ' VAL . 33.0 m -70.28 -49.71 52.22 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.209 0 CA-C-N 116.71 -0.223 . . . . 0.0 111.057 -179.865 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 54' ' ' MET . . . . . 0.492 ' N ' HG23 ' A' ' 53' ' ' VAL . 73.1 mtm -60.75 -32.29 71.59 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-O 121.099 0.476 . . . . 0.0 109.916 179.429 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -63.26 -22.9 67.16 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 115.552 -0.749 . . . . 0.0 111.283 179.677 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 80.2 mt -89.1 -14.35 36.45 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.459 -0.337 . . . . 0.0 111.033 -179.906 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 102.53 -2.99 49.77 Favored Glycine 0 C--N 1.33 0.248 0 C-N-CA 120.689 -0.767 . . . . 0.0 113.352 179.371 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 58' ' ' VAL . . . . . 0.535 HG22 ' O ' ' A' ' 53' ' ' VAL . 15.8 m -78.63 154.25 4.97 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.166 0 CA-C-N 116.981 0.39 . . . . 0.0 111.145 -179.901 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 59' ' ' GLY . . . . . 0.438 ' HA3' ' CG ' ' A' ' 71' ' ' PRO . . . 80.69 -2.39 79.3 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.89 -0.671 . . . . 0.0 112.859 -179.943 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 60' ' ' TRP . . . . . . . . . . . . . 23.2 m0 -78.28 121.49 24.49 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 120.724 0.297 . . . . 0.0 110.503 179.718 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 7.3 p -112.8 132.25 22.37 Favored Pre-proline 0 CA--C 1.533 0.29 0 CA-C-N 116.416 -0.356 . . . . 0.0 111.343 -179.796 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 72.0 Cg_endo -77.45 145.56 23.78 Favored 'Trans proline' 0 C--N 1.35 0.638 0 C-N-CA 122.51 2.14 . . . . 0.0 112.512 179.941 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 96.6 t -142.65 94.08 0.54 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 115.872 -0.604 . . . . 0.0 110.926 -179.94 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . 57.67 -89.55 0.02 OUTLIER 'General case' 0 C--N 1.332 -0.178 0 CA-C-N 116.13 -0.486 . . . . 0.0 111.418 179.96 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 12.8 pt-20 -119.79 -19.93 7.79 Favored 'General case' 0 C--O 1.233 0.204 0 CA-C-O 120.806 0.336 . . . . 0.0 110.872 -179.987 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 66' ' ' ARG . . . . . 0.496 HH22 ' HA ' ' A' ' 183' ' ' PRO . 13.1 ptm180 -101.93 166.29 10.72 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.385 179.83 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 35.3 m -125.72 123.89 39.85 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-O 120.975 0.417 . . . . 0.0 111.462 -179.725 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 23.4 t -101.29 147.16 8.54 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.221 0 CA-C-N 115.88 -0.6 . . . . 0.0 110.284 179.41 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 69' ' ' PHE . . . . . . . . . . . . . 46.8 m-85 -106.94 112.41 25.36 Favored 'General case' 0 C--N 1.328 -0.329 0 N-CA-C 110.03 -0.359 . . . . 0.0 110.03 -179.363 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 70' ' ' VAL . . . . . 0.523 ' HB ' ' HD3' ' A' ' 71' ' ' PRO . 21.7 t -68.96 -49.89 24.04 Favored Pre-proline 0 C--N 1.327 -0.408 0 N-CA-C 112.455 0.539 . . . . 0.0 112.455 -178.891 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 71' ' ' PRO . . . . . 0.523 ' HD3' ' HB ' ' A' ' 70' ' ' VAL . 31.8 Cg_exo -58.55 -25.97 76.68 Favored 'Trans proline' 0 C--N 1.35 0.627 0 C-N-CA 121.983 1.788 . . . . 0.0 112.174 179.97 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 72' ' ' ARG . . . . . 0.406 ' HB2' ' SD ' ' A' ' 54' ' ' MET . 46.3 ttp180 -72.52 -53.27 12.52 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.975 0.417 . . . . 0.0 110.665 179.932 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 73' ' ' TYR . . . . . 0.409 ' O ' HG13 ' A' ' 77' ' ' ILE . 23.0 m-85 -65.2 -38.07 89.29 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 115.831 -0.622 . . . . 0.0 110.694 179.934 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 74' ' ' ILE . . . . . 0.444 ' O ' HD13 ' A' ' 74' ' ' ILE . 0.4 OUTLIER -70.32 -37.62 71.6 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 N-CA-C 110.008 -0.367 . . . . 0.0 110.008 179.583 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 75' ' ' ASP . . . . . 0.457 ' O ' HG23 ' A' ' 79' ' ' THR . 31.2 t70 -57.24 -38.61 74.06 Favored 'General case' 0 CA--C 1.521 -0.138 0 N-CA-C 109.453 -0.573 . . . . 0.0 109.453 178.991 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 76' ' ' TRP . . . . . . . . . . . . . 45.4 m0 -66.8 -39.72 87.85 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 115.553 -0.749 . . . . 0.0 110.27 179.375 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 77' ' ' ILE . . . . . 0.428 HD12 ' HA ' ' A' ' 74' ' ' ILE . 89.3 mt -60.49 -28.93 43.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 115.953 -0.567 . . . . 0.0 110.788 179.551 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 43.1 mt -91.97 -29.19 16.77 Favored 'General case' 0 C--N 1.33 -0.255 0 N-CA-C 112.275 0.472 . . . . 0.0 112.275 179.96 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 79' ' ' THR . . . . . 0.457 HG23 ' O ' ' A' ' 75' ' ' ASP . 66.8 p -89.38 -52.09 5.22 Favored 'General case' 0 N--CA 1.464 0.27 0 N-CA-C 113.506 0.928 . . . . 0.0 113.506 -177.725 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 80' ' ' THR . . . . . 0.447 ' N ' ' HD2' ' A' ' 81' ' ' PRO . 86.1 m -47.3 -55.03 17.47 Favored Pre-proline 0 C--N 1.328 -0.34 0 N-CA-C 112.773 0.657 . . . . 0.0 112.773 -178.683 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 81' ' ' PRO . . . . . 0.447 ' HD2' ' N ' ' A' ' 80' ' ' THR . 36.1 Cg_endo -63.2 -20.82 71.7 Favored 'Trans proline' 0 C--N 1.351 0.69 0 C-N-CA 121.55 1.5 . . . . 0.0 111.06 179.997 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 82' ' ' LEU . . . . . 0.435 ' HB3' HG22 ' A' ' 43' ' ' ILE . 0.1 OUTLIER -76.2 -34.8 59.29 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 115.364 -0.834 . . . . 0.0 109.94 179.558 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 47.9 mm -69.25 -52.74 30.28 Favored 'Isoleucine or valine' 0 CA--C 1.522 -0.126 0 CA-C-N 115.849 -0.614 . . . . 0.0 110.205 179.429 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 84' ' ' VAL . . . . . 0.429 HG22 ' HA ' ' A' ' 81' ' ' PRO . 27.7 m -59.64 -31.16 46.38 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.215 0 N-CA-C 109.614 -0.513 . . . . 0.0 109.614 178.912 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 85' ' ' TYR . . . . . . . . . . . . . 85.2 t80 -63.69 -36.54 84.19 Favored 'General case' 0 N--CA 1.454 -0.246 0 CA-C-N 115.657 -0.701 . . . . 0.0 109.188 178.457 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 86' ' ' PHE . . . . . . . . . . . . . 8.0 t80 -61.42 -44.87 96.38 Favored 'General case' 0 C--O 1.231 0.121 0 CA-C-N 115.636 -0.711 . . . . 0.0 109.457 178.87 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 3.7 mm? -61.66 -34.11 75.14 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 115.453 -0.794 . . . . 0.0 110.153 179.177 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 88' ' ' GLY . . . . . 0.516 ' HA2' HD13 ' A' ' 93' ' ' LEU . . . -69.08 -29.45 72.28 Favored Glycine 0 N--CA 1.449 -0.462 0 C-N-CA 120.812 -0.709 . . . . 0.0 112.252 179.695 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 95.9 mt -71.66 -39.48 70.29 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 121.028 0.442 . . . . 0.0 110.362 179.69 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 42.8 mt -61.14 -59.73 4.88 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 115.796 -0.638 . . . . 0.0 110.872 179.782 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 91' ' ' ALA . . . . . 0.493 ' HB2' ' HB2' ' A' ' 149' ' ' ALA . . . -70.25 -54.79 11.22 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.081 -0.509 . . . . 0.0 111.339 -179.833 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 98.85 68.77 0.91 Allowed Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.787 -0.72 . . . . 0.0 112.212 -179.861 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 93' ' ' LEU . . . . . 0.552 HD23 ' HB3' ' A' ' 97' ' ' GLU . 8.1 mp -72.0 -174.35 1.21 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.775 0.322 . . . . 0.0 110.945 -179.824 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 94' ' ' ASP . . . . . 0.452 ' HB3' ' OE2' ' A' ' 97' ' ' GLU . 10.2 t70 -97.28 -177.12 3.73 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.868 -179.73 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 77.9 p -65.58 -45.34 83.62 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.574 -179.369 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 36.2 mtp180 -74.14 -39.48 63.27 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-O 121.246 0.546 . . . . 0.0 110.438 -179.657 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 97' ' ' GLU . . . . . 0.552 ' HB3' HD23 ' A' ' 93' ' ' LEU . 0.3 OUTLIER -58.01 -44.68 87.38 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-N 115.457 -0.792 . . . . 0.0 111.039 -179.826 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 98' ' ' PHE . . . . . 0.441 ' O ' HG12 ' A' ' 102' ' ' ILE . 2.2 m-85 -61.52 -35.47 77.82 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.956 0.408 . . . . 0.0 110.502 179.543 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -70.08 -25.97 74.91 Favored Glycine 0 N--CA 1.451 -0.359 0 C-N-CA 120.7 -0.762 . . . . 0.0 112.144 179.795 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 96.4 mt -73.17 -43.71 57.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 N-CA-C 111.841 0.311 . . . . 0.0 111.841 -179.819 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 25.7 m -69.45 -39.16 78.33 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-O 120.676 0.275 . . . . 0.0 111.716 -179.389 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 102' ' ' ILE . . . . . 0.441 HG12 ' O ' ' A' ' 98' ' ' PHE . 42.0 mm -73.65 -41.0 55.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.582 -0.281 . . . . 0.0 111.621 -179.435 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 13.9 t -63.76 -35.97 82.34 Favored 'General case' 0 C--N 1.332 -0.153 0 CA-C-O 120.775 0.322 . . . . 0.0 110.884 -179.948 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 104' ' ' LEU . . . . . 0.439 ' O ' HG23 ' A' ' 108' ' ' VAL . 56.5 tp -67.52 -43.77 79.99 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.288 179.766 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 105' ' ' ASN . . . . . 0.529 ' N ' HD22 ' A' ' 105' ' ' ASN . 0.9 OUTLIER -62.72 -27.3 69.17 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.532 179.57 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 91.9 m -69.4 -52.15 29.77 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.054 -0.521 . . . . 0.0 111.502 -179.912 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 107' ' ' VAL . . . . . 0.444 HG22 ' HE2' ' A' ' 129' ' ' MET . 7.5 p -66.09 -36.35 77.23 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.214 0 CA-C-N 116.38 -0.373 . . . . 0.0 111.226 -179.976 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . 0.439 HG23 ' O ' ' A' ' 104' ' ' LEU . 51.0 t -62.85 -54.68 30.57 Favored 'Isoleucine or valine' 0 C--O 1.234 0.281 0 CA-C-N 116.294 -0.412 . . . . 0.0 110.866 179.746 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 109' ' ' MET . . . . . . . . . . . . . 5.6 tpp -61.66 -26.82 68.26 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.049 -0.523 . . . . 0.0 110.383 179.897 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 29.7 tp -73.05 -31.98 64.77 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.062 -0.517 . . . . 0.0 110.226 179.487 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -64.31 -51.17 64.79 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 115.926 -0.579 . . . . 0.0 110.284 179.225 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . -62.76 -44.26 97.75 Favored Glycine 0 CA--C 1.518 0.248 0 C-N-CA 120.796 -0.716 . . . . 0.0 112.42 179.539 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 113' ' ' PHE . . . . . 0.455 ' HZ ' HG13 ' A' ' 70' ' ' VAL . 0.8 OUTLIER -47.98 -61.01 2.18 Favored 'General case' 0 C--N 1.333 -0.141 0 CA-C-O 120.911 0.386 . . . . 0.0 110.397 179.592 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -69.83 -18.25 63.44 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.025 -0.534 . . . . 0.0 110.797 179.918 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -57.14 -49.06 74.98 Favored Glycine 0 C--N 1.333 0.389 0 C-N-CA 120.79 -0.719 . . . . 0.0 111.9 179.375 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -78.55 -15.51 58.48 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-O 120.782 0.325 . . . . 0.0 111.376 179.817 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 117' ' ' MET . . . . . . . . . . . . . 23.1 mmt -88.22 19.18 3.85 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 116.384 -0.371 . . . . 0.0 111.612 -179.553 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 35.7 m -84.64 141.62 38.97 Favored Pre-proline 0 C--N 1.329 -0.315 0 CA-C-O 120.57 0.224 . . . . 0.0 111.285 -179.846 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 119' ' ' PRO . . . . . . . . . . . . . 93.4 Cg_endo -87.07 -2.43 7.98 Favored 'Trans proline' 0 N--CA 1.459 -0.513 0 C-N-CA 122.77 2.314 . . . . 0.0 112.36 179.797 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -144.12 -110.05 0.7 Allowed Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.789 -0.72 . . . . 0.0 112.684 -179.911 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 42.9 pt -133.29 11.8 1.42 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.23 0 CA-C-O 120.681 0.277 . . . . 0.0 111.468 -179.646 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 46.9 mt-10 -59.24 -18.23 35.17 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.344 -0.389 . . . . 0.0 111.015 179.912 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 123' ' ' ARG . . . . . 0.524 ' HA ' HD13 ' A' ' 126' ' ' LEU . 11.1 ptt180 -50.45 -37.15 36.71 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.05 -0.523 . . . . 0.0 111.946 -179.661 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 124' ' ' TYR . . . . . . . . . . . . . 28.4 m-85 -51.19 -35.54 36.85 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.844 0.354 . . . . 0.0 111.171 -179.828 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 125' ' ' ALA . . . . . . . . . . . . . . . -74.8 -49.65 20.03 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.141 -0.481 . . . . 0.0 111.008 179.878 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 126' ' ' LEU . . . . . 0.524 HD13 ' HA ' ' A' ' 123' ' ' ARG . 6.5 mp -52.51 -55.67 20.48 Favored 'General case' 0 C--N 1.332 -0.182 0 CA-C-N 115.999 -0.546 . . . . 0.0 110.327 179.964 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 127' ' ' PHE . . . . . . . . . . . . . 10.9 t80 -64.51 -28.84 69.93 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 115.909 -0.587 . . . . 0.0 110.155 179.45 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 128' ' ' GLY . . . . . . . . . . . . . . . -49.16 -48.53 32.16 Favored Glycine 0 N--CA 1.449 -0.451 0 C-N-CA 120.121 -1.038 . . . . 0.0 110.593 178.79 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 129' ' ' MET . . . . . 0.445 ' HE3' ' HA2' ' A' ' 130' ' ' GLY . 0.0 OUTLIER -72.29 -31.72 65.98 Favored 'General case' 0 N--CA 1.452 -0.365 0 N-CA-C 109.079 -0.712 . . . . 0.0 109.079 178.467 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 130' ' ' GLY . . . . . 0.445 ' HA2' ' HE3' ' A' ' 129' ' ' MET . . . -61.52 -33.18 83.89 Favored Glycine 0 C--N 1.333 0.411 0 CA-C-N 115.749 -0.66 . . . . 0.0 112.035 179.458 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 131' ' ' ALA . . . . . 0.42 ' O ' ' HB3' ' A' ' 134' ' ' PHE . . . -74.8 -53.35 9.31 Favored 'General case' 0 N--CA 1.452 -0.326 0 CA-C-O 120.743 0.306 . . . . 0.0 110.362 179.648 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 40.8 t -55.15 -49.0 75.59 Favored 'Isoleucine or valine' 0 C--O 1.234 0.253 0 N-CA-C 109.462 -0.57 . . . . 0.0 109.462 178.783 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -59.68 -39.13 83.49 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 115.504 -0.771 . . . . 0.0 110.323 178.589 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 134' ' ' PHE . . . . . 0.459 ' CZ ' ' HA ' ' A' ' 172' ' ' ALA . 65.4 t80 -55.1 -51.13 67.37 Favored 'General case' 0 N--CA 1.451 -0.388 0 CA-C-N 115.892 -0.594 . . . . 0.0 110.367 179.68 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 135' ' ' ILE . . . . . 0.475 ' O ' HG22 ' A' ' 138' ' ' VAL . 60.2 mt -56.15 -32.05 33.31 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.238 0 CA-C-N 115.946 -0.57 . . . . 0.0 110.112 179.24 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 136' ' ' GLY . . . . . 0.402 ' O ' ' HB3' ' A' ' 139' ' ' TYR . . . -61.67 -41.24 99.56 Favored Glycine 0 N--CA 1.447 -0.598 0 C-N-CA 120.16 -1.019 . . . . 0.0 111.343 178.69 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 137' ' ' LEU . . . . . . . . . . . . . 30.0 tp -69.57 -50.71 42.08 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 115.846 -0.177 . . . . 0.0 111.09 179.935 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 138' ' ' VAL . . . . . 0.591 ' HA ' HD12 ' A' ' 141' ' ' LEU . 5.2 m -55.96 -32.62 33.53 Favored 'Isoleucine or valine' 0 C--O 1.234 0.245 0 CA-C-O 121.31 0.576 . . . . 0.0 109.754 179.478 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 139' ' ' TYR . . . . . 0.405 ' O ' ' N ' ' A' ' 143' ' ' GLY . 65.9 t80 -60.09 -48.09 83.16 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 115.353 -0.839 . . . . 0.0 109.412 178.511 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 37.0 m-85 -58.95 -35.5 73.23 Favored 'General case' 0 C--N 1.332 -0.169 0 CA-C-N 115.938 -0.573 . . . . 0.0 110.576 179.096 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 141' ' ' LEU . . . . . 0.591 HD12 ' HA ' ' A' ' 138' ' ' VAL . 95.6 mt -55.56 -46.74 77.13 Favored 'General case' 0 C--N 1.332 -0.174 0 CA-C-N 116.322 -0.399 . . . . 0.0 110.27 179.504 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 142' ' ' VAL . . . . . 0.405 HG22 ' O ' ' A' ' 142' ' ' VAL . 9.2 p -105.39 15.04 7.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 115.926 -0.579 . . . . 0.0 110.828 179.752 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 143' ' ' GLY . . . . . 0.405 ' N ' ' O ' ' A' ' 139' ' ' TYR . . . -90.86 -130.66 4.68 Favored Glycine 0 CA--C 1.52 0.393 0 C-N-CA 120.913 -0.661 . . . . 0.0 112.9 -179.627 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 144' ' ' PRO . . . . . . . . . . . . . 45.3 Cg_exo -57.23 -25.44 64.66 Favored 'Trans proline' 0 C--N 1.351 0.686 0 C-N-CA 122.585 2.19 . . . . 0.0 112.726 -179.632 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 145' ' ' MET . . . . . . . . . . . . . 60.6 mtt -56.76 -25.13 54.44 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.355 -0.384 . . . . 0.0 111.134 -179.896 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 146' ' ' THR . . . . . . . . . . . . . 78.1 p -63.83 -51.2 65.77 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.112 -0.495 . . . . 0.0 111.685 -179.786 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 43.6 mt-10 -75.56 -28.64 59.09 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.371 -0.377 . . . . 0.0 111.62 -179.252 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 148' ' ' SER . . . . . . . . . . . . . 36.8 t -70.53 -44.66 67.09 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.743 0.306 . . . . 0.0 111.208 -179.469 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 149' ' ' ALA . . . . . 0.493 ' HB2' ' HB2' ' A' ' 91' ' ' ALA . . . -77.92 -42.99 31.28 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.324 -0.398 . . . . 0.0 111.923 -179.53 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 150' ' ' SER . . . . . 0.586 ' HA ' ' HG2' ' A' ' 157' ' ' LYS . 47.5 t -63.65 -8.0 8.89 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.548 -179.504 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 151' ' ' GLN . . . . . . . . . . . . . 47.5 mt-30 -125.54 17.34 8.18 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.668 0.271 . . . . 0.0 111.279 -179.955 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 152' ' ' ARG . . . . . 0.6 ' HD2' HG13 ' A' ' 156' ' ' ILE . 3.6 tmt_? -93.24 -51.81 4.84 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-O 120.967 0.413 . . . . 0.0 110.509 179.782 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 153' ' ' SER . . . . . 0.679 ' HB3' HG12 ' A' ' 156' ' ' ILE . 20.0 t -157.42 172.41 18.63 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 115.904 -0.589 . . . . 0.0 110.451 179.304 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 154' ' ' SER . . . . . . . . . . . . . 79.0 p -71.62 -42.18 67.95 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.278 -0.419 . . . . 0.0 111.006 179.744 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -76.87 -25.72 64.04 Favored Glycine 0 C--N 1.331 0.265 0 C-N-CA 120.834 -0.698 . . . . 0.0 113.093 -179.669 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 156' ' ' ILE . . . . . 0.679 HG12 ' HB3' ' A' ' 153' ' ' SER . 27.7 mm -57.89 -38.48 66.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-O 120.551 0.215 . . . . 0.0 111.519 -179.718 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 157' ' ' LYS . . . . . 0.586 ' HG2' ' HA ' ' A' ' 150' ' ' SER . 35.8 mtmm -56.72 -39.91 74.77 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-O 120.806 0.336 . . . . 0.0 111.214 179.908 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 43.7 t -70.95 -48.1 55.28 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.569 -179.315 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 159' ' ' LEU . . . . . 0.458 ' O ' ' HB2' ' A' ' 163' ' ' LEU . 9.9 mt -68.18 -28.89 67.67 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 116.482 -0.326 . . . . 0.0 111.65 -179.609 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 160' ' ' TYR . . . . . . . . . . . . . 83.8 t80 -73.95 -45.91 47.41 Favored 'General case' 0 C--N 1.326 -0.429 0 N-CA-C 112.061 0.393 . . . . 0.0 112.061 -178.941 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 161' ' ' VAL . . . . . 0.426 HG23 ' N ' ' A' ' 162' ' ' ARG . 30.9 m -66.57 -43.89 90.34 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.419 0 N-CA-C 112.169 0.433 . . . . 0.0 112.169 -179.007 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 162' ' ' ARG . . . . . 0.426 ' N ' HG23 ' A' ' 161' ' ' VAL . 35.3 mmt180 -68.68 -41.69 78.86 Favored 'General case' 0 C--N 1.328 -0.349 0 N-CA-C 111.884 0.327 . . . . 0.0 111.884 -178.906 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 163' ' ' LEU . . . . . 0.609 ' HG ' ' HB2' ' A' ' 208' ' ' PHE . 7.7 mp -73.79 -50.06 22.38 Favored 'General case' 0 C--N 1.329 -0.326 0 N-CA-C 112.015 0.376 . . . . 0.0 112.015 -179.182 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 164' ' ' ARG . . . . . 0.465 ' HG2' ' HB3' ' A' ' 141' ' ' LEU . 6.4 tmm_? -59.45 -50.12 75.18 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.624 -0.262 . . . . 0.0 111.577 -179.139 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 165' ' ' ASN . . . . . 0.56 HD22 ' N ' ' A' ' 165' ' ' ASN . 0.8 OUTLIER -61.29 -51.41 69.02 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.45 -0.341 . . . . 0.0 111.524 -179.464 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 166' ' ' LEU . . . . . 0.482 ' O ' ' HG ' ' A' ' 170' ' ' LEU . 4.9 tt -60.76 -54.85 40.22 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.457 -0.338 . . . . 0.0 111.865 -179.198 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 167' ' ' THR . . . . . 0.411 ' O ' ' HB2' ' A' ' 171' ' ' TRP . 64.5 m -55.17 -54.22 45.98 Favored 'General case' 0 C--N 1.329 -0.292 0 N-CA-C 112.898 0.703 . . . . 0.0 112.898 -178.585 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 168' ' ' VAL . . . . . 0.438 ' HB ' HD13 ' A' ' 141' ' ' LEU . 9.9 p -55.1 -40.51 55.12 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.195 0 N-CA-C 112.418 0.525 . . . . 0.0 112.418 -178.924 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 169' ' ' VAL . . . . . 0.548 HG23 ' O ' ' A' ' 165' ' ' ASN . 58.5 t -60.47 -65.11 0.5 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 N-CA-C 111.874 0.324 . . . . 0.0 111.874 -179.159 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 170' ' ' LEU . . . . . 0.482 ' HG ' ' O ' ' A' ' 166' ' ' LEU . 1.0 OUTLIER -61.3 -29.2 69.72 Favored 'General case' 0 C--N 1.329 -0.283 0 C-N-CA 121.166 -0.213 . . . . 0.0 111.41 -179.273 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 171' ' ' TRP . . . . . 0.413 ' N ' HD12 ' A' ' 170' ' ' LEU . 2.8 m0 -71.03 -35.3 71.93 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-O 120.934 0.397 . . . . 0.0 110.038 178.983 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 172' ' ' ALA . . . . . 0.459 ' HA ' ' CZ ' ' A' ' 134' ' ' PHE . . . -68.32 -6.61 25.09 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 115.872 -0.604 . . . . 0.0 110.62 179.572 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 173' ' ' ILE . . . . . 0.509 HG22 HD11 ' A' ' 177' ' ' ILE . 40.4 mm -85.9 -22.19 7.39 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 115.873 -0.603 . . . . 0.0 110.798 179.515 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 174' ' ' TYR . . . . . 0.59 ' N ' ' HD2' ' A' ' 175' ' ' PRO . 12.9 m-85 -54.22 -50.81 82.57 Favored Pre-proline 0 CA--C 1.533 0.299 0 CA-C-N 116.159 -0.473 . . . . 0.0 112.109 -179.684 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 175' ' ' PRO . . . . . 0.59 ' HD2' ' N ' ' A' ' 174' ' ' TYR . 8.1 Cg_endo -50.65 -27.75 20.46 Favored 'Trans proline' 0 C--N 1.352 0.752 0 C-N-CA 122.067 1.845 . . . . 0.0 112.355 -179.797 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 176' ' ' PHE . . . . . 0.457 ' O ' ' HG ' ' A' ' 180' ' ' LEU . 49.5 m-85 -80.59 -46.43 15.71 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.291 -0.413 . . . . 0.0 111.668 -179.995 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 177' ' ' ILE . . . . . 0.509 HD11 HG22 ' A' ' 173' ' ' ILE . 3.5 mm -66.19 -36.35 77.19 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.497 0 N-CA-C 112.299 0.481 . . . . 0.0 112.299 -178.211 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 178' ' ' TRP . . . . . 0.471 ' HH2' ' HB2' ' A' ' 123' ' ' ARG . 67.8 t90 -73.94 -45.95 47.21 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-O 120.907 0.384 . . . . 0.0 110.772 179.602 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 179' ' ' LEU . . . . . 0.459 ' O ' HG22 ' A' ' 185' ' ' VAL . 2.5 tm? -67.92 -49.6 60.91 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 115.921 -0.581 . . . . 0.0 111.403 -179.077 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 180' ' ' LEU . . . . . 0.556 HD22 HD11 ' A' ' 187' ' ' LEU . 22.7 mt -77.7 -47.23 19.65 Favored 'General case' 0 C--N 1.328 -0.358 0 N-CA-C 111.812 0.301 . . . . 0.0 111.812 -179.165 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . -58.75 -178.21 0.96 Allowed Glycine 0 C--N 1.337 0.591 0 C-N-CA 120.256 -0.973 . . . . 0.0 112.772 -179.98 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 182' ' ' PRO . . . . . 0.644 ' HA ' ' HB2' ' A' ' 186' ' ' ALA . 85.7 Cg_exo -47.81 -44.32 27.14 Favored 'Trans proline' 0 CA--C 1.536 0.623 0 C-N-CA 122.967 2.445 . . . . 0.0 113.802 -179.97 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 183' ' ' PRO . . . . . 0.496 ' HA ' HH22 ' A' ' 66' ' ' ARG . 51.8 Cg_exo -55.3 -9.95 2.79 Favored 'Trans proline' 0 C--N 1.354 0.833 0 C-N-CA 122.154 1.902 . . . . 0.0 113.199 -179.736 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 184' ' ' GLY . . . . . 0.414 ' HA3' ' O ' ' A' ' 179' ' ' LEU . . . -123.21 -87.39 0.81 Allowed Glycine 0 N--CA 1.45 -0.387 0 C-N-CA 120.421 -0.895 . . . . 0.0 112.901 -179.887 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 185' ' ' VAL . . . . . 0.459 HG22 ' O ' ' A' ' 179' ' ' LEU . 8.6 m -120.43 -7.02 10.53 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-O 120.773 0.321 . . . . 0.0 111.779 -179.603 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 186' ' ' ALA . . . . . 0.644 ' HB2' ' HA ' ' A' ' 182' ' ' PRO . . . 56.18 85.36 0.07 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.116 -0.493 . . . . 0.0 111.716 179.576 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 187' ' ' LEU . . . . . 0.556 HD11 HD22 ' A' ' 180' ' ' LEU . 18.8 mt -91.78 -49.25 6.36 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.93 0.395 . . . . 0.0 110.878 179.528 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 188' ' ' LEU . . . . . 0.403 ' HB3' ' H ' ' A' ' 189' ' ' THR . 96.6 mt -90.13 -154.99 0.35 Allowed 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 115.839 -0.619 . . . . 0.0 110.947 -179.661 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 189' ' ' THR . . . . . 0.481 ' HB ' HG23 ' A' ' 192' ' ' VAL . 58.8 m -92.6 136.17 25.56 Favored Pre-proline 0 C--N 1.329 -0.326 0 CA-C-N 116.05 -0.523 . . . . 0.0 110.568 -179.719 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 190' ' ' PRO . . . . . 0.468 ' O ' HG23 ' A' ' 194' ' ' VAL . 2.2 Cg_endo -45.5 -37.69 15.23 Favored 'Trans proline' 0 C--N 1.35 0.652 0 C-N-CA 122.837 2.358 . . . . 0.0 112.776 -179.747 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 191' ' ' THR . . . . . 0.413 ' H ' HG22 ' A' ' 189' ' ' THR . 41.7 p -74.24 -45.42 48.09 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 116.487 -0.324 . . . . 0.0 111.415 -179.835 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 192' ' ' VAL . . . . . 0.481 HG23 ' HB ' ' A' ' 189' ' ' THR . 96.9 t -59.66 -52.79 56.9 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.302 -0.408 . . . . 0.0 111.415 -179.781 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 193' ' ' ASP . . . . . . . . . . . . . 25.9 t70 -54.6 -48.2 72.46 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.946 -179.761 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 194' ' ' VAL . . . . . 0.62 ' O ' HG22 ' A' ' 198' ' ' VAL . 40.6 t -55.22 -44.03 73.22 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.241 0 CA-C-N 116.376 -0.375 . . . . 0.0 110.492 179.492 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 195' ' ' ALA . . . . . . . . . . . . . . . -52.46 -42.91 64.61 Favored 'General case' 0 C--N 1.332 -0.185 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.778 179.895 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 196' ' ' LEU . . . . . . . . . . . . . 62.5 mt -67.8 -40.27 83.9 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.785 179.356 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 197' ' ' ILE . . . . . 0.42 HG12 HG21 ' A' ' 177' ' ' ILE . 12.0 mm -59.39 -60.87 1.82 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 115.766 -0.652 . . . . 0.0 111.405 -179.847 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 198' ' ' VAL . . . . . 0.62 HG22 ' O ' ' A' ' 194' ' ' VAL . 1.3 m -53.94 -34.85 26.61 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.439 0 CA-C-O 121.544 0.687 . . . . 0.0 109.566 179.053 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 199' ' ' TYR . . . . . . . . . . . . . 63.8 t80 -66.57 -33.56 75.94 Favored 'General case' 0 C--N 1.323 -0.587 0 CA-C-N 114.639 -1.164 . . . . 0.0 110.575 179.722 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 200' ' ' LEU . . . . . 0.483 ' O ' HG12 ' A' ' 203' ' ' VAL . 26.6 mt -66.67 -41.77 87.62 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.088 -0.505 . . . . 0.0 111.315 -179.897 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 201' ' ' ASP . . . . . . . . . . . . . 5.0 m-20 -74.83 -37.94 62.14 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-O 121.253 0.549 . . . . 0.0 110.044 179.499 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 202' ' ' LEU . . . . . 0.481 HD13 ' SD ' ' A' ' 15' ' ' MET . 40.5 tp -70.6 -26.79 63.67 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 115.256 -0.884 . . . . 0.0 111.559 -179.343 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 203' ' ' VAL . . . . . 0.483 HG12 ' O ' ' A' ' 200' ' ' LEU . 14.2 p -81.73 -36.7 14.59 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.13 0 CA-C-N 116.765 -0.198 . . . . 0.0 110.813 -179.141 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 204' ' ' THR . . . . . . . . . . . . . 65.8 m -63.43 -58.56 6.67 Favored 'General case' 0 C--N 1.329 -0.305 0 C-N-CA 120.713 -0.395 . . . . 0.0 110.642 179.169 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 205' ' ' LYS . . . . . 0.757 ' HE2' ' HB2' ' A' ' 47' ' ' ALA . 57.7 mttp -60.88 -58.01 10.26 Favored 'General case' 0 C--N 1.328 -0.361 0 N-CA-C 112.609 0.596 . . . . 0.0 112.609 -178.464 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 56.5 t -71.77 -37.36 62.02 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 N-CA-C 112.317 0.488 . . . . 0.0 112.317 -178.432 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 207' ' ' GLY . . . . . 0.53 ' O ' HG13 ' A' ' 211' ' ' ILE . . . -56.92 -61.67 7.24 Favored Glycine 0 CA--C 1.517 0.18 0 C-N-CA 120.665 -0.779 . . . . 0.0 113.793 -178.799 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 208' ' ' PHE . . . . . 0.609 ' HB2' ' HG ' ' A' ' 163' ' ' LEU . 0.9 OUTLIER -72.73 -27.25 61.93 Favored 'General case' 0 C--O 1.222 -0.368 0 CA-C-N 117.571 0.686 . . . . 0.0 110.771 -179.31 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 209' ' ' GLY . . . . . 0.52 ' O ' ' HB3' ' A' ' 212' ' ' ALA . . . -63.34 -32.73 85.15 Favored Glycine 0 N--CA 1.448 -0.542 0 N-CA-C 111.629 -0.588 . . . . 0.0 111.629 178.471 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 210' ' ' PHE . . . . . . . . . . . . . 0.8 OUTLIER -74.06 -47.81 34.09 Favored 'General case' 0 CA--C 1.515 -0.397 0 N-CA-C 108.221 -1.029 . . . . 0.0 108.221 178.543 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 211' ' ' ILE . . . . . 0.53 HG13 ' O ' ' A' ' 207' ' ' GLY . 4.4 mt -63.43 -27.52 43.18 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.434 0 N-CA-C 107.678 -1.23 . . . . 0.0 107.678 176.83 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 212' ' ' ALA . . . . . 0.52 ' HB3' ' O ' ' A' ' 209' ' ' GLY . . . -62.76 -40.81 98.42 Favored 'General case' 0 N--CA 1.451 -0.418 0 CA-C-N 114.447 -1.252 . . . . 0.0 110.622 -179.788 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 213' ' ' LEU . . . . . . . . . . . . . 86.4 mt -69.44 -47.29 64.54 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 115.171 -0.922 . . . . 0.0 111.44 -179.501 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 214' ' ' ASP . . . . . . . . . . . . . 14.3 t70 -56.32 -53.1 61.34 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.391 -0.368 . . . . 0.0 111.079 -179.944 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 215' ' ' ALA . . . . . . . . . . . . . . . -56.88 -56.24 24.22 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.06 -0.518 . . . . 0.0 111.341 -179.813 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 216' ' ' ALA . . . . . . . . . . . . . . . -56.78 -32.13 65.34 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.234 -179.897 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 217' ' ' ALA . . . . . . . . . . . . . . . -64.73 -34.38 78.18 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.298 -0.41 . . . . 0.0 110.197 179.793 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 218' ' ' THR . . . . . . . . . . . . . 93.0 m . . . . . 0 C--N 1.328 -0.33 0 CA-C-N 115.789 -0.641 . . . . 0.0 110.76 179.536 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.322 0 N-CA-C 112.672 -0.171 . . . . 0.0 112.672 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 4' ' ' LEU . . . . . 0.412 ' HB2' ' HH2' ' A' ' 60' ' ' TRP . 81.9 mt -65.64 -36.65 84.32 Favored 'General case' 0 N--CA 1.45 -0.436 0 CA-C-O 120.804 0.335 . . . . 0.0 111.117 -179.844 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 67.1 p -57.21 -30.64 64.73 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.01 -0.541 . . . . 0.0 111.725 -179.651 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 27.3 p -58.8 -38.32 78.32 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 116.524 -0.307 . . . . 0.0 111.344 -179.609 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 7' ' ' LEU . . . . . . . . . . . . . 4.2 mm? -63.5 -51.45 65.49 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.106 -179.941 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 8' ' ' PHE . . . . . 0.484 ' HB2' ' HB2' ' A' ' 55' ' ' ALA . 74.1 m-85 -61.2 -33.23 73.13 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.512 179.928 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 9' ' ' TRP . . . . . 0.473 ' O ' HG13 ' A' ' 13' ' ' ILE . 9.1 m95 -66.15 -38.52 88.31 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 116.067 -0.515 . . . . 0.0 110.241 179.999 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 73.2 mt -65.7 -32.63 74.3 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 115.787 -0.642 . . . . 0.0 110.005 179.464 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -71.02 -33.64 65.31 Favored Glycine 0 N--CA 1.448 -0.517 0 C-N-CA 120.953 -0.642 . . . . 0.0 111.757 179.129 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 12' ' ' ALA . . . . . 0.456 ' O ' HD23 ' A' ' 16' ' ' LEU . . . -70.02 -32.43 70.58 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 120.889 0.376 . . . . 0.0 110.53 179.315 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 13' ' ' ILE . . . . . 0.473 HG13 ' O ' ' A' ' 9' ' ' TRP . 73.8 mt -66.95 -53.81 30.65 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.233 0 CA-C-N 116.021 -0.536 . . . . 0.0 110.577 179.721 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -64.11 -25.09 69.28 Favored Glycine 0 N--CA 1.451 -0.366 0 C-N-CA 120.657 -0.783 . . . . 0.0 112.042 179.677 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 15' ' ' MET . . . . . 0.536 ' HB3' ' HB2' ' A' ' 48' ' ' ALA . 0.0 OUTLIER -72.54 -54.47 9.11 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.559 0.219 . . . . 0.0 110.933 179.82 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 16' ' ' LEU . . . . . 0.456 HD23 ' O ' ' A' ' 12' ' ' ALA . 3.9 mm? -53.13 -45.72 68.47 Favored 'General case' 0 C--N 1.332 -0.179 0 CA-C-N 116.403 -0.362 . . . . 0.0 110.921 179.527 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 83.7 t -61.06 -40.29 85.18 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.153 0 CA-C-N 116.372 -0.376 . . . . 0.0 110.457 179.666 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -67.68 -41.73 88.81 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.859 -0.686 . . . . 0.0 111.802 179.188 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 16.3 m -51.14 -53.76 31.44 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.989 0.423 . . . . 0.0 110.711 -179.982 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 62.6 mt -71.71 -32.22 67.55 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 115.786 -0.643 . . . . 0.0 111.083 179.84 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 21' ' ' ALA . . . . . 0.46 ' O ' ' HB2' ' A' ' 25' ' ' ALA . . . -58.33 -56.67 19.13 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.793 -179.605 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 22' ' ' PHE . . . . . 0.496 ' HB2' HG22 ' A' ' 41' ' ' VAL . 4.7 m-85 -71.11 -30.75 66.91 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.409 -0.359 . . . . 0.0 111.337 -179.128 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -64.03 -51.24 65.11 Favored 'General case' 0 C--N 1.327 -0.4 0 N-CA-C 112.369 0.507 . . . . 0.0 112.369 -179.17 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 24' ' ' TRP . . . . . 0.53 ' CE3' ' HA ' ' A' ' 24' ' ' TRP . 2.4 t-105 -86.67 -26.76 24.15 Favored 'General case' 0 N--CA 1.442 -0.842 0 N-CA-C 113.326 0.861 . . . . 0.0 113.326 -177.655 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 25' ' ' ALA . . . . . 0.46 ' HB2' ' O ' ' A' ' 21' ' ' ALA . . . . . . . . 0 C--N 1.314 -0.947 0 N-CA-C 109.586 -0.524 . . . . 0.0 109.586 178.785 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.453 -0.215 0 N-CA-C 112.767 -0.133 . . . . 0.0 112.767 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 8.8 mm-40 -92.14 -23.6 19.36 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.794 0.331 . . . . 0.0 110.949 -179.964 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 34' ' ' ARG . . . . . . . . . . . . . 53.1 mtm180 -56.4 -28.34 59.04 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.156 -0.475 . . . . 0.0 111.848 -179.677 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 19.0 tpp180 -55.27 -59.05 5.33 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-O 120.744 0.307 . . . . 0.0 111.408 -179.634 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 42.3 m-85 -71.96 -34.81 69.29 Favored 'General case' 0 C--N 1.33 -0.244 0 N-CA-C 112.333 0.494 . . . . 0.0 112.333 -178.783 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 37' ' ' TYR . . . . . 0.412 ' O ' HG23 ' A' ' 41' ' ' VAL . 29.4 m-85 -70.39 -56.25 7.13 Favored 'General case' 0 N--CA 1.464 0.226 0 N-CA-C 111.619 0.229 . . . . 0.0 111.619 -179.221 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 77.9 t -56.85 -37.23 52.85 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.232 0 CA-C-O 120.8 0.333 . . . . 0.0 110.87 179.799 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 21.9 m -62.25 -51.18 68.75 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.845 179.313 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 40' ' ' LEU . . . . . 0.4 HD13 ' CE1' ' A' ' 208' ' ' PHE . 18.1 tp -59.87 -50.93 71.86 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 115.926 -0.579 . . . . 0.0 110.792 179.978 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . 0.496 HG22 ' HB2' ' A' ' 22' ' ' PHE . 65.3 t -58.84 -34.09 51.31 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.373 0 CA-C-N 115.775 -0.648 . . . . 0.0 109.998 179.169 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -58.76 -41.81 96.11 Favored Glycine 0 N--CA 1.448 -0.542 0 C-N-CA 120.829 -0.7 . . . . 0.0 111.657 179.429 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 43' ' ' ILE . . . . . 0.501 HD13 HD13 ' A' ' 83' ' ' ILE . 1.1 mt -61.75 -51.16 75.97 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.176 0 CA-C-O 120.847 0.356 . . . . 0.0 110.508 179.201 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 79.3 p -62.2 -23.27 66.53 Favored 'General case' 0 C--N 1.333 -0.132 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.088 179.756 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -77.55 -56.94 3.72 Favored Glycine 0 C--N 1.33 0.225 0 C-N-CA 120.832 -0.699 . . . . 0.0 112.406 179.916 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 46' ' ' ILE . . . . . 0.571 HD12 HD12 ' A' ' 78' ' ' LEU . 13.1 pt -58.49 -37.14 62.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-O 121.051 0.453 . . . . 0.0 110.721 179.77 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 47' ' ' ALA . . . . . 0.692 ' HB2' ' HE2' ' A' ' 205' ' ' LYS . . . -68.46 -41.02 80.78 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 115.97 -0.559 . . . . 0.0 110.89 179.113 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 48' ' ' ALA . . . . . 0.536 ' HB2' ' HB3' ' A' ' 15' ' ' MET . . . -55.69 -42.09 74.67 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-N 115.805 -0.634 . . . . 0.0 111.763 -179.486 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 49' ' ' VAL . . . . . 0.46 ' O ' HG13 ' A' ' 53' ' ' VAL . 8.6 m -75.56 -37.44 36.98 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.545 -0.298 . . . . 0.0 111.6 -179.516 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -60.61 -43.59 97.26 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 121.035 0.445 . . . . 0.0 111.061 179.809 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 51' ' ' TYR . . . . . 0.514 ' HE2' ' HE2' ' A' ' 15' ' ' MET . 43.3 m-85 -73.1 -32.38 64.94 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-N 115.933 -0.576 . . . . 0.0 110.484 -179.77 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -69.34 -38.97 78.41 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-N 115.897 -0.592 . . . . 0.0 111.1 179.549 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 53' ' ' VAL . . . . . 0.46 HG13 ' O ' ' A' ' 49' ' ' VAL . 33.3 m -74.62 -47.39 39.04 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.224 0 CA-C-N 116.418 -0.356 . . . . 0.0 110.573 180.0 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 54' ' ' MET . . . . . 0.454 ' N ' HG23 ' A' ' 53' ' ' VAL . 75.3 mtm -61.37 -31.77 71.67 Favored 'General case' 0 N--CA 1.455 -0.178 0 N-CA-C 109.62 -0.511 . . . . 0.0 109.62 179.058 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 55' ' ' ALA . . . . . 0.484 ' HB2' ' HB2' ' A' ' 8' ' ' PHE . . . -69.31 -22.83 63.76 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 115.588 -0.733 . . . . 0.0 110.933 179.215 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 63.8 mt -87.51 0.12 56.02 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 116.167 -0.469 . . . . 0.0 111.409 -179.797 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 90.5 -21.49 32.12 Favored Glycine 0 N--CA 1.452 -0.261 0 C-N-CA 120.564 -0.827 . . . . 0.0 113.115 179.522 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 58' ' ' VAL . . . . . 0.437 HG12 ' O ' ' A' ' 53' ' ' VAL . 13.7 p -68.36 148.7 11.68 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.215 0 CA-C-N 116.887 0.344 . . . . 0.0 110.822 179.955 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 59' ' ' GLY . . . . . 0.402 ' HA3' ' HG2' ' A' ' 71' ' ' PRO . . . 92.44 -5.06 77.37 Favored Glycine 0 N--CA 1.45 -0.403 0 C-N-CA 120.648 -0.787 . . . . 0.0 112.403 -179.573 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 60' ' ' TRP . . . . . 0.412 ' HH2' ' HB2' ' A' ' 4' ' ' LEU . 15.9 m0 -86.19 108.09 18.19 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.55 0.214 . . . . 0.0 110.954 -179.861 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 61' ' ' VAL . . . . . 0.463 HG13 HG23 ' A' ' 68' ' ' VAL . 7.5 p -111.8 128.26 25.69 Favored Pre-proline 0 CA--C 1.533 0.317 0 CA-C-N 116.52 -0.309 . . . . 0.0 111.108 179.804 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 73.8 Cg_endo -75.23 155.27 41.85 Favored 'Trans proline' 0 C--N 1.35 0.645 0 C-N-CA 122.422 2.082 . . . . 0.0 112.648 -179.679 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 80.7 t -143.21 89.73 0.4 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 115.826 -0.625 . . . . 0.0 110.858 179.929 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . 59.9 -86.86 0.02 OUTLIER 'General case' 0 C--N 1.331 -0.199 0 CA-C-N 116.065 -0.516 . . . . 0.0 111.467 179.953 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 6.2 mp0 -121.52 -19.64 6.84 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 116.286 -0.415 . . . . 0.0 110.652 179.962 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 66' ' ' ARG . . . . . . . . . . . . . 45.6 mtm180 -101.24 161.52 13.56 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 115.919 -0.582 . . . . 0.0 110.499 179.913 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 56.2 m -122.44 137.63 54.81 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.35 -0.386 . . . . 0.0 111.269 -179.804 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 68' ' ' VAL . . . . . 0.463 HG23 HG13 ' A' ' 61' ' ' VAL . 21.7 m -127.37 146.64 32.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.025 -0.534 . . . . 0.0 110.802 179.772 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 69' ' ' PHE . . . . . . . . . . . . . 23.1 m-85 -109.44 112.18 24.15 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.154 -179.261 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 70' ' ' VAL . . . . . 0.546 ' HB ' ' HD3' ' A' ' 71' ' ' PRO . 13.0 t -62.95 -49.61 80.89 Favored Pre-proline 0 C--N 1.324 -0.508 0 CA-C-N 116.227 -0.442 . . . . 0.0 112.021 -178.901 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 71' ' ' PRO . . . . . 0.546 ' HD3' ' HB ' ' A' ' 70' ' ' VAL . 38.2 Cg_exo -60.74 -18.46 55.98 Favored 'Trans proline' 0 C--N 1.35 0.616 0 C-N-CA 122.039 1.826 . . . . 0.0 112.985 -179.663 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 72' ' ' ARG . . . . . 0.478 ' NH2' HG13 ' A' ' 197' ' ' ILE . 77.5 ttt180 -76.08 -55.6 5.44 Favored 'General case' 0 C--O 1.235 0.303 0 CA-C-O 120.796 0.331 . . . . 0.0 111.86 -179.093 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 73' ' ' TYR . . . . . . . . . . . . . 27.1 m-85 -67.52 -36.15 80.49 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-O 120.817 0.342 . . . . 0.0 110.321 -179.545 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 74' ' ' ILE . . . . . 0.586 ' O ' HD23 ' A' ' 78' ' ' LEU . 0.3 OUTLIER -67.14 -43.05 88.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 N-CA-C 109.686 -0.487 . . . . 0.0 109.686 179.344 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 75' ' ' ASP . . . . . 0.403 ' HA ' HD21 ' A' ' 78' ' ' LEU . 12.0 t70 -51.95 -40.72 61.3 Favored 'General case' 0 CA--C 1.519 -0.226 0 N-CA-C 109.534 -0.543 . . . . 0.0 109.534 179.009 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 76' ' ' TRP . . . . . 0.411 ' HZ2' HG23 ' A' ' 197' ' ' ILE . 44.2 m0 -66.34 -35.5 80.51 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 115.794 -0.639 . . . . 0.0 110.825 179.425 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 77' ' ' ILE . . . . . 0.466 ' O ' ' HG2' ' A' ' 81' ' ' PRO . 88.0 mt -59.75 -40.73 83.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.094 -0.503 . . . . 0.0 112.318 -179.446 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 78' ' ' LEU . . . . . 0.586 HD23 ' O ' ' A' ' 74' ' ' ILE . 0.6 OUTLIER -91.94 -28.34 17.31 Favored 'General case' 0 CA--C 1.535 0.371 0 N-CA-C 113.038 0.755 . . . . 0.0 113.038 -179.546 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 65.3 p -79.65 -53.09 7.17 Favored 'General case' 0 N--CA 1.469 0.511 0 N-CA-C 113.468 0.914 . . . . 0.0 113.468 -178.41 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 80' ' ' THR . . . . . 0.593 ' HB ' ' HD3' ' A' ' 81' ' ' PRO . 3.8 m -50.92 -54.02 41.6 Favored Pre-proline 0 CA--C 1.533 0.291 0 N-CA-C 112.409 0.522 . . . . 0.0 112.409 -178.27 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 81' ' ' PRO . . . . . 0.593 ' HD3' ' HB ' ' A' ' 80' ' ' THR . 32.3 Cg_exo -60.08 -22.41 69.51 Favored 'Trans proline' 0 C--N 1.351 0.687 0 C-N-CA 121.869 1.712 . . . . 0.0 111.761 179.723 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 82' ' ' LEU . . . . . . . . . . . . . 15.4 tp -74.32 -33.03 63.06 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.067 -0.515 . . . . 0.0 109.921 179.647 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 83' ' ' ILE . . . . . 0.501 HD13 HD13 ' A' ' 43' ' ' ILE . 35.4 mm -68.79 -53.03 29.24 Favored 'Isoleucine or valine' 0 C--O 1.235 0.309 0 CA-C-N 115.845 -0.616 . . . . 0.0 110.037 179.04 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 84' ' ' VAL . . . . . 0.458 HG22 ' HA ' ' A' ' 81' ' ' PRO . 30.8 m -61.67 -30.18 47.75 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.221 0 CA-C-N 116.085 -0.507 . . . . 0.0 109.832 179.043 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 85' ' ' TYR . . . . . 0.41 ' HB2' ' O ' ' A' ' 81' ' ' PRO . 44.2 t80 -66.82 -34.68 78.35 Favored 'General case' 0 N--CA 1.454 -0.251 0 CA-C-N 115.665 -0.698 . . . . 0.0 109.386 178.724 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 86' ' ' PHE . . . . . . . . . . . . . 18.9 t80 -59.2 -51.45 69.94 Favored 'General case' 0 CA--C 1.519 -0.234 0 CA-C-N 115.735 -0.666 . . . . 0.0 109.427 178.983 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 10.5 mp -60.51 -32.29 71.32 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 115.55 -0.75 . . . . 0.0 110.04 179.28 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 88' ' ' GLY . . . . . 0.455 ' HA2' HD13 ' A' ' 93' ' ' LEU . . . -68.59 -28.21 73.32 Favored Glycine 0 N--CA 1.449 -0.438 0 C-N-CA 120.751 -0.738 . . . . 0.0 111.697 179.382 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 75.9 mt -72.49 -39.25 67.82 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-O 120.982 0.42 . . . . 0.0 110.278 179.43 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 70.5 mt -59.9 -53.1 61.86 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 115.76 -0.654 . . . . 0.0 110.603 179.569 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 91' ' ' ALA . . . . . 0.551 ' HB2' ' HB2' ' A' ' 149' ' ' ALA . . . -72.33 -52.07 17.81 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.126 -0.488 . . . . 0.0 111.062 179.89 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 97.21 57.24 1.08 Allowed Glycine 0 N--CA 1.453 -0.228 0 C-N-CA 120.817 -0.706 . . . . 0.0 112.207 -179.899 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 93' ' ' LEU . . . . . 0.592 HD23 ' HB3' ' A' ' 97' ' ' GLU . 8.9 mp -60.5 172.65 0.84 Allowed 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 121.045 0.45 . . . . 0.0 111.35 -179.704 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 94' ' ' ASP . . . . . 0.429 ' HB2' ' HG2' ' A' ' 97' ' ' GLU . 8.0 m-20 -82.63 172.55 12.82 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-N 115.904 -0.589 . . . . 0.0 110.634 179.907 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 38.3 t -56.24 -48.68 76.04 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.206 -179.839 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 99.2 mtt180 -70.4 -43.38 70.15 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.268 -0.424 . . . . 0.0 111.196 -179.835 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 97' ' ' GLU . . . . . 0.592 ' HB3' HD23 ' A' ' 93' ' ' LEU . 21.5 mm-40 -52.19 -48.0 65.26 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.991 -179.59 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 98' ' ' PHE . . . . . 0.453 ' O ' HG12 ' A' ' 102' ' ' ILE . 11.6 m-85 -57.5 -45.2 85.18 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-O 120.988 0.423 . . . . 0.0 110.19 179.177 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -62.59 -26.43 68.36 Favored Glycine 0 N--CA 1.45 -0.417 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.421 179.811 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 97.1 mt -73.28 -47.4 46.76 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.238 0 N-CA-C 111.876 0.324 . . . . 0.0 111.876 -179.632 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 26.5 m -69.19 -35.13 66.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 N-CA-C 111.9 0.333 . . . . 0.0 111.9 -179.169 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 102' ' ' ILE . . . . . 0.453 HG12 ' O ' ' A' ' 98' ' ' PHE . 48.6 mm -72.23 -47.92 51.17 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.25 0 CA-C-N 116.674 -0.239 . . . . 0.0 111.596 -179.294 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 14.4 t -60.22 -37.63 80.92 Favored 'General case' 0 C--O 1.234 0.273 0 CA-C-O 121.02 0.438 . . . . 0.0 110.879 179.895 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 104' ' ' LEU . . . . . 0.541 ' O ' HG12 ' A' ' 107' ' ' VAL . 31.3 tp -60.52 -50.15 74.68 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 115.975 -0.557 . . . . 0.0 110.512 179.648 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 105' ' ' ASN . . . . . 0.553 ' N ' HD22 ' A' ' 105' ' ' ASN . 0.8 OUTLIER -59.27 -31.69 69.33 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.012 179.778 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 96.9 m -61.01 -57.82 11.0 Favored 'General case' 0 C--N 1.331 -0.204 0 CA-C-N 116.547 -0.297 . . . . 0.0 111.478 -179.292 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 107' ' ' VAL . . . . . 0.541 HG12 ' O ' ' A' ' 104' ' ' LEU . 14.2 p -56.4 -35.46 43.76 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.242 -0.436 . . . . 0.0 110.742 -179.912 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . 0.508 HG23 ' O ' ' A' ' 104' ' ' LEU . 82.1 t -61.68 -57.8 10.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.038 -0.528 . . . . 0.0 111.424 179.624 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 109' ' ' MET . . . . . 0.505 ' HG2' ' O ' ' A' ' 105' ' ' ASN . 5.4 mmt -58.39 -35.2 71.64 Favored 'General case' 0 C--N 1.333 -0.146 0 CA-C-N 116.546 -0.297 . . . . 0.0 110.928 -179.683 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 8.3 mt -68.39 -33.17 73.77 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.307 -0.406 . . . . 0.0 110.696 179.785 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -61.75 -45.0 95.8 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 121.153 0.502 . . . . 0.0 109.745 178.989 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . -73.81 -33.34 57.89 Favored Glycine 0 N--CA 1.448 -0.507 0 CA-C-N 115.595 -0.729 . . . . 0.0 111.384 179.111 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 113' ' ' PHE . . . . . 0.405 ' HD2' HD11 ' A' ' 77' ' ' ILE . 1.1 t80 -53.27 -73.53 0.04 OUTLIER 'General case' 0 N--CA 1.455 -0.186 0 CA-C-O 121.093 0.473 . . . . 0.0 109.749 179.298 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 114' ' ' ALA . . . . . 0.413 ' O ' HG13 ' A' ' 118' ' ' VAL . . . -63.1 -21.44 66.18 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 115.68 -0.691 . . . . 0.0 110.805 179.618 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 115' ' ' GLY . . . . . 0.414 ' HA2' HD22 ' A' ' 126' ' ' LEU . . . -52.57 -49.24 53.46 Favored Glycine 0 C--N 1.335 0.473 0 C-N-CA 120.785 -0.721 . . . . 0.0 112.155 179.492 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -78.38 -15.75 58.36 Favored 'General case' 0 C--N 1.326 -0.414 0 N-CA-C 111.698 0.258 . . . . 0.0 111.698 179.939 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 117' ' ' MET . . . . . 0.462 ' HG2' HG21 ' A' ' 68' ' ' VAL . 57.6 mtt -102.35 15.6 28.69 Favored 'General case' 0 C--N 1.332 -0.194 0 CA-C-O 120.687 0.279 . . . . 0.0 111.731 -179.295 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 118' ' ' VAL . . . . . 0.413 HG13 ' O ' ' A' ' 114' ' ' ALA . 19.2 m -65.62 150.26 96.33 Favored Pre-proline 0 C--N 1.329 -0.303 0 CA-C-N 116.509 -0.314 . . . . 0.0 111.213 179.9 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 119' ' ' PRO . . . . . . . . . . . . . 91.5 Cg_endo -80.97 4.48 6.94 Favored 'Trans proline' 0 C--N 1.348 0.529 0 C-N-CA 122.508 2.139 . . . . 0.0 112.501 179.68 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -170.31 -123.71 0.7 Allowed Glycine 0 C--N 1.33 0.231 0 C-N-CA 120.637 -0.792 . . . . 0.0 112.747 -179.816 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 26.2 pt -105.44 9.77 9.3 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-O 120.698 0.285 . . . . 0.0 111.467 -179.716 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 13.9 mm-40 -58.0 -19.23 29.46 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-O 120.95 0.405 . . . . 0.0 110.75 179.626 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 123' ' ' ARG . . . . . 0.503 ' HB2' ' HH2' ' A' ' 178' ' ' TRP . 23.2 ptt180 -51.5 -35.37 39.98 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 115.67 -0.695 . . . . 0.0 111.903 -179.781 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 124' ' ' TYR . . . . . . . . . . . . . 25.7 m-85 -57.29 -35.31 69.65 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.807 0.337 . . . . 0.0 110.891 -179.875 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 125' ' ' ALA . . . . . . . . . . . . . . . -74.35 -48.97 24.8 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.064 179.813 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 126' ' ' LEU . . . . . 0.414 HD22 ' HA2' ' A' ' 115' ' ' GLY . 6.9 mp -53.33 -52.48 59.02 Favored 'General case' 0 C--N 1.332 -0.158 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.787 -179.981 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 127' ' ' PHE . . . . . . . . . . . . . 6.6 t80 -64.38 -37.54 87.87 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.281 -0.418 . . . . 0.0 110.684 179.999 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 128' ' ' GLY . . . . . . . . . . . . . . . -46.42 -45.02 16.52 Favored Glycine 0 C--N 1.332 0.337 0 C-N-CA 120.118 -1.039 . . . . 0.0 110.959 179.265 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 129' ' ' MET . . . . . . . . . . . . . 0.5 OUTLIER -70.46 -38.04 74.39 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 120.868 0.366 . . . . 0.0 110.073 178.722 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -63.61 -30.81 78.73 Favored Glycine 0 C--N 1.333 0.365 0 C-N-CA 121.056 -0.592 . . . . 0.0 112.951 -179.816 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -74.48 -53.56 9.26 Favored 'General case' 0 CA--C 1.519 -0.22 0 CA-C-N 116.779 0.29 . . . . 0.0 110.369 179.94 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 43.1 t -57.42 -40.33 73.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 N-CA-C 109.251 -0.648 . . . . 0.0 109.251 178.766 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -66.09 -37.09 84.9 Favored 'General case' 0 N--CA 1.452 -0.34 0 CA-C-N 115.218 -0.901 . . . . 0.0 110.041 178.893 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 134' ' ' PHE . . . . . 0.415 ' CZ ' ' HA ' ' A' ' 172' ' ' ALA . 82.9 t80 -57.01 -50.76 71.74 Favored 'General case' 0 N--CA 1.45 -0.461 0 CA-C-N 115.919 -0.582 . . . . 0.0 109.99 179.254 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 135' ' ' ILE . . . . . 0.53 ' O ' HG22 ' A' ' 138' ' ' VAL . 57.6 mt -58.13 -30.81 40.21 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.342 0 CA-C-N 115.668 -0.696 . . . . 0.0 109.779 179.161 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 136' ' ' GLY . . . . . 0.425 ' O ' ' HB3' ' A' ' 139' ' ' TYR . . . -65.48 -38.07 94.42 Favored Glycine 0 N--CA 1.447 -0.58 0 C-N-CA 120.224 -0.988 . . . . 0.0 110.966 178.438 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 137' ' ' LEU . . . . . 0.55 HD13 HD21 ' A' ' 105' ' ' ASN . 29.2 tp -69.32 -46.78 66.26 Favored 'General case' 0 C--N 1.331 -0.205 0 N-CA-C 110.449 -0.204 . . . . 0.0 110.449 179.399 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 138' ' ' VAL . . . . . 0.548 ' HA ' HD12 ' A' ' 141' ' ' LEU . 4.6 m -62.13 -31.89 52.85 Favored 'Isoleucine or valine' 0 C--O 1.234 0.255 0 N-CA-C 109.029 -0.73 . . . . 0.0 109.029 178.882 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 139' ' ' TYR . . . . . 0.425 ' HB3' ' O ' ' A' ' 136' ' ' GLY . 45.6 t80 -60.99 -37.2 81.62 Favored 'General case' 0 N--CA 1.453 -0.317 0 CA-C-N 115.176 -0.92 . . . . 0.0 108.879 178.053 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 140' ' ' TYR . . . . . 0.516 ' HB3' ' SD ' ' A' ' 145' ' ' MET . 24.0 m-85 -70.25 -35.22 73.65 Favored 'General case' 0 C--N 1.332 -0.168 0 CA-C-N 115.489 -0.778 . . . . 0.0 110.122 178.478 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 141' ' ' LEU . . . . . 0.548 HD12 ' HA ' ' A' ' 138' ' ' VAL . 96.1 mt -55.55 -39.83 71.12 Favored 'General case' 0 C--O 1.232 0.149 0 CA-C-N 115.976 -0.556 . . . . 0.0 110.156 179.343 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 2.3 t -104.05 0.15 10.19 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 115.775 -0.648 . . . . 0.0 110.953 179.889 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 143' ' ' GLY . . . . . 0.416 ' O ' HG22 ' A' ' 146' ' ' THR . . . -72.89 -148.81 0.97 Allowed Glycine 0 CA--C 1.519 0.33 0 C-N-CA 120.965 -0.636 . . . . 0.0 112.876 -179.726 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 144' ' ' PRO . . . . . . . . . . . . . 31.8 Cg_endo -63.73 -23.56 69.34 Favored 'Trans proline' 0 C--N 1.347 0.497 0 C-N-CA 122.629 2.22 . . . . 0.0 112.523 -179.901 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 145' ' ' MET . . . . . 0.576 ' HG2' HD21 ' A' ' 93' ' ' LEU . 84.2 mtp -53.57 -58.37 7.4 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.451 -179.81 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 146' ' ' THR . . . . . 0.416 HG22 ' O ' ' A' ' 143' ' ' GLY . 7.4 t -60.65 -32.2 71.39 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.382 -0.372 . . . . 0.0 111.337 -179.831 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 40.5 mt-10 -66.71 -34.65 78.33 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.283 -0.417 . . . . 0.0 111.071 -179.993 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 148' ' ' SER . . . . . . . . . . . . . 47.0 t -69.58 -45.32 68.94 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.051 -179.641 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 149' ' ' ALA . . . . . 0.558 ' HB1' HG22 ' A' ' 156' ' ' ILE . . . -63.88 -38.84 92.59 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.464 -179.665 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 150' ' ' SER . . . . . 0.586 ' HA ' ' HB2' ' A' ' 157' ' ' LYS . 81.8 p -67.54 -2.53 6.73 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.295 -0.411 . . . . 0.0 111.059 -179.817 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 151' ' ' GLN . . . . . . . . . . . . . 49.4 mt-30 -119.72 -1.64 10.53 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.26 -0.427 . . . . 0.0 111.244 -179.967 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 37.7 mmt180 -81.65 -51.6 8.04 Favored 'General case' 0 C--N 1.332 -0.185 0 CA-C-O 120.945 0.403 . . . . 0.0 110.746 179.712 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 153' ' ' SER . . . . . 0.577 ' HB3' HG12 ' A' ' 156' ' ' ILE . 23.1 t -158.17 172.28 18.68 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-N 115.865 -0.607 . . . . 0.0 110.544 179.254 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 154' ' ' SER . . . . . . . . . . . . . 39.6 t -69.91 -39.87 75.92 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-O 120.871 0.367 . . . . 0.0 110.317 179.418 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -76.99 -42.39 20.02 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.943 -0.646 . . . . 0.0 112.659 179.808 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 156' ' ' ILE . . . . . 0.577 HG12 ' HB3' ' A' ' 153' ' ' SER . 36.5 mm -48.86 -37.45 9.11 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.162 0 CA-C-O 120.863 0.363 . . . . 0.0 111.495 -179.778 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 157' ' ' LYS . . . . . 0.586 ' HB2' ' HA ' ' A' ' 150' ' ' SER . 54.8 tttm -67.72 -36.36 80.46 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.277 -179.712 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 43.3 t -71.8 -42.22 67.32 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.658 -179.378 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 159' ' ' LEU . . . . . 0.414 ' O ' ' HB2' ' A' ' 163' ' ' LEU . 10.7 mp -67.42 -35.23 78.86 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.342 -0.39 . . . . 0.0 111.74 -179.372 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 160' ' ' TYR . . . . . . . . . . . . . 23.8 t80 -72.78 -46.84 51.19 Favored 'General case' 0 C--N 1.33 -0.274 0 N-CA-C 112.179 0.437 . . . . 0.0 112.179 -178.676 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 161' ' ' VAL . . . . . 0.443 HG23 ' N ' ' A' ' 162' ' ' ARG . 24.6 m -62.98 -45.95 97.55 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 N-CA-C 112.353 0.501 . . . . 0.0 112.353 -178.952 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 162' ' ' ARG . . . . . 0.443 ' N ' HG23 ' A' ' 161' ' ' VAL . 36.2 mmt180 -66.33 -42.71 87.79 Favored 'General case' 0 C--N 1.328 -0.329 0 N-CA-C 111.807 0.299 . . . . 0.0 111.807 -179.141 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 163' ' ' LEU . . . . . 0.472 ' HG ' ' HB2' ' A' ' 208' ' ' PHE . 6.1 mp -71.45 -43.86 65.87 Favored 'General case' 0 C--N 1.329 -0.297 0 N-CA-C 111.957 0.354 . . . . 0.0 111.957 -179.251 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 164' ' ' ARG . . . . . 0.459 ' HG3' ' N ' ' A' ' 165' ' ' ASN . 5.6 ppt_? -68.38 -40.71 81.29 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 120.456 0.169 . . . . 0.0 111.073 -179.374 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 165' ' ' ASN . . . . . 0.594 ' O ' HG23 ' A' ' 169' ' ' VAL . 0.9 OUTLIER -58.89 -48.0 82.96 Favored 'General case' 0 C--N 1.332 -0.19 0 CA-C-O 120.945 0.403 . . . . 0.0 110.558 179.35 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 166' ' ' LEU . . . . . 0.522 ' O ' ' HG ' ' A' ' 170' ' ' LEU . 4.1 tt -63.69 -48.39 77.32 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 116.109 -0.496 . . . . 0.0 111.017 -179.958 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 167' ' ' THR . . . . . 0.427 ' O ' ' HB2' ' A' ' 171' ' ' TRP . 93.0 m -57.4 -53.91 52.74 Favored 'General case' 0 C--N 1.33 -0.251 0 N-CA-C 112.426 0.528 . . . . 0.0 112.426 -178.971 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 168' ' ' VAL . . . . . 0.513 ' HB ' HD13 ' A' ' 141' ' ' LEU . 12.9 p -55.95 -40.75 64.6 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 N-CA-C 112.335 0.494 . . . . 0.0 112.335 -179.281 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 169' ' ' VAL . . . . . 0.594 HG23 ' O ' ' A' ' 165' ' ' ASN . 61.2 t -57.71 -65.8 0.39 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.389 0 N-CA-C 111.987 0.366 . . . . 0.0 111.987 -179.518 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 170' ' ' LEU . . . . . 0.522 ' HG ' ' O ' ' A' ' 166' ' ' LEU . 0.8 OUTLIER -65.18 -27.75 68.92 Favored 'General case' 0 C--N 1.331 -0.212 0 N-CA-C 112.146 0.425 . . . . 0.0 112.146 -178.813 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 171' ' ' TRP . . . . . 0.44 ' N ' HD12 ' A' ' 170' ' ' LEU . 6.9 m0 -71.77 -30.23 65.35 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.83 0.348 . . . . 0.0 110.612 179.615 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 172' ' ' ALA . . . . . 0.415 ' HA ' ' CZ ' ' A' ' 134' ' ' PHE . . . -73.7 -6.77 48.93 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.768 179.997 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 173' ' ' ILE . . . . . 0.627 HG22 HD11 ' A' ' 177' ' ' ILE . 23.6 mm -87.43 -21.63 7.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 115.93 -0.577 . . . . 0.0 110.771 179.739 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 174' ' ' TYR . . . . . 0.417 ' HB2' ' HD3' ' A' ' 175' ' ' PRO . 24.3 m-85 -54.86 -49.55 91.18 Favored Pre-proline 0 N--CA 1.464 0.228 0 CA-C-N 116.287 -0.415 . . . . 0.0 111.833 -179.796 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 175' ' ' PRO . . . . . 0.417 ' HD3' ' HB2' ' A' ' 174' ' ' TYR . 88.6 Cg_exo -47.02 -29.27 8.34 Favored 'Trans proline' 0 C--N 1.352 0.756 0 C-N-CA 122.131 1.887 . . . . 0.0 112.161 179.894 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 176' ' ' PHE . . . . . 0.444 ' O ' ' HG ' ' A' ' 180' ' ' LEU . 81.8 m-85 -80.47 -46.76 15.36 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 115.918 -0.583 . . . . 0.0 111.757 -179.965 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 177' ' ' ILE . . . . . 0.627 HD11 HG22 ' A' ' 173' ' ' ILE . 2.0 mm -64.49 -38.41 82.52 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.54 0 CA-C-N 116.166 -0.47 . . . . 0.0 112.177 -178.299 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 178' ' ' TRP . . . . . 0.503 ' HH2' ' HB2' ' A' ' 123' ' ' ARG . 60.2 t90 -73.83 -41.98 61.54 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.91 0.386 . . . . 0.0 110.779 179.67 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 179' ' ' LEU . . . . . 0.461 ' O ' HG22 ' A' ' 185' ' ' VAL . 1.7 tm? -66.27 -49.95 65.39 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.066 -0.516 . . . . 0.0 111.078 -179.622 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 180' ' ' LEU . . . . . 0.611 HD22 HD11 ' A' ' 187' ' ' LEU . 14.0 mt -78.21 -47.94 16.91 Favored 'General case' 0 C--N 1.329 -0.301 0 N-CA-C 112.038 0.384 . . . . 0.0 112.038 -179.22 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . -54.32 177.94 0.27 Allowed Glycine 0 C--N 1.337 0.6 0 C-N-CA 120.649 -0.786 . . . . 0.0 113.066 -179.701 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 182' ' ' PRO . . . . . 0.587 ' HA ' ' HB2' ' A' ' 186' ' ' ALA . 71.9 Cg_exo -48.13 -44.93 27.12 Favored 'Trans proline' 0 CA--C 1.536 0.598 0 C-N-CA 122.908 2.405 . . . . 0.0 113.764 -179.793 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 183' ' ' PRO . . . . . 0.416 ' HD3' ' HB2' ' A' ' 182' ' ' PRO . 50.6 Cg_exo -54.85 -13.68 6.6 Favored 'Trans proline' 0 C--N 1.355 0.906 0 C-N-CA 122.028 1.819 . . . . 0.0 113.017 -179.845 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 184' ' ' GLY . . . . . . . . . . . . . . . -115.5 -101.05 2.3 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.517 -0.849 . . . . 0.0 112.635 -179.776 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 185' ' ' VAL . . . . . 0.461 HG22 ' O ' ' A' ' 179' ' ' LEU . 9.0 m -105.98 -5.35 9.97 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-O 120.904 0.383 . . . . 0.0 111.305 -179.803 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 186' ' ' ALA . . . . . 0.587 ' HB2' ' HA ' ' A' ' 182' ' ' PRO . . . 55.17 85.4 0.06 Allowed 'General case' 0 C--N 1.331 -0.203 0 CA-C-N 115.991 -0.549 . . . . 0.0 111.991 179.302 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 187' ' ' LEU . . . . . 0.611 HD11 HD22 ' A' ' 180' ' ' LEU . 16.7 mt -92.21 -49.5 6.15 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.512 179.146 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 188' ' ' LEU . . . . . . . . . . . . . 95.5 mt -96.61 -160.96 0.83 Allowed 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 115.698 -0.683 . . . . 0.0 110.635 -179.944 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 189' ' ' THR . . . . . . . . . . . . . 1.9 t -99.76 146.49 31.94 Favored Pre-proline 0 C--N 1.329 -0.318 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.855 179.951 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 190' ' ' PRO . . . . . 0.44 ' O ' HG23 ' A' ' 194' ' ' VAL . 86.9 Cg_exo -46.76 -44.09 22.53 Favored 'Trans proline' 0 C--N 1.349 0.567 0 C-N-CA 122.698 2.266 . . . . 0.0 113.244 -179.417 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 191' ' ' THR . . . . . . . . . . . . . 7.9 t -58.85 -43.4 90.78 Favored 'General case' 0 C--N 1.328 -0.345 0 N-CA-C 111.899 0.333 . . . . 0.0 111.899 -179.286 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 192' ' ' VAL . . . . . . . . . . . . . 45.7 t -71.77 -50.71 36.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.633 -0.258 . . . . 0.0 111.402 -179.743 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 193' ' ' ASP . . . . . . . . . . . . . 30.5 t70 -55.23 -45.34 75.98 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.452 -0.34 . . . . 0.0 111.066 -179.848 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 194' ' ' VAL . . . . . 0.44 HG23 ' O ' ' A' ' 190' ' ' PRO . 74.6 t -64.34 -35.55 74.51 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.944 179.706 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 195' ' ' ALA . . . . . . . . . . . . . . . -56.97 -48.59 78.02 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 116.577 -0.283 . . . . 0.0 111.211 179.726 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 196' ' ' LEU . . . . . 0.412 ' O ' ' HB3' ' A' ' 199' ' ' TYR . 97.5 mt -67.76 -40.82 84.02 Favored 'General case' 0 N--CA 1.462 0.169 0 CA-C-O 120.708 0.289 . . . . 0.0 110.687 179.696 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 197' ' ' ILE . . . . . 0.489 HG12 HG21 ' A' ' 177' ' ' ILE . 11.2 mm -57.83 -60.25 2.41 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.373 179.256 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 198' ' ' VAL . . . . . 0.409 ' O ' ' HB2' ' A' ' 202' ' ' LEU . 76.3 t -52.02 -33.96 16.86 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.452 0 CA-C-N 115.486 -0.779 . . . . 0.0 109.574 178.324 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 199' ' ' TYR . . . . . 0.428 ' O ' HG23 ' A' ' 203' ' ' VAL . 68.5 t80 -69.27 -37.98 78.15 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 115.353 -0.84 . . . . 0.0 110.365 179.889 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 200' ' ' LEU . . . . . . . . . . . . . 42.0 mt -62.35 -45.71 91.97 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 115.667 -0.697 . . . . 0.0 111.212 -179.56 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 201' ' ' ASP . . . . . . . . . . . . . 7.3 m-20 -71.07 -43.64 67.38 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.114 -179.659 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 202' ' ' LEU . . . . . 0.409 ' HB2' ' O ' ' A' ' 198' ' ' VAL . 1.1 tt -59.95 -30.25 68.95 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 115.884 -0.598 . . . . 0.0 111.411 -179.476 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 203' ' ' VAL . . . . . 0.428 HG23 ' O ' ' A' ' 199' ' ' TYR . 48.5 t -81.43 -36.84 15.04 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.293 -0.412 . . . . 0.0 111.552 -178.726 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 204' ' ' THR . . . . . . . . . . . . . 71.0 m -62.46 -54.99 31.94 Favored 'General case' 0 C--N 1.328 -0.365 0 C-N-CA 120.508 -0.477 . . . . 0.0 111.009 179.497 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 205' ' ' LYS . . . . . 0.692 ' HE2' ' HB2' ' A' ' 47' ' ' ALA . 50.5 mttp -67.84 -59.13 3.53 Favored 'General case' 0 C--N 1.33 -0.245 0 N-CA-C 112.529 0.566 . . . . 0.0 112.529 -178.495 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 59.9 t -70.42 -37.55 70.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 N-CA-C 112.168 0.433 . . . . 0.0 112.168 -178.609 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 207' ' ' GLY . . . . . 0.544 ' O ' HG13 ' A' ' 211' ' ' ILE . . . -64.0 -60.66 6.96 Favored Glycine 0 N--CA 1.452 -0.254 0 C-N-CA 120.438 -0.887 . . . . 0.0 113.359 -178.866 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 208' ' ' PHE . . . . . 0.509 ' O ' ' HB2' ' A' ' 212' ' ' ALA . 0.1 OUTLIER -65.25 -26.91 68.31 Favored 'General case' 0 C--O 1.224 -0.289 0 CA-C-N 117.051 0.425 . . . . 0.0 111.064 -179.289 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 209' ' ' GLY . . . . . 0.515 ' O ' ' HB3' ' A' ' 212' ' ' ALA . . . -69.39 -32.7 71.99 Favored Glycine 0 N--CA 1.447 -0.588 0 N-CA-C 111.593 -0.603 . . . . 0.0 111.593 178.726 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 210' ' ' PHE . . . . . . . . . . . . . 2.0 m-85 -74.56 -48.28 27.74 Favored 'General case' 0 CA--C 1.513 -0.462 0 N-CA-C 108.159 -1.052 . . . . 0.0 108.159 178.343 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 211' ' ' ILE . . . . . 0.544 HG13 ' O ' ' A' ' 207' ' ' GLY . 5.5 mt -62.03 -28.63 44.77 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.594 0 N-CA-C 107.517 -1.29 . . . . 0.0 107.517 176.423 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 212' ' ' ALA . . . . . 0.515 ' HB3' ' O ' ' A' ' 209' ' ' GLY . . . -62.53 -41.14 98.68 Favored 'General case' 0 N--CA 1.447 -0.587 0 CA-C-N 114.527 -1.215 . . . . 0.0 109.915 179.394 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 213' ' ' LEU . . . . . 0.425 ' HG ' ' O ' ' A' ' 209' ' ' GLY . 74.0 mt -70.31 -46.71 63.7 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-N 115.027 -0.988 . . . . 0.0 111.712 -179.826 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 214' ' ' ASP . . . . . . . . . . . . . 10.9 t70 -51.16 -54.86 21.36 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 120.923 0.392 . . . . 0.0 111.278 -179.476 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 215' ' ' ALA . . . . . 0.409 ' HB1' HD11 ' A' ' 159' ' ' LEU . . . -58.7 -52.79 64.19 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-N 115.978 -0.555 . . . . 0.0 111.367 -179.718 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 216' ' ' ALA . . . . . . . . . . . . . . . -58.92 -33.23 70.33 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.333 -0.394 . . . . 0.0 111.619 -179.586 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 217' ' ' ALA . . . . . . . . . . . . . . . -64.05 -36.11 82.92 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 121.012 0.434 . . . . 0.0 110.36 179.893 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 218' ' ' THR . . . . . . . . . . . . . 94.1 m . . . . . 0 C--N 1.328 -0.338 0 CA-C-N 115.69 -0.686 . . . . 0.0 110.977 179.572 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.288 0 N-CA-C 112.532 -0.227 . . . . 0.0 112.532 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 4' ' ' LEU . . . . . 0.471 ' HA ' HD23 ' A' ' 7' ' ' LEU . 70.9 mt -72.97 -36.13 67.04 Favored 'General case' 0 N--CA 1.449 -0.491 0 CA-C-O 120.878 0.371 . . . . 0.0 110.989 179.835 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 45.5 p -53.09 -37.84 62.03 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 115.877 -0.601 . . . . 0.0 111.874 -179.466 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 70.8 p -56.34 -40.54 74.61 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.438 -0.346 . . . . 0.0 111.579 -179.491 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 7' ' ' LEU . . . . . 0.471 HD23 ' HA ' ' A' ' 4' ' ' LEU . 3.4 mm? -59.85 -52.49 65.21 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 116.402 -0.363 . . . . 0.0 110.967 179.997 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 8' ' ' PHE . . . . . 0.459 ' HB2' ' HB2' ' A' ' 55' ' ' ALA . 75.8 m-85 -58.5 -32.11 68.49 Favored 'General case' 0 C--N 1.331 -0.204 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.613 -179.907 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 9' ' ' TRP . . . . . 0.416 ' O ' HG12 ' A' ' 13' ' ' ILE . 17.1 m95 -67.19 -45.63 76.33 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.036 -0.529 . . . . 0.0 109.833 179.576 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 95.1 mt -58.1 -46.82 84.89 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 115.607 -0.724 . . . . 0.0 110.15 179.305 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -60.08 -34.56 84.3 Favored Glycine 0 N--CA 1.45 -0.415 0 C-N-CA 120.746 -0.74 . . . . 0.0 111.781 179.351 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -67.67 -30.4 69.93 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.767 0.317 . . . . 0.0 110.604 179.608 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 13' ' ' ILE . . . . . 0.416 HG12 ' O ' ' A' ' 9' ' ' TRP . 50.8 mm -67.35 -52.5 41.58 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.226 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.16 179.486 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -59.93 -34.67 84.13 Favored Glycine 0 N--CA 1.448 -0.503 0 C-N-CA 120.696 -0.764 . . . . 0.0 111.641 179.105 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 15' ' ' MET . . . . . 0.557 ' HB3' ' HB2' ' A' ' 48' ' ' ALA . 18.9 mmt -66.5 -40.42 89.24 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 120.666 0.269 . . . . 0.0 110.628 179.479 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -59.69 -40.46 87.92 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.313 -0.403 . . . . 0.0 110.149 179.353 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 60.5 t -61.4 -42.76 95.02 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.201 0 CA-C-N 116.058 -0.519 . . . . 0.0 110.53 179.34 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -69.36 -46.17 57.68 Favored Glycine 0 N--CA 1.452 -0.266 0 C-N-CA 120.793 -0.718 . . . . 0.0 111.927 179.626 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 24.6 m -50.69 -49.06 58.32 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-O 120.702 0.287 . . . . 0.0 111.249 -179.82 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 96.3 mt -72.06 -44.99 62.45 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 116.305 -0.407 . . . . 0.0 111.687 -179.85 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -59.78 -31.49 69.73 Favored 'General case' 0 C--N 1.329 -0.304 0 N-CA-C 112.095 0.405 . . . . 0.0 112.095 -179.007 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 22' ' ' PHE . . . . . 0.484 ' HB2' HG22 ' A' ' 41' ' ' VAL . 12.8 m-85 -91.19 -30.71 16.51 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 120.667 0.27 . . . . 0.0 111.429 -179.329 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -72.89 -50.68 22.3 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.948 0.404 . . . . 0.0 111.341 -179.69 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 24' ' ' TRP . . . . . . . . . . . . . 3.6 t-105 -61.62 -38.51 87.91 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-N 115.784 -0.643 . . . . 0.0 111.069 -179.809 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.33 -0.28 0 CA-C-O 120.718 0.294 . . . . 0.0 111.221 179.992 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.351 0 N-CA-C 112.19 -0.364 . . . . 0.0 112.19 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 11.8 mm-40 -89.65 -20.6 23.47 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 121.009 0.433 . . . . 0.0 110.502 179.674 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 34' ' ' ARG . . . . . . . . . . . . . 34.2 ttm180 -52.09 -29.23 20.65 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 115.66 -0.7 . . . . 0.0 111.363 -179.862 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 41.8 ttm180 -59.39 -40.54 86.92 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-O 120.759 0.314 . . . . 0.0 110.845 179.861 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 91.8 m-85 -71.04 -32.4 69.13 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.878 179.753 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 37' ' ' TYR . . . . . 0.524 ' O ' HG23 ' A' ' 41' ' ' VAL . 61.0 m-85 -70.55 -54.7 11.09 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 116.055 -0.52 . . . . 0.0 111.243 -179.743 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 11.0 p -57.17 -36.5 51.93 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-O 120.914 0.388 . . . . 0.0 110.479 179.649 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 26.3 m -65.38 -45.2 85.03 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 115.896 -0.593 . . . . 0.0 110.565 179.474 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 40' ' ' LEU . . . . . 0.649 HD12 HD11 ' A' ' 43' ' ' ILE . 51.5 tp -65.6 -38.48 89.59 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 115.949 -0.568 . . . . 0.0 110.483 179.556 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . 0.524 HG23 ' O ' ' A' ' 37' ' ' TYR . 97.3 t -67.34 -34.34 68.32 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.446 0 CA-C-N 115.789 -0.641 . . . . 0.0 110.253 179.429 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 42' ' ' GLY . . . . . 0.416 ' O ' HG12 ' A' ' 46' ' ' ILE . . . -64.01 -46.59 90.96 Favored Glycine 0 N--CA 1.448 -0.545 0 CA-C-N 115.76 -0.655 . . . . 0.0 112.971 179.991 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 43' ' ' ILE . . . . . 0.649 HD11 HD12 ' A' ' 40' ' ' LEU . 39.4 pt -63.04 -44.03 99.36 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.217 0 CA-C-N 116.847 0.323 . . . . 0.0 111.659 -179.558 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 44' ' ' SER . . . . . 0.466 ' N ' HG13 ' A' ' 43' ' ' ILE . 72.1 m -66.62 -27.19 67.5 Favored 'General case' 0 C--N 1.332 -0.159 0 CA-C-O 120.911 0.386 . . . . 0.0 110.808 179.604 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -78.56 -49.74 6.48 Favored Glycine 0 CA--C 1.519 0.286 0 C-N-CA 121.036 -0.602 . . . . 0.0 113.306 -179.256 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 46' ' ' ILE . . . . . 0.682 HD12 HD12 ' A' ' 78' ' ' LEU . 7.7 pt -58.09 -44.02 86.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-O 120.848 0.356 . . . . 0.0 111.04 -179.588 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 47' ' ' ALA . . . . . 0.546 ' HB2' ' HE2' ' A' ' 205' ' ' LYS . . . -67.73 -39.01 84.31 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-O 120.794 0.331 . . . . 0.0 110.578 179.077 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 48' ' ' ALA . . . . . 0.557 ' HB2' ' HB3' ' A' ' 15' ' ' MET . . . -55.0 -48.01 73.88 Favored 'General case' 0 C--N 1.332 -0.18 0 CA-C-N 116.11 -0.496 . . . . 0.0 111.579 -179.888 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 49' ' ' VAL . . . . . 0.485 HG22 ' O ' ' A' ' 46' ' ' ILE . 28.7 m -67.78 -34.28 66.69 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.473 -0.33 . . . . 0.0 111.275 -179.548 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -63.7 -37.63 88.06 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-O 120.986 0.422 . . . . 0.0 111.132 179.627 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 51' ' ' TYR . . . . . 0.412 ' O ' ' HB3' ' A' ' 8' ' ' PHE . 33.4 m-85 -72.67 -34.56 67.3 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 116.082 -0.508 . . . . 0.0 110.516 -179.766 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -68.25 -42.76 79.21 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 115.979 -0.555 . . . . 0.0 111.056 179.566 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 53' ' ' VAL . . . . . 0.414 HG23 ' N ' ' A' ' 54' ' ' MET . 33.0 m -69.62 -43.75 80.08 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.126 0 CA-C-N 116.44 -0.346 . . . . 0.0 110.876 179.978 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 54' ' ' MET . . . . . 0.567 ' HG2' ' HG2' ' A' ' 71' ' ' PRO . 74.6 mtm -65.03 -34.19 77.83 Favored 'General case' 0 CA--C 1.519 -0.222 0 N-CA-C 109.582 -0.525 . . . . 0.0 109.582 178.955 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 55' ' ' ALA . . . . . 0.459 ' HB2' ' HB2' ' A' ' 8' ' ' PHE . . . -65.97 -17.31 64.59 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.414 -0.812 . . . . 0.0 111.009 179.49 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 95.9 mt -100.08 8.61 43.81 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.339 -0.391 . . . . 0.0 111.0 179.952 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 74.26 20.91 79.55 Favored Glycine 0 N--CA 1.45 -0.371 0 C-N-CA 120.809 -0.71 . . . . 0.0 112.492 179.991 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 24.9 t -92.19 130.72 40.89 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-O 120.784 0.326 . . . . 0.0 110.903 179.884 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 94.0 0.73 65.76 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.855 -0.688 . . . . 0.0 112.753 -179.911 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 60' ' ' TRP . . . . . . . . . . . . . 13.0 m0 -75.21 111.15 10.17 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.76 0.314 . . . . 0.0 110.89 179.864 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 8.4 p -110.77 132.0 21.83 Favored Pre-proline 0 C--N 1.33 -0.271 0 CA-C-N 116.344 -0.389 . . . . 0.0 111.059 179.887 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 74.4 Cg_endo -76.25 147.18 29.13 Favored 'Trans proline' 0 C--N 1.349 0.576 0 C-N-CA 122.372 2.048 . . . . 0.0 112.229 179.742 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 93.9 t -141.51 91.98 0.55 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 115.996 -0.547 . . . . 0.0 111.181 -179.791 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . 58.04 -87.79 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.01 -0.541 . . . . 0.0 111.771 179.574 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 9.0 tp10 -118.08 -21.43 8.26 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.452 -0.34 . . . . 0.0 111.251 -179.59 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 66' ' ' ARG . . . . . . . . . . . . . 99.6 mtt180 -107.03 162.98 13.37 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.368 -0.378 . . . . 0.0 110.63 179.875 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 33.4 m -118.96 124.6 47.43 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.968 0.414 . . . . 0.0 111.455 -179.843 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 68' ' ' VAL . . . . . 0.515 HG21 ' HB3' ' A' ' 117' ' ' MET . 57.7 t -103.6 146.64 10.95 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.361 0 CA-C-N 115.815 -0.63 . . . . 0.0 110.645 179.744 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 69' ' ' PHE . . . . . . . . . . . . . 16.8 m-85 -107.79 112.19 24.72 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.399 -0.364 . . . . 0.0 110.039 -179.688 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 70' ' ' VAL . . . . . 0.607 ' N ' ' HD2' ' A' ' 71' ' ' PRO . 21.5 t -66.73 -48.83 52.13 Favored Pre-proline 0 C--N 1.323 -0.56 0 CA-C-N 116.047 -0.524 . . . . 0.0 111.953 -179.285 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 71' ' ' PRO . . . . . 0.607 ' HD2' ' N ' ' A' ' 70' ' ' VAL . 18.2 Cg_endo -59.8 -17.78 45.24 Favored 'Trans proline' 0 C--N 1.35 0.654 0 C-N-CA 122.279 1.986 . . . . 0.0 113.183 -179.64 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 72' ' ' ARG . . . . . 0.409 HH22 HG22 ' A' ' 194' ' ' VAL . 23.9 ttm180 -78.46 -55.82 4.92 Favored 'General case' 0 C--O 1.234 0.278 0 C-N-CA 120.961 -0.296 . . . . 0.0 111.621 -179.607 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 73' ' ' TYR . . . . . 0.473 ' O ' HG13 ' A' ' 77' ' ' ILE . 95.2 m-85 -70.47 -31.64 68.87 Favored 'General case' 0 C--N 1.329 -0.29 0 C-N-CA 120.89 -0.324 . . . . 0.0 110.482 -179.652 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 74' ' ' ILE . . . . . 0.55 ' HA ' HD12 ' A' ' 77' ' ' ILE . 0.3 OUTLIER -69.5 -39.29 78.36 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 N-CA-C 109.259 -0.645 . . . . 0.0 109.259 178.716 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 75' ' ' ASP . . . . . 0.443 ' O ' ' HG ' ' A' ' 78' ' ' LEU . 14.8 t70 -57.23 -37.38 72.19 Favored 'General case' 0 N--CA 1.452 -0.334 0 N-CA-C 109.113 -0.699 . . . . 0.0 109.113 178.461 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 76' ' ' TRP . . . . . 0.435 ' HA ' ' OG1' ' A' ' 79' ' ' THR . 44.7 m0 -70.26 -34.03 72.31 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 115.611 -0.722 . . . . 0.0 110.527 179.086 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 77' ' ' ILE . . . . . 0.55 HD12 ' HA ' ' A' ' 74' ' ' ILE . 94.2 mt -58.45 -38.71 71.66 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.236 0 CA-C-N 116.285 -0.416 . . . . 0.0 111.022 179.781 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 78' ' ' LEU . . . . . 0.682 HD12 HD12 ' A' ' 46' ' ' ILE . 1.1 pp -91.52 -34.12 14.9 Favored 'General case' 0 CA--C 1.536 0.41 0 N-CA-C 113.205 0.817 . . . . 0.0 113.205 -179.643 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 79' ' ' THR . . . . . 0.467 HG22 ' CD1' ' A' ' 46' ' ' ILE . 52.1 p -76.09 -52.5 10.01 Favored 'General case' 0 N--CA 1.47 0.538 0 N-CA-C 113.316 0.858 . . . . 0.0 113.316 -178.314 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 80' ' ' THR . . . . . 0.543 ' N ' ' HD2' ' A' ' 81' ' ' PRO . 3.9 m -50.76 -48.94 82.1 Favored Pre-proline 0 CA--C 1.532 0.255 0 N-CA-C 112.961 0.726 . . . . 0.0 112.961 -178.162 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 81' ' ' PRO . . . . . 0.543 ' HD2' ' N ' ' A' ' 80' ' ' THR . 28.9 Cg_endo -61.37 -25.31 79.97 Favored 'Trans proline' 0 C--N 1.352 0.717 0 C-N-CA 121.549 1.499 . . . . 0.0 111.631 -179.885 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 82' ' ' LEU . . . . . 0.506 ' HB3' HG22 ' A' ' 43' ' ' ILE . 0.1 OUTLIER -74.43 -34.76 63.3 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 115.876 -0.602 . . . . 0.0 110.23 179.698 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 49.6 mm -67.46 -53.64 30.41 Favored 'Isoleucine or valine' 0 C--O 1.234 0.253 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.029 179.165 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 33.0 m -59.94 -30.03 44.55 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.255 0 CA-C-N 115.959 -0.564 . . . . 0.0 109.552 178.96 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 85' ' ' TYR . . . . . . . . . . . . . 89.8 t80 -67.35 -33.39 75.15 Favored 'General case' 0 N--CA 1.454 -0.275 0 CA-C-N 115.536 -0.757 . . . . 0.0 109.591 178.772 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 86' ' ' PHE . . . . . . . . . . . . . 8.3 t80 -61.81 -50.72 71.16 Favored 'General case' 0 C--O 1.234 0.259 0 CA-C-N 115.769 -0.651 . . . . 0.0 109.87 179.317 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 8.0 mp -60.91 -31.1 70.62 Favored 'General case' 0 C--N 1.332 -0.193 0 CA-C-N 115.872 -0.604 . . . . 0.0 110.232 179.617 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -70.89 -27.67 71.88 Favored Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.971 -0.633 . . . . 0.0 112.122 179.461 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 73.4 mt -71.55 -45.52 62.06 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-O 120.94 0.4 . . . . 0.0 110.514 179.934 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 90' ' ' LEU . . . . . 0.463 HD11 HD22 ' A' ' 163' ' ' LEU . 98.0 mt -54.48 -43.21 71.55 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 115.797 -0.638 . . . . 0.0 111.477 -179.918 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 91' ' ' ALA . . . . . 0.435 ' HB2' ' HB2' ' A' ' 149' ' ' ALA . . . -78.6 -54.99 5.55 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 116.488 -0.324 . . . . 0.0 111.399 -179.748 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 105.23 63.96 0.65 Allowed Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.89 -0.672 . . . . 0.0 112.331 179.98 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 93' ' ' LEU . . . . . 0.572 HD23 ' HB3' ' A' ' 97' ' ' GLU . 7.4 mp -80.69 172.62 13.52 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.794 0.33 . . . . 0.0 111.032 -179.874 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 94' ' ' ASP . . . . . . . . . . . . . 14.2 m-20 -89.19 164.9 14.78 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.099 -0.5 . . . . 0.0 110.808 179.841 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 80.7 p -53.92 -34.54 59.85 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.113 -0.494 . . . . 0.0 111.086 -179.954 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 41.5 mmt180 -72.61 -48.4 40.02 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.374 -179.631 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 97' ' ' GLU . . . . . 0.572 ' HB3' HD23 ' A' ' 93' ' ' LEU . 42.3 mt-10 -54.94 -49.23 71.86 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 116.404 -0.362 . . . . 0.0 111.134 -179.837 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 98' ' ' PHE . . . . . 0.483 ' O ' HG12 ' A' ' 102' ' ' ILE . 33.0 m-85 -55.25 -49.94 70.74 Favored 'General case' 0 C--N 1.332 -0.175 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.689 179.755 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -54.42 -32.68 52.58 Favored Glycine 0 N--CA 1.452 -0.286 0 C-N-CA 120.93 -0.652 . . . . 0.0 112.694 -179.756 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 96.4 mt -69.54 -43.07 80.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-O 120.882 0.372 . . . . 0.0 111.629 -179.684 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 61.0 t -71.87 -40.58 68.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.325 -0.398 . . . . 0.0 111.989 -179.225 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 102' ' ' ILE . . . . . 0.483 HG12 ' O ' ' A' ' 98' ' ' PHE . 38.0 mm -68.78 -41.24 82.26 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.363 0 N-CA-C 111.954 0.353 . . . . 0.0 111.954 -179.097 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 103' ' ' THR . . . . . 0.429 HG23 ' N ' ' A' ' 104' ' ' LEU . 12.4 t -64.93 -44.5 89.31 Favored 'General case' 0 C--O 1.234 0.247 0 CA-C-O 120.679 0.276 . . . . 0.0 111.314 -179.719 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 104' ' ' LEU . . . . . 0.434 ' O ' HG23 ' A' ' 108' ' ' VAL . 9.2 tt -58.47 -44.18 89.21 Favored 'General case' 0 C--N 1.332 -0.164 0 CA-C-O 120.813 0.339 . . . . 0.0 110.252 179.776 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 105' ' ' ASN . . . . . 0.618 HD21 HD13 ' A' ' 137' ' ' LEU . 0.9 OUTLIER -56.29 -41.63 76.21 Favored 'General case' 0 N--CA 1.455 -0.179 0 CA-C-N 116.149 -0.478 . . . . 0.0 109.857 178.852 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 85.2 m -54.71 -40.14 68.91 Favored 'General case' 0 C--N 1.332 -0.157 0 CA-C-N 116.075 -0.511 . . . . 0.0 110.269 179.508 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 107' ' ' VAL . . . . . 0.404 HG12 ' SD ' ' A' ' 129' ' ' MET . 0.9 OUTLIER -67.45 -37.4 78.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 115.843 -0.617 . . . . 0.0 110.189 179.114 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . 0.434 HG23 ' O ' ' A' ' 104' ' ' LEU . 64.4 t -65.72 -52.04 54.99 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-N 115.33 -0.85 . . . . 0.0 111.686 -179.471 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 109' ' ' MET . . . . . 0.55 ' HG3' ' HA ' ' A' ' 77' ' ' ILE . 5.4 mmt -61.33 -39.72 91.57 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.35 -0.386 . . . . 0.0 111.18 -179.514 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 21.6 tp -64.42 -31.59 72.87 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.339 -0.392 . . . . 0.0 110.436 179.762 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 111' ' ' ALA . . . . . 0.403 ' O ' ' HB3' ' A' ' 126' ' ' LEU . . . -62.94 -56.59 15.85 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.528 179.344 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . -60.58 -36.8 92.25 Favored Glycine 0 C--N 1.329 0.193 0 C-N-CA 120.445 -0.883 . . . . 0.0 111.813 179.483 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 113' ' ' PHE . . . . . . . . . . . . . 10.1 t80 -49.45 -63.04 1.22 Allowed 'General case' 0 C--N 1.331 -0.222 0 CA-C-O 121.119 0.485 . . . . 0.0 110.201 179.429 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 114' ' ' ALA . . . . . 0.452 ' O ' HG13 ' A' ' 118' ' ' VAL . . . -69.66 -28.1 65.6 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 115.562 -0.744 . . . . 0.0 111.189 179.591 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -52.18 -35.87 43.16 Favored Glycine 0 C--N 1.332 0.316 0 CA-C-N 116.061 -0.518 . . . . 0.0 112.785 179.907 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -78.13 -44.81 25.04 Favored 'General case' 0 C--N 1.329 -0.316 0 N-CA-C 112.132 0.419 . . . . 0.0 112.132 -179.862 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 117' ' ' MET . . . . . 0.515 ' HB3' HG21 ' A' ' 68' ' ' VAL . 15.7 ptp -85.58 19.72 2.32 Favored 'General case' 0 C--N 1.33 -0.243 0 N-CA-C 112.149 0.426 . . . . 0.0 112.149 -179.007 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 118' ' ' VAL . . . . . 0.573 HG21 ' HB3' ' A' ' 123' ' ' ARG . 8.8 m -57.87 146.34 67.89 Favored Pre-proline 0 C--N 1.328 -0.332 0 CA-C-N 116.807 -0.178 . . . . 0.0 111.253 179.618 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 119' ' ' PRO . . . . . . . . . . . . . 71.8 Cg_endo -75.56 -9.06 19.87 Favored 'Trans proline' 0 C--N 1.347 0.476 0 C-N-CA 122.574 2.183 . . . . 0.0 112.381 -179.88 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -172.35 -122.95 0.68 Allowed Glycine 0 C--N 1.331 0.277 0 C-N-CA 120.662 -0.78 . . . . 0.0 112.711 -179.98 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 50.5 pt -83.38 8.06 1.39 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.23 0 CA-C-O 120.827 0.346 . . . . 0.0 111.334 -179.915 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 122' ' ' GLU . . . . . 0.478 ' HB2' ' HB ' ' A' ' 118' ' ' VAL . 11.7 mm-40 -58.57 -19.03 34.74 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.086 179.993 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 123' ' ' ARG . . . . . 0.573 ' HB3' HG21 ' A' ' 118' ' ' VAL . 12.6 ptt180 -52.33 -30.95 30.98 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.062 -0.517 . . . . 0.0 111.494 -179.842 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 124' ' ' TYR . . . . . . . . . . . . . 24.7 m-85 -71.96 -32.54 67.37 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.378 -0.373 . . . . 0.0 111.116 -179.686 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 125' ' ' ALA . . . . . . . . . . . . . . . -68.88 -51.07 44.14 Favored 'General case' 0 C--O 1.235 0.321 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.939 179.626 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 126' ' ' LEU . . . . . 0.403 ' HB3' ' O ' ' A' ' 111' ' ' ALA . 2.9 mm? -54.99 -55.85 26.28 Favored 'General case' 0 CA--C 1.52 -0.209 0 CA-C-N 116.015 -0.539 . . . . 0.0 110.882 -179.827 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 127' ' ' PHE . . . . . 0.464 ' HZ ' ' HB3' ' A' ' 175' ' ' PRO . 7.8 t80 -65.33 -33.25 75.52 Favored 'General case' 0 N--CA 1.45 -0.435 0 CA-C-N 116.258 -0.428 . . . . 0.0 111.466 -179.065 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 128' ' ' GLY . . . . . . . . . . . . . . . -49.67 -45.3 38.89 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 119.816 -1.183 . . . . 0.0 110.623 179.009 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 129' ' ' MET . . . . . 0.404 ' SD ' HG12 ' A' ' 107' ' ' VAL . 0.6 OUTLIER -71.71 -38.89 70.46 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 115.072 -0.564 . . . . 0.0 110.356 178.881 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -67.05 -27.41 73.44 Favored Glycine 0 C--N 1.331 0.283 0 CA-C-N 115.897 -0.592 . . . . 0.0 113.002 -179.613 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -74.85 -53.23 9.46 Favored 'General case' 0 C--N 1.328 -0.348 0 N-CA-C 110.012 -0.366 . . . . 0.0 110.012 179.86 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 95.9 t -57.23 -39.83 69.86 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.234 0 CA-C-O 121.347 0.594 . . . . 0.0 109.458 178.507 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -70.39 -34.17 72.24 Favored 'General case' 0 N--CA 1.452 -0.344 0 CA-C-N 115.297 -0.865 . . . . 0.0 110.69 179.423 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 134' ' ' PHE . . . . . 0.404 ' CZ ' ' HA ' ' A' ' 172' ' ' ALA . 50.2 t80 -55.4 -60.14 3.82 Favored 'General case' 0 N--CA 1.453 -0.304 0 CA-C-O 120.985 0.422 . . . . 0.0 110.164 179.689 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 135' ' ' ILE . . . . . 0.494 ' O ' HG22 ' A' ' 138' ' ' VAL . 0.0 OUTLIER -55.75 -34.74 37.24 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 115.764 -0.653 . . . . 0.0 109.854 178.975 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 136' ' ' GLY . . . . . 0.413 ' O ' ' HB3' ' A' ' 139' ' ' TYR . . . -58.1 -41.66 94.72 Favored Glycine 0 N--CA 1.449 -0.477 0 C-N-CA 120.389 -0.91 . . . . 0.0 111.488 178.777 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 137' ' ' LEU . . . . . 0.618 HD13 HD21 ' A' ' 105' ' ' ASN . 45.1 tp -66.05 -56.25 12.51 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-O 120.68 0.276 . . . . 0.0 110.446 179.215 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 138' ' ' VAL . . . . . 0.517 ' O ' HG23 ' A' ' 142' ' ' VAL . 2.7 m -55.12 -30.33 23.96 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.237 0 CA-C-O 121.134 0.492 . . . . 0.0 109.813 -179.994 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 139' ' ' TYR . . . . . 0.413 ' HB3' ' O ' ' A' ' 136' ' ' GLY . 12.2 t80 -61.8 -42.33 98.87 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 115.682 -0.69 . . . . 0.0 109.804 178.566 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 29.1 m-85 -69.29 -35.22 75.79 Favored 'General case' 0 C--N 1.333 -0.15 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.494 179.064 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 141' ' ' LEU . . . . . 0.406 ' HB3' ' HD3' ' A' ' 164' ' ' ARG . 11.0 mp -62.8 -27.22 69.16 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.502 179.578 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 142' ' ' VAL . . . . . 0.619 HG22 HH11 ' A' ' 164' ' ' ARG . 12.4 t -103.88 -11.6 9.28 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.226 0 CA-C-N 116.008 -0.542 . . . . 0.0 111.103 179.964 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . -76.66 -117.24 0.15 Allowed Glycine 0 CA--C 1.523 0.566 0 C-N-CA 120.937 -0.649 . . . . 0.0 113.115 -179.702 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 144' ' ' PRO . . . . . . . . . . . . . 47.2 Cg_endo -68.35 -23.51 38.2 Favored 'Trans proline' 0 C--N 1.35 0.638 0 C-N-CA 122.67 2.246 . . . . 0.0 113.195 -179.298 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 145' ' ' MET . . . . . . . . . . . . . 58.2 mtt -65.47 -30.27 71.03 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.676 0.274 . . . . 0.0 111.403 -179.775 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 146' ' ' THR . . . . . 0.422 ' OG1' ' HA ' ' A' ' 142' ' ' VAL . 82.9 m -81.16 -32.38 33.66 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.852 0.358 . . . . 0.0 111.345 -179.31 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 38.6 tt0 -75.92 -40.65 53.82 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.119 -179.919 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 148' ' ' SER . . . . . 0.433 ' HB3' ' HB1' ' A' ' 91' ' ' ALA . 46.0 t -70.3 -45.26 66.65 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.278 -0.419 . . . . 0.0 111.242 -179.473 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 149' ' ' ALA . . . . . 0.435 ' HB2' ' HB2' ' A' ' 91' ' ' ALA . . . -65.69 -32.33 73.82 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.27 -0.423 . . . . 0.0 111.416 -179.543 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 150' ' ' SER . . . . . . . . . . . . . 80.3 p -74.47 0.45 14.64 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.283 -0.417 . . . . 0.0 111.331 -179.717 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 151' ' ' GLN . . . . . . . . . . . . . 10.3 pt20 -136.3 9.84 3.22 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.54 -0.3 . . . . 0.0 110.996 179.787 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 1.5 tmt_? -83.84 -51.81 6.89 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-O 120.833 0.349 . . . . 0.0 110.435 179.997 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 153' ' ' SER . . . . . 0.676 ' HB2' HG12 ' A' ' 156' ' ' ILE . 20.8 m -157.54 172.47 18.5 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.024 -0.535 . . . . 0.0 110.507 179.314 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 154' ' ' SER . . . . . . . . . . . . . 48.1 t -73.05 -38.32 66.53 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.378 -0.374 . . . . 0.0 110.729 179.849 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -77.36 -27.55 59.4 Favored Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.944 -0.646 . . . . 0.0 112.718 179.993 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 156' ' ' ILE . . . . . 0.676 HG12 ' HB2' ' A' ' 153' ' ' SER . 38.1 mm -62.03 -35.44 68.52 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-O 120.799 0.333 . . . . 0.0 110.923 -179.944 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 157' ' ' LYS . . . . . . . . . . . . . 91.3 mttt -58.93 -55.55 33.75 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.067 -0.515 . . . . 0.0 111.617 -179.888 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 69.0 m -70.49 -38.58 74.38 Favored 'General case' 0 N--CA 1.463 0.21 0 N-CA-C 112.256 0.465 . . . . 0.0 112.256 -178.847 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 159' ' ' LEU . . . . . . . . . . . . . 39.0 tp -69.13 -36.25 77.26 Favored 'General case' 0 C--N 1.327 -0.411 0 N-CA-C 111.74 0.274 . . . . 0.0 111.74 -179.148 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 160' ' ' TYR . . . . . . . . . . . . . 57.0 t80 -73.96 -46.11 46.05 Favored 'General case' 0 C--N 1.328 -0.366 0 N-CA-C 111.9 0.333 . . . . 0.0 111.9 -179.027 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 29.4 m -59.96 -41.73 87.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-O 120.721 0.296 . . . . 0.0 111.332 -179.634 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 162' ' ' ARG . . . . . 0.537 ' HG2' HG21 ' A' ' 211' ' ' ILE . 23.3 tpp180 -68.99 -39.89 79.11 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 120.944 0.402 . . . . 0.0 110.97 179.949 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 163' ' ' LEU . . . . . 0.54 ' HG ' ' HB2' ' A' ' 208' ' ' PHE . 4.5 mp -68.25 -44.32 75.9 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.069 -0.514 . . . . 0.0 111.668 -179.505 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 164' ' ' ARG . . . . . 0.619 HH11 HG22 ' A' ' 142' ' ' VAL . 18.4 ttp85 -72.01 -52.97 14.45 Favored 'General case' 0 C--N 1.329 -0.324 0 N-CA-C 112.125 0.417 . . . . 0.0 112.125 -179.003 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 165' ' ' ASN . . . . . 0.508 HD22 ' N ' ' A' ' 165' ' ' ASN . 0.9 OUTLIER -52.31 -46.31 65.93 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-O 121.056 0.455 . . . . 0.0 110.534 -179.291 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 166' ' ' LEU . . . . . 0.528 ' O ' ' HG ' ' A' ' 170' ' ' LEU . 6.8 tt -64.9 -52.08 58.45 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-N 115.809 -0.632 . . . . 0.0 111.141 179.955 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 167' ' ' THR . . . . . 0.476 ' O ' ' HB2' ' A' ' 171' ' ' TRP . 96.4 m -61.32 -54.09 48.34 Favored 'General case' 0 N--CA 1.463 0.185 0 N-CA-C 112.608 0.596 . . . . 0.0 112.608 -178.653 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 168' ' ' VAL . . . . . . . . . . . . . 94.0 t -52.2 -41.09 32.56 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.185 0 N-CA-C 112.134 0.42 . . . . 0.0 112.134 -179.284 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 169' ' ' VAL . . . . . 0.444 HG23 ' O ' ' A' ' 165' ' ' ASN . 43.9 t -61.96 -64.63 0.6 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 N-CA-C 111.965 0.357 . . . . 0.0 111.965 -179.452 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 170' ' ' LEU . . . . . 0.528 ' HG ' ' O ' ' A' ' 166' ' ' LEU . 1.3 pp -62.55 -29.37 70.52 Favored 'General case' 0 C--N 1.331 -0.206 0 N-CA-C 112.081 0.4 . . . . 0.0 112.081 -178.777 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 171' ' ' TRP . . . . . 0.476 ' HB2' ' O ' ' A' ' 167' ' ' THR . 2.7 m0 -72.87 -30.78 64.25 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.842 0.353 . . . . 0.0 110.737 179.83 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 172' ' ' ALA . . . . . 0.404 ' HA ' ' CZ ' ' A' ' 134' ' ' PHE . . . -73.65 -6.21 45.29 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-O 121.093 0.473 . . . . 0.0 110.286 179.647 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 173' ' ' ILE . . . . . 0.467 ' O ' HG12 ' A' ' 177' ' ' ILE . 44.1 mm -85.14 -20.93 8.07 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.241 0 CA-C-N 115.678 -0.692 . . . . 0.0 110.484 179.148 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 174' ' ' TYR . . . . . . . . . . . . . 13.2 m-85 -53.21 -50.07 84.4 Favored Pre-proline 0 N--CA 1.464 0.268 0 CA-C-N 116.126 -0.488 . . . . 0.0 111.18 -179.867 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 175' ' ' PRO . . . . . 0.464 ' HB3' ' HZ ' ' A' ' 127' ' ' PHE . 93.1 Cg_exo -45.17 -33.07 7.78 Favored 'Trans proline' 0 C--N 1.351 0.684 0 C-N-CA 122.252 1.968 . . . . 0.0 112.152 179.308 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 176' ' ' PHE . . . . . 0.504 ' O ' ' HG ' ' A' ' 180' ' ' LEU . 85.4 m-85 -80.82 -50.12 10.23 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 115.772 -0.649 . . . . 0.0 112.023 -179.618 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 177' ' ' ILE . . . . . 0.531 HG13 HD11 ' A' ' 200' ' ' LEU . 4.1 mm -63.42 -35.03 70.8 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.547 0 N-CA-C 112.546 0.573 . . . . 0.0 112.546 -177.867 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 178' ' ' TRP . . . . . . . . . . . . . 73.5 t90 -73.87 -52.37 13.2 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-O 120.887 0.375 . . . . 0.0 110.856 179.87 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 179' ' ' LEU . . . . . 0.487 HD23 HD23 ' A' ' 180' ' ' LEU . 0.5 OUTLIER -64.83 -54.34 32.55 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.079 -0.51 . . . . 0.0 111.677 -179.004 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 180' ' ' LEU . . . . . 0.6 HD22 HD11 ' A' ' 187' ' ' LEU . 27.9 mt -64.32 -49.09 73.09 Favored 'General case' 0 C--N 1.326 -0.448 0 C-N-CA 120.812 -0.355 . . . . 0.0 111.201 -179.529 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . -57.38 179.93 0.77 Allowed Glycine 0 C--N 1.338 0.651 0 C-N-CA 120.284 -0.96 . . . . 0.0 112.37 179.511 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 182' ' ' PRO . . . . . 0.717 ' HA ' ' HB2' ' A' ' 186' ' ' ALA . 89.0 Cg_exo -46.99 -45.04 21.89 Favored 'Trans proline' 0 CA--C 1.536 0.593 0 C-N-CA 122.969 2.446 . . . . 0.0 113.994 -179.657 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 183' ' ' PRO . . . . . 0.424 ' HD3' ' HB2' ' A' ' 182' ' ' PRO . 88.4 Cg_exo -48.14 -25.29 6.55 Favored 'Trans proline' 0 C--N 1.354 0.845 0 C-N-CA 122.303 2.002 . . . . 0.0 113.762 -179.509 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 184' ' ' GLY . . . . . 0.433 ' HA3' ' O ' ' A' ' 179' ' ' LEU . . . -112.86 -81.63 1.1 Allowed Glycine 0 C--N 1.334 0.437 0 C-N-CA 120.098 -1.049 . . . . 0.0 113.617 -179.443 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 185' ' ' VAL . . . . . . . . . . . . . 14.5 m -120.86 -8.6 10.27 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.203 0 N-CA-C 112.17 0.433 . . . . 0.0 112.17 -178.696 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 186' ' ' ALA . . . . . 0.717 ' HB2' ' HA ' ' A' ' 182' ' ' PRO . . . 57.56 85.9 0.08 Allowed 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.494 -0.321 . . . . 0.0 111.714 179.562 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 187' ' ' LEU . . . . . 0.6 HD11 HD22 ' A' ' 180' ' ' LEU . 17.9 mt -91.99 -49.33 6.28 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-O 120.963 0.411 . . . . 0.0 110.695 179.518 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 188' ' ' LEU . . . . . . . . . . . . . 86.2 mt -95.87 -158.39 0.65 Allowed 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 115.807 -0.633 . . . . 0.0 110.792 -179.766 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 189' ' ' THR . . . . . 0.511 HG22 HG22 ' A' ' 191' ' ' THR . 24.9 m -91.38 136.91 26.38 Favored Pre-proline 0 C--N 1.327 -0.378 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.566 -179.885 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 190' ' ' PRO . . . . . 0.449 ' O ' HG23 ' A' ' 194' ' ' VAL . 93.7 Cg_exo -44.35 -53.63 4.69 Favored 'Trans proline' 0 C--N 1.351 0.68 0 C-N-CA 122.559 2.172 . . . . 0.0 113.094 -179.786 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 191' ' ' THR . . . . . 0.511 HG22 HG22 ' A' ' 189' ' ' THR . 3.0 t -56.81 -36.8 70.34 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.703 0.287 . . . . 0.0 111.455 -179.721 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 192' ' ' VAL . . . . . 0.43 HG23 ' HB ' ' A' ' 189' ' ' THR . 92.7 t -70.46 -42.06 78.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.423 -0.353 . . . . 0.0 110.982 179.952 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 193' ' ' ASP . . . . . . . . . . . . . 24.8 t70 -61.6 -40.17 93.82 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.468 179.743 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 194' ' ' VAL . . . . . 0.449 HG23 ' O ' ' A' ' 190' ' ' PRO . 99.9 t -65.11 -35.88 76.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.026 -0.534 . . . . 0.0 110.229 179.323 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 195' ' ' ALA . . . . . . . . . . . . . . . -57.7 -48.4 79.66 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.846 179.48 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 196' ' ' LEU . . . . . . . . . . . . . 92.5 mt -67.9 -43.22 79.78 Favored 'General case' 0 C--N 1.332 -0.176 0 CA-C-N 116.417 -0.356 . . . . 0.0 110.816 179.634 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 197' ' ' ILE . . . . . . . . . . . . . 14.7 mm -57.86 -57.69 9.43 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.075 -0.511 . . . . 0.0 110.632 179.56 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 198' ' ' VAL . . . . . . . . . . . . . 74.7 t -55.15 -34.16 31.83 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.5 0 N-CA-C 109.078 -0.712 . . . . 0.0 109.078 178.317 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 199' ' ' TYR . . . . . . . . . . . . . 62.7 t80 -69.48 -30.66 68.59 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 115.205 -0.907 . . . . 0.0 110.62 179.843 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 200' ' ' LEU . . . . . 0.571 ' O ' HG12 ' A' ' 203' ' ' VAL . 32.1 mt -69.61 -47.69 62.63 Favored 'General case' 0 C--N 1.332 -0.153 0 CA-C-N 116.099 -0.5 . . . . 0.0 111.584 -179.56 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 201' ' ' ASP . . . . . 0.402 ' HB2' ' OH ' ' A' ' 51' ' ' TYR . 4.7 m-20 -70.62 -39.63 73.62 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-O 121.29 0.567 . . . . 0.0 110.192 179.757 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 202' ' ' LEU . . . . . . . . . . . . . 59.8 tp -71.13 -26.75 63.15 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 115.343 -0.844 . . . . 0.0 111.951 -179.292 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 203' ' ' VAL . . . . . 0.571 HG12 ' O ' ' A' ' 200' ' ' LEU . 9.3 p -79.34 -35.73 17.34 Favored 'Isoleucine or valine' 0 C--O 1.226 -0.153 0 C-N-CA 121.005 -0.278 . . . . 0.0 110.805 -179.483 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 204' ' ' THR . . . . . . . . . . . . . 95.8 m -65.71 -58.89 4.62 Favored 'General case' 0 C--N 1.329 -0.31 0 C-N-CA 120.748 -0.381 . . . . 0.0 110.797 179.33 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 205' ' ' LYS . . . . . 0.546 ' HE2' ' HB2' ' A' ' 47' ' ' ALA . 60.9 mttp -58.17 -57.29 13.53 Favored 'General case' 0 C--N 1.329 -0.296 0 N-CA-C 112.061 0.393 . . . . 0.0 112.061 -178.9 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 59.8 t -71.04 -37.35 67.15 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.365 0 N-CA-C 112.326 0.491 . . . . 0.0 112.326 -178.702 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 207' ' ' GLY . . . . . 0.531 ' O ' HG13 ' A' ' 211' ' ' ILE . . . -58.07 -61.86 6.94 Favored Glycine 0 CA--C 1.518 0.267 0 C-N-CA 120.658 -0.782 . . . . 0.0 113.966 -178.605 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 208' ' ' PHE . . . . . 0.54 ' HB2' ' HG ' ' A' ' 163' ' ' LEU . 2.1 p90 -72.93 -27.36 61.81 Favored 'General case' 0 C--O 1.222 -0.38 0 CA-C-N 117.48 0.64 . . . . 0.0 110.75 -179.308 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 209' ' ' GLY . . . . . 0.595 ' O ' ' HB3' ' A' ' 212' ' ' ALA . . . -63.34 -34.17 89.23 Favored Glycine 0 N--CA 1.449 -0.473 0 N-CA-C 111.786 -0.525 . . . . 0.0 111.786 178.65 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 210' ' ' PHE . . . . . . . . . . . . . 0.7 OUTLIER -72.75 -47.46 46.7 Favored 'General case' 0 CA--C 1.514 -0.425 0 N-CA-C 108.239 -1.023 . . . . 0.0 108.239 178.379 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 211' ' ' ILE . . . . . 0.537 HG21 ' HG2' ' A' ' 162' ' ' ARG . 4.8 mt -62.91 -27.48 43.2 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.465 0 N-CA-C 107.632 -1.248 . . . . 0.0 107.632 176.588 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 212' ' ' ALA . . . . . 0.595 ' HB3' ' O ' ' A' ' 209' ' ' GLY . . . -61.86 -41.67 98.12 Favored 'General case' 0 N--CA 1.45 -0.45 0 CA-C-N 114.436 -1.256 . . . . 0.0 110.622 -179.846 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 213' ' ' LEU . . . . . . . . . . . . . 99.1 mt -66.56 -50.39 63.29 Favored 'General case' 0 C--N 1.331 -0.202 0 CA-C-N 115.345 -0.843 . . . . 0.0 111.255 -179.872 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 214' ' ' ASP . . . . . . . . . . . . . 25.8 t70 -56.08 -54.41 45.29 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.282 -0.417 . . . . 0.0 111.152 -179.761 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 215' ' ' ALA . . . . . . . . . . . . . . . -57.44 -57.27 13.39 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.136 -0.484 . . . . 0.0 111.417 -179.865 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 216' ' ' ALA . . . . . . . . . . . . . . . -55.18 -33.48 63.04 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.353 -0.385 . . . . 0.0 111.331 -179.828 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 217' ' ' ALA . . . . . . . . . . . . . . . -61.72 -37.77 85.43 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 121.096 0.474 . . . . 0.0 110.129 179.426 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 218' ' ' THR . . . . . . . . . . . . . 98.4 m . . . . . 0 C--N 1.329 -0.288 0 CA-C-N 115.648 -0.705 . . . . 0.0 110.824 179.384 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.307 0 N-CA-C 112.727 -0.149 . . . . 0.0 112.727 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 4' ' ' LEU . . . . . 0.409 ' HA ' HD23 ' A' ' 7' ' ' LEU . 82.9 mt -59.2 -35.24 73.25 Favored 'General case' 0 N--CA 1.449 -0.483 0 CA-C-O 120.812 0.339 . . . . 0.0 111.273 -179.822 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 46.4 p -61.6 -34.91 76.44 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.11 -0.495 . . . . 0.0 111.795 -179.588 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 16.4 p -56.16 -35.64 67.41 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.333 -0.394 . . . . 0.0 111.507 -179.321 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 7' ' ' LEU . . . . . 0.42 ' N ' HD22 ' A' ' 7' ' ' LEU . 3.6 mm? -61.81 -53.5 55.04 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.364 -0.38 . . . . 0.0 111.271 -179.752 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 8' ' ' PHE . . . . . 0.563 ' HB2' ' HB2' ' A' ' 55' ' ' ALA . 53.9 m-85 -59.18 -30.21 68.03 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.291 -0.413 . . . . 0.0 111.066 -179.631 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 9' ' ' TRP . . . . . . . . . . . . . 19.7 m95 -69.25 -46.76 66.5 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.345 -179.971 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 85.4 mt -62.3 -41.86 98.88 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 115.88 -0.6 . . . . 0.0 110.042 179.206 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -62.29 -33.72 86.96 Favored Glycine 0 N--CA 1.448 -0.509 0 C-N-CA 120.779 -0.724 . . . . 0.0 111.769 179.3 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -67.87 -34.48 76.76 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-O 120.84 0.352 . . . . 0.0 110.523 179.585 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 46.8 mm -62.68 -51.67 69.19 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.187 0 CA-C-N 116.029 -0.532 . . . . 0.0 110.505 179.451 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -60.18 -33.21 79.02 Favored Glycine 0 N--CA 1.449 -0.447 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.108 179.648 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 15' ' ' MET . . . . . 0.611 ' HB3' ' HB2' ' A' ' 48' ' ' ALA . 20.0 mmt -66.75 -47.05 73.44 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.624 0.25 . . . . 0.0 110.821 179.689 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -54.07 -42.14 68.95 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.301 179.583 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 79.6 t -61.26 -48.05 90.69 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-N 115.946 -0.57 . . . . 0.0 110.79 179.548 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -63.51 -46.34 92.67 Favored Glycine 0 C--N 1.331 0.272 0 C-N-CA 120.773 -0.727 . . . . 0.0 112.165 179.809 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 23.2 m -49.95 -43.19 49.86 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 120.726 0.298 . . . . 0.0 111.114 -179.644 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 81.8 mt -71.93 -47.06 55.15 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.284 -0.416 . . . . 0.0 111.446 179.905 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -57.61 -29.9 64.89 Favored 'General case' 0 C--N 1.33 -0.272 0 N-CA-C 111.982 0.364 . . . . 0.0 111.982 -179.525 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 22' ' ' PHE . . . . . 0.587 ' HB2' HG22 ' A' ' 41' ' ' VAL . 9.5 m-85 -89.42 -41.12 12.27 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.531 -0.304 . . . . 0.0 111.594 -179.097 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -65.58 -50.39 65.31 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.828 0.347 . . . . 0.0 111.38 -179.729 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 24' ' ' TRP . . . . . . . . . . . . . 1.1 t-105 -57.92 -50.3 73.81 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.078 -0.51 . . . . 0.0 111.057 179.884 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.328 -0.329 0 CA-C-N 116.284 -0.416 . . . . 0.0 111.221 -179.911 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.258 0 N-CA-C 112.603 -0.199 . . . . 0.0 112.603 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 12.9 mm-40 -63.68 -24.31 67.73 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.835 0.35 . . . . 0.0 110.729 179.981 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 34' ' ' ARG . . . . . . . . . . . . . 75.6 ttt180 -50.56 -30.45 13.16 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 115.905 -0.588 . . . . 0.0 111.694 -179.77 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 88.2 mtm180 -59.24 -52.62 64.88 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.487 -0.324 . . . . 0.0 111.604 -179.677 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 86.3 m-85 -58.89 -27.58 65.36 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.51 -179.618 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 37' ' ' TYR . . . . . 0.443 ' O ' HG23 ' A' ' 41' ' ' VAL . 72.7 m-85 -77.96 -53.81 7.02 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-N 116.292 -0.413 . . . . 0.0 111.08 -179.642 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 86.6 t -56.78 -36.9 50.86 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-O 121.024 0.44 . . . . 0.0 110.292 179.634 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 99.3 m -63.06 -50.52 70.28 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 115.759 -0.655 . . . . 0.0 110.164 179.153 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 40' ' ' LEU . . . . . 0.471 HD12 HD12 ' A' ' 43' ' ' ILE . 53.7 tp -56.36 -43.46 79.18 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 115.441 -0.8 . . . . 0.0 110.252 179.44 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . 0.587 HG22 ' HB2' ' A' ' 22' ' ' PHE . 97.3 t -63.77 -34.35 67.52 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.253 0 CA-C-N 115.708 -0.678 . . . . 0.0 109.648 178.731 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -60.46 -35.34 88.6 Favored Glycine 0 N--CA 1.448 -0.524 0 CA-C-N 115.627 -0.715 . . . . 0.0 112.102 179.753 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 43' ' ' ILE . . . . . 0.625 HG22 ' HE3' ' A' ' 205' ' ' LYS . 0.3 OUTLIER -70.11 -57.77 7.23 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.159 0 CA-C-O 120.646 0.26 . . . . 0.0 110.796 179.704 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 67.1 m -62.89 -20.28 65.0 Favored 'General case' 0 C--O 1.232 0.153 0 CA-C-N 116.406 -0.361 . . . . 0.0 111.315 -179.732 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -77.99 -57.52 3.45 Favored Glycine 0 N--CA 1.452 -0.25 0 C-N-CA 120.778 -0.725 . . . . 0.0 112.8 -179.598 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 23.8 pt -58.87 -36.14 59.87 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.213 0 CA-C-O 120.958 0.409 . . . . 0.0 110.969 179.925 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 47' ' ' ALA . . . . . 0.587 ' HB2' ' HE2' ' A' ' 205' ' ' LYS . . . -67.63 -45.46 75.28 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.067 -0.515 . . . . 0.0 111.26 179.832 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 48' ' ' ALA . . . . . 0.611 ' HB2' ' HB3' ' A' ' 15' ' ' MET . . . -55.1 -43.81 74.36 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.106 -0.497 . . . . 0.0 111.829 -179.578 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 35.9 m -73.37 -34.17 42.6 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.353 0 CA-C-N 116.332 -0.395 . . . . 0.0 111.519 -179.325 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -65.78 -35.09 79.73 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-O 120.924 0.393 . . . . 0.0 110.869 179.925 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 26.7 m-85 -73.33 -40.03 64.78 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-N 115.96 -0.564 . . . . 0.0 110.518 179.96 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -63.84 -44.7 92.39 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 115.938 -0.574 . . . . 0.0 111.258 179.848 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 53' ' ' VAL . . . . . 0.519 HG23 ' N ' ' A' ' 54' ' ' MET . 34.2 m -68.56 -48.97 69.42 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.226 0 CA-C-N 116.404 -0.362 . . . . 0.0 110.868 179.923 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 54' ' ' MET . . . . . 0.519 ' N ' HG23 ' A' ' 53' ' ' VAL . 7.1 ttp -62.77 -30.1 71.2 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.126 179.852 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 55' ' ' ALA . . . . . 0.563 ' HB2' ' HB2' ' A' ' 8' ' ' PHE . . . -65.55 -40.04 92.39 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 115.849 -0.614 . . . . 0.0 111.023 179.336 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 95.3 mt -73.23 2.77 6.71 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.022 -0.536 . . . . 0.0 111.092 -179.864 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 90.7 7.37 66.69 Favored Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.685 -0.769 . . . . 0.0 112.592 179.942 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 41.3 t -74.46 135.85 26.5 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-O 120.864 0.364 . . . . 0.0 110.869 179.895 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 83.92 -2.55 87.4 Favored Glycine 0 N--CA 1.452 -0.286 0 C-N-CA 120.942 -0.647 . . . . 0.0 112.903 179.988 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 60' ' ' TRP . . . . . . . . . . . . . 12.0 m0 -73.74 102.32 3.95 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.56 0.219 . . . . 0.0 110.931 179.63 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 61' ' ' VAL . . . . . 0.4 ' HA ' ' HD3' ' A' ' 62' ' ' PRO . 7.6 p -115.13 124.25 30.52 Favored Pre-proline 0 CA--C 1.536 0.414 0 CA-C-N 116.559 -0.291 . . . . 0.0 111.208 179.794 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 62' ' ' PRO . . . . . 0.4 ' HD3' ' HA ' ' A' ' 61' ' ' VAL . 14.2 Cg_exo -69.47 157.3 61.44 Favored 'Trans proline' 0 C--N 1.353 0.796 0 C-N-CA 122.783 2.322 . . . . 0.0 112.744 -179.725 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . 0.423 HG23 HG22 ' A' ' 68' ' ' VAL . 76.5 t -144.13 94.63 0.47 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.223 0 CA-C-N 115.856 -0.611 . . . . 0.0 110.98 179.88 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . 59.51 -86.42 0.02 OUTLIER 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 116.088 -0.506 . . . . 0.0 111.503 179.789 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 11.1 tp10 -118.16 -26.88 6.22 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-N 116.526 -0.306 . . . . 0.0 111.261 -179.723 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 66' ' ' ARG . . . . . . . . . . . . . 17.4 ptp180 -107.69 153.76 22.46 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.46 -0.336 . . . . 0.0 110.443 179.903 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 60.4 m -105.88 141.52 37.15 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-O 121.047 0.451 . . . . 0.0 111.543 -179.521 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 68' ' ' VAL . . . . . 0.431 HG21 ' HG3' ' A' ' 117' ' ' MET . 33.0 m -119.89 146.37 24.77 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 115.725 -0.67 . . . . 0.0 110.367 179.537 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 69' ' ' PHE . . . . . . . . . . . . . 22.1 m-85 -109.0 112.44 24.63 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 116.318 -0.401 . . . . 0.0 110.066 -179.398 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 70' ' ' VAL . . . . . 0.481 ' HB ' ' HD3' ' A' ' 71' ' ' PRO . 3.2 t -63.78 -48.98 78.41 Favored Pre-proline 0 C--N 1.326 -0.441 0 CA-C-N 116.274 -0.421 . . . . 0.0 111.905 -179.126 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 71' ' ' PRO . . . . . 0.583 ' HA ' HG22 ' A' ' 74' ' ' ILE . 47.4 Cg_exo -56.9 -18.06 26.3 Favored 'Trans proline' 0 C--N 1.351 0.698 0 C-N-CA 122.289 1.993 . . . . 0.0 112.877 -179.606 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 68.2 ttt180 -70.95 -55.79 7.6 Favored 'General case' 0 C--O 1.236 0.362 0 CA-C-O 120.886 0.374 . . . . 0.0 111.559 -179.323 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 73' ' ' TYR . . . . . 0.458 ' O ' HG13 ' A' ' 77' ' ' ILE . 7.0 m-85 -70.64 -34.45 72.08 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.439 -0.346 . . . . 0.0 110.281 -179.497 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 74' ' ' ILE . . . . . 0.583 HG22 ' HA ' ' A' ' 71' ' ' PRO . 0.4 OUTLIER -68.01 -37.98 79.15 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.226 0 CA-C-N 116.334 -0.394 . . . . 0.0 110.013 179.322 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 75' ' ' ASP . . . . . 0.442 ' O ' HG23 ' A' ' 79' ' ' THR . 8.1 t70 -58.02 -39.56 78.65 Favored 'General case' 0 CA--C 1.518 -0.259 0 N-CA-C 109.045 -0.724 . . . . 0.0 109.045 178.806 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 76' ' ' TRP . . . . . 0.434 ' HZ2' HG23 ' A' ' 197' ' ' ILE . 39.0 m0 -67.06 -31.56 72.15 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 115.612 -0.722 . . . . 0.0 110.584 179.108 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 77' ' ' ILE . . . . . 0.544 ' HA ' ' HG3' ' A' ' 109' ' ' MET . 85.8 mt -66.71 -32.8 59.66 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.233 0 CA-C-N 116.284 -0.416 . . . . 0.0 111.035 179.468 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 21.5 mt -91.16 -17.47 26.04 Favored 'General case' 0 C--N 1.327 -0.41 0 N-CA-C 112.149 0.426 . . . . 0.0 112.149 -179.515 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 79' ' ' THR . . . . . 0.442 HG23 ' O ' ' A' ' 75' ' ' ASP . 76.9 p -103.4 -52.65 2.96 Favored 'General case' 0 CA--C 1.532 0.275 0 N-CA-C 113.784 1.031 . . . . 0.0 113.784 -177.915 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 80' ' ' THR . . . . . 0.682 ' HB ' ' HD3' ' A' ' 81' ' ' PRO . 29.4 m -51.36 -54.86 34.12 Favored Pre-proline 0 CA--C 1.531 0.246 0 N-CA-C 112.478 0.547 . . . . 0.0 112.478 -178.508 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 81' ' ' PRO . . . . . 0.682 ' HD3' ' HB ' ' A' ' 80' ' ' THR . 36.9 Cg_exo -60.51 -20.93 66.41 Favored 'Trans proline' 0 C--N 1.351 0.683 0 C-N-CA 121.575 1.516 . . . . 0.0 111.368 179.763 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 82' ' ' LEU . . . . . 0.436 HD23 HG23 ' A' ' 43' ' ' ILE . 17.3 tp -76.91 -33.34 57.77 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 115.812 -0.631 . . . . 0.0 110.302 179.751 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 48.9 mm -68.4 -52.06 40.91 Favored 'Isoleucine or valine' 0 C--O 1.233 0.221 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.055 179.109 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 34.5 m -61.86 -30.0 47.56 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.142 0 N-CA-C 109.545 -0.539 . . . . 0.0 109.545 178.728 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 85' ' ' TYR . . . . . . . . . . . . . 73.4 t80 -67.63 -33.35 74.78 Favored 'General case' 0 N--CA 1.454 -0.235 0 CA-C-N 115.546 -0.752 . . . . 0.0 109.615 178.873 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 86' ' ' PHE . . . . . . . . . . . . . 5.5 t80 -61.99 -51.67 67.11 Favored 'General case' 0 C--O 1.233 0.221 0 CA-C-N 115.697 -0.683 . . . . 0.0 109.822 179.204 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 87' ' ' LEU . . . . . 0.401 ' N ' HD12 ' A' ' 87' ' ' LEU . 8.7 mp -62.43 -29.5 70.55 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 115.755 -0.657 . . . . 0.0 110.101 179.476 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -71.49 -27.76 70.74 Favored Glycine 0 N--CA 1.449 -0.455 0 C-N-CA 120.799 -0.715 . . . . 0.0 111.569 179.237 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 72.6 mt -69.92 -45.57 67.24 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-O 121.074 0.464 . . . . 0.0 109.985 179.504 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 90' ' ' LEU . . . . . 0.485 ' HB3' HG23 ' A' ' 156' ' ' ILE . 64.7 mt -60.17 -30.43 69.33 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 115.582 -0.735 . . . . 0.0 110.741 179.616 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 91' ' ' ALA . . . . . 0.458 ' HA ' ' HA ' ' A' ' 149' ' ' ALA . . . -86.32 -29.44 23.02 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.264 -179.787 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 75.03 44.69 22.93 Favored Glycine 0 N--CA 1.452 -0.258 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.146 -179.902 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 93' ' ' LEU . . . . . 0.427 ' HB3' ' HB2' ' A' ' 97' ' ' GLU . 30.1 mt -60.36 168.04 2.24 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.955 0.407 . . . . 0.0 111.206 -179.646 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 94' ' ' ASP . . . . . . . . . . . . . 5.5 m-20 -90.77 179.57 5.76 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 115.936 -0.575 . . . . 0.0 110.834 179.994 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 80.5 p -60.58 -42.83 97.48 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.906 -179.94 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 68.9 mtm180 -68.62 -49.77 56.6 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.108 -0.496 . . . . 0.0 111.027 -179.826 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 97' ' ' GLU . . . . . 0.427 ' HB2' ' HB3' ' A' ' 93' ' ' LEU . 44.9 mt-10 -54.51 -47.6 72.9 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.335 -0.393 . . . . 0.0 111.033 -179.883 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 98' ' ' PHE . . . . . 0.453 ' O ' HG12 ' A' ' 102' ' ' ILE . 11.3 m-85 -60.29 -43.62 96.09 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.416 -0.357 . . . . 0.0 110.496 179.61 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -60.63 -27.53 66.37 Favored Glycine 0 N--CA 1.451 -0.358 0 C-N-CA 120.611 -0.804 . . . . 0.0 112.414 179.746 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 96.1 mt -73.9 -47.64 42.23 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.229 0 N-CA-C 111.875 0.324 . . . . 0.0 111.875 -179.537 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 101' ' ' VAL . . . . . 0.41 HG11 ' HE3' ' A' ' 145' ' ' MET . 27.7 m -69.49 -39.01 78.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 N-CA-C 111.731 0.271 . . . . 0.0 111.731 -179.353 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 102' ' ' ILE . . . . . 0.453 HG12 ' O ' ' A' ' 98' ' ' PHE . 43.3 mm -67.67 -46.55 82.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.55 -0.296 . . . . 0.0 111.347 -179.54 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 14.7 t -62.42 -33.27 74.46 Favored 'General case' 0 C--O 1.233 0.187 0 CA-C-O 120.975 0.417 . . . . 0.0 110.404 179.643 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -58.84 -52.04 67.42 Favored 'General case' 0 C--N 1.332 -0.191 0 CA-C-N 115.995 -0.548 . . . . 0.0 109.528 179.248 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 105' ' ' ASN . . . . . 0.567 ' N ' HD22 ' A' ' 105' ' ' ASN . 0.8 OUTLIER -56.72 -35.45 68.56 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 115.736 -0.666 . . . . 0.0 110.53 179.455 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 39.3 m -55.6 -50.9 68.88 Favored 'General case' 0 C--N 1.332 -0.169 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.996 179.918 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 107' ' ' VAL . . . . . 0.409 ' H ' HG23 ' A' ' 107' ' ' VAL . 0.9 OUTLIER -60.5 -39.67 81.97 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.223 0 CA-C-O 121.174 0.512 . . . . 0.0 110.39 179.6 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 81.0 t -63.66 -39.91 87.12 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-N 115.506 -0.77 . . . . 0.0 111.285 -179.821 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 109' ' ' MET . . . . . 0.544 ' HG3' ' HA ' ' A' ' 77' ' ' ILE . 28.6 mmt -67.17 -51.35 54.8 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.078 -0.51 . . . . 0.0 111.329 -179.568 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 21.1 tp -58.95 -34.73 72.09 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-N 115.96 -0.564 . . . . 0.0 110.927 -179.592 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -61.11 -57.09 13.98 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.18 -179.994 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . -67.23 -28.03 73.62 Favored Glycine 0 N--CA 1.45 -0.374 0 C-N-CA 120.724 -0.75 . . . . 0.0 112.143 179.68 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 113' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER -57.67 -75.09 0.05 OUTLIER 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 121.035 0.445 . . . . 0.0 110.132 179.817 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -61.45 -26.43 67.87 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 115.793 -0.639 . . . . 0.0 111.095 179.771 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -53.06 -50.07 52.97 Favored Glycine 0 C--N 1.331 0.28 0 C-N-CA 121.028 -0.606 . . . . 0.0 112.616 -179.974 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 116' ' ' ALA . . . . . 0.571 ' HB2' ' HB3' ' A' ' 183' ' ' PRO . . . -77.65 -16.42 58.54 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.672 0.272 . . . . 0.0 111.613 -179.739 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 117' ' ' MET . . . . . 0.431 ' HG3' HG21 ' A' ' 68' ' ' VAL . 29.7 ttm -101.85 19.22 18.69 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.407 -0.361 . . . . 0.0 111.341 -179.506 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 118' ' ' VAL . . . . . 0.58 HG21 ' HB3' ' A' ' 123' ' ' ARG . 21.4 m -70.15 145.49 93.75 Favored Pre-proline 0 C--N 1.33 -0.245 0 CA-C-N 116.432 -0.349 . . . . 0.0 111.502 179.982 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 119' ' ' PRO . . . . . . . . . . . . . 85.9 Cg_endo -93.4 15.8 1.33 Allowed 'Trans proline' 0 N--CA 1.456 -0.732 0 C-N-CA 122.997 2.465 . . . . 0.0 112.353 179.419 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -164.62 -120.38 0.52 Allowed Glycine 0 C--N 1.332 0.339 0 C-N-CA 120.66 -0.781 . . . . 0.0 112.674 -179.564 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 40.9 pt -114.68 9.84 7.74 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.232 0 CA-C-O 120.723 0.297 . . . . 0.0 111.493 -179.727 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 45.7 mt-10 -58.84 -18.08 29.48 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.304 -0.407 . . . . 0.0 110.699 179.725 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 123' ' ' ARG . . . . . 0.58 ' HB3' HG21 ' A' ' 118' ' ' VAL . 10.2 ptp180 -50.5 -33.24 20.65 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 115.794 -0.639 . . . . 0.0 111.642 -179.959 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 124' ' ' TYR . . . . . . . . . . . . . 19.3 m-85 -73.11 -32.63 65.07 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.428 -0.351 . . . . 0.0 111.513 -179.459 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 125' ' ' ALA . . . . . . . . . . . . . . . -74.32 -56.11 5.25 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.386 -0.37 . . . . 0.0 111.398 -179.492 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -55.09 -44.19 74.66 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.904 -179.931 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 127' ' ' PHE . . . . . . . . . . . . . 5.4 t80 -70.92 -37.21 72.89 Favored 'General case' 0 C--N 1.33 -0.279 0 C-N-CA 120.898 -0.321 . . . . 0.0 110.575 179.825 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 128' ' ' GLY . . . . . . . . . . . . . . . -46.79 -46.85 19.03 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.167 -1.016 . . . . 0.0 110.844 179.052 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 129' ' ' MET . . . . . . . . . . . . . 0.4 OUTLIER -69.69 -38.84 77.16 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 115.367 -0.417 . . . . 0.0 109.894 178.781 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -62.87 -29.3 73.71 Favored Glycine 0 C--N 1.333 0.38 0 CA-C-N 115.892 -0.595 . . . . 0.0 112.792 -179.893 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 131' ' ' ALA . . . . . 0.402 ' O ' ' HB3' ' A' ' 134' ' ' PHE . . . -74.29 -53.61 9.37 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 120.761 0.315 . . . . 0.0 110.317 179.871 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 28.3 t -58.03 -40.07 75.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 N-CA-C 109.321 -0.622 . . . . 0.0 109.321 178.741 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -68.64 -33.4 73.94 Favored 'General case' 0 N--CA 1.454 -0.259 0 CA-C-N 115.387 -0.824 . . . . 0.0 110.342 179.177 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 134' ' ' PHE . . . . . 0.402 ' HB3' ' O ' ' A' ' 131' ' ' ALA . 44.1 t80 -57.77 -55.14 38.7 Favored 'General case' 0 N--CA 1.452 -0.34 0 CA-C-N 116.132 -0.486 . . . . 0.0 109.752 179.239 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 135' ' ' ILE . . . . . 0.46 ' O ' HG22 ' A' ' 138' ' ' VAL . 39.2 mt -57.69 -31.87 40.97 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 115.673 -0.694 . . . . 0.0 109.86 178.861 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . -64.19 -35.31 91.81 Favored Glycine 0 N--CA 1.448 -0.515 0 C-N-CA 120.488 -0.863 . . . . 0.0 111.577 179.13 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 137' ' ' LEU . . . . . . . . . . . . . 38.9 tp -73.44 -51.13 18.3 Favored 'General case' 0 C--N 1.331 -0.205 0 CA-C-O 120.628 0.252 . . . . 0.0 110.51 179.492 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 138' ' ' VAL . . . . . 0.46 HG22 ' O ' ' A' ' 135' ' ' ILE . 4.0 m -57.37 -30.96 37.04 Favored 'Isoleucine or valine' 0 C--O 1.233 0.208 0 N-CA-C 109.376 -0.601 . . . . 0.0 109.376 179.048 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 139' ' ' TYR . . . . . . . . . . . . . 24.9 t80 -66.19 -43.34 87.12 Favored 'General case' 0 C--N 1.332 -0.196 0 CA-C-N 115.324 -0.853 . . . . 0.0 110.15 178.706 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 140' ' ' TYR . . . . . 0.435 ' HB3' ' SD ' ' A' ' 145' ' ' MET . 11.9 m-85 -53.06 -51.62 61.22 Favored 'General case' 0 C--O 1.231 0.13 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.514 179.355 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 141' ' ' LEU . . . . . . . . . . . . . 70.5 mt -53.39 -53.56 49.39 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 115.726 -0.67 . . . . 0.0 111.213 -179.788 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 17.2 t -73.42 -11.29 14.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.113 -0.494 . . . . 0.0 111.334 -179.623 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . -71.45 -140.91 0.26 Allowed Glycine 0 CA--C 1.52 0.354 0 C-N-CA 120.832 -0.699 . . . . 0.0 112.635 -179.799 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 144' ' ' PRO . . . . . . . . . . . . . 32.2 Cg_endo -62.99 -23.25 74.08 Favored 'Trans proline' 0 C--N 1.347 0.493 0 C-N-CA 122.486 2.124 . . . . 0.0 112.121 -179.991 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 145' ' ' MET . . . . . 0.435 ' SD ' ' HB3' ' A' ' 140' ' ' TYR . 82.4 mtp -57.61 -27.9 63.18 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 116.024 -0.535 . . . . 0.0 110.975 179.921 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 146' ' ' THR . . . . . . . . . . . . . 60.0 m -71.89 -40.79 68.64 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.308 -0.406 . . . . 0.0 111.042 179.82 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 2.2 mp0 -74.25 -27.57 60.83 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.008 -179.835 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 148' ' ' SER . . . . . . . . . . . . . 49.1 m -70.19 -43.16 71.33 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.388 -0.369 . . . . 0.0 111.085 -179.882 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 149' ' ' ALA . . . . . 0.458 ' HA ' ' HA ' ' A' ' 91' ' ' ALA . . . -77.84 -44.08 28.41 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.845 -179.457 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 150' ' ' SER . . . . . . . . . . . . . 66.3 m -63.72 -21.97 66.67 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.388 -0.369 . . . . 0.0 111.443 -179.451 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 151' ' ' GLN . . . . . . . . . . . . . 78.7 mt-30 -106.87 6.49 29.41 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.51 -0.314 . . . . 0.0 111.298 -179.784 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 30.2 tpt180 -82.58 -50.31 8.92 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.437 -0.347 . . . . 0.0 110.729 179.823 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 153' ' ' SER . . . . . 0.514 ' HB2' HG13 ' A' ' 156' ' ' ILE . 45.8 m -154.55 149.34 26.59 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.824 179.267 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 154' ' ' SER . . . . . . . . . . . . . 42.7 t -55.24 -40.37 70.83 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.113 -0.494 . . . . 0.0 111.055 179.947 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 155' ' ' GLY . . . . . 0.404 ' O ' ' HG ' ' A' ' 159' ' ' LEU . . . -75.01 -35.93 48.23 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.79 -0.719 . . . . 0.0 112.562 179.994 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 156' ' ' ILE . . . . . 0.514 HG13 ' HB2' ' A' ' 153' ' ' SER . 68.9 mt -60.95 -36.22 70.58 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-O 120.707 0.289 . . . . 0.0 111.307 -179.948 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 157' ' ' LYS . . . . . 0.402 ' O ' HG13 ' A' ' 161' ' ' VAL . 88.6 tttt -52.9 -45.66 67.64 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-N 116.187 -0.461 . . . . 0.0 111.499 -179.783 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 48.4 t -71.83 -37.41 70.32 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 121.003 0.43 . . . . 0.0 111.29 -179.558 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 159' ' ' LEU . . . . . 0.404 ' HG ' ' O ' ' A' ' 155' ' ' GLY . 78.0 mt -65.85 -39.18 90.52 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-N 115.936 -0.575 . . . . 0.0 111.643 -179.413 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 160' ' ' TYR . . . . . . . . . . . . . 45.5 t80 -73.94 -44.37 55.19 Favored 'General case' 0 C--N 1.327 -0.401 0 N-CA-C 112.155 0.428 . . . . 0.0 112.155 -178.647 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 161' ' ' VAL . . . . . 0.402 HG13 ' O ' ' A' ' 157' ' ' LYS . 30.8 m -59.86 -43.96 93.15 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 N-CA-C 112.226 0.454 . . . . 0.0 112.226 -178.916 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 162' ' ' ARG . . . . . 0.541 ' O ' HD12 ' A' ' 166' ' ' LEU . 93.8 mtt180 -69.16 -50.74 44.98 Favored 'General case' 0 C--N 1.33 -0.269 0 N-CA-C 112.18 0.437 . . . . 0.0 112.18 -179.134 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 163' ' ' LEU . . . . . . . . . . . . . 7.5 mp -65.71 -43.83 87.92 Favored 'General case' 0 C--N 1.33 -0.254 0 N-CA-C 111.789 0.292 . . . . 0.0 111.789 -179.06 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 164' ' ' ARG . . . . . . . . . . . . . 6.1 tmm_? -57.42 -50.98 71.26 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-N 116.56 -0.291 . . . . 0.0 111.004 -179.693 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 165' ' ' ASN . . . . . 0.508 HD22 ' N ' ' A' ' 165' ' ' ASN . 0.9 OUTLIER -53.04 -44.99 67.81 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-O 120.934 0.397 . . . . 0.0 110.346 179.809 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 166' ' ' LEU . . . . . 0.541 HD12 ' O ' ' A' ' 162' ' ' ARG . 1.5 mt -60.05 -48.65 80.82 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 115.931 -0.577 . . . . 0.0 111.2 179.478 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 167' ' ' THR . . . . . 0.624 ' HA ' HD11 ' A' ' 170' ' ' LEU . 12.0 m -53.68 -51.0 64.59 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.021 -0.536 . . . . 0.0 112.218 -178.265 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 168' ' ' VAL . . . . . . . . . . . . . 27.0 t -59.26 -40.6 81.66 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.566 0 N-CA-C 112.105 0.409 . . . . 0.0 112.105 -179.061 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 169' ' ' VAL . . . . . 0.486 HG23 ' O ' ' A' ' 165' ' ' ASN . 83.9 t -66.08 -66.82 0.45 Allowed 'Isoleucine or valine' 0 CA--C 1.533 0.3 0 N-CA-C 113.557 0.947 . . . . 0.0 113.557 -178.194 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 170' ' ' LEU . . . . . 0.624 HD11 ' HA ' ' A' ' 167' ' ' THR . 0.4 OUTLIER -61.66 -32.18 72.34 Favored 'General case' 0 N--CA 1.467 0.388 0 N-CA-C 112.974 0.731 . . . . 0.0 112.974 -177.529 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 171' ' ' TRP . . . . . 0.5 ' H ' HD12 ' A' ' 170' ' ' LEU . 21.4 m0 -73.53 -29.54 62.52 Favored 'General case' 0 C--N 1.329 -0.323 0 C-N-CA 120.371 -0.531 . . . . 0.0 111.087 -179.619 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 172' ' ' ALA . . . . . . . . . . . . . . . -72.24 -7.87 51.68 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-O 121.011 0.434 . . . . 0.0 110.253 179.499 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 173' ' ' ILE . . . . . 0.552 HG22 HD11 ' A' ' 177' ' ' ILE . 18.5 mm -88.92 -25.42 5.75 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.21 0 CA-C-N 115.789 -0.642 . . . . 0.0 110.939 179.528 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 174' ' ' TYR . . . . . 0.491 ' HD1' ' HA ' ' A' ' 171' ' ' TRP . 16.1 m-85 -54.62 -48.54 94.94 Favored Pre-proline 0 CA--C 1.531 0.218 0 CA-C-N 116.104 -0.498 . . . . 0.0 112.156 -179.384 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 175' ' ' PRO . . . . . . . . . . . . . 74.8 Cg_exo -47.07 -29.99 9.55 Favored 'Trans proline' 0 C--N 1.352 0.747 0 C-N-CA 121.909 1.739 . . . . 0.0 111.808 179.677 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 176' ' ' PHE . . . . . 0.497 ' O ' ' HG ' ' A' ' 180' ' ' LEU . 72.0 m-85 -80.35 -49.89 10.89 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 115.713 -0.676 . . . . 0.0 111.37 179.687 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 177' ' ' ILE . . . . . 0.552 HD11 HG22 ' A' ' 173' ' ' ILE . 3.6 mm -59.28 -36.25 62.5 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.525 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.722 -178.632 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 178' ' ' TRP . . . . . 0.407 ' O ' ' HB2' ' A' ' 183' ' ' PRO . 58.7 t90 -73.3 -51.82 16.18 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-O 121.066 0.46 . . . . 0.0 110.658 179.879 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 179' ' ' LEU . . . . . 0.563 HD13 HG22 ' A' ' 185' ' ' VAL . 1.4 tm? -61.07 -53.4 57.54 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 115.701 -0.681 . . . . 0.0 111.56 -179.159 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 180' ' ' LEU . . . . . 0.723 HD22 HD11 ' A' ' 187' ' ' LEU . 12.5 mt -74.78 -29.47 61.13 Favored 'General case' 0 C--N 1.327 -0.385 0 N-CA-C 112.2 0.444 . . . . 0.0 112.2 -178.861 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . -71.42 -177.66 27.28 Favored Glycine 0 N--CA 1.45 -0.407 0 C-N-CA 119.977 -1.106 . . . . 0.0 112.173 179.777 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 182' ' ' PRO . . . . . 0.427 ' N ' ' HD2' ' A' ' 183' ' ' PRO . 76.8 Cg_exo -47.93 -43.36 30.05 Favored 'Trans proline' 0 CA--C 1.538 0.681 0 C-N-CA 122.649 2.233 . . . . 0.0 113.386 179.527 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 183' ' ' PRO . . . . . 0.571 ' HB3' ' HB2' ' A' ' 116' ' ' ALA . 65.9 Cg_exo -41.54 -31.87 1.27 Allowed 'Trans proline' 0 C--N 1.358 1.046 0 C-N-CA 122.609 2.206 . . . . 0.0 113.601 179.824 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 184' ' ' GLY . . . . . . . . . . . . . . . -130.03 -107.65 1.24 Allowed Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.413 -0.899 . . . . 0.0 112.323 180.0 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 185' ' ' VAL . . . . . 0.563 HG22 HD13 ' A' ' 179' ' ' LEU . 27.4 m -92.41 89.87 2.96 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.44 0 CA-C-O 121.414 0.626 . . . . 0.0 110.365 179.668 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 186' ' ' ALA . . . . . . . . . . . . . . . -56.94 86.7 0.01 OUTLIER 'General case' 0 C--N 1.325 -0.491 0 CA-C-N 115.687 -0.688 . . . . 0.0 111.855 -179.448 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 187' ' ' LEU . . . . . 0.723 HD11 HD22 ' A' ' 180' ' ' LEU . 12.5 mt -74.8 -48.91 22.8 Favored 'General case' 0 C--N 1.331 -0.199 0 CA-C-O 120.985 0.422 . . . . 0.0 110.361 179.236 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 188' ' ' LEU . . . . . . . . . . . . . 63.4 mt -97.8 -147.97 0.32 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 115.775 -0.648 . . . . 0.0 110.65 -179.87 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 189' ' ' THR . . . . . . . . . . . . . 1.2 t -111.8 148.46 39.0 Favored Pre-proline 0 C--N 1.331 -0.231 0 CA-C-N 116.276 -0.42 . . . . 0.0 110.813 -179.964 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 190' ' ' PRO . . . . . 0.406 ' O ' HG23 ' A' ' 194' ' ' VAL . 7.3 Cg_endo -49.12 -42.14 39.75 Favored 'Trans proline' 0 C--N 1.349 0.57 0 C-N-CA 123.027 2.485 . . . . 0.0 113.261 -179.474 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 191' ' ' THR . . . . . . . . . . . . . 7.6 t -59.54 -40.86 88.6 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.65 0.262 . . . . 0.0 111.598 -179.341 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 192' ' ' VAL . . . . . . . . . . . . . 42.3 t -71.94 -47.92 53.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.499 -0.319 . . . . 0.0 111.398 -179.809 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 193' ' ' ASP . . . . . . . . . . . . . 30.7 t70 -57.99 -51.2 70.65 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.742 0.306 . . . . 0.0 111.038 -179.815 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 194' ' ' VAL . . . . . 0.406 HG23 ' O ' ' A' ' 190' ' ' PRO . 97.8 t -59.88 -36.15 64.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.883 179.973 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 195' ' ' ALA . . . . . . . . . . . . . . . -58.1 -46.1 86.1 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.542 -0.299 . . . . 0.0 110.942 179.697 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 196' ' ' LEU . . . . . . . . . . . . . 86.3 mt -65.69 -41.34 92.5 Favored 'General case' 0 C--N 1.332 -0.171 0 CA-C-N 116.368 -0.378 . . . . 0.0 110.404 179.596 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 197' ' ' ILE . . . . . 0.434 HG23 ' HZ2' ' A' ' 76' ' ' TRP . 19.9 mm -58.56 -58.26 7.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 115.995 -0.548 . . . . 0.0 110.239 179.366 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 198' ' ' VAL . . . . . . . . . . . . . 94.6 t -53.27 -34.52 22.39 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.416 0 CA-C-N 115.736 -0.665 . . . . 0.0 109.276 178.281 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 199' ' ' TYR . . . . . . . . . . . . . 65.4 t80 -69.7 -33.66 72.83 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 115.295 -0.866 . . . . 0.0 110.519 179.604 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 200' ' ' LEU . . . . . . . . . . . . . 40.7 mt -69.6 -39.62 77.14 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 115.855 -0.611 . . . . 0.0 111.019 -179.807 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 201' ' ' ASP . . . . . 0.455 ' HB3' ' NZ ' ' A' ' 205' ' ' LYS . 9.6 m-20 -72.86 -32.23 65.28 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.41 179.749 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 202' ' ' LEU . . . . . 0.466 ' O ' ' HB ' ' A' ' 206' ' ' VAL . 3.7 mt -73.04 -33.13 65.51 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 115.656 -0.702 . . . . 0.0 112.014 -179.376 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 203' ' ' VAL . . . . . 0.45 ' O ' ' HA3' ' A' ' 207' ' ' GLY . 7.8 p -77.9 -36.66 22.39 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-O 120.582 0.23 . . . . 0.0 111.432 -178.801 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 204' ' ' THR . . . . . . . . . . . . . 19.1 m -68.91 -53.62 20.06 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-O 120.877 0.37 . . . . 0.0 111.407 -179.956 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 205' ' ' LYS . . . . . 0.625 ' HE3' HG22 ' A' ' 43' ' ' ILE . 43.9 mttp -70.73 -58.68 3.39 Favored 'General case' 0 C--N 1.327 -0.405 0 N-CA-C 112.435 0.531 . . . . 0.0 112.435 -178.569 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 206' ' ' VAL . . . . . 0.466 ' HB ' ' O ' ' A' ' 202' ' ' LEU . 48.1 t -72.25 -37.43 58.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 N-CA-C 111.952 0.353 . . . . 0.0 111.952 -178.878 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 207' ' ' GLY . . . . . 0.514 ' O ' HG13 ' A' ' 211' ' ' ILE . . . -65.37 -59.88 7.32 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.442 -0.885 . . . . 0.0 112.516 -179.366 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 208' ' ' PHE . . . . . 0.482 ' O ' ' N ' ' A' ' 212' ' ' ALA . 2.1 m-30 -54.19 -45.17 72.1 Favored 'General case' 0 C--O 1.222 -0.388 0 N-CA-C 109.947 -0.39 . . . . 0.0 109.947 179.772 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 209' ' ' GLY . . . . . 0.498 ' HA2' ' HB3' ' A' ' 212' ' ' ALA . . . -59.07 -34.22 78.28 Favored Glycine 0 N--CA 1.448 -0.515 0 CA-C-N 115.376 -0.829 . . . . 0.0 112.821 179.43 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 210' ' ' PHE . . . . . . . . . . . . . 1.2 m-85 -70.26 -46.8 63.67 Favored 'General case' 0 CA--C 1.515 -0.369 0 N-CA-C 108.754 -0.832 . . . . 0.0 108.754 179.163 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 211' ' ' ILE . . . . . 0.514 HG13 ' O ' ' A' ' 207' ' ' GLY . 2.6 mt -67.4 -27.42 38.7 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.473 0 N-CA-C 107.416 -1.327 . . . . 0.0 107.416 176.846 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 212' ' ' ALA . . . . . 0.498 ' HB3' ' HA2' ' A' ' 209' ' ' GLY . . . -66.84 -40.09 87.83 Favored 'General case' 0 N--CA 1.449 -0.525 0 CA-C-N 114.32 -1.309 . . . . 0.0 110.214 -179.991 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 213' ' ' LEU . . . . . 0.467 ' HG ' ' O ' ' A' ' 209' ' ' GLY . 69.7 mt -70.68 -54.77 10.59 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 114.991 -1.004 . . . . 0.0 111.744 -179.555 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 214' ' ' ASP . . . . . . . . . . . . . 20.6 t70 -54.38 -47.19 72.95 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-O 120.758 0.313 . . . . 0.0 111.42 -179.464 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 215' ' ' ALA . . . . . . . . . . . . . . . -63.69 -56.17 17.8 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.309 -0.405 . . . . 0.0 111.171 -179.781 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 216' ' ' ALA . . . . . . . . . . . . . . . -56.24 -31.22 63.33 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.834 179.924 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 217' ' ' ALA . . . . . . . . . . . . . . . -65.97 -40.56 91.38 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 115.991 -0.549 . . . . 0.0 110.431 179.767 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 218' ' ' THR . . . . . . . . . . . . . 72.7 m . . . . . 0 C--N 1.329 -0.299 0 CA-C-N 115.957 -0.565 . . . . 0.0 110.437 179.41 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.251 0 N-CA-C 112.685 -0.166 . . . . 0.0 112.685 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 96.6 mt -61.04 -35.44 76.91 Favored 'General case' 0 N--CA 1.448 -0.529 0 CA-C-O 120.758 0.313 . . . . 0.0 111.118 179.961 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 46.6 p -51.48 -36.92 46.52 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 116.013 -0.54 . . . . 0.0 111.68 -179.472 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 20.4 p -56.79 -38.94 73.23 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.209 -0.451 . . . . 0.0 111.576 -179.542 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 7' ' ' LEU . . . . . . . . . . . . . 3.9 mm? -61.81 -53.51 54.88 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.265 -0.425 . . . . 0.0 111.304 -179.716 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 8' ' ' PHE . . . . . 0.425 ' HB2' ' HB2' ' A' ' 55' ' ' ALA . 68.5 m-85 -55.43 -31.93 62.3 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.255 -0.429 . . . . 0.0 111.108 -179.607 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 9' ' ' TRP . . . . . 0.415 ' O ' HG12 ' A' ' 13' ' ' ILE . 21.7 m95 -66.01 -42.78 89.26 Favored 'General case' 0 C--N 1.326 -0.447 0 N-CA-C 109.695 -0.484 . . . . 0.0 109.695 179.694 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 84.6 mt -61.08 -38.97 88.14 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 115.62 -0.718 . . . . 0.0 110.238 179.223 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -65.84 -35.55 91.0 Favored Glycine 0 N--CA 1.449 -0.437 0 C-N-CA 120.85 -0.691 . . . . 0.0 111.865 179.349 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -65.6 -32.58 74.23 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-O 120.892 0.377 . . . . 0.0 110.672 179.585 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 13' ' ' ILE . . . . . 0.415 HG12 ' O ' ' A' ' 9' ' ' TRP . 50.5 mm -67.35 -51.03 56.94 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.245 0 CA-C-N 116.034 -0.53 . . . . 0.0 110.654 179.667 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -58.6 -31.6 67.45 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.141 179.669 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 15' ' ' MET . . . . . 0.567 ' HB3' ' HB2' ' A' ' 48' ' ' ALA . 23.9 mmt -69.89 -40.91 75.38 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-O 120.722 0.296 . . . . 0.0 110.64 179.661 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -57.47 -43.66 84.23 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.307 179.54 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 42.5 t -61.41 -49.83 82.86 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.214 0 CA-C-N 116.065 -0.516 . . . . 0.0 110.955 179.846 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -62.36 -48.27 83.59 Favored Glycine 0 C--N 1.331 0.285 0 C-N-CA 120.651 -0.785 . . . . 0.0 112.206 179.708 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 50.3 m -49.93 -41.13 45.55 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-O 120.67 0.271 . . . . 0.0 111.378 -179.754 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 52.3 mt -72.53 -46.06 56.35 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.329 -0.396 . . . . 0.0 111.41 179.903 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -60.59 -29.71 69.37 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.315 -0.402 . . . . 0.0 111.654 -179.604 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 22' ' ' PHE . . . . . 0.601 ' HB2' HG22 ' A' ' 41' ' ' VAL . 5.1 m-85 -91.23 -30.01 16.88 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.515 -0.311 . . . . 0.0 111.436 -179.56 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -72.66 -50.55 24.26 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-O 120.949 0.404 . . . . 0.0 110.997 -179.971 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 24' ' ' TRP . . . . . . . . . . . . . 2.8 t-105 -61.23 -39.49 90.48 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-N 115.737 -0.665 . . . . 0.0 110.501 179.806 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.329 -0.321 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.756 179.549 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.257 0 N-CA-C 112.6 -0.2 . . . . 0.0 112.6 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 22.8 mm-40 -61.31 -21.14 63.7 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.757 0.313 . . . . 0.0 111.007 -179.935 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 34' ' ' ARG . . . . . . . . . . . . . 48.6 ttp180 -51.17 -29.63 14.4 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 116.043 -0.526 . . . . 0.0 111.271 -179.959 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 35' ' ' ARG . . . . . 0.439 ' CZ ' HD22 ' A' ' 89' ' ' LEU . 51.8 ttp180 -59.47 -48.19 82.58 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.326 -0.397 . . . . 0.0 111.075 -179.994 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 53.5 m-85 -64.43 -34.61 78.59 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.984 -179.922 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 37' ' ' TYR . . . . . 0.468 ' O ' HG23 ' A' ' 41' ' ' VAL . 63.6 m-85 -66.84 -54.15 25.32 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 115.993 -0.549 . . . . 0.0 111.05 -179.762 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 77.7 t -56.98 -37.05 52.67 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.242 0 CA-C-O 120.889 0.376 . . . . 0.0 110.455 179.723 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 24.2 m -66.73 -40.24 88.27 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 121.355 0.598 . . . . 0.0 110.171 179.044 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 40' ' ' LEU . . . . . 0.503 HD11 ' HA2' ' A' ' 209' ' ' GLY . 12.7 tp -65.5 -41.87 92.75 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 115.258 -0.883 . . . . 0.0 110.372 179.757 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . 0.601 HG22 ' HB2' ' A' ' 22' ' ' PHE . 59.7 t -69.68 -34.17 59.85 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.426 0 CA-C-N 115.561 -0.745 . . . . 0.0 110.312 179.379 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 42' ' ' GLY . . . . . 0.463 ' O ' HG12 ' A' ' 46' ' ' ILE . . . -59.26 -46.57 93.63 Favored Glycine 0 N--CA 1.448 -0.541 0 C-N-CA 120.971 -0.633 . . . . 0.0 112.554 179.999 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 43' ' ' ILE . . . . . 0.554 HG23 HD23 ' A' ' 82' ' ' LEU . 10.2 pt -65.63 -51.57 61.21 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.157 0 N-CA-C 111.729 0.27 . . . . 0.0 111.729 -179.767 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 48.1 t -63.84 -24.19 67.65 Favored 'General case' 0 C--O 1.234 0.247 0 CA-C-O 120.924 0.392 . . . . 0.0 111.396 -179.762 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -78.14 -59.05 3.02 Favored Glycine 0 CA--C 1.518 0.22 0 C-N-CA 120.92 -0.657 . . . . 0.0 113.466 -178.856 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 46' ' ' ILE . . . . . 0.498 ' O ' HG22 ' A' ' 49' ' ' VAL . 17.7 pt -57.79 -35.29 50.62 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.207 0 CA-C-O 120.751 0.31 . . . . 0.0 110.957 -179.606 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 47' ' ' ALA . . . . . 0.682 ' HB2' ' HE2' ' A' ' 205' ' ' LYS . . . -67.62 -40.12 84.7 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-O 120.841 0.353 . . . . 0.0 110.085 178.559 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 48' ' ' ALA . . . . . 0.567 ' HB2' ' HB3' ' A' ' 15' ' ' MET . . . -54.48 -43.39 71.69 Favored 'General case' 0 C--N 1.334 -0.101 0 CA-C-N 115.987 -0.551 . . . . 0.0 111.291 179.801 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 49' ' ' VAL . . . . . 0.498 HG22 ' O ' ' A' ' 46' ' ' ILE . 21.4 m -75.62 -34.36 28.88 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.221 0 CA-C-N 116.463 -0.335 . . . . 0.0 111.452 -179.82 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -59.12 -45.5 90.75 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.824 0.345 . . . . 0.0 111.392 -179.849 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 57.6 m-85 -73.16 -40.15 65.08 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 115.919 -0.582 . . . . 0.0 111.257 -179.31 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -60.64 -47.03 88.04 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 115.886 -0.597 . . . . 0.0 111.318 -179.921 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 53' ' ' VAL . . . . . 0.469 HG13 ' O ' ' A' ' 49' ' ' VAL . 16.8 m -71.89 -43.14 69.07 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.243 0 CA-C-N 116.324 -0.398 . . . . 0.0 110.969 -179.876 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 54' ' ' MET . . . . . 0.429 ' N ' HG23 ' A' ' 53' ' ' VAL . 17.0 ttp -63.71 -29.49 70.71 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 121.085 0.469 . . . . 0.0 110.101 179.509 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 55' ' ' ALA . . . . . 0.425 ' HB2' ' HB2' ' A' ' 8' ' ' PHE . . . -63.84 -36.22 83.2 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 115.63 -0.714 . . . . 0.0 111.539 179.773 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 78.6 mt -80.99 13.15 2.85 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.475 -0.33 . . . . 0.0 111.427 -179.626 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 84.39 -2.21 88.09 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.638 -0.792 . . . . 0.0 112.87 179.712 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 55.0 t -68.83 141.69 17.14 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-O 120.732 0.301 . . . . 0.0 110.768 179.777 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 59' ' ' GLY . . . . . 0.623 ' HA3' ' HD3' ' A' ' 71' ' ' PRO . . . 86.18 -16.07 45.62 Favored Glycine 0 N--CA 1.45 -0.411 0 C-N-CA 120.595 -0.812 . . . . 0.0 112.275 -179.857 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 60' ' ' TRP . . . . . . . . . . . . . 13.7 m0 -66.88 92.94 0.24 Allowed 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 120.825 0.345 . . . . 0.0 110.602 179.665 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 7.1 p -96.23 123.25 55.57 Favored Pre-proline 0 C--N 1.328 -0.347 0 CA-C-N 116.303 -0.408 . . . . 0.0 111.211 -179.832 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 46.5 Cg_endo -68.41 141.03 49.89 Favored 'Trans proline' 0 C--N 1.35 0.649 0 C-N-CA 122.403 2.068 . . . . 0.0 112.231 179.93 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . 0.411 HG21 ' HG3' ' A' ' 117' ' ' MET . 60.2 t -137.31 92.69 0.91 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.046 -0.525 . . . . 0.0 111.172 -179.789 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . 58.09 -88.93 0.02 OUTLIER 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 116.178 -0.465 . . . . 0.0 111.514 179.789 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 45.4 mt-10 -120.42 -17.98 8.01 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 116.486 -0.324 . . . . 0.0 110.856 179.973 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 66' ' ' ARG . . . . . . . . . . . . . 20.9 mmm180 -105.03 165.51 11.03 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 116.064 -0.516 . . . . 0.0 110.344 179.776 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 38.4 m -122.52 143.15 49.9 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-O 120.834 0.349 . . . . 0.0 111.201 -179.805 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 40.0 t -125.19 146.0 31.6 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.02 -0.537 . . . . 0.0 110.879 -179.991 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 69' ' ' PHE . . . . . . . . . . . . . 8.3 m-85 -109.31 114.32 27.9 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.371 -0.377 . . . . 0.0 110.161 179.837 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 70' ' ' VAL . . . . . 0.67 HG12 ' HD3' ' A' ' 71' ' ' PRO . 1.3 p -68.26 -35.64 7.58 Favored Pre-proline 0 CA--C 1.542 0.653 0 N-CA-C 112.945 0.72 . . . . 0.0 112.945 -179.34 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 71' ' ' PRO . . . . . 0.67 ' HD3' HG12 ' A' ' 70' ' ' VAL . 61.9 Cg_endo -71.16 -20.82 27.97 Favored 'Trans proline' 0 C--N 1.359 1.116 0 C-N-CA 121.822 1.681 . . . . 0.0 113.266 -179.352 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 66.7 ttt180 -74.23 -54.96 6.65 Favored 'General case' 0 C--N 1.329 -0.32 0 N-CA-C 112.019 0.377 . . . . 0.0 112.019 -178.993 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 73' ' ' TYR . . . . . 0.481 ' O ' HG13 ' A' ' 77' ' ' ILE . 65.9 m-85 -74.08 -32.84 63.42 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.533 -0.303 . . . . 0.0 111.526 -178.803 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 74' ' ' ILE . . . . . 0.467 ' O ' HD13 ' A' ' 74' ' ' ILE . 0.3 OUTLIER -70.23 -44.53 77.72 Favored 'Isoleucine or valine' 0 C--O 1.234 0.257 0 C-N-CA 120.615 -0.434 . . . . 0.0 110.18 179.486 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 75' ' ' ASP . . . . . 0.444 ' O ' HG23 ' A' ' 79' ' ' THR . 22.9 t70 -58.33 -35.89 72.58 Favored 'General case' 0 CA--C 1.52 -0.2 0 N-CA-C 109.094 -0.706 . . . . 0.0 109.094 178.959 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 76' ' ' TRP . . . . . 0.424 ' HA ' ' OG1' ' A' ' 79' ' ' THR . 44.7 m0 -64.95 -34.9 79.53 Favored 'General case' 0 C--N 1.332 -0.164 0 CA-C-N 115.769 -0.651 . . . . 0.0 110.228 178.801 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 77' ' ' ILE . . . . . 0.51 HG12 ' HB3' ' A' ' 109' ' ' MET . 98.0 mt -66.21 -30.42 49.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 115.981 -0.554 . . . . 0.0 110.745 179.561 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 82.0 mt -91.88 -17.89 24.58 Favored 'General case' 0 CA--C 1.532 0.257 0 N-CA-C 112.278 0.473 . . . . 0.0 112.278 179.644 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 79' ' ' THR . . . . . 0.444 HG23 ' O ' ' A' ' 75' ' ' ASP . 46.9 p -94.65 -51.65 4.64 Favored 'General case' 0 N--CA 1.465 0.319 0 N-CA-C 112.974 0.731 . . . . 0.0 112.974 -178.486 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 80' ' ' THR . . . . . 0.71 HG21 ' HE1' ' A' ' 109' ' ' MET . 27.5 m -50.25 -51.03 66.81 Favored Pre-proline 0 C--N 1.328 -0.354 0 N-CA-C 112.95 0.722 . . . . 0.0 112.95 -178.425 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 81' ' ' PRO . . . . . 0.531 ' HD2' ' N ' ' A' ' 80' ' ' THR . 19.4 Cg_endo -57.94 -23.57 60.44 Favored 'Trans proline' 0 C--N 1.352 0.732 0 C-N-CA 121.526 1.484 . . . . 0.0 111.703 -179.48 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 82' ' ' LEU . . . . . 0.554 HD23 HG23 ' A' ' 43' ' ' ILE . 3.5 mp -76.91 -38.36 53.63 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 115.923 -0.58 . . . . 0.0 110.704 179.834 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 49.9 mm -65.42 -53.44 39.82 Favored 'Isoleucine or valine' 0 C--O 1.234 0.267 0 CA-C-O 120.936 0.398 . . . . 0.0 110.221 179.371 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 26.8 m -60.68 -31.66 49.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.04 -0.527 . . . . 0.0 109.774 178.983 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 85' ' ' TYR . . . . . . . . . . . . . 87.7 t80 -67.81 -34.09 76.07 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-N 115.697 -0.683 . . . . 0.0 109.442 178.755 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 86' ' ' PHE . . . . . . . . . . . . . 1.8 t80 -58.95 -51.82 68.39 Favored 'General case' 0 C--O 1.233 0.225 0 CA-C-N 115.828 -0.624 . . . . 0.0 109.81 179.319 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 7.8 mp -63.87 -33.63 76.13 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 115.865 -0.607 . . . . 0.0 110.013 179.216 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -61.44 -28.34 69.35 Favored Glycine 0 N--CA 1.449 -0.454 0 C-N-CA 120.784 -0.722 . . . . 0.0 111.566 179.191 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 89' ' ' LEU . . . . . 0.439 HD22 ' CZ ' ' A' ' 35' ' ' ARG . 82.1 mt -79.04 -36.61 40.76 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.953 0.406 . . . . 0.0 110.165 179.325 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 97.0 mt -63.18 -37.67 88.13 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 115.821 -0.627 . . . . 0.0 111.017 179.802 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 91' ' ' ALA . . . . . 0.541 ' HB1' ' HB2' ' A' ' 148' ' ' SER . . . -87.22 -54.57 4.23 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.328 -179.837 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 103.33 70.6 0.84 Allowed Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.831 -0.699 . . . . 0.0 112.415 -179.775 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 93' ' ' LEU . . . . . 0.609 HD11 ' HG2' ' A' ' 145' ' ' MET . 7.5 mp -87.99 166.8 14.23 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.81 0.338 . . . . 0.0 111.047 -179.843 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 94' ' ' ASP . . . . . . . . . . . . . 7.9 m-20 -84.5 174.35 10.11 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.887 179.779 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 88.8 p -60.09 -35.72 75.82 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.308 -0.406 . . . . 0.0 111.004 -179.788 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 69.7 mtm180 -72.9 -48.79 34.2 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.148 -179.835 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 97' ' ' GLU . . . . . 0.593 ' HB3' HD23 ' A' ' 93' ' ' LEU . 37.5 mt-10 -56.16 -46.59 79.23 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.295 -0.412 . . . . 0.0 111.235 -179.73 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 98' ' ' PHE . . . . . 0.404 ' O ' HG12 ' A' ' 102' ' ' ILE . 6.5 m-85 -55.88 -50.59 70.23 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.366 -0.379 . . . . 0.0 111.07 -179.951 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -55.59 -34.28 60.14 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.858 -0.687 . . . . 0.0 112.637 -179.867 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 97.8 mt -66.82 -44.13 89.31 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.207 0 CA-C-O 120.773 0.32 . . . . 0.0 111.803 -179.748 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 25.0 t -68.59 -46.93 79.24 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.369 0 CA-C-N 116.263 -0.426 . . . . 0.0 111.936 -179.045 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 102' ' ' ILE . . . . . 0.404 HG12 ' O ' ' A' ' 98' ' ' PHE . 36.2 mm -63.64 -48.63 85.87 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 CA-C-N 116.283 -0.417 . . . . 0.0 111.922 -179.014 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 12.0 t -61.04 -37.2 81.75 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-O 120.761 0.315 . . . . 0.0 111.23 -179.528 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 104' ' ' LEU . . . . . 0.481 ' O ' HG23 ' A' ' 108' ' ' VAL . 10.1 tt -60.91 -42.93 99.01 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.411 179.721 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 105' ' ' ASN . . . . . 0.611 HD21 HD13 ' A' ' 137' ' ' LEU . 0.8 OUTLIER -67.68 -26.35 66.15 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.605 179.614 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 56.6 m -63.5 -53.57 49.98 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 115.941 -0.572 . . . . 0.0 111.149 179.82 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 7.8 p -63.93 -36.13 75.7 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.162 0 CA-C-N 116.336 -0.393 . . . . 0.0 111.127 179.919 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . 0.481 HG23 ' O ' ' A' ' 104' ' ' LEU . 79.6 t -63.3 -51.71 67.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-O 121.201 0.524 . . . . 0.0 110.604 179.44 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 109' ' ' MET . . . . . 0.71 ' HE1' HG21 ' A' ' 80' ' ' THR . 3.5 tpp -60.49 -33.73 73.02 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 115.67 -0.695 . . . . 0.0 110.422 179.759 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 20.8 tp -68.91 -33.52 73.88 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 115.9 -0.591 . . . . 0.0 110.166 179.693 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 111' ' ' ALA . . . . . 0.4 ' O ' HD13 ' A' ' 126' ' ' LEU . . . -59.7 -57.1 14.39 Favored 'General case' 0 C--N 1.332 -0.179 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.177 179.315 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . -57.31 -41.22 92.92 Favored Glycine 0 CA--C 1.518 0.233 0 C-N-CA 120.598 -0.81 . . . . 0.0 112.116 179.164 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 113' ' ' PHE . . . . . . . . . . . . . 1.5 t80 -47.16 -67.79 0.25 Allowed 'General case' 0 C--N 1.333 -0.137 0 CA-C-O 121.127 0.489 . . . . 0.0 110.081 179.473 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 114' ' ' ALA . . . . . 0.419 ' O ' HG13 ' A' ' 118' ' ' VAL . . . -64.43 -21.09 66.54 Favored 'General case' 0 C--N 1.326 -0.449 0 CA-C-N 115.512 -0.767 . . . . 0.0 110.864 179.661 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 115' ' ' GLY . . . . . 0.638 ' HA2' HD11 ' A' ' 126' ' ' LEU . . . -52.96 -49.38 55.37 Favored Glycine 0 C--N 1.333 0.375 0 C-N-CA 121.008 -0.615 . . . . 0.0 112.367 179.912 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -78.08 -15.79 58.59 Favored 'General case' 0 C--N 1.324 -0.506 0 N-CA-C 111.665 0.246 . . . . 0.0 111.665 179.742 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 117' ' ' MET . . . . . 0.411 ' HG3' HG21 ' A' ' 63' ' ' VAL . 36.1 ttm -100.94 19.89 16.49 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.497 -0.32 . . . . 0.0 111.674 -179.091 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 118' ' ' VAL . . . . . 0.444 HG21 ' HB3' ' A' ' 123' ' ' ARG . 28.3 m -74.11 147.5 85.84 Favored Pre-proline 0 C--N 1.328 -0.36 0 CA-C-N 116.559 -0.291 . . . . 0.0 111.305 179.789 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 119' ' ' PRO . . . . . . . . . . . . . 81.3 Cg_endo -88.94 -6.28 5.68 Favored 'Trans proline' 0 N--CA 1.457 -0.622 0 C-N-CA 122.688 2.259 . . . . 0.0 112.283 179.683 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -148.4 -114.69 0.78 Allowed Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.711 -0.757 . . . . 0.0 112.915 -179.783 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 44.7 pt -122.59 14.56 5.58 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 CA-C-O 120.802 0.334 . . . . 0.0 111.39 -179.51 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 36.9 mt-10 -63.4 -18.85 64.14 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.134 -179.999 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 123' ' ' ARG . . . . . 0.486 ' HA ' HD21 ' A' ' 126' ' ' LEU . 35.9 ptt180 -53.41 -32.42 49.56 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.106 -0.497 . . . . 0.0 111.925 -179.544 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 124' ' ' TYR . . . . . . . . . . . . . 91.5 m-85 -72.54 -31.41 65.27 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 116.476 -0.329 . . . . 0.0 111.466 -179.652 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 125' ' ' ALA . . . . . . . . . . . . . . . -74.51 -58.28 3.39 Favored 'General case' 0 C--O 1.237 0.44 0 CA-C-O 121.196 0.522 . . . . 0.0 111.573 -179.374 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 126' ' ' LEU . . . . . 0.638 HD11 ' HA2' ' A' ' 115' ' ' GLY . 0.7 OUTLIER -56.49 -37.24 70.1 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 115.701 -0.681 . . . . 0.0 110.511 179.789 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 127' ' ' PHE . . . . . . . . . . . . . 7.8 t80 -69.37 -42.6 74.99 Favored 'General case' 0 N--CA 1.453 -0.311 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.114 179.304 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 128' ' ' GLY . . . . . . . . . . . . . . . -48.09 -35.33 13.52 Favored Glycine 0 C--N 1.333 0.379 0 N-CA-C 110.673 -0.971 . . . . 0.0 110.673 178.746 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 129' ' ' MET . . . . . . . . . . . . . 0.2 OUTLIER -72.03 -43.67 64.63 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 115.154 -0.523 . . . . 0.0 109.877 178.619 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -67.25 -22.22 72.6 Favored Glycine 0 N--CA 1.449 -0.474 0 C-N-CA 120.869 -0.682 . . . . 0.0 112.378 179.602 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 131' ' ' ALA . . . . . 0.436 ' O ' ' HB3' ' A' ' 134' ' ' PHE . . . -74.61 -53.9 8.48 Favored 'General case' 0 CA--C 1.519 -0.234 0 CA-C-O 120.739 0.304 . . . . 0.0 110.211 179.681 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 58.1 t -58.32 -39.47 74.24 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.319 0 N-CA-C 108.535 -0.913 . . . . 0.0 108.535 178.096 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -62.77 -37.44 86.67 Favored 'General case' 0 N--CA 1.451 -0.378 0 CA-C-N 114.915 -1.039 . . . . 0.0 110.198 178.767 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 134' ' ' PHE . . . . . 0.436 ' HB3' ' O ' ' A' ' 131' ' ' ALA . 68.0 t80 -55.64 -50.09 71.11 Favored 'General case' 0 N--CA 1.453 -0.325 0 CA-C-N 116.159 -0.473 . . . . 0.0 109.88 179.364 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 135' ' ' ILE . . . . . 0.504 ' O ' HG22 ' A' ' 138' ' ' VAL . 59.0 mt -59.54 -32.45 49.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 115.667 -0.697 . . . . 0.0 110.14 179.228 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . -59.46 -41.76 97.25 Favored Glycine 0 N--CA 1.449 -0.494 0 C-N-CA 120.409 -0.901 . . . . 0.0 111.271 179.054 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 137' ' ' LEU . . . . . 0.611 HD13 HD21 ' A' ' 105' ' ' ASN . 42.7 tp -65.85 -55.61 16.17 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 120.666 0.27 . . . . 0.0 110.722 179.541 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 138' ' ' VAL . . . . . 0.637 ' HB ' HH22 ' A' ' 164' ' ' ARG . 2.5 m -54.79 -32.3 25.79 Favored 'Isoleucine or valine' 0 C--O 1.234 0.267 0 CA-C-O 121.125 0.488 . . . . 0.0 109.802 -179.506 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 139' ' ' TYR . . . . . . . . . . . . . 10.2 t80 -61.43 -42.31 98.54 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 115.654 -0.703 . . . . 0.0 109.964 178.293 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 28.1 m-85 -65.99 -42.37 89.89 Favored 'General case' 0 C--N 1.332 -0.184 0 CA-C-N 116.11 -0.496 . . . . 0.0 111.002 179.517 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 141' ' ' LEU . . . . . 0.435 ' HA ' ' SD ' ' A' ' 145' ' ' MET . 10.8 mp -56.62 -32.86 65.71 Favored 'General case' 0 N--CA 1.462 0.139 0 CA-C-N 116.356 -0.384 . . . . 0.0 110.883 -179.973 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 21.6 t -97.05 -12.75 8.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.82 179.662 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . -76.33 -123.83 0.19 Allowed Glycine 0 CA--C 1.522 0.529 0 C-N-CA 120.845 -0.693 . . . . 0.0 112.932 -179.721 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 144' ' ' PRO . . . . . . . . . . . . . 31.7 Cg_exo -58.87 -29.95 91.58 Favored 'Trans proline' 0 C--N 1.351 0.659 0 C-N-CA 122.596 2.198 . . . . 0.0 112.726 -179.672 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 145' ' ' MET . . . . . 0.609 ' HG2' HD11 ' A' ' 93' ' ' LEU . 60.1 mtt -58.7 -26.98 64.42 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.316 -0.402 . . . . 0.0 111.235 -179.893 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 146' ' ' THR . . . . . . . . . . . . . 24.0 m -81.08 -33.67 33.2 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-N 116.119 -0.491 . . . . 0.0 111.478 -179.058 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 15.0 tp10 -71.89 -43.43 65.41 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.98 -179.896 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 148' ' ' SER . . . . . 0.541 ' HB2' ' HB1' ' A' ' 91' ' ' ALA . 61.7 m -71.98 -40.15 68.79 Favored 'General case' 0 C--N 1.327 -0.405 0 N-CA-C 112.334 0.494 . . . . 0.0 112.334 -179.205 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 149' ' ' ALA . . . . . . . . . . . . . . . -76.68 -44.64 32.85 Favored 'General case' 0 C--N 1.33 -0.278 0 N-CA-C 113.395 0.887 . . . . 0.0 113.395 -177.974 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 150' ' ' SER . . . . . . . . . . . . . 54.2 m -69.12 -14.29 62.92 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.909 0.385 . . . . 0.0 110.85 -178.495 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 151' ' ' GLN . . . . . . . . . . . . . 3.0 mp0 -116.56 10.38 14.46 Favored 'General case' 0 C--N 1.324 -0.502 0 CA-C-N 115.928 -0.578 . . . . 0.0 111.494 -179.462 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 72.2 ttt180 -82.99 -51.94 7.12 Favored 'General case' 0 C--N 1.334 -0.102 0 CA-C-O 120.868 0.366 . . . . 0.0 110.943 -179.968 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 153' ' ' SER . . . . . 0.598 ' HB2' HG12 ' A' ' 156' ' ' ILE . 17.6 m -157.45 172.18 19.04 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 116.032 -0.531 . . . . 0.0 110.861 179.596 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 154' ' ' SER . . . . . . . . . . . . . 67.9 m -71.09 -37.3 72.41 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.687 179.636 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -76.82 -35.0 41.24 Favored Glycine 0 N--CA 1.452 -0.276 0 C-N-CA 120.887 -0.673 . . . . 0.0 112.568 179.908 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 156' ' ' ILE . . . . . 0.598 HG12 ' HB2' ' A' ' 153' ' ' SER . 41.4 mm -56.42 -37.72 52.51 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-O 120.887 0.375 . . . . 0.0 110.92 -179.972 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 157' ' ' LYS . . . . . . . . . . . . . 24.3 ttpp -60.98 -32.9 72.45 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.903 179.82 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 47.1 m -70.9 -45.23 64.7 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.073 -179.863 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 159' ' ' LEU . . . . . 0.487 HD22 HD21 ' A' ' 163' ' ' LEU . 11.2 mt -65.67 -36.12 82.76 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.338 -0.392 . . . . 0.0 111.07 179.931 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 160' ' ' TYR . . . . . 0.49 ' O ' ' HB3' ' A' ' 164' ' ' ARG . 57.3 t80 -65.57 -47.86 74.36 Favored 'General case' 0 C--N 1.329 -0.317 0 N-CA-C 112.206 0.447 . . . . 0.0 112.206 -178.952 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 161' ' ' VAL . . . . . 0.43 HG23 ' N ' ' A' ' 162' ' ' ARG . 17.3 m -62.17 -49.28 84.69 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 N-CA-C 112.304 0.483 . . . . 0.0 112.304 -178.608 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 162' ' ' ARG . . . . . 0.43 ' N ' HG23 ' A' ' 161' ' ' VAL . 81.9 mtt180 -68.46 -46.11 70.66 Favored 'General case' 0 C--N 1.329 -0.291 0 N-CA-C 112.076 0.398 . . . . 0.0 112.076 -179.044 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 163' ' ' LEU . . . . . 0.487 HD21 HD22 ' A' ' 159' ' ' LEU . 1.7 mp -67.67 -54.95 15.35 Favored 'General case' 0 C--N 1.328 -0.332 0 N-CA-C 112.243 0.46 . . . . 0.0 112.243 -178.62 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 164' ' ' ARG . . . . . 0.637 HH22 ' HB ' ' A' ' 138' ' ' VAL . 25.2 tpt180 -55.78 -54.89 38.91 Favored 'General case' 0 N--CA 1.465 0.292 0 N-CA-C 112.629 0.603 . . . . 0.0 112.629 -178.46 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 165' ' ' ASN . . . . . . . . . . . . . 13.8 m-80 -58.0 -49.25 77.5 Favored 'General case' 0 C--N 1.33 -0.255 0 N-CA-C 112.071 0.397 . . . . 0.0 112.071 -178.75 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 166' ' ' LEU . . . . . . . . . . . . . 4.4 tt -63.45 -55.37 24.73 Favored 'General case' 0 C--N 1.325 -0.47 0 N-CA-C 111.876 0.325 . . . . 0.0 111.876 -179.262 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 167' ' ' THR . . . . . . . . . . . . . 53.7 m -57.02 -52.92 63.34 Favored 'General case' 0 C--N 1.328 -0.368 0 N-CA-C 113.037 0.754 . . . . 0.0 113.037 -178.613 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 168' ' ' VAL . . . . . 0.451 HG12 ' O ' ' A' ' 164' ' ' ARG . 7.9 p -57.5 -41.22 78.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 N-CA-C 112.482 0.549 . . . . 0.0 112.482 -178.529 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 169' ' ' VAL . . . . . 0.463 ' CG1' ' N ' ' A' ' 170' ' ' LEU . 0.4 OUTLIER -63.72 -54.07 36.76 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.443 0 N-CA-C 111.867 0.321 . . . . 0.0 111.867 -178.76 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 170' ' ' LEU . . . . . 0.463 ' N ' ' CG1' ' A' ' 169' ' ' VAL . 3.0 pp -68.03 -31.12 70.57 Favored 'General case' 0 C--N 1.33 -0.268 0 C-N-CA 121.173 -0.211 . . . . 0.0 111.543 -178.562 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 171' ' ' TRP . . . . . 0.443 ' N ' HD12 ' A' ' 170' ' ' LEU . 3.3 m0 -72.29 -28.59 63.19 Favored 'General case' 0 C--N 1.329 -0.295 0 N-CA-C 109.952 -0.388 . . . . 0.0 109.952 178.895 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 172' ' ' ALA . . . . . . . . . . . . . . . -76.0 -6.87 53.03 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-N 115.919 -0.582 . . . . 0.0 110.554 -179.821 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 173' ' ' ILE . . . . . 0.486 ' O ' HG12 ' A' ' 177' ' ' ILE . 34.1 mm -85.86 -21.12 7.75 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.204 0 CA-C-N 115.719 -0.673 . . . . 0.0 110.853 179.41 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 174' ' ' TYR . . . . . 0.417 ' HB2' ' HD3' ' A' ' 175' ' ' PRO . 11.8 m-85 -53.76 -50.22 84.83 Favored Pre-proline 0 CA--C 1.53 0.194 0 CA-C-N 116.313 -0.403 . . . . 0.0 111.799 -179.446 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 175' ' ' PRO . . . . . 0.417 ' HD3' ' HB2' ' A' ' 174' ' ' TYR . 74.5 Cg_exo -50.42 -29.9 25.5 Favored 'Trans proline' 0 C--N 1.349 0.572 0 C-N-CA 122.191 1.927 . . . . 0.0 112.517 179.84 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 176' ' ' PHE . . . . . 0.432 ' HD2' ' HA ' ' A' ' 173' ' ' ILE . 38.9 m-85 -80.44 -50.24 10.35 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.233 -0.44 . . . . 0.0 111.846 -179.707 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 177' ' ' ILE . . . . . 0.486 HG12 ' O ' ' A' ' 173' ' ' ILE . 5.7 mm -65.65 -33.54 64.29 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.519 0 N-CA-C 112.27 0.47 . . . . 0.0 112.27 -178.229 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 178' ' ' TRP . . . . . 0.442 ' HH2' ' HB2' ' A' ' 123' ' ' ARG . 88.7 t90 -72.86 -56.53 5.08 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.873 0.368 . . . . 0.0 110.807 -179.925 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 179' ' ' LEU . . . . . 0.416 HD23 HD23 ' A' ' 180' ' ' LEU . 0.6 OUTLIER -63.04 -54.23 41.33 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 115.931 -0.577 . . . . 0.0 111.324 -179.36 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 180' ' ' LEU . . . . . 0.54 HD22 HD11 ' A' ' 187' ' ' LEU . 43.3 mt -64.67 -41.41 96.1 Favored 'General case' 0 C--N 1.331 -0.213 0 C-N-CA 120.832 -0.347 . . . . 0.0 111.068 -179.607 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . -62.6 -178.79 3.98 Favored Glycine 0 C--N 1.334 0.43 0 C-N-CA 119.952 -1.118 . . . . 0.0 112.002 179.103 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 182' ' ' PRO . . . . . 0.577 ' HA ' ' HB2' ' A' ' 186' ' ' ALA . 83.2 Cg_exo -47.84 -44.8 26.17 Favored 'Trans proline' 0 CA--C 1.536 0.58 0 C-N-CA 122.741 2.294 . . . . 0.0 113.74 179.962 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 183' ' ' PRO . . . . . 0.411 ' HD3' ' HB2' ' A' ' 182' ' ' PRO . 84.1 Cg_exo -47.04 -22.51 2.15 Favored 'Trans proline' 0 C--N 1.356 0.933 0 C-N-CA 122.209 1.939 . . . . 0.0 113.286 -179.688 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 184' ' ' GLY . . . . . . . . . . . . . . . -126.12 -124.12 2.74 Favored Glycine 0 C--N 1.333 0.367 0 C-N-CA 120.305 -0.95 . . . . 0.0 112.926 179.874 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 185' ' ' VAL . . . . . 0.41 ' CG2' ' HA ' ' A' ' 180' ' ' LEU . 19.4 m -61.28 -25.31 36.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 N-CA-C 112.281 0.474 . . . . 0.0 112.281 -179.248 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 186' ' ' ALA . . . . . 0.577 ' HB2' ' HA ' ' A' ' 182' ' ' PRO . . . 57.65 85.41 0.09 Allowed 'General case' 0 N--CA 1.465 0.318 0 CA-C-O 120.832 0.348 . . . . 0.0 111.7 179.555 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 187' ' ' LEU . . . . . 0.54 HD11 HD22 ' A' ' 180' ' ' LEU . 10.7 mt -92.88 -49.27 6.13 Favored 'General case' 0 C--N 1.332 -0.184 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.359 179.911 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 188' ' ' LEU . . . . . . . . . . . . . 53.7 mt -95.47 -161.43 0.86 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 115.988 -0.551 . . . . 0.0 111.691 -179.052 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 189' ' ' THR . . . . . . . . . . . . . 9.9 m -91.5 137.06 26.09 Favored Pre-proline 0 C--N 1.33 -0.261 0 CA-C-N 115.77 -0.65 . . . . 0.0 110.682 -179.716 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 190' ' ' PRO . . . . . . . . . . . . . 96.4 Cg_exo -44.65 -46.01 12.76 Favored 'Trans proline' 0 C--N 1.35 0.655 0 C-N-CA 122.812 2.341 . . . . 0.0 113.539 -179.735 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 191' ' ' THR . . . . . . . . . . . . . 6.7 t -59.1 -36.83 75.8 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.822 0.344 . . . . 0.0 111.329 -179.764 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 192' ' ' VAL . . . . . . . . . . . . . 58.0 t -74.79 -53.63 16.19 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.22 -0.446 . . . . 0.0 111.696 -179.591 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 193' ' ' ASP . . . . . . . . . . . . . 23.9 m-20 -56.45 -48.36 77.22 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.45 -0.341 . . . . 0.0 110.973 -179.588 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 194' ' ' VAL . . . . . . . . . . . . . 78.0 t -61.92 -36.38 73.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.432 179.602 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 195' ' ' ALA . . . . . . . . . . . . . . . -56.28 -42.34 77.33 Favored 'General case' 0 C--N 1.331 -0.197 0 CA-C-N 116.344 -0.389 . . . . 0.0 110.823 179.335 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 196' ' ' LEU . . . . . . . . . . . . . 96.1 mt -67.19 -38.86 86.09 Favored 'General case' 0 C--N 1.332 -0.174 0 CA-C-O 120.952 0.406 . . . . 0.0 110.332 179.486 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 197' ' ' ILE . . . . . . . . . . . . . 21.6 mm -59.79 -52.6 59.19 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 115.937 -0.574 . . . . 0.0 110.18 179.153 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 198' ' ' VAL . . . . . . . . . . . . . 90.8 t -57.26 -34.15 45.17 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.458 0 N-CA-C 108.908 -0.775 . . . . 0.0 108.908 178.179 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 199' ' ' TYR . . . . . . . . . . . . . 46.0 t80 -69.44 -30.3 68.19 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-N 115.115 -0.948 . . . . 0.0 110.568 179.46 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 200' ' ' LEU . . . . . 0.467 ' O ' HG12 ' A' ' 203' ' ' VAL . 48.2 mt -70.25 -42.37 72.27 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 115.944 -0.571 . . . . 0.0 111.158 -179.854 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 201' ' ' ASP . . . . . . . . . . . . . 12.3 m-20 -73.3 -34.65 65.84 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-O 121.167 0.508 . . . . 0.0 110.15 179.378 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 202' ' ' LEU . . . . . . . . . . . . . 2.5 mt -70.78 -31.33 68.07 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 115.562 -0.745 . . . . 0.0 111.795 -179.799 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 203' ' ' VAL . . . . . 0.467 HG12 ' O ' ' A' ' 200' ' ' LEU . 11.9 p -77.18 -37.1 25.42 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.235 0 C-N-CA 120.946 -0.302 . . . . 0.0 111.209 -179.143 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 204' ' ' THR . . . . . . . . . . . . . 68.0 m -65.13 -57.49 8.44 Favored 'General case' 0 C--O 1.222 -0.392 0 C-N-CA 120.76 -0.376 . . . . 0.0 111.318 179.718 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 205' ' ' LYS . . . . . 0.682 ' HE2' ' HB2' ' A' ' 47' ' ' ALA . 60.6 mttp -65.13 -55.51 18.3 Favored 'General case' 0 C--N 1.326 -0.414 0 N-CA-C 112.301 0.482 . . . . 0.0 112.301 -178.716 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 59.2 t -65.31 -47.18 88.17 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 N-CA-C 111.841 0.312 . . . . 0.0 111.841 -179.606 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 207' ' ' GLY . . . . . . . . . . . . . . . -63.94 -59.62 8.34 Favored Glycine 0 C--N 1.331 0.28 0 C-N-CA 120.708 -0.758 . . . . 0.0 112.771 -179.795 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 208' ' ' PHE . . . . . 0.42 ' O ' ' N ' ' A' ' 212' ' ' ALA . 4.1 t80 -54.71 -40.74 69.52 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.672 0.272 . . . . 0.0 110.97 179.965 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 209' ' ' GLY . . . . . 0.503 ' HA2' HD11 ' A' ' 40' ' ' LEU . . . -69.78 -38.65 76.63 Favored Glycine 0 C--N 1.329 0.189 0 CA-C-N 115.877 -0.601 . . . . 0.0 113.356 -179.558 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 210' ' ' PHE . . . . . . . . . . . . . 1.4 m-85 -69.66 -39.95 76.75 Favored 'General case' 0 CA--C 1.51 -0.571 0 N-CA-C 107.649 -1.241 . . . . 0.0 107.649 179.118 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 211' ' ' ILE . . . . . . . . . . . . . 29.9 mt -69.73 -28.6 37.84 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.87 0 CA-C-N 114.235 -1.348 . . . . 0.0 107.416 176.737 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 212' ' ' ALA . . . . . 0.461 ' HB3' ' O ' ' A' ' 209' ' ' GLY . . . -68.08 -38.8 82.78 Favored 'General case' 0 N--CA 1.447 -0.59 0 CA-C-N 114.293 -1.321 . . . . 0.0 110.637 179.856 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 213' ' ' LEU . . . . . . . . . . . . . 96.4 mt -70.6 -53.09 17.3 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 115.257 -0.883 . . . . 0.0 112.043 -179.238 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 214' ' ' ASP . . . . . . . . . . . . . 45.0 m-20 -52.09 -53.06 47.11 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.443 -0.344 . . . . 0.0 111.636 -179.428 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 215' ' ' ALA . . . . . 0.421 ' HB3' HD21 ' A' ' 159' ' ' LEU . . . -59.68 -57.36 13.26 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.344 -0.389 . . . . 0.0 111.818 -179.511 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 216' ' ' ALA . . . . . . . . . . . . . . . -58.11 -31.73 67.43 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.441 -0.345 . . . . 0.0 111.601 -179.519 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 217' ' ' ALA . . . . . . . . . . . . . . . -62.24 -42.16 99.06 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 121.015 0.436 . . . . 0.0 110.151 179.832 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 218' ' ' THR . . . . . . . . . . . . . 97.2 m . . . . . 0 C--N 1.329 -0.314 0 CA-C-N 115.827 -0.624 . . . . 0.0 110.33 179.154 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.353 0 N-CA-C 112.384 -0.286 . . . . 0.0 112.384 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 59.4 tp -74.42 -35.52 63.41 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 120.844 0.355 . . . . 0.0 111.101 179.886 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 65.2 p -62.64 -30.06 71.09 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.517 -179.626 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 36.1 p -55.11 -35.46 64.68 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.44 -0.345 . . . . 0.0 111.118 -179.92 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 7' ' ' LEU . . . . . . . . . . . . . 4.2 mm? -56.65 -53.26 59.77 Favored 'General case' 0 C--N 1.331 -0.205 0 CA-C-N 116.082 -0.508 . . . . 0.0 111.052 -179.974 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 8' ' ' PHE . . . . . 0.708 ' HB2' ' HB2' ' A' ' 55' ' ' ALA . 67.9 m-85 -60.96 -36.41 79.32 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.873 -179.958 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 9' ' ' TRP . . . . . . . . . . . . . 30.4 m95 -61.4 -44.16 97.63 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.047 -179.876 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 51.8 mt -60.94 -42.65 98.59 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 115.638 -0.71 . . . . 0.0 110.239 179.246 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -62.09 -29.94 74.22 Favored Glycine 0 N--CA 1.448 -0.549 0 C-N-CA 120.69 -0.766 . . . . 0.0 111.888 179.259 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -72.58 -33.51 66.8 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-O 120.698 0.285 . . . . 0.0 110.968 179.719 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 13' ' ' ILE . . . . . 0.434 ' O ' HG23 ' A' ' 17' ' ' VAL . 83.3 mt -64.16 -54.32 32.7 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.226 0 CA-C-N 116.343 -0.39 . . . . 0.0 110.749 179.758 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -66.02 -34.15 87.59 Favored Glycine 0 N--CA 1.452 -0.291 0 C-N-CA 120.685 -0.769 . . . . 0.0 112.227 179.833 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 15' ' ' MET . . . . . 0.534 ' SD ' ' HA ' ' A' ' 44' ' ' SER . 52.7 tpp -65.69 -49.79 67.27 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.733 0.301 . . . . 0.0 110.646 179.986 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 51.0 mt -53.42 -42.23 66.84 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.506 179.382 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 17' ' ' VAL . . . . . 0.434 HG23 ' O ' ' A' ' 13' ' ' ILE . 99.5 t -58.89 -41.46 82.98 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.226 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.125 179.128 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -64.76 -40.49 97.43 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.606 -0.806 . . . . 0.0 111.49 179.029 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 3.6 m -50.97 -54.17 26.69 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.883 0.373 . . . . 0.0 111.102 179.917 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 75.2 mt -71.74 -39.72 69.88 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.061 -0.518 . . . . 0.0 111.454 -179.887 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 21' ' ' ALA . . . . . 0.567 ' O ' ' HB2' ' A' ' 25' ' ' ALA . . . -54.71 -43.88 72.95 Favored 'General case' 0 C--N 1.329 -0.316 0 N-CA-C 112.381 0.512 . . . . 0.0 112.381 -178.953 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 4.3 m-85 -84.36 -28.24 27.14 Favored 'General case' 0 C--N 1.329 -0.315 0 N-CA-C 111.889 0.329 . . . . 0.0 111.889 -178.969 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -64.98 -51.48 61.48 Favored 'General case' 0 C--N 1.326 -0.442 0 N-CA-C 112.59 0.589 . . . . 0.0 112.59 -178.965 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 24' ' ' TRP . . . . . 0.504 ' CE3' ' HA ' ' A' ' 24' ' ' TRP . 2.3 t-105 -87.1 -26.75 23.5 Favored 'General case' 0 N--CA 1.442 -0.827 0 N-CA-C 113.383 0.882 . . . . 0.0 113.383 -177.497 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 25' ' ' ALA . . . . . 0.567 ' HB2' ' O ' ' A' ' 21' ' ' ALA . . . . . . . . 0 C--N 1.318 -0.778 0 C-N-CA 120.636 -0.426 . . . . 0.0 109.947 178.896 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.306 0 N-CA-C 112.445 -0.262 . . . . 0.0 112.445 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 9.0 mm-40 -89.27 -20.59 23.91 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.776 0.322 . . . . 0.0 110.872 -179.957 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 34' ' ' ARG . . . . . . . . . . . . . 92.8 mtt180 -56.35 -28.7 59.86 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.129 -0.487 . . . . 0.0 111.385 -179.815 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 99.2 mtt180 -54.96 -56.46 19.44 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-O 120.863 0.363 . . . . 0.0 111.286 -179.807 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 76.1 m-85 -71.29 -40.16 71.06 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.944 -179.052 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 37' ' ' TYR . . . . . . . . . . . . . 20.7 m-85 -65.52 -56.3 13.12 Favored 'General case' 0 C--N 1.329 -0.305 0 N-CA-C 111.707 0.262 . . . . 0.0 111.707 -179.08 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 89.3 t -57.08 -37.17 53.9 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.326 0 CA-C-O 120.724 0.297 . . . . 0.0 110.935 179.981 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 15.2 m -64.36 -51.55 62.73 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 121.037 0.446 . . . . 0.0 110.748 179.33 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 40' ' ' LEU . . . . . 0.477 HD12 HD12 ' A' ' 43' ' ' ILE . 61.1 tp -59.22 -50.83 72.5 Favored 'General case' 0 C--O 1.235 0.306 0 CA-C-N 115.877 -0.601 . . . . 0.0 110.641 179.913 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 96.4 t -59.78 -34.4 55.54 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 115.974 -0.557 . . . . 0.0 109.62 178.902 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -57.22 -39.28 89.82 Favored Glycine 0 N--CA 1.447 -0.603 0 CA-C-N 115.644 -0.707 . . . . 0.0 111.767 179.407 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 43' ' ' ILE . . . . . 0.498 HG22 ' HE3' ' A' ' 205' ' ' LYS . 1.0 OUTLIER -65.65 -53.12 42.48 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.205 0 CA-C-O 120.832 0.348 . . . . 0.0 110.128 179.306 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 44' ' ' SER . . . . . 0.534 ' HA ' ' SD ' ' A' ' 15' ' ' MET . 83.0 p -61.86 -21.2 64.47 Favored 'General case' 0 C--N 1.333 -0.146 0 CA-C-N 116.104 -0.498 . . . . 0.0 111.12 179.985 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -76.25 -59.23 3.4 Favored Glycine 0 N--CA 1.452 -0.265 0 C-N-CA 120.726 -0.75 . . . . 0.0 112.662 -179.737 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 20.7 pt -61.0 -35.68 66.96 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-O 120.724 0.297 . . . . 0.0 111.425 -179.79 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 47' ' ' ALA . . . . . 0.64 ' HB2' ' HE2' ' A' ' 205' ' ' LYS . . . -67.06 -43.87 81.56 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.843 0.354 . . . . 0.0 111.065 179.478 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -54.78 -49.33 71.16 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.094 -0.503 . . . . 0.0 111.359 -179.749 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 26.9 m -67.75 -34.14 65.96 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.328 -0.396 . . . . 0.0 111.09 -179.718 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -62.75 -38.65 91.41 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-O 121.12 0.486 . . . . 0.0 110.657 179.576 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 51' ' ' TYR . . . . . 0.451 ' OH ' ' HB2' ' A' ' 201' ' ' ASP . 30.6 m-85 -72.93 -31.42 64.6 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-N 115.763 -0.653 . . . . 0.0 110.169 179.852 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -70.04 -42.52 72.8 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-N 115.749 -0.659 . . . . 0.0 111.091 179.609 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 53' ' ' VAL . . . . . 0.448 HG23 ' N ' ' A' ' 54' ' ' MET . 32.9 m -69.43 -45.5 78.48 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.197 0 CA-C-N 116.548 -0.296 . . . . 0.0 110.985 -179.848 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 54' ' ' MET . . . . . 0.448 ' N ' HG23 ' A' ' 53' ' ' VAL . 76.7 mtm -64.66 -31.06 72.12 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-O 121.034 0.445 . . . . 0.0 110.094 179.319 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 55' ' ' ALA . . . . . 0.708 ' HB2' ' HB2' ' A' ' 8' ' ' PHE . . . -74.46 -15.35 60.9 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 115.672 -0.694 . . . . 0.0 111.403 179.637 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 69.6 mt -92.1 -13.36 30.92 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.458 -0.337 . . . . 0.0 111.492 -179.697 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 104.2 -20.92 39.07 Favored Glycine 0 N--CA 1.452 -0.263 0 C-N-CA 120.52 -0.848 . . . . 0.0 113.112 179.8 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 58' ' ' VAL . . . . . 0.436 HG12 ' O ' ' A' ' 53' ' ' VAL . 11.7 p -67.08 149.61 11.52 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-N 116.861 0.331 . . . . 0.0 110.623 179.989 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 88.09 -14.47 58.92 Favored Glycine 0 N--CA 1.449 -0.471 0 C-N-CA 120.663 -0.779 . . . . 0.0 111.774 -179.155 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 60' ' ' TRP . . . . . . . . . . . . . 18.2 m0 -76.02 97.77 4.12 Favored 'General case' 0 C--N 1.331 -0.197 0 CA-C-O 120.836 0.35 . . . . 0.0 110.673 179.917 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 61' ' ' VAL . . . . . 0.511 HG13 HG23 ' A' ' 68' ' ' VAL . 5.2 p -100.32 129.26 28.41 Favored Pre-proline 0 C--N 1.328 -0.327 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.81 179.766 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 73.5 Cg_endo -73.97 146.22 36.91 Favored 'Trans proline' 0 C--N 1.35 0.619 0 C-N-CA 122.478 2.118 . . . . 0.0 112.245 -179.826 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 92.1 t -140.37 95.35 0.78 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.181 -179.67 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . 57.94 -91.42 0.03 OUTLIER 'General case' 0 C--N 1.331 -0.212 0 CA-C-N 116.123 -0.489 . . . . 0.0 111.27 -179.969 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -122.57 -11.78 8.22 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-O 120.968 0.413 . . . . 0.0 110.702 179.715 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 66' ' ' ARG . . . . . 0.451 HH22 HH12 ' A' ' 123' ' ' ARG . 16.9 ptp180 -105.52 165.6 11.03 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 115.9 -0.591 . . . . 0.0 110.364 179.454 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 61.5 m -126.33 141.51 51.88 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 120.965 0.412 . . . . 0.0 111.357 -179.842 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 68' ' ' VAL . . . . . 0.513 HG21 ' HG3' ' A' ' 117' ' ' MET . 9.1 m -133.25 146.18 32.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 115.942 -0.572 . . . . 0.0 110.669 179.575 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 69' ' ' PHE . . . . . . . . . . . . . 5.8 m-85 -107.59 118.31 36.4 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-O 121.049 0.452 . . . . 0.0 110.389 -179.056 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 70' ' ' VAL . . . . . 0.634 HG12 ' HD3' ' A' ' 71' ' ' PRO . 1.3 p -67.1 -35.32 8.63 Favored Pre-proline 0 CA--C 1.54 0.583 0 CA-C-N 115.687 -0.688 . . . . 0.0 112.829 -178.978 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 71' ' ' PRO . . . . . 0.634 ' HD3' HG12 ' A' ' 70' ' ' VAL . 8.7 Cg_exo -70.38 -18.65 33.94 Favored 'Trans proline' 0 C--N 1.356 0.948 0 C-N-CA 121.902 1.734 . . . . 0.0 112.66 -179.37 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 46.8 ttp180 -75.16 -54.3 7.36 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.55 -0.295 . . . . 0.0 111.791 -178.948 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 73' ' ' TYR . . . . . 0.414 ' O ' HG13 ' A' ' 77' ' ' ILE . 18.4 m-85 -67.66 -37.1 81.9 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.755 0.312 . . . . 0.0 110.491 -179.569 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 0.4 OUTLIER -68.39 -38.37 79.25 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.219 0 CA-C-N 116.293 -0.412 . . . . 0.0 110.139 179.526 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 19.5 t70 -59.65 -36.97 77.45 Favored 'General case' 0 CA--C 1.52 -0.199 0 N-CA-C 109.712 -0.477 . . . . 0.0 109.712 179.08 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 76' ' ' TRP . . . . . . . . . . . . . 46.0 m0 -65.03 -41.67 95.07 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 115.781 -0.645 . . . . 0.0 110.081 179.427 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 77' ' ' ILE . . . . . 0.414 HG13 ' O ' ' A' ' 73' ' ' TYR . 66.7 mt -61.79 -28.64 44.62 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.425 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.902 179.544 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 29.8 mt -90.74 -27.98 18.59 Favored 'General case' 0 CA--C 1.531 0.232 0 N-CA-C 112.481 0.549 . . . . 0.0 112.481 -179.376 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 64.6 p -91.28 -43.44 9.8 Favored 'General case' 0 C--N 1.329 -0.322 0 N-CA-C 113.002 0.741 . . . . 0.0 113.002 -178.022 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 80' ' ' THR . . . . . 0.566 ' N ' ' HD2' ' A' ' 81' ' ' PRO . 38.9 p -52.33 -45.01 94.96 Favored Pre-proline 0 C--N 1.328 -0.356 0 N-CA-C 113.072 0.767 . . . . 0.0 113.072 -179.044 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 81' ' ' PRO . . . . . 0.566 ' HD2' ' N ' ' A' ' 80' ' ' THR . 35.8 Cg_endo -62.99 -23.03 74.11 Favored 'Trans proline' 0 C--N 1.354 0.847 0 C-N-CA 121.406 1.404 . . . . 0.0 111.776 -179.78 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 82' ' ' LEU . . . . . 0.443 HD23 HG12 ' A' ' 43' ' ' ILE . 7.5 mp -76.82 -43.03 38.09 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 115.779 -0.646 . . . . 0.0 111.365 -179.494 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 83' ' ' ILE . . . . . 0.415 HD13 HD13 ' A' ' 43' ' ' ILE . 39.8 mm -63.29 -53.85 40.51 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.413 -0.358 . . . . 0.0 110.955 -179.851 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 33.5 m -60.05 -36.95 70.63 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.222 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.467 179.668 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 85' ' ' TYR . . . . . . . . . . . . . 69.8 t80 -63.48 -32.85 74.42 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.098 -0.501 . . . . 0.0 109.809 179.246 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 86' ' ' PHE . . . . . . . . . . . . . 6.0 t80 -61.64 -51.91 66.54 Favored 'General case' 0 C--O 1.233 0.193 0 CA-C-N 115.973 -0.558 . . . . 0.0 109.963 179.34 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 8.5 mp -61.06 -31.85 71.5 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 115.859 -0.61 . . . . 0.0 110.169 179.199 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -71.13 -27.87 71.2 Favored Glycine 0 N--CA 1.45 -0.392 0 C-N-CA 120.871 -0.68 . . . . 0.0 111.787 179.321 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 71.1 mt -73.13 -34.82 66.34 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-O 120.972 0.415 . . . . 0.0 110.38 179.517 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 74.8 mt -66.47 -35.66 80.82 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 115.761 -0.654 . . . . 0.0 111.303 -179.984 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -87.93 -32.33 18.96 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.589 -179.472 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 82.83 55.14 3.04 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.675 -0.774 . . . . 0.0 112.195 -179.72 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 33.8 mt -69.44 167.24 17.04 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.899 0.381 . . . . 0.0 111.128 -179.815 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 94' ' ' ASP . . . . . . . . . . . . . 18.4 t70 -86.15 168.29 14.14 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 115.987 -0.551 . . . . 0.0 110.361 179.683 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 80.8 p -57.62 -33.13 67.93 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.439 -0.346 . . . . 0.0 110.974 179.972 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 98.2 mtt180 -73.82 -53.47 10.18 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.208 179.944 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 44.0 mt-10 -53.76 -42.14 67.9 Favored 'General case' 0 C--N 1.332 -0.175 0 CA-C-N 116.362 -0.381 . . . . 0.0 110.914 -179.892 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 98' ' ' PHE . . . . . 0.423 ' O ' HG12 ' A' ' 102' ' ' ILE . 9.0 m-85 -59.91 -46.86 88.0 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.77 179.668 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -58.82 -29.59 64.87 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.816 -0.707 . . . . 0.0 112.56 -179.922 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 95.1 mt -73.51 -42.36 56.11 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.243 0 CA-C-O 120.872 0.368 . . . . 0.0 111.436 -179.847 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 42.1 t -68.61 -43.89 83.08 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.365 0 CA-C-N 116.329 -0.396 . . . . 0.0 111.208 -179.815 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 102' ' ' ILE . . . . . 0.423 HG12 ' O ' ' A' ' 98' ' ' PHE . 42.2 mm -68.53 -46.36 80.32 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.355 0 CA-C-N 116.086 -0.506 . . . . 0.0 111.688 -179.338 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 14.6 t -58.44 -35.85 72.75 Favored 'General case' 0 C--O 1.232 0.161 0 CA-C-O 120.778 0.323 . . . . 0.0 110.673 179.945 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 104' ' ' LEU . . . . . 0.443 HD22 ' HE2' ' A' ' 140' ' ' TYR . 30.1 tp -62.84 -45.99 90.03 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.036 179.124 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 105' ' ' ASN . . . . . 0.408 ' N ' HD22 ' A' ' 105' ' ' ASN . 0.9 OUTLIER -62.58 -25.75 68.24 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 115.978 -0.555 . . . . 0.0 110.712 179.354 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 24.6 m -68.57 -52.1 35.47 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.371 -0.377 . . . . 0.0 111.491 -179.803 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 10.9 p -70.24 -40.57 78.16 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.212 0 CA-C-N 116.429 -0.35 . . . . 0.0 111.888 -179.428 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . 0.57 ' HA ' ' HE1' ' A' ' 129' ' ' MET . 73.1 t -62.66 -58.46 7.48 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.254 0 CA-C-O 120.977 0.418 . . . . 0.0 111.458 -179.74 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 109' ' ' MET . . . . . 0.578 ' N ' ' SD ' ' A' ' 109' ' ' MET . 0.0 OUTLIER -58.39 -32.46 68.62 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 115.957 -0.565 . . . . 0.0 110.827 -179.396 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 28.4 tp -67.69 -35.29 78.54 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.296 -0.411 . . . . 0.0 110.089 179.292 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 111' ' ' ALA . . . . . 0.403 ' O ' ' HB3' ' A' ' 126' ' ' LEU . . . -60.88 -49.11 78.8 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-N 115.989 -0.551 . . . . 0.0 110.167 179.155 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . -59.82 -33.83 79.95 Favored Glycine 0 N--CA 1.45 -0.43 0 C-N-CA 120.574 -0.822 . . . . 0.0 111.716 179.271 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 113' ' ' PHE . . . . . 0.407 ' HD2' HD11 ' A' ' 77' ' ' ILE . 0.3 OUTLIER -54.71 -65.04 0.65 Allowed 'General case' 0 C--N 1.332 -0.191 0 CA-C-O 121.052 0.454 . . . . 0.0 110.226 179.326 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 114' ' ' ALA . . . . . 0.495 ' O ' HG13 ' A' ' 118' ' ' VAL . . . -66.43 -30.53 70.91 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 115.609 -0.723 . . . . 0.0 111.575 -179.64 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 115' ' ' GLY . . . . . 0.401 ' O ' HG22 ' A' ' 118' ' ' VAL . . . -52.12 -51.08 43.04 Favored Glycine 0 C--N 1.332 0.358 0 C-N-CA 121.059 -0.591 . . . . 0.0 112.988 -179.644 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 116' ' ' ALA . . . . . 0.497 ' HB2' ' HB3' ' A' ' 183' ' ' PRO . . . -78.09 -15.45 58.87 Favored 'General case' 0 C--N 1.327 -0.405 0 N-CA-C 111.829 0.307 . . . . 0.0 111.829 -179.558 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 117' ' ' MET . . . . . 0.513 ' HG3' HG21 ' A' ' 68' ' ' VAL . 35.5 ttm -106.23 17.0 24.12 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.79 0.328 . . . . 0.0 111.277 -179.425 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 118' ' ' VAL . . . . . 0.532 HG11 ' N ' ' A' ' 123' ' ' ARG . 15.9 m -63.81 148.57 94.46 Favored Pre-proline 0 C--N 1.331 -0.239 0 CA-C-N 116.414 -0.357 . . . . 0.0 111.413 179.847 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 119' ' ' PRO . . . . . . . . . . . . . 88.7 Cg_endo -82.66 -1.64 10.64 Favored 'Trans proline' 0 C--N 1.347 0.461 0 C-N-CA 122.605 2.204 . . . . 0.0 112.273 179.58 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -157.6 -121.18 0.65 Allowed Glycine 0 C--N 1.33 0.246 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.522 -179.994 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 1.9 pp -106.69 12.93 8.43 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.207 0 CA-C-O 120.866 0.365 . . . . 0.0 111.291 -179.932 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 41.9 mt-10 -59.97 -17.49 38.47 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.012 -0.54 . . . . 0.0 111.293 179.929 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 123' ' ' ARG . . . . . 0.532 ' N ' HG11 ' A' ' 118' ' ' VAL . 27.6 ptt180 -50.37 -29.66 10.52 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-N 116.118 -0.492 . . . . 0.0 111.853 -179.757 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 124' ' ' TYR . . . . . . . . . . . . . 28.9 m-85 -67.64 -33.03 74.14 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.771 0.319 . . . . 0.0 111.201 -179.783 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 125' ' ' ALA . . . . . . . . . . . . . . . -72.38 -48.54 40.84 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.254 -0.43 . . . . 0.0 111.426 -179.982 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 126' ' ' LEU . . . . . 0.417 HD13 ' HA ' ' A' ' 126' ' ' LEU . 3.3 mm? -54.6 -55.58 27.9 Favored 'General case' 0 C--N 1.331 -0.206 0 CA-C-N 116.351 -0.386 . . . . 0.0 110.987 -179.673 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 127' ' ' PHE . . . . . 0.438 ' HZ ' ' HB3' ' A' ' 175' ' ' PRO . 6.7 t80 -64.97 -39.2 93.12 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.185 -0.462 . . . . 0.0 111.456 -179.304 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 128' ' ' GLY . . . . . . . . . . . . . . . -46.44 -45.72 16.83 Favored Glycine 0 C--O 1.237 0.322 0 C-N-CA 120.228 -0.987 . . . . 0.0 111.261 179.531 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 129' ' ' MET . . . . . 0.57 ' HE1' ' HA ' ' A' ' 108' ' ' VAL . 0.3 OUTLIER -68.87 -40.18 79.41 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 115.348 -0.426 . . . . 0.0 109.907 178.986 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -68.56 -21.13 74.43 Favored Glycine 0 N--CA 1.449 -0.464 0 CA-C-N 115.701 -0.682 . . . . 0.0 112.486 179.972 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 131' ' ' ALA . . . . . 0.445 ' O ' ' HB3' ' A' ' 134' ' ' PHE . . . -75.5 -54.16 7.47 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-O 120.621 0.248 . . . . 0.0 110.596 179.886 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 46.5 t -62.94 -40.46 89.02 Favored 'Isoleucine or valine' 0 C--O 1.234 0.249 0 N-CA-C 108.839 -0.8 . . . . 0.0 108.839 178.417 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -66.82 -32.04 73.06 Favored 'General case' 0 N--CA 1.452 -0.352 0 CA-C-N 115.124 -0.943 . . . . 0.0 110.184 178.828 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 134' ' ' PHE . . . . . 0.445 ' HB3' ' O ' ' A' ' 131' ' ' ALA . 38.5 t80 -56.78 -55.61 32.14 Favored 'General case' 0 N--CA 1.452 -0.353 0 N-CA-C 109.738 -0.467 . . . . 0.0 109.738 179.402 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 135' ' ' ILE . . . . . 0.53 ' O ' HG22 ' A' ' 138' ' ' VAL . 47.9 mt -56.8 -32.71 39.19 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.407 0 CA-C-N 115.583 -0.735 . . . . 0.0 109.979 179.409 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . -59.92 -37.81 93.17 Favored Glycine 0 N--CA 1.448 -0.522 0 C-N-CA 120.113 -1.041 . . . . 0.0 110.94 178.567 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 137' ' ' LEU . . . . . . . . . . . . . 46.6 tp -71.12 -50.26 35.47 Favored 'General case' 0 N--CA 1.454 -0.247 0 CA-C-N 115.719 -0.241 . . . . 0.0 110.611 179.499 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 138' ' ' VAL . . . . . 0.649 ' HA ' HD12 ' A' ' 141' ' ' LEU . 3.7 m -57.8 -30.62 38.21 Favored 'Isoleucine or valine' 0 CA--C 1.521 -0.164 0 N-CA-C 109.23 -0.656 . . . . 0.0 109.23 179.138 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 139' ' ' TYR . . . . . . . . . . . . . 39.3 t80 -63.52 -39.8 95.37 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 115.246 -0.888 . . . . 0.0 109.173 178.205 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 140' ' ' TYR . . . . . 0.443 ' HE2' HD22 ' A' ' 104' ' ' LEU . 22.3 m-85 -65.28 -31.97 73.38 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 115.733 -0.667 . . . . 0.0 110.256 178.617 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 141' ' ' LEU . . . . . 0.649 HD12 ' HA ' ' A' ' 138' ' ' VAL . 56.8 mt -65.06 -36.71 85.22 Favored 'General case' 0 CA--C 1.519 -0.222 0 CA-C-O 121.35 0.595 . . . . 0.0 109.591 179.973 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 16.6 m -98.0 0.08 10.44 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.822 0 CA-C-N 115.112 -0.949 . . . . 0.0 111.081 -179.866 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . -81.82 -135.35 1.97 Allowed Glycine 0 CA--C 1.521 0.447 0 C-N-CA 121.035 -0.603 . . . . 0.0 113.058 -179.486 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 144' ' ' PRO . . . . . . . . . . . . . 18.3 Cg_endo -58.32 -24.85 70.06 Favored 'Trans proline' 0 C--N 1.349 0.599 0 C-N-CA 122.726 2.284 . . . . 0.0 112.527 -179.664 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 145' ' ' MET . . . . . . . . . . . . . 62.0 mtt -59.96 -25.91 65.59 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 121.14 0.495 . . . . 0.0 110.798 179.788 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 146' ' ' THR . . . . . . . . . . . . . 17.5 m -73.79 -51.2 17.2 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 115.636 -0.711 . . . . 0.0 112.364 -178.802 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 45.7 mt-10 -75.85 -28.76 58.32 Favored 'General case' 0 C--N 1.328 -0.327 0 N-CA-C 111.856 0.317 . . . . 0.0 111.856 -178.845 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 148' ' ' SER . . . . . . . . . . . . . 37.1 t -70.66 -48.09 56.64 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-O 120.746 0.307 . . . . 0.0 111.607 -179.103 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 149' ' ' ALA . . . . . . . . . . . . . . . -74.7 -44.74 48.55 Favored 'General case' 0 C--N 1.329 -0.324 0 N-CA-C 111.994 0.368 . . . . 0.0 111.994 -179.068 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 150' ' ' SER . . . . . . . . . . . . . 87.7 p -63.65 -11.83 28.73 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.647 0.261 . . . . 0.0 111.273 -179.629 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 151' ' ' GLN . . . . . . . . . . . . . 25.5 mt-30 -124.37 21.75 8.62 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.333 -0.394 . . . . 0.0 111.248 -179.702 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 28.9 tpt180 -92.02 -51.43 5.2 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.916 0.389 . . . . 0.0 110.418 179.659 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 153' ' ' SER . . . . . 0.681 ' HB3' HG12 ' A' ' 156' ' ' ILE . 32.4 t -157.43 167.76 29.29 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.09 -0.505 . . . . 0.0 110.71 179.092 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 154' ' ' SER . . . . . . . . . . . . . 44.8 t -67.65 -36.3 80.5 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-O 120.968 0.413 . . . . 0.0 110.608 179.476 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -76.97 -36.84 34.71 Favored Glycine 0 N--CA 1.451 -0.361 0 C-N-CA 120.97 -0.633 . . . . 0.0 112.887 -179.912 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 156' ' ' ILE . . . . . 0.681 HG12 ' HB3' ' A' ' 153' ' ' SER . 39.7 mm -52.83 -36.24 23.1 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.21 0 CA-C-O 120.722 0.296 . . . . 0.0 111.315 -179.922 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 157' ' ' LYS . . . . . . . . . . . . . 85.3 tttt -54.38 -49.14 70.54 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.75 -179.611 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 42.8 t -63.97 -48.43 76.47 Favored 'General case' 0 C--N 1.33 -0.245 0 N-CA-C 111.891 0.33 . . . . 0.0 111.891 -179.189 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 159' ' ' LEU . . . . . 0.526 HD23 ' O ' ' A' ' 159' ' ' LEU . 2.8 tt -67.36 -28.56 68.06 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-O 120.943 0.401 . . . . 0.0 110.673 -179.622 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 160' ' ' TYR . . . . . . . . . . . . . 25.3 t80 -73.57 -47.72 38.38 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.87 -179.245 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 31.0 m -62.46 -42.72 96.8 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.391 0 N-CA-C 112.414 0.524 . . . . 0.0 112.414 -178.565 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 162' ' ' ARG . . . . . 0.449 ' O ' HD12 ' A' ' 166' ' ' LEU . 22.3 mmm180 -68.6 -49.81 56.43 Favored 'General case' 0 C--N 1.328 -0.362 0 N-CA-C 111.746 0.276 . . . . 0.0 111.746 -178.747 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 163' ' ' LEU . . . . . 0.402 HD22 ' CD2' ' A' ' 159' ' ' LEU . 7.6 mp -70.2 -39.15 75.36 Favored 'General case' 0 C--N 1.328 -0.335 0 N-CA-C 112.195 0.443 . . . . 0.0 112.195 -178.722 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 164' ' ' ARG . . . . . 0.46 ' NH1' ' HA ' ' A' ' 141' ' ' LEU . 21.9 tpp180 -58.37 -54.37 47.75 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 120.751 0.31 . . . . 0.0 110.786 -179.783 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 165' ' ' ASN . . . . . 0.54 HD22 ' N ' ' A' ' 165' ' ' ASN . 0.8 OUTLIER -57.06 -37.82 72.36 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.005 -0.543 . . . . 0.0 110.18 179.812 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 166' ' ' LEU . . . . . 0.449 HD12 ' O ' ' A' ' 162' ' ' ARG . 3.6 mt -61.24 -56.3 22.22 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 115.914 -0.585 . . . . 0.0 111.562 179.877 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 167' ' ' THR . . . . . 0.508 ' HA ' HD11 ' A' ' 170' ' ' LEU . 16.7 m -54.31 -54.42 40.49 Favored 'General case' 0 C--N 1.331 -0.202 0 N-CA-C 112.198 0.444 . . . . 0.0 112.198 -177.981 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 168' ' ' VAL . . . . . 0.568 HG22 HD13 ' A' ' 141' ' ' LEU . 42.1 t -52.64 -41.75 38.66 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.603 0 N-CA-C 112.594 0.59 . . . . 0.0 112.594 -179.3 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 169' ' ' VAL . . . . . 0.517 ' O ' HG12 ' A' ' 173' ' ' ILE . 74.7 t -71.21 -68.08 0.42 Allowed 'Isoleucine or valine' 0 CA--C 1.531 0.245 0 N-CA-C 113.988 1.107 . . . . 0.0 113.988 -177.446 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 170' ' ' LEU . . . . . 0.508 HD11 ' HA ' ' A' ' 167' ' ' THR . 0.3 OUTLIER -57.61 -36.47 71.81 Favored 'General case' 0 N--CA 1.467 0.39 0 N-CA-C 112.835 0.68 . . . . 0.0 112.835 -177.382 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 171' ' ' TRP . . . . . 0.482 ' HB2' ' O ' ' A' ' 167' ' ' THR . 7.9 m0 -70.97 -34.21 71.19 Favored 'General case' 0 C--N 1.329 -0.321 0 C-N-CA 120.477 -0.489 . . . . 0.0 111.356 -179.785 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 172' ' ' ALA . . . . . 0.42 ' HA ' ' CZ ' ' A' ' 134' ' ' PHE . . . -72.4 -7.08 47.84 Favored 'General case' 0 C--N 1.332 -0.182 0 C-N-CA 120.797 -0.361 . . . . 0.0 110.862 179.848 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 173' ' ' ILE . . . . . 0.518 HG22 HD11 ' A' ' 177' ' ' ILE . 50.8 mm -87.59 -25.75 5.98 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.23 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.795 179.607 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 174' ' ' TYR . . . . . 0.42 ' HB2' ' HD3' ' A' ' 175' ' ' PRO . 38.8 m-85 -55.0 -49.02 94.5 Favored Pre-proline 0 CA--C 1.531 0.216 0 CA-C-N 116.253 -0.431 . . . . 0.0 111.684 -179.741 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 175' ' ' PRO . . . . . 0.438 ' HB3' ' HZ ' ' A' ' 127' ' ' PHE . 79.9 Cg_exo -45.8 -30.94 7.2 Favored 'Trans proline' 0 C--N 1.352 0.739 0 C-N-CA 122.169 1.913 . . . . 0.0 111.954 179.422 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 176' ' ' PHE . . . . . 0.481 ' O ' ' HG ' ' A' ' 180' ' ' LEU . 86.3 m-85 -80.08 -49.16 12.14 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 115.81 -0.632 . . . . 0.0 111.388 179.83 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 177' ' ' ILE . . . . . 0.518 HD11 HG22 ' A' ' 173' ' ' ILE . 3.8 mm -60.16 -36.94 71.23 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.551 0 N-CA-C 112.307 0.484 . . . . 0.0 112.307 -178.49 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 178' ' ' TRP . . . . . . . . . . . . . 76.5 t90 -73.35 -44.45 58.74 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.942 0.401 . . . . 0.0 110.619 -179.87 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 179' ' ' LEU . . . . . 0.488 ' O ' HG22 ' A' ' 185' ' ' VAL . 1.4 tm? -67.51 -54.3 21.27 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 115.952 -0.567 . . . . 0.0 111.155 -179.48 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 180' ' ' LEU . . . . . 0.645 HD22 HD11 ' A' ' 187' ' ' LEU . 16.5 mt -68.42 -50.3 53.78 Favored 'General case' 0 C--N 1.328 -0.327 0 N-CA-C 111.992 0.367 . . . . 0.0 111.992 -179.021 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . -54.62 176.35 0.44 Allowed Glycine 0 C--N 1.337 0.602 0 C-N-CA 120.219 -0.991 . . . . 0.0 112.861 -179.948 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 182' ' ' PRO . . . . . 0.492 ' HA ' ' HB2' ' A' ' 186' ' ' ALA . 83.8 Cg_exo -45.3 -44.77 15.88 Favored 'Trans proline' 0 C--N 1.349 0.583 0 C-N-CA 122.92 2.413 . . . . 0.0 113.599 179.692 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 183' ' ' PRO . . . . . 0.497 ' HB3' ' HB2' ' A' ' 116' ' ' ALA . 88.7 Cg_exo -46.38 -23.42 2.08 Favored 'Trans proline' 0 C--N 1.356 0.944 0 C-N-CA 122.277 1.985 . . . . 0.0 113.122 179.815 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 184' ' ' GLY . . . . . . . . . . . . . . . -123.53 -127.07 3.19 Favored Glycine 0 C--N 1.331 0.298 0 C-N-CA 120.554 -0.831 . . . . 0.0 112.797 -179.901 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 185' ' ' VAL . . . . . 0.488 HG22 ' O ' ' A' ' 179' ' ' LEU . 16.5 m -60.05 -19.9 18.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 N-CA-C 111.992 0.368 . . . . 0.0 111.992 -179.541 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 186' ' ' ALA . . . . . 0.492 ' HB2' ' HA ' ' A' ' 182' ' ' PRO . . . 57.51 87.18 0.07 Allowed 'General case' 0 C--N 1.331 -0.2 0 CA-C-O 120.712 0.291 . . . . 0.0 111.4 179.863 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 187' ' ' LEU . . . . . 0.645 HD11 HD22 ' A' ' 180' ' ' LEU . 21.2 mt -91.95 -49.59 6.15 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.299 -0.41 . . . . 0.0 111.079 -179.821 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 188' ' ' LEU . . . . . . . . . . . . . 90.5 mt -103.52 -161.65 0.85 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 115.961 -0.563 . . . . 0.0 110.983 -179.82 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 189' ' ' THR . . . . . . . . . . . . . 1.6 t -92.44 147.04 33.6 Favored Pre-proline 0 C--N 1.329 -0.298 0 CA-C-N 116.079 -0.509 . . . . 0.0 111.061 -179.83 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 190' ' ' PRO . . . . . . . . . . . . . 9.2 Cg_endo -52.58 -33.15 57.16 Favored 'Trans proline' 0 C--N 1.349 0.579 0 C-N-CA 122.772 2.315 . . . . 0.0 112.422 -179.949 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 191' ' ' THR . . . . . . . . . . . . . 80.6 p -62.73 -43.73 98.06 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.34 -0.391 . . . . 0.0 111.033 179.882 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 192' ' ' VAL . . . . . . . . . . . . . 30.3 t -71.51 -46.62 62.55 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 115.94 -0.573 . . . . 0.0 111.118 -179.857 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 193' ' ' ASP . . . . . . . . . . . . . 34.3 t70 -56.78 -51.59 68.35 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.398 -0.365 . . . . 0.0 111.139 -179.749 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 194' ' ' VAL . . . . . . . . . . . . . 76.3 t -61.06 -36.56 73.31 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.391 -0.368 . . . . 0.0 110.988 179.818 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 195' ' ' ALA . . . . . . . . . . . . . . . -56.01 -48.15 76.47 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.493 -0.321 . . . . 0.0 111.168 179.89 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 196' ' ' LEU . . . . . . . . . . . . . 72.1 mt -67.38 -41.39 85.1 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.421 -0.354 . . . . 0.0 110.713 179.83 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 197' ' ' ILE . . . . . . . . . . . . . 17.2 mm -57.13 -56.08 16.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.473 179.407 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 198' ' ' VAL . . . . . . . . . . . . . 71.5 t -52.9 -35.03 21.25 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.417 0 CA-C-N 115.509 -0.769 . . . . 0.0 109.471 178.612 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 199' ' ' TYR . . . . . . . . . . . . . 53.3 t80 -70.54 -36.31 73.62 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 115.333 -0.849 . . . . 0.0 110.594 179.661 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 200' ' ' LEU . . . . . . . . . . . . . 73.0 mt -64.44 -38.74 92.1 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 115.658 -0.701 . . . . 0.0 111.343 -179.63 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 201' ' ' ASP . . . . . 0.451 ' HB2' ' OH ' ' A' ' 51' ' ' TYR . 0.8 OUTLIER -73.6 -32.32 64.04 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-O 121.04 0.447 . . . . 0.0 110.39 179.663 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 202' ' ' LEU . . . . . 0.424 ' O ' ' HB ' ' A' ' 206' ' ' VAL . 3.7 mt -71.64 -32.52 68.02 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 115.831 -0.622 . . . . 0.0 111.92 -179.649 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 203' ' ' VAL . . . . . 0.474 ' O ' ' HA3' ' A' ' 207' ' ' GLY . 7.4 p -78.83 -37.02 19.7 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-O 120.639 0.257 . . . . 0.0 111.375 -178.927 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 204' ' ' THR . . . . . 0.402 HG21 ' HE1' ' A' ' 171' ' ' TRP . 26.2 m -72.87 -49.99 26.56 Favored 'General case' 0 C--N 1.326 -0.448 0 C-N-CA 120.728 -0.389 . . . . 0.0 111.31 179.696 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 205' ' ' LYS . . . . . 0.64 ' HE2' ' HB2' ' A' ' 47' ' ' ALA . 54.5 mttp -69.98 -59.26 3.03 Favored 'General case' 0 C--N 1.326 -0.421 0 N-CA-C 112.165 0.431 . . . . 0.0 112.165 -178.8 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 206' ' ' VAL . . . . . 0.424 ' HB ' ' O ' ' A' ' 202' ' ' LEU . 48.6 t -74.69 -37.61 43.34 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.25 0 N-CA-C 111.964 0.357 . . . . 0.0 111.964 -178.727 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 207' ' ' GLY . . . . . 0.566 ' O ' HD12 ' A' ' 211' ' ' ILE . . . -62.86 -56.63 19.88 Favored Glycine 0 N--CA 1.45 -0.379 0 C-N-CA 120.258 -0.972 . . . . 0.0 112.01 -179.405 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 208' ' ' PHE . . . . . 0.513 ' O ' ' N ' ' A' ' 212' ' ' ALA . 3.1 m-85 -53.95 -47.75 70.98 Favored 'General case' 0 C--O 1.22 -0.469 0 N-CA-C 109.896 -0.409 . . . . 0.0 109.896 179.606 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 209' ' ' GLY . . . . . 0.492 ' O ' ' HG ' ' A' ' 213' ' ' LEU . . . -53.9 -35.21 52.9 Favored Glycine 0 N--CA 1.45 -0.374 0 CA-C-N 115.091 -0.959 . . . . 0.0 113.399 179.585 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 210' ' ' PHE . . . . . . . . . . . . . 5.2 m-85 -72.46 -47.23 50.52 Favored 'General case' 0 CA--C 1.512 -0.498 0 N-CA-C 108.716 -0.846 . . . . 0.0 108.716 179.801 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 211' ' ' ILE . . . . . 0.566 HD12 ' O ' ' A' ' 207' ' ' GLY . 3.6 mt -65.05 -26.93 41.11 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.65 0 N-CA-C 107.665 -1.235 . . . . 0.0 107.665 176.444 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 212' ' ' ALA . . . . . 0.513 ' N ' ' O ' ' A' ' 208' ' ' PHE . . . -68.44 -38.66 81.37 Favored 'General case' 0 N--CA 1.45 -0.466 0 CA-C-N 114.3 -1.318 . . . . 0.0 110.422 -179.869 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 213' ' ' LEU . . . . . 0.492 ' HG ' ' O ' ' A' ' 209' ' ' GLY . 47.2 mt -69.82 -54.31 14.16 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-N 115.301 -0.863 . . . . 0.0 111.636 -179.498 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 214' ' ' ASP . . . . . . . . . . . . . 14.6 m-20 -52.21 -54.66 28.2 Favored 'General case' 0 C--O 1.234 0.26 0 CA-C-N 116.389 -0.369 . . . . 0.0 111.326 -179.514 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 215' ' ' ALA . . . . . . . . . . . . . . . -57.48 -54.87 41.92 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.357 -0.383 . . . . 0.0 111.036 179.984 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 216' ' ' ALA . . . . . . . . . . . . . . . -57.52 -30.73 65.39 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.28 179.925 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 217' ' ' ALA . . . . . . . . . . . . . . . -64.02 -38.34 90.73 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.557 -179.918 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 218' ' ' THR . . . . . . . . . . . . . 69.7 m . . . . . 0 C--N 1.33 -0.26 0 CA-C-N 115.82 -0.627 . . . . 0.0 111.247 179.855 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.323 0 N-CA-C 112.514 -0.235 . . . . 0.0 112.514 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 55.3 tp -74.02 -36.31 64.45 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.685 0.279 . . . . 0.0 111.21 -179.88 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 82.6 p -66.3 -29.97 70.29 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.432 -0.349 . . . . 0.0 111.409 -179.693 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 22.7 p -54.22 -35.13 62.09 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.269 179.996 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 7' ' ' LEU . . . . . . . . . . . . . 3.9 mm? -57.66 -53.13 61.66 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.111 -0.495 . . . . 0.0 111.172 -179.971 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 8' ' ' PHE . . . . . 0.675 ' HB2' ' HB2' ' A' ' 55' ' ' ALA . 77.8 m-85 -59.07 -35.66 73.75 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.346 -0.388 . . . . 0.0 110.762 179.858 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 9' ' ' TRP . . . . . . . . . . . . . 47.5 m95 -64.67 -45.91 84.67 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.024 -0.534 . . . . 0.0 110.059 -179.824 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . 0.444 ' HA ' HD12 ' A' ' 13' ' ' ILE . 87.2 mt -61.08 -37.83 84.11 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-N 115.545 -0.752 . . . . 0.0 110.154 179.333 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -65.82 -35.46 90.9 Favored Glycine 0 N--CA 1.448 -0.53 0 C-N-CA 120.814 -0.708 . . . . 0.0 111.486 179.124 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -67.44 -31.21 71.24 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 120.977 0.418 . . . . 0.0 110.476 179.448 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 13' ' ' ILE . . . . . 0.444 HD12 ' HA ' ' A' ' 10' ' ' LEU . 88.5 mt -64.68 -54.22 32.78 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.235 0 CA-C-N 115.864 -0.607 . . . . 0.0 110.214 179.418 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -65.99 -32.45 82.6 Favored Glycine 0 N--CA 1.45 -0.377 0 C-N-CA 120.61 -0.805 . . . . 0.0 111.637 179.109 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 15' ' ' MET . . . . . 0.495 ' SD ' ' HA ' ' A' ' 44' ' ' SER . 51.3 tpp -65.83 -40.16 91.53 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-O 120.823 0.344 . . . . 0.0 110.448 179.657 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 1.6 mm? -64.02 -37.98 89.4 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-N 116.08 -0.509 . . . . 0.0 110.207 179.173 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 17' ' ' VAL . . . . . 0.442 HG23 ' O ' ' A' ' 13' ' ' ILE . 72.0 t -59.04 -42.63 86.91 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.205 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.158 179.07 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -68.8 -46.2 61.63 Favored Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.731 -0.747 . . . . 0.0 111.679 178.965 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 47.9 m -50.25 -46.66 55.08 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 120.865 0.364 . . . . 0.0 111.081 179.896 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 93.6 mt -72.19 -45.75 59.08 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.035 -0.529 . . . . 0.0 111.639 179.939 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -58.85 -30.85 68.0 Favored 'General case' 0 C--N 1.329 -0.296 0 N-CA-C 112.081 0.4 . . . . 0.0 112.081 -179.23 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 22' ' ' PHE . . . . . 0.413 ' HB2' HG22 ' A' ' 41' ' ' VAL . 13.0 m-85 -90.79 -31.36 16.54 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 120.666 0.27 . . . . 0.0 111.509 -179.252 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -71.63 -50.28 32.22 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 121.101 0.477 . . . . 0.0 111.173 -179.811 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 24' ' ' TRP . . . . . . . . . . . . . 3.1 t-105 -61.43 -43.82 98.19 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-N 115.614 -0.721 . . . . 0.0 111.329 -179.624 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.328 -0.338 0 CA-C-O 120.698 0.285 . . . . 0.0 111.057 -179.989 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.25 0 N-CA-C 112.153 -0.379 . . . . 0.0 112.153 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 10.0 mm-40 -90.59 -20.68 22.32 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 120.752 0.311 . . . . 0.0 110.83 179.838 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 34' ' ' ARG . . . . . . . . . . . . . 54.3 mtp180 -48.43 -29.49 4.12 Favored 'General case' 0 C--N 1.333 -0.151 0 CA-C-N 115.997 -0.547 . . . . 0.0 111.547 -179.819 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 75.2 mtp180 -60.85 -48.38 82.07 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.44 -0.346 . . . . 0.0 111.023 -179.899 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 62.9 m-85 -68.66 -31.66 70.94 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.021 -0.536 . . . . 0.0 111.362 -179.678 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 37' ' ' TYR . . . . . . . . . . . . . 53.6 m-85 -69.4 -54.49 14.13 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.301 -0.409 . . . . 0.0 111.279 -179.498 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 85.3 t -57.08 -36.7 52.04 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.249 0 CA-C-O 121.011 0.434 . . . . 0.0 110.525 179.729 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 30.3 m -64.38 -49.43 71.65 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 115.789 -0.641 . . . . 0.0 110.502 179.354 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 30.5 tp -55.99 -47.73 77.17 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.718 -0.674 . . . . 0.0 110.286 179.614 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . 0.413 HG22 ' HB2' ' A' ' 22' ' ' PHE . 62.3 t -62.24 -34.32 63.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 115.733 -0.667 . . . . 0.0 110.016 178.95 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -57.85 -38.77 89.96 Favored Glycine 0 N--CA 1.448 -0.501 0 C-N-CA 120.859 -0.686 . . . . 0.0 112.035 179.684 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 43' ' ' ILE . . . . . 0.678 HG22 ' HE3' ' A' ' 205' ' ' LYS . 0.2 OUTLIER -68.44 -53.42 28.26 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.186 0 CA-C-O 120.825 0.345 . . . . 0.0 110.698 179.583 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 44' ' ' SER . . . . . 0.495 ' HA ' ' SD ' ' A' ' 15' ' ' MET . 45.8 m -59.11 -24.47 63.0 Favored 'General case' 0 C--N 1.333 -0.146 0 CA-C-N 116.136 -0.484 . . . . 0.0 111.466 -179.777 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -75.89 -57.16 4.19 Favored Glycine 0 CA--C 1.518 0.281 0 C-N-CA 120.766 -0.731 . . . . 0.0 113.106 -179.333 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 17.0 pt -58.17 -35.71 54.19 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-O 120.818 0.342 . . . . 0.0 111.262 -179.602 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 47' ' ' ALA . . . . . 0.694 ' HB2' ' HE2' ' A' ' 205' ' ' LYS . . . -67.73 -44.39 77.71 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-O 120.966 0.412 . . . . 0.0 110.943 179.158 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -54.38 -44.46 72.29 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 115.791 -0.641 . . . . 0.0 111.723 -179.385 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 34.2 m -71.54 -34.04 51.48 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.228 0 CA-C-N 116.532 -0.304 . . . . 0.0 111.415 -179.63 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -64.34 -37.33 87.13 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 121.046 0.45 . . . . 0.0 110.874 179.695 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 51' ' ' TYR . . . . . 0.43 ' OH ' ' HB2' ' A' ' 201' ' ' ASP . 33.2 m-85 -73.36 -36.19 66.07 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 115.946 -0.57 . . . . 0.0 110.62 179.979 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -65.99 -38.97 89.88 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 115.826 -0.625 . . . . 0.0 111.025 179.796 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 53' ' ' VAL . . . . . 0.509 ' O ' HG12 ' A' ' 58' ' ' VAL . 33.6 m -74.81 -50.35 25.9 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.194 0 CA-C-N 116.588 -0.278 . . . . 0.0 111.05 -179.887 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 54' ' ' MET . . . . . 0.504 ' N ' HG23 ' A' ' 53' ' ' VAL . 75.8 mtm -58.02 -29.69 65.51 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-O 121.009 0.433 . . . . 0.0 110.309 179.514 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 55' ' ' ALA . . . . . 0.675 ' HB2' ' HB2' ' A' ' 8' ' ' PHE . . . -73.85 -25.92 60.31 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 115.786 -0.643 . . . . 0.0 111.278 179.732 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 74.6 mt -80.28 -8.37 59.44 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.276 -0.42 . . . . 0.0 111.622 -179.625 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 102.31 -17.48 53.63 Favored Glycine 0 N--CA 1.453 -0.226 0 C-N-CA 120.438 -0.887 . . . . 0.0 113.054 179.671 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 58' ' ' VAL . . . . . 0.509 HG12 ' O ' ' A' ' 53' ' ' VAL . 12.7 p -69.43 150.86 10.21 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.957 0.379 . . . . 0.0 110.439 179.717 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 75.55 27.24 63.67 Favored Glycine 0 N--CA 1.449 -0.472 0 C-N-CA 120.723 -0.751 . . . . 0.0 111.731 -178.946 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 60' ' ' TRP . . . . . . . . . . . . . 13.8 m0 -108.7 99.15 8.55 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-O 120.947 0.403 . . . . 0.0 110.285 -179.879 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 61' ' ' VAL . . . . . 0.575 ' HB ' HG23 ' A' ' 68' ' ' VAL . 25.6 t -97.77 110.69 56.45 Favored Pre-proline 0 C--N 1.325 -0.459 0 CA-C-N 115.877 -0.601 . . . . 0.0 111.526 -179.299 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 17.2 Cg_exo -67.2 138.87 48.49 Favored 'Trans proline' 0 C--N 1.35 0.606 0 C-N-CA 122.577 2.184 . . . . 0.0 111.866 179.678 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 93.1 t -139.96 92.17 0.65 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.38 -179.694 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . 56.65 -91.7 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.117 -0.492 . . . . 0.0 111.85 179.656 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 42.9 mt-10 -115.23 -17.61 11.31 Favored 'General case' 0 C--N 1.332 -0.195 0 CA-C-O 120.837 0.351 . . . . 0.0 111.054 -179.652 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 66' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -104.81 165.56 10.99 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.285 179.77 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 91.0 m -130.09 118.81 22.08 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-N 116.295 -0.411 . . . . 0.0 111.414 -179.573 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 68' ' ' VAL . . . . . 0.575 HG23 ' HB ' ' A' ' 61' ' ' VAL . 18.5 m -100.37 141.51 17.18 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.377 0 CA-C-N 115.991 -0.55 . . . . 0.0 110.53 179.495 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 69' ' ' PHE . . . . . . . . . . . . . 24.2 m-85 -109.84 122.75 48.24 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.276 -0.42 . . . . 0.0 110.248 -179.428 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 70' ' ' VAL . . . . . 0.621 HG12 ' HD3' ' A' ' 71' ' ' PRO . 1.3 p -68.13 -35.97 8.33 Favored Pre-proline 0 CA--C 1.54 0.573 0 N-CA-C 112.549 0.574 . . . . 0.0 112.549 -179.541 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 71' ' ' PRO . . . . . 0.621 ' HD3' HG12 ' A' ' 70' ' ' VAL . 5.7 Cg_exo -71.48 -19.87 28.0 Favored 'Trans proline' 0 C--N 1.359 1.122 0 C-N-CA 121.942 1.762 . . . . 0.0 112.47 -179.729 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 56.5 ttt180 -68.68 -55.28 11.95 Favored 'General case' 0 C--O 1.236 0.378 0 CA-C-N 116.403 -0.362 . . . . 0.0 111.67 -179.181 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 73' ' ' TYR . . . . . 0.436 ' O ' HG13 ' A' ' 77' ' ' ILE . 28.2 m-85 -72.17 -30.16 64.71 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.492 -0.322 . . . . 0.0 110.655 -179.418 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 74' ' ' ILE . . . . . 0.524 HG22 ' HA ' ' A' ' 71' ' ' PRO . 0.4 OUTLIER -72.52 -38.29 59.31 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.237 0 N-CA-C 109.829 -0.434 . . . . 0.0 109.829 179.253 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 75' ' ' ASP . . . . . 0.454 ' O ' HG23 ' A' ' 79' ' ' THR . 12.9 t70 -59.11 -38.69 80.15 Favored 'General case' 0 CA--C 1.518 -0.257 0 N-CA-C 109.322 -0.621 . . . . 0.0 109.322 178.861 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 76' ' ' TRP . . . . . . . . . . . . . 45.6 m0 -65.73 -37.74 87.23 Favored 'General case' 0 C--N 1.331 -0.21 0 CA-C-N 115.702 -0.681 . . . . 0.0 110.358 179.166 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 77' ' ' ILE . . . . . 0.51 ' O ' ' HG2' ' A' ' 81' ' ' PRO . 89.5 mt -62.4 -30.67 49.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.468 178.973 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 41.7 mt -92.06 -19.81 21.96 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.07 -0.514 . . . . 0.0 112.222 -179.717 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 79' ' ' THR . . . . . 0.454 HG23 ' O ' ' A' ' 75' ' ' ASP . 73.6 p -101.28 -52.99 3.12 Favored 'General case' 0 N--CA 1.463 0.205 0 N-CA-C 113.446 0.906 . . . . 0.0 113.446 -178.033 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 80' ' ' THR . . . . . 0.661 ' HB ' ' HD3' ' A' ' 81' ' ' PRO . 59.8 m -48.74 -53.97 31.75 Favored Pre-proline 0 C--N 1.331 -0.219 0 N-CA-C 112.406 0.521 . . . . 0.0 112.406 -178.838 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 81' ' ' PRO . . . . . 0.661 ' HD3' ' HB ' ' A' ' 80' ' ' THR . 31.5 Cg_exo -59.87 -23.4 72.29 Favored 'Trans proline' 0 C--N 1.353 0.805 0 C-N-CA 121.718 1.612 . . . . 0.0 111.772 179.965 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 82' ' ' LEU . . . . . . . . . . . . . 18.4 tp -76.93 -33.11 57.74 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.043 -0.526 . . . . 0.0 110.469 179.68 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 83' ' ' ILE . . . . . 0.449 HD11 HG21 ' A' ' 43' ' ' ILE . 35.0 mm -68.26 -53.71 26.96 Favored 'Isoleucine or valine' 0 C--O 1.234 0.244 0 CA-C-N 116.367 -0.379 . . . . 0.0 110.036 179.246 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 20.7 m -59.98 -30.98 46.65 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.23 0 N-CA-C 109.415 -0.587 . . . . 0.0 109.415 178.506 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 85' ' ' TYR . . . . . . . . . . . . . 80.8 t80 -66.38 -31.49 72.3 Favored 'General case' 0 N--CA 1.454 -0.242 0 CA-C-N 115.382 -0.827 . . . . 0.0 109.637 178.764 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 86' ' ' PHE . . . . . . . . . . . . . 14.6 t80 -64.33 -51.34 63.88 Favored 'General case' 0 C--O 1.232 0.169 0 CA-C-N 115.819 -0.628 . . . . 0.0 109.865 179.385 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 7.4 mp -60.8 -36.04 78.03 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 115.729 -0.668 . . . . 0.0 110.253 179.445 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -67.24 -27.67 73.54 Favored Glycine 0 N--CA 1.45 -0.395 0 C-N-CA 120.904 -0.665 . . . . 0.0 112.082 179.657 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 40.5 mt -71.66 -42.55 67.37 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-O 121.027 0.441 . . . . 0.0 110.421 179.801 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 90' ' ' LEU . . . . . 0.417 ' HB3' HG23 ' A' ' 156' ' ' ILE . 81.0 mt -56.13 -42.43 76.89 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 115.688 -0.687 . . . . 0.0 111.198 -179.971 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 91' ' ' ALA . . . . . 0.597 ' HB2' ' HB2' ' A' ' 149' ' ' ALA . . . -79.3 -45.99 18.59 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.311 -0.404 . . . . 0.0 111.393 -179.597 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 97.73 50.66 1.63 Allowed Glycine 0 N--CA 1.45 -0.373 0 C-N-CA 120.712 -0.756 . . . . 0.0 112.229 -179.583 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 93' ' ' LEU . . . . . 0.527 HD23 ' HB3' ' A' ' 97' ' ' GLU . 10.8 mp -61.61 171.55 1.5 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.958 0.409 . . . . 0.0 111.24 -179.891 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 94' ' ' ASP . . . . . . . . . . . . . 24.2 t70 -90.46 167.61 12.47 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 115.963 -0.562 . . . . 0.0 110.462 179.722 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 47.3 t -55.04 -35.42 64.46 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.355 -0.384 . . . . 0.0 111.107 179.983 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 5.3 mmp_? -73.83 -50.49 20.18 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.09 -0.504 . . . . 0.0 111.33 -179.858 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 97' ' ' GLU . . . . . 0.527 ' HB3' HD23 ' A' ' 93' ' ' LEU . 46.6 mt-10 -52.37 -45.2 65.66 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.34 -0.391 . . . . 0.0 111.291 -179.606 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 98' ' ' PHE . . . . . 0.416 ' O ' HG12 ' A' ' 102' ' ' ILE . 28.2 m-85 -59.55 -46.69 88.16 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.488 -0.324 . . . . 0.0 110.864 179.824 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -57.67 -28.58 60.21 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.524 -0.846 . . . . 0.0 112.466 179.848 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 79.6 mt -73.83 -48.7 38.26 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.181 0 N-CA-C 112.125 0.417 . . . . 0.0 112.125 -179.563 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 29.4 m -67.98 -41.75 84.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 N-CA-C 112.049 0.388 . . . . 0.0 112.049 -179.001 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 102' ' ' ILE . . . . . 0.482 HG23 ' HB3' ' A' ' 81' ' ' PRO . 50.9 mm -63.88 -49.35 82.22 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.675 -0.239 . . . . 0.0 111.505 -179.463 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 15.3 t -59.72 -34.75 73.33 Favored 'General case' 0 C--O 1.233 0.208 0 CA-C-O 120.951 0.405 . . . . 0.0 110.643 179.873 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 1.3 tm? -56.29 -54.08 49.67 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.008 -0.542 . . . . 0.0 109.698 179.05 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 105' ' ' ASN . . . . . 0.638 ' N ' HD22 ' A' ' 105' ' ' ASN . 0.8 OUTLIER -58.23 -34.03 69.99 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 115.591 -0.731 . . . . 0.0 110.83 179.605 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 85.4 m -56.54 -43.79 80.24 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.295 -0.411 . . . . 0.0 110.734 179.803 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 1.5 t -66.81 -42.18 88.87 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-O 121.2 0.524 . . . . 0.0 110.348 179.383 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 93.5 t -57.99 -51.17 73.99 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.386 0 CA-C-N 115.318 -0.856 . . . . 0.0 111.679 -179.722 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 109' ' ' MET . . . . . 0.61 ' HE1' HG21 ' A' ' 80' ' ' THR . 1.5 mpp? -65.22 -37.52 87.53 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.37 -179.588 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 32.4 tp -66.71 -31.5 72.2 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 116.39 -0.368 . . . . 0.0 110.58 -179.893 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -65.42 -52.56 52.5 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.394 179.487 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . -66.26 -31.43 79.07 Favored Glycine 0 N--CA 1.449 -0.434 0 C-N-CA 120.749 -0.738 . . . . 0.0 111.883 179.37 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 113' ' ' PHE . . . . . . . . . . . . . 0.4 OUTLIER -57.14 -70.69 0.12 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 121.032 0.444 . . . . 0.0 110.061 179.567 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 114' ' ' ALA . . . . . 0.505 ' HB3' HD22 ' A' ' 126' ' ' LEU . . . -64.09 -18.55 64.49 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 115.72 -0.673 . . . . 0.0 110.758 179.577 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -57.77 -53.62 43.79 Favored Glycine 0 C--N 1.332 0.314 0 C-N-CA 120.943 -0.646 . . . . 0.0 112.263 179.802 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 116' ' ' ALA . . . . . 0.547 ' HB2' ' HB3' ' A' ' 183' ' ' PRO . . . -77.48 -14.98 59.56 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.784 0.326 . . . . 0.0 111.271 179.927 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 117' ' ' MET . . . . . 0.479 ' SD ' HG21 ' A' ' 68' ' ' VAL . 17.9 mmt -86.33 13.71 7.71 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.129 -0.487 . . . . 0.0 111.589 -179.504 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 20.4 m -87.22 143.03 33.99 Favored Pre-proline 0 C--N 1.33 -0.255 0 CA-C-O 120.563 0.221 . . . . 0.0 111.371 -179.916 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 119' ' ' PRO . . . . . . . . . . . . . 68.2 Cg_endo -92.56 -2.66 3.76 Favored 'Trans proline' 0 N--CA 1.455 -0.776 0 C-N-CA 122.945 2.43 . . . . 0.0 112.267 179.441 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -132.81 -117.66 1.86 Allowed Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.779 -0.724 . . . . 0.0 112.805 -179.668 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 39.6 pt -123.26 12.97 5.31 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.234 0 CA-C-O 120.654 0.264 . . . . 0.0 111.547 -179.514 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 37.7 mt-10 -61.23 -18.65 59.4 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.375 -0.375 . . . . 0.0 110.822 179.912 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 123' ' ' ARG . . . . . 0.471 ' HB2' ' HH2' ' A' ' 178' ' ' TRP . 23.0 ptt180 -51.93 -33.79 38.92 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 115.927 -0.579 . . . . 0.0 111.615 -179.84 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 124' ' ' TYR . . . . . . . . . . . . . 59.0 m-85 -67.49 -33.3 74.81 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.459 -0.337 . . . . 0.0 111.397 -179.622 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 125' ' ' ALA . . . . . . . . . . . . . . . -72.71 -56.46 5.25 Favored 'General case' 0 C--O 1.237 0.411 0 CA-C-O 121.105 0.479 . . . . 0.0 111.073 179.835 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 126' ' ' LEU . . . . . 0.505 HD22 ' HB3' ' A' ' 114' ' ' ALA . 1.3 mt -55.24 -48.1 74.44 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 115.729 -0.669 . . . . 0.0 110.395 179.847 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 127' ' ' PHE . . . . . 0.418 ' HZ ' ' HB3' ' A' ' 175' ' ' PRO . 9.2 t80 -67.76 -30.76 70.3 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.11 -0.496 . . . . 0.0 110.334 179.316 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 128' ' ' GLY . . . . . . . . . . . . . . . -49.12 -50.58 27.76 Favored Glycine 0 N--CA 1.449 -0.441 0 C-N-CA 120.125 -1.036 . . . . 0.0 110.553 178.734 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 129' ' ' MET . . . . . 0.541 ' HE3' ' HA2' ' A' ' 130' ' ' GLY . 0.0 OUTLIER -70.84 -28.24 64.45 Favored 'General case' 0 N--CA 1.453 -0.293 0 N-CA-C 109.02 -0.733 . . . . 0.0 109.02 178.283 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 130' ' ' GLY . . . . . 0.541 ' HA2' ' HE3' ' A' ' 129' ' ' MET . . . -60.09 -41.63 98.14 Favored Glycine 0 C--N 1.335 0.48 0 CA-C-N 115.772 -0.649 . . . . 0.0 112.441 179.364 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -71.04 -49.43 44.99 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-O 120.66 0.267 . . . . 0.0 110.503 179.733 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 57.7 t -57.4 -43.72 83.07 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.217 0 CA-C-O 121.139 0.495 . . . . 0.0 109.81 179.068 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -65.86 -33.01 74.87 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 115.538 -0.756 . . . . 0.0 110.603 179.193 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 134' ' ' PHE . . . . . 0.409 ' HE1' ' HB3' ' A' ' 171' ' ' TRP . 71.6 t80 -59.02 -54.62 45.11 Favored 'General case' 0 N--CA 1.451 -0.385 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.038 179.58 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 135' ' ' ILE . . . . . 0.508 ' O ' HG22 ' A' ' 138' ' ' VAL . 38.2 mt -57.19 -30.38 34.74 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.312 0 CA-C-N 115.805 -0.634 . . . . 0.0 109.916 178.98 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . -62.88 -37.37 94.79 Favored Glycine 0 N--CA 1.447 -0.601 0 C-N-CA 120.31 -0.948 . . . . 0.0 111.301 178.877 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 137' ' ' LEU . . . . . 0.58 HD13 HD21 ' A' ' 105' ' ' ASN . 21.4 tp -71.45 -51.77 22.05 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 120.582 0.23 . . . . 0.0 110.8 179.536 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 138' ' ' VAL . . . . . 0.508 HG22 ' O ' ' A' ' 135' ' ' ILE . 3.9 m -56.15 -31.9 32.92 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.213 0 CA-C-O 121.299 0.571 . . . . 0.0 109.479 179.377 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 139' ' ' TYR . . . . . . . . . . . . . 35.3 t80 -63.99 -44.67 91.96 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 115.29 -0.868 . . . . 0.0 110.136 178.882 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 140' ' ' TYR . . . . . 0.47 ' HB3' ' SD ' ' A' ' 145' ' ' MET . 23.6 m-85 -54.65 -47.01 74.04 Favored 'General case' 0 C--N 1.332 -0.167 0 CA-C-N 115.974 -0.557 . . . . 0.0 111.006 179.622 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 141' ' ' LEU . . . . . . . . . . . . . 93.2 mt -59.04 -40.81 86.23 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.252 -0.431 . . . . 0.0 111.064 -179.885 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 37.8 t -79.73 -12.46 13.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-O 121.063 0.459 . . . . 0.0 110.823 179.902 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . -70.88 -140.64 0.2 Allowed Glycine 0 CA--C 1.522 0.471 0 C-N-CA 120.989 -0.624 . . . . 0.0 112.715 -179.913 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 144' ' ' PRO . . . . . . . . . . . . . 56.6 Cg_endo -70.1 -22.77 30.07 Favored 'Trans proline' 0 C--N 1.349 0.575 0 C-N-CA 122.767 2.312 . . . . 0.0 112.894 -179.93 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 145' ' ' MET . . . . . 0.47 ' SD ' ' HB3' ' A' ' 140' ' ' TYR . 81.0 mtp -52.5 -53.48 45.4 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.281 -0.418 . . . . 0.0 111.794 -179.223 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 146' ' ' THR . . . . . . . . . . . . . 10.2 t -62.45 -32.83 73.75 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.726 0.298 . . . . 0.0 111.586 -179.53 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 45.0 mt-10 -71.35 -32.64 68.78 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.309 -0.405 . . . . 0.0 111.087 -179.837 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 148' ' ' SER . . . . . . . . . . . . . 59.6 m -70.23 -36.6 74.62 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.114 -0.494 . . . . 0.0 111.21 -179.788 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 149' ' ' ALA . . . . . 0.597 ' HB2' ' HB2' ' A' ' 91' ' ' ALA . . . -75.47 -39.46 58.64 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.265 -0.425 . . . . 0.0 111.69 -179.585 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 150' ' ' SER . . . . . . . . . . . . . 69.8 m -66.19 -4.39 7.54 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.39 -0.368 . . . . 0.0 111.217 -179.792 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 151' ' ' GLN . . . . . . . . . . . . . 47.8 mt-30 -124.59 14.53 8.77 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.389 -0.369 . . . . 0.0 111.303 -179.907 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 31.9 tpt180 -91.74 -51.55 5.18 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 120.972 0.415 . . . . 0.0 110.653 179.786 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 153' ' ' SER . . . . . 0.598 ' HB2' HG12 ' A' ' 156' ' ' ILE . 45.4 m -157.54 172.63 18.2 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 115.87 -0.604 . . . . 0.0 110.576 179.466 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 154' ' ' SER . . . . . . . . . . . . . 47.9 t -67.53 -41.84 83.69 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.393 -0.367 . . . . 0.0 110.769 179.841 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -76.69 -35.89 39.19 Favored Glycine 0 C--N 1.332 0.312 0 C-N-CA 120.85 -0.691 . . . . 0.0 112.804 -179.946 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 156' ' ' ILE . . . . . 0.598 HG12 ' HB2' ' A' ' 153' ' ' SER . 39.9 mm -56.23 -39.37 59.23 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.224 0 CA-C-O 120.729 0.299 . . . . 0.0 111.46 -179.729 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 157' ' ' LYS . . . . . 0.409 ' O ' HG13 ' A' ' 161' ' ' VAL . 62.3 tttp -61.92 -51.08 69.6 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.296 -0.411 . . . . 0.0 111.329 -179.758 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 51.4 m -64.87 -35.41 81.04 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.37 -0.377 . . . . 0.0 111.499 -179.154 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 159' ' ' LEU . . . . . 0.554 HD21 ' HB3' ' A' ' 215' ' ' ALA . 10.8 mt -68.84 -59.28 3.19 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-N 116.312 -0.403 . . . . 0.0 111.655 -179.507 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 160' ' ' TYR . . . . . . . . . . . . . 19.4 t80 -52.45 -44.97 65.82 Favored 'General case' 0 C--N 1.327 -0.374 0 N-CA-C 112.228 0.455 . . . . 0.0 112.228 -178.947 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 161' ' ' VAL . . . . . 0.475 HG23 ' N ' ' A' ' 162' ' ' ARG . 36.0 m -63.65 -45.8 96.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 N-CA-C 112.504 0.557 . . . . 0.0 112.504 -178.289 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 162' ' ' ARG . . . . . 0.595 ' O ' HD12 ' A' ' 166' ' ' LEU . 99.4 mtt180 -63.65 -49.72 72.1 Favored 'General case' 0 C--N 1.327 -0.377 0 N-CA-C 111.78 0.289 . . . . 0.0 111.78 -179.009 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 163' ' ' LEU . . . . . 0.488 ' HG ' ' O ' ' A' ' 159' ' ' LEU . 11.0 mt -67.7 -39.86 84.35 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.39 -0.368 . . . . 0.0 111.345 -178.873 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 164' ' ' ARG . . . . . . . . . . . . . 4.1 tmm_? -59.11 -47.78 84.0 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.446 -0.343 . . . . 0.0 110.756 -179.847 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 165' ' ' ASN . . . . . 0.495 HD22 ' N ' ' A' ' 165' ' ' ASN . 0.9 OUTLIER -56.02 -48.74 75.39 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.303 -0.408 . . . . 0.0 110.297 179.708 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 166' ' ' LEU . . . . . 0.595 HD12 ' O ' ' A' ' 162' ' ' ARG . 1.4 mt -57.89 -45.82 85.85 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.016 -0.538 . . . . 0.0 110.763 179.364 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 167' ' ' THR . . . . . 0.656 ' HA ' HD11 ' A' ' 170' ' ' LEU . 13.9 m -54.4 -51.42 64.91 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-N 115.936 -0.574 . . . . 0.0 112.051 -178.767 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 168' ' ' VAL . . . . . . . . . . . . . 49.3 t -57.76 -40.02 73.62 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.449 0 N-CA-C 111.903 0.334 . . . . 0.0 111.903 -179.386 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 169' ' ' VAL . . . . . 0.43 ' O ' HG12 ' A' ' 173' ' ' ILE . 93.0 t -66.74 -67.69 0.39 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 N-CA-C 113.622 0.971 . . . . 0.0 113.622 -177.947 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 170' ' ' LEU . . . . . 0.656 HD11 ' HA ' ' A' ' 167' ' ' THR . 0.4 OUTLIER -61.14 -34.06 74.39 Favored 'General case' 0 N--CA 1.463 0.222 0 N-CA-C 112.899 0.703 . . . . 0.0 112.899 -177.475 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 171' ' ' TRP . . . . . 0.582 ' H ' HD12 ' A' ' 170' ' ' LEU . 26.9 m0 -72.59 -30.64 64.55 Favored 'General case' 0 C--N 1.327 -0.401 0 C-N-CA 120.612 -0.435 . . . . 0.0 111.514 -179.283 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 172' ' ' ALA . . . . . . . . . . . . . . . -73.04 -7.86 53.15 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-O 121.036 0.446 . . . . 0.0 110.474 179.916 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 173' ' ' ILE . . . . . 0.498 ' O ' HG12 ' A' ' 177' ' ' ILE . 37.3 mm -88.7 -26.05 5.66 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.222 0 CA-C-N 115.808 -0.633 . . . . 0.0 110.784 179.564 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 174' ' ' TYR . . . . . 0.448 ' HD1' ' HA ' ' A' ' 171' ' ' TRP . 24.1 m-85 -54.28 -49.02 92.75 Favored Pre-proline 0 N--CA 1.462 0.17 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.933 -179.197 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 175' ' ' PRO . . . . . 0.418 ' HB3' ' HZ ' ' A' ' 127' ' ' PHE . 82.8 Cg_exo -45.85 -32.74 9.63 Favored 'Trans proline' 0 C--N 1.351 0.675 0 C-N-CA 121.898 1.732 . . . . 0.0 111.798 179.555 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 176' ' ' PHE . . . . . 0.476 ' O ' ' HG ' ' A' ' 180' ' ' LEU . 60.1 m-85 -80.98 -50.77 9.29 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 115.692 -0.686 . . . . 0.0 111.717 -179.995 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 177' ' ' ILE . . . . . 0.498 HG12 ' O ' ' A' ' 173' ' ' ILE . 10.8 mm -58.69 -38.33 71.01 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.567 0 CA-C-N 116.015 -0.539 . . . . 0.0 111.897 -178.283 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 178' ' ' TRP . . . . . 0.471 ' HH2' ' HB2' ' A' ' 123' ' ' ARG . 83.4 t90 -65.88 -56.26 12.74 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-O 120.875 0.369 . . . . 0.0 110.894 -179.951 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 179' ' ' LEU . . . . . 0.688 ' HG ' HG22 ' A' ' 185' ' ' VAL . 34.0 tp -64.1 -55.24 23.42 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 115.971 -0.559 . . . . 0.0 112.066 -178.689 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 180' ' ' LEU . . . . . 0.698 HD22 HD11 ' A' ' 187' ' ' LEU . 10.1 mt -62.69 -28.65 70.09 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.661 -0.245 . . . . 0.0 111.283 -179.171 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . -72.18 -171.61 17.0 Favored Glycine 0 N--CA 1.45 -0.419 0 C-N-CA 119.929 -1.129 . . . . 0.0 111.922 179.157 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 182' ' ' PRO . . . . . 0.44 ' N ' ' HD2' ' A' ' 183' ' ' PRO . 71.4 Cg_exo -49.84 -43.63 40.08 Favored 'Trans proline' 0 CA--C 1.538 0.708 0 C-N-CA 122.759 2.306 . . . . 0.0 113.756 179.609 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 183' ' ' PRO . . . . . 0.547 ' HB3' ' HB2' ' A' ' 116' ' ' ALA . 60.7 Cg_exo -39.37 -55.74 1.46 Allowed 'Trans proline' 0 C--N 1.358 1.036 0 C-N-CA 122.73 2.287 . . . . 0.0 113.904 -179.414 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 184' ' ' GLY . . . . . . . . . . . . . . . -115.79 -111.91 2.78 Favored Glycine 0 N--CA 1.45 -0.387 0 C-N-CA 120.203 -0.999 . . . . 0.0 112.672 -179.551 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 185' ' ' VAL . . . . . 0.688 HG22 ' HG ' ' A' ' 179' ' ' LEU . 35.8 m -76.39 84.74 0.74 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.466 0 CA-C-O 121.467 0.651 . . . . 0.0 110.693 -179.74 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 186' ' ' ALA . . . . . . . . . . . . . . . -62.9 84.07 0.02 OUTLIER 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 115.73 -0.668 . . . . 0.0 111.361 179.999 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 187' ' ' LEU . . . . . 0.698 HD11 HD22 ' A' ' 180' ' ' LEU . 5.0 mt -77.27 -48.99 16.01 Favored 'General case' 0 C--N 1.332 -0.181 0 CA-C-O 120.964 0.411 . . . . 0.0 110.64 179.73 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 188' ' ' LEU . . . . . . . . . . . . . 83.1 mt -92.41 -162.13 0.9 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 115.811 -0.631 . . . . 0.0 111.378 -179.421 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 189' ' ' THR . . . . . . . . . . . . . 88.4 m -94.58 136.57 23.05 Favored Pre-proline 0 C--N 1.328 -0.349 0 CA-C-N 115.708 -0.678 . . . . 0.0 110.729 -179.974 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 190' ' ' PRO . . . . . 0.402 ' O ' HG23 ' A' ' 194' ' ' VAL . 80.0 Cg_exo -45.33 -43.68 16.84 Favored 'Trans proline' 0 C--N 1.35 0.609 0 C-N-CA 122.561 2.174 . . . . 0.0 112.63 179.743 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 191' ' ' THR . . . . . . . . . . . . . 82.6 p -58.72 -46.39 87.46 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.329 -0.396 . . . . 0.0 111.042 179.922 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 192' ' ' VAL . . . . . . . . . . . . . 87.6 t -63.14 -47.37 92.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.117 -0.492 . . . . 0.0 111.195 -179.983 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 193' ' ' ASP . . . . . . . . . . . . . 22.3 t70 -54.83 -48.12 73.24 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.055 -0.521 . . . . 0.0 111.311 -179.705 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 194' ' ' VAL . . . . . 0.417 ' O ' HG23 ' A' ' 198' ' ' VAL . 99.7 t -64.35 -36.12 76.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.281 -0.418 . . . . 0.0 110.887 -179.848 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 195' ' ' ALA . . . . . . . . . . . . . . . -58.2 -46.03 86.54 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.413 -0.358 . . . . 0.0 111.04 179.915 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 196' ' ' LEU . . . . . 0.416 ' O ' ' HG ' ' A' ' 200' ' ' LEU . 94.1 mt -67.01 -42.07 85.6 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.419 -0.355 . . . . 0.0 110.38 179.713 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 197' ' ' ILE . . . . . . . . . . . . . 18.7 mm -57.31 -57.83 8.46 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.231 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.398 179.256 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 198' ' ' VAL . . . . . 0.417 HG23 ' O ' ' A' ' 194' ' ' VAL . 91.0 t -52.65 -34.82 20.08 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.493 0 CA-C-N 115.598 -0.728 . . . . 0.0 109.328 178.618 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 199' ' ' TYR . . . . . . . . . . . . . 64.4 t80 -70.41 -35.36 73.39 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 115.288 -0.869 . . . . 0.0 110.73 179.704 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 200' ' ' LEU . . . . . 0.416 ' HG ' ' O ' ' A' ' 196' ' ' LEU . 73.1 mt -66.15 -41.34 90.54 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 115.762 -0.654 . . . . 0.0 111.322 -179.485 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 201' ' ' ASP . . . . . 0.43 ' HB2' ' OH ' ' A' ' 51' ' ' TYR . 9.9 m-20 -71.81 -31.83 66.97 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 116.29 -0.414 . . . . 0.0 110.482 179.879 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 202' ' ' LEU . . . . . 0.455 ' O ' ' HB ' ' A' ' 206' ' ' VAL . 3.6 mt -72.66 -34.11 67.02 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 115.831 -0.622 . . . . 0.0 111.997 -179.558 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 203' ' ' VAL . . . . . 0.472 ' O ' ' HA3' ' A' ' 207' ' ' GLY . 7.7 p -75.42 -36.68 36.34 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-O 120.609 0.242 . . . . 0.0 111.177 -179.032 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 204' ' ' THR . . . . . . . . . . . . . 25.6 m -68.41 -55.26 12.54 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-O 120.879 0.371 . . . . 0.0 111.397 179.789 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 205' ' ' LYS . . . . . 0.694 ' HE2' ' HB2' ' A' ' 47' ' ' ALA . 54.3 mttp -68.6 -58.96 3.5 Favored 'General case' 0 C--N 1.328 -0.359 0 N-CA-C 112.397 0.517 . . . . 0.0 112.397 -178.599 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 206' ' ' VAL . . . . . 0.455 ' HB ' ' O ' ' A' ' 202' ' ' LEU . 76.6 t -73.3 -38.13 53.19 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 N-CA-C 112.217 0.451 . . . . 0.0 112.217 -178.702 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 207' ' ' GLY . . . . . 0.472 ' HA3' ' O ' ' A' ' 203' ' ' VAL . . . -63.85 -59.78 8.17 Favored Glycine 0 N--CA 1.452 -0.261 0 C-N-CA 120.341 -0.933 . . . . 0.0 112.514 -179.324 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 208' ' ' PHE . . . . . 0.512 ' O ' ' N ' ' A' ' 212' ' ' ALA . 1.8 m-30 -54.53 -47.89 72.61 Favored 'General case' 0 C--O 1.221 -0.407 0 N-CA-C 109.795 -0.446 . . . . 0.0 109.795 179.515 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 209' ' ' GLY . . . . . 0.492 ' HA2' ' HB3' ' A' ' 212' ' ' ALA . . . -54.29 -35.07 54.73 Favored Glycine 0 N--CA 1.448 -0.508 0 CA-C-N 115.366 -0.834 . . . . 0.0 113.144 179.558 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 210' ' ' PHE . . . . . . . . . . . . . 1.9 m-85 -69.69 -47.67 62.41 Favored 'General case' 0 CA--C 1.515 -0.403 0 N-CA-C 108.677 -0.86 . . . . 0.0 108.677 179.334 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 211' ' ' ILE . . . . . 0.423 HG13 ' O ' ' A' ' 207' ' ' GLY . 4.0 mt -66.14 -27.47 40.9 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.486 0 N-CA-C 107.587 -1.264 . . . . 0.0 107.587 176.757 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 212' ' ' ALA . . . . . 0.512 ' N ' ' O ' ' A' ' 208' ' ' PHE . . . -67.4 -39.07 85.52 Favored 'General case' 0 N--CA 1.448 -0.536 0 CA-C-N 114.302 -1.317 . . . . 0.0 110.018 -179.768 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 213' ' ' LEU . . . . . . . . . . . . . 80.7 mt -70.21 -38.05 75.19 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 114.991 -1.004 . . . . 0.0 111.275 -179.841 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 214' ' ' ASP . . . . . . . . . . . . . 26.9 t70 -60.3 -55.09 37.87 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 116.328 -0.396 . . . . 0.0 111.016 -179.808 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 215' ' ' ALA . . . . . 0.554 ' HB3' HD21 ' A' ' 159' ' ' LEU . . . -61.05 -50.89 71.49 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.758 179.709 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 216' ' ' ALA . . . . . . . . . . . . . . . -57.45 -32.49 66.98 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.946 179.683 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 217' ' ' ALA . . . . . . . . . . . . . . . -62.72 -43.3 99.15 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-N 116.086 -0.506 . . . . 0.0 110.17 179.544 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 218' ' ' THR . . . . . . . . . . . . . 91.8 m . . . . . 0 C--N 1.331 -0.229 0 CA-C-N 115.897 -0.592 . . . . 0.0 110.472 179.267 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.422 0 N-CA-C 112.744 -0.143 . . . . 0.0 112.744 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 52.0 tp -74.15 -35.47 64.05 Favored 'General case' 0 C--N 1.331 -0.21 0 CA-C-O 120.867 0.365 . . . . 0.0 110.752 179.928 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 64.9 p -64.15 -32.61 74.24 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.014 -0.539 . . . . 0.0 111.276 -179.99 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 15.9 p -52.87 -35.4 57.71 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.264 -179.647 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 7' ' ' LEU . . . . . 0.412 HD12 ' HA ' ' A' ' 195' ' ' ALA . 4.2 mm? -60.8 -53.34 58.52 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.242 -179.814 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 8' ' ' PHE . . . . . 0.437 ' HB2' ' HB2' ' A' ' 55' ' ' ALA . 64.0 m-85 -60.08 -32.7 71.2 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.928 0.394 . . . . 0.0 110.641 -179.986 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 9' ' ' TRP . . . . . 0.432 ' O ' HG13 ' A' ' 13' ' ' ILE . 35.8 m95 -67.08 -41.69 85.93 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 115.943 -0.571 . . . . 0.0 110.092 179.622 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 82.5 mt -61.57 -52.75 63.15 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 115.721 -0.672 . . . . 0.0 110.205 179.244 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -53.48 -36.46 53.77 Favored Glycine 0 N--CA 1.449 -0.492 0 C-N-CA 120.775 -0.726 . . . . 0.0 111.612 178.766 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -64.07 -34.68 78.58 Favored 'General case' 0 C--N 1.332 -0.191 0 CA-C-O 120.91 0.386 . . . . 0.0 110.226 179.258 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 13' ' ' ILE . . . . . 0.432 HG13 ' O ' ' A' ' 9' ' ' TRP . 80.1 mt -66.13 -48.48 81.3 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.219 0 CA-C-N 115.884 -0.598 . . . . 0.0 110.363 179.268 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -60.94 -32.96 81.81 Favored Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.662 -0.78 . . . . 0.0 111.482 179.35 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 15' ' ' MET . . . . . 0.656 ' HB3' ' HB2' ' A' ' 48' ' ' ALA . 0.0 OUTLIER -67.99 -42.68 80.39 Favored 'General case' 0 C--N 1.331 -0.218 0 CA-C-O 120.92 0.391 . . . . 0.0 110.553 179.186 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 32.4 tp -57.8 -41.41 82.09 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.029 -0.532 . . . . 0.0 110.442 179.474 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 89.4 t -64.65 -51.03 72.68 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.22 0 CA-C-N 115.824 -0.625 . . . . 0.0 111.094 179.972 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -62.03 -49.51 74.57 Favored Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.686 -0.769 . . . . 0.0 112.183 179.913 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 51.9 m -49.77 -41.58 44.58 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-O 120.752 0.31 . . . . 0.0 111.326 -179.561 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 78.1 mt -72.07 -48.59 43.05 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.272 -0.422 . . . . 0.0 111.427 179.836 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -59.5 -29.64 68.0 Favored 'General case' 0 C--N 1.329 -0.296 0 N-CA-C 112.192 0.442 . . . . 0.0 112.192 -179.284 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 8.0 m-85 -88.11 -45.57 10.04 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-O 120.661 0.267 . . . . 0.0 111.53 -179.307 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -60.7 -50.37 73.76 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.884 0.373 . . . . 0.0 111.589 -179.615 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 24' ' ' TRP . . . . . . . . . . . . . 2.0 t-105 -58.54 -44.19 89.53 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 116.007 -0.542 . . . . 0.0 111.119 -179.727 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.328 -0.351 0 CA-C-O 120.854 0.359 . . . . 0.0 110.998 -179.998 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.246 0 N-CA-C 112.435 -0.266 . . . . 0.0 112.435 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 11.0 mm-40 -92.12 -24.64 19.05 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.841 0.353 . . . . 0.0 110.83 179.959 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 34' ' ' ARG . . . . . . . . . . . . . 78.6 mtm180 -50.48 -29.24 9.94 Favored 'General case' 0 C--N 1.332 -0.177 0 CA-C-N 115.943 -0.572 . . . . 0.0 111.575 -179.647 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 41.3 mmt180 -60.45 -46.5 89.82 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.767 0.318 . . . . 0.0 111.33 -179.904 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 76.6 m-85 -69.88 -30.58 68.06 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.282 -0.417 . . . . 0.0 111.456 -179.605 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 37' ' ' TYR . . . . . . . . . . . . . 62.8 m-85 -70.62 -55.12 9.51 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.289 -0.414 . . . . 0.0 111.302 -179.619 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 60.7 t -57.04 -37.84 57.19 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-O 120.957 0.408 . . . . 0.0 110.453 179.774 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 41.8 m -63.58 -47.98 79.29 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 115.847 -0.615 . . . . 0.0 110.316 179.209 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 27.6 tp -57.4 -48.21 79.69 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 115.52 -0.764 . . . . 0.0 110.539 179.677 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 76.3 t -60.63 -34.48 58.78 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.231 0 CA-C-N 115.717 -0.674 . . . . 0.0 110.382 179.242 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -60.03 -40.18 96.68 Favored Glycine 0 N--CA 1.449 -0.484 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.118 179.824 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 43' ' ' ILE . . . . . 0.531 HG22 ' HE3' ' A' ' 205' ' ' LYS . 0.4 OUTLIER -65.2 -53.86 35.74 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-O 120.728 0.299 . . . . 0.0 111.008 179.583 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 49.1 m -60.31 -25.75 66.0 Favored 'General case' 0 C--N 1.332 -0.181 0 CA-C-O 120.793 0.33 . . . . 0.0 111.37 -179.942 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -78.42 -51.74 5.49 Favored Glycine 0 CA--C 1.519 0.313 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.978 -179.54 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 46' ' ' ILE . . . . . 0.484 ' CD1' HG22 ' A' ' 79' ' ' THR . 21.8 pt -58.97 -38.73 75.41 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.217 0 CA-C-O 120.873 0.368 . . . . 0.0 111.035 -179.976 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 47' ' ' ALA . . . . . 0.736 ' HB2' ' HE2' ' A' ' 205' ' ' LYS . . . -67.85 -45.0 75.85 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.544 179.636 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 48' ' ' ALA . . . . . 0.656 ' HB2' ' HB3' ' A' ' 15' ' ' MET . . . -54.54 -41.58 69.9 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.069 -0.514 . . . . 0.0 112.024 -179.295 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 49' ' ' VAL . . . . . 0.417 ' O ' HG13 ' A' ' 53' ' ' VAL . 30.4 m -76.79 -34.35 22.84 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.36 0 CA-C-N 116.48 -0.327 . . . . 0.0 111.815 -179.21 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -66.92 -36.39 82.14 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 120.91 0.386 . . . . 0.0 111.101 179.922 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 3.3 m-85 -73.29 -40.09 64.83 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 115.987 -0.551 . . . . 0.0 110.452 179.951 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -62.79 -49.91 73.1 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-N 115.726 -0.67 . . . . 0.0 111.227 179.854 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 53' ' ' VAL . . . . . 0.491 ' O ' HG22 ' A' ' 58' ' ' VAL . 27.6 m -63.83 -46.02 95.48 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.218 0 CA-C-N 116.366 -0.379 . . . . 0.0 110.749 -179.975 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 54' ' ' MET . . . . . 0.5 ' HB2' ' HB2' ' A' ' 71' ' ' PRO . 11.0 ttp -64.11 -29.73 70.84 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.313 179.756 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 55' ' ' ALA . . . . . 0.437 ' HB2' ' HB2' ' A' ' 8' ' ' PHE . . . -63.0 -23.71 67.58 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 115.871 -0.604 . . . . 0.0 110.926 179.442 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 54.0 mt -94.47 -8.85 37.31 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-N 116.079 -0.51 . . . . 0.0 110.726 179.812 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 57' ' ' GLY . . . . . 0.432 ' HA2' ' CD1' ' A' ' 60' ' ' TRP . . . 75.19 30.66 58.55 Favored Glycine 0 N--CA 1.451 -0.361 0 C-N-CA 120.876 -0.678 . . . . 0.0 112.953 179.723 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 58' ' ' VAL . . . . . 0.491 HG22 ' O ' ' A' ' 53' ' ' VAL . 26.3 m -84.04 18.2 0.37 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-O 120.808 0.337 . . . . 0.0 111.504 179.992 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -152.87 6.6 0.45 Allowed Glycine 0 N--CA 1.449 -0.485 0 C-N-CA 120.751 -0.737 . . . . 0.0 112.888 179.947 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 60' ' ' TRP . . . . . 0.432 ' CD1' ' HA2' ' A' ' 57' ' ' GLY . 34.5 m0 -71.95 121.5 19.21 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-O 120.783 0.325 . . . . 0.0 110.48 179.921 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 7.5 p -114.91 128.59 25.78 Favored Pre-proline 0 CA--C 1.533 0.303 0 CA-C-N 116.263 -0.426 . . . . 0.0 111.388 -179.733 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 65.0 Cg_endo -73.95 144.01 33.73 Favored 'Trans proline' 0 C--N 1.351 0.686 0 C-N-CA 122.396 2.064 . . . . 0.0 112.107 179.719 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 59.0 t -137.83 90.42 0.72 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.384 0 CA-C-N 116.086 -0.506 . . . . 0.0 111.061 -179.645 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . 58.43 -88.05 0.02 OUTLIER 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 116.116 -0.493 . . . . 0.0 111.587 -179.996 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 45.6 mt-10 -119.19 -19.96 8.16 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-O 120.775 0.321 . . . . 0.0 110.958 179.995 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 66' ' ' ARG . . . . . . . . . . . . . 9.9 ptp180 -103.23 165.19 11.17 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.268 -0.423 . . . . 0.0 110.449 179.651 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 53.9 m -123.35 129.64 51.6 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.937 0.398 . . . . 0.0 111.472 -179.677 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 99.2 t -109.73 146.33 15.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 115.889 -0.596 . . . . 0.0 110.492 179.644 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 69' ' ' PHE . . . . . . . . . . . . . 30.3 m-85 -105.59 115.47 30.3 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 121.049 0.452 . . . . 0.0 110.484 -179.474 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 70' ' ' VAL . . . . . 0.628 HG12 ' HD3' ' A' ' 71' ' ' PRO . 0.3 OUTLIER -67.98 -36.29 9.13 Favored Pre-proline 0 CA--C 1.54 0.58 0 CA-C-N 115.863 -0.608 . . . . 0.0 112.601 -179.48 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 71' ' ' PRO . . . . . 0.628 ' HD3' HG12 ' A' ' 70' ' ' VAL . 7.7 Cg_exo -71.09 -19.12 30.28 Favored 'Trans proline' 0 C--N 1.357 1.016 0 C-N-CA 122.21 1.94 . . . . 0.0 113.308 -179.198 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 43.0 ttm180 -76.35 -55.09 5.87 Favored 'General case' 0 C--N 1.331 -0.206 0 N-CA-C 112.372 0.508 . . . . 0.0 112.372 -178.505 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 73' ' ' TYR . . . . . 0.452 ' O ' HG13 ' A' ' 77' ' ' ILE . 68.5 m-85 -71.19 -36.76 72.06 Favored 'General case' 0 C--N 1.329 -0.286 0 C-N-CA 120.841 -0.344 . . . . 0.0 110.956 -179.248 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 74' ' ' ILE . . . . . 0.432 ' O ' HD13 ' A' ' 74' ' ' ILE . 0.3 OUTLIER -64.95 -40.43 89.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 N-CA-C 109.766 -0.457 . . . . 0.0 109.766 179.309 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 75' ' ' ASP . . . . . 0.517 ' O ' HG23 ' A' ' 79' ' ' THR . 12.0 t70 -60.23 -37.51 80.55 Favored 'General case' 0 CA--C 1.518 -0.251 0 N-CA-C 109.437 -0.579 . . . . 0.0 109.437 178.772 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 76' ' ' TRP . . . . . . . . . . . . . 46.6 m0 -64.03 -31.44 72.63 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 115.899 -0.591 . . . . 0.0 110.319 179.478 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 77' ' ' ILE . . . . . 0.512 ' O ' ' HG2' ' A' ' 81' ' ' PRO . 61.8 mt -71.28 -31.72 44.79 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.478 178.963 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 25.6 mt -91.82 -15.13 28.66 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.172 -0.467 . . . . 0.0 112.165 -179.707 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 79' ' ' THR . . . . . 0.517 HG23 ' O ' ' A' ' 75' ' ' ASP . 79.8 p -104.61 -52.97 2.78 Favored 'General case' 0 N--CA 1.465 0.296 0 N-CA-C 113.614 0.968 . . . . 0.0 113.614 -177.891 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 80' ' ' THR . . . . . 0.583 ' HB ' ' HD3' ' A' ' 81' ' ' PRO . 4.5 m -52.66 -53.68 51.41 Favored Pre-proline 0 C--N 1.331 -0.237 0 N-CA-C 112.36 0.504 . . . . 0.0 112.36 -178.369 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 81' ' ' PRO . . . . . 0.583 ' HD3' ' HB ' ' A' ' 80' ' ' THR . 52.6 Cg_exo -57.01 -23.43 52.01 Favored 'Trans proline' 0 C--N 1.352 0.752 0 C-N-CA 121.612 1.541 . . . . 0.0 111.68 179.543 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 82' ' ' LEU . . . . . . . . . . . . . 18.0 tp -76.76 -33.19 58.1 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 115.926 -0.579 . . . . 0.0 110.054 179.604 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 83' ' ' ILE . . . . . 0.451 HD11 HG21 ' A' ' 43' ' ' ILE . 37.6 mm -69.36 -53.37 25.49 Favored 'Isoleucine or valine' 0 C--O 1.232 0.161 0 CA-C-N 116.007 -0.542 . . . . 0.0 110.386 179.226 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 29.0 m -59.36 -32.8 49.34 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.183 0 N-CA-C 109.8 -0.444 . . . . 0.0 109.8 179.005 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 85' ' ' TYR . . . . . . . . . . . . . 55.4 t80 -64.66 -34.57 78.6 Favored 'General case' 0 N--CA 1.454 -0.272 0 CA-C-N 115.657 -0.701 . . . . 0.0 109.561 178.801 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 86' ' ' PHE . . . . . . . . . . . . . 8.8 t80 -61.48 -51.82 67.07 Favored 'General case' 0 C--O 1.232 0.181 0 CA-C-N 115.635 -0.711 . . . . 0.0 110.232 179.507 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 7.3 mp -61.71 -31.93 72.11 Favored 'General case' 0 C--N 1.331 -0.204 0 CA-C-N 116.136 -0.483 . . . . 0.0 110.116 179.49 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -71.59 -27.57 70.89 Favored Glycine 0 N--CA 1.449 -0.44 0 CA-C-N 115.8 -0.636 . . . . 0.0 111.795 179.31 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 42.0 mt -72.07 -39.2 69.18 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.919 0.39 . . . . 0.0 110.538 179.733 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 53.6 mt -58.5 -45.8 88.01 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 115.782 -0.645 . . . . 0.0 111.106 -179.967 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 91' ' ' ALA . . . . . 0.588 ' HB2' ' HB2' ' A' ' 149' ' ' ALA . . . -79.88 -54.94 5.35 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.403 -179.728 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 102.84 65.64 0.73 Allowed Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.826 -0.702 . . . . 0.0 112.346 -179.888 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 93' ' ' LEU . . . . . 0.46 HD11 ' HG2' ' A' ' 145' ' ' MET . 8.1 mp -71.93 172.04 10.67 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.804 0.335 . . . . 0.0 111.053 179.998 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 94' ' ' ASP . . . . . 0.47 ' HB2' ' HG2' ' A' ' 97' ' ' GLU . 10.1 m-20 -78.54 174.3 11.5 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.811 179.942 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 71.4 p -61.62 -51.27 69.19 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.176 -0.466 . . . . 0.0 111.215 -179.858 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 97.8 mtt180 -65.39 -42.15 92.93 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.374 -179.66 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 97' ' ' GLU . . . . . 0.47 ' HG2' ' HB2' ' A' ' 94' ' ' ASP . 10.3 mm-40 -52.49 -50.76 62.1 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.311 -0.404 . . . . 0.0 111.163 -179.625 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 98' ' ' PHE . . . . . 0.458 ' O ' HG12 ' A' ' 102' ' ' ILE . 12.2 m-85 -56.18 -46.23 79.44 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.354 -0.385 . . . . 0.0 110.683 179.633 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -60.54 -29.67 70.09 Favored Glycine 0 N--CA 1.448 -0.505 0 C-N-CA 120.688 -0.768 . . . . 0.0 112.34 179.978 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 96.6 mt -73.87 -42.63 53.59 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.238 0 CA-C-O 120.786 0.327 . . . . 0.0 111.717 -179.853 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 39.8 t -70.61 -42.58 77.98 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 CA-C-N 116.427 -0.351 . . . . 0.0 111.519 -179.335 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 102' ' ' ILE . . . . . 0.458 HG12 ' O ' ' A' ' 98' ' ' PHE . 49.2 mm -64.92 -45.78 93.72 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.368 -0.378 . . . . 0.0 111.552 -179.548 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 13.7 t -62.22 -35.52 79.14 Favored 'General case' 0 C--O 1.233 0.211 0 CA-C-O 120.847 0.356 . . . . 0.0 110.661 179.879 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 104' ' ' LEU . . . . . 0.441 ' O ' HG23 ' A' ' 108' ' ' VAL . 29.8 tp -57.39 -53.82 53.86 Favored 'General case' 0 C--N 1.331 -0.202 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.258 179.241 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 105' ' ' ASN . . . . . 0.607 ' N ' HD22 ' A' ' 105' ' ' ASN . 0.8 OUTLIER -56.25 -36.67 68.81 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 115.952 -0.567 . . . . 0.0 110.433 179.709 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 30.6 m -54.92 -43.41 73.28 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.511 179.621 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 107' ' ' VAL . . . . . 0.454 HG12 ' SD ' ' A' ' 129' ' ' MET . 1.2 t -65.64 -39.49 85.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-O 121.274 0.559 . . . . 0.0 110.187 179.206 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . 0.441 HG23 ' O ' ' A' ' 104' ' ' LEU . 41.7 t -60.03 -53.16 52.4 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.38 0 CA-C-N 115.291 -0.868 . . . . 0.0 111.782 -179.728 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 109' ' ' MET . . . . . 0.449 ' HG2' ' O ' ' A' ' 105' ' ' ASN . 8.0 mmt -61.85 -41.86 98.34 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-N 116.306 -0.406 . . . . 0.0 111.257 -179.284 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 28.6 tp -60.21 -30.27 69.27 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 116.377 -0.374 . . . . 0.0 110.461 -179.906 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -66.55 -54.87 18.97 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.552 179.217 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . -60.02 -36.22 89.66 Favored Glycine 0 N--CA 1.452 -0.24 0 C-N-CA 120.497 -0.859 . . . . 0.0 111.722 179.373 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 113' ' ' PHE . . . . . . . . . . . . . 0.9 OUTLIER -56.1 -75.09 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 121.051 0.453 . . . . 0.0 110.357 179.647 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -58.44 -29.72 66.37 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 115.679 -0.691 . . . . 0.0 111.418 -179.91 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -52.3 -49.12 52.2 Favored Glycine 0 C--N 1.331 0.254 0 C-N-CA 121.075 -0.583 . . . . 0.0 112.726 -179.993 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -77.71 -16.87 58.16 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-O 120.697 0.284 . . . . 0.0 111.458 -179.976 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 117' ' ' MET . . . . . . . . . . . . . 38.3 ttm -100.95 18.08 20.57 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.352 -0.385 . . . . 0.0 111.321 -179.387 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 118' ' ' VAL . . . . . 0.479 HG21 ' HB3' ' A' ' 123' ' ' ARG . 27.1 m -70.05 148.31 96.03 Favored Pre-proline 0 C--N 1.329 -0.302 0 CA-C-N 116.451 -0.34 . . . . 0.0 111.15 179.794 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 119' ' ' PRO . . . . . . . . . . . . . 90.6 Cg_endo -83.7 -3.77 10.63 Favored 'Trans proline' 0 C--N 1.348 0.52 0 C-N-CA 122.567 2.178 . . . . 0.0 112.136 179.719 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -156.25 -141.51 3.21 Favored Glycine 0 N--CA 1.453 -0.229 0 C-N-CA 120.926 -0.654 . . . . 0.0 112.452 -179.981 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 41.0 pt -84.71 18.87 0.37 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.229 0 CA-C-O 120.845 0.355 . . . . 0.0 111.062 -179.99 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 122' ' ' GLU . . . . . 0.459 ' HB2' ' HB ' ' A' ' 118' ' ' VAL . 12.3 mm-40 -67.52 -18.01 64.88 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.0 -0.545 . . . . 0.0 111.36 -179.926 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 123' ' ' ARG . . . . . 0.479 ' HB3' HG21 ' A' ' 118' ' ' VAL . 0.0 OUTLIER -51.11 -30.2 15.56 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-N 116.424 -0.353 . . . . 0.0 111.457 -179.532 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 124' ' ' TYR . . . . . . . . . . . . . 34.6 m-85 -70.23 -32.52 70.42 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-O 120.735 0.302 . . . . 0.0 111.202 -179.717 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 125' ' ' ALA . . . . . . . . . . . . . . . -67.88 -52.2 39.33 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.268 -0.423 . . . . 0.0 110.887 179.88 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 126' ' ' LEU . . . . . 0.402 HD13 ' HA ' ' A' ' 126' ' ' LEU . 3.2 mm? -53.24 -54.44 36.07 Favored 'General case' 0 CA--C 1.521 -0.168 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.581 179.69 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 127' ' ' PHE . . . . . 0.481 ' HZ ' ' HB3' ' A' ' 175' ' ' PRO . 9.4 t80 -62.33 -35.74 80.03 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.082 -179.63 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 128' ' ' GLY . . . . . . . . . . . . . . . -47.23 -48.1 20.76 Favored Glycine 0 C--N 1.332 0.314 0 C-N-CA 119.925 -1.131 . . . . 0.0 110.287 178.718 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 129' ' ' MET . . . . . 0.454 ' SD ' HG12 ' A' ' 107' ' ' VAL . 0.4 OUTLIER -71.21 -31.41 67.55 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 115.019 -0.591 . . . . 0.0 109.697 178.379 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -60.96 -41.09 99.25 Favored Glycine 0 C--N 1.332 0.359 0 CA-C-N 115.821 -0.627 . . . . 0.0 112.753 -179.864 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -71.28 -51.92 21.75 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.644 0.259 . . . . 0.0 110.518 179.807 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 57.4 t -55.04 -39.95 52.19 Favored 'Isoleucine or valine' 0 C--O 1.233 0.226 0 CA-C-O 121.3 0.571 . . . . 0.0 109.694 178.95 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -70.77 -37.35 73.36 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 115.407 -0.815 . . . . 0.0 110.658 179.602 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 134' ' ' PHE . . . . . . . . . . . . . 43.6 t80 -56.62 -53.35 58.64 Favored 'General case' 0 N--CA 1.451 -0.386 0 CA-C-O 120.995 0.426 . . . . 0.0 109.984 179.567 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 135' ' ' ILE . . . . . . . . . . . . . 48.4 mt -58.02 -33.48 46.46 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.405 0 CA-C-N 115.787 -0.642 . . . . 0.0 109.838 179.227 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . -58.82 -40.73 95.47 Favored Glycine 0 N--CA 1.448 -0.53 0 C-N-CA 120.394 -0.908 . . . . 0.0 111.473 178.905 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 137' ' ' LEU . . . . . 0.416 HD13 HD21 ' A' ' 105' ' ' ASN . 53.5 tp -69.73 -45.04 69.05 Favored 'General case' 0 N--CA 1.455 -0.193 0 CA-C-O 120.693 0.282 . . . . 0.0 110.588 179.411 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 138' ' ' VAL . . . . . . . . . . . . . 98.8 t -56.05 -40.99 66.9 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.9 0 CA-C-O 121.222 0.534 . . . . 0.0 109.896 179.231 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 139' ' ' TYR . . . . . . . . . . . . . 29.4 t80 -59.05 -47.14 86.31 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 115.416 -0.811 . . . . 0.0 110.612 178.937 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 22.9 m-85 -54.52 -37.77 65.74 Favored 'General case' 0 C--N 1.332 -0.16 0 CA-C-N 116.39 -0.368 . . . . 0.0 110.911 179.942 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 141' ' ' LEU . . . . . 0.491 HD23 ' SD ' ' A' ' 145' ' ' MET . 79.8 mt -60.89 -50.7 72.37 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-O 120.905 0.383 . . . . 0.0 110.366 179.502 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 22.0 t -70.52 -15.21 18.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.034 -0.53 . . . . 0.0 110.723 179.531 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . -70.37 -140.24 0.16 Allowed Glycine 0 CA--C 1.521 0.461 0 C-N-CA 121.015 -0.612 . . . . 0.0 112.842 -179.88 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 144' ' ' PRO . . . . . . . . . . . . . 42.0 Cg_exo -56.64 -23.69 50.35 Favored 'Trans proline' 0 C--N 1.35 0.639 0 C-N-CA 122.641 2.227 . . . . 0.0 112.63 -179.794 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 145' ' ' MET . . . . . 0.491 ' SD ' HD23 ' A' ' 141' ' ' LEU . 54.5 mtt -57.93 -31.65 67.01 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.391 -0.368 . . . . 0.0 111.429 -179.867 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 146' ' ' THR . . . . . . . . . . . . . 25.0 m -74.11 -48.34 30.24 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.278 -0.419 . . . . 0.0 112.05 -179.061 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 45.1 mt-10 -72.92 -29.02 62.81 Favored 'General case' 0 C--N 1.329 -0.302 0 N-CA-C 111.762 0.282 . . . . 0.0 111.762 -179.157 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 148' ' ' SER . . . . . 0.408 ' HB3' ' HB1' ' A' ' 91' ' ' ALA . 46.8 t -70.76 -47.81 57.68 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.519 -0.31 . . . . 0.0 111.497 -179.179 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 149' ' ' ALA . . . . . 0.588 ' HB2' ' HB2' ' A' ' 91' ' ' ALA . . . -73.54 -43.23 60.44 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.378 -0.374 . . . . 0.0 111.865 -179.259 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 150' ' ' SER . . . . . 0.493 ' HA ' ' HB3' ' A' ' 157' ' ' LYS . 42.8 t -65.51 -8.4 19.34 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.457 -0.338 . . . . 0.0 111.286 -179.613 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 151' ' ' GLN . . . . . . . . . . . . . 46.2 mt-30 -124.89 15.73 8.59 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.454 -0.339 . . . . 0.0 111.161 179.999 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 31.3 tpt180 -90.79 -52.02 5.08 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 121.093 0.473 . . . . 0.0 110.275 179.646 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 153' ' ' SER . . . . . 0.613 ' HB2' HG12 ' A' ' 156' ' ' ILE . 24.6 m -158.02 172.69 17.98 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 115.719 -0.673 . . . . 0.0 110.473 179.228 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 154' ' ' SER . . . . . . . . . . . . . 78.3 p -70.55 -38.69 74.19 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.335 -0.393 . . . . 0.0 110.482 179.438 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -77.87 -38.01 28.22 Favored Glycine 0 N--CA 1.452 -0.265 0 C-N-CA 121.04 -0.6 . . . . 0.0 112.845 179.781 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 156' ' ' ILE . . . . . 0.613 HG12 ' HB2' ' A' ' 153' ' ' SER . 39.0 mm -53.4 -44.48 55.08 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.202 0 N-CA-C 111.917 0.34 . . . . 0.0 111.917 -179.204 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 157' ' ' LYS . . . . . 0.493 ' HB3' ' HA ' ' A' ' 150' ' ' SER . 18.9 ptpt -65.78 -30.88 71.59 Favored 'General case' 0 C--N 1.329 -0.288 0 N-CA-C 111.714 0.264 . . . . 0.0 111.714 -179.225 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 47.8 t -71.7 -48.37 47.76 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 121.076 0.465 . . . . 0.0 111.077 -179.539 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 159' ' ' LEU . . . . . 0.482 ' O ' ' HB2' ' A' ' 163' ' ' LEU . 8.4 mp -71.53 -29.81 65.19 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 115.875 -0.602 . . . . 0.0 111.313 -179.785 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 160' ' ' TYR . . . . . . . . . . . . . 92.8 t80 -70.73 -44.84 65.99 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.397 -0.365 . . . . 0.0 111.739 -179.402 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 161' ' ' VAL . . . . . 0.421 HG13 ' O ' ' A' ' 157' ' ' LYS . 28.6 m -66.05 -42.34 91.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 N-CA-C 111.624 0.231 . . . . 0.0 111.624 -179.365 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 162' ' ' ARG . . . . . . . . . . . . . 95.7 mtt180 -67.99 -44.71 75.99 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.796 0.331 . . . . 0.0 111.497 -179.808 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 163' ' ' LEU . . . . . 0.482 ' HB2' ' O ' ' A' ' 159' ' ' LEU . 4.5 mp -71.55 -54.16 11.41 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.264 -0.426 . . . . 0.0 112.039 -179.19 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 164' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -53.05 -41.64 65.01 Favored 'General case' 0 C--N 1.328 -0.353 0 N-CA-C 111.957 0.354 . . . . 0.0 111.957 -178.783 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 165' ' ' ASN . . . . . 0.51 HD22 ' N ' ' A' ' 165' ' ' ASN . 0.9 OUTLIER -67.03 -52.31 43.93 Favored 'General case' 0 C--N 1.329 -0.318 0 N-CA-C 112.013 0.375 . . . . 0.0 112.013 -179.114 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 166' ' ' LEU . . . . . 0.46 HD21 ' CE1' ' A' ' 208' ' ' PHE . 0.0 OUTLIER -67.45 -33.13 74.5 Favored 'General case' 0 C--N 1.329 -0.288 0 N-CA-C 111.643 0.238 . . . . 0.0 111.643 -178.871 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 167' ' ' THR . . . . . 0.451 ' O ' ' HB2' ' A' ' 171' ' ' TRP . 27.5 m -63.04 -53.83 47.72 Favored 'General case' 0 C--N 1.332 -0.195 0 N-CA-C 111.939 0.348 . . . . 0.0 111.939 -179.976 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 168' ' ' VAL . . . . . 0.426 HG12 ' O ' ' A' ' 165' ' ' ASN . 9.9 p -59.28 -40.07 80.41 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.242 0 CA-C-N 116.486 -0.325 . . . . 0.0 111.541 -178.924 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 169' ' ' VAL . . . . . 0.505 HG23 ' O ' ' A' ' 165' ' ' ASN . 74.0 t -57.14 -65.38 0.41 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.563 -0.29 . . . . 0.0 111.45 -179.767 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 170' ' ' LEU . . . . . 0.433 ' HG ' ' O ' ' A' ' 166' ' ' LEU . 2.7 pp -63.09 -29.78 71.08 Favored 'General case' 0 C--N 1.331 -0.228 0 N-CA-C 111.908 0.336 . . . . 0.0 111.908 -179.085 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 171' ' ' TRP . . . . . 0.451 ' HB2' ' O ' ' A' ' 167' ' ' THR . 2.5 m0 -72.51 -31.47 65.37 Favored 'General case' 0 C--N 1.331 -0.21 0 C-N-CA 120.797 -0.361 . . . . 0.0 110.761 179.612 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 172' ' ' ALA . . . . . . . . . . . . . . . -72.94 -6.24 43.92 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-O 121.055 0.455 . . . . 0.0 110.367 179.439 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 173' ' ' ILE . . . . . 0.61 HG22 HD11 ' A' ' 177' ' ' ILE . 37.2 mm -82.89 -25.99 8.19 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.206 0 CA-C-N 115.771 -0.649 . . . . 0.0 110.999 179.791 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 174' ' ' TYR . . . . . 0.489 ' HB2' ' HD3' ' A' ' 175' ' ' PRO . 49.9 m-85 -54.55 -50.7 83.95 Favored Pre-proline 0 N--CA 1.464 0.272 0 CA-C-N 116.353 -0.385 . . . . 0.0 111.671 -179.665 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 175' ' ' PRO . . . . . 0.489 ' HD3' ' HB2' ' A' ' 174' ' ' TYR . 97.2 Cg_exo -45.19 -30.29 4.96 Favored 'Trans proline' 0 C--N 1.35 0.647 0 C-N-CA 122.186 1.924 . . . . 0.0 112.403 179.65 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 176' ' ' PHE . . . . . 0.459 ' O ' ' HG ' ' A' ' 180' ' ' LEU . 65.8 m-85 -80.57 -49.67 11.01 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 115.979 -0.555 . . . . 0.0 111.989 -179.729 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 177' ' ' ILE . . . . . 0.61 HD11 HG22 ' A' ' 173' ' ' ILE . 2.3 mm -61.59 -37.37 77.74 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.53 0 N-CA-C 112.723 0.638 . . . . 0.0 112.723 -177.693 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 178' ' ' TRP . . . . . . . . . . . . . 63.0 t90 -72.55 -44.9 61.48 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 120.875 0.369 . . . . 0.0 110.823 179.7 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 179' ' ' LEU . . . . . 0.492 ' O ' HG22 ' A' ' 185' ' ' VAL . 2.5 tm? -67.15 -49.25 65.43 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 115.907 -0.588 . . . . 0.0 111.72 -179.0 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 180' ' ' LEU . . . . . 0.549 HD22 HD11 ' A' ' 187' ' ' LEU . 23.1 mt -77.24 -45.28 26.98 Favored 'General case' 0 C--N 1.326 -0.424 0 N-CA-C 111.982 0.364 . . . . 0.0 111.982 -178.796 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . -57.32 178.91 0.88 Allowed Glycine 0 C--N 1.334 0.47 0 C-N-CA 120.438 -0.887 . . . . 0.0 112.82 -179.878 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 182' ' ' PRO . . . . . 0.609 ' HA ' ' HB2' ' A' ' 186' ' ' ALA . 71.5 Cg_exo -47.78 -46.06 22.41 Favored 'Trans proline' 0 CA--C 1.537 0.67 0 C-N-CA 123.0 2.466 . . . . 0.0 114.177 -179.709 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 183' ' ' PRO . . . . . 0.578 ' HD2' ' N ' ' A' ' 182' ' ' PRO . 16.9 Cg_endo -57.53 -9.92 6.05 Favored 'Trans proline' 0 C--N 1.355 0.885 0 C-N-CA 122.02 1.813 . . . . 0.0 113.246 -179.409 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 184' ' ' GLY . . . . . 0.434 ' HA3' ' O ' ' A' ' 179' ' ' LEU . . . -116.23 -86.8 1.3 Allowed Glycine 0 N--CA 1.45 -0.379 0 C-N-CA 120.536 -0.84 . . . . 0.0 112.722 179.781 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 185' ' ' VAL . . . . . 0.492 HG22 ' O ' ' A' ' 179' ' ' LEU . 9.0 m -123.47 -4.1 7.18 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.246 0 CA-C-O 120.781 0.324 . . . . 0.0 111.544 -179.817 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 186' ' ' ALA . . . . . 0.609 ' HB2' ' HA ' ' A' ' 182' ' ' PRO . . . 54.56 84.83 0.06 Allowed 'General case' 0 N--CA 1.463 0.195 0 CA-C-N 116.113 -0.494 . . . . 0.0 111.828 179.557 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 187' ' ' LEU . . . . . 0.549 HD11 HD22 ' A' ' 180' ' ' LEU . 14.8 mt -92.1 -48.72 6.58 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-O 120.973 0.416 . . . . 0.0 110.906 179.509 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 188' ' ' LEU . . . . . . . . . . . . . 89.7 mt -96.82 -152.91 0.4 Allowed 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 115.883 -0.599 . . . . 0.0 111.014 -179.575 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 189' ' ' THR . . . . . 0.413 ' HB ' HG23 ' A' ' 192' ' ' VAL . 86.5 m -96.37 136.25 22.04 Favored Pre-proline 0 C--N 1.33 -0.261 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.712 -179.71 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 190' ' ' PRO . . . . . . . . . . . . . 88.7 Cg_exo -46.48 -43.07 22.75 Favored 'Trans proline' 0 C--N 1.349 0.585 0 C-N-CA 122.459 2.106 . . . . 0.0 112.855 -179.825 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 191' ' ' THR . . . . . . . . . . . . . 82.0 p -65.41 -38.64 90.57 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.376 -0.375 . . . . 0.0 111.731 -179.601 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 192' ' ' VAL . . . . . 0.413 HG23 ' HB ' ' A' ' 189' ' ' THR . 58.1 t -71.78 -53.71 19.44 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.394 -0.366 . . . . 0.0 111.415 -179.628 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 193' ' ' ASP . . . . . . . . . . . . . 26.5 t70 -54.19 -47.97 71.48 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.244 -0.435 . . . . 0.0 111.049 -179.867 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 194' ' ' VAL . . . . . 0.493 ' O ' HG22 ' A' ' 198' ' ' VAL . 46.7 t -60.13 -40.18 82.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.281 -0.418 . . . . 0.0 110.674 179.769 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 195' ' ' ALA . . . . . 0.412 ' HA ' HD12 ' A' ' 7' ' ' LEU . . . -52.86 -44.64 66.97 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.928 179.756 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 196' ' ' LEU . . . . . . . . . . . . . 94.5 mt -68.42 -36.19 78.71 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.096 179.711 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 197' ' ' ILE . . . . . 0.454 HD11 ' HB ' ' A' ' 177' ' ' ILE . 12.4 mm -61.31 -59.83 3.66 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.203 179.911 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 198' ' ' VAL . . . . . 0.493 HG22 ' O ' ' A' ' 194' ' ' VAL . 2.8 m -54.08 -35.36 28.79 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.47 0 CA-C-O 121.669 0.747 . . . . 0.0 109.523 179.307 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 199' ' ' TYR . . . . . . . . . . . . . 74.9 t80 -64.59 -41.6 96.14 Favored 'General case' 0 C--N 1.321 -0.658 0 CA-C-N 114.454 -1.248 . . . . 0.0 110.482 179.577 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 200' ' ' LEU . . . . . 0.419 ' HB3' ' CZ ' ' A' ' 174' ' ' TYR . 23.2 mt -59.04 -46.55 87.94 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 115.747 -0.66 . . . . 0.0 111.08 -179.885 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 201' ' ' ASP . . . . . . . . . . . . . 8.6 m-20 -69.95 -33.52 72.22 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 121.089 0.471 . . . . 0.0 110.426 179.709 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 202' ' ' LEU . . . . . . . . . . . . . 1.2 tt -66.54 -33.53 75.88 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 115.604 -0.725 . . . . 0.0 110.738 -179.93 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 203' ' ' VAL . . . . . 0.448 ' O ' ' HA3' ' A' ' 207' ' ' GLY . 42.3 t -76.66 -36.94 28.2 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 115.88 -0.6 . . . . 0.0 111.552 -179.007 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 204' ' ' THR . . . . . 0.473 HG23 ' CE2' ' A' ' 208' ' ' PHE . 36.5 m -64.58 -56.12 16.01 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-O 120.894 0.378 . . . . 0.0 111.679 -179.869 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 205' ' ' LYS . . . . . 0.736 ' HE2' ' HB2' ' A' ' 47' ' ' ALA . 48.9 mttp -69.03 -58.62 3.85 Favored 'General case' 0 C--N 1.326 -0.421 0 N-CA-C 112.576 0.584 . . . . 0.0 112.576 -178.351 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 48.9 t -71.57 -38.12 66.32 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 N-CA-C 112.064 0.394 . . . . 0.0 112.064 -178.515 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 207' ' ' GLY . . . . . 0.496 ' O ' HG12 ' A' ' 211' ' ' ILE . . . -63.38 -59.62 8.63 Favored Glycine 0 N--CA 1.453 -0.23 0 C-N-CA 120.579 -0.819 . . . . 0.0 112.86 -179.319 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 208' ' ' PHE . . . . . 0.509 ' O ' ' N ' ' A' ' 212' ' ' ALA . 1.8 m-30 -54.88 -47.91 73.67 Favored 'General case' 0 C--O 1.221 -0.405 0 N-CA-C 110.18 -0.304 . . . . 0.0 110.18 -179.633 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 209' ' ' GLY . . . . . 0.491 ' HA2' ' HB3' ' A' ' 212' ' ' ALA . . . -53.46 -32.36 45.27 Favored Glycine 0 N--CA 1.45 -0.432 0 CA-C-N 115.623 -0.717 . . . . 0.0 112.488 178.937 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 210' ' ' PHE . . . . . . . . . . . . . 3.0 m-85 -71.94 -45.96 59.24 Favored 'General case' 0 CA--C 1.516 -0.34 0 N-CA-C 108.694 -0.854 . . . . 0.0 108.694 178.769 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 211' ' ' ILE . . . . . 0.496 HG12 ' O ' ' A' ' 207' ' ' GLY . 2.4 mm -66.12 -27.5 41.0 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.51 0 N-CA-C 107.256 -1.387 . . . . 0.0 107.256 176.655 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 212' ' ' ALA . . . . . 0.509 ' N ' ' O ' ' A' ' 208' ' ' PHE . . . -68.67 -40.13 80.28 Favored 'General case' 0 N--CA 1.447 -0.582 0 CA-C-N 113.965 -1.471 . . . . 0.0 110.925 -179.34 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 213' ' ' LEU . . . . . . . . . . . . . 65.1 mt -70.26 -55.51 9.07 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 115.314 -0.857 . . . . 0.0 112.07 -179.164 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 214' ' ' ASP . . . . . . . . . . . . . 20.1 t70 -56.45 -50.56 71.33 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.859 0.361 . . . . 0.0 111.352 -179.429 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 215' ' ' ALA . . . . . . . . . . . . . . . -57.69 -55.39 35.49 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.467 -179.781 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 216' ' ' ALA . . . . . . . . . . . . . . . -60.59 -31.19 70.35 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.273 -0.421 . . . . 0.0 111.321 -179.697 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 217' ' ' ALA . . . . . . . . . . . . . . . -62.62 -35.82 80.82 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.342 -0.39 . . . . 0.0 110.264 179.609 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 218' ' ' THR . . . . . . . . . . . . . 86.7 m . . . . . 0 C--N 1.329 -0.285 0 CA-C-N 115.887 -0.597 . . . . 0.0 110.614 179.24 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.299 0 N-CA-C 112.605 -0.198 . . . . 0.0 112.605 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 94.5 mt -56.72 -35.55 68.67 Favored 'General case' 0 N--CA 1.449 -0.514 0 CA-C-O 120.868 0.366 . . . . 0.0 111.242 -179.859 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 42.9 p -63.4 -39.01 93.34 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.08 -0.509 . . . . 0.0 111.774 -179.414 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 18.7 p -52.84 -35.33 57.22 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-N 116.484 -0.325 . . . . 0.0 111.538 -179.442 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 7' ' ' LEU . . . . . . . . . . . . . 3.8 mm? -60.62 -53.13 61.13 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.37 -0.377 . . . . 0.0 111.245 -179.755 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 8' ' ' PHE . . . . . 0.559 ' HB2' ' HB2' ' A' ' 55' ' ' ALA . 64.4 m-85 -61.67 -30.84 70.99 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.304 -0.407 . . . . 0.0 111.014 -179.726 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 9' ' ' TRP . . . . . 0.474 ' O ' HG12 ' A' ' 13' ' ' ILE . 34.9 m95 -66.79 -43.3 84.31 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 116.226 -0.443 . . . . 0.0 109.966 179.939 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 87.5 mt -65.51 -49.02 70.54 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 115.615 -0.721 . . . . 0.0 110.526 179.638 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . 0.4 ' O ' HD21 ' A' ' 202' ' ' LEU . . . -58.47 -32.22 68.19 Favored Glycine 0 N--CA 1.449 -0.475 0 C-N-CA 120.559 -0.829 . . . . 0.0 111.677 179.3 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -68.69 -35.43 77.18 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 120.842 0.353 . . . . 0.0 110.615 179.453 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 13' ' ' ILE . . . . . 0.474 HG12 ' O ' ' A' ' 9' ' ' TRP . 46.8 mm -64.73 -53.98 35.59 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.205 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.609 179.566 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -60.71 -32.83 80.2 Favored Glycine 0 N--CA 1.45 -0.432 0 C-N-CA 120.718 -0.753 . . . . 0.0 111.7 179.477 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 15' ' ' MET . . . . . 0.591 ' SD ' ' HA ' ' A' ' 44' ' ' SER . 54.0 tpp -64.33 -50.98 65.66 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.792 0.33 . . . . 0.0 110.619 179.896 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -52.77 -40.58 63.3 Favored 'General case' 0 C--N 1.332 -0.192 0 CA-C-N 116.021 -0.536 . . . . 0.0 110.355 179.538 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 97.6 t -59.94 -42.86 90.86 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.219 0 CA-C-N 116.034 -0.53 . . . . 0.0 110.541 179.534 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -66.12 -43.39 93.35 Favored Glycine 0 N--CA 1.452 -0.272 0 C-N-CA 120.771 -0.728 . . . . 0.0 111.74 179.067 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 17.8 m -50.28 -46.56 55.22 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 115.556 -0.322 . . . . 0.0 111.48 -179.762 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 86.0 mt -71.76 -39.85 69.71 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.316 -0.402 . . . . 0.0 111.772 -179.74 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -61.64 -31.52 71.63 Favored 'General case' 0 C--N 1.33 -0.272 0 N-CA-C 111.987 0.366 . . . . 0.0 111.987 -179.219 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 4.9 m-85 -90.75 -33.34 15.78 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-O 120.731 0.301 . . . . 0.0 111.421 -179.599 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -69.3 -50.0 50.71 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.973 0.416 . . . . 0.0 111.19 -179.824 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 24' ' ' TRP . . . . . . . . . . . . . 2.4 t-105 -61.57 -47.54 85.06 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 115.805 -0.634 . . . . 0.0 111.169 -179.842 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.331 -0.23 0 CA-C-O 120.782 0.325 . . . . 0.0 110.692 179.715 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.517 0.201 0 N-CA-C 112.781 -0.127 . . . . 0.0 112.781 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 33.3 mm-40 -87.28 -20.93 26.13 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.811 0.339 . . . . 0.0 111.015 -179.85 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 34' ' ' ARG . . . . . . . . . . . . . 42.3 ttm180 -53.12 -31.96 44.94 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.596 -179.546 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 15.3 tpp180 -61.64 -44.47 96.92 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 120.836 0.351 . . . . 0.0 110.874 -179.908 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 54.9 m-85 -68.69 -31.04 69.86 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.91 179.978 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 37' ' ' TYR . . . . . 0.423 ' O ' HG23 ' A' ' 41' ' ' VAL . 44.2 m-85 -70.43 -53.6 15.81 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.219 -179.897 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 71.2 t -56.8 -36.4 49.38 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.194 0 CA-C-O 121.008 0.432 . . . . 0.0 110.265 179.615 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 24.0 m -63.89 -47.92 78.71 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 115.673 -0.694 . . . . 0.0 110.296 179.213 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 40' ' ' LEU . . . . . 0.639 HD12 HD12 ' A' ' 43' ' ' ILE . 45.5 tp -58.46 -47.79 82.88 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 115.678 -0.692 . . . . 0.0 110.153 179.493 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . 0.423 HG23 ' O ' ' A' ' 37' ' ' TYR . 57.6 t -60.33 -34.57 58.06 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.365 0 CA-C-N 115.645 -0.707 . . . . 0.0 109.804 178.906 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -59.97 -37.09 92.14 Favored Glycine 0 N--CA 1.448 -0.559 0 C-N-CA 120.784 -0.722 . . . . 0.0 111.591 179.479 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 43' ' ' ILE . . . . . 0.639 HD12 HD12 ' A' ' 40' ' ' LEU . 1.3 mt -65.26 -57.98 8.84 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.195 0 CA-C-O 120.833 0.349 . . . . 0.0 110.468 179.391 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 44' ' ' SER . . . . . 0.591 ' HA ' ' SD ' ' A' ' 15' ' ' MET . 64.7 m -57.51 -23.01 47.76 Favored 'General case' 0 C--N 1.332 -0.173 0 CA-C-N 116.037 -0.529 . . . . 0.0 111.71 -179.67 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -76.64 -59.17 3.32 Favored Glycine 0 CA--C 1.52 0.353 0 C-N-CA 120.638 -0.792 . . . . 0.0 112.912 -179.614 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 21.6 pt -58.42 -35.89 56.27 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.239 0 CA-C-O 120.91 0.386 . . . . 0.0 111.263 -179.796 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 47' ' ' ALA . . . . . 0.671 ' HB2' ' HE2' ' A' ' 205' ' ' LYS . . . -67.42 -45.77 75.13 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.309 179.626 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -54.42 -44.77 72.7 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.878 -179.183 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 27.0 m -73.29 -34.2 43.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 N-CA-C 111.845 0.313 . . . . 0.0 111.845 -179.363 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -65.92 -33.95 77.01 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.869 0.366 . . . . 0.0 111.266 -179.785 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 51' ' ' TYR . . . . . 0.436 ' OH ' ' HB2' ' A' ' 201' ' ' ASP . 5.3 m-85 -72.99 -47.03 48.78 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 115.987 -0.551 . . . . 0.0 110.611 -179.943 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -58.81 -44.34 90.8 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 115.652 -0.703 . . . . 0.0 111.812 -179.562 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 53' ' ' VAL . . . . . 0.545 HG23 ' N ' ' A' ' 54' ' ' MET . 34.7 m -69.96 -51.72 37.43 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.183 0 CA-C-N 116.64 -0.254 . . . . 0.0 111.429 -179.549 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 54' ' ' MET . . . . . 0.545 ' N ' HG23 ' A' ' 53' ' ' VAL . 8.3 ttp -59.14 -29.28 67.3 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 121.064 0.459 . . . . 0.0 110.287 -179.964 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 55' ' ' ALA . . . . . 0.559 ' HB2' ' HB2' ' A' ' 8' ' ' PHE . . . -67.74 -32.2 72.65 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 115.703 -0.68 . . . . 0.0 111.329 179.698 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 96.6 mt -79.93 16.66 1.12 Allowed 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.282 -0.417 . . . . 0.0 111.102 -179.875 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 81.15 -4.93 68.82 Favored Glycine 0 N--CA 1.451 -0.365 0 C-N-CA 120.501 -0.857 . . . . 0.0 112.087 -179.656 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 58' ' ' VAL . . . . . 0.426 ' HB ' ' O ' ' A' ' 53' ' ' VAL . 77.0 t -66.25 142.34 16.89 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-O 120.799 0.333 . . . . 0.0 110.779 179.698 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 87.31 -22.28 16.66 Favored Glycine 0 N--CA 1.448 -0.558 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.529 -179.703 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 60' ' ' TRP . . . . . . . . . . . . . 13.5 m0 -60.21 99.22 0.07 Allowed 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 120.745 0.307 . . . . 0.0 110.327 179.823 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 61' ' ' VAL . . . . . 0.483 ' HA ' ' HD3' ' A' ' 62' ' ' PRO . 7.7 p -98.27 129.82 29.77 Favored Pre-proline 0 C--N 1.328 -0.328 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.412 -179.593 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 62' ' ' PRO . . . . . 0.483 ' HD3' ' HA ' ' A' ' 61' ' ' VAL . 12.1 Cg_exo -71.96 136.36 27.24 Favored 'Trans proline' 0 C--N 1.349 0.588 0 C-N-CA 122.628 2.219 . . . . 0.0 112.042 179.824 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 64.6 t -132.13 89.78 1.14 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.396 0 CA-C-N 116.054 -0.521 . . . . 0.0 110.876 -179.94 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . 58.54 -84.54 0.02 OUTLIER 'General case' 0 C--N 1.333 -0.138 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.26 -179.739 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 11.3 pt-20 -124.57 -19.9 5.26 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-O 121.104 0.478 . . . . 0.0 110.351 179.724 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 66' ' ' ARG . . . . . . . . . . . . . 59.3 mtp180 -95.39 166.03 12.08 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 115.576 -0.738 . . . . 0.0 110.676 179.814 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 54.1 m -129.2 122.32 29.5 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.996 179.862 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 15.1 t -111.17 146.27 16.4 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.368 0 CA-C-N 116.082 -0.508 . . . . 0.0 110.929 -179.972 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 69' ' ' PHE . . . . . . . . . . . . . 12.0 m-85 -101.9 112.76 25.49 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.134 -0.484 . . . . 0.0 110.177 -179.803 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 70' ' ' VAL . . . . . 0.567 HG12 ' HD3' ' A' ' 71' ' ' PRO . 0.6 OUTLIER -69.31 -33.35 3.88 Favored Pre-proline 0 CA--C 1.543 0.697 0 N-CA-C 113.089 0.774 . . . . 0.0 113.089 -179.302 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 71' ' ' PRO . . . . . 0.567 ' HD3' HG12 ' A' ' 70' ' ' VAL . 11.3 Cg_exo -69.57 -22.26 33.19 Favored 'Trans proline' 0 C--N 1.357 0.985 0 C-N-CA 121.952 1.768 . . . . 0.0 112.993 -179.073 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 72' ' ' ARG . . . . . 0.483 ' HD2' HG21 ' A' ' 197' ' ' ILE . 50.5 ttp180 -68.6 -55.04 12.88 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.902 0.382 . . . . 0.0 111.663 -179.124 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 73' ' ' TYR . . . . . . . . . . . . . 61.4 m-85 -72.14 -35.06 68.98 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.417 -0.356 . . . . 0.0 110.875 -179.483 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 74' ' ' ILE . . . . . 0.53 HG22 ' HA ' ' A' ' 71' ' ' PRO . 0.3 OUTLIER -65.87 -38.45 82.2 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.189 0 N-CA-C 109.476 -0.564 . . . . 0.0 109.476 179.01 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 17.8 t70 -60.21 -37.64 80.9 Favored 'General case' 0 N--CA 1.453 -0.278 0 N-CA-C 109.147 -0.686 . . . . 0.0 109.147 178.692 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 76' ' ' TRP . . . . . 0.452 ' HZ2' HG23 ' A' ' 197' ' ' ILE . 52.1 m0 -65.7 -34.99 79.47 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 115.681 -0.69 . . . . 0.0 110.345 179.06 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 77' ' ' ILE . . . . . 0.494 HD12 ' HA ' ' A' ' 74' ' ' ILE . 77.4 mt -66.26 -31.84 55.44 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.299 -0.409 . . . . 0.0 110.5 179.504 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 22.3 mt -91.6 -21.47 20.81 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.052 -0.522 . . . . 0.0 112.097 -179.725 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 81.5 p -102.86 -53.25 2.89 Favored 'General case' 0 N--CA 1.463 0.215 0 N-CA-C 113.536 0.939 . . . . 0.0 113.536 -177.924 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 80' ' ' THR . . . . . 0.583 ' HB ' ' HD3' ' A' ' 81' ' ' PRO . 4.9 m -48.57 -53.32 36.85 Favored Pre-proline 0 CA--C 1.53 0.21 0 N-CA-C 112.32 0.489 . . . . 0.0 112.32 -178.223 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 81' ' ' PRO . . . . . 0.583 ' HD3' ' HB ' ' A' ' 80' ' ' THR . 31.6 Cg_exo -61.29 -21.41 71.67 Favored 'Trans proline' 0 C--N 1.351 0.71 0 C-N-CA 121.722 1.615 . . . . 0.0 111.857 179.631 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 82' ' ' LEU . . . . . . . . . . . . . 17.3 tp -76.64 -36.56 57.31 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-N 116.076 -0.511 . . . . 0.0 110.677 -179.983 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 1.9 mp -68.39 -51.92 42.39 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.174 0 CA-C-O 120.803 0.335 . . . . 0.0 110.157 179.094 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 26.6 m -60.18 -31.92 49.29 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.225 0 N-CA-C 109.582 -0.525 . . . . 0.0 109.582 179.026 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 85' ' ' TYR . . . . . . . . . . . . . 74.9 t80 -66.66 -31.27 71.84 Favored 'General case' 0 N--CA 1.452 -0.33 0 CA-C-N 115.698 -0.683 . . . . 0.0 109.372 178.542 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 86' ' ' PHE . . . . . . . . . . . . . 2.0 t80 -62.65 -51.81 65.79 Favored 'General case' 0 C--O 1.231 0.103 0 CA-C-N 115.743 -0.662 . . . . 0.0 109.829 179.061 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 87' ' ' LEU . . . . . 0.405 ' N ' HD12 ' A' ' 87' ' ' LEU . 8.0 mp -63.67 -29.2 70.47 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 115.658 -0.701 . . . . 0.0 110.467 179.556 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -70.53 -28.49 71.0 Favored Glycine 0 N--CA 1.449 -0.465 0 C-N-CA 120.843 -0.694 . . . . 0.0 112.007 179.559 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 79.8 mt -75.32 -42.38 54.64 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-O 120.929 0.395 . . . . 0.0 110.605 179.474 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 72.4 mt -57.71 -32.65 67.6 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 115.887 -0.597 . . . . 0.0 110.766 179.744 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 91' ' ' ALA . . . . . 0.442 ' HB1' ' HB3' ' A' ' 148' ' ' SER . . . -88.9 -34.02 17.1 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.104 -0.498 . . . . 0.0 111.208 179.891 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 84.28 53.77 3.19 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.853 -0.689 . . . . 0.0 112.401 179.926 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 55.0 mt -59.39 162.96 4.31 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 120.897 0.38 . . . . 0.0 111.109 -179.907 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 94' ' ' ASP . . . . . . . . . . . . . 18.4 m-20 -77.17 -178.37 5.02 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.069 -0.514 . . . . 0.0 110.923 179.878 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 50.8 m -63.64 -50.98 67.19 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.083 -0.508 . . . . 0.0 111.197 -179.881 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 14.2 ptm180 -73.65 -35.63 65.29 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.308 -0.405 . . . . 0.0 111.293 -179.596 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 19.9 mm-40 -54.96 -45.68 74.97 Favored 'General case' 0 C--N 1.331 -0.197 0 CA-C-N 116.56 -0.291 . . . . 0.0 110.771 -179.977 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 98' ' ' PHE . . . . . 0.493 ' O ' HG12 ' A' ' 102' ' ' ILE . 10.6 m-85 -60.86 -36.06 78.2 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-O 120.92 0.39 . . . . 0.0 110.272 179.422 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -67.19 -27.53 73.5 Favored Glycine 0 N--CA 1.449 -0.5 0 C-N-CA 120.589 -0.815 . . . . 0.0 112.225 179.511 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 97.0 mt -73.83 -44.88 51.12 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.198 0 N-CA-C 111.855 0.317 . . . . 0.0 111.855 -179.783 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 35.3 m -69.35 -40.78 80.5 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 N-CA-C 112.256 0.465 . . . . 0.0 112.256 -178.806 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 102' ' ' ILE . . . . . 0.493 HG12 ' O ' ' A' ' 98' ' ' PHE . 46.1 mm -68.53 -48.49 71.97 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.697 -0.229 . . . . 0.0 111.456 -179.501 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 14.2 t -60.42 -33.77 72.99 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-O 120.983 0.42 . . . . 0.0 110.645 179.875 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 104' ' ' LEU . . . . . 0.485 HD22 ' HE2' ' A' ' 140' ' ' TYR . 48.4 tp -60.44 -53.56 56.08 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 115.954 -0.567 . . . . 0.0 110.428 179.578 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 105' ' ' ASN . . . . . 0.611 ' N ' HD22 ' A' ' 105' ' ' ASN . 0.8 OUTLIER -61.22 -25.19 66.88 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 115.892 -0.594 . . . . 0.0 110.835 179.845 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 28.6 m -64.31 -54.13 38.02 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.258 179.961 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 107' ' ' VAL . . . . . 0.433 HG12 ' O ' ' A' ' 104' ' ' LEU . 12.5 p -64.85 -36.11 76.84 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.245 0 CA-C-N 116.504 -0.316 . . . . 0.0 111.194 -179.962 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . 0.401 HG23 ' O ' ' A' ' 104' ' ' LEU . 92.6 t -64.78 -52.76 50.26 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.246 0 CA-C-O 120.84 0.352 . . . . 0.0 110.89 179.743 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 109' ' ' MET . . . . . 0.547 ' HE1' HG21 ' A' ' 80' ' ' THR . 1.9 tpp -60.06 -32.13 70.65 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.06 -0.518 . . . . 0.0 110.758 179.774 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 36.4 tp -75.21 -30.17 60.52 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 115.974 -0.557 . . . . 0.0 110.261 179.46 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -60.94 -52.4 65.18 Favored 'General case' 0 C--N 1.331 -0.199 0 CA-C-N 116.081 -0.508 . . . . 0.0 110.308 179.337 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . -70.58 -38.43 68.35 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.636 -0.792 . . . . 0.0 111.851 179.268 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 113' ' ' PHE . . . . . . . . . . . . . 1.9 t80 -53.87 -63.21 1.22 Allowed 'General case' 0 C--N 1.332 -0.194 0 CA-C-O 120.849 0.356 . . . . 0.0 110.063 179.349 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 114' ' ' ALA . . . . . 0.413 ' O ' HG13 ' A' ' 118' ' ' VAL . . . -69.62 -17.43 63.52 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.135 178.949 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 115' ' ' GLY . . . . . 0.438 ' HA2' HD22 ' A' ' 126' ' ' LEU . . . -55.48 -52.62 46.69 Favored Glycine 0 C--N 1.333 0.389 0 CA-C-N 115.871 -0.604 . . . . 0.0 112.042 179.545 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 116' ' ' ALA . . . . . 0.61 ' HB2' ' HB3' ' A' ' 183' ' ' PRO . . . -77.41 -14.69 59.65 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-O 120.763 0.316 . . . . 0.0 111.192 -179.962 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 117' ' ' MET . . . . . . . . . . . . . 23.2 mmt -87.24 6.88 30.98 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.284 -0.417 . . . . 0.0 111.947 -179.413 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 118' ' ' VAL . . . . . 0.413 HG13 ' O ' ' A' ' 114' ' ' ALA . 16.5 m -80.43 145.52 59.57 Favored Pre-proline 0 C--N 1.331 -0.206 0 CA-C-O 120.498 0.19 . . . . 0.0 111.322 -179.9 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 119' ' ' PRO . . . . . . . . . . . . . 85.9 Cg_endo -85.14 -6.59 9.33 Favored 'Trans proline' 0 C--N 1.348 0.509 0 C-N-CA 122.689 2.26 . . . . 0.0 112.099 179.51 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -133.17 -143.2 4.96 Favored Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.871 -0.68 . . . . 0.0 112.615 -179.894 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 121' ' ' ILE . . . . . 0.425 ' H ' HG13 ' A' ' 121' ' ' ILE . 2.7 pp -101.31 11.46 7.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-O 120.782 0.325 . . . . 0.0 111.308 -179.908 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 9.9 mm-40 -59.47 -19.08 45.09 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.047 179.975 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 123' ' ' ARG . . . . . 0.463 ' HB2' ' HH2' ' A' ' 178' ' ' TRP . 16.4 ptt180 -52.04 -34.55 43.74 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.037 -0.529 . . . . 0.0 111.538 -179.786 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 124' ' ' TYR . . . . . . . . . . . . . 49.6 m-85 -61.18 -33.13 72.96 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-O 120.748 0.308 . . . . 0.0 110.884 -179.956 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 125' ' ' ALA . . . . . . . . . . . . . . . -72.4 -50.58 25.47 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.278 -0.419 . . . . 0.0 110.666 179.55 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 126' ' ' LEU . . . . . 0.438 HD22 ' HA2' ' A' ' 115' ' ' GLY . 7.3 mp -54.53 -54.22 44.11 Favored 'General case' 0 C--N 1.332 -0.18 0 CA-C-N 116.018 -0.537 . . . . 0.0 110.182 179.726 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 127' ' ' PHE . . . . . . . . . . . . . 8.9 t80 -63.15 -37.08 85.79 Favored 'General case' 0 N--CA 1.451 -0.409 0 CA-C-N 115.973 -0.558 . . . . 0.0 110.784 179.724 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 128' ' ' GLY . . . . . . . . . . . . . . . -46.22 -45.0 15.48 Favored Glycine 0 C--N 1.332 0.306 0 C-N-CA 120.19 -1.005 . . . . 0.0 110.918 179.109 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 129' ' ' MET . . . . . . . . . . . . . 0.4 OUTLIER -69.82 -37.74 76.34 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 115.311 -0.444 . . . . 0.0 109.85 178.646 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -61.99 -34.25 88.29 Favored Glycine 0 C--N 1.332 0.335 0 CA-C-N 115.677 -0.692 . . . . 0.0 112.942 -179.872 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -71.41 -53.77 12.95 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.697 0.284 . . . . 0.0 110.52 179.908 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 38.4 t -56.85 -39.95 68.16 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-O 121.439 0.638 . . . . 0.0 109.38 178.899 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -66.9 -35.37 79.85 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 115.151 -0.931 . . . . 0.0 110.532 179.357 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 134' ' ' PHE . . . . . . . . . . . . . 86.4 t80 -55.37 -55.27 33.53 Favored 'General case' 0 N--CA 1.452 -0.337 0 CA-C-O 121.012 0.434 . . . . 0.0 110.019 179.428 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 135' ' ' ILE . . . . . 0.429 ' O ' HG22 ' A' ' 138' ' ' VAL . 29.6 mt -56.28 -33.95 38.84 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.295 0 CA-C-N 115.761 -0.654 . . . . 0.0 109.913 179.136 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . -61.99 -40.66 99.19 Favored Glycine 0 N--CA 1.448 -0.547 0 C-N-CA 120.299 -0.953 . . . . 0.0 111.321 178.812 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 137' ' ' LEU . . . . . 0.496 HD13 HD21 ' A' ' 105' ' ' ASN . 64.8 tp -69.33 -53.1 21.3 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-O 120.532 0.205 . . . . 0.0 111.04 179.97 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 138' ' ' VAL . . . . . 0.429 HG22 ' O ' ' A' ' 135' ' ' ILE . 4.9 m -55.43 -34.62 34.87 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.167 0 N-CA-C 109.521 -0.548 . . . . 0.0 109.521 179.775 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 139' ' ' TYR . . . . . . . . . . . . . 21.4 t80 -61.58 -40.9 96.4 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 115.454 -0.794 . . . . 0.0 110.403 178.548 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 140' ' ' TYR . . . . . 0.485 ' HE2' HD22 ' A' ' 104' ' ' LEU . 20.9 m-85 -64.89 -52.17 57.97 Favored 'General case' 0 C--N 1.332 -0.189 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.673 -179.848 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 141' ' ' LEU . . . . . 0.516 HD12 ' N ' ' A' ' 142' ' ' VAL . 3.6 pp -64.27 -18.23 64.37 Favored 'General case' 0 N--CA 1.463 0.176 0 N-CA-C 111.74 0.274 . . . . 0.0 111.74 -179.271 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 142' ' ' VAL . . . . . 0.516 ' N ' HD12 ' A' ' 141' ' ' LEU . 5.2 p -109.36 -2.77 10.23 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-O 120.898 0.38 . . . . 0.0 110.924 179.866 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . -99.81 -102.51 2.44 Favored Glycine 0 CA--C 1.522 0.503 0 C-N-CA 120.767 -0.73 . . . . 0.0 113.104 -179.849 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 144' ' ' PRO . . . . . . . . . . . . . 58.2 Cg_endo -70.15 -27.87 24.07 Favored 'Trans proline' 0 C--N 1.348 0.503 0 C-N-CA 122.628 2.219 . . . . 0.0 113.285 -179.313 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 145' ' ' MET . . . . . 0.484 ' SD ' ' HA ' ' A' ' 141' ' ' LEU . 50.7 mtt -62.68 -39.07 92.78 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.669 0.271 . . . . 0.0 111.461 -179.583 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 146' ' ' THR . . . . . . . . . . . . . 67.2 p -66.21 -43.6 86.28 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.456 -0.338 . . . . 0.0 111.448 -179.524 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 39.7 mt-10 -70.45 -33.69 71.58 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.344 -0.389 . . . . 0.0 111.268 -179.651 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 148' ' ' SER . . . . . 0.442 ' HB3' ' HB1' ' A' ' 91' ' ' ALA . 48.0 t -70.34 -44.55 67.94 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.357 -0.383 . . . . 0.0 111.464 -179.485 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 149' ' ' ALA . . . . . . . . . . . . . . . -73.74 -33.94 64.54 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.339 -0.391 . . . . 0.0 111.399 -179.699 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 150' ' ' SER . . . . . 0.445 ' HB2' ' NZ ' ' A' ' 157' ' ' LYS . 81.0 p -67.33 -5.76 15.74 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 121.007 0.432 . . . . 0.0 110.657 179.783 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 151' ' ' GLN . . . . . . . . . . . . . 74.0 mt-30 -110.3 5.28 21.55 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 115.899 -0.591 . . . . 0.0 111.336 -179.812 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 31.2 ttt180 -91.8 -52.64 4.64 Favored 'General case' 0 C--N 1.331 -0.23 0 C-N-CA 120.902 -0.319 . . . . 0.0 111.213 -179.895 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 153' ' ' SER . . . . . 0.674 ' HB3' HG12 ' A' ' 156' ' ' ILE . 20.5 t -157.67 172.44 18.52 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.444 -0.344 . . . . 0.0 111.002 179.327 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 154' ' ' SER . . . . . . . . . . . . . 72.6 p -73.41 -41.7 62.98 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.705 179.576 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -72.64 -29.59 65.37 Favored Glycine 0 N--CA 1.452 -0.288 0 C-N-CA 120.804 -0.712 . . . . 0.0 112.334 179.88 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 156' ' ' ILE . . . . . 0.674 HG12 ' HB3' ' A' ' 153' ' ' SER . 34.6 mm -58.99 -38.45 73.86 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-O 120.84 0.352 . . . . 0.0 111.066 179.862 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 157' ' ' LYS . . . . . 0.445 ' NZ ' ' HB2' ' A' ' 150' ' ' SER . 21.3 ttmm -65.06 -47.86 75.82 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.129 -0.487 . . . . 0.0 111.085 179.811 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 69.1 m -60.65 -43.3 97.74 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 115.981 -0.554 . . . . 0.0 111.69 -179.042 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 159' ' ' LEU . . . . . 0.767 ' HG ' HD11 ' A' ' 163' ' ' LEU . 3.7 tp -66.5 -58.59 4.9 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-O 120.943 0.401 . . . . 0.0 110.66 -179.861 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 160' ' ' TYR . . . . . . . . . . . . . 30.1 t80 -51.14 -36.23 39.68 Favored 'General case' 0 C--N 1.326 -0.416 0 N-CA-C 113.302 0.853 . . . . 0.0 113.302 -178.13 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 161' ' ' VAL . . . . . 0.423 HG23 ' N ' ' A' ' 162' ' ' ARG . 30.7 m -73.27 -47.04 48.25 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.373 0 N-CA-C 112.159 0.429 . . . . 0.0 112.159 -177.791 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 162' ' ' ARG . . . . . 0.423 ' N ' HG23 ' A' ' 161' ' ' VAL . 24.2 ttm180 -63.68 -41.23 98.18 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-O 120.953 0.406 . . . . 0.0 111.014 -179.701 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 163' ' ' LEU . . . . . 0.767 HD11 ' HG ' ' A' ' 159' ' ' LEU . 6.6 mt -70.38 -50.34 39.76 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 115.89 -0.595 . . . . 0.0 111.712 -179.197 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 164' ' ' ARG . . . . . 0.606 ' HG3' HD22 ' A' ' 165' ' ' ASN . 0.4 OUTLIER -58.14 -40.96 82.69 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.517 -0.31 . . . . 0.0 110.917 -178.986 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 165' ' ' ASN . . . . . 0.606 HD22 ' HG3' ' A' ' 164' ' ' ARG . 0.9 OUTLIER -58.46 -51.34 70.28 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-O 120.832 0.349 . . . . 0.0 110.295 179.545 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 166' ' ' LEU . . . . . 0.513 ' O ' ' HG ' ' A' ' 170' ' ' LEU . 2.3 tt -59.39 -54.74 43.25 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 115.93 -0.577 . . . . 0.0 111.712 -179.931 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 167' ' ' THR . . . . . 0.456 ' N ' HD23 ' A' ' 166' ' ' LEU . 52.6 m -55.08 -53.03 61.12 Favored 'General case' 0 C--N 1.33 -0.245 0 N-CA-C 112.773 0.657 . . . . 0.0 112.773 -178.398 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 168' ' ' VAL . . . . . 0.417 HG23 ' O ' ' A' ' 164' ' ' ARG . 75.4 t -53.96 -42.23 53.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 N-CA-C 112.329 0.492 . . . . 0.0 112.329 -179.004 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 169' ' ' VAL . . . . . 0.479 HG23 ' O ' ' A' ' 165' ' ' ASN . 72.7 t -60.93 -64.74 0.57 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 N-CA-C 112.124 0.416 . . . . 0.0 112.124 -179.225 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 170' ' ' LEU . . . . . 0.513 ' HG ' ' O ' ' A' ' 166' ' ' LEU . 0.4 OUTLIER -61.92 -34.12 75.49 Favored 'General case' 0 N--CA 1.465 0.276 0 N-CA-C 112.354 0.502 . . . . 0.0 112.354 -178.815 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 171' ' ' TRP . . . . . 0.42 ' HA ' ' HD2' ' A' ' 174' ' ' TYR . 6.1 m0 -68.06 -29.56 68.56 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-O 120.792 0.33 . . . . 0.0 110.634 179.629 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 172' ' ' ALA . . . . . . . . . . . . . . . -73.92 -7.12 51.14 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.759 179.781 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 173' ' ' ILE . . . . . 0.49 ' O ' HG12 ' A' ' 177' ' ' ILE . 28.8 mm -87.68 -21.46 7.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 115.839 -0.619 . . . . 0.0 110.526 179.476 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 174' ' ' TYR . . . . . 0.42 ' HD2' ' HA ' ' A' ' 171' ' ' TRP . 8.2 m-85 -53.84 -48.38 93.81 Favored Pre-proline 0 CA--C 1.528 0.105 0 CA-C-N 116.055 -0.52 . . . . 0.0 111.681 -179.567 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 175' ' ' PRO . . . . . 0.403 ' CD ' ' N ' ' A' ' 174' ' ' TYR . 83.2 Cg_exo -46.65 -32.15 11.38 Favored 'Trans proline' 0 C--N 1.351 0.667 0 C-N-CA 121.831 1.687 . . . . 0.0 111.95 179.358 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 176' ' ' PHE . . . . . 0.433 ' O ' ' HG ' ' A' ' 180' ' ' LEU . 84.3 m-85 -81.1 -49.79 10.43 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 115.697 -0.683 . . . . 0.0 111.799 179.867 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 177' ' ' ILE . . . . . 0.49 HG12 ' O ' ' A' ' 173' ' ' ILE . 8.5 mm -61.01 -38.83 80.36 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.498 0 N-CA-C 112.708 0.633 . . . . 0.0 112.708 -177.896 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 178' ' ' TRP . . . . . 0.463 ' HH2' ' HB2' ' A' ' 123' ' ' ARG . 78.5 t90 -71.58 -51.88 21.05 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.79 0.328 . . . . 0.0 111.213 -179.735 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 179' ' ' LEU . . . . . 0.55 HD23 HD23 ' A' ' 180' ' ' LEU . 0.6 OUTLIER -64.55 -55.08 22.82 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.323 -0.399 . . . . 0.0 111.601 -178.997 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 180' ' ' LEU . . . . . 0.55 HD23 HD23 ' A' ' 179' ' ' LEU . 32.4 mt -65.96 -37.64 86.52 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 116.341 -0.39 . . . . 0.0 111.345 -179.332 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . -60.53 176.15 4.25 Favored Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 119.988 -1.101 . . . . 0.0 112.33 179.589 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 182' ' ' PRO . . . . . 0.555 ' HA ' ' HB2' ' A' ' 186' ' ' ALA . 88.3 Cg_exo -46.63 -44.97 20.69 Favored 'Trans proline' 0 CA--C 1.536 0.607 0 C-N-CA 122.681 2.254 . . . . 0.0 113.402 179.912 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 183' ' ' PRO . . . . . 0.61 ' HB3' ' HB2' ' A' ' 116' ' ' ALA . 97.3 Cg_exo -45.31 -35.25 11.23 Favored 'Trans proline' 0 C--N 1.356 0.926 0 C-N-CA 122.328 2.019 . . . . 0.0 113.439 179.89 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 184' ' ' GLY . . . . . . . . . . . . . . . -110.29 -123.23 4.52 Favored Glycine 0 C--N 1.332 0.344 0 C-N-CA 120.299 -0.953 . . . . 0.0 113.204 -179.453 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 185' ' ' VAL . . . . . . . . . . . . . 8.1 m -63.04 -26.93 42.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 N-CA-C 112.16 0.43 . . . . 0.0 112.16 -179.225 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 186' ' ' ALA . . . . . 0.555 ' HB2' ' HA ' ' A' ' 182' ' ' PRO . . . 60.25 81.05 0.19 Allowed 'General case' 0 C--N 1.331 -0.207 0 N-CA-C 111.858 0.318 . . . . 0.0 111.858 179.48 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 187' ' ' LEU . . . . . . . . . . . . . 6.9 mt -92.8 -49.78 5.9 Favored 'General case' 0 C--N 1.332 -0.156 0 CA-C-O 120.995 0.426 . . . . 0.0 111.012 179.587 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 188' ' ' LEU . . . . . . . . . . . . . 95.2 mt -89.32 -166.7 1.66 Allowed 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 115.795 -0.639 . . . . 0.0 111.247 -179.48 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 189' ' ' THR . . . . . 0.429 HG22 ' H ' ' A' ' 191' ' ' THR . 74.9 m -94.08 136.13 23.95 Favored Pre-proline 0 C--N 1.328 -0.357 0 CA-C-N 115.781 -0.645 . . . . 0.0 110.626 -179.811 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 190' ' ' PRO . . . . . . . . . . . . . 2.4 Cg_endo -44.99 -38.58 13.66 Favored 'Trans proline' 0 C--N 1.35 0.61 0 C-N-CA 122.854 2.369 . . . . 0.0 112.649 -179.983 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 191' ' ' THR . . . . . 0.429 ' H ' HG22 ' A' ' 189' ' ' THR . 71.2 p -61.98 -42.95 99.7 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-O 120.965 0.412 . . . . 0.0 110.911 179.711 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 192' ' ' VAL . . . . . . . . . . . . . 88.8 t -71.29 -53.54 20.7 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 115.92 -0.582 . . . . 0.0 111.434 -179.816 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 193' ' ' ASP . . . . . . . . . . . . . 29.3 t70 -54.49 -52.01 63.28 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.242 -0.436 . . . . 0.0 111.442 -179.396 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 194' ' ' VAL . . . . . 0.531 ' O ' HG22 ' A' ' 198' ' ' VAL . 71.1 t -59.23 -38.22 73.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.371 -0.377 . . . . 0.0 110.614 -179.874 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 195' ' ' ALA . . . . . . . . . . . . . . . -55.22 -44.86 75.8 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.754 179.605 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 196' ' ' LEU . . . . . . . . . . . . . 95.6 mt -68.36 -35.86 78.35 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.934 179.461 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 197' ' ' ILE . . . . . 0.483 HG21 ' HD2' ' A' ' 72' ' ' ARG . 11.0 mm -59.49 -61.09 1.61 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.06 -0.518 . . . . 0.0 110.874 179.96 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 198' ' ' VAL . . . . . 0.531 HG22 ' O ' ' A' ' 194' ' ' VAL . 1.4 m -55.74 -35.0 37.83 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.462 0 CA-C-O 121.626 0.727 . . . . 0.0 109.191 178.772 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 199' ' ' TYR . . . . . . . . . . . . . 86.7 t80 -64.04 -32.5 74.07 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-N 114.56 -1.2 . . . . 0.0 110.415 179.336 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 200' ' ' LEU . . . . . 0.444 HD11 HG13 ' A' ' 177' ' ' ILE . 38.1 mt -71.11 -37.78 72.36 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 115.99 -0.55 . . . . 0.0 110.648 179.591 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 201' ' ' ASP . . . . . 0.436 ' HB2' ' OH ' ' A' ' 51' ' ' TYR . 7.9 m-20 -74.58 -32.98 62.55 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 115.953 -0.567 . . . . 0.0 110.161 179.63 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 202' ' ' LEU . . . . . 0.4 HD21 ' O ' ' A' ' 11' ' ' GLY . 0.5 OUTLIER -72.52 -28.45 62.87 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 115.29 -0.868 . . . . 0.0 111.623 -179.527 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 203' ' ' VAL . . . . . 0.425 HG12 ' O ' ' A' ' 200' ' ' LEU . 9.6 p -82.17 -37.78 14.99 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.18 0 N-CA-C 111.946 0.35 . . . . 0.0 111.946 -178.805 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 204' ' ' THR . . . . . . . . . . . . . 86.5 m -69.6 -41.87 75.16 Favored 'General case' 0 C--N 1.328 -0.337 0 C-N-CA 120.821 -0.352 . . . . 0.0 111.569 179.93 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 205' ' ' LYS . . . . . 0.671 ' HE2' ' HB2' ' A' ' 47' ' ' ALA . 59.7 mttp -76.52 -57.93 3.58 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.398 -0.365 . . . . 0.0 111.557 -178.872 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 60.4 t -69.47 -36.83 73.34 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.372 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.471 -179.503 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 207' ' ' GLY . . . . . . . . . . . . . . . -66.44 -52.76 32.87 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.615 -0.802 . . . . 0.0 112.43 -179.326 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 208' ' ' PHE . . . . . 0.689 ' CZ ' HD13 ' A' ' 163' ' ' LEU . 11.3 t80 -55.21 -49.86 70.87 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-O 120.748 0.309 . . . . 0.0 110.941 179.771 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 209' ' ' GLY . . . . . 0.477 ' CA ' HD21 ' A' ' 40' ' ' LEU . . . -63.64 -37.46 94.77 Favored Glycine 0 N--CA 1.451 -0.339 0 CA-C-N 115.632 -0.713 . . . . 0.0 113.985 -179.184 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 210' ' ' PHE . . . . . . . . . . . . . 0.6 OUTLIER -68.65 -46.66 68.57 Favored 'General case' 0 CA--C 1.512 -0.484 0 N-CA-C 108.217 -1.031 . . . . 0.0 108.217 179.272 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 211' ' ' ILE . . . . . . . . . . . . . 92.8 mt -64.9 -28.21 44.26 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.702 0 N-CA-C 107.694 -1.224 . . . . 0.0 107.694 176.656 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 212' ' ' ALA . . . . . 0.474 ' HB3' ' HA2' ' A' ' 209' ' ' GLY . . . -68.29 -45.71 72.33 Favored 'General case' 0 N--CA 1.449 -0.492 0 CA-C-N 114.419 -1.264 . . . . 0.0 111.087 -179.851 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 213' ' ' LEU . . . . . . . . . . . . . 92.8 mt -70.55 -55.32 9.16 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-N 115.442 -0.799 . . . . 0.0 112.415 -178.828 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 214' ' ' ASP . . . . . . . . . . . . . 31.9 m-20 -53.11 -52.1 59.76 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.713 0.292 . . . . 0.0 111.607 -179.295 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 215' ' ' ALA . . . . . . . . . . . . . . . -62.14 -57.77 10.29 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 116.339 -0.391 . . . . 0.0 111.691 -179.438 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 216' ' ' ALA . . . . . . . . . . . . . . . -56.4 -34.85 67.11 Favored 'General case' 0 C--N 1.332 -0.188 0 CA-C-N 116.469 -0.332 . . . . 0.0 111.469 -179.537 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 217' ' ' ALA . . . . . . . . . . . . . . . -60.55 -40.7 92.55 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-O 121.048 0.452 . . . . 0.0 110.082 179.703 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 218' ' ' THR . . . . . . . . . . . . . 95.9 m . . . . . 0 C--N 1.33 -0.253 0 CA-C-N 115.659 -0.7 . . . . 0.0 110.71 179.331 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.368 0 N-CA-C 112.582 -0.207 . . . . 0.0 112.582 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 4' ' ' LEU . . . . . 0.443 ' HA ' HD23 ' A' ' 7' ' ' LEU . 92.7 mt -74.04 -35.25 64.3 Favored 'General case' 0 N--CA 1.449 -0.508 0 CA-C-O 120.858 0.361 . . . . 0.0 110.94 179.88 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 55.1 p -54.44 -38.84 66.76 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 115.928 -0.578 . . . . 0.0 111.718 -179.587 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 72.0 p -54.81 -35.52 63.98 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.451 -0.34 . . . . 0.0 111.619 -179.578 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 7' ' ' LEU . . . . . 0.443 HD23 ' HA ' ' A' ' 4' ' ' LEU . 3.9 mm? -60.14 -53.29 59.45 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.317 -0.401 . . . . 0.0 111.272 -179.748 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 8' ' ' PHE . . . . . 0.604 ' HB2' ' HB2' ' A' ' 55' ' ' ALA . 75.8 m-85 -64.17 -34.53 78.29 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.994 -179.645 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 9' ' ' TRP . . . . . . . . . . . . . 21.5 m95 -62.34 -46.17 89.88 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-O 121.074 0.464 . . . . 0.0 109.835 179.939 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 41.9 mt -63.11 -35.88 81.75 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 115.629 -0.714 . . . . 0.0 110.154 179.138 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -69.66 -28.85 71.71 Favored Glycine 0 N--CA 1.448 -0.545 0 CA-C-N 115.643 -0.708 . . . . 0.0 111.784 179.419 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -73.71 -30.8 63.05 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-O 120.896 0.379 . . . . 0.0 110.473 179.526 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 13' ' ' ILE . . . . . 0.42 ' O ' HG23 ' A' ' 17' ' ' VAL . 50.2 mm -68.39 -54.33 22.36 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.124 0 CA-C-N 116.058 -0.519 . . . . 0.0 110.442 179.221 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -61.42 -37.39 94.02 Favored Glycine 0 N--CA 1.448 -0.534 0 C-N-CA 120.661 -0.781 . . . . 0.0 111.744 179.43 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 15' ' ' MET . . . . . 0.524 ' SD ' ' HA ' ' A' ' 44' ' ' SER . 55.5 tpp -63.65 -44.36 94.04 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.845 0.355 . . . . 0.0 110.44 179.527 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 16' ' ' LEU . . . . . 0.429 HD13 ' O ' ' A' ' 16' ' ' LEU . 0.4 OUTLIER -54.82 -42.13 71.5 Favored 'General case' 0 C--N 1.332 -0.187 0 CA-C-N 115.943 -0.572 . . . . 0.0 110.02 179.291 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 17' ' ' VAL . . . . . 0.42 HG23 ' O ' ' A' ' 13' ' ' ILE . 45.0 t -58.94 -44.55 91.19 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.188 0 CA-C-N 116.011 -0.54 . . . . 0.0 110.328 179.404 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -64.45 -40.44 97.74 Favored Glycine 0 C--N 1.332 0.337 0 C-N-CA 120.852 -0.689 . . . . 0.0 111.726 179.124 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 11.8 m -53.45 -48.18 69.05 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-O 120.839 0.352 . . . . 0.0 110.988 -179.943 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 97.2 mt -71.75 -36.13 70.33 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.513 -179.977 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -58.14 -38.01 75.75 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 116.528 -0.305 . . . . 0.0 111.586 -179.761 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 22' ' ' PHE . . . . . 0.606 ' HB2' HG22 ' A' ' 41' ' ' VAL . 4.0 m-85 -90.91 -28.22 18.24 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.347 -0.388 . . . . 0.0 111.394 -179.457 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -69.81 -50.8 39.43 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.961 0.41 . . . . 0.0 111.503 -179.444 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 24' ' ' TRP . . . . . . . . . . . . . 5.5 t-105 -66.19 -43.26 87.34 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 115.842 -0.617 . . . . 0.0 111.111 -179.659 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.329 -0.316 0 CA-C-O 120.94 0.4 . . . . 0.0 110.866 179.799 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.363 0 N-CA-C 112.472 -0.251 . . . . 0.0 112.472 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 16.3 mm-40 -83.57 -21.68 32.56 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 120.689 0.28 . . . . 0.0 110.994 179.929 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 34' ' ' ARG . . . . . . . . . . . . . 60.1 ttp180 -52.11 -30.5 26.54 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-N 116.158 -0.473 . . . . 0.0 111.252 -179.645 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 80.2 ttt180 -61.28 -42.55 98.83 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.871 0.367 . . . . 0.0 110.761 179.879 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 66.4 m-85 -70.75 -30.47 66.99 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.054 -0.521 . . . . 0.0 110.925 179.941 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 37' ' ' TYR . . . . . 0.502 ' O ' HG23 ' A' ' 41' ' ' VAL . 59.2 m-85 -72.37 -56.13 5.96 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.324 -179.44 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 52.1 t -57.05 -37.4 54.94 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.189 0 CA-C-O 120.955 0.407 . . . . 0.0 110.766 -179.826 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 33.8 m -60.73 -51.01 71.19 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 115.863 -0.608 . . . . 0.0 110.628 179.521 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 40' ' ' LEU . . . . . 0.61 HD12 HD12 ' A' ' 43' ' ' ILE . 66.0 tp -60.86 -46.89 88.79 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 115.838 -0.619 . . . . 0.0 110.63 179.694 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . 0.606 HG22 ' HB2' ' A' ' 22' ' ' PHE . 90.0 t -56.7 -35.24 44.96 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.242 0 CA-C-N 115.884 -0.598 . . . . 0.0 110.041 179.289 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -61.74 -40.95 99.49 Favored Glycine 0 N--CA 1.448 -0.527 0 C-N-CA 120.673 -0.775 . . . . 0.0 111.504 179.175 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 43' ' ' ILE . . . . . 0.61 HD12 HD12 ' A' ' 40' ' ' LEU . 18.7 mt -57.46 -56.62 14.2 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.22 0 CA-C-O 120.76 0.314 . . . . 0.0 110.933 179.318 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 44' ' ' SER . . . . . 0.524 ' HA ' ' SD ' ' A' ' 15' ' ' MET . 49.7 m -58.71 -26.35 63.82 Favored 'General case' 0 C--N 1.332 -0.182 0 CA-C-N 116.315 -0.402 . . . . 0.0 111.482 -179.696 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -73.53 -53.99 7.05 Favored Glycine 0 CA--C 1.518 0.229 0 C-N-CA 120.681 -0.771 . . . . 0.0 112.879 -179.625 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 19.6 pt -61.18 -38.38 79.59 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.222 0 CA-C-O 120.871 0.367 . . . . 0.0 111.377 -179.712 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 47' ' ' ALA . . . . . 0.665 ' HB2' ' HE2' ' A' ' 205' ' ' LYS . . . -67.71 -43.21 80.57 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.814 0.34 . . . . 0.0 111.002 179.602 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -54.75 -46.71 74.36 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 115.947 -0.569 . . . . 0.0 111.754 -179.531 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 31.4 m -68.59 -34.19 63.89 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.241 0 CA-C-N 116.527 -0.306 . . . . 0.0 111.275 -179.595 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -66.01 -37.07 84.98 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-O 120.884 0.373 . . . . 0.0 111.005 179.638 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 51' ' ' TYR . . . . . 0.433 ' CE1' HG13 ' A' ' 198' ' ' VAL . 26.7 m-85 -68.75 -38.75 80.34 Favored 'General case' 0 C--N 1.327 -0.413 0 CA-C-O 121.117 0.484 . . . . 0.0 110.084 179.772 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -65.29 -45.09 85.84 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 115.635 -0.712 . . . . 0.0 111.314 179.676 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 53' ' ' VAL . . . . . 0.466 HG23 ' N ' ' A' ' 54' ' ' MET . 27.6 m -67.76 -46.5 82.36 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.139 0 CA-C-O 120.794 0.33 . . . . 0.0 110.621 179.886 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 54' ' ' MET . . . . . 0.498 ' HG2' ' HG2' ' A' ' 71' ' ' PRO . 72.0 mtm -62.27 -30.44 71.12 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 121.156 0.503 . . . . 0.0 109.854 179.111 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 55' ' ' ALA . . . . . 0.604 ' HB2' ' HB2' ' A' ' 8' ' ' PHE . . . -74.28 -30.53 62.14 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 115.601 -0.727 . . . . 0.0 111.355 179.797 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 76.3 mt -77.37 -9.74 59.03 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.457 -0.338 . . . . 0.0 111.214 -179.764 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 95.31 -11.93 68.48 Favored Glycine 0 N--CA 1.452 -0.254 0 C-N-CA 120.666 -0.778 . . . . 0.0 113.017 179.729 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 8.8 p -74.29 140.58 17.38 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-O 120.846 0.355 . . . . 0.0 110.885 -179.97 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 59' ' ' GLY . . . . . 0.465 ' HA3' ' HG3' ' A' ' 71' ' ' PRO . . . 101.29 -9.71 57.76 Favored Glycine 0 N--CA 1.45 -0.377 0 C-N-CA 120.907 -0.663 . . . . 0.0 112.286 -179.715 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 60' ' ' TRP . . . . . . . . . . . . . 15.8 m0 -76.32 118.08 18.66 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-O 120.579 0.228 . . . . 0.0 110.393 179.67 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 61' ' ' VAL . . . . . 0.483 ' HA ' ' HD3' ' A' ' 62' ' ' PRO . 7.5 p -113.26 127.63 26.61 Favored Pre-proline 0 CA--C 1.533 0.321 0 CA-C-N 116.582 -0.281 . . . . 0.0 111.716 -179.603 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 62' ' ' PRO . . . . . 0.483 ' HD3' ' HA ' ' A' ' 61' ' ' VAL . 6.8 Cg_exo -74.03 146.61 37.25 Favored 'Trans proline' 0 C--N 1.351 0.685 0 C-N-CA 122.88 2.386 . . . . 0.0 112.159 179.518 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 75.5 t -139.71 90.42 0.6 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.044 179.859 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . 59.16 -86.12 0.02 OUTLIER 'General case' 0 C--N 1.331 -0.196 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.463 179.891 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 9.7 tp10 -122.42 -19.98 6.24 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 121.011 0.434 . . . . 0.0 110.653 -179.991 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 66' ' ' ARG . . . . . 0.418 HH22 HH12 ' A' ' 123' ' ' ARG . 18.4 ptp180 -100.76 165.82 11.18 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 115.893 -0.594 . . . . 0.0 110.373 179.878 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 26.3 m -125.42 139.66 53.46 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.886 0.374 . . . . 0.0 111.3 -179.838 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 21.5 t -124.17 146.57 29.46 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.238 0 CA-C-N 115.972 -0.558 . . . . 0.0 110.583 179.887 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 69' ' ' PHE . . . . . . . . . . . . . 27.5 m-85 -109.37 111.05 22.39 Favored 'General case' 0 C--N 1.331 -0.206 0 CA-C-N 116.41 -0.359 . . . . 0.0 110.062 -179.629 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 70' ' ' VAL . . . . . 0.599 ' N ' ' HD2' ' A' ' 71' ' ' PRO . 47.4 t -70.02 -49.82 18.15 Favored Pre-proline 0 C--N 1.325 -0.471 0 N-CA-C 112.759 0.651 . . . . 0.0 112.759 -179.186 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 71' ' ' PRO . . . . . 0.599 ' HD2' ' N ' ' A' ' 70' ' ' VAL . 11.3 Cg_endo -54.03 -19.12 14.94 Favored 'Trans proline' 0 C--N 1.352 0.739 0 C-N-CA 122.031 1.82 . . . . 0.0 112.339 -179.616 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 72' ' ' ARG . . . . . 0.517 ' HE ' HG21 ' A' ' 197' ' ' ILE . 32.1 ttt180 -77.02 -53.49 7.74 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.596 179.605 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 73' ' ' TYR . . . . . 0.423 ' O ' HG13 ' A' ' 77' ' ' ILE . 79.9 m-85 -66.37 -39.41 89.08 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 115.816 -0.629 . . . . 0.0 110.922 -179.811 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 0.3 OUTLIER -67.4 -36.35 76.24 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-N 116.348 -0.387 . . . . 0.0 110.043 179.504 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 12.6 t70 -61.02 -37.37 82.32 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.235 -0.439 . . . . 0.0 109.951 179.253 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 76' ' ' TRP . . . . . . . . . . . . . 48.6 m0 -66.3 -36.21 82.36 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 115.927 -0.579 . . . . 0.0 110.067 179.414 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 77' ' ' ILE . . . . . 0.5 ' O ' ' HG2' ' A' ' 81' ' ' PRO . 68.3 mt -66.54 -30.07 48.55 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.364 0 CA-C-N 115.959 -0.564 . . . . 0.0 110.91 179.511 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 53.4 mt -91.91 -21.95 20.32 Favored 'General case' 0 C--N 1.328 -0.347 0 N-CA-C 112.511 0.56 . . . . 0.0 112.511 -179.644 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 79' ' ' THR . . . . . 0.401 ' HB ' ' HE3' ' A' ' 205' ' ' LYS . 70.0 p -100.27 -52.0 3.5 Favored 'General case' 0 N--CA 1.464 0.269 0 N-CA-C 113.619 0.97 . . . . 0.0 113.619 -177.792 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 80' ' ' THR . . . . . 0.675 ' HB ' ' HD3' ' A' ' 81' ' ' PRO . 86.3 m -51.35 -55.35 29.65 Favored Pre-proline 0 CA--C 1.532 0.271 0 N-CA-C 112.421 0.526 . . . . 0.0 112.421 -178.502 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 81' ' ' PRO . . . . . 0.675 ' HD3' ' HB ' ' A' ' 80' ' ' THR . 52.0 Cg_exo -56.49 -20.13 32.13 Favored 'Trans proline' 0 C--N 1.352 0.762 0 C-N-CA 121.542 1.495 . . . . 0.0 111.481 179.574 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 82' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -76.63 -38.2 55.08 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 115.716 -0.675 . . . . 0.0 110.223 179.552 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 83' ' ' ILE . . . . . 0.486 HD13 HD13 ' A' ' 43' ' ' ILE . 16.7 mm -66.17 -51.24 61.68 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.16 0 CA-C-N 116.004 -0.543 . . . . 0.0 110.293 179.516 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 31.0 m -61.49 -31.76 51.48 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.166 0 N-CA-C 109.71 -0.478 . . . . 0.0 109.71 178.962 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 85' ' ' TYR . . . . . . . . . . . . . 83.4 t80 -66.48 -31.94 72.99 Favored 'General case' 0 N--CA 1.454 -0.249 0 CA-C-N 115.656 -0.702 . . . . 0.0 109.569 178.763 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 86' ' ' PHE . . . . . . . . . . . . . 11.5 t80 -63.69 -50.84 67.6 Favored 'General case' 0 C--O 1.233 0.185 0 CA-C-N 115.889 -0.596 . . . . 0.0 109.793 179.179 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 3.1 mt -61.02 -35.5 77.02 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 115.786 -0.643 . . . . 0.0 109.714 179.537 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -67.08 -28.14 73.68 Favored Glycine 0 N--CA 1.45 -0.393 0 CA-C-N 115.28 -0.873 . . . . 0.0 111.865 179.49 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 50.0 mt -72.59 -37.36 68.15 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.893 0.378 . . . . 0.0 110.277 179.534 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 41.5 mt -60.4 -50.6 72.96 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 115.741 -0.663 . . . . 0.0 110.73 179.617 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 91' ' ' ALA . . . . . 0.498 ' HB1' ' HB2' ' A' ' 148' ' ' SER . . . -71.52 -48.57 47.98 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 115.981 -0.554 . . . . 0.0 111.374 -179.815 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 96.88 62.66 0.93 Allowed Glycine 0 N--CA 1.452 -0.271 0 C-N-CA 120.764 -0.731 . . . . 0.0 112.399 -179.902 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 93' ' ' LEU . . . . . 0.587 HD23 ' HB3' ' A' ' 97' ' ' GLU . 7.1 mp -77.08 175.09 9.94 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.782 0.325 . . . . 0.0 110.868 -179.958 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 94' ' ' ASP . . . . . . . . . . . . . 13.0 m-20 -91.23 172.82 8.28 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.827 179.708 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 78.5 p -60.04 -36.55 77.52 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.246 -0.434 . . . . 0.0 111.09 -179.848 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 15.9 ptm180 -73.89 -43.54 58.16 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.06 -179.965 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 97' ' ' GLU . . . . . 0.587 ' HB3' HD23 ' A' ' 93' ' ' LEU . 37.1 mt-10 -57.59 -46.49 83.97 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.384 -0.371 . . . . 0.0 110.764 -179.926 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 98' ' ' PHE . . . . . . . . . . . . . 21.4 m-85 -60.25 -41.29 92.9 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.361 179.53 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -58.73 -32.55 69.91 Favored Glycine 0 N--CA 1.449 -0.469 0 C-N-CA 120.687 -0.768 . . . . 0.0 112.265 179.75 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 86.7 mt -73.51 -44.54 53.6 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-O 120.747 0.308 . . . . 0.0 111.675 -179.83 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 35.3 t -68.46 -48.8 70.77 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 CA-C-N 116.318 -0.401 . . . . 0.0 111.76 -179.252 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 102' ' ' ILE . . . . . 0.558 HG23 ' HB3' ' A' ' 81' ' ' PRO . 48.2 mm -63.56 -45.87 96.5 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.379 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.868 -179.357 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 6.0 t -62.02 -33.67 74.79 Favored 'General case' 0 C--N 1.332 -0.192 0 CA-C-O 120.867 0.365 . . . . 0.0 110.759 -179.813 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 104' ' ' LEU . . . . . 0.416 HD22 ' HE2' ' A' ' 140' ' ' TYR . 48.5 tp -60.17 -53.28 59.59 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.221 179.348 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 105' ' ' ASN . . . . . 0.577 ' N ' HD22 ' A' ' 105' ' ' ASN . 0.8 OUTLIER -56.26 -31.31 63.47 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.063 -0.517 . . . . 0.0 110.115 179.38 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 24.8 m -61.88 -38.75 89.47 Favored 'General case' 0 C--N 1.332 -0.179 0 CA-C-N 116.038 -0.528 . . . . 0.0 109.996 179.078 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 107' ' ' VAL . . . . . 0.419 ' H ' HG23 ' A' ' 107' ' ' VAL . 1.8 t -70.35 -41.21 78.45 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.198 0 CA-C-N 116.051 -0.522 . . . . 0.0 109.964 178.97 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 54.0 t -57.22 -47.19 84.62 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 115.367 -0.833 . . . . 0.0 111.23 179.885 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 109' ' ' MET . . . . . 0.418 ' O ' ' HB2' ' A' ' 113' ' ' PHE . 21.5 mmt -69.27 -32.31 71.41 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.017 -0.538 . . . . 0.0 111.124 -179.714 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 27.8 tp -65.3 -33.28 75.6 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-O 120.964 0.411 . . . . 0.0 110.324 179.793 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -68.82 -53.84 19.24 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 115.855 -0.611 . . . . 0.0 110.743 179.465 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . -63.09 -35.62 92.33 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.652 -0.785 . . . . 0.0 112.135 179.642 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 113' ' ' PHE . . . . . 0.47 ' HZ ' HG13 ' A' ' 70' ' ' VAL . 0.7 OUTLIER -55.63 -65.31 0.61 Allowed 'General case' 0 C--N 1.33 -0.255 0 CA-C-O 121.066 0.46 . . . . 0.0 110.249 179.6 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 114' ' ' ALA . . . . . 0.576 ' HB3' HD22 ' A' ' 126' ' ' LEU . . . -66.09 -22.55 66.41 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 115.722 -0.672 . . . . 0.0 110.951 179.816 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -55.8 -48.96 68.71 Favored Glycine 0 C--N 1.333 0.392 0 C-N-CA 120.659 -0.781 . . . . 0.0 111.85 179.401 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -78.32 -15.03 59.14 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-O 120.836 0.35 . . . . 0.0 111.016 179.508 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 117' ' ' MET . . . . . . . . . . . . . 32.3 tpp -91.58 18.73 7.02 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.105 -0.498 . . . . 0.0 111.497 -179.204 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 118' ' ' VAL . . . . . 0.459 HG21 ' HB3' ' A' ' 123' ' ' ARG . 27.5 m -88.57 139.1 29.71 Favored Pre-proline 0 C--N 1.33 -0.27 0 CA-C-N 116.633 -0.258 . . . . 0.0 111.308 -179.865 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 119' ' ' PRO . . . . . . . . . . . . . 95.4 Cg_endo -89.67 -10.08 3.81 Favored 'Trans proline' 0 N--CA 1.456 -0.697 0 C-N-CA 122.699 2.266 . . . . 0.0 112.195 179.371 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -128.64 -106.71 1.3 Allowed Glycine 0 C--N 1.331 0.305 0 C-N-CA 120.848 -0.691 . . . . 0.0 112.722 -179.74 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 2.6 pp -136.93 19.52 0.85 Allowed 'Isoleucine or valine' 0 C--N 1.332 -0.185 0 CA-C-O 120.742 0.306 . . . . 0.0 111.652 -179.713 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 41.3 mt-10 -65.05 -17.71 64.68 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.311 -0.404 . . . . 0.0 110.853 179.757 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 123' ' ' ARG . . . . . 0.459 ' HB3' HG21 ' A' ' 118' ' ' VAL . 12.2 ptt180 -50.16 -42.05 50.25 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 115.736 -0.666 . . . . 0.0 112.023 -179.64 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 124' ' ' TYR . . . . . . . . . . . . . 59.0 m-85 -57.56 -32.18 66.87 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.522 -0.308 . . . . 0.0 111.511 -179.239 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 125' ' ' ALA . . . . . . . . . . . . . . . -74.2 -56.29 5.07 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-O 121.03 0.443 . . . . 0.0 111.156 -179.728 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 126' ' ' LEU . . . . . 0.576 HD22 ' HB3' ' A' ' 114' ' ' ALA . 1.1 mt -53.25 -48.83 67.92 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 115.746 -0.661 . . . . 0.0 110.494 179.96 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 127' ' ' PHE . . . . . . . . . . . . . 7.0 t80 -63.65 -35.65 81.24 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.306 -0.406 . . . . 0.0 110.483 179.396 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 128' ' ' GLY . . . . . . . . . . . . . . . -47.22 -50.73 16.21 Favored Glycine 0 C--N 1.333 0.402 0 C-N-CA 120.055 -1.069 . . . . 0.0 110.609 178.854 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 129' ' ' MET . . . . . . . . . . . . . 0.5 OUTLIER -65.31 -34.31 78.03 Favored 'General case' 0 C--N 1.329 -0.314 0 N-CA-C 109.679 -0.489 . . . . 0.0 109.679 178.293 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -57.81 -51.61 57.1 Favored Glycine 0 C--N 1.331 0.284 0 CA-C-N 115.463 -0.789 . . . . 0.0 112.597 -179.973 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -58.91 -49.47 77.66 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 120.66 0.267 . . . . 0.0 110.684 179.865 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 132' ' ' VAL . . . . . 0.426 ' O ' HG13 ' A' ' 135' ' ' ILE . 49.9 t -54.55 -39.99 48.21 Favored 'Isoleucine or valine' 0 C--O 1.233 0.228 0 CA-C-O 121.269 0.557 . . . . 0.0 109.794 179.007 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -69.98 -34.19 73.05 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 115.474 -0.784 . . . . 0.0 110.947 179.469 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 134' ' ' PHE . . . . . 0.457 ' CZ ' ' HA ' ' A' ' 172' ' ' ALA . 51.9 t80 -56.87 -58.58 7.5 Favored 'General case' 0 CA--C 1.517 -0.294 0 CA-C-N 116.341 -0.39 . . . . 0.0 110.118 179.817 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 135' ' ' ILE . . . . . 0.487 ' O ' HG22 ' A' ' 138' ' ' VAL . 0.0 OUTLIER -55.6 -34.85 36.56 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 115.799 -0.637 . . . . 0.0 109.663 179.104 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . -58.19 -36.47 82.61 Favored Glycine 0 N--CA 1.448 -0.524 0 C-N-CA 120.447 -0.882 . . . . 0.0 111.482 178.944 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 137' ' ' LEU . . . . . 0.536 HD13 HD21 ' A' ' 105' ' ' ASN . 38.3 tp -71.91 -54.18 10.82 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-O 120.615 0.245 . . . . 0.0 110.721 179.537 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 138' ' ' VAL . . . . . 0.487 HG22 ' O ' ' A' ' 135' ' ' ILE . 3.4 m -55.92 -30.32 28.09 Favored 'Isoleucine or valine' 0 C--O 1.233 0.197 0 CA-C-O 121.312 0.577 . . . . 0.0 109.712 179.351 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 139' ' ' TYR . . . . . . . . . . . . . 31.4 t80 -63.58 -47.03 83.14 Favored 'General case' 0 N--CA 1.453 -0.285 0 CA-C-N 115.31 -0.859 . . . . 0.0 110.021 178.975 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 140' ' ' TYR . . . . . 0.416 ' HE2' HD22 ' A' ' 104' ' ' LEU . 18.2 m-85 -57.38 -35.98 70.68 Favored 'General case' 0 C--N 1.332 -0.191 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.596 179.362 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 141' ' ' LEU . . . . . 0.445 HD13 ' HG2' ' A' ' 164' ' ' ARG . 69.5 mt -59.49 -54.69 43.7 Favored 'General case' 0 C--N 1.333 -0.152 0 CA-C-N 116.262 -0.426 . . . . 0.0 110.51 179.522 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 18.6 t -70.02 -15.79 19.58 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.246 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.765 179.597 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . -68.68 -138.67 0.08 OUTLIER Glycine 0 CA--C 1.522 0.469 0 C-N-CA 121.025 -0.607 . . . . 0.0 112.779 -179.899 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 144' ' ' PRO . . . . . . . . . . . . . 19.2 Cg_endo -59.11 -23.42 68.94 Favored 'Trans proline' 0 C--N 1.349 0.587 0 C-N-CA 122.672 2.248 . . . . 0.0 112.654 -179.723 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 145' ' ' MET . . . . . . . . . . . . . 45.5 mtt -59.07 -28.52 66.55 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.517 -0.311 . . . . 0.0 111.28 -179.997 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 146' ' ' THR . . . . . . . . . . . . . 35.2 m -80.45 -42.9 21.81 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.913 0.387 . . . . 0.0 111.194 -179.167 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 9.1 tp10 -70.42 -34.53 72.6 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 115.964 -0.562 . . . . 0.0 111.107 -179.818 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 148' ' ' SER . . . . . 0.498 ' HB2' ' HB1' ' A' ' 91' ' ' ALA . 64.2 m -70.47 -50.85 33.75 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.054 -179.41 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 149' ' ' ALA . . . . . 0.423 ' HB1' HG22 ' A' ' 156' ' ' ILE . . . -64.79 -38.38 90.8 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.332 -179.828 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 150' ' ' SER . . . . . . . . . . . . . 100.0 p -72.15 -4.29 28.26 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.896 179.856 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 151' ' ' GLN . . . . . . . . . . . . . 24.3 mt-30 -125.46 1.54 7.66 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.168 -179.98 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 152' ' ' ARG . . . . . 0.418 ' HA ' ' HE ' ' A' ' 152' ' ' ARG . 0.0 OUTLIER -80.34 -52.54 7.57 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-O 121.013 0.435 . . . . 0.0 110.333 179.883 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 153' ' ' SER . . . . . 0.606 ' HB2' HG12 ' A' ' 156' ' ' ILE . 44.3 m -158.22 171.01 20.98 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-N 115.83 -0.623 . . . . 0.0 110.49 179.18 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 154' ' ' SER . . . . . . . . . . . . . 64.1 m -71.21 -36.82 72.01 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 121.028 0.442 . . . . 0.0 110.059 179.127 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -76.93 -41.21 23.49 Favored Glycine 0 N--CA 1.45 -0.417 0 CA-C-N 115.785 -0.643 . . . . 0.0 112.386 179.611 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 156' ' ' ILE . . . . . 0.606 HG12 ' HB2' ' A' ' 153' ' ' SER . 38.1 mm -51.76 -38.17 21.81 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.196 0 CA-C-O 120.879 0.371 . . . . 0.0 111.177 179.91 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 157' ' ' LYS . . . . . . . . . . . . . 63.1 tttm -58.93 -42.92 90.88 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 115.961 -0.563 . . . . 0.0 110.92 -179.989 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 51.0 m -71.19 -40.94 70.91 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.547 -179.732 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 159' ' ' LEU . . . . . 0.417 ' O ' ' HB2' ' A' ' 163' ' ' LEU . 2.2 mm? -63.78 -38.72 92.17 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.418 -0.355 . . . . 0.0 111.601 -179.419 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 160' ' ' TYR . . . . . . . . . . . . . 43.5 t80 -74.2 -46.79 39.71 Favored 'General case' 0 C--N 1.327 -0.38 0 N-CA-C 112.598 0.592 . . . . 0.0 112.598 -178.533 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 161' ' ' VAL . . . . . 0.438 HG23 ' N ' ' A' ' 162' ' ' ARG . 21.2 m -57.25 -48.83 81.59 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 N-CA-C 112.395 0.517 . . . . 0.0 112.395 -178.788 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 162' ' ' ARG . . . . . 0.438 ' N ' HG23 ' A' ' 161' ' ' VAL . 27.1 ttm180 -69.04 -45.92 69.21 Favored 'General case' 0 C--N 1.329 -0.324 0 N-CA-C 111.783 0.29 . . . . 0.0 111.783 -179.302 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 163' ' ' LEU . . . . . 0.681 ' HG ' ' HB2' ' A' ' 208' ' ' PHE . 6.6 mp -61.78 -49.75 75.12 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.451 -0.34 . . . . 0.0 111.733 -179.661 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 164' ' ' ARG . . . . . 0.445 ' HG2' HD13 ' A' ' 141' ' ' LEU . 4.0 tmt_? -62.64 -45.51 92.52 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.312 -0.404 . . . . 0.0 111.749 -179.036 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 165' ' ' ASN . . . . . 0.523 ' O ' HG23 ' A' ' 169' ' ' VAL . 0.9 OUTLIER -59.49 -52.19 66.62 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.783 0.325 . . . . 0.0 111.546 -179.434 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 166' ' ' LEU . . . . . 0.511 ' O ' ' HG ' ' A' ' 170' ' ' LEU . 4.6 tt -63.88 -53.41 50.9 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-O 120.852 0.358 . . . . 0.0 111.314 -179.552 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 167' ' ' THR . . . . . 0.487 ' HA ' HD11 ' A' ' 170' ' ' LEU . 88.3 m -54.67 -53.09 59.37 Favored 'General case' 0 C--N 1.327 -0.381 0 N-CA-C 112.581 0.585 . . . . 0.0 112.581 -178.744 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 168' ' ' VAL . . . . . 0.404 HG12 ' O ' ' A' ' 165' ' ' ASN . 9.1 p -56.74 -40.58 71.23 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.204 0 N-CA-C 112.158 0.429 . . . . 0.0 112.158 -178.753 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 169' ' ' VAL . . . . . 0.523 HG23 ' O ' ' A' ' 165' ' ' ASN . 51.5 t -58.26 -65.37 0.44 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 N-CA-C 111.821 0.304 . . . . 0.0 111.821 -179.487 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 170' ' ' LEU . . . . . 0.511 ' HG ' ' O ' ' A' ' 166' ' ' LEU . 0.4 OUTLIER -64.48 -28.26 69.54 Favored 'General case' 0 C--N 1.331 -0.216 0 N-CA-C 111.982 0.364 . . . . 0.0 111.982 -178.865 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 171' ' ' TRP . . . . . 0.436 ' HB2' ' O ' ' A' ' 167' ' ' THR . 5.2 m0 -71.38 -31.18 67.01 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.848 0.356 . . . . 0.0 110.742 179.488 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 172' ' ' ALA . . . . . 0.457 ' HA ' ' CZ ' ' A' ' 134' ' ' PHE . . . -73.78 -6.4 46.75 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.861 -179.727 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 173' ' ' ILE . . . . . 0.663 HG22 HD11 ' A' ' 177' ' ' ILE . 13.9 mm -86.12 -21.46 7.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 115.927 -0.579 . . . . 0.0 110.806 179.629 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 174' ' ' TYR . . . . . . . . . . . . . 14.2 m-85 -54.27 -51.24 79.5 Favored Pre-proline 0 CA--C 1.531 0.236 0 CA-C-N 116.115 -0.493 . . . . 0.0 112.109 -179.535 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 175' ' ' PRO . . . . . . . . . . . . . 89.1 Cg_exo -47.4 -29.14 9.43 Favored 'Trans proline' 0 C--N 1.352 0.728 0 C-N-CA 121.998 1.798 . . . . 0.0 112.176 179.748 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 176' ' ' PHE . . . . . 0.459 ' O ' ' HG ' ' A' ' 180' ' ' LEU . 98.3 m-85 -80.52 -50.12 10.46 Favored 'General case' 0 CA--C 1.517 -0.323 0 CA-C-N 116.057 -0.52 . . . . 0.0 111.69 179.968 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 177' ' ' ILE . . . . . 0.663 HD11 HG22 ' A' ' 173' ' ' ILE . 3.1 mm -58.4 -46.47 89.36 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.533 0 CA-C-N 115.884 -0.598 . . . . 0.0 112.073 -178.227 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 178' ' ' TRP . . . . . 0.485 ' HA ' ' HG2' ' A' ' 182' ' ' PRO . 75.1 t90 -62.5 -42.45 99.51 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 121.026 0.441 . . . . 0.0 110.974 -179.986 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 179' ' ' LEU . . . . . 0.551 HD13 HG22 ' A' ' 185' ' ' VAL . 1.2 tm? -67.27 -49.51 64.04 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 115.831 -0.622 . . . . 0.0 111.369 -179.061 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 180' ' ' LEU . . . . . 0.653 HD22 HD11 ' A' ' 187' ' ' LEU . 9.9 mt -76.95 -52.29 9.65 Favored 'General case' 0 CA--C 1.535 0.374 0 N-CA-C 112.498 0.555 . . . . 0.0 112.498 -178.474 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . -64.97 -84.1 0.08 OUTLIER Glycine 0 CA--C 1.522 0.521 0 C-N-CA 120.72 -0.752 . . . . 0.0 113.425 -179.557 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 182' ' ' PRO . . . . . 0.557 ' HD2' ' O ' ' A' ' 177' ' ' ILE . 75.0 Cg_exo -44.86 -179.79 0.0 OUTLIER 'Trans proline' 0 C--N 1.351 0.671 0 C-N-CA 123.567 2.845 . . . . 0.0 113.574 179.684 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 183' ' ' PRO . . . . . . . . . . . . . 82.8 Cg_exo -50.11 5.06 0.02 OUTLIER 'Trans proline' 0 C--N 1.354 0.864 0 C-N-CA 123.196 2.597 . . . . 0.0 115.274 -179.566 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 184' ' ' GLY . . . . . 0.459 ' H ' ' C ' ' A' ' 182' ' ' PRO . . . -55.32 -70.28 1.01 Allowed Glycine 0 C--N 1.335 0.514 0 C-N-CA 119.724 -1.226 . . . . 0.0 110.899 179.236 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 185' ' ' VAL . . . . . 0.551 HG22 HD13 ' A' ' 179' ' ' LEU . 3.6 m -135.65 -5.77 0.95 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.372 0 N-CA-C 111.722 0.267 . . . . 0.0 111.722 178.559 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 186' ' ' ALA . . . . . . . . . . . . . . . 41.99 81.19 0.03 OUTLIER 'General case' 0 N--CA 1.466 0.349 0 N-CA-C 112.43 0.529 . . . . 0.0 112.43 179.372 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 187' ' ' LEU . . . . . 0.653 HD11 HD22 ' A' ' 180' ' ' LEU . 7.0 mt -92.92 -49.47 6.03 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.767 0.318 . . . . 0.0 111.548 179.871 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 188' ' ' LEU . . . . . . . . . . . . . 89.3 mt -105.8 -166.56 1.22 Allowed 'General case' 0 C--N 1.33 -0.244 0 CA-C-O 121.073 0.463 . . . . 0.0 111.515 -179.261 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 189' ' ' THR . . . . . 0.432 ' HB ' HG23 ' A' ' 192' ' ' VAL . 4.7 m -82.72 136.12 45.25 Favored Pre-proline 0 C--N 1.328 -0.339 0 CA-C-N 115.668 -0.696 . . . . 0.0 110.685 -179.615 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 190' ' ' PRO . . . . . 0.418 ' O ' HG23 ' A' ' 194' ' ' VAL . 84.5 Cg_exo -45.76 -48.64 12.0 Favored 'Trans proline' 0 C--N 1.349 0.559 0 C-N-CA 122.628 2.219 . . . . 0.0 113.026 -179.788 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 191' ' ' THR . . . . . 0.429 HG22 HG22 ' A' ' 189' ' ' THR . 3.9 t -56.8 -39.69 74.59 Favored 'General case' 0 C--N 1.33 -0.255 0 N-CA-C 111.921 0.341 . . . . 0.0 111.921 -179.492 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 192' ' ' VAL . . . . . 0.432 HG23 ' HB ' ' A' ' 189' ' ' THR . 58.6 t -67.33 -53.58 31.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-O 120.877 0.37 . . . . 0.0 111.546 -179.55 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 193' ' ' ASP . . . . . . . . . . . . . 13.5 m-20 -59.0 -43.05 91.43 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.09 -179.636 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 194' ' ' VAL . . . . . 0.418 HG23 ' O ' ' A' ' 190' ' ' PRO . 54.3 t -60.99 -36.16 70.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.345 -0.389 . . . . 0.0 110.404 179.497 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 195' ' ' ALA . . . . . . . . . . . . . . . -58.51 -46.42 86.78 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-N 116.346 -0.388 . . . . 0.0 110.404 179.232 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 196' ' ' LEU . . . . . . . . . . . . . 90.6 mt -62.66 -38.04 88.74 Favored 'General case' 0 C--N 1.332 -0.192 0 CA-C-N 116.055 -0.52 . . . . 0.0 110.323 179.309 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 197' ' ' ILE . . . . . 0.517 HG21 ' HE ' ' A' ' 72' ' ' ARG . 20.3 mm -61.36 -57.14 13.49 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 115.947 -0.57 . . . . 0.0 110.223 179.262 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 198' ' ' VAL . . . . . 0.433 HG13 ' CE1' ' A' ' 51' ' ' TYR . 83.9 t -52.75 -34.88 20.52 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.465 0 CA-C-N 115.734 -0.666 . . . . 0.0 109.243 178.374 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 199' ' ' TYR . . . . . . . . . . . . . 62.5 t80 -69.99 -33.62 72.28 Favored 'General case' 0 C--N 1.332 -0.176 0 CA-C-N 115.388 -0.824 . . . . 0.0 110.626 179.498 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 200' ' ' LEU . . . . . 0.573 ' O ' HG12 ' A' ' 203' ' ' VAL . 31.8 mt -68.87 -44.17 73.86 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 115.919 -0.582 . . . . 0.0 111.409 -179.685 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 201' ' ' ASP . . . . . 0.425 ' HB2' ' OH ' ' A' ' 51' ' ' TYR . 11.8 m-20 -67.39 -36.05 80.52 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-O 121.293 0.568 . . . . 0.0 109.963 179.476 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 202' ' ' LEU . . . . . . . . . . . . . 3.3 mt -74.35 -28.28 61.06 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 115.232 -0.895 . . . . 0.0 112.356 -179.394 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 203' ' ' VAL . . . . . 0.573 HG12 ' O ' ' A' ' 200' ' ' LEU . 11.6 p -77.25 -36.15 23.71 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.303 0 C-N-CA 120.757 -0.377 . . . . 0.0 111.21 -178.533 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 204' ' ' THR . . . . . . . . . . . . . 90.2 m -70.7 -58.49 3.59 Favored 'General case' 0 C--N 1.327 -0.389 0 C-N-CA 120.719 -0.392 . . . . 0.0 111.068 179.316 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 205' ' ' LYS . . . . . 0.665 ' HE2' ' HB2' ' A' ' 47' ' ' ALA . 56.6 mttp -57.33 -58.02 10.09 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.242 -0.436 . . . . 0.0 111.728 -178.785 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 39.7 t -71.17 -36.3 61.94 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.431 0 CA-C-N 116.015 -0.539 . . . . 0.0 111.977 -179.061 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 207' ' ' GLY . . . . . 0.571 ' O ' HG13 ' A' ' 211' ' ' ILE . . . -58.9 -61.5 7.29 Favored Glycine 0 C--N 1.33 0.229 0 C-N-CA 120.624 -0.798 . . . . 0.0 113.816 -178.445 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 208' ' ' PHE . . . . . 0.681 ' HB2' ' HG ' ' A' ' 163' ' ' LEU . 1.0 OUTLIER -72.23 -27.47 62.54 Favored 'General case' 0 C--O 1.223 -0.333 0 CA-C-N 117.473 0.636 . . . . 0.0 111.05 -179.08 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 209' ' ' GLY . . . . . 0.513 ' O ' ' HB3' ' A' ' 212' ' ' ALA . . . -64.07 -34.2 89.3 Favored Glycine 0 N--CA 1.45 -0.369 0 N-CA-C 112.009 -0.436 . . . . 0.0 112.009 178.825 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 210' ' ' PHE . . . . . . . . . . . . . 1.2 m-85 -73.71 -48.71 30.02 Favored 'General case' 0 CA--C 1.514 -0.432 0 N-CA-C 108.21 -1.034 . . . . 0.0 108.21 178.446 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 211' ' ' ILE . . . . . 0.571 HG13 ' O ' ' A' ' 207' ' ' GLY . 5.4 mt -61.66 -28.07 43.39 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.499 0 N-CA-C 107.646 -1.242 . . . . 0.0 107.646 176.815 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 212' ' ' ALA . . . . . 0.513 ' HB3' ' O ' ' A' ' 209' ' ' GLY . . . -63.7 -41.71 98.08 Favored 'General case' 0 N--CA 1.448 -0.565 0 CA-C-N 114.384 -1.28 . . . . 0.0 110.139 179.952 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 213' ' ' LEU . . . . . . . . . . . . . 93.0 mt -70.1 -54.27 13.76 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 115.044 -0.98 . . . . 0.0 111.545 -179.729 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 214' ' ' ASP . . . . . . . . . . . . . 14.6 t70 -52.82 -54.63 31.57 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.189 -0.459 . . . . 0.0 111.605 -179.504 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 215' ' ' ALA . . . . . . . . . . . . . . . -57.53 -57.2 13.74 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.046 -0.524 . . . . 0.0 111.781 -179.476 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 216' ' ' ALA . . . . . . . . . . . . . . . -55.1 -37.38 66.77 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.375 -0.375 . . . . 0.0 111.494 -179.636 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 217' ' ' ALA . . . . . . . . . . . . . . . -62.41 -32.89 73.8 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.382 179.799 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 218' ' ' THR . . . . . . . . . . . . . 94.4 m . . . . . 0 C--N 1.331 -0.237 0 CA-C-N 115.806 -0.633 . . . . 0.0 110.74 179.567 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.307 0 N-CA-C 112.354 -0.299 . . . . 0.0 112.354 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 67.8 tp -74.22 -35.41 63.88 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 120.778 0.323 . . . . 0.0 110.796 179.723 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 69.9 p -69.62 -32.85 71.8 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.72 -179.697 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 29.0 p -54.93 -35.56 64.33 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.35 -0.386 . . . . 0.0 111.381 -179.644 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 7' ' ' LEU . . . . . . . . . . . . . 9.3 mp -59.24 -53.36 59.18 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.098 -0.501 . . . . 0.0 111.557 -179.813 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 8' ' ' PHE . . . . . 0.564 ' HB2' ' HB2' ' A' ' 55' ' ' ALA . 63.4 m-85 -59.95 -34.93 73.92 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.317 -0.402 . . . . 0.0 110.997 -179.73 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 9' ' ' TRP . . . . . . . . . . . . . 28.8 m95 -64.36 -47.61 78.62 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 116.058 -0.519 . . . . 0.0 110.357 -179.902 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 13.1 mt -58.32 -42.76 87.45 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 115.929 -0.578 . . . . 0.0 110.304 179.204 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . 0.433 ' HA2' HD11 ' A' ' 202' ' ' LEU . . . -61.62 -34.58 89.03 Favored Glycine 0 N--CA 1.448 -0.545 0 C-N-CA 120.588 -0.815 . . . . 0.0 111.544 178.971 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 12' ' ' ALA . . . . . 0.407 ' O ' HD23 ' A' ' 16' ' ' LEU . . . -66.22 -33.15 75.1 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 120.616 0.246 . . . . 0.0 110.608 179.701 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 1.5 mt -63.21 -49.29 83.76 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.259 0 N-CA-C 109.347 -0.612 . . . . 0.0 109.347 178.987 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . 0.411 ' HA3' HD21 ' A' ' 202' ' ' LEU . . . -61.7 -24.82 64.76 Favored Glycine 0 N--CA 1.447 -0.584 0 C-N-CA 120.638 -0.791 . . . . 0.0 111.47 178.908 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 15' ' ' MET . . . . . 0.677 ' HB3' ' HB2' ' A' ' 48' ' ' ALA . 0.0 OUTLIER -77.3 -47.93 18.76 Favored 'General case' 0 C--N 1.331 -0.227 0 N-CA-C 111.763 0.283 . . . . 0.0 111.763 179.841 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 16' ' ' LEU . . . . . 0.407 HD23 ' O ' ' A' ' 12' ' ' ALA . 4.6 mm? -63.78 -39.22 93.72 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.778 0.323 . . . . 0.0 110.965 -179.958 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 17' ' ' VAL . . . . . 0.454 HG13 ' N ' ' A' ' 18' ' ' GLY . 8.5 p -68.09 -44.26 84.68 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.375 0 CA-C-O 121.388 0.613 . . . . 0.0 110.471 179.7 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . 0.454 ' N ' HG13 ' A' ' 17' ' ' VAL . . . -64.87 -49.79 61.47 Favored Glycine 0 C--N 1.319 -0.38 0 CA-C-N 114.928 -1.033 . . . . 0.0 111.349 179.135 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 94.2 m -54.11 -42.6 69.62 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-O 120.858 0.361 . . . . 0.0 111.008 179.828 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 20' ' ' LEU . . . . . 0.409 ' O ' ' HB3' ' A' ' 24' ' ' TRP . 67.6 mt -71.83 -42.96 66.36 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.061 -0.518 . . . . 0.0 111.264 179.947 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -59.02 -43.96 91.66 Favored 'General case' 0 C--N 1.329 -0.292 0 N-CA-C 111.805 0.298 . . . . 0.0 111.805 -179.797 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 22' ' ' PHE . . . . . 0.645 ' HB2' HG22 ' A' ' 41' ' ' VAL . 10.6 m-85 -75.53 -42.26 52.93 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.46 -0.337 . . . . 0.0 111.431 -179.291 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -61.79 -50.25 73.11 Favored 'General case' 0 C--N 1.33 -0.283 0 CA-C-O 120.814 0.34 . . . . 0.0 111.023 -179.845 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 24' ' ' TRP . . . . . 0.409 ' HB3' ' O ' ' A' ' 20' ' ' LEU . 1.0 OUTLIER -57.92 -35.77 71.54 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.711 179.75 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.328 -0.346 0 CA-C-O 120.955 0.407 . . . . 0.0 110.627 179.56 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.298 0 N-CA-C 112.192 -0.363 . . . . 0.0 112.192 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 26.7 mt-10 -91.32 -20.84 21.43 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.7 0.286 . . . . 0.0 110.764 179.999 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 34' ' ' ARG . . . . . . . . . . . . . 15.8 ptp180 -51.51 -31.25 23.17 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 116.106 -0.497 . . . . 0.0 111.48 -179.652 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 89.9 mtm180 -73.51 -52.9 11.96 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.503 -0.317 . . . . 0.0 111.502 -179.7 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 73.6 m-85 -61.74 -30.53 70.83 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.247 -0.433 . . . . 0.0 111.702 -179.483 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 37' ' ' TYR . . . . . 0.416 ' O ' HG23 ' A' ' 41' ' ' VAL . 26.1 m-85 -76.19 -55.27 5.73 Favored 'General case' 0 C--N 1.329 -0.307 0 N-CA-C 111.799 0.296 . . . . 0.0 111.799 -179.129 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 83.8 t -56.89 -36.27 49.47 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-O 120.939 0.4 . . . . 0.0 110.59 179.91 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 39' ' ' THR . . . . . 0.406 ' O ' HG13 ' A' ' 43' ' ' ILE . 54.9 m -64.08 -52.11 60.85 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 115.991 -0.549 . . . . 0.0 111.116 179.718 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 40' ' ' LEU . . . . . 0.458 HD13 ' CE1' ' A' ' 208' ' ' PHE . 7.8 tp -63.3 -50.74 68.88 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.722 -179.81 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . 0.645 HG22 ' HB2' ' A' ' 22' ' ' PHE . 96.9 t -55.27 -34.84 34.38 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.356 0 CA-C-N 116.132 -0.485 . . . . 0.0 109.962 178.887 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -62.52 -37.25 94.4 Favored Glycine 0 N--CA 1.448 -0.558 0 C-N-CA 120.821 -0.704 . . . . 0.0 111.616 179.069 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 43' ' ' ILE . . . . . 0.506 HD13 HD13 ' A' ' 83' ' ' ILE . 3.8 mt -62.54 -57.95 9.77 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.158 0 CA-C-O 120.824 0.345 . . . . 0.0 110.732 179.505 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 24.6 t -59.92 -24.79 64.63 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-N 116.293 -0.412 . . . . 0.0 110.983 -179.904 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -71.99 -57.25 5.88 Favored Glycine 0 N--CA 1.452 -0.242 0 C-N-CA 120.805 -0.712 . . . . 0.0 112.427 179.825 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 15.5 pt -59.74 -37.47 71.37 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.229 0 CA-C-O 120.823 0.344 . . . . 0.0 111.007 179.888 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 47' ' ' ALA . . . . . 0.587 ' HB2' ' HE2' ' A' ' 205' ' ' LYS . . . -67.76 -39.33 84.15 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 116.316 -0.402 . . . . 0.0 111.027 179.313 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 48' ' ' ALA . . . . . 0.677 ' HB2' ' HB3' ' A' ' 15' ' ' MET . . . -57.07 -47.2 81.57 Favored 'General case' 0 C--O 1.232 0.177 0 CA-C-N 116.076 -0.511 . . . . 0.0 111.617 -179.658 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 49' ' ' VAL . . . . . 0.454 ' O ' HG13 ' A' ' 53' ' ' VAL . 29.9 m -70.66 -33.64 53.79 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-N 116.11 -0.496 . . . . 0.0 111.414 -179.359 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -62.96 -44.43 96.08 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.932 0.396 . . . . 0.0 111.286 -179.571 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 51' ' ' TYR . . . . . 0.456 ' HE2' ' HE2' ' A' ' 15' ' ' MET . 33.3 m-85 -73.87 -36.22 64.82 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 115.829 -0.623 . . . . 0.0 110.942 -179.419 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -62.74 -45.8 91.01 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 115.841 -0.618 . . . . 0.0 111.157 -179.992 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 53' ' ' VAL . . . . . 0.504 ' HB ' HG11 ' A' ' 58' ' ' VAL . 19.7 m -73.32 -43.51 56.53 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.147 -0.478 . . . . 0.0 111.036 -179.802 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 54' ' ' MET . . . . . 0.492 ' HG3' ' HE1' ' A' ' 60' ' ' TRP . 11.4 ttp -64.94 -29.65 70.6 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.284 179.89 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 55' ' ' ALA . . . . . 0.564 ' HB2' ' HB2' ' A' ' 8' ' ' PHE . . . -65.47 -37.32 86.51 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 115.885 -0.598 . . . . 0.0 111.014 179.254 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 87.2 mt -70.85 -11.47 60.98 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.082 -0.508 . . . . 0.0 111.215 -179.781 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 104.68 17.4 14.95 Favored Glycine 0 CA--C 1.518 0.227 0 C-N-CA 120.742 -0.742 . . . . 0.0 113.296 179.487 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 58' ' ' VAL . . . . . 0.504 HG11 ' HB ' ' A' ' 53' ' ' VAL . 0.4 OUTLIER -89.46 159.36 2.89 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.231 0 CA-C-N 116.913 0.356 . . . . 0.0 110.577 179.729 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 72.44 -12.52 3.38 Favored Glycine 0 N--CA 1.45 -0.412 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.387 -179.456 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 60' ' ' TRP . . . . . 0.492 ' HE1' ' HG3' ' A' ' 54' ' ' MET . 35.1 m0 -69.79 106.68 3.2 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-O 120.663 0.268 . . . . 0.0 110.883 -179.935 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 61' ' ' VAL . . . . . 0.456 HG13 HG23 ' A' ' 68' ' ' VAL . 7.5 p -116.03 128.54 25.9 Favored Pre-proline 0 CA--C 1.533 0.312 0 CA-C-N 116.406 -0.361 . . . . 0.0 111.155 179.821 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 74.0 Cg_endo -75.72 148.48 32.62 Favored 'Trans proline' 0 C--N 1.35 0.646 0 C-N-CA 122.533 2.155 . . . . 0.0 112.441 179.923 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 96.6 t -137.76 91.53 0.79 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.005 -0.543 . . . . 0.0 111.036 -179.878 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . 59.11 -88.53 0.02 OUTLIER 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 116.03 -0.532 . . . . 0.0 111.438 179.961 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 65' ' ' GLU . . . . . 0.524 ' HB2' HH11 ' A' ' 66' ' ' ARG . 11.1 mm-40 -120.54 -18.51 7.79 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-O 120.907 0.384 . . . . 0.0 110.735 179.984 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 66' ' ' ARG . . . . . 0.524 HH11 ' HB2' ' A' ' 65' ' ' GLU . 10.5 mpt_? -102.78 162.62 12.78 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 115.938 -0.574 . . . . 0.0 110.439 179.916 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 31.6 m -123.37 139.9 53.56 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.964 0.411 . . . . 0.0 111.52 -179.654 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 68' ' ' VAL . . . . . 0.523 HG21 ' SD ' ' A' ' 117' ' ' MET . 18.0 m -130.3 146.12 34.56 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.375 0 CA-C-N 115.932 -0.576 . . . . 0.0 110.685 179.711 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 69' ' ' PHE . . . . . . . . . . . . . 9.9 m-85 -109.1 118.03 35.71 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-O 121.048 0.452 . . . . 0.0 110.224 -179.473 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 70' ' ' VAL . . . . . 0.63 HG12 ' HD3' ' A' ' 71' ' ' PRO . 0.5 OUTLIER -67.0 -34.44 7.33 Favored Pre-proline 0 CA--C 1.541 0.6 0 N-CA-C 112.883 0.697 . . . . 0.0 112.883 -179.295 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 71' ' ' PRO . . . . . 0.63 ' HD3' HG12 ' A' ' 70' ' ' VAL . 12.2 Cg_exo -69.63 -17.75 38.01 Favored 'Trans proline' 0 C--N 1.359 1.079 0 C-N-CA 122.259 1.973 . . . . 0.0 113.059 -179.165 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 45.3 ttp180 -74.76 -55.42 5.86 Favored 'General case' 0 C--N 1.33 -0.271 0 N-CA-C 112.276 0.473 . . . . 0.0 112.276 -178.514 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 73' ' ' TYR . . . . . 0.461 ' O ' HG13 ' A' ' 77' ' ' ILE . 24.9 m-85 -71.31 -33.55 69.79 Favored 'General case' 0 C--N 1.329 -0.325 0 C-N-CA 120.764 -0.374 . . . . 0.0 110.669 -179.418 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 74' ' ' ILE . . . . . 0.476 HG22 ' HA ' ' A' ' 71' ' ' PRO . 0.3 OUTLIER -68.95 -39.73 80.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 N-CA-C 110.072 -0.344 . . . . 0.0 110.072 179.256 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 15.4 t70 -59.98 -37.3 79.23 Favored 'General case' 0 CA--C 1.52 -0.197 0 N-CA-C 109.423 -0.584 . . . . 0.0 109.423 179.023 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 76' ' ' TRP . . . . . 0.523 ' HB3' ' SD ' ' A' ' 109' ' ' MET . 49.2 m0 -65.29 -35.49 81.17 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 115.652 -0.703 . . . . 0.0 110.427 179.521 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 77' ' ' ILE . . . . . 0.474 ' O ' ' HG2' ' A' ' 81' ' ' PRO . 78.5 mt -68.12 -30.66 48.73 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.374 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.964 179.773 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 35.2 mt -91.81 -19.55 22.43 Favored 'General case' 0 C--N 1.327 -0.371 0 N-CA-C 112.23 0.456 . . . . 0.0 112.23 -179.76 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 79' ' ' THR . . . . . 0.494 ' HB ' ' HE3' ' A' ' 205' ' ' LYS . 79.3 p -102.35 -47.6 4.44 Favored 'General case' 0 N--CA 1.464 0.238 0 N-CA-C 113.458 0.91 . . . . 0.0 113.458 -177.932 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 80' ' ' THR . . . . . 0.659 ' HB ' ' HD3' ' A' ' 81' ' ' PRO . 80.3 m -51.28 -53.4 49.53 Favored Pre-proline 0 C--N 1.329 -0.297 0 N-CA-C 112.047 0.388 . . . . 0.0 112.047 -179.019 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 81' ' ' PRO . . . . . 0.659 ' HD3' ' HB ' ' A' ' 80' ' ' THR . 50.4 Cg_exo -55.83 -22.03 35.63 Favored 'Trans proline' 0 C--N 1.351 0.691 0 C-N-CA 121.612 1.542 . . . . 0.0 111.704 179.723 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 82' ' ' LEU . . . . . 0.488 ' HB2' ' O ' ' A' ' 79' ' ' THR . 2.8 mm? -76.77 -37.1 56.49 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 115.877 -0.601 . . . . 0.0 110.745 179.807 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 83' ' ' ILE . . . . . 0.506 HD13 HD13 ' A' ' 43' ' ' ILE . 11.9 mm -65.22 -53.76 36.78 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-O 120.857 0.36 . . . . 0.0 110.469 179.67 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 21.9 m -62.63 -31.27 51.5 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.176 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.251 179.335 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 85' ' ' TYR . . . . . . . . . . . . . 82.9 t80 -67.28 -32.44 73.44 Favored 'General case' 0 C--N 1.333 -0.135 0 CA-C-N 115.999 -0.546 . . . . 0.0 110.223 179.158 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 86' ' ' PHE . . . . . . . . . . . . . 9.2 t80 -64.72 -51.96 59.6 Favored 'General case' 0 C--N 1.331 -0.196 0 CA-C-N 116.118 -0.492 . . . . 0.0 109.839 179.37 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 9.2 mp -62.95 -30.45 71.58 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 115.806 -0.634 . . . . 0.0 110.098 179.477 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -69.25 -27.31 73.83 Favored Glycine 0 N--CA 1.448 -0.523 0 C-N-CA 120.914 -0.66 . . . . 0.0 111.546 178.943 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 58.0 mt -72.05 -46.16 58.04 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 120.974 0.416 . . . . 0.0 110.4 179.701 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 98.0 mt -59.27 -37.55 77.93 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 115.844 -0.616 . . . . 0.0 111.074 179.824 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -79.86 -32.75 40.46 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.231 -0.441 . . . . 0.0 111.4 -179.877 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 78.81 51.77 5.31 Favored Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.701 -0.761 . . . . 0.0 111.937 -179.737 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 35.2 mt -62.21 167.16 4.24 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.892 0.377 . . . . 0.0 111.103 -179.632 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 94' ' ' ASP . . . . . . . . . . . . . 28.6 t70 -85.47 168.96 14.07 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.618 179.839 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 75.0 m -54.34 -41.52 69.16 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.45 -0.341 . . . . 0.0 110.975 -179.989 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 34.0 ttm180 -73.89 -44.1 56.36 Favored 'General case' 0 C--N 1.331 -0.197 0 CA-C-N 116.398 -0.364 . . . . 0.0 110.94 179.732 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 97' ' ' GLU . . . . . 0.558 ' HA ' HD12 ' A' ' 100' ' ' ILE . 43.7 mt-10 -53.42 -47.08 69.92 Favored 'General case' 0 C--N 1.331 -0.197 0 CA-C-N 116.128 -0.487 . . . . 0.0 111.435 -179.484 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 98' ' ' PHE . . . . . 0.421 ' O ' HG12 ' A' ' 102' ' ' ILE . 16.9 m-85 -58.03 -49.6 76.3 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-O 120.773 0.321 . . . . 0.0 110.7 179.64 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -58.28 -26.12 58.51 Favored Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.879 -0.677 . . . . 0.0 112.644 -179.95 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 100' ' ' ILE . . . . . 0.558 HD12 ' HA ' ' A' ' 97' ' ' GLU . 94.4 mt -71.56 -52.24 27.4 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-O 120.815 0.34 . . . . 0.0 111.638 -179.71 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 43.4 t -68.21 -37.77 78.58 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.38 0 CA-C-N 116.401 -0.363 . . . . 0.0 111.669 -179.378 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 102' ' ' ILE . . . . . 0.421 HG12 ' O ' ' A' ' 98' ' ' PHE . 49.0 mm -68.22 -47.72 76.89 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.391 -0.368 . . . . 0.0 111.48 -179.628 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 103' ' ' THR . . . . . 0.404 HG22 ' O ' ' A' ' 100' ' ' ILE . 11.1 t -62.03 -31.1 71.46 Favored 'General case' 0 C--N 1.332 -0.174 0 CA-C-O 120.804 0.335 . . . . 0.0 110.723 -179.935 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 104' ' ' LEU . . . . . 0.429 ' O ' HG23 ' A' ' 108' ' ' VAL . 53.3 tp -64.38 -52.98 55.53 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.701 179.556 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 105' ' ' ASN . . . . . 0.616 ' N ' HD22 ' A' ' 105' ' ' ASN . 0.8 OUTLIER -61.51 -26.19 67.76 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.079 -0.51 . . . . 0.0 110.946 179.929 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 40.3 m -65.65 -54.96 20.4 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 115.995 -0.548 . . . . 0.0 111.419 -179.66 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 11.3 p -64.7 -36.41 77.45 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.232 0 CA-C-N 116.366 -0.379 . . . . 0.0 111.215 -179.724 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . 0.429 HG23 ' O ' ' A' ' 104' ' ' LEU . 70.1 t -63.46 -49.21 83.63 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.244 0 CA-C-N 116.36 -0.382 . . . . 0.0 110.839 179.67 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 109' ' ' MET . . . . . 0.523 ' SD ' ' HB3' ' A' ' 76' ' ' TRP . 7.7 tpp -63.21 -37.41 87.13 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.749 -179.978 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 22.9 tp -65.9 -30.27 70.84 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-N 115.987 -0.552 . . . . 0.0 110.259 179.782 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -65.03 -54.77 25.12 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-N 115.939 -0.573 . . . . 0.0 110.391 179.354 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . -57.82 -39.67 91.83 Favored Glycine 0 C--N 1.333 0.382 0 C-N-CA 120.576 -0.821 . . . . 0.0 111.701 179.395 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 113' ' ' PHE . . . . . . . . . . . . . 1.3 t80 -51.33 -66.03 0.45 Allowed 'General case' 0 C--N 1.332 -0.181 0 CA-C-O 121.059 0.456 . . . . 0.0 109.934 179.255 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -59.84 -29.31 68.19 Favored 'General case' 0 C--N 1.327 -0.413 0 CA-C-N 115.501 -0.772 . . . . 0.0 111.471 179.809 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 115' ' ' GLY . . . . . 0.403 ' N ' ' HG ' ' A' ' 126' ' ' LEU . . . -52.4 -49.62 50.79 Favored Glycine 0 C--N 1.333 0.377 0 C-N-CA 120.901 -0.666 . . . . 0.0 112.452 179.85 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -77.88 -14.71 59.47 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-O 120.8 0.333 . . . . 0.0 111.168 179.692 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 117' ' ' MET . . . . . 0.523 ' SD ' HG21 ' A' ' 68' ' ' VAL . 24.3 mmt -93.7 15.16 17.02 Favored 'General case' 0 N--CA 1.463 0.185 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.732 -179.391 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 23.3 m -82.13 144.61 51.08 Favored Pre-proline 0 C--N 1.33 -0.267 0 CA-C-O 120.568 0.223 . . . . 0.0 111.565 -179.616 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 119' ' ' PRO . . . . . . . . . . . . . 84.9 Cg_endo -91.18 -9.0 3.15 Favored 'Trans proline' 0 N--CA 1.456 -0.684 0 C-N-CA 122.758 2.305 . . . . 0.0 112.348 179.471 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -132.5 -117.09 1.81 Allowed Glycine 0 C--N 1.332 0.312 0 C-N-CA 120.748 -0.739 . . . . 0.0 113.071 -179.649 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 41.7 pt -116.13 13.72 7.74 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.151 0 CA-C-O 120.723 0.297 . . . . 0.0 111.5 -179.552 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 44.1 mt-10 -62.59 -18.46 62.19 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 116.284 -0.416 . . . . 0.0 111.349 -179.737 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 123' ' ' ARG . . . . . . . . . . . . . 20.4 ptt180 -50.43 -39.44 47.48 Favored 'General case' 0 C--N 1.332 -0.166 0 CA-C-N 116.28 -0.418 . . . . 0.0 111.7 -179.66 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 124' ' ' TYR . . . . . . . . . . . . . 59.5 m-85 -65.87 -32.38 73.86 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-O 120.748 0.308 . . . . 0.0 110.997 -179.851 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 125' ' ' ALA . . . . . . . . . . . . . . . -70.05 -47.64 61.19 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.308 -0.406 . . . . 0.0 111.179 -179.913 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 126' ' ' LEU . . . . . 0.425 HD13 ' HA ' ' A' ' 126' ' ' LEU . 2.6 mm? -54.16 -55.6 26.24 Favored 'General case' 0 C--O 1.233 0.209 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.904 179.924 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 127' ' ' PHE . . . . . . . . . . . . . 10.0 t80 -63.73 -36.77 84.95 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.305 -0.407 . . . . 0.0 111.033 -179.553 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 128' ' ' GLY . . . . . . . . . . . . . . . -46.81 -47.24 19.03 Favored Glycine 0 C--N 1.332 0.321 0 C-N-CA 120.019 -1.086 . . . . 0.0 111.033 179.182 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 129' ' ' MET . . . . . 0.428 ' HE1' ' HA ' ' A' ' 108' ' ' VAL . 0.6 OUTLIER -66.96 -40.04 87.4 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 120.978 0.418 . . . . 0.0 109.994 178.788 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -67.62 -22.9 73.7 Favored Glycine 0 N--CA 1.45 -0.379 0 CA-C-N 115.721 -0.672 . . . . 0.0 112.809 -179.997 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 131' ' ' ALA . . . . . 0.419 ' O ' ' HB3' ' A' ' 134' ' ' PHE . . . -74.63 -53.77 8.71 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.78 0.324 . . . . 0.0 110.423 -179.991 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 16.1 t -60.2 -40.39 83.44 Favored 'Isoleucine or valine' 0 C--O 1.236 0.36 0 N-CA-C 109.085 -0.709 . . . . 0.0 109.085 178.629 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -67.0 -34.55 77.99 Favored 'General case' 0 N--CA 1.451 -0.41 0 CA-C-N 115.125 -0.943 . . . . 0.0 110.302 179.054 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 134' ' ' PHE . . . . . 0.482 ' CZ ' ' HA ' ' A' ' 172' ' ' ALA . 19.4 t80 -56.47 -52.67 63.83 Favored 'General case' 0 N--CA 1.452 -0.352 0 CA-C-N 115.939 -0.573 . . . . 0.0 109.88 179.366 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 135' ' ' ILE . . . . . 0.566 ' O ' HG22 ' A' ' 138' ' ' VAL . 57.6 mt -57.06 -34.13 44.28 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.299 0 CA-C-N 115.742 -0.663 . . . . 0.0 109.857 179.189 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 136' ' ' GLY . . . . . 0.413 ' O ' ' HB3' ' A' ' 139' ' ' TYR . . . -59.99 -34.72 84.58 Favored Glycine 0 N--CA 1.448 -0.538 0 C-N-CA 120.08 -1.057 . . . . 0.0 110.843 178.418 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 137' ' ' LEU . . . . . 0.529 HD13 HD21 ' A' ' 105' ' ' ASN . 38.6 tp -71.11 -52.14 21.05 Favored 'General case' 0 N--CA 1.455 -0.223 0 CA-C-N 115.643 -0.278 . . . . 0.0 110.554 179.399 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 138' ' ' VAL . . . . . 0.566 HG22 ' O ' ' A' ' 135' ' ' ILE . 3.1 m -55.69 -33.92 34.83 Favored 'Isoleucine or valine' 0 C--O 1.233 0.211 0 N-CA-C 109.201 -0.666 . . . . 0.0 109.201 179.063 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 139' ' ' TYR . . . . . 0.413 ' HB3' ' O ' ' A' ' 136' ' ' GLY . 32.0 t80 -57.12 -45.93 83.07 Favored 'General case' 0 C--N 1.331 -0.22 0 N-CA-C 108.848 -0.797 . . . . 0.0 108.848 177.657 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 140' ' ' TYR . . . . . 0.522 ' HB3' ' SD ' ' A' ' 145' ' ' MET . 24.1 m-85 -64.53 -36.54 84.55 Favored 'General case' 0 C--N 1.331 -0.197 0 CA-C-N 115.675 -0.693 . . . . 0.0 109.99 178.422 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 141' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -54.06 -33.61 57.88 Favored 'General case' 0 C--N 1.333 -0.144 0 CA-C-N 115.874 -0.603 . . . . 0.0 110.39 179.142 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 142' ' ' VAL . . . . . 0.568 HG22 HH12 ' A' ' 164' ' ' ARG . 2.6 t -111.09 2.28 8.91 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 115.858 -0.61 . . . . 0.0 110.703 179.642 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . -74.26 -153.05 2.92 Favored Glycine 0 CA--C 1.519 0.338 0 C-N-CA 121.042 -0.599 . . . . 0.0 113.146 -179.415 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 144' ' ' PRO . . . . . . . . . . . . . 31.2 Cg_exo -59.06 -23.6 69.56 Favored 'Trans proline' 0 C--N 1.349 0.588 0 C-N-CA 122.844 2.363 . . . . 0.0 112.768 -179.697 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 145' ' ' MET . . . . . 0.522 ' SD ' ' HB3' ' A' ' 140' ' ' TYR . 80.9 mtp -57.57 -32.81 67.5 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-O 120.89 0.376 . . . . 0.0 111.088 -179.731 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 146' ' ' THR . . . . . . . . . . . . . 36.0 m -75.35 -50.04 17.18 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.087 -0.506 . . . . 0.0 111.452 -179.733 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 43.5 mt-10 -65.68 -29.44 69.99 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.319 -0.401 . . . . 0.0 111.477 -179.615 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 148' ' ' SER . . . . . . . . . . . . . 80.1 p -70.36 -50.04 43.0 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.365 -0.38 . . . . 0.0 110.795 -179.515 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 149' ' ' ALA . . . . . . . . . . . . . . . -69.46 -32.7 71.79 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.4 -179.982 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 150' ' ' SER . . . . . 0.537 ' HA ' ' HB3' ' A' ' 157' ' ' LYS . 90.8 p -68.56 -15.98 63.71 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.361 -179.529 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 151' ' ' GLN . . . . . . . . . . . . . 46.7 mt-30 -113.55 3.55 15.77 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.59 -0.277 . . . . 0.0 111.336 -179.779 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 21.2 tpp180 -75.23 -51.79 12.46 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-O 120.987 0.422 . . . . 0.0 110.536 179.924 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 153' ' ' SER . . . . . 0.676 ' HB3' HG12 ' A' ' 156' ' ' ILE . 8.7 t -157.77 172.48 18.41 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 115.794 -0.639 . . . . 0.0 110.306 179.025 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 154' ' ' SER . . . . . . . . . . . . . 48.7 m -70.01 -40.97 74.91 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.872 0.367 . . . . 0.0 110.846 179.794 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -77.44 -34.48 40.15 Favored Glycine 0 N--CA 1.45 -0.389 0 C-N-CA 120.89 -0.671 . . . . 0.0 113.03 -179.962 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 156' ' ' ILE . . . . . 0.676 HG12 ' HB3' ' A' ' 153' ' ' SER . 39.5 mm -54.93 -46.42 76.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 N-CA-C 112.147 0.425 . . . . 0.0 112.147 -179.237 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 157' ' ' LYS . . . . . 0.537 ' HB3' ' HA ' ' A' ' 150' ' ' SER . 21.7 pttp -60.62 -39.73 89.28 Favored 'General case' 0 C--N 1.328 -0.34 0 N-CA-C 111.727 0.269 . . . . 0.0 111.727 -179.133 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 59.4 m -65.76 -48.18 72.73 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-O 120.724 0.297 . . . . 0.0 111.76 -179.387 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 159' ' ' LEU . . . . . 0.726 HD13 ' HB3' ' A' ' 215' ' ' ALA . 45.9 tp -68.08 -31.24 70.73 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.382 -0.372 . . . . 0.0 111.197 -179.714 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 160' ' ' TYR . . . . . . . . . . . . . 45.1 t80 -74.15 -47.05 38.45 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.186 -0.461 . . . . 0.0 112.028 -178.988 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 161' ' ' VAL . . . . . 0.454 HG22 ' O ' ' A' ' 157' ' ' LYS . 23.7 m -61.51 -47.34 93.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 N-CA-C 112.149 0.426 . . . . 0.0 112.149 -178.841 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 162' ' ' ARG . . . . . 0.447 ' N ' HG23 ' A' ' 161' ' ' VAL . 27.1 tpt180 -63.24 -49.2 75.08 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.791 0.329 . . . . 0.0 111.423 -179.369 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 163' ' ' LEU . . . . . 0.582 HD13 HD12 ' A' ' 159' ' ' LEU . 6.9 mp -64.73 -53.61 44.53 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.922 -179.266 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 164' ' ' ARG . . . . . 0.568 HH12 HG22 ' A' ' 142' ' ' VAL . 0.9 OUTLIER -59.37 -41.32 89.05 Favored 'General case' 0 CA--C 1.53 0.199 0 CA-C-N 116.373 -0.376 . . . . 0.0 111.99 -178.554 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 165' ' ' ASN . . . . . 0.527 ' O ' HG23 ' A' ' 169' ' ' VAL . 0.9 OUTLIER -57.25 -51.84 67.74 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-O 120.887 0.375 . . . . 0.0 110.744 179.921 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 166' ' ' LEU . . . . . 0.485 ' O ' ' HG ' ' A' ' 170' ' ' LEU . 3.9 tt -64.25 -43.15 95.76 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-N 115.954 -0.566 . . . . 0.0 111.639 -179.377 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 167' ' ' THR . . . . . 0.475 ' O ' HD12 ' A' ' 170' ' ' LEU . 49.2 m -56.03 -53.74 53.35 Favored 'General case' 0 C--N 1.329 -0.296 0 N-CA-C 112.629 0.603 . . . . 0.0 112.629 -178.576 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 168' ' ' VAL . . . . . . . . . . . . . 9.7 p -61.99 -39.57 84.15 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 N-CA-C 111.956 0.354 . . . . 0.0 111.956 -179.455 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 169' ' ' VAL . . . . . 0.527 HG23 ' O ' ' A' ' 165' ' ' ASN . 46.8 t -55.78 -65.27 0.39 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 N-CA-C 112.558 0.577 . . . . 0.0 112.558 -179.174 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 170' ' ' LEU . . . . . 0.485 ' HG ' ' O ' ' A' ' 166' ' ' LEU . 0.3 OUTLIER -66.71 -24.45 66.25 Favored 'General case' 0 N--CA 1.464 0.229 0 N-CA-C 111.855 0.317 . . . . 0.0 111.855 -178.745 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 171' ' ' TRP . . . . . 0.481 ' HZ3' HD21 ' A' ' 137' ' ' LEU . 9.8 m0 -73.49 -29.27 62.4 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.999 0.428 . . . . 0.0 109.847 179.245 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 172' ' ' ALA . . . . . 0.482 ' HA ' ' CZ ' ' A' ' 134' ' ' PHE . . . -74.7 -8.5 56.58 Favored 'General case' 0 N--CA 1.451 -0.382 0 CA-C-N 115.827 -0.624 . . . . 0.0 110.065 179.232 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 173' ' ' ILE . . . . . 0.7 HG22 HD11 ' A' ' 177' ' ' ILE . 44.5 mm -89.06 -22.8 6.45 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.256 0 CA-C-N 115.516 -0.765 . . . . 0.0 110.405 178.936 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 174' ' ' TYR . . . . . 0.607 ' N ' ' HD2' ' A' ' 175' ' ' PRO . 12.1 m-85 -54.87 -50.26 87.13 Favored Pre-proline 0 N--CA 1.463 0.199 0 CA-C-N 116.047 -0.524 . . . . 0.0 111.831 -179.893 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 175' ' ' PRO . . . . . 0.607 ' HD2' ' N ' ' A' ' 174' ' ' TYR . 2.0 Cg_endo -45.56 -29.31 4.98 Favored 'Trans proline' 0 C--N 1.353 0.791 0 C-N-CA 122.359 2.039 . . . . 0.0 111.768 179.275 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 176' ' ' PHE . . . . . 0.449 ' O ' ' HG ' ' A' ' 180' ' ' LEU . 99.6 m-85 -79.98 -45.7 17.98 Favored 'General case' 0 CA--C 1.516 -0.335 0 CA-C-N 115.921 -0.582 . . . . 0.0 111.078 179.396 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 177' ' ' ILE . . . . . 0.7 HD11 HG22 ' A' ' 173' ' ' ILE . 3.1 mm -58.09 -44.75 87.95 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.613 0 CA-C-N 115.787 -0.642 . . . . 0.0 112.093 -178.491 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 178' ' ' TRP . . . . . 0.407 ' HA ' ' HG2' ' A' ' 182' ' ' PRO . 72.0 t90 -69.04 -38.55 79.2 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-O 121.088 0.471 . . . . 0.0 110.64 179.951 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 179' ' ' LEU . . . . . 0.495 ' O ' HG22 ' A' ' 185' ' ' VAL . 0.4 OUTLIER -66.44 -53.64 33.2 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-N 115.557 -0.747 . . . . 0.0 111.168 -179.273 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 180' ' ' LEU . . . . . 0.523 HD13 HD12 ' A' ' 187' ' ' LEU . 8.3 mt -77.75 -52.03 9.59 Favored 'General case' 0 C--N 1.328 -0.366 0 N-CA-C 112.307 0.484 . . . . 0.0 112.307 -178.674 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 181' ' ' GLY . . . . . 0.42 ' HA3' ' OD1' ' A' ' 193' ' ' ASP . . . -58.34 -85.25 0.04 OUTLIER Glycine 0 C--N 1.336 0.552 0 C-N-CA 120.447 -0.882 . . . . 0.0 112.797 -179.739 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 182' ' ' PRO . . . . . 0.495 ' HD2' ' O ' ' A' ' 177' ' ' ILE . 89.2 Cg_exo -46.1 178.55 0.0 OUTLIER 'Trans proline' 0 C--N 1.349 0.599 0 C-N-CA 123.388 2.725 . . . . 0.0 112.954 179.088 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 183' ' ' PRO . . . . . . . . . . . . . 51.5 Cg_exo -56.82 12.25 0.03 OUTLIER 'Trans proline' 0 C--N 1.351 0.667 0 C-N-CA 122.862 2.375 . . . . 0.0 114.696 -179.558 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 184' ' ' GLY . . . . . 0.458 ' H ' ' C ' ' A' ' 182' ' ' PRO . . . -54.17 -65.08 3.72 Favored Glycine 0 C--N 1.335 0.484 0 C-N-CA 119.84 -1.172 . . . . 0.0 111.06 179.149 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 185' ' ' VAL . . . . . 0.495 HG22 ' O ' ' A' ' 179' ' ' LEU . 3.4 m -135.52 -3.27 1.01 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.368 0 N-CA-C 111.574 0.213 . . . . 0.0 111.574 178.813 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 186' ' ' ALA . . . . . . . . . . . . . . . 45.5 76.49 0.09 Allowed 'General case' 0 N--CA 1.463 0.198 0 N-CA-C 112.316 0.487 . . . . 0.0 112.316 179.324 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 187' ' ' LEU . . . . . 0.523 HD12 HD13 ' A' ' 180' ' ' LEU . 4.2 mt -92.49 -49.31 6.19 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.463 -0.335 . . . . 0.0 111.267 179.683 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 188' ' ' LEU . . . . . . . . . . . . . 92.3 mt -115.48 -168.59 1.43 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 121.087 0.47 . . . . 0.0 111.586 -179.502 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 189' ' ' THR . . . . . 0.484 ' HB ' HG23 ' A' ' 192' ' ' VAL . 96.7 m -76.96 135.28 67.36 Favored Pre-proline 0 C--N 1.329 -0.318 0 CA-C-N 115.667 -0.697 . . . . 0.0 111.039 -179.681 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 190' ' ' PRO . . . . . . . . . . . . . 10.2 Cg_endo -50.29 -41.7 49.85 Favored 'Trans proline' 0 C--N 1.35 0.609 0 C-N-CA 122.684 2.256 . . . . 0.0 112.185 -179.967 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 191' ' ' THR . . . . . 0.451 ' H ' HG22 ' A' ' 189' ' ' THR . 41.5 p -57.2 -46.49 82.82 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.763 179.525 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 192' ' ' VAL . . . . . 0.484 HG23 ' HB ' ' A' ' 189' ' ' THR . 60.3 t -59.13 -39.75 79.3 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.725 179.584 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 193' ' ' ASP . . . . . 0.425 ' OD1' HG22 ' A' ' 177' ' ' ILE . 7.9 t70 -57.72 -41.89 82.72 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 115.932 -0.576 . . . . 0.0 110.646 179.672 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 194' ' ' VAL . . . . . . . . . . . . . 52.5 t -64.71 -36.06 76.53 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 115.984 -0.553 . . . . 0.0 110.918 179.814 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 195' ' ' ALA . . . . . . . . . . . . . . . -59.4 -47.62 84.75 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.451 -0.341 . . . . 0.0 111.017 179.93 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 196' ' ' LEU . . . . . . . . . . . . . 95.9 mt -67.84 -43.13 80.22 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 120.793 0.33 . . . . 0.0 110.525 179.648 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 197' ' ' ILE . . . . . . . . . . . . . 15.5 mm -57.03 -58.89 4.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.012 -0.54 . . . . 0.0 110.296 179.381 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 198' ' ' VAL . . . . . . . . . . . . . 75.2 t -52.74 -34.71 20.25 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.439 0 CA-C-N 115.773 -0.648 . . . . 0.0 109.38 178.429 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 199' ' ' TYR . . . . . . . . . . . . . 46.0 t80 -70.25 -31.44 68.83 Favored 'General case' 0 C--N 1.331 -0.205 0 CA-C-N 115.587 -0.733 . . . . 0.0 110.421 179.678 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 200' ' ' LEU . . . . . . . . . . . . . 54.4 mt -74.07 -38.45 63.92 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 115.756 -0.656 . . . . 0.0 111.365 -179.722 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 201' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -71.44 -35.1 70.79 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 121.15 0.5 . . . . 0.0 110.121 179.483 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 202' ' ' LEU . . . . . 0.433 HD11 ' HA2' ' A' ' 11' ' ' GLY . 4.3 mt -67.21 -41.9 85.01 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 115.43 -0.805 . . . . 0.0 111.721 179.596 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 203' ' ' VAL . . . . . 0.44 ' O ' ' HA3' ' A' ' 207' ' ' GLY . 7.4 p -70.19 -36.82 69.42 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-N 116.376 -0.375 . . . . 0.0 111.946 -178.479 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 204' ' ' THR . . . . . . . . . . . . . 95.1 m -68.9 -57.46 5.5 Favored 'General case' 0 C--N 1.328 -0.353 0 C-N-CA 120.308 -0.557 . . . . 0.0 111.252 179.83 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 205' ' ' LYS . . . . . 0.587 ' HE2' ' HB2' ' A' ' 47' ' ' ALA . 41.7 mttp -67.0 -59.35 3.55 Favored 'General case' 0 C--N 1.328 -0.345 0 N-CA-C 112.714 0.635 . . . . 0.0 112.714 -178.311 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 25.5 t -73.87 -37.3 47.87 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.415 0 N-CA-C 112.184 0.438 . . . . 0.0 112.184 -178.29 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 207' ' ' GLY . . . . . 0.44 ' HA3' ' O ' ' A' ' 203' ' ' VAL . . . -66.89 -57.97 8.94 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.361 -0.923 . . . . 0.0 112.434 -179.309 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 208' ' ' PHE . . . . . 0.458 ' CE1' HD13 ' A' ' 40' ' ' LEU . 0.0 OUTLIER -62.6 -29.24 70.46 Favored 'General case' 0 C--N 1.329 -0.316 0 N-CA-C 110.439 -0.208 . . . . 0.0 110.439 -179.957 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 209' ' ' GLY . . . . . 0.501 ' O ' ' HB3' ' A' ' 212' ' ' ALA . . . -70.78 -36.13 66.32 Favored Glycine 0 N--CA 1.447 -0.574 0 N-CA-C 111.137 -0.785 . . . . 0.0 111.137 178.112 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 210' ' ' PHE . . . . . . . . . . . . . 1.0 OUTLIER -70.13 -43.09 71.65 Favored 'General case' 0 CA--C 1.512 -0.519 0 N-CA-C 107.508 -1.293 . . . . 0.0 107.508 178.37 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 211' ' ' ILE . . . . . . . . . . . . . 36.6 mt -67.41 -28.45 42.25 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.728 0 N-CA-C 107.277 -1.379 . . . . 0.0 107.277 176.502 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 212' ' ' ALA . . . . . 0.501 ' HB3' ' O ' ' A' ' 209' ' ' GLY . . . -66.88 -36.42 82.26 Favored 'General case' 0 N--CA 1.448 -0.549 0 CA-C-N 114.516 -1.22 . . . . 0.0 110.141 179.646 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 213' ' ' LEU . . . . . 0.414 ' HG ' ' O ' ' A' ' 209' ' ' GLY . 92.8 mt -70.31 -52.64 21.27 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 115.086 -0.961 . . . . 0.0 111.872 -179.678 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 214' ' ' ASP . . . . . . . . . . . . . 44.7 m-20 -53.21 -50.71 64.14 Favored 'General case' 0 C--N 1.331 -0.204 0 CA-C-N 116.292 -0.413 . . . . 0.0 111.837 -178.974 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 215' ' ' ALA . . . . . 0.726 ' HB3' HD13 ' A' ' 159' ' ' LEU . . . -65.48 -57.63 7.79 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.558 -0.292 . . . . 0.0 111.726 -179.243 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 216' ' ' ALA . . . . . . . . . . . . . . . -52.12 -43.38 63.94 Favored 'General case' 0 C--N 1.332 -0.184 0 CA-C-O 120.799 0.333 . . . . 0.0 111.497 -179.488 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 217' ' ' ALA . . . . . . . . . . . . . . . -59.05 -42.11 89.49 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.098 179.69 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 218' ' ' THR . . . . . . . . . . . . . 78.4 m . . . . . 0 C--N 1.331 -0.214 0 CA-C-N 115.584 -0.734 . . . . 0.0 110.983 179.715 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.277 0 N-CA-C 112.692 -0.163 . . . . 0.0 112.692 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 56.2 tp -73.96 -35.82 64.56 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.817 0.341 . . . . 0.0 111.121 -179.913 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 60.7 p -68.08 -31.69 71.5 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.501 -179.59 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 21.3 p -52.31 -35.32 50.24 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.257 -0.429 . . . . 0.0 111.384 -179.772 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 7' ' ' LEU . . . . . . . . . . . . . 4.1 mm? -57.87 -53.75 54.74 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.26 -0.427 . . . . 0.0 111.364 -179.731 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 8' ' ' PHE . . . . . 0.68 ' HB2' ' HB2' ' A' ' 55' ' ' ALA . 63.4 m-85 -62.32 -33.29 74.39 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.31 -0.405 . . . . 0.0 110.763 -179.81 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 9' ' ' TRP . . . . . 0.465 ' O ' HG13 ' A' ' 13' ' ' ILE . 55.1 m95 -65.97 -40.83 91.59 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 116.029 -0.532 . . . . 0.0 110.101 -179.988 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 63.9 mt -66.48 -39.61 88.88 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 115.854 -0.612 . . . . 0.0 110.136 179.387 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . 0.425 ' HA2' HD11 ' A' ' 202' ' ' LEU . . . -68.32 -28.8 73.11 Favored Glycine 0 N--CA 1.446 -0.665 0 C-N-CA 120.804 -0.712 . . . . 0.0 111.796 179.357 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -71.99 -33.87 68.46 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 120.786 0.327 . . . . 0.0 110.578 179.52 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 13' ' ' ILE . . . . . 0.465 HG13 ' O ' ' A' ' 9' ' ' TRP . 75.0 mt -64.95 -54.08 33.95 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.173 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.248 179.172 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -61.17 -39.05 96.61 Favored Glycine 0 N--CA 1.45 -0.42 0 C-N-CA 120.5 -0.857 . . . . 0.0 111.55 179.4 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 15' ' ' MET . . . . . 0.473 ' SD ' ' HA ' ' A' ' 44' ' ' SER . 60.3 tpp -61.56 -41.44 97.37 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 120.868 0.366 . . . . 0.0 110.014 179.366 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 6.3 tt -57.53 -38.88 75.43 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 115.888 -0.596 . . . . 0.0 109.911 179.334 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 17' ' ' VAL . . . . . 0.41 HG23 ' O ' ' A' ' 13' ' ' ILE . 34.6 t -59.38 -46.65 92.44 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.221 0 CA-C-N 115.946 -0.57 . . . . 0.0 110.162 179.19 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -62.91 -41.96 99.77 Favored Glycine 0 N--CA 1.45 -0.375 0 C-N-CA 120.616 -0.802 . . . . 0.0 111.66 178.981 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 9.7 m -50.3 -49.19 54.36 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.698 0.285 . . . . 0.0 111.354 -179.942 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 87.5 mt -71.87 -42.09 67.25 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.694 -179.594 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -58.43 -33.42 69.67 Favored 'General case' 0 C--N 1.33 -0.265 0 N-CA-C 112.155 0.428 . . . . 0.0 112.155 -179.135 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 22' ' ' PHE . . . . . 0.576 ' HB2' HG22 ' A' ' 41' ' ' VAL . 6.8 m-85 -91.46 -37.09 13.39 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.851 0.358 . . . . 0.0 111.535 -179.526 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -64.7 -51.31 63.14 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.912 -179.231 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 24' ' ' TRP . . . . . . . . . . . . . 7.1 t-105 -63.42 -49.45 73.68 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-N 115.754 -0.657 . . . . 0.0 111.312 -179.295 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.328 -0.339 0 CA-C-O 120.879 0.371 . . . . 0.0 110.793 179.906 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.264 0 N-CA-C 112.432 -0.267 . . . . 0.0 112.432 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 7.8 mm-40 -69.35 -20.47 63.85 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-O 120.759 0.314 . . . . 0.0 110.762 179.88 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 34' ' ' ARG . . . . . . . . . . . . . 75.0 ttt180 -48.67 -29.68 4.65 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 115.972 -0.558 . . . . 0.0 111.615 -179.688 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 37.4 ttm180 -58.34 -46.53 86.06 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-O 120.818 0.342 . . . . 0.0 111.046 -179.986 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 68.1 m-85 -69.51 -29.73 67.41 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.081 -0.508 . . . . 0.0 111.388 -179.678 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 37' ' ' TYR . . . . . 0.47 ' O ' HG23 ' A' ' 41' ' ' VAL . 63.2 m-85 -73.96 -56.1 5.35 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.413 -179.478 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 60.3 t -57.09 -38.64 61.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-O 120.984 0.421 . . . . 0.0 110.682 179.891 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 48.9 m -62.31 -49.05 77.18 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 115.858 -0.61 . . . . 0.0 110.447 179.243 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 40' ' ' LEU . . . . . 0.594 HD12 HD12 ' A' ' 43' ' ' ILE . 46.4 tp -55.56 -45.57 77.26 Favored 'General case' 0 C--O 1.236 0.346 0 CA-C-N 115.612 -0.722 . . . . 0.0 110.233 179.495 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . 0.576 HG22 ' HB2' ' A' ' 22' ' ' PHE . 60.1 t -63.17 -34.31 66.09 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.345 0 CA-C-N 115.645 -0.707 . . . . 0.0 110.172 179.283 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -59.49 -35.19 84.46 Favored Glycine 0 N--CA 1.449 -0.44 0 C-N-CA 120.69 -0.767 . . . . 0.0 111.538 179.554 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 43' ' ' ILE . . . . . 0.594 HD12 HD12 ' A' ' 40' ' ' LEU . 1.0 OUTLIER -68.91 -54.71 18.9 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.229 0 CA-C-O 120.797 0.332 . . . . 0.0 110.591 179.331 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 44' ' ' SER . . . . . 0.473 ' HA ' ' SD ' ' A' ' 15' ' ' MET . 32.3 t -58.74 -24.95 62.46 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.306 -179.943 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -76.16 -55.35 4.81 Favored Glycine 0 N--CA 1.45 -0.405 0 C-N-CA 120.683 -0.77 . . . . 0.0 112.747 -179.791 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 20.3 pt -59.78 -36.81 68.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-O 120.745 0.307 . . . . 0.0 111.421 -179.793 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 47' ' ' ALA . . . . . 0.764 ' HB2' ' HE2' ' A' ' 205' ' ' LYS . . . -67.89 -44.51 76.84 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-N 116.395 -0.366 . . . . 0.0 111.243 179.708 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -54.46 -48.0 72.28 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 115.918 -0.583 . . . . 0.0 111.672 -179.398 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 49' ' ' VAL . . . . . 0.415 ' O ' HG13 ' A' ' 53' ' ' VAL . 18.0 m -68.33 -33.92 63.15 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-N 116.255 -0.429 . . . . 0.0 111.371 -179.481 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -66.06 -37.5 85.99 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 120.864 0.364 . . . . 0.0 111.275 179.97 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 51' ' ' TYR . . . . . 0.447 ' OH ' ' HB2' ' A' ' 201' ' ' ASP . 29.5 m-85 -70.82 -44.0 67.45 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.458 -179.829 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -61.14 -51.92 67.06 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-N 115.53 -0.759 . . . . 0.0 111.251 179.814 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 53' ' ' VAL . . . . . 0.527 HG23 ' N ' ' A' ' 54' ' ' MET . 33.0 m -60.88 -50.95 78.43 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.2 0 CA-C-N 116.455 -0.338 . . . . 0.0 110.869 -179.976 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 54' ' ' MET . . . . . 0.57 ' HG3' ' HE1' ' A' ' 60' ' ' TRP . 8.8 ttp -60.34 -29.2 68.74 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 121.082 0.468 . . . . 0.0 109.792 179.499 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 55' ' ' ALA . . . . . 0.68 ' HB2' ' HB2' ' A' ' 8' ' ' PHE . . . -73.17 -30.6 63.68 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 115.71 -0.677 . . . . 0.0 110.843 179.043 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 87.4 mt -78.25 0.4 25.38 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.058 -179.865 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 92.0 -22.15 33.17 Favored Glycine 0 N--CA 1.45 -0.397 0 C-N-CA 120.63 -0.795 . . . . 0.0 113.127 179.776 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 58' ' ' VAL . . . . . 0.458 HG12 ' O ' ' A' ' 53' ' ' VAL . 12.5 p -67.79 142.8 16.01 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.176 0 CA-C-O 120.885 0.374 . . . . 0.0 110.77 -179.966 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 97.72 -11.66 64.55 Favored Glycine 0 N--CA 1.452 -0.287 0 C-N-CA 120.88 -0.676 . . . . 0.0 112.105 -179.329 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 60' ' ' TRP . . . . . 0.57 ' HE1' ' HG3' ' A' ' 54' ' ' MET . 28.6 m0 -78.49 115.09 17.96 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.685 0.279 . . . . 0.0 110.504 179.869 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 61' ' ' VAL . . . . . 0.402 ' HA ' ' HD3' ' A' ' 62' ' ' PRO . 10.7 p -118.02 125.29 28.06 Favored Pre-proline 0 CA--C 1.532 0.287 0 CA-C-N 116.518 -0.31 . . . . 0.0 111.518 -179.838 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 62' ' ' PRO . . . . . 0.402 ' HD3' ' HA ' ' A' ' 61' ' ' VAL . 17.1 Cg_exo -67.75 155.53 69.58 Favored 'Trans proline' 0 C--N 1.351 0.678 0 C-N-CA 122.553 2.168 . . . . 0.0 111.965 179.652 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 93.2 t -143.09 92.15 0.47 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-N 115.989 -0.55 . . . . 0.0 111.041 179.995 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . 58.41 -85.78 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.039 -0.528 . . . . 0.0 111.63 179.801 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 37.7 mt-10 -119.72 -22.57 6.81 Favored 'General case' 0 C--N 1.332 -0.192 0 CA-C-N 116.42 -0.355 . . . . 0.0 111.141 -179.659 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 66' ' ' ARG . . . . . . . . . . . . . 32.3 mmt180 -105.94 158.06 17.05 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.683 -179.872 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 92.9 m -111.68 131.11 55.52 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.905 0.384 . . . . 0.0 111.492 -179.635 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 61.8 t -113.8 146.46 18.35 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 115.899 -0.591 . . . . 0.0 110.534 179.343 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 69' ' ' PHE . . . . . . . . . . . . . 44.6 m-85 -108.89 111.97 23.96 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-N 116.174 -0.467 . . . . 0.0 110.141 -179.447 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 70' ' ' VAL . . . . . 0.63 ' N ' ' HD2' ' A' ' 71' ' ' PRO . 21.8 t -69.2 -49.62 23.48 Favored Pre-proline 0 C--N 1.324 -0.535 0 CA-C-N 116.219 -0.446 . . . . 0.0 112.202 -179.252 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 71' ' ' PRO . . . . . 0.63 ' HD2' ' N ' ' A' ' 70' ' ' VAL . 6.3 Cg_endo -48.45 -26.27 8.55 Favored 'Trans proline' 0 C--N 1.353 0.779 0 C-N-CA 122.422 2.081 . . . . 0.0 112.63 -179.524 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 55.5 ttp180 -75.23 -53.79 8.21 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-O 120.922 0.392 . . . . 0.0 111.123 -179.934 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 73' ' ' TYR . . . . . 0.441 ' OH ' ' HB2' ' A' ' 116' ' ' ALA . 67.4 m-85 -65.27 -47.97 74.82 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.094 -0.503 . . . . 0.0 111.3 -179.574 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 74' ' ' ILE . . . . . 0.48 ' O ' HD13 ' A' ' 74' ' ' ILE . 0.3 OUTLIER -59.35 -41.45 84.33 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-N 116.499 -0.319 . . . . 0.0 110.557 179.884 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 31.7 t70 -59.23 -36.53 75.61 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-O 121.023 0.44 . . . . 0.0 109.916 179.283 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 76' ' ' TRP . . . . . . . . . . . . . 47.4 m0 -66.97 -31.27 71.72 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 115.786 -0.643 . . . . 0.0 110.627 179.798 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 77' ' ' ILE . . . . . 0.485 HG12 ' HB3' ' A' ' 109' ' ' MET . 51.0 mt -73.22 -28.87 26.75 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.614 179.479 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 43.7 mt -91.75 -20.35 21.63 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.985 179.872 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 71.0 p -101.63 -52.67 3.15 Favored 'General case' 0 C--N 1.332 -0.176 0 N-CA-C 113.432 0.901 . . . . 0.0 113.432 -177.817 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 80' ' ' THR . . . . . 0.678 ' HB ' ' HD3' ' A' ' 81' ' ' PRO . 26.9 m -51.24 -55.17 30.86 Favored Pre-proline 0 C--N 1.33 -0.242 0 N-CA-C 112.327 0.491 . . . . 0.0 112.327 -178.258 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 81' ' ' PRO . . . . . 0.678 ' HD3' ' HB ' ' A' ' 80' ' ' THR . 36.0 Cg_exo -60.86 -20.41 66.41 Favored 'Trans proline' 0 C--N 1.352 0.752 0 C-N-CA 121.613 1.542 . . . . 0.0 111.459 179.74 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 82' ' ' LEU . . . . . . . . . . . . . 14.7 tp -76.79 -33.77 58.01 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 115.823 -0.626 . . . . 0.0 110.258 179.599 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 83' ' ' ILE . . . . . 0.498 HD13 HD13 ' A' ' 43' ' ' ILE . 42.2 mm -70.01 -52.54 29.83 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.149 0 CA-C-N 116.087 -0.506 . . . . 0.0 110.296 179.096 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 84' ' ' VAL . . . . . 0.425 HG22 ' HA ' ' A' ' 81' ' ' PRO . 29.8 m -59.51 -31.79 47.5 Favored 'Isoleucine or valine' 0 CA--C 1.52 -0.193 0 N-CA-C 109.736 -0.468 . . . . 0.0 109.736 178.693 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 85' ' ' TYR . . . . . . . . . . . . . 67.7 t80 -65.69 -33.54 76.12 Favored 'General case' 0 N--CA 1.453 -0.317 0 CA-C-N 115.636 -0.711 . . . . 0.0 109.334 178.72 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 86' ' ' PHE . . . . . . . . . . . . . 4.3 t80 -60.63 -51.71 68.26 Favored 'General case' 0 C--O 1.233 0.22 0 CA-C-N 115.646 -0.707 . . . . 0.0 109.719 178.858 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 9.1 mp -61.37 -31.22 71.11 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 115.741 -0.663 . . . . 0.0 110.506 179.526 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -71.89 -28.01 69.56 Favored Glycine 0 N--CA 1.449 -0.476 0 C-N-CA 120.81 -0.71 . . . . 0.0 112.144 179.801 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 65.5 mt -71.28 -45.06 64.0 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-O 120.877 0.37 . . . . 0.0 110.591 179.838 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 69.5 mt -58.44 -51.84 68.15 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 115.988 -0.551 . . . . 0.0 110.926 179.844 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 91' ' ' ALA . . . . . 0.464 ' HA ' ' HA ' ' A' ' 149' ' ' ALA . . . -61.69 -36.81 81.96 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.278 -0.419 . . . . 0.0 111.427 -179.872 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 88.38 49.56 3.66 Favored Glycine 0 N--CA 1.452 -0.271 0 C-N-CA 120.826 -0.702 . . . . 0.0 112.033 -179.633 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 93' ' ' LEU . . . . . 0.484 ' HB3' ' HB2' ' A' ' 97' ' ' GLU . 71.6 mt -67.53 178.55 1.58 Allowed 'General case' 0 C--N 1.328 -0.349 0 CA-C-O 120.917 0.389 . . . . 0.0 111.357 -179.662 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 94' ' ' ASP . . . . . . . . . . . . . 20.6 t70 -106.18 167.05 10.07 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-N 116.019 -0.537 . . . . 0.0 110.448 179.75 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 65.7 m -52.72 -34.99 55.01 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 116.46 -0.337 . . . . 0.0 111.26 -179.889 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 12.7 ptm180 -73.32 -46.79 47.39 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.381 -0.372 . . . . 0.0 111.066 -179.978 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 97' ' ' GLU . . . . . 0.484 ' HB2' ' HB3' ' A' ' 93' ' ' LEU . 45.9 mt-10 -57.74 -45.41 85.89 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.429 -0.35 . . . . 0.0 110.837 179.964 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 98' ' ' PHE . . . . . 0.49 ' O ' HG12 ' A' ' 102' ' ' ILE . 42.3 m-85 -60.18 -45.87 91.64 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.303 -0.408 . . . . 0.0 110.377 179.464 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -56.6 -30.0 58.54 Favored Glycine 0 N--CA 1.45 -0.414 0 C-N-CA 120.549 -0.834 . . . . 0.0 112.304 179.776 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 74.1 mt -73.5 -47.24 46.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 N-CA-C 112.097 0.406 . . . . 0.0 112.097 -179.761 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 101' ' ' VAL . . . . . 0.42 HG12 ' H ' ' A' ' 101' ' ' VAL . 1.1 p -70.52 -42.76 78.22 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-O 120.654 0.264 . . . . 0.0 111.634 -179.712 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 102' ' ' ILE . . . . . 0.49 HG12 ' O ' ' A' ' 98' ' ' PHE . 45.2 mm -62.13 -45.14 99.41 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.36 0 CA-C-N 116.426 -0.352 . . . . 0.0 111.042 -179.627 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 103' ' ' THR . . . . . 0.412 ' O ' HG23 ' A' ' 107' ' ' VAL . 13.6 t -66.88 -29.87 69.89 Favored 'General case' 0 C--N 1.332 -0.167 0 CA-C-O 120.817 0.341 . . . . 0.0 110.346 179.559 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 1.2 tm? -59.76 -56.06 26.51 Favored 'General case' 0 C--N 1.331 -0.206 0 N-CA-C 109.501 -0.555 . . . . 0.0 109.501 179.108 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 105' ' ' ASN . . . . . 0.624 ' N ' HD22 ' A' ' 105' ' ' ASN . 0.8 OUTLIER -57.3 -32.45 66.67 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 115.855 -0.611 . . . . 0.0 110.663 179.232 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 58.0 m -57.65 -48.86 78.32 Favored 'General case' 0 C--N 1.332 -0.183 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.95 179.78 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 107' ' ' VAL . . . . . 0.412 HG23 ' O ' ' A' ' 103' ' ' THR . 2.1 t -61.54 -40.85 87.94 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-O 121.149 0.5 . . . . 0.0 110.122 179.623 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 99.0 t -58.92 -43.73 89.25 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.377 0 CA-C-N 115.294 -0.867 . . . . 0.0 111.406 -179.956 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 109' ' ' MET . . . . . 0.485 ' HB3' HG12 ' A' ' 77' ' ' ILE . 15.3 mmt -70.51 -41.51 72.52 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.666 -179.332 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 32.5 tp -59.65 -31.09 69.21 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-O 120.882 0.372 . . . . 0.0 110.569 -179.872 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -70.15 -53.48 17.04 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.758 179.649 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . -59.58 -45.62 95.33 Favored Glycine 0 C--N 1.331 0.299 0 C-N-CA 120.707 -0.759 . . . . 0.0 112.301 179.751 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 113' ' ' PHE . . . . . . . . . . . . . 1.5 t80 -50.97 -60.5 3.03 Favored 'General case' 0 C--N 1.332 -0.171 0 CA-C-O 120.996 0.427 . . . . 0.0 110.116 179.488 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 114' ' ' ALA . . . . . 0.49 ' HB3' HD22 ' A' ' 126' ' ' LEU . . . -66.45 -19.81 65.89 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 115.733 -0.667 . . . . 0.0 110.6 179.451 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -59.0 -45.84 94.61 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.86 -0.686 . . . . 0.0 112.042 179.646 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 116' ' ' ALA . . . . . 0.441 ' HB2' ' OH ' ' A' ' 73' ' ' TYR . . . -78.16 -21.2 50.56 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.804 0.335 . . . . 0.0 111.359 179.67 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 117' ' ' MET . . . . . . . . . . . . . 24.8 mmt -83.24 19.87 1.4 Allowed 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.846 -179.253 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 118' ' ' VAL . . . . . 0.549 HG21 ' HB3' ' A' ' 123' ' ' ARG . 24.7 m -90.73 141.67 27.13 Favored Pre-proline 0 C--N 1.329 -0.294 0 CA-C-O 120.646 0.26 . . . . 0.0 111.614 -179.717 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 119' ' ' PRO . . . . . . . . . . . . . 97.3 Cg_endo -92.52 -6.75 3.05 Favored 'Trans proline' 0 N--CA 1.455 -0.774 0 C-N-CA 122.882 2.388 . . . . 0.0 112.379 179.455 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -139.41 -115.38 1.27 Allowed Glycine 0 C--N 1.332 0.314 0 C-N-CA 120.589 -0.815 . . . . 0.0 113.023 -179.586 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 38.3 pt -119.29 15.03 6.85 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.233 0 CA-C-O 120.686 0.279 . . . . 0.0 111.67 -179.345 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 10.9 mm-40 -62.11 -18.61 61.33 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.383 -0.371 . . . . 0.0 110.99 179.752 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 123' ' ' ARG . . . . . 0.549 ' HB3' HG21 ' A' ' 118' ' ' VAL . 24.2 ptt180 -54.54 -33.42 60.05 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 115.973 -0.558 . . . . 0.0 111.785 -179.751 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 124' ' ' TYR . . . . . . . . . . . . . 37.3 m-85 -65.73 -32.22 73.65 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 120.829 0.347 . . . . 0.0 111.108 -179.593 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 125' ' ' ALA . . . . . . . . . . . . . . . -72.62 -56.17 5.73 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.0 179.92 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 126' ' ' LEU . . . . . 0.49 HD22 ' HB3' ' A' ' 114' ' ' ALA . 1.3 mt -55.68 -45.44 77.77 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 115.789 -0.642 . . . . 0.0 110.488 -179.991 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 127' ' ' PHE . . . . . . . . . . . . . 7.6 t80 -67.3 -37.37 83.27 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.464 179.612 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 128' ' ' GLY . . . . . . . . . . . . . . . -47.1 -45.03 20.14 Favored Glycine 0 C--N 1.332 0.331 0 C-N-CA 120.2 -1.0 . . . . 0.0 110.748 178.866 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 129' ' ' MET . . . . . . . . . . . . . 0.4 OUTLIER -70.95 -35.85 72.35 Favored 'General case' 0 C--N 1.328 -0.328 0 N-CA-C 109.826 -0.435 . . . . 0.0 109.826 178.578 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -62.67 -36.38 93.19 Favored Glycine 0 C--N 1.332 0.354 0 CA-C-N 115.777 -0.647 . . . . 0.0 112.626 -179.926 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -69.66 -53.34 19.13 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.602 0.239 . . . . 0.0 110.42 179.78 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 54.5 t -55.38 -39.99 55.31 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.234 0 CA-C-O 121.376 0.608 . . . . 0.0 109.595 178.879 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -69.12 -35.29 76.26 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 115.278 -0.874 . . . . 0.0 110.51 179.316 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 134' ' ' PHE . . . . . . . . . . . . . 73.5 t80 -56.94 -57.58 11.89 Favored 'General case' 0 N--CA 1.451 -0.415 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.146 179.823 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 135' ' ' ILE . . . . . 0.555 ' O ' HG22 ' A' ' 138' ' ' VAL . 0.0 OUTLIER -56.18 -32.84 35.48 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.002 -0.545 . . . . 0.0 109.61 178.761 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 136' ' ' GLY . . . . . 0.4 ' O ' ' HB3' ' A' ' 139' ' ' TYR . . . -57.33 -39.15 89.9 Favored Glycine 0 N--CA 1.447 -0.58 0 C-N-CA 120.302 -0.951 . . . . 0.0 111.086 178.389 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 137' ' ' LEU . . . . . 0.456 HD13 HD21 ' A' ' 105' ' ' ASN . 27.8 tp -68.3 -53.84 21.58 Favored 'General case' 0 C--N 1.331 -0.197 0 CA-C-O 120.579 0.228 . . . . 0.0 110.644 179.212 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 138' ' ' VAL . . . . . 0.555 HG22 ' O ' ' A' ' 135' ' ' ILE . 3.0 m -56.15 -30.24 29.07 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.204 0 CA-C-O 121.137 0.494 . . . . 0.0 109.742 179.482 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 139' ' ' TYR . . . . . 0.4 ' HB3' ' O ' ' A' ' 136' ' ' GLY . 35.2 t80 -63.7 -44.22 94.29 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 115.441 -0.8 . . . . 0.0 110.202 178.945 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 37.8 m-85 -63.04 -34.95 78.68 Favored 'General case' 0 C--N 1.331 -0.198 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.696 179.434 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 141' ' ' LEU . . . . . 0.407 HD23 ' SD ' ' A' ' 145' ' ' MET . 89.7 mt -62.92 -51.11 68.21 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.005 -179.943 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 15.0 p -81.87 -11.01 12.31 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.358 0 CA-C-N 116.076 -0.511 . . . . 0.0 111.032 -179.874 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . -72.32 -130.31 0.12 Allowed Glycine 0 CA--C 1.521 0.44 0 C-N-CA 120.973 -0.632 . . . . 0.0 112.988 -179.68 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 144' ' ' PRO . . . . . . . . . . . . . 33.1 Cg_endo -64.34 -23.57 65.46 Favored 'Trans proline' 0 C--N 1.349 0.586 0 C-N-CA 122.549 2.166 . . . . 0.0 112.521 -179.696 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 145' ' ' MET . . . . . 0.407 ' SD ' HD23 ' A' ' 141' ' ' LEU . 45.6 mtt -54.65 -34.43 62.17 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.352 -0.385 . . . . 0.0 111.446 -179.888 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 146' ' ' THR . . . . . . . . . . . . . 53.9 p -71.62 -37.47 70.9 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 116.53 -0.304 . . . . 0.0 111.584 -179.74 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 43.4 mt-10 -71.98 -37.48 69.88 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.374 -0.376 . . . . 0.0 111.203 -179.586 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 148' ' ' SER . . . . . . . . . . . . . 66.5 m -70.35 -40.09 74.29 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.152 -0.477 . . . . 0.0 111.454 -179.684 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 149' ' ' ALA . . . . . 0.464 ' HA ' ' HA ' ' A' ' 91' ' ' ALA . . . -74.9 -48.36 25.17 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.354 -0.385 . . . . 0.0 111.832 -179.397 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 150' ' ' SER . . . . . . . . . . . . . 47.1 t -61.07 -23.04 65.17 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.358 -0.383 . . . . 0.0 111.316 -179.652 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 151' ' ' GLN . . . . . . . . . . . . . 49.1 mt-30 -108.78 13.49 24.95 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.455 -0.339 . . . . 0.0 111.209 -179.849 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 30.7 tpt180 -89.77 -52.02 5.21 Favored 'General case' 0 C--N 1.332 -0.194 0 CA-C-O 120.933 0.397 . . . . 0.0 110.616 179.751 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 153' ' ' SER . . . . . 0.62 ' HB2' HG12 ' A' ' 156' ' ' ILE . 13.2 m -157.57 172.69 18.1 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 115.852 -0.613 . . . . 0.0 110.331 179.426 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 154' ' ' SER . . . . . . . . . . . . . 94.9 p -67.75 -44.87 76.52 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.798 0.332 . . . . 0.0 110.899 179.844 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 155' ' ' GLY . . . . . 0.486 ' O ' HD23 ' A' ' 159' ' ' LEU . . . -76.7 -38.24 32.41 Favored Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 121.096 -0.573 . . . . 0.0 113.219 -179.684 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 156' ' ' ILE . . . . . 0.62 HG12 ' HB2' ' A' ' 153' ' ' SER . 36.1 mm -48.07 -37.75 7.12 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.229 0 CA-C-O 120.704 0.288 . . . . 0.0 111.404 -179.527 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 157' ' ' LYS . . . . . . . . . . . . . 87.5 tttt -64.76 -42.03 95.44 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 116.351 -0.386 . . . . 0.0 111.316 -179.93 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 85.9 p -71.28 -46.33 61.07 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.94 0.4 . . . . 0.0 111.375 -179.48 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 159' ' ' LEU . . . . . 0.486 HD23 ' O ' ' A' ' 155' ' ' GLY . 4.1 mm? -61.61 -36.29 80.28 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-N 116.006 -0.543 . . . . 0.0 111.558 -179.595 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 160' ' ' TYR . . . . . . . . . . . . . 46.9 t80 -74.25 -46.86 38.84 Favored 'General case' 0 C--N 1.33 -0.274 0 N-CA-C 112.668 0.618 . . . . 0.0 112.668 -178.73 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 21.6 m -58.57 -45.23 90.49 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 N-CA-C 112.277 0.473 . . . . 0.0 112.277 -178.712 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 162' ' ' ARG . . . . . . . . . . . . . 99.9 mtt180 -68.71 -44.78 73.2 Favored 'General case' 0 C--N 1.328 -0.363 0 N-CA-C 111.781 0.289 . . . . 0.0 111.781 -179.38 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 163' ' ' LEU . . . . . 0.689 ' HG ' ' HB2' ' A' ' 208' ' ' PHE . 6.0 mp -67.37 -54.18 22.76 Favored 'General case' 0 C--N 1.328 -0.368 0 N-CA-C 112.006 0.373 . . . . 0.0 112.006 -179.199 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 164' ' ' ARG . . . . . . . . . . . . . 3.7 tmm_? -56.25 -53.12 60.95 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.348 -0.387 . . . . 0.0 111.998 -179.071 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 165' ' ' ASN . . . . . 0.57 ' O ' HG23 ' A' ' 169' ' ' VAL . 0.9 OUTLIER -54.43 -51.73 64.01 Favored 'General case' 0 C--N 1.331 -0.204 0 CA-C-O 120.788 0.327 . . . . 0.0 111.81 -179.332 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 166' ' ' LEU . . . . . 0.451 ' O ' ' HG ' ' A' ' 170' ' ' LEU . 4.5 tt -60.29 -53.33 59.0 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-N 116.357 -0.383 . . . . 0.0 111.548 -179.31 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 167' ' ' THR . . . . . . . . . . . . . 63.7 m -55.85 -52.74 62.98 Favored 'General case' 0 C--N 1.329 -0.295 0 N-CA-C 113.167 0.803 . . . . 0.0 113.167 -178.767 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 168' ' ' VAL . . . . . 0.426 HG12 ' O ' ' A' ' 165' ' ' ASN . 8.2 p -56.84 -41.23 75.48 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.209 0 N-CA-C 112.226 0.454 . . . . 0.0 112.226 -178.451 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 169' ' ' VAL . . . . . 0.57 HG23 ' O ' ' A' ' 165' ' ' ASN . 74.5 t -58.3 -63.47 0.69 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.395 0 CA-C-N 116.542 -0.299 . . . . 0.0 111.534 -179.716 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 170' ' ' LEU . . . . . 0.451 ' HG ' ' O ' ' A' ' 166' ' ' LEU . 0.8 OUTLIER -64.3 -28.26 69.59 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.551 -0.295 . . . . 0.0 111.769 -179.292 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 171' ' ' TRP . . . . . 0.41 ' HZ3' HD21 ' A' ' 137' ' ' LEU . 4.5 m0 -71.11 -29.96 65.92 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 121.151 0.501 . . . . 0.0 110.216 179.146 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 172' ' ' ALA . . . . . . . . . . . . . . . -71.49 -7.1 45.32 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 115.495 -0.775 . . . . 0.0 110.967 -179.962 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 173' ' ' ILE . . . . . 0.524 ' O ' HG12 ' A' ' 177' ' ' ILE . 16.1 mm -86.75 -23.2 6.82 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.032 -0.531 . . . . 0.0 111.243 -179.993 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 174' ' ' TYR . . . . . 0.452 ' HB2' ' HD3' ' A' ' 175' ' ' PRO . 29.0 m-85 -54.11 -49.94 87.18 Favored Pre-proline 0 N--CA 1.464 0.273 0 CA-C-N 116.409 -0.36 . . . . 0.0 111.89 -179.426 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 175' ' ' PRO . . . . . 0.452 ' HD3' ' HB2' ' A' ' 174' ' ' TYR . 71.2 Cg_exo -48.45 -31.65 18.53 Favored 'Trans proline' 0 C--N 1.351 0.663 0 C-N-CA 121.935 1.757 . . . . 0.0 112.338 179.797 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 176' ' ' PHE . . . . . 0.485 ' O ' ' HG ' ' A' ' 180' ' ' LEU . 82.0 m-85 -80.38 -50.39 10.2 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.005 -0.543 . . . . 0.0 111.882 -179.843 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 177' ' ' ILE . . . . . 0.524 HG12 ' O ' ' A' ' 173' ' ' ILE . 5.3 mm -62.12 -36.16 72.75 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.534 0 N-CA-C 112.562 0.579 . . . . 0.0 112.562 -178.016 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 178' ' ' TRP . . . . . 0.455 ' HH2' ' HB2' ' A' ' 123' ' ' ARG . 83.8 t90 -69.74 -50.18 45.98 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.738 0.304 . . . . 0.0 111.007 179.973 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 179' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -68.99 -55.06 12.03 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.262 -0.426 . . . . 0.0 111.582 -179.159 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 180' ' ' LEU . . . . . 0.757 HD22 HD11 ' A' ' 187' ' ' LEU . 43.3 mt -60.42 -46.75 88.89 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 116.501 -0.318 . . . . 0.0 111.29 -179.473 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . -56.61 177.43 0.85 Allowed Glycine 0 C--N 1.335 0.512 0 C-N-CA 120.384 -0.912 . . . . 0.0 112.715 179.636 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 182' ' ' PRO . . . . . 0.499 ' HA ' ' HB2' ' A' ' 186' ' ' ALA . 83.7 Cg_exo -47.15 -45.24 22.1 Favored 'Trans proline' 0 CA--C 1.536 0.575 0 C-N-CA 122.878 2.385 . . . . 0.0 113.697 -179.802 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 183' ' ' PRO . . . . . 0.423 ' HD3' ' HB2' ' A' ' 182' ' ' PRO . 79.7 Cg_exo -46.38 -29.95 7.66 Favored 'Trans proline' 0 C--N 1.356 0.922 0 C-N-CA 122.195 1.93 . . . . 0.0 113.171 -179.796 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 184' ' ' GLY . . . . . 0.409 ' HA2' ' HD2' ' A' ' 123' ' ' ARG . . . -114.5 -121.3 3.55 Favored Glycine 0 C--N 1.332 0.342 0 C-N-CA 120.335 -0.936 . . . . 0.0 113.001 -179.896 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 185' ' ' VAL . . . . . . . . . . . . . 16.6 m -64.49 -18.57 23.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 N-CA-C 112.02 0.378 . . . . 0.0 112.02 -179.46 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 186' ' ' ALA . . . . . 0.499 ' HB2' ' HA ' ' A' ' 182' ' ' PRO . . . 56.39 87.55 0.06 Allowed 'General case' 0 N--CA 1.463 0.209 0 CA-C-O 120.731 0.301 . . . . 0.0 111.453 179.585 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 187' ' ' LEU . . . . . 0.757 HD11 HD22 ' A' ' 180' ' ' LEU . 18.8 mt -92.05 -49.67 6.09 Favored 'General case' 0 C--N 1.332 -0.195 0 CA-C-O 120.904 0.383 . . . . 0.0 111.367 -179.867 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 188' ' ' LEU . . . . . . . . . . . . . 95.2 mt -106.79 -156.7 0.59 Allowed 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.165 -0.471 . . . . 0.0 111.027 -179.574 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 189' ' ' THR . . . . . . . . . . . . . 1.6 t -96.27 149.18 35.58 Favored Pre-proline 0 C--N 1.329 -0.304 0 CA-C-N 116.056 -0.52 . . . . 0.0 111.203 -179.686 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 190' ' ' PRO . . . . . 0.436 ' O ' HG23 ' A' ' 194' ' ' VAL . 9.9 Cg_endo -51.42 -37.41 61.39 Favored 'Trans proline' 0 C--N 1.349 0.582 0 C-N-CA 122.75 2.3 . . . . 0.0 112.688 -179.869 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 191' ' ' THR . . . . . . . . . . . . . 70.2 p -58.93 -48.66 80.7 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.97 0.415 . . . . 0.0 110.975 179.947 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 192' ' ' VAL . . . . . . . . . . . . . 40.6 t -67.45 -48.48 77.13 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 115.882 -0.599 . . . . 0.0 111.566 -179.772 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 193' ' ' ASP . . . . . . . . . . . . . 22.4 t70 -56.45 -51.92 66.64 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.31 -0.405 . . . . 0.0 111.497 -179.586 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 194' ' ' VAL . . . . . 0.436 HG23 ' O ' ' A' ' 190' ' ' PRO . 79.7 t -58.68 -35.86 57.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.439 -0.346 . . . . 0.0 110.898 179.929 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 195' ' ' ALA . . . . . . . . . . . . . . . -57.57 -44.88 85.62 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.4 -0.363 . . . . 0.0 110.856 179.708 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 196' ' ' LEU . . . . . . . . . . . . . 96.0 mt -68.08 -44.0 77.26 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-N 116.329 -0.396 . . . . 0.0 110.53 179.433 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 197' ' ' ILE . . . . . . . . . . . . . 18.7 mm -56.95 -59.34 3.21 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 115.986 -0.552 . . . . 0.0 110.635 179.53 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 198' ' ' VAL . . . . . . . . . . . . . 79.5 t -52.21 -34.94 18.66 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.509 0 CA-C-N 115.688 -0.687 . . . . 0.0 109.594 178.6 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 199' ' ' TYR . . . . . . . . . . . . . 48.0 t80 -70.52 -32.35 69.79 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 115.47 -0.786 . . . . 0.0 110.819 179.885 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 200' ' ' LEU . . . . . 0.552 ' O ' HG12 ' A' ' 203' ' ' VAL . 21.6 mt -69.99 -40.51 75.29 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 115.973 -0.558 . . . . 0.0 111.458 -179.673 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 201' ' ' ASP . . . . . 0.447 ' HB2' ' OH ' ' A' ' 51' ' ' TYR . 12.8 m-20 -71.83 -35.79 70.01 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-O 121.293 0.568 . . . . 0.0 109.991 179.471 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 202' ' ' LEU . . . . . 0.425 HD11 ' HA2' ' A' ' 11' ' ' GLY . 3.0 mt -69.71 -31.36 69.34 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 115.306 -0.861 . . . . 0.0 111.856 -179.734 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 203' ' ' VAL . . . . . 0.552 HG12 ' O ' ' A' ' 200' ' ' LEU . 13.1 p -76.7 -36.06 26.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 C-N-CA 121.004 -0.279 . . . . 0.0 110.911 -179.087 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 204' ' ' THR . . . . . 0.408 ' O ' ' CD1' ' A' ' 208' ' ' PHE . 53.7 m -63.8 -58.41 6.9 Favored 'General case' 0 C--N 1.33 -0.279 0 C-N-CA 120.585 -0.446 . . . . 0.0 111.389 179.376 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 205' ' ' LYS . . . . . 0.764 ' HE2' ' HB2' ' A' ' 47' ' ' ALA . 52.2 mttp -65.06 -58.31 6.39 Favored 'General case' 0 N--CA 1.464 0.231 0 N-CA-C 112.494 0.553 . . . . 0.0 112.494 -178.347 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 42.6 t -68.42 -36.81 76.4 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.475 0 N-CA-C 112.168 0.432 . . . . 0.0 112.168 -178.898 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 207' ' ' GLY . . . . . 0.546 ' O ' HG13 ' A' ' 211' ' ' ILE . . . -60.2 -60.76 8.03 Favored Glycine 0 N--CA 1.453 -0.226 0 C-N-CA 120.682 -0.771 . . . . 0.0 114.035 -178.349 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 208' ' ' PHE . . . . . 0.689 ' HB2' ' HG ' ' A' ' 163' ' ' LEU . 0.1 OUTLIER -71.55 -26.83 62.79 Favored 'General case' 0 C--O 1.224 -0.287 0 CA-C-N 117.277 0.539 . . . . 0.0 111.653 -178.643 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 209' ' ' GLY . . . . . 0.487 ' O ' ' HB3' ' A' ' 212' ' ' ALA . . . -67.6 -32.44 78.57 Favored Glycine 0 N--CA 1.449 -0.457 0 N-CA-C 111.853 -0.499 . . . . 0.0 111.853 178.966 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 210' ' ' PHE . . . . . . . . . . . . . 0.9 OUTLIER -73.21 -48.29 36.31 Favored 'General case' 0 CA--C 1.514 -0.43 0 N-CA-C 108.291 -1.003 . . . . 0.0 108.291 178.532 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 211' ' ' ILE . . . . . 0.546 HG13 ' O ' ' A' ' 207' ' ' GLY . 5.3 mt -63.48 -27.96 44.04 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.535 0 N-CA-C 107.626 -1.25 . . . . 0.0 107.626 176.715 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 212' ' ' ALA . . . . . 0.487 ' HB3' ' O ' ' A' ' 209' ' ' GLY . . . -63.72 -40.83 97.71 Favored 'General case' 0 N--CA 1.449 -0.483 0 CA-C-N 114.45 -1.25 . . . . 0.0 110.881 179.887 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 213' ' ' LEU . . . . . . . . . . . . . 97.3 mt -69.98 -55.0 10.75 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 115.273 -0.876 . . . . 0.0 112.17 -179.135 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 214' ' ' ASP . . . . . . . . . . . . . 36.2 t70 -53.81 -55.03 30.23 Favored 'General case' 0 C--O 1.234 0.27 0 CA-C-O 120.758 0.313 . . . . 0.0 111.498 -179.417 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 215' ' ' ALA . . . . . . . . . . . . . . . -56.99 -53.06 62.29 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.306 -0.406 . . . . 0.0 111.159 -179.878 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 216' ' ' ALA . . . . . . . . . . . . . . . -58.73 -31.35 68.22 Favored 'General case' 0 C--N 1.332 -0.187 0 CA-C-N 116.443 -0.344 . . . . 0.0 111.286 -179.891 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 217' ' ' ALA . . . . . . . . . . . . . . . -61.82 -39.7 92.7 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 121.076 0.465 . . . . 0.0 109.991 179.573 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 218' ' ' THR . . . . . . . . . . . . . 97.9 m . . . . . 0 C--N 1.331 -0.228 0 CA-C-N 115.726 -0.67 . . . . 0.0 110.793 179.299 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.453 -0.216 0 N-CA-C 112.577 -0.209 . . . . 0.0 112.577 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 32.0 tp -74.83 -36.46 62.41 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-O 120.779 0.323 . . . . 0.0 111.215 -179.913 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 81.5 p -59.43 -29.84 68.05 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.082 -0.508 . . . . 0.0 111.372 -179.641 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 31.3 p -53.55 -35.91 61.27 Favored 'General case' 0 C--N 1.331 -0.196 0 CA-C-N 116.231 -0.441 . . . . 0.0 111.413 -179.798 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 7' ' ' LEU . . . . . . . . . . . . . 3.9 mm? -61.15 -51.09 70.52 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 116.382 -0.372 . . . . 0.0 111.224 -179.774 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 8' ' ' PHE . . . . . . . . . . . . . 83.9 m-85 -60.33 -36.39 77.83 Favored 'General case' 0 C--N 1.331 -0.198 0 CA-C-O 120.978 0.418 . . . . 0.0 110.775 179.871 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 9' ' ' TRP . . . . . 0.442 ' O ' HG12 ' A' ' 13' ' ' ILE . 21.7 m95 -63.58 -41.9 98.34 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 115.781 -0.645 . . . . 0.0 109.897 179.827 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 87.6 mt -60.87 -45.0 96.28 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 115.549 -0.75 . . . . 0.0 110.392 179.315 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -64.42 -26.76 70.94 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.715 -0.755 . . . . 0.0 111.965 179.368 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -74.37 -30.51 62.01 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.772 0.32 . . . . 0.0 110.755 179.716 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 13' ' ' ILE . . . . . 0.442 HG12 ' O ' ' A' ' 9' ' ' TRP . 51.6 mm -69.62 -54.39 19.71 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.227 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.62 179.776 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -61.84 -34.76 89.85 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.582 -0.818 . . . . 0.0 112.033 179.64 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 15' ' ' MET . . . . . 0.516 ' SD ' ' HA ' ' A' ' 44' ' ' SER . 49.1 tpp -66.52 -45.8 78.29 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 120.778 0.323 . . . . 0.0 110.39 179.71 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -54.19 -41.46 68.62 Favored 'General case' 0 C--N 1.331 -0.206 0 CA-C-N 116.053 -0.521 . . . . 0.0 109.759 179.196 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 17' ' ' VAL . . . . . 0.439 HG23 ' O ' ' A' ' 13' ' ' ILE . 63.5 t -59.8 -43.21 91.29 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.187 0 CA-C-N 115.8 -0.636 . . . . 0.0 110.263 179.302 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -65.3 -40.31 96.48 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.694 -0.765 . . . . 0.0 111.58 178.95 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 15.5 m -53.79 -48.84 69.42 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.876 0.369 . . . . 0.0 110.991 -179.997 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 20' ' ' LEU . . . . . 0.418 ' O ' ' HB3' ' A' ' 24' ' ' TRP . 89.2 mt -71.61 -35.05 70.36 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.038 -0.528 . . . . 0.0 111.152 179.894 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -64.06 -34.2 77.48 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.166 -0.47 . . . . 0.0 112.252 -179.332 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 22' ' ' PHE . . . . . 0.56 ' HB2' HG22 ' A' ' 41' ' ' VAL . 4.1 m-85 -90.29 -37.81 13.82 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.67 0.271 . . . . 0.0 111.512 -179.045 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -64.85 -50.75 65.4 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 121.004 0.43 . . . . 0.0 111.731 -179.542 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 24' ' ' TRP . . . . . 0.418 ' HB3' ' O ' ' A' ' 20' ' ' LEU . 5.0 t-105 -63.42 -51.54 65.3 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 115.803 -0.635 . . . . 0.0 111.174 -179.605 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.328 -0.336 0 CA-C-N 116.36 -0.382 . . . . 0.0 111.162 -179.842 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.313 0 N-CA-C 112.359 -0.297 . . . . 0.0 112.359 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 17.6 mm-40 -66.38 -20.51 66.09 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.674 0.273 . . . . 0.0 111.141 179.897 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 34' ' ' ARG . . . . . . . . . . . . . 93.0 mtt180 -48.25 -34.07 9.69 Favored 'General case' 0 C--N 1.332 -0.192 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.623 -179.491 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 82.7 mtp180 -59.01 -52.67 64.77 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-O 120.841 0.353 . . . . 0.0 111.078 -179.83 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 73.4 m-85 -61.22 -29.5 69.86 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 116.058 -0.519 . . . . 0.0 111.189 -179.953 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 37' ' ' TYR . . . . . . . . . . . . . 42.8 m-85 -73.3 -52.62 13.28 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.347 -179.758 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 91.2 t -57.03 -36.92 52.49 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.243 0 CA-C-O 121.064 0.459 . . . . 0.0 110.265 179.536 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 25.6 m -68.07 -46.08 72.03 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 115.649 -0.705 . . . . 0.0 110.467 179.35 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 40' ' ' LEU . . . . . 0.401 HD11 ' HA2' ' A' ' 209' ' ' GLY . 15.8 tp -60.38 -45.51 93.28 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 115.628 -0.715 . . . . 0.0 110.51 179.877 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . 0.56 HG22 ' HB2' ' A' ' 22' ' ' PHE . 98.4 t -65.18 -34.02 67.66 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.476 0 CA-C-N 115.843 -0.617 . . . . 0.0 110.125 179.221 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 42' ' ' GLY . . . . . 0.437 ' O ' HG12 ' A' ' 46' ' ' ILE . . . -55.86 -51.57 54.43 Favored Glycine 0 N--CA 1.449 -0.485 0 CA-C-N 115.697 -0.683 . . . . 0.0 112.759 179.854 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 43' ' ' ILE . . . . . 0.737 HG23 HD23 ' A' ' 82' ' ' LEU . 10.7 pt -63.76 -48.93 84.29 Favored 'Isoleucine or valine' 0 C--O 1.231 0.12 0 CA-C-N 116.972 0.386 . . . . 0.0 111.473 -179.963 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 44' ' ' SER . . . . . 0.516 ' HA ' ' SD ' ' A' ' 15' ' ' MET . 47.8 t -60.51 -26.62 66.98 Favored 'General case' 0 CA--C 1.529 0.147 0 CA-C-O 120.968 0.413 . . . . 0.0 111.116 179.831 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -75.85 -60.44 3.16 Favored Glycine 0 CA--C 1.517 0.179 0 C-N-CA 120.966 -0.635 . . . . 0.0 113.206 -179.278 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 46' ' ' ILE . . . . . 0.484 HD11 HG22 ' A' ' 79' ' ' THR . 9.3 pt -57.95 -34.83 49.69 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-O 120.738 0.304 . . . . 0.0 111.339 -179.444 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 47' ' ' ALA . . . . . 0.69 ' HB2' ' HE2' ' A' ' 205' ' ' LYS . . . -67.22 -44.03 80.56 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.526 -0.306 . . . . 0.0 111.035 179.277 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -54.39 -47.07 73.12 Favored 'General case' 0 C--O 1.232 0.151 0 CA-C-N 116.273 -0.421 . . . . 0.0 111.179 -179.975 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 49' ' ' VAL . . . . . 0.445 ' O ' HG13 ' A' ' 53' ' ' VAL . 14.5 m -71.81 -34.11 50.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.292 -0.413 . . . . 0.0 111.004 179.704 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -60.07 -41.32 92.13 Favored 'General case' 0 N--CA 1.462 0.172 0 CA-C-O 121.006 0.432 . . . . 0.0 111.012 179.422 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 38.8 m-85 -73.25 -34.76 66.02 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 115.877 -0.601 . . . . 0.0 110.496 -179.883 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -66.58 -44.86 81.09 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 115.923 -0.581 . . . . 0.0 111.052 179.599 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 53' ' ' VAL . . . . . 0.455 HG23 ' N ' ' A' ' 54' ' ' MET . 31.2 m -66.61 -45.49 88.39 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.137 0 CA-C-N 116.47 -0.332 . . . . 0.0 110.87 -179.997 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 54' ' ' MET . . . . . 0.455 ' N ' HG23 ' A' ' 53' ' ' VAL . 73.1 mtm -64.27 -34.49 78.23 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-O 121.183 0.516 . . . . 0.0 109.941 179.251 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -63.61 -23.29 67.32 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 115.432 -0.804 . . . . 0.0 111.103 179.515 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 93.2 mt -94.12 -5.37 47.39 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 116.262 -0.426 . . . . 0.0 111.077 -179.864 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 98.12 19.42 23.84 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.636 -0.792 . . . . 0.0 112.935 179.743 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 59.7 t -83.61 135.4 24.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-O 120.739 0.304 . . . . 0.0 110.853 179.861 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 59' ' ' GLY . . . . . 0.53 ' HA3' ' HD3' ' A' ' 71' ' ' PRO . . . 81.03 -4.84 68.7 Favored Glycine 0 N--CA 1.45 -0.423 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.599 -179.806 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 60' ' ' TRP . . . . . . . . . . . . . 14.3 m0 -67.3 90.75 0.23 Allowed 'General case' 0 C--N 1.33 -0.248 0 CA-C-O 120.655 0.264 . . . . 0.0 110.836 179.97 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 61' ' ' VAL . . . . . 0.509 HG13 HG23 ' A' ' 68' ' ' VAL . 7.0 p -101.36 130.0 25.75 Favored Pre-proline 0 C--N 1.33 -0.277 0 CA-C-N 116.415 -0.357 . . . . 0.0 111.266 179.914 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 62' ' ' PRO . . . . . 0.449 ' HD3' ' HA ' ' A' ' 61' ' ' VAL . 7.7 Cg_exo -73.84 148.17 40.56 Favored 'Trans proline' 0 C--N 1.35 0.64 0 C-N-CA 122.966 2.444 . . . . 0.0 112.33 179.938 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 86.6 t -143.18 93.73 0.5 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.141 -0.481 . . . . 0.0 111.073 -179.956 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . 59.4 -88.31 0.02 OUTLIER 'General case' 0 C--N 1.332 -0.157 0 CA-C-N 116.129 -0.487 . . . . 0.0 111.485 179.846 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 12.6 pt-20 -123.9 -17.15 6.39 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.292 -0.413 . . . . 0.0 110.763 -179.851 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 66' ' ' ARG . . . . . 0.437 ' NH1' ' HA ' ' A' ' 183' ' ' PRO . 32.7 ptt180 -105.77 159.7 15.8 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 115.902 -0.59 . . . . 0.0 110.532 -179.925 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 40.0 m -119.23 138.54 52.91 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-O 120.902 0.382 . . . . 0.0 111.466 -179.646 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 68' ' ' VAL . . . . . 0.509 HG23 HG13 ' A' ' 61' ' ' VAL . 14.8 m -125.82 146.49 31.48 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.412 0 CA-C-N 115.846 -0.615 . . . . 0.0 110.732 179.666 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 69' ' ' PHE . . . . . . . . . . . . . 17.7 m-85 -108.78 115.7 30.59 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.195 -179.423 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 70' ' ' VAL . . . . . 0.55 HG12 ' HD3' ' A' ' 71' ' ' PRO . 0.3 OUTLIER -68.08 -33.47 5.01 Favored Pre-proline 0 CA--C 1.54 0.579 0 N-CA-C 112.749 0.648 . . . . 0.0 112.749 -179.24 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 71' ' ' PRO . . . . . 0.55 ' HD3' HG12 ' A' ' 70' ' ' VAL . 17.6 Cg_exo -66.39 -32.31 41.03 Favored 'Trans proline' 0 C--N 1.358 1.078 0 C-N-CA 121.781 1.654 . . . . 0.0 112.389 -178.989 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 72' ' ' ARG . . . . . 0.405 ' HD2' HG21 ' A' ' 197' ' ' ILE . 61.8 ttp180 -65.56 -51.13 62.11 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 121.178 0.513 . . . . 0.0 109.845 179.419 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 73' ' ' TYR . . . . . . . . . . . . . 45.9 m-85 -63.67 -46.92 83.4 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 115.522 -0.763 . . . . 0.0 110.697 179.752 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 0.4 OUTLIER -63.62 -34.84 70.22 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.308 -0.405 . . . . 0.0 110.175 179.64 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 75' ' ' ASP . . . . . 0.489 ' O ' HG23 ' A' ' 79' ' ' THR . 28.6 t70 -58.31 -39.37 79.2 Favored 'General case' 0 C--N 1.332 -0.157 0 N-CA-C 109.497 -0.557 . . . . 0.0 109.497 179.263 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 76' ' ' TRP . . . . . . . . . . . . . 53.1 m0 -67.44 -37.13 82.52 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 115.728 -0.669 . . . . 0.0 110.485 179.479 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 77' ' ' ILE . . . . . 0.431 ' O ' ' HG2' ' A' ' 81' ' ' PRO . 66.8 mt -59.74 -34.07 54.31 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 CA-C-N 115.971 -0.559 . . . . 0.0 110.844 179.79 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 20.0 mt -91.79 -27.03 18.26 Favored 'General case' 0 C--N 1.329 -0.313 0 N-CA-C 112.655 0.613 . . . . 0.0 112.655 -179.581 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 79' ' ' THR . . . . . 0.489 HG23 ' O ' ' A' ' 75' ' ' ASP . 78.6 p -90.49 -52.74 4.76 Favored 'General case' 0 N--CA 1.464 0.267 0 N-CA-C 113.747 1.017 . . . . 0.0 113.747 -177.688 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 80' ' ' THR . . . . . 0.642 ' HB ' ' HD3' ' A' ' 81' ' ' PRO . 33.1 m -48.35 -54.06 29.1 Favored Pre-proline 0 CA--C 1.531 0.228 0 N-CA-C 112.804 0.668 . . . . 0.0 112.804 -178.126 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 81' ' ' PRO . . . . . 0.642 ' HD3' ' HB ' ' A' ' 80' ' ' THR . 49.0 Cg_exo -56.43 -27.38 67.86 Favored 'Trans proline' 0 C--N 1.351 0.702 0 C-N-CA 121.572 1.515 . . . . 0.0 111.683 -179.76 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 82' ' ' LEU . . . . . 0.737 HD23 HG23 ' A' ' 43' ' ' ILE . 12.9 tp -76.96 -32.95 57.66 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 115.882 -0.599 . . . . 0.0 110.655 -179.999 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 48.5 mm -65.95 -53.85 33.52 Favored 'Isoleucine or valine' 0 C--O 1.233 0.215 0 N-CA-C 110.05 -0.352 . . . . 0.0 110.05 179.06 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 12.6 m -60.6 -29.93 45.76 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.26 0 N-CA-C 109.253 -0.647 . . . . 0.0 109.253 178.43 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 85' ' ' TYR . . . . . . . . . . . . . 66.3 t80 -65.53 -34.34 78.02 Favored 'General case' 0 N--CA 1.455 -0.215 0 CA-C-N 115.432 -0.804 . . . . 0.0 109.252 178.354 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 86' ' ' PHE . . . . . . . . . . . . . 2.1 t80 -61.31 -51.47 68.72 Favored 'General case' 0 C--O 1.231 0.129 0 CA-C-N 115.762 -0.654 . . . . 0.0 109.623 179.217 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 7.4 mp -64.0 -31.38 72.55 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 115.801 -0.636 . . . . 0.0 110.119 179.414 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -66.6 -27.78 73.39 Favored Glycine 0 N--CA 1.449 -0.459 0 C-N-CA 120.807 -0.711 . . . . 0.0 111.742 179.322 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 88.6 mt -75.96 -44.93 37.54 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 120.81 0.338 . . . . 0.0 110.691 179.586 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 80.3 mt -54.97 -38.24 67.53 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 115.904 -0.589 . . . . 0.0 110.859 179.898 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -84.34 -54.02 5.07 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.058 -0.519 . . . . 0.0 111.079 179.953 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 100.14 65.13 0.81 Allowed Glycine 0 N--CA 1.452 -0.234 0 C-N-CA 120.887 -0.673 . . . . 0.0 112.416 179.989 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 93' ' ' LEU . . . . . 0.532 ' HB3' ' HB2' ' A' ' 97' ' ' GLU . 6.9 mp -81.51 165.63 21.02 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-O 120.795 0.331 . . . . 0.0 110.746 179.932 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 94' ' ' ASP . . . . . . . . . . . . . 9.0 m-20 -82.75 178.0 8.4 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.837 179.928 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 82.5 p -64.11 -34.47 78.11 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.07 -0.513 . . . . 0.0 111.072 -179.983 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 84.6 mtm180 -73.6 -51.27 17.42 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.279 -0.418 . . . . 0.0 111.094 -179.751 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 97' ' ' GLU . . . . . 0.532 ' HB2' ' HB3' ' A' ' 93' ' ' LEU . 20.2 mt-10 -57.39 -44.4 84.44 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.453 -0.34 . . . . 0.0 110.748 -179.842 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 98' ' ' PHE . . . . . . . . . . . . . 1.7 m-85 -57.46 -50.58 72.58 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.311 -0.404 . . . . 0.0 110.933 179.812 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -54.45 -34.8 55.21 Favored Glycine 0 N--CA 1.452 -0.278 0 C-N-CA 120.883 -0.675 . . . . 0.0 112.584 -179.966 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 96.5 mt -66.74 -43.17 90.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-O 120.89 0.376 . . . . 0.0 111.632 -179.823 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 59.6 t -69.17 -44.26 80.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.629 -179.545 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 102' ' ' ILE . . . . . . . . . . . . . 37.7 mm -65.52 -46.69 89.06 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.378 0 CA-C-N 116.405 -0.361 . . . . 0.0 111.629 -179.227 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 15.3 t -61.85 -35.93 79.74 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 120.643 0.259 . . . . 0.0 111.258 -179.588 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 29.4 tp -62.62 -46.68 87.17 Favored 'General case' 0 C--N 1.332 -0.169 0 CA-C-O 120.843 0.354 . . . . 0.0 110.761 179.781 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 105' ' ' ASN . . . . . 0.621 HD21 HD13 ' A' ' 137' ' ' LEU . 0.9 OUTLIER -64.73 -26.18 68.25 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.69 179.697 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 53.8 m -67.1 -55.23 15.14 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.124 -0.489 . . . . 0.0 111.401 -179.927 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 7.1 p -62.43 -38.53 81.53 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.193 0 CA-C-N 116.477 -0.329 . . . . 0.0 111.103 -179.841 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 59.4 t -62.58 -44.75 99.65 Favored 'Isoleucine or valine' 0 C--O 1.234 0.269 0 CA-C-O 121.051 0.453 . . . . 0.0 110.573 179.545 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 109' ' ' MET . . . . . 0.521 ' HE1' HG21 ' A' ' 80' ' ' THR . 7.7 tpp -67.38 -25.69 66.09 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 115.979 -0.555 . . . . 0.0 110.113 179.594 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 20.2 tp -75.93 -30.95 58.9 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 115.764 -0.653 . . . . 0.0 110.296 179.633 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -66.83 -54.23 24.6 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 115.934 -0.575 . . . . 0.0 110.72 179.662 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . -62.1 -47.55 89.1 Favored Glycine 0 C--N 1.331 0.283 0 C-N-CA 120.627 -0.797 . . . . 0.0 111.976 179.558 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 113' ' ' PHE . . . . . . . . . . . . . 3.4 t80 -50.5 -58.08 6.61 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.717 0.294 . . . . 0.0 110.68 179.362 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -71.95 -16.82 62.1 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.687 179.587 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -60.4 -48.69 84.94 Favored Glycine 0 C--N 1.331 0.295 0 C-N-CA 121.091 -0.576 . . . . 0.0 112.412 179.948 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 116' ' ' ALA . . . . . 0.516 ' HB2' ' HB3' ' A' ' 183' ' ' PRO . . . -77.83 -15.05 59.35 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-O 120.773 0.321 . . . . 0.0 111.361 179.991 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 117' ' ' MET . . . . . 0.439 ' SD ' HG21 ' A' ' 68' ' ' VAL . 25.4 mmt -90.29 14.32 13.04 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.298 -0.41 . . . . 0.0 111.6 -179.433 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 118' ' ' VAL . . . . . 0.432 HG21 ' HB3' ' A' ' 123' ' ' ARG . 26.0 m -82.16 143.72 49.44 Favored Pre-proline 0 C--N 1.331 -0.229 0 CA-C-N 116.649 -0.251 . . . . 0.0 111.196 -179.959 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 119' ' ' PRO . . . . . . . . . . . . . 67.8 Cg_endo -92.9 -1.48 3.64 Favored 'Trans proline' 0 N--CA 1.457 -0.668 0 C-N-CA 122.907 2.405 . . . . 0.0 112.416 179.551 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -138.18 -114.16 1.23 Allowed Glycine 0 C--N 1.333 0.371 0 C-N-CA 120.694 -0.765 . . . . 0.0 113.029 -179.655 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 37.0 pt -126.15 13.13 3.99 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.188 0 CA-C-O 120.781 0.324 . . . . 0.0 111.683 -179.564 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 12.2 mm-40 -61.27 -18.8 60.24 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.332 -0.395 . . . . 0.0 111.187 -179.986 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 123' ' ' ARG . . . . . 0.432 ' HB3' HG21 ' A' ' 118' ' ' VAL . 28.0 ptt180 -50.65 -38.26 45.42 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 116.0 -0.545 . . . . 0.0 111.672 -179.828 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 124' ' ' TYR . . . . . . . . . . . . . 57.5 m-85 -64.9 -33.5 76.17 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.401 -0.363 . . . . 0.0 111.241 -179.605 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 125' ' ' ALA . . . . . . . . . . . . . . . -71.98 -56.0 6.44 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 120.946 0.403 . . . . 0.0 111.204 -179.998 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 1.2 mt -52.11 -52.36 51.98 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 115.923 -0.58 . . . . 0.0 111.011 -179.871 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 127' ' ' PHE . . . . . . . . . . . . . 11.6 t80 -64.0 -37.66 88.24 Favored 'General case' 0 N--CA 1.453 -0.304 0 C-N-CA 120.778 -0.369 . . . . 0.0 110.866 179.927 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 128' ' ' GLY . . . . . . . . . . . . . . . -46.47 -44.6 16.28 Favored Glycine 0 C--N 1.332 0.349 0 C-N-CA 120.227 -0.987 . . . . 0.0 110.95 179.35 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 129' ' ' MET . . . . . . . . . . . . . 0.3 OUTLIER -70.56 -37.01 73.94 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 115.392 -0.404 . . . . 0.0 109.947 178.839 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -68.77 -26.92 74.24 Favored Glycine 0 C--N 1.331 0.3 0 CA-C-N 115.842 -0.617 . . . . 0.0 112.94 -179.872 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 131' ' ' ALA . . . . . 0.456 ' O ' ' HB3' ' A' ' 134' ' ' PHE . . . -74.66 -53.6 9.0 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.821 0.343 . . . . 0.0 110.208 179.869 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 58.0 t -58.56 -39.92 77.19 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 N-CA-C 109.09 -0.707 . . . . 0.0 109.09 178.486 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -66.87 -35.31 79.74 Favored 'General case' 0 N--CA 1.453 -0.313 0 CA-C-N 115.276 -0.875 . . . . 0.0 110.412 179.21 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 134' ' ' PHE . . . . . 0.456 ' HB3' ' O ' ' A' ' 131' ' ' ALA . 17.6 t80 -54.26 -56.63 16.49 Favored 'General case' 0 N--CA 1.455 -0.208 0 CA-C-N 116.128 -0.487 . . . . 0.0 109.889 179.425 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 135' ' ' ILE . . . . . 0.479 ' O ' HG22 ' A' ' 138' ' ' VAL . 34.7 mt -56.69 -33.4 40.26 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.323 0 CA-C-N 115.564 -0.744 . . . . 0.0 110.082 179.388 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . -59.87 -35.99 88.57 Favored Glycine 0 N--CA 1.449 -0.447 0 C-N-CA 120.241 -0.981 . . . . 0.0 111.108 178.679 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 137' ' ' LEU . . . . . 0.621 HD13 HD21 ' A' ' 105' ' ' ASN . 56.1 tp -70.86 -55.49 8.38 Favored 'General case' 0 N--CA 1.453 -0.276 0 CA-C-N 115.772 -0.214 . . . . 0.0 110.671 179.376 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 138' ' ' VAL . . . . . 0.479 HG22 ' O ' ' A' ' 135' ' ' ILE . 3.1 m -54.87 -30.3 22.83 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.222 0 N-CA-C 109.171 -0.677 . . . . 0.0 109.171 179.715 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 139' ' ' TYR . . . . . . . . . . . . . 27.1 t80 -62.49 -43.61 98.39 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 115.168 -0.923 . . . . 0.0 109.956 178.083 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 22.2 m-85 -67.48 -44.35 78.78 Favored 'General case' 0 C--O 1.232 0.151 0 CA-C-N 116.301 -0.409 . . . . 0.0 110.467 179.011 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 141' ' ' LEU . . . . . 0.441 HD13 ' O ' ' A' ' 137' ' ' LEU . 11.0 mp -55.02 -32.57 61.94 Favored 'General case' 0 C--N 1.332 -0.183 0 CA-C-N 116.004 -0.544 . . . . 0.0 111.253 -179.719 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 10.8 p -101.44 -10.19 8.99 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-O 121.055 0.455 . . . . 0.0 110.693 179.929 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . -75.99 -135.54 0.56 Allowed Glycine 0 CA--C 1.522 0.476 0 CA-C-N 115.852 -0.613 . . . . 0.0 112.693 -179.902 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 144' ' ' PRO . . . . . . . . . . . . . 50.0 Cg_exo -53.25 -23.95 24.98 Favored 'Trans proline' 0 C--N 1.347 0.478 0 C-N-CA 122.659 2.239 . . . . 0.0 113.055 -179.688 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 145' ' ' MET . . . . . 0.429 ' HB3' ' OH ' ' A' ' 160' ' ' TYR . 41.2 mtt -57.33 -38.01 73.41 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-O 120.67 0.271 . . . . 0.0 111.549 -179.623 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 146' ' ' THR . . . . . . . . . . . . . 60.4 p -65.45 -49.06 70.55 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.443 -0.344 . . . . 0.0 111.686 -179.443 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 43.9 mt-10 -71.48 -25.4 62.26 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.422 -0.354 . . . . 0.0 111.532 -179.462 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 148' ' ' SER . . . . . . . . . . . . . 48.2 t -68.89 -46.28 68.78 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-O 120.935 0.398 . . . . 0.0 110.827 -179.574 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 149' ' ' ALA . . . . . 0.506 ' HB1' HG22 ' A' ' 156' ' ' ILE . . . -78.13 -32.14 50.25 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.028 -0.533 . . . . 0.0 111.357 -179.858 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 150' ' ' SER . . . . . . . . . . . . . 41.6 t -63.07 -14.83 53.08 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.02 -0.536 . . . . 0.0 111.555 -179.603 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 151' ' ' GLN . . . . . . . . . . . . . 9.8 pt20 -110.71 17.2 20.87 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.659 -0.246 . . . . 0.0 111.624 -179.747 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 29.7 mmt180 -98.64 -52.51 3.59 Favored 'General case' 0 C--N 1.332 -0.184 0 C-N-CA 120.856 -0.338 . . . . 0.0 110.803 179.613 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 153' ' ' SER . . . . . 0.654 ' HB3' HG12 ' A' ' 156' ' ' ILE . 21.0 t -158.1 172.2 18.84 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.792 179.007 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 154' ' ' SER . . . . . . . . . . . . . 43.3 t -71.94 -38.4 69.83 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.307 -0.406 . . . . 0.0 110.385 179.303 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -76.87 -37.68 33.02 Favored Glycine 0 N--CA 1.45 -0.384 0 C-N-CA 120.924 -0.655 . . . . 0.0 112.647 179.8 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 156' ' ' ILE . . . . . 0.654 HG12 ' HB3' ' A' ' 153' ' ' SER . 37.8 mm -52.25 -39.79 28.77 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.236 0 CA-C-O 120.724 0.297 . . . . 0.0 111.431 -179.563 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 157' ' ' LYS . . . . . . . . . . . . . 56.0 tttm -69.65 -34.59 74.22 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-N 116.318 -0.401 . . . . 0.0 111.138 -179.921 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 46.5 t -72.25 -39.96 68.06 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 120.942 0.401 . . . . 0.0 111.309 -179.208 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 159' ' ' LEU . . . . . 0.44 HD13 ' HB1' ' A' ' 215' ' ' ALA . 12.9 mt -72.58 -35.19 67.86 Favored 'General case' 0 C--N 1.326 -0.449 0 CA-C-N 116.066 -0.516 . . . . 0.0 111.315 -179.314 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 160' ' ' TYR . . . . . 0.429 ' OH ' ' HB3' ' A' ' 145' ' ' MET . 37.5 t80 -70.38 -42.36 71.83 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.648 -0.251 . . . . 0.0 111.599 -179.075 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 161' ' ' VAL . . . . . 0.41 HG23 ' N ' ' A' ' 162' ' ' ARG . 23.0 m -65.06 -43.91 95.87 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-O 120.719 0.295 . . . . 0.0 111.367 -179.644 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 162' ' ' ARG . . . . . 0.41 ' N ' HG23 ' A' ' 161' ' ' VAL . 21.2 mmm180 -69.29 -46.53 66.96 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.914 0.387 . . . . 0.0 111.248 179.994 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 163' ' ' LEU . . . . . . . . . . . . . 1.3 mp -61.79 -54.8 37.33 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 115.971 -0.559 . . . . 0.0 111.702 -179.548 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 164' ' ' ARG . . . . . . . . . . . . . 25.4 ttp85 -58.09 -48.23 80.8 Favored 'General case' 0 C--N 1.331 -0.237 0 N-CA-C 112.459 0.54 . . . . 0.0 112.459 -178.843 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 165' ' ' ASN . . . . . 0.491 ' O ' HG23 ' A' ' 169' ' ' VAL . 0.9 OUTLIER -52.34 -51.38 59.1 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-O 120.942 0.401 . . . . 0.0 110.719 -179.205 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 166' ' ' LEU . . . . . 0.529 ' O ' ' HG ' ' A' ' 170' ' ' LEU . 3.6 tt -65.41 -41.48 93.58 Favored 'General case' 0 C--N 1.324 -0.515 0 CA-C-N 116.089 -0.505 . . . . 0.0 111.36 -179.895 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 167' ' ' THR . . . . . . . . . . . . . 51.1 m -65.18 -54.11 34.69 Favored 'General case' 0 C--N 1.331 -0.232 0 N-CA-C 112.51 0.559 . . . . 0.0 112.51 -178.465 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 168' ' ' VAL . . . . . . . . . . . . . 9.1 p -54.47 -40.46 49.54 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-O 120.644 0.259 . . . . 0.0 111.67 -179.385 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 169' ' ' VAL . . . . . 0.491 HG23 ' O ' ' A' ' 165' ' ' ASN . 55.5 t -59.72 -65.11 0.49 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.486 -0.324 . . . . 0.0 111.634 -179.844 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 170' ' ' LEU . . . . . 0.529 ' HG ' ' O ' ' A' ' 166' ' ' LEU . 2.0 pp -62.79 -27.14 69.09 Favored 'General case' 0 C--N 1.33 -0.262 0 N-CA-C 112.139 0.422 . . . . 0.0 112.139 -178.806 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 171' ' ' TRP . . . . . 0.473 ' HZ3' HD21 ' A' ' 137' ' ' LEU . 1.8 m0 -73.35 -32.48 64.56 Favored 'General case' 0 C--N 1.33 -0.245 0 C-N-CA 120.588 -0.445 . . . . 0.0 110.707 179.69 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 172' ' ' ALA . . . . . 0.415 ' HA ' ' CZ ' ' A' ' 134' ' ' PHE . . . -67.94 -7.76 31.26 Favored 'General case' 0 CA--C 1.52 -0.208 0 CA-C-O 121.345 0.593 . . . . 0.0 110.157 179.287 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 173' ' ' ILE . . . . . 0.723 HG22 ' CG1' ' A' ' 177' ' ' ILE . 9.0 mm -84.15 -36.26 11.79 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.555 0 CA-C-N 114.954 -1.021 . . . . 0.0 111.501 -179.03 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 174' ' ' TYR . . . . . 0.548 ' N ' ' HD2' ' A' ' 175' ' ' PRO . 70.2 m-85 -55.56 -51.66 78.26 Favored Pre-proline 0 C--N 1.328 -0.33 0 N-CA-C 112.507 0.558 . . . . 0.0 112.507 -178.9 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 175' ' ' PRO . . . . . 0.548 ' HD2' ' N ' ' A' ' 174' ' ' TYR . 26.7 Cg_endo -60.19 -41.12 53.98 Favored 'Trans proline' 0 C--N 1.349 0.57 0 C-N-CA 122.107 1.871 . . . . 0.0 113.359 -178.776 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 176' ' ' PHE . . . . . 0.529 ' CE2' ' HA ' ' A' ' 173' ' ' ILE . 0.1 OUTLIER -79.83 -37.83 34.18 Favored 'General case' 0 C--N 1.329 -0.32 0 C-N-CA 120.609 -0.437 . . . . 0.0 112.12 -178.413 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 177' ' ' ILE . . . . . 0.723 ' CG1' HG22 ' A' ' 173' ' ' ILE . 32.4 mm -63.76 -47.33 91.49 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.614 0 CA-C-O 120.873 0.368 . . . . 0.0 110.032 178.425 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 178' ' ' TRP . . . . . . . . . . . . . 60.5 t90 -52.91 -29.61 29.46 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 115.788 -0.642 . . . . 0.0 109.857 179.202 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 179' ' ' LEU . . . . . 0.528 HD13 ' O ' ' A' ' 179' ' ' LEU . 0.9 OUTLIER -72.76 -37.56 67.63 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 115.359 -0.837 . . . . 0.0 110.689 179.898 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 180' ' ' LEU . . . . . 0.447 ' HB3' HD12 ' A' ' 187' ' ' LEU . 0.9 OUTLIER -78.31 -51.79 9.59 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.548 -0.296 . . . . 0.0 111.626 -179.399 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . -51.13 171.8 0.2 Allowed Glycine 0 C--N 1.336 0.551 0 C-N-CA 120.941 -0.647 . . . . 0.0 113.292 -179.685 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 182' ' ' PRO . . . . . 0.585 ' N ' ' HD2' ' A' ' 183' ' ' PRO . 2.5 Cg_endo -42.68 -47.81 7.59 Favored 'Trans proline' 0 C--N 1.351 0.661 0 C-N-CA 123.316 2.678 . . . . 0.0 114.015 -179.837 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 183' ' ' PRO . . . . . 0.585 ' HD2' ' N ' ' A' ' 182' ' ' PRO . 9.4 Cg_endo -50.04 -29.93 23.2 Favored 'Trans proline' 0 C--N 1.357 0.992 0 C-N-CA 122.269 1.979 . . . . 0.0 112.62 -179.754 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 184' ' ' GLY . . . . . . . . . . . . . . . -95.93 -105.08 2.12 Favored Glycine 0 N--CA 1.45 -0.368 0 C-N-CA 120.716 -0.754 . . . . 0.0 112.73 -179.904 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 185' ' ' VAL . . . . . . . . . . . . . 0.9 OUTLIER -109.4 -0.37 9.68 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-O 120.672 0.272 . . . . 0.0 111.654 -179.525 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 186' ' ' ALA . . . . . 0.49 ' HB2' ' HA ' ' A' ' 182' ' ' PRO . . . 55.31 84.88 0.07 Allowed 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.26 -0.427 . . . . 0.0 111.74 179.535 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 187' ' ' LEU . . . . . 0.447 HD12 ' HB3' ' A' ' 180' ' ' LEU . 16.4 mt -92.3 -49.44 6.16 Favored 'General case' 0 C--N 1.332 -0.162 0 CA-C-O 121.041 0.448 . . . . 0.0 110.676 179.452 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 188' ' ' LEU . . . . . . . . . . . . . 72.8 mt -102.81 -160.64 0.79 Allowed 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 115.763 -0.653 . . . . 0.0 111.282 -179.409 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 189' ' ' THR . . . . . 0.452 ' HB ' HG23 ' A' ' 192' ' ' VAL . 10.4 m -88.11 136.64 31.85 Favored Pre-proline 0 C--N 1.33 -0.249 0 CA-C-N 115.866 -0.607 . . . . 0.0 110.615 -179.805 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 190' ' ' PRO . . . . . . . . . . . . . 82.1 Cg_exo -46.58 -49.74 11.55 Favored 'Trans proline' 0 C--N 1.35 0.607 0 C-N-CA 122.614 2.209 . . . . 0.0 113.053 -179.63 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 191' ' ' THR . . . . . 0.427 HG22 HG22 ' A' ' 189' ' ' THR . 7.1 t -61.4 -35.6 77.95 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.485 -0.325 . . . . 0.0 111.77 -179.478 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 192' ' ' VAL . . . . . 0.452 HG23 ' HB ' ' A' ' 189' ' ' THR . 89.3 t -71.45 -47.09 60.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-O 120.833 0.349 . . . . 0.0 111.278 -179.708 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 193' ' ' ASP . . . . . . . . . . . . . 24.4 t70 -58.93 -43.98 91.27 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.752 -179.944 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 194' ' ' VAL . . . . . . . . . . . . . 78.3 t -63.16 -37.98 80.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.929 179.787 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 195' ' ' ALA . . . . . . . . . . . . . . . -57.22 -46.56 82.83 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.484 -0.325 . . . . 0.0 111.093 179.829 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 196' ' ' LEU . . . . . 0.426 ' O ' ' HB3' ' A' ' 199' ' ' TYR . 80.8 mt -67.75 -33.44 74.87 Favored 'General case' 0 C--N 1.332 -0.188 0 CA-C-N 116.381 -0.372 . . . . 0.0 110.633 179.691 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 197' ' ' ILE . . . . . 0.507 HD13 HD12 ' A' ' 200' ' ' LEU . 21.1 mm -64.57 -50.48 75.69 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.112 179.126 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 198' ' ' VAL . . . . . . . . . . . . . 85.0 t -56.72 -34.08 42.11 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.478 0 N-CA-C 108.707 -0.849 . . . . 0.0 108.707 178.171 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 199' ' ' TYR . . . . . 0.502 ' O ' HG23 ' A' ' 203' ' ' VAL . 80.5 t80 -68.38 -43.72 76.69 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 114.939 -1.028 . . . . 0.0 110.167 179.544 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 200' ' ' LEU . . . . . 0.507 HD12 HD13 ' A' ' 197' ' ' ILE . 65.0 mt -56.61 -55.02 39.25 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 115.496 -0.775 . . . . 0.0 111.172 -179.667 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 201' ' ' ASP . . . . . . . . . . . . . 11.6 m-20 -64.82 -38.07 89.74 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.85 179.918 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 202' ' ' LEU . . . . . . . . . . . . . 23.5 tp -64.99 -26.05 68.12 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 115.703 -0.681 . . . . 0.0 111.393 -179.554 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 203' ' ' VAL . . . . . 0.502 HG23 ' O ' ' A' ' 199' ' ' TYR . 45.0 t -82.58 -36.55 13.54 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.365 0 CA-C-N 116.635 -0.257 . . . . 0.0 111.454 -179.397 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 204' ' ' THR . . . . . 0.402 ' O ' ' HB3' ' A' ' 208' ' ' PHE . 88.2 m -63.51 -49.18 74.55 Favored 'General case' 0 C--N 1.329 -0.318 0 C-N-CA 120.773 -0.371 . . . . 0.0 111.319 179.837 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 205' ' ' LYS . . . . . 0.69 ' HE2' ' HB2' ' A' ' 47' ' ' ALA . 61.0 mttp -73.32 -46.79 47.38 Favored 'General case' 0 C--N 1.326 -0.429 0 N-CA-C 111.934 0.346 . . . . 0.0 111.934 -178.926 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 94.9 t -74.14 -50.57 27.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-O 120.572 0.225 . . . . 0.0 111.398 -179.805 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 207' ' ' GLY . . . . . . . . . . . . . . . -60.0 -58.19 15.43 Favored Glycine 0 CA--C 1.519 0.292 0 C-N-CA 121.112 -0.566 . . . . 0.0 112.862 179.988 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 208' ' ' PHE . . . . . 0.443 ' O ' ' N ' ' A' ' 212' ' ' ALA . 4.3 t80 -56.27 -44.35 79.66 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.601 0.239 . . . . 0.0 110.744 179.75 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 209' ' ' GLY . . . . . 0.491 ' HA2' ' HB3' ' A' ' 212' ' ' ALA . . . -66.36 -37.7 93.0 Favored Glycine 0 C--N 1.33 0.243 0 CA-C-N 115.811 -0.631 . . . . 0.0 113.41 -179.686 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 210' ' ' PHE . . . . . . . . . . . . . 1.7 m-85 -69.14 -43.85 73.52 Favored 'General case' 0 CA--C 1.51 -0.592 0 N-CA-C 107.64 -1.244 . . . . 0.0 107.64 178.99 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 211' ' ' ILE . . . . . . . . . . . . . 79.8 mt -65.76 -29.62 47.54 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.827 0 N-CA-C 107.193 -1.41 . . . . 0.0 107.193 176.319 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 212' ' ' ALA . . . . . 0.491 ' HB3' ' HA2' ' A' ' 209' ' ' GLY . . . -68.94 -34.92 76.14 Favored 'General case' 0 N--CA 1.449 -0.483 0 CA-C-N 114.437 -1.256 . . . . 0.0 109.969 179.413 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 213' ' ' LEU . . . . . . . . . . . . . 57.6 mt -70.35 -55.34 9.37 Favored 'General case' 0 C--N 1.331 -0.205 0 CA-C-N 115.056 -0.975 . . . . 0.0 111.458 -179.55 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 214' ' ' ASP . . . . . . . . . . . . . 16.7 t70 -59.48 -26.88 65.63 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.284 -0.416 . . . . 0.0 110.59 179.974 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 215' ' ' ALA . . . . . 0.44 ' HB1' HD13 ' A' ' 159' ' ' LEU . . . -71.04 -57.69 4.29 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 115.906 -0.588 . . . . 0.0 111.521 -179.911 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 216' ' ' ALA . . . . . . . . . . . . . . . -62.76 -37.49 86.84 Favored 'General case' 0 C--N 1.332 -0.187 0 CA-C-N 116.43 -0.35 . . . . 0.0 111.267 -179.702 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 217' ' ' ALA . . . . . . . . . . . . . . . -60.06 -42.98 95.66 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.312 -0.404 . . . . 0.0 110.3 179.531 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 218' ' ' THR . . . . . . . . . . . . . 98.3 m . . . . . 0 C--N 1.329 -0.284 0 CA-C-N 115.865 -0.607 . . . . 0.0 110.57 179.405 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.3 0 N-CA-C 112.72 -0.152 . . . . 0.0 112.72 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 59.0 tp -74.44 -38.16 63.08 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.886 0.375 . . . . 0.0 110.988 -179.967 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 40.6 p -65.0 -29.57 70.5 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 115.936 -0.574 . . . . 0.0 111.442 -179.74 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 17.8 p -51.92 -35.22 44.92 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.278 -0.419 . . . . 0.0 111.561 -179.497 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 7' ' ' LEU . . . . . . . . . . . . . 4.0 mm? -58.22 -53.4 58.73 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.332 -0.395 . . . . 0.0 111.216 -179.877 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 8' ' ' PHE . . . . . 0.479 ' HB2' ' HB2' ' A' ' 55' ' ' ALA . 74.2 m-85 -61.47 -35.21 77.0 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.826 179.998 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 9' ' ' TRP . . . . . . . . . . . . . 55.2 m95 -64.74 -41.26 96.07 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 115.991 -0.55 . . . . 0.0 110.227 179.916 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 44.9 mt -62.37 -46.46 88.54 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 115.817 -0.629 . . . . 0.0 110.461 179.53 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . 0.419 ' O ' ' HG2' ' A' ' 15' ' ' MET . . . -61.99 -32.57 82.62 Favored Glycine 0 N--CA 1.45 -0.425 0 C-N-CA 120.703 -0.761 . . . . 0.0 111.817 179.369 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -67.56 -34.26 76.7 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-O 120.83 0.348 . . . . 0.0 110.707 179.852 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 65.6 mt -65.97 -46.94 86.9 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.238 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.144 179.396 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -59.83 -33.48 78.43 Favored Glycine 0 N--CA 1.45 -0.388 0 C-N-CA 120.726 -0.75 . . . . 0.0 111.712 179.208 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 15' ' ' MET . . . . . 0.545 ' HE3' ' CB ' ' A' ' 47' ' ' ALA . 24.1 mmt -70.33 -40.56 74.08 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 120.861 0.362 . . . . 0.0 110.507 179.425 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 27.9 tp -57.66 -39.31 76.77 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.047 -0.524 . . . . 0.0 110.562 179.792 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 56.1 t -67.28 -48.0 79.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.062 -0.517 . . . . 0.0 110.89 179.973 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -62.57 -49.33 74.45 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.705 -0.759 . . . . 0.0 111.86 179.507 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 38.2 m -49.65 -44.49 47.7 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-O 120.721 0.296 . . . . 0.0 111.279 -179.828 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 79.6 mt -72.14 -44.32 63.31 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.244 -0.434 . . . . 0.0 111.664 179.819 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -60.93 -29.93 69.91 Favored 'General case' 0 C--N 1.329 -0.299 0 N-CA-C 112.18 0.437 . . . . 0.0 112.18 -179.14 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 22' ' ' PHE . . . . . 0.644 ' HB2' HG22 ' A' ' 41' ' ' VAL . 8.7 m-85 -90.61 -34.57 15.42 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.757 0.313 . . . . 0.0 111.411 -179.31 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -67.58 -50.61 57.55 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 121.038 0.447 . . . . 0.0 111.319 -179.764 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 24' ' ' TRP . . . . . . . . . . . . . 4.7 t-105 -62.18 -37.16 84.19 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-N 115.698 -0.683 . . . . 0.0 111.187 -179.899 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.329 -0.325 0 CA-C-O 120.853 0.359 . . . . 0.0 111.118 -179.994 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.326 0 N-CA-C 112.87 -0.092 . . . . 0.0 112.87 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 13.7 mm-40 -86.69 -21.47 26.65 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.663 0.268 . . . . 0.0 111.106 -179.654 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 34' ' ' ARG . . . . . . . . . . . . . 37.2 ttm180 -54.54 -29.63 51.5 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.31 -0.405 . . . . 0.0 111.416 -179.401 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 55.0 ttp180 -59.17 -40.87 86.96 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.852 0.358 . . . . 0.0 110.828 -179.899 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 63.7 m-85 -72.74 -31.21 64.78 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.123 -0.489 . . . . 0.0 110.997 -179.971 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 37' ' ' TYR . . . . . 0.467 ' O ' HG23 ' A' ' 41' ' ' VAL . 65.9 m-85 -70.34 -54.85 10.84 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.197 -179.876 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 78.4 t -57.14 -38.99 63.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-O 120.873 0.368 . . . . 0.0 110.573 179.776 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 19.1 m -63.19 -50.48 70.14 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 115.929 -0.578 . . . . 0.0 110.79 179.405 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 40' ' ' LEU . . . . . 0.691 HD12 HD11 ' A' ' 43' ' ' ILE . 41.4 tp -56.99 -45.77 82.74 Favored 'General case' 0 C--O 1.235 0.323 0 CA-C-N 115.693 -0.685 . . . . 0.0 110.739 179.937 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . 0.644 HG22 ' HB2' ' A' ' 22' ' ' PHE . 94.3 t -62.16 -33.56 59.24 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.497 0 CA-C-N 116.103 -0.498 . . . . 0.0 109.698 179.001 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -58.17 -48.78 81.11 Favored Glycine 0 N--CA 1.45 -0.378 0 CA-C-N 115.49 -0.777 . . . . 0.0 113.135 179.888 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 43' ' ' ILE . . . . . 0.691 HD11 HD12 ' A' ' 40' ' ' LEU . 17.0 pt -64.72 -47.02 90.45 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.215 0 CA-C-N 117.213 0.506 . . . . 0.0 111.599 -179.61 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 67.9 m -61.92 -27.88 69.13 Favored 'General case' 0 C--O 1.232 0.149 0 CA-C-O 120.907 0.384 . . . . 0.0 110.945 179.496 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -79.45 -52.86 4.6 Favored Glycine 0 CA--C 1.517 0.212 0 CA-C-N 115.934 -0.575 . . . . 0.0 113.423 -179.119 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 46' ' ' ILE . . . . . 0.504 HG13 HG22 ' A' ' 79' ' ' THR . 7.2 pt -57.81 -40.22 74.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-O 121.001 0.429 . . . . 0.0 111.002 -179.613 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 47' ' ' ALA . . . . . 0.596 ' HB2' ' HE2' ' A' ' 205' ' ' LYS . . . -68.31 -42.82 78.83 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.21 179.195 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 48' ' ' ALA . . . . . 0.453 ' HB2' ' HB3' ' A' ' 15' ' ' MET . . . -54.24 -43.18 70.69 Favored 'General case' 0 C--O 1.232 0.16 0 CA-C-N 116.326 -0.397 . . . . 0.0 111.763 -179.339 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 49' ' ' VAL . . . . . 0.443 HG22 ' O ' ' A' ' 46' ' ' ILE . 32.5 m -73.28 -34.22 43.38 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 116.492 -0.322 . . . . 0.0 111.445 -179.572 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -64.07 -37.79 88.73 Favored 'General case' 0 C--N 1.332 -0.174 0 CA-C-O 120.897 0.379 . . . . 0.0 111.217 179.827 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 35.6 m-85 -72.18 -39.27 68.77 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 115.996 -0.547 . . . . 0.0 110.704 -179.623 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -62.82 -50.52 70.63 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 115.944 -0.571 . . . . 0.0 111.301 179.739 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 53' ' ' VAL . . . . . 0.428 HG23 ' N ' ' A' ' 54' ' ' MET . 18.5 m -65.6 -43.06 94.13 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.189 0 CA-C-N 116.365 -0.379 . . . . 0.0 111.281 -179.666 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 54' ' ' MET . . . . . 0.507 ' HG3' ' HE1' ' A' ' 60' ' ' TRP . 10.9 ttp -68.55 -29.98 68.66 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.886 0.374 . . . . 0.0 110.306 179.897 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 55' ' ' ALA . . . . . 0.479 ' HB2' ' HB2' ' A' ' 8' ' ' PHE . . . -64.67 -36.86 85.65 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 115.939 -0.573 . . . . 0.0 110.939 179.328 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 86.7 mt -74.45 -1.0 19.23 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.061 -0.518 . . . . 0.0 111.245 -179.681 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 92.78 4.31 65.48 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.668 -0.777 . . . . 0.0 112.448 179.987 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 46.8 t -74.08 144.63 12.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-O 120.819 0.342 . . . . 0.0 111.187 -179.915 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 59' ' ' GLY . . . . . 0.43 ' HA3' ' HD3' ' A' ' 71' ' ' PRO . . . 76.7 5.86 84.09 Favored Glycine 0 CA--C 1.519 0.335 0 C-N-CA 120.946 -0.645 . . . . 0.0 112.815 -179.975 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 60' ' ' TRP . . . . . 0.507 ' HE1' ' HG3' ' A' ' 54' ' ' MET . 24.7 m0 -81.8 118.06 22.58 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.684 0.278 . . . . 0.0 111.076 -179.908 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 7.3 p -115.49 126.33 27.87 Favored Pre-proline 0 CA--C 1.533 0.313 0 CA-C-N 116.491 -0.322 . . . . 0.0 111.307 179.757 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 9.2 Cg_exo -72.13 142.69 38.52 Favored 'Trans proline' 0 C--N 1.349 0.603 0 C-N-CA 122.705 2.27 . . . . 0.0 112.081 179.739 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 98.1 t -142.36 94.33 0.57 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.064 179.968 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . 58.58 -90.14 0.03 OUTLIER 'General case' 0 C--N 1.332 -0.182 0 CA-C-N 115.973 -0.558 . . . . 0.0 111.622 179.857 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 18.5 mm-40 -117.36 -21.53 8.65 Favored 'General case' 0 C--N 1.332 -0.161 0 CA-C-N 116.39 -0.368 . . . . 0.0 111.048 -179.694 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 66' ' ' ARG . . . . . . . . . . . . . 30.7 ptt180 -107.17 158.64 16.94 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.174 -0.467 . . . . 0.0 110.629 179.911 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 60.5 m -117.76 115.24 24.62 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.386 -0.37 . . . . 0.0 111.651 -179.514 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 21.0 t -87.47 146.79 5.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 115.92 -0.582 . . . . 0.0 110.415 179.436 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 69' ' ' PHE . . . . . . . . . . . . . 26.6 m-85 -108.03 114.19 27.92 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-O 120.903 0.382 . . . . 0.0 110.096 -179.557 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 70' ' ' VAL . . . . . 0.595 ' N ' ' HD2' ' A' ' 71' ' ' PRO . 12.4 t -67.7 -48.98 41.19 Favored Pre-proline 0 C--N 1.324 -0.524 0 CA-C-N 115.921 -0.582 . . . . 0.0 112.117 -178.982 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 71' ' ' PRO . . . . . 0.595 ' HD2' ' N ' ' A' ' 70' ' ' VAL . 30.0 Cg_endo -62.64 -17.67 59.88 Favored 'Trans proline' 0 C--N 1.351 0.677 0 C-N-CA 122.166 1.91 . . . . 0.0 112.508 -179.64 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 34.2 ttp180 -69.75 -55.4 9.99 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.431 -0.349 . . . . 0.0 111.53 -179.455 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 73' ' ' TYR . . . . . 0.496 ' O ' HG13 ' A' ' 77' ' ' ILE . 74.0 m-85 -70.99 -36.39 72.47 Favored 'General case' 0 C--N 1.33 -0.264 0 C-N-CA 120.854 -0.338 . . . . 0.0 110.602 -179.577 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 74' ' ' ILE . . . . . 0.518 HG22 ' HA ' ' A' ' 71' ' ' PRO . 0.3 OUTLIER -64.78 -41.43 92.17 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.199 0 N-CA-C 109.935 -0.394 . . . . 0.0 109.935 179.291 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 10.7 t70 -56.97 -38.1 72.51 Favored 'General case' 0 CA--C 1.518 -0.276 0 N-CA-C 109.007 -0.738 . . . . 0.0 109.007 178.531 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 76' ' ' TRP . . . . . 0.446 ' HA ' ' OG1' ' A' ' 79' ' ' THR . 44.6 m0 -66.88 -30.31 70.44 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 115.588 -0.733 . . . . 0.0 110.895 179.27 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 77' ' ' ILE . . . . . 0.531 ' O ' ' HG2' ' A' ' 81' ' ' PRO . 69.8 mt -67.13 -36.54 77.18 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.302 -0.408 . . . . 0.0 111.032 179.842 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 78' ' ' LEU . . . . . 0.524 HD12 HG23 ' A' ' 79' ' ' THR . 2.7 pp -91.59 -23.24 19.95 Favored 'General case' 0 C--N 1.326 -0.448 0 N-CA-C 112.76 0.652 . . . . 0.0 112.76 -179.871 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 79' ' ' THR . . . . . 0.524 HG23 HD12 ' A' ' 78' ' ' LEU . 40.9 p -88.05 -53.77 4.56 Favored 'General case' 0 N--CA 1.471 0.582 0 N-CA-C 113.49 0.922 . . . . 0.0 113.49 -179.011 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 80' ' ' THR . . . . . 0.628 ' HB ' ' HD3' ' A' ' 81' ' ' PRO . 18.2 m -53.69 -55.45 35.3 Favored Pre-proline 0 C--N 1.331 -0.21 0 N-CA-C 113.192 0.812 . . . . 0.0 113.192 -177.475 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 81' ' ' PRO . . . . . 0.628 ' HD3' ' HB ' ' A' ' 80' ' ' THR . 77.1 Cg_exo -53.45 -25.47 32.04 Favored 'Trans proline' 0 C--N 1.35 0.63 0 C-N-CA 121.567 1.511 . . . . 0.0 112.09 -179.842 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 82' ' ' LEU . . . . . 0.444 HD23 HG23 ' A' ' 43' ' ' ILE . 11.5 tp -76.69 -33.17 58.24 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.171 179.521 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 83' ' ' ILE . . . . . 0.45 HD13 HG21 ' A' ' 43' ' ' ILE . 36.6 mm -66.54 -53.37 36.32 Favored 'Isoleucine or valine' 0 C--O 1.234 0.255 0 CA-C-N 116.172 -0.467 . . . . 0.0 109.955 178.678 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 33.8 m -61.21 -30.05 47.06 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.217 0 CA-C-N 115.887 -0.597 . . . . 0.0 109.61 178.875 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 85' ' ' TYR . . . . . . . . . . . . . 85.4 t80 -67.92 -31.41 71.15 Favored 'General case' 0 N--CA 1.453 -0.285 0 CA-C-N 115.566 -0.743 . . . . 0.0 109.379 178.758 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 86' ' ' PHE . . . . . . . . . . . . . 7.6 t80 -62.51 -51.51 67.13 Favored 'General case' 0 N--CA 1.455 -0.211 0 CA-C-N 115.755 -0.657 . . . . 0.0 109.598 179.087 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 7.2 mt -61.91 -33.06 73.54 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 115.813 -0.631 . . . . 0.0 109.913 179.205 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -66.58 -27.66 73.31 Favored Glycine 0 N--CA 1.452 -0.293 0 CA-C-N 115.25 -0.886 . . . . 0.0 112.044 179.425 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 65.4 mt -74.18 -44.48 53.29 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-O 121.028 0.442 . . . . 0.0 110.749 179.826 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 78.4 mt -61.23 -31.85 71.63 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 115.823 -0.626 . . . . 0.0 111.151 -179.937 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 91' ' ' ALA . . . . . 0.406 ' HB2' ' HB2' ' A' ' 149' ' ' ALA . . . -88.36 -38.77 14.84 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.328 -0.396 . . . . 0.0 111.788 -179.433 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 85.09 70.62 1.33 Allowed Glycine 0 CA--C 1.517 0.187 0 C-N-CA 120.701 -0.761 . . . . 0.0 112.145 -179.316 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 20.0 mt -87.58 169.11 12.45 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.906 0.384 . . . . 0.0 111.371 -179.447 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 94' ' ' ASP . . . . . 0.456 ' HB3' ' HG3' ' A' ' 97' ' ' GLU . 18.6 t70 -79.77 161.56 25.64 Favored 'General case' 0 C--N 1.332 -0.168 0 CA-C-N 116.027 -0.533 . . . . 0.0 110.599 179.661 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 71.0 m -55.91 -44.79 78.61 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.418 -0.356 . . . . 0.0 111.126 -179.972 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 10.2 mpt_? -68.78 -48.02 64.72 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.169 -179.804 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 97' ' ' GLU . . . . . 0.521 ' HA ' HD12 ' A' ' 100' ' ' ILE . 47.3 mt-10 -53.95 -38.7 65.23 Favored 'General case' 0 C--O 1.234 0.238 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.839 -179.931 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 98' ' ' PHE . . . . . 0.491 ' O ' HG12 ' A' ' 102' ' ' ILE . 5.6 m-85 -60.08 -49.96 75.58 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.392 179.4 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -59.26 -26.16 61.15 Favored Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.705 -0.759 . . . . 0.0 112.515 179.97 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 100' ' ' ILE . . . . . 0.521 HD12 ' HA ' ' A' ' 97' ' ' GLU . 97.7 mt -68.85 -50.61 52.98 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.194 0 CA-C-O 120.803 0.335 . . . . 0.0 111.527 -179.921 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 101' ' ' VAL . . . . . 0.43 HG11 ' HE1' ' A' ' 145' ' ' MET . 29.6 m -70.59 -36.24 64.83 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.369 0 CA-C-N 116.437 -0.347 . . . . 0.0 111.748 -179.567 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 102' ' ' ILE . . . . . 0.621 HG23 ' HB3' ' A' ' 81' ' ' PRO . 49.5 mm -67.0 -46.72 84.11 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.626 -0.261 . . . . 0.0 111.35 -179.707 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 15.3 t -63.51 -35.32 80.09 Favored 'General case' 0 C--O 1.233 0.201 0 CA-C-O 120.75 0.309 . . . . 0.0 110.954 179.925 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 104' ' ' LEU . . . . . 0.428 ' O ' HG23 ' A' ' 108' ' ' VAL . 2.8 tm? -57.52 -53.75 54.62 Favored 'General case' 0 C--N 1.331 -0.199 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.259 179.54 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 105' ' ' ASN . . . . . 0.644 HD21 HD13 ' A' ' 137' ' ' LEU . 0.8 OUTLIER -55.71 -37.93 69.06 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.498 179.527 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 44.0 m -55.19 -41.72 72.31 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-O 120.886 0.374 . . . . 0.0 110.467 179.576 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 107' ' ' VAL . . . . . 0.425 HG23 ' H ' ' A' ' 107' ' ' VAL . 2.1 t -64.5 -37.59 80.41 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.198 0 CA-C-O 121.38 0.61 . . . . 0.0 109.867 178.99 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . 0.428 HG23 ' O ' ' A' ' 104' ' ' LEU . 26.1 t -61.49 -50.16 81.48 Favored 'Isoleucine or valine' 0 C--O 1.236 0.361 0 CA-C-N 115.089 -0.959 . . . . 0.0 111.502 -179.91 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 109' ' ' MET . . . . . 0.517 ' HE1' HG21 ' A' ' 80' ' ' THR . 9.1 mmt -63.02 -37.14 85.99 Favored 'General case' 0 C--N 1.331 -0.2 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.872 -179.838 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 31.8 tp -62.04 -33.84 75.13 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.54 179.776 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -64.75 -52.06 58.98 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 115.988 -0.551 . . . . 0.0 110.711 179.473 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . -62.23 -39.13 97.29 Favored Glycine 0 C--N 1.331 0.252 0 C-N-CA 120.484 -0.865 . . . . 0.0 112.137 179.5 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 113' ' ' PHE . . . . . . . . . . . . . 0.5 OUTLIER -52.86 -72.69 0.05 Allowed 'General case' 0 C--N 1.33 -0.255 0 CA-C-O 121.052 0.453 . . . . 0.0 110.454 179.825 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 114' ' ' ALA . . . . . 0.456 ' HB3' HD22 ' A' ' 126' ' ' LEU . . . -65.46 -12.66 54.66 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 115.708 -0.678 . . . . 0.0 111.385 -179.899 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -66.31 -43.58 92.51 Favored Glycine 0 C--N 1.33 0.238 0 C-N-CA 120.804 -0.712 . . . . 0.0 112.69 -179.959 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -78.06 -25.73 47.89 Favored 'General case' 0 C--N 1.329 -0.29 0 N-CA-C 112.154 0.427 . . . . 0.0 112.154 -179.721 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 117' ' ' MET . . . . . . . . . . . . . 67.5 mtt -91.81 19.42 6.55 Favored 'General case' 0 C--N 1.329 -0.292 0 N-CA-C 111.868 0.321 . . . . 0.0 111.868 -179.164 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 118' ' ' VAL . . . . . 0.553 HG21 ' HB3' ' A' ' 123' ' ' ARG . 17.5 m -68.33 138.88 91.85 Favored Pre-proline 0 C--N 1.329 -0.324 0 CA-C-O 120.54 0.21 . . . . 0.0 111.169 179.862 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 119' ' ' PRO . . . . . . . . . . . . . 95.1 Cg_endo -86.6 11.56 3.25 Favored 'Trans proline' 0 C--N 1.348 0.55 0 C-N-CA 122.554 2.17 . . . . 0.0 112.339 179.922 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -164.6 -120.7 0.53 Allowed Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.86 -0.686 . . . . 0.0 112.616 -179.811 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 42.3 pt -113.89 14.04 8.22 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.219 0 CA-C-O 120.812 0.339 . . . . 0.0 111.319 -179.861 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 49.0 mt-10 -61.38 -17.53 54.49 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.081 -0.509 . . . . 0.0 111.082 179.808 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 123' ' ' ARG . . . . . 0.553 ' HB3' HG21 ' A' ' 118' ' ' VAL . 14.7 ptt180 -50.44 -29.33 10.03 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.003 -0.544 . . . . 0.0 111.769 -179.821 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 124' ' ' TYR . . . . . . . . . . . . . 33.2 m-85 -74.79 -31.93 61.87 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.46 -0.336 . . . . 0.0 111.302 -179.461 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 125' ' ' ALA . . . . . . . . . . . . . . . -73.0 -56.47 5.08 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-N 116.296 -0.411 . . . . 0.0 111.045 -179.776 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 126' ' ' LEU . . . . . 0.456 HD22 ' HB3' ' A' ' 114' ' ' ALA . 1.3 mt -54.62 -46.52 73.89 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 115.968 -0.56 . . . . 0.0 110.676 179.826 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 127' ' ' PHE . . . . . . . . . . . . . 4.9 t80 -68.22 -37.37 80.76 Favored 'General case' 0 N--CA 1.453 -0.319 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.648 179.766 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 128' ' ' GLY . . . . . . . . . . . . . . . -46.38 -44.15 15.35 Favored Glycine 0 C--N 1.333 0.387 0 C-N-CA 120.14 -1.029 . . . . 0.0 110.607 178.941 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 129' ' ' MET . . . . . 0.47 ' HE3' ' N ' ' A' ' 130' ' ' GLY . 6.0 tmm? -69.52 -41.54 75.86 Favored 'General case' 0 C--N 1.328 -0.357 0 N-CA-C 109.357 -0.608 . . . . 0.0 109.357 178.266 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 130' ' ' GLY . . . . . 0.47 ' N ' ' HE3' ' A' ' 129' ' ' MET . . . -55.49 -39.49 74.2 Favored Glycine 0 N--CA 1.452 -0.278 0 CA-C-N 115.724 -0.671 . . . . 0.0 113.044 -179.711 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -70.03 -53.12 19.03 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.699 0.285 . . . . 0.0 110.609 179.955 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 53.0 t -54.93 -39.93 51.08 Favored 'Isoleucine or valine' 0 C--O 1.233 0.215 0 CA-C-O 121.307 0.575 . . . . 0.0 109.607 178.88 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -69.25 -35.99 76.69 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 115.381 -0.827 . . . . 0.0 110.279 179.391 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 134' ' ' PHE . . . . . . . . . . . . . 47.6 t80 -58.48 -52.95 63.48 Favored 'General case' 0 N--CA 1.45 -0.43 0 CA-C-N 115.932 -0.577 . . . . 0.0 109.817 179.281 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 135' ' ' ILE . . . . . 0.497 ' O ' HG22 ' A' ' 138' ' ' VAL . 45.2 mt -58.34 -30.52 40.55 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.282 0 CA-C-N 115.699 -0.682 . . . . 0.0 109.741 178.892 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 136' ' ' GLY . . . . . 0.43 ' O ' ' HB3' ' A' ' 139' ' ' TYR . . . -59.47 -42.69 97.71 Favored Glycine 0 N--CA 1.447 -0.574 0 C-N-CA 120.42 -0.895 . . . . 0.0 111.364 178.867 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 137' ' ' LEU . . . . . 0.644 HD13 HD21 ' A' ' 105' ' ' ASN . 53.8 tp -67.24 -54.62 19.29 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.565 0.222 . . . . 0.0 110.666 179.316 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 138' ' ' VAL . . . . . 0.497 HG22 ' O ' ' A' ' 135' ' ' ILE . 3.0 m -54.71 -30.4 22.38 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.134 0 CA-C-O 121.08 0.466 . . . . 0.0 109.805 -179.672 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 139' ' ' TYR . . . . . 0.43 ' HB3' ' O ' ' A' ' 136' ' ' GLY . 20.8 t80 -61.68 -48.14 82.16 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 115.526 -0.761 . . . . 0.0 110.076 178.227 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 37.5 m-85 -63.27 -40.32 97.06 Favored 'General case' 0 C--O 1.232 0.156 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.971 179.537 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 141' ' ' LEU . . . . . 0.454 HD13 ' O ' ' A' ' 137' ' ' LEU . 11.1 mp -54.63 -55.06 33.48 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.09 -179.824 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 10.7 p -76.95 -15.93 14.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-O 121.024 0.44 . . . . 0.0 110.985 179.911 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . -73.55 -133.34 0.22 Allowed Glycine 0 CA--C 1.522 0.528 0 C-N-CA 120.867 -0.683 . . . . 0.0 112.812 -179.883 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 144' ' ' PRO . . . . . . . . . . . . . 52.2 Cg_exo -55.5 -28.56 64.98 Favored 'Trans proline' 0 C--N 1.349 0.579 0 C-N-CA 122.746 2.297 . . . . 0.0 112.885 -179.653 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 145' ' ' MET . . . . . 0.43 ' HE1' HG11 ' A' ' 101' ' ' VAL . 43.2 mtt -56.67 -36.31 69.43 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.382 -0.372 . . . . 0.0 111.352 -179.875 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 146' ' ' THR . . . . . . . . . . . . . 24.7 m -68.09 -48.0 66.71 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.836 -179.303 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 20.0 mm-40 -71.16 -26.31 62.93 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.557 -0.292 . . . . 0.0 111.369 -179.544 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 148' ' ' SER . . . . . . . . . . . . . 47.7 t -70.71 -49.47 46.66 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.312 -0.403 . . . . 0.0 111.312 -179.557 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 149' ' ' ALA . . . . . 0.406 ' HB2' ' HB2' ' A' ' 91' ' ' ALA . . . -75.1 -33.87 61.67 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.074 -0.512 . . . . 0.0 111.678 -179.416 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 150' ' ' SER . . . . . . . . . . . . . 43.5 t -67.24 -12.74 60.88 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.328 -179.636 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 151' ' ' GLN . . . . . . . . . . . . . 77.7 mt-30 -119.03 12.1 12.65 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.486 -0.325 . . . . 0.0 111.42 -179.756 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 31.4 tpt180 -84.56 -51.36 6.94 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 120.81 0.338 . . . . 0.0 110.865 -179.759 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 153' ' ' SER . . . . . 0.677 ' HB3' HG12 ' A' ' 156' ' ' ILE . 18.3 t -157.69 172.46 18.48 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 116.119 -0.492 . . . . 0.0 110.715 179.41 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 154' ' ' SER . . . . . . . . . . . . . 47.0 t -68.86 -41.05 78.93 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.303 -0.408 . . . . 0.0 110.802 179.787 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -76.69 -35.79 39.49 Favored Glycine 0 N--CA 1.452 -0.259 0 C-N-CA 120.98 -0.629 . . . . 0.0 112.974 -179.909 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 156' ' ' ILE . . . . . 0.677 HG12 ' HB3' ' A' ' 153' ' ' SER . 43.1 mm -55.34 -36.82 41.99 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.237 0 CA-C-O 120.714 0.292 . . . . 0.0 111.518 -179.769 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 157' ' ' LYS . . . . . 0.421 ' HB3' ' NZ ' ' A' ' 157' ' ' LYS . 6.5 ttpm? -59.51 -53.75 54.53 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 116.415 -0.357 . . . . 0.0 111.759 -179.45 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 42.8 t -67.37 -41.01 85.75 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.445 -0.343 . . . . 0.0 111.714 -179.198 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 159' ' ' LEU . . . . . 0.505 HD23 HD13 ' A' ' 163' ' ' LEU . 4.1 tt -67.72 -34.55 77.08 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 116.432 -0.349 . . . . 0.0 111.045 -179.554 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 160' ' ' TYR . . . . . . . . . . . . . 67.6 t80 -73.88 -45.81 48.6 Favored 'General case' 0 C--N 1.33 -0.278 0 N-CA-C 112.026 0.38 . . . . 0.0 112.026 -179.165 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 22.7 m -59.82 -43.55 92.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 N-CA-C 111.673 0.249 . . . . 0.0 111.673 -179.252 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 162' ' ' ARG . . . . . 0.514 HH22 ' HB2' ' A' ' 215' ' ' ALA . 86.8 mtm180 -68.99 -38.02 79.06 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.77 0.319 . . . . 0.0 111.218 -179.977 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 163' ' ' LEU . . . . . 0.558 ' HG ' ' HB2' ' A' ' 208' ' ' PHE . 3.4 mp -69.5 -54.17 15.51 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.643 -179.58 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 164' ' ' ARG . . . . . . . . . . . . . 4.7 tmm_? -58.71 -53.54 57.2 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.545 -179.236 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 165' ' ' ASN . . . . . 0.507 ' O ' HG23 ' A' ' 169' ' ' VAL . 0.9 OUTLIER -53.59 -52.12 60.81 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 120.876 0.37 . . . . 0.0 111.659 -179.273 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 166' ' ' LEU . . . . . 0.496 ' O ' ' HG ' ' A' ' 170' ' ' LEU . 2.1 tt -61.09 -53.33 58.46 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.065 -0.516 . . . . 0.0 111.771 -179.129 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 167' ' ' THR . . . . . 0.494 ' O ' ' HB2' ' A' ' 171' ' ' TRP . 86.0 m -55.47 -53.7 53.02 Favored 'General case' 0 C--N 1.327 -0.395 0 N-CA-C 112.8 0.667 . . . . 0.0 112.8 -178.661 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 168' ' ' VAL . . . . . . . . . . . . . 89.7 t -54.64 -44.61 70.4 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.244 0 N-CA-C 112.371 0.508 . . . . 0.0 112.371 -178.563 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 169' ' ' VAL . . . . . 0.507 HG23 ' O ' ' A' ' 165' ' ' ASN . 75.4 t -58.43 -64.79 0.5 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.421 0 N-CA-C 112.149 0.426 . . . . 0.0 112.149 -178.962 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 170' ' ' LEU . . . . . 0.496 ' HG ' ' O ' ' A' ' 166' ' ' LEU . 1.4 pp -62.3 -29.75 70.65 Favored 'General case' 0 C--N 1.33 -0.255 0 N-CA-C 112.011 0.374 . . . . 0.0 112.011 -178.863 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 171' ' ' TRP . . . . . 0.494 ' HB2' ' O ' ' A' ' 167' ' ' THR . 2.2 m0 -71.88 -31.2 66.21 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.861 0.362 . . . . 0.0 110.939 179.827 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 172' ' ' ALA . . . . . . . . . . . . . . . -72.18 -6.1 40.36 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.667 179.962 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 173' ' ' ILE . . . . . 0.554 HG22 HD11 ' A' ' 177' ' ' ILE . 29.0 mm -85.24 -21.28 7.91 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.188 0 CA-C-N 115.764 -0.653 . . . . 0.0 111.141 179.79 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 174' ' ' TYR . . . . . 0.445 ' HB2' ' HD3' ' A' ' 175' ' ' PRO . 28.0 m-85 -54.44 -50.47 84.98 Favored Pre-proline 0 N--CA 1.466 0.326 0 CA-C-N 116.437 -0.347 . . . . 0.0 111.673 -179.836 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 175' ' ' PRO . . . . . 0.445 ' HD3' ' HB2' ' A' ' 174' ' ' TYR . 86.7 Cg_exo -45.87 -29.9 6.32 Favored 'Trans proline' 0 C--N 1.353 0.777 0 C-N-CA 122.233 1.955 . . . . 0.0 112.358 179.844 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 176' ' ' PHE . . . . . 0.443 ' O ' ' HG ' ' A' ' 180' ' ' LEU . 92.1 m-85 -80.15 -49.3 11.88 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 115.976 -0.556 . . . . 0.0 111.699 -179.822 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 177' ' ' ILE . . . . . 0.554 HD11 HG22 ' A' ' 173' ' ' ILE . 2.9 mm -60.3 -38.0 75.93 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.528 0 CA-C-N 116.024 -0.535 . . . . 0.0 112.008 -178.459 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 178' ' ' TRP . . . . . 0.409 ' HH2' ' HB2' ' A' ' 123' ' ' ARG . 70.4 t90 -73.32 -44.9 58.13 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.864 0.364 . . . . 0.0 110.922 179.748 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 179' ' ' LEU . . . . . 0.431 ' O ' HG22 ' A' ' 185' ' ' VAL . 1.5 tm? -65.46 -54.22 31.55 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 115.998 -0.546 . . . . 0.0 111.246 -179.323 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 180' ' ' LEU . . . . . 0.5 HD22 ' CD1' ' A' ' 187' ' ' LEU . 18.8 mt -72.46 -45.39 59.73 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.542 -0.299 . . . . 0.0 111.631 -179.267 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 181' ' ' GLY . . . . . 0.405 ' HA3' ' OD1' ' A' ' 193' ' ' ASP . . . -55.35 175.69 0.71 Allowed Glycine 0 C--N 1.336 0.537 0 C-N-CA 120.487 -0.863 . . . . 0.0 112.896 179.646 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 182' ' ' PRO . . . . . 0.654 ' HA ' ' HB2' ' A' ' 186' ' ' ALA . 72.2 Cg_exo -48.07 -45.34 25.64 Favored 'Trans proline' 0 CA--C 1.536 0.596 0 C-N-CA 122.983 2.455 . . . . 0.0 113.86 -179.994 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 183' ' ' PRO . . . . . 0.424 ' HD3' ' HB2' ' A' ' 182' ' ' PRO . 52.2 Cg_exo -53.96 -13.34 4.39 Favored 'Trans proline' 0 C--N 1.355 0.92 0 C-N-CA 122.056 1.837 . . . . 0.0 112.916 -179.853 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 184' ' ' GLY . . . . . 0.423 ' HA3' ' O ' ' A' ' 179' ' ' LEU . . . -115.93 -86.34 1.28 Allowed Glycine 0 N--CA 1.45 -0.414 0 C-N-CA 120.377 -0.916 . . . . 0.0 112.871 -179.779 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 185' ' ' VAL . . . . . 0.431 HG22 ' O ' ' A' ' 179' ' ' LEU . 6.6 m -124.59 -5.06 6.48 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 N-CA-C 112.169 0.433 . . . . 0.0 112.169 -179.495 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 186' ' ' ALA . . . . . 0.654 ' HB2' ' HA ' ' A' ' 182' ' ' PRO . . . 53.41 86.59 0.04 OUTLIER 'General case' 0 N--CA 1.463 0.224 0 CA-C-N 116.479 -0.328 . . . . 0.0 111.682 179.606 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 187' ' ' LEU . . . . . 0.5 ' CD1' HD22 ' A' ' 180' ' ' LEU . 14.1 mt -92.15 -49.36 6.23 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.396 -0.366 . . . . 0.0 111.452 179.851 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 188' ' ' LEU . . . . . 0.468 ' N ' HD12 ' A' ' 188' ' ' LEU . 6.9 mp -92.93 -88.97 0.21 Allowed 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.361 -0.381 . . . . 0.0 111.272 -179.256 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 189' ' ' THR . . . . . . . . . . . . . 1.8 t -169.82 148.7 3.28 Favored Pre-proline 0 C--N 1.325 -0.483 0 CA-C-N 116.01 -0.541 . . . . 0.0 111.078 -179.55 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 190' ' ' PRO . . . . . 0.417 ' O ' HG23 ' A' ' 194' ' ' VAL . 10.2 Cg_endo -51.99 -42.86 56.17 Favored 'Trans proline' 0 C--N 1.35 0.649 0 C-N-CA 122.798 2.332 . . . . 0.0 113.152 -179.761 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 191' ' ' THR . . . . . . . . . . . . . 5.4 t -56.4 -44.74 80.57 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-O 120.689 0.281 . . . . 0.0 111.336 -179.59 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 192' ' ' VAL . . . . . . . . . . . . . 38.5 t -70.56 -43.62 77.62 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.389 -0.369 . . . . 0.0 111.088 179.846 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 193' ' ' ASP . . . . . 0.405 ' OD1' ' HA3' ' A' ' 181' ' ' GLY . 11.3 t70 -55.62 -49.16 73.56 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.942 179.867 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 194' ' ' VAL . . . . . 0.417 HG23 ' O ' ' A' ' 190' ' ' PRO . 85.9 t -63.03 -36.98 78.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.05 -179.985 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 195' ' ' ALA . . . . . . . . . . . . . . . -59.24 -48.41 81.74 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.491 -0.322 . . . . 0.0 110.979 179.827 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 196' ' ' LEU . . . . . . . . . . . . . 65.0 mt -67.91 -43.61 78.84 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.307 -0.406 . . . . 0.0 110.641 179.761 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 197' ' ' ILE . . . . . 0.415 HG12 HG21 ' A' ' 177' ' ' ILE . 17.6 mm -56.51 -59.78 2.59 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 115.961 -0.563 . . . . 0.0 110.444 179.435 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 198' ' ' VAL . . . . . . . . . . . . . 76.8 t -53.06 -34.69 21.5 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.496 0 CA-C-N 115.601 -0.727 . . . . 0.0 109.467 178.512 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 199' ' ' TYR . . . . . . . . . . . . . 64.9 t80 -70.24 -31.61 69.09 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 115.524 -0.762 . . . . 0.0 110.588 179.692 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 200' ' ' LEU . . . . . 0.537 ' O ' HG12 ' A' ' 203' ' ' VAL . 32.2 mt -73.23 -43.44 61.21 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 115.841 -0.618 . . . . 0.0 111.484 -179.478 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 201' ' ' ASP . . . . . . . . . . . . . 10.5 m-20 -71.94 -36.81 70.02 Favored 'General case' 0 C--N 1.327 -0.413 0 CA-C-O 121.251 0.548 . . . . 0.0 110.087 179.511 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 202' ' ' LEU . . . . . . . . . . . . . 39.5 tp -72.73 -27.78 62.25 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 115.311 -0.859 . . . . 0.0 111.779 -179.293 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 203' ' ' VAL . . . . . 0.537 HG12 ' O ' ' A' ' 200' ' ' LEU . 12.3 p -78.71 -35.94 18.96 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.215 0 C-N-CA 120.854 -0.338 . . . . 0.0 110.779 -179.087 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 204' ' ' THR . . . . . 0.418 ' HG1' ' HE1' ' A' ' 171' ' ' TRP . 97.2 m -66.48 -59.0 4.05 Favored 'General case' 0 C--N 1.329 -0.304 0 C-N-CA 120.598 -0.441 . . . . 0.0 110.861 179.34 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 205' ' ' LYS . . . . . 0.596 ' HE2' ' HB2' ' A' ' 47' ' ' ALA . 62.7 mttp -58.76 -57.78 11.5 Favored 'General case' 0 C--N 1.331 -0.209 0 N-CA-C 112.14 0.422 . . . . 0.0 112.14 -178.675 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 49.8 t -70.55 -37.35 69.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 N-CA-C 112.324 0.49 . . . . 0.0 112.324 -178.823 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 207' ' ' GLY . . . . . 0.553 ' O ' HG13 ' A' ' 211' ' ' ILE . . . -55.76 -62.07 6.72 Favored Glycine 0 CA--C 1.518 0.242 0 C-N-CA 120.614 -0.803 . . . . 0.0 113.873 -178.608 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 208' ' ' PHE . . . . . 0.558 ' HB2' ' HG ' ' A' ' 163' ' ' LEU . 3.0 p90 -72.86 -27.63 62.03 Favored 'General case' 0 C--O 1.221 -0.416 0 CA-C-N 117.457 0.628 . . . . 0.0 110.925 -179.231 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 209' ' ' GLY . . . . . 0.555 ' O ' ' HB3' ' A' ' 212' ' ' ALA . . . -62.06 -34.78 90.12 Favored Glycine 0 N--CA 1.449 -0.447 0 N-CA-C 111.91 -0.476 . . . . 0.0 111.91 178.761 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 210' ' ' PHE . . . . . . . . . . . . . 1.2 m-85 -73.59 -48.23 34.35 Favored 'General case' 0 CA--C 1.513 -0.456 0 N-CA-C 108.153 -1.055 . . . . 0.0 108.153 178.398 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 211' ' ' ILE . . . . . 0.553 HG13 ' O ' ' A' ' 207' ' ' GLY . 4.8 mt -61.61 -27.48 42.17 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.51 0 N-CA-C 107.784 -1.191 . . . . 0.0 107.784 176.711 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 212' ' ' ALA . . . . . 0.555 ' HB3' ' O ' ' A' ' 209' ' ' GLY . . . -63.57 -41.75 98.37 Favored 'General case' 0 N--CA 1.45 -0.474 0 CA-C-N 114.478 -1.237 . . . . 0.0 110.664 -179.775 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 213' ' ' LEU . . . . . . . . . . . . . 95.3 mt -69.29 -53.04 21.75 Favored 'General case' 0 C--N 1.332 -0.162 0 CA-C-N 115.26 -0.882 . . . . 0.0 111.398 -179.68 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 214' ' ' ASP . . . . . . . . . . . . . 9.6 m-20 -55.7 -48.66 74.75 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-O 120.878 0.37 . . . . 0.0 110.746 -179.997 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 215' ' ' ALA . . . . . 0.514 ' HB2' HH22 ' A' ' 162' ' ' ARG . . . -59.44 -57.33 13.44 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 115.988 -0.551 . . . . 0.0 110.958 179.721 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 216' ' ' ALA . . . . . . . . . . . . . . . -56.36 -31.55 63.9 Favored 'General case' 0 C--N 1.332 -0.187 0 CA-C-N 116.06 -0.518 . . . . 0.0 111.065 -179.998 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 217' ' ' ALA . . . . . . . . . . . . . . . -62.68 -39.26 93.38 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.407 179.615 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 218' ' ' THR . . . . . . . . . . . . . 79.1 m . . . . . 0 C--N 1.329 -0.296 0 CA-C-N 115.81 -0.632 . . . . 0.0 111.044 179.682 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.303 0 N-CA-C 112.506 -0.238 . . . . 0.0 112.506 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 50.6 tp -73.88 -36.13 64.77 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.786 0.327 . . . . 0.0 110.948 179.87 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 73.7 p -61.39 -29.71 70.09 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.115 -0.493 . . . . 0.0 111.19 179.946 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 23.1 p -53.46 -35.42 60.51 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.09 -0.504 . . . . 0.0 111.071 -179.904 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 7' ' ' LEU . . . . . . . . . . . . . 4.1 mm? -60.25 -53.44 57.65 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.034 -0.53 . . . . 0.0 111.101 179.991 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 8' ' ' PHE . . . . . . . . . . . . . 81.4 m-85 -59.89 -37.1 78.44 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 120.964 0.412 . . . . 0.0 110.806 179.951 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 9' ' ' TRP . . . . . . . . . . . . . 35.9 m95 -63.57 -41.58 98.39 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 115.897 -0.592 . . . . 0.0 110.173 -179.972 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 38.5 mt -64.85 -49.02 72.2 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-N 115.767 -0.651 . . . . 0.0 110.159 179.244 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . 0.438 ' HA2' HD11 ' A' ' 202' ' ' LEU . . . -57.19 -28.09 58.33 Favored Glycine 0 N--CA 1.447 -0.571 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.216 179.293 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -74.09 -38.48 63.87 Favored 'General case' 0 C--N 1.332 -0.186 0 CA-C-O 120.714 0.292 . . . . 0.0 110.79 179.636 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 63.6 mt -61.87 -54.18 38.04 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.31 -0.404 . . . . 0.0 110.436 179.475 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -60.96 -35.23 90.25 Favored Glycine 0 N--CA 1.45 -0.41 0 C-N-CA 120.591 -0.814 . . . . 0.0 111.676 179.257 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 15' ' ' MET . . . . . 0.542 ' SD ' ' HA ' ' A' ' 44' ' ' SER . 47.5 tpp -64.51 -39.98 94.79 Favored 'General case' 0 N--CA 1.454 -0.246 0 N-CA-C 110.167 -0.309 . . . . 0.0 110.167 179.343 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 16' ' ' LEU . . . . . 0.498 HD13 ' O ' ' A' ' 16' ' ' LEU . 0.7 OUTLIER -59.91 -37.55 79.76 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 116.018 -0.537 . . . . 0.0 109.571 179.1 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 94.0 t -59.07 -50.5 79.53 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.172 0 CA-C-N 115.937 -0.574 . . . . 0.0 110.107 179.1 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -61.45 -45.33 96.6 Favored Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.64 -0.791 . . . . 0.0 111.726 179.163 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 32.8 m -51.7 -44.76 63.28 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-O 120.678 0.275 . . . . 0.0 111.301 -179.858 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 81.2 mt -71.59 -36.54 70.89 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.321 -0.4 . . . . 0.0 111.172 179.904 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -63.23 -33.29 75.17 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.348 -0.387 . . . . 0.0 111.338 -179.873 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 22' ' ' PHE . . . . . 0.512 ' HB2' HG22 ' A' ' 41' ' ' VAL . 4.1 m-85 -90.86 -28.76 17.94 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.296 -0.411 . . . . 0.0 111.185 -179.472 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -71.77 -50.69 27.69 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.943 0.402 . . . . 0.0 111.118 179.919 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 24' ' ' TRP . . . . . . . . . . . . . 3.2 t-105 -64.41 -44.66 90.53 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 115.86 -0.609 . . . . 0.0 110.938 -179.946 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.329 -0.3 0 CA-C-O 120.895 0.379 . . . . 0.0 110.915 179.776 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.454 -0.144 0 N-CA-C 112.588 -0.205 . . . . 0.0 112.588 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 2.9 mp0 -68.34 -20.86 64.76 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 120.727 0.299 . . . . 0.0 110.944 -179.957 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 34' ' ' ARG . . . . . . . . . . . . . 78.9 ttt180 -57.63 -28.95 64.15 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.501 -179.619 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 27.7 tpt180 -59.17 -48.4 81.75 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.704 0.288 . . . . 0.0 111.508 -179.607 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 80.7 m-85 -64.96 -29.81 70.76 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.432 -0.349 . . . . 0.0 111.427 -179.511 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 37' ' ' TYR . . . . . 0.531 ' O ' HG23 ' A' ' 41' ' ' VAL . 52.2 m-85 -74.31 -54.27 8.01 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.413 -0.358 . . . . 0.0 111.342 -179.521 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 83.3 t -56.93 -36.32 49.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-O 120.969 0.414 . . . . 0.0 110.372 179.747 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 53.8 m -65.78 -51.53 58.29 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 115.846 -0.616 . . . . 0.0 110.929 179.518 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 40' ' ' LEU . . . . . 0.608 HD12 HD12 ' A' ' 43' ' ' ILE . 54.2 tp -59.23 -48.12 82.79 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 115.986 -0.552 . . . . 0.0 110.802 -179.94 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . 0.531 HG23 ' O ' ' A' ' 37' ' ' TYR . 67.6 t -57.86 -34.88 49.44 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.075 -0.511 . . . . 0.0 109.976 179.058 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -62.4 -36.23 92.82 Favored Glycine 0 N--CA 1.447 -0.606 0 C-N-CA 120.738 -0.744 . . . . 0.0 111.724 179.563 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 43' ' ' ILE . . . . . 0.608 HD12 HD12 ' A' ' 40' ' ' LEU . 1.9 mt -65.25 -55.14 21.79 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.187 0 CA-C-O 120.903 0.383 . . . . 0.0 110.935 179.629 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 44' ' ' SER . . . . . 0.542 ' HA ' ' SD ' ' A' ' 15' ' ' MET . 77.9 p -59.7 -26.23 65.42 Favored 'General case' 0 C--N 1.331 -0.201 0 CA-C-N 115.92 -0.582 . . . . 0.0 111.782 -179.529 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -76.16 -54.97 4.97 Favored Glycine 0 CA--C 1.52 0.39 0 C-N-CA 120.573 -0.823 . . . . 0.0 112.858 -179.513 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 46' ' ' ILE . . . . . 0.507 ' O ' HG22 ' A' ' 49' ' ' VAL . 20.5 pt -59.25 -35.8 59.91 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.219 0 CA-C-O 120.974 0.416 . . . . 0.0 111.13 -179.935 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 47' ' ' ALA . . . . . 0.684 ' HB2' ' HE2' ' A' ' 205' ' ' LYS . . . -68.16 -45.56 73.16 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.031 179.341 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -54.83 -41.94 71.32 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 115.87 -0.605 . . . . 0.0 111.769 -179.448 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 49' ' ' VAL . . . . . 0.507 HG22 ' O ' ' A' ' 46' ' ' ILE . 19.3 m -72.42 -34.19 47.89 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-N 116.521 -0.308 . . . . 0.0 111.138 -179.519 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -67.0 -34.73 78.4 Favored 'General case' 0 C--N 1.331 -0.2 0 CA-C-O 120.872 0.368 . . . . 0.0 111.227 179.853 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 28.3 m-85 -72.44 -41.34 66.25 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.623 -179.737 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -64.04 -46.71 83.2 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 115.769 -0.65 . . . . 0.0 111.245 -179.816 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 53' ' ' VAL . . . . . 0.623 ' O ' HG22 ' A' ' 58' ' ' VAL . 31.9 m -62.96 -53.61 44.39 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.159 0 CA-C-N 116.425 -0.352 . . . . 0.0 111.039 -179.903 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 54' ' ' MET . . . . . 0.546 ' N ' HG23 ' A' ' 53' ' ' VAL . 74.0 mtm -60.08 -31.1 69.7 Favored 'General case' 0 C--N 1.332 -0.182 0 CA-C-O 120.996 0.426 . . . . 0.0 110.289 179.659 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -64.9 -37.88 89.1 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 115.758 -0.655 . . . . 0.0 111.196 179.363 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 93.3 mt -71.15 -2.75 16.83 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.462 -179.586 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 93.66 -5.85 73.73 Favored Glycine 0 N--CA 1.45 -0.368 0 C-N-CA 120.597 -0.811 . . . . 0.0 112.925 179.702 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 58' ' ' VAL . . . . . 0.623 HG22 ' O ' ' A' ' 53' ' ' VAL . 1.5 m -72.64 154.2 7.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-O 120.718 0.294 . . . . 0.0 110.33 179.714 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 73.85 19.27 79.75 Favored Glycine 0 N--CA 1.45 -0.373 0 C-N-CA 120.483 -0.865 . . . . 0.0 112.188 -179.433 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 60' ' ' TRP . . . . . . . . . . . . . 22.0 m0 -99.11 99.26 10.24 Favored 'General case' 0 C--N 1.33 -0.259 0 N-CA-C 109.981 -0.377 . . . . 0.0 109.981 179.824 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 61' ' ' VAL . . . . . 0.563 ' HB ' HG23 ' A' ' 68' ' ' VAL . 61.4 t -97.95 109.51 51.75 Favored Pre-proline 0 C--N 1.324 -0.507 0 CA-C-N 115.996 -0.547 . . . . 0.0 111.542 -179.113 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 39.6 Cg_endo -66.2 135.74 41.35 Favored 'Trans proline' 0 C--N 1.35 0.639 0 C-N-CA 122.532 2.155 . . . . 0.0 112.085 179.731 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 80.9 t -137.89 95.13 1.06 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.38 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.387 -179.604 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . 58.11 -90.16 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.111 -0.495 . . . . 0.0 111.566 179.855 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 44.7 mt-10 -115.45 -24.67 8.26 Favored 'General case' 0 C--N 1.332 -0.193 0 CA-C-O 120.842 0.353 . . . . 0.0 111.157 -179.842 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 66' ' ' ARG . . . . . 0.424 ' HD2' ' N ' ' A' ' 66' ' ' ARG . 9.3 mpt_? -105.74 154.07 20.99 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.415 179.871 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 90.7 m -117.39 115.5 25.33 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.892 0.377 . . . . 0.0 111.433 -179.696 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 68' ' ' VAL . . . . . 0.563 HG23 ' HB ' ' A' ' 61' ' ' VAL . 29.0 m -83.81 146.34 6.99 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.368 0 CA-C-N 115.914 -0.584 . . . . 0.0 110.891 179.672 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 69' ' ' PHE . . . . . . . . . . . . . 64.8 m-85 -108.92 115.87 30.9 Favored 'General case' 0 N--CA 1.443 -0.794 0 CA-C-N 116.273 -0.421 . . . . 0.0 110.185 -179.377 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 70' ' ' VAL . . . . . 0.526 ' HB ' ' HD3' ' A' ' 71' ' ' PRO . 24.5 t -67.49 -49.6 40.84 Favored Pre-proline 0 C--N 1.325 -0.477 0 N-CA-C 112.616 0.599 . . . . 0.0 112.616 -178.932 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 71' ' ' PRO . . . . . 0.526 ' HD3' ' HB ' ' A' ' 70' ' ' VAL . 15.4 Cg_exo -67.08 -17.93 51.16 Favored 'Trans proline' 0 C--N 1.351 0.702 0 C-N-CA 122.315 2.01 . . . . 0.0 113.091 -178.918 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 67.2 ttt180 -66.66 -55.5 14.92 Favored 'General case' 0 C--O 1.237 0.396 0 CA-C-O 120.838 0.351 . . . . 0.0 111.626 -179.404 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 73' ' ' TYR . . . . . 0.475 ' O ' HG13 ' A' ' 77' ' ' ILE . 65.4 m-85 -71.52 -34.54 70.15 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.486 -0.324 . . . . 0.0 110.603 -179.453 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 74' ' ' ILE . . . . . 0.51 ' HA ' HD12 ' A' ' 77' ' ' ILE . 0.4 OUTLIER -66.48 -37.86 80.5 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.242 0 N-CA-C 109.833 -0.432 . . . . 0.0 109.833 179.182 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 13.8 t70 -59.14 -38.95 80.89 Favored 'General case' 0 CA--C 1.517 -0.288 0 N-CA-C 109.128 -0.693 . . . . 0.0 109.128 178.62 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 76' ' ' TRP . . . . . . . . . . . . . 51.1 m0 -65.58 -32.67 74.38 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 115.59 -0.732 . . . . 0.0 110.236 179.138 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 77' ' ' ILE . . . . . 0.51 HD12 ' HA ' ' A' ' 74' ' ' ILE . 69.0 mt -68.76 -28.61 40.55 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.25 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.078 178.984 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 34.0 mt -92.22 -20.43 21.18 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 115.772 -0.649 . . . . 0.0 112.332 179.949 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 82.1 p -103.93 -52.94 2.85 Favored 'General case' 0 N--CA 1.465 0.279 0 N-CA-C 114.025 1.12 . . . . 0.0 114.025 -177.295 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 80' ' ' THR . . . . . 0.456 ' N ' ' HD2' ' A' ' 81' ' ' PRO . 25.3 m -50.41 -54.81 30.86 Favored Pre-proline 0 C--N 1.329 -0.317 0 N-CA-C 113.016 0.747 . . . . 0.0 113.016 -178.007 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 81' ' ' PRO . . . . . 0.485 ' HA ' HG22 ' A' ' 84' ' ' VAL . 20.5 Cg_endo -59.78 -21.27 62.86 Favored 'Trans proline' 0 C--N 1.35 0.654 0 C-N-CA 121.346 1.364 . . . . 0.0 111.141 -179.655 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 82' ' ' LEU . . . . . 0.528 HD23 HG12 ' A' ' 43' ' ' ILE . 13.4 tp -77.13 -33.55 56.76 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 115.58 -0.736 . . . . 0.0 109.829 179.436 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 83' ' ' ILE . . . . . 0.421 HD11 HG21 ' A' ' 43' ' ' ILE . 35.2 mm -70.29 -53.44 23.08 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.191 0 CA-C-N 115.984 -0.553 . . . . 0.0 109.848 179.063 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 84' ' ' VAL . . . . . 0.485 HG22 ' HA ' ' A' ' 81' ' ' PRO . 33.9 m -59.51 -30.19 43.98 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.183 0 N-CA-C 109.546 -0.539 . . . . 0.0 109.546 178.863 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 85' ' ' TYR . . . . . 0.426 ' HB2' ' O ' ' A' ' 81' ' ' PRO . 68.3 t80 -69.74 -32.57 71.18 Favored 'General case' 0 N--CA 1.454 -0.26 0 CA-C-N 115.537 -0.756 . . . . 0.0 109.623 178.873 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 86' ' ' PHE . . . . . . . . . . . . . 9.9 t80 -61.33 -51.93 66.78 Favored 'General case' 0 C--O 1.232 0.149 0 CA-C-N 115.919 -0.582 . . . . 0.0 109.857 179.326 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 87' ' ' LEU . . . . . 0.402 ' N ' HD12 ' A' ' 87' ' ' LEU . 8.1 mp -61.01 -33.16 72.83 Favored 'General case' 0 C--N 1.332 -0.189 0 CA-C-N 115.873 -0.603 . . . . 0.0 110.08 179.374 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 88' ' ' GLY . . . . . 0.427 ' HA2' HD13 ' A' ' 93' ' ' LEU . . . -67.22 -27.74 73.56 Favored Glycine 0 N--CA 1.449 -0.49 0 C-N-CA 120.836 -0.697 . . . . 0.0 111.755 179.233 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 79.3 mt -72.89 -42.95 63.08 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-O 120.924 0.392 . . . . 0.0 110.468 179.622 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 54.9 mt -59.59 -43.83 93.57 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 115.822 -0.626 . . . . 0.0 110.972 179.878 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 91' ' ' ALA . . . . . 0.49 ' HB2' ' HB2' ' A' ' 149' ' ' ALA . . . -74.46 -55.05 6.39 Favored 'General case' 0 C--N 1.331 -0.21 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.325 -179.886 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 103.55 51.62 0.96 Allowed Glycine 0 N--CA 1.452 -0.251 0 C-N-CA 120.843 -0.694 . . . . 0.0 112.447 179.959 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 93' ' ' LEU . . . . . 0.601 HD23 ' HB3' ' A' ' 97' ' ' GLU . 7.9 mp -65.77 170.83 4.83 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.875 0.369 . . . . 0.0 111.193 -179.884 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 94' ' ' ASP . . . . . . . . . . . . . 5.5 m-20 -85.05 164.66 18.09 Favored 'General case' 0 C--N 1.33 -0.239 0 CA-C-N 116.057 -0.519 . . . . 0.0 110.435 179.643 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 46.8 t -55.86 -34.63 65.65 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.326 -0.397 . . . . 0.0 110.97 -179.753 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 96' ' ' ARG . . . . . 0.468 ' HA ' ' NE ' ' A' ' 96' ' ' ARG . 5.6 tpm_? -73.69 -44.87 55.41 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.254 -0.43 . . . . 0.0 111.195 -179.914 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 97' ' ' GLU . . . . . 0.601 ' HB3' HD23 ' A' ' 93' ' ' LEU . 39.1 mt-10 -54.58 -47.39 73.36 Favored 'General case' 0 C--N 1.333 -0.129 0 CA-C-N 116.274 -0.421 . . . . 0.0 111.102 -179.777 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 98' ' ' PHE . . . . . 0.491 ' O ' HG12 ' A' ' 102' ' ' ILE . 41.1 m-85 -58.31 -48.85 79.19 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.859 0.362 . . . . 0.0 110.571 179.489 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -54.25 -29.89 46.67 Favored Glycine 0 N--CA 1.45 -0.383 0 C-N-CA 120.662 -0.78 . . . . 0.0 112.466 179.816 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 100' ' ' ILE . . . . . 0.472 HD12 ' HA ' ' A' ' 97' ' ' GLU . 66.6 mt -73.81 -48.32 39.99 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.229 0 N-CA-C 112.02 0.378 . . . . 0.0 112.02 -179.735 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 101' ' ' VAL . . . . . 0.431 HG12 ' H ' ' A' ' 101' ' ' VAL . 1.4 p -68.84 -41.76 82.34 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.246 0 N-CA-C 112.044 0.387 . . . . 0.0 112.044 -179.404 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 102' ' ' ILE . . . . . 0.491 HG12 ' O ' ' A' ' 98' ' ' PHE . 42.6 mm -64.58 -48.24 85.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.774 -0.194 . . . . 0.0 111.368 -179.358 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 14.7 t -60.95 -34.24 74.42 Favored 'General case' 0 C--N 1.332 -0.166 0 CA-C-O 120.83 0.347 . . . . 0.0 110.385 179.784 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 104' ' ' LEU . . . . . 0.454 HD22 ' HE2' ' A' ' 140' ' ' TYR . 38.0 tp -62.02 -52.92 62.02 Favored 'General case' 0 C--N 1.332 -0.174 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.251 179.296 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 105' ' ' ASN . . . . . 0.559 ' N ' HD22 ' A' ' 105' ' ' ASN . 0.8 OUTLIER -56.95 -27.4 61.13 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.765 179.524 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 30.9 m -64.9 -56.97 10.12 Favored 'General case' 0 C--N 1.332 -0.183 0 CA-C-N 116.313 -0.403 . . . . 0.0 111.481 -179.863 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 107' ' ' VAL . . . . . 0.451 HG12 ' O ' ' A' ' 104' ' ' LEU . 7.4 p -58.93 -36.19 60.39 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.144 0 CA-C-O 120.852 0.358 . . . . 0.0 111.087 -179.892 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . 0.452 HG23 ' O ' ' A' ' 104' ' ' LEU . 91.4 t -61.84 -49.47 84.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.099 -0.5 . . . . 0.0 111.133 179.816 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 109' ' ' MET . . . . . 0.471 ' HG2' ' O ' ' A' ' 105' ' ' ASN . 17.7 mmt -64.52 -31.51 72.75 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.244 -0.434 . . . . 0.0 111.104 179.974 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 27.7 tp -68.05 -36.18 79.45 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.247 179.675 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -62.66 -53.67 51.02 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.067 -0.515 . . . . 0.0 110.539 179.48 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . -62.23 -40.97 99.68 Favored Glycine 0 C--N 1.332 0.327 0 C-N-CA 120.638 -0.791 . . . . 0.0 111.868 179.362 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 113' ' ' PHE . . . . . . . . . . . . . 1.4 t80 -48.88 -68.58 0.17 Allowed 'General case' 0 CA--C 1.52 -0.18 0 N-CA-C 109.858 -0.423 . . . . 0.0 109.858 179.33 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 114' ' ' ALA . . . . . 0.52 ' HA ' ' HB2' ' A' ' 117' ' ' MET . . . -67.49 -15.48 63.69 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-N 115.924 -0.58 . . . . 0.0 110.213 179.365 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 115' ' ' GLY . . . . . 0.666 ' O ' HG22 ' A' ' 118' ' ' VAL . . . -53.65 -49.81 56.25 Favored Glycine 0 C--N 1.336 0.557 0 C-N-CA 120.978 -0.629 . . . . 0.0 111.561 179.299 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 116' ' ' ALA . . . . . 0.4 ' HB1' HG12 ' A' ' 68' ' ' VAL . . . -79.36 -22.11 44.86 Favored 'General case' 0 C--N 1.321 -0.638 0 N-CA-C 111.878 0.325 . . . . 0.0 111.878 179.902 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 117' ' ' MET . . . . . 0.52 ' HB2' ' HA ' ' A' ' 114' ' ' ALA . 0.2 OUTLIER -76.67 19.45 0.27 Allowed 'General case' 0 C--N 1.328 -0.33 0 N-CA-C 112.363 0.505 . . . . 0.0 112.363 -178.84 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 118' ' ' VAL . . . . . 0.666 HG22 ' O ' ' A' ' 115' ' ' GLY . 23.3 m -123.67 138.71 30.78 Favored Pre-proline 0 C--N 1.33 -0.278 0 C-N-CA 121.131 -0.227 . . . . 0.0 111.369 179.823 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 119' ' ' PRO . . . . . . . . . . . . . 77.4 Cg_endo -96.63 23.47 0.33 Allowed 'Trans proline' 0 N--CA 1.455 -0.787 0 C-N-CA 123.19 2.593 . . . . 0.0 112.769 179.892 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -139.73 -159.16 7.87 Favored Glycine 0 C--N 1.332 0.308 0 C-N-CA 120.493 -0.86 . . . . 0.0 113.215 -179.578 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 121' ' ' ILE . . . . . 0.427 HG22 ' O ' ' A' ' 121' ' ' ILE . 14.3 mm -80.33 1.89 2.7 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.205 0 CA-C-O 121.136 0.493 . . . . 0.0 110.938 -179.77 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 33.6 mt-10 -59.34 -37.39 77.71 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 115.799 -0.637 . . . . 0.0 110.89 -179.991 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 123' ' ' ARG . . . . . 0.538 ' HB2' ' HH2' ' A' ' 178' ' ' TRP . 3.7 ptp180 -50.6 -32.99 20.41 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.018 -0.537 . . . . 0.0 111.654 -179.659 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 124' ' ' TYR . . . . . . . . . . . . . 91.3 m-85 -71.57 -33.2 68.88 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.385 -0.371 . . . . 0.0 111.236 -179.645 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 125' ' ' ALA . . . . . . . . . . . . . . . -70.07 -50.86 36.8 Favored 'General case' 0 C--O 1.237 0.405 0 CA-C-O 120.995 0.426 . . . . 0.0 110.047 179.194 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 126' ' ' LEU . . . . . 0.439 HD22 ' HA2' ' A' ' 115' ' ' GLY . 8.2 mp -55.55 -54.04 48.94 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 115.695 -0.684 . . . . 0.0 110.074 179.345 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 127' ' ' PHE . . . . . . . . . . . . . 11.0 t80 -63.53 -35.73 81.44 Favored 'General case' 0 N--CA 1.452 -0.374 0 CA-C-N 115.782 -0.645 . . . . 0.0 110.611 179.958 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 128' ' ' GLY . . . . . . . . . . . . . . . -47.46 -44.48 21.87 Favored Glycine 0 C--N 1.332 0.313 0 C-N-CA 120.228 -0.987 . . . . 0.0 110.805 179.138 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 129' ' ' MET . . . . . . . . . . . . . 0.3 OUTLIER -70.51 -36.56 73.83 Favored 'General case' 0 N--CA 1.453 -0.318 0 N-CA-C 109.828 -0.434 . . . . 0.0 109.828 178.688 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -66.52 -28.56 73.81 Favored Glycine 0 C--N 1.332 0.342 0 CA-C-N 115.702 -0.681 . . . . 0.0 112.839 -179.993 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -74.67 -53.7 8.81 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-O 120.699 0.285 . . . . 0.0 110.358 179.83 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 98.4 t -57.84 -39.91 73.49 Favored 'Isoleucine or valine' 0 C--O 1.234 0.276 0 N-CA-C 109.024 -0.732 . . . . 0.0 109.024 178.433 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -67.23 -33.92 76.37 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 115.123 -0.944 . . . . 0.0 110.642 179.269 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 134' ' ' PHE . . . . . 0.425 ' CZ ' ' HA ' ' A' ' 172' ' ' ALA . 74.6 t80 -56.43 -55.81 28.92 Favored 'General case' 0 N--CA 1.449 -0.484 0 CA-C-O 120.926 0.393 . . . . 0.0 109.951 179.388 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 135' ' ' ILE . . . . . 0.421 ' O ' HG22 ' A' ' 138' ' ' VAL . 40.1 mt -56.58 -33.23 39.14 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.298 0 CA-C-N 115.761 -0.654 . . . . 0.0 109.876 178.942 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . -61.44 -36.9 93.24 Favored Glycine 0 N--CA 1.447 -0.574 0 C-N-CA 120.424 -0.893 . . . . 0.0 111.456 179.067 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 137' ' ' LEU . . . . . 0.545 HD13 HD21 ' A' ' 105' ' ' ASN . 47.9 tp -72.22 -54.02 10.85 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-O 120.527 0.203 . . . . 0.0 110.633 179.657 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 138' ' ' VAL . . . . . 0.421 HG22 ' O ' ' A' ' 135' ' ' ILE . 3.4 m -56.17 -31.51 32.08 Favored 'Isoleucine or valine' 0 C--O 1.233 0.192 0 CA-C-O 121.242 0.544 . . . . 0.0 109.676 179.462 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 139' ' ' TYR . . . . . . . . . . . . . 24.9 t80 -63.41 -46.96 83.98 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 115.432 -0.804 . . . . 0.0 110.311 178.819 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 140' ' ' TYR . . . . . 0.454 ' HE2' HD22 ' A' ' 104' ' ' LEU . 17.2 m-85 -58.89 -37.98 77.84 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.626 179.638 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 141' ' ' LEU . . . . . . . . . . . . . 62.6 mt -57.61 -48.2 80.07 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.189 179.542 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 17.1 t -78.31 -12.58 13.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 115.943 -0.571 . . . . 0.0 110.658 179.654 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 143' ' ' GLY . . . . . 0.43 ' HA3' ' HD2' ' A' ' 144' ' ' PRO . . . -72.44 -134.62 0.18 Allowed Glycine 0 CA--C 1.521 0.425 0 C-N-CA 120.982 -0.627 . . . . 0.0 112.906 -179.845 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 144' ' ' PRO . . . . . 0.43 ' HD2' ' HA3' ' A' ' 143' ' ' GLY . 20.7 Cg_endo -60.43 -23.72 75.76 Favored 'Trans proline' 0 C--N 1.349 0.586 0 C-N-CA 122.647 2.231 . . . . 0.0 112.593 -179.658 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 145' ' ' MET . . . . . . . . . . . . . 55.1 mtt -59.33 -36.73 76.2 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.507 -0.315 . . . . 0.0 111.303 -179.865 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 146' ' ' THR . . . . . . . . . . . . . 86.2 m -79.63 -42.33 25.09 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.508 -0.314 . . . . 0.0 111.431 -179.154 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 8.8 tp10 -61.84 -41.46 97.83 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.243 -179.784 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 148' ' ' SER . . . . . . . . . . . . . 48.7 m -70.61 -46.32 63.59 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.263 -0.426 . . . . 0.0 111.614 -179.325 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 149' ' ' ALA . . . . . 0.49 ' HB2' ' HB2' ' A' ' 91' ' ' ALA . . . -68.33 -30.71 69.75 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.3 -0.409 . . . . 0.0 111.892 -179.206 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 150' ' ' SER . . . . . . . . . . . . . 43.3 t -72.36 -5.9 39.62 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.439 -0.346 . . . . 0.0 111.656 -179.275 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 151' ' ' GLN . . . . . . . . . . . . . 10.3 pt20 -133.55 5.79 3.74 Favored 'General case' 0 C--N 1.33 -0.251 0 N-CA-C 111.649 0.24 . . . . 0.0 111.649 -179.835 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 1.6 tmt_? -73.69 -51.88 15.15 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-O 120.994 0.426 . . . . 0.0 110.251 179.946 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 153' ' ' SER . . . . . 0.637 ' HB2' HG12 ' A' ' 156' ' ' ILE . 49.1 m -158.1 172.08 19.06 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-N 115.759 -0.655 . . . . 0.0 110.256 179.227 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 154' ' ' SER . . . . . . . . . . . . . 88.6 p -70.65 -37.67 73.76 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-O 120.883 0.373 . . . . 0.0 110.474 179.542 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -76.98 -30.26 55.95 Favored Glycine 0 N--CA 1.452 -0.276 0 C-N-CA 120.935 -0.65 . . . . 0.0 112.751 -179.914 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 156' ' ' ILE . . . . . 0.637 HG12 ' HB2' ' A' ' 153' ' ' SER . 39.1 mm -64.48 -39.21 84.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-O 120.765 0.317 . . . . 0.0 111.243 -179.988 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 157' ' ' LYS . . . . . . . . . . . . . 87.1 tttt -63.55 -41.28 98.44 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 116.306 -0.406 . . . . 0.0 111.624 -179.37 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 87.9 p -71.34 -48.33 51.02 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-O 120.956 0.408 . . . . 0.0 111.493 -179.338 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 159' ' ' LEU . . . . . 0.554 HD21 ' HB3' ' A' ' 215' ' ' ALA . 17.4 mt -66.77 -31.85 72.75 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 116.084 -0.507 . . . . 0.0 111.726 -179.269 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 160' ' ' TYR . . . . . . . . . . . . . 50.9 t80 -74.25 -46.79 39.3 Favored 'General case' 0 C--N 1.327 -0.372 0 N-CA-C 112.051 0.389 . . . . 0.0 112.051 -178.841 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 24.4 m -60.12 -44.74 95.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 N-CA-C 111.848 0.314 . . . . 0.0 111.848 -179.154 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 162' ' ' ARG . . . . . 0.487 ' HG2' HG21 ' A' ' 211' ' ' ILE . 22.3 tpp180 -68.88 -40.88 79.01 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.755 0.312 . . . . 0.0 111.638 -179.598 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 163' ' ' LEU . . . . . 0.631 ' HG ' ' HB2' ' A' ' 208' ' ' PHE . 6.3 mp -69.23 -55.14 11.45 Favored 'General case' 0 C--N 1.329 -0.323 0 N-CA-C 112.77 0.656 . . . . 0.0 112.77 -178.724 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 164' ' ' ARG . . . . . 0.493 ' O ' HG23 ' A' ' 168' ' ' VAL . 5.0 ppt_? -61.04 -45.5 94.5 Favored 'General case' 0 C--N 1.328 -0.339 0 N-CA-C 112.28 0.474 . . . . 0.0 112.28 -178.316 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 165' ' ' ASN . . . . . 0.499 ' O ' HG23 ' A' ' 169' ' ' VAL . 9.5 m-80 -59.88 -51.48 69.5 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.763 0.316 . . . . 0.0 111.28 -179.736 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 166' ' ' LEU . . . . . 0.473 ' O ' ' HG ' ' A' ' 170' ' ' LEU . 3.2 tt -61.21 -50.84 71.49 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.461 -179.511 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 167' ' ' THR . . . . . 0.439 ' O ' ' HB2' ' A' ' 171' ' ' TRP . 92.1 m -55.01 -53.32 57.31 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 115.911 -0.586 . . . . 0.0 112.514 -178.999 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 168' ' ' VAL . . . . . 0.493 HG23 ' O ' ' A' ' 164' ' ' ARG . 85.3 t -55.16 -43.97 72.67 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.236 0 N-CA-C 112.044 0.387 . . . . 0.0 112.044 -178.803 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 169' ' ' VAL . . . . . 0.499 HG23 ' O ' ' A' ' 165' ' ' ASN . 72.3 t -56.41 -65.05 0.42 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 N-CA-C 111.969 0.359 . . . . 0.0 111.969 -179.288 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 170' ' ' LEU . . . . . 0.473 ' HG ' ' O ' ' A' ' 166' ' ' LEU . 0.7 OUTLIER -64.76 -28.08 69.33 Favored 'General case' 0 C--N 1.331 -0.238 0 N-CA-C 112.238 0.458 . . . . 0.0 112.238 -178.852 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 171' ' ' TRP . . . . . 0.439 ' HB2' ' O ' ' A' ' 167' ' ' THR . 4.0 m0 -71.13 -30.01 65.96 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-O 121.006 0.431 . . . . 0.0 110.495 179.495 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 172' ' ' ALA . . . . . 0.425 ' HA ' ' CZ ' ' A' ' 134' ' ' PHE . . . -72.67 -6.36 43.85 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 115.917 -0.583 . . . . 0.0 111.056 -179.722 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 173' ' ' ILE . . . . . 0.51 HG22 HD11 ' A' ' 177' ' ' ILE . 21.6 mm -87.29 -21.82 7.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 115.93 -0.577 . . . . 0.0 111.288 -179.972 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 174' ' ' TYR . . . . . 0.597 ' N ' ' HD2' ' A' ' 175' ' ' PRO . 37.0 m-85 -54.35 -51.24 79.66 Favored Pre-proline 0 CA--C 1.532 0.267 0 N-CA-C 111.955 0.354 . . . . 0.0 111.955 -179.762 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 175' ' ' PRO . . . . . 0.597 ' HD2' ' N ' ' A' ' 174' ' ' TYR . 5.3 Cg_endo -48.41 -29.57 13.76 Favored 'Trans proline' 0 C--N 1.352 0.717 0 C-N-CA 122.106 1.87 . . . . 0.0 112.299 -179.967 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 176' ' ' PHE . . . . . 0.475 ' HD2' ' HA ' ' A' ' 173' ' ' ILE . 58.9 m-85 -80.84 -49.45 11.05 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.044 -0.525 . . . . 0.0 112.053 -179.885 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 177' ' ' ILE . . . . . 0.51 HD11 HG22 ' A' ' 173' ' ' ILE . 4.4 mm -62.47 -34.79 66.55 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.496 0 N-CA-C 112.389 0.515 . . . . 0.0 112.389 -178.155 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 178' ' ' TRP . . . . . 0.538 ' HH2' ' HB2' ' A' ' 123' ' ' ARG . 70.0 t90 -73.71 -46.7 44.56 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-O 121.03 0.443 . . . . 0.0 110.766 179.551 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 179' ' ' LEU . . . . . 0.428 ' O ' HG22 ' A' ' 185' ' ' VAL . 1.7 tm? -69.5 -48.42 60.64 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 115.856 -0.611 . . . . 0.0 111.396 -179.172 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 180' ' ' LEU . . . . . 0.669 HD22 HD11 ' A' ' 187' ' ' LEU . 42.2 mt -75.15 -46.62 33.13 Favored 'General case' 0 C--N 1.327 -0.395 0 N-CA-C 111.911 0.338 . . . . 0.0 111.911 -179.153 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . -58.35 -179.59 1.06 Allowed Glycine 0 C--N 1.336 0.582 0 C-N-CA 120.256 -0.973 . . . . 0.0 112.383 179.767 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 182' ' ' PRO . . . . . 0.662 ' HA ' ' HB2' ' A' ' 186' ' ' ALA . 84.7 Cg_exo -47.05 -44.05 23.84 Favored 'Trans proline' 0 CA--C 1.535 0.571 0 C-N-CA 122.834 2.356 . . . . 0.0 113.94 -179.97 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 183' ' ' PRO . . . . . 0.407 ' CD ' ' N ' ' A' ' 182' ' ' PRO . 74.7 Cg_exo -51.19 -17.71 4.12 Favored 'Trans proline' 0 C--N 1.355 0.891 0 C-N-CA 122.257 1.971 . . . . 0.0 113.456 -179.707 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 184' ' ' GLY . . . . . . . . . . . . . . . -120.51 -92.02 1.27 Allowed Glycine 0 C--N 1.332 0.343 0 C-N-CA 120.207 -0.997 . . . . 0.0 113.294 -179.743 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 185' ' ' VAL . . . . . 0.428 HG22 ' O ' ' A' ' 179' ' ' LEU . 17.8 m -106.39 -13.0 9.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 N-CA-C 112.152 0.427 . . . . 0.0 112.152 -179.004 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 186' ' ' ALA . . . . . 0.662 ' HB2' ' HA ' ' A' ' 182' ' ' PRO . . . 58.36 86.78 0.08 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.794 0.33 . . . . 0.0 111.469 179.848 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 187' ' ' LEU . . . . . 0.669 HD11 HD22 ' A' ' 180' ' ' LEU . 22.8 mt -91.79 -49.02 6.48 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 120.953 0.406 . . . . 0.0 110.968 179.909 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 188' ' ' LEU . . . . . . . . . . . . . 77.5 mt -95.87 -151.66 0.35 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 115.939 -0.573 . . . . 0.0 111.339 -179.365 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 189' ' ' THR . . . . . 0.447 HG22 ' H ' ' A' ' 191' ' ' THR . 29.0 m -96.96 137.45 21.31 Favored Pre-proline 0 C--N 1.331 -0.221 0 CA-C-N 115.922 -0.581 . . . . 0.0 110.852 -179.483 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 190' ' ' PRO . . . . . . . . . . . . . 82.0 Cg_exo -46.95 -29.86 8.97 Favored 'Trans proline' 0 C--N 1.349 0.577 0 C-N-CA 122.478 2.118 . . . . 0.0 112.692 179.9 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 191' ' ' THR . . . . . 0.447 ' H ' HG22 ' A' ' 189' ' ' THR . 76.7 p -77.4 -40.6 43.08 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.486 -0.324 . . . . 0.0 111.412 -179.948 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 192' ' ' VAL . . . . . . . . . . . . . 61.7 t -72.09 -53.27 20.47 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.289 -0.414 . . . . 0.0 111.564 -179.608 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 193' ' ' ASP . . . . . . . . . . . . . 30.7 m-20 -52.15 -48.79 64.74 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.36 -0.382 . . . . 0.0 111.015 -179.921 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 194' ' ' VAL . . . . . 0.489 ' O ' HG22 ' A' ' 198' ' ' VAL . 55.3 t -62.38 -36.38 74.41 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.645 179.724 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 195' ' ' ALA . . . . . . . . . . . . . . . -56.27 -39.84 73.28 Favored 'General case' 0 C--N 1.332 -0.155 0 CA-C-N 116.348 -0.387 . . . . 0.0 110.571 179.344 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 196' ' ' LEU . . . . . . . . . . . . . 96.4 mt -68.43 -39.62 81.49 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.018 -0.537 . . . . 0.0 110.557 179.251 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 197' ' ' ILE . . . . . 0.407 HD11 ' HB ' ' A' ' 177' ' ' ILE . 18.3 mm -60.43 -60.38 2.67 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.254 0 CA-C-N 115.856 -0.611 . . . . 0.0 111.238 179.957 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 198' ' ' VAL . . . . . 0.489 HG22 ' O ' ' A' ' 194' ' ' VAL . 3.3 m -52.98 -36.05 23.36 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.4 0 CA-C-O 121.596 0.712 . . . . 0.0 109.808 179.003 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 199' ' ' TYR . . . . . . . . . . . . . 37.1 t80 -67.97 -33.04 73.89 Favored 'General case' 0 C--N 1.321 -0.666 0 CA-C-N 114.629 -1.168 . . . . 0.0 110.849 179.858 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 200' ' ' LEU . . . . . 0.569 ' O ' HG12 ' A' ' 203' ' ' VAL . 25.5 mt -68.71 -41.85 78.52 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 121.13 0.49 . . . . 0.0 110.844 179.927 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 201' ' ' ASP . . . . . . . . . . . . . 15.8 m-20 -70.09 -33.18 71.56 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-O 121.321 0.581 . . . . 0.0 109.727 179.109 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 202' ' ' LEU . . . . . 0.438 HD11 ' HA2' ' A' ' 11' ' ' GLY . 3.1 mt -72.33 -31.14 65.41 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 115.213 -0.903 . . . . 0.0 112.014 -179.741 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 203' ' ' VAL . . . . . 0.569 HG12 ' O ' ' A' ' 200' ' ' LEU . 13.0 p -76.44 -35.91 27.64 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 C-N-CA 121.06 -0.256 . . . . 0.0 110.958 -178.621 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 204' ' ' THR . . . . . . . . . . . . . 88.8 m -67.66 -58.24 5.01 Favored 'General case' 0 C--N 1.326 -0.443 0 C-N-CA 120.651 -0.42 . . . . 0.0 111.289 179.498 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 205' ' ' LYS . . . . . 0.684 ' HE2' ' HB2' ' A' ' 47' ' ' ALA . 48.7 mttp -62.15 -58.49 7.59 Favored 'General case' 0 C--N 1.329 -0.303 0 N-CA-C 112.21 0.448 . . . . 0.0 112.21 -178.513 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 44.5 t -70.35 -36.22 65.96 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.48 0 CA-C-N 116.025 -0.534 . . . . 0.0 112.068 -178.836 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 207' ' ' GLY . . . . . 0.548 ' O ' HG13 ' A' ' 211' ' ' ILE . . . -58.33 -61.66 7.15 Favored Glycine 0 N--CA 1.452 -0.271 0 C-N-CA 120.634 -0.793 . . . . 0.0 113.844 -178.128 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 208' ' ' PHE . . . . . 0.631 ' HB2' ' HG ' ' A' ' 163' ' ' LEU . 0.8 OUTLIER -72.69 -27.61 62.19 Favored 'General case' 0 C--O 1.221 -0.436 0 CA-C-N 117.515 0.657 . . . . 0.0 110.854 -179.12 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 209' ' ' GLY . . . . . 0.497 ' O ' ' HB3' ' A' ' 212' ' ' ALA . . . -64.1 -31.87 82.29 Favored Glycine 0 N--CA 1.45 -0.399 0 N-CA-C 111.546 -0.622 . . . . 0.0 111.546 178.697 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 210' ' ' PHE . . . . . . . . . . . . . 0.5 OUTLIER -74.79 -47.9 28.32 Favored 'General case' 0 CA--C 1.514 -0.41 0 N-CA-C 108.425 -0.954 . . . . 0.0 108.425 178.451 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 211' ' ' ILE . . . . . 0.548 HG13 ' O ' ' A' ' 207' ' ' GLY . 4.3 mt -63.69 -27.61 43.27 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.45 0 N-CA-C 107.712 -1.218 . . . . 0.0 107.712 176.787 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 212' ' ' ALA . . . . . 0.497 ' HB3' ' O ' ' A' ' 209' ' ' GLY . . . -62.46 -46.1 90.02 Favored 'General case' 0 N--CA 1.449 -0.524 0 CA-C-N 114.469 -1.242 . . . . 0.0 110.549 -179.888 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 213' ' ' LEU . . . . . . . . . . . . . 95.8 mt -70.33 -46.03 65.01 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 115.182 -0.917 . . . . 0.0 111.864 -179.437 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 214' ' ' ASP . . . . . . . . . . . . . 19.9 t70 -56.06 -55.19 35.89 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.466 -0.334 . . . . 0.0 111.604 -179.299 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 215' ' ' ALA . . . . . 0.554 ' HB3' HD21 ' A' ' 159' ' ' LEU . . . -58.95 -53.14 61.77 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.327 -0.397 . . . . 0.0 111.406 -179.559 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 216' ' ' ALA . . . . . . . . . . . . . . . -53.14 -45.08 68.24 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.506 -179.666 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 217' ' ' ALA . . . . . . . . . . . . . . . -55.85 -39.86 72.06 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-O 121.062 0.458 . . . . 0.0 110.301 179.738 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 218' ' ' THR . . . . . . . . . . . . . 92.1 m . . . . . 0 C--N 1.329 -0.306 0 CA-C-N 115.634 -0.712 . . . . 0.0 110.861 179.48 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.33 0 N-CA-C 112.768 -0.133 . . . . 0.0 112.768 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 32.5 tp -74.16 -35.35 64.04 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.808 0.337 . . . . 0.0 110.884 179.967 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 74.7 p -61.67 -30.56 70.81 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.132 -0.486 . . . . 0.0 111.411 -179.985 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 29.0 p -58.98 -36.12 74.36 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-O 120.783 0.325 . . . . 0.0 111.07 -179.852 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 7' ' ' LEU . . . . . . . . . . . . . 4.5 mm? -56.61 -52.06 66.28 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.861 179.862 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 8' ' ' PHE . . . . . 0.667 ' HB2' ' HB2' ' A' ' 55' ' ' ALA . 83.5 m-85 -58.1 -37.84 75.29 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.223 179.477 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 9' ' ' TRP . . . . . . . . . . . . . 15.8 m95 -63.0 -41.81 99.68 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 115.987 -0.551 . . . . 0.0 110.102 -179.987 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 84.9 mt -59.74 -43.87 94.06 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 115.617 -0.719 . . . . 0.0 110.09 179.299 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -61.36 -33.97 86.54 Favored Glycine 0 N--CA 1.448 -0.516 0 C-N-CA 120.656 -0.783 . . . . 0.0 111.554 179.168 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -66.96 -31.23 71.66 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-O 120.912 0.387 . . . . 0.0 110.376 179.447 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 75.5 mt -66.06 -47.52 84.7 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.245 0 CA-C-N 115.985 -0.552 . . . . 0.0 110.097 179.343 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -60.63 -39.43 96.54 Favored Glycine 0 N--CA 1.45 -0.409 0 C-N-CA 120.758 -0.734 . . . . 0.0 111.7 179.315 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 15' ' ' MET . . . . . 0.592 ' HE2' ' HE2' ' A' ' 51' ' ' TYR . 0.1 OUTLIER -63.54 -41.06 98.46 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 120.665 0.269 . . . . 0.0 110.575 179.422 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -55.98 -50.66 70.21 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.758 179.841 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 35.6 t -59.6 -46.4 93.19 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.389 -179.792 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -63.96 -48.5 75.32 Favored Glycine 0 C--N 1.331 0.262 0 C-N-CA 120.718 -0.753 . . . . 0.0 112.437 179.919 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 31.9 m -50.6 -44.24 56.97 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-O 120.723 0.297 . . . . 0.0 111.131 -179.774 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 95.2 mt -72.35 -40.28 67.48 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.622 179.907 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -63.19 -33.78 76.21 Favored 'General case' 0 C--N 1.331 -0.196 0 N-CA-C 112.065 0.395 . . . . 0.0 112.065 -179.294 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 22' ' ' PHE . . . . . 0.66 ' HB2' HG22 ' A' ' 41' ' ' VAL . 7.6 m-85 -86.2 -33.7 20.7 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.657 0.265 . . . . 0.0 111.658 -179.131 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -73.6 -50.7 19.85 Favored 'General case' 0 C--N 1.329 -0.297 0 N-CA-C 111.991 0.367 . . . . 0.0 111.991 -179.206 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 24' ' ' TRP . . . . . . . . . . . . . 2.7 t-105 -58.99 -46.62 87.7 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 116.029 -0.532 . . . . 0.0 111.239 -179.503 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.328 -0.361 0 CA-C-O 120.828 0.347 . . . . 0.0 110.925 179.796 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.3 0 N-CA-C 112.562 -0.215 . . . . 0.0 112.562 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 9.1 mm-40 -60.63 -21.07 62.32 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 120.698 0.285 . . . . 0.0 110.989 179.868 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 34' ' ' ARG . . . . . . . . . . . . . 38.6 ttm180 -48.44 -34.99 11.96 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-N 115.969 -0.559 . . . . 0.0 111.525 -179.758 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 70.3 mtm180 -55.1 -54.84 38.08 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.314 -0.403 . . . . 0.0 111.303 -179.986 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 82.0 m-85 -59.7 -28.7 67.53 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.097 -179.946 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 37' ' ' TYR . . . . . 0.428 ' O ' HG23 ' A' ' 41' ' ' VAL . 52.5 m-85 -71.97 -52.42 17.18 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.3 -0.409 . . . . 0.0 111.314 -179.893 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 59.8 t -57.69 -39.26 69.3 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.219 0 CA-C-O 121.116 0.484 . . . . 0.0 110.528 179.658 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 19.6 m -62.81 -50.93 69.05 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 115.576 -0.738 . . . . 0.0 110.715 179.403 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 40' ' ' LEU . . . . . 0.48 HD21 ' CA ' ' A' ' 209' ' ' GLY . 19.6 tp -57.57 -50.21 73.86 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 115.652 -0.704 . . . . 0.0 110.578 -179.997 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . 0.66 HG22 ' HB2' ' A' ' 22' ' ' PHE . 85.5 t -59.02 -34.9 54.39 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.235 0 CA-C-N 115.856 -0.611 . . . . 0.0 110.236 179.142 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -59.19 -39.56 94.66 Favored Glycine 0 N--CA 1.448 -0.505 0 C-N-CA 120.834 -0.698 . . . . 0.0 112.06 179.652 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 43' ' ' ILE . . . . . 0.535 HG12 HD12 ' A' ' 82' ' ' LEU . 1.2 mt -64.84 -55.59 20.15 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.193 0 CA-C-O 120.683 0.278 . . . . 0.0 110.728 179.567 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 51.3 m -57.72 -23.81 53.7 Favored 'General case' 0 C--O 1.232 0.178 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.181 -179.963 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -78.18 -56.23 3.79 Favored Glycine 0 CA--C 1.518 0.251 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.668 -179.772 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 26.6 pt -58.31 -35.4 53.49 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.215 0 CA-C-O 121.08 0.467 . . . . 0.0 110.912 179.944 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 47' ' ' ALA . . . . . 0.745 ' HB2' ' HE2' ' A' ' 205' ' ' LYS . . . -67.51 -46.74 71.99 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-N 116.031 -0.531 . . . . 0.0 111.307 179.346 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 48' ' ' ALA . . . . . 0.561 ' HB2' ' HB3' ' A' ' 15' ' ' MET . . . -54.87 -40.6 69.87 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 116.04 -0.527 . . . . 0.0 111.951 -179.485 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 25.1 m -73.08 -34.69 46.04 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 CA-C-N 116.63 -0.259 . . . . 0.0 111.516 -179.207 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . 0.403 ' O ' HG22 ' A' ' 53' ' ' VAL . . . -65.96 -38.18 87.93 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-O 121.145 0.498 . . . . 0.0 110.749 179.346 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 51' ' ' TYR . . . . . 0.592 ' HE2' ' HE2' ' A' ' 15' ' ' MET . 42.9 m-85 -73.09 -28.31 62.21 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-N 115.813 -0.631 . . . . 0.0 109.734 179.466 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -72.35 -38.88 68.48 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 115.419 -0.809 . . . . 0.0 110.97 179.517 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 53' ' ' VAL . . . . . 0.575 ' O ' HG22 ' A' ' 58' ' ' VAL . 33.8 m -73.95 -47.49 42.53 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.159 0 CA-C-N 116.402 -0.363 . . . . 0.0 110.78 -179.941 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 54' ' ' MET . . . . . 0.458 ' N ' HG23 ' A' ' 53' ' ' VAL . 75.0 mtm -57.75 -36.44 72.1 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-O 121.241 0.543 . . . . 0.0 109.949 179.094 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 55' ' ' ALA . . . . . 0.667 ' HB2' ' HB2' ' A' ' 8' ' ' PHE . . . -68.91 -11.69 60.86 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 115.317 -0.856 . . . . 0.0 111.705 179.876 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 47.4 mt -97.57 -4.21 38.15 Favored 'General case' 0 C--N 1.33 -0.259 0 N-CA-C 111.944 0.35 . . . . 0.0 111.944 -179.475 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 105.13 -23.0 31.77 Favored Glycine 0 CA--C 1.52 0.352 0 C-N-CA 120.373 -0.917 . . . . 0.0 114.004 179.23 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 58' ' ' VAL . . . . . 0.575 HG22 ' O ' ' A' ' 53' ' ' VAL . 16.3 m -62.05 160.41 2.21 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.128 0 CA-C-N 117.722 0.761 . . . . 0.0 109.768 179.343 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 59' ' ' GLY . . . . . 0.683 ' HA3' ' HD3' ' A' ' 71' ' ' PRO . . . 79.58 -25.56 2.86 Favored Glycine 0 N--CA 1.441 -1.033 0 C-N-CA 119.999 -1.096 . . . . 0.0 112.71 -178.844 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 60' ' ' TRP . . . . . . . . . . . . . 11.6 m0 -67.77 80.13 0.19 Allowed 'General case' 0 C--N 1.327 -0.388 0 N-CA-C 110.176 -0.305 . . . . 0.0 110.176 179.561 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 4.7 p -90.83 119.35 68.96 Favored Pre-proline 0 C--N 1.33 -0.266 0 CA-C-N 116.461 -0.336 . . . . 0.0 111.202 -179.747 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 35.8 Cg_exo -60.49 119.44 6.63 Favored 'Trans proline' 0 C--N 1.35 0.615 0 C-N-CA 122.451 2.101 . . . . 0.0 112.176 179.841 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 78.4 t -117.21 99.59 8.54 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.364 0 CA-C-N 115.931 -0.577 . . . . 0.0 110.918 179.914 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . 59.9 -85.65 0.02 OUTLIER 'General case' 0 C--N 1.332 -0.174 0 CA-C-N 116.095 -0.502 . . . . 0.0 111.254 -179.926 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 53.8 mm-40 -126.74 -26.69 3.18 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.335 179.521 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 66' ' ' ARG . . . . . . . . . . . . . 34.5 ptt180 -95.41 164.23 12.9 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 115.823 -0.626 . . . . 0.0 110.306 179.474 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 13.8 m -114.94 132.02 56.7 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.848 0.356 . . . . 0.0 111.265 -179.999 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 29.4 t -116.78 145.77 22.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.023 -0.535 . . . . 0.0 110.634 179.728 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 69' ' ' PHE . . . . . . . . . . . . . 10.8 m-85 -102.09 119.8 39.39 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-O 120.917 0.389 . . . . 0.0 110.659 -179.357 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 70' ' ' VAL . . . . . 0.632 HG13 ' O ' ' A' ' 59' ' ' GLY . 1.2 m -69.67 -35.57 5.7 Favored Pre-proline 0 CA--C 1.544 0.727 0 N-CA-C 113.05 0.759 . . . . 0.0 113.05 -179.344 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 71' ' ' PRO . . . . . 0.683 ' HD3' ' HA3' ' A' ' 59' ' ' GLY . 8.4 Cg_exo -70.56 -19.87 31.78 Favored 'Trans proline' 0 C--N 1.358 1.055 0 C-N-CA 122.579 2.186 . . . . 0.0 112.88 -178.146 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 72' ' ' ARG . . . . . 0.449 ' NH2' ' HG3' ' A' ' 183' ' ' PRO . 38.5 ttp180 -64.72 -53.46 46.84 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-O 120.949 0.404 . . . . 0.0 110.66 -179.916 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 73' ' ' TYR . . . . . . . . . . . . . 19.6 m-85 -73.19 -37.36 66.51 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.572 -179.97 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 74' ' ' ILE . . . . . 0.605 HG22 ' HA ' ' A' ' 71' ' ' PRO . 0.4 OUTLIER -64.08 -39.86 87.0 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 N-CA-C 109.877 -0.416 . . . . 0.0 109.877 179.439 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 75' ' ' ASP . . . . . 0.409 ' O ' HG23 ' A' ' 79' ' ' THR . 33.9 t70 -64.06 -34.8 78.84 Favored 'General case' 0 CA--C 1.516 -0.362 0 N-CA-C 108.882 -0.785 . . . . 0.0 108.882 178.868 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 76' ' ' TRP . . . . . 0.444 ' HB3' ' SD ' ' A' ' 109' ' ' MET . 44.5 m0 -66.42 -28.1 68.35 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 115.531 -0.759 . . . . 0.0 110.251 179.064 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 77' ' ' ILE . . . . . 0.497 ' O ' ' HG2' ' A' ' 81' ' ' PRO . 85.0 mt -75.89 -28.75 19.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-O 121.184 0.516 . . . . 0.0 109.69 178.827 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 52.0 mt -91.55 -18.32 24.27 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 115.758 -0.655 . . . . 0.0 111.446 179.183 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 79' ' ' THR . . . . . 0.409 HG23 ' O ' ' A' ' 75' ' ' ASP . 76.1 p -104.22 -50.98 3.22 Favored 'General case' 0 N--CA 1.464 0.225 0 N-CA-C 113.278 0.844 . . . . 0.0 113.278 -178.084 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 80' ' ' THR . . . . . 0.68 ' HB ' ' HD3' ' A' ' 81' ' ' PRO . 40.2 m -51.98 -55.19 32.89 Favored Pre-proline 0 CA--C 1.53 0.19 0 N-CA-C 111.947 0.351 . . . . 0.0 111.947 -178.642 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 81' ' ' PRO . . . . . 0.68 ' HD3' ' HB ' ' A' ' 80' ' ' THR . 40.6 Cg_exo -58.72 -21.8 57.97 Favored 'Trans proline' 0 C--N 1.352 0.748 0 C-N-CA 121.426 1.417 . . . . 0.0 111.133 179.406 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 82' ' ' LEU . . . . . 0.535 HD12 HG12 ' A' ' 43' ' ' ILE . 0.2 OUTLIER -76.36 -43.42 40.99 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 115.555 -0.748 . . . . 0.0 109.999 179.638 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 50.4 mm -63.76 -52.38 57.9 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.192 0 CA-C-N 116.074 -0.512 . . . . 0.0 110.424 179.512 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 29.3 m -57.98 -33.79 47.11 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.202 0 N-CA-C 109.738 -0.467 . . . . 0.0 109.738 179.104 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 85' ' ' TYR . . . . . 0.409 ' O ' ' HG ' ' A' ' 89' ' ' LEU . 61.6 t80 -62.1 -36.13 80.79 Favored 'General case' 0 N--CA 1.454 -0.27 0 CA-C-N 115.796 -0.638 . . . . 0.0 109.463 178.601 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 86' ' ' PHE . . . . . . . . . . . . . 13.0 t80 -59.7 -49.12 78.98 Favored 'General case' 0 C--O 1.232 0.183 0 CA-C-N 115.641 -0.709 . . . . 0.0 109.726 179.0 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 3.9 mm? -56.42 -41.8 76.96 Favored 'General case' 0 C--N 1.332 -0.176 0 CA-C-N 115.696 -0.684 . . . . 0.0 110.02 179.334 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -66.51 -27.97 73.46 Favored Glycine 0 N--CA 1.45 -0.397 0 CA-C-N 115.721 -0.672 . . . . 0.0 112.432 179.748 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 89' ' ' LEU . . . . . 0.409 ' HG ' ' O ' ' A' ' 85' ' ' TYR . 87.9 mt -71.0 -33.05 70.02 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.973 0.416 . . . . 0.0 110.516 179.814 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 95.6 mt -73.53 -30.98 63.42 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 115.884 -0.598 . . . . 0.0 111.134 179.824 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -88.47 -28.58 20.75 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.452 -0.34 . . . . 0.0 111.694 -179.603 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 80.62 58.05 2.78 Favored Glycine 0 N--CA 1.452 -0.3 0 C-N-CA 120.72 -0.752 . . . . 0.0 111.93 -179.5 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 94.5 mt -74.97 177.75 6.1 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.986 0.422 . . . . 0.0 111.506 -179.384 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 94' ' ' ASP . . . . . . . . . . . . . 9.9 m-20 -102.13 171.3 7.57 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-N 115.818 -0.628 . . . . 0.0 110.654 179.666 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 45.8 t -57.4 -36.91 71.91 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.292 -0.413 . . . . 0.0 111.192 -179.63 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 15.2 ptm180 -73.5 -48.12 35.75 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.467 -0.333 . . . . 0.0 111.343 -179.846 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 48.0 mt-10 -53.18 -45.69 68.65 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.303 -0.408 . . . . 0.0 111.079 -179.846 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 98' ' ' PHE . . . . . 0.472 ' O ' HG12 ' A' ' 102' ' ' ILE . 26.3 m-85 -59.25 -49.48 77.67 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.673 179.611 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -55.77 -28.02 51.25 Favored Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.811 -0.709 . . . . 0.0 112.862 -179.754 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 100' ' ' ILE . . . . . 0.424 ' O ' HG22 ' A' ' 103' ' ' THR . 93.5 mt -73.77 -49.05 37.16 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 N-CA-C 111.914 0.339 . . . . 0.0 111.914 -179.641 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 33.1 m -70.58 -32.55 50.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 N-CA-C 111.962 0.356 . . . . 0.0 111.962 -179.251 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 102' ' ' ILE . . . . . 0.504 HG23 ' HB3' ' A' ' 81' ' ' PRO . 50.2 mm -74.93 -43.0 46.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.536 -0.302 . . . . 0.0 111.426 -179.573 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 103' ' ' THR . . . . . 0.424 HG22 ' O ' ' A' ' 100' ' ' ILE . 14.7 t -63.52 -34.0 76.82 Favored 'General case' 0 C--O 1.232 0.134 0 CA-C-O 121.075 0.464 . . . . 0.0 110.116 179.532 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 104' ' ' LEU . . . . . 0.496 ' O ' HG23 ' A' ' 108' ' ' VAL . 42.8 tp -61.82 -57.11 13.11 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 115.796 -0.638 . . . . 0.0 110.072 179.101 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 105' ' ' ASN . . . . . 0.628 HD21 HD13 ' A' ' 137' ' ' LEU . 0.8 OUTLIER -55.95 -25.82 45.3 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 115.967 -0.561 . . . . 0.0 110.873 179.411 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 79.0 m -64.07 -57.53 9.36 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.422 -0.353 . . . . 0.0 111.205 -179.93 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 107' ' ' VAL . . . . . 0.416 HG12 ' O ' ' A' ' 104' ' ' LEU . 7.1 p -62.25 -35.83 71.29 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.211 0 CA-C-N 116.394 -0.366 . . . . 0.0 110.952 179.916 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . 0.496 HG23 ' O ' ' A' ' 104' ' ' LEU . 84.6 t -62.87 -56.99 14.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-O 121.052 0.453 . . . . 0.0 110.783 179.645 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 109' ' ' MET . . . . . 0.482 ' HE1' HG21 ' A' ' 80' ' ' THR . 5.5 tpp -58.07 -32.43 68.03 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 115.793 -0.639 . . . . 0.0 110.932 -179.729 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 22.4 tp -66.93 -35.97 81.19 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.243 179.663 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -62.46 -44.12 97.18 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 115.855 -0.611 . . . . 0.0 110.491 179.312 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . -64.17 -44.7 95.28 Favored Glycine 0 N--CA 1.452 -0.278 0 C-N-CA 120.751 -0.737 . . . . 0.0 112.289 179.519 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 113' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -51.04 -63.73 1.04 Allowed 'General case' 0 C--N 1.333 -0.149 0 CA-C-O 121.075 0.464 . . . . 0.0 110.347 179.765 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -67.31 -16.71 64.42 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 115.782 -0.645 . . . . 0.0 110.862 179.575 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -60.85 -47.01 93.34 Favored Glycine 0 C--N 1.332 0.35 0 C-N-CA 120.768 -0.729 . . . . 0.0 112.267 179.7 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 116' ' ' ALA . . . . . 0.414 ' HB2' ' HB3' ' A' ' 183' ' ' PRO . . . -78.48 -22.57 47.29 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 120.666 0.27 . . . . 0.0 111.631 179.796 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 117' ' ' MET . . . . . . . . . . . . . 1.1 mpt? -87.11 18.33 3.7 Favored 'General case' 0 C--N 1.332 -0.162 0 CA-C-N 116.53 -0.304 . . . . 0.0 111.712 -179.705 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 118' ' ' VAL . . . . . 0.5 HG21 ' HB3' ' A' ' 123' ' ' ARG . 27.3 m -76.13 147.69 80.28 Favored Pre-proline 0 C--N 1.327 -0.37 0 CA-C-N 116.668 -0.242 . . . . 0.0 111.305 179.99 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 119' ' ' PRO . . . . . . . . . . . . . 67.7 Cg_endo -84.55 -15.78 6.01 Favored 'Trans proline' 0 C--N 1.347 0.476 0 C-N-CA 122.667 2.245 . . . . 0.0 112.645 -179.987 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -143.68 -110.79 0.75 Allowed Glycine 0 C--N 1.333 0.369 0 C-N-CA 120.462 -0.875 . . . . 0.0 113.282 -179.53 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 47.9 pt -111.16 11.59 8.61 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.218 0 N-CA-C 111.783 0.29 . . . . 0.0 111.783 -179.225 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 15.7 mm-40 -58.39 -19.06 32.79 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.867 0.365 . . . . 0.0 110.815 179.819 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 123' ' ' ARG . . . . . 0.5 ' HB3' HG21 ' A' ' 118' ' ' VAL . 32.0 ptt180 -53.09 -30.02 33.83 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 115.714 -0.675 . . . . 0.0 111.843 -179.817 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 124' ' ' TYR . . . . . . . . . . . . . 48.5 m-85 -75.3 -32.62 61.03 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 116.316 -0.402 . . . . 0.0 111.907 -178.985 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 125' ' ' ALA . . . . . . . . . . . . . . . -70.68 -55.65 8.23 Favored 'General case' 0 C--O 1.238 0.453 0 CA-C-O 121.121 0.486 . . . . 0.0 110.892 179.953 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 1.3 mt -55.85 -46.07 78.31 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 115.591 -0.732 . . . . 0.0 110.607 -179.613 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 127' ' ' PHE . . . . . 0.459 ' HZ ' ' HB3' ' A' ' 175' ' ' PRO . 3.0 t80 -67.29 -39.01 85.95 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.442 -0.345 . . . . 0.0 110.555 179.618 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 128' ' ' GLY . . . . . . . . . . . . . . . -46.44 -43.72 15.1 Favored Glycine 0 C--O 1.237 0.284 0 C-N-CA 120.129 -1.034 . . . . 0.0 111.09 179.356 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 129' ' ' MET . . . . . . . . . . . . . 0.4 OUTLIER -70.92 -40.34 72.16 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 121.014 0.435 . . . . 0.0 110.263 178.999 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -66.32 -26.4 72.62 Favored Glycine 0 N--CA 1.452 -0.254 0 CA-C-N 115.727 -0.67 . . . . 0.0 113.018 -179.691 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -75.08 -53.66 8.5 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 120.664 0.269 . . . . 0.0 110.588 179.98 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 56.2 t -59.27 -41.01 82.7 Favored 'Isoleucine or valine' 0 C--O 1.234 0.275 0 N-CA-C 109.203 -0.666 . . . . 0.0 109.203 178.7 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -67.54 -34.53 77.26 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-N 115.207 -0.906 . . . . 0.0 110.549 179.214 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 134' ' ' PHE . . . . . . . . . . . . . 39.8 t80 -55.86 -54.77 40.55 Favored 'General case' 0 N--CA 1.452 -0.344 0 CA-C-N 116.209 -0.451 . . . . 0.0 109.992 179.485 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 135' ' ' ILE . . . . . 0.495 ' HA ' HG22 ' A' ' 138' ' ' VAL . 33.1 mt -58.15 -31.89 42.97 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 CA-C-N 115.711 -0.677 . . . . 0.0 110.116 179.164 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . -59.27 -44.89 96.17 Favored Glycine 0 N--CA 1.449 -0.488 0 C-N-CA 120.401 -0.904 . . . . 0.0 112.119 179.124 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 137' ' ' LEU . . . . . 0.628 HD13 HD21 ' A' ' 105' ' ' ASN . 13.9 tp -70.76 -52.02 23.38 Favored 'General case' 0 C--N 1.33 -0.258 0 C-N-CA 121.055 -0.258 . . . . 0.0 111.173 -179.867 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 138' ' ' VAL . . . . . 0.495 HG22 ' HA ' ' A' ' 135' ' ' ILE . 4.2 m -54.53 -31.56 23.49 Favored 'Isoleucine or valine' 0 C--O 1.232 0.168 0 N-CA-C 109.604 -0.517 . . . . 0.0 109.604 -179.737 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 139' ' ' TYR . . . . . . . . . . . . . 13.9 t80 -63.69 -44.53 93.41 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 115.616 -0.72 . . . . 0.0 109.596 178.16 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 24.9 m-85 -59.01 -42.83 91.06 Favored 'General case' 0 C--O 1.233 0.189 0 CA-C-N 115.971 -0.559 . . . . 0.0 111.05 179.402 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 141' ' ' LEU . . . . . 0.499 ' HA ' ' SD ' ' A' ' 145' ' ' MET . 9.4 mp -55.59 -49.76 71.91 Favored 'General case' 0 N--CA 1.462 0.17 0 CA-C-N 116.429 -0.351 . . . . 0.0 110.994 -179.774 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 12.6 p -82.46 -10.27 11.97 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.364 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.99 -179.98 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 143' ' ' GLY . . . . . 0.592 ' O ' HG22 ' A' ' 146' ' ' THR . . . -74.99 -144.97 1.1 Allowed Glycine 0 CA--C 1.521 0.455 0 C-N-CA 121.05 -0.595 . . . . 0.0 112.889 -179.766 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 144' ' ' PRO . . . . . . . . . . . . . 78.1 Cg_exo -50.07 -23.27 9.05 Favored 'Trans proline' 0 C--N 1.348 0.537 0 C-N-CA 122.794 2.329 . . . . 0.0 112.93 -179.934 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 145' ' ' MET . . . . . 0.499 ' SD ' ' HA ' ' A' ' 141' ' ' LEU . 27.4 mtt -52.4 -43.87 65.02 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.392 -0.367 . . . . 0.0 111.636 -179.681 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 146' ' ' THR . . . . . 0.592 HG22 ' O ' ' A' ' 143' ' ' GLY . 8.3 t -76.67 -31.77 57.51 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-O 120.907 0.384 . . . . 0.0 110.862 -179.471 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 34.0 tt0 -64.5 -40.4 95.59 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 115.989 -0.55 . . . . 0.0 110.769 179.858 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 148' ' ' SER . . . . . . . . . . . . . 55.5 m -70.41 -46.88 63.1 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.75 -179.972 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 149' ' ' ALA . . . . . . . . . . . . . . . -62.38 -32.41 73.21 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 115.935 -0.575 . . . . 0.0 111.19 -179.995 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 150' ' ' SER . . . . . . . . . . . . . 48.1 t -70.56 -1.64 11.66 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.815 179.843 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 151' ' ' GLN . . . . . . . . . . . . . 48.8 mt-30 -120.18 1.64 10.83 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.121 -0.491 . . . . 0.0 111.168 -179.832 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 26.6 mmm180 -81.88 -52.45 7.08 Favored 'General case' 0 C--N 1.332 -0.171 0 CA-C-O 121.11 0.481 . . . . 0.0 110.51 179.699 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 153' ' ' SER . . . . . 0.573 ' HB2' HG12 ' A' ' 156' ' ' ILE . 25.3 m -157.41 172.31 18.81 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-N 115.599 -0.728 . . . . 0.0 110.842 179.296 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 154' ' ' SER . . . . . . . . . . . . . 81.0 p -70.41 -39.1 74.64 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.303 -0.408 . . . . 0.0 110.709 179.579 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -77.21 -39.35 27.2 Favored Glycine 0 CA--C 1.518 0.269 0 C-N-CA 121.057 -0.592 . . . . 0.0 112.905 -179.83 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 156' ' ' ILE . . . . . 0.573 HG12 ' HB2' ' A' ' 153' ' ' SER . 35.6 mm -49.73 -38.92 14.08 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.175 0 CA-C-O 120.774 0.321 . . . . 0.0 111.823 -179.616 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 157' ' ' LYS . . . . . 0.434 ' O ' HG22 ' A' ' 161' ' ' VAL . 64.7 tttm -66.72 -37.91 85.63 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-N 116.304 -0.407 . . . . 0.0 111.363 -179.559 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 49.5 m -71.38 -37.91 71.56 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 121.003 0.43 . . . . 0.0 111.157 -178.815 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 159' ' ' LEU . . . . . 0.571 ' O ' ' HG ' ' A' ' 163' ' ' LEU . 31.3 mt -70.6 -56.79 5.66 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-N 116.043 -0.526 . . . . 0.0 111.13 -179.642 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 160' ' ' TYR . . . . . 0.45 ' OH ' ' HB3' ' A' ' 145' ' ' MET . 31.9 t80 -51.88 -41.83 62.2 Favored 'General case' 0 C--N 1.325 -0.466 0 N-CA-C 112.416 0.524 . . . . 0.0 112.416 -178.764 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 161' ' ' VAL . . . . . 0.468 HG23 ' N ' ' A' ' 162' ' ' ARG . 30.5 m -66.28 -49.07 78.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 N-CA-C 112.022 0.379 . . . . 0.0 112.022 -178.529 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 162' ' ' ARG . . . . . 0.468 ' N ' HG23 ' A' ' 161' ' ' VAL . 98.4 mtt180 -66.02 -49.38 67.94 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.768 0.318 . . . . 0.0 111.731 -179.205 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 163' ' ' LEU . . . . . 0.571 ' HG ' ' O ' ' A' ' 159' ' ' LEU . 19.7 mt -60.65 -55.43 33.32 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.635 -179.164 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 164' ' ' ARG . . . . . . . . . . . . . 3.8 ppt_? -58.85 -38.71 79.34 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.363 -0.38 . . . . 0.0 111.959 -178.967 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 165' ' ' ASN . . . . . 0.462 ' O ' HG23 ' A' ' 169' ' ' VAL . 0.9 OUTLIER -56.6 -53.62 55.49 Favored 'General case' 0 C--O 1.237 0.408 0 CA-C-O 120.751 0.31 . . . . 0.0 111.133 -178.383 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 166' ' ' LEU . . . . . 0.465 ' O ' ' HG ' ' A' ' 170' ' ' LEU . 0.2 OUTLIER -68.01 -28.89 67.81 Favored 'General case' 0 C--N 1.326 -0.439 0 C-N-CA 120.588 -0.445 . . . . 0.0 110.267 -179.917 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 167' ' ' THR . . . . . 0.412 ' O ' ' HB2' ' A' ' 171' ' ' TRP . 21.7 m -61.19 -53.35 57.98 Favored 'General case' 0 N--CA 1.462 0.131 0 CA-C-N 116.313 -0.403 . . . . 0.0 111.259 179.743 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 168' ' ' VAL . . . . . . . . . . . . . 60.4 t -60.04 -40.64 83.79 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 115.826 -0.624 . . . . 0.0 111.799 -179.054 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 169' ' ' VAL . . . . . 0.462 HG23 ' O ' ' A' ' 165' ' ' ASN . 93.9 t -56.74 -65.5 0.39 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 C-N-CA 120.914 -0.314 . . . . 0.0 111.739 -179.69 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 170' ' ' LEU . . . . . 0.465 ' HG ' ' O ' ' A' ' 166' ' ' LEU . 1.1 pp -62.8 -33.11 74.52 Favored 'General case' 0 C--N 1.33 -0.269 0 N-CA-C 112.467 0.543 . . . . 0.0 112.467 -178.576 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 171' ' ' TRP . . . . . 0.412 ' HB2' ' O ' ' A' ' 167' ' ' THR . 2.2 m0 -69.01 -31.28 69.99 Favored 'General case' 0 N--CA 1.463 0.22 0 C-N-CA 120.846 -0.341 . . . . 0.0 110.844 179.644 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 172' ' ' ALA . . . . . . . . . . . . . . . -74.53 -7.08 51.93 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-O 120.909 0.385 . . . . 0.0 110.587 -179.768 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 173' ' ' ILE . . . . . 0.527 HG22 HD11 ' A' ' 177' ' ' ILE . 40.6 mm -85.48 -21.84 7.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 115.787 -0.642 . . . . 0.0 110.865 179.62 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 174' ' ' TYR . . . . . 0.437 ' HB2' ' HD3' ' A' ' 175' ' ' PRO . 26.9 m-85 -54.56 -50.05 87.59 Favored Pre-proline 0 N--CA 1.464 0.242 0 CA-C-N 116.33 -0.396 . . . . 0.0 111.542 -179.975 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 175' ' ' PRO . . . . . 0.459 ' HB3' ' HZ ' ' A' ' 127' ' ' PHE . 86.8 Cg_exo -46.93 -30.79 10.16 Favored 'Trans proline' 0 C--N 1.352 0.749 0 C-N-CA 122.121 1.88 . . . . 0.0 112.215 179.575 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 176' ' ' PHE . . . . . 0.47 ' HD2' ' HA ' ' A' ' 173' ' ' ILE . 76.8 m-85 -80.38 -48.81 12.35 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 115.928 -0.578 . . . . 0.0 111.65 -179.768 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 177' ' ' ILE . . . . . 0.527 HD11 HG22 ' A' ' 173' ' ' ILE . 3.4 mm -63.47 -34.24 66.25 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.516 0 CA-C-N 116.374 -0.375 . . . . 0.0 111.881 -178.5 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 178' ' ' TRP . . . . . 0.431 ' HH2' ' HB2' ' A' ' 123' ' ' ARG . 73.8 t90 -74.03 -48.78 27.7 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 121.041 0.448 . . . . 0.0 110.449 179.438 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 179' ' ' LEU . . . . . 0.51 ' O ' HG22 ' A' ' 185' ' ' VAL . 1.9 tm? -63.55 -52.3 61.7 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 115.68 -0.691 . . . . 0.0 111.239 -179.395 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 180' ' ' LEU . . . . . 0.68 HD22 HD11 ' A' ' 187' ' ' LEU . 15.6 mt -76.73 -41.83 43.56 Favored 'General case' 0 C--N 1.329 -0.324 0 N-CA-C 112.076 0.398 . . . . 0.0 112.076 -178.914 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . -58.18 179.02 1.26 Allowed Glycine 0 C--N 1.334 0.456 0 C-N-CA 120.166 -1.016 . . . . 0.0 112.426 179.759 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 182' ' ' PRO . . . . . 0.451 ' HA ' ' HB2' ' A' ' 186' ' ' ALA . 72.0 Cg_exo -47.27 -45.29 22.47 Favored 'Trans proline' 0 CA--C 1.536 0.61 0 C-N-CA 122.741 2.294 . . . . 0.0 113.798 -179.856 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 183' ' ' PRO . . . . . 0.449 ' HG3' ' NH2' ' A' ' 72' ' ' ARG . 71.6 Cg_exo -49.49 -22.98 6.91 Favored 'Trans proline' 0 C--N 1.356 0.955 0 C-N-CA 122.223 1.949 . . . . 0.0 113.121 -179.786 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 184' ' ' GLY . . . . . . . . . . . . . . . -119.07 -132.99 4.58 Favored Glycine 0 N--CA 1.449 -0.448 0 C-N-CA 120.484 -0.865 . . . . 0.0 112.906 -179.824 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 185' ' ' VAL . . . . . 0.51 HG22 ' O ' ' A' ' 179' ' ' LEU . 13.3 m -58.75 -21.02 17.93 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.396 0 N-CA-C 112.13 0.418 . . . . 0.0 112.13 -179.485 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 186' ' ' ALA . . . . . 0.451 ' HB2' ' HA ' ' A' ' 182' ' ' PRO . . . 55.61 87.18 0.05 Allowed 'General case' 0 N--CA 1.463 0.194 0 CA-C-O 120.74 0.305 . . . . 0.0 111.391 179.906 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 187' ' ' LEU . . . . . 0.68 HD11 HD22 ' A' ' 180' ' ' LEU . 15.8 mt -91.75 -49.54 6.21 Favored 'General case' 0 C--N 1.332 -0.195 0 CA-C-N 116.291 -0.413 . . . . 0.0 111.341 -179.713 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 188' ' ' LEU . . . . . . . . . . . . . 68.6 mt -96.85 -155.07 0.47 Allowed 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 115.923 -0.58 . . . . 0.0 110.991 -179.573 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 189' ' ' THR . . . . . . . . . . . . . 1.9 t -101.6 146.74 32.76 Favored Pre-proline 0 C--N 1.328 -0.367 0 CA-C-N 116.001 -0.545 . . . . 0.0 110.817 -179.987 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 190' ' ' PRO . . . . . . . . . . . . . 86.5 Cg_exo -47.09 -45.2 21.97 Favored 'Trans proline' 0 C--N 1.348 0.502 0 C-N-CA 122.694 2.262 . . . . 0.0 113.35 -179.528 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 191' ' ' THR . . . . . . . . . . . . . 5.6 t -56.58 -39.95 74.4 Favored 'General case' 0 C--N 1.329 -0.316 0 N-CA-C 112.061 0.393 . . . . 0.0 112.061 -179.338 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 192' ' ' VAL . . . . . . . . . . . . . 40.6 t -73.37 -53.82 17.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 N-CA-C 111.909 0.337 . . . . 0.0 111.909 -179.435 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 193' ' ' ASP . . . . . . . . . . . . . 19.0 m-20 -58.36 -50.11 74.84 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.516 -0.311 . . . . 0.0 111.217 -179.829 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 194' ' ' VAL . . . . . . . . . . . . . 78.0 t -59.9 -36.33 66.04 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 116.339 -0.392 . . . . 0.0 110.691 179.557 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 195' ' ' ALA . . . . . . . . . . . . . . . -56.26 -47.85 77.72 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 116.397 -0.365 . . . . 0.0 111.121 179.792 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 196' ' ' LEU . . . . . . . . . . . . . 91.6 mt -64.99 -35.39 81.02 Favored 'General case' 0 C--N 1.332 -0.177 0 CA-C-O 120.771 0.319 . . . . 0.0 110.464 179.658 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 197' ' ' ILE . . . . . 0.477 HG12 HG21 ' A' ' 177' ' ' ILE . 19.6 mm -61.46 -53.8 43.7 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-O 121.142 0.496 . . . . 0.0 110.022 178.972 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 198' ' ' VAL . . . . . . . . . . . . . 98.3 t -54.91 -34.32 30.81 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.47 0 CA-C-N 115.344 -0.844 . . . . 0.0 109.33 178.471 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 199' ' ' TYR . . . . . 0.406 ' O ' HG23 ' A' ' 203' ' ' VAL . 68.8 t80 -69.35 -40.4 77.53 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 115.083 -0.962 . . . . 0.0 110.246 179.925 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 200' ' ' LEU . . . . . . . . . . . . . 38.1 mt -61.72 -41.56 97.79 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 115.74 -0.663 . . . . 0.0 111.371 -179.773 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 201' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -71.87 -40.39 68.98 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.041 -179.807 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 202' ' ' LEU . . . . . 0.403 ' O ' ' HB ' ' A' ' 206' ' ' VAL . 2.7 mt -65.2 -33.71 76.66 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.119 -0.491 . . . . 0.0 111.617 -179.401 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 203' ' ' VAL . . . . . 0.523 ' O ' ' HA3' ' A' ' 207' ' ' GLY . 65.9 t -77.31 -36.07 23.4 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.384 0 CA-C-O 120.74 0.305 . . . . 0.0 111.381 -179.12 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 204' ' ' THR . . . . . 0.42 HG23 ' CE2' ' A' ' 208' ' ' PHE . 88.8 m -66.46 -58.61 4.9 Favored 'General case' 0 C--N 1.325 -0.497 0 C-N-CA 120.745 -0.382 . . . . 0.0 111.298 179.95 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 205' ' ' LYS . . . . . 0.745 ' HE2' ' HB2' ' A' ' 47' ' ' ALA . 36.1 mttp -68.13 -58.75 3.96 Favored 'General case' 0 C--N 1.328 -0.338 0 N-CA-C 112.489 0.551 . . . . 0.0 112.489 -178.348 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 206' ' ' VAL . . . . . 0.403 ' HB ' ' O ' ' A' ' 202' ' ' LEU . 17.9 t -73.46 -37.0 49.77 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.369 0 N-CA-C 112.084 0.401 . . . . 0.0 112.084 -178.281 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 207' ' ' GLY . . . . . 0.523 ' HA3' ' O ' ' A' ' 203' ' ' VAL . . . -59.35 -60.05 9.52 Favored Glycine 0 N--CA 1.452 -0.278 0 C-N-CA 120.313 -0.946 . . . . 0.0 112.502 -179.36 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 208' ' ' PHE . . . . . 0.513 ' O ' ' N ' ' A' ' 212' ' ' ALA . 1.2 m-30 -58.48 -43.76 89.09 Favored 'General case' 0 C--O 1.221 -0.402 0 CA-C-N 117.111 0.456 . . . . 0.0 110.069 179.739 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 209' ' ' GLY . . . . . 0.487 ' O ' ' HB3' ' A' ' 212' ' ' ALA . . . -53.72 -37.89 57.99 Favored Glycine 0 CA--C 1.518 0.239 0 CA-C-N 115.501 -0.772 . . . . 0.0 113.957 -179.923 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 210' ' ' PHE . . . . . . . . . . . . . 2.6 m-85 -70.01 -48.68 57.12 Favored 'General case' 0 CA--C 1.515 -0.39 0 N-CA-C 108.906 -0.775 . . . . 0.0 108.906 179.664 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 211' ' ' ILE . . . . . 0.435 HG13 ' O ' ' A' ' 207' ' ' GLY . 5.3 mt -63.87 -27.43 42.82 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.569 0 N-CA-C 107.47 -1.308 . . . . 0.0 107.47 176.629 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 212' ' ' ALA . . . . . 0.513 ' N ' ' O ' ' A' ' 208' ' ' PHE . . . -68.37 -38.61 81.56 Favored 'General case' 0 N--CA 1.449 -0.488 0 CA-C-N 114.173 -1.376 . . . . 0.0 110.481 -179.866 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 213' ' ' LEU . . . . . . . . . . . . . 52.9 mt -65.44 -54.65 25.4 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-N 115.139 -0.937 . . . . 0.0 111.093 -179.811 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 214' ' ' ASP . . . . . . . . . . . . . 15.8 m-20 -60.57 -27.05 67.4 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.367 -0.379 . . . . 0.0 110.466 179.746 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 215' ' ' ALA . . . . . . . . . . . . . . . -68.94 -57.77 5.04 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.073 -0.512 . . . . 0.0 111.193 -179.964 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 216' ' ' ALA . . . . . . . . . . . . . . . -63.28 -31.27 72.37 Favored 'General case' 0 C--N 1.331 -0.21 0 CA-C-N 116.332 -0.395 . . . . 0.0 110.972 -179.974 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 217' ' ' ALA . . . . . . . . . . . . . . . -64.64 -37.56 87.98 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.045 -0.525 . . . . 0.0 110.433 179.73 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 218' ' ' THR . . . . . . . . . . . . . 99.1 m . . . . . 0 C--N 1.33 -0.27 0 CA-C-N 115.817 -0.628 . . . . 0.0 110.508 179.456 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.238 0 N-CA-C 112.34 -0.304 . . . . 0.0 112.34 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 4' ' ' LEU . . . . . 0.514 HD11 HG21 ' A' ' 194' ' ' VAL . 47.6 tp -74.12 -36.95 64.23 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-O 120.849 0.356 . . . . 0.0 110.989 179.934 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 70.8 p -59.44 -31.99 69.8 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.077 -0.51 . . . . 0.0 111.665 -179.616 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 32.3 p -55.62 -35.45 65.9 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-O 120.844 0.354 . . . . 0.0 111.191 -179.773 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 7' ' ' LEU . . . . . . . . . . . . . 4.0 mm? -58.98 -53.05 62.81 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.123 -0.49 . . . . 0.0 111.087 179.952 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 8' ' ' PHE . . . . . 0.457 ' HB2' ' HB2' ' A' ' 55' ' ' ALA . 73.6 m-85 -58.81 -33.11 70.01 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 116.34 -0.391 . . . . 0.0 110.817 179.932 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 9' ' ' TRP . . . . . 0.433 ' O ' HG13 ' A' ' 13' ' ' ILE . 27.8 m95 -66.35 -46.61 76.18 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 116.013 -0.54 . . . . 0.0 110.152 -179.862 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 94.1 mt -59.82 -42.07 92.7 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 115.651 -0.704 . . . . 0.0 110.347 179.377 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -63.42 -30.42 77.53 Favored Glycine 0 N--CA 1.449 -0.496 0 C-N-CA 120.712 -0.756 . . . . 0.0 111.724 179.348 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -73.19 -30.79 63.78 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.795 0.331 . . . . 0.0 110.82 179.678 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 13' ' ' ILE . . . . . 0.433 HG13 ' O ' ' A' ' 9' ' ' TRP . 67.0 mt -67.61 -54.7 21.22 Favored 'Isoleucine or valine' 0 C--O 1.233 0.206 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.399 179.473 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -62.46 -35.09 91.23 Favored Glycine 0 N--CA 1.449 -0.474 0 C-N-CA 120.716 -0.755 . . . . 0.0 111.399 179.209 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 15' ' ' MET . . . . . 0.496 ' SD ' ' HA ' ' A' ' 44' ' ' SER . 45.5 tpp -62.75 -41.96 99.45 Favored 'General case' 0 N--CA 1.453 -0.294 0 CA-C-O 120.814 0.34 . . . . 0.0 110.209 179.376 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 16' ' ' LEU . . . . . 0.415 HD13 ' O ' ' A' ' 16' ' ' LEU . 0.3 OUTLIER -59.46 -37.74 78.96 Favored 'General case' 0 C--N 1.331 -0.201 0 N-CA-C 109.635 -0.505 . . . . 0.0 109.635 178.893 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 46.5 t -59.24 -43.23 89.28 Favored 'Isoleucine or valine' 0 C--O 1.232 0.176 0 CA-C-N 116.033 -0.531 . . . . 0.0 110.134 179.143 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -68.25 -42.89 81.98 Favored Glycine 0 C--N 1.331 0.291 0 C-N-CA 120.795 -0.717 . . . . 0.0 111.884 179.187 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 9.9 m -50.14 -46.24 53.74 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.698 0.285 . . . . 0.0 111.352 -179.604 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 92.7 mt -72.01 -43.17 65.46 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.271 -0.422 . . . . 0.0 111.618 -179.712 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -58.31 -33.23 69.25 Favored 'General case' 0 C--N 1.33 -0.267 0 N-CA-C 112.048 0.388 . . . . 0.0 112.048 -179.252 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 22' ' ' PHE . . . . . 0.42 ' HB2' HG22 ' A' ' 41' ' ' VAL . 5.3 m-85 -90.57 -37.67 13.68 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 120.624 0.249 . . . . 0.0 111.495 -179.367 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -65.91 -51.18 60.83 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.874 0.369 . . . . 0.0 111.659 -179.507 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 24' ' ' TRP . . . . . . . . . . . . . 3.4 t-105 -60.44 -52.87 63.37 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-N 115.948 -0.569 . . . . 0.0 111.145 -179.66 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.328 -0.363 0 CA-C-N 116.358 -0.383 . . . . 0.0 111.032 179.942 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.247 0 N-CA-C 112.569 -0.212 . . . . 0.0 112.569 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 11.0 pt-20 -58.94 -20.53 53.0 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 120.644 0.259 . . . . 0.0 111.255 179.893 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 34' ' ' ARG . . . . . 0.46 ' O ' HG23 ' A' ' 38' ' ' VAL . 74.2 mtp180 -49.2 -29.43 5.61 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.379 -179.89 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 98.9 mtt180 -60.21 -46.62 89.13 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.82 0.343 . . . . 0.0 111.057 179.899 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 52.7 m-85 -66.79 -42.66 85.62 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.176 -0.466 . . . . 0.0 111.068 -179.933 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 37' ' ' TYR . . . . . 0.404 ' O ' HG23 ' A' ' 41' ' ' VAL . 51.9 m-85 -63.45 -51.82 64.08 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.213 -0.448 . . . . 0.0 111.449 -179.6 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 38' ' ' VAL . . . . . 0.46 HG23 ' O ' ' A' ' 34' ' ' ARG . 78.2 t -56.81 -36.73 50.51 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-O 121.005 0.431 . . . . 0.0 110.222 179.662 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 17.4 m -65.35 -47.85 75.05 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 115.852 -0.613 . . . . 0.0 110.257 178.976 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 48.8 tp -56.11 -45.84 79.32 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 115.665 -0.698 . . . . 0.0 110.096 179.21 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . 0.42 HG22 ' HB2' ' A' ' 22' ' ' PHE . 96.5 t -60.81 -34.48 59.38 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.249 0 CA-C-N 115.698 -0.683 . . . . 0.0 109.983 179.068 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -57.03 -44.17 93.02 Favored Glycine 0 N--CA 1.447 -0.593 0 C-N-CA 120.813 -0.708 . . . . 0.0 111.834 179.599 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 43' ' ' ILE . . . . . 0.551 HG22 ' HE3' ' A' ' 205' ' ' LYS . 0.3 OUTLIER -63.1 -51.58 69.81 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.179 0 CA-C-O 120.7 0.286 . . . . 0.0 110.951 179.501 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 44' ' ' SER . . . . . 0.496 ' HA ' ' SD ' ' A' ' 15' ' ' MET . 87.5 p -60.41 -29.33 68.91 Favored 'General case' 0 C--O 1.232 0.155 0 CA-C-O 120.841 0.353 . . . . 0.0 111.305 -179.981 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -77.34 -51.31 6.16 Favored Glycine 0 CA--C 1.519 0.322 0 C-N-CA 120.668 -0.777 . . . . 0.0 113.11 -179.344 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 46' ' ' ILE . . . . . 0.669 HD12 HD12 ' A' ' 78' ' ' LEU . 12.4 pt -58.62 -37.53 65.8 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.242 0 CA-C-O 120.936 0.398 . . . . 0.0 110.979 -179.839 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 47' ' ' ALA . . . . . 0.688 ' HB2' ' HE2' ' A' ' 205' ' ' LYS . . . -67.87 -44.03 78.02 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.124 -0.489 . . . . 0.0 111.426 179.47 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 48' ' ' ALA . . . . . 0.425 ' HB2' ' HG3' ' A' ' 15' ' ' MET . . . -55.19 -43.25 74.22 Favored 'General case' 0 C--N 1.332 -0.194 0 CA-C-N 116.05 -0.523 . . . . 0.0 112.051 -179.326 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 35.5 m -73.2 -35.29 46.87 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.245 0 CA-C-O 120.684 0.278 . . . . 0.0 111.461 -179.541 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -63.29 -39.21 93.95 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-O 121.035 0.445 . . . . 0.0 110.965 179.955 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 24.5 m-85 -73.08 -38.96 66.23 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-N 115.817 -0.629 . . . . 0.0 110.648 -179.831 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -62.64 -45.46 92.73 Favored 'General case' 0 C--N 1.327 -0.413 0 CA-C-N 115.983 -0.553 . . . . 0.0 111.255 179.854 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 53' ' ' VAL . . . . . 0.551 ' O ' HG12 ' A' ' 58' ' ' VAL . 32.3 m -66.43 -52.9 41.57 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.122 0 CA-C-N 116.504 -0.316 . . . . 0.0 111.056 -179.949 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 54' ' ' MET . . . . . 0.539 ' N ' HG23 ' A' ' 53' ' ' VAL . 76.0 mtm -58.35 -34.96 71.22 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-O 121.156 0.503 . . . . 0.0 110.134 179.508 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 55' ' ' ALA . . . . . 0.457 ' HB2' ' HB2' ' A' ' 8' ' ' PHE . . . -63.31 -29.49 70.8 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 115.588 -0.733 . . . . 0.0 111.322 179.474 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 96.3 mt -79.23 -8.23 58.87 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.383 -0.371 . . . . 0.0 111.383 -179.633 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 98.75 -6.89 60.77 Favored Glycine 0 N--CA 1.45 -0.368 0 C-N-CA 120.531 -0.842 . . . . 0.0 113.018 179.545 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 58' ' ' VAL . . . . . 0.551 HG12 ' O ' ' A' ' 53' ' ' VAL . 3.8 p -75.26 154.4 6.3 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.235 0 CA-C-N 116.906 0.353 . . . . 0.0 110.636 179.926 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 76.3 22.77 72.62 Favored Glycine 0 N--CA 1.452 -0.261 0 C-N-CA 120.634 -0.794 . . . . 0.0 112.275 -179.408 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 60' ' ' TRP . . . . . . . . . . . . . 19.1 m0 -104.75 100.88 10.52 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-O 120.972 0.415 . . . . 0.0 110.043 179.967 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 61' ' ' VAL . . . . . 0.485 ' HB ' HG23 ' A' ' 68' ' ' VAL . 57.3 t -97.01 107.58 38.49 Favored Pre-proline 0 C--N 1.327 -0.389 0 CA-C-N 115.894 -0.594 . . . . 0.0 111.521 -179.448 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 62' ' ' PRO . . . . . 0.424 ' HD2' ' HA ' ' A' ' 61' ' ' VAL . 31.3 Cg_endo -63.53 135.0 47.18 Favored 'Trans proline' 0 C--N 1.35 0.613 0 C-N-CA 122.384 2.056 . . . . 0.0 111.894 179.461 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 85.8 t -136.68 94.02 1.12 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.38 0 CA-C-N 116.109 -0.496 . . . . 0.0 111.319 -179.43 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . 57.38 -88.95 0.02 OUTLIER 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.485 179.905 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 38.0 tt0 -117.65 -22.8 7.89 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-O 120.913 0.387 . . . . 0.0 110.638 179.981 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 66' ' ' ARG . . . . . . . . . . . . . 41.5 mmt180 -102.79 157.64 16.82 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.039 -0.528 . . . . 0.0 110.225 179.747 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 26.2 m -124.14 116.43 22.73 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-O 120.869 0.366 . . . . 0.0 111.334 -179.854 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 68' ' ' VAL . . . . . 0.504 HG11 ' HA ' ' A' ' 117' ' ' MET . 24.0 m -90.77 145.53 7.31 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 115.986 -0.552 . . . . 0.0 110.84 179.664 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 69' ' ' PHE . . . . . . . . . . . . . 42.5 m-85 -109.65 111.35 22.77 Favored 'General case' 0 N--CA 1.441 -0.918 0 N-CA-C 109.879 -0.415 . . . . 0.0 109.879 -179.819 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 70' ' ' VAL . . . . . 0.577 ' N ' ' HD2' ' A' ' 71' ' ' PRO . 38.6 t -60.73 -50.11 86.66 Favored Pre-proline 0 C--N 1.326 -0.427 0 CA-C-N 116.42 -0.355 . . . . 0.0 111.903 -179.042 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 71' ' ' PRO . . . . . 0.577 ' HD2' ' N ' ' A' ' 70' ' ' VAL . 36.6 Cg_endo -64.7 -17.84 60.78 Favored 'Trans proline' 0 C--N 1.35 0.638 0 C-N-CA 122.288 1.992 . . . . 0.0 112.971 -179.343 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 37.3 ttp180 -70.95 -55.24 8.79 Favored 'General case' 0 C--O 1.235 0.321 0 C-N-CA 121.025 -0.27 . . . . 0.0 111.332 -179.492 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 73' ' ' TYR . . . . . 0.463 ' O ' HG13 ' A' ' 77' ' ' ILE . 5.7 m-85 -68.48 -34.52 76.08 Favored 'General case' 0 C--N 1.332 -0.185 0 C-N-CA 120.686 -0.406 . . . . 0.0 109.994 179.911 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 74' ' ' ILE . . . . . 0.524 ' HA ' HD12 ' A' ' 77' ' ' ILE . 0.4 OUTLIER -67.72 -36.75 77.03 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.173 0 CA-C-N 116.174 -0.467 . . . . 0.0 110.123 179.526 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 75' ' ' ASP . . . . . 0.43 ' O ' HG23 ' A' ' 79' ' ' THR . 11.3 t70 -60.5 -37.61 81.68 Favored 'General case' 0 CA--C 1.518 -0.262 0 N-CA-C 109.188 -0.671 . . . . 0.0 109.188 178.749 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 76' ' ' TRP . . . . . . . . . . . . . 40.6 m0 -69.86 -28.1 65.38 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 115.638 -0.71 . . . . 0.0 110.562 179.247 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 77' ' ' ILE . . . . . 0.573 ' HA ' ' HG3' ' A' ' 109' ' ' MET . 96.3 mt -68.56 -36.27 73.89 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.34 179.596 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 78' ' ' LEU . . . . . 0.669 HD12 HD12 ' A' ' 46' ' ' ILE . 0.7 OUTLIER -90.75 -26.76 19.33 Favored 'General case' 0 C--N 1.328 -0.358 0 N-CA-C 112.81 0.671 . . . . 0.0 112.81 -179.65 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 79' ' ' THR . . . . . 0.43 HG23 ' O ' ' A' ' 75' ' ' ASP . 64.8 p -84.71 -52.27 6.2 Favored 'General case' 0 C--N 1.327 -0.374 0 N-CA-C 113.71 1.004 . . . . 0.0 113.71 -178.548 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 80' ' ' THR . . . . . 0.696 ' HB ' ' HD3' ' A' ' 81' ' ' PRO . 34.0 m -53.42 -56.12 27.73 Favored Pre-proline 0 CA--C 1.533 0.314 0 N-CA-C 112.567 0.581 . . . . 0.0 112.567 -177.902 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 81' ' ' PRO . . . . . 0.696 ' HD3' ' HB ' ' A' ' 80' ' ' THR . 43.5 Cg_exo -58.33 -19.21 41.88 Favored 'Trans proline' 0 C--N 1.352 0.744 0 C-N-CA 121.728 1.618 . . . . 0.0 111.956 179.966 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 82' ' ' LEU . . . . . . . . . . . . . 16.2 tp -76.72 -35.66 57.67 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.078 179.575 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 83' ' ' ILE . . . . . 0.523 HD11 HG21 ' A' ' 43' ' ' ILE . 41.3 mm -69.57 -51.27 43.25 Favored 'Isoleucine or valine' 0 C--O 1.233 0.222 0 CA-C-N 115.926 -0.579 . . . . 0.0 110.379 179.214 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 84' ' ' VAL . . . . . 0.48 HG22 ' HA ' ' A' ' 81' ' ' PRO . 33.0 m -60.95 -31.96 51.16 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.212 0 N-CA-C 109.505 -0.554 . . . . 0.0 109.505 179.062 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 85' ' ' TYR . . . . . 0.416 ' O ' ' HG ' ' A' ' 89' ' ' LEU . 81.3 t80 -65.42 -33.6 76.32 Favored 'General case' 0 N--CA 1.453 -0.291 0 CA-C-N 115.559 -0.746 . . . . 0.0 109.344 178.739 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 86' ' ' PHE . . . . . . . . . . . . . 3.0 t80 -61.87 -50.93 70.26 Favored 'General case' 0 C--O 1.233 0.235 0 CA-C-N 115.617 -0.719 . . . . 0.0 110.066 179.436 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 6.1 mt -62.95 -29.15 70.58 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 115.905 -0.589 . . . . 0.0 110.316 179.778 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -70.56 -28.06 71.62 Favored Glycine 0 N--CA 1.451 -0.323 0 CA-C-N 115.486 -0.779 . . . . 0.0 112.026 179.542 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 89' ' ' LEU . . . . . 0.416 ' HG ' ' O ' ' A' ' 85' ' ' TYR . 91.2 mt -74.91 -41.99 58.66 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.92 0.391 . . . . 0.0 110.772 179.744 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 97.6 mt -63.99 -36.41 83.88 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 115.959 -0.564 . . . . 0.0 111.123 179.927 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -77.19 -53.92 7.14 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.352 -0.385 . . . . 0.0 111.131 -179.854 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 107.8 52.67 0.69 Allowed Glycine 0 C--N 1.33 0.248 0 C-N-CA 120.899 -0.667 . . . . 0.0 112.213 -179.726 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 64.8 mt -75.82 162.24 28.33 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-O 120.909 0.385 . . . . 0.0 111.04 -179.773 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 94' ' ' ASP . . . . . . . . . . . . . 7.0 m-20 -88.86 175.14 7.58 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.707 179.881 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 65.3 m -60.44 -35.2 75.27 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.255 -179.767 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 96' ' ' ARG . . . . . 0.456 ' HG3' ' N ' ' A' ' 97' ' ' GLU . 10.5 ptp180 -73.64 -46.65 45.48 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 116.312 -0.404 . . . . 0.0 111.251 -179.842 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 97' ' ' GLU . . . . . 0.456 ' N ' ' HG3' ' A' ' 96' ' ' ARG . 42.0 mt-10 -57.02 -40.47 76.73 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.326 -0.397 . . . . 0.0 111.08 -179.68 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 98' ' ' PHE . . . . . 0.447 ' O ' HG12 ' A' ' 102' ' ' ILE . 13.5 m-85 -62.63 -50.3 71.75 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.772 179.656 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -55.29 -30.44 55.07 Favored Glycine 0 N--CA 1.452 -0.253 0 C-N-CA 120.647 -0.787 . . . . 0.0 112.695 -179.906 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 100' ' ' ILE . . . . . 0.441 ' O ' HG22 ' A' ' 103' ' ' THR . 86.8 mt -72.13 -47.78 52.52 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-O 120.864 0.364 . . . . 0.0 111.561 -179.735 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 43.2 t -67.67 -48.68 75.38 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.371 0 CA-C-N 116.289 -0.414 . . . . 0.0 111.516 -179.572 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 102' ' ' ILE . . . . . 0.447 HG12 ' O ' ' A' ' 98' ' ' PHE . 34.9 mm -59.15 -47.19 91.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.898 -179.23 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 103' ' ' THR . . . . . 0.441 HG22 ' O ' ' A' ' 100' ' ' ILE . 14.2 t -60.81 -36.26 78.58 Favored 'General case' 0 C--O 1.234 0.245 0 CA-C-O 120.772 0.32 . . . . 0.0 110.879 -179.968 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 104' ' ' LEU . . . . . 0.434 HD12 ' HB2' ' A' ' 137' ' ' LEU . 3.0 tm? -57.01 -50.65 72.06 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-N 116.344 -0.389 . . . . 0.0 110.043 179.15 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 105' ' ' ASN . . . . . 0.414 ' O ' ' HG2' ' A' ' 109' ' ' MET . 16.6 m-80 -59.39 -31.42 69.22 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.014 -0.539 . . . . 0.0 110.674 179.368 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 41.5 m -56.92 -47.85 79.62 Favored 'General case' 0 C--O 1.232 0.177 0 CA-C-O 120.836 0.35 . . . . 0.0 110.154 179.329 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 107' ' ' VAL . . . . . 0.401 ' H ' HG23 ' A' ' 107' ' ' VAL . 1.9 t -61.06 -42.12 91.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 115.996 -0.547 . . . . 0.0 109.963 179.107 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 66.4 t -57.72 -45.69 86.84 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 115.171 -0.922 . . . . 0.0 111.669 -179.723 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 109' ' ' MET . . . . . 0.573 ' HG3' ' HA ' ' A' ' 77' ' ' ILE . 16.0 mmt -67.71 -44.33 77.92 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.712 -179.27 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 32.9 tp -60.64 -39.61 88.94 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-O 120.766 0.317 . . . . 0.0 110.806 -179.747 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -58.48 -54.67 44.46 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.685 179.635 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . -66.41 -32.3 81.45 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.387 179.632 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 113' ' ' PHE . . . . . . . . . . . . . 0.7 OUTLIER -52.77 -71.34 0.07 Allowed 'General case' 0 C--N 1.331 -0.202 0 CA-C-O 120.945 0.402 . . . . 0.0 110.183 179.829 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 114' ' ' ALA . . . . . 0.45 ' HB3' HD22 ' A' ' 126' ' ' LEU . . . -64.47 -22.6 67.01 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 115.796 -0.638 . . . . 0.0 110.975 179.742 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -53.57 -49.37 57.71 Favored Glycine 0 C--N 1.331 0.269 0 C-N-CA 121.025 -0.607 . . . . 0.0 112.518 179.985 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 116' ' ' ALA . . . . . 0.554 ' HB2' ' HB3' ' A' ' 183' ' ' PRO . . . -78.06 -18.14 56.15 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-O 120.742 0.306 . . . . 0.0 111.464 -179.899 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 117' ' ' MET . . . . . 0.504 ' HA ' HG11 ' A' ' 68' ' ' VAL . 33.3 ttm -99.31 19.57 15.22 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.32 -0.4 . . . . 0.0 111.556 -179.161 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 118' ' ' VAL . . . . . 0.453 HG21 ' HB3' ' A' ' 123' ' ' ARG . 25.1 m -71.34 143.33 87.89 Favored Pre-proline 0 C--N 1.33 -0.279 0 CA-C-N 116.524 -0.307 . . . . 0.0 111.514 179.993 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 119' ' ' PRO . . . . . . . . . . . . . 92.2 Cg_endo -89.49 14.89 2.09 Favored 'Trans proline' 0 N--CA 1.456 -0.677 0 C-N-CA 122.715 2.277 . . . . 0.0 112.418 179.373 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -166.07 -118.37 0.44 Allowed Glycine 0 C--N 1.334 0.421 0 C-N-CA 120.644 -0.789 . . . . 0.0 112.834 -179.668 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 2.0 pp -119.89 13.37 6.64 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.183 0 CA-C-O 120.675 0.274 . . . . 0.0 111.597 -179.595 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 43.6 mt-10 -62.62 -17.98 61.35 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.865 179.722 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 123' ' ' ARG . . . . . 0.453 ' HB3' HG21 ' A' ' 118' ' ' VAL . 3.2 ptp180 -50.28 -28.07 7.17 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 115.834 -0.621 . . . . 0.0 111.93 -179.764 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 124' ' ' TYR . . . . . . . . . . . . . 29.2 m-85 -71.42 -33.53 69.5 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.632 0.254 . . . . 0.0 111.385 -179.592 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 125' ' ' ALA . . . . . . . . . . . . . . . -74.21 -55.93 5.49 Favored 'General case' 0 C--O 1.235 0.315 0 CA-C-O 120.79 0.328 . . . . 0.0 111.184 179.918 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 126' ' ' LEU . . . . . 0.45 HD22 ' HB3' ' A' ' 114' ' ' ALA . 1.1 mp -52.16 -51.12 59.95 Favored 'General case' 0 C--N 1.332 -0.182 0 CA-C-N 116.041 -0.527 . . . . 0.0 110.313 179.79 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 127' ' ' PHE . . . . . . . . . . . . . 10.4 t80 -65.46 -30.36 71.14 Favored 'General case' 0 N--CA 1.452 -0.354 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.089 179.308 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 128' ' ' GLY . . . . . . . . . . . . . . . -48.19 -52.93 16.63 Favored Glycine 0 N--CA 1.449 -0.461 0 C-N-CA 120.196 -1.002 . . . . 0.0 110.757 178.848 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 129' ' ' MET . . . . . 0.549 ' HE3' ' HA2' ' A' ' 130' ' ' GLY . 0.0 OUTLIER -70.36 -27.24 64.18 Favored 'General case' 0 C--N 1.328 -0.367 0 N-CA-C 109.036 -0.727 . . . . 0.0 109.036 178.515 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 130' ' ' GLY . . . . . 0.549 ' HA2' ' HE3' ' A' ' 129' ' ' MET . . . -59.7 -45.27 95.99 Favored Glycine 0 C--N 1.333 0.366 0 CA-C-N 115.745 -0.661 . . . . 0.0 112.558 179.607 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 131' ' ' ALA . . . . . 0.403 ' O ' ' HB3' ' A' ' 134' ' ' PHE . . . -69.8 -47.53 62.5 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-O 120.738 0.304 . . . . 0.0 110.421 179.751 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 65.4 t -56.32 -44.31 79.4 Favored 'Isoleucine or valine' 0 C--O 1.235 0.293 0 CA-C-O 121.261 0.553 . . . . 0.0 109.662 178.865 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -63.25 -35.22 79.62 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 115.57 -0.741 . . . . 0.0 110.465 179.231 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 134' ' ' PHE . . . . . 0.414 ' HE1' ' HB3' ' A' ' 171' ' ' TRP . 72.6 t80 -56.92 -54.56 45.25 Favored 'General case' 0 N--CA 1.451 -0.375 0 CA-C-O 120.984 0.421 . . . . 0.0 110.156 179.494 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 135' ' ' ILE . . . . . 0.484 ' O ' HG22 ' A' ' 138' ' ' VAL . 39.8 mt -56.6 -31.05 33.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 115.733 -0.667 . . . . 0.0 110.198 179.285 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . -62.73 -42.41 99.69 Favored Glycine 0 N--CA 1.447 -0.607 0 C-N-CA 120.221 -0.99 . . . . 0.0 111.344 178.922 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 137' ' ' LEU . . . . . 0.446 ' O ' HD13 ' A' ' 141' ' ' LEU . 64.9 tp -67.12 -52.64 39.29 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-O 120.464 0.174 . . . . 0.0 111.033 179.778 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 138' ' ' VAL . . . . . 0.484 HG22 ' O ' ' A' ' 135' ' ' ILE . 4.5 m -54.31 -34.43 27.87 Favored 'Isoleucine or valine' 0 CA--C 1.52 -0.177 0 N-CA-C 109.728 -0.471 . . . . 0.0 109.728 -179.642 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 139' ' ' TYR . . . . . . . . . . . . . 35.6 t80 -58.56 -46.49 86.76 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 115.785 -0.643 . . . . 0.0 109.633 178.05 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 24.6 m-85 -63.65 -40.78 97.73 Favored 'General case' 0 C--N 1.333 -0.111 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.486 179.105 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 141' ' ' LEU . . . . . 0.507 ' HA ' ' SD ' ' A' ' 145' ' ' MET . 11.2 mp -59.14 -25.64 64.04 Favored 'General case' 0 C--N 1.332 -0.186 0 CA-C-N 116.073 -0.512 . . . . 0.0 110.973 179.982 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 142' ' ' VAL . . . . . 0.419 HG23 ' O ' ' A' ' 138' ' ' VAL . 15.7 t -107.9 -5.18 10.5 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.254 0 CA-C-N 116.24 -0.437 . . . . 0.0 110.875 179.851 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . -75.81 -133.2 0.41 Allowed Glycine 0 CA--C 1.522 0.487 0 C-N-CA 120.874 -0.679 . . . . 0.0 112.704 179.993 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 144' ' ' PRO . . . . . . . . . . . . . 48.7 Cg_exo -55.55 -24.17 43.3 Favored 'Trans proline' 0 C--N 1.35 0.639 0 C-N-CA 122.5 2.133 . . . . 0.0 112.868 -179.732 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 145' ' ' MET . . . . . 0.507 ' SD ' ' HA ' ' A' ' 141' ' ' LEU . 57.5 mtt -54.15 -32.91 56.6 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 116.402 -0.363 . . . . 0.0 111.408 -179.864 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 146' ' ' THR . . . . . . . . . . . . . 79.1 p -65.9 -49.25 68.7 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.3 -0.409 . . . . 0.0 111.937 -179.407 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 14.1 mm-40 -74.89 -25.39 58.9 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.734 0.302 . . . . 0.0 111.766 -179.394 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 148' ' ' SER . . . . . . . . . . . . . 45.9 t -70.1 -45.43 66.95 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.834 0.35 . . . . 0.0 111.098 -179.623 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 149' ' ' ALA . . . . . 0.416 ' HB1' HG22 ' A' ' 156' ' ' ILE . . . -78.33 -35.14 48.06 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.119 -0.492 . . . . 0.0 111.849 -179.582 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 150' ' ' SER . . . . . 0.559 ' HA ' ' HG2' ' A' ' 157' ' ' LYS . 35.7 t -69.71 0.72 5.12 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.303 -0.408 . . . . 0.0 111.44 -179.539 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 151' ' ' GLN . . . . . . . . . . . . . 49.1 mt-30 -134.3 15.53 3.78 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.512 -0.313 . . . . 0.0 111.207 179.877 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 152' ' ' ARG . . . . . 0.411 ' NE ' ' HA ' ' A' ' 152' ' ' ARG . 6.7 tpm_? -91.6 -51.89 5.04 Favored 'General case' 0 C--N 1.332 -0.195 0 CA-C-O 120.906 0.384 . . . . 0.0 110.772 179.954 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 153' ' ' SER . . . . . 0.679 ' HB3' HG12 ' A' ' 156' ' ' ILE . 24.3 t -157.76 172.6 18.2 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 115.978 -0.555 . . . . 0.0 110.746 179.256 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 154' ' ' SER . . . . . 0.513 ' HA ' ' NZ ' ' A' ' 157' ' ' LYS . 77.7 p -70.49 -40.68 73.45 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.427 -0.351 . . . . 0.0 110.859 179.727 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -77.08 -28.59 58.2 Favored Glycine 0 CA--C 1.521 0.41 0 C-N-CA 121.07 -0.585 . . . . 0.0 113.389 -179.631 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 156' ' ' ILE . . . . . 0.679 HG12 ' HB3' ' A' ' 153' ' ' SER . 33.4 mm -56.77 -37.68 54.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-O 120.678 0.275 . . . . 0.0 111.522 -179.507 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 157' ' ' LYS . . . . . 0.559 ' HG2' ' HA ' ' A' ' 150' ' ' SER . 36.7 mtmm -58.96 -41.26 87.04 Favored 'General case' 0 C--N 1.327 -0.393 0 N-CA-C 112.178 0.436 . . . . 0.0 112.178 -179.527 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 71.2 m -70.57 -48.32 55.9 Favored 'General case' 0 C--N 1.33 -0.256 0 N-CA-C 111.958 0.355 . . . . 0.0 111.958 -179.003 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 159' ' ' LEU . . . . . 0.402 ' O ' ' HB2' ' A' ' 163' ' ' LEU . 3.8 mm? -67.68 -30.2 69.67 Favored 'General case' 0 C--N 1.327 -0.384 0 N-CA-C 111.789 0.292 . . . . 0.0 111.789 -179.373 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 160' ' ' TYR . . . . . . . . . . . . . 72.4 t80 -73.98 -47.41 37.48 Favored 'General case' 0 C--N 1.329 -0.3 0 N-CA-C 112.313 0.486 . . . . 0.0 112.313 -179.06 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 161' ' ' VAL . . . . . 0.422 HG23 ' N ' ' A' ' 162' ' ' ARG . 27.3 m -64.25 -43.17 97.21 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.373 0 N-CA-C 112.347 0.499 . . . . 0.0 112.347 -178.616 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 162' ' ' ARG . . . . . 0.446 ' HA ' ' NE ' ' A' ' 162' ' ' ARG . 6.7 tpm_? -68.96 -49.27 59.47 Favored 'General case' 0 C--N 1.328 -0.33 0 N-CA-C 112.001 0.371 . . . . 0.0 112.001 -178.904 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 163' ' ' LEU . . . . . 0.402 ' HB2' ' O ' ' A' ' 159' ' ' LEU . 8.1 mp -67.62 -43.23 80.88 Favored 'General case' 0 C--N 1.329 -0.313 0 N-CA-C 111.928 0.344 . . . . 0.0 111.928 -179.149 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 164' ' ' ARG . . . . . . . . . . . . . 3.4 tmm_? -56.88 -50.79 71.43 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 120.695 0.283 . . . . 0.0 110.683 179.965 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 165' ' ' ASN . . . . . 0.524 HD22 ' N ' ' A' ' 165' ' ' ASN . 0.9 OUTLIER -57.29 -42.27 81.39 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.998 0.427 . . . . 0.0 110.301 179.576 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 166' ' ' LEU . . . . . 0.467 ' HB3' ' CE1' ' A' ' 208' ' ' PHE . 2.7 mt -58.7 -52.18 66.79 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 115.83 -0.623 . . . . 0.0 111.097 179.344 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 167' ' ' THR . . . . . 0.637 ' HA ' HD11 ' A' ' 170' ' ' LEU . 3.1 m -54.59 -51.86 63.95 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 115.733 -0.667 . . . . 0.0 112.442 -178.454 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 168' ' ' VAL . . . . . . . . . . . . . 59.2 t -57.26 -40.36 73.34 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.504 0 N-CA-C 112.485 0.55 . . . . 0.0 112.485 -178.894 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 169' ' ' VAL . . . . . 0.483 ' O ' HG12 ' A' ' 173' ' ' ILE . 98.2 t -68.03 -66.7 0.49 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 N-CA-C 113.499 0.926 . . . . 0.0 113.499 -177.912 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 170' ' ' LEU . . . . . 0.637 HD11 ' HA ' ' A' ' 167' ' ' THR . 0.4 OUTLIER -59.89 -33.2 71.52 Favored 'General case' 0 N--CA 1.467 0.386 0 N-CA-C 112.887 0.699 . . . . 0.0 112.887 -177.71 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 171' ' ' TRP . . . . . 0.543 ' H ' HD12 ' A' ' 170' ' ' LEU . 25.9 m0 -73.54 -30.51 63.12 Favored 'General case' 0 C--N 1.329 -0.296 0 C-N-CA 120.57 -0.452 . . . . 0.0 111.473 -179.429 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 172' ' ' ALA . . . . . . . . . . . . . . . -73.2 -7.53 51.84 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.944 0.402 . . . . 0.0 110.348 179.455 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 173' ' ' ILE . . . . . 0.592 HG22 HD11 ' A' ' 177' ' ' ILE . 31.4 mm -88.75 -24.5 6.03 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.15 0 CA-C-N 115.877 -0.601 . . . . 0.0 110.758 179.402 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 174' ' ' TYR . . . . . 0.598 ' N ' ' HD2' ' A' ' 175' ' ' PRO . 21.4 m-85 -55.11 -50.29 87.35 Favored Pre-proline 0 CA--C 1.53 0.192 0 N-CA-C 112.216 0.45 . . . . 0.0 112.216 -179.614 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 175' ' ' PRO . . . . . 0.598 ' HD2' ' N ' ' A' ' 174' ' ' TYR . 4.1 Cg_endo -47.06 -28.47 7.45 Favored 'Trans proline' 0 C--N 1.352 0.762 0 C-N-CA 122.148 1.899 . . . . 0.0 112.1 179.976 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 176' ' ' PHE . . . . . 0.519 ' O ' ' HG ' ' A' ' 180' ' ' LEU . 92.2 m-85 -80.27 -49.97 10.85 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.31 179.568 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 177' ' ' ILE . . . . . 0.592 HD11 HG22 ' A' ' 173' ' ' ILE . 2.8 mm -59.71 -37.38 70.83 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.581 0 CA-C-N 115.995 -0.548 . . . . 0.0 111.781 -178.593 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 178' ' ' TRP . . . . . . . . . . . . . 70.7 t90 -73.58 -45.38 53.57 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.915 0.388 . . . . 0.0 110.856 179.814 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 179' ' ' LEU . . . . . 0.451 ' O ' ' HA3' ' A' ' 184' ' ' GLY . 1.9 tm? -65.09 -53.12 50.29 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 115.976 -0.556 . . . . 0.0 111.417 -179.233 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 180' ' ' LEU . . . . . 0.604 HD22 HD11 ' A' ' 187' ' ' LEU . 11.1 mt -71.79 -42.96 66.46 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 116.705 -0.225 . . . . 0.0 111.515 -179.208 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . -58.54 175.41 2.56 Favored Glycine 0 C--N 1.335 0.493 0 C-N-CA 120.472 -0.87 . . . . 0.0 112.664 179.772 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 182' ' ' PRO . . . . . 0.714 ' HA ' ' HB2' ' A' ' 186' ' ' ALA . 73.1 Cg_exo -47.91 -44.27 27.72 Favored 'Trans proline' 0 C--N 1.349 0.581 0 C-N-CA 122.767 2.312 . . . . 0.0 113.38 179.791 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 183' ' ' PRO . . . . . 0.554 ' HB3' ' HB2' ' A' ' 116' ' ' ALA . 73.4 Cg_exo -52.08 -17.19 5.41 Favored 'Trans proline' 0 C--N 1.355 0.905 0 C-N-CA 122.119 1.88 . . . . 0.0 112.84 179.557 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 184' ' ' GLY . . . . . 0.451 ' HA3' ' O ' ' A' ' 179' ' ' LEU . . . -114.74 -82.79 1.08 Allowed Glycine 0 N--CA 1.45 -0.379 0 C-N-CA 120.644 -0.789 . . . . 0.0 112.942 -179.715 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 185' ' ' VAL . . . . . 0.409 HG22 ' O ' ' A' ' 179' ' ' LEU . 8.4 m -129.71 -4.16 2.89 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.24 0 N-CA-C 112.349 0.5 . . . . 0.0 112.349 -179.376 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 186' ' ' ALA . . . . . 0.714 ' HB2' ' HA ' ' A' ' 182' ' ' PRO . . . 52.22 89.56 0.03 OUTLIER 'General case' 0 N--CA 1.464 0.241 0 CA-C-O 120.72 0.295 . . . . 0.0 111.635 179.752 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 187' ' ' LEU . . . . . 0.604 HD11 HD22 ' A' ' 180' ' ' LEU . 24.3 mt -92.24 -49.49 6.15 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.443 -0.344 . . . . 0.0 111.678 -179.81 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 188' ' ' LEU . . . . . . . . . . . . . 88.7 mt -93.27 -93.93 0.16 Allowed 'General case' 0 C--N 1.331 -0.23 0 CA-C-O 120.799 0.333 . . . . 0.0 111.23 -179.604 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 189' ' ' THR . . . . . . . . . . . . . 2.2 t -161.44 145.02 9.62 Favored Pre-proline 0 C--N 1.326 -0.418 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.957 179.979 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 190' ' ' PRO . . . . . . . . . . . . . 74.7 Cg_exo -49.15 -40.24 42.05 Favored 'Trans proline' 0 C--N 1.349 0.596 0 C-N-CA 122.747 2.298 . . . . 0.0 113.137 -179.601 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 191' ' ' THR . . . . . . . . . . . . . 38.3 p -58.97 -44.52 91.53 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.795 0.331 . . . . 0.0 111.515 -179.621 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 192' ' ' VAL . . . . . . . . . . . . . 37.2 t -72.65 -46.12 55.5 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.266 -179.947 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 193' ' ' ASP . . . . . . . . . . . . . 32.6 t70 -55.1 -44.07 74.59 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.388 -0.369 . . . . 0.0 111.006 179.844 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 194' ' ' VAL . . . . . 0.514 HG21 HD11 ' A' ' 4' ' ' LEU . 79.8 t -68.64 -36.02 72.66 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.032 179.902 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 195' ' ' ALA . . . . . . . . . . . . . . . -59.12 -46.77 87.48 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-O 120.671 0.272 . . . . 0.0 110.977 179.734 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 196' ' ' LEU . . . . . . . . . . . . . 88.3 mt -67.83 -41.02 83.68 Favored 'General case' 0 C--N 1.332 -0.192 0 CA-C-O 120.841 0.353 . . . . 0.0 110.577 179.576 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 197' ' ' ILE . . . . . . . . . . . . . 17.6 mm -59.16 -58.41 7.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.011 -0.54 . . . . 0.0 110.225 179.203 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 198' ' ' VAL . . . . . 0.421 HG23 ' O ' ' A' ' 194' ' ' VAL . 75.7 t -52.53 -34.79 19.62 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.432 0 CA-C-N 115.633 -0.712 . . . . 0.0 109.199 178.226 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 199' ' ' TYR . . . . . . . . . . . . . 67.5 t80 -70.23 -33.39 71.6 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 115.227 -0.897 . . . . 0.0 110.811 179.965 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 200' ' ' LEU . . . . . 0.443 ' O ' HG12 ' A' ' 203' ' ' VAL . 36.5 mt -68.65 -40.78 80.08 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.039 -0.528 . . . . 0.0 111.375 -179.597 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 201' ' ' ASP . . . . . . . . . . . . . 8.1 m-20 -71.49 -31.64 67.34 Favored 'General case' 0 C--N 1.327 -0.413 0 CA-C-O 121.117 0.484 . . . . 0.0 110.038 179.447 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 202' ' ' LEU . . . . . . . . . . . . . 3.3 mt -71.01 -33.74 70.67 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 115.546 -0.752 . . . . 0.0 111.955 -179.671 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 203' ' ' VAL . . . . . 0.495 ' O ' ' HA3' ' A' ' 207' ' ' GLY . 7.8 p -77.1 -36.39 24.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 N-CA-C 111.593 0.22 . . . . 0.0 111.593 -178.743 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 204' ' ' THR . . . . . . . . . . . . . 57.5 m -70.58 -52.25 22.81 Favored 'General case' 0 C--N 1.327 -0.372 0 C-N-CA 120.682 -0.407 . . . . 0.0 111.6 179.735 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 205' ' ' LYS . . . . . 0.688 ' HE2' ' HB2' ' A' ' 47' ' ' ALA . 53.8 mttp -70.53 -59.12 3.02 Favored 'General case' 0 C--N 1.327 -0.385 0 N-CA-C 112.27 0.47 . . . . 0.0 112.27 -178.67 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 23.3 t -72.87 -37.82 55.4 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.357 0 CA-C-N 116.333 -0.394 . . . . 0.0 111.724 -178.814 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 207' ' ' GLY . . . . . 0.53 ' O ' HG12 ' A' ' 211' ' ' ILE . . . -62.71 -59.04 9.81 Favored Glycine 0 N--CA 1.452 -0.286 0 C-N-CA 120.353 -0.927 . . . . 0.0 112.429 -179.641 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 208' ' ' PHE . . . . . 0.473 ' O ' ' N ' ' A' ' 212' ' ' ALA . 2.2 m-30 -53.66 -49.95 66.85 Favored 'General case' 0 C--O 1.221 -0.4 0 CA-C-O 120.798 0.332 . . . . 0.0 110.112 179.992 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 209' ' ' GLY . . . . . 0.476 ' O ' ' HB3' ' A' ' 212' ' ' ALA . . . -54.19 -31.42 49.42 Favored Glycine 0 N--CA 1.449 -0.487 0 CA-C-N 115.444 -0.798 . . . . 0.0 112.456 178.927 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 210' ' ' PHE . . . . . . . . . . . . . 1.8 m-85 -72.41 -48.73 39.1 Favored 'General case' 0 C--N 1.328 -0.33 0 N-CA-C 108.764 -0.828 . . . . 0.0 108.764 178.755 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 211' ' ' ILE . . . . . 0.53 HG12 ' O ' ' A' ' 207' ' ' GLY . 0.6 OUTLIER -63.7 -27.21 42.43 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.297 0 N-CA-C 107.246 -1.39 . . . . 0.0 107.246 176.685 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 212' ' ' ALA . . . . . 0.476 ' HB3' ' O ' ' A' ' 209' ' ' GLY . . . -68.03 -43.66 78.24 Favored 'General case' 0 N--CA 1.448 -0.534 0 CA-C-N 114.044 -1.434 . . . . 0.0 110.764 -179.418 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 213' ' ' LEU . . . . . . . . . . . . . 71.5 mt -70.52 -54.98 10.05 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 115.191 -0.913 . . . . 0.0 112.112 -179.19 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 214' ' ' ASP . . . . . . . . . . . . . 29.4 t70 -54.96 -54.44 42.76 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.392 -0.367 . . . . 0.0 111.858 -179.099 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 215' ' ' ALA . . . . . . . . . . . . . . . -58.44 -57.16 14.14 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 116.312 -0.404 . . . . 0.0 111.898 -179.344 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 216' ' ' ALA . . . . . . . . . . . . . . . -57.57 -33.97 68.71 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.331 -0.395 . . . . 0.0 111.682 -179.367 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 217' ' ' ALA . . . . . . . . . . . . . . . -61.06 -41.58 96.88 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.953 0.406 . . . . 0.0 110.451 179.887 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 218' ' ' THR . . . . . . . . . . . . . 95.9 m . . . . . 0 C--N 1.329 -0.321 0 CA-C-N 115.829 -0.623 . . . . 0.0 110.896 179.737 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.28 0 N-CA-C 112.33 -0.308 . . . . 0.0 112.33 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 49.8 tp -74.38 -35.54 63.49 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-O 120.778 0.323 . . . . 0.0 111.06 -179.974 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 69.1 p -61.06 -30.32 70.26 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.361 -179.751 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 28.0 p -54.56 -35.49 63.33 Favored 'General case' 0 C--N 1.331 -0.2 0 CA-C-N 116.278 -0.419 . . . . 0.0 111.248 -179.965 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 7' ' ' LEU . . . . . . . . . . . . . 4.0 mm? -56.65 -52.3 65.43 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 115.951 -0.568 . . . . 0.0 111.103 -179.903 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 8' ' ' PHE . . . . . 0.6 ' HB2' ' HB2' ' A' ' 55' ' ' ALA . 62.9 m-85 -64.47 -31.96 73.38 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.34 -0.391 . . . . 0.0 110.934 -179.989 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 9' ' ' TRP . . . . . 0.402 ' O ' HG12 ' A' ' 13' ' ' ILE . 35.3 m95 -65.61 -41.69 92.47 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.173 -179.92 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 56.1 mt -67.17 -32.43 73.51 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-N 115.761 -0.654 . . . . 0.0 109.962 179.377 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . 0.436 ' HA2' HD11 ' A' ' 202' ' ' LEU . . . -73.65 -27.72 66.74 Favored Glycine 0 N--CA 1.446 -0.67 0 CA-C-N 115.665 -0.698 . . . . 0.0 111.702 179.3 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -73.62 -33.91 64.78 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.834 0.35 . . . . 0.0 110.543 179.396 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 13' ' ' ILE . . . . . 0.439 ' O ' HG23 ' A' ' 17' ' ' VAL . 48.8 mm -68.22 -54.2 23.66 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.232 0 CA-C-N 116.002 -0.545 . . . . 0.0 110.397 179.423 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -59.18 -40.06 95.28 Favored Glycine 0 N--CA 1.45 -0.385 0 C-N-CA 120.635 -0.793 . . . . 0.0 111.48 179.221 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 15' ' ' MET . . . . . 0.516 ' SD ' ' HA ' ' A' ' 44' ' ' SER . 52.7 tpp -62.1 -43.6 98.49 Favored 'General case' 0 N--CA 1.453 -0.301 0 N-CA-C 109.99 -0.374 . . . . 0.0 109.99 179.295 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 45.4 tp -55.19 -38.18 68.02 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 115.746 -0.661 . . . . 0.0 110.222 179.184 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 17' ' ' VAL . . . . . 0.439 HG23 ' O ' ' A' ' 13' ' ' ILE . 44.2 t -62.13 -42.09 93.75 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.215 0 CA-C-N 115.891 -0.595 . . . . 0.0 109.971 179.243 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -66.26 -42.52 94.11 Favored Glycine 0 C--N 1.331 0.272 0 C-N-CA 120.69 -0.767 . . . . 0.0 111.58 178.928 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 7.9 m -52.09 -49.82 62.82 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.812 0.339 . . . . 0.0 111.074 179.945 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 20' ' ' LEU . . . . . 0.409 ' O ' ' HB3' ' A' ' 24' ' ' TRP . 95.0 mt -71.91 -35.6 69.73 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.435 179.926 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -62.21 -34.55 76.69 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.68 0.276 . . . . 0.0 111.648 -179.569 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 22' ' ' PHE . . . . . 0.543 ' HB2' HG22 ' A' ' 41' ' ' VAL . 11.0 m-85 -89.95 -30.33 17.89 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.478 -0.328 . . . . 0.0 111.434 -179.442 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -72.88 -50.03 26.31 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.479 -0.328 . . . . 0.0 111.228 -179.941 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 24' ' ' TRP . . . . . 0.409 ' HB3' ' O ' ' A' ' 20' ' ' LEU . 1.1 t-105 -60.66 -43.42 97.67 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.054 -0.521 . . . . 0.0 111.012 179.907 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.33 -0.282 0 CA-C-N 116.334 -0.393 . . . . 0.0 110.907 179.927 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.317 0 N-CA-C 111.77 -0.532 . . . . 0.0 111.77 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 31.9 mm-40 -91.93 -20.16 21.7 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-O 120.792 0.33 . . . . 0.0 110.686 179.819 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 34' ' ' ARG . . . . . . . . . . . . . 55.4 ttp180 -47.95 -31.68 5.52 Favored 'General case' 0 C--N 1.332 -0.162 0 CA-C-N 115.974 -0.557 . . . . 0.0 111.385 -179.81 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 40.4 ttm180 -61.23 -49.46 77.02 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-O 120.856 0.36 . . . . 0.0 110.894 -179.943 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 75.9 m-85 -70.04 -37.47 75.59 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.025 -0.534 . . . . 0.0 111.568 -179.593 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 37' ' ' TYR . . . . . 0.539 ' O ' HG23 ' A' ' 41' ' ' VAL . 35.3 m-85 -65.74 -54.75 22.95 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.318 -0.401 . . . . 0.0 111.516 -179.396 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 90.6 t -56.7 -38.18 56.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-O 120.918 0.39 . . . . 0.0 110.667 179.894 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 17.4 m -61.68 -50.95 70.42 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 115.933 -0.576 . . . . 0.0 110.616 179.346 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 40' ' ' LEU . . . . . 0.56 HD12 HD12 ' A' ' 43' ' ' ILE . 40.2 tp -59.71 -50.52 73.52 Favored 'General case' 0 C--O 1.235 0.333 0 CA-C-N 115.745 -0.661 . . . . 0.0 110.831 179.894 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . 0.543 HG22 ' HB2' ' A' ' 22' ' ' PHE . 60.2 t -56.1 -34.3 38.53 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 115.834 -0.621 . . . . 0.0 110.294 179.26 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -60.94 -43.59 99.18 Favored Glycine 0 N--CA 1.45 -0.411 0 C-N-CA 120.739 -0.743 . . . . 0.0 111.826 179.597 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 43' ' ' ILE . . . . . 0.56 HD12 HD12 ' A' ' 40' ' ' LEU . 1.3 mt -58.55 -51.92 65.81 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.195 0 CA-C-O 120.792 0.329 . . . . 0.0 110.791 179.426 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 44' ' ' SER . . . . . 0.516 ' HA ' ' SD ' ' A' ' 15' ' ' MET . 44.7 m -59.66 -27.02 66.02 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.557 -179.772 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -73.79 -56.55 5.35 Favored Glycine 0 CA--C 1.519 0.33 0 C-N-CA 120.643 -0.789 . . . . 0.0 113.002 -179.588 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 24.3 pt -58.46 -35.45 54.41 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.214 0 CA-C-O 121.025 0.441 . . . . 0.0 111.295 -179.856 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 47' ' ' ALA . . . . . 0.74 ' HB2' ' HE2' ' A' ' 205' ' ' LYS . . . -66.98 -49.25 65.97 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.586 179.851 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -54.16 -44.39 71.42 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 115.983 -0.553 . . . . 0.0 111.962 -179.112 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 49' ' ' VAL . . . . . 0.406 ' O ' HG13 ' A' ' 53' ' ' VAL . 30.1 m -68.29 -34.24 64.99 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 C-N-CA 120.98 -0.288 . . . . 0.0 111.073 -179.731 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -67.54 -37.06 82.15 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-O 121.016 0.436 . . . . 0.0 110.939 179.264 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 38.7 m-85 -68.54 -38.76 81.11 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.028 -0.533 . . . . 0.0 110.214 -179.948 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -65.02 -50.71 65.19 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 115.804 -0.635 . . . . 0.0 111.088 179.592 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 53' ' ' VAL . . . . . 0.485 HG23 ' N ' ' A' ' 54' ' ' MET . 25.3 m -60.78 -47.9 91.16 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.109 0 CA-C-N 116.527 -0.306 . . . . 0.0 110.85 -179.939 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 54' ' ' MET . . . . . 0.514 ' HG2' ' HG2' ' A' ' 71' ' ' PRO . 74.3 mtm -62.42 -31.55 72.26 Favored 'General case' 0 C--N 1.331 -0.225 0 N-CA-C 109.607 -0.516 . . . . 0.0 109.607 179.068 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 55' ' ' ALA . . . . . 0.6 ' HB2' ' HB2' ' A' ' 8' ' ' PHE . . . -72.69 -22.49 60.9 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 115.527 -0.761 . . . . 0.0 110.981 179.583 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 81.0 mt -87.42 -5.52 58.81 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.118 179.996 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 90.15 -14.68 61.55 Favored Glycine 0 N--CA 1.45 -0.418 0 C-N-CA 120.622 -0.799 . . . . 0.0 112.911 179.765 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 58' ' ' VAL . . . . . 0.424 HG12 ' O ' ' A' ' 53' ' ' VAL . 9.0 p -69.5 141.64 17.01 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-O 120.85 0.357 . . . . 0.0 110.801 179.885 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 59' ' ' GLY . . . . . 0.411 ' HA3' ' HG3' ' A' ' 71' ' ' PRO . . . 92.39 -5.62 77.74 Favored Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.868 -0.682 . . . . 0.0 112.153 -179.268 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 60' ' ' TRP . . . . . . . . . . . . . 19.6 m0 -80.1 111.98 16.97 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-O 120.578 0.228 . . . . 0.0 110.785 179.919 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 61' ' ' VAL . . . . . 0.569 HG13 HG23 ' A' ' 68' ' ' VAL . 7.1 p -115.02 128.75 25.66 Favored Pre-proline 0 CA--C 1.533 0.315 0 CA-C-N 116.512 -0.313 . . . . 0.0 110.951 179.566 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 71.7 Cg_endo -76.39 156.0 36.76 Favored 'Trans proline' 0 C--N 1.35 0.629 0 C-N-CA 122.47 2.113 . . . . 0.0 112.725 -179.873 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 84.2 t -143.15 89.89 0.41 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 115.764 -0.653 . . . . 0.0 110.599 179.879 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . 58.71 -88.38 0.02 OUTLIER 'General case' 0 C--N 1.331 -0.196 0 CA-C-N 116.115 -0.493 . . . . 0.0 111.306 -179.756 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 45.5 mt-10 -120.5 -17.78 8.02 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 116.386 -0.37 . . . . 0.0 110.828 179.807 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 66' ' ' ARG . . . . . 0.468 ' HA ' ' HE ' ' A' ' 66' ' ' ARG . 3.0 mmp_? -100.29 163.5 12.37 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.25 179.672 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 85.3 m -125.83 133.91 51.82 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 121.023 0.439 . . . . 0.0 111.516 -179.673 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 68' ' ' VAL . . . . . 0.569 HG23 HG13 ' A' ' 61' ' ' VAL . 17.9 m -123.3 144.69 32.02 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-N 115.857 -0.611 . . . . 0.0 110.469 179.417 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 69' ' ' PHE . . . . . . . . . . . . . 19.4 m-85 -110.45 112.21 23.98 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.359 -0.382 . . . . 0.0 110.109 -179.217 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 70' ' ' VAL . . . . . 0.63 ' N ' ' HD2' ' A' ' 71' ' ' PRO . 28.3 t -66.02 -47.49 62.83 Favored Pre-proline 0 C--N 1.323 -0.553 0 CA-C-N 116.234 -0.439 . . . . 0.0 112.01 -179.362 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 71' ' ' PRO . . . . . 0.63 ' HD2' ' N ' ' A' ' 70' ' ' VAL . 13.9 Cg_endo -57.15 -22.22 46.9 Favored 'Trans proline' 0 C--N 1.351 0.709 0 C-N-CA 121.982 1.788 . . . . 0.0 111.773 179.518 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 60.7 ttp180 -75.91 -53.3 8.63 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.585 179.694 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 73' ' ' TYR . . . . . . . . . . . . . 69.3 m-85 -64.6 -45.76 85.56 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 115.967 -0.56 . . . . 0.0 110.709 179.912 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 0.4 OUTLIER -60.86 -36.56 72.46 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 N-CA-C 109.807 -0.442 . . . . 0.0 109.807 179.362 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 75' ' ' ASP . . . . . 0.415 ' O ' HG23 ' A' ' 79' ' ' THR . 24.3 t70 -60.38 -37.97 82.44 Favored 'General case' 0 C--N 1.331 -0.209 0 N-CA-C 109.466 -0.568 . . . . 0.0 109.466 178.918 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 76' ' ' TRP . . . . . . . . . . . . . 47.4 m0 -67.08 -29.2 68.9 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 115.717 -0.674 . . . . 0.0 110.289 179.452 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 77' ' ' ILE . . . . . 0.426 ' O ' ' HG2' ' A' ' 81' ' ' PRO . 73.7 mt -72.4 -30.42 34.77 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.373 0 CA-C-N 115.838 -0.619 . . . . 0.0 110.626 179.395 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 40.2 mt -91.88 -16.69 26.33 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.209 -0.451 . . . . 0.0 111.989 -179.954 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 79' ' ' THR . . . . . 0.415 HG23 ' O ' ' A' ' 75' ' ' ASP . 76.7 p -101.97 -49.02 4.06 Favored 'General case' 0 N--CA 1.464 0.262 0 N-CA-C 113.465 0.913 . . . . 0.0 113.465 -178.27 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 80' ' ' THR . . . . . 0.679 ' HB ' ' HD3' ' A' ' 81' ' ' PRO . 44.2 m -53.11 -54.46 44.2 Favored Pre-proline 0 CA--C 1.531 0.22 0 N-CA-C 112.226 0.454 . . . . 0.0 112.226 -178.338 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 81' ' ' PRO . . . . . 0.679 ' HD3' ' HB ' ' A' ' 80' ' ' THR . 34.2 Cg_exo -61.12 -19.72 64.64 Favored 'Trans proline' 0 C--N 1.352 0.735 0 C-N-CA 121.552 1.502 . . . . 0.0 111.28 179.578 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 82' ' ' LEU . . . . . . . . . . . . . 13.1 tp -76.89 -36.56 56.61 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 115.66 -0.7 . . . . 0.0 110.558 179.909 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 35.2 mm -68.02 -52.54 37.83 Favored 'Isoleucine or valine' 0 C--O 1.233 0.235 0 CA-C-N 116.308 -0.405 . . . . 0.0 110.08 179.251 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 30.9 m -59.58 -32.74 49.78 Favored 'Isoleucine or valine' 0 CA--C 1.52 -0.195 0 N-CA-C 109.482 -0.562 . . . . 0.0 109.482 178.796 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 85' ' ' TYR . . . . . . . . . . . . . 89.5 t80 -62.65 -34.63 77.46 Favored 'General case' 0 N--CA 1.454 -0.258 0 CA-C-N 115.528 -0.76 . . . . 0.0 109.163 178.595 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 86' ' ' PHE . . . . . . . . . . . . . 11.3 t80 -61.36 -51.72 67.65 Favored 'General case' 0 N--CA 1.456 -0.126 0 CA-C-N 115.561 -0.745 . . . . 0.0 109.879 179.201 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 7.6 mp -58.6 -36.43 74.0 Favored 'General case' 0 C--N 1.331 -0.202 0 CA-C-N 115.89 -0.595 . . . . 0.0 110.194 179.426 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 88' ' ' GLY . . . . . 0.475 ' HA2' HD13 ' A' ' 93' ' ' LEU . . . -64.93 -28.1 73.04 Favored Glycine 0 N--CA 1.45 -0.399 0 C-N-CA 120.916 -0.659 . . . . 0.0 112.165 179.575 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 86.5 mt -74.08 -41.25 61.97 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.902 0.382 . . . . 0.0 110.741 179.732 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 74.8 mt -58.73 -47.56 84.19 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 115.913 -0.585 . . . . 0.0 111.158 -179.756 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -74.77 -42.44 58.17 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.376 -0.375 . . . . 0.0 111.149 -179.875 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 93.06 55.96 1.54 Allowed Glycine 0 N--CA 1.45 -0.422 0 C-N-CA 120.832 -0.699 . . . . 0.0 112.466 -179.945 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 93' ' ' LEU . . . . . 0.565 HD23 ' HB3' ' A' ' 97' ' ' GLU . 9.7 mp -67.71 -176.4 0.64 Allowed 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.809 0.338 . . . . 0.0 110.908 -179.943 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 94' ' ' ASP . . . . . . . . . . . . . 10.4 m-20 -113.47 172.97 6.64 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.472 -179.929 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 45.4 t -54.03 -36.27 62.85 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.312 -0.404 . . . . 0.0 111.372 -179.759 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 96' ' ' ARG . . . . . 0.402 ' O ' HG13 ' A' ' 100' ' ' ILE . 29.3 mmm180 -73.98 -47.88 34.21 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 116.279 -0.419 . . . . 0.0 111.457 -179.85 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 97' ' ' GLU . . . . . 0.565 ' HB3' HD23 ' A' ' 93' ' ' LEU . 47.6 mt-10 -60.19 -44.59 94.96 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-O 120.912 0.387 . . . . 0.0 110.584 -179.387 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 98' ' ' PHE . . . . . 0.448 ' O ' HG12 ' A' ' 102' ' ' ILE . 12.8 m-85 -59.91 -47.95 83.66 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 115.869 -0.605 . . . . 0.0 110.514 179.325 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -55.22 -32.02 56.86 Favored Glycine 0 N--CA 1.452 -0.276 0 C-N-CA 120.799 -0.715 . . . . 0.0 112.697 179.922 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 100' ' ' ILE . . . . . 0.451 ' O ' HG22 ' A' ' 103' ' ' THR . 89.5 mt -69.51 -54.0 21.91 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.222 0 CA-C-O 120.956 0.408 . . . . 0.0 111.676 -179.894 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 17.2 t -64.7 -42.79 96.0 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.355 0 CA-C-N 116.136 -0.484 . . . . 0.0 111.933 -179.203 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 102' ' ' ILE . . . . . 0.448 HG12 ' O ' ' A' ' 98' ' ' PHE . 48.8 mm -63.67 -53.13 48.69 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-N 116.326 -0.397 . . . . 0.0 111.698 -179.325 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 103' ' ' THR . . . . . 0.451 HG22 ' O ' ' A' ' 100' ' ' ILE . 12.8 t -55.03 -35.38 64.39 Favored 'General case' 0 C--O 1.234 0.244 0 CA-C-O 120.869 0.366 . . . . 0.0 110.726 -179.909 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 104' ' ' LEU . . . . . 0.48 HD22 ' HE2' ' A' ' 140' ' ' TYR . 29.3 tp -61.08 -49.45 77.26 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.296 179.216 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 105' ' ' ASN . . . . . 0.58 ' N ' HD22 ' A' ' 105' ' ' ASN . 0.8 OUTLIER -59.1 -26.36 64.62 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.054 -0.521 . . . . 0.0 110.562 179.808 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 33.2 m -66.47 -54.16 27.22 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.276 -0.42 . . . . 0.0 111.158 179.697 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 12.8 p -66.25 -36.29 77.04 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.152 0 CA-C-N 116.486 -0.325 . . . . 0.0 111.356 -179.834 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . 0.412 HG23 ' O ' ' A' ' 104' ' ' LEU . 73.7 t -62.62 -56.86 14.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-O 120.885 0.374 . . . . 0.0 111.104 -179.949 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 109' ' ' MET . . . . . 0.442 ' HE1' HG21 ' A' ' 80' ' ' THR . 7.1 tpp -60.48 -31.66 70.67 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.451 179.998 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 110' ' ' LEU . . . . . 0.491 HD23 ' C ' ' A' ' 110' ' ' LEU . 5.0 tt -64.19 -37.86 88.97 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-N 115.81 -0.632 . . . . 0.0 109.595 178.714 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -60.78 -50.58 72.86 Favored 'General case' 0 C--N 1.333 -0.137 0 CA-C-N 115.883 -0.598 . . . . 0.0 110.827 179.671 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . -59.38 -45.91 94.72 Favored Glycine 0 C--N 1.331 0.263 0 C-N-CA 120.687 -0.768 . . . . 0.0 112.074 179.645 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 113' ' ' PHE . . . . . . . . . . . . . 3.0 t80 -49.73 -65.66 0.53 Allowed 'General case' 0 C--N 1.333 -0.128 0 CA-C-O 120.91 0.386 . . . . 0.0 110.382 179.696 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -64.79 -17.77 64.5 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 115.901 -0.59 . . . . 0.0 110.952 179.927 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 115' ' ' GLY . . . . . 0.506 ' O ' HG22 ' A' ' 118' ' ' VAL . . . -57.24 -52.32 52.2 Favored Glycine 0 N--CA 1.45 -0.385 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.045 179.579 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -78.32 -15.06 59.11 Favored 'General case' 0 C--N 1.328 -0.351 0 N-CA-C 111.984 0.364 . . . . 0.0 111.984 179.904 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 117' ' ' MET . . . . . 0.501 ' SD ' HG21 ' A' ' 68' ' ' VAL . 26.0 mmt -80.88 19.86 0.82 Allowed 'General case' 0 N--CA 1.464 0.259 0 N-CA-C 112.182 0.438 . . . . 0.0 112.182 -178.985 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 118' ' ' VAL . . . . . 0.524 HG21 ' N ' ' A' ' 123' ' ' ARG . 17.6 m -113.24 157.74 40.16 Favored Pre-proline 0 C--N 1.328 -0.343 0 CA-C-N 116.756 -0.202 . . . . 0.0 111.208 179.819 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 119' ' ' PRO . . . . . 0.435 ' HD2' ' HB ' ' A' ' 118' ' ' VAL . 69.2 Cg_endo -73.96 -24.44 15.17 Favored 'Trans proline' 0 C--N 1.347 0.493 0 C-N-CA 122.414 2.076 . . . . 0.0 112.382 179.667 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . 152.56 151.86 5.8 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.831 179.935 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 18.9 mm 73.73 -46.94 0.17 Allowed 'Isoleucine or valine' 0 N--CA 1.466 0.334 0 C-N-CA 122.956 0.503 . . . . 0.0 111.715 -179.821 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 14.3 mm-40 -60.17 -28.25 67.78 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.103 180.0 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 123' ' ' ARG . . . . . 0.564 ' HD3' ' HA2' ' A' ' 184' ' ' GLY . 6.5 ptp180 -60.23 -29.49 68.8 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.012 -0.54 . . . . 0.0 111.03 179.896 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 124' ' ' TYR . . . . . . . . . . . . . 30.2 m-85 -69.24 -32.15 71.18 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 115.84 -0.618 . . . . 0.0 111.349 -179.707 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 125' ' ' ALA . . . . . . . . . . . . . . . -73.32 -56.41 5.11 Favored 'General case' 0 C--O 1.236 0.364 0 CA-C-O 121.05 0.452 . . . . 0.0 111.03 179.961 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 1.4 mt -56.04 -50.47 70.84 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.814 -0.63 . . . . 0.0 110.719 -179.926 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 127' ' ' PHE . . . . . 0.429 ' HZ ' ' HB3' ' A' ' 175' ' ' PRO . 9.4 t80 -65.69 -36.19 82.93 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.378 -0.374 . . . . 0.0 110.229 179.459 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 128' ' ' GLY . . . . . . . . . . . . . . . -46.29 -44.54 15.36 Favored Glycine 0 C--N 1.332 0.347 0 C-N-CA 120.171 -1.014 . . . . 0.0 110.822 178.925 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 129' ' ' MET . . . . . . . . . . . . . 0.5 OUTLIER -71.83 -36.47 70.2 Favored 'General case' 0 N--CA 1.453 -0.315 0 N-CA-C 109.833 -0.432 . . . . 0.0 109.833 178.663 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -63.13 -33.08 86.27 Favored Glycine 0 C--N 1.333 0.364 0 CA-C-N 115.794 -0.639 . . . . 0.0 112.867 -179.756 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -74.11 -53.87 9.0 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.681 0.277 . . . . 0.0 110.454 -179.99 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 44.2 t -56.91 -39.94 68.54 Favored 'Isoleucine or valine' 0 C--O 1.234 0.26 0 N-CA-C 109.344 -0.613 . . . . 0.0 109.344 178.764 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -67.4 -36.46 81.33 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 115.305 -0.862 . . . . 0.0 110.167 178.986 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 134' ' ' PHE . . . . . . . . . . . . . 84.7 t80 -56.6 -50.63 71.41 Favored 'General case' 0 N--CA 1.452 -0.335 0 CA-C-N 116.126 -0.488 . . . . 0.0 109.81 179.394 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 135' ' ' ILE . . . . . 0.485 ' O ' HG22 ' A' ' 138' ' ' VAL . 52.8 mt -59.28 -33.53 51.2 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.38 0 CA-C-N 115.67 -0.695 . . . . 0.0 110.207 179.204 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . -63.02 -41.09 99.95 Favored Glycine 0 N--CA 1.448 -0.548 0 C-N-CA 120.209 -0.996 . . . . 0.0 111.292 178.87 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 137' ' ' LEU . . . . . 0.478 HD13 HD21 ' A' ' 105' ' ' ASN . 57.9 tp -67.11 -53.94 26.07 Favored 'General case' 0 N--CA 1.454 -0.269 0 CA-C-O 120.499 0.19 . . . . 0.0 110.889 179.733 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 138' ' ' VAL . . . . . 0.485 HG22 ' O ' ' A' ' 135' ' ' ILE . 4.9 m -54.48 -33.84 27.43 Favored 'Isoleucine or valine' 0 C--O 1.233 0.205 0 CA-C-O 121.09 0.471 . . . . 0.0 109.746 -179.696 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 139' ' ' TYR . . . . . . . . . . . . . 24.2 t80 -59.8 -42.96 94.57 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 115.621 -0.718 . . . . 0.0 109.864 178.299 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 140' ' ' TYR . . . . . 0.48 ' HE2' HD22 ' A' ' 104' ' ' LEU . 25.8 m-85 -65.19 -45.74 83.59 Favored 'General case' 0 C--N 1.333 -0.142 0 CA-C-N 116.083 -0.508 . . . . 0.0 111.13 179.38 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 141' ' ' LEU . . . . . . . . . . . . . 10.6 mp -54.48 -32.65 58.2 Favored 'General case' 0 C--N 1.332 -0.171 0 CA-C-N 116.283 -0.417 . . . . 0.0 111.178 -179.745 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 142' ' ' VAL . . . . . 0.417 HG22 ' O ' ' A' ' 142' ' ' VAL . 11.1 p -106.84 -2.41 9.98 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-N 116.233 -0.44 . . . . 0.0 111.121 -179.812 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . -75.61 -120.61 0.13 Allowed Glycine 0 CA--C 1.522 0.469 0 C-N-CA 120.829 -0.701 . . . . 0.0 112.68 -179.848 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 144' ' ' PRO . . . . . . . . . . . . . 56.1 Cg_endo -69.64 -23.65 31.09 Favored 'Trans proline' 0 C--N 1.348 0.54 0 C-N-CA 122.489 2.126 . . . . 0.0 112.433 179.923 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 145' ' ' MET . . . . . 0.433 ' HB3' ' OH ' ' A' ' 160' ' ' TYR . 48.8 mtt -53.62 -58.85 5.7 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.103 -0.499 . . . . 0.0 111.84 -179.712 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 146' ' ' THR . . . . . . . . . . . . . 9.0 t -56.03 -32.45 64.04 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.327 -0.397 . . . . 0.0 111.888 -179.118 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 43.0 mt-10 -70.41 -41.16 73.31 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.645 -0.252 . . . . 0.0 111.329 -179.735 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 148' ' ' SER . . . . . . . . . . . . . 67.4 m -69.74 -41.81 74.76 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.432 -0.349 . . . . 0.0 111.304 -179.329 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 149' ' ' ALA . . . . . . . . . . . . . . . -70.23 -37.54 75.0 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.255 -0.429 . . . . 0.0 111.444 -179.656 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 150' ' ' SER . . . . . . . . . . . . . 75.8 m -68.2 -4.12 12.93 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.381 -0.372 . . . . 0.0 111.057 179.98 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 151' ' ' GLN . . . . . . . . . . . . . 50.4 mt-30 -117.66 4.29 12.33 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.333 -0.394 . . . . 0.0 111.043 179.876 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 7.9 tpm_? -83.81 -51.81 6.9 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 120.971 0.415 . . . . 0.0 110.617 179.863 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 153' ' ' SER . . . . . 0.565 ' HB2' HG12 ' A' ' 156' ' ' ILE . 35.3 m -157.65 172.9 17.69 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 115.768 -0.651 . . . . 0.0 110.544 179.612 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 154' ' ' SER . . . . . . . . . . . . . 66.4 p -71.86 -37.92 70.14 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-O 120.828 0.347 . . . . 0.0 110.433 179.432 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -76.63 -34.71 43.23 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 121.001 -0.619 . . . . 0.0 112.646 179.848 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 156' ' ' ILE . . . . . 0.565 HG12 ' HB2' ' A' ' 153' ' ' SER . 34.2 mm -59.52 -36.76 66.59 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-O 120.84 0.353 . . . . 0.0 111.167 179.958 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 157' ' ' LYS . . . . . . . . . . . . . 86.4 tttt -61.23 -54.99 37.25 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 116.078 -0.51 . . . . 0.0 111.524 -179.713 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 49.0 m -66.39 -38.99 88.76 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.964 -179.152 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 159' ' ' LEU . . . . . . . . . . . . . 6.4 tt -68.55 -37.05 79.6 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.725 -0.216 . . . . 0.0 111.546 -179.119 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 160' ' ' TYR . . . . . 0.433 ' OH ' ' HB3' ' A' ' 145' ' ' MET . 37.7 t80 -74.09 -47.43 36.53 Favored 'General case' 0 C--N 1.33 -0.265 0 N-CA-C 111.807 0.299 . . . . 0.0 111.807 -179.087 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 27.9 m -57.21 -41.73 78.57 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-O 120.674 0.273 . . . . 0.0 111.453 -179.332 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 162' ' ' ARG . . . . . 0.405 ' O ' HD23 ' A' ' 166' ' ' LEU . 32.5 tpt180 -68.96 -43.92 74.01 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-O 120.867 0.365 . . . . 0.0 111.204 -179.913 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 163' ' ' LEU . . . . . 0.496 ' HG ' ' HB2' ' A' ' 208' ' ' PHE . 3.9 mp -62.41 -47.41 84.22 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 115.917 -0.583 . . . . 0.0 111.973 -179.247 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 164' ' ' ARG . . . . . 0.462 ' HG3' ' N ' ' A' ' 165' ' ' ASN . 4.5 ptt180 -67.64 -40.86 84.55 Favored 'General case' 0 C--N 1.329 -0.288 0 N-CA-C 111.829 0.307 . . . . 0.0 111.829 -178.926 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 165' ' ' ASN . . . . . 0.501 ' O ' HG23 ' A' ' 169' ' ' VAL . 0.9 OUTLIER -58.77 -52.07 67.28 Favored 'General case' 0 C--N 1.327 -0.372 0 N-CA-C 111.946 0.35 . . . . 0.0 111.946 -179.231 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 166' ' ' LEU . . . . . 0.405 HD23 ' O ' ' A' ' 162' ' ' ARG . 3.0 pp -68.22 -44.29 76.09 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.707 0.289 . . . . 0.0 111.455 -179.485 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 167' ' ' THR . . . . . . . . . . . . . 71.5 m -58.48 -50.87 72.18 Favored 'General case' 0 C--N 1.331 -0.218 0 N-CA-C 112.198 0.444 . . . . 0.0 112.198 -179.402 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 168' ' ' VAL . . . . . 0.409 HG13 ' N ' ' A' ' 169' ' ' VAL . 9.2 p -61.7 -41.12 89.22 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 N-CA-C 111.713 0.264 . . . . 0.0 111.713 -179.014 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 169' ' ' VAL . . . . . 0.501 HG23 ' O ' ' A' ' 165' ' ' ASN . 55.1 t -60.98 -59.41 4.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-O 120.769 0.318 . . . . 0.0 111.175 -179.883 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 170' ' ' LEU . . . . . 0.577 HD22 HG12 ' A' ' 203' ' ' VAL . 3.9 pp -61.86 -31.63 71.91 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.358 -0.383 . . . . 0.0 110.982 -179.455 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 171' ' ' TRP . . . . . 0.425 ' HD1' HD12 ' A' ' 170' ' ' LEU . 3.4 m0 -72.07 -32.08 66.71 Favored 'General case' 0 N--CA 1.463 0.205 0 CA-C-O 120.89 0.376 . . . . 0.0 110.095 178.952 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 172' ' ' ALA . . . . . . . . . . . . . . . -69.07 -7.17 33.37 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 115.982 -0.554 . . . . 0.0 110.692 179.646 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 173' ' ' ILE . . . . . 0.494 ' O ' HG12 ' A' ' 177' ' ' ILE . 29.2 mm -88.19 -26.65 5.65 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.263 0 CA-C-N 115.939 -0.573 . . . . 0.0 110.919 179.794 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 174' ' ' TYR . . . . . 0.465 ' HB2' ' HD3' ' A' ' 175' ' ' PRO . 34.4 m-85 -53.77 -48.81 92.25 Favored Pre-proline 0 C--N 1.332 -0.163 0 CA-C-N 116.311 -0.404 . . . . 0.0 111.574 -179.737 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 175' ' ' PRO . . . . . 0.465 ' HD3' ' HB2' ' A' ' 174' ' ' TYR . 84.8 Cg_exo -47.93 -32.39 17.69 Favored 'Trans proline' 0 C--N 1.352 0.722 0 C-N-CA 122.007 1.805 . . . . 0.0 112.199 179.558 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 176' ' ' PHE . . . . . 0.439 ' O ' ' HG ' ' A' ' 180' ' ' LEU . 81.5 m-85 -80.76 -50.59 9.67 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.059 -0.519 . . . . 0.0 111.803 -179.931 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 177' ' ' ILE . . . . . 0.494 HG12 ' O ' ' A' ' 173' ' ' ILE . 6.8 mm -62.07 -30.86 49.64 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.585 0 CA-C-N 116.104 -0.498 . . . . 0.0 112.022 -178.338 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 178' ' ' TRP . . . . . 0.435 ' HH2' ' HB2' ' A' ' 123' ' ' ARG . 73.9 t90 -73.6 -47.42 40.48 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-O 120.854 0.359 . . . . 0.0 110.662 179.714 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 179' ' ' LEU . . . . . 0.56 HD23 HD23 ' A' ' 180' ' ' LEU . 0.7 OUTLIER -70.96 -54.61 10.69 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 115.97 -0.559 . . . . 0.0 111.409 -179.287 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 180' ' ' LEU . . . . . 0.56 HD23 HD23 ' A' ' 179' ' ' LEU . 24.8 mt -64.78 -38.02 89.58 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.556 -0.293 . . . . 0.0 111.151 -179.779 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . -61.73 178.46 4.43 Favored Glycine 0 C--N 1.334 0.453 0 C-N-CA 120.086 -1.054 . . . . 0.0 112.231 179.185 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 182' ' ' PRO . . . . . 0.525 ' HA ' ' HB2' ' A' ' 186' ' ' ALA . 75.2 Cg_exo -48.02 -45.33 25.45 Favored 'Trans proline' 0 CA--C 1.534 0.507 0 C-N-CA 122.827 2.351 . . . . 0.0 113.613 179.856 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 183' ' ' PRO . . . . . 0.416 ' HD3' ' HB2' ' A' ' 182' ' ' PRO . 82.4 Cg_exo -46.65 -29.84 8.21 Favored 'Trans proline' 0 C--N 1.356 0.954 0 C-N-CA 122.14 1.894 . . . . 0.0 113.232 -179.788 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 184' ' ' GLY . . . . . 0.564 ' HA2' ' HD3' ' A' ' 123' ' ' ARG . . . -115.81 -128.19 4.28 Favored Glycine 0 N--CA 1.449 -0.453 0 C-N-CA 120.249 -0.977 . . . . 0.0 113.129 -179.663 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 185' ' ' VAL . . . . . . . . . . . . . 13.0 m -58.13 -27.33 31.65 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 N-CA-C 112.18 0.437 . . . . 0.0 112.18 -179.429 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 186' ' ' ALA . . . . . 0.525 ' HB2' ' HA ' ' A' ' 182' ' ' PRO . . . 59.34 82.25 0.15 Allowed 'General case' 0 C--N 1.33 -0.251 0 N-CA-C 111.983 0.364 . . . . 0.0 111.983 179.445 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 187' ' ' LEU . . . . . 0.56 ' HB2' HD12 ' A' ' 188' ' ' LEU . 8.6 mt -92.47 -49.59 6.05 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-O 121.039 0.447 . . . . 0.0 110.721 179.381 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 188' ' ' LEU . . . . . 0.56 HD12 ' HB2' ' A' ' 187' ' ' LEU . 6.9 mp -87.4 -166.38 1.56 Allowed 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 115.696 -0.684 . . . . 0.0 111.489 -179.233 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 189' ' ' THR . . . . . . . . . . . . . 10.2 m -94.39 137.43 22.71 Favored Pre-proline 0 C--N 1.33 -0.265 0 CA-C-N 115.743 -0.662 . . . . 0.0 110.498 -179.94 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 190' ' ' PRO . . . . . 0.473 ' O ' HG23 ' A' ' 194' ' ' VAL . 87.6 Cg_exo -44.31 -47.01 11.2 Favored 'Trans proline' 0 C--N 1.35 0.612 0 C-N-CA 122.661 2.241 . . . . 0.0 113.097 -179.859 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 191' ' ' THR . . . . . . . . . . . . . 6.8 t -59.27 -39.47 83.02 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 120.817 0.342 . . . . 0.0 111.28 -179.906 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 192' ' ' VAL . . . . . . . . . . . . . 58.8 t -70.58 -45.42 74.44 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.262 -0.426 . . . . 0.0 111.171 -179.952 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 193' ' ' ASP . . . . . . . . . . . . . 30.5 t70 -57.54 -43.85 84.7 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.294 -0.412 . . . . 0.0 110.678 179.937 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 194' ' ' VAL . . . . . 0.473 HG23 ' O ' ' A' ' 190' ' ' PRO . 98.1 t -64.28 -35.72 74.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 115.944 -0.571 . . . . 0.0 110.559 179.743 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 195' ' ' ALA . . . . . . . . . . . . . . . -59.19 -47.87 83.72 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 120.824 0.345 . . . . 0.0 110.793 179.551 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 196' ' ' LEU . . . . . . . . . . . . . 61.3 mt -67.83 -40.73 83.71 Favored 'General case' 0 C--N 1.332 -0.172 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.705 179.681 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 197' ' ' ILE . . . . . . . . . . . . . 14.3 mm -59.98 -58.18 8.37 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.239 0 CA-C-N 116.041 -0.527 . . . . 0.0 110.348 179.436 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 198' ' ' VAL . . . . . . . . . . . . . 64.1 t -52.28 -34.21 18.05 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.515 0 CA-C-N 115.599 -0.728 . . . . 0.0 109.311 178.469 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 199' ' ' TYR . . . . . 0.479 ' O ' HG23 ' A' ' 203' ' ' VAL . 64.9 t80 -69.32 -41.16 77.08 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 115.378 -0.828 . . . . 0.0 110.401 179.83 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 200' ' ' LEU . . . . . 0.438 HD11 HG13 ' A' ' 177' ' ' ILE . 31.4 mt -59.03 -54.81 42.91 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 115.563 -0.744 . . . . 0.0 111.524 -179.521 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 201' ' ' ASP . . . . . . . . . . . . . 10.7 m-20 -60.23 -38.64 84.04 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.322 -0.399 . . . . 0.0 110.888 -179.853 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 202' ' ' LEU . . . . . 0.436 HD11 ' HA2' ' A' ' 11' ' ' GLY . 2.0 mt -66.81 -28.43 68.37 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 115.868 -0.606 . . . . 0.0 111.409 -179.637 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 203' ' ' VAL . . . . . 0.577 HG12 HD22 ' A' ' 170' ' ' LEU . 41.3 t -79.47 -36.37 17.72 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.439 -0.346 . . . . 0.0 110.841 -179.055 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 204' ' ' THR . . . . . 0.434 ' O ' ' CD1' ' A' ' 208' ' ' PHE . 27.7 m -63.46 -58.32 7.43 Favored 'General case' 0 C--N 1.324 -0.512 0 C-N-CA 120.575 -0.45 . . . . 0.0 110.928 179.768 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 205' ' ' LYS . . . . . 0.74 ' HE2' ' HB2' ' A' ' 47' ' ' ALA . 44.2 mttp -66.32 -58.57 5.04 Favored 'General case' 0 C--N 1.331 -0.229 0 N-CA-C 112.624 0.602 . . . . 0.0 112.624 -178.254 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 43.8 t -70.83 -36.68 65.46 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.374 0 N-CA-C 112.182 0.438 . . . . 0.0 112.182 -178.444 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 207' ' ' GLY . . . . . 0.518 ' O ' HG13 ' A' ' 211' ' ' ILE . . . -61.54 -60.38 8.3 Favored Glycine 0 N--CA 1.452 -0.234 0 C-N-CA 120.58 -0.819 . . . . 0.0 113.598 -178.561 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 208' ' ' PHE . . . . . 0.496 ' HB2' ' HG ' ' A' ' 163' ' ' LEU . 0.1 OUTLIER -70.83 -26.66 63.38 Favored 'General case' 0 N--CA 1.464 0.249 0 CA-C-N 117.14 0.47 . . . . 0.0 111.515 -178.9 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 209' ' ' GLY . . . . . 0.508 ' O ' ' HB3' ' A' ' 212' ' ' ALA . . . -68.29 -32.65 76.24 Favored Glycine 0 N--CA 1.449 -0.49 0 N-CA-C 111.81 -0.516 . . . . 0.0 111.81 179.084 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 210' ' ' PHE . . . . . . . . . . . . . 0.8 OUTLIER -71.62 -48.47 47.74 Favored 'General case' 0 CA--C 1.512 -0.494 0 N-CA-C 108.053 -1.092 . . . . 0.0 108.053 178.491 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 211' ' ' ILE . . . . . 0.518 HG13 ' O ' ' A' ' 207' ' ' GLY . 4.9 mt -63.61 -27.75 43.58 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.544 0 N-CA-C 107.645 -1.243 . . . . 0.0 107.645 176.65 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 212' ' ' ALA . . . . . 0.508 ' HB3' ' O ' ' A' ' 209' ' ' GLY . . . -64.42 -40.97 96.79 Favored 'General case' 0 N--CA 1.45 -0.463 0 CA-C-N 114.583 -1.19 . . . . 0.0 110.5 179.793 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 213' ' ' LEU . . . . . . . . . . . . . 91.5 mt -70.52 -55.07 9.78 Favored 'General case' 0 N--CA 1.461 0.105 0 CA-C-N 115.489 -0.778 . . . . 0.0 111.748 -179.671 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 214' ' ' ASP . . . . . . . . . . . . . 25.1 m-20 -53.98 -49.92 67.73 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.28 -0.418 . . . . 0.0 111.648 -179.273 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 215' ' ' ALA . . . . . . . . . . . . . . . -59.8 -57.51 12.6 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.372 -0.376 . . . . 0.0 111.48 -179.633 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 216' ' ' ALA . . . . . . . . . . . . . . . -57.66 -35.31 70.38 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.31 -0.405 . . . . 0.0 111.421 -179.703 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 217' ' ' ALA . . . . . . . . . . . . . . . -63.67 -31.75 73.02 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 121.001 0.429 . . . . 0.0 110.424 179.831 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 218' ' ' THR . . . . . . . . . . . . . 93.8 m . . . . . 0 C--N 1.33 -0.256 0 CA-C-N 115.759 -0.655 . . . . 0.0 110.79 179.532 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.342 0 N-CA-C 112.789 -0.124 . . . . 0.0 112.789 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 49.2 tp -74.1 -35.37 64.18 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-O 120.782 0.325 . . . . 0.0 110.921 179.951 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 82.7 p -62.34 -31.63 72.29 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.447 -179.774 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 28.9 p -54.23 -35.78 62.81 Favored 'General case' 0 C--N 1.332 -0.175 0 CA-C-N 116.368 -0.378 . . . . 0.0 111.276 -179.906 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 7' ' ' LEU . . . . . . . . . . . . . 4.2 mm? -59.79 -50.73 72.66 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.202 -179.847 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 8' ' ' PHE . . . . . 0.664 ' HB2' ' HB2' ' A' ' 55' ' ' ALA . 64.2 m-85 -65.5 -34.91 79.37 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.9 -179.829 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 9' ' ' TRP . . . . . 0.416 ' O ' HG12 ' A' ' 13' ' ' ILE . 29.4 m95 -65.27 -44.77 87.0 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.292 -179.668 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 75.3 mt -60.51 -41.43 94.33 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 115.639 -0.71 . . . . 0.0 110.095 179.396 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -64.86 -34.65 90.46 Favored Glycine 0 N--CA 1.448 -0.501 0 C-N-CA 120.677 -0.773 . . . . 0.0 111.667 179.304 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -65.5 -31.32 72.33 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-O 120.849 0.357 . . . . 0.0 110.388 179.602 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 13' ' ' ILE . . . . . 0.416 HG12 ' O ' ' A' ' 9' ' ' TRP . 42.3 mm -67.72 -48.47 75.89 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 116.032 -0.531 . . . . 0.0 110.153 179.339 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -61.57 -28.12 69.2 Favored Glycine 0 N--CA 1.45 -0.386 0 C-N-CA 120.698 -0.763 . . . . 0.0 111.81 179.436 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 15' ' ' MET . . . . . 0.56 ' HE3' ' CB ' ' A' ' 47' ' ' ALA . 23.2 mmt -75.07 -39.43 60.87 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.731 0.3 . . . . 0.0 110.645 179.693 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 20.6 tp -59.09 -40.64 85.9 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.312 179.345 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 41.3 t -69.94 -45.52 76.49 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.215 0 CA-C-N 115.902 -0.59 . . . . 0.0 111.114 -179.938 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -63.84 -49.59 67.07 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.562 -0.827 . . . . 0.0 111.686 179.635 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 85.1 m -50.24 -45.23 53.92 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 115.448 -0.376 . . . . 0.0 111.014 179.767 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 77.9 mt -71.89 -39.3 69.68 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.382 179.764 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -64.1 -30.62 71.67 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.659 0.266 . . . . 0.0 111.528 -179.626 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 22' ' ' PHE . . . . . 0.575 ' HB2' HG22 ' A' ' 41' ' ' VAL . 6.3 m-85 -90.84 -31.12 16.58 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.503 -0.317 . . . . 0.0 111.113 -179.388 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -71.58 -49.78 37.27 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-O 120.907 0.384 . . . . 0.0 110.841 179.797 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 24' ' ' TRP . . . . . . . . . . . . . 1.2 t-105 -60.32 -41.61 93.85 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 115.893 -0.594 . . . . 0.0 110.72 179.797 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.328 -0.341 0 CA-C-N 116.356 -0.384 . . . . 0.0 110.665 179.619 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.342 0 N-CA-C 112.561 -0.216 . . . . 0.0 112.561 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 45.8 mt-10 -85.58 -20.82 28.98 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.672 0.272 . . . . 0.0 111.05 179.953 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 34' ' ' ARG . . . . . 0.455 ' O ' HG23 ' A' ' 38' ' ' VAL . 56.7 ttp180 -50.44 -29.51 10.45 Favored 'General case' 0 C--N 1.332 -0.175 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.339 -179.761 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 37.2 mmt180 -64.59 -43.92 92.3 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.329 -0.396 . . . . 0.0 110.953 179.981 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 64.8 m-85 -69.36 -33.76 73.56 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 116.13 -0.486 . . . . 0.0 111.44 -179.596 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 37' ' ' TYR . . . . . . . . . . . . . 54.2 m-85 -70.81 -53.01 16.93 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.533 -179.386 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 38' ' ' VAL . . . . . 0.455 HG23 ' O ' ' A' ' 34' ' ' ARG . 87.4 t -56.82 -36.79 50.75 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.249 0 CA-C-O 121.18 0.514 . . . . 0.0 110.21 179.509 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 40.9 m -66.76 -47.53 71.93 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 115.51 -0.768 . . . . 0.0 110.525 179.222 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 40' ' ' LEU . . . . . 0.405 ' O ' HG13 ' A' ' 43' ' ' ILE . 21.9 tp -57.1 -47.57 80.73 Favored 'General case' 0 C--O 1.235 0.3 0 CA-C-N 115.67 -0.695 . . . . 0.0 110.787 179.881 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . 0.575 HG22 ' HB2' ' A' ' 22' ' ' PHE . 94.8 t -63.05 -34.81 68.74 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-N 115.81 -0.632 . . . . 0.0 110.249 179.436 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -58.78 -39.79 94.18 Favored Glycine 0 N--CA 1.449 -0.471 0 CA-C-N 115.689 -0.687 . . . . 0.0 112.238 179.667 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 43' ' ' ILE . . . . . 0.609 HG22 ' HE3' ' A' ' 205' ' ' LYS . 0.1 OUTLIER -67.93 -50.97 54.54 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.166 0 CA-C-O 120.695 0.283 . . . . 0.0 110.984 179.851 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 50.5 m -63.59 -25.28 68.16 Favored 'General case' 0 C--N 1.331 -0.199 0 CA-C-O 120.824 0.345 . . . . 0.0 110.945 179.895 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -77.81 -52.15 5.55 Favored Glycine 0 N--CA 1.452 -0.263 0 C-N-CA 120.949 -0.643 . . . . 0.0 112.865 -179.542 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 46' ' ' ILE . . . . . 0.72 HD12 HD12 ' A' ' 78' ' ' LEU . 10.5 pt -58.32 -40.92 79.82 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.242 0 CA-C-O 120.874 0.369 . . . . 0.0 110.975 -179.75 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 47' ' ' ALA . . . . . 0.669 ' HB2' ' HE2' ' A' ' 205' ' ' LYS . . . -68.12 -40.24 82.58 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.124 179.468 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 48' ' ' ALA . . . . . 0.528 ' HB2' ' HB3' ' A' ' 15' ' ' MET . . . -54.59 -45.42 73.61 Favored 'General case' 0 C--O 1.233 0.197 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.31 -179.666 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 27.6 m -73.05 -33.9 44.0 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.257 -0.429 . . . . 0.0 111.26 -179.68 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -61.67 -37.75 85.22 Favored 'General case' 0 C--N 1.331 -0.21 0 CA-C-O 121.102 0.477 . . . . 0.0 110.576 179.256 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 51' ' ' TYR . . . . . 0.487 ' HB3' ' O ' ' A' ' 8' ' ' PHE . 29.6 m-85 -72.85 -35.63 67.28 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 115.767 -0.651 . . . . 0.0 110.266 179.682 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -66.08 -40.88 91.18 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 115.798 -0.637 . . . . 0.0 111.082 179.3 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 27.6 m -74.1 -41.52 52.03 Favored 'Isoleucine or valine' 0 C--O 1.231 0.123 0 CA-C-N 116.47 -0.332 . . . . 0.0 111.016 179.95 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 54' ' ' MET . . . . . 0.623 ' HG2' ' HG2' ' A' ' 71' ' ' PRO . 72.0 mtm -64.93 -36.21 83.65 Favored 'General case' 0 CA--C 1.519 -0.233 0 CA-C-O 121.171 0.51 . . . . 0.0 109.831 179.128 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 55' ' ' ALA . . . . . 0.664 ' HB2' ' HB2' ' A' ' 8' ' ' PHE . . . -69.55 -16.71 63.47 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 115.489 -0.778 . . . . 0.0 111.193 179.764 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 73.5 mt -97.06 2.55 51.48 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.328 -0.396 . . . . 0.0 111.407 -179.632 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 84.75 3.23 88.28 Favored Glycine 0 N--CA 1.452 -0.258 0 C-N-CA 120.628 -0.796 . . . . 0.0 112.941 179.66 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 49.2 t -69.87 132.94 32.67 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-O 120.631 0.253 . . . . 0.0 110.907 179.875 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 59' ' ' GLY . . . . . 0.695 ' HA3' ' HD3' ' A' ' 71' ' ' PRO . . . 88.56 -13.01 63.45 Favored Glycine 0 N--CA 1.449 -0.476 0 C-N-CA 120.656 -0.783 . . . . 0.0 112.487 -179.866 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 60' ' ' TRP . . . . . . . . . . . . . 15.5 m0 -66.2 89.46 0.13 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.833 0.349 . . . . 0.0 110.7 179.901 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 61' ' ' VAL . . . . . 0.523 HG13 HG23 ' A' ' 68' ' ' VAL . 4.0 p -101.52 132.32 21.94 Favored Pre-proline 0 CA--C 1.532 0.265 0 CA-C-N 116.266 -0.424 . . . . 0.0 110.928 179.928 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 62' ' ' PRO . . . . . 0.452 ' HD3' ' HA ' ' A' ' 61' ' ' VAL . 4.6 Cg_exo -76.94 151.21 30.83 Favored 'Trans proline' 0 C--N 1.35 0.617 0 C-N-CA 122.673 2.249 . . . . 0.0 112.494 -179.763 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 73.3 t -142.32 91.84 0.5 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 115.964 -0.562 . . . . 0.0 110.804 179.774 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . 59.56 -87.43 0.02 OUTLIER 'General case' 0 N--CA 1.463 0.183 0 CA-C-N 116.097 -0.501 . . . . 0.0 111.529 179.962 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 10.3 pt-20 -124.21 -16.26 6.51 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.903 0.383 . . . . 0.0 110.673 179.972 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 66' ' ' ARG . . . . . 0.431 HH11 ' HD2' ' A' ' 66' ' ' ARG . 64.6 mtt180 -104.58 160.77 14.68 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 115.922 -0.581 . . . . 0.0 110.362 179.535 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 37.2 m -120.97 142.66 49.56 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.971 0.415 . . . . 0.0 111.473 -179.613 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 68' ' ' VAL . . . . . 0.523 HG23 HG13 ' A' ' 61' ' ' VAL . 15.3 m -131.68 145.04 35.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 115.799 -0.637 . . . . 0.0 110.552 179.609 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 69' ' ' PHE . . . . . 0.406 ' C ' ' HD2' ' A' ' 71' ' ' PRO . 16.7 m-85 -109.48 115.84 30.68 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.364 -0.38 . . . . 0.0 110.365 -179.358 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 70' ' ' VAL . . . . . 0.741 HG12 ' HD3' ' A' ' 71' ' ' PRO . 0.8 OUTLIER -64.59 -36.79 19.28 Favored Pre-proline 0 CA--C 1.541 0.627 0 N-CA-C 112.701 0.63 . . . . 0.0 112.701 -179.321 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 71' ' ' PRO . . . . . 0.741 ' HD3' HG12 ' A' ' 70' ' ' VAL . 61.4 Cg_endo -70.52 -20.81 30.77 Favored 'Trans proline' 0 C--N 1.36 1.154 0 C-N-CA 121.934 1.756 . . . . 0.0 113.382 -179.451 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 46.6 ttp180 -73.06 -55.13 6.93 Favored 'General case' 0 C--O 1.235 0.323 0 N-CA-C 111.658 0.244 . . . . 0.0 111.658 -179.031 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 73' ' ' TYR . . . . . 0.431 ' O ' HG13 ' A' ' 77' ' ' ILE . 11.8 m-85 -65.84 -37.54 86.46 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.907 0.384 . . . . 0.0 110.022 -179.883 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 74' ' ' ILE . . . . . 0.529 ' HA ' HD12 ' A' ' 77' ' ' ILE . 0.4 OUTLIER -67.22 -41.23 86.5 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.219 0 CA-C-N 116.058 -0.519 . . . . 0.0 110.631 179.704 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 75' ' ' ASP . . . . . 0.433 ' O ' HG23 ' A' ' 79' ' ' THR . 17.7 t70 -55.08 -39.7 69.57 Favored 'General case' 0 CA--C 1.519 -0.245 0 N-CA-C 109.584 -0.524 . . . . 0.0 109.584 179.235 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 76' ' ' TRP . . . . . 0.485 ' HZ2' HG23 ' A' ' 197' ' ' ILE . 30.7 m0 -68.44 -32.52 72.6 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 115.927 -0.579 . . . . 0.0 110.683 179.61 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 77' ' ' ILE . . . . . 0.629 ' HA ' ' HG3' ' A' ' 109' ' ' MET . 92.2 mt -60.95 -41.64 89.79 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.245 0 CA-C-N 116.104 -0.498 . . . . 0.0 111.954 -179.828 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 78' ' ' LEU . . . . . 0.72 HD12 HD12 ' A' ' 46' ' ' ILE . 0.7 OUTLIER -91.38 -30.02 16.76 Favored 'General case' 0 CA--C 1.536 0.409 0 N-CA-C 113.392 0.886 . . . . 0.0 113.392 -178.883 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 79' ' ' THR . . . . . 0.438 HG22 ' CD1' ' A' ' 46' ' ' ILE . 46.0 p -75.2 -53.32 9.01 Favored 'General case' 0 N--CA 1.47 0.558 0 N-CA-C 113.447 0.906 . . . . 0.0 113.447 -178.275 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 80' ' ' THR . . . . . 0.617 HG21 ' HE1' ' A' ' 109' ' ' MET . 7.3 m -51.47 -48.95 85.04 Favored Pre-proline 0 C--N 1.329 -0.312 0 N-CA-C 112.948 0.721 . . . . 0.0 112.948 -178.36 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 81' ' ' PRO . . . . . 0.569 ' HD2' ' N ' ' A' ' 80' ' ' THR . 23.3 Cg_endo -58.99 -26.35 81.2 Favored 'Trans proline' 0 C--N 1.351 0.659 0 C-N-CA 121.72 1.613 . . . . 0.0 111.846 -179.511 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 82' ' ' LEU . . . . . . . . . . . . . 14.1 tp -76.73 -36.5 57.12 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 115.908 -0.587 . . . . 0.0 110.557 179.991 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 83' ' ' ILE . . . . . 0.518 HD13 HD13 ' A' ' 43' ' ' ILE . 38.8 mm -67.91 -51.22 51.96 Favored 'Isoleucine or valine' 0 C--O 1.234 0.275 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.137 179.086 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 27.0 m -61.14 -31.13 49.24 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.214 0 CA-C-N 116.014 -0.539 . . . . 0.0 109.632 179.129 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 85' ' ' TYR . . . . . 0.408 ' HB2' ' O ' ' A' ' 81' ' ' PRO . 58.6 t80 -65.23 -34.47 78.44 Favored 'General case' 0 N--CA 1.452 -0.332 0 CA-C-N 115.638 -0.71 . . . . 0.0 109.36 178.965 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 86' ' ' PHE . . . . . . . . . . . . . 4.2 t80 -61.39 -51.63 67.98 Favored 'General case' 0 C--O 1.231 0.131 0 CA-C-N 115.586 -0.734 . . . . 0.0 110.064 179.222 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 7.4 mt -65.05 -28.69 69.65 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 121.309 0.576 . . . . 0.0 109.772 179.66 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -72.57 -27.43 69.43 Favored Glycine 0 N--CA 1.45 -0.41 0 CA-C-N 115.2 -0.909 . . . . 0.0 111.545 179.139 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 52.8 mt -73.21 -43.35 61.42 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 121.006 0.431 . . . . 0.0 110.549 179.652 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 59.1 mt -60.14 -33.19 71.82 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 115.707 -0.679 . . . . 0.0 111.047 179.887 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 91' ' ' ALA . . . . . 0.566 ' HB1' ' HB2' ' A' ' 148' ' ' SER . . . -85.76 -47.97 9.25 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.514 -179.532 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 89.27 61.15 1.41 Allowed Glycine 0 N--CA 1.45 -0.378 0 C-N-CA 120.811 -0.709 . . . . 0.0 112.383 -179.742 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 93' ' ' LEU . . . . . 0.442 HD11 ' HG2' ' A' ' 145' ' ' MET . 6.5 mp -72.76 179.12 3.78 Favored 'General case' 0 C--N 1.332 -0.184 0 CA-C-O 120.753 0.311 . . . . 0.0 110.866 -179.951 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 94' ' ' ASP . . . . . . . . . . . . . 30.3 m-20 -85.5 175.3 8.9 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.883 179.948 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 48.9 m -61.69 -46.71 88.52 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.1 -179.74 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 96' ' ' ARG . . . . . 0.404 ' O ' HG13 ' A' ' 100' ' ' ILE . 80.1 ttt180 -71.94 -45.36 61.42 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.934 -179.953 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 97' ' ' GLU . . . . . 0.482 ' HA ' HD12 ' A' ' 100' ' ' ILE . 19.1 mm-40 -52.51 -46.02 66.48 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.158 -179.802 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 98' ' ' PHE . . . . . 0.474 ' O ' HG12 ' A' ' 102' ' ' ILE . 2.2 m-85 -55.33 -50.87 68.52 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.384 -0.371 . . . . 0.0 110.236 179.385 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -60.85 -30.38 72.8 Favored Glycine 0 N--CA 1.45 -0.383 0 C-N-CA 120.862 -0.685 . . . . 0.0 112.627 -179.949 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 100' ' ' ILE . . . . . 0.482 HD12 ' HA ' ' A' ' 97' ' ' GLU . 94.5 mt -64.04 -43.3 97.52 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-O 120.89 0.376 . . . . 0.0 111.393 -179.857 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 29.4 t -72.26 -41.42 66.12 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.38 0 CA-C-N 116.34 -0.391 . . . . 0.0 111.592 179.976 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 102' ' ' ILE . . . . . 0.474 HG12 ' O ' ' A' ' 98' ' ' PHE . 35.2 mm -65.38 -40.07 87.27 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 CA-C-N 116.416 -0.357 . . . . 0.0 111.65 -179.266 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 11.0 t -67.92 -40.36 83.37 Favored 'General case' 0 C--O 1.234 0.239 0 CA-C-O 120.713 0.292 . . . . 0.0 110.939 -179.958 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 104' ' ' LEU . . . . . 0.426 HD22 ' HE2' ' A' ' 140' ' ' TYR . 29.2 tp -55.34 -51.54 66.4 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-N 116.349 -0.387 . . . . 0.0 110.079 179.311 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 105' ' ' ASN . . . . . 0.607 HD21 HD13 ' A' ' 137' ' ' LEU . 0.8 OUTLIER -58.05 -37.31 74.16 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 115.855 -0.611 . . . . 0.0 110.461 179.465 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 31.0 m -54.61 -41.1 69.56 Favored 'General case' 0 C--N 1.332 -0.184 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.659 179.706 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 0.6 OUTLIER -69.24 -36.42 72.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-O 121.258 0.551 . . . . 0.0 110.0 179.245 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . 0.426 HG23 ' O ' ' A' ' 104' ' ' LEU . 60.7 t -63.87 -42.63 96.47 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 115.406 -0.816 . . . . 0.0 111.571 -179.677 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 109' ' ' MET . . . . . 0.629 ' HG3' ' HA ' ' A' ' 77' ' ' ILE . 6.9 mmt -70.07 -44.04 69.92 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.407 -0.36 . . . . 0.0 110.961 -179.624 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 21.4 tp -60.73 -32.18 71.46 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 116.349 -0.387 . . . . 0.0 110.38 179.966 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -65.27 -56.63 11.65 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.019 -0.537 . . . . 0.0 110.612 179.398 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . -60.88 -30.0 71.94 Favored Glycine 0 C--N 1.332 0.334 0 C-N-CA 120.644 -0.789 . . . . 0.0 112.117 179.655 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 113' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER -57.68 -69.0 0.19 Allowed 'General case' 0 C--N 1.33 -0.266 0 CA-C-O 121.015 0.436 . . . . 0.0 110.255 179.585 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 114' ' ' ALA . . . . . 0.446 ' O ' HG13 ' A' ' 118' ' ' VAL . . . -64.6 -29.13 70.15 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 115.79 -0.641 . . . . 0.0 111.414 -179.969 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -51.92 -51.2 41.21 Favored Glycine 0 C--N 1.332 0.324 0 C-N-CA 121.081 -0.58 . . . . 0.0 112.672 -179.888 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -77.99 -15.01 59.31 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-O 120.542 0.21 . . . . 0.0 111.553 -179.781 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 117' ' ' MET . . . . . 0.45 ' HE2' HG21 ' A' ' 68' ' ' VAL . 37.5 ttm -100.67 18.46 19.24 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-O 120.692 0.282 . . . . 0.0 111.436 -179.464 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 118' ' ' VAL . . . . . 0.506 HG11 ' N ' ' A' ' 123' ' ' ARG . 27.4 m -74.03 144.76 82.65 Favored Pre-proline 0 C--N 1.328 -0.327 0 CA-C-N 116.692 -0.231 . . . . 0.0 111.141 179.802 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 119' ' ' PRO . . . . . . . . . . . . . 97.0 Cg_endo -87.53 -10.11 5.53 Favored 'Trans proline' 0 N--CA 1.458 -0.568 0 C-N-CA 122.709 2.273 . . . . 0.0 112.484 179.756 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -136.72 -108.26 0.89 Allowed Glycine 0 C--N 1.331 0.302 0 C-N-CA 120.706 -0.759 . . . . 0.0 112.907 -179.629 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 34.3 pt -124.53 12.26 4.72 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.156 0 CA-C-O 120.652 0.263 . . . . 0.0 111.664 -179.548 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 41.7 mt-10 -58.24 -18.26 25.18 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.779 0.323 . . . . 0.0 111.03 179.722 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 123' ' ' ARG . . . . . 0.506 ' N ' HG11 ' A' ' 118' ' ' VAL . 4.9 ptm180 -50.6 -31.39 15.77 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 116.107 -0.497 . . . . 0.0 111.504 -179.868 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 124' ' ' TYR . . . . . . . . . . . . . 30.4 m-85 -70.28 -33.03 71.08 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.458 -0.337 . . . . 0.0 111.017 -179.735 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 125' ' ' ALA . . . . . . . . . . . . . . . -71.24 -50.12 36.22 Favored 'General case' 0 C--O 1.235 0.333 0 CA-C-N 116.298 -0.41 . . . . 0.0 110.942 179.687 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 3.1 mm? -53.6 -52.76 58.77 Favored 'General case' 0 C--N 1.333 -0.137 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.53 179.739 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 127' ' ' PHE . . . . . 0.433 ' HZ ' ' HB3' ' A' ' 175' ' ' PRO . 6.5 t80 -64.88 -37.21 86.87 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.316 -0.402 . . . . 0.0 111.231 -179.615 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 128' ' ' GLY . . . . . . . . . . . . . . . -46.16 -47.75 15.4 Favored Glycine 0 C--O 1.237 0.283 0 C-N-CA 119.705 -1.235 . . . . 0.0 110.517 179.192 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 129' ' ' MET . . . . . . . . . . . . . 0.5 OUTLIER -72.18 -34.91 68.79 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 115.178 -0.511 . . . . 0.0 110.101 178.665 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -62.99 -37.26 94.66 Favored Glycine 0 C--N 1.332 0.331 0 CA-C-N 115.804 -0.634 . . . . 0.0 113.347 -179.515 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -73.56 -52.61 12.9 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.788 0.294 . . . . 0.0 110.755 -179.781 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 62.2 t -55.61 -42.0 66.93 Favored 'Isoleucine or valine' 0 C--O 1.234 0.28 0 CA-C-O 121.331 0.586 . . . . 0.0 109.546 179.128 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -68.69 -37.35 79.49 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 115.342 -0.844 . . . . 0.0 110.669 179.407 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 134' ' ' PHE . . . . . . . . . . . . . 87.7 t80 -55.88 -54.78 40.44 Favored 'General case' 0 N--CA 1.452 -0.363 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.135 179.669 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 135' ' ' ILE . . . . . 0.425 ' O ' HG22 ' A' ' 138' ' ' VAL . 32.8 mt -56.38 -33.53 38.49 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.363 0 CA-C-N 115.884 -0.598 . . . . 0.0 110.126 179.303 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . -61.65 -39.64 97.67 Favored Glycine 0 N--CA 1.449 -0.484 0 C-N-CA 120.072 -1.061 . . . . 0.0 111.295 178.784 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 137' ' ' LEU . . . . . 0.607 HD13 HD21 ' A' ' 105' ' ' ASN . 31.1 tp -68.75 -54.02 18.44 Favored 'General case' 0 C--N 1.332 -0.185 0 CA-C-O 120.598 0.237 . . . . 0.0 111.173 179.933 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 138' ' ' VAL . . . . . 0.425 HG22 ' O ' ' A' ' 135' ' ' ILE . 3.3 m -55.85 -31.68 30.59 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.176 0 CA-C-O 121.182 0.515 . . . . 0.0 109.9 179.957 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 139' ' ' TYR . . . . . . . . . . . . . 21.3 t80 -66.19 -38.62 88.45 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 115.429 -0.805 . . . . 0.0 110.289 178.674 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 140' ' ' TYR . . . . . 0.426 ' HE2' HD22 ' A' ' 104' ' ' LEU . 19.2 m-85 -65.28 -32.14 73.64 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 116.097 -0.501 . . . . 0.0 111.055 179.377 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 141' ' ' LEU . . . . . 0.49 HD23 ' SD ' ' A' ' 145' ' ' MET . 75.1 mt -69.9 -41.49 74.65 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-O 121.039 0.447 . . . . 0.0 110.351 -179.508 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 24.2 m -84.84 -10.58 11.53 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.631 0 CA-C-N 115.72 -0.673 . . . . 0.0 111.159 179.957 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . -76.91 -118.78 0.16 Allowed Glycine 0 CA--C 1.52 0.405 0 C-N-CA 120.894 -0.669 . . . . 0.0 112.986 -179.551 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 144' ' ' PRO . . . . . . . . . . . . . 55.8 Cg_endo -69.25 -30.19 25.08 Favored 'Trans proline' 0 C--N 1.349 0.6 0 C-N-CA 122.47 2.113 . . . . 0.0 112.825 -179.411 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 145' ' ' MET . . . . . 0.49 ' SD ' HD23 ' A' ' 141' ' ' LEU . 53.1 mtt -55.59 -31.14 61.97 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-O 120.726 0.298 . . . . 0.0 111.484 -179.664 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 146' ' ' THR . . . . . . . . . . . . . 14.3 m -71.12 -44.2 66.1 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.284 -0.416 . . . . 0.0 111.723 -179.45 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 43.6 mt-10 -75.92 -29.04 58.23 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.385 -0.371 . . . . 0.0 111.844 -179.411 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 148' ' ' SER . . . . . 0.566 ' HB2' ' HB1' ' A' ' 91' ' ' ALA . 66.2 m -70.26 -47.05 63.03 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 120.736 0.303 . . . . 0.0 111.281 -179.327 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 149' ' ' ALA . . . . . . . . . . . . . . . -72.6 -34.93 67.74 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.289 -0.414 . . . . 0.0 111.242 -179.833 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 150' ' ' SER . . . . . . . . . . . . . 47.7 t -70.42 -8.19 48.95 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.965 179.943 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 151' ' ' GLN . . . . . . . . . . . . . 47.9 mt-30 -122.32 10.04 9.85 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.262 -0.426 . . . . 0.0 111.255 -179.875 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 152' ' ' ARG . . . . . 0.635 ' HE ' HG13 ' A' ' 156' ' ' ILE . 1.2 tmm_? -85.05 -51.33 6.74 Favored 'General case' 0 C--N 1.332 -0.19 0 CA-C-O 120.979 0.418 . . . . 0.0 110.363 179.669 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 153' ' ' SER . . . . . 0.594 ' HB2' HG12 ' A' ' 156' ' ' ILE . 49.1 m -157.48 172.56 18.35 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 115.751 -0.659 . . . . 0.0 110.667 179.434 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 154' ' ' SER . . . . . . . . . . . . . 46.6 t -69.38 -42.17 75.52 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.339 -0.392 . . . . 0.0 110.76 179.754 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -77.28 -32.75 46.73 Favored Glycine 0 N--CA 1.452 -0.275 0 C-N-CA 120.948 -0.644 . . . . 0.0 113.029 -179.831 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 156' ' ' ILE . . . . . 0.635 HG13 ' HE ' ' A' ' 152' ' ' ARG . 32.2 mm -57.23 -38.65 62.72 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.199 0 CA-C-N 116.776 0.288 . . . . 0.0 111.356 -179.753 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 157' ' ' LYS . . . . . 0.435 ' O ' ' HB ' ' A' ' 161' ' ' VAL . 58.3 tttp -62.47 -43.48 98.72 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.385 -0.37 . . . . 0.0 111.372 -179.735 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 93.8 p -70.98 -48.32 53.95 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 116.102 -0.499 . . . . 0.0 111.551 -179.102 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 159' ' ' LEU . . . . . 0.436 ' O ' ' HB2' ' A' ' 163' ' ' LEU . 10.5 tt -62.08 -42.54 99.31 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.176 -179.395 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 160' ' ' TYR . . . . . . . . . . . . . 77.6 t80 -71.59 -36.87 71.0 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 116.263 -0.426 . . . . 0.0 111.987 -179.077 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 161' ' ' VAL . . . . . 0.538 HG12 ' N ' ' A' ' 162' ' ' ARG . 1.1 t -58.4 -53.64 43.69 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.686 0 N-CA-C 111.699 0.259 . . . . 0.0 111.699 -179.181 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 162' ' ' ARG . . . . . 0.538 ' N ' HG12 ' A' ' 161' ' ' VAL . 97.3 mtt180 -69.89 -41.15 75.13 Favored 'General case' 0 C--N 1.329 -0.317 0 N-CA-C 112.04 0.385 . . . . 0.0 112.04 -179.174 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 163' ' ' LEU . . . . . 0.45 ' O ' HD23 ' A' ' 166' ' ' LEU . 2.7 mp -62.49 -56.14 20.93 Favored 'General case' 0 C--N 1.329 -0.314 0 N-CA-C 112.277 0.473 . . . . 0.0 112.277 -178.674 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 164' ' ' ARG . . . . . 0.438 ' NE ' ' ND2' ' A' ' 165' ' ' ASN . 5.4 ppt_? -62.42 -40.63 97.18 Favored 'General case' 0 C--N 1.328 -0.356 0 N-CA-C 112.002 0.371 . . . . 0.0 112.002 -178.361 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 165' ' ' ASN . . . . . 0.448 ' O ' HG23 ' A' ' 169' ' ' VAL . 0.9 OUTLIER -54.73 -53.29 56.89 Favored 'General case' 0 C--O 1.237 0.402 0 CA-C-O 120.826 0.346 . . . . 0.0 111.557 -179.373 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 166' ' ' LEU . . . . . 0.48 ' O ' ' HG ' ' A' ' 170' ' ' LEU . 0.1 OUTLIER -67.67 -31.59 71.67 Favored 'General case' 0 C--N 1.331 -0.238 0 C-N-CA 120.847 -0.341 . . . . 0.0 111.022 -179.146 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 167' ' ' THR . . . . . 0.428 ' O ' ' HB2' ' A' ' 171' ' ' TRP . 17.7 m -59.75 -53.02 62.81 Favored 'General case' 0 C--N 1.333 -0.147 0 CA-C-O 120.842 0.353 . . . . 0.0 111.304 179.814 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 168' ' ' VAL . . . . . . . . . . . . . 58.4 t -58.97 -41.27 82.66 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.385 0 CA-C-N 115.785 -0.643 . . . . 0.0 111.749 -179.103 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 169' ' ' VAL . . . . . 0.448 HG23 ' O ' ' A' ' 165' ' ' ASN . 88.8 t -59.34 -64.87 0.51 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 N-CA-C 112.383 0.512 . . . . 0.0 112.383 -179.236 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 170' ' ' LEU . . . . . 0.48 ' HG ' ' O ' ' A' ' 166' ' ' LEU . 1.6 pp -61.04 -36.3 79.19 Favored 'General case' 0 N--CA 1.463 0.214 0 N-CA-C 112.219 0.451 . . . . 0.0 112.219 -178.67 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 171' ' ' TRP . . . . . 0.428 ' HB2' ' O ' ' A' ' 167' ' ' THR . 3.0 m0 -67.73 -29.4 68.62 Favored 'General case' 0 C--N 1.331 -0.231 0 C-N-CA 120.914 -0.314 . . . . 0.0 110.946 179.843 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 172' ' ' ALA . . . . . . . . . . . . . . . -73.28 -7.07 49.98 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 116.337 -0.392 . . . . 0.0 110.986 -179.938 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 173' ' ' ILE . . . . . 0.686 HG22 HD11 ' A' ' 177' ' ' ILE . 19.2 mm -87.97 -21.0 7.21 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.067 -0.515 . . . . 0.0 110.876 179.88 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 174' ' ' TYR . . . . . 0.409 ' HD2' ' HA ' ' A' ' 171' ' ' TRP . 13.0 m-85 -53.67 -48.53 92.95 Favored Pre-proline 0 CA--C 1.531 0.235 0 CA-C-N 116.249 -0.432 . . . . 0.0 111.478 -179.752 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 175' ' ' PRO . . . . . 0.433 ' HB3' ' HZ ' ' A' ' 127' ' ' PHE . 92.4 Cg_exo -46.48 -31.77 10.31 Favored 'Trans proline' 0 C--N 1.352 0.756 0 C-N-CA 122.173 1.915 . . . . 0.0 112.117 179.059 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 176' ' ' PHE . . . . . 0.466 ' O ' ' HG ' ' A' ' 180' ' ' LEU . 80.5 m-85 -80.25 -40.67 26.53 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 115.927 -0.578 . . . . 0.0 111.421 -179.893 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 177' ' ' ILE . . . . . 0.686 HD11 HG22 ' A' ' 173' ' ' ILE . 2.3 mm -65.2 -41.55 91.92 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.533 0 CA-C-N 116.346 -0.388 . . . . 0.0 111.838 -178.651 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 178' ' ' TRP . . . . . . . . . . . . . 63.9 t90 -73.65 -44.62 56.37 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.902 0.382 . . . . 0.0 111.064 -179.952 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 179' ' ' LEU . . . . . 0.535 ' O ' HG22 ' A' ' 185' ' ' VAL . 1.9 tm? -64.31 -51.86 61.36 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 115.952 -0.567 . . . . 0.0 111.451 -179.151 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 180' ' ' LEU . . . . . 0.712 HD22 HD11 ' A' ' 187' ' ' LEU . 20.7 mt -77.48 -44.98 27.04 Favored 'General case' 0 C--N 1.328 -0.336 0 N-CA-C 111.974 0.361 . . . . 0.0 111.974 -178.711 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 181' ' ' GLY . . . . . 0.412 ' HA3' ' OD1' ' A' ' 193' ' ' ASP . . . -57.5 174.99 1.91 Allowed Glycine 0 C--N 1.335 0.494 0 C-N-CA 120.365 -0.921 . . . . 0.0 112.771 179.927 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 182' ' ' PRO . . . . . 0.648 ' HA ' ' HB2' ' A' ' 186' ' ' ALA . 1.7 Cg_endo -44.99 -45.6 13.93 Favored 'Trans proline' 0 CA--C 1.537 0.671 0 C-N-CA 123.228 2.619 . . . . 0.0 113.84 179.615 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 183' ' ' PRO . . . . . 0.578 ' HD2' ' N ' ' A' ' 182' ' ' PRO . 18.5 Cg_endo -58.54 -4.75 1.97 Allowed 'Trans proline' 0 C--N 1.356 0.937 0 C-N-CA 121.967 1.778 . . . . 0.0 113.017 -179.762 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 184' ' ' GLY . . . . . 0.434 ' HA3' ' O ' ' A' ' 179' ' ' LEU . . . -122.09 -87.93 0.91 Allowed Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.63 -0.795 . . . . 0.0 112.636 179.94 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 185' ' ' VAL . . . . . 0.535 HG22 ' O ' ' A' ' 179' ' ' LEU . 4.3 m -123.63 -4.64 7.19 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 N-CA-C 111.658 0.244 . . . . 0.0 111.658 -179.822 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 186' ' ' ALA . . . . . 0.648 ' HB2' ' HA ' ' A' ' 182' ' ' PRO . . . 51.62 88.88 0.03 OUTLIER 'General case' 0 N--CA 1.462 0.156 0 CA-C-N 116.398 -0.364 . . . . 0.0 111.367 179.833 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 187' ' ' LEU . . . . . 0.712 HD11 HD22 ' A' ' 180' ' ' LEU . 20.2 mt -91.76 -49.4 6.29 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.396 -0.366 . . . . 0.0 111.774 -179.502 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 188' ' ' LEU . . . . . . . . . . . . . 87.5 mt -97.36 -94.3 0.22 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.462 -0.336 . . . . 0.0 111.539 -179.138 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 189' ' ' THR . . . . . . . . . . . . . 1.8 t -160.42 149.36 13.72 Favored Pre-proline 0 C--N 1.327 -0.39 0 CA-C-N 116.284 -0.416 . . . . 0.0 111.282 -179.499 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 190' ' ' PRO . . . . . 0.437 ' O ' HG23 ' A' ' 194' ' ' VAL . 72.9 Cg_exo -50.37 -42.98 46.25 Favored 'Trans proline' 0 C--N 1.349 0.557 0 C-N-CA 122.591 2.194 . . . . 0.0 112.932 -179.853 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 191' ' ' THR . . . . . . . . . . . . . 70.9 p -55.33 -46.55 76.35 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-O 120.77 0.319 . . . . 0.0 111.514 -179.729 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 192' ' ' VAL . . . . . . . . . . . . . 39.4 t -68.36 -50.6 55.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.626 -179.745 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 193' ' ' ASP . . . . . 0.428 ' OD1' HG22 ' A' ' 177' ' ' ILE . 30.8 t70 -55.24 -49.58 71.66 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.752 0.311 . . . . 0.0 111.284 -179.824 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 194' ' ' VAL . . . . . 0.437 HG23 ' O ' ' A' ' 190' ' ' PRO . 76.1 t -59.62 -36.44 65.28 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.886 179.914 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 195' ' ' ALA . . . . . . . . . . . . . . . -58.71 -46.72 86.68 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.41 -0.359 . . . . 0.0 110.968 179.848 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 196' ' ' LEU . . . . . . . . . . . . . 85.3 mt -67.71 -40.17 84.3 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.348 -0.387 . . . . 0.0 110.615 179.692 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 197' ' ' ILE . . . . . 0.485 HG23 ' HZ2' ' A' ' 76' ' ' TRP . 16.2 mm -59.97 -59.86 3.38 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 CA-C-N 115.988 -0.551 . . . . 0.0 110.302 179.388 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 198' ' ' VAL . . . . . . . . . . . . . 76.3 t -52.78 -34.26 19.81 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.515 0 CA-C-N 115.458 -0.792 . . . . 0.0 109.454 178.394 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 199' ' ' TYR . . . . . . . . . . . . . 65.7 t80 -70.07 -34.96 73.85 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.222 -0.899 . . . . 0.0 110.63 179.753 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 200' ' ' LEU . . . . . 0.468 ' O ' HG12 ' A' ' 203' ' ' VAL . 28.0 mt -67.95 -39.02 83.47 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 115.845 -0.616 . . . . 0.0 111.27 -179.631 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 201' ' ' ASP . . . . . 0.403 ' HB2' ' OH ' ' A' ' 51' ' ' TYR . 0.9 OUTLIER -71.9 -32.35 67.31 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-N 116.099 -0.501 . . . . 0.0 110.776 179.804 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 202' ' ' LEU . . . . . . . . . . . . . 3.7 mt -70.91 -36.5 72.72 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.0 -0.545 . . . . 0.0 111.736 -179.556 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 203' ' ' VAL . . . . . 0.473 ' O ' ' HA3' ' A' ' 207' ' ' GLY . 11.8 p -74.62 -36.32 40.5 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.613 -0.267 . . . . 0.0 111.643 -179.008 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 204' ' ' THR . . . . . 0.462 HG23 ' CE2' ' A' ' 208' ' ' PHE . 43.7 m -67.69 -57.21 6.78 Favored 'General case' 0 C--N 1.326 -0.44 0 C-N-CA 120.84 -0.344 . . . . 0.0 111.53 -179.969 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 205' ' ' LYS . . . . . 0.669 ' HE2' ' HB2' ' A' ' 47' ' ' ALA . 60.0 mttp -69.49 -59.02 3.25 Favored 'General case' 0 C--N 1.329 -0.299 0 N-CA-C 112.549 0.574 . . . . 0.0 112.549 -178.472 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 22.1 t -72.57 -37.53 56.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 N-CA-C 112.158 0.429 . . . . 0.0 112.158 -178.473 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 207' ' ' GLY . . . . . 0.473 ' HA3' ' O ' ' A' ' 203' ' ' VAL . . . -61.51 -55.36 29.34 Favored Glycine 0 CA--C 1.517 0.195 0 C-N-CA 120.51 -0.852 . . . . 0.0 112.922 -179.464 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 208' ' ' PHE . . . . . 0.483 ' O ' ' N ' ' A' ' 212' ' ' ALA . 2.4 m-30 -61.03 -41.58 96.84 Favored 'General case' 0 C--O 1.221 -0.399 0 N-CA-C 110.026 -0.361 . . . . 0.0 110.026 -179.882 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 209' ' ' GLY . . . . . 0.499 ' O ' ' HB3' ' A' ' 212' ' ' ALA . . . -58.26 -37.57 87.4 Favored Glycine 0 N--CA 1.451 -0.33 0 CA-C-N 115.372 -0.831 . . . . 0.0 112.873 179.492 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 210' ' ' PHE . . . . . . . . . . . . . 2.7 m-85 -68.79 -49.56 57.61 Favored 'General case' 0 CA--C 1.514 -0.407 0 N-CA-C 108.548 -0.908 . . . . 0.0 108.548 179.238 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 211' ' ' ILE . . . . . . . . . . . . . 64.9 mt -63.2 -27.45 43.13 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.553 0 N-CA-C 107.61 -1.256 . . . . 0.0 107.61 176.658 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 212' ' ' ALA . . . . . 0.499 ' HB3' ' O ' ' A' ' 209' ' ' GLY . . . -67.99 -38.02 82.18 Favored 'General case' 0 N--CA 1.448 -0.557 0 CA-C-N 114.488 -1.233 . . . . 0.0 110.527 -179.802 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 213' ' ' LEU . . . . . 0.411 ' HG ' ' O ' ' A' ' 209' ' ' GLY . 89.2 mt -70.26 -52.52 22.43 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-N 115.373 -0.831 . . . . 0.0 111.53 -179.606 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 214' ' ' ASP . . . . . . . . . . . . . 24.5 m-20 -57.89 -52.41 65.62 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.396 -0.366 . . . . 0.0 110.954 -179.878 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 215' ' ' ALA . . . . . . . . . . . . . . . -57.25 -53.57 56.66 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.216 179.817 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 216' ' ' ALA . . . . . . . . . . . . . . . -59.98 -31.33 69.8 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-N 116.22 -0.445 . . . . 0.0 111.319 179.947 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 217' ' ' ALA . . . . . . . . . . . . . . . -62.19 -38.67 89.97 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-O 120.949 0.404 . . . . 0.0 110.281 179.651 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 218' ' ' THR . . . . . . . . . . . . . 93.5 m . . . . . 0 C--N 1.33 -0.264 0 CA-C-N 115.821 -0.627 . . . . 0.0 110.635 179.322 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.397 0 N-CA-C 112.224 -0.35 . . . . 0.0 112.224 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 60.5 tp -73.92 -35.55 64.63 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-O 120.881 0.372 . . . . 0.0 110.822 -179.982 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 64.0 p -61.59 -29.94 70.35 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 115.958 -0.565 . . . . 0.0 111.399 -179.819 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 26.9 p -55.37 -35.61 65.45 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 116.365 -0.38 . . . . 0.0 111.118 -179.725 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 7' ' ' LEU . . . . . . . . . . . . . 9.3 mp -55.98 -53.71 53.58 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.093 179.898 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 8' ' ' PHE . . . . . 0.507 ' HB2' ' HB2' ' A' ' 55' ' ' ALA . 65.1 m-85 -62.43 -34.23 76.37 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.716 -179.887 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 9' ' ' TRP . . . . . . . . . . . . . 37.8 m95 -64.46 -41.3 96.59 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-O 121.214 0.53 . . . . 0.0 109.896 179.69 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 86.2 mt -65.91 -31.53 72.51 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-N 115.303 -0.862 . . . . 0.0 110.052 179.227 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . 0.464 ' O ' ' HG2' ' A' ' 15' ' ' MET . . . -68.22 -34.04 79.65 Favored Glycine 0 N--CA 1.448 -0.526 0 C-N-CA 120.823 -0.703 . . . . 0.0 111.43 179.268 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -69.45 -37.18 77.23 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.839 0.352 . . . . 0.0 110.421 179.415 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 50.1 mm -62.41 -53.44 47.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 115.918 -0.583 . . . . 0.0 110.939 179.601 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -56.33 -42.03 88.24 Favored Glycine 0 C--N 1.33 0.245 0 C-N-CA 120.747 -0.74 . . . . 0.0 112.161 179.889 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 15' ' ' MET . . . . . 0.464 ' HG2' ' O ' ' A' ' 11' ' ' GLY . 24.5 mmt -63.45 -41.87 98.64 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.737 0.303 . . . . 0.0 110.53 179.613 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 39.7 tp -54.19 -40.6 67.71 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.051 -0.522 . . . . 0.0 110.601 179.835 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 41.3 t -65.41 -49.03 80.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 115.963 -0.562 . . . . 0.0 111.067 179.955 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -63.31 -47.67 85.73 Favored Glycine 0 C--N 1.331 0.251 0 C-N-CA 120.769 -0.729 . . . . 0.0 112.219 179.724 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 24.9 m -50.32 -44.18 54.09 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-O 120.665 0.269 . . . . 0.0 111.295 -179.973 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 56.9 mt -71.43 -38.73 71.34 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 116.343 -0.39 . . . . 0.0 111.282 179.973 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -60.77 -32.18 71.5 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.242 -0.436 . . . . 0.0 111.549 -179.551 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 22' ' ' PHE . . . . . 0.629 ' HB2' HG22 ' A' ' 41' ' ' VAL . 2.8 m-85 -90.75 -34.46 15.34 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.419 -0.355 . . . . 0.0 111.209 -179.481 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -64.88 -48.49 74.06 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.245 -179.822 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 24' ' ' TRP . . . . . . . . . . . . . 3.6 t-105 -68.03 -53.63 24.34 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 115.906 -0.588 . . . . 0.0 111.25 -179.617 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.329 -0.315 0 CA-C-O 120.862 0.363 . . . . 0.0 111.114 -179.99 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.453 -0.216 0 N-CA-C 112.523 -0.231 . . . . 0.0 112.523 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 45.7 mt-10 -68.98 -20.72 64.18 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.69 0.281 . . . . 0.0 111.064 -179.901 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 34' ' ' ARG . . . . . 0.444 ' O ' HG23 ' A' ' 38' ' ' VAL . 99.9 mtt180 -49.28 -31.15 8.44 Favored 'General case' 0 C--N 1.332 -0.174 0 CA-C-N 116.123 -0.49 . . . . 0.0 111.681 -179.665 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 23.2 ttp180 -64.62 -47.89 76.91 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-O 120.805 0.336 . . . . 0.0 110.816 179.829 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 76.1 m-85 -67.12 -29.52 69.28 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.123 -0.489 . . . . 0.0 111.047 179.859 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 37' ' ' TYR . . . . . 0.447 ' O ' HG23 ' A' ' 41' ' ' VAL . 35.5 m-85 -71.48 -52.62 17.41 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.3 -179.628 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 38' ' ' VAL . . . . . 0.444 HG23 ' O ' ' A' ' 34' ' ' ARG . 84.9 t -56.75 -36.61 49.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-O 121.077 0.465 . . . . 0.0 110.263 179.664 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 17.3 m -69.07 -51.12 42.15 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 115.686 -0.688 . . . . 0.0 110.865 179.392 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 40' ' ' LEU . . . . . 0.408 HD23 ' CG ' ' A' ' 22' ' ' PHE . 11.4 tp -55.48 -50.81 68.92 Favored 'General case' 0 C--O 1.237 0.43 0 CA-C-N 115.914 -0.584 . . . . 0.0 110.707 -179.972 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . 0.629 HG22 ' HB2' ' A' ' 22' ' ' PHE . 60.0 t -62.1 -34.46 63.59 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.367 0 CA-C-N 115.675 -0.693 . . . . 0.0 110.287 179.29 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 42' ' ' GLY . . . . . 0.427 ' O ' HG12 ' A' ' 46' ' ' ILE . . . -60.21 -34.91 86.36 Favored Glycine 0 N--CA 1.449 -0.493 0 C-N-CA 120.864 -0.684 . . . . 0.0 112.337 179.949 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 43' ' ' ILE . . . . . 0.667 HG22 ' HE3' ' A' ' 205' ' ' LYS . 0.3 OUTLIER -71.83 -58.47 5.05 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.218 0 CA-C-O 120.752 0.311 . . . . 0.0 110.944 179.901 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 80.7 p -61.03 -20.59 62.71 Favored 'General case' 0 C--N 1.332 -0.153 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.262 -179.621 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -79.51 -57.15 3.19 Favored Glycine 0 CA--C 1.519 0.287 0 C-N-CA 120.792 -0.718 . . . . 0.0 112.94 -179.327 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 46' ' ' ILE . . . . . 0.427 HG12 ' O ' ' A' ' 42' ' ' GLY . 16.5 pt -58.36 -36.25 57.61 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.213 0 CA-C-O 120.976 0.417 . . . . 0.0 111.071 -179.994 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 47' ' ' ALA . . . . . 0.663 ' HB2' ' HE2' ' A' ' 205' ' ' LYS . . . -68.15 -45.94 72.17 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-N 116.079 -0.51 . . . . 0.0 111.314 179.518 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 48' ' ' ALA . . . . . 0.429 ' HB2' ' HB3' ' A' ' 15' ' ' MET . . . -54.71 -40.41 69.18 Favored 'General case' 0 C--N 1.332 -0.186 0 CA-C-N 116.271 -0.422 . . . . 0.0 111.909 -179.451 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 35.7 m -76.01 -34.11 26.36 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.384 0 CA-C-N 116.452 -0.34 . . . . 0.0 111.482 -179.318 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -65.03 -36.54 84.69 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.905 0.383 . . . . 0.0 111.033 179.718 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 38.1 m-85 -73.29 -39.8 65.06 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.021 -0.536 . . . . 0.0 110.685 -179.862 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -63.29 -46.72 85.43 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 115.92 -0.582 . . . . 0.0 111.527 179.86 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 53' ' ' VAL . . . . . 0.464 HG23 ' N ' ' A' ' 54' ' ' MET . 30.4 m -67.77 -46.14 83.04 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.19 0 CA-C-N 116.341 -0.39 . . . . 0.0 111.109 -179.78 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 54' ' ' MET . . . . . 0.483 ' HG3' ' HE1' ' A' ' 60' ' ' TRP . 13.3 ttp -64.44 -29.31 70.36 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.995 0.426 . . . . 0.0 110.294 179.834 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 55' ' ' ALA . . . . . 0.507 ' HB2' ' HB2' ' A' ' 8' ' ' PHE . . . -64.36 -32.23 73.75 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 115.919 -0.582 . . . . 0.0 111.092 179.502 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 97.4 mt -82.85 6.26 18.97 Favored 'General case' 0 C--N 1.331 -0.204 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.197 -179.674 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 94.33 -5.25 70.97 Favored Glycine 0 N--CA 1.452 -0.265 0 C-N-CA 120.667 -0.778 . . . . 0.0 112.759 179.787 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 58.8 t -62.66 140.52 19.34 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.243 0 CA-C-O 120.701 0.286 . . . . 0.0 110.825 179.861 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 85.89 -23.64 8.91 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.615 -179.859 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 60' ' ' TRP . . . . . 0.483 ' HE1' ' HG3' ' A' ' 54' ' ' MET . 13.3 m0 -61.08 108.02 0.82 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.806 0.336 . . . . 0.0 110.722 179.909 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 7.4 p -118.67 131.58 24.23 Favored Pre-proline 0 CA--C 1.533 0.293 0 CA-C-N 116.343 -0.39 . . . . 0.0 111.469 -179.863 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 57.7 Cg_endo -71.9 147.77 50.36 Favored 'Trans proline' 0 C--N 1.35 0.637 0 C-N-CA 122.481 2.121 . . . . 0.0 112.501 179.842 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 76.8 t -141.91 99.19 0.82 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 115.92 -0.582 . . . . 0.0 111.019 -179.813 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . 58.72 -85.82 0.02 OUTLIER 'General case' 0 C--N 1.332 -0.172 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.229 -179.927 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 41.2 mt-10 -127.96 -20.39 3.84 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.319 179.723 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 66' ' ' ARG . . . . . . . . . . . . . 18.6 ptp180 -100.26 164.3 12.01 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 115.773 -0.649 . . . . 0.0 110.148 179.709 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 44.5 m -123.15 138.26 54.7 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-O 120.935 0.398 . . . . 0.0 111.213 -179.779 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 68' ' ' VAL . . . . . 0.485 HG11 ' HB3' ' A' ' 117' ' ' MET . 23.9 m -125.48 146.06 31.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.012 -0.54 . . . . 0.0 110.849 179.792 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 69' ' ' PHE . . . . . . . . . . . . . 8.5 m-85 -104.85 114.97 29.5 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.044 -179.732 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 70' ' ' VAL . . . . . 0.561 HG12 ' HD3' ' A' ' 71' ' ' PRO . 0.5 OUTLIER -66.94 -32.08 4.55 Favored Pre-proline 0 CA--C 1.54 0.58 0 N-CA-C 112.849 0.685 . . . . 0.0 112.849 -179.241 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 71' ' ' PRO . . . . . 0.561 ' HD3' HG12 ' A' ' 70' ' ' VAL . 14.5 Cg_exo -68.39 -18.04 44.07 Favored 'Trans proline' 0 C--N 1.36 1.157 0 C-N-CA 121.944 1.763 . . . . 0.0 112.704 -179.603 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 59.0 ttt180 -72.97 -55.2 6.9 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.767 0.317 . . . . 0.0 111.637 -179.224 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 73' ' ' TYR . . . . . . . . . . . . . 4.0 m-85 -71.8 -34.44 69.39 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.482 -0.326 . . . . 0.0 110.74 -179.143 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 74' ' ' ILE . . . . . 0.531 HG22 ' HA ' ' A' ' 71' ' ' PRO . 0.4 OUTLIER -69.38 -41.2 80.75 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.192 0 CA-C-N 116.515 -0.311 . . . . 0.0 110.333 179.736 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 11.3 t70 -58.36 -37.64 75.62 Favored 'General case' 0 CA--C 1.518 -0.256 0 N-CA-C 109.427 -0.583 . . . . 0.0 109.427 178.901 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 76' ' ' TRP . . . . . 0.499 ' HB3' ' SD ' ' A' ' 109' ' ' MET . 42.6 m0 -64.97 -38.56 91.36 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 115.567 -0.742 . . . . 0.0 110.824 179.531 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 77' ' ' ILE . . . . . 0.512 ' O ' ' HG2' ' A' ' 81' ' ' PRO . 83.7 mt -66.54 -28.63 43.95 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-N 116.39 -0.368 . . . . 0.0 110.894 179.633 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 53.9 mt -91.47 -21.13 21.08 Favored 'General case' 0 C--N 1.327 -0.41 0 N-CA-C 112.044 0.387 . . . . 0.0 112.044 -179.969 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 71.5 p -102.3 -52.68 3.07 Favored 'General case' 0 CA--C 1.531 0.219 0 N-CA-C 113.425 0.898 . . . . 0.0 113.425 -178.099 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 80' ' ' THR . . . . . 0.643 ' HB ' ' HD3' ' A' ' 81' ' ' PRO . 26.2 m -50.2 -54.78 30.29 Favored Pre-proline 0 CA--C 1.532 0.283 0 N-CA-C 112.749 0.648 . . . . 0.0 112.749 -178.513 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 81' ' ' PRO . . . . . 0.643 ' HD3' ' HB ' ' A' ' 80' ' ' THR . 52.7 Cg_exo -57.1 -23.7 54.23 Favored 'Trans proline' 0 C--N 1.351 0.696 0 C-N-CA 121.513 1.475 . . . . 0.0 111.35 179.63 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 82' ' ' LEU . . . . . . . . . . . . . 16.4 tp -76.96 -32.72 57.5 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 115.445 -0.798 . . . . 0.0 109.764 179.39 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 83' ' ' ILE . . . . . 0.456 HG23 ' HE2' ' A' ' 208' ' ' PHE . 40.4 mm -66.44 -54.38 26.63 Favored 'Isoleucine or valine' 0 C--O 1.233 0.185 0 CA-C-N 115.835 -0.62 . . . . 0.0 110.514 179.329 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 27.5 m -61.13 -31.07 49.09 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.31 0 N-CA-C 109.378 -0.601 . . . . 0.0 109.378 179.092 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 85' ' ' TYR . . . . . 0.422 ' O ' ' HG ' ' A' ' 89' ' ' LEU . 80.4 t80 -61.64 -35.58 78.33 Favored 'General case' 0 N--CA 1.453 -0.282 0 CA-C-N 115.593 -0.73 . . . . 0.0 109.155 178.338 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 86' ' ' PHE . . . . . . . . . . . . . 34.1 t80 -61.9 -49.67 75.26 Favored 'General case' 0 CA--C 1.52 -0.178 0 CA-C-N 115.78 -0.645 . . . . 0.0 109.623 179.046 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 3.9 mm? -57.71 -32.8 67.75 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 115.655 -0.702 . . . . 0.0 110.034 179.131 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -73.15 -27.43 68.37 Favored Glycine 0 N--CA 1.451 -0.305 0 CA-C-N 115.642 -0.708 . . . . 0.0 112.826 179.784 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 89' ' ' LEU . . . . . 0.422 ' HG ' ' O ' ' A' ' 85' ' ' TYR . 94.3 mt -72.39 -44.42 62.54 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.904 0.383 . . . . 0.0 111.084 -179.622 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 70.3 mt -70.49 -27.29 64.09 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 115.986 -0.552 . . . . 0.0 111.363 -179.748 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 91' ' ' ALA . . . . . 0.659 ' HA ' ' HB2' ' A' ' 149' ' ' ALA . . . -87.49 -52.65 5.23 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.426 -0.352 . . . . 0.0 111.239 -179.93 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 90.31 59.96 1.42 Allowed Glycine 0 N--CA 1.451 -0.361 0 C-N-CA 120.93 -0.652 . . . . 0.0 112.418 -179.966 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 93' ' ' LEU . . . . . 0.593 HD23 ' HB3' ' A' ' 97' ' ' GLU . 8.1 mp -71.28 -174.72 1.07 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.741 0.305 . . . . 0.0 110.845 -179.894 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 94' ' ' ASP . . . . . 0.451 ' HB2' ' OE2' ' A' ' 97' ' ' GLU . 12.5 m-20 -94.09 -172.16 2.75 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 121.023 0.439 . . . . 0.0 111.545 -179.446 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 43.5 m -67.8 -48.98 64.75 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 115.836 -0.62 . . . . 0.0 111.657 -179.266 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 31.9 ttm180 -73.33 -41.01 64.0 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 121.05 0.452 . . . . 0.0 110.619 -179.338 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 97' ' ' GLU . . . . . 0.593 ' HB3' HD23 ' A' ' 93' ' ' LEU . 0.3 OUTLIER -56.47 -45.83 80.72 Favored 'General case' 0 C--N 1.326 -0.449 0 CA-C-N 115.692 -0.686 . . . . 0.0 111.069 179.983 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 98' ' ' PHE . . . . . 0.448 ' O ' HG12 ' A' ' 102' ' ' ILE . 1.2 m-85 -60.79 -43.97 97.41 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.338 -0.392 . . . . 0.0 110.731 179.63 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -64.8 -29.73 76.08 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.901 -0.666 . . . . 0.0 112.639 -179.995 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 93.1 mt -68.29 -41.68 83.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-O 120.756 0.313 . . . . 0.0 111.249 -179.81 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 34.2 t -68.07 -41.16 84.12 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.411 0 CA-C-N 116.264 -0.425 . . . . 0.0 111.432 -179.573 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 102' ' ' ILE . . . . . 0.448 HG12 ' O ' ' A' ' 98' ' ' PHE . 42.0 mm -68.67 -51.36 46.64 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.447 -0.342 . . . . 0.0 111.44 -179.756 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 15.3 t -56.86 -32.21 65.59 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-O 120.916 0.389 . . . . 0.0 111.04 -179.894 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 104' ' ' LEU . . . . . 0.475 HD23 HD13 ' A' ' 137' ' ' LEU . 33.7 tp -66.06 -48.41 71.14 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.573 179.483 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 105' ' ' ASN . . . . . 0.542 ' N ' HD22 ' A' ' 105' ' ' ASN . 0.9 OUTLIER -62.52 -27.0 68.85 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.045 179.972 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 89.2 m -70.21 -53.36 17.41 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.334 -0.394 . . . . 0.0 111.419 -179.887 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 8.8 p -65.6 -37.07 79.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.296 -0.411 . . . . 0.0 111.304 -179.652 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 55.6 t -65.41 -50.16 74.33 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.249 0 CA-C-N 116.43 -0.35 . . . . 0.0 110.958 179.86 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 109' ' ' MET . . . . . 0.626 ' HE1' HG21 ' A' ' 80' ' ' THR . 7.2 tpp -64.12 -33.54 75.99 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.622 -179.899 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 110' ' ' LEU . . . . . 0.472 HD23 ' C ' ' A' ' 110' ' ' LEU . 3.4 tt -63.06 -41.62 99.5 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-N 115.921 -0.581 . . . . 0.0 109.706 179.052 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -58.12 -47.83 82.08 Favored 'General case' 0 C--N 1.331 -0.203 0 CA-C-N 115.824 -0.625 . . . . 0.0 110.494 179.536 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . -68.47 -32.68 75.57 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.64 -0.791 . . . . 0.0 111.929 179.374 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 113' ' ' PHE . . . . . . . . . . . . . 0.5 OUTLIER -51.79 -68.45 0.17 Allowed 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 121.058 0.456 . . . . 0.0 109.998 179.566 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 114' ' ' ALA . . . . . 0.456 ' O ' HG13 ' A' ' 118' ' ' VAL . . . -70.48 -24.02 62.79 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 115.586 -0.733 . . . . 0.0 111.155 179.819 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -54.08 -40.86 67.68 Favored Glycine 0 C--N 1.331 0.282 0 C-N-CA 121.149 -0.548 . . . . 0.0 112.994 -179.699 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -77.81 -39.15 44.77 Favored 'General case' 0 C--N 1.328 -0.326 0 N-CA-C 112.142 0.423 . . . . 0.0 112.142 -179.429 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 117' ' ' MET . . . . . 0.485 ' HB3' HG11 ' A' ' 68' ' ' VAL . 19.3 ptp -91.4 19.74 5.84 Favored 'General case' 0 C--N 1.329 -0.324 0 N-CA-C 111.788 0.292 . . . . 0.0 111.788 -179.287 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 118' ' ' VAL . . . . . 0.544 HG21 ' HB3' ' A' ' 123' ' ' ARG . 5.0 m -54.08 149.45 18.37 Favored Pre-proline 0 C--N 1.33 -0.282 0 CA-C-N 116.598 -0.274 . . . . 0.0 111.231 179.723 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 119' ' ' PRO . . . . . . . . . . . . . 90.3 Cg_endo -87.34 3.97 6.24 Favored 'Trans proline' 0 N--CA 1.458 -0.581 0 C-N-CA 122.64 2.227 . . . . 0.0 112.236 179.622 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -168.37 -133.96 1.64 Allowed Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.786 -0.721 . . . . 0.0 112.457 -179.951 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 42.4 pt -99.18 18.01 2.77 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.246 0 CA-C-O 120.885 0.374 . . . . 0.0 111.182 -179.834 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 45.1 mt-10 -67.51 -18.46 65.05 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.274 -179.975 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 123' ' ' ARG . . . . . 0.544 ' HB3' HG21 ' A' ' 118' ' ' VAL . 20.5 ptt180 -53.07 -29.82 32.52 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 116.222 -0.444 . . . . 0.0 111.67 -179.678 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 124' ' ' TYR . . . . . . . . . . . . . 28.2 m-85 -67.48 -34.41 77.1 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.589 -0.278 . . . . 0.0 110.795 -179.858 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 125' ' ' ALA . . . . . . . . . . . . . . . -74.78 -56.08 5.16 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.17 -179.978 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 1.1 mt -52.49 -54.34 33.81 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 115.908 -0.587 . . . . 0.0 110.961 -179.86 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 127' ' ' PHE . . . . . . . . . . . . . 8.8 t80 -62.78 -36.4 82.99 Favored 'General case' 0 C--N 1.331 -0.231 0 C-N-CA 120.847 -0.341 . . . . 0.0 110.567 179.756 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 128' ' ' GLY . . . . . . . . . . . . . . . -47.31 -43.98 20.15 Favored Glycine 0 C--N 1.332 0.314 0 C-N-CA 120.136 -1.031 . . . . 0.0 111.153 179.154 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 129' ' ' MET . . . . . . . . . . . . . 0.3 OUTLIER -71.87 -37.05 70.26 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 120.865 0.364 . . . . 0.0 110.026 178.868 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -67.18 -28.19 73.67 Favored Glycine 0 N--CA 1.45 -0.378 0 CA-C-N 115.822 -0.626 . . . . 0.0 112.688 -179.722 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -74.81 -54.18 7.79 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.624 0.25 . . . . 0.0 110.67 -179.953 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 31.7 t -57.95 -41.17 79.55 Favored 'Isoleucine or valine' 0 C--O 1.235 0.318 0 N-CA-C 109.129 -0.693 . . . . 0.0 109.129 178.698 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -66.29 -35.8 81.32 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 115.173 -0.921 . . . . 0.0 110.106 178.929 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 134' ' ' PHE . . . . . 0.418 ' CZ ' ' HA ' ' A' ' 172' ' ' ALA . 57.9 t80 -57.48 -50.9 71.55 Favored 'General case' 0 N--CA 1.45 -0.469 0 CA-C-N 115.937 -0.574 . . . . 0.0 110.022 179.548 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 135' ' ' ILE . . . . . 0.451 ' O ' HG22 ' A' ' 138' ' ' VAL . 60.2 mt -56.64 -33.59 40.39 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.312 0 CA-C-N 115.911 -0.586 . . . . 0.0 109.663 178.95 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . -63.21 -35.21 91.76 Favored Glycine 0 N--CA 1.447 -0.568 0 C-N-CA 120.249 -0.977 . . . . 0.0 111.205 178.507 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 137' ' ' LEU . . . . . 0.475 HD13 HD23 ' A' ' 104' ' ' LEU . 29.1 tp -73.43 -52.13 14.82 Favored 'General case' 0 C--N 1.332 -0.158 0 N-CA-C 110.422 -0.214 . . . . 0.0 110.422 179.612 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 138' ' ' VAL . . . . . 0.791 ' HA ' HD12 ' A' ' 141' ' ' LEU . 4.9 m -55.95 -30.55 28.72 Favored 'Isoleucine or valine' 0 C--O 1.234 0.28 0 N-CA-C 109.069 -0.715 . . . . 0.0 109.069 178.92 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 139' ' ' TYR . . . . . 0.413 ' O ' ' N ' ' A' ' 143' ' ' GLY . 49.8 t80 -64.82 -41.96 95.35 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 114.958 -1.019 . . . . 0.0 109.337 178.462 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 19.4 m-85 -65.02 -33.0 74.99 Favored 'General case' 0 C--N 1.333 -0.143 0 CA-C-N 116.036 -0.529 . . . . 0.0 109.791 178.577 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 141' ' ' LEU . . . . . 0.791 HD12 ' HA ' ' A' ' 138' ' ' VAL . 81.9 mt -61.21 -36.38 79.75 Favored 'General case' 0 C--O 1.232 0.149 0 CA-C-N 115.977 -0.556 . . . . 0.0 109.895 179.078 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 142' ' ' VAL . . . . . 0.404 HG22 ' NH1' ' A' ' 164' ' ' ARG . 2.9 t -109.27 10.48 8.96 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-N 115.751 -0.659 . . . . 0.0 110.658 179.729 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 143' ' ' GLY . . . . . 0.413 ' N ' ' O ' ' A' ' 139' ' ' TYR . . . -85.52 -147.6 9.81 Favored Glycine 0 CA--C 1.519 0.291 0 C-N-CA 120.968 -0.634 . . . . 0.0 113.008 -179.511 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 144' ' ' PRO . . . . . . . . . . . . . 51.3 Cg_exo -52.98 -24.87 26.11 Favored 'Trans proline' 0 C--N 1.349 0.579 0 C-N-CA 122.716 2.278 . . . . 0.0 112.754 -179.799 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 145' ' ' MET . . . . . 0.464 ' HG2' HD11 ' A' ' 93' ' ' LEU . 55.3 mtt -53.22 -39.15 63.55 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 116.352 -0.385 . . . . 0.0 111.244 179.975 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 146' ' ' THR . . . . . . . . . . . . . 81.2 p -62.1 -51.2 68.89 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.794 -179.36 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 147' ' ' GLU . . . . . 0.479 ' O ' ' HG2' ' A' ' 151' ' ' GLN . 40.0 mt-10 -74.1 -18.06 60.86 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.394 -0.366 . . . . 0.0 111.249 -179.534 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 148' ' ' SER . . . . . . . . . . . . . 44.6 t -71.21 -47.69 55.9 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.764 0.316 . . . . 0.0 111.231 -179.807 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 149' ' ' ALA . . . . . 0.659 ' HB2' ' HA ' ' A' ' 91' ' ' ALA . . . -78.02 -31.99 50.79 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.128 -0.487 . . . . 0.0 112.242 -178.975 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 150' ' ' SER . . . . . . . . . . . . . 70.2 m -62.68 -6.67 3.79 Favored 'General case' 0 C--N 1.328 -0.337 0 N-CA-C 111.993 0.368 . . . . 0.0 111.993 -179.384 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 151' ' ' GLN . . . . . 0.479 ' HG2' ' O ' ' A' ' 147' ' ' GLU . 67.0 mm-40 -111.58 17.14 20.27 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.731 -0.213 . . . . 0.0 111.095 -179.775 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 25.6 mtp180 -101.71 -52.24 3.25 Favored 'General case' 0 C--N 1.331 -0.201 0 CA-C-O 120.832 0.349 . . . . 0.0 111.351 -179.839 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 153' ' ' SER . . . . . 0.594 ' HB3' HG12 ' A' ' 156' ' ' ILE . 31.5 t -156.83 172.27 18.93 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.959 179.691 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 154' ' ' SER . . . . . . . . . . . . . 61.4 m -73.05 -39.78 65.64 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 116.257 -0.428 . . . . 0.0 110.65 179.679 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -76.6 -28.81 58.78 Favored Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.904 -0.665 . . . . 0.0 112.7 -179.936 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 156' ' ' ILE . . . . . 0.594 HG12 ' HB3' ' A' ' 153' ' ' SER . 25.8 mm -58.37 -42.45 84.05 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.233 0 CA-C-O 120.764 0.316 . . . . 0.0 111.486 -179.96 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 157' ' ' LYS . . . . . 0.422 ' O ' HG13 ' A' ' 161' ' ' VAL . 25.0 ttpp -63.31 -42.24 99.0 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.272 -0.422 . . . . 0.0 111.499 -179.496 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 46.5 t -65.23 -47.68 75.98 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.418 -0.355 . . . . 0.0 111.88 -179.257 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 159' ' ' LEU . . . . . 0.501 ' O ' HD13 ' A' ' 163' ' ' LEU . 4.9 tt -66.13 -34.68 78.61 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.507 -0.315 . . . . 0.0 111.241 -179.396 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 160' ' ' TYR . . . . . . . . . . . . . 58.4 t80 -73.69 -46.16 48.01 Favored 'General case' 0 C--N 1.327 -0.382 0 N-CA-C 112.365 0.506 . . . . 0.0 112.365 -178.767 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 161' ' ' VAL . . . . . 0.442 HG23 ' N ' ' A' ' 162' ' ' ARG . 28.8 m -59.97 -46.52 93.99 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 N-CA-C 112.171 0.434 . . . . 0.0 112.171 -178.933 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 162' ' ' ARG . . . . . 0.442 ' N ' HG23 ' A' ' 161' ' ' VAL . 79.0 ttt180 -65.61 -46.04 80.85 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.71 0.291 . . . . 0.0 111.552 -179.331 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 163' ' ' LEU . . . . . 0.501 HD13 ' O ' ' A' ' 159' ' ' LEU . 7.8 mp -65.44 -52.02 56.13 Favored 'General case' 0 C--N 1.329 -0.317 0 N-CA-C 112.106 0.41 . . . . 0.0 112.106 -179.186 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 164' ' ' ARG . . . . . 0.602 ' O ' HG23 ' A' ' 168' ' ' VAL . 5.7 ppt_? -58.62 -43.34 89.62 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.598 -0.274 . . . . 0.0 111.605 -178.861 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 165' ' ' ASN . . . . . 0.471 ' O ' HG23 ' A' ' 169' ' ' VAL . 0.9 OUTLIER -55.97 -49.44 73.57 Favored 'General case' 0 C--N 1.331 -0.202 0 CA-C-O 121.129 0.49 . . . . 0.0 110.427 179.513 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 166' ' ' LEU . . . . . 0.485 ' O ' ' HG ' ' A' ' 170' ' ' LEU . 3.1 tt -60.15 -50.04 75.24 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 115.563 -0.744 . . . . 0.0 111.681 -179.52 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 167' ' ' THR . . . . . 0.479 ' O ' ' HB2' ' A' ' 171' ' ' TRP . 60.1 m -56.41 -54.01 50.63 Favored 'General case' 0 C--N 1.331 -0.232 0 N-CA-C 112.324 0.49 . . . . 0.0 112.324 -178.796 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 168' ' ' VAL . . . . . 0.644 HG22 HD13 ' A' ' 141' ' ' LEU . 45.4 t -52.27 -43.8 40.43 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.227 0 N-CA-C 112.339 0.496 . . . . 0.0 112.339 -179.764 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 169' ' ' VAL . . . . . 0.471 HG23 ' O ' ' A' ' 165' ' ' ASN . 72.8 t -59.92 -65.75 0.44 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 N-CA-C 113.016 0.747 . . . . 0.0 113.016 -178.47 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 170' ' ' LEU . . . . . 0.485 ' HG ' ' O ' ' A' ' 166' ' ' LEU . 0.7 OUTLIER -63.08 -37.78 88.56 Favored 'General case' 0 C--N 1.33 -0.26 0 N-CA-C 112.593 0.59 . . . . 0.0 112.593 -178.163 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 171' ' ' TRP . . . . . 0.479 ' HB2' ' O ' ' A' ' 167' ' ' THR . 2.9 m0 -64.25 -27.58 69.15 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.832 0.349 . . . . 0.0 110.771 179.813 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 172' ' ' ALA . . . . . 0.418 ' HA ' ' CZ ' ' A' ' 134' ' ' PHE . . . -72.48 -6.93 47.19 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.948 -179.818 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 173' ' ' ILE . . . . . 0.492 ' O ' HG12 ' A' ' 177' ' ' ILE . 28.8 mm -88.4 -21.24 7.05 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 115.952 -0.567 . . . . 0.0 111.175 -179.985 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 174' ' ' TYR . . . . . 0.403 ' N ' ' CD ' ' A' ' 175' ' ' PRO . 8.7 m-85 -53.59 -48.25 93.74 Favored Pre-proline 0 N--CA 1.464 0.261 0 CA-C-N 116.339 -0.392 . . . . 0.0 111.93 -179.375 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 175' ' ' PRO . . . . . 0.403 ' CD ' ' N ' ' A' ' 174' ' ' TYR . 84.6 Cg_exo -48.43 -33.27 22.52 Favored 'Trans proline' 0 C--N 1.351 0.667 0 C-N-CA 121.854 1.703 . . . . 0.0 112.048 179.588 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 176' ' ' PHE . . . . . 0.465 ' HD2' ' HA ' ' A' ' 173' ' ' ILE . 60.9 m-85 -80.9 -50.35 9.87 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 115.873 -0.603 . . . . 0.0 111.954 -179.905 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 177' ' ' ILE . . . . . 0.507 HG13 HD11 ' A' ' 200' ' ' LEU . 13.6 mm -60.25 -32.08 49.86 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.443 0 CA-C-N 116.279 -0.418 . . . . 0.0 112.036 -178.386 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 178' ' ' TRP . . . . . 0.458 ' HH2' ' HB2' ' A' ' 123' ' ' ARG . 82.0 t90 -73.18 -52.06 15.52 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.91 0.386 . . . . 0.0 110.81 179.928 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 179' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -68.76 -54.77 14.07 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-N 115.989 -0.55 . . . . 0.0 111.484 -179.119 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 180' ' ' LEU . . . . . 0.542 HD22 HD11 ' A' ' 187' ' ' LEU . 26.6 mt -64.06 -29.7 70.82 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.55 -0.295 . . . . 0.0 111.298 -179.37 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . -69.12 -175.79 12.24 Favored Glycine 0 N--CA 1.449 -0.44 0 C-N-CA 119.817 -1.183 . . . . 0.0 111.629 178.957 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 182' ' ' PRO . . . . . 0.502 ' HG3' ' HA ' ' A' ' 190' ' ' PRO . 82.3 Cg_exo -47.47 -43.54 27.07 Favored 'Trans proline' 0 CA--C 1.537 0.669 0 C-N-CA 122.678 2.252 . . . . 0.0 113.76 179.943 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 183' ' ' PRO . . . . . 0.424 ' HB2' ' O ' ' A' ' 178' ' ' TRP . 83.4 Cg_exo -43.07 -51.77 5.31 Favored 'Trans proline' 0 C--N 1.356 0.957 0 C-N-CA 122.491 2.127 . . . . 0.0 114.065 -179.744 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 184' ' ' GLY . . . . . . . . . . . . . . . -102.74 -123.95 5.36 Favored Glycine 0 C--N 1.335 0.515 0 C-N-CA 119.942 -1.123 . . . . 0.0 113.631 -179.063 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 185' ' ' VAL . . . . . 0.406 ' CG2' HD21 ' A' ' 187' ' ' LEU . 23.6 m -54.09 -33.33 24.49 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.405 0 N-CA-C 112.647 0.61 . . . . 0.0 112.647 -178.95 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 186' ' ' ALA . . . . . 0.421 ' HB2' ' HA ' ' A' ' 182' ' ' PRO . . . 58.92 83.35 0.13 Allowed 'General case' 0 N--CA 1.464 0.246 0 CA-C-O 120.675 0.274 . . . . 0.0 111.624 179.786 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 187' ' ' LEU . . . . . 0.542 HD11 HD22 ' A' ' 180' ' ' LEU . 7.7 mt -92.32 -49.92 5.91 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-O 120.902 0.382 . . . . 0.0 111.351 179.795 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 188' ' ' LEU . . . . . 0.463 HD12 ' HB2' ' A' ' 187' ' ' LEU . 7.3 mp -79.79 -164.59 0.68 Allowed 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.001 -0.545 . . . . 0.0 111.197 -179.268 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 189' ' ' THR . . . . . 0.497 ' HB ' HG23 ' A' ' 192' ' ' VAL . 20.8 m -91.08 137.46 26.46 Favored Pre-proline 0 C--N 1.329 -0.295 0 CA-C-N 115.868 -0.605 . . . . 0.0 110.634 -179.73 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 190' ' ' PRO . . . . . 0.502 ' HA ' ' HG3' ' A' ' 182' ' ' PRO . 92.3 Cg_exo -44.23 -37.24 9.87 Favored 'Trans proline' 0 C--N 1.35 0.656 0 C-N-CA 122.519 2.146 . . . . 0.0 113.278 -179.649 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 191' ' ' THR . . . . . 0.433 HG22 HG22 ' A' ' 189' ' ' THR . 6.2 t -78.52 -40.82 34.05 Favored 'General case' 0 C--N 1.33 -0.275 0 N-CA-C 111.683 0.253 . . . . 0.0 111.683 -179.616 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 192' ' ' VAL . . . . . 0.497 HG23 ' HB ' ' A' ' 189' ' ' THR . 96.9 t -62.52 -48.69 87.08 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-O 120.658 0.266 . . . . 0.0 111.463 -179.729 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 193' ' ' ASP . . . . . . . . . . . . . 21.6 m-20 -56.0 -46.58 78.7 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.397 -0.365 . . . . 0.0 111.089 -179.714 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 194' ' ' VAL . . . . . 0.429 HG23 ' O ' ' A' ' 190' ' ' PRO . 71.0 t -59.34 -37.07 67.36 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.412 -0.358 . . . . 0.0 110.739 179.547 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 195' ' ' ALA . . . . . . . . . . . . . . . -59.32 -41.71 89.72 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.303 -0.408 . . . . 0.0 110.608 179.534 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 196' ' ' LEU . . . . . . . . . . . . . 98.1 mt -67.3 -38.4 84.95 Favored 'General case' 0 C--N 1.333 -0.143 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.197 179.248 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 197' ' ' ILE . . . . . 0.445 HG23 ' HZ2' ' A' ' 76' ' ' TRP . 15.8 mm -60.57 -56.24 19.06 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.242 0 CA-C-N 115.901 -0.59 . . . . 0.0 110.248 179.122 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 198' ' ' VAL . . . . . . . . . . . . . 93.7 t -54.28 -34.58 28.01 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.516 0 CA-C-N 115.623 -0.717 . . . . 0.0 109.321 178.303 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 199' ' ' TYR . . . . . . . . . . . . . 29.7 t80 -69.83 -32.99 71.71 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 115.112 -0.949 . . . . 0.0 110.609 179.794 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 200' ' ' LEU . . . . . 0.516 ' O ' HG12 ' A' ' 203' ' ' VAL . 23.0 mt -69.86 -39.33 76.41 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 115.97 -0.559 . . . . 0.0 111.024 179.984 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 201' ' ' ASP . . . . . . . . . . . . . 15.2 m-20 -72.95 -34.6 66.64 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-O 121.204 0.526 . . . . 0.0 110.103 179.625 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 202' ' ' LEU . . . . . . . . . . . . . 3.1 mt -75.01 -27.13 59.99 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 115.514 -0.766 . . . . 0.0 111.749 -179.439 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 203' ' ' VAL . . . . . 0.516 HG12 ' O ' ' A' ' 200' ' ' LEU . 10.9 p -79.61 -36.36 17.47 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.334 0 C-N-CA 120.834 -0.347 . . . . 0.0 110.856 -178.924 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 204' ' ' THR . . . . . . . . . . . . . 96.9 m -67.87 -58.27 4.85 Favored 'General case' 0 C--N 1.328 -0.333 0 C-N-CA 120.933 -0.307 . . . . 0.0 110.902 179.212 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 205' ' ' LYS . . . . . 0.667 ' HE3' HG22 ' A' ' 43' ' ' ILE . 60.5 mttp -60.52 -58.29 9.11 Favored 'General case' 0 C--N 1.331 -0.212 0 N-CA-C 112.067 0.395 . . . . 0.0 112.067 -178.937 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 52.8 t -67.69 -37.02 77.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 N-CA-C 111.818 0.303 . . . . 0.0 111.818 -179.303 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 207' ' ' GLY . . . . . 0.407 ' HA3' ' O ' ' A' ' 203' ' ' VAL . . . -53.55 -60.48 8.19 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.908 -0.663 . . . . 0.0 113.975 -178.818 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 208' ' ' PHE . . . . . 0.506 ' O ' ' HB2' ' A' ' 212' ' ' ALA . 1.1 p90 -75.45 -26.75 58.53 Favored 'General case' 0 C--O 1.219 -0.513 0 CA-C-N 117.317 0.559 . . . . 0.0 111.778 -179.14 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 209' ' ' GLY . . . . . 0.45 ' O ' ' HB3' ' A' ' 212' ' ' ALA . . . -66.4 -35.24 89.88 Favored Glycine 0 N--CA 1.452 -0.267 0 C-N-CA 121.491 -0.385 . . . . 0.0 112.202 179.597 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 210' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER -75.75 -44.86 39.54 Favored 'General case' 0 CA--C 1.514 -0.433 0 N-CA-C 108.316 -0.994 . . . . 0.0 108.316 178.742 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 211' ' ' ILE . . . . . . . . . . . . . 44.3 mt -65.6 -27.55 41.85 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.55 0 N-CA-C 107.91 -1.144 . . . . 0.0 107.91 176.86 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 212' ' ' ALA . . . . . 0.506 ' HB2' ' O ' ' A' ' 208' ' ' PHE . . . -62.37 -45.47 93.02 Favored 'General case' 0 N--CA 1.451 -0.418 0 CA-C-N 114.741 -1.118 . . . . 0.0 110.508 179.89 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 213' ' ' LEU . . . . . . . . . . . . . 93.9 mt -69.73 -54.55 13.22 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 115.151 -0.931 . . . . 0.0 111.676 -179.181 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 214' ' ' ASP . . . . . . . . . . . . . 19.5 t70 -55.21 -41.52 72.11 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.331 -0.395 . . . . 0.0 111.511 -179.608 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 215' ' ' ALA . . . . . . . . . . . . . . . -70.25 -57.7 4.59 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.407 -0.36 . . . . 0.0 111.781 -179.419 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 216' ' ' ALA . . . . . . . . . . . . . . . -55.59 -34.92 65.26 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.5 -0.318 . . . . 0.0 111.428 -179.541 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 217' ' ' ALA . . . . . . . . . . . . . . . -67.02 -41.02 87.33 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.506 179.894 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 218' ' ' THR . . . . . . . . . . . . . 42.3 m . . . . . 0 C--N 1.33 -0.28 0 CA-C-N 115.775 -0.648 . . . . 0.0 110.916 179.707 . . . . . . . . 0 0 . 1 . 021 nuclear nobuild core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.266 0 N-CA-C 112.626 -0.189 . . . . 0.0 112.626 . . . . . . . . . 0 0 . 1 . 021 nuclear nobuild core ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 31.1 tp -73.95 -35.47 64.53 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-O 120.837 0.351 . . . . 0.0 110.727 -179.967 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 74.0 p -58.23 -30.99 66.94 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.079 -0.51 . . . . 0.0 111.519 -179.863 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 30.9 p -54.29 -35.71 62.88 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.377 -0.374 . . . . 0.0 111.2 -179.964 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 7' ' ' LEU . . . . . . . . . . . . . 4.1 mm? -60.22 -52.23 66.17 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.883 179.868 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 8' ' ' PHE . . . . . 0.542 ' HB2' ' HB2' ' A' ' 55' ' ' ALA . 58.2 m-85 -62.82 -30.92 71.85 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.031 -0.532 . . . . 0.0 110.909 -179.981 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 9' ' ' TRP . . . . . . . . . . . . . 21.5 m95 -67.5 -46.87 71.65 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.087 -0.506 . . . . 0.0 110.212 -179.797 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 88.9 mt -59.67 -38.44 81.49 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 115.69 -0.687 . . . . 0.0 110.343 179.411 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -65.04 -34.24 89.32 Favored Glycine 0 N--CA 1.448 -0.506 0 C-N-CA 120.679 -0.772 . . . . 0.0 111.866 179.36 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -67.91 -32.48 72.97 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-O 120.883 0.373 . . . . 0.0 110.62 179.554 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 70.2 mt -65.22 -53.42 40.8 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 115.91 -0.586 . . . . 0.0 110.624 179.611 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -64.21 -40.16 97.74 Favored Glycine 0 N--CA 1.451 -0.364 0 C-N-CA 120.6 -0.81 . . . . 0.0 112.198 179.72 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 15' ' ' MET . . . . . 0.513 ' HE3' ' HD2' ' A' ' 205' ' ' LYS . 12.5 mmt -63.14 -47.96 80.49 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.676 0.274 . . . . 0.0 110.99 179.797 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 16' ' ' LEU . . . . . 0.706 ' O ' HD23 ' A' ' 20' ' ' LEU . 50.9 tp -54.4 -55.71 25.92 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.329 -179.877 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 46.9 t -56.97 -33.36 42.05 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-O 120.958 0.409 . . . . 0.0 110.45 -179.355 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -67.26 -49.88 49.19 Favored Glycine 0 N--CA 1.452 -0.297 0 N-CA-C 111.185 -0.766 . . . . 0.0 111.185 179.483 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 19' ' ' THR . . . . . 0.538 HG22 HD22 ' A' ' 20' ' ' LEU . 1.4 m -53.39 -43.45 67.89 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 115.28 -0.46 . . . . 0.0 110.84 179.518 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 20' ' ' LEU . . . . . 0.706 HD23 ' O ' ' A' ' 16' ' ' LEU . 0.5 OUTLIER -69.79 -41.96 74.41 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-N 115.755 -0.657 . . . . 0.0 111.943 -179.559 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -59.38 -32.14 69.87 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.521 -0.309 . . . . 0.0 111.795 -179.344 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 22' ' ' PHE . . . . . 0.756 ' HB2' HG22 ' A' ' 41' ' ' VAL . 5.8 m-85 -90.96 -28.66 17.9 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.711 0.291 . . . . 0.0 111.256 -179.722 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -70.33 -50.72 36.22 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 121.007 0.432 . . . . 0.0 111.576 -179.716 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 24' ' ' TRP . . . . . . . . . . . . . 4.6 t-105 -66.06 -38.91 89.51 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 115.867 -0.606 . . . . 0.0 111.494 -179.438 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.33 -0.256 0 CA-C-O 120.836 0.35 . . . . 0.0 110.77 179.712 . . . . . . . . 0 0 . 1 . 021 nuclear nobuild core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.453 -0.209 0 N-CA-C 112.86 -0.096 . . . . 0.0 112.86 . . . . . . . . . 0 0 . 1 . 021 nuclear nobuild core ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 2.7 mp0 -66.42 -20.88 66.18 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.898 0.38 . . . . 0.0 110.933 -179.846 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 34' ' ' ARG . . . . . . . . . . . . . 99.2 mtt180 -51.4 -29.54 16.06 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 115.914 -0.584 . . . . 0.0 111.679 -179.776 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 31.1 mmm180 -67.17 -44.78 78.83 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.393 -0.367 . . . . 0.0 111.42 -179.731 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 78.3 m-85 -70.54 -31.35 68.36 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.466 -0.333 . . . . 0.0 110.983 -179.946 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 37' ' ' TYR . . . . . 0.446 ' O ' HG23 ' A' ' 41' ' ' VAL . 48.5 m-85 -72.11 -51.33 21.93 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 116.327 -0.397 . . . . 0.0 111.228 -179.757 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 10.7 p -57.27 -36.21 51.43 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-O 120.994 0.426 . . . . 0.0 109.979 179.344 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 24.0 m -66.22 -43.83 85.55 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 115.629 -0.714 . . . . 0.0 110.584 179.127 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 40' ' ' LEU . . . . . 0.589 HD11 ' HA2' ' A' ' 209' ' ' GLY . 0.3 OUTLIER -62.64 -50.51 70.92 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-O 121.585 0.707 . . . . 0.0 110.501 179.559 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . 0.756 HG22 ' HB2' ' A' ' 22' ' ' PHE . 43.8 t -62.87 -33.49 60.64 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.626 0 CA-C-N 115.435 -0.802 . . . . 0.0 110.316 179.43 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 42' ' ' GLY . . . . . 0.442 ' O ' HG12 ' A' ' 46' ' ' ILE . . . -58.07 -47.79 86.93 Favored Glycine 0 N--CA 1.448 -0.527 0 CA-C-N 115.635 -0.712 . . . . 0.0 112.822 179.889 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 43' ' ' ILE . . . . . 0.572 HG23 HD23 ' A' ' 82' ' ' LEU . 9.0 pt -65.43 -51.32 65.35 Favored 'Isoleucine or valine' 0 C--O 1.233 0.201 0 CA-C-N 117.019 0.409 . . . . 0.0 111.502 -179.704 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 60.5 m -63.61 -20.47 65.69 Favored 'General case' 0 C--O 1.233 0.188 0 CA-C-O 120.92 0.39 . . . . 0.0 110.79 -179.899 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -80.61 -58.58 2.67 Favored Glycine 0 N--CA 1.452 -0.287 0 C-N-CA 121.008 -0.615 . . . . 0.0 113.103 -179.301 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 46' ' ' ILE . . . . . 0.536 ' O ' HG22 ' A' ' 49' ' ' VAL . 14.7 pt -58.19 -36.6 58.22 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.185 0 CA-C-O 120.881 0.372 . . . . 0.0 110.949 -179.758 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 47' ' ' ALA . . . . . 0.647 ' HB2' ' HE2' ' A' ' 205' ' ' LYS . . . -68.78 -42.54 77.27 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.704 178.776 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -54.39 -40.49 68.24 Favored 'General case' 0 C--O 1.232 0.181 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.329 -179.786 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 49' ' ' VAL . . . . . 0.536 HG22 ' O ' ' A' ' 46' ' ' ILE . 17.9 m -76.22 -34.1 25.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.487 -0.324 . . . . 0.0 110.98 -179.883 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -61.42 -39.96 92.7 Favored 'General case' 0 C--N 1.332 -0.165 0 CA-C-O 121.141 0.496 . . . . 0.0 110.715 179.215 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 51' ' ' TYR . . . . . 0.445 ' HE2' ' HE2' ' A' ' 15' ' ' MET . 43.5 m-85 -73.19 -35.93 66.47 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 115.651 -0.704 . . . . 0.0 110.439 179.84 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -66.68 -39.95 88.36 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 115.885 -0.598 . . . . 0.0 111.261 179.558 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 53' ' ' VAL . . . . . 0.402 HG13 ' O ' ' A' ' 49' ' ' VAL . 33.5 m -74.42 -42.44 49.79 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.173 0 CA-C-N 116.362 -0.381 . . . . 0.0 110.972 -179.785 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 54' ' ' MET . . . . . . . . . . . . . 70.7 mtm -65.27 -31.17 72.18 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 121.111 0.481 . . . . 0.0 109.852 179.118 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 55' ' ' ALA . . . . . 0.542 ' HB2' ' HB2' ' A' ' 8' ' ' PHE . . . -67.82 -18.56 64.88 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 115.544 -0.753 . . . . 0.0 111.188 179.52 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 96.5 mt -98.84 8.68 44.71 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.196 179.957 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 81.22 16.81 73.33 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.587 -0.816 . . . . 0.0 112.604 -179.993 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 58.0 t -84.53 137.19 21.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-O 120.794 0.33 . . . . 0.0 110.888 179.907 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 59' ' ' GLY . . . . . 0.484 ' HA3' ' HD3' ' A' ' 71' ' ' PRO . . . 85.08 -7.79 73.53 Favored Glycine 0 N--CA 1.449 -0.478 0 C-N-CA 120.776 -0.726 . . . . 0.0 112.476 -179.942 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 60' ' ' TRP . . . . . . . . . . . . . 12.0 m0 -65.36 99.21 0.39 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.642 0.258 . . . . 0.0 110.863 179.955 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 5.1 p -107.31 128.32 26.21 Favored Pre-proline 0 C--N 1.329 -0.298 0 CA-C-N 116.356 -0.384 . . . . 0.0 111.141 179.885 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 58.3 Cg_endo -71.68 141.11 37.1 Favored 'Trans proline' 0 C--N 1.349 0.581 0 C-N-CA 122.25 1.967 . . . . 0.0 112.039 179.817 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 61.1 t -137.39 90.77 0.77 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.356 0 CA-C-N 116.075 -0.511 . . . . 0.0 111.249 -179.621 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . 59.96 -85.49 0.02 OUTLIER 'General case' 0 C--N 1.331 -0.202 0 CA-C-N 116.0 -0.545 . . . . 0.0 111.42 179.948 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 65' ' ' GLU . . . . . 0.413 ' HG3' ' HG3' ' A' ' 66' ' ' ARG . 11.6 pt-20 -121.81 -22.69 5.7 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.886 0.374 . . . . 0.0 110.937 -179.966 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 66' ' ' ARG . . . . . 0.413 ' HG3' ' HG3' ' A' ' 65' ' ' GLU . 84.8 mtm180 -104.72 156.78 17.69 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.041 -0.527 . . . . 0.0 110.802 -179.919 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 40.9 m -113.61 130.62 56.35 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.981 179.854 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 26.3 t -113.61 146.33 18.34 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.394 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.973 179.943 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 69' ' ' PHE . . . . . . . . . . . . . 16.8 m-85 -104.33 116.68 32.57 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 116.209 -0.451 . . . . 0.0 109.919 -179.894 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 70' ' ' VAL . . . . . 0.641 HG12 ' HD3' ' A' ' 71' ' ' PRO . 0.8 OUTLIER -66.73 -35.58 9.84 Favored Pre-proline 0 CA--C 1.541 0.612 0 N-CA-C 112.602 0.593 . . . . 0.0 112.602 -179.424 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild core ' A' A ' 71' ' ' PRO . . . . . 0.641 ' HD3' HG12 ' A' ' 70' ' ' VAL . 9.5 Cg_exo -70.77 -22.39 27.51 Favored 'Trans proline' 0 C--N 1.36 1.138 0 C-N-CA 122.032 1.821 . . . . 0.0 112.815 -179.508 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 67.6 ttt180 -68.56 -55.63 11.0 Favored 'General case' 0 C--N 1.329 -0.323 0 N-CA-C 112.157 0.429 . . . . 0.0 112.157 -178.791 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 73' ' ' TYR . . . . . 0.509 ' O ' HG13 ' A' ' 77' ' ' ILE . 73.7 m-85 -73.53 -33.74 64.88 Favored 'General case' 0 C--N 1.328 -0.328 0 C-N-CA 120.863 -0.335 . . . . 0.0 110.892 -179.112 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 74' ' ' ILE . . . . . 0.53 HG22 ' HA ' ' A' ' 71' ' ' PRO . 0.3 OUTLIER -67.57 -41.27 85.59 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 N-CA-C 109.703 -0.48 . . . . 0.0 109.703 179.164 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild core ' A' A ' 75' ' ' ASP . . . . . 0.457 ' O ' HG23 ' A' ' 79' ' ' THR . 27.0 t70 -58.85 -37.54 76.7 Favored 'General case' 0 CA--C 1.519 -0.242 0 N-CA-C 109.241 -0.651 . . . . 0.0 109.241 178.703 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 76' ' ' TRP . . . . . 0.46 ' HB3' ' SD ' ' A' ' 109' ' ' MET . 48.6 m0 -66.12 -31.13 71.8 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 115.624 -0.717 . . . . 0.0 110.575 179.337 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 77' ' ' ILE . . . . . 0.509 HG13 ' O ' ' A' ' 73' ' ' TYR . 76.1 mt -69.41 -29.6 42.57 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.353 0 CA-C-O 121.036 0.446 . . . . 0.0 110.333 178.973 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 24.8 mt -91.45 -15.84 28.23 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 115.984 -0.553 . . . . 0.0 111.986 179.898 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 79' ' ' THR . . . . . 0.457 HG23 ' O ' ' A' ' 75' ' ' ASP . 73.6 p -101.84 -52.6 3.15 Favored 'General case' 0 N--CA 1.464 0.225 0 N-CA-C 113.06 0.763 . . . . 0.0 113.06 -178.613 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 80' ' ' THR . . . . . 0.694 ' HB ' ' HD3' ' A' ' 81' ' ' PRO . 62.8 m -51.26 -56.26 21.79 Favored Pre-proline 0 CA--C 1.533 0.291 0 N-CA-C 112.854 0.687 . . . . 0.0 112.854 -178.287 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 81' ' ' PRO . . . . . 0.694 ' HD3' ' HB ' ' A' ' 80' ' ' THR . 52.2 Cg_exo -57.43 -25.12 64.54 Favored 'Trans proline' 0 C--N 1.353 0.766 0 C-N-CA 121.517 1.478 . . . . 0.0 111.613 -179.945 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 82' ' ' LEU . . . . . 0.572 HD23 HG23 ' A' ' 43' ' ' ILE . 12.3 tp -77.14 -32.96 56.75 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 115.741 -0.663 . . . . 0.0 110.393 179.838 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 47.4 mm -67.56 -53.34 32.55 Favored 'Isoleucine or valine' 0 C--O 1.232 0.164 0 CA-C-N 116.377 -0.374 . . . . 0.0 110.227 179.17 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 24.6 m -60.73 -29.96 46.1 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.224 0 N-CA-C 108.897 -0.779 . . . . 0.0 108.897 178.411 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 85' ' ' TYR . . . . . . . . . . . . . 93.4 t80 -65.28 -30.29 71.14 Favored 'General case' 0 N--CA 1.453 -0.297 0 CA-C-N 115.395 -0.82 . . . . 0.0 109.248 178.371 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 86' ' ' PHE . . . . . . . . . . . . . 31.6 t80 -65.44 -51.95 56.62 Favored 'General case' 0 CA--C 1.519 -0.212 0 CA-C-N 115.811 -0.631 . . . . 0.0 109.623 178.988 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 87' ' ' LEU . . . . . 0.639 HD22 HD22 ' A' ' 141' ' ' LEU . 6.0 mp -63.22 -28.85 70.32 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 115.803 -0.635 . . . . 0.0 109.854 179.117 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -68.35 -27.98 73.49 Favored Glycine 0 N--CA 1.449 -0.478 0 C-N-CA 120.707 -0.759 . . . . 0.0 111.256 178.833 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 46.4 mt -76.19 -34.33 59.31 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-O 120.963 0.411 . . . . 0.0 110.282 179.012 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 88.9 mt -79.41 -23.69 43.06 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 115.937 -0.574 . . . . 0.0 110.984 179.681 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 91' ' ' ALA . . . . . 0.46 ' HA ' ' HB2' ' A' ' 149' ' ' ALA . . . -88.46 -45.46 9.93 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.249 -179.903 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 91.92 57.8 1.47 Allowed Glycine 0 N--CA 1.451 -0.364 0 C-N-CA 120.802 -0.713 . . . . 0.0 112.611 -179.833 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 93' ' ' LEU . . . . . 0.496 HD23 ' HB3' ' A' ' 97' ' ' GLU . 10.6 mp -74.07 176.94 6.06 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-O 120.758 0.313 . . . . 0.0 110.779 179.836 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 94' ' ' ASP . . . . . 0.557 ' H ' ' HB2' ' A' ' 97' ' ' GLU . 5.7 m-20 -99.23 -167.0 1.41 Allowed 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.095 -179.947 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 48.8 m -67.58 -49.63 62.25 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 115.903 -0.589 . . . . 0.0 111.509 -179.542 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 96' ' ' ARG . . . . . 0.424 ' O ' HG13 ' A' ' 100' ' ' ILE . 31.4 tpt180 -74.08 -39.77 63.21 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-O 120.904 0.383 . . . . 0.0 110.601 -179.457 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 97' ' ' GLU . . . . . 0.557 ' HB2' ' H ' ' A' ' 94' ' ' ASP . 0.3 OUTLIER -55.53 -47.19 76.7 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 115.824 -0.626 . . . . 0.0 111.391 -179.757 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild core ' A' A ' 98' ' ' PHE . . . . . 0.459 ' O ' HG12 ' A' ' 102' ' ' ILE . 3.3 m-85 -62.53 -41.53 98.92 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.487 -0.324 . . . . 0.0 110.879 179.675 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -65.47 -26.33 71.78 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.553 -0.832 . . . . 0.0 112.66 -179.777 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 100' ' ' ILE . . . . . 0.424 HG13 ' O ' ' A' ' 96' ' ' ARG . 96.5 mt -73.4 -48.82 40.41 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-O 120.688 0.28 . . . . 0.0 111.648 -179.663 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 17.0 m -64.82 -37.78 81.05 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.498 -0.319 . . . . 0.0 111.691 -179.649 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 102' ' ' ILE . . . . . 0.459 HG12 ' O ' ' A' ' 98' ' ' PHE . 49.5 mm -71.55 -49.48 46.34 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.452 -0.34 . . . . 0.0 111.41 -179.757 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 14.0 t -59.74 -30.94 69.18 Favored 'General case' 0 C--N 1.332 -0.164 0 CA-C-O 120.825 0.345 . . . . 0.0 110.938 -179.933 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 104' ' ' LEU . . . . . 0.458 ' O ' HG12 ' A' ' 107' ' ' VAL . 46.3 tp -65.49 -54.37 29.2 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.465 179.498 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 105' ' ' ASN . . . . . 0.634 ' N ' HD22 ' A' ' 105' ' ' ASN . 0.7 OUTLIER -56.91 -26.45 59.25 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 115.996 -0.547 . . . . 0.0 110.764 179.827 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild core ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 39.6 m -68.4 -56.76 7.38 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.13 -0.486 . . . . 0.0 111.38 -179.855 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 107' ' ' VAL . . . . . 0.458 HG12 ' O ' ' A' ' 104' ' ' LEU . 13.2 p -60.45 -36.66 70.98 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.16 0 CA-C-N 116.524 -0.307 . . . . 0.0 111.335 -179.779 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 93.3 t -66.36 -50.24 69.31 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-O 120.957 0.408 . . . . 0.0 111.005 179.716 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 109' ' ' MET . . . . . 0.46 ' SD ' ' HB3' ' A' ' 76' ' ' TRP . 10.0 tpp -59.95 -36.33 76.86 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 115.954 -0.566 . . . . 0.0 110.62 179.948 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 23.1 tp -65.19 -34.27 77.98 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.037 -0.528 . . . . 0.0 110.291 179.607 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -60.01 -51.28 70.32 Favored 'General case' 0 C--N 1.331 -0.218 0 CA-C-N 116.041 -0.527 . . . . 0.0 110.339 179.263 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . -62.21 -39.27 97.47 Favored Glycine 0 C--N 1.331 0.269 0 C-N-CA 120.604 -0.808 . . . . 0.0 111.911 179.245 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 113' ' ' PHE . . . . . . . . . . . . . 2.2 t80 -47.43 -68.22 0.21 Allowed 'General case' 0 C--N 1.332 -0.196 0 CA-C-O 121.063 0.459 . . . . 0.0 110.203 179.318 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -65.12 -21.66 66.83 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 115.512 -0.767 . . . . 0.0 110.856 179.453 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -53.58 -45.03 68.3 Favored Glycine 0 C--N 1.334 0.423 0 C-N-CA 121.068 -0.587 . . . . 0.0 112.496 179.992 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -77.88 -23.59 48.73 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.721 0.295 . . . . 0.0 111.55 179.744 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 117' ' ' MET . . . . . . . . . . . . . 65.3 mtt -96.0 19.15 12.01 Favored 'General case' 0 C--N 1.331 -0.2 0 CA-C-N 116.29 -0.414 . . . . 0.0 111.613 -179.473 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 118' ' ' VAL . . . . . 0.494 HG11 ' N ' ' A' ' 123' ' ' ARG . 19.3 m -68.34 142.61 94.79 Favored Pre-proline 0 C--N 1.328 -0.338 0 CA-C-N 116.71 -0.223 . . . . 0.0 111.586 -179.902 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 119' ' ' PRO . . . . . . . . . . . . . 98.4 Cg_endo -88.0 6.09 5.11 Favored 'Trans proline' 0 N--CA 1.459 -0.513 0 C-N-CA 122.761 2.307 . . . . 0.0 112.524 179.593 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -166.09 -115.15 0.31 Allowed Glycine 0 C--N 1.332 0.327 0 C-N-CA 120.697 -0.763 . . . . 0.0 112.803 -179.814 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 43.5 pt -111.4 12.68 8.58 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.216 0 CA-C-O 120.698 0.285 . . . . 0.0 111.43 -179.634 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 11.2 mm-40 -58.83 -18.88 36.43 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.37 -0.377 . . . . 0.0 110.991 -179.993 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 123' ' ' ARG . . . . . 0.494 ' N ' HG11 ' A' ' 118' ' ' VAL . 17.5 ptt180 -53.32 -30.01 36.76 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.017 -0.538 . . . . 0.0 111.484 -179.964 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 124' ' ' TYR . . . . . . . . . . . . . 29.7 m-85 -76.5 -32.45 58.32 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.352 -0.385 . . . . 0.0 110.927 179.924 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 125' ' ' ALA . . . . . . . . . . . . . . . -72.38 -56.1 6.0 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.067 179.924 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 1.5 mt -56.13 -54.08 49.43 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 115.888 -0.596 . . . . 0.0 110.829 -179.89 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 127' ' ' PHE . . . . . . . . . . . . . 11.0 t80 -64.86 -35.9 82.63 Favored 'General case' 0 N--CA 1.453 -0.306 0 C-N-CA 120.738 -0.385 . . . . 0.0 110.694 179.623 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 128' ' ' GLY . . . . . . . . . . . . . . . -47.53 -44.16 21.93 Favored Glycine 0 C--N 1.332 0.337 0 C-N-CA 120.054 -1.069 . . . . 0.0 110.825 179.111 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 129' ' ' MET . . . . . . . . . . . . . 0.2 OUTLIER -71.77 -37.24 70.5 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.991 0.424 . . . . 0.0 109.99 178.78 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -67.69 -27.59 73.59 Favored Glycine 0 N--CA 1.452 -0.29 0 CA-C-N 115.653 -0.703 . . . . 0.0 112.761 -179.852 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -75.04 -53.85 8.18 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-O 120.696 0.284 . . . . 0.0 110.48 179.944 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 45.4 t -58.54 -40.09 77.65 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.206 0 N-CA-C 109.064 -0.717 . . . . 0.0 109.064 178.546 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -69.09 -35.0 76.01 Favored 'General case' 0 N--CA 1.451 -0.389 0 CA-C-N 115.133 -0.939 . . . . 0.0 110.445 179.174 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 134' ' ' PHE . . . . . 0.442 ' CZ ' ' HA ' ' A' ' 172' ' ' ALA . 76.2 t80 -57.51 -55.27 36.95 Favored 'General case' 0 N--CA 1.451 -0.376 0 N-CA-C 109.763 -0.458 . . . . 0.0 109.763 179.492 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 135' ' ' ILE . . . . . 0.458 ' HA ' HG22 ' A' ' 138' ' ' VAL . 34.7 mt -57.25 -31.5 38.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 115.687 -0.688 . . . . 0.0 109.642 178.888 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . -65.77 -36.11 91.82 Favored Glycine 0 N--CA 1.446 -0.669 0 C-N-CA 120.386 -0.911 . . . . 0.0 111.017 178.537 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 137' ' ' LEU . . . . . 0.454 HD13 HD21 ' A' ' 105' ' ' ASN . 39.1 tp -71.47 -53.23 14.64 Favored 'General case' 0 N--CA 1.454 -0.25 0 N-CA-C 110.355 -0.239 . . . . 0.0 110.355 179.321 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 138' ' ' VAL . . . . . 0.458 HG22 ' HA ' ' A' ' 135' ' ' ILE . 5.0 m -56.36 -31.86 34.12 Favored 'Isoleucine or valine' 0 C--O 1.233 0.194 0 N-CA-C 109.08 -0.711 . . . . 0.0 109.08 178.929 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 139' ' ' TYR . . . . . . . . . . . . . 39.0 t80 -61.41 -45.82 92.74 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 115.367 -0.833 . . . . 0.0 110.127 178.54 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 140' ' ' TYR . . . . . 0.445 ' HE2' HD22 ' A' ' 104' ' ' LEU . 27.4 m-85 -60.95 -37.67 83.2 Favored 'General case' 0 C--N 1.332 -0.157 0 CA-C-N 116.29 -0.414 . . . . 0.0 110.724 179.543 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 141' ' ' LEU . . . . . 0.639 HD22 HD22 ' A' ' 87' ' ' LEU . 83.5 mt -61.92 -35.0 77.1 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.615 179.916 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 17.1 t -96.25 -4.75 10.08 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.071 -0.513 . . . . 0.0 110.546 179.581 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . -74.12 -134.36 0.29 Allowed Glycine 0 CA--C 1.52 0.398 0 C-N-CA 121.129 -0.558 . . . . 0.0 112.885 -179.809 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 144' ' ' PRO . . . . . . . . . . . . . 34.1 Cg_exo -59.91 -23.96 74.5 Favored 'Trans proline' 0 C--N 1.349 0.578 0 C-N-CA 122.752 2.301 . . . . 0.0 112.839 -179.536 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 145' ' ' MET . . . . . . . . . . . . . 59.1 mtt -53.66 -28.69 34.66 Favored 'General case' 0 C--N 1.332 -0.179 0 CA-C-N 116.34 -0.391 . . . . 0.0 111.417 -179.854 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 146' ' ' THR . . . . . . . . . . . . . 74.9 p -70.34 -50.43 39.12 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.233 -0.44 . . . . 0.0 112.063 -179.219 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 47.4 mt-10 -73.62 -24.13 59.99 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.546 -0.297 . . . . 0.0 111.797 -179.025 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 148' ' ' SER . . . . . . . . . . . . . 81.4 p -70.78 -49.14 49.76 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 116.444 -0.343 . . . . 0.0 111.645 -179.281 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 149' ' ' ALA . . . . . 0.46 ' HB2' ' HA ' ' A' ' 91' ' ' ALA . . . -77.98 -38.83 44.21 Favored 'General case' 0 C--N 1.329 -0.319 0 N-CA-C 112.237 0.458 . . . . 0.0 112.237 -179.026 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 150' ' ' SER . . . . . . . . . . . . . 68.4 m -60.92 -8.13 2.92 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.537 -0.302 . . . . 0.0 111.705 -179.382 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 151' ' ' GLN . . . . . . . . . . . . . 78.2 mt-30 -119.02 25.19 10.36 Favored 'General case' 0 C--N 1.329 -0.296 0 N-CA-C 111.588 0.218 . . . . 0.0 111.588 -179.812 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 49.6 mtp180 -103.25 -52.24 3.07 Favored 'General case' 0 C--N 1.331 -0.197 0 CA-C-O 120.868 0.366 . . . . 0.0 111.153 179.717 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 153' ' ' SER . . . . . 0.605 ' HB3' HG12 ' A' ' 156' ' ' ILE . 32.8 t -157.02 169.16 25.44 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-N 115.981 -0.554 . . . . 0.0 110.854 179.407 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 154' ' ' SER . . . . . . . . . . . . . 37.0 t -70.39 -35.75 73.68 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.659 179.784 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -76.71 -31.47 53.71 Favored Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.883 -0.675 . . . . 0.0 112.503 179.827 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 156' ' ' ILE . . . . . 0.605 HG12 ' HB3' ' A' ' 153' ' ' SER . 36.2 mm -61.72 -37.63 78.48 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.234 0 CA-C-O 120.651 0.262 . . . . 0.0 111.1 -179.97 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 157' ' ' LYS . . . . . . . . . . . . . 57.8 tptt -60.73 -55.49 32.59 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 116.306 -0.407 . . . . 0.0 111.871 -179.445 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 62.2 m -60.61 -45.35 94.35 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.323 -0.398 . . . . 0.0 111.885 -179.125 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 159' ' ' LEU . . . . . . . . . . . . . 8.3 tt -68.35 -32.6 72.81 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-N 116.336 -0.393 . . . . 0.0 111.499 -179.198 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 160' ' ' TYR . . . . . . . . . . . . . 79.9 t80 -73.53 -45.62 52.61 Favored 'General case' 0 C--N 1.33 -0.261 0 N-CA-C 111.858 0.318 . . . . 0.0 111.858 -179.148 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 30.0 m -62.81 -40.85 90.28 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.363 0 N-CA-C 111.772 0.286 . . . . 0.0 111.772 -179.292 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 162' ' ' ARG . . . . . 0.405 ' HG2' HG21 ' A' ' 211' ' ' ILE . 29.1 tpt180 -69.35 -45.68 68.83 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.772 0.32 . . . . 0.0 111.388 -179.632 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 163' ' ' LEU . . . . . 0.588 ' HG ' ' HB2' ' A' ' 208' ' ' PHE . 4.3 mp -69.62 -52.5 25.43 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.806 -179.294 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 164' ' ' ARG . . . . . . . . . . . . . 4.6 tmm_? -53.88 -54.01 44.6 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.393 -0.367 . . . . 0.0 111.338 -179.163 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 165' ' ' ASN . . . . . 0.53 HD22 ' N ' ' A' ' 165' ' ' ASN . 0.9 OUTLIER -56.67 -43.78 80.74 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.937 0.398 . . . . 0.0 110.441 179.715 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild core ' A' A ' 166' ' ' LEU . . . . . 0.552 ' O ' ' HG ' ' A' ' 170' ' ' LEU . 5.6 tp -57.84 -54.53 45.92 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 115.858 -0.61 . . . . 0.0 111.067 -179.938 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 167' ' ' THR . . . . . 0.641 ' HA ' HD11 ' A' ' 170' ' ' LEU . 89.0 m -54.07 -52.25 61.52 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 115.966 -0.561 . . . . 0.0 112.21 -178.925 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 168' ' ' VAL . . . . . . . . . . . . . 94.5 t -53.92 -40.14 43.46 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.366 0 N-CA-C 112.141 0.423 . . . . 0.0 112.141 -179.172 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 169' ' ' VAL . . . . . 0.41 HG23 ' O ' ' A' ' 165' ' ' ASN . 75.2 t -65.82 -65.57 0.56 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.326 0 N-CA-C 112.346 0.498 . . . . 0.0 112.346 -178.959 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 170' ' ' LEU . . . . . 0.718 HD22 HG13 ' A' ' 203' ' ' VAL . 1.0 OUTLIER -61.66 -28.78 69.63 Favored 'General case' 0 C--N 1.33 -0.25 0 N-CA-C 112.544 0.572 . . . . 0.0 112.544 -178.428 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild core ' A' A ' 171' ' ' TRP . . . . . 0.562 ' N ' HD12 ' A' ' 170' ' ' LEU . 4.8 m0 -74.1 -30.77 62.5 Favored 'General case' 0 C--N 1.33 -0.277 0 C-N-CA 120.538 -0.465 . . . . 0.0 110.842 179.801 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 172' ' ' ALA . . . . . 0.442 ' HA ' ' CZ ' ' A' ' 134' ' ' PHE . . . -66.51 -7.87 22.75 Favored 'General case' 0 CA--C 1.516 -0.344 0 CA-C-O 121.273 0.559 . . . . 0.0 110.026 179.163 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 173' ' ' ILE . . . . . 0.718 HG22 ' CG1' ' A' ' 177' ' ' ILE . 6.6 mm -87.19 -35.81 9.02 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.624 0 CA-C-N 115.123 -0.944 . . . . 0.0 111.47 -178.966 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 174' ' ' TYR . . . . . 0.531 ' N ' ' HD2' ' A' ' 175' ' ' PRO . 55.5 m-85 -54.95 -52.09 73.86 Favored Pre-proline 0 C--N 1.329 -0.323 0 N-CA-C 112.75 0.648 . . . . 0.0 112.75 -178.91 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 175' ' ' PRO . . . . . 0.531 ' HD2' ' N ' ' A' ' 174' ' ' TYR . 28.4 Cg_endo -61.99 -39.57 49.52 Favored 'Trans proline' 0 C--N 1.348 0.539 0 C-N-CA 121.963 1.775 . . . . 0.0 113.419 -178.351 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 176' ' ' PHE . . . . . 0.519 ' CE2' ' HA ' ' A' ' 173' ' ' ILE . 0.1 OUTLIER -79.99 -38.15 32.76 Favored 'General case' 0 C--N 1.329 -0.304 0 C-N-CA 120.688 -0.405 . . . . 0.0 111.904 -178.786 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild core ' A' A ' 177' ' ' ILE . . . . . 0.718 ' CG1' HG22 ' A' ' 173' ' ' ILE . 31.7 mm -62.42 -43.58 98.36 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.477 0 N-CA-C 109.723 -0.473 . . . . 0.0 109.723 178.285 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 178' ' ' TRP . . . . . . . . . . . . . 70.3 t90 -60.87 -27.68 68.31 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 115.687 -0.688 . . . . 0.0 109.418 178.789 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 179' ' ' LEU . . . . . 0.422 HD13 ' O ' ' A' ' 179' ' ' LEU . 1.4 tm? -74.04 -45.8 47.32 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 115.187 -0.915 . . . . 0.0 110.764 -179.963 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 180' ' ' LEU . . . . . 0.478 ' HG ' ' O ' ' A' ' 176' ' ' PHE . 4.8 mt -71.33 -49.34 43.54 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.615 -0.266 . . . . 0.0 111.394 -179.372 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . -52.61 174.81 0.2 Allowed Glycine 0 C--N 1.334 0.43 0 C-N-CA 120.659 -0.781 . . . . 0.0 112.937 -179.954 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 182' ' ' PRO . . . . . 0.613 ' HA ' ' HB2' ' A' ' 186' ' ' ALA . 76.4 Cg_exo -46.93 -45.35 21.01 Favored 'Trans proline' 0 CA--C 1.536 0.602 0 C-N-CA 122.853 2.368 . . . . 0.0 113.796 -179.874 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 183' ' ' PRO . . . . . 0.431 ' HD3' ' HB2' ' A' ' 182' ' ' PRO . 79.5 Cg_exo -49.27 -23.48 6.98 Favored 'Trans proline' 0 C--N 1.355 0.908 0 C-N-CA 122.24 1.96 . . . . 0.0 113.194 -179.787 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 184' ' ' GLY . . . . . . . . . . . . . . . -108.74 -99.06 2.58 Favored Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.466 -0.873 . . . . 0.0 113.069 -179.57 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 185' ' ' VAL . . . . . . . . . . . . . 3.5 m -109.07 -5.49 10.89 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 N-CA-C 111.726 0.269 . . . . 0.0 111.726 -179.231 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 186' ' ' ALA . . . . . 0.613 ' HB2' ' HA ' ' A' ' 182' ' ' PRO . . . 55.14 87.28 0.05 OUTLIER 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.366 -0.379 . . . . 0.0 111.629 179.542 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 187' ' ' LEU . . . . . 0.454 HD12 ' HB3' ' A' ' 180' ' ' LEU . 23.5 mt -91.81 -48.97 6.5 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.332 -0.394 . . . . 0.0 110.779 179.637 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 188' ' ' LEU . . . . . . . . . . . . . 55.6 mt -106.9 -154.14 0.51 Allowed 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 115.835 -0.621 . . . . 0.0 110.642 -179.905 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 189' ' ' THR . . . . . . . . . . . . . 2.6 t -97.52 146.16 30.92 Favored Pre-proline 0 C--N 1.329 -0.315 0 CA-C-N 116.406 -0.361 . . . . 0.0 110.918 179.905 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 190' ' ' PRO . . . . . 0.403 ' O ' HG23 ' A' ' 194' ' ' VAL . 9.6 Cg_endo -50.14 -38.46 50.58 Favored 'Trans proline' 0 C--N 1.349 0.597 0 C-N-CA 122.862 2.374 . . . . 0.0 112.769 -179.594 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 191' ' ' THR . . . . . . . . . . . . . 81.6 p -58.25 -44.34 88.27 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.911 0.386 . . . . 0.0 111.249 -179.842 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 192' ' ' VAL . . . . . . . . . . . . . 35.1 t -71.85 -43.13 69.41 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.391 0 CA-C-N 116.03 -0.532 . . . . 0.0 111.401 -179.708 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 193' ' ' ASP . . . . . . . . . . . . . 21.1 t70 -56.55 -49.01 76.07 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.403 -0.362 . . . . 0.0 111.186 -179.783 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 194' ' ' VAL . . . . . 0.501 ' O ' HG23 ' A' ' 198' ' ' VAL . 78.2 t -64.42 -38.15 81.82 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.372 0 CA-C-N 116.262 -0.426 . . . . 0.0 111.198 -179.723 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 195' ' ' ALA . . . . . . . . . . . . . . . -54.15 -48.59 70.69 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 116.518 -0.31 . . . . 0.0 111.482 -179.802 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 196' ' ' LEU . . . . . 0.455 ' O ' ' HB3' ' A' ' 199' ' ' TYR . 94.3 mt -65.65 -39.96 91.97 Favored 'General case' 0 C--N 1.332 -0.166 0 CA-C-O 120.777 0.322 . . . . 0.0 110.814 179.884 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 197' ' ' ILE . . . . . 0.423 HD13 HD12 ' A' ' 200' ' ' LEU . 24.7 mm -58.73 -53.42 47.52 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.37 0 CA-C-O 121.017 0.437 . . . . 0.0 110.198 179.307 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 198' ' ' VAL . . . . . 0.501 HG23 ' O ' ' A' ' 194' ' ' VAL . 87.6 t -55.07 -34.64 32.57 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.459 0 CA-C-N 115.582 -0.736 . . . . 0.0 109.04 178.215 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 199' ' ' TYR . . . . . 0.455 ' HB3' ' O ' ' A' ' 196' ' ' LEU . 79.7 t80 -69.73 -32.58 71.2 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 114.98 -1.009 . . . . 0.0 110.643 179.635 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 200' ' ' LEU . . . . . 0.423 HD12 HD13 ' A' ' 197' ' ' ILE . 68.2 mt -69.17 -41.04 77.74 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 115.756 -0.656 . . . . 0.0 111.697 -179.373 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 201' ' ' ASP . . . . . . . . . . . . . 9.5 m-20 -71.39 -36.31 71.34 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 121.162 0.506 . . . . 0.0 110.451 179.529 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 202' ' ' LEU . . . . . 0.41 ' O ' ' HB ' ' A' ' 206' ' ' VAL . 1.2 mm? -65.99 -33.64 76.27 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 115.462 -0.79 . . . . 0.0 111.918 -179.731 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 203' ' ' VAL . . . . . 0.718 HG13 HD22 ' A' ' 170' ' ' LEU . 9.0 p -79.07 -36.3 18.31 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 N-CA-C 111.885 0.328 . . . . 0.0 111.885 -178.241 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 204' ' ' THR . . . . . 0.429 ' OG1' HD13 ' A' ' 170' ' ' LEU . 94.1 m -64.77 -58.93 4.91 Favored 'General case' 0 C--N 1.328 -0.343 0 C-N-CA 120.082 -0.647 . . . . 0.0 111.101 179.642 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 205' ' ' LYS . . . . . 0.647 ' HE2' ' HB2' ' A' ' 47' ' ' ALA . 60.1 mttp -68.35 -57.83 5.31 Favored 'General case' 0 C--N 1.33 -0.281 0 N-CA-C 112.774 0.657 . . . . 0.0 112.774 -178.028 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 206' ' ' VAL . . . . . 0.41 ' HB ' ' O ' ' A' ' 202' ' ' LEU . 19.3 t -71.16 -37.17 65.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 N-CA-C 112.02 0.378 . . . . 0.0 112.02 -178.654 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 207' ' ' GLY . . . . . 0.511 ' O ' HG13 ' A' ' 211' ' ' ILE . . . -61.75 -61.1 7.12 Favored Glycine 0 N--CA 1.452 -0.263 0 C-N-CA 120.577 -0.821 . . . . 0.0 113.72 -178.997 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 208' ' ' PHE . . . . . 0.588 ' HB2' ' HG ' ' A' ' 163' ' ' LEU . 0.1 OUTLIER -68.84 -29.95 68.38 Favored 'General case' 0 C--O 1.222 -0.362 0 CA-C-N 117.799 0.799 . . . . 0.0 110.8 -179.292 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild core ' A' A ' 209' ' ' GLY . . . . . 0.589 ' HA2' HD11 ' A' ' 40' ' ' LEU . . . -62.07 -35.66 91.78 Favored Glycine 0 N--CA 1.45 -0.368 0 CA-C-N 116.189 -0.46 . . . . 0.0 112.418 179.4 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 210' ' ' PHE . . . . . . . . . . . . . 3.3 m-85 -72.68 -47.38 47.79 Favored 'General case' 0 CA--C 1.513 -0.461 0 N-CA-C 108.513 -0.921 . . . . 0.0 108.513 178.81 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 211' ' ' ILE . . . . . 0.511 HG13 ' O ' ' A' ' 207' ' ' GLY . 3.7 mt -62.8 -27.32 42.8 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.58 0 N-CA-C 107.192 -1.41 . . . . 0.0 107.192 176.468 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 212' ' ' ALA . . . . . 0.531 ' HB3' ' O ' ' A' ' 209' ' ' GLY . . . -67.43 -36.55 81.44 Favored 'General case' 0 N--CA 1.45 -0.468 0 CA-C-N 114.308 -1.314 . . . . 0.0 110.171 179.56 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 213' ' ' LEU . . . . . 0.437 ' HG ' ' O ' ' A' ' 209' ' ' GLY . 81.3 mt -70.17 -53.38 17.45 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 115.012 -0.994 . . . . 0.0 111.594 -179.649 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 214' ' ' ASP . . . . . . . . . . . . . 16.5 m-20 -57.44 -51.54 69.02 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.827 0.346 . . . . 0.0 111.227 -179.592 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 215' ' ' ALA . . . . . . . . . . . . . . . -56.63 -57.25 13.19 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.226 -179.762 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 216' ' ' ALA . . . . . . . . . . . . . . . -58.4 -33.81 70.06 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.275 -0.421 . . . . 0.0 111.387 -179.741 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 217' ' ' ALA . . . . . . . . . . . . . . . -61.04 -34.68 75.25 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 121.029 0.442 . . . . 0.0 110.137 179.635 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 218' ' ' THR . . . . . . . . . . . . . 91.5 m . . . . . 0 C--N 1.331 -0.231 0 CA-C-N 115.716 -0.675 . . . . 0.0 110.821 179.48 . . . . . . . . 0 0 . 1 . 022 nuclear nobuild core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.261 0 N-CA-C 112.719 -0.152 . . . . 0.0 112.719 . . . . . . . . . 0 0 . 1 . 022 nuclear nobuild core ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -73.74 -40.67 63.35 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.858 0.361 . . . . 0.0 110.772 -179.929 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 76.4 p -60.52 -29.49 69.15 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.329 -179.842 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 13.6 p -57.38 -36.13 70.87 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.502 -179.715 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 7' ' ' LEU . . . . . . . . . . . . . 4.1 mm? -57.56 -53.16 61.29 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-N 116.328 -0.396 . . . . 0.0 111.165 -179.839 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 8' ' ' PHE . . . . . 0.516 ' HB2' ' HB2' ' A' ' 55' ' ' ALA . 78.9 m-85 -60.91 -33.48 73.2 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 120.866 0.365 . . . . 0.0 110.752 179.901 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 9' ' ' TRP . . . . . . . . . . . . . 18.9 m95 -63.78 -45.34 90.16 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-O 121.245 0.545 . . . . 0.0 109.678 179.82 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 72.3 mt -63.45 -34.34 77.55 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-N 115.383 -0.826 . . . . 0.0 110.12 179.302 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -66.29 -37.02 92.5 Favored Glycine 0 N--CA 1.449 -0.46 0 C-N-CA 120.77 -0.728 . . . . 0.0 111.596 179.179 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -66.74 -33.18 75.06 Favored 'General case' 0 C--N 1.332 -0.17 0 CA-C-O 120.961 0.41 . . . . 0.0 110.303 179.337 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 45.0 mm -65.19 -50.79 71.99 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.212 0 CA-C-N 115.904 -0.589 . . . . 0.0 110.235 179.099 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -59.35 -31.42 69.88 Favored Glycine 0 N--CA 1.449 -0.466 0 C-N-CA 120.773 -0.727 . . . . 0.0 111.836 179.394 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 15' ' ' MET . . . . . 0.45 ' HB3' ' HB2' ' A' ' 48' ' ' ALA . 22.0 mmt -70.87 -45.61 64.11 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-O 120.686 0.279 . . . . 0.0 110.583 179.586 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 21.8 tp -54.66 -38.31 66.78 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.668 179.59 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 64.2 t -67.06 -47.54 81.76 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.191 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.03 179.927 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -64.65 -49.45 64.22 Favored Glycine 0 C--N 1.331 0.281 0 C-N-CA 120.684 -0.77 . . . . 0.0 112.17 179.679 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 22.2 m -49.56 -46.22 48.55 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-O 120.72 0.295 . . . . 0.0 111.12 -179.807 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 85.6 mt -72.22 -40.01 68.11 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-N 116.359 -0.382 . . . . 0.0 111.403 179.646 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -61.28 -30.17 70.31 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.454 -0.339 . . . . 0.0 111.817 -179.484 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 22' ' ' PHE . . . . . 0.692 ' HB2' HG22 ' A' ' 41' ' ' VAL . 13.7 m-85 -90.74 -40.43 11.84 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.735 0.302 . . . . 0.0 111.149 -179.622 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -62.75 -50.71 69.97 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.343 -179.732 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 24' ' ' TRP . . . . . . . . . . . . . 2.2 t-105 -60.96 -41.7 96.84 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 115.968 -0.56 . . . . 0.0 111.042 -179.945 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.329 -0.302 0 CA-C-O 120.877 0.37 . . . . 0.0 110.946 179.752 . . . . . . . . 0 0 . 1 . 022 nuclear nobuild core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.305 0 N-CA-C 112.593 -0.203 . . . . 0.0 112.593 . . . . . . . . . 0 0 . 1 . 022 nuclear nobuild core ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 12.7 mm-40 -69.34 -20.88 63.86 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-O 120.86 0.362 . . . . 0.0 110.917 179.95 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 34' ' ' ARG . . . . . . . . . . . . . 41.5 ttm180 -51.02 -29.01 11.38 Favored 'General case' 0 C--N 1.332 -0.185 0 CA-C-N 115.958 -0.564 . . . . 0.0 111.539 -179.772 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 86.4 mtm180 -61.99 -45.89 91.65 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.899 0.38 . . . . 0.0 110.917 -179.969 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 88.0 m-85 -67.55 -29.26 68.59 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.044 -0.526 . . . . 0.0 111.224 179.961 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 37' ' ' TYR . . . . . 0.528 ' O ' HG23 ' A' ' 41' ' ' VAL . 51.7 m-85 -74.6 -54.11 8.08 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.255 -179.577 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 9.4 p -56.99 -36.6 51.18 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-O 120.949 0.405 . . . . 0.0 110.474 179.794 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 48.3 m -65.66 -51.37 60.04 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 115.901 -0.59 . . . . 0.0 110.608 179.493 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 40' ' ' LEU . . . . . 0.453 HD13 ' CE1' ' A' ' 208' ' ' PHE . 16.6 tp -57.05 -47.24 81.43 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 115.832 -0.622 . . . . 0.0 110.624 179.702 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . 0.692 HG22 ' HB2' ' A' ' 22' ' ' PHE . 64.8 t -60.0 -34.74 57.45 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.41 0 CA-C-N 115.836 -0.62 . . . . 0.0 110.11 179.183 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -60.31 -36.2 90.3 Favored Glycine 0 N--CA 1.449 -0.448 0 C-N-CA 120.682 -0.77 . . . . 0.0 111.817 179.494 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 43' ' ' ILE . . . . . 0.675 HG22 ' HE3' ' A' ' 205' ' ' LYS . 0.8 OUTLIER -67.31 -57.27 10.38 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.139 0 CA-C-O 120.65 0.262 . . . . 0.0 110.817 179.44 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild core ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 55.6 m -57.11 -25.0 58.07 Favored 'General case' 0 C--O 1.231 0.113 0 CA-C-N 116.42 -0.354 . . . . 0.0 111.188 -179.945 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -77.33 -54.71 4.59 Favored Glycine 0 CA--C 1.518 0.267 0 C-N-CA 120.793 -0.718 . . . . 0.0 113.162 -179.504 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 46' ' ' ILE . . . . . 0.41 ' O ' HG22 ' A' ' 49' ' ' VAL . 25.8 pt -58.06 -40.89 78.92 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.185 0 CA-C-O 120.93 0.395 . . . . 0.0 111.01 -179.647 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 47' ' ' ALA . . . . . 0.66 ' HB2' ' HE2' ' A' ' 205' ' ' LYS . . . -67.92 -38.62 83.13 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.004 179.205 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 48' ' ' ALA . . . . . 0.45 ' HB2' ' HB3' ' A' ' 15' ' ' MET . . . -55.41 -44.56 76.29 Favored 'General case' 0 C--O 1.232 0.152 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.733 -179.708 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 49' ' ' VAL . . . . . 0.41 HG22 ' O ' ' A' ' 46' ' ' ILE . 30.5 m -72.56 -33.82 46.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.544 -0.298 . . . . 0.0 111.141 -179.562 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -63.37 -36.62 84.31 Favored 'General case' 0 C--N 1.331 -0.206 0 CA-C-O 120.989 0.424 . . . . 0.0 110.748 179.473 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 28.5 m-85 -73.0 -36.25 67.0 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 115.915 -0.584 . . . . 0.0 110.442 179.794 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -65.47 -42.35 92.35 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 115.979 -0.555 . . . . 0.0 110.957 179.54 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 53' ' ' VAL . . . . . 0.506 ' O ' HG12 ' A' ' 58' ' ' VAL . 25.4 m -71.48 -47.33 59.17 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.188 0 CA-C-N 116.451 -0.341 . . . . 0.0 110.83 179.821 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 54' ' ' MET . . . . . 0.517 ' HG2' ' HG2' ' A' ' 71' ' ' PRO . 72.6 mtm -62.14 -31.97 72.51 Favored 'General case' 0 C--N 1.332 -0.19 0 CA-C-O 121.058 0.456 . . . . 0.0 110.007 179.439 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 55' ' ' ALA . . . . . 0.516 ' HB2' ' HB2' ' A' ' 8' ' ' PHE . . . -67.31 -32.51 73.53 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 115.701 -0.681 . . . . 0.0 111.04 179.306 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 76.3 mt -79.77 -4.4 51.82 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.28 -179.871 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 90.82 -16.09 59.12 Favored Glycine 0 CA--C 1.518 0.234 0 C-N-CA 120.539 -0.839 . . . . 0.0 113.288 179.54 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 58' ' ' VAL . . . . . 0.506 HG12 ' O ' ' A' ' 53' ' ' VAL . 13.0 p -67.4 144.37 14.6 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 117.108 0.454 . . . . 0.0 110.819 -179.884 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 94.05 -12.47 69.12 Favored Glycine 0 N--CA 1.45 -0.412 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.053 -179.461 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 60' ' ' TRP . . . . . . . . . . . . . 13.3 m0 -80.02 111.15 16.08 Favored 'General case' 0 C--N 1.331 -0.213 0 N-CA-C 110.329 -0.249 . . . . 0.0 110.329 179.703 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 6.9 p -111.29 129.56 23.93 Favored Pre-proline 0 C--N 1.329 -0.305 0 CA-C-N 116.61 -0.268 . . . . 0.0 111.201 -179.866 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 60.1 Cg_endo -71.81 152.15 57.96 Favored 'Trans proline' 0 C--N 1.35 0.618 0 C-N-CA 122.373 2.048 . . . . 0.0 112.292 179.96 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 93.7 t -143.38 94.37 0.51 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 115.929 -0.578 . . . . 0.0 110.761 -179.74 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . 58.19 -87.04 0.02 OUTLIER 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.11 -179.813 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 12.1 mm-40 -120.84 -23.19 6.0 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.288 -0.415 . . . . 0.0 110.591 179.773 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 66' ' ' ARG . . . . . . . . . . . . . 20.3 mmm180 -98.69 165.95 11.56 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.013 -0.539 . . . . 0.0 110.449 179.994 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 88.1 m -128.1 123.36 34.31 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-O 120.898 0.38 . . . . 0.0 111.173 179.947 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 68' ' ' VAL . . . . . 0.494 HG21 ' SD ' ' A' ' 117' ' ' MET . 27.3 m -106.73 146.68 12.89 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.054 -0.521 . . . . 0.0 110.702 179.834 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 69' ' ' PHE . . . . . . . . . . . . . 21.7 m-85 -106.59 112.92 26.13 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 116.132 -0.485 . . . . 0.0 109.989 -179.511 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 70' ' ' VAL . . . . . 0.58 ' N ' ' HD2' ' A' ' 71' ' ' PRO . 15.0 t -66.31 -47.9 58.82 Favored Pre-proline 0 C--N 1.322 -0.61 0 CA-C-N 116.24 -0.436 . . . . 0.0 112.076 -179.293 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 71' ' ' PRO . . . . . 0.58 ' HD2' ' N ' ' A' ' 70' ' ' VAL . 40.5 Cg_endo -66.16 -18.07 55.67 Favored 'Trans proline' 0 C--N 1.351 0.697 0 C-N-CA 122.115 1.877 . . . . 0.0 113.274 -179.327 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 72.3 ttt180 -72.85 -55.49 6.58 Favored 'General case' 0 C--O 1.235 0.296 0 CA-C-O 120.664 0.268 . . . . 0.0 111.712 -179.434 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 73' ' ' TYR . . . . . . . . . . . . . 71.5 m-85 -70.52 -31.58 68.72 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.524 -0.307 . . . . 0.0 110.769 -179.321 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 74' ' ' ILE . . . . . 0.46 HG22 ' HA ' ' A' ' 71' ' ' PRO . 0.4 OUTLIER -69.97 -39.56 77.59 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.229 0 N-CA-C 109.793 -0.447 . . . . 0.0 109.793 179.137 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild core ' A' A ' 75' ' ' ASP . . . . . 0.473 ' O ' HG23 ' A' ' 79' ' ' THR . 18.8 t70 -58.55 -37.6 76.07 Favored 'General case' 0 CA--C 1.519 -0.232 0 N-CA-C 109.25 -0.648 . . . . 0.0 109.25 178.713 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 76' ' ' TRP . . . . . 0.482 ' HB3' ' SD ' ' A' ' 109' ' ' MET . 43.9 m0 -66.97 -34.99 78.97 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 115.742 -0.663 . . . . 0.0 110.194 178.926 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 77' ' ' ILE . . . . . 0.425 HD12 ' HA ' ' A' ' 74' ' ' ILE . 97.0 mt -65.43 -28.65 44.93 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 115.948 -0.569 . . . . 0.0 110.688 179.497 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 38.3 mt -91.86 -25.01 19.16 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.223 -0.444 . . . . 0.0 112.12 -179.955 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 79' ' ' THR . . . . . 0.473 HG23 ' O ' ' A' ' 75' ' ' ASP . 67.2 p -92.69 -52.31 4.69 Favored 'General case' 0 N--CA 1.464 0.261 0 N-CA-C 113.671 0.989 . . . . 0.0 113.671 -177.74 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 80' ' ' THR . . . . . 0.442 ' N ' ' HD2' ' A' ' 81' ' ' PRO . 33.4 m -49.33 -54.55 28.8 Favored Pre-proline 0 C--N 1.329 -0.314 0 N-CA-C 113.159 0.8 . . . . 0.0 113.159 -178.163 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 81' ' ' PRO . . . . . 0.442 ' HD2' ' N ' ' A' ' 80' ' ' THR . 36.6 Cg_endo -63.13 -19.11 68.02 Favored 'Trans proline' 0 C--N 1.351 0.674 0 C-N-CA 121.463 1.442 . . . . 0.0 111.376 -179.513 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 82' ' ' LEU . . . . . . . . . . . . . 14.1 tp -77.05 -33.54 57.24 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 115.643 -0.708 . . . . 0.0 110.256 179.727 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 83' ' ' ILE . . . . . 0.428 HD11 HG21 ' A' ' 43' ' ' ILE . 32.8 mm -68.89 -52.62 32.83 Favored 'Isoleucine or valine' 0 C--O 1.232 0.174 0 CA-C-N 115.98 -0.555 . . . . 0.0 109.867 179.05 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 84' ' ' VAL . . . . . 0.433 HG22 ' HA ' ' A' ' 81' ' ' PRO . 27.9 m -61.21 -30.39 47.74 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.209 0 N-CA-C 109.513 -0.551 . . . . 0.0 109.513 178.797 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 85' ' ' TYR . . . . . 0.4 ' HB2' ' O ' ' A' ' 81' ' ' PRO . 82.7 t80 -65.87 -32.91 74.69 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 115.48 -0.782 . . . . 0.0 109.347 178.741 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 86' ' ' PHE . . . . . 0.418 ' HE2' ' HB2' ' A' ' 40' ' ' LEU . 10.8 t80 -63.91 -51.74 63.08 Favored 'General case' 0 N--CA 1.456 -0.133 0 CA-C-N 115.681 -0.691 . . . . 0.0 109.956 179.219 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 8.8 mp -61.32 -32.66 72.53 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 115.701 -0.681 . . . . 0.0 110.457 179.67 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -68.71 -27.96 73.47 Favored Glycine 0 N--CA 1.45 -0.407 0 C-N-CA 120.731 -0.747 . . . . 0.0 111.65 179.368 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 47.5 mt -72.13 -41.8 66.77 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.87 0.367 . . . . 0.0 110.646 179.539 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 57.0 mt -65.16 -45.8 83.47 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 115.951 -0.568 . . . . 0.0 111.059 179.942 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 91' ' ' ALA . . . . . 0.466 ' HB1' ' HB3' ' A' ' 148' ' ' SER . . . -71.55 -55.2 8.28 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.318 -0.401 . . . . 0.0 111.167 -179.696 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 99.5 67.62 0.86 Allowed Glycine 0 CA--C 1.519 0.283 0 C-N-CA 120.812 -0.709 . . . . 0.0 112.684 179.893 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 9.2 mp -75.34 -172.74 1.85 Allowed 'General case' 0 C--N 1.33 -0.245 0 CA-C-O 120.74 0.305 . . . . 0.0 110.856 179.911 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 94' ' ' ASP . . . . . 0.474 ' H ' ' HB2' ' A' ' 97' ' ' GLU . 6.7 m-20 -96.91 -173.98 2.86 Favored 'General case' 0 C--N 1.332 -0.174 0 CA-C-O 121.073 0.464 . . . . 0.0 111.266 -179.823 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 50.4 m -67.64 -51.58 48.34 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 115.78 -0.646 . . . . 0.0 111.308 -179.793 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 79.8 ttt180 -74.22 -34.86 63.82 Favored 'General case' 0 C--N 1.331 -0.197 0 CA-C-O 120.964 0.412 . . . . 0.0 110.575 -179.579 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 97' ' ' GLU . . . . . 0.474 ' HB2' ' H ' ' A' ' 94' ' ' ASP . 0.3 OUTLIER -56.88 -45.15 82.72 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 115.687 -0.688 . . . . 0.0 111.241 -179.812 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild core ' A' A ' 98' ' ' PHE . . . . . 0.443 ' O ' HG12 ' A' ' 102' ' ' ILE . 4.8 m-85 -62.17 -42.92 99.73 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.834 0.35 . . . . 0.0 110.71 179.487 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -62.6 -28.8 72.01 Favored Glycine 0 N--CA 1.45 -0.401 0 C-N-CA 120.8 -0.714 . . . . 0.0 112.682 -179.865 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 96.1 mt -72.46 -41.91 64.32 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.234 0 CA-C-O 120.873 0.368 . . . . 0.0 111.198 -179.927 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 53.8 t -67.45 -43.64 87.34 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.32 -179.932 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 102' ' ' ILE . . . . . 0.443 HG12 ' O ' ' A' ' 98' ' ' PHE . 43.0 mm -68.07 -49.59 66.49 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.63 -179.495 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 14.9 t -57.71 -33.59 68.57 Favored 'General case' 0 C--O 1.233 0.186 0 CA-C-O 120.762 0.315 . . . . 0.0 111.173 -179.701 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 41.2 tp -65.75 -48.16 72.84 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.3 -0.409 . . . . 0.0 110.545 179.601 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 105' ' ' ASN . . . . . 0.597 ' N ' HD22 ' A' ' 105' ' ' ASN . 0.8 OUTLIER -61.16 -26.08 67.45 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.766 179.758 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild core ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 91.6 m -69.07 -57.6 5.2 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-N 116.378 -0.374 . . . . 0.0 111.425 -179.934 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 8.3 p -58.58 -37.32 64.3 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.237 0 CA-C-N 116.531 -0.304 . . . . 0.0 110.942 -179.816 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 73.9 t -66.46 -51.97 51.76 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.898 179.532 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 109' ' ' MET . . . . . 0.482 ' SD ' ' HB3' ' A' ' 76' ' ' TRP . 9.8 tpp -61.36 -32.61 72.52 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.018 -0.537 . . . . 0.0 110.387 179.753 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 10.0 mt -72.31 -30.29 64.64 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 115.848 -0.615 . . . . 0.0 109.939 179.38 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -60.06 -45.63 92.22 Favored 'General case' 0 CA--C 1.519 -0.234 0 N-CA-C 109.249 -0.649 . . . . 0.0 109.249 178.248 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . -70.26 -41.74 67.98 Favored Glycine 0 N--CA 1.449 -0.441 0 CA-C-N 115.501 -0.772 . . . . 0.0 111.19 178.392 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 113' ' ' PHE . . . . . . . . . . . . . 2.0 t80 -48.81 -65.95 0.48 Allowed 'General case' 0 CA--C 1.52 -0.186 0 N-CA-C 109.353 -0.61 . . . . 0.0 109.353 178.82 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 114' ' ' ALA . . . . . 0.504 ' HB3' HD22 ' A' ' 126' ' ' LEU . . . -64.41 -19.23 65.38 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 115.467 -0.788 . . . . 0.0 110.406 178.699 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -53.1 -51.1 48.59 Favored Glycine 0 C--N 1.335 0.488 0 C-N-CA 120.892 -0.671 . . . . 0.0 111.86 179.495 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 116' ' ' ALA . . . . . 0.455 ' HB1' HG12 ' A' ' 68' ' ' VAL . . . -78.02 -18.44 55.87 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-O 120.87 0.367 . . . . 0.0 110.948 179.279 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 117' ' ' MET . . . . . 0.494 ' SD ' HG21 ' A' ' 68' ' ' VAL . 22.3 mmt -81.9 18.56 1.28 Allowed 'General case' 0 C--N 1.331 -0.218 0 CA-C-N 116.015 -0.539 . . . . 0.0 111.673 -179.441 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 118' ' ' VAL . . . . . 0.441 HG11 ' N ' ' A' ' 123' ' ' ARG . 32.6 m -89.85 138.71 27.72 Favored Pre-proline 0 C--N 1.327 -0.371 0 CA-C-N 116.73 -0.213 . . . . 0.0 111.375 -179.95 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 119' ' ' PRO . . . . . . . . . . . . . 70.3 Cg_endo -89.98 -3.76 5.4 Favored 'Trans proline' 0 N--CA 1.456 -0.692 0 C-N-CA 122.73 2.286 . . . . 0.0 112.235 179.61 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -138.2 -110.83 0.97 Allowed Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.908 -179.765 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 46.8 pt -126.99 14.93 3.6 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.214 0 CA-C-O 120.738 0.304 . . . . 0.0 111.585 -179.384 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 25.6 mt-10 -61.74 -18.64 60.53 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-N 116.353 -0.385 . . . . 0.0 111.041 -179.8 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 123' ' ' ARG . . . . . 0.464 ' HB2' ' HH2' ' A' ' 178' ' ' TRP . 7.6 ptt180 -52.6 -30.12 29.5 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 115.976 -0.557 . . . . 0.0 112.085 -179.66 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 124' ' ' TYR . . . . . . . . . . . . . 50.9 m-85 -69.16 -32.44 71.79 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.794 0.331 . . . . 0.0 111.364 -179.668 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 125' ' ' ALA . . . . . . . . . . . . . . . -72.59 -56.14 5.81 Favored 'General case' 0 C--O 1.236 0.346 0 CA-C-N 116.304 -0.407 . . . . 0.0 111.296 -179.504 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 126' ' ' LEU . . . . . 0.504 HD22 ' HB3' ' A' ' 114' ' ' ALA . 1.2 mt -51.49 -45.35 62.79 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 115.839 -0.619 . . . . 0.0 110.922 -179.821 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 127' ' ' PHE . . . . . . . . . . . . . 3.6 t80 -67.65 -38.64 84.11 Favored 'General case' 0 C--N 1.33 -0.269 0 C-N-CA 120.874 -0.33 . . . . 0.0 110.394 179.581 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 128' ' ' GLY . . . . . . . . . . . . . . . -46.48 -43.1 14.56 Favored Glycine 0 C--N 1.332 0.337 0 C-N-CA 120.21 -0.995 . . . . 0.0 110.991 179.219 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 129' ' ' MET . . . . . . . . . . . . . 0.4 OUTLIER -71.59 -41.32 69.13 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 115.383 -0.408 . . . . 0.0 110.18 179.04 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -63.61 -28.98 73.34 Favored Glycine 0 C--N 1.332 0.321 0 C-N-CA 121.066 -0.588 . . . . 0.0 113.016 -179.665 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -74.69 -53.64 8.89 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.729 0.265 . . . . 0.0 110.529 -179.901 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 61.4 t -59.32 -40.47 81.52 Favored 'Isoleucine or valine' 0 C--O 1.234 0.289 0 N-CA-C 109.205 -0.665 . . . . 0.0 109.205 178.832 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -67.51 -34.08 76.38 Favored 'General case' 0 N--CA 1.452 -0.353 0 CA-C-N 115.201 -0.908 . . . . 0.0 110.48 179.175 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 134' ' ' PHE . . . . . 0.421 ' CZ ' ' HA ' ' A' ' 172' ' ' ALA . 82.2 t80 -56.04 -52.59 63.7 Favored 'General case' 0 N--CA 1.451 -0.417 0 CA-C-N 116.072 -0.513 . . . . 0.0 109.875 179.328 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 135' ' ' ILE . . . . . 0.457 ' HA ' HG22 ' A' ' 138' ' ' VAL . 53.3 mt -58.14 -34.31 49.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 115.798 -0.637 . . . . 0.0 109.855 179.094 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . -63.73 -36.62 93.56 Favored Glycine 0 C--N 1.334 0.422 0 C-N-CA 120.312 -0.947 . . . . 0.0 111.356 178.75 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 137' ' ' LEU . . . . . 0.426 HD13 HD21 ' A' ' 105' ' ' ASN . 35.1 tp -71.24 -53.56 13.95 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.7 0.286 . . . . 0.0 110.453 179.448 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 138' ' ' VAL . . . . . 0.457 HG22 ' HA ' ' A' ' 135' ' ' ILE . 5.3 m -55.98 -31.94 32.02 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.218 0 CA-C-O 121.164 0.507 . . . . 0.0 109.656 179.458 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 139' ' ' TYR . . . . . . . . . . . . . 38.6 t80 -60.82 -47.99 83.83 Favored 'General case' 0 N--CA 1.454 -0.228 0 CA-C-N 115.528 -0.76 . . . . 0.0 109.909 178.511 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 15.5 m-85 -56.5 -37.98 71.13 Favored 'General case' 0 C--N 1.334 -0.093 0 CA-C-N 116.056 -0.52 . . . . 0.0 110.81 179.22 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 141' ' ' LEU . . . . . . . . . . . . . 70.5 mt -64.28 -34.95 79.29 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.057 -0.519 . . . . 0.0 110.708 -179.853 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 13.8 t -94.29 -7.57 10.03 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.79 179.828 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . -73.89 -131.8 0.21 Allowed Glycine 0 CA--C 1.521 0.43 0 C-N-CA 120.891 -0.671 . . . . 0.0 112.673 -179.765 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 144' ' ' PRO . . . . . . . . . . . . . 28.1 Cg_endo -62.04 -23.7 75.95 Favored 'Trans proline' 0 C--N 1.347 0.478 0 C-N-CA 122.528 2.152 . . . . 0.0 112.673 -179.859 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 145' ' ' MET . . . . . . . . . . . . . 52.4 mtt -53.99 -32.02 52.78 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-O 120.661 0.267 . . . . 0.0 111.436 -179.815 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 146' ' ' THR . . . . . . . . . . . . . 73.2 p -72.06 -46.0 58.59 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.426 -0.352 . . . . 0.0 111.479 -179.693 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 42.4 mt-10 -72.7 -28.11 62.48 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.471 -179.64 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 148' ' ' SER . . . . . 0.466 ' HB3' ' HB1' ' A' ' 91' ' ' ALA . 32.6 t -70.32 -43.87 69.42 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-O 120.754 0.311 . . . . 0.0 111.105 -179.622 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 149' ' ' ALA . . . . . . . . . . . . . . . -75.11 -40.12 60.13 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.147 -0.479 . . . . 0.0 111.198 -179.838 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 150' ' ' SER . . . . . . . . . . . . . 69.0 m -63.61 -22.91 67.15 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.096 -179.909 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 151' ' ' GLN . . . . . . . . . . . . . 46.2 mt-30 -105.53 6.82 32.6 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.263 -0.426 . . . . 0.0 111.435 -179.751 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 31.9 tpt180 -84.11 -51.7 6.87 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.88 0.372 . . . . 0.0 110.542 179.646 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 153' ' ' SER . . . . . 0.596 ' HB3' HG12 ' A' ' 156' ' ' ILE . 23.1 t -157.67 169.98 23.43 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-N 115.902 -0.59 . . . . 0.0 110.449 179.091 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 154' ' ' SER . . . . . . . . . . . . . 82.7 p -71.01 -39.72 72.22 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.788 0.328 . . . . 0.0 110.5 179.555 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -77.09 -36.6 34.94 Favored Glycine 0 N--CA 1.452 -0.241 0 C-N-CA 120.864 -0.684 . . . . 0.0 112.595 179.752 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 156' ' ' ILE . . . . . 0.596 HG12 ' HB3' ' A' ' 153' ' ' SER . 28.4 mm -51.64 -38.18 21.17 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.215 0 CA-C-O 120.623 0.249 . . . . 0.0 111.438 -179.859 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 157' ' ' LYS . . . . . 0.414 ' O ' HG13 ' A' ' 161' ' ' VAL . 63.6 tttp -60.03 -48.78 80.3 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.283 -0.417 . . . . 0.0 111.678 -179.795 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 41.3 t -63.78 -47.48 80.75 Favored 'General case' 0 C--N 1.328 -0.351 0 N-CA-C 111.96 0.355 . . . . 0.0 111.96 -179.095 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 159' ' ' LEU . . . . . 0.528 HD23 HD13 ' A' ' 163' ' ' LEU . 1.6 tt -67.71 -31.81 72.02 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 116.494 -0.321 . . . . 0.0 111.28 -179.326 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 160' ' ' TYR . . . . . . . . . . . . . 79.9 t80 -74.05 -44.42 54.33 Favored 'General case' 0 C--N 1.329 -0.315 0 N-CA-C 111.946 0.35 . . . . 0.0 111.946 -179.218 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 161' ' ' VAL . . . . . 0.414 HG13 ' O ' ' A' ' 157' ' ' LYS . 30.4 m -62.01 -41.18 90.03 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 N-CA-C 111.691 0.256 . . . . 0.0 111.691 -179.205 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 162' ' ' ARG . . . . . . . . . . . . . 94.7 mtt180 -67.87 -41.29 83.09 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-O 120.778 0.323 . . . . 0.0 111.312 -179.85 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 163' ' ' LEU . . . . . 0.601 ' HG ' ' HB2' ' A' ' 208' ' ' PHE . 7.1 mp -71.96 -54.93 8.46 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.302 -0.408 . . . . 0.0 112.064 -179.208 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 164' ' ' ARG . . . . . 0.434 ' O ' HG23 ' A' ' 168' ' ' VAL . 4.8 tmm_? -53.97 -53.18 56.4 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.273 -0.422 . . . . 0.0 111.568 -179.408 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 165' ' ' ASN . . . . . 0.543 HD22 ' N ' ' A' ' 165' ' ' ASN . 0.9 OUTLIER -57.05 -51.75 68.02 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.4 -0.364 . . . . 0.0 111.368 -179.255 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild core ' A' A ' 166' ' ' LEU . . . . . 0.472 ' O ' ' HG ' ' A' ' 170' ' ' LEU . 5.5 tt -58.28 -52.12 66.94 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.124 -0.489 . . . . 0.0 111.867 -179.241 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 167' ' ' THR . . . . . 0.453 ' O ' ' HB2' ' A' ' 171' ' ' TRP . 91.3 m -55.37 -53.38 56.94 Favored 'General case' 0 C--N 1.328 -0.34 0 N-CA-C 112.643 0.609 . . . . 0.0 112.643 -178.71 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 168' ' ' VAL . . . . . 0.434 HG23 ' O ' ' A' ' 164' ' ' ARG . 96.3 t -55.21 -40.83 57.63 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.195 0 N-CA-C 112.312 0.486 . . . . 0.0 112.312 -178.558 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 169' ' ' VAL . . . . . 0.485 HG23 ' O ' ' A' ' 165' ' ' ASN . 80.2 t -60.54 -64.66 0.57 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.39 0 N-CA-C 111.798 0.296 . . . . 0.0 111.798 -179.343 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 170' ' ' LEU . . . . . 0.489 HD12 ' N ' ' A' ' 171' ' ' TRP . 1.6 pp -63.98 -27.63 69.26 Favored 'General case' 0 C--N 1.33 -0.26 0 N-CA-C 112.08 0.4 . . . . 0.0 112.08 -178.781 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 171' ' ' TRP . . . . . 0.489 ' N ' HD12 ' A' ' 170' ' ' LEU . 1.5 m0 -72.14 -31.14 65.71 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-O 120.926 0.393 . . . . 0.0 110.312 179.383 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 172' ' ' ALA . . . . . 0.421 ' HA ' ' CZ ' ' A' ' 134' ' ' PHE . . . -73.04 -6.19 43.87 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 115.816 -0.629 . . . . 0.0 110.615 179.94 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 173' ' ' ILE . . . . . 0.602 HG22 HD11 ' A' ' 177' ' ' ILE . 36.5 mm -87.78 -21.78 7.01 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.216 0 CA-C-N 115.838 -0.619 . . . . 0.0 111.132 179.787 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 174' ' ' TYR . . . . . 0.437 ' HB2' ' HD3' ' A' ' 175' ' ' PRO . 25.9 m-85 -54.57 -49.55 90.46 Favored Pre-proline 0 N--CA 1.465 0.3 0 CA-C-N 116.49 -0.323 . . . . 0.0 111.694 -179.913 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 175' ' ' PRO . . . . . 0.437 ' HD3' ' HB2' ' A' ' 174' ' ' TYR . 82.7 Cg_exo -47.63 -28.37 9.13 Favored 'Trans proline' 0 C--N 1.353 0.768 0 C-N-CA 122.163 1.909 . . . . 0.0 112.259 179.912 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 176' ' ' PHE . . . . . 0.457 ' O ' ' HG ' ' A' ' 180' ' ' LEU . 95.9 m-85 -80.31 -49.61 11.31 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.026 -0.534 . . . . 0.0 111.72 -179.99 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 177' ' ' ILE . . . . . 0.602 HD11 HG22 ' A' ' 173' ' ' ILE . 2.6 mm -60.1 -45.12 96.14 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.537 0 N-CA-C 112.568 0.581 . . . . 0.0 112.568 -177.894 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 178' ' ' TRP . . . . . 0.464 ' HH2' ' HB2' ' A' ' 123' ' ' ARG . 80.5 t90 -66.63 -40.5 88.76 Favored 'General case' 0 N--CA 1.464 0.255 0 CA-C-O 121.095 0.474 . . . . 0.0 110.644 179.867 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 179' ' ' LEU . . . . . 0.544 ' O ' HG22 ' A' ' 185' ' ' VAL . 0.9 OUTLIER -65.28 -52.43 54.31 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-N 115.732 -0.667 . . . . 0.0 111.272 -179.216 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild core ' A' A ' 180' ' ' LEU . . . . . 0.551 HD22 HD11 ' A' ' 187' ' ' LEU . 9.8 mt -77.6 -52.44 9.02 Favored 'General case' 0 CA--C 1.532 0.266 0 N-CA-C 112.395 0.517 . . . . 0.0 112.395 -178.586 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . -59.89 -85.54 0.04 OUTLIER Glycine 0 C--N 1.333 0.389 0 C-N-CA 120.631 -0.795 . . . . 0.0 113.196 -179.578 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 182' ' ' PRO . . . . . 0.49 ' HD2' ' O ' ' A' ' 177' ' ' ILE . 73.1 Cg_exo -45.01 178.04 0.0 OUTLIER 'Trans proline' 0 C--N 1.351 0.696 0 C-N-CA 123.368 2.712 . . . . 0.0 113.326 179.474 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 183' ' ' PRO . . . . . . . . . . . . . 62.2 Cg_exo -53.68 8.27 0.03 OUTLIER 'Trans proline' 0 C--N 1.352 0.713 0 C-N-CA 123.057 2.505 . . . . 0.0 114.991 -179.384 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 184' ' ' GLY . . . . . 0.45 ' H ' ' C ' ' A' ' 182' ' ' PRO . . . -53.69 -66.94 2.41 Favored Glycine 0 C--N 1.337 0.608 0 C-N-CA 119.795 -1.193 . . . . 0.0 110.971 179.01 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 185' ' ' VAL . . . . . 0.544 HG22 ' O ' ' A' ' 179' ' ' LEU . 4.4 m -134.4 -4.61 1.21 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.389 0 CA-C-N 115.797 -0.202 . . . . 0.0 111.433 178.553 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 186' ' ' ALA . . . . . . . . . . . . . . . 43.85 79.01 0.05 OUTLIER 'General case' 0 N--CA 1.466 0.35 0 N-CA-C 112.289 0.477 . . . . 0.0 112.289 179.386 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 187' ' ' LEU . . . . . 0.551 HD11 HD22 ' A' ' 180' ' ' LEU . 4.9 mt -92.77 -49.83 5.88 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-O 120.71 0.291 . . . . 0.0 111.718 179.971 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 188' ' ' LEU . . . . . 0.414 HD13 HG11 ' A' ' 192' ' ' VAL . 96.0 mt -114.95 -166.45 1.11 Allowed 'General case' 0 C--N 1.331 -0.223 0 CA-C-O 120.983 0.421 . . . . 0.0 111.362 -179.169 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 189' ' ' THR . . . . . . . . . . . . . 3.0 t -85.77 148.11 47.76 Favored Pre-proline 0 C--N 1.328 -0.354 0 CA-C-N 115.826 -0.625 . . . . 0.0 111.279 -179.732 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 190' ' ' PRO . . . . . . . . . . . . . 78.2 Cg_exo -49.42 -44.59 33.98 Favored 'Trans proline' 0 C--N 1.348 0.524 0 C-N-CA 122.849 2.366 . . . . 0.0 113.503 -179.74 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 191' ' ' THR . . . . . . . . . . . . . 9.7 t -56.12 -34.51 66.14 Favored 'General case' 0 C--N 1.33 -0.276 0 N-CA-C 112.308 0.484 . . . . 0.0 112.308 -179.056 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 192' ' ' VAL . . . . . 0.414 HG11 HD13 ' A' ' 188' ' ' LEU . 19.1 t -72.06 -54.39 16.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 N-CA-C 111.851 0.315 . . . . 0.0 111.851 -179.204 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 193' ' ' ASP . . . . . . . . . . . . . 1.1 p30 -62.17 -46.14 90.3 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.699 0.285 . . . . 0.0 110.948 -179.735 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 194' ' ' VAL . . . . . 0.433 ' O ' HG23 ' A' ' 198' ' ' VAL . 63.8 t -58.32 -35.94 55.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.331 -0.395 . . . . 0.0 110.44 179.4 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 195' ' ' ALA . . . . . . . . . . . . . . . -59.93 -48.25 82.45 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.281 -0.418 . . . . 0.0 111.141 179.918 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 196' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -67.88 -35.54 78.69 Favored 'General case' 0 N--CA 1.462 0.173 0 N-CA-C 109.882 -0.414 . . . . 0.0 109.882 179.543 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 197' ' ' ILE . . . . . . . . . . . . . 18.9 mm -58.43 -57.67 9.88 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.289 0 CA-C-N 115.922 -0.581 . . . . 0.0 109.776 178.949 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 198' ' ' VAL . . . . . 0.433 HG23 ' O ' ' A' ' 194' ' ' VAL . 93.5 t -53.92 -35.27 27.56 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.44 0 N-CA-C 108.873 -0.788 . . . . 0.0 108.873 178.138 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 199' ' ' TYR . . . . . . . . . . . . . 17.7 t80 -70.76 -30.21 66.65 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 114.951 -1.022 . . . . 0.0 110.885 179.467 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 200' ' ' LEU . . . . . 0.521 HD11 HG13 ' A' ' 177' ' ' ILE . 34.9 mt -71.75 -44.0 64.81 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 116.048 -0.524 . . . . 0.0 111.703 -179.21 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 201' ' ' ASP . . . . . . . . . . . . . 11.9 m-20 -68.26 -35.21 77.54 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-O 121.117 0.484 . . . . 0.0 110.417 179.89 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 202' ' ' LEU . . . . . 0.439 ' O ' ' HB ' ' A' ' 206' ' ' VAL . 3.4 mt -70.89 -32.59 69.59 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 115.587 -0.733 . . . . 0.0 111.977 -179.507 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 203' ' ' VAL . . . . . 0.484 ' O ' ' HA3' ' A' ' 207' ' ' GLY . 12.5 p -78.17 -36.59 21.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 C-N-CA 121.102 -0.239 . . . . 0.0 111.376 -178.915 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 204' ' ' THR . . . . . 0.402 ' O ' ' CD1' ' A' ' 208' ' ' PHE . 45.4 m -64.73 -57.46 8.91 Favored 'General case' 0 C--N 1.325 -0.457 0 C-N-CA 120.494 -0.482 . . . . 0.0 111.134 179.655 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 205' ' ' LYS . . . . . 0.675 ' HE3' HG22 ' A' ' 43' ' ' ILE . 47.4 mttp -70.2 -58.91 3.25 Favored 'General case' 0 C--N 1.33 -0.251 0 N-CA-C 112.791 0.663 . . . . 0.0 112.791 -178.071 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 206' ' ' VAL . . . . . 0.439 ' HB ' ' O ' ' A' ' 202' ' ' LEU . 23.3 t -70.08 -36.31 67.76 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.411 0 CA-C-N 116.454 -0.339 . . . . 0.0 111.832 -178.692 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 207' ' ' GLY . . . . . 0.496 ' O ' HG13 ' A' ' 211' ' ' ILE . . . -63.3 -60.25 7.78 Favored Glycine 0 N--CA 1.45 -0.382 0 C-N-CA 120.513 -0.851 . . . . 0.0 113.424 -178.844 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 208' ' ' PHE . . . . . 0.601 ' HB2' ' HG ' ' A' ' 163' ' ' LEU . 0.1 OUTLIER -66.47 -27.07 67.51 Favored 'General case' 0 C--O 1.225 -0.219 0 CA-C-N 117.3 0.55 . . . . 0.0 111.037 -179.136 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild core ' A' A ' 209' ' ' GLY . . . . . 0.506 ' O ' ' HB3' ' A' ' 212' ' ' ALA . . . -69.72 -33.12 70.91 Favored Glycine 0 N--CA 1.448 -0.513 0 N-CA-C 111.683 -0.567 . . . . 0.0 111.683 178.852 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 210' ' ' PHE . . . . . . . . . . . . . 1.1 m-85 -70.85 -49.27 47.99 Favored 'General case' 0 CA--C 1.512 -0.494 0 N-CA-C 107.954 -1.128 . . . . 0.0 107.954 178.404 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 211' ' ' ILE . . . . . 0.496 HG13 ' O ' ' A' ' 207' ' ' GLY . 5.6 mt -62.59 -28.36 44.65 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.604 0 N-CA-C 107.618 -1.253 . . . . 0.0 107.618 176.572 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 212' ' ' ALA . . . . . 0.506 ' HB3' ' O ' ' A' ' 209' ' ' GLY . . . -65.05 -39.92 94.01 Favored 'General case' 0 N--CA 1.447 -0.59 0 CA-C-N 114.698 -1.137 . . . . 0.0 110.084 179.431 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 213' ' ' LEU . . . . . 0.41 ' HG ' ' O ' ' A' ' 209' ' ' GLY . 88.4 mt -70.28 -53.16 18.05 Favored 'General case' 0 C--N 1.331 -0.203 0 CA-C-N 115.132 -0.94 . . . . 0.0 111.601 -179.772 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 214' ' ' ASP . . . . . . . . . . . . . 29.4 m-20 -54.01 -50.04 67.53 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.33 -0.395 . . . . 0.0 111.294 -179.38 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 215' ' ' ALA . . . . . . . . . . . . . . . -61.02 -56.42 21.26 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.289 -0.414 . . . . 0.0 111.362 -179.735 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 216' ' ' ALA . . . . . . . . . . . . . . . -56.26 -36.38 68.49 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.233 -0.439 . . . . 0.0 111.467 -179.543 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 217' ' ' ALA . . . . . . . . . . . . . . . -62.46 -40.87 98.01 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.291 -0.413 . . . . 0.0 110.392 179.765 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 218' ' ' THR . . . . . . . . . . . . . 90.9 m . . . . . 0 C--N 1.329 -0.306 0 CA-C-N 115.794 -0.639 . . . . 0.0 110.737 179.623 . . . . . . . . 0 0 . 1 . 023 nuclear nobuild core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.235 0 N-CA-C 112.625 -0.19 . . . . 0.0 112.625 . . . . . . . . . 0 0 . 1 . 023 nuclear nobuild core ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 59.6 tp -74.98 -38.0 61.77 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.832 0.349 . . . . 0.0 111.095 179.953 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 71.1 p -61.73 -32.59 72.82 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.096 -0.502 . . . . 0.0 111.207 -179.819 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 20.5 p -54.53 -35.86 63.64 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.127 -179.785 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 7' ' ' LEU . . . . . . . . . . . . . 4.2 mm? -57.48 -52.86 63.66 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.809 179.836 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 8' ' ' PHE . . . . . 0.689 ' HB2' ' HB2' ' A' ' 55' ' ' ALA . 57.8 m-85 -64.87 -32.99 74.95 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 115.989 -0.551 . . . . 0.0 110.831 179.975 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 9' ' ' TRP . . . . . 0.413 ' O ' HG13 ' A' ' 13' ' ' ILE . 27.8 m95 -64.5 -44.7 90.13 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.978 0.418 . . . . 0.0 109.992 179.808 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 41.9 mt -61.8 -44.51 96.71 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 115.773 -0.649 . . . . 0.0 110.387 179.161 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -65.54 -29.22 74.67 Favored Glycine 0 N--CA 1.45 -0.433 0 C-N-CA 120.704 -0.76 . . . . 0.0 111.922 179.59 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -71.22 -33.42 69.88 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.624 0.25 . . . . 0.0 110.775 179.689 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 13' ' ' ILE . . . . . 0.413 HG13 ' O ' ' A' ' 9' ' ' TRP . 66.4 mt -66.33 -54.02 30.5 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.208 0 CA-C-O 120.9 0.381 . . . . 0.0 110.142 179.32 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -61.77 -38.07 95.34 Favored Glycine 0 N--CA 1.45 -0.432 0 C-N-CA 120.735 -0.745 . . . . 0.0 111.658 179.298 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 15' ' ' MET . . . . . 0.4 ' HG3' ' HB2' ' A' ' 48' ' ' ALA . 45.7 tpp -63.35 -43.51 97.5 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.794 0.331 . . . . 0.0 110.249 179.503 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -55.63 -38.96 70.2 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 115.969 -0.559 . . . . 0.0 109.834 179.23 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 98.8 t -59.91 -45.74 94.76 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.168 0 CA-C-N 115.954 -0.566 . . . . 0.0 109.926 178.955 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -62.74 -45.97 94.63 Favored Glycine 0 C--N 1.333 0.373 0 C-N-CA 120.476 -0.869 . . . . 0.0 111.448 178.801 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 23.7 m -51.86 -44.95 63.88 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 115.548 -0.326 . . . . 0.0 111.405 -179.888 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 85.4 mt -71.65 -42.98 66.9 Favored 'General case' 0 C--N 1.332 -0.184 0 CA-C-N 116.402 -0.363 . . . . 0.0 111.362 -179.921 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -56.89 -34.07 67.51 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.334 -0.393 . . . . 0.0 111.707 -179.662 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 22' ' ' PHE . . . . . 0.467 ' HB2' HG22 ' A' ' 41' ' ' VAL . 1.9 m-85 -90.96 -31.1 16.48 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.598 -0.274 . . . . 0.0 111.242 -179.418 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -68.31 -50.54 52.83 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.901 0.382 . . . . 0.0 111.543 -179.643 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 24' ' ' TRP . . . . . . . . . . . . . 5.3 t-105 -64.77 -42.27 95.24 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-N 115.898 -0.592 . . . . 0.0 111.119 -179.685 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.329 -0.312 0 CA-C-O 120.866 0.365 . . . . 0.0 110.643 179.764 . . . . . . . . 0 0 . 1 . 023 nuclear nobuild core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.249 0 N-CA-C 112.598 -0.201 . . . . 0.0 112.598 . . . . . . . . . 0 0 . 1 . 023 nuclear nobuild core ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 19.9 mm-40 -79.41 -20.65 47.06 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.82 0.343 . . . . 0.0 110.688 179.906 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 34' ' ' ARG . . . . . . . . . . . . . 52.0 ttp180 -55.11 -28.9 56.01 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.005 -0.543 . . . . 0.0 111.319 -179.784 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 31.1 mmm180 -55.04 -45.12 75.2 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.788 0.328 . . . . 0.0 111.28 -179.938 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 61.2 m-85 -69.05 -33.38 73.49 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.414 -179.528 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 37' ' ' TYR . . . . . . . . . . . . . 75.4 m-85 -72.69 -53.06 12.77 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.331 -0.395 . . . . 0.0 111.413 -179.238 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 11.5 p -56.75 -36.16 48.26 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.225 0 CA-C-O 121.092 0.472 . . . . 0.0 110.474 179.751 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 18.7 m -68.2 -46.9 69.34 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 115.714 -0.676 . . . . 0.0 110.718 179.276 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 40' ' ' LEU . . . . . 0.606 HD12 HD11 ' A' ' 43' ' ' ILE . 26.8 tp -61.18 -45.33 95.07 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 115.813 -0.631 . . . . 0.0 110.917 179.96 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . 0.467 HG22 ' HB2' ' A' ' 22' ' ' PHE . 95.7 t -62.97 -34.35 65.87 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.484 0 CA-C-N 115.988 -0.551 . . . . 0.0 110.284 179.471 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 42' ' ' GLY . . . . . 0.482 ' O ' HG13 ' A' ' 46' ' ' ILE . . . -58.62 -51.88 56.3 Favored Glycine 0 N--CA 1.448 -0.508 0 C-N-CA 120.902 -0.666 . . . . 0.0 112.921 -179.964 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 43' ' ' ILE . . . . . 0.731 HG23 HD23 ' A' ' 82' ' ' LEU . 18.0 pt -60.9 -49.16 85.79 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.161 0 CA-C-N 117.02 0.41 . . . . 0.0 111.566 -179.558 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 44' ' ' SER . . . . . 0.423 ' N ' HG13 ' A' ' 43' ' ' ILE . 41.0 t -61.32 -27.1 68.25 Favored 'General case' 0 C--N 1.332 -0.191 0 CA-C-O 120.889 0.375 . . . . 0.0 111.193 179.648 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -78.01 -47.59 8.35 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.803 -0.713 . . . . 0.0 113.217 -179.112 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 46' ' ' ILE . . . . . 0.482 HG13 ' O ' ' A' ' 42' ' ' GLY . 61.6 mt -59.14 -42.09 85.62 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.229 0 CA-C-O 120.846 0.355 . . . . 0.0 110.968 -179.75 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 47' ' ' ALA . . . . . 0.631 ' HB2' ' HE2' ' A' ' 205' ' ' LYS . . . -67.49 -40.83 85.25 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 116.333 -0.394 . . . . 0.0 111.084 179.336 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 48' ' ' ALA . . . . . 0.4 ' HB2' ' HG3' ' A' ' 15' ' ' MET . . . -54.65 -44.27 73.1 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 116.129 -0.487 . . . . 0.0 111.382 -179.771 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 49' ' ' VAL . . . . . 0.418 HG22 ' O ' ' A' ' 46' ' ' ILE . 33.3 m -75.36 -34.65 30.98 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.384 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.351 -179.742 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -62.17 -38.86 90.67 Favored 'General case' 0 C--N 1.332 -0.156 0 CA-C-O 120.965 0.412 . . . . 0.0 111.071 179.849 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 51' ' ' TYR . . . . . 0.426 ' HB3' ' O ' ' A' ' 8' ' ' PHE . 26.5 m-85 -72.77 -42.65 63.74 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 115.993 -0.549 . . . . 0.0 110.693 -179.861 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -62.5 -39.84 94.81 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 115.987 -0.551 . . . . 0.0 111.45 -179.919 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 53' ' ' VAL . . . . . 0.473 HG23 ' N ' ' A' ' 54' ' ' MET . 35.1 m -72.28 -48.71 47.19 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.16 0 CA-C-N 116.498 -0.319 . . . . 0.0 111.299 -179.679 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 54' ' ' MET . . . . . 0.48 ' HG3' ' HB2' ' A' ' 71' ' ' PRO . 74.0 mtm -61.85 -31.26 71.51 Favored 'General case' 0 C--N 1.331 -0.196 0 CA-C-O 120.979 0.419 . . . . 0.0 110.417 179.693 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 55' ' ' ALA . . . . . 0.689 ' HB2' ' HB2' ' A' ' 8' ' ' PHE . . . -70.42 -12.51 61.63 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 115.767 -0.652 . . . . 0.0 111.645 179.962 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 71.2 mt -97.71 -13.15 21.61 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 116.483 -0.326 . . . . 0.0 111.466 -179.78 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 105.18 -6.62 42.98 Favored Glycine 0 CA--C 1.52 0.353 0 C-N-CA 120.496 -0.859 . . . . 0.0 113.545 179.5 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 58' ' ' VAL . . . . . 0.46 HG22 ' O ' ' A' ' 53' ' ' VAL . 27.0 m -81.54 149.8 4.76 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.201 0 CA-C-N 117.185 0.492 . . . . 0.0 110.587 179.483 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 81.74 25.61 52.72 Favored Glycine 0 N--CA 1.45 -0.418 0 C-N-CA 120.588 -0.815 . . . . 0.0 111.768 -179.219 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 60' ' ' TRP . . . . . . . . . . . . . 17.9 m0 -104.23 95.06 5.71 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 121.101 0.477 . . . . 0.0 110.018 -179.897 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 6.0 t -91.24 124.21 62.08 Favored Pre-proline 0 C--N 1.324 -0.539 0 CA-C-N 115.712 -0.676 . . . . 0.0 111.405 -178.984 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 56.2 Cg_endo -71.81 136.42 27.72 Favored 'Trans proline' 0 C--N 1.35 0.649 0 C-N-CA 122.353 2.036 . . . . 0.0 112.345 -179.987 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 86.4 t -143.02 105.23 1.06 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.02 -0.537 . . . . 0.0 111.209 -179.573 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . 58.88 -90.08 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.295 -0.411 . . . . 0.0 111.361 179.921 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 41.2 tt0 -122.85 -25.71 4.57 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 116.306 -0.406 . . . . 0.0 110.52 179.901 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 66' ' ' ARG . . . . . . . . . . . . . 20.0 ttm180 -101.73 162.62 12.77 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 115.942 -0.572 . . . . 0.0 110.333 179.905 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 87.3 m -117.56 120.73 38.96 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-O 120.858 0.361 . . . . 0.0 111.648 -179.448 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 38.8 t -86.07 146.37 6.55 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 115.927 -0.579 . . . . 0.0 110.558 179.406 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 69' ' ' PHE . . . . . . . . . . . . . 29.8 m-85 -106.77 112.97 26.19 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 121.044 0.45 . . . . 0.0 110.177 -179.679 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 70' ' ' VAL . . . . . 0.561 HG12 ' HD3' ' A' ' 71' ' ' PRO . 0.3 OUTLIER -68.65 -33.92 4.95 Favored Pre-proline 0 CA--C 1.541 0.603 0 N-CA-C 113.217 0.821 . . . . 0.0 113.217 -179.108 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild core ' A' A ' 71' ' ' PRO . . . . . 0.561 ' HD3' HG12 ' A' ' 70' ' ' VAL . 23.9 Cg_exo -63.71 -32.63 68.07 Favored 'Trans proline' 0 C--N 1.357 1.02 0 C-N-CA 121.766 1.644 . . . . 0.0 112.453 -179.276 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 40.0 ttm180 -69.82 -50.54 41.87 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 121.075 0.465 . . . . 0.0 110.352 179.464 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 73' ' ' TYR . . . . . 0.469 ' O ' HG13 ' A' ' 77' ' ' ILE . 33.9 m-85 -65.94 -33.09 75.02 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 115.767 -0.651 . . . . 0.0 111.341 -179.706 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 74' ' ' ILE . . . . . 0.432 ' O ' HD13 ' A' ' 74' ' ' ILE . 0.4 OUTLIER -75.74 -38.73 37.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-O 121.02 0.438 . . . . 0.0 109.908 179.329 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild core ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 5.9 t70 -58.58 -32.77 69.26 Favored 'General case' 0 N--CA 1.455 -0.203 0 CA-C-N 115.975 -0.557 . . . . 0.0 109.965 179.294 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 76' ' ' TRP . . . . . 0.41 ' HB3' ' SD ' ' A' ' 109' ' ' MET . 51.0 m0 -73.24 -46.23 51.31 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 115.914 -0.585 . . . . 0.0 110.568 179.204 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 77' ' ' ILE . . . . . 0.538 HG12 ' HB3' ' A' ' 109' ' ' MET . 88.2 mt -53.52 -29.94 17.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 115.941 -0.572 . . . . 0.0 111.253 -179.84 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 47.3 mt -91.07 -52.02 5.04 Favored 'General case' 0 CA--C 1.533 0.325 0 N-CA-C 112.521 0.563 . . . . 0.0 112.521 -179.541 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 79.7 p -71.49 -50.37 32.22 Favored 'General case' 0 N--CA 1.465 0.315 0 N-CA-C 113.931 1.085 . . . . 0.0 113.931 -177.688 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 80' ' ' THR . . . . . 0.705 HG21 ' HE1' ' A' ' 109' ' ' MET . 15.2 m -46.47 -53.32 24.75 Favored Pre-proline 0 CA--C 1.534 0.331 0 N-CA-C 112.78 0.659 . . . . 0.0 112.78 -178.173 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 81' ' ' PRO . . . . . 0.475 ' HD2' ' N ' ' A' ' 80' ' ' THR . 29.1 Cg_endo -61.99 -23.95 76.31 Favored 'Trans proline' 0 C--N 1.351 0.689 0 C-N-CA 121.639 1.559 . . . . 0.0 111.523 179.949 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 82' ' ' LEU . . . . . 0.731 HD23 HG23 ' A' ' 43' ' ' ILE . 15.6 tp -76.59 -32.62 58.23 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 115.751 -0.658 . . . . 0.0 110.156 179.507 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 41.8 mm -64.71 -53.55 40.83 Favored 'Isoleucine or valine' 0 C--O 1.235 0.304 0 CA-C-N 116.181 -0.463 . . . . 0.0 109.872 178.94 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 12.6 m -61.3 -30.33 47.71 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.228 0 N-CA-C 109.297 -0.631 . . . . 0.0 109.297 178.582 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 85' ' ' TYR . . . . . . . . . . . . . 87.4 t80 -66.82 -32.61 74.0 Favored 'General case' 0 N--CA 1.453 -0.282 0 CA-C-N 115.478 -0.783 . . . . 0.0 109.371 178.585 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 86' ' ' PHE . . . . . . . . . . . . . 3.5 t80 -61.34 -51.89 66.94 Favored 'General case' 0 C--O 1.232 0.17 0 CA-C-N 115.68 -0.691 . . . . 0.0 109.767 179.259 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 7.2 mp -62.37 -31.82 72.53 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 115.741 -0.663 . . . . 0.0 110.242 179.358 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -66.27 -28.06 73.44 Favored Glycine 0 N--CA 1.45 -0.412 0 C-N-CA 120.771 -0.728 . . . . 0.0 111.615 179.365 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 92.6 mt -75.4 -38.88 59.62 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.815 0.341 . . . . 0.0 110.53 179.426 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 94.2 mt -59.96 -43.34 95.1 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.042 -0.526 . . . . 0.0 111.097 179.859 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 91' ' ' ALA . . . . . 0.497 ' HB2' ' HB2' ' A' ' 149' ' ' ALA . . . -82.76 -52.22 6.96 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 116.253 -0.43 . . . . 0.0 111.369 -179.798 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 100.16 68.21 0.86 Allowed Glycine 0 N--CA 1.452 -0.284 0 C-N-CA 120.81 -0.71 . . . . 0.0 112.4 -179.941 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 93' ' ' LEU . . . . . 0.57 ' HB3' ' HB2' ' A' ' 97' ' ' GLU . 8.2 mp -77.29 177.69 7.72 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.905 0.383 . . . . 0.0 111.159 -179.862 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 94' ' ' ASP . . . . . . . . . . . . . 19.7 t70 -89.66 166.96 13.29 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 115.941 -0.572 . . . . 0.0 110.808 -179.986 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 52.8 m -55.68 -38.96 70.35 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.348 -0.387 . . . . 0.0 111.177 -179.806 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 37.6 mmt180 -73.46 -44.3 58.34 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.303 -0.408 . . . . 0.0 111.13 -179.981 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 97' ' ' GLU . . . . . 0.57 ' HB2' ' HB3' ' A' ' 93' ' ' LEU . 13.2 mm-40 -55.43 -47.99 75.11 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.859 -179.969 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 98' ' ' PHE . . . . . 0.436 ' O ' HG12 ' A' ' 102' ' ' ILE . 24.3 m-85 -57.1 -47.63 80.58 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.447 179.456 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -57.27 -29.83 60.55 Favored Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.438 179.828 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 97.3 mt -73.98 -44.28 51.06 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.171 0 CA-C-O 120.93 0.395 . . . . 0.0 111.555 -179.882 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 44.7 t -67.46 -46.41 83.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.062 -0.517 . . . . 0.0 111.929 -179.247 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 102' ' ' ILE . . . . . 0.436 HG12 ' O ' ' A' ' 98' ' ' PHE . 45.4 mm -62.22 -52.49 59.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.395 -0.366 . . . . 0.0 111.722 -179.272 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 14.7 t -57.29 -35.94 70.44 Favored 'General case' 0 C--N 1.332 -0.16 0 CA-C-O 120.849 0.357 . . . . 0.0 111.174 -179.74 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 104' ' ' LEU . . . . . 0.446 HD22 ' HE2' ' A' ' 140' ' ' TYR . 50.4 tp -61.02 -46.43 90.77 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.746 179.838 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 105' ' ' ASN . . . . . 0.591 ' N ' HD22 ' A' ' 105' ' ' ASN . 0.8 OUTLIER -65.46 -26.09 67.79 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.877 179.946 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild core ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 61.4 m -65.44 -55.35 18.49 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.292 -0.413 . . . . 0.0 111.216 -179.975 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 7.3 p -61.87 -37.35 77.96 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.184 0 CA-C-N 116.532 -0.304 . . . . 0.0 110.995 -179.734 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . 0.432 HG23 ' O ' ' A' ' 104' ' ' LEU . 53.4 t -59.58 -50.14 81.07 Favored 'Isoleucine or valine' 0 C--O 1.235 0.303 0 CA-C-O 121.002 0.429 . . . . 0.0 110.589 179.364 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 109' ' ' MET . . . . . 0.705 ' HE1' HG21 ' A' ' 80' ' ' THR . 3.0 tpp -63.46 -30.67 71.76 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 115.946 -0.57 . . . . 0.0 110.337 179.579 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 20.1 tp -68.59 -32.69 72.77 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.104 -0.498 . . . . 0.0 109.956 179.318 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 111' ' ' ALA . . . . . 0.437 ' O ' ' HB3' ' A' ' 126' ' ' LEU . . . -63.49 -56.69 14.08 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-N 115.736 -0.666 . . . . 0.0 110.418 179.25 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . -56.59 -42.99 91.08 Favored Glycine 0 C--N 1.331 0.252 0 C-N-CA 120.646 -0.788 . . . . 0.0 112.055 179.493 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 113' ' ' PHE . . . . . . . . . . . . . 6.5 t80 -47.28 -66.84 0.34 Allowed 'General case' 0 C--N 1.331 -0.222 0 CA-C-O 121.025 0.44 . . . . 0.0 110.956 179.55 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -63.25 -30.36 71.52 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 115.865 -0.607 . . . . 0.0 111.702 -179.401 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -52.11 -43.0 55.92 Favored Glycine 0 C--N 1.33 0.239 0 C-N-CA 121.057 -0.592 . . . . 0.0 112.96 -179.614 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -78.22 -27.88 47.84 Favored 'General case' 0 C--N 1.328 -0.352 0 N-CA-C 112.172 0.434 . . . . 0.0 112.172 -179.643 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 117' ' ' MET . . . . . . . . . . . . . 66.1 mtt -95.66 19.45 11.16 Favored 'General case' 0 C--N 1.33 -0.282 0 N-CA-C 111.77 0.285 . . . . 0.0 111.77 -179.191 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 118' ' ' VAL . . . . . 0.578 HG21 ' HB3' ' A' ' 123' ' ' ARG . 18.2 m -64.79 149.53 95.97 Favored Pre-proline 0 C--N 1.329 -0.296 0 CA-C-N 116.577 -0.283 . . . . 0.0 111.128 179.602 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 119' ' ' PRO . . . . . . . . . . . . . 93.9 Cg_endo -84.89 -17.83 4.68 Favored 'Trans proline' 0 N--CA 1.459 -0.517 0 C-N-CA 122.504 2.136 . . . . 0.0 112.135 179.808 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -145.41 -123.27 1.58 Allowed Glycine 0 N--CA 1.45 -0.386 0 C-N-CA 120.714 -0.755 . . . . 0.0 112.79 -179.923 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 45.1 pt -96.44 10.86 5.27 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.222 0 CA-C-O 120.714 0.293 . . . . 0.0 111.541 -179.535 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 43.6 mt-10 -59.6 -17.75 35.62 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.331 -0.395 . . . . 0.0 111.166 179.9 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 123' ' ' ARG . . . . . 0.578 ' HB3' HG21 ' A' ' 118' ' ' VAL . 19.8 ptt180 -49.69 -34.96 20.08 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 116.307 -0.406 . . . . 0.0 111.46 -179.928 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 124' ' ' TYR . . . . . . . . . . . . . 49.3 m-85 -70.98 -32.41 69.23 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.438 -0.346 . . . . 0.0 111.041 179.997 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 125' ' ' ALA . . . . . . . . . . . . . . . -68.25 -52.02 38.64 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.012 179.595 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 126' ' ' LEU . . . . . 0.437 ' HB3' ' O ' ' A' ' 111' ' ' ALA . 2.6 mm? -53.61 -56.17 19.53 Favored 'General case' 0 CA--C 1.521 -0.141 0 CA-C-N 116.09 -0.504 . . . . 0.0 110.687 179.973 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 127' ' ' PHE . . . . . 0.449 ' HZ ' ' HB3' ' A' ' 175' ' ' PRO . 9.6 t80 -67.39 -29.6 69.15 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.741 -179.91 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 128' ' ' GLY . . . . . . . . . . . . . . . -47.14 -54.49 9.73 Favored Glycine 0 N--CA 1.451 -0.36 0 C-N-CA 119.991 -1.099 . . . . 0.0 110.768 178.968 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 129' ' ' MET . . . . . 0.435 ' HE3' ' HB3' ' A' ' 133' ' ' ALA . 0.0 OUTLIER -72.21 -27.56 62.62 Favored 'General case' 0 C--N 1.328 -0.359 0 N-CA-C 109.144 -0.687 . . . . 0.0 109.144 178.624 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -61.72 -37.46 94.29 Favored Glycine 0 C--N 1.334 0.435 0 CA-C-N 115.792 -0.64 . . . . 0.0 112.288 179.541 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -74.75 -52.3 11.88 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.754 0.311 . . . . 0.0 110.457 179.696 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 42.1 t -54.88 -47.33 75.58 Favored 'Isoleucine or valine' 0 C--O 1.234 0.257 0 CA-C-O 121.243 0.544 . . . . 0.0 109.602 178.981 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 133' ' ' ALA . . . . . 0.435 ' HB3' ' HE3' ' A' ' 129' ' ' MET . . . -65.45 -37.08 85.82 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 115.523 -0.762 . . . . 0.0 110.915 179.245 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 134' ' ' PHE . . . . . 0.411 ' CZ ' ' HA ' ' A' ' 172' ' ' ALA . 45.9 t80 -53.27 -54.02 42.34 Favored 'General case' 0 N--CA 1.452 -0.361 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.26 179.816 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 135' ' ' ILE . . . . . 0.51 ' O ' HG22 ' A' ' 138' ' ' VAL . 42.5 mt -59.66 -32.85 50.24 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 CA-C-N 115.85 -0.614 . . . . 0.0 110.23 179.473 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 136' ' ' GLY . . . . . 0.445 ' O ' ' HB3' ' A' ' 139' ' ' TYR . . . -58.93 -40.06 94.85 Favored Glycine 0 N--CA 1.449 -0.463 0 C-N-CA 120.153 -1.023 . . . . 0.0 111.236 178.706 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 137' ' ' LEU . . . . . 0.498 HD13 HD21 ' A' ' 105' ' ' ASN . 64.0 tp -69.61 -53.37 19.11 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 115.863 -0.169 . . . . 0.0 110.806 179.541 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 138' ' ' VAL . . . . . 0.51 HG22 ' O ' ' A' ' 135' ' ' ILE . 3.3 m -54.69 -31.38 23.82 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.144 0 N-CA-C 109.333 -0.617 . . . . 0.0 109.333 -179.915 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 139' ' ' TYR . . . . . 0.445 ' HB3' ' O ' ' A' ' 136' ' ' GLY . 44.1 t80 -60.19 -46.35 90.03 Favored 'General case' 0 N--CA 1.453 -0.29 0 CA-C-N 115.544 -0.753 . . . . 0.0 109.404 178.183 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 140' ' ' TYR . . . . . 0.446 ' HE2' HD22 ' A' ' 104' ' ' LEU . 22.2 m-85 -63.86 -42.33 97.58 Favored 'General case' 0 C--N 1.333 -0.132 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.526 178.813 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 141' ' ' LEU . . . . . 0.483 HD13 ' O ' ' A' ' 137' ' ' LEU . 11.0 mp -57.13 -27.62 61.99 Favored 'General case' 0 C--N 1.332 -0.173 0 CA-C-N 115.948 -0.569 . . . . 0.0 111.193 -179.743 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 142' ' ' VAL . . . . . 0.47 HG23 ' O ' ' A' ' 138' ' ' VAL . 12.0 t -106.15 -7.91 10.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-O 120.992 0.425 . . . . 0.0 110.926 179.866 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . -73.84 -133.71 0.25 Allowed Glycine 0 CA--C 1.522 0.48 0 C-N-CA 120.812 -0.709 . . . . 0.0 112.814 -179.849 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 144' ' ' PRO . . . . . . . . . . . . . 51.5 Cg_exo -55.57 -23.96 42.47 Favored 'Trans proline' 0 C--N 1.349 0.555 0 C-N-CA 122.672 2.248 . . . . 0.0 113.03 -179.693 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 145' ' ' MET . . . . . 0.422 ' SD ' ' HA ' ' A' ' 141' ' ' LEU . 54.9 mtt -53.77 -27.92 31.71 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-O 120.727 0.299 . . . . 0.0 111.497 -179.583 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 146' ' ' THR . . . . . . . . . . . . . 70.5 p -79.04 -32.99 45.11 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.357 -0.383 . . . . 0.0 110.991 -179.558 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 39.7 tt0 -73.93 -40.26 63.23 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 115.861 -0.609 . . . . 0.0 111.354 -179.636 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 148' ' ' SER . . . . . . . . . . . . . 46.9 t -70.0 -42.26 73.28 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.325 -0.398 . . . . 0.0 111.327 -179.524 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 149' ' ' ALA . . . . . 0.497 ' HB2' ' HB2' ' A' ' 91' ' ' ALA . . . -70.83 -40.27 72.51 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.443 -0.344 . . . . 0.0 111.827 -179.649 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 150' ' ' SER . . . . . 0.604 ' HA ' ' HG2' ' A' ' 157' ' ' LYS . 39.2 t -69.46 -0.02 5.88 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.516 -0.311 . . . . 0.0 111.431 -179.564 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 151' ' ' GLN . . . . . . . . . . . . . 46.1 mt-30 -132.52 6.47 4.09 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.583 -0.28 . . . . 0.0 111.238 179.955 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 25.7 tpt180 -78.73 -52.41 8.43 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-O 120.94 0.4 . . . . 0.0 110.671 179.994 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 153' ' ' SER . . . . . 0.682 ' HB2' HG12 ' A' ' 156' ' ' ILE . 19.8 m -157.51 172.52 18.42 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 115.829 -0.623 . . . . 0.0 110.359 179.183 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 154' ' ' SER . . . . . 0.476 ' HA ' ' NZ ' ' A' ' 157' ' ' LYS . 49.9 m -68.68 -41.08 79.75 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.775 0.321 . . . . 0.0 110.983 179.728 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -76.78 -35.5 39.92 Favored Glycine 0 CA--C 1.519 0.343 0 C-N-CA 120.982 -0.627 . . . . 0.0 113.427 -179.537 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 156' ' ' ILE . . . . . 0.682 HG12 ' HB2' ' A' ' 153' ' ' SER . 41.8 mm -50.15 -38.48 15.06 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.217 0 N-CA-C 111.764 0.283 . . . . 0.0 111.764 -179.421 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 157' ' ' LYS . . . . . 0.604 ' HG2' ' HA ' ' A' ' 150' ' ' SER . 33.3 mtmm -59.78 -40.28 87.72 Favored 'General case' 0 C--N 1.327 -0.371 0 N-CA-C 112.034 0.383 . . . . 0.0 112.034 -179.254 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 36.5 t -72.53 -47.26 49.73 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 121.047 0.451 . . . . 0.0 111.425 -179.046 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 159' ' ' LEU . . . . . 0.432 ' O ' ' HB2' ' A' ' 163' ' ' LEU . 10.2 mt -68.67 -29.17 67.58 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-N 115.986 -0.552 . . . . 0.0 111.534 -179.108 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 160' ' ' TYR . . . . . . . . . . . . . 77.9 t80 -72.63 -46.84 52.08 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.454 -0.339 . . . . 0.0 111.629 -179.336 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 161' ' ' VAL . . . . . 0.409 HG23 ' N ' ' A' ' 162' ' ' ARG . 27.3 m -62.42 -42.79 96.98 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 N-CA-C 111.84 0.311 . . . . 0.0 111.84 -179.154 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 162' ' ' ARG . . . . . 0.409 ' N ' HG23 ' A' ' 161' ' ' VAL . 77.3 mtp180 -68.84 -48.53 63.28 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 120.647 0.26 . . . . 0.0 111.53 -179.678 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 163' ' ' LEU . . . . . 0.432 ' HB2' ' O ' ' A' ' 159' ' ' LEU . 6.8 mp -67.5 -45.08 76.88 Favored 'General case' 0 CA--C 1.531 0.24 0 CA-C-N 116.388 -0.369 . . . . 0.0 111.968 -179.01 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 164' ' ' ARG . . . . . . . . . . . . . 4.3 tmm_? -57.78 -50.97 71.46 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-O 120.635 0.255 . . . . 0.0 110.867 -179.719 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 165' ' ' ASN . . . . . 0.526 ' O ' HG23 ' A' ' 169' ' ' VAL . 0.9 OUTLIER -55.37 -41.37 72.52 Favored 'General case' 0 N--CA 1.448 -0.567 0 CA-C-N 116.352 -0.385 . . . . 0.0 110.486 179.78 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild core ' A' A ' 166' ' ' LEU . . . . . 0.479 ' O ' ' HG ' ' A' ' 170' ' ' LEU . 3.6 mt -58.16 -53.61 56.31 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 115.944 -0.571 . . . . 0.0 110.894 179.496 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 167' ' ' THR . . . . . 0.661 ' HA ' HD11 ' A' ' 170' ' ' LEU . 13.7 m -54.39 -52.58 61.23 Favored 'General case' 0 C--N 1.331 -0.204 0 N-CA-C 112.451 0.537 . . . . 0.0 112.451 -178.431 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 168' ' ' VAL . . . . . . . . . . . . . 85.9 t -54.96 -40.57 54.12 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.483 0 N-CA-C 112.612 0.597 . . . . 0.0 112.612 -178.724 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 169' ' ' VAL . . . . . 0.526 HG23 ' O ' ' A' ' 165' ' ' ASN . 68.7 t -69.18 -67.19 0.46 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 N-CA-C 113.526 0.936 . . . . 0.0 113.526 -177.894 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 170' ' ' LEU . . . . . 0.661 HD11 ' HA ' ' A' ' 167' ' ' THR . 0.4 OUTLIER -59.18 -34.58 72.29 Favored 'General case' 0 N--CA 1.465 0.323 0 N-CA-C 112.869 0.692 . . . . 0.0 112.869 -177.7 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild core ' A' A ' 171' ' ' TRP . . . . . 0.537 ' H ' HD12 ' A' ' 170' ' ' LEU . 16.8 m0 -73.29 -31.52 64.1 Favored 'General case' 0 C--N 1.329 -0.29 0 C-N-CA 120.607 -0.437 . . . . 0.0 111.24 -179.507 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 172' ' ' ALA . . . . . 0.411 ' HA ' ' CZ ' ' A' ' 134' ' ' PHE . . . -71.17 -7.15 44.76 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-O 120.912 0.387 . . . . 0.0 110.337 179.52 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 173' ' ' ILE . . . . . 0.537 ' O ' HG12 ' A' ' 177' ' ' ILE . 38.6 mm -88.44 -28.12 5.41 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.173 0 CA-C-N 115.896 -0.593 . . . . 0.0 111.044 179.512 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 174' ' ' TYR . . . . . 0.505 ' HD2' ' HA ' ' A' ' 171' ' ' TRP . 19.2 m-85 -54.11 -48.71 93.33 Favored Pre-proline 0 N--CA 1.467 0.392 0 CA-C-N 116.523 -0.308 . . . . 0.0 111.699 -179.512 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 175' ' ' PRO . . . . . 0.449 ' HB3' ' HZ ' ' A' ' 127' ' ' PHE . 82.5 Cg_exo -45.36 -33.29 8.73 Favored 'Trans proline' 0 C--N 1.351 0.658 0 C-N-CA 121.964 1.776 . . . . 0.0 111.857 179.467 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 176' ' ' PHE . . . . . 0.512 ' O ' ' HG ' ' A' ' 180' ' ' LEU . 96.6 m-85 -80.97 -50.6 9.5 Favored 'General case' 0 CA--C 1.518 -0.287 0 CA-C-N 115.843 -0.617 . . . . 0.0 111.792 179.937 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 177' ' ' ILE . . . . . 0.537 HG12 ' O ' ' A' ' 173' ' ' ILE . 6.6 mm -58.17 -32.49 44.5 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.517 0 CA-C-N 115.927 -0.579 . . . . 0.0 112.56 -177.494 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 178' ' ' TRP . . . . . . . . . . . . . 84.3 t90 -73.45 -32.2 64.22 Favored 'General case' 0 CA--C 1.52 -0.205 0 CA-C-O 120.884 0.373 . . . . 0.0 110.577 179.629 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 179' ' ' LEU . . . . . 0.651 ' HG ' HG22 ' A' ' 185' ' ' VAL . 17.3 tp -81.88 -55.29 4.7 Favored 'General case' 0 C--N 1.322 -0.601 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.851 -179.478 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 180' ' ' LEU . . . . . 0.625 HD22 HD11 ' A' ' 187' ' ' LEU . 7.0 mt -62.04 -51.33 68.42 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.109 -0.496 . . . . 0.0 111.287 -179.479 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 181' ' ' GLY . . . . . 0.452 ' HA3' ' OD1' ' A' ' 193' ' ' ASP . . . -65.7 -84.76 0.08 OUTLIER Glycine 0 C--N 1.332 0.316 0 C-N-CA 120.338 -0.934 . . . . 0.0 111.925 179.414 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 182' ' ' PRO . . . . . 0.541 ' HB3' ' HD2' ' A' ' 183' ' ' PRO . 81.7 Cg_exo -48.25 176.98 0.02 OUTLIER 'Trans proline' 0 C--N 1.35 0.631 0 C-N-CA 122.999 2.466 . . . . 0.0 112.244 178.743 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 183' ' ' PRO . . . . . 0.541 ' HD2' ' HB3' ' A' ' 182' ' ' PRO . 19.2 Cg_endo -59.95 16.03 0.04 OUTLIER 'Trans proline' 0 C--N 1.351 0.674 0 C-N-CA 122.58 2.187 . . . . 0.0 115.142 -178.908 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 184' ' ' GLY . . . . . 0.508 ' HA3' HD12 ' A' ' 179' ' ' LEU . . . -59.51 -45.51 95.46 Favored Glycine 0 C--N 1.336 0.562 0 C-N-CA 119.48 -1.343 . . . . 0.0 110.693 178.756 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 185' ' ' VAL . . . . . 0.651 HG22 ' HG ' ' A' ' 179' ' ' LEU . 2.5 m -148.94 -35.63 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.327 -0.4 0 CA-C-N 114.867 -0.666 . . . . 0.0 110.528 178.635 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 186' ' ' ALA . . . . . . . . . . . . . . . 66.82 77.77 0.27 Allowed 'General case' 0 N--CA 1.462 0.138 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.863 178.607 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 187' ' ' LEU . . . . . 0.625 HD11 HD22 ' A' ' 180' ' ' LEU . 4.2 mt -92.67 -46.66 7.47 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.608 179.502 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 188' ' ' LEU . . . . . . . . . . . . . 97.8 mt -111.28 -166.36 1.07 Allowed 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 115.948 -0.569 . . . . 0.0 111.267 -179.808 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 189' ' ' THR . . . . . 0.449 ' HB ' HG23 ' A' ' 192' ' ' VAL . 26.8 m -81.81 136.3 48.02 Favored Pre-proline 0 C--N 1.328 -0.355 0 CA-C-N 115.822 -0.626 . . . . 0.0 110.932 -179.966 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 190' ' ' PRO . . . . . . . . . . . . . 5.6 Cg_endo -48.56 -38.99 36.95 Favored 'Trans proline' 0 C--N 1.35 0.644 0 C-N-CA 122.713 2.276 . . . . 0.0 112.08 179.611 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 191' ' ' THR . . . . . . . . . . . . . 59.5 p -58.27 -44.71 88.53 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.24 -0.437 . . . . 0.0 110.584 179.613 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 192' ' ' VAL . . . . . 0.449 HG23 ' HB ' ' A' ' 189' ' ' THR . 75.1 t -60.23 -40.38 83.5 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.229 0 CA-C-N 115.867 -0.606 . . . . 0.0 110.649 179.433 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 193' ' ' ASP . . . . . 0.487 ' OD1' HG22 ' A' ' 177' ' ' ILE . 3.4 t70 -56.15 -45.23 79.72 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 115.777 -0.647 . . . . 0.0 110.989 179.834 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 194' ' ' VAL . . . . . . . . . . . . . 48.4 t -63.07 -36.99 78.17 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.053 -0.521 . . . . 0.0 110.944 -179.839 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 195' ' ' ALA . . . . . . . . . . . . . . . -57.24 -47.64 80.86 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 116.393 -0.367 . . . . 0.0 110.838 179.674 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 196' ' ' LEU . . . . . . . . . . . . . 89.3 mt -68.37 -44.95 74.06 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-N 116.308 -0.406 . . . . 0.0 110.903 179.661 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 197' ' ' ILE . . . . . . . . . . . . . 20.2 mm -55.63 -58.37 4.93 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.58 179.633 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 198' ' ' VAL . . . . . . . . . . . . . 77.2 t -52.15 -35.1 18.64 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.568 0 CA-C-N 115.469 -0.787 . . . . 0.0 109.514 178.629 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 199' ' ' TYR . . . . . . . . . . . . . 42.2 t80 -70.38 -33.42 71.39 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 115.521 -0.763 . . . . 0.0 110.62 179.691 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 200' ' ' LEU . . . . . 0.449 HD11 HG13 ' A' ' 177' ' ' ILE . 51.7 mt -67.13 -42.54 84.25 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-N 115.97 -0.559 . . . . 0.0 111.135 -179.683 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 201' ' ' ASP . . . . . . . . . . . . . 8.3 m-20 -72.85 -31.65 64.91 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-O 121.083 0.468 . . . . 0.0 110.235 179.656 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 202' ' ' LEU . . . . . 0.442 ' O ' ' HB ' ' A' ' 206' ' ' VAL . 3.3 mt -70.88 -31.57 68.28 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 115.65 -0.705 . . . . 0.0 112.082 -179.476 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 203' ' ' VAL . . . . . 0.496 HG13 HD22 ' A' ' 170' ' ' LEU . 7.1 p -80.82 -37.01 15.95 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-O 120.637 0.256 . . . . 0.0 111.25 -178.815 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 204' ' ' THR . . . . . 0.426 ' O ' ' HB2' ' A' ' 208' ' ' PHE . 22.2 m -70.1 -48.8 56.14 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-O 120.836 0.351 . . . . 0.0 111.406 179.945 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 205' ' ' LYS . . . . . 0.631 ' HE2' ' HB2' ' A' ' 47' ' ' ALA . 62.7 mttp -72.94 -57.65 3.9 Favored 'General case' 0 C--N 1.326 -0.429 0 N-CA-C 112.129 0.418 . . . . 0.0 112.129 -179.004 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 206' ' ' VAL . . . . . 0.442 ' HB ' ' O ' ' A' ' 202' ' ' LEU . 51.7 t -70.98 -41.89 76.99 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-O 120.631 0.253 . . . . 0.0 111.626 -179.363 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 207' ' ' GLY . . . . . 0.49 ' O ' HD12 ' A' ' 211' ' ' ILE . . . -61.2 -59.6 9.74 Favored Glycine 0 C--N 1.33 0.216 0 C-N-CA 120.631 -0.795 . . . . 0.0 112.698 -179.766 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 208' ' ' PHE . . . . . 0.48 ' O ' ' N ' ' A' ' 212' ' ' ALA . 8.1 m-85 -54.29 -47.08 72.77 Favored 'General case' 0 C--O 1.222 -0.391 0 CA-C-O 121.058 0.456 . . . . 0.0 110.202 -179.986 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 209' ' ' GLY . . . . . 0.519 ' HA2' ' HB3' ' A' ' 212' ' ' ALA . . . -56.21 -32.87 60.57 Favored Glycine 0 N--CA 1.449 -0.454 0 CA-C-N 115.004 -0.998 . . . . 0.0 113.299 179.747 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 210' ' ' PHE . . . . . . . . . . . . . 2.2 m-85 -72.03 -46.02 58.65 Favored 'General case' 0 CA--C 1.513 -0.469 0 N-CA-C 108.811 -0.811 . . . . 0.0 108.811 179.556 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 211' ' ' ILE . . . . . 0.49 HD12 ' O ' ' A' ' 207' ' ' GLY . 3.3 mt -67.59 -27.3 37.87 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.658 0 N-CA-C 107.625 -1.25 . . . . 0.0 107.625 176.481 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 212' ' ' ALA . . . . . 0.519 ' HB3' ' HA2' ' A' ' 209' ' ' GLY . . . -68.18 -43.54 77.94 Favored 'General case' 0 N--CA 1.452 -0.371 0 CA-C-N 114.415 -1.266 . . . . 0.0 110.785 -179.712 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 213' ' ' LEU . . . . . 0.4 ' HG ' ' O ' ' A' ' 209' ' ' GLY . 81.0 mt -70.1 -54.18 14.16 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 115.329 -0.85 . . . . 0.0 111.221 -179.514 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 214' ' ' ASP . . . . . . . . . . . . . 12.8 t70 -55.51 -35.36 65.53 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.801 -179.865 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 215' ' ' ALA . . . . . . . . . . . . . . . -65.65 -57.92 6.95 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.024 -0.535 . . . . 0.0 111.338 -179.916 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 216' ' ' ALA . . . . . . . . . . . . . . . -61.43 -31.09 71.02 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.112 -0.495 . . . . 0.0 111.103 -179.892 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 217' ' ' ALA . . . . . . . . . . . . . . . -62.51 -40.0 95.32 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.31 179.776 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 218' ' ' THR . . . . . . . . . . . . . 93.7 m . . . . . 0 C--N 1.33 -0.256 0 CA-C-N 115.94 -0.573 . . . . 0.0 110.693 179.408 . . . . . . . . 0 0 . 1 . 024 nuclear nobuild core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.275 0 N-CA-C 112.5 -0.24 . . . . 0.0 112.5 . . . . . . . . . 0 0 . 1 . 024 nuclear nobuild core ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 67.0 tp -74.22 -36.6 63.96 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.795 0.331 . . . . 0.0 111.006 179.964 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 82.6 p -58.22 -32.96 68.81 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.531 -179.78 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 30.4 p -54.47 -34.9 62.4 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.343 -0.39 . . . . 0.0 111.109 -179.979 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 7' ' ' LEU . . . . . . . . . . . . . 4.3 mm? -58.22 -53.9 53.04 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 115.994 -0.548 . . . . 0.0 111.514 -179.732 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 8' ' ' PHE . . . . . 0.518 ' HB2' ' HB2' ' A' ' 55' ' ' ALA . 68.3 m-85 -64.22 -36.07 82.86 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.293 -0.412 . . . . 0.0 111.232 -179.484 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 9' ' ' TRP . . . . . . . . . . . . . 44.8 m95 -65.02 -48.98 71.99 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-O 121.098 0.475 . . . . 0.0 110.16 -179.675 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 79.9 mt -60.33 -38.7 84.57 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-N 115.587 -0.733 . . . . 0.0 110.532 179.685 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -65.03 -31.13 79.87 Favored Glycine 0 N--CA 1.448 -0.504 0 C-N-CA 120.647 -0.787 . . . . 0.0 111.642 179.199 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -71.13 -30.71 66.83 Favored 'General case' 0 N--CA 1.454 -0.231 0 CA-C-O 120.81 0.338 . . . . 0.0 110.56 179.393 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 71.8 mt -66.57 -54.61 24.07 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.235 0 CA-C-N 115.959 -0.564 . . . . 0.0 110.335 179.345 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -62.95 -35.56 92.22 Favored Glycine 0 N--CA 1.449 -0.455 0 C-N-CA 120.645 -0.788 . . . . 0.0 111.441 179.374 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 15' ' ' MET . . . . . 0.503 ' SD ' ' HA ' ' A' ' 44' ' ' SER . 53.1 tpp -62.9 -46.37 88.16 Favored 'General case' 0 C--N 1.329 -0.296 0 N-CA-C 110.088 -0.338 . . . . 0.0 110.088 179.358 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 16' ' ' LEU . . . . . 0.463 HD13 ' O ' ' A' ' 16' ' ' LEU . 0.8 OUTLIER -53.22 -39.99 64.16 Favored 'General case' 0 C--N 1.332 -0.187 0 CA-C-N 115.866 -0.606 . . . . 0.0 109.689 179.057 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 70.3 t -58.98 -45.55 92.09 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.206 0 CA-C-N 116.036 -0.529 . . . . 0.0 110.177 179.156 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -63.93 -42.73 98.22 Favored Glycine 0 N--CA 1.45 -0.392 0 C-N-CA 120.749 -0.739 . . . . 0.0 111.737 179.038 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 11.3 m -52.74 -46.51 67.48 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-O 120.847 0.356 . . . . 0.0 111.146 -179.806 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 92.3 mt -71.8 -39.02 70.15 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.337 -179.826 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -59.8 -33.65 72.02 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.574 -0.285 . . . . 0.0 111.698 -179.615 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 22' ' ' PHE . . . . . 0.52 ' HB2' HG22 ' A' ' 41' ' ' VAL . 4.5 m-85 -90.99 -34.83 14.99 Favored 'General case' 0 C--N 1.331 -0.196 0 CA-C-O 120.727 0.299 . . . . 0.0 111.52 -179.446 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -66.53 -50.98 61.39 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 120.93 0.395 . . . . 0.0 111.539 -179.464 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 24' ' ' TRP . . . . . . . . . . . . . 5.1 t-105 -65.42 -45.11 85.16 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 115.877 -0.601 . . . . 0.0 111.176 -179.715 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.328 -0.327 0 CA-C-O 120.854 0.359 . . . . 0.0 111.009 179.874 . . . . . . . . 0 0 . 1 . 024 nuclear nobuild core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.276 0 N-CA-C 112.494 -0.242 . . . . 0.0 112.494 . . . . . . . . . 0 0 . 1 . 024 nuclear nobuild core ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 12.4 mm-40 -72.49 -21.11 61.25 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.652 0.263 . . . . 0.0 110.945 -179.922 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 34' ' ' ARG . . . . . 0.411 ' O ' HG23 ' A' ' 38' ' ' VAL . 79.0 ttt180 -51.57 -29.36 16.88 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 116.111 -0.495 . . . . 0.0 111.468 -179.607 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 80.2 ttt180 -60.19 -48.8 80.21 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.856 0.36 . . . . 0.0 110.882 179.896 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 59.4 m-85 -67.46 -29.87 69.43 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.028 -0.533 . . . . 0.0 111.139 179.896 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 37' ' ' TYR . . . . . 0.426 ' O ' HG23 ' A' ' 41' ' ' VAL . 43.8 m-85 -72.13 -53.0 14.05 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.071 -0.513 . . . . 0.0 111.62 -179.365 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 38' ' ' VAL . . . . . 0.411 HG23 ' O ' ' A' ' 34' ' ' ARG . 96.7 t -56.92 -37.39 54.05 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-O 121.103 0.477 . . . . 0.0 110.129 179.594 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 38.1 m -65.72 -46.27 79.57 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 115.662 -0.699 . . . . 0.0 110.182 179.158 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 40' ' ' LEU . . . . . 0.475 HD12 HD12 ' A' ' 43' ' ' ILE . 28.2 tp -59.67 -50.17 74.91 Favored 'General case' 0 C--O 1.235 0.318 0 CA-C-N 115.771 -0.649 . . . . 0.0 110.459 179.588 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . 0.52 HG22 ' HB2' ' A' ' 22' ' ' PHE . 61.3 t -59.1 -34.63 53.88 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.254 0 CA-C-N 115.842 -0.617 . . . . 0.0 109.938 179.186 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -59.07 -39.19 94.03 Favored Glycine 0 N--CA 1.449 -0.475 0 C-N-CA 120.727 -0.749 . . . . 0.0 111.832 179.252 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 43' ' ' ILE . . . . . 0.475 HD12 HD12 ' A' ' 40' ' ' LEU . 0.9 OUTLIER -64.96 -57.08 12.63 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.153 0 CA-C-O 120.831 0.348 . . . . 0.0 110.786 179.402 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild core ' A' A ' 44' ' ' SER . . . . . 0.503 ' HA ' ' SD ' ' A' ' 15' ' ' MET . 40.8 t -59.72 -24.21 63.81 Favored 'General case' 0 C--N 1.332 -0.168 0 CA-C-N 116.103 -0.499 . . . . 0.0 111.56 -179.691 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -74.15 -59.55 3.89 Favored Glycine 0 CA--C 1.518 0.262 0 C-N-CA 120.72 -0.752 . . . . 0.0 113.039 -179.647 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 46' ' ' ILE . . . . . 0.409 HD11 HG22 ' A' ' 79' ' ' THR . 21.1 pt -58.72 -35.02 53.54 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.19 0 CA-C-O 120.745 0.307 . . . . 0.0 111.286 -179.876 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 47' ' ' ALA . . . . . 0.619 ' HB2' ' HE2' ' A' ' 205' ' ' LYS . . . -65.98 -45.74 80.53 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-N 116.32 -0.4 . . . . 0.0 111.058 179.833 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -54.84 -52.18 63.58 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.246 -0.434 . . . . 0.0 111.216 -179.713 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 49' ' ' VAL . . . . . 0.41 ' O ' HG13 ' A' ' 53' ' ' VAL . 34.6 m -64.35 -34.04 66.66 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.393 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.821 179.931 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -65.23 -37.93 88.81 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.367 -0.379 . . . . 0.0 110.845 179.576 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 51' ' ' TYR . . . . . 0.416 ' OH ' ' HB2' ' A' ' 201' ' ' ASP . 30.3 m-85 -70.79 -29.06 65.15 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.193 179.944 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -74.5 -41.67 60.29 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-N 115.613 -0.721 . . . . 0.0 111.184 179.59 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 53' ' ' VAL . . . . . 0.425 HG23 ' N ' ' A' ' 54' ' ' MET . 20.8 m -73.25 -43.52 56.99 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.125 0 CA-C-N 116.498 -0.319 . . . . 0.0 111.008 179.883 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 54' ' ' MET . . . . . 0.448 ' HG2' ' HB2' ' A' ' 71' ' ' PRO . 72.8 mtm -63.49 -32.46 73.92 Favored 'General case' 0 C--N 1.332 -0.183 0 CA-C-O 121.038 0.447 . . . . 0.0 110.023 179.443 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 55' ' ' ALA . . . . . 0.518 ' HB2' ' HB2' ' A' ' 8' ' ' PHE . . . -65.23 -37.06 86.07 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 115.667 -0.697 . . . . 0.0 110.712 179.349 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 93.8 mt -76.5 -13.03 60.12 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 115.869 -0.605 . . . . 0.0 110.851 179.756 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 71.53 31.21 65.7 Favored Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.782 -0.723 . . . . 0.0 112.818 179.991 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 32.3 m -79.92 19.98 0.15 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.211 0 CA-C-O 120.834 0.35 . . . . 0.0 111.557 179.869 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -159.1 14.93 0.23 Allowed Glycine 0 N--CA 1.451 -0.358 0 C-N-CA 120.795 -0.717 . . . . 0.0 112.844 179.866 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 60' ' ' TRP . . . . . . . . . . . . . 41.0 m0 -81.09 107.57 14.01 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.728 0.299 . . . . 0.0 110.633 179.862 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 61' ' ' VAL . . . . . 0.42 ' HA ' ' HD3' ' A' ' 62' ' ' PRO . 4.9 p -106.38 119.33 52.19 Favored Pre-proline 0 CA--C 1.533 0.306 0 CA-C-N 116.342 -0.39 . . . . 0.0 111.572 -179.624 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 62' ' ' PRO . . . . . 0.42 ' HD3' ' HA ' ' A' ' 61' ' ' VAL . 16.8 Cg_exo -67.6 133.76 30.84 Favored 'Trans proline' 0 C--N 1.351 0.659 0 C-N-CA 122.35 2.033 . . . . 0.0 111.79 179.423 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 78.2 t -132.48 100.54 4.06 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.373 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.214 -179.716 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . 59.53 -86.85 0.02 OUTLIER 'General case' 0 C--N 1.331 -0.212 0 CA-C-N 116.043 -0.526 . . . . 0.0 111.265 -179.999 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 45.1 mt-10 -122.36 -27.26 4.49 Favored 'General case' 0 C--N 1.332 -0.195 0 CA-C-N 116.362 -0.381 . . . . 0.0 110.724 179.992 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 66' ' ' ARG . . . . . 0.444 ' HD2' ' N ' ' A' ' 66' ' ' ARG . 8.1 mpt_? -104.64 140.62 37.76 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.611 179.826 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 22.3 m -98.17 113.19 25.03 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.345 -0.389 . . . . 0.0 111.113 -179.74 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 26.3 t -85.11 146.84 6.06 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.354 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.474 179.498 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 69' ' ' PHE . . . . . . . . . . . . . 19.8 m-85 -108.51 115.17 29.59 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-O 120.91 0.386 . . . . 0.0 110.111 -179.315 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 70' ' ' VAL . . . . . 0.521 ' HB ' ' HD3' ' A' ' 71' ' ' PRO . 13.4 t -68.9 -49.35 26.81 Favored Pre-proline 0 C--N 1.323 -0.557 0 CA-C-N 115.946 -0.57 . . . . 0.0 112.243 -179.006 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 71' ' ' PRO . . . . . 0.521 ' HD3' ' HB ' ' A' ' 70' ' ' VAL . 29.5 Cg_exo -61.97 -17.48 56.1 Favored 'Trans proline' 0 C--N 1.35 0.608 0 C-N-CA 122.176 1.917 . . . . 0.0 112.449 -179.525 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 51.6 ttp180 -71.34 -54.68 9.97 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.482 -0.327 . . . . 0.0 111.43 -179.727 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 73' ' ' TYR . . . . . 0.431 ' O ' HG13 ' A' ' 77' ' ' ILE . 96.2 m-85 -69.74 -31.69 69.82 Favored 'General case' 0 C--N 1.331 -0.235 0 C-N-CA 120.919 -0.313 . . . . 0.0 110.648 -179.84 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 74' ' ' ILE . . . . . 0.477 ' HA ' HD12 ' A' ' 77' ' ' ILE . 0.3 OUTLIER -69.74 -38.56 76.44 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.18 0 N-CA-C 109.672 -0.492 . . . . 0.0 109.672 178.993 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild core ' A' A ' 75' ' ' ASP . . . . . 0.473 ' O ' HG23 ' A' ' 79' ' ' THR . 11.4 t70 -59.08 -37.59 77.45 Favored 'General case' 0 N--CA 1.454 -0.24 0 N-CA-C 109.211 -0.663 . . . . 0.0 109.211 178.595 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 76' ' ' TRP . . . . . . . . . . . . . 53.6 m0 -67.97 -32.45 72.88 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 115.689 -0.687 . . . . 0.0 110.323 179.006 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 77' ' ' ILE . . . . . 0.477 HD12 ' HA ' ' A' ' 74' ' ' ILE . 97.6 mt -66.57 -29.37 46.29 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.362 179.232 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 48.9 mt -91.59 -19.98 22.15 Favored 'General case' 0 CA--C 1.532 0.277 0 CA-C-N 116.1 -0.5 . . . . 0.0 112.016 179.983 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 79' ' ' THR . . . . . 0.473 HG23 ' O ' ' A' ' 75' ' ' ASP . 81.4 p -101.16 -52.63 3.22 Favored 'General case' 0 N--CA 1.465 0.323 0 N-CA-C 113.538 0.94 . . . . 0.0 113.538 -177.889 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 80' ' ' THR . . . . . 0.467 HG21 ' HE1' ' A' ' 109' ' ' MET . 61.3 m -46.69 -53.87 22.72 Favored Pre-proline 0 CA--C 1.533 0.296 0 N-CA-C 112.886 0.699 . . . . 0.0 112.886 -178.557 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 81' ' ' PRO . . . . . 0.465 ' HD2' ' N ' ' A' ' 80' ' ' THR . 35.0 Cg_endo -62.2 -22.16 73.71 Favored 'Trans proline' 0 C--N 1.35 0.622 0 C-N-CA 121.543 1.495 . . . . 0.0 111.603 -179.598 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 82' ' ' LEU . . . . . . . . . . . . . 16.2 tp -76.91 -33.31 57.77 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 115.657 -0.701 . . . . 0.0 110.234 179.674 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 28.1 mm -69.2 -53.18 26.86 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.226 0 CA-C-N 116.087 -0.506 . . . . 0.0 110.122 179.162 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 84' ' ' VAL . . . . . 0.416 HG13 ' HH2' ' A' ' 171' ' ' TRP . 28.9 m -60.13 -31.97 49.32 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.218 0 N-CA-C 109.645 -0.502 . . . . 0.0 109.645 178.907 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 85' ' ' TYR . . . . . 0.405 ' O ' ' HG ' ' A' ' 89' ' ' LEU . 79.8 t80 -65.12 -34.11 77.63 Favored 'General case' 0 N--CA 1.452 -0.366 0 CA-C-N 115.641 -0.709 . . . . 0.0 109.532 178.963 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 86' ' ' PHE . . . . . . . . . . . . . 7.9 t80 -62.62 -51.08 68.68 Favored 'General case' 0 C--N 1.333 -0.14 0 CA-C-N 115.768 -0.651 . . . . 0.0 110.247 179.404 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 9.3 mp -61.53 -36.05 79.46 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 115.992 -0.549 . . . . 0.0 110.407 179.785 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -66.33 -27.96 73.39 Favored Glycine 0 N--CA 1.45 -0.404 0 C-N-CA 120.767 -0.73 . . . . 0.0 111.875 179.282 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 89' ' ' LEU . . . . . 0.405 ' HG ' ' O ' ' A' ' 85' ' ' TYR . 75.9 mt -72.73 -40.88 65.74 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 120.994 0.426 . . . . 0.0 110.624 179.716 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 47.3 mt -58.44 -47.53 83.68 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 115.648 -0.706 . . . . 0.0 111.336 -179.644 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 91' ' ' ALA . . . . . 0.423 ' HB2' ' HB2' ' A' ' 149' ' ' ALA . . . -75.46 -54.52 6.9 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.635 -179.545 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 107.11 69.51 0.7 Allowed Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.854 -0.689 . . . . 0.0 112.009 -179.591 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 93' ' ' LEU . . . . . 0.544 HD23 ' HB3' ' A' ' 97' ' ' GLU . 8.5 mp -87.41 171.66 10.39 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.794 0.331 . . . . 0.0 111.131 -179.6 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 94' ' ' ASP . . . . . . . . . . . . . 8.9 m-20 -90.93 166.25 13.14 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.928 179.826 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 49.6 m -55.56 -33.02 63.49 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-N 116.312 -0.404 . . . . 0.0 111.029 -179.987 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 9.4 ptp180 -71.53 -48.05 51.25 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.842 179.88 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 97' ' ' GLU . . . . . 0.544 ' HB3' HD23 ' A' ' 93' ' ' LEU . 44.6 mt-10 -58.2 -45.14 88.16 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.923 -179.969 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 98' ' ' PHE . . . . . 0.443 ' O ' HG12 ' A' ' 102' ' ' ILE . 31.2 m-85 -59.1 -48.85 80.09 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.374 -0.375 . . . . 0.0 110.615 179.568 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -55.9 -31.07 58.07 Favored Glycine 0 N--CA 1.45 -0.381 0 C-N-CA 120.888 -0.672 . . . . 0.0 112.587 -179.775 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 98.0 mt -71.5 -44.29 71.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-O 120.798 0.332 . . . . 0.0 111.531 -179.94 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 39.7 t -68.12 -51.07 52.51 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.729 -179.344 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 102' ' ' ILE . . . . . 0.443 HG12 ' O ' ' A' ' 98' ' ' PHE . 34.0 mm -59.38 -50.0 81.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.325 -0.398 . . . . 0.0 111.771 -179.253 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 7.9 t -59.37 -36.11 75.14 Favored 'General case' 0 C--N 1.331 -0.204 0 CA-C-O 120.761 0.315 . . . . 0.0 110.911 -179.739 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 104' ' ' LEU . . . . . 0.457 ' O ' HG23 ' A' ' 108' ' ' VAL . 27.4 tp -63.03 -44.44 95.9 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.218 -0.447 . . . . 0.0 110.403 179.542 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 105' ' ' ASN . . . . . 0.578 ' N ' HD22 ' A' ' 105' ' ' ASN . 0.8 OUTLIER -63.66 -26.47 68.68 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 115.955 -0.566 . . . . 0.0 110.555 179.726 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild core ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 84.7 m -67.15 -54.59 19.81 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 115.998 -0.546 . . . . 0.0 111.167 179.954 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 7.5 p -63.6 -36.59 76.98 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.213 0 CA-C-N 116.42 -0.354 . . . . 0.0 111.05 -179.895 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . 0.457 HG23 ' O ' ' A' ' 104' ' ' LEU . 72.3 t -65.74 -45.5 91.62 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.226 0 CA-C-N 116.386 -0.37 . . . . 0.0 110.894 179.496 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 109' ' ' MET . . . . . 0.467 ' HE1' HG21 ' A' ' 80' ' ' THR . 8.7 tpp -65.15 -39.24 92.7 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.829 -179.82 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 29.0 tp -66.98 -30.75 70.95 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.215 179.701 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -62.5 -52.37 63.77 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 116.068 -0.515 . . . . 0.0 110.313 179.136 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . -67.62 -32.56 78.74 Favored Glycine 0 N--CA 1.45 -0.395 0 C-N-CA 120.566 -0.826 . . . . 0.0 111.649 179.127 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 113' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER -52.79 -75.89 0.03 OUTLIER 'General case' 0 C--N 1.332 -0.179 0 CA-C-O 121.008 0.432 . . . . 0.0 109.883 179.357 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 114' ' ' ALA . . . . . 0.431 ' HB3' HD22 ' A' ' 126' ' ' LEU . . . -61.05 -21.43 63.62 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-N 115.619 -0.719 . . . . 0.0 110.646 179.206 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -52.57 -50.98 46.32 Favored Glycine 0 C--N 1.333 0.385 0 C-N-CA 120.905 -0.664 . . . . 0.0 112.125 179.739 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 116' ' ' ALA . . . . . 0.574 ' HB2' ' HB3' ' A' ' 183' ' ' PRO . . . -78.19 -15.7 58.58 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 121.008 0.432 . . . . 0.0 110.723 179.217 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 117' ' ' MET . . . . . 0.419 ' HB3' ' HA ' ' A' ' 114' ' ' ALA . 45.1 tpp -87.49 -5.95 58.58 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 115.883 -0.599 . . . . 0.0 111.502 -179.588 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 118' ' ' VAL . . . . . 0.406 HG11 ' N ' ' A' ' 123' ' ' ARG . 21.7 m -58.81 146.67 74.78 Favored Pre-proline 0 C--N 1.331 -0.219 0 CA-C-N 116.683 -0.235 . . . . 0.0 111.449 -179.608 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 119' ' ' PRO . . . . . . . . . . . . . 69.2 Cg_endo -90.76 -5.45 4.43 Favored 'Trans proline' 0 N--CA 1.455 -0.748 0 C-N-CA 122.912 2.408 . . . . 0.0 112.228 179.431 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -145.41 -127.99 1.98 Allowed Glycine 0 C--N 1.333 0.362 0 C-N-CA 120.867 -0.683 . . . . 0.0 112.84 -179.733 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 46.6 pt -99.16 11.56 6.21 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.212 0 CA-C-O 120.596 0.236 . . . . 0.0 111.595 -179.491 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 122' ' ' GLU . . . . . 0.47 ' O ' HD12 ' A' ' 126' ' ' LEU . 15.1 mm-40 -60.53 -21.03 62.05 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.754 0.311 . . . . 0.0 110.997 -179.914 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 123' ' ' ARG . . . . . 0.439 HH11 ' HD2' ' A' ' 123' ' ' ARG . 10.0 ptt180 -52.22 -34.47 45.91 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.027 -0.533 . . . . 0.0 111.471 -179.935 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 124' ' ' TYR . . . . . . . . . . . . . 39.6 m-85 -69.16 -32.08 71.16 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.531 -179.574 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 125' ' ' ALA . . . . . . . . . . . . . . . -72.88 -56.51 5.09 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-O 120.831 0.348 . . . . 0.0 111.098 -179.699 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 126' ' ' LEU . . . . . 0.47 HD12 ' O ' ' A' ' 122' ' ' GLU . 1.3 mp -57.26 -49.61 75.51 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.662 179.92 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 127' ' ' PHE . . . . . . . . . . . . . 7.5 t80 -66.45 -37.42 85.12 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.335 -0.393 . . . . 0.0 110.857 -179.991 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 128' ' ' GLY . . . . . . . . . . . . . . . -47.18 -46.29 21.1 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.057 -1.068 . . . . 0.0 110.904 179.045 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 129' ' ' MET . . . . . . . . . . . . . 0.3 OUTLIER -70.13 -35.77 74.31 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 115.388 -0.406 . . . . 0.0 110.041 178.848 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -68.09 -28.2 73.45 Favored Glycine 0 C--N 1.334 0.434 0 CA-C-N 115.88 -0.6 . . . . 0.0 112.94 -179.659 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -74.42 -53.65 9.15 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 120.722 0.296 . . . . 0.0 110.313 179.915 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 22.2 t -58.2 -42.69 84.04 Favored 'Isoleucine or valine' 0 C--O 1.235 0.338 0 N-CA-C 109.022 -0.733 . . . . 0.0 109.022 178.476 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -64.31 -35.27 80.32 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.264 -0.88 . . . . 0.0 110.351 179.086 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 134' ' ' PHE . . . . . . . . . . . . . 75.3 t80 -56.74 -50.67 71.54 Favored 'General case' 0 N--CA 1.453 -0.323 0 CA-C-N 116.284 -0.416 . . . . 0.0 109.901 179.447 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 135' ' ' ILE . . . . . 0.479 ' O ' HG22 ' A' ' 138' ' ' VAL . 63.0 mt -57.44 -33.17 43.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 115.779 -0.646 . . . . 0.0 109.967 179.114 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 136' ' ' GLY . . . . . 0.446 ' O ' ' HB3' ' A' ' 139' ' ' TYR . . . -62.13 -40.62 99.19 Favored Glycine 0 N--CA 1.449 -0.478 0 C-N-CA 120.134 -1.032 . . . . 0.0 111.44 178.689 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 137' ' ' LEU . . . . . . . . . . . . . 26.8 tp -68.91 -49.91 54.01 Favored 'General case' 0 N--CA 1.455 -0.219 0 CA-C-O 120.43 0.157 . . . . 0.0 110.701 179.673 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 138' ' ' VAL . . . . . 0.554 ' HA ' HD12 ' A' ' 141' ' ' LEU . 4.7 m -58.2 -31.39 41.97 Favored 'Isoleucine or valine' 0 C--O 1.233 0.22 0 CA-C-O 121.338 0.589 . . . . 0.0 109.618 179.219 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 139' ' ' TYR . . . . . 0.446 ' HB3' ' O ' ' A' ' 136' ' ' GLY . 55.7 t80 -60.48 -43.21 97.21 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 115.34 -0.845 . . . . 0.0 109.302 178.373 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 36.7 m-85 -64.03 -32.72 74.38 Favored 'General case' 0 C--N 1.332 -0.16 0 CA-C-N 115.839 -0.619 . . . . 0.0 110.451 178.887 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 141' ' ' LEU . . . . . 0.554 HD12 ' HA ' ' A' ' 138' ' ' VAL . 95.3 mt -57.67 -47.43 82.32 Favored 'General case' 0 N--CA 1.462 0.168 0 CA-C-N 116.349 -0.387 . . . . 0.0 110.588 179.671 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 9.5 p -95.85 1.28 10.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.818 179.868 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 143' ' ' GLY . . . . . 0.4 ' HA3' ' HD2' ' A' ' 144' ' ' PRO . . . -75.95 -140.55 0.94 Allowed Glycine 0 CA--C 1.52 0.361 0 C-N-CA 120.99 -0.624 . . . . 0.0 112.878 -179.572 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 144' ' ' PRO . . . . . 0.4 ' HD2' ' HA3' ' A' ' 143' ' ' GLY . 19.5 Cg_endo -58.88 -23.92 69.9 Favored 'Trans proline' 0 C--N 1.347 0.488 0 C-N-CA 122.745 2.297 . . . . 0.0 112.685 -179.776 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 145' ' ' MET . . . . . . . . . . . . . 56.8 mtt -58.19 -33.13 68.94 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 120.806 0.336 . . . . 0.0 111.242 179.966 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 146' ' ' THR . . . . . . . . . . . . . 12.1 m -80.86 -32.35 35.05 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.385 -179.05 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 40.2 tt0 -71.8 -42.32 67.21 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-N 116.165 -0.47 . . . . 0.0 111.169 -179.743 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 148' ' ' SER . . . . . . . . . . . . . 58.2 m -70.61 -46.86 62.58 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-N 116.263 -0.426 . . . . 0.0 111.407 -179.432 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 149' ' ' ALA . . . . . 0.423 ' HB2' ' HB2' ' A' ' 91' ' ' ALA . . . -63.03 -41.33 99.49 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.309 -0.405 . . . . 0.0 111.742 -179.496 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 150' ' ' SER . . . . . . . . . . . . . 66.2 m -68.91 -0.58 5.73 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.38 -0.373 . . . . 0.0 111.501 -179.617 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 151' ' ' GLN . . . . . . . . . . . . . 44.8 mt-30 -129.09 3.69 5.26 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.628 -0.26 . . . . 0.0 111.246 179.991 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 31.0 tpt180 -76.42 -51.31 12.09 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.895 0.379 . . . . 0.0 110.651 -179.985 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 153' ' ' SER . . . . . 0.658 ' HB3' HG12 ' A' ' 156' ' ' ILE . 22.8 t -157.21 172.4 18.7 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-N 115.885 -0.598 . . . . 0.0 110.473 179.496 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 154' ' ' SER . . . . . . . . . . . . . 70.2 p -67.65 -41.22 84.18 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.382 -0.372 . . . . 0.0 110.912 179.937 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -77.07 -37.03 33.71 Favored Glycine 0 CA--C 1.519 0.305 0 C-N-CA 120.961 -0.638 . . . . 0.0 113.158 -179.657 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 156' ' ' ILE . . . . . 0.658 HG12 ' HB3' ' A' ' 153' ' ' SER . 42.4 mm -52.66 -37.22 24.19 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.186 0 CA-C-O 120.628 0.252 . . . . 0.0 111.56 -179.47 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 157' ' ' LYS . . . . . 0.44 ' O ' HG13 ' A' ' 161' ' ' VAL . 38.3 ttpt -60.29 -53.84 52.89 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.457 -0.338 . . . . 0.0 111.555 -179.629 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 48.9 m -63.5 -44.22 94.96 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 121.008 0.432 . . . . 0.0 111.468 -179.43 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 159' ' ' LEU . . . . . 0.422 HD23 ' O ' ' A' ' 159' ' ' LEU . 6.0 tt -63.71 -37.94 89.23 Favored 'General case' 0 C--N 1.326 -0.438 0 CA-C-N 115.993 -0.549 . . . . 0.0 110.983 -179.485 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 160' ' ' TYR . . . . . . . . . . . . . 54.1 t80 -74.4 -46.84 37.68 Favored 'General case' 0 C--N 1.329 -0.317 0 N-CA-C 112.548 0.573 . . . . 0.0 112.548 -178.796 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 161' ' ' VAL . . . . . 0.44 HG13 ' O ' ' A' ' 157' ' ' LYS . 28.2 m -56.13 -44.65 79.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 N-CA-C 111.908 0.336 . . . . 0.0 111.908 -178.685 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 162' ' ' ARG . . . . . 0.467 ' O ' HD12 ' A' ' 166' ' ' LEU . 97.8 mtt180 -68.65 -49.44 59.11 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.746 0.308 . . . . 0.0 111.475 -179.452 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 163' ' ' LEU . . . . . . . . . . . . . 6.1 mp -63.46 -51.58 65.04 Favored 'General case' 0 C--N 1.33 -0.239 0 CA-C-N 116.232 -0.44 . . . . 0.0 112.034 -179.097 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 164' ' ' ARG . . . . . 0.433 HH11 HG21 ' A' ' 168' ' ' VAL . 5.2 tmm_? -53.42 -50.32 65.46 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.411 -0.358 . . . . 0.0 111.208 -179.406 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 165' ' ' ASN . . . . . 0.496 HD22 ' N ' ' A' ' 165' ' ' ASN . 0.9 OUTLIER -53.55 -42.28 67.32 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.894 0.378 . . . . 0.0 110.609 179.898 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild core ' A' A ' 166' ' ' LEU . . . . . 0.504 ' O ' ' HG ' ' A' ' 170' ' ' LEU . 1.4 mt -58.31 -51.24 70.61 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 115.998 -0.546 . . . . 0.0 111.205 179.54 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 167' ' ' THR . . . . . 0.645 ' HA ' HD11 ' A' ' 170' ' ' LEU . 6.0 m -53.93 -53.88 46.62 Favored 'General case' 0 C--N 1.332 -0.178 0 N-CA-C 112.299 0.481 . . . . 0.0 112.299 -178.198 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 168' ' ' VAL . . . . . 0.433 HG21 HH11 ' A' ' 164' ' ' ARG . 25.2 t -53.66 -42.51 51.29 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.525 0 N-CA-C 112.327 0.492 . . . . 0.0 112.327 -179.432 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 169' ' ' VAL . . . . . 0.413 HG23 ' O ' ' A' ' 165' ' ' ASN . 92.4 t -68.75 -66.73 0.49 Allowed 'Isoleucine or valine' 0 CA--C 1.532 0.281 0 N-CA-C 113.789 1.033 . . . . 0.0 113.789 -177.774 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 170' ' ' LEU . . . . . 0.645 HD11 ' HA ' ' A' ' 167' ' ' THR . 0.4 OUTLIER -59.62 -33.1 71.06 Favored 'General case' 0 N--CA 1.465 0.295 0 N-CA-C 113.01 0.744 . . . . 0.0 113.01 -177.565 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild core ' A' A ' 171' ' ' TRP . . . . . 0.554 ' H ' HD12 ' A' ' 170' ' ' LEU . 19.6 m0 -73.43 -30.9 63.53 Favored 'General case' 0 C--N 1.329 -0.315 0 C-N-CA 120.411 -0.516 . . . . 0.0 111.171 -179.509 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 172' ' ' ALA . . . . . . . . . . . . . . . -70.99 -7.28 45.09 Favored 'General case' 0 C--N 1.33 -0.275 0 C-N-CA 120.847 -0.341 . . . . 0.0 110.817 179.453 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 173' ' ' ILE . . . . . 0.478 ' O ' HG12 ' A' ' 177' ' ' ILE . 22.9 mm -88.46 -27.07 5.5 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.21 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.951 179.627 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 174' ' ' TYR . . . . . 0.459 ' HD1' ' HA ' ' A' ' 171' ' ' TRP . 29.6 m-85 -54.02 -47.7 96.28 Favored Pre-proline 0 CA--C 1.529 0.143 0 CA-C-N 116.309 -0.405 . . . . 0.0 111.943 -179.286 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 175' ' ' PRO . . . . . 0.402 ' CD ' ' N ' ' A' ' 174' ' ' TYR . 81.8 Cg_exo -47.08 -34.86 17.98 Favored 'Trans proline' 0 C--N 1.35 0.625 0 C-N-CA 121.77 1.647 . . . . 0.0 111.852 179.093 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 176' ' ' PHE . . . . . 0.515 ' O ' ' HG ' ' A' ' 180' ' ' LEU . 67.6 m-85 -80.9 -51.02 9.04 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 115.749 -0.659 . . . . 0.0 111.554 179.729 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 177' ' ' ILE . . . . . 0.478 HG12 ' O ' ' A' ' 173' ' ' ILE . 31.5 mm -58.13 -30.48 39.42 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.558 0 CA-C-N 115.742 -0.663 . . . . 0.0 111.471 -178.674 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 178' ' ' TRP . . . . . 0.423 ' O ' ' HB2' ' A' ' 183' ' ' PRO . 90.7 t90 -73.77 -59.14 2.86 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-O 121.005 0.431 . . . . 0.0 110.865 179.791 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 179' ' ' LEU . . . . . 0.634 ' HG ' HG22 ' A' ' 185' ' ' VAL . 15.4 tp -61.31 -54.72 40.3 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 115.996 -0.547 . . . . 0.0 111.711 -178.989 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 180' ' ' LEU . . . . . 0.677 HD22 HD11 ' A' ' 187' ' ' LEU . 11.6 mt -63.65 -28.68 70.07 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 116.449 -0.341 . . . . 0.0 111.744 -179.112 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 181' ' ' GLY . . . . . 0.432 ' C ' ' HD2' ' A' ' 183' ' ' PRO . . . -73.96 -173.59 28.61 Favored Glycine 0 N--CA 1.451 -0.359 0 C-N-CA 120.05 -1.071 . . . . 0.0 111.823 179.422 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 182' ' ' PRO . . . . . 0.457 ' HG2' ' HD3' ' A' ' 183' ' ' PRO . 1.3 Cg_endo -47.01 -43.19 25.06 Favored 'Trans proline' 0 CA--C 1.541 0.831 0 C-N-CA 122.856 2.371 . . . . 0.0 113.789 179.561 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 183' ' ' PRO . . . . . 0.574 ' HB3' ' HB2' ' A' ' 116' ' ' ALA . 44.2 Cg_exo -37.86 -59.22 0.55 Allowed 'Trans proline' 0 C--N 1.357 0.989 0 C-N-CA 122.819 2.346 . . . . 0.0 114.12 -179.89 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 184' ' ' GLY . . . . . . . . . . . . . . . -115.65 -107.2 2.59 Favored Glycine 0 N--CA 1.45 -0.369 0 C-N-CA 120.162 -1.018 . . . . 0.0 113.174 -179.052 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 185' ' ' VAL . . . . . 0.667 HG23 ' HA ' ' A' ' 180' ' ' LEU . 26.8 m -76.81 86.11 0.81 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.405 0 CA-C-O 121.461 0.648 . . . . 0.0 111.021 -179.492 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 186' ' ' ALA . . . . . . . . . . . . . . . -63.38 85.27 0.03 OUTLIER 'General case' 0 C--N 1.323 -0.555 0 CA-C-N 115.683 -0.69 . . . . 0.0 111.08 179.67 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 187' ' ' LEU . . . . . 0.677 HD11 HD22 ' A' ' 180' ' ' LEU . 6.2 mt -78.99 -49.21 13.09 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 116.317 -0.402 . . . . 0.0 110.9 179.843 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 188' ' ' LEU . . . . . 0.484 ' HB3' ' H ' ' A' ' 189' ' ' THR . 3.9 mm? -94.98 -157.48 0.57 Allowed 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.034 -0.53 . . . . 0.0 111.437 -179.405 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 189' ' ' THR . . . . . 0.508 ' HB ' HG23 ' A' ' 192' ' ' VAL . 32.3 m -96.12 136.32 22.16 Favored Pre-proline 0 C--N 1.331 -0.218 0 CA-C-N 115.944 -0.571 . . . . 0.0 110.96 -179.654 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 190' ' ' PRO . . . . . 0.458 ' O ' HG23 ' A' ' 194' ' ' VAL . 80.6 Cg_exo -46.64 -42.98 23.61 Favored 'Trans proline' 0 C--N 1.35 0.639 0 C-N-CA 122.61 2.207 . . . . 0.0 113.022 -179.977 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 191' ' ' THR . . . . . . . . . . . . . 75.2 p -62.19 -45.78 91.83 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-O 120.792 0.33 . . . . 0.0 111.162 -179.822 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 192' ' ' VAL . . . . . 0.508 HG23 ' HB ' ' A' ' 189' ' ' THR . 58.9 t -60.04 -44.44 94.85 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.267 -0.424 . . . . 0.0 111.031 179.922 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 193' ' ' ASP . . . . . . . . . . . . . 28.2 t70 -56.81 -43.49 81.05 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.079 -0.509 . . . . 0.0 111.074 -179.935 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 194' ' ' VAL . . . . . 0.458 HG23 ' O ' ' A' ' 190' ' ' PRO . 93.1 t -63.06 -36.03 74.17 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.354 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.867 179.765 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 195' ' ' ALA . . . . . . . . . . . . . . . -58.62 -47.15 85.34 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.081 179.809 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 196' ' ' LEU . . . . . . . . . . . . . 57.5 mt -65.74 -37.52 86.6 Favored 'General case' 0 C--N 1.332 -0.177 0 CA-C-O 120.749 0.309 . . . . 0.0 110.591 179.714 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 197' ' ' ILE . . . . . . . . . . . . . 19.7 mm -61.55 -56.99 14.16 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.114 179.28 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 198' ' ' VAL . . . . . . . . . . . . . 73.0 t -52.39 -35.26 19.79 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.43 0 CA-C-N 115.743 -0.662 . . . . 0.0 109.519 178.472 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 199' ' ' TYR . . . . . . . . . . . . . 74.5 t80 -70.09 -38.55 75.7 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 115.228 -0.897 . . . . 0.0 110.583 179.849 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 200' ' ' LEU . . . . . . . . . . . . . 38.7 mt -63.65 -44.1 94.84 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 115.752 -0.658 . . . . 0.0 111.355 -179.607 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 201' ' ' ASP . . . . . 0.416 ' HB2' ' OH ' ' A' ' 51' ' ' TYR . 0.7 OUTLIER -72.03 -37.35 69.76 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.071 -0.513 . . . . 0.0 111.212 -179.753 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild core ' A' A ' 202' ' ' LEU . . . . . 0.445 ' O ' ' HB ' ' A' ' 206' ' ' VAL . 3.2 mt -68.52 -30.8 69.69 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.686 -179.452 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 203' ' ' VAL . . . . . 0.491 ' O ' ' HA3' ' A' ' 207' ' ' GLY . 42.6 t -78.98 -36.57 18.77 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.437 0 CA-C-O 120.683 0.278 . . . . 0.0 111.125 -179.449 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 204' ' ' THR . . . . . . . . . . . . . 25.8 m -70.83 -50.83 31.17 Favored 'General case' 0 C--N 1.324 -0.519 0 C-N-CA 120.747 -0.381 . . . . 0.0 111.325 179.938 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 205' ' ' LYS . . . . . 0.619 ' HE2' ' HB2' ' A' ' 47' ' ' ALA . 50.5 mttp -71.99 -58.48 3.41 Favored 'General case' 0 C--N 1.328 -0.341 0 N-CA-C 112.313 0.486 . . . . 0.0 112.313 -178.629 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 206' ' ' VAL . . . . . 0.445 ' HB ' ' O ' ' A' ' 202' ' ' LEU . 61.9 t -74.82 -37.55 42.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 N-CA-C 111.817 0.303 . . . . 0.0 111.817 -178.983 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 207' ' ' GLY . . . . . 0.491 ' HA3' ' O ' ' A' ' 203' ' ' VAL . . . -63.07 -57.48 15.51 Favored Glycine 0 N--CA 1.452 -0.244 0 C-N-CA 120.372 -0.918 . . . . 0.0 112.117 -179.767 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 208' ' ' PHE . . . . . 0.523 ' O ' ' N ' ' A' ' 212' ' ' ALA . 4.8 m-85 -55.42 -49.05 73.43 Favored 'General case' 0 C--O 1.22 -0.478 0 N-CA-C 109.865 -0.42 . . . . 0.0 109.865 179.45 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 209' ' ' GLY . . . . . 0.519 ' HA2' ' HB3' ' A' ' 212' ' ' ALA . . . -53.71 -34.81 51.11 Favored Glycine 0 N--CA 1.451 -0.315 0 CA-C-N 115.183 -0.917 . . . . 0.0 113.382 179.641 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 210' ' ' PHE . . . . . . . . . . . . . 2.1 m-85 -70.7 -48.28 55.49 Favored 'General case' 0 CA--C 1.514 -0.427 0 N-CA-C 108.775 -0.824 . . . . 0.0 108.775 179.355 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 211' ' ' ILE . . . . . 0.483 HD13 HD11 ' A' ' 166' ' ' LEU . 5.6 mt -65.48 -27.59 42.11 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.608 0 N-CA-C 107.712 -1.218 . . . . 0.0 107.712 176.698 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 212' ' ' ALA . . . . . 0.523 ' N ' ' O ' ' A' ' 208' ' ' PHE . . . -68.59 -40.13 80.63 Favored 'General case' 0 N--CA 1.448 -0.555 0 CA-C-N 114.131 -1.395 . . . . 0.0 110.332 -179.763 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 213' ' ' LEU . . . . . 0.408 ' HG ' ' O ' ' A' ' 209' ' ' GLY . 74.8 mt -70.16 -50.42 40.52 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 114.974 -1.012 . . . . 0.0 111.405 -179.572 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 214' ' ' ASP . . . . . . . . . . . . . 24.0 t70 -59.05 -49.9 76.12 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.931 -179.714 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 215' ' ' ALA . . . . . . . . . . . . . . . -56.57 -55.46 33.58 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.888 179.944 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 216' ' ' ALA . . . . . . . . . . . . . . . -62.0 -30.94 71.29 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.143 -0.48 . . . . 0.0 111.32 -179.95 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 217' ' ' ALA . . . . . . . . . . . . . . . -58.28 -43.56 88.03 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-O 120.966 0.412 . . . . 0.0 110.275 179.881 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 218' ' ' THR . . . . . . . . . . . . . 89.5 m . . . . . 0 C--N 1.33 -0.275 0 CA-C-N 115.826 -0.625 . . . . 0.0 110.355 179.287 . . . . . . . . 0 0 . 1 . 025 nuclear nobuild core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.301 0 N-CA-C 112.517 -0.233 . . . . 0.0 112.517 . . . . . . . . . 0 0 . 1 . 025 nuclear nobuild core ' A' A ' 4' ' ' LEU . . . . . 0.504 HD22 HG21 ' A' ' 194' ' ' VAL . 85.8 mt -74.48 -38.36 62.93 Favored 'General case' 0 N--CA 1.449 -0.477 0 CA-C-O 120.723 0.297 . . . . 0.0 111.509 -179.906 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 69.2 p -54.77 -37.33 65.88 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.138 -0.483 . . . . 0.0 112.03 -179.171 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 69.2 p -56.12 -35.19 66.82 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.481 -0.327 . . . . 0.0 111.548 -179.625 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 7' ' ' LEU . . . . . . . . . . . . . 4.0 mm? -63.2 -53.47 52.67 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.429 -0.35 . . . . 0.0 111.419 -179.648 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 8' ' ' PHE . . . . . 0.673 ' HB2' ' HB2' ' A' ' 55' ' ' ALA . 65.8 m-85 -60.25 -33.06 71.78 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.332 -0.395 . . . . 0.0 110.946 -179.586 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 9' ' ' TRP . . . . . . . . . . . . . 18.3 m95 -68.71 -49.36 59.49 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.246 -179.825 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 75.9 mt -59.39 -38.81 81.46 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 115.814 -0.63 . . . . 0.0 109.825 179.134 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -67.12 -36.24 90.04 Favored Glycine 0 N--CA 1.446 -0.64 0 CA-C-N 115.473 -0.785 . . . . 0.0 111.73 179.403 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -61.98 -33.38 74.21 Favored 'General case' 0 C--O 1.232 0.18 0 CA-C-O 121.037 0.446 . . . . 0.0 109.97 179.183 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 50.7 mm -65.61 -49.92 74.85 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 115.694 -0.685 . . . . 0.0 110.266 179.115 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -58.3 -36.24 82.36 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.798 -0.715 . . . . 0.0 112.218 179.539 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 15' ' ' MET . . . . . . . . . . . . . 19.3 mmt -66.21 -44.6 83.41 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.74 0.305 . . . . 0.0 110.783 179.733 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 16' ' ' LEU . . . . . 0.4 HD13 ' O ' ' A' ' 16' ' ' LEU . 0.5 OUTLIER -53.79 -45.43 70.72 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 115.995 -0.548 . . . . 0.0 110.742 179.809 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 49.2 t -61.12 -43.94 97.3 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.238 0 CA-C-N 116.112 -0.495 . . . . 0.0 111.149 179.943 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -66.72 -43.95 90.65 Favored Glycine 0 N--CA 1.452 -0.256 0 C-N-CA 120.699 -0.762 . . . . 0.0 112.073 179.645 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 19.2 m -52.3 -42.72 64.02 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-O 120.675 0.274 . . . . 0.0 111.341 -179.776 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 80.9 mt -71.82 -44.8 63.3 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.406 -0.361 . . . . 0.0 111.554 -179.903 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -57.01 -32.59 66.29 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.37 -0.377 . . . . 0.0 111.759 -179.405 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 22' ' ' PHE . . . . . 0.623 ' HB2' HG22 ' A' ' 41' ' ' VAL . 10.0 m-85 -90.92 -38.63 12.77 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.537 -0.301 . . . . 0.0 111.62 -179.356 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -64.03 -50.49 68.24 Favored 'General case' 0 C--N 1.332 -0.166 0 CA-C-O 120.878 0.37 . . . . 0.0 111.25 -179.685 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 24' ' ' TRP . . . . . . . . . . . . . 1.3 t-105 -59.88 -49.84 76.13 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 115.958 -0.565 . . . . 0.0 110.68 179.685 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.329 -0.313 0 CA-C-N 116.266 -0.424 . . . . 0.0 111.033 179.88 . . . . . . . . 0 0 . 1 . 025 nuclear nobuild core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.373 0 N-CA-C 112.753 -0.139 . . . . 0.0 112.753 . . . . . . . . . 0 0 . 1 . 025 nuclear nobuild core ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 43.6 mt-10 -88.43 -21.49 24.22 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.686 0.279 . . . . 0.0 110.988 -179.937 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 34' ' ' ARG . . . . . 0.432 ' O ' HG23 ' A' ' 38' ' ' VAL . 35.7 ttp180 -49.87 -35.25 22.67 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.141 -0.481 . . . . 0.0 111.527 -179.798 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 77.6 mtm180 -61.59 -54.33 44.48 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 120.85 0.357 . . . . 0.0 111.497 -179.772 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 59.4 m-85 -62.04 -30.02 70.69 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.134 -0.484 . . . . 0.0 111.421 -179.441 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 37' ' ' TYR . . . . . 0.526 ' O ' HG23 ' A' ' 41' ' ' VAL . 32.5 m-85 -73.76 -56.11 5.4 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.503 -179.411 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 38' ' ' VAL . . . . . 0.432 HG23 ' O ' ' A' ' 34' ' ' ARG . 96.0 t -56.68 -36.7 49.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-O 120.98 0.419 . . . . 0.0 110.628 179.923 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 78.3 m -63.44 -51.62 64.92 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 115.872 -0.604 . . . . 0.0 110.918 179.713 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 40' ' ' LEU . . . . . 0.603 HD12 HD12 ' A' ' 43' ' ' ILE . 51.7 tp -61.29 -45.98 92.22 Favored 'General case' 0 C--O 1.236 0.35 0 CA-C-N 115.966 -0.561 . . . . 0.0 110.722 179.989 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . 0.623 HG22 ' HB2' ' A' ' 22' ' ' PHE . 85.8 t -60.13 -34.77 58.05 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.399 0 CA-C-N 115.684 -0.689 . . . . 0.0 109.858 178.974 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -63.15 -35.39 92.02 Favored Glycine 0 N--CA 1.445 -0.724 0 C-N-CA 120.877 -0.678 . . . . 0.0 112.026 179.592 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 43' ' ' ILE . . . . . 0.662 HG22 ' HE3' ' A' ' 205' ' ' LYS . 0.8 OUTLIER -66.23 -57.75 9.28 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.126 0 C-N-CA 121.074 -0.25 . . . . 0.0 111.148 179.811 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild core ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 85.1 p -59.57 -21.56 60.48 Favored 'General case' 0 C--O 1.232 0.154 0 CA-C-N 116.485 -0.325 . . . . 0.0 111.554 -179.518 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -79.43 -56.23 3.46 Favored Glycine 0 CA--C 1.518 0.23 0 C-N-CA 120.843 -0.694 . . . . 0.0 113.063 -179.363 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 46' ' ' ILE . . . . . 0.431 ' O ' HG22 ' A' ' 49' ' ' VAL . 20.2 pt -58.2 -37.39 62.25 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.243 0 CA-C-O 121.138 0.494 . . . . 0.0 110.873 -179.896 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 47' ' ' ALA . . . . . 0.713 ' HB2' ' HE2' ' A' ' 205' ' ' LYS . . . -68.21 -45.26 73.82 Favored 'General case' 0 C--N 1.324 -0.525 0 CA-C-N 115.945 -0.571 . . . . 0.0 111.363 179.513 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -54.13 -42.71 69.79 Favored 'General case' 0 C--O 1.233 0.203 0 CA-C-N 116.299 -0.41 . . . . 0.0 111.807 -179.219 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 49' ' ' VAL . . . . . 0.431 HG22 ' O ' ' A' ' 46' ' ' ILE . 33.1 m -72.23 -34.5 49.77 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.363 0 CA-C-N 116.665 -0.243 . . . . 0.0 111.333 -179.517 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -66.9 -33.48 75.69 Favored 'General case' 0 CA--C 1.521 -0.146 0 CA-C-O 120.988 0.423 . . . . 0.0 110.73 179.402 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 3.0 m-30 -69.55 -40.72 76.66 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-N 115.909 -0.587 . . . . 0.0 110.12 179.784 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -61.44 -45.1 95.73 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 115.704 -0.68 . . . . 0.0 111.367 179.829 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 53' ' ' VAL . . . . . 0.502 HG23 ' N ' ' A' ' 54' ' ' MET . 25.3 m -67.62 -50.08 64.41 Favored 'Isoleucine or valine' 0 C--N 1.334 -0.087 0 C-N-CA 121.11 -0.236 . . . . 0.0 111.011 -179.956 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 54' ' ' MET . . . . . 0.541 ' HG2' ' HG2' ' A' ' 71' ' ' PRO . 74.7 mtm -58.04 -30.35 66.08 Favored 'General case' 0 CA--C 1.521 -0.172 0 CA-C-O 121.224 0.535 . . . . 0.0 109.866 179.336 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 55' ' ' ALA . . . . . 0.673 ' HB2' ' HB2' ' A' ' 8' ' ' PHE . . . -74.5 -33.93 62.93 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 115.414 -0.812 . . . . 0.0 111.365 179.526 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 74.8 mt -70.88 -5.19 28.78 Favored 'General case' 0 C--N 1.331 -0.203 0 CA-C-N 116.371 -0.377 . . . . 0.0 111.573 -179.416 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 98.8 -20.77 49.01 Favored Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.46 -0.876 . . . . 0.0 113.036 179.638 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 58' ' ' VAL . . . . . 0.428 HG22 ' O ' ' A' ' 53' ' ' VAL . 32.9 m -70.03 149.11 10.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-O 120.88 0.371 . . . . 0.0 110.826 179.805 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 59' ' ' GLY . . . . . 0.472 ' HA3' ' HG3' ' A' ' 71' ' ' PRO . . . 85.05 22.49 52.31 Favored Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.913 -0.661 . . . . 0.0 112.578 -179.47 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 60' ' ' TRP . . . . . . . . . . . . . 13.8 m0 -105.71 96.07 6.24 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-O 121.091 0.472 . . . . 0.0 109.986 -179.837 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 5.1 t -98.53 116.54 65.4 Favored Pre-proline 0 C--N 1.326 -0.435 0 CA-C-N 115.696 -0.683 . . . . 0.0 111.635 -178.87 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 57.1 Cg_endo -70.4 143.96 49.25 Favored 'Trans proline' 0 C--N 1.351 0.709 0 C-N-CA 122.437 2.092 . . . . 0.0 112.262 179.578 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 99.5 t -138.93 96.12 0.99 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.053 -0.521 . . . . 0.0 111.165 -179.88 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . 57.24 -88.1 0.02 OUTLIER 'General case' 0 C--N 1.331 -0.204 0 CA-C-N 116.189 -0.459 . . . . 0.0 111.439 179.781 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 45.7 mt-10 -121.85 -19.08 6.85 Favored 'General case' 0 C--N 1.332 -0.193 0 CA-C-N 116.433 -0.349 . . . . 0.0 110.939 179.935 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 66' ' ' ARG . . . . . . . . . . . . . 39.7 mmt180 -105.4 155.72 18.86 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.342 179.629 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 30.3 m -114.01 143.32 44.94 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-O 120.947 0.404 . . . . 0.0 111.351 -179.591 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 19.9 m -127.42 145.84 34.2 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.402 0 CA-C-N 115.83 -0.623 . . . . 0.0 110.818 179.659 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 69' ' ' PHE . . . . . . . . . . . . . 17.2 m-85 -110.73 115.6 29.84 Favored 'General case' 0 C--N 1.327 -0.38 0 N-CA-C 109.738 -0.467 . . . . 0.0 109.738 -179.63 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 70' ' ' VAL . . . . . 0.566 ' N ' ' HD2' ' A' ' 71' ' ' PRO . 59.4 t -68.43 -51.17 24.66 Favored Pre-proline 0 C--N 1.323 -0.559 0 N-CA-C 112.436 0.532 . . . . 0.0 112.436 -178.741 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 71' ' ' PRO . . . . . 0.566 ' HD2' ' N ' ' A' ' 70' ' ' VAL . 11.2 Cg_endo -54.87 -19.89 20.79 Favored 'Trans proline' 0 C--N 1.353 0.791 0 C-N-CA 122.089 1.859 . . . . 0.0 112.012 179.831 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 72' ' ' ARG . . . . . 0.412 ' NH2' HG13 ' A' ' 197' ' ' ILE . 53.1 ttt180 -74.96 -53.8 8.34 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.043 -0.526 . . . . 0.0 110.586 179.673 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 73' ' ' TYR . . . . . 0.4 ' O ' HG13 ' A' ' 77' ' ' ILE . 75.8 m-85 -65.02 -36.91 85.91 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 115.774 -0.648 . . . . 0.0 110.704 -179.994 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 0.3 OUTLIER -70.05 -36.78 69.98 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 N-CA-C 109.744 -0.465 . . . . 0.0 109.744 179.048 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 75' ' ' ASP . . . . . 0.401 ' O ' HG23 ' A' ' 79' ' ' THR . 12.3 t70 -56.52 -38.95 72.54 Favored 'General case' 0 CA--C 1.52 -0.176 0 CA-C-N 116.033 -0.531 . . . . 0.0 109.642 179.06 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 76' ' ' TRP . . . . . . . . . . . . . 50.2 m0 -69.45 -38.54 77.84 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 115.615 -0.72 . . . . 0.0 110.624 179.418 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 77' ' ' ILE . . . . . 0.4 HG13 ' O ' ' A' ' 73' ' ' TYR . 92.5 mt -59.17 -28.77 39.97 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.725 179.674 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 35.4 mt -91.83 -26.91 18.29 Favored 'General case' 0 CA--C 1.533 0.293 0 N-CA-C 112.317 0.488 . . . . 0.0 112.317 -179.941 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 79' ' ' THR . . . . . 0.413 HG22 HD11 ' A' ' 46' ' ' ILE . 71.3 p -92.44 -52.24 4.75 Favored 'General case' 0 N--CA 1.466 0.342 0 N-CA-C 113.622 0.971 . . . . 0.0 113.622 -177.884 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 80' ' ' THR . . . . . 0.425 ' N ' ' HD2' ' A' ' 81' ' ' PRO . 89.0 m -47.3 -55.25 16.7 Favored Pre-proline 0 C--N 1.329 -0.325 0 N-CA-C 112.858 0.688 . . . . 0.0 112.858 -178.418 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 81' ' ' PRO . . . . . 0.437 ' HA ' HG22 ' A' ' 84' ' ' VAL . 37.2 Cg_endo -64.19 -18.99 65.42 Favored 'Trans proline' 0 C--N 1.35 0.614 0 C-N-CA 121.495 1.463 . . . . 0.0 111.232 -179.833 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 82' ' ' LEU . . . . . . . . . . . . . 18.4 tp -76.93 -33.6 57.72 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 115.529 -0.759 . . . . 0.0 110.169 179.641 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 83' ' ' ILE . . . . . 0.414 HD13 HD13 ' A' ' 43' ' ' ILE . 41.2 mm -70.12 -52.23 32.29 Favored 'Isoleucine or valine' 0 C--O 1.232 0.175 0 CA-C-N 116.058 -0.519 . . . . 0.0 110.101 179.203 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 84' ' ' VAL . . . . . 0.437 HG22 ' HA ' ' A' ' 81' ' ' PRO . 27.9 m -60.61 -30.47 46.89 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.179 0 N-CA-C 109.63 -0.507 . . . . 0.0 109.63 178.795 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 85' ' ' TYR . . . . . . . . . . . . . 81.1 t80 -65.33 -35.79 82.07 Favored 'General case' 0 N--CA 1.453 -0.28 0 CA-C-N 115.542 -0.754 . . . . 0.0 109.276 178.684 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 86' ' ' PHE . . . . . . . . . . . . . 7.2 t80 -61.15 -50.13 74.41 Favored 'General case' 0 C--O 1.234 0.237 0 CA-C-N 115.633 -0.712 . . . . 0.0 109.919 179.186 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 8.8 mp -62.23 -31.84 72.44 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 115.838 -0.619 . . . . 0.0 109.861 179.384 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -68.96 -27.69 73.69 Favored Glycine 0 N--CA 1.449 -0.459 0 C-N-CA 120.856 -0.688 . . . . 0.0 111.678 179.113 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 82.7 mt -73.72 -37.36 65.17 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-O 120.948 0.404 . . . . 0.0 110.482 179.549 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 90' ' ' LEU . . . . . 0.437 HD11 HD22 ' A' ' 163' ' ' LEU . 93.6 mt -64.3 -42.67 96.26 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 115.945 -0.571 . . . . 0.0 111.144 179.9 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -80.13 -54.99 5.25 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.4 -179.654 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 95.37 67.88 1.0 Allowed Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.814 -0.708 . . . . 0.0 112.132 -179.733 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 93' ' ' LEU . . . . . 0.426 ' N ' HD12 ' A' ' 93' ' ' LEU . 6.6 mp -71.21 -171.13 0.55 Allowed 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.783 0.325 . . . . 0.0 111.033 -179.71 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 94' ' ' ASP . . . . . 0.419 ' HB2' ' OE2' ' A' ' 97' ' ' GLU . 5.9 m-20 -96.43 -173.41 2.76 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-N 116.246 -0.433 . . . . 0.0 111.28 -179.807 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 47.5 t -67.52 -51.26 53.04 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 115.946 -0.57 . . . . 0.0 111.624 -179.425 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 96' ' ' ARG . . . . . 0.425 ' O ' HG13 ' A' ' 100' ' ' ILE . 31.6 mmt180 -73.72 -40.07 63.83 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 120.944 0.402 . . . . 0.0 110.699 -179.505 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 97' ' ' GLU . . . . . 0.54 ' HA ' HD12 ' A' ' 100' ' ' ILE . 0.3 OUTLIER -55.48 -47.39 76.21 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 115.763 -0.653 . . . . 0.0 111.501 -179.622 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild core ' A' A ' 98' ' ' PHE . . . . . 0.444 ' O ' HG12 ' A' ' 102' ' ' ILE . 1.2 m-85 -57.13 -45.23 83.69 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.821 0.343 . . . . 0.0 110.796 179.813 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -62.68 -30.25 76.26 Favored Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.586 -179.92 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 100' ' ' ILE . . . . . 0.54 HD12 ' HA ' ' A' ' 97' ' ' GLU . 95.5 mt -65.65 -44.79 93.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-O 120.81 0.338 . . . . 0.0 111.221 -179.939 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 101' ' ' VAL . . . . . 0.431 HG21 ' CE ' ' A' ' 145' ' ' MET . 56.2 t -68.64 -43.89 82.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.322 -0.399 . . . . 0.0 111.51 -179.732 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 102' ' ' ILE . . . . . 0.444 HG12 ' O ' ' A' ' 98' ' ' PHE . 48.5 mm -61.45 -51.1 76.84 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.348 -0.387 . . . . 0.0 111.189 -179.789 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 14.9 t -61.35 -29.01 69.64 Favored 'General case' 0 C--O 1.232 0.153 0 CA-C-O 120.866 0.365 . . . . 0.0 110.614 179.925 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 104' ' ' LEU . . . . . 0.458 ' O ' HG23 ' A' ' 108' ' ' VAL . 1.4 tm? -59.6 -52.65 64.61 Favored 'General case' 0 C--N 1.331 -0.198 0 CA-C-N 116.073 -0.512 . . . . 0.0 109.807 179.217 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 105' ' ' ASN . . . . . 0.569 ' N ' HD22 ' A' ' 105' ' ' ASN . 0.8 OUTLIER -64.33 -26.18 68.37 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 115.965 -0.561 . . . . 0.0 111.024 179.732 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild core ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 53.7 m -63.95 -56.7 13.26 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.38 -0.373 . . . . 0.0 111.478 -179.795 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 7.2 p -62.33 -36.47 74.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.272 -0.422 . . . . 0.0 111.214 -179.851 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . 0.458 HG23 ' O ' ' A' ' 104' ' ' LEU . 81.3 t -65.59 -54.41 28.37 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.197 0 CA-C-N 116.376 -0.375 . . . . 0.0 111.01 179.817 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 109' ' ' MET . . . . . . . . . . . . . 11.2 tpp -59.58 -36.29 75.94 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.94 -179.766 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 30.2 tp -66.52 -32.94 74.6 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.309 -0.405 . . . . 0.0 110.226 179.779 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -62.02 -54.21 44.68 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 115.97 -0.559 . . . . 0.0 110.683 179.526 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . -56.87 -36.51 73.25 Favored Glycine 0 C--N 1.331 0.283 0 C-N-CA 120.605 -0.807 . . . . 0.0 112.044 179.549 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 113' ' ' PHE . . . . . . . . . . . . . 2.6 t80 -54.06 -63.67 1.07 Allowed 'General case' 0 C--N 1.332 -0.186 0 CA-C-O 120.918 0.389 . . . . 0.0 110.262 179.589 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 114' ' ' ALA . . . . . 0.447 ' O ' HG13 ' A' ' 118' ' ' VAL . . . -62.25 -28.29 69.6 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 115.88 -0.6 . . . . 0.0 111.172 179.942 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 115' ' ' GLY . . . . . 0.465 ' N ' ' HG ' ' A' ' 126' ' ' LEU . . . -52.22 -52.88 33.84 Favored Glycine 0 C--N 1.333 0.363 0 C-N-CA 121.081 -0.58 . . . . 0.0 112.729 179.971 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -77.91 -15.06 59.3 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-O 120.711 0.291 . . . . 0.0 111.535 179.84 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 117' ' ' MET . . . . . . . . . . . . . 0.5 OUTLIER -93.83 19.34 8.99 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.468 -0.333 . . . . 0.0 111.488 -179.704 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 118' ' ' VAL . . . . . 0.447 HG13 ' O ' ' A' ' 114' ' ' ALA . 33.2 m -84.55 146.74 47.73 Favored Pre-proline 0 C--N 1.331 -0.223 0 CA-C-N 116.594 -0.276 . . . . 0.0 111.335 179.86 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 119' ' ' PRO . . . . . . . . . . . . . 96.6 Cg_endo -87.91 1.92 6.64 Favored 'Trans proline' 0 N--CA 1.458 -0.593 0 C-N-CA 122.709 2.273 . . . . 0.0 112.233 179.325 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -155.55 -138.39 2.56 Favored Glycine 0 C--N 1.332 0.334 0 C-N-CA 120.806 -0.711 . . . . 0.0 112.79 -179.674 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 47.1 pt -88.55 8.72 2.64 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.193 0 CA-C-O 120.645 0.26 . . . . 0.0 111.523 -179.634 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 38.4 mt-10 -60.07 -18.55 47.61 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.423 -0.353 . . . . 0.0 111.11 -179.853 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 123' ' ' ARG . . . . . 0.4 ' HB2' ' HH2' ' A' ' 178' ' ' TRP . 2.6 ptp180 -52.07 -33.8 40.86 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.176 -0.465 . . . . 0.0 111.737 -179.871 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 124' ' ' TYR . . . . . . . . . . . . . 40.8 m-85 -65.01 -32.67 74.51 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.599 -0.273 . . . . 0.0 111.362 -179.659 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 125' ' ' ALA . . . . . . . . . . . . . . . -68.73 -52.96 25.05 Favored 'General case' 0 C--O 1.237 0.419 0 CA-C-O 120.79 0.328 . . . . 0.0 111.064 179.909 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 126' ' ' LEU . . . . . 0.465 ' HG ' ' N ' ' A' ' 115' ' ' GLY . 2.6 mm? -49.86 -54.32 20.17 Favored 'General case' 0 CA--C 1.52 -0.187 0 CA-C-N 116.016 -0.538 . . . . 0.0 110.61 -179.988 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 127' ' ' PHE . . . . . 0.505 ' HZ ' ' HB3' ' A' ' 175' ' ' PRO . 7.1 t80 -67.5 -31.53 71.73 Favored 'General case' 0 N--CA 1.452 -0.35 0 CA-C-N 116.285 -0.416 . . . . 0.0 111.074 -179.652 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 128' ' ' GLY . . . . . . . . . . . . . . . -46.38 -48.38 16.2 Favored Glycine 0 C--N 1.331 0.283 0 C-N-CA 119.793 -1.194 . . . . 0.0 110.737 179.07 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 129' ' ' MET . . . . . 0.491 ' HE3' ' N ' ' A' ' 130' ' ' GLY . 6.0 tmm? -70.43 -45.79 65.18 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 115.139 -0.53 . . . . 0.0 109.894 178.75 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 130' ' ' GLY . . . . . 0.491 ' N ' ' HE3' ' A' ' 129' ' ' MET . . . -57.37 -29.63 60.6 Favored Glycine 0 C--N 1.331 0.265 0 CA-C-N 115.85 -0.614 . . . . 0.0 113.174 -179.315 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -75.02 -53.65 8.55 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-O 120.702 0.287 . . . . 0.0 110.58 -179.798 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 60.0 t -57.67 -42.08 80.77 Favored 'Isoleucine or valine' 0 C--O 1.234 0.252 0 CA-C-O 121.372 0.606 . . . . 0.0 109.672 178.815 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -68.9 -33.47 73.81 Favored 'General case' 0 N--CA 1.451 -0.377 0 CA-C-N 115.272 -0.877 . . . . 0.0 110.781 179.441 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 134' ' ' PHE . . . . . . . . . . . . . 70.5 t80 -54.59 -57.42 11.51 Favored 'General case' 0 N--CA 1.451 -0.394 0 CA-C-O 121.01 0.433 . . . . 0.0 110.031 179.542 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 135' ' ' ILE . . . . . 0.457 ' O ' HG22 ' A' ' 138' ' ' VAL . 26.4 mt -57.22 -33.27 42.88 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.388 0 CA-C-N 115.728 -0.669 . . . . 0.0 109.891 178.87 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . -59.26 -39.46 94.63 Favored Glycine 0 N--CA 1.448 -0.52 0 C-N-CA 120.31 -0.948 . . . . 0.0 111.511 178.851 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 137' ' ' LEU . . . . . . . . . . . . . 54.6 tp -68.68 -55.34 11.74 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-O 120.715 0.293 . . . . 0.0 110.729 179.549 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 138' ' ' VAL . . . . . 0.457 HG22 ' O ' ' A' ' 135' ' ' ILE . 2.8 m -55.86 -32.08 31.64 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.24 0 CA-C-O 121.45 0.643 . . . . 0.0 109.478 179.747 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 139' ' ' TYR . . . . . . . . . . . . . 9.8 t80 -64.23 -36.89 85.55 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 115.28 -0.873 . . . . 0.0 109.995 178.667 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 16.1 m-85 -66.18 -53.15 40.87 Favored 'General case' 0 C--N 1.332 -0.186 0 CA-C-N 115.959 -0.564 . . . . 0.0 111.332 179.669 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 141' ' ' LEU . . . . . 0.644 HD12 HG23 ' A' ' 142' ' ' VAL . 3.0 pp -64.31 -17.12 63.36 Favored 'General case' 0 C--N 1.333 -0.148 0 CA-C-O 120.657 0.265 . . . . 0.0 111.268 -179.418 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 142' ' ' VAL . . . . . 0.644 HG23 HD12 ' A' ' 141' ' ' LEU . 47.1 t -94.93 -22.71 5.3 Favored 'Isoleucine or valine' 0 C--O 1.233 0.208 0 CA-C-O 121.054 0.454 . . . . 0.0 110.366 178.343 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . -74.25 -124.6 0.12 Allowed Glycine 0 CA--C 1.524 0.612 0 C-N-CA 121.114 -0.565 . . . . 0.0 113.485 -179.234 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 144' ' ' PRO . . . . . . . . . . . . . 46.6 Cg_endo -67.55 -23.13 43.62 Favored 'Trans proline' 0 C--N 1.35 0.642 0 C-N-CA 122.769 2.313 . . . . 0.0 113.253 -179.157 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 145' ' ' MET . . . . . 0.493 ' HB3' ' OH ' ' A' ' 160' ' ' TYR . 5.7 mtt -52.18 -57.61 9.13 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.508 -0.315 . . . . 0.0 111.658 -179.609 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 146' ' ' THR . . . . . . . . . . . . . 8.8 t -62.78 -32.2 73.32 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.488 -0.324 . . . . 0.0 111.719 -179.343 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 45.6 mt-10 -70.57 -33.9 71.61 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.425 -0.352 . . . . 0.0 111.311 -179.609 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 148' ' ' SER . . . . . . . . . . . . . 38.8 m -70.52 -49.87 43.62 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.956 0.408 . . . . 0.0 110.843 -179.889 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 149' ' ' ALA . . . . . 0.498 ' HB1' HG22 ' A' ' 156' ' ' ILE . . . -64.05 -35.23 80.06 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 115.992 -0.549 . . . . 0.0 111.757 -179.553 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 150' ' ' SER . . . . . 0.444 ' HA ' ' HB2' ' A' ' 157' ' ' LYS . 86.3 p -67.71 -5.59 16.71 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.379 -0.373 . . . . 0.0 111.232 -179.664 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 151' ' ' GLN . . . . . . . . . . . . . 78.9 mt-30 -115.3 -1.16 12.98 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.503 -0.317 . . . . 0.0 111.338 179.947 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 32.4 mmt180 -80.97 -51.63 8.33 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-O 120.843 0.354 . . . . 0.0 110.989 179.812 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 153' ' ' SER . . . . . 0.58 ' HB3' HG12 ' A' ' 156' ' ' ILE . 27.5 t -158.08 172.41 18.48 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 116.141 -0.482 . . . . 0.0 110.844 179.635 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 154' ' ' SER . . . . . . . . . . . . . 50.8 m -71.59 -40.47 69.85 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.285 -0.416 . . . . 0.0 110.455 179.327 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -76.75 -31.97 51.86 Favored Glycine 0 N--CA 1.452 -0.281 0 C-N-CA 121.013 -0.613 . . . . 0.0 112.708 179.916 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 156' ' ' ILE . . . . . 0.58 HG12 ' HB3' ' A' ' 153' ' ' SER . 29.5 mm -60.14 -38.21 76.17 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.229 0 CA-C-O 120.834 0.349 . . . . 0.0 111.131 -179.896 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 157' ' ' LYS . . . . . 0.444 ' HB2' ' HA ' ' A' ' 150' ' ' SER . 61.7 tttm -66.85 -50.87 61.14 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.327 -179.601 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 48.5 t -62.72 -39.45 94.08 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.3 -0.409 . . . . 0.0 111.549 -179.464 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 159' ' ' LEU . . . . . 0.456 ' O ' HD13 ' A' ' 163' ' ' LEU . 32.0 tp -71.11 -33.45 70.15 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.364 -0.38 . . . . 0.0 111.211 -179.477 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 160' ' ' TYR . . . . . 0.493 ' OH ' ' HB3' ' A' ' 145' ' ' MET . 48.3 t80 -73.24 -46.82 47.93 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.569 -0.287 . . . . 0.0 111.473 -179.559 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 161' ' ' VAL . . . . . 0.429 HG23 ' N ' ' A' ' 162' ' ' ARG . 27.8 m -58.52 -45.4 90.24 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 CA-C-N 116.718 -0.219 . . . . 0.0 111.531 -179.408 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 162' ' ' ARG . . . . . 0.429 ' N ' HG23 ' A' ' 161' ' ' VAL . 40.7 mmt180 -65.05 -39.71 93.69 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-O 120.854 0.359 . . . . 0.0 111.324 -179.723 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 163' ' ' LEU . . . . . 0.605 ' HG ' ' HB2' ' A' ' 208' ' ' PHE . 6.3 mp -70.2 -46.84 63.73 Favored 'General case' 0 C--N 1.328 -0.366 0 N-CA-C 112.453 0.538 . . . . 0.0 112.453 -179.149 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 164' ' ' ARG . . . . . 0.427 ' O ' HG23 ' A' ' 168' ' ' VAL . 5.8 ppt_? -70.96 -47.71 57.44 Favored 'General case' 0 C--N 1.33 -0.262 0 N-CA-C 112.107 0.41 . . . . 0.0 112.107 -178.418 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 165' ' ' ASN . . . . . 0.472 ' O ' HG23 ' A' ' 169' ' ' VAL . 16.2 m-80 -57.75 -49.24 77.24 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-O 120.761 0.315 . . . . 0.0 111.129 -179.847 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 166' ' ' LEU . . . . . 0.458 ' O ' ' HG ' ' A' ' 170' ' ' LEU . 5.8 tt -63.57 -52.35 61.43 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.533 -179.427 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 167' ' ' THR . . . . . . . . . . . . . 98.7 m -56.4 -53.27 59.38 Favored 'General case' 0 C--N 1.33 -0.26 0 N-CA-C 112.528 0.566 . . . . 0.0 112.528 -178.88 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 168' ' ' VAL . . . . . 0.427 HG23 ' O ' ' A' ' 164' ' ' ARG . 72.1 t -54.08 -45.15 65.24 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.225 0 N-CA-C 112.016 0.376 . . . . 0.0 112.016 -179.127 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 169' ' ' VAL . . . . . 0.472 HG23 ' O ' ' A' ' 165' ' ' ASN . 54.2 t -55.39 -64.45 0.47 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 N-CA-C 111.831 0.308 . . . . 0.0 111.831 -179.387 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 170' ' ' LEU . . . . . 0.458 ' HG ' ' O ' ' A' ' 166' ' ' LEU . 1.1 pp -62.67 -29.68 70.82 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.657 -0.247 . . . . 0.0 111.626 -179.39 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 171' ' ' TRP . . . . . . . . . . . . . 4.1 m0 -69.79 -32.32 70.73 Favored 'General case' 0 C--N 1.332 -0.183 0 CA-C-O 121.126 0.488 . . . . 0.0 110.184 179.207 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 172' ' ' ALA . . . . . 0.401 ' C ' ' HD2' ' A' ' 175' ' ' PRO . . . -71.83 -6.5 42.12 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 115.595 -0.73 . . . . 0.0 110.996 -179.848 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 173' ' ' ILE . . . . . 0.475 ' O ' HG12 ' A' ' 177' ' ' ILE . 48.2 mm -85.41 -23.76 7.09 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.245 0 CA-C-N 115.99 -0.55 . . . . 0.0 110.736 179.647 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 174' ' ' TYR . . . . . 0.408 ' N ' ' CD ' ' A' ' 175' ' ' PRO . 20.6 m-85 -54.08 -48.48 93.95 Favored Pre-proline 0 N--CA 1.464 0.232 0 CA-C-N 116.341 -0.39 . . . . 0.0 111.203 179.791 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 175' ' ' PRO . . . . . 0.505 ' HB3' ' HZ ' ' A' ' 127' ' ' PHE . 93.3 Cg_exo -44.6 -33.2 6.51 Favored 'Trans proline' 0 C--N 1.351 0.697 0 C-N-CA 122.287 1.991 . . . . 0.0 112.097 178.894 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 176' ' ' PHE . . . . . 0.517 ' O ' ' HG ' ' A' ' 180' ' ' LEU . 93.0 m-85 -80.63 -50.32 10.1 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 115.691 -0.686 . . . . 0.0 111.851 -179.876 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 177' ' ' ILE . . . . . 0.475 HG12 ' O ' ' A' ' 173' ' ' ILE . 4.6 mm -63.78 -30.91 51.18 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.56 0 N-CA-C 112.533 0.568 . . . . 0.0 112.533 -177.966 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 178' ' ' TRP . . . . . 0.4 ' HH2' ' HB2' ' A' ' 123' ' ' ARG . 84.0 t90 -73.7 -45.67 50.88 Favored 'General case' 0 C--N 1.331 -0.2 0 CA-C-O 120.833 0.349 . . . . 0.0 110.904 179.904 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 179' ' ' LEU . . . . . 0.527 HD23 HD23 ' A' ' 180' ' ' LEU . 0.5 OUTLIER -73.86 -54.82 7.14 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.027 -0.533 . . . . 0.0 111.635 -179.053 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild core ' A' A ' 180' ' ' LEU . . . . . 0.629 HD22 HD11 ' A' ' 187' ' ' LEU . 16.6 mt -62.41 -46.34 89.02 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.563 -0.29 . . . . 0.0 111.378 -179.245 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . -54.64 173.55 0.77 Allowed Glycine 0 CA--C 1.523 0.536 0 C-N-CA 120.296 -0.954 . . . . 0.0 112.514 179.707 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 182' ' ' PRO . . . . . 0.501 ' HA ' ' HB2' ' A' ' 186' ' ' ALA . 86.9 Cg_exo -45.95 -45.3 17.65 Favored 'Trans proline' 0 CA--C 1.536 0.615 0 C-N-CA 122.813 2.342 . . . . 0.0 113.801 -179.849 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 183' ' ' PRO . . . . . 0.434 ' HD3' ' HB2' ' A' ' 182' ' ' PRO . 89.0 Cg_exo -45.37 -34.24 10.09 Favored 'Trans proline' 0 C--N 1.356 0.924 0 C-N-CA 122.281 1.987 . . . . 0.0 113.429 -179.828 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 184' ' ' GLY . . . . . . . . . . . . . . . -109.68 -123.75 4.71 Favored Glycine 0 C--N 1.333 0.368 0 C-N-CA 120.299 -0.953 . . . . 0.0 113.114 -179.652 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 185' ' ' VAL . . . . . . . . . . . . . 11.2 m -62.44 -21.77 27.93 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.218 0 N-CA-C 112.252 0.464 . . . . 0.0 112.252 -179.315 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 186' ' ' ALA . . . . . 0.501 ' HB2' ' HA ' ' A' ' 182' ' ' PRO . . . 57.12 85.63 0.08 Allowed 'General case' 0 N--CA 1.463 0.222 0 CA-C-O 120.862 0.363 . . . . 0.0 111.761 179.693 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 187' ' ' LEU . . . . . 0.629 HD11 HD22 ' A' ' 180' ' ' LEU . 12.6 mt -92.62 -49.66 5.99 Favored 'General case' 0 C--N 1.332 -0.192 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.375 179.806 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 188' ' ' LEU . . . . . 0.588 HD13 HG11 ' A' ' 192' ' ' VAL . 79.7 mt -101.41 -159.81 0.76 Allowed 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 115.946 -0.57 . . . . 0.0 111.1 -179.333 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 189' ' ' THR . . . . . . . . . . . . . 2.0 t -96.55 147.66 33.28 Favored Pre-proline 0 C--N 1.33 -0.277 0 CA-C-N 116.089 -0.505 . . . . 0.0 111.256 -179.793 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 190' ' ' PRO . . . . . 0.435 ' O ' HG23 ' A' ' 194' ' ' VAL . 77.1 Cg_exo -47.62 -39.29 29.77 Favored 'Trans proline' 0 C--N 1.351 0.685 0 C-N-CA 122.681 2.254 . . . . 0.0 112.74 179.967 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 191' ' ' THR . . . . . . . . . . . . . 73.7 p -57.77 -44.05 85.94 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.315 -0.402 . . . . 0.0 111.357 -179.754 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 192' ' ' VAL . . . . . 0.588 HG11 HD13 ' A' ' 188' ' ' LEU . 40.8 t -68.25 -42.64 84.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.242 -0.436 . . . . 0.0 111.146 179.933 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 193' ' ' ASP . . . . . . . . . . . . . 25.6 t70 -58.29 -50.32 74.02 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.254 -0.43 . . . . 0.0 111.176 -179.849 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 194' ' ' VAL . . . . . 0.504 HG21 HD22 ' A' ' 4' ' ' LEU . 59.6 t -60.93 -35.71 66.89 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.35 -0.386 . . . . 0.0 110.982 179.896 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 195' ' ' ALA . . . . . . . . . . . . . . . -58.39 -48.39 80.8 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.466 -0.334 . . . . 0.0 111.143 179.858 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 196' ' ' LEU . . . . . . . . . . . . . 52.7 mt -68.27 -44.99 74.34 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.327 -0.397 . . . . 0.0 110.651 179.696 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 197' ' ' ILE . . . . . 0.412 HG13 ' NH2' ' A' ' 72' ' ' ARG . 20.2 mm -56.29 -59.12 3.16 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.368 0 CA-C-N 115.805 -0.634 . . . . 0.0 110.787 179.643 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 198' ' ' VAL . . . . . . . . . . . . . 49.3 t -52.26 -35.1 19.04 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.484 0 CA-C-N 115.657 -0.701 . . . . 0.0 109.55 178.728 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 199' ' ' TYR . . . . . . . . . . . . . 48.7 t80 -70.15 -32.1 69.92 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 115.482 -0.781 . . . . 0.0 110.523 179.641 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 200' ' ' LEU . . . . . 0.511 ' O ' HG12 ' A' ' 203' ' ' VAL . 40.8 mt -70.35 -43.97 69.12 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 115.903 -0.589 . . . . 0.0 111.553 -179.609 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 201' ' ' ASP . . . . . . . . . . . . . 8.5 m-20 -70.04 -38.37 75.83 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 121.087 0.47 . . . . 0.0 110.521 -179.971 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 202' ' ' LEU . . . . . 0.573 ' O ' HG22 ' A' ' 206' ' ' VAL . 2.7 mt -70.67 -33.09 70.56 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 115.721 -0.672 . . . . 0.0 111.95 -179.389 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 203' ' ' VAL . . . . . 0.511 HG12 ' O ' ' A' ' 200' ' ' LEU . 13.4 p -72.47 -36.08 53.34 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.297 0 C-N-CA 120.856 -0.338 . . . . 0.0 110.848 -178.651 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 204' ' ' THR . . . . . . . . . . . . . 82.4 m -66.29 -58.32 5.61 Favored 'General case' 0 C--N 1.328 -0.328 0 C-N-CA 120.797 -0.361 . . . . 0.0 111.47 179.443 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 205' ' ' LYS . . . . . 0.713 ' HE2' ' HB2' ' A' ' 47' ' ' ALA . 57.3 mttp -61.1 -60.15 4.23 Favored 'General case' 0 C--N 1.329 -0.304 0 N-CA-C 112.974 0.731 . . . . 0.0 112.974 -177.697 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 206' ' ' VAL . . . . . 0.573 HG22 ' O ' ' A' ' 202' ' ' LEU . 1.0 OUTLIER -71.1 -36.31 62.35 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.434 0 N-CA-C 112.103 0.409 . . . . 0.0 112.103 -179.471 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild core ' A' A ' 207' ' ' GLY . . . . . 0.564 ' O ' HG13 ' A' ' 211' ' ' ILE . . . -55.91 -61.48 7.39 Favored Glycine 0 C--N 1.331 0.258 0 C-N-CA 120.534 -0.841 . . . . 0.0 113.623 -178.691 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 208' ' ' PHE . . . . . 0.605 ' HB2' ' HG ' ' A' ' 163' ' ' LEU . 0.7 OUTLIER -72.35 -29.67 64.01 Favored 'General case' 0 C--O 1.224 -0.289 0 CA-C-N 117.433 0.617 . . . . 0.0 110.465 -179.632 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild core ' A' A ' 209' ' ' GLY . . . . . 0.53 ' O ' ' HB3' ' A' ' 212' ' ' ALA . . . -64.66 -32.08 83.03 Favored Glycine 0 N--CA 1.448 -0.514 0 CA-C-N 115.89 -0.595 . . . . 0.0 111.916 179.24 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 210' ' ' PHE . . . . . . . . . . . . . 3.3 m-85 -73.39 -47.23 43.62 Favored 'General case' 0 CA--C 1.512 -0.5 0 N-CA-C 108.242 -1.021 . . . . 0.0 108.242 178.536 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 211' ' ' ILE . . . . . 0.564 HG13 ' O ' ' A' ' 207' ' ' GLY . 4.7 mt -63.81 -27.5 42.99 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.56 0 N-CA-C 107.342 -1.355 . . . . 0.0 107.342 176.273 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 212' ' ' ALA . . . . . 0.53 ' HB3' ' O ' ' A' ' 209' ' ' GLY . . . -64.85 -39.62 93.86 Favored 'General case' 0 N--CA 1.45 -0.463 0 CA-C-N 114.335 -1.302 . . . . 0.0 110.745 179.986 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 213' ' ' LEU . . . . . . . . . . . . . 48.6 mt -67.49 -49.55 62.99 Favored 'General case' 0 C--N 1.333 -0.128 0 CA-C-N 115.511 -0.768 . . . . 0.0 111.445 -179.565 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 214' ' ' ASP . . . . . . . . . . . . . 15.9 t70 -58.62 -51.08 71.45 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.938 0.399 . . . . 0.0 110.766 -179.908 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 215' ' ' ALA . . . . . . . . . . . . . . . -60.85 -53.42 57.5 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 115.936 -0.574 . . . . 0.0 111.214 -179.901 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 216' ' ' ALA . . . . . . . . . . . . . . . -53.32 -37.02 61.91 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.128 -179.963 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 217' ' ' ALA . . . . . . . . . . . . . . . -65.4 -33.87 76.96 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.108 -0.497 . . . . 0.0 110.347 179.577 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 218' ' ' THR . . . . . . . . . . . . . 67.0 m . . . . . 0 C--N 1.33 -0.263 0 CA-C-N 115.742 -0.663 . . . . 0.0 110.976 179.483 . . . . . . . . 0 0 . 1 . 026 nuclear nobuild core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.449 -0.439 0 N-CA-C 112.465 -0.254 . . . . 0.0 112.465 . . . . . . . . . 0 0 . 1 . 026 nuclear nobuild core ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -71.47 -37.43 71.33 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.909 0.385 . . . . 0.0 110.742 -179.971 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 65.4 p -64.19 -32.39 73.95 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.149 -179.967 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 11.8 p -57.29 -35.37 69.72 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.034 -0.53 . . . . 0.0 111.145 -179.818 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 7' ' ' LEU . . . . . . . . . . . . . 4.3 mm? -57.57 -50.94 71.47 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.295 -0.412 . . . . 0.0 111.154 179.793 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 8' ' ' PHE . . . . . 0.593 ' HB2' ' HB2' ' A' ' 55' ' ' ALA . 65.6 m-85 -65.84 -32.54 74.12 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.34 -0.391 . . . . 0.0 110.916 -179.706 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 9' ' ' TRP . . . . . 0.428 ' O ' HG13 ' A' ' 13' ' ' ILE . 23.2 m95 -67.09 -49.89 63.45 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-N 116.065 -0.516 . . . . 0.0 110.388 -179.524 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 89.5 mt -59.18 -47.05 86.74 Favored 'General case' 0 C--N 1.326 -0.45 0 CA-C-N 115.72 -0.673 . . . . 0.0 109.973 179.57 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . 0.422 ' O ' ' HG2' ' A' ' 15' ' ' MET . . . -57.67 -42.96 94.55 Favored Glycine 0 N--CA 1.445 -0.722 0 C-N-CA 120.634 -0.794 . . . . 0.0 111.363 179.062 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -56.36 -35.31 67.54 Favored 'General case' 0 C--N 1.331 -0.196 0 CA-C-O 120.939 0.4 . . . . 0.0 110.68 179.737 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 13' ' ' ILE . . . . . 0.428 HG13 ' O ' ' A' ' 9' ' ' TRP . 63.7 mt -62.32 -46.46 96.37 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 CA-C-N 116.002 -0.545 . . . . 0.0 110.082 179.334 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -59.41 -40.67 96.4 Favored Glycine 0 N--CA 1.45 -0.399 0 C-N-CA 120.799 -0.715 . . . . 0.0 112.512 179.666 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 15' ' ' MET . . . . . 0.422 ' HG2' ' O ' ' A' ' 11' ' ' GLY . 13.8 mmm -62.93 -39.14 93.68 Favored 'General case' 0 C--N 1.332 -0.189 0 CA-C-O 120.824 0.345 . . . . 0.0 110.656 -179.946 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 16' ' ' LEU . . . . . 0.427 HD13 ' O ' ' A' ' 16' ' ' LEU . 0.5 OUTLIER -59.11 -45.18 91.56 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.029 -0.532 . . . . 0.0 110.582 179.741 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 51.1 t -59.21 -48.63 86.26 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.2 0 CA-C-N 116.354 -0.384 . . . . 0.0 110.98 179.965 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -63.69 -48.42 77.39 Favored Glycine 0 N--CA 1.452 -0.283 0 C-N-CA 120.805 -0.712 . . . . 0.0 112.438 179.926 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 47.6 m -49.71 -41.19 42.87 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.735 0.302 . . . . 0.0 111.552 -179.445 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 78.0 mt -72.04 -41.61 67.29 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.425 -0.352 . . . . 0.0 111.393 179.841 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -62.57 -29.91 70.93 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.309 -0.405 . . . . 0.0 111.792 -179.65 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 22' ' ' PHE . . . . . 0.632 ' HB2' HG22 ' A' ' 41' ' ' VAL . 3.4 m-85 -89.99 -34.84 15.84 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.501 -0.318 . . . . 0.0 111.261 -179.256 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -70.43 -49.84 44.61 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.455 -0.339 . . . . 0.0 111.238 -179.993 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 24' ' ' TRP . . . . . . . . . . . . . 1.2 t-105 -59.46 -39.24 83.02 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.045 -0.525 . . . . 0.0 110.899 179.974 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.328 -0.342 0 CA-C-N 116.293 -0.412 . . . . 0.0 110.992 179.938 . . . . . . . . 0 0 . 1 . 026 nuclear nobuild core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.453 -0.229 0 N-CA-C 112.711 -0.156 . . . . 0.0 112.711 . . . . . . . . . 0 0 . 1 . 026 nuclear nobuild core ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 38.5 mt-10 -90.53 -20.74 22.31 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-O 120.807 0.336 . . . . 0.0 110.812 179.951 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 34' ' ' ARG . . . . . . . . . . . . . 38.5 ttm180 -48.37 -29.36 3.9 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 115.9 -0.591 . . . . 0.0 111.68 -179.512 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 35' ' ' ARG . . . . . 0.424 ' NE ' ' HA ' ' A' ' 35' ' ' ARG . 5.5 mmp_? -59.23 -46.6 88.04 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.808 0.337 . . . . 0.0 111.118 179.923 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 73.8 m-85 -67.63 -30.23 69.74 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.252 -179.848 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 37' ' ' TYR . . . . . 0.429 ' O ' HG23 ' A' ' 41' ' ' VAL . 76.5 m-85 -74.13 -54.7 7.24 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.538 -179.406 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 10.5 p -56.72 -36.18 48.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-O 120.979 0.418 . . . . 0.0 110.387 179.884 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 52.5 m -68.9 -49.96 53.69 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 115.617 -0.72 . . . . 0.0 110.559 179.216 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 40' ' ' LEU . . . . . 0.499 HD12 HD12 ' A' ' 43' ' ' ILE . 22.5 tp -55.53 -50.02 71.08 Favored 'General case' 0 C--O 1.237 0.438 0 CA-C-N 115.718 -0.674 . . . . 0.0 110.374 179.651 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . 0.632 HG22 ' HB2' ' A' ' 22' ' ' PHE . 83.7 t -59.36 -34.24 53.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 115.769 -0.65 . . . . 0.0 109.94 178.912 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -58.56 -38.25 90.83 Favored Glycine 0 N--CA 1.448 -0.547 0 C-N-CA 120.71 -0.757 . . . . 0.0 111.453 179.503 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 43' ' ' ILE . . . . . 0.499 HD12 HD12 ' A' ' 40' ' ' LEU . 2.4 mt -65.21 -59.31 4.31 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.217 0 CA-C-O 120.863 0.363 . . . . 0.0 110.593 179.464 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 77.6 p -59.56 -24.67 63.91 Favored 'General case' 0 C--N 1.331 -0.218 0 CA-C-N 115.991 -0.549 . . . . 0.0 111.344 -179.666 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -75.3 -57.69 4.21 Favored Glycine 0 CA--C 1.518 0.24 0 C-N-CA 120.745 -0.74 . . . . 0.0 112.861 -179.653 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 22.6 pt -58.25 -35.27 52.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-O 120.908 0.385 . . . . 0.0 110.762 -179.896 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 47' ' ' ALA . . . . . 0.71 ' HB2' ' HE2' ' A' ' 205' ' ' LYS . . . -63.91 -49.73 71.48 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.001 -0.545 . . . . 0.0 111.07 179.764 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -54.52 -36.55 64.37 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.857 179.999 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 0.5 OUTLIER -67.04 -42.99 89.21 Favored 'Isoleucine or valine' 0 N--CA 1.432 -1.371 0 CA-C-N 116.031 -0.531 . . . . 0.0 111.486 179.797 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . 0.435 ' HA ' HG22 ' A' ' 53' ' ' VAL . . . -67.85 -33.67 75.21 Favored 'General case' 0 C--N 1.333 -0.137 0 CA-C-N 116.43 -0.35 . . . . 0.0 111.463 179.954 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 51' ' ' TYR . . . . . 0.461 ' O ' ' HB3' ' A' ' 8' ' ' PHE . 31.5 m-85 -70.59 -36.77 73.73 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.77 -179.525 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -71.55 -42.42 67.9 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-N 115.985 -0.552 . . . . 0.0 111.531 179.985 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 53' ' ' VAL . . . . . 0.508 HG23 ' N ' ' A' ' 54' ' ' MET . 35.5 m -67.06 -50.7 61.59 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.173 0 CA-C-N 116.556 -0.293 . . . . 0.0 111.451 -179.629 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 54' ' ' MET . . . . . 0.508 ' N ' HG23 ' A' ' 53' ' ' VAL . 78.1 mtm -61.14 -32.04 71.75 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-O 121.047 0.451 . . . . 0.0 110.296 179.775 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 55' ' ' ALA . . . . . 0.593 ' HB2' ' HB2' ' A' ' 8' ' ' PHE . . . -66.44 -38.43 87.38 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 115.753 -0.658 . . . . 0.0 111.015 179.42 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 97.2 mt -71.25 -12.88 61.69 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.039 -0.528 . . . . 0.0 111.238 -179.817 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 101.05 -21.03 45.13 Favored Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.649 -0.786 . . . . 0.0 112.817 179.819 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 30.1 m -66.63 138.58 22.66 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.238 0 CA-C-O 120.872 0.367 . . . . 0.0 111.018 -179.981 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 101.8 -11.52 57.67 Favored Glycine 0 N--CA 1.45 -0.402 0 C-N-CA 120.815 -0.707 . . . . 0.0 112.413 -179.7 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 60' ' ' TRP . . . . . . . . . . . . . 22.0 m0 -78.39 117.38 19.56 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.699 0.285 . . . . 0.0 110.727 179.793 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 10.0 p -109.99 129.54 23.83 Favored Pre-proline 0 C--N 1.329 -0.295 0 CA-C-N 116.438 -0.347 . . . . 0.0 111.078 179.836 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 86.5 Cg_endo -75.96 140.61 23.08 Favored 'Trans proline' 0 C--N 1.35 0.637 0 C-N-CA 122.404 2.07 . . . . 0.0 112.111 179.897 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 81.9 t -138.94 96.13 0.99 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.041 -0.527 . . . . 0.0 110.937 -179.767 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . 58.48 -86.71 0.02 OUTLIER 'General case' 0 C--N 1.332 -0.195 0 CA-C-N 116.001 -0.545 . . . . 0.0 111.315 -179.906 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 40.8 tt0 -121.04 -26.19 5.19 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.398 -0.364 . . . . 0.0 110.781 179.959 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 66' ' ' ARG . . . . . . . . . . . . . 76.0 ttt-85 -102.11 154.55 18.89 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.576 -179.954 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 86.0 m -113.37 121.24 43.76 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 120.882 0.373 . . . . 0.0 111.57 -179.741 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 68' ' ' VAL . . . . . 0.417 HG21 ' HA ' ' A' ' 117' ' ' MET . 21.8 t -93.21 146.89 5.88 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-N 115.978 -0.555 . . . . 0.0 110.374 179.344 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 69' ' ' PHE . . . . . . . . . . . . . 30.3 m-85 -106.87 112.31 25.21 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-O 120.836 0.351 . . . . 0.0 110.152 -179.494 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 70' ' ' VAL . . . . . 0.561 ' HB ' ' HD3' ' A' ' 71' ' ' PRO . 11.2 t -68.6 -50.22 26.61 Favored Pre-proline 0 C--N 1.326 -0.45 0 CA-C-N 115.986 -0.552 . . . . 0.0 112.361 -178.85 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 71' ' ' PRO . . . . . 0.561 ' HD3' ' HB ' ' A' ' 70' ' ' VAL . 24.6 Cg_exo -63.28 -18.35 64.41 Favored 'Trans proline' 0 C--N 1.351 0.7 0 C-N-CA 122.253 1.968 . . . . 0.0 113.068 -179.455 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 70.6 ttt180 -70.69 -55.48 8.6 Favored 'General case' 0 C--O 1.235 0.316 0 CA-C-O 120.88 0.371 . . . . 0.0 111.661 -179.33 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 73' ' ' TYR . . . . . . . . . . . . . 98.8 m-85 -71.86 -33.27 68.27 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.525 -0.307 . . . . 0.0 110.72 -179.519 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 74' ' ' ILE . . . . . 0.489 HG22 ' HA ' ' A' ' 71' ' ' PRO . 0.3 OUTLIER -65.96 -37.67 80.37 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.307 0 N-CA-C 109.446 -0.575 . . . . 0.0 109.446 179.017 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild core ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 33.1 t70 -61.65 -37.33 83.65 Favored 'General case' 0 N--CA 1.453 -0.286 0 N-CA-C 109.251 -0.648 . . . . 0.0 109.251 178.734 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 76' ' ' TRP . . . . . . . . . . . . . 45.8 m0 -66.66 -29.91 70.05 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 115.642 -0.708 . . . . 0.0 110.114 179.019 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 77' ' ' ILE . . . . . 0.463 HG12 ' HB3' ' A' ' 109' ' ' MET . 97.0 mt -71.73 -29.62 34.84 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 115.87 -0.605 . . . . 0.0 110.737 179.447 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 51.8 mt -90.43 -17.17 27.66 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 116.0 -0.546 . . . . 0.0 111.776 179.994 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 79' ' ' THR . . . . . 0.409 ' O ' HG12 ' A' ' 83' ' ' ILE . 69.7 p -102.94 -52.63 3.01 Favored 'General case' 0 C--N 1.332 -0.189 0 N-CA-C 113.311 0.856 . . . . 0.0 113.311 -178.371 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 80' ' ' THR . . . . . 0.697 ' HB ' ' HD3' ' A' ' 81' ' ' PRO . 37.4 m -50.2 -55.7 23.15 Favored Pre-proline 0 CA--C 1.533 0.292 0 N-CA-C 112.537 0.569 . . . . 0.0 112.537 -178.284 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 81' ' ' PRO . . . . . 0.697 ' HD3' ' HB ' ' A' ' 80' ' ' THR . 39.2 Cg_exo -61.06 -21.07 70.42 Favored 'Trans proline' 0 C--N 1.351 0.666 0 C-N-CA 121.55 1.5 . . . . 0.0 111.587 179.818 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 82' ' ' LEU . . . . . . . . . . . . . 14.4 tp -76.99 -33.17 57.62 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 115.811 -0.631 . . . . 0.0 110.599 179.847 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 83' ' ' ILE . . . . . 0.409 HG12 ' O ' ' A' ' 79' ' ' THR . 36.3 mm -69.92 -53.45 23.84 Favored 'Isoleucine or valine' 0 C--O 1.232 0.173 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.214 179.326 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 84' ' ' VAL . . . . . 0.467 HG21 ' OD1' ' A' ' 105' ' ' ASN . 34.6 m -59.61 -32.46 49.22 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.224 0 N-CA-C 109.4 -0.592 . . . . 0.0 109.4 178.637 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 85' ' ' TYR . . . . . . . . . . . . . 68.7 t80 -60.68 -43.88 97.17 Favored 'General case' 0 N--CA 1.452 -0.356 0 CA-C-N 115.455 -0.793 . . . . 0.0 109.047 178.606 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 86' ' ' PHE . . . . . . . . . . . . . 2.1 t80 -53.52 -50.25 65.84 Favored 'General case' 0 C--O 1.233 0.199 0 CA-C-N 115.632 -0.713 . . . . 0.0 109.734 179.407 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 87' ' ' LEU . . . . . 0.568 ' HA ' HD12 ' A' ' 90' ' ' LEU . 8.9 mp -59.72 -28.34 67.25 Favored 'General case' 0 C--N 1.332 -0.188 0 CA-C-N 115.785 -0.643 . . . . 0.0 110.665 179.618 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -65.28 -42.45 96.2 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.65 -0.786 . . . . 0.0 111.903 179.697 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 89' ' ' LEU . . . . . 0.423 ' N ' HD12 ' A' ' 89' ' ' LEU . 8.8 mp -64.5 -37.22 86.77 Favored 'General case' 0 N--CA 1.45 -0.474 0 CA-C-O 121.118 0.485 . . . . 0.0 110.504 179.387 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 90' ' ' LEU . . . . . 0.568 HD12 ' HA ' ' A' ' 87' ' ' LEU . 97.9 mt -55.32 -59.07 5.31 Favored 'General case' 0 C--N 1.326 -0.455 0 CA-C-N 115.368 -0.833 . . . . 0.0 111.162 179.905 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 91' ' ' ALA . . . . . 0.564 ' HB2' ' HB2' ' A' ' 149' ' ' ALA . . . -71.69 -54.82 9.1 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.085 -0.507 . . . . 0.0 111.382 -179.79 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 110.88 59.46 0.48 Allowed Glycine 0 N--CA 1.45 -0.372 0 C-N-CA 120.95 -0.643 . . . . 0.0 112.255 -179.892 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 93' ' ' LEU . . . . . 0.501 HD23 ' HB3' ' A' ' 97' ' ' GLU . 8.9 mp -77.19 169.29 18.6 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.915 0.388 . . . . 0.0 111.133 -179.722 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 94' ' ' ASP . . . . . . . . . . . . . 9.7 m-20 -91.09 163.65 14.22 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.05 -0.523 . . . . 0.0 110.704 179.827 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 80.6 p -53.96 -27.56 32.05 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.331 -0.395 . . . . 0.0 110.988 -179.926 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 80.5 mtm180 -73.07 -53.43 11.09 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.299 -0.409 . . . . 0.0 110.757 179.81 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 97' ' ' GLU . . . . . 0.501 ' HB3' HD23 ' A' ' 93' ' ' LEU . 44.9 mt-10 -57.44 -39.41 76.19 Favored 'General case' 0 C--N 1.332 -0.191 0 CA-C-N 116.122 -0.49 . . . . 0.0 111.104 -179.857 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 98' ' ' PHE . . . . . 0.45 ' O ' HG12 ' A' ' 102' ' ' ILE . 12.6 m-85 -60.29 -51.54 69.12 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.366 -0.379 . . . . 0.0 110.857 179.969 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -59.31 -28.15 64.08 Favored Glycine 0 N--CA 1.452 -0.291 0 C-N-CA 120.675 -0.774 . . . . 0.0 112.497 -179.85 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 96.3 mt -73.4 -47.05 47.4 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-O 120.823 0.344 . . . . 0.0 111.345 -179.868 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 59.4 t -67.38 -43.2 87.89 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.399 0 CA-C-N 116.235 -0.438 . . . . 0.0 111.545 -179.675 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 102' ' ' ILE . . . . . 0.45 HG12 ' O ' ' A' ' 98' ' ' PHE . 49.5 mm -64.83 -48.92 82.4 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.386 -0.37 . . . . 0.0 111.4 -179.516 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 14.0 t -60.4 -31.05 70.0 Favored 'General case' 0 C--N 1.332 -0.169 0 CA-C-O 120.811 0.339 . . . . 0.0 110.814 -179.982 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 104' ' ' LEU . . . . . 0.499 ' O ' HG23 ' A' ' 108' ' ' VAL . 45.6 tp -61.95 -54.45 41.58 Favored 'General case' 0 C--N 1.332 -0.185 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.382 179.486 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 105' ' ' ASN . . . . . 0.538 HD21 HD13 ' A' ' 137' ' ' LEU . 4.9 m120 -61.87 -25.48 67.57 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 116.053 -0.521 . . . . 0.0 110.959 -179.986 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 52.2 m -64.27 -54.89 26.24 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.343 -0.39 . . . . 0.0 111.12 179.992 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 107' ' ' VAL . . . . . 0.438 HG12 ' O ' ' A' ' 104' ' ' LEU . 13.4 p -64.14 -36.37 76.75 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.205 0 CA-C-N 116.382 -0.372 . . . . 0.0 111.049 -179.989 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . 0.499 HG23 ' O ' ' A' ' 104' ' ' LEU . 96.4 t -64.13 -52.65 53.44 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.761 179.664 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 109' ' ' MET . . . . . 0.463 ' HB3' HG12 ' A' ' 77' ' ' ILE . 9.7 tpp -62.11 -26.15 68.13 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 115.872 -0.604 . . . . 0.0 110.705 -179.973 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 29.7 tp -75.69 -33.87 60.38 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.163 -0.472 . . . . 0.0 110.204 179.396 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -62.13 -54.37 42.18 Favored 'General case' 0 C--N 1.332 -0.177 0 CA-C-N 115.924 -0.58 . . . . 0.0 110.377 179.301 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . -61.75 -37.32 94.09 Favored Glycine 0 N--CA 1.45 -0.388 0 C-N-CA 120.645 -0.788 . . . . 0.0 111.652 179.435 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 113' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER -48.23 -69.88 0.11 Allowed 'General case' 0 CA--C 1.521 -0.158 0 N-CA-C 109.755 -0.461 . . . . 0.0 109.755 179.219 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 114' ' ' ALA . . . . . 0.403 ' O ' HG13 ' A' ' 118' ' ' VAL . . . -65.1 -17.79 64.76 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 115.615 -0.72 . . . . 0.0 110.271 178.875 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 115' ' ' GLY . . . . . 0.528 ' HA2' HD22 ' A' ' 126' ' ' LEU . . . -52.52 -47.99 56.15 Favored Glycine 0 C--N 1.334 0.465 0 C-N-CA 121.005 -0.617 . . . . 0.0 111.791 179.45 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -78.26 -23.1 47.46 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-O 120.666 0.27 . . . . 0.0 111.571 179.705 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 117' ' ' MET . . . . . 0.417 ' HA ' HG21 ' A' ' 68' ' ' VAL . 40.9 ttm -94.8 19.2 10.44 Favored 'General case' 0 CA--C 1.533 0.305 0 CA-C-N 116.457 -0.338 . . . . 0.0 111.859 -179.257 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 118' ' ' VAL . . . . . 0.45 HG21 ' HB3' ' A' ' 123' ' ' ARG . 21.8 m -69.17 150.88 97.28 Favored Pre-proline 0 C--N 1.331 -0.227 0 CA-C-O 120.554 0.216 . . . . 0.0 111.17 179.736 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 119' ' ' PRO . . . . . . . . . . . . . 92.9 Cg_endo -81.29 -4.96 12.66 Favored 'Trans proline' 0 C--N 1.348 0.515 0 C-N-CA 122.699 2.266 . . . . 0.0 112.364 179.846 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -158.2 -131.23 1.26 Allowed Glycine 0 C--N 1.331 0.267 0 C-N-CA 120.834 -0.698 . . . . 0.0 112.653 -179.994 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 37.9 pt -97.48 10.88 5.79 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.226 0 CA-C-O 120.877 0.37 . . . . 0.0 111.161 -179.951 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 16.4 mm-40 -59.8 -18.12 41.13 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.016 -0.538 . . . . 0.0 111.096 179.8 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 123' ' ' ARG . . . . . 0.45 ' HB3' HG21 ' A' ' 118' ' ' VAL . 23.0 ptt180 -50.74 -28.9 10.1 Favored 'General case' 0 C--N 1.331 -0.197 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.778 -179.884 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 124' ' ' TYR . . . . . . . . . . . . . 38.1 m-85 -69.46 -32.91 72.13 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-O 120.828 0.347 . . . . 0.0 110.975 179.965 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 125' ' ' ALA . . . . . . . . . . . . . . . -73.52 -49.94 23.99 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.094 -0.503 . . . . 0.0 111.13 179.942 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 126' ' ' LEU . . . . . 0.528 HD22 ' HA2' ' A' ' 115' ' ' GLY . 7.9 mp -53.36 -55.49 24.49 Favored 'General case' 0 C--N 1.331 -0.201 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.316 179.771 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 127' ' ' PHE . . . . . 0.407 ' HZ ' ' HB3' ' A' ' 175' ' ' PRO . 9.7 t80 -62.82 -33.9 76.18 Favored 'General case' 0 N--CA 1.452 -0.372 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.264 179.568 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 128' ' ' GLY . . . . . . . . . . . . . . . -47.97 -43.23 23.9 Favored Glycine 0 C--N 1.333 0.394 0 C-N-CA 120.167 -1.016 . . . . 0.0 110.778 178.907 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 129' ' ' MET . . . . . 0.421 ' HE1' ' HA ' ' A' ' 108' ' ' VAL . 0.4 OUTLIER -71.27 -38.22 71.86 Favored 'General case' 0 C--N 1.329 -0.312 0 N-CA-C 109.786 -0.45 . . . . 0.0 109.786 178.565 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -65.72 -27.49 72.73 Favored Glycine 0 N--CA 1.451 -0.313 0 CA-C-N 115.757 -0.656 . . . . 0.0 112.695 179.907 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -74.77 -53.66 8.78 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.664 0.268 . . . . 0.0 110.545 179.828 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 132' ' ' VAL . . . . . 0.526 ' O ' HG13 ' A' ' 135' ' ' ILE . 38.7 t -57.2 -39.74 69.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-O 121.567 0.699 . . . . 0.0 109.311 178.675 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -70.99 -33.97 70.93 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-N 115.15 -0.932 . . . . 0.0 110.831 179.41 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 134' ' ' PHE . . . . . 0.437 ' CZ ' ' HA ' ' A' ' 172' ' ' ALA . 35.9 t80 -55.03 -59.22 5.04 Favored 'General case' 0 N--CA 1.453 -0.281 0 CA-C-N 116.353 -0.385 . . . . 0.0 110.397 179.809 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 135' ' ' ILE . . . . . 0.526 HG13 ' O ' ' A' ' 132' ' ' VAL . 0.2 OUTLIER -55.71 -36.63 43.52 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.368 0 CA-C-N 116.012 -0.54 . . . . 0.0 109.862 179.176 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild core ' A' A ' 136' ' ' GLY . . . . . 0.413 ' O ' ' HB3' ' A' ' 139' ' ' TYR . . . -52.77 -42.28 59.06 Favored Glycine 0 C--N 1.334 0.437 0 C-N-CA 120.396 -0.907 . . . . 0.0 111.686 178.86 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 137' ' ' LEU . . . . . 0.538 HD13 HD21 ' A' ' 105' ' ' ASN . 49.1 tp -64.52 -49.25 72.02 Favored 'General case' 0 C--N 1.33 -0.261 0 N-CA-C 110.187 -0.301 . . . . 0.0 110.187 179.161 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 138' ' ' VAL . . . . . . . . . . . . . 59.9 t -54.82 -33.12 27.4 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.928 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.238 179.847 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 139' ' ' TYR . . . . . 0.413 ' HB3' ' O ' ' A' ' 136' ' ' GLY . 18.2 t80 -63.0 -43.32 99.13 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 115.867 -0.606 . . . . 0.0 110.112 178.74 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 140' ' ' TYR . . . . . 0.472 ' HE2' HD22 ' A' ' 104' ' ' LEU . 29.1 m-85 -63.75 -44.49 93.34 Favored 'General case' 0 C--N 1.332 -0.171 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.025 179.658 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 141' ' ' LEU . . . . . 0.445 ' HA ' ' SD ' ' A' ' 145' ' ' MET . 10.4 mp -55.99 -34.37 65.69 Favored 'General case' 0 C--N 1.332 -0.191 0 CA-C-N 116.449 -0.341 . . . . 0.0 110.96 179.887 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 22.2 t -94.62 -17.3 7.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.111 179.85 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . -68.96 -140.61 0.1 OUTLIER Glycine 0 CA--C 1.521 0.441 0 C-N-CA 121.034 -0.603 . . . . 0.0 113.218 -179.789 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 144' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_exo -51.88 -23.58 16.65 Favored 'Trans proline' 0 C--N 1.35 0.614 0 C-N-CA 122.841 2.361 . . . . 0.0 113.004 -179.597 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 145' ' ' MET . . . . . 0.445 ' SD ' ' HA ' ' A' ' 141' ' ' LEU . 34.9 mtt -54.1 -35.68 62.39 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.354 -0.384 . . . . 0.0 111.734 -179.648 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 146' ' ' THR . . . . . . . . . . . . . 46.0 p -79.1 -32.1 44.5 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.83 0.347 . . . . 0.0 111.265 -179.413 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 43.3 tt0 -61.96 -48.91 78.29 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 116.114 -0.494 . . . . 0.0 111.108 -179.917 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 148' ' ' SER . . . . . . . . . . . . . 51.6 m -70.56 -44.89 66.49 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.654 -179.342 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 149' ' ' ALA . . . . . 0.564 ' HB2' ' HB2' ' A' ' 91' ' ' ALA . . . -60.31 -55.08 38.0 Favored 'General case' 0 C--N 1.329 -0.291 0 N-CA-C 112.065 0.395 . . . . 0.0 112.065 -179.256 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 150' ' ' SER . . . . . 0.489 ' HA ' ' HB3' ' A' ' 157' ' ' LYS . 67.6 m -64.03 -8.03 10.48 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.415 -0.357 . . . . 0.0 111.09 -179.681 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 151' ' ' GLN . . . . . . . . . . . . . 24.2 mt-30 -120.99 7.51 10.36 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.342 -0.39 . . . . 0.0 111.193 179.959 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 152' ' ' ARG . . . . . 0.534 ' HA ' ' HE ' ' A' ' 152' ' ' ARG . 5.3 tpm_? -85.55 -52.49 5.79 Favored 'General case' 0 C--N 1.332 -0.165 0 CA-C-O 120.841 0.353 . . . . 0.0 110.678 179.944 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 153' ' ' SER . . . . . 0.653 ' HB2' HG12 ' A' ' 156' ' ' ILE . 18.6 m -158.24 172.9 17.53 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 115.949 -0.568 . . . . 0.0 110.617 179.168 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 154' ' ' SER . . . . . . . . . . . . . 48.4 t -72.17 -40.26 68.08 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.512 179.455 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -77.45 -30.21 54.19 Favored Glycine 0 CA--C 1.518 0.274 0 C-N-CA 120.986 -0.626 . . . . 0.0 112.998 179.917 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 156' ' ' ILE . . . . . 0.653 HG12 ' HB2' ' A' ' 153' ' ' SER . 34.9 mm -58.84 -46.76 90.87 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.226 0 N-CA-C 111.974 0.361 . . . . 0.0 111.974 -179.264 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 157' ' ' LYS . . . . . 0.489 ' HB3' ' HA ' ' A' ' 150' ' ' SER . 6.5 ptpp? -60.64 -35.67 76.76 Favored 'General case' 0 C--N 1.331 -0.234 0 N-CA-C 111.588 0.218 . . . . 0.0 111.588 -179.394 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 49.0 m -66.24 -44.53 83.46 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.941 0.401 . . . . 0.0 111.236 -179.752 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 159' ' ' LEU . . . . . 0.459 HD21 ' HB3' ' A' ' 215' ' ' ALA . 5.1 mt -68.64 -37.66 79.87 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.544 -179.743 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 160' ' ' TYR . . . . . 0.406 ' OH ' ' HB3' ' A' ' 145' ' ' MET . 13.8 t80 -68.55 -43.24 77.1 Favored 'General case' 0 C--N 1.327 -0.407 0 N-CA-C 112.267 0.469 . . . . 0.0 112.267 -178.705 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 161' ' ' VAL . . . . . 0.415 HG23 ' N ' ' A' ' 162' ' ' ARG . 24.0 m -63.78 -46.21 95.07 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 C-N-CA 120.989 -0.284 . . . . 0.0 111.717 -179.23 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 162' ' ' ARG . . . . . 0.415 ' N ' HG23 ' A' ' 161' ' ' VAL . 24.9 tpt180 -69.25 -48.63 61.32 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.815 0.34 . . . . 0.0 111.491 -179.76 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 163' ' ' LEU . . . . . . . . . . . . . 1.5 mp -60.89 -54.8 40.62 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.089 -0.505 . . . . 0.0 111.937 -179.183 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 164' ' ' ARG . . . . . . . . . . . . . 6.1 tmm_? -55.94 -50.52 70.53 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 116.073 -0.512 . . . . 0.0 112.179 -178.498 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 165' ' ' ASN . . . . . 0.507 ' O ' HG23 ' A' ' 169' ' ' VAL . 0.9 OUTLIER -52.7 -51.52 59.97 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-O 120.662 0.268 . . . . 0.0 111.458 -179.261 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild core ' A' A ' 166' ' ' LEU . . . . . 0.503 ' O ' ' HG ' ' A' ' 170' ' ' LEU . 3.4 tt -62.6 -52.55 62.92 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 116.385 -0.37 . . . . 0.0 111.713 -179.566 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 167' ' ' THR . . . . . . . . . . . . . 85.1 m -54.72 -53.17 58.46 Favored 'General case' 0 C--N 1.329 -0.296 0 N-CA-C 112.734 0.642 . . . . 0.0 112.734 -178.64 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 168' ' ' VAL . . . . . . . . . . . . . 81.8 t -55.53 -44.34 75.94 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 N-CA-C 112.281 0.474 . . . . 0.0 112.281 -178.723 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 169' ' ' VAL . . . . . 0.507 HG23 ' O ' ' A' ' 165' ' ' ASN . 68.8 t -57.93 -65.19 0.45 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.367 0 N-CA-C 112.409 0.522 . . . . 0.0 112.409 -179.039 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 170' ' ' LEU . . . . . 0.503 ' HG ' ' O ' ' A' ' 166' ' ' LEU . 0.7 OUTLIER -62.4 -31.68 72.4 Favored 'General case' 0 C--N 1.332 -0.195 0 N-CA-C 112.453 0.538 . . . . 0.0 112.453 -178.355 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild core ' A' A ' 171' ' ' TRP . . . . . . . . . . . . . 5.8 m0 -70.12 -31.2 68.62 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-O 120.816 0.341 . . . . 0.0 110.658 179.48 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 172' ' ' ALA . . . . . 0.437 ' HA ' ' CZ ' ' A' ' 134' ' ' PHE . . . -74.21 -6.86 50.3 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.799 -179.763 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 173' ' ' ILE . . . . . 0.504 ' O ' HG12 ' A' ' 177' ' ' ILE . 34.9 mm -85.95 -21.76 7.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 115.901 -0.59 . . . . 0.0 110.383 179.43 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 174' ' ' TYR . . . . . . . . . . . . . 15.7 m-85 -54.42 -50.72 83.5 Favored Pre-proline 0 N--CA 1.463 0.222 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.744 -179.735 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 175' ' ' PRO . . . . . 0.407 ' HB3' ' HZ ' ' A' ' 127' ' ' PHE . 80.3 Cg_exo -46.13 -31.02 8.22 Favored 'Trans proline' 0 C--N 1.352 0.732 0 C-N-CA 122.131 1.887 . . . . 0.0 112.155 179.83 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 176' ' ' PHE . . . . . 0.455 ' O ' ' HG ' ' A' ' 180' ' ' LEU . 74.4 m-85 -80.7 -49.97 10.51 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.88 -0.6 . . . . 0.0 111.826 -179.783 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 177' ' ' ILE . . . . . 0.504 HG12 ' O ' ' A' ' 173' ' ' ILE . 5.3 mm -62.82 -36.33 75.03 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.525 0 N-CA-C 112.454 0.539 . . . . 0.0 112.454 -177.958 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 178' ' ' TRP . . . . . 0.449 ' HH2' ' HB2' ' A' ' 123' ' ' ARG . 71.3 t90 -71.27 -47.55 56.29 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.827 0.346 . . . . 0.0 110.997 -179.89 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 179' ' ' LEU . . . . . 0.441 HD23 HD23 ' A' ' 180' ' ' LEU . 0.5 OUTLIER -69.84 -54.57 12.9 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.677 -179.045 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild core ' A' A ' 180' ' ' LEU . . . . . 0.597 HD22 HD11 ' A' ' 187' ' ' LEU . 26.4 mt -65.06 -39.42 93.24 Favored 'General case' 0 C--N 1.328 -0.355 0 C-N-CA 121.025 -0.27 . . . . 0.0 111.469 -179.252 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . -62.26 -179.38 3.93 Favored Glycine 0 C--N 1.335 0.474 0 C-N-CA 120.031 -1.08 . . . . 0.0 112.196 179.074 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 182' ' ' PRO . . . . . 0.561 ' HA ' ' HB2' ' A' ' 186' ' ' ALA . 72.6 Cg_exo -48.85 -44.12 32.89 Favored 'Trans proline' 0 CA--C 1.536 0.623 0 C-N-CA 122.784 2.323 . . . . 0.0 113.87 179.896 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 183' ' ' PRO . . . . . . . . . . . . . 87.8 Cg_exo -47.62 -26.92 7.11 Favored 'Trans proline' 0 C--N 1.356 0.947 0 C-N-CA 122.279 1.986 . . . . 0.0 113.398 -179.782 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 184' ' ' GLY . . . . . . . . . . . . . . . -120.02 -125.92 3.36 Favored Glycine 0 N--CA 1.45 -0.369 0 C-N-CA 120.271 -0.966 . . . . 0.0 113.212 -179.598 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 185' ' ' VAL . . . . . . . . . . . . . 6.1 m -60.45 -27.58 40.35 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.369 0 N-CA-C 112.319 0.489 . . . . 0.0 112.319 -179.315 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 186' ' ' ALA . . . . . 0.561 ' HB2' ' HA ' ' A' ' 182' ' ' PRO . . . 58.23 82.79 0.13 Allowed 'General case' 0 C--N 1.331 -0.214 0 CA-C-O 120.801 0.334 . . . . 0.0 111.697 179.613 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 187' ' ' LEU . . . . . 0.597 HD11 HD22 ' A' ' 180' ' ' LEU . 8.4 mt -92.21 -49.78 6.0 Favored 'General case' 0 C--N 1.333 -0.151 0 CA-C-N 116.297 -0.411 . . . . 0.0 111.271 179.853 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 188' ' ' LEU . . . . . 0.471 ' HB3' ' H ' ' A' ' 189' ' ' THR . 4.3 mm? -91.16 -161.3 0.8 Allowed 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.002 -0.545 . . . . 0.0 111.571 -179.051 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 189' ' ' THR . . . . . 0.471 ' H ' ' HB3' ' A' ' 188' ' ' LEU . 21.6 m -92.76 137.86 23.89 Favored Pre-proline 0 C--N 1.329 -0.326 0 CA-C-N 115.704 -0.68 . . . . 0.0 110.917 -179.479 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 190' ' ' PRO . . . . . 0.456 ' O ' HG23 ' A' ' 194' ' ' VAL . 95.5 Cg_exo -44.86 -50.04 8.97 Favored 'Trans proline' 0 C--N 1.35 0.626 0 C-N-CA 122.674 2.249 . . . . 0.0 113.259 -179.951 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 191' ' ' THR . . . . . 0.419 HG22 HG22 ' A' ' 189' ' ' THR . 9.7 t -56.26 -39.79 73.18 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-O 120.668 0.271 . . . . 0.0 111.434 -179.606 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 192' ' ' VAL . . . . . 0.454 HG23 ' HB ' ' A' ' 189' ' ' THR . 72.8 t -64.71 -48.66 83.69 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.358 -0.383 . . . . 0.0 111.102 179.93 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 193' ' ' ASP . . . . . . . . . . . . . 27.0 t70 -57.12 -44.58 83.44 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.136 -0.484 . . . . 0.0 111.063 -179.875 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 194' ' ' VAL . . . . . 0.456 HG23 ' O ' ' A' ' 190' ' ' PRO . 89.3 t -60.82 -35.86 67.42 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.247 0 CA-C-N 116.132 -0.486 . . . . 0.0 110.776 179.953 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 195' ' ' ALA . . . . . . . . . . . . . . . -60.1 -47.83 84.26 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-N 116.429 -0.35 . . . . 0.0 111.003 179.583 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 196' ' ' LEU . . . . . . . . . . . . . 86.1 mt -66.58 -42.82 86.39 Favored 'General case' 0 C--N 1.332 -0.158 0 CA-C-N 116.388 -0.369 . . . . 0.0 110.5 179.489 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 197' ' ' ILE . . . . . . . . . . . . . 15.6 mm -56.99 -59.53 3.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.077 -0.51 . . . . 0.0 110.341 179.221 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 198' ' ' VAL . . . . . . . . . . . . . 52.9 t -52.16 -34.76 18.29 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.5 0 CA-C-N 115.717 -0.674 . . . . 0.0 109.375 178.388 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 199' ' ' TYR . . . . . . . . . . . . . 57.5 t80 -69.54 -32.91 72.01 Favored 'General case' 0 C--N 1.331 -0.204 0 CA-C-N 115.462 -0.79 . . . . 0.0 110.623 -179.844 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 200' ' ' LEU . . . . . 0.446 ' O ' HG12 ' A' ' 203' ' ' VAL . 34.6 mt -67.75 -41.55 83.21 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 115.885 -0.598 . . . . 0.0 111.081 -179.896 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 201' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -73.48 -35.02 65.63 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-O 121.147 0.499 . . . . 0.0 110.273 179.447 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 202' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -69.45 -28.38 66.06 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 115.495 -0.775 . . . . 0.0 111.924 -179.823 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 203' ' ' VAL . . . . . 0.446 HG12 ' O ' ' A' ' 200' ' ' LEU . 9.5 p -82.44 -37.75 14.68 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.183 0 N-CA-C 111.804 0.298 . . . . 0.0 111.804 -178.831 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 204' ' ' THR . . . . . . . . . . . . . 88.9 m -67.35 -41.71 84.68 Favored 'General case' 0 C--N 1.33 -0.279 0 C-N-CA 120.798 -0.361 . . . . 0.0 111.297 179.664 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 205' ' ' LYS . . . . . 0.71 ' HE2' ' HB2' ' A' ' 47' ' ' ALA . 57.3 mttp -78.39 -51.56 9.87 Favored 'General case' 0 C--N 1.326 -0.455 0 N-CA-C 112.238 0.458 . . . . 0.0 112.238 -178.601 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 84.8 t -73.22 -37.37 52.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 N-CA-C 111.735 0.272 . . . . 0.0 111.735 -179.514 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 207' ' ' GLY . . . . . . . . . . . . . . . -71.52 -52.62 12.08 Favored Glycine 0 N--CA 1.453 -0.219 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.603 -179.654 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 208' ' ' PHE . . . . . 0.446 ' O ' ' HB2' ' A' ' 212' ' ' ALA . 10.1 t80 -59.6 -40.46 87.54 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-O 120.71 0.29 . . . . 0.0 110.477 179.648 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 209' ' ' GLY . . . . . 0.476 ' O ' ' HB3' ' A' ' 212' ' ' ALA . . . -70.18 -39.27 72.39 Favored Glycine 0 N--CA 1.451 -0.315 0 CA-C-N 115.699 -0.682 . . . . 0.0 113.302 -179.734 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 210' ' ' PHE . . . . . . . . . . . . . 1.1 m-85 -68.35 -43.0 78.41 Favored 'General case' 0 CA--C 1.508 -0.67 0 N-CA-C 107.794 -1.187 . . . . 0.0 107.794 179.099 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 211' ' ' ILE . . . . . . . . . . . . . 85.7 mt -67.49 -28.85 43.52 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.815 0 CA-C-N 114.296 -1.32 . . . . 0.0 107.548 176.688 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 212' ' ' ALA . . . . . 0.476 ' HB3' ' O ' ' A' ' 209' ' ' GLY . . . -67.0 -40.86 87.43 Favored 'General case' 0 N--CA 1.45 -0.472 0 CA-C-N 114.599 -1.182 . . . . 0.0 110.494 179.876 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 213' ' ' LEU . . . . . . . . . . . . . 91.0 mt -70.35 -52.2 24.33 Favored 'General case' 0 C--N 1.33 -0.239 0 CA-C-N 115.304 -0.862 . . . . 0.0 111.754 -179.407 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 214' ' ' ASP . . . . . . . . . . . . . 45.4 m-20 -50.04 -54.63 18.98 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.218 -0.447 . . . . 0.0 111.847 -179.277 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 215' ' ' ALA . . . . . 0.459 ' HB3' HD21 ' A' ' 159' ' ' LEU . . . -60.46 -54.49 44.87 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.432 -0.349 . . . . 0.0 111.541 -179.448 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 216' ' ' ALA . . . . . . . . . . . . . . . -55.86 -32.51 63.71 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-O 120.926 0.394 . . . . 0.0 111.317 -179.763 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 217' ' ' ALA . . . . . . . . . . . . . . . -65.57 -39.89 92.15 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.03 -0.532 . . . . 0.0 110.601 179.877 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 218' ' ' THR . . . . . . . . . . . . . 54.7 m . . . . . 0 C--N 1.329 -0.296 0 CA-C-N 115.993 -0.549 . . . . 0.0 110.757 179.588 . . . . . . . . 0 0 . 1 . 027 nuclear nobuild core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.27 0 CA-C-O 120.464 -0.075 . . . . 0.0 112.975 . . . . . . . . . 0 0 . 1 . 027 nuclear nobuild core ' A' A ' 4' ' ' LEU . . . . . 0.453 HD12 HD22 ' A' ' 7' ' ' LEU . 24.7 tp -57.04 -35.21 69.04 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.828 0.347 . . . . 0.0 111.265 -179.693 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 74.1 p -54.87 -37.88 66.82 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 116.211 -0.45 . . . . 0.0 112.015 -179.637 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 32.1 p -53.84 -35.29 61.32 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 120.823 0.344 . . . . 0.0 111.44 -179.452 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 7' ' ' LEU . . . . . 0.48 HD21 ' O ' ' A' ' 191' ' ' THR . 9.0 mp -58.6 -53.42 58.58 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.227 -179.83 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 8' ' ' PHE . . . . . 0.543 ' HB2' ' HB2' ' A' ' 55' ' ' ALA . 69.9 m-85 -60.46 -32.47 71.42 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.002 -0.544 . . . . 0.0 110.887 -179.837 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 9' ' ' TRP . . . . . . . . . . . . . 32.2 m95 -64.4 -44.39 91.43 Favored 'General case' 0 C--N 1.327 -0.371 0 N-CA-C 109.563 -0.532 . . . . 0.0 109.563 179.612 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 78.8 mt -63.56 -36.76 84.87 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 115.472 -0.785 . . . . 0.0 110.09 179.243 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -64.22 -37.13 94.11 Favored Glycine 0 N--CA 1.448 -0.535 0 CA-C-N 115.619 -0.719 . . . . 0.0 111.806 179.332 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -65.45 -37.51 87.09 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-O 120.856 0.36 . . . . 0.0 110.337 179.634 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 50.1 mm -59.14 -50.22 80.55 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.222 0 CA-C-N 115.937 -0.574 . . . . 0.0 110.432 179.119 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -58.42 -35.09 77.78 Favored Glycine 0 N--CA 1.45 -0.411 0 C-N-CA 120.772 -0.727 . . . . 0.0 112.12 179.536 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 15' ' ' MET . . . . . 0.451 ' HE3' ' CB ' ' A' ' 47' ' ' ALA . 22.7 mmt -66.37 -43.29 86.35 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-O 120.752 0.311 . . . . 0.0 110.892 179.718 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -55.96 -43.71 77.79 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.462 179.739 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 60.6 t -60.71 -46.59 95.68 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.283 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.989 179.903 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -66.17 -49.2 59.13 Favored Glycine 0 C--N 1.33 0.246 0 C-N-CA 120.787 -0.72 . . . . 0.0 112.41 179.685 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 23.6 m -49.61 -42.94 46.08 Favored 'General case' 0 C--N 1.327 -0.39 0 C-N-CA 122.365 0.266 . . . . 0.0 111.579 -179.458 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 65.7 mt -72.38 -42.16 65.55 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.478 -0.328 . . . . 0.0 111.753 179.858 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -61.61 -30.09 70.46 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.312 -0.404 . . . . 0.0 111.577 -179.362 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 22' ' ' PHE . . . . . 0.699 ' HB2' HG22 ' A' ' 41' ' ' VAL . 6.5 m-85 -90.88 -30.76 16.74 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.41 -0.359 . . . . 0.0 111.262 -179.594 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -72.36 -50.38 27.08 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.956 0.407 . . . . 0.0 111.558 -179.548 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 24' ' ' TRP . . . . . . . . . . . . . 4.1 t-105 -62.68 -43.12 99.62 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 115.978 -0.556 . . . . 0.0 111.171 -179.72 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.329 -0.289 0 CA-C-N 116.398 -0.365 . . . . 0.0 110.862 179.855 . . . . . . . . 0 0 . 1 . 027 nuclear nobuild core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.518 0.253 0 N-CA-C 112.644 -0.183 . . . . 0.0 112.644 . . . . . . . . . 0 0 . 1 . 027 nuclear nobuild core ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 37.4 mt-10 -69.43 -25.69 64.24 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.742 0.306 . . . . 0.0 110.99 -179.941 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 34' ' ' ARG . . . . . . . . . . . . . 17.5 tpt180 -53.13 -28.72 27.23 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.076 -0.511 . . . . 0.0 111.478 -179.654 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 41.0 mmt180 -60.17 -43.31 95.91 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-O 120.833 0.349 . . . . 0.0 111.207 -179.843 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 82.0 m-85 -71.72 -29.73 64.87 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.294 -0.412 . . . . 0.0 111.348 -179.779 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 37' ' ' TYR . . . . . 0.467 ' O ' HG23 ' A' ' 41' ' ' VAL . 70.0 m-85 -75.79 -54.98 6.09 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.189 -0.459 . . . . 0.0 111.182 -179.549 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 14.8 p -56.61 -36.52 48.64 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-O 121.007 0.432 . . . . 0.0 110.578 179.774 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 28.5 m -66.06 -51.07 61.54 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 115.9 -0.591 . . . . 0.0 110.82 179.457 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 40' ' ' LEU . . . . . 0.459 HD12 HD12 ' A' ' 43' ' ' ILE . 49.3 tp -59.12 -47.77 84.07 Favored 'General case' 0 C--O 1.235 0.314 0 CA-C-N 115.922 -0.581 . . . . 0.0 110.886 179.964 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . 0.699 HG22 ' HB2' ' A' ' 22' ' ' PHE . 89.9 t -60.63 -34.73 59.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.097 179.195 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 42' ' ' GLY . . . . . 0.428 ' O ' HG12 ' A' ' 46' ' ' ILE . . . -60.98 -38.59 95.74 Favored Glycine 0 N--CA 1.447 -0.587 0 CA-C-N 115.712 -0.676 . . . . 0.0 112.309 179.751 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 43' ' ' ILE . . . . . 0.76 HG22 ' HE3' ' A' ' 205' ' ' LYS . 0.1 OUTLIER -66.97 -56.94 11.82 Favored 'Isoleucine or valine' 0 C--O 1.232 0.145 0 CA-C-O 120.651 0.262 . . . . 0.0 110.989 179.903 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild core ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 48.1 t -62.39 -21.31 65.26 Favored 'General case' 0 C--O 1.233 0.185 0 CA-C-O 120.833 0.349 . . . . 0.0 111.241 -179.892 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -77.06 -58.53 3.39 Favored Glycine 0 CA--C 1.519 0.305 0 C-N-CA 120.754 -0.736 . . . . 0.0 112.642 -179.758 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 46' ' ' ILE . . . . . 0.428 HG12 ' O ' ' A' ' 42' ' ' GLY . 16.1 pt -58.32 -35.87 55.63 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.157 0 CA-C-O 120.932 0.396 . . . . 0.0 110.726 179.94 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 47' ' ' ALA . . . . . 0.687 ' HB2' ' HE2' ' A' ' 205' ' ' LYS . . . -67.96 -39.89 83.29 Favored 'General case' 0 C--N 1.326 -0.45 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.771 179.056 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 48' ' ' ALA . . . . . 0.438 ' HB2' ' HB3' ' A' ' 15' ' ' MET . . . -54.58 -47.29 73.49 Favored 'General case' 0 C--O 1.233 0.205 0 CA-C-N 116.007 -0.542 . . . . 0.0 111.046 179.897 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 27.5 m -72.08 -34.09 49.18 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.379 0 CA-C-N 116.047 -0.524 . . . . 0.0 111.009 -179.901 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -60.1 -41.49 92.65 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-O 121.017 0.436 . . . . 0.0 110.761 179.503 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 51' ' ' TYR . . . . . 0.421 ' HB3' ' O ' ' A' ' 8' ' ' PHE . 43.8 m-85 -73.24 -31.5 64.16 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 115.899 -0.592 . . . . 0.0 110.262 -179.982 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -66.26 -43.3 86.85 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 115.887 -0.597 . . . . 0.0 110.624 179.126 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 16.5 m -75.15 -37.72 40.54 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.166 0 CA-C-N 116.277 -0.419 . . . . 0.0 111.028 179.798 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 54' ' ' MET . . . . . 0.531 ' HG2' ' HG2' ' A' ' 71' ' ' PRO . 68.5 mtm -67.22 -34.42 77.43 Favored 'General case' 0 CA--C 1.52 -0.18 0 CA-C-O 121.213 0.53 . . . . 0.0 109.776 179.215 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 55' ' ' ALA . . . . . 0.543 ' HB2' ' HB2' ' A' ' 8' ' ' PHE . . . -66.53 -19.29 65.75 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-N 115.382 -0.827 . . . . 0.0 111.124 179.481 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 87.5 mt -94.95 -3.73 48.04 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.329 -0.396 . . . . 0.0 111.01 -179.927 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 85.57 24.48 42.63 Favored Glycine 0 C--N 1.331 0.271 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.712 179.939 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 58' ' ' VAL . . . . . 0.441 ' O ' ' HG3' ' A' ' 71' ' ' PRO . 48.3 t -86.84 142.36 13.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-O 120.714 0.293 . . . . 0.0 110.829 179.882 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 59' ' ' GLY . . . . . 0.638 ' HA3' ' HD3' ' A' ' 71' ' ' PRO . . . 81.33 -3.74 76.01 Favored Glycine 0 N--CA 1.449 -0.458 0 C-N-CA 120.807 -0.711 . . . . 0.0 112.569 -179.976 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 60' ' ' TRP . . . . . . . . . . . . . 14.4 m0 -70.73 101.08 2.0 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.809 0.338 . . . . 0.0 110.646 179.853 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 61' ' ' VAL . . . . . 0.422 ' HA ' ' HD3' ' A' ' 62' ' ' PRO . 3.2 p -105.5 125.42 33.46 Favored Pre-proline 0 CA--C 1.534 0.334 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.35 -179.982 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 62' ' ' PRO . . . . . 0.422 ' HD3' ' HA ' ' A' ' 61' ' ' VAL . 8.4 Cg_exo -71.52 148.32 53.67 Favored 'Trans proline' 0 C--N 1.35 0.644 0 C-N-CA 122.617 2.211 . . . . 0.0 112.06 179.729 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 77.9 t -142.23 92.43 0.52 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-N 116.112 -0.495 . . . . 0.0 110.894 -179.932 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . 59.67 -85.99 0.02 OUTLIER 'General case' 0 C--N 1.331 -0.209 0 CA-C-N 116.158 -0.473 . . . . 0.0 111.346 -179.865 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 10.2 tp10 -121.05 -24.61 5.52 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.438 -0.346 . . . . 0.0 110.604 179.902 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 66' ' ' ARG . . . . . . . . . . . . . 80.7 mtt180 -103.54 152.96 21.1 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.132 -0.486 . . . . 0.0 110.396 -179.88 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 94.1 m -116.0 127.41 54.91 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 120.955 0.407 . . . . 0.0 111.426 -179.536 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 10.7 t -104.71 146.26 12.18 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.24 0 CA-C-N 115.941 -0.572 . . . . 0.0 110.39 179.488 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 69' ' ' PHE . . . . . . . . . . . . . 12.2 m-85 -109.81 111.76 23.38 Favored 'General case' 0 N--CA 1.452 -0.358 0 N-CA-C 109.519 -0.549 . . . . 0.0 109.519 -179.572 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 70' ' ' VAL . . . . . 0.64 ' N ' ' HD2' ' A' ' 71' ' ' PRO . 0.5 OUTLIER -66.21 -40.42 35.77 Favored Pre-proline 0 C--N 1.321 -0.654 0 N-CA-C 112.428 0.529 . . . . 0.0 112.428 -179.507 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild core ' A' A ' 71' ' ' PRO . . . . . 0.64 ' HD2' ' N ' ' A' ' 70' ' ' VAL . 27.1 Cg_endo -63.23 -27.04 72.2 Favored 'Trans proline' 0 C--N 1.356 0.93 0 C-N-CA 121.779 1.652 . . . . 0.0 112.821 -179.03 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 61.0 ttp180 -73.25 -52.99 11.99 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 121.0 0.428 . . . . 0.0 110.212 179.629 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 73' ' ' TYR . . . . . 0.425 ' O ' HG13 ' A' ' 77' ' ' ILE . 52.9 m-85 -66.49 -34.4 77.84 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.012 -0.54 . . . . 0.0 110.716 179.758 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 74' ' ' ILE . . . . . 0.427 ' HB ' ' O ' ' A' ' 70' ' ' VAL . 0.4 OUTLIER -72.83 -37.69 55.39 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.209 0 CA-C-N 116.282 -0.417 . . . . 0.0 110.121 179.675 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild core ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 18.2 t70 -58.02 -37.79 74.99 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-N 116.212 -0.449 . . . . 0.0 109.863 179.226 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 76' ' ' TRP . . . . . . . . . . . . . 53.3 m0 -68.69 -42.16 78.19 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 115.894 -0.594 . . . . 0.0 110.601 179.428 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 77' ' ' ILE . . . . . 0.495 ' O ' ' HG3' ' A' ' 81' ' ' PRO . 86.1 mt -58.72 -28.67 37.96 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.062 -0.517 . . . . 0.0 111.016 179.567 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 45.5 mt -92.03 -38.89 11.96 Favored 'General case' 0 CA--C 1.534 0.343 0 N-CA-C 112.551 0.574 . . . . 0.0 112.551 -179.614 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 79' ' ' THR . . . . . 0.428 HG22 HD11 ' A' ' 46' ' ' ILE . 74.8 p -82.99 -52.43 6.68 Favored 'General case' 0 N--CA 1.465 0.299 0 N-CA-C 113.929 1.085 . . . . 0.0 113.929 -177.422 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 80' ' ' THR . . . . . 0.466 ' N ' ' HD2' ' A' ' 81' ' ' PRO . 39.2 m -48.01 -54.28 25.69 Favored Pre-proline 0 C--N 1.33 -0.252 0 N-CA-C 113.089 0.774 . . . . 0.0 113.089 -178.132 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 81' ' ' PRO . . . . . 0.495 ' HG3' ' O ' ' A' ' 77' ' ' ILE . 25.1 Cg_endo -60.14 -21.09 64.57 Favored 'Trans proline' 0 C--N 1.351 0.689 0 C-N-CA 121.481 1.454 . . . . 0.0 111.397 -179.683 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 82' ' ' LEU . . . . . . . . . . . . . 17.6 tp -77.03 -32.95 57.41 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 115.633 -0.712 . . . . 0.0 110.005 179.555 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 83' ' ' ILE . . . . . 0.517 HD13 HD13 ' A' ' 43' ' ' ILE . 41.4 mm -67.9 -53.14 32.57 Favored 'Isoleucine or valine' 0 C--O 1.233 0.206 0 CA-C-N 116.059 -0.519 . . . . 0.0 109.909 178.976 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 35.9 m -60.87 -29.86 46.22 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.219 0 CA-C-N 115.97 -0.559 . . . . 0.0 109.513 178.975 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 85' ' ' TYR . . . . . . . . . . . . . 78.8 t80 -68.52 -32.8 73.01 Favored 'General case' 0 N--CA 1.453 -0.303 0 CA-C-N 115.569 -0.741 . . . . 0.0 109.623 178.792 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 86' ' ' PHE . . . . . . . . . . . . . 8.8 t80 -62.36 -51.21 68.5 Favored 'General case' 0 C--N 1.333 -0.117 0 CA-C-N 115.87 -0.605 . . . . 0.0 109.733 179.298 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 10.5 mp -61.61 -29.63 70.17 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-N 115.83 -0.623 . . . . 0.0 110.136 179.339 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -69.96 -27.85 72.56 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.899 -0.667 . . . . 0.0 111.889 179.362 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 88.1 mt -74.29 -44.57 52.17 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-O 120.994 0.426 . . . . 0.0 110.597 179.587 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 43.4 mt -63.27 -28.4 70.0 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 115.75 -0.659 . . . . 0.0 111.05 -179.976 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -88.46 -39.88 13.89 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.379 -179.628 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 88.14 59.43 1.67 Allowed Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.662 -0.78 . . . . 0.0 112.26 -179.736 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 93' ' ' LEU . . . . . 0.417 ' HB3' ' HB2' ' A' ' 97' ' ' GLU . 45.6 mt -75.79 -175.97 3.17 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.849 0.357 . . . . 0.0 110.957 -179.883 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 94' ' ' ASP . . . . . . . . . . . . . 7.8 m-20 -109.12 171.93 7.14 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.057 -0.519 . . . . 0.0 110.709 179.847 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 66.2 m -55.07 -36.4 65.57 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.345 -179.653 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 96' ' ' ARG . . . . . 0.425 ' O ' HG13 ' A' ' 100' ' ' ILE . 38.1 ttp180 -73.26 -52.77 12.8 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.352 -0.386 . . . . 0.0 111.054 -179.687 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 97' ' ' GLU . . . . . 0.417 ' HB2' ' HB3' ' A' ' 93' ' ' LEU . 47.9 mt-10 -53.14 -48.3 68.04 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.404 -0.362 . . . . 0.0 111.441 -179.48 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 98' ' ' PHE . . . . . 0.451 ' O ' HG12 ' A' ' 102' ' ' ILE . 18.1 m-85 -55.91 -52.07 65.39 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.524 -0.307 . . . . 0.0 111.112 179.921 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -57.66 -28.09 59.59 Favored Glycine 0 N--CA 1.452 -0.277 0 C-N-CA 120.771 -0.728 . . . . 0.0 112.768 -179.72 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 100' ' ' ILE . . . . . 0.425 HG13 ' O ' ' A' ' 96' ' ' ARG . 95.7 mt -72.51 -42.69 63.84 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-O 120.839 0.352 . . . . 0.0 111.279 -179.787 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 48.3 t -69.35 -48.62 66.5 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.439 0 CA-C-N 116.222 -0.444 . . . . 0.0 111.577 -179.534 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 102' ' ' ILE . . . . . 0.451 HG12 ' O ' ' A' ' 98' ' ' PHE . 34.2 mm -59.79 -48.93 85.73 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.736 -179.284 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 15.1 t -58.77 -38.34 78.27 Favored 'General case' 0 C--O 1.233 0.198 0 CA-C-O 120.707 0.289 . . . . 0.0 111.083 -179.813 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 104' ' ' LEU . . . . . 0.474 ' O ' HG23 ' A' ' 108' ' ' VAL . 36.6 tp -58.98 -43.45 91.41 Favored 'General case' 0 C--N 1.332 -0.177 0 CA-C-O 120.986 0.422 . . . . 0.0 110.272 179.296 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 105' ' ' ASN . . . . . 0.676 HD21 HD13 ' A' ' 137' ' ' LEU . 0.8 OUTLIER -65.87 -27.69 68.41 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-N 116.019 -0.537 . . . . 0.0 110.644 -179.981 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild core ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 62.4 m -63.52 -57.31 10.59 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 116.372 -0.377 . . . . 0.0 111.031 -179.89 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 107' ' ' VAL . . . . . 0.423 HG12 ' O ' ' A' ' 104' ' ' LEU . 12.8 p -57.99 -36.35 56.01 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.184 0 CA-C-N 116.399 -0.364 . . . . 0.0 110.857 179.937 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . 0.474 HG23 ' O ' ' A' ' 104' ' ' LEU . 54.3 t -58.32 -45.39 89.4 Favored 'Isoleucine or valine' 0 C--O 1.234 0.282 0 CA-C-O 121.069 0.462 . . . . 0.0 110.675 179.351 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 109' ' ' MET . . . . . 0.456 ' HG2' ' O ' ' A' ' 105' ' ' ASN . 21.3 mmt -71.96 -31.81 66.67 Favored 'General case' 0 CA--C 1.516 -0.361 0 CA-C-N 115.921 -0.582 . . . . 0.0 110.57 179.942 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 110' ' ' LEU . . . . . 0.456 HD23 ' C ' ' A' ' 110' ' ' LEU . 4.0 tt -62.6 -34.14 76.4 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-N 115.98 -0.555 . . . . 0.0 109.54 178.854 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -67.78 -53.73 24.82 Favored 'General case' 0 C--N 1.332 -0.18 0 CA-C-N 115.761 -0.654 . . . . 0.0 110.667 179.468 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . -62.4 -38.89 97.04 Favored Glycine 0 C--N 1.332 0.309 0 C-N-CA 120.641 -0.79 . . . . 0.0 112.286 179.566 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 113' ' ' PHE . . . . . . . . . . . . . 4.3 t80 -53.61 -66.93 0.3 Allowed 'General case' 0 C--N 1.331 -0.236 0 CA-C-O 121.088 0.47 . . . . 0.0 110.194 179.718 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 114' ' ' ALA . . . . . 0.408 ' HB3' HD22 ' A' ' 126' ' ' LEU . . . -65.22 -17.67 64.68 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 115.767 -0.651 . . . . 0.0 110.491 179.287 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -58.54 -48.43 84.42 Favored Glycine 0 C--N 1.332 0.333 0 CA-C-N 115.784 -0.644 . . . . 0.0 111.914 179.42 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -78.32 -17.49 56.49 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.739 0.304 . . . . 0.0 110.988 179.322 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 117' ' ' MET . . . . . . . . . . . . . 21.1 mmt -84.95 13.9 5.49 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.098 -0.501 . . . . 0.0 111.353 -179.452 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 118' ' ' VAL . . . . . 0.466 HG21 ' HB3' ' A' ' 123' ' ' ARG . 33.6 m -81.4 139.01 48.03 Favored Pre-proline 0 C--N 1.33 -0.266 0 N-CA-C 111.838 0.31 . . . . 0.0 111.838 -179.398 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 119' ' ' PRO . . . . . . . . . . . . . 85.7 Cg_endo -92.22 -2.63 3.99 Favored 'Trans proline' 0 N--CA 1.455 -0.788 0 C-N-CA 122.91 2.407 . . . . 0.0 112.463 179.052 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -138.89 -110.34 0.91 Allowed Glycine 0 C--N 1.333 0.379 0 C-N-CA 120.675 -0.774 . . . . 0.0 112.863 -179.775 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 2.4 pp -127.07 15.29 3.56 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.192 0 N-CA-C 111.849 0.314 . . . . 0.0 111.849 -179.775 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 46.5 mt-10 -61.22 -18.54 58.83 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.906 0.384 . . . . 0.0 110.838 179.82 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 123' ' ' ARG . . . . . 0.582 ' HD2' ' HA2' ' A' ' 184' ' ' GLY . 24.4 ptt180 -51.46 -27.63 10.9 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 115.871 -0.604 . . . . 0.0 111.729 -179.92 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 124' ' ' TYR . . . . . . . . . . . . . 22.2 m-85 -75.15 -33.34 61.51 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.582 -0.281 . . . . 0.0 111.382 -179.524 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 125' ' ' ALA . . . . . . . . . . . . . . . -74.14 -56.64 4.67 Favored 'General case' 0 C--O 1.235 0.34 0 CA-C-O 120.96 0.41 . . . . 0.0 111.155 -179.933 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 126' ' ' LEU . . . . . 0.408 HD22 ' HB3' ' A' ' 114' ' ' ALA . 1.2 mt -53.48 -51.2 63.51 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.016 -0.538 . . . . 0.0 110.275 179.749 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 127' ' ' PHE . . . . . . . . . . . . . 11.0 t80 -65.29 -30.1 70.93 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.03 179.318 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 128' ' ' GLY . . . . . . . . . . . . . . . -49.02 -49.31 29.94 Favored Glycine 0 N--CA 1.45 -0.42 0 C-N-CA 120.179 -1.01 . . . . 0.0 110.581 178.703 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 129' ' ' MET . . . . . 0.479 ' HE3' ' HA2' ' A' ' 130' ' ' GLY . 0.0 OUTLIER -71.71 -27.84 63.29 Favored 'General case' 0 C--N 1.328 -0.351 0 N-CA-C 109.067 -0.716 . . . . 0.0 109.067 178.303 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild core ' A' A ' 130' ' ' GLY . . . . . 0.479 ' HA2' ' HE3' ' A' ' 129' ' ' MET . . . -60.68 -41.23 98.88 Favored Glycine 0 C--N 1.332 0.36 0 CA-C-N 115.712 -0.676 . . . . 0.0 112.241 179.49 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -71.9 -48.99 41.71 Favored 'General case' 0 C--N 1.331 -0.21 0 CA-C-O 120.627 0.251 . . . . 0.0 110.403 179.668 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 57.2 t -55.68 -46.5 79.51 Favored 'Isoleucine or valine' 0 C--O 1.234 0.271 0 CA-C-O 121.302 0.573 . . . . 0.0 109.506 178.826 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -62.29 -38.19 88.39 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 115.397 -0.82 . . . . 0.0 110.507 178.962 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 134' ' ' PHE . . . . . . . . . . . . . 82.3 t80 -55.71 -53.47 56.15 Favored 'General case' 0 N--CA 1.452 -0.371 0 CA-C-N 116.058 -0.519 . . . . 0.0 110.305 179.793 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 135' ' ' ILE . . . . . 0.434 ' O ' HG22 ' A' ' 138' ' ' VAL . 47.5 mt -55.95 -32.08 32.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 115.841 -0.618 . . . . 0.0 110.193 179.573 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . -62.54 -42.6 99.68 Favored Glycine 0 N--CA 1.448 -0.522 0 C-N-CA 120.176 -1.012 . . . . 0.0 111.232 178.738 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 137' ' ' LEU . . . . . 0.676 HD13 HD21 ' A' ' 105' ' ' ASN . 61.0 tp -66.27 -54.42 25.13 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.583 0.23 . . . . 0.0 110.855 179.617 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 138' ' ' VAL . . . . . 0.434 HG22 ' O ' ' A' ' 135' ' ' ILE . 3.8 m -55.05 -31.56 25.67 Favored 'Isoleucine or valine' 0 C--O 1.232 0.184 0 N-CA-C 109.891 -0.411 . . . . 0.0 109.891 -179.7 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 139' ' ' TYR . . . . . . . . . . . . . 14.2 t80 -61.37 -42.83 99.34 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 115.871 -0.604 . . . . 0.0 109.748 178.313 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 140' ' ' TYR . . . . . 0.437 ' HE2' HD22 ' A' ' 104' ' ' LEU . 21.7 m-85 -66.95 -45.71 76.94 Favored 'General case' 0 CA--C 1.529 0.153 0 CA-C-N 116.034 -0.53 . . . . 0.0 111.096 179.262 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 141' ' ' LEU . . . . . . . . . . . . . 11.2 mp -52.4 -37.41 56.51 Favored 'General case' 0 N--CA 1.464 0.23 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.791 -179.417 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 8.6 p -104.58 -5.28 9.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-O 120.927 0.394 . . . . 0.0 111.394 -179.514 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 143' ' ' GLY . . . . . 0.434 ' HA3' ' HD2' ' A' ' 144' ' ' PRO . . . -75.51 -130.89 0.3 Allowed Glycine 0 CA--C 1.521 0.427 0 C-N-CA 120.768 -0.729 . . . . 0.0 113.009 -179.625 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 144' ' ' PRO . . . . . 0.434 ' HD2' ' HA3' ' A' ' 143' ' ' GLY . 13.2 Cg_endo -56.21 -23.47 45.46 Favored 'Trans proline' 0 C--N 1.348 0.549 0 C-N-CA 122.741 2.294 . . . . 0.0 112.658 -179.587 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 145' ' ' MET . . . . . . . . . . . . . 50.4 mtt -56.96 -29.22 63.02 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.286 -0.415 . . . . 0.0 111.696 -179.652 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 146' ' ' THR . . . . . . . . . . . . . 72.9 p -77.28 -34.65 55.62 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.837 0.351 . . . . 0.0 110.91 -179.531 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 36.9 tt0 -75.92 -32.25 59.51 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 115.989 -0.55 . . . . 0.0 111.028 -179.869 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 148' ' ' SER . . . . . . . . . . . . . 48.2 t -70.83 -47.43 59.45 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.502 -179.659 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 149' ' ' ALA . . . . . 0.432 ' HB1' HG22 ' A' ' 156' ' ' ILE . . . -70.76 -30.57 67.11 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.294 -0.412 . . . . 0.0 111.748 -179.39 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 150' ' ' SER . . . . . 0.412 ' HB3' ' HD3' ' A' ' 157' ' ' LYS . 78.4 p -69.12 0.0 5.29 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.38 -0.373 . . . . 0.0 111.12 -179.878 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 151' ' ' GLN . . . . . . . . . . . . . 77.0 mt-30 -121.99 9.58 9.99 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.378 -0.374 . . . . 0.0 111.494 -179.836 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 25.6 mmm180 -91.45 -53.16 4.44 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-O 121.1 0.476 . . . . 0.0 110.789 -179.994 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 153' ' ' SER . . . . . 0.675 ' HB2' HG12 ' A' ' 156' ' ' ILE . 23.5 m -158.3 172.22 18.76 Favored 'General case' 0 C--N 1.324 -0.509 0 CA-C-N 115.643 -0.708 . . . . 0.0 110.481 179.232 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 154' ' ' SER . . . . . . . . . . . . . 46.9 t -72.05 -37.08 69.76 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-O 120.977 0.418 . . . . 0.0 110.142 179.073 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -77.43 -35.38 37.32 Favored Glycine 0 N--CA 1.45 -0.423 0 CA-C-N 115.818 -0.628 . . . . 0.0 112.902 179.83 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 156' ' ' ILE . . . . . 0.675 HG12 ' HB2' ' A' ' 153' ' ' SER . 38.0 mm -52.72 -38.74 28.36 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.164 0 CA-C-O 120.687 0.28 . . . . 0.0 111.515 -179.56 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 157' ' ' LYS . . . . . 0.412 ' HD3' ' HB3' ' A' ' 150' ' ' SER . 57.4 tptt -64.78 -40.53 95.41 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.434 -0.348 . . . . 0.0 111.175 -179.9 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 49.3 m -71.16 -42.73 68.74 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.415 -0.357 . . . . 0.0 111.342 -179.733 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 159' ' ' LEU . . . . . 0.474 HD23 HD13 ' A' ' 163' ' ' LEU . 4.7 tt -64.44 -40.83 96.47 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.998 -179.573 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 160' ' ' TYR . . . . . . . . . . . . . 29.0 t80 -73.29 -37.17 66.34 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.711 -179.204 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 161' ' ' VAL . . . . . 0.492 HG12 ' N ' ' A' ' 162' ' ' ARG . 1.0 OUTLIER -59.85 -50.52 79.78 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.746 0 CA-C-O 120.628 0.251 . . . . 0.0 111.623 -179.438 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild core ' A' A ' 162' ' ' ARG . . . . . 0.492 ' N ' HG12 ' A' ' 161' ' ' VAL . 99.8 mtt180 -69.5 -34.82 74.87 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-O 120.929 0.395 . . . . 0.0 111.254 179.989 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 163' ' ' LEU . . . . . 0.661 ' HG ' ' HB2' ' A' ' 208' ' ' PHE . 1.2 mp -65.49 -55.12 19.61 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 115.945 -0.57 . . . . 0.0 112.173 -178.831 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 164' ' ' ARG . . . . . . . . . . . . . 5.1 ppt_? -66.05 -41.22 91.13 Favored 'General case' 0 C--N 1.329 -0.286 0 N-CA-C 111.997 0.369 . . . . 0.0 111.997 -178.596 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 165' ' ' ASN . . . . . 0.489 ' O ' HG23 ' A' ' 169' ' ' VAL . 0.9 OUTLIER -54.35 -52.28 62.09 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-O 120.969 0.414 . . . . 0.0 111.024 -179.948 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild core ' A' A ' 166' ' ' LEU . . . . . 0.516 ' O ' ' HG ' ' A' ' 170' ' ' LEU . 2.8 tt -64.99 -51.93 58.96 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 115.925 -0.579 . . . . 0.0 111.513 -179.377 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 167' ' ' THR . . . . . 0.431 ' O ' ' HB2' ' A' ' 171' ' ' TRP . 91.4 m -54.74 -52.81 61.37 Favored 'General case' 0 C--N 1.328 -0.357 0 N-CA-C 112.345 0.498 . . . . 0.0 112.345 -178.817 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 168' ' ' VAL . . . . . . . . . . . . . 53.0 t -54.54 -46.1 71.48 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 N-CA-C 112.22 0.452 . . . . 0.0 112.22 -179.044 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 169' ' ' VAL . . . . . 0.489 HG23 ' O ' ' A' ' 165' ' ' ASN . 77.5 t -56.04 -65.18 0.4 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 N-CA-C 112.019 0.378 . . . . 0.0 112.019 -179.18 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 170' ' ' LEU . . . . . 0.516 ' HG ' ' O ' ' A' ' 166' ' ' LEU . 0.6 OUTLIER -63.65 -31.09 72.15 Favored 'General case' 0 C--N 1.328 -0.341 0 N-CA-C 112.43 0.53 . . . . 0.0 112.43 -178.486 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild core ' A' A ' 171' ' ' TRP . . . . . 0.431 ' HB2' ' O ' ' A' ' 167' ' ' THR . 3.5 m0 -68.67 -30.87 69.65 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-O 120.941 0.4 . . . . 0.0 110.37 179.24 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 172' ' ' ALA . . . . . . . . . . . . . . . -73.03 -6.88 48.43 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 115.92 -0.582 . . . . 0.0 110.641 -179.991 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 173' ' ' ILE . . . . . 0.513 HG22 HD11 ' A' ' 177' ' ' ILE . 29.0 mm -86.67 -22.2 7.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 115.818 -0.628 . . . . 0.0 111.203 -179.952 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 174' ' ' TYR . . . . . 0.453 ' HB2' ' HD3' ' A' ' 175' ' ' PRO . 25.5 m-85 -54.25 -49.8 88.28 Favored Pre-proline 0 N--CA 1.464 0.245 0 CA-C-N 116.514 -0.312 . . . . 0.0 111.702 -179.771 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 175' ' ' PRO . . . . . 0.453 ' HD3' ' HB2' ' A' ' 174' ' ' TYR . 79.8 Cg_exo -49.01 -30.06 17.13 Favored 'Trans proline' 0 C--N 1.349 0.591 0 C-N-CA 121.97 1.78 . . . . 0.0 112.138 179.641 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 176' ' ' PHE . . . . . 0.45 ' O ' ' HG ' ' A' ' 180' ' ' LEU . 46.8 m-85 -80.75 -50.0 10.43 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 115.985 -0.552 . . . . 0.0 111.663 -179.897 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 177' ' ' ILE . . . . . 0.513 HD11 HG22 ' A' ' 173' ' ' ILE . 4.2 mm -63.13 -32.64 57.03 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.501 0 N-CA-C 112.364 0.505 . . . . 0.0 112.364 -178.037 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 178' ' ' TRP . . . . . . . . . . . . . 77.7 t90 -71.95 -50.94 24.68 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.934 0.397 . . . . 0.0 110.555 179.771 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 179' ' ' LEU . . . . . 0.625 HD23 HD23 ' A' ' 180' ' ' LEU . 0.7 OUTLIER -68.95 -54.71 13.89 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.001 -0.545 . . . . 0.0 111.482 -179.341 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild core ' A' A ' 180' ' ' LEU . . . . . 0.674 HD22 HD11 ' A' ' 187' ' ' LEU . 39.3 mt -63.54 -43.68 96.39 Favored 'General case' 0 C--N 1.329 -0.324 0 C-N-CA 121.043 -0.263 . . . . 0.0 111.025 -179.729 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . -58.04 178.26 1.38 Allowed Glycine 0 CA--C 1.521 0.462 0 C-N-CA 120.12 -1.038 . . . . 0.0 112.12 179.085 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 182' ' ' PRO . . . . . 0.492 ' HA ' ' HB2' ' A' ' 186' ' ' ALA . 74.8 Cg_exo -47.45 -44.97 24.04 Favored 'Trans proline' 0 CA--C 1.536 0.611 0 C-N-CA 122.91 2.406 . . . . 0.0 113.918 -179.886 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 183' ' ' PRO . . . . . . . . . . . . . 86.7 Cg_exo -46.96 -26.91 5.29 Favored 'Trans proline' 0 C--N 1.355 0.874 0 C-N-CA 122.191 1.928 . . . . 0.0 113.364 -179.665 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 184' ' ' GLY . . . . . 0.582 ' HA2' ' HD2' ' A' ' 123' ' ' ARG . . . -120.5 -129.92 3.83 Favored Glycine 0 C--N 1.333 0.368 0 C-N-CA 120.29 -0.957 . . . . 0.0 113.081 -179.685 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 185' ' ' VAL . . . . . . . . . . . . . 15.4 m -54.68 -23.67 12.03 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 N-CA-C 112.066 0.395 . . . . 0.0 112.066 -179.526 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 186' ' ' ALA . . . . . 0.492 ' HB2' ' HA ' ' A' ' 182' ' ' PRO . . . 55.13 86.72 0.05 Allowed 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 116.446 -0.343 . . . . 0.0 111.659 179.509 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 187' ' ' LEU . . . . . 0.674 HD11 HD22 ' A' ' 180' ' ' LEU . 12.7 mt -92.3 -49.28 6.24 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.287 -0.415 . . . . 0.0 110.904 179.905 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 188' ' ' LEU . . . . . 0.521 HD13 HG11 ' A' ' 192' ' ' VAL . 78.2 mt -98.06 -161.93 0.91 Allowed 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 115.998 -0.546 . . . . 0.0 110.832 -179.72 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 189' ' ' THR . . . . . . . . . . . . . 2.3 t -98.41 146.93 32.41 Favored Pre-proline 0 C--N 1.329 -0.288 0 CA-C-N 116.132 -0.486 . . . . 0.0 110.766 179.993 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 190' ' ' PRO . . . . . . . . . . . . . 95.8 Cg_exo -44.41 -42.51 13.87 Favored 'Trans proline' 0 C--N 1.349 0.587 0 C-N-CA 122.763 2.309 . . . . 0.0 113.374 -179.511 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 191' ' ' THR . . . . . 0.48 ' O ' HD21 ' A' ' 7' ' ' LEU . 41.6 p -59.29 -44.74 92.47 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-O 120.78 0.324 . . . . 0.0 111.707 -179.596 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 192' ' ' VAL . . . . . 0.521 HG11 HD13 ' A' ' 188' ' ' LEU . 55.3 t -70.39 -51.52 37.34 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.42 0 N-CA-C 111.858 0.318 . . . . 0.0 111.858 -179.344 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 193' ' ' ASP . . . . . . . . . . . . . 20.7 m-20 -59.11 -51.98 67.7 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 116.444 -0.344 . . . . 0.0 111.626 -179.349 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 194' ' ' VAL . . . . . . . . . . . . . 69.2 t -58.88 -35.92 58.74 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.221 0 CA-C-O 120.712 0.292 . . . . 0.0 110.907 179.885 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 195' ' ' ALA . . . . . . . . . . . . . . . -57.33 -47.7 80.88 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.329 -0.396 . . . . 0.0 110.655 179.612 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 196' ' ' LEU . . . . . 0.402 HD23 ' N ' ' A' ' 196' ' ' LEU . 0.3 OUTLIER -61.85 -40.44 95.36 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.301 -0.409 . . . . 0.0 110.424 179.355 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild core ' A' A ' 197' ' ' ILE . . . . . . . . . . . . . 17.0 mm -57.25 -59.3 3.35 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.32 0 CA-C-N 115.939 -0.573 . . . . 0.0 110.062 179.019 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 198' ' ' VAL . . . . . . . . . . . . . 92.9 t -52.01 -35.1 18.13 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.426 0 CA-C-N 115.473 -0.785 . . . . 0.0 109.468 178.346 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 199' ' ' TYR . . . . . . . . . . . . . 59.3 t80 -70.24 -31.01 68.23 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 115.374 -0.83 . . . . 0.0 110.725 179.873 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 200' ' ' LEU . . . . . 0.496 ' O ' HG12 ' A' ' 203' ' ' VAL . 43.4 mt -73.23 -37.49 66.38 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 115.821 -0.627 . . . . 0.0 111.383 -179.736 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 201' ' ' ASP . . . . . . . . . . . . . 16.1 m-20 -73.84 -39.37 64.06 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-O 121.043 0.449 . . . . 0.0 110.498 179.663 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 202' ' ' LEU . . . . . . . . . . . . . 2.2 mt -69.9 -28.94 66.04 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 115.735 -0.666 . . . . 0.0 111.765 -179.465 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 203' ' ' VAL . . . . . 0.496 HG12 ' O ' ' A' ' 200' ' ' LEU . 12.3 p -78.17 -36.43 21.2 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.331 0 C-N-CA 121.094 -0.242 . . . . 0.0 110.962 -178.979 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 204' ' ' THR . . . . . . . . . . . . . 95.6 m -64.88 -58.43 6.2 Favored 'General case' 0 C--N 1.327 -0.399 0 C-N-CA 120.563 -0.455 . . . . 0.0 110.934 179.335 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 205' ' ' LYS . . . . . 0.76 ' HE3' HG22 ' A' ' 43' ' ' ILE . 54.4 mttp -61.86 -58.09 9.28 Favored 'General case' 0 C--N 1.329 -0.292 0 N-CA-C 112.343 0.497 . . . . 0.0 112.343 -178.395 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 51.0 t -71.83 -37.01 60.44 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.396 0 N-CA-C 112.428 0.529 . . . . 0.0 112.428 -178.515 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 207' ' ' GLY . . . . . 0.433 ' HA3' ' O ' ' A' ' 203' ' ' VAL . . . -57.59 -60.26 9.33 Favored Glycine 0 N--CA 1.455 -0.097 0 C-N-CA 120.704 -0.76 . . . . 0.0 113.416 -178.798 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 208' ' ' PHE . . . . . 0.661 ' HB2' ' HG ' ' A' ' 163' ' ' LEU . 0.3 OUTLIER -71.67 -27.13 62.85 Favored 'General case' 0 C--O 1.223 -0.3 0 CA-C-N 117.183 0.492 . . . . 0.0 110.562 -179.713 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild core ' A' A ' 209' ' ' GLY . . . . . 0.51 ' O ' ' HB3' ' A' ' 212' ' ' ALA . . . -65.18 -33.86 88.08 Favored Glycine 0 N--CA 1.448 -0.521 0 N-CA-C 111.718 -0.553 . . . . 0.0 111.718 178.623 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 210' ' ' PHE . . . . . . . . . . . . . 0.6 OUTLIER -73.57 -44.93 56.16 Favored 'General case' 0 CA--C 1.512 -0.502 0 N-CA-C 107.757 -1.201 . . . . 0.0 107.757 178.321 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 211' ' ' ILE . . . . . 0.416 HD12 ' HA ' ' A' ' 208' ' ' PHE . 34.5 mt -64.73 -27.65 42.99 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.653 0 N-CA-C 107.649 -1.241 . . . . 0.0 107.649 176.646 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 212' ' ' ALA . . . . . 0.51 ' HB3' ' O ' ' A' ' 209' ' ' GLY . . . -64.35 -44.02 92.78 Favored 'General case' 0 N--CA 1.45 -0.452 0 CA-C-N 114.505 -1.225 . . . . 0.0 110.6 -179.859 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 213' ' ' LEU . . . . . . . . . . . . . 97.6 mt -69.67 -46.08 66.91 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 115.308 -0.86 . . . . 0.0 111.487 -179.574 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 214' ' ' ASP . . . . . . . . . . . . . 36.3 m-20 -58.11 -47.15 84.14 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-O 120.85 0.357 . . . . 0.0 110.933 -179.952 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 215' ' ' ALA . . . . . . . . . . . . . . . -62.82 -54.05 44.9 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 115.992 -0.549 . . . . 0.0 111.239 -179.896 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 216' ' ' ALA . . . . . . . . . . . . . . . -56.36 -37.5 70.12 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-N 116.281 -0.418 . . . . 0.0 111.04 179.928 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 217' ' ' ALA . . . . . . . . . . . . . . . -63.33 -37.96 89.3 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.167 179.655 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 218' ' ' THR . . . . . . . . . . . . . 92.4 m . . . . . 0 C--N 1.328 -0.336 0 CA-C-N 115.677 -0.692 . . . . 0.0 110.605 179.334 . . . . . . . . 0 0 . 1 . 028 nuclear nobuild core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.367 0 N-CA-C 112.546 -0.222 . . . . 0.0 112.546 . . . . . . . . . 0 0 . 1 . 028 nuclear nobuild core ' A' A ' 4' ' ' LEU . . . . . 0.463 HD13 HG22 ' A' ' 191' ' ' THR . 59.5 tp -74.12 -40.69 62.5 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-O 120.823 0.344 . . . . 0.0 110.889 179.945 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 61.3 p -60.79 -29.85 69.7 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.136 179.98 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 10.9 p -53.11 -35.5 59.72 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 116.043 -0.526 . . . . 0.0 111.172 -179.785 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 7' ' ' LEU . . . . . . . . . . . . . 10.0 mp -57.22 -53.59 56.36 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.297 179.961 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 8' ' ' PHE . . . . . 0.49 ' O ' ' HB3' ' A' ' 51' ' ' TYR . 65.7 m-85 -59.4 -34.63 72.68 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.006 -0.543 . . . . 0.0 110.957 -179.599 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 9' ' ' TRP . . . . . 0.404 ' O ' HG12 ' A' ' 13' ' ' ILE . 32.0 m95 -66.71 -41.81 87.37 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-N 116.296 -0.411 . . . . 0.0 110.099 179.831 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 84.2 mt -59.64 -48.4 81.82 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 115.88 -0.6 . . . . 0.0 110.26 179.233 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . 0.489 ' HA2' HD11 ' A' ' 202' ' ' LEU . . . -61.22 -35.28 90.65 Favored Glycine 0 N--CA 1.449 -0.461 0 C-N-CA 120.621 -0.799 . . . . 0.0 111.587 179.169 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -63.29 -30.28 71.44 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.597 0.237 . . . . 0.0 110.442 179.41 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 13' ' ' ILE . . . . . 0.404 HG12 ' O ' ' A' ' 9' ' ' TRP . 47.9 mm -68.58 -54.12 23.21 Favored 'Isoleucine or valine' 0 CA--C 1.52 -0.189 0 CA-C-N 116.41 -0.359 . . . . 0.0 110.309 179.057 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -53.21 -30.67 39.95 Favored Glycine 0 N--CA 1.452 -0.281 0 C-N-CA 120.689 -0.767 . . . . 0.0 111.747 179.475 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 15' ' ' MET . . . . . 0.718 ' HB3' ' HB2' ' A' ' 48' ' ' ALA . 0.0 OUTLIER -76.77 -49.54 15.67 Favored 'General case' 0 C--O 1.223 -0.33 0 CA-C-O 120.564 0.221 . . . . 0.0 110.928 179.523 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -55.67 -50.87 69.1 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-O 120.78 0.324 . . . . 0.0 110.621 179.804 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 17' ' ' VAL . . . . . 0.481 HG13 ' N ' ' A' ' 18' ' ' GLY . 14.7 p -63.55 -46.31 95.35 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.377 0 CA-C-O 121.356 0.598 . . . . 0.0 110.718 179.824 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . 0.481 ' N ' HG13 ' A' ' 17' ' ' VAL . . . -58.97 -46.31 93.87 Favored Glycine 0 C--N 1.317 -0.484 0 CA-C-N 114.973 -1.012 . . . . 0.0 111.891 179.179 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 57.4 m -53.78 -45.06 70.55 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-O 120.707 0.289 . . . . 0.0 110.827 -179.839 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 81.7 mt -71.58 -39.68 70.42 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.273 -0.421 . . . . 0.0 110.766 179.376 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -60.42 -33.39 72.44 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.085 -0.507 . . . . 0.0 111.736 -179.767 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 22' ' ' PHE . . . . . 0.586 ' HB2' HG22 ' A' ' 41' ' ' VAL . 8.2 m-85 -91.15 -31.05 16.36 Favored 'General case' 0 N--CA 1.463 0.197 0 CA-C-O 120.753 0.311 . . . . 0.0 111.311 -179.679 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -68.72 -50.32 51.78 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.335 -179.514 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 24' ' ' TRP . . . . . . . . . . . . . 4.4 t-105 -64.18 -45.05 90.07 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-N 115.834 -0.621 . . . . 0.0 111.24 -179.595 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.33 -0.258 0 CA-C-O 120.858 0.361 . . . . 0.0 110.983 179.84 . . . . . . . . 0 0 . 1 . 028 nuclear nobuild core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.24 0 N-CA-C 112.457 -0.257 . . . . 0.0 112.457 . . . . . . . . . 0 0 . 1 . 028 nuclear nobuild core ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 28.7 mm-40 -86.63 -20.85 27.25 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 120.741 0.305 . . . . 0.0 110.953 -179.959 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 34' ' ' ARG . . . . . . . . . . . . . 14.7 ptm180 -48.9 -36.31 16.88 Favored 'General case' 0 C--N 1.332 -0.17 0 CA-C-N 116.076 -0.511 . . . . 0.0 111.668 -179.757 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 29.2 mmt180 -61.77 -50.47 72.22 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 120.874 0.368 . . . . 0.0 111.277 -179.686 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 46.6 m-85 -63.2 -30.58 71.7 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.044 -0.525 . . . . 0.0 111.473 -179.607 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 37' ' ' TYR . . . . . 0.431 ' O ' HG23 ' A' ' 41' ' ' VAL . 39.1 m-85 -74.67 -55.8 5.49 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.641 -179.237 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 88.8 t -56.63 -36.85 49.81 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.205 0 CA-C-O 121.0 0.429 . . . . 0.0 110.485 179.914 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 90.7 m -63.97 -50.96 66.52 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 115.747 -0.661 . . . . 0.0 110.465 179.226 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 40' ' ' LEU . . . . . 0.529 HD12 HD12 ' A' ' 43' ' ' ILE . 40.4 tp -56.8 -50.16 73.18 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 115.549 -0.75 . . . . 0.0 110.809 -179.858 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . 0.586 HG22 ' HB2' ' A' ' 22' ' ' PHE . 69.0 t -57.76 -36.53 55.39 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 115.858 -0.61 . . . . 0.0 110.446 179.565 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -61.52 -36.1 92.08 Favored Glycine 0 N--CA 1.449 -0.493 0 C-N-CA 120.907 -0.663 . . . . 0.0 112.17 179.815 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 43' ' ' ILE . . . . . 0.572 HG12 HD23 ' A' ' 82' ' ' LEU . 2.0 mt -65.22 -56.94 13.08 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.234 0 CA-C-O 120.958 0.409 . . . . 0.0 110.802 179.713 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 32.4 t -58.26 -25.17 61.44 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 115.879 -0.601 . . . . 0.0 111.685 -179.5 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -73.83 -58.48 4.43 Favored Glycine 0 CA--C 1.517 0.191 0 C-N-CA 120.696 -0.764 . . . . 0.0 112.986 -179.576 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 46' ' ' ILE . . . . . 0.644 ' O ' HG22 ' A' ' 49' ' ' VAL . 15.8 pt -57.92 -35.87 53.63 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.221 0 CA-C-O 120.818 0.342 . . . . 0.0 110.924 -179.674 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 47' ' ' ALA . . . . . 0.67 ' HB2' ' HE2' ' A' ' 205' ' ' LYS . . . -67.04 -37.59 84.36 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.962 0.41 . . . . 0.0 110.261 178.754 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 48' ' ' ALA . . . . . 0.718 ' HB2' ' HB3' ' A' ' 15' ' ' MET . . . -60.57 -33.08 72.18 Favored 'General case' 0 C--N 1.332 -0.173 0 CA-C-N 115.736 -0.665 . . . . 0.0 111.343 179.889 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 49' ' ' VAL . . . . . 0.644 HG22 ' O ' ' A' ' 46' ' ' ILE . 1.3 m -76.54 -38.39 31.46 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.496 -0.32 . . . . 0.0 111.643 -179.425 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -62.95 -41.65 99.58 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-O 120.968 0.413 . . . . 0.0 111.393 -179.636 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 51' ' ' TYR . . . . . 0.595 ' HE2' ' HE2' ' A' ' 15' ' ' MET . 38.5 m-85 -72.74 -40.41 66.1 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-N 115.894 -0.594 . . . . 0.0 110.813 -179.283 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -63.13 -40.87 98.84 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-N 115.943 -0.571 . . . . 0.0 111.467 179.793 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 53' ' ' VAL . . . . . 0.515 HG23 ' N ' ' A' ' 54' ' ' MET . 33.3 m -74.42 -50.56 26.47 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 N-CA-C 111.754 0.279 . . . . 0.0 111.754 -179.475 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 54' ' ' MET . . . . . 0.534 ' HG2' ' HG2' ' A' ' 71' ' ' PRO . 72.0 mtm -57.57 -30.2 65.06 Favored 'General case' 0 CA--C 1.521 -0.143 0 CA-C-O 121.013 0.435 . . . . 0.0 110.744 179.914 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -58.95 -36.97 75.7 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 115.601 -0.727 . . . . 0.0 111.643 -179.816 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 6.2 mp -87.2 4.38 42.71 Favored 'General case' 0 C--N 1.332 -0.173 0 CA-C-N 116.639 -0.255 . . . . 0.0 111.456 179.974 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 92.98 30.76 9.09 Favored Glycine 0 N--CA 1.452 -0.246 0 C-N-CA 120.674 -0.774 . . . . 0.0 113.111 179.526 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 73.7 t -88.63 130.19 38.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-O 120.71 0.29 . . . . 0.0 110.878 179.716 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 59' ' ' GLY . . . . . 0.581 ' HA3' ' HD3' ' A' ' 71' ' ' PRO . . . 87.59 -5.96 84.17 Favored Glycine 0 N--CA 1.448 -0.548 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.471 -179.815 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 60' ' ' TRP . . . . . . . . . . . . . 11.5 m0 -69.43 83.03 0.39 Allowed 'General case' 0 C--N 1.328 -0.358 0 CA-C-O 120.759 0.314 . . . . 0.0 110.59 179.835 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 6.5 p -98.99 132.25 23.94 Favored Pre-proline 0 C--N 1.33 -0.282 0 CA-C-N 116.351 -0.386 . . . . 0.0 111.298 -179.87 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 73.3 Cg_endo -75.75 148.33 32.33 Favored 'Trans proline' 0 C--N 1.35 0.612 0 C-N-CA 122.447 2.098 . . . . 0.0 112.169 179.68 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 83.7 t -141.98 97.27 0.71 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.351 -179.84 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . 57.38 -88.93 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.054 -0.521 . . . . 0.0 111.87 179.611 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 11.8 mm-40 -118.89 -20.94 7.97 Favored 'General case' 0 C--N 1.332 -0.174 0 CA-C-N 116.501 -0.318 . . . . 0.0 111.428 -179.486 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 66' ' ' ARG . . . . . . . . . . . . . 28.4 ptt180 -110.91 161.68 15.59 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.461 -0.336 . . . . 0.0 110.766 179.971 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 91.6 m -114.88 143.3 45.34 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.256 -0.429 . . . . 0.0 111.264 -179.8 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 68' ' ' VAL . . . . . 0.559 HG21 ' SD ' ' A' ' 117' ' ' MET . 30.1 m -129.14 146.51 34.14 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 115.954 -0.566 . . . . 0.0 110.924 179.943 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 69' ' ' PHE . . . . . . . . . . . . . 19.2 m-85 -106.38 117.54 34.31 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.123 -0.49 . . . . 0.0 109.833 -179.724 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 70' ' ' VAL . . . . . 0.561 HG12 ' HD3' ' A' ' 71' ' ' PRO . 1.4 p -68.77 -33.19 4.11 Favored Pre-proline 0 CA--C 1.543 0.692 0 N-CA-C 113.66 0.985 . . . . 0.0 113.66 -178.538 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 71' ' ' PRO . . . . . 0.581 ' HD3' ' HA3' ' A' ' 59' ' ' GLY . 14.2 Cg_exo -69.48 -19.11 37.87 Favored 'Trans proline' 0 C--N 1.356 0.942 0 C-N-CA 122.099 1.866 . . . . 0.0 113.46 -178.643 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 72' ' ' ARG . . . . . 0.469 ' HE ' ' HA ' ' A' ' 72' ' ' ARG . 0.9 OUTLIER -67.77 -55.27 13.7 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.917 0.389 . . . . 0.0 111.564 -179.449 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild core ' A' A ' 73' ' ' TYR . . . . . 0.42 ' O ' HG13 ' A' ' 77' ' ' ILE . 14.2 m-85 -71.17 -33.19 69.76 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 116.081 -0.509 . . . . 0.0 111.315 -178.962 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 74' ' ' ILE . . . . . 0.541 HG22 ' HA ' ' A' ' 71' ' ' PRO . 0.3 OUTLIER -71.09 -44.93 74.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 C-N-CA 120.864 -0.334 . . . . 0.0 110.88 -179.773 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild core ' A' A ' 75' ' ' ASP . . . . . 0.492 ' O ' HG23 ' A' ' 79' ' ' THR . 37.4 t70 -58.99 -35.49 73.31 Favored 'General case' 0 N--CA 1.455 -0.183 0 N-CA-C 109.561 -0.533 . . . . 0.0 109.561 179.334 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 76' ' ' TRP . . . . . . . . . . . . . 50.2 m0 -66.0 -35.84 81.66 Favored 'General case' 0 C--N 1.332 -0.165 0 CA-C-N 116.029 -0.532 . . . . 0.0 110.129 179.141 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 77' ' ' ILE . . . . . 0.512 HG12 ' HB3' ' A' ' 109' ' ' MET . 96.4 mt -65.62 -30.78 51.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.028 -0.533 . . . . 0.0 110.718 179.378 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 69.7 mt -92.2 -20.46 21.17 Favored 'General case' 0 C--N 1.329 -0.294 0 N-CA-C 112.342 0.497 . . . . 0.0 112.342 -179.782 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 79' ' ' THR . . . . . 0.492 HG23 ' O ' ' A' ' 75' ' ' ASP . 62.7 p -94.39 -47.99 6.34 Favored 'General case' 0 N--CA 1.466 0.333 0 N-CA-C 112.845 0.683 . . . . 0.0 112.845 -178.406 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 80' ' ' THR . . . . . 0.582 ' N ' ' HD2' ' A' ' 81' ' ' PRO . 86.6 m -51.29 -48.72 85.07 Favored Pre-proline 0 C--N 1.328 -0.357 0 N-CA-C 112.545 0.572 . . . . 0.0 112.545 -179.319 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 81' ' ' PRO . . . . . 0.582 ' HD2' ' N ' ' A' ' 80' ' ' THR . 13.8 Cg_endo -56.02 -24.39 48.54 Favored 'Trans proline' 0 C--N 1.352 0.712 0 C-N-CA 121.536 1.491 . . . . 0.0 111.463 179.973 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 82' ' ' LEU . . . . . 0.572 HD23 HG12 ' A' ' 43' ' ' ILE . 7.2 mp -77.03 -46.03 25.14 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-N 115.707 -0.679 . . . . 0.0 110.847 179.9 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 83' ' ' ILE . . . . . 0.556 HD13 HD13 ' A' ' 43' ' ' ILE . 28.0 mm -60.8 -53.49 48.36 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.203 0 CA-C-N 116.305 -0.407 . . . . 0.0 110.527 179.655 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 84' ' ' VAL . . . . . 0.413 HG11 ' ND2' ' A' ' 105' ' ' ASN . 29.4 m -59.15 -35.47 57.7 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.211 0 CA-C-N 116.076 -0.511 . . . . 0.0 110.386 179.451 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 85' ' ' TYR . . . . . . . . . . . . . 72.7 t80 -65.51 -32.38 73.95 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.097 -0.501 . . . . 0.0 110.008 179.004 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 86' ' ' PHE . . . . . . . . . . . . . 1.4 t80 -61.54 -51.13 69.88 Favored 'General case' 0 C--N 1.333 -0.141 0 CA-C-N 115.963 -0.562 . . . . 0.0 109.707 179.547 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 6.9 mp -67.09 -31.57 72.15 Favored 'General case' 0 C--N 1.331 -0.2 0 CA-C-N 115.974 -0.557 . . . . 0.0 110.137 179.209 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -62.77 -28.01 70.96 Favored Glycine 0 N--CA 1.45 -0.418 0 C-N-CA 120.878 -0.677 . . . . 0.0 111.615 179.441 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 71.9 mt -78.45 -49.71 12.97 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.86 0.362 . . . . 0.0 110.536 179.411 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 96.1 mt -56.44 -32.5 64.97 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 115.994 -0.548 . . . . 0.0 110.649 179.608 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 91' ' ' ALA . . . . . 0.55 ' HB1' ' HB2' ' A' ' 148' ' ' SER . . . -83.67 -52.88 6.06 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 115.91 -0.587 . . . . 0.0 110.937 179.838 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 92' ' ' GLY . . . . . 0.462 ' HA3' HH21 ' A' ' 152' ' ' ARG . . . 90.68 71.82 1.23 Allowed Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.849 -0.691 . . . . 0.0 112.529 179.967 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 93' ' ' LEU . . . . . 0.551 HD11 ' HG2' ' A' ' 145' ' ' MET . 6.4 mp -84.18 -172.49 4.19 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-O 120.801 0.334 . . . . 0.0 110.912 -179.934 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 94' ' ' ASP . . . . . 0.453 ' H ' ' HB2' ' A' ' 97' ' ' GLU . 4.6 m-20 -98.88 -172.24 2.25 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.201 -179.966 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 46.1 t -67.87 -52.91 31.09 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 115.994 -0.548 . . . . 0.0 111.527 -179.668 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 75.3 mtp180 -74.14 -35.38 64.07 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-O 120.893 0.378 . . . . 0.0 110.899 -179.358 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 97' ' ' GLU . . . . . 0.453 ' HB2' ' H ' ' A' ' 94' ' ' ASP . 0.3 OUTLIER -60.8 -42.31 97.37 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 115.992 -0.549 . . . . 0.0 111.032 -179.873 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild core ' A' A ' 98' ' ' PHE . . . . . . . . . . . . . 0.6 OUTLIER -61.69 -40.73 96.03 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.337 -0.392 . . . . 0.0 110.572 179.468 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -65.6 -31.55 80.4 Favored Glycine 0 N--CA 1.452 -0.27 0 C-N-CA 120.795 -0.717 . . . . 0.0 112.538 -179.932 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 96.7 mt -67.82 -43.3 86.28 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.209 0 CA-C-O 120.909 0.385 . . . . 0.0 111.239 -179.826 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 101' ' ' VAL . . . . . 0.671 HG21 ' HE3' ' A' ' 145' ' ' MET . 42.2 t -66.36 -50.49 67.27 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.358 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.367 -179.801 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 102' ' ' ILE . . . . . . . . . . . . . 48.6 mm -59.46 -49.57 83.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.59 -179.526 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 14.2 t -59.95 -29.97 68.76 Favored 'General case' 0 C--N 1.332 -0.181 0 CA-C-O 120.77 0.319 . . . . 0.0 110.903 -179.829 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -60.66 -57.0 14.56 Favored 'General case' 0 C--N 1.332 -0.178 0 CA-C-N 116.325 -0.398 . . . . 0.0 109.983 179.342 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 105' ' ' ASN . . . . . 0.413 ' ND2' HG11 ' A' ' 84' ' ' VAL . 32.7 m-80 -59.27 -26.4 64.91 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-N 116.022 -0.535 . . . . 0.0 110.782 179.533 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 76.3 m -61.49 -52.76 63.19 Favored 'General case' 0 C--N 1.332 -0.185 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.958 179.87 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 107' ' ' VAL . . . . . 0.424 HG23 ' H ' ' A' ' 107' ' ' VAL . 2.1 t -62.0 -37.21 77.76 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.248 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.59 179.966 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 70.3 t -60.14 -57.86 9.89 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 115.73 -0.668 . . . . 0.0 111.461 -179.898 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 109' ' ' MET . . . . . 0.512 ' HB3' HG12 ' A' ' 77' ' ' ILE . 3.7 tpp -56.91 -42.89 80.75 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.485 -179.55 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 24.1 tp -62.54 -31.0 71.71 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.318 -0.401 . . . . 0.0 110.693 -179.899 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -63.57 -55.7 21.75 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 116.038 -0.528 . . . . 0.0 110.655 179.545 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . -61.49 -36.7 92.96 Favored Glycine 0 N--CA 1.45 -0.389 0 C-N-CA 120.775 -0.726 . . . . 0.0 112.081 179.576 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 113' ' ' PHE . . . . . 0.417 ' O ' ' HG2' ' A' ' 117' ' ' MET . 0.3 OUTLIER -52.25 -71.77 0.06 Allowed 'General case' 0 C--N 1.332 -0.174 0 CA-C-O 120.961 0.41 . . . . 0.0 110.195 179.619 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild core ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -63.9 -19.44 65.1 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 115.924 -0.58 . . . . 0.0 111.022 179.758 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 115' ' ' GLY . . . . . 0.495 ' HA2' HD22 ' A' ' 126' ' ' LEU . . . -54.8 -51.58 52.05 Favored Glycine 0 C--N 1.332 0.334 0 C-N-CA 120.86 -0.686 . . . . 0.0 111.841 179.611 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -78.2 -14.91 59.26 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-O 120.748 0.309 . . . . 0.0 111.227 179.659 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 117' ' ' MET . . . . . 0.559 ' SD ' HG21 ' A' ' 68' ' ' VAL . 23.5 mmt -90.59 17.07 7.93 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-N 116.358 -0.383 . . . . 0.0 111.739 -179.238 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 118' ' ' VAL . . . . . 0.426 HG21 ' HB3' ' A' ' 123' ' ' ARG . 34.4 m -81.1 144.01 53.85 Favored Pre-proline 0 C--N 1.33 -0.277 0 CA-C-O 120.505 0.193 . . . . 0.0 111.43 -179.845 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 119' ' ' PRO . . . . . . . . . . . . . 83.4 Cg_endo -82.49 -1.9 10.82 Favored 'Trans proline' 0 C--N 1.348 0.525 0 C-N-CA 122.55 2.167 . . . . 0.0 112.349 179.649 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -148.85 -129.1 1.77 Allowed Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.722 -0.751 . . . . 0.0 112.747 -179.878 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 39.8 pt -107.92 12.15 8.78 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.207 0 CA-C-O 120.676 0.274 . . . . 0.0 111.577 -179.729 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 43.9 mt-10 -60.25 -18.19 47.13 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.372 -0.376 . . . . 0.0 111.034 179.802 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 123' ' ' ARG . . . . . 0.432 ' HB2' ' HH2' ' A' ' 178' ' ' TRP . 15.7 ptt180 -50.08 -37.59 34.4 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 116.031 -0.532 . . . . 0.0 111.71 -179.578 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 124' ' ' TYR . . . . . . . . . . . . . 30.1 m-85 -58.46 -33.9 70.26 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.518 -0.31 . . . . 0.0 111.271 -179.628 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 125' ' ' ALA . . . . . . . . . . . . . . . -74.2 -49.75 22.15 Favored 'General case' 0 C--O 1.235 0.336 0 CA-C-O 120.909 0.385 . . . . 0.0 111.128 179.958 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 126' ' ' LEU . . . . . 0.495 HD22 ' HA2' ' A' ' 115' ' ' GLY . 7.4 mp -53.09 -46.46 68.66 Favored 'General case' 0 C--N 1.333 -0.144 0 CA-C-N 115.972 -0.558 . . . . 0.0 110.5 -179.928 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 127' ' ' PHE . . . . . 0.449 ' HZ ' ' HB3' ' A' ' 175' ' ' PRO . 4.8 t80 -67.23 -37.73 84.05 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.644 179.839 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 128' ' ' GLY . . . . . . . . . . . . . . . -46.38 -46.21 16.68 Favored Glycine 0 C--N 1.332 0.356 0 C-N-CA 120.193 -1.003 . . . . 0.0 110.911 179.237 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 129' ' ' MET . . . . . . . . . . . . . 0.6 OUTLIER -68.1 -40.95 82.46 Favored 'General case' 0 C--N 1.327 -0.386 0 N-CA-C 109.749 -0.463 . . . . 0.0 109.749 178.48 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -64.15 -23.15 67.73 Favored Glycine 0 N--CA 1.45 -0.411 0 CA-C-N 115.822 -0.626 . . . . 0.0 112.345 179.792 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 131' ' ' ALA . . . . . 0.4 ' O ' ' HB3' ' A' ' 134' ' ' PHE . . . -75.03 -53.54 8.73 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.717 0.294 . . . . 0.0 110.419 179.648 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 39.4 t -55.36 -40.33 56.77 Favored 'Isoleucine or valine' 0 C--O 1.233 0.217 0 CA-C-O 121.387 0.613 . . . . 0.0 109.638 178.799 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -69.79 -36.53 75.77 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 115.339 -0.846 . . . . 0.0 110.721 179.172 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 134' ' ' PHE . . . . . 0.442 ' CZ ' ' HA ' ' A' ' 172' ' ' ALA . 18.9 t80 -53.43 -60.06 3.79 Favored 'General case' 0 N--CA 1.454 -0.251 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.22 179.869 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 135' ' ' ILE . . . . . 0.526 ' O ' HG22 ' A' ' 138' ' ' VAL . 0.0 OUTLIER -56.11 -35.23 41.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 115.959 -0.564 . . . . 0.0 110.31 179.143 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild core ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . -57.56 -43.13 94.31 Favored Glycine 0 N--CA 1.45 -0.398 0 C-N-CA 120.226 -0.987 . . . . 0.0 111.755 179.024 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 137' ' ' LEU . . . . . 0.569 HD13 ' N ' ' A' ' 138' ' ' VAL . 1.4 tm? -63.29 -58.22 7.85 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 121.016 0.436 . . . . 0.0 110.519 179.678 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 138' ' ' VAL . . . . . 0.569 ' N ' HD13 ' A' ' 137' ' ' LEU . 2.4 m -54.22 -31.77 22.55 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.466 0 CA-C-N 115.562 -0.744 . . . . 0.0 110.213 179.68 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 139' ' ' TYR . . . . . . . . . . . . . 17.3 t80 -64.26 -34.92 79.21 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 115.885 -0.598 . . . . 0.0 110.05 179.091 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 15.4 m-85 -68.43 -48.69 63.94 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 115.989 -0.55 . . . . 0.0 111.613 179.733 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 141' ' ' LEU . . . . . 0.517 HD12 HG23 ' A' ' 142' ' ' VAL . 4.0 pp -68.52 -16.23 63.81 Favored 'General case' 0 CA--C 1.53 0.178 0 C-N-CA 120.974 -0.29 . . . . 0.0 111.327 -179.33 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 142' ' ' VAL . . . . . 0.517 HG23 HD12 ' A' ' 141' ' ' LEU . 95.2 t -101.17 -18.77 6.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-O 121.079 0.466 . . . . 0.0 110.57 178.801 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . -85.26 -123.46 1.25 Allowed Glycine 0 CA--C 1.522 0.498 0 C-N-CA 120.929 -0.653 . . . . 0.0 113.145 -179.342 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 144' ' ' PRO . . . . . . . . . . . . . 69.3 Cg_exo -52.15 -35.94 64.63 Favored 'Trans proline' 0 C--N 1.35 0.634 0 C-N-CA 122.722 2.281 . . . . 0.0 113.178 -179.392 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 145' ' ' MET . . . . . 0.671 ' HE3' HG21 ' A' ' 101' ' ' VAL . 40.3 mtt -55.36 -37.72 67.87 Favored 'General case' 0 C--N 1.331 -0.206 0 CA-C-O 120.751 0.31 . . . . 0.0 111.446 -179.798 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 146' ' ' THR . . . . . . . . . . . . . 18.3 m -68.28 -41.64 80.72 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.725 -179.368 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 42.6 mt-10 -75.77 -26.32 57.26 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.403 -0.362 . . . . 0.0 111.423 -179.543 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 148' ' ' SER . . . . . 0.55 ' HB2' ' HB1' ' A' ' 91' ' ' ALA . 68.9 m -70.65 -43.67 68.7 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.372 -0.376 . . . . 0.0 111.564 -179.402 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 149' ' ' ALA . . . . . 0.43 ' HB2' ' HA ' ' A' ' 91' ' ' ALA . . . -76.04 -32.34 59.29 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.781 0.324 . . . . 0.0 111.635 -179.441 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 150' ' ' SER . . . . . . . . . . . . . 86.7 p -69.46 -1.26 8.05 Favored 'General case' 0 C--N 1.326 -0.413 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.037 179.995 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 151' ' ' GLN . . . . . . . . . . . . . 77.2 mt-30 -118.69 0.26 11.44 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.097 -0.501 . . . . 0.0 111.331 -179.838 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 152' ' ' ARG . . . . . 0.462 HH21 ' HA3' ' A' ' 92' ' ' GLY . 38.9 mmt180 -82.26 -52.62 6.77 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-O 120.833 0.349 . . . . 0.0 111.004 -179.997 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 153' ' ' SER . . . . . 0.634 ' HB3' HG12 ' A' ' 156' ' ' ILE . 35.5 t -158.36 167.64 29.15 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.749 179.241 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 154' ' ' SER . . . . . . . . . . . . . 45.9 t -70.32 -34.85 73.18 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 121.037 0.446 . . . . 0.0 110.151 179.277 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -76.91 -37.92 32.14 Favored Glycine 0 N--CA 1.45 -0.368 0 C-N-CA 120.971 -0.633 . . . . 0.0 112.264 179.618 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 156' ' ' ILE . . . . . 0.634 HG12 ' HB3' ' A' ' 153' ' ' SER . 34.2 mm -53.51 -37.75 31.28 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.178 0 CA-C-O 120.897 0.379 . . . . 0.0 111.092 179.877 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 157' ' ' LYS . . . . . . . . . . . . . 39.9 ttpt -65.49 -32.29 73.82 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 116.078 -0.51 . . . . 0.0 111.441 -179.761 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 46.0 t -72.54 -47.93 44.27 Favored 'General case' 0 C--O 1.235 0.3 0 CA-C-O 121.143 0.497 . . . . 0.0 111.006 -179.604 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 159' ' ' LEU . . . . . 0.528 HD13 ' HB1' ' A' ' 215' ' ' ALA . 0.4 OUTLIER -68.63 -39.74 80.62 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 115.923 -0.58 . . . . 0.0 110.976 -179.415 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild core ' A' A ' 160' ' ' TYR . . . . . 0.47 ' OH ' ' HB3' ' A' ' 145' ' ' MET . 37.2 t80 -62.25 -47.15 85.63 Favored 'General case' 0 C--N 1.326 -0.419 0 N-CA-C 112.086 0.402 . . . . 0.0 112.086 -178.596 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 161' ' ' VAL . . . . . 0.412 HG23 ' N ' ' A' ' 162' ' ' ARG . 24.9 m -61.49 -45.97 97.54 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 C-N-CA 120.909 -0.316 . . . . 0.0 111.365 -179.488 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 162' ' ' ARG . . . . . 0.412 ' N ' HG23 ' A' ' 161' ' ' VAL . 28.1 tpt180 -68.85 -38.48 79.81 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 121.005 0.431 . . . . 0.0 111.103 -179.955 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 163' ' ' LEU . . . . . 0.416 HD13 ' O ' ' A' ' 159' ' ' LEU . 1.7 mp -64.67 -55.5 19.74 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 115.72 -0.673 . . . . 0.0 112.095 -179.23 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 164' ' ' ARG . . . . . 0.664 ' HG3' HD22 ' A' ' 165' ' ' ASN . 22.7 ptt180 -64.59 -41.72 96.05 Favored 'General case' 0 C--N 1.333 -0.15 0 N-CA-C 111.828 0.307 . . . . 0.0 111.828 -178.671 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 165' ' ' ASN . . . . . 0.664 HD22 ' HG3' ' A' ' 164' ' ' ARG . 0.9 OUTLIER -54.4 -48.37 71.67 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.91 0.386 . . . . 0.0 110.771 -179.922 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild core ' A' A ' 166' ' ' LEU . . . . . . . . . . . . . 3.9 tt -64.06 -54.23 37.35 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 116.026 -0.533 . . . . 0.0 111.431 -179.787 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 167' ' ' THR . . . . . 0.446 ' O ' ' HB2' ' A' ' 171' ' ' TRP . 34.4 m -57.24 -54.28 48.61 Favored 'General case' 0 C--N 1.329 -0.307 0 N-CA-C 112.868 0.692 . . . . 0.0 112.868 -178.568 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 168' ' ' VAL . . . . . 0.404 HG13 ' N ' ' A' ' 169' ' ' VAL . 9.8 p -55.58 -41.59 64.84 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.243 0 N-CA-C 112.425 0.528 . . . . 0.0 112.425 -178.694 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 169' ' ' VAL . . . . . 0.501 HG23 ' O ' ' A' ' 165' ' ' ASN . 48.7 t -59.82 -64.62 0.56 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 C-N-CA 121.122 -0.231 . . . . 0.0 111.488 -179.628 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 170' ' ' LEU . . . . . 0.526 HD12 ' HD1' ' A' ' 171' ' ' TRP . 1.3 pp -62.07 -27.18 68.72 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.64 -0.254 . . . . 0.0 111.295 -179.582 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 171' ' ' TRP . . . . . 0.526 ' HD1' HD12 ' A' ' 170' ' ' LEU . 2.0 m0 -70.73 -36.12 73.02 Favored 'General case' 0 CA--C 1.519 -0.217 0 CA-C-O 121.099 0.476 . . . . 0.0 109.739 178.772 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 172' ' ' ALA . . . . . 0.442 ' HA ' ' CZ ' ' A' ' 134' ' ' PHE . . . -71.33 -6.85 43.08 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 115.465 -0.788 . . . . 0.0 110.877 179.573 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 173' ' ' ILE . . . . . 0.483 ' O ' HG12 ' A' ' 177' ' ' ILE . 42.1 mm -85.67 -23.29 7.13 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.191 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.943 179.571 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 174' ' ' TYR . . . . . 0.43 ' HB2' ' HD3' ' A' ' 175' ' ' PRO . 29.3 m-85 -53.87 -49.58 88.65 Favored Pre-proline 0 CA--C 1.53 0.201 0 CA-C-N 116.363 -0.38 . . . . 0.0 111.607 -179.72 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 175' ' ' PRO . . . . . 0.449 ' HB3' ' HZ ' ' A' ' 127' ' ' PHE . 81.2 Cg_exo -47.46 -31.62 13.82 Favored 'Trans proline' 0 C--N 1.351 0.701 0 C-N-CA 122.177 1.918 . . . . 0.0 112.228 179.446 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 176' ' ' PHE . . . . . 0.482 ' O ' ' HG ' ' A' ' 180' ' ' LEU . 75.0 m-85 -80.39 -50.04 10.66 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.02 -0.536 . . . . 0.0 111.908 -179.856 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 177' ' ' ILE . . . . . 0.483 HG12 ' O ' ' A' ' 173' ' ' ILE . 6.4 mm -62.52 -35.84 72.03 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.556 0 CA-C-N 116.091 -0.504 . . . . 0.0 112.269 -178.144 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 178' ' ' TRP . . . . . 0.432 ' HH2' ' HB2' ' A' ' 123' ' ' ARG . 68.6 t90 -73.71 -43.1 60.18 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 121.001 0.429 . . . . 0.0 110.73 179.642 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 179' ' ' LEU . . . . . 0.441 ' O ' HG22 ' A' ' 185' ' ' VAL . 1.6 tm? -68.71 -51.25 43.61 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 115.765 -0.652 . . . . 0.0 111.188 -179.497 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 180' ' ' LEU . . . . . 0.589 HD22 HD11 ' A' ' 187' ' ' LEU . 13.8 mt -75.22 -47.24 29.16 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-N 116.442 -0.345 . . . . 0.0 111.78 -179.223 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . -57.01 178.91 0.73 Allowed Glycine 0 C--N 1.337 0.622 0 C-N-CA 120.415 -0.898 . . . . 0.0 112.71 179.858 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 182' ' ' PRO . . . . . 0.694 ' HA ' ' HB2' ' A' ' 186' ' ' ALA . 72.9 Cg_exo -47.73 -45.27 24.46 Favored 'Trans proline' 0 CA--C 1.536 0.582 0 C-N-CA 122.848 2.365 . . . . 0.0 113.762 -179.842 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 183' ' ' PRO . . . . . 0.427 ' HD3' ' HB2' ' A' ' 182' ' ' PRO . 76.2 Cg_exo -51.83 -16.98 4.62 Favored 'Trans proline' 0 C--N 1.356 0.945 0 C-N-CA 122.173 1.916 . . . . 0.0 113.145 -179.787 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 184' ' ' GLY . . . . . 0.409 ' HA3' ' O ' ' A' ' 179' ' ' LEU . . . -115.93 -90.91 1.66 Allowed Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.463 -0.875 . . . . 0.0 113.001 -179.749 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 185' ' ' VAL . . . . . 0.441 HG22 ' O ' ' A' ' 179' ' ' LEU . 9.4 m -116.48 -7.66 12.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 N-CA-C 111.716 0.265 . . . . 0.0 111.716 -179.43 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 186' ' ' ALA . . . . . 0.694 ' HB2' ' HA ' ' A' ' 182' ' ' PRO . . . 56.66 85.69 0.08 Allowed 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.404 -0.362 . . . . 0.0 111.717 179.567 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 187' ' ' LEU . . . . . 0.589 HD11 HD22 ' A' ' 180' ' ' LEU . 20.9 mt -91.87 -49.45 6.24 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-O 120.927 0.394 . . . . 0.0 110.713 179.567 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 188' ' ' LEU . . . . . 0.428 ' HB3' ' H ' ' A' ' 189' ' ' THR . 95.6 mt -90.23 -154.48 0.33 Allowed 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 115.883 -0.599 . . . . 0.0 110.896 -179.962 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 189' ' ' THR . . . . . 0.428 ' H ' ' HB3' ' A' ' 188' ' ' LEU . 29.8 m -95.99 134.89 23.21 Favored Pre-proline 0 C--N 1.328 -0.342 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.649 -179.862 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 190' ' ' PRO . . . . . 0.407 ' O ' HG23 ' A' ' 194' ' ' VAL . 82.3 Cg_exo -44.99 -31.31 5.31 Favored 'Trans proline' 0 C--N 1.351 0.664 0 C-N-CA 122.592 2.195 . . . . 0.0 112.884 179.999 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 191' ' ' THR . . . . . 0.463 HG22 HD13 ' A' ' 4' ' ' LEU . 81.5 p -76.37 -42.05 45.94 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.481 -0.327 . . . . 0.0 111.326 -179.896 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 192' ' ' VAL . . . . . . . . . . . . . 58.3 t -70.08 -48.94 59.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.312 -0.404 . . . . 0.0 111.562 -179.504 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 193' ' ' ASP . . . . . . . . . . . . . 19.3 m-20 -53.78 -46.3 70.95 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.349 -0.387 . . . . 0.0 110.965 -179.89 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 194' ' ' VAL . . . . . 0.407 HG23 ' O ' ' A' ' 190' ' ' PRO . 69.5 t -65.36 -36.05 76.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.28 -0.418 . . . . 0.0 110.883 179.712 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 195' ' ' ALA . . . . . . . . . . . . . . . -55.0 -44.45 74.51 Favored 'General case' 0 C--N 1.331 -0.199 0 CA-C-N 116.421 -0.354 . . . . 0.0 110.843 179.783 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 196' ' ' LEU . . . . . . . . . . . . . 91.2 mt -68.07 -39.05 83.03 Favored 'General case' 0 C--N 1.332 -0.195 0 CA-C-O 120.895 0.379 . . . . 0.0 110.387 179.26 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 197' ' ' ILE . . . . . 0.449 HG12 HG21 ' A' ' 177' ' ' ILE . 13.2 mm -58.57 -56.31 17.24 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-N 115.971 -0.559 . . . . 0.0 110.083 179.091 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 198' ' ' VAL . . . . . . . . . . . . . 73.6 t -53.6 -34.46 24.09 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.509 0 CA-C-N 115.442 -0.799 . . . . 0.0 109.368 178.208 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 199' ' ' TYR . . . . . . . . . . . . . 70.0 t80 -69.92 -31.43 69.2 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 115.203 -0.908 . . . . 0.0 110.628 180.0 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 200' ' ' LEU . . . . . 0.446 HD12 HD13 ' A' ' 197' ' ' ILE . 62.5 mt -67.75 -45.53 74.7 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 115.9 -0.591 . . . . 0.0 111.299 -179.73 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 201' ' ' ASP . . . . . . . . . . . . . 7.8 m-20 -70.56 -32.61 70.1 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 121.063 0.459 . . . . 0.0 110.396 179.957 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 202' ' ' LEU . . . . . 0.489 HD11 ' HA2' ' A' ' 11' ' ' GLY . 3.9 mt -66.81 -41.99 86.64 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 115.544 -0.753 . . . . 0.0 111.882 -179.892 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 203' ' ' VAL . . . . . 0.406 ' CG1' HD22 ' A' ' 170' ' ' LEU . 8.2 p -71.47 -37.01 62.81 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.366 0 N-CA-C 111.883 0.327 . . . . 0.0 111.883 -178.582 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 204' ' ' THR . . . . . 0.439 ' O ' ' HB2' ' A' ' 208' ' ' PHE . 24.5 m -65.37 -47.29 76.89 Favored 'General case' 0 C--N 1.329 -0.312 0 C-N-CA 120.832 -0.347 . . . . 0.0 111.674 -179.92 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 205' ' ' LYS . . . . . 0.67 ' HE2' ' HB2' ' A' ' 47' ' ' ALA . 60.4 mttp -79.3 -57.93 3.47 Favored 'General case' 0 C--N 1.326 -0.429 0 N-CA-C 112.168 0.432 . . . . 0.0 112.168 -178.225 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 44.4 t -67.33 -37.39 78.93 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.388 0 CA-C-N 116.331 -0.395 . . . . 0.0 111.522 -179.413 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 207' ' ' GLY . . . . . . . . . . . . . . . -70.75 -53.65 11.42 Favored Glycine 0 C--N 1.331 0.278 0 C-N-CA 120.663 -0.78 . . . . 0.0 112.668 -179.622 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 208' ' ' PHE . . . . . 0.439 ' HB2' ' O ' ' A' ' 204' ' ' THR . 5.4 t80 -57.3 -42.42 81.75 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 120.872 0.368 . . . . 0.0 110.67 179.699 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 209' ' ' GLY . . . . . 0.487 ' O ' ' HB3' ' A' ' 212' ' ' ALA . . . -69.93 -38.51 75.0 Favored Glycine 0 N--CA 1.452 -0.296 0 CA-C-N 115.405 -0.816 . . . . 0.0 113.417 -179.766 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 210' ' ' PHE . . . . . . . . . . . . . 1.1 m-85 -69.43 -38.7 77.96 Favored 'General case' 0 CA--C 1.51 -0.58 0 N-CA-C 107.944 -1.132 . . . . 0.0 107.944 179.201 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 211' ' ' ILE . . . . . . . . . . . . . 82.9 mt -70.67 -28.69 35.18 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.825 0 N-CA-C 107.133 -1.432 . . . . 0.0 107.133 176.353 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 212' ' ' ALA . . . . . 0.487 ' HB3' ' O ' ' A' ' 209' ' ' GLY . . . -68.14 -37.94 81.61 Favored 'General case' 0 N--CA 1.45 -0.469 0 CA-C-N 114.394 -1.276 . . . . 0.0 110.572 179.704 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 213' ' ' LEU . . . . . . . . . . . . . 88.3 mt -70.1 -53.44 17.38 Favored 'General case' 0 C--N 1.331 -0.198 0 CA-C-N 115.28 -0.873 . . . . 0.0 111.444 -179.608 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 214' ' ' ASP . . . . . . . . . . . . . 25.6 t70 -54.15 -36.32 63.19 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.308 -0.406 . . . . 0.0 110.933 -179.764 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 215' ' ' ALA . . . . . 0.528 ' HB1' HD13 ' A' ' 159' ' ' LEU . . . -67.29 -57.27 6.97 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.026 -0.534 . . . . 0.0 111.457 -179.935 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 216' ' ' ALA . . . . . . . . . . . . . . . -58.57 -43.03 89.28 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.414 -0.357 . . . . 0.0 111.218 -179.735 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 217' ' ' ALA . . . . . . . . . . . . . . . -57.76 -36.8 72.6 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.502 179.831 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 218' ' ' THR . . . . . . . . . . . . . 90.9 m . . . . . 0 C--N 1.33 -0.268 0 CA-C-N 115.905 -0.589 . . . . 0.0 110.802 179.558 . . . . . . . . 0 0 . 1 . 029 nuclear nobuild core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.253 0 N-CA-C 112.763 -0.135 . . . . 0.0 112.763 . . . . . . . . . 0 0 . 1 . 029 nuclear nobuild core ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 89.1 mt -64.28 -37.42 87.42 Favored 'General case' 0 N--CA 1.45 -0.46 0 CA-C-O 120.841 0.353 . . . . 0.0 111.199 -179.945 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 5' ' ' THR . . . . . 0.46 ' HA ' ' HD2' ' A' ' 8' ' ' PHE . 78.5 p -59.79 -37.34 78.82 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.047 -0.524 . . . . 0.0 111.968 -179.6 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 20.1 p -54.24 -36.88 64.02 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.45 -0.341 . . . . 0.0 111.515 -179.441 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 7' ' ' LEU . . . . . . . . . . . . . 4.2 mm? -61.9 -53.05 61.06 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.308 -0.406 . . . . 0.0 111.344 -179.705 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 8' ' ' PHE . . . . . 0.721 ' HB2' ' HB2' ' A' ' 55' ' ' ALA . 29.2 m-85 -61.99 -27.32 68.78 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.367 -0.379 . . . . 0.0 111.223 -179.574 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 9' ' ' TRP . . . . . . . . . . . . . 19.7 m95 -69.61 -44.61 70.35 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 121.008 0.433 . . . . 0.0 110.204 179.882 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 90.2 mt -65.72 -37.12 85.53 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 115.926 -0.579 . . . . 0.0 109.997 179.181 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . 0.415 ' HA2' HD11 ' A' ' 202' ' ' LEU . . . -66.12 -32.9 83.72 Favored Glycine 0 N--CA 1.446 -0.677 0 CA-C-N 115.597 -0.729 . . . . 0.0 111.746 179.568 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -68.44 -37.29 80.11 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.856 0.36 . . . . 0.0 110.442 179.428 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 67.7 mt -59.47 -53.57 46.45 Favored 'Isoleucine or valine' 0 C--O 1.234 0.247 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.254 179.114 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -58.26 -34.78 75.38 Favored Glycine 0 C--N 1.332 0.36 0 C-N-CA 120.652 -0.785 . . . . 0.0 111.977 179.291 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 15' ' ' MET . . . . . 0.497 ' HE3' ' CB ' ' A' ' 47' ' ' ALA . 17.3 mmt -66.17 -41.23 90.59 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-O 120.772 0.32 . . . . 0.0 110.57 179.426 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 16' ' ' LEU . . . . . 0.429 HD22 ' HA ' ' A' ' 16' ' ' LEU . 0.3 OUTLIER -57.01 -40.74 77.2 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.067 -0.515 . . . . 0.0 109.95 179.371 . . . . . . . . 3 3 . 1 . 029 nuclear nobuild core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 60.5 t -60.28 -48.86 86.5 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.241 0 CA-C-N 115.856 -0.611 . . . . 0.0 110.655 179.358 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -63.34 -48.55 77.95 Favored Glycine 0 C--N 1.332 0.356 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.058 179.337 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 43.9 m -50.13 -43.26 51.74 Favored 'General case' 0 C--N 1.328 -0.366 0 C-N-CA 122.317 0.247 . . . . 0.0 111.434 -179.659 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 87.2 mt -71.51 -44.41 64.69 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.597 -0.274 . . . . 0.0 111.694 -179.781 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -61.45 -31.67 71.63 Favored 'General case' 0 C--N 1.33 -0.28 0 N-CA-C 111.866 0.321 . . . . 0.0 111.866 -179.589 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 22' ' ' PHE . . . . . 0.511 ' HB2' HG22 ' A' ' 41' ' ' VAL . 6.9 m-85 -90.97 -35.37 14.72 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.693 0.283 . . . . 0.0 111.679 -179.32 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -66.84 -51.28 57.43 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-O 120.98 0.419 . . . . 0.0 111.781 -179.412 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 24' ' ' TRP . . . . . . . . . . . . . 7.3 t-105 -62.93 -50.68 69.87 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-N 115.804 -0.634 . . . . 0.0 110.891 -179.696 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.327 -0.379 0 CA-C-N 116.364 -0.38 . . . . 0.0 110.741 179.552 . . . . . . . . 0 0 . 1 . 029 nuclear nobuild core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.343 0 N-CA-C 112.454 -0.258 . . . . 0.0 112.454 . . . . . . . . . 0 0 . 1 . 029 nuclear nobuild core ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 36.3 mt-10 -63.1 -21.03 65.9 Favored 'General case' 0 C--N 1.331 -0.218 0 CA-C-O 120.697 0.284 . . . . 0.0 110.946 179.993 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 34' ' ' ARG . . . . . . . . . . . . . 5.0 tmt_? -50.43 -38.2 41.98 Favored 'General case' 0 C--N 1.332 -0.169 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.202 -179.93 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 29.7 mmt180 -64.5 -44.86 89.6 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 116.343 -0.39 . . . . 0.0 111.211 -179.928 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 57.1 m-85 -66.78 -31.06 71.44 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.113 -179.989 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 37' ' ' TYR . . . . . 0.519 ' O ' HG23 ' A' ' 41' ' ' VAL . 32.2 m-85 -70.97 -52.32 20.46 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.087 -179.687 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 85.4 t -57.04 -36.84 52.24 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-O 121.141 0.496 . . . . 0.0 110.232 179.387 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 55.4 m -62.21 -50.32 72.26 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 115.629 -0.714 . . . . 0.0 110.8 179.489 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 40' ' ' LEU . . . . . 0.722 HD12 HD11 ' A' ' 43' ' ' ILE . 44.5 tp -63.06 -44.66 95.19 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 115.644 -0.707 . . . . 0.0 110.922 179.877 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . 0.519 HG23 ' O ' ' A' ' 37' ' ' TYR . 86.8 t -62.72 -34.04 63.34 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.43 0 CA-C-N 116.043 -0.526 . . . . 0.0 110.076 179.142 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 42' ' ' GLY . . . . . 0.433 ' O ' HG12 ' A' ' 46' ' ' ILE . . . -60.82 -49.76 75.1 Favored Glycine 0 N--CA 1.448 -0.546 0 CA-C-N 115.461 -0.79 . . . . 0.0 113.197 -179.897 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 43' ' ' ILE . . . . . 0.722 HD11 HD12 ' A' ' 40' ' ' LEU . 22.8 pt -62.29 -48.94 86.04 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.202 0 CA-C-N 117.03 0.415 . . . . 0.0 111.993 -179.296 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 44' ' ' SER . . . . . 0.426 ' N ' HG13 ' A' ' 43' ' ' ILE . 99.0 p -59.52 -29.56 67.96 Favored 'General case' 0 C--O 1.233 0.227 0 CA-C-O 120.993 0.425 . . . . 0.0 111.016 179.961 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -77.65 -54.57 4.54 Favored Glycine 0 N--CA 1.453 -0.207 0 C-N-CA 121.075 -0.583 . . . . 0.0 113.343 -179.07 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 46' ' ' ILE . . . . . 0.587 ' O ' HG22 ' A' ' 49' ' ' VAL . 10.3 pt -58.35 -36.23 57.42 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.248 0 CA-C-O 120.758 0.313 . . . . 0.0 111.143 -179.552 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 47' ' ' ALA . . . . . 0.73 ' HB2' ' HE2' ' A' ' 205' ' ' LYS . . . -68.32 -43.06 78.42 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-O 120.939 0.4 . . . . 0.0 110.443 178.621 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -55.16 -38.17 67.94 Favored 'General case' 0 C--N 1.332 -0.193 0 CA-C-N 115.805 -0.634 . . . . 0.0 111.823 -179.795 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 49' ' ' VAL . . . . . 0.587 HG22 ' O ' ' A' ' 46' ' ' ILE . 17.5 m -76.6 -34.35 23.84 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.221 0 CA-C-O 120.611 0.244 . . . . 0.0 111.457 -179.7 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -63.64 -38.41 91.03 Favored 'General case' 0 CA--C 1.52 -0.179 0 CA-C-O 121.037 0.446 . . . . 0.0 111.042 179.897 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 28.5 m-85 -72.57 -42.64 64.41 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-N 115.824 -0.625 . . . . 0.0 110.482 -179.773 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -59.99 -53.48 57.37 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-N 115.734 -0.666 . . . . 0.0 110.925 179.681 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 53' ' ' VAL . . . . . 0.507 HG23 ' N ' ' A' ' 54' ' ' MET . 31.3 m -60.21 -48.67 87.16 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.234 0 CA-C-N 116.317 -0.402 . . . . 0.0 110.874 179.936 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 54' ' ' MET . . . . . 0.507 ' N ' HG23 ' A' ' 53' ' ' VAL . 7.0 ttp -60.74 -29.11 69.18 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 121.206 0.527 . . . . 0.0 109.922 179.431 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 55' ' ' ALA . . . . . 0.721 ' HB2' ' HB2' ' A' ' 8' ' ' PHE . . . -75.58 -19.23 59.4 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 115.622 -0.717 . . . . 0.0 111.528 179.62 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 96.8 mt -89.09 -0.83 57.76 Favored 'General case' 0 C--N 1.331 -0.198 0 CA-C-N 116.454 -0.339 . . . . 0.0 111.523 -179.441 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 99.94 -22.56 39.71 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.583 -0.818 . . . . 0.0 113.14 179.521 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 58' ' ' VAL . . . . . 0.432 HG22 ' O ' ' A' ' 53' ' ' VAL . 34.0 m -73.05 147.33 9.9 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.202 0 CA-C-N 117.008 0.404 . . . . 0.0 110.568 179.729 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 59' ' ' GLY . . . . . 0.456 ' HA3' ' HD3' ' A' ' 71' ' ' PRO . . . 90.86 13.71 58.9 Favored Glycine 0 N--CA 1.448 -0.525 0 C-N-CA 120.694 -0.765 . . . . 0.0 111.869 -178.934 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 60' ' ' TRP . . . . . . . . . . . . . 13.3 m0 -103.34 98.42 8.33 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-O 121.14 0.495 . . . . 0.0 109.891 -179.978 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 20.8 t -91.4 117.03 67.58 Favored Pre-proline 0 C--N 1.323 -0.56 0 CA-C-N 115.524 -0.762 . . . . 0.0 111.209 -178.972 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 64.8 Cg_endo -73.12 135.9 23.7 Favored 'Trans proline' 0 C--N 1.35 0.617 0 C-N-CA 122.346 2.031 . . . . 0.0 112.435 -179.928 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 46.0 t -135.18 89.05 0.82 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 115.94 -0.573 . . . . 0.0 110.718 179.696 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . 55.97 -88.7 0.02 OUTLIER 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.021 -0.536 . . . . 0.0 111.538 -179.917 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 5.2 mp0 -116.78 -19.25 9.99 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-O 121.009 0.433 . . . . 0.0 110.745 -179.866 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 66' ' ' ARG . . . . . . . . . . . . . 67.8 mtp180 -98.22 166.18 11.52 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 115.677 -0.692 . . . . 0.0 110.564 179.938 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 39.4 m -136.83 125.79 24.29 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.886 0.374 . . . . 0.0 111.381 -179.882 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 11.3 t -109.7 146.31 15.25 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.04 -0.527 . . . . 0.0 110.691 179.767 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 69' ' ' PHE . . . . . 0.405 ' HA ' ' O ' ' A' ' 59' ' ' GLY . 27.5 m-85 -108.19 115.24 29.75 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.82 0.343 . . . . 0.0 110.602 -179.717 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 70' ' ' VAL . . . . . 0.668 HG12 ' HD3' ' A' ' 71' ' ' PRO . 1.4 p -69.0 -35.42 6.19 Favored Pre-proline 0 CA--C 1.542 0.651 0 N-CA-C 113.148 0.795 . . . . 0.0 113.148 -179.317 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 71' ' ' PRO . . . . . 0.668 ' HD3' HG12 ' A' ' 70' ' ' VAL . 61.2 Cg_endo -70.49 -18.19 33.74 Favored 'Trans proline' 0 C--N 1.36 1.148 0 C-N-CA 121.741 1.627 . . . . 0.0 112.574 -179.399 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 72' ' ' ARG . . . . . 0.448 ' NH2' HG13 ' A' ' 197' ' ' ILE . 72.4 ttt180 -75.9 -54.49 6.81 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.277 -0.42 . . . . 0.0 111.835 -179.026 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 73' ' ' TYR . . . . . . . . . . . . . 83.4 m-85 -73.34 -35.68 66.06 Favored 'General case' 0 C--N 1.331 -0.21 0 C-N-CA 121.085 -0.246 . . . . 0.0 111.203 -179.103 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 74' ' ' ILE . . . . . 0.437 ' O ' HD13 ' A' ' 74' ' ' ILE . 0.3 OUTLIER -67.17 -43.87 88.2 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.238 0 C-N-CA 120.818 -0.353 . . . . 0.0 110.354 179.72 . . . . . . . . 3 3 . 1 . 029 nuclear nobuild core ' A' A ' 75' ' ' ASP . . . . . 0.508 ' O ' HG23 ' A' ' 79' ' ' THR . 20.3 t70 -59.27 -35.87 74.5 Favored 'General case' 0 N--CA 1.455 -0.188 0 N-CA-C 109.267 -0.642 . . . . 0.0 109.267 178.986 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 76' ' ' TRP . . . . . 0.5 ' HB3' ' SD ' ' A' ' 109' ' ' MET . 39.3 m0 -64.0 -36.57 84.41 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 115.702 -0.681 . . . . 0.0 110.577 179.134 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 77' ' ' ILE . . . . . 0.472 ' O ' ' HG2' ' A' ' 81' ' ' PRO . 79.5 mt -67.29 -28.95 44.16 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.239 179.5 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 81.9 mt -91.33 -14.74 30.24 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.068 -0.515 . . . . 0.0 112.023 179.868 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 79' ' ' THR . . . . . 0.508 HG23 ' O ' ' A' ' 75' ' ' ASP . 70.1 p -104.38 -53.3 2.74 Favored 'General case' 0 N--CA 1.463 0.182 0 N-CA-C 113.272 0.842 . . . . 0.0 113.272 -178.652 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 80' ' ' THR . . . . . 0.641 ' HB ' ' HD3' ' A' ' 81' ' ' PRO . 8.9 m -51.75 -55.44 29.98 Favored Pre-proline 0 C--N 1.329 -0.296 0 N-CA-C 113.014 0.746 . . . . 0.0 113.014 -178.033 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 81' ' ' PRO . . . . . 0.641 ' HD3' ' HB ' ' A' ' 80' ' ' THR . 52.7 Cg_exo -56.96 -25.58 63.35 Favored 'Trans proline' 0 C--N 1.352 0.752 0 C-N-CA 121.505 1.47 . . . . 0.0 111.77 -179.799 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 82' ' ' LEU . . . . . 0.477 HD23 HG23 ' A' ' 43' ' ' ILE . 10.9 tp -76.83 -33.16 57.96 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 115.806 -0.634 . . . . 0.0 110.577 179.961 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 83' ' ' ILE . . . . . 0.413 HG12 ' O ' ' A' ' 79' ' ' THR . 43.5 mm -65.99 -52.75 45.27 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.204 0 CA-C-O 120.883 0.373 . . . . 0.0 110.201 179.176 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 33.7 m -61.42 -30.02 47.19 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.256 0 N-CA-C 109.472 -0.566 . . . . 0.0 109.472 178.759 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 85' ' ' TYR . . . . . . . . . . . . . 68.0 t80 -67.75 -30.64 70.16 Favored 'General case' 0 N--CA 1.452 -0.329 0 CA-C-N 115.391 -0.822 . . . . 0.0 109.588 178.568 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 86' ' ' PHE . . . . . . . . . . . . . 3.3 t80 -65.14 -49.78 68.55 Favored 'General case' 0 C--O 1.232 0.172 0 CA-C-N 115.823 -0.626 . . . . 0.0 109.766 179.069 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 6.5 mt -63.87 -30.8 71.85 Favored 'General case' 0 CA--C 1.518 -0.259 0 CA-C-N 115.878 -0.601 . . . . 0.0 109.742 179.468 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -69.86 -29.08 71.18 Favored Glycine 0 N--CA 1.449 -0.455 0 CA-C-N 115.291 -0.868 . . . . 0.0 112.167 179.74 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 54.1 mt -74.04 -38.93 63.85 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-O 120.913 0.387 . . . . 0.0 110.524 179.622 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 94.6 mt -63.71 -35.82 81.81 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.002 -0.545 . . . . 0.0 110.975 179.801 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 91' ' ' ALA . . . . . 0.425 ' HB1' ' OG ' ' A' ' 148' ' ' SER . . . -80.97 -54.77 5.28 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.351 -179.677 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 101.51 61.56 0.77 Allowed Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.791 -0.719 . . . . 0.0 112.369 -179.668 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 93' ' ' LEU . . . . . 0.505 ' HB3' ' HB2' ' A' ' 97' ' ' GLU . 6.8 mp -80.37 178.37 8.34 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-O 120.797 0.332 . . . . 0.0 110.907 -179.771 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 94' ' ' ASP . . . . . . . . . . . . . 22.4 m-20 -96.15 168.09 10.81 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.658 179.73 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 67.8 m -55.32 -35.09 64.77 Favored 'General case' 0 C--N 1.33 -0.239 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.256 -179.899 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 27.6 tpt180 -69.33 -54.01 16.74 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.412 -0.358 . . . . 0.0 110.895 -179.815 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 97' ' ' GLU . . . . . 0.505 ' HB2' ' HB3' ' A' ' 93' ' ' LEU . 32.9 mt-10 -53.82 -49.55 68.12 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.098 -0.501 . . . . 0.0 111.184 -179.639 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 98' ' ' PHE . . . . . 0.42 ' O ' HG12 ' A' ' 102' ' ' ILE . 25.4 m-85 -55.26 -51.19 67.43 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.397 -0.365 . . . . 0.0 111.002 179.902 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -56.9 -29.89 59.44 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.858 -0.687 . . . . 0.0 112.637 -179.74 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 100' ' ' ILE . . . . . 0.41 HD12 ' HA ' ' A' ' 97' ' ' GLU . 77.4 mt -72.85 -43.26 60.45 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-O 120.85 0.357 . . . . 0.0 111.308 -179.903 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 61.3 t -68.29 -49.8 63.41 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.355 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.702 -179.435 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 102' ' ' ILE . . . . . 0.42 HG12 ' O ' ' A' ' 98' ' ' PHE . 39.9 mm -58.11 -52.23 61.11 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 CA-C-N 116.317 -0.401 . . . . 0.0 111.584 -179.367 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 14.7 t -58.28 -34.65 70.75 Favored 'General case' 0 C--N 1.331 -0.203 0 CA-C-O 120.746 0.308 . . . . 0.0 110.82 -179.801 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 104' ' ' LEU . . . . . 0.47 HD22 ' HE2' ' A' ' 140' ' ' TYR . 30.5 tp -61.61 -45.83 92.41 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.625 179.224 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 105' ' ' ASN . . . . . 0.579 ' N ' HD22 ' A' ' 105' ' ' ASN . 0.8 OUTLIER -64.83 -26.87 68.52 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.095 -0.502 . . . . 0.0 111.117 -179.818 . . . . . . . . 3 3 . 1 . 029 nuclear nobuild core ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 99.3 m -66.29 -57.37 7.66 Favored 'General case' 0 C--N 1.331 -0.204 0 CA-C-N 116.548 -0.296 . . . . 0.0 111.351 179.878 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 8.8 p -58.16 -36.32 56.8 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.213 0 CA-C-N 116.383 -0.372 . . . . 0.0 110.862 -179.88 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . 0.423 HG23 ' O ' ' A' ' 104' ' ' LEU . 59.9 t -64.82 -53.3 43.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.554 179.358 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 109' ' ' MET . . . . . 0.563 ' HE1' HG21 ' A' ' 80' ' ' THR . 5.7 tpp -60.89 -31.06 70.56 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 115.941 -0.572 . . . . 0.0 110.417 179.885 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 11.9 mt -74.44 -30.34 61.85 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 115.976 -0.556 . . . . 0.0 110.267 179.507 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -62.43 -42.52 99.51 Favored 'General case' 0 C--N 1.332 -0.194 0 N-CA-C 109.514 -0.55 . . . . 0.0 109.514 178.607 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . -74.42 -39.18 43.25 Favored Glycine 0 N--CA 1.449 -0.438 0 N-CA-C 111.187 -0.765 . . . . 0.0 111.187 178.748 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 113' ' ' PHE . . . . . . . . . . . . . 0.7 OUTLIER -50.66 -70.92 0.07 Allowed 'General case' 0 C--N 1.332 -0.162 0 N-CA-C 109.539 -0.541 . . . . 0.0 109.539 179.02 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 114' ' ' ALA . . . . . 0.479 ' HA ' ' HB2' ' A' ' 117' ' ' MET . . . -64.13 -21.05 66.39 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 115.387 -0.824 . . . . 0.0 110.947 179.218 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 115' ' ' GLY . . . . . 0.52 ' HA2' HD22 ' A' ' 126' ' ' LEU . . . -52.25 -49.48 50.38 Favored Glycine 0 C--N 1.335 0.508 0 C-N-CA 120.765 -0.731 . . . . 0.0 111.925 179.635 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -78.5 -18.48 54.73 Favored 'General case' 0 C--N 1.325 -0.465 0 CA-C-O 120.85 0.357 . . . . 0.0 110.983 179.392 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 117' ' ' MET . . . . . 0.479 ' HB2' ' HA ' ' A' ' 114' ' ' ALA . 19.9 mmt -84.85 3.78 36.29 Favored 'General case' 0 C--N 1.332 -0.189 0 CA-C-N 116.103 -0.499 . . . . 0.0 112.03 -179.361 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 118' ' ' VAL . . . . . 0.493 HG21 ' HB3' ' A' ' 123' ' ' ARG . 35.5 m -66.31 146.32 99.03 Favored Pre-proline 0 C--N 1.328 -0.364 0 C-N-CA 121.046 -0.262 . . . . 0.0 111.407 -179.588 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 119' ' ' PRO . . . . . . . . . . . . . 92.9 Cg_endo -86.86 -11.35 5.61 Favored 'Trans proline' 0 C--N 1.348 0.535 0 C-N-CA 122.674 2.25 . . . . 0.0 112.226 179.781 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -140.27 -124.98 2.15 Favored Glycine 0 C--N 1.331 0.281 0 C-N-CA 120.84 -0.695 . . . . 0.0 112.795 -179.907 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 2.3 pp -109.94 18.15 7.06 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.187 0 CA-C-O 120.782 0.325 . . . . 0.0 111.695 -179.564 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 42.8 mt-10 -66.47 -18.53 65.41 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.306 -0.407 . . . . 0.0 111.159 -179.9 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 123' ' ' ARG . . . . . 0.493 ' HB3' HG21 ' A' ' 118' ' ' VAL . 17.8 ptt180 -50.47 -34.61 25.52 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.825 -179.516 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 124' ' ' TYR . . . . . . . . . . . . . 29.2 m-85 -61.5 -34.13 74.96 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.766 0.317 . . . . 0.0 111.13 -179.552 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 125' ' ' ALA . . . . . . . . . . . . . . . -74.5 -49.69 21.1 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.908 179.788 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 126' ' ' LEU . . . . . 0.52 HD22 ' HA2' ' A' ' 115' ' ' GLY . 7.3 mp -53.39 -49.15 67.84 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-N 116.051 -0.522 . . . . 0.0 110.588 179.921 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 127' ' ' PHE . . . . . . . . . . . . . 5.4 t80 -67.0 -37.77 84.78 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.821 179.958 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 128' ' ' GLY . . . . . . . . . . . . . . . -46.34 -43.09 13.98 Favored Glycine 0 C--N 1.332 0.338 0 C-N-CA 120.156 -1.021 . . . . 0.0 110.817 179.097 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 129' ' ' MET . . . . . . . . . . . . . 0.8 OUTLIER -71.81 -39.05 70.11 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.921 0.391 . . . . 0.0 109.971 178.509 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -60.95 -32.88 81.57 Favored Glycine 0 C--N 1.333 0.401 0 CA-C-N 115.916 -0.584 . . . . 0.0 113.043 -179.911 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -74.84 -53.87 8.32 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-O 120.669 0.271 . . . . 0.0 110.883 179.959 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 48.2 t -56.4 -40.35 66.54 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.228 0 CA-C-O 121.478 0.656 . . . . 0.0 109.477 179.055 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -68.52 -37.82 80.35 Favored 'General case' 0 N--CA 1.451 -0.424 0 CA-C-N 115.102 -0.954 . . . . 0.0 110.408 179.24 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 134' ' ' PHE . . . . . . . . . . . . . 79.5 t80 -54.64 -51.93 63.87 Favored 'General case' 0 N--CA 1.451 -0.388 0 CA-C-N 116.09 -0.505 . . . . 0.0 109.901 179.387 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 135' ' ' ILE . . . . . 0.523 ' O ' HG22 ' A' ' 138' ' ' VAL . 56.5 mt -58.75 -33.55 49.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 115.647 -0.706 . . . . 0.0 110.046 179.068 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . -58.4 -36.35 83.55 Favored Glycine 0 N--CA 1.449 -0.449 0 C-N-CA 120.239 -0.982 . . . . 0.0 111.136 178.616 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 137' ' ' LEU . . . . . . . . . . . . . 38.4 tp -71.1 -53.15 15.64 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 115.769 -0.216 . . . . 0.0 110.805 179.494 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 138' ' ' VAL . . . . . 0.523 HG22 ' O ' ' A' ' 135' ' ' ILE . 3.3 m -55.97 -32.55 33.38 Favored 'Isoleucine or valine' 0 C--O 1.232 0.137 0 CA-C-O 121.233 0.539 . . . . 0.0 109.863 179.483 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 139' ' ' TYR . . . . . . . . . . . . . 34.4 t80 -60.3 -50.15 74.78 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 115.5 -0.773 . . . . 0.0 110.303 178.894 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 140' ' ' TYR . . . . . 0.47 ' HE2' HD22 ' A' ' 104' ' ' LEU . 22.4 m-85 -56.9 -35.41 68.96 Favored 'General case' 0 C--N 1.332 -0.152 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.741 179.64 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 141' ' ' LEU . . . . . . . . . . . . . 96.0 mt -57.73 -52.0 67.23 Favored 'General case' 0 C--N 1.332 -0.172 0 CA-C-N 116.355 -0.384 . . . . 0.0 110.504 179.602 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 10.2 t -78.48 -10.35 12.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.09 -0.505 . . . . 0.0 110.778 179.672 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . -71.58 -131.39 0.11 Allowed Glycine 0 CA--C 1.521 0.45 0 C-N-CA 120.886 -0.673 . . . . 0.0 112.677 -179.887 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 144' ' ' PRO . . . . . . . . . . . . . 44.8 Cg_endo -67.84 -24.09 40.71 Favored 'Trans proline' 0 C--N 1.348 0.542 0 C-N-CA 122.403 2.069 . . . . 0.0 112.5 -179.888 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 145' ' ' MET . . . . . . . . . . . . . 45.2 mtt -55.41 -34.62 64.57 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 120.983 0.421 . . . . 0.0 111.063 179.876 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 146' ' ' THR . . . . . . . . . . . . . 27.4 m -70.78 -45.82 64.02 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 115.991 -0.55 . . . . 0.0 112.077 -179.181 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 46.3 mt-10 -72.22 -29.51 64.03 Favored 'General case' 0 C--N 1.328 -0.345 0 N-CA-C 111.846 0.313 . . . . 0.0 111.846 -179.101 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 148' ' ' SER . . . . . 0.425 ' OG ' ' HB1' ' A' ' 91' ' ' ALA . 42.0 p -70.15 -45.04 67.6 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.551 -0.295 . . . . 0.0 111.488 -179.241 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 149' ' ' ALA . . . . . . . . . . . . . . . -77.98 -39.84 41.13 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.772 0.32 . . . . 0.0 111.79 -179.514 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 150' ' ' SER . . . . . . . . . . . . . 40.3 t -65.82 -5.09 7.9 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.284 -0.416 . . . . 0.0 111.517 -179.536 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 151' ' ' GLN . . . . . . . . . . . . . 48.4 mt-30 -127.1 17.44 7.2 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.614 -0.266 . . . . 0.0 111.232 179.876 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 25.2 tpt180 -93.82 -52.04 4.62 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-O 120.817 0.341 . . . . 0.0 111.074 179.944 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 153' ' ' SER . . . . . 0.611 ' HB3' HG12 ' A' ' 156' ' ' ILE . 23.1 t -157.38 172.57 18.35 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.581 179.466 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 154' ' ' SER . . . . . . . . . . . . . 47.6 t -70.39 -39.8 74.33 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.773 0.32 . . . . 0.0 110.949 179.961 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -76.95 -34.7 41.54 Favored Glycine 0 CA--C 1.518 0.254 0 C-N-CA 120.862 -0.685 . . . . 0.0 112.986 -179.899 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 156' ' ' ILE . . . . . 0.611 HG12 ' HB3' ' A' ' 153' ' ' SER . 38.5 mm -54.46 -38.18 40.4 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 CA-C-O 120.605 0.24 . . . . 0.0 111.492 -179.664 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 157' ' ' LYS . . . . . 0.435 ' O ' HG22 ' A' ' 161' ' ' VAL . 27.2 ttpp -68.22 -31.98 71.87 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.41 -0.359 . . . . 0.0 111.371 -179.724 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 53.5 m -71.39 -48.5 49.56 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-O 120.898 0.38 . . . . 0.0 111.411 -179.631 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 159' ' ' LEU . . . . . 0.524 HD21 ' HB3' ' A' ' 215' ' ' ALA . 14.3 mt -71.16 -35.48 71.67 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.607 -179.637 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 160' ' ' TYR . . . . . . . . . . . . . 76.3 t80 -64.95 -44.86 88.04 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.471 -0.331 . . . . 0.0 111.874 -179.098 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 161' ' ' VAL . . . . . 0.435 HG22 ' O ' ' A' ' 157' ' ' LYS . 31.0 m -67.35 -46.28 84.06 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 N-CA-C 111.927 0.343 . . . . 0.0 111.927 -179.172 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 162' ' ' ARG . . . . . 0.433 ' N ' HG23 ' A' ' 161' ' ' VAL . 78.5 mtm180 -64.78 -35.9 82.57 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.73 0.3 . . . . 0.0 111.529 -179.631 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 163' ' ' LEU . . . . . 0.56 ' HG ' ' HB2' ' A' ' 208' ' ' PHE . 7.7 mp -76.87 -51.37 11.38 Favored 'General case' 0 C--N 1.328 -0.349 0 N-CA-C 112.179 0.437 . . . . 0.0 112.179 -179.074 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 164' ' ' ARG . . . . . . . . . . . . . 5.6 ppt_? -62.11 -41.68 98.47 Favored 'General case' 0 C--N 1.328 -0.331 0 N-CA-C 112.064 0.394 . . . . 0.0 112.064 -178.514 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 165' ' ' ASN . . . . . 0.463 ' O ' HG23 ' A' ' 169' ' ' VAL . 17.4 m-80 -69.38 -51.38 37.18 Favored 'General case' 0 C--N 1.332 -0.188 0 CA-C-O 120.696 0.284 . . . . 0.0 111.616 -179.788 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 166' ' ' LEU . . . . . 0.476 ' O ' ' HG ' ' A' ' 170' ' ' LEU . 4.2 tt -60.32 -51.33 69.97 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-O 120.844 0.354 . . . . 0.0 111.421 -179.601 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 167' ' ' THR . . . . . . . . . . . . . 88.3 m -59.91 -52.54 64.98 Favored 'General case' 0 C--N 1.329 -0.317 0 N-CA-C 112.923 0.712 . . . . 0.0 112.923 -178.826 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 168' ' ' VAL . . . . . 0.454 HG12 ' O ' ' A' ' 165' ' ' ASN . 8.9 p -54.32 -40.28 47.44 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.195 0 N-CA-C 112.297 0.48 . . . . 0.0 112.297 -178.546 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 169' ' ' VAL . . . . . 0.463 HG23 ' O ' ' A' ' 165' ' ' ASN . 79.1 t -62.03 -64.37 0.65 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-N 116.574 -0.285 . . . . 0.0 111.621 -179.721 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 170' ' ' LEU . . . . . 0.476 ' HG ' ' O ' ' A' ' 166' ' ' LEU . 1.2 pp -60.59 -30.96 70.14 Favored 'General case' 0 C--N 1.33 -0.272 0 N-CA-C 111.97 0.359 . . . . 0.0 111.97 -179.011 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 171' ' ' TRP . . . . . 0.414 ' N ' HD12 ' A' ' 170' ' ' LEU . 3.2 m0 -70.32 -35.09 73.42 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-O 120.928 0.394 . . . . 0.0 110.383 179.431 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 172' ' ' ALA . . . . . . . . . . . . . . . -69.3 -7.28 35.67 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 115.844 -0.617 . . . . 0.0 110.801 -179.793 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 173' ' ' ILE . . . . . 0.624 HG22 HD11 ' A' ' 177' ' ' ILE . 43.6 mm -84.78 -23.53 7.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 115.917 -0.583 . . . . 0.0 110.736 179.536 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 174' ' ' TYR . . . . . 0.457 ' HB2' ' HD3' ' A' ' 175' ' ' PRO . 22.2 m-85 -54.41 -51.16 80.48 Favored Pre-proline 0 N--CA 1.464 0.254 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.768 -179.89 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 175' ' ' PRO . . . . . 0.457 ' HD3' ' HB2' ' A' ' 174' ' ' TYR . 87.5 Cg_exo -46.84 -29.07 7.62 Favored 'Trans proline' 0 C--N 1.352 0.752 0 C-N-CA 122.225 1.95 . . . . 0.0 112.387 -179.905 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 176' ' ' PHE . . . . . 0.5 ' O ' ' HG ' ' A' ' 180' ' ' LEU . 81.0 m-85 -80.6 -49.81 10.8 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 115.992 -0.549 . . . . 0.0 111.802 -179.893 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 177' ' ' ILE . . . . . 0.624 HD11 HG22 ' A' ' 173' ' ' ILE . 2.4 mm -61.19 -37.15 76.83 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.54 0 CA-C-N 116.201 -0.454 . . . . 0.0 112.133 -178.043 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 178' ' ' TRP . . . . . . . . . . . . . 63.8 t90 -73.45 -41.08 63.66 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-O 120.84 0.352 . . . . 0.0 110.637 179.628 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 179' ' ' LEU . . . . . 0.479 ' O ' HG22 ' A' ' 185' ' ' VAL . 2.6 tm? -68.54 -54.07 19.02 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 115.97 -0.559 . . . . 0.0 111.259 -179.426 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 180' ' ' LEU . . . . . 0.584 HD22 HD11 ' A' ' 187' ' ' LEU . 11.9 mt -72.58 -46.49 54.05 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.541 -0.3 . . . . 0.0 111.489 -179.408 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 181' ' ' GLY . . . . . 0.424 ' HA3' ' OD1' ' A' ' 193' ' ' ASP . . . -55.1 173.13 0.99 Allowed Glycine 0 C--N 1.336 0.557 0 C-N-CA 120.558 -0.829 . . . . 0.0 112.682 179.865 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 182' ' ' PRO . . . . . 0.659 ' HA ' ' HB2' ' A' ' 186' ' ' ALA . 82.9 Cg_exo -47.78 -44.67 26.17 Favored 'Trans proline' 0 C--N 1.347 0.49 0 C-N-CA 122.776 2.317 . . . . 0.0 113.611 179.87 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 183' ' ' PRO . . . . . 0.419 ' HD3' ' HB2' ' A' ' 182' ' ' PRO . 57.6 Cg_exo -52.65 -14.85 3.6 Favored 'Trans proline' 0 C--N 1.355 0.877 0 C-N-CA 121.982 1.788 . . . . 0.0 112.551 179.633 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 184' ' ' GLY . . . . . 0.401 ' HA3' ' O ' ' A' ' 179' ' ' LEU . . . -115.08 -81.03 0.93 Allowed Glycine 0 N--CA 1.45 -0.373 0 C-N-CA 120.776 -0.726 . . . . 0.0 112.678 -179.982 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 185' ' ' VAL . . . . . 0.479 HG22 ' O ' ' A' ' 179' ' ' LEU . 6.3 m -132.05 -2.9 1.85 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.208 0 N-CA-C 112.409 0.522 . . . . 0.0 112.409 -179.572 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 186' ' ' ALA . . . . . 0.659 ' HB2' ' HA ' ' A' ' 182' ' ' PRO . . . 53.02 87.31 0.04 OUTLIER 'General case' 0 C--N 1.331 -0.22 0 CA-C-O 120.723 0.297 . . . . 0.0 111.642 179.78 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 187' ' ' LEU . . . . . 0.584 HD11 HD22 ' A' ' 180' ' ' LEU . 18.6 mt -92.01 -49.82 6.02 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 120.838 0.351 . . . . 0.0 111.406 179.934 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 188' ' ' LEU . . . . . . . . . . . . . 38.8 mt -94.84 -89.45 0.23 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.087 -0.506 . . . . 0.0 111.412 -179.325 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 189' ' ' THR . . . . . . . . . . . . . 1.1 t -165.36 148.34 6.93 Favored Pre-proline 0 C--N 1.325 -0.461 0 CA-C-N 115.856 -0.611 . . . . 0.0 111.06 -179.56 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 190' ' ' PRO . . . . . . . . . . . . . 12.1 Cg_endo -55.83 -30.31 76.17 Favored 'Trans proline' 0 C--N 1.347 0.494 0 C-N-CA 122.513 2.142 . . . . 0.0 112.427 -179.994 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 191' ' ' THR . . . . . . . . . . . . . 77.9 p -64.56 -45.28 87.78 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 121.012 0.434 . . . . 0.0 110.686 179.682 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 192' ' ' VAL . . . . . . . . . . . . . 25.4 t -73.89 -38.47 50.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 115.81 -0.632 . . . . 0.0 111.056 179.857 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 193' ' ' ASP . . . . . 0.478 ' OD1' HG22 ' A' ' 177' ' ' ILE . 14.5 t70 -59.49 -51.51 69.56 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.9 179.8 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 194' ' ' VAL . . . . . . . . . . . . . 94.6 t -64.34 -36.37 76.96 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-N 116.02 -0.536 . . . . 0.0 111.185 -179.896 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 195' ' ' ALA . . . . . . . . . . . . . . . -57.64 -48.68 78.79 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.695 0.283 . . . . 0.0 111.092 179.92 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 196' ' ' LEU . . . . . . . . . . . . . 63.0 mt -68.44 -43.27 77.47 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 116.389 -0.369 . . . . 0.0 110.589 179.617 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 197' ' ' ILE . . . . . 0.499 HG12 HG21 ' A' ' 177' ' ' ILE . 17.2 mm -56.2 -59.34 2.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 115.944 -0.571 . . . . 0.0 110.56 179.416 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 198' ' ' VAL . . . . . . . . . . . . . 61.0 t -52.3 -35.39 19.63 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.505 0 CA-C-N 115.594 -0.73 . . . . 0.0 109.433 178.62 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 199' ' ' TYR . . . . . . . . . . . . . 67.3 t80 -70.58 -31.14 68.04 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 115.244 -0.889 . . . . 0.0 110.916 -179.904 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 200' ' ' LEU . . . . . 0.536 ' O ' HG12 ' A' ' 203' ' ' VAL . 37.1 mt -71.88 -40.23 69.06 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 115.902 -0.59 . . . . 0.0 111.544 -179.545 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 201' ' ' ASP . . . . . . . . . . . . . 14.7 m-20 -72.81 -34.87 67.15 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-O 121.237 0.542 . . . . 0.0 110.114 179.519 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 202' ' ' LEU . . . . . 0.415 HD11 ' HA2' ' A' ' 11' ' ' GLY . 2.5 mt -73.01 -29.28 62.91 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 115.415 -0.811 . . . . 0.0 111.601 -179.634 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 203' ' ' VAL . . . . . 0.536 HG12 ' O ' ' A' ' 200' ' ' LEU . 12.5 p -77.6 -36.25 22.77 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.382 0 C-N-CA 121.045 -0.262 . . . . 0.0 110.669 -179.083 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 204' ' ' THR . . . . . . . . . . . . . 98.6 m -65.49 -58.79 4.97 Favored 'General case' 0 C--N 1.329 -0.307 0 C-N-CA 120.596 -0.442 . . . . 0.0 110.994 179.306 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 205' ' ' LYS . . . . . 0.73 ' HE2' ' HB2' ' A' ' 47' ' ' ALA . 61.5 mttp -63.27 -58.1 8.27 Favored 'General case' 0 C--N 1.33 -0.24 0 N-CA-C 112.461 0.541 . . . . 0.0 112.461 -178.259 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 44.6 t -69.97 -37.54 72.94 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.412 0 N-CA-C 112.235 0.458 . . . . 0.0 112.235 -178.751 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 207' ' ' GLY . . . . . 0.52 ' O ' HG13 ' A' ' 211' ' ' ILE . . . -58.22 -61.83 6.97 Favored Glycine 0 CA--C 1.52 0.365 0 C-N-CA 120.67 -0.776 . . . . 0.0 114.059 -178.486 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 208' ' ' PHE . . . . . 0.56 ' HB2' ' HG ' ' A' ' 163' ' ' LEU . 0.9 OUTLIER -73.41 -27.04 61.24 Favored 'General case' 0 C--O 1.221 -0.414 0 CA-C-N 117.47 0.635 . . . . 0.0 110.802 -179.14 . . . . . . . . 3 3 . 1 . 029 nuclear nobuild core ' A' A ' 209' ' ' GLY . . . . . 0.502 ' O ' ' HB3' ' A' ' 212' ' ' ALA . . . -63.19 -32.39 83.99 Favored Glycine 0 N--CA 1.447 -0.626 0 N-CA-C 111.663 -0.575 . . . . 0.0 111.663 178.616 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 210' ' ' PHE . . . . . . . . . . . . . 1.3 m-85 -75.08 -46.91 31.52 Favored 'General case' 0 CA--C 1.514 -0.439 0 N-CA-C 108.37 -0.974 . . . . 0.0 108.37 178.336 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 211' ' ' ILE . . . . . 0.52 HG13 ' O ' ' A' ' 207' ' ' GLY . 4.1 mt -63.41 -27.59 43.34 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.411 0 N-CA-C 107.473 -1.306 . . . . 0.0 107.473 176.67 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 212' ' ' ALA . . . . . 0.502 ' HB3' ' O ' ' A' ' 209' ' ' GLY . . . -63.79 -41.23 97.98 Favored 'General case' 0 N--CA 1.45 -0.461 0 CA-C-N 114.303 -1.317 . . . . 0.0 110.634 -179.772 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 213' ' ' LEU . . . . . . . . . . . . . 72.9 mt -70.12 -50.17 43.43 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 115.179 -0.919 . . . . 0.0 111.783 -179.393 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 214' ' ' ASP . . . . . . . . . . . . . 21.7 t70 -53.24 -51.83 60.94 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.331 -0.395 . . . . 0.0 111.581 -179.315 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 215' ' ' ALA . . . . . 0.524 ' HB3' HD21 ' A' ' 159' ' ' LEU . . . -64.63 -55.32 20.99 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.379 -0.373 . . . . 0.0 111.772 -179.54 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 216' ' ' ALA . . . . . . . . . . . . . . . -51.87 -37.07 50.78 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 116.414 -0.357 . . . . 0.0 111.496 -179.707 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 217' ' ' ALA . . . . . . . . . . . . . . . -63.65 -44.26 94.36 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.997 0.427 . . . . 0.0 110.06 179.577 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 218' ' ' THR . . . . . . . . . . . . . 54.3 m . . . . . 0 C--N 1.33 -0.258 0 CA-C-N 115.669 -0.696 . . . . 0.0 110.626 179.376 . . . . . . . . 0 0 . 1 . 030 nuclear nobuild core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.338 0 N-CA-C 112.481 -0.248 . . . . 0.0 112.481 . . . . . . . . . 0 0 . 1 . 030 nuclear nobuild core ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 55.3 tp -74.26 -35.84 63.82 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.904 0.383 . . . . 0.0 110.801 179.785 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 68.3 p -64.22 -29.67 70.76 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 115.935 -0.575 . . . . 0.0 111.569 -179.74 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 29.9 p -52.8 -38.07 60.67 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.601 -179.52 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 7' ' ' LEU . . . . . 0.498 HD12 ' HA ' ' A' ' 195' ' ' ALA . 3.4 mm? -59.4 -53.27 60.09 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.475 -0.33 . . . . 0.0 110.84 -179.798 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 8' ' ' PHE . . . . . 0.444 ' O ' ' HB3' ' A' ' 51' ' ' TYR . 73.9 m-85 -58.43 -36.2 73.28 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.594 179.879 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 9' ' ' TRP . . . . . . . . . . . . . 25.4 m95 -64.94 -41.03 95.87 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-O 121.161 0.505 . . . . 0.0 110.151 179.825 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 83.1 mt -62.35 -49.51 75.3 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 115.562 -0.744 . . . . 0.0 110.519 179.512 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -55.21 -34.81 59.19 Favored Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.683 -0.77 . . . . 0.0 111.999 179.291 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -67.86 -36.23 79.94 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-O 120.795 0.331 . . . . 0.0 110.847 179.745 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 91.1 mt -60.28 -54.16 38.79 Favored 'Isoleucine or valine' 0 C--O 1.234 0.241 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.668 179.556 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -63.02 -30.64 78.1 Favored Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 120.688 -0.768 . . . . 0.0 111.871 179.478 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 15' ' ' MET . . . . . 0.617 ' HB3' ' HB2' ' A' ' 48' ' ' ALA . 0.0 OUTLIER -64.46 -48.93 73.42 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.666 0.27 . . . . 0.0 110.835 179.656 . . . . . . . . 3 3 . 1 . 030 nuclear nobuild core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -57.7 -41.3 81.42 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.334 -0.393 . . . . 0.0 110.94 179.73 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 96.5 t -59.33 -42.57 87.73 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.25 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.554 179.503 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -70.44 -46.73 46.88 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.845 -0.693 . . . . 0.0 112.1 179.588 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 20.5 m -49.5 -45.39 47.03 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-O 120.78 0.324 . . . . 0.0 111.134 -179.755 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 68.3 mt -71.51 -36.74 71.17 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.099 179.618 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -64.09 -31.85 73.19 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.316 -0.402 . . . . 0.0 111.537 -179.801 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 22' ' ' PHE . . . . . 0.714 ' HB2' HG22 ' A' ' 41' ' ' VAL . 7.5 m-85 -90.28 -28.4 18.82 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-O 120.813 0.34 . . . . 0.0 110.939 -179.688 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -72.28 -50.56 26.17 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.176 -0.465 . . . . 0.0 111.288 -179.784 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 24' ' ' TRP . . . . . . . . . . . . . 5.5 t-105 -64.73 -40.07 94.7 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-N 115.73 -0.668 . . . . 0.0 111.195 -179.641 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.33 -0.258 0 CA-C-O 120.855 0.36 . . . . 0.0 110.936 179.622 . . . . . . . . 0 0 . 1 . 030 nuclear nobuild core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.338 0 N-CA-C 112.464 -0.254 . . . . 0.0 112.464 . . . . . . . . . 0 0 . 1 . 030 nuclear nobuild core ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 16.7 mm-40 -65.05 -23.67 67.25 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.562 0.22 . . . . 0.0 111.167 -179.891 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 34' ' ' ARG . . . . . . . . . . . . . 52.9 ttt180 -50.85 -30.74 15.27 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.367 -0.379 . . . . 0.0 111.29 -179.716 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 79.7 ttt180 -60.13 -50.69 72.71 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.294 -0.412 . . . . 0.0 111.011 -179.838 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 73.7 m-85 -61.74 -30.47 70.8 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.091 -0.504 . . . . 0.0 111.211 -179.847 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 37' ' ' TYR . . . . . 0.595 ' O ' HG23 ' A' ' 41' ' ' VAL . 64.0 m-85 -70.88 -54.08 12.77 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.281 -0.418 . . . . 0.0 111.141 -179.805 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 61.8 t -56.99 -38.45 60.0 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.223 0 CA-C-O 120.959 0.409 . . . . 0.0 110.654 179.86 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 20.5 m -65.39 -51.18 62.15 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 115.832 -0.622 . . . . 0.0 110.864 179.645 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 40' ' ' LEU . . . . . 0.561 HD12 HD12 ' A' ' 43' ' ' ILE . 38.0 tp -56.98 -46.84 81.95 Favored 'General case' 0 C--O 1.236 0.343 0 CA-C-N 115.894 -0.593 . . . . 0.0 110.578 179.721 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . 0.714 HG22 ' HB2' ' A' ' 22' ' ' PHE . 62.9 t -60.26 -34.28 56.76 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.326 0 CA-C-N 115.857 -0.61 . . . . 0.0 110.3 179.083 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -61.27 -39.3 97.01 Favored Glycine 0 N--CA 1.448 -0.539 0 C-N-CA 120.743 -0.742 . . . . 0.0 111.988 179.925 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 43' ' ' ILE . . . . . 0.561 HD12 HD12 ' A' ' 40' ' ' LEU . 0.7 OUTLIER -65.13 -56.59 14.87 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.223 0 CA-C-O 120.827 0.346 . . . . 0.0 110.998 179.797 . . . . . . . . 3 3 . 1 . 030 nuclear nobuild core ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 36.3 t -57.24 -27.6 62.17 Favored 'General case' 0 C--N 1.332 -0.156 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.431 -179.747 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -76.2 -53.57 5.59 Favored Glycine 0 CA--C 1.519 0.342 0 C-N-CA 120.664 -0.779 . . . . 0.0 113.327 -179.288 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 19.7 pt -58.34 -40.03 76.5 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.168 0 CA-C-O 120.738 0.304 . . . . 0.0 111.522 -179.418 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 47' ' ' ALA . . . . . 0.695 ' HB2' ' HE2' ' A' ' 205' ' ' LYS . . . -67.44 -43.67 80.56 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-N 116.436 -0.347 . . . . 0.0 111.364 179.603 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 48' ' ' ALA . . . . . 0.617 ' HB2' ' HB3' ' A' ' 15' ' ' MET . . . -55.1 -43.76 74.32 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.079 -0.51 . . . . 0.0 111.831 -179.423 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 28.4 m -73.8 -33.89 38.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.454 -0.339 . . . . 0.0 111.503 -179.428 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -65.35 -38.54 90.39 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-O 120.927 0.394 . . . . 0.0 111.148 179.74 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 51' ' ' TYR . . . . . 0.557 ' HE2' ' HE2' ' A' ' 15' ' ' MET . 29.0 m-85 -73.06 -35.56 66.71 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 116.132 -0.486 . . . . 0.0 110.756 -179.736 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -63.9 -42.22 97.51 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.291 -0.413 . . . . 0.0 110.938 179.263 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 53' ' ' VAL . . . . . 0.429 HG23 ' N ' ' A' ' 54' ' ' MET . 21.7 m -74.87 -45.1 44.41 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.177 0 CA-C-N 116.271 -0.422 . . . . 0.0 111.42 -179.981 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 54' ' ' MET . . . . . 0.429 ' N ' HG23 ' A' ' 53' ' ' VAL . 70.6 mtm -62.74 -32.01 73.05 Favored 'General case' 0 C--N 1.332 -0.174 0 CA-C-O 120.952 0.406 . . . . 0.0 110.296 179.572 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -63.02 -18.05 62.9 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 115.772 -0.649 . . . . 0.0 111.01 179.476 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 81.8 mt -99.14 -9.16 24.15 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 115.998 -0.546 . . . . 0.0 110.933 179.771 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 73.59 31.1 61.1 Favored Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.809 -0.71 . . . . 0.0 112.96 179.784 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 58' ' ' VAL . . . . . 0.418 HG22 ' O ' ' A' ' 53' ' ' VAL . 32.6 m -81.24 14.5 0.45 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-O 120.907 0.384 . . . . 0.0 111.525 179.893 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -151.85 10.27 0.67 Allowed Glycine 0 N--CA 1.45 -0.389 0 C-N-CA 120.882 -0.675 . . . . 0.0 112.734 179.938 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 60' ' ' TRP . . . . . . . . . . . . . 38.4 m0 -78.33 109.52 12.54 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.631 0.253 . . . . 0.0 110.573 179.842 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 7.6 p -102.32 130.75 23.53 Favored Pre-proline 0 C--N 1.329 -0.294 0 CA-C-N 116.431 -0.35 . . . . 0.0 111.255 -179.723 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 7.8 Cg_exo -72.87 144.14 38.18 Favored 'Trans proline' 0 C--N 1.35 0.622 0 C-N-CA 122.675 2.25 . . . . 0.0 112.383 -179.851 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 85.9 t -143.85 96.29 0.53 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.201 0 CA-C-N 115.993 -0.549 . . . . 0.0 111.031 179.968 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . 60.58 -86.15 0.02 OUTLIER 'General case' 0 C--N 1.333 -0.122 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.223 -179.902 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 11.4 tp10 -124.66 -23.93 4.27 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-O 120.927 0.394 . . . . 0.0 110.38 179.793 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 66' ' ' ARG . . . . . . . . . . . . . 96.9 mtt180 -103.13 153.41 20.34 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 115.809 -0.632 . . . . 0.0 110.4 179.739 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 91.2 m -111.94 119.34 38.19 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-O 120.952 0.406 . . . . 0.0 111.671 -179.336 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 68' ' ' VAL . . . . . 0.582 HG11 ' HG3' ' A' ' 117' ' ' MET . 42.4 t -90.52 147.03 5.49 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-N 115.938 -0.574 . . . . 0.0 110.401 179.224 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 69' ' ' PHE . . . . . . . . . . . . . 21.9 m-85 -105.11 114.55 28.82 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-O 121.008 0.432 . . . . 0.0 110.247 -179.367 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 70' ' ' VAL . . . . . 0.54 ' HB ' ' HD3' ' A' ' 71' ' ' PRO . 13.6 t -68.83 -50.09 24.66 Favored Pre-proline 0 C--N 1.325 -0.486 0 CA-C-N 115.937 -0.574 . . . . 0.0 112.471 -178.856 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 71' ' ' PRO . . . . . 0.54 ' HD3' ' HB ' ' A' ' 70' ' ' VAL . 16.4 Cg_exo -66.57 -17.84 53.47 Favored 'Trans proline' 0 C--N 1.351 0.671 0 C-N-CA 122.252 1.968 . . . . 0.0 112.698 -179.304 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 72' ' ' ARG . . . . . 0.417 ' NH2' HG13 ' A' ' 197' ' ' ILE . 66.2 ttt180 -66.25 -55.31 16.76 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-O 120.866 0.365 . . . . 0.0 111.539 -179.346 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 73' ' ' TYR . . . . . 0.473 ' O ' HG13 ' A' ' 77' ' ' ILE . 77.7 m-85 -71.59 -33.76 69.31 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.38 -0.373 . . . . 0.0 110.687 -179.492 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 74' ' ' ILE . . . . . 0.487 ' HA ' HD12 ' A' ' 77' ' ' ILE . 0.4 OUTLIER -67.51 -36.84 77.55 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.2 0 N-CA-C 109.768 -0.456 . . . . 0.0 109.768 179.106 . . . . . . . . 3 3 . 1 . 030 nuclear nobuild core ' A' A ' 75' ' ' ASP . . . . . 0.402 ' O ' HG23 ' A' ' 79' ' ' THR . 24.0 t70 -60.52 -38.51 84.65 Favored 'General case' 0 CA--C 1.519 -0.219 0 N-CA-C 108.959 -0.756 . . . . 0.0 108.959 178.506 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 76' ' ' TRP . . . . . . . . . . . . . 37.5 m0 -66.72 -30.86 71.2 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 115.438 -0.801 . . . . 0.0 110.468 179.193 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 77' ' ' ILE . . . . . 0.487 HD12 ' HA ' ' A' ' 74' ' ' ILE . 82.3 mt -68.58 -31.11 49.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-O 121.017 0.437 . . . . 0.0 110.554 179.241 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 34.4 mt -91.51 -17.55 25.51 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.11 -0.495 . . . . 0.0 112.137 -179.889 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 79' ' ' THR . . . . . 0.402 HG23 ' O ' ' A' ' 75' ' ' ASP . 72.7 p -102.32 -52.77 3.05 Favored 'General case' 0 N--CA 1.464 0.27 0 N-CA-C 113.417 0.895 . . . . 0.0 113.417 -178.238 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 80' ' ' THR . . . . . 0.695 ' HB ' ' HD3' ' A' ' 81' ' ' PRO . 49.8 m -52.39 -56.01 26.49 Favored Pre-proline 0 CA--C 1.532 0.251 0 N-CA-C 112.643 0.608 . . . . 0.0 112.643 -178.306 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 81' ' ' PRO . . . . . 0.695 ' HD3' ' HB ' ' A' ' 80' ' ' THR . 38.8 Cg_exo -58.98 -21.1 56.68 Favored 'Trans proline' 0 C--N 1.351 0.69 0 C-N-CA 121.507 1.471 . . . . 0.0 111.478 -179.942 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 82' ' ' LEU . . . . . . . . . . . . . 15.2 tp -77.03 -33.12 57.42 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 115.699 -0.682 . . . . 0.0 110.328 179.695 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 83' ' ' ILE . . . . . 0.427 HD11 HG21 ' A' ' 43' ' ' ILE . 49.1 mm -69.64 -51.86 37.36 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.166 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.232 179.25 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 35.5 m -61.1 -31.05 48.99 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.227 0 N-CA-C 109.407 -0.59 . . . . 0.0 109.407 178.706 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 85' ' ' TYR . . . . . . . . . . . . . 89.9 t80 -64.43 -34.7 78.79 Favored 'General case' 0 N--CA 1.454 -0.269 0 CA-C-N 115.472 -0.786 . . . . 0.0 109.427 178.601 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 86' ' ' PHE . . . . . . . . . . . . . 12.0 t80 -62.97 -49.6 74.06 Favored 'General case' 0 C--O 1.232 0.146 0 CA-C-N 115.765 -0.652 . . . . 0.0 110.01 179.136 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 87' ' ' LEU . . . . . 0.562 HD12 HD22 ' A' ' 141' ' ' LEU . 5.3 mt -63.59 -33.06 74.78 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 115.733 -0.667 . . . . 0.0 109.852 179.839 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -66.67 -27.52 73.28 Favored Glycine 0 N--CA 1.449 -0.474 0 CA-C-N 115.377 -0.829 . . . . 0.0 111.555 179.251 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 61.9 mt -74.58 -43.78 54.02 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.763 0.316 . . . . 0.0 111.032 179.89 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 82.6 mt -60.47 -32.34 71.31 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.123 -0.489 . . . . 0.0 111.216 -179.94 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -83.83 -54.14 5.1 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.309 -0.405 . . . . 0.0 111.424 -179.732 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 103.93 68.32 0.76 Allowed Glycine 0 N--CA 1.45 -0.369 0 C-N-CA 120.808 -0.71 . . . . 0.0 112.491 -179.706 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 93' ' ' LEU . . . . . 0.577 HD23 ' HB3' ' A' ' 97' ' ' GLU . 6.5 mp -91.23 164.77 13.77 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.712 0.291 . . . . 0.0 110.733 -179.933 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 94' ' ' ASP . . . . . . . . . . . . . 1.8 p30 -87.82 177.43 7.0 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.356 -0.384 . . . . 0.0 110.915 179.807 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 48.1 t -60.39 -32.16 71.04 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.027 -0.533 . . . . 0.0 111.881 -179.418 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 38.8 mmt180 -73.31 -53.31 11.12 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.55 -0.295 . . . . 0.0 111.62 -179.332 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 97' ' ' GLU . . . . . 0.577 ' HB3' HD23 ' A' ' 93' ' ' LEU . 44.0 mt-10 -53.3 -47.25 69.38 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.314 -0.403 . . . . 0.0 111.388 -179.671 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 98' ' ' PHE . . . . . 0.45 ' O ' HG12 ' A' ' 102' ' ' ILE . 12.6 m-85 -58.29 -49.86 75.65 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.373 -0.376 . . . . 0.0 110.876 179.975 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -54.88 -30.45 53.18 Favored Glycine 0 CA--C 1.518 0.255 0 C-N-CA 120.751 -0.737 . . . . 0.0 112.776 -179.81 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 96.3 mt -73.95 -45.53 48.72 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.214 0 CA-C-O 120.841 0.353 . . . . 0.0 111.622 -179.708 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 47.6 t -65.95 -46.74 87.52 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.411 0 CA-C-N 116.147 -0.478 . . . . 0.0 111.91 -179.161 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 102' ' ' ILE . . . . . 0.45 HG12 ' O ' ' A' ' 98' ' ' PHE . 37.6 mm -63.17 -51.77 67.19 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 N-CA-C 111.905 0.335 . . . . 0.0 111.905 -179.101 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 15.2 t -55.95 -36.72 68.1 Favored 'General case' 0 C--O 1.234 0.248 0 CA-C-O 120.869 0.366 . . . . 0.0 110.952 -179.61 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 104' ' ' LEU . . . . . 0.49 ' O ' HG23 ' A' ' 108' ' ' VAL . 29.7 tp -61.37 -47.73 84.5 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.06 -0.518 . . . . 0.0 110.683 179.464 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 105' ' ' ASN . . . . . 0.61 ' N ' HD22 ' A' ' 105' ' ' ASN . 0.8 OUTLIER -61.55 -26.33 67.87 Favored 'General case' 0 C--N 1.326 -0.438 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.745 179.848 . . . . . . . . 3 3 . 1 . 030 nuclear nobuild core ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 66.2 m -66.46 -57.3 7.65 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 116.374 -0.375 . . . . 0.0 111.331 -179.926 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 107' ' ' VAL . . . . . 0.404 HG12 ' O ' ' A' ' 104' ' ' LEU . 9.1 p -58.27 -36.57 58.51 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.142 0 CA-C-O 120.727 0.298 . . . . 0.0 111.114 -179.881 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . 0.49 HG23 ' O ' ' A' ' 104' ' ' LEU . 68.3 t -57.84 -49.58 80.52 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.372 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.519 179.513 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 109' ' ' MET . . . . . 0.453 ' HG2' ' O ' ' A' ' 105' ' ' ASN . 20.6 mmt -64.35 -30.4 71.44 Favored 'General case' 0 CA--C 1.519 -0.248 0 CA-C-N 115.868 -0.605 . . . . 0.0 110.666 179.707 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 19.4 tp -66.34 -35.61 80.8 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.069 179.555 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -64.31 -51.38 63.76 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 115.903 -0.59 . . . . 0.0 110.601 179.462 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . -66.96 -37.33 92.07 Favored Glycine 0 C--N 1.331 0.262 0 C-N-CA 120.576 -0.821 . . . . 0.0 111.861 179.478 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 113' ' ' PHE . . . . . 0.424 ' HB2' ' O ' ' A' ' 109' ' ' MET . 1.0 OUTLIER -51.02 -70.03 0.1 Allowed 'General case' 0 C--N 1.332 -0.161 0 CA-C-O 121.05 0.452 . . . . 0.0 110.02 179.541 . . . . . . . . 3 3 . 1 . 030 nuclear nobuild core ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -67.43 -19.89 65.43 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 115.663 -0.699 . . . . 0.0 110.748 179.407 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 115' ' ' GLY . . . . . 0.479 ' HA2' HD22 ' A' ' 126' ' ' LEU . . . -53.67 -44.43 69.09 Favored Glycine 0 C--N 1.334 0.441 0 C-N-CA 120.915 -0.659 . . . . 0.0 111.8 179.533 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -78.49 -28.46 46.4 Favored 'General case' 0 C--N 1.327 -0.41 0 N-CA-C 111.639 0.237 . . . . 0.0 111.639 179.741 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 117' ' ' MET . . . . . 0.582 ' HG3' HG11 ' A' ' 68' ' ' VAL . 62.9 mtt -86.08 11.37 11.89 Favored 'General case' 0 N--CA 1.463 0.224 0 N-CA-C 112.16 0.429 . . . . 0.0 112.16 -179.162 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 118' ' ' VAL . . . . . 0.495 HG21 ' HB3' ' A' ' 123' ' ' ARG . 29.9 m -63.64 146.06 96.99 Favored Pre-proline 0 C--N 1.327 -0.374 0 C-N-CA 121.037 -0.265 . . . . 0.0 111.081 179.845 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 119' ' ' PRO . . . . . . . . . . . . . 92.0 Cg_endo -81.99 -4.59 12.01 Favored 'Trans proline' 0 C--N 1.347 0.478 0 C-N-CA 122.534 2.156 . . . . 0.0 112.25 179.821 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -156.43 -132.1 1.46 Allowed Glycine 0 C--N 1.331 0.293 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.735 -179.982 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 2.0 pp -100.31 22.46 1.58 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-O 120.838 0.352 . . . . 0.0 111.265 -179.833 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 10.8 mm-40 -70.72 -19.27 62.76 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.846 179.942 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 123' ' ' ARG . . . . . 0.495 ' HB3' HG21 ' A' ' 118' ' ' VAL . 12.7 ptt180 -50.55 -31.0 14.42 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 115.923 -0.58 . . . . 0.0 111.907 -179.67 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 124' ' ' TYR . . . . . . . . . . . . . 40.2 m-85 -65.13 -35.61 81.65 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.675 0.274 . . . . 0.0 110.919 -179.629 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 125' ' ' ALA . . . . . . . . . . . . . . . -72.74 -51.08 20.64 Favored 'General case' 0 C--O 1.235 0.311 0 CA-C-O 120.849 0.357 . . . . 0.0 110.604 179.248 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 126' ' ' LEU . . . . . 0.479 HD22 ' HA2' ' A' ' 115' ' ' GLY . 7.0 mp -51.55 -52.39 47.52 Favored 'General case' 0 CA--C 1.52 -0.191 0 CA-C-N 116.005 -0.543 . . . . 0.0 110.135 179.488 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 127' ' ' PHE . . . . . 0.464 ' HZ ' ' HB3' ' A' ' 175' ' ' PRO . 8.7 t80 -63.93 -35.79 81.82 Favored 'General case' 0 N--CA 1.451 -0.419 0 CA-C-N 115.848 -0.615 . . . . 0.0 110.533 179.523 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 128' ' ' GLY . . . . . . . . . . . . . . . -46.22 -45.51 15.62 Favored Glycine 0 C--N 1.333 0.38 0 C-N-CA 120.195 -1.002 . . . . 0.0 110.86 179.027 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 129' ' ' MET . . . . . . . . . . . . . 0.6 OUTLIER -69.47 -39.36 77.76 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 115.319 -0.441 . . . . 0.0 109.977 178.586 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -65.15 -27.89 72.89 Favored Glycine 0 C--N 1.331 0.299 0 CA-C-N 115.783 -0.644 . . . . 0.0 112.995 -179.842 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -74.61 -54.01 8.27 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.615 0.245 . . . . 0.0 110.406 -179.964 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 47.2 t -55.83 -40.54 62.31 Favored 'Isoleucine or valine' 0 C--O 1.234 0.241 0 CA-C-O 121.459 0.647 . . . . 0.0 109.285 178.786 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -69.1 -37.8 78.61 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 115.117 -0.947 . . . . 0.0 110.613 179.41 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 134' ' ' PHE . . . . . 0.428 ' CZ ' ' HA ' ' A' ' 172' ' ' ALA . 45.3 t80 -55.45 -52.71 62.72 Favored 'General case' 0 N--CA 1.45 -0.429 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.263 179.748 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 135' ' ' ILE . . . . . . . . . . . . . 43.7 mt -59.58 -32.75 49.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 115.915 -0.584 . . . . 0.0 109.935 179.308 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . -59.43 -40.45 96.14 Favored Glycine 0 N--CA 1.448 -0.535 0 C-N-CA 120.298 -0.954 . . . . 0.0 111.45 178.926 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 137' ' ' LEU . . . . . 0.442 HD13 HD21 ' A' ' 105' ' ' ASN . 22.4 tp -65.87 -53.07 44.5 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-O 120.683 0.277 . . . . 0.0 110.616 179.617 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 138' ' ' VAL . . . . . . . . . . . . . 13.1 t -55.48 -37.48 45.39 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.836 0 CA-C-O 121.114 0.483 . . . . 0.0 110.131 179.183 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 139' ' ' TYR . . . . . . . . . . . . . 29.9 t80 -57.84 -43.22 85.71 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 115.43 -0.805 . . . . 0.0 110.738 179.024 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 28.7 m-85 -64.17 -41.6 97.07 Favored 'General case' 0 C--N 1.332 -0.156 0 CA-C-N 116.406 -0.361 . . . . 0.0 111.467 -179.978 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 141' ' ' LEU . . . . . 0.562 HD22 HD12 ' A' ' 87' ' ' LEU . 95.4 mt -56.24 -50.34 71.59 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 116.42 -0.355 . . . . 0.0 111.143 -179.761 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 142' ' ' VAL . . . . . 0.558 HG23 HH12 ' A' ' 164' ' ' ARG . 7.7 p -83.78 -9.02 11.48 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.369 0 CA-C-O 121.153 0.501 . . . . 0.0 110.59 179.956 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 143' ' ' GLY . . . . . 0.426 ' O ' HG22 ' A' ' 146' ' ' THR . . . -73.34 -141.18 0.5 Allowed Glycine 0 CA--C 1.521 0.452 0 C-N-CA 120.881 -0.676 . . . . 0.0 112.579 179.929 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 144' ' ' PRO . . . . . . . . . . . . . 52.2 Cg_exo -54.69 -23.24 32.09 Favored 'Trans proline' 0 C--N 1.349 0.564 0 C-N-CA 122.588 2.192 . . . . 0.0 112.75 179.971 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 145' ' ' MET . . . . . . . . . . . . . 37.2 mtt -52.81 -59.22 4.76 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.479 -0.328 . . . . 0.0 111.831 -179.641 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 146' ' ' THR . . . . . 0.426 HG22 ' O ' ' A' ' 143' ' ' GLY . 11.0 t -61.04 -31.71 71.35 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.423 -0.353 . . . . 0.0 111.588 -179.476 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 29.2 mm-40 -65.13 -44.0 90.11 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 120.839 0.352 . . . . 0.0 111.223 -179.942 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 148' ' ' SER . . . . . . . . . . . . . 80.0 p -70.24 -42.28 72.43 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.236 -179.32 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 149' ' ' ALA . . . . . . . . . . . . . . . -65.34 -40.42 93.62 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.377 -179.747 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 150' ' ' SER . . . . . 0.464 ' HA ' ' HB2' ' A' ' 157' ' ' LYS . 83.6 p -68.21 -6.8 25.51 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.784 -179.913 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 151' ' ' GLN . . . . . . . . . . . . . 63.3 mt-30 -110.48 -7.54 14.74 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.119 -0.492 . . . . 0.0 110.914 179.883 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 78.3 ttt180 -75.06 -52.47 10.96 Favored 'General case' 0 C--N 1.332 -0.193 0 CA-C-N 116.443 -0.344 . . . . 0.0 110.831 -179.883 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 153' ' ' SER . . . . . 0.643 ' HB3' HG12 ' A' ' 156' ' ' ILE . 22.8 t -158.04 170.62 21.88 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.667 179.238 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 154' ' ' SER . . . . . . . . . . . . . 51.3 m -70.22 -37.62 75.07 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.288 -0.415 . . . . 0.0 110.392 179.382 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -77.0 -39.0 28.88 Favored Glycine 0 CA--C 1.519 0.298 0 C-N-CA 120.984 -0.627 . . . . 0.0 112.674 179.821 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 156' ' ' ILE . . . . . 0.643 HG12 ' HB3' ' A' ' 153' ' ' SER . 39.6 mm -52.88 -35.65 22.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-O 120.922 0.392 . . . . 0.0 111.315 -179.81 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 157' ' ' LYS . . . . . 0.464 ' HB2' ' HA ' ' A' ' 150' ' ' SER . 86.4 tttt -69.83 -37.23 76.13 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 115.967 -0.561 . . . . 0.0 112.028 -179.436 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 67.6 p -72.05 -45.0 62.46 Favored 'General case' 0 C--N 1.331 -0.205 0 CA-C-O 120.784 0.326 . . . . 0.0 111.601 -178.719 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 159' ' ' LEU . . . . . . . . . . . . . 10.0 mt -67.05 -46.26 74.92 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.632 -179.078 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 160' ' ' TYR . . . . . . . . . . . . . 55.1 t80 -61.58 -37.82 85.27 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.509 -0.314 . . . . 0.0 111.26 -179.468 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 161' ' ' VAL . . . . . 0.515 HG12 ' N ' ' A' ' 162' ' ' ARG . 1.2 t -63.23 -50.49 78.86 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.747 0 CA-C-N 116.529 -0.305 . . . . 0.0 111.64 -179.487 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 162' ' ' ARG . . . . . 0.515 ' N ' HG12 ' A' ' 161' ' ' VAL . 22.9 tpp180 -69.1 -34.86 75.76 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.44 -0.345 . . . . 0.0 111.439 -179.446 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 163' ' ' LEU . . . . . 0.576 ' HG ' ' HB2' ' A' ' 208' ' ' PHE . 3.2 mp -69.5 -45.02 69.89 Favored 'General case' 0 C--N 1.328 -0.37 0 CA-C-N 116.27 -0.423 . . . . 0.0 111.604 -179.408 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 164' ' ' ARG . . . . . 0.59 ' HE ' HD21 ' A' ' 165' ' ' ASN . 0.1 OUTLIER -71.95 -41.07 68.23 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.557 -0.292 . . . . 0.0 111.308 -179.125 . . . . . . . . 3 3 . 1 . 030 nuclear nobuild core ' A' A ' 165' ' ' ASN . . . . . 0.59 HD21 ' HE ' ' A' ' 164' ' ' ARG . 0.9 OUTLIER -57.25 -50.88 71.49 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.795 0.331 . . . . 0.0 111.05 179.953 . . . . . . . . 3 3 . 1 . 030 nuclear nobuild core ' A' A ' 166' ' ' LEU . . . . . . . . . . . . . 3.8 tt -64.17 -54.59 31.32 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.109 -0.496 . . . . 0.0 111.548 -179.47 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 167' ' ' THR . . . . . 0.416 ' O ' ' HB2' ' A' ' 171' ' ' TRP . 76.5 m -54.81 -53.13 59.21 Favored 'General case' 0 C--N 1.33 -0.277 0 N-CA-C 112.263 0.468 . . . . 0.0 112.263 -179.158 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 168' ' ' VAL . . . . . . . . . . . . . 55.1 t -55.06 -44.93 76.45 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.218 0 N-CA-C 112.328 0.492 . . . . 0.0 112.328 -178.999 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 169' ' ' VAL . . . . . 0.48 HG23 ' O ' ' A' ' 165' ' ' ASN . 43.9 t -55.91 -64.32 0.5 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-O 120.555 0.217 . . . . 0.0 111.544 -179.362 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 170' ' ' LEU . . . . . 0.555 HD12 ' HD1' ' A' ' 171' ' ' TRP . 1.1 pp -63.41 -28.56 70.06 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.661 -0.245 . . . . 0.0 111.642 -179.39 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 171' ' ' TRP . . . . . 0.555 ' HD1' HD12 ' A' ' 170' ' ' LEU . 3.5 m0 -70.54 -32.11 69.43 Favored 'General case' 0 C--N 1.333 -0.152 0 CA-C-O 120.998 0.427 . . . . 0.0 110.413 179.418 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 172' ' ' ALA . . . . . 0.428 ' HA ' ' CZ ' ' A' ' 134' ' ' PHE . . . -72.19 -6.68 44.53 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-N 115.822 -0.626 . . . . 0.0 111.102 -179.624 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 173' ' ' ILE . . . . . 0.555 ' O ' HG12 ' A' ' 177' ' ' ILE . 23.8 mm -87.54 -22.57 6.82 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.244 0 CA-C-N 116.083 -0.508 . . . . 0.0 111.17 179.925 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 174' ' ' TYR . . . . . 0.465 ' HB2' ' HD3' ' A' ' 175' ' ' PRO . 30.9 m-85 -53.79 -49.25 90.25 Favored Pre-proline 0 N--CA 1.464 0.265 0 CA-C-N 116.567 -0.288 . . . . 0.0 111.638 -179.537 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 175' ' ' PRO . . . . . 0.465 ' HD3' ' HB2' ' A' ' 174' ' ' TYR . 86.5 Cg_exo -47.73 -32.97 17.83 Favored 'Trans proline' 0 C--N 1.351 0.677 0 C-N-CA 122.134 1.89 . . . . 0.0 112.164 179.523 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 176' ' ' PHE . . . . . 0.518 ' O ' ' HG ' ' A' ' 180' ' ' LEU . 88.2 m-85 -80.62 -50.36 10.06 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 115.911 -0.586 . . . . 0.0 112.18 -179.531 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 177' ' ' ILE . . . . . 0.555 HG12 ' O ' ' A' ' 173' ' ' ILE . 6.2 mm -60.22 -39.58 81.09 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.548 0 N-CA-C 112.609 0.596 . . . . 0.0 112.609 -177.777 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 178' ' ' TRP . . . . . 0.492 ' HH2' ' HB2' ' A' ' 123' ' ' ARG . 78.4 t90 -67.37 -39.3 85.68 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 120.721 0.296 . . . . 0.0 111.157 -179.669 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 179' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -77.88 -52.89 8.14 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 116.462 -0.335 . . . . 0.0 111.879 -179.01 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 180' ' ' LEU . . . . . 0.717 HD22 HD11 ' A' ' 187' ' ' LEU . 39.8 mt -61.66 -51.7 67.38 Favored 'General case' 0 C--N 1.328 -0.362 0 N-CA-C 111.699 0.259 . . . . 0.0 111.699 -179.114 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 181' ' ' GLY . . . . . 0.437 ' HA3' ' OD1' ' A' ' 193' ' ' ASP . . . -57.03 179.16 0.71 Allowed Glycine 0 C--N 1.336 0.557 0 C-N-CA 120.413 -0.898 . . . . 0.0 112.92 -179.883 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 182' ' ' PRO . . . . . 0.628 ' N ' ' HD2' ' A' ' 183' ' ' PRO . 80.8 Cg_exo -44.06 -46.56 11.04 Favored 'Trans proline' 0 C--N 1.35 0.654 0 C-N-CA 122.925 2.417 . . . . 0.0 113.915 179.865 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 183' ' ' PRO . . . . . 0.628 ' HD2' ' N ' ' A' ' 182' ' ' PRO . 1.0 OUTLIER -44.28 -30.44 3.61 Favored 'Trans proline' 0 C--N 1.358 1.062 0 C-N-CA 122.497 2.131 . . . . 0.0 113.172 -179.758 . . . . . . . . 3 3 . 1 . 030 nuclear nobuild core ' A' A ' 184' ' ' GLY . . . . . 0.451 ' HA2' ' HD2' ' A' ' 123' ' ' ARG . . . -117.73 -120.75 3.08 Favored Glycine 0 C--N 1.332 0.326 0 C-N-CA 120.392 -0.908 . . . . 0.0 113.19 179.89 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 185' ' ' VAL . . . . . . . . . . . . . 22.6 m -64.92 -16.77 20.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 N-CA-C 112.264 0.468 . . . . 0.0 112.264 -179.405 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 186' ' ' ALA . . . . . 0.487 ' HB2' ' HA ' ' A' ' 182' ' ' PRO . . . 55.51 88.75 0.04 OUTLIER 'General case' 0 C--N 1.332 -0.17 0 CA-C-O 120.872 0.368 . . . . 0.0 111.266 -179.899 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 187' ' ' LEU . . . . . 0.717 HD11 HD22 ' A' ' 180' ' ' LEU . 19.5 mt -91.8 -33.06 15.12 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.391 -179.603 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 188' ' ' LEU . . . . . 0.58 HD13 ' N ' ' A' ' 188' ' ' LEU . 0.0 OUTLIER -134.27 -162.07 1.21 Allowed 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.868 0.366 . . . . 0.0 111.501 -179.494 . . . . . . . . 3 3 . 1 . 030 nuclear nobuild core ' A' A ' 189' ' ' THR . . . . . . . . . . . . . 3.2 t -86.26 147.48 44.89 Favored Pre-proline 0 C--N 1.33 -0.24 0 CA-C-N 116.045 -0.525 . . . . 0.0 111.969 -178.873 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 190' ' ' PRO . . . . . . . . . . . . . 77.8 Cg_exo -51.02 -35.93 52.27 Favored 'Trans proline' 0 C--N 1.351 0.691 0 C-N-CA 122.581 2.187 . . . . 0.0 112.665 179.708 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 191' ' ' THR . . . . . . . . . . . . . 59.5 p -57.89 -40.8 81.17 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 121.052 0.453 . . . . 0.0 110.753 179.904 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 192' ' ' VAL . . . . . . . . . . . . . 41.4 t -74.96 -52.8 17.94 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-N 115.705 -0.679 . . . . 0.0 111.484 -179.871 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 193' ' ' ASP . . . . . 0.437 ' OD1' ' HA3' ' A' ' 181' ' ' GLY . 25.4 t70 -54.94 -51.93 64.59 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-N 116.31 -0.405 . . . . 0.0 111.142 -179.716 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 194' ' ' VAL . . . . . 0.549 ' O ' HG22 ' A' ' 198' ' ' VAL . 90.8 t -61.41 -36.96 76.45 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.357 0 CA-C-N 115.927 -0.579 . . . . 0.0 111.026 -179.832 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 195' ' ' ALA . . . . . 0.498 ' HA ' HD12 ' A' ' 7' ' ' LEU . . . -52.4 -48.58 65.58 Favored 'General case' 0 C--O 1.234 0.27 0 CA-C-O 120.91 0.386 . . . . 0.0 111.006 179.723 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 196' ' ' LEU . . . . . 0.5 ' O ' ' HB3' ' A' ' 199' ' ' TYR . 98.5 mt -68.3 -39.45 82.04 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 116.432 -0.349 . . . . 0.0 110.448 179.281 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 197' ' ' ILE . . . . . 0.417 HG13 ' NH2' ' A' ' 72' ' ' ARG . 15.5 mm -55.59 -60.36 1.79 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.358 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.178 179.92 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 198' ' ' VAL . . . . . 0.549 HG22 ' O ' ' A' ' 194' ' ' VAL . 3.3 m -52.19 -35.93 20.01 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.424 0 CA-C-O 121.359 0.6 . . . . 0.0 109.902 179.08 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 199' ' ' TYR . . . . . 0.5 ' HB3' ' O ' ' A' ' 196' ' ' LEU . 69.2 t80 -62.15 -47.02 86.41 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-N 115.062 -0.972 . . . . 0.0 110.095 179.224 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 200' ' ' LEU . . . . . 0.504 HD21 ' HB ' ' A' ' 173' ' ' ILE . 5.4 mp -55.78 -38.99 70.63 Favored 'General case' 0 N--CA 1.452 -0.367 0 CA-C-N 115.973 -0.558 . . . . 0.0 111.561 179.097 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 201' ' ' ASP . . . . . . . . . . . . . 16.0 m-20 -74.19 -41.88 60.73 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 121.063 0.458 . . . . 0.0 110.683 -179.974 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 202' ' ' LEU . . . . . 0.402 ' O ' ' HB ' ' A' ' 206' ' ' VAL . 2.2 mt -63.18 -33.33 75.24 Favored 'General case' 0 C--N 1.327 -0.413 0 CA-C-N 115.624 -0.716 . . . . 0.0 111.682 -179.851 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 203' ' ' VAL . . . . . 0.494 HG13 HD13 ' A' ' 170' ' ' LEU . 10.8 p -78.26 -36.29 20.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.815 -0.175 . . . . 0.0 111.329 -178.696 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 204' ' ' THR . . . . . 0.427 ' O ' ' CD1' ' A' ' 208' ' ' PHE . 55.4 m -62.47 -58.64 6.89 Favored 'General case' 0 C--N 1.328 -0.331 0 C-N-CA 120.454 -0.499 . . . . 0.0 111.315 179.761 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 205' ' ' LYS . . . . . 0.695 ' HE2' ' HB2' ' A' ' 47' ' ' ALA . 49.5 mttp -69.07 -58.18 4.43 Favored 'General case' 0 N--CA 1.464 0.241 0 N-CA-C 112.849 0.685 . . . . 0.0 112.849 -177.921 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 206' ' ' VAL . . . . . 0.402 ' HB ' ' O ' ' A' ' 202' ' ' LEU . 26.1 t -68.92 -36.34 73.58 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.444 0 CA-C-N 116.401 -0.363 . . . . 0.0 111.89 -178.706 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 207' ' ' GLY . . . . . 0.569 ' O ' HG13 ' A' ' 211' ' ' ILE . . . -61.66 -60.45 8.13 Favored Glycine 0 N--CA 1.452 -0.273 0 C-N-CA 120.698 -0.763 . . . . 0.0 113.672 -178.619 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 208' ' ' PHE . . . . . 0.576 ' HB2' ' HG ' ' A' ' 163' ' ' LEU . 0.1 OUTLIER -71.58 -25.96 62.41 Favored 'General case' 0 C--O 1.224 -0.258 0 CA-C-N 117.383 0.591 . . . . 0.0 111.319 -178.976 . . . . . . . . 3 3 . 1 . 030 nuclear nobuild core ' A' A ' 209' ' ' GLY . . . . . 0.473 ' O ' ' HB3' ' A' ' 212' ' ' ALA . . . -68.55 -32.4 74.89 Favored Glycine 0 N--CA 1.449 -0.464 0 N-CA-C 111.676 -0.57 . . . . 0.0 111.676 179.077 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 210' ' ' PHE . . . . . . . . . . . . . 0.8 OUTLIER -72.87 -47.39 46.41 Favored 'General case' 0 CA--C 1.514 -0.421 0 N-CA-C 108.107 -1.072 . . . . 0.0 108.107 178.505 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 211' ' ' ILE . . . . . 0.569 HG13 ' O ' ' A' ' 207' ' ' GLY . 4.6 mt -64.85 -27.73 43.14 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.544 0 N-CA-C 107.629 -1.248 . . . . 0.0 107.629 176.677 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 212' ' ' ALA . . . . . 0.473 ' HB3' ' O ' ' A' ' 209' ' ' GLY . . . -63.86 -39.86 95.2 Favored 'General case' 0 N--CA 1.451 -0.412 0 CA-C-N 114.628 -1.169 . . . . 0.0 110.381 179.794 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 213' ' ' LEU . . . . . 0.406 ' HG ' ' O ' ' A' ' 209' ' ' GLY . 92.8 mt -69.72 -54.42 13.84 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 115.215 -0.902 . . . . 0.0 111.252 -179.596 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 214' ' ' ASP . . . . . . . . . . . . . 18.5 m-20 -56.57 -44.94 81.49 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.968 0.413 . . . . 0.0 110.933 -179.819 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 215' ' ' ALA . . . . . . . . . . . . . . . -61.0 -58.19 9.47 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.055 -0.52 . . . . 0.0 111.004 179.969 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 216' ' ' ALA . . . . . . . . . . . . . . . -55.53 -30.43 60.71 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.84 179.923 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 217' ' ' ALA . . . . . . . . . . . . . . . -61.36 -41.59 97.31 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 115.874 -0.603 . . . . 0.0 109.685 179.525 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 218' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER . . . . . 0 C--N 1.329 -0.293 0 CA-C-N 115.437 -0.801 . . . . 0.0 109.994 178.64 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 70.2 mtm . . . . . 0 N--CA 1.486 1.329 0 CA-C-O 120.723 0.297 . . . . 0.0 110.822 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 13.4 p -96.38 -29.65 3.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.268 -0.423 . . . . 0.0 110.931 179.927 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -90.73 -15.43 56.6 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.869 -0.682 . . . . 0.0 112.292 179.802 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 67.1 tp -72.58 -35.5 67.95 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.873 0.368 . . . . 0.0 110.833 179.967 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 74.5 p -56.38 -29.64 61.72 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 115.953 -0.567 . . . . 0.0 111.589 -179.8 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 47.5 p -52.2 -35.19 48.51 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.407 -0.36 . . . . 0.0 111.335 -179.617 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 7' ' ' LEU . . . . . . . . . . . . . 3.9 mm? -61.28 -53.02 62.12 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.312 -0.404 . . . . 0.0 111.347 -179.751 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 8' ' ' PHE . . . . . . . . . . . . . 74.7 m-85 -60.93 -32.6 72.1 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-O 121.003 0.43 . . . . 0.0 110.696 179.943 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 9' ' ' TRP . . . . . 0.407 ' O ' HG13 ' A' ' 13' ' ' ILE . 26.0 m95 -66.39 -48.65 69.4 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 115.93 -0.577 . . . . 0.0 110.077 -179.986 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 82.1 mt -57.94 -51.07 71.15 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 115.654 -0.703 . . . . 0.0 110.542 179.526 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -57.41 -35.17 70.65 Favored Glycine 0 N--CA 1.45 -0.411 0 C-N-CA 120.739 -0.743 . . . . 0.0 111.8 179.369 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -65.33 -30.82 71.7 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 120.863 0.363 . . . . 0.0 110.504 179.558 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 13' ' ' ILE . . . . . 0.407 HG13 ' O ' ' A' ' 9' ' ' TRP . 80.9 mt -66.89 -46.43 85.14 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.217 0 CA-C-N 116.062 -0.517 . . . . 0.0 110.075 179.353 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -61.84 -31.29 77.77 Favored Glycine 0 N--CA 1.45 -0.367 0 C-N-CA 120.653 -0.784 . . . . 0.0 111.862 179.329 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 15' ' ' MET . . . . . 0.533 ' HB3' ' HB2' ' A' ' 48' ' ' ALA . 0.0 OUTLIER -67.03 -46.89 73.08 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-O 120.848 0.356 . . . . 0.0 110.626 179.33 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -56.53 -40.45 75.08 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.033 -0.531 . . . . 0.0 110.483 179.547 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 84.4 t -60.36 -48.07 89.82 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.861 179.653 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -65.62 -47.27 78.73 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.775 -0.726 . . . . 0.0 112.439 179.816 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 25.2 m -49.44 -47.43 48.19 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-O 120.637 0.256 . . . . 0.0 111.433 -179.258 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 94.6 mt -71.63 -44.67 63.95 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.481 -0.327 . . . . 0.0 111.516 -179.914 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -55.14 -35.11 64.37 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.384 -0.371 . . . . 0.0 111.918 -179.436 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 22' ' ' PHE . . . . . 0.66 ' HB2' HG22 ' A' ' 41' ' ' VAL . 4.2 m-85 -91.07 -29.56 17.25 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.557 -0.292 . . . . 0.0 111.777 -179.207 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -70.31 -51.02 33.28 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.966 0.412 . . . . 0.0 111.524 -179.362 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 24' ' ' TRP . . . . . . . . . . . . . 5.8 t-105 -66.42 -50.01 64.85 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-N 115.881 -0.6 . . . . 0.0 110.999 -179.778 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -68.07 -25.4 65.33 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.49 -0.323 . . . . 0.0 111.002 179.989 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -72.76 -41.66 49.1 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.821 -0.704 . . . . 0.0 112.512 -179.969 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 96.5 mtt180 -65.94 -25.69 67.25 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.875 0.369 . . . . 0.0 110.725 179.799 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 19.5 t70 -82.92 -10.37 58.85 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 115.969 -0.56 . . . . 0.0 110.92 179.953 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -70.42 179.96 2.29 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.176 -0.465 . . . . 0.0 111.308 -179.813 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -96.96 -157.17 30.94 Favored Glycine 0 N--CA 1.451 -0.359 0 C-N-CA 120.914 -0.66 . . . . 0.0 112.242 179.953 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 37.1 t -95.22 120.05 34.77 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.781 0.324 . . . . 0.0 110.738 179.82 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 125.18 -49.52 0.91 Allowed Glycine 0 N--CA 1.452 -0.278 0 C-N-CA 120.902 -0.666 . . . . 0.0 112.291 -179.647 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 38.6 mt-10 -69.99 -20.66 63.28 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.779 0.323 . . . . 0.0 110.645 179.776 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 34' ' ' ARG . . . . . . . . . . . . . 99.8 mtt180 -49.09 -29.09 4.74 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 115.862 -0.608 . . . . 0.0 111.535 -179.862 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 21.4 mmm180 -64.3 -46.98 81.26 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-O 120.783 0.325 . . . . 0.0 111.041 179.905 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 90.2 m-85 -69.2 -32.01 71.01 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.162 179.875 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 37' ' ' TYR . . . . . 0.477 ' O ' HG23 ' A' ' 41' ' ' VAL . 43.4 m-85 -71.97 -54.75 8.99 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.085 -0.507 . . . . 0.0 111.41 -179.485 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 14.6 p -56.76 -36.34 48.91 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-O 120.972 0.415 . . . . 0.0 110.441 -179.995 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 40.9 m -64.85 -50.19 67.6 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 115.758 -0.655 . . . . 0.0 110.41 179.219 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 40' ' ' LEU . . . . . 0.654 HD12 HD11 ' A' ' 43' ' ' ILE . 57.7 tp -61.0 -38.28 85.47 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 115.573 -0.739 . . . . 0.0 110.657 179.741 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . 0.66 HG22 ' HB2' ' A' ' 22' ' ' PHE . 95.8 t -69.48 -34.0 59.9 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.453 0 CA-C-N 115.932 -0.576 . . . . 0.0 109.975 179.011 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -61.22 -42.31 99.75 Favored Glycine 0 N--CA 1.449 -0.483 0 CA-C-N 115.615 -0.721 . . . . 0.0 112.892 179.905 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 43' ' ' ILE . . . . . 0.654 HD11 HD12 ' A' ' 40' ' ' LEU . 38.9 pt -70.03 -44.0 78.74 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.153 0 CA-C-N 116.952 0.376 . . . . 0.0 111.31 -179.786 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 44' ' ' SER . . . . . 0.458 ' N ' HG13 ' A' ' 43' ' ' ILE . 38.7 t -66.29 -25.98 67.11 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-O 120.985 0.421 . . . . 0.0 110.713 179.461 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -79.85 -52.69 4.56 Favored Glycine 0 C--N 1.33 0.233 0 C-N-CA 121.033 -0.603 . . . . 0.0 112.907 -179.295 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 46' ' ' ILE . . . . . 0.462 ' O ' HG22 ' A' ' 49' ' ' VAL . 15.3 pt -57.88 -36.95 57.79 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.248 0 CA-C-O 121.148 0.499 . . . . 0.0 110.33 179.978 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 47' ' ' ALA . . . . . 0.757 ' HB2' ' HE2' ' A' ' 205' ' ' LYS . . . -68.2 -42.05 80.45 Favored 'General case' 0 C--N 1.326 -0.45 0 CA-C-N 115.81 -0.632 . . . . 0.0 110.78 178.716 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 48' ' ' ALA . . . . . 0.533 ' HB2' ' HB3' ' A' ' 15' ' ' MET . . . -54.48 -42.66 70.99 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 115.881 -0.599 . . . . 0.0 112.038 -179.451 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 49' ' ' VAL . . . . . 0.462 HG22 ' O ' ' A' ' 46' ' ' ILE . 31.0 m -73.42 -36.24 47.93 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.24 0 N-CA-C 111.606 0.224 . . . . 0.0 111.606 -179.437 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -62.49 -40.39 96.54 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-O 121.001 0.429 . . . . 0.0 111.285 179.792 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 4.2 m-85 -70.58 -40.2 73.42 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-N 115.997 -0.547 . . . . 0.0 110.726 -179.613 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -63.13 -42.26 99.47 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 115.882 -0.599 . . . . 0.0 111.459 179.999 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 53' ' ' VAL . . . . . 0.535 ' O ' HG22 ' A' ' 58' ' ' VAL . 33.0 m -70.28 -49.71 52.22 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.209 0 CA-C-N 116.71 -0.223 . . . . 0.0 111.057 -179.865 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 54' ' ' MET . . . . . 0.492 ' N ' HG23 ' A' ' 53' ' ' VAL . 73.1 mtm -60.75 -32.29 71.59 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-O 121.099 0.476 . . . . 0.0 109.916 179.429 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -63.26 -22.9 67.16 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 115.552 -0.749 . . . . 0.0 111.283 179.677 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 80.2 mt -89.1 -14.35 36.45 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.459 -0.337 . . . . 0.0 111.033 -179.906 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 102.53 -2.99 49.77 Favored Glycine 0 C--N 1.33 0.248 0 C-N-CA 120.689 -0.767 . . . . 0.0 113.352 179.371 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 58' ' ' VAL . . . . . 0.535 HG22 ' O ' ' A' ' 53' ' ' VAL . 15.8 m -78.63 154.25 4.97 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.166 0 CA-C-N 116.981 0.39 . . . . 0.0 111.145 -179.901 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 59' ' ' GLY . . . . . 0.438 ' HA3' ' CG ' ' A' ' 71' ' ' PRO . . . 80.69 -2.39 79.3 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.89 -0.671 . . . . 0.0 112.859 -179.943 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 60' ' ' TRP . . . . . . . . . . . . . 23.2 m0 -78.28 121.49 24.49 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 120.724 0.297 . . . . 0.0 110.503 179.718 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 7.3 p -112.8 132.25 22.37 Favored Pre-proline 0 CA--C 1.533 0.29 0 CA-C-N 116.416 -0.356 . . . . 0.0 111.343 -179.796 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 72.0 Cg_endo -77.45 145.56 23.78 Favored 'Trans proline' 0 C--N 1.35 0.638 0 C-N-CA 122.51 2.14 . . . . 0.0 112.512 179.941 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 96.6 t -142.65 94.08 0.54 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 115.872 -0.604 . . . . 0.0 110.926 -179.94 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . 57.67 -89.55 0.02 OUTLIER 'General case' 0 C--N 1.332 -0.178 0 CA-C-N 116.13 -0.486 . . . . 0.0 111.418 179.96 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 12.8 pt-20 -119.79 -19.93 7.79 Favored 'General case' 0 C--O 1.233 0.204 0 CA-C-O 120.806 0.336 . . . . 0.0 110.872 -179.987 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 66' ' ' ARG . . . . . 0.496 HH22 ' HA ' ' A' ' 183' ' ' PRO . 13.1 ptm180 -101.93 166.29 10.72 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.385 179.83 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 35.3 m -125.72 123.89 39.85 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-O 120.975 0.417 . . . . 0.0 111.462 -179.725 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 23.4 t -101.29 147.16 8.54 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.221 0 CA-C-N 115.88 -0.6 . . . . 0.0 110.284 179.41 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 69' ' ' PHE . . . . . . . . . . . . . 46.8 m-85 -106.94 112.41 25.36 Favored 'General case' 0 C--N 1.328 -0.329 0 N-CA-C 110.03 -0.359 . . . . 0.0 110.03 -179.363 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 70' ' ' VAL . . . . . 0.523 ' HB ' ' HD3' ' A' ' 71' ' ' PRO . 21.7 t -68.96 -49.89 24.04 Favored Pre-proline 0 C--N 1.327 -0.408 0 N-CA-C 112.455 0.539 . . . . 0.0 112.455 -178.891 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 71' ' ' PRO . . . . . 0.523 ' HD3' ' HB ' ' A' ' 70' ' ' VAL . 31.8 Cg_exo -58.55 -25.97 76.68 Favored 'Trans proline' 0 C--N 1.35 0.627 0 C-N-CA 121.983 1.788 . . . . 0.0 112.174 179.97 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 72' ' ' ARG . . . . . 0.406 ' HB2' ' SD ' ' A' ' 54' ' ' MET . 46.3 ttp180 -72.52 -53.27 12.52 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.975 0.417 . . . . 0.0 110.665 179.932 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 73' ' ' TYR . . . . . 0.409 ' O ' HG13 ' A' ' 77' ' ' ILE . 23.0 m-85 -65.2 -38.07 89.29 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 115.831 -0.622 . . . . 0.0 110.694 179.934 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 74' ' ' ILE . . . . . 0.444 ' O ' HD13 ' A' ' 74' ' ' ILE . 0.4 OUTLIER -70.32 -37.62 71.6 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 N-CA-C 110.008 -0.367 . . . . 0.0 110.008 179.583 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 75' ' ' ASP . . . . . 0.457 ' O ' HG23 ' A' ' 79' ' ' THR . 31.2 t70 -57.24 -38.61 74.06 Favored 'General case' 0 CA--C 1.521 -0.138 0 N-CA-C 109.453 -0.573 . . . . 0.0 109.453 178.991 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 76' ' ' TRP . . . . . . . . . . . . . 45.4 m0 -66.8 -39.72 87.85 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 115.553 -0.749 . . . . 0.0 110.27 179.375 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 77' ' ' ILE . . . . . 0.428 HD12 ' HA ' ' A' ' 74' ' ' ILE . 89.3 mt -60.49 -28.93 43.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 115.953 -0.567 . . . . 0.0 110.788 179.551 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 43.1 mt -91.97 -29.19 16.77 Favored 'General case' 0 C--N 1.33 -0.255 0 N-CA-C 112.275 0.472 . . . . 0.0 112.275 179.96 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 79' ' ' THR . . . . . 0.457 HG23 ' O ' ' A' ' 75' ' ' ASP . 66.8 p -89.38 -52.09 5.22 Favored 'General case' 0 N--CA 1.464 0.27 0 N-CA-C 113.506 0.928 . . . . 0.0 113.506 -177.725 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 80' ' ' THR . . . . . 0.447 ' N ' ' HD2' ' A' ' 81' ' ' PRO . 86.1 m -47.3 -55.03 17.47 Favored Pre-proline 0 C--N 1.328 -0.34 0 N-CA-C 112.773 0.657 . . . . 0.0 112.773 -178.683 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 81' ' ' PRO . . . . . 0.447 ' HD2' ' N ' ' A' ' 80' ' ' THR . 36.1 Cg_endo -63.2 -20.82 71.7 Favored 'Trans proline' 0 C--N 1.351 0.69 0 C-N-CA 121.55 1.5 . . . . 0.0 111.06 179.997 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 82' ' ' LEU . . . . . 0.435 ' HB3' HG22 ' A' ' 43' ' ' ILE . 0.1 OUTLIER -76.2 -34.8 59.29 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 115.364 -0.834 . . . . 0.0 109.94 179.558 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 47.9 mm -69.25 -52.74 30.28 Favored 'Isoleucine or valine' 0 CA--C 1.522 -0.126 0 CA-C-N 115.849 -0.614 . . . . 0.0 110.205 179.429 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . 0.429 HG22 ' HA ' ' A' ' 81' ' ' PRO . 27.7 m -59.64 -31.16 46.38 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.215 0 N-CA-C 109.614 -0.513 . . . . 0.0 109.614 178.912 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 85' ' ' TYR . . . . . . . . . . . . . 85.2 t80 -63.69 -36.54 84.19 Favored 'General case' 0 N--CA 1.454 -0.246 0 CA-C-N 115.657 -0.701 . . . . 0.0 109.188 178.457 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 86' ' ' PHE . . . . . . . . . . . . . 8.0 t80 -61.42 -44.87 96.38 Favored 'General case' 0 C--O 1.231 0.121 0 CA-C-N 115.636 -0.711 . . . . 0.0 109.457 178.87 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 3.7 mm? -61.66 -34.11 75.14 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 115.453 -0.794 . . . . 0.0 110.153 179.177 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 88' ' ' GLY . . . . . 0.516 ' HA2' HD13 ' A' ' 93' ' ' LEU . . . -69.08 -29.45 72.28 Favored Glycine 0 N--CA 1.449 -0.462 0 C-N-CA 120.812 -0.709 . . . . 0.0 112.252 179.695 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 95.9 mt -71.66 -39.48 70.29 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 121.028 0.442 . . . . 0.0 110.362 179.69 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 42.8 mt -61.14 -59.73 4.88 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 115.796 -0.638 . . . . 0.0 110.872 179.782 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . 0.493 ' HB2' ' HB2' ' A' ' 149' ' ' ALA . . . -70.25 -54.79 11.22 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.081 -0.509 . . . . 0.0 111.339 -179.833 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 98.85 68.77 0.91 Allowed Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.787 -0.72 . . . . 0.0 112.212 -179.861 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 93' ' ' LEU . . . . . 0.552 HD23 ' HB3' ' A' ' 97' ' ' GLU . 8.1 mp -72.0 -174.35 1.21 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.775 0.322 . . . . 0.0 110.945 -179.824 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 94' ' ' ASP . . . . . 0.452 ' HB3' ' OE2' ' A' ' 97' ' ' GLU . 10.2 t70 -97.28 -177.12 3.73 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.868 -179.73 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 77.9 p -65.58 -45.34 83.62 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.574 -179.369 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 36.2 mtp180 -74.14 -39.48 63.27 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-O 121.246 0.546 . . . . 0.0 110.438 -179.657 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 97' ' ' GLU . . . . . 0.552 ' HB3' HD23 ' A' ' 93' ' ' LEU . 0.3 OUTLIER -58.01 -44.68 87.38 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-N 115.457 -0.792 . . . . 0.0 111.039 -179.826 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 98' ' ' PHE . . . . . 0.441 ' O ' HG12 ' A' ' 102' ' ' ILE . 2.2 m-85 -61.52 -35.47 77.82 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.956 0.408 . . . . 0.0 110.502 179.543 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -70.08 -25.97 74.91 Favored Glycine 0 N--CA 1.451 -0.359 0 C-N-CA 120.7 -0.762 . . . . 0.0 112.144 179.795 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 96.4 mt -73.17 -43.71 57.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 N-CA-C 111.841 0.311 . . . . 0.0 111.841 -179.819 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 25.7 m -69.45 -39.16 78.33 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-O 120.676 0.275 . . . . 0.0 111.716 -179.389 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 102' ' ' ILE . . . . . 0.441 HG12 ' O ' ' A' ' 98' ' ' PHE . 42.0 mm -73.65 -41.0 55.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.582 -0.281 . . . . 0.0 111.621 -179.435 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 13.9 t -63.76 -35.97 82.34 Favored 'General case' 0 C--N 1.332 -0.153 0 CA-C-O 120.775 0.322 . . . . 0.0 110.884 -179.948 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 104' ' ' LEU . . . . . 0.439 ' O ' HG23 ' A' ' 108' ' ' VAL . 56.5 tp -67.52 -43.77 79.99 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.288 179.766 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 105' ' ' ASN . . . . . 0.529 ' N ' HD22 ' A' ' 105' ' ' ASN . 0.9 OUTLIER -62.72 -27.3 69.17 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.532 179.57 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 91.9 m -69.4 -52.15 29.77 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.054 -0.521 . . . . 0.0 111.502 -179.912 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 107' ' ' VAL . . . . . 0.444 HG22 ' HE2' ' A' ' 129' ' ' MET . 7.5 p -66.09 -36.35 77.23 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.214 0 CA-C-N 116.38 -0.373 . . . . 0.0 111.226 -179.976 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . 0.439 HG23 ' O ' ' A' ' 104' ' ' LEU . 51.0 t -62.85 -54.68 30.57 Favored 'Isoleucine or valine' 0 C--O 1.234 0.281 0 CA-C-N 116.294 -0.412 . . . . 0.0 110.866 179.746 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 109' ' ' MET . . . . . . . . . . . . . 5.6 tpp -61.66 -26.82 68.26 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.049 -0.523 . . . . 0.0 110.383 179.897 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 29.7 tp -73.05 -31.98 64.77 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.062 -0.517 . . . . 0.0 110.226 179.487 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -64.31 -51.17 64.79 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 115.926 -0.579 . . . . 0.0 110.284 179.225 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 112' ' ' GLY . . . . . 0.629 ' HA3' ' H21' ' A' ' 301' ' ' RET . . . -62.76 -44.26 97.75 Favored Glycine 0 CA--C 1.518 0.248 0 C-N-CA 120.796 -0.716 . . . . 0.0 112.42 179.539 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 113' ' ' PHE . . . . . 0.455 ' HZ ' HG13 ' A' ' 70' ' ' VAL . 0.8 OUTLIER -47.98 -61.01 2.18 Favored 'General case' 0 C--N 1.333 -0.141 0 CA-C-O 120.911 0.386 . . . . 0.0 110.397 179.592 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -69.83 -18.25 63.44 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.025 -0.534 . . . . 0.0 110.797 179.918 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -57.14 -49.06 74.98 Favored Glycine 0 C--N 1.333 0.389 0 C-N-CA 120.79 -0.719 . . . . 0.0 111.9 179.375 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -78.55 -15.51 58.48 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-O 120.782 0.325 . . . . 0.0 111.376 179.817 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 117' ' ' MET . . . . . . . . . . . . . 23.1 mmt -88.22 19.18 3.85 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 116.384 -0.371 . . . . 0.0 111.612 -179.553 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 35.7 m -84.64 141.62 38.97 Favored Pre-proline 0 C--N 1.329 -0.315 0 CA-C-O 120.57 0.224 . . . . 0.0 111.285 -179.846 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 119' ' ' PRO . . . . . . . . . . . . . 93.4 Cg_endo -87.07 -2.43 7.98 Favored 'Trans proline' 0 N--CA 1.459 -0.513 0 C-N-CA 122.77 2.314 . . . . 0.0 112.36 179.797 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -144.12 -110.05 0.7 Allowed Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.789 -0.72 . . . . 0.0 112.684 -179.911 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 42.9 pt -133.29 11.8 1.42 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.23 0 CA-C-O 120.681 0.277 . . . . 0.0 111.468 -179.646 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 46.9 mt-10 -59.24 -18.23 35.17 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.344 -0.389 . . . . 0.0 111.015 179.912 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 123' ' ' ARG . . . . . 0.524 ' HA ' HD13 ' A' ' 126' ' ' LEU . 11.1 ptt180 -50.45 -37.15 36.71 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.05 -0.523 . . . . 0.0 111.946 -179.661 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 124' ' ' TYR . . . . . . . . . . . . . 28.4 m-85 -51.19 -35.54 36.85 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.844 0.354 . . . . 0.0 111.171 -179.828 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 125' ' ' ALA . . . . . . . . . . . . . . . -74.8 -49.65 20.03 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.141 -0.481 . . . . 0.0 111.008 179.878 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 126' ' ' LEU . . . . . 0.524 HD13 ' HA ' ' A' ' 123' ' ' ARG . 6.5 mp -52.51 -55.67 20.48 Favored 'General case' 0 C--N 1.332 -0.182 0 CA-C-N 115.999 -0.546 . . . . 0.0 110.327 179.964 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 127' ' ' PHE . . . . . 0.427 ' CE1' ' H42' ' A' ' 301' ' ' RET . 10.9 t80 -64.51 -28.84 69.93 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 115.909 -0.587 . . . . 0.0 110.155 179.45 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 128' ' ' GLY . . . . . . . . . . . . . . . -49.16 -48.53 32.16 Favored Glycine 0 N--CA 1.449 -0.451 0 C-N-CA 120.121 -1.038 . . . . 0.0 110.593 178.79 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 129' ' ' MET . . . . . 0.445 ' HE3' ' HA2' ' A' ' 130' ' ' GLY . 0.0 OUTLIER -72.29 -31.72 65.98 Favored 'General case' 0 N--CA 1.452 -0.365 0 N-CA-C 109.079 -0.712 . . . . 0.0 109.079 178.467 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 130' ' ' GLY . . . . . 0.445 ' HA2' ' HE3' ' A' ' 129' ' ' MET . . . -61.52 -33.18 83.89 Favored Glycine 0 C--N 1.333 0.411 0 CA-C-N 115.749 -0.66 . . . . 0.0 112.035 179.458 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 131' ' ' ALA . . . . . 0.42 ' O ' ' HB3' ' A' ' 134' ' ' PHE . . . -74.8 -53.35 9.31 Favored 'General case' 0 N--CA 1.452 -0.326 0 CA-C-O 120.743 0.306 . . . . 0.0 110.362 179.648 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 40.8 t -55.15 -49.0 75.59 Favored 'Isoleucine or valine' 0 C--O 1.234 0.253 0 N-CA-C 109.462 -0.57 . . . . 0.0 109.462 178.783 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -59.68 -39.13 83.49 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 115.504 -0.771 . . . . 0.0 110.323 178.589 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 134' ' ' PHE . . . . . 0.459 ' CZ ' ' HA ' ' A' ' 172' ' ' ALA . 65.4 t80 -55.1 -51.13 67.37 Favored 'General case' 0 N--CA 1.451 -0.388 0 CA-C-N 115.892 -0.594 . . . . 0.0 110.367 179.68 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 135' ' ' ILE . . . . . 0.475 ' O ' HG22 ' A' ' 138' ' ' VAL . 60.2 mt -56.15 -32.05 33.31 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.238 0 CA-C-N 115.946 -0.57 . . . . 0.0 110.112 179.24 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 136' ' ' GLY . . . . . 0.402 ' O ' ' HB3' ' A' ' 139' ' ' TYR . . . -61.67 -41.24 99.56 Favored Glycine 0 N--CA 1.447 -0.598 0 C-N-CA 120.16 -1.019 . . . . 0.0 111.343 178.69 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 137' ' ' LEU . . . . . . . . . . . . . 30.0 tp -69.57 -50.71 42.08 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 115.846 -0.177 . . . . 0.0 111.09 179.935 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 138' ' ' VAL . . . . . 0.591 ' HA ' HD12 ' A' ' 141' ' ' LEU . 5.2 m -55.96 -32.62 33.53 Favored 'Isoleucine or valine' 0 C--O 1.234 0.245 0 CA-C-O 121.31 0.576 . . . . 0.0 109.754 179.478 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 139' ' ' TYR . . . . . 0.405 ' O ' ' N ' ' A' ' 143' ' ' GLY . 65.9 t80 -60.09 -48.09 83.16 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 115.353 -0.839 . . . . 0.0 109.412 178.511 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 37.0 m-85 -58.95 -35.5 73.23 Favored 'General case' 0 C--N 1.332 -0.169 0 CA-C-N 115.938 -0.573 . . . . 0.0 110.576 179.096 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 141' ' ' LEU . . . . . 0.591 HD12 ' HA ' ' A' ' 138' ' ' VAL . 95.6 mt -55.56 -46.74 77.13 Favored 'General case' 0 C--N 1.332 -0.174 0 CA-C-N 116.322 -0.399 . . . . 0.0 110.27 179.504 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 142' ' ' VAL . . . . . 0.405 HG22 ' O ' ' A' ' 142' ' ' VAL . 9.2 p -105.39 15.04 7.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 115.926 -0.579 . . . . 0.0 110.828 179.752 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 143' ' ' GLY . . . . . 0.405 ' N ' ' O ' ' A' ' 139' ' ' TYR . . . -90.86 -130.66 4.68 Favored Glycine 0 CA--C 1.52 0.393 0 C-N-CA 120.913 -0.661 . . . . 0.0 112.9 -179.627 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 144' ' ' PRO . . . . . . . . . . . . . 45.3 Cg_exo -57.23 -25.44 64.66 Favored 'Trans proline' 0 C--N 1.351 0.686 0 C-N-CA 122.585 2.19 . . . . 0.0 112.726 -179.632 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 145' ' ' MET . . . . . . . . . . . . . 60.6 mtt -56.76 -25.13 54.44 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.355 -0.384 . . . . 0.0 111.134 -179.896 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 146' ' ' THR . . . . . . . . . . . . . 78.1 p -63.83 -51.2 65.77 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.112 -0.495 . . . . 0.0 111.685 -179.786 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 43.6 mt-10 -75.56 -28.64 59.09 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.371 -0.377 . . . . 0.0 111.62 -179.252 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 148' ' ' SER . . . . . . . . . . . . . 36.8 t -70.53 -44.66 67.09 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.743 0.306 . . . . 0.0 111.208 -179.469 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 149' ' ' ALA . . . . . 0.493 ' HB2' ' HB2' ' A' ' 91' ' ' ALA . . . -77.92 -42.99 31.28 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.324 -0.398 . . . . 0.0 111.923 -179.53 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 150' ' ' SER . . . . . 0.586 ' HA ' ' HG2' ' A' ' 157' ' ' LYS . 47.5 t -63.65 -8.0 8.89 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.548 -179.504 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 151' ' ' GLN . . . . . . . . . . . . . 47.5 mt-30 -125.54 17.34 8.18 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.668 0.271 . . . . 0.0 111.279 -179.955 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 152' ' ' ARG . . . . . 0.6 ' HD2' HG13 ' A' ' 156' ' ' ILE . 3.6 tmt_? -93.24 -51.81 4.84 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-O 120.967 0.413 . . . . 0.0 110.509 179.782 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 153' ' ' SER . . . . . 0.679 ' HB3' HG12 ' A' ' 156' ' ' ILE . 20.0 t -157.42 172.41 18.63 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 115.904 -0.589 . . . . 0.0 110.451 179.304 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 154' ' ' SER . . . . . . . . . . . . . 79.0 p -71.62 -42.18 67.95 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.278 -0.419 . . . . 0.0 111.006 179.744 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -76.87 -25.72 64.04 Favored Glycine 0 C--N 1.331 0.265 0 C-N-CA 120.834 -0.698 . . . . 0.0 113.093 -179.669 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 156' ' ' ILE . . . . . 0.679 HG12 ' HB3' ' A' ' 153' ' ' SER . 27.7 mm -57.89 -38.48 66.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-O 120.551 0.215 . . . . 0.0 111.519 -179.718 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 157' ' ' LYS . . . . . 0.586 ' HG2' ' HA ' ' A' ' 150' ' ' SER . 35.8 mtmm -56.72 -39.91 74.77 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-O 120.806 0.336 . . . . 0.0 111.214 179.908 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 43.7 t -70.95 -48.1 55.28 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.569 -179.315 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 159' ' ' LEU . . . . . 0.458 ' O ' ' HB2' ' A' ' 163' ' ' LEU . 9.9 mt -68.18 -28.89 67.67 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 116.482 -0.326 . . . . 0.0 111.65 -179.609 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 160' ' ' TYR . . . . . . . . . . . . . 83.8 t80 -73.95 -45.91 47.41 Favored 'General case' 0 C--N 1.326 -0.429 0 N-CA-C 112.061 0.393 . . . . 0.0 112.061 -178.941 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 161' ' ' VAL . . . . . 0.426 HG23 ' N ' ' A' ' 162' ' ' ARG . 30.9 m -66.57 -43.89 90.34 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.419 0 N-CA-C 112.169 0.433 . . . . 0.0 112.169 -179.007 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 162' ' ' ARG . . . . . 0.426 ' N ' HG23 ' A' ' 161' ' ' VAL . 35.3 mmt180 -68.68 -41.69 78.86 Favored 'General case' 0 C--N 1.328 -0.349 0 N-CA-C 111.884 0.327 . . . . 0.0 111.884 -178.906 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 163' ' ' LEU . . . . . 0.609 ' HG ' ' HB2' ' A' ' 208' ' ' PHE . 7.7 mp -73.79 -50.06 22.38 Favored 'General case' 0 C--N 1.329 -0.326 0 N-CA-C 112.015 0.376 . . . . 0.0 112.015 -179.182 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 164' ' ' ARG . . . . . 0.465 ' HG2' ' HB3' ' A' ' 141' ' ' LEU . 6.4 tmm_? -59.45 -50.12 75.18 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.624 -0.262 . . . . 0.0 111.577 -179.139 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 165' ' ' ASN . . . . . 0.56 HD22 ' N ' ' A' ' 165' ' ' ASN . 0.8 OUTLIER -61.29 -51.41 69.02 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.45 -0.341 . . . . 0.0 111.524 -179.464 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 166' ' ' LEU . . . . . 0.482 ' O ' ' HG ' ' A' ' 170' ' ' LEU . 4.9 tt -60.76 -54.85 40.22 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.457 -0.338 . . . . 0.0 111.865 -179.198 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 167' ' ' THR . . . . . 0.411 ' O ' ' HB2' ' A' ' 171' ' ' TRP . 64.5 m -55.17 -54.22 45.98 Favored 'General case' 0 C--N 1.329 -0.292 0 N-CA-C 112.898 0.703 . . . . 0.0 112.898 -178.585 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 168' ' ' VAL . . . . . 0.438 ' HB ' HD13 ' A' ' 141' ' ' LEU . 9.9 p -55.1 -40.51 55.12 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.195 0 N-CA-C 112.418 0.525 . . . . 0.0 112.418 -178.924 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 169' ' ' VAL . . . . . 0.548 HG23 ' O ' ' A' ' 165' ' ' ASN . 58.5 t -60.47 -65.11 0.5 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 N-CA-C 111.874 0.324 . . . . 0.0 111.874 -179.159 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 170' ' ' LEU . . . . . 0.482 ' HG ' ' O ' ' A' ' 166' ' ' LEU . 1.0 OUTLIER -61.3 -29.2 69.72 Favored 'General case' 0 C--N 1.329 -0.283 0 C-N-CA 121.166 -0.213 . . . . 0.0 111.41 -179.273 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 171' ' ' TRP . . . . . 0.766 ' HE1' H203 ' A' ' 301' ' ' RET . 2.8 m0 -71.03 -35.3 71.93 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-O 120.934 0.397 . . . . 0.0 110.038 178.983 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 172' ' ' ALA . . . . . 0.459 ' HA ' ' CZ ' ' A' ' 134' ' ' PHE . . . -68.32 -6.61 25.09 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 115.872 -0.604 . . . . 0.0 110.62 179.572 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 173' ' ' ILE . . . . . 0.509 HG22 HD11 ' A' ' 177' ' ' ILE . 40.4 mm -85.9 -22.19 7.39 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 115.873 -0.603 . . . . 0.0 110.798 179.515 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 174' ' ' TYR . . . . . 0.59 ' N ' ' HD2' ' A' ' 175' ' ' PRO . 12.9 m-85 -54.22 -50.81 82.57 Favored Pre-proline 0 CA--C 1.533 0.299 0 CA-C-N 116.159 -0.473 . . . . 0.0 112.109 -179.684 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 175' ' ' PRO . . . . . 0.59 ' HD2' ' N ' ' A' ' 174' ' ' TYR . 8.1 Cg_endo -50.65 -27.75 20.46 Favored 'Trans proline' 0 C--N 1.352 0.752 0 C-N-CA 122.067 1.845 . . . . 0.0 112.355 -179.797 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 176' ' ' PHE . . . . . 0.457 ' O ' ' HG ' ' A' ' 180' ' ' LEU . 49.5 m-85 -80.59 -46.43 15.71 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.291 -0.413 . . . . 0.0 111.668 -179.995 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 177' ' ' ILE . . . . . 0.509 HD11 HG22 ' A' ' 173' ' ' ILE . 3.5 mm -66.19 -36.35 77.19 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.497 0 N-CA-C 112.299 0.481 . . . . 0.0 112.299 -178.211 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 178' ' ' TRP . . . . . 0.471 ' HH2' ' HB2' ' A' ' 123' ' ' ARG . 67.8 t90 -73.94 -45.95 47.21 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-O 120.907 0.384 . . . . 0.0 110.772 179.602 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 179' ' ' LEU . . . . . 0.459 ' O ' HG22 ' A' ' 185' ' ' VAL . 2.5 tm? -67.92 -49.6 60.91 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 115.921 -0.581 . . . . 0.0 111.403 -179.077 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 180' ' ' LEU . . . . . 0.556 HD22 HD11 ' A' ' 187' ' ' LEU . 22.7 mt -77.7 -47.23 19.65 Favored 'General case' 0 C--N 1.328 -0.358 0 N-CA-C 111.812 0.301 . . . . 0.0 111.812 -179.165 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . -58.75 -178.21 0.96 Allowed Glycine 0 C--N 1.337 0.591 0 C-N-CA 120.256 -0.973 . . . . 0.0 112.772 -179.98 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 182' ' ' PRO . . . . . 0.644 ' HA ' ' HB2' ' A' ' 186' ' ' ALA . 85.7 Cg_exo -47.81 -44.32 27.14 Favored 'Trans proline' 0 CA--C 1.536 0.623 0 C-N-CA 122.967 2.445 . . . . 0.0 113.802 -179.97 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 183' ' ' PRO . . . . . 0.496 ' HA ' HH22 ' A' ' 66' ' ' ARG . 51.8 Cg_exo -55.3 -9.95 2.79 Favored 'Trans proline' 0 C--N 1.354 0.833 0 C-N-CA 122.154 1.902 . . . . 0.0 113.199 -179.736 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 184' ' ' GLY . . . . . 0.414 ' HA3' ' O ' ' A' ' 179' ' ' LEU . . . -123.21 -87.39 0.81 Allowed Glycine 0 N--CA 1.45 -0.387 0 C-N-CA 120.421 -0.895 . . . . 0.0 112.901 -179.887 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 185' ' ' VAL . . . . . 0.459 HG22 ' O ' ' A' ' 179' ' ' LEU . 8.6 m -120.43 -7.02 10.53 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-O 120.773 0.321 . . . . 0.0 111.779 -179.603 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 186' ' ' ALA . . . . . 0.644 ' HB2' ' HA ' ' A' ' 182' ' ' PRO . . . 56.18 85.36 0.07 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.116 -0.493 . . . . 0.0 111.716 179.576 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 187' ' ' LEU . . . . . 0.556 HD11 HD22 ' A' ' 180' ' ' LEU . 18.8 mt -91.78 -49.25 6.36 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.93 0.395 . . . . 0.0 110.878 179.528 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 188' ' ' LEU . . . . . 0.403 ' HB3' ' H ' ' A' ' 189' ' ' THR . 96.6 mt -90.13 -154.99 0.35 Allowed 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 115.839 -0.619 . . . . 0.0 110.947 -179.661 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 189' ' ' THR . . . . . 0.481 ' HB ' HG23 ' A' ' 192' ' ' VAL . 58.8 m -92.6 136.17 25.56 Favored Pre-proline 0 C--N 1.329 -0.326 0 CA-C-N 116.05 -0.523 . . . . 0.0 110.568 -179.719 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 190' ' ' PRO . . . . . 0.468 ' O ' HG23 ' A' ' 194' ' ' VAL . 2.2 Cg_endo -45.5 -37.69 15.23 Favored 'Trans proline' 0 C--N 1.35 0.652 0 C-N-CA 122.837 2.358 . . . . 0.0 112.776 -179.747 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 191' ' ' THR . . . . . 0.413 ' H ' HG22 ' A' ' 189' ' ' THR . 41.7 p -74.24 -45.42 48.09 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 116.487 -0.324 . . . . 0.0 111.415 -179.835 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 192' ' ' VAL . . . . . 0.481 HG23 ' HB ' ' A' ' 189' ' ' THR . 96.9 t -59.66 -52.79 56.9 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.302 -0.408 . . . . 0.0 111.415 -179.781 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 193' ' ' ASP . . . . . . . . . . . . . 25.9 t70 -54.6 -48.2 72.46 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.946 -179.761 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 194' ' ' VAL . . . . . 0.62 ' O ' HG22 ' A' ' 198' ' ' VAL . 40.6 t -55.22 -44.03 73.22 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.241 0 CA-C-N 116.376 -0.375 . . . . 0.0 110.492 179.492 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 195' ' ' ALA . . . . . . . . . . . . . . . -52.46 -42.91 64.61 Favored 'General case' 0 C--N 1.332 -0.185 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.778 179.895 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 196' ' ' LEU . . . . . . . . . . . . . 62.5 mt -67.8 -40.27 83.9 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.785 179.356 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 197' ' ' ILE . . . . . 0.42 HG12 HG21 ' A' ' 177' ' ' ILE . 12.0 mm -59.39 -60.87 1.82 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 115.766 -0.652 . . . . 0.0 111.405 -179.847 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 198' ' ' VAL . . . . . 0.62 HG22 ' O ' ' A' ' 194' ' ' VAL . 1.3 m -53.94 -34.85 26.61 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.439 0 CA-C-O 121.544 0.687 . . . . 0.0 109.566 179.053 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 199' ' ' TYR . . . . . . . . . . . . . 63.8 t80 -66.57 -33.56 75.94 Favored 'General case' 0 C--N 1.323 -0.587 0 CA-C-N 114.639 -1.164 . . . . 0.0 110.575 179.722 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 200' ' ' LEU . . . . . 0.483 ' O ' HG12 ' A' ' 203' ' ' VAL . 26.6 mt -66.67 -41.77 87.62 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.088 -0.505 . . . . 0.0 111.315 -179.897 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 201' ' ' ASP . . . . . . . . . . . . . 5.0 m-20 -74.83 -37.94 62.14 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-O 121.253 0.549 . . . . 0.0 110.044 179.499 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 202' ' ' LEU . . . . . 0.481 HD13 ' SD ' ' A' ' 15' ' ' MET . 40.5 tp -70.6 -26.79 63.67 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 115.256 -0.884 . . . . 0.0 111.559 -179.343 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 203' ' ' VAL . . . . . 0.483 HG12 ' O ' ' A' ' 200' ' ' LEU . 14.2 p -81.73 -36.7 14.59 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.13 0 CA-C-N 116.765 -0.198 . . . . 0.0 110.813 -179.141 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 204' ' ' THR . . . . . . . . . . . . . 65.8 m -63.43 -58.56 6.67 Favored 'General case' 0 C--N 1.329 -0.305 0 C-N-CA 120.713 -0.395 . . . . 0.0 110.642 179.169 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 205' ' ' LYS . . . . . 0.757 ' HE2' ' HB2' ' A' ' 47' ' ' ALA . 57.7 mttp -60.88 -58.01 10.26 Favored 'General case' 0 C--N 1.328 -0.361 0 N-CA-C 112.609 0.596 . . . . 0.0 112.609 -178.464 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 56.5 t -71.77 -37.36 62.02 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 N-CA-C 112.317 0.488 . . . . 0.0 112.317 -178.432 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 207' ' ' GLY . . . . . 0.53 ' O ' HG13 ' A' ' 211' ' ' ILE . . . -56.92 -61.67 7.24 Favored Glycine 0 CA--C 1.517 0.18 0 C-N-CA 120.665 -0.779 . . . . 0.0 113.793 -178.799 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 208' ' ' PHE . . . . . 0.609 ' HB2' ' HG ' ' A' ' 163' ' ' LEU . 0.9 OUTLIER -72.73 -27.25 61.93 Favored 'General case' 0 C--O 1.222 -0.368 0 CA-C-N 117.571 0.686 . . . . 0.0 110.771 -179.31 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 209' ' ' GLY . . . . . 0.52 ' O ' ' HB3' ' A' ' 212' ' ' ALA . . . -63.34 -32.73 85.15 Favored Glycine 0 N--CA 1.448 -0.542 0 N-CA-C 111.629 -0.588 . . . . 0.0 111.629 178.471 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 210' ' ' PHE . . . . . . . . . . . . . 0.8 OUTLIER -74.06 -47.81 34.09 Favored 'General case' 0 CA--C 1.515 -0.397 0 N-CA-C 108.221 -1.029 . . . . 0.0 108.221 178.543 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 211' ' ' ILE . . . . . 0.53 HG13 ' O ' ' A' ' 207' ' ' GLY . 4.4 mt -63.43 -27.52 43.18 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.434 0 N-CA-C 107.678 -1.23 . . . . 0.0 107.678 176.83 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 212' ' ' ALA . . . . . 0.52 ' HB3' ' O ' ' A' ' 209' ' ' GLY . . . -62.76 -40.81 98.42 Favored 'General case' 0 N--CA 1.451 -0.418 0 CA-C-N 114.447 -1.252 . . . . 0.0 110.622 -179.788 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 213' ' ' LEU . . . . . . . . . . . . . 86.4 mt -69.44 -47.29 64.54 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 115.171 -0.922 . . . . 0.0 111.44 -179.501 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 214' ' ' ASP . . . . . . . . . . . . . 14.3 t70 -56.32 -53.1 61.34 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.391 -0.368 . . . . 0.0 111.079 -179.944 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 215' ' ' ALA . . . . . . . . . . . . . . . -56.88 -56.24 24.22 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.06 -0.518 . . . . 0.0 111.341 -179.813 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 216' ' ' ALA . . . . . . . . . . . . . . . -56.78 -32.13 65.34 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.234 -179.897 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 217' ' ' ALA . . . . . . . . . . . . . . . -64.73 -34.38 78.18 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.298 -0.41 . . . . 0.0 110.197 179.793 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 218' ' ' THR . . . . . . . . . . . . . 93.0 m -76.17 -32.61 59.13 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 115.789 -0.641 . . . . 0.0 110.76 179.536 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 219' ' ' LEU . . . . . 0.474 ' O ' ' HG2' ' A' ' 222' ' ' GLU . 69.4 mt -62.23 -41.16 98.16 Favored 'General case' 0 C--N 1.333 -0.15 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.697 -179.999 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 220' ' ' ARG . . . . . . . . . . . . . 35.9 ptt180 -83.89 -24.53 30.76 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.044 -0.525 . . . . 0.0 111.012 179.841 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 221' ' ' ALA . . . . . . . . . . . . . . . -77.24 -19.2 56.94 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.074 -0.512 . . . . 0.0 112.227 -179.38 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 222' ' ' GLU . . . . . 0.474 ' HG2' ' O ' ' A' ' 219' ' ' LEU . 10.2 pt-20 -70.1 -10.91 60.28 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-O 120.811 0.339 . . . . 0.0 110.722 -178.918 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 223' ' ' HIS . . . . . . . . . . . . . 1.6 p-80 -150.05 5.69 0.58 Allowed 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.058 -0.519 . . . . 0.0 111.285 -179.744 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 224' ' ' GLY . . . . . . . . . . . . . . . 60.46 82.49 0.07 OUTLIER Glycine 0 N--CA 1.452 -0.272 0 C-N-CA 120.659 -0.782 . . . . 0.0 112.368 -179.969 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 225' ' ' GLU . . . . . . . . . . . . . 25.8 mm-40 65.19 147.07 0.03 OUTLIER 'General case' 0 N--CA 1.463 0.182 0 CA-C-O 121.026 0.441 . . . . 0.0 111.411 -179.975 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 226' ' ' SER . . . . . . . . . . . . . 60.6 m -61.08 146.07 48.65 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 115.939 -0.573 . . . . 0.0 110.936 179.974 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 227' ' ' LEU . . . . . . . . . . . . . 93.5 mt -76.34 162.53 27.81 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.761 179.989 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 228' ' ' ALA . . . . . . . . . . . . . . . -155.19 -179.71 8.34 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.2 -0.454 . . . . 0.0 111.028 179.856 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 229' ' ' GLY . . . . . . . . . . . . . . . -73.44 160.89 53.99 Favored Glycine 0 N--CA 1.45 -0.388 0 C-N-CA 120.709 -0.758 . . . . 0.0 112.548 179.9 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 230' ' ' VAL . . . . . . . . . . . . . 21.7 m -128.21 149.02 32.71 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.229 0 CA-C-O 120.738 0.304 . . . . 0.0 111.038 179.948 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 231' ' ' ASP . . . . . . . . . . . . . 22.3 t70 -101.35 109.81 21.72 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.75 179.911 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 232' ' ' THR . . . . . . . . . . . . . 3.6 t -152.61 122.41 6.94 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.29 -179.785 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 233' ' ' ASP . . . . . . . . . . . . . 5.3 p-10 -101.76 135.41 43.35 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.017 -0.538 . . . . 0.0 110.598 179.668 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 234' ' ' THR . . . . . . . . . . . . . 51.2 m 58.37 89.32 0.11 Allowed Pre-proline 0 C--N 1.331 -0.222 0 CA-C-N 116.324 -0.398 . . . . 0.0 111.0 179.97 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 235' ' ' PRO . . . . . . . . . . . . . 31.5 Cg_endo -63.28 172.64 4.98 Favored 'Trans proline' 0 C--N 1.347 0.5 0 C-N-CA 122.636 2.224 . . . . 0.0 112.387 179.972 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 236' ' ' ALA . . . . . . . . . . . . . . . -96.82 119.02 34.52 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.944 -179.984 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 237' ' ' VAL . . . . . . . . . . . . . 27.3 m -81.66 148.86 5.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.262 179.957 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 238' ' ' ALA . . . . . . . . . . . . . . . -140.83 -31.95 0.59 Allowed 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.925 179.97 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 239' ' ' ASP . . . . . . . . . . . . . 5.5 p-10 -136.82 139.62 41.87 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.659 179.866 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 240' ' ' LEU . . . . . . . . . . . . . 61.1 tp -151.22 -36.01 0.14 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.306 -0.406 . . . . 0.0 111.068 -179.738 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 241' ' ' GLU . . . . . . . . . . . . . 10.7 tp10 63.98 112.94 0.03 OUTLIER 'General case' 0 C--N 1.332 -0.155 0 CA-C-N 116.176 -0.466 . . . . 0.0 111.126 179.935 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 242' ' ' HIS . . . . . . . . . . . . . 85.1 m-70 -81.45 146.72 30.1 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.123 -179.674 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 243' ' ' HIS . . . . . . . . . . . . . 36.5 t-80 -109.15 -18.18 13.69 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 115.945 -0.571 . . . . 0.0 110.622 179.924 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 244' ' ' HIS . . . . . . . . . . . . . 44.4 m80 -99.95 119.98 39.09 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.025 -0.534 . . . . 0.0 110.87 179.989 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 245' ' ' HIS . . . . . . . . . . . . . 60.1 t-80 -136.37 -40.9 0.64 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.68 179.865 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 246' ' ' HIS . . . . . . . . . . . . . 62.2 t-80 -131.87 116.11 16.77 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.068 -0.515 . . . . 0.0 110.862 -179.867 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 247' ' ' HIS . . . . . . . . . . . . . 58.5 t-80 . . . . . 0 C--O 1.249 1.03 0 CA-C-O 118.208 -0.901 . . . . 0.0 110.848 179.933 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 301' ' ' RET . . . . . 0.766 H203 ' HE1' ' A' ' 171' ' ' TRP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 93.8 mmm . . . . . 0 N--CA 1.486 1.358 0 CA-C-O 120.828 0.347 . . . . 0.0 110.834 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 8.3 p -113.15 -11.46 11.97 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.087 -179.858 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -86.81 -42.81 6.26 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.839 -0.696 . . . . 0.0 112.672 179.994 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 4' ' ' LEU . . . . . 0.412 ' HB2' ' HH2' ' A' ' 60' ' ' TRP . 81.9 mt -65.64 -36.65 84.32 Favored 'General case' 0 N--CA 1.45 -0.436 0 CA-C-O 120.804 0.335 . . . . 0.0 111.117 -179.844 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 67.1 p -57.21 -30.64 64.73 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.01 -0.541 . . . . 0.0 111.725 -179.651 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 27.3 p -58.8 -38.32 78.32 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 116.524 -0.307 . . . . 0.0 111.344 -179.609 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 7' ' ' LEU . . . . . . . . . . . . . 4.2 mm? -63.5 -51.45 65.49 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.106 -179.941 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 8' ' ' PHE . . . . . 0.484 ' HB2' ' HB2' ' A' ' 55' ' ' ALA . 74.1 m-85 -61.2 -33.23 73.13 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.512 179.928 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 9' ' ' TRP . . . . . 0.473 ' O ' HG13 ' A' ' 13' ' ' ILE . 9.1 m95 -66.15 -38.52 88.31 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 116.067 -0.515 . . . . 0.0 110.241 179.999 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 73.2 mt -65.7 -32.63 74.3 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 115.787 -0.642 . . . . 0.0 110.005 179.464 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -71.02 -33.64 65.31 Favored Glycine 0 N--CA 1.448 -0.517 0 C-N-CA 120.953 -0.642 . . . . 0.0 111.757 179.129 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 12' ' ' ALA . . . . . 0.456 ' O ' HD23 ' A' ' 16' ' ' LEU . . . -70.02 -32.43 70.58 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 120.889 0.376 . . . . 0.0 110.53 179.315 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 13' ' ' ILE . . . . . 0.473 HG13 ' O ' ' A' ' 9' ' ' TRP . 73.8 mt -66.95 -53.81 30.65 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.233 0 CA-C-N 116.021 -0.536 . . . . 0.0 110.577 179.721 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -64.11 -25.09 69.28 Favored Glycine 0 N--CA 1.451 -0.366 0 C-N-CA 120.657 -0.783 . . . . 0.0 112.042 179.677 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 15' ' ' MET . . . . . 0.536 ' HB3' ' HB2' ' A' ' 48' ' ' ALA . 0.0 OUTLIER -72.54 -54.47 9.11 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.559 0.219 . . . . 0.0 110.933 179.82 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 16' ' ' LEU . . . . . 0.456 HD23 ' O ' ' A' ' 12' ' ' ALA . 3.9 mm? -53.13 -45.72 68.47 Favored 'General case' 0 C--N 1.332 -0.179 0 CA-C-N 116.403 -0.362 . . . . 0.0 110.921 179.527 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 83.7 t -61.06 -40.29 85.18 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.153 0 CA-C-N 116.372 -0.376 . . . . 0.0 110.457 179.666 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -67.68 -41.73 88.81 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.859 -0.686 . . . . 0.0 111.802 179.188 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 16.3 m -51.14 -53.76 31.44 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.989 0.423 . . . . 0.0 110.711 -179.982 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 62.6 mt -71.71 -32.22 67.55 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 115.786 -0.643 . . . . 0.0 111.083 179.84 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 21' ' ' ALA . . . . . 0.46 ' O ' ' HB2' ' A' ' 25' ' ' ALA . . . -58.33 -56.67 19.13 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.793 -179.605 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 22' ' ' PHE . . . . . 0.496 ' HB2' HG22 ' A' ' 41' ' ' VAL . 4.7 m-85 -71.11 -30.75 66.91 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.409 -0.359 . . . . 0.0 111.337 -179.128 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -64.03 -51.24 65.11 Favored 'General case' 0 C--N 1.327 -0.4 0 N-CA-C 112.369 0.507 . . . . 0.0 112.369 -179.17 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 24' ' ' TRP . . . . . 0.53 ' CE3' ' HA ' ' A' ' 24' ' ' TRP . 2.4 t-105 -86.67 -26.76 24.15 Favored 'General case' 0 N--CA 1.442 -0.842 0 N-CA-C 113.326 0.861 . . . . 0.0 113.326 -177.655 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 25' ' ' ALA . . . . . 0.46 ' HB2' ' O ' ' A' ' 21' ' ' ALA . . . -46.86 -48.61 21.02 Favored 'General case' 0 C--N 1.314 -0.947 0 N-CA-C 109.586 -0.524 . . . . 0.0 109.586 178.785 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -74.35 -21.29 79.09 Favored Glycine 0 N--CA 1.45 -0.426 0 N-CA-C 110.039 -1.224 . . . . 0.0 110.039 177.354 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 27' ' ' ARG . . . . . 0.47 ' HA ' ' CE3' ' A' ' 24' ' ' TRP . 19.0 mtt180 59.88 77.49 0.31 Allowed 'General case' 0 CA--C 1.516 -0.34 0 CA-C-N 114.676 -0.762 . . . . 0.0 111.855 179.357 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 20.2 t70 50.97 86.76 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 115.638 -0.71 . . . . 0.0 111.046 178.975 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -76.01 158.57 31.75 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.4 -179.601 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -72.58 -79.13 0.48 Allowed Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.877 -0.677 . . . . 0.0 112.515 -179.967 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 31' ' ' SER . . . . . 0.422 ' HA ' ' HE ' ' A' ' 34' ' ' ARG . 44.3 t -156.63 -55.22 0.08 Allowed 'General case' 0 C--N 1.331 -0.239 0 CA-C-O 120.644 0.259 . . . . 0.0 111.183 -179.904 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -56.11 -28.39 53.84 Favored Glycine 0 C--N 1.33 0.231 0 C-N-CA 120.823 -0.703 . . . . 0.0 112.767 -179.97 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 8.8 mm-40 -92.14 -23.6 19.36 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.794 0.331 . . . . 0.0 110.949 -179.964 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 34' ' ' ARG . . . . . 0.422 ' HE ' ' HA ' ' A' ' 31' ' ' SER . 53.1 mtm180 -56.4 -28.34 59.04 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.156 -0.475 . . . . 0.0 111.848 -179.677 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 19.0 tpp180 -55.27 -59.05 5.33 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-O 120.744 0.307 . . . . 0.0 111.408 -179.634 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 42.3 m-85 -71.96 -34.81 69.29 Favored 'General case' 0 C--N 1.33 -0.244 0 N-CA-C 112.333 0.494 . . . . 0.0 112.333 -178.783 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 37' ' ' TYR . . . . . 0.412 ' O ' HG23 ' A' ' 41' ' ' VAL . 29.4 m-85 -70.39 -56.25 7.13 Favored 'General case' 0 N--CA 1.464 0.226 0 N-CA-C 111.619 0.229 . . . . 0.0 111.619 -179.221 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 77.9 t -56.85 -37.23 52.85 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.232 0 CA-C-O 120.8 0.333 . . . . 0.0 110.87 179.799 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 21.9 m -62.25 -51.18 68.75 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.845 179.313 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 40' ' ' LEU . . . . . 0.4 HD13 ' CE1' ' A' ' 208' ' ' PHE . 18.1 tp -59.87 -50.93 71.86 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 115.926 -0.579 . . . . 0.0 110.792 179.978 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . 0.496 HG22 ' HB2' ' A' ' 22' ' ' PHE . 65.3 t -58.84 -34.09 51.31 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.373 0 CA-C-N 115.775 -0.648 . . . . 0.0 109.998 179.169 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -58.76 -41.81 96.11 Favored Glycine 0 N--CA 1.448 -0.542 0 C-N-CA 120.829 -0.7 . . . . 0.0 111.657 179.429 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 43' ' ' ILE . . . . . 0.501 HD13 HD13 ' A' ' 83' ' ' ILE . 1.1 mt -61.75 -51.16 75.97 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.176 0 CA-C-O 120.847 0.356 . . . . 0.0 110.508 179.201 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 79.3 p -62.2 -23.27 66.53 Favored 'General case' 0 C--N 1.333 -0.132 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.088 179.756 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -77.55 -56.94 3.72 Favored Glycine 0 C--N 1.33 0.225 0 C-N-CA 120.832 -0.699 . . . . 0.0 112.406 179.916 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 46' ' ' ILE . . . . . 0.571 HD12 HD12 ' A' ' 78' ' ' LEU . 13.1 pt -58.49 -37.14 62.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-O 121.051 0.453 . . . . 0.0 110.721 179.77 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 47' ' ' ALA . . . . . 0.692 ' HB2' ' HE2' ' A' ' 205' ' ' LYS . . . -68.46 -41.02 80.78 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 115.97 -0.559 . . . . 0.0 110.89 179.113 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 48' ' ' ALA . . . . . 0.536 ' HB2' ' HB3' ' A' ' 15' ' ' MET . . . -55.69 -42.09 74.67 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-N 115.805 -0.634 . . . . 0.0 111.763 -179.486 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 49' ' ' VAL . . . . . 0.46 ' O ' HG13 ' A' ' 53' ' ' VAL . 8.6 m -75.56 -37.44 36.98 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.545 -0.298 . . . . 0.0 111.6 -179.516 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -60.61 -43.59 97.26 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 121.035 0.445 . . . . 0.0 111.061 179.809 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 51' ' ' TYR . . . . . 0.514 ' HE2' ' HE2' ' A' ' 15' ' ' MET . 43.3 m-85 -73.1 -32.38 64.94 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-N 115.933 -0.576 . . . . 0.0 110.484 -179.77 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -69.34 -38.97 78.41 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-N 115.897 -0.592 . . . . 0.0 111.1 179.549 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 53' ' ' VAL . . . . . 0.46 HG13 ' O ' ' A' ' 49' ' ' VAL . 33.3 m -74.62 -47.39 39.04 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.224 0 CA-C-N 116.418 -0.356 . . . . 0.0 110.573 180.0 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 54' ' ' MET . . . . . 0.454 ' N ' HG23 ' A' ' 53' ' ' VAL . 75.3 mtm -61.37 -31.77 71.67 Favored 'General case' 0 N--CA 1.455 -0.178 0 N-CA-C 109.62 -0.511 . . . . 0.0 109.62 179.058 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 55' ' ' ALA . . . . . 0.484 ' HB2' ' HB2' ' A' ' 8' ' ' PHE . . . -69.31 -22.83 63.76 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 115.588 -0.733 . . . . 0.0 110.933 179.215 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 63.8 mt -87.51 0.12 56.02 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 116.167 -0.469 . . . . 0.0 111.409 -179.797 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 90.5 -21.49 32.12 Favored Glycine 0 N--CA 1.452 -0.261 0 C-N-CA 120.564 -0.827 . . . . 0.0 113.115 179.522 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 58' ' ' VAL . . . . . 0.437 HG12 ' O ' ' A' ' 53' ' ' VAL . 13.7 p -68.36 148.7 11.68 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.215 0 CA-C-N 116.887 0.344 . . . . 0.0 110.822 179.955 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 59' ' ' GLY . . . . . 0.402 ' HA3' ' HG2' ' A' ' 71' ' ' PRO . . . 92.44 -5.06 77.37 Favored Glycine 0 N--CA 1.45 -0.403 0 C-N-CA 120.648 -0.787 . . . . 0.0 112.403 -179.573 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 60' ' ' TRP . . . . . 0.412 ' HH2' ' HB2' ' A' ' 4' ' ' LEU . 15.9 m0 -86.19 108.09 18.19 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.55 0.214 . . . . 0.0 110.954 -179.861 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 61' ' ' VAL . . . . . 0.463 HG13 HG23 ' A' ' 68' ' ' VAL . 7.5 p -111.8 128.26 25.69 Favored Pre-proline 0 CA--C 1.533 0.317 0 CA-C-N 116.52 -0.309 . . . . 0.0 111.108 179.804 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 73.8 Cg_endo -75.23 155.27 41.85 Favored 'Trans proline' 0 C--N 1.35 0.645 0 C-N-CA 122.422 2.082 . . . . 0.0 112.648 -179.679 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 80.7 t -143.21 89.73 0.4 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 115.826 -0.625 . . . . 0.0 110.858 179.929 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . 59.9 -86.86 0.02 OUTLIER 'General case' 0 C--N 1.331 -0.199 0 CA-C-N 116.065 -0.516 . . . . 0.0 111.467 179.953 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 6.2 mp0 -121.52 -19.64 6.84 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 116.286 -0.415 . . . . 0.0 110.652 179.962 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 66' ' ' ARG . . . . . . . . . . . . . 45.6 mtm180 -101.24 161.52 13.56 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 115.919 -0.582 . . . . 0.0 110.499 179.913 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 56.2 m -122.44 137.63 54.81 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.35 -0.386 . . . . 0.0 111.269 -179.804 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 68' ' ' VAL . . . . . 0.463 HG23 HG13 ' A' ' 61' ' ' VAL . 21.7 m -127.37 146.64 32.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.025 -0.534 . . . . 0.0 110.802 179.772 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 69' ' ' PHE . . . . . . . . . . . . . 23.1 m-85 -109.44 112.18 24.15 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.154 -179.261 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 70' ' ' VAL . . . . . 0.546 ' HB ' ' HD3' ' A' ' 71' ' ' PRO . 13.0 t -62.95 -49.61 80.89 Favored Pre-proline 0 C--N 1.324 -0.508 0 CA-C-N 116.227 -0.442 . . . . 0.0 112.021 -178.901 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 71' ' ' PRO . . . . . 0.546 ' HD3' ' HB ' ' A' ' 70' ' ' VAL . 38.2 Cg_exo -60.74 -18.46 55.98 Favored 'Trans proline' 0 C--N 1.35 0.616 0 C-N-CA 122.039 1.826 . . . . 0.0 112.985 -179.663 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 72' ' ' ARG . . . . . 0.478 ' NH2' HG13 ' A' ' 197' ' ' ILE . 77.5 ttt180 -76.08 -55.6 5.44 Favored 'General case' 0 C--O 1.235 0.303 0 CA-C-O 120.796 0.331 . . . . 0.0 111.86 -179.093 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 73' ' ' TYR . . . . . . . . . . . . . 27.1 m-85 -67.52 -36.15 80.49 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-O 120.817 0.342 . . . . 0.0 110.321 -179.545 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 74' ' ' ILE . . . . . 0.586 ' O ' HD23 ' A' ' 78' ' ' LEU . 0.3 OUTLIER -67.14 -43.05 88.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 N-CA-C 109.686 -0.487 . . . . 0.0 109.686 179.344 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 75' ' ' ASP . . . . . 0.403 ' HA ' HD21 ' A' ' 78' ' ' LEU . 12.0 t70 -51.95 -40.72 61.3 Favored 'General case' 0 CA--C 1.519 -0.226 0 N-CA-C 109.534 -0.543 . . . . 0.0 109.534 179.009 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 76' ' ' TRP . . . . . 0.411 ' HZ2' HG23 ' A' ' 197' ' ' ILE . 44.2 m0 -66.34 -35.5 80.51 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 115.794 -0.639 . . . . 0.0 110.825 179.425 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 77' ' ' ILE . . . . . 0.466 ' O ' ' HG2' ' A' ' 81' ' ' PRO . 88.0 mt -59.75 -40.73 83.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.094 -0.503 . . . . 0.0 112.318 -179.446 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 78' ' ' LEU . . . . . 0.586 HD23 ' O ' ' A' ' 74' ' ' ILE . 0.6 OUTLIER -91.94 -28.34 17.31 Favored 'General case' 0 CA--C 1.535 0.371 0 N-CA-C 113.038 0.755 . . . . 0.0 113.038 -179.546 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 65.3 p -79.65 -53.09 7.17 Favored 'General case' 0 N--CA 1.469 0.511 0 N-CA-C 113.468 0.914 . . . . 0.0 113.468 -178.41 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 80' ' ' THR . . . . . 0.593 ' HB ' ' HD3' ' A' ' 81' ' ' PRO . 3.8 m -50.92 -54.02 41.6 Favored Pre-proline 0 CA--C 1.533 0.291 0 N-CA-C 112.409 0.522 . . . . 0.0 112.409 -178.27 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 81' ' ' PRO . . . . . 0.593 ' HD3' ' HB ' ' A' ' 80' ' ' THR . 32.3 Cg_exo -60.08 -22.41 69.51 Favored 'Trans proline' 0 C--N 1.351 0.687 0 C-N-CA 121.869 1.712 . . . . 0.0 111.761 179.723 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 82' ' ' LEU . . . . . . . . . . . . . 15.4 tp -74.32 -33.03 63.06 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.067 -0.515 . . . . 0.0 109.921 179.647 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 83' ' ' ILE . . . . . 0.501 HD13 HD13 ' A' ' 43' ' ' ILE . 35.4 mm -68.79 -53.03 29.24 Favored 'Isoleucine or valine' 0 C--O 1.235 0.309 0 CA-C-N 115.845 -0.616 . . . . 0.0 110.037 179.04 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . 0.458 HG22 ' HA ' ' A' ' 81' ' ' PRO . 30.8 m -61.67 -30.18 47.75 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.221 0 CA-C-N 116.085 -0.507 . . . . 0.0 109.832 179.043 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 85' ' ' TYR . . . . . 0.41 ' HB2' ' O ' ' A' ' 81' ' ' PRO . 44.2 t80 -66.82 -34.68 78.35 Favored 'General case' 0 N--CA 1.454 -0.251 0 CA-C-N 115.665 -0.698 . . . . 0.0 109.386 178.724 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 86' ' ' PHE . . . . . . . . . . . . . 18.9 t80 -59.2 -51.45 69.94 Favored 'General case' 0 CA--C 1.519 -0.234 0 CA-C-N 115.735 -0.666 . . . . 0.0 109.427 178.983 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 10.5 mp -60.51 -32.29 71.32 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 115.55 -0.75 . . . . 0.0 110.04 179.28 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 88' ' ' GLY . . . . . 0.455 ' HA2' HD13 ' A' ' 93' ' ' LEU . . . -68.59 -28.21 73.32 Favored Glycine 0 N--CA 1.449 -0.438 0 C-N-CA 120.751 -0.738 . . . . 0.0 111.697 179.382 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 75.9 mt -72.49 -39.25 67.82 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-O 120.982 0.42 . . . . 0.0 110.278 179.43 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 70.5 mt -59.9 -53.1 61.86 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 115.76 -0.654 . . . . 0.0 110.603 179.569 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . 0.551 ' HB2' ' HB2' ' A' ' 149' ' ' ALA . . . -72.33 -52.07 17.81 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.126 -0.488 . . . . 0.0 111.062 179.89 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 97.21 57.24 1.08 Allowed Glycine 0 N--CA 1.453 -0.228 0 C-N-CA 120.817 -0.706 . . . . 0.0 112.207 -179.899 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 93' ' ' LEU . . . . . 0.592 HD23 ' HB3' ' A' ' 97' ' ' GLU . 8.9 mp -60.5 172.65 0.84 Allowed 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 121.045 0.45 . . . . 0.0 111.35 -179.704 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 94' ' ' ASP . . . . . 0.429 ' HB2' ' HG2' ' A' ' 97' ' ' GLU . 8.0 m-20 -82.63 172.55 12.82 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-N 115.904 -0.589 . . . . 0.0 110.634 179.907 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 38.3 t -56.24 -48.68 76.04 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.206 -179.839 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 99.2 mtt180 -70.4 -43.38 70.15 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.268 -0.424 . . . . 0.0 111.196 -179.835 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 97' ' ' GLU . . . . . 0.592 ' HB3' HD23 ' A' ' 93' ' ' LEU . 21.5 mm-40 -52.19 -48.0 65.26 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.991 -179.59 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 98' ' ' PHE . . . . . 0.453 ' O ' HG12 ' A' ' 102' ' ' ILE . 11.6 m-85 -57.5 -45.2 85.18 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-O 120.988 0.423 . . . . 0.0 110.19 179.177 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -62.59 -26.43 68.36 Favored Glycine 0 N--CA 1.45 -0.417 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.421 179.811 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 97.1 mt -73.28 -47.4 46.76 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.238 0 N-CA-C 111.876 0.324 . . . . 0.0 111.876 -179.632 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 26.5 m -69.19 -35.13 66.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 N-CA-C 111.9 0.333 . . . . 0.0 111.9 -179.169 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 102' ' ' ILE . . . . . 0.453 HG12 ' O ' ' A' ' 98' ' ' PHE . 48.6 mm -72.23 -47.92 51.17 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.25 0 CA-C-N 116.674 -0.239 . . . . 0.0 111.596 -179.294 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 14.4 t -60.22 -37.63 80.92 Favored 'General case' 0 C--O 1.234 0.273 0 CA-C-O 121.02 0.438 . . . . 0.0 110.879 179.895 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 104' ' ' LEU . . . . . 0.541 ' O ' HG12 ' A' ' 107' ' ' VAL . 31.3 tp -60.52 -50.15 74.68 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 115.975 -0.557 . . . . 0.0 110.512 179.648 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 105' ' ' ASN . . . . . 0.553 ' N ' HD22 ' A' ' 105' ' ' ASN . 0.8 OUTLIER -59.27 -31.69 69.33 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.012 179.778 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 96.9 m -61.01 -57.82 11.0 Favored 'General case' 0 C--N 1.331 -0.204 0 CA-C-N 116.547 -0.297 . . . . 0.0 111.478 -179.292 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 107' ' ' VAL . . . . . 0.541 HG12 ' O ' ' A' ' 104' ' ' LEU . 14.2 p -56.4 -35.46 43.76 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.242 -0.436 . . . . 0.0 110.742 -179.912 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . 0.508 HG23 ' O ' ' A' ' 104' ' ' LEU . 82.1 t -61.68 -57.8 10.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.038 -0.528 . . . . 0.0 111.424 179.624 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 109' ' ' MET . . . . . 0.505 ' HG2' ' O ' ' A' ' 105' ' ' ASN . 5.4 mmt -58.39 -35.2 71.64 Favored 'General case' 0 C--N 1.333 -0.146 0 CA-C-N 116.546 -0.297 . . . . 0.0 110.928 -179.683 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 8.3 mt -68.39 -33.17 73.77 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.307 -0.406 . . . . 0.0 110.696 179.785 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -61.75 -45.0 95.8 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 121.153 0.502 . . . . 0.0 109.745 178.989 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 112' ' ' GLY . . . . . 0.562 ' HA3' ' H21' ' A' ' 301' ' ' RET . . . -73.81 -33.34 57.89 Favored Glycine 0 N--CA 1.448 -0.507 0 CA-C-N 115.595 -0.729 . . . . 0.0 111.384 179.111 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 113' ' ' PHE . . . . . 0.405 ' HD2' HD11 ' A' ' 77' ' ' ILE . 1.1 t80 -53.27 -73.53 0.04 OUTLIER 'General case' 0 N--CA 1.455 -0.186 0 CA-C-O 121.093 0.473 . . . . 0.0 109.749 179.298 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 114' ' ' ALA . . . . . 0.413 ' O ' HG13 ' A' ' 118' ' ' VAL . . . -63.1 -21.44 66.18 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 115.68 -0.691 . . . . 0.0 110.805 179.618 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 115' ' ' GLY . . . . . 0.414 ' HA2' HD22 ' A' ' 126' ' ' LEU . . . -52.57 -49.24 53.46 Favored Glycine 0 C--N 1.335 0.473 0 C-N-CA 120.785 -0.721 . . . . 0.0 112.155 179.492 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -78.38 -15.75 58.36 Favored 'General case' 0 C--N 1.326 -0.414 0 N-CA-C 111.698 0.258 . . . . 0.0 111.698 179.939 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 117' ' ' MET . . . . . 0.462 ' HG2' HG21 ' A' ' 68' ' ' VAL . 57.6 mtt -102.35 15.6 28.69 Favored 'General case' 0 C--N 1.332 -0.194 0 CA-C-O 120.687 0.279 . . . . 0.0 111.731 -179.295 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 118' ' ' VAL . . . . . 0.413 HG13 ' O ' ' A' ' 114' ' ' ALA . 19.2 m -65.62 150.26 96.33 Favored Pre-proline 0 C--N 1.329 -0.303 0 CA-C-N 116.509 -0.314 . . . . 0.0 111.213 179.9 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 119' ' ' PRO . . . . . . . . . . . . . 91.5 Cg_endo -80.97 4.48 6.94 Favored 'Trans proline' 0 C--N 1.348 0.529 0 C-N-CA 122.508 2.139 . . . . 0.0 112.501 179.68 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -170.31 -123.71 0.7 Allowed Glycine 0 C--N 1.33 0.231 0 C-N-CA 120.637 -0.792 . . . . 0.0 112.747 -179.816 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 26.2 pt -105.44 9.77 9.3 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-O 120.698 0.285 . . . . 0.0 111.467 -179.716 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 13.9 mm-40 -58.0 -19.23 29.46 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-O 120.95 0.405 . . . . 0.0 110.75 179.626 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 123' ' ' ARG . . . . . 0.503 ' HB2' ' HH2' ' A' ' 178' ' ' TRP . 23.2 ptt180 -51.5 -35.37 39.98 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 115.67 -0.695 . . . . 0.0 111.903 -179.781 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 124' ' ' TYR . . . . . . . . . . . . . 25.7 m-85 -57.29 -35.31 69.65 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.807 0.337 . . . . 0.0 110.891 -179.875 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 125' ' ' ALA . . . . . . . . . . . . . . . -74.35 -48.97 24.8 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.064 179.813 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 126' ' ' LEU . . . . . 0.414 HD22 ' HA2' ' A' ' 115' ' ' GLY . 6.9 mp -53.33 -52.48 59.02 Favored 'General case' 0 C--N 1.332 -0.158 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.787 -179.981 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 127' ' ' PHE . . . . . 0.458 ' CE1' ' H42' ' A' ' 301' ' ' RET . 6.6 t80 -64.38 -37.54 87.87 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.281 -0.418 . . . . 0.0 110.684 179.999 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 128' ' ' GLY . . . . . . . . . . . . . . . -46.42 -45.02 16.52 Favored Glycine 0 C--N 1.332 0.337 0 C-N-CA 120.118 -1.039 . . . . 0.0 110.959 179.265 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 129' ' ' MET . . . . . . . . . . . . . 0.5 OUTLIER -70.46 -38.04 74.39 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 120.868 0.366 . . . . 0.0 110.073 178.722 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -63.61 -30.81 78.73 Favored Glycine 0 C--N 1.333 0.365 0 C-N-CA 121.056 -0.592 . . . . 0.0 112.951 -179.816 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -74.48 -53.56 9.26 Favored 'General case' 0 CA--C 1.519 -0.22 0 CA-C-N 116.779 0.29 . . . . 0.0 110.369 179.94 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 43.1 t -57.42 -40.33 73.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 N-CA-C 109.251 -0.648 . . . . 0.0 109.251 178.766 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -66.09 -37.09 84.9 Favored 'General case' 0 N--CA 1.452 -0.34 0 CA-C-N 115.218 -0.901 . . . . 0.0 110.041 178.893 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 134' ' ' PHE . . . . . 0.415 ' CZ ' ' HA ' ' A' ' 172' ' ' ALA . 82.9 t80 -57.01 -50.76 71.74 Favored 'General case' 0 N--CA 1.45 -0.461 0 CA-C-N 115.919 -0.582 . . . . 0.0 109.99 179.254 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 135' ' ' ILE . . . . . 0.53 ' O ' HG22 ' A' ' 138' ' ' VAL . 57.6 mt -58.13 -30.81 40.21 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.342 0 CA-C-N 115.668 -0.696 . . . . 0.0 109.779 179.161 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 136' ' ' GLY . . . . . 0.425 ' O ' ' HB3' ' A' ' 139' ' ' TYR . . . -65.48 -38.07 94.42 Favored Glycine 0 N--CA 1.447 -0.58 0 C-N-CA 120.224 -0.988 . . . . 0.0 110.966 178.438 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 137' ' ' LEU . . . . . 0.55 HD13 HD21 ' A' ' 105' ' ' ASN . 29.2 tp -69.32 -46.78 66.26 Favored 'General case' 0 C--N 1.331 -0.205 0 N-CA-C 110.449 -0.204 . . . . 0.0 110.449 179.399 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 138' ' ' VAL . . . . . 0.548 ' HA ' HD12 ' A' ' 141' ' ' LEU . 4.6 m -62.13 -31.89 52.85 Favored 'Isoleucine or valine' 0 C--O 1.234 0.255 0 N-CA-C 109.029 -0.73 . . . . 0.0 109.029 178.882 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 139' ' ' TYR . . . . . 0.425 ' HB3' ' O ' ' A' ' 136' ' ' GLY . 45.6 t80 -60.99 -37.2 81.62 Favored 'General case' 0 N--CA 1.453 -0.317 0 CA-C-N 115.176 -0.92 . . . . 0.0 108.879 178.053 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 140' ' ' TYR . . . . . 0.516 ' HB3' ' SD ' ' A' ' 145' ' ' MET . 24.0 m-85 -70.25 -35.22 73.65 Favored 'General case' 0 C--N 1.332 -0.168 0 CA-C-N 115.489 -0.778 . . . . 0.0 110.122 178.478 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 141' ' ' LEU . . . . . 0.548 HD12 ' HA ' ' A' ' 138' ' ' VAL . 96.1 mt -55.55 -39.83 71.12 Favored 'General case' 0 C--O 1.232 0.149 0 CA-C-N 115.976 -0.556 . . . . 0.0 110.156 179.343 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 2.3 t -104.05 0.15 10.19 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 115.775 -0.648 . . . . 0.0 110.953 179.889 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 143' ' ' GLY . . . . . 0.416 ' O ' HG22 ' A' ' 146' ' ' THR . . . -72.89 -148.81 0.97 Allowed Glycine 0 CA--C 1.519 0.33 0 C-N-CA 120.965 -0.636 . . . . 0.0 112.876 -179.726 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 144' ' ' PRO . . . . . . . . . . . . . 31.8 Cg_endo -63.73 -23.56 69.34 Favored 'Trans proline' 0 C--N 1.347 0.497 0 C-N-CA 122.629 2.22 . . . . 0.0 112.523 -179.901 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 145' ' ' MET . . . . . 0.576 ' HG2' HD21 ' A' ' 93' ' ' LEU . 84.2 mtp -53.57 -58.37 7.4 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.451 -179.81 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 146' ' ' THR . . . . . 0.416 HG22 ' O ' ' A' ' 143' ' ' GLY . 7.4 t -60.65 -32.2 71.39 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.382 -0.372 . . . . 0.0 111.337 -179.831 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 40.5 mt-10 -66.71 -34.65 78.33 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.283 -0.417 . . . . 0.0 111.071 -179.993 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 148' ' ' SER . . . . . . . . . . . . . 47.0 t -69.58 -45.32 68.94 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.051 -179.641 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 149' ' ' ALA . . . . . 0.558 ' HB1' HG22 ' A' ' 156' ' ' ILE . . . -63.88 -38.84 92.59 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.464 -179.665 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 150' ' ' SER . . . . . 0.586 ' HA ' ' HB2' ' A' ' 157' ' ' LYS . 81.8 p -67.54 -2.53 6.73 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.295 -0.411 . . . . 0.0 111.059 -179.817 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 151' ' ' GLN . . . . . . . . . . . . . 49.4 mt-30 -119.72 -1.64 10.53 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.26 -0.427 . . . . 0.0 111.244 -179.967 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 37.7 mmt180 -81.65 -51.6 8.04 Favored 'General case' 0 C--N 1.332 -0.185 0 CA-C-O 120.945 0.403 . . . . 0.0 110.746 179.712 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 153' ' ' SER . . . . . 0.577 ' HB3' HG12 ' A' ' 156' ' ' ILE . 23.1 t -158.17 172.28 18.68 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-N 115.865 -0.607 . . . . 0.0 110.544 179.254 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 154' ' ' SER . . . . . . . . . . . . . 39.6 t -69.91 -39.87 75.92 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-O 120.871 0.367 . . . . 0.0 110.317 179.418 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -76.99 -42.39 20.02 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.943 -0.646 . . . . 0.0 112.659 179.808 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 156' ' ' ILE . . . . . 0.577 HG12 ' HB3' ' A' ' 153' ' ' SER . 36.5 mm -48.86 -37.45 9.11 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.162 0 CA-C-O 120.863 0.363 . . . . 0.0 111.495 -179.778 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 157' ' ' LYS . . . . . 0.586 ' HB2' ' HA ' ' A' ' 150' ' ' SER . 54.8 tttm -67.72 -36.36 80.46 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.277 -179.712 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 43.3 t -71.8 -42.22 67.32 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.658 -179.378 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 159' ' ' LEU . . . . . 0.414 ' O ' ' HB2' ' A' ' 163' ' ' LEU . 10.7 mp -67.42 -35.23 78.86 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.342 -0.39 . . . . 0.0 111.74 -179.372 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 160' ' ' TYR . . . . . . . . . . . . . 23.8 t80 -72.78 -46.84 51.19 Favored 'General case' 0 C--N 1.33 -0.274 0 N-CA-C 112.179 0.437 . . . . 0.0 112.179 -178.676 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 161' ' ' VAL . . . . . 0.443 HG23 ' N ' ' A' ' 162' ' ' ARG . 24.6 m -62.98 -45.95 97.55 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 N-CA-C 112.353 0.501 . . . . 0.0 112.353 -178.952 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 162' ' ' ARG . . . . . 0.443 ' N ' HG23 ' A' ' 161' ' ' VAL . 36.2 mmt180 -66.33 -42.71 87.79 Favored 'General case' 0 C--N 1.328 -0.329 0 N-CA-C 111.807 0.299 . . . . 0.0 111.807 -179.141 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 163' ' ' LEU . . . . . 0.472 ' HG ' ' HB2' ' A' ' 208' ' ' PHE . 6.1 mp -71.45 -43.86 65.87 Favored 'General case' 0 C--N 1.329 -0.297 0 N-CA-C 111.957 0.354 . . . . 0.0 111.957 -179.251 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 164' ' ' ARG . . . . . 0.459 ' HG3' ' N ' ' A' ' 165' ' ' ASN . 5.6 ppt_? -68.38 -40.71 81.29 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 120.456 0.169 . . . . 0.0 111.073 -179.374 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 165' ' ' ASN . . . . . 0.594 ' O ' HG23 ' A' ' 169' ' ' VAL . 0.9 OUTLIER -58.89 -48.0 82.96 Favored 'General case' 0 C--N 1.332 -0.19 0 CA-C-O 120.945 0.403 . . . . 0.0 110.558 179.35 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 166' ' ' LEU . . . . . 0.522 ' O ' ' HG ' ' A' ' 170' ' ' LEU . 4.1 tt -63.69 -48.39 77.32 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 116.109 -0.496 . . . . 0.0 111.017 -179.958 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 167' ' ' THR . . . . . 0.427 ' O ' ' HB2' ' A' ' 171' ' ' TRP . 93.0 m -57.4 -53.91 52.74 Favored 'General case' 0 C--N 1.33 -0.251 0 N-CA-C 112.426 0.528 . . . . 0.0 112.426 -178.971 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 168' ' ' VAL . . . . . 0.513 ' HB ' HD13 ' A' ' 141' ' ' LEU . 12.9 p -55.95 -40.75 64.6 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 N-CA-C 112.335 0.494 . . . . 0.0 112.335 -179.281 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 169' ' ' VAL . . . . . 0.594 HG23 ' O ' ' A' ' 165' ' ' ASN . 61.2 t -57.71 -65.8 0.39 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.389 0 N-CA-C 111.987 0.366 . . . . 0.0 111.987 -179.518 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 170' ' ' LEU . . . . . 0.522 ' HG ' ' O ' ' A' ' 166' ' ' LEU . 0.8 OUTLIER -65.18 -27.75 68.92 Favored 'General case' 0 C--N 1.331 -0.212 0 N-CA-C 112.146 0.425 . . . . 0.0 112.146 -178.813 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 171' ' ' TRP . . . . . 0.73 ' HE1' H203 ' A' ' 301' ' ' RET . 6.9 m0 -71.77 -30.23 65.35 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.83 0.348 . . . . 0.0 110.612 179.615 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 172' ' ' ALA . . . . . 0.415 ' HA ' ' CZ ' ' A' ' 134' ' ' PHE . . . -73.7 -6.77 48.93 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.768 179.997 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 173' ' ' ILE . . . . . 0.627 HG22 HD11 ' A' ' 177' ' ' ILE . 23.6 mm -87.43 -21.63 7.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 115.93 -0.577 . . . . 0.0 110.771 179.739 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 174' ' ' TYR . . . . . 0.417 ' HB2' ' HD3' ' A' ' 175' ' ' PRO . 24.3 m-85 -54.86 -49.55 91.18 Favored Pre-proline 0 N--CA 1.464 0.228 0 CA-C-N 116.287 -0.415 . . . . 0.0 111.833 -179.796 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 175' ' ' PRO . . . . . 0.417 ' HD3' ' HB2' ' A' ' 174' ' ' TYR . 88.6 Cg_exo -47.02 -29.27 8.34 Favored 'Trans proline' 0 C--N 1.352 0.756 0 C-N-CA 122.131 1.887 . . . . 0.0 112.161 179.894 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 176' ' ' PHE . . . . . 0.444 ' O ' ' HG ' ' A' ' 180' ' ' LEU . 81.8 m-85 -80.47 -46.76 15.36 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 115.918 -0.583 . . . . 0.0 111.757 -179.965 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 177' ' ' ILE . . . . . 0.627 HD11 HG22 ' A' ' 173' ' ' ILE . 2.0 mm -64.49 -38.41 82.52 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.54 0 CA-C-N 116.166 -0.47 . . . . 0.0 112.177 -178.299 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 178' ' ' TRP . . . . . 0.503 ' HH2' ' HB2' ' A' ' 123' ' ' ARG . 60.2 t90 -73.83 -41.98 61.54 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.91 0.386 . . . . 0.0 110.779 179.67 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 179' ' ' LEU . . . . . 0.461 ' O ' HG22 ' A' ' 185' ' ' VAL . 1.7 tm? -66.27 -49.95 65.39 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.066 -0.516 . . . . 0.0 111.078 -179.622 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 180' ' ' LEU . . . . . 0.611 HD22 HD11 ' A' ' 187' ' ' LEU . 14.0 mt -78.21 -47.94 16.91 Favored 'General case' 0 C--N 1.329 -0.301 0 N-CA-C 112.038 0.384 . . . . 0.0 112.038 -179.22 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . -54.32 177.94 0.27 Allowed Glycine 0 C--N 1.337 0.6 0 C-N-CA 120.649 -0.786 . . . . 0.0 113.066 -179.701 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 182' ' ' PRO . . . . . 0.587 ' HA ' ' HB2' ' A' ' 186' ' ' ALA . 71.9 Cg_exo -48.13 -44.93 27.12 Favored 'Trans proline' 0 CA--C 1.536 0.598 0 C-N-CA 122.908 2.405 . . . . 0.0 113.764 -179.793 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 183' ' ' PRO . . . . . 0.416 ' HD3' ' HB2' ' A' ' 182' ' ' PRO . 50.6 Cg_exo -54.85 -13.68 6.6 Favored 'Trans proline' 0 C--N 1.355 0.906 0 C-N-CA 122.028 1.819 . . . . 0.0 113.017 -179.845 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 184' ' ' GLY . . . . . . . . . . . . . . . -115.5 -101.05 2.3 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.517 -0.849 . . . . 0.0 112.635 -179.776 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 185' ' ' VAL . . . . . 0.461 HG22 ' O ' ' A' ' 179' ' ' LEU . 9.0 m -105.98 -5.35 9.97 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-O 120.904 0.383 . . . . 0.0 111.305 -179.803 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 186' ' ' ALA . . . . . 0.587 ' HB2' ' HA ' ' A' ' 182' ' ' PRO . . . 55.17 85.4 0.06 Allowed 'General case' 0 C--N 1.331 -0.203 0 CA-C-N 115.991 -0.549 . . . . 0.0 111.991 179.302 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 187' ' ' LEU . . . . . 0.611 HD11 HD22 ' A' ' 180' ' ' LEU . 16.7 mt -92.21 -49.5 6.15 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.512 179.146 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 188' ' ' LEU . . . . . . . . . . . . . 95.5 mt -96.61 -160.96 0.83 Allowed 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 115.698 -0.683 . . . . 0.0 110.635 -179.944 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 189' ' ' THR . . . . . . . . . . . . . 1.9 t -99.76 146.49 31.94 Favored Pre-proline 0 C--N 1.329 -0.318 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.855 179.951 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 190' ' ' PRO . . . . . 0.44 ' O ' HG23 ' A' ' 194' ' ' VAL . 86.9 Cg_exo -46.76 -44.09 22.53 Favored 'Trans proline' 0 C--N 1.349 0.567 0 C-N-CA 122.698 2.266 . . . . 0.0 113.244 -179.417 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 191' ' ' THR . . . . . . . . . . . . . 7.9 t -58.85 -43.4 90.78 Favored 'General case' 0 C--N 1.328 -0.345 0 N-CA-C 111.899 0.333 . . . . 0.0 111.899 -179.286 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 192' ' ' VAL . . . . . . . . . . . . . 45.7 t -71.77 -50.71 36.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.633 -0.258 . . . . 0.0 111.402 -179.743 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 193' ' ' ASP . . . . . . . . . . . . . 30.5 t70 -55.23 -45.34 75.98 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.452 -0.34 . . . . 0.0 111.066 -179.848 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 194' ' ' VAL . . . . . 0.44 HG23 ' O ' ' A' ' 190' ' ' PRO . 74.6 t -64.34 -35.55 74.51 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.944 179.706 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 195' ' ' ALA . . . . . . . . . . . . . . . -56.97 -48.59 78.02 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 116.577 -0.283 . . . . 0.0 111.211 179.726 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 196' ' ' LEU . . . . . 0.412 ' O ' ' HB3' ' A' ' 199' ' ' TYR . 97.5 mt -67.76 -40.82 84.02 Favored 'General case' 0 N--CA 1.462 0.169 0 CA-C-O 120.708 0.289 . . . . 0.0 110.687 179.696 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 197' ' ' ILE . . . . . 0.489 HG12 HG21 ' A' ' 177' ' ' ILE . 11.2 mm -57.83 -60.25 2.41 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.373 179.256 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 198' ' ' VAL . . . . . 0.409 ' O ' ' HB2' ' A' ' 202' ' ' LEU . 76.3 t -52.02 -33.96 16.86 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.452 0 CA-C-N 115.486 -0.779 . . . . 0.0 109.574 178.324 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 199' ' ' TYR . . . . . 0.428 ' O ' HG23 ' A' ' 203' ' ' VAL . 68.5 t80 -69.27 -37.98 78.15 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 115.353 -0.84 . . . . 0.0 110.365 179.889 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 200' ' ' LEU . . . . . . . . . . . . . 42.0 mt -62.35 -45.71 91.97 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 115.667 -0.697 . . . . 0.0 111.212 -179.56 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 201' ' ' ASP . . . . . . . . . . . . . 7.3 m-20 -71.07 -43.64 67.38 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.114 -179.659 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 202' ' ' LEU . . . . . 0.409 ' HB2' ' O ' ' A' ' 198' ' ' VAL . 1.1 tt -59.95 -30.25 68.95 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 115.884 -0.598 . . . . 0.0 111.411 -179.476 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 203' ' ' VAL . . . . . 0.428 HG23 ' O ' ' A' ' 199' ' ' TYR . 48.5 t -81.43 -36.84 15.04 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.293 -0.412 . . . . 0.0 111.552 -178.726 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 204' ' ' THR . . . . . . . . . . . . . 71.0 m -62.46 -54.99 31.94 Favored 'General case' 0 C--N 1.328 -0.365 0 C-N-CA 120.508 -0.477 . . . . 0.0 111.009 179.497 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 205' ' ' LYS . . . . . 0.692 ' HE2' ' HB2' ' A' ' 47' ' ' ALA . 50.5 mttp -67.84 -59.13 3.53 Favored 'General case' 0 C--N 1.33 -0.245 0 N-CA-C 112.529 0.566 . . . . 0.0 112.529 -178.495 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 59.9 t -70.42 -37.55 70.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 N-CA-C 112.168 0.433 . . . . 0.0 112.168 -178.609 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 207' ' ' GLY . . . . . 0.544 ' O ' HG13 ' A' ' 211' ' ' ILE . . . -64.0 -60.66 6.96 Favored Glycine 0 N--CA 1.452 -0.254 0 C-N-CA 120.438 -0.887 . . . . 0.0 113.359 -178.866 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 208' ' ' PHE . . . . . 0.509 ' O ' ' HB2' ' A' ' 212' ' ' ALA . 0.1 OUTLIER -65.25 -26.91 68.31 Favored 'General case' 0 C--O 1.224 -0.289 0 CA-C-N 117.051 0.425 . . . . 0.0 111.064 -179.289 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 209' ' ' GLY . . . . . 0.515 ' O ' ' HB3' ' A' ' 212' ' ' ALA . . . -69.39 -32.7 71.99 Favored Glycine 0 N--CA 1.447 -0.588 0 N-CA-C 111.593 -0.603 . . . . 0.0 111.593 178.726 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 210' ' ' PHE . . . . . . . . . . . . . 2.0 m-85 -74.56 -48.28 27.74 Favored 'General case' 0 CA--C 1.513 -0.462 0 N-CA-C 108.159 -1.052 . . . . 0.0 108.159 178.343 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 211' ' ' ILE . . . . . 0.544 HG13 ' O ' ' A' ' 207' ' ' GLY . 5.5 mt -62.03 -28.63 44.77 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.594 0 N-CA-C 107.517 -1.29 . . . . 0.0 107.517 176.423 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 212' ' ' ALA . . . . . 0.515 ' HB3' ' O ' ' A' ' 209' ' ' GLY . . . -62.53 -41.14 98.68 Favored 'General case' 0 N--CA 1.447 -0.587 0 CA-C-N 114.527 -1.215 . . . . 0.0 109.915 179.394 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 213' ' ' LEU . . . . . 0.425 ' HG ' ' O ' ' A' ' 209' ' ' GLY . 74.0 mt -70.31 -46.71 63.7 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-N 115.027 -0.988 . . . . 0.0 111.712 -179.826 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 214' ' ' ASP . . . . . . . . . . . . . 10.9 t70 -51.16 -54.86 21.36 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 120.923 0.392 . . . . 0.0 111.278 -179.476 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 215' ' ' ALA . . . . . 0.412 ' O ' ' HG ' ' A' ' 219' ' ' LEU . . . -58.7 -52.79 64.19 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-N 115.978 -0.555 . . . . 0.0 111.367 -179.718 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 216' ' ' ALA . . . . . . . . . . . . . . . -58.92 -33.23 70.33 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.333 -0.394 . . . . 0.0 111.619 -179.586 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 217' ' ' ALA . . . . . . . . . . . . . . . -64.05 -36.11 82.92 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 121.012 0.434 . . . . 0.0 110.36 179.893 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 218' ' ' THR . . . . . . . . . . . . . 94.1 m -72.09 -38.79 69.3 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 115.69 -0.686 . . . . 0.0 110.977 179.572 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 219' ' ' LEU . . . . . 0.412 ' HG ' ' O ' ' A' ' 215' ' ' ALA . 54.3 mt -63.85 -33.7 76.27 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.163 -0.472 . . . . 0.0 111.018 -179.883 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 220' ' ' ARG . . . . . . . . . . . . . 45.9 mtp180 -83.64 -30.21 27.05 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.884 179.802 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 221' ' ' ALA . . . . . . . . . . . . . . . -72.24 -24.01 61.31 Favored 'General case' 0 C--N 1.331 -0.203 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.233 -179.992 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 222' ' ' GLU . . . . . . . . . . . . . 10.0 pt-20 -92.25 -26.66 18.05 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.987 0.422 . . . . 0.0 110.32 179.967 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 223' ' ' HIS . . . . . . . . . . . . . 77.5 m-70 62.17 -176.24 0.13 Allowed 'General case' 0 C--N 1.331 -0.206 0 CA-C-N 115.532 -0.758 . . . . 0.0 111.222 179.999 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 224' ' ' GLY . . . . . . . . . . . . . . . -159.95 129.1 2.11 Favored Glycine 0 N--CA 1.45 -0.372 0 C-N-CA 120.637 -0.792 . . . . 0.0 112.685 -179.904 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 225' ' ' GLU . . . . . . . . . . . . . 44.5 mt-10 59.93 101.41 0.02 OUTLIER 'General case' 0 C--N 1.331 -0.2 0 CA-C-O 120.976 0.417 . . . . 0.0 111.178 179.908 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 226' ' ' SER . . . . . . . . . . . . . 63.3 m -96.9 149.63 21.66 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 115.979 -0.555 . . . . 0.0 110.865 179.983 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 227' ' ' LEU . . . . . . . . . . . . . 71.6 mt -73.53 127.49 32.88 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.968 179.981 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 228' ' ' ALA . . . . . . . . . . . . . . . -105.79 -43.2 4.95 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.1 179.966 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 229' ' ' GLY . . . . . . . . . . . . . . . 170.62 -118.79 0.77 Allowed Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.681 -0.771 . . . . 0.0 112.726 -179.874 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 230' ' ' VAL . . . . . . . . . . . . . 50.8 t -72.27 140.71 17.59 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.197 0 CA-C-O 120.875 0.369 . . . . 0.0 111.213 -179.825 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 231' ' ' ASP . . . . . . . . . . . . . 6.0 p-10 -83.7 104.79 14.09 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.779 179.99 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 232' ' ' THR . . . . . . . . . . . . . 82.6 p -132.2 15.23 4.63 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.257 -179.867 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 233' ' ' ASP . . . . . . . . . . . . . 4.4 p30 -79.9 2.73 22.22 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.386 -0.37 . . . . 0.0 110.893 179.96 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 234' ' ' THR . . . . . . . . . . . . . 74.1 p -114.41 150.61 44.09 Favored Pre-proline 0 C--N 1.33 -0.254 0 CA-C-N 116.284 -0.416 . . . . 0.0 111.071 -179.998 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 235' ' ' PRO . . . . . . . . . . . . . 60.2 Cg_endo -72.19 -55.31 0.12 Allowed 'Trans proline' 0 C--N 1.347 0.456 0 C-N-CA 122.488 2.125 . . . . 0.0 112.605 -179.693 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 236' ' ' ALA . . . . . . . . . . . . . . . -82.12 173.47 12.12 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.353 -0.385 . . . . 0.0 111.464 -179.801 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 237' ' ' VAL . . . . . . . . . . . . . 11.5 p -144.09 141.15 24.85 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 115.948 -0.569 . . . . 0.0 110.855 179.939 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 238' ' ' ALA . . . . . . . . . . . . . . . -116.35 160.81 19.97 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.373 -0.376 . . . . 0.0 111.248 -179.791 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 239' ' ' ASP . . . . . . . . . . . . . 5.4 m-20 -94.01 164.06 13.24 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.854 -179.969 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 240' ' ' LEU . . . . . 0.435 HD23 ' N ' ' A' ' 240' ' ' LEU . 2.4 pt? -155.26 4.14 0.2 Allowed 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.381 -0.372 . . . . 0.0 110.972 179.899 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 241' ' ' GLU . . . . . . . . . . . . . 43.9 mt-10 -126.18 129.6 49.32 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.736 179.953 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 242' ' ' HIS . . . . . . . . . . . . . 69.2 m80 -85.45 171.75 11.55 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.158 -179.646 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 243' ' ' HIS . . . . . . . . . . . . . 42.8 m80 62.01 109.04 0.02 OUTLIER 'General case' 0 C--N 1.332 -0.169 0 CA-C-N 115.895 -0.593 . . . . 0.0 111.408 179.79 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 244' ' ' HIS . . . . . . . . . . . . . 69.2 m80 -116.05 5.26 13.83 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.027 -0.533 . . . . 0.0 110.795 179.899 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 245' ' ' HIS . . . . . . . . . . . . . 61.4 m80 61.39 102.04 0.03 OUTLIER 'General case' 0 N--CA 1.462 0.163 0 CA-C-N 116.027 -0.533 . . . . 0.0 110.913 -179.914 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 246' ' ' HIS . . . . . . . . . . . . . 8.3 p80 -147.02 -178.56 6.27 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.266 -0.424 . . . . 0.0 110.971 -179.804 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 247' ' ' HIS . . . . . . . . . . . . . 58.6 t-80 . . . . . 0 C--O 1.249 1.046 0 CA-C-O 118.34 -0.838 . . . . 0.0 110.968 -179.931 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 301' ' ' RET . . . . . 0.73 H203 ' HE1' ' A' ' 171' ' ' TRP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . 0.665 ' HG2' ' H ' ' A' ' 3' ' ' GLY . 54.6 ttp . . . . . 0 N--CA 1.486 1.343 0 CA-C-O 120.794 0.33 . . . . 0.0 110.726 . . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 32.7 m -97.5 -7.25 9.37 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-N 116.268 -0.424 . . . . 0.0 111.389 -179.783 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 3' ' ' GLY . . . . . 0.665 ' H ' ' HG2' ' A' ' 1' ' ' MET . . . -72.43 -14.0 77.29 Favored Glycine 0 N--CA 1.452 -0.288 0 C-N-CA 120.814 -0.708 . . . . 0.0 112.532 -179.824 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 4' ' ' LEU . . . . . 0.471 ' HA ' HD23 ' A' ' 7' ' ' LEU . 70.9 mt -72.97 -36.13 67.04 Favored 'General case' 0 N--CA 1.449 -0.491 0 CA-C-O 120.878 0.371 . . . . 0.0 110.989 179.835 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 45.5 p -53.09 -37.84 62.03 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 115.877 -0.601 . . . . 0.0 111.874 -179.466 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 70.8 p -56.34 -40.54 74.61 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.438 -0.346 . . . . 0.0 111.579 -179.491 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 7' ' ' LEU . . . . . 0.471 HD23 ' HA ' ' A' ' 4' ' ' LEU . 3.4 mm? -59.85 -52.49 65.21 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 116.402 -0.363 . . . . 0.0 110.967 179.997 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 8' ' ' PHE . . . . . 0.459 ' HB2' ' HB2' ' A' ' 55' ' ' ALA . 75.8 m-85 -58.5 -32.11 68.49 Favored 'General case' 0 C--N 1.331 -0.204 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.613 -179.907 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 9' ' ' TRP . . . . . 0.416 ' O ' HG12 ' A' ' 13' ' ' ILE . 17.1 m95 -67.19 -45.63 76.33 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.036 -0.529 . . . . 0.0 109.833 179.576 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 95.1 mt -58.1 -46.82 84.89 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 115.607 -0.724 . . . . 0.0 110.15 179.305 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -60.08 -34.56 84.3 Favored Glycine 0 N--CA 1.45 -0.415 0 C-N-CA 120.746 -0.74 . . . . 0.0 111.781 179.351 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -67.67 -30.4 69.93 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.767 0.317 . . . . 0.0 110.604 179.608 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 13' ' ' ILE . . . . . 0.416 HG12 ' O ' ' A' ' 9' ' ' TRP . 50.8 mm -67.35 -52.5 41.58 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.226 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.16 179.486 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -59.93 -34.67 84.13 Favored Glycine 0 N--CA 1.448 -0.503 0 C-N-CA 120.696 -0.764 . . . . 0.0 111.641 179.105 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 15' ' ' MET . . . . . 0.557 ' HB3' ' HB2' ' A' ' 48' ' ' ALA . 18.9 mmt -66.5 -40.42 89.24 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 120.666 0.269 . . . . 0.0 110.628 179.479 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -59.69 -40.46 87.92 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.313 -0.403 . . . . 0.0 110.149 179.353 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 60.5 t -61.4 -42.76 95.02 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.201 0 CA-C-N 116.058 -0.519 . . . . 0.0 110.53 179.34 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -69.36 -46.17 57.68 Favored Glycine 0 N--CA 1.452 -0.266 0 C-N-CA 120.793 -0.718 . . . . 0.0 111.927 179.626 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 24.6 m -50.69 -49.06 58.32 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-O 120.702 0.287 . . . . 0.0 111.249 -179.82 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 96.3 mt -72.06 -44.99 62.45 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 116.305 -0.407 . . . . 0.0 111.687 -179.85 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -59.78 -31.49 69.73 Favored 'General case' 0 C--N 1.329 -0.304 0 N-CA-C 112.095 0.405 . . . . 0.0 112.095 -179.007 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 22' ' ' PHE . . . . . 0.484 ' HB2' HG22 ' A' ' 41' ' ' VAL . 12.8 m-85 -91.19 -30.71 16.51 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 120.667 0.27 . . . . 0.0 111.429 -179.329 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -72.89 -50.68 22.3 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.948 0.404 . . . . 0.0 111.341 -179.69 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 24' ' ' TRP . . . . . . . . . . . . . 3.6 t-105 -61.62 -38.51 87.91 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-N 115.784 -0.643 . . . . 0.0 111.069 -179.809 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -80.63 -24.19 39.22 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.718 0.294 . . . . 0.0 111.221 179.992 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -73.05 -43.03 41.94 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.722 -0.752 . . . . 0.0 112.577 179.976 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 12.2 ptp180 -66.98 -18.26 65.3 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 120.759 0.314 . . . . 0.0 111.085 -179.953 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 31.3 t70 -97.0 17.66 16.46 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-O 121.057 0.456 . . . . 0.0 110.686 -179.659 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -99.33 176.3 5.57 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 115.935 -0.575 . . . . 0.0 111.176 -179.914 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -104.63 167.08 15.21 Favored Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.805 -0.712 . . . . 0.0 112.419 -179.991 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 73.4 m -64.36 120.49 12.33 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 120.9 0.381 . . . . 0.0 110.772 -179.953 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 128.11 -50.19 0.9 Allowed Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.959 -0.638 . . . . 0.0 112.19 -179.78 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 11.8 mm-40 -89.65 -20.6 23.47 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 121.009 0.433 . . . . 0.0 110.502 179.674 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 34' ' ' ARG . . . . . . . . . . . . . 34.2 ttm180 -52.09 -29.23 20.65 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 115.66 -0.7 . . . . 0.0 111.363 -179.862 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 41.8 ttm180 -59.39 -40.54 86.92 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-O 120.759 0.314 . . . . 0.0 110.845 179.861 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 91.8 m-85 -71.04 -32.4 69.13 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.878 179.753 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 37' ' ' TYR . . . . . 0.524 ' O ' HG23 ' A' ' 41' ' ' VAL . 61.0 m-85 -70.55 -54.7 11.09 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 116.055 -0.52 . . . . 0.0 111.243 -179.743 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 11.0 p -57.17 -36.5 51.93 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-O 120.914 0.388 . . . . 0.0 110.479 179.649 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 26.3 m -65.38 -45.2 85.03 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 115.896 -0.593 . . . . 0.0 110.565 179.474 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 40' ' ' LEU . . . . . 0.649 HD12 HD11 ' A' ' 43' ' ' ILE . 51.5 tp -65.6 -38.48 89.59 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 115.949 -0.568 . . . . 0.0 110.483 179.556 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . 0.524 HG23 ' O ' ' A' ' 37' ' ' TYR . 97.3 t -67.34 -34.34 68.32 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.446 0 CA-C-N 115.789 -0.641 . . . . 0.0 110.253 179.429 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . 0.416 ' O ' HG12 ' A' ' 46' ' ' ILE . . . -64.01 -46.59 90.96 Favored Glycine 0 N--CA 1.448 -0.545 0 CA-C-N 115.76 -0.655 . . . . 0.0 112.971 179.991 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 43' ' ' ILE . . . . . 0.649 HD11 HD12 ' A' ' 40' ' ' LEU . 39.4 pt -63.04 -44.03 99.36 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.217 0 CA-C-N 116.847 0.323 . . . . 0.0 111.659 -179.558 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 44' ' ' SER . . . . . 0.466 ' N ' HG13 ' A' ' 43' ' ' ILE . 72.1 m -66.62 -27.19 67.5 Favored 'General case' 0 C--N 1.332 -0.159 0 CA-C-O 120.911 0.386 . . . . 0.0 110.808 179.604 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -78.56 -49.74 6.48 Favored Glycine 0 CA--C 1.519 0.286 0 C-N-CA 121.036 -0.602 . . . . 0.0 113.306 -179.256 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 46' ' ' ILE . . . . . 0.682 HD12 HD12 ' A' ' 78' ' ' LEU . 7.7 pt -58.09 -44.02 86.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-O 120.848 0.356 . . . . 0.0 111.04 -179.588 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 47' ' ' ALA . . . . . 0.546 ' HB2' ' HE2' ' A' ' 205' ' ' LYS . . . -67.73 -39.01 84.31 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-O 120.794 0.331 . . . . 0.0 110.578 179.077 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 48' ' ' ALA . . . . . 0.557 ' HB2' ' HB3' ' A' ' 15' ' ' MET . . . -55.0 -48.01 73.88 Favored 'General case' 0 C--N 1.332 -0.18 0 CA-C-N 116.11 -0.496 . . . . 0.0 111.579 -179.888 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 49' ' ' VAL . . . . . 0.485 HG22 ' O ' ' A' ' 46' ' ' ILE . 28.7 m -67.78 -34.28 66.69 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.473 -0.33 . . . . 0.0 111.275 -179.548 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -63.7 -37.63 88.06 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-O 120.986 0.422 . . . . 0.0 111.132 179.627 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 51' ' ' TYR . . . . . 0.412 ' O ' ' HB3' ' A' ' 8' ' ' PHE . 33.4 m-85 -72.67 -34.56 67.3 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 116.082 -0.508 . . . . 0.0 110.516 -179.766 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -68.25 -42.76 79.21 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 115.979 -0.555 . . . . 0.0 111.056 179.566 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 53' ' ' VAL . . . . . 0.414 HG23 ' N ' ' A' ' 54' ' ' MET . 33.0 m -69.62 -43.75 80.08 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.126 0 CA-C-N 116.44 -0.346 . . . . 0.0 110.876 179.978 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 54' ' ' MET . . . . . 0.567 ' HG2' ' HG2' ' A' ' 71' ' ' PRO . 74.6 mtm -65.03 -34.19 77.83 Favored 'General case' 0 CA--C 1.519 -0.222 0 N-CA-C 109.582 -0.525 . . . . 0.0 109.582 178.955 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 55' ' ' ALA . . . . . 0.459 ' HB2' ' HB2' ' A' ' 8' ' ' PHE . . . -65.97 -17.31 64.59 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.414 -0.812 . . . . 0.0 111.009 179.49 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 95.9 mt -100.08 8.61 43.81 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.339 -0.391 . . . . 0.0 111.0 179.952 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 74.26 20.91 79.55 Favored Glycine 0 N--CA 1.45 -0.371 0 C-N-CA 120.809 -0.71 . . . . 0.0 112.492 179.991 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 24.9 t -92.19 130.72 40.89 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-O 120.784 0.326 . . . . 0.0 110.903 179.884 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 94.0 0.73 65.76 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.855 -0.688 . . . . 0.0 112.753 -179.911 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 60' ' ' TRP . . . . . . . . . . . . . 13.0 m0 -75.21 111.15 10.17 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.76 0.314 . . . . 0.0 110.89 179.864 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 8.4 p -110.77 132.0 21.83 Favored Pre-proline 0 C--N 1.33 -0.271 0 CA-C-N 116.344 -0.389 . . . . 0.0 111.059 179.887 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 74.4 Cg_endo -76.25 147.18 29.13 Favored 'Trans proline' 0 C--N 1.349 0.576 0 C-N-CA 122.372 2.048 . . . . 0.0 112.229 179.742 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 93.9 t -141.51 91.98 0.55 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 115.996 -0.547 . . . . 0.0 111.181 -179.791 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . 58.04 -87.79 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.01 -0.541 . . . . 0.0 111.771 179.574 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 9.0 tp10 -118.08 -21.43 8.26 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.452 -0.34 . . . . 0.0 111.251 -179.59 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 66' ' ' ARG . . . . . . . . . . . . . 99.6 mtt180 -107.03 162.98 13.37 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.368 -0.378 . . . . 0.0 110.63 179.875 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 33.4 m -118.96 124.6 47.43 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.968 0.414 . . . . 0.0 111.455 -179.843 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 68' ' ' VAL . . . . . 0.515 HG21 ' HB3' ' A' ' 117' ' ' MET . 57.7 t -103.6 146.64 10.95 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.361 0 CA-C-N 115.815 -0.63 . . . . 0.0 110.645 179.744 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 69' ' ' PHE . . . . . . . . . . . . . 16.8 m-85 -107.79 112.19 24.72 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.399 -0.364 . . . . 0.0 110.039 -179.688 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 70' ' ' VAL . . . . . 0.607 ' N ' ' HD2' ' A' ' 71' ' ' PRO . 21.5 t -66.73 -48.83 52.13 Favored Pre-proline 0 C--N 1.323 -0.56 0 CA-C-N 116.047 -0.524 . . . . 0.0 111.953 -179.285 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 71' ' ' PRO . . . . . 0.607 ' HD2' ' N ' ' A' ' 70' ' ' VAL . 18.2 Cg_endo -59.8 -17.78 45.24 Favored 'Trans proline' 0 C--N 1.35 0.654 0 C-N-CA 122.279 1.986 . . . . 0.0 113.183 -179.64 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 72' ' ' ARG . . . . . 0.409 HH22 HG22 ' A' ' 194' ' ' VAL . 23.9 ttm180 -78.46 -55.82 4.92 Favored 'General case' 0 C--O 1.234 0.278 0 C-N-CA 120.961 -0.296 . . . . 0.0 111.621 -179.607 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 73' ' ' TYR . . . . . 0.473 ' O ' HG13 ' A' ' 77' ' ' ILE . 95.2 m-85 -70.47 -31.64 68.87 Favored 'General case' 0 C--N 1.329 -0.29 0 C-N-CA 120.89 -0.324 . . . . 0.0 110.482 -179.652 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 74' ' ' ILE . . . . . 0.55 ' HA ' HD12 ' A' ' 77' ' ' ILE . 0.3 OUTLIER -69.5 -39.29 78.36 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 N-CA-C 109.259 -0.645 . . . . 0.0 109.259 178.716 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 75' ' ' ASP . . . . . 0.443 ' O ' ' HG ' ' A' ' 78' ' ' LEU . 14.8 t70 -57.23 -37.38 72.19 Favored 'General case' 0 N--CA 1.452 -0.334 0 N-CA-C 109.113 -0.699 . . . . 0.0 109.113 178.461 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 76' ' ' TRP . . . . . 0.435 ' HA ' ' OG1' ' A' ' 79' ' ' THR . 44.7 m0 -70.26 -34.03 72.31 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 115.611 -0.722 . . . . 0.0 110.527 179.086 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 77' ' ' ILE . . . . . 0.55 HD12 ' HA ' ' A' ' 74' ' ' ILE . 94.2 mt -58.45 -38.71 71.66 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.236 0 CA-C-N 116.285 -0.416 . . . . 0.0 111.022 179.781 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 78' ' ' LEU . . . . . 0.682 HD12 HD12 ' A' ' 46' ' ' ILE . 1.1 pp -91.52 -34.12 14.9 Favored 'General case' 0 CA--C 1.536 0.41 0 N-CA-C 113.205 0.817 . . . . 0.0 113.205 -179.643 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 79' ' ' THR . . . . . 0.467 HG22 ' CD1' ' A' ' 46' ' ' ILE . 52.1 p -76.09 -52.5 10.01 Favored 'General case' 0 N--CA 1.47 0.538 0 N-CA-C 113.316 0.858 . . . . 0.0 113.316 -178.314 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 80' ' ' THR . . . . . 0.543 ' N ' ' HD2' ' A' ' 81' ' ' PRO . 3.9 m -50.76 -48.94 82.1 Favored Pre-proline 0 CA--C 1.532 0.255 0 N-CA-C 112.961 0.726 . . . . 0.0 112.961 -178.162 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 81' ' ' PRO . . . . . 0.543 ' HD2' ' N ' ' A' ' 80' ' ' THR . 28.9 Cg_endo -61.37 -25.31 79.97 Favored 'Trans proline' 0 C--N 1.352 0.717 0 C-N-CA 121.549 1.499 . . . . 0.0 111.631 -179.885 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 82' ' ' LEU . . . . . 0.506 ' HB3' HG22 ' A' ' 43' ' ' ILE . 0.1 OUTLIER -74.43 -34.76 63.3 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 115.876 -0.602 . . . . 0.0 110.23 179.698 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 49.6 mm -67.46 -53.64 30.41 Favored 'Isoleucine or valine' 0 C--O 1.234 0.253 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.029 179.165 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 33.0 m -59.94 -30.03 44.55 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.255 0 CA-C-N 115.959 -0.564 . . . . 0.0 109.552 178.96 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 85' ' ' TYR . . . . . . . . . . . . . 89.8 t80 -67.35 -33.39 75.15 Favored 'General case' 0 N--CA 1.454 -0.275 0 CA-C-N 115.536 -0.757 . . . . 0.0 109.591 178.772 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 86' ' ' PHE . . . . . . . . . . . . . 8.3 t80 -61.81 -50.72 71.16 Favored 'General case' 0 C--O 1.234 0.259 0 CA-C-N 115.769 -0.651 . . . . 0.0 109.87 179.317 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 8.0 mp -60.91 -31.1 70.62 Favored 'General case' 0 C--N 1.332 -0.193 0 CA-C-N 115.872 -0.604 . . . . 0.0 110.232 179.617 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -70.89 -27.67 71.88 Favored Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.971 -0.633 . . . . 0.0 112.122 179.461 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 73.4 mt -71.55 -45.52 62.06 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-O 120.94 0.4 . . . . 0.0 110.514 179.934 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 90' ' ' LEU . . . . . 0.463 HD11 HD22 ' A' ' 163' ' ' LEU . 98.0 mt -54.48 -43.21 71.55 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 115.797 -0.638 . . . . 0.0 111.477 -179.918 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . 0.435 ' HB2' ' HB2' ' A' ' 149' ' ' ALA . . . -78.6 -54.99 5.55 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 116.488 -0.324 . . . . 0.0 111.399 -179.748 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 105.23 63.96 0.65 Allowed Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.89 -0.672 . . . . 0.0 112.331 179.98 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 93' ' ' LEU . . . . . 0.572 HD23 ' HB3' ' A' ' 97' ' ' GLU . 7.4 mp -80.69 172.62 13.52 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.794 0.33 . . . . 0.0 111.032 -179.874 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 94' ' ' ASP . . . . . . . . . . . . . 14.2 m-20 -89.19 164.9 14.78 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.099 -0.5 . . . . 0.0 110.808 179.841 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 80.7 p -53.92 -34.54 59.85 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.113 -0.494 . . . . 0.0 111.086 -179.954 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 41.5 mmt180 -72.61 -48.4 40.02 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.374 -179.631 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 97' ' ' GLU . . . . . 0.572 ' HB3' HD23 ' A' ' 93' ' ' LEU . 42.3 mt-10 -54.94 -49.23 71.86 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 116.404 -0.362 . . . . 0.0 111.134 -179.837 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 98' ' ' PHE . . . . . 0.483 ' O ' HG12 ' A' ' 102' ' ' ILE . 33.0 m-85 -55.25 -49.94 70.74 Favored 'General case' 0 C--N 1.332 -0.175 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.689 179.755 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -54.42 -32.68 52.58 Favored Glycine 0 N--CA 1.452 -0.286 0 C-N-CA 120.93 -0.652 . . . . 0.0 112.694 -179.756 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 96.4 mt -69.54 -43.07 80.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-O 120.882 0.372 . . . . 0.0 111.629 -179.684 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 61.0 t -71.87 -40.58 68.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.325 -0.398 . . . . 0.0 111.989 -179.225 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 102' ' ' ILE . . . . . 0.483 HG12 ' O ' ' A' ' 98' ' ' PHE . 38.0 mm -68.78 -41.24 82.26 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.363 0 N-CA-C 111.954 0.353 . . . . 0.0 111.954 -179.097 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 103' ' ' THR . . . . . 0.429 HG23 ' N ' ' A' ' 104' ' ' LEU . 12.4 t -64.93 -44.5 89.31 Favored 'General case' 0 C--O 1.234 0.247 0 CA-C-O 120.679 0.276 . . . . 0.0 111.314 -179.719 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 104' ' ' LEU . . . . . 0.434 ' O ' HG23 ' A' ' 108' ' ' VAL . 9.2 tt -58.47 -44.18 89.21 Favored 'General case' 0 C--N 1.332 -0.164 0 CA-C-O 120.813 0.339 . . . . 0.0 110.252 179.776 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 105' ' ' ASN . . . . . 0.618 HD21 HD13 ' A' ' 137' ' ' LEU . 0.9 OUTLIER -56.29 -41.63 76.21 Favored 'General case' 0 N--CA 1.455 -0.179 0 CA-C-N 116.149 -0.478 . . . . 0.0 109.857 178.852 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 85.2 m -54.71 -40.14 68.91 Favored 'General case' 0 C--N 1.332 -0.157 0 CA-C-N 116.075 -0.511 . . . . 0.0 110.269 179.508 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 107' ' ' VAL . . . . . 0.404 HG12 ' SD ' ' A' ' 129' ' ' MET . 0.9 OUTLIER -67.45 -37.4 78.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 115.843 -0.617 . . . . 0.0 110.189 179.114 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . 0.439 HG12 H173 ' A' ' 301' ' ' RET . 64.4 t -65.72 -52.04 54.99 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-N 115.33 -0.85 . . . . 0.0 111.686 -179.471 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 109' ' ' MET . . . . . 0.55 ' HG3' ' HA ' ' A' ' 77' ' ' ILE . 5.4 mmt -61.33 -39.72 91.57 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.35 -0.386 . . . . 0.0 111.18 -179.514 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 21.6 tp -64.42 -31.59 72.87 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.339 -0.392 . . . . 0.0 110.436 179.762 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 111' ' ' ALA . . . . . 0.403 ' O ' ' HB3' ' A' ' 126' ' ' LEU . . . -62.94 -56.59 15.85 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.528 179.344 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . -60.58 -36.8 92.25 Favored Glycine 0 C--N 1.329 0.193 0 C-N-CA 120.445 -0.883 . . . . 0.0 111.813 179.483 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 113' ' ' PHE . . . . . . . . . . . . . 10.1 t80 -49.45 -63.04 1.22 Allowed 'General case' 0 C--N 1.331 -0.222 0 CA-C-O 121.119 0.485 . . . . 0.0 110.201 179.429 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 114' ' ' ALA . . . . . 0.452 ' O ' HG13 ' A' ' 118' ' ' VAL . . . -69.66 -28.1 65.6 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 115.562 -0.744 . . . . 0.0 111.189 179.591 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -52.18 -35.87 43.16 Favored Glycine 0 C--N 1.332 0.316 0 CA-C-N 116.061 -0.518 . . . . 0.0 112.785 179.907 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -78.13 -44.81 25.04 Favored 'General case' 0 C--N 1.329 -0.316 0 N-CA-C 112.132 0.419 . . . . 0.0 112.132 -179.862 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 117' ' ' MET . . . . . 0.515 ' HB3' HG21 ' A' ' 68' ' ' VAL . 15.7 ptp -85.58 19.72 2.32 Favored 'General case' 0 C--N 1.33 -0.243 0 N-CA-C 112.149 0.426 . . . . 0.0 112.149 -179.007 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 118' ' ' VAL . . . . . 0.573 HG21 ' HB3' ' A' ' 123' ' ' ARG . 8.8 m -57.87 146.34 67.89 Favored Pre-proline 0 C--N 1.328 -0.332 0 CA-C-N 116.807 -0.178 . . . . 0.0 111.253 179.618 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 119' ' ' PRO . . . . . . . . . . . . . 71.8 Cg_endo -75.56 -9.06 19.87 Favored 'Trans proline' 0 C--N 1.347 0.476 0 C-N-CA 122.574 2.183 . . . . 0.0 112.381 -179.88 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -172.35 -122.95 0.68 Allowed Glycine 0 C--N 1.331 0.277 0 C-N-CA 120.662 -0.78 . . . . 0.0 112.711 -179.98 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 50.5 pt -83.38 8.06 1.39 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.23 0 CA-C-O 120.827 0.346 . . . . 0.0 111.334 -179.915 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 122' ' ' GLU . . . . . 0.478 ' HB2' ' HB ' ' A' ' 118' ' ' VAL . 11.7 mm-40 -58.57 -19.03 34.74 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.086 179.993 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 123' ' ' ARG . . . . . 0.573 ' HB3' HG21 ' A' ' 118' ' ' VAL . 12.6 ptt180 -52.33 -30.95 30.98 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.062 -0.517 . . . . 0.0 111.494 -179.842 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 124' ' ' TYR . . . . . . . . . . . . . 24.7 m-85 -71.96 -32.54 67.37 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.378 -0.373 . . . . 0.0 111.116 -179.686 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 125' ' ' ALA . . . . . . . . . . . . . . . -68.88 -51.07 44.14 Favored 'General case' 0 C--O 1.235 0.321 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.939 179.626 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 126' ' ' LEU . . . . . 0.403 ' HB3' ' O ' ' A' ' 111' ' ' ALA . 2.9 mm? -54.99 -55.85 26.28 Favored 'General case' 0 CA--C 1.52 -0.209 0 CA-C-N 116.015 -0.539 . . . . 0.0 110.882 -179.827 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 127' ' ' PHE . . . . . 0.464 ' HZ ' ' HB3' ' A' ' 175' ' ' PRO . 7.8 t80 -65.33 -33.25 75.52 Favored 'General case' 0 N--CA 1.45 -0.435 0 CA-C-N 116.258 -0.428 . . . . 0.0 111.466 -179.065 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 128' ' ' GLY . . . . . . . . . . . . . . . -49.67 -45.3 38.89 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 119.816 -1.183 . . . . 0.0 110.623 179.009 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 129' ' ' MET . . . . . 0.404 ' SD ' HG12 ' A' ' 107' ' ' VAL . 0.6 OUTLIER -71.71 -38.89 70.46 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 115.072 -0.564 . . . . 0.0 110.356 178.881 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -67.05 -27.41 73.44 Favored Glycine 0 C--N 1.331 0.283 0 CA-C-N 115.897 -0.592 . . . . 0.0 113.002 -179.613 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -74.85 -53.23 9.46 Favored 'General case' 0 C--N 1.328 -0.348 0 N-CA-C 110.012 -0.366 . . . . 0.0 110.012 179.86 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 95.9 t -57.23 -39.83 69.86 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.234 0 CA-C-O 121.347 0.594 . . . . 0.0 109.458 178.507 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -70.39 -34.17 72.24 Favored 'General case' 0 N--CA 1.452 -0.344 0 CA-C-N 115.297 -0.865 . . . . 0.0 110.69 179.423 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 134' ' ' PHE . . . . . 0.46 ' HB2' H182 ' A' ' 301' ' ' RET . 50.2 t80 -55.4 -60.14 3.82 Favored 'General case' 0 N--CA 1.453 -0.304 0 CA-C-O 120.985 0.422 . . . . 0.0 110.164 179.689 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 135' ' ' ILE . . . . . 0.494 ' O ' HG22 ' A' ' 138' ' ' VAL . 0.0 OUTLIER -55.75 -34.74 37.24 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 115.764 -0.653 . . . . 0.0 109.854 178.975 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 136' ' ' GLY . . . . . 0.413 ' O ' ' HB3' ' A' ' 139' ' ' TYR . . . -58.1 -41.66 94.72 Favored Glycine 0 N--CA 1.449 -0.477 0 C-N-CA 120.389 -0.91 . . . . 0.0 111.488 178.777 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 137' ' ' LEU . . . . . 0.618 HD13 HD21 ' A' ' 105' ' ' ASN . 45.1 tp -66.05 -56.25 12.51 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-O 120.68 0.276 . . . . 0.0 110.446 179.215 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 138' ' ' VAL . . . . . 0.517 ' O ' HG23 ' A' ' 142' ' ' VAL . 2.7 m -55.12 -30.33 23.96 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.237 0 CA-C-O 121.134 0.492 . . . . 0.0 109.813 -179.994 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 139' ' ' TYR . . . . . 0.413 ' HB3' ' O ' ' A' ' 136' ' ' GLY . 12.2 t80 -61.8 -42.33 98.87 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 115.682 -0.69 . . . . 0.0 109.804 178.566 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 29.1 m-85 -69.29 -35.22 75.79 Favored 'General case' 0 C--N 1.333 -0.15 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.494 179.064 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 141' ' ' LEU . . . . . 0.406 ' HB3' ' HD3' ' A' ' 164' ' ' ARG . 11.0 mp -62.8 -27.22 69.16 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.502 179.578 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 142' ' ' VAL . . . . . 0.619 HG22 HH11 ' A' ' 164' ' ' ARG . 12.4 t -103.88 -11.6 9.28 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.226 0 CA-C-N 116.008 -0.542 . . . . 0.0 111.103 179.964 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . -76.66 -117.24 0.15 Allowed Glycine 0 CA--C 1.523 0.566 0 C-N-CA 120.937 -0.649 . . . . 0.0 113.115 -179.702 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 144' ' ' PRO . . . . . . . . . . . . . 47.2 Cg_endo -68.35 -23.51 38.2 Favored 'Trans proline' 0 C--N 1.35 0.638 0 C-N-CA 122.67 2.246 . . . . 0.0 113.195 -179.298 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 145' ' ' MET . . . . . . . . . . . . . 58.2 mtt -65.47 -30.27 71.03 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.676 0.274 . . . . 0.0 111.403 -179.775 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 146' ' ' THR . . . . . 0.422 ' OG1' ' HA ' ' A' ' 142' ' ' VAL . 82.9 m -81.16 -32.38 33.66 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.852 0.358 . . . . 0.0 111.345 -179.31 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 38.6 tt0 -75.92 -40.65 53.82 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.119 -179.919 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 148' ' ' SER . . . . . 0.433 ' HB3' ' HB1' ' A' ' 91' ' ' ALA . 46.0 t -70.3 -45.26 66.65 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.278 -0.419 . . . . 0.0 111.242 -179.473 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 149' ' ' ALA . . . . . 0.435 ' HB2' ' HB2' ' A' ' 91' ' ' ALA . . . -65.69 -32.33 73.82 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.27 -0.423 . . . . 0.0 111.416 -179.543 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 150' ' ' SER . . . . . . . . . . . . . 80.3 p -74.47 0.45 14.64 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.283 -0.417 . . . . 0.0 111.331 -179.717 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 151' ' ' GLN . . . . . . . . . . . . . 10.3 pt20 -136.3 9.84 3.22 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.54 -0.3 . . . . 0.0 110.996 179.787 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 1.5 tmt_? -83.84 -51.81 6.89 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-O 120.833 0.349 . . . . 0.0 110.435 179.997 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 153' ' ' SER . . . . . 0.676 ' HB2' HG12 ' A' ' 156' ' ' ILE . 20.8 m -157.54 172.47 18.5 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.024 -0.535 . . . . 0.0 110.507 179.314 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 154' ' ' SER . . . . . . . . . . . . . 48.1 t -73.05 -38.32 66.53 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.378 -0.374 . . . . 0.0 110.729 179.849 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -77.36 -27.55 59.4 Favored Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.944 -0.646 . . . . 0.0 112.718 179.993 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 156' ' ' ILE . . . . . 0.676 HG12 ' HB2' ' A' ' 153' ' ' SER . 38.1 mm -62.03 -35.44 68.52 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-O 120.799 0.333 . . . . 0.0 110.923 -179.944 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 157' ' ' LYS . . . . . . . . . . . . . 91.3 mttt -58.93 -55.55 33.75 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.067 -0.515 . . . . 0.0 111.617 -179.888 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 69.0 m -70.49 -38.58 74.38 Favored 'General case' 0 N--CA 1.463 0.21 0 N-CA-C 112.256 0.465 . . . . 0.0 112.256 -178.847 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 159' ' ' LEU . . . . . . . . . . . . . 39.0 tp -69.13 -36.25 77.26 Favored 'General case' 0 C--N 1.327 -0.411 0 N-CA-C 111.74 0.274 . . . . 0.0 111.74 -179.148 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 160' ' ' TYR . . . . . . . . . . . . . 57.0 t80 -73.96 -46.11 46.05 Favored 'General case' 0 C--N 1.328 -0.366 0 N-CA-C 111.9 0.333 . . . . 0.0 111.9 -179.027 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 29.4 m -59.96 -41.73 87.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-O 120.721 0.296 . . . . 0.0 111.332 -179.634 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 162' ' ' ARG . . . . . 0.537 ' HG2' HG21 ' A' ' 211' ' ' ILE . 23.3 tpp180 -68.99 -39.89 79.11 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 120.944 0.402 . . . . 0.0 110.97 179.949 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 163' ' ' LEU . . . . . 0.54 ' HG ' ' HB2' ' A' ' 208' ' ' PHE . 4.5 mp -68.25 -44.32 75.9 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.069 -0.514 . . . . 0.0 111.668 -179.505 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 164' ' ' ARG . . . . . 0.619 HH11 HG22 ' A' ' 142' ' ' VAL . 18.4 ttp85 -72.01 -52.97 14.45 Favored 'General case' 0 C--N 1.329 -0.324 0 N-CA-C 112.125 0.417 . . . . 0.0 112.125 -179.003 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 165' ' ' ASN . . . . . 0.508 HD22 ' N ' ' A' ' 165' ' ' ASN . 0.9 OUTLIER -52.31 -46.31 65.93 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-O 121.056 0.455 . . . . 0.0 110.534 -179.291 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 166' ' ' LEU . . . . . 0.528 ' O ' ' HG ' ' A' ' 170' ' ' LEU . 6.8 tt -64.9 -52.08 58.45 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-N 115.809 -0.632 . . . . 0.0 111.141 179.955 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 167' ' ' THR . . . . . 0.476 ' O ' ' HB2' ' A' ' 171' ' ' TRP . 96.4 m -61.32 -54.09 48.34 Favored 'General case' 0 N--CA 1.463 0.185 0 N-CA-C 112.608 0.596 . . . . 0.0 112.608 -178.653 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 168' ' ' VAL . . . . . . . . . . . . . 94.0 t -52.2 -41.09 32.56 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.185 0 N-CA-C 112.134 0.42 . . . . 0.0 112.134 -179.284 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 169' ' ' VAL . . . . . 0.444 HG23 ' O ' ' A' ' 165' ' ' ASN . 43.9 t -61.96 -64.63 0.6 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 N-CA-C 111.965 0.357 . . . . 0.0 111.965 -179.452 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 170' ' ' LEU . . . . . 0.528 ' HG ' ' O ' ' A' ' 166' ' ' LEU . 1.3 pp -62.55 -29.37 70.52 Favored 'General case' 0 C--N 1.331 -0.206 0 N-CA-C 112.081 0.4 . . . . 0.0 112.081 -178.777 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 171' ' ' TRP . . . . . 0.624 ' HZ2' H202 ' A' ' 301' ' ' RET . 2.7 m0 -72.87 -30.78 64.25 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.842 0.353 . . . . 0.0 110.737 179.83 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 172' ' ' ALA . . . . . 0.404 ' HA ' ' CZ ' ' A' ' 134' ' ' PHE . . . -73.65 -6.21 45.29 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-O 121.093 0.473 . . . . 0.0 110.286 179.647 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 173' ' ' ILE . . . . . 0.467 ' O ' HG12 ' A' ' 177' ' ' ILE . 44.1 mm -85.14 -20.93 8.07 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.241 0 CA-C-N 115.678 -0.692 . . . . 0.0 110.484 179.148 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 174' ' ' TYR . . . . . . . . . . . . . 13.2 m-85 -53.21 -50.07 84.4 Favored Pre-proline 0 N--CA 1.464 0.268 0 CA-C-N 116.126 -0.488 . . . . 0.0 111.18 -179.867 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 175' ' ' PRO . . . . . 0.464 ' HB3' ' HZ ' ' A' ' 127' ' ' PHE . 93.1 Cg_exo -45.17 -33.07 7.78 Favored 'Trans proline' 0 C--N 1.351 0.684 0 C-N-CA 122.252 1.968 . . . . 0.0 112.152 179.308 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 176' ' ' PHE . . . . . 0.504 ' O ' ' HG ' ' A' ' 180' ' ' LEU . 85.4 m-85 -80.82 -50.12 10.23 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 115.772 -0.649 . . . . 0.0 112.023 -179.618 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 177' ' ' ILE . . . . . 0.531 HG13 HD11 ' A' ' 200' ' ' LEU . 4.1 mm -63.42 -35.03 70.8 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.547 0 N-CA-C 112.546 0.573 . . . . 0.0 112.546 -177.867 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 178' ' ' TRP . . . . . . . . . . . . . 73.5 t90 -73.87 -52.37 13.2 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-O 120.887 0.375 . . . . 0.0 110.856 179.87 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 179' ' ' LEU . . . . . 0.487 HD23 HD23 ' A' ' 180' ' ' LEU . 0.5 OUTLIER -64.83 -54.34 32.55 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.079 -0.51 . . . . 0.0 111.677 -179.004 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 180' ' ' LEU . . . . . 0.6 HD22 HD11 ' A' ' 187' ' ' LEU . 27.9 mt -64.32 -49.09 73.09 Favored 'General case' 0 C--N 1.326 -0.448 0 C-N-CA 120.812 -0.355 . . . . 0.0 111.201 -179.529 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . -57.38 179.93 0.77 Allowed Glycine 0 C--N 1.338 0.651 0 C-N-CA 120.284 -0.96 . . . . 0.0 112.37 179.511 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 182' ' ' PRO . . . . . 0.717 ' HA ' ' HB2' ' A' ' 186' ' ' ALA . 89.0 Cg_exo -46.99 -45.04 21.89 Favored 'Trans proline' 0 CA--C 1.536 0.593 0 C-N-CA 122.969 2.446 . . . . 0.0 113.994 -179.657 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 183' ' ' PRO . . . . . 0.424 ' HD3' ' HB2' ' A' ' 182' ' ' PRO . 88.4 Cg_exo -48.14 -25.29 6.55 Favored 'Trans proline' 0 C--N 1.354 0.845 0 C-N-CA 122.303 2.002 . . . . 0.0 113.762 -179.509 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 184' ' ' GLY . . . . . 0.433 ' HA3' ' O ' ' A' ' 179' ' ' LEU . . . -112.86 -81.63 1.1 Allowed Glycine 0 C--N 1.334 0.437 0 C-N-CA 120.098 -1.049 . . . . 0.0 113.617 -179.443 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 185' ' ' VAL . . . . . . . . . . . . . 14.5 m -120.86 -8.6 10.27 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.203 0 N-CA-C 112.17 0.433 . . . . 0.0 112.17 -178.696 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 186' ' ' ALA . . . . . 0.717 ' HB2' ' HA ' ' A' ' 182' ' ' PRO . . . 57.56 85.9 0.08 Allowed 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.494 -0.321 . . . . 0.0 111.714 179.562 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 187' ' ' LEU . . . . . 0.6 HD11 HD22 ' A' ' 180' ' ' LEU . 17.9 mt -91.99 -49.33 6.28 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-O 120.963 0.411 . . . . 0.0 110.695 179.518 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 188' ' ' LEU . . . . . . . . . . . . . 86.2 mt -95.87 -158.39 0.65 Allowed 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 115.807 -0.633 . . . . 0.0 110.792 -179.766 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 189' ' ' THR . . . . . 0.511 HG22 HG22 ' A' ' 191' ' ' THR . 24.9 m -91.38 136.91 26.38 Favored Pre-proline 0 C--N 1.327 -0.378 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.566 -179.885 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 190' ' ' PRO . . . . . 0.449 ' O ' HG23 ' A' ' 194' ' ' VAL . 93.7 Cg_exo -44.35 -53.63 4.69 Favored 'Trans proline' 0 C--N 1.351 0.68 0 C-N-CA 122.559 2.172 . . . . 0.0 113.094 -179.786 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 191' ' ' THR . . . . . 0.511 HG22 HG22 ' A' ' 189' ' ' THR . 3.0 t -56.81 -36.8 70.34 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.703 0.287 . . . . 0.0 111.455 -179.721 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 192' ' ' VAL . . . . . 0.43 HG23 ' HB ' ' A' ' 189' ' ' THR . 92.7 t -70.46 -42.06 78.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.423 -0.353 . . . . 0.0 110.982 179.952 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 193' ' ' ASP . . . . . . . . . . . . . 24.8 t70 -61.6 -40.17 93.82 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.468 179.743 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 194' ' ' VAL . . . . . 0.449 HG23 ' O ' ' A' ' 190' ' ' PRO . 99.9 t -65.11 -35.88 76.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.026 -0.534 . . . . 0.0 110.229 179.323 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 195' ' ' ALA . . . . . . . . . . . . . . . -57.7 -48.4 79.66 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.846 179.48 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 196' ' ' LEU . . . . . . . . . . . . . 92.5 mt -67.9 -43.22 79.78 Favored 'General case' 0 C--N 1.332 -0.176 0 CA-C-N 116.417 -0.356 . . . . 0.0 110.816 179.634 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 197' ' ' ILE . . . . . . . . . . . . . 14.7 mm -57.86 -57.69 9.43 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.075 -0.511 . . . . 0.0 110.632 179.56 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 198' ' ' VAL . . . . . . . . . . . . . 74.7 t -55.15 -34.16 31.83 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.5 0 N-CA-C 109.078 -0.712 . . . . 0.0 109.078 178.317 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 199' ' ' TYR . . . . . . . . . . . . . 62.7 t80 -69.48 -30.66 68.59 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 115.205 -0.907 . . . . 0.0 110.62 179.843 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 200' ' ' LEU . . . . . 0.571 ' O ' HG12 ' A' ' 203' ' ' VAL . 32.1 mt -69.61 -47.69 62.63 Favored 'General case' 0 C--N 1.332 -0.153 0 CA-C-N 116.099 -0.5 . . . . 0.0 111.584 -179.56 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 201' ' ' ASP . . . . . 0.402 ' HB2' ' OH ' ' A' ' 51' ' ' TYR . 4.7 m-20 -70.62 -39.63 73.62 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-O 121.29 0.567 . . . . 0.0 110.192 179.757 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 202' ' ' LEU . . . . . . . . . . . . . 59.8 tp -71.13 -26.75 63.15 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 115.343 -0.844 . . . . 0.0 111.951 -179.292 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 203' ' ' VAL . . . . . 0.571 HG12 ' O ' ' A' ' 200' ' ' LEU . 9.3 p -79.34 -35.73 17.34 Favored 'Isoleucine or valine' 0 C--O 1.226 -0.153 0 C-N-CA 121.005 -0.278 . . . . 0.0 110.805 -179.483 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 204' ' ' THR . . . . . . . . . . . . . 95.8 m -65.71 -58.89 4.62 Favored 'General case' 0 C--N 1.329 -0.31 0 C-N-CA 120.748 -0.381 . . . . 0.0 110.797 179.33 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 205' ' ' LYS . . . . . 0.546 ' HE2' ' HB2' ' A' ' 47' ' ' ALA . 60.9 mttp -58.17 -57.29 13.53 Favored 'General case' 0 C--N 1.329 -0.296 0 N-CA-C 112.061 0.393 . . . . 0.0 112.061 -178.9 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 59.8 t -71.04 -37.35 67.15 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.365 0 N-CA-C 112.326 0.491 . . . . 0.0 112.326 -178.702 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 207' ' ' GLY . . . . . 0.531 ' O ' HG13 ' A' ' 211' ' ' ILE . . . -58.07 -61.86 6.94 Favored Glycine 0 CA--C 1.518 0.267 0 C-N-CA 120.658 -0.782 . . . . 0.0 113.966 -178.605 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 208' ' ' PHE . . . . . 0.54 ' HB2' ' HG ' ' A' ' 163' ' ' LEU . 2.1 p90 -72.93 -27.36 61.81 Favored 'General case' 0 C--O 1.222 -0.38 0 CA-C-N 117.48 0.64 . . . . 0.0 110.75 -179.308 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 209' ' ' GLY . . . . . 0.595 ' O ' ' HB3' ' A' ' 212' ' ' ALA . . . -63.34 -34.17 89.23 Favored Glycine 0 N--CA 1.449 -0.473 0 N-CA-C 111.786 -0.525 . . . . 0.0 111.786 178.65 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 210' ' ' PHE . . . . . . . . . . . . . 0.7 OUTLIER -72.75 -47.46 46.7 Favored 'General case' 0 CA--C 1.514 -0.425 0 N-CA-C 108.239 -1.023 . . . . 0.0 108.239 178.379 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 211' ' ' ILE . . . . . 0.537 HG21 ' HG2' ' A' ' 162' ' ' ARG . 4.8 mt -62.91 -27.48 43.2 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.465 0 N-CA-C 107.632 -1.248 . . . . 0.0 107.632 176.588 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 212' ' ' ALA . . . . . 0.595 ' HB3' ' O ' ' A' ' 209' ' ' GLY . . . -61.86 -41.67 98.12 Favored 'General case' 0 N--CA 1.45 -0.45 0 CA-C-N 114.436 -1.256 . . . . 0.0 110.622 -179.846 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 213' ' ' LEU . . . . . . . . . . . . . 99.1 mt -66.56 -50.39 63.29 Favored 'General case' 0 C--N 1.331 -0.202 0 CA-C-N 115.345 -0.843 . . . . 0.0 111.255 -179.872 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 214' ' ' ASP . . . . . . . . . . . . . 25.8 t70 -56.08 -54.41 45.29 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.282 -0.417 . . . . 0.0 111.152 -179.761 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 215' ' ' ALA . . . . . 0.414 ' O ' ' HG ' ' A' ' 219' ' ' LEU . . . -57.44 -57.27 13.39 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.136 -0.484 . . . . 0.0 111.417 -179.865 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 216' ' ' ALA . . . . . . . . . . . . . . . -55.18 -33.48 63.04 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.353 -0.385 . . . . 0.0 111.331 -179.828 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 217' ' ' ALA . . . . . . . . . . . . . . . -61.72 -37.77 85.43 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 121.096 0.474 . . . . 0.0 110.129 179.426 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 218' ' ' THR . . . . . . . . . . . . . 98.4 m -76.92 -35.0 57.65 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 115.648 -0.705 . . . . 0.0 110.824 179.384 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 219' ' ' LEU . . . . . 0.414 ' HG ' ' O ' ' A' ' 215' ' ' ALA . 81.3 mt -60.1 -39.6 86.74 Favored 'General case' 0 C--N 1.332 -0.17 0 CA-C-O 120.926 0.393 . . . . 0.0 110.529 179.666 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 220' ' ' ARG . . . . . . . . . . . . . 8.6 ptm180 -83.52 -24.25 31.75 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.396 179.485 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 221' ' ' ALA . . . . . . . . . . . . . . . -75.51 -24.93 56.87 Favored 'General case' 0 C--N 1.331 -0.204 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.179 179.798 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 222' ' ' GLU . . . . . . . . . . . . . 9.7 pt-20 -92.13 -24.16 19.2 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 121.084 0.469 . . . . 0.0 110.101 179.882 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 223' ' ' HIS . . . . . . . . . . . . . 57.6 m-70 64.83 164.76 0.15 Allowed 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 115.338 -0.846 . . . . 0.0 111.244 179.91 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 224' ' ' GLY . . . . . . . . . . . . . . . -93.08 72.83 1.34 Allowed Glycine 0 N--CA 1.452 -0.283 0 C-N-CA 120.846 -0.693 . . . . 0.0 112.518 -179.887 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 225' ' ' GLU . . . . . . . . . . . . . 8.3 tp10 -96.3 141.48 29.59 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-O 120.782 0.325 . . . . 0.0 110.767 179.85 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 226' ' ' SER . . . . . . . . . . . . . 42.8 m -73.17 175.4 6.81 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.242 -0.436 . . . . 0.0 110.809 -179.987 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 227' ' ' LEU . . . . . . . . . . . . . 4.1 mm? -94.47 134.13 37.33 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.082 -0.508 . . . . 0.0 110.704 179.903 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 228' ' ' ALA . . . . . . . . . . . . . . . -97.56 8.99 43.63 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.193 179.996 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 229' ' ' GLY . . . . . . . . . . . . . . . -82.96 -56.46 2.73 Favored Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.567 -179.977 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 230' ' ' VAL . . . . . . . . . . . . . 16.3 m -117.84 174.1 4.22 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-O 120.835 0.35 . . . . 0.0 111.283 -179.891 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 231' ' ' ASP . . . . . . . . . . . . . 5.8 m-20 -132.88 102.89 5.81 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.107 -0.497 . . . . 0.0 111.049 -179.947 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 232' ' ' THR . . . . . . . . . . . . . 8.4 t -132.78 -32.4 1.26 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.145 -0.48 . . . . 0.0 111.017 179.597 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 233' ' ' ASP . . . . . . . . . . . . . 3.7 p30 -128.64 152.73 48.03 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.717 179.679 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 234' ' ' THR . . . . . . . . . . . . . 69.1 p -96.46 143.04 25.43 Favored Pre-proline 0 C--N 1.33 -0.279 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.973 179.965 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 235' ' ' PRO . . . . . . . . . . . . . 32.5 Cg_exo -60.64 166.65 9.55 Favored 'Trans proline' 0 C--N 1.347 0.475 0 C-N-CA 122.435 2.09 . . . . 0.0 112.243 179.945 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 236' ' ' ALA . . . . . . . . . . . . . . . -70.68 171.12 10.95 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.095 179.844 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 237' ' ' VAL . . . . . . . . . . . . . 61.0 t 64.1 120.76 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.332 -0.155 0 CA-C-N 116.01 -0.541 . . . . 0.0 111.433 179.873 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 238' ' ' ALA . . . . . . . . . . . . . . . -54.81 144.13 23.47 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 115.971 -0.559 . . . . 0.0 111.211 -179.867 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 239' ' ' ASP . . . . . . . . . . . . . 8.5 m-20 -67.58 114.76 6.49 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.98 -179.801 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 240' ' ' LEU . . . . . . . . . . . . . 96.0 mt -82.95 118.15 23.28 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.036 -0.529 . . . . 0.0 110.776 179.874 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 241' ' ' GLU . . . . . . . . . . . . . 39.6 tt0 -108.9 -32.07 7.42 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.112 -179.813 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 242' ' ' HIS . . . . . . . . . . . . . 19.5 p80 -69.11 -15.81 63.52 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.363 -0.381 . . . . 0.0 110.934 -179.884 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 243' ' ' HIS . . . . . . . . . . . . . 60.1 t-80 -169.29 111.83 0.5 Allowed 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.302 -0.408 . . . . 0.0 110.952 -179.998 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 244' ' ' HIS . . . . . . . . . . . . . 15.9 t-80 -110.11 -49.44 3.07 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.829 179.788 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 245' ' ' HIS . . . . . . . . . . . . . 19.0 t60 -124.47 141.09 52.35 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.752 179.921 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 246' ' ' HIS . . . . . . . . . . . . . 60.1 m80 -61.32 107.63 0.8 Allowed 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.92 179.926 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 247' ' ' HIS . . . . . . . . . . . . . 8.7 p80 . . . . . 0 C--O 1.248 1.008 0 CA-C-O 118.097 -0.954 . . . . 0.0 110.964 -179.98 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 301' ' ' RET . . . . . 0.624 H202 ' HZ2' ' A' ' 171' ' ' TRP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 94.2 mmm . . . . . 0 N--CA 1.486 1.353 0 CA-C-O 120.818 0.342 . . . . 0.0 111.004 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 14.7 p -117.6 -15.26 9.21 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.22 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.98 -179.957 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -81.42 -44.22 8.09 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.727 -179.717 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 4' ' ' LEU . . . . . 0.409 ' HA ' HD23 ' A' ' 7' ' ' LEU . 82.9 mt -59.2 -35.24 73.25 Favored 'General case' 0 N--CA 1.449 -0.483 0 CA-C-O 120.812 0.339 . . . . 0.0 111.273 -179.822 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 46.4 p -61.6 -34.91 76.44 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.11 -0.495 . . . . 0.0 111.795 -179.588 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 16.4 p -56.16 -35.64 67.41 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.333 -0.394 . . . . 0.0 111.507 -179.321 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 7' ' ' LEU . . . . . 0.42 ' N ' HD22 ' A' ' 7' ' ' LEU . 3.6 mm? -61.81 -53.5 55.04 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.364 -0.38 . . . . 0.0 111.271 -179.752 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 8' ' ' PHE . . . . . 0.563 ' HB2' ' HB2' ' A' ' 55' ' ' ALA . 53.9 m-85 -59.18 -30.21 68.03 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.291 -0.413 . . . . 0.0 111.066 -179.631 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 9' ' ' TRP . . . . . . . . . . . . . 19.7 m95 -69.25 -46.76 66.5 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.345 -179.971 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 85.4 mt -62.3 -41.86 98.88 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 115.88 -0.6 . . . . 0.0 110.042 179.206 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -62.29 -33.72 86.96 Favored Glycine 0 N--CA 1.448 -0.509 0 C-N-CA 120.779 -0.724 . . . . 0.0 111.769 179.3 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -67.87 -34.48 76.76 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-O 120.84 0.352 . . . . 0.0 110.523 179.585 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 46.8 mm -62.68 -51.67 69.19 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.187 0 CA-C-N 116.029 -0.532 . . . . 0.0 110.505 179.451 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -60.18 -33.21 79.02 Favored Glycine 0 N--CA 1.449 -0.447 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.108 179.648 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 15' ' ' MET . . . . . 0.611 ' HB3' ' HB2' ' A' ' 48' ' ' ALA . 20.0 mmt -66.75 -47.05 73.44 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.624 0.25 . . . . 0.0 110.821 179.689 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -54.07 -42.14 68.95 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.301 179.583 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 79.6 t -61.26 -48.05 90.69 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-N 115.946 -0.57 . . . . 0.0 110.79 179.548 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -63.51 -46.34 92.67 Favored Glycine 0 C--N 1.331 0.272 0 C-N-CA 120.773 -0.727 . . . . 0.0 112.165 179.809 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 23.2 m -49.95 -43.19 49.86 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 120.726 0.298 . . . . 0.0 111.114 -179.644 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 81.8 mt -71.93 -47.06 55.15 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.284 -0.416 . . . . 0.0 111.446 179.905 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -57.61 -29.9 64.89 Favored 'General case' 0 C--N 1.33 -0.272 0 N-CA-C 111.982 0.364 . . . . 0.0 111.982 -179.525 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 22' ' ' PHE . . . . . 0.587 ' HB2' HG22 ' A' ' 41' ' ' VAL . 9.5 m-85 -89.42 -41.12 12.27 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.531 -0.304 . . . . 0.0 111.594 -179.097 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -65.58 -50.39 65.31 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.828 0.347 . . . . 0.0 111.38 -179.729 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 24' ' ' TRP . . . . . . . . . . . . . 1.1 t-105 -57.92 -50.3 73.81 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.078 -0.51 . . . . 0.0 111.057 179.884 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -69.66 -23.46 63.47 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.284 -0.416 . . . . 0.0 111.221 -179.911 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -73.42 -42.65 40.71 Favored Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.808 -0.71 . . . . 0.0 112.651 179.92 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 18.5 mmm180 -61.42 -22.16 64.76 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-O 120.799 0.333 . . . . 0.0 110.991 -179.989 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 13.7 t70 -116.6 97.3 5.92 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.074 -0.512 . . . . 0.0 110.702 179.974 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -160.92 -66.26 0.06 Allowed 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.134 -179.833 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 160.5 -138.66 5.63 Favored Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.865 -0.683 . . . . 0.0 112.449 -179.937 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 58.1 m -119.98 125.89 49.49 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.808 0.337 . . . . 0.0 110.824 179.987 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 105.41 -53.48 0.65 Allowed Glycine 0 N--CA 1.452 -0.258 0 C-N-CA 120.875 -0.679 . . . . 0.0 112.603 179.925 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 12.9 mm-40 -63.68 -24.31 67.73 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.835 0.35 . . . . 0.0 110.729 179.981 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 34' ' ' ARG . . . . . . . . . . . . . 75.6 ttt180 -50.56 -30.45 13.16 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 115.905 -0.588 . . . . 0.0 111.694 -179.77 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 88.2 mtm180 -59.24 -52.62 64.88 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.487 -0.324 . . . . 0.0 111.604 -179.677 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 86.3 m-85 -58.89 -27.58 65.36 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.51 -179.618 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 37' ' ' TYR . . . . . 0.443 ' O ' HG23 ' A' ' 41' ' ' VAL . 72.7 m-85 -77.96 -53.81 7.02 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-N 116.292 -0.413 . . . . 0.0 111.08 -179.642 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 86.6 t -56.78 -36.9 50.86 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-O 121.024 0.44 . . . . 0.0 110.292 179.634 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 99.3 m -63.06 -50.52 70.28 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 115.759 -0.655 . . . . 0.0 110.164 179.153 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 40' ' ' LEU . . . . . 0.471 HD12 HD12 ' A' ' 43' ' ' ILE . 53.7 tp -56.36 -43.46 79.18 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 115.441 -0.8 . . . . 0.0 110.252 179.44 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . 0.587 HG22 ' HB2' ' A' ' 22' ' ' PHE . 97.3 t -63.77 -34.35 67.52 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.253 0 CA-C-N 115.708 -0.678 . . . . 0.0 109.648 178.731 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -60.46 -35.34 88.6 Favored Glycine 0 N--CA 1.448 -0.524 0 CA-C-N 115.627 -0.715 . . . . 0.0 112.102 179.753 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 43' ' ' ILE . . . . . 0.625 HG22 ' HE3' ' A' ' 205' ' ' LYS . 0.3 OUTLIER -70.11 -57.77 7.23 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.159 0 CA-C-O 120.646 0.26 . . . . 0.0 110.796 179.704 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 67.1 m -62.89 -20.28 65.0 Favored 'General case' 0 C--O 1.232 0.153 0 CA-C-N 116.406 -0.361 . . . . 0.0 111.315 -179.732 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -77.99 -57.52 3.45 Favored Glycine 0 N--CA 1.452 -0.25 0 C-N-CA 120.778 -0.725 . . . . 0.0 112.8 -179.598 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 23.8 pt -58.87 -36.14 59.87 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.213 0 CA-C-O 120.958 0.409 . . . . 0.0 110.969 179.925 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 47' ' ' ALA . . . . . 0.587 ' HB2' ' HE2' ' A' ' 205' ' ' LYS . . . -67.63 -45.46 75.28 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.067 -0.515 . . . . 0.0 111.26 179.832 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 48' ' ' ALA . . . . . 0.611 ' HB2' ' HB3' ' A' ' 15' ' ' MET . . . -55.1 -43.81 74.36 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.106 -0.497 . . . . 0.0 111.829 -179.578 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 35.9 m -73.37 -34.17 42.6 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.353 0 CA-C-N 116.332 -0.395 . . . . 0.0 111.519 -179.325 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -65.78 -35.09 79.73 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-O 120.924 0.393 . . . . 0.0 110.869 179.925 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 26.7 m-85 -73.33 -40.03 64.78 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-N 115.96 -0.564 . . . . 0.0 110.518 179.96 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -63.84 -44.7 92.39 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 115.938 -0.574 . . . . 0.0 111.258 179.848 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 53' ' ' VAL . . . . . 0.519 HG23 ' N ' ' A' ' 54' ' ' MET . 34.2 m -68.56 -48.97 69.42 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.226 0 CA-C-N 116.404 -0.362 . . . . 0.0 110.868 179.923 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 54' ' ' MET . . . . . 0.519 ' N ' HG23 ' A' ' 53' ' ' VAL . 7.1 ttp -62.77 -30.1 71.2 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.126 179.852 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 55' ' ' ALA . . . . . 0.563 ' HB2' ' HB2' ' A' ' 8' ' ' PHE . . . -65.55 -40.04 92.39 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 115.849 -0.614 . . . . 0.0 111.023 179.336 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 95.3 mt -73.23 2.77 6.71 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.022 -0.536 . . . . 0.0 111.092 -179.864 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 90.7 7.37 66.69 Favored Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.685 -0.769 . . . . 0.0 112.592 179.942 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 41.3 t -74.46 135.85 26.5 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-O 120.864 0.364 . . . . 0.0 110.869 179.895 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 83.92 -2.55 87.4 Favored Glycine 0 N--CA 1.452 -0.286 0 C-N-CA 120.942 -0.647 . . . . 0.0 112.903 179.988 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 60' ' ' TRP . . . . . . . . . . . . . 12.0 m0 -73.74 102.32 3.95 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.56 0.219 . . . . 0.0 110.931 179.63 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 61' ' ' VAL . . . . . 0.4 ' HA ' ' HD3' ' A' ' 62' ' ' PRO . 7.6 p -115.13 124.25 30.52 Favored Pre-proline 0 CA--C 1.536 0.414 0 CA-C-N 116.559 -0.291 . . . . 0.0 111.208 179.794 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 62' ' ' PRO . . . . . 0.4 ' HD3' ' HA ' ' A' ' 61' ' ' VAL . 14.2 Cg_exo -69.47 157.3 61.44 Favored 'Trans proline' 0 C--N 1.353 0.796 0 C-N-CA 122.783 2.322 . . . . 0.0 112.744 -179.725 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.423 HG23 HG22 ' A' ' 68' ' ' VAL . 76.5 t -144.13 94.63 0.47 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.223 0 CA-C-N 115.856 -0.611 . . . . 0.0 110.98 179.88 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . 59.51 -86.42 0.02 OUTLIER 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 116.088 -0.506 . . . . 0.0 111.503 179.789 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 11.1 tp10 -118.16 -26.88 6.22 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-N 116.526 -0.306 . . . . 0.0 111.261 -179.723 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 66' ' ' ARG . . . . . . . . . . . . . 17.4 ptp180 -107.69 153.76 22.46 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.46 -0.336 . . . . 0.0 110.443 179.903 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 60.4 m -105.88 141.52 37.15 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-O 121.047 0.451 . . . . 0.0 111.543 -179.521 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 68' ' ' VAL . . . . . 0.431 HG21 ' HG3' ' A' ' 117' ' ' MET . 33.0 m -119.89 146.37 24.77 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 115.725 -0.67 . . . . 0.0 110.367 179.537 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 69' ' ' PHE . . . . . . . . . . . . . 22.1 m-85 -109.0 112.44 24.63 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 116.318 -0.401 . . . . 0.0 110.066 -179.398 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 70' ' ' VAL . . . . . 0.481 ' HB ' ' HD3' ' A' ' 71' ' ' PRO . 3.2 t -63.78 -48.98 78.41 Favored Pre-proline 0 C--N 1.326 -0.441 0 CA-C-N 116.274 -0.421 . . . . 0.0 111.905 -179.126 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 71' ' ' PRO . . . . . 0.583 ' HA ' HG22 ' A' ' 74' ' ' ILE . 47.4 Cg_exo -56.9 -18.06 26.3 Favored 'Trans proline' 0 C--N 1.351 0.698 0 C-N-CA 122.289 1.993 . . . . 0.0 112.877 -179.606 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 68.2 ttt180 -70.95 -55.79 7.6 Favored 'General case' 0 C--O 1.236 0.362 0 CA-C-O 120.886 0.374 . . . . 0.0 111.559 -179.323 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 73' ' ' TYR . . . . . 0.458 ' O ' HG13 ' A' ' 77' ' ' ILE . 7.0 m-85 -70.64 -34.45 72.08 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.439 -0.346 . . . . 0.0 110.281 -179.497 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 74' ' ' ILE . . . . . 0.583 HG22 ' HA ' ' A' ' 71' ' ' PRO . 0.4 OUTLIER -68.01 -37.98 79.15 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.226 0 CA-C-N 116.334 -0.394 . . . . 0.0 110.013 179.322 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 75' ' ' ASP . . . . . 0.442 ' O ' HG23 ' A' ' 79' ' ' THR . 8.1 t70 -58.02 -39.56 78.65 Favored 'General case' 0 CA--C 1.518 -0.259 0 N-CA-C 109.045 -0.724 . . . . 0.0 109.045 178.806 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 76' ' ' TRP . . . . . 0.434 ' HZ2' HG23 ' A' ' 197' ' ' ILE . 39.0 m0 -67.06 -31.56 72.15 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 115.612 -0.722 . . . . 0.0 110.584 179.108 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 77' ' ' ILE . . . . . 0.544 ' HA ' ' HG3' ' A' ' 109' ' ' MET . 85.8 mt -66.71 -32.8 59.66 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.233 0 CA-C-N 116.284 -0.416 . . . . 0.0 111.035 179.468 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 21.5 mt -91.16 -17.47 26.04 Favored 'General case' 0 C--N 1.327 -0.41 0 N-CA-C 112.149 0.426 . . . . 0.0 112.149 -179.515 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 79' ' ' THR . . . . . 0.442 HG23 ' O ' ' A' ' 75' ' ' ASP . 76.9 p -103.4 -52.65 2.96 Favored 'General case' 0 CA--C 1.532 0.275 0 N-CA-C 113.784 1.031 . . . . 0.0 113.784 -177.915 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 80' ' ' THR . . . . . 0.682 ' HB ' ' HD3' ' A' ' 81' ' ' PRO . 29.4 m -51.36 -54.86 34.12 Favored Pre-proline 0 CA--C 1.531 0.246 0 N-CA-C 112.478 0.547 . . . . 0.0 112.478 -178.508 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 81' ' ' PRO . . . . . 0.682 ' HD3' ' HB ' ' A' ' 80' ' ' THR . 36.9 Cg_exo -60.51 -20.93 66.41 Favored 'Trans proline' 0 C--N 1.351 0.683 0 C-N-CA 121.575 1.516 . . . . 0.0 111.368 179.763 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 82' ' ' LEU . . . . . 0.436 HD23 HG23 ' A' ' 43' ' ' ILE . 17.3 tp -76.91 -33.34 57.77 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 115.812 -0.631 . . . . 0.0 110.302 179.751 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 48.9 mm -68.4 -52.06 40.91 Favored 'Isoleucine or valine' 0 C--O 1.233 0.221 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.055 179.109 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 34.5 m -61.86 -30.0 47.56 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.142 0 N-CA-C 109.545 -0.539 . . . . 0.0 109.545 178.728 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 85' ' ' TYR . . . . . . . . . . . . . 73.4 t80 -67.63 -33.35 74.78 Favored 'General case' 0 N--CA 1.454 -0.235 0 CA-C-N 115.546 -0.752 . . . . 0.0 109.615 178.873 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 86' ' ' PHE . . . . . . . . . . . . . 5.5 t80 -61.99 -51.67 67.11 Favored 'General case' 0 C--O 1.233 0.221 0 CA-C-N 115.697 -0.683 . . . . 0.0 109.822 179.204 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 87' ' ' LEU . . . . . 0.401 ' N ' HD12 ' A' ' 87' ' ' LEU . 8.7 mp -62.43 -29.5 70.55 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 115.755 -0.657 . . . . 0.0 110.101 179.476 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -71.49 -27.76 70.74 Favored Glycine 0 N--CA 1.449 -0.455 0 C-N-CA 120.799 -0.715 . . . . 0.0 111.569 179.237 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 72.6 mt -69.92 -45.57 67.24 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-O 121.074 0.464 . . . . 0.0 109.985 179.504 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 90' ' ' LEU . . . . . 0.485 ' HB3' HG23 ' A' ' 156' ' ' ILE . 64.7 mt -60.17 -30.43 69.33 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 115.582 -0.735 . . . . 0.0 110.741 179.616 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . 0.458 ' HA ' ' HA ' ' A' ' 149' ' ' ALA . . . -86.32 -29.44 23.02 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.264 -179.787 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 75.03 44.69 22.93 Favored Glycine 0 N--CA 1.452 -0.258 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.146 -179.902 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 93' ' ' LEU . . . . . 0.427 ' HB3' ' HB2' ' A' ' 97' ' ' GLU . 30.1 mt -60.36 168.04 2.24 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.955 0.407 . . . . 0.0 111.206 -179.646 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 94' ' ' ASP . . . . . . . . . . . . . 5.5 m-20 -90.77 179.57 5.76 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 115.936 -0.575 . . . . 0.0 110.834 179.994 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 80.5 p -60.58 -42.83 97.48 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.906 -179.94 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 68.9 mtm180 -68.62 -49.77 56.6 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.108 -0.496 . . . . 0.0 111.027 -179.826 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 97' ' ' GLU . . . . . 0.427 ' HB2' ' HB3' ' A' ' 93' ' ' LEU . 44.9 mt-10 -54.51 -47.6 72.9 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.335 -0.393 . . . . 0.0 111.033 -179.883 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 98' ' ' PHE . . . . . 0.453 ' O ' HG12 ' A' ' 102' ' ' ILE . 11.3 m-85 -60.29 -43.62 96.09 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.416 -0.357 . . . . 0.0 110.496 179.61 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -60.63 -27.53 66.37 Favored Glycine 0 N--CA 1.451 -0.358 0 C-N-CA 120.611 -0.804 . . . . 0.0 112.414 179.746 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 96.1 mt -73.9 -47.64 42.23 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.229 0 N-CA-C 111.875 0.324 . . . . 0.0 111.875 -179.537 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 101' ' ' VAL . . . . . 0.41 HG11 ' HE3' ' A' ' 145' ' ' MET . 27.7 m -69.49 -39.01 78.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 N-CA-C 111.731 0.271 . . . . 0.0 111.731 -179.353 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 102' ' ' ILE . . . . . 0.453 HG12 ' O ' ' A' ' 98' ' ' PHE . 43.3 mm -67.67 -46.55 82.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.55 -0.296 . . . . 0.0 111.347 -179.54 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 14.7 t -62.42 -33.27 74.46 Favored 'General case' 0 C--O 1.233 0.187 0 CA-C-O 120.975 0.417 . . . . 0.0 110.404 179.643 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -58.84 -52.04 67.42 Favored 'General case' 0 C--N 1.332 -0.191 0 CA-C-N 115.995 -0.548 . . . . 0.0 109.528 179.248 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 105' ' ' ASN . . . . . 0.567 ' N ' HD22 ' A' ' 105' ' ' ASN . 0.8 OUTLIER -56.72 -35.45 68.56 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 115.736 -0.666 . . . . 0.0 110.53 179.455 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 39.3 m -55.6 -50.9 68.88 Favored 'General case' 0 C--N 1.332 -0.169 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.996 179.918 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 107' ' ' VAL . . . . . 0.409 ' H ' HG23 ' A' ' 107' ' ' VAL . 0.9 OUTLIER -60.5 -39.67 81.97 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.223 0 CA-C-O 121.174 0.512 . . . . 0.0 110.39 179.6 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 81.0 t -63.66 -39.91 87.12 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-N 115.506 -0.77 . . . . 0.0 111.285 -179.821 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 109' ' ' MET . . . . . 0.544 ' HG3' ' HA ' ' A' ' 77' ' ' ILE . 28.6 mmt -67.17 -51.35 54.8 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.078 -0.51 . . . . 0.0 111.329 -179.568 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 21.1 tp -58.95 -34.73 72.09 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-N 115.96 -0.564 . . . . 0.0 110.927 -179.592 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -61.11 -57.09 13.98 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.18 -179.994 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 112' ' ' GLY . . . . . 0.584 ' HA3' ' H21' ' A' ' 301' ' ' RET . . . -67.23 -28.03 73.62 Favored Glycine 0 N--CA 1.45 -0.374 0 C-N-CA 120.724 -0.75 . . . . 0.0 112.143 179.68 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 113' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER -57.67 -75.09 0.05 OUTLIER 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 121.035 0.445 . . . . 0.0 110.132 179.817 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -61.45 -26.43 67.87 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 115.793 -0.639 . . . . 0.0 111.095 179.771 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -53.06 -50.07 52.97 Favored Glycine 0 C--N 1.331 0.28 0 C-N-CA 121.028 -0.606 . . . . 0.0 112.616 -179.974 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 116' ' ' ALA . . . . . 0.571 ' HB2' ' HB3' ' A' ' 183' ' ' PRO . . . -77.65 -16.42 58.54 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.672 0.272 . . . . 0.0 111.613 -179.739 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 117' ' ' MET . . . . . 0.431 ' HG3' HG21 ' A' ' 68' ' ' VAL . 29.7 ttm -101.85 19.22 18.69 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.407 -0.361 . . . . 0.0 111.341 -179.506 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 118' ' ' VAL . . . . . 0.58 HG21 ' HB3' ' A' ' 123' ' ' ARG . 21.4 m -70.15 145.49 93.75 Favored Pre-proline 0 C--N 1.33 -0.245 0 CA-C-N 116.432 -0.349 . . . . 0.0 111.502 179.982 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 119' ' ' PRO . . . . . . . . . . . . . 85.9 Cg_endo -93.4 15.8 1.33 Allowed 'Trans proline' 0 N--CA 1.456 -0.732 0 C-N-CA 122.997 2.465 . . . . 0.0 112.353 179.419 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -164.62 -120.38 0.52 Allowed Glycine 0 C--N 1.332 0.339 0 C-N-CA 120.66 -0.781 . . . . 0.0 112.674 -179.564 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 40.9 pt -114.68 9.84 7.74 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.232 0 CA-C-O 120.723 0.297 . . . . 0.0 111.493 -179.727 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 45.7 mt-10 -58.84 -18.08 29.48 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.304 -0.407 . . . . 0.0 110.699 179.725 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 123' ' ' ARG . . . . . 0.58 ' HB3' HG21 ' A' ' 118' ' ' VAL . 10.2 ptp180 -50.5 -33.24 20.65 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 115.794 -0.639 . . . . 0.0 111.642 -179.959 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 124' ' ' TYR . . . . . . . . . . . . . 19.3 m-85 -73.11 -32.63 65.07 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.428 -0.351 . . . . 0.0 111.513 -179.459 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 125' ' ' ALA . . . . . . . . . . . . . . . -74.32 -56.11 5.25 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.386 -0.37 . . . . 0.0 111.398 -179.492 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -55.09 -44.19 74.66 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.904 -179.931 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 127' ' ' PHE . . . . . 0.439 ' CE1' ' H42' ' A' ' 301' ' ' RET . 5.4 t80 -70.92 -37.21 72.89 Favored 'General case' 0 C--N 1.33 -0.279 0 C-N-CA 120.898 -0.321 . . . . 0.0 110.575 179.825 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 128' ' ' GLY . . . . . . . . . . . . . . . -46.79 -46.85 19.03 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.167 -1.016 . . . . 0.0 110.844 179.052 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 129' ' ' MET . . . . . . . . . . . . . 0.4 OUTLIER -69.69 -38.84 77.16 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 115.367 -0.417 . . . . 0.0 109.894 178.781 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -62.87 -29.3 73.71 Favored Glycine 0 C--N 1.333 0.38 0 CA-C-N 115.892 -0.595 . . . . 0.0 112.792 -179.893 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 131' ' ' ALA . . . . . 0.402 ' O ' ' HB3' ' A' ' 134' ' ' PHE . . . -74.29 -53.61 9.37 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 120.761 0.315 . . . . 0.0 110.317 179.871 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 28.3 t -58.03 -40.07 75.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 N-CA-C 109.321 -0.622 . . . . 0.0 109.321 178.741 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -68.64 -33.4 73.94 Favored 'General case' 0 N--CA 1.454 -0.259 0 CA-C-N 115.387 -0.824 . . . . 0.0 110.342 179.177 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 134' ' ' PHE . . . . . 0.402 ' HB3' ' O ' ' A' ' 131' ' ' ALA . 44.1 t80 -57.77 -55.14 38.7 Favored 'General case' 0 N--CA 1.452 -0.34 0 CA-C-N 116.132 -0.486 . . . . 0.0 109.752 179.239 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 135' ' ' ILE . . . . . 0.46 ' O ' HG22 ' A' ' 138' ' ' VAL . 39.2 mt -57.69 -31.87 40.97 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 115.673 -0.694 . . . . 0.0 109.86 178.861 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . -64.19 -35.31 91.81 Favored Glycine 0 N--CA 1.448 -0.515 0 C-N-CA 120.488 -0.863 . . . . 0.0 111.577 179.13 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 137' ' ' LEU . . . . . . . . . . . . . 38.9 tp -73.44 -51.13 18.3 Favored 'General case' 0 C--N 1.331 -0.205 0 CA-C-O 120.628 0.252 . . . . 0.0 110.51 179.492 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 138' ' ' VAL . . . . . 0.46 HG22 ' O ' ' A' ' 135' ' ' ILE . 4.0 m -57.37 -30.96 37.04 Favored 'Isoleucine or valine' 0 C--O 1.233 0.208 0 N-CA-C 109.376 -0.601 . . . . 0.0 109.376 179.048 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 139' ' ' TYR . . . . . . . . . . . . . 24.9 t80 -66.19 -43.34 87.12 Favored 'General case' 0 C--N 1.332 -0.196 0 CA-C-N 115.324 -0.853 . . . . 0.0 110.15 178.706 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 140' ' ' TYR . . . . . 0.435 ' HB3' ' SD ' ' A' ' 145' ' ' MET . 11.9 m-85 -53.06 -51.62 61.22 Favored 'General case' 0 C--O 1.231 0.13 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.514 179.355 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 141' ' ' LEU . . . . . . . . . . . . . 70.5 mt -53.39 -53.56 49.39 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 115.726 -0.67 . . . . 0.0 111.213 -179.788 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 17.2 t -73.42 -11.29 14.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.113 -0.494 . . . . 0.0 111.334 -179.623 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . -71.45 -140.91 0.26 Allowed Glycine 0 CA--C 1.52 0.354 0 C-N-CA 120.832 -0.699 . . . . 0.0 112.635 -179.799 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 144' ' ' PRO . . . . . . . . . . . . . 32.2 Cg_endo -62.99 -23.25 74.08 Favored 'Trans proline' 0 C--N 1.347 0.493 0 C-N-CA 122.486 2.124 . . . . 0.0 112.121 -179.991 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 145' ' ' MET . . . . . 0.435 ' SD ' ' HB3' ' A' ' 140' ' ' TYR . 82.4 mtp -57.61 -27.9 63.18 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 116.024 -0.535 . . . . 0.0 110.975 179.921 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 146' ' ' THR . . . . . . . . . . . . . 60.0 m -71.89 -40.79 68.64 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.308 -0.406 . . . . 0.0 111.042 179.82 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 2.2 mp0 -74.25 -27.57 60.83 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.008 -179.835 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 148' ' ' SER . . . . . . . . . . . . . 49.1 m -70.19 -43.16 71.33 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.388 -0.369 . . . . 0.0 111.085 -179.882 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 149' ' ' ALA . . . . . 0.458 ' HA ' ' HA ' ' A' ' 91' ' ' ALA . . . -77.84 -44.08 28.41 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.845 -179.457 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 150' ' ' SER . . . . . . . . . . . . . 66.3 m -63.72 -21.97 66.67 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.388 -0.369 . . . . 0.0 111.443 -179.451 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 151' ' ' GLN . . . . . . . . . . . . . 78.7 mt-30 -106.87 6.49 29.41 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.51 -0.314 . . . . 0.0 111.298 -179.784 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 30.2 tpt180 -82.58 -50.31 8.92 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.437 -0.347 . . . . 0.0 110.729 179.823 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 153' ' ' SER . . . . . 0.514 ' HB2' HG13 ' A' ' 156' ' ' ILE . 45.8 m -154.55 149.34 26.59 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.824 179.267 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 154' ' ' SER . . . . . . . . . . . . . 42.7 t -55.24 -40.37 70.83 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.113 -0.494 . . . . 0.0 111.055 179.947 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 155' ' ' GLY . . . . . 0.404 ' O ' ' HG ' ' A' ' 159' ' ' LEU . . . -75.01 -35.93 48.23 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.79 -0.719 . . . . 0.0 112.562 179.994 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 156' ' ' ILE . . . . . 0.514 HG13 ' HB2' ' A' ' 153' ' ' SER . 68.9 mt -60.95 -36.22 70.58 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-O 120.707 0.289 . . . . 0.0 111.307 -179.948 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 157' ' ' LYS . . . . . 0.402 ' O ' HG13 ' A' ' 161' ' ' VAL . 88.6 tttt -52.9 -45.66 67.64 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-N 116.187 -0.461 . . . . 0.0 111.499 -179.783 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 48.4 t -71.83 -37.41 70.32 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 121.003 0.43 . . . . 0.0 111.29 -179.558 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 159' ' ' LEU . . . . . 0.404 ' HG ' ' O ' ' A' ' 155' ' ' GLY . 78.0 mt -65.85 -39.18 90.52 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-N 115.936 -0.575 . . . . 0.0 111.643 -179.413 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 160' ' ' TYR . . . . . . . . . . . . . 45.5 t80 -73.94 -44.37 55.19 Favored 'General case' 0 C--N 1.327 -0.401 0 N-CA-C 112.155 0.428 . . . . 0.0 112.155 -178.647 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 161' ' ' VAL . . . . . 0.402 HG13 ' O ' ' A' ' 157' ' ' LYS . 30.8 m -59.86 -43.96 93.15 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 N-CA-C 112.226 0.454 . . . . 0.0 112.226 -178.916 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 162' ' ' ARG . . . . . 0.541 ' O ' HD12 ' A' ' 166' ' ' LEU . 93.8 mtt180 -69.16 -50.74 44.98 Favored 'General case' 0 C--N 1.33 -0.269 0 N-CA-C 112.18 0.437 . . . . 0.0 112.18 -179.134 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 163' ' ' LEU . . . . . . . . . . . . . 7.5 mp -65.71 -43.83 87.92 Favored 'General case' 0 C--N 1.33 -0.254 0 N-CA-C 111.789 0.292 . . . . 0.0 111.789 -179.06 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 164' ' ' ARG . . . . . . . . . . . . . 6.1 tmm_? -57.42 -50.98 71.26 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-N 116.56 -0.291 . . . . 0.0 111.004 -179.693 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 165' ' ' ASN . . . . . 0.508 HD22 ' N ' ' A' ' 165' ' ' ASN . 0.9 OUTLIER -53.04 -44.99 67.81 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-O 120.934 0.397 . . . . 0.0 110.346 179.809 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 166' ' ' LEU . . . . . 0.541 HD12 ' O ' ' A' ' 162' ' ' ARG . 1.5 mt -60.05 -48.65 80.82 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 115.931 -0.577 . . . . 0.0 111.2 179.478 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 167' ' ' THR . . . . . 0.624 ' HA ' HD11 ' A' ' 170' ' ' LEU . 12.0 m -53.68 -51.0 64.59 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.021 -0.536 . . . . 0.0 112.218 -178.265 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 168' ' ' VAL . . . . . . . . . . . . . 27.0 t -59.26 -40.6 81.66 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.566 0 N-CA-C 112.105 0.409 . . . . 0.0 112.105 -179.061 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 169' ' ' VAL . . . . . 0.486 HG23 ' O ' ' A' ' 165' ' ' ASN . 83.9 t -66.08 -66.82 0.45 Allowed 'Isoleucine or valine' 0 CA--C 1.533 0.3 0 N-CA-C 113.557 0.947 . . . . 0.0 113.557 -178.194 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 170' ' ' LEU . . . . . 0.624 HD11 ' HA ' ' A' ' 167' ' ' THR . 0.4 OUTLIER -61.66 -32.18 72.34 Favored 'General case' 0 N--CA 1.467 0.388 0 N-CA-C 112.974 0.731 . . . . 0.0 112.974 -177.529 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 171' ' ' TRP . . . . . 0.695 ' HE1' H203 ' A' ' 301' ' ' RET . 21.4 m0 -73.53 -29.54 62.52 Favored 'General case' 0 C--N 1.329 -0.323 0 C-N-CA 120.371 -0.531 . . . . 0.0 111.087 -179.619 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 172' ' ' ALA . . . . . . . . . . . . . . . -72.24 -7.87 51.68 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-O 121.011 0.434 . . . . 0.0 110.253 179.499 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 173' ' ' ILE . . . . . 0.552 HG22 HD11 ' A' ' 177' ' ' ILE . 18.5 mm -88.92 -25.42 5.75 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.21 0 CA-C-N 115.789 -0.642 . . . . 0.0 110.939 179.528 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 174' ' ' TYR . . . . . 0.491 ' HD1' ' HA ' ' A' ' 171' ' ' TRP . 16.1 m-85 -54.62 -48.54 94.94 Favored Pre-proline 0 CA--C 1.531 0.218 0 CA-C-N 116.104 -0.498 . . . . 0.0 112.156 -179.384 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 175' ' ' PRO . . . . . . . . . . . . . 74.8 Cg_exo -47.07 -29.99 9.55 Favored 'Trans proline' 0 C--N 1.352 0.747 0 C-N-CA 121.909 1.739 . . . . 0.0 111.808 179.677 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 176' ' ' PHE . . . . . 0.497 ' O ' ' HG ' ' A' ' 180' ' ' LEU . 72.0 m-85 -80.35 -49.89 10.89 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 115.713 -0.676 . . . . 0.0 111.37 179.687 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 177' ' ' ILE . . . . . 0.552 HD11 HG22 ' A' ' 173' ' ' ILE . 3.6 mm -59.28 -36.25 62.5 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.525 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.722 -178.632 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 178' ' ' TRP . . . . . 0.407 ' O ' ' HB2' ' A' ' 183' ' ' PRO . 58.7 t90 -73.3 -51.82 16.18 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-O 121.066 0.46 . . . . 0.0 110.658 179.879 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 179' ' ' LEU . . . . . 0.563 HD13 HG22 ' A' ' 185' ' ' VAL . 1.4 tm? -61.07 -53.4 57.54 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 115.701 -0.681 . . . . 0.0 111.56 -179.159 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 180' ' ' LEU . . . . . 0.723 HD22 HD11 ' A' ' 187' ' ' LEU . 12.5 mt -74.78 -29.47 61.13 Favored 'General case' 0 C--N 1.327 -0.385 0 N-CA-C 112.2 0.444 . . . . 0.0 112.2 -178.861 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . -71.42 -177.66 27.28 Favored Glycine 0 N--CA 1.45 -0.407 0 C-N-CA 119.977 -1.106 . . . . 0.0 112.173 179.777 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 182' ' ' PRO . . . . . 0.427 ' N ' ' HD2' ' A' ' 183' ' ' PRO . 76.8 Cg_exo -47.93 -43.36 30.05 Favored 'Trans proline' 0 CA--C 1.538 0.681 0 C-N-CA 122.649 2.233 . . . . 0.0 113.386 179.527 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 183' ' ' PRO . . . . . 0.571 ' HB3' ' HB2' ' A' ' 116' ' ' ALA . 65.9 Cg_exo -41.54 -31.87 1.27 Allowed 'Trans proline' 0 C--N 1.358 1.046 0 C-N-CA 122.609 2.206 . . . . 0.0 113.601 179.824 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 184' ' ' GLY . . . . . . . . . . . . . . . -130.03 -107.65 1.24 Allowed Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.413 -0.899 . . . . 0.0 112.323 180.0 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 185' ' ' VAL . . . . . 0.563 HG22 HD13 ' A' ' 179' ' ' LEU . 27.4 m -92.41 89.87 2.96 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.44 0 CA-C-O 121.414 0.626 . . . . 0.0 110.365 179.668 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 186' ' ' ALA . . . . . . . . . . . . . . . -56.94 86.7 0.01 OUTLIER 'General case' 0 C--N 1.325 -0.491 0 CA-C-N 115.687 -0.688 . . . . 0.0 111.855 -179.448 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 187' ' ' LEU . . . . . 0.723 HD11 HD22 ' A' ' 180' ' ' LEU . 12.5 mt -74.8 -48.91 22.8 Favored 'General case' 0 C--N 1.331 -0.199 0 CA-C-O 120.985 0.422 . . . . 0.0 110.361 179.236 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 188' ' ' LEU . . . . . . . . . . . . . 63.4 mt -97.8 -147.97 0.32 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 115.775 -0.648 . . . . 0.0 110.65 -179.87 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 189' ' ' THR . . . . . . . . . . . . . 1.2 t -111.8 148.46 39.0 Favored Pre-proline 0 C--N 1.331 -0.231 0 CA-C-N 116.276 -0.42 . . . . 0.0 110.813 -179.964 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 190' ' ' PRO . . . . . 0.406 ' O ' HG23 ' A' ' 194' ' ' VAL . 7.3 Cg_endo -49.12 -42.14 39.75 Favored 'Trans proline' 0 C--N 1.349 0.57 0 C-N-CA 123.027 2.485 . . . . 0.0 113.261 -179.474 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 191' ' ' THR . . . . . . . . . . . . . 7.6 t -59.54 -40.86 88.6 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.65 0.262 . . . . 0.0 111.598 -179.341 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 192' ' ' VAL . . . . . . . . . . . . . 42.3 t -71.94 -47.92 53.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.499 -0.319 . . . . 0.0 111.398 -179.809 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 193' ' ' ASP . . . . . . . . . . . . . 30.7 t70 -57.99 -51.2 70.65 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.742 0.306 . . . . 0.0 111.038 -179.815 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 194' ' ' VAL . . . . . 0.406 HG23 ' O ' ' A' ' 190' ' ' PRO . 97.8 t -59.88 -36.15 64.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.883 179.973 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 195' ' ' ALA . . . . . . . . . . . . . . . -58.1 -46.1 86.1 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.542 -0.299 . . . . 0.0 110.942 179.697 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 196' ' ' LEU . . . . . . . . . . . . . 86.3 mt -65.69 -41.34 92.5 Favored 'General case' 0 C--N 1.332 -0.171 0 CA-C-N 116.368 -0.378 . . . . 0.0 110.404 179.596 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 197' ' ' ILE . . . . . 0.434 HG23 ' HZ2' ' A' ' 76' ' ' TRP . 19.9 mm -58.56 -58.26 7.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 115.995 -0.548 . . . . 0.0 110.239 179.366 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 198' ' ' VAL . . . . . . . . . . . . . 94.6 t -53.27 -34.52 22.39 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.416 0 CA-C-N 115.736 -0.665 . . . . 0.0 109.276 178.281 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 199' ' ' TYR . . . . . . . . . . . . . 65.4 t80 -69.7 -33.66 72.83 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 115.295 -0.866 . . . . 0.0 110.519 179.604 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 200' ' ' LEU . . . . . . . . . . . . . 40.7 mt -69.6 -39.62 77.14 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 115.855 -0.611 . . . . 0.0 111.019 -179.807 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 201' ' ' ASP . . . . . 0.455 ' HB3' ' NZ ' ' A' ' 205' ' ' LYS . 9.6 m-20 -72.86 -32.23 65.28 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.41 179.749 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 202' ' ' LEU . . . . . 0.466 ' O ' ' HB ' ' A' ' 206' ' ' VAL . 3.7 mt -73.04 -33.13 65.51 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 115.656 -0.702 . . . . 0.0 112.014 -179.376 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 203' ' ' VAL . . . . . 0.45 ' O ' ' HA3' ' A' ' 207' ' ' GLY . 7.8 p -77.9 -36.66 22.39 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-O 120.582 0.23 . . . . 0.0 111.432 -178.801 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 204' ' ' THR . . . . . . . . . . . . . 19.1 m -68.91 -53.62 20.06 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-O 120.877 0.37 . . . . 0.0 111.407 -179.956 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 205' ' ' LYS . . . . . 0.625 ' HE3' HG22 ' A' ' 43' ' ' ILE . 43.9 mttp -70.73 -58.68 3.39 Favored 'General case' 0 C--N 1.327 -0.405 0 N-CA-C 112.435 0.531 . . . . 0.0 112.435 -178.569 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 206' ' ' VAL . . . . . 0.466 ' HB ' ' O ' ' A' ' 202' ' ' LEU . 48.1 t -72.25 -37.43 58.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 N-CA-C 111.952 0.353 . . . . 0.0 111.952 -178.878 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 207' ' ' GLY . . . . . 0.514 ' O ' HG13 ' A' ' 211' ' ' ILE . . . -65.37 -59.88 7.32 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.442 -0.885 . . . . 0.0 112.516 -179.366 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 208' ' ' PHE . . . . . 0.482 ' O ' ' N ' ' A' ' 212' ' ' ALA . 2.1 m-30 -54.19 -45.17 72.1 Favored 'General case' 0 C--O 1.222 -0.388 0 N-CA-C 109.947 -0.39 . . . . 0.0 109.947 179.772 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 209' ' ' GLY . . . . . 0.498 ' HA2' ' HB3' ' A' ' 212' ' ' ALA . . . -59.07 -34.22 78.28 Favored Glycine 0 N--CA 1.448 -0.515 0 CA-C-N 115.376 -0.829 . . . . 0.0 112.821 179.43 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 210' ' ' PHE . . . . . . . . . . . . . 1.2 m-85 -70.26 -46.8 63.67 Favored 'General case' 0 CA--C 1.515 -0.369 0 N-CA-C 108.754 -0.832 . . . . 0.0 108.754 179.163 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 211' ' ' ILE . . . . . 0.514 HG13 ' O ' ' A' ' 207' ' ' GLY . 2.6 mt -67.4 -27.42 38.7 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.473 0 N-CA-C 107.416 -1.327 . . . . 0.0 107.416 176.846 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 212' ' ' ALA . . . . . 0.498 ' HB3' ' HA2' ' A' ' 209' ' ' GLY . . . -66.84 -40.09 87.83 Favored 'General case' 0 N--CA 1.449 -0.525 0 CA-C-N 114.32 -1.309 . . . . 0.0 110.214 -179.991 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 213' ' ' LEU . . . . . 0.467 ' HG ' ' O ' ' A' ' 209' ' ' GLY . 69.7 mt -70.68 -54.77 10.59 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 114.991 -1.004 . . . . 0.0 111.744 -179.555 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 214' ' ' ASP . . . . . . . . . . . . . 20.6 t70 -54.38 -47.19 72.95 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-O 120.758 0.313 . . . . 0.0 111.42 -179.464 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 215' ' ' ALA . . . . . . . . . . . . . . . -63.69 -56.17 17.8 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.309 -0.405 . . . . 0.0 111.171 -179.781 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 216' ' ' ALA . . . . . . . . . . . . . . . -56.24 -31.22 63.33 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.834 179.924 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 217' ' ' ALA . . . . . . . . . . . . . . . -65.97 -40.56 91.38 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 115.991 -0.549 . . . . 0.0 110.431 179.767 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 218' ' ' THR . . . . . . . . . . . . . 72.7 m -62.93 -36.88 84.86 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 115.957 -0.565 . . . . 0.0 110.437 179.41 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 219' ' ' LEU . . . . . . . . . . . . . 43.1 mt -69.93 -32.78 71.23 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 115.891 -0.595 . . . . 0.0 110.606 179.732 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 220' ' ' ARG . . . . . . . . . . . . . 91.4 mtm180 -83.29 -23.2 32.73 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 116.064 -0.517 . . . . 0.0 111.021 179.952 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 221' ' ' ALA . . . . . . . . . . . . . . . -82.33 -28.32 31.69 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.378 -0.374 . . . . 0.0 111.288 -179.791 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 222' ' ' GLU . . . . . . . . . . . . . 10.6 pt-20 -91.76 -30.74 16.08 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.296 179.998 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 223' ' ' HIS . . . . . . . . . . . . . 56.4 m-70 64.82 131.34 0.02 OUTLIER 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 115.525 -0.761 . . . . 0.0 111.215 -179.981 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 224' ' ' GLY . . . . . . . . . . . . . . . -99.81 10.93 60.81 Favored Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.804 -0.712 . . . . 0.0 112.283 179.827 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 225' ' ' GLU . . . . . . . . . . . . . 12.6 pt-20 -167.9 157.73 10.15 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-O 120.926 0.393 . . . . 0.0 111.051 -179.903 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 226' ' ' SER . . . . . . . . . . . . . 30.8 p -143.16 -30.02 0.52 Allowed 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 115.898 -0.592 . . . . 0.0 110.577 179.639 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 227' ' ' LEU . . . . . . . . . . . . . 2.3 pt? -60.53 152.05 26.98 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 115.949 -0.569 . . . . 0.0 110.72 179.684 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 228' ' ' ALA . . . . . . . . . . . . . . . -91.51 -45.89 8.27 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.348 -0.387 . . . . 0.0 110.974 179.812 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 229' ' ' GLY . . . . . . . . . . . . . . . -157.67 -122.56 0.71 Allowed Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.802 -0.713 . . . . 0.0 112.336 179.944 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 230' ' ' VAL . . . . . . . . . . . . . 46.8 t -128.15 140.25 49.69 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-O 120.749 0.309 . . . . 0.0 110.87 179.826 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 231' ' ' ASP . . . . . . . . . . . . . 4.0 p-10 -92.01 121.92 34.04 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.015 -179.846 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 232' ' ' THR . . . . . . . . . . . . . 9.5 t -110.1 8.52 23.93 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 115.974 -0.557 . . . . 0.0 110.896 -179.952 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 233' ' ' ASP . . . . . . . . . . . . . 24.1 t70 -79.1 -27.81 42.97 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.105 -0.498 . . . . 0.0 111.0 -179.931 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 234' ' ' THR . . . . . . . . . . . . . 8.1 t -72.69 141.5 82.46 Favored Pre-proline 0 C--N 1.329 -0.309 0 CA-C-N 116.321 -0.4 . . . . 0.0 111.029 -179.934 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 235' ' ' PRO . . . . . . . . . . . . . 70.3 Cg_endo -74.68 108.26 2.66 Favored 'Trans proline' 0 C--N 1.348 0.518 0 C-N-CA 122.324 2.016 . . . . 0.0 112.518 179.843 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 236' ' ' ALA . . . . . . . . . . . . . . . -107.75 113.08 26.08 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.09 -0.505 . . . . 0.0 110.831 179.771 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 237' ' ' VAL . . . . . . . . . . . . . 35.0 m -100.62 150.37 5.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.256 -0.429 . . . . 0.0 111.426 -179.698 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 238' ' ' ALA . . . . . . . . . . . . . . . 59.38 99.58 0.02 OUTLIER 'General case' 0 C--N 1.333 -0.138 0 CA-C-N 115.876 -0.602 . . . . 0.0 111.479 179.973 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 239' ' ' ASP . . . . . . . . . . . . . 10.7 m-20 -143.04 -3.55 0.96 Allowed 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.868 179.871 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 240' ' ' LEU . . . . . . . . . . . . . 84.5 mt -91.3 3.74 54.12 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 116.264 -0.425 . . . . 0.0 110.921 179.855 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 241' ' ' GLU . . . . . . . . . . . . . 15.4 mm-40 58.34 21.56 8.44 Favored 'General case' 0 C--N 1.332 -0.176 0 CA-C-N 116.038 -0.528 . . . . 0.0 111.263 179.826 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 242' ' ' HIS . . . . . . . . . . . . . 59.4 t60 -137.83 118.77 14.27 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.851 0.358 . . . . 0.0 111.018 -179.953 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 243' ' ' HIS . . . . . . . . . . . . . 32.6 t60 -80.38 125.16 29.57 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.705 179.89 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 244' ' ' HIS . . . . . . . . . . . . . 64.1 m-70 -87.11 120.63 28.58 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.888 -179.969 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 245' ' ' HIS . . . . . . . . . . . . . 76.7 t60 -92.64 -62.24 1.43 Allowed 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.296 -0.411 . . . . 0.0 110.923 179.978 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 246' ' ' HIS . . . . . . . . . . . . . 31.0 p80 -89.83 138.31 31.6 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.999 -179.972 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 247' ' ' HIS . . . . . . . . . . . . . 57.2 m-70 . . . . . 0 C--O 1.249 1.028 0 CA-C-O 118.274 -0.869 . . . . 0.0 110.729 179.815 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 301' ' ' RET . . . . . 0.695 H203 ' HE1' ' A' ' 171' ' ' TRP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 83.5 mtp . . . . . 0 N--CA 1.486 1.33 0 CA-C-O 120.842 0.353 . . . . 0.0 111.011 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 36.0 m -133.19 7.49 1.42 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.25 0 CA-C-N 116.071 -0.513 . . . . 0.0 111.049 179.941 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -104.84 -59.18 0.66 Allowed Glycine 0 C--N 1.331 0.286 0 C-N-CA 120.784 -0.722 . . . . 0.0 112.685 -179.897 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 96.6 mt -61.04 -35.44 76.91 Favored 'General case' 0 N--CA 1.448 -0.529 0 CA-C-O 120.758 0.313 . . . . 0.0 111.118 179.961 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 46.6 p -51.48 -36.92 46.52 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 116.013 -0.54 . . . . 0.0 111.68 -179.472 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 20.4 p -56.79 -38.94 73.23 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.209 -0.451 . . . . 0.0 111.576 -179.542 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 7' ' ' LEU . . . . . . . . . . . . . 3.9 mm? -61.81 -53.51 54.88 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.265 -0.425 . . . . 0.0 111.304 -179.716 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 8' ' ' PHE . . . . . 0.425 ' HB2' ' HB2' ' A' ' 55' ' ' ALA . 68.5 m-85 -55.43 -31.93 62.3 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.255 -0.429 . . . . 0.0 111.108 -179.607 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 9' ' ' TRP . . . . . 0.415 ' O ' HG12 ' A' ' 13' ' ' ILE . 21.7 m95 -66.01 -42.78 89.26 Favored 'General case' 0 C--N 1.326 -0.447 0 N-CA-C 109.695 -0.484 . . . . 0.0 109.695 179.694 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 84.6 mt -61.08 -38.97 88.14 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 115.62 -0.718 . . . . 0.0 110.238 179.223 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -65.84 -35.55 91.0 Favored Glycine 0 N--CA 1.449 -0.437 0 C-N-CA 120.85 -0.691 . . . . 0.0 111.865 179.349 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -65.6 -32.58 74.23 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-O 120.892 0.377 . . . . 0.0 110.672 179.585 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 13' ' ' ILE . . . . . 0.415 HG12 ' O ' ' A' ' 9' ' ' TRP . 50.5 mm -67.35 -51.03 56.94 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.245 0 CA-C-N 116.034 -0.53 . . . . 0.0 110.654 179.667 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -58.6 -31.6 67.45 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.141 179.669 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 15' ' ' MET . . . . . 0.567 ' HB3' ' HB2' ' A' ' 48' ' ' ALA . 23.9 mmt -69.89 -40.91 75.38 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-O 120.722 0.296 . . . . 0.0 110.64 179.661 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -57.47 -43.66 84.23 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.307 179.54 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 42.5 t -61.41 -49.83 82.86 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.214 0 CA-C-N 116.065 -0.516 . . . . 0.0 110.955 179.846 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -62.36 -48.27 83.59 Favored Glycine 0 C--N 1.331 0.285 0 C-N-CA 120.651 -0.785 . . . . 0.0 112.206 179.708 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 50.3 m -49.93 -41.13 45.55 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-O 120.67 0.271 . . . . 0.0 111.378 -179.754 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 52.3 mt -72.53 -46.06 56.35 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.329 -0.396 . . . . 0.0 111.41 179.903 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -60.59 -29.71 69.37 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.315 -0.402 . . . . 0.0 111.654 -179.604 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 22' ' ' PHE . . . . . 0.601 ' HB2' HG22 ' A' ' 41' ' ' VAL . 5.1 m-85 -91.23 -30.01 16.88 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.515 -0.311 . . . . 0.0 111.436 -179.56 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -72.66 -50.55 24.26 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-O 120.949 0.404 . . . . 0.0 110.997 -179.971 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 24' ' ' TRP . . . . . . . . . . . . . 2.8 t-105 -61.23 -39.49 90.48 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-N 115.737 -0.665 . . . . 0.0 110.501 179.806 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -80.69 -20.05 43.82 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.756 179.549 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -73.51 -46.85 23.87 Favored Glycine 0 C--N 1.331 0.271 0 C-N-CA 121.065 -0.588 . . . . 0.0 112.644 179.919 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 15.7 ptp180 -61.0 -20.16 62.15 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-O 120.804 0.335 . . . . 0.0 110.921 179.951 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 18.4 t70 -105.18 84.46 2.12 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.683 179.796 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -129.05 -175.15 3.47 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.032 -179.891 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -126.3 48.86 0.94 Allowed Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.701 -0.761 . . . . 0.0 112.671 -179.777 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 44.4 t 55.91 90.57 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.874 0.368 . . . . 0.0 111.171 179.871 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 137.68 -65.3 0.55 Allowed Glycine 0 N--CA 1.452 -0.257 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.6 179.684 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 22.8 mm-40 -61.31 -21.14 63.7 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.757 0.313 . . . . 0.0 111.007 -179.935 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 34' ' ' ARG . . . . . . . . . . . . . 48.6 ttp180 -51.17 -29.63 14.4 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 116.043 -0.526 . . . . 0.0 111.271 -179.959 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 35' ' ' ARG . . . . . 0.439 ' CZ ' HD22 ' A' ' 89' ' ' LEU . 51.8 ttp180 -59.47 -48.19 82.58 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.326 -0.397 . . . . 0.0 111.075 -179.994 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 53.5 m-85 -64.43 -34.61 78.59 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.984 -179.922 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 37' ' ' TYR . . . . . 0.468 ' O ' HG23 ' A' ' 41' ' ' VAL . 63.6 m-85 -66.84 -54.15 25.32 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 115.993 -0.549 . . . . 0.0 111.05 -179.762 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 77.7 t -56.98 -37.05 52.67 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.242 0 CA-C-O 120.889 0.376 . . . . 0.0 110.455 179.723 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 24.2 m -66.73 -40.24 88.27 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 121.355 0.598 . . . . 0.0 110.171 179.044 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 40' ' ' LEU . . . . . 0.503 HD11 ' HA2' ' A' ' 209' ' ' GLY . 12.7 tp -65.5 -41.87 92.75 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 115.258 -0.883 . . . . 0.0 110.372 179.757 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . 0.601 HG22 ' HB2' ' A' ' 22' ' ' PHE . 59.7 t -69.68 -34.17 59.85 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.426 0 CA-C-N 115.561 -0.745 . . . . 0.0 110.312 179.379 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . 0.463 ' O ' HG12 ' A' ' 46' ' ' ILE . . . -59.26 -46.57 93.63 Favored Glycine 0 N--CA 1.448 -0.541 0 C-N-CA 120.971 -0.633 . . . . 0.0 112.554 179.999 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 43' ' ' ILE . . . . . 0.554 HG23 HD23 ' A' ' 82' ' ' LEU . 10.2 pt -65.63 -51.57 61.21 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.157 0 N-CA-C 111.729 0.27 . . . . 0.0 111.729 -179.767 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 48.1 t -63.84 -24.19 67.65 Favored 'General case' 0 C--O 1.234 0.247 0 CA-C-O 120.924 0.392 . . . . 0.0 111.396 -179.762 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -78.14 -59.05 3.02 Favored Glycine 0 CA--C 1.518 0.22 0 C-N-CA 120.92 -0.657 . . . . 0.0 113.466 -178.856 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 46' ' ' ILE . . . . . 0.498 ' O ' HG22 ' A' ' 49' ' ' VAL . 17.7 pt -57.79 -35.29 50.62 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.207 0 CA-C-O 120.751 0.31 . . . . 0.0 110.957 -179.606 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 47' ' ' ALA . . . . . 0.682 ' HB2' ' HE2' ' A' ' 205' ' ' LYS . . . -67.62 -40.12 84.7 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-O 120.841 0.353 . . . . 0.0 110.085 178.559 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 48' ' ' ALA . . . . . 0.567 ' HB2' ' HB3' ' A' ' 15' ' ' MET . . . -54.48 -43.39 71.69 Favored 'General case' 0 C--N 1.334 -0.101 0 CA-C-N 115.987 -0.551 . . . . 0.0 111.291 179.801 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 49' ' ' VAL . . . . . 0.498 HG22 ' O ' ' A' ' 46' ' ' ILE . 21.4 m -75.62 -34.36 28.88 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.221 0 CA-C-N 116.463 -0.335 . . . . 0.0 111.452 -179.82 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -59.12 -45.5 90.75 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.824 0.345 . . . . 0.0 111.392 -179.849 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 57.6 m-85 -73.16 -40.15 65.08 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 115.919 -0.582 . . . . 0.0 111.257 -179.31 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -60.64 -47.03 88.04 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 115.886 -0.597 . . . . 0.0 111.318 -179.921 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 53' ' ' VAL . . . . . 0.469 HG13 ' O ' ' A' ' 49' ' ' VAL . 16.8 m -71.89 -43.14 69.07 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.243 0 CA-C-N 116.324 -0.398 . . . . 0.0 110.969 -179.876 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 54' ' ' MET . . . . . 0.429 ' N ' HG23 ' A' ' 53' ' ' VAL . 17.0 ttp -63.71 -29.49 70.71 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 121.085 0.469 . . . . 0.0 110.101 179.509 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 55' ' ' ALA . . . . . 0.425 ' HB2' ' HB2' ' A' ' 8' ' ' PHE . . . -63.84 -36.22 83.2 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 115.63 -0.714 . . . . 0.0 111.539 179.773 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 78.6 mt -80.99 13.15 2.85 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.475 -0.33 . . . . 0.0 111.427 -179.626 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 84.39 -2.21 88.09 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.638 -0.792 . . . . 0.0 112.87 179.712 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 55.0 t -68.83 141.69 17.14 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-O 120.732 0.301 . . . . 0.0 110.768 179.777 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 59' ' ' GLY . . . . . 0.623 ' HA3' ' HD3' ' A' ' 71' ' ' PRO . . . 86.18 -16.07 45.62 Favored Glycine 0 N--CA 1.45 -0.411 0 C-N-CA 120.595 -0.812 . . . . 0.0 112.275 -179.857 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 60' ' ' TRP . . . . . . . . . . . . . 13.7 m0 -66.88 92.94 0.24 Allowed 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 120.825 0.345 . . . . 0.0 110.602 179.665 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 7.1 p -96.23 123.25 55.57 Favored Pre-proline 0 C--N 1.328 -0.347 0 CA-C-N 116.303 -0.408 . . . . 0.0 111.211 -179.832 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 46.5 Cg_endo -68.41 141.03 49.89 Favored 'Trans proline' 0 C--N 1.35 0.649 0 C-N-CA 122.403 2.068 . . . . 0.0 112.231 179.93 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.411 HG21 ' HG3' ' A' ' 117' ' ' MET . 60.2 t -137.31 92.69 0.91 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.046 -0.525 . . . . 0.0 111.172 -179.789 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . 58.09 -88.93 0.02 OUTLIER 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 116.178 -0.465 . . . . 0.0 111.514 179.789 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 45.4 mt-10 -120.42 -17.98 8.01 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 116.486 -0.324 . . . . 0.0 110.856 179.973 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 66' ' ' ARG . . . . . . . . . . . . . 20.9 mmm180 -105.03 165.51 11.03 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 116.064 -0.516 . . . . 0.0 110.344 179.776 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 38.4 m -122.52 143.15 49.9 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-O 120.834 0.349 . . . . 0.0 111.201 -179.805 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 40.0 t -125.19 146.0 31.6 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.02 -0.537 . . . . 0.0 110.879 -179.991 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 69' ' ' PHE . . . . . . . . . . . . . 8.3 m-85 -109.31 114.32 27.9 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.371 -0.377 . . . . 0.0 110.161 179.837 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 70' ' ' VAL . . . . . 0.67 HG12 ' HD3' ' A' ' 71' ' ' PRO . 1.3 p -68.26 -35.64 7.58 Favored Pre-proline 0 CA--C 1.542 0.653 0 N-CA-C 112.945 0.72 . . . . 0.0 112.945 -179.34 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 71' ' ' PRO . . . . . 0.67 ' HD3' HG12 ' A' ' 70' ' ' VAL . 61.9 Cg_endo -71.16 -20.82 27.97 Favored 'Trans proline' 0 C--N 1.359 1.116 0 C-N-CA 121.822 1.681 . . . . 0.0 113.266 -179.352 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 66.7 ttt180 -74.23 -54.96 6.65 Favored 'General case' 0 C--N 1.329 -0.32 0 N-CA-C 112.019 0.377 . . . . 0.0 112.019 -178.993 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 73' ' ' TYR . . . . . 0.481 ' O ' HG13 ' A' ' 77' ' ' ILE . 65.9 m-85 -74.08 -32.84 63.42 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.533 -0.303 . . . . 0.0 111.526 -178.803 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 74' ' ' ILE . . . . . 0.467 ' O ' HD13 ' A' ' 74' ' ' ILE . 0.3 OUTLIER -70.23 -44.53 77.72 Favored 'Isoleucine or valine' 0 C--O 1.234 0.257 0 C-N-CA 120.615 -0.434 . . . . 0.0 110.18 179.486 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 75' ' ' ASP . . . . . 0.444 ' O ' HG23 ' A' ' 79' ' ' THR . 22.9 t70 -58.33 -35.89 72.58 Favored 'General case' 0 CA--C 1.52 -0.2 0 N-CA-C 109.094 -0.706 . . . . 0.0 109.094 178.959 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 76' ' ' TRP . . . . . 0.424 ' HA ' ' OG1' ' A' ' 79' ' ' THR . 44.7 m0 -64.95 -34.9 79.53 Favored 'General case' 0 C--N 1.332 -0.164 0 CA-C-N 115.769 -0.651 . . . . 0.0 110.228 178.801 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 77' ' ' ILE . . . . . 0.51 HG12 ' HB3' ' A' ' 109' ' ' MET . 98.0 mt -66.21 -30.42 49.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 115.981 -0.554 . . . . 0.0 110.745 179.561 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 82.0 mt -91.88 -17.89 24.58 Favored 'General case' 0 CA--C 1.532 0.257 0 N-CA-C 112.278 0.473 . . . . 0.0 112.278 179.644 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 79' ' ' THR . . . . . 0.444 HG23 ' O ' ' A' ' 75' ' ' ASP . 46.9 p -94.65 -51.65 4.64 Favored 'General case' 0 N--CA 1.465 0.319 0 N-CA-C 112.974 0.731 . . . . 0.0 112.974 -178.486 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 80' ' ' THR . . . . . 0.71 HG21 ' HE1' ' A' ' 109' ' ' MET . 27.5 m -50.25 -51.03 66.81 Favored Pre-proline 0 C--N 1.328 -0.354 0 N-CA-C 112.95 0.722 . . . . 0.0 112.95 -178.425 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 81' ' ' PRO . . . . . 0.531 ' HD2' ' N ' ' A' ' 80' ' ' THR . 19.4 Cg_endo -57.94 -23.57 60.44 Favored 'Trans proline' 0 C--N 1.352 0.732 0 C-N-CA 121.526 1.484 . . . . 0.0 111.703 -179.48 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 82' ' ' LEU . . . . . 0.554 HD23 HG23 ' A' ' 43' ' ' ILE . 3.5 mp -76.91 -38.36 53.63 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 115.923 -0.58 . . . . 0.0 110.704 179.834 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 49.9 mm -65.42 -53.44 39.82 Favored 'Isoleucine or valine' 0 C--O 1.234 0.267 0 CA-C-O 120.936 0.398 . . . . 0.0 110.221 179.371 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 26.8 m -60.68 -31.66 49.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.04 -0.527 . . . . 0.0 109.774 178.983 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 85' ' ' TYR . . . . . . . . . . . . . 87.7 t80 -67.81 -34.09 76.07 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-N 115.697 -0.683 . . . . 0.0 109.442 178.755 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 86' ' ' PHE . . . . . . . . . . . . . 1.8 t80 -58.95 -51.82 68.39 Favored 'General case' 0 C--O 1.233 0.225 0 CA-C-N 115.828 -0.624 . . . . 0.0 109.81 179.319 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 7.8 mp -63.87 -33.63 76.13 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 115.865 -0.607 . . . . 0.0 110.013 179.216 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -61.44 -28.34 69.35 Favored Glycine 0 N--CA 1.449 -0.454 0 C-N-CA 120.784 -0.722 . . . . 0.0 111.566 179.191 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 89' ' ' LEU . . . . . 0.439 HD22 ' CZ ' ' A' ' 35' ' ' ARG . 82.1 mt -79.04 -36.61 40.76 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.953 0.406 . . . . 0.0 110.165 179.325 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 97.0 mt -63.18 -37.67 88.13 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 115.821 -0.627 . . . . 0.0 111.017 179.802 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . 0.541 ' HB1' ' HB2' ' A' ' 148' ' ' SER . . . -87.22 -54.57 4.23 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.328 -179.837 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 103.33 70.6 0.84 Allowed Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.831 -0.699 . . . . 0.0 112.415 -179.775 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 93' ' ' LEU . . . . . 0.609 HD11 ' HG2' ' A' ' 145' ' ' MET . 7.5 mp -87.99 166.8 14.23 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.81 0.338 . . . . 0.0 111.047 -179.843 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 94' ' ' ASP . . . . . . . . . . . . . 7.9 m-20 -84.5 174.35 10.11 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.887 179.779 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 88.8 p -60.09 -35.72 75.82 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.308 -0.406 . . . . 0.0 111.004 -179.788 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 69.7 mtm180 -72.9 -48.79 34.2 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.148 -179.835 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 97' ' ' GLU . . . . . 0.593 ' HB3' HD23 ' A' ' 93' ' ' LEU . 37.5 mt-10 -56.16 -46.59 79.23 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.295 -0.412 . . . . 0.0 111.235 -179.73 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 98' ' ' PHE . . . . . 0.404 ' O ' HG12 ' A' ' 102' ' ' ILE . 6.5 m-85 -55.88 -50.59 70.23 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.366 -0.379 . . . . 0.0 111.07 -179.951 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -55.59 -34.28 60.14 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.858 -0.687 . . . . 0.0 112.637 -179.867 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 97.8 mt -66.82 -44.13 89.31 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.207 0 CA-C-O 120.773 0.32 . . . . 0.0 111.803 -179.748 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 25.0 t -68.59 -46.93 79.24 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.369 0 CA-C-N 116.263 -0.426 . . . . 0.0 111.936 -179.045 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 102' ' ' ILE . . . . . 0.404 HG12 ' O ' ' A' ' 98' ' ' PHE . 36.2 mm -63.64 -48.63 85.87 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 CA-C-N 116.283 -0.417 . . . . 0.0 111.922 -179.014 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 12.0 t -61.04 -37.2 81.75 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-O 120.761 0.315 . . . . 0.0 111.23 -179.528 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 104' ' ' LEU . . . . . 0.481 ' O ' HG23 ' A' ' 108' ' ' VAL . 10.1 tt -60.91 -42.93 99.01 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.411 179.721 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 105' ' ' ASN . . . . . 0.611 HD21 HD13 ' A' ' 137' ' ' LEU . 0.8 OUTLIER -67.68 -26.35 66.15 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.605 179.614 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 56.6 m -63.5 -53.57 49.98 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 115.941 -0.572 . . . . 0.0 111.149 179.82 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 7.8 p -63.93 -36.13 75.7 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.162 0 CA-C-N 116.336 -0.393 . . . . 0.0 111.127 179.919 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . 0.481 HG23 ' O ' ' A' ' 104' ' ' LEU . 79.6 t -63.3 -51.71 67.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-O 121.201 0.524 . . . . 0.0 110.604 179.44 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 109' ' ' MET . . . . . 0.71 ' HE1' HG21 ' A' ' 80' ' ' THR . 3.5 tpp -60.49 -33.73 73.02 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 115.67 -0.695 . . . . 0.0 110.422 179.759 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 20.8 tp -68.91 -33.52 73.88 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 115.9 -0.591 . . . . 0.0 110.166 179.693 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 111' ' ' ALA . . . . . 0.4 ' O ' HD13 ' A' ' 126' ' ' LEU . . . -59.7 -57.1 14.39 Favored 'General case' 0 C--N 1.332 -0.179 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.177 179.315 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 112' ' ' GLY . . . . . 0.697 ' HA3' ' H21' ' A' ' 301' ' ' RET . . . -57.31 -41.22 92.92 Favored Glycine 0 CA--C 1.518 0.233 0 C-N-CA 120.598 -0.81 . . . . 0.0 112.116 179.164 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 113' ' ' PHE . . . . . . . . . . . . . 1.5 t80 -47.16 -67.79 0.25 Allowed 'General case' 0 C--N 1.333 -0.137 0 CA-C-O 121.127 0.489 . . . . 0.0 110.081 179.473 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 114' ' ' ALA . . . . . 0.419 ' O ' HG13 ' A' ' 118' ' ' VAL . . . -64.43 -21.09 66.54 Favored 'General case' 0 C--N 1.326 -0.449 0 CA-C-N 115.512 -0.767 . . . . 0.0 110.864 179.661 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 115' ' ' GLY . . . . . 0.638 ' HA2' HD11 ' A' ' 126' ' ' LEU . . . -52.96 -49.38 55.37 Favored Glycine 0 C--N 1.333 0.375 0 C-N-CA 121.008 -0.615 . . . . 0.0 112.367 179.912 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -78.08 -15.79 58.59 Favored 'General case' 0 C--N 1.324 -0.506 0 N-CA-C 111.665 0.246 . . . . 0.0 111.665 179.742 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 117' ' ' MET . . . . . 0.411 ' HG3' HG21 ' A' ' 63' ' ' VAL . 36.1 ttm -100.94 19.89 16.49 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.497 -0.32 . . . . 0.0 111.674 -179.091 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 118' ' ' VAL . . . . . 0.444 HG21 ' HB3' ' A' ' 123' ' ' ARG . 28.3 m -74.11 147.5 85.84 Favored Pre-proline 0 C--N 1.328 -0.36 0 CA-C-N 116.559 -0.291 . . . . 0.0 111.305 179.789 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 119' ' ' PRO . . . . . . . . . . . . . 81.3 Cg_endo -88.94 -6.28 5.68 Favored 'Trans proline' 0 N--CA 1.457 -0.622 0 C-N-CA 122.688 2.259 . . . . 0.0 112.283 179.683 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -148.4 -114.69 0.78 Allowed Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.711 -0.757 . . . . 0.0 112.915 -179.783 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 44.7 pt -122.59 14.56 5.58 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 CA-C-O 120.802 0.334 . . . . 0.0 111.39 -179.51 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 36.9 mt-10 -63.4 -18.85 64.14 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.134 -179.999 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 123' ' ' ARG . . . . . 0.486 ' HA ' HD21 ' A' ' 126' ' ' LEU . 35.9 ptt180 -53.41 -32.42 49.56 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.106 -0.497 . . . . 0.0 111.925 -179.544 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 124' ' ' TYR . . . . . . . . . . . . . 91.5 m-85 -72.54 -31.41 65.27 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 116.476 -0.329 . . . . 0.0 111.466 -179.652 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 125' ' ' ALA . . . . . . . . . . . . . . . -74.51 -58.28 3.39 Favored 'General case' 0 C--O 1.237 0.44 0 CA-C-O 121.196 0.522 . . . . 0.0 111.573 -179.374 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 126' ' ' LEU . . . . . 0.638 HD11 ' HA2' ' A' ' 115' ' ' GLY . 0.7 OUTLIER -56.49 -37.24 70.1 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 115.701 -0.681 . . . . 0.0 110.511 179.789 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 127' ' ' PHE . . . . . 0.477 ' HE1' ' H42' ' A' ' 301' ' ' RET . 7.8 t80 -69.37 -42.6 74.99 Favored 'General case' 0 N--CA 1.453 -0.311 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.114 179.304 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 128' ' ' GLY . . . . . . . . . . . . . . . -48.09 -35.33 13.52 Favored Glycine 0 C--N 1.333 0.379 0 N-CA-C 110.673 -0.971 . . . . 0.0 110.673 178.746 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 129' ' ' MET . . . . . . . . . . . . . 0.2 OUTLIER -72.03 -43.67 64.63 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 115.154 -0.523 . . . . 0.0 109.877 178.619 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -67.25 -22.22 72.6 Favored Glycine 0 N--CA 1.449 -0.474 0 C-N-CA 120.869 -0.682 . . . . 0.0 112.378 179.602 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 131' ' ' ALA . . . . . 0.436 ' O ' ' HB3' ' A' ' 134' ' ' PHE . . . -74.61 -53.9 8.48 Favored 'General case' 0 CA--C 1.519 -0.234 0 CA-C-O 120.739 0.304 . . . . 0.0 110.211 179.681 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 58.1 t -58.32 -39.47 74.24 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.319 0 N-CA-C 108.535 -0.913 . . . . 0.0 108.535 178.096 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -62.77 -37.44 86.67 Favored 'General case' 0 N--CA 1.451 -0.378 0 CA-C-N 114.915 -1.039 . . . . 0.0 110.198 178.767 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 134' ' ' PHE . . . . . 0.436 ' HB3' ' O ' ' A' ' 131' ' ' ALA . 68.0 t80 -55.64 -50.09 71.11 Favored 'General case' 0 N--CA 1.453 -0.325 0 CA-C-N 116.159 -0.473 . . . . 0.0 109.88 179.364 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 135' ' ' ILE . . . . . 0.504 ' O ' HG22 ' A' ' 138' ' ' VAL . 59.0 mt -59.54 -32.45 49.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 115.667 -0.697 . . . . 0.0 110.14 179.228 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . -59.46 -41.76 97.25 Favored Glycine 0 N--CA 1.449 -0.494 0 C-N-CA 120.409 -0.901 . . . . 0.0 111.271 179.054 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 137' ' ' LEU . . . . . 0.611 HD13 HD21 ' A' ' 105' ' ' ASN . 42.7 tp -65.85 -55.61 16.17 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 120.666 0.27 . . . . 0.0 110.722 179.541 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 138' ' ' VAL . . . . . 0.637 ' HB ' HH22 ' A' ' 164' ' ' ARG . 2.5 m -54.79 -32.3 25.79 Favored 'Isoleucine or valine' 0 C--O 1.234 0.267 0 CA-C-O 121.125 0.488 . . . . 0.0 109.802 -179.506 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 139' ' ' TYR . . . . . . . . . . . . . 10.2 t80 -61.43 -42.31 98.54 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 115.654 -0.703 . . . . 0.0 109.964 178.293 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 28.1 m-85 -65.99 -42.37 89.89 Favored 'General case' 0 C--N 1.332 -0.184 0 CA-C-N 116.11 -0.496 . . . . 0.0 111.002 179.517 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 141' ' ' LEU . . . . . 0.435 ' HA ' ' SD ' ' A' ' 145' ' ' MET . 10.8 mp -56.62 -32.86 65.71 Favored 'General case' 0 N--CA 1.462 0.139 0 CA-C-N 116.356 -0.384 . . . . 0.0 110.883 -179.973 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 21.6 t -97.05 -12.75 8.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.82 179.662 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . -76.33 -123.83 0.19 Allowed Glycine 0 CA--C 1.522 0.529 0 C-N-CA 120.845 -0.693 . . . . 0.0 112.932 -179.721 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 144' ' ' PRO . . . . . . . . . . . . . 31.7 Cg_exo -58.87 -29.95 91.58 Favored 'Trans proline' 0 C--N 1.351 0.659 0 C-N-CA 122.596 2.198 . . . . 0.0 112.726 -179.672 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 145' ' ' MET . . . . . 0.609 ' HG2' HD11 ' A' ' 93' ' ' LEU . 60.1 mtt -58.7 -26.98 64.42 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.316 -0.402 . . . . 0.0 111.235 -179.893 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 146' ' ' THR . . . . . . . . . . . . . 24.0 m -81.08 -33.67 33.2 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-N 116.119 -0.491 . . . . 0.0 111.478 -179.058 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 15.0 tp10 -71.89 -43.43 65.41 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.98 -179.896 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 148' ' ' SER . . . . . 0.541 ' HB2' ' HB1' ' A' ' 91' ' ' ALA . 61.7 m -71.98 -40.15 68.79 Favored 'General case' 0 C--N 1.327 -0.405 0 N-CA-C 112.334 0.494 . . . . 0.0 112.334 -179.205 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 149' ' ' ALA . . . . . . . . . . . . . . . -76.68 -44.64 32.85 Favored 'General case' 0 C--N 1.33 -0.278 0 N-CA-C 113.395 0.887 . . . . 0.0 113.395 -177.974 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 150' ' ' SER . . . . . . . . . . . . . 54.2 m -69.12 -14.29 62.92 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.909 0.385 . . . . 0.0 110.85 -178.495 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 151' ' ' GLN . . . . . . . . . . . . . 3.0 mp0 -116.56 10.38 14.46 Favored 'General case' 0 C--N 1.324 -0.502 0 CA-C-N 115.928 -0.578 . . . . 0.0 111.494 -179.462 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 72.2 ttt180 -82.99 -51.94 7.12 Favored 'General case' 0 C--N 1.334 -0.102 0 CA-C-O 120.868 0.366 . . . . 0.0 110.943 -179.968 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 153' ' ' SER . . . . . 0.598 ' HB2' HG12 ' A' ' 156' ' ' ILE . 17.6 m -157.45 172.18 19.04 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 116.032 -0.531 . . . . 0.0 110.861 179.596 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 154' ' ' SER . . . . . . . . . . . . . 67.9 m -71.09 -37.3 72.41 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.687 179.636 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -76.82 -35.0 41.24 Favored Glycine 0 N--CA 1.452 -0.276 0 C-N-CA 120.887 -0.673 . . . . 0.0 112.568 179.908 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 156' ' ' ILE . . . . . 0.598 HG12 ' HB2' ' A' ' 153' ' ' SER . 41.4 mm -56.42 -37.72 52.51 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-O 120.887 0.375 . . . . 0.0 110.92 -179.972 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 157' ' ' LYS . . . . . . . . . . . . . 24.3 ttpp -60.98 -32.9 72.45 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.903 179.82 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 47.1 m -70.9 -45.23 64.7 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.073 -179.863 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 159' ' ' LEU . . . . . 0.487 HD22 HD21 ' A' ' 163' ' ' LEU . 11.2 mt -65.67 -36.12 82.76 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.338 -0.392 . . . . 0.0 111.07 179.931 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 160' ' ' TYR . . . . . 0.49 ' O ' ' HB3' ' A' ' 164' ' ' ARG . 57.3 t80 -65.57 -47.86 74.36 Favored 'General case' 0 C--N 1.329 -0.317 0 N-CA-C 112.206 0.447 . . . . 0.0 112.206 -178.952 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 161' ' ' VAL . . . . . 0.43 HG23 ' N ' ' A' ' 162' ' ' ARG . 17.3 m -62.17 -49.28 84.69 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 N-CA-C 112.304 0.483 . . . . 0.0 112.304 -178.608 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 162' ' ' ARG . . . . . 0.43 ' N ' HG23 ' A' ' 161' ' ' VAL . 81.9 mtt180 -68.46 -46.11 70.66 Favored 'General case' 0 C--N 1.329 -0.291 0 N-CA-C 112.076 0.398 . . . . 0.0 112.076 -179.044 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 163' ' ' LEU . . . . . 0.487 HD21 HD22 ' A' ' 159' ' ' LEU . 1.7 mp -67.67 -54.95 15.35 Favored 'General case' 0 C--N 1.328 -0.332 0 N-CA-C 112.243 0.46 . . . . 0.0 112.243 -178.62 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 164' ' ' ARG . . . . . 0.637 HH22 ' HB ' ' A' ' 138' ' ' VAL . 25.2 tpt180 -55.78 -54.89 38.91 Favored 'General case' 0 N--CA 1.465 0.292 0 N-CA-C 112.629 0.603 . . . . 0.0 112.629 -178.46 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 165' ' ' ASN . . . . . . . . . . . . . 13.8 m-80 -58.0 -49.25 77.5 Favored 'General case' 0 C--N 1.33 -0.255 0 N-CA-C 112.071 0.397 . . . . 0.0 112.071 -178.75 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 166' ' ' LEU . . . . . . . . . . . . . 4.4 tt -63.45 -55.37 24.73 Favored 'General case' 0 C--N 1.325 -0.47 0 N-CA-C 111.876 0.325 . . . . 0.0 111.876 -179.262 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 167' ' ' THR . . . . . . . . . . . . . 53.7 m -57.02 -52.92 63.34 Favored 'General case' 0 C--N 1.328 -0.368 0 N-CA-C 113.037 0.754 . . . . 0.0 113.037 -178.613 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 168' ' ' VAL . . . . . 0.451 HG12 ' O ' ' A' ' 164' ' ' ARG . 7.9 p -57.5 -41.22 78.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 N-CA-C 112.482 0.549 . . . . 0.0 112.482 -178.529 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 169' ' ' VAL . . . . . 0.463 ' CG1' ' N ' ' A' ' 170' ' ' LEU . 0.4 OUTLIER -63.72 -54.07 36.76 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.443 0 N-CA-C 111.867 0.321 . . . . 0.0 111.867 -178.76 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 170' ' ' LEU . . . . . 0.463 ' N ' ' CG1' ' A' ' 169' ' ' VAL . 3.0 pp -68.03 -31.12 70.57 Favored 'General case' 0 C--N 1.33 -0.268 0 C-N-CA 121.173 -0.211 . . . . 0.0 111.543 -178.562 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 171' ' ' TRP . . . . . 0.768 ' HE1' H203 ' A' ' 301' ' ' RET . 3.3 m0 -72.29 -28.59 63.19 Favored 'General case' 0 C--N 1.329 -0.295 0 N-CA-C 109.952 -0.388 . . . . 0.0 109.952 178.895 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 172' ' ' ALA . . . . . . . . . . . . . . . -76.0 -6.87 53.03 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-N 115.919 -0.582 . . . . 0.0 110.554 -179.821 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 173' ' ' ILE . . . . . 0.486 ' O ' HG12 ' A' ' 177' ' ' ILE . 34.1 mm -85.86 -21.12 7.75 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.204 0 CA-C-N 115.719 -0.673 . . . . 0.0 110.853 179.41 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 174' ' ' TYR . . . . . 0.417 ' HB2' ' HD3' ' A' ' 175' ' ' PRO . 11.8 m-85 -53.76 -50.22 84.83 Favored Pre-proline 0 CA--C 1.53 0.194 0 CA-C-N 116.313 -0.403 . . . . 0.0 111.799 -179.446 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 175' ' ' PRO . . . . . 0.417 ' HD3' ' HB2' ' A' ' 174' ' ' TYR . 74.5 Cg_exo -50.42 -29.9 25.5 Favored 'Trans proline' 0 C--N 1.349 0.572 0 C-N-CA 122.191 1.927 . . . . 0.0 112.517 179.84 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 176' ' ' PHE . . . . . 0.432 ' HD2' ' HA ' ' A' ' 173' ' ' ILE . 38.9 m-85 -80.44 -50.24 10.35 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.233 -0.44 . . . . 0.0 111.846 -179.707 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 177' ' ' ILE . . . . . 0.486 HG12 ' O ' ' A' ' 173' ' ' ILE . 5.7 mm -65.65 -33.54 64.29 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.519 0 N-CA-C 112.27 0.47 . . . . 0.0 112.27 -178.229 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 178' ' ' TRP . . . . . 0.442 ' HH2' ' HB2' ' A' ' 123' ' ' ARG . 88.7 t90 -72.86 -56.53 5.08 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.873 0.368 . . . . 0.0 110.807 -179.925 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 179' ' ' LEU . . . . . 0.416 HD23 HD23 ' A' ' 180' ' ' LEU . 0.6 OUTLIER -63.04 -54.23 41.33 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 115.931 -0.577 . . . . 0.0 111.324 -179.36 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 180' ' ' LEU . . . . . 0.54 HD22 HD11 ' A' ' 187' ' ' LEU . 43.3 mt -64.67 -41.41 96.1 Favored 'General case' 0 C--N 1.331 -0.213 0 C-N-CA 120.832 -0.347 . . . . 0.0 111.068 -179.607 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . -62.6 -178.79 3.98 Favored Glycine 0 C--N 1.334 0.43 0 C-N-CA 119.952 -1.118 . . . . 0.0 112.002 179.103 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 182' ' ' PRO . . . . . 0.577 ' HA ' ' HB2' ' A' ' 186' ' ' ALA . 83.2 Cg_exo -47.84 -44.8 26.17 Favored 'Trans proline' 0 CA--C 1.536 0.58 0 C-N-CA 122.741 2.294 . . . . 0.0 113.74 179.962 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 183' ' ' PRO . . . . . 0.411 ' HD3' ' HB2' ' A' ' 182' ' ' PRO . 84.1 Cg_exo -47.04 -22.51 2.15 Favored 'Trans proline' 0 C--N 1.356 0.933 0 C-N-CA 122.209 1.939 . . . . 0.0 113.286 -179.688 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 184' ' ' GLY . . . . . . . . . . . . . . . -126.12 -124.12 2.74 Favored Glycine 0 C--N 1.333 0.367 0 C-N-CA 120.305 -0.95 . . . . 0.0 112.926 179.874 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 185' ' ' VAL . . . . . 0.41 ' CG2' ' HA ' ' A' ' 180' ' ' LEU . 19.4 m -61.28 -25.31 36.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 N-CA-C 112.281 0.474 . . . . 0.0 112.281 -179.248 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 186' ' ' ALA . . . . . 0.577 ' HB2' ' HA ' ' A' ' 182' ' ' PRO . . . 57.65 85.41 0.09 Allowed 'General case' 0 N--CA 1.465 0.318 0 CA-C-O 120.832 0.348 . . . . 0.0 111.7 179.555 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 187' ' ' LEU . . . . . 0.54 HD11 HD22 ' A' ' 180' ' ' LEU . 10.7 mt -92.88 -49.27 6.13 Favored 'General case' 0 C--N 1.332 -0.184 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.359 179.911 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 188' ' ' LEU . . . . . . . . . . . . . 53.7 mt -95.47 -161.43 0.86 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 115.988 -0.551 . . . . 0.0 111.691 -179.052 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 189' ' ' THR . . . . . . . . . . . . . 9.9 m -91.5 137.06 26.09 Favored Pre-proline 0 C--N 1.33 -0.261 0 CA-C-N 115.77 -0.65 . . . . 0.0 110.682 -179.716 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 190' ' ' PRO . . . . . . . . . . . . . 96.4 Cg_exo -44.65 -46.01 12.76 Favored 'Trans proline' 0 C--N 1.35 0.655 0 C-N-CA 122.812 2.341 . . . . 0.0 113.539 -179.735 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 191' ' ' THR . . . . . . . . . . . . . 6.7 t -59.1 -36.83 75.8 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.822 0.344 . . . . 0.0 111.329 -179.764 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 192' ' ' VAL . . . . . . . . . . . . . 58.0 t -74.79 -53.63 16.19 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.22 -0.446 . . . . 0.0 111.696 -179.591 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 193' ' ' ASP . . . . . . . . . . . . . 23.9 m-20 -56.45 -48.36 77.22 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.45 -0.341 . . . . 0.0 110.973 -179.588 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 194' ' ' VAL . . . . . . . . . . . . . 78.0 t -61.92 -36.38 73.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.432 179.602 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 195' ' ' ALA . . . . . . . . . . . . . . . -56.28 -42.34 77.33 Favored 'General case' 0 C--N 1.331 -0.197 0 CA-C-N 116.344 -0.389 . . . . 0.0 110.823 179.335 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 196' ' ' LEU . . . . . . . . . . . . . 96.1 mt -67.19 -38.86 86.09 Favored 'General case' 0 C--N 1.332 -0.174 0 CA-C-O 120.952 0.406 . . . . 0.0 110.332 179.486 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 197' ' ' ILE . . . . . . . . . . . . . 21.6 mm -59.79 -52.6 59.19 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 115.937 -0.574 . . . . 0.0 110.18 179.153 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 198' ' ' VAL . . . . . . . . . . . . . 90.8 t -57.26 -34.15 45.17 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.458 0 N-CA-C 108.908 -0.775 . . . . 0.0 108.908 178.179 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 199' ' ' TYR . . . . . . . . . . . . . 46.0 t80 -69.44 -30.3 68.19 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-N 115.115 -0.948 . . . . 0.0 110.568 179.46 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 200' ' ' LEU . . . . . 0.467 ' O ' HG12 ' A' ' 203' ' ' VAL . 48.2 mt -70.25 -42.37 72.27 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 115.944 -0.571 . . . . 0.0 111.158 -179.854 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 201' ' ' ASP . . . . . . . . . . . . . 12.3 m-20 -73.3 -34.65 65.84 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-O 121.167 0.508 . . . . 0.0 110.15 179.378 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 202' ' ' LEU . . . . . . . . . . . . . 2.5 mt -70.78 -31.33 68.07 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 115.562 -0.745 . . . . 0.0 111.795 -179.799 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 203' ' ' VAL . . . . . 0.467 HG12 ' O ' ' A' ' 200' ' ' LEU . 11.9 p -77.18 -37.1 25.42 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.235 0 C-N-CA 120.946 -0.302 . . . . 0.0 111.209 -179.143 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 204' ' ' THR . . . . . . . . . . . . . 68.0 m -65.13 -57.49 8.44 Favored 'General case' 0 C--O 1.222 -0.392 0 C-N-CA 120.76 -0.376 . . . . 0.0 111.318 179.718 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 205' ' ' LYS . . . . . 0.682 ' HE2' ' HB2' ' A' ' 47' ' ' ALA . 60.6 mttp -65.13 -55.51 18.3 Favored 'General case' 0 C--N 1.326 -0.414 0 N-CA-C 112.301 0.482 . . . . 0.0 112.301 -178.716 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 59.2 t -65.31 -47.18 88.17 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 N-CA-C 111.841 0.312 . . . . 0.0 111.841 -179.606 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 207' ' ' GLY . . . . . . . . . . . . . . . -63.94 -59.62 8.34 Favored Glycine 0 C--N 1.331 0.28 0 C-N-CA 120.708 -0.758 . . . . 0.0 112.771 -179.795 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 208' ' ' PHE . . . . . 0.42 ' O ' ' N ' ' A' ' 212' ' ' ALA . 4.1 t80 -54.71 -40.74 69.52 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.672 0.272 . . . . 0.0 110.97 179.965 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 209' ' ' GLY . . . . . 0.503 ' HA2' HD11 ' A' ' 40' ' ' LEU . . . -69.78 -38.65 76.63 Favored Glycine 0 C--N 1.329 0.189 0 CA-C-N 115.877 -0.601 . . . . 0.0 113.356 -179.558 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 210' ' ' PHE . . . . . . . . . . . . . 1.4 m-85 -69.66 -39.95 76.75 Favored 'General case' 0 CA--C 1.51 -0.571 0 N-CA-C 107.649 -1.241 . . . . 0.0 107.649 179.118 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 211' ' ' ILE . . . . . . . . . . . . . 29.9 mt -69.73 -28.6 37.84 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.87 0 CA-C-N 114.235 -1.348 . . . . 0.0 107.416 176.737 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 212' ' ' ALA . . . . . 0.461 ' HB3' ' O ' ' A' ' 209' ' ' GLY . . . -68.08 -38.8 82.78 Favored 'General case' 0 N--CA 1.447 -0.59 0 CA-C-N 114.293 -1.321 . . . . 0.0 110.637 179.856 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 213' ' ' LEU . . . . . . . . . . . . . 96.4 mt -70.6 -53.09 17.3 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 115.257 -0.883 . . . . 0.0 112.043 -179.238 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 214' ' ' ASP . . . . . . . . . . . . . 45.0 m-20 -52.09 -53.06 47.11 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.443 -0.344 . . . . 0.0 111.636 -179.428 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 215' ' ' ALA . . . . . 0.421 ' HB3' HD21 ' A' ' 159' ' ' LEU . . . -59.68 -57.36 13.26 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.344 -0.389 . . . . 0.0 111.818 -179.511 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 216' ' ' ALA . . . . . . . . . . . . . . . -58.11 -31.73 67.43 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.441 -0.345 . . . . 0.0 111.601 -179.519 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 217' ' ' ALA . . . . . . . . . . . . . . . -62.24 -42.16 99.06 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 121.015 0.436 . . . . 0.0 110.151 179.832 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 218' ' ' THR . . . . . . . . . . . . . 97.2 m -67.44 -39.2 85.41 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 115.827 -0.624 . . . . 0.0 110.33 179.154 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 219' ' ' LEU . . . . . 0.491 ' O ' ' HG2' ' A' ' 222' ' ' GLU . 82.9 mt -58.77 -41.88 87.64 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 115.784 -0.644 . . . . 0.0 110.669 179.733 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 220' ' ' ARG . . . . . . . . . . . . . 36.0 ptt180 -83.96 -14.12 51.66 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.213 -0.448 . . . . 0.0 110.587 179.435 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 221' ' ' ALA . . . . . . . . . . . . . . . -82.55 -20.21 37.05 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.13 -0.486 . . . . 0.0 111.931 -179.57 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 222' ' ' GLU . . . . . 0.491 ' HG2' ' O ' ' A' ' 219' ' ' LEU . 11.4 pt-20 -67.17 -28.39 68.07 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-O 121.058 0.456 . . . . 0.0 110.352 -179.732 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 223' ' ' HIS . . . . . . . . . . . . . 84.2 m-70 -66.76 -24.82 66.26 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 115.68 -0.691 . . . . 0.0 110.908 -179.924 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 224' ' ' GLY . . . . . . . . . . . . . . . 73.04 -124.78 9.28 Favored Glycine 0 N--CA 1.452 -0.235 0 C-N-CA 120.85 -0.69 . . . . 0.0 112.458 179.91 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 225' ' ' GLU . . . . . . . . . . . . . 8.9 tp10 -163.95 148.81 10.42 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.83 0.348 . . . . 0.0 110.912 179.977 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 226' ' ' SER . . . . . . . . . . . . . 50.5 m -109.15 -32.17 7.32 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.889 179.966 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 227' ' ' LEU . . . . . . . . . . . . . 53.5 tp -61.36 143.2 56.19 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.067 -0.515 . . . . 0.0 110.884 179.903 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 228' ' ' ALA . . . . . . . . . . . . . . . -88.11 135.98 33.18 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.964 179.858 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 229' ' ' GLY . . . . . . . . . . . . . . . 139.21 138.68 3.69 Favored Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.807 -0.711 . . . . 0.0 112.302 -179.738 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 230' ' ' VAL . . . . . . . . . . . . . 5.6 m -119.8 29.74 2.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-O 120.874 0.369 . . . . 0.0 111.364 -179.911 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 231' ' ' ASP . . . . . . . . . . . . . 5.7 m-20 49.0 67.96 0.79 Allowed 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 115.695 -0.684 . . . . 0.0 110.832 -179.846 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 232' ' ' THR . . . . . . . . . . . . . 38.6 p -139.12 -65.46 0.48 Allowed 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.273 -0.422 . . . . 0.0 111.429 -179.538 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 233' ' ' ASP . . . . . . . . . . . . . 17.1 m-20 -88.79 -78.35 0.34 Allowed 'General case' 0 C--N 1.33 -0.239 0 CA-C-N 116.33 -0.396 . . . . 0.0 111.242 -179.631 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 234' ' ' THR . . . . . . . . . . . . . 81.9 p -140.87 146.07 42.36 Favored Pre-proline 0 C--N 1.33 -0.275 0 CA-C-N 116.363 -0.38 . . . . 0.0 111.021 -179.797 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 235' ' ' PRO . . . . . . . . . . . . . 58.5 Cg_endo -71.94 153.1 58.16 Favored 'Trans proline' 0 C--N 1.348 0.544 0 C-N-CA 122.298 1.998 . . . . 0.0 112.096 179.801 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 236' ' ' ALA . . . . . 0.546 ' O ' HG12 ' A' ' 237' ' ' VAL . . . 63.16 109.81 0.03 OUTLIER 'General case' 0 C--N 1.333 -0.139 0 CA-C-N 116.095 -0.502 . . . . 0.0 111.211 -179.893 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 237' ' ' VAL . . . . . 0.563 HG22 ' H ' ' A' ' 238' ' ' ALA . 0.5 OUTLIER 52.23 176.94 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.466 0.328 0 CA-C-N 115.882 -0.599 . . . . 0.0 111.606 -179.905 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 238' ' ' ALA . . . . . 0.563 ' H ' HG22 ' A' ' 237' ' ' VAL . . . -149.32 0.2 0.5 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.349 -0.387 . . . . 0.0 111.135 179.903 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 239' ' ' ASP . . . . . . . . . . . . . 7.8 m-20 59.89 98.1 0.03 OUTLIER 'General case' 0 C--N 1.332 -0.185 0 CA-C-N 116.019 -0.537 . . . . 0.0 111.411 179.78 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 240' ' ' LEU . . . . . . . . . . . . . 7.5 mp -111.96 104.74 13.03 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.08 -0.509 . . . . 0.0 110.692 179.717 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 241' ' ' GLU . . . . . . . . . . . . . 2.2 mp0 -96.38 0.73 50.99 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 116.293 -0.412 . . . . 0.0 110.921 179.986 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 242' ' ' HIS . . . . . . . . . . . . . 14.6 t-80 -88.37 118.85 28.28 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.299 -0.41 . . . . 0.0 110.855 179.936 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 243' ' ' HIS . . . . . . . . . . . . . 18.4 p-80 -85.71 171.17 11.83 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.041 -179.982 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 244' ' ' HIS . . . . . . . . . . . . . 56.1 t-80 -138.52 97.15 3.29 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 115.977 -0.556 . . . . 0.0 110.812 179.997 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 245' ' ' HIS . . . . . . . . . . . . . 58.8 m-70 60.05 106.0 0.02 OUTLIER 'General case' 0 C--N 1.331 -0.218 0 CA-C-N 116.115 -0.493 . . . . 0.0 111.32 -179.942 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 246' ' ' HIS . . . . . . . . . . . . . 12.4 p-80 -106.68 -14.19 15.08 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.067 -0.515 . . . . 0.0 110.8 179.771 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 247' ' ' HIS . . . . . . . . . . . . . 82.0 m-70 . . . . . 0 C--O 1.248 1.006 0 CA-C-O 118.218 -0.896 . . . . 0.0 110.946 -179.942 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 301' ' ' RET . . . . . 0.768 H203 ' HE1' ' A' ' 171' ' ' TRP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 59.9 ttp . . . . . 0 N--CA 1.486 1.348 0 CA-C-O 120.678 0.275 . . . . 0.0 110.865 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 42.1 t 62.47 103.77 0.04 OUTLIER 'Isoleucine or valine' 0 C--N 1.332 -0.195 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.332 179.807 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . 145.07 -37.72 1.31 Allowed Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.846 -0.692 . . . . 0.0 112.384 179.976 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 59.4 tp -74.42 -35.52 63.41 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 120.844 0.355 . . . . 0.0 111.101 179.886 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 65.2 p -62.64 -30.06 71.09 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.517 -179.626 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 36.1 p -55.11 -35.46 64.68 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.44 -0.345 . . . . 0.0 111.118 -179.92 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 7' ' ' LEU . . . . . . . . . . . . . 4.2 mm? -56.65 -53.26 59.77 Favored 'General case' 0 C--N 1.331 -0.205 0 CA-C-N 116.082 -0.508 . . . . 0.0 111.052 -179.974 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 8' ' ' PHE . . . . . 0.708 ' HB2' ' HB2' ' A' ' 55' ' ' ALA . 67.9 m-85 -60.96 -36.41 79.32 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.873 -179.958 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 9' ' ' TRP . . . . . . . . . . . . . 30.4 m95 -61.4 -44.16 97.63 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.047 -179.876 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 51.8 mt -60.94 -42.65 98.59 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 115.638 -0.71 . . . . 0.0 110.239 179.246 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -62.09 -29.94 74.22 Favored Glycine 0 N--CA 1.448 -0.549 0 C-N-CA 120.69 -0.766 . . . . 0.0 111.888 179.259 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -72.58 -33.51 66.8 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-O 120.698 0.285 . . . . 0.0 110.968 179.719 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 13' ' ' ILE . . . . . 0.434 ' O ' HG23 ' A' ' 17' ' ' VAL . 83.3 mt -64.16 -54.32 32.7 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.226 0 CA-C-N 116.343 -0.39 . . . . 0.0 110.749 179.758 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -66.02 -34.15 87.59 Favored Glycine 0 N--CA 1.452 -0.291 0 C-N-CA 120.685 -0.769 . . . . 0.0 112.227 179.833 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 15' ' ' MET . . . . . 0.534 ' SD ' ' HA ' ' A' ' 44' ' ' SER . 52.7 tpp -65.69 -49.79 67.27 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.733 0.301 . . . . 0.0 110.646 179.986 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 51.0 mt -53.42 -42.23 66.84 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.506 179.382 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . 0.434 HG23 ' O ' ' A' ' 13' ' ' ILE . 99.5 t -58.89 -41.46 82.98 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.226 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.125 179.128 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -64.76 -40.49 97.43 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.606 -0.806 . . . . 0.0 111.49 179.029 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 3.6 m -50.97 -54.17 26.69 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.883 0.373 . . . . 0.0 111.102 179.917 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 75.2 mt -71.74 -39.72 69.88 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.061 -0.518 . . . . 0.0 111.454 -179.887 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 21' ' ' ALA . . . . . 0.567 ' O ' ' HB2' ' A' ' 25' ' ' ALA . . . -54.71 -43.88 72.95 Favored 'General case' 0 C--N 1.329 -0.316 0 N-CA-C 112.381 0.512 . . . . 0.0 112.381 -178.953 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 4.3 m-85 -84.36 -28.24 27.14 Favored 'General case' 0 C--N 1.329 -0.315 0 N-CA-C 111.889 0.329 . . . . 0.0 111.889 -178.969 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -64.98 -51.48 61.48 Favored 'General case' 0 C--N 1.326 -0.442 0 N-CA-C 112.59 0.589 . . . . 0.0 112.59 -178.965 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 24' ' ' TRP . . . . . 0.504 ' CE3' ' HA ' ' A' ' 24' ' ' TRP . 2.3 t-105 -87.1 -26.75 23.5 Favored 'General case' 0 N--CA 1.442 -0.827 0 N-CA-C 113.383 0.882 . . . . 0.0 113.383 -177.497 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 25' ' ' ALA . . . . . 0.567 ' HB2' ' O ' ' A' ' 21' ' ' ALA . . . -47.28 -48.25 24.91 Favored 'General case' 0 C--N 1.318 -0.778 0 C-N-CA 120.636 -0.426 . . . . 0.0 109.947 178.896 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -70.34 -23.85 77.12 Favored Glycine 0 N--CA 1.449 -0.454 0 N-CA-C 109.427 -1.469 . . . . 0.0 109.427 177.478 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 27' ' ' ARG . . . . . 0.491 ' HG3' ' O ' ' A' ' 24' ' ' TRP . 16.0 mtm180 59.37 73.41 0.48 Allowed 'General case' 0 CA--C 1.512 -0.505 0 CA-C-N 114.384 -0.908 . . . . 0.0 111.859 178.63 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 28' ' ' ASP . . . . . 0.401 ' HB3' ' O ' ' A' ' 27' ' ' ARG . 4.4 t70 65.52 -71.34 0.08 Allowed 'General case' 0 N--CA 1.453 -0.319 0 CA-C-N 115.406 -0.815 . . . . 0.0 111.53 178.721 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . 64.41 -176.24 0.17 Allowed 'General case' 0 C--N 1.333 -0.133 0 CA-C-O 120.93 0.395 . . . . 0.0 111.317 179.234 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -82.9 -99.55 0.51 Allowed Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.809 -0.71 . . . . 0.0 112.768 -179.779 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 61.6 m -149.45 -27.57 0.27 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.646 0.26 . . . . 0.0 111.123 -179.653 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -63.98 -32.81 85.42 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.683 -0.77 . . . . 0.0 112.445 -179.988 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 9.0 mm-40 -89.27 -20.59 23.91 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.776 0.322 . . . . 0.0 110.872 -179.957 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 34' ' ' ARG . . . . . . . . . . . . . 92.8 mtt180 -56.35 -28.7 59.86 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.129 -0.487 . . . . 0.0 111.385 -179.815 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 99.2 mtt180 -54.96 -56.46 19.44 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-O 120.863 0.363 . . . . 0.0 111.286 -179.807 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 76.1 m-85 -71.29 -40.16 71.06 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.944 -179.052 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 37' ' ' TYR . . . . . . . . . . . . . 20.7 m-85 -65.52 -56.3 13.12 Favored 'General case' 0 C--N 1.329 -0.305 0 N-CA-C 111.707 0.262 . . . . 0.0 111.707 -179.08 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 89.3 t -57.08 -37.17 53.9 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.326 0 CA-C-O 120.724 0.297 . . . . 0.0 110.935 179.981 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 15.2 m -64.36 -51.55 62.73 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 121.037 0.446 . . . . 0.0 110.748 179.33 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 40' ' ' LEU . . . . . 0.477 HD12 HD12 ' A' ' 43' ' ' ILE . 61.1 tp -59.22 -50.83 72.5 Favored 'General case' 0 C--O 1.235 0.306 0 CA-C-N 115.877 -0.601 . . . . 0.0 110.641 179.913 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 96.4 t -59.78 -34.4 55.54 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 115.974 -0.557 . . . . 0.0 109.62 178.902 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -57.22 -39.28 89.82 Favored Glycine 0 N--CA 1.447 -0.603 0 CA-C-N 115.644 -0.707 . . . . 0.0 111.767 179.407 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 43' ' ' ILE . . . . . 0.498 HG22 ' HE3' ' A' ' 205' ' ' LYS . 1.0 OUTLIER -65.65 -53.12 42.48 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.205 0 CA-C-O 120.832 0.348 . . . . 0.0 110.128 179.306 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 44' ' ' SER . . . . . 0.534 ' HA ' ' SD ' ' A' ' 15' ' ' MET . 83.0 p -61.86 -21.2 64.47 Favored 'General case' 0 C--N 1.333 -0.146 0 CA-C-N 116.104 -0.498 . . . . 0.0 111.12 179.985 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -76.25 -59.23 3.4 Favored Glycine 0 N--CA 1.452 -0.265 0 C-N-CA 120.726 -0.75 . . . . 0.0 112.662 -179.737 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 20.7 pt -61.0 -35.68 66.96 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-O 120.724 0.297 . . . . 0.0 111.425 -179.79 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 47' ' ' ALA . . . . . 0.64 ' HB2' ' HE2' ' A' ' 205' ' ' LYS . . . -67.06 -43.87 81.56 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.843 0.354 . . . . 0.0 111.065 179.478 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -54.78 -49.33 71.16 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.094 -0.503 . . . . 0.0 111.359 -179.749 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 26.9 m -67.75 -34.14 65.96 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.328 -0.396 . . . . 0.0 111.09 -179.718 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -62.75 -38.65 91.41 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-O 121.12 0.486 . . . . 0.0 110.657 179.576 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 51' ' ' TYR . . . . . 0.451 ' OH ' ' HB2' ' A' ' 201' ' ' ASP . 30.6 m-85 -72.93 -31.42 64.6 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-N 115.763 -0.653 . . . . 0.0 110.169 179.852 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -70.04 -42.52 72.8 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-N 115.749 -0.659 . . . . 0.0 111.091 179.609 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 53' ' ' VAL . . . . . 0.448 HG23 ' N ' ' A' ' 54' ' ' MET . 32.9 m -69.43 -45.5 78.48 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.197 0 CA-C-N 116.548 -0.296 . . . . 0.0 110.985 -179.848 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 54' ' ' MET . . . . . 0.448 ' N ' HG23 ' A' ' 53' ' ' VAL . 76.7 mtm -64.66 -31.06 72.12 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-O 121.034 0.445 . . . . 0.0 110.094 179.319 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 55' ' ' ALA . . . . . 0.708 ' HB2' ' HB2' ' A' ' 8' ' ' PHE . . . -74.46 -15.35 60.9 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 115.672 -0.694 . . . . 0.0 111.403 179.637 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 69.6 mt -92.1 -13.36 30.92 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.458 -0.337 . . . . 0.0 111.492 -179.697 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 104.2 -20.92 39.07 Favored Glycine 0 N--CA 1.452 -0.263 0 C-N-CA 120.52 -0.848 . . . . 0.0 113.112 179.8 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 58' ' ' VAL . . . . . 0.436 HG12 ' O ' ' A' ' 53' ' ' VAL . 11.7 p -67.08 149.61 11.52 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-N 116.861 0.331 . . . . 0.0 110.623 179.989 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 88.09 -14.47 58.92 Favored Glycine 0 N--CA 1.449 -0.471 0 C-N-CA 120.663 -0.779 . . . . 0.0 111.774 -179.155 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 60' ' ' TRP . . . . . . . . . . . . . 18.2 m0 -76.02 97.77 4.12 Favored 'General case' 0 C--N 1.331 -0.197 0 CA-C-O 120.836 0.35 . . . . 0.0 110.673 179.917 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 61' ' ' VAL . . . . . 0.511 HG13 HG23 ' A' ' 68' ' ' VAL . 5.2 p -100.32 129.26 28.41 Favored Pre-proline 0 C--N 1.328 -0.327 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.81 179.766 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 73.5 Cg_endo -73.97 146.22 36.91 Favored 'Trans proline' 0 C--N 1.35 0.619 0 C-N-CA 122.478 2.118 . . . . 0.0 112.245 -179.826 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 92.1 t -140.37 95.35 0.78 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.181 -179.67 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . 57.94 -91.42 0.03 OUTLIER 'General case' 0 C--N 1.331 -0.212 0 CA-C-N 116.123 -0.489 . . . . 0.0 111.27 -179.969 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -122.57 -11.78 8.22 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-O 120.968 0.413 . . . . 0.0 110.702 179.715 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 66' ' ' ARG . . . . . 0.451 HH22 HH12 ' A' ' 123' ' ' ARG . 16.9 ptp180 -105.52 165.6 11.03 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 115.9 -0.591 . . . . 0.0 110.364 179.454 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 61.5 m -126.33 141.51 51.88 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 120.965 0.412 . . . . 0.0 111.357 -179.842 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 68' ' ' VAL . . . . . 0.513 HG21 ' HG3' ' A' ' 117' ' ' MET . 9.1 m -133.25 146.18 32.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 115.942 -0.572 . . . . 0.0 110.669 179.575 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 69' ' ' PHE . . . . . . . . . . . . . 5.8 m-85 -107.59 118.31 36.4 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-O 121.049 0.452 . . . . 0.0 110.389 -179.056 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 70' ' ' VAL . . . . . 0.634 HG12 ' HD3' ' A' ' 71' ' ' PRO . 1.3 p -67.1 -35.32 8.63 Favored Pre-proline 0 CA--C 1.54 0.583 0 CA-C-N 115.687 -0.688 . . . . 0.0 112.829 -178.978 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 71' ' ' PRO . . . . . 0.634 ' HD3' HG12 ' A' ' 70' ' ' VAL . 8.7 Cg_exo -70.38 -18.65 33.94 Favored 'Trans proline' 0 C--N 1.356 0.948 0 C-N-CA 121.902 1.734 . . . . 0.0 112.66 -179.37 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 46.8 ttp180 -75.16 -54.3 7.36 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.55 -0.295 . . . . 0.0 111.791 -178.948 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 73' ' ' TYR . . . . . 0.414 ' O ' HG13 ' A' ' 77' ' ' ILE . 18.4 m-85 -67.66 -37.1 81.9 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.755 0.312 . . . . 0.0 110.491 -179.569 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 0.4 OUTLIER -68.39 -38.37 79.25 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.219 0 CA-C-N 116.293 -0.412 . . . . 0.0 110.139 179.526 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 19.5 t70 -59.65 -36.97 77.45 Favored 'General case' 0 CA--C 1.52 -0.199 0 N-CA-C 109.712 -0.477 . . . . 0.0 109.712 179.08 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 76' ' ' TRP . . . . . . . . . . . . . 46.0 m0 -65.03 -41.67 95.07 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 115.781 -0.645 . . . . 0.0 110.081 179.427 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 77' ' ' ILE . . . . . 0.414 HG13 ' O ' ' A' ' 73' ' ' TYR . 66.7 mt -61.79 -28.64 44.62 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.425 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.902 179.544 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 29.8 mt -90.74 -27.98 18.59 Favored 'General case' 0 CA--C 1.531 0.232 0 N-CA-C 112.481 0.549 . . . . 0.0 112.481 -179.376 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 64.6 p -91.28 -43.44 9.8 Favored 'General case' 0 C--N 1.329 -0.322 0 N-CA-C 113.002 0.741 . . . . 0.0 113.002 -178.022 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 80' ' ' THR . . . . . 0.566 ' N ' ' HD2' ' A' ' 81' ' ' PRO . 38.9 p -52.33 -45.01 94.96 Favored Pre-proline 0 C--N 1.328 -0.356 0 N-CA-C 113.072 0.767 . . . . 0.0 113.072 -179.044 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 81' ' ' PRO . . . . . 0.566 ' HD2' ' N ' ' A' ' 80' ' ' THR . 35.8 Cg_endo -62.99 -23.03 74.11 Favored 'Trans proline' 0 C--N 1.354 0.847 0 C-N-CA 121.406 1.404 . . . . 0.0 111.776 -179.78 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 82' ' ' LEU . . . . . 0.443 HD23 HG12 ' A' ' 43' ' ' ILE . 7.5 mp -76.82 -43.03 38.09 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 115.779 -0.646 . . . . 0.0 111.365 -179.494 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 83' ' ' ILE . . . . . 0.415 HD13 HD13 ' A' ' 43' ' ' ILE . 39.8 mm -63.29 -53.85 40.51 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.413 -0.358 . . . . 0.0 110.955 -179.851 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 33.5 m -60.05 -36.95 70.63 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.222 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.467 179.668 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 85' ' ' TYR . . . . . . . . . . . . . 69.8 t80 -63.48 -32.85 74.42 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.098 -0.501 . . . . 0.0 109.809 179.246 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 86' ' ' PHE . . . . . . . . . . . . . 6.0 t80 -61.64 -51.91 66.54 Favored 'General case' 0 C--O 1.233 0.193 0 CA-C-N 115.973 -0.558 . . . . 0.0 109.963 179.34 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 8.5 mp -61.06 -31.85 71.5 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 115.859 -0.61 . . . . 0.0 110.169 179.199 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -71.13 -27.87 71.2 Favored Glycine 0 N--CA 1.45 -0.392 0 C-N-CA 120.871 -0.68 . . . . 0.0 111.787 179.321 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 71.1 mt -73.13 -34.82 66.34 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-O 120.972 0.415 . . . . 0.0 110.38 179.517 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 74.8 mt -66.47 -35.66 80.82 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 115.761 -0.654 . . . . 0.0 111.303 -179.984 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -87.93 -32.33 18.96 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.589 -179.472 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 82.83 55.14 3.04 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.675 -0.774 . . . . 0.0 112.195 -179.72 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 33.8 mt -69.44 167.24 17.04 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.899 0.381 . . . . 0.0 111.128 -179.815 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 94' ' ' ASP . . . . . . . . . . . . . 18.4 t70 -86.15 168.29 14.14 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 115.987 -0.551 . . . . 0.0 110.361 179.683 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 80.8 p -57.62 -33.13 67.93 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.439 -0.346 . . . . 0.0 110.974 179.972 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 98.2 mtt180 -73.82 -53.47 10.18 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.208 179.944 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 44.0 mt-10 -53.76 -42.14 67.9 Favored 'General case' 0 C--N 1.332 -0.175 0 CA-C-N 116.362 -0.381 . . . . 0.0 110.914 -179.892 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 98' ' ' PHE . . . . . 0.423 ' O ' HG12 ' A' ' 102' ' ' ILE . 9.0 m-85 -59.91 -46.86 88.0 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.77 179.668 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -58.82 -29.59 64.87 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.816 -0.707 . . . . 0.0 112.56 -179.922 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 95.1 mt -73.51 -42.36 56.11 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.243 0 CA-C-O 120.872 0.368 . . . . 0.0 111.436 -179.847 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 42.1 t -68.61 -43.89 83.08 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.365 0 CA-C-N 116.329 -0.396 . . . . 0.0 111.208 -179.815 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 102' ' ' ILE . . . . . 0.423 HG12 ' O ' ' A' ' 98' ' ' PHE . 42.2 mm -68.53 -46.36 80.32 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.355 0 CA-C-N 116.086 -0.506 . . . . 0.0 111.688 -179.338 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 14.6 t -58.44 -35.85 72.75 Favored 'General case' 0 C--O 1.232 0.161 0 CA-C-O 120.778 0.323 . . . . 0.0 110.673 179.945 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 104' ' ' LEU . . . . . 0.443 HD22 ' HE2' ' A' ' 140' ' ' TYR . 30.1 tp -62.84 -45.99 90.03 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.036 179.124 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 105' ' ' ASN . . . . . 0.408 ' N ' HD22 ' A' ' 105' ' ' ASN . 0.9 OUTLIER -62.58 -25.75 68.24 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 115.978 -0.555 . . . . 0.0 110.712 179.354 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 24.6 m -68.57 -52.1 35.47 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.371 -0.377 . . . . 0.0 111.491 -179.803 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 10.9 p -70.24 -40.57 78.16 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.212 0 CA-C-N 116.429 -0.35 . . . . 0.0 111.888 -179.428 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . 0.57 ' HA ' ' HE1' ' A' ' 129' ' ' MET . 73.1 t -62.66 -58.46 7.48 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.254 0 CA-C-O 120.977 0.418 . . . . 0.0 111.458 -179.74 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 109' ' ' MET . . . . . 0.578 ' N ' ' SD ' ' A' ' 109' ' ' MET . 0.0 OUTLIER -58.39 -32.46 68.62 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 115.957 -0.565 . . . . 0.0 110.827 -179.396 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 28.4 tp -67.69 -35.29 78.54 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.296 -0.411 . . . . 0.0 110.089 179.292 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 111' ' ' ALA . . . . . 0.403 ' O ' ' HB3' ' A' ' 126' ' ' LEU . . . -60.88 -49.11 78.8 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-N 115.989 -0.551 . . . . 0.0 110.167 179.155 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 112' ' ' GLY . . . . . 0.502 ' HA3' ' H21' ' A' ' 301' ' ' RET . . . -59.82 -33.83 79.95 Favored Glycine 0 N--CA 1.45 -0.43 0 C-N-CA 120.574 -0.822 . . . . 0.0 111.716 179.271 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 113' ' ' PHE . . . . . 0.407 ' HD2' HD11 ' A' ' 77' ' ' ILE . 0.3 OUTLIER -54.71 -65.04 0.65 Allowed 'General case' 0 C--N 1.332 -0.191 0 CA-C-O 121.052 0.454 . . . . 0.0 110.226 179.326 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 114' ' ' ALA . . . . . 0.495 ' O ' HG13 ' A' ' 118' ' ' VAL . . . -66.43 -30.53 70.91 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 115.609 -0.723 . . . . 0.0 111.575 -179.64 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 115' ' ' GLY . . . . . 0.401 ' O ' HG22 ' A' ' 118' ' ' VAL . . . -52.12 -51.08 43.04 Favored Glycine 0 C--N 1.332 0.358 0 C-N-CA 121.059 -0.591 . . . . 0.0 112.988 -179.644 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 116' ' ' ALA . . . . . 0.497 ' HB2' ' HB3' ' A' ' 183' ' ' PRO . . . -78.09 -15.45 58.87 Favored 'General case' 0 C--N 1.327 -0.405 0 N-CA-C 111.829 0.307 . . . . 0.0 111.829 -179.558 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 117' ' ' MET . . . . . 0.513 ' HG3' HG21 ' A' ' 68' ' ' VAL . 35.5 ttm -106.23 17.0 24.12 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.79 0.328 . . . . 0.0 111.277 -179.425 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 118' ' ' VAL . . . . . 0.532 HG11 ' N ' ' A' ' 123' ' ' ARG . 15.9 m -63.81 148.57 94.46 Favored Pre-proline 0 C--N 1.331 -0.239 0 CA-C-N 116.414 -0.357 . . . . 0.0 111.413 179.847 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 119' ' ' PRO . . . . . . . . . . . . . 88.7 Cg_endo -82.66 -1.64 10.64 Favored 'Trans proline' 0 C--N 1.347 0.461 0 C-N-CA 122.605 2.204 . . . . 0.0 112.273 179.58 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -157.6 -121.18 0.65 Allowed Glycine 0 C--N 1.33 0.246 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.522 -179.994 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 1.9 pp -106.69 12.93 8.43 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.207 0 CA-C-O 120.866 0.365 . . . . 0.0 111.291 -179.932 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 41.9 mt-10 -59.97 -17.49 38.47 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.012 -0.54 . . . . 0.0 111.293 179.929 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 123' ' ' ARG . . . . . 0.532 ' N ' HG11 ' A' ' 118' ' ' VAL . 27.6 ptt180 -50.37 -29.66 10.52 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-N 116.118 -0.492 . . . . 0.0 111.853 -179.757 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 124' ' ' TYR . . . . . . . . . . . . . 28.9 m-85 -67.64 -33.03 74.14 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.771 0.319 . . . . 0.0 111.201 -179.783 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 125' ' ' ALA . . . . . . . . . . . . . . . -72.38 -48.54 40.84 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.254 -0.43 . . . . 0.0 111.426 -179.982 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 126' ' ' LEU . . . . . 0.417 HD13 ' HA ' ' A' ' 126' ' ' LEU . 3.3 mm? -54.6 -55.58 27.9 Favored 'General case' 0 C--N 1.331 -0.206 0 CA-C-N 116.351 -0.386 . . . . 0.0 110.987 -179.673 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 127' ' ' PHE . . . . . 0.438 ' HZ ' ' HB3' ' A' ' 175' ' ' PRO . 6.7 t80 -64.97 -39.2 93.12 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.185 -0.462 . . . . 0.0 111.456 -179.304 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 128' ' ' GLY . . . . . . . . . . . . . . . -46.44 -45.72 16.83 Favored Glycine 0 C--O 1.237 0.322 0 C-N-CA 120.228 -0.987 . . . . 0.0 111.261 179.531 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 129' ' ' MET . . . . . 0.57 ' HE1' ' HA ' ' A' ' 108' ' ' VAL . 0.3 OUTLIER -68.87 -40.18 79.41 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 115.348 -0.426 . . . . 0.0 109.907 178.986 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -68.56 -21.13 74.43 Favored Glycine 0 N--CA 1.449 -0.464 0 CA-C-N 115.701 -0.682 . . . . 0.0 112.486 179.972 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 131' ' ' ALA . . . . . 0.445 ' O ' ' HB3' ' A' ' 134' ' ' PHE . . . -75.5 -54.16 7.47 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-O 120.621 0.248 . . . . 0.0 110.596 179.886 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 46.5 t -62.94 -40.46 89.02 Favored 'Isoleucine or valine' 0 C--O 1.234 0.249 0 N-CA-C 108.839 -0.8 . . . . 0.0 108.839 178.417 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -66.82 -32.04 73.06 Favored 'General case' 0 N--CA 1.452 -0.352 0 CA-C-N 115.124 -0.943 . . . . 0.0 110.184 178.828 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 134' ' ' PHE . . . . . 0.445 ' HB3' ' O ' ' A' ' 131' ' ' ALA . 38.5 t80 -56.78 -55.61 32.14 Favored 'General case' 0 N--CA 1.452 -0.353 0 N-CA-C 109.738 -0.467 . . . . 0.0 109.738 179.402 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 135' ' ' ILE . . . . . 0.53 ' O ' HG22 ' A' ' 138' ' ' VAL . 47.9 mt -56.8 -32.71 39.19 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.407 0 CA-C-N 115.583 -0.735 . . . . 0.0 109.979 179.409 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . -59.92 -37.81 93.17 Favored Glycine 0 N--CA 1.448 -0.522 0 C-N-CA 120.113 -1.041 . . . . 0.0 110.94 178.567 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 137' ' ' LEU . . . . . . . . . . . . . 46.6 tp -71.12 -50.26 35.47 Favored 'General case' 0 N--CA 1.454 -0.247 0 CA-C-N 115.719 -0.241 . . . . 0.0 110.611 179.499 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 138' ' ' VAL . . . . . 0.649 ' HA ' HD12 ' A' ' 141' ' ' LEU . 3.7 m -57.8 -30.62 38.21 Favored 'Isoleucine or valine' 0 CA--C 1.521 -0.164 0 N-CA-C 109.23 -0.656 . . . . 0.0 109.23 179.138 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 139' ' ' TYR . . . . . . . . . . . . . 39.3 t80 -63.52 -39.8 95.37 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 115.246 -0.888 . . . . 0.0 109.173 178.205 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 140' ' ' TYR . . . . . 0.443 ' HE2' HD22 ' A' ' 104' ' ' LEU . 22.3 m-85 -65.28 -31.97 73.38 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 115.733 -0.667 . . . . 0.0 110.256 178.617 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 141' ' ' LEU . . . . . 0.649 HD12 ' HA ' ' A' ' 138' ' ' VAL . 56.8 mt -65.06 -36.71 85.22 Favored 'General case' 0 CA--C 1.519 -0.222 0 CA-C-O 121.35 0.595 . . . . 0.0 109.591 179.973 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 16.6 m -98.0 0.08 10.44 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.822 0 CA-C-N 115.112 -0.949 . . . . 0.0 111.081 -179.866 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . -81.82 -135.35 1.97 Allowed Glycine 0 CA--C 1.521 0.447 0 C-N-CA 121.035 -0.603 . . . . 0.0 113.058 -179.486 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 144' ' ' PRO . . . . . . . . . . . . . 18.3 Cg_endo -58.32 -24.85 70.06 Favored 'Trans proline' 0 C--N 1.349 0.599 0 C-N-CA 122.726 2.284 . . . . 0.0 112.527 -179.664 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 145' ' ' MET . . . . . . . . . . . . . 62.0 mtt -59.96 -25.91 65.59 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 121.14 0.495 . . . . 0.0 110.798 179.788 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 146' ' ' THR . . . . . . . . . . . . . 17.5 m -73.79 -51.2 17.2 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 115.636 -0.711 . . . . 0.0 112.364 -178.802 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 45.7 mt-10 -75.85 -28.76 58.32 Favored 'General case' 0 C--N 1.328 -0.327 0 N-CA-C 111.856 0.317 . . . . 0.0 111.856 -178.845 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 148' ' ' SER . . . . . . . . . . . . . 37.1 t -70.66 -48.09 56.64 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-O 120.746 0.307 . . . . 0.0 111.607 -179.103 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 149' ' ' ALA . . . . . . . . . . . . . . . -74.7 -44.74 48.55 Favored 'General case' 0 C--N 1.329 -0.324 0 N-CA-C 111.994 0.368 . . . . 0.0 111.994 -179.068 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 150' ' ' SER . . . . . . . . . . . . . 87.7 p -63.65 -11.83 28.73 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.647 0.261 . . . . 0.0 111.273 -179.629 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 151' ' ' GLN . . . . . . . . . . . . . 25.5 mt-30 -124.37 21.75 8.62 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.333 -0.394 . . . . 0.0 111.248 -179.702 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 28.9 tpt180 -92.02 -51.43 5.2 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.916 0.389 . . . . 0.0 110.418 179.659 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 153' ' ' SER . . . . . 0.681 ' HB3' HG12 ' A' ' 156' ' ' ILE . 32.4 t -157.43 167.76 29.29 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.09 -0.505 . . . . 0.0 110.71 179.092 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 154' ' ' SER . . . . . . . . . . . . . 44.8 t -67.65 -36.3 80.5 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-O 120.968 0.413 . . . . 0.0 110.608 179.476 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -76.97 -36.84 34.71 Favored Glycine 0 N--CA 1.451 -0.361 0 C-N-CA 120.97 -0.633 . . . . 0.0 112.887 -179.912 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 156' ' ' ILE . . . . . 0.681 HG12 ' HB3' ' A' ' 153' ' ' SER . 39.7 mm -52.83 -36.24 23.1 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.21 0 CA-C-O 120.722 0.296 . . . . 0.0 111.315 -179.922 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 157' ' ' LYS . . . . . . . . . . . . . 85.3 tttt -54.38 -49.14 70.54 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.75 -179.611 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 42.8 t -63.97 -48.43 76.47 Favored 'General case' 0 C--N 1.33 -0.245 0 N-CA-C 111.891 0.33 . . . . 0.0 111.891 -179.189 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 159' ' ' LEU . . . . . 0.526 HD23 ' O ' ' A' ' 159' ' ' LEU . 2.8 tt -67.36 -28.56 68.06 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-O 120.943 0.401 . . . . 0.0 110.673 -179.622 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 160' ' ' TYR . . . . . . . . . . . . . 25.3 t80 -73.57 -47.72 38.38 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.87 -179.245 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 31.0 m -62.46 -42.72 96.8 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.391 0 N-CA-C 112.414 0.524 . . . . 0.0 112.414 -178.565 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 162' ' ' ARG . . . . . 0.449 ' O ' HD12 ' A' ' 166' ' ' LEU . 22.3 mmm180 -68.6 -49.81 56.43 Favored 'General case' 0 C--N 1.328 -0.362 0 N-CA-C 111.746 0.276 . . . . 0.0 111.746 -178.747 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 163' ' ' LEU . . . . . 0.402 HD22 ' CD2' ' A' ' 159' ' ' LEU . 7.6 mp -70.2 -39.15 75.36 Favored 'General case' 0 C--N 1.328 -0.335 0 N-CA-C 112.195 0.443 . . . . 0.0 112.195 -178.722 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 164' ' ' ARG . . . . . 0.46 ' NH1' ' HA ' ' A' ' 141' ' ' LEU . 21.9 tpp180 -58.37 -54.37 47.75 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 120.751 0.31 . . . . 0.0 110.786 -179.783 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 165' ' ' ASN . . . . . 0.54 HD22 ' N ' ' A' ' 165' ' ' ASN . 0.8 OUTLIER -57.06 -37.82 72.36 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.005 -0.543 . . . . 0.0 110.18 179.812 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 166' ' ' LEU . . . . . 0.449 HD12 ' O ' ' A' ' 162' ' ' ARG . 3.6 mt -61.24 -56.3 22.22 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 115.914 -0.585 . . . . 0.0 111.562 179.877 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 167' ' ' THR . . . . . 0.508 ' HA ' HD11 ' A' ' 170' ' ' LEU . 16.7 m -54.31 -54.42 40.49 Favored 'General case' 0 C--N 1.331 -0.202 0 N-CA-C 112.198 0.444 . . . . 0.0 112.198 -177.981 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 168' ' ' VAL . . . . . 0.568 HG22 HD13 ' A' ' 141' ' ' LEU . 42.1 t -52.64 -41.75 38.66 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.603 0 N-CA-C 112.594 0.59 . . . . 0.0 112.594 -179.3 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 169' ' ' VAL . . . . . 0.517 ' O ' HG12 ' A' ' 173' ' ' ILE . 74.7 t -71.21 -68.08 0.42 Allowed 'Isoleucine or valine' 0 CA--C 1.531 0.245 0 N-CA-C 113.988 1.107 . . . . 0.0 113.988 -177.446 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 170' ' ' LEU . . . . . 0.508 HD11 ' HA ' ' A' ' 167' ' ' THR . 0.3 OUTLIER -57.61 -36.47 71.81 Favored 'General case' 0 N--CA 1.467 0.39 0 N-CA-C 112.835 0.68 . . . . 0.0 112.835 -177.382 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 171' ' ' TRP . . . . . 0.482 ' HB2' ' O ' ' A' ' 167' ' ' THR . 7.9 m0 -70.97 -34.21 71.19 Favored 'General case' 0 C--N 1.329 -0.321 0 C-N-CA 120.477 -0.489 . . . . 0.0 111.356 -179.785 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 172' ' ' ALA . . . . . 0.42 ' HA ' ' CZ ' ' A' ' 134' ' ' PHE . . . -72.4 -7.08 47.84 Favored 'General case' 0 C--N 1.332 -0.182 0 C-N-CA 120.797 -0.361 . . . . 0.0 110.862 179.848 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 173' ' ' ILE . . . . . 0.518 HG22 HD11 ' A' ' 177' ' ' ILE . 50.8 mm -87.59 -25.75 5.98 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.23 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.795 179.607 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 174' ' ' TYR . . . . . 0.42 ' HB2' ' HD3' ' A' ' 175' ' ' PRO . 38.8 m-85 -55.0 -49.02 94.5 Favored Pre-proline 0 CA--C 1.531 0.216 0 CA-C-N 116.253 -0.431 . . . . 0.0 111.684 -179.741 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 175' ' ' PRO . . . . . 0.438 ' HB3' ' HZ ' ' A' ' 127' ' ' PHE . 79.9 Cg_exo -45.8 -30.94 7.2 Favored 'Trans proline' 0 C--N 1.352 0.739 0 C-N-CA 122.169 1.913 . . . . 0.0 111.954 179.422 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 176' ' ' PHE . . . . . 0.481 ' O ' ' HG ' ' A' ' 180' ' ' LEU . 86.3 m-85 -80.08 -49.16 12.14 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 115.81 -0.632 . . . . 0.0 111.388 179.83 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 177' ' ' ILE . . . . . 0.518 HD11 HG22 ' A' ' 173' ' ' ILE . 3.8 mm -60.16 -36.94 71.23 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.551 0 N-CA-C 112.307 0.484 . . . . 0.0 112.307 -178.49 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 178' ' ' TRP . . . . . . . . . . . . . 76.5 t90 -73.35 -44.45 58.74 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.942 0.401 . . . . 0.0 110.619 -179.87 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 179' ' ' LEU . . . . . 0.488 ' O ' HG22 ' A' ' 185' ' ' VAL . 1.4 tm? -67.51 -54.3 21.27 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 115.952 -0.567 . . . . 0.0 111.155 -179.48 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 180' ' ' LEU . . . . . 0.645 HD22 HD11 ' A' ' 187' ' ' LEU . 16.5 mt -68.42 -50.3 53.78 Favored 'General case' 0 C--N 1.328 -0.327 0 N-CA-C 111.992 0.367 . . . . 0.0 111.992 -179.021 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . -54.62 176.35 0.44 Allowed Glycine 0 C--N 1.337 0.602 0 C-N-CA 120.219 -0.991 . . . . 0.0 112.861 -179.948 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 182' ' ' PRO . . . . . 0.492 ' HA ' ' HB2' ' A' ' 186' ' ' ALA . 83.8 Cg_exo -45.3 -44.77 15.88 Favored 'Trans proline' 0 C--N 1.349 0.583 0 C-N-CA 122.92 2.413 . . . . 0.0 113.599 179.692 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 183' ' ' PRO . . . . . 0.497 ' HB3' ' HB2' ' A' ' 116' ' ' ALA . 88.7 Cg_exo -46.38 -23.42 2.08 Favored 'Trans proline' 0 C--N 1.356 0.944 0 C-N-CA 122.277 1.985 . . . . 0.0 113.122 179.815 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 184' ' ' GLY . . . . . . . . . . . . . . . -123.53 -127.07 3.19 Favored Glycine 0 C--N 1.331 0.298 0 C-N-CA 120.554 -0.831 . . . . 0.0 112.797 -179.901 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 185' ' ' VAL . . . . . 0.488 HG22 ' O ' ' A' ' 179' ' ' LEU . 16.5 m -60.05 -19.9 18.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 N-CA-C 111.992 0.368 . . . . 0.0 111.992 -179.541 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 186' ' ' ALA . . . . . 0.492 ' HB2' ' HA ' ' A' ' 182' ' ' PRO . . . 57.51 87.18 0.07 Allowed 'General case' 0 C--N 1.331 -0.2 0 CA-C-O 120.712 0.291 . . . . 0.0 111.4 179.863 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 187' ' ' LEU . . . . . 0.645 HD11 HD22 ' A' ' 180' ' ' LEU . 21.2 mt -91.95 -49.59 6.15 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.299 -0.41 . . . . 0.0 111.079 -179.821 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 188' ' ' LEU . . . . . . . . . . . . . 90.5 mt -103.52 -161.65 0.85 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 115.961 -0.563 . . . . 0.0 110.983 -179.82 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 189' ' ' THR . . . . . . . . . . . . . 1.6 t -92.44 147.04 33.6 Favored Pre-proline 0 C--N 1.329 -0.298 0 CA-C-N 116.079 -0.509 . . . . 0.0 111.061 -179.83 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 190' ' ' PRO . . . . . . . . . . . . . 9.2 Cg_endo -52.58 -33.15 57.16 Favored 'Trans proline' 0 C--N 1.349 0.579 0 C-N-CA 122.772 2.315 . . . . 0.0 112.422 -179.949 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 191' ' ' THR . . . . . . . . . . . . . 80.6 p -62.73 -43.73 98.06 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.34 -0.391 . . . . 0.0 111.033 179.882 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 192' ' ' VAL . . . . . . . . . . . . . 30.3 t -71.51 -46.62 62.55 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 115.94 -0.573 . . . . 0.0 111.118 -179.857 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 193' ' ' ASP . . . . . . . . . . . . . 34.3 t70 -56.78 -51.59 68.35 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.398 -0.365 . . . . 0.0 111.139 -179.749 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 194' ' ' VAL . . . . . . . . . . . . . 76.3 t -61.06 -36.56 73.31 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.391 -0.368 . . . . 0.0 110.988 179.818 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 195' ' ' ALA . . . . . . . . . . . . . . . -56.01 -48.15 76.47 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.493 -0.321 . . . . 0.0 111.168 179.89 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 196' ' ' LEU . . . . . . . . . . . . . 72.1 mt -67.38 -41.39 85.1 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.421 -0.354 . . . . 0.0 110.713 179.83 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 197' ' ' ILE . . . . . . . . . . . . . 17.2 mm -57.13 -56.08 16.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.473 179.407 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 198' ' ' VAL . . . . . . . . . . . . . 71.5 t -52.9 -35.03 21.25 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.417 0 CA-C-N 115.509 -0.769 . . . . 0.0 109.471 178.612 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 199' ' ' TYR . . . . . . . . . . . . . 53.3 t80 -70.54 -36.31 73.62 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 115.333 -0.849 . . . . 0.0 110.594 179.661 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 200' ' ' LEU . . . . . . . . . . . . . 73.0 mt -64.44 -38.74 92.1 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 115.658 -0.701 . . . . 0.0 111.343 -179.63 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 201' ' ' ASP . . . . . 0.451 ' HB2' ' OH ' ' A' ' 51' ' ' TYR . 0.8 OUTLIER -73.6 -32.32 64.04 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-O 121.04 0.447 . . . . 0.0 110.39 179.663 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 202' ' ' LEU . . . . . 0.424 ' O ' ' HB ' ' A' ' 206' ' ' VAL . 3.7 mt -71.64 -32.52 68.02 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 115.831 -0.622 . . . . 0.0 111.92 -179.649 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 203' ' ' VAL . . . . . 0.474 ' O ' ' HA3' ' A' ' 207' ' ' GLY . 7.4 p -78.83 -37.02 19.7 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-O 120.639 0.257 . . . . 0.0 111.375 -178.927 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 204' ' ' THR . . . . . 0.402 HG21 ' HE1' ' A' ' 171' ' ' TRP . 26.2 m -72.87 -49.99 26.56 Favored 'General case' 0 C--N 1.326 -0.448 0 C-N-CA 120.728 -0.389 . . . . 0.0 111.31 179.696 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 205' ' ' LYS . . . . . 0.64 ' HE2' ' HB2' ' A' ' 47' ' ' ALA . 54.5 mttp -69.98 -59.26 3.03 Favored 'General case' 0 C--N 1.326 -0.421 0 N-CA-C 112.165 0.431 . . . . 0.0 112.165 -178.8 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 206' ' ' VAL . . . . . 0.424 ' HB ' ' O ' ' A' ' 202' ' ' LEU . 48.6 t -74.69 -37.61 43.34 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.25 0 N-CA-C 111.964 0.357 . . . . 0.0 111.964 -178.727 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 207' ' ' GLY . . . . . 0.566 ' O ' HD12 ' A' ' 211' ' ' ILE . . . -62.86 -56.63 19.88 Favored Glycine 0 N--CA 1.45 -0.379 0 C-N-CA 120.258 -0.972 . . . . 0.0 112.01 -179.405 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 208' ' ' PHE . . . . . 0.513 ' O ' ' N ' ' A' ' 212' ' ' ALA . 3.1 m-85 -53.95 -47.75 70.98 Favored 'General case' 0 C--O 1.22 -0.469 0 N-CA-C 109.896 -0.409 . . . . 0.0 109.896 179.606 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 209' ' ' GLY . . . . . 0.492 ' O ' ' HG ' ' A' ' 213' ' ' LEU . . . -53.9 -35.21 52.9 Favored Glycine 0 N--CA 1.45 -0.374 0 CA-C-N 115.091 -0.959 . . . . 0.0 113.399 179.585 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 210' ' ' PHE . . . . . . . . . . . . . 5.2 m-85 -72.46 -47.23 50.52 Favored 'General case' 0 CA--C 1.512 -0.498 0 N-CA-C 108.716 -0.846 . . . . 0.0 108.716 179.801 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 211' ' ' ILE . . . . . 0.566 HD12 ' O ' ' A' ' 207' ' ' GLY . 3.6 mt -65.05 -26.93 41.11 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.65 0 N-CA-C 107.665 -1.235 . . . . 0.0 107.665 176.444 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 212' ' ' ALA . . . . . 0.513 ' N ' ' O ' ' A' ' 208' ' ' PHE . . . -68.44 -38.66 81.37 Favored 'General case' 0 N--CA 1.45 -0.466 0 CA-C-N 114.3 -1.318 . . . . 0.0 110.422 -179.869 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 213' ' ' LEU . . . . . 0.492 ' HG ' ' O ' ' A' ' 209' ' ' GLY . 47.2 mt -69.82 -54.31 14.16 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-N 115.301 -0.863 . . . . 0.0 111.636 -179.498 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 214' ' ' ASP . . . . . . . . . . . . . 14.6 m-20 -52.21 -54.66 28.2 Favored 'General case' 0 C--O 1.234 0.26 0 CA-C-N 116.389 -0.369 . . . . 0.0 111.326 -179.514 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 215' ' ' ALA . . . . . . . . . . . . . . . -57.48 -54.87 41.92 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.357 -0.383 . . . . 0.0 111.036 179.984 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 216' ' ' ALA . . . . . . . . . . . . . . . -57.52 -30.73 65.39 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.28 179.925 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 217' ' ' ALA . . . . . . . . . . . . . . . -64.02 -38.34 90.73 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.557 -179.918 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 218' ' ' THR . . . . . . . . . . . . . 69.7 m -72.75 -49.09 33.16 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 115.82 -0.627 . . . . 0.0 111.247 179.855 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 219' ' ' LEU . . . . . . . . . . . . . 25.4 mt -56.82 -29.07 62.41 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.955 -179.784 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 220' ' ' ARG . . . . . . . . . . . . . 79.3 ttt180 -83.82 -36.22 23.65 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.059 -0.518 . . . . 0.0 110.978 179.904 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 221' ' ' ALA . . . . . . . . . . . . . . . -62.76 -27.08 69.04 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.278 -0.419 . . . . 0.0 111.41 -179.837 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 222' ' ' GLU . . . . . 0.6 ' HG3' ' H ' ' A' ' 224' ' ' GLY . 11.0 pt-20 -92.0 -21.97 20.24 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 121.04 0.447 . . . . 0.0 110.398 -179.947 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 223' ' ' HIS . . . . . . . . . . . . . 65.7 m-70 59.21 19.06 7.1 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 115.649 -0.705 . . . . 0.0 111.245 179.551 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 224' ' ' GLY . . . . . 0.6 ' H ' ' HG3' ' A' ' 222' ' ' GLU . . . 88.58 45.41 4.93 Favored Glycine 0 N--CA 1.452 -0.272 0 C-N-CA 120.716 -0.754 . . . . 0.0 112.319 -179.929 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 225' ' ' GLU . . . . . . . . . . . . . 8.8 tp10 -121.82 144.91 48.55 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-O 120.827 0.346 . . . . 0.0 110.936 -179.957 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 226' ' ' SER . . . . . . . . . . . . . 31.6 t -136.89 -63.42 0.61 Allowed 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.287 -0.415 . . . . 0.0 111.154 -179.753 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 227' ' ' LEU . . . . . 0.51 ' HG ' ' H ' ' A' ' 229' ' ' GLY . 44.2 tp -103.98 119.79 39.67 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.266 -0.424 . . . . 0.0 111.077 -179.737 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 228' ' ' ALA . . . . . . . . . . . . . . . -92.02 3.97 54.08 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.021 179.815 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 229' ' ' GLY . . . . . 0.51 ' H ' ' HG ' ' A' ' 227' ' ' LEU . . . -71.96 -172.52 17.61 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.853 -0.689 . . . . 0.0 112.56 -179.967 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 230' ' ' VAL . . . . . . . . . . . . . 4.9 p -158.19 125.42 0.58 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-O 120.869 0.366 . . . . 0.0 111.017 -179.945 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 231' ' ' ASP . . . . . . . . . . . . . 11.8 m-20 -100.36 91.31 4.66 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.679 179.881 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 232' ' ' THR . . . . . . . . . . . . . 8.7 t -126.19 152.09 46.48 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.143 -0.481 . . . . 0.0 111.035 -179.912 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 233' ' ' ASP . . . . . . . . . . . . . 17.5 m-20 65.14 134.19 0.02 OUTLIER 'General case' 0 C--N 1.333 -0.143 0 CA-C-N 116.029 -0.532 . . . . 0.0 111.226 179.979 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 234' ' ' THR . . . . . . . . . . . . . 70.4 p -65.94 154.42 89.39 Favored Pre-proline 0 C--N 1.329 -0.306 0 CA-C-N 116.076 -0.511 . . . . 0.0 111.097 179.977 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 235' ' ' PRO . . . . . . . . . . . . . 73.5 Cg_endo -74.97 10.53 1.68 Allowed 'Trans proline' 0 C--N 1.348 0.527 0 C-N-CA 122.456 2.104 . . . . 0.0 112.529 -179.957 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 236' ' ' ALA . . . . . . . . . . . . . . . -101.49 106.95 18.12 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.309 -0.405 . . . . 0.0 111.287 -179.943 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 237' ' ' VAL . . . . . . . . . . . . . 22.2 t -116.52 121.3 67.31 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.192 0 CA-C-N 116.18 -0.463 . . . . 0.0 111.061 179.931 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 238' ' ' ALA . . . . . . . . . . . . . . . -81.0 -67.97 0.73 Allowed 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.217 179.98 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 239' ' ' ASP . . . . . . . . . . . . . 14.7 t70 -147.49 104.73 3.65 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.77 -179.996 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 240' ' ' LEU . . . . . . . . . . . . . 49.1 tp -114.77 -29.03 6.88 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.923 -179.829 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 241' ' ' GLU . . . . . . . . . . . . . 10.9 mm-40 -72.64 134.85 45.31 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.897 -179.98 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 242' ' ' HIS . . . . . . . . . . . . . 84.6 t60 -139.19 -45.34 0.46 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.599 179.834 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 243' ' ' HIS . . . . . . . . . . . . . 72.2 m80 -88.82 179.64 6.17 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.049 -0.523 . . . . 0.0 110.669 179.766 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 244' ' ' HIS . . . . . . . . . . . . . 95.5 m-70 -103.31 162.93 12.59 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.299 -0.409 . . . . 0.0 111.06 179.953 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 245' ' ' HIS . . . . . . . . . . . . . 65.5 m-70 60.91 -87.22 0.02 OUTLIER 'General case' 0 C--N 1.331 -0.206 0 CA-C-N 115.842 -0.617 . . . . 0.0 111.06 179.899 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 246' ' ' HIS . . . . . . . . . . . . . 56.6 m80 -102.66 168.61 9.15 Favored 'General case' 0 C--N 1.332 -0.172 0 CA-C-N 116.331 -0.395 . . . . 0.0 110.886 -179.903 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 247' ' ' HIS . . . . . . . . . . . . . 68.9 m-70 . . . . . 0 C--O 1.25 1.115 0 CA-C-O 118.314 -0.85 . . . . 0.0 111.057 179.938 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 301' ' ' RET . . . . . 0.502 ' H21' ' HA3' ' A' ' 112' ' ' GLY . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 96.7 mmm . . . . . 0 N--CA 1.486 1.333 0 CA-C-O 120.773 0.321 . . . . 0.0 110.919 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 42.9 t -119.74 -32.99 1.56 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.976 179.82 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -82.06 -23.94 56.11 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.798 -0.715 . . . . 0.0 112.514 -179.961 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 55.3 tp -74.02 -36.31 64.45 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.685 0.279 . . . . 0.0 111.21 -179.88 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 82.6 p -66.3 -29.97 70.29 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.432 -0.349 . . . . 0.0 111.409 -179.693 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 22.7 p -54.22 -35.13 62.09 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.269 179.996 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 7' ' ' LEU . . . . . . . . . . . . . 3.9 mm? -57.66 -53.13 61.66 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.111 -0.495 . . . . 0.0 111.172 -179.971 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 8' ' ' PHE . . . . . 0.675 ' HB2' ' HB2' ' A' ' 55' ' ' ALA . 77.8 m-85 -59.07 -35.66 73.75 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.346 -0.388 . . . . 0.0 110.762 179.858 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 9' ' ' TRP . . . . . . . . . . . . . 47.5 m95 -64.67 -45.91 84.67 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.024 -0.534 . . . . 0.0 110.059 -179.824 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . 0.444 ' HA ' HD12 ' A' ' 13' ' ' ILE . 87.2 mt -61.08 -37.83 84.11 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-N 115.545 -0.752 . . . . 0.0 110.154 179.333 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -65.82 -35.46 90.9 Favored Glycine 0 N--CA 1.448 -0.53 0 C-N-CA 120.814 -0.708 . . . . 0.0 111.486 179.124 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -67.44 -31.21 71.24 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 120.977 0.418 . . . . 0.0 110.476 179.448 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 13' ' ' ILE . . . . . 0.444 HD12 ' HA ' ' A' ' 10' ' ' LEU . 88.5 mt -64.68 -54.22 32.78 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.235 0 CA-C-N 115.864 -0.607 . . . . 0.0 110.214 179.418 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -65.99 -32.45 82.6 Favored Glycine 0 N--CA 1.45 -0.377 0 C-N-CA 120.61 -0.805 . . . . 0.0 111.637 179.109 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 15' ' ' MET . . . . . 0.495 ' SD ' ' HA ' ' A' ' 44' ' ' SER . 51.3 tpp -65.83 -40.16 91.53 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-O 120.823 0.344 . . . . 0.0 110.448 179.657 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 1.6 mm? -64.02 -37.98 89.4 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-N 116.08 -0.509 . . . . 0.0 110.207 179.173 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . 0.442 HG23 ' O ' ' A' ' 13' ' ' ILE . 72.0 t -59.04 -42.63 86.91 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.205 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.158 179.07 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -68.8 -46.2 61.63 Favored Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.731 -0.747 . . . . 0.0 111.679 178.965 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 47.9 m -50.25 -46.66 55.08 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 120.865 0.364 . . . . 0.0 111.081 179.896 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 93.6 mt -72.19 -45.75 59.08 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.035 -0.529 . . . . 0.0 111.639 179.939 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -58.85 -30.85 68.0 Favored 'General case' 0 C--N 1.329 -0.296 0 N-CA-C 112.081 0.4 . . . . 0.0 112.081 -179.23 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 22' ' ' PHE . . . . . 0.413 ' HB2' HG22 ' A' ' 41' ' ' VAL . 13.0 m-85 -90.79 -31.36 16.54 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 120.666 0.27 . . . . 0.0 111.509 -179.252 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -71.63 -50.28 32.22 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 121.101 0.477 . . . . 0.0 111.173 -179.811 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 24' ' ' TRP . . . . . . . . . . . . . 3.1 t-105 -61.43 -43.82 98.19 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-N 115.614 -0.721 . . . . 0.0 111.329 -179.624 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -66.26 -25.3 66.81 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.698 0.285 . . . . 0.0 111.057 -179.989 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -71.07 -41.02 61.35 Favored Glycine 0 N--CA 1.452 -0.253 0 C-N-CA 120.817 -0.706 . . . . 0.0 112.503 -179.893 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 99.0 mtt180 -68.03 -26.96 66.14 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.838 0.352 . . . . 0.0 110.996 -179.99 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 23.9 t70 -94.3 9.17 39.2 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.046 -0.524 . . . . 0.0 110.86 -179.742 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -87.6 -177.77 5.95 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.201 -179.99 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -96.99 -149.23 25.27 Favored Glycine 0 N--CA 1.452 -0.254 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.643 -179.911 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 59.4 m -109.2 127.96 54.65 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.861 0.362 . . . . 0.0 110.797 179.966 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 112.66 -32.35 6.27 Favored Glycine 0 N--CA 1.452 -0.25 0 C-N-CA 120.873 -0.68 . . . . 0.0 112.153 -179.962 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 10.0 mm-40 -90.59 -20.68 22.32 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 120.752 0.311 . . . . 0.0 110.83 179.838 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 34' ' ' ARG . . . . . . . . . . . . . 54.3 mtp180 -48.43 -29.49 4.12 Favored 'General case' 0 C--N 1.333 -0.151 0 CA-C-N 115.997 -0.547 . . . . 0.0 111.547 -179.819 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 75.2 mtp180 -60.85 -48.38 82.07 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.44 -0.346 . . . . 0.0 111.023 -179.899 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 62.9 m-85 -68.66 -31.66 70.94 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.021 -0.536 . . . . 0.0 111.362 -179.678 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 37' ' ' TYR . . . . . . . . . . . . . 53.6 m-85 -69.4 -54.49 14.13 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.301 -0.409 . . . . 0.0 111.279 -179.498 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 85.3 t -57.08 -36.7 52.04 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.249 0 CA-C-O 121.011 0.434 . . . . 0.0 110.525 179.729 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 30.3 m -64.38 -49.43 71.65 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 115.789 -0.641 . . . . 0.0 110.502 179.354 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 30.5 tp -55.99 -47.73 77.17 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.718 -0.674 . . . . 0.0 110.286 179.614 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . 0.413 HG22 ' HB2' ' A' ' 22' ' ' PHE . 62.3 t -62.24 -34.32 63.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 115.733 -0.667 . . . . 0.0 110.016 178.95 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -57.85 -38.77 89.96 Favored Glycine 0 N--CA 1.448 -0.501 0 C-N-CA 120.859 -0.686 . . . . 0.0 112.035 179.684 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 43' ' ' ILE . . . . . 0.678 HG22 ' HE3' ' A' ' 205' ' ' LYS . 0.2 OUTLIER -68.44 -53.42 28.26 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.186 0 CA-C-O 120.825 0.345 . . . . 0.0 110.698 179.583 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 44' ' ' SER . . . . . 0.495 ' HA ' ' SD ' ' A' ' 15' ' ' MET . 45.8 m -59.11 -24.47 63.0 Favored 'General case' 0 C--N 1.333 -0.146 0 CA-C-N 116.136 -0.484 . . . . 0.0 111.466 -179.777 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -75.89 -57.16 4.19 Favored Glycine 0 CA--C 1.518 0.281 0 C-N-CA 120.766 -0.731 . . . . 0.0 113.106 -179.333 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 17.0 pt -58.17 -35.71 54.19 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-O 120.818 0.342 . . . . 0.0 111.262 -179.602 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 47' ' ' ALA . . . . . 0.694 ' HB2' ' HE2' ' A' ' 205' ' ' LYS . . . -67.73 -44.39 77.71 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-O 120.966 0.412 . . . . 0.0 110.943 179.158 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -54.38 -44.46 72.29 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 115.791 -0.641 . . . . 0.0 111.723 -179.385 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 34.2 m -71.54 -34.04 51.48 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.228 0 CA-C-N 116.532 -0.304 . . . . 0.0 111.415 -179.63 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -64.34 -37.33 87.13 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 121.046 0.45 . . . . 0.0 110.874 179.695 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 51' ' ' TYR . . . . . 0.43 ' OH ' ' HB2' ' A' ' 201' ' ' ASP . 33.2 m-85 -73.36 -36.19 66.07 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 115.946 -0.57 . . . . 0.0 110.62 179.979 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -65.99 -38.97 89.88 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 115.826 -0.625 . . . . 0.0 111.025 179.796 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 53' ' ' VAL . . . . . 0.509 ' O ' HG12 ' A' ' 58' ' ' VAL . 33.6 m -74.81 -50.35 25.9 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.194 0 CA-C-N 116.588 -0.278 . . . . 0.0 111.05 -179.887 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 54' ' ' MET . . . . . 0.504 ' N ' HG23 ' A' ' 53' ' ' VAL . 75.8 mtm -58.02 -29.69 65.51 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-O 121.009 0.433 . . . . 0.0 110.309 179.514 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 55' ' ' ALA . . . . . 0.675 ' HB2' ' HB2' ' A' ' 8' ' ' PHE . . . -73.85 -25.92 60.31 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 115.786 -0.643 . . . . 0.0 111.278 179.732 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 74.6 mt -80.28 -8.37 59.44 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.276 -0.42 . . . . 0.0 111.622 -179.625 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 102.31 -17.48 53.63 Favored Glycine 0 N--CA 1.453 -0.226 0 C-N-CA 120.438 -0.887 . . . . 0.0 113.054 179.671 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 58' ' ' VAL . . . . . 0.509 HG12 ' O ' ' A' ' 53' ' ' VAL . 12.7 p -69.43 150.86 10.21 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.957 0.379 . . . . 0.0 110.439 179.717 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 75.55 27.24 63.67 Favored Glycine 0 N--CA 1.449 -0.472 0 C-N-CA 120.723 -0.751 . . . . 0.0 111.731 -178.946 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 60' ' ' TRP . . . . . . . . . . . . . 13.8 m0 -108.7 99.15 8.55 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-O 120.947 0.403 . . . . 0.0 110.285 -179.879 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 61' ' ' VAL . . . . . 0.575 ' HB ' HG23 ' A' ' 68' ' ' VAL . 25.6 t -97.77 110.69 56.45 Favored Pre-proline 0 C--N 1.325 -0.459 0 CA-C-N 115.877 -0.601 . . . . 0.0 111.526 -179.299 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 17.2 Cg_exo -67.2 138.87 48.49 Favored 'Trans proline' 0 C--N 1.35 0.606 0 C-N-CA 122.577 2.184 . . . . 0.0 111.866 179.678 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 93.1 t -139.96 92.17 0.65 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.38 -179.694 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . 56.65 -91.7 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.117 -0.492 . . . . 0.0 111.85 179.656 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 42.9 mt-10 -115.23 -17.61 11.31 Favored 'General case' 0 C--N 1.332 -0.195 0 CA-C-O 120.837 0.351 . . . . 0.0 111.054 -179.652 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 66' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -104.81 165.56 10.99 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.285 179.77 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 91.0 m -130.09 118.81 22.08 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-N 116.295 -0.411 . . . . 0.0 111.414 -179.573 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 68' ' ' VAL . . . . . 0.575 HG23 ' HB ' ' A' ' 61' ' ' VAL . 18.5 m -100.37 141.51 17.18 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.377 0 CA-C-N 115.991 -0.55 . . . . 0.0 110.53 179.495 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 69' ' ' PHE . . . . . . . . . . . . . 24.2 m-85 -109.84 122.75 48.24 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.276 -0.42 . . . . 0.0 110.248 -179.428 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 70' ' ' VAL . . . . . 0.621 HG12 ' HD3' ' A' ' 71' ' ' PRO . 1.3 p -68.13 -35.97 8.33 Favored Pre-proline 0 CA--C 1.54 0.573 0 N-CA-C 112.549 0.574 . . . . 0.0 112.549 -179.541 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 71' ' ' PRO . . . . . 0.621 ' HD3' HG12 ' A' ' 70' ' ' VAL . 5.7 Cg_exo -71.48 -19.87 28.0 Favored 'Trans proline' 0 C--N 1.359 1.122 0 C-N-CA 121.942 1.762 . . . . 0.0 112.47 -179.729 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 56.5 ttt180 -68.68 -55.28 11.95 Favored 'General case' 0 C--O 1.236 0.378 0 CA-C-N 116.403 -0.362 . . . . 0.0 111.67 -179.181 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 73' ' ' TYR . . . . . 0.436 ' O ' HG13 ' A' ' 77' ' ' ILE . 28.2 m-85 -72.17 -30.16 64.71 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.492 -0.322 . . . . 0.0 110.655 -179.418 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 74' ' ' ILE . . . . . 0.524 HG22 ' HA ' ' A' ' 71' ' ' PRO . 0.4 OUTLIER -72.52 -38.29 59.31 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.237 0 N-CA-C 109.829 -0.434 . . . . 0.0 109.829 179.253 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 75' ' ' ASP . . . . . 0.454 ' O ' HG23 ' A' ' 79' ' ' THR . 12.9 t70 -59.11 -38.69 80.15 Favored 'General case' 0 CA--C 1.518 -0.257 0 N-CA-C 109.322 -0.621 . . . . 0.0 109.322 178.861 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 76' ' ' TRP . . . . . 0.412 ' CD1' ' H12' ' A' ' 301' ' ' RET . 45.6 m0 -65.73 -37.74 87.23 Favored 'General case' 0 C--N 1.331 -0.21 0 CA-C-N 115.702 -0.681 . . . . 0.0 110.358 179.166 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 77' ' ' ILE . . . . . 0.51 ' O ' ' HG2' ' A' ' 81' ' ' PRO . 89.5 mt -62.4 -30.67 49.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.468 178.973 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 41.7 mt -92.06 -19.81 21.96 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.07 -0.514 . . . . 0.0 112.222 -179.717 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 79' ' ' THR . . . . . 0.454 HG23 ' O ' ' A' ' 75' ' ' ASP . 73.6 p -101.28 -52.99 3.12 Favored 'General case' 0 N--CA 1.463 0.205 0 N-CA-C 113.446 0.906 . . . . 0.0 113.446 -178.033 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 80' ' ' THR . . . . . 0.661 ' HB ' ' HD3' ' A' ' 81' ' ' PRO . 59.8 m -48.74 -53.97 31.75 Favored Pre-proline 0 C--N 1.331 -0.219 0 N-CA-C 112.406 0.521 . . . . 0.0 112.406 -178.838 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 81' ' ' PRO . . . . . 0.661 ' HD3' ' HB ' ' A' ' 80' ' ' THR . 31.5 Cg_exo -59.87 -23.4 72.29 Favored 'Trans proline' 0 C--N 1.353 0.805 0 C-N-CA 121.718 1.612 . . . . 0.0 111.772 179.965 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 82' ' ' LEU . . . . . . . . . . . . . 18.4 tp -76.93 -33.11 57.74 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.043 -0.526 . . . . 0.0 110.469 179.68 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 83' ' ' ILE . . . . . 0.449 HD11 HG21 ' A' ' 43' ' ' ILE . 35.0 mm -68.26 -53.71 26.96 Favored 'Isoleucine or valine' 0 C--O 1.234 0.244 0 CA-C-N 116.367 -0.379 . . . . 0.0 110.036 179.246 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 20.7 m -59.98 -30.98 46.65 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.23 0 N-CA-C 109.415 -0.587 . . . . 0.0 109.415 178.506 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 85' ' ' TYR . . . . . . . . . . . . . 80.8 t80 -66.38 -31.49 72.3 Favored 'General case' 0 N--CA 1.454 -0.242 0 CA-C-N 115.382 -0.827 . . . . 0.0 109.637 178.764 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 86' ' ' PHE . . . . . . . . . . . . . 14.6 t80 -64.33 -51.34 63.88 Favored 'General case' 0 C--O 1.232 0.169 0 CA-C-N 115.819 -0.628 . . . . 0.0 109.865 179.385 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 7.4 mp -60.8 -36.04 78.03 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 115.729 -0.668 . . . . 0.0 110.253 179.445 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -67.24 -27.67 73.54 Favored Glycine 0 N--CA 1.45 -0.395 0 C-N-CA 120.904 -0.665 . . . . 0.0 112.082 179.657 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 40.5 mt -71.66 -42.55 67.37 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-O 121.027 0.441 . . . . 0.0 110.421 179.801 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 90' ' ' LEU . . . . . 0.417 ' HB3' HG23 ' A' ' 156' ' ' ILE . 81.0 mt -56.13 -42.43 76.89 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 115.688 -0.687 . . . . 0.0 111.198 -179.971 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . 0.597 ' HB2' ' HB2' ' A' ' 149' ' ' ALA . . . -79.3 -45.99 18.59 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.311 -0.404 . . . . 0.0 111.393 -179.597 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 97.73 50.66 1.63 Allowed Glycine 0 N--CA 1.45 -0.373 0 C-N-CA 120.712 -0.756 . . . . 0.0 112.229 -179.583 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 93' ' ' LEU . . . . . 0.527 HD23 ' HB3' ' A' ' 97' ' ' GLU . 10.8 mp -61.61 171.55 1.5 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.958 0.409 . . . . 0.0 111.24 -179.891 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 94' ' ' ASP . . . . . . . . . . . . . 24.2 t70 -90.46 167.61 12.47 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 115.963 -0.562 . . . . 0.0 110.462 179.722 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 47.3 t -55.04 -35.42 64.46 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.355 -0.384 . . . . 0.0 111.107 179.983 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 5.3 mmp_? -73.83 -50.49 20.18 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.09 -0.504 . . . . 0.0 111.33 -179.858 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 97' ' ' GLU . . . . . 0.527 ' HB3' HD23 ' A' ' 93' ' ' LEU . 46.6 mt-10 -52.37 -45.2 65.66 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.34 -0.391 . . . . 0.0 111.291 -179.606 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 98' ' ' PHE . . . . . 0.416 ' O ' HG12 ' A' ' 102' ' ' ILE . 28.2 m-85 -59.55 -46.69 88.16 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.488 -0.324 . . . . 0.0 110.864 179.824 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -57.67 -28.58 60.21 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.524 -0.846 . . . . 0.0 112.466 179.848 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 79.6 mt -73.83 -48.7 38.26 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.181 0 N-CA-C 112.125 0.417 . . . . 0.0 112.125 -179.563 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 29.4 m -67.98 -41.75 84.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 N-CA-C 112.049 0.388 . . . . 0.0 112.049 -179.001 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 102' ' ' ILE . . . . . 0.482 HG23 ' HB3' ' A' ' 81' ' ' PRO . 50.9 mm -63.88 -49.35 82.22 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.675 -0.239 . . . . 0.0 111.505 -179.463 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 15.3 t -59.72 -34.75 73.33 Favored 'General case' 0 C--O 1.233 0.208 0 CA-C-O 120.951 0.405 . . . . 0.0 110.643 179.873 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 1.3 tm? -56.29 -54.08 49.67 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.008 -0.542 . . . . 0.0 109.698 179.05 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 105' ' ' ASN . . . . . 0.638 ' N ' HD22 ' A' ' 105' ' ' ASN . 0.8 OUTLIER -58.23 -34.03 69.99 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 115.591 -0.731 . . . . 0.0 110.83 179.605 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 85.4 m -56.54 -43.79 80.24 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.295 -0.411 . . . . 0.0 110.734 179.803 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 1.5 t -66.81 -42.18 88.87 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-O 121.2 0.524 . . . . 0.0 110.348 179.383 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 93.5 t -57.99 -51.17 73.99 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.386 0 CA-C-N 115.318 -0.856 . . . . 0.0 111.679 -179.722 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 109' ' ' MET . . . . . 0.61 ' HE1' HG21 ' A' ' 80' ' ' THR . 1.5 mpp? -65.22 -37.52 87.53 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.37 -179.588 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 32.4 tp -66.71 -31.5 72.2 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 116.39 -0.368 . . . . 0.0 110.58 -179.893 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -65.42 -52.56 52.5 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.394 179.487 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 112' ' ' GLY . . . . . 0.622 ' HA3' ' H21' ' A' ' 301' ' ' RET . . . -66.26 -31.43 79.07 Favored Glycine 0 N--CA 1.449 -0.434 0 C-N-CA 120.749 -0.738 . . . . 0.0 111.883 179.37 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 113' ' ' PHE . . . . . . . . . . . . . 0.4 OUTLIER -57.14 -70.69 0.12 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 121.032 0.444 . . . . 0.0 110.061 179.567 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 114' ' ' ALA . . . . . 0.505 ' HB3' HD22 ' A' ' 126' ' ' LEU . . . -64.09 -18.55 64.49 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 115.72 -0.673 . . . . 0.0 110.758 179.577 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -57.77 -53.62 43.79 Favored Glycine 0 C--N 1.332 0.314 0 C-N-CA 120.943 -0.646 . . . . 0.0 112.263 179.802 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 116' ' ' ALA . . . . . 0.547 ' HB2' ' HB3' ' A' ' 183' ' ' PRO . . . -77.48 -14.98 59.56 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.784 0.326 . . . . 0.0 111.271 179.927 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 117' ' ' MET . . . . . 0.479 ' SD ' HG21 ' A' ' 68' ' ' VAL . 17.9 mmt -86.33 13.71 7.71 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.129 -0.487 . . . . 0.0 111.589 -179.504 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 20.4 m -87.22 143.03 33.99 Favored Pre-proline 0 C--N 1.33 -0.255 0 CA-C-O 120.563 0.221 . . . . 0.0 111.371 -179.916 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 119' ' ' PRO . . . . . . . . . . . . . 68.2 Cg_endo -92.56 -2.66 3.76 Favored 'Trans proline' 0 N--CA 1.455 -0.776 0 C-N-CA 122.945 2.43 . . . . 0.0 112.267 179.441 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -132.81 -117.66 1.86 Allowed Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.779 -0.724 . . . . 0.0 112.805 -179.668 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 39.6 pt -123.26 12.97 5.31 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.234 0 CA-C-O 120.654 0.264 . . . . 0.0 111.547 -179.514 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 37.7 mt-10 -61.23 -18.65 59.4 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.375 -0.375 . . . . 0.0 110.822 179.912 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 123' ' ' ARG . . . . . 0.471 ' HB2' ' HH2' ' A' ' 178' ' ' TRP . 23.0 ptt180 -51.93 -33.79 38.92 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 115.927 -0.579 . . . . 0.0 111.615 -179.84 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 124' ' ' TYR . . . . . . . . . . . . . 59.0 m-85 -67.49 -33.3 74.81 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.459 -0.337 . . . . 0.0 111.397 -179.622 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 125' ' ' ALA . . . . . . . . . . . . . . . -72.71 -56.46 5.25 Favored 'General case' 0 C--O 1.237 0.411 0 CA-C-O 121.105 0.479 . . . . 0.0 111.073 179.835 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 126' ' ' LEU . . . . . 0.505 HD22 ' HB3' ' A' ' 114' ' ' ALA . 1.3 mt -55.24 -48.1 74.44 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 115.729 -0.669 . . . . 0.0 110.395 179.847 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 127' ' ' PHE . . . . . 0.418 ' HZ ' ' HB3' ' A' ' 175' ' ' PRO . 9.2 t80 -67.76 -30.76 70.3 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.11 -0.496 . . . . 0.0 110.334 179.316 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 128' ' ' GLY . . . . . . . . . . . . . . . -49.12 -50.58 27.76 Favored Glycine 0 N--CA 1.449 -0.441 0 C-N-CA 120.125 -1.036 . . . . 0.0 110.553 178.734 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 129' ' ' MET . . . . . 0.541 ' HE3' ' HA2' ' A' ' 130' ' ' GLY . 0.0 OUTLIER -70.84 -28.24 64.45 Favored 'General case' 0 N--CA 1.453 -0.293 0 N-CA-C 109.02 -0.733 . . . . 0.0 109.02 178.283 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 130' ' ' GLY . . . . . 0.541 ' HA2' ' HE3' ' A' ' 129' ' ' MET . . . -60.09 -41.63 98.14 Favored Glycine 0 C--N 1.335 0.48 0 CA-C-N 115.772 -0.649 . . . . 0.0 112.441 179.364 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -71.04 -49.43 44.99 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-O 120.66 0.267 . . . . 0.0 110.503 179.733 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 57.7 t -57.4 -43.72 83.07 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.217 0 CA-C-O 121.139 0.495 . . . . 0.0 109.81 179.068 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -65.86 -33.01 74.87 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 115.538 -0.756 . . . . 0.0 110.603 179.193 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 134' ' ' PHE . . . . . 0.409 ' HE1' ' HB3' ' A' ' 171' ' ' TRP . 71.6 t80 -59.02 -54.62 45.11 Favored 'General case' 0 N--CA 1.451 -0.385 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.038 179.58 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 135' ' ' ILE . . . . . 0.508 ' O ' HG22 ' A' ' 138' ' ' VAL . 38.2 mt -57.19 -30.38 34.74 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.312 0 CA-C-N 115.805 -0.634 . . . . 0.0 109.916 178.98 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . -62.88 -37.37 94.79 Favored Glycine 0 N--CA 1.447 -0.601 0 C-N-CA 120.31 -0.948 . . . . 0.0 111.301 178.877 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 137' ' ' LEU . . . . . 0.58 HD13 HD21 ' A' ' 105' ' ' ASN . 21.4 tp -71.45 -51.77 22.05 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 120.582 0.23 . . . . 0.0 110.8 179.536 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 138' ' ' VAL . . . . . 0.508 HG22 ' O ' ' A' ' 135' ' ' ILE . 3.9 m -56.15 -31.9 32.92 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.213 0 CA-C-O 121.299 0.571 . . . . 0.0 109.479 179.377 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 139' ' ' TYR . . . . . . . . . . . . . 35.3 t80 -63.99 -44.67 91.96 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 115.29 -0.868 . . . . 0.0 110.136 178.882 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 140' ' ' TYR . . . . . 0.47 ' HB3' ' SD ' ' A' ' 145' ' ' MET . 23.6 m-85 -54.65 -47.01 74.04 Favored 'General case' 0 C--N 1.332 -0.167 0 CA-C-N 115.974 -0.557 . . . . 0.0 111.006 179.622 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 141' ' ' LEU . . . . . . . . . . . . . 93.2 mt -59.04 -40.81 86.23 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.252 -0.431 . . . . 0.0 111.064 -179.885 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 37.8 t -79.73 -12.46 13.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-O 121.063 0.459 . . . . 0.0 110.823 179.902 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . -70.88 -140.64 0.2 Allowed Glycine 0 CA--C 1.522 0.471 0 C-N-CA 120.989 -0.624 . . . . 0.0 112.715 -179.913 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 144' ' ' PRO . . . . . . . . . . . . . 56.6 Cg_endo -70.1 -22.77 30.07 Favored 'Trans proline' 0 C--N 1.349 0.575 0 C-N-CA 122.767 2.312 . . . . 0.0 112.894 -179.93 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 145' ' ' MET . . . . . 0.47 ' SD ' ' HB3' ' A' ' 140' ' ' TYR . 81.0 mtp -52.5 -53.48 45.4 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.281 -0.418 . . . . 0.0 111.794 -179.223 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 146' ' ' THR . . . . . . . . . . . . . 10.2 t -62.45 -32.83 73.75 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.726 0.298 . . . . 0.0 111.586 -179.53 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 45.0 mt-10 -71.35 -32.64 68.78 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.309 -0.405 . . . . 0.0 111.087 -179.837 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 148' ' ' SER . . . . . . . . . . . . . 59.6 m -70.23 -36.6 74.62 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.114 -0.494 . . . . 0.0 111.21 -179.788 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 149' ' ' ALA . . . . . 0.597 ' HB2' ' HB2' ' A' ' 91' ' ' ALA . . . -75.47 -39.46 58.64 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.265 -0.425 . . . . 0.0 111.69 -179.585 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 150' ' ' SER . . . . . . . . . . . . . 69.8 m -66.19 -4.39 7.54 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.39 -0.368 . . . . 0.0 111.217 -179.792 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 151' ' ' GLN . . . . . . . . . . . . . 47.8 mt-30 -124.59 14.53 8.77 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.389 -0.369 . . . . 0.0 111.303 -179.907 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 31.9 tpt180 -91.74 -51.55 5.18 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 120.972 0.415 . . . . 0.0 110.653 179.786 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 153' ' ' SER . . . . . 0.598 ' HB2' HG12 ' A' ' 156' ' ' ILE . 45.4 m -157.54 172.63 18.2 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 115.87 -0.604 . . . . 0.0 110.576 179.466 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 154' ' ' SER . . . . . . . . . . . . . 47.9 t -67.53 -41.84 83.69 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.393 -0.367 . . . . 0.0 110.769 179.841 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -76.69 -35.89 39.19 Favored Glycine 0 C--N 1.332 0.312 0 C-N-CA 120.85 -0.691 . . . . 0.0 112.804 -179.946 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 156' ' ' ILE . . . . . 0.598 HG12 ' HB2' ' A' ' 153' ' ' SER . 39.9 mm -56.23 -39.37 59.23 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.224 0 CA-C-O 120.729 0.299 . . . . 0.0 111.46 -179.729 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 157' ' ' LYS . . . . . 0.409 ' O ' HG13 ' A' ' 161' ' ' VAL . 62.3 tttp -61.92 -51.08 69.6 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.296 -0.411 . . . . 0.0 111.329 -179.758 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 51.4 m -64.87 -35.41 81.04 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.37 -0.377 . . . . 0.0 111.499 -179.154 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 159' ' ' LEU . . . . . 0.554 HD21 ' HB3' ' A' ' 215' ' ' ALA . 10.8 mt -68.84 -59.28 3.19 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-N 116.312 -0.403 . . . . 0.0 111.655 -179.507 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 160' ' ' TYR . . . . . . . . . . . . . 19.4 t80 -52.45 -44.97 65.82 Favored 'General case' 0 C--N 1.327 -0.374 0 N-CA-C 112.228 0.455 . . . . 0.0 112.228 -178.947 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 161' ' ' VAL . . . . . 0.475 HG23 ' N ' ' A' ' 162' ' ' ARG . 36.0 m -63.65 -45.8 96.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 N-CA-C 112.504 0.557 . . . . 0.0 112.504 -178.289 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 162' ' ' ARG . . . . . 0.595 ' O ' HD12 ' A' ' 166' ' ' LEU . 99.4 mtt180 -63.65 -49.72 72.1 Favored 'General case' 0 C--N 1.327 -0.377 0 N-CA-C 111.78 0.289 . . . . 0.0 111.78 -179.009 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 163' ' ' LEU . . . . . 0.488 ' HG ' ' O ' ' A' ' 159' ' ' LEU . 11.0 mt -67.7 -39.86 84.35 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.39 -0.368 . . . . 0.0 111.345 -178.873 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 164' ' ' ARG . . . . . . . . . . . . . 4.1 tmm_? -59.11 -47.78 84.0 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.446 -0.343 . . . . 0.0 110.756 -179.847 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 165' ' ' ASN . . . . . 0.495 HD22 ' N ' ' A' ' 165' ' ' ASN . 0.9 OUTLIER -56.02 -48.74 75.39 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.303 -0.408 . . . . 0.0 110.297 179.708 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 166' ' ' LEU . . . . . 0.595 HD12 ' O ' ' A' ' 162' ' ' ARG . 1.4 mt -57.89 -45.82 85.85 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.016 -0.538 . . . . 0.0 110.763 179.364 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 167' ' ' THR . . . . . 0.656 ' HA ' HD11 ' A' ' 170' ' ' LEU . 13.9 m -54.4 -51.42 64.91 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-N 115.936 -0.574 . . . . 0.0 112.051 -178.767 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 168' ' ' VAL . . . . . . . . . . . . . 49.3 t -57.76 -40.02 73.62 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.449 0 N-CA-C 111.903 0.334 . . . . 0.0 111.903 -179.386 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 169' ' ' VAL . . . . . 0.43 ' O ' HG12 ' A' ' 173' ' ' ILE . 93.0 t -66.74 -67.69 0.39 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 N-CA-C 113.622 0.971 . . . . 0.0 113.622 -177.947 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 170' ' ' LEU . . . . . 0.656 HD11 ' HA ' ' A' ' 167' ' ' THR . 0.4 OUTLIER -61.14 -34.06 74.39 Favored 'General case' 0 N--CA 1.463 0.222 0 N-CA-C 112.899 0.703 . . . . 0.0 112.899 -177.475 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 171' ' ' TRP . . . . . 0.818 ' HE1' H203 ' A' ' 301' ' ' RET . 26.9 m0 -72.59 -30.64 64.55 Favored 'General case' 0 C--N 1.327 -0.401 0 C-N-CA 120.612 -0.435 . . . . 0.0 111.514 -179.283 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 172' ' ' ALA . . . . . . . . . . . . . . . -73.04 -7.86 53.15 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-O 121.036 0.446 . . . . 0.0 110.474 179.916 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 173' ' ' ILE . . . . . 0.498 ' O ' HG12 ' A' ' 177' ' ' ILE . 37.3 mm -88.7 -26.05 5.66 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.222 0 CA-C-N 115.808 -0.633 . . . . 0.0 110.784 179.564 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 174' ' ' TYR . . . . . 0.448 ' HD1' ' HA ' ' A' ' 171' ' ' TRP . 24.1 m-85 -54.28 -49.02 92.75 Favored Pre-proline 0 N--CA 1.462 0.17 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.933 -179.197 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 175' ' ' PRO . . . . . 0.418 ' HB3' ' HZ ' ' A' ' 127' ' ' PHE . 82.8 Cg_exo -45.85 -32.74 9.63 Favored 'Trans proline' 0 C--N 1.351 0.675 0 C-N-CA 121.898 1.732 . . . . 0.0 111.798 179.555 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 176' ' ' PHE . . . . . 0.476 ' O ' ' HG ' ' A' ' 180' ' ' LEU . 60.1 m-85 -80.98 -50.77 9.29 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 115.692 -0.686 . . . . 0.0 111.717 -179.995 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 177' ' ' ILE . . . . . 0.498 HG12 ' O ' ' A' ' 173' ' ' ILE . 10.8 mm -58.69 -38.33 71.01 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.567 0 CA-C-N 116.015 -0.539 . . . . 0.0 111.897 -178.283 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 178' ' ' TRP . . . . . 0.471 ' HH2' ' HB2' ' A' ' 123' ' ' ARG . 83.4 t90 -65.88 -56.26 12.74 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-O 120.875 0.369 . . . . 0.0 110.894 -179.951 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 179' ' ' LEU . . . . . 0.688 ' HG ' HG22 ' A' ' 185' ' ' VAL . 34.0 tp -64.1 -55.24 23.42 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 115.971 -0.559 . . . . 0.0 112.066 -178.689 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 180' ' ' LEU . . . . . 0.698 HD22 HD11 ' A' ' 187' ' ' LEU . 10.1 mt -62.69 -28.65 70.09 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.661 -0.245 . . . . 0.0 111.283 -179.171 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . -72.18 -171.61 17.0 Favored Glycine 0 N--CA 1.45 -0.419 0 C-N-CA 119.929 -1.129 . . . . 0.0 111.922 179.157 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 182' ' ' PRO . . . . . 0.44 ' N ' ' HD2' ' A' ' 183' ' ' PRO . 71.4 Cg_exo -49.84 -43.63 40.08 Favored 'Trans proline' 0 CA--C 1.538 0.708 0 C-N-CA 122.759 2.306 . . . . 0.0 113.756 179.609 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 183' ' ' PRO . . . . . 0.547 ' HB3' ' HB2' ' A' ' 116' ' ' ALA . 60.7 Cg_exo -39.37 -55.74 1.46 Allowed 'Trans proline' 0 C--N 1.358 1.036 0 C-N-CA 122.73 2.287 . . . . 0.0 113.904 -179.414 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 184' ' ' GLY . . . . . . . . . . . . . . . -115.79 -111.91 2.78 Favored Glycine 0 N--CA 1.45 -0.387 0 C-N-CA 120.203 -0.999 . . . . 0.0 112.672 -179.551 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 185' ' ' VAL . . . . . 0.688 HG22 ' HG ' ' A' ' 179' ' ' LEU . 35.8 m -76.39 84.74 0.74 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.466 0 CA-C-O 121.467 0.651 . . . . 0.0 110.693 -179.74 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 186' ' ' ALA . . . . . . . . . . . . . . . -62.9 84.07 0.02 OUTLIER 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 115.73 -0.668 . . . . 0.0 111.361 179.999 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 187' ' ' LEU . . . . . 0.698 HD11 HD22 ' A' ' 180' ' ' LEU . 5.0 mt -77.27 -48.99 16.01 Favored 'General case' 0 C--N 1.332 -0.181 0 CA-C-O 120.964 0.411 . . . . 0.0 110.64 179.73 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 188' ' ' LEU . . . . . . . . . . . . . 83.1 mt -92.41 -162.13 0.9 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 115.811 -0.631 . . . . 0.0 111.378 -179.421 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 189' ' ' THR . . . . . . . . . . . . . 88.4 m -94.58 136.57 23.05 Favored Pre-proline 0 C--N 1.328 -0.349 0 CA-C-N 115.708 -0.678 . . . . 0.0 110.729 -179.974 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 190' ' ' PRO . . . . . 0.402 ' O ' HG23 ' A' ' 194' ' ' VAL . 80.0 Cg_exo -45.33 -43.68 16.84 Favored 'Trans proline' 0 C--N 1.35 0.609 0 C-N-CA 122.561 2.174 . . . . 0.0 112.63 179.743 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 191' ' ' THR . . . . . . . . . . . . . 82.6 p -58.72 -46.39 87.46 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.329 -0.396 . . . . 0.0 111.042 179.922 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 192' ' ' VAL . . . . . . . . . . . . . 87.6 t -63.14 -47.37 92.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.117 -0.492 . . . . 0.0 111.195 -179.983 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 193' ' ' ASP . . . . . . . . . . . . . 22.3 t70 -54.83 -48.12 73.24 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.055 -0.521 . . . . 0.0 111.311 -179.705 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 194' ' ' VAL . . . . . 0.417 ' O ' HG23 ' A' ' 198' ' ' VAL . 99.7 t -64.35 -36.12 76.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.281 -0.418 . . . . 0.0 110.887 -179.848 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 195' ' ' ALA . . . . . . . . . . . . . . . -58.2 -46.03 86.54 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.413 -0.358 . . . . 0.0 111.04 179.915 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 196' ' ' LEU . . . . . 0.416 ' O ' ' HG ' ' A' ' 200' ' ' LEU . 94.1 mt -67.01 -42.07 85.6 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.419 -0.355 . . . . 0.0 110.38 179.713 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 197' ' ' ILE . . . . . . . . . . . . . 18.7 mm -57.31 -57.83 8.46 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.231 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.398 179.256 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 198' ' ' VAL . . . . . 0.417 HG23 ' O ' ' A' ' 194' ' ' VAL . 91.0 t -52.65 -34.82 20.08 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.493 0 CA-C-N 115.598 -0.728 . . . . 0.0 109.328 178.618 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 199' ' ' TYR . . . . . . . . . . . . . 64.4 t80 -70.41 -35.36 73.39 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 115.288 -0.869 . . . . 0.0 110.73 179.704 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 200' ' ' LEU . . . . . 0.416 ' HG ' ' O ' ' A' ' 196' ' ' LEU . 73.1 mt -66.15 -41.34 90.54 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 115.762 -0.654 . . . . 0.0 111.322 -179.485 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 201' ' ' ASP . . . . . 0.43 ' HB2' ' OH ' ' A' ' 51' ' ' TYR . 9.9 m-20 -71.81 -31.83 66.97 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 116.29 -0.414 . . . . 0.0 110.482 179.879 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 202' ' ' LEU . . . . . 0.455 ' O ' ' HB ' ' A' ' 206' ' ' VAL . 3.6 mt -72.66 -34.11 67.02 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 115.831 -0.622 . . . . 0.0 111.997 -179.558 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 203' ' ' VAL . . . . . 0.472 ' O ' ' HA3' ' A' ' 207' ' ' GLY . 7.7 p -75.42 -36.68 36.34 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-O 120.609 0.242 . . . . 0.0 111.177 -179.032 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 204' ' ' THR . . . . . . . . . . . . . 25.6 m -68.41 -55.26 12.54 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-O 120.879 0.371 . . . . 0.0 111.397 179.789 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 205' ' ' LYS . . . . . 0.694 ' HE2' ' HB2' ' A' ' 47' ' ' ALA . 54.3 mttp -68.6 -58.96 3.5 Favored 'General case' 0 C--N 1.328 -0.359 0 N-CA-C 112.397 0.517 . . . . 0.0 112.397 -178.599 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 206' ' ' VAL . . . . . 0.455 ' HB ' ' O ' ' A' ' 202' ' ' LEU . 76.6 t -73.3 -38.13 53.19 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 N-CA-C 112.217 0.451 . . . . 0.0 112.217 -178.702 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 207' ' ' GLY . . . . . 0.472 ' HA3' ' O ' ' A' ' 203' ' ' VAL . . . -63.85 -59.78 8.17 Favored Glycine 0 N--CA 1.452 -0.261 0 C-N-CA 120.341 -0.933 . . . . 0.0 112.514 -179.324 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 208' ' ' PHE . . . . . 0.512 ' O ' ' N ' ' A' ' 212' ' ' ALA . 1.8 m-30 -54.53 -47.89 72.61 Favored 'General case' 0 C--O 1.221 -0.407 0 N-CA-C 109.795 -0.446 . . . . 0.0 109.795 179.515 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 209' ' ' GLY . . . . . 0.492 ' HA2' ' HB3' ' A' ' 212' ' ' ALA . . . -54.29 -35.07 54.73 Favored Glycine 0 N--CA 1.448 -0.508 0 CA-C-N 115.366 -0.834 . . . . 0.0 113.144 179.558 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 210' ' ' PHE . . . . . . . . . . . . . 1.9 m-85 -69.69 -47.67 62.41 Favored 'General case' 0 CA--C 1.515 -0.403 0 N-CA-C 108.677 -0.86 . . . . 0.0 108.677 179.334 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 211' ' ' ILE . . . . . 0.423 HG13 ' O ' ' A' ' 207' ' ' GLY . 4.0 mt -66.14 -27.47 40.9 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.486 0 N-CA-C 107.587 -1.264 . . . . 0.0 107.587 176.757 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 212' ' ' ALA . . . . . 0.512 ' N ' ' O ' ' A' ' 208' ' ' PHE . . . -67.4 -39.07 85.52 Favored 'General case' 0 N--CA 1.448 -0.536 0 CA-C-N 114.302 -1.317 . . . . 0.0 110.018 -179.768 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 213' ' ' LEU . . . . . . . . . . . . . 80.7 mt -70.21 -38.05 75.19 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 114.991 -1.004 . . . . 0.0 111.275 -179.841 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 214' ' ' ASP . . . . . . . . . . . . . 26.9 t70 -60.3 -55.09 37.87 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 116.328 -0.396 . . . . 0.0 111.016 -179.808 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 215' ' ' ALA . . . . . 0.554 ' HB3' HD21 ' A' ' 159' ' ' LEU . . . -61.05 -50.89 71.49 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.758 179.709 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 216' ' ' ALA . . . . . . . . . . . . . . . -57.45 -32.49 66.98 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.946 179.683 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 217' ' ' ALA . . . . . . . . . . . . . . . -62.72 -43.3 99.15 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-N 116.086 -0.506 . . . . 0.0 110.17 179.544 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 218' ' ' THR . . . . . . . . . . . . . 91.8 m -64.88 -46.99 79.46 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 115.897 -0.592 . . . . 0.0 110.472 179.267 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 219' ' ' LEU . . . . . 0.421 ' HG ' ' O ' ' A' ' 215' ' ' ALA . 30.1 mt -61.58 -26.46 67.98 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-O 121.302 0.573 . . . . 0.0 109.944 179.273 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 220' ' ' ARG . . . . . . . . . . . . . 56.7 ttp180 -84.49 -26.6 28.03 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 115.305 -0.861 . . . . 0.0 110.933 179.614 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 221' ' ' ALA . . . . . . . . . . . . . . . -82.64 -26.83 31.82 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.093 -0.503 . . . . 0.0 112.05 -179.191 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 222' ' ' GLU . . . . . 0.402 ' HG2' ' O ' ' A' ' 219' ' ' LEU . 11.0 pt-20 -68.81 -15.62 63.56 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.862 0.363 . . . . 0.0 110.741 -179.486 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 223' ' ' HIS . . . . . . . . . . . . . 75.4 m-70 -73.38 -68.6 0.49 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.049 -0.523 . . . . 0.0 111.038 179.855 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 224' ' ' GLY . . . . . . . . . . . . . . . 90.89 -42.52 2.87 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.847 -0.692 . . . . 0.0 112.441 -179.864 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 225' ' ' GLU . . . . . . . . . . . . . 1.6 mp0 -60.1 134.38 57.0 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 120.919 0.39 . . . . 0.0 111.046 -179.825 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 226' ' ' SER . . . . . . . . . . . . . 24.7 m -124.12 170.32 10.82 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.808 -179.931 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 227' ' ' LEU . . . . . 0.438 ' N ' HD12 ' A' ' 227' ' ' LEU . 7.4 mp -91.04 129.22 37.06 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.307 -0.406 . . . . 0.0 110.563 179.688 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 228' ' ' ALA . . . . . . . . . . . . . . . -145.75 144.9 30.61 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.426 -0.352 . . . . 0.0 111.056 179.934 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 229' ' ' GLY . . . . . . . . . . . . . . . 167.98 179.07 40.33 Favored Glycine 0 N--CA 1.45 -0.411 0 C-N-CA 120.623 -0.799 . . . . 0.0 112.603 -179.946 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 230' ' ' VAL . . . . . . . . . . . . . 6.8 p -156.18 139.88 7.9 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-O 120.848 0.356 . . . . 0.0 110.772 -179.997 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 231' ' ' ASP . . . . . . . . . . . . . 17.9 t70 -96.49 93.72 6.97 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.032 -179.799 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 232' ' ' THR . . . . . . . . . . . . . 10.1 t -122.29 -31.53 3.81 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.104 -0.498 . . . . 0.0 111.112 179.957 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 233' ' ' ASP . . . . . . . . . . . . . 21.7 t70 -150.66 -68.07 0.19 Allowed 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.304 -0.407 . . . . 0.0 110.941 179.996 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 234' ' ' THR . . . . . . . . . . . . . 5.1 t -133.66 142.77 45.06 Favored Pre-proline 0 C--N 1.328 -0.348 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.039 179.924 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 235' ' ' PRO . . . . . . . . . . . . . 37.4 Cg_endo -66.14 151.55 83.39 Favored 'Trans proline' 0 C--N 1.348 0.508 0 C-N-CA 122.402 2.068 . . . . 0.0 112.234 179.984 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 236' ' ' ALA . . . . . . . . . . . . . . . 60.02 97.93 0.03 OUTLIER 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 116.057 -0.519 . . . . 0.0 111.345 179.99 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 237' ' ' VAL . . . . . . . . . . . . . 80.1 t -91.36 111.5 23.97 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-N 116.107 -0.497 . . . . 0.0 111.104 179.924 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 238' ' ' ALA . . . . . 0.429 ' H ' ' H ' ' A' ' 239' ' ' ASP . . . -155.39 -12.53 0.11 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.087 -0.506 . . . . 0.0 111.072 179.928 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 239' ' ' ASP . . . . . 0.429 ' H ' ' H ' ' A' ' 238' ' ' ALA . 16.3 m-20 58.62 96.33 0.03 OUTLIER 'General case' 0 N--CA 1.463 0.176 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.854 -179.821 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 240' ' ' LEU . . . . . . . . . . . . . 61.9 mt -115.24 0.6 13.57 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.233 -0.44 . . . . 0.0 111.243 -179.748 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 241' ' ' GLU . . . . . . . . . . . . . 1.5 mp0 -81.99 162.63 22.58 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.424 -0.353 . . . . 0.0 110.667 179.768 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 242' ' ' HIS . . . . . . . . . . . . . 63.4 t60 -143.59 -44.44 0.28 Allowed 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.377 -0.374 . . . . 0.0 110.932 -179.881 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 243' ' ' HIS . . . . . . . . . . . . . 43.3 m80 -66.18 121.49 15.31 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.774 -179.974 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 244' ' ' HIS . . . . . . . . . . . . . 54.8 t-80 -134.44 114.01 12.44 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.287 -0.415 . . . . 0.0 110.973 179.938 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 245' ' ' HIS . . . . . . . . . . . . . 47.8 m80 -107.64 147.76 30.24 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.894 -179.94 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 246' ' ' HIS . . . . . . . . . . . . . 93.5 m-70 -93.77 -36.7 12.15 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.901 -179.967 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 247' ' ' HIS . . . . . . . . . . . . . 7.2 m80 . . . . . 0 C--O 1.25 1.11 0 CA-C-O 118.193 -0.908 . . . . 0.0 110.892 -179.962 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 301' ' ' RET . . . . . 0.818 H203 ' HE1' ' A' ' 171' ' ' TRP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 2.7 mpp? . . . . . 0 N--CA 1.486 1.375 0 CA-C-O 120.905 0.383 . . . . 0.0 110.867 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 16.2 m -138.64 -39.95 0.31 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 115.971 -0.559 . . . . 0.0 111.251 -179.948 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -106.76 -13.37 22.21 Favored Glycine 0 N--CA 1.45 -0.422 0 C-N-CA 120.785 -0.721 . . . . 0.0 112.744 -179.989 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 52.0 tp -74.15 -35.47 64.05 Favored 'General case' 0 C--N 1.331 -0.21 0 CA-C-O 120.867 0.365 . . . . 0.0 110.752 179.928 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 64.9 p -64.15 -32.61 74.24 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.014 -0.539 . . . . 0.0 111.276 -179.99 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 15.9 p -52.87 -35.4 57.71 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.264 -179.647 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 7' ' ' LEU . . . . . 0.412 HD12 ' HA ' ' A' ' 195' ' ' ALA . 4.2 mm? -60.8 -53.34 58.52 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.242 -179.814 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 8' ' ' PHE . . . . . 0.437 ' HB2' ' HB2' ' A' ' 55' ' ' ALA . 64.0 m-85 -60.08 -32.7 71.2 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.928 0.394 . . . . 0.0 110.641 -179.986 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 9' ' ' TRP . . . . . 0.432 ' O ' HG13 ' A' ' 13' ' ' ILE . 35.8 m95 -67.08 -41.69 85.93 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 115.943 -0.571 . . . . 0.0 110.092 179.622 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 82.5 mt -61.57 -52.75 63.15 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 115.721 -0.672 . . . . 0.0 110.205 179.244 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -53.48 -36.46 53.77 Favored Glycine 0 N--CA 1.449 -0.492 0 C-N-CA 120.775 -0.726 . . . . 0.0 111.612 178.766 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -64.07 -34.68 78.58 Favored 'General case' 0 C--N 1.332 -0.191 0 CA-C-O 120.91 0.386 . . . . 0.0 110.226 179.258 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 13' ' ' ILE . . . . . 0.432 HG13 ' O ' ' A' ' 9' ' ' TRP . 80.1 mt -66.13 -48.48 81.3 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.219 0 CA-C-N 115.884 -0.598 . . . . 0.0 110.363 179.268 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -60.94 -32.96 81.81 Favored Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.662 -0.78 . . . . 0.0 111.482 179.35 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 15' ' ' MET . . . . . 0.656 ' HB3' ' HB2' ' A' ' 48' ' ' ALA . 0.0 OUTLIER -67.99 -42.68 80.39 Favored 'General case' 0 C--N 1.331 -0.218 0 CA-C-O 120.92 0.391 . . . . 0.0 110.553 179.186 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 32.4 tp -57.8 -41.41 82.09 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.029 -0.532 . . . . 0.0 110.442 179.474 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 89.4 t -64.65 -51.03 72.68 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.22 0 CA-C-N 115.824 -0.625 . . . . 0.0 111.094 179.972 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -62.03 -49.51 74.57 Favored Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.686 -0.769 . . . . 0.0 112.183 179.913 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 51.9 m -49.77 -41.58 44.58 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-O 120.752 0.31 . . . . 0.0 111.326 -179.561 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 78.1 mt -72.07 -48.59 43.05 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.272 -0.422 . . . . 0.0 111.427 179.836 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -59.5 -29.64 68.0 Favored 'General case' 0 C--N 1.329 -0.296 0 N-CA-C 112.192 0.442 . . . . 0.0 112.192 -179.284 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 8.0 m-85 -88.11 -45.57 10.04 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-O 120.661 0.267 . . . . 0.0 111.53 -179.307 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -60.7 -50.37 73.76 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.884 0.373 . . . . 0.0 111.589 -179.615 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 24' ' ' TRP . . . . . . . . . . . . . 2.0 t-105 -58.54 -44.19 89.53 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 116.007 -0.542 . . . . 0.0 111.119 -179.727 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -74.98 -18.26 60.4 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-O 120.854 0.359 . . . . 0.0 110.998 -179.998 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -73.81 -48.31 17.16 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.849 -0.691 . . . . 0.0 112.493 179.923 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 21.4 mmm180 -57.98 -30.57 66.14 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-O 120.838 0.352 . . . . 0.0 110.908 -179.926 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 25.4 t70 -102.05 91.84 4.51 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.067 -0.515 . . . . 0.0 110.799 -179.958 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -169.96 -176.46 2.32 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.058 -0.519 . . . . 0.0 111.081 -179.962 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -92.04 177.54 39.93 Favored Glycine 0 N--CA 1.452 -0.275 0 C-N-CA 120.784 -0.722 . . . . 0.0 112.444 179.795 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 78.2 p -80.84 127.32 32.4 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.784 0.325 . . . . 0.0 111.057 -179.947 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 115.66 -27.95 8.06 Favored Glycine 0 N--CA 1.452 -0.246 0 C-N-CA 120.847 -0.692 . . . . 0.0 112.435 179.916 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 11.0 mm-40 -92.12 -24.64 19.05 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.841 0.353 . . . . 0.0 110.83 179.959 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 34' ' ' ARG . . . . . . . . . . . . . 78.6 mtm180 -50.48 -29.24 9.94 Favored 'General case' 0 C--N 1.332 -0.177 0 CA-C-N 115.943 -0.572 . . . . 0.0 111.575 -179.647 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 41.3 mmt180 -60.45 -46.5 89.82 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.767 0.318 . . . . 0.0 111.33 -179.904 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 76.6 m-85 -69.88 -30.58 68.06 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.282 -0.417 . . . . 0.0 111.456 -179.605 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 37' ' ' TYR . . . . . . . . . . . . . 62.8 m-85 -70.62 -55.12 9.51 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.289 -0.414 . . . . 0.0 111.302 -179.619 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 60.7 t -57.04 -37.84 57.19 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-O 120.957 0.408 . . . . 0.0 110.453 179.774 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 41.8 m -63.58 -47.98 79.29 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 115.847 -0.615 . . . . 0.0 110.316 179.209 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 27.6 tp -57.4 -48.21 79.69 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 115.52 -0.764 . . . . 0.0 110.539 179.677 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 76.3 t -60.63 -34.48 58.78 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.231 0 CA-C-N 115.717 -0.674 . . . . 0.0 110.382 179.242 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -60.03 -40.18 96.68 Favored Glycine 0 N--CA 1.449 -0.484 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.118 179.824 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 43' ' ' ILE . . . . . 0.531 HG22 ' HE3' ' A' ' 205' ' ' LYS . 0.4 OUTLIER -65.2 -53.86 35.74 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-O 120.728 0.299 . . . . 0.0 111.008 179.583 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 49.1 m -60.31 -25.75 66.0 Favored 'General case' 0 C--N 1.332 -0.181 0 CA-C-O 120.793 0.33 . . . . 0.0 111.37 -179.942 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -78.42 -51.74 5.49 Favored Glycine 0 CA--C 1.519 0.313 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.978 -179.54 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 46' ' ' ILE . . . . . 0.484 ' CD1' HG22 ' A' ' 79' ' ' THR . 21.8 pt -58.97 -38.73 75.41 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.217 0 CA-C-O 120.873 0.368 . . . . 0.0 111.035 -179.976 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 47' ' ' ALA . . . . . 0.736 ' HB2' ' HE2' ' A' ' 205' ' ' LYS . . . -67.85 -45.0 75.85 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.544 179.636 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 48' ' ' ALA . . . . . 0.656 ' HB2' ' HB3' ' A' ' 15' ' ' MET . . . -54.54 -41.58 69.9 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.069 -0.514 . . . . 0.0 112.024 -179.295 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 49' ' ' VAL . . . . . 0.417 ' O ' HG13 ' A' ' 53' ' ' VAL . 30.4 m -76.79 -34.35 22.84 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.36 0 CA-C-N 116.48 -0.327 . . . . 0.0 111.815 -179.21 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -66.92 -36.39 82.14 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 120.91 0.386 . . . . 0.0 111.101 179.922 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 3.3 m-85 -73.29 -40.09 64.83 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 115.987 -0.551 . . . . 0.0 110.452 179.951 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -62.79 -49.91 73.1 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-N 115.726 -0.67 . . . . 0.0 111.227 179.854 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 53' ' ' VAL . . . . . 0.491 ' O ' HG22 ' A' ' 58' ' ' VAL . 27.6 m -63.83 -46.02 95.48 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.218 0 CA-C-N 116.366 -0.379 . . . . 0.0 110.749 -179.975 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 54' ' ' MET . . . . . 0.5 ' HB2' ' HB2' ' A' ' 71' ' ' PRO . 11.0 ttp -64.11 -29.73 70.84 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.313 179.756 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 55' ' ' ALA . . . . . 0.437 ' HB2' ' HB2' ' A' ' 8' ' ' PHE . . . -63.0 -23.71 67.58 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 115.871 -0.604 . . . . 0.0 110.926 179.442 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 54.0 mt -94.47 -8.85 37.31 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-N 116.079 -0.51 . . . . 0.0 110.726 179.812 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . 0.432 ' HA2' ' CD1' ' A' ' 60' ' ' TRP . . . 75.19 30.66 58.55 Favored Glycine 0 N--CA 1.451 -0.361 0 C-N-CA 120.876 -0.678 . . . . 0.0 112.953 179.723 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 58' ' ' VAL . . . . . 0.491 HG22 ' O ' ' A' ' 53' ' ' VAL . 26.3 m -84.04 18.2 0.37 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-O 120.808 0.337 . . . . 0.0 111.504 179.992 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -152.87 6.6 0.45 Allowed Glycine 0 N--CA 1.449 -0.485 0 C-N-CA 120.751 -0.737 . . . . 0.0 112.888 179.947 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 60' ' ' TRP . . . . . 0.432 ' CD1' ' HA2' ' A' ' 57' ' ' GLY . 34.5 m0 -71.95 121.5 19.21 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-O 120.783 0.325 . . . . 0.0 110.48 179.921 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 7.5 p -114.91 128.59 25.78 Favored Pre-proline 0 CA--C 1.533 0.303 0 CA-C-N 116.263 -0.426 . . . . 0.0 111.388 -179.733 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 65.0 Cg_endo -73.95 144.01 33.73 Favored 'Trans proline' 0 C--N 1.351 0.686 0 C-N-CA 122.396 2.064 . . . . 0.0 112.107 179.719 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 59.0 t -137.83 90.42 0.72 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.384 0 CA-C-N 116.086 -0.506 . . . . 0.0 111.061 -179.645 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . 58.43 -88.05 0.02 OUTLIER 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 116.116 -0.493 . . . . 0.0 111.587 -179.996 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 45.6 mt-10 -119.19 -19.96 8.16 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-O 120.775 0.321 . . . . 0.0 110.958 179.995 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 66' ' ' ARG . . . . . . . . . . . . . 9.9 ptp180 -103.23 165.19 11.17 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.268 -0.423 . . . . 0.0 110.449 179.651 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 53.9 m -123.35 129.64 51.6 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.937 0.398 . . . . 0.0 111.472 -179.677 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 99.2 t -109.73 146.33 15.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 115.889 -0.596 . . . . 0.0 110.492 179.644 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 69' ' ' PHE . . . . . . . . . . . . . 30.3 m-85 -105.59 115.47 30.3 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 121.049 0.452 . . . . 0.0 110.484 -179.474 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 70' ' ' VAL . . . . . 0.628 HG12 ' HD3' ' A' ' 71' ' ' PRO . 0.3 OUTLIER -67.98 -36.29 9.13 Favored Pre-proline 0 CA--C 1.54 0.58 0 CA-C-N 115.863 -0.608 . . . . 0.0 112.601 -179.48 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 71' ' ' PRO . . . . . 0.628 ' HD3' HG12 ' A' ' 70' ' ' VAL . 7.7 Cg_exo -71.09 -19.12 30.28 Favored 'Trans proline' 0 C--N 1.357 1.016 0 C-N-CA 122.21 1.94 . . . . 0.0 113.308 -179.198 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 43.0 ttm180 -76.35 -55.09 5.87 Favored 'General case' 0 C--N 1.331 -0.206 0 N-CA-C 112.372 0.508 . . . . 0.0 112.372 -178.505 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 73' ' ' TYR . . . . . 0.452 ' O ' HG13 ' A' ' 77' ' ' ILE . 68.5 m-85 -71.19 -36.76 72.06 Favored 'General case' 0 C--N 1.329 -0.286 0 C-N-CA 120.841 -0.344 . . . . 0.0 110.956 -179.248 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 74' ' ' ILE . . . . . 0.432 ' O ' HD13 ' A' ' 74' ' ' ILE . 0.3 OUTLIER -64.95 -40.43 89.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 N-CA-C 109.766 -0.457 . . . . 0.0 109.766 179.309 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 75' ' ' ASP . . . . . 0.517 ' O ' HG23 ' A' ' 79' ' ' THR . 12.0 t70 -60.23 -37.51 80.55 Favored 'General case' 0 CA--C 1.518 -0.251 0 N-CA-C 109.437 -0.579 . . . . 0.0 109.437 178.772 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 76' ' ' TRP . . . . . . . . . . . . . 46.6 m0 -64.03 -31.44 72.63 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 115.899 -0.591 . . . . 0.0 110.319 179.478 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 77' ' ' ILE . . . . . 0.512 ' O ' ' HG2' ' A' ' 81' ' ' PRO . 61.8 mt -71.28 -31.72 44.79 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.478 178.963 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 25.6 mt -91.82 -15.13 28.66 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.172 -0.467 . . . . 0.0 112.165 -179.707 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 79' ' ' THR . . . . . 0.517 HG23 ' O ' ' A' ' 75' ' ' ASP . 79.8 p -104.61 -52.97 2.78 Favored 'General case' 0 N--CA 1.465 0.296 0 N-CA-C 113.614 0.968 . . . . 0.0 113.614 -177.891 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 80' ' ' THR . . . . . 0.583 ' HB ' ' HD3' ' A' ' 81' ' ' PRO . 4.5 m -52.66 -53.68 51.41 Favored Pre-proline 0 C--N 1.331 -0.237 0 N-CA-C 112.36 0.504 . . . . 0.0 112.36 -178.369 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 81' ' ' PRO . . . . . 0.583 ' HD3' ' HB ' ' A' ' 80' ' ' THR . 52.6 Cg_exo -57.01 -23.43 52.01 Favored 'Trans proline' 0 C--N 1.352 0.752 0 C-N-CA 121.612 1.541 . . . . 0.0 111.68 179.543 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 82' ' ' LEU . . . . . . . . . . . . . 18.0 tp -76.76 -33.19 58.1 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 115.926 -0.579 . . . . 0.0 110.054 179.604 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 83' ' ' ILE . . . . . 0.451 HD11 HG21 ' A' ' 43' ' ' ILE . 37.6 mm -69.36 -53.37 25.49 Favored 'Isoleucine or valine' 0 C--O 1.232 0.161 0 CA-C-N 116.007 -0.542 . . . . 0.0 110.386 179.226 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 29.0 m -59.36 -32.8 49.34 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.183 0 N-CA-C 109.8 -0.444 . . . . 0.0 109.8 179.005 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 85' ' ' TYR . . . . . . . . . . . . . 55.4 t80 -64.66 -34.57 78.6 Favored 'General case' 0 N--CA 1.454 -0.272 0 CA-C-N 115.657 -0.701 . . . . 0.0 109.561 178.801 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 86' ' ' PHE . . . . . . . . . . . . . 8.8 t80 -61.48 -51.82 67.07 Favored 'General case' 0 C--O 1.232 0.181 0 CA-C-N 115.635 -0.711 . . . . 0.0 110.232 179.507 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 7.3 mp -61.71 -31.93 72.11 Favored 'General case' 0 C--N 1.331 -0.204 0 CA-C-N 116.136 -0.483 . . . . 0.0 110.116 179.49 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -71.59 -27.57 70.89 Favored Glycine 0 N--CA 1.449 -0.44 0 CA-C-N 115.8 -0.636 . . . . 0.0 111.795 179.31 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 42.0 mt -72.07 -39.2 69.18 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.919 0.39 . . . . 0.0 110.538 179.733 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 53.6 mt -58.5 -45.8 88.01 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 115.782 -0.645 . . . . 0.0 111.106 -179.967 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . 0.588 ' HB2' ' HB2' ' A' ' 149' ' ' ALA . . . -79.88 -54.94 5.35 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.403 -179.728 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 102.84 65.64 0.73 Allowed Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.826 -0.702 . . . . 0.0 112.346 -179.888 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 93' ' ' LEU . . . . . 0.46 HD11 ' HG2' ' A' ' 145' ' ' MET . 8.1 mp -71.93 172.04 10.67 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.804 0.335 . . . . 0.0 111.053 179.998 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 94' ' ' ASP . . . . . 0.47 ' HB2' ' HG2' ' A' ' 97' ' ' GLU . 10.1 m-20 -78.54 174.3 11.5 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.811 179.942 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 71.4 p -61.62 -51.27 69.19 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.176 -0.466 . . . . 0.0 111.215 -179.858 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 97.8 mtt180 -65.39 -42.15 92.93 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.374 -179.66 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 97' ' ' GLU . . . . . 0.47 ' HG2' ' HB2' ' A' ' 94' ' ' ASP . 10.3 mm-40 -52.49 -50.76 62.1 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.311 -0.404 . . . . 0.0 111.163 -179.625 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 98' ' ' PHE . . . . . 0.458 ' O ' HG12 ' A' ' 102' ' ' ILE . 12.2 m-85 -56.18 -46.23 79.44 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.354 -0.385 . . . . 0.0 110.683 179.633 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -60.54 -29.67 70.09 Favored Glycine 0 N--CA 1.448 -0.505 0 C-N-CA 120.688 -0.768 . . . . 0.0 112.34 179.978 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 96.6 mt -73.87 -42.63 53.59 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.238 0 CA-C-O 120.786 0.327 . . . . 0.0 111.717 -179.853 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 39.8 t -70.61 -42.58 77.98 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 CA-C-N 116.427 -0.351 . . . . 0.0 111.519 -179.335 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 102' ' ' ILE . . . . . 0.458 HG12 ' O ' ' A' ' 98' ' ' PHE . 49.2 mm -64.92 -45.78 93.72 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.368 -0.378 . . . . 0.0 111.552 -179.548 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 13.7 t -62.22 -35.52 79.14 Favored 'General case' 0 C--O 1.233 0.211 0 CA-C-O 120.847 0.356 . . . . 0.0 110.661 179.879 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 104' ' ' LEU . . . . . 0.441 ' O ' HG23 ' A' ' 108' ' ' VAL . 29.8 tp -57.39 -53.82 53.86 Favored 'General case' 0 C--N 1.331 -0.202 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.258 179.241 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 105' ' ' ASN . . . . . 0.607 ' N ' HD22 ' A' ' 105' ' ' ASN . 0.8 OUTLIER -56.25 -36.67 68.81 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 115.952 -0.567 . . . . 0.0 110.433 179.709 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 30.6 m -54.92 -43.41 73.28 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.511 179.621 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 107' ' ' VAL . . . . . 0.454 HG12 ' SD ' ' A' ' 129' ' ' MET . 1.2 t -65.64 -39.49 85.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-O 121.274 0.559 . . . . 0.0 110.187 179.206 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . 0.441 HG23 ' O ' ' A' ' 104' ' ' LEU . 41.7 t -60.03 -53.16 52.4 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.38 0 CA-C-N 115.291 -0.868 . . . . 0.0 111.782 -179.728 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 109' ' ' MET . . . . . 0.449 ' HG2' ' O ' ' A' ' 105' ' ' ASN . 8.0 mmt -61.85 -41.86 98.34 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-N 116.306 -0.406 . . . . 0.0 111.257 -179.284 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 28.6 tp -60.21 -30.27 69.27 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 116.377 -0.374 . . . . 0.0 110.461 -179.906 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -66.55 -54.87 18.97 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.552 179.217 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . -60.02 -36.22 89.66 Favored Glycine 0 N--CA 1.452 -0.24 0 C-N-CA 120.497 -0.859 . . . . 0.0 111.722 179.373 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 113' ' ' PHE . . . . . . . . . . . . . 0.9 OUTLIER -56.1 -75.09 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 121.051 0.453 . . . . 0.0 110.357 179.647 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -58.44 -29.72 66.37 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 115.679 -0.691 . . . . 0.0 111.418 -179.91 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -52.3 -49.12 52.2 Favored Glycine 0 C--N 1.331 0.254 0 C-N-CA 121.075 -0.583 . . . . 0.0 112.726 -179.993 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -77.71 -16.87 58.16 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-O 120.697 0.284 . . . . 0.0 111.458 -179.976 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 117' ' ' MET . . . . . . . . . . . . . 38.3 ttm -100.95 18.08 20.57 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.352 -0.385 . . . . 0.0 111.321 -179.387 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 118' ' ' VAL . . . . . 0.479 HG21 ' HB3' ' A' ' 123' ' ' ARG . 27.1 m -70.05 148.31 96.03 Favored Pre-proline 0 C--N 1.329 -0.302 0 CA-C-N 116.451 -0.34 . . . . 0.0 111.15 179.794 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 119' ' ' PRO . . . . . . . . . . . . . 90.6 Cg_endo -83.7 -3.77 10.63 Favored 'Trans proline' 0 C--N 1.348 0.52 0 C-N-CA 122.567 2.178 . . . . 0.0 112.136 179.719 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -156.25 -141.51 3.21 Favored Glycine 0 N--CA 1.453 -0.229 0 C-N-CA 120.926 -0.654 . . . . 0.0 112.452 -179.981 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 41.0 pt -84.71 18.87 0.37 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.229 0 CA-C-O 120.845 0.355 . . . . 0.0 111.062 -179.99 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 122' ' ' GLU . . . . . 0.459 ' HB2' ' HB ' ' A' ' 118' ' ' VAL . 12.3 mm-40 -67.52 -18.01 64.88 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.0 -0.545 . . . . 0.0 111.36 -179.926 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 123' ' ' ARG . . . . . 0.479 ' HB3' HG21 ' A' ' 118' ' ' VAL . 0.0 OUTLIER -51.11 -30.2 15.56 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-N 116.424 -0.353 . . . . 0.0 111.457 -179.532 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 124' ' ' TYR . . . . . . . . . . . . . 34.6 m-85 -70.23 -32.52 70.42 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-O 120.735 0.302 . . . . 0.0 111.202 -179.717 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 125' ' ' ALA . . . . . . . . . . . . . . . -67.88 -52.2 39.33 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.268 -0.423 . . . . 0.0 110.887 179.88 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 126' ' ' LEU . . . . . 0.402 HD13 ' HA ' ' A' ' 126' ' ' LEU . 3.2 mm? -53.24 -54.44 36.07 Favored 'General case' 0 CA--C 1.521 -0.168 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.581 179.69 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 127' ' ' PHE . . . . . 0.481 ' HZ ' ' HB3' ' A' ' 175' ' ' PRO . 9.4 t80 -62.33 -35.74 80.03 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.082 -179.63 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 128' ' ' GLY . . . . . . . . . . . . . . . -47.23 -48.1 20.76 Favored Glycine 0 C--N 1.332 0.314 0 C-N-CA 119.925 -1.131 . . . . 0.0 110.287 178.718 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 129' ' ' MET . . . . . 0.454 ' SD ' HG12 ' A' ' 107' ' ' VAL . 0.4 OUTLIER -71.21 -31.41 67.55 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 115.019 -0.591 . . . . 0.0 109.697 178.379 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -60.96 -41.09 99.25 Favored Glycine 0 C--N 1.332 0.359 0 CA-C-N 115.821 -0.627 . . . . 0.0 112.753 -179.864 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -71.28 -51.92 21.75 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.644 0.259 . . . . 0.0 110.518 179.807 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 57.4 t -55.04 -39.95 52.19 Favored 'Isoleucine or valine' 0 C--O 1.233 0.226 0 CA-C-O 121.3 0.571 . . . . 0.0 109.694 178.95 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -70.77 -37.35 73.36 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 115.407 -0.815 . . . . 0.0 110.658 179.602 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 134' ' ' PHE . . . . . . . . . . . . . 43.6 t80 -56.62 -53.35 58.64 Favored 'General case' 0 N--CA 1.451 -0.386 0 CA-C-O 120.995 0.426 . . . . 0.0 109.984 179.567 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 135' ' ' ILE . . . . . . . . . . . . . 48.4 mt -58.02 -33.48 46.46 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.405 0 CA-C-N 115.787 -0.642 . . . . 0.0 109.838 179.227 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . -58.82 -40.73 95.47 Favored Glycine 0 N--CA 1.448 -0.53 0 C-N-CA 120.394 -0.908 . . . . 0.0 111.473 178.905 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 137' ' ' LEU . . . . . 0.416 HD13 HD21 ' A' ' 105' ' ' ASN . 53.5 tp -69.73 -45.04 69.05 Favored 'General case' 0 N--CA 1.455 -0.193 0 CA-C-O 120.693 0.282 . . . . 0.0 110.588 179.411 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 138' ' ' VAL . . . . . . . . . . . . . 98.8 t -56.05 -40.99 66.9 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.9 0 CA-C-O 121.222 0.534 . . . . 0.0 109.896 179.231 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 139' ' ' TYR . . . . . . . . . . . . . 29.4 t80 -59.05 -47.14 86.31 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 115.416 -0.811 . . . . 0.0 110.612 178.937 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 22.9 m-85 -54.52 -37.77 65.74 Favored 'General case' 0 C--N 1.332 -0.16 0 CA-C-N 116.39 -0.368 . . . . 0.0 110.911 179.942 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 141' ' ' LEU . . . . . 0.491 HD23 ' SD ' ' A' ' 145' ' ' MET . 79.8 mt -60.89 -50.7 72.37 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-O 120.905 0.383 . . . . 0.0 110.366 179.502 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 22.0 t -70.52 -15.21 18.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.034 -0.53 . . . . 0.0 110.723 179.531 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . -70.37 -140.24 0.16 Allowed Glycine 0 CA--C 1.521 0.461 0 C-N-CA 121.015 -0.612 . . . . 0.0 112.842 -179.88 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 144' ' ' PRO . . . . . . . . . . . . . 42.0 Cg_exo -56.64 -23.69 50.35 Favored 'Trans proline' 0 C--N 1.35 0.639 0 C-N-CA 122.641 2.227 . . . . 0.0 112.63 -179.794 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 145' ' ' MET . . . . . 0.491 ' SD ' HD23 ' A' ' 141' ' ' LEU . 54.5 mtt -57.93 -31.65 67.01 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.391 -0.368 . . . . 0.0 111.429 -179.867 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 146' ' ' THR . . . . . . . . . . . . . 25.0 m -74.11 -48.34 30.24 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.278 -0.419 . . . . 0.0 112.05 -179.061 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 45.1 mt-10 -72.92 -29.02 62.81 Favored 'General case' 0 C--N 1.329 -0.302 0 N-CA-C 111.762 0.282 . . . . 0.0 111.762 -179.157 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 148' ' ' SER . . . . . 0.408 ' HB3' ' HB1' ' A' ' 91' ' ' ALA . 46.8 t -70.76 -47.81 57.68 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.519 -0.31 . . . . 0.0 111.497 -179.179 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 149' ' ' ALA . . . . . 0.588 ' HB2' ' HB2' ' A' ' 91' ' ' ALA . . . -73.54 -43.23 60.44 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.378 -0.374 . . . . 0.0 111.865 -179.259 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 150' ' ' SER . . . . . 0.493 ' HA ' ' HB3' ' A' ' 157' ' ' LYS . 42.8 t -65.51 -8.4 19.34 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.457 -0.338 . . . . 0.0 111.286 -179.613 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 151' ' ' GLN . . . . . . . . . . . . . 46.2 mt-30 -124.89 15.73 8.59 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.454 -0.339 . . . . 0.0 111.161 179.999 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 31.3 tpt180 -90.79 -52.02 5.08 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 121.093 0.473 . . . . 0.0 110.275 179.646 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 153' ' ' SER . . . . . 0.613 ' HB2' HG12 ' A' ' 156' ' ' ILE . 24.6 m -158.02 172.69 17.98 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 115.719 -0.673 . . . . 0.0 110.473 179.228 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 154' ' ' SER . . . . . . . . . . . . . 78.3 p -70.55 -38.69 74.19 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.335 -0.393 . . . . 0.0 110.482 179.438 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -77.87 -38.01 28.22 Favored Glycine 0 N--CA 1.452 -0.265 0 C-N-CA 121.04 -0.6 . . . . 0.0 112.845 179.781 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 156' ' ' ILE . . . . . 0.613 HG12 ' HB2' ' A' ' 153' ' ' SER . 39.0 mm -53.4 -44.48 55.08 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.202 0 N-CA-C 111.917 0.34 . . . . 0.0 111.917 -179.204 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 157' ' ' LYS . . . . . 0.493 ' HB3' ' HA ' ' A' ' 150' ' ' SER . 18.9 ptpt -65.78 -30.88 71.59 Favored 'General case' 0 C--N 1.329 -0.288 0 N-CA-C 111.714 0.264 . . . . 0.0 111.714 -179.225 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 47.8 t -71.7 -48.37 47.76 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 121.076 0.465 . . . . 0.0 111.077 -179.539 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 159' ' ' LEU . . . . . 0.482 ' O ' ' HB2' ' A' ' 163' ' ' LEU . 8.4 mp -71.53 -29.81 65.19 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 115.875 -0.602 . . . . 0.0 111.313 -179.785 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 160' ' ' TYR . . . . . . . . . . . . . 92.8 t80 -70.73 -44.84 65.99 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.397 -0.365 . . . . 0.0 111.739 -179.402 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 161' ' ' VAL . . . . . 0.421 HG13 ' O ' ' A' ' 157' ' ' LYS . 28.6 m -66.05 -42.34 91.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 N-CA-C 111.624 0.231 . . . . 0.0 111.624 -179.365 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 162' ' ' ARG . . . . . . . . . . . . . 95.7 mtt180 -67.99 -44.71 75.99 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.796 0.331 . . . . 0.0 111.497 -179.808 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 163' ' ' LEU . . . . . 0.482 ' HB2' ' O ' ' A' ' 159' ' ' LEU . 4.5 mp -71.55 -54.16 11.41 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.264 -0.426 . . . . 0.0 112.039 -179.19 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 164' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -53.05 -41.64 65.01 Favored 'General case' 0 C--N 1.328 -0.353 0 N-CA-C 111.957 0.354 . . . . 0.0 111.957 -178.783 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 165' ' ' ASN . . . . . 0.51 HD22 ' N ' ' A' ' 165' ' ' ASN . 0.9 OUTLIER -67.03 -52.31 43.93 Favored 'General case' 0 C--N 1.329 -0.318 0 N-CA-C 112.013 0.375 . . . . 0.0 112.013 -179.114 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 166' ' ' LEU . . . . . 0.46 HD21 ' CE1' ' A' ' 208' ' ' PHE . 0.0 OUTLIER -67.45 -33.13 74.5 Favored 'General case' 0 C--N 1.329 -0.288 0 N-CA-C 111.643 0.238 . . . . 0.0 111.643 -178.871 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 167' ' ' THR . . . . . 0.451 ' O ' ' HB2' ' A' ' 171' ' ' TRP . 27.5 m -63.04 -53.83 47.72 Favored 'General case' 0 C--N 1.332 -0.195 0 N-CA-C 111.939 0.348 . . . . 0.0 111.939 -179.976 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 168' ' ' VAL . . . . . 0.426 HG12 ' O ' ' A' ' 165' ' ' ASN . 9.9 p -59.28 -40.07 80.41 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.242 0 CA-C-N 116.486 -0.325 . . . . 0.0 111.541 -178.924 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 169' ' ' VAL . . . . . 0.505 HG23 ' O ' ' A' ' 165' ' ' ASN . 74.0 t -57.14 -65.38 0.41 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.563 -0.29 . . . . 0.0 111.45 -179.767 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 170' ' ' LEU . . . . . 0.433 ' HG ' ' O ' ' A' ' 166' ' ' LEU . 2.7 pp -63.09 -29.78 71.08 Favored 'General case' 0 C--N 1.331 -0.228 0 N-CA-C 111.908 0.336 . . . . 0.0 111.908 -179.085 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 171' ' ' TRP . . . . . 0.77 ' HE1' H203 ' A' ' 301' ' ' RET . 2.5 m0 -72.51 -31.47 65.37 Favored 'General case' 0 C--N 1.331 -0.21 0 C-N-CA 120.797 -0.361 . . . . 0.0 110.761 179.612 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 172' ' ' ALA . . . . . . . . . . . . . . . -72.94 -6.24 43.92 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-O 121.055 0.455 . . . . 0.0 110.367 179.439 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 173' ' ' ILE . . . . . 0.61 HG22 HD11 ' A' ' 177' ' ' ILE . 37.2 mm -82.89 -25.99 8.19 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.206 0 CA-C-N 115.771 -0.649 . . . . 0.0 110.999 179.791 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 174' ' ' TYR . . . . . 0.489 ' HB2' ' HD3' ' A' ' 175' ' ' PRO . 49.9 m-85 -54.55 -50.7 83.95 Favored Pre-proline 0 N--CA 1.464 0.272 0 CA-C-N 116.353 -0.385 . . . . 0.0 111.671 -179.665 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 175' ' ' PRO . . . . . 0.489 ' HD3' ' HB2' ' A' ' 174' ' ' TYR . 97.2 Cg_exo -45.19 -30.29 4.96 Favored 'Trans proline' 0 C--N 1.35 0.647 0 C-N-CA 122.186 1.924 . . . . 0.0 112.403 179.65 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 176' ' ' PHE . . . . . 0.459 ' O ' ' HG ' ' A' ' 180' ' ' LEU . 65.8 m-85 -80.57 -49.67 11.01 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 115.979 -0.555 . . . . 0.0 111.989 -179.729 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 177' ' ' ILE . . . . . 0.61 HD11 HG22 ' A' ' 173' ' ' ILE . 2.3 mm -61.59 -37.37 77.74 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.53 0 N-CA-C 112.723 0.638 . . . . 0.0 112.723 -177.693 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 178' ' ' TRP . . . . . . . . . . . . . 63.0 t90 -72.55 -44.9 61.48 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 120.875 0.369 . . . . 0.0 110.823 179.7 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 179' ' ' LEU . . . . . 0.492 ' O ' HG22 ' A' ' 185' ' ' VAL . 2.5 tm? -67.15 -49.25 65.43 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 115.907 -0.588 . . . . 0.0 111.72 -179.0 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 180' ' ' LEU . . . . . 0.549 HD22 HD11 ' A' ' 187' ' ' LEU . 23.1 mt -77.24 -45.28 26.98 Favored 'General case' 0 C--N 1.326 -0.424 0 N-CA-C 111.982 0.364 . . . . 0.0 111.982 -178.796 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . -57.32 178.91 0.88 Allowed Glycine 0 C--N 1.334 0.47 0 C-N-CA 120.438 -0.887 . . . . 0.0 112.82 -179.878 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 182' ' ' PRO . . . . . 0.609 ' HA ' ' HB2' ' A' ' 186' ' ' ALA . 71.5 Cg_exo -47.78 -46.06 22.41 Favored 'Trans proline' 0 CA--C 1.537 0.67 0 C-N-CA 123.0 2.466 . . . . 0.0 114.177 -179.709 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 183' ' ' PRO . . . . . 0.578 ' HD2' ' N ' ' A' ' 182' ' ' PRO . 16.9 Cg_endo -57.53 -9.92 6.05 Favored 'Trans proline' 0 C--N 1.355 0.885 0 C-N-CA 122.02 1.813 . . . . 0.0 113.246 -179.409 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 184' ' ' GLY . . . . . 0.434 ' HA3' ' O ' ' A' ' 179' ' ' LEU . . . -116.23 -86.8 1.3 Allowed Glycine 0 N--CA 1.45 -0.379 0 C-N-CA 120.536 -0.84 . . . . 0.0 112.722 179.781 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 185' ' ' VAL . . . . . 0.492 HG22 ' O ' ' A' ' 179' ' ' LEU . 9.0 m -123.47 -4.1 7.18 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.246 0 CA-C-O 120.781 0.324 . . . . 0.0 111.544 -179.817 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 186' ' ' ALA . . . . . 0.609 ' HB2' ' HA ' ' A' ' 182' ' ' PRO . . . 54.56 84.83 0.06 Allowed 'General case' 0 N--CA 1.463 0.195 0 CA-C-N 116.113 -0.494 . . . . 0.0 111.828 179.557 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 187' ' ' LEU . . . . . 0.549 HD11 HD22 ' A' ' 180' ' ' LEU . 14.8 mt -92.1 -48.72 6.58 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-O 120.973 0.416 . . . . 0.0 110.906 179.509 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 188' ' ' LEU . . . . . . . . . . . . . 89.7 mt -96.82 -152.91 0.4 Allowed 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 115.883 -0.599 . . . . 0.0 111.014 -179.575 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 189' ' ' THR . . . . . 0.413 ' HB ' HG23 ' A' ' 192' ' ' VAL . 86.5 m -96.37 136.25 22.04 Favored Pre-proline 0 C--N 1.33 -0.261 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.712 -179.71 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 190' ' ' PRO . . . . . . . . . . . . . 88.7 Cg_exo -46.48 -43.07 22.75 Favored 'Trans proline' 0 C--N 1.349 0.585 0 C-N-CA 122.459 2.106 . . . . 0.0 112.855 -179.825 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 191' ' ' THR . . . . . . . . . . . . . 82.0 p -65.41 -38.64 90.57 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.376 -0.375 . . . . 0.0 111.731 -179.601 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 192' ' ' VAL . . . . . 0.413 HG23 ' HB ' ' A' ' 189' ' ' THR . 58.1 t -71.78 -53.71 19.44 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.394 -0.366 . . . . 0.0 111.415 -179.628 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 193' ' ' ASP . . . . . . . . . . . . . 26.5 t70 -54.19 -47.97 71.48 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.244 -0.435 . . . . 0.0 111.049 -179.867 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 194' ' ' VAL . . . . . 0.493 ' O ' HG22 ' A' ' 198' ' ' VAL . 46.7 t -60.13 -40.18 82.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.281 -0.418 . . . . 0.0 110.674 179.769 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 195' ' ' ALA . . . . . 0.412 ' HA ' HD12 ' A' ' 7' ' ' LEU . . . -52.86 -44.64 66.97 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.928 179.756 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 196' ' ' LEU . . . . . . . . . . . . . 94.5 mt -68.42 -36.19 78.71 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.096 179.711 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 197' ' ' ILE . . . . . 0.454 HD11 ' HB ' ' A' ' 177' ' ' ILE . 12.4 mm -61.31 -59.83 3.66 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.203 179.911 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 198' ' ' VAL . . . . . 0.493 HG22 ' O ' ' A' ' 194' ' ' VAL . 2.8 m -54.08 -35.36 28.79 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.47 0 CA-C-O 121.669 0.747 . . . . 0.0 109.523 179.307 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 199' ' ' TYR . . . . . . . . . . . . . 74.9 t80 -64.59 -41.6 96.14 Favored 'General case' 0 C--N 1.321 -0.658 0 CA-C-N 114.454 -1.248 . . . . 0.0 110.482 179.577 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 200' ' ' LEU . . . . . 0.419 ' HB3' ' CZ ' ' A' ' 174' ' ' TYR . 23.2 mt -59.04 -46.55 87.94 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 115.747 -0.66 . . . . 0.0 111.08 -179.885 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 201' ' ' ASP . . . . . . . . . . . . . 8.6 m-20 -69.95 -33.52 72.22 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 121.089 0.471 . . . . 0.0 110.426 179.709 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 202' ' ' LEU . . . . . . . . . . . . . 1.2 tt -66.54 -33.53 75.88 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 115.604 -0.725 . . . . 0.0 110.738 -179.93 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 203' ' ' VAL . . . . . 0.448 ' O ' ' HA3' ' A' ' 207' ' ' GLY . 42.3 t -76.66 -36.94 28.2 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 115.88 -0.6 . . . . 0.0 111.552 -179.007 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 204' ' ' THR . . . . . 0.473 HG23 ' CE2' ' A' ' 208' ' ' PHE . 36.5 m -64.58 -56.12 16.01 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-O 120.894 0.378 . . . . 0.0 111.679 -179.869 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 205' ' ' LYS . . . . . 0.736 ' HE2' ' HB2' ' A' ' 47' ' ' ALA . 48.9 mttp -69.03 -58.62 3.85 Favored 'General case' 0 C--N 1.326 -0.421 0 N-CA-C 112.576 0.584 . . . . 0.0 112.576 -178.351 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 48.9 t -71.57 -38.12 66.32 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 N-CA-C 112.064 0.394 . . . . 0.0 112.064 -178.515 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 207' ' ' GLY . . . . . 0.496 ' O ' HG12 ' A' ' 211' ' ' ILE . . . -63.38 -59.62 8.63 Favored Glycine 0 N--CA 1.453 -0.23 0 C-N-CA 120.579 -0.819 . . . . 0.0 112.86 -179.319 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 208' ' ' PHE . . . . . 0.509 ' O ' ' N ' ' A' ' 212' ' ' ALA . 1.8 m-30 -54.88 -47.91 73.67 Favored 'General case' 0 C--O 1.221 -0.405 0 N-CA-C 110.18 -0.304 . . . . 0.0 110.18 -179.633 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 209' ' ' GLY . . . . . 0.491 ' HA2' ' HB3' ' A' ' 212' ' ' ALA . . . -53.46 -32.36 45.27 Favored Glycine 0 N--CA 1.45 -0.432 0 CA-C-N 115.623 -0.717 . . . . 0.0 112.488 178.937 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 210' ' ' PHE . . . . . . . . . . . . . 3.0 m-85 -71.94 -45.96 59.24 Favored 'General case' 0 CA--C 1.516 -0.34 0 N-CA-C 108.694 -0.854 . . . . 0.0 108.694 178.769 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 211' ' ' ILE . . . . . 0.496 HG12 ' O ' ' A' ' 207' ' ' GLY . 2.4 mm -66.12 -27.5 41.0 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.51 0 N-CA-C 107.256 -1.387 . . . . 0.0 107.256 176.655 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 212' ' ' ALA . . . . . 0.509 ' N ' ' O ' ' A' ' 208' ' ' PHE . . . -68.67 -40.13 80.28 Favored 'General case' 0 N--CA 1.447 -0.582 0 CA-C-N 113.965 -1.471 . . . . 0.0 110.925 -179.34 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 213' ' ' LEU . . . . . . . . . . . . . 65.1 mt -70.26 -55.51 9.07 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 115.314 -0.857 . . . . 0.0 112.07 -179.164 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 214' ' ' ASP . . . . . . . . . . . . . 20.1 t70 -56.45 -50.56 71.33 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.859 0.361 . . . . 0.0 111.352 -179.429 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 215' ' ' ALA . . . . . . . . . . . . . . . -57.69 -55.39 35.49 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.467 -179.781 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 216' ' ' ALA . . . . . 0.475 ' HA ' HD12 ' A' ' 219' ' ' LEU . . . -60.59 -31.19 70.35 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.273 -0.421 . . . . 0.0 111.321 -179.697 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 217' ' ' ALA . . . . . . . . . . . . . . . -62.62 -35.82 80.82 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.342 -0.39 . . . . 0.0 110.264 179.609 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 218' ' ' THR . . . . . . . . . . . . . 86.7 m -75.68 -34.19 60.43 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 115.887 -0.597 . . . . 0.0 110.614 179.24 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 219' ' ' LEU . . . . . 0.475 HD12 ' HA ' ' A' ' 216' ' ' ALA . 81.9 mt -61.97 -38.18 87.58 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 116.051 -0.522 . . . . 0.0 110.686 179.672 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 220' ' ' ARG . . . . . . . . . . . . . 87.3 mtm180 -84.49 -26.81 27.89 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 115.938 -0.574 . . . . 0.0 111.021 179.773 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 221' ' ' ALA . . . . . . . . . . . . . . . -77.53 -19.8 55.19 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.121 -0.49 . . . . 0.0 112.091 -179.342 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 222' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -70.04 -12.56 61.7 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-O 120.862 0.363 . . . . 0.0 110.862 -179.339 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 223' ' ' HIS . . . . . . . . . . . . . 94.2 m-70 -75.79 -68.62 0.55 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.072 -0.513 . . . . 0.0 111.13 -179.984 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 224' ' ' GLY . . . . . . . . . . . . . . . 157.84 19.6 0.03 OUTLIER Glycine 0 C--N 1.331 0.271 0 C-N-CA 120.675 -0.774 . . . . 0.0 112.637 179.938 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 225' ' ' GLU . . . . . . . . . . . . . 29.9 mm-40 -68.12 116.72 9.06 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 120.837 0.351 . . . . 0.0 110.943 -179.966 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 226' ' ' SER . . . . . . . . . . . . . 70.1 m -115.56 143.33 45.49 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.904 179.993 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 227' ' ' LEU . . . . . 0.411 HD22 ' N ' ' A' ' 227' ' ' LEU . 3.6 mm? -101.22 -15.61 17.27 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.801 179.974 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 228' ' ' ALA . . . . . . . . . . . . . . . 52.78 26.92 4.86 Favored 'General case' 0 C--N 1.332 -0.181 0 CA-C-N 116.1 -0.5 . . . . 0.0 111.467 -179.95 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 229' ' ' GLY . . . . . . . . . . . . . . . 176.4 160.1 23.09 Favored Glycine 0 N--CA 1.453 -0.224 0 C-N-CA 120.866 -0.683 . . . . 0.0 112.45 179.916 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 230' ' ' VAL . . . . . . . . . . . . . 27.7 m -128.41 147.09 32.97 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.239 0 CA-C-O 120.871 0.367 . . . . 0.0 111.387 -179.897 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 231' ' ' ASP . . . . . . . . . . . . . 4.8 m-20 -104.8 95.75 6.1 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.086 -0.506 . . . . 0.0 110.81 179.868 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 232' ' ' THR . . . . . . . . . . . . . 79.7 p -120.95 120.55 35.8 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.122 -0.49 . . . . 0.0 111.088 -179.858 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 233' ' ' ASP . . . . . . . . . . . . . 5.0 p-10 -106.59 -47.86 3.67 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.873 -179.996 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 234' ' ' THR . . . . . . . . . . . . . 80.5 p -129.28 151.24 77.47 Favored Pre-proline 0 C--N 1.329 -0.293 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.969 179.866 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 235' ' ' PRO . . . . . . . . . . . . . 46.9 Cg_exo -56.02 133.93 61.02 Favored 'Trans proline' 0 C--N 1.347 0.494 0 C-N-CA 122.496 2.131 . . . . 0.0 112.363 -179.885 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 236' ' ' ALA . . . . . . . . . . . . . . . -78.55 121.07 24.14 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.029 -0.532 . . . . 0.0 111.028 179.918 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 237' ' ' VAL . . . . . . . . . . . . . 13.0 p -82.95 149.86 4.46 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.988 -179.893 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 238' ' ' ALA . . . . . . . . . . . . . . . -117.16 -56.15 2.27 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.077 179.995 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 239' ' ' ASP . . . . . . . . . . . . . 4.0 p30 -109.24 129.94 55.5 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.953 -179.942 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 240' ' ' LEU . . . . . . . . . . . . . 1.1 tm? -86.83 115.98 24.61 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.522 -179.944 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 241' ' ' GLU . . . . . . . . . . . . . 15.5 mm-40 -118.36 150.7 39.07 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.134 -0.484 . . . . 0.0 110.877 179.917 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 242' ' ' HIS . . . . . . . . . . . . . 24.6 p-80 -85.88 173.04 10.27 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.887 -179.974 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 243' ' ' HIS . . . . . . . . . . . . . 29.0 t-80 -84.63 138.48 32.67 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.895 -179.855 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 244' ' ' HIS . . . . . . . . . . . . . 99.4 m-70 -100.72 165.99 11.1 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.198 -0.456 . . . . 0.0 111.076 -179.91 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 245' ' ' HIS . . . . . . . . . . . . . 58.4 m80 -77.23 106.4 8.94 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.894 179.849 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 246' ' ' HIS . . . . . . . . . . . . . 68.3 m80 -105.15 156.0 18.5 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.01 -0.541 . . . . 0.0 110.861 179.944 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 247' ' ' HIS . . . . . . . . . . . . . 50.9 t-80 . . . . . 0 C--O 1.249 1.05 0 CA-C-O 118.334 -0.841 . . . . 0.0 110.844 -179.952 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 301' ' ' RET . . . . . 0.77 H203 ' HE1' ' A' ' 171' ' ' TRP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . 0.483 ' HG2' ' N ' ' A' ' 2' ' ' VAL . 0.0 OUTLIER . . . . . 0 N--CA 1.486 1.348 0 CA-C-O 120.818 0.342 . . . . 0.0 111.213 . . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 2' ' ' VAL . . . . . 0.483 ' N ' ' HG2' ' A' ' 1' ' ' MET . 8.8 p -154.2 17.16 0.05 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-O 121.02 0.438 . . . . 0.0 110.871 -179.888 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -155.41 -53.8 0.01 OUTLIER Glycine 0 C--N 1.332 0.331 0 C-N-CA 120.705 -0.759 . . . . 0.0 112.605 -179.76 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 94.5 mt -56.72 -35.55 68.67 Favored 'General case' 0 N--CA 1.449 -0.514 0 CA-C-O 120.868 0.366 . . . . 0.0 111.242 -179.859 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 42.9 p -63.4 -39.01 93.34 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.08 -0.509 . . . . 0.0 111.774 -179.414 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 18.7 p -52.84 -35.33 57.22 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-N 116.484 -0.325 . . . . 0.0 111.538 -179.442 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 7' ' ' LEU . . . . . . . . . . . . . 3.8 mm? -60.62 -53.13 61.13 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.37 -0.377 . . . . 0.0 111.245 -179.755 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 8' ' ' PHE . . . . . 0.559 ' HB2' ' HB2' ' A' ' 55' ' ' ALA . 64.4 m-85 -61.67 -30.84 70.99 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.304 -0.407 . . . . 0.0 111.014 -179.726 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 9' ' ' TRP . . . . . 0.474 ' O ' HG12 ' A' ' 13' ' ' ILE . 34.9 m95 -66.79 -43.3 84.31 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 116.226 -0.443 . . . . 0.0 109.966 179.939 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 87.5 mt -65.51 -49.02 70.54 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 115.615 -0.721 . . . . 0.0 110.526 179.638 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . 0.4 ' O ' HD21 ' A' ' 202' ' ' LEU . . . -58.47 -32.22 68.19 Favored Glycine 0 N--CA 1.449 -0.475 0 C-N-CA 120.559 -0.829 . . . . 0.0 111.677 179.3 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -68.69 -35.43 77.18 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 120.842 0.353 . . . . 0.0 110.615 179.453 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 13' ' ' ILE . . . . . 0.474 HG12 ' O ' ' A' ' 9' ' ' TRP . 46.8 mm -64.73 -53.98 35.59 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.205 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.609 179.566 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -60.71 -32.83 80.2 Favored Glycine 0 N--CA 1.45 -0.432 0 C-N-CA 120.718 -0.753 . . . . 0.0 111.7 179.477 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 15' ' ' MET . . . . . 0.591 ' SD ' ' HA ' ' A' ' 44' ' ' SER . 54.0 tpp -64.33 -50.98 65.66 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.792 0.33 . . . . 0.0 110.619 179.896 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -52.77 -40.58 63.3 Favored 'General case' 0 C--N 1.332 -0.192 0 CA-C-N 116.021 -0.536 . . . . 0.0 110.355 179.538 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 97.6 t -59.94 -42.86 90.86 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.219 0 CA-C-N 116.034 -0.53 . . . . 0.0 110.541 179.534 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -66.12 -43.39 93.35 Favored Glycine 0 N--CA 1.452 -0.272 0 C-N-CA 120.771 -0.728 . . . . 0.0 111.74 179.067 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 17.8 m -50.28 -46.56 55.22 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 115.556 -0.322 . . . . 0.0 111.48 -179.762 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 86.0 mt -71.76 -39.85 69.71 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.316 -0.402 . . . . 0.0 111.772 -179.74 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -61.64 -31.52 71.63 Favored 'General case' 0 C--N 1.33 -0.272 0 N-CA-C 111.987 0.366 . . . . 0.0 111.987 -179.219 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 4.9 m-85 -90.75 -33.34 15.78 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-O 120.731 0.301 . . . . 0.0 111.421 -179.599 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -69.3 -50.0 50.71 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.973 0.416 . . . . 0.0 111.19 -179.824 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 24' ' ' TRP . . . . . . . . . . . . . 2.4 t-105 -61.57 -47.54 85.06 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 115.805 -0.634 . . . . 0.0 111.169 -179.842 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -75.12 -19.44 59.91 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-O 120.782 0.325 . . . . 0.0 110.692 179.715 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -73.44 -45.77 28.45 Favored Glycine 0 N--CA 1.453 -0.22 0 C-N-CA 120.932 -0.651 . . . . 0.0 112.497 179.806 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 99.4 mtt180 -59.96 -26.41 65.98 Favored 'General case' 0 C--N 1.33 -0.239 0 CA-C-O 120.843 0.354 . . . . 0.0 111.038 -179.91 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 17.8 t70 -106.81 99.28 8.86 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.775 179.873 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -163.36 -167.91 1.57 Allowed 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.043 -179.772 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -89.64 -133.54 5.07 Favored Glycine 0 N--CA 1.45 -0.415 0 C-N-CA 120.751 -0.738 . . . . 0.0 112.445 179.94 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 32.0 t -127.0 125.84 42.14 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.822 0.344 . . . . 0.0 110.982 -179.932 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 106.1 -24.83 25.45 Favored Glycine 0 C--N 1.331 0.255 0 C-N-CA 120.78 -0.724 . . . . 0.0 112.781 179.553 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 33.3 mm-40 -87.28 -20.93 26.13 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.811 0.339 . . . . 0.0 111.015 -179.85 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 34' ' ' ARG . . . . . . . . . . . . . 42.3 ttm180 -53.12 -31.96 44.94 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.596 -179.546 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 15.3 tpp180 -61.64 -44.47 96.92 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 120.836 0.351 . . . . 0.0 110.874 -179.908 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 54.9 m-85 -68.69 -31.04 69.86 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.91 179.978 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 37' ' ' TYR . . . . . 0.423 ' O ' HG23 ' A' ' 41' ' ' VAL . 44.2 m-85 -70.43 -53.6 15.81 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.219 -179.897 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 71.2 t -56.8 -36.4 49.38 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.194 0 CA-C-O 121.008 0.432 . . . . 0.0 110.265 179.615 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 24.0 m -63.89 -47.92 78.71 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 115.673 -0.694 . . . . 0.0 110.296 179.213 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 40' ' ' LEU . . . . . 0.639 HD12 HD12 ' A' ' 43' ' ' ILE . 45.5 tp -58.46 -47.79 82.88 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 115.678 -0.692 . . . . 0.0 110.153 179.493 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . 0.423 HG23 ' O ' ' A' ' 37' ' ' TYR . 57.6 t -60.33 -34.57 58.06 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.365 0 CA-C-N 115.645 -0.707 . . . . 0.0 109.804 178.906 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -59.97 -37.09 92.14 Favored Glycine 0 N--CA 1.448 -0.559 0 C-N-CA 120.784 -0.722 . . . . 0.0 111.591 179.479 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 43' ' ' ILE . . . . . 0.639 HD12 HD12 ' A' ' 40' ' ' LEU . 1.3 mt -65.26 -57.98 8.84 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.195 0 CA-C-O 120.833 0.349 . . . . 0.0 110.468 179.391 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 44' ' ' SER . . . . . 0.591 ' HA ' ' SD ' ' A' ' 15' ' ' MET . 64.7 m -57.51 -23.01 47.76 Favored 'General case' 0 C--N 1.332 -0.173 0 CA-C-N 116.037 -0.529 . . . . 0.0 111.71 -179.67 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -76.64 -59.17 3.32 Favored Glycine 0 CA--C 1.52 0.353 0 C-N-CA 120.638 -0.792 . . . . 0.0 112.912 -179.614 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 21.6 pt -58.42 -35.89 56.27 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.239 0 CA-C-O 120.91 0.386 . . . . 0.0 111.263 -179.796 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 47' ' ' ALA . . . . . 0.671 ' HB2' ' HE2' ' A' ' 205' ' ' LYS . . . -67.42 -45.77 75.13 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.309 179.626 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -54.42 -44.77 72.7 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.878 -179.183 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 27.0 m -73.29 -34.2 43.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 N-CA-C 111.845 0.313 . . . . 0.0 111.845 -179.363 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -65.92 -33.95 77.01 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.869 0.366 . . . . 0.0 111.266 -179.785 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 51' ' ' TYR . . . . . 0.436 ' OH ' ' HB2' ' A' ' 201' ' ' ASP . 5.3 m-85 -72.99 -47.03 48.78 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 115.987 -0.551 . . . . 0.0 110.611 -179.943 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -58.81 -44.34 90.8 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 115.652 -0.703 . . . . 0.0 111.812 -179.562 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 53' ' ' VAL . . . . . 0.545 HG23 ' N ' ' A' ' 54' ' ' MET . 34.7 m -69.96 -51.72 37.43 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.183 0 CA-C-N 116.64 -0.254 . . . . 0.0 111.429 -179.549 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 54' ' ' MET . . . . . 0.545 ' N ' HG23 ' A' ' 53' ' ' VAL . 8.3 ttp -59.14 -29.28 67.3 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 121.064 0.459 . . . . 0.0 110.287 -179.964 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 55' ' ' ALA . . . . . 0.559 ' HB2' ' HB2' ' A' ' 8' ' ' PHE . . . -67.74 -32.2 72.65 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 115.703 -0.68 . . . . 0.0 111.329 179.698 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 96.6 mt -79.93 16.66 1.12 Allowed 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.282 -0.417 . . . . 0.0 111.102 -179.875 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 81.15 -4.93 68.82 Favored Glycine 0 N--CA 1.451 -0.365 0 C-N-CA 120.501 -0.857 . . . . 0.0 112.087 -179.656 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 58' ' ' VAL . . . . . 0.426 ' HB ' ' O ' ' A' ' 53' ' ' VAL . 77.0 t -66.25 142.34 16.89 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-O 120.799 0.333 . . . . 0.0 110.779 179.698 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 87.31 -22.28 16.66 Favored Glycine 0 N--CA 1.448 -0.558 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.529 -179.703 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 60' ' ' TRP . . . . . . . . . . . . . 13.5 m0 -60.21 99.22 0.07 Allowed 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 120.745 0.307 . . . . 0.0 110.327 179.823 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 61' ' ' VAL . . . . . 0.483 ' HA ' ' HD3' ' A' ' 62' ' ' PRO . 7.7 p -98.27 129.82 29.77 Favored Pre-proline 0 C--N 1.328 -0.328 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.412 -179.593 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 62' ' ' PRO . . . . . 0.483 ' HD3' ' HA ' ' A' ' 61' ' ' VAL . 12.1 Cg_exo -71.96 136.36 27.24 Favored 'Trans proline' 0 C--N 1.349 0.588 0 C-N-CA 122.628 2.219 . . . . 0.0 112.042 179.824 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 64.6 t -132.13 89.78 1.14 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.396 0 CA-C-N 116.054 -0.521 . . . . 0.0 110.876 -179.94 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . 58.54 -84.54 0.02 OUTLIER 'General case' 0 C--N 1.333 -0.138 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.26 -179.739 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 11.3 pt-20 -124.57 -19.9 5.26 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-O 121.104 0.478 . . . . 0.0 110.351 179.724 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 66' ' ' ARG . . . . . . . . . . . . . 59.3 mtp180 -95.39 166.03 12.08 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 115.576 -0.738 . . . . 0.0 110.676 179.814 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 54.1 m -129.2 122.32 29.5 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.996 179.862 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 15.1 t -111.17 146.27 16.4 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.368 0 CA-C-N 116.082 -0.508 . . . . 0.0 110.929 -179.972 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 69' ' ' PHE . . . . . . . . . . . . . 12.0 m-85 -101.9 112.76 25.49 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.134 -0.484 . . . . 0.0 110.177 -179.803 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 70' ' ' VAL . . . . . 0.567 HG12 ' HD3' ' A' ' 71' ' ' PRO . 0.6 OUTLIER -69.31 -33.35 3.88 Favored Pre-proline 0 CA--C 1.543 0.697 0 N-CA-C 113.089 0.774 . . . . 0.0 113.089 -179.302 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 71' ' ' PRO . . . . . 0.567 ' HD3' HG12 ' A' ' 70' ' ' VAL . 11.3 Cg_exo -69.57 -22.26 33.19 Favored 'Trans proline' 0 C--N 1.357 0.985 0 C-N-CA 121.952 1.768 . . . . 0.0 112.993 -179.073 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 72' ' ' ARG . . . . . 0.483 ' HD2' HG21 ' A' ' 197' ' ' ILE . 50.5 ttp180 -68.6 -55.04 12.88 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.902 0.382 . . . . 0.0 111.663 -179.124 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 73' ' ' TYR . . . . . . . . . . . . . 61.4 m-85 -72.14 -35.06 68.98 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.417 -0.356 . . . . 0.0 110.875 -179.483 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 74' ' ' ILE . . . . . 0.53 HG22 ' HA ' ' A' ' 71' ' ' PRO . 0.3 OUTLIER -65.87 -38.45 82.2 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.189 0 N-CA-C 109.476 -0.564 . . . . 0.0 109.476 179.01 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 17.8 t70 -60.21 -37.64 80.9 Favored 'General case' 0 N--CA 1.453 -0.278 0 N-CA-C 109.147 -0.686 . . . . 0.0 109.147 178.692 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 76' ' ' TRP . . . . . 0.452 ' HZ2' HG23 ' A' ' 197' ' ' ILE . 52.1 m0 -65.7 -34.99 79.47 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 115.681 -0.69 . . . . 0.0 110.345 179.06 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 77' ' ' ILE . . . . . 0.494 HD12 ' HA ' ' A' ' 74' ' ' ILE . 77.4 mt -66.26 -31.84 55.44 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.299 -0.409 . . . . 0.0 110.5 179.504 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 22.3 mt -91.6 -21.47 20.81 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.052 -0.522 . . . . 0.0 112.097 -179.725 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 81.5 p -102.86 -53.25 2.89 Favored 'General case' 0 N--CA 1.463 0.215 0 N-CA-C 113.536 0.939 . . . . 0.0 113.536 -177.924 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 80' ' ' THR . . . . . 0.583 ' HB ' ' HD3' ' A' ' 81' ' ' PRO . 4.9 m -48.57 -53.32 36.85 Favored Pre-proline 0 CA--C 1.53 0.21 0 N-CA-C 112.32 0.489 . . . . 0.0 112.32 -178.223 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 81' ' ' PRO . . . . . 0.583 ' HD3' ' HB ' ' A' ' 80' ' ' THR . 31.6 Cg_exo -61.29 -21.41 71.67 Favored 'Trans proline' 0 C--N 1.351 0.71 0 C-N-CA 121.722 1.615 . . . . 0.0 111.857 179.631 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 82' ' ' LEU . . . . . . . . . . . . . 17.3 tp -76.64 -36.56 57.31 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-N 116.076 -0.511 . . . . 0.0 110.677 -179.983 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 1.9 mp -68.39 -51.92 42.39 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.174 0 CA-C-O 120.803 0.335 . . . . 0.0 110.157 179.094 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 26.6 m -60.18 -31.92 49.29 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.225 0 N-CA-C 109.582 -0.525 . . . . 0.0 109.582 179.026 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 85' ' ' TYR . . . . . . . . . . . . . 74.9 t80 -66.66 -31.27 71.84 Favored 'General case' 0 N--CA 1.452 -0.33 0 CA-C-N 115.698 -0.683 . . . . 0.0 109.372 178.542 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 86' ' ' PHE . . . . . . . . . . . . . 2.0 t80 -62.65 -51.81 65.79 Favored 'General case' 0 C--O 1.231 0.103 0 CA-C-N 115.743 -0.662 . . . . 0.0 109.829 179.061 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 87' ' ' LEU . . . . . 0.405 ' N ' HD12 ' A' ' 87' ' ' LEU . 8.0 mp -63.67 -29.2 70.47 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 115.658 -0.701 . . . . 0.0 110.467 179.556 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -70.53 -28.49 71.0 Favored Glycine 0 N--CA 1.449 -0.465 0 C-N-CA 120.843 -0.694 . . . . 0.0 112.007 179.559 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 79.8 mt -75.32 -42.38 54.64 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-O 120.929 0.395 . . . . 0.0 110.605 179.474 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 72.4 mt -57.71 -32.65 67.6 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 115.887 -0.597 . . . . 0.0 110.766 179.744 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . 0.442 ' HB1' ' HB3' ' A' ' 148' ' ' SER . . . -88.9 -34.02 17.1 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.104 -0.498 . . . . 0.0 111.208 179.891 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 84.28 53.77 3.19 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.853 -0.689 . . . . 0.0 112.401 179.926 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 55.0 mt -59.39 162.96 4.31 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 120.897 0.38 . . . . 0.0 111.109 -179.907 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 94' ' ' ASP . . . . . . . . . . . . . 18.4 m-20 -77.17 -178.37 5.02 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.069 -0.514 . . . . 0.0 110.923 179.878 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 50.8 m -63.64 -50.98 67.19 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.083 -0.508 . . . . 0.0 111.197 -179.881 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 14.2 ptm180 -73.65 -35.63 65.29 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.308 -0.405 . . . . 0.0 111.293 -179.596 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 19.9 mm-40 -54.96 -45.68 74.97 Favored 'General case' 0 C--N 1.331 -0.197 0 CA-C-N 116.56 -0.291 . . . . 0.0 110.771 -179.977 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 98' ' ' PHE . . . . . 0.493 ' O ' HG12 ' A' ' 102' ' ' ILE . 10.6 m-85 -60.86 -36.06 78.2 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-O 120.92 0.39 . . . . 0.0 110.272 179.422 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -67.19 -27.53 73.5 Favored Glycine 0 N--CA 1.449 -0.5 0 C-N-CA 120.589 -0.815 . . . . 0.0 112.225 179.511 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 97.0 mt -73.83 -44.88 51.12 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.198 0 N-CA-C 111.855 0.317 . . . . 0.0 111.855 -179.783 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 35.3 m -69.35 -40.78 80.5 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 N-CA-C 112.256 0.465 . . . . 0.0 112.256 -178.806 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 102' ' ' ILE . . . . . 0.493 HG12 ' O ' ' A' ' 98' ' ' PHE . 46.1 mm -68.53 -48.49 71.97 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.697 -0.229 . . . . 0.0 111.456 -179.501 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 14.2 t -60.42 -33.77 72.99 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-O 120.983 0.42 . . . . 0.0 110.645 179.875 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 104' ' ' LEU . . . . . 0.485 HD22 ' HE2' ' A' ' 140' ' ' TYR . 48.4 tp -60.44 -53.56 56.08 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 115.954 -0.567 . . . . 0.0 110.428 179.578 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 105' ' ' ASN . . . . . 0.611 ' N ' HD22 ' A' ' 105' ' ' ASN . 0.8 OUTLIER -61.22 -25.19 66.88 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 115.892 -0.594 . . . . 0.0 110.835 179.845 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 28.6 m -64.31 -54.13 38.02 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.258 179.961 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 107' ' ' VAL . . . . . 0.433 HG12 ' O ' ' A' ' 104' ' ' LEU . 12.5 p -64.85 -36.11 76.84 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.245 0 CA-C-N 116.504 -0.316 . . . . 0.0 111.194 -179.962 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . 0.401 HG23 ' O ' ' A' ' 104' ' ' LEU . 92.6 t -64.78 -52.76 50.26 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.246 0 CA-C-O 120.84 0.352 . . . . 0.0 110.89 179.743 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 109' ' ' MET . . . . . 0.547 ' HE1' HG21 ' A' ' 80' ' ' THR . 1.9 tpp -60.06 -32.13 70.65 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.06 -0.518 . . . . 0.0 110.758 179.774 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 36.4 tp -75.21 -30.17 60.52 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 115.974 -0.557 . . . . 0.0 110.261 179.46 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -60.94 -52.4 65.18 Favored 'General case' 0 C--N 1.331 -0.199 0 CA-C-N 116.081 -0.508 . . . . 0.0 110.308 179.337 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 112' ' ' GLY . . . . . 0.681 ' HA3' ' H21' ' A' ' 301' ' ' RET . . . -70.58 -38.43 68.35 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.636 -0.792 . . . . 0.0 111.851 179.268 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 113' ' ' PHE . . . . . . . . . . . . . 1.9 t80 -53.87 -63.21 1.22 Allowed 'General case' 0 C--N 1.332 -0.194 0 CA-C-O 120.849 0.356 . . . . 0.0 110.063 179.349 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 114' ' ' ALA . . . . . 0.413 ' O ' HG13 ' A' ' 118' ' ' VAL . . . -69.62 -17.43 63.52 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.135 178.949 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 115' ' ' GLY . . . . . 0.438 ' HA2' HD22 ' A' ' 126' ' ' LEU . . . -55.48 -52.62 46.69 Favored Glycine 0 C--N 1.333 0.389 0 CA-C-N 115.871 -0.604 . . . . 0.0 112.042 179.545 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 116' ' ' ALA . . . . . 0.61 ' HB2' ' HB3' ' A' ' 183' ' ' PRO . . . -77.41 -14.69 59.65 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-O 120.763 0.316 . . . . 0.0 111.192 -179.962 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 117' ' ' MET . . . . . . . . . . . . . 23.2 mmt -87.24 6.88 30.98 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.284 -0.417 . . . . 0.0 111.947 -179.413 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 118' ' ' VAL . . . . . 0.413 HG13 ' O ' ' A' ' 114' ' ' ALA . 16.5 m -80.43 145.52 59.57 Favored Pre-proline 0 C--N 1.331 -0.206 0 CA-C-O 120.498 0.19 . . . . 0.0 111.322 -179.9 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 119' ' ' PRO . . . . . . . . . . . . . 85.9 Cg_endo -85.14 -6.59 9.33 Favored 'Trans proline' 0 C--N 1.348 0.509 0 C-N-CA 122.689 2.26 . . . . 0.0 112.099 179.51 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -133.17 -143.2 4.96 Favored Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.871 -0.68 . . . . 0.0 112.615 -179.894 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 121' ' ' ILE . . . . . 0.425 ' H ' HG13 ' A' ' 121' ' ' ILE . 2.7 pp -101.31 11.46 7.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-O 120.782 0.325 . . . . 0.0 111.308 -179.908 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 9.9 mm-40 -59.47 -19.08 45.09 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.047 179.975 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 123' ' ' ARG . . . . . 0.463 ' HB2' ' HH2' ' A' ' 178' ' ' TRP . 16.4 ptt180 -52.04 -34.55 43.74 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.037 -0.529 . . . . 0.0 111.538 -179.786 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 124' ' ' TYR . . . . . . . . . . . . . 49.6 m-85 -61.18 -33.13 72.96 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-O 120.748 0.308 . . . . 0.0 110.884 -179.956 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 125' ' ' ALA . . . . . . . . . . . . . . . -72.4 -50.58 25.47 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.278 -0.419 . . . . 0.0 110.666 179.55 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 126' ' ' LEU . . . . . 0.438 HD22 ' HA2' ' A' ' 115' ' ' GLY . 7.3 mp -54.53 -54.22 44.11 Favored 'General case' 0 C--N 1.332 -0.18 0 CA-C-N 116.018 -0.537 . . . . 0.0 110.182 179.726 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 127' ' ' PHE . . . . . 0.422 ' HE1' ' H42' ' A' ' 301' ' ' RET . 8.9 t80 -63.15 -37.08 85.79 Favored 'General case' 0 N--CA 1.451 -0.409 0 CA-C-N 115.973 -0.558 . . . . 0.0 110.784 179.724 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 128' ' ' GLY . . . . . . . . . . . . . . . -46.22 -45.0 15.48 Favored Glycine 0 C--N 1.332 0.306 0 C-N-CA 120.19 -1.005 . . . . 0.0 110.918 179.109 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 129' ' ' MET . . . . . . . . . . . . . 0.4 OUTLIER -69.82 -37.74 76.34 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 115.311 -0.444 . . . . 0.0 109.85 178.646 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -61.99 -34.25 88.29 Favored Glycine 0 C--N 1.332 0.335 0 CA-C-N 115.677 -0.692 . . . . 0.0 112.942 -179.872 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -71.41 -53.77 12.95 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.697 0.284 . . . . 0.0 110.52 179.908 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 38.4 t -56.85 -39.95 68.16 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-O 121.439 0.638 . . . . 0.0 109.38 178.899 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -66.9 -35.37 79.85 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 115.151 -0.931 . . . . 0.0 110.532 179.357 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 134' ' ' PHE . . . . . . . . . . . . . 86.4 t80 -55.37 -55.27 33.53 Favored 'General case' 0 N--CA 1.452 -0.337 0 CA-C-O 121.012 0.434 . . . . 0.0 110.019 179.428 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 135' ' ' ILE . . . . . 0.429 ' O ' HG22 ' A' ' 138' ' ' VAL . 29.6 mt -56.28 -33.95 38.84 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.295 0 CA-C-N 115.761 -0.654 . . . . 0.0 109.913 179.136 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . -61.99 -40.66 99.19 Favored Glycine 0 N--CA 1.448 -0.547 0 C-N-CA 120.299 -0.953 . . . . 0.0 111.321 178.812 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 137' ' ' LEU . . . . . 0.496 HD13 HD21 ' A' ' 105' ' ' ASN . 64.8 tp -69.33 -53.1 21.3 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-O 120.532 0.205 . . . . 0.0 111.04 179.97 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 138' ' ' VAL . . . . . 0.429 HG22 ' O ' ' A' ' 135' ' ' ILE . 4.9 m -55.43 -34.62 34.87 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.167 0 N-CA-C 109.521 -0.548 . . . . 0.0 109.521 179.775 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 139' ' ' TYR . . . . . . . . . . . . . 21.4 t80 -61.58 -40.9 96.4 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 115.454 -0.794 . . . . 0.0 110.403 178.548 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 140' ' ' TYR . . . . . 0.485 ' HE2' HD22 ' A' ' 104' ' ' LEU . 20.9 m-85 -64.89 -52.17 57.97 Favored 'General case' 0 C--N 1.332 -0.189 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.673 -179.848 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 141' ' ' LEU . . . . . 0.516 HD12 ' N ' ' A' ' 142' ' ' VAL . 3.6 pp -64.27 -18.23 64.37 Favored 'General case' 0 N--CA 1.463 0.176 0 N-CA-C 111.74 0.274 . . . . 0.0 111.74 -179.271 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 142' ' ' VAL . . . . . 0.516 ' N ' HD12 ' A' ' 141' ' ' LEU . 5.2 p -109.36 -2.77 10.23 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-O 120.898 0.38 . . . . 0.0 110.924 179.866 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . -99.81 -102.51 2.44 Favored Glycine 0 CA--C 1.522 0.503 0 C-N-CA 120.767 -0.73 . . . . 0.0 113.104 -179.849 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 144' ' ' PRO . . . . . . . . . . . . . 58.2 Cg_endo -70.15 -27.87 24.07 Favored 'Trans proline' 0 C--N 1.348 0.503 0 C-N-CA 122.628 2.219 . . . . 0.0 113.285 -179.313 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 145' ' ' MET . . . . . 0.484 ' SD ' ' HA ' ' A' ' 141' ' ' LEU . 50.7 mtt -62.68 -39.07 92.78 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.669 0.271 . . . . 0.0 111.461 -179.583 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 146' ' ' THR . . . . . . . . . . . . . 67.2 p -66.21 -43.6 86.28 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.456 -0.338 . . . . 0.0 111.448 -179.524 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 39.7 mt-10 -70.45 -33.69 71.58 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.344 -0.389 . . . . 0.0 111.268 -179.651 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 148' ' ' SER . . . . . 0.442 ' HB3' ' HB1' ' A' ' 91' ' ' ALA . 48.0 t -70.34 -44.55 67.94 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.357 -0.383 . . . . 0.0 111.464 -179.485 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 149' ' ' ALA . . . . . . . . . . . . . . . -73.74 -33.94 64.54 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.339 -0.391 . . . . 0.0 111.399 -179.699 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 150' ' ' SER . . . . . 0.445 ' HB2' ' NZ ' ' A' ' 157' ' ' LYS . 81.0 p -67.33 -5.76 15.74 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 121.007 0.432 . . . . 0.0 110.657 179.783 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 151' ' ' GLN . . . . . . . . . . . . . 74.0 mt-30 -110.3 5.28 21.55 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 115.899 -0.591 . . . . 0.0 111.336 -179.812 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 31.2 ttt180 -91.8 -52.64 4.64 Favored 'General case' 0 C--N 1.331 -0.23 0 C-N-CA 120.902 -0.319 . . . . 0.0 111.213 -179.895 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 153' ' ' SER . . . . . 0.674 ' HB3' HG12 ' A' ' 156' ' ' ILE . 20.5 t -157.67 172.44 18.52 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.444 -0.344 . . . . 0.0 111.002 179.327 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 154' ' ' SER . . . . . . . . . . . . . 72.6 p -73.41 -41.7 62.98 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.705 179.576 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -72.64 -29.59 65.37 Favored Glycine 0 N--CA 1.452 -0.288 0 C-N-CA 120.804 -0.712 . . . . 0.0 112.334 179.88 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 156' ' ' ILE . . . . . 0.674 HG12 ' HB3' ' A' ' 153' ' ' SER . 34.6 mm -58.99 -38.45 73.86 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-O 120.84 0.352 . . . . 0.0 111.066 179.862 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 157' ' ' LYS . . . . . 0.445 ' NZ ' ' HB2' ' A' ' 150' ' ' SER . 21.3 ttmm -65.06 -47.86 75.82 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.129 -0.487 . . . . 0.0 111.085 179.811 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 69.1 m -60.65 -43.3 97.74 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 115.981 -0.554 . . . . 0.0 111.69 -179.042 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 159' ' ' LEU . . . . . 0.767 ' HG ' HD11 ' A' ' 163' ' ' LEU . 3.7 tp -66.5 -58.59 4.9 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-O 120.943 0.401 . . . . 0.0 110.66 -179.861 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 160' ' ' TYR . . . . . . . . . . . . . 30.1 t80 -51.14 -36.23 39.68 Favored 'General case' 0 C--N 1.326 -0.416 0 N-CA-C 113.302 0.853 . . . . 0.0 113.302 -178.13 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 161' ' ' VAL . . . . . 0.423 HG23 ' N ' ' A' ' 162' ' ' ARG . 30.7 m -73.27 -47.04 48.25 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.373 0 N-CA-C 112.159 0.429 . . . . 0.0 112.159 -177.791 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 162' ' ' ARG . . . . . 0.423 ' N ' HG23 ' A' ' 161' ' ' VAL . 24.2 ttm180 -63.68 -41.23 98.18 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-O 120.953 0.406 . . . . 0.0 111.014 -179.701 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 163' ' ' LEU . . . . . 0.767 HD11 ' HG ' ' A' ' 159' ' ' LEU . 6.6 mt -70.38 -50.34 39.76 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 115.89 -0.595 . . . . 0.0 111.712 -179.197 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 164' ' ' ARG . . . . . 0.606 ' HG3' HD22 ' A' ' 165' ' ' ASN . 0.4 OUTLIER -58.14 -40.96 82.69 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.517 -0.31 . . . . 0.0 110.917 -178.986 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 165' ' ' ASN . . . . . 0.606 HD22 ' HG3' ' A' ' 164' ' ' ARG . 0.9 OUTLIER -58.46 -51.34 70.28 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-O 120.832 0.349 . . . . 0.0 110.295 179.545 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 166' ' ' LEU . . . . . 0.513 ' O ' ' HG ' ' A' ' 170' ' ' LEU . 2.3 tt -59.39 -54.74 43.25 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 115.93 -0.577 . . . . 0.0 111.712 -179.931 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 167' ' ' THR . . . . . 0.456 ' N ' HD23 ' A' ' 166' ' ' LEU . 52.6 m -55.08 -53.03 61.12 Favored 'General case' 0 C--N 1.33 -0.245 0 N-CA-C 112.773 0.657 . . . . 0.0 112.773 -178.398 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 168' ' ' VAL . . . . . 0.417 HG23 ' O ' ' A' ' 164' ' ' ARG . 75.4 t -53.96 -42.23 53.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 N-CA-C 112.329 0.492 . . . . 0.0 112.329 -179.004 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 169' ' ' VAL . . . . . 0.479 HG23 ' O ' ' A' ' 165' ' ' ASN . 72.7 t -60.93 -64.74 0.57 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 N-CA-C 112.124 0.416 . . . . 0.0 112.124 -179.225 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 170' ' ' LEU . . . . . 0.513 ' HG ' ' O ' ' A' ' 166' ' ' LEU . 0.4 OUTLIER -61.92 -34.12 75.49 Favored 'General case' 0 N--CA 1.465 0.276 0 N-CA-C 112.354 0.502 . . . . 0.0 112.354 -178.815 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 171' ' ' TRP . . . . . 0.69 ' HE1' H203 ' A' ' 301' ' ' RET . 6.1 m0 -68.06 -29.56 68.56 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-O 120.792 0.33 . . . . 0.0 110.634 179.629 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 172' ' ' ALA . . . . . . . . . . . . . . . -73.92 -7.12 51.14 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.759 179.781 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 173' ' ' ILE . . . . . 0.49 ' O ' HG12 ' A' ' 177' ' ' ILE . 28.8 mm -87.68 -21.46 7.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 115.839 -0.619 . . . . 0.0 110.526 179.476 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 174' ' ' TYR . . . . . 0.42 ' HD2' ' HA ' ' A' ' 171' ' ' TRP . 8.2 m-85 -53.84 -48.38 93.81 Favored Pre-proline 0 CA--C 1.528 0.105 0 CA-C-N 116.055 -0.52 . . . . 0.0 111.681 -179.567 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 175' ' ' PRO . . . . . 0.403 ' CD ' ' N ' ' A' ' 174' ' ' TYR . 83.2 Cg_exo -46.65 -32.15 11.38 Favored 'Trans proline' 0 C--N 1.351 0.667 0 C-N-CA 121.831 1.687 . . . . 0.0 111.95 179.358 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 176' ' ' PHE . . . . . 0.433 ' O ' ' HG ' ' A' ' 180' ' ' LEU . 84.3 m-85 -81.1 -49.79 10.43 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 115.697 -0.683 . . . . 0.0 111.799 179.867 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 177' ' ' ILE . . . . . 0.49 HG12 ' O ' ' A' ' 173' ' ' ILE . 8.5 mm -61.01 -38.83 80.36 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.498 0 N-CA-C 112.708 0.633 . . . . 0.0 112.708 -177.896 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 178' ' ' TRP . . . . . 0.463 ' HH2' ' HB2' ' A' ' 123' ' ' ARG . 78.5 t90 -71.58 -51.88 21.05 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.79 0.328 . . . . 0.0 111.213 -179.735 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 179' ' ' LEU . . . . . 0.55 HD23 HD23 ' A' ' 180' ' ' LEU . 0.6 OUTLIER -64.55 -55.08 22.82 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.323 -0.399 . . . . 0.0 111.601 -178.997 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 180' ' ' LEU . . . . . 0.55 HD23 HD23 ' A' ' 179' ' ' LEU . 32.4 mt -65.96 -37.64 86.52 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 116.341 -0.39 . . . . 0.0 111.345 -179.332 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . -60.53 176.15 4.25 Favored Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 119.988 -1.101 . . . . 0.0 112.33 179.589 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 182' ' ' PRO . . . . . 0.555 ' HA ' ' HB2' ' A' ' 186' ' ' ALA . 88.3 Cg_exo -46.63 -44.97 20.69 Favored 'Trans proline' 0 CA--C 1.536 0.607 0 C-N-CA 122.681 2.254 . . . . 0.0 113.402 179.912 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 183' ' ' PRO . . . . . 0.61 ' HB3' ' HB2' ' A' ' 116' ' ' ALA . 97.3 Cg_exo -45.31 -35.25 11.23 Favored 'Trans proline' 0 C--N 1.356 0.926 0 C-N-CA 122.328 2.019 . . . . 0.0 113.439 179.89 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 184' ' ' GLY . . . . . . . . . . . . . . . -110.29 -123.23 4.52 Favored Glycine 0 C--N 1.332 0.344 0 C-N-CA 120.299 -0.953 . . . . 0.0 113.204 -179.453 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 185' ' ' VAL . . . . . . . . . . . . . 8.1 m -63.04 -26.93 42.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 N-CA-C 112.16 0.43 . . . . 0.0 112.16 -179.225 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 186' ' ' ALA . . . . . 0.555 ' HB2' ' HA ' ' A' ' 182' ' ' PRO . . . 60.25 81.05 0.19 Allowed 'General case' 0 C--N 1.331 -0.207 0 N-CA-C 111.858 0.318 . . . . 0.0 111.858 179.48 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 187' ' ' LEU . . . . . . . . . . . . . 6.9 mt -92.8 -49.78 5.9 Favored 'General case' 0 C--N 1.332 -0.156 0 CA-C-O 120.995 0.426 . . . . 0.0 111.012 179.587 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 188' ' ' LEU . . . . . . . . . . . . . 95.2 mt -89.32 -166.7 1.66 Allowed 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 115.795 -0.639 . . . . 0.0 111.247 -179.48 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 189' ' ' THR . . . . . 0.429 HG22 ' H ' ' A' ' 191' ' ' THR . 74.9 m -94.08 136.13 23.95 Favored Pre-proline 0 C--N 1.328 -0.357 0 CA-C-N 115.781 -0.645 . . . . 0.0 110.626 -179.811 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 190' ' ' PRO . . . . . . . . . . . . . 2.4 Cg_endo -44.99 -38.58 13.66 Favored 'Trans proline' 0 C--N 1.35 0.61 0 C-N-CA 122.854 2.369 . . . . 0.0 112.649 -179.983 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 191' ' ' THR . . . . . 0.429 ' H ' HG22 ' A' ' 189' ' ' THR . 71.2 p -61.98 -42.95 99.7 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-O 120.965 0.412 . . . . 0.0 110.911 179.711 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 192' ' ' VAL . . . . . . . . . . . . . 88.8 t -71.29 -53.54 20.7 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 115.92 -0.582 . . . . 0.0 111.434 -179.816 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 193' ' ' ASP . . . . . . . . . . . . . 29.3 t70 -54.49 -52.01 63.28 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.242 -0.436 . . . . 0.0 111.442 -179.396 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 194' ' ' VAL . . . . . 0.531 ' O ' HG22 ' A' ' 198' ' ' VAL . 71.1 t -59.23 -38.22 73.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.371 -0.377 . . . . 0.0 110.614 -179.874 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 195' ' ' ALA . . . . . . . . . . . . . . . -55.22 -44.86 75.8 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.754 179.605 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 196' ' ' LEU . . . . . . . . . . . . . 95.6 mt -68.36 -35.86 78.35 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.934 179.461 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 197' ' ' ILE . . . . . 0.483 HG21 ' HD2' ' A' ' 72' ' ' ARG . 11.0 mm -59.49 -61.09 1.61 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.06 -0.518 . . . . 0.0 110.874 179.96 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 198' ' ' VAL . . . . . 0.531 HG22 ' O ' ' A' ' 194' ' ' VAL . 1.4 m -55.74 -35.0 37.83 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.462 0 CA-C-O 121.626 0.727 . . . . 0.0 109.191 178.772 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 199' ' ' TYR . . . . . . . . . . . . . 86.7 t80 -64.04 -32.5 74.07 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-N 114.56 -1.2 . . . . 0.0 110.415 179.336 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 200' ' ' LEU . . . . . 0.444 HD11 HG13 ' A' ' 177' ' ' ILE . 38.1 mt -71.11 -37.78 72.36 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 115.99 -0.55 . . . . 0.0 110.648 179.591 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 201' ' ' ASP . . . . . 0.436 ' HB2' ' OH ' ' A' ' 51' ' ' TYR . 7.9 m-20 -74.58 -32.98 62.55 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 115.953 -0.567 . . . . 0.0 110.161 179.63 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 202' ' ' LEU . . . . . 0.4 HD21 ' O ' ' A' ' 11' ' ' GLY . 0.5 OUTLIER -72.52 -28.45 62.87 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 115.29 -0.868 . . . . 0.0 111.623 -179.527 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 203' ' ' VAL . . . . . 0.425 HG12 ' O ' ' A' ' 200' ' ' LEU . 9.6 p -82.17 -37.78 14.99 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.18 0 N-CA-C 111.946 0.35 . . . . 0.0 111.946 -178.805 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 204' ' ' THR . . . . . . . . . . . . . 86.5 m -69.6 -41.87 75.16 Favored 'General case' 0 C--N 1.328 -0.337 0 C-N-CA 120.821 -0.352 . . . . 0.0 111.569 179.93 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 205' ' ' LYS . . . . . 0.671 ' HE2' ' HB2' ' A' ' 47' ' ' ALA . 59.7 mttp -76.52 -57.93 3.58 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.398 -0.365 . . . . 0.0 111.557 -178.872 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 60.4 t -69.47 -36.83 73.34 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.372 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.471 -179.503 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 207' ' ' GLY . . . . . . . . . . . . . . . -66.44 -52.76 32.87 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.615 -0.802 . . . . 0.0 112.43 -179.326 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 208' ' ' PHE . . . . . 0.689 ' CZ ' HD13 ' A' ' 163' ' ' LEU . 11.3 t80 -55.21 -49.86 70.87 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-O 120.748 0.309 . . . . 0.0 110.941 179.771 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 209' ' ' GLY . . . . . 0.477 ' CA ' HD21 ' A' ' 40' ' ' LEU . . . -63.64 -37.46 94.77 Favored Glycine 0 N--CA 1.451 -0.339 0 CA-C-N 115.632 -0.713 . . . . 0.0 113.985 -179.184 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 210' ' ' PHE . . . . . . . . . . . . . 0.6 OUTLIER -68.65 -46.66 68.57 Favored 'General case' 0 CA--C 1.512 -0.484 0 N-CA-C 108.217 -1.031 . . . . 0.0 108.217 179.272 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 211' ' ' ILE . . . . . . . . . . . . . 92.8 mt -64.9 -28.21 44.26 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.702 0 N-CA-C 107.694 -1.224 . . . . 0.0 107.694 176.656 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 212' ' ' ALA . . . . . 0.474 ' HB3' ' HA2' ' A' ' 209' ' ' GLY . . . -68.29 -45.71 72.33 Favored 'General case' 0 N--CA 1.449 -0.492 0 CA-C-N 114.419 -1.264 . . . . 0.0 111.087 -179.851 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 213' ' ' LEU . . . . . . . . . . . . . 92.8 mt -70.55 -55.32 9.16 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-N 115.442 -0.799 . . . . 0.0 112.415 -178.828 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 214' ' ' ASP . . . . . . . . . . . . . 31.9 m-20 -53.11 -52.1 59.76 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.713 0.292 . . . . 0.0 111.607 -179.295 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 215' ' ' ALA . . . . . 0.401 ' O ' ' HG ' ' A' ' 219' ' ' LEU . . . -62.14 -57.77 10.29 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 116.339 -0.391 . . . . 0.0 111.691 -179.438 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 216' ' ' ALA . . . . . 0.424 ' HA ' HD12 ' A' ' 219' ' ' LEU . . . -56.4 -34.85 67.11 Favored 'General case' 0 C--N 1.332 -0.188 0 CA-C-N 116.469 -0.332 . . . . 0.0 111.469 -179.537 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 217' ' ' ALA . . . . . . . . . . . . . . . -60.55 -40.7 92.55 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-O 121.048 0.452 . . . . 0.0 110.082 179.703 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 218' ' ' THR . . . . . . . . . . . . . 95.9 m -71.09 -38.5 72.4 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 115.659 -0.7 . . . . 0.0 110.71 179.331 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 219' ' ' LEU . . . . . 0.491 ' O ' ' HG2' ' A' ' 222' ' ' GLU . 87.2 mt -56.33 -43.94 79.52 Favored 'General case' 0 C--N 1.332 -0.175 0 CA-C-N 115.915 -0.584 . . . . 0.0 110.666 179.899 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 220' ' ' ARG . . . . . . . . . . . . . 7.3 ptm180 -84.45 -15.95 44.28 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.459 179.358 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 221' ' ' ALA . . . . . . . . . . . . . . . -67.84 -34.82 77.45 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 116.021 -0.536 . . . . 0.0 111.606 -179.674 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 222' ' ' GLU . . . . . 0.491 ' HG2' ' O ' ' A' ' 219' ' ' LEU . 13.1 pt-20 -67.79 -14.71 63.17 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-O 120.937 0.398 . . . . 0.0 110.541 -179.716 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 223' ' ' HIS . . . . . 0.407 ' HB3' ' HG3' ' A' ' 225' ' ' GLU . 77.9 m-70 -84.49 -36.2 22.42 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 115.852 -0.613 . . . . 0.0 110.761 179.617 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 224' ' ' GLY . . . . . . . . . . . . . . . 60.28 27.83 65.99 Favored Glycine 0 N--CA 1.45 -0.384 0 C-N-CA 120.884 -0.674 . . . . 0.0 112.771 179.9 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 225' ' ' GLU . . . . . 0.407 ' HG3' ' HB3' ' A' ' 223' ' ' HIS . 41.6 mt-10 -93.38 115.08 27.64 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.741 0.305 . . . . 0.0 110.895 -179.949 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 226' ' ' SER . . . . . . . . . . . . . 79.0 p -138.14 -56.5 0.66 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.112 179.912 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 227' ' ' LEU . . . . . . . . . . . . . 82.3 mt -81.85 158.98 23.83 Favored 'General case' 0 C--N 1.332 -0.182 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.992 -179.868 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 228' ' ' ALA . . . . . . . . . . . . . . . -97.99 154.24 17.83 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.061 179.808 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 229' ' ' GLY . . . . . . . . . . . . . . . 112.25 87.31 1.67 Allowed Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.874 -0.679 . . . . 0.0 112.432 179.987 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 230' ' ' VAL . . . . . . . . . . . . . 30.9 t -98.83 127.46 51.42 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.245 0 CA-C-O 120.741 0.305 . . . . 0.0 111.043 -179.962 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 231' ' ' ASP . . . . . . . . . . . . . 18.9 t70 -96.73 132.74 42.1 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.081 179.919 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 232' ' ' THR . . . . . . . . . . . . . 8.4 t -161.95 -34.83 0.04 OUTLIER 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.297 -0.411 . . . . 0.0 111.249 -179.911 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 233' ' ' ASP . . . . . . . . . . . . . 16.6 t70 -126.88 113.34 16.43 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.273 -0.421 . . . . 0.0 111.039 -179.876 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 234' ' ' THR . . . . . . . . . . . . . 55.6 p -140.4 151.07 63.11 Favored Pre-proline 0 C--N 1.331 -0.225 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.928 179.854 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 235' ' ' PRO . . . . . . . . . . . . . 31.3 Cg_endo -64.33 117.29 4.34 Favored 'Trans proline' 0 C--N 1.348 0.526 0 C-N-CA 122.384 2.056 . . . . 0.0 112.109 179.891 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 236' ' ' ALA . . . . . . . . . . . . . . . -137.74 122.78 19.08 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.143 -0.48 . . . . 0.0 111.198 -179.915 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 237' ' ' VAL . . . . . . . . . . . . . 7.7 p -120.31 18.78 6.19 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.238 0 CA-C-O 121.259 0.552 . . . . 0.0 110.764 179.826 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 238' ' ' ALA . . . . . . . . . . . . . . . -88.14 -4.44 58.75 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 115.858 -0.61 . . . . 0.0 110.926 179.976 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 239' ' ' ASP . . . . . . . . . . . . . 19.7 t70 58.24 91.69 0.04 OUTLIER 'General case' 0 C--N 1.332 -0.187 0 CA-C-N 115.9 -0.591 . . . . 0.0 111.002 179.904 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 240' ' ' LEU . . . . . 0.44 ' H ' ' H ' ' A' ' 241' ' ' GLU . 2.7 pt? -160.95 -12.99 0.05 OUTLIER 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.069 -0.514 . . . . 0.0 110.694 179.861 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 241' ' ' GLU . . . . . 0.44 ' H ' ' H ' ' A' ' 240' ' ' LEU . 12.1 pt-20 -70.28 -15.77 62.94 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-N 116.037 -0.528 . . . . 0.0 110.719 179.801 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 242' ' ' HIS . . . . . . . . . . . . . 66.6 t60 -67.86 -47.59 68.49 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.97 -179.988 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 243' ' ' HIS . . . . . . . . . . . . . 66.5 m80 -57.87 142.18 46.79 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.141 -179.853 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 244' ' ' HIS . . . . . . . . . . . . . 23.4 t-80 -106.67 -38.42 6.13 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.035 -0.529 . . . . 0.0 110.707 179.926 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 245' ' ' HIS . . . . . . . . . . . . . 65.9 m80 -68.96 163.8 23.7 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.691 179.785 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 246' ' ' HIS . . . . . . . . . . . . . 8.3 p80 -96.78 176.69 5.9 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.941 179.898 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 247' ' ' HIS . . . . . . . . . . . . . 8.4 m80 . . . . . 0 C--O 1.248 1.013 0 CA-C-O 118.282 -0.865 . . . . 0.0 110.88 -179.959 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 301' ' ' RET . . . . . 0.69 H203 ' HE1' ' A' ' 171' ' ' TRP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . 0.57 ' HE1' ' H ' ' A' ' 4' ' ' LEU . 14.0 tmm? . . . . . 0 N--CA 1.485 1.311 0 CA-C-O 120.69 0.281 . . . . 0.0 110.617 . . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 62.5 t 58.75 101.65 0.04 OUTLIER 'Isoleucine or valine' 0 C--N 1.333 -0.146 0 CA-C-N 116.122 -0.49 . . . . 0.0 111.37 179.82 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . 178.89 -27.58 0.06 OUTLIER Glycine 0 N--CA 1.45 -0.368 0 C-N-CA 120.786 -0.721 . . . . 0.0 112.582 179.938 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 4' ' ' LEU . . . . . 0.57 ' H ' ' HE1' ' A' ' 1' ' ' MET . 92.7 mt -74.04 -35.25 64.3 Favored 'General case' 0 N--CA 1.449 -0.508 0 CA-C-O 120.858 0.361 . . . . 0.0 110.94 179.88 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 55.1 p -54.44 -38.84 66.76 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 115.928 -0.578 . . . . 0.0 111.718 -179.587 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 72.0 p -54.81 -35.52 63.98 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.451 -0.34 . . . . 0.0 111.619 -179.578 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 7' ' ' LEU . . . . . 0.443 HD23 ' HA ' ' A' ' 4' ' ' LEU . 3.9 mm? -60.14 -53.29 59.45 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.317 -0.401 . . . . 0.0 111.272 -179.748 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 8' ' ' PHE . . . . . 0.604 ' HB2' ' HB2' ' A' ' 55' ' ' ALA . 75.8 m-85 -64.17 -34.53 78.29 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.994 -179.645 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 9' ' ' TRP . . . . . . . . . . . . . 21.5 m95 -62.34 -46.17 89.88 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-O 121.074 0.464 . . . . 0.0 109.835 179.939 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 41.9 mt -63.11 -35.88 81.75 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 115.629 -0.714 . . . . 0.0 110.154 179.138 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -69.66 -28.85 71.71 Favored Glycine 0 N--CA 1.448 -0.545 0 CA-C-N 115.643 -0.708 . . . . 0.0 111.784 179.419 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -73.71 -30.8 63.05 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-O 120.896 0.379 . . . . 0.0 110.473 179.526 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 13' ' ' ILE . . . . . 0.42 ' O ' HG23 ' A' ' 17' ' ' VAL . 50.2 mm -68.39 -54.33 22.36 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.124 0 CA-C-N 116.058 -0.519 . . . . 0.0 110.442 179.221 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -61.42 -37.39 94.02 Favored Glycine 0 N--CA 1.448 -0.534 0 C-N-CA 120.661 -0.781 . . . . 0.0 111.744 179.43 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 15' ' ' MET . . . . . 0.524 ' SD ' ' HA ' ' A' ' 44' ' ' SER . 55.5 tpp -63.65 -44.36 94.04 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.845 0.355 . . . . 0.0 110.44 179.527 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 16' ' ' LEU . . . . . 0.429 HD13 ' O ' ' A' ' 16' ' ' LEU . 0.4 OUTLIER -54.82 -42.13 71.5 Favored 'General case' 0 C--N 1.332 -0.187 0 CA-C-N 115.943 -0.572 . . . . 0.0 110.02 179.291 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . 0.42 HG23 ' O ' ' A' ' 13' ' ' ILE . 45.0 t -58.94 -44.55 91.19 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.188 0 CA-C-N 116.011 -0.54 . . . . 0.0 110.328 179.404 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -64.45 -40.44 97.74 Favored Glycine 0 C--N 1.332 0.337 0 C-N-CA 120.852 -0.689 . . . . 0.0 111.726 179.124 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 11.8 m -53.45 -48.18 69.05 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-O 120.839 0.352 . . . . 0.0 110.988 -179.943 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 97.2 mt -71.75 -36.13 70.33 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.513 -179.977 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -58.14 -38.01 75.75 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 116.528 -0.305 . . . . 0.0 111.586 -179.761 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 22' ' ' PHE . . . . . 0.606 ' HB2' HG22 ' A' ' 41' ' ' VAL . 4.0 m-85 -90.91 -28.22 18.24 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.347 -0.388 . . . . 0.0 111.394 -179.457 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -69.81 -50.8 39.43 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.961 0.41 . . . . 0.0 111.503 -179.444 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 24' ' ' TRP . . . . . . . . . . . . . 5.5 t-105 -66.19 -43.26 87.34 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 115.842 -0.617 . . . . 0.0 111.111 -179.659 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -73.82 -26.96 60.87 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.94 0.4 . . . . 0.0 110.866 179.799 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -69.6 -44.32 64.29 Favored Glycine 0 N--CA 1.452 -0.287 0 C-N-CA 120.772 -0.727 . . . . 0.0 112.066 179.743 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 40.9 mmt180 -58.7 -27.35 64.77 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-O 120.849 0.357 . . . . 0.0 110.535 179.694 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 32.5 t70 -105.42 92.36 4.16 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.003 -0.544 . . . . 0.0 110.463 179.675 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 29' ' ' ALA . . . . . 0.411 ' HA ' ' NH1' ' A' ' 220' ' ' ARG . . . -154.38 -167.87 2.76 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.15 -179.778 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -98.92 -126.33 5.6 Favored Glycine 0 N--CA 1.451 -0.3 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.438 179.972 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 88.1 p -132.2 123.06 26.27 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-O 120.773 0.321 . . . . 0.0 110.906 179.993 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 107.76 -31.14 8.27 Favored Glycine 0 N--CA 1.451 -0.363 0 C-N-CA 120.868 -0.682 . . . . 0.0 112.472 179.976 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 16.3 mm-40 -83.57 -21.68 32.56 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 120.689 0.28 . . . . 0.0 110.994 179.929 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 34' ' ' ARG . . . . . . . . . . . . . 60.1 ttp180 -52.11 -30.5 26.54 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-N 116.158 -0.473 . . . . 0.0 111.252 -179.645 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 80.2 ttt180 -61.28 -42.55 98.83 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.871 0.367 . . . . 0.0 110.761 179.879 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 66.4 m-85 -70.75 -30.47 66.99 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.054 -0.521 . . . . 0.0 110.925 179.941 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 37' ' ' TYR . . . . . 0.502 ' O ' HG23 ' A' ' 41' ' ' VAL . 59.2 m-85 -72.37 -56.13 5.96 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.324 -179.44 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 52.1 t -57.05 -37.4 54.94 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.189 0 CA-C-O 120.955 0.407 . . . . 0.0 110.766 -179.826 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 33.8 m -60.73 -51.01 71.19 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 115.863 -0.608 . . . . 0.0 110.628 179.521 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 40' ' ' LEU . . . . . 0.61 HD12 HD12 ' A' ' 43' ' ' ILE . 66.0 tp -60.86 -46.89 88.79 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 115.838 -0.619 . . . . 0.0 110.63 179.694 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . 0.606 HG22 ' HB2' ' A' ' 22' ' ' PHE . 90.0 t -56.7 -35.24 44.96 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.242 0 CA-C-N 115.884 -0.598 . . . . 0.0 110.041 179.289 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -61.74 -40.95 99.49 Favored Glycine 0 N--CA 1.448 -0.527 0 C-N-CA 120.673 -0.775 . . . . 0.0 111.504 179.175 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 43' ' ' ILE . . . . . 0.61 HD12 HD12 ' A' ' 40' ' ' LEU . 18.7 mt -57.46 -56.62 14.2 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.22 0 CA-C-O 120.76 0.314 . . . . 0.0 110.933 179.318 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 44' ' ' SER . . . . . 0.524 ' HA ' ' SD ' ' A' ' 15' ' ' MET . 49.7 m -58.71 -26.35 63.82 Favored 'General case' 0 C--N 1.332 -0.182 0 CA-C-N 116.315 -0.402 . . . . 0.0 111.482 -179.696 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -73.53 -53.99 7.05 Favored Glycine 0 CA--C 1.518 0.229 0 C-N-CA 120.681 -0.771 . . . . 0.0 112.879 -179.625 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 19.6 pt -61.18 -38.38 79.59 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.222 0 CA-C-O 120.871 0.367 . . . . 0.0 111.377 -179.712 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 47' ' ' ALA . . . . . 0.665 ' HB2' ' HE2' ' A' ' 205' ' ' LYS . . . -67.71 -43.21 80.57 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.814 0.34 . . . . 0.0 111.002 179.602 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -54.75 -46.71 74.36 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 115.947 -0.569 . . . . 0.0 111.754 -179.531 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 31.4 m -68.59 -34.19 63.89 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.241 0 CA-C-N 116.527 -0.306 . . . . 0.0 111.275 -179.595 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -66.01 -37.07 84.98 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-O 120.884 0.373 . . . . 0.0 111.005 179.638 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 51' ' ' TYR . . . . . 0.433 ' CE1' HG13 ' A' ' 198' ' ' VAL . 26.7 m-85 -68.75 -38.75 80.34 Favored 'General case' 0 C--N 1.327 -0.413 0 CA-C-O 121.117 0.484 . . . . 0.0 110.084 179.772 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -65.29 -45.09 85.84 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 115.635 -0.712 . . . . 0.0 111.314 179.676 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 53' ' ' VAL . . . . . 0.466 HG23 ' N ' ' A' ' 54' ' ' MET . 27.6 m -67.76 -46.5 82.36 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.139 0 CA-C-O 120.794 0.33 . . . . 0.0 110.621 179.886 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 54' ' ' MET . . . . . 0.498 ' HG2' ' HG2' ' A' ' 71' ' ' PRO . 72.0 mtm -62.27 -30.44 71.12 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 121.156 0.503 . . . . 0.0 109.854 179.111 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 55' ' ' ALA . . . . . 0.604 ' HB2' ' HB2' ' A' ' 8' ' ' PHE . . . -74.28 -30.53 62.14 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 115.601 -0.727 . . . . 0.0 111.355 179.797 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 76.3 mt -77.37 -9.74 59.03 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.457 -0.338 . . . . 0.0 111.214 -179.764 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 95.31 -11.93 68.48 Favored Glycine 0 N--CA 1.452 -0.254 0 C-N-CA 120.666 -0.778 . . . . 0.0 113.017 179.729 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 8.8 p -74.29 140.58 17.38 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-O 120.846 0.355 . . . . 0.0 110.885 -179.97 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 59' ' ' GLY . . . . . 0.465 ' HA3' ' HG3' ' A' ' 71' ' ' PRO . . . 101.29 -9.71 57.76 Favored Glycine 0 N--CA 1.45 -0.377 0 C-N-CA 120.907 -0.663 . . . . 0.0 112.286 -179.715 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 60' ' ' TRP . . . . . . . . . . . . . 15.8 m0 -76.32 118.08 18.66 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-O 120.579 0.228 . . . . 0.0 110.393 179.67 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 61' ' ' VAL . . . . . 0.483 ' HA ' ' HD3' ' A' ' 62' ' ' PRO . 7.5 p -113.26 127.63 26.61 Favored Pre-proline 0 CA--C 1.533 0.321 0 CA-C-N 116.582 -0.281 . . . . 0.0 111.716 -179.603 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 62' ' ' PRO . . . . . 0.483 ' HD3' ' HA ' ' A' ' 61' ' ' VAL . 6.8 Cg_exo -74.03 146.61 37.25 Favored 'Trans proline' 0 C--N 1.351 0.685 0 C-N-CA 122.88 2.386 . . . . 0.0 112.159 179.518 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 75.5 t -139.71 90.42 0.6 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.044 179.859 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . 59.16 -86.12 0.02 OUTLIER 'General case' 0 C--N 1.331 -0.196 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.463 179.891 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 9.7 tp10 -122.42 -19.98 6.24 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 121.011 0.434 . . . . 0.0 110.653 -179.991 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 66' ' ' ARG . . . . . 0.418 HH22 HH12 ' A' ' 123' ' ' ARG . 18.4 ptp180 -100.76 165.82 11.18 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 115.893 -0.594 . . . . 0.0 110.373 179.878 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 26.3 m -125.42 139.66 53.46 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.886 0.374 . . . . 0.0 111.3 -179.838 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 21.5 t -124.17 146.57 29.46 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.238 0 CA-C-N 115.972 -0.558 . . . . 0.0 110.583 179.887 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 69' ' ' PHE . . . . . . . . . . . . . 27.5 m-85 -109.37 111.05 22.39 Favored 'General case' 0 C--N 1.331 -0.206 0 CA-C-N 116.41 -0.359 . . . . 0.0 110.062 -179.629 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 70' ' ' VAL . . . . . 0.599 ' N ' ' HD2' ' A' ' 71' ' ' PRO . 47.4 t -70.02 -49.82 18.15 Favored Pre-proline 0 C--N 1.325 -0.471 0 N-CA-C 112.759 0.651 . . . . 0.0 112.759 -179.186 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 71' ' ' PRO . . . . . 0.599 ' HD2' ' N ' ' A' ' 70' ' ' VAL . 11.3 Cg_endo -54.03 -19.12 14.94 Favored 'Trans proline' 0 C--N 1.352 0.739 0 C-N-CA 122.031 1.82 . . . . 0.0 112.339 -179.616 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 72' ' ' ARG . . . . . 0.517 ' HE ' HG21 ' A' ' 197' ' ' ILE . 32.1 ttt180 -77.02 -53.49 7.74 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.596 179.605 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 73' ' ' TYR . . . . . 0.423 ' O ' HG13 ' A' ' 77' ' ' ILE . 79.9 m-85 -66.37 -39.41 89.08 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 115.816 -0.629 . . . . 0.0 110.922 -179.811 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 0.3 OUTLIER -67.4 -36.35 76.24 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-N 116.348 -0.387 . . . . 0.0 110.043 179.504 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 12.6 t70 -61.02 -37.37 82.32 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.235 -0.439 . . . . 0.0 109.951 179.253 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 76' ' ' TRP . . . . . . . . . . . . . 48.6 m0 -66.3 -36.21 82.36 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 115.927 -0.579 . . . . 0.0 110.067 179.414 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 77' ' ' ILE . . . . . 0.5 ' O ' ' HG2' ' A' ' 81' ' ' PRO . 68.3 mt -66.54 -30.07 48.55 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.364 0 CA-C-N 115.959 -0.564 . . . . 0.0 110.91 179.511 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 53.4 mt -91.91 -21.95 20.32 Favored 'General case' 0 C--N 1.328 -0.347 0 N-CA-C 112.511 0.56 . . . . 0.0 112.511 -179.644 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 79' ' ' THR . . . . . 0.401 ' HB ' ' HE3' ' A' ' 205' ' ' LYS . 70.0 p -100.27 -52.0 3.5 Favored 'General case' 0 N--CA 1.464 0.269 0 N-CA-C 113.619 0.97 . . . . 0.0 113.619 -177.792 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 80' ' ' THR . . . . . 0.675 ' HB ' ' HD3' ' A' ' 81' ' ' PRO . 86.3 m -51.35 -55.35 29.65 Favored Pre-proline 0 CA--C 1.532 0.271 0 N-CA-C 112.421 0.526 . . . . 0.0 112.421 -178.502 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 81' ' ' PRO . . . . . 0.675 ' HD3' ' HB ' ' A' ' 80' ' ' THR . 52.0 Cg_exo -56.49 -20.13 32.13 Favored 'Trans proline' 0 C--N 1.352 0.762 0 C-N-CA 121.542 1.495 . . . . 0.0 111.481 179.574 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 82' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -76.63 -38.2 55.08 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 115.716 -0.675 . . . . 0.0 110.223 179.552 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 83' ' ' ILE . . . . . 0.486 HD13 HD13 ' A' ' 43' ' ' ILE . 16.7 mm -66.17 -51.24 61.68 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.16 0 CA-C-N 116.004 -0.543 . . . . 0.0 110.293 179.516 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 31.0 m -61.49 -31.76 51.48 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.166 0 N-CA-C 109.71 -0.478 . . . . 0.0 109.71 178.962 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 85' ' ' TYR . . . . . . . . . . . . . 83.4 t80 -66.48 -31.94 72.99 Favored 'General case' 0 N--CA 1.454 -0.249 0 CA-C-N 115.656 -0.702 . . . . 0.0 109.569 178.763 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 86' ' ' PHE . . . . . . . . . . . . . 11.5 t80 -63.69 -50.84 67.6 Favored 'General case' 0 C--O 1.233 0.185 0 CA-C-N 115.889 -0.596 . . . . 0.0 109.793 179.179 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 3.1 mt -61.02 -35.5 77.02 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 115.786 -0.643 . . . . 0.0 109.714 179.537 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -67.08 -28.14 73.68 Favored Glycine 0 N--CA 1.45 -0.393 0 CA-C-N 115.28 -0.873 . . . . 0.0 111.865 179.49 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 50.0 mt -72.59 -37.36 68.15 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.893 0.378 . . . . 0.0 110.277 179.534 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 41.5 mt -60.4 -50.6 72.96 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 115.741 -0.663 . . . . 0.0 110.73 179.617 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . 0.498 ' HB1' ' HB2' ' A' ' 148' ' ' SER . . . -71.52 -48.57 47.98 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 115.981 -0.554 . . . . 0.0 111.374 -179.815 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 96.88 62.66 0.93 Allowed Glycine 0 N--CA 1.452 -0.271 0 C-N-CA 120.764 -0.731 . . . . 0.0 112.399 -179.902 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 93' ' ' LEU . . . . . 0.587 HD23 ' HB3' ' A' ' 97' ' ' GLU . 7.1 mp -77.08 175.09 9.94 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.782 0.325 . . . . 0.0 110.868 -179.958 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 94' ' ' ASP . . . . . . . . . . . . . 13.0 m-20 -91.23 172.82 8.28 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.827 179.708 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 78.5 p -60.04 -36.55 77.52 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.246 -0.434 . . . . 0.0 111.09 -179.848 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 15.9 ptm180 -73.89 -43.54 58.16 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.06 -179.965 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 97' ' ' GLU . . . . . 0.587 ' HB3' HD23 ' A' ' 93' ' ' LEU . 37.1 mt-10 -57.59 -46.49 83.97 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.384 -0.371 . . . . 0.0 110.764 -179.926 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 98' ' ' PHE . . . . . . . . . . . . . 21.4 m-85 -60.25 -41.29 92.9 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.361 179.53 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -58.73 -32.55 69.91 Favored Glycine 0 N--CA 1.449 -0.469 0 C-N-CA 120.687 -0.768 . . . . 0.0 112.265 179.75 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 86.7 mt -73.51 -44.54 53.6 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-O 120.747 0.308 . . . . 0.0 111.675 -179.83 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 35.3 t -68.46 -48.8 70.77 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 CA-C-N 116.318 -0.401 . . . . 0.0 111.76 -179.252 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 102' ' ' ILE . . . . . 0.558 HG23 ' HB3' ' A' ' 81' ' ' PRO . 48.2 mm -63.56 -45.87 96.5 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.379 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.868 -179.357 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 6.0 t -62.02 -33.67 74.79 Favored 'General case' 0 C--N 1.332 -0.192 0 CA-C-O 120.867 0.365 . . . . 0.0 110.759 -179.813 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 104' ' ' LEU . . . . . 0.416 HD22 ' HE2' ' A' ' 140' ' ' TYR . 48.5 tp -60.17 -53.28 59.59 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.221 179.348 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 105' ' ' ASN . . . . . 0.577 ' N ' HD22 ' A' ' 105' ' ' ASN . 0.8 OUTLIER -56.26 -31.31 63.47 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.063 -0.517 . . . . 0.0 110.115 179.38 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 24.8 m -61.88 -38.75 89.47 Favored 'General case' 0 C--N 1.332 -0.179 0 CA-C-N 116.038 -0.528 . . . . 0.0 109.996 179.078 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 107' ' ' VAL . . . . . 0.419 ' H ' HG23 ' A' ' 107' ' ' VAL . 1.8 t -70.35 -41.21 78.45 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.198 0 CA-C-N 116.051 -0.522 . . . . 0.0 109.964 178.97 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 54.0 t -57.22 -47.19 84.62 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 115.367 -0.833 . . . . 0.0 111.23 179.885 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 109' ' ' MET . . . . . 0.418 ' O ' ' HB2' ' A' ' 113' ' ' PHE . 21.5 mmt -69.27 -32.31 71.41 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.017 -0.538 . . . . 0.0 111.124 -179.714 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 27.8 tp -65.3 -33.28 75.6 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-O 120.964 0.411 . . . . 0.0 110.324 179.793 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -68.82 -53.84 19.24 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 115.855 -0.611 . . . . 0.0 110.743 179.465 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 112' ' ' GLY . . . . . 0.59 ' HA3' ' H21' ' A' ' 301' ' ' RET . . . -63.09 -35.62 92.33 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.652 -0.785 . . . . 0.0 112.135 179.642 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 113' ' ' PHE . . . . . 0.47 ' HZ ' HG13 ' A' ' 70' ' ' VAL . 0.7 OUTLIER -55.63 -65.31 0.61 Allowed 'General case' 0 C--N 1.33 -0.255 0 CA-C-O 121.066 0.46 . . . . 0.0 110.249 179.6 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 114' ' ' ALA . . . . . 0.576 ' HB3' HD22 ' A' ' 126' ' ' LEU . . . -66.09 -22.55 66.41 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 115.722 -0.672 . . . . 0.0 110.951 179.816 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -55.8 -48.96 68.71 Favored Glycine 0 C--N 1.333 0.392 0 C-N-CA 120.659 -0.781 . . . . 0.0 111.85 179.401 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -78.32 -15.03 59.14 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-O 120.836 0.35 . . . . 0.0 111.016 179.508 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 117' ' ' MET . . . . . . . . . . . . . 32.3 tpp -91.58 18.73 7.02 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.105 -0.498 . . . . 0.0 111.497 -179.204 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 118' ' ' VAL . . . . . 0.459 HG21 ' HB3' ' A' ' 123' ' ' ARG . 27.5 m -88.57 139.1 29.71 Favored Pre-proline 0 C--N 1.33 -0.27 0 CA-C-N 116.633 -0.258 . . . . 0.0 111.308 -179.865 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 119' ' ' PRO . . . . . . . . . . . . . 95.4 Cg_endo -89.67 -10.08 3.81 Favored 'Trans proline' 0 N--CA 1.456 -0.697 0 C-N-CA 122.699 2.266 . . . . 0.0 112.195 179.371 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -128.64 -106.71 1.3 Allowed Glycine 0 C--N 1.331 0.305 0 C-N-CA 120.848 -0.691 . . . . 0.0 112.722 -179.74 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 2.6 pp -136.93 19.52 0.85 Allowed 'Isoleucine or valine' 0 C--N 1.332 -0.185 0 CA-C-O 120.742 0.306 . . . . 0.0 111.652 -179.713 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 41.3 mt-10 -65.05 -17.71 64.68 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.311 -0.404 . . . . 0.0 110.853 179.757 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 123' ' ' ARG . . . . . 0.459 ' HB3' HG21 ' A' ' 118' ' ' VAL . 12.2 ptt180 -50.16 -42.05 50.25 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 115.736 -0.666 . . . . 0.0 112.023 -179.64 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 124' ' ' TYR . . . . . . . . . . . . . 59.0 m-85 -57.56 -32.18 66.87 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.522 -0.308 . . . . 0.0 111.511 -179.239 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 125' ' ' ALA . . . . . . . . . . . . . . . -74.2 -56.29 5.07 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-O 121.03 0.443 . . . . 0.0 111.156 -179.728 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 126' ' ' LEU . . . . . 0.576 HD22 ' HB3' ' A' ' 114' ' ' ALA . 1.1 mt -53.25 -48.83 67.92 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 115.746 -0.661 . . . . 0.0 110.494 179.96 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 127' ' ' PHE . . . . . 0.429 ' HE1' ' H42' ' A' ' 301' ' ' RET . 7.0 t80 -63.65 -35.65 81.24 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.306 -0.406 . . . . 0.0 110.483 179.396 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 128' ' ' GLY . . . . . . . . . . . . . . . -47.22 -50.73 16.21 Favored Glycine 0 C--N 1.333 0.402 0 C-N-CA 120.055 -1.069 . . . . 0.0 110.609 178.854 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 129' ' ' MET . . . . . . . . . . . . . 0.5 OUTLIER -65.31 -34.31 78.03 Favored 'General case' 0 C--N 1.329 -0.314 0 N-CA-C 109.679 -0.489 . . . . 0.0 109.679 178.293 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -57.81 -51.61 57.1 Favored Glycine 0 C--N 1.331 0.284 0 CA-C-N 115.463 -0.789 . . . . 0.0 112.597 -179.973 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -58.91 -49.47 77.66 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 120.66 0.267 . . . . 0.0 110.684 179.865 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 132' ' ' VAL . . . . . 0.426 ' O ' HG13 ' A' ' 135' ' ' ILE . 49.9 t -54.55 -39.99 48.21 Favored 'Isoleucine or valine' 0 C--O 1.233 0.228 0 CA-C-O 121.269 0.557 . . . . 0.0 109.794 179.007 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -69.98 -34.19 73.05 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 115.474 -0.784 . . . . 0.0 110.947 179.469 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 134' ' ' PHE . . . . . 0.457 ' CZ ' ' HA ' ' A' ' 172' ' ' ALA . 51.9 t80 -56.87 -58.58 7.5 Favored 'General case' 0 CA--C 1.517 -0.294 0 CA-C-N 116.341 -0.39 . . . . 0.0 110.118 179.817 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 135' ' ' ILE . . . . . 0.487 ' O ' HG22 ' A' ' 138' ' ' VAL . 0.0 OUTLIER -55.6 -34.85 36.56 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 115.799 -0.637 . . . . 0.0 109.663 179.104 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . -58.19 -36.47 82.61 Favored Glycine 0 N--CA 1.448 -0.524 0 C-N-CA 120.447 -0.882 . . . . 0.0 111.482 178.944 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 137' ' ' LEU . . . . . 0.536 HD13 HD21 ' A' ' 105' ' ' ASN . 38.3 tp -71.91 -54.18 10.82 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-O 120.615 0.245 . . . . 0.0 110.721 179.537 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 138' ' ' VAL . . . . . 0.487 HG22 ' O ' ' A' ' 135' ' ' ILE . 3.4 m -55.92 -30.32 28.09 Favored 'Isoleucine or valine' 0 C--O 1.233 0.197 0 CA-C-O 121.312 0.577 . . . . 0.0 109.712 179.351 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 139' ' ' TYR . . . . . . . . . . . . . 31.4 t80 -63.58 -47.03 83.14 Favored 'General case' 0 N--CA 1.453 -0.285 0 CA-C-N 115.31 -0.859 . . . . 0.0 110.021 178.975 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 140' ' ' TYR . . . . . 0.416 ' HE2' HD22 ' A' ' 104' ' ' LEU . 18.2 m-85 -57.38 -35.98 70.68 Favored 'General case' 0 C--N 1.332 -0.191 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.596 179.362 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 141' ' ' LEU . . . . . 0.445 HD13 ' HG2' ' A' ' 164' ' ' ARG . 69.5 mt -59.49 -54.69 43.7 Favored 'General case' 0 C--N 1.333 -0.152 0 CA-C-N 116.262 -0.426 . . . . 0.0 110.51 179.522 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 18.6 t -70.02 -15.79 19.58 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.246 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.765 179.597 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . -68.68 -138.67 0.08 OUTLIER Glycine 0 CA--C 1.522 0.469 0 C-N-CA 121.025 -0.607 . . . . 0.0 112.779 -179.899 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 144' ' ' PRO . . . . . . . . . . . . . 19.2 Cg_endo -59.11 -23.42 68.94 Favored 'Trans proline' 0 C--N 1.349 0.587 0 C-N-CA 122.672 2.248 . . . . 0.0 112.654 -179.723 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 145' ' ' MET . . . . . . . . . . . . . 45.5 mtt -59.07 -28.52 66.55 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.517 -0.311 . . . . 0.0 111.28 -179.997 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 146' ' ' THR . . . . . . . . . . . . . 35.2 m -80.45 -42.9 21.81 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.913 0.387 . . . . 0.0 111.194 -179.167 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 9.1 tp10 -70.42 -34.53 72.6 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 115.964 -0.562 . . . . 0.0 111.107 -179.818 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 148' ' ' SER . . . . . 0.498 ' HB2' ' HB1' ' A' ' 91' ' ' ALA . 64.2 m -70.47 -50.85 33.75 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.054 -179.41 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 149' ' ' ALA . . . . . 0.423 ' HB1' HG22 ' A' ' 156' ' ' ILE . . . -64.79 -38.38 90.8 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.332 -179.828 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 150' ' ' SER . . . . . . . . . . . . . 100.0 p -72.15 -4.29 28.26 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.896 179.856 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 151' ' ' GLN . . . . . . . . . . . . . 24.3 mt-30 -125.46 1.54 7.66 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.168 -179.98 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 152' ' ' ARG . . . . . 0.418 ' HA ' ' HE ' ' A' ' 152' ' ' ARG . 0.0 OUTLIER -80.34 -52.54 7.57 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-O 121.013 0.435 . . . . 0.0 110.333 179.883 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 153' ' ' SER . . . . . 0.606 ' HB2' HG12 ' A' ' 156' ' ' ILE . 44.3 m -158.22 171.01 20.98 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-N 115.83 -0.623 . . . . 0.0 110.49 179.18 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 154' ' ' SER . . . . . . . . . . . . . 64.1 m -71.21 -36.82 72.01 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 121.028 0.442 . . . . 0.0 110.059 179.127 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -76.93 -41.21 23.49 Favored Glycine 0 N--CA 1.45 -0.417 0 CA-C-N 115.785 -0.643 . . . . 0.0 112.386 179.611 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 156' ' ' ILE . . . . . 0.606 HG12 ' HB2' ' A' ' 153' ' ' SER . 38.1 mm -51.76 -38.17 21.81 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.196 0 CA-C-O 120.879 0.371 . . . . 0.0 111.177 179.91 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 157' ' ' LYS . . . . . . . . . . . . . 63.1 tttm -58.93 -42.92 90.88 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 115.961 -0.563 . . . . 0.0 110.92 -179.989 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 51.0 m -71.19 -40.94 70.91 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.547 -179.732 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 159' ' ' LEU . . . . . 0.417 ' O ' ' HB2' ' A' ' 163' ' ' LEU . 2.2 mm? -63.78 -38.72 92.17 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.418 -0.355 . . . . 0.0 111.601 -179.419 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 160' ' ' TYR . . . . . . . . . . . . . 43.5 t80 -74.2 -46.79 39.71 Favored 'General case' 0 C--N 1.327 -0.38 0 N-CA-C 112.598 0.592 . . . . 0.0 112.598 -178.533 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 161' ' ' VAL . . . . . 0.438 HG23 ' N ' ' A' ' 162' ' ' ARG . 21.2 m -57.25 -48.83 81.59 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 N-CA-C 112.395 0.517 . . . . 0.0 112.395 -178.788 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 162' ' ' ARG . . . . . 0.438 ' N ' HG23 ' A' ' 161' ' ' VAL . 27.1 ttm180 -69.04 -45.92 69.21 Favored 'General case' 0 C--N 1.329 -0.324 0 N-CA-C 111.783 0.29 . . . . 0.0 111.783 -179.302 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 163' ' ' LEU . . . . . 0.681 ' HG ' ' HB2' ' A' ' 208' ' ' PHE . 6.6 mp -61.78 -49.75 75.12 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.451 -0.34 . . . . 0.0 111.733 -179.661 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 164' ' ' ARG . . . . . 0.445 ' HG2' HD13 ' A' ' 141' ' ' LEU . 4.0 tmt_? -62.64 -45.51 92.52 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.312 -0.404 . . . . 0.0 111.749 -179.036 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 165' ' ' ASN . . . . . 0.523 ' O ' HG23 ' A' ' 169' ' ' VAL . 0.9 OUTLIER -59.49 -52.19 66.62 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.783 0.325 . . . . 0.0 111.546 -179.434 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 166' ' ' LEU . . . . . 0.511 ' O ' ' HG ' ' A' ' 170' ' ' LEU . 4.6 tt -63.88 -53.41 50.9 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-O 120.852 0.358 . . . . 0.0 111.314 -179.552 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 167' ' ' THR . . . . . 0.487 ' HA ' HD11 ' A' ' 170' ' ' LEU . 88.3 m -54.67 -53.09 59.37 Favored 'General case' 0 C--N 1.327 -0.381 0 N-CA-C 112.581 0.585 . . . . 0.0 112.581 -178.744 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 168' ' ' VAL . . . . . 0.404 HG12 ' O ' ' A' ' 165' ' ' ASN . 9.1 p -56.74 -40.58 71.23 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.204 0 N-CA-C 112.158 0.429 . . . . 0.0 112.158 -178.753 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 169' ' ' VAL . . . . . 0.523 HG23 ' O ' ' A' ' 165' ' ' ASN . 51.5 t -58.26 -65.37 0.44 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 N-CA-C 111.821 0.304 . . . . 0.0 111.821 -179.487 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 170' ' ' LEU . . . . . 0.511 ' HG ' ' O ' ' A' ' 166' ' ' LEU . 0.4 OUTLIER -64.48 -28.26 69.54 Favored 'General case' 0 C--N 1.331 -0.216 0 N-CA-C 111.982 0.364 . . . . 0.0 111.982 -178.865 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 171' ' ' TRP . . . . . 0.436 ' HB2' ' O ' ' A' ' 167' ' ' THR . 5.2 m0 -71.38 -31.18 67.01 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.848 0.356 . . . . 0.0 110.742 179.488 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 172' ' ' ALA . . . . . 0.457 ' HA ' ' CZ ' ' A' ' 134' ' ' PHE . . . -73.78 -6.4 46.75 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.861 -179.727 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 173' ' ' ILE . . . . . 0.663 HG22 HD11 ' A' ' 177' ' ' ILE . 13.9 mm -86.12 -21.46 7.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 115.927 -0.579 . . . . 0.0 110.806 179.629 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 174' ' ' TYR . . . . . . . . . . . . . 14.2 m-85 -54.27 -51.24 79.5 Favored Pre-proline 0 CA--C 1.531 0.236 0 CA-C-N 116.115 -0.493 . . . . 0.0 112.109 -179.535 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 175' ' ' PRO . . . . . . . . . . . . . 89.1 Cg_exo -47.4 -29.14 9.43 Favored 'Trans proline' 0 C--N 1.352 0.728 0 C-N-CA 121.998 1.798 . . . . 0.0 112.176 179.748 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 176' ' ' PHE . . . . . 0.459 ' O ' ' HG ' ' A' ' 180' ' ' LEU . 98.3 m-85 -80.52 -50.12 10.46 Favored 'General case' 0 CA--C 1.517 -0.323 0 CA-C-N 116.057 -0.52 . . . . 0.0 111.69 179.968 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 177' ' ' ILE . . . . . 0.663 HD11 HG22 ' A' ' 173' ' ' ILE . 3.1 mm -58.4 -46.47 89.36 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.533 0 CA-C-N 115.884 -0.598 . . . . 0.0 112.073 -178.227 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 178' ' ' TRP . . . . . 0.485 ' HA ' ' HG2' ' A' ' 182' ' ' PRO . 75.1 t90 -62.5 -42.45 99.51 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 121.026 0.441 . . . . 0.0 110.974 -179.986 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 179' ' ' LEU . . . . . 0.551 HD13 HG22 ' A' ' 185' ' ' VAL . 1.2 tm? -67.27 -49.51 64.04 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 115.831 -0.622 . . . . 0.0 111.369 -179.061 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 180' ' ' LEU . . . . . 0.653 HD22 HD11 ' A' ' 187' ' ' LEU . 9.9 mt -76.95 -52.29 9.65 Favored 'General case' 0 CA--C 1.535 0.374 0 N-CA-C 112.498 0.555 . . . . 0.0 112.498 -178.474 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . -64.97 -84.1 0.08 OUTLIER Glycine 0 CA--C 1.522 0.521 0 C-N-CA 120.72 -0.752 . . . . 0.0 113.425 -179.557 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 182' ' ' PRO . . . . . 0.557 ' HD2' ' O ' ' A' ' 177' ' ' ILE . 75.0 Cg_exo -44.86 -179.79 0.0 OUTLIER 'Trans proline' 0 C--N 1.351 0.671 0 C-N-CA 123.567 2.845 . . . . 0.0 113.574 179.684 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 183' ' ' PRO . . . . . . . . . . . . . 82.8 Cg_exo -50.11 5.06 0.02 OUTLIER 'Trans proline' 0 C--N 1.354 0.864 0 C-N-CA 123.196 2.597 . . . . 0.0 115.274 -179.566 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 184' ' ' GLY . . . . . 0.459 ' H ' ' C ' ' A' ' 182' ' ' PRO . . . -55.32 -70.28 1.01 Allowed Glycine 0 C--N 1.335 0.514 0 C-N-CA 119.724 -1.226 . . . . 0.0 110.899 179.236 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 185' ' ' VAL . . . . . 0.551 HG22 HD13 ' A' ' 179' ' ' LEU . 3.6 m -135.65 -5.77 0.95 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.372 0 N-CA-C 111.722 0.267 . . . . 0.0 111.722 178.559 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 186' ' ' ALA . . . . . . . . . . . . . . . 41.99 81.19 0.03 OUTLIER 'General case' 0 N--CA 1.466 0.349 0 N-CA-C 112.43 0.529 . . . . 0.0 112.43 179.372 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 187' ' ' LEU . . . . . 0.653 HD11 HD22 ' A' ' 180' ' ' LEU . 7.0 mt -92.92 -49.47 6.03 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.767 0.318 . . . . 0.0 111.548 179.871 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 188' ' ' LEU . . . . . . . . . . . . . 89.3 mt -105.8 -166.56 1.22 Allowed 'General case' 0 C--N 1.33 -0.244 0 CA-C-O 121.073 0.463 . . . . 0.0 111.515 -179.261 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 189' ' ' THR . . . . . 0.432 ' HB ' HG23 ' A' ' 192' ' ' VAL . 4.7 m -82.72 136.12 45.25 Favored Pre-proline 0 C--N 1.328 -0.339 0 CA-C-N 115.668 -0.696 . . . . 0.0 110.685 -179.615 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 190' ' ' PRO . . . . . 0.418 ' O ' HG23 ' A' ' 194' ' ' VAL . 84.5 Cg_exo -45.76 -48.64 12.0 Favored 'Trans proline' 0 C--N 1.349 0.559 0 C-N-CA 122.628 2.219 . . . . 0.0 113.026 -179.788 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 191' ' ' THR . . . . . 0.429 HG22 HG22 ' A' ' 189' ' ' THR . 3.9 t -56.8 -39.69 74.59 Favored 'General case' 0 C--N 1.33 -0.255 0 N-CA-C 111.921 0.341 . . . . 0.0 111.921 -179.492 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 192' ' ' VAL . . . . . 0.432 HG23 ' HB ' ' A' ' 189' ' ' THR . 58.6 t -67.33 -53.58 31.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-O 120.877 0.37 . . . . 0.0 111.546 -179.55 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 193' ' ' ASP . . . . . . . . . . . . . 13.5 m-20 -59.0 -43.05 91.43 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.09 -179.636 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 194' ' ' VAL . . . . . 0.418 HG23 ' O ' ' A' ' 190' ' ' PRO . 54.3 t -60.99 -36.16 70.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.345 -0.389 . . . . 0.0 110.404 179.497 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 195' ' ' ALA . . . . . . . . . . . . . . . -58.51 -46.42 86.78 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-N 116.346 -0.388 . . . . 0.0 110.404 179.232 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 196' ' ' LEU . . . . . . . . . . . . . 90.6 mt -62.66 -38.04 88.74 Favored 'General case' 0 C--N 1.332 -0.192 0 CA-C-N 116.055 -0.52 . . . . 0.0 110.323 179.309 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 197' ' ' ILE . . . . . 0.517 HG21 ' HE ' ' A' ' 72' ' ' ARG . 20.3 mm -61.36 -57.14 13.49 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 115.947 -0.57 . . . . 0.0 110.223 179.262 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 198' ' ' VAL . . . . . 0.433 HG13 ' CE1' ' A' ' 51' ' ' TYR . 83.9 t -52.75 -34.88 20.52 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.465 0 CA-C-N 115.734 -0.666 . . . . 0.0 109.243 178.374 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 199' ' ' TYR . . . . . . . . . . . . . 62.5 t80 -69.99 -33.62 72.28 Favored 'General case' 0 C--N 1.332 -0.176 0 CA-C-N 115.388 -0.824 . . . . 0.0 110.626 179.498 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 200' ' ' LEU . . . . . 0.573 ' O ' HG12 ' A' ' 203' ' ' VAL . 31.8 mt -68.87 -44.17 73.86 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 115.919 -0.582 . . . . 0.0 111.409 -179.685 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 201' ' ' ASP . . . . . 0.425 ' HB2' ' OH ' ' A' ' 51' ' ' TYR . 11.8 m-20 -67.39 -36.05 80.52 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-O 121.293 0.568 . . . . 0.0 109.963 179.476 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 202' ' ' LEU . . . . . . . . . . . . . 3.3 mt -74.35 -28.28 61.06 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 115.232 -0.895 . . . . 0.0 112.356 -179.394 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 203' ' ' VAL . . . . . 0.573 HG12 ' O ' ' A' ' 200' ' ' LEU . 11.6 p -77.25 -36.15 23.71 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.303 0 C-N-CA 120.757 -0.377 . . . . 0.0 111.21 -178.533 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 204' ' ' THR . . . . . . . . . . . . . 90.2 m -70.7 -58.49 3.59 Favored 'General case' 0 C--N 1.327 -0.389 0 C-N-CA 120.719 -0.392 . . . . 0.0 111.068 179.316 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 205' ' ' LYS . . . . . 0.665 ' HE2' ' HB2' ' A' ' 47' ' ' ALA . 56.6 mttp -57.33 -58.02 10.09 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.242 -0.436 . . . . 0.0 111.728 -178.785 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 39.7 t -71.17 -36.3 61.94 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.431 0 CA-C-N 116.015 -0.539 . . . . 0.0 111.977 -179.061 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 207' ' ' GLY . . . . . 0.571 ' O ' HG13 ' A' ' 211' ' ' ILE . . . -58.9 -61.5 7.29 Favored Glycine 0 C--N 1.33 0.229 0 C-N-CA 120.624 -0.798 . . . . 0.0 113.816 -178.445 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 208' ' ' PHE . . . . . 0.681 ' HB2' ' HG ' ' A' ' 163' ' ' LEU . 1.0 OUTLIER -72.23 -27.47 62.54 Favored 'General case' 0 C--O 1.223 -0.333 0 CA-C-N 117.473 0.636 . . . . 0.0 111.05 -179.08 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 209' ' ' GLY . . . . . 0.513 ' O ' ' HB3' ' A' ' 212' ' ' ALA . . . -64.07 -34.2 89.3 Favored Glycine 0 N--CA 1.45 -0.369 0 N-CA-C 112.009 -0.436 . . . . 0.0 112.009 178.825 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 210' ' ' PHE . . . . . . . . . . . . . 1.2 m-85 -73.71 -48.71 30.02 Favored 'General case' 0 CA--C 1.514 -0.432 0 N-CA-C 108.21 -1.034 . . . . 0.0 108.21 178.446 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 211' ' ' ILE . . . . . 0.571 HG13 ' O ' ' A' ' 207' ' ' GLY . 5.4 mt -61.66 -28.07 43.39 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.499 0 N-CA-C 107.646 -1.242 . . . . 0.0 107.646 176.815 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 212' ' ' ALA . . . . . 0.513 ' HB3' ' O ' ' A' ' 209' ' ' GLY . . . -63.7 -41.71 98.08 Favored 'General case' 0 N--CA 1.448 -0.565 0 CA-C-N 114.384 -1.28 . . . . 0.0 110.139 179.952 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 213' ' ' LEU . . . . . . . . . . . . . 93.0 mt -70.1 -54.27 13.76 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 115.044 -0.98 . . . . 0.0 111.545 -179.729 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 214' ' ' ASP . . . . . . . . . . . . . 14.6 t70 -52.82 -54.63 31.57 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.189 -0.459 . . . . 0.0 111.605 -179.504 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 215' ' ' ALA . . . . . 0.405 ' O ' ' HG ' ' A' ' 219' ' ' LEU . . . -57.53 -57.2 13.74 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.046 -0.524 . . . . 0.0 111.781 -179.476 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 216' ' ' ALA . . . . . . . . . . . . . . . -55.1 -37.38 66.77 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.375 -0.375 . . . . 0.0 111.494 -179.636 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 217' ' ' ALA . . . . . . . . . . . . . . . -62.41 -32.89 73.8 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.382 179.799 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 218' ' ' THR . . . . . . . . . . . . . 94.4 m -76.25 -41.66 48.37 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 115.806 -0.633 . . . . 0.0 110.74 179.567 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 219' ' ' LEU . . . . . 0.405 ' HG ' ' O ' ' A' ' 215' ' ' ALA . 44.8 mt -61.78 -30.78 71.03 Favored 'General case' 0 C--N 1.332 -0.194 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.507 179.716 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 220' ' ' ARG . . . . . 0.411 ' NH1' ' HA ' ' A' ' 29' ' ' ALA . 77.1 ttt180 -83.79 -31.69 25.76 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 115.849 -0.614 . . . . 0.0 110.687 179.86 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 221' ' ' ALA . . . . . . . . . . . . . . . -72.66 -22.95 60.85 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 115.996 -0.547 . . . . 0.0 111.357 -179.88 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 222' ' ' GLU . . . . . . . . . . . . . 11.9 pt-20 -92.23 -28.58 16.93 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.415 -0.357 . . . . 0.0 110.493 -179.927 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 223' ' ' HIS . . . . . . . . . . . . . 84.3 m-70 64.29 111.61 0.03 OUTLIER 'General case' 0 C--N 1.331 -0.2 0 CA-C-N 115.794 -0.639 . . . . 0.0 111.339 179.79 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 224' ' ' GLY . . . . . . . . . . . . . . . -162.29 84.35 0.11 Allowed Glycine 0 C--N 1.33 0.21 0 C-N-CA 120.843 -0.694 . . . . 0.0 112.416 179.92 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 225' ' ' GLU . . . . . . . . . . . . . 8.8 tp10 -63.52 135.17 56.66 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.564 0.221 . . . . 0.0 110.771 -179.998 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 226' ' ' SER . . . . . . . . . . . . . 69.2 m 59.61 -86.34 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.045 -0.525 . . . . 0.0 111.236 -179.977 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 227' ' ' LEU . . . . . . . . . . . . . 27.4 tp -112.71 129.77 56.29 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.372 -0.376 . . . . 0.0 110.909 -179.918 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 228' ' ' ALA . . . . . . . . . . . . . . . -96.03 -179.29 4.63 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.262 -0.426 . . . . 0.0 110.932 179.822 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 229' ' ' GLY . . . . . . . . . . . . . . . -107.34 109.06 2.92 Favored Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.728 -0.749 . . . . 0.0 112.631 179.975 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 230' ' ' VAL . . . . . . . . . . . . . 37.0 t -71.27 136.28 26.18 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-O 120.702 0.286 . . . . 0.0 111.034 -179.866 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 231' ' ' ASP . . . . . . . . . . . . . 12.1 m-20 -76.42 111.63 12.08 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.859 179.848 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 232' ' ' THR . . . . . . . . . . . . . 72.5 p -121.68 -48.64 2.15 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.071 -0.513 . . . . 0.0 111.037 -179.975 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 233' ' ' ASP . . . . . . . . . . . . . 18.4 t70 -89.03 125.67 35.1 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.823 179.877 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 234' ' ' THR . . . . . . . . . . . . . 74.9 p -71.89 148.95 92.44 Favored Pre-proline 0 C--N 1.329 -0.322 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.1 -179.992 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 235' ' ' PRO . . . . . . . . . . . . . 55.6 Cg_endo -70.12 -39.1 6.18 Favored 'Trans proline' 0 C--N 1.348 0.543 0 C-N-CA 122.288 1.992 . . . . 0.0 111.996 179.812 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 236' ' ' ALA . . . . . . . . . . . . . . . -105.25 145.34 30.79 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.026 -0.534 . . . . 0.0 110.926 179.743 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 237' ' ' VAL . . . . . . . . . . . . . 46.2 t -118.13 117.67 55.56 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.248 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.147 -179.94 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 238' ' ' ALA . . . . . . . . . . . . . . . -125.96 -50.33 1.58 Allowed 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.359 -179.912 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 239' ' ' ASP . . . . . . . . . . . . . 15.6 m-20 57.86 100.41 0.02 OUTLIER 'General case' 0 C--N 1.332 -0.178 0 CA-C-N 116.102 -0.499 . . . . 0.0 111.088 -179.916 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 240' ' ' LEU . . . . . . . . . . . . . 81.3 mt -126.95 -8.11 6.03 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.86 179.976 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 241' ' ' GLU . . . . . . . . . . . . . 10.3 tp10 -67.27 125.45 26.1 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.861 179.981 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 242' ' ' HIS . . . . . . . . . . . . . 58.7 t-80 -85.96 114.83 23.17 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.291 -0.413 . . . . 0.0 111.02 -179.855 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 243' ' ' HIS . . . . . . . . . . . . . 8.5 p80 -137.04 147.26 46.06 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.746 179.823 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 244' ' ' HIS . . . . . . . . . . . . . 42.9 p-80 -91.11 156.9 17.55 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.918 0.39 . . . . 0.0 111.057 -179.811 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 245' ' ' HIS . . . . . . . . . . . . . 45.2 p-80 -64.38 161.73 16.37 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 115.93 -0.577 . . . . 0.0 111.223 -179.771 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 246' ' ' HIS . . . . . . . . . . . . . 96.4 m-70 -120.22 154.48 34.8 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.018 179.852 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 247' ' ' HIS . . . . . . . . . . . . . 47.2 m80 . . . . . 0 C--O 1.249 1.055 0 CA-C-O 118.19 -0.909 . . . . 0.0 111.024 -179.919 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 301' ' ' RET . . . . . 0.59 ' H21' ' HA3' ' A' ' 112' ' ' GLY . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . 0.431 ' HG2' ' N ' ' A' ' 2' ' ' VAL . 0.0 OUTLIER . . . . . 0 N--CA 1.486 1.351 0 CA-C-O 120.807 0.337 . . . . 0.0 111.034 . . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 2' ' ' VAL . . . . . 0.431 ' N ' ' HG2' ' A' ' 1' ' ' MET . 58.6 t -141.24 -73.8 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.331 -0.225 0 CA-C-N 116.18 -0.463 . . . . 0.0 110.898 179.865 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -97.83 -9.51 54.26 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.841 -0.695 . . . . 0.0 112.354 -179.996 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 67.8 tp -74.22 -35.41 63.88 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 120.778 0.323 . . . . 0.0 110.796 179.723 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 69.9 p -69.62 -32.85 71.8 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.72 -179.697 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 29.0 p -54.93 -35.56 64.33 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.35 -0.386 . . . . 0.0 111.381 -179.644 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 7' ' ' LEU . . . . . . . . . . . . . 9.3 mp -59.24 -53.36 59.18 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.098 -0.501 . . . . 0.0 111.557 -179.813 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 8' ' ' PHE . . . . . 0.564 ' HB2' ' HB2' ' A' ' 55' ' ' ALA . 63.4 m-85 -59.95 -34.93 73.92 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.317 -0.402 . . . . 0.0 110.997 -179.73 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 9' ' ' TRP . . . . . . . . . . . . . 28.8 m95 -64.36 -47.61 78.62 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 116.058 -0.519 . . . . 0.0 110.357 -179.902 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 13.1 mt -58.32 -42.76 87.45 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 115.929 -0.578 . . . . 0.0 110.304 179.204 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . 0.433 ' HA2' HD11 ' A' ' 202' ' ' LEU . . . -61.62 -34.58 89.03 Favored Glycine 0 N--CA 1.448 -0.545 0 C-N-CA 120.588 -0.815 . . . . 0.0 111.544 178.971 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 12' ' ' ALA . . . . . 0.407 ' O ' HD23 ' A' ' 16' ' ' LEU . . . -66.22 -33.15 75.1 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 120.616 0.246 . . . . 0.0 110.608 179.701 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 1.5 mt -63.21 -49.29 83.76 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.259 0 N-CA-C 109.347 -0.612 . . . . 0.0 109.347 178.987 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . 0.411 ' HA3' HD21 ' A' ' 202' ' ' LEU . . . -61.7 -24.82 64.76 Favored Glycine 0 N--CA 1.447 -0.584 0 C-N-CA 120.638 -0.791 . . . . 0.0 111.47 178.908 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 15' ' ' MET . . . . . 0.677 ' HB3' ' HB2' ' A' ' 48' ' ' ALA . 0.0 OUTLIER -77.3 -47.93 18.76 Favored 'General case' 0 C--N 1.331 -0.227 0 N-CA-C 111.763 0.283 . . . . 0.0 111.763 179.841 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 16' ' ' LEU . . . . . 0.407 HD23 ' O ' ' A' ' 12' ' ' ALA . 4.6 mm? -63.78 -39.22 93.72 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.778 0.323 . . . . 0.0 110.965 -179.958 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . 0.454 HG13 ' N ' ' A' ' 18' ' ' GLY . 8.5 p -68.09 -44.26 84.68 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.375 0 CA-C-O 121.388 0.613 . . . . 0.0 110.471 179.7 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . 0.454 ' N ' HG13 ' A' ' 17' ' ' VAL . . . -64.87 -49.79 61.47 Favored Glycine 0 C--N 1.319 -0.38 0 CA-C-N 114.928 -1.033 . . . . 0.0 111.349 179.135 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 94.2 m -54.11 -42.6 69.62 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-O 120.858 0.361 . . . . 0.0 111.008 179.828 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 20' ' ' LEU . . . . . 0.409 ' O ' ' HB3' ' A' ' 24' ' ' TRP . 67.6 mt -71.83 -42.96 66.36 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.061 -0.518 . . . . 0.0 111.264 179.947 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -59.02 -43.96 91.66 Favored 'General case' 0 C--N 1.329 -0.292 0 N-CA-C 111.805 0.298 . . . . 0.0 111.805 -179.797 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 22' ' ' PHE . . . . . 0.645 ' HB2' HG22 ' A' ' 41' ' ' VAL . 10.6 m-85 -75.53 -42.26 52.93 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.46 -0.337 . . . . 0.0 111.431 -179.291 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -61.79 -50.25 73.11 Favored 'General case' 0 C--N 1.33 -0.283 0 CA-C-O 120.814 0.34 . . . . 0.0 111.023 -179.845 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 24' ' ' TRP . . . . . 0.409 ' HB3' ' O ' ' A' ' 20' ' ' LEU . 1.0 OUTLIER -57.92 -35.77 71.54 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.711 179.75 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -74.55 -30.17 61.64 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 120.955 0.407 . . . . 0.0 110.627 179.56 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -73.69 -38.98 49.79 Favored Glycine 0 N--CA 1.45 -0.387 0 C-N-CA 120.856 -0.687 . . . . 0.0 112.474 179.667 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 82.7 mtp180 -60.66 -41.19 94.49 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 120.879 0.371 . . . . 0.0 110.763 -179.851 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 11.4 t70 -64.51 -17.71 64.14 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.052 -0.522 . . . . 0.0 110.697 179.788 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -114.93 -178.44 3.37 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-N 116.014 -0.539 . . . . 0.0 110.915 179.816 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 164.56 59.32 0.02 OUTLIER Glycine 0 N--CA 1.452 -0.267 0 C-N-CA 120.532 -0.842 . . . . 0.0 112.869 179.89 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 46.5 t -164.07 87.55 0.5 Allowed 'General case' 0 C--N 1.327 -0.398 0 CA-C-O 120.995 0.426 . . . . 0.0 110.66 179.454 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 83.4 -22.08 7.84 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.834 -0.698 . . . . 0.0 112.192 -179.96 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 26.7 mt-10 -91.32 -20.84 21.43 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.7 0.286 . . . . 0.0 110.764 179.999 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 34' ' ' ARG . . . . . . . . . . . . . 15.8 ptp180 -51.51 -31.25 23.17 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 116.106 -0.497 . . . . 0.0 111.48 -179.652 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 89.9 mtm180 -73.51 -52.9 11.96 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.503 -0.317 . . . . 0.0 111.502 -179.7 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 73.6 m-85 -61.74 -30.53 70.83 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.247 -0.433 . . . . 0.0 111.702 -179.483 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 37' ' ' TYR . . . . . 0.416 ' O ' HG23 ' A' ' 41' ' ' VAL . 26.1 m-85 -76.19 -55.27 5.73 Favored 'General case' 0 C--N 1.329 -0.307 0 N-CA-C 111.799 0.296 . . . . 0.0 111.799 -179.129 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 83.8 t -56.89 -36.27 49.47 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-O 120.939 0.4 . . . . 0.0 110.59 179.91 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 39' ' ' THR . . . . . 0.406 ' O ' HG13 ' A' ' 43' ' ' ILE . 54.9 m -64.08 -52.11 60.85 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 115.991 -0.549 . . . . 0.0 111.116 179.718 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 40' ' ' LEU . . . . . 0.458 HD13 ' CE1' ' A' ' 208' ' ' PHE . 7.8 tp -63.3 -50.74 68.88 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.722 -179.81 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . 0.645 HG22 ' HB2' ' A' ' 22' ' ' PHE . 96.9 t -55.27 -34.84 34.38 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.356 0 CA-C-N 116.132 -0.485 . . . . 0.0 109.962 178.887 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -62.52 -37.25 94.4 Favored Glycine 0 N--CA 1.448 -0.558 0 C-N-CA 120.821 -0.704 . . . . 0.0 111.616 179.069 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 43' ' ' ILE . . . . . 0.506 HD13 HD13 ' A' ' 83' ' ' ILE . 3.8 mt -62.54 -57.95 9.77 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.158 0 CA-C-O 120.824 0.345 . . . . 0.0 110.732 179.505 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 24.6 t -59.92 -24.79 64.63 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-N 116.293 -0.412 . . . . 0.0 110.983 -179.904 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -71.99 -57.25 5.88 Favored Glycine 0 N--CA 1.452 -0.242 0 C-N-CA 120.805 -0.712 . . . . 0.0 112.427 179.825 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 15.5 pt -59.74 -37.47 71.37 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.229 0 CA-C-O 120.823 0.344 . . . . 0.0 111.007 179.888 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 47' ' ' ALA . . . . . 0.587 ' HB2' ' HE2' ' A' ' 205' ' ' LYS . . . -67.76 -39.33 84.15 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 116.316 -0.402 . . . . 0.0 111.027 179.313 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 48' ' ' ALA . . . . . 0.677 ' HB2' ' HB3' ' A' ' 15' ' ' MET . . . -57.07 -47.2 81.57 Favored 'General case' 0 C--O 1.232 0.177 0 CA-C-N 116.076 -0.511 . . . . 0.0 111.617 -179.658 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 49' ' ' VAL . . . . . 0.454 ' O ' HG13 ' A' ' 53' ' ' VAL . 29.9 m -70.66 -33.64 53.79 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-N 116.11 -0.496 . . . . 0.0 111.414 -179.359 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -62.96 -44.43 96.08 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.932 0.396 . . . . 0.0 111.286 -179.571 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 51' ' ' TYR . . . . . 0.456 ' HE2' ' HE2' ' A' ' 15' ' ' MET . 33.3 m-85 -73.87 -36.22 64.82 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 115.829 -0.623 . . . . 0.0 110.942 -179.419 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -62.74 -45.8 91.01 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 115.841 -0.618 . . . . 0.0 111.157 -179.992 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 53' ' ' VAL . . . . . 0.504 ' HB ' HG11 ' A' ' 58' ' ' VAL . 19.7 m -73.32 -43.51 56.53 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.147 -0.478 . . . . 0.0 111.036 -179.802 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 54' ' ' MET . . . . . 0.492 ' HG3' ' HE1' ' A' ' 60' ' ' TRP . 11.4 ttp -64.94 -29.65 70.6 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.284 179.89 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 55' ' ' ALA . . . . . 0.564 ' HB2' ' HB2' ' A' ' 8' ' ' PHE . . . -65.47 -37.32 86.51 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 115.885 -0.598 . . . . 0.0 111.014 179.254 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 87.2 mt -70.85 -11.47 60.98 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.082 -0.508 . . . . 0.0 111.215 -179.781 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 104.68 17.4 14.95 Favored Glycine 0 CA--C 1.518 0.227 0 C-N-CA 120.742 -0.742 . . . . 0.0 113.296 179.487 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 58' ' ' VAL . . . . . 0.504 HG11 ' HB ' ' A' ' 53' ' ' VAL . 0.4 OUTLIER -89.46 159.36 2.89 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.231 0 CA-C-N 116.913 0.356 . . . . 0.0 110.577 179.729 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 72.44 -12.52 3.38 Favored Glycine 0 N--CA 1.45 -0.412 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.387 -179.456 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 60' ' ' TRP . . . . . 0.492 ' HE1' ' HG3' ' A' ' 54' ' ' MET . 35.1 m0 -69.79 106.68 3.2 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-O 120.663 0.268 . . . . 0.0 110.883 -179.935 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 61' ' ' VAL . . . . . 0.456 HG13 HG23 ' A' ' 68' ' ' VAL . 7.5 p -116.03 128.54 25.9 Favored Pre-proline 0 CA--C 1.533 0.312 0 CA-C-N 116.406 -0.361 . . . . 0.0 111.155 179.821 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 74.0 Cg_endo -75.72 148.48 32.62 Favored 'Trans proline' 0 C--N 1.35 0.646 0 C-N-CA 122.533 2.155 . . . . 0.0 112.441 179.923 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 96.6 t -137.76 91.53 0.79 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.005 -0.543 . . . . 0.0 111.036 -179.878 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . 59.11 -88.53 0.02 OUTLIER 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 116.03 -0.532 . . . . 0.0 111.438 179.961 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 65' ' ' GLU . . . . . 0.524 ' HB2' HH11 ' A' ' 66' ' ' ARG . 11.1 mm-40 -120.54 -18.51 7.79 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-O 120.907 0.384 . . . . 0.0 110.735 179.984 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 66' ' ' ARG . . . . . 0.524 HH11 ' HB2' ' A' ' 65' ' ' GLU . 10.5 mpt_? -102.78 162.62 12.78 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 115.938 -0.574 . . . . 0.0 110.439 179.916 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 31.6 m -123.37 139.9 53.56 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.964 0.411 . . . . 0.0 111.52 -179.654 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 68' ' ' VAL . . . . . 0.523 HG21 ' SD ' ' A' ' 117' ' ' MET . 18.0 m -130.3 146.12 34.56 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.375 0 CA-C-N 115.932 -0.576 . . . . 0.0 110.685 179.711 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 69' ' ' PHE . . . . . . . . . . . . . 9.9 m-85 -109.1 118.03 35.71 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-O 121.048 0.452 . . . . 0.0 110.224 -179.473 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 70' ' ' VAL . . . . . 0.63 HG12 ' HD3' ' A' ' 71' ' ' PRO . 0.5 OUTLIER -67.0 -34.44 7.33 Favored Pre-proline 0 CA--C 1.541 0.6 0 N-CA-C 112.883 0.697 . . . . 0.0 112.883 -179.295 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 71' ' ' PRO . . . . . 0.63 ' HD3' HG12 ' A' ' 70' ' ' VAL . 12.2 Cg_exo -69.63 -17.75 38.01 Favored 'Trans proline' 0 C--N 1.359 1.079 0 C-N-CA 122.259 1.973 . . . . 0.0 113.059 -179.165 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 45.3 ttp180 -74.76 -55.42 5.86 Favored 'General case' 0 C--N 1.33 -0.271 0 N-CA-C 112.276 0.473 . . . . 0.0 112.276 -178.514 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 73' ' ' TYR . . . . . 0.461 ' O ' HG13 ' A' ' 77' ' ' ILE . 24.9 m-85 -71.31 -33.55 69.79 Favored 'General case' 0 C--N 1.329 -0.325 0 C-N-CA 120.764 -0.374 . . . . 0.0 110.669 -179.418 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 74' ' ' ILE . . . . . 0.476 HG22 ' HA ' ' A' ' 71' ' ' PRO . 0.3 OUTLIER -68.95 -39.73 80.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 N-CA-C 110.072 -0.344 . . . . 0.0 110.072 179.256 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 15.4 t70 -59.98 -37.3 79.23 Favored 'General case' 0 CA--C 1.52 -0.197 0 N-CA-C 109.423 -0.584 . . . . 0.0 109.423 179.023 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 76' ' ' TRP . . . . . 0.523 ' HB3' ' SD ' ' A' ' 109' ' ' MET . 49.2 m0 -65.29 -35.49 81.17 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 115.652 -0.703 . . . . 0.0 110.427 179.521 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 77' ' ' ILE . . . . . 0.474 ' O ' ' HG2' ' A' ' 81' ' ' PRO . 78.5 mt -68.12 -30.66 48.73 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.374 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.964 179.773 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 35.2 mt -91.81 -19.55 22.43 Favored 'General case' 0 C--N 1.327 -0.371 0 N-CA-C 112.23 0.456 . . . . 0.0 112.23 -179.76 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 79' ' ' THR . . . . . 0.494 ' HB ' ' HE3' ' A' ' 205' ' ' LYS . 79.3 p -102.35 -47.6 4.44 Favored 'General case' 0 N--CA 1.464 0.238 0 N-CA-C 113.458 0.91 . . . . 0.0 113.458 -177.932 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 80' ' ' THR . . . . . 0.659 ' HB ' ' HD3' ' A' ' 81' ' ' PRO . 80.3 m -51.28 -53.4 49.53 Favored Pre-proline 0 C--N 1.329 -0.297 0 N-CA-C 112.047 0.388 . . . . 0.0 112.047 -179.019 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 81' ' ' PRO . . . . . 0.659 ' HD3' ' HB ' ' A' ' 80' ' ' THR . 50.4 Cg_exo -55.83 -22.03 35.63 Favored 'Trans proline' 0 C--N 1.351 0.691 0 C-N-CA 121.612 1.542 . . . . 0.0 111.704 179.723 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 82' ' ' LEU . . . . . 0.488 ' HB2' ' O ' ' A' ' 79' ' ' THR . 2.8 mm? -76.77 -37.1 56.49 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 115.877 -0.601 . . . . 0.0 110.745 179.807 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 83' ' ' ILE . . . . . 0.506 HD13 HD13 ' A' ' 43' ' ' ILE . 11.9 mm -65.22 -53.76 36.78 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-O 120.857 0.36 . . . . 0.0 110.469 179.67 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 21.9 m -62.63 -31.27 51.5 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.176 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.251 179.335 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 85' ' ' TYR . . . . . . . . . . . . . 82.9 t80 -67.28 -32.44 73.44 Favored 'General case' 0 C--N 1.333 -0.135 0 CA-C-N 115.999 -0.546 . . . . 0.0 110.223 179.158 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 86' ' ' PHE . . . . . . . . . . . . . 9.2 t80 -64.72 -51.96 59.6 Favored 'General case' 0 C--N 1.331 -0.196 0 CA-C-N 116.118 -0.492 . . . . 0.0 109.839 179.37 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 9.2 mp -62.95 -30.45 71.58 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 115.806 -0.634 . . . . 0.0 110.098 179.477 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -69.25 -27.31 73.83 Favored Glycine 0 N--CA 1.448 -0.523 0 C-N-CA 120.914 -0.66 . . . . 0.0 111.546 178.943 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 58.0 mt -72.05 -46.16 58.04 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 120.974 0.416 . . . . 0.0 110.4 179.701 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 98.0 mt -59.27 -37.55 77.93 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 115.844 -0.616 . . . . 0.0 111.074 179.824 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -79.86 -32.75 40.46 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.231 -0.441 . . . . 0.0 111.4 -179.877 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 78.81 51.77 5.31 Favored Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.701 -0.761 . . . . 0.0 111.937 -179.737 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 35.2 mt -62.21 167.16 4.24 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.892 0.377 . . . . 0.0 111.103 -179.632 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 94' ' ' ASP . . . . . . . . . . . . . 28.6 t70 -85.47 168.96 14.07 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.618 179.839 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 75.0 m -54.34 -41.52 69.16 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.45 -0.341 . . . . 0.0 110.975 -179.989 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 34.0 ttm180 -73.89 -44.1 56.36 Favored 'General case' 0 C--N 1.331 -0.197 0 CA-C-N 116.398 -0.364 . . . . 0.0 110.94 179.732 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 97' ' ' GLU . . . . . 0.558 ' HA ' HD12 ' A' ' 100' ' ' ILE . 43.7 mt-10 -53.42 -47.08 69.92 Favored 'General case' 0 C--N 1.331 -0.197 0 CA-C-N 116.128 -0.487 . . . . 0.0 111.435 -179.484 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 98' ' ' PHE . . . . . 0.421 ' O ' HG12 ' A' ' 102' ' ' ILE . 16.9 m-85 -58.03 -49.6 76.3 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-O 120.773 0.321 . . . . 0.0 110.7 179.64 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -58.28 -26.12 58.51 Favored Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.879 -0.677 . . . . 0.0 112.644 -179.95 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 100' ' ' ILE . . . . . 0.558 HD12 ' HA ' ' A' ' 97' ' ' GLU . 94.4 mt -71.56 -52.24 27.4 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-O 120.815 0.34 . . . . 0.0 111.638 -179.71 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 43.4 t -68.21 -37.77 78.58 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.38 0 CA-C-N 116.401 -0.363 . . . . 0.0 111.669 -179.378 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 102' ' ' ILE . . . . . 0.421 HG12 ' O ' ' A' ' 98' ' ' PHE . 49.0 mm -68.22 -47.72 76.89 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.391 -0.368 . . . . 0.0 111.48 -179.628 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 103' ' ' THR . . . . . 0.404 HG22 ' O ' ' A' ' 100' ' ' ILE . 11.1 t -62.03 -31.1 71.46 Favored 'General case' 0 C--N 1.332 -0.174 0 CA-C-O 120.804 0.335 . . . . 0.0 110.723 -179.935 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 104' ' ' LEU . . . . . 0.429 ' O ' HG23 ' A' ' 108' ' ' VAL . 53.3 tp -64.38 -52.98 55.53 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.701 179.556 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 105' ' ' ASN . . . . . 0.616 ' N ' HD22 ' A' ' 105' ' ' ASN . 0.8 OUTLIER -61.51 -26.19 67.76 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.079 -0.51 . . . . 0.0 110.946 179.929 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 40.3 m -65.65 -54.96 20.4 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 115.995 -0.548 . . . . 0.0 111.419 -179.66 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 11.3 p -64.7 -36.41 77.45 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.232 0 CA-C-N 116.366 -0.379 . . . . 0.0 111.215 -179.724 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . 0.429 HG23 ' O ' ' A' ' 104' ' ' LEU . 70.1 t -63.46 -49.21 83.63 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.244 0 CA-C-N 116.36 -0.382 . . . . 0.0 110.839 179.67 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 109' ' ' MET . . . . . 0.523 ' SD ' ' HB3' ' A' ' 76' ' ' TRP . 7.7 tpp -63.21 -37.41 87.13 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.749 -179.978 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 22.9 tp -65.9 -30.27 70.84 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-N 115.987 -0.552 . . . . 0.0 110.259 179.782 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -65.03 -54.77 25.12 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-N 115.939 -0.573 . . . . 0.0 110.391 179.354 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 112' ' ' GLY . . . . . 0.455 ' HA3' ' H21' ' A' ' 301' ' ' RET . . . -57.82 -39.67 91.83 Favored Glycine 0 C--N 1.333 0.382 0 C-N-CA 120.576 -0.821 . . . . 0.0 111.701 179.395 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 113' ' ' PHE . . . . . . . . . . . . . 1.3 t80 -51.33 -66.03 0.45 Allowed 'General case' 0 C--N 1.332 -0.181 0 CA-C-O 121.059 0.456 . . . . 0.0 109.934 179.255 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -59.84 -29.31 68.19 Favored 'General case' 0 C--N 1.327 -0.413 0 CA-C-N 115.501 -0.772 . . . . 0.0 111.471 179.809 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 115' ' ' GLY . . . . . 0.403 ' N ' ' HG ' ' A' ' 126' ' ' LEU . . . -52.4 -49.62 50.79 Favored Glycine 0 C--N 1.333 0.377 0 C-N-CA 120.901 -0.666 . . . . 0.0 112.452 179.85 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -77.88 -14.71 59.47 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-O 120.8 0.333 . . . . 0.0 111.168 179.692 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 117' ' ' MET . . . . . 0.523 ' SD ' HG21 ' A' ' 68' ' ' VAL . 24.3 mmt -93.7 15.16 17.02 Favored 'General case' 0 N--CA 1.463 0.185 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.732 -179.391 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 23.3 m -82.13 144.61 51.08 Favored Pre-proline 0 C--N 1.33 -0.267 0 CA-C-O 120.568 0.223 . . . . 0.0 111.565 -179.616 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 119' ' ' PRO . . . . . . . . . . . . . 84.9 Cg_endo -91.18 -9.0 3.15 Favored 'Trans proline' 0 N--CA 1.456 -0.684 0 C-N-CA 122.758 2.305 . . . . 0.0 112.348 179.471 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -132.5 -117.09 1.81 Allowed Glycine 0 C--N 1.332 0.312 0 C-N-CA 120.748 -0.739 . . . . 0.0 113.071 -179.649 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 41.7 pt -116.13 13.72 7.74 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.151 0 CA-C-O 120.723 0.297 . . . . 0.0 111.5 -179.552 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 44.1 mt-10 -62.59 -18.46 62.19 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 116.284 -0.416 . . . . 0.0 111.349 -179.737 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 123' ' ' ARG . . . . . . . . . . . . . 20.4 ptt180 -50.43 -39.44 47.48 Favored 'General case' 0 C--N 1.332 -0.166 0 CA-C-N 116.28 -0.418 . . . . 0.0 111.7 -179.66 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 124' ' ' TYR . . . . . . . . . . . . . 59.5 m-85 -65.87 -32.38 73.86 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-O 120.748 0.308 . . . . 0.0 110.997 -179.851 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 125' ' ' ALA . . . . . . . . . . . . . . . -70.05 -47.64 61.19 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.308 -0.406 . . . . 0.0 111.179 -179.913 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 126' ' ' LEU . . . . . 0.425 HD13 ' HA ' ' A' ' 126' ' ' LEU . 2.6 mm? -54.16 -55.6 26.24 Favored 'General case' 0 C--O 1.233 0.209 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.904 179.924 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 127' ' ' PHE . . . . . . . . . . . . . 10.0 t80 -63.73 -36.77 84.95 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.305 -0.407 . . . . 0.0 111.033 -179.553 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 128' ' ' GLY . . . . . . . . . . . . . . . -46.81 -47.24 19.03 Favored Glycine 0 C--N 1.332 0.321 0 C-N-CA 120.019 -1.086 . . . . 0.0 111.033 179.182 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 129' ' ' MET . . . . . 0.428 ' HE1' ' HA ' ' A' ' 108' ' ' VAL . 0.6 OUTLIER -66.96 -40.04 87.4 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 120.978 0.418 . . . . 0.0 109.994 178.788 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -67.62 -22.9 73.7 Favored Glycine 0 N--CA 1.45 -0.379 0 CA-C-N 115.721 -0.672 . . . . 0.0 112.809 -179.997 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 131' ' ' ALA . . . . . 0.419 ' O ' ' HB3' ' A' ' 134' ' ' PHE . . . -74.63 -53.77 8.71 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.78 0.324 . . . . 0.0 110.423 -179.991 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 16.1 t -60.2 -40.39 83.44 Favored 'Isoleucine or valine' 0 C--O 1.236 0.36 0 N-CA-C 109.085 -0.709 . . . . 0.0 109.085 178.629 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -67.0 -34.55 77.99 Favored 'General case' 0 N--CA 1.451 -0.41 0 CA-C-N 115.125 -0.943 . . . . 0.0 110.302 179.054 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 134' ' ' PHE . . . . . 0.482 ' CZ ' ' HA ' ' A' ' 172' ' ' ALA . 19.4 t80 -56.47 -52.67 63.83 Favored 'General case' 0 N--CA 1.452 -0.352 0 CA-C-N 115.939 -0.573 . . . . 0.0 109.88 179.366 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 135' ' ' ILE . . . . . 0.566 ' O ' HG22 ' A' ' 138' ' ' VAL . 57.6 mt -57.06 -34.13 44.28 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.299 0 CA-C-N 115.742 -0.663 . . . . 0.0 109.857 179.189 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 136' ' ' GLY . . . . . 0.413 ' O ' ' HB3' ' A' ' 139' ' ' TYR . . . -59.99 -34.72 84.58 Favored Glycine 0 N--CA 1.448 -0.538 0 C-N-CA 120.08 -1.057 . . . . 0.0 110.843 178.418 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 137' ' ' LEU . . . . . 0.529 HD13 HD21 ' A' ' 105' ' ' ASN . 38.6 tp -71.11 -52.14 21.05 Favored 'General case' 0 N--CA 1.455 -0.223 0 CA-C-N 115.643 -0.278 . . . . 0.0 110.554 179.399 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 138' ' ' VAL . . . . . 0.566 HG22 ' O ' ' A' ' 135' ' ' ILE . 3.1 m -55.69 -33.92 34.83 Favored 'Isoleucine or valine' 0 C--O 1.233 0.211 0 N-CA-C 109.201 -0.666 . . . . 0.0 109.201 179.063 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 139' ' ' TYR . . . . . 0.413 ' HB3' ' O ' ' A' ' 136' ' ' GLY . 32.0 t80 -57.12 -45.93 83.07 Favored 'General case' 0 C--N 1.331 -0.22 0 N-CA-C 108.848 -0.797 . . . . 0.0 108.848 177.657 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 140' ' ' TYR . . . . . 0.522 ' HB3' ' SD ' ' A' ' 145' ' ' MET . 24.1 m-85 -64.53 -36.54 84.55 Favored 'General case' 0 C--N 1.331 -0.197 0 CA-C-N 115.675 -0.693 . . . . 0.0 109.99 178.422 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 141' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -54.06 -33.61 57.88 Favored 'General case' 0 C--N 1.333 -0.144 0 CA-C-N 115.874 -0.603 . . . . 0.0 110.39 179.142 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 142' ' ' VAL . . . . . 0.568 HG22 HH12 ' A' ' 164' ' ' ARG . 2.6 t -111.09 2.28 8.91 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 115.858 -0.61 . . . . 0.0 110.703 179.642 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . -74.26 -153.05 2.92 Favored Glycine 0 CA--C 1.519 0.338 0 C-N-CA 121.042 -0.599 . . . . 0.0 113.146 -179.415 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 144' ' ' PRO . . . . . . . . . . . . . 31.2 Cg_exo -59.06 -23.6 69.56 Favored 'Trans proline' 0 C--N 1.349 0.588 0 C-N-CA 122.844 2.363 . . . . 0.0 112.768 -179.697 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 145' ' ' MET . . . . . 0.522 ' SD ' ' HB3' ' A' ' 140' ' ' TYR . 80.9 mtp -57.57 -32.81 67.5 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-O 120.89 0.376 . . . . 0.0 111.088 -179.731 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 146' ' ' THR . . . . . . . . . . . . . 36.0 m -75.35 -50.04 17.18 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.087 -0.506 . . . . 0.0 111.452 -179.733 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 43.5 mt-10 -65.68 -29.44 69.99 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.319 -0.401 . . . . 0.0 111.477 -179.615 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 148' ' ' SER . . . . . . . . . . . . . 80.1 p -70.36 -50.04 43.0 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.365 -0.38 . . . . 0.0 110.795 -179.515 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 149' ' ' ALA . . . . . . . . . . . . . . . -69.46 -32.7 71.79 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.4 -179.982 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 150' ' ' SER . . . . . 0.537 ' HA ' ' HB3' ' A' ' 157' ' ' LYS . 90.8 p -68.56 -15.98 63.71 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.361 -179.529 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 151' ' ' GLN . . . . . . . . . . . . . 46.7 mt-30 -113.55 3.55 15.77 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.59 -0.277 . . . . 0.0 111.336 -179.779 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 21.2 tpp180 -75.23 -51.79 12.46 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-O 120.987 0.422 . . . . 0.0 110.536 179.924 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 153' ' ' SER . . . . . 0.676 ' HB3' HG12 ' A' ' 156' ' ' ILE . 8.7 t -157.77 172.48 18.41 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 115.794 -0.639 . . . . 0.0 110.306 179.025 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 154' ' ' SER . . . . . . . . . . . . . 48.7 m -70.01 -40.97 74.91 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.872 0.367 . . . . 0.0 110.846 179.794 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 155' ' ' GLY . . . . . 0.494 ' HA3' HD22 ' A' ' 219' ' ' LEU . . . -77.44 -34.48 40.15 Favored Glycine 0 N--CA 1.45 -0.389 0 C-N-CA 120.89 -0.671 . . . . 0.0 113.03 -179.962 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 156' ' ' ILE . . . . . 0.676 HG12 ' HB3' ' A' ' 153' ' ' SER . 39.5 mm -54.93 -46.42 76.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 N-CA-C 112.147 0.425 . . . . 0.0 112.147 -179.237 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 157' ' ' LYS . . . . . 0.537 ' HB3' ' HA ' ' A' ' 150' ' ' SER . 21.7 pttp -60.62 -39.73 89.28 Favored 'General case' 0 C--N 1.328 -0.34 0 N-CA-C 111.727 0.269 . . . . 0.0 111.727 -179.133 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 59.4 m -65.76 -48.18 72.73 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-O 120.724 0.297 . . . . 0.0 111.76 -179.387 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 159' ' ' LEU . . . . . 0.726 HD13 ' HB3' ' A' ' 215' ' ' ALA . 45.9 tp -68.08 -31.24 70.73 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.382 -0.372 . . . . 0.0 111.197 -179.714 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 160' ' ' TYR . . . . . . . . . . . . . 45.1 t80 -74.15 -47.05 38.45 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.186 -0.461 . . . . 0.0 112.028 -178.988 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 161' ' ' VAL . . . . . 0.454 HG22 ' O ' ' A' ' 157' ' ' LYS . 23.7 m -61.51 -47.34 93.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 N-CA-C 112.149 0.426 . . . . 0.0 112.149 -178.841 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 162' ' ' ARG . . . . . 0.447 ' N ' HG23 ' A' ' 161' ' ' VAL . 27.1 tpt180 -63.24 -49.2 75.08 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.791 0.329 . . . . 0.0 111.423 -179.369 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 163' ' ' LEU . . . . . 0.582 HD13 HD12 ' A' ' 159' ' ' LEU . 6.9 mp -64.73 -53.61 44.53 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.922 -179.266 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 164' ' ' ARG . . . . . 0.568 HH12 HG22 ' A' ' 142' ' ' VAL . 0.9 OUTLIER -59.37 -41.32 89.05 Favored 'General case' 0 CA--C 1.53 0.199 0 CA-C-N 116.373 -0.376 . . . . 0.0 111.99 -178.554 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 165' ' ' ASN . . . . . 0.527 ' O ' HG23 ' A' ' 169' ' ' VAL . 0.9 OUTLIER -57.25 -51.84 67.74 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-O 120.887 0.375 . . . . 0.0 110.744 179.921 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 166' ' ' LEU . . . . . 0.485 ' O ' ' HG ' ' A' ' 170' ' ' LEU . 3.9 tt -64.25 -43.15 95.76 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-N 115.954 -0.566 . . . . 0.0 111.639 -179.377 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 167' ' ' THR . . . . . 0.475 ' O ' HD12 ' A' ' 170' ' ' LEU . 49.2 m -56.03 -53.74 53.35 Favored 'General case' 0 C--N 1.329 -0.296 0 N-CA-C 112.629 0.603 . . . . 0.0 112.629 -178.576 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 168' ' ' VAL . . . . . . . . . . . . . 9.7 p -61.99 -39.57 84.15 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 N-CA-C 111.956 0.354 . . . . 0.0 111.956 -179.455 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 169' ' ' VAL . . . . . 0.527 HG23 ' O ' ' A' ' 165' ' ' ASN . 46.8 t -55.78 -65.27 0.39 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 N-CA-C 112.558 0.577 . . . . 0.0 112.558 -179.174 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 170' ' ' LEU . . . . . 0.485 ' HG ' ' O ' ' A' ' 166' ' ' LEU . 0.3 OUTLIER -66.71 -24.45 66.25 Favored 'General case' 0 N--CA 1.464 0.229 0 N-CA-C 111.855 0.317 . . . . 0.0 111.855 -178.745 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 171' ' ' TRP . . . . . 0.556 ' HE1' H203 ' A' ' 301' ' ' RET . 9.8 m0 -73.49 -29.27 62.4 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.999 0.428 . . . . 0.0 109.847 179.245 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 172' ' ' ALA . . . . . 0.482 ' HA ' ' CZ ' ' A' ' 134' ' ' PHE . . . -74.7 -8.5 56.58 Favored 'General case' 0 N--CA 1.451 -0.382 0 CA-C-N 115.827 -0.624 . . . . 0.0 110.065 179.232 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 173' ' ' ILE . . . . . 0.7 HG22 HD11 ' A' ' 177' ' ' ILE . 44.5 mm -89.06 -22.8 6.45 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.256 0 CA-C-N 115.516 -0.765 . . . . 0.0 110.405 178.936 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 174' ' ' TYR . . . . . 0.607 ' N ' ' HD2' ' A' ' 175' ' ' PRO . 12.1 m-85 -54.87 -50.26 87.13 Favored Pre-proline 0 N--CA 1.463 0.199 0 CA-C-N 116.047 -0.524 . . . . 0.0 111.831 -179.893 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 175' ' ' PRO . . . . . 0.607 ' HD2' ' N ' ' A' ' 174' ' ' TYR . 2.0 Cg_endo -45.56 -29.31 4.98 Favored 'Trans proline' 0 C--N 1.353 0.791 0 C-N-CA 122.359 2.039 . . . . 0.0 111.768 179.275 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 176' ' ' PHE . . . . . 0.449 ' O ' ' HG ' ' A' ' 180' ' ' LEU . 99.6 m-85 -79.98 -45.7 17.98 Favored 'General case' 0 CA--C 1.516 -0.335 0 CA-C-N 115.921 -0.582 . . . . 0.0 111.078 179.396 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 177' ' ' ILE . . . . . 0.7 HD11 HG22 ' A' ' 173' ' ' ILE . 3.1 mm -58.09 -44.75 87.95 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.613 0 CA-C-N 115.787 -0.642 . . . . 0.0 112.093 -178.491 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 178' ' ' TRP . . . . . 0.407 ' HA ' ' HG2' ' A' ' 182' ' ' PRO . 72.0 t90 -69.04 -38.55 79.2 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-O 121.088 0.471 . . . . 0.0 110.64 179.951 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 179' ' ' LEU . . . . . 0.495 ' O ' HG22 ' A' ' 185' ' ' VAL . 0.4 OUTLIER -66.44 -53.64 33.2 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-N 115.557 -0.747 . . . . 0.0 111.168 -179.273 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 180' ' ' LEU . . . . . 0.523 HD13 HD12 ' A' ' 187' ' ' LEU . 8.3 mt -77.75 -52.03 9.59 Favored 'General case' 0 C--N 1.328 -0.366 0 N-CA-C 112.307 0.484 . . . . 0.0 112.307 -178.674 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 181' ' ' GLY . . . . . 0.42 ' HA3' ' OD1' ' A' ' 193' ' ' ASP . . . -58.34 -85.25 0.04 OUTLIER Glycine 0 C--N 1.336 0.552 0 C-N-CA 120.447 -0.882 . . . . 0.0 112.797 -179.739 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 182' ' ' PRO . . . . . 0.495 ' HD2' ' O ' ' A' ' 177' ' ' ILE . 89.2 Cg_exo -46.1 178.55 0.0 OUTLIER 'Trans proline' 0 C--N 1.349 0.599 0 C-N-CA 123.388 2.725 . . . . 0.0 112.954 179.088 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 183' ' ' PRO . . . . . . . . . . . . . 51.5 Cg_exo -56.82 12.25 0.03 OUTLIER 'Trans proline' 0 C--N 1.351 0.667 0 C-N-CA 122.862 2.375 . . . . 0.0 114.696 -179.558 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 184' ' ' GLY . . . . . 0.458 ' H ' ' C ' ' A' ' 182' ' ' PRO . . . -54.17 -65.08 3.72 Favored Glycine 0 C--N 1.335 0.484 0 C-N-CA 119.84 -1.172 . . . . 0.0 111.06 179.149 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 185' ' ' VAL . . . . . 0.495 HG22 ' O ' ' A' ' 179' ' ' LEU . 3.4 m -135.52 -3.27 1.01 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.368 0 N-CA-C 111.574 0.213 . . . . 0.0 111.574 178.813 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 186' ' ' ALA . . . . . . . . . . . . . . . 45.5 76.49 0.09 Allowed 'General case' 0 N--CA 1.463 0.198 0 N-CA-C 112.316 0.487 . . . . 0.0 112.316 179.324 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 187' ' ' LEU . . . . . 0.523 HD12 HD13 ' A' ' 180' ' ' LEU . 4.2 mt -92.49 -49.31 6.19 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.463 -0.335 . . . . 0.0 111.267 179.683 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 188' ' ' LEU . . . . . . . . . . . . . 92.3 mt -115.48 -168.59 1.43 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 121.087 0.47 . . . . 0.0 111.586 -179.502 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 189' ' ' THR . . . . . 0.484 ' HB ' HG23 ' A' ' 192' ' ' VAL . 96.7 m -76.96 135.28 67.36 Favored Pre-proline 0 C--N 1.329 -0.318 0 CA-C-N 115.667 -0.697 . . . . 0.0 111.039 -179.681 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 190' ' ' PRO . . . . . . . . . . . . . 10.2 Cg_endo -50.29 -41.7 49.85 Favored 'Trans proline' 0 C--N 1.35 0.609 0 C-N-CA 122.684 2.256 . . . . 0.0 112.185 -179.967 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 191' ' ' THR . . . . . 0.451 ' H ' HG22 ' A' ' 189' ' ' THR . 41.5 p -57.2 -46.49 82.82 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.763 179.525 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 192' ' ' VAL . . . . . 0.484 HG23 ' HB ' ' A' ' 189' ' ' THR . 60.3 t -59.13 -39.75 79.3 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.725 179.584 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 193' ' ' ASP . . . . . 0.425 ' OD1' HG22 ' A' ' 177' ' ' ILE . 7.9 t70 -57.72 -41.89 82.72 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 115.932 -0.576 . . . . 0.0 110.646 179.672 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 194' ' ' VAL . . . . . . . . . . . . . 52.5 t -64.71 -36.06 76.53 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 115.984 -0.553 . . . . 0.0 110.918 179.814 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 195' ' ' ALA . . . . . . . . . . . . . . . -59.4 -47.62 84.75 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.451 -0.341 . . . . 0.0 111.017 179.93 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 196' ' ' LEU . . . . . . . . . . . . . 95.9 mt -67.84 -43.13 80.22 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 120.793 0.33 . . . . 0.0 110.525 179.648 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 197' ' ' ILE . . . . . . . . . . . . . 15.5 mm -57.03 -58.89 4.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.012 -0.54 . . . . 0.0 110.296 179.381 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 198' ' ' VAL . . . . . . . . . . . . . 75.2 t -52.74 -34.71 20.25 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.439 0 CA-C-N 115.773 -0.648 . . . . 0.0 109.38 178.429 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 199' ' ' TYR . . . . . . . . . . . . . 46.0 t80 -70.25 -31.44 68.83 Favored 'General case' 0 C--N 1.331 -0.205 0 CA-C-N 115.587 -0.733 . . . . 0.0 110.421 179.678 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 200' ' ' LEU . . . . . . . . . . . . . 54.4 mt -74.07 -38.45 63.92 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 115.756 -0.656 . . . . 0.0 111.365 -179.722 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 201' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -71.44 -35.1 70.79 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 121.15 0.5 . . . . 0.0 110.121 179.483 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 202' ' ' LEU . . . . . 0.433 HD11 ' HA2' ' A' ' 11' ' ' GLY . 4.3 mt -67.21 -41.9 85.01 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 115.43 -0.805 . . . . 0.0 111.721 179.596 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 203' ' ' VAL . . . . . 0.44 ' O ' ' HA3' ' A' ' 207' ' ' GLY . 7.4 p -70.19 -36.82 69.42 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-N 116.376 -0.375 . . . . 0.0 111.946 -178.479 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 204' ' ' THR . . . . . . . . . . . . . 95.1 m -68.9 -57.46 5.5 Favored 'General case' 0 C--N 1.328 -0.353 0 C-N-CA 120.308 -0.557 . . . . 0.0 111.252 179.83 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 205' ' ' LYS . . . . . 0.587 ' HE2' ' HB2' ' A' ' 47' ' ' ALA . 41.7 mttp -67.0 -59.35 3.55 Favored 'General case' 0 C--N 1.328 -0.345 0 N-CA-C 112.714 0.635 . . . . 0.0 112.714 -178.311 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 25.5 t -73.87 -37.3 47.87 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.415 0 N-CA-C 112.184 0.438 . . . . 0.0 112.184 -178.29 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 207' ' ' GLY . . . . . 0.44 ' HA3' ' O ' ' A' ' 203' ' ' VAL . . . -66.89 -57.97 8.94 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.361 -0.923 . . . . 0.0 112.434 -179.309 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 208' ' ' PHE . . . . . 0.458 ' CE1' HD13 ' A' ' 40' ' ' LEU . 0.0 OUTLIER -62.6 -29.24 70.46 Favored 'General case' 0 C--N 1.329 -0.316 0 N-CA-C 110.439 -0.208 . . . . 0.0 110.439 -179.957 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 209' ' ' GLY . . . . . 0.501 ' O ' ' HB3' ' A' ' 212' ' ' ALA . . . -70.78 -36.13 66.32 Favored Glycine 0 N--CA 1.447 -0.574 0 N-CA-C 111.137 -0.785 . . . . 0.0 111.137 178.112 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 210' ' ' PHE . . . . . . . . . . . . . 1.0 OUTLIER -70.13 -43.09 71.65 Favored 'General case' 0 CA--C 1.512 -0.519 0 N-CA-C 107.508 -1.293 . . . . 0.0 107.508 178.37 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 211' ' ' ILE . . . . . . . . . . . . . 36.6 mt -67.41 -28.45 42.25 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.728 0 N-CA-C 107.277 -1.379 . . . . 0.0 107.277 176.502 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 212' ' ' ALA . . . . . 0.501 ' HB3' ' O ' ' A' ' 209' ' ' GLY . . . -66.88 -36.42 82.26 Favored 'General case' 0 N--CA 1.448 -0.549 0 CA-C-N 114.516 -1.22 . . . . 0.0 110.141 179.646 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 213' ' ' LEU . . . . . 0.414 ' HG ' ' O ' ' A' ' 209' ' ' GLY . 92.8 mt -70.31 -52.64 21.27 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 115.086 -0.961 . . . . 0.0 111.872 -179.678 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 214' ' ' ASP . . . . . . . . . . . . . 44.7 m-20 -53.21 -50.71 64.14 Favored 'General case' 0 C--N 1.331 -0.204 0 CA-C-N 116.292 -0.413 . . . . 0.0 111.837 -178.974 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 215' ' ' ALA . . . . . 0.726 ' HB3' HD13 ' A' ' 159' ' ' LEU . . . -65.48 -57.63 7.79 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.558 -0.292 . . . . 0.0 111.726 -179.243 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 216' ' ' ALA . . . . . . . . . . . . . . . -52.12 -43.38 63.94 Favored 'General case' 0 C--N 1.332 -0.184 0 CA-C-O 120.799 0.333 . . . . 0.0 111.497 -179.488 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 217' ' ' ALA . . . . . . . . . . . . . . . -59.05 -42.11 89.49 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.098 179.69 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 218' ' ' THR . . . . . 0.536 ' HA ' ' HB3' ' A' ' 221' ' ' ALA . 78.4 m -65.78 -35.68 81.4 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 115.584 -0.734 . . . . 0.0 110.983 179.715 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 219' ' ' LEU . . . . . 0.514 ' O ' ' HG2' ' A' ' 222' ' ' GLU . 74.3 mt -57.74 -46.15 84.87 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-O 120.936 0.398 . . . . 0.0 110.246 179.822 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 220' ' ' ARG . . . . . 0.47 HH11 ' HB2' ' A' ' 219' ' ' LEU . 10.4 mpt_? -84.63 -14.13 49.54 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 115.961 -0.563 . . . . 0.0 110.798 179.178 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 221' ' ' ALA . . . . . 0.536 ' HB3' ' HA ' ' A' ' 218' ' ' THR . . . -80.4 -19.74 45.57 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 116.169 -0.469 . . . . 0.0 112.206 -179.581 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 222' ' ' GLU . . . . . 0.514 ' HG2' ' O ' ' A' ' 219' ' ' LEU . 12.9 pt-20 -81.79 -7.73 59.63 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-O 120.771 0.32 . . . . 0.0 111.052 -179.437 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 223' ' ' HIS . . . . . . . . . . . . . 23.0 p80 -146.61 -164.32 1.95 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.267 -0.424 . . . . 0.0 111.092 -179.865 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 224' ' ' GLY . . . . . . . . . . . . . . . 163.48 -35.03 0.3 Allowed Glycine 0 N--CA 1.452 -0.262 0 C-N-CA 120.978 -0.63 . . . . 0.0 112.312 -179.843 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 225' ' ' GLU . . . . . 0.617 ' HG2' ' H ' ' A' ' 227' ' ' LEU . 44.1 tt0 -118.24 131.65 56.35 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.722 0.296 . . . . 0.0 110.608 179.787 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 226' ' ' SER . . . . . . . . . . . . . 54.3 m -94.19 -3.35 51.01 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.263 -0.426 . . . . 0.0 111.231 -179.606 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 227' ' ' LEU . . . . . 0.617 ' H ' ' HG2' ' A' ' 225' ' ' GLU . 4.0 tt -86.53 125.65 33.91 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.351 -0.386 . . . . 0.0 110.814 -179.741 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 228' ' ' ALA . . . . . 0.438 ' N ' HD23 ' A' ' 227' ' ' LEU . . . -144.46 118.74 9.56 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.198 -0.456 . . . . 0.0 111.08 179.791 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 229' ' ' GLY . . . . . . . . . . . . . . . 173.37 48.57 0.05 OUTLIER Glycine 0 CA--C 1.518 0.257 0 C-N-CA 120.806 -0.711 . . . . 0.0 112.512 179.94 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 230' ' ' VAL . . . . . . . . . . . . . 30.4 m -112.52 158.36 12.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-O 120.809 0.338 . . . . 0.0 111.381 -179.996 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 231' ' ' ASP . . . . . . . . . . . . . 24.5 t70 -134.67 99.28 4.29 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.086 -0.507 . . . . 0.0 110.704 179.739 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 232' ' ' THR . . . . . . . . . . . . . 67.8 p -122.11 -20.94 6.09 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.185 -0.462 . . . . 0.0 111.184 -179.755 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 233' ' ' ASP . . . . . . . . . . . . . 10.3 m-20 -64.02 -22.21 66.83 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.9 179.987 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 234' ' ' THR . . . . . . . . . . . . . 49.4 p -134.88 91.1 20.69 Favored Pre-proline 0 C--N 1.329 -0.319 0 CA-C-N 116.123 -0.49 . . . . 0.0 111.047 179.904 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 235' ' ' PRO . . . . . . . . . . . . . 78.1 Cg_exo -52.59 138.37 58.18 Favored 'Trans proline' 0 C--N 1.347 0.491 0 C-N-CA 122.543 2.162 . . . . 0.0 112.453 179.982 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 236' ' ' ALA . . . . . . . . . . . . . . . 61.0 173.74 0.1 Allowed 'General case' 0 C--N 1.331 -0.2 0 CA-C-N 115.985 -0.552 . . . . 0.0 111.311 179.908 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 237' ' ' VAL . . . . . . . . . . . . . 26.0 m -92.78 140.38 16.38 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.379 0 CA-C-N 116.055 -0.521 . . . . 0.0 111.329 -179.828 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 238' ' ' ALA . . . . . . . . . . . . . . . -161.67 -62.39 0.05 Allowed 'General case' 0 C--N 1.331 -0.216 0 CA-C-N 115.929 -0.578 . . . . 0.0 110.942 -179.96 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 239' ' ' ASP . . . . . . . . . . . . . 7.2 m-20 -97.62 107.36 19.84 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.255 -0.429 . . . . 0.0 110.994 179.86 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 240' ' ' LEU . . . . . . . . . . . . . 90.4 mt -116.56 107.33 14.59 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.96 179.937 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 241' ' ' GLU . . . . . . . . . . . . . 44.3 mt-10 57.28 -171.0 0.09 Allowed 'General case' 0 C--N 1.332 -0.169 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.109 -179.95 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 242' ' ' HIS . . . . . . . . . . . . . 32.0 p80 -88.34 175.35 7.68 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.839 179.841 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 243' ' ' HIS . . . . . . . . . . . . . 35.7 t-80 -70.45 123.52 21.98 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.312 -0.404 . . . . 0.0 111.115 -179.784 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 244' ' ' HIS . . . . . . . . . . . . . 52.8 t-80 -173.97 114.61 0.21 Allowed 'General case' 0 C--N 1.332 -0.186 0 CA-C-N 116.059 -0.519 . . . . 0.0 110.976 179.946 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 245' ' ' HIS . . . . . . . . . . . . . 10.9 p-80 -70.9 164.76 24.72 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.397 -0.365 . . . . 0.0 110.714 179.748 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 246' ' ' HIS . . . . . . . . . . . . . 66.1 m80 -128.0 -26.84 2.83 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.38 -0.373 . . . . 0.0 111.197 -179.772 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 247' ' ' HIS . . . . . . . . . . . . . 40.4 t-80 . . . . . 0 C--O 1.249 1.045 0 CA-C-O 118.25 -0.881 . . . . 0.0 110.686 -179.993 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 301' ' ' RET . . . . . 0.556 H203 ' HE1' ' A' ' 171' ' ' TRP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 71.7 mtm . . . . . 0 N--CA 1.485 1.303 0 CA-C-O 120.901 0.381 . . . . 0.0 110.994 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 34.5 m -74.83 -23.49 17.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.062 -0.517 . . . . 0.0 111.185 -179.957 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -111.5 -15.91 9.94 Favored Glycine 0 N--CA 1.452 -0.277 0 C-N-CA 120.793 -0.718 . . . . 0.0 112.692 -179.857 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 56.2 tp -73.96 -35.82 64.56 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.817 0.341 . . . . 0.0 111.121 -179.913 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 60.7 p -68.08 -31.69 71.5 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.501 -179.59 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 21.3 p -52.31 -35.32 50.24 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.257 -0.429 . . . . 0.0 111.384 -179.772 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 7' ' ' LEU . . . . . . . . . . . . . 4.1 mm? -57.87 -53.75 54.74 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.26 -0.427 . . . . 0.0 111.364 -179.731 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 8' ' ' PHE . . . . . 0.68 ' HB2' ' HB2' ' A' ' 55' ' ' ALA . 63.4 m-85 -62.32 -33.29 74.39 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.31 -0.405 . . . . 0.0 110.763 -179.81 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 9' ' ' TRP . . . . . 0.465 ' O ' HG13 ' A' ' 13' ' ' ILE . 55.1 m95 -65.97 -40.83 91.59 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 116.029 -0.532 . . . . 0.0 110.101 -179.988 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 63.9 mt -66.48 -39.61 88.88 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 115.854 -0.612 . . . . 0.0 110.136 179.387 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . 0.425 ' HA2' HD11 ' A' ' 202' ' ' LEU . . . -68.32 -28.8 73.11 Favored Glycine 0 N--CA 1.446 -0.665 0 C-N-CA 120.804 -0.712 . . . . 0.0 111.796 179.357 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -71.99 -33.87 68.46 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 120.786 0.327 . . . . 0.0 110.578 179.52 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 13' ' ' ILE . . . . . 0.465 HG13 ' O ' ' A' ' 9' ' ' TRP . 75.0 mt -64.95 -54.08 33.95 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.173 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.248 179.172 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -61.17 -39.05 96.61 Favored Glycine 0 N--CA 1.45 -0.42 0 C-N-CA 120.5 -0.857 . . . . 0.0 111.55 179.4 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 15' ' ' MET . . . . . 0.473 ' SD ' ' HA ' ' A' ' 44' ' ' SER . 60.3 tpp -61.56 -41.44 97.37 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 120.868 0.366 . . . . 0.0 110.014 179.366 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 6.3 tt -57.53 -38.88 75.43 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 115.888 -0.596 . . . . 0.0 109.911 179.334 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . 0.41 HG23 ' O ' ' A' ' 13' ' ' ILE . 34.6 t -59.38 -46.65 92.44 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.221 0 CA-C-N 115.946 -0.57 . . . . 0.0 110.162 179.19 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -62.91 -41.96 99.77 Favored Glycine 0 N--CA 1.45 -0.375 0 C-N-CA 120.616 -0.802 . . . . 0.0 111.66 178.981 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 9.7 m -50.3 -49.19 54.36 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.698 0.285 . . . . 0.0 111.354 -179.942 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 87.5 mt -71.87 -42.09 67.25 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.694 -179.594 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -58.43 -33.42 69.67 Favored 'General case' 0 C--N 1.33 -0.265 0 N-CA-C 112.155 0.428 . . . . 0.0 112.155 -179.135 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 22' ' ' PHE . . . . . 0.576 ' HB2' HG22 ' A' ' 41' ' ' VAL . 6.8 m-85 -91.46 -37.09 13.39 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.851 0.358 . . . . 0.0 111.535 -179.526 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -64.7 -51.31 63.14 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.912 -179.231 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 24' ' ' TRP . . . . . . . . . . . . . 7.1 t-105 -63.42 -49.45 73.68 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-N 115.754 -0.657 . . . . 0.0 111.312 -179.295 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -64.63 -23.02 67.13 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 120.879 0.371 . . . . 0.0 110.793 179.906 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -73.07 -40.06 51.99 Favored Glycine 0 N--CA 1.45 -0.423 0 C-N-CA 120.807 -0.711 . . . . 0.0 112.263 179.655 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 97.9 mtt180 -71.56 -19.3 62.17 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 120.839 0.352 . . . . 0.0 110.814 179.797 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 19.2 t70 -93.08 -9.93 37.88 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.541 179.843 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -73.29 -169.52 0.65 Allowed 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 115.998 -0.546 . . . . 0.0 111.37 -179.904 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -84.31 -129.56 1.84 Allowed Glycine 0 N--CA 1.452 -0.276 0 C-N-CA 120.818 -0.706 . . . . 0.0 112.642 -179.828 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 44.0 t -125.81 -42.92 1.88 Allowed 'General case' 0 C--N 1.332 -0.191 0 CA-C-O 120.83 0.347 . . . . 0.0 111.099 -179.966 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -73.53 -45.17 30.3 Favored Glycine 0 C--N 1.332 0.316 0 C-N-CA 120.702 -0.761 . . . . 0.0 112.432 -179.998 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 7.8 mm-40 -69.35 -20.47 63.85 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-O 120.759 0.314 . . . . 0.0 110.762 179.88 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 34' ' ' ARG . . . . . . . . . . . . . 75.0 ttt180 -48.67 -29.68 4.65 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 115.972 -0.558 . . . . 0.0 111.615 -179.688 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 37.4 ttm180 -58.34 -46.53 86.06 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-O 120.818 0.342 . . . . 0.0 111.046 -179.986 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 68.1 m-85 -69.51 -29.73 67.41 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.081 -0.508 . . . . 0.0 111.388 -179.678 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 37' ' ' TYR . . . . . 0.47 ' O ' HG23 ' A' ' 41' ' ' VAL . 63.2 m-85 -73.96 -56.1 5.35 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.413 -179.478 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 60.3 t -57.09 -38.64 61.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-O 120.984 0.421 . . . . 0.0 110.682 179.891 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 48.9 m -62.31 -49.05 77.18 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 115.858 -0.61 . . . . 0.0 110.447 179.243 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 40' ' ' LEU . . . . . 0.594 HD12 HD12 ' A' ' 43' ' ' ILE . 46.4 tp -55.56 -45.57 77.26 Favored 'General case' 0 C--O 1.236 0.346 0 CA-C-N 115.612 -0.722 . . . . 0.0 110.233 179.495 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . 0.576 HG22 ' HB2' ' A' ' 22' ' ' PHE . 60.1 t -63.17 -34.31 66.09 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.345 0 CA-C-N 115.645 -0.707 . . . . 0.0 110.172 179.283 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -59.49 -35.19 84.46 Favored Glycine 0 N--CA 1.449 -0.44 0 C-N-CA 120.69 -0.767 . . . . 0.0 111.538 179.554 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 43' ' ' ILE . . . . . 0.594 HD12 HD12 ' A' ' 40' ' ' LEU . 1.0 OUTLIER -68.91 -54.71 18.9 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.229 0 CA-C-O 120.797 0.332 . . . . 0.0 110.591 179.331 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 44' ' ' SER . . . . . 0.473 ' HA ' ' SD ' ' A' ' 15' ' ' MET . 32.3 t -58.74 -24.95 62.46 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.306 -179.943 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -76.16 -55.35 4.81 Favored Glycine 0 N--CA 1.45 -0.405 0 C-N-CA 120.683 -0.77 . . . . 0.0 112.747 -179.791 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 20.3 pt -59.78 -36.81 68.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-O 120.745 0.307 . . . . 0.0 111.421 -179.793 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 47' ' ' ALA . . . . . 0.764 ' HB2' ' HE2' ' A' ' 205' ' ' LYS . . . -67.89 -44.51 76.84 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-N 116.395 -0.366 . . . . 0.0 111.243 179.708 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -54.46 -48.0 72.28 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 115.918 -0.583 . . . . 0.0 111.672 -179.398 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 49' ' ' VAL . . . . . 0.415 ' O ' HG13 ' A' ' 53' ' ' VAL . 18.0 m -68.33 -33.92 63.15 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-N 116.255 -0.429 . . . . 0.0 111.371 -179.481 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -66.06 -37.5 85.99 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 120.864 0.364 . . . . 0.0 111.275 179.97 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 51' ' ' TYR . . . . . 0.447 ' OH ' ' HB2' ' A' ' 201' ' ' ASP . 29.5 m-85 -70.82 -44.0 67.45 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.458 -179.829 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -61.14 -51.92 67.06 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-N 115.53 -0.759 . . . . 0.0 111.251 179.814 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 53' ' ' VAL . . . . . 0.527 HG23 ' N ' ' A' ' 54' ' ' MET . 33.0 m -60.88 -50.95 78.43 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.2 0 CA-C-N 116.455 -0.338 . . . . 0.0 110.869 -179.976 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 54' ' ' MET . . . . . 0.57 ' HG3' ' HE1' ' A' ' 60' ' ' TRP . 8.8 ttp -60.34 -29.2 68.74 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 121.082 0.468 . . . . 0.0 109.792 179.499 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 55' ' ' ALA . . . . . 0.68 ' HB2' ' HB2' ' A' ' 8' ' ' PHE . . . -73.17 -30.6 63.68 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 115.71 -0.677 . . . . 0.0 110.843 179.043 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 87.4 mt -78.25 0.4 25.38 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.058 -179.865 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 92.0 -22.15 33.17 Favored Glycine 0 N--CA 1.45 -0.397 0 C-N-CA 120.63 -0.795 . . . . 0.0 113.127 179.776 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 58' ' ' VAL . . . . . 0.458 HG12 ' O ' ' A' ' 53' ' ' VAL . 12.5 p -67.79 142.8 16.01 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.176 0 CA-C-O 120.885 0.374 . . . . 0.0 110.77 -179.966 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 97.72 -11.66 64.55 Favored Glycine 0 N--CA 1.452 -0.287 0 C-N-CA 120.88 -0.676 . . . . 0.0 112.105 -179.329 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 60' ' ' TRP . . . . . 0.57 ' HE1' ' HG3' ' A' ' 54' ' ' MET . 28.6 m0 -78.49 115.09 17.96 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.685 0.279 . . . . 0.0 110.504 179.869 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 61' ' ' VAL . . . . . 0.402 ' HA ' ' HD3' ' A' ' 62' ' ' PRO . 10.7 p -118.02 125.29 28.06 Favored Pre-proline 0 CA--C 1.532 0.287 0 CA-C-N 116.518 -0.31 . . . . 0.0 111.518 -179.838 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 62' ' ' PRO . . . . . 0.402 ' HD3' ' HA ' ' A' ' 61' ' ' VAL . 17.1 Cg_exo -67.75 155.53 69.58 Favored 'Trans proline' 0 C--N 1.351 0.678 0 C-N-CA 122.553 2.168 . . . . 0.0 111.965 179.652 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 93.2 t -143.09 92.15 0.47 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-N 115.989 -0.55 . . . . 0.0 111.041 179.995 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . 58.41 -85.78 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.039 -0.528 . . . . 0.0 111.63 179.801 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 37.7 mt-10 -119.72 -22.57 6.81 Favored 'General case' 0 C--N 1.332 -0.192 0 CA-C-N 116.42 -0.355 . . . . 0.0 111.141 -179.659 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 66' ' ' ARG . . . . . . . . . . . . . 32.3 mmt180 -105.94 158.06 17.05 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.683 -179.872 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 92.9 m -111.68 131.11 55.52 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.905 0.384 . . . . 0.0 111.492 -179.635 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 61.8 t -113.8 146.46 18.35 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 115.899 -0.591 . . . . 0.0 110.534 179.343 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 69' ' ' PHE . . . . . . . . . . . . . 44.6 m-85 -108.89 111.97 23.96 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-N 116.174 -0.467 . . . . 0.0 110.141 -179.447 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 70' ' ' VAL . . . . . 0.63 ' N ' ' HD2' ' A' ' 71' ' ' PRO . 21.8 t -69.2 -49.62 23.48 Favored Pre-proline 0 C--N 1.324 -0.535 0 CA-C-N 116.219 -0.446 . . . . 0.0 112.202 -179.252 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 71' ' ' PRO . . . . . 0.63 ' HD2' ' N ' ' A' ' 70' ' ' VAL . 6.3 Cg_endo -48.45 -26.27 8.55 Favored 'Trans proline' 0 C--N 1.353 0.779 0 C-N-CA 122.422 2.081 . . . . 0.0 112.63 -179.524 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 55.5 ttp180 -75.23 -53.79 8.21 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-O 120.922 0.392 . . . . 0.0 111.123 -179.934 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 73' ' ' TYR . . . . . 0.441 ' OH ' ' HB2' ' A' ' 116' ' ' ALA . 67.4 m-85 -65.27 -47.97 74.82 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.094 -0.503 . . . . 0.0 111.3 -179.574 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 74' ' ' ILE . . . . . 0.48 ' O ' HD13 ' A' ' 74' ' ' ILE . 0.3 OUTLIER -59.35 -41.45 84.33 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-N 116.499 -0.319 . . . . 0.0 110.557 179.884 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 31.7 t70 -59.23 -36.53 75.61 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-O 121.023 0.44 . . . . 0.0 109.916 179.283 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 76' ' ' TRP . . . . . . . . . . . . . 47.4 m0 -66.97 -31.27 71.72 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 115.786 -0.643 . . . . 0.0 110.627 179.798 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 77' ' ' ILE . . . . . 0.485 HG12 ' HB3' ' A' ' 109' ' ' MET . 51.0 mt -73.22 -28.87 26.75 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.614 179.479 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 43.7 mt -91.75 -20.35 21.63 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.985 179.872 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 71.0 p -101.63 -52.67 3.15 Favored 'General case' 0 C--N 1.332 -0.176 0 N-CA-C 113.432 0.901 . . . . 0.0 113.432 -177.817 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 80' ' ' THR . . . . . 0.678 ' HB ' ' HD3' ' A' ' 81' ' ' PRO . 26.9 m -51.24 -55.17 30.86 Favored Pre-proline 0 C--N 1.33 -0.242 0 N-CA-C 112.327 0.491 . . . . 0.0 112.327 -178.258 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 81' ' ' PRO . . . . . 0.678 ' HD3' ' HB ' ' A' ' 80' ' ' THR . 36.0 Cg_exo -60.86 -20.41 66.41 Favored 'Trans proline' 0 C--N 1.352 0.752 0 C-N-CA 121.613 1.542 . . . . 0.0 111.459 179.74 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 82' ' ' LEU . . . . . . . . . . . . . 14.7 tp -76.79 -33.77 58.01 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 115.823 -0.626 . . . . 0.0 110.258 179.599 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 83' ' ' ILE . . . . . 0.498 HD13 HD13 ' A' ' 43' ' ' ILE . 42.2 mm -70.01 -52.54 29.83 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.149 0 CA-C-N 116.087 -0.506 . . . . 0.0 110.296 179.096 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . 0.425 HG22 ' HA ' ' A' ' 81' ' ' PRO . 29.8 m -59.51 -31.79 47.5 Favored 'Isoleucine or valine' 0 CA--C 1.52 -0.193 0 N-CA-C 109.736 -0.468 . . . . 0.0 109.736 178.693 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 85' ' ' TYR . . . . . . . . . . . . . 67.7 t80 -65.69 -33.54 76.12 Favored 'General case' 0 N--CA 1.453 -0.317 0 CA-C-N 115.636 -0.711 . . . . 0.0 109.334 178.72 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 86' ' ' PHE . . . . . . . . . . . . . 4.3 t80 -60.63 -51.71 68.26 Favored 'General case' 0 C--O 1.233 0.22 0 CA-C-N 115.646 -0.707 . . . . 0.0 109.719 178.858 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 9.1 mp -61.37 -31.22 71.11 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 115.741 -0.663 . . . . 0.0 110.506 179.526 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -71.89 -28.01 69.56 Favored Glycine 0 N--CA 1.449 -0.476 0 C-N-CA 120.81 -0.71 . . . . 0.0 112.144 179.801 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 65.5 mt -71.28 -45.06 64.0 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-O 120.877 0.37 . . . . 0.0 110.591 179.838 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 69.5 mt -58.44 -51.84 68.15 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 115.988 -0.551 . . . . 0.0 110.926 179.844 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . 0.464 ' HA ' ' HA ' ' A' ' 149' ' ' ALA . . . -61.69 -36.81 81.96 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.278 -0.419 . . . . 0.0 111.427 -179.872 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 88.38 49.56 3.66 Favored Glycine 0 N--CA 1.452 -0.271 0 C-N-CA 120.826 -0.702 . . . . 0.0 112.033 -179.633 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 93' ' ' LEU . . . . . 0.484 ' HB3' ' HB2' ' A' ' 97' ' ' GLU . 71.6 mt -67.53 178.55 1.58 Allowed 'General case' 0 C--N 1.328 -0.349 0 CA-C-O 120.917 0.389 . . . . 0.0 111.357 -179.662 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 94' ' ' ASP . . . . . . . . . . . . . 20.6 t70 -106.18 167.05 10.07 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-N 116.019 -0.537 . . . . 0.0 110.448 179.75 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 65.7 m -52.72 -34.99 55.01 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 116.46 -0.337 . . . . 0.0 111.26 -179.889 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 12.7 ptm180 -73.32 -46.79 47.39 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.381 -0.372 . . . . 0.0 111.066 -179.978 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 97' ' ' GLU . . . . . 0.484 ' HB2' ' HB3' ' A' ' 93' ' ' LEU . 45.9 mt-10 -57.74 -45.41 85.89 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.429 -0.35 . . . . 0.0 110.837 179.964 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 98' ' ' PHE . . . . . 0.49 ' O ' HG12 ' A' ' 102' ' ' ILE . 42.3 m-85 -60.18 -45.87 91.64 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.303 -0.408 . . . . 0.0 110.377 179.464 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -56.6 -30.0 58.54 Favored Glycine 0 N--CA 1.45 -0.414 0 C-N-CA 120.549 -0.834 . . . . 0.0 112.304 179.776 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 74.1 mt -73.5 -47.24 46.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 N-CA-C 112.097 0.406 . . . . 0.0 112.097 -179.761 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 101' ' ' VAL . . . . . 0.42 HG12 ' H ' ' A' ' 101' ' ' VAL . 1.1 p -70.52 -42.76 78.22 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-O 120.654 0.264 . . . . 0.0 111.634 -179.712 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 102' ' ' ILE . . . . . 0.49 HG12 ' O ' ' A' ' 98' ' ' PHE . 45.2 mm -62.13 -45.14 99.41 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.36 0 CA-C-N 116.426 -0.352 . . . . 0.0 111.042 -179.627 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 103' ' ' THR . . . . . 0.412 ' O ' HG23 ' A' ' 107' ' ' VAL . 13.6 t -66.88 -29.87 69.89 Favored 'General case' 0 C--N 1.332 -0.167 0 CA-C-O 120.817 0.341 . . . . 0.0 110.346 179.559 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 1.2 tm? -59.76 -56.06 26.51 Favored 'General case' 0 C--N 1.331 -0.206 0 N-CA-C 109.501 -0.555 . . . . 0.0 109.501 179.108 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 105' ' ' ASN . . . . . 0.624 ' N ' HD22 ' A' ' 105' ' ' ASN . 0.8 OUTLIER -57.3 -32.45 66.67 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 115.855 -0.611 . . . . 0.0 110.663 179.232 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 58.0 m -57.65 -48.86 78.32 Favored 'General case' 0 C--N 1.332 -0.183 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.95 179.78 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 107' ' ' VAL . . . . . 0.412 HG23 ' O ' ' A' ' 103' ' ' THR . 2.1 t -61.54 -40.85 87.94 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-O 121.149 0.5 . . . . 0.0 110.122 179.623 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 99.0 t -58.92 -43.73 89.25 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.377 0 CA-C-N 115.294 -0.867 . . . . 0.0 111.406 -179.956 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 109' ' ' MET . . . . . 0.485 ' HB3' HG12 ' A' ' 77' ' ' ILE . 15.3 mmt -70.51 -41.51 72.52 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.666 -179.332 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 32.5 tp -59.65 -31.09 69.21 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-O 120.882 0.372 . . . . 0.0 110.569 -179.872 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -70.15 -53.48 17.04 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.758 179.649 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 112' ' ' GLY . . . . . 0.541 ' HA3' ' H21' ' A' ' 301' ' ' RET . . . -59.58 -45.62 95.33 Favored Glycine 0 C--N 1.331 0.299 0 C-N-CA 120.707 -0.759 . . . . 0.0 112.301 179.751 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 113' ' ' PHE . . . . . . . . . . . . . 1.5 t80 -50.97 -60.5 3.03 Favored 'General case' 0 C--N 1.332 -0.171 0 CA-C-O 120.996 0.427 . . . . 0.0 110.116 179.488 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 114' ' ' ALA . . . . . 0.49 ' HB3' HD22 ' A' ' 126' ' ' LEU . . . -66.45 -19.81 65.89 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 115.733 -0.667 . . . . 0.0 110.6 179.451 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -59.0 -45.84 94.61 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.86 -0.686 . . . . 0.0 112.042 179.646 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 116' ' ' ALA . . . . . 0.441 ' HB2' ' OH ' ' A' ' 73' ' ' TYR . . . -78.16 -21.2 50.56 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.804 0.335 . . . . 0.0 111.359 179.67 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 117' ' ' MET . . . . . . . . . . . . . 24.8 mmt -83.24 19.87 1.4 Allowed 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.846 -179.253 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 118' ' ' VAL . . . . . 0.549 HG21 ' HB3' ' A' ' 123' ' ' ARG . 24.7 m -90.73 141.67 27.13 Favored Pre-proline 0 C--N 1.329 -0.294 0 CA-C-O 120.646 0.26 . . . . 0.0 111.614 -179.717 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 119' ' ' PRO . . . . . . . . . . . . . 97.3 Cg_endo -92.52 -6.75 3.05 Favored 'Trans proline' 0 N--CA 1.455 -0.774 0 C-N-CA 122.882 2.388 . . . . 0.0 112.379 179.455 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -139.41 -115.38 1.27 Allowed Glycine 0 C--N 1.332 0.314 0 C-N-CA 120.589 -0.815 . . . . 0.0 113.023 -179.586 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 38.3 pt -119.29 15.03 6.85 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.233 0 CA-C-O 120.686 0.279 . . . . 0.0 111.67 -179.345 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 10.9 mm-40 -62.11 -18.61 61.33 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.383 -0.371 . . . . 0.0 110.99 179.752 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 123' ' ' ARG . . . . . 0.549 ' HB3' HG21 ' A' ' 118' ' ' VAL . 24.2 ptt180 -54.54 -33.42 60.05 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 115.973 -0.558 . . . . 0.0 111.785 -179.751 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 124' ' ' TYR . . . . . . . . . . . . . 37.3 m-85 -65.73 -32.22 73.65 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 120.829 0.347 . . . . 0.0 111.108 -179.593 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 125' ' ' ALA . . . . . . . . . . . . . . . -72.62 -56.17 5.73 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.0 179.92 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 126' ' ' LEU . . . . . 0.49 HD22 ' HB3' ' A' ' 114' ' ' ALA . 1.3 mt -55.68 -45.44 77.77 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 115.789 -0.642 . . . . 0.0 110.488 -179.991 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 127' ' ' PHE . . . . . 0.437 ' CE1' ' H42' ' A' ' 301' ' ' RET . 7.6 t80 -67.3 -37.37 83.27 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.464 179.612 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 128' ' ' GLY . . . . . . . . . . . . . . . -47.1 -45.03 20.14 Favored Glycine 0 C--N 1.332 0.331 0 C-N-CA 120.2 -1.0 . . . . 0.0 110.748 178.866 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 129' ' ' MET . . . . . . . . . . . . . 0.4 OUTLIER -70.95 -35.85 72.35 Favored 'General case' 0 C--N 1.328 -0.328 0 N-CA-C 109.826 -0.435 . . . . 0.0 109.826 178.578 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -62.67 -36.38 93.19 Favored Glycine 0 C--N 1.332 0.354 0 CA-C-N 115.777 -0.647 . . . . 0.0 112.626 -179.926 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -69.66 -53.34 19.13 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.602 0.239 . . . . 0.0 110.42 179.78 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 54.5 t -55.38 -39.99 55.31 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.234 0 CA-C-O 121.376 0.608 . . . . 0.0 109.595 178.879 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -69.12 -35.29 76.26 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 115.278 -0.874 . . . . 0.0 110.51 179.316 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 134' ' ' PHE . . . . . . . . . . . . . 73.5 t80 -56.94 -57.58 11.89 Favored 'General case' 0 N--CA 1.451 -0.415 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.146 179.823 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 135' ' ' ILE . . . . . 0.555 ' O ' HG22 ' A' ' 138' ' ' VAL . 0.0 OUTLIER -56.18 -32.84 35.48 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.002 -0.545 . . . . 0.0 109.61 178.761 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 136' ' ' GLY . . . . . 0.4 ' O ' ' HB3' ' A' ' 139' ' ' TYR . . . -57.33 -39.15 89.9 Favored Glycine 0 N--CA 1.447 -0.58 0 C-N-CA 120.302 -0.951 . . . . 0.0 111.086 178.389 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 137' ' ' LEU . . . . . 0.456 HD13 HD21 ' A' ' 105' ' ' ASN . 27.8 tp -68.3 -53.84 21.58 Favored 'General case' 0 C--N 1.331 -0.197 0 CA-C-O 120.579 0.228 . . . . 0.0 110.644 179.212 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 138' ' ' VAL . . . . . 0.555 HG22 ' O ' ' A' ' 135' ' ' ILE . 3.0 m -56.15 -30.24 29.07 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.204 0 CA-C-O 121.137 0.494 . . . . 0.0 109.742 179.482 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 139' ' ' TYR . . . . . 0.4 ' HB3' ' O ' ' A' ' 136' ' ' GLY . 35.2 t80 -63.7 -44.22 94.29 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 115.441 -0.8 . . . . 0.0 110.202 178.945 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 37.8 m-85 -63.04 -34.95 78.68 Favored 'General case' 0 C--N 1.331 -0.198 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.696 179.434 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 141' ' ' LEU . . . . . 0.407 HD23 ' SD ' ' A' ' 145' ' ' MET . 89.7 mt -62.92 -51.11 68.21 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.005 -179.943 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 15.0 p -81.87 -11.01 12.31 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.358 0 CA-C-N 116.076 -0.511 . . . . 0.0 111.032 -179.874 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . -72.32 -130.31 0.12 Allowed Glycine 0 CA--C 1.521 0.44 0 C-N-CA 120.973 -0.632 . . . . 0.0 112.988 -179.68 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 144' ' ' PRO . . . . . . . . . . . . . 33.1 Cg_endo -64.34 -23.57 65.46 Favored 'Trans proline' 0 C--N 1.349 0.586 0 C-N-CA 122.549 2.166 . . . . 0.0 112.521 -179.696 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 145' ' ' MET . . . . . 0.407 ' SD ' HD23 ' A' ' 141' ' ' LEU . 45.6 mtt -54.65 -34.43 62.17 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.352 -0.385 . . . . 0.0 111.446 -179.888 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 146' ' ' THR . . . . . . . . . . . . . 53.9 p -71.62 -37.47 70.9 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 116.53 -0.304 . . . . 0.0 111.584 -179.74 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 43.4 mt-10 -71.98 -37.48 69.88 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.374 -0.376 . . . . 0.0 111.203 -179.586 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 148' ' ' SER . . . . . . . . . . . . . 66.5 m -70.35 -40.09 74.29 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.152 -0.477 . . . . 0.0 111.454 -179.684 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 149' ' ' ALA . . . . . 0.464 ' HA ' ' HA ' ' A' ' 91' ' ' ALA . . . -74.9 -48.36 25.17 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.354 -0.385 . . . . 0.0 111.832 -179.397 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 150' ' ' SER . . . . . . . . . . . . . 47.1 t -61.07 -23.04 65.17 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.358 -0.383 . . . . 0.0 111.316 -179.652 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 151' ' ' GLN . . . . . . . . . . . . . 49.1 mt-30 -108.78 13.49 24.95 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.455 -0.339 . . . . 0.0 111.209 -179.849 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 30.7 tpt180 -89.77 -52.02 5.21 Favored 'General case' 0 C--N 1.332 -0.194 0 CA-C-O 120.933 0.397 . . . . 0.0 110.616 179.751 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 153' ' ' SER . . . . . 0.62 ' HB2' HG12 ' A' ' 156' ' ' ILE . 13.2 m -157.57 172.69 18.1 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 115.852 -0.613 . . . . 0.0 110.331 179.426 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 154' ' ' SER . . . . . . . . . . . . . 94.9 p -67.75 -44.87 76.52 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.798 0.332 . . . . 0.0 110.899 179.844 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 155' ' ' GLY . . . . . 0.486 ' O ' HD23 ' A' ' 159' ' ' LEU . . . -76.7 -38.24 32.41 Favored Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 121.096 -0.573 . . . . 0.0 113.219 -179.684 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 156' ' ' ILE . . . . . 0.62 HG12 ' HB2' ' A' ' 153' ' ' SER . 36.1 mm -48.07 -37.75 7.12 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.229 0 CA-C-O 120.704 0.288 . . . . 0.0 111.404 -179.527 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 157' ' ' LYS . . . . . . . . . . . . . 87.5 tttt -64.76 -42.03 95.44 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 116.351 -0.386 . . . . 0.0 111.316 -179.93 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 85.9 p -71.28 -46.33 61.07 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.94 0.4 . . . . 0.0 111.375 -179.48 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 159' ' ' LEU . . . . . 0.646 HD21 HD11 ' A' ' 219' ' ' LEU . 4.1 mm? -61.61 -36.29 80.28 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-N 116.006 -0.543 . . . . 0.0 111.558 -179.595 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 160' ' ' TYR . . . . . . . . . . . . . 46.9 t80 -74.25 -46.86 38.84 Favored 'General case' 0 C--N 1.33 -0.274 0 N-CA-C 112.668 0.618 . . . . 0.0 112.668 -178.73 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 21.6 m -58.57 -45.23 90.49 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 N-CA-C 112.277 0.473 . . . . 0.0 112.277 -178.712 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 162' ' ' ARG . . . . . . . . . . . . . 99.9 mtt180 -68.71 -44.78 73.2 Favored 'General case' 0 C--N 1.328 -0.363 0 N-CA-C 111.781 0.289 . . . . 0.0 111.781 -179.38 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 163' ' ' LEU . . . . . 0.689 ' HG ' ' HB2' ' A' ' 208' ' ' PHE . 6.0 mp -67.37 -54.18 22.76 Favored 'General case' 0 C--N 1.328 -0.368 0 N-CA-C 112.006 0.373 . . . . 0.0 112.006 -179.199 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 164' ' ' ARG . . . . . . . . . . . . . 3.7 tmm_? -56.25 -53.12 60.95 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.348 -0.387 . . . . 0.0 111.998 -179.071 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 165' ' ' ASN . . . . . 0.57 ' O ' HG23 ' A' ' 169' ' ' VAL . 0.9 OUTLIER -54.43 -51.73 64.01 Favored 'General case' 0 C--N 1.331 -0.204 0 CA-C-O 120.788 0.327 . . . . 0.0 111.81 -179.332 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 166' ' ' LEU . . . . . 0.451 ' O ' ' HG ' ' A' ' 170' ' ' LEU . 4.5 tt -60.29 -53.33 59.0 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-N 116.357 -0.383 . . . . 0.0 111.548 -179.31 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 167' ' ' THR . . . . . . . . . . . . . 63.7 m -55.85 -52.74 62.98 Favored 'General case' 0 C--N 1.329 -0.295 0 N-CA-C 113.167 0.803 . . . . 0.0 113.167 -178.767 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 168' ' ' VAL . . . . . 0.426 HG12 ' O ' ' A' ' 165' ' ' ASN . 8.2 p -56.84 -41.23 75.48 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.209 0 N-CA-C 112.226 0.454 . . . . 0.0 112.226 -178.451 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 169' ' ' VAL . . . . . 0.57 HG23 ' O ' ' A' ' 165' ' ' ASN . 74.5 t -58.3 -63.47 0.69 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.395 0 CA-C-N 116.542 -0.299 . . . . 0.0 111.534 -179.716 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 170' ' ' LEU . . . . . 0.451 ' HG ' ' O ' ' A' ' 166' ' ' LEU . 0.8 OUTLIER -64.3 -28.26 69.59 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.551 -0.295 . . . . 0.0 111.769 -179.292 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 171' ' ' TRP . . . . . 0.657 ' HE1' H203 ' A' ' 301' ' ' RET . 4.5 m0 -71.11 -29.96 65.92 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 121.151 0.501 . . . . 0.0 110.216 179.146 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 172' ' ' ALA . . . . . . . . . . . . . . . -71.49 -7.1 45.32 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 115.495 -0.775 . . . . 0.0 110.967 -179.962 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 173' ' ' ILE . . . . . 0.524 ' O ' HG12 ' A' ' 177' ' ' ILE . 16.1 mm -86.75 -23.2 6.82 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.032 -0.531 . . . . 0.0 111.243 -179.993 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 174' ' ' TYR . . . . . 0.452 ' HB2' ' HD3' ' A' ' 175' ' ' PRO . 29.0 m-85 -54.11 -49.94 87.18 Favored Pre-proline 0 N--CA 1.464 0.273 0 CA-C-N 116.409 -0.36 . . . . 0.0 111.89 -179.426 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 175' ' ' PRO . . . . . 0.452 ' HD3' ' HB2' ' A' ' 174' ' ' TYR . 71.2 Cg_exo -48.45 -31.65 18.53 Favored 'Trans proline' 0 C--N 1.351 0.663 0 C-N-CA 121.935 1.757 . . . . 0.0 112.338 179.797 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 176' ' ' PHE . . . . . 0.485 ' O ' ' HG ' ' A' ' 180' ' ' LEU . 82.0 m-85 -80.38 -50.39 10.2 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.005 -0.543 . . . . 0.0 111.882 -179.843 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 177' ' ' ILE . . . . . 0.524 HG12 ' O ' ' A' ' 173' ' ' ILE . 5.3 mm -62.12 -36.16 72.75 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.534 0 N-CA-C 112.562 0.579 . . . . 0.0 112.562 -178.016 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 178' ' ' TRP . . . . . 0.455 ' HH2' ' HB2' ' A' ' 123' ' ' ARG . 83.8 t90 -69.74 -50.18 45.98 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.738 0.304 . . . . 0.0 111.007 179.973 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 179' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -68.99 -55.06 12.03 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.262 -0.426 . . . . 0.0 111.582 -179.159 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 180' ' ' LEU . . . . . 0.757 HD22 HD11 ' A' ' 187' ' ' LEU . 43.3 mt -60.42 -46.75 88.89 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 116.501 -0.318 . . . . 0.0 111.29 -179.473 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . -56.61 177.43 0.85 Allowed Glycine 0 C--N 1.335 0.512 0 C-N-CA 120.384 -0.912 . . . . 0.0 112.715 179.636 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 182' ' ' PRO . . . . . 0.499 ' HA ' ' HB2' ' A' ' 186' ' ' ALA . 83.7 Cg_exo -47.15 -45.24 22.1 Favored 'Trans proline' 0 CA--C 1.536 0.575 0 C-N-CA 122.878 2.385 . . . . 0.0 113.697 -179.802 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 183' ' ' PRO . . . . . 0.423 ' HD3' ' HB2' ' A' ' 182' ' ' PRO . 79.7 Cg_exo -46.38 -29.95 7.66 Favored 'Trans proline' 0 C--N 1.356 0.922 0 C-N-CA 122.195 1.93 . . . . 0.0 113.171 -179.796 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 184' ' ' GLY . . . . . 0.409 ' HA2' ' HD2' ' A' ' 123' ' ' ARG . . . -114.5 -121.3 3.55 Favored Glycine 0 C--N 1.332 0.342 0 C-N-CA 120.335 -0.936 . . . . 0.0 113.001 -179.896 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 185' ' ' VAL . . . . . . . . . . . . . 16.6 m -64.49 -18.57 23.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 N-CA-C 112.02 0.378 . . . . 0.0 112.02 -179.46 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 186' ' ' ALA . . . . . 0.499 ' HB2' ' HA ' ' A' ' 182' ' ' PRO . . . 56.39 87.55 0.06 Allowed 'General case' 0 N--CA 1.463 0.209 0 CA-C-O 120.731 0.301 . . . . 0.0 111.453 179.585 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 187' ' ' LEU . . . . . 0.757 HD11 HD22 ' A' ' 180' ' ' LEU . 18.8 mt -92.05 -49.67 6.09 Favored 'General case' 0 C--N 1.332 -0.195 0 CA-C-O 120.904 0.383 . . . . 0.0 111.367 -179.867 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 188' ' ' LEU . . . . . . . . . . . . . 95.2 mt -106.79 -156.7 0.59 Allowed 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.165 -0.471 . . . . 0.0 111.027 -179.574 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 189' ' ' THR . . . . . . . . . . . . . 1.6 t -96.27 149.18 35.58 Favored Pre-proline 0 C--N 1.329 -0.304 0 CA-C-N 116.056 -0.52 . . . . 0.0 111.203 -179.686 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 190' ' ' PRO . . . . . 0.436 ' O ' HG23 ' A' ' 194' ' ' VAL . 9.9 Cg_endo -51.42 -37.41 61.39 Favored 'Trans proline' 0 C--N 1.349 0.582 0 C-N-CA 122.75 2.3 . . . . 0.0 112.688 -179.869 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 191' ' ' THR . . . . . . . . . . . . . 70.2 p -58.93 -48.66 80.7 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.97 0.415 . . . . 0.0 110.975 179.947 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 192' ' ' VAL . . . . . . . . . . . . . 40.6 t -67.45 -48.48 77.13 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 115.882 -0.599 . . . . 0.0 111.566 -179.772 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 193' ' ' ASP . . . . . . . . . . . . . 22.4 t70 -56.45 -51.92 66.64 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.31 -0.405 . . . . 0.0 111.497 -179.586 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 194' ' ' VAL . . . . . 0.436 HG23 ' O ' ' A' ' 190' ' ' PRO . 79.7 t -58.68 -35.86 57.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.439 -0.346 . . . . 0.0 110.898 179.929 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 195' ' ' ALA . . . . . . . . . . . . . . . -57.57 -44.88 85.62 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.4 -0.363 . . . . 0.0 110.856 179.708 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 196' ' ' LEU . . . . . . . . . . . . . 96.0 mt -68.08 -44.0 77.26 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-N 116.329 -0.396 . . . . 0.0 110.53 179.433 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 197' ' ' ILE . . . . . . . . . . . . . 18.7 mm -56.95 -59.34 3.21 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 115.986 -0.552 . . . . 0.0 110.635 179.53 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 198' ' ' VAL . . . . . . . . . . . . . 79.5 t -52.21 -34.94 18.66 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.509 0 CA-C-N 115.688 -0.687 . . . . 0.0 109.594 178.6 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 199' ' ' TYR . . . . . . . . . . . . . 48.0 t80 -70.52 -32.35 69.79 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 115.47 -0.786 . . . . 0.0 110.819 179.885 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 200' ' ' LEU . . . . . 0.552 ' O ' HG12 ' A' ' 203' ' ' VAL . 21.6 mt -69.99 -40.51 75.29 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 115.973 -0.558 . . . . 0.0 111.458 -179.673 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 201' ' ' ASP . . . . . 0.447 ' HB2' ' OH ' ' A' ' 51' ' ' TYR . 12.8 m-20 -71.83 -35.79 70.01 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-O 121.293 0.568 . . . . 0.0 109.991 179.471 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 202' ' ' LEU . . . . . 0.425 HD11 ' HA2' ' A' ' 11' ' ' GLY . 3.0 mt -69.71 -31.36 69.34 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 115.306 -0.861 . . . . 0.0 111.856 -179.734 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 203' ' ' VAL . . . . . 0.552 HG12 ' O ' ' A' ' 200' ' ' LEU . 13.1 p -76.7 -36.06 26.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 C-N-CA 121.004 -0.279 . . . . 0.0 110.911 -179.087 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 204' ' ' THR . . . . . 0.408 ' O ' ' CD1' ' A' ' 208' ' ' PHE . 53.7 m -63.8 -58.41 6.9 Favored 'General case' 0 C--N 1.33 -0.279 0 C-N-CA 120.585 -0.446 . . . . 0.0 111.389 179.376 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 205' ' ' LYS . . . . . 0.764 ' HE2' ' HB2' ' A' ' 47' ' ' ALA . 52.2 mttp -65.06 -58.31 6.39 Favored 'General case' 0 N--CA 1.464 0.231 0 N-CA-C 112.494 0.553 . . . . 0.0 112.494 -178.347 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 42.6 t -68.42 -36.81 76.4 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.475 0 N-CA-C 112.168 0.432 . . . . 0.0 112.168 -178.898 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 207' ' ' GLY . . . . . 0.546 ' O ' HG13 ' A' ' 211' ' ' ILE . . . -60.2 -60.76 8.03 Favored Glycine 0 N--CA 1.453 -0.226 0 C-N-CA 120.682 -0.771 . . . . 0.0 114.035 -178.349 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 208' ' ' PHE . . . . . 0.689 ' HB2' ' HG ' ' A' ' 163' ' ' LEU . 0.1 OUTLIER -71.55 -26.83 62.79 Favored 'General case' 0 C--O 1.224 -0.287 0 CA-C-N 117.277 0.539 . . . . 0.0 111.653 -178.643 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 209' ' ' GLY . . . . . 0.487 ' O ' ' HB3' ' A' ' 212' ' ' ALA . . . -67.6 -32.44 78.57 Favored Glycine 0 N--CA 1.449 -0.457 0 N-CA-C 111.853 -0.499 . . . . 0.0 111.853 178.966 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 210' ' ' PHE . . . . . . . . . . . . . 0.9 OUTLIER -73.21 -48.29 36.31 Favored 'General case' 0 CA--C 1.514 -0.43 0 N-CA-C 108.291 -1.003 . . . . 0.0 108.291 178.532 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 211' ' ' ILE . . . . . 0.546 HG13 ' O ' ' A' ' 207' ' ' GLY . 5.3 mt -63.48 -27.96 44.04 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.535 0 N-CA-C 107.626 -1.25 . . . . 0.0 107.626 176.715 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 212' ' ' ALA . . . . . 0.487 ' HB3' ' O ' ' A' ' 209' ' ' GLY . . . -63.72 -40.83 97.71 Favored 'General case' 0 N--CA 1.449 -0.483 0 CA-C-N 114.45 -1.25 . . . . 0.0 110.881 179.887 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 213' ' ' LEU . . . . . . . . . . . . . 97.3 mt -69.98 -55.0 10.75 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 115.273 -0.876 . . . . 0.0 112.17 -179.135 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 214' ' ' ASP . . . . . . . . . . . . . 36.2 t70 -53.81 -55.03 30.23 Favored 'General case' 0 C--O 1.234 0.27 0 CA-C-O 120.758 0.313 . . . . 0.0 111.498 -179.417 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 215' ' ' ALA . . . . . 0.435 ' O ' ' HG ' ' A' ' 219' ' ' LEU . . . -56.99 -53.06 62.29 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.306 -0.406 . . . . 0.0 111.159 -179.878 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 216' ' ' ALA . . . . . 0.622 ' HA ' HD12 ' A' ' 219' ' ' LEU . . . -58.73 -31.35 68.22 Favored 'General case' 0 C--N 1.332 -0.187 0 CA-C-N 116.443 -0.344 . . . . 0.0 111.286 -179.891 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 217' ' ' ALA . . . . . . . . . . . . . . . -61.82 -39.7 92.7 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 121.076 0.465 . . . . 0.0 109.991 179.573 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 218' ' ' THR . . . . . . . . . . . . . 97.9 m -76.02 -34.04 59.67 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 115.726 -0.67 . . . . 0.0 110.793 179.299 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 219' ' ' LEU . . . . . 0.646 HD11 HD21 ' A' ' 159' ' ' LEU . 97.3 mt -56.38 -43.07 78.88 Favored 'General case' 0 C--N 1.331 -0.202 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.665 179.723 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 220' ' ' ARG . . . . . . . . . . . . . 39.8 ptt180 -84.15 -23.93 30.42 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.0 -0.546 . . . . 0.0 110.649 179.494 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 221' ' ' ALA . . . . . . . . . . . . . . . -61.91 -35.6 78.85 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.032 -0.531 . . . . 0.0 112.007 -179.513 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 222' ' ' GLU . . . . . 0.444 ' HG2' ' O ' ' A' ' 219' ' ' LEU . 12.2 pt-20 -70.52 -18.3 62.95 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-O 120.868 0.366 . . . . 0.0 110.669 -179.444 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 223' ' ' HIS . . . . . . . . . . . . . 96.4 m-70 -88.61 -167.23 1.81 Allowed 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 115.986 -0.552 . . . . 0.0 110.62 179.701 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 224' ' ' GLY . . . . . 0.417 ' H ' ' H ' ' A' ' 225' ' ' GLU . . . -165.88 -6.15 0.03 OUTLIER Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.526 -179.858 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 225' ' ' GLU . . . . . 0.417 ' H ' ' H ' ' A' ' 224' ' ' GLY . 9.4 tp10 -92.08 103.78 16.25 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.845 0.355 . . . . 0.0 110.996 179.999 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 226' ' ' SER . . . . . . . . . . . . . 55.0 m -147.23 160.08 42.89 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.699 179.932 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 227' ' ' LEU . . . . . 0.425 ' N ' HD12 ' A' ' 227' ' ' LEU . 6.3 mp -106.12 148.53 27.73 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.288 -0.415 . . . . 0.0 111.099 -179.856 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 228' ' ' ALA . . . . . . . . . . . . . . . -134.73 168.61 18.71 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.012 -0.54 . . . . 0.0 110.801 179.759 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 229' ' ' GLY . . . . . . . . . . . . . . . 57.32 23.92 49.83 Favored Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.668 -0.777 . . . . 0.0 112.349 -179.743 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 230' ' ' VAL . . . . . . . . . . . . . 47.4 t -65.89 140.63 19.27 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.245 0 CA-C-O 120.822 0.344 . . . . 0.0 111.145 -179.965 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 231' ' ' ASP . . . . . . . . . . . . . 18.0 m-20 -93.04 104.45 16.66 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.964 -179.805 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 232' ' ' THR . . . . . . . . . . . . . 5.7 t -165.6 135.35 3.47 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.114 -0.494 . . . . 0.0 111.033 179.851 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 233' ' ' ASP . . . . . . . . . . . . . 19.9 m-20 58.45 17.66 5.04 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.836 -179.959 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 234' ' ' THR . . . . . 0.483 ' N ' ' HD2' ' A' ' 235' ' ' PRO . 88.1 m -84.11 -50.84 0.62 Allowed Pre-proline 0 CA--C 1.533 0.308 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.53 179.926 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 235' ' ' PRO . . . . . 0.483 ' HD2' ' N ' ' A' ' 234' ' ' THR . 55.2 Cg_endo -71.41 -47.3 0.52 Allowed 'Trans proline' 0 C--N 1.353 0.77 0 C-N-CA 122.016 1.81 . . . . 0.0 112.336 179.944 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 236' ' ' ALA . . . . . . . . . . . . . . . 58.23 95.71 0.03 OUTLIER 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.404 179.846 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 237' ' ' VAL . . . . . . . . . . . . . 60.5 t -82.02 120.83 34.3 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.89 179.81 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 238' ' ' ALA . . . . . . . . . . . . . . . -163.17 -48.96 0.04 OUTLIER 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 115.984 -0.553 . . . . 0.0 110.849 179.997 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 239' ' ' ASP . . . . . . . . . . . . . 10.6 m-20 -143.83 -31.87 0.45 Allowed 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.088 -0.505 . . . . 0.0 110.858 -179.919 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 240' ' ' LEU . . . . . 0.434 ' N ' HD22 ' A' ' 240' ' ' LEU . 3.7 mm? 61.41 106.78 0.02 OUTLIER 'General case' 0 C--N 1.331 -0.199 0 CA-C-N 115.93 -0.577 . . . . 0.0 110.771 -179.825 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 241' ' ' GLU . . . . . . . . . . . . . 10.2 tp10 60.63 99.6 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.027 -0.533 . . . . 0.0 110.882 -179.822 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 242' ' ' HIS . . . . . . . . . . . . . 62.7 m80 -67.08 166.02 14.69 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.057 -179.818 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 243' ' ' HIS . . . . . . . . . . . . . 28.4 t-80 -135.89 -65.43 0.59 Allowed 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 115.988 -0.551 . . . . 0.0 110.743 179.808 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 244' ' ' HIS . . . . . . . . . . . . . 16.5 p-80 -87.89 138.22 31.65 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.757 179.81 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 245' ' ' HIS . . . . . . . . . . . . . 22.2 t60 -123.13 109.11 13.62 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.977 -179.84 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 246' ' ' HIS . . . . . . . . . . . . . 71.6 m-70 -134.33 -14.98 2.23 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.802 179.89 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 247' ' ' HIS . . . . . . . . . . . . . 51.9 t-80 . . . . . 0 C--O 1.249 1.077 0 CA-C-O 118.232 -0.89 . . . . 0.0 110.891 -179.947 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 301' ' ' RET . . . . . 0.657 H203 ' HE1' ' A' ' 171' ' ' TRP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 12.5 tpt . . . . . 0 N--CA 1.486 1.344 0 CA-C-O 120.753 0.311 . . . . 0.0 110.766 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 7.3 p -125.73 -27.87 1.34 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.233 0 CA-C-N 116.289 -0.414 . . . . 0.0 111.449 -179.707 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -76.53 -0.29 67.01 Favored Glycine 0 N--CA 1.453 -0.216 0 C-N-CA 120.7 -0.762 . . . . 0.0 112.577 -179.503 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 32.0 tp -74.83 -36.46 62.41 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-O 120.779 0.323 . . . . 0.0 111.215 -179.913 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 81.5 p -59.43 -29.84 68.05 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.082 -0.508 . . . . 0.0 111.372 -179.641 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 31.3 p -53.55 -35.91 61.27 Favored 'General case' 0 C--N 1.331 -0.196 0 CA-C-N 116.231 -0.441 . . . . 0.0 111.413 -179.798 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 7' ' ' LEU . . . . . . . . . . . . . 3.9 mm? -61.15 -51.09 70.52 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 116.382 -0.372 . . . . 0.0 111.224 -179.774 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 8' ' ' PHE . . . . . . . . . . . . . 83.9 m-85 -60.33 -36.39 77.83 Favored 'General case' 0 C--N 1.331 -0.198 0 CA-C-O 120.978 0.418 . . . . 0.0 110.775 179.871 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 9' ' ' TRP . . . . . 0.442 ' O ' HG12 ' A' ' 13' ' ' ILE . 21.7 m95 -63.58 -41.9 98.34 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 115.781 -0.645 . . . . 0.0 109.897 179.827 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 87.6 mt -60.87 -45.0 96.28 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 115.549 -0.75 . . . . 0.0 110.392 179.315 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -64.42 -26.76 70.94 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.715 -0.755 . . . . 0.0 111.965 179.368 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -74.37 -30.51 62.01 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.772 0.32 . . . . 0.0 110.755 179.716 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 13' ' ' ILE . . . . . 0.442 HG12 ' O ' ' A' ' 9' ' ' TRP . 51.6 mm -69.62 -54.39 19.71 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.227 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.62 179.776 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -61.84 -34.76 89.85 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.582 -0.818 . . . . 0.0 112.033 179.64 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 15' ' ' MET . . . . . 0.516 ' SD ' ' HA ' ' A' ' 44' ' ' SER . 49.1 tpp -66.52 -45.8 78.29 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 120.778 0.323 . . . . 0.0 110.39 179.71 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -54.19 -41.46 68.62 Favored 'General case' 0 C--N 1.331 -0.206 0 CA-C-N 116.053 -0.521 . . . . 0.0 109.759 179.196 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . 0.439 HG23 ' O ' ' A' ' 13' ' ' ILE . 63.5 t -59.8 -43.21 91.29 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.187 0 CA-C-N 115.8 -0.636 . . . . 0.0 110.263 179.302 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -65.3 -40.31 96.48 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.694 -0.765 . . . . 0.0 111.58 178.95 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 15.5 m -53.79 -48.84 69.42 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.876 0.369 . . . . 0.0 110.991 -179.997 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 20' ' ' LEU . . . . . 0.418 ' O ' ' HB3' ' A' ' 24' ' ' TRP . 89.2 mt -71.61 -35.05 70.36 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.038 -0.528 . . . . 0.0 111.152 179.894 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -64.06 -34.2 77.48 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.166 -0.47 . . . . 0.0 112.252 -179.332 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 22' ' ' PHE . . . . . 0.56 ' HB2' HG22 ' A' ' 41' ' ' VAL . 4.1 m-85 -90.29 -37.81 13.82 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.67 0.271 . . . . 0.0 111.512 -179.045 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -64.85 -50.75 65.4 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 121.004 0.43 . . . . 0.0 111.731 -179.542 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 24' ' ' TRP . . . . . 0.418 ' HB3' ' O ' ' A' ' 20' ' ' LEU . 5.0 t-105 -63.42 -51.54 65.3 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 115.803 -0.635 . . . . 0.0 111.174 -179.605 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -67.07 -24.92 66.02 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.36 -0.382 . . . . 0.0 111.162 -179.842 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -71.43 -44.4 51.24 Favored Glycine 0 N--CA 1.452 -0.28 0 C-N-CA 120.88 -0.676 . . . . 0.0 112.386 179.889 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 38.5 mmt180 -63.63 -14.94 56.46 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.797 0.332 . . . . 0.0 110.873 -179.937 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 18.4 t70 -114.73 93.58 4.39 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.5 179.672 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -163.37 -168.54 1.72 Allowed 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.015 -0.539 . . . . 0.0 110.984 -179.785 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -91.06 -122.69 2.69 Favored Glycine 0 N--CA 1.45 -0.397 0 C-N-CA 120.762 -0.732 . . . . 0.0 112.522 -179.993 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 55.8 m -134.84 122.04 21.47 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.902 0.382 . . . . 0.0 110.87 -179.941 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 115.65 -42.26 1.94 Allowed Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.885 -0.674 . . . . 0.0 112.359 179.951 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 17.6 mm-40 -66.38 -20.51 66.09 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.674 0.273 . . . . 0.0 111.141 179.897 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 34' ' ' ARG . . . . . . . . . . . . . 93.0 mtt180 -48.25 -34.07 9.69 Favored 'General case' 0 C--N 1.332 -0.192 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.623 -179.491 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 82.7 mtp180 -59.01 -52.67 64.77 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-O 120.841 0.353 . . . . 0.0 111.078 -179.83 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 73.4 m-85 -61.22 -29.5 69.86 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 116.058 -0.519 . . . . 0.0 111.189 -179.953 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 37' ' ' TYR . . . . . . . . . . . . . 42.8 m-85 -73.3 -52.62 13.28 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.347 -179.758 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 91.2 t -57.03 -36.92 52.49 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.243 0 CA-C-O 121.064 0.459 . . . . 0.0 110.265 179.536 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 25.6 m -68.07 -46.08 72.03 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 115.649 -0.705 . . . . 0.0 110.467 179.35 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 40' ' ' LEU . . . . . 0.401 HD11 ' HA2' ' A' ' 209' ' ' GLY . 15.8 tp -60.38 -45.51 93.28 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 115.628 -0.715 . . . . 0.0 110.51 179.877 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . 0.56 HG22 ' HB2' ' A' ' 22' ' ' PHE . 98.4 t -65.18 -34.02 67.66 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.476 0 CA-C-N 115.843 -0.617 . . . . 0.0 110.125 179.221 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . 0.437 ' O ' HG12 ' A' ' 46' ' ' ILE . . . -55.86 -51.57 54.43 Favored Glycine 0 N--CA 1.449 -0.485 0 CA-C-N 115.697 -0.683 . . . . 0.0 112.759 179.854 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 43' ' ' ILE . . . . . 0.737 HG23 HD23 ' A' ' 82' ' ' LEU . 10.7 pt -63.76 -48.93 84.29 Favored 'Isoleucine or valine' 0 C--O 1.231 0.12 0 CA-C-N 116.972 0.386 . . . . 0.0 111.473 -179.963 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 44' ' ' SER . . . . . 0.516 ' HA ' ' SD ' ' A' ' 15' ' ' MET . 47.8 t -60.51 -26.62 66.98 Favored 'General case' 0 CA--C 1.529 0.147 0 CA-C-O 120.968 0.413 . . . . 0.0 111.116 179.831 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -75.85 -60.44 3.16 Favored Glycine 0 CA--C 1.517 0.179 0 C-N-CA 120.966 -0.635 . . . . 0.0 113.206 -179.278 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 46' ' ' ILE . . . . . 0.484 HD11 HG22 ' A' ' 79' ' ' THR . 9.3 pt -57.95 -34.83 49.69 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-O 120.738 0.304 . . . . 0.0 111.339 -179.444 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 47' ' ' ALA . . . . . 0.69 ' HB2' ' HE2' ' A' ' 205' ' ' LYS . . . -67.22 -44.03 80.56 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.526 -0.306 . . . . 0.0 111.035 179.277 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -54.39 -47.07 73.12 Favored 'General case' 0 C--O 1.232 0.151 0 CA-C-N 116.273 -0.421 . . . . 0.0 111.179 -179.975 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 49' ' ' VAL . . . . . 0.445 ' O ' HG13 ' A' ' 53' ' ' VAL . 14.5 m -71.81 -34.11 50.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.292 -0.413 . . . . 0.0 111.004 179.704 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -60.07 -41.32 92.13 Favored 'General case' 0 N--CA 1.462 0.172 0 CA-C-O 121.006 0.432 . . . . 0.0 111.012 179.422 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 38.8 m-85 -73.25 -34.76 66.02 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 115.877 -0.601 . . . . 0.0 110.496 -179.883 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -66.58 -44.86 81.09 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 115.923 -0.581 . . . . 0.0 111.052 179.599 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 53' ' ' VAL . . . . . 0.455 HG23 ' N ' ' A' ' 54' ' ' MET . 31.2 m -66.61 -45.49 88.39 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.137 0 CA-C-N 116.47 -0.332 . . . . 0.0 110.87 -179.997 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 54' ' ' MET . . . . . 0.455 ' N ' HG23 ' A' ' 53' ' ' VAL . 73.1 mtm -64.27 -34.49 78.23 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-O 121.183 0.516 . . . . 0.0 109.941 179.251 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -63.61 -23.29 67.32 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 115.432 -0.804 . . . . 0.0 111.103 179.515 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 93.2 mt -94.12 -5.37 47.39 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 116.262 -0.426 . . . . 0.0 111.077 -179.864 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 98.12 19.42 23.84 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.636 -0.792 . . . . 0.0 112.935 179.743 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 59.7 t -83.61 135.4 24.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-O 120.739 0.304 . . . . 0.0 110.853 179.861 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 59' ' ' GLY . . . . . 0.53 ' HA3' ' HD3' ' A' ' 71' ' ' PRO . . . 81.03 -4.84 68.7 Favored Glycine 0 N--CA 1.45 -0.423 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.599 -179.806 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 60' ' ' TRP . . . . . . . . . . . . . 14.3 m0 -67.3 90.75 0.23 Allowed 'General case' 0 C--N 1.33 -0.248 0 CA-C-O 120.655 0.264 . . . . 0.0 110.836 179.97 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 61' ' ' VAL . . . . . 0.509 HG13 HG23 ' A' ' 68' ' ' VAL . 7.0 p -101.36 130.0 25.75 Favored Pre-proline 0 C--N 1.33 -0.277 0 CA-C-N 116.415 -0.357 . . . . 0.0 111.266 179.914 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 62' ' ' PRO . . . . . 0.449 ' HD3' ' HA ' ' A' ' 61' ' ' VAL . 7.7 Cg_exo -73.84 148.17 40.56 Favored 'Trans proline' 0 C--N 1.35 0.64 0 C-N-CA 122.966 2.444 . . . . 0.0 112.33 179.938 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 86.6 t -143.18 93.73 0.5 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.141 -0.481 . . . . 0.0 111.073 -179.956 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . 59.4 -88.31 0.02 OUTLIER 'General case' 0 C--N 1.332 -0.157 0 CA-C-N 116.129 -0.487 . . . . 0.0 111.485 179.846 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 12.6 pt-20 -123.9 -17.15 6.39 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.292 -0.413 . . . . 0.0 110.763 -179.851 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 66' ' ' ARG . . . . . 0.437 ' NH1' ' HA ' ' A' ' 183' ' ' PRO . 32.7 ptt180 -105.77 159.7 15.8 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 115.902 -0.59 . . . . 0.0 110.532 -179.925 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 40.0 m -119.23 138.54 52.91 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-O 120.902 0.382 . . . . 0.0 111.466 -179.646 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 68' ' ' VAL . . . . . 0.509 HG23 HG13 ' A' ' 61' ' ' VAL . 14.8 m -125.82 146.49 31.48 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.412 0 CA-C-N 115.846 -0.615 . . . . 0.0 110.732 179.666 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 69' ' ' PHE . . . . . . . . . . . . . 17.7 m-85 -108.78 115.7 30.59 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.195 -179.423 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 70' ' ' VAL . . . . . 0.55 HG12 ' HD3' ' A' ' 71' ' ' PRO . 0.3 OUTLIER -68.08 -33.47 5.01 Favored Pre-proline 0 CA--C 1.54 0.579 0 N-CA-C 112.749 0.648 . . . . 0.0 112.749 -179.24 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 71' ' ' PRO . . . . . 0.55 ' HD3' HG12 ' A' ' 70' ' ' VAL . 17.6 Cg_exo -66.39 -32.31 41.03 Favored 'Trans proline' 0 C--N 1.358 1.078 0 C-N-CA 121.781 1.654 . . . . 0.0 112.389 -178.989 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 72' ' ' ARG . . . . . 0.405 ' HD2' HG21 ' A' ' 197' ' ' ILE . 61.8 ttp180 -65.56 -51.13 62.11 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 121.178 0.513 . . . . 0.0 109.845 179.419 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 73' ' ' TYR . . . . . . . . . . . . . 45.9 m-85 -63.67 -46.92 83.4 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 115.522 -0.763 . . . . 0.0 110.697 179.752 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 0.4 OUTLIER -63.62 -34.84 70.22 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.308 -0.405 . . . . 0.0 110.175 179.64 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 75' ' ' ASP . . . . . 0.489 ' O ' HG23 ' A' ' 79' ' ' THR . 28.6 t70 -58.31 -39.37 79.2 Favored 'General case' 0 C--N 1.332 -0.157 0 N-CA-C 109.497 -0.557 . . . . 0.0 109.497 179.263 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 76' ' ' TRP . . . . . . . . . . . . . 53.1 m0 -67.44 -37.13 82.52 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 115.728 -0.669 . . . . 0.0 110.485 179.479 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 77' ' ' ILE . . . . . 0.431 ' O ' ' HG2' ' A' ' 81' ' ' PRO . 66.8 mt -59.74 -34.07 54.31 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 CA-C-N 115.971 -0.559 . . . . 0.0 110.844 179.79 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 20.0 mt -91.79 -27.03 18.26 Favored 'General case' 0 C--N 1.329 -0.313 0 N-CA-C 112.655 0.613 . . . . 0.0 112.655 -179.581 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 79' ' ' THR . . . . . 0.489 HG23 ' O ' ' A' ' 75' ' ' ASP . 78.6 p -90.49 -52.74 4.76 Favored 'General case' 0 N--CA 1.464 0.267 0 N-CA-C 113.747 1.017 . . . . 0.0 113.747 -177.688 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 80' ' ' THR . . . . . 0.642 ' HB ' ' HD3' ' A' ' 81' ' ' PRO . 33.1 m -48.35 -54.06 29.1 Favored Pre-proline 0 CA--C 1.531 0.228 0 N-CA-C 112.804 0.668 . . . . 0.0 112.804 -178.126 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 81' ' ' PRO . . . . . 0.642 ' HD3' ' HB ' ' A' ' 80' ' ' THR . 49.0 Cg_exo -56.43 -27.38 67.86 Favored 'Trans proline' 0 C--N 1.351 0.702 0 C-N-CA 121.572 1.515 . . . . 0.0 111.683 -179.76 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 82' ' ' LEU . . . . . 0.737 HD23 HG23 ' A' ' 43' ' ' ILE . 12.9 tp -76.96 -32.95 57.66 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 115.882 -0.599 . . . . 0.0 110.655 -179.999 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 48.5 mm -65.95 -53.85 33.52 Favored 'Isoleucine or valine' 0 C--O 1.233 0.215 0 N-CA-C 110.05 -0.352 . . . . 0.0 110.05 179.06 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 12.6 m -60.6 -29.93 45.76 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.26 0 N-CA-C 109.253 -0.647 . . . . 0.0 109.253 178.43 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 85' ' ' TYR . . . . . . . . . . . . . 66.3 t80 -65.53 -34.34 78.02 Favored 'General case' 0 N--CA 1.455 -0.215 0 CA-C-N 115.432 -0.804 . . . . 0.0 109.252 178.354 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 86' ' ' PHE . . . . . . . . . . . . . 2.1 t80 -61.31 -51.47 68.72 Favored 'General case' 0 C--O 1.231 0.129 0 CA-C-N 115.762 -0.654 . . . . 0.0 109.623 179.217 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 7.4 mp -64.0 -31.38 72.55 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 115.801 -0.636 . . . . 0.0 110.119 179.414 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -66.6 -27.78 73.39 Favored Glycine 0 N--CA 1.449 -0.459 0 C-N-CA 120.807 -0.711 . . . . 0.0 111.742 179.322 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 88.6 mt -75.96 -44.93 37.54 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 120.81 0.338 . . . . 0.0 110.691 179.586 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 80.3 mt -54.97 -38.24 67.53 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 115.904 -0.589 . . . . 0.0 110.859 179.898 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -84.34 -54.02 5.07 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.058 -0.519 . . . . 0.0 111.079 179.953 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 100.14 65.13 0.81 Allowed Glycine 0 N--CA 1.452 -0.234 0 C-N-CA 120.887 -0.673 . . . . 0.0 112.416 179.989 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 93' ' ' LEU . . . . . 0.532 ' HB3' ' HB2' ' A' ' 97' ' ' GLU . 6.9 mp -81.51 165.63 21.02 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-O 120.795 0.331 . . . . 0.0 110.746 179.932 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 94' ' ' ASP . . . . . . . . . . . . . 9.0 m-20 -82.75 178.0 8.4 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.837 179.928 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 82.5 p -64.11 -34.47 78.11 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.07 -0.513 . . . . 0.0 111.072 -179.983 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 84.6 mtm180 -73.6 -51.27 17.42 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.279 -0.418 . . . . 0.0 111.094 -179.751 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 97' ' ' GLU . . . . . 0.532 ' HB2' ' HB3' ' A' ' 93' ' ' LEU . 20.2 mt-10 -57.39 -44.4 84.44 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.453 -0.34 . . . . 0.0 110.748 -179.842 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 98' ' ' PHE . . . . . . . . . . . . . 1.7 m-85 -57.46 -50.58 72.58 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.311 -0.404 . . . . 0.0 110.933 179.812 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -54.45 -34.8 55.21 Favored Glycine 0 N--CA 1.452 -0.278 0 C-N-CA 120.883 -0.675 . . . . 0.0 112.584 -179.966 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 96.5 mt -66.74 -43.17 90.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-O 120.89 0.376 . . . . 0.0 111.632 -179.823 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 59.6 t -69.17 -44.26 80.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.629 -179.545 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 102' ' ' ILE . . . . . . . . . . . . . 37.7 mm -65.52 -46.69 89.06 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.378 0 CA-C-N 116.405 -0.361 . . . . 0.0 111.629 -179.227 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 15.3 t -61.85 -35.93 79.74 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 120.643 0.259 . . . . 0.0 111.258 -179.588 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 29.4 tp -62.62 -46.68 87.17 Favored 'General case' 0 C--N 1.332 -0.169 0 CA-C-O 120.843 0.354 . . . . 0.0 110.761 179.781 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 105' ' ' ASN . . . . . 0.621 HD21 HD13 ' A' ' 137' ' ' LEU . 0.9 OUTLIER -64.73 -26.18 68.25 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.69 179.697 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 53.8 m -67.1 -55.23 15.14 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.124 -0.489 . . . . 0.0 111.401 -179.927 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 7.1 p -62.43 -38.53 81.53 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.193 0 CA-C-N 116.477 -0.329 . . . . 0.0 111.103 -179.841 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 59.4 t -62.58 -44.75 99.65 Favored 'Isoleucine or valine' 0 C--O 1.234 0.269 0 CA-C-O 121.051 0.453 . . . . 0.0 110.573 179.545 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 109' ' ' MET . . . . . 0.521 ' HE1' HG21 ' A' ' 80' ' ' THR . 7.7 tpp -67.38 -25.69 66.09 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 115.979 -0.555 . . . . 0.0 110.113 179.594 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 20.2 tp -75.93 -30.95 58.9 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 115.764 -0.653 . . . . 0.0 110.296 179.633 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -66.83 -54.23 24.6 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 115.934 -0.575 . . . . 0.0 110.72 179.662 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 112' ' ' GLY . . . . . 0.684 ' HA3' ' H21' ' A' ' 301' ' ' RET . . . -62.1 -47.55 89.1 Favored Glycine 0 C--N 1.331 0.283 0 C-N-CA 120.627 -0.797 . . . . 0.0 111.976 179.558 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 113' ' ' PHE . . . . . . . . . . . . . 3.4 t80 -50.5 -58.08 6.61 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.717 0.294 . . . . 0.0 110.68 179.362 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -71.95 -16.82 62.1 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.687 179.587 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -60.4 -48.69 84.94 Favored Glycine 0 C--N 1.331 0.295 0 C-N-CA 121.091 -0.576 . . . . 0.0 112.412 179.948 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 116' ' ' ALA . . . . . 0.516 ' HB2' ' HB3' ' A' ' 183' ' ' PRO . . . -77.83 -15.05 59.35 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-O 120.773 0.321 . . . . 0.0 111.361 179.991 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 117' ' ' MET . . . . . 0.439 ' SD ' HG21 ' A' ' 68' ' ' VAL . 25.4 mmt -90.29 14.32 13.04 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.298 -0.41 . . . . 0.0 111.6 -179.433 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 118' ' ' VAL . . . . . 0.432 HG21 ' HB3' ' A' ' 123' ' ' ARG . 26.0 m -82.16 143.72 49.44 Favored Pre-proline 0 C--N 1.331 -0.229 0 CA-C-N 116.649 -0.251 . . . . 0.0 111.196 -179.959 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 119' ' ' PRO . . . . . . . . . . . . . 67.8 Cg_endo -92.9 -1.48 3.64 Favored 'Trans proline' 0 N--CA 1.457 -0.668 0 C-N-CA 122.907 2.405 . . . . 0.0 112.416 179.551 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -138.18 -114.16 1.23 Allowed Glycine 0 C--N 1.333 0.371 0 C-N-CA 120.694 -0.765 . . . . 0.0 113.029 -179.655 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 37.0 pt -126.15 13.13 3.99 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.188 0 CA-C-O 120.781 0.324 . . . . 0.0 111.683 -179.564 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 12.2 mm-40 -61.27 -18.8 60.24 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.332 -0.395 . . . . 0.0 111.187 -179.986 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 123' ' ' ARG . . . . . 0.432 ' HB3' HG21 ' A' ' 118' ' ' VAL . 28.0 ptt180 -50.65 -38.26 45.42 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 116.0 -0.545 . . . . 0.0 111.672 -179.828 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 124' ' ' TYR . . . . . . . . . . . . . 57.5 m-85 -64.9 -33.5 76.17 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.401 -0.363 . . . . 0.0 111.241 -179.605 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 125' ' ' ALA . . . . . . . . . . . . . . . -71.98 -56.0 6.44 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 120.946 0.403 . . . . 0.0 111.204 -179.998 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 1.2 mt -52.11 -52.36 51.98 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 115.923 -0.58 . . . . 0.0 111.011 -179.871 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 127' ' ' PHE . . . . . . . . . . . . . 11.6 t80 -64.0 -37.66 88.24 Favored 'General case' 0 N--CA 1.453 -0.304 0 C-N-CA 120.778 -0.369 . . . . 0.0 110.866 179.927 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 128' ' ' GLY . . . . . . . . . . . . . . . -46.47 -44.6 16.28 Favored Glycine 0 C--N 1.332 0.349 0 C-N-CA 120.227 -0.987 . . . . 0.0 110.95 179.35 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 129' ' ' MET . . . . . . . . . . . . . 0.3 OUTLIER -70.56 -37.01 73.94 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 115.392 -0.404 . . . . 0.0 109.947 178.839 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -68.77 -26.92 74.24 Favored Glycine 0 C--N 1.331 0.3 0 CA-C-N 115.842 -0.617 . . . . 0.0 112.94 -179.872 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 131' ' ' ALA . . . . . 0.456 ' O ' ' HB3' ' A' ' 134' ' ' PHE . . . -74.66 -53.6 9.0 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.821 0.343 . . . . 0.0 110.208 179.869 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 58.0 t -58.56 -39.92 77.19 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 N-CA-C 109.09 -0.707 . . . . 0.0 109.09 178.486 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -66.87 -35.31 79.74 Favored 'General case' 0 N--CA 1.453 -0.313 0 CA-C-N 115.276 -0.875 . . . . 0.0 110.412 179.21 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 134' ' ' PHE . . . . . 0.456 ' HB3' ' O ' ' A' ' 131' ' ' ALA . 17.6 t80 -54.26 -56.63 16.49 Favored 'General case' 0 N--CA 1.455 -0.208 0 CA-C-N 116.128 -0.487 . . . . 0.0 109.889 179.425 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 135' ' ' ILE . . . . . 0.479 ' O ' HG22 ' A' ' 138' ' ' VAL . 34.7 mt -56.69 -33.4 40.26 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.323 0 CA-C-N 115.564 -0.744 . . . . 0.0 110.082 179.388 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . -59.87 -35.99 88.57 Favored Glycine 0 N--CA 1.449 -0.447 0 C-N-CA 120.241 -0.981 . . . . 0.0 111.108 178.679 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 137' ' ' LEU . . . . . 0.621 HD13 HD21 ' A' ' 105' ' ' ASN . 56.1 tp -70.86 -55.49 8.38 Favored 'General case' 0 N--CA 1.453 -0.276 0 CA-C-N 115.772 -0.214 . . . . 0.0 110.671 179.376 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 138' ' ' VAL . . . . . 0.479 HG22 ' O ' ' A' ' 135' ' ' ILE . 3.1 m -54.87 -30.3 22.83 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.222 0 N-CA-C 109.171 -0.677 . . . . 0.0 109.171 179.715 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 139' ' ' TYR . . . . . . . . . . . . . 27.1 t80 -62.49 -43.61 98.39 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 115.168 -0.923 . . . . 0.0 109.956 178.083 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 22.2 m-85 -67.48 -44.35 78.78 Favored 'General case' 0 C--O 1.232 0.151 0 CA-C-N 116.301 -0.409 . . . . 0.0 110.467 179.011 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 141' ' ' LEU . . . . . 0.441 HD13 ' O ' ' A' ' 137' ' ' LEU . 11.0 mp -55.02 -32.57 61.94 Favored 'General case' 0 C--N 1.332 -0.183 0 CA-C-N 116.004 -0.544 . . . . 0.0 111.253 -179.719 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 10.8 p -101.44 -10.19 8.99 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-O 121.055 0.455 . . . . 0.0 110.693 179.929 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . -75.99 -135.54 0.56 Allowed Glycine 0 CA--C 1.522 0.476 0 CA-C-N 115.852 -0.613 . . . . 0.0 112.693 -179.902 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 144' ' ' PRO . . . . . . . . . . . . . 50.0 Cg_exo -53.25 -23.95 24.98 Favored 'Trans proline' 0 C--N 1.347 0.478 0 C-N-CA 122.659 2.239 . . . . 0.0 113.055 -179.688 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 145' ' ' MET . . . . . 0.429 ' HB3' ' OH ' ' A' ' 160' ' ' TYR . 41.2 mtt -57.33 -38.01 73.41 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-O 120.67 0.271 . . . . 0.0 111.549 -179.623 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 146' ' ' THR . . . . . . . . . . . . . 60.4 p -65.45 -49.06 70.55 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.443 -0.344 . . . . 0.0 111.686 -179.443 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 43.9 mt-10 -71.48 -25.4 62.26 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.422 -0.354 . . . . 0.0 111.532 -179.462 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 148' ' ' SER . . . . . . . . . . . . . 48.2 t -68.89 -46.28 68.78 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-O 120.935 0.398 . . . . 0.0 110.827 -179.574 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 149' ' ' ALA . . . . . 0.506 ' HB1' HG22 ' A' ' 156' ' ' ILE . . . -78.13 -32.14 50.25 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.028 -0.533 . . . . 0.0 111.357 -179.858 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 150' ' ' SER . . . . . . . . . . . . . 41.6 t -63.07 -14.83 53.08 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.02 -0.536 . . . . 0.0 111.555 -179.603 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 151' ' ' GLN . . . . . . . . . . . . . 9.8 pt20 -110.71 17.2 20.87 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.659 -0.246 . . . . 0.0 111.624 -179.747 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 29.7 mmt180 -98.64 -52.51 3.59 Favored 'General case' 0 C--N 1.332 -0.184 0 C-N-CA 120.856 -0.338 . . . . 0.0 110.803 179.613 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 153' ' ' SER . . . . . 0.654 ' HB3' HG12 ' A' ' 156' ' ' ILE . 21.0 t -158.1 172.2 18.84 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.792 179.007 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 154' ' ' SER . . . . . . . . . . . . . 43.3 t -71.94 -38.4 69.83 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.307 -0.406 . . . . 0.0 110.385 179.303 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -76.87 -37.68 33.02 Favored Glycine 0 N--CA 1.45 -0.384 0 C-N-CA 120.924 -0.655 . . . . 0.0 112.647 179.8 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 156' ' ' ILE . . . . . 0.654 HG12 ' HB3' ' A' ' 153' ' ' SER . 37.8 mm -52.25 -39.79 28.77 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.236 0 CA-C-O 120.724 0.297 . . . . 0.0 111.431 -179.563 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 157' ' ' LYS . . . . . . . . . . . . . 56.0 tttm -69.65 -34.59 74.22 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-N 116.318 -0.401 . . . . 0.0 111.138 -179.921 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 46.5 t -72.25 -39.96 68.06 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 120.942 0.401 . . . . 0.0 111.309 -179.208 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 159' ' ' LEU . . . . . 0.44 HD13 ' HB1' ' A' ' 215' ' ' ALA . 12.9 mt -72.58 -35.19 67.86 Favored 'General case' 0 C--N 1.326 -0.449 0 CA-C-N 116.066 -0.516 . . . . 0.0 111.315 -179.314 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 160' ' ' TYR . . . . . 0.429 ' OH ' ' HB3' ' A' ' 145' ' ' MET . 37.5 t80 -70.38 -42.36 71.83 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.648 -0.251 . . . . 0.0 111.599 -179.075 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 161' ' ' VAL . . . . . 0.41 HG23 ' N ' ' A' ' 162' ' ' ARG . 23.0 m -65.06 -43.91 95.87 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-O 120.719 0.295 . . . . 0.0 111.367 -179.644 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 162' ' ' ARG . . . . . 0.41 ' N ' HG23 ' A' ' 161' ' ' VAL . 21.2 mmm180 -69.29 -46.53 66.96 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.914 0.387 . . . . 0.0 111.248 179.994 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 163' ' ' LEU . . . . . . . . . . . . . 1.3 mp -61.79 -54.8 37.33 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 115.971 -0.559 . . . . 0.0 111.702 -179.548 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 164' ' ' ARG . . . . . . . . . . . . . 25.4 ttp85 -58.09 -48.23 80.8 Favored 'General case' 0 C--N 1.331 -0.237 0 N-CA-C 112.459 0.54 . . . . 0.0 112.459 -178.843 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 165' ' ' ASN . . . . . 0.491 ' O ' HG23 ' A' ' 169' ' ' VAL . 0.9 OUTLIER -52.34 -51.38 59.1 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-O 120.942 0.401 . . . . 0.0 110.719 -179.205 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 166' ' ' LEU . . . . . 0.529 ' O ' ' HG ' ' A' ' 170' ' ' LEU . 3.6 tt -65.41 -41.48 93.58 Favored 'General case' 0 C--N 1.324 -0.515 0 CA-C-N 116.089 -0.505 . . . . 0.0 111.36 -179.895 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 167' ' ' THR . . . . . . . . . . . . . 51.1 m -65.18 -54.11 34.69 Favored 'General case' 0 C--N 1.331 -0.232 0 N-CA-C 112.51 0.559 . . . . 0.0 112.51 -178.465 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 168' ' ' VAL . . . . . . . . . . . . . 9.1 p -54.47 -40.46 49.54 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-O 120.644 0.259 . . . . 0.0 111.67 -179.385 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 169' ' ' VAL . . . . . 0.491 HG23 ' O ' ' A' ' 165' ' ' ASN . 55.5 t -59.72 -65.11 0.49 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.486 -0.324 . . . . 0.0 111.634 -179.844 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 170' ' ' LEU . . . . . 0.529 ' HG ' ' O ' ' A' ' 166' ' ' LEU . 2.0 pp -62.79 -27.14 69.09 Favored 'General case' 0 C--N 1.33 -0.262 0 N-CA-C 112.139 0.422 . . . . 0.0 112.139 -178.806 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 171' ' ' TRP . . . . . 0.736 ' HE1' H203 ' A' ' 301' ' ' RET . 1.8 m0 -73.35 -32.48 64.56 Favored 'General case' 0 C--N 1.33 -0.245 0 C-N-CA 120.588 -0.445 . . . . 0.0 110.707 179.69 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 172' ' ' ALA . . . . . 0.415 ' HA ' ' CZ ' ' A' ' 134' ' ' PHE . . . -67.94 -7.76 31.26 Favored 'General case' 0 CA--C 1.52 -0.208 0 CA-C-O 121.345 0.593 . . . . 0.0 110.157 179.287 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 173' ' ' ILE . . . . . 0.723 HG22 ' CG1' ' A' ' 177' ' ' ILE . 9.0 mm -84.15 -36.26 11.79 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.555 0 CA-C-N 114.954 -1.021 . . . . 0.0 111.501 -179.03 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 174' ' ' TYR . . . . . 0.548 ' N ' ' HD2' ' A' ' 175' ' ' PRO . 70.2 m-85 -55.56 -51.66 78.26 Favored Pre-proline 0 C--N 1.328 -0.33 0 N-CA-C 112.507 0.558 . . . . 0.0 112.507 -178.9 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 175' ' ' PRO . . . . . 0.548 ' HD2' ' N ' ' A' ' 174' ' ' TYR . 26.7 Cg_endo -60.19 -41.12 53.98 Favored 'Trans proline' 0 C--N 1.349 0.57 0 C-N-CA 122.107 1.871 . . . . 0.0 113.359 -178.776 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 176' ' ' PHE . . . . . 0.529 ' CE2' ' HA ' ' A' ' 173' ' ' ILE . 0.1 OUTLIER -79.83 -37.83 34.18 Favored 'General case' 0 C--N 1.329 -0.32 0 C-N-CA 120.609 -0.437 . . . . 0.0 112.12 -178.413 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 177' ' ' ILE . . . . . 0.723 ' CG1' HG22 ' A' ' 173' ' ' ILE . 32.4 mm -63.76 -47.33 91.49 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.614 0 CA-C-O 120.873 0.368 . . . . 0.0 110.032 178.425 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 178' ' ' TRP . . . . . . . . . . . . . 60.5 t90 -52.91 -29.61 29.46 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 115.788 -0.642 . . . . 0.0 109.857 179.202 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 179' ' ' LEU . . . . . 0.528 HD13 ' O ' ' A' ' 179' ' ' LEU . 0.9 OUTLIER -72.76 -37.56 67.63 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 115.359 -0.837 . . . . 0.0 110.689 179.898 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 180' ' ' LEU . . . . . 0.447 ' HB3' HD12 ' A' ' 187' ' ' LEU . 0.9 OUTLIER -78.31 -51.79 9.59 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.548 -0.296 . . . . 0.0 111.626 -179.399 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . -51.13 171.8 0.2 Allowed Glycine 0 C--N 1.336 0.551 0 C-N-CA 120.941 -0.647 . . . . 0.0 113.292 -179.685 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 182' ' ' PRO . . . . . 0.585 ' N ' ' HD2' ' A' ' 183' ' ' PRO . 2.5 Cg_endo -42.68 -47.81 7.59 Favored 'Trans proline' 0 C--N 1.351 0.661 0 C-N-CA 123.316 2.678 . . . . 0.0 114.015 -179.837 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 183' ' ' PRO . . . . . 0.585 ' HD2' ' N ' ' A' ' 182' ' ' PRO . 9.4 Cg_endo -50.04 -29.93 23.2 Favored 'Trans proline' 0 C--N 1.357 0.992 0 C-N-CA 122.269 1.979 . . . . 0.0 112.62 -179.754 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 184' ' ' GLY . . . . . . . . . . . . . . . -95.93 -105.08 2.12 Favored Glycine 0 N--CA 1.45 -0.368 0 C-N-CA 120.716 -0.754 . . . . 0.0 112.73 -179.904 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 185' ' ' VAL . . . . . . . . . . . . . 0.9 OUTLIER -109.4 -0.37 9.68 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-O 120.672 0.272 . . . . 0.0 111.654 -179.525 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 186' ' ' ALA . . . . . 0.49 ' HB2' ' HA ' ' A' ' 182' ' ' PRO . . . 55.31 84.88 0.07 Allowed 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.26 -0.427 . . . . 0.0 111.74 179.535 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 187' ' ' LEU . . . . . 0.447 HD12 ' HB3' ' A' ' 180' ' ' LEU . 16.4 mt -92.3 -49.44 6.16 Favored 'General case' 0 C--N 1.332 -0.162 0 CA-C-O 121.041 0.448 . . . . 0.0 110.676 179.452 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 188' ' ' LEU . . . . . . . . . . . . . 72.8 mt -102.81 -160.64 0.79 Allowed 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 115.763 -0.653 . . . . 0.0 111.282 -179.409 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 189' ' ' THR . . . . . 0.452 ' HB ' HG23 ' A' ' 192' ' ' VAL . 10.4 m -88.11 136.64 31.85 Favored Pre-proline 0 C--N 1.33 -0.249 0 CA-C-N 115.866 -0.607 . . . . 0.0 110.615 -179.805 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 190' ' ' PRO . . . . . . . . . . . . . 82.1 Cg_exo -46.58 -49.74 11.55 Favored 'Trans proline' 0 C--N 1.35 0.607 0 C-N-CA 122.614 2.209 . . . . 0.0 113.053 -179.63 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 191' ' ' THR . . . . . 0.427 HG22 HG22 ' A' ' 189' ' ' THR . 7.1 t -61.4 -35.6 77.95 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.485 -0.325 . . . . 0.0 111.77 -179.478 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 192' ' ' VAL . . . . . 0.452 HG23 ' HB ' ' A' ' 189' ' ' THR . 89.3 t -71.45 -47.09 60.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-O 120.833 0.349 . . . . 0.0 111.278 -179.708 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 193' ' ' ASP . . . . . . . . . . . . . 24.4 t70 -58.93 -43.98 91.27 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.752 -179.944 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 194' ' ' VAL . . . . . . . . . . . . . 78.3 t -63.16 -37.98 80.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.929 179.787 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 195' ' ' ALA . . . . . . . . . . . . . . . -57.22 -46.56 82.83 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.484 -0.325 . . . . 0.0 111.093 179.829 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 196' ' ' LEU . . . . . 0.426 ' O ' ' HB3' ' A' ' 199' ' ' TYR . 80.8 mt -67.75 -33.44 74.87 Favored 'General case' 0 C--N 1.332 -0.188 0 CA-C-N 116.381 -0.372 . . . . 0.0 110.633 179.691 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 197' ' ' ILE . . . . . 0.507 HD13 HD12 ' A' ' 200' ' ' LEU . 21.1 mm -64.57 -50.48 75.69 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.112 179.126 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 198' ' ' VAL . . . . . . . . . . . . . 85.0 t -56.72 -34.08 42.11 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.478 0 N-CA-C 108.707 -0.849 . . . . 0.0 108.707 178.171 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 199' ' ' TYR . . . . . 0.502 ' O ' HG23 ' A' ' 203' ' ' VAL . 80.5 t80 -68.38 -43.72 76.69 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 114.939 -1.028 . . . . 0.0 110.167 179.544 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 200' ' ' LEU . . . . . 0.507 HD12 HD13 ' A' ' 197' ' ' ILE . 65.0 mt -56.61 -55.02 39.25 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 115.496 -0.775 . . . . 0.0 111.172 -179.667 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 201' ' ' ASP . . . . . . . . . . . . . 11.6 m-20 -64.82 -38.07 89.74 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.85 179.918 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 202' ' ' LEU . . . . . . . . . . . . . 23.5 tp -64.99 -26.05 68.12 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 115.703 -0.681 . . . . 0.0 111.393 -179.554 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 203' ' ' VAL . . . . . 0.502 HG23 ' O ' ' A' ' 199' ' ' TYR . 45.0 t -82.58 -36.55 13.54 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.365 0 CA-C-N 116.635 -0.257 . . . . 0.0 111.454 -179.397 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 204' ' ' THR . . . . . 0.402 ' O ' ' HB3' ' A' ' 208' ' ' PHE . 88.2 m -63.51 -49.18 74.55 Favored 'General case' 0 C--N 1.329 -0.318 0 C-N-CA 120.773 -0.371 . . . . 0.0 111.319 179.837 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 205' ' ' LYS . . . . . 0.69 ' HE2' ' HB2' ' A' ' 47' ' ' ALA . 61.0 mttp -73.32 -46.79 47.38 Favored 'General case' 0 C--N 1.326 -0.429 0 N-CA-C 111.934 0.346 . . . . 0.0 111.934 -178.926 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 94.9 t -74.14 -50.57 27.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-O 120.572 0.225 . . . . 0.0 111.398 -179.805 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 207' ' ' GLY . . . . . . . . . . . . . . . -60.0 -58.19 15.43 Favored Glycine 0 CA--C 1.519 0.292 0 C-N-CA 121.112 -0.566 . . . . 0.0 112.862 179.988 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 208' ' ' PHE . . . . . 0.443 ' O ' ' N ' ' A' ' 212' ' ' ALA . 4.3 t80 -56.27 -44.35 79.66 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.601 0.239 . . . . 0.0 110.744 179.75 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 209' ' ' GLY . . . . . 0.491 ' HA2' ' HB3' ' A' ' 212' ' ' ALA . . . -66.36 -37.7 93.0 Favored Glycine 0 C--N 1.33 0.243 0 CA-C-N 115.811 -0.631 . . . . 0.0 113.41 -179.686 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 210' ' ' PHE . . . . . . . . . . . . . 1.7 m-85 -69.14 -43.85 73.52 Favored 'General case' 0 CA--C 1.51 -0.592 0 N-CA-C 107.64 -1.244 . . . . 0.0 107.64 178.99 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 211' ' ' ILE . . . . . . . . . . . . . 79.8 mt -65.76 -29.62 47.54 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.827 0 N-CA-C 107.193 -1.41 . . . . 0.0 107.193 176.319 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 212' ' ' ALA . . . . . 0.491 ' HB3' ' HA2' ' A' ' 209' ' ' GLY . . . -68.94 -34.92 76.14 Favored 'General case' 0 N--CA 1.449 -0.483 0 CA-C-N 114.437 -1.256 . . . . 0.0 109.969 179.413 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 213' ' ' LEU . . . . . . . . . . . . . 57.6 mt -70.35 -55.34 9.37 Favored 'General case' 0 C--N 1.331 -0.205 0 CA-C-N 115.056 -0.975 . . . . 0.0 111.458 -179.55 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 214' ' ' ASP . . . . . . . . . . . . . 16.7 t70 -59.48 -26.88 65.63 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.284 -0.416 . . . . 0.0 110.59 179.974 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 215' ' ' ALA . . . . . 0.44 ' HB1' HD13 ' A' ' 159' ' ' LEU . . . -71.04 -57.69 4.29 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 115.906 -0.588 . . . . 0.0 111.521 -179.911 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 216' ' ' ALA . . . . . . . . . . . . . . . -62.76 -37.49 86.84 Favored 'General case' 0 C--N 1.332 -0.187 0 CA-C-N 116.43 -0.35 . . . . 0.0 111.267 -179.702 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 217' ' ' ALA . . . . . . . . . . . . . . . -60.06 -42.98 95.66 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.312 -0.404 . . . . 0.0 110.3 179.531 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 218' ' ' THR . . . . . 0.451 ' HA ' ' HB3' ' A' ' 221' ' ' ALA . 98.3 m -62.43 -37.96 87.88 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 115.865 -0.607 . . . . 0.0 110.57 179.405 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 219' ' ' LEU . . . . . 0.494 ' O ' ' HG2' ' A' ' 222' ' ' GLU . 82.4 mt -56.95 -46.16 82.31 Favored 'General case' 0 C--N 1.331 -0.198 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.419 179.672 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 220' ' ' ARG . . . . . 0.459 ' HA ' ' NE2' ' A' ' 223' ' ' HIS . 8.9 mpt_? -84.52 -13.72 51.06 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.083 -0.508 . . . . 0.0 111.088 179.376 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 221' ' ' ALA . . . . . 0.451 ' HB3' ' HA ' ' A' ' 218' ' ' THR . . . -81.09 -19.94 42.59 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.249 -0.432 . . . . 0.0 111.864 -179.551 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 222' ' ' GLU . . . . . 0.494 ' HG2' ' O ' ' A' ' 219' ' ' LEU . 11.6 pt-20 -79.06 -11.26 59.99 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.754 0.311 . . . . 0.0 111.154 -179.182 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 223' ' ' HIS . . . . . 0.459 ' NE2' ' HA ' ' A' ' 220' ' ' ARG . 30.9 p80 -134.43 -5.1 2.6 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.316 -0.402 . . . . 0.0 110.969 -179.975 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 224' ' ' GLY . . . . . . . . . . . . . . . -76.09 -4.12 77.31 Favored Glycine 0 C--N 1.33 0.201 0 C-N-CA 120.749 -0.739 . . . . 0.0 112.421 179.904 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 225' ' ' GLU . . . . . . . . . . . . . 12.4 pt-20 -106.58 144.2 33.59 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-O 120.749 0.309 . . . . 0.0 110.932 179.952 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 226' ' ' SER . . . . . . . . . . . . . 67.1 m 59.96 107.53 0.02 OUTLIER 'General case' 0 C--N 1.331 -0.202 0 CA-C-N 115.994 -0.548 . . . . 0.0 111.172 -179.82 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 227' ' ' LEU . . . . . 0.457 ' N ' HD12 ' A' ' 227' ' ' LEU . 6.9 mp -84.14 -35.98 23.24 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 115.996 -0.547 . . . . 0.0 110.792 -179.854 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 228' ' ' ALA . . . . . . . . . . . . . . . 51.18 30.59 5.85 Favored 'General case' 0 C--N 1.332 -0.172 0 CA-C-N 116.136 -0.484 . . . . 0.0 111.537 179.875 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 229' ' ' GLY . . . . . . . . . . . . . . . -121.16 -50.24 0.26 Allowed Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.665 -0.779 . . . . 0.0 112.747 -179.934 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 230' ' ' VAL . . . . . . . . . . . . . 44.5 t -103.11 114.0 41.47 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-O 120.68 0.276 . . . . 0.0 111.038 -179.873 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 231' ' ' ASP . . . . . . . . . . . . . 6.4 p-10 -58.8 131.49 51.09 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.82 -179.984 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 232' ' ' THR . . . . . . . . . . . . . 4.9 t -167.16 136.56 2.82 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.115 -0.493 . . . . 0.0 111.346 -179.855 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 233' ' ' ASP . . . . . . . . . . . . . 9.5 m-20 -137.08 150.66 48.18 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.001 -0.545 . . . . 0.0 110.864 179.76 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 234' ' ' THR . . . . . 0.541 ' HB ' ' HD3' ' A' ' 235' ' ' PRO . 83.4 m -77.03 -48.91 2.52 Favored Pre-proline 0 CA--C 1.533 0.301 0 CA-C-N 116.326 -0.397 . . . . 0.0 111.827 -179.867 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 235' ' ' PRO . . . . . 0.541 ' HD3' ' HB ' ' A' ' 234' ' ' THR . 71.5 Cg_exo -48.72 141.26 21.15 Favored 'Trans proline' 0 C--N 1.355 0.87 0 C-N-CA 122.3 2.0 . . . . 0.0 112.454 -179.997 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 236' ' ' ALA . . . . . . . . . . . . . . . -58.52 134.85 57.06 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-N 116.132 -0.485 . . . . 0.0 111.228 -179.87 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 237' ' ' VAL . . . . . 0.558 HG22 ' H ' ' A' ' 239' ' ' ASP . 15.0 p -105.33 148.94 9.16 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.23 0 CA-C-N 116.112 -0.495 . . . . 0.0 111.055 -179.998 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 238' ' ' ALA . . . . . . . . . . . . . . . -95.06 21.33 7.88 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.27 -0.423 . . . . 0.0 111.233 -179.991 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 239' ' ' ASP . . . . . 0.558 ' H ' HG22 ' A' ' 237' ' ' VAL . 7.1 m-20 59.11 -177.82 0.08 Allowed 'General case' 0 C--N 1.331 -0.201 0 CA-C-N 116.265 -0.425 . . . . 0.0 111.308 179.847 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 240' ' ' LEU . . . . . 0.456 ' N ' HD22 ' A' ' 240' ' ' LEU . 3.3 mm? -108.45 130.83 55.24 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.821 179.812 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 241' ' ' GLU . . . . . . . . . . . . . 44.5 mt-10 -116.68 -26.28 7.06 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.373 -0.376 . . . . 0.0 110.849 179.746 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 242' ' ' HIS . . . . . . . . . . . . . 70.2 m80 -95.29 -40.87 9.32 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.902 179.875 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 243' ' ' HIS . . . . . . . . . . . . . 78.4 m80 -79.93 141.45 36.04 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.125 -0.488 . . . . 0.0 110.787 179.962 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 244' ' ' HIS . . . . . . . . . . . . . 2.7 p80 -113.05 168.17 9.92 Favored 'General case' 0 C--N 1.331 -0.218 0 CA-C-N 116.246 -0.434 . . . . 0.0 111.123 -179.737 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 245' ' ' HIS . . . . . . . . . . . . . 55.9 t-80 58.65 96.86 0.02 OUTLIER 'General case' 0 C--O 1.233 0.201 0 CA-C-N 115.823 -0.626 . . . . 0.0 111.078 179.844 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 246' ' ' HIS . . . . . . . . . . . . . 44.9 t-80 -157.63 149.95 22.57 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.833 -179.995 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 247' ' ' HIS . . . . . . . . . . . . . 62.2 m80 . . . . . 0 C--O 1.25 1.107 0 CA-C-O 118.341 -0.838 . . . . 0.0 110.957 -179.909 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 301' ' ' RET . . . . . 0.736 H203 ' HE1' ' A' ' 171' ' ' TRP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 87.3 mmm . . . . . 0 N--CA 1.485 1.317 0 CA-C-O 120.667 0.27 . . . . 0.0 110.997 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 41.8 t 56.57 89.36 0.04 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.114 179.99 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . 146.06 -37.65 1.23 Allowed Glycine 0 N--CA 1.452 -0.3 0 C-N-CA 120.846 -0.693 . . . . 0.0 112.72 -179.897 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 59.0 tp -74.44 -38.16 63.08 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.886 0.375 . . . . 0.0 110.988 -179.967 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 40.6 p -65.0 -29.57 70.5 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 115.936 -0.574 . . . . 0.0 111.442 -179.74 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 17.8 p -51.92 -35.22 44.92 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.278 -0.419 . . . . 0.0 111.561 -179.497 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 7' ' ' LEU . . . . . . . . . . . . . 4.0 mm? -58.22 -53.4 58.73 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.332 -0.395 . . . . 0.0 111.216 -179.877 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 8' ' ' PHE . . . . . 0.479 ' HB2' ' HB2' ' A' ' 55' ' ' ALA . 74.2 m-85 -61.47 -35.21 77.0 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.826 179.998 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 9' ' ' TRP . . . . . . . . . . . . . 55.2 m95 -64.74 -41.26 96.07 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 115.991 -0.55 . . . . 0.0 110.227 179.916 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 44.9 mt -62.37 -46.46 88.54 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 115.817 -0.629 . . . . 0.0 110.461 179.53 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . 0.419 ' O ' ' HG2' ' A' ' 15' ' ' MET . . . -61.99 -32.57 82.62 Favored Glycine 0 N--CA 1.45 -0.425 0 C-N-CA 120.703 -0.761 . . . . 0.0 111.817 179.369 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -67.56 -34.26 76.7 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-O 120.83 0.348 . . . . 0.0 110.707 179.852 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 65.6 mt -65.97 -46.94 86.9 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.238 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.144 179.396 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -59.83 -33.48 78.43 Favored Glycine 0 N--CA 1.45 -0.388 0 C-N-CA 120.726 -0.75 . . . . 0.0 111.712 179.208 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 15' ' ' MET . . . . . 0.545 ' HE3' ' CB ' ' A' ' 47' ' ' ALA . 24.1 mmt -70.33 -40.56 74.08 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 120.861 0.362 . . . . 0.0 110.507 179.425 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 27.9 tp -57.66 -39.31 76.77 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.047 -0.524 . . . . 0.0 110.562 179.792 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 56.1 t -67.28 -48.0 79.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.062 -0.517 . . . . 0.0 110.89 179.973 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -62.57 -49.33 74.45 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.705 -0.759 . . . . 0.0 111.86 179.507 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 38.2 m -49.65 -44.49 47.7 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-O 120.721 0.296 . . . . 0.0 111.279 -179.828 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 79.6 mt -72.14 -44.32 63.31 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.244 -0.434 . . . . 0.0 111.664 179.819 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -60.93 -29.93 69.91 Favored 'General case' 0 C--N 1.329 -0.299 0 N-CA-C 112.18 0.437 . . . . 0.0 112.18 -179.14 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 22' ' ' PHE . . . . . 0.644 ' HB2' HG22 ' A' ' 41' ' ' VAL . 8.7 m-85 -90.61 -34.57 15.42 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.757 0.313 . . . . 0.0 111.411 -179.31 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -67.58 -50.61 57.55 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 121.038 0.447 . . . . 0.0 111.319 -179.764 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 24' ' ' TRP . . . . . . . . . . . . . 4.7 t-105 -62.18 -37.16 84.19 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-N 115.698 -0.683 . . . . 0.0 111.187 -179.899 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -80.4 -21.23 42.46 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.853 0.359 . . . . 0.0 111.118 -179.994 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -73.56 -39.78 48.72 Favored Glycine 0 CA--C 1.519 0.295 0 C-N-CA 121.021 -0.609 . . . . 0.0 112.778 179.972 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 14.4 ptp180 -71.5 -4.21 25.46 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-O 120.715 0.293 . . . . 0.0 111.249 -179.665 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 23.6 t70 -134.91 87.06 2.31 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.316 -0.402 . . . . 0.0 110.658 179.871 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -165.95 -79.54 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.066 -0.515 . . . . 0.0 111.281 -179.908 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -169.04 -146.61 5.08 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.697 -179.853 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 57.8 m -117.06 -53.2 2.49 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.801 0.334 . . . . 0.0 111.125 -179.948 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -65.47 -27.69 72.79 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.811 -0.709 . . . . 0.0 112.87 -179.861 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 13.7 mm-40 -86.69 -21.47 26.65 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.663 0.268 . . . . 0.0 111.106 -179.654 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 34' ' ' ARG . . . . . . . . . . . . . 37.2 ttm180 -54.54 -29.63 51.5 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.31 -0.405 . . . . 0.0 111.416 -179.401 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 55.0 ttp180 -59.17 -40.87 86.96 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.852 0.358 . . . . 0.0 110.828 -179.899 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 63.7 m-85 -72.74 -31.21 64.78 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.123 -0.489 . . . . 0.0 110.997 -179.971 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 37' ' ' TYR . . . . . 0.467 ' O ' HG23 ' A' ' 41' ' ' VAL . 65.9 m-85 -70.34 -54.85 10.84 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.197 -179.876 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 78.4 t -57.14 -38.99 63.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-O 120.873 0.368 . . . . 0.0 110.573 179.776 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 19.1 m -63.19 -50.48 70.14 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 115.929 -0.578 . . . . 0.0 110.79 179.405 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 40' ' ' LEU . . . . . 0.691 HD12 HD11 ' A' ' 43' ' ' ILE . 41.4 tp -56.99 -45.77 82.74 Favored 'General case' 0 C--O 1.235 0.323 0 CA-C-N 115.693 -0.685 . . . . 0.0 110.739 179.937 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . 0.644 HG22 ' HB2' ' A' ' 22' ' ' PHE . 94.3 t -62.16 -33.56 59.24 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.497 0 CA-C-N 116.103 -0.498 . . . . 0.0 109.698 179.001 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -58.17 -48.78 81.11 Favored Glycine 0 N--CA 1.45 -0.378 0 CA-C-N 115.49 -0.777 . . . . 0.0 113.135 179.888 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 43' ' ' ILE . . . . . 0.691 HD11 HD12 ' A' ' 40' ' ' LEU . 17.0 pt -64.72 -47.02 90.45 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.215 0 CA-C-N 117.213 0.506 . . . . 0.0 111.599 -179.61 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 67.9 m -61.92 -27.88 69.13 Favored 'General case' 0 C--O 1.232 0.149 0 CA-C-O 120.907 0.384 . . . . 0.0 110.945 179.496 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -79.45 -52.86 4.6 Favored Glycine 0 CA--C 1.517 0.212 0 CA-C-N 115.934 -0.575 . . . . 0.0 113.423 -179.119 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 46' ' ' ILE . . . . . 0.504 HG13 HG22 ' A' ' 79' ' ' THR . 7.2 pt -57.81 -40.22 74.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-O 121.001 0.429 . . . . 0.0 111.002 -179.613 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 47' ' ' ALA . . . . . 0.596 ' HB2' ' HE2' ' A' ' 205' ' ' LYS . . . -68.31 -42.82 78.83 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.21 179.195 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 48' ' ' ALA . . . . . 0.453 ' HB2' ' HB3' ' A' ' 15' ' ' MET . . . -54.24 -43.18 70.69 Favored 'General case' 0 C--O 1.232 0.16 0 CA-C-N 116.326 -0.397 . . . . 0.0 111.763 -179.339 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 49' ' ' VAL . . . . . 0.443 HG22 ' O ' ' A' ' 46' ' ' ILE . 32.5 m -73.28 -34.22 43.38 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 116.492 -0.322 . . . . 0.0 111.445 -179.572 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -64.07 -37.79 88.73 Favored 'General case' 0 C--N 1.332 -0.174 0 CA-C-O 120.897 0.379 . . . . 0.0 111.217 179.827 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 35.6 m-85 -72.18 -39.27 68.77 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 115.996 -0.547 . . . . 0.0 110.704 -179.623 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -62.82 -50.52 70.63 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 115.944 -0.571 . . . . 0.0 111.301 179.739 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 53' ' ' VAL . . . . . 0.428 HG23 ' N ' ' A' ' 54' ' ' MET . 18.5 m -65.6 -43.06 94.13 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.189 0 CA-C-N 116.365 -0.379 . . . . 0.0 111.281 -179.666 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 54' ' ' MET . . . . . 0.507 ' HG3' ' HE1' ' A' ' 60' ' ' TRP . 10.9 ttp -68.55 -29.98 68.66 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.886 0.374 . . . . 0.0 110.306 179.897 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 55' ' ' ALA . . . . . 0.479 ' HB2' ' HB2' ' A' ' 8' ' ' PHE . . . -64.67 -36.86 85.65 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 115.939 -0.573 . . . . 0.0 110.939 179.328 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 86.7 mt -74.45 -1.0 19.23 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.061 -0.518 . . . . 0.0 111.245 -179.681 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 92.78 4.31 65.48 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.668 -0.777 . . . . 0.0 112.448 179.987 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 46.8 t -74.08 144.63 12.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-O 120.819 0.342 . . . . 0.0 111.187 -179.915 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 59' ' ' GLY . . . . . 0.43 ' HA3' ' HD3' ' A' ' 71' ' ' PRO . . . 76.7 5.86 84.09 Favored Glycine 0 CA--C 1.519 0.335 0 C-N-CA 120.946 -0.645 . . . . 0.0 112.815 -179.975 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 60' ' ' TRP . . . . . 0.507 ' HE1' ' HG3' ' A' ' 54' ' ' MET . 24.7 m0 -81.8 118.06 22.58 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.684 0.278 . . . . 0.0 111.076 -179.908 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 7.3 p -115.49 126.33 27.87 Favored Pre-proline 0 CA--C 1.533 0.313 0 CA-C-N 116.491 -0.322 . . . . 0.0 111.307 179.757 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 9.2 Cg_exo -72.13 142.69 38.52 Favored 'Trans proline' 0 C--N 1.349 0.603 0 C-N-CA 122.705 2.27 . . . . 0.0 112.081 179.739 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 98.1 t -142.36 94.33 0.57 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.064 179.968 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . 58.58 -90.14 0.03 OUTLIER 'General case' 0 C--N 1.332 -0.182 0 CA-C-N 115.973 -0.558 . . . . 0.0 111.622 179.857 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 18.5 mm-40 -117.36 -21.53 8.65 Favored 'General case' 0 C--N 1.332 -0.161 0 CA-C-N 116.39 -0.368 . . . . 0.0 111.048 -179.694 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 66' ' ' ARG . . . . . . . . . . . . . 30.7 ptt180 -107.17 158.64 16.94 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.174 -0.467 . . . . 0.0 110.629 179.911 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 60.5 m -117.76 115.24 24.62 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.386 -0.37 . . . . 0.0 111.651 -179.514 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 21.0 t -87.47 146.79 5.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 115.92 -0.582 . . . . 0.0 110.415 179.436 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 69' ' ' PHE . . . . . . . . . . . . . 26.6 m-85 -108.03 114.19 27.92 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-O 120.903 0.382 . . . . 0.0 110.096 -179.557 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 70' ' ' VAL . . . . . 0.595 ' N ' ' HD2' ' A' ' 71' ' ' PRO . 12.4 t -67.7 -48.98 41.19 Favored Pre-proline 0 C--N 1.324 -0.524 0 CA-C-N 115.921 -0.582 . . . . 0.0 112.117 -178.982 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 71' ' ' PRO . . . . . 0.595 ' HD2' ' N ' ' A' ' 70' ' ' VAL . 30.0 Cg_endo -62.64 -17.67 59.88 Favored 'Trans proline' 0 C--N 1.351 0.677 0 C-N-CA 122.166 1.91 . . . . 0.0 112.508 -179.64 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 34.2 ttp180 -69.75 -55.4 9.99 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.431 -0.349 . . . . 0.0 111.53 -179.455 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 73' ' ' TYR . . . . . 0.496 ' O ' HG13 ' A' ' 77' ' ' ILE . 74.0 m-85 -70.99 -36.39 72.47 Favored 'General case' 0 C--N 1.33 -0.264 0 C-N-CA 120.854 -0.338 . . . . 0.0 110.602 -179.577 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 74' ' ' ILE . . . . . 0.518 HG22 ' HA ' ' A' ' 71' ' ' PRO . 0.3 OUTLIER -64.78 -41.43 92.17 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.199 0 N-CA-C 109.935 -0.394 . . . . 0.0 109.935 179.291 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 10.7 t70 -56.97 -38.1 72.51 Favored 'General case' 0 CA--C 1.518 -0.276 0 N-CA-C 109.007 -0.738 . . . . 0.0 109.007 178.531 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 76' ' ' TRP . . . . . 0.446 ' HA ' ' OG1' ' A' ' 79' ' ' THR . 44.6 m0 -66.88 -30.31 70.44 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 115.588 -0.733 . . . . 0.0 110.895 179.27 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 77' ' ' ILE . . . . . 0.531 ' O ' ' HG2' ' A' ' 81' ' ' PRO . 69.8 mt -67.13 -36.54 77.18 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.302 -0.408 . . . . 0.0 111.032 179.842 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 78' ' ' LEU . . . . . 0.524 HD12 HG23 ' A' ' 79' ' ' THR . 2.7 pp -91.59 -23.24 19.95 Favored 'General case' 0 C--N 1.326 -0.448 0 N-CA-C 112.76 0.652 . . . . 0.0 112.76 -179.871 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 79' ' ' THR . . . . . 0.524 HG23 HD12 ' A' ' 78' ' ' LEU . 40.9 p -88.05 -53.77 4.56 Favored 'General case' 0 N--CA 1.471 0.582 0 N-CA-C 113.49 0.922 . . . . 0.0 113.49 -179.011 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 80' ' ' THR . . . . . 0.628 ' HB ' ' HD3' ' A' ' 81' ' ' PRO . 18.2 m -53.69 -55.45 35.3 Favored Pre-proline 0 C--N 1.331 -0.21 0 N-CA-C 113.192 0.812 . . . . 0.0 113.192 -177.475 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 81' ' ' PRO . . . . . 0.628 ' HD3' ' HB ' ' A' ' 80' ' ' THR . 77.1 Cg_exo -53.45 -25.47 32.04 Favored 'Trans proline' 0 C--N 1.35 0.63 0 C-N-CA 121.567 1.511 . . . . 0.0 112.09 -179.842 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 82' ' ' LEU . . . . . 0.444 HD23 HG23 ' A' ' 43' ' ' ILE . 11.5 tp -76.69 -33.17 58.24 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.171 179.521 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 83' ' ' ILE . . . . . 0.45 HD13 HG21 ' A' ' 43' ' ' ILE . 36.6 mm -66.54 -53.37 36.32 Favored 'Isoleucine or valine' 0 C--O 1.234 0.255 0 CA-C-N 116.172 -0.467 . . . . 0.0 109.955 178.678 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 33.8 m -61.21 -30.05 47.06 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.217 0 CA-C-N 115.887 -0.597 . . . . 0.0 109.61 178.875 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 85' ' ' TYR . . . . . . . . . . . . . 85.4 t80 -67.92 -31.41 71.15 Favored 'General case' 0 N--CA 1.453 -0.285 0 CA-C-N 115.566 -0.743 . . . . 0.0 109.379 178.758 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 86' ' ' PHE . . . . . . . . . . . . . 7.6 t80 -62.51 -51.51 67.13 Favored 'General case' 0 N--CA 1.455 -0.211 0 CA-C-N 115.755 -0.657 . . . . 0.0 109.598 179.087 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 7.2 mt -61.91 -33.06 73.54 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 115.813 -0.631 . . . . 0.0 109.913 179.205 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -66.58 -27.66 73.31 Favored Glycine 0 N--CA 1.452 -0.293 0 CA-C-N 115.25 -0.886 . . . . 0.0 112.044 179.425 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 65.4 mt -74.18 -44.48 53.29 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-O 121.028 0.442 . . . . 0.0 110.749 179.826 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 78.4 mt -61.23 -31.85 71.63 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 115.823 -0.626 . . . . 0.0 111.151 -179.937 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . 0.406 ' HB2' ' HB2' ' A' ' 149' ' ' ALA . . . -88.36 -38.77 14.84 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.328 -0.396 . . . . 0.0 111.788 -179.433 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 85.09 70.62 1.33 Allowed Glycine 0 CA--C 1.517 0.187 0 C-N-CA 120.701 -0.761 . . . . 0.0 112.145 -179.316 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 20.0 mt -87.58 169.11 12.45 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.906 0.384 . . . . 0.0 111.371 -179.447 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 94' ' ' ASP . . . . . 0.456 ' HB3' ' HG3' ' A' ' 97' ' ' GLU . 18.6 t70 -79.77 161.56 25.64 Favored 'General case' 0 C--N 1.332 -0.168 0 CA-C-N 116.027 -0.533 . . . . 0.0 110.599 179.661 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 71.0 m -55.91 -44.79 78.61 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.418 -0.356 . . . . 0.0 111.126 -179.972 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 10.2 mpt_? -68.78 -48.02 64.72 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.169 -179.804 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 97' ' ' GLU . . . . . 0.521 ' HA ' HD12 ' A' ' 100' ' ' ILE . 47.3 mt-10 -53.95 -38.7 65.23 Favored 'General case' 0 C--O 1.234 0.238 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.839 -179.931 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 98' ' ' PHE . . . . . 0.491 ' O ' HG12 ' A' ' 102' ' ' ILE . 5.6 m-85 -60.08 -49.96 75.58 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.392 179.4 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -59.26 -26.16 61.15 Favored Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.705 -0.759 . . . . 0.0 112.515 179.97 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 100' ' ' ILE . . . . . 0.521 HD12 ' HA ' ' A' ' 97' ' ' GLU . 97.7 mt -68.85 -50.61 52.98 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.194 0 CA-C-O 120.803 0.335 . . . . 0.0 111.527 -179.921 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 101' ' ' VAL . . . . . 0.43 HG11 ' HE1' ' A' ' 145' ' ' MET . 29.6 m -70.59 -36.24 64.83 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.369 0 CA-C-N 116.437 -0.347 . . . . 0.0 111.748 -179.567 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 102' ' ' ILE . . . . . 0.621 HG23 ' HB3' ' A' ' 81' ' ' PRO . 49.5 mm -67.0 -46.72 84.11 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.626 -0.261 . . . . 0.0 111.35 -179.707 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 15.3 t -63.51 -35.32 80.09 Favored 'General case' 0 C--O 1.233 0.201 0 CA-C-O 120.75 0.309 . . . . 0.0 110.954 179.925 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 104' ' ' LEU . . . . . 0.428 ' O ' HG23 ' A' ' 108' ' ' VAL . 2.8 tm? -57.52 -53.75 54.62 Favored 'General case' 0 C--N 1.331 -0.199 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.259 179.54 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 105' ' ' ASN . . . . . 0.644 HD21 HD13 ' A' ' 137' ' ' LEU . 0.8 OUTLIER -55.71 -37.93 69.06 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.498 179.527 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 44.0 m -55.19 -41.72 72.31 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-O 120.886 0.374 . . . . 0.0 110.467 179.576 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 107' ' ' VAL . . . . . 0.425 HG23 ' H ' ' A' ' 107' ' ' VAL . 2.1 t -64.5 -37.59 80.41 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.198 0 CA-C-O 121.38 0.61 . . . . 0.0 109.867 178.99 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . 0.428 HG23 ' O ' ' A' ' 104' ' ' LEU . 26.1 t -61.49 -50.16 81.48 Favored 'Isoleucine or valine' 0 C--O 1.236 0.361 0 CA-C-N 115.089 -0.959 . . . . 0.0 111.502 -179.91 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 109' ' ' MET . . . . . 0.517 ' HE1' HG21 ' A' ' 80' ' ' THR . 9.1 mmt -63.02 -37.14 85.99 Favored 'General case' 0 C--N 1.331 -0.2 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.872 -179.838 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 31.8 tp -62.04 -33.84 75.13 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.54 179.776 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -64.75 -52.06 58.98 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 115.988 -0.551 . . . . 0.0 110.711 179.473 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . -62.23 -39.13 97.29 Favored Glycine 0 C--N 1.331 0.252 0 C-N-CA 120.484 -0.865 . . . . 0.0 112.137 179.5 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 113' ' ' PHE . . . . . . . . . . . . . 0.5 OUTLIER -52.86 -72.69 0.05 Allowed 'General case' 0 C--N 1.33 -0.255 0 CA-C-O 121.052 0.453 . . . . 0.0 110.454 179.825 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 114' ' ' ALA . . . . . 0.456 ' HB3' HD22 ' A' ' 126' ' ' LEU . . . -65.46 -12.66 54.66 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 115.708 -0.678 . . . . 0.0 111.385 -179.899 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -66.31 -43.58 92.51 Favored Glycine 0 C--N 1.33 0.238 0 C-N-CA 120.804 -0.712 . . . . 0.0 112.69 -179.959 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -78.06 -25.73 47.89 Favored 'General case' 0 C--N 1.329 -0.29 0 N-CA-C 112.154 0.427 . . . . 0.0 112.154 -179.721 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 117' ' ' MET . . . . . . . . . . . . . 67.5 mtt -91.81 19.42 6.55 Favored 'General case' 0 C--N 1.329 -0.292 0 N-CA-C 111.868 0.321 . . . . 0.0 111.868 -179.164 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 118' ' ' VAL . . . . . 0.553 HG21 ' HB3' ' A' ' 123' ' ' ARG . 17.5 m -68.33 138.88 91.85 Favored Pre-proline 0 C--N 1.329 -0.324 0 CA-C-O 120.54 0.21 . . . . 0.0 111.169 179.862 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 119' ' ' PRO . . . . . . . . . . . . . 95.1 Cg_endo -86.6 11.56 3.25 Favored 'Trans proline' 0 C--N 1.348 0.55 0 C-N-CA 122.554 2.17 . . . . 0.0 112.339 179.922 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -164.6 -120.7 0.53 Allowed Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.86 -0.686 . . . . 0.0 112.616 -179.811 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 42.3 pt -113.89 14.04 8.22 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.219 0 CA-C-O 120.812 0.339 . . . . 0.0 111.319 -179.861 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 49.0 mt-10 -61.38 -17.53 54.49 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.081 -0.509 . . . . 0.0 111.082 179.808 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 123' ' ' ARG . . . . . 0.553 ' HB3' HG21 ' A' ' 118' ' ' VAL . 14.7 ptt180 -50.44 -29.33 10.03 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.003 -0.544 . . . . 0.0 111.769 -179.821 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 124' ' ' TYR . . . . . . . . . . . . . 33.2 m-85 -74.79 -31.93 61.87 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.46 -0.336 . . . . 0.0 111.302 -179.461 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 125' ' ' ALA . . . . . . . . . . . . . . . -73.0 -56.47 5.08 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-N 116.296 -0.411 . . . . 0.0 111.045 -179.776 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 126' ' ' LEU . . . . . 0.456 HD22 ' HB3' ' A' ' 114' ' ' ALA . 1.3 mt -54.62 -46.52 73.89 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 115.968 -0.56 . . . . 0.0 110.676 179.826 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 127' ' ' PHE . . . . . . . . . . . . . 4.9 t80 -68.22 -37.37 80.76 Favored 'General case' 0 N--CA 1.453 -0.319 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.648 179.766 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 128' ' ' GLY . . . . . . . . . . . . . . . -46.38 -44.15 15.35 Favored Glycine 0 C--N 1.333 0.387 0 C-N-CA 120.14 -1.029 . . . . 0.0 110.607 178.941 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 129' ' ' MET . . . . . 0.47 ' HE3' ' N ' ' A' ' 130' ' ' GLY . 6.0 tmm? -69.52 -41.54 75.86 Favored 'General case' 0 C--N 1.328 -0.357 0 N-CA-C 109.357 -0.608 . . . . 0.0 109.357 178.266 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 130' ' ' GLY . . . . . 0.47 ' N ' ' HE3' ' A' ' 129' ' ' MET . . . -55.49 -39.49 74.2 Favored Glycine 0 N--CA 1.452 -0.278 0 CA-C-N 115.724 -0.671 . . . . 0.0 113.044 -179.711 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -70.03 -53.12 19.03 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.699 0.285 . . . . 0.0 110.609 179.955 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 53.0 t -54.93 -39.93 51.08 Favored 'Isoleucine or valine' 0 C--O 1.233 0.215 0 CA-C-O 121.307 0.575 . . . . 0.0 109.607 178.88 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -69.25 -35.99 76.69 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 115.381 -0.827 . . . . 0.0 110.279 179.391 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 134' ' ' PHE . . . . . 0.489 ' HB2' H182 ' A' ' 301' ' ' RET . 47.6 t80 -58.48 -52.95 63.48 Favored 'General case' 0 N--CA 1.45 -0.43 0 CA-C-N 115.932 -0.577 . . . . 0.0 109.817 179.281 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 135' ' ' ILE . . . . . 0.497 ' O ' HG22 ' A' ' 138' ' ' VAL . 45.2 mt -58.34 -30.52 40.55 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.282 0 CA-C-N 115.699 -0.682 . . . . 0.0 109.741 178.892 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 136' ' ' GLY . . . . . 0.43 ' O ' ' HB3' ' A' ' 139' ' ' TYR . . . -59.47 -42.69 97.71 Favored Glycine 0 N--CA 1.447 -0.574 0 C-N-CA 120.42 -0.895 . . . . 0.0 111.364 178.867 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 137' ' ' LEU . . . . . 0.644 HD13 HD21 ' A' ' 105' ' ' ASN . 53.8 tp -67.24 -54.62 19.29 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.565 0.222 . . . . 0.0 110.666 179.316 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 138' ' ' VAL . . . . . 0.497 HG22 ' O ' ' A' ' 135' ' ' ILE . 3.0 m -54.71 -30.4 22.38 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.134 0 CA-C-O 121.08 0.466 . . . . 0.0 109.805 -179.672 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 139' ' ' TYR . . . . . 0.43 ' HB3' ' O ' ' A' ' 136' ' ' GLY . 20.8 t80 -61.68 -48.14 82.16 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 115.526 -0.761 . . . . 0.0 110.076 178.227 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 37.5 m-85 -63.27 -40.32 97.06 Favored 'General case' 0 C--O 1.232 0.156 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.971 179.537 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 141' ' ' LEU . . . . . 0.454 HD13 ' O ' ' A' ' 137' ' ' LEU . 11.1 mp -54.63 -55.06 33.48 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.09 -179.824 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 10.7 p -76.95 -15.93 14.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-O 121.024 0.44 . . . . 0.0 110.985 179.911 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . -73.55 -133.34 0.22 Allowed Glycine 0 CA--C 1.522 0.528 0 C-N-CA 120.867 -0.683 . . . . 0.0 112.812 -179.883 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 144' ' ' PRO . . . . . . . . . . . . . 52.2 Cg_exo -55.5 -28.56 64.98 Favored 'Trans proline' 0 C--N 1.349 0.579 0 C-N-CA 122.746 2.297 . . . . 0.0 112.885 -179.653 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 145' ' ' MET . . . . . 0.43 ' HE1' HG11 ' A' ' 101' ' ' VAL . 43.2 mtt -56.67 -36.31 69.43 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.382 -0.372 . . . . 0.0 111.352 -179.875 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 146' ' ' THR . . . . . . . . . . . . . 24.7 m -68.09 -48.0 66.71 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.836 -179.303 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 20.0 mm-40 -71.16 -26.31 62.93 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.557 -0.292 . . . . 0.0 111.369 -179.544 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 148' ' ' SER . . . . . . . . . . . . . 47.7 t -70.71 -49.47 46.66 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.312 -0.403 . . . . 0.0 111.312 -179.557 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 149' ' ' ALA . . . . . 0.406 ' HB2' ' HB2' ' A' ' 91' ' ' ALA . . . -75.1 -33.87 61.67 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.074 -0.512 . . . . 0.0 111.678 -179.416 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 150' ' ' SER . . . . . . . . . . . . . 43.5 t -67.24 -12.74 60.88 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.328 -179.636 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 151' ' ' GLN . . . . . . . . . . . . . 77.7 mt-30 -119.03 12.1 12.65 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.486 -0.325 . . . . 0.0 111.42 -179.756 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 31.4 tpt180 -84.56 -51.36 6.94 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 120.81 0.338 . . . . 0.0 110.865 -179.759 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 153' ' ' SER . . . . . 0.677 ' HB3' HG12 ' A' ' 156' ' ' ILE . 18.3 t -157.69 172.46 18.48 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 116.119 -0.492 . . . . 0.0 110.715 179.41 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 154' ' ' SER . . . . . . . . . . . . . 47.0 t -68.86 -41.05 78.93 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.303 -0.408 . . . . 0.0 110.802 179.787 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -76.69 -35.79 39.49 Favored Glycine 0 N--CA 1.452 -0.259 0 C-N-CA 120.98 -0.629 . . . . 0.0 112.974 -179.909 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 156' ' ' ILE . . . . . 0.677 HG12 ' HB3' ' A' ' 153' ' ' SER . 43.1 mm -55.34 -36.82 41.99 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.237 0 CA-C-O 120.714 0.292 . . . . 0.0 111.518 -179.769 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 157' ' ' LYS . . . . . 0.421 ' HB3' ' NZ ' ' A' ' 157' ' ' LYS . 6.5 ttpm? -59.51 -53.75 54.53 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 116.415 -0.357 . . . . 0.0 111.759 -179.45 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 42.8 t -67.37 -41.01 85.75 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.445 -0.343 . . . . 0.0 111.714 -179.198 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 159' ' ' LEU . . . . . 0.505 HD23 HD13 ' A' ' 163' ' ' LEU . 4.1 tt -67.72 -34.55 77.08 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 116.432 -0.349 . . . . 0.0 111.045 -179.554 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 160' ' ' TYR . . . . . . . . . . . . . 67.6 t80 -73.88 -45.81 48.6 Favored 'General case' 0 C--N 1.33 -0.278 0 N-CA-C 112.026 0.38 . . . . 0.0 112.026 -179.165 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 22.7 m -59.82 -43.55 92.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 N-CA-C 111.673 0.249 . . . . 0.0 111.673 -179.252 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 162' ' ' ARG . . . . . 0.514 HH22 ' HB2' ' A' ' 215' ' ' ALA . 86.8 mtm180 -68.99 -38.02 79.06 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.77 0.319 . . . . 0.0 111.218 -179.977 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 163' ' ' LEU . . . . . 0.558 ' HG ' ' HB2' ' A' ' 208' ' ' PHE . 3.4 mp -69.5 -54.17 15.51 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.643 -179.58 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 164' ' ' ARG . . . . . . . . . . . . . 4.7 tmm_? -58.71 -53.54 57.2 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.545 -179.236 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 165' ' ' ASN . . . . . 0.507 ' O ' HG23 ' A' ' 169' ' ' VAL . 0.9 OUTLIER -53.59 -52.12 60.81 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 120.876 0.37 . . . . 0.0 111.659 -179.273 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 166' ' ' LEU . . . . . 0.496 ' O ' ' HG ' ' A' ' 170' ' ' LEU . 2.1 tt -61.09 -53.33 58.46 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.065 -0.516 . . . . 0.0 111.771 -179.129 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 167' ' ' THR . . . . . 0.494 ' O ' ' HB2' ' A' ' 171' ' ' TRP . 86.0 m -55.47 -53.7 53.02 Favored 'General case' 0 C--N 1.327 -0.395 0 N-CA-C 112.8 0.667 . . . . 0.0 112.8 -178.661 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 168' ' ' VAL . . . . . . . . . . . . . 89.7 t -54.64 -44.61 70.4 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.244 0 N-CA-C 112.371 0.508 . . . . 0.0 112.371 -178.563 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 169' ' ' VAL . . . . . 0.507 HG23 ' O ' ' A' ' 165' ' ' ASN . 75.4 t -58.43 -64.79 0.5 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.421 0 N-CA-C 112.149 0.426 . . . . 0.0 112.149 -178.962 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 170' ' ' LEU . . . . . 0.496 ' HG ' ' O ' ' A' ' 166' ' ' LEU . 1.4 pp -62.3 -29.75 70.65 Favored 'General case' 0 C--N 1.33 -0.255 0 N-CA-C 112.011 0.374 . . . . 0.0 112.011 -178.863 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 171' ' ' TRP . . . . . 0.616 ' HE1' H203 ' A' ' 301' ' ' RET . 2.2 m0 -71.88 -31.2 66.21 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.861 0.362 . . . . 0.0 110.939 179.827 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 172' ' ' ALA . . . . . . . . . . . . . . . -72.18 -6.1 40.36 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.667 179.962 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 173' ' ' ILE . . . . . 0.554 HG22 HD11 ' A' ' 177' ' ' ILE . 29.0 mm -85.24 -21.28 7.91 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.188 0 CA-C-N 115.764 -0.653 . . . . 0.0 111.141 179.79 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 174' ' ' TYR . . . . . 0.445 ' HB2' ' HD3' ' A' ' 175' ' ' PRO . 28.0 m-85 -54.44 -50.47 84.98 Favored Pre-proline 0 N--CA 1.466 0.326 0 CA-C-N 116.437 -0.347 . . . . 0.0 111.673 -179.836 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 175' ' ' PRO . . . . . 0.445 ' HD3' ' HB2' ' A' ' 174' ' ' TYR . 86.7 Cg_exo -45.87 -29.9 6.32 Favored 'Trans proline' 0 C--N 1.353 0.777 0 C-N-CA 122.233 1.955 . . . . 0.0 112.358 179.844 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 176' ' ' PHE . . . . . 0.443 ' O ' ' HG ' ' A' ' 180' ' ' LEU . 92.1 m-85 -80.15 -49.3 11.88 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 115.976 -0.556 . . . . 0.0 111.699 -179.822 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 177' ' ' ILE . . . . . 0.554 HD11 HG22 ' A' ' 173' ' ' ILE . 2.9 mm -60.3 -38.0 75.93 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.528 0 CA-C-N 116.024 -0.535 . . . . 0.0 112.008 -178.459 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 178' ' ' TRP . . . . . 0.409 ' HH2' ' HB2' ' A' ' 123' ' ' ARG . 70.4 t90 -73.32 -44.9 58.13 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.864 0.364 . . . . 0.0 110.922 179.748 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 179' ' ' LEU . . . . . 0.431 ' O ' HG22 ' A' ' 185' ' ' VAL . 1.5 tm? -65.46 -54.22 31.55 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 115.998 -0.546 . . . . 0.0 111.246 -179.323 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 180' ' ' LEU . . . . . 0.5 HD22 ' CD1' ' A' ' 187' ' ' LEU . 18.8 mt -72.46 -45.39 59.73 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.542 -0.299 . . . . 0.0 111.631 -179.267 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 181' ' ' GLY . . . . . 0.405 ' HA3' ' OD1' ' A' ' 193' ' ' ASP . . . -55.35 175.69 0.71 Allowed Glycine 0 C--N 1.336 0.537 0 C-N-CA 120.487 -0.863 . . . . 0.0 112.896 179.646 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 182' ' ' PRO . . . . . 0.654 ' HA ' ' HB2' ' A' ' 186' ' ' ALA . 72.2 Cg_exo -48.07 -45.34 25.64 Favored 'Trans proline' 0 CA--C 1.536 0.596 0 C-N-CA 122.983 2.455 . . . . 0.0 113.86 -179.994 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 183' ' ' PRO . . . . . 0.424 ' HD3' ' HB2' ' A' ' 182' ' ' PRO . 52.2 Cg_exo -53.96 -13.34 4.39 Favored 'Trans proline' 0 C--N 1.355 0.92 0 C-N-CA 122.056 1.837 . . . . 0.0 112.916 -179.853 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 184' ' ' GLY . . . . . 0.423 ' HA3' ' O ' ' A' ' 179' ' ' LEU . . . -115.93 -86.34 1.28 Allowed Glycine 0 N--CA 1.45 -0.414 0 C-N-CA 120.377 -0.916 . . . . 0.0 112.871 -179.779 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 185' ' ' VAL . . . . . 0.431 HG22 ' O ' ' A' ' 179' ' ' LEU . 6.6 m -124.59 -5.06 6.48 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 N-CA-C 112.169 0.433 . . . . 0.0 112.169 -179.495 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 186' ' ' ALA . . . . . 0.654 ' HB2' ' HA ' ' A' ' 182' ' ' PRO . . . 53.41 86.59 0.04 OUTLIER 'General case' 0 N--CA 1.463 0.224 0 CA-C-N 116.479 -0.328 . . . . 0.0 111.682 179.606 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 187' ' ' LEU . . . . . 0.5 ' CD1' HD22 ' A' ' 180' ' ' LEU . 14.1 mt -92.15 -49.36 6.23 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.396 -0.366 . . . . 0.0 111.452 179.851 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 188' ' ' LEU . . . . . 0.468 ' N ' HD12 ' A' ' 188' ' ' LEU . 6.9 mp -92.93 -88.97 0.21 Allowed 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.361 -0.381 . . . . 0.0 111.272 -179.256 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 189' ' ' THR . . . . . . . . . . . . . 1.8 t -169.82 148.7 3.28 Favored Pre-proline 0 C--N 1.325 -0.483 0 CA-C-N 116.01 -0.541 . . . . 0.0 111.078 -179.55 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 190' ' ' PRO . . . . . 0.417 ' O ' HG23 ' A' ' 194' ' ' VAL . 10.2 Cg_endo -51.99 -42.86 56.17 Favored 'Trans proline' 0 C--N 1.35 0.649 0 C-N-CA 122.798 2.332 . . . . 0.0 113.152 -179.761 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 191' ' ' THR . . . . . . . . . . . . . 5.4 t -56.4 -44.74 80.57 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-O 120.689 0.281 . . . . 0.0 111.336 -179.59 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 192' ' ' VAL . . . . . . . . . . . . . 38.5 t -70.56 -43.62 77.62 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.389 -0.369 . . . . 0.0 111.088 179.846 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 193' ' ' ASP . . . . . 0.405 ' OD1' ' HA3' ' A' ' 181' ' ' GLY . 11.3 t70 -55.62 -49.16 73.56 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.942 179.867 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 194' ' ' VAL . . . . . 0.417 HG23 ' O ' ' A' ' 190' ' ' PRO . 85.9 t -63.03 -36.98 78.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.05 -179.985 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 195' ' ' ALA . . . . . . . . . . . . . . . -59.24 -48.41 81.74 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.491 -0.322 . . . . 0.0 110.979 179.827 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 196' ' ' LEU . . . . . . . . . . . . . 65.0 mt -67.91 -43.61 78.84 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.307 -0.406 . . . . 0.0 110.641 179.761 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 197' ' ' ILE . . . . . 0.415 HG12 HG21 ' A' ' 177' ' ' ILE . 17.6 mm -56.51 -59.78 2.59 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 115.961 -0.563 . . . . 0.0 110.444 179.435 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 198' ' ' VAL . . . . . . . . . . . . . 76.8 t -53.06 -34.69 21.5 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.496 0 CA-C-N 115.601 -0.727 . . . . 0.0 109.467 178.512 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 199' ' ' TYR . . . . . . . . . . . . . 64.9 t80 -70.24 -31.61 69.09 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 115.524 -0.762 . . . . 0.0 110.588 179.692 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 200' ' ' LEU . . . . . 0.537 ' O ' HG12 ' A' ' 203' ' ' VAL . 32.2 mt -73.23 -43.44 61.21 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 115.841 -0.618 . . . . 0.0 111.484 -179.478 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 201' ' ' ASP . . . . . . . . . . . . . 10.5 m-20 -71.94 -36.81 70.02 Favored 'General case' 0 C--N 1.327 -0.413 0 CA-C-O 121.251 0.548 . . . . 0.0 110.087 179.511 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 202' ' ' LEU . . . . . . . . . . . . . 39.5 tp -72.73 -27.78 62.25 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 115.311 -0.859 . . . . 0.0 111.779 -179.293 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 203' ' ' VAL . . . . . 0.537 HG12 ' O ' ' A' ' 200' ' ' LEU . 12.3 p -78.71 -35.94 18.96 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.215 0 C-N-CA 120.854 -0.338 . . . . 0.0 110.779 -179.087 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 204' ' ' THR . . . . . 0.418 ' HG1' ' HE1' ' A' ' 171' ' ' TRP . 97.2 m -66.48 -59.0 4.05 Favored 'General case' 0 C--N 1.329 -0.304 0 C-N-CA 120.598 -0.441 . . . . 0.0 110.861 179.34 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 205' ' ' LYS . . . . . 0.596 ' HE2' ' HB2' ' A' ' 47' ' ' ALA . 62.7 mttp -58.76 -57.78 11.5 Favored 'General case' 0 C--N 1.331 -0.209 0 N-CA-C 112.14 0.422 . . . . 0.0 112.14 -178.675 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 49.8 t -70.55 -37.35 69.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 N-CA-C 112.324 0.49 . . . . 0.0 112.324 -178.823 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 207' ' ' GLY . . . . . 0.553 ' O ' HG13 ' A' ' 211' ' ' ILE . . . -55.76 -62.07 6.72 Favored Glycine 0 CA--C 1.518 0.242 0 C-N-CA 120.614 -0.803 . . . . 0.0 113.873 -178.608 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 208' ' ' PHE . . . . . 0.558 ' HB2' ' HG ' ' A' ' 163' ' ' LEU . 3.0 p90 -72.86 -27.63 62.03 Favored 'General case' 0 C--O 1.221 -0.416 0 CA-C-N 117.457 0.628 . . . . 0.0 110.925 -179.231 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 209' ' ' GLY . . . . . 0.555 ' O ' ' HB3' ' A' ' 212' ' ' ALA . . . -62.06 -34.78 90.12 Favored Glycine 0 N--CA 1.449 -0.447 0 N-CA-C 111.91 -0.476 . . . . 0.0 111.91 178.761 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 210' ' ' PHE . . . . . . . . . . . . . 1.2 m-85 -73.59 -48.23 34.35 Favored 'General case' 0 CA--C 1.513 -0.456 0 N-CA-C 108.153 -1.055 . . . . 0.0 108.153 178.398 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 211' ' ' ILE . . . . . 0.553 HG13 ' O ' ' A' ' 207' ' ' GLY . 4.8 mt -61.61 -27.48 42.17 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.51 0 N-CA-C 107.784 -1.191 . . . . 0.0 107.784 176.711 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 212' ' ' ALA . . . . . 0.555 ' HB3' ' O ' ' A' ' 209' ' ' GLY . . . -63.57 -41.75 98.37 Favored 'General case' 0 N--CA 1.45 -0.474 0 CA-C-N 114.478 -1.237 . . . . 0.0 110.664 -179.775 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 213' ' ' LEU . . . . . . . . . . . . . 95.3 mt -69.29 -53.04 21.75 Favored 'General case' 0 C--N 1.332 -0.162 0 CA-C-N 115.26 -0.882 . . . . 0.0 111.398 -179.68 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 214' ' ' ASP . . . . . . . . . . . . . 9.6 m-20 -55.7 -48.66 74.75 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-O 120.878 0.37 . . . . 0.0 110.746 -179.997 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 215' ' ' ALA . . . . . 0.514 ' HB2' HH22 ' A' ' 162' ' ' ARG . . . -59.44 -57.33 13.44 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 115.988 -0.551 . . . . 0.0 110.958 179.721 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 216' ' ' ALA . . . . . 0.415 ' HA ' HD12 ' A' ' 219' ' ' LEU . . . -56.36 -31.55 63.9 Favored 'General case' 0 C--N 1.332 -0.187 0 CA-C-N 116.06 -0.518 . . . . 0.0 111.065 -179.998 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 217' ' ' ALA . . . . . 0.559 ' HA ' ' HE ' ' A' ' 220' ' ' ARG . . . -62.68 -39.26 93.38 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.407 179.615 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 218' ' ' THR . . . . . . . . . . . . . 79.1 m -73.27 -37.58 66.23 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 115.81 -0.632 . . . . 0.0 111.044 179.682 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 219' ' ' LEU . . . . . 0.438 ' HG ' ' O ' ' A' ' 215' ' ' ALA . 56.0 mt -59.49 -46.88 87.55 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.873 -179.879 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 220' ' ' ARG . . . . . 0.559 ' HE ' ' HA ' ' A' ' 217' ' ' ALA . 26.5 ptt180 -77.18 -25.33 51.72 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.815 179.923 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 221' ' ' ALA . . . . . . . . . . . . . . . -59.98 -41.56 92.3 Favored 'General case' 0 C--N 1.331 -0.201 0 CA-C-N 116.061 -0.518 . . . . 0.0 111.172 -179.943 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 222' ' ' GLU . . . . . . . . . . . . . 10.2 pt-20 -86.24 -35.18 20.15 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.782 179.957 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 223' ' ' HIS . . . . . . . . . . . . . 33.6 p80 39.94 -156.63 0.01 OUTLIER 'General case' 0 N--CA 1.466 0.352 0 CA-C-N 115.755 -0.657 . . . . 0.0 111.981 -179.982 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 224' ' ' GLY . . . . . . . . . . . . . . . 158.62 134.95 1.79 Allowed Glycine 0 N--CA 1.452 -0.257 0 C-N-CA 120.886 -0.673 . . . . 0.0 112.441 -179.839 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 225' ' ' GLU . . . . . . . . . . . . . 35.6 tt0 58.89 98.66 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.256 0 CA-C-O 120.81 0.338 . . . . 0.0 110.978 -179.963 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 226' ' ' SER . . . . . . . . . . . . . 50.3 m -62.91 148.49 47.21 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.677 179.864 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 227' ' ' LEU . . . . . 0.409 HD22 ' N ' ' A' ' 227' ' ' LEU . 3.7 mm? -82.59 144.48 30.31 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.311 -0.404 . . . . 0.0 111.007 -179.831 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 228' ' ' ALA . . . . . . . . . . . . . . . -109.21 -7.69 15.24 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 115.949 -0.569 . . . . 0.0 111.021 179.875 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 229' ' ' GLY . . . . . . . . . . . . . . . 145.71 -170.22 27.02 Favored Glycine 0 C--N 1.331 0.277 0 C-N-CA 120.741 -0.742 . . . . 0.0 112.525 179.982 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 230' ' ' VAL . . . . . . . . . . . . . 19.7 t -84.26 146.02 7.35 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.242 0 CA-C-O 120.768 0.318 . . . . 0.0 110.807 179.998 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 231' ' ' ASP . . . . . . . . . . . . . 6.7 p-10 -67.6 116.86 8.8 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.825 -179.969 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 232' ' ' THR . . . . . . . . . . . . . 71.9 p -132.0 2.08 3.96 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.094 -0.503 . . . . 0.0 111.175 -179.904 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 233' ' ' ASP . . . . . . . . . . . . . 14.2 t70 -77.17 -24.45 51.47 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.961 179.956 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 234' ' ' THR . . . . . . . . . . . . . 48.0 m 57.05 87.05 0.15 Allowed Pre-proline 0 C--N 1.33 -0.247 0 CA-C-N 116.134 -0.484 . . . . 0.0 111.339 179.978 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 235' ' ' PRO . . . . . . . . . . . . . 43.3 Cg_exo -57.4 115.8 2.76 Favored 'Trans proline' 0 C--N 1.348 0.544 0 C-N-CA 122.44 2.093 . . . . 0.0 112.111 179.838 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 236' ' ' ALA . . . . . . . . . . . . . . . -146.94 124.39 11.66 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.13 -0.486 . . . . 0.0 111.251 -179.825 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 237' ' ' VAL . . . . . . . . . . . . . 51.5 t 62.25 108.13 0.04 OUTLIER 'Isoleucine or valine' 0 C--N 1.333 -0.147 0 CA-C-N 116.048 -0.524 . . . . 0.0 111.407 179.798 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 238' ' ' ALA . . . . . . . . . . . . . . . -160.13 -16.67 0.06 Allowed 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.019 -0.537 . . . . 0.0 110.972 179.869 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 239' ' ' ASP . . . . . . . . . . . . . 9.7 m-20 -144.36 -6.22 0.73 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.758 179.849 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 240' ' ' LEU . . . . . . . . . . . . . 49.5 tp -62.69 116.2 4.98 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.039 -0.528 . . . . 0.0 110.762 179.954 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 241' ' ' GLU . . . . . . . . . . . . . 38.6 tt0 -143.97 135.46 25.91 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.82 -179.94 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 242' ' ' HIS . . . . . . . . . . . . . 12.1 p80 -140.62 136.63 32.93 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.856 -179.857 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 243' ' ' HIS . . . . . . . . . . . . . 96.4 m-70 -87.83 159.08 18.55 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.125 -179.775 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 244' ' ' HIS . . . . . . . . . . . . . 36.9 m80 -105.06 158.9 16.25 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 115.989 -0.551 . . . . 0.0 110.833 179.783 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 245' ' ' HIS . . . . . . . . . . . . . 92.9 m-70 -85.16 107.73 17.37 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.803 179.98 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 246' ' ' HIS . . . . . . . . . . . . . 34.1 t-80 -76.43 -56.89 4.22 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.077 -0.511 . . . . 0.0 110.926 -179.842 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 247' ' ' HIS . . . . . . . . . . . . . 14.1 p-80 . . . . . 0 C--O 1.249 1.054 0 CA-C-O 118.098 -0.953 . . . . 0.0 111.099 179.949 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 301' ' ' RET . . . . . 0.616 H203 ' HE1' ' A' ' 171' ' ' TRP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 75.1 mmm . . . . . 0 N--CA 1.486 1.35 0 CA-C-O 120.767 0.318 . . . . 0.0 111.042 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 28.2 t 56.86 86.06 0.05 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.014 -0.539 . . . . 0.0 110.95 -179.81 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . 152.08 -34.59 0.85 Allowed Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.841 -0.695 . . . . 0.0 112.506 -179.87 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 50.6 tp -73.88 -36.13 64.77 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.786 0.327 . . . . 0.0 110.948 179.87 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 73.7 p -61.39 -29.71 70.09 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.115 -0.493 . . . . 0.0 111.19 179.946 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 23.1 p -53.46 -35.42 60.51 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.09 -0.504 . . . . 0.0 111.071 -179.904 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 7' ' ' LEU . . . . . . . . . . . . . 4.1 mm? -60.25 -53.44 57.65 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.034 -0.53 . . . . 0.0 111.101 179.991 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 8' ' ' PHE . . . . . . . . . . . . . 81.4 m-85 -59.89 -37.1 78.44 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 120.964 0.412 . . . . 0.0 110.806 179.951 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 9' ' ' TRP . . . . . . . . . . . . . 35.9 m95 -63.57 -41.58 98.39 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 115.897 -0.592 . . . . 0.0 110.173 -179.972 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 38.5 mt -64.85 -49.02 72.2 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-N 115.767 -0.651 . . . . 0.0 110.159 179.244 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . 0.438 ' HA2' HD11 ' A' ' 202' ' ' LEU . . . -57.19 -28.09 58.33 Favored Glycine 0 N--CA 1.447 -0.571 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.216 179.293 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -74.09 -38.48 63.87 Favored 'General case' 0 C--N 1.332 -0.186 0 CA-C-O 120.714 0.292 . . . . 0.0 110.79 179.636 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 63.6 mt -61.87 -54.18 38.04 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.31 -0.404 . . . . 0.0 110.436 179.475 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -60.96 -35.23 90.25 Favored Glycine 0 N--CA 1.45 -0.41 0 C-N-CA 120.591 -0.814 . . . . 0.0 111.676 179.257 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 15' ' ' MET . . . . . 0.542 ' SD ' ' HA ' ' A' ' 44' ' ' SER . 47.5 tpp -64.51 -39.98 94.79 Favored 'General case' 0 N--CA 1.454 -0.246 0 N-CA-C 110.167 -0.309 . . . . 0.0 110.167 179.343 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 16' ' ' LEU . . . . . 0.498 HD13 ' O ' ' A' ' 16' ' ' LEU . 0.7 OUTLIER -59.91 -37.55 79.76 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 116.018 -0.537 . . . . 0.0 109.571 179.1 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 94.0 t -59.07 -50.5 79.53 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.172 0 CA-C-N 115.937 -0.574 . . . . 0.0 110.107 179.1 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -61.45 -45.33 96.6 Favored Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.64 -0.791 . . . . 0.0 111.726 179.163 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 32.8 m -51.7 -44.76 63.28 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-O 120.678 0.275 . . . . 0.0 111.301 -179.858 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 81.2 mt -71.59 -36.54 70.89 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.321 -0.4 . . . . 0.0 111.172 179.904 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -63.23 -33.29 75.17 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.348 -0.387 . . . . 0.0 111.338 -179.873 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 22' ' ' PHE . . . . . 0.512 ' HB2' HG22 ' A' ' 41' ' ' VAL . 4.1 m-85 -90.86 -28.76 17.94 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.296 -0.411 . . . . 0.0 111.185 -179.472 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -71.77 -50.69 27.69 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.943 0.402 . . . . 0.0 111.118 179.919 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 24' ' ' TRP . . . . . . . . . . . . . 3.2 t-105 -64.41 -44.66 90.53 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 115.86 -0.609 . . . . 0.0 110.938 -179.946 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -77.62 -18.56 56.67 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.895 0.379 . . . . 0.0 110.915 179.776 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -73.08 -42.17 45.0 Favored Glycine 0 C--N 1.331 0.269 0 C-N-CA 120.959 -0.638 . . . . 0.0 112.383 179.947 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 94.2 mtt180 -68.17 -7.86 33.71 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-O 120.952 0.406 . . . . 0.0 110.463 179.668 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 18.6 t70 -117.21 88.98 3.01 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 115.823 -0.626 . . . . 0.0 110.496 179.729 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -165.42 -162.24 0.58 Allowed 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.141 -0.481 . . . . 0.0 111.219 -179.81 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -95.84 -131.72 6.78 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.963 -0.637 . . . . 0.0 112.631 -179.856 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 47.1 t -113.4 -63.6 1.42 Allowed 'General case' 0 C--N 1.33 -0.241 0 CA-C-O 120.812 0.339 . . . . 0.0 111.364 -179.747 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -65.44 -34.43 89.24 Favored Glycine 0 C--N 1.33 0.198 0 C-N-CA 120.802 -0.713 . . . . 0.0 112.588 -179.75 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 2.9 mp0 -68.34 -20.86 64.76 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 120.727 0.299 . . . . 0.0 110.944 -179.957 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 34' ' ' ARG . . . . . . . . . . . . . 78.9 ttt180 -57.63 -28.95 64.15 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.501 -179.619 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 27.7 tpt180 -59.17 -48.4 81.75 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.704 0.288 . . . . 0.0 111.508 -179.607 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 80.7 m-85 -64.96 -29.81 70.76 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.432 -0.349 . . . . 0.0 111.427 -179.511 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 37' ' ' TYR . . . . . 0.531 ' O ' HG23 ' A' ' 41' ' ' VAL . 52.2 m-85 -74.31 -54.27 8.01 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.413 -0.358 . . . . 0.0 111.342 -179.521 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 83.3 t -56.93 -36.32 49.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-O 120.969 0.414 . . . . 0.0 110.372 179.747 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 53.8 m -65.78 -51.53 58.29 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 115.846 -0.616 . . . . 0.0 110.929 179.518 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 40' ' ' LEU . . . . . 0.608 HD12 HD12 ' A' ' 43' ' ' ILE . 54.2 tp -59.23 -48.12 82.79 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 115.986 -0.552 . . . . 0.0 110.802 -179.94 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . 0.531 HG23 ' O ' ' A' ' 37' ' ' TYR . 67.6 t -57.86 -34.88 49.44 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.075 -0.511 . . . . 0.0 109.976 179.058 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -62.4 -36.23 92.82 Favored Glycine 0 N--CA 1.447 -0.606 0 C-N-CA 120.738 -0.744 . . . . 0.0 111.724 179.563 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 43' ' ' ILE . . . . . 0.608 HD12 HD12 ' A' ' 40' ' ' LEU . 1.9 mt -65.25 -55.14 21.79 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.187 0 CA-C-O 120.903 0.383 . . . . 0.0 110.935 179.629 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 44' ' ' SER . . . . . 0.542 ' HA ' ' SD ' ' A' ' 15' ' ' MET . 77.9 p -59.7 -26.23 65.42 Favored 'General case' 0 C--N 1.331 -0.201 0 CA-C-N 115.92 -0.582 . . . . 0.0 111.782 -179.529 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -76.16 -54.97 4.97 Favored Glycine 0 CA--C 1.52 0.39 0 C-N-CA 120.573 -0.823 . . . . 0.0 112.858 -179.513 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 46' ' ' ILE . . . . . 0.507 ' O ' HG22 ' A' ' 49' ' ' VAL . 20.5 pt -59.25 -35.8 59.91 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.219 0 CA-C-O 120.974 0.416 . . . . 0.0 111.13 -179.935 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 47' ' ' ALA . . . . . 0.684 ' HB2' ' HE2' ' A' ' 205' ' ' LYS . . . -68.16 -45.56 73.16 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.031 179.341 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -54.83 -41.94 71.32 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 115.87 -0.605 . . . . 0.0 111.769 -179.448 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 49' ' ' VAL . . . . . 0.507 HG22 ' O ' ' A' ' 46' ' ' ILE . 19.3 m -72.42 -34.19 47.89 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-N 116.521 -0.308 . . . . 0.0 111.138 -179.519 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -67.0 -34.73 78.4 Favored 'General case' 0 C--N 1.331 -0.2 0 CA-C-O 120.872 0.368 . . . . 0.0 111.227 179.853 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 28.3 m-85 -72.44 -41.34 66.25 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.623 -179.737 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -64.04 -46.71 83.2 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 115.769 -0.65 . . . . 0.0 111.245 -179.816 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 53' ' ' VAL . . . . . 0.623 ' O ' HG22 ' A' ' 58' ' ' VAL . 31.9 m -62.96 -53.61 44.39 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.159 0 CA-C-N 116.425 -0.352 . . . . 0.0 111.039 -179.903 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 54' ' ' MET . . . . . 0.546 ' N ' HG23 ' A' ' 53' ' ' VAL . 74.0 mtm -60.08 -31.1 69.7 Favored 'General case' 0 C--N 1.332 -0.182 0 CA-C-O 120.996 0.426 . . . . 0.0 110.289 179.659 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -64.9 -37.88 89.1 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 115.758 -0.655 . . . . 0.0 111.196 179.363 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 93.3 mt -71.15 -2.75 16.83 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.462 -179.586 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 93.66 -5.85 73.73 Favored Glycine 0 N--CA 1.45 -0.368 0 C-N-CA 120.597 -0.811 . . . . 0.0 112.925 179.702 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 58' ' ' VAL . . . . . 0.623 HG22 ' O ' ' A' ' 53' ' ' VAL . 1.5 m -72.64 154.2 7.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-O 120.718 0.294 . . . . 0.0 110.33 179.714 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 73.85 19.27 79.75 Favored Glycine 0 N--CA 1.45 -0.373 0 C-N-CA 120.483 -0.865 . . . . 0.0 112.188 -179.433 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 60' ' ' TRP . . . . . . . . . . . . . 22.0 m0 -99.11 99.26 10.24 Favored 'General case' 0 C--N 1.33 -0.259 0 N-CA-C 109.981 -0.377 . . . . 0.0 109.981 179.824 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 61' ' ' VAL . . . . . 0.563 ' HB ' HG23 ' A' ' 68' ' ' VAL . 61.4 t -97.95 109.51 51.75 Favored Pre-proline 0 C--N 1.324 -0.507 0 CA-C-N 115.996 -0.547 . . . . 0.0 111.542 -179.113 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 39.6 Cg_endo -66.2 135.74 41.35 Favored 'Trans proline' 0 C--N 1.35 0.639 0 C-N-CA 122.532 2.155 . . . . 0.0 112.085 179.731 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 80.9 t -137.89 95.13 1.06 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.38 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.387 -179.604 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . 58.11 -90.16 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.111 -0.495 . . . . 0.0 111.566 179.855 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 44.7 mt-10 -115.45 -24.67 8.26 Favored 'General case' 0 C--N 1.332 -0.193 0 CA-C-O 120.842 0.353 . . . . 0.0 111.157 -179.842 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 66' ' ' ARG . . . . . 0.424 ' HD2' ' N ' ' A' ' 66' ' ' ARG . 9.3 mpt_? -105.74 154.07 20.99 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.415 179.871 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 90.7 m -117.39 115.5 25.33 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.892 0.377 . . . . 0.0 111.433 -179.696 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 68' ' ' VAL . . . . . 0.563 HG23 ' HB ' ' A' ' 61' ' ' VAL . 29.0 m -83.81 146.34 6.99 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.368 0 CA-C-N 115.914 -0.584 . . . . 0.0 110.891 179.672 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 69' ' ' PHE . . . . . . . . . . . . . 64.8 m-85 -108.92 115.87 30.9 Favored 'General case' 0 N--CA 1.443 -0.794 0 CA-C-N 116.273 -0.421 . . . . 0.0 110.185 -179.377 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 70' ' ' VAL . . . . . 0.526 ' HB ' ' HD3' ' A' ' 71' ' ' PRO . 24.5 t -67.49 -49.6 40.84 Favored Pre-proline 0 C--N 1.325 -0.477 0 N-CA-C 112.616 0.599 . . . . 0.0 112.616 -178.932 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 71' ' ' PRO . . . . . 0.526 ' HD3' ' HB ' ' A' ' 70' ' ' VAL . 15.4 Cg_exo -67.08 -17.93 51.16 Favored 'Trans proline' 0 C--N 1.351 0.702 0 C-N-CA 122.315 2.01 . . . . 0.0 113.091 -178.918 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 67.2 ttt180 -66.66 -55.5 14.92 Favored 'General case' 0 C--O 1.237 0.396 0 CA-C-O 120.838 0.351 . . . . 0.0 111.626 -179.404 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 73' ' ' TYR . . . . . 0.475 ' O ' HG13 ' A' ' 77' ' ' ILE . 65.4 m-85 -71.52 -34.54 70.15 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.486 -0.324 . . . . 0.0 110.603 -179.453 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 74' ' ' ILE . . . . . 0.51 ' HA ' HD12 ' A' ' 77' ' ' ILE . 0.4 OUTLIER -66.48 -37.86 80.5 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.242 0 N-CA-C 109.833 -0.432 . . . . 0.0 109.833 179.182 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 13.8 t70 -59.14 -38.95 80.89 Favored 'General case' 0 CA--C 1.517 -0.288 0 N-CA-C 109.128 -0.693 . . . . 0.0 109.128 178.62 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 76' ' ' TRP . . . . . . . . . . . . . 51.1 m0 -65.58 -32.67 74.38 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 115.59 -0.732 . . . . 0.0 110.236 179.138 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 77' ' ' ILE . . . . . 0.51 HD12 ' HA ' ' A' ' 74' ' ' ILE . 69.0 mt -68.76 -28.61 40.55 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.25 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.078 178.984 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 34.0 mt -92.22 -20.43 21.18 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 115.772 -0.649 . . . . 0.0 112.332 179.949 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 82.1 p -103.93 -52.94 2.85 Favored 'General case' 0 N--CA 1.465 0.279 0 N-CA-C 114.025 1.12 . . . . 0.0 114.025 -177.295 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 80' ' ' THR . . . . . 0.456 ' N ' ' HD2' ' A' ' 81' ' ' PRO . 25.3 m -50.41 -54.81 30.86 Favored Pre-proline 0 C--N 1.329 -0.317 0 N-CA-C 113.016 0.747 . . . . 0.0 113.016 -178.007 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 81' ' ' PRO . . . . . 0.485 ' HA ' HG22 ' A' ' 84' ' ' VAL . 20.5 Cg_endo -59.78 -21.27 62.86 Favored 'Trans proline' 0 C--N 1.35 0.654 0 C-N-CA 121.346 1.364 . . . . 0.0 111.141 -179.655 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 82' ' ' LEU . . . . . 0.528 HD23 HG12 ' A' ' 43' ' ' ILE . 13.4 tp -77.13 -33.55 56.76 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 115.58 -0.736 . . . . 0.0 109.829 179.436 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 83' ' ' ILE . . . . . 0.421 HD11 HG21 ' A' ' 43' ' ' ILE . 35.2 mm -70.29 -53.44 23.08 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.191 0 CA-C-N 115.984 -0.553 . . . . 0.0 109.848 179.063 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . 0.485 HG22 ' HA ' ' A' ' 81' ' ' PRO . 33.9 m -59.51 -30.19 43.98 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.183 0 N-CA-C 109.546 -0.539 . . . . 0.0 109.546 178.863 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 85' ' ' TYR . . . . . 0.426 ' HB2' ' O ' ' A' ' 81' ' ' PRO . 68.3 t80 -69.74 -32.57 71.18 Favored 'General case' 0 N--CA 1.454 -0.26 0 CA-C-N 115.537 -0.756 . . . . 0.0 109.623 178.873 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 86' ' ' PHE . . . . . . . . . . . . . 9.9 t80 -61.33 -51.93 66.78 Favored 'General case' 0 C--O 1.232 0.149 0 CA-C-N 115.919 -0.582 . . . . 0.0 109.857 179.326 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 87' ' ' LEU . . . . . 0.402 ' N ' HD12 ' A' ' 87' ' ' LEU . 8.1 mp -61.01 -33.16 72.83 Favored 'General case' 0 C--N 1.332 -0.189 0 CA-C-N 115.873 -0.603 . . . . 0.0 110.08 179.374 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 88' ' ' GLY . . . . . 0.427 ' HA2' HD13 ' A' ' 93' ' ' LEU . . . -67.22 -27.74 73.56 Favored Glycine 0 N--CA 1.449 -0.49 0 C-N-CA 120.836 -0.697 . . . . 0.0 111.755 179.233 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 79.3 mt -72.89 -42.95 63.08 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-O 120.924 0.392 . . . . 0.0 110.468 179.622 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 54.9 mt -59.59 -43.83 93.57 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 115.822 -0.626 . . . . 0.0 110.972 179.878 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . 0.49 ' HB2' ' HB2' ' A' ' 149' ' ' ALA . . . -74.46 -55.05 6.39 Favored 'General case' 0 C--N 1.331 -0.21 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.325 -179.886 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 103.55 51.62 0.96 Allowed Glycine 0 N--CA 1.452 -0.251 0 C-N-CA 120.843 -0.694 . . . . 0.0 112.447 179.959 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 93' ' ' LEU . . . . . 0.601 HD23 ' HB3' ' A' ' 97' ' ' GLU . 7.9 mp -65.77 170.83 4.83 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.875 0.369 . . . . 0.0 111.193 -179.884 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 94' ' ' ASP . . . . . . . . . . . . . 5.5 m-20 -85.05 164.66 18.09 Favored 'General case' 0 C--N 1.33 -0.239 0 CA-C-N 116.057 -0.519 . . . . 0.0 110.435 179.643 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 46.8 t -55.86 -34.63 65.65 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.326 -0.397 . . . . 0.0 110.97 -179.753 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 96' ' ' ARG . . . . . 0.468 ' HA ' ' NE ' ' A' ' 96' ' ' ARG . 5.6 tpm_? -73.69 -44.87 55.41 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.254 -0.43 . . . . 0.0 111.195 -179.914 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 97' ' ' GLU . . . . . 0.601 ' HB3' HD23 ' A' ' 93' ' ' LEU . 39.1 mt-10 -54.58 -47.39 73.36 Favored 'General case' 0 C--N 1.333 -0.129 0 CA-C-N 116.274 -0.421 . . . . 0.0 111.102 -179.777 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 98' ' ' PHE . . . . . 0.491 ' O ' HG12 ' A' ' 102' ' ' ILE . 41.1 m-85 -58.31 -48.85 79.19 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.859 0.362 . . . . 0.0 110.571 179.489 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -54.25 -29.89 46.67 Favored Glycine 0 N--CA 1.45 -0.383 0 C-N-CA 120.662 -0.78 . . . . 0.0 112.466 179.816 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 100' ' ' ILE . . . . . 0.472 HD12 ' HA ' ' A' ' 97' ' ' GLU . 66.6 mt -73.81 -48.32 39.99 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.229 0 N-CA-C 112.02 0.378 . . . . 0.0 112.02 -179.735 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 101' ' ' VAL . . . . . 0.431 HG12 ' H ' ' A' ' 101' ' ' VAL . 1.4 p -68.84 -41.76 82.34 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.246 0 N-CA-C 112.044 0.387 . . . . 0.0 112.044 -179.404 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 102' ' ' ILE . . . . . 0.491 HG12 ' O ' ' A' ' 98' ' ' PHE . 42.6 mm -64.58 -48.24 85.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.774 -0.194 . . . . 0.0 111.368 -179.358 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 14.7 t -60.95 -34.24 74.42 Favored 'General case' 0 C--N 1.332 -0.166 0 CA-C-O 120.83 0.347 . . . . 0.0 110.385 179.784 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 104' ' ' LEU . . . . . 0.454 HD22 ' HE2' ' A' ' 140' ' ' TYR . 38.0 tp -62.02 -52.92 62.02 Favored 'General case' 0 C--N 1.332 -0.174 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.251 179.296 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 105' ' ' ASN . . . . . 0.559 ' N ' HD22 ' A' ' 105' ' ' ASN . 0.8 OUTLIER -56.95 -27.4 61.13 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.765 179.524 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 30.9 m -64.9 -56.97 10.12 Favored 'General case' 0 C--N 1.332 -0.183 0 CA-C-N 116.313 -0.403 . . . . 0.0 111.481 -179.863 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 107' ' ' VAL . . . . . 0.451 HG12 ' O ' ' A' ' 104' ' ' LEU . 7.4 p -58.93 -36.19 60.39 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.144 0 CA-C-O 120.852 0.358 . . . . 0.0 111.087 -179.892 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . 0.452 HG23 ' O ' ' A' ' 104' ' ' LEU . 91.4 t -61.84 -49.47 84.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.099 -0.5 . . . . 0.0 111.133 179.816 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 109' ' ' MET . . . . . 0.471 ' HG2' ' O ' ' A' ' 105' ' ' ASN . 17.7 mmt -64.52 -31.51 72.75 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.244 -0.434 . . . . 0.0 111.104 179.974 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 27.7 tp -68.05 -36.18 79.45 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.247 179.675 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -62.66 -53.67 51.02 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.067 -0.515 . . . . 0.0 110.539 179.48 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 112' ' ' GLY . . . . . 0.673 ' HA3' ' H21' ' A' ' 301' ' ' RET . . . -62.23 -40.97 99.68 Favored Glycine 0 C--N 1.332 0.327 0 C-N-CA 120.638 -0.791 . . . . 0.0 111.868 179.362 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 113' ' ' PHE . . . . . . . . . . . . . 1.4 t80 -48.88 -68.58 0.17 Allowed 'General case' 0 CA--C 1.52 -0.18 0 N-CA-C 109.858 -0.423 . . . . 0.0 109.858 179.33 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 114' ' ' ALA . . . . . 0.52 ' HA ' ' HB2' ' A' ' 117' ' ' MET . . . -67.49 -15.48 63.69 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-N 115.924 -0.58 . . . . 0.0 110.213 179.365 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 115' ' ' GLY . . . . . 0.666 ' O ' HG22 ' A' ' 118' ' ' VAL . . . -53.65 -49.81 56.25 Favored Glycine 0 C--N 1.336 0.557 0 C-N-CA 120.978 -0.629 . . . . 0.0 111.561 179.299 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 116' ' ' ALA . . . . . 0.4 ' HB1' HG12 ' A' ' 68' ' ' VAL . . . -79.36 -22.11 44.86 Favored 'General case' 0 C--N 1.321 -0.638 0 N-CA-C 111.878 0.325 . . . . 0.0 111.878 179.902 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 117' ' ' MET . . . . . 0.52 ' HB2' ' HA ' ' A' ' 114' ' ' ALA . 0.2 OUTLIER -76.67 19.45 0.27 Allowed 'General case' 0 C--N 1.328 -0.33 0 N-CA-C 112.363 0.505 . . . . 0.0 112.363 -178.84 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 118' ' ' VAL . . . . . 0.666 HG22 ' O ' ' A' ' 115' ' ' GLY . 23.3 m -123.67 138.71 30.78 Favored Pre-proline 0 C--N 1.33 -0.278 0 C-N-CA 121.131 -0.227 . . . . 0.0 111.369 179.823 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 119' ' ' PRO . . . . . . . . . . . . . 77.4 Cg_endo -96.63 23.47 0.33 Allowed 'Trans proline' 0 N--CA 1.455 -0.787 0 C-N-CA 123.19 2.593 . . . . 0.0 112.769 179.892 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -139.73 -159.16 7.87 Favored Glycine 0 C--N 1.332 0.308 0 C-N-CA 120.493 -0.86 . . . . 0.0 113.215 -179.578 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 121' ' ' ILE . . . . . 0.427 HG22 ' O ' ' A' ' 121' ' ' ILE . 14.3 mm -80.33 1.89 2.7 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.205 0 CA-C-O 121.136 0.493 . . . . 0.0 110.938 -179.77 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 33.6 mt-10 -59.34 -37.39 77.71 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 115.799 -0.637 . . . . 0.0 110.89 -179.991 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 123' ' ' ARG . . . . . 0.538 ' HB2' ' HH2' ' A' ' 178' ' ' TRP . 3.7 ptp180 -50.6 -32.99 20.41 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.018 -0.537 . . . . 0.0 111.654 -179.659 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 124' ' ' TYR . . . . . . . . . . . . . 91.3 m-85 -71.57 -33.2 68.88 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.385 -0.371 . . . . 0.0 111.236 -179.645 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 125' ' ' ALA . . . . . . . . . . . . . . . -70.07 -50.86 36.8 Favored 'General case' 0 C--O 1.237 0.405 0 CA-C-O 120.995 0.426 . . . . 0.0 110.047 179.194 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 126' ' ' LEU . . . . . 0.439 HD22 ' HA2' ' A' ' 115' ' ' GLY . 8.2 mp -55.55 -54.04 48.94 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 115.695 -0.684 . . . . 0.0 110.074 179.345 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 127' ' ' PHE . . . . . 0.407 ' CE1' ' H42' ' A' ' 301' ' ' RET . 11.0 t80 -63.53 -35.73 81.44 Favored 'General case' 0 N--CA 1.452 -0.374 0 CA-C-N 115.782 -0.645 . . . . 0.0 110.611 179.958 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 128' ' ' GLY . . . . . . . . . . . . . . . -47.46 -44.48 21.87 Favored Glycine 0 C--N 1.332 0.313 0 C-N-CA 120.228 -0.987 . . . . 0.0 110.805 179.138 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 129' ' ' MET . . . . . . . . . . . . . 0.3 OUTLIER -70.51 -36.56 73.83 Favored 'General case' 0 N--CA 1.453 -0.318 0 N-CA-C 109.828 -0.434 . . . . 0.0 109.828 178.688 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -66.52 -28.56 73.81 Favored Glycine 0 C--N 1.332 0.342 0 CA-C-N 115.702 -0.681 . . . . 0.0 112.839 -179.993 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -74.67 -53.7 8.81 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-O 120.699 0.285 . . . . 0.0 110.358 179.83 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 98.4 t -57.84 -39.91 73.49 Favored 'Isoleucine or valine' 0 C--O 1.234 0.276 0 N-CA-C 109.024 -0.732 . . . . 0.0 109.024 178.433 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -67.23 -33.92 76.37 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 115.123 -0.944 . . . . 0.0 110.642 179.269 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 134' ' ' PHE . . . . . 0.425 ' CZ ' ' HA ' ' A' ' 172' ' ' ALA . 74.6 t80 -56.43 -55.81 28.92 Favored 'General case' 0 N--CA 1.449 -0.484 0 CA-C-O 120.926 0.393 . . . . 0.0 109.951 179.388 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 135' ' ' ILE . . . . . 0.421 ' O ' HG22 ' A' ' 138' ' ' VAL . 40.1 mt -56.58 -33.23 39.14 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.298 0 CA-C-N 115.761 -0.654 . . . . 0.0 109.876 178.942 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . -61.44 -36.9 93.24 Favored Glycine 0 N--CA 1.447 -0.574 0 C-N-CA 120.424 -0.893 . . . . 0.0 111.456 179.067 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 137' ' ' LEU . . . . . 0.545 HD13 HD21 ' A' ' 105' ' ' ASN . 47.9 tp -72.22 -54.02 10.85 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-O 120.527 0.203 . . . . 0.0 110.633 179.657 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 138' ' ' VAL . . . . . 0.421 HG22 ' O ' ' A' ' 135' ' ' ILE . 3.4 m -56.17 -31.51 32.08 Favored 'Isoleucine or valine' 0 C--O 1.233 0.192 0 CA-C-O 121.242 0.544 . . . . 0.0 109.676 179.462 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 139' ' ' TYR . . . . . . . . . . . . . 24.9 t80 -63.41 -46.96 83.98 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 115.432 -0.804 . . . . 0.0 110.311 178.819 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 140' ' ' TYR . . . . . 0.454 ' HE2' HD22 ' A' ' 104' ' ' LEU . 17.2 m-85 -58.89 -37.98 77.84 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.626 179.638 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 141' ' ' LEU . . . . . . . . . . . . . 62.6 mt -57.61 -48.2 80.07 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.189 179.542 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 17.1 t -78.31 -12.58 13.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 115.943 -0.571 . . . . 0.0 110.658 179.654 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 143' ' ' GLY . . . . . 0.43 ' HA3' ' HD2' ' A' ' 144' ' ' PRO . . . -72.44 -134.62 0.18 Allowed Glycine 0 CA--C 1.521 0.425 0 C-N-CA 120.982 -0.627 . . . . 0.0 112.906 -179.845 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 144' ' ' PRO . . . . . 0.43 ' HD2' ' HA3' ' A' ' 143' ' ' GLY . 20.7 Cg_endo -60.43 -23.72 75.76 Favored 'Trans proline' 0 C--N 1.349 0.586 0 C-N-CA 122.647 2.231 . . . . 0.0 112.593 -179.658 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 145' ' ' MET . . . . . . . . . . . . . 55.1 mtt -59.33 -36.73 76.2 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.507 -0.315 . . . . 0.0 111.303 -179.865 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 146' ' ' THR . . . . . . . . . . . . . 86.2 m -79.63 -42.33 25.09 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.508 -0.314 . . . . 0.0 111.431 -179.154 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 8.8 tp10 -61.84 -41.46 97.83 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.243 -179.784 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 148' ' ' SER . . . . . . . . . . . . . 48.7 m -70.61 -46.32 63.59 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.263 -0.426 . . . . 0.0 111.614 -179.325 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 149' ' ' ALA . . . . . 0.49 ' HB2' ' HB2' ' A' ' 91' ' ' ALA . . . -68.33 -30.71 69.75 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.3 -0.409 . . . . 0.0 111.892 -179.206 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 150' ' ' SER . . . . . . . . . . . . . 43.3 t -72.36 -5.9 39.62 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.439 -0.346 . . . . 0.0 111.656 -179.275 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 151' ' ' GLN . . . . . . . . . . . . . 10.3 pt20 -133.55 5.79 3.74 Favored 'General case' 0 C--N 1.33 -0.251 0 N-CA-C 111.649 0.24 . . . . 0.0 111.649 -179.835 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 1.6 tmt_? -73.69 -51.88 15.15 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-O 120.994 0.426 . . . . 0.0 110.251 179.946 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 153' ' ' SER . . . . . 0.637 ' HB2' HG12 ' A' ' 156' ' ' ILE . 49.1 m -158.1 172.08 19.06 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-N 115.759 -0.655 . . . . 0.0 110.256 179.227 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 154' ' ' SER . . . . . . . . . . . . . 88.6 p -70.65 -37.67 73.76 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-O 120.883 0.373 . . . . 0.0 110.474 179.542 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -76.98 -30.26 55.95 Favored Glycine 0 N--CA 1.452 -0.276 0 C-N-CA 120.935 -0.65 . . . . 0.0 112.751 -179.914 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 156' ' ' ILE . . . . . 0.637 HG12 ' HB2' ' A' ' 153' ' ' SER . 39.1 mm -64.48 -39.21 84.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-O 120.765 0.317 . . . . 0.0 111.243 -179.988 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 157' ' ' LYS . . . . . . . . . . . . . 87.1 tttt -63.55 -41.28 98.44 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 116.306 -0.406 . . . . 0.0 111.624 -179.37 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 87.9 p -71.34 -48.33 51.02 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-O 120.956 0.408 . . . . 0.0 111.493 -179.338 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 159' ' ' LEU . . . . . 0.554 HD21 ' HB3' ' A' ' 215' ' ' ALA . 17.4 mt -66.77 -31.85 72.75 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 116.084 -0.507 . . . . 0.0 111.726 -179.269 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 160' ' ' TYR . . . . . . . . . . . . . 50.9 t80 -74.25 -46.79 39.3 Favored 'General case' 0 C--N 1.327 -0.372 0 N-CA-C 112.051 0.389 . . . . 0.0 112.051 -178.841 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 24.4 m -60.12 -44.74 95.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 N-CA-C 111.848 0.314 . . . . 0.0 111.848 -179.154 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 162' ' ' ARG . . . . . 0.487 ' HG2' HG21 ' A' ' 211' ' ' ILE . 22.3 tpp180 -68.88 -40.88 79.01 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.755 0.312 . . . . 0.0 111.638 -179.598 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 163' ' ' LEU . . . . . 0.631 ' HG ' ' HB2' ' A' ' 208' ' ' PHE . 6.3 mp -69.23 -55.14 11.45 Favored 'General case' 0 C--N 1.329 -0.323 0 N-CA-C 112.77 0.656 . . . . 0.0 112.77 -178.724 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 164' ' ' ARG . . . . . 0.493 ' O ' HG23 ' A' ' 168' ' ' VAL . 5.0 ppt_? -61.04 -45.5 94.5 Favored 'General case' 0 C--N 1.328 -0.339 0 N-CA-C 112.28 0.474 . . . . 0.0 112.28 -178.316 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 165' ' ' ASN . . . . . 0.499 ' O ' HG23 ' A' ' 169' ' ' VAL . 9.5 m-80 -59.88 -51.48 69.5 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.763 0.316 . . . . 0.0 111.28 -179.736 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 166' ' ' LEU . . . . . 0.473 ' O ' ' HG ' ' A' ' 170' ' ' LEU . 3.2 tt -61.21 -50.84 71.49 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.461 -179.511 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 167' ' ' THR . . . . . 0.439 ' O ' ' HB2' ' A' ' 171' ' ' TRP . 92.1 m -55.01 -53.32 57.31 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 115.911 -0.586 . . . . 0.0 112.514 -178.999 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 168' ' ' VAL . . . . . 0.493 HG23 ' O ' ' A' ' 164' ' ' ARG . 85.3 t -55.16 -43.97 72.67 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.236 0 N-CA-C 112.044 0.387 . . . . 0.0 112.044 -178.803 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 169' ' ' VAL . . . . . 0.499 HG23 ' O ' ' A' ' 165' ' ' ASN . 72.3 t -56.41 -65.05 0.42 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 N-CA-C 111.969 0.359 . . . . 0.0 111.969 -179.288 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 170' ' ' LEU . . . . . 0.473 ' HG ' ' O ' ' A' ' 166' ' ' LEU . 0.7 OUTLIER -64.76 -28.08 69.33 Favored 'General case' 0 C--N 1.331 -0.238 0 N-CA-C 112.238 0.458 . . . . 0.0 112.238 -178.852 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 171' ' ' TRP . . . . . 0.645 ' HE1' H203 ' A' ' 301' ' ' RET . 4.0 m0 -71.13 -30.01 65.96 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-O 121.006 0.431 . . . . 0.0 110.495 179.495 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 172' ' ' ALA . . . . . 0.425 ' HA ' ' CZ ' ' A' ' 134' ' ' PHE . . . -72.67 -6.36 43.85 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 115.917 -0.583 . . . . 0.0 111.056 -179.722 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 173' ' ' ILE . . . . . 0.51 HG22 HD11 ' A' ' 177' ' ' ILE . 21.6 mm -87.29 -21.82 7.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 115.93 -0.577 . . . . 0.0 111.288 -179.972 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 174' ' ' TYR . . . . . 0.597 ' N ' ' HD2' ' A' ' 175' ' ' PRO . 37.0 m-85 -54.35 -51.24 79.66 Favored Pre-proline 0 CA--C 1.532 0.267 0 N-CA-C 111.955 0.354 . . . . 0.0 111.955 -179.762 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 175' ' ' PRO . . . . . 0.597 ' HD2' ' N ' ' A' ' 174' ' ' TYR . 5.3 Cg_endo -48.41 -29.57 13.76 Favored 'Trans proline' 0 C--N 1.352 0.717 0 C-N-CA 122.106 1.87 . . . . 0.0 112.299 -179.967 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 176' ' ' PHE . . . . . 0.475 ' HD2' ' HA ' ' A' ' 173' ' ' ILE . 58.9 m-85 -80.84 -49.45 11.05 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.044 -0.525 . . . . 0.0 112.053 -179.885 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 177' ' ' ILE . . . . . 0.51 HD11 HG22 ' A' ' 173' ' ' ILE . 4.4 mm -62.47 -34.79 66.55 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.496 0 N-CA-C 112.389 0.515 . . . . 0.0 112.389 -178.155 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 178' ' ' TRP . . . . . 0.538 ' HH2' ' HB2' ' A' ' 123' ' ' ARG . 70.0 t90 -73.71 -46.7 44.56 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-O 121.03 0.443 . . . . 0.0 110.766 179.551 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 179' ' ' LEU . . . . . 0.428 ' O ' HG22 ' A' ' 185' ' ' VAL . 1.7 tm? -69.5 -48.42 60.64 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 115.856 -0.611 . . . . 0.0 111.396 -179.172 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 180' ' ' LEU . . . . . 0.669 HD22 HD11 ' A' ' 187' ' ' LEU . 42.2 mt -75.15 -46.62 33.13 Favored 'General case' 0 C--N 1.327 -0.395 0 N-CA-C 111.911 0.338 . . . . 0.0 111.911 -179.153 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . -58.35 -179.59 1.06 Allowed Glycine 0 C--N 1.336 0.582 0 C-N-CA 120.256 -0.973 . . . . 0.0 112.383 179.767 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 182' ' ' PRO . . . . . 0.662 ' HA ' ' HB2' ' A' ' 186' ' ' ALA . 84.7 Cg_exo -47.05 -44.05 23.84 Favored 'Trans proline' 0 CA--C 1.535 0.571 0 C-N-CA 122.834 2.356 . . . . 0.0 113.94 -179.97 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 183' ' ' PRO . . . . . 0.407 ' CD ' ' N ' ' A' ' 182' ' ' PRO . 74.7 Cg_exo -51.19 -17.71 4.12 Favored 'Trans proline' 0 C--N 1.355 0.891 0 C-N-CA 122.257 1.971 . . . . 0.0 113.456 -179.707 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 184' ' ' GLY . . . . . . . . . . . . . . . -120.51 -92.02 1.27 Allowed Glycine 0 C--N 1.332 0.343 0 C-N-CA 120.207 -0.997 . . . . 0.0 113.294 -179.743 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 185' ' ' VAL . . . . . 0.428 HG22 ' O ' ' A' ' 179' ' ' LEU . 17.8 m -106.39 -13.0 9.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 N-CA-C 112.152 0.427 . . . . 0.0 112.152 -179.004 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 186' ' ' ALA . . . . . 0.662 ' HB2' ' HA ' ' A' ' 182' ' ' PRO . . . 58.36 86.78 0.08 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.794 0.33 . . . . 0.0 111.469 179.848 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 187' ' ' LEU . . . . . 0.669 HD11 HD22 ' A' ' 180' ' ' LEU . 22.8 mt -91.79 -49.02 6.48 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 120.953 0.406 . . . . 0.0 110.968 179.909 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 188' ' ' LEU . . . . . . . . . . . . . 77.5 mt -95.87 -151.66 0.35 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 115.939 -0.573 . . . . 0.0 111.339 -179.365 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 189' ' ' THR . . . . . 0.447 HG22 ' H ' ' A' ' 191' ' ' THR . 29.0 m -96.96 137.45 21.31 Favored Pre-proline 0 C--N 1.331 -0.221 0 CA-C-N 115.922 -0.581 . . . . 0.0 110.852 -179.483 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 190' ' ' PRO . . . . . . . . . . . . . 82.0 Cg_exo -46.95 -29.86 8.97 Favored 'Trans proline' 0 C--N 1.349 0.577 0 C-N-CA 122.478 2.118 . . . . 0.0 112.692 179.9 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 191' ' ' THR . . . . . 0.447 ' H ' HG22 ' A' ' 189' ' ' THR . 76.7 p -77.4 -40.6 43.08 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.486 -0.324 . . . . 0.0 111.412 -179.948 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 192' ' ' VAL . . . . . . . . . . . . . 61.7 t -72.09 -53.27 20.47 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.289 -0.414 . . . . 0.0 111.564 -179.608 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 193' ' ' ASP . . . . . . . . . . . . . 30.7 m-20 -52.15 -48.79 64.74 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.36 -0.382 . . . . 0.0 111.015 -179.921 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 194' ' ' VAL . . . . . 0.489 ' O ' HG22 ' A' ' 198' ' ' VAL . 55.3 t -62.38 -36.38 74.41 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.645 179.724 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 195' ' ' ALA . . . . . . . . . . . . . . . -56.27 -39.84 73.28 Favored 'General case' 0 C--N 1.332 -0.155 0 CA-C-N 116.348 -0.387 . . . . 0.0 110.571 179.344 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 196' ' ' LEU . . . . . . . . . . . . . 96.4 mt -68.43 -39.62 81.49 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.018 -0.537 . . . . 0.0 110.557 179.251 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 197' ' ' ILE . . . . . 0.407 HD11 ' HB ' ' A' ' 177' ' ' ILE . 18.3 mm -60.43 -60.38 2.67 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.254 0 CA-C-N 115.856 -0.611 . . . . 0.0 111.238 179.957 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 198' ' ' VAL . . . . . 0.489 HG22 ' O ' ' A' ' 194' ' ' VAL . 3.3 m -52.98 -36.05 23.36 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.4 0 CA-C-O 121.596 0.712 . . . . 0.0 109.808 179.003 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 199' ' ' TYR . . . . . . . . . . . . . 37.1 t80 -67.97 -33.04 73.89 Favored 'General case' 0 C--N 1.321 -0.666 0 CA-C-N 114.629 -1.168 . . . . 0.0 110.849 179.858 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 200' ' ' LEU . . . . . 0.569 ' O ' HG12 ' A' ' 203' ' ' VAL . 25.5 mt -68.71 -41.85 78.52 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 121.13 0.49 . . . . 0.0 110.844 179.927 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 201' ' ' ASP . . . . . . . . . . . . . 15.8 m-20 -70.09 -33.18 71.56 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-O 121.321 0.581 . . . . 0.0 109.727 179.109 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 202' ' ' LEU . . . . . 0.438 HD11 ' HA2' ' A' ' 11' ' ' GLY . 3.1 mt -72.33 -31.14 65.41 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 115.213 -0.903 . . . . 0.0 112.014 -179.741 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 203' ' ' VAL . . . . . 0.569 HG12 ' O ' ' A' ' 200' ' ' LEU . 13.0 p -76.44 -35.91 27.64 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 C-N-CA 121.06 -0.256 . . . . 0.0 110.958 -178.621 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 204' ' ' THR . . . . . . . . . . . . . 88.8 m -67.66 -58.24 5.01 Favored 'General case' 0 C--N 1.326 -0.443 0 C-N-CA 120.651 -0.42 . . . . 0.0 111.289 179.498 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 205' ' ' LYS . . . . . 0.684 ' HE2' ' HB2' ' A' ' 47' ' ' ALA . 48.7 mttp -62.15 -58.49 7.59 Favored 'General case' 0 C--N 1.329 -0.303 0 N-CA-C 112.21 0.448 . . . . 0.0 112.21 -178.513 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 44.5 t -70.35 -36.22 65.96 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.48 0 CA-C-N 116.025 -0.534 . . . . 0.0 112.068 -178.836 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 207' ' ' GLY . . . . . 0.548 ' O ' HG13 ' A' ' 211' ' ' ILE . . . -58.33 -61.66 7.15 Favored Glycine 0 N--CA 1.452 -0.271 0 C-N-CA 120.634 -0.793 . . . . 0.0 113.844 -178.128 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 208' ' ' PHE . . . . . 0.631 ' HB2' ' HG ' ' A' ' 163' ' ' LEU . 0.8 OUTLIER -72.69 -27.61 62.19 Favored 'General case' 0 C--O 1.221 -0.436 0 CA-C-N 117.515 0.657 . . . . 0.0 110.854 -179.12 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 209' ' ' GLY . . . . . 0.497 ' O ' ' HB3' ' A' ' 212' ' ' ALA . . . -64.1 -31.87 82.29 Favored Glycine 0 N--CA 1.45 -0.399 0 N-CA-C 111.546 -0.622 . . . . 0.0 111.546 178.697 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 210' ' ' PHE . . . . . . . . . . . . . 0.5 OUTLIER -74.79 -47.9 28.32 Favored 'General case' 0 CA--C 1.514 -0.41 0 N-CA-C 108.425 -0.954 . . . . 0.0 108.425 178.451 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 211' ' ' ILE . . . . . 0.548 HG13 ' O ' ' A' ' 207' ' ' GLY . 4.3 mt -63.69 -27.61 43.27 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.45 0 N-CA-C 107.712 -1.218 . . . . 0.0 107.712 176.787 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 212' ' ' ALA . . . . . 0.497 ' HB3' ' O ' ' A' ' 209' ' ' GLY . . . -62.46 -46.1 90.02 Favored 'General case' 0 N--CA 1.449 -0.524 0 CA-C-N 114.469 -1.242 . . . . 0.0 110.549 -179.888 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 213' ' ' LEU . . . . . . . . . . . . . 95.8 mt -70.33 -46.03 65.01 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 115.182 -0.917 . . . . 0.0 111.864 -179.437 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 214' ' ' ASP . . . . . . . . . . . . . 19.9 t70 -56.06 -55.19 35.89 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.466 -0.334 . . . . 0.0 111.604 -179.299 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 215' ' ' ALA . . . . . 0.554 ' HB3' HD21 ' A' ' 159' ' ' LEU . . . -58.95 -53.14 61.77 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.327 -0.397 . . . . 0.0 111.406 -179.559 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 216' ' ' ALA . . . . . . . . . . . . . . . -53.14 -45.08 68.24 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.506 -179.666 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 217' ' ' ALA . . . . . . . . . . . . . . . -55.85 -39.86 72.06 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-O 121.062 0.458 . . . . 0.0 110.301 179.738 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 218' ' ' THR . . . . . . . . . . . . . 92.1 m -69.3 -34.0 74.03 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.634 -0.712 . . . . 0.0 110.861 179.48 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 219' ' ' LEU . . . . . 0.438 ' HG ' ' O ' ' A' ' 215' ' ' ALA . 75.5 mt -64.31 -39.82 94.67 Favored 'General case' 0 C--N 1.331 -0.2 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.698 179.755 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 220' ' ' ARG . . . . . . . . . . . . . 15.2 mmm180 -80.21 -27.01 38.89 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.387 179.756 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 221' ' ' ALA . . . . . . . . . . . . . . . -71.17 -26.11 62.83 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 115.986 -0.552 . . . . 0.0 111.5 -179.981 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 222' ' ' GLU . . . . . . . . . . . . . 12.7 pt-20 -92.44 -22.18 19.76 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-O 120.934 0.397 . . . . 0.0 110.385 -179.869 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 223' ' ' HIS . . . . . . . . . . . . . 46.8 m-70 61.88 -176.09 0.13 Allowed 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 115.672 -0.695 . . . . 0.0 111.235 179.871 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 224' ' ' GLY . . . . . . . . . . . . . . . 178.35 43.45 0.07 OUTLIER Glycine 0 N--CA 1.452 -0.269 0 C-N-CA 120.821 -0.704 . . . . 0.0 112.398 -179.93 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 225' ' ' GLU . . . . . . . . . . . . . 10.0 mm-40 -118.22 120.33 37.37 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 120.841 0.353 . . . . 0.0 110.833 -179.998 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 226' ' ' SER . . . . . . . . . . . . . 50.6 m -86.81 151.83 23.02 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.958 -179.929 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 227' ' ' LEU . . . . . . . . . . . . . 60.9 tp -91.22 -60.27 1.94 Allowed 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.84 -179.954 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 228' ' ' ALA . . . . . . . . . . . . . . . 56.19 178.45 0.04 OUTLIER 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 116.082 -0.508 . . . . 0.0 111.624 -179.897 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 229' ' ' GLY . . . . . . . . . . . . . . . 74.02 77.72 0.62 Allowed Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.658 -0.782 . . . . 0.0 112.621 179.901 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 230' ' ' VAL . . . . . . . . . . . . . 21.3 t -81.66 123.87 38.39 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-O 120.801 0.334 . . . . 0.0 110.861 179.768 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 231' ' ' ASP . . . . . . . . . . . . . 19.3 t70 -74.98 125.61 29.25 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.134 -179.664 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 232' ' ' THR . . . . . . . . . . . . . 9.1 t -124.45 -26.59 3.87 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.007 -0.542 . . . . 0.0 110.837 179.688 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 233' ' ' ASP . . . . . . . . . . . . . 27.1 t70 62.51 107.84 0.03 OUTLIER 'General case' 0 C--N 1.333 -0.151 0 CA-C-N 115.832 -0.622 . . . . 0.0 111.336 179.801 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 234' ' ' THR . . . . . . . . . . . . . 1.4 t -108.15 96.92 19.56 Favored Pre-proline 0 C--N 1.33 -0.282 0 CA-C-N 115.951 -0.568 . . . . 0.0 110.837 179.744 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 235' ' ' PRO . . . . . . . . . . . . . 85.9 Cg_endo -78.34 4.18 6.5 Favored 'Trans proline' 0 C--N 1.349 0.564 0 C-N-CA 122.462 2.108 . . . . 0.0 112.801 -179.696 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 236' ' ' ALA . . . . . . . . . . . . . . . -63.82 153.49 36.5 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.374 -0.375 . . . . 0.0 111.026 179.962 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 237' ' ' VAL . . . . . . . . . . . . . 13.5 p -164.3 147.57 2.61 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.249 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.914 -179.938 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 238' ' ' ALA . . . . . . . . . . . . . . . -149.1 -27.1 0.29 Allowed 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.3 -0.409 . . . . 0.0 111.294 -179.931 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 239' ' ' ASP . . . . . . . . . . . . . 15.1 m-20 -113.0 123.7 50.93 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.268 -0.424 . . . . 0.0 111.108 -179.959 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 240' ' ' LEU . . . . . . . . . . . . . 3.3 pp -125.99 -12.3 6.44 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.895 179.787 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 241' ' ' GLU . . . . . . . . . . . . . 44.6 mt-10 -73.17 134.41 44.39 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.756 179.837 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 242' ' ' HIS . . . . . . . . . . . . . 40.9 m80 -92.51 173.74 7.64 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.326 -0.397 . . . . 0.0 111.12 -179.832 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 243' ' ' HIS . . . . . . . . . . . . . 60.9 t60 -160.9 -45.85 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 115.845 -0.616 . . . . 0.0 110.568 179.821 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 244' ' ' HIS . . . . . . . . . . . . . 34.0 t-80 -107.24 -17.17 14.22 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 115.895 -0.593 . . . . 0.0 110.802 -179.989 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 245' ' ' HIS . . . . . . . . . . . . . 52.5 m-70 57.79 84.85 0.09 Allowed 'General case' 0 C--O 1.232 0.139 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.889 -179.666 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 246' ' ' HIS . . . . . . . . . . . . . 29.5 p-80 -103.55 159.49 15.55 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.018 -0.537 . . . . 0.0 110.673 -179.93 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 247' ' ' HIS . . . . . . . . . . . . . 53.3 t-80 . . . . . 0 C--O 1.249 1.059 0 CA-C-O 118.324 -0.846 . . . . 0.0 111.027 179.939 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 301' ' ' RET . . . . . 0.673 ' H21' ' HA3' ' A' ' 112' ' ' GLY . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 51.5 mtm . . . . . 0 N--CA 1.487 1.377 0 CA-C-O 120.709 0.29 . . . . 0.0 110.942 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 9.4 p -175.1 -34.78 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-N 116.141 -0.481 . . . . 0.0 111.224 -179.926 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -97.29 -28.98 8.18 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.768 -0.729 . . . . 0.0 112.768 -179.866 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 32.5 tp -74.16 -35.35 64.04 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.808 0.337 . . . . 0.0 110.884 179.967 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 74.7 p -61.67 -30.56 70.81 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.132 -0.486 . . . . 0.0 111.411 -179.985 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 29.0 p -58.98 -36.12 74.36 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-O 120.783 0.325 . . . . 0.0 111.07 -179.852 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 7' ' ' LEU . . . . . . . . . . . . . 4.5 mm? -56.61 -52.06 66.28 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.861 179.862 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 8' ' ' PHE . . . . . 0.667 ' HB2' ' HB2' ' A' ' 55' ' ' ALA . 83.5 m-85 -58.1 -37.84 75.29 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.223 179.477 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 9' ' ' TRP . . . . . . . . . . . . . 15.8 m95 -63.0 -41.81 99.68 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 115.987 -0.551 . . . . 0.0 110.102 -179.987 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 84.9 mt -59.74 -43.87 94.06 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 115.617 -0.719 . . . . 0.0 110.09 179.299 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -61.36 -33.97 86.54 Favored Glycine 0 N--CA 1.448 -0.516 0 C-N-CA 120.656 -0.783 . . . . 0.0 111.554 179.168 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -66.96 -31.23 71.66 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-O 120.912 0.387 . . . . 0.0 110.376 179.447 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 75.5 mt -66.06 -47.52 84.7 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.245 0 CA-C-N 115.985 -0.552 . . . . 0.0 110.097 179.343 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -60.63 -39.43 96.54 Favored Glycine 0 N--CA 1.45 -0.409 0 C-N-CA 120.758 -0.734 . . . . 0.0 111.7 179.315 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 15' ' ' MET . . . . . 0.592 ' HE2' ' HE2' ' A' ' 51' ' ' TYR . 0.1 OUTLIER -63.54 -41.06 98.46 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 120.665 0.269 . . . . 0.0 110.575 179.422 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -55.98 -50.66 70.21 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.758 179.841 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 35.6 t -59.6 -46.4 93.19 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.389 -179.792 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -63.96 -48.5 75.32 Favored Glycine 0 C--N 1.331 0.262 0 C-N-CA 120.718 -0.753 . . . . 0.0 112.437 179.919 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 31.9 m -50.6 -44.24 56.97 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-O 120.723 0.297 . . . . 0.0 111.131 -179.774 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 95.2 mt -72.35 -40.28 67.48 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.622 179.907 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -63.19 -33.78 76.21 Favored 'General case' 0 C--N 1.331 -0.196 0 N-CA-C 112.065 0.395 . . . . 0.0 112.065 -179.294 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 22' ' ' PHE . . . . . 0.66 ' HB2' HG22 ' A' ' 41' ' ' VAL . 7.6 m-85 -86.2 -33.7 20.7 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.657 0.265 . . . . 0.0 111.658 -179.131 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -73.6 -50.7 19.85 Favored 'General case' 0 C--N 1.329 -0.297 0 N-CA-C 111.991 0.367 . . . . 0.0 111.991 -179.206 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 24' ' ' TRP . . . . . . . . . . . . . 2.7 t-105 -58.99 -46.62 87.7 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 116.029 -0.532 . . . . 0.0 111.239 -179.503 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -71.55 -21.1 61.94 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-O 120.828 0.347 . . . . 0.0 110.925 179.796 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -73.6 -37.73 52.14 Favored Glycine 0 N--CA 1.452 -0.269 0 C-N-CA 120.913 -0.66 . . . . 0.0 112.833 179.997 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 28.1 mmm180 -71.07 -39.04 72.44 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-O 120.688 0.28 . . . . 0.0 111.064 -179.761 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 30.5 t70 -78.51 -4.1 46.89 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.317 -0.402 . . . . 0.0 110.772 179.853 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -73.73 -171.93 1.16 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.177 -179.928 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -100.27 -174.44 30.07 Favored Glycine 0 N--CA 1.45 -0.386 0 C-N-CA 120.806 -0.712 . . . . 0.0 112.634 -179.856 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 75.4 p -81.37 126.7 31.93 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.827 0.346 . . . . 0.0 110.981 179.971 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 115.42 -61.94 0.37 Allowed Glycine 0 N--CA 1.451 -0.3 0 C-N-CA 120.88 -0.676 . . . . 0.0 112.562 -179.999 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 9.1 mm-40 -60.63 -21.07 62.32 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 120.698 0.285 . . . . 0.0 110.989 179.868 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 34' ' ' ARG . . . . . . . . . . . . . 38.6 ttm180 -48.44 -34.99 11.96 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-N 115.969 -0.559 . . . . 0.0 111.525 -179.758 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 70.3 mtm180 -55.1 -54.84 38.08 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.314 -0.403 . . . . 0.0 111.303 -179.986 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 82.0 m-85 -59.7 -28.7 67.53 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.097 -179.946 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 37' ' ' TYR . . . . . 0.428 ' O ' HG23 ' A' ' 41' ' ' VAL . 52.5 m-85 -71.97 -52.42 17.18 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.3 -0.409 . . . . 0.0 111.314 -179.893 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 59.8 t -57.69 -39.26 69.3 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.219 0 CA-C-O 121.116 0.484 . . . . 0.0 110.528 179.658 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 19.6 m -62.81 -50.93 69.05 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 115.576 -0.738 . . . . 0.0 110.715 179.403 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 40' ' ' LEU . . . . . 0.48 HD21 ' CA ' ' A' ' 209' ' ' GLY . 19.6 tp -57.57 -50.21 73.86 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 115.652 -0.704 . . . . 0.0 110.578 -179.997 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . 0.66 HG22 ' HB2' ' A' ' 22' ' ' PHE . 85.5 t -59.02 -34.9 54.39 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.235 0 CA-C-N 115.856 -0.611 . . . . 0.0 110.236 179.142 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -59.19 -39.56 94.66 Favored Glycine 0 N--CA 1.448 -0.505 0 C-N-CA 120.834 -0.698 . . . . 0.0 112.06 179.652 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 43' ' ' ILE . . . . . 0.535 HG12 HD12 ' A' ' 82' ' ' LEU . 1.2 mt -64.84 -55.59 20.15 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.193 0 CA-C-O 120.683 0.278 . . . . 0.0 110.728 179.567 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 51.3 m -57.72 -23.81 53.7 Favored 'General case' 0 C--O 1.232 0.178 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.181 -179.963 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -78.18 -56.23 3.79 Favored Glycine 0 CA--C 1.518 0.251 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.668 -179.772 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 26.6 pt -58.31 -35.4 53.49 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.215 0 CA-C-O 121.08 0.467 . . . . 0.0 110.912 179.944 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 47' ' ' ALA . . . . . 0.745 ' HB2' ' HE2' ' A' ' 205' ' ' LYS . . . -67.51 -46.74 71.99 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-N 116.031 -0.531 . . . . 0.0 111.307 179.346 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 48' ' ' ALA . . . . . 0.561 ' HB2' ' HB3' ' A' ' 15' ' ' MET . . . -54.87 -40.6 69.87 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 116.04 -0.527 . . . . 0.0 111.951 -179.485 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 25.1 m -73.08 -34.69 46.04 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 CA-C-N 116.63 -0.259 . . . . 0.0 111.516 -179.207 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . 0.403 ' O ' HG22 ' A' ' 53' ' ' VAL . . . -65.96 -38.18 87.93 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-O 121.145 0.498 . . . . 0.0 110.749 179.346 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 51' ' ' TYR . . . . . 0.592 ' HE2' ' HE2' ' A' ' 15' ' ' MET . 42.9 m-85 -73.09 -28.31 62.21 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-N 115.813 -0.631 . . . . 0.0 109.734 179.466 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -72.35 -38.88 68.48 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 115.419 -0.809 . . . . 0.0 110.97 179.517 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 53' ' ' VAL . . . . . 0.575 ' O ' HG22 ' A' ' 58' ' ' VAL . 33.8 m -73.95 -47.49 42.53 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.159 0 CA-C-N 116.402 -0.363 . . . . 0.0 110.78 -179.941 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 54' ' ' MET . . . . . 0.458 ' N ' HG23 ' A' ' 53' ' ' VAL . 75.0 mtm -57.75 -36.44 72.1 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-O 121.241 0.543 . . . . 0.0 109.949 179.094 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 55' ' ' ALA . . . . . 0.667 ' HB2' ' HB2' ' A' ' 8' ' ' PHE . . . -68.91 -11.69 60.86 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 115.317 -0.856 . . . . 0.0 111.705 179.876 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 47.4 mt -97.57 -4.21 38.15 Favored 'General case' 0 C--N 1.33 -0.259 0 N-CA-C 111.944 0.35 . . . . 0.0 111.944 -179.475 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 105.13 -23.0 31.77 Favored Glycine 0 CA--C 1.52 0.352 0 C-N-CA 120.373 -0.917 . . . . 0.0 114.004 179.23 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 58' ' ' VAL . . . . . 0.575 HG22 ' O ' ' A' ' 53' ' ' VAL . 16.3 m -62.05 160.41 2.21 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.128 0 CA-C-N 117.722 0.761 . . . . 0.0 109.768 179.343 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 59' ' ' GLY . . . . . 0.683 ' HA3' ' HD3' ' A' ' 71' ' ' PRO . . . 79.58 -25.56 2.86 Favored Glycine 0 N--CA 1.441 -1.033 0 C-N-CA 119.999 -1.096 . . . . 0.0 112.71 -178.844 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 60' ' ' TRP . . . . . . . . . . . . . 11.6 m0 -67.77 80.13 0.19 Allowed 'General case' 0 C--N 1.327 -0.388 0 N-CA-C 110.176 -0.305 . . . . 0.0 110.176 179.561 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 4.7 p -90.83 119.35 68.96 Favored Pre-proline 0 C--N 1.33 -0.266 0 CA-C-N 116.461 -0.336 . . . . 0.0 111.202 -179.747 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 35.8 Cg_exo -60.49 119.44 6.63 Favored 'Trans proline' 0 C--N 1.35 0.615 0 C-N-CA 122.451 2.101 . . . . 0.0 112.176 179.841 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 78.4 t -117.21 99.59 8.54 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.364 0 CA-C-N 115.931 -0.577 . . . . 0.0 110.918 179.914 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . 59.9 -85.65 0.02 OUTLIER 'General case' 0 C--N 1.332 -0.174 0 CA-C-N 116.095 -0.502 . . . . 0.0 111.254 -179.926 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 53.8 mm-40 -126.74 -26.69 3.18 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.335 179.521 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 66' ' ' ARG . . . . . . . . . . . . . 34.5 ptt180 -95.41 164.23 12.9 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 115.823 -0.626 . . . . 0.0 110.306 179.474 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 13.8 m -114.94 132.02 56.7 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.848 0.356 . . . . 0.0 111.265 -179.999 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 29.4 t -116.78 145.77 22.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.023 -0.535 . . . . 0.0 110.634 179.728 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 69' ' ' PHE . . . . . . . . . . . . . 10.8 m-85 -102.09 119.8 39.39 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-O 120.917 0.389 . . . . 0.0 110.659 -179.357 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 70' ' ' VAL . . . . . 0.632 HG13 ' O ' ' A' ' 59' ' ' GLY . 1.2 m -69.67 -35.57 5.7 Favored Pre-proline 0 CA--C 1.544 0.727 0 N-CA-C 113.05 0.759 . . . . 0.0 113.05 -179.344 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 71' ' ' PRO . . . . . 0.683 ' HD3' ' HA3' ' A' ' 59' ' ' GLY . 8.4 Cg_exo -70.56 -19.87 31.78 Favored 'Trans proline' 0 C--N 1.358 1.055 0 C-N-CA 122.579 2.186 . . . . 0.0 112.88 -178.146 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 72' ' ' ARG . . . . . 0.449 ' NH2' ' HG3' ' A' ' 183' ' ' PRO . 38.5 ttp180 -64.72 -53.46 46.84 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-O 120.949 0.404 . . . . 0.0 110.66 -179.916 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 73' ' ' TYR . . . . . . . . . . . . . 19.6 m-85 -73.19 -37.36 66.51 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.572 -179.97 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 74' ' ' ILE . . . . . 0.605 HG22 ' HA ' ' A' ' 71' ' ' PRO . 0.4 OUTLIER -64.08 -39.86 87.0 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 N-CA-C 109.877 -0.416 . . . . 0.0 109.877 179.439 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 75' ' ' ASP . . . . . 0.409 ' O ' HG23 ' A' ' 79' ' ' THR . 33.9 t70 -64.06 -34.8 78.84 Favored 'General case' 0 CA--C 1.516 -0.362 0 N-CA-C 108.882 -0.785 . . . . 0.0 108.882 178.868 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 76' ' ' TRP . . . . . 0.444 ' HB3' ' SD ' ' A' ' 109' ' ' MET . 44.5 m0 -66.42 -28.1 68.35 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 115.531 -0.759 . . . . 0.0 110.251 179.064 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 77' ' ' ILE . . . . . 0.497 ' O ' ' HG2' ' A' ' 81' ' ' PRO . 85.0 mt -75.89 -28.75 19.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-O 121.184 0.516 . . . . 0.0 109.69 178.827 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 52.0 mt -91.55 -18.32 24.27 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 115.758 -0.655 . . . . 0.0 111.446 179.183 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 79' ' ' THR . . . . . 0.409 HG23 ' O ' ' A' ' 75' ' ' ASP . 76.1 p -104.22 -50.98 3.22 Favored 'General case' 0 N--CA 1.464 0.225 0 N-CA-C 113.278 0.844 . . . . 0.0 113.278 -178.084 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 80' ' ' THR . . . . . 0.68 ' HB ' ' HD3' ' A' ' 81' ' ' PRO . 40.2 m -51.98 -55.19 32.89 Favored Pre-proline 0 CA--C 1.53 0.19 0 N-CA-C 111.947 0.351 . . . . 0.0 111.947 -178.642 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 81' ' ' PRO . . . . . 0.68 ' HD3' ' HB ' ' A' ' 80' ' ' THR . 40.6 Cg_exo -58.72 -21.8 57.97 Favored 'Trans proline' 0 C--N 1.352 0.748 0 C-N-CA 121.426 1.417 . . . . 0.0 111.133 179.406 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 82' ' ' LEU . . . . . 0.535 HD12 HG12 ' A' ' 43' ' ' ILE . 0.2 OUTLIER -76.36 -43.42 40.99 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 115.555 -0.748 . . . . 0.0 109.999 179.638 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 50.4 mm -63.76 -52.38 57.9 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.192 0 CA-C-N 116.074 -0.512 . . . . 0.0 110.424 179.512 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 29.3 m -57.98 -33.79 47.11 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.202 0 N-CA-C 109.738 -0.467 . . . . 0.0 109.738 179.104 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 85' ' ' TYR . . . . . 0.409 ' O ' ' HG ' ' A' ' 89' ' ' LEU . 61.6 t80 -62.1 -36.13 80.79 Favored 'General case' 0 N--CA 1.454 -0.27 0 CA-C-N 115.796 -0.638 . . . . 0.0 109.463 178.601 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 86' ' ' PHE . . . . . . . . . . . . . 13.0 t80 -59.7 -49.12 78.98 Favored 'General case' 0 C--O 1.232 0.183 0 CA-C-N 115.641 -0.709 . . . . 0.0 109.726 179.0 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 3.9 mm? -56.42 -41.8 76.96 Favored 'General case' 0 C--N 1.332 -0.176 0 CA-C-N 115.696 -0.684 . . . . 0.0 110.02 179.334 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -66.51 -27.97 73.46 Favored Glycine 0 N--CA 1.45 -0.397 0 CA-C-N 115.721 -0.672 . . . . 0.0 112.432 179.748 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 89' ' ' LEU . . . . . 0.409 ' HG ' ' O ' ' A' ' 85' ' ' TYR . 87.9 mt -71.0 -33.05 70.02 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.973 0.416 . . . . 0.0 110.516 179.814 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 95.6 mt -73.53 -30.98 63.42 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 115.884 -0.598 . . . . 0.0 111.134 179.824 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -88.47 -28.58 20.75 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.452 -0.34 . . . . 0.0 111.694 -179.603 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 80.62 58.05 2.78 Favored Glycine 0 N--CA 1.452 -0.3 0 C-N-CA 120.72 -0.752 . . . . 0.0 111.93 -179.5 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 94.5 mt -74.97 177.75 6.1 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.986 0.422 . . . . 0.0 111.506 -179.384 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 94' ' ' ASP . . . . . . . . . . . . . 9.9 m-20 -102.13 171.3 7.57 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-N 115.818 -0.628 . . . . 0.0 110.654 179.666 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 45.8 t -57.4 -36.91 71.91 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.292 -0.413 . . . . 0.0 111.192 -179.63 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 15.2 ptm180 -73.5 -48.12 35.75 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.467 -0.333 . . . . 0.0 111.343 -179.846 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 48.0 mt-10 -53.18 -45.69 68.65 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.303 -0.408 . . . . 0.0 111.079 -179.846 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 98' ' ' PHE . . . . . 0.472 ' O ' HG12 ' A' ' 102' ' ' ILE . 26.3 m-85 -59.25 -49.48 77.67 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.673 179.611 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -55.77 -28.02 51.25 Favored Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.811 -0.709 . . . . 0.0 112.862 -179.754 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 100' ' ' ILE . . . . . 0.424 ' O ' HG22 ' A' ' 103' ' ' THR . 93.5 mt -73.77 -49.05 37.16 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 N-CA-C 111.914 0.339 . . . . 0.0 111.914 -179.641 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 33.1 m -70.58 -32.55 50.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 N-CA-C 111.962 0.356 . . . . 0.0 111.962 -179.251 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 102' ' ' ILE . . . . . 0.504 HG23 ' HB3' ' A' ' 81' ' ' PRO . 50.2 mm -74.93 -43.0 46.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.536 -0.302 . . . . 0.0 111.426 -179.573 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 103' ' ' THR . . . . . 0.424 HG22 ' O ' ' A' ' 100' ' ' ILE . 14.7 t -63.52 -34.0 76.82 Favored 'General case' 0 C--O 1.232 0.134 0 CA-C-O 121.075 0.464 . . . . 0.0 110.116 179.532 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 104' ' ' LEU . . . . . 0.496 ' O ' HG23 ' A' ' 108' ' ' VAL . 42.8 tp -61.82 -57.11 13.11 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 115.796 -0.638 . . . . 0.0 110.072 179.101 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 105' ' ' ASN . . . . . 0.628 HD21 HD13 ' A' ' 137' ' ' LEU . 0.8 OUTLIER -55.95 -25.82 45.3 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 115.967 -0.561 . . . . 0.0 110.873 179.411 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 79.0 m -64.07 -57.53 9.36 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.422 -0.353 . . . . 0.0 111.205 -179.93 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 107' ' ' VAL . . . . . 0.416 HG12 ' O ' ' A' ' 104' ' ' LEU . 7.1 p -62.25 -35.83 71.29 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.211 0 CA-C-N 116.394 -0.366 . . . . 0.0 110.952 179.916 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . 0.496 HG23 ' O ' ' A' ' 104' ' ' LEU . 84.6 t -62.87 -56.99 14.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-O 121.052 0.453 . . . . 0.0 110.783 179.645 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 109' ' ' MET . . . . . 0.482 ' HE1' HG21 ' A' ' 80' ' ' THR . 5.5 tpp -58.07 -32.43 68.03 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 115.793 -0.639 . . . . 0.0 110.932 -179.729 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 22.4 tp -66.93 -35.97 81.19 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.243 179.663 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -62.46 -44.12 97.18 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 115.855 -0.611 . . . . 0.0 110.491 179.312 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . -64.17 -44.7 95.28 Favored Glycine 0 N--CA 1.452 -0.278 0 C-N-CA 120.751 -0.737 . . . . 0.0 112.289 179.519 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 113' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -51.04 -63.73 1.04 Allowed 'General case' 0 C--N 1.333 -0.149 0 CA-C-O 121.075 0.464 . . . . 0.0 110.347 179.765 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -67.31 -16.71 64.42 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 115.782 -0.645 . . . . 0.0 110.862 179.575 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -60.85 -47.01 93.34 Favored Glycine 0 C--N 1.332 0.35 0 C-N-CA 120.768 -0.729 . . . . 0.0 112.267 179.7 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 116' ' ' ALA . . . . . 0.414 ' HB2' ' HB3' ' A' ' 183' ' ' PRO . . . -78.48 -22.57 47.29 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 120.666 0.27 . . . . 0.0 111.631 179.796 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 117' ' ' MET . . . . . . . . . . . . . 1.1 mpt? -87.11 18.33 3.7 Favored 'General case' 0 C--N 1.332 -0.162 0 CA-C-N 116.53 -0.304 . . . . 0.0 111.712 -179.705 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 118' ' ' VAL . . . . . 0.5 HG21 ' HB3' ' A' ' 123' ' ' ARG . 27.3 m -76.13 147.69 80.28 Favored Pre-proline 0 C--N 1.327 -0.37 0 CA-C-N 116.668 -0.242 . . . . 0.0 111.305 179.99 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 119' ' ' PRO . . . . . . . . . . . . . 67.7 Cg_endo -84.55 -15.78 6.01 Favored 'Trans proline' 0 C--N 1.347 0.476 0 C-N-CA 122.667 2.245 . . . . 0.0 112.645 -179.987 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -143.68 -110.79 0.75 Allowed Glycine 0 C--N 1.333 0.369 0 C-N-CA 120.462 -0.875 . . . . 0.0 113.282 -179.53 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 47.9 pt -111.16 11.59 8.61 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.218 0 N-CA-C 111.783 0.29 . . . . 0.0 111.783 -179.225 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 15.7 mm-40 -58.39 -19.06 32.79 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.867 0.365 . . . . 0.0 110.815 179.819 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 123' ' ' ARG . . . . . 0.5 ' HB3' HG21 ' A' ' 118' ' ' VAL . 32.0 ptt180 -53.09 -30.02 33.83 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 115.714 -0.675 . . . . 0.0 111.843 -179.817 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 124' ' ' TYR . . . . . . . . . . . . . 48.5 m-85 -75.3 -32.62 61.03 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 116.316 -0.402 . . . . 0.0 111.907 -178.985 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 125' ' ' ALA . . . . . . . . . . . . . . . -70.68 -55.65 8.23 Favored 'General case' 0 C--O 1.238 0.453 0 CA-C-O 121.121 0.486 . . . . 0.0 110.892 179.953 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 1.3 mt -55.85 -46.07 78.31 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 115.591 -0.732 . . . . 0.0 110.607 -179.613 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 127' ' ' PHE . . . . . 0.459 ' HZ ' ' HB3' ' A' ' 175' ' ' PRO . 3.0 t80 -67.29 -39.01 85.95 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.442 -0.345 . . . . 0.0 110.555 179.618 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 128' ' ' GLY . . . . . . . . . . . . . . . -46.44 -43.72 15.1 Favored Glycine 0 C--O 1.237 0.284 0 C-N-CA 120.129 -1.034 . . . . 0.0 111.09 179.356 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 129' ' ' MET . . . . . . . . . . . . . 0.4 OUTLIER -70.92 -40.34 72.16 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 121.014 0.435 . . . . 0.0 110.263 178.999 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -66.32 -26.4 72.62 Favored Glycine 0 N--CA 1.452 -0.254 0 CA-C-N 115.727 -0.67 . . . . 0.0 113.018 -179.691 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -75.08 -53.66 8.5 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 120.664 0.269 . . . . 0.0 110.588 179.98 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 56.2 t -59.27 -41.01 82.7 Favored 'Isoleucine or valine' 0 C--O 1.234 0.275 0 N-CA-C 109.203 -0.666 . . . . 0.0 109.203 178.7 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -67.54 -34.53 77.26 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-N 115.207 -0.906 . . . . 0.0 110.549 179.214 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 134' ' ' PHE . . . . . . . . . . . . . 39.8 t80 -55.86 -54.77 40.55 Favored 'General case' 0 N--CA 1.452 -0.344 0 CA-C-N 116.209 -0.451 . . . . 0.0 109.992 179.485 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 135' ' ' ILE . . . . . 0.495 ' HA ' HG22 ' A' ' 138' ' ' VAL . 33.1 mt -58.15 -31.89 42.97 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 CA-C-N 115.711 -0.677 . . . . 0.0 110.116 179.164 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . -59.27 -44.89 96.17 Favored Glycine 0 N--CA 1.449 -0.488 0 C-N-CA 120.401 -0.904 . . . . 0.0 112.119 179.124 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 137' ' ' LEU . . . . . 0.628 HD13 HD21 ' A' ' 105' ' ' ASN . 13.9 tp -70.76 -52.02 23.38 Favored 'General case' 0 C--N 1.33 -0.258 0 C-N-CA 121.055 -0.258 . . . . 0.0 111.173 -179.867 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 138' ' ' VAL . . . . . 0.495 HG22 ' HA ' ' A' ' 135' ' ' ILE . 4.2 m -54.53 -31.56 23.49 Favored 'Isoleucine or valine' 0 C--O 1.232 0.168 0 N-CA-C 109.604 -0.517 . . . . 0.0 109.604 -179.737 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 139' ' ' TYR . . . . . . . . . . . . . 13.9 t80 -63.69 -44.53 93.41 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 115.616 -0.72 . . . . 0.0 109.596 178.16 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 24.9 m-85 -59.01 -42.83 91.06 Favored 'General case' 0 C--O 1.233 0.189 0 CA-C-N 115.971 -0.559 . . . . 0.0 111.05 179.402 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 141' ' ' LEU . . . . . 0.499 ' HA ' ' SD ' ' A' ' 145' ' ' MET . 9.4 mp -55.59 -49.76 71.91 Favored 'General case' 0 N--CA 1.462 0.17 0 CA-C-N 116.429 -0.351 . . . . 0.0 110.994 -179.774 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 12.6 p -82.46 -10.27 11.97 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.364 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.99 -179.98 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 143' ' ' GLY . . . . . 0.592 ' O ' HG22 ' A' ' 146' ' ' THR . . . -74.99 -144.97 1.1 Allowed Glycine 0 CA--C 1.521 0.455 0 C-N-CA 121.05 -0.595 . . . . 0.0 112.889 -179.766 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 144' ' ' PRO . . . . . . . . . . . . . 78.1 Cg_exo -50.07 -23.27 9.05 Favored 'Trans proline' 0 C--N 1.348 0.537 0 C-N-CA 122.794 2.329 . . . . 0.0 112.93 -179.934 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 145' ' ' MET . . . . . 0.499 ' SD ' ' HA ' ' A' ' 141' ' ' LEU . 27.4 mtt -52.4 -43.87 65.02 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.392 -0.367 . . . . 0.0 111.636 -179.681 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 146' ' ' THR . . . . . 0.592 HG22 ' O ' ' A' ' 143' ' ' GLY . 8.3 t -76.67 -31.77 57.51 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-O 120.907 0.384 . . . . 0.0 110.862 -179.471 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 34.0 tt0 -64.5 -40.4 95.59 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 115.989 -0.55 . . . . 0.0 110.769 179.858 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 148' ' ' SER . . . . . . . . . . . . . 55.5 m -70.41 -46.88 63.1 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.75 -179.972 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 149' ' ' ALA . . . . . . . . . . . . . . . -62.38 -32.41 73.21 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 115.935 -0.575 . . . . 0.0 111.19 -179.995 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 150' ' ' SER . . . . . . . . . . . . . 48.1 t -70.56 -1.64 11.66 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.815 179.843 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 151' ' ' GLN . . . . . . . . . . . . . 48.8 mt-30 -120.18 1.64 10.83 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.121 -0.491 . . . . 0.0 111.168 -179.832 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 26.6 mmm180 -81.88 -52.45 7.08 Favored 'General case' 0 C--N 1.332 -0.171 0 CA-C-O 121.11 0.481 . . . . 0.0 110.51 179.699 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 153' ' ' SER . . . . . 0.573 ' HB2' HG12 ' A' ' 156' ' ' ILE . 25.3 m -157.41 172.31 18.81 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-N 115.599 -0.728 . . . . 0.0 110.842 179.296 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 154' ' ' SER . . . . . . . . . . . . . 81.0 p -70.41 -39.1 74.64 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.303 -0.408 . . . . 0.0 110.709 179.579 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -77.21 -39.35 27.2 Favored Glycine 0 CA--C 1.518 0.269 0 C-N-CA 121.057 -0.592 . . . . 0.0 112.905 -179.83 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 156' ' ' ILE . . . . . 0.573 HG12 ' HB2' ' A' ' 153' ' ' SER . 35.6 mm -49.73 -38.92 14.08 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.175 0 CA-C-O 120.774 0.321 . . . . 0.0 111.823 -179.616 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 157' ' ' LYS . . . . . 0.434 ' O ' HG22 ' A' ' 161' ' ' VAL . 64.7 tttm -66.72 -37.91 85.63 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-N 116.304 -0.407 . . . . 0.0 111.363 -179.559 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 49.5 m -71.38 -37.91 71.56 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 121.003 0.43 . . . . 0.0 111.157 -178.815 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 159' ' ' LEU . . . . . 0.571 ' O ' ' HG ' ' A' ' 163' ' ' LEU . 31.3 mt -70.6 -56.79 5.66 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-N 116.043 -0.526 . . . . 0.0 111.13 -179.642 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 160' ' ' TYR . . . . . 0.45 ' OH ' ' HB3' ' A' ' 145' ' ' MET . 31.9 t80 -51.88 -41.83 62.2 Favored 'General case' 0 C--N 1.325 -0.466 0 N-CA-C 112.416 0.524 . . . . 0.0 112.416 -178.764 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 161' ' ' VAL . . . . . 0.468 HG23 ' N ' ' A' ' 162' ' ' ARG . 30.5 m -66.28 -49.07 78.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 N-CA-C 112.022 0.379 . . . . 0.0 112.022 -178.529 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 162' ' ' ARG . . . . . 0.468 ' N ' HG23 ' A' ' 161' ' ' VAL . 98.4 mtt180 -66.02 -49.38 67.94 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.768 0.318 . . . . 0.0 111.731 -179.205 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 163' ' ' LEU . . . . . 0.571 ' HG ' ' O ' ' A' ' 159' ' ' LEU . 19.7 mt -60.65 -55.43 33.32 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.635 -179.164 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 164' ' ' ARG . . . . . . . . . . . . . 3.8 ppt_? -58.85 -38.71 79.34 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.363 -0.38 . . . . 0.0 111.959 -178.967 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 165' ' ' ASN . . . . . 0.462 ' O ' HG23 ' A' ' 169' ' ' VAL . 0.9 OUTLIER -56.6 -53.62 55.49 Favored 'General case' 0 C--O 1.237 0.408 0 CA-C-O 120.751 0.31 . . . . 0.0 111.133 -178.383 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 166' ' ' LEU . . . . . 0.465 ' O ' ' HG ' ' A' ' 170' ' ' LEU . 0.2 OUTLIER -68.01 -28.89 67.81 Favored 'General case' 0 C--N 1.326 -0.439 0 C-N-CA 120.588 -0.445 . . . . 0.0 110.267 -179.917 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 167' ' ' THR . . . . . 0.412 ' O ' ' HB2' ' A' ' 171' ' ' TRP . 21.7 m -61.19 -53.35 57.98 Favored 'General case' 0 N--CA 1.462 0.131 0 CA-C-N 116.313 -0.403 . . . . 0.0 111.259 179.743 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 168' ' ' VAL . . . . . . . . . . . . . 60.4 t -60.04 -40.64 83.79 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 115.826 -0.624 . . . . 0.0 111.799 -179.054 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 169' ' ' VAL . . . . . 0.462 HG23 ' O ' ' A' ' 165' ' ' ASN . 93.9 t -56.74 -65.5 0.39 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 C-N-CA 120.914 -0.314 . . . . 0.0 111.739 -179.69 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 170' ' ' LEU . . . . . 0.465 ' HG ' ' O ' ' A' ' 166' ' ' LEU . 1.1 pp -62.8 -33.11 74.52 Favored 'General case' 0 C--N 1.33 -0.269 0 N-CA-C 112.467 0.543 . . . . 0.0 112.467 -178.576 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 171' ' ' TRP . . . . . 0.801 ' HE1' H203 ' A' ' 301' ' ' RET . 2.2 m0 -69.01 -31.28 69.99 Favored 'General case' 0 N--CA 1.463 0.22 0 C-N-CA 120.846 -0.341 . . . . 0.0 110.844 179.644 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 172' ' ' ALA . . . . . . . . . . . . . . . -74.53 -7.08 51.93 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-O 120.909 0.385 . . . . 0.0 110.587 -179.768 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 173' ' ' ILE . . . . . 0.527 HG22 HD11 ' A' ' 177' ' ' ILE . 40.6 mm -85.48 -21.84 7.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 115.787 -0.642 . . . . 0.0 110.865 179.62 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 174' ' ' TYR . . . . . 0.437 ' HB2' ' HD3' ' A' ' 175' ' ' PRO . 26.9 m-85 -54.56 -50.05 87.59 Favored Pre-proline 0 N--CA 1.464 0.242 0 CA-C-N 116.33 -0.396 . . . . 0.0 111.542 -179.975 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 175' ' ' PRO . . . . . 0.459 ' HB3' ' HZ ' ' A' ' 127' ' ' PHE . 86.8 Cg_exo -46.93 -30.79 10.16 Favored 'Trans proline' 0 C--N 1.352 0.749 0 C-N-CA 122.121 1.88 . . . . 0.0 112.215 179.575 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 176' ' ' PHE . . . . . 0.47 ' HD2' ' HA ' ' A' ' 173' ' ' ILE . 76.8 m-85 -80.38 -48.81 12.35 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 115.928 -0.578 . . . . 0.0 111.65 -179.768 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 177' ' ' ILE . . . . . 0.527 HD11 HG22 ' A' ' 173' ' ' ILE . 3.4 mm -63.47 -34.24 66.25 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.516 0 CA-C-N 116.374 -0.375 . . . . 0.0 111.881 -178.5 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 178' ' ' TRP . . . . . 0.431 ' HH2' ' HB2' ' A' ' 123' ' ' ARG . 73.8 t90 -74.03 -48.78 27.7 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 121.041 0.448 . . . . 0.0 110.449 179.438 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 179' ' ' LEU . . . . . 0.51 ' O ' HG22 ' A' ' 185' ' ' VAL . 1.9 tm? -63.55 -52.3 61.7 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 115.68 -0.691 . . . . 0.0 111.239 -179.395 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 180' ' ' LEU . . . . . 0.68 HD22 HD11 ' A' ' 187' ' ' LEU . 15.6 mt -76.73 -41.83 43.56 Favored 'General case' 0 C--N 1.329 -0.324 0 N-CA-C 112.076 0.398 . . . . 0.0 112.076 -178.914 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . -58.18 179.02 1.26 Allowed Glycine 0 C--N 1.334 0.456 0 C-N-CA 120.166 -1.016 . . . . 0.0 112.426 179.759 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 182' ' ' PRO . . . . . 0.451 ' HA ' ' HB2' ' A' ' 186' ' ' ALA . 72.0 Cg_exo -47.27 -45.29 22.47 Favored 'Trans proline' 0 CA--C 1.536 0.61 0 C-N-CA 122.741 2.294 . . . . 0.0 113.798 -179.856 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 183' ' ' PRO . . . . . 0.449 ' HG3' ' NH2' ' A' ' 72' ' ' ARG . 71.6 Cg_exo -49.49 -22.98 6.91 Favored 'Trans proline' 0 C--N 1.356 0.955 0 C-N-CA 122.223 1.949 . . . . 0.0 113.121 -179.786 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 184' ' ' GLY . . . . . . . . . . . . . . . -119.07 -132.99 4.58 Favored Glycine 0 N--CA 1.449 -0.448 0 C-N-CA 120.484 -0.865 . . . . 0.0 112.906 -179.824 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 185' ' ' VAL . . . . . 0.51 HG22 ' O ' ' A' ' 179' ' ' LEU . 13.3 m -58.75 -21.02 17.93 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.396 0 N-CA-C 112.13 0.418 . . . . 0.0 112.13 -179.485 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 186' ' ' ALA . . . . . 0.451 ' HB2' ' HA ' ' A' ' 182' ' ' PRO . . . 55.61 87.18 0.05 Allowed 'General case' 0 N--CA 1.463 0.194 0 CA-C-O 120.74 0.305 . . . . 0.0 111.391 179.906 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 187' ' ' LEU . . . . . 0.68 HD11 HD22 ' A' ' 180' ' ' LEU . 15.8 mt -91.75 -49.54 6.21 Favored 'General case' 0 C--N 1.332 -0.195 0 CA-C-N 116.291 -0.413 . . . . 0.0 111.341 -179.713 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 188' ' ' LEU . . . . . . . . . . . . . 68.6 mt -96.85 -155.07 0.47 Allowed 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 115.923 -0.58 . . . . 0.0 110.991 -179.573 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 189' ' ' THR . . . . . . . . . . . . . 1.9 t -101.6 146.74 32.76 Favored Pre-proline 0 C--N 1.328 -0.367 0 CA-C-N 116.001 -0.545 . . . . 0.0 110.817 -179.987 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 190' ' ' PRO . . . . . . . . . . . . . 86.5 Cg_exo -47.09 -45.2 21.97 Favored 'Trans proline' 0 C--N 1.348 0.502 0 C-N-CA 122.694 2.262 . . . . 0.0 113.35 -179.528 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 191' ' ' THR . . . . . . . . . . . . . 5.6 t -56.58 -39.95 74.4 Favored 'General case' 0 C--N 1.329 -0.316 0 N-CA-C 112.061 0.393 . . . . 0.0 112.061 -179.338 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 192' ' ' VAL . . . . . . . . . . . . . 40.6 t -73.37 -53.82 17.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 N-CA-C 111.909 0.337 . . . . 0.0 111.909 -179.435 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 193' ' ' ASP . . . . . . . . . . . . . 19.0 m-20 -58.36 -50.11 74.84 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.516 -0.311 . . . . 0.0 111.217 -179.829 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 194' ' ' VAL . . . . . . . . . . . . . 78.0 t -59.9 -36.33 66.04 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 116.339 -0.392 . . . . 0.0 110.691 179.557 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 195' ' ' ALA . . . . . . . . . . . . . . . -56.26 -47.85 77.72 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 116.397 -0.365 . . . . 0.0 111.121 179.792 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 196' ' ' LEU . . . . . . . . . . . . . 91.6 mt -64.99 -35.39 81.02 Favored 'General case' 0 C--N 1.332 -0.177 0 CA-C-O 120.771 0.319 . . . . 0.0 110.464 179.658 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 197' ' ' ILE . . . . . 0.477 HG12 HG21 ' A' ' 177' ' ' ILE . 19.6 mm -61.46 -53.8 43.7 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-O 121.142 0.496 . . . . 0.0 110.022 178.972 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 198' ' ' VAL . . . . . . . . . . . . . 98.3 t -54.91 -34.32 30.81 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.47 0 CA-C-N 115.344 -0.844 . . . . 0.0 109.33 178.471 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 199' ' ' TYR . . . . . 0.406 ' O ' HG23 ' A' ' 203' ' ' VAL . 68.8 t80 -69.35 -40.4 77.53 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 115.083 -0.962 . . . . 0.0 110.246 179.925 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 200' ' ' LEU . . . . . . . . . . . . . 38.1 mt -61.72 -41.56 97.79 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 115.74 -0.663 . . . . 0.0 111.371 -179.773 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 201' ' ' ASP . . . . . 0.459 ' OD2' ' H14' ' A' ' 301' ' ' RET . 0.9 OUTLIER -71.87 -40.39 68.98 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.041 -179.807 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 202' ' ' LEU . . . . . 0.403 ' O ' ' HB ' ' A' ' 206' ' ' VAL . 2.7 mt -65.2 -33.71 76.66 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.119 -0.491 . . . . 0.0 111.617 -179.401 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 203' ' ' VAL . . . . . 0.523 ' O ' ' HA3' ' A' ' 207' ' ' GLY . 65.9 t -77.31 -36.07 23.4 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.384 0 CA-C-O 120.74 0.305 . . . . 0.0 111.381 -179.12 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 204' ' ' THR . . . . . 0.42 HG23 ' CE2' ' A' ' 208' ' ' PHE . 88.8 m -66.46 -58.61 4.9 Favored 'General case' 0 C--N 1.325 -0.497 0 C-N-CA 120.745 -0.382 . . . . 0.0 111.298 179.95 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 205' ' ' LYS . . . . . 0.745 ' HE2' ' HB2' ' A' ' 47' ' ' ALA . 36.1 mttp -68.13 -58.75 3.96 Favored 'General case' 0 C--N 1.328 -0.338 0 N-CA-C 112.489 0.551 . . . . 0.0 112.489 -178.348 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 206' ' ' VAL . . . . . 0.403 ' HB ' ' O ' ' A' ' 202' ' ' LEU . 17.9 t -73.46 -37.0 49.77 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.369 0 N-CA-C 112.084 0.401 . . . . 0.0 112.084 -178.281 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 207' ' ' GLY . . . . . 0.523 ' HA3' ' O ' ' A' ' 203' ' ' VAL . . . -59.35 -60.05 9.52 Favored Glycine 0 N--CA 1.452 -0.278 0 C-N-CA 120.313 -0.946 . . . . 0.0 112.502 -179.36 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 208' ' ' PHE . . . . . 0.513 ' O ' ' N ' ' A' ' 212' ' ' ALA . 1.2 m-30 -58.48 -43.76 89.09 Favored 'General case' 0 C--O 1.221 -0.402 0 CA-C-N 117.111 0.456 . . . . 0.0 110.069 179.739 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 209' ' ' GLY . . . . . 0.487 ' O ' ' HB3' ' A' ' 212' ' ' ALA . . . -53.72 -37.89 57.99 Favored Glycine 0 CA--C 1.518 0.239 0 CA-C-N 115.501 -0.772 . . . . 0.0 113.957 -179.923 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 210' ' ' PHE . . . . . . . . . . . . . 2.6 m-85 -70.01 -48.68 57.12 Favored 'General case' 0 CA--C 1.515 -0.39 0 N-CA-C 108.906 -0.775 . . . . 0.0 108.906 179.664 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 211' ' ' ILE . . . . . 0.435 HG13 ' O ' ' A' ' 207' ' ' GLY . 5.3 mt -63.87 -27.43 42.82 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.569 0 N-CA-C 107.47 -1.308 . . . . 0.0 107.47 176.629 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 212' ' ' ALA . . . . . 0.513 ' N ' ' O ' ' A' ' 208' ' ' PHE . . . -68.37 -38.61 81.56 Favored 'General case' 0 N--CA 1.449 -0.488 0 CA-C-N 114.173 -1.376 . . . . 0.0 110.481 -179.866 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 213' ' ' LEU . . . . . . . . . . . . . 52.9 mt -65.44 -54.65 25.4 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-N 115.139 -0.937 . . . . 0.0 111.093 -179.811 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 214' ' ' ASP . . . . . . . . . . . . . 15.8 m-20 -60.57 -27.05 67.4 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.367 -0.379 . . . . 0.0 110.466 179.746 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 215' ' ' ALA . . . . . 0.437 ' O ' ' HG ' ' A' ' 219' ' ' LEU . . . -68.94 -57.77 5.04 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.073 -0.512 . . . . 0.0 111.193 -179.964 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 216' ' ' ALA . . . . . . . . . . . . . . . -63.28 -31.27 72.37 Favored 'General case' 0 C--N 1.331 -0.21 0 CA-C-N 116.332 -0.395 . . . . 0.0 110.972 -179.974 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 217' ' ' ALA . . . . . . . . . . . . . . . -64.64 -37.56 87.98 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.045 -0.525 . . . . 0.0 110.433 179.73 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 218' ' ' THR . . . . . . . . . . . . . 99.1 m -69.08 -40.74 78.26 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 115.817 -0.628 . . . . 0.0 110.508 179.456 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 219' ' ' LEU . . . . . 0.437 ' HG ' ' O ' ' A' ' 215' ' ' ALA . 42.9 mt -63.93 -33.54 75.94 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.373 179.491 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 220' ' ' ARG . . . . . . . . . . . . . 58.4 ttt180 -78.7 -30.85 46.29 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 115.879 -0.601 . . . . 0.0 110.531 179.821 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 221' ' ' ALA . . . . . . . . . . . . . . . -70.45 -29.44 66.01 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.009 179.776 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 222' ' ' GLU . . . . . 0.672 ' HG3' ' H ' ' A' ' 224' ' ' GLY . 12.3 pt-20 -92.01 -21.88 20.27 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.334 179.849 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 223' ' ' HIS . . . . . . . . . . . . . 53.9 m-70 60.48 11.27 2.9 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 115.687 -0.688 . . . . 0.0 111.156 179.648 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 224' ' ' GLY . . . . . 0.672 ' H ' ' HG3' ' A' ' 222' ' ' GLU . . . 82.62 -54.86 4.96 Favored Glycine 0 N--CA 1.45 -0.389 0 C-N-CA 120.872 -0.68 . . . . 0.0 112.239 -179.835 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 225' ' ' GLU . . . . . . . . . . . . . 44.9 mt-10 -107.96 146.2 32.78 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.761 0.315 . . . . 0.0 110.509 179.719 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 226' ' ' SER . . . . . . . . . . . . . 81.7 p -139.98 125.71 19.38 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.296 -0.411 . . . . 0.0 111.005 -179.703 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 227' ' ' LEU . . . . . . . . . . . . . 4.3 pp -54.79 152.34 7.32 Favored 'General case' 0 C--N 1.331 -0.21 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.959 -179.96 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 228' ' ' ALA . . . . . . . . . . . . . . . -117.04 131.55 56.91 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.058 179.875 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 229' ' ' GLY . . . . . . . . . . . . . . . 132.89 -109.36 0.83 Allowed Glycine 0 N--CA 1.45 -0.37 0 C-N-CA 120.834 -0.698 . . . . 0.0 112.378 -179.953 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 230' ' ' VAL . . . . . . . . . . . . . 60.7 t -99.53 116.83 43.64 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.355 0 CA-C-O 120.824 0.345 . . . . 0.0 111.103 179.9 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 231' ' ' ASP . . . . . . . . . . . . . 7.5 p-10 -97.98 132.9 43.15 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.976 -179.858 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 232' ' ' THR . . . . . . . . . . . . . 4.1 t -157.24 128.53 6.84 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.15 179.852 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 233' ' ' ASP . . . . . . . . . . . . . 6.4 p-10 -167.52 156.34 9.76 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.132 -0.486 . . . . 0.0 110.807 179.971 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 234' ' ' THR . . . . . 0.4 ' HA ' ' HD3' ' A' ' 235' ' ' PRO . 5.4 t -127.77 142.52 44.51 Favored Pre-proline 0 C--N 1.33 -0.278 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.889 179.836 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 235' ' ' PRO . . . . . 0.4 ' HD3' ' HA ' ' A' ' 234' ' ' THR . 32.4 Cg_exo -58.45 138.44 85.83 Favored 'Trans proline' 0 C--N 1.348 0.537 0 C-N-CA 122.448 2.099 . . . . 0.0 112.287 179.932 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 236' ' ' ALA . . . . . . . . . . . . . . . -159.84 106.41 1.63 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.031 -0.531 . . . . 0.0 110.87 -179.978 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 237' ' ' VAL . . . . . . . . . . . . . 46.7 t -116.53 102.75 14.07 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-N 116.085 -0.507 . . . . 0.0 111.022 -179.777 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 238' ' ' ALA . . . . . . . . . . . . . . . -164.54 124.48 1.98 Allowed 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.144 -179.987 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 239' ' ' ASP . . . . . . . . . . . . . 7.8 p-10 -76.33 149.75 36.99 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.275 -0.42 . . . . 0.0 111.037 -179.907 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 240' ' ' LEU . . . . . . . . . . . . . 88.5 mt -94.96 -36.79 11.44 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.052 -0.522 . . . . 0.0 110.928 -179.998 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 241' ' ' GLU . . . . . . . . . . . . . 11.0 tp10 59.58 94.86 0.03 OUTLIER 'General case' 0 C--N 1.333 -0.12 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.934 179.992 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 242' ' ' HIS . . . . . . . . . . . . . 27.2 p80 -148.37 144.76 27.73 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.947 179.953 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 243' ' ' HIS . . . . . . . . . . . . . 35.6 m-70 -72.99 175.57 6.52 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.877 179.861 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 244' ' ' HIS . . . . . . . . . . . . . 32.0 m80 -82.56 -56.48 3.84 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.123 -0.489 . . . . 0.0 110.761 179.711 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 245' ' ' HIS . . . . . . . . . . . . . 25.1 t60 -87.68 143.65 27.06 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.412 179.549 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 246' ' ' HIS . . . . . . . . . . . . . 12.1 t60 -60.02 -71.98 0.12 Allowed 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.343 -0.39 . . . . 0.0 111.331 -179.421 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 247' ' ' HIS . . . . . . . . . . . . . 55.7 t-80 . . . . . 0 C--O 1.25 1.081 0 CA-C-O 118.284 -0.865 . . . . 0.0 111.075 -179.754 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 301' ' ' RET . . . . . 0.801 H203 ' HE1' ' A' ' 171' ' ' TRP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 86.9 mtp . . . . . 0 N--CA 1.485 1.325 0 CA-C-O 120.789 0.328 . . . . 0.0 110.823 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 55.4 t -132.04 -34.15 0.54 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.221 0 CA-C-N 116.178 -0.465 . . . . 0.0 111.331 -179.985 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -78.8 -31.85 42.82 Favored Glycine 0 N--CA 1.452 -0.238 0 C-N-CA 120.639 -0.791 . . . . 0.0 112.34 179.973 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 4' ' ' LEU . . . . . 0.514 HD11 HG21 ' A' ' 194' ' ' VAL . 47.6 tp -74.12 -36.95 64.23 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-O 120.849 0.356 . . . . 0.0 110.989 179.934 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 70.8 p -59.44 -31.99 69.8 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.077 -0.51 . . . . 0.0 111.665 -179.616 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 32.3 p -55.62 -35.45 65.9 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-O 120.844 0.354 . . . . 0.0 111.191 -179.773 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 7' ' ' LEU . . . . . . . . . . . . . 4.0 mm? -58.98 -53.05 62.81 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.123 -0.49 . . . . 0.0 111.087 179.952 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 8' ' ' PHE . . . . . 0.457 ' HB2' ' HB2' ' A' ' 55' ' ' ALA . 73.6 m-85 -58.81 -33.11 70.01 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 116.34 -0.391 . . . . 0.0 110.817 179.932 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 9' ' ' TRP . . . . . 0.433 ' O ' HG13 ' A' ' 13' ' ' ILE . 27.8 m95 -66.35 -46.61 76.18 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 116.013 -0.54 . . . . 0.0 110.152 -179.862 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 94.1 mt -59.82 -42.07 92.7 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 115.651 -0.704 . . . . 0.0 110.347 179.377 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -63.42 -30.42 77.53 Favored Glycine 0 N--CA 1.449 -0.496 0 C-N-CA 120.712 -0.756 . . . . 0.0 111.724 179.348 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -73.19 -30.79 63.78 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.795 0.331 . . . . 0.0 110.82 179.678 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 13' ' ' ILE . . . . . 0.433 HG13 ' O ' ' A' ' 9' ' ' TRP . 67.0 mt -67.61 -54.7 21.22 Favored 'Isoleucine or valine' 0 C--O 1.233 0.206 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.399 179.473 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -62.46 -35.09 91.23 Favored Glycine 0 N--CA 1.449 -0.474 0 C-N-CA 120.716 -0.755 . . . . 0.0 111.399 179.209 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 15' ' ' MET . . . . . 0.496 ' SD ' ' HA ' ' A' ' 44' ' ' SER . 45.5 tpp -62.75 -41.96 99.45 Favored 'General case' 0 N--CA 1.453 -0.294 0 CA-C-O 120.814 0.34 . . . . 0.0 110.209 179.376 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 16' ' ' LEU . . . . . 0.415 HD13 ' O ' ' A' ' 16' ' ' LEU . 0.3 OUTLIER -59.46 -37.74 78.96 Favored 'General case' 0 C--N 1.331 -0.201 0 N-CA-C 109.635 -0.505 . . . . 0.0 109.635 178.893 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 46.5 t -59.24 -43.23 89.28 Favored 'Isoleucine or valine' 0 C--O 1.232 0.176 0 CA-C-N 116.033 -0.531 . . . . 0.0 110.134 179.143 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -68.25 -42.89 81.98 Favored Glycine 0 C--N 1.331 0.291 0 C-N-CA 120.795 -0.717 . . . . 0.0 111.884 179.187 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 9.9 m -50.14 -46.24 53.74 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.698 0.285 . . . . 0.0 111.352 -179.604 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 92.7 mt -72.01 -43.17 65.46 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.271 -0.422 . . . . 0.0 111.618 -179.712 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -58.31 -33.23 69.25 Favored 'General case' 0 C--N 1.33 -0.267 0 N-CA-C 112.048 0.388 . . . . 0.0 112.048 -179.252 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 22' ' ' PHE . . . . . 0.42 ' HB2' HG22 ' A' ' 41' ' ' VAL . 5.3 m-85 -90.57 -37.67 13.68 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 120.624 0.249 . . . . 0.0 111.495 -179.367 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -65.91 -51.18 60.83 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.874 0.369 . . . . 0.0 111.659 -179.507 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 24' ' ' TRP . . . . . . . . . . . . . 3.4 t-105 -60.44 -52.87 63.37 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-N 115.948 -0.569 . . . . 0.0 111.145 -179.66 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -68.67 -20.6 64.44 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.358 -0.383 . . . . 0.0 111.032 179.942 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -73.65 -43.75 34.99 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.855 -0.688 . . . . 0.0 112.599 179.896 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 31.2 mmt180 -62.89 -24.56 67.88 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-O 120.826 0.346 . . . . 0.0 110.997 -179.877 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 14.3 t70 -120.05 98.09 5.91 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.788 179.93 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 29' ' ' ALA . . . . . 0.4 ' HB1' ' OE1' ' A' ' 33' ' ' GLU . . . -162.46 -78.51 0.04 OUTLIER 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.385 -0.37 . . . . 0.0 111.387 -179.872 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -150.67 -147.46 4.55 Favored Glycine 0 N--CA 1.452 -0.245 0 C-N-CA 120.66 -0.781 . . . . 0.0 112.49 -179.876 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 43.9 t -120.09 -34.33 3.72 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-O 120.775 0.321 . . . . 0.0 111.155 -179.895 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -97.47 -41.05 3.51 Favored Glycine 0 N--CA 1.452 -0.247 0 C-N-CA 120.693 -0.765 . . . . 0.0 112.569 -179.992 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 33' ' ' GLU . . . . . 0.4 ' OE1' ' HB1' ' A' ' 29' ' ' ALA . 11.0 pt-20 -58.94 -20.53 53.0 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 120.644 0.259 . . . . 0.0 111.255 179.893 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 34' ' ' ARG . . . . . 0.46 ' O ' HG23 ' A' ' 38' ' ' VAL . 74.2 mtp180 -49.2 -29.43 5.61 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.379 -179.89 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 98.9 mtt180 -60.21 -46.62 89.13 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.82 0.343 . . . . 0.0 111.057 179.899 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 52.7 m-85 -66.79 -42.66 85.62 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.176 -0.466 . . . . 0.0 111.068 -179.933 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 37' ' ' TYR . . . . . 0.404 ' O ' HG23 ' A' ' 41' ' ' VAL . 51.9 m-85 -63.45 -51.82 64.08 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.213 -0.448 . . . . 0.0 111.449 -179.6 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 38' ' ' VAL . . . . . 0.46 HG23 ' O ' ' A' ' 34' ' ' ARG . 78.2 t -56.81 -36.73 50.51 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-O 121.005 0.431 . . . . 0.0 110.222 179.662 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 17.4 m -65.35 -47.85 75.05 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 115.852 -0.613 . . . . 0.0 110.257 178.976 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 48.8 tp -56.11 -45.84 79.32 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 115.665 -0.698 . . . . 0.0 110.096 179.21 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . 0.42 HG22 ' HB2' ' A' ' 22' ' ' PHE . 96.5 t -60.81 -34.48 59.38 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.249 0 CA-C-N 115.698 -0.683 . . . . 0.0 109.983 179.068 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -57.03 -44.17 93.02 Favored Glycine 0 N--CA 1.447 -0.593 0 C-N-CA 120.813 -0.708 . . . . 0.0 111.834 179.599 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 43' ' ' ILE . . . . . 0.551 HG22 ' HE3' ' A' ' 205' ' ' LYS . 0.3 OUTLIER -63.1 -51.58 69.81 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.179 0 CA-C-O 120.7 0.286 . . . . 0.0 110.951 179.501 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 44' ' ' SER . . . . . 0.496 ' HA ' ' SD ' ' A' ' 15' ' ' MET . 87.5 p -60.41 -29.33 68.91 Favored 'General case' 0 C--O 1.232 0.155 0 CA-C-O 120.841 0.353 . . . . 0.0 111.305 -179.981 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -77.34 -51.31 6.16 Favored Glycine 0 CA--C 1.519 0.322 0 C-N-CA 120.668 -0.777 . . . . 0.0 113.11 -179.344 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 46' ' ' ILE . . . . . 0.669 HD12 HD12 ' A' ' 78' ' ' LEU . 12.4 pt -58.62 -37.53 65.8 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.242 0 CA-C-O 120.936 0.398 . . . . 0.0 110.979 -179.839 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 47' ' ' ALA . . . . . 0.688 ' HB2' ' HE2' ' A' ' 205' ' ' LYS . . . -67.87 -44.03 78.02 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.124 -0.489 . . . . 0.0 111.426 179.47 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 48' ' ' ALA . . . . . 0.425 ' HB2' ' HG3' ' A' ' 15' ' ' MET . . . -55.19 -43.25 74.22 Favored 'General case' 0 C--N 1.332 -0.194 0 CA-C-N 116.05 -0.523 . . . . 0.0 112.051 -179.326 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 35.5 m -73.2 -35.29 46.87 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.245 0 CA-C-O 120.684 0.278 . . . . 0.0 111.461 -179.541 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -63.29 -39.21 93.95 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-O 121.035 0.445 . . . . 0.0 110.965 179.955 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 24.5 m-85 -73.08 -38.96 66.23 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-N 115.817 -0.629 . . . . 0.0 110.648 -179.831 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -62.64 -45.46 92.73 Favored 'General case' 0 C--N 1.327 -0.413 0 CA-C-N 115.983 -0.553 . . . . 0.0 111.255 179.854 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 53' ' ' VAL . . . . . 0.551 ' O ' HG12 ' A' ' 58' ' ' VAL . 32.3 m -66.43 -52.9 41.57 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.122 0 CA-C-N 116.504 -0.316 . . . . 0.0 111.056 -179.949 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 54' ' ' MET . . . . . 0.539 ' N ' HG23 ' A' ' 53' ' ' VAL . 76.0 mtm -58.35 -34.96 71.22 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-O 121.156 0.503 . . . . 0.0 110.134 179.508 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 55' ' ' ALA . . . . . 0.457 ' HB2' ' HB2' ' A' ' 8' ' ' PHE . . . -63.31 -29.49 70.8 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 115.588 -0.733 . . . . 0.0 111.322 179.474 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 96.3 mt -79.23 -8.23 58.87 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.383 -0.371 . . . . 0.0 111.383 -179.633 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 98.75 -6.89 60.77 Favored Glycine 0 N--CA 1.45 -0.368 0 C-N-CA 120.531 -0.842 . . . . 0.0 113.018 179.545 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 58' ' ' VAL . . . . . 0.551 HG12 ' O ' ' A' ' 53' ' ' VAL . 3.8 p -75.26 154.4 6.3 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.235 0 CA-C-N 116.906 0.353 . . . . 0.0 110.636 179.926 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 76.3 22.77 72.62 Favored Glycine 0 N--CA 1.452 -0.261 0 C-N-CA 120.634 -0.794 . . . . 0.0 112.275 -179.408 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 60' ' ' TRP . . . . . . . . . . . . . 19.1 m0 -104.75 100.88 10.52 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-O 120.972 0.415 . . . . 0.0 110.043 179.967 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 61' ' ' VAL . . . . . 0.485 ' HB ' HG23 ' A' ' 68' ' ' VAL . 57.3 t -97.01 107.58 38.49 Favored Pre-proline 0 C--N 1.327 -0.389 0 CA-C-N 115.894 -0.594 . . . . 0.0 111.521 -179.448 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 62' ' ' PRO . . . . . 0.424 ' HD2' ' HA ' ' A' ' 61' ' ' VAL . 31.3 Cg_endo -63.53 135.0 47.18 Favored 'Trans proline' 0 C--N 1.35 0.613 0 C-N-CA 122.384 2.056 . . . . 0.0 111.894 179.461 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 85.8 t -136.68 94.02 1.12 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.38 0 CA-C-N 116.109 -0.496 . . . . 0.0 111.319 -179.43 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . 57.38 -88.95 0.02 OUTLIER 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.485 179.905 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 38.0 tt0 -117.65 -22.8 7.89 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-O 120.913 0.387 . . . . 0.0 110.638 179.981 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 66' ' ' ARG . . . . . . . . . . . . . 41.5 mmt180 -102.79 157.64 16.82 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.039 -0.528 . . . . 0.0 110.225 179.747 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 26.2 m -124.14 116.43 22.73 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-O 120.869 0.366 . . . . 0.0 111.334 -179.854 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 68' ' ' VAL . . . . . 0.504 HG11 ' HA ' ' A' ' 117' ' ' MET . 24.0 m -90.77 145.53 7.31 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 115.986 -0.552 . . . . 0.0 110.84 179.664 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 69' ' ' PHE . . . . . . . . . . . . . 42.5 m-85 -109.65 111.35 22.77 Favored 'General case' 0 N--CA 1.441 -0.918 0 N-CA-C 109.879 -0.415 . . . . 0.0 109.879 -179.819 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 70' ' ' VAL . . . . . 0.577 ' N ' ' HD2' ' A' ' 71' ' ' PRO . 38.6 t -60.73 -50.11 86.66 Favored Pre-proline 0 C--N 1.326 -0.427 0 CA-C-N 116.42 -0.355 . . . . 0.0 111.903 -179.042 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 71' ' ' PRO . . . . . 0.577 ' HD2' ' N ' ' A' ' 70' ' ' VAL . 36.6 Cg_endo -64.7 -17.84 60.78 Favored 'Trans proline' 0 C--N 1.35 0.638 0 C-N-CA 122.288 1.992 . . . . 0.0 112.971 -179.343 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 37.3 ttp180 -70.95 -55.24 8.79 Favored 'General case' 0 C--O 1.235 0.321 0 C-N-CA 121.025 -0.27 . . . . 0.0 111.332 -179.492 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 73' ' ' TYR . . . . . 0.463 ' O ' HG13 ' A' ' 77' ' ' ILE . 5.7 m-85 -68.48 -34.52 76.08 Favored 'General case' 0 C--N 1.332 -0.185 0 C-N-CA 120.686 -0.406 . . . . 0.0 109.994 179.911 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 74' ' ' ILE . . . . . 0.524 ' HA ' HD12 ' A' ' 77' ' ' ILE . 0.4 OUTLIER -67.72 -36.75 77.03 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.173 0 CA-C-N 116.174 -0.467 . . . . 0.0 110.123 179.526 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 75' ' ' ASP . . . . . 0.43 ' O ' HG23 ' A' ' 79' ' ' THR . 11.3 t70 -60.5 -37.61 81.68 Favored 'General case' 0 CA--C 1.518 -0.262 0 N-CA-C 109.188 -0.671 . . . . 0.0 109.188 178.749 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 76' ' ' TRP . . . . . . . . . . . . . 40.6 m0 -69.86 -28.1 65.38 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 115.638 -0.71 . . . . 0.0 110.562 179.247 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 77' ' ' ILE . . . . . 0.573 ' HA ' ' HG3' ' A' ' 109' ' ' MET . 96.3 mt -68.56 -36.27 73.89 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.34 179.596 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 78' ' ' LEU . . . . . 0.669 HD12 HD12 ' A' ' 46' ' ' ILE . 0.7 OUTLIER -90.75 -26.76 19.33 Favored 'General case' 0 C--N 1.328 -0.358 0 N-CA-C 112.81 0.671 . . . . 0.0 112.81 -179.65 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 79' ' ' THR . . . . . 0.43 HG23 ' O ' ' A' ' 75' ' ' ASP . 64.8 p -84.71 -52.27 6.2 Favored 'General case' 0 C--N 1.327 -0.374 0 N-CA-C 113.71 1.004 . . . . 0.0 113.71 -178.548 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 80' ' ' THR . . . . . 0.696 ' HB ' ' HD3' ' A' ' 81' ' ' PRO . 34.0 m -53.42 -56.12 27.73 Favored Pre-proline 0 CA--C 1.533 0.314 0 N-CA-C 112.567 0.581 . . . . 0.0 112.567 -177.902 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 81' ' ' PRO . . . . . 0.696 ' HD3' ' HB ' ' A' ' 80' ' ' THR . 43.5 Cg_exo -58.33 -19.21 41.88 Favored 'Trans proline' 0 C--N 1.352 0.744 0 C-N-CA 121.728 1.618 . . . . 0.0 111.956 179.966 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 82' ' ' LEU . . . . . . . . . . . . . 16.2 tp -76.72 -35.66 57.67 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.078 179.575 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 83' ' ' ILE . . . . . 0.523 HD11 HG21 ' A' ' 43' ' ' ILE . 41.3 mm -69.57 -51.27 43.25 Favored 'Isoleucine or valine' 0 C--O 1.233 0.222 0 CA-C-N 115.926 -0.579 . . . . 0.0 110.379 179.214 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . 0.48 HG22 ' HA ' ' A' ' 81' ' ' PRO . 33.0 m -60.95 -31.96 51.16 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.212 0 N-CA-C 109.505 -0.554 . . . . 0.0 109.505 179.062 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 85' ' ' TYR . . . . . 0.416 ' O ' ' HG ' ' A' ' 89' ' ' LEU . 81.3 t80 -65.42 -33.6 76.32 Favored 'General case' 0 N--CA 1.453 -0.291 0 CA-C-N 115.559 -0.746 . . . . 0.0 109.344 178.739 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 86' ' ' PHE . . . . . . . . . . . . . 3.0 t80 -61.87 -50.93 70.26 Favored 'General case' 0 C--O 1.233 0.235 0 CA-C-N 115.617 -0.719 . . . . 0.0 110.066 179.436 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 6.1 mt -62.95 -29.15 70.58 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 115.905 -0.589 . . . . 0.0 110.316 179.778 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -70.56 -28.06 71.62 Favored Glycine 0 N--CA 1.451 -0.323 0 CA-C-N 115.486 -0.779 . . . . 0.0 112.026 179.542 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 89' ' ' LEU . . . . . 0.416 ' HG ' ' O ' ' A' ' 85' ' ' TYR . 91.2 mt -74.91 -41.99 58.66 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.92 0.391 . . . . 0.0 110.772 179.744 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 97.6 mt -63.99 -36.41 83.88 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 115.959 -0.564 . . . . 0.0 111.123 179.927 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -77.19 -53.92 7.14 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.352 -0.385 . . . . 0.0 111.131 -179.854 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 107.8 52.67 0.69 Allowed Glycine 0 C--N 1.33 0.248 0 C-N-CA 120.899 -0.667 . . . . 0.0 112.213 -179.726 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 64.8 mt -75.82 162.24 28.33 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-O 120.909 0.385 . . . . 0.0 111.04 -179.773 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 94' ' ' ASP . . . . . . . . . . . . . 7.0 m-20 -88.86 175.14 7.58 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.707 179.881 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 65.3 m -60.44 -35.2 75.27 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.255 -179.767 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 96' ' ' ARG . . . . . 0.456 ' HG3' ' N ' ' A' ' 97' ' ' GLU . 10.5 ptp180 -73.64 -46.65 45.48 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 116.312 -0.404 . . . . 0.0 111.251 -179.842 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 97' ' ' GLU . . . . . 0.456 ' N ' ' HG3' ' A' ' 96' ' ' ARG . 42.0 mt-10 -57.02 -40.47 76.73 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.326 -0.397 . . . . 0.0 111.08 -179.68 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 98' ' ' PHE . . . . . 0.447 ' O ' HG12 ' A' ' 102' ' ' ILE . 13.5 m-85 -62.63 -50.3 71.75 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.772 179.656 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -55.29 -30.44 55.07 Favored Glycine 0 N--CA 1.452 -0.253 0 C-N-CA 120.647 -0.787 . . . . 0.0 112.695 -179.906 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 100' ' ' ILE . . . . . 0.441 ' O ' HG22 ' A' ' 103' ' ' THR . 86.8 mt -72.13 -47.78 52.52 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-O 120.864 0.364 . . . . 0.0 111.561 -179.735 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 43.2 t -67.67 -48.68 75.38 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.371 0 CA-C-N 116.289 -0.414 . . . . 0.0 111.516 -179.572 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 102' ' ' ILE . . . . . 0.447 HG12 ' O ' ' A' ' 98' ' ' PHE . 34.9 mm -59.15 -47.19 91.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.898 -179.23 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 103' ' ' THR . . . . . 0.441 HG22 ' O ' ' A' ' 100' ' ' ILE . 14.2 t -60.81 -36.26 78.58 Favored 'General case' 0 C--O 1.234 0.245 0 CA-C-O 120.772 0.32 . . . . 0.0 110.879 -179.968 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 104' ' ' LEU . . . . . 0.434 HD12 ' HB2' ' A' ' 137' ' ' LEU . 3.0 tm? -57.01 -50.65 72.06 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-N 116.344 -0.389 . . . . 0.0 110.043 179.15 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 105' ' ' ASN . . . . . 0.414 ' O ' ' HG2' ' A' ' 109' ' ' MET . 16.6 m-80 -59.39 -31.42 69.22 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.014 -0.539 . . . . 0.0 110.674 179.368 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 41.5 m -56.92 -47.85 79.62 Favored 'General case' 0 C--O 1.232 0.177 0 CA-C-O 120.836 0.35 . . . . 0.0 110.154 179.329 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 107' ' ' VAL . . . . . 0.401 ' H ' HG23 ' A' ' 107' ' ' VAL . 1.9 t -61.06 -42.12 91.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 115.996 -0.547 . . . . 0.0 109.963 179.107 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 66.4 t -57.72 -45.69 86.84 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 115.171 -0.922 . . . . 0.0 111.669 -179.723 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 109' ' ' MET . . . . . 0.573 ' HG3' ' HA ' ' A' ' 77' ' ' ILE . 16.0 mmt -67.71 -44.33 77.92 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.712 -179.27 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 32.9 tp -60.64 -39.61 88.94 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-O 120.766 0.317 . . . . 0.0 110.806 -179.747 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -58.48 -54.67 44.46 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.685 179.635 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 112' ' ' GLY . . . . . 0.659 ' HA3' ' H21' ' A' ' 301' ' ' RET . . . -66.41 -32.3 81.45 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.387 179.632 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 113' ' ' PHE . . . . . . . . . . . . . 0.7 OUTLIER -52.77 -71.34 0.07 Allowed 'General case' 0 C--N 1.331 -0.202 0 CA-C-O 120.945 0.402 . . . . 0.0 110.183 179.829 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 114' ' ' ALA . . . . . 0.45 ' HB3' HD22 ' A' ' 126' ' ' LEU . . . -64.47 -22.6 67.01 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 115.796 -0.638 . . . . 0.0 110.975 179.742 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -53.57 -49.37 57.71 Favored Glycine 0 C--N 1.331 0.269 0 C-N-CA 121.025 -0.607 . . . . 0.0 112.518 179.985 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 116' ' ' ALA . . . . . 0.554 ' HB2' ' HB3' ' A' ' 183' ' ' PRO . . . -78.06 -18.14 56.15 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-O 120.742 0.306 . . . . 0.0 111.464 -179.899 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 117' ' ' MET . . . . . 0.504 ' HA ' HG11 ' A' ' 68' ' ' VAL . 33.3 ttm -99.31 19.57 15.22 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.32 -0.4 . . . . 0.0 111.556 -179.161 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 118' ' ' VAL . . . . . 0.453 HG21 ' HB3' ' A' ' 123' ' ' ARG . 25.1 m -71.34 143.33 87.89 Favored Pre-proline 0 C--N 1.33 -0.279 0 CA-C-N 116.524 -0.307 . . . . 0.0 111.514 179.993 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 119' ' ' PRO . . . . . . . . . . . . . 92.2 Cg_endo -89.49 14.89 2.09 Favored 'Trans proline' 0 N--CA 1.456 -0.677 0 C-N-CA 122.715 2.277 . . . . 0.0 112.418 179.373 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -166.07 -118.37 0.44 Allowed Glycine 0 C--N 1.334 0.421 0 C-N-CA 120.644 -0.789 . . . . 0.0 112.834 -179.668 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 2.0 pp -119.89 13.37 6.64 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.183 0 CA-C-O 120.675 0.274 . . . . 0.0 111.597 -179.595 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 43.6 mt-10 -62.62 -17.98 61.35 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.865 179.722 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 123' ' ' ARG . . . . . 0.453 ' HB3' HG21 ' A' ' 118' ' ' VAL . 3.2 ptp180 -50.28 -28.07 7.17 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 115.834 -0.621 . . . . 0.0 111.93 -179.764 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 124' ' ' TYR . . . . . . . . . . . . . 29.2 m-85 -71.42 -33.53 69.5 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.632 0.254 . . . . 0.0 111.385 -179.592 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 125' ' ' ALA . . . . . . . . . . . . . . . -74.21 -55.93 5.49 Favored 'General case' 0 C--O 1.235 0.315 0 CA-C-O 120.79 0.328 . . . . 0.0 111.184 179.918 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 126' ' ' LEU . . . . . 0.45 HD22 ' HB3' ' A' ' 114' ' ' ALA . 1.1 mp -52.16 -51.12 59.95 Favored 'General case' 0 C--N 1.332 -0.182 0 CA-C-N 116.041 -0.527 . . . . 0.0 110.313 179.79 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 127' ' ' PHE . . . . . 0.463 ' HE1' ' H42' ' A' ' 301' ' ' RET . 10.4 t80 -65.46 -30.36 71.14 Favored 'General case' 0 N--CA 1.452 -0.354 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.089 179.308 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 128' ' ' GLY . . . . . . . . . . . . . . . -48.19 -52.93 16.63 Favored Glycine 0 N--CA 1.449 -0.461 0 C-N-CA 120.196 -1.002 . . . . 0.0 110.757 178.848 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 129' ' ' MET . . . . . 0.549 ' HE3' ' HA2' ' A' ' 130' ' ' GLY . 0.0 OUTLIER -70.36 -27.24 64.18 Favored 'General case' 0 C--N 1.328 -0.367 0 N-CA-C 109.036 -0.727 . . . . 0.0 109.036 178.515 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 130' ' ' GLY . . . . . 0.549 ' HA2' ' HE3' ' A' ' 129' ' ' MET . . . -59.7 -45.27 95.99 Favored Glycine 0 C--N 1.333 0.366 0 CA-C-N 115.745 -0.661 . . . . 0.0 112.558 179.607 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 131' ' ' ALA . . . . . 0.403 ' O ' ' HB3' ' A' ' 134' ' ' PHE . . . -69.8 -47.53 62.5 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-O 120.738 0.304 . . . . 0.0 110.421 179.751 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 65.4 t -56.32 -44.31 79.4 Favored 'Isoleucine or valine' 0 C--O 1.235 0.293 0 CA-C-O 121.261 0.553 . . . . 0.0 109.662 178.865 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -63.25 -35.22 79.62 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 115.57 -0.741 . . . . 0.0 110.465 179.231 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 134' ' ' PHE . . . . . 0.414 ' HE1' ' HB3' ' A' ' 171' ' ' TRP . 72.6 t80 -56.92 -54.56 45.25 Favored 'General case' 0 N--CA 1.451 -0.375 0 CA-C-O 120.984 0.421 . . . . 0.0 110.156 179.494 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 135' ' ' ILE . . . . . 0.484 ' O ' HG22 ' A' ' 138' ' ' VAL . 39.8 mt -56.6 -31.05 33.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 115.733 -0.667 . . . . 0.0 110.198 179.285 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . -62.73 -42.41 99.69 Favored Glycine 0 N--CA 1.447 -0.607 0 C-N-CA 120.221 -0.99 . . . . 0.0 111.344 178.922 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 137' ' ' LEU . . . . . 0.446 ' O ' HD13 ' A' ' 141' ' ' LEU . 64.9 tp -67.12 -52.64 39.29 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-O 120.464 0.174 . . . . 0.0 111.033 179.778 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 138' ' ' VAL . . . . . 0.484 HG22 ' O ' ' A' ' 135' ' ' ILE . 4.5 m -54.31 -34.43 27.87 Favored 'Isoleucine or valine' 0 CA--C 1.52 -0.177 0 N-CA-C 109.728 -0.471 . . . . 0.0 109.728 -179.642 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 139' ' ' TYR . . . . . . . . . . . . . 35.6 t80 -58.56 -46.49 86.76 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 115.785 -0.643 . . . . 0.0 109.633 178.05 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 24.6 m-85 -63.65 -40.78 97.73 Favored 'General case' 0 C--N 1.333 -0.111 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.486 179.105 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 141' ' ' LEU . . . . . 0.507 ' HA ' ' SD ' ' A' ' 145' ' ' MET . 11.2 mp -59.14 -25.64 64.04 Favored 'General case' 0 C--N 1.332 -0.186 0 CA-C-N 116.073 -0.512 . . . . 0.0 110.973 179.982 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 142' ' ' VAL . . . . . 0.419 HG23 ' O ' ' A' ' 138' ' ' VAL . 15.7 t -107.9 -5.18 10.5 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.254 0 CA-C-N 116.24 -0.437 . . . . 0.0 110.875 179.851 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . -75.81 -133.2 0.41 Allowed Glycine 0 CA--C 1.522 0.487 0 C-N-CA 120.874 -0.679 . . . . 0.0 112.704 179.993 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 144' ' ' PRO . . . . . . . . . . . . . 48.7 Cg_exo -55.55 -24.17 43.3 Favored 'Trans proline' 0 C--N 1.35 0.639 0 C-N-CA 122.5 2.133 . . . . 0.0 112.868 -179.732 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 145' ' ' MET . . . . . 0.507 ' SD ' ' HA ' ' A' ' 141' ' ' LEU . 57.5 mtt -54.15 -32.91 56.6 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 116.402 -0.363 . . . . 0.0 111.408 -179.864 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 146' ' ' THR . . . . . . . . . . . . . 79.1 p -65.9 -49.25 68.7 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.3 -0.409 . . . . 0.0 111.937 -179.407 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 14.1 mm-40 -74.89 -25.39 58.9 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.734 0.302 . . . . 0.0 111.766 -179.394 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 148' ' ' SER . . . . . . . . . . . . . 45.9 t -70.1 -45.43 66.95 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.834 0.35 . . . . 0.0 111.098 -179.623 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 149' ' ' ALA . . . . . 0.416 ' HB1' HG22 ' A' ' 156' ' ' ILE . . . -78.33 -35.14 48.06 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.119 -0.492 . . . . 0.0 111.849 -179.582 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 150' ' ' SER . . . . . 0.559 ' HA ' ' HG2' ' A' ' 157' ' ' LYS . 35.7 t -69.71 0.72 5.12 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.303 -0.408 . . . . 0.0 111.44 -179.539 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 151' ' ' GLN . . . . . . . . . . . . . 49.1 mt-30 -134.3 15.53 3.78 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.512 -0.313 . . . . 0.0 111.207 179.877 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 152' ' ' ARG . . . . . 0.411 ' NE ' ' HA ' ' A' ' 152' ' ' ARG . 6.7 tpm_? -91.6 -51.89 5.04 Favored 'General case' 0 C--N 1.332 -0.195 0 CA-C-O 120.906 0.384 . . . . 0.0 110.772 179.954 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 153' ' ' SER . . . . . 0.679 ' HB3' HG12 ' A' ' 156' ' ' ILE . 24.3 t -157.76 172.6 18.2 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 115.978 -0.555 . . . . 0.0 110.746 179.256 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 154' ' ' SER . . . . . 0.513 ' HA ' ' NZ ' ' A' ' 157' ' ' LYS . 77.7 p -70.49 -40.68 73.45 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.427 -0.351 . . . . 0.0 110.859 179.727 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -77.08 -28.59 58.2 Favored Glycine 0 CA--C 1.521 0.41 0 C-N-CA 121.07 -0.585 . . . . 0.0 113.389 -179.631 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 156' ' ' ILE . . . . . 0.679 HG12 ' HB3' ' A' ' 153' ' ' SER . 33.4 mm -56.77 -37.68 54.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-O 120.678 0.275 . . . . 0.0 111.522 -179.507 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 157' ' ' LYS . . . . . 0.559 ' HG2' ' HA ' ' A' ' 150' ' ' SER . 36.7 mtmm -58.96 -41.26 87.04 Favored 'General case' 0 C--N 1.327 -0.393 0 N-CA-C 112.178 0.436 . . . . 0.0 112.178 -179.527 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 71.2 m -70.57 -48.32 55.9 Favored 'General case' 0 C--N 1.33 -0.256 0 N-CA-C 111.958 0.355 . . . . 0.0 111.958 -179.003 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 159' ' ' LEU . . . . . 0.402 ' O ' ' HB2' ' A' ' 163' ' ' LEU . 3.8 mm? -67.68 -30.2 69.67 Favored 'General case' 0 C--N 1.327 -0.384 0 N-CA-C 111.789 0.292 . . . . 0.0 111.789 -179.373 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 160' ' ' TYR . . . . . . . . . . . . . 72.4 t80 -73.98 -47.41 37.48 Favored 'General case' 0 C--N 1.329 -0.3 0 N-CA-C 112.313 0.486 . . . . 0.0 112.313 -179.06 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 161' ' ' VAL . . . . . 0.422 HG23 ' N ' ' A' ' 162' ' ' ARG . 27.3 m -64.25 -43.17 97.21 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.373 0 N-CA-C 112.347 0.499 . . . . 0.0 112.347 -178.616 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 162' ' ' ARG . . . . . 0.446 ' HA ' ' NE ' ' A' ' 162' ' ' ARG . 6.7 tpm_? -68.96 -49.27 59.47 Favored 'General case' 0 C--N 1.328 -0.33 0 N-CA-C 112.001 0.371 . . . . 0.0 112.001 -178.904 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 163' ' ' LEU . . . . . 0.402 ' HB2' ' O ' ' A' ' 159' ' ' LEU . 8.1 mp -67.62 -43.23 80.88 Favored 'General case' 0 C--N 1.329 -0.313 0 N-CA-C 111.928 0.344 . . . . 0.0 111.928 -179.149 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 164' ' ' ARG . . . . . . . . . . . . . 3.4 tmm_? -56.88 -50.79 71.43 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 120.695 0.283 . . . . 0.0 110.683 179.965 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 165' ' ' ASN . . . . . 0.524 HD22 ' N ' ' A' ' 165' ' ' ASN . 0.9 OUTLIER -57.29 -42.27 81.39 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.998 0.427 . . . . 0.0 110.301 179.576 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 166' ' ' LEU . . . . . 0.467 ' HB3' ' CE1' ' A' ' 208' ' ' PHE . 2.7 mt -58.7 -52.18 66.79 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 115.83 -0.623 . . . . 0.0 111.097 179.344 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 167' ' ' THR . . . . . 0.637 ' HA ' HD11 ' A' ' 170' ' ' LEU . 3.1 m -54.59 -51.86 63.95 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 115.733 -0.667 . . . . 0.0 112.442 -178.454 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 168' ' ' VAL . . . . . . . . . . . . . 59.2 t -57.26 -40.36 73.34 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.504 0 N-CA-C 112.485 0.55 . . . . 0.0 112.485 -178.894 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 169' ' ' VAL . . . . . 0.483 ' O ' HG12 ' A' ' 173' ' ' ILE . 98.2 t -68.03 -66.7 0.49 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 N-CA-C 113.499 0.926 . . . . 0.0 113.499 -177.912 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 170' ' ' LEU . . . . . 0.637 HD11 ' HA ' ' A' ' 167' ' ' THR . 0.4 OUTLIER -59.89 -33.2 71.52 Favored 'General case' 0 N--CA 1.467 0.386 0 N-CA-C 112.887 0.699 . . . . 0.0 112.887 -177.71 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 171' ' ' TRP . . . . . 0.721 ' HE1' H203 ' A' ' 301' ' ' RET . 25.9 m0 -73.54 -30.51 63.12 Favored 'General case' 0 C--N 1.329 -0.296 0 C-N-CA 120.57 -0.452 . . . . 0.0 111.473 -179.429 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 172' ' ' ALA . . . . . . . . . . . . . . . -73.2 -7.53 51.84 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.944 0.402 . . . . 0.0 110.348 179.455 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 173' ' ' ILE . . . . . 0.592 HG22 HD11 ' A' ' 177' ' ' ILE . 31.4 mm -88.75 -24.5 6.03 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.15 0 CA-C-N 115.877 -0.601 . . . . 0.0 110.758 179.402 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 174' ' ' TYR . . . . . 0.598 ' N ' ' HD2' ' A' ' 175' ' ' PRO . 21.4 m-85 -55.11 -50.29 87.35 Favored Pre-proline 0 CA--C 1.53 0.192 0 N-CA-C 112.216 0.45 . . . . 0.0 112.216 -179.614 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 175' ' ' PRO . . . . . 0.598 ' HD2' ' N ' ' A' ' 174' ' ' TYR . 4.1 Cg_endo -47.06 -28.47 7.45 Favored 'Trans proline' 0 C--N 1.352 0.762 0 C-N-CA 122.148 1.899 . . . . 0.0 112.1 179.976 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 176' ' ' PHE . . . . . 0.519 ' O ' ' HG ' ' A' ' 180' ' ' LEU . 92.2 m-85 -80.27 -49.97 10.85 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.31 179.568 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 177' ' ' ILE . . . . . 0.592 HD11 HG22 ' A' ' 173' ' ' ILE . 2.8 mm -59.71 -37.38 70.83 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.581 0 CA-C-N 115.995 -0.548 . . . . 0.0 111.781 -178.593 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 178' ' ' TRP . . . . . . . . . . . . . 70.7 t90 -73.58 -45.38 53.57 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.915 0.388 . . . . 0.0 110.856 179.814 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 179' ' ' LEU . . . . . 0.451 ' O ' ' HA3' ' A' ' 184' ' ' GLY . 1.9 tm? -65.09 -53.12 50.29 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 115.976 -0.556 . . . . 0.0 111.417 -179.233 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 180' ' ' LEU . . . . . 0.604 HD22 HD11 ' A' ' 187' ' ' LEU . 11.1 mt -71.79 -42.96 66.46 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 116.705 -0.225 . . . . 0.0 111.515 -179.208 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . -58.54 175.41 2.56 Favored Glycine 0 C--N 1.335 0.493 0 C-N-CA 120.472 -0.87 . . . . 0.0 112.664 179.772 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 182' ' ' PRO . . . . . 0.714 ' HA ' ' HB2' ' A' ' 186' ' ' ALA . 73.1 Cg_exo -47.91 -44.27 27.72 Favored 'Trans proline' 0 C--N 1.349 0.581 0 C-N-CA 122.767 2.312 . . . . 0.0 113.38 179.791 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 183' ' ' PRO . . . . . 0.554 ' HB3' ' HB2' ' A' ' 116' ' ' ALA . 73.4 Cg_exo -52.08 -17.19 5.41 Favored 'Trans proline' 0 C--N 1.355 0.905 0 C-N-CA 122.119 1.88 . . . . 0.0 112.84 179.557 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 184' ' ' GLY . . . . . 0.451 ' HA3' ' O ' ' A' ' 179' ' ' LEU . . . -114.74 -82.79 1.08 Allowed Glycine 0 N--CA 1.45 -0.379 0 C-N-CA 120.644 -0.789 . . . . 0.0 112.942 -179.715 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 185' ' ' VAL . . . . . 0.409 HG22 ' O ' ' A' ' 179' ' ' LEU . 8.4 m -129.71 -4.16 2.89 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.24 0 N-CA-C 112.349 0.5 . . . . 0.0 112.349 -179.376 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 186' ' ' ALA . . . . . 0.714 ' HB2' ' HA ' ' A' ' 182' ' ' PRO . . . 52.22 89.56 0.03 OUTLIER 'General case' 0 N--CA 1.464 0.241 0 CA-C-O 120.72 0.295 . . . . 0.0 111.635 179.752 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 187' ' ' LEU . . . . . 0.604 HD11 HD22 ' A' ' 180' ' ' LEU . 24.3 mt -92.24 -49.49 6.15 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.443 -0.344 . . . . 0.0 111.678 -179.81 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 188' ' ' LEU . . . . . . . . . . . . . 88.7 mt -93.27 -93.93 0.16 Allowed 'General case' 0 C--N 1.331 -0.23 0 CA-C-O 120.799 0.333 . . . . 0.0 111.23 -179.604 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 189' ' ' THR . . . . . . . . . . . . . 2.2 t -161.44 145.02 9.62 Favored Pre-proline 0 C--N 1.326 -0.418 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.957 179.979 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 190' ' ' PRO . . . . . . . . . . . . . 74.7 Cg_exo -49.15 -40.24 42.05 Favored 'Trans proline' 0 C--N 1.349 0.596 0 C-N-CA 122.747 2.298 . . . . 0.0 113.137 -179.601 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 191' ' ' THR . . . . . . . . . . . . . 38.3 p -58.97 -44.52 91.53 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.795 0.331 . . . . 0.0 111.515 -179.621 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 192' ' ' VAL . . . . . . . . . . . . . 37.2 t -72.65 -46.12 55.5 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.266 -179.947 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 193' ' ' ASP . . . . . . . . . . . . . 32.6 t70 -55.1 -44.07 74.59 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.388 -0.369 . . . . 0.0 111.006 179.844 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 194' ' ' VAL . . . . . 0.514 HG21 HD11 ' A' ' 4' ' ' LEU . 79.8 t -68.64 -36.02 72.66 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.032 179.902 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 195' ' ' ALA . . . . . . . . . . . . . . . -59.12 -46.77 87.48 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-O 120.671 0.272 . . . . 0.0 110.977 179.734 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 196' ' ' LEU . . . . . . . . . . . . . 88.3 mt -67.83 -41.02 83.68 Favored 'General case' 0 C--N 1.332 -0.192 0 CA-C-O 120.841 0.353 . . . . 0.0 110.577 179.576 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 197' ' ' ILE . . . . . . . . . . . . . 17.6 mm -59.16 -58.41 7.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.011 -0.54 . . . . 0.0 110.225 179.203 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 198' ' ' VAL . . . . . 0.421 HG23 ' O ' ' A' ' 194' ' ' VAL . 75.7 t -52.53 -34.79 19.62 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.432 0 CA-C-N 115.633 -0.712 . . . . 0.0 109.199 178.226 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 199' ' ' TYR . . . . . . . . . . . . . 67.5 t80 -70.23 -33.39 71.6 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 115.227 -0.897 . . . . 0.0 110.811 179.965 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 200' ' ' LEU . . . . . 0.443 ' O ' HG12 ' A' ' 203' ' ' VAL . 36.5 mt -68.65 -40.78 80.08 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.039 -0.528 . . . . 0.0 111.375 -179.597 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 201' ' ' ASP . . . . . . . . . . . . . 8.1 m-20 -71.49 -31.64 67.34 Favored 'General case' 0 C--N 1.327 -0.413 0 CA-C-O 121.117 0.484 . . . . 0.0 110.038 179.447 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 202' ' ' LEU . . . . . . . . . . . . . 3.3 mt -71.01 -33.74 70.67 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 115.546 -0.752 . . . . 0.0 111.955 -179.671 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 203' ' ' VAL . . . . . 0.495 ' O ' ' HA3' ' A' ' 207' ' ' GLY . 7.8 p -77.1 -36.39 24.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 N-CA-C 111.593 0.22 . . . . 0.0 111.593 -178.743 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 204' ' ' THR . . . . . . . . . . . . . 57.5 m -70.58 -52.25 22.81 Favored 'General case' 0 C--N 1.327 -0.372 0 C-N-CA 120.682 -0.407 . . . . 0.0 111.6 179.735 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 205' ' ' LYS . . . . . 0.688 ' HE2' ' HB2' ' A' ' 47' ' ' ALA . 53.8 mttp -70.53 -59.12 3.02 Favored 'General case' 0 C--N 1.327 -0.385 0 N-CA-C 112.27 0.47 . . . . 0.0 112.27 -178.67 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 23.3 t -72.87 -37.82 55.4 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.357 0 CA-C-N 116.333 -0.394 . . . . 0.0 111.724 -178.814 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 207' ' ' GLY . . . . . 0.53 ' O ' HG12 ' A' ' 211' ' ' ILE . . . -62.71 -59.04 9.81 Favored Glycine 0 N--CA 1.452 -0.286 0 C-N-CA 120.353 -0.927 . . . . 0.0 112.429 -179.641 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 208' ' ' PHE . . . . . 0.473 ' O ' ' N ' ' A' ' 212' ' ' ALA . 2.2 m-30 -53.66 -49.95 66.85 Favored 'General case' 0 C--O 1.221 -0.4 0 CA-C-O 120.798 0.332 . . . . 0.0 110.112 179.992 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 209' ' ' GLY . . . . . 0.476 ' O ' ' HB3' ' A' ' 212' ' ' ALA . . . -54.19 -31.42 49.42 Favored Glycine 0 N--CA 1.449 -0.487 0 CA-C-N 115.444 -0.798 . . . . 0.0 112.456 178.927 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 210' ' ' PHE . . . . . . . . . . . . . 1.8 m-85 -72.41 -48.73 39.1 Favored 'General case' 0 C--N 1.328 -0.33 0 N-CA-C 108.764 -0.828 . . . . 0.0 108.764 178.755 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 211' ' ' ILE . . . . . 0.53 HG12 ' O ' ' A' ' 207' ' ' GLY . 0.6 OUTLIER -63.7 -27.21 42.43 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.297 0 N-CA-C 107.246 -1.39 . . . . 0.0 107.246 176.685 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 212' ' ' ALA . . . . . 0.476 ' HB3' ' O ' ' A' ' 209' ' ' GLY . . . -68.03 -43.66 78.24 Favored 'General case' 0 N--CA 1.448 -0.534 0 CA-C-N 114.044 -1.434 . . . . 0.0 110.764 -179.418 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 213' ' ' LEU . . . . . . . . . . . . . 71.5 mt -70.52 -54.98 10.05 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 115.191 -0.913 . . . . 0.0 112.112 -179.19 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 214' ' ' ASP . . . . . . . . . . . . . 29.4 t70 -54.96 -54.44 42.76 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.392 -0.367 . . . . 0.0 111.858 -179.099 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 215' ' ' ALA . . . . . . . . . . . . . . . -58.44 -57.16 14.14 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 116.312 -0.404 . . . . 0.0 111.898 -179.344 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 216' ' ' ALA . . . . . 0.413 ' HA ' HD12 ' A' ' 219' ' ' LEU . . . -57.57 -33.97 68.71 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.331 -0.395 . . . . 0.0 111.682 -179.367 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 217' ' ' ALA . . . . . . . . . . . . . . . -61.06 -41.58 96.88 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.953 0.406 . . . . 0.0 110.451 179.887 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 218' ' ' THR . . . . . . . . . . . . . 95.9 m -66.9 -34.6 78.13 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 115.829 -0.623 . . . . 0.0 110.896 179.737 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 219' ' ' LEU . . . . . 0.413 HD12 ' HA ' ' A' ' 216' ' ' ALA . 87.8 mt -60.83 -45.81 93.02 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.136 -0.483 . . . . 0.0 111.126 -179.871 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 220' ' ' ARG . . . . . . . . . . . . . 11.1 mpt_? -83.45 -20.09 34.7 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.305 -0.407 . . . . 0.0 111.248 -179.806 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 221' ' ' ALA . . . . . . . . . . . . . . . -77.35 -27.21 52.61 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.415 -0.357 . . . . 0.0 111.182 179.805 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 222' ' ' GLU . . . . . . . . . . . . . 9.3 pt-20 -92.22 -27.26 17.76 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.297 -0.411 . . . . 0.0 110.505 -179.667 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 223' ' ' HIS . . . . . . . . . . . . . 81.1 m-70 62.43 -179.31 0.13 Allowed 'General case' 0 C--N 1.331 -0.223 0 CA-C-N 115.647 -0.706 . . . . 0.0 111.346 179.956 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 224' ' ' GLY . . . . . . . . . . . . . . . 165.57 15.14 0.02 OUTLIER Glycine 0 N--CA 1.452 -0.269 0 C-N-CA 120.9 -0.666 . . . . 0.0 112.45 179.978 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 225' ' ' GLU . . . . . . . . . . . . . 44.0 tt0 -75.22 139.0 42.32 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.855 0.359 . . . . 0.0 111.131 -179.815 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 226' ' ' SER . . . . . . . . . . . . . 42.1 t -139.72 2.56 2.0 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.05 -0.523 . . . . 0.0 110.725 179.852 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 227' ' ' LEU . . . . . . . . . . . . . 74.8 mt -76.1 -42.92 45.65 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.553 179.737 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 228' ' ' ALA . . . . . . . . . . . . . . . 52.7 92.98 0.02 OUTLIER 'General case' 0 C--N 1.332 -0.173 0 CA-C-N 115.826 -0.625 . . . . 0.0 111.666 179.887 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 229' ' ' GLY . . . . . . . . . . . . . . . 148.78 84.92 0.05 OUTLIER Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.929 -0.653 . . . . 0.0 112.46 179.909 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 230' ' ' VAL . . . . . . . . . . . . . 23.9 m -125.35 140.59 47.85 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.247 0 CA-C-O 120.865 0.364 . . . . 0.0 111.291 -179.905 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 231' ' ' ASP . . . . . . . . . . . . . 4.5 p-10 -93.57 112.46 24.36 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.087 -0.506 . . . . 0.0 110.833 179.894 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 232' ' ' THR . . . . . . . . . . . . . 48.3 p -143.47 -55.94 0.39 Allowed 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.081 -0.509 . . . . 0.0 111.229 -179.951 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 233' ' ' ASP . . . . . . . . . . . . . 10.3 m-20 -71.76 121.35 18.76 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.043 -179.77 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 234' ' ' THR . . . . . . . . . . . . . 81.4 p -134.79 94.72 16.33 Favored Pre-proline 0 C--N 1.329 -0.287 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.924 179.701 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 235' ' ' PRO . . . . . . . . . . . . . 73.8 Cg_endo -75.81 8.49 2.7 Favored 'Trans proline' 0 C--N 1.348 0.505 0 C-N-CA 122.426 2.084 . . . . 0.0 112.576 -179.763 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 236' ' ' ALA . . . . . . . . . . . . . . . -86.23 167.94 14.39 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.372 -0.376 . . . . 0.0 111.171 -179.884 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 237' ' ' VAL . . . . . 0.447 ' O ' HG12 ' A' ' 237' ' ' VAL . 4.8 t -119.57 19.76 6.23 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-O 121.208 0.528 . . . . 0.0 110.573 179.984 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 238' ' ' ALA . . . . . . . . . . . . . . . 55.32 88.54 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 115.721 -0.672 . . . . 0.0 111.162 -179.899 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 239' ' ' ASP . . . . . . . . . . . . . 18.9 t70 -125.15 -28.92 3.35 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.183 -179.806 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 240' ' ' LEU . . . . . 0.409 HD12 ' N ' ' A' ' 240' ' ' LEU . 7.1 mp -64.53 -45.32 87.66 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.414 -0.357 . . . . 0.0 111.012 -179.896 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 241' ' ' GLU . . . . . . . . . . . . . 41.4 tt0 -104.32 129.86 52.18 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.27 -0.423 . . . . 0.0 111.146 -179.754 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 242' ' ' HIS . . . . . . . . . . . . . 46.3 t-80 -146.93 155.36 42.22 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.781 -179.91 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 243' ' ' HIS . . . . . . . . . . . . . 20.6 t60 -63.8 -52.4 60.44 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.406 -0.361 . . . . 0.0 111.076 -179.9 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 244' ' ' HIS . . . . . . . . . . . . . 58.4 t-80 59.14 95.1 0.03 OUTLIER 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.735 -179.784 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 245' ' ' HIS . . . . . . . . . . . . . 78.9 m80 -60.42 138.38 58.0 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.316 -179.683 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 246' ' ' HIS . . . . . . . . . . . . . 25.8 p80 -106.65 140.17 39.94 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 116.0 -0.546 . . . . 0.0 110.747 179.76 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 247' ' ' HIS . . . . . . . . . . . . . 30.6 t60 . . . . . 0 C--O 1.249 1.031 0 CA-C-O 118.278 -0.868 . . . . 0.0 110.847 -179.868 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' A' A ' 301' ' ' RET . . . . . 0.721 H203 ' HE1' ' A' ' 171' ' ' TRP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 10.6 tpt . . . . . 0 N--CA 1.487 1.377 0 CA-C-O 120.71 0.291 . . . . 0.0 110.587 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 10.6 p -127.31 -25.68 1.37 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.395 -179.849 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -78.02 -1.58 79.91 Favored Glycine 0 N--CA 1.452 -0.28 0 C-N-CA 120.703 -0.76 . . . . 0.0 112.33 -179.997 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 49.8 tp -74.38 -35.54 63.49 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-O 120.778 0.323 . . . . 0.0 111.06 -179.974 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 69.1 p -61.06 -30.32 70.26 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.361 -179.751 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 28.0 p -54.56 -35.49 63.33 Favored 'General case' 0 C--N 1.331 -0.2 0 CA-C-N 116.278 -0.419 . . . . 0.0 111.248 -179.965 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 7' ' ' LEU . . . . . . . . . . . . . 4.0 mm? -56.65 -52.3 65.43 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 115.951 -0.568 . . . . 0.0 111.103 -179.903 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 8' ' ' PHE . . . . . 0.6 ' HB2' ' HB2' ' A' ' 55' ' ' ALA . 62.9 m-85 -64.47 -31.96 73.38 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.34 -0.391 . . . . 0.0 110.934 -179.989 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 9' ' ' TRP . . . . . 0.402 ' O ' HG12 ' A' ' 13' ' ' ILE . 35.3 m95 -65.61 -41.69 92.47 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.173 -179.92 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 56.1 mt -67.17 -32.43 73.51 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-N 115.761 -0.654 . . . . 0.0 109.962 179.377 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . 0.436 ' HA2' HD11 ' A' ' 202' ' ' LEU . . . -73.65 -27.72 66.74 Favored Glycine 0 N--CA 1.446 -0.67 0 CA-C-N 115.665 -0.698 . . . . 0.0 111.702 179.3 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -73.62 -33.91 64.78 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.834 0.35 . . . . 0.0 110.543 179.396 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 13' ' ' ILE . . . . . 0.439 ' O ' HG23 ' A' ' 17' ' ' VAL . 48.8 mm -68.22 -54.2 23.66 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.232 0 CA-C-N 116.002 -0.545 . . . . 0.0 110.397 179.423 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -59.18 -40.06 95.28 Favored Glycine 0 N--CA 1.45 -0.385 0 C-N-CA 120.635 -0.793 . . . . 0.0 111.48 179.221 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 15' ' ' MET . . . . . 0.516 ' SD ' ' HA ' ' A' ' 44' ' ' SER . 52.7 tpp -62.1 -43.6 98.49 Favored 'General case' 0 N--CA 1.453 -0.301 0 N-CA-C 109.99 -0.374 . . . . 0.0 109.99 179.295 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 45.4 tp -55.19 -38.18 68.02 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 115.746 -0.661 . . . . 0.0 110.222 179.184 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . 0.439 HG23 ' O ' ' A' ' 13' ' ' ILE . 44.2 t -62.13 -42.09 93.75 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.215 0 CA-C-N 115.891 -0.595 . . . . 0.0 109.971 179.243 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -66.26 -42.52 94.11 Favored Glycine 0 C--N 1.331 0.272 0 C-N-CA 120.69 -0.767 . . . . 0.0 111.58 178.928 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 7.9 m -52.09 -49.82 62.82 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.812 0.339 . . . . 0.0 111.074 179.945 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 20' ' ' LEU . . . . . 0.409 ' O ' ' HB3' ' A' ' 24' ' ' TRP . 95.0 mt -71.91 -35.6 69.73 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.435 179.926 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -62.21 -34.55 76.69 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.68 0.276 . . . . 0.0 111.648 -179.569 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 22' ' ' PHE . . . . . 0.543 ' HB2' HG22 ' A' ' 41' ' ' VAL . 11.0 m-85 -89.95 -30.33 17.89 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.478 -0.328 . . . . 0.0 111.434 -179.442 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -72.88 -50.03 26.31 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.479 -0.328 . . . . 0.0 111.228 -179.941 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 24' ' ' TRP . . . . . 0.409 ' HB3' ' O ' ' A' ' 20' ' ' LEU . 1.1 t-105 -60.66 -43.42 97.67 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.054 -0.521 . . . . 0.0 111.012 179.907 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -72.73 -25.03 61.06 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.334 -0.393 . . . . 0.0 110.907 179.927 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -74.03 -44.12 31.1 Favored Glycine 0 C--N 1.33 0.225 0 C-N-CA 121.008 -0.615 . . . . 0.0 112.469 179.695 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 85.6 mtm180 -65.89 -17.74 64.86 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.873 0.368 . . . . 0.0 110.629 179.976 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 18.4 t70 -91.82 -18.77 23.34 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.03 -0.532 . . . . 0.0 110.587 179.841 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -147.47 110.05 4.65 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.086 -0.506 . . . . 0.0 110.955 179.868 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -139.19 -122.84 2.03 Favored Glycine 0 N--CA 1.452 -0.271 0 C-N-CA 120.671 -0.776 . . . . 0.0 112.853 -179.765 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 47.9 t 62.49 -89.46 0.03 OUTLIER 'General case' 0 C--O 1.233 0.184 0 CA-C-O 120.625 0.25 . . . . 0.0 110.795 -179.566 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -93.32 -23.69 23.73 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.729 -0.748 . . . . 0.0 111.77 179.574 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 31.9 mm-40 -91.93 -20.16 21.7 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-O 120.792 0.33 . . . . 0.0 110.686 179.819 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 34' ' ' ARG . . . . . . . . . . . . . 55.4 ttp180 -47.95 -31.68 5.52 Favored 'General case' 0 C--N 1.332 -0.162 0 CA-C-N 115.974 -0.557 . . . . 0.0 111.385 -179.81 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 40.4 ttm180 -61.23 -49.46 77.02 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-O 120.856 0.36 . . . . 0.0 110.894 -179.943 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 75.9 m-85 -70.04 -37.47 75.59 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.025 -0.534 . . . . 0.0 111.568 -179.593 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 37' ' ' TYR . . . . . 0.539 ' O ' HG23 ' A' ' 41' ' ' VAL . 35.3 m-85 -65.74 -54.75 22.95 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.318 -0.401 . . . . 0.0 111.516 -179.396 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 90.6 t -56.7 -38.18 56.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-O 120.918 0.39 . . . . 0.0 110.667 179.894 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 17.4 m -61.68 -50.95 70.42 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 115.933 -0.576 . . . . 0.0 110.616 179.346 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 40' ' ' LEU . . . . . 0.56 HD12 HD12 ' A' ' 43' ' ' ILE . 40.2 tp -59.71 -50.52 73.52 Favored 'General case' 0 C--O 1.235 0.333 0 CA-C-N 115.745 -0.661 . . . . 0.0 110.831 179.894 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . 0.543 HG22 ' HB2' ' A' ' 22' ' ' PHE . 60.2 t -56.1 -34.3 38.53 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 115.834 -0.621 . . . . 0.0 110.294 179.26 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -60.94 -43.59 99.18 Favored Glycine 0 N--CA 1.45 -0.411 0 C-N-CA 120.739 -0.743 . . . . 0.0 111.826 179.597 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 43' ' ' ILE . . . . . 0.56 HD12 HD12 ' A' ' 40' ' ' LEU . 1.3 mt -58.55 -51.92 65.81 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.195 0 CA-C-O 120.792 0.329 . . . . 0.0 110.791 179.426 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 44' ' ' SER . . . . . 0.516 ' HA ' ' SD ' ' A' ' 15' ' ' MET . 44.7 m -59.66 -27.02 66.02 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.557 -179.772 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -73.79 -56.55 5.35 Favored Glycine 0 CA--C 1.519 0.33 0 C-N-CA 120.643 -0.789 . . . . 0.0 113.002 -179.588 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 24.3 pt -58.46 -35.45 54.41 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.214 0 CA-C-O 121.025 0.441 . . . . 0.0 111.295 -179.856 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 47' ' ' ALA . . . . . 0.74 ' HB2' ' HE2' ' A' ' 205' ' ' LYS . . . -66.98 -49.25 65.97 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.586 179.851 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -54.16 -44.39 71.42 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 115.983 -0.553 . . . . 0.0 111.962 -179.112 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 49' ' ' VAL . . . . . 0.406 ' O ' HG13 ' A' ' 53' ' ' VAL . 30.1 m -68.29 -34.24 64.99 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 C-N-CA 120.98 -0.288 . . . . 0.0 111.073 -179.731 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -67.54 -37.06 82.15 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-O 121.016 0.436 . . . . 0.0 110.939 179.264 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 38.7 m-85 -68.54 -38.76 81.11 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.028 -0.533 . . . . 0.0 110.214 -179.948 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -65.02 -50.71 65.19 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 115.804 -0.635 . . . . 0.0 111.088 179.592 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 53' ' ' VAL . . . . . 0.485 HG23 ' N ' ' A' ' 54' ' ' MET . 25.3 m -60.78 -47.9 91.16 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.109 0 CA-C-N 116.527 -0.306 . . . . 0.0 110.85 -179.939 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 54' ' ' MET . . . . . 0.514 ' HG2' ' HG2' ' A' ' 71' ' ' PRO . 74.3 mtm -62.42 -31.55 72.26 Favored 'General case' 0 C--N 1.331 -0.225 0 N-CA-C 109.607 -0.516 . . . . 0.0 109.607 179.068 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 55' ' ' ALA . . . . . 0.6 ' HB2' ' HB2' ' A' ' 8' ' ' PHE . . . -72.69 -22.49 60.9 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 115.527 -0.761 . . . . 0.0 110.981 179.583 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 81.0 mt -87.42 -5.52 58.81 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.118 179.996 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 90.15 -14.68 61.55 Favored Glycine 0 N--CA 1.45 -0.418 0 C-N-CA 120.622 -0.799 . . . . 0.0 112.911 179.765 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 58' ' ' VAL . . . . . 0.424 HG12 ' O ' ' A' ' 53' ' ' VAL . 9.0 p -69.5 141.64 17.01 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-O 120.85 0.357 . . . . 0.0 110.801 179.885 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 59' ' ' GLY . . . . . 0.411 ' HA3' ' HG3' ' A' ' 71' ' ' PRO . . . 92.39 -5.62 77.74 Favored Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.868 -0.682 . . . . 0.0 112.153 -179.268 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 60' ' ' TRP . . . . . . . . . . . . . 19.6 m0 -80.1 111.98 16.97 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-O 120.578 0.228 . . . . 0.0 110.785 179.919 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 61' ' ' VAL . . . . . 0.569 HG13 HG23 ' A' ' 68' ' ' VAL . 7.1 p -115.02 128.75 25.66 Favored Pre-proline 0 CA--C 1.533 0.315 0 CA-C-N 116.512 -0.313 . . . . 0.0 110.951 179.566 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 71.7 Cg_endo -76.39 156.0 36.76 Favored 'Trans proline' 0 C--N 1.35 0.629 0 C-N-CA 122.47 2.113 . . . . 0.0 112.725 -179.873 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 84.2 t -143.15 89.89 0.41 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 115.764 -0.653 . . . . 0.0 110.599 179.879 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . 58.71 -88.38 0.02 OUTLIER 'General case' 0 C--N 1.331 -0.196 0 CA-C-N 116.115 -0.493 . . . . 0.0 111.306 -179.756 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 45.5 mt-10 -120.5 -17.78 8.02 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 116.386 -0.37 . . . . 0.0 110.828 179.807 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 66' ' ' ARG . . . . . 0.468 ' HA ' ' HE ' ' A' ' 66' ' ' ARG . 3.0 mmp_? -100.29 163.5 12.37 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.25 179.672 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 85.3 m -125.83 133.91 51.82 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 121.023 0.439 . . . . 0.0 111.516 -179.673 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 68' ' ' VAL . . . . . 0.569 HG23 HG13 ' A' ' 61' ' ' VAL . 17.9 m -123.3 144.69 32.02 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-N 115.857 -0.611 . . . . 0.0 110.469 179.417 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 69' ' ' PHE . . . . . . . . . . . . . 19.4 m-85 -110.45 112.21 23.98 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.359 -0.382 . . . . 0.0 110.109 -179.217 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 70' ' ' VAL . . . . . 0.63 ' N ' ' HD2' ' A' ' 71' ' ' PRO . 28.3 t -66.02 -47.49 62.83 Favored Pre-proline 0 C--N 1.323 -0.553 0 CA-C-N 116.234 -0.439 . . . . 0.0 112.01 -179.362 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 71' ' ' PRO . . . . . 0.63 ' HD2' ' N ' ' A' ' 70' ' ' VAL . 13.9 Cg_endo -57.15 -22.22 46.9 Favored 'Trans proline' 0 C--N 1.351 0.709 0 C-N-CA 121.982 1.788 . . . . 0.0 111.773 179.518 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 60.7 ttp180 -75.91 -53.3 8.63 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.585 179.694 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 73' ' ' TYR . . . . . . . . . . . . . 69.3 m-85 -64.6 -45.76 85.56 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 115.967 -0.56 . . . . 0.0 110.709 179.912 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 0.4 OUTLIER -60.86 -36.56 72.46 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 N-CA-C 109.807 -0.442 . . . . 0.0 109.807 179.362 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 75' ' ' ASP . . . . . 0.415 ' O ' HG23 ' A' ' 79' ' ' THR . 24.3 t70 -60.38 -37.97 82.44 Favored 'General case' 0 C--N 1.331 -0.209 0 N-CA-C 109.466 -0.568 . . . . 0.0 109.466 178.918 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 76' ' ' TRP . . . . . . . . . . . . . 47.4 m0 -67.08 -29.2 68.9 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 115.717 -0.674 . . . . 0.0 110.289 179.452 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 77' ' ' ILE . . . . . 0.426 ' O ' ' HG2' ' A' ' 81' ' ' PRO . 73.7 mt -72.4 -30.42 34.77 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.373 0 CA-C-N 115.838 -0.619 . . . . 0.0 110.626 179.395 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 40.2 mt -91.88 -16.69 26.33 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.209 -0.451 . . . . 0.0 111.989 -179.954 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 79' ' ' THR . . . . . 0.415 HG23 ' O ' ' A' ' 75' ' ' ASP . 76.7 p -101.97 -49.02 4.06 Favored 'General case' 0 N--CA 1.464 0.262 0 N-CA-C 113.465 0.913 . . . . 0.0 113.465 -178.27 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 80' ' ' THR . . . . . 0.679 ' HB ' ' HD3' ' A' ' 81' ' ' PRO . 44.2 m -53.11 -54.46 44.2 Favored Pre-proline 0 CA--C 1.531 0.22 0 N-CA-C 112.226 0.454 . . . . 0.0 112.226 -178.338 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 81' ' ' PRO . . . . . 0.679 ' HD3' ' HB ' ' A' ' 80' ' ' THR . 34.2 Cg_exo -61.12 -19.72 64.64 Favored 'Trans proline' 0 C--N 1.352 0.735 0 C-N-CA 121.552 1.502 . . . . 0.0 111.28 179.578 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 82' ' ' LEU . . . . . . . . . . . . . 13.1 tp -76.89 -36.56 56.61 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 115.66 -0.7 . . . . 0.0 110.558 179.909 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 35.2 mm -68.02 -52.54 37.83 Favored 'Isoleucine or valine' 0 C--O 1.233 0.235 0 CA-C-N 116.308 -0.405 . . . . 0.0 110.08 179.251 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 30.9 m -59.58 -32.74 49.78 Favored 'Isoleucine or valine' 0 CA--C 1.52 -0.195 0 N-CA-C 109.482 -0.562 . . . . 0.0 109.482 178.796 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 85' ' ' TYR . . . . . . . . . . . . . 89.5 t80 -62.65 -34.63 77.46 Favored 'General case' 0 N--CA 1.454 -0.258 0 CA-C-N 115.528 -0.76 . . . . 0.0 109.163 178.595 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 86' ' ' PHE . . . . . . . . . . . . . 11.3 t80 -61.36 -51.72 67.65 Favored 'General case' 0 N--CA 1.456 -0.126 0 CA-C-N 115.561 -0.745 . . . . 0.0 109.879 179.201 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 7.6 mp -58.6 -36.43 74.0 Favored 'General case' 0 C--N 1.331 -0.202 0 CA-C-N 115.89 -0.595 . . . . 0.0 110.194 179.426 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 88' ' ' GLY . . . . . 0.475 ' HA2' HD13 ' A' ' 93' ' ' LEU . . . -64.93 -28.1 73.04 Favored Glycine 0 N--CA 1.45 -0.399 0 C-N-CA 120.916 -0.659 . . . . 0.0 112.165 179.575 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 86.5 mt -74.08 -41.25 61.97 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.902 0.382 . . . . 0.0 110.741 179.732 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 74.8 mt -58.73 -47.56 84.19 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 115.913 -0.585 . . . . 0.0 111.158 -179.756 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -74.77 -42.44 58.17 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.376 -0.375 . . . . 0.0 111.149 -179.875 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 93.06 55.96 1.54 Allowed Glycine 0 N--CA 1.45 -0.422 0 C-N-CA 120.832 -0.699 . . . . 0.0 112.466 -179.945 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 93' ' ' LEU . . . . . 0.565 HD23 ' HB3' ' A' ' 97' ' ' GLU . 9.7 mp -67.71 -176.4 0.64 Allowed 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.809 0.338 . . . . 0.0 110.908 -179.943 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 94' ' ' ASP . . . . . . . . . . . . . 10.4 m-20 -113.47 172.97 6.64 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.472 -179.929 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 45.4 t -54.03 -36.27 62.85 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.312 -0.404 . . . . 0.0 111.372 -179.759 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 96' ' ' ARG . . . . . 0.402 ' O ' HG13 ' A' ' 100' ' ' ILE . 29.3 mmm180 -73.98 -47.88 34.21 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 116.279 -0.419 . . . . 0.0 111.457 -179.85 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 97' ' ' GLU . . . . . 0.565 ' HB3' HD23 ' A' ' 93' ' ' LEU . 47.6 mt-10 -60.19 -44.59 94.96 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-O 120.912 0.387 . . . . 0.0 110.584 -179.387 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 98' ' ' PHE . . . . . 0.448 ' O ' HG12 ' A' ' 102' ' ' ILE . 12.8 m-85 -59.91 -47.95 83.66 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 115.869 -0.605 . . . . 0.0 110.514 179.325 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -55.22 -32.02 56.86 Favored Glycine 0 N--CA 1.452 -0.276 0 C-N-CA 120.799 -0.715 . . . . 0.0 112.697 179.922 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 100' ' ' ILE . . . . . 0.451 ' O ' HG22 ' A' ' 103' ' ' THR . 89.5 mt -69.51 -54.0 21.91 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.222 0 CA-C-O 120.956 0.408 . . . . 0.0 111.676 -179.894 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 17.2 t -64.7 -42.79 96.0 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.355 0 CA-C-N 116.136 -0.484 . . . . 0.0 111.933 -179.203 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 102' ' ' ILE . . . . . 0.448 HG12 ' O ' ' A' ' 98' ' ' PHE . 48.8 mm -63.67 -53.13 48.69 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-N 116.326 -0.397 . . . . 0.0 111.698 -179.325 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 103' ' ' THR . . . . . 0.451 HG22 ' O ' ' A' ' 100' ' ' ILE . 12.8 t -55.03 -35.38 64.39 Favored 'General case' 0 C--O 1.234 0.244 0 CA-C-O 120.869 0.366 . . . . 0.0 110.726 -179.909 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 104' ' ' LEU . . . . . 0.48 HD22 ' HE2' ' A' ' 140' ' ' TYR . 29.3 tp -61.08 -49.45 77.26 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.296 179.216 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 105' ' ' ASN . . . . . 0.58 ' N ' HD22 ' A' ' 105' ' ' ASN . 0.8 OUTLIER -59.1 -26.36 64.62 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.054 -0.521 . . . . 0.0 110.562 179.808 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 33.2 m -66.47 -54.16 27.22 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.276 -0.42 . . . . 0.0 111.158 179.697 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 12.8 p -66.25 -36.29 77.04 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.152 0 CA-C-N 116.486 -0.325 . . . . 0.0 111.356 -179.834 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . 0.412 HG23 ' O ' ' A' ' 104' ' ' LEU . 73.7 t -62.62 -56.86 14.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-O 120.885 0.374 . . . . 0.0 111.104 -179.949 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 109' ' ' MET . . . . . 0.442 ' HE1' HG21 ' A' ' 80' ' ' THR . 7.1 tpp -60.48 -31.66 70.67 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.451 179.998 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 110' ' ' LEU . . . . . 0.491 HD23 ' C ' ' A' ' 110' ' ' LEU . 5.0 tt -64.19 -37.86 88.97 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-N 115.81 -0.632 . . . . 0.0 109.595 178.714 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -60.78 -50.58 72.86 Favored 'General case' 0 C--N 1.333 -0.137 0 CA-C-N 115.883 -0.598 . . . . 0.0 110.827 179.671 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . -59.38 -45.91 94.72 Favored Glycine 0 C--N 1.331 0.263 0 C-N-CA 120.687 -0.768 . . . . 0.0 112.074 179.645 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 113' ' ' PHE . . . . . . . . . . . . . 3.0 t80 -49.73 -65.66 0.53 Allowed 'General case' 0 C--N 1.333 -0.128 0 CA-C-O 120.91 0.386 . . . . 0.0 110.382 179.696 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -64.79 -17.77 64.5 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 115.901 -0.59 . . . . 0.0 110.952 179.927 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 115' ' ' GLY . . . . . 0.506 ' O ' HG22 ' A' ' 118' ' ' VAL . . . -57.24 -52.32 52.2 Favored Glycine 0 N--CA 1.45 -0.385 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.045 179.579 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -78.32 -15.06 59.11 Favored 'General case' 0 C--N 1.328 -0.351 0 N-CA-C 111.984 0.364 . . . . 0.0 111.984 179.904 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 117' ' ' MET . . . . . 0.501 ' SD ' HG21 ' A' ' 68' ' ' VAL . 26.0 mmt -80.88 19.86 0.82 Allowed 'General case' 0 N--CA 1.464 0.259 0 N-CA-C 112.182 0.438 . . . . 0.0 112.182 -178.985 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 118' ' ' VAL . . . . . 0.524 HG21 ' N ' ' A' ' 123' ' ' ARG . 17.6 m -113.24 157.74 40.16 Favored Pre-proline 0 C--N 1.328 -0.343 0 CA-C-N 116.756 -0.202 . . . . 0.0 111.208 179.819 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 119' ' ' PRO . . . . . 0.435 ' HD2' ' HB ' ' A' ' 118' ' ' VAL . 69.2 Cg_endo -73.96 -24.44 15.17 Favored 'Trans proline' 0 C--N 1.347 0.493 0 C-N-CA 122.414 2.076 . . . . 0.0 112.382 179.667 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . 152.56 151.86 5.8 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.831 179.935 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 18.9 mm 73.73 -46.94 0.17 Allowed 'Isoleucine or valine' 0 N--CA 1.466 0.334 0 C-N-CA 122.956 0.503 . . . . 0.0 111.715 -179.821 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 14.3 mm-40 -60.17 -28.25 67.78 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.103 180.0 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 123' ' ' ARG . . . . . 0.564 ' HD3' ' HA2' ' A' ' 184' ' ' GLY . 6.5 ptp180 -60.23 -29.49 68.8 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.012 -0.54 . . . . 0.0 111.03 179.896 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 124' ' ' TYR . . . . . . . . . . . . . 30.2 m-85 -69.24 -32.15 71.18 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 115.84 -0.618 . . . . 0.0 111.349 -179.707 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 125' ' ' ALA . . . . . . . . . . . . . . . -73.32 -56.41 5.11 Favored 'General case' 0 C--O 1.236 0.364 0 CA-C-O 121.05 0.452 . . . . 0.0 111.03 179.961 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 1.4 mt -56.04 -50.47 70.84 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.814 -0.63 . . . . 0.0 110.719 -179.926 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 127' ' ' PHE . . . . . 0.429 ' HZ ' ' HB3' ' A' ' 175' ' ' PRO . 9.4 t80 -65.69 -36.19 82.93 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.378 -0.374 . . . . 0.0 110.229 179.459 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 128' ' ' GLY . . . . . . . . . . . . . . . -46.29 -44.54 15.36 Favored Glycine 0 C--N 1.332 0.347 0 C-N-CA 120.171 -1.014 . . . . 0.0 110.822 178.925 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 129' ' ' MET . . . . . . . . . . . . . 0.5 OUTLIER -71.83 -36.47 70.2 Favored 'General case' 0 N--CA 1.453 -0.315 0 N-CA-C 109.833 -0.432 . . . . 0.0 109.833 178.663 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -63.13 -33.08 86.27 Favored Glycine 0 C--N 1.333 0.364 0 CA-C-N 115.794 -0.639 . . . . 0.0 112.867 -179.756 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -74.11 -53.87 9.0 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.681 0.277 . . . . 0.0 110.454 -179.99 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 44.2 t -56.91 -39.94 68.54 Favored 'Isoleucine or valine' 0 C--O 1.234 0.26 0 N-CA-C 109.344 -0.613 . . . . 0.0 109.344 178.764 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -67.4 -36.46 81.33 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 115.305 -0.862 . . . . 0.0 110.167 178.986 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 134' ' ' PHE . . . . . . . . . . . . . 84.7 t80 -56.6 -50.63 71.41 Favored 'General case' 0 N--CA 1.452 -0.335 0 CA-C-N 116.126 -0.488 . . . . 0.0 109.81 179.394 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 135' ' ' ILE . . . . . 0.485 ' O ' HG22 ' A' ' 138' ' ' VAL . 52.8 mt -59.28 -33.53 51.2 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.38 0 CA-C-N 115.67 -0.695 . . . . 0.0 110.207 179.204 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . -63.02 -41.09 99.95 Favored Glycine 0 N--CA 1.448 -0.548 0 C-N-CA 120.209 -0.996 . . . . 0.0 111.292 178.87 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 137' ' ' LEU . . . . . 0.478 HD13 HD21 ' A' ' 105' ' ' ASN . 57.9 tp -67.11 -53.94 26.07 Favored 'General case' 0 N--CA 1.454 -0.269 0 CA-C-O 120.499 0.19 . . . . 0.0 110.889 179.733 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 138' ' ' VAL . . . . . 0.485 HG22 ' O ' ' A' ' 135' ' ' ILE . 4.9 m -54.48 -33.84 27.43 Favored 'Isoleucine or valine' 0 C--O 1.233 0.205 0 CA-C-O 121.09 0.471 . . . . 0.0 109.746 -179.696 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 139' ' ' TYR . . . . . . . . . . . . . 24.2 t80 -59.8 -42.96 94.57 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 115.621 -0.718 . . . . 0.0 109.864 178.299 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 140' ' ' TYR . . . . . 0.48 ' HE2' HD22 ' A' ' 104' ' ' LEU . 25.8 m-85 -65.19 -45.74 83.59 Favored 'General case' 0 C--N 1.333 -0.142 0 CA-C-N 116.083 -0.508 . . . . 0.0 111.13 179.38 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 141' ' ' LEU . . . . . . . . . . . . . 10.6 mp -54.48 -32.65 58.2 Favored 'General case' 0 C--N 1.332 -0.171 0 CA-C-N 116.283 -0.417 . . . . 0.0 111.178 -179.745 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 142' ' ' VAL . . . . . 0.417 HG22 ' O ' ' A' ' 142' ' ' VAL . 11.1 p -106.84 -2.41 9.98 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-N 116.233 -0.44 . . . . 0.0 111.121 -179.812 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . -75.61 -120.61 0.13 Allowed Glycine 0 CA--C 1.522 0.469 0 C-N-CA 120.829 -0.701 . . . . 0.0 112.68 -179.848 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 144' ' ' PRO . . . . . . . . . . . . . 56.1 Cg_endo -69.64 -23.65 31.09 Favored 'Trans proline' 0 C--N 1.348 0.54 0 C-N-CA 122.489 2.126 . . . . 0.0 112.433 179.923 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 145' ' ' MET . . . . . 0.433 ' HB3' ' OH ' ' A' ' 160' ' ' TYR . 48.8 mtt -53.62 -58.85 5.7 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.103 -0.499 . . . . 0.0 111.84 -179.712 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 146' ' ' THR . . . . . . . . . . . . . 9.0 t -56.03 -32.45 64.04 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.327 -0.397 . . . . 0.0 111.888 -179.118 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 43.0 mt-10 -70.41 -41.16 73.31 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.645 -0.252 . . . . 0.0 111.329 -179.735 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 148' ' ' SER . . . . . . . . . . . . . 67.4 m -69.74 -41.81 74.76 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.432 -0.349 . . . . 0.0 111.304 -179.329 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 149' ' ' ALA . . . . . . . . . . . . . . . -70.23 -37.54 75.0 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.255 -0.429 . . . . 0.0 111.444 -179.656 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 150' ' ' SER . . . . . . . . . . . . . 75.8 m -68.2 -4.12 12.93 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.381 -0.372 . . . . 0.0 111.057 179.98 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 151' ' ' GLN . . . . . . . . . . . . . 50.4 mt-30 -117.66 4.29 12.33 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.333 -0.394 . . . . 0.0 111.043 179.876 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 7.9 tpm_? -83.81 -51.81 6.9 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 120.971 0.415 . . . . 0.0 110.617 179.863 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 153' ' ' SER . . . . . 0.565 ' HB2' HG12 ' A' ' 156' ' ' ILE . 35.3 m -157.65 172.9 17.69 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 115.768 -0.651 . . . . 0.0 110.544 179.612 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 154' ' ' SER . . . . . . . . . . . . . 66.4 p -71.86 -37.92 70.14 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-O 120.828 0.347 . . . . 0.0 110.433 179.432 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -76.63 -34.71 43.23 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 121.001 -0.619 . . . . 0.0 112.646 179.848 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 156' ' ' ILE . . . . . 0.565 HG12 ' HB2' ' A' ' 153' ' ' SER . 34.2 mm -59.52 -36.76 66.59 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-O 120.84 0.353 . . . . 0.0 111.167 179.958 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 157' ' ' LYS . . . . . . . . . . . . . 86.4 tttt -61.23 -54.99 37.25 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 116.078 -0.51 . . . . 0.0 111.524 -179.713 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 49.0 m -66.39 -38.99 88.76 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.964 -179.152 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 159' ' ' LEU . . . . . . . . . . . . . 6.4 tt -68.55 -37.05 79.6 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.725 -0.216 . . . . 0.0 111.546 -179.119 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 160' ' ' TYR . . . . . 0.433 ' OH ' ' HB3' ' A' ' 145' ' ' MET . 37.7 t80 -74.09 -47.43 36.53 Favored 'General case' 0 C--N 1.33 -0.265 0 N-CA-C 111.807 0.299 . . . . 0.0 111.807 -179.087 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 27.9 m -57.21 -41.73 78.57 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-O 120.674 0.273 . . . . 0.0 111.453 -179.332 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 162' ' ' ARG . . . . . 0.405 ' O ' HD23 ' A' ' 166' ' ' LEU . 32.5 tpt180 -68.96 -43.92 74.01 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-O 120.867 0.365 . . . . 0.0 111.204 -179.913 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 163' ' ' LEU . . . . . 0.496 ' HG ' ' HB2' ' A' ' 208' ' ' PHE . 3.9 mp -62.41 -47.41 84.22 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 115.917 -0.583 . . . . 0.0 111.973 -179.247 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 164' ' ' ARG . . . . . 0.462 ' HG3' ' N ' ' A' ' 165' ' ' ASN . 4.5 ptt180 -67.64 -40.86 84.55 Favored 'General case' 0 C--N 1.329 -0.288 0 N-CA-C 111.829 0.307 . . . . 0.0 111.829 -178.926 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 165' ' ' ASN . . . . . 0.501 ' O ' HG23 ' A' ' 169' ' ' VAL . 0.9 OUTLIER -58.77 -52.07 67.28 Favored 'General case' 0 C--N 1.327 -0.372 0 N-CA-C 111.946 0.35 . . . . 0.0 111.946 -179.231 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 166' ' ' LEU . . . . . 0.405 HD23 ' O ' ' A' ' 162' ' ' ARG . 3.0 pp -68.22 -44.29 76.09 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.707 0.289 . . . . 0.0 111.455 -179.485 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 167' ' ' THR . . . . . . . . . . . . . 71.5 m -58.48 -50.87 72.18 Favored 'General case' 0 C--N 1.331 -0.218 0 N-CA-C 112.198 0.444 . . . . 0.0 112.198 -179.402 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 168' ' ' VAL . . . . . 0.409 HG13 ' N ' ' A' ' 169' ' ' VAL . 9.2 p -61.7 -41.12 89.22 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 N-CA-C 111.713 0.264 . . . . 0.0 111.713 -179.014 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 169' ' ' VAL . . . . . 0.501 HG23 ' O ' ' A' ' 165' ' ' ASN . 55.1 t -60.98 -59.41 4.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-O 120.769 0.318 . . . . 0.0 111.175 -179.883 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 170' ' ' LEU . . . . . 0.577 HD22 HG12 ' A' ' 203' ' ' VAL . 3.9 pp -61.86 -31.63 71.91 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.358 -0.383 . . . . 0.0 110.982 -179.455 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 171' ' ' TRP . . . . . 0.925 ' HE1' H203 ' A' ' 301' ' ' RET . 3.4 m0 -72.07 -32.08 66.71 Favored 'General case' 0 N--CA 1.463 0.205 0 CA-C-O 120.89 0.376 . . . . 0.0 110.095 178.952 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 172' ' ' ALA . . . . . . . . . . . . . . . -69.07 -7.17 33.37 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 115.982 -0.554 . . . . 0.0 110.692 179.646 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 173' ' ' ILE . . . . . 0.494 ' O ' HG12 ' A' ' 177' ' ' ILE . 29.2 mm -88.19 -26.65 5.65 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.263 0 CA-C-N 115.939 -0.573 . . . . 0.0 110.919 179.794 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 174' ' ' TYR . . . . . 0.465 ' HB2' ' HD3' ' A' ' 175' ' ' PRO . 34.4 m-85 -53.77 -48.81 92.25 Favored Pre-proline 0 C--N 1.332 -0.163 0 CA-C-N 116.311 -0.404 . . . . 0.0 111.574 -179.737 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 175' ' ' PRO . . . . . 0.465 ' HD3' ' HB2' ' A' ' 174' ' ' TYR . 84.8 Cg_exo -47.93 -32.39 17.69 Favored 'Trans proline' 0 C--N 1.352 0.722 0 C-N-CA 122.007 1.805 . . . . 0.0 112.199 179.558 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 176' ' ' PHE . . . . . 0.439 ' O ' ' HG ' ' A' ' 180' ' ' LEU . 81.5 m-85 -80.76 -50.59 9.67 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.059 -0.519 . . . . 0.0 111.803 -179.931 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 177' ' ' ILE . . . . . 0.494 HG12 ' O ' ' A' ' 173' ' ' ILE . 6.8 mm -62.07 -30.86 49.64 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.585 0 CA-C-N 116.104 -0.498 . . . . 0.0 112.022 -178.338 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 178' ' ' TRP . . . . . 0.435 ' HH2' ' HB2' ' A' ' 123' ' ' ARG . 73.9 t90 -73.6 -47.42 40.48 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-O 120.854 0.359 . . . . 0.0 110.662 179.714 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 179' ' ' LEU . . . . . 0.56 HD23 HD23 ' A' ' 180' ' ' LEU . 0.7 OUTLIER -70.96 -54.61 10.69 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 115.97 -0.559 . . . . 0.0 111.409 -179.287 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 180' ' ' LEU . . . . . 0.56 HD23 HD23 ' A' ' 179' ' ' LEU . 24.8 mt -64.78 -38.02 89.58 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.556 -0.293 . . . . 0.0 111.151 -179.779 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . -61.73 178.46 4.43 Favored Glycine 0 C--N 1.334 0.453 0 C-N-CA 120.086 -1.054 . . . . 0.0 112.231 179.185 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 182' ' ' PRO . . . . . 0.525 ' HA ' ' HB2' ' A' ' 186' ' ' ALA . 75.2 Cg_exo -48.02 -45.33 25.45 Favored 'Trans proline' 0 CA--C 1.534 0.507 0 C-N-CA 122.827 2.351 . . . . 0.0 113.613 179.856 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 183' ' ' PRO . . . . . 0.416 ' HD3' ' HB2' ' A' ' 182' ' ' PRO . 82.4 Cg_exo -46.65 -29.84 8.21 Favored 'Trans proline' 0 C--N 1.356 0.954 0 C-N-CA 122.14 1.894 . . . . 0.0 113.232 -179.788 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 184' ' ' GLY . . . . . 0.564 ' HA2' ' HD3' ' A' ' 123' ' ' ARG . . . -115.81 -128.19 4.28 Favored Glycine 0 N--CA 1.449 -0.453 0 C-N-CA 120.249 -0.977 . . . . 0.0 113.129 -179.663 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 185' ' ' VAL . . . . . . . . . . . . . 13.0 m -58.13 -27.33 31.65 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 N-CA-C 112.18 0.437 . . . . 0.0 112.18 -179.429 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 186' ' ' ALA . . . . . 0.525 ' HB2' ' HA ' ' A' ' 182' ' ' PRO . . . 59.34 82.25 0.15 Allowed 'General case' 0 C--N 1.33 -0.251 0 N-CA-C 111.983 0.364 . . . . 0.0 111.983 179.445 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 187' ' ' LEU . . . . . 0.56 ' HB2' HD12 ' A' ' 188' ' ' LEU . 8.6 mt -92.47 -49.59 6.05 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-O 121.039 0.447 . . . . 0.0 110.721 179.381 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 188' ' ' LEU . . . . . 0.56 HD12 ' HB2' ' A' ' 187' ' ' LEU . 6.9 mp -87.4 -166.38 1.56 Allowed 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 115.696 -0.684 . . . . 0.0 111.489 -179.233 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 189' ' ' THR . . . . . . . . . . . . . 10.2 m -94.39 137.43 22.71 Favored Pre-proline 0 C--N 1.33 -0.265 0 CA-C-N 115.743 -0.662 . . . . 0.0 110.498 -179.94 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 190' ' ' PRO . . . . . 0.473 ' O ' HG23 ' A' ' 194' ' ' VAL . 87.6 Cg_exo -44.31 -47.01 11.2 Favored 'Trans proline' 0 C--N 1.35 0.612 0 C-N-CA 122.661 2.241 . . . . 0.0 113.097 -179.859 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 191' ' ' THR . . . . . . . . . . . . . 6.8 t -59.27 -39.47 83.02 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 120.817 0.342 . . . . 0.0 111.28 -179.906 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 192' ' ' VAL . . . . . . . . . . . . . 58.8 t -70.58 -45.42 74.44 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.262 -0.426 . . . . 0.0 111.171 -179.952 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 193' ' ' ASP . . . . . . . . . . . . . 30.5 t70 -57.54 -43.85 84.7 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.294 -0.412 . . . . 0.0 110.678 179.937 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 194' ' ' VAL . . . . . 0.473 HG23 ' O ' ' A' ' 190' ' ' PRO . 98.1 t -64.28 -35.72 74.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 115.944 -0.571 . . . . 0.0 110.559 179.743 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 195' ' ' ALA . . . . . . . . . . . . . . . -59.19 -47.87 83.72 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 120.824 0.345 . . . . 0.0 110.793 179.551 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 196' ' ' LEU . . . . . . . . . . . . . 61.3 mt -67.83 -40.73 83.71 Favored 'General case' 0 C--N 1.332 -0.172 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.705 179.681 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 197' ' ' ILE . . . . . . . . . . . . . 14.3 mm -59.98 -58.18 8.37 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.239 0 CA-C-N 116.041 -0.527 . . . . 0.0 110.348 179.436 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 198' ' ' VAL . . . . . . . . . . . . . 64.1 t -52.28 -34.21 18.05 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.515 0 CA-C-N 115.599 -0.728 . . . . 0.0 109.311 178.469 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 199' ' ' TYR . . . . . 0.479 ' O ' HG23 ' A' ' 203' ' ' VAL . 64.9 t80 -69.32 -41.16 77.08 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 115.378 -0.828 . . . . 0.0 110.401 179.83 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 200' ' ' LEU . . . . . 0.438 HD11 HG13 ' A' ' 177' ' ' ILE . 31.4 mt -59.03 -54.81 42.91 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 115.563 -0.744 . . . . 0.0 111.524 -179.521 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 201' ' ' ASP . . . . . . . . . . . . . 10.7 m-20 -60.23 -38.64 84.04 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.322 -0.399 . . . . 0.0 110.888 -179.853 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 202' ' ' LEU . . . . . 0.436 HD11 ' HA2' ' A' ' 11' ' ' GLY . 2.0 mt -66.81 -28.43 68.37 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 115.868 -0.606 . . . . 0.0 111.409 -179.637 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 203' ' ' VAL . . . . . 0.577 HG12 HD22 ' A' ' 170' ' ' LEU . 41.3 t -79.47 -36.37 17.72 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.439 -0.346 . . . . 0.0 110.841 -179.055 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 204' ' ' THR . . . . . 0.434 ' O ' ' CD1' ' A' ' 208' ' ' PHE . 27.7 m -63.46 -58.32 7.43 Favored 'General case' 0 C--N 1.324 -0.512 0 C-N-CA 120.575 -0.45 . . . . 0.0 110.928 179.768 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 205' ' ' LYS . . . . . 0.74 ' HE2' ' HB2' ' A' ' 47' ' ' ALA . 44.2 mttp -66.32 -58.57 5.04 Favored 'General case' 0 C--N 1.331 -0.229 0 N-CA-C 112.624 0.602 . . . . 0.0 112.624 -178.254 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 43.8 t -70.83 -36.68 65.46 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.374 0 N-CA-C 112.182 0.438 . . . . 0.0 112.182 -178.444 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 207' ' ' GLY . . . . . 0.518 ' O ' HG13 ' A' ' 211' ' ' ILE . . . -61.54 -60.38 8.3 Favored Glycine 0 N--CA 1.452 -0.234 0 C-N-CA 120.58 -0.819 . . . . 0.0 113.598 -178.561 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 208' ' ' PHE . . . . . 0.496 ' HB2' ' HG ' ' A' ' 163' ' ' LEU . 0.1 OUTLIER -70.83 -26.66 63.38 Favored 'General case' 0 N--CA 1.464 0.249 0 CA-C-N 117.14 0.47 . . . . 0.0 111.515 -178.9 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 209' ' ' GLY . . . . . 0.508 ' O ' ' HB3' ' A' ' 212' ' ' ALA . . . -68.29 -32.65 76.24 Favored Glycine 0 N--CA 1.449 -0.49 0 N-CA-C 111.81 -0.516 . . . . 0.0 111.81 179.084 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 210' ' ' PHE . . . . . . . . . . . . . 0.8 OUTLIER -71.62 -48.47 47.74 Favored 'General case' 0 CA--C 1.512 -0.494 0 N-CA-C 108.053 -1.092 . . . . 0.0 108.053 178.491 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 211' ' ' ILE . . . . . 0.518 HG13 ' O ' ' A' ' 207' ' ' GLY . 4.9 mt -63.61 -27.75 43.58 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.544 0 N-CA-C 107.645 -1.243 . . . . 0.0 107.645 176.65 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 212' ' ' ALA . . . . . 0.508 ' HB3' ' O ' ' A' ' 209' ' ' GLY . . . -64.42 -40.97 96.79 Favored 'General case' 0 N--CA 1.45 -0.463 0 CA-C-N 114.583 -1.19 . . . . 0.0 110.5 179.793 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 213' ' ' LEU . . . . . . . . . . . . . 91.5 mt -70.52 -55.07 9.78 Favored 'General case' 0 N--CA 1.461 0.105 0 CA-C-N 115.489 -0.778 . . . . 0.0 111.748 -179.671 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 214' ' ' ASP . . . . . . . . . . . . . 25.1 m-20 -53.98 -49.92 67.73 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.28 -0.418 . . . . 0.0 111.648 -179.273 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 215' ' ' ALA . . . . . 0.45 ' O ' ' HG ' ' A' ' 219' ' ' LEU . . . -59.8 -57.51 12.6 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.372 -0.376 . . . . 0.0 111.48 -179.633 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 216' ' ' ALA . . . . . . . . . . . . . . . -57.66 -35.31 70.38 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.31 -0.405 . . . . 0.0 111.421 -179.703 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 217' ' ' ALA . . . . . . . . . . . . . . . -63.67 -31.75 73.02 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 121.001 0.429 . . . . 0.0 110.424 179.831 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 218' ' ' THR . . . . . . . . . . . . . 93.8 m -77.15 -46.46 23.34 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 115.759 -0.655 . . . . 0.0 110.79 179.532 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 219' ' ' LEU . . . . . 0.45 ' HG ' ' O ' ' A' ' 215' ' ' ALA . 20.4 mt -63.65 -27.72 69.42 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.585 179.753 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 220' ' ' ARG . . . . . 0.402 HH11 ' HD2' ' A' ' 220' ' ' ARG . 10.0 ttp180 -82.95 -34.24 26.53 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 115.868 -0.606 . . . . 0.0 110.708 179.887 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 221' ' ' ALA . . . . . . . . . . . . . . . -62.13 -41.43 98.24 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-N 115.975 -0.557 . . . . 0.0 111.125 -179.939 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 222' ' ' GLU . . . . . . . . . . . . . 10.7 pt-20 -85.62 -38.25 18.61 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.716 -179.922 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 223' ' ' HIS . . . . . . . . . . . . . 35.1 p80 40.06 31.06 0.08 Allowed 'General case' 0 N--CA 1.465 0.314 0 CA-C-N 115.795 -0.639 . . . . 0.0 111.872 -179.928 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 224' ' ' GLY . . . . . . . . . . . . . . . -70.26 109.25 2.78 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.375 179.817 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 225' ' ' GLU . . . . . . . . . . . . . 9.1 tp10 -113.54 150.43 32.98 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.764 0.316 . . . . 0.0 110.858 -179.8 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 226' ' ' SER . . . . . . . . . . . . . 40.7 t -104.42 -31.14 9.64 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.93 -179.972 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 227' ' ' LEU . . . . . . . . . . . . . 93.7 mt -107.85 97.61 7.31 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.934 -179.986 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 228' ' ' ALA . . . . . . . . . . . . . . . -125.25 -0.86 7.67 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.909 179.881 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 229' ' ' GLY . . . . . . . . . . . . . . . -62.03 -61.89 6.23 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.803 -0.713 . . . . 0.0 112.484 179.936 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 230' ' ' VAL . . . . . . . . . . . . . 4.1 m -143.49 145.83 21.94 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.22 0 CA-C-O 120.728 0.299 . . . . 0.0 111.329 179.979 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 231' ' ' ASP . . . . . . . . . . . . . 11.4 m-20 -86.14 80.5 8.77 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.252 179.324 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 232' ' ' THR . . . . . . . . . . . . . 41.4 p -58.68 146.59 35.87 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 115.9 -0.591 . . . . 0.0 111.408 -179.43 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 233' ' ' ASP . . . . . . . . . . . . . 10.4 m-20 -90.82 -5.77 55.17 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.031 -0.531 . . . . 0.0 110.921 -179.956 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 234' ' ' THR . . . . . . . . . . . . . 68.0 p 47.45 83.16 0.22 Allowed Pre-proline 0 CA--C 1.529 0.168 0 CA-C-N 115.916 -0.584 . . . . 0.0 111.559 -179.945 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 235' ' ' PRO . . . . . . . . . . . . . 72.4 Cg_endo -76.98 149.3 28.77 Favored 'Trans proline' 0 C--N 1.346 0.424 0 C-N-CA 122.485 2.123 . . . . 0.0 112.457 179.888 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 236' ' ' ALA . . . . . . . . . . . . . . . -75.11 140.76 43.65 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.982 179.883 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 237' ' ' VAL . . . . . 0.476 HG11 HD13 ' A' ' 240' ' ' LEU . 51.1 t -92.31 132.66 36.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.289 -0.414 . . . . 0.0 111.143 179.975 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 238' ' ' ALA . . . . . . . . . . . . . . . -88.1 -40.89 13.42 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.053 179.85 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 239' ' ' ASP . . . . . . . . . . . . . 5.0 p-10 -124.57 120.02 30.75 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.728 179.866 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 240' ' ' LEU . . . . . 0.476 HD13 HG11 ' A' ' 237' ' ' VAL . 3.9 mm? -96.01 -54.28 3.37 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.123 -0.489 . . . . 0.0 111.0 -179.771 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 241' ' ' GLU . . . . . . . . . . . . . 39.7 tt0 -147.72 -49.5 0.17 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.891 -179.924 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 242' ' ' HIS . . . . . . . . . . . . . 66.6 m80 -77.19 146.13 37.22 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.102 -0.499 . . . . 0.0 111.195 -179.781 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 243' ' ' HIS . . . . . . . . . . . . . 32.4 t-80 -112.78 109.24 18.61 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.515 179.707 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 244' ' ' HIS . . . . . . . . . . . . . 52.7 m-70 -77.49 -171.12 2.02 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.022 -179.739 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 245' ' ' HIS . . . . . . . . . . . . . 57.8 t-80 -124.31 112.67 17.27 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.918 179.979 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 246' ' ' HIS . . . . . . . . . . . . . 44.1 m-70 -124.44 115.29 20.7 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.796 179.772 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 247' ' ' HIS . . . . . . . . . . . . . 47.4 t60 . . . . . 0 C--O 1.249 1.073 0 CA-C-O 118.313 -0.851 . . . . 0.0 110.786 -179.876 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' A' A ' 301' ' ' RET . . . . . 0.925 H203 ' HE1' ' A' ' 171' ' ' TRP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 66.5 mtm . . . . . 0 N--CA 1.485 1.287 0 CA-C-O 120.712 0.291 . . . . 0.0 110.887 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 28.2 m -88.66 -14.16 9.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.255 -0.429 . . . . 0.0 111.39 -179.755 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -121.75 -9.67 6.82 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.653 -0.784 . . . . 0.0 112.789 -179.88 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 49.2 tp -74.1 -35.37 64.18 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-O 120.782 0.325 . . . . 0.0 110.921 179.951 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 82.7 p -62.34 -31.63 72.29 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.447 -179.774 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 28.9 p -54.23 -35.78 62.81 Favored 'General case' 0 C--N 1.332 -0.175 0 CA-C-N 116.368 -0.378 . . . . 0.0 111.276 -179.906 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 7' ' ' LEU . . . . . . . . . . . . . 4.2 mm? -59.79 -50.73 72.66 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.202 -179.847 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 8' ' ' PHE . . . . . 0.664 ' HB2' ' HB2' ' A' ' 55' ' ' ALA . 64.2 m-85 -65.5 -34.91 79.37 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.9 -179.829 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 9' ' ' TRP . . . . . 0.416 ' O ' HG12 ' A' ' 13' ' ' ILE . 29.4 m95 -65.27 -44.77 87.0 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.292 -179.668 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 75.3 mt -60.51 -41.43 94.33 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 115.639 -0.71 . . . . 0.0 110.095 179.396 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -64.86 -34.65 90.46 Favored Glycine 0 N--CA 1.448 -0.501 0 C-N-CA 120.677 -0.773 . . . . 0.0 111.667 179.304 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -65.5 -31.32 72.33 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-O 120.849 0.357 . . . . 0.0 110.388 179.602 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 13' ' ' ILE . . . . . 0.416 HG12 ' O ' ' A' ' 9' ' ' TRP . 42.3 mm -67.72 -48.47 75.89 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 116.032 -0.531 . . . . 0.0 110.153 179.339 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -61.57 -28.12 69.2 Favored Glycine 0 N--CA 1.45 -0.386 0 C-N-CA 120.698 -0.763 . . . . 0.0 111.81 179.436 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 15' ' ' MET . . . . . 0.56 ' HE3' ' CB ' ' A' ' 47' ' ' ALA . 23.2 mmt -75.07 -39.43 60.87 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.731 0.3 . . . . 0.0 110.645 179.693 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 20.6 tp -59.09 -40.64 85.9 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.312 179.345 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 41.3 t -69.94 -45.52 76.49 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.215 0 CA-C-N 115.902 -0.59 . . . . 0.0 111.114 -179.938 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -63.84 -49.59 67.07 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.562 -0.827 . . . . 0.0 111.686 179.635 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 85.1 m -50.24 -45.23 53.92 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 115.448 -0.376 . . . . 0.0 111.014 179.767 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 77.9 mt -71.89 -39.3 69.68 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.382 179.764 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -64.1 -30.62 71.67 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.659 0.266 . . . . 0.0 111.528 -179.626 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 22' ' ' PHE . . . . . 0.575 ' HB2' HG22 ' A' ' 41' ' ' VAL . 6.3 m-85 -90.84 -31.12 16.58 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.503 -0.317 . . . . 0.0 111.113 -179.388 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -71.58 -49.78 37.27 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-O 120.907 0.384 . . . . 0.0 110.841 179.797 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 24' ' ' TRP . . . . . . . . . . . . . 1.2 t-105 -60.32 -41.61 93.85 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 115.893 -0.594 . . . . 0.0 110.72 179.797 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -73.84 -25.77 60.25 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.356 -0.384 . . . . 0.0 110.665 179.619 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -73.54 -40.44 47.13 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.907 -0.663 . . . . 0.0 112.674 179.835 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 72.2 mtp180 -72.44 -2.22 18.66 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-O 120.753 0.311 . . . . 0.0 111.068 179.965 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 19.3 t70 -107.02 -8.38 16.58 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.704 179.94 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -79.02 -174.6 4.13 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.232 -179.926 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -122.18 -170.87 13.82 Favored Glycine 0 N--CA 1.452 -0.266 0 C-N-CA 120.82 -0.705 . . . . 0.0 112.461 -179.985 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 74.8 p -68.28 113.38 5.84 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-O 120.812 0.339 . . . . 0.0 111.011 179.981 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 134.33 -54.2 0.77 Allowed Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.805 -0.712 . . . . 0.0 112.561 -179.94 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 45.8 mt-10 -85.58 -20.82 28.98 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.672 0.272 . . . . 0.0 111.05 179.953 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 34' ' ' ARG . . . . . 0.455 ' O ' HG23 ' A' ' 38' ' ' VAL . 56.7 ttp180 -50.44 -29.51 10.45 Favored 'General case' 0 C--N 1.332 -0.175 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.339 -179.761 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 37.2 mmt180 -64.59 -43.92 92.3 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.329 -0.396 . . . . 0.0 110.953 179.981 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 64.8 m-85 -69.36 -33.76 73.56 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 116.13 -0.486 . . . . 0.0 111.44 -179.596 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 37' ' ' TYR . . . . . . . . . . . . . 54.2 m-85 -70.81 -53.01 16.93 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.533 -179.386 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 38' ' ' VAL . . . . . 0.455 HG23 ' O ' ' A' ' 34' ' ' ARG . 87.4 t -56.82 -36.79 50.75 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.249 0 CA-C-O 121.18 0.514 . . . . 0.0 110.21 179.509 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 40.9 m -66.76 -47.53 71.93 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 115.51 -0.768 . . . . 0.0 110.525 179.222 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 40' ' ' LEU . . . . . 0.405 ' O ' HG13 ' A' ' 43' ' ' ILE . 21.9 tp -57.1 -47.57 80.73 Favored 'General case' 0 C--O 1.235 0.3 0 CA-C-N 115.67 -0.695 . . . . 0.0 110.787 179.881 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . 0.575 HG22 ' HB2' ' A' ' 22' ' ' PHE . 94.8 t -63.05 -34.81 68.74 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-N 115.81 -0.632 . . . . 0.0 110.249 179.436 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -58.78 -39.79 94.18 Favored Glycine 0 N--CA 1.449 -0.471 0 CA-C-N 115.689 -0.687 . . . . 0.0 112.238 179.667 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 43' ' ' ILE . . . . . 0.609 HG22 ' HE3' ' A' ' 205' ' ' LYS . 0.1 OUTLIER -67.93 -50.97 54.54 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.166 0 CA-C-O 120.695 0.283 . . . . 0.0 110.984 179.851 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 50.5 m -63.59 -25.28 68.16 Favored 'General case' 0 C--N 1.331 -0.199 0 CA-C-O 120.824 0.345 . . . . 0.0 110.945 179.895 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -77.81 -52.15 5.55 Favored Glycine 0 N--CA 1.452 -0.263 0 C-N-CA 120.949 -0.643 . . . . 0.0 112.865 -179.542 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 46' ' ' ILE . . . . . 0.72 HD12 HD12 ' A' ' 78' ' ' LEU . 10.5 pt -58.32 -40.92 79.82 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.242 0 CA-C-O 120.874 0.369 . . . . 0.0 110.975 -179.75 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 47' ' ' ALA . . . . . 0.669 ' HB2' ' HE2' ' A' ' 205' ' ' LYS . . . -68.12 -40.24 82.58 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.124 179.468 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 48' ' ' ALA . . . . . 0.528 ' HB2' ' HB3' ' A' ' 15' ' ' MET . . . -54.59 -45.42 73.61 Favored 'General case' 0 C--O 1.233 0.197 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.31 -179.666 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 27.6 m -73.05 -33.9 44.0 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.257 -0.429 . . . . 0.0 111.26 -179.68 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -61.67 -37.75 85.22 Favored 'General case' 0 C--N 1.331 -0.21 0 CA-C-O 121.102 0.477 . . . . 0.0 110.576 179.256 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 51' ' ' TYR . . . . . 0.487 ' HB3' ' O ' ' A' ' 8' ' ' PHE . 29.6 m-85 -72.85 -35.63 67.28 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 115.767 -0.651 . . . . 0.0 110.266 179.682 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -66.08 -40.88 91.18 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 115.798 -0.637 . . . . 0.0 111.082 179.3 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 27.6 m -74.1 -41.52 52.03 Favored 'Isoleucine or valine' 0 C--O 1.231 0.123 0 CA-C-N 116.47 -0.332 . . . . 0.0 111.016 179.95 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 54' ' ' MET . . . . . 0.623 ' HG2' ' HG2' ' A' ' 71' ' ' PRO . 72.0 mtm -64.93 -36.21 83.65 Favored 'General case' 0 CA--C 1.519 -0.233 0 CA-C-O 121.171 0.51 . . . . 0.0 109.831 179.128 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 55' ' ' ALA . . . . . 0.664 ' HB2' ' HB2' ' A' ' 8' ' ' PHE . . . -69.55 -16.71 63.47 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 115.489 -0.778 . . . . 0.0 111.193 179.764 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 73.5 mt -97.06 2.55 51.48 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.328 -0.396 . . . . 0.0 111.407 -179.632 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 84.75 3.23 88.28 Favored Glycine 0 N--CA 1.452 -0.258 0 C-N-CA 120.628 -0.796 . . . . 0.0 112.941 179.66 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 49.2 t -69.87 132.94 32.67 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-O 120.631 0.253 . . . . 0.0 110.907 179.875 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 59' ' ' GLY . . . . . 0.695 ' HA3' ' HD3' ' A' ' 71' ' ' PRO . . . 88.56 -13.01 63.45 Favored Glycine 0 N--CA 1.449 -0.476 0 C-N-CA 120.656 -0.783 . . . . 0.0 112.487 -179.866 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 60' ' ' TRP . . . . . . . . . . . . . 15.5 m0 -66.2 89.46 0.13 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.833 0.349 . . . . 0.0 110.7 179.901 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 61' ' ' VAL . . . . . 0.523 HG13 HG23 ' A' ' 68' ' ' VAL . 4.0 p -101.52 132.32 21.94 Favored Pre-proline 0 CA--C 1.532 0.265 0 CA-C-N 116.266 -0.424 . . . . 0.0 110.928 179.928 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 62' ' ' PRO . . . . . 0.452 ' HD3' ' HA ' ' A' ' 61' ' ' VAL . 4.6 Cg_exo -76.94 151.21 30.83 Favored 'Trans proline' 0 C--N 1.35 0.617 0 C-N-CA 122.673 2.249 . . . . 0.0 112.494 -179.763 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 73.3 t -142.32 91.84 0.5 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 115.964 -0.562 . . . . 0.0 110.804 179.774 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . 59.56 -87.43 0.02 OUTLIER 'General case' 0 N--CA 1.463 0.183 0 CA-C-N 116.097 -0.501 . . . . 0.0 111.529 179.962 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 10.3 pt-20 -124.21 -16.26 6.51 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.903 0.383 . . . . 0.0 110.673 179.972 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 66' ' ' ARG . . . . . 0.431 HH11 ' HD2' ' A' ' 66' ' ' ARG . 64.6 mtt180 -104.58 160.77 14.68 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 115.922 -0.581 . . . . 0.0 110.362 179.535 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 37.2 m -120.97 142.66 49.56 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.971 0.415 . . . . 0.0 111.473 -179.613 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 68' ' ' VAL . . . . . 0.523 HG23 HG13 ' A' ' 61' ' ' VAL . 15.3 m -131.68 145.04 35.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 115.799 -0.637 . . . . 0.0 110.552 179.609 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 69' ' ' PHE . . . . . 0.406 ' C ' ' HD2' ' A' ' 71' ' ' PRO . 16.7 m-85 -109.48 115.84 30.68 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.364 -0.38 . . . . 0.0 110.365 -179.358 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 70' ' ' VAL . . . . . 0.741 HG12 ' HD3' ' A' ' 71' ' ' PRO . 0.8 OUTLIER -64.59 -36.79 19.28 Favored Pre-proline 0 CA--C 1.541 0.627 0 N-CA-C 112.701 0.63 . . . . 0.0 112.701 -179.321 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 71' ' ' PRO . . . . . 0.741 ' HD3' HG12 ' A' ' 70' ' ' VAL . 61.4 Cg_endo -70.52 -20.81 30.77 Favored 'Trans proline' 0 C--N 1.36 1.154 0 C-N-CA 121.934 1.756 . . . . 0.0 113.382 -179.451 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 46.6 ttp180 -73.06 -55.13 6.93 Favored 'General case' 0 C--O 1.235 0.323 0 N-CA-C 111.658 0.244 . . . . 0.0 111.658 -179.031 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 73' ' ' TYR . . . . . 0.431 ' O ' HG13 ' A' ' 77' ' ' ILE . 11.8 m-85 -65.84 -37.54 86.46 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.907 0.384 . . . . 0.0 110.022 -179.883 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 74' ' ' ILE . . . . . 0.529 ' HA ' HD12 ' A' ' 77' ' ' ILE . 0.4 OUTLIER -67.22 -41.23 86.5 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.219 0 CA-C-N 116.058 -0.519 . . . . 0.0 110.631 179.704 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 75' ' ' ASP . . . . . 0.433 ' O ' HG23 ' A' ' 79' ' ' THR . 17.7 t70 -55.08 -39.7 69.57 Favored 'General case' 0 CA--C 1.519 -0.245 0 N-CA-C 109.584 -0.524 . . . . 0.0 109.584 179.235 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 76' ' ' TRP . . . . . 0.485 ' HZ2' HG23 ' A' ' 197' ' ' ILE . 30.7 m0 -68.44 -32.52 72.6 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 115.927 -0.579 . . . . 0.0 110.683 179.61 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 77' ' ' ILE . . . . . 0.629 ' HA ' ' HG3' ' A' ' 109' ' ' MET . 92.2 mt -60.95 -41.64 89.79 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.245 0 CA-C-N 116.104 -0.498 . . . . 0.0 111.954 -179.828 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 78' ' ' LEU . . . . . 0.72 HD12 HD12 ' A' ' 46' ' ' ILE . 0.7 OUTLIER -91.38 -30.02 16.76 Favored 'General case' 0 CA--C 1.536 0.409 0 N-CA-C 113.392 0.886 . . . . 0.0 113.392 -178.883 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 79' ' ' THR . . . . . 0.438 HG22 ' CD1' ' A' ' 46' ' ' ILE . 46.0 p -75.2 -53.32 9.01 Favored 'General case' 0 N--CA 1.47 0.558 0 N-CA-C 113.447 0.906 . . . . 0.0 113.447 -178.275 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 80' ' ' THR . . . . . 0.617 HG21 ' HE1' ' A' ' 109' ' ' MET . 7.3 m -51.47 -48.95 85.04 Favored Pre-proline 0 C--N 1.329 -0.312 0 N-CA-C 112.948 0.721 . . . . 0.0 112.948 -178.36 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 81' ' ' PRO . . . . . 0.569 ' HD2' ' N ' ' A' ' 80' ' ' THR . 23.3 Cg_endo -58.99 -26.35 81.2 Favored 'Trans proline' 0 C--N 1.351 0.659 0 C-N-CA 121.72 1.613 . . . . 0.0 111.846 -179.511 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 82' ' ' LEU . . . . . . . . . . . . . 14.1 tp -76.73 -36.5 57.12 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 115.908 -0.587 . . . . 0.0 110.557 179.991 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 83' ' ' ILE . . . . . 0.518 HD13 HD13 ' A' ' 43' ' ' ILE . 38.8 mm -67.91 -51.22 51.96 Favored 'Isoleucine or valine' 0 C--O 1.234 0.275 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.137 179.086 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 27.0 m -61.14 -31.13 49.24 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.214 0 CA-C-N 116.014 -0.539 . . . . 0.0 109.632 179.129 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 85' ' ' TYR . . . . . 0.408 ' HB2' ' O ' ' A' ' 81' ' ' PRO . 58.6 t80 -65.23 -34.47 78.44 Favored 'General case' 0 N--CA 1.452 -0.332 0 CA-C-N 115.638 -0.71 . . . . 0.0 109.36 178.965 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 86' ' ' PHE . . . . . . . . . . . . . 4.2 t80 -61.39 -51.63 67.98 Favored 'General case' 0 C--O 1.231 0.131 0 CA-C-N 115.586 -0.734 . . . . 0.0 110.064 179.222 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 7.4 mt -65.05 -28.69 69.65 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 121.309 0.576 . . . . 0.0 109.772 179.66 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -72.57 -27.43 69.43 Favored Glycine 0 N--CA 1.45 -0.41 0 CA-C-N 115.2 -0.909 . . . . 0.0 111.545 179.139 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 52.8 mt -73.21 -43.35 61.42 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 121.006 0.431 . . . . 0.0 110.549 179.652 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 59.1 mt -60.14 -33.19 71.82 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 115.707 -0.679 . . . . 0.0 111.047 179.887 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . 0.566 ' HB1' ' HB2' ' A' ' 148' ' ' SER . . . -85.76 -47.97 9.25 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.514 -179.532 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 89.27 61.15 1.41 Allowed Glycine 0 N--CA 1.45 -0.378 0 C-N-CA 120.811 -0.709 . . . . 0.0 112.383 -179.742 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 93' ' ' LEU . . . . . 0.442 HD11 ' HG2' ' A' ' 145' ' ' MET . 6.5 mp -72.76 179.12 3.78 Favored 'General case' 0 C--N 1.332 -0.184 0 CA-C-O 120.753 0.311 . . . . 0.0 110.866 -179.951 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 94' ' ' ASP . . . . . . . . . . . . . 30.3 m-20 -85.5 175.3 8.9 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.883 179.948 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 48.9 m -61.69 -46.71 88.52 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.1 -179.74 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 96' ' ' ARG . . . . . 0.404 ' O ' HG13 ' A' ' 100' ' ' ILE . 80.1 ttt180 -71.94 -45.36 61.42 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.934 -179.953 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 97' ' ' GLU . . . . . 0.482 ' HA ' HD12 ' A' ' 100' ' ' ILE . 19.1 mm-40 -52.51 -46.02 66.48 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.158 -179.802 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 98' ' ' PHE . . . . . 0.474 ' O ' HG12 ' A' ' 102' ' ' ILE . 2.2 m-85 -55.33 -50.87 68.52 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.384 -0.371 . . . . 0.0 110.236 179.385 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -60.85 -30.38 72.8 Favored Glycine 0 N--CA 1.45 -0.383 0 C-N-CA 120.862 -0.685 . . . . 0.0 112.627 -179.949 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 100' ' ' ILE . . . . . 0.482 HD12 ' HA ' ' A' ' 97' ' ' GLU . 94.5 mt -64.04 -43.3 97.52 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-O 120.89 0.376 . . . . 0.0 111.393 -179.857 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 29.4 t -72.26 -41.42 66.12 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.38 0 CA-C-N 116.34 -0.391 . . . . 0.0 111.592 179.976 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 102' ' ' ILE . . . . . 0.474 HG12 ' O ' ' A' ' 98' ' ' PHE . 35.2 mm -65.38 -40.07 87.27 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 CA-C-N 116.416 -0.357 . . . . 0.0 111.65 -179.266 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 11.0 t -67.92 -40.36 83.37 Favored 'General case' 0 C--O 1.234 0.239 0 CA-C-O 120.713 0.292 . . . . 0.0 110.939 -179.958 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 104' ' ' LEU . . . . . 0.426 HD22 ' HE2' ' A' ' 140' ' ' TYR . 29.2 tp -55.34 -51.54 66.4 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-N 116.349 -0.387 . . . . 0.0 110.079 179.311 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 105' ' ' ASN . . . . . 0.607 HD21 HD13 ' A' ' 137' ' ' LEU . 0.8 OUTLIER -58.05 -37.31 74.16 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 115.855 -0.611 . . . . 0.0 110.461 179.465 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 31.0 m -54.61 -41.1 69.56 Favored 'General case' 0 C--N 1.332 -0.184 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.659 179.706 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 0.6 OUTLIER -69.24 -36.42 72.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-O 121.258 0.551 . . . . 0.0 110.0 179.245 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . 0.426 HG23 ' O ' ' A' ' 104' ' ' LEU . 60.7 t -63.87 -42.63 96.47 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 115.406 -0.816 . . . . 0.0 111.571 -179.677 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 109' ' ' MET . . . . . 0.629 ' HG3' ' HA ' ' A' ' 77' ' ' ILE . 6.9 mmt -70.07 -44.04 69.92 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.407 -0.36 . . . . 0.0 110.961 -179.624 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 21.4 tp -60.73 -32.18 71.46 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 116.349 -0.387 . . . . 0.0 110.38 179.966 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -65.27 -56.63 11.65 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.019 -0.537 . . . . 0.0 110.612 179.398 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . -60.88 -30.0 71.94 Favored Glycine 0 C--N 1.332 0.334 0 C-N-CA 120.644 -0.789 . . . . 0.0 112.117 179.655 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 113' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER -57.68 -69.0 0.19 Allowed 'General case' 0 C--N 1.33 -0.266 0 CA-C-O 121.015 0.436 . . . . 0.0 110.255 179.585 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 114' ' ' ALA . . . . . 0.446 ' O ' HG13 ' A' ' 118' ' ' VAL . . . -64.6 -29.13 70.15 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 115.79 -0.641 . . . . 0.0 111.414 -179.969 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -51.92 -51.2 41.21 Favored Glycine 0 C--N 1.332 0.324 0 C-N-CA 121.081 -0.58 . . . . 0.0 112.672 -179.888 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -77.99 -15.01 59.31 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-O 120.542 0.21 . . . . 0.0 111.553 -179.781 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 117' ' ' MET . . . . . 0.45 ' HE2' HG21 ' A' ' 68' ' ' VAL . 37.5 ttm -100.67 18.46 19.24 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-O 120.692 0.282 . . . . 0.0 111.436 -179.464 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 118' ' ' VAL . . . . . 0.506 HG11 ' N ' ' A' ' 123' ' ' ARG . 27.4 m -74.03 144.76 82.65 Favored Pre-proline 0 C--N 1.328 -0.327 0 CA-C-N 116.692 -0.231 . . . . 0.0 111.141 179.802 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 119' ' ' PRO . . . . . . . . . . . . . 97.0 Cg_endo -87.53 -10.11 5.53 Favored 'Trans proline' 0 N--CA 1.458 -0.568 0 C-N-CA 122.709 2.273 . . . . 0.0 112.484 179.756 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -136.72 -108.26 0.89 Allowed Glycine 0 C--N 1.331 0.302 0 C-N-CA 120.706 -0.759 . . . . 0.0 112.907 -179.629 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 34.3 pt -124.53 12.26 4.72 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.156 0 CA-C-O 120.652 0.263 . . . . 0.0 111.664 -179.548 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 41.7 mt-10 -58.24 -18.26 25.18 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.779 0.323 . . . . 0.0 111.03 179.722 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 123' ' ' ARG . . . . . 0.506 ' N ' HG11 ' A' ' 118' ' ' VAL . 4.9 ptm180 -50.6 -31.39 15.77 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 116.107 -0.497 . . . . 0.0 111.504 -179.868 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 124' ' ' TYR . . . . . . . . . . . . . 30.4 m-85 -70.28 -33.03 71.08 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.458 -0.337 . . . . 0.0 111.017 -179.735 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 125' ' ' ALA . . . . . . . . . . . . . . . -71.24 -50.12 36.22 Favored 'General case' 0 C--O 1.235 0.333 0 CA-C-N 116.298 -0.41 . . . . 0.0 110.942 179.687 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 3.1 mm? -53.6 -52.76 58.77 Favored 'General case' 0 C--N 1.333 -0.137 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.53 179.739 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 127' ' ' PHE . . . . . 0.433 ' HZ ' ' HB3' ' A' ' 175' ' ' PRO . 6.5 t80 -64.88 -37.21 86.87 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.316 -0.402 . . . . 0.0 111.231 -179.615 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 128' ' ' GLY . . . . . . . . . . . . . . . -46.16 -47.75 15.4 Favored Glycine 0 C--O 1.237 0.283 0 C-N-CA 119.705 -1.235 . . . . 0.0 110.517 179.192 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 129' ' ' MET . . . . . . . . . . . . . 0.5 OUTLIER -72.18 -34.91 68.79 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 115.178 -0.511 . . . . 0.0 110.101 178.665 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -62.99 -37.26 94.66 Favored Glycine 0 C--N 1.332 0.331 0 CA-C-N 115.804 -0.634 . . . . 0.0 113.347 -179.515 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -73.56 -52.61 12.9 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.788 0.294 . . . . 0.0 110.755 -179.781 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 62.2 t -55.61 -42.0 66.93 Favored 'Isoleucine or valine' 0 C--O 1.234 0.28 0 CA-C-O 121.331 0.586 . . . . 0.0 109.546 179.128 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -68.69 -37.35 79.49 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 115.342 -0.844 . . . . 0.0 110.669 179.407 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 134' ' ' PHE . . . . . . . . . . . . . 87.7 t80 -55.88 -54.78 40.44 Favored 'General case' 0 N--CA 1.452 -0.363 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.135 179.669 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 135' ' ' ILE . . . . . 0.425 ' O ' HG22 ' A' ' 138' ' ' VAL . 32.8 mt -56.38 -33.53 38.49 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.363 0 CA-C-N 115.884 -0.598 . . . . 0.0 110.126 179.303 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . -61.65 -39.64 97.67 Favored Glycine 0 N--CA 1.449 -0.484 0 C-N-CA 120.072 -1.061 . . . . 0.0 111.295 178.784 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 137' ' ' LEU . . . . . 0.607 HD13 HD21 ' A' ' 105' ' ' ASN . 31.1 tp -68.75 -54.02 18.44 Favored 'General case' 0 C--N 1.332 -0.185 0 CA-C-O 120.598 0.237 . . . . 0.0 111.173 179.933 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 138' ' ' VAL . . . . . 0.425 HG22 ' O ' ' A' ' 135' ' ' ILE . 3.3 m -55.85 -31.68 30.59 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.176 0 CA-C-O 121.182 0.515 . . . . 0.0 109.9 179.957 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 139' ' ' TYR . . . . . . . . . . . . . 21.3 t80 -66.19 -38.62 88.45 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 115.429 -0.805 . . . . 0.0 110.289 178.674 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 140' ' ' TYR . . . . . 0.426 ' HE2' HD22 ' A' ' 104' ' ' LEU . 19.2 m-85 -65.28 -32.14 73.64 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 116.097 -0.501 . . . . 0.0 111.055 179.377 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 141' ' ' LEU . . . . . 0.49 HD23 ' SD ' ' A' ' 145' ' ' MET . 75.1 mt -69.9 -41.49 74.65 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-O 121.039 0.447 . . . . 0.0 110.351 -179.508 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 24.2 m -84.84 -10.58 11.53 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.631 0 CA-C-N 115.72 -0.673 . . . . 0.0 111.159 179.957 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . -76.91 -118.78 0.16 Allowed Glycine 0 CA--C 1.52 0.405 0 C-N-CA 120.894 -0.669 . . . . 0.0 112.986 -179.551 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 144' ' ' PRO . . . . . . . . . . . . . 55.8 Cg_endo -69.25 -30.19 25.08 Favored 'Trans proline' 0 C--N 1.349 0.6 0 C-N-CA 122.47 2.113 . . . . 0.0 112.825 -179.411 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 145' ' ' MET . . . . . 0.49 ' SD ' HD23 ' A' ' 141' ' ' LEU . 53.1 mtt -55.59 -31.14 61.97 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-O 120.726 0.298 . . . . 0.0 111.484 -179.664 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 146' ' ' THR . . . . . . . . . . . . . 14.3 m -71.12 -44.2 66.1 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.284 -0.416 . . . . 0.0 111.723 -179.45 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 43.6 mt-10 -75.92 -29.04 58.23 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.385 -0.371 . . . . 0.0 111.844 -179.411 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 148' ' ' SER . . . . . 0.566 ' HB2' ' HB1' ' A' ' 91' ' ' ALA . 66.2 m -70.26 -47.05 63.03 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 120.736 0.303 . . . . 0.0 111.281 -179.327 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 149' ' ' ALA . . . . . . . . . . . . . . . -72.6 -34.93 67.74 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.289 -0.414 . . . . 0.0 111.242 -179.833 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 150' ' ' SER . . . . . . . . . . . . . 47.7 t -70.42 -8.19 48.95 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.965 179.943 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 151' ' ' GLN . . . . . . . . . . . . . 47.9 mt-30 -122.32 10.04 9.85 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.262 -0.426 . . . . 0.0 111.255 -179.875 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 152' ' ' ARG . . . . . 0.635 ' HE ' HG13 ' A' ' 156' ' ' ILE . 1.2 tmm_? -85.05 -51.33 6.74 Favored 'General case' 0 C--N 1.332 -0.19 0 CA-C-O 120.979 0.418 . . . . 0.0 110.363 179.669 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 153' ' ' SER . . . . . 0.594 ' HB2' HG12 ' A' ' 156' ' ' ILE . 49.1 m -157.48 172.56 18.35 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 115.751 -0.659 . . . . 0.0 110.667 179.434 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 154' ' ' SER . . . . . . . . . . . . . 46.6 t -69.38 -42.17 75.52 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.339 -0.392 . . . . 0.0 110.76 179.754 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -77.28 -32.75 46.73 Favored Glycine 0 N--CA 1.452 -0.275 0 C-N-CA 120.948 -0.644 . . . . 0.0 113.029 -179.831 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 156' ' ' ILE . . . . . 0.635 HG13 ' HE ' ' A' ' 152' ' ' ARG . 32.2 mm -57.23 -38.65 62.72 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.199 0 CA-C-N 116.776 0.288 . . . . 0.0 111.356 -179.753 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 157' ' ' LYS . . . . . 0.435 ' O ' ' HB ' ' A' ' 161' ' ' VAL . 58.3 tttp -62.47 -43.48 98.72 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.385 -0.37 . . . . 0.0 111.372 -179.735 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 93.8 p -70.98 -48.32 53.95 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 116.102 -0.499 . . . . 0.0 111.551 -179.102 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 159' ' ' LEU . . . . . 0.436 ' O ' ' HB2' ' A' ' 163' ' ' LEU . 10.5 tt -62.08 -42.54 99.31 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.176 -179.395 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 160' ' ' TYR . . . . . . . . . . . . . 77.6 t80 -71.59 -36.87 71.0 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 116.263 -0.426 . . . . 0.0 111.987 -179.077 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 161' ' ' VAL . . . . . 0.538 HG12 ' N ' ' A' ' 162' ' ' ARG . 1.1 t -58.4 -53.64 43.69 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.686 0 N-CA-C 111.699 0.259 . . . . 0.0 111.699 -179.181 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 162' ' ' ARG . . . . . 0.538 ' N ' HG12 ' A' ' 161' ' ' VAL . 97.3 mtt180 -69.89 -41.15 75.13 Favored 'General case' 0 C--N 1.329 -0.317 0 N-CA-C 112.04 0.385 . . . . 0.0 112.04 -179.174 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 163' ' ' LEU . . . . . 0.45 ' O ' HD23 ' A' ' 166' ' ' LEU . 2.7 mp -62.49 -56.14 20.93 Favored 'General case' 0 C--N 1.329 -0.314 0 N-CA-C 112.277 0.473 . . . . 0.0 112.277 -178.674 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 164' ' ' ARG . . . . . 0.438 ' NE ' ' ND2' ' A' ' 165' ' ' ASN . 5.4 ppt_? -62.42 -40.63 97.18 Favored 'General case' 0 C--N 1.328 -0.356 0 N-CA-C 112.002 0.371 . . . . 0.0 112.002 -178.361 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 165' ' ' ASN . . . . . 0.448 ' O ' HG23 ' A' ' 169' ' ' VAL . 0.9 OUTLIER -54.73 -53.29 56.89 Favored 'General case' 0 C--O 1.237 0.402 0 CA-C-O 120.826 0.346 . . . . 0.0 111.557 -179.373 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 166' ' ' LEU . . . . . 0.48 ' O ' ' HG ' ' A' ' 170' ' ' LEU . 0.1 OUTLIER -67.67 -31.59 71.67 Favored 'General case' 0 C--N 1.331 -0.238 0 C-N-CA 120.847 -0.341 . . . . 0.0 111.022 -179.146 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 167' ' ' THR . . . . . 0.428 ' O ' ' HB2' ' A' ' 171' ' ' TRP . 17.7 m -59.75 -53.02 62.81 Favored 'General case' 0 C--N 1.333 -0.147 0 CA-C-O 120.842 0.353 . . . . 0.0 111.304 179.814 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 168' ' ' VAL . . . . . . . . . . . . . 58.4 t -58.97 -41.27 82.66 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.385 0 CA-C-N 115.785 -0.643 . . . . 0.0 111.749 -179.103 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 169' ' ' VAL . . . . . 0.448 HG23 ' O ' ' A' ' 165' ' ' ASN . 88.8 t -59.34 -64.87 0.51 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 N-CA-C 112.383 0.512 . . . . 0.0 112.383 -179.236 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 170' ' ' LEU . . . . . 0.48 ' HG ' ' O ' ' A' ' 166' ' ' LEU . 1.6 pp -61.04 -36.3 79.19 Favored 'General case' 0 N--CA 1.463 0.214 0 N-CA-C 112.219 0.451 . . . . 0.0 112.219 -178.67 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 171' ' ' TRP . . . . . 0.716 ' HE1' H203 ' A' ' 301' ' ' RET . 3.0 m0 -67.73 -29.4 68.62 Favored 'General case' 0 C--N 1.331 -0.231 0 C-N-CA 120.914 -0.314 . . . . 0.0 110.946 179.843 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 172' ' ' ALA . . . . . . . . . . . . . . . -73.28 -7.07 49.98 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 116.337 -0.392 . . . . 0.0 110.986 -179.938 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 173' ' ' ILE . . . . . 0.686 HG22 HD11 ' A' ' 177' ' ' ILE . 19.2 mm -87.97 -21.0 7.21 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.067 -0.515 . . . . 0.0 110.876 179.88 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 174' ' ' TYR . . . . . 0.409 ' HD2' ' HA ' ' A' ' 171' ' ' TRP . 13.0 m-85 -53.67 -48.53 92.95 Favored Pre-proline 0 CA--C 1.531 0.235 0 CA-C-N 116.249 -0.432 . . . . 0.0 111.478 -179.752 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 175' ' ' PRO . . . . . 0.433 ' HB3' ' HZ ' ' A' ' 127' ' ' PHE . 92.4 Cg_exo -46.48 -31.77 10.31 Favored 'Trans proline' 0 C--N 1.352 0.756 0 C-N-CA 122.173 1.915 . . . . 0.0 112.117 179.059 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 176' ' ' PHE . . . . . 0.466 ' O ' ' HG ' ' A' ' 180' ' ' LEU . 80.5 m-85 -80.25 -40.67 26.53 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 115.927 -0.578 . . . . 0.0 111.421 -179.893 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 177' ' ' ILE . . . . . 0.686 HD11 HG22 ' A' ' 173' ' ' ILE . 2.3 mm -65.2 -41.55 91.92 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.533 0 CA-C-N 116.346 -0.388 . . . . 0.0 111.838 -178.651 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 178' ' ' TRP . . . . . . . . . . . . . 63.9 t90 -73.65 -44.62 56.37 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.902 0.382 . . . . 0.0 111.064 -179.952 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 179' ' ' LEU . . . . . 0.535 ' O ' HG22 ' A' ' 185' ' ' VAL . 1.9 tm? -64.31 -51.86 61.36 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 115.952 -0.567 . . . . 0.0 111.451 -179.151 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 180' ' ' LEU . . . . . 0.712 HD22 HD11 ' A' ' 187' ' ' LEU . 20.7 mt -77.48 -44.98 27.04 Favored 'General case' 0 C--N 1.328 -0.336 0 N-CA-C 111.974 0.361 . . . . 0.0 111.974 -178.711 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 181' ' ' GLY . . . . . 0.412 ' HA3' ' OD1' ' A' ' 193' ' ' ASP . . . -57.5 174.99 1.91 Allowed Glycine 0 C--N 1.335 0.494 0 C-N-CA 120.365 -0.921 . . . . 0.0 112.771 179.927 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 182' ' ' PRO . . . . . 0.648 ' HA ' ' HB2' ' A' ' 186' ' ' ALA . 1.7 Cg_endo -44.99 -45.6 13.93 Favored 'Trans proline' 0 CA--C 1.537 0.671 0 C-N-CA 123.228 2.619 . . . . 0.0 113.84 179.615 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 183' ' ' PRO . . . . . 0.578 ' HD2' ' N ' ' A' ' 182' ' ' PRO . 18.5 Cg_endo -58.54 -4.75 1.97 Allowed 'Trans proline' 0 C--N 1.356 0.937 0 C-N-CA 121.967 1.778 . . . . 0.0 113.017 -179.762 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 184' ' ' GLY . . . . . 0.434 ' HA3' ' O ' ' A' ' 179' ' ' LEU . . . -122.09 -87.93 0.91 Allowed Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.63 -0.795 . . . . 0.0 112.636 179.94 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 185' ' ' VAL . . . . . 0.535 HG22 ' O ' ' A' ' 179' ' ' LEU . 4.3 m -123.63 -4.64 7.19 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 N-CA-C 111.658 0.244 . . . . 0.0 111.658 -179.822 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 186' ' ' ALA . . . . . 0.648 ' HB2' ' HA ' ' A' ' 182' ' ' PRO . . . 51.62 88.88 0.03 OUTLIER 'General case' 0 N--CA 1.462 0.156 0 CA-C-N 116.398 -0.364 . . . . 0.0 111.367 179.833 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 187' ' ' LEU . . . . . 0.712 HD11 HD22 ' A' ' 180' ' ' LEU . 20.2 mt -91.76 -49.4 6.29 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.396 -0.366 . . . . 0.0 111.774 -179.502 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 188' ' ' LEU . . . . . . . . . . . . . 87.5 mt -97.36 -94.3 0.22 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.462 -0.336 . . . . 0.0 111.539 -179.138 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 189' ' ' THR . . . . . . . . . . . . . 1.8 t -160.42 149.36 13.72 Favored Pre-proline 0 C--N 1.327 -0.39 0 CA-C-N 116.284 -0.416 . . . . 0.0 111.282 -179.499 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 190' ' ' PRO . . . . . 0.437 ' O ' HG23 ' A' ' 194' ' ' VAL . 72.9 Cg_exo -50.37 -42.98 46.25 Favored 'Trans proline' 0 C--N 1.349 0.557 0 C-N-CA 122.591 2.194 . . . . 0.0 112.932 -179.853 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 191' ' ' THR . . . . . . . . . . . . . 70.9 p -55.33 -46.55 76.35 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-O 120.77 0.319 . . . . 0.0 111.514 -179.729 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 192' ' ' VAL . . . . . . . . . . . . . 39.4 t -68.36 -50.6 55.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.626 -179.745 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 193' ' ' ASP . . . . . 0.428 ' OD1' HG22 ' A' ' 177' ' ' ILE . 30.8 t70 -55.24 -49.58 71.66 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.752 0.311 . . . . 0.0 111.284 -179.824 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 194' ' ' VAL . . . . . 0.437 HG23 ' O ' ' A' ' 190' ' ' PRO . 76.1 t -59.62 -36.44 65.28 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.886 179.914 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 195' ' ' ALA . . . . . . . . . . . . . . . -58.71 -46.72 86.68 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.41 -0.359 . . . . 0.0 110.968 179.848 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 196' ' ' LEU . . . . . . . . . . . . . 85.3 mt -67.71 -40.17 84.3 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.348 -0.387 . . . . 0.0 110.615 179.692 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 197' ' ' ILE . . . . . 0.485 HG23 ' HZ2' ' A' ' 76' ' ' TRP . 16.2 mm -59.97 -59.86 3.38 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 CA-C-N 115.988 -0.551 . . . . 0.0 110.302 179.388 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 198' ' ' VAL . . . . . . . . . . . . . 76.3 t -52.78 -34.26 19.81 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.515 0 CA-C-N 115.458 -0.792 . . . . 0.0 109.454 178.394 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 199' ' ' TYR . . . . . . . . . . . . . 65.7 t80 -70.07 -34.96 73.85 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.222 -0.899 . . . . 0.0 110.63 179.753 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 200' ' ' LEU . . . . . 0.468 ' O ' HG12 ' A' ' 203' ' ' VAL . 28.0 mt -67.95 -39.02 83.47 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 115.845 -0.616 . . . . 0.0 111.27 -179.631 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 201' ' ' ASP . . . . . 0.403 ' HB2' ' OH ' ' A' ' 51' ' ' TYR . 0.9 OUTLIER -71.9 -32.35 67.31 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-N 116.099 -0.501 . . . . 0.0 110.776 179.804 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 202' ' ' LEU . . . . . . . . . . . . . 3.7 mt -70.91 -36.5 72.72 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.0 -0.545 . . . . 0.0 111.736 -179.556 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 203' ' ' VAL . . . . . 0.473 ' O ' ' HA3' ' A' ' 207' ' ' GLY . 11.8 p -74.62 -36.32 40.5 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.613 -0.267 . . . . 0.0 111.643 -179.008 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 204' ' ' THR . . . . . 0.462 HG23 ' CE2' ' A' ' 208' ' ' PHE . 43.7 m -67.69 -57.21 6.78 Favored 'General case' 0 C--N 1.326 -0.44 0 C-N-CA 120.84 -0.344 . . . . 0.0 111.53 -179.969 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 205' ' ' LYS . . . . . 0.669 ' HE2' ' HB2' ' A' ' 47' ' ' ALA . 60.0 mttp -69.49 -59.02 3.25 Favored 'General case' 0 C--N 1.329 -0.299 0 N-CA-C 112.549 0.574 . . . . 0.0 112.549 -178.472 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 22.1 t -72.57 -37.53 56.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 N-CA-C 112.158 0.429 . . . . 0.0 112.158 -178.473 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 207' ' ' GLY . . . . . 0.473 ' HA3' ' O ' ' A' ' 203' ' ' VAL . . . -61.51 -55.36 29.34 Favored Glycine 0 CA--C 1.517 0.195 0 C-N-CA 120.51 -0.852 . . . . 0.0 112.922 -179.464 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 208' ' ' PHE . . . . . 0.483 ' O ' ' N ' ' A' ' 212' ' ' ALA . 2.4 m-30 -61.03 -41.58 96.84 Favored 'General case' 0 C--O 1.221 -0.399 0 N-CA-C 110.026 -0.361 . . . . 0.0 110.026 -179.882 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 209' ' ' GLY . . . . . 0.499 ' O ' ' HB3' ' A' ' 212' ' ' ALA . . . -58.26 -37.57 87.4 Favored Glycine 0 N--CA 1.451 -0.33 0 CA-C-N 115.372 -0.831 . . . . 0.0 112.873 179.492 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 210' ' ' PHE . . . . . . . . . . . . . 2.7 m-85 -68.79 -49.56 57.61 Favored 'General case' 0 CA--C 1.514 -0.407 0 N-CA-C 108.548 -0.908 . . . . 0.0 108.548 179.238 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 211' ' ' ILE . . . . . . . . . . . . . 64.9 mt -63.2 -27.45 43.13 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.553 0 N-CA-C 107.61 -1.256 . . . . 0.0 107.61 176.658 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 212' ' ' ALA . . . . . 0.499 ' HB3' ' O ' ' A' ' 209' ' ' GLY . . . -67.99 -38.02 82.18 Favored 'General case' 0 N--CA 1.448 -0.557 0 CA-C-N 114.488 -1.233 . . . . 0.0 110.527 -179.802 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 213' ' ' LEU . . . . . 0.411 ' HG ' ' O ' ' A' ' 209' ' ' GLY . 89.2 mt -70.26 -52.52 22.43 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-N 115.373 -0.831 . . . . 0.0 111.53 -179.606 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 214' ' ' ASP . . . . . . . . . . . . . 24.5 m-20 -57.89 -52.41 65.62 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.396 -0.366 . . . . 0.0 110.954 -179.878 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 215' ' ' ALA . . . . . . . . . . . . . . . -57.25 -53.57 56.66 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.216 179.817 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 216' ' ' ALA . . . . . . . . . . . . . . . -59.98 -31.33 69.8 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-N 116.22 -0.445 . . . . 0.0 111.319 179.947 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 217' ' ' ALA . . . . . . . . . . . . . . . -62.19 -38.67 89.97 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-O 120.949 0.404 . . . . 0.0 110.281 179.651 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 218' ' ' THR . . . . . . . . . . . . . 93.5 m -72.12 -33.99 68.24 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 115.821 -0.627 . . . . 0.0 110.635 179.322 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 219' ' ' LEU . . . . . 0.484 ' O ' ' HG2' ' A' ' 222' ' ' GLU . 83.1 mt -63.2 -41.28 99.15 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 115.996 -0.547 . . . . 0.0 110.892 179.956 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 220' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -84.71 -19.88 32.05 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 116.145 -0.479 . . . . 0.0 111.162 179.682 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 221' ' ' ALA . . . . . . . . . . . . . . . -82.7 -24.81 33.47 Favored 'General case' 0 C--N 1.332 -0.181 0 N-CA-C 112.126 0.417 . . . . 0.0 112.126 -179.358 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 222' ' ' GLU . . . . . 0.484 ' HG2' ' O ' ' A' ' 219' ' ' LEU . 11.9 pt-20 -72.83 -7.8 52.5 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-O 120.782 0.325 . . . . 0.0 111.026 -179.485 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 223' ' ' HIS . . . . . . . . . . . . . 90.8 m-70 -92.83 -58.79 2.23 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.935 179.873 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 224' ' ' GLY . . . . . . . . . . . . . . . 75.79 97.12 0.14 Allowed Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.679 -0.772 . . . . 0.0 112.353 -179.822 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 225' ' ' GLU . . . . . . . . . . . . . 40.9 tt0 -55.41 118.61 4.6 Favored 'General case' 0 C--N 1.331 -0.21 0 CA-C-O 120.874 0.368 . . . . 0.0 111.075 -179.881 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 226' ' ' SER . . . . . . . . . . . . . 45.9 t -75.6 147.56 39.49 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.913 -179.968 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 227' ' ' LEU . . . . . . . . . . . . . 63.3 mt -67.86 135.4 52.48 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.781 -179.979 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 228' ' ' ALA . . . . . . . . . . . . . . . -145.33 122.92 11.77 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.254 -0.43 . . . . 0.0 111.331 -179.915 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 229' ' ' GLY . . . . . . . . . . . . . . . 68.11 -104.65 1.22 Allowed Glycine 0 N--CA 1.45 -0.368 0 C-N-CA 120.914 -0.66 . . . . 0.0 112.802 179.542 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 230' ' ' VAL . . . . . . . . . . . . . 46.1 t -77.19 111.89 14.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-O 120.852 0.358 . . . . 0.0 111.213 -179.798 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 231' ' ' ASP . . . . . . . . . . . . . 7.4 m-20 -85.66 100.73 12.17 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.861 179.964 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 232' ' ' THR . . . . . . . . . . . . . 4.8 t -158.84 140.2 13.21 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.246 -0.434 . . . . 0.0 111.342 179.989 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 233' ' ' ASP . . . . . . . . . . . . . 28.5 t70 -156.22 -52.98 0.08 Allowed 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 115.885 -0.598 . . . . 0.0 110.764 179.887 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 234' ' ' THR . . . . . . . . . . . . . 85.2 m -155.1 97.34 2.45 Favored Pre-proline 0 C--N 1.331 -0.215 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.104 179.935 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 235' ' ' PRO . . . . . . . . . . . . . 39.6 Cg_exo -57.91 -22.88 56.66 Favored 'Trans proline' 0 C--N 1.349 0.578 0 C-N-CA 122.419 2.08 . . . . 0.0 112.265 179.697 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 236' ' ' ALA . . . . . . . . . . . . . . . -73.29 173.34 9.64 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.26 -0.427 . . . . 0.0 111.104 179.941 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 237' ' ' VAL . . . . . . . . . . . . . 7.4 p -139.71 136.92 39.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.27 -179.707 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 238' ' ' ALA . . . . . . . . . . . . . . . -136.89 -64.05 0.59 Allowed 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.098 179.935 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 239' ' ' ASP . . . . . . . . . . . . . 6.4 m-20 -108.6 -179.46 3.88 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.731 179.931 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 240' ' ' LEU . . . . . 0.417 ' N ' HD22 ' A' ' 240' ' ' LEU . 3.6 mm? -107.19 121.92 45.49 Favored 'General case' 0 C--N 1.332 -0.188 0 CA-C-N 116.246 -0.433 . . . . 0.0 110.912 179.991 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 241' ' ' GLU . . . . . . . . . . . . . 41.9 mt-10 -95.28 -40.25 9.64 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.026 -0.534 . . . . 0.0 110.947 -179.9 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 242' ' ' HIS . . . . . . . . . . . . . 25.4 p-80 -87.02 166.97 14.65 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.13 -179.702 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 243' ' ' HIS . . . . . . . . . . . . . 74.3 m80 -137.1 -71.87 0.44 Allowed 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.069 -0.514 . . . . 0.0 110.584 179.874 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 244' ' ' HIS . . . . . . . . . . . . . 70.1 m80 58.26 -178.49 0.07 Allowed 'General case' 0 C--N 1.332 -0.193 0 CA-C-N 115.933 -0.576 . . . . 0.0 111.484 179.65 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 245' ' ' HIS . . . . . . . . . . . . . 26.7 p-80 -153.89 163.34 40.22 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 115.912 -0.585 . . . . 0.0 110.596 179.984 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 246' ' ' HIS . . . . . . . . . . . . . 18.0 p-80 -99.17 -27.85 13.62 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.408 -0.36 . . . . 0.0 110.941 -179.868 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 247' ' ' HIS . . . . . . . . . . . . . 59.5 t60 . . . . . 0 C--O 1.249 1.041 0 CA-C-O 118.254 -0.879 . . . . 0.0 110.889 -179.837 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' A' A ' 301' ' ' RET . . . . . 0.716 H203 ' HE1' ' A' ' 171' ' ' TRP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . 0.559 ' HG2' ' H ' ' A' ' 3' ' ' GLY . 58.1 ttp . . . . . 0 N--CA 1.486 1.337 0 CA-C-O 120.512 0.196 . . . . 0.0 110.808 . . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 2' ' ' VAL . . . . . 0.443 HG12 ' O ' ' A' ' 1' ' ' MET . 5.2 p 45.02 23.33 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.466 0.349 0 CA-C-N 115.997 -0.547 . . . . 0.0 111.772 179.75 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 3' ' ' GLY . . . . . 0.559 ' H ' ' HG2' ' A' ' 1' ' ' MET . . . -109.32 -5.64 30.03 Favored Glycine 0 N--CA 1.45 -0.397 0 C-N-CA 120.87 -0.681 . . . . 0.0 112.224 179.855 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 60.5 tp -73.92 -35.55 64.63 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-O 120.881 0.372 . . . . 0.0 110.822 -179.982 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 64.0 p -61.59 -29.94 70.35 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 115.958 -0.565 . . . . 0.0 111.399 -179.819 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 26.9 p -55.37 -35.61 65.45 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 116.365 -0.38 . . . . 0.0 111.118 -179.725 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 7' ' ' LEU . . . . . . . . . . . . . 9.3 mp -55.98 -53.71 53.58 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.093 179.898 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 8' ' ' PHE . . . . . 0.507 ' HB2' ' HB2' ' A' ' 55' ' ' ALA . 65.1 m-85 -62.43 -34.23 76.37 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.716 -179.887 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 9' ' ' TRP . . . . . . . . . . . . . 37.8 m95 -64.46 -41.3 96.59 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-O 121.214 0.53 . . . . 0.0 109.896 179.69 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 86.2 mt -65.91 -31.53 72.51 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-N 115.303 -0.862 . . . . 0.0 110.052 179.227 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . 0.464 ' O ' ' HG2' ' A' ' 15' ' ' MET . . . -68.22 -34.04 79.65 Favored Glycine 0 N--CA 1.448 -0.526 0 C-N-CA 120.823 -0.703 . . . . 0.0 111.43 179.268 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -69.45 -37.18 77.23 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.839 0.352 . . . . 0.0 110.421 179.415 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 50.1 mm -62.41 -53.44 47.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 115.918 -0.583 . . . . 0.0 110.939 179.601 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -56.33 -42.03 88.24 Favored Glycine 0 C--N 1.33 0.245 0 C-N-CA 120.747 -0.74 . . . . 0.0 112.161 179.889 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 15' ' ' MET . . . . . 0.464 ' HG2' ' O ' ' A' ' 11' ' ' GLY . 24.5 mmt -63.45 -41.87 98.64 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.737 0.303 . . . . 0.0 110.53 179.613 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 39.7 tp -54.19 -40.6 67.71 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.051 -0.522 . . . . 0.0 110.601 179.835 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 41.3 t -65.41 -49.03 80.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 115.963 -0.562 . . . . 0.0 111.067 179.955 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -63.31 -47.67 85.73 Favored Glycine 0 C--N 1.331 0.251 0 C-N-CA 120.769 -0.729 . . . . 0.0 112.219 179.724 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 24.9 m -50.32 -44.18 54.09 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-O 120.665 0.269 . . . . 0.0 111.295 -179.973 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 56.9 mt -71.43 -38.73 71.34 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 116.343 -0.39 . . . . 0.0 111.282 179.973 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -60.77 -32.18 71.5 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.242 -0.436 . . . . 0.0 111.549 -179.551 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 22' ' ' PHE . . . . . 0.629 ' HB2' HG22 ' A' ' 41' ' ' VAL . 2.8 m-85 -90.75 -34.46 15.34 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.419 -0.355 . . . . 0.0 111.209 -179.481 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -64.88 -48.49 74.06 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.245 -179.822 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 24' ' ' TRP . . . . . . . . . . . . . 3.6 t-105 -68.03 -53.63 24.34 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 115.906 -0.588 . . . . 0.0 111.25 -179.617 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -65.17 -19.52 66.02 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.862 0.363 . . . . 0.0 111.114 -179.99 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -73.63 -46.54 24.35 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.815 -0.707 . . . . 0.0 112.559 179.99 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 25.4 mmm180 -60.99 -21.86 63.94 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.878 0.37 . . . . 0.0 111.076 -179.861 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 15.6 t70 -117.19 97.63 6.02 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.924 -179.969 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -167.72 -71.42 0.03 OUTLIER 'General case' 0 C--N 1.331 -0.204 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.113 179.958 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 159.35 -166.41 34.72 Favored Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 120.826 -0.702 . . . . 0.0 112.516 -179.949 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 77.9 p -94.65 111.15 22.93 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 120.827 0.346 . . . . 0.0 111.081 -179.839 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 139.02 -50.89 0.78 Allowed Glycine 0 C--N 1.331 0.261 0 C-N-CA 120.942 -0.647 . . . . 0.0 112.523 179.832 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 45.7 mt-10 -68.98 -20.72 64.18 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.69 0.281 . . . . 0.0 111.064 -179.901 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 34' ' ' ARG . . . . . 0.444 ' O ' HG23 ' A' ' 38' ' ' VAL . 99.9 mtt180 -49.28 -31.15 8.44 Favored 'General case' 0 C--N 1.332 -0.174 0 CA-C-N 116.123 -0.49 . . . . 0.0 111.681 -179.665 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 23.2 ttp180 -64.62 -47.89 76.91 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-O 120.805 0.336 . . . . 0.0 110.816 179.829 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 76.1 m-85 -67.12 -29.52 69.28 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.123 -0.489 . . . . 0.0 111.047 179.859 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 37' ' ' TYR . . . . . 0.447 ' O ' HG23 ' A' ' 41' ' ' VAL . 35.5 m-85 -71.48 -52.62 17.41 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.3 -179.628 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 38' ' ' VAL . . . . . 0.444 HG23 ' O ' ' A' ' 34' ' ' ARG . 84.9 t -56.75 -36.61 49.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-O 121.077 0.465 . . . . 0.0 110.263 179.664 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 17.3 m -69.07 -51.12 42.15 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 115.686 -0.688 . . . . 0.0 110.865 179.392 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 40' ' ' LEU . . . . . 0.408 HD23 ' CG ' ' A' ' 22' ' ' PHE . 11.4 tp -55.48 -50.81 68.92 Favored 'General case' 0 C--O 1.237 0.43 0 CA-C-N 115.914 -0.584 . . . . 0.0 110.707 -179.972 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . 0.629 HG22 ' HB2' ' A' ' 22' ' ' PHE . 60.0 t -62.1 -34.46 63.59 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.367 0 CA-C-N 115.675 -0.693 . . . . 0.0 110.287 179.29 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . 0.427 ' O ' HG12 ' A' ' 46' ' ' ILE . . . -60.21 -34.91 86.36 Favored Glycine 0 N--CA 1.449 -0.493 0 C-N-CA 120.864 -0.684 . . . . 0.0 112.337 179.949 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 43' ' ' ILE . . . . . 0.667 HG22 ' HE3' ' A' ' 205' ' ' LYS . 0.3 OUTLIER -71.83 -58.47 5.05 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.218 0 CA-C-O 120.752 0.311 . . . . 0.0 110.944 179.901 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 80.7 p -61.03 -20.59 62.71 Favored 'General case' 0 C--N 1.332 -0.153 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.262 -179.621 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -79.51 -57.15 3.19 Favored Glycine 0 CA--C 1.519 0.287 0 C-N-CA 120.792 -0.718 . . . . 0.0 112.94 -179.327 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 46' ' ' ILE . . . . . 0.427 HG12 ' O ' ' A' ' 42' ' ' GLY . 16.5 pt -58.36 -36.25 57.61 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.213 0 CA-C-O 120.976 0.417 . . . . 0.0 111.071 -179.994 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 47' ' ' ALA . . . . . 0.663 ' HB2' ' HE2' ' A' ' 205' ' ' LYS . . . -68.15 -45.94 72.17 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-N 116.079 -0.51 . . . . 0.0 111.314 179.518 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 48' ' ' ALA . . . . . 0.429 ' HB2' ' HB3' ' A' ' 15' ' ' MET . . . -54.71 -40.41 69.18 Favored 'General case' 0 C--N 1.332 -0.186 0 CA-C-N 116.271 -0.422 . . . . 0.0 111.909 -179.451 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 35.7 m -76.01 -34.11 26.36 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.384 0 CA-C-N 116.452 -0.34 . . . . 0.0 111.482 -179.318 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -65.03 -36.54 84.69 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.905 0.383 . . . . 0.0 111.033 179.718 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 38.1 m-85 -73.29 -39.8 65.06 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.021 -0.536 . . . . 0.0 110.685 -179.862 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -63.29 -46.72 85.43 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 115.92 -0.582 . . . . 0.0 111.527 179.86 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 53' ' ' VAL . . . . . 0.464 HG23 ' N ' ' A' ' 54' ' ' MET . 30.4 m -67.77 -46.14 83.04 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.19 0 CA-C-N 116.341 -0.39 . . . . 0.0 111.109 -179.78 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 54' ' ' MET . . . . . 0.483 ' HG3' ' HE1' ' A' ' 60' ' ' TRP . 13.3 ttp -64.44 -29.31 70.36 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.995 0.426 . . . . 0.0 110.294 179.834 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 55' ' ' ALA . . . . . 0.507 ' HB2' ' HB2' ' A' ' 8' ' ' PHE . . . -64.36 -32.23 73.75 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 115.919 -0.582 . . . . 0.0 111.092 179.502 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 97.4 mt -82.85 6.26 18.97 Favored 'General case' 0 C--N 1.331 -0.204 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.197 -179.674 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 94.33 -5.25 70.97 Favored Glycine 0 N--CA 1.452 -0.265 0 C-N-CA 120.667 -0.778 . . . . 0.0 112.759 179.787 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 58.8 t -62.66 140.52 19.34 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.243 0 CA-C-O 120.701 0.286 . . . . 0.0 110.825 179.861 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 85.89 -23.64 8.91 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.615 -179.859 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 60' ' ' TRP . . . . . 0.483 ' HE1' ' HG3' ' A' ' 54' ' ' MET . 13.3 m0 -61.08 108.02 0.82 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.806 0.336 . . . . 0.0 110.722 179.909 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 7.4 p -118.67 131.58 24.23 Favored Pre-proline 0 CA--C 1.533 0.293 0 CA-C-N 116.343 -0.39 . . . . 0.0 111.469 -179.863 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 57.7 Cg_endo -71.9 147.77 50.36 Favored 'Trans proline' 0 C--N 1.35 0.637 0 C-N-CA 122.481 2.121 . . . . 0.0 112.501 179.842 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 76.8 t -141.91 99.19 0.82 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 115.92 -0.582 . . . . 0.0 111.019 -179.813 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . 58.72 -85.82 0.02 OUTLIER 'General case' 0 C--N 1.332 -0.172 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.229 -179.927 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 41.2 mt-10 -127.96 -20.39 3.84 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.319 179.723 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 66' ' ' ARG . . . . . . . . . . . . . 18.6 ptp180 -100.26 164.3 12.01 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 115.773 -0.649 . . . . 0.0 110.148 179.709 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 44.5 m -123.15 138.26 54.7 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-O 120.935 0.398 . . . . 0.0 111.213 -179.779 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 68' ' ' VAL . . . . . 0.485 HG11 ' HB3' ' A' ' 117' ' ' MET . 23.9 m -125.48 146.06 31.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.012 -0.54 . . . . 0.0 110.849 179.792 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 69' ' ' PHE . . . . . . . . . . . . . 8.5 m-85 -104.85 114.97 29.5 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.044 -179.732 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 70' ' ' VAL . . . . . 0.561 HG12 ' HD3' ' A' ' 71' ' ' PRO . 0.5 OUTLIER -66.94 -32.08 4.55 Favored Pre-proline 0 CA--C 1.54 0.58 0 N-CA-C 112.849 0.685 . . . . 0.0 112.849 -179.241 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 71' ' ' PRO . . . . . 0.561 ' HD3' HG12 ' A' ' 70' ' ' VAL . 14.5 Cg_exo -68.39 -18.04 44.07 Favored 'Trans proline' 0 C--N 1.36 1.157 0 C-N-CA 121.944 1.763 . . . . 0.0 112.704 -179.603 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 59.0 ttt180 -72.97 -55.2 6.9 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.767 0.317 . . . . 0.0 111.637 -179.224 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 73' ' ' TYR . . . . . . . . . . . . . 4.0 m-85 -71.8 -34.44 69.39 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.482 -0.326 . . . . 0.0 110.74 -179.143 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 74' ' ' ILE . . . . . 0.531 HG22 ' HA ' ' A' ' 71' ' ' PRO . 0.4 OUTLIER -69.38 -41.2 80.75 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.192 0 CA-C-N 116.515 -0.311 . . . . 0.0 110.333 179.736 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 11.3 t70 -58.36 -37.64 75.62 Favored 'General case' 0 CA--C 1.518 -0.256 0 N-CA-C 109.427 -0.583 . . . . 0.0 109.427 178.901 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 76' ' ' TRP . . . . . 0.499 ' HB3' ' SD ' ' A' ' 109' ' ' MET . 42.6 m0 -64.97 -38.56 91.36 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 115.567 -0.742 . . . . 0.0 110.824 179.531 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 77' ' ' ILE . . . . . 0.512 ' O ' ' HG2' ' A' ' 81' ' ' PRO . 83.7 mt -66.54 -28.63 43.95 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-N 116.39 -0.368 . . . . 0.0 110.894 179.633 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 53.9 mt -91.47 -21.13 21.08 Favored 'General case' 0 C--N 1.327 -0.41 0 N-CA-C 112.044 0.387 . . . . 0.0 112.044 -179.969 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 71.5 p -102.3 -52.68 3.07 Favored 'General case' 0 CA--C 1.531 0.219 0 N-CA-C 113.425 0.898 . . . . 0.0 113.425 -178.099 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 80' ' ' THR . . . . . 0.643 ' HB ' ' HD3' ' A' ' 81' ' ' PRO . 26.2 m -50.2 -54.78 30.29 Favored Pre-proline 0 CA--C 1.532 0.283 0 N-CA-C 112.749 0.648 . . . . 0.0 112.749 -178.513 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 81' ' ' PRO . . . . . 0.643 ' HD3' ' HB ' ' A' ' 80' ' ' THR . 52.7 Cg_exo -57.1 -23.7 54.23 Favored 'Trans proline' 0 C--N 1.351 0.696 0 C-N-CA 121.513 1.475 . . . . 0.0 111.35 179.63 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 82' ' ' LEU . . . . . . . . . . . . . 16.4 tp -76.96 -32.72 57.5 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 115.445 -0.798 . . . . 0.0 109.764 179.39 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 83' ' ' ILE . . . . . 0.456 HG23 ' HE2' ' A' ' 208' ' ' PHE . 40.4 mm -66.44 -54.38 26.63 Favored 'Isoleucine or valine' 0 C--O 1.233 0.185 0 CA-C-N 115.835 -0.62 . . . . 0.0 110.514 179.329 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 27.5 m -61.13 -31.07 49.09 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.31 0 N-CA-C 109.378 -0.601 . . . . 0.0 109.378 179.092 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 85' ' ' TYR . . . . . 0.422 ' O ' ' HG ' ' A' ' 89' ' ' LEU . 80.4 t80 -61.64 -35.58 78.33 Favored 'General case' 0 N--CA 1.453 -0.282 0 CA-C-N 115.593 -0.73 . . . . 0.0 109.155 178.338 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 86' ' ' PHE . . . . . . . . . . . . . 34.1 t80 -61.9 -49.67 75.26 Favored 'General case' 0 CA--C 1.52 -0.178 0 CA-C-N 115.78 -0.645 . . . . 0.0 109.623 179.046 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 3.9 mm? -57.71 -32.8 67.75 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 115.655 -0.702 . . . . 0.0 110.034 179.131 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -73.15 -27.43 68.37 Favored Glycine 0 N--CA 1.451 -0.305 0 CA-C-N 115.642 -0.708 . . . . 0.0 112.826 179.784 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 89' ' ' LEU . . . . . 0.422 ' HG ' ' O ' ' A' ' 85' ' ' TYR . 94.3 mt -72.39 -44.42 62.54 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.904 0.383 . . . . 0.0 111.084 -179.622 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 70.3 mt -70.49 -27.29 64.09 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 115.986 -0.552 . . . . 0.0 111.363 -179.748 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . 0.659 ' HA ' ' HB2' ' A' ' 149' ' ' ALA . . . -87.49 -52.65 5.23 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.426 -0.352 . . . . 0.0 111.239 -179.93 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 90.31 59.96 1.42 Allowed Glycine 0 N--CA 1.451 -0.361 0 C-N-CA 120.93 -0.652 . . . . 0.0 112.418 -179.966 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 93' ' ' LEU . . . . . 0.593 HD23 ' HB3' ' A' ' 97' ' ' GLU . 8.1 mp -71.28 -174.72 1.07 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.741 0.305 . . . . 0.0 110.845 -179.894 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 94' ' ' ASP . . . . . 0.451 ' HB2' ' OE2' ' A' ' 97' ' ' GLU . 12.5 m-20 -94.09 -172.16 2.75 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 121.023 0.439 . . . . 0.0 111.545 -179.446 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 43.5 m -67.8 -48.98 64.75 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 115.836 -0.62 . . . . 0.0 111.657 -179.266 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 31.9 ttm180 -73.33 -41.01 64.0 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 121.05 0.452 . . . . 0.0 110.619 -179.338 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 97' ' ' GLU . . . . . 0.593 ' HB3' HD23 ' A' ' 93' ' ' LEU . 0.3 OUTLIER -56.47 -45.83 80.72 Favored 'General case' 0 C--N 1.326 -0.449 0 CA-C-N 115.692 -0.686 . . . . 0.0 111.069 179.983 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 98' ' ' PHE . . . . . 0.448 ' O ' HG12 ' A' ' 102' ' ' ILE . 1.2 m-85 -60.79 -43.97 97.41 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.338 -0.392 . . . . 0.0 110.731 179.63 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -64.8 -29.73 76.08 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.901 -0.666 . . . . 0.0 112.639 -179.995 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 93.1 mt -68.29 -41.68 83.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-O 120.756 0.313 . . . . 0.0 111.249 -179.81 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 34.2 t -68.07 -41.16 84.12 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.411 0 CA-C-N 116.264 -0.425 . . . . 0.0 111.432 -179.573 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 102' ' ' ILE . . . . . 0.448 HG12 ' O ' ' A' ' 98' ' ' PHE . 42.0 mm -68.67 -51.36 46.64 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.447 -0.342 . . . . 0.0 111.44 -179.756 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 15.3 t -56.86 -32.21 65.59 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-O 120.916 0.389 . . . . 0.0 111.04 -179.894 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 104' ' ' LEU . . . . . 0.475 HD23 HD13 ' A' ' 137' ' ' LEU . 33.7 tp -66.06 -48.41 71.14 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.573 179.483 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 105' ' ' ASN . . . . . 0.542 ' N ' HD22 ' A' ' 105' ' ' ASN . 0.9 OUTLIER -62.52 -27.0 68.85 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.045 179.972 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 89.2 m -70.21 -53.36 17.41 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.334 -0.394 . . . . 0.0 111.419 -179.887 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 8.8 p -65.6 -37.07 79.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.296 -0.411 . . . . 0.0 111.304 -179.652 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 55.6 t -65.41 -50.16 74.33 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.249 0 CA-C-N 116.43 -0.35 . . . . 0.0 110.958 179.86 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 109' ' ' MET . . . . . 0.626 ' HE1' HG21 ' A' ' 80' ' ' THR . 7.2 tpp -64.12 -33.54 75.99 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.622 -179.899 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 110' ' ' LEU . . . . . 0.472 HD23 ' C ' ' A' ' 110' ' ' LEU . 3.4 tt -63.06 -41.62 99.5 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-N 115.921 -0.581 . . . . 0.0 109.706 179.052 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -58.12 -47.83 82.08 Favored 'General case' 0 C--N 1.331 -0.203 0 CA-C-N 115.824 -0.625 . . . . 0.0 110.494 179.536 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 112' ' ' GLY . . . . . 0.652 ' HA3' ' H21' ' A' ' 301' ' ' RET . . . -68.47 -32.68 75.57 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.64 -0.791 . . . . 0.0 111.929 179.374 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 113' ' ' PHE . . . . . . . . . . . . . 0.5 OUTLIER -51.79 -68.45 0.17 Allowed 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 121.058 0.456 . . . . 0.0 109.998 179.566 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 114' ' ' ALA . . . . . 0.456 ' O ' HG13 ' A' ' 118' ' ' VAL . . . -70.48 -24.02 62.79 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 115.586 -0.733 . . . . 0.0 111.155 179.819 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -54.08 -40.86 67.68 Favored Glycine 0 C--N 1.331 0.282 0 C-N-CA 121.149 -0.548 . . . . 0.0 112.994 -179.699 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -77.81 -39.15 44.77 Favored 'General case' 0 C--N 1.328 -0.326 0 N-CA-C 112.142 0.423 . . . . 0.0 112.142 -179.429 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 117' ' ' MET . . . . . 0.485 ' HB3' HG11 ' A' ' 68' ' ' VAL . 19.3 ptp -91.4 19.74 5.84 Favored 'General case' 0 C--N 1.329 -0.324 0 N-CA-C 111.788 0.292 . . . . 0.0 111.788 -179.287 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 118' ' ' VAL . . . . . 0.544 HG21 ' HB3' ' A' ' 123' ' ' ARG . 5.0 m -54.08 149.45 18.37 Favored Pre-proline 0 C--N 1.33 -0.282 0 CA-C-N 116.598 -0.274 . . . . 0.0 111.231 179.723 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 119' ' ' PRO . . . . . . . . . . . . . 90.3 Cg_endo -87.34 3.97 6.24 Favored 'Trans proline' 0 N--CA 1.458 -0.581 0 C-N-CA 122.64 2.227 . . . . 0.0 112.236 179.622 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -168.37 -133.96 1.64 Allowed Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.786 -0.721 . . . . 0.0 112.457 -179.951 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 42.4 pt -99.18 18.01 2.77 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.246 0 CA-C-O 120.885 0.374 . . . . 0.0 111.182 -179.834 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 45.1 mt-10 -67.51 -18.46 65.05 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.274 -179.975 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 123' ' ' ARG . . . . . 0.544 ' HB3' HG21 ' A' ' 118' ' ' VAL . 20.5 ptt180 -53.07 -29.82 32.52 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 116.222 -0.444 . . . . 0.0 111.67 -179.678 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 124' ' ' TYR . . . . . . . . . . . . . 28.2 m-85 -67.48 -34.41 77.1 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.589 -0.278 . . . . 0.0 110.795 -179.858 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 125' ' ' ALA . . . . . . . . . . . . . . . -74.78 -56.08 5.16 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.17 -179.978 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 1.1 mt -52.49 -54.34 33.81 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 115.908 -0.587 . . . . 0.0 110.961 -179.86 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 127' ' ' PHE . . . . . 0.417 ' CE1' ' H42' ' A' ' 301' ' ' RET . 8.8 t80 -62.78 -36.4 82.99 Favored 'General case' 0 C--N 1.331 -0.231 0 C-N-CA 120.847 -0.341 . . . . 0.0 110.567 179.756 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 128' ' ' GLY . . . . . . . . . . . . . . . -47.31 -43.98 20.15 Favored Glycine 0 C--N 1.332 0.314 0 C-N-CA 120.136 -1.031 . . . . 0.0 111.153 179.154 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 129' ' ' MET . . . . . . . . . . . . . 0.3 OUTLIER -71.87 -37.05 70.26 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 120.865 0.364 . . . . 0.0 110.026 178.868 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -67.18 -28.19 73.67 Favored Glycine 0 N--CA 1.45 -0.378 0 CA-C-N 115.822 -0.626 . . . . 0.0 112.688 -179.722 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -74.81 -54.18 7.79 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.624 0.25 . . . . 0.0 110.67 -179.953 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 31.7 t -57.95 -41.17 79.55 Favored 'Isoleucine or valine' 0 C--O 1.235 0.318 0 N-CA-C 109.129 -0.693 . . . . 0.0 109.129 178.698 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -66.29 -35.8 81.32 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 115.173 -0.921 . . . . 0.0 110.106 178.929 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 134' ' ' PHE . . . . . 0.418 ' CZ ' ' HA ' ' A' ' 172' ' ' ALA . 57.9 t80 -57.48 -50.9 71.55 Favored 'General case' 0 N--CA 1.45 -0.469 0 CA-C-N 115.937 -0.574 . . . . 0.0 110.022 179.548 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 135' ' ' ILE . . . . . 0.451 ' O ' HG22 ' A' ' 138' ' ' VAL . 60.2 mt -56.64 -33.59 40.39 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.312 0 CA-C-N 115.911 -0.586 . . . . 0.0 109.663 178.95 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . -63.21 -35.21 91.76 Favored Glycine 0 N--CA 1.447 -0.568 0 C-N-CA 120.249 -0.977 . . . . 0.0 111.205 178.507 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 137' ' ' LEU . . . . . 0.475 HD13 HD23 ' A' ' 104' ' ' LEU . 29.1 tp -73.43 -52.13 14.82 Favored 'General case' 0 C--N 1.332 -0.158 0 N-CA-C 110.422 -0.214 . . . . 0.0 110.422 179.612 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 138' ' ' VAL . . . . . 0.791 ' HA ' HD12 ' A' ' 141' ' ' LEU . 4.9 m -55.95 -30.55 28.72 Favored 'Isoleucine or valine' 0 C--O 1.234 0.28 0 N-CA-C 109.069 -0.715 . . . . 0.0 109.069 178.92 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 139' ' ' TYR . . . . . 0.413 ' O ' ' N ' ' A' ' 143' ' ' GLY . 49.8 t80 -64.82 -41.96 95.35 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 114.958 -1.019 . . . . 0.0 109.337 178.462 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 19.4 m-85 -65.02 -33.0 74.99 Favored 'General case' 0 C--N 1.333 -0.143 0 CA-C-N 116.036 -0.529 . . . . 0.0 109.791 178.577 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 141' ' ' LEU . . . . . 0.791 HD12 ' HA ' ' A' ' 138' ' ' VAL . 81.9 mt -61.21 -36.38 79.75 Favored 'General case' 0 C--O 1.232 0.149 0 CA-C-N 115.977 -0.556 . . . . 0.0 109.895 179.078 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 142' ' ' VAL . . . . . 0.404 HG22 ' NH1' ' A' ' 164' ' ' ARG . 2.9 t -109.27 10.48 8.96 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-N 115.751 -0.659 . . . . 0.0 110.658 179.729 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 143' ' ' GLY . . . . . 0.413 ' N ' ' O ' ' A' ' 139' ' ' TYR . . . -85.52 -147.6 9.81 Favored Glycine 0 CA--C 1.519 0.291 0 C-N-CA 120.968 -0.634 . . . . 0.0 113.008 -179.511 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 144' ' ' PRO . . . . . . . . . . . . . 51.3 Cg_exo -52.98 -24.87 26.11 Favored 'Trans proline' 0 C--N 1.349 0.579 0 C-N-CA 122.716 2.278 . . . . 0.0 112.754 -179.799 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 145' ' ' MET . . . . . 0.464 ' HG2' HD11 ' A' ' 93' ' ' LEU . 55.3 mtt -53.22 -39.15 63.55 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 116.352 -0.385 . . . . 0.0 111.244 179.975 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 146' ' ' THR . . . . . . . . . . . . . 81.2 p -62.1 -51.2 68.89 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.794 -179.36 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 147' ' ' GLU . . . . . 0.479 ' O ' ' HG2' ' A' ' 151' ' ' GLN . 40.0 mt-10 -74.1 -18.06 60.86 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.394 -0.366 . . . . 0.0 111.249 -179.534 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 148' ' ' SER . . . . . . . . . . . . . 44.6 t -71.21 -47.69 55.9 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.764 0.316 . . . . 0.0 111.231 -179.807 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 149' ' ' ALA . . . . . 0.659 ' HB2' ' HA ' ' A' ' 91' ' ' ALA . . . -78.02 -31.99 50.79 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.128 -0.487 . . . . 0.0 112.242 -178.975 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 150' ' ' SER . . . . . . . . . . . . . 70.2 m -62.68 -6.67 3.79 Favored 'General case' 0 C--N 1.328 -0.337 0 N-CA-C 111.993 0.368 . . . . 0.0 111.993 -179.384 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 151' ' ' GLN . . . . . 0.479 ' HG2' ' O ' ' A' ' 147' ' ' GLU . 67.0 mm-40 -111.58 17.14 20.27 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.731 -0.213 . . . . 0.0 111.095 -179.775 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 25.6 mtp180 -101.71 -52.24 3.25 Favored 'General case' 0 C--N 1.331 -0.201 0 CA-C-O 120.832 0.349 . . . . 0.0 111.351 -179.839 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 153' ' ' SER . . . . . 0.594 ' HB3' HG12 ' A' ' 156' ' ' ILE . 31.5 t -156.83 172.27 18.93 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.959 179.691 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 154' ' ' SER . . . . . . . . . . . . . 61.4 m -73.05 -39.78 65.64 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 116.257 -0.428 . . . . 0.0 110.65 179.679 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -76.6 -28.81 58.78 Favored Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.904 -0.665 . . . . 0.0 112.7 -179.936 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 156' ' ' ILE . . . . . 0.594 HG12 ' HB3' ' A' ' 153' ' ' SER . 25.8 mm -58.37 -42.45 84.05 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.233 0 CA-C-O 120.764 0.316 . . . . 0.0 111.486 -179.96 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 157' ' ' LYS . . . . . 0.422 ' O ' HG13 ' A' ' 161' ' ' VAL . 25.0 ttpp -63.31 -42.24 99.0 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.272 -0.422 . . . . 0.0 111.499 -179.496 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 46.5 t -65.23 -47.68 75.98 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.418 -0.355 . . . . 0.0 111.88 -179.257 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 159' ' ' LEU . . . . . 0.501 ' O ' HD13 ' A' ' 163' ' ' LEU . 4.9 tt -66.13 -34.68 78.61 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.507 -0.315 . . . . 0.0 111.241 -179.396 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 160' ' ' TYR . . . . . . . . . . . . . 58.4 t80 -73.69 -46.16 48.01 Favored 'General case' 0 C--N 1.327 -0.382 0 N-CA-C 112.365 0.506 . . . . 0.0 112.365 -178.767 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 161' ' ' VAL . . . . . 0.442 HG23 ' N ' ' A' ' 162' ' ' ARG . 28.8 m -59.97 -46.52 93.99 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 N-CA-C 112.171 0.434 . . . . 0.0 112.171 -178.933 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 162' ' ' ARG . . . . . 0.442 ' N ' HG23 ' A' ' 161' ' ' VAL . 79.0 ttt180 -65.61 -46.04 80.85 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.71 0.291 . . . . 0.0 111.552 -179.331 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 163' ' ' LEU . . . . . 0.501 HD13 ' O ' ' A' ' 159' ' ' LEU . 7.8 mp -65.44 -52.02 56.13 Favored 'General case' 0 C--N 1.329 -0.317 0 N-CA-C 112.106 0.41 . . . . 0.0 112.106 -179.186 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 164' ' ' ARG . . . . . 0.602 ' O ' HG23 ' A' ' 168' ' ' VAL . 5.7 ppt_? -58.62 -43.34 89.62 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.598 -0.274 . . . . 0.0 111.605 -178.861 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 165' ' ' ASN . . . . . 0.471 ' O ' HG23 ' A' ' 169' ' ' VAL . 0.9 OUTLIER -55.97 -49.44 73.57 Favored 'General case' 0 C--N 1.331 -0.202 0 CA-C-O 121.129 0.49 . . . . 0.0 110.427 179.513 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 166' ' ' LEU . . . . . 0.485 ' O ' ' HG ' ' A' ' 170' ' ' LEU . 3.1 tt -60.15 -50.04 75.24 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 115.563 -0.744 . . . . 0.0 111.681 -179.52 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 167' ' ' THR . . . . . 0.479 ' O ' ' HB2' ' A' ' 171' ' ' TRP . 60.1 m -56.41 -54.01 50.63 Favored 'General case' 0 C--N 1.331 -0.232 0 N-CA-C 112.324 0.49 . . . . 0.0 112.324 -178.796 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 168' ' ' VAL . . . . . 0.644 HG22 HD13 ' A' ' 141' ' ' LEU . 45.4 t -52.27 -43.8 40.43 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.227 0 N-CA-C 112.339 0.496 . . . . 0.0 112.339 -179.764 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 169' ' ' VAL . . . . . 0.471 HG23 ' O ' ' A' ' 165' ' ' ASN . 72.8 t -59.92 -65.75 0.44 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 N-CA-C 113.016 0.747 . . . . 0.0 113.016 -178.47 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 170' ' ' LEU . . . . . 0.485 ' HG ' ' O ' ' A' ' 166' ' ' LEU . 0.7 OUTLIER -63.08 -37.78 88.56 Favored 'General case' 0 C--N 1.33 -0.26 0 N-CA-C 112.593 0.59 . . . . 0.0 112.593 -178.163 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 171' ' ' TRP . . . . . 0.657 ' HE1' H203 ' A' ' 301' ' ' RET . 2.9 m0 -64.25 -27.58 69.15 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.832 0.349 . . . . 0.0 110.771 179.813 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 172' ' ' ALA . . . . . 0.418 ' HA ' ' CZ ' ' A' ' 134' ' ' PHE . . . -72.48 -6.93 47.19 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.948 -179.818 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 173' ' ' ILE . . . . . 0.492 ' O ' HG12 ' A' ' 177' ' ' ILE . 28.8 mm -88.4 -21.24 7.05 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 115.952 -0.567 . . . . 0.0 111.175 -179.985 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 174' ' ' TYR . . . . . 0.403 ' N ' ' CD ' ' A' ' 175' ' ' PRO . 8.7 m-85 -53.59 -48.25 93.74 Favored Pre-proline 0 N--CA 1.464 0.261 0 CA-C-N 116.339 -0.392 . . . . 0.0 111.93 -179.375 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 175' ' ' PRO . . . . . 0.403 ' CD ' ' N ' ' A' ' 174' ' ' TYR . 84.6 Cg_exo -48.43 -33.27 22.52 Favored 'Trans proline' 0 C--N 1.351 0.667 0 C-N-CA 121.854 1.703 . . . . 0.0 112.048 179.588 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 176' ' ' PHE . . . . . 0.465 ' HD2' ' HA ' ' A' ' 173' ' ' ILE . 60.9 m-85 -80.9 -50.35 9.87 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 115.873 -0.603 . . . . 0.0 111.954 -179.905 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 177' ' ' ILE . . . . . 0.507 HG13 HD11 ' A' ' 200' ' ' LEU . 13.6 mm -60.25 -32.08 49.86 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.443 0 CA-C-N 116.279 -0.418 . . . . 0.0 112.036 -178.386 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 178' ' ' TRP . . . . . 0.458 ' HH2' ' HB2' ' A' ' 123' ' ' ARG . 82.0 t90 -73.18 -52.06 15.52 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.91 0.386 . . . . 0.0 110.81 179.928 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 179' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -68.76 -54.77 14.07 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-N 115.989 -0.55 . . . . 0.0 111.484 -179.119 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 180' ' ' LEU . . . . . 0.542 HD22 HD11 ' A' ' 187' ' ' LEU . 26.6 mt -64.06 -29.7 70.82 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.55 -0.295 . . . . 0.0 111.298 -179.37 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . -69.12 -175.79 12.24 Favored Glycine 0 N--CA 1.449 -0.44 0 C-N-CA 119.817 -1.183 . . . . 0.0 111.629 178.957 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 182' ' ' PRO . . . . . 0.502 ' HG3' ' HA ' ' A' ' 190' ' ' PRO . 82.3 Cg_exo -47.47 -43.54 27.07 Favored 'Trans proline' 0 CA--C 1.537 0.669 0 C-N-CA 122.678 2.252 . . . . 0.0 113.76 179.943 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 183' ' ' PRO . . . . . 0.424 ' HB2' ' O ' ' A' ' 178' ' ' TRP . 83.4 Cg_exo -43.07 -51.77 5.31 Favored 'Trans proline' 0 C--N 1.356 0.957 0 C-N-CA 122.491 2.127 . . . . 0.0 114.065 -179.744 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 184' ' ' GLY . . . . . . . . . . . . . . . -102.74 -123.95 5.36 Favored Glycine 0 C--N 1.335 0.515 0 C-N-CA 119.942 -1.123 . . . . 0.0 113.631 -179.063 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 185' ' ' VAL . . . . . 0.406 ' CG2' HD21 ' A' ' 187' ' ' LEU . 23.6 m -54.09 -33.33 24.49 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.405 0 N-CA-C 112.647 0.61 . . . . 0.0 112.647 -178.95 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 186' ' ' ALA . . . . . 0.421 ' HB2' ' HA ' ' A' ' 182' ' ' PRO . . . 58.92 83.35 0.13 Allowed 'General case' 0 N--CA 1.464 0.246 0 CA-C-O 120.675 0.274 . . . . 0.0 111.624 179.786 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 187' ' ' LEU . . . . . 0.542 HD11 HD22 ' A' ' 180' ' ' LEU . 7.7 mt -92.32 -49.92 5.91 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-O 120.902 0.382 . . . . 0.0 111.351 179.795 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 188' ' ' LEU . . . . . 0.463 HD12 ' HB2' ' A' ' 187' ' ' LEU . 7.3 mp -79.79 -164.59 0.68 Allowed 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.001 -0.545 . . . . 0.0 111.197 -179.268 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 189' ' ' THR . . . . . 0.497 ' HB ' HG23 ' A' ' 192' ' ' VAL . 20.8 m -91.08 137.46 26.46 Favored Pre-proline 0 C--N 1.329 -0.295 0 CA-C-N 115.868 -0.605 . . . . 0.0 110.634 -179.73 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 190' ' ' PRO . . . . . 0.502 ' HA ' ' HG3' ' A' ' 182' ' ' PRO . 92.3 Cg_exo -44.23 -37.24 9.87 Favored 'Trans proline' 0 C--N 1.35 0.656 0 C-N-CA 122.519 2.146 . . . . 0.0 113.278 -179.649 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 191' ' ' THR . . . . . 0.433 HG22 HG22 ' A' ' 189' ' ' THR . 6.2 t -78.52 -40.82 34.05 Favored 'General case' 0 C--N 1.33 -0.275 0 N-CA-C 111.683 0.253 . . . . 0.0 111.683 -179.616 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 192' ' ' VAL . . . . . 0.497 HG23 ' HB ' ' A' ' 189' ' ' THR . 96.9 t -62.52 -48.69 87.08 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-O 120.658 0.266 . . . . 0.0 111.463 -179.729 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 193' ' ' ASP . . . . . . . . . . . . . 21.6 m-20 -56.0 -46.58 78.7 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.397 -0.365 . . . . 0.0 111.089 -179.714 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 194' ' ' VAL . . . . . 0.429 HG23 ' O ' ' A' ' 190' ' ' PRO . 71.0 t -59.34 -37.07 67.36 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.412 -0.358 . . . . 0.0 110.739 179.547 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 195' ' ' ALA . . . . . . . . . . . . . . . -59.32 -41.71 89.72 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.303 -0.408 . . . . 0.0 110.608 179.534 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 196' ' ' LEU . . . . . . . . . . . . . 98.1 mt -67.3 -38.4 84.95 Favored 'General case' 0 C--N 1.333 -0.143 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.197 179.248 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 197' ' ' ILE . . . . . 0.445 HG23 ' HZ2' ' A' ' 76' ' ' TRP . 15.8 mm -60.57 -56.24 19.06 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.242 0 CA-C-N 115.901 -0.59 . . . . 0.0 110.248 179.122 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 198' ' ' VAL . . . . . . . . . . . . . 93.7 t -54.28 -34.58 28.01 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.516 0 CA-C-N 115.623 -0.717 . . . . 0.0 109.321 178.303 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 199' ' ' TYR . . . . . . . . . . . . . 29.7 t80 -69.83 -32.99 71.71 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 115.112 -0.949 . . . . 0.0 110.609 179.794 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 200' ' ' LEU . . . . . 0.516 ' O ' HG12 ' A' ' 203' ' ' VAL . 23.0 mt -69.86 -39.33 76.41 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 115.97 -0.559 . . . . 0.0 111.024 179.984 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 201' ' ' ASP . . . . . . . . . . . . . 15.2 m-20 -72.95 -34.6 66.64 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-O 121.204 0.526 . . . . 0.0 110.103 179.625 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 202' ' ' LEU . . . . . . . . . . . . . 3.1 mt -75.01 -27.13 59.99 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 115.514 -0.766 . . . . 0.0 111.749 -179.439 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 203' ' ' VAL . . . . . 0.516 HG12 ' O ' ' A' ' 200' ' ' LEU . 10.9 p -79.61 -36.36 17.47 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.334 0 C-N-CA 120.834 -0.347 . . . . 0.0 110.856 -178.924 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 204' ' ' THR . . . . . . . . . . . . . 96.9 m -67.87 -58.27 4.85 Favored 'General case' 0 C--N 1.328 -0.333 0 C-N-CA 120.933 -0.307 . . . . 0.0 110.902 179.212 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 205' ' ' LYS . . . . . 0.667 ' HE3' HG22 ' A' ' 43' ' ' ILE . 60.5 mttp -60.52 -58.29 9.11 Favored 'General case' 0 C--N 1.331 -0.212 0 N-CA-C 112.067 0.395 . . . . 0.0 112.067 -178.937 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 52.8 t -67.69 -37.02 77.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 N-CA-C 111.818 0.303 . . . . 0.0 111.818 -179.303 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 207' ' ' GLY . . . . . 0.407 ' HA3' ' O ' ' A' ' 203' ' ' VAL . . . -53.55 -60.48 8.19 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.908 -0.663 . . . . 0.0 113.975 -178.818 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 208' ' ' PHE . . . . . 0.506 ' O ' ' HB2' ' A' ' 212' ' ' ALA . 1.1 p90 -75.45 -26.75 58.53 Favored 'General case' 0 C--O 1.219 -0.513 0 CA-C-N 117.317 0.559 . . . . 0.0 111.778 -179.14 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 209' ' ' GLY . . . . . 0.45 ' O ' ' HB3' ' A' ' 212' ' ' ALA . . . -66.4 -35.24 89.88 Favored Glycine 0 N--CA 1.452 -0.267 0 C-N-CA 121.491 -0.385 . . . . 0.0 112.202 179.597 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 210' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER -75.75 -44.86 39.54 Favored 'General case' 0 CA--C 1.514 -0.433 0 N-CA-C 108.316 -0.994 . . . . 0.0 108.316 178.742 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 211' ' ' ILE . . . . . . . . . . . . . 44.3 mt -65.6 -27.55 41.85 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.55 0 N-CA-C 107.91 -1.144 . . . . 0.0 107.91 176.86 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 212' ' ' ALA . . . . . 0.506 ' HB2' ' O ' ' A' ' 208' ' ' PHE . . . -62.37 -45.47 93.02 Favored 'General case' 0 N--CA 1.451 -0.418 0 CA-C-N 114.741 -1.118 . . . . 0.0 110.508 179.89 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 213' ' ' LEU . . . . . . . . . . . . . 93.9 mt -69.73 -54.55 13.22 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 115.151 -0.931 . . . . 0.0 111.676 -179.181 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 214' ' ' ASP . . . . . . . . . . . . . 19.5 t70 -55.21 -41.52 72.11 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.331 -0.395 . . . . 0.0 111.511 -179.608 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 215' ' ' ALA . . . . . 0.459 ' O ' ' HG ' ' A' ' 219' ' ' LEU . . . -70.25 -57.7 4.59 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.407 -0.36 . . . . 0.0 111.781 -179.419 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 216' ' ' ALA . . . . . . . . . . . . . . . -55.59 -34.92 65.26 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.5 -0.318 . . . . 0.0 111.428 -179.541 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 217' ' ' ALA . . . . . . . . . . . . . . . -67.02 -41.02 87.33 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.506 179.894 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 218' ' ' THR . . . . . . . . . . . . . 42.3 m -64.84 -37.57 88.06 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 115.775 -0.648 . . . . 0.0 110.916 179.707 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 219' ' ' LEU . . . . . 0.459 ' HG ' ' O ' ' A' ' 215' ' ' ALA . 68.9 mt -61.59 -46.25 90.64 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.851 -179.896 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 220' ' ' ARG . . . . . 0.427 ' HD2' ' N ' ' A' ' 220' ' ' ARG . 10.0 mpt_? -82.38 -14.26 55.52 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.163 -0.472 . . . . 0.0 111.086 -179.834 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 221' ' ' ALA . . . . . . . . . . . . . . . -70.67 -47.75 58.33 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.363 -0.381 . . . . 0.0 111.229 179.971 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 222' ' ' GLU . . . . . . . . . . . . . 12.3 pt-20 -91.42 -30.5 16.47 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.933 -179.737 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 223' ' ' HIS . . . . . . . . . . . . . 18.6 p80 36.92 81.9 0.02 OUTLIER 'General case' 0 N--CA 1.463 0.21 0 CA-C-N 115.898 -0.592 . . . . 0.0 111.536 -179.769 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 224' ' ' GLY . . . . . . . . . . . . . . . -99.93 54.0 0.94 Allowed Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.771 -179.682 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 225' ' ' GLU . . . . . . . . . . . . . 45.6 mt-10 -80.5 134.51 35.97 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.769 0.319 . . . . 0.0 110.68 179.726 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 226' ' ' SER . . . . . . . . . . . . . 46.0 t -69.32 -59.85 2.73 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.081 -179.737 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 227' ' ' LEU . . . . . . . . . . . . . 92.3 mt -61.53 114.54 3.31 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-O 120.88 0.372 . . . . 0.0 111.078 -179.901 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 228' ' ' ALA . . . . . . . . . . . . . . . -152.32 -0.67 0.29 Allowed 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.084 -0.507 . . . . 0.0 111.028 179.885 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 229' ' ' GLY . . . . . . . . . . . . . . . -68.03 146.26 46.07 Favored Glycine 0 N--CA 1.45 -0.369 0 C-N-CA 120.884 -0.674 . . . . 0.0 112.461 179.893 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 230' ' ' VAL . . . . . . . . . . . . . 31.1 t -84.21 132.24 32.03 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-O 120.832 0.348 . . . . 0.0 111.077 -179.845 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 231' ' ' ASP . . . . . . . . . . . . . 20.9 t70 -72.58 101.68 3.07 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.848 179.887 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 232' ' ' THR . . . . . . . . . . . . . 48.9 p -129.28 6.69 5.35 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.176 179.843 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 233' ' ' ASP . . . . . . . . . . . . . 6.1 p-10 -82.08 8.93 9.5 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.834 179.908 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 234' ' ' THR . . . . . . . . . . . . . 4.4 t -59.31 142.13 86.74 Favored Pre-proline 0 C--N 1.33 -0.282 0 CA-C-N 116.111 -0.495 . . . . 0.0 111.318 -179.957 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 235' ' ' PRO . . . . . . . . . . . . . 74.3 Cg_endo -74.81 -172.53 1.26 Allowed 'Trans proline' 0 C--N 1.347 0.492 0 C-N-CA 122.495 2.13 . . . . 0.0 112.345 179.976 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 236' ' ' ALA . . . . . . . . . . . . . . . -135.44 155.73 50.06 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.124 -0.489 . . . . 0.0 111.041 -179.987 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 237' ' ' VAL . . . . . . . . . . . . . 31.0 m -110.42 23.55 4.25 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 116.102 -0.499 . . . . 0.0 111.074 -179.931 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 238' ' ' ALA . . . . . . . . . . . . . . . -78.48 -18.57 54.64 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.22 -179.911 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 239' ' ' ASP . . . . . . . . . . . . . 15.1 m-20 64.17 157.95 0.08 Allowed 'General case' 0 N--CA 1.462 0.168 0 CA-C-N 116.156 -0.475 . . . . 0.0 111.342 179.894 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 240' ' ' LEU . . . . . . . . . . . . . 78.8 mt -103.38 -62.45 1.29 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.015 -0.539 . . . . 0.0 110.687 179.917 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 241' ' ' GLU . . . . . . . . . . . . . 12.4 pt-20 -117.9 172.96 7.04 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.775 179.91 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 242' ' ' HIS . . . . . . . . . . . . . 69.3 m-70 -100.17 -60.83 1.46 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.281 -0.418 . . . . 0.0 110.813 179.991 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 243' ' ' HIS . . . . . . . . . . . . . 6.4 p-80 -128.02 171.14 12.13 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.224 -179.752 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 244' ' ' HIS . . . . . . . . . . . . . 17.0 p80 -98.53 142.63 29.88 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 115.983 -0.553 . . . . 0.0 110.727 179.852 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 245' ' ' HIS . . . . . . . . . . . . . 48.3 t-80 -153.67 -57.27 0.12 Allowed 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.373 -0.376 . . . . 0.0 111.152 -179.783 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 246' ' ' HIS . . . . . . . . . . . . . 8.6 p80 -118.29 -14.83 9.79 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.18 -179.851 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 247' ' ' HIS . . . . . . . . . . . . . 59.5 m80 . . . . . 0 C--O 1.249 1.075 0 CA-C-O 118.215 -0.898 . . . . 0.0 111.057 -179.951 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' A' A ' 301' ' ' RET . . . . . 0.657 H203 ' HE1' ' A' ' 171' ' ' TRP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 64.2 mtm . . . . . 0 N--CA 1.485 1.291 0 CA-C-O 120.797 0.332 . . . . 0.0 110.838 . . . . . . . . . 0 0 . 1 . 021 nuclear nobuild full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 41.1 t -91.71 -34.83 6.47 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.242 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.118 179.962 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -88.9 -9.72 67.67 Favored Glycine 0 N--CA 1.452 -0.266 0 C-N-CA 120.867 -0.682 . . . . 0.0 112.626 -179.947 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 31.1 tp -73.95 -35.47 64.53 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-O 120.837 0.351 . . . . 0.0 110.727 -179.967 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 74.0 p -58.23 -30.99 66.94 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.079 -0.51 . . . . 0.0 111.519 -179.863 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 30.9 p -54.29 -35.71 62.88 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.377 -0.374 . . . . 0.0 111.2 -179.964 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 7' ' ' LEU . . . . . . . . . . . . . 4.1 mm? -60.22 -52.23 66.17 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.883 179.868 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 8' ' ' PHE . . . . . 0.542 ' HB2' ' HB2' ' A' ' 55' ' ' ALA . 58.2 m-85 -62.82 -30.92 71.85 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.031 -0.532 . . . . 0.0 110.909 -179.981 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 9' ' ' TRP . . . . . . . . . . . . . 21.5 m95 -67.5 -46.87 71.65 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.087 -0.506 . . . . 0.0 110.212 -179.797 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 88.9 mt -59.67 -38.44 81.49 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 115.69 -0.687 . . . . 0.0 110.343 179.411 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -65.04 -34.24 89.32 Favored Glycine 0 N--CA 1.448 -0.506 0 C-N-CA 120.679 -0.772 . . . . 0.0 111.866 179.36 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -67.91 -32.48 72.97 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-O 120.883 0.373 . . . . 0.0 110.62 179.554 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 70.2 mt -65.22 -53.42 40.8 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 115.91 -0.586 . . . . 0.0 110.624 179.611 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -64.21 -40.16 97.74 Favored Glycine 0 N--CA 1.451 -0.364 0 C-N-CA 120.6 -0.81 . . . . 0.0 112.198 179.72 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 15' ' ' MET . . . . . 0.513 ' HE3' ' HD2' ' A' ' 205' ' ' LYS . 12.5 mmt -63.14 -47.96 80.49 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.676 0.274 . . . . 0.0 110.99 179.797 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 16' ' ' LEU . . . . . 0.706 ' O ' HD23 ' A' ' 20' ' ' LEU . 50.9 tp -54.4 -55.71 25.92 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.329 -179.877 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 46.9 t -56.97 -33.36 42.05 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-O 120.958 0.409 . . . . 0.0 110.45 -179.355 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -67.26 -49.88 49.19 Favored Glycine 0 N--CA 1.452 -0.297 0 N-CA-C 111.185 -0.766 . . . . 0.0 111.185 179.483 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 19' ' ' THR . . . . . 0.538 HG22 HD22 ' A' ' 20' ' ' LEU . 1.4 m -53.39 -43.45 67.89 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 115.28 -0.46 . . . . 0.0 110.84 179.518 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 20' ' ' LEU . . . . . 0.706 HD23 ' O ' ' A' ' 16' ' ' LEU . 0.5 OUTLIER -69.79 -41.96 74.41 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-N 115.755 -0.657 . . . . 0.0 111.943 -179.559 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -59.38 -32.14 69.87 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.521 -0.309 . . . . 0.0 111.795 -179.344 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 22' ' ' PHE . . . . . 0.756 ' HB2' HG22 ' A' ' 41' ' ' VAL . 5.8 m-85 -90.96 -28.66 17.9 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.711 0.291 . . . . 0.0 111.256 -179.722 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -70.33 -50.72 36.22 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 121.007 0.432 . . . . 0.0 111.576 -179.716 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 24' ' ' TRP . . . . . . . . . . . . . 4.6 t-105 -66.06 -38.91 89.51 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 115.867 -0.606 . . . . 0.0 111.494 -179.438 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -78.67 -23.92 45.41 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-O 120.836 0.35 . . . . 0.0 110.77 179.712 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -73.53 -43.21 37.84 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 121.034 -0.603 . . . . 0.0 112.98 -179.756 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 13.4 ptp180 -61.73 -18.11 58.45 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 120.664 0.269 . . . . 0.0 111.227 -179.719 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 17.8 t70 -121.74 97.53 5.54 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 116.44 -0.345 . . . . 0.0 111.105 -179.795 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -164.69 -83.65 0.02 OUTLIER 'General case' 0 C--N 1.331 -0.239 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.167 179.623 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -148.69 -113.24 0.69 Allowed Glycine 0 N--CA 1.452 -0.283 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.441 -179.784 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 79.3 p -145.84 -44.8 0.21 Allowed 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.706 0.289 . . . . 0.0 111.115 -179.927 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -80.84 -29.82 41.23 Favored Glycine 0 C--N 1.331 0.254 0 C-N-CA 120.792 -0.718 . . . . 0.0 112.86 -179.709 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 2.7 mp0 -66.42 -20.88 66.18 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.898 0.38 . . . . 0.0 110.933 -179.846 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 34' ' ' ARG . . . . . . . . . . . . . 99.2 mtt180 -51.4 -29.54 16.06 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 115.914 -0.584 . . . . 0.0 111.679 -179.776 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 31.1 mmm180 -67.17 -44.78 78.83 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.393 -0.367 . . . . 0.0 111.42 -179.731 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 78.3 m-85 -70.54 -31.35 68.36 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.466 -0.333 . . . . 0.0 110.983 -179.946 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 37' ' ' TYR . . . . . 0.446 ' O ' HG23 ' A' ' 41' ' ' VAL . 48.5 m-85 -72.11 -51.33 21.93 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 116.327 -0.397 . . . . 0.0 111.228 -179.757 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 10.7 p -57.27 -36.21 51.43 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-O 120.994 0.426 . . . . 0.0 109.979 179.344 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 24.0 m -66.22 -43.83 85.55 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 115.629 -0.714 . . . . 0.0 110.584 179.127 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 40' ' ' LEU . . . . . 0.589 HD11 ' HA2' ' A' ' 209' ' ' GLY . 0.3 OUTLIER -62.64 -50.51 70.92 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-O 121.585 0.707 . . . . 0.0 110.501 179.559 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . 0.756 HG22 ' HB2' ' A' ' 22' ' ' PHE . 43.8 t -62.87 -33.49 60.64 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.626 0 CA-C-N 115.435 -0.802 . . . . 0.0 110.316 179.43 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . 0.442 ' O ' HG12 ' A' ' 46' ' ' ILE . . . -58.07 -47.79 86.93 Favored Glycine 0 N--CA 1.448 -0.527 0 CA-C-N 115.635 -0.712 . . . . 0.0 112.822 179.889 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 43' ' ' ILE . . . . . 0.572 HG23 HD23 ' A' ' 82' ' ' LEU . 9.0 pt -65.43 -51.32 65.35 Favored 'Isoleucine or valine' 0 C--O 1.233 0.201 0 CA-C-N 117.019 0.409 . . . . 0.0 111.502 -179.704 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 60.5 m -63.61 -20.47 65.69 Favored 'General case' 0 C--O 1.233 0.188 0 CA-C-O 120.92 0.39 . . . . 0.0 110.79 -179.899 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -80.61 -58.58 2.67 Favored Glycine 0 N--CA 1.452 -0.287 0 C-N-CA 121.008 -0.615 . . . . 0.0 113.103 -179.301 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 46' ' ' ILE . . . . . 0.536 ' O ' HG22 ' A' ' 49' ' ' VAL . 14.7 pt -58.19 -36.6 58.22 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.185 0 CA-C-O 120.881 0.372 . . . . 0.0 110.949 -179.758 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 47' ' ' ALA . . . . . 0.647 ' HB2' ' HE2' ' A' ' 205' ' ' LYS . . . -68.78 -42.54 77.27 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.704 178.776 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -54.39 -40.49 68.24 Favored 'General case' 0 C--O 1.232 0.181 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.329 -179.786 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 49' ' ' VAL . . . . . 0.536 HG22 ' O ' ' A' ' 46' ' ' ILE . 17.9 m -76.22 -34.1 25.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.487 -0.324 . . . . 0.0 110.98 -179.883 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -61.42 -39.96 92.7 Favored 'General case' 0 C--N 1.332 -0.165 0 CA-C-O 121.141 0.496 . . . . 0.0 110.715 179.215 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 51' ' ' TYR . . . . . 0.445 ' HE2' ' HE2' ' A' ' 15' ' ' MET . 43.5 m-85 -73.19 -35.93 66.47 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 115.651 -0.704 . . . . 0.0 110.439 179.84 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -66.68 -39.95 88.36 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 115.885 -0.598 . . . . 0.0 111.261 179.558 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 53' ' ' VAL . . . . . 0.402 HG13 ' O ' ' A' ' 49' ' ' VAL . 33.5 m -74.42 -42.44 49.79 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.173 0 CA-C-N 116.362 -0.381 . . . . 0.0 110.972 -179.785 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 54' ' ' MET . . . . . . . . . . . . . 70.7 mtm -65.27 -31.17 72.18 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 121.111 0.481 . . . . 0.0 109.852 179.118 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 55' ' ' ALA . . . . . 0.542 ' HB2' ' HB2' ' A' ' 8' ' ' PHE . . . -67.82 -18.56 64.88 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 115.544 -0.753 . . . . 0.0 111.188 179.52 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 96.5 mt -98.84 8.68 44.71 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.196 179.957 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 81.22 16.81 73.33 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.587 -0.816 . . . . 0.0 112.604 -179.993 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 58.0 t -84.53 137.19 21.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-O 120.794 0.33 . . . . 0.0 110.888 179.907 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 59' ' ' GLY . . . . . 0.484 ' HA3' ' HD3' ' A' ' 71' ' ' PRO . . . 85.08 -7.79 73.53 Favored Glycine 0 N--CA 1.449 -0.478 0 C-N-CA 120.776 -0.726 . . . . 0.0 112.476 -179.942 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 60' ' ' TRP . . . . . . . . . . . . . 12.0 m0 -65.36 99.21 0.39 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.642 0.258 . . . . 0.0 110.863 179.955 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 5.1 p -107.31 128.32 26.21 Favored Pre-proline 0 C--N 1.329 -0.298 0 CA-C-N 116.356 -0.384 . . . . 0.0 111.141 179.885 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 58.3 Cg_endo -71.68 141.11 37.1 Favored 'Trans proline' 0 C--N 1.349 0.581 0 C-N-CA 122.25 1.967 . . . . 0.0 112.039 179.817 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 61.1 t -137.39 90.77 0.77 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.356 0 CA-C-N 116.075 -0.511 . . . . 0.0 111.249 -179.621 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . 59.96 -85.49 0.02 OUTLIER 'General case' 0 C--N 1.331 -0.202 0 CA-C-N 116.0 -0.545 . . . . 0.0 111.42 179.948 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 65' ' ' GLU . . . . . 0.413 ' HG3' ' HG3' ' A' ' 66' ' ' ARG . 11.6 pt-20 -121.81 -22.69 5.7 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.886 0.374 . . . . 0.0 110.937 -179.966 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 66' ' ' ARG . . . . . 0.413 ' HG3' ' HG3' ' A' ' 65' ' ' GLU . 84.8 mtm180 -104.72 156.78 17.69 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.041 -0.527 . . . . 0.0 110.802 -179.919 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 40.9 m -113.61 130.62 56.35 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.981 179.854 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 26.3 t -113.61 146.33 18.34 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.394 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.973 179.943 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 69' ' ' PHE . . . . . . . . . . . . . 16.8 m-85 -104.33 116.68 32.57 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 116.209 -0.451 . . . . 0.0 109.919 -179.894 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 70' ' ' VAL . . . . . 0.641 HG12 ' HD3' ' A' ' 71' ' ' PRO . 0.8 OUTLIER -66.73 -35.58 9.84 Favored Pre-proline 0 CA--C 1.541 0.612 0 N-CA-C 112.602 0.593 . . . . 0.0 112.602 -179.424 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild full ' A' A ' 71' ' ' PRO . . . . . 0.641 ' HD3' HG12 ' A' ' 70' ' ' VAL . 9.5 Cg_exo -70.77 -22.39 27.51 Favored 'Trans proline' 0 C--N 1.36 1.138 0 C-N-CA 122.032 1.821 . . . . 0.0 112.815 -179.508 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 67.6 ttt180 -68.56 -55.63 11.0 Favored 'General case' 0 C--N 1.329 -0.323 0 N-CA-C 112.157 0.429 . . . . 0.0 112.157 -178.791 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 73' ' ' TYR . . . . . 0.509 ' O ' HG13 ' A' ' 77' ' ' ILE . 73.7 m-85 -73.53 -33.74 64.88 Favored 'General case' 0 C--N 1.328 -0.328 0 C-N-CA 120.863 -0.335 . . . . 0.0 110.892 -179.112 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 74' ' ' ILE . . . . . 0.53 HG22 ' HA ' ' A' ' 71' ' ' PRO . 0.3 OUTLIER -67.57 -41.27 85.59 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 N-CA-C 109.703 -0.48 . . . . 0.0 109.703 179.164 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild full ' A' A ' 75' ' ' ASP . . . . . 0.457 ' O ' HG23 ' A' ' 79' ' ' THR . 27.0 t70 -58.85 -37.54 76.7 Favored 'General case' 0 CA--C 1.519 -0.242 0 N-CA-C 109.241 -0.651 . . . . 0.0 109.241 178.703 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 76' ' ' TRP . . . . . 0.46 ' HB3' ' SD ' ' A' ' 109' ' ' MET . 48.6 m0 -66.12 -31.13 71.8 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 115.624 -0.717 . . . . 0.0 110.575 179.337 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 77' ' ' ILE . . . . . 0.509 HG13 ' O ' ' A' ' 73' ' ' TYR . 76.1 mt -69.41 -29.6 42.57 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.353 0 CA-C-O 121.036 0.446 . . . . 0.0 110.333 178.973 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 24.8 mt -91.45 -15.84 28.23 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 115.984 -0.553 . . . . 0.0 111.986 179.898 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 79' ' ' THR . . . . . 0.457 HG23 ' O ' ' A' ' 75' ' ' ASP . 73.6 p -101.84 -52.6 3.15 Favored 'General case' 0 N--CA 1.464 0.225 0 N-CA-C 113.06 0.763 . . . . 0.0 113.06 -178.613 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 80' ' ' THR . . . . . 0.694 ' HB ' ' HD3' ' A' ' 81' ' ' PRO . 62.8 m -51.26 -56.26 21.79 Favored Pre-proline 0 CA--C 1.533 0.291 0 N-CA-C 112.854 0.687 . . . . 0.0 112.854 -178.287 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 81' ' ' PRO . . . . . 0.694 ' HD3' ' HB ' ' A' ' 80' ' ' THR . 52.2 Cg_exo -57.43 -25.12 64.54 Favored 'Trans proline' 0 C--N 1.353 0.766 0 C-N-CA 121.517 1.478 . . . . 0.0 111.613 -179.945 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 82' ' ' LEU . . . . . 0.572 HD23 HG23 ' A' ' 43' ' ' ILE . 12.3 tp -77.14 -32.96 56.75 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 115.741 -0.663 . . . . 0.0 110.393 179.838 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 47.4 mm -67.56 -53.34 32.55 Favored 'Isoleucine or valine' 0 C--O 1.232 0.164 0 CA-C-N 116.377 -0.374 . . . . 0.0 110.227 179.17 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 24.6 m -60.73 -29.96 46.1 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.224 0 N-CA-C 108.897 -0.779 . . . . 0.0 108.897 178.411 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 85' ' ' TYR . . . . . . . . . . . . . 93.4 t80 -65.28 -30.29 71.14 Favored 'General case' 0 N--CA 1.453 -0.297 0 CA-C-N 115.395 -0.82 . . . . 0.0 109.248 178.371 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 86' ' ' PHE . . . . . . . . . . . . . 31.6 t80 -65.44 -51.95 56.62 Favored 'General case' 0 CA--C 1.519 -0.212 0 CA-C-N 115.811 -0.631 . . . . 0.0 109.623 178.988 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 87' ' ' LEU . . . . . 0.639 HD22 HD22 ' A' ' 141' ' ' LEU . 6.0 mp -63.22 -28.85 70.32 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 115.803 -0.635 . . . . 0.0 109.854 179.117 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -68.35 -27.98 73.49 Favored Glycine 0 N--CA 1.449 -0.478 0 C-N-CA 120.707 -0.759 . . . . 0.0 111.256 178.833 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 46.4 mt -76.19 -34.33 59.31 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-O 120.963 0.411 . . . . 0.0 110.282 179.012 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 88.9 mt -79.41 -23.69 43.06 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 115.937 -0.574 . . . . 0.0 110.984 179.681 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . 0.46 ' HA ' ' HB2' ' A' ' 149' ' ' ALA . . . -88.46 -45.46 9.93 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.249 -179.903 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 91.92 57.8 1.47 Allowed Glycine 0 N--CA 1.451 -0.364 0 C-N-CA 120.802 -0.713 . . . . 0.0 112.611 -179.833 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 93' ' ' LEU . . . . . 0.496 HD23 ' HB3' ' A' ' 97' ' ' GLU . 10.6 mp -74.07 176.94 6.06 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-O 120.758 0.313 . . . . 0.0 110.779 179.836 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 94' ' ' ASP . . . . . 0.557 ' H ' ' HB2' ' A' ' 97' ' ' GLU . 5.7 m-20 -99.23 -167.0 1.41 Allowed 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.095 -179.947 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 48.8 m -67.58 -49.63 62.25 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 115.903 -0.589 . . . . 0.0 111.509 -179.542 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 96' ' ' ARG . . . . . 0.424 ' O ' HG13 ' A' ' 100' ' ' ILE . 31.4 tpt180 -74.08 -39.77 63.21 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-O 120.904 0.383 . . . . 0.0 110.601 -179.457 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 97' ' ' GLU . . . . . 0.557 ' HB2' ' H ' ' A' ' 94' ' ' ASP . 0.3 OUTLIER -55.53 -47.19 76.7 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 115.824 -0.626 . . . . 0.0 111.391 -179.757 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild full ' A' A ' 98' ' ' PHE . . . . . 0.459 ' O ' HG12 ' A' ' 102' ' ' ILE . 3.3 m-85 -62.53 -41.53 98.92 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.487 -0.324 . . . . 0.0 110.879 179.675 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -65.47 -26.33 71.78 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.553 -0.832 . . . . 0.0 112.66 -179.777 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 100' ' ' ILE . . . . . 0.424 HG13 ' O ' ' A' ' 96' ' ' ARG . 96.5 mt -73.4 -48.82 40.41 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-O 120.688 0.28 . . . . 0.0 111.648 -179.663 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 17.0 m -64.82 -37.78 81.05 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.498 -0.319 . . . . 0.0 111.691 -179.649 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 102' ' ' ILE . . . . . 0.459 HG12 ' O ' ' A' ' 98' ' ' PHE . 49.5 mm -71.55 -49.48 46.34 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.452 -0.34 . . . . 0.0 111.41 -179.757 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 14.0 t -59.74 -30.94 69.18 Favored 'General case' 0 C--N 1.332 -0.164 0 CA-C-O 120.825 0.345 . . . . 0.0 110.938 -179.933 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 104' ' ' LEU . . . . . 0.458 ' O ' HG12 ' A' ' 107' ' ' VAL . 46.3 tp -65.49 -54.37 29.2 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.465 179.498 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 105' ' ' ASN . . . . . 0.634 ' N ' HD22 ' A' ' 105' ' ' ASN . 0.7 OUTLIER -56.91 -26.45 59.25 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 115.996 -0.547 . . . . 0.0 110.764 179.827 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild full ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 39.6 m -68.4 -56.76 7.38 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.13 -0.486 . . . . 0.0 111.38 -179.855 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 107' ' ' VAL . . . . . 0.458 HG12 ' O ' ' A' ' 104' ' ' LEU . 13.2 p -60.45 -36.66 70.98 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.16 0 CA-C-N 116.524 -0.307 . . . . 0.0 111.335 -179.779 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . 0.418 ' CG1' H182 ' A' ' 301' ' ' RET . 93.3 t -66.36 -50.24 69.31 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-O 120.957 0.408 . . . . 0.0 111.005 179.716 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 109' ' ' MET . . . . . 0.46 ' SD ' ' HB3' ' A' ' 76' ' ' TRP . 10.0 tpp -59.95 -36.33 76.86 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 115.954 -0.566 . . . . 0.0 110.62 179.948 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 23.1 tp -65.19 -34.27 77.98 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.037 -0.528 . . . . 0.0 110.291 179.607 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -60.01 -51.28 70.32 Favored 'General case' 0 C--N 1.331 -0.218 0 CA-C-N 116.041 -0.527 . . . . 0.0 110.339 179.263 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 112' ' ' GLY . . . . . 0.628 ' HA3' ' H21' ' A' ' 301' ' ' RET . . . -62.21 -39.27 97.47 Favored Glycine 0 C--N 1.331 0.269 0 C-N-CA 120.604 -0.808 . . . . 0.0 111.911 179.245 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 113' ' ' PHE . . . . . . . . . . . . . 2.2 t80 -47.43 -68.22 0.21 Allowed 'General case' 0 C--N 1.332 -0.196 0 CA-C-O 121.063 0.459 . . . . 0.0 110.203 179.318 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -65.12 -21.66 66.83 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 115.512 -0.767 . . . . 0.0 110.856 179.453 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -53.58 -45.03 68.3 Favored Glycine 0 C--N 1.334 0.423 0 C-N-CA 121.068 -0.587 . . . . 0.0 112.496 179.992 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -77.88 -23.59 48.73 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.721 0.295 . . . . 0.0 111.55 179.744 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 117' ' ' MET . . . . . . . . . . . . . 65.3 mtt -96.0 19.15 12.01 Favored 'General case' 0 C--N 1.331 -0.2 0 CA-C-N 116.29 -0.414 . . . . 0.0 111.613 -179.473 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 118' ' ' VAL . . . . . 0.494 HG11 ' N ' ' A' ' 123' ' ' ARG . 19.3 m -68.34 142.61 94.79 Favored Pre-proline 0 C--N 1.328 -0.338 0 CA-C-N 116.71 -0.223 . . . . 0.0 111.586 -179.902 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 119' ' ' PRO . . . . . . . . . . . . . 98.4 Cg_endo -88.0 6.09 5.11 Favored 'Trans proline' 0 N--CA 1.459 -0.513 0 C-N-CA 122.761 2.307 . . . . 0.0 112.524 179.593 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -166.09 -115.15 0.31 Allowed Glycine 0 C--N 1.332 0.327 0 C-N-CA 120.697 -0.763 . . . . 0.0 112.803 -179.814 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 43.5 pt -111.4 12.68 8.58 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.216 0 CA-C-O 120.698 0.285 . . . . 0.0 111.43 -179.634 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 11.2 mm-40 -58.83 -18.88 36.43 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.37 -0.377 . . . . 0.0 110.991 -179.993 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 123' ' ' ARG . . . . . 0.494 ' N ' HG11 ' A' ' 118' ' ' VAL . 17.5 ptt180 -53.32 -30.01 36.76 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.017 -0.538 . . . . 0.0 111.484 -179.964 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 124' ' ' TYR . . . . . . . . . . . . . 29.7 m-85 -76.5 -32.45 58.32 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.352 -0.385 . . . . 0.0 110.927 179.924 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 125' ' ' ALA . . . . . . . . . . . . . . . -72.38 -56.1 6.0 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.067 179.924 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 1.5 mt -56.13 -54.08 49.43 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 115.888 -0.596 . . . . 0.0 110.829 -179.89 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 127' ' ' PHE . . . . . 0.403 ' CE1' ' H42' ' A' ' 301' ' ' RET . 11.0 t80 -64.86 -35.9 82.63 Favored 'General case' 0 N--CA 1.453 -0.306 0 C-N-CA 120.738 -0.385 . . . . 0.0 110.694 179.623 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 128' ' ' GLY . . . . . . . . . . . . . . . -47.53 -44.16 21.93 Favored Glycine 0 C--N 1.332 0.337 0 C-N-CA 120.054 -1.069 . . . . 0.0 110.825 179.111 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 129' ' ' MET . . . . . . . . . . . . . 0.2 OUTLIER -71.77 -37.24 70.5 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.991 0.424 . . . . 0.0 109.99 178.78 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -67.69 -27.59 73.59 Favored Glycine 0 N--CA 1.452 -0.29 0 CA-C-N 115.653 -0.703 . . . . 0.0 112.761 -179.852 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -75.04 -53.85 8.18 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-O 120.696 0.284 . . . . 0.0 110.48 179.944 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 45.4 t -58.54 -40.09 77.65 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.206 0 N-CA-C 109.064 -0.717 . . . . 0.0 109.064 178.546 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -69.09 -35.0 76.01 Favored 'General case' 0 N--CA 1.451 -0.389 0 CA-C-N 115.133 -0.939 . . . . 0.0 110.445 179.174 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 134' ' ' PHE . . . . . 0.442 ' CZ ' ' HA ' ' A' ' 172' ' ' ALA . 76.2 t80 -57.51 -55.27 36.95 Favored 'General case' 0 N--CA 1.451 -0.376 0 N-CA-C 109.763 -0.458 . . . . 0.0 109.763 179.492 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 135' ' ' ILE . . . . . 0.458 ' HA ' HG22 ' A' ' 138' ' ' VAL . 34.7 mt -57.25 -31.5 38.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 115.687 -0.688 . . . . 0.0 109.642 178.888 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . -65.77 -36.11 91.82 Favored Glycine 0 N--CA 1.446 -0.669 0 C-N-CA 120.386 -0.911 . . . . 0.0 111.017 178.537 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 137' ' ' LEU . . . . . 0.454 HD13 HD21 ' A' ' 105' ' ' ASN . 39.1 tp -71.47 -53.23 14.64 Favored 'General case' 0 N--CA 1.454 -0.25 0 N-CA-C 110.355 -0.239 . . . . 0.0 110.355 179.321 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 138' ' ' VAL . . . . . 0.458 HG22 ' HA ' ' A' ' 135' ' ' ILE . 5.0 m -56.36 -31.86 34.12 Favored 'Isoleucine or valine' 0 C--O 1.233 0.194 0 N-CA-C 109.08 -0.711 . . . . 0.0 109.08 178.929 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 139' ' ' TYR . . . . . . . . . . . . . 39.0 t80 -61.41 -45.82 92.74 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 115.367 -0.833 . . . . 0.0 110.127 178.54 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 140' ' ' TYR . . . . . 0.445 ' HE2' HD22 ' A' ' 104' ' ' LEU . 27.4 m-85 -60.95 -37.67 83.2 Favored 'General case' 0 C--N 1.332 -0.157 0 CA-C-N 116.29 -0.414 . . . . 0.0 110.724 179.543 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 141' ' ' LEU . . . . . 0.639 HD22 HD22 ' A' ' 87' ' ' LEU . 83.5 mt -61.92 -35.0 77.1 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.615 179.916 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 17.1 t -96.25 -4.75 10.08 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.071 -0.513 . . . . 0.0 110.546 179.581 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . -74.12 -134.36 0.29 Allowed Glycine 0 CA--C 1.52 0.398 0 C-N-CA 121.129 -0.558 . . . . 0.0 112.885 -179.809 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 144' ' ' PRO . . . . . . . . . . . . . 34.1 Cg_exo -59.91 -23.96 74.5 Favored 'Trans proline' 0 C--N 1.349 0.578 0 C-N-CA 122.752 2.301 . . . . 0.0 112.839 -179.536 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 145' ' ' MET . . . . . . . . . . . . . 59.1 mtt -53.66 -28.69 34.66 Favored 'General case' 0 C--N 1.332 -0.179 0 CA-C-N 116.34 -0.391 . . . . 0.0 111.417 -179.854 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 146' ' ' THR . . . . . . . . . . . . . 74.9 p -70.34 -50.43 39.12 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.233 -0.44 . . . . 0.0 112.063 -179.219 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 47.4 mt-10 -73.62 -24.13 59.99 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.546 -0.297 . . . . 0.0 111.797 -179.025 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 148' ' ' SER . . . . . . . . . . . . . 81.4 p -70.78 -49.14 49.76 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 116.444 -0.343 . . . . 0.0 111.645 -179.281 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 149' ' ' ALA . . . . . 0.46 ' HB2' ' HA ' ' A' ' 91' ' ' ALA . . . -77.98 -38.83 44.21 Favored 'General case' 0 C--N 1.329 -0.319 0 N-CA-C 112.237 0.458 . . . . 0.0 112.237 -179.026 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 150' ' ' SER . . . . . . . . . . . . . 68.4 m -60.92 -8.13 2.92 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.537 -0.302 . . . . 0.0 111.705 -179.382 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 151' ' ' GLN . . . . . . . . . . . . . 78.2 mt-30 -119.02 25.19 10.36 Favored 'General case' 0 C--N 1.329 -0.296 0 N-CA-C 111.588 0.218 . . . . 0.0 111.588 -179.812 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 49.6 mtp180 -103.25 -52.24 3.07 Favored 'General case' 0 C--N 1.331 -0.197 0 CA-C-O 120.868 0.366 . . . . 0.0 111.153 179.717 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 153' ' ' SER . . . . . 0.605 ' HB3' HG12 ' A' ' 156' ' ' ILE . 32.8 t -157.02 169.16 25.44 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-N 115.981 -0.554 . . . . 0.0 110.854 179.407 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 154' ' ' SER . . . . . . . . . . . . . 37.0 t -70.39 -35.75 73.68 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.659 179.784 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -76.71 -31.47 53.71 Favored Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.883 -0.675 . . . . 0.0 112.503 179.827 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 156' ' ' ILE . . . . . 0.605 HG12 ' HB3' ' A' ' 153' ' ' SER . 36.2 mm -61.72 -37.63 78.48 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.234 0 CA-C-O 120.651 0.262 . . . . 0.0 111.1 -179.97 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 157' ' ' LYS . . . . . . . . . . . . . 57.8 tptt -60.73 -55.49 32.59 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 116.306 -0.407 . . . . 0.0 111.871 -179.445 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 62.2 m -60.61 -45.35 94.35 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.323 -0.398 . . . . 0.0 111.885 -179.125 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 159' ' ' LEU . . . . . . . . . . . . . 8.3 tt -68.35 -32.6 72.81 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-N 116.336 -0.393 . . . . 0.0 111.499 -179.198 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 160' ' ' TYR . . . . . . . . . . . . . 79.9 t80 -73.53 -45.62 52.61 Favored 'General case' 0 C--N 1.33 -0.261 0 N-CA-C 111.858 0.318 . . . . 0.0 111.858 -179.148 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 30.0 m -62.81 -40.85 90.28 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.363 0 N-CA-C 111.772 0.286 . . . . 0.0 111.772 -179.292 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 162' ' ' ARG . . . . . 0.405 ' HG2' HG21 ' A' ' 211' ' ' ILE . 29.1 tpt180 -69.35 -45.68 68.83 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.772 0.32 . . . . 0.0 111.388 -179.632 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 163' ' ' LEU . . . . . 0.588 ' HG ' ' HB2' ' A' ' 208' ' ' PHE . 4.3 mp -69.62 -52.5 25.43 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.806 -179.294 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 164' ' ' ARG . . . . . . . . . . . . . 4.6 tmm_? -53.88 -54.01 44.6 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.393 -0.367 . . . . 0.0 111.338 -179.163 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 165' ' ' ASN . . . . . 0.53 HD22 ' N ' ' A' ' 165' ' ' ASN . 0.9 OUTLIER -56.67 -43.78 80.74 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.937 0.398 . . . . 0.0 110.441 179.715 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild full ' A' A ' 166' ' ' LEU . . . . . 0.552 ' O ' ' HG ' ' A' ' 170' ' ' LEU . 5.6 tp -57.84 -54.53 45.92 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 115.858 -0.61 . . . . 0.0 111.067 -179.938 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 167' ' ' THR . . . . . 0.641 ' HA ' HD11 ' A' ' 170' ' ' LEU . 89.0 m -54.07 -52.25 61.52 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 115.966 -0.561 . . . . 0.0 112.21 -178.925 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 168' ' ' VAL . . . . . . . . . . . . . 94.5 t -53.92 -40.14 43.46 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.366 0 N-CA-C 112.141 0.423 . . . . 0.0 112.141 -179.172 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 169' ' ' VAL . . . . . 0.41 HG23 ' O ' ' A' ' 165' ' ' ASN . 75.2 t -65.82 -65.57 0.56 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.326 0 N-CA-C 112.346 0.498 . . . . 0.0 112.346 -178.959 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 170' ' ' LEU . . . . . 0.718 HD22 HG13 ' A' ' 203' ' ' VAL . 1.0 OUTLIER -61.66 -28.78 69.63 Favored 'General case' 0 C--N 1.33 -0.25 0 N-CA-C 112.544 0.572 . . . . 0.0 112.544 -178.428 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild full ' A' A ' 171' ' ' TRP . . . . . 0.766 ' HE1' H203 ' A' ' 301' ' ' RET . 4.8 m0 -74.1 -30.77 62.5 Favored 'General case' 0 C--N 1.33 -0.277 0 C-N-CA 120.538 -0.465 . . . . 0.0 110.842 179.801 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 172' ' ' ALA . . . . . 0.442 ' HA ' ' CZ ' ' A' ' 134' ' ' PHE . . . -66.51 -7.87 22.75 Favored 'General case' 0 CA--C 1.516 -0.344 0 CA-C-O 121.273 0.559 . . . . 0.0 110.026 179.163 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 173' ' ' ILE . . . . . 0.718 HG22 ' CG1' ' A' ' 177' ' ' ILE . 6.6 mm -87.19 -35.81 9.02 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.624 0 CA-C-N 115.123 -0.944 . . . . 0.0 111.47 -178.966 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 174' ' ' TYR . . . . . 0.531 ' N ' ' HD2' ' A' ' 175' ' ' PRO . 55.5 m-85 -54.95 -52.09 73.86 Favored Pre-proline 0 C--N 1.329 -0.323 0 N-CA-C 112.75 0.648 . . . . 0.0 112.75 -178.91 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 175' ' ' PRO . . . . . 0.531 ' HD2' ' N ' ' A' ' 174' ' ' TYR . 28.4 Cg_endo -61.99 -39.57 49.52 Favored 'Trans proline' 0 C--N 1.348 0.539 0 C-N-CA 121.963 1.775 . . . . 0.0 113.419 -178.351 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 176' ' ' PHE . . . . . 0.519 ' CE2' ' HA ' ' A' ' 173' ' ' ILE . 0.1 OUTLIER -79.99 -38.15 32.76 Favored 'General case' 0 C--N 1.329 -0.304 0 C-N-CA 120.688 -0.405 . . . . 0.0 111.904 -178.786 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild full ' A' A ' 177' ' ' ILE . . . . . 0.718 ' CG1' HG22 ' A' ' 173' ' ' ILE . 31.7 mm -62.42 -43.58 98.36 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.477 0 N-CA-C 109.723 -0.473 . . . . 0.0 109.723 178.285 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 178' ' ' TRP . . . . . . . . . . . . . 70.3 t90 -60.87 -27.68 68.31 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 115.687 -0.688 . . . . 0.0 109.418 178.789 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 179' ' ' LEU . . . . . 0.422 HD13 ' O ' ' A' ' 179' ' ' LEU . 1.4 tm? -74.04 -45.8 47.32 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 115.187 -0.915 . . . . 0.0 110.764 -179.963 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 180' ' ' LEU . . . . . 0.478 ' HG ' ' O ' ' A' ' 176' ' ' PHE . 4.8 mt -71.33 -49.34 43.54 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.615 -0.266 . . . . 0.0 111.394 -179.372 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . -52.61 174.81 0.2 Allowed Glycine 0 C--N 1.334 0.43 0 C-N-CA 120.659 -0.781 . . . . 0.0 112.937 -179.954 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 182' ' ' PRO . . . . . 0.613 ' HA ' ' HB2' ' A' ' 186' ' ' ALA . 76.4 Cg_exo -46.93 -45.35 21.01 Favored 'Trans proline' 0 CA--C 1.536 0.602 0 C-N-CA 122.853 2.368 . . . . 0.0 113.796 -179.874 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 183' ' ' PRO . . . . . 0.431 ' HD3' ' HB2' ' A' ' 182' ' ' PRO . 79.5 Cg_exo -49.27 -23.48 6.98 Favored 'Trans proline' 0 C--N 1.355 0.908 0 C-N-CA 122.24 1.96 . . . . 0.0 113.194 -179.787 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 184' ' ' GLY . . . . . . . . . . . . . . . -108.74 -99.06 2.58 Favored Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.466 -0.873 . . . . 0.0 113.069 -179.57 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 185' ' ' VAL . . . . . . . . . . . . . 3.5 m -109.07 -5.49 10.89 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 N-CA-C 111.726 0.269 . . . . 0.0 111.726 -179.231 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 186' ' ' ALA . . . . . 0.613 ' HB2' ' HA ' ' A' ' 182' ' ' PRO . . . 55.14 87.28 0.05 OUTLIER 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.366 -0.379 . . . . 0.0 111.629 179.542 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 187' ' ' LEU . . . . . 0.454 HD12 ' HB3' ' A' ' 180' ' ' LEU . 23.5 mt -91.81 -48.97 6.5 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.332 -0.394 . . . . 0.0 110.779 179.637 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 188' ' ' LEU . . . . . . . . . . . . . 55.6 mt -106.9 -154.14 0.51 Allowed 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 115.835 -0.621 . . . . 0.0 110.642 -179.905 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 189' ' ' THR . . . . . . . . . . . . . 2.6 t -97.52 146.16 30.92 Favored Pre-proline 0 C--N 1.329 -0.315 0 CA-C-N 116.406 -0.361 . . . . 0.0 110.918 179.905 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 190' ' ' PRO . . . . . 0.403 ' O ' HG23 ' A' ' 194' ' ' VAL . 9.6 Cg_endo -50.14 -38.46 50.58 Favored 'Trans proline' 0 C--N 1.349 0.597 0 C-N-CA 122.862 2.374 . . . . 0.0 112.769 -179.594 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 191' ' ' THR . . . . . . . . . . . . . 81.6 p -58.25 -44.34 88.27 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.911 0.386 . . . . 0.0 111.249 -179.842 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 192' ' ' VAL . . . . . . . . . . . . . 35.1 t -71.85 -43.13 69.41 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.391 0 CA-C-N 116.03 -0.532 . . . . 0.0 111.401 -179.708 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 193' ' ' ASP . . . . . . . . . . . . . 21.1 t70 -56.55 -49.01 76.07 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.403 -0.362 . . . . 0.0 111.186 -179.783 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 194' ' ' VAL . . . . . 0.501 ' O ' HG23 ' A' ' 198' ' ' VAL . 78.2 t -64.42 -38.15 81.82 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.372 0 CA-C-N 116.262 -0.426 . . . . 0.0 111.198 -179.723 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 195' ' ' ALA . . . . . . . . . . . . . . . -54.15 -48.59 70.69 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 116.518 -0.31 . . . . 0.0 111.482 -179.802 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 196' ' ' LEU . . . . . 0.455 ' O ' ' HB3' ' A' ' 199' ' ' TYR . 94.3 mt -65.65 -39.96 91.97 Favored 'General case' 0 C--N 1.332 -0.166 0 CA-C-O 120.777 0.322 . . . . 0.0 110.814 179.884 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 197' ' ' ILE . . . . . 0.423 HD13 HD12 ' A' ' 200' ' ' LEU . 24.7 mm -58.73 -53.42 47.52 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.37 0 CA-C-O 121.017 0.437 . . . . 0.0 110.198 179.307 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 198' ' ' VAL . . . . . 0.501 HG23 ' O ' ' A' ' 194' ' ' VAL . 87.6 t -55.07 -34.64 32.57 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.459 0 CA-C-N 115.582 -0.736 . . . . 0.0 109.04 178.215 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 199' ' ' TYR . . . . . 0.455 ' HB3' ' O ' ' A' ' 196' ' ' LEU . 79.7 t80 -69.73 -32.58 71.2 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 114.98 -1.009 . . . . 0.0 110.643 179.635 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 200' ' ' LEU . . . . . 0.423 HD12 HD13 ' A' ' 197' ' ' ILE . 68.2 mt -69.17 -41.04 77.74 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 115.756 -0.656 . . . . 0.0 111.697 -179.373 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 201' ' ' ASP . . . . . . . . . . . . . 9.5 m-20 -71.39 -36.31 71.34 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 121.162 0.506 . . . . 0.0 110.451 179.529 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 202' ' ' LEU . . . . . 0.41 ' O ' ' HB ' ' A' ' 206' ' ' VAL . 1.2 mm? -65.99 -33.64 76.27 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 115.462 -0.79 . . . . 0.0 111.918 -179.731 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 203' ' ' VAL . . . . . 0.718 HG13 HD22 ' A' ' 170' ' ' LEU . 9.0 p -79.07 -36.3 18.31 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 N-CA-C 111.885 0.328 . . . . 0.0 111.885 -178.241 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 204' ' ' THR . . . . . 0.429 ' OG1' HD13 ' A' ' 170' ' ' LEU . 94.1 m -64.77 -58.93 4.91 Favored 'General case' 0 C--N 1.328 -0.343 0 C-N-CA 120.082 -0.647 . . . . 0.0 111.101 179.642 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 205' ' ' LYS . . . . . 0.647 ' HE2' ' HB2' ' A' ' 47' ' ' ALA . 60.1 mttp -68.35 -57.83 5.31 Favored 'General case' 0 C--N 1.33 -0.281 0 N-CA-C 112.774 0.657 . . . . 0.0 112.774 -178.028 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 206' ' ' VAL . . . . . 0.41 ' HB ' ' O ' ' A' ' 202' ' ' LEU . 19.3 t -71.16 -37.17 65.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 N-CA-C 112.02 0.378 . . . . 0.0 112.02 -178.654 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 207' ' ' GLY . . . . . 0.511 ' O ' HG13 ' A' ' 211' ' ' ILE . . . -61.75 -61.1 7.12 Favored Glycine 0 N--CA 1.452 -0.263 0 C-N-CA 120.577 -0.821 . . . . 0.0 113.72 -178.997 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 208' ' ' PHE . . . . . 0.588 ' HB2' ' HG ' ' A' ' 163' ' ' LEU . 0.1 OUTLIER -68.84 -29.95 68.38 Favored 'General case' 0 C--O 1.222 -0.362 0 CA-C-N 117.799 0.799 . . . . 0.0 110.8 -179.292 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild full ' A' A ' 209' ' ' GLY . . . . . 0.589 ' HA2' HD11 ' A' ' 40' ' ' LEU . . . -62.07 -35.66 91.78 Favored Glycine 0 N--CA 1.45 -0.368 0 CA-C-N 116.189 -0.46 . . . . 0.0 112.418 179.4 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 210' ' ' PHE . . . . . . . . . . . . . 3.3 m-85 -72.68 -47.38 47.79 Favored 'General case' 0 CA--C 1.513 -0.461 0 N-CA-C 108.513 -0.921 . . . . 0.0 108.513 178.81 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 211' ' ' ILE . . . . . 0.511 HG13 ' O ' ' A' ' 207' ' ' GLY . 3.7 mt -62.8 -27.32 42.8 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.58 0 N-CA-C 107.192 -1.41 . . . . 0.0 107.192 176.468 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 212' ' ' ALA . . . . . 0.531 ' HB3' ' O ' ' A' ' 209' ' ' GLY . . . -67.43 -36.55 81.44 Favored 'General case' 0 N--CA 1.45 -0.468 0 CA-C-N 114.308 -1.314 . . . . 0.0 110.171 179.56 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 213' ' ' LEU . . . . . 0.437 ' HG ' ' O ' ' A' ' 209' ' ' GLY . 81.3 mt -70.17 -53.38 17.45 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 115.012 -0.994 . . . . 0.0 111.594 -179.649 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 214' ' ' ASP . . . . . . . . . . . . . 16.5 m-20 -57.44 -51.54 69.02 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.827 0.346 . . . . 0.0 111.227 -179.592 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 215' ' ' ALA . . . . . 0.448 ' O ' ' HG ' ' A' ' 219' ' ' LEU . . . -56.63 -57.25 13.19 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.226 -179.762 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 216' ' ' ALA . . . . . . . . . . . . . . . -58.4 -33.81 70.06 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.275 -0.421 . . . . 0.0 111.387 -179.741 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 217' ' ' ALA . . . . . . . . . . . . . . . -61.04 -34.68 75.25 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 121.029 0.442 . . . . 0.0 110.137 179.635 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 218' ' ' THR . . . . . . . . . . . . . 91.5 m -80.2 -34.24 37.54 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 115.716 -0.675 . . . . 0.0 110.821 179.48 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 219' ' ' LEU . . . . . 0.448 ' HG ' ' O ' ' A' ' 215' ' ' ALA . 83.6 mt -61.03 -39.01 88.16 Favored 'General case' 0 C--N 1.331 -0.202 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.721 179.845 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 220' ' ' ARG . . . . . . . . . . . . . 29.8 ptt180 -82.91 -31.12 27.96 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 116.066 -0.516 . . . . 0.0 110.639 179.875 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 221' ' ' ALA . . . . . . . . . . . . . . . -60.41 -33.06 71.95 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 116.062 -0.517 . . . . 0.0 111.279 179.936 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 222' ' ' GLU . . . . . . . . . . . . . 12.4 pt-20 -92.47 -18.49 23.14 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.057 179.955 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 223' ' ' HIS . . . . . . . . . . . . . 63.2 m-70 60.59 -179.04 0.1 Allowed 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 115.462 -0.79 . . . . 0.0 111.234 179.972 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 224' ' ' GLY . . . . . . . . . . . . . . . -176.86 -32.96 0.05 OUTLIER Glycine 0 N--CA 1.452 -0.28 0 C-N-CA 120.941 -0.647 . . . . 0.0 112.196 179.993 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 225' ' ' GLU . . . . . . . . . . . . . 12.9 pt-20 -87.82 144.67 26.48 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.783 0.325 . . . . 0.0 110.592 179.771 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 226' ' ' SER . . . . . . . . . . . . . 60.9 m -109.59 -178.71 3.62 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.287 -0.415 . . . . 0.0 111.025 -179.884 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 227' ' ' LEU . . . . . . . . . . . . . 50.3 mt -70.34 -56.44 6.71 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 115.932 -0.577 . . . . 0.0 110.898 -179.895 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 228' ' ' ALA . . . . . . . . . . . . . . . 51.92 -165.65 0.06 Allowed 'General case' 0 C--N 1.331 -0.213 0 CA-C-N 115.97 -0.559 . . . . 0.0 111.608 -179.981 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 229' ' ' GLY . . . . . . . . . . . . . . . -169.31 -54.14 0.03 OUTLIER Glycine 0 N--CA 1.452 -0.284 0 C-N-CA 120.813 -0.708 . . . . 0.0 112.386 179.994 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 230' ' ' VAL . . . . . . . . . . . . . 59.2 t -110.35 132.9 57.43 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.25 0 CA-C-O 120.828 0.347 . . . . 0.0 111.003 179.881 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 231' ' ' ASP . . . . . . . . . . . . . 18.6 t70 -100.29 120.82 40.52 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.884 -179.942 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 232' ' ' THR . . . . . . . . . . . . . 5.6 t -133.74 3.53 3.53 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.13 -0.486 . . . . 0.0 111.137 179.952 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 233' ' ' ASP . . . . . . . . . . . . . 10.9 m-20 -75.42 -178.08 3.87 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.117 -0.492 . . . . 0.0 111.007 -179.933 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 234' ' ' THR . . . . . . . . . . . . . 72.6 m -116.16 93.49 39.12 Favored Pre-proline 0 C--N 1.33 -0.269 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.029 -179.92 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 235' ' ' PRO . . . . . . . . . . . . . 38.1 Cg_endo -67.22 -54.1 0.42 Allowed 'Trans proline' 0 C--N 1.348 0.531 0 C-N-CA 122.413 2.076 . . . . 0.0 112.267 179.824 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 236' ' ' ALA . . . . . . . . . . . . . . . -122.06 131.13 53.82 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.928 179.917 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 237' ' ' VAL . . . . . . . . . . . . . 27.5 m -60.89 162.86 1.21 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.242 0 CA-C-N 116.082 -0.508 . . . . 0.0 111.198 -179.941 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 238' ' ' ALA . . . . . . . . . . . . . . . -126.99 -64.03 1.03 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.048 -0.524 . . . . 0.0 111.083 -179.985 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 239' ' ' ASP . . . . . . . . . . . . . 7.8 m-20 -95.01 118.97 32.73 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.11 -0.495 . . . . 0.0 110.94 -179.929 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 240' ' ' LEU . . . . . . . . . . . . . 62.0 tp -106.73 -46.32 4.0 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.903 179.914 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 241' ' ' GLU . . . . . . . . . . . . . 1.3 mp0 -66.82 -10.23 45.73 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 116.304 -0.407 . . . . 0.0 110.898 179.941 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 242' ' ' HIS . . . . . . . . . . . . . 18.1 t60 -131.43 102.23 5.86 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.502 179.964 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 243' ' ' HIS . . . . . . . . . . . . . 50.7 t-80 -88.59 -67.2 0.85 Allowed 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.116 -179.83 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 244' ' ' HIS . . . . . . . . . . . . . 66.5 m-70 -58.72 96.63 0.03 OUTLIER 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.947 -179.857 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 245' ' ' HIS . . . . . . . . . . . . . 2.6 p-80 -122.88 -168.83 1.82 Allowed 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.942 -179.966 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 246' ' ' HIS . . . . . . . . . . . . . 57.3 t-80 -160.53 -51.04 0.05 OUTLIER 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.729 179.836 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 247' ' ' HIS . . . . . . . . . . . . . 34.1 t-80 . . . . . 0 C--O 1.249 1.072 0 CA-C-O 118.369 -0.824 . . . . 0.0 110.839 179.909 . . . . . . . . 0 0 . 1 . 021 nuclear nobuild full ' A' A ' 301' ' ' RET . . . . . 0.766 H203 ' HE1' ' A' ' 171' ' ' TRP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . 0.472 ' N ' HG23 ' A' ' 5' ' ' THR . 49.5 mtm . . . . . 0 N--CA 1.486 1.329 0 CA-C-O 120.831 0.348 . . . . 0.0 110.885 . . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 60.4 t -142.85 -50.43 0.19 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.222 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.921 -179.906 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -111.53 -16.38 9.49 Favored Glycine 0 N--CA 1.452 -0.261 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.719 -179.798 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -73.74 -40.67 63.35 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.858 0.361 . . . . 0.0 110.772 -179.929 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 5' ' ' THR . . . . . 0.472 HG23 ' N ' ' A' ' 1' ' ' MET . 76.4 p -60.52 -29.49 69.15 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.329 -179.842 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 13.6 p -57.38 -36.13 70.87 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.502 -179.715 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 7' ' ' LEU . . . . . . . . . . . . . 4.1 mm? -57.56 -53.16 61.29 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-N 116.328 -0.396 . . . . 0.0 111.165 -179.839 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 8' ' ' PHE . . . . . 0.516 ' HB2' ' HB2' ' A' ' 55' ' ' ALA . 78.9 m-85 -60.91 -33.48 73.2 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 120.866 0.365 . . . . 0.0 110.752 179.901 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 9' ' ' TRP . . . . . . . . . . . . . 18.9 m95 -63.78 -45.34 90.16 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-O 121.245 0.545 . . . . 0.0 109.678 179.82 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 72.3 mt -63.45 -34.34 77.55 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-N 115.383 -0.826 . . . . 0.0 110.12 179.302 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -66.29 -37.02 92.5 Favored Glycine 0 N--CA 1.449 -0.46 0 C-N-CA 120.77 -0.728 . . . . 0.0 111.596 179.179 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -66.74 -33.18 75.06 Favored 'General case' 0 C--N 1.332 -0.17 0 CA-C-O 120.961 0.41 . . . . 0.0 110.303 179.337 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 45.0 mm -65.19 -50.79 71.99 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.212 0 CA-C-N 115.904 -0.589 . . . . 0.0 110.235 179.099 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -59.35 -31.42 69.88 Favored Glycine 0 N--CA 1.449 -0.466 0 C-N-CA 120.773 -0.727 . . . . 0.0 111.836 179.394 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 15' ' ' MET . . . . . 0.45 ' HB3' ' HB2' ' A' ' 48' ' ' ALA . 22.0 mmt -70.87 -45.61 64.11 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-O 120.686 0.279 . . . . 0.0 110.583 179.586 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 21.8 tp -54.66 -38.31 66.78 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.668 179.59 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 64.2 t -67.06 -47.54 81.76 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.191 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.03 179.927 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -64.65 -49.45 64.22 Favored Glycine 0 C--N 1.331 0.281 0 C-N-CA 120.684 -0.77 . . . . 0.0 112.17 179.679 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 22.2 m -49.56 -46.22 48.55 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-O 120.72 0.295 . . . . 0.0 111.12 -179.807 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 85.6 mt -72.22 -40.01 68.11 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-N 116.359 -0.382 . . . . 0.0 111.403 179.646 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -61.28 -30.17 70.31 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.454 -0.339 . . . . 0.0 111.817 -179.484 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 22' ' ' PHE . . . . . 0.692 ' HB2' HG22 ' A' ' 41' ' ' VAL . 13.7 m-85 -90.74 -40.43 11.84 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.735 0.302 . . . . 0.0 111.149 -179.622 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -62.75 -50.71 69.97 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.343 -179.732 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 24' ' ' TRP . . . . . . . . . . . . . 2.2 t-105 -60.96 -41.7 96.84 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 115.968 -0.56 . . . . 0.0 111.042 -179.945 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -77.72 -14.29 59.65 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.877 0.37 . . . . 0.0 110.946 179.752 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -73.53 -47.95 19.79 Favored Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.923 -0.656 . . . . 0.0 112.606 179.892 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 15.8 ptm180 -65.42 -29.95 70.7 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-O 120.889 0.376 . . . . 0.0 110.894 179.991 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 26.4 t70 -78.28 -12.52 60.01 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.059 -0.518 . . . . 0.0 110.944 179.931 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -69.8 -174.68 0.78 Allowed 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.125 179.879 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -101.25 -155.14 26.74 Favored Glycine 0 N--CA 1.452 -0.274 0 C-N-CA 120.797 -0.716 . . . . 0.0 112.451 179.931 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 78.0 p -97.18 127.42 43.13 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.808 0.337 . . . . 0.0 110.884 -179.995 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 110.96 -50.3 0.78 Allowed Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.826 -0.702 . . . . 0.0 112.593 179.969 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 12.7 mm-40 -69.34 -20.88 63.86 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-O 120.86 0.362 . . . . 0.0 110.917 179.95 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 34' ' ' ARG . . . . . . . . . . . . . 41.5 ttm180 -51.02 -29.01 11.38 Favored 'General case' 0 C--N 1.332 -0.185 0 CA-C-N 115.958 -0.564 . . . . 0.0 111.539 -179.772 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 86.4 mtm180 -61.99 -45.89 91.65 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.899 0.38 . . . . 0.0 110.917 -179.969 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 88.0 m-85 -67.55 -29.26 68.59 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.044 -0.526 . . . . 0.0 111.224 179.961 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 37' ' ' TYR . . . . . 0.528 ' O ' HG23 ' A' ' 41' ' ' VAL . 51.7 m-85 -74.6 -54.11 8.08 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.255 -179.577 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 9.4 p -56.99 -36.6 51.18 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-O 120.949 0.405 . . . . 0.0 110.474 179.794 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 48.3 m -65.66 -51.37 60.04 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 115.901 -0.59 . . . . 0.0 110.608 179.493 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 40' ' ' LEU . . . . . 0.453 HD13 ' CE1' ' A' ' 208' ' ' PHE . 16.6 tp -57.05 -47.24 81.43 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 115.832 -0.622 . . . . 0.0 110.624 179.702 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . 0.692 HG22 ' HB2' ' A' ' 22' ' ' PHE . 64.8 t -60.0 -34.74 57.45 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.41 0 CA-C-N 115.836 -0.62 . . . . 0.0 110.11 179.183 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -60.31 -36.2 90.3 Favored Glycine 0 N--CA 1.449 -0.448 0 C-N-CA 120.682 -0.77 . . . . 0.0 111.817 179.494 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 43' ' ' ILE . . . . . 0.675 HG22 ' HE3' ' A' ' 205' ' ' LYS . 0.8 OUTLIER -67.31 -57.27 10.38 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.139 0 CA-C-O 120.65 0.262 . . . . 0.0 110.817 179.44 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 55.6 m -57.11 -25.0 58.07 Favored 'General case' 0 C--O 1.231 0.113 0 CA-C-N 116.42 -0.354 . . . . 0.0 111.188 -179.945 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -77.33 -54.71 4.59 Favored Glycine 0 CA--C 1.518 0.267 0 C-N-CA 120.793 -0.718 . . . . 0.0 113.162 -179.504 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 46' ' ' ILE . . . . . 0.41 ' O ' HG22 ' A' ' 49' ' ' VAL . 25.8 pt -58.06 -40.89 78.92 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.185 0 CA-C-O 120.93 0.395 . . . . 0.0 111.01 -179.647 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 47' ' ' ALA . . . . . 0.66 ' HB2' ' HE2' ' A' ' 205' ' ' LYS . . . -67.92 -38.62 83.13 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.004 179.205 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 48' ' ' ALA . . . . . 0.45 ' HB2' ' HB3' ' A' ' 15' ' ' MET . . . -55.41 -44.56 76.29 Favored 'General case' 0 C--O 1.232 0.152 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.733 -179.708 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 49' ' ' VAL . . . . . 0.41 HG22 ' O ' ' A' ' 46' ' ' ILE . 30.5 m -72.56 -33.82 46.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.544 -0.298 . . . . 0.0 111.141 -179.562 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -63.37 -36.62 84.31 Favored 'General case' 0 C--N 1.331 -0.206 0 CA-C-O 120.989 0.424 . . . . 0.0 110.748 179.473 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 28.5 m-85 -73.0 -36.25 67.0 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 115.915 -0.584 . . . . 0.0 110.442 179.794 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -65.47 -42.35 92.35 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 115.979 -0.555 . . . . 0.0 110.957 179.54 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 53' ' ' VAL . . . . . 0.506 ' O ' HG12 ' A' ' 58' ' ' VAL . 25.4 m -71.48 -47.33 59.17 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.188 0 CA-C-N 116.451 -0.341 . . . . 0.0 110.83 179.821 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 54' ' ' MET . . . . . 0.517 ' HG2' ' HG2' ' A' ' 71' ' ' PRO . 72.6 mtm -62.14 -31.97 72.51 Favored 'General case' 0 C--N 1.332 -0.19 0 CA-C-O 121.058 0.456 . . . . 0.0 110.007 179.439 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 55' ' ' ALA . . . . . 0.516 ' HB2' ' HB2' ' A' ' 8' ' ' PHE . . . -67.31 -32.51 73.53 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 115.701 -0.681 . . . . 0.0 111.04 179.306 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 76.3 mt -79.77 -4.4 51.82 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.28 -179.871 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 90.82 -16.09 59.12 Favored Glycine 0 CA--C 1.518 0.234 0 C-N-CA 120.539 -0.839 . . . . 0.0 113.288 179.54 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 58' ' ' VAL . . . . . 0.506 HG12 ' O ' ' A' ' 53' ' ' VAL . 13.0 p -67.4 144.37 14.6 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 117.108 0.454 . . . . 0.0 110.819 -179.884 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 94.05 -12.47 69.12 Favored Glycine 0 N--CA 1.45 -0.412 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.053 -179.461 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 60' ' ' TRP . . . . . . . . . . . . . 13.3 m0 -80.02 111.15 16.08 Favored 'General case' 0 C--N 1.331 -0.213 0 N-CA-C 110.329 -0.249 . . . . 0.0 110.329 179.703 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 6.9 p -111.29 129.56 23.93 Favored Pre-proline 0 C--N 1.329 -0.305 0 CA-C-N 116.61 -0.268 . . . . 0.0 111.201 -179.866 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 60.1 Cg_endo -71.81 152.15 57.96 Favored 'Trans proline' 0 C--N 1.35 0.618 0 C-N-CA 122.373 2.048 . . . . 0.0 112.292 179.96 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 93.7 t -143.38 94.37 0.51 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 115.929 -0.578 . . . . 0.0 110.761 -179.74 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . 58.19 -87.04 0.02 OUTLIER 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.11 -179.813 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 12.1 mm-40 -120.84 -23.19 6.0 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.288 -0.415 . . . . 0.0 110.591 179.773 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 66' ' ' ARG . . . . . . . . . . . . . 20.3 mmm180 -98.69 165.95 11.56 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.013 -0.539 . . . . 0.0 110.449 179.994 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 88.1 m -128.1 123.36 34.31 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-O 120.898 0.38 . . . . 0.0 111.173 179.947 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 68' ' ' VAL . . . . . 0.494 HG21 ' SD ' ' A' ' 117' ' ' MET . 27.3 m -106.73 146.68 12.89 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.054 -0.521 . . . . 0.0 110.702 179.834 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 69' ' ' PHE . . . . . . . . . . . . . 21.7 m-85 -106.59 112.92 26.13 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 116.132 -0.485 . . . . 0.0 109.989 -179.511 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 70' ' ' VAL . . . . . 0.58 ' N ' ' HD2' ' A' ' 71' ' ' PRO . 15.0 t -66.31 -47.9 58.82 Favored Pre-proline 0 C--N 1.322 -0.61 0 CA-C-N 116.24 -0.436 . . . . 0.0 112.076 -179.293 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 71' ' ' PRO . . . . . 0.58 ' HD2' ' N ' ' A' ' 70' ' ' VAL . 40.5 Cg_endo -66.16 -18.07 55.67 Favored 'Trans proline' 0 C--N 1.351 0.697 0 C-N-CA 122.115 1.877 . . . . 0.0 113.274 -179.327 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 72.3 ttt180 -72.85 -55.49 6.58 Favored 'General case' 0 C--O 1.235 0.296 0 CA-C-O 120.664 0.268 . . . . 0.0 111.712 -179.434 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 73' ' ' TYR . . . . . . . . . . . . . 71.5 m-85 -70.52 -31.58 68.72 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.524 -0.307 . . . . 0.0 110.769 -179.321 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 74' ' ' ILE . . . . . 0.46 HG22 ' HA ' ' A' ' 71' ' ' PRO . 0.4 OUTLIER -69.97 -39.56 77.59 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.229 0 N-CA-C 109.793 -0.447 . . . . 0.0 109.793 179.137 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild full ' A' A ' 75' ' ' ASP . . . . . 0.473 ' O ' HG23 ' A' ' 79' ' ' THR . 18.8 t70 -58.55 -37.6 76.07 Favored 'General case' 0 CA--C 1.519 -0.232 0 N-CA-C 109.25 -0.648 . . . . 0.0 109.25 178.713 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 76' ' ' TRP . . . . . 0.482 ' HB3' ' SD ' ' A' ' 109' ' ' MET . 43.9 m0 -66.97 -34.99 78.97 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 115.742 -0.663 . . . . 0.0 110.194 178.926 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 77' ' ' ILE . . . . . 0.425 HD12 ' HA ' ' A' ' 74' ' ' ILE . 97.0 mt -65.43 -28.65 44.93 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 115.948 -0.569 . . . . 0.0 110.688 179.497 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 38.3 mt -91.86 -25.01 19.16 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.223 -0.444 . . . . 0.0 112.12 -179.955 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 79' ' ' THR . . . . . 0.473 HG23 ' O ' ' A' ' 75' ' ' ASP . 67.2 p -92.69 -52.31 4.69 Favored 'General case' 0 N--CA 1.464 0.261 0 N-CA-C 113.671 0.989 . . . . 0.0 113.671 -177.74 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 80' ' ' THR . . . . . 0.442 ' N ' ' HD2' ' A' ' 81' ' ' PRO . 33.4 m -49.33 -54.55 28.8 Favored Pre-proline 0 C--N 1.329 -0.314 0 N-CA-C 113.159 0.8 . . . . 0.0 113.159 -178.163 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 81' ' ' PRO . . . . . 0.442 ' HD2' ' N ' ' A' ' 80' ' ' THR . 36.6 Cg_endo -63.13 -19.11 68.02 Favored 'Trans proline' 0 C--N 1.351 0.674 0 C-N-CA 121.463 1.442 . . . . 0.0 111.376 -179.513 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 82' ' ' LEU . . . . . . . . . . . . . 14.1 tp -77.05 -33.54 57.24 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 115.643 -0.708 . . . . 0.0 110.256 179.727 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 83' ' ' ILE . . . . . 0.428 HD11 HG21 ' A' ' 43' ' ' ILE . 32.8 mm -68.89 -52.62 32.83 Favored 'Isoleucine or valine' 0 C--O 1.232 0.174 0 CA-C-N 115.98 -0.555 . . . . 0.0 109.867 179.05 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . 0.433 HG22 ' HA ' ' A' ' 81' ' ' PRO . 27.9 m -61.21 -30.39 47.74 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.209 0 N-CA-C 109.513 -0.551 . . . . 0.0 109.513 178.797 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 85' ' ' TYR . . . . . 0.4 ' HB2' ' O ' ' A' ' 81' ' ' PRO . 82.7 t80 -65.87 -32.91 74.69 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 115.48 -0.782 . . . . 0.0 109.347 178.741 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 86' ' ' PHE . . . . . 0.418 ' HE2' ' HB2' ' A' ' 40' ' ' LEU . 10.8 t80 -63.91 -51.74 63.08 Favored 'General case' 0 N--CA 1.456 -0.133 0 CA-C-N 115.681 -0.691 . . . . 0.0 109.956 179.219 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 8.8 mp -61.32 -32.66 72.53 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 115.701 -0.681 . . . . 0.0 110.457 179.67 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -68.71 -27.96 73.47 Favored Glycine 0 N--CA 1.45 -0.407 0 C-N-CA 120.731 -0.747 . . . . 0.0 111.65 179.368 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 47.5 mt -72.13 -41.8 66.77 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.87 0.367 . . . . 0.0 110.646 179.539 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 57.0 mt -65.16 -45.8 83.47 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 115.951 -0.568 . . . . 0.0 111.059 179.942 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . 0.466 ' HB1' ' HB3' ' A' ' 148' ' ' SER . . . -71.55 -55.2 8.28 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.318 -0.401 . . . . 0.0 111.167 -179.696 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 99.5 67.62 0.86 Allowed Glycine 0 CA--C 1.519 0.283 0 C-N-CA 120.812 -0.709 . . . . 0.0 112.684 179.893 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 9.2 mp -75.34 -172.74 1.85 Allowed 'General case' 0 C--N 1.33 -0.245 0 CA-C-O 120.74 0.305 . . . . 0.0 110.856 179.911 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 94' ' ' ASP . . . . . 0.474 ' H ' ' HB2' ' A' ' 97' ' ' GLU . 6.7 m-20 -96.91 -173.98 2.86 Favored 'General case' 0 C--N 1.332 -0.174 0 CA-C-O 121.073 0.464 . . . . 0.0 111.266 -179.823 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 50.4 m -67.64 -51.58 48.34 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 115.78 -0.646 . . . . 0.0 111.308 -179.793 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 79.8 ttt180 -74.22 -34.86 63.82 Favored 'General case' 0 C--N 1.331 -0.197 0 CA-C-O 120.964 0.412 . . . . 0.0 110.575 -179.579 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 97' ' ' GLU . . . . . 0.474 ' HB2' ' H ' ' A' ' 94' ' ' ASP . 0.3 OUTLIER -56.88 -45.15 82.72 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 115.687 -0.688 . . . . 0.0 111.241 -179.812 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild full ' A' A ' 98' ' ' PHE . . . . . 0.443 ' O ' HG12 ' A' ' 102' ' ' ILE . 4.8 m-85 -62.17 -42.92 99.73 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.834 0.35 . . . . 0.0 110.71 179.487 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -62.6 -28.8 72.01 Favored Glycine 0 N--CA 1.45 -0.401 0 C-N-CA 120.8 -0.714 . . . . 0.0 112.682 -179.865 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 96.1 mt -72.46 -41.91 64.32 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.234 0 CA-C-O 120.873 0.368 . . . . 0.0 111.198 -179.927 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 53.8 t -67.45 -43.64 87.34 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.32 -179.932 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 102' ' ' ILE . . . . . 0.443 HG12 ' O ' ' A' ' 98' ' ' PHE . 43.0 mm -68.07 -49.59 66.49 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.63 -179.495 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 14.9 t -57.71 -33.59 68.57 Favored 'General case' 0 C--O 1.233 0.186 0 CA-C-O 120.762 0.315 . . . . 0.0 111.173 -179.701 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 41.2 tp -65.75 -48.16 72.84 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.3 -0.409 . . . . 0.0 110.545 179.601 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 105' ' ' ASN . . . . . 0.597 ' N ' HD22 ' A' ' 105' ' ' ASN . 0.8 OUTLIER -61.16 -26.08 67.45 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.766 179.758 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild full ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 91.6 m -69.07 -57.6 5.2 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-N 116.378 -0.374 . . . . 0.0 111.425 -179.934 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 8.3 p -58.58 -37.32 64.3 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.237 0 CA-C-N 116.531 -0.304 . . . . 0.0 110.942 -179.816 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 73.9 t -66.46 -51.97 51.76 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.898 179.532 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 109' ' ' MET . . . . . 0.482 ' SD ' ' HB3' ' A' ' 76' ' ' TRP . 9.8 tpp -61.36 -32.61 72.52 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.018 -0.537 . . . . 0.0 110.387 179.753 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 10.0 mt -72.31 -30.29 64.64 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 115.848 -0.615 . . . . 0.0 109.939 179.38 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -60.06 -45.63 92.22 Favored 'General case' 0 CA--C 1.519 -0.234 0 N-CA-C 109.249 -0.649 . . . . 0.0 109.249 178.248 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 112' ' ' GLY . . . . . 0.542 ' HA3' ' H21' ' A' ' 301' ' ' RET . . . -70.26 -41.74 67.98 Favored Glycine 0 N--CA 1.449 -0.441 0 CA-C-N 115.501 -0.772 . . . . 0.0 111.19 178.392 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 113' ' ' PHE . . . . . . . . . . . . . 2.0 t80 -48.81 -65.95 0.48 Allowed 'General case' 0 CA--C 1.52 -0.186 0 N-CA-C 109.353 -0.61 . . . . 0.0 109.353 178.82 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 114' ' ' ALA . . . . . 0.504 ' HB3' HD22 ' A' ' 126' ' ' LEU . . . -64.41 -19.23 65.38 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 115.467 -0.788 . . . . 0.0 110.406 178.699 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -53.1 -51.1 48.59 Favored Glycine 0 C--N 1.335 0.488 0 C-N-CA 120.892 -0.671 . . . . 0.0 111.86 179.495 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 116' ' ' ALA . . . . . 0.455 ' HB1' HG12 ' A' ' 68' ' ' VAL . . . -78.02 -18.44 55.87 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-O 120.87 0.367 . . . . 0.0 110.948 179.279 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 117' ' ' MET . . . . . 0.494 ' SD ' HG21 ' A' ' 68' ' ' VAL . 22.3 mmt -81.9 18.56 1.28 Allowed 'General case' 0 C--N 1.331 -0.218 0 CA-C-N 116.015 -0.539 . . . . 0.0 111.673 -179.441 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 118' ' ' VAL . . . . . 0.441 HG11 ' N ' ' A' ' 123' ' ' ARG . 32.6 m -89.85 138.71 27.72 Favored Pre-proline 0 C--N 1.327 -0.371 0 CA-C-N 116.73 -0.213 . . . . 0.0 111.375 -179.95 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 119' ' ' PRO . . . . . . . . . . . . . 70.3 Cg_endo -89.98 -3.76 5.4 Favored 'Trans proline' 0 N--CA 1.456 -0.692 0 C-N-CA 122.73 2.286 . . . . 0.0 112.235 179.61 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -138.2 -110.83 0.97 Allowed Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.908 -179.765 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 46.8 pt -126.99 14.93 3.6 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.214 0 CA-C-O 120.738 0.304 . . . . 0.0 111.585 -179.384 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 25.6 mt-10 -61.74 -18.64 60.53 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-N 116.353 -0.385 . . . . 0.0 111.041 -179.8 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 123' ' ' ARG . . . . . 0.464 ' HB2' ' HH2' ' A' ' 178' ' ' TRP . 7.6 ptt180 -52.6 -30.12 29.5 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 115.976 -0.557 . . . . 0.0 112.085 -179.66 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 124' ' ' TYR . . . . . . . . . . . . . 50.9 m-85 -69.16 -32.44 71.79 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.794 0.331 . . . . 0.0 111.364 -179.668 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 125' ' ' ALA . . . . . . . . . . . . . . . -72.59 -56.14 5.81 Favored 'General case' 0 C--O 1.236 0.346 0 CA-C-N 116.304 -0.407 . . . . 0.0 111.296 -179.504 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 126' ' ' LEU . . . . . 0.504 HD22 ' HB3' ' A' ' 114' ' ' ALA . 1.2 mt -51.49 -45.35 62.79 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 115.839 -0.619 . . . . 0.0 110.922 -179.821 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 127' ' ' PHE . . . . . . . . . . . . . 3.6 t80 -67.65 -38.64 84.11 Favored 'General case' 0 C--N 1.33 -0.269 0 C-N-CA 120.874 -0.33 . . . . 0.0 110.394 179.581 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 128' ' ' GLY . . . . . . . . . . . . . . . -46.48 -43.1 14.56 Favored Glycine 0 C--N 1.332 0.337 0 C-N-CA 120.21 -0.995 . . . . 0.0 110.991 179.219 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 129' ' ' MET . . . . . . . . . . . . . 0.4 OUTLIER -71.59 -41.32 69.13 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 115.383 -0.408 . . . . 0.0 110.18 179.04 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -63.61 -28.98 73.34 Favored Glycine 0 C--N 1.332 0.321 0 C-N-CA 121.066 -0.588 . . . . 0.0 113.016 -179.665 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -74.69 -53.64 8.89 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.729 0.265 . . . . 0.0 110.529 -179.901 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 61.4 t -59.32 -40.47 81.52 Favored 'Isoleucine or valine' 0 C--O 1.234 0.289 0 N-CA-C 109.205 -0.665 . . . . 0.0 109.205 178.832 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -67.51 -34.08 76.38 Favored 'General case' 0 N--CA 1.452 -0.353 0 CA-C-N 115.201 -0.908 . . . . 0.0 110.48 179.175 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 134' ' ' PHE . . . . . 0.421 ' CZ ' ' HA ' ' A' ' 172' ' ' ALA . 82.2 t80 -56.04 -52.59 63.7 Favored 'General case' 0 N--CA 1.451 -0.417 0 CA-C-N 116.072 -0.513 . . . . 0.0 109.875 179.328 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 135' ' ' ILE . . . . . 0.457 ' HA ' HG22 ' A' ' 138' ' ' VAL . 53.3 mt -58.14 -34.31 49.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 115.798 -0.637 . . . . 0.0 109.855 179.094 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . -63.73 -36.62 93.56 Favored Glycine 0 C--N 1.334 0.422 0 C-N-CA 120.312 -0.947 . . . . 0.0 111.356 178.75 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 137' ' ' LEU . . . . . 0.426 HD13 HD21 ' A' ' 105' ' ' ASN . 35.1 tp -71.24 -53.56 13.95 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.7 0.286 . . . . 0.0 110.453 179.448 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 138' ' ' VAL . . . . . 0.457 HG22 ' HA ' ' A' ' 135' ' ' ILE . 5.3 m -55.98 -31.94 32.02 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.218 0 CA-C-O 121.164 0.507 . . . . 0.0 109.656 179.458 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 139' ' ' TYR . . . . . . . . . . . . . 38.6 t80 -60.82 -47.99 83.83 Favored 'General case' 0 N--CA 1.454 -0.228 0 CA-C-N 115.528 -0.76 . . . . 0.0 109.909 178.511 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 15.5 m-85 -56.5 -37.98 71.13 Favored 'General case' 0 C--N 1.334 -0.093 0 CA-C-N 116.056 -0.52 . . . . 0.0 110.81 179.22 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 141' ' ' LEU . . . . . . . . . . . . . 70.5 mt -64.28 -34.95 79.29 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.057 -0.519 . . . . 0.0 110.708 -179.853 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 13.8 t -94.29 -7.57 10.03 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.79 179.828 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . -73.89 -131.8 0.21 Allowed Glycine 0 CA--C 1.521 0.43 0 C-N-CA 120.891 -0.671 . . . . 0.0 112.673 -179.765 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 144' ' ' PRO . . . . . . . . . . . . . 28.1 Cg_endo -62.04 -23.7 75.95 Favored 'Trans proline' 0 C--N 1.347 0.478 0 C-N-CA 122.528 2.152 . . . . 0.0 112.673 -179.859 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 145' ' ' MET . . . . . . . . . . . . . 52.4 mtt -53.99 -32.02 52.78 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-O 120.661 0.267 . . . . 0.0 111.436 -179.815 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 146' ' ' THR . . . . . . . . . . . . . 73.2 p -72.06 -46.0 58.59 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.426 -0.352 . . . . 0.0 111.479 -179.693 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 42.4 mt-10 -72.7 -28.11 62.48 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.471 -179.64 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 148' ' ' SER . . . . . 0.466 ' HB3' ' HB1' ' A' ' 91' ' ' ALA . 32.6 t -70.32 -43.87 69.42 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-O 120.754 0.311 . . . . 0.0 111.105 -179.622 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 149' ' ' ALA . . . . . . . . . . . . . . . -75.11 -40.12 60.13 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.147 -0.479 . . . . 0.0 111.198 -179.838 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 150' ' ' SER . . . . . . . . . . . . . 69.0 m -63.61 -22.91 67.15 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.096 -179.909 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 151' ' ' GLN . . . . . . . . . . . . . 46.2 mt-30 -105.53 6.82 32.6 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.263 -0.426 . . . . 0.0 111.435 -179.751 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 31.9 tpt180 -84.11 -51.7 6.87 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.88 0.372 . . . . 0.0 110.542 179.646 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 153' ' ' SER . . . . . 0.596 ' HB3' HG12 ' A' ' 156' ' ' ILE . 23.1 t -157.67 169.98 23.43 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-N 115.902 -0.59 . . . . 0.0 110.449 179.091 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 154' ' ' SER . . . . . . . . . . . . . 82.7 p -71.01 -39.72 72.22 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.788 0.328 . . . . 0.0 110.5 179.555 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -77.09 -36.6 34.94 Favored Glycine 0 N--CA 1.452 -0.241 0 C-N-CA 120.864 -0.684 . . . . 0.0 112.595 179.752 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 156' ' ' ILE . . . . . 0.596 HG12 ' HB3' ' A' ' 153' ' ' SER . 28.4 mm -51.64 -38.18 21.17 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.215 0 CA-C-O 120.623 0.249 . . . . 0.0 111.438 -179.859 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 157' ' ' LYS . . . . . 0.414 ' O ' HG13 ' A' ' 161' ' ' VAL . 63.6 tttp -60.03 -48.78 80.3 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.283 -0.417 . . . . 0.0 111.678 -179.795 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 41.3 t -63.78 -47.48 80.75 Favored 'General case' 0 C--N 1.328 -0.351 0 N-CA-C 111.96 0.355 . . . . 0.0 111.96 -179.095 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 159' ' ' LEU . . . . . 0.528 HD23 HD13 ' A' ' 163' ' ' LEU . 1.6 tt -67.71 -31.81 72.02 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 116.494 -0.321 . . . . 0.0 111.28 -179.326 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 160' ' ' TYR . . . . . . . . . . . . . 79.9 t80 -74.05 -44.42 54.33 Favored 'General case' 0 C--N 1.329 -0.315 0 N-CA-C 111.946 0.35 . . . . 0.0 111.946 -179.218 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 161' ' ' VAL . . . . . 0.414 HG13 ' O ' ' A' ' 157' ' ' LYS . 30.4 m -62.01 -41.18 90.03 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 N-CA-C 111.691 0.256 . . . . 0.0 111.691 -179.205 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 162' ' ' ARG . . . . . . . . . . . . . 94.7 mtt180 -67.87 -41.29 83.09 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-O 120.778 0.323 . . . . 0.0 111.312 -179.85 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 163' ' ' LEU . . . . . 0.601 ' HG ' ' HB2' ' A' ' 208' ' ' PHE . 7.1 mp -71.96 -54.93 8.46 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.302 -0.408 . . . . 0.0 112.064 -179.208 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 164' ' ' ARG . . . . . 0.434 ' O ' HG23 ' A' ' 168' ' ' VAL . 4.8 tmm_? -53.97 -53.18 56.4 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.273 -0.422 . . . . 0.0 111.568 -179.408 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 165' ' ' ASN . . . . . 0.543 HD22 ' N ' ' A' ' 165' ' ' ASN . 0.9 OUTLIER -57.05 -51.75 68.02 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.4 -0.364 . . . . 0.0 111.368 -179.255 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild full ' A' A ' 166' ' ' LEU . . . . . 0.472 ' O ' ' HG ' ' A' ' 170' ' ' LEU . 5.5 tt -58.28 -52.12 66.94 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.124 -0.489 . . . . 0.0 111.867 -179.241 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 167' ' ' THR . . . . . 0.453 ' O ' ' HB2' ' A' ' 171' ' ' TRP . 91.3 m -55.37 -53.38 56.94 Favored 'General case' 0 C--N 1.328 -0.34 0 N-CA-C 112.643 0.609 . . . . 0.0 112.643 -178.71 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 168' ' ' VAL . . . . . 0.434 HG23 ' O ' ' A' ' 164' ' ' ARG . 96.3 t -55.21 -40.83 57.63 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.195 0 N-CA-C 112.312 0.486 . . . . 0.0 112.312 -178.558 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 169' ' ' VAL . . . . . 0.485 HG23 ' O ' ' A' ' 165' ' ' ASN . 80.2 t -60.54 -64.66 0.57 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.39 0 N-CA-C 111.798 0.296 . . . . 0.0 111.798 -179.343 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 170' ' ' LEU . . . . . 0.489 HD12 ' N ' ' A' ' 171' ' ' TRP . 1.6 pp -63.98 -27.63 69.26 Favored 'General case' 0 C--N 1.33 -0.26 0 N-CA-C 112.08 0.4 . . . . 0.0 112.08 -178.781 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 171' ' ' TRP . . . . . 0.686 ' HE1' H203 ' A' ' 301' ' ' RET . 1.5 m0 -72.14 -31.14 65.71 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-O 120.926 0.393 . . . . 0.0 110.312 179.383 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 172' ' ' ALA . . . . . 0.421 ' HA ' ' CZ ' ' A' ' 134' ' ' PHE . . . -73.04 -6.19 43.87 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 115.816 -0.629 . . . . 0.0 110.615 179.94 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 173' ' ' ILE . . . . . 0.602 HG22 HD11 ' A' ' 177' ' ' ILE . 36.5 mm -87.78 -21.78 7.01 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.216 0 CA-C-N 115.838 -0.619 . . . . 0.0 111.132 179.787 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 174' ' ' TYR . . . . . 0.437 ' HB2' ' HD3' ' A' ' 175' ' ' PRO . 25.9 m-85 -54.57 -49.55 90.46 Favored Pre-proline 0 N--CA 1.465 0.3 0 CA-C-N 116.49 -0.323 . . . . 0.0 111.694 -179.913 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 175' ' ' PRO . . . . . 0.437 ' HD3' ' HB2' ' A' ' 174' ' ' TYR . 82.7 Cg_exo -47.63 -28.37 9.13 Favored 'Trans proline' 0 C--N 1.353 0.768 0 C-N-CA 122.163 1.909 . . . . 0.0 112.259 179.912 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 176' ' ' PHE . . . . . 0.457 ' O ' ' HG ' ' A' ' 180' ' ' LEU . 95.9 m-85 -80.31 -49.61 11.31 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.026 -0.534 . . . . 0.0 111.72 -179.99 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 177' ' ' ILE . . . . . 0.602 HD11 HG22 ' A' ' 173' ' ' ILE . 2.6 mm -60.1 -45.12 96.14 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.537 0 N-CA-C 112.568 0.581 . . . . 0.0 112.568 -177.894 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 178' ' ' TRP . . . . . 0.464 ' HH2' ' HB2' ' A' ' 123' ' ' ARG . 80.5 t90 -66.63 -40.5 88.76 Favored 'General case' 0 N--CA 1.464 0.255 0 CA-C-O 121.095 0.474 . . . . 0.0 110.644 179.867 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 179' ' ' LEU . . . . . 0.544 ' O ' HG22 ' A' ' 185' ' ' VAL . 0.9 OUTLIER -65.28 -52.43 54.31 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-N 115.732 -0.667 . . . . 0.0 111.272 -179.216 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild full ' A' A ' 180' ' ' LEU . . . . . 0.551 HD22 HD11 ' A' ' 187' ' ' LEU . 9.8 mt -77.6 -52.44 9.02 Favored 'General case' 0 CA--C 1.532 0.266 0 N-CA-C 112.395 0.517 . . . . 0.0 112.395 -178.586 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . -59.89 -85.54 0.04 OUTLIER Glycine 0 C--N 1.333 0.389 0 C-N-CA 120.631 -0.795 . . . . 0.0 113.196 -179.578 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 182' ' ' PRO . . . . . 0.49 ' HD2' ' O ' ' A' ' 177' ' ' ILE . 73.1 Cg_exo -45.01 178.04 0.0 OUTLIER 'Trans proline' 0 C--N 1.351 0.696 0 C-N-CA 123.368 2.712 . . . . 0.0 113.326 179.474 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 183' ' ' PRO . . . . . . . . . . . . . 62.2 Cg_exo -53.68 8.27 0.03 OUTLIER 'Trans proline' 0 C--N 1.352 0.713 0 C-N-CA 123.057 2.505 . . . . 0.0 114.991 -179.384 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 184' ' ' GLY . . . . . 0.45 ' H ' ' C ' ' A' ' 182' ' ' PRO . . . -53.69 -66.94 2.41 Favored Glycine 0 C--N 1.337 0.608 0 C-N-CA 119.795 -1.193 . . . . 0.0 110.971 179.01 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 185' ' ' VAL . . . . . 0.544 HG22 ' O ' ' A' ' 179' ' ' LEU . 4.4 m -134.4 -4.61 1.21 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.389 0 CA-C-N 115.797 -0.202 . . . . 0.0 111.433 178.553 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 186' ' ' ALA . . . . . . . . . . . . . . . 43.85 79.01 0.05 OUTLIER 'General case' 0 N--CA 1.466 0.35 0 N-CA-C 112.289 0.477 . . . . 0.0 112.289 179.386 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 187' ' ' LEU . . . . . 0.551 HD11 HD22 ' A' ' 180' ' ' LEU . 4.9 mt -92.77 -49.83 5.88 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-O 120.71 0.291 . . . . 0.0 111.718 179.971 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 188' ' ' LEU . . . . . 0.414 HD13 HG11 ' A' ' 192' ' ' VAL . 96.0 mt -114.95 -166.45 1.11 Allowed 'General case' 0 C--N 1.331 -0.223 0 CA-C-O 120.983 0.421 . . . . 0.0 111.362 -179.169 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 189' ' ' THR . . . . . . . . . . . . . 3.0 t -85.77 148.11 47.76 Favored Pre-proline 0 C--N 1.328 -0.354 0 CA-C-N 115.826 -0.625 . . . . 0.0 111.279 -179.732 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 190' ' ' PRO . . . . . . . . . . . . . 78.2 Cg_exo -49.42 -44.59 33.98 Favored 'Trans proline' 0 C--N 1.348 0.524 0 C-N-CA 122.849 2.366 . . . . 0.0 113.503 -179.74 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 191' ' ' THR . . . . . . . . . . . . . 9.7 t -56.12 -34.51 66.14 Favored 'General case' 0 C--N 1.33 -0.276 0 N-CA-C 112.308 0.484 . . . . 0.0 112.308 -179.056 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 192' ' ' VAL . . . . . 0.414 HG11 HD13 ' A' ' 188' ' ' LEU . 19.1 t -72.06 -54.39 16.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 N-CA-C 111.851 0.315 . . . . 0.0 111.851 -179.204 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 193' ' ' ASP . . . . . . . . . . . . . 1.1 p30 -62.17 -46.14 90.3 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.699 0.285 . . . . 0.0 110.948 -179.735 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 194' ' ' VAL . . . . . 0.433 ' O ' HG23 ' A' ' 198' ' ' VAL . 63.8 t -58.32 -35.94 55.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.331 -0.395 . . . . 0.0 110.44 179.4 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 195' ' ' ALA . . . . . . . . . . . . . . . -59.93 -48.25 82.45 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.281 -0.418 . . . . 0.0 111.141 179.918 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 196' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -67.88 -35.54 78.69 Favored 'General case' 0 N--CA 1.462 0.173 0 N-CA-C 109.882 -0.414 . . . . 0.0 109.882 179.543 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 197' ' ' ILE . . . . . . . . . . . . . 18.9 mm -58.43 -57.67 9.88 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.289 0 CA-C-N 115.922 -0.581 . . . . 0.0 109.776 178.949 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 198' ' ' VAL . . . . . 0.433 HG23 ' O ' ' A' ' 194' ' ' VAL . 93.5 t -53.92 -35.27 27.56 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.44 0 N-CA-C 108.873 -0.788 . . . . 0.0 108.873 178.138 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 199' ' ' TYR . . . . . . . . . . . . . 17.7 t80 -70.76 -30.21 66.65 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 114.951 -1.022 . . . . 0.0 110.885 179.467 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 200' ' ' LEU . . . . . 0.521 HD11 HG13 ' A' ' 177' ' ' ILE . 34.9 mt -71.75 -44.0 64.81 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 116.048 -0.524 . . . . 0.0 111.703 -179.21 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 201' ' ' ASP . . . . . . . . . . . . . 11.9 m-20 -68.26 -35.21 77.54 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-O 121.117 0.484 . . . . 0.0 110.417 179.89 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 202' ' ' LEU . . . . . 0.439 ' O ' ' HB ' ' A' ' 206' ' ' VAL . 3.4 mt -70.89 -32.59 69.59 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 115.587 -0.733 . . . . 0.0 111.977 -179.507 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 203' ' ' VAL . . . . . 0.484 ' O ' ' HA3' ' A' ' 207' ' ' GLY . 12.5 p -78.17 -36.59 21.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 C-N-CA 121.102 -0.239 . . . . 0.0 111.376 -178.915 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 204' ' ' THR . . . . . 0.402 ' O ' ' CD1' ' A' ' 208' ' ' PHE . 45.4 m -64.73 -57.46 8.91 Favored 'General case' 0 C--N 1.325 -0.457 0 C-N-CA 120.494 -0.482 . . . . 0.0 111.134 179.655 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 205' ' ' LYS . . . . . 0.675 ' HE3' HG22 ' A' ' 43' ' ' ILE . 47.4 mttp -70.2 -58.91 3.25 Favored 'General case' 0 C--N 1.33 -0.251 0 N-CA-C 112.791 0.663 . . . . 0.0 112.791 -178.071 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 206' ' ' VAL . . . . . 0.439 ' HB ' ' O ' ' A' ' 202' ' ' LEU . 23.3 t -70.08 -36.31 67.76 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.411 0 CA-C-N 116.454 -0.339 . . . . 0.0 111.832 -178.692 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 207' ' ' GLY . . . . . 0.496 ' O ' HG13 ' A' ' 211' ' ' ILE . . . -63.3 -60.25 7.78 Favored Glycine 0 N--CA 1.45 -0.382 0 C-N-CA 120.513 -0.851 . . . . 0.0 113.424 -178.844 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 208' ' ' PHE . . . . . 0.601 ' HB2' ' HG ' ' A' ' 163' ' ' LEU . 0.1 OUTLIER -66.47 -27.07 67.51 Favored 'General case' 0 C--O 1.225 -0.219 0 CA-C-N 117.3 0.55 . . . . 0.0 111.037 -179.136 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild full ' A' A ' 209' ' ' GLY . . . . . 0.506 ' O ' ' HB3' ' A' ' 212' ' ' ALA . . . -69.72 -33.12 70.91 Favored Glycine 0 N--CA 1.448 -0.513 0 N-CA-C 111.683 -0.567 . . . . 0.0 111.683 178.852 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 210' ' ' PHE . . . . . . . . . . . . . 1.1 m-85 -70.85 -49.27 47.99 Favored 'General case' 0 CA--C 1.512 -0.494 0 N-CA-C 107.954 -1.128 . . . . 0.0 107.954 178.404 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 211' ' ' ILE . . . . . 0.496 HG13 ' O ' ' A' ' 207' ' ' GLY . 5.6 mt -62.59 -28.36 44.65 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.604 0 N-CA-C 107.618 -1.253 . . . . 0.0 107.618 176.572 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 212' ' ' ALA . . . . . 0.506 ' HB3' ' O ' ' A' ' 209' ' ' GLY . . . -65.05 -39.92 94.01 Favored 'General case' 0 N--CA 1.447 -0.59 0 CA-C-N 114.698 -1.137 . . . . 0.0 110.084 179.431 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 213' ' ' LEU . . . . . 0.41 ' HG ' ' O ' ' A' ' 209' ' ' GLY . 88.4 mt -70.28 -53.16 18.05 Favored 'General case' 0 C--N 1.331 -0.203 0 CA-C-N 115.132 -0.94 . . . . 0.0 111.601 -179.772 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 214' ' ' ASP . . . . . . . . . . . . . 29.4 m-20 -54.01 -50.04 67.53 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.33 -0.395 . . . . 0.0 111.294 -179.38 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 215' ' ' ALA . . . . . . . . . . . . . . . -61.02 -56.42 21.26 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.289 -0.414 . . . . 0.0 111.362 -179.735 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 216' ' ' ALA . . . . . . . . . . . . . . . -56.26 -36.38 68.49 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.233 -0.439 . . . . 0.0 111.467 -179.543 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 217' ' ' ALA . . . . . . . . . . . . . . . -62.46 -40.87 98.01 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.291 -0.413 . . . . 0.0 110.392 179.765 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 218' ' ' THR . . . . . . . . . . . . . 90.9 m -65.95 -37.86 87.12 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.794 -0.639 . . . . 0.0 110.737 179.623 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 219' ' ' LEU . . . . . 0.504 ' O ' ' HG2' ' A' ' 222' ' ' GLU . 71.1 mt -57.95 -44.39 86.96 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.086 -0.506 . . . . 0.0 110.596 179.805 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 220' ' ' ARG . . . . . . . . . . . . . 7.7 mpt_? -84.05 -17.26 40.93 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.095 179.678 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 221' ' ' ALA . . . . . . . . . . . . . . . -77.27 -22.45 52.06 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.269 -0.423 . . . . 0.0 112.024 -179.458 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 222' ' ' GLU . . . . . 0.504 ' HG2' ' O ' ' A' ' 219' ' ' LEU . 11.6 pt-20 -75.4 -7.76 54.91 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-O 120.795 0.331 . . . . 0.0 111.113 -179.532 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 223' ' ' HIS . . . . . . . . . . . . . 89.8 m-70 -87.8 -16.21 34.76 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.266 -0.424 . . . . 0.0 111.056 -179.982 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 224' ' ' GLY . . . . . . . . . . . . . . . -83.52 73.72 2.63 Favored Glycine 0 N--CA 1.452 -0.234 0 C-N-CA 120.806 -0.711 . . . . 0.0 112.424 179.9 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 225' ' ' GLU . . . . . . . . . . . . . 10.0 tp10 -148.25 130.02 15.13 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 120.702 0.287 . . . . 0.0 110.939 -179.853 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 226' ' ' SER . . . . . . . . . . . . . 41.4 t 60.71 -85.95 0.02 OUTLIER 'General case' 0 C--N 1.332 -0.195 0 CA-C-N 116.035 -0.53 . . . . 0.0 111.665 179.678 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 227' ' ' LEU . . . . . . . . . . . . . 3.9 mm? -71.97 -34.13 68.72 Favored 'General case' 0 C--N 1.332 -0.185 0 CA-C-N 116.426 -0.352 . . . . 0.0 111.176 -179.441 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 228' ' ' ALA . . . . . . . . . . . . . . . 52.49 -165.85 0.06 Allowed 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.285 -0.416 . . . . 0.0 111.33 -179.8 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 229' ' ' GLY . . . . . . . . . . . . . . . -128.18 48.69 0.96 Allowed Glycine 0 C--N 1.331 0.293 0 C-N-CA 120.743 -0.741 . . . . 0.0 112.717 -179.752 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 230' ' ' VAL . . . . . . . . . . . . . 47.5 t -85.86 133.77 28.83 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.225 0 CA-C-O 120.782 0.325 . . . . 0.0 110.958 179.865 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 231' ' ' ASP . . . . . . . . . . . . . 23.8 t70 -67.6 107.48 2.54 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.313 -0.403 . . . . 0.0 110.978 179.991 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 232' ' ' THR . . . . . . . . . . . . . 8.2 t -157.6 147.66 20.55 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.039 -0.528 . . . . 0.0 110.958 179.844 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 233' ' ' ASP . . . . . . . . . . . . . 22.1 t70 58.23 90.54 0.05 OUTLIER 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.877 -179.816 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 234' ' ' THR . . . . . . . . . . . . . 4.1 t -73.29 141.05 80.15 Favored Pre-proline 0 C--N 1.33 -0.246 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.332 -179.829 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 235' ' ' PRO . . . . . . . . . . . . . 58.5 Cg_endo -71.36 -36.87 6.36 Favored 'Trans proline' 0 C--N 1.347 0.488 0 C-N-CA 122.453 2.102 . . . . 0.0 112.334 179.942 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 236' ' ' ALA . . . . . . . . . . . . . . . -76.6 164.57 25.79 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.001 179.948 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 237' ' ' VAL . . . . . . . . . . . . . 35.2 m -90.76 -178.68 0.43 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.327 -0.397 . . . . 0.0 111.166 -179.879 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 238' ' ' ALA . . . . . . . . . . . . . . . -87.07 118.3 26.37 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.263 -0.426 . . . . 0.0 111.15 -179.982 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 239' ' ' ASP . . . . . . . . . . . . . 10.9 m-20 61.05 177.5 0.11 Allowed 'General case' 0 C--N 1.332 -0.186 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.202 179.819 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 240' ' ' LEU . . . . . . . . . . . . . 95.0 mt -131.84 110.45 10.83 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 116.055 -0.52 . . . . 0.0 110.983 179.922 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 241' ' ' GLU . . . . . . . . . . . . . 39.1 tt0 -115.55 111.33 20.54 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.706 179.825 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 242' ' ' HIS . . . . . . . . . . . . . 72.4 m80 -92.68 138.83 31.15 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.983 -179.815 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 243' ' ' HIS . . . . . . . . . . . . . 45.8 t-80 -156.44 -40.35 0.08 Allowed 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.786 179.834 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 244' ' ' HIS . . . . . . . . . . . . . 47.2 m-70 -62.02 159.07 15.06 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.529 179.72 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 245' ' ' HIS . . . . . . . . . . . . . 23.5 m-70 57.95 -170.64 0.11 Allowed 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 116.295 -0.411 . . . . 0.0 110.915 -179.821 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 246' ' ' HIS . . . . . . . . . . . . . 26.2 p80 -155.37 -22.8 0.11 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.944 179.804 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 247' ' ' HIS . . . . . . . . . . . . . 60.7 t60 . . . . . 0 C--O 1.249 1.064 0 CA-C-O 118.179 -0.915 . . . . 0.0 110.886 -179.873 . . . . . . . . 0 0 . 1 . 022 nuclear nobuild full ' A' A ' 301' ' ' RET . . . . . 0.686 H203 ' HE1' ' A' ' 171' ' ' TRP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 85.2 mtp . . . . . 0 N--CA 1.485 1.322 0 CA-C-O 120.838 0.351 . . . . 0.0 110.807 . . . . . . . . . 0 0 . 1 . 023 nuclear nobuild full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 27.6 m -134.57 -31.52 0.46 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.662 -179.923 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -79.48 -20.25 69.5 Favored Glycine 0 C--N 1.33 0.242 0 C-N-CA 120.683 -0.77 . . . . 0.0 112.625 -179.925 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 59.6 tp -74.98 -38.0 61.77 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.832 0.349 . . . . 0.0 111.095 179.953 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 71.1 p -61.73 -32.59 72.82 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.096 -0.502 . . . . 0.0 111.207 -179.819 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 20.5 p -54.53 -35.86 63.64 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.127 -179.785 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 7' ' ' LEU . . . . . . . . . . . . . 4.2 mm? -57.48 -52.86 63.66 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.809 179.836 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 8' ' ' PHE . . . . . 0.689 ' HB2' ' HB2' ' A' ' 55' ' ' ALA . 57.8 m-85 -64.87 -32.99 74.95 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 115.989 -0.551 . . . . 0.0 110.831 179.975 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 9' ' ' TRP . . . . . 0.413 ' O ' HG13 ' A' ' 13' ' ' ILE . 27.8 m95 -64.5 -44.7 90.13 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.978 0.418 . . . . 0.0 109.992 179.808 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 41.9 mt -61.8 -44.51 96.71 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 115.773 -0.649 . . . . 0.0 110.387 179.161 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -65.54 -29.22 74.67 Favored Glycine 0 N--CA 1.45 -0.433 0 C-N-CA 120.704 -0.76 . . . . 0.0 111.922 179.59 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -71.22 -33.42 69.88 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.624 0.25 . . . . 0.0 110.775 179.689 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 13' ' ' ILE . . . . . 0.413 HG13 ' O ' ' A' ' 9' ' ' TRP . 66.4 mt -66.33 -54.02 30.5 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.208 0 CA-C-O 120.9 0.381 . . . . 0.0 110.142 179.32 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -61.77 -38.07 95.34 Favored Glycine 0 N--CA 1.45 -0.432 0 C-N-CA 120.735 -0.745 . . . . 0.0 111.658 179.298 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 15' ' ' MET . . . . . 0.4 ' HG3' ' HB2' ' A' ' 48' ' ' ALA . 45.7 tpp -63.35 -43.51 97.5 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.794 0.331 . . . . 0.0 110.249 179.503 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -55.63 -38.96 70.2 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 115.969 -0.559 . . . . 0.0 109.834 179.23 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 98.8 t -59.91 -45.74 94.76 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.168 0 CA-C-N 115.954 -0.566 . . . . 0.0 109.926 178.955 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -62.74 -45.97 94.63 Favored Glycine 0 C--N 1.333 0.373 0 C-N-CA 120.476 -0.869 . . . . 0.0 111.448 178.801 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 23.7 m -51.86 -44.95 63.88 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 115.548 -0.326 . . . . 0.0 111.405 -179.888 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 85.4 mt -71.65 -42.98 66.9 Favored 'General case' 0 C--N 1.332 -0.184 0 CA-C-N 116.402 -0.363 . . . . 0.0 111.362 -179.921 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -56.89 -34.07 67.51 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.334 -0.393 . . . . 0.0 111.707 -179.662 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 22' ' ' PHE . . . . . 0.467 ' HB2' HG22 ' A' ' 41' ' ' VAL . 1.9 m-85 -90.96 -31.1 16.48 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.598 -0.274 . . . . 0.0 111.242 -179.418 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -68.31 -50.54 52.83 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.901 0.382 . . . . 0.0 111.543 -179.643 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 24' ' ' TRP . . . . . . . . . . . . . 5.3 t-105 -64.77 -42.27 95.24 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-N 115.898 -0.592 . . . . 0.0 111.119 -179.685 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -77.42 -18.4 57.28 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.866 0.365 . . . . 0.0 110.643 179.764 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -74.15 -48.47 15.15 Favored Glycine 0 N--CA 1.452 -0.286 0 C-N-CA 121.028 -0.606 . . . . 0.0 112.33 179.548 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 98.9 mtt180 -55.51 -38.26 68.96 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-O 120.832 0.349 . . . . 0.0 110.506 179.878 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 20.1 t70 -92.53 91.37 7.56 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 115.996 -0.547 . . . . 0.0 110.567 179.82 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -159.35 -162.62 1.07 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.122 -0.49 . . . . 0.0 111.061 -179.792 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -96.11 -113.02 2.82 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.782 -0.723 . . . . 0.0 112.668 -179.887 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 65.4 m -138.0 -56.71 0.66 Allowed 'General case' 0 C--N 1.331 -0.228 0 CA-C-O 120.773 0.32 . . . . 0.0 111.131 -179.785 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -75.2 -21.54 77.8 Favored Glycine 0 C--N 1.331 0.261 0 C-N-CA 120.905 -0.664 . . . . 0.0 112.598 -179.981 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 19.9 mm-40 -79.41 -20.65 47.06 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.82 0.343 . . . . 0.0 110.688 179.906 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 34' ' ' ARG . . . . . . . . . . . . . 52.0 ttp180 -55.11 -28.9 56.01 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.005 -0.543 . . . . 0.0 111.319 -179.784 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 31.1 mmm180 -55.04 -45.12 75.2 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.788 0.328 . . . . 0.0 111.28 -179.938 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 61.2 m-85 -69.05 -33.38 73.49 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.414 -179.528 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 37' ' ' TYR . . . . . . . . . . . . . 75.4 m-85 -72.69 -53.06 12.77 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.331 -0.395 . . . . 0.0 111.413 -179.238 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 11.5 p -56.75 -36.16 48.26 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.225 0 CA-C-O 121.092 0.472 . . . . 0.0 110.474 179.751 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 18.7 m -68.2 -46.9 69.34 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 115.714 -0.676 . . . . 0.0 110.718 179.276 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 40' ' ' LEU . . . . . 0.606 HD12 HD11 ' A' ' 43' ' ' ILE . 26.8 tp -61.18 -45.33 95.07 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 115.813 -0.631 . . . . 0.0 110.917 179.96 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . 0.467 HG22 ' HB2' ' A' ' 22' ' ' PHE . 95.7 t -62.97 -34.35 65.87 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.484 0 CA-C-N 115.988 -0.551 . . . . 0.0 110.284 179.471 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . 0.482 ' O ' HG13 ' A' ' 46' ' ' ILE . . . -58.62 -51.88 56.3 Favored Glycine 0 N--CA 1.448 -0.508 0 C-N-CA 120.902 -0.666 . . . . 0.0 112.921 -179.964 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 43' ' ' ILE . . . . . 0.731 HG23 HD23 ' A' ' 82' ' ' LEU . 18.0 pt -60.9 -49.16 85.79 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.161 0 CA-C-N 117.02 0.41 . . . . 0.0 111.566 -179.558 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 44' ' ' SER . . . . . 0.423 ' N ' HG13 ' A' ' 43' ' ' ILE . 41.0 t -61.32 -27.1 68.25 Favored 'General case' 0 C--N 1.332 -0.191 0 CA-C-O 120.889 0.375 . . . . 0.0 111.193 179.648 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -78.01 -47.59 8.35 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.803 -0.713 . . . . 0.0 113.217 -179.112 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 46' ' ' ILE . . . . . 0.482 HG13 ' O ' ' A' ' 42' ' ' GLY . 61.6 mt -59.14 -42.09 85.62 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.229 0 CA-C-O 120.846 0.355 . . . . 0.0 110.968 -179.75 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 47' ' ' ALA . . . . . 0.631 ' HB2' ' HE2' ' A' ' 205' ' ' LYS . . . -67.49 -40.83 85.25 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 116.333 -0.394 . . . . 0.0 111.084 179.336 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 48' ' ' ALA . . . . . 0.4 ' HB2' ' HG3' ' A' ' 15' ' ' MET . . . -54.65 -44.27 73.1 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 116.129 -0.487 . . . . 0.0 111.382 -179.771 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 49' ' ' VAL . . . . . 0.418 HG22 ' O ' ' A' ' 46' ' ' ILE . 33.3 m -75.36 -34.65 30.98 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.384 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.351 -179.742 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -62.17 -38.86 90.67 Favored 'General case' 0 C--N 1.332 -0.156 0 CA-C-O 120.965 0.412 . . . . 0.0 111.071 179.849 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 51' ' ' TYR . . . . . 0.426 ' HB3' ' O ' ' A' ' 8' ' ' PHE . 26.5 m-85 -72.77 -42.65 63.74 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 115.993 -0.549 . . . . 0.0 110.693 -179.861 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -62.5 -39.84 94.81 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 115.987 -0.551 . . . . 0.0 111.45 -179.919 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 53' ' ' VAL . . . . . 0.473 HG23 ' N ' ' A' ' 54' ' ' MET . 35.1 m -72.28 -48.71 47.19 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.16 0 CA-C-N 116.498 -0.319 . . . . 0.0 111.299 -179.679 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 54' ' ' MET . . . . . 0.48 ' HG3' ' HB2' ' A' ' 71' ' ' PRO . 74.0 mtm -61.85 -31.26 71.51 Favored 'General case' 0 C--N 1.331 -0.196 0 CA-C-O 120.979 0.419 . . . . 0.0 110.417 179.693 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 55' ' ' ALA . . . . . 0.689 ' HB2' ' HB2' ' A' ' 8' ' ' PHE . . . -70.42 -12.51 61.63 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 115.767 -0.652 . . . . 0.0 111.645 179.962 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 71.2 mt -97.71 -13.15 21.61 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 116.483 -0.326 . . . . 0.0 111.466 -179.78 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 105.18 -6.62 42.98 Favored Glycine 0 CA--C 1.52 0.353 0 C-N-CA 120.496 -0.859 . . . . 0.0 113.545 179.5 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 58' ' ' VAL . . . . . 0.46 HG22 ' O ' ' A' ' 53' ' ' VAL . 27.0 m -81.54 149.8 4.76 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.201 0 CA-C-N 117.185 0.492 . . . . 0.0 110.587 179.483 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 81.74 25.61 52.72 Favored Glycine 0 N--CA 1.45 -0.418 0 C-N-CA 120.588 -0.815 . . . . 0.0 111.768 -179.219 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 60' ' ' TRP . . . . . . . . . . . . . 17.9 m0 -104.23 95.06 5.71 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 121.101 0.477 . . . . 0.0 110.018 -179.897 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 6.0 t -91.24 124.21 62.08 Favored Pre-proline 0 C--N 1.324 -0.539 0 CA-C-N 115.712 -0.676 . . . . 0.0 111.405 -178.984 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 56.2 Cg_endo -71.81 136.42 27.72 Favored 'Trans proline' 0 C--N 1.35 0.649 0 C-N-CA 122.353 2.036 . . . . 0.0 112.345 -179.987 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 86.4 t -143.02 105.23 1.06 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.02 -0.537 . . . . 0.0 111.209 -179.573 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . 58.88 -90.08 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.295 -0.411 . . . . 0.0 111.361 179.921 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 41.2 tt0 -122.85 -25.71 4.57 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 116.306 -0.406 . . . . 0.0 110.52 179.901 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 66' ' ' ARG . . . . . . . . . . . . . 20.0 ttm180 -101.73 162.62 12.77 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 115.942 -0.572 . . . . 0.0 110.333 179.905 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 87.3 m -117.56 120.73 38.96 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-O 120.858 0.361 . . . . 0.0 111.648 -179.448 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 38.8 t -86.07 146.37 6.55 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 115.927 -0.579 . . . . 0.0 110.558 179.406 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 69' ' ' PHE . . . . . . . . . . . . . 29.8 m-85 -106.77 112.97 26.19 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 121.044 0.45 . . . . 0.0 110.177 -179.679 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 70' ' ' VAL . . . . . 0.561 HG12 ' HD3' ' A' ' 71' ' ' PRO . 0.3 OUTLIER -68.65 -33.92 4.95 Favored Pre-proline 0 CA--C 1.541 0.603 0 N-CA-C 113.217 0.821 . . . . 0.0 113.217 -179.108 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild full ' A' A ' 71' ' ' PRO . . . . . 0.561 ' HD3' HG12 ' A' ' 70' ' ' VAL . 23.9 Cg_exo -63.71 -32.63 68.07 Favored 'Trans proline' 0 C--N 1.357 1.02 0 C-N-CA 121.766 1.644 . . . . 0.0 112.453 -179.276 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 40.0 ttm180 -69.82 -50.54 41.87 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 121.075 0.465 . . . . 0.0 110.352 179.464 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 73' ' ' TYR . . . . . 0.469 ' O ' HG13 ' A' ' 77' ' ' ILE . 33.9 m-85 -65.94 -33.09 75.02 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 115.767 -0.651 . . . . 0.0 111.341 -179.706 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 74' ' ' ILE . . . . . 0.432 ' O ' HD13 ' A' ' 74' ' ' ILE . 0.4 OUTLIER -75.74 -38.73 37.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-O 121.02 0.438 . . . . 0.0 109.908 179.329 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 5.9 t70 -58.58 -32.77 69.26 Favored 'General case' 0 N--CA 1.455 -0.203 0 CA-C-N 115.975 -0.557 . . . . 0.0 109.965 179.294 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 76' ' ' TRP . . . . . 0.41 ' HB3' ' SD ' ' A' ' 109' ' ' MET . 51.0 m0 -73.24 -46.23 51.31 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 115.914 -0.585 . . . . 0.0 110.568 179.204 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 77' ' ' ILE . . . . . 0.538 HG12 ' HB3' ' A' ' 109' ' ' MET . 88.2 mt -53.52 -29.94 17.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 115.941 -0.572 . . . . 0.0 111.253 -179.84 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 47.3 mt -91.07 -52.02 5.04 Favored 'General case' 0 CA--C 1.533 0.325 0 N-CA-C 112.521 0.563 . . . . 0.0 112.521 -179.541 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 79.7 p -71.49 -50.37 32.22 Favored 'General case' 0 N--CA 1.465 0.315 0 N-CA-C 113.931 1.085 . . . . 0.0 113.931 -177.688 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 80' ' ' THR . . . . . 0.705 HG21 ' HE1' ' A' ' 109' ' ' MET . 15.2 m -46.47 -53.32 24.75 Favored Pre-proline 0 CA--C 1.534 0.331 0 N-CA-C 112.78 0.659 . . . . 0.0 112.78 -178.173 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 81' ' ' PRO . . . . . 0.475 ' HD2' ' N ' ' A' ' 80' ' ' THR . 29.1 Cg_endo -61.99 -23.95 76.31 Favored 'Trans proline' 0 C--N 1.351 0.689 0 C-N-CA 121.639 1.559 . . . . 0.0 111.523 179.949 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 82' ' ' LEU . . . . . 0.731 HD23 HG23 ' A' ' 43' ' ' ILE . 15.6 tp -76.59 -32.62 58.23 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 115.751 -0.658 . . . . 0.0 110.156 179.507 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 41.8 mm -64.71 -53.55 40.83 Favored 'Isoleucine or valine' 0 C--O 1.235 0.304 0 CA-C-N 116.181 -0.463 . . . . 0.0 109.872 178.94 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 12.6 m -61.3 -30.33 47.71 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.228 0 N-CA-C 109.297 -0.631 . . . . 0.0 109.297 178.582 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 85' ' ' TYR . . . . . . . . . . . . . 87.4 t80 -66.82 -32.61 74.0 Favored 'General case' 0 N--CA 1.453 -0.282 0 CA-C-N 115.478 -0.783 . . . . 0.0 109.371 178.585 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 86' ' ' PHE . . . . . . . . . . . . . 3.5 t80 -61.34 -51.89 66.94 Favored 'General case' 0 C--O 1.232 0.17 0 CA-C-N 115.68 -0.691 . . . . 0.0 109.767 179.259 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 7.2 mp -62.37 -31.82 72.53 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 115.741 -0.663 . . . . 0.0 110.242 179.358 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -66.27 -28.06 73.44 Favored Glycine 0 N--CA 1.45 -0.412 0 C-N-CA 120.771 -0.728 . . . . 0.0 111.615 179.365 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 92.6 mt -75.4 -38.88 59.62 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.815 0.341 . . . . 0.0 110.53 179.426 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 94.2 mt -59.96 -43.34 95.1 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.042 -0.526 . . . . 0.0 111.097 179.859 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . 0.497 ' HB2' ' HB2' ' A' ' 149' ' ' ALA . . . -82.76 -52.22 6.96 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 116.253 -0.43 . . . . 0.0 111.369 -179.798 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 100.16 68.21 0.86 Allowed Glycine 0 N--CA 1.452 -0.284 0 C-N-CA 120.81 -0.71 . . . . 0.0 112.4 -179.941 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 93' ' ' LEU . . . . . 0.57 ' HB3' ' HB2' ' A' ' 97' ' ' GLU . 8.2 mp -77.29 177.69 7.72 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.905 0.383 . . . . 0.0 111.159 -179.862 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 94' ' ' ASP . . . . . . . . . . . . . 19.7 t70 -89.66 166.96 13.29 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 115.941 -0.572 . . . . 0.0 110.808 -179.986 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 52.8 m -55.68 -38.96 70.35 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.348 -0.387 . . . . 0.0 111.177 -179.806 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 37.6 mmt180 -73.46 -44.3 58.34 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.303 -0.408 . . . . 0.0 111.13 -179.981 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 97' ' ' GLU . . . . . 0.57 ' HB2' ' HB3' ' A' ' 93' ' ' LEU . 13.2 mm-40 -55.43 -47.99 75.11 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.859 -179.969 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 98' ' ' PHE . . . . . 0.436 ' O ' HG12 ' A' ' 102' ' ' ILE . 24.3 m-85 -57.1 -47.63 80.58 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.447 179.456 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -57.27 -29.83 60.55 Favored Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.438 179.828 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 97.3 mt -73.98 -44.28 51.06 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.171 0 CA-C-O 120.93 0.395 . . . . 0.0 111.555 -179.882 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 44.7 t -67.46 -46.41 83.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.062 -0.517 . . . . 0.0 111.929 -179.247 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 102' ' ' ILE . . . . . 0.436 HG12 ' O ' ' A' ' 98' ' ' PHE . 45.4 mm -62.22 -52.49 59.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.395 -0.366 . . . . 0.0 111.722 -179.272 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 14.7 t -57.29 -35.94 70.44 Favored 'General case' 0 C--N 1.332 -0.16 0 CA-C-O 120.849 0.357 . . . . 0.0 111.174 -179.74 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 104' ' ' LEU . . . . . 0.446 HD22 ' HE2' ' A' ' 140' ' ' TYR . 50.4 tp -61.02 -46.43 90.77 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.746 179.838 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 105' ' ' ASN . . . . . 0.591 ' N ' HD22 ' A' ' 105' ' ' ASN . 0.8 OUTLIER -65.46 -26.09 67.79 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.877 179.946 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild full ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 61.4 m -65.44 -55.35 18.49 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.292 -0.413 . . . . 0.0 111.216 -179.975 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 7.3 p -61.87 -37.35 77.96 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.184 0 CA-C-N 116.532 -0.304 . . . . 0.0 110.995 -179.734 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . 0.432 HG23 ' O ' ' A' ' 104' ' ' LEU . 53.4 t -59.58 -50.14 81.07 Favored 'Isoleucine or valine' 0 C--O 1.235 0.303 0 CA-C-O 121.002 0.429 . . . . 0.0 110.589 179.364 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 109' ' ' MET . . . . . 0.705 ' HE1' HG21 ' A' ' 80' ' ' THR . 3.0 tpp -63.46 -30.67 71.76 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 115.946 -0.57 . . . . 0.0 110.337 179.579 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 20.1 tp -68.59 -32.69 72.77 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.104 -0.498 . . . . 0.0 109.956 179.318 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 111' ' ' ALA . . . . . 0.437 ' O ' ' HB3' ' A' ' 126' ' ' LEU . . . -63.49 -56.69 14.08 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-N 115.736 -0.666 . . . . 0.0 110.418 179.25 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 112' ' ' GLY . . . . . 0.53 ' HA3' ' H21' ' A' ' 301' ' ' RET . . . -56.59 -42.99 91.08 Favored Glycine 0 C--N 1.331 0.252 0 C-N-CA 120.646 -0.788 . . . . 0.0 112.055 179.493 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 113' ' ' PHE . . . . . . . . . . . . . 6.5 t80 -47.28 -66.84 0.34 Allowed 'General case' 0 C--N 1.331 -0.222 0 CA-C-O 121.025 0.44 . . . . 0.0 110.956 179.55 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -63.25 -30.36 71.52 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 115.865 -0.607 . . . . 0.0 111.702 -179.401 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -52.11 -43.0 55.92 Favored Glycine 0 C--N 1.33 0.239 0 C-N-CA 121.057 -0.592 . . . . 0.0 112.96 -179.614 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -78.22 -27.88 47.84 Favored 'General case' 0 C--N 1.328 -0.352 0 N-CA-C 112.172 0.434 . . . . 0.0 112.172 -179.643 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 117' ' ' MET . . . . . . . . . . . . . 66.1 mtt -95.66 19.45 11.16 Favored 'General case' 0 C--N 1.33 -0.282 0 N-CA-C 111.77 0.285 . . . . 0.0 111.77 -179.191 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 118' ' ' VAL . . . . . 0.578 HG21 ' HB3' ' A' ' 123' ' ' ARG . 18.2 m -64.79 149.53 95.97 Favored Pre-proline 0 C--N 1.329 -0.296 0 CA-C-N 116.577 -0.283 . . . . 0.0 111.128 179.602 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 119' ' ' PRO . . . . . . . . . . . . . 93.9 Cg_endo -84.89 -17.83 4.68 Favored 'Trans proline' 0 N--CA 1.459 -0.517 0 C-N-CA 122.504 2.136 . . . . 0.0 112.135 179.808 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -145.41 -123.27 1.58 Allowed Glycine 0 N--CA 1.45 -0.386 0 C-N-CA 120.714 -0.755 . . . . 0.0 112.79 -179.923 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 45.1 pt -96.44 10.86 5.27 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.222 0 CA-C-O 120.714 0.293 . . . . 0.0 111.541 -179.535 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 43.6 mt-10 -59.6 -17.75 35.62 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.331 -0.395 . . . . 0.0 111.166 179.9 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 123' ' ' ARG . . . . . 0.578 ' HB3' HG21 ' A' ' 118' ' ' VAL . 19.8 ptt180 -49.69 -34.96 20.08 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 116.307 -0.406 . . . . 0.0 111.46 -179.928 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 124' ' ' TYR . . . . . . . . . . . . . 49.3 m-85 -70.98 -32.41 69.23 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.438 -0.346 . . . . 0.0 111.041 179.997 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 125' ' ' ALA . . . . . . . . . . . . . . . -68.25 -52.02 38.64 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.012 179.595 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 126' ' ' LEU . . . . . 0.437 ' HB3' ' O ' ' A' ' 111' ' ' ALA . 2.6 mm? -53.61 -56.17 19.53 Favored 'General case' 0 CA--C 1.521 -0.141 0 CA-C-N 116.09 -0.504 . . . . 0.0 110.687 179.973 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 127' ' ' PHE . . . . . 0.449 ' HZ ' ' HB3' ' A' ' 175' ' ' PRO . 9.6 t80 -67.39 -29.6 69.15 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.741 -179.91 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 128' ' ' GLY . . . . . . . . . . . . . . . -47.14 -54.49 9.73 Favored Glycine 0 N--CA 1.451 -0.36 0 C-N-CA 119.991 -1.099 . . . . 0.0 110.768 178.968 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 129' ' ' MET . . . . . 0.435 ' HE3' ' HB3' ' A' ' 133' ' ' ALA . 0.0 OUTLIER -72.21 -27.56 62.62 Favored 'General case' 0 C--N 1.328 -0.359 0 N-CA-C 109.144 -0.687 . . . . 0.0 109.144 178.624 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -61.72 -37.46 94.29 Favored Glycine 0 C--N 1.334 0.435 0 CA-C-N 115.792 -0.64 . . . . 0.0 112.288 179.541 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -74.75 -52.3 11.88 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.754 0.311 . . . . 0.0 110.457 179.696 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 42.1 t -54.88 -47.33 75.58 Favored 'Isoleucine or valine' 0 C--O 1.234 0.257 0 CA-C-O 121.243 0.544 . . . . 0.0 109.602 178.981 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 133' ' ' ALA . . . . . 0.435 ' HB3' ' HE3' ' A' ' 129' ' ' MET . . . -65.45 -37.08 85.82 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 115.523 -0.762 . . . . 0.0 110.915 179.245 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 134' ' ' PHE . . . . . 0.411 ' CZ ' ' HA ' ' A' ' 172' ' ' ALA . 45.9 t80 -53.27 -54.02 42.34 Favored 'General case' 0 N--CA 1.452 -0.361 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.26 179.816 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 135' ' ' ILE . . . . . 0.51 ' O ' HG22 ' A' ' 138' ' ' VAL . 42.5 mt -59.66 -32.85 50.24 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 CA-C-N 115.85 -0.614 . . . . 0.0 110.23 179.473 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 136' ' ' GLY . . . . . 0.445 ' O ' ' HB3' ' A' ' 139' ' ' TYR . . . -58.93 -40.06 94.85 Favored Glycine 0 N--CA 1.449 -0.463 0 C-N-CA 120.153 -1.023 . . . . 0.0 111.236 178.706 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 137' ' ' LEU . . . . . 0.498 HD13 HD21 ' A' ' 105' ' ' ASN . 64.0 tp -69.61 -53.37 19.11 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 115.863 -0.169 . . . . 0.0 110.806 179.541 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 138' ' ' VAL . . . . . 0.51 HG22 ' O ' ' A' ' 135' ' ' ILE . 3.3 m -54.69 -31.38 23.82 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.144 0 N-CA-C 109.333 -0.617 . . . . 0.0 109.333 -179.915 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 139' ' ' TYR . . . . . 0.445 ' HB3' ' O ' ' A' ' 136' ' ' GLY . 44.1 t80 -60.19 -46.35 90.03 Favored 'General case' 0 N--CA 1.453 -0.29 0 CA-C-N 115.544 -0.753 . . . . 0.0 109.404 178.183 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 140' ' ' TYR . . . . . 0.446 ' HE2' HD22 ' A' ' 104' ' ' LEU . 22.2 m-85 -63.86 -42.33 97.58 Favored 'General case' 0 C--N 1.333 -0.132 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.526 178.813 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 141' ' ' LEU . . . . . 0.483 HD13 ' O ' ' A' ' 137' ' ' LEU . 11.0 mp -57.13 -27.62 61.99 Favored 'General case' 0 C--N 1.332 -0.173 0 CA-C-N 115.948 -0.569 . . . . 0.0 111.193 -179.743 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 142' ' ' VAL . . . . . 0.47 HG23 ' O ' ' A' ' 138' ' ' VAL . 12.0 t -106.15 -7.91 10.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-O 120.992 0.425 . . . . 0.0 110.926 179.866 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . -73.84 -133.71 0.25 Allowed Glycine 0 CA--C 1.522 0.48 0 C-N-CA 120.812 -0.709 . . . . 0.0 112.814 -179.849 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 144' ' ' PRO . . . . . . . . . . . . . 51.5 Cg_exo -55.57 -23.96 42.47 Favored 'Trans proline' 0 C--N 1.349 0.555 0 C-N-CA 122.672 2.248 . . . . 0.0 113.03 -179.693 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 145' ' ' MET . . . . . 0.422 ' SD ' ' HA ' ' A' ' 141' ' ' LEU . 54.9 mtt -53.77 -27.92 31.71 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-O 120.727 0.299 . . . . 0.0 111.497 -179.583 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 146' ' ' THR . . . . . . . . . . . . . 70.5 p -79.04 -32.99 45.11 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.357 -0.383 . . . . 0.0 110.991 -179.558 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 39.7 tt0 -73.93 -40.26 63.23 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 115.861 -0.609 . . . . 0.0 111.354 -179.636 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 148' ' ' SER . . . . . . . . . . . . . 46.9 t -70.0 -42.26 73.28 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.325 -0.398 . . . . 0.0 111.327 -179.524 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 149' ' ' ALA . . . . . 0.497 ' HB2' ' HB2' ' A' ' 91' ' ' ALA . . . -70.83 -40.27 72.51 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.443 -0.344 . . . . 0.0 111.827 -179.649 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 150' ' ' SER . . . . . 0.604 ' HA ' ' HG2' ' A' ' 157' ' ' LYS . 39.2 t -69.46 -0.02 5.88 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.516 -0.311 . . . . 0.0 111.431 -179.564 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 151' ' ' GLN . . . . . . . . . . . . . 46.1 mt-30 -132.52 6.47 4.09 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.583 -0.28 . . . . 0.0 111.238 179.955 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 25.7 tpt180 -78.73 -52.41 8.43 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-O 120.94 0.4 . . . . 0.0 110.671 179.994 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 153' ' ' SER . . . . . 0.682 ' HB2' HG12 ' A' ' 156' ' ' ILE . 19.8 m -157.51 172.52 18.42 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 115.829 -0.623 . . . . 0.0 110.359 179.183 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 154' ' ' SER . . . . . 0.476 ' HA ' ' NZ ' ' A' ' 157' ' ' LYS . 49.9 m -68.68 -41.08 79.75 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.775 0.321 . . . . 0.0 110.983 179.728 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -76.78 -35.5 39.92 Favored Glycine 0 CA--C 1.519 0.343 0 C-N-CA 120.982 -0.627 . . . . 0.0 113.427 -179.537 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 156' ' ' ILE . . . . . 0.682 HG12 ' HB2' ' A' ' 153' ' ' SER . 41.8 mm -50.15 -38.48 15.06 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.217 0 N-CA-C 111.764 0.283 . . . . 0.0 111.764 -179.421 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 157' ' ' LYS . . . . . 0.604 ' HG2' ' HA ' ' A' ' 150' ' ' SER . 33.3 mtmm -59.78 -40.28 87.72 Favored 'General case' 0 C--N 1.327 -0.371 0 N-CA-C 112.034 0.383 . . . . 0.0 112.034 -179.254 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 36.5 t -72.53 -47.26 49.73 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 121.047 0.451 . . . . 0.0 111.425 -179.046 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 159' ' ' LEU . . . . . 0.432 ' O ' ' HB2' ' A' ' 163' ' ' LEU . 10.2 mt -68.67 -29.17 67.58 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-N 115.986 -0.552 . . . . 0.0 111.534 -179.108 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 160' ' ' TYR . . . . . . . . . . . . . 77.9 t80 -72.63 -46.84 52.08 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.454 -0.339 . . . . 0.0 111.629 -179.336 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 161' ' ' VAL . . . . . 0.409 HG23 ' N ' ' A' ' 162' ' ' ARG . 27.3 m -62.42 -42.79 96.98 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 N-CA-C 111.84 0.311 . . . . 0.0 111.84 -179.154 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 162' ' ' ARG . . . . . 0.409 ' N ' HG23 ' A' ' 161' ' ' VAL . 77.3 mtp180 -68.84 -48.53 63.28 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 120.647 0.26 . . . . 0.0 111.53 -179.678 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 163' ' ' LEU . . . . . 0.432 ' HB2' ' O ' ' A' ' 159' ' ' LEU . 6.8 mp -67.5 -45.08 76.88 Favored 'General case' 0 CA--C 1.531 0.24 0 CA-C-N 116.388 -0.369 . . . . 0.0 111.968 -179.01 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 164' ' ' ARG . . . . . . . . . . . . . 4.3 tmm_? -57.78 -50.97 71.46 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-O 120.635 0.255 . . . . 0.0 110.867 -179.719 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 165' ' ' ASN . . . . . 0.526 ' O ' HG23 ' A' ' 169' ' ' VAL . 0.9 OUTLIER -55.37 -41.37 72.52 Favored 'General case' 0 N--CA 1.448 -0.567 0 CA-C-N 116.352 -0.385 . . . . 0.0 110.486 179.78 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild full ' A' A ' 166' ' ' LEU . . . . . 0.479 ' O ' ' HG ' ' A' ' 170' ' ' LEU . 3.6 mt -58.16 -53.61 56.31 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 115.944 -0.571 . . . . 0.0 110.894 179.496 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 167' ' ' THR . . . . . 0.661 ' HA ' HD11 ' A' ' 170' ' ' LEU . 13.7 m -54.39 -52.58 61.23 Favored 'General case' 0 C--N 1.331 -0.204 0 N-CA-C 112.451 0.537 . . . . 0.0 112.451 -178.431 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 168' ' ' VAL . . . . . . . . . . . . . 85.9 t -54.96 -40.57 54.12 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.483 0 N-CA-C 112.612 0.597 . . . . 0.0 112.612 -178.724 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 169' ' ' VAL . . . . . 0.526 HG23 ' O ' ' A' ' 165' ' ' ASN . 68.7 t -69.18 -67.19 0.46 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 N-CA-C 113.526 0.936 . . . . 0.0 113.526 -177.894 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 170' ' ' LEU . . . . . 0.661 HD11 ' HA ' ' A' ' 167' ' ' THR . 0.4 OUTLIER -59.18 -34.58 72.29 Favored 'General case' 0 N--CA 1.465 0.323 0 N-CA-C 112.869 0.692 . . . . 0.0 112.869 -177.7 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild full ' A' A ' 171' ' ' TRP . . . . . 0.749 ' HE1' H203 ' A' ' 301' ' ' RET . 16.8 m0 -73.29 -31.52 64.1 Favored 'General case' 0 C--N 1.329 -0.29 0 C-N-CA 120.607 -0.437 . . . . 0.0 111.24 -179.507 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 172' ' ' ALA . . . . . 0.411 ' HA ' ' CZ ' ' A' ' 134' ' ' PHE . . . -71.17 -7.15 44.76 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-O 120.912 0.387 . . . . 0.0 110.337 179.52 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 173' ' ' ILE . . . . . 0.537 ' O ' HG12 ' A' ' 177' ' ' ILE . 38.6 mm -88.44 -28.12 5.41 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.173 0 CA-C-N 115.896 -0.593 . . . . 0.0 111.044 179.512 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 174' ' ' TYR . . . . . 0.505 ' HD2' ' HA ' ' A' ' 171' ' ' TRP . 19.2 m-85 -54.11 -48.71 93.33 Favored Pre-proline 0 N--CA 1.467 0.392 0 CA-C-N 116.523 -0.308 . . . . 0.0 111.699 -179.512 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 175' ' ' PRO . . . . . 0.449 ' HB3' ' HZ ' ' A' ' 127' ' ' PHE . 82.5 Cg_exo -45.36 -33.29 8.73 Favored 'Trans proline' 0 C--N 1.351 0.658 0 C-N-CA 121.964 1.776 . . . . 0.0 111.857 179.467 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 176' ' ' PHE . . . . . 0.512 ' O ' ' HG ' ' A' ' 180' ' ' LEU . 96.6 m-85 -80.97 -50.6 9.5 Favored 'General case' 0 CA--C 1.518 -0.287 0 CA-C-N 115.843 -0.617 . . . . 0.0 111.792 179.937 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 177' ' ' ILE . . . . . 0.537 HG12 ' O ' ' A' ' 173' ' ' ILE . 6.6 mm -58.17 -32.49 44.5 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.517 0 CA-C-N 115.927 -0.579 . . . . 0.0 112.56 -177.494 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 178' ' ' TRP . . . . . . . . . . . . . 84.3 t90 -73.45 -32.2 64.22 Favored 'General case' 0 CA--C 1.52 -0.205 0 CA-C-O 120.884 0.373 . . . . 0.0 110.577 179.629 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 179' ' ' LEU . . . . . 0.651 ' HG ' HG22 ' A' ' 185' ' ' VAL . 17.3 tp -81.88 -55.29 4.7 Favored 'General case' 0 C--N 1.322 -0.601 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.851 -179.478 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 180' ' ' LEU . . . . . 0.625 HD22 HD11 ' A' ' 187' ' ' LEU . 7.0 mt -62.04 -51.33 68.42 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.109 -0.496 . . . . 0.0 111.287 -179.479 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 181' ' ' GLY . . . . . 0.452 ' HA3' ' OD1' ' A' ' 193' ' ' ASP . . . -65.7 -84.76 0.08 OUTLIER Glycine 0 C--N 1.332 0.316 0 C-N-CA 120.338 -0.934 . . . . 0.0 111.925 179.414 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 182' ' ' PRO . . . . . 0.541 ' HB3' ' HD2' ' A' ' 183' ' ' PRO . 81.7 Cg_exo -48.25 176.98 0.02 OUTLIER 'Trans proline' 0 C--N 1.35 0.631 0 C-N-CA 122.999 2.466 . . . . 0.0 112.244 178.743 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 183' ' ' PRO . . . . . 0.541 ' HD2' ' HB3' ' A' ' 182' ' ' PRO . 19.2 Cg_endo -59.95 16.03 0.04 OUTLIER 'Trans proline' 0 C--N 1.351 0.674 0 C-N-CA 122.58 2.187 . . . . 0.0 115.142 -178.908 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 184' ' ' GLY . . . . . 0.508 ' HA3' HD12 ' A' ' 179' ' ' LEU . . . -59.51 -45.51 95.46 Favored Glycine 0 C--N 1.336 0.562 0 C-N-CA 119.48 -1.343 . . . . 0.0 110.693 178.756 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 185' ' ' VAL . . . . . 0.651 HG22 ' HG ' ' A' ' 179' ' ' LEU . 2.5 m -148.94 -35.63 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.327 -0.4 0 CA-C-N 114.867 -0.666 . . . . 0.0 110.528 178.635 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 186' ' ' ALA . . . . . . . . . . . . . . . 66.82 77.77 0.27 Allowed 'General case' 0 N--CA 1.462 0.138 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.863 178.607 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 187' ' ' LEU . . . . . 0.625 HD11 HD22 ' A' ' 180' ' ' LEU . 4.2 mt -92.67 -46.66 7.47 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.608 179.502 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 188' ' ' LEU . . . . . . . . . . . . . 97.8 mt -111.28 -166.36 1.07 Allowed 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 115.948 -0.569 . . . . 0.0 111.267 -179.808 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 189' ' ' THR . . . . . 0.449 ' HB ' HG23 ' A' ' 192' ' ' VAL . 26.8 m -81.81 136.3 48.02 Favored Pre-proline 0 C--N 1.328 -0.355 0 CA-C-N 115.822 -0.626 . . . . 0.0 110.932 -179.966 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 190' ' ' PRO . . . . . . . . . . . . . 5.6 Cg_endo -48.56 -38.99 36.95 Favored 'Trans proline' 0 C--N 1.35 0.644 0 C-N-CA 122.713 2.276 . . . . 0.0 112.08 179.611 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 191' ' ' THR . . . . . . . . . . . . . 59.5 p -58.27 -44.71 88.53 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.24 -0.437 . . . . 0.0 110.584 179.613 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 192' ' ' VAL . . . . . 0.449 HG23 ' HB ' ' A' ' 189' ' ' THR . 75.1 t -60.23 -40.38 83.5 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.229 0 CA-C-N 115.867 -0.606 . . . . 0.0 110.649 179.433 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 193' ' ' ASP . . . . . 0.487 ' OD1' HG22 ' A' ' 177' ' ' ILE . 3.4 t70 -56.15 -45.23 79.72 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 115.777 -0.647 . . . . 0.0 110.989 179.834 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 194' ' ' VAL . . . . . . . . . . . . . 48.4 t -63.07 -36.99 78.17 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.053 -0.521 . . . . 0.0 110.944 -179.839 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 195' ' ' ALA . . . . . . . . . . . . . . . -57.24 -47.64 80.86 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 116.393 -0.367 . . . . 0.0 110.838 179.674 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 196' ' ' LEU . . . . . . . . . . . . . 89.3 mt -68.37 -44.95 74.06 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-N 116.308 -0.406 . . . . 0.0 110.903 179.661 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 197' ' ' ILE . . . . . . . . . . . . . 20.2 mm -55.63 -58.37 4.93 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.58 179.633 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 198' ' ' VAL . . . . . . . . . . . . . 77.2 t -52.15 -35.1 18.64 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.568 0 CA-C-N 115.469 -0.787 . . . . 0.0 109.514 178.629 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 199' ' ' TYR . . . . . . . . . . . . . 42.2 t80 -70.38 -33.42 71.39 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 115.521 -0.763 . . . . 0.0 110.62 179.691 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 200' ' ' LEU . . . . . 0.449 HD11 HG13 ' A' ' 177' ' ' ILE . 51.7 mt -67.13 -42.54 84.25 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-N 115.97 -0.559 . . . . 0.0 111.135 -179.683 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 201' ' ' ASP . . . . . . . . . . . . . 8.3 m-20 -72.85 -31.65 64.91 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-O 121.083 0.468 . . . . 0.0 110.235 179.656 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 202' ' ' LEU . . . . . 0.442 ' O ' ' HB ' ' A' ' 206' ' ' VAL . 3.3 mt -70.88 -31.57 68.28 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 115.65 -0.705 . . . . 0.0 112.082 -179.476 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 203' ' ' VAL . . . . . 0.496 HG13 HD22 ' A' ' 170' ' ' LEU . 7.1 p -80.82 -37.01 15.95 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-O 120.637 0.256 . . . . 0.0 111.25 -178.815 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 204' ' ' THR . . . . . 0.426 ' O ' ' HB2' ' A' ' 208' ' ' PHE . 22.2 m -70.1 -48.8 56.14 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-O 120.836 0.351 . . . . 0.0 111.406 179.945 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 205' ' ' LYS . . . . . 0.631 ' HE2' ' HB2' ' A' ' 47' ' ' ALA . 62.7 mttp -72.94 -57.65 3.9 Favored 'General case' 0 C--N 1.326 -0.429 0 N-CA-C 112.129 0.418 . . . . 0.0 112.129 -179.004 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 206' ' ' VAL . . . . . 0.442 ' HB ' ' O ' ' A' ' 202' ' ' LEU . 51.7 t -70.98 -41.89 76.99 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-O 120.631 0.253 . . . . 0.0 111.626 -179.363 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 207' ' ' GLY . . . . . 0.49 ' O ' HD12 ' A' ' 211' ' ' ILE . . . -61.2 -59.6 9.74 Favored Glycine 0 C--N 1.33 0.216 0 C-N-CA 120.631 -0.795 . . . . 0.0 112.698 -179.766 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 208' ' ' PHE . . . . . 0.48 ' O ' ' N ' ' A' ' 212' ' ' ALA . 8.1 m-85 -54.29 -47.08 72.77 Favored 'General case' 0 C--O 1.222 -0.391 0 CA-C-O 121.058 0.456 . . . . 0.0 110.202 -179.986 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 209' ' ' GLY . . . . . 0.519 ' HA2' ' HB3' ' A' ' 212' ' ' ALA . . . -56.21 -32.87 60.57 Favored Glycine 0 N--CA 1.449 -0.454 0 CA-C-N 115.004 -0.998 . . . . 0.0 113.299 179.747 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 210' ' ' PHE . . . . . . . . . . . . . 2.2 m-85 -72.03 -46.02 58.65 Favored 'General case' 0 CA--C 1.513 -0.469 0 N-CA-C 108.811 -0.811 . . . . 0.0 108.811 179.556 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 211' ' ' ILE . . . . . 0.49 HD12 ' O ' ' A' ' 207' ' ' GLY . 3.3 mt -67.59 -27.3 37.87 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.658 0 N-CA-C 107.625 -1.25 . . . . 0.0 107.625 176.481 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 212' ' ' ALA . . . . . 0.519 ' HB3' ' HA2' ' A' ' 209' ' ' GLY . . . -68.18 -43.54 77.94 Favored 'General case' 0 N--CA 1.452 -0.371 0 CA-C-N 114.415 -1.266 . . . . 0.0 110.785 -179.712 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 213' ' ' LEU . . . . . 0.4 ' HG ' ' O ' ' A' ' 209' ' ' GLY . 81.0 mt -70.1 -54.18 14.16 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 115.329 -0.85 . . . . 0.0 111.221 -179.514 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 214' ' ' ASP . . . . . . . . . . . . . 12.8 t70 -55.51 -35.36 65.53 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.801 -179.865 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 215' ' ' ALA . . . . . . . . . . . . . . . -65.65 -57.92 6.95 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.024 -0.535 . . . . 0.0 111.338 -179.916 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 216' ' ' ALA . . . . . . . . . . . . . . . -61.43 -31.09 71.02 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.112 -0.495 . . . . 0.0 111.103 -179.892 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 217' ' ' ALA . . . . . . . . . . . . . . . -62.51 -40.0 95.32 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.31 179.776 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 218' ' ' THR . . . . . . . . . . . . . 93.7 m -69.36 -38.87 78.27 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 115.94 -0.573 . . . . 0.0 110.693 179.408 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 219' ' ' LEU . . . . . . . . . . . . . 70.6 mt -59.6 -40.53 87.77 Favored 'General case' 0 C--N 1.332 -0.185 0 CA-C-N 116.097 -0.501 . . . . 0.0 110.63 179.683 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 220' ' ' ARG . . . . . . . . . . . . . 76.2 mtp180 -82.58 -18.61 40.69 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 115.963 -0.562 . . . . 0.0 110.395 179.598 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 221' ' ' ALA . . . . . . . . . . . . . . . -75.42 -26.09 58.08 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 115.865 -0.607 . . . . 0.0 111.21 179.918 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 222' ' ' GLU . . . . . . . . . . . . . 10.1 pt-20 -92.34 -23.34 19.28 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.39 -0.368 . . . . 0.0 110.381 -179.9 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 223' ' ' HIS . . . . . . . . . . . . . 79.7 m-70 59.71 100.32 0.02 OUTLIER 'General case' 0 C--N 1.331 -0.206 0 CA-C-N 115.726 -0.67 . . . . 0.0 111.118 179.885 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 224' ' ' GLY . . . . . . . . . . . . . . . -94.3 53.31 2.13 Favored Glycine 0 N--CA 1.452 -0.269 0 C-N-CA 120.767 -0.73 . . . . 0.0 112.615 -179.805 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 225' ' ' GLU . . . . . . . . . . . . . 12.1 pt-20 -124.34 148.12 47.71 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.911 0.386 . . . . 0.0 110.941 179.827 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 226' ' ' SER . . . . . . . . . . . . . 80.2 p -83.94 -175.44 5.81 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-N 116.08 -0.509 . . . . 0.0 110.803 179.895 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 227' ' ' LEU . . . . . . . . . . . . . 73.7 mt -81.39 122.26 27.26 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.944 -179.928 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 228' ' ' ALA . . . . . . . . . . . . . . . -93.72 143.84 25.95 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.161 -179.958 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 229' ' ' GLY . . . . . . . . . . . . . . . -161.32 99.78 0.18 Allowed Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.847 -0.692 . . . . 0.0 112.44 179.917 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 230' ' ' VAL . . . . . . . . . . . . . 22.1 t -99.67 137.09 28.22 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.224 0 CA-C-O 120.856 0.36 . . . . 0.0 111.105 -179.808 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 231' ' ' ASP . . . . . . . . . . . . . 5.4 m-20 -87.7 97.66 11.01 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.972 179.913 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 232' ' ' THR . . . . . . . . . . . . . 64.7 p -128.14 124.01 35.85 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.94 179.939 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 233' ' ' ASP . . . . . . . . . . . . . 17.5 t70 -87.11 -34.4 19.13 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.059 -179.857 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 234' ' ' THR . . . . . . . . . . . . . 72.6 p -99.51 117.13 64.31 Favored Pre-proline 0 C--N 1.328 -0.356 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.994 -179.999 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 235' ' ' PRO . . . . . . . . . . . . . 28.3 Cg_endo -61.88 159.22 34.45 Favored 'Trans proline' 0 C--N 1.347 0.474 0 C-N-CA 122.38 2.053 . . . . 0.0 111.991 179.879 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 236' ' ' ALA . . . . . . . . . . . . . . . -149.38 113.77 5.25 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.342 -0.39 . . . . 0.0 111.18 -179.933 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 237' ' ' VAL . . . . . . . . . . . . . 31.6 m -107.76 159.87 7.12 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.134 -0.485 . . . . 0.0 111.112 179.888 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 238' ' ' ALA . . . . . . . . . . . . . . . -76.07 -68.94 0.53 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.184 -179.989 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 239' ' ' ASP . . . . . . . . . . . . . 12.3 m-20 -97.12 148.82 22.65 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.122 -0.49 . . . . 0.0 111.043 -179.954 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 240' ' ' LEU . . . . . . . . . . . . . 71.5 mt -89.31 106.31 18.36 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.803 179.868 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 241' ' ' GLU . . . . . . . . . . . . . 18.3 mm-40 -111.96 -26.89 8.67 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.99 -179.878 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 242' ' ' HIS . . . . . . . . . . . . . 53.8 m-70 58.04 18.18 4.97 Favored 'General case' 0 C--N 1.331 -0.203 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.927 -179.948 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 243' ' ' HIS . . . . . . . . . . . . . 52.2 t-80 -113.55 -51.62 2.79 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.554 -179.993 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 244' ' ' HIS . . . . . . . . . . . . . 71.2 m80 60.13 176.7 0.09 Allowed 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 115.914 -0.584 . . . . 0.0 111.527 179.588 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 245' ' ' HIS . . . . . . . . . . . . . 85.9 m-70 -79.01 121.77 25.34 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 115.911 -0.586 . . . . 0.0 110.946 -179.934 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 246' ' ' HIS . . . . . . . . . . . . . 36.3 p-80 -99.0 176.38 5.59 Favored 'General case' 0 C--N 1.332 -0.175 0 CA-C-N 116.37 -0.377 . . . . 0.0 110.852 179.833 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 247' ' ' HIS . . . . . . . . . . . . . 23.2 t60 . . . . . 0 C--O 1.249 1.036 0 CA-C-O 118.208 -0.901 . . . . 0.0 110.922 179.881 . . . . . . . . 0 0 . 1 . 023 nuclear nobuild full ' A' A ' 301' ' ' RET . . . . . 0.749 H203 ' HE1' ' A' ' 171' ' ' TRP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 95.9 mmm . . . . . 0 N--CA 1.486 1.357 0 CA-C-O 120.888 0.375 . . . . 0.0 110.94 . . . . . . . . . 0 0 . 1 . 024 nuclear nobuild full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 42.2 t -126.36 -34.25 0.88 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.121 -179.903 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -86.75 -12.2 69.43 Favored Glycine 0 N--CA 1.452 -0.275 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.5 -179.813 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 67.0 tp -74.22 -36.6 63.96 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.795 0.331 . . . . 0.0 111.006 179.964 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 82.6 p -58.22 -32.96 68.81 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.531 -179.78 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 30.4 p -54.47 -34.9 62.4 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.343 -0.39 . . . . 0.0 111.109 -179.979 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 7' ' ' LEU . . . . . . . . . . . . . 4.3 mm? -58.22 -53.9 53.04 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 115.994 -0.548 . . . . 0.0 111.514 -179.732 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 8' ' ' PHE . . . . . 0.518 ' HB2' ' HB2' ' A' ' 55' ' ' ALA . 68.3 m-85 -64.22 -36.07 82.86 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.293 -0.412 . . . . 0.0 111.232 -179.484 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 9' ' ' TRP . . . . . . . . . . . . . 44.8 m95 -65.02 -48.98 71.99 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-O 121.098 0.475 . . . . 0.0 110.16 -179.675 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 79.9 mt -60.33 -38.7 84.57 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-N 115.587 -0.733 . . . . 0.0 110.532 179.685 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -65.03 -31.13 79.87 Favored Glycine 0 N--CA 1.448 -0.504 0 C-N-CA 120.647 -0.787 . . . . 0.0 111.642 179.199 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -71.13 -30.71 66.83 Favored 'General case' 0 N--CA 1.454 -0.231 0 CA-C-O 120.81 0.338 . . . . 0.0 110.56 179.393 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 71.8 mt -66.57 -54.61 24.07 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.235 0 CA-C-N 115.959 -0.564 . . . . 0.0 110.335 179.345 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -62.95 -35.56 92.22 Favored Glycine 0 N--CA 1.449 -0.455 0 C-N-CA 120.645 -0.788 . . . . 0.0 111.441 179.374 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 15' ' ' MET . . . . . 0.503 ' SD ' ' HA ' ' A' ' 44' ' ' SER . 53.1 tpp -62.9 -46.37 88.16 Favored 'General case' 0 C--N 1.329 -0.296 0 N-CA-C 110.088 -0.338 . . . . 0.0 110.088 179.358 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 16' ' ' LEU . . . . . 0.463 HD13 ' O ' ' A' ' 16' ' ' LEU . 0.8 OUTLIER -53.22 -39.99 64.16 Favored 'General case' 0 C--N 1.332 -0.187 0 CA-C-N 115.866 -0.606 . . . . 0.0 109.689 179.057 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 70.3 t -58.98 -45.55 92.09 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.206 0 CA-C-N 116.036 -0.529 . . . . 0.0 110.177 179.156 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -63.93 -42.73 98.22 Favored Glycine 0 N--CA 1.45 -0.392 0 C-N-CA 120.749 -0.739 . . . . 0.0 111.737 179.038 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 11.3 m -52.74 -46.51 67.48 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-O 120.847 0.356 . . . . 0.0 111.146 -179.806 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 92.3 mt -71.8 -39.02 70.15 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.337 -179.826 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -59.8 -33.65 72.02 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.574 -0.285 . . . . 0.0 111.698 -179.615 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 22' ' ' PHE . . . . . 0.52 ' HB2' HG22 ' A' ' 41' ' ' VAL . 4.5 m-85 -90.99 -34.83 14.99 Favored 'General case' 0 C--N 1.331 -0.196 0 CA-C-O 120.727 0.299 . . . . 0.0 111.52 -179.446 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -66.53 -50.98 61.39 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 120.93 0.395 . . . . 0.0 111.539 -179.464 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 24' ' ' TRP . . . . . . . . . . . . . 5.1 t-105 -65.42 -45.11 85.16 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 115.877 -0.601 . . . . 0.0 111.176 -179.715 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -71.12 -24.02 62.2 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.854 0.359 . . . . 0.0 111.009 179.874 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -72.47 -41.23 52.39 Favored Glycine 0 N--CA 1.45 -0.371 0 C-N-CA 120.93 -0.652 . . . . 0.0 112.733 -179.866 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 99.3 mtt180 -69.16 -10.03 55.74 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.752 0.31 . . . . 0.0 110.908 -179.894 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 13.1 t70 -127.21 88.74 2.85 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.714 179.876 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -161.12 -80.91 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.199 179.921 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -162.05 -127.98 0.92 Allowed Glycine 0 N--CA 1.452 -0.248 0 C-N-CA 120.806 -0.711 . . . . 0.0 112.476 -179.96 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 89.3 p -136.78 -37.7 0.66 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.749 0.309 . . . . 0.0 110.862 -179.923 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -81.2 -36.24 21.62 Favored Glycine 0 N--CA 1.452 -0.276 0 C-N-CA 120.706 -0.759 . . . . 0.0 112.494 179.921 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 12.4 mm-40 -72.49 -21.11 61.25 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.652 0.263 . . . . 0.0 110.945 -179.922 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 34' ' ' ARG . . . . . 0.411 ' O ' HG23 ' A' ' 38' ' ' VAL . 79.0 ttt180 -51.57 -29.36 16.88 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 116.111 -0.495 . . . . 0.0 111.468 -179.607 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 80.2 ttt180 -60.19 -48.8 80.21 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.856 0.36 . . . . 0.0 110.882 179.896 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 59.4 m-85 -67.46 -29.87 69.43 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.028 -0.533 . . . . 0.0 111.139 179.896 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 37' ' ' TYR . . . . . 0.426 ' O ' HG23 ' A' ' 41' ' ' VAL . 43.8 m-85 -72.13 -53.0 14.05 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.071 -0.513 . . . . 0.0 111.62 -179.365 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 38' ' ' VAL . . . . . 0.411 HG23 ' O ' ' A' ' 34' ' ' ARG . 96.7 t -56.92 -37.39 54.05 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-O 121.103 0.477 . . . . 0.0 110.129 179.594 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 38.1 m -65.72 -46.27 79.57 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 115.662 -0.699 . . . . 0.0 110.182 179.158 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 40' ' ' LEU . . . . . 0.475 HD12 HD12 ' A' ' 43' ' ' ILE . 28.2 tp -59.67 -50.17 74.91 Favored 'General case' 0 C--O 1.235 0.318 0 CA-C-N 115.771 -0.649 . . . . 0.0 110.459 179.588 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . 0.52 HG22 ' HB2' ' A' ' 22' ' ' PHE . 61.3 t -59.1 -34.63 53.88 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.254 0 CA-C-N 115.842 -0.617 . . . . 0.0 109.938 179.186 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -59.07 -39.19 94.03 Favored Glycine 0 N--CA 1.449 -0.475 0 C-N-CA 120.727 -0.749 . . . . 0.0 111.832 179.252 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 43' ' ' ILE . . . . . 0.475 HD12 HD12 ' A' ' 40' ' ' LEU . 0.9 OUTLIER -64.96 -57.08 12.63 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.153 0 CA-C-O 120.831 0.348 . . . . 0.0 110.786 179.402 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild full ' A' A ' 44' ' ' SER . . . . . 0.503 ' HA ' ' SD ' ' A' ' 15' ' ' MET . 40.8 t -59.72 -24.21 63.81 Favored 'General case' 0 C--N 1.332 -0.168 0 CA-C-N 116.103 -0.499 . . . . 0.0 111.56 -179.691 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -74.15 -59.55 3.89 Favored Glycine 0 CA--C 1.518 0.262 0 C-N-CA 120.72 -0.752 . . . . 0.0 113.039 -179.647 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 46' ' ' ILE . . . . . 0.409 HD11 HG22 ' A' ' 79' ' ' THR . 21.1 pt -58.72 -35.02 53.54 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.19 0 CA-C-O 120.745 0.307 . . . . 0.0 111.286 -179.876 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 47' ' ' ALA . . . . . 0.619 ' HB2' ' HE2' ' A' ' 205' ' ' LYS . . . -65.98 -45.74 80.53 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-N 116.32 -0.4 . . . . 0.0 111.058 179.833 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -54.84 -52.18 63.58 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.246 -0.434 . . . . 0.0 111.216 -179.713 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 49' ' ' VAL . . . . . 0.41 ' O ' HG13 ' A' ' 53' ' ' VAL . 34.6 m -64.35 -34.04 66.66 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.393 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.821 179.931 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -65.23 -37.93 88.81 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.367 -0.379 . . . . 0.0 110.845 179.576 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 51' ' ' TYR . . . . . 0.416 ' OH ' ' HB2' ' A' ' 201' ' ' ASP . 30.3 m-85 -70.79 -29.06 65.15 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.193 179.944 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -74.5 -41.67 60.29 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-N 115.613 -0.721 . . . . 0.0 111.184 179.59 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 53' ' ' VAL . . . . . 0.425 HG23 ' N ' ' A' ' 54' ' ' MET . 20.8 m -73.25 -43.52 56.99 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.125 0 CA-C-N 116.498 -0.319 . . . . 0.0 111.008 179.883 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 54' ' ' MET . . . . . 0.448 ' HG2' ' HB2' ' A' ' 71' ' ' PRO . 72.8 mtm -63.49 -32.46 73.92 Favored 'General case' 0 C--N 1.332 -0.183 0 CA-C-O 121.038 0.447 . . . . 0.0 110.023 179.443 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 55' ' ' ALA . . . . . 0.518 ' HB2' ' HB2' ' A' ' 8' ' ' PHE . . . -65.23 -37.06 86.07 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 115.667 -0.697 . . . . 0.0 110.712 179.349 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 93.8 mt -76.5 -13.03 60.12 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 115.869 -0.605 . . . . 0.0 110.851 179.756 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 71.53 31.21 65.7 Favored Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.782 -0.723 . . . . 0.0 112.818 179.991 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 32.3 m -79.92 19.98 0.15 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.211 0 CA-C-O 120.834 0.35 . . . . 0.0 111.557 179.869 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -159.1 14.93 0.23 Allowed Glycine 0 N--CA 1.451 -0.358 0 C-N-CA 120.795 -0.717 . . . . 0.0 112.844 179.866 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 60' ' ' TRP . . . . . . . . . . . . . 41.0 m0 -81.09 107.57 14.01 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.728 0.299 . . . . 0.0 110.633 179.862 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 61' ' ' VAL . . . . . 0.42 ' HA ' ' HD3' ' A' ' 62' ' ' PRO . 4.9 p -106.38 119.33 52.19 Favored Pre-proline 0 CA--C 1.533 0.306 0 CA-C-N 116.342 -0.39 . . . . 0.0 111.572 -179.624 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 62' ' ' PRO . . . . . 0.42 ' HD3' ' HA ' ' A' ' 61' ' ' VAL . 16.8 Cg_exo -67.6 133.76 30.84 Favored 'Trans proline' 0 C--N 1.351 0.659 0 C-N-CA 122.35 2.033 . . . . 0.0 111.79 179.423 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 78.2 t -132.48 100.54 4.06 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.373 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.214 -179.716 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . 59.53 -86.85 0.02 OUTLIER 'General case' 0 C--N 1.331 -0.212 0 CA-C-N 116.043 -0.526 . . . . 0.0 111.265 -179.999 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 45.1 mt-10 -122.36 -27.26 4.49 Favored 'General case' 0 C--N 1.332 -0.195 0 CA-C-N 116.362 -0.381 . . . . 0.0 110.724 179.992 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 66' ' ' ARG . . . . . 0.444 ' HD2' ' N ' ' A' ' 66' ' ' ARG . 8.1 mpt_? -104.64 140.62 37.76 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.611 179.826 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 22.3 m -98.17 113.19 25.03 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.345 -0.389 . . . . 0.0 111.113 -179.74 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 26.3 t -85.11 146.84 6.06 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.354 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.474 179.498 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 69' ' ' PHE . . . . . . . . . . . . . 19.8 m-85 -108.51 115.17 29.59 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-O 120.91 0.386 . . . . 0.0 110.111 -179.315 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 70' ' ' VAL . . . . . 0.521 ' HB ' ' HD3' ' A' ' 71' ' ' PRO . 13.4 t -68.9 -49.35 26.81 Favored Pre-proline 0 C--N 1.323 -0.557 0 CA-C-N 115.946 -0.57 . . . . 0.0 112.243 -179.006 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 71' ' ' PRO . . . . . 0.521 ' HD3' ' HB ' ' A' ' 70' ' ' VAL . 29.5 Cg_exo -61.97 -17.48 56.1 Favored 'Trans proline' 0 C--N 1.35 0.608 0 C-N-CA 122.176 1.917 . . . . 0.0 112.449 -179.525 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 51.6 ttp180 -71.34 -54.68 9.97 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.482 -0.327 . . . . 0.0 111.43 -179.727 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 73' ' ' TYR . . . . . 0.431 ' O ' HG13 ' A' ' 77' ' ' ILE . 96.2 m-85 -69.74 -31.69 69.82 Favored 'General case' 0 C--N 1.331 -0.235 0 C-N-CA 120.919 -0.313 . . . . 0.0 110.648 -179.84 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 74' ' ' ILE . . . . . 0.477 ' HA ' HD12 ' A' ' 77' ' ' ILE . 0.3 OUTLIER -69.74 -38.56 76.44 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.18 0 N-CA-C 109.672 -0.492 . . . . 0.0 109.672 178.993 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild full ' A' A ' 75' ' ' ASP . . . . . 0.473 ' O ' HG23 ' A' ' 79' ' ' THR . 11.4 t70 -59.08 -37.59 77.45 Favored 'General case' 0 N--CA 1.454 -0.24 0 N-CA-C 109.211 -0.663 . . . . 0.0 109.211 178.595 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 76' ' ' TRP . . . . . . . . . . . . . 53.6 m0 -67.97 -32.45 72.88 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 115.689 -0.687 . . . . 0.0 110.323 179.006 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 77' ' ' ILE . . . . . 0.477 HD12 ' HA ' ' A' ' 74' ' ' ILE . 97.6 mt -66.57 -29.37 46.29 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.362 179.232 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 48.9 mt -91.59 -19.98 22.15 Favored 'General case' 0 CA--C 1.532 0.277 0 CA-C-N 116.1 -0.5 . . . . 0.0 112.016 179.983 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 79' ' ' THR . . . . . 0.473 HG23 ' O ' ' A' ' 75' ' ' ASP . 81.4 p -101.16 -52.63 3.22 Favored 'General case' 0 N--CA 1.465 0.323 0 N-CA-C 113.538 0.94 . . . . 0.0 113.538 -177.889 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 80' ' ' THR . . . . . 0.467 HG21 ' HE1' ' A' ' 109' ' ' MET . 61.3 m -46.69 -53.87 22.72 Favored Pre-proline 0 CA--C 1.533 0.296 0 N-CA-C 112.886 0.699 . . . . 0.0 112.886 -178.557 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 81' ' ' PRO . . . . . 0.465 ' HD2' ' N ' ' A' ' 80' ' ' THR . 35.0 Cg_endo -62.2 -22.16 73.71 Favored 'Trans proline' 0 C--N 1.35 0.622 0 C-N-CA 121.543 1.495 . . . . 0.0 111.603 -179.598 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 82' ' ' LEU . . . . . . . . . . . . . 16.2 tp -76.91 -33.31 57.77 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 115.657 -0.701 . . . . 0.0 110.234 179.674 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 28.1 mm -69.2 -53.18 26.86 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.226 0 CA-C-N 116.087 -0.506 . . . . 0.0 110.122 179.162 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . 0.416 HG13 ' HH2' ' A' ' 171' ' ' TRP . 28.9 m -60.13 -31.97 49.32 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.218 0 N-CA-C 109.645 -0.502 . . . . 0.0 109.645 178.907 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 85' ' ' TYR . . . . . 0.405 ' O ' ' HG ' ' A' ' 89' ' ' LEU . 79.8 t80 -65.12 -34.11 77.63 Favored 'General case' 0 N--CA 1.452 -0.366 0 CA-C-N 115.641 -0.709 . . . . 0.0 109.532 178.963 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 86' ' ' PHE . . . . . . . . . . . . . 7.9 t80 -62.62 -51.08 68.68 Favored 'General case' 0 C--N 1.333 -0.14 0 CA-C-N 115.768 -0.651 . . . . 0.0 110.247 179.404 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 9.3 mp -61.53 -36.05 79.46 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 115.992 -0.549 . . . . 0.0 110.407 179.785 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -66.33 -27.96 73.39 Favored Glycine 0 N--CA 1.45 -0.404 0 C-N-CA 120.767 -0.73 . . . . 0.0 111.875 179.282 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 89' ' ' LEU . . . . . 0.405 ' HG ' ' O ' ' A' ' 85' ' ' TYR . 75.9 mt -72.73 -40.88 65.74 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 120.994 0.426 . . . . 0.0 110.624 179.716 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 47.3 mt -58.44 -47.53 83.68 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 115.648 -0.706 . . . . 0.0 111.336 -179.644 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . 0.423 ' HB2' ' HB2' ' A' ' 149' ' ' ALA . . . -75.46 -54.52 6.9 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.635 -179.545 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 107.11 69.51 0.7 Allowed Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.854 -0.689 . . . . 0.0 112.009 -179.591 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 93' ' ' LEU . . . . . 0.544 HD23 ' HB3' ' A' ' 97' ' ' GLU . 8.5 mp -87.41 171.66 10.39 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.794 0.331 . . . . 0.0 111.131 -179.6 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 94' ' ' ASP . . . . . . . . . . . . . 8.9 m-20 -90.93 166.25 13.14 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.928 179.826 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 49.6 m -55.56 -33.02 63.49 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-N 116.312 -0.404 . . . . 0.0 111.029 -179.987 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 9.4 ptp180 -71.53 -48.05 51.25 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.842 179.88 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 97' ' ' GLU . . . . . 0.544 ' HB3' HD23 ' A' ' 93' ' ' LEU . 44.6 mt-10 -58.2 -45.14 88.16 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.923 -179.969 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 98' ' ' PHE . . . . . 0.443 ' O ' HG12 ' A' ' 102' ' ' ILE . 31.2 m-85 -59.1 -48.85 80.09 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.374 -0.375 . . . . 0.0 110.615 179.568 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -55.9 -31.07 58.07 Favored Glycine 0 N--CA 1.45 -0.381 0 C-N-CA 120.888 -0.672 . . . . 0.0 112.587 -179.775 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 98.0 mt -71.5 -44.29 71.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-O 120.798 0.332 . . . . 0.0 111.531 -179.94 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 39.7 t -68.12 -51.07 52.51 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.729 -179.344 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 102' ' ' ILE . . . . . 0.443 HG12 ' O ' ' A' ' 98' ' ' PHE . 34.0 mm -59.38 -50.0 81.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.325 -0.398 . . . . 0.0 111.771 -179.253 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 7.9 t -59.37 -36.11 75.14 Favored 'General case' 0 C--N 1.331 -0.204 0 CA-C-O 120.761 0.315 . . . . 0.0 110.911 -179.739 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 104' ' ' LEU . . . . . 0.457 ' O ' HG23 ' A' ' 108' ' ' VAL . 27.4 tp -63.03 -44.44 95.9 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.218 -0.447 . . . . 0.0 110.403 179.542 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 105' ' ' ASN . . . . . 0.578 ' N ' HD22 ' A' ' 105' ' ' ASN . 0.8 OUTLIER -63.66 -26.47 68.68 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 115.955 -0.566 . . . . 0.0 110.555 179.726 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild full ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 84.7 m -67.15 -54.59 19.81 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 115.998 -0.546 . . . . 0.0 111.167 179.954 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 7.5 p -63.6 -36.59 76.98 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.213 0 CA-C-N 116.42 -0.354 . . . . 0.0 111.05 -179.895 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . 0.457 HG23 ' O ' ' A' ' 104' ' ' LEU . 72.3 t -65.74 -45.5 91.62 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.226 0 CA-C-N 116.386 -0.37 . . . . 0.0 110.894 179.496 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 109' ' ' MET . . . . . 0.467 ' HE1' HG21 ' A' ' 80' ' ' THR . 8.7 tpp -65.15 -39.24 92.7 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.829 -179.82 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 29.0 tp -66.98 -30.75 70.95 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.215 179.701 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -62.5 -52.37 63.77 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 116.068 -0.515 . . . . 0.0 110.313 179.136 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 112' ' ' GLY . . . . . 0.712 ' HA3' ' H21' ' A' ' 301' ' ' RET . . . -67.62 -32.56 78.74 Favored Glycine 0 N--CA 1.45 -0.395 0 C-N-CA 120.566 -0.826 . . . . 0.0 111.649 179.127 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 113' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER -52.79 -75.89 0.03 OUTLIER 'General case' 0 C--N 1.332 -0.179 0 CA-C-O 121.008 0.432 . . . . 0.0 109.883 179.357 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 114' ' ' ALA . . . . . 0.431 ' HB3' HD22 ' A' ' 126' ' ' LEU . . . -61.05 -21.43 63.62 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-N 115.619 -0.719 . . . . 0.0 110.646 179.206 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -52.57 -50.98 46.32 Favored Glycine 0 C--N 1.333 0.385 0 C-N-CA 120.905 -0.664 . . . . 0.0 112.125 179.739 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 116' ' ' ALA . . . . . 0.574 ' HB2' ' HB3' ' A' ' 183' ' ' PRO . . . -78.19 -15.7 58.58 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 121.008 0.432 . . . . 0.0 110.723 179.217 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 117' ' ' MET . . . . . 0.419 ' HB3' ' HA ' ' A' ' 114' ' ' ALA . 45.1 tpp -87.49 -5.95 58.58 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 115.883 -0.599 . . . . 0.0 111.502 -179.588 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 118' ' ' VAL . . . . . 0.406 HG11 ' N ' ' A' ' 123' ' ' ARG . 21.7 m -58.81 146.67 74.78 Favored Pre-proline 0 C--N 1.331 -0.219 0 CA-C-N 116.683 -0.235 . . . . 0.0 111.449 -179.608 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 119' ' ' PRO . . . . . . . . . . . . . 69.2 Cg_endo -90.76 -5.45 4.43 Favored 'Trans proline' 0 N--CA 1.455 -0.748 0 C-N-CA 122.912 2.408 . . . . 0.0 112.228 179.431 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -145.41 -127.99 1.98 Allowed Glycine 0 C--N 1.333 0.362 0 C-N-CA 120.867 -0.683 . . . . 0.0 112.84 -179.733 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 46.6 pt -99.16 11.56 6.21 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.212 0 CA-C-O 120.596 0.236 . . . . 0.0 111.595 -179.491 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 122' ' ' GLU . . . . . 0.47 ' O ' HD12 ' A' ' 126' ' ' LEU . 15.1 mm-40 -60.53 -21.03 62.05 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.754 0.311 . . . . 0.0 110.997 -179.914 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 123' ' ' ARG . . . . . 0.439 HH11 ' HD2' ' A' ' 123' ' ' ARG . 10.0 ptt180 -52.22 -34.47 45.91 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.027 -0.533 . . . . 0.0 111.471 -179.935 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 124' ' ' TYR . . . . . . . . . . . . . 39.6 m-85 -69.16 -32.08 71.16 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.531 -179.574 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 125' ' ' ALA . . . . . . . . . . . . . . . -72.88 -56.51 5.09 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-O 120.831 0.348 . . . . 0.0 111.098 -179.699 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 126' ' ' LEU . . . . . 0.47 HD12 ' O ' ' A' ' 122' ' ' GLU . 1.3 mp -57.26 -49.61 75.51 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.662 179.92 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 127' ' ' PHE . . . . . . . . . . . . . 7.5 t80 -66.45 -37.42 85.12 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.335 -0.393 . . . . 0.0 110.857 -179.991 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 128' ' ' GLY . . . . . . . . . . . . . . . -47.18 -46.29 21.1 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.057 -1.068 . . . . 0.0 110.904 179.045 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 129' ' ' MET . . . . . . . . . . . . . 0.3 OUTLIER -70.13 -35.77 74.31 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 115.388 -0.406 . . . . 0.0 110.041 178.848 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -68.09 -28.2 73.45 Favored Glycine 0 C--N 1.334 0.434 0 CA-C-N 115.88 -0.6 . . . . 0.0 112.94 -179.659 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -74.42 -53.65 9.15 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 120.722 0.296 . . . . 0.0 110.313 179.915 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 22.2 t -58.2 -42.69 84.04 Favored 'Isoleucine or valine' 0 C--O 1.235 0.338 0 N-CA-C 109.022 -0.733 . . . . 0.0 109.022 178.476 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -64.31 -35.27 80.32 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.264 -0.88 . . . . 0.0 110.351 179.086 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 134' ' ' PHE . . . . . . . . . . . . . 75.3 t80 -56.74 -50.67 71.54 Favored 'General case' 0 N--CA 1.453 -0.323 0 CA-C-N 116.284 -0.416 . . . . 0.0 109.901 179.447 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 135' ' ' ILE . . . . . 0.479 ' O ' HG22 ' A' ' 138' ' ' VAL . 63.0 mt -57.44 -33.17 43.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 115.779 -0.646 . . . . 0.0 109.967 179.114 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 136' ' ' GLY . . . . . 0.446 ' O ' ' HB3' ' A' ' 139' ' ' TYR . . . -62.13 -40.62 99.19 Favored Glycine 0 N--CA 1.449 -0.478 0 C-N-CA 120.134 -1.032 . . . . 0.0 111.44 178.689 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 137' ' ' LEU . . . . . . . . . . . . . 26.8 tp -68.91 -49.91 54.01 Favored 'General case' 0 N--CA 1.455 -0.219 0 CA-C-O 120.43 0.157 . . . . 0.0 110.701 179.673 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 138' ' ' VAL . . . . . 0.554 ' HA ' HD12 ' A' ' 141' ' ' LEU . 4.7 m -58.2 -31.39 41.97 Favored 'Isoleucine or valine' 0 C--O 1.233 0.22 0 CA-C-O 121.338 0.589 . . . . 0.0 109.618 179.219 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 139' ' ' TYR . . . . . 0.446 ' HB3' ' O ' ' A' ' 136' ' ' GLY . 55.7 t80 -60.48 -43.21 97.21 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 115.34 -0.845 . . . . 0.0 109.302 178.373 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 36.7 m-85 -64.03 -32.72 74.38 Favored 'General case' 0 C--N 1.332 -0.16 0 CA-C-N 115.839 -0.619 . . . . 0.0 110.451 178.887 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 141' ' ' LEU . . . . . 0.554 HD12 ' HA ' ' A' ' 138' ' ' VAL . 95.3 mt -57.67 -47.43 82.32 Favored 'General case' 0 N--CA 1.462 0.168 0 CA-C-N 116.349 -0.387 . . . . 0.0 110.588 179.671 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 9.5 p -95.85 1.28 10.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.818 179.868 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 143' ' ' GLY . . . . . 0.4 ' HA3' ' HD2' ' A' ' 144' ' ' PRO . . . -75.95 -140.55 0.94 Allowed Glycine 0 CA--C 1.52 0.361 0 C-N-CA 120.99 -0.624 . . . . 0.0 112.878 -179.572 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 144' ' ' PRO . . . . . 0.4 ' HD2' ' HA3' ' A' ' 143' ' ' GLY . 19.5 Cg_endo -58.88 -23.92 69.9 Favored 'Trans proline' 0 C--N 1.347 0.488 0 C-N-CA 122.745 2.297 . . . . 0.0 112.685 -179.776 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 145' ' ' MET . . . . . . . . . . . . . 56.8 mtt -58.19 -33.13 68.94 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 120.806 0.336 . . . . 0.0 111.242 179.966 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 146' ' ' THR . . . . . . . . . . . . . 12.1 m -80.86 -32.35 35.05 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.385 -179.05 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 40.2 tt0 -71.8 -42.32 67.21 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-N 116.165 -0.47 . . . . 0.0 111.169 -179.743 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 148' ' ' SER . . . . . . . . . . . . . 58.2 m -70.61 -46.86 62.58 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-N 116.263 -0.426 . . . . 0.0 111.407 -179.432 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 149' ' ' ALA . . . . . 0.423 ' HB2' ' HB2' ' A' ' 91' ' ' ALA . . . -63.03 -41.33 99.49 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.309 -0.405 . . . . 0.0 111.742 -179.496 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 150' ' ' SER . . . . . . . . . . . . . 66.2 m -68.91 -0.58 5.73 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.38 -0.373 . . . . 0.0 111.501 -179.617 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 151' ' ' GLN . . . . . . . . . . . . . 44.8 mt-30 -129.09 3.69 5.26 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.628 -0.26 . . . . 0.0 111.246 179.991 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 31.0 tpt180 -76.42 -51.31 12.09 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.895 0.379 . . . . 0.0 110.651 -179.985 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 153' ' ' SER . . . . . 0.658 ' HB3' HG12 ' A' ' 156' ' ' ILE . 22.8 t -157.21 172.4 18.7 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-N 115.885 -0.598 . . . . 0.0 110.473 179.496 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 154' ' ' SER . . . . . . . . . . . . . 70.2 p -67.65 -41.22 84.18 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.382 -0.372 . . . . 0.0 110.912 179.937 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -77.07 -37.03 33.71 Favored Glycine 0 CA--C 1.519 0.305 0 C-N-CA 120.961 -0.638 . . . . 0.0 113.158 -179.657 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 156' ' ' ILE . . . . . 0.658 HG12 ' HB3' ' A' ' 153' ' ' SER . 42.4 mm -52.66 -37.22 24.19 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.186 0 CA-C-O 120.628 0.252 . . . . 0.0 111.56 -179.47 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 157' ' ' LYS . . . . . 0.44 ' O ' HG13 ' A' ' 161' ' ' VAL . 38.3 ttpt -60.29 -53.84 52.89 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.457 -0.338 . . . . 0.0 111.555 -179.629 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 48.9 m -63.5 -44.22 94.96 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 121.008 0.432 . . . . 0.0 111.468 -179.43 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 159' ' ' LEU . . . . . 0.422 HD23 ' O ' ' A' ' 159' ' ' LEU . 6.0 tt -63.71 -37.94 89.23 Favored 'General case' 0 C--N 1.326 -0.438 0 CA-C-N 115.993 -0.549 . . . . 0.0 110.983 -179.485 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 160' ' ' TYR . . . . . . . . . . . . . 54.1 t80 -74.4 -46.84 37.68 Favored 'General case' 0 C--N 1.329 -0.317 0 N-CA-C 112.548 0.573 . . . . 0.0 112.548 -178.796 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 161' ' ' VAL . . . . . 0.44 HG13 ' O ' ' A' ' 157' ' ' LYS . 28.2 m -56.13 -44.65 79.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 N-CA-C 111.908 0.336 . . . . 0.0 111.908 -178.685 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 162' ' ' ARG . . . . . 0.467 ' O ' HD12 ' A' ' 166' ' ' LEU . 97.8 mtt180 -68.65 -49.44 59.11 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.746 0.308 . . . . 0.0 111.475 -179.452 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 163' ' ' LEU . . . . . . . . . . . . . 6.1 mp -63.46 -51.58 65.04 Favored 'General case' 0 C--N 1.33 -0.239 0 CA-C-N 116.232 -0.44 . . . . 0.0 112.034 -179.097 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 164' ' ' ARG . . . . . 0.433 HH11 HG21 ' A' ' 168' ' ' VAL . 5.2 tmm_? -53.42 -50.32 65.46 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.411 -0.358 . . . . 0.0 111.208 -179.406 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 165' ' ' ASN . . . . . 0.496 HD22 ' N ' ' A' ' 165' ' ' ASN . 0.9 OUTLIER -53.55 -42.28 67.32 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.894 0.378 . . . . 0.0 110.609 179.898 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild full ' A' A ' 166' ' ' LEU . . . . . 0.504 ' O ' ' HG ' ' A' ' 170' ' ' LEU . 1.4 mt -58.31 -51.24 70.61 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 115.998 -0.546 . . . . 0.0 111.205 179.54 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 167' ' ' THR . . . . . 0.645 ' HA ' HD11 ' A' ' 170' ' ' LEU . 6.0 m -53.93 -53.88 46.62 Favored 'General case' 0 C--N 1.332 -0.178 0 N-CA-C 112.299 0.481 . . . . 0.0 112.299 -178.198 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 168' ' ' VAL . . . . . 0.433 HG21 HH11 ' A' ' 164' ' ' ARG . 25.2 t -53.66 -42.51 51.29 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.525 0 N-CA-C 112.327 0.492 . . . . 0.0 112.327 -179.432 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 169' ' ' VAL . . . . . 0.413 HG23 ' O ' ' A' ' 165' ' ' ASN . 92.4 t -68.75 -66.73 0.49 Allowed 'Isoleucine or valine' 0 CA--C 1.532 0.281 0 N-CA-C 113.789 1.033 . . . . 0.0 113.789 -177.774 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 170' ' ' LEU . . . . . 0.645 HD11 ' HA ' ' A' ' 167' ' ' THR . 0.4 OUTLIER -59.62 -33.1 71.06 Favored 'General case' 0 N--CA 1.465 0.295 0 N-CA-C 113.01 0.744 . . . . 0.0 113.01 -177.565 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild full ' A' A ' 171' ' ' TRP . . . . . 0.773 ' HE1' H203 ' A' ' 301' ' ' RET . 19.6 m0 -73.43 -30.9 63.53 Favored 'General case' 0 C--N 1.329 -0.315 0 C-N-CA 120.411 -0.516 . . . . 0.0 111.171 -179.509 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 172' ' ' ALA . . . . . . . . . . . . . . . -70.99 -7.28 45.09 Favored 'General case' 0 C--N 1.33 -0.275 0 C-N-CA 120.847 -0.341 . . . . 0.0 110.817 179.453 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 173' ' ' ILE . . . . . 0.478 ' O ' HG12 ' A' ' 177' ' ' ILE . 22.9 mm -88.46 -27.07 5.5 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.21 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.951 179.627 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 174' ' ' TYR . . . . . 0.459 ' HD1' ' HA ' ' A' ' 171' ' ' TRP . 29.6 m-85 -54.02 -47.7 96.28 Favored Pre-proline 0 CA--C 1.529 0.143 0 CA-C-N 116.309 -0.405 . . . . 0.0 111.943 -179.286 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 175' ' ' PRO . . . . . 0.402 ' CD ' ' N ' ' A' ' 174' ' ' TYR . 81.8 Cg_exo -47.08 -34.86 17.98 Favored 'Trans proline' 0 C--N 1.35 0.625 0 C-N-CA 121.77 1.647 . . . . 0.0 111.852 179.093 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 176' ' ' PHE . . . . . 0.515 ' O ' ' HG ' ' A' ' 180' ' ' LEU . 67.6 m-85 -80.9 -51.02 9.04 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 115.749 -0.659 . . . . 0.0 111.554 179.729 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 177' ' ' ILE . . . . . 0.478 HG12 ' O ' ' A' ' 173' ' ' ILE . 31.5 mm -58.13 -30.48 39.42 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.558 0 CA-C-N 115.742 -0.663 . . . . 0.0 111.471 -178.674 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 178' ' ' TRP . . . . . 0.423 ' O ' ' HB2' ' A' ' 183' ' ' PRO . 90.7 t90 -73.77 -59.14 2.86 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-O 121.005 0.431 . . . . 0.0 110.865 179.791 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 179' ' ' LEU . . . . . 0.634 ' HG ' HG22 ' A' ' 185' ' ' VAL . 15.4 tp -61.31 -54.72 40.3 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 115.996 -0.547 . . . . 0.0 111.711 -178.989 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 180' ' ' LEU . . . . . 0.677 HD22 HD11 ' A' ' 187' ' ' LEU . 11.6 mt -63.65 -28.68 70.07 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 116.449 -0.341 . . . . 0.0 111.744 -179.112 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 181' ' ' GLY . . . . . 0.432 ' C ' ' HD2' ' A' ' 183' ' ' PRO . . . -73.96 -173.59 28.61 Favored Glycine 0 N--CA 1.451 -0.359 0 C-N-CA 120.05 -1.071 . . . . 0.0 111.823 179.422 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 182' ' ' PRO . . . . . 0.457 ' HG2' ' HD3' ' A' ' 183' ' ' PRO . 1.3 Cg_endo -47.01 -43.19 25.06 Favored 'Trans proline' 0 CA--C 1.541 0.831 0 C-N-CA 122.856 2.371 . . . . 0.0 113.789 179.561 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 183' ' ' PRO . . . . . 0.574 ' HB3' ' HB2' ' A' ' 116' ' ' ALA . 44.2 Cg_exo -37.86 -59.22 0.55 Allowed 'Trans proline' 0 C--N 1.357 0.989 0 C-N-CA 122.819 2.346 . . . . 0.0 114.12 -179.89 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 184' ' ' GLY . . . . . . . . . . . . . . . -115.65 -107.2 2.59 Favored Glycine 0 N--CA 1.45 -0.369 0 C-N-CA 120.162 -1.018 . . . . 0.0 113.174 -179.052 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 185' ' ' VAL . . . . . 0.667 HG23 ' HA ' ' A' ' 180' ' ' LEU . 26.8 m -76.81 86.11 0.81 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.405 0 CA-C-O 121.461 0.648 . . . . 0.0 111.021 -179.492 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 186' ' ' ALA . . . . . . . . . . . . . . . -63.38 85.27 0.03 OUTLIER 'General case' 0 C--N 1.323 -0.555 0 CA-C-N 115.683 -0.69 . . . . 0.0 111.08 179.67 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 187' ' ' LEU . . . . . 0.677 HD11 HD22 ' A' ' 180' ' ' LEU . 6.2 mt -78.99 -49.21 13.09 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 116.317 -0.402 . . . . 0.0 110.9 179.843 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 188' ' ' LEU . . . . . 0.484 ' HB3' ' H ' ' A' ' 189' ' ' THR . 3.9 mm? -94.98 -157.48 0.57 Allowed 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.034 -0.53 . . . . 0.0 111.437 -179.405 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 189' ' ' THR . . . . . 0.508 ' HB ' HG23 ' A' ' 192' ' ' VAL . 32.3 m -96.12 136.32 22.16 Favored Pre-proline 0 C--N 1.331 -0.218 0 CA-C-N 115.944 -0.571 . . . . 0.0 110.96 -179.654 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 190' ' ' PRO . . . . . 0.458 ' O ' HG23 ' A' ' 194' ' ' VAL . 80.6 Cg_exo -46.64 -42.98 23.61 Favored 'Trans proline' 0 C--N 1.35 0.639 0 C-N-CA 122.61 2.207 . . . . 0.0 113.022 -179.977 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 191' ' ' THR . . . . . . . . . . . . . 75.2 p -62.19 -45.78 91.83 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-O 120.792 0.33 . . . . 0.0 111.162 -179.822 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 192' ' ' VAL . . . . . 0.508 HG23 ' HB ' ' A' ' 189' ' ' THR . 58.9 t -60.04 -44.44 94.85 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.267 -0.424 . . . . 0.0 111.031 179.922 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 193' ' ' ASP . . . . . . . . . . . . . 28.2 t70 -56.81 -43.49 81.05 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.079 -0.509 . . . . 0.0 111.074 -179.935 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 194' ' ' VAL . . . . . 0.458 HG23 ' O ' ' A' ' 190' ' ' PRO . 93.1 t -63.06 -36.03 74.17 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.354 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.867 179.765 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 195' ' ' ALA . . . . . . . . . . . . . . . -58.62 -47.15 85.34 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.081 179.809 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 196' ' ' LEU . . . . . . . . . . . . . 57.5 mt -65.74 -37.52 86.6 Favored 'General case' 0 C--N 1.332 -0.177 0 CA-C-O 120.749 0.309 . . . . 0.0 110.591 179.714 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 197' ' ' ILE . . . . . . . . . . . . . 19.7 mm -61.55 -56.99 14.16 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.114 179.28 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 198' ' ' VAL . . . . . . . . . . . . . 73.0 t -52.39 -35.26 19.79 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.43 0 CA-C-N 115.743 -0.662 . . . . 0.0 109.519 178.472 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 199' ' ' TYR . . . . . . . . . . . . . 74.5 t80 -70.09 -38.55 75.7 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 115.228 -0.897 . . . . 0.0 110.583 179.849 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 200' ' ' LEU . . . . . . . . . . . . . 38.7 mt -63.65 -44.1 94.84 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 115.752 -0.658 . . . . 0.0 111.355 -179.607 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 201' ' ' ASP . . . . . 0.416 ' HB2' ' OH ' ' A' ' 51' ' ' TYR . 0.7 OUTLIER -72.03 -37.35 69.76 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.071 -0.513 . . . . 0.0 111.212 -179.753 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild full ' A' A ' 202' ' ' LEU . . . . . 0.445 ' O ' ' HB ' ' A' ' 206' ' ' VAL . 3.2 mt -68.52 -30.8 69.69 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.686 -179.452 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 203' ' ' VAL . . . . . 0.491 ' O ' ' HA3' ' A' ' 207' ' ' GLY . 42.6 t -78.98 -36.57 18.77 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.437 0 CA-C-O 120.683 0.278 . . . . 0.0 111.125 -179.449 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 204' ' ' THR . . . . . . . . . . . . . 25.8 m -70.83 -50.83 31.17 Favored 'General case' 0 C--N 1.324 -0.519 0 C-N-CA 120.747 -0.381 . . . . 0.0 111.325 179.938 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 205' ' ' LYS . . . . . 0.619 ' HE2' ' HB2' ' A' ' 47' ' ' ALA . 50.5 mttp -71.99 -58.48 3.41 Favored 'General case' 0 C--N 1.328 -0.341 0 N-CA-C 112.313 0.486 . . . . 0.0 112.313 -178.629 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 206' ' ' VAL . . . . . 0.445 ' HB ' ' O ' ' A' ' 202' ' ' LEU . 61.9 t -74.82 -37.55 42.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 N-CA-C 111.817 0.303 . . . . 0.0 111.817 -178.983 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 207' ' ' GLY . . . . . 0.491 ' HA3' ' O ' ' A' ' 203' ' ' VAL . . . -63.07 -57.48 15.51 Favored Glycine 0 N--CA 1.452 -0.244 0 C-N-CA 120.372 -0.918 . . . . 0.0 112.117 -179.767 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 208' ' ' PHE . . . . . 0.523 ' O ' ' N ' ' A' ' 212' ' ' ALA . 4.8 m-85 -55.42 -49.05 73.43 Favored 'General case' 0 C--O 1.22 -0.478 0 N-CA-C 109.865 -0.42 . . . . 0.0 109.865 179.45 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 209' ' ' GLY . . . . . 0.519 ' HA2' ' HB3' ' A' ' 212' ' ' ALA . . . -53.71 -34.81 51.11 Favored Glycine 0 N--CA 1.451 -0.315 0 CA-C-N 115.183 -0.917 . . . . 0.0 113.382 179.641 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 210' ' ' PHE . . . . . . . . . . . . . 2.1 m-85 -70.7 -48.28 55.49 Favored 'General case' 0 CA--C 1.514 -0.427 0 N-CA-C 108.775 -0.824 . . . . 0.0 108.775 179.355 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 211' ' ' ILE . . . . . 0.483 HD13 HD11 ' A' ' 166' ' ' LEU . 5.6 mt -65.48 -27.59 42.11 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.608 0 N-CA-C 107.712 -1.218 . . . . 0.0 107.712 176.698 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 212' ' ' ALA . . . . . 0.523 ' N ' ' O ' ' A' ' 208' ' ' PHE . . . -68.59 -40.13 80.63 Favored 'General case' 0 N--CA 1.448 -0.555 0 CA-C-N 114.131 -1.395 . . . . 0.0 110.332 -179.763 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 213' ' ' LEU . . . . . 0.408 ' HG ' ' O ' ' A' ' 209' ' ' GLY . 74.8 mt -70.16 -50.42 40.52 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 114.974 -1.012 . . . . 0.0 111.405 -179.572 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 214' ' ' ASP . . . . . . . . . . . . . 24.0 t70 -59.05 -49.9 76.12 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.931 -179.714 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 215' ' ' ALA . . . . . . . . . . . . . . . -56.57 -55.46 33.58 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.888 179.944 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 216' ' ' ALA . . . . . . . . . . . . . . . -62.0 -30.94 71.29 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.143 -0.48 . . . . 0.0 111.32 -179.95 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 217' ' ' ALA . . . . . . . . . . . . . . . -58.28 -43.56 88.03 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-O 120.966 0.412 . . . . 0.0 110.275 179.881 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 218' ' ' THR . . . . . . . . . . . . . 89.5 m -66.51 -46.43 76.24 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 115.826 -0.625 . . . . 0.0 110.355 179.287 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 219' ' ' LEU . . . . . 0.463 ' O ' ' HG2' ' A' ' 222' ' ' GLU . 29.3 mt -60.97 -29.21 69.53 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 115.967 -0.561 . . . . 0.0 110.074 179.497 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 220' ' ' ARG . . . . . . . . . . . . . 57.9 ttp180 -84.11 -21.77 31.33 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-N 115.637 -0.71 . . . . 0.0 110.327 179.504 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 221' ' ' ALA . . . . . . . . . . . . . . . -82.72 -20.19 36.52 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 115.851 -0.613 . . . . 0.0 112.22 -179.496 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 222' ' ' GLU . . . . . 0.463 ' HG2' ' O ' ' A' ' 219' ' ' LEU . 12.3 pt-20 -81.48 -18.1 46.36 Favored 'General case' 0 C--N 1.332 -0.156 0 CA-C-O 120.731 0.3 . . . . 0.0 110.958 -179.23 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 223' ' ' HIS . . . . . . . . . . . . . 1.6 p-80 -145.73 -166.46 2.45 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.354 -0.385 . . . . 0.0 111.211 179.871 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 224' ' ' GLY . . . . . . . . . . . . . . . 66.77 22.46 71.9 Favored Glycine 0 N--CA 1.452 -0.28 0 C-N-CA 120.785 -0.722 . . . . 0.0 112.441 179.963 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 225' ' ' GLU . . . . . . . . . . . . . 12.1 mm-40 -76.14 113.34 13.57 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 120.715 0.293 . . . . 0.0 110.784 -179.965 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 226' ' ' SER . . . . . . . . . . . . . 47.9 t -123.42 -4.16 8.33 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.233 -0.439 . . . . 0.0 111.159 -179.846 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 227' ' ' LEU . . . . . . . . . . . . . 56.3 tp -126.03 -60.35 1.29 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.408 -0.36 . . . . 0.0 111.158 -179.687 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 228' ' ' ALA . . . . . . . . . . . . . . . 54.28 -168.9 0.07 Allowed 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.52 -179.727 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 229' ' ' GLY . . . . . . . . . . . . . . . -99.7 151.51 19.28 Favored Glycine 0 C--N 1.331 0.261 0 C-N-CA 120.827 -0.701 . . . . 0.0 112.452 -179.983 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 230' ' ' VAL . . . . . . . . . . . . . 17.4 m -117.6 27.41 3.48 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.191 0 CA-C-O 120.916 0.388 . . . . 0.0 111.411 -179.868 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 231' ' ' ASP . . . . . . . . . . . . . 11.9 m-20 47.47 68.19 0.69 Allowed 'General case' 0 C--N 1.326 -0.453 0 CA-C-N 115.594 -0.73 . . . . 0.0 111.169 -179.92 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 232' ' ' THR . . . . . . . . . . . . . 35.1 p -144.71 -48.13 0.25 Allowed 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.304 -179.909 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 233' ' ' ASP . . . . . . . . . . . . . 13.1 m-20 -60.5 110.91 1.39 Allowed 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.085 -0.507 . . . . 0.0 111.211 -179.733 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 234' ' ' THR . . . . . . . . . . . . . 39.0 m -99.45 131.48 24.88 Favored Pre-proline 0 C--N 1.331 -0.222 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.9 179.873 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 235' ' ' PRO . . . . . . . . . . . . . 51.1 Cg_exo -53.86 154.53 16.73 Favored 'Trans proline' 0 C--N 1.348 0.55 0 C-N-CA 122.48 2.12 . . . . 0.0 112.437 179.887 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 236' ' ' ALA . . . . . . . . . . . . . . . 61.68 103.15 0.03 OUTLIER 'General case' 0 C--N 1.332 -0.161 0 CA-C-N 116.006 -0.543 . . . . 0.0 111.465 179.66 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 237' ' ' VAL . . . . . . . . . . . . . 14.4 p -89.07 143.11 11.86 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.226 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.86 179.838 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 238' ' ' ALA . . . . . . . . . . . . . . . -104.93 -51.88 2.96 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.286 -0.416 . . . . 0.0 111.266 -179.886 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 239' ' ' ASP . . . . . . . . . . . . . 33.1 t70 -163.08 -71.23 0.05 OUTLIER 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.377 -0.374 . . . . 0.0 110.793 -179.822 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 240' ' ' LEU . . . . . . . . . . . . . 17.0 tp 56.41 17.23 2.81 Favored 'General case' 0 N--CA 1.462 0.165 0 CA-C-N 116.355 -0.384 . . . . 0.0 110.934 179.843 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 241' ' ' GLU . . . . . . . . . . . . . 9.9 tp10 -87.63 -71.14 0.58 Allowed 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.878 -179.835 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 242' ' ' HIS . . . . . . . . . . . . . 24.9 t60 57.06 91.51 0.03 OUTLIER 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 116.092 -0.503 . . . . 0.0 110.992 179.901 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 243' ' ' HIS . . . . . . . . . . . . . 54.7 t-80 -111.06 120.64 43.03 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.08 -0.509 . . . . 0.0 110.993 -179.815 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 244' ' ' HIS . . . . . . . . . . . . . 31.1 m-70 -67.6 125.35 25.91 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.726 179.921 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 245' ' ' HIS . . . . . . . . . . . . . 41.3 t60 -150.51 -60.71 0.19 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.923 -179.955 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 246' ' ' HIS . . . . . . . . . . . . . 3.0 t-160 -130.62 -62.96 0.9 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.664 -179.935 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 247' ' ' HIS . . . . . . . . . . . . . 38.0 m-70 . . . . . 0 C--O 1.249 1.052 0 CA-C-O 118.287 -0.863 . . . . 0.0 110.864 179.89 . . . . . . . . 0 0 . 1 . 024 nuclear nobuild full ' A' A ' 301' ' ' RET . . . . . 0.773 H203 ' HE1' ' A' ' 171' ' ' TRP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 23.9 ptm . . . . . 0 N--CA 1.485 1.32 0 CA-C-O 120.754 0.311 . . . . 0.0 110.845 . . . . . . . . . 0 0 . 1 . 025 nuclear nobuild full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 29.9 m -140.65 10.93 0.52 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.095 -0.502 . . . . 0.0 111.153 -179.953 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -72.43 -31.47 63.25 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.673 -0.775 . . . . 0.0 112.517 -179.965 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 4' ' ' LEU . . . . . 0.504 HD22 HG21 ' A' ' 194' ' ' VAL . 85.8 mt -74.48 -38.36 62.93 Favored 'General case' 0 N--CA 1.449 -0.477 0 CA-C-O 120.723 0.297 . . . . 0.0 111.509 -179.906 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 69.2 p -54.77 -37.33 65.88 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.138 -0.483 . . . . 0.0 112.03 -179.171 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 69.2 p -56.12 -35.19 66.82 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.481 -0.327 . . . . 0.0 111.548 -179.625 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 7' ' ' LEU . . . . . . . . . . . . . 4.0 mm? -63.2 -53.47 52.67 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.429 -0.35 . . . . 0.0 111.419 -179.648 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 8' ' ' PHE . . . . . 0.673 ' HB2' ' HB2' ' A' ' 55' ' ' ALA . 65.8 m-85 -60.25 -33.06 71.78 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.332 -0.395 . . . . 0.0 110.946 -179.586 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 9' ' ' TRP . . . . . . . . . . . . . 18.3 m95 -68.71 -49.36 59.49 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.246 -179.825 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 75.9 mt -59.39 -38.81 81.46 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 115.814 -0.63 . . . . 0.0 109.825 179.134 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -67.12 -36.24 90.04 Favored Glycine 0 N--CA 1.446 -0.64 0 CA-C-N 115.473 -0.785 . . . . 0.0 111.73 179.403 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -61.98 -33.38 74.21 Favored 'General case' 0 C--O 1.232 0.18 0 CA-C-O 121.037 0.446 . . . . 0.0 109.97 179.183 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 50.7 mm -65.61 -49.92 74.85 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 115.694 -0.685 . . . . 0.0 110.266 179.115 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -58.3 -36.24 82.36 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.798 -0.715 . . . . 0.0 112.218 179.539 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 15' ' ' MET . . . . . . . . . . . . . 19.3 mmt -66.21 -44.6 83.41 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.74 0.305 . . . . 0.0 110.783 179.733 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 16' ' ' LEU . . . . . 0.4 HD13 ' O ' ' A' ' 16' ' ' LEU . 0.5 OUTLIER -53.79 -45.43 70.72 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 115.995 -0.548 . . . . 0.0 110.742 179.809 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 49.2 t -61.12 -43.94 97.3 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.238 0 CA-C-N 116.112 -0.495 . . . . 0.0 111.149 179.943 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -66.72 -43.95 90.65 Favored Glycine 0 N--CA 1.452 -0.256 0 C-N-CA 120.699 -0.762 . . . . 0.0 112.073 179.645 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 19.2 m -52.3 -42.72 64.02 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-O 120.675 0.274 . . . . 0.0 111.341 -179.776 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 80.9 mt -71.82 -44.8 63.3 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.406 -0.361 . . . . 0.0 111.554 -179.903 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -57.01 -32.59 66.29 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.37 -0.377 . . . . 0.0 111.759 -179.405 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 22' ' ' PHE . . . . . 0.623 ' HB2' HG22 ' A' ' 41' ' ' VAL . 10.0 m-85 -90.92 -38.63 12.77 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.537 -0.301 . . . . 0.0 111.62 -179.356 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -64.03 -50.49 68.24 Favored 'General case' 0 C--N 1.332 -0.166 0 CA-C-O 120.878 0.37 . . . . 0.0 111.25 -179.685 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 24' ' ' TRP . . . . . . . . . . . . . 1.3 t-105 -59.88 -49.84 76.13 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 115.958 -0.565 . . . . 0.0 110.68 179.685 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -70.5 -17.63 62.96 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.266 -0.424 . . . . 0.0 111.033 179.88 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -73.3 -52.73 8.33 Favored Glycine 0 N--CA 1.452 -0.245 0 C-N-CA 120.822 -0.704 . . . . 0.0 112.635 -179.964 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 50.4 mtp180 -55.06 -43.05 73.5 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-O 120.861 0.363 . . . . 0.0 110.805 179.999 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 33.7 t70 -89.2 87.82 7.3 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.631 179.878 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -161.39 -170.56 2.67 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.03 -0.532 . . . . 0.0 111.061 -179.72 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -76.9 -118.04 0.16 Allowed Glycine 0 N--CA 1.45 -0.399 0 C-N-CA 120.786 -0.721 . . . . 0.0 112.551 179.797 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 46.8 t -139.3 -33.85 0.6 Allowed 'General case' 0 C--N 1.331 -0.237 0 CA-C-O 120.726 0.298 . . . . 0.0 111.076 -179.897 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -87.04 -12.18 68.61 Favored Glycine 0 N--CA 1.45 -0.373 0 C-N-CA 120.724 -0.75 . . . . 0.0 112.753 -179.792 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 43.6 mt-10 -88.43 -21.49 24.22 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.686 0.279 . . . . 0.0 110.988 -179.937 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 34' ' ' ARG . . . . . 0.432 ' O ' HG23 ' A' ' 38' ' ' VAL . 35.7 ttp180 -49.87 -35.25 22.67 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.141 -0.481 . . . . 0.0 111.527 -179.798 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 77.6 mtm180 -61.59 -54.33 44.48 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 120.85 0.357 . . . . 0.0 111.497 -179.772 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 59.4 m-85 -62.04 -30.02 70.69 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.134 -0.484 . . . . 0.0 111.421 -179.441 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 37' ' ' TYR . . . . . 0.526 ' O ' HG23 ' A' ' 41' ' ' VAL . 32.5 m-85 -73.76 -56.11 5.4 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.503 -179.411 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 38' ' ' VAL . . . . . 0.432 HG23 ' O ' ' A' ' 34' ' ' ARG . 96.0 t -56.68 -36.7 49.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-O 120.98 0.419 . . . . 0.0 110.628 179.923 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 78.3 m -63.44 -51.62 64.92 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 115.872 -0.604 . . . . 0.0 110.918 179.713 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 40' ' ' LEU . . . . . 0.603 HD12 HD12 ' A' ' 43' ' ' ILE . 51.7 tp -61.29 -45.98 92.22 Favored 'General case' 0 C--O 1.236 0.35 0 CA-C-N 115.966 -0.561 . . . . 0.0 110.722 179.989 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . 0.623 HG22 ' HB2' ' A' ' 22' ' ' PHE . 85.8 t -60.13 -34.77 58.05 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.399 0 CA-C-N 115.684 -0.689 . . . . 0.0 109.858 178.974 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -63.15 -35.39 92.02 Favored Glycine 0 N--CA 1.445 -0.724 0 C-N-CA 120.877 -0.678 . . . . 0.0 112.026 179.592 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 43' ' ' ILE . . . . . 0.662 HG22 ' HE3' ' A' ' 205' ' ' LYS . 0.8 OUTLIER -66.23 -57.75 9.28 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.126 0 C-N-CA 121.074 -0.25 . . . . 0.0 111.148 179.811 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 85.1 p -59.57 -21.56 60.48 Favored 'General case' 0 C--O 1.232 0.154 0 CA-C-N 116.485 -0.325 . . . . 0.0 111.554 -179.518 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -79.43 -56.23 3.46 Favored Glycine 0 CA--C 1.518 0.23 0 C-N-CA 120.843 -0.694 . . . . 0.0 113.063 -179.363 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 46' ' ' ILE . . . . . 0.431 ' O ' HG22 ' A' ' 49' ' ' VAL . 20.2 pt -58.2 -37.39 62.25 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.243 0 CA-C-O 121.138 0.494 . . . . 0.0 110.873 -179.896 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 47' ' ' ALA . . . . . 0.713 ' HB2' ' HE2' ' A' ' 205' ' ' LYS . . . -68.21 -45.26 73.82 Favored 'General case' 0 C--N 1.324 -0.525 0 CA-C-N 115.945 -0.571 . . . . 0.0 111.363 179.513 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -54.13 -42.71 69.79 Favored 'General case' 0 C--O 1.233 0.203 0 CA-C-N 116.299 -0.41 . . . . 0.0 111.807 -179.219 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 49' ' ' VAL . . . . . 0.431 HG22 ' O ' ' A' ' 46' ' ' ILE . 33.1 m -72.23 -34.5 49.77 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.363 0 CA-C-N 116.665 -0.243 . . . . 0.0 111.333 -179.517 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -66.9 -33.48 75.69 Favored 'General case' 0 CA--C 1.521 -0.146 0 CA-C-O 120.988 0.423 . . . . 0.0 110.73 179.402 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 3.0 m-30 -69.55 -40.72 76.66 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-N 115.909 -0.587 . . . . 0.0 110.12 179.784 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -61.44 -45.1 95.73 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 115.704 -0.68 . . . . 0.0 111.367 179.829 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 53' ' ' VAL . . . . . 0.502 HG23 ' N ' ' A' ' 54' ' ' MET . 25.3 m -67.62 -50.08 64.41 Favored 'Isoleucine or valine' 0 C--N 1.334 -0.087 0 C-N-CA 121.11 -0.236 . . . . 0.0 111.011 -179.956 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 54' ' ' MET . . . . . 0.541 ' HG2' ' HG2' ' A' ' 71' ' ' PRO . 74.7 mtm -58.04 -30.35 66.08 Favored 'General case' 0 CA--C 1.521 -0.172 0 CA-C-O 121.224 0.535 . . . . 0.0 109.866 179.336 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 55' ' ' ALA . . . . . 0.673 ' HB2' ' HB2' ' A' ' 8' ' ' PHE . . . -74.5 -33.93 62.93 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 115.414 -0.812 . . . . 0.0 111.365 179.526 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 74.8 mt -70.88 -5.19 28.78 Favored 'General case' 0 C--N 1.331 -0.203 0 CA-C-N 116.371 -0.377 . . . . 0.0 111.573 -179.416 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 98.8 -20.77 49.01 Favored Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.46 -0.876 . . . . 0.0 113.036 179.638 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 58' ' ' VAL . . . . . 0.428 HG22 ' O ' ' A' ' 53' ' ' VAL . 32.9 m -70.03 149.11 10.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-O 120.88 0.371 . . . . 0.0 110.826 179.805 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 59' ' ' GLY . . . . . 0.472 ' HA3' ' HG3' ' A' ' 71' ' ' PRO . . . 85.05 22.49 52.31 Favored Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.913 -0.661 . . . . 0.0 112.578 -179.47 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 60' ' ' TRP . . . . . . . . . . . . . 13.8 m0 -105.71 96.07 6.24 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-O 121.091 0.472 . . . . 0.0 109.986 -179.837 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 5.1 t -98.53 116.54 65.4 Favored Pre-proline 0 C--N 1.326 -0.435 0 CA-C-N 115.696 -0.683 . . . . 0.0 111.635 -178.87 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 57.1 Cg_endo -70.4 143.96 49.25 Favored 'Trans proline' 0 C--N 1.351 0.709 0 C-N-CA 122.437 2.092 . . . . 0.0 112.262 179.578 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 99.5 t -138.93 96.12 0.99 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.053 -0.521 . . . . 0.0 111.165 -179.88 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . 57.24 -88.1 0.02 OUTLIER 'General case' 0 C--N 1.331 -0.204 0 CA-C-N 116.189 -0.459 . . . . 0.0 111.439 179.781 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 45.7 mt-10 -121.85 -19.08 6.85 Favored 'General case' 0 C--N 1.332 -0.193 0 CA-C-N 116.433 -0.349 . . . . 0.0 110.939 179.935 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 66' ' ' ARG . . . . . . . . . . . . . 39.7 mmt180 -105.4 155.72 18.86 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.342 179.629 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 30.3 m -114.01 143.32 44.94 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-O 120.947 0.404 . . . . 0.0 111.351 -179.591 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 19.9 m -127.42 145.84 34.2 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.402 0 CA-C-N 115.83 -0.623 . . . . 0.0 110.818 179.659 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 69' ' ' PHE . . . . . . . . . . . . . 17.2 m-85 -110.73 115.6 29.84 Favored 'General case' 0 C--N 1.327 -0.38 0 N-CA-C 109.738 -0.467 . . . . 0.0 109.738 -179.63 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 70' ' ' VAL . . . . . 0.566 ' N ' ' HD2' ' A' ' 71' ' ' PRO . 59.4 t -68.43 -51.17 24.66 Favored Pre-proline 0 C--N 1.323 -0.559 0 N-CA-C 112.436 0.532 . . . . 0.0 112.436 -178.741 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 71' ' ' PRO . . . . . 0.566 ' HD2' ' N ' ' A' ' 70' ' ' VAL . 11.2 Cg_endo -54.87 -19.89 20.79 Favored 'Trans proline' 0 C--N 1.353 0.791 0 C-N-CA 122.089 1.859 . . . . 0.0 112.012 179.831 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 72' ' ' ARG . . . . . 0.412 ' NH2' HG13 ' A' ' 197' ' ' ILE . 53.1 ttt180 -74.96 -53.8 8.34 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.043 -0.526 . . . . 0.0 110.586 179.673 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 73' ' ' TYR . . . . . 0.4 ' O ' HG13 ' A' ' 77' ' ' ILE . 75.8 m-85 -65.02 -36.91 85.91 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 115.774 -0.648 . . . . 0.0 110.704 -179.994 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 0.3 OUTLIER -70.05 -36.78 69.98 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 N-CA-C 109.744 -0.465 . . . . 0.0 109.744 179.048 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 75' ' ' ASP . . . . . 0.401 ' O ' HG23 ' A' ' 79' ' ' THR . 12.3 t70 -56.52 -38.95 72.54 Favored 'General case' 0 CA--C 1.52 -0.176 0 CA-C-N 116.033 -0.531 . . . . 0.0 109.642 179.06 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 76' ' ' TRP . . . . . . . . . . . . . 50.2 m0 -69.45 -38.54 77.84 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 115.615 -0.72 . . . . 0.0 110.624 179.418 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 77' ' ' ILE . . . . . 0.4 HG13 ' O ' ' A' ' 73' ' ' TYR . 92.5 mt -59.17 -28.77 39.97 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.725 179.674 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 35.4 mt -91.83 -26.91 18.29 Favored 'General case' 0 CA--C 1.533 0.293 0 N-CA-C 112.317 0.488 . . . . 0.0 112.317 -179.941 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 79' ' ' THR . . . . . 0.413 HG22 HD11 ' A' ' 46' ' ' ILE . 71.3 p -92.44 -52.24 4.75 Favored 'General case' 0 N--CA 1.466 0.342 0 N-CA-C 113.622 0.971 . . . . 0.0 113.622 -177.884 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 80' ' ' THR . . . . . 0.425 ' N ' ' HD2' ' A' ' 81' ' ' PRO . 89.0 m -47.3 -55.25 16.7 Favored Pre-proline 0 C--N 1.329 -0.325 0 N-CA-C 112.858 0.688 . . . . 0.0 112.858 -178.418 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 81' ' ' PRO . . . . . 0.437 ' HA ' HG22 ' A' ' 84' ' ' VAL . 37.2 Cg_endo -64.19 -18.99 65.42 Favored 'Trans proline' 0 C--N 1.35 0.614 0 C-N-CA 121.495 1.463 . . . . 0.0 111.232 -179.833 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 82' ' ' LEU . . . . . . . . . . . . . 18.4 tp -76.93 -33.6 57.72 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 115.529 -0.759 . . . . 0.0 110.169 179.641 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 83' ' ' ILE . . . . . 0.414 HD13 HD13 ' A' ' 43' ' ' ILE . 41.2 mm -70.12 -52.23 32.29 Favored 'Isoleucine or valine' 0 C--O 1.232 0.175 0 CA-C-N 116.058 -0.519 . . . . 0.0 110.101 179.203 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . 0.437 HG22 ' HA ' ' A' ' 81' ' ' PRO . 27.9 m -60.61 -30.47 46.89 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.179 0 N-CA-C 109.63 -0.507 . . . . 0.0 109.63 178.795 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 85' ' ' TYR . . . . . . . . . . . . . 81.1 t80 -65.33 -35.79 82.07 Favored 'General case' 0 N--CA 1.453 -0.28 0 CA-C-N 115.542 -0.754 . . . . 0.0 109.276 178.684 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 86' ' ' PHE . . . . . . . . . . . . . 7.2 t80 -61.15 -50.13 74.41 Favored 'General case' 0 C--O 1.234 0.237 0 CA-C-N 115.633 -0.712 . . . . 0.0 109.919 179.186 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 8.8 mp -62.23 -31.84 72.44 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 115.838 -0.619 . . . . 0.0 109.861 179.384 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -68.96 -27.69 73.69 Favored Glycine 0 N--CA 1.449 -0.459 0 C-N-CA 120.856 -0.688 . . . . 0.0 111.678 179.113 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 82.7 mt -73.72 -37.36 65.17 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-O 120.948 0.404 . . . . 0.0 110.482 179.549 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 90' ' ' LEU . . . . . 0.437 HD11 HD22 ' A' ' 163' ' ' LEU . 93.6 mt -64.3 -42.67 96.26 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 115.945 -0.571 . . . . 0.0 111.144 179.9 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -80.13 -54.99 5.25 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.4 -179.654 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 95.37 67.88 1.0 Allowed Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.814 -0.708 . . . . 0.0 112.132 -179.733 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 93' ' ' LEU . . . . . 0.426 ' N ' HD12 ' A' ' 93' ' ' LEU . 6.6 mp -71.21 -171.13 0.55 Allowed 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.783 0.325 . . . . 0.0 111.033 -179.71 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 94' ' ' ASP . . . . . 0.419 ' HB2' ' OE2' ' A' ' 97' ' ' GLU . 5.9 m-20 -96.43 -173.41 2.76 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-N 116.246 -0.433 . . . . 0.0 111.28 -179.807 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 47.5 t -67.52 -51.26 53.04 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 115.946 -0.57 . . . . 0.0 111.624 -179.425 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 96' ' ' ARG . . . . . 0.425 ' O ' HG13 ' A' ' 100' ' ' ILE . 31.6 mmt180 -73.72 -40.07 63.83 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 120.944 0.402 . . . . 0.0 110.699 -179.505 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 97' ' ' GLU . . . . . 0.54 ' HA ' HD12 ' A' ' 100' ' ' ILE . 0.3 OUTLIER -55.48 -47.39 76.21 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 115.763 -0.653 . . . . 0.0 111.501 -179.622 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild full ' A' A ' 98' ' ' PHE . . . . . 0.444 ' O ' HG12 ' A' ' 102' ' ' ILE . 1.2 m-85 -57.13 -45.23 83.69 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.821 0.343 . . . . 0.0 110.796 179.813 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -62.68 -30.25 76.26 Favored Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.586 -179.92 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 100' ' ' ILE . . . . . 0.54 HD12 ' HA ' ' A' ' 97' ' ' GLU . 95.5 mt -65.65 -44.79 93.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-O 120.81 0.338 . . . . 0.0 111.221 -179.939 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 101' ' ' VAL . . . . . 0.431 HG21 ' CE ' ' A' ' 145' ' ' MET . 56.2 t -68.64 -43.89 82.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.322 -0.399 . . . . 0.0 111.51 -179.732 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 102' ' ' ILE . . . . . 0.444 HG12 ' O ' ' A' ' 98' ' ' PHE . 48.5 mm -61.45 -51.1 76.84 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.348 -0.387 . . . . 0.0 111.189 -179.789 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 14.9 t -61.35 -29.01 69.64 Favored 'General case' 0 C--O 1.232 0.153 0 CA-C-O 120.866 0.365 . . . . 0.0 110.614 179.925 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 104' ' ' LEU . . . . . 0.458 ' O ' HG23 ' A' ' 108' ' ' VAL . 1.4 tm? -59.6 -52.65 64.61 Favored 'General case' 0 C--N 1.331 -0.198 0 CA-C-N 116.073 -0.512 . . . . 0.0 109.807 179.217 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 105' ' ' ASN . . . . . 0.569 ' N ' HD22 ' A' ' 105' ' ' ASN . 0.8 OUTLIER -64.33 -26.18 68.37 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 115.965 -0.561 . . . . 0.0 111.024 179.732 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild full ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 53.7 m -63.95 -56.7 13.26 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.38 -0.373 . . . . 0.0 111.478 -179.795 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 7.2 p -62.33 -36.47 74.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.272 -0.422 . . . . 0.0 111.214 -179.851 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . 0.458 HG23 ' O ' ' A' ' 104' ' ' LEU . 81.3 t -65.59 -54.41 28.37 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.197 0 CA-C-N 116.376 -0.375 . . . . 0.0 111.01 179.817 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 109' ' ' MET . . . . . . . . . . . . . 11.2 tpp -59.58 -36.29 75.94 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.94 -179.766 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 30.2 tp -66.52 -32.94 74.6 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.309 -0.405 . . . . 0.0 110.226 179.779 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -62.02 -54.21 44.68 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 115.97 -0.559 . . . . 0.0 110.683 179.526 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 112' ' ' GLY . . . . . 0.555 ' HA3' ' H21' ' A' ' 301' ' ' RET . . . -56.87 -36.51 73.25 Favored Glycine 0 C--N 1.331 0.283 0 C-N-CA 120.605 -0.807 . . . . 0.0 112.044 179.549 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 113' ' ' PHE . . . . . . . . . . . . . 2.6 t80 -54.06 -63.67 1.07 Allowed 'General case' 0 C--N 1.332 -0.186 0 CA-C-O 120.918 0.389 . . . . 0.0 110.262 179.589 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 114' ' ' ALA . . . . . 0.447 ' O ' HG13 ' A' ' 118' ' ' VAL . . . -62.25 -28.29 69.6 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 115.88 -0.6 . . . . 0.0 111.172 179.942 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 115' ' ' GLY . . . . . 0.465 ' N ' ' HG ' ' A' ' 126' ' ' LEU . . . -52.22 -52.88 33.84 Favored Glycine 0 C--N 1.333 0.363 0 C-N-CA 121.081 -0.58 . . . . 0.0 112.729 179.971 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -77.91 -15.06 59.3 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-O 120.711 0.291 . . . . 0.0 111.535 179.84 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 117' ' ' MET . . . . . . . . . . . . . 0.5 OUTLIER -93.83 19.34 8.99 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.468 -0.333 . . . . 0.0 111.488 -179.704 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 118' ' ' VAL . . . . . 0.447 HG13 ' O ' ' A' ' 114' ' ' ALA . 33.2 m -84.55 146.74 47.73 Favored Pre-proline 0 C--N 1.331 -0.223 0 CA-C-N 116.594 -0.276 . . . . 0.0 111.335 179.86 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 119' ' ' PRO . . . . . . . . . . . . . 96.6 Cg_endo -87.91 1.92 6.64 Favored 'Trans proline' 0 N--CA 1.458 -0.593 0 C-N-CA 122.709 2.273 . . . . 0.0 112.233 179.325 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -155.55 -138.39 2.56 Favored Glycine 0 C--N 1.332 0.334 0 C-N-CA 120.806 -0.711 . . . . 0.0 112.79 -179.674 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 47.1 pt -88.55 8.72 2.64 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.193 0 CA-C-O 120.645 0.26 . . . . 0.0 111.523 -179.634 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 38.4 mt-10 -60.07 -18.55 47.61 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.423 -0.353 . . . . 0.0 111.11 -179.853 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 123' ' ' ARG . . . . . 0.4 ' HB2' ' HH2' ' A' ' 178' ' ' TRP . 2.6 ptp180 -52.07 -33.8 40.86 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.176 -0.465 . . . . 0.0 111.737 -179.871 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 124' ' ' TYR . . . . . . . . . . . . . 40.8 m-85 -65.01 -32.67 74.51 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.599 -0.273 . . . . 0.0 111.362 -179.659 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 125' ' ' ALA . . . . . . . . . . . . . . . -68.73 -52.96 25.05 Favored 'General case' 0 C--O 1.237 0.419 0 CA-C-O 120.79 0.328 . . . . 0.0 111.064 179.909 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 126' ' ' LEU . . . . . 0.465 ' HG ' ' N ' ' A' ' 115' ' ' GLY . 2.6 mm? -49.86 -54.32 20.17 Favored 'General case' 0 CA--C 1.52 -0.187 0 CA-C-N 116.016 -0.538 . . . . 0.0 110.61 -179.988 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 127' ' ' PHE . . . . . 0.505 ' HZ ' ' HB3' ' A' ' 175' ' ' PRO . 7.1 t80 -67.5 -31.53 71.73 Favored 'General case' 0 N--CA 1.452 -0.35 0 CA-C-N 116.285 -0.416 . . . . 0.0 111.074 -179.652 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 128' ' ' GLY . . . . . . . . . . . . . . . -46.38 -48.38 16.2 Favored Glycine 0 C--N 1.331 0.283 0 C-N-CA 119.793 -1.194 . . . . 0.0 110.737 179.07 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 129' ' ' MET . . . . . 0.491 ' HE3' ' N ' ' A' ' 130' ' ' GLY . 6.0 tmm? -70.43 -45.79 65.18 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 115.139 -0.53 . . . . 0.0 109.894 178.75 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 130' ' ' GLY . . . . . 0.491 ' N ' ' HE3' ' A' ' 129' ' ' MET . . . -57.37 -29.63 60.6 Favored Glycine 0 C--N 1.331 0.265 0 CA-C-N 115.85 -0.614 . . . . 0.0 113.174 -179.315 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -75.02 -53.65 8.55 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-O 120.702 0.287 . . . . 0.0 110.58 -179.798 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 60.0 t -57.67 -42.08 80.77 Favored 'Isoleucine or valine' 0 C--O 1.234 0.252 0 CA-C-O 121.372 0.606 . . . . 0.0 109.672 178.815 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -68.9 -33.47 73.81 Favored 'General case' 0 N--CA 1.451 -0.377 0 CA-C-N 115.272 -0.877 . . . . 0.0 110.781 179.441 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 134' ' ' PHE . . . . . . . . . . . . . 70.5 t80 -54.59 -57.42 11.51 Favored 'General case' 0 N--CA 1.451 -0.394 0 CA-C-O 121.01 0.433 . . . . 0.0 110.031 179.542 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 135' ' ' ILE . . . . . 0.457 ' O ' HG22 ' A' ' 138' ' ' VAL . 26.4 mt -57.22 -33.27 42.88 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.388 0 CA-C-N 115.728 -0.669 . . . . 0.0 109.891 178.87 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . -59.26 -39.46 94.63 Favored Glycine 0 N--CA 1.448 -0.52 0 C-N-CA 120.31 -0.948 . . . . 0.0 111.511 178.851 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 137' ' ' LEU . . . . . . . . . . . . . 54.6 tp -68.68 -55.34 11.74 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-O 120.715 0.293 . . . . 0.0 110.729 179.549 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 138' ' ' VAL . . . . . 0.457 HG22 ' O ' ' A' ' 135' ' ' ILE . 2.8 m -55.86 -32.08 31.64 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.24 0 CA-C-O 121.45 0.643 . . . . 0.0 109.478 179.747 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 139' ' ' TYR . . . . . . . . . . . . . 9.8 t80 -64.23 -36.89 85.55 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 115.28 -0.873 . . . . 0.0 109.995 178.667 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 16.1 m-85 -66.18 -53.15 40.87 Favored 'General case' 0 C--N 1.332 -0.186 0 CA-C-N 115.959 -0.564 . . . . 0.0 111.332 179.669 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 141' ' ' LEU . . . . . 0.644 HD12 HG23 ' A' ' 142' ' ' VAL . 3.0 pp -64.31 -17.12 63.36 Favored 'General case' 0 C--N 1.333 -0.148 0 CA-C-O 120.657 0.265 . . . . 0.0 111.268 -179.418 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 142' ' ' VAL . . . . . 0.644 HG23 HD12 ' A' ' 141' ' ' LEU . 47.1 t -94.93 -22.71 5.3 Favored 'Isoleucine or valine' 0 C--O 1.233 0.208 0 CA-C-O 121.054 0.454 . . . . 0.0 110.366 178.343 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . -74.25 -124.6 0.12 Allowed Glycine 0 CA--C 1.524 0.612 0 C-N-CA 121.114 -0.565 . . . . 0.0 113.485 -179.234 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 144' ' ' PRO . . . . . . . . . . . . . 46.6 Cg_endo -67.55 -23.13 43.62 Favored 'Trans proline' 0 C--N 1.35 0.642 0 C-N-CA 122.769 2.313 . . . . 0.0 113.253 -179.157 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 145' ' ' MET . . . . . 0.493 ' HB3' ' OH ' ' A' ' 160' ' ' TYR . 5.7 mtt -52.18 -57.61 9.13 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.508 -0.315 . . . . 0.0 111.658 -179.609 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 146' ' ' THR . . . . . . . . . . . . . 8.8 t -62.78 -32.2 73.32 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.488 -0.324 . . . . 0.0 111.719 -179.343 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 45.6 mt-10 -70.57 -33.9 71.61 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.425 -0.352 . . . . 0.0 111.311 -179.609 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 148' ' ' SER . . . . . . . . . . . . . 38.8 m -70.52 -49.87 43.62 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.956 0.408 . . . . 0.0 110.843 -179.889 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 149' ' ' ALA . . . . . 0.498 ' HB1' HG22 ' A' ' 156' ' ' ILE . . . -64.05 -35.23 80.06 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 115.992 -0.549 . . . . 0.0 111.757 -179.553 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 150' ' ' SER . . . . . 0.444 ' HA ' ' HB2' ' A' ' 157' ' ' LYS . 86.3 p -67.71 -5.59 16.71 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.379 -0.373 . . . . 0.0 111.232 -179.664 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 151' ' ' GLN . . . . . . . . . . . . . 78.9 mt-30 -115.3 -1.16 12.98 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.503 -0.317 . . . . 0.0 111.338 179.947 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 32.4 mmt180 -80.97 -51.63 8.33 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-O 120.843 0.354 . . . . 0.0 110.989 179.812 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 153' ' ' SER . . . . . 0.58 ' HB3' HG12 ' A' ' 156' ' ' ILE . 27.5 t -158.08 172.41 18.48 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 116.141 -0.482 . . . . 0.0 110.844 179.635 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 154' ' ' SER . . . . . . . . . . . . . 50.8 m -71.59 -40.47 69.85 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.285 -0.416 . . . . 0.0 110.455 179.327 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -76.75 -31.97 51.86 Favored Glycine 0 N--CA 1.452 -0.281 0 C-N-CA 121.013 -0.613 . . . . 0.0 112.708 179.916 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 156' ' ' ILE . . . . . 0.58 HG12 ' HB3' ' A' ' 153' ' ' SER . 29.5 mm -60.14 -38.21 76.17 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.229 0 CA-C-O 120.834 0.349 . . . . 0.0 111.131 -179.896 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 157' ' ' LYS . . . . . 0.444 ' HB2' ' HA ' ' A' ' 150' ' ' SER . 61.7 tttm -66.85 -50.87 61.14 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.327 -179.601 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 48.5 t -62.72 -39.45 94.08 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.3 -0.409 . . . . 0.0 111.549 -179.464 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 159' ' ' LEU . . . . . 0.456 ' O ' HD13 ' A' ' 163' ' ' LEU . 32.0 tp -71.11 -33.45 70.15 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.364 -0.38 . . . . 0.0 111.211 -179.477 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 160' ' ' TYR . . . . . 0.493 ' OH ' ' HB3' ' A' ' 145' ' ' MET . 48.3 t80 -73.24 -46.82 47.93 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.569 -0.287 . . . . 0.0 111.473 -179.559 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 161' ' ' VAL . . . . . 0.429 HG23 ' N ' ' A' ' 162' ' ' ARG . 27.8 m -58.52 -45.4 90.24 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 CA-C-N 116.718 -0.219 . . . . 0.0 111.531 -179.408 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 162' ' ' ARG . . . . . 0.429 ' N ' HG23 ' A' ' 161' ' ' VAL . 40.7 mmt180 -65.05 -39.71 93.69 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-O 120.854 0.359 . . . . 0.0 111.324 -179.723 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 163' ' ' LEU . . . . . 0.605 ' HG ' ' HB2' ' A' ' 208' ' ' PHE . 6.3 mp -70.2 -46.84 63.73 Favored 'General case' 0 C--N 1.328 -0.366 0 N-CA-C 112.453 0.538 . . . . 0.0 112.453 -179.149 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 164' ' ' ARG . . . . . 0.427 ' O ' HG23 ' A' ' 168' ' ' VAL . 5.8 ppt_? -70.96 -47.71 57.44 Favored 'General case' 0 C--N 1.33 -0.262 0 N-CA-C 112.107 0.41 . . . . 0.0 112.107 -178.418 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 165' ' ' ASN . . . . . 0.472 ' O ' HG23 ' A' ' 169' ' ' VAL . 16.2 m-80 -57.75 -49.24 77.24 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-O 120.761 0.315 . . . . 0.0 111.129 -179.847 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 166' ' ' LEU . . . . . 0.458 ' O ' ' HG ' ' A' ' 170' ' ' LEU . 5.8 tt -63.57 -52.35 61.43 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.533 -179.427 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 167' ' ' THR . . . . . . . . . . . . . 98.7 m -56.4 -53.27 59.38 Favored 'General case' 0 C--N 1.33 -0.26 0 N-CA-C 112.528 0.566 . . . . 0.0 112.528 -178.88 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 168' ' ' VAL . . . . . 0.427 HG23 ' O ' ' A' ' 164' ' ' ARG . 72.1 t -54.08 -45.15 65.24 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.225 0 N-CA-C 112.016 0.376 . . . . 0.0 112.016 -179.127 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 169' ' ' VAL . . . . . 0.472 HG23 ' O ' ' A' ' 165' ' ' ASN . 54.2 t -55.39 -64.45 0.47 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 N-CA-C 111.831 0.308 . . . . 0.0 111.831 -179.387 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 170' ' ' LEU . . . . . 0.458 ' HG ' ' O ' ' A' ' 166' ' ' LEU . 1.1 pp -62.67 -29.68 70.82 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.657 -0.247 . . . . 0.0 111.626 -179.39 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 171' ' ' TRP . . . . . 0.818 ' HE1' H203 ' A' ' 301' ' ' RET . 4.1 m0 -69.79 -32.32 70.73 Favored 'General case' 0 C--N 1.332 -0.183 0 CA-C-O 121.126 0.488 . . . . 0.0 110.184 179.207 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 172' ' ' ALA . . . . . 0.401 ' C ' ' HD2' ' A' ' 175' ' ' PRO . . . -71.83 -6.5 42.12 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 115.595 -0.73 . . . . 0.0 110.996 -179.848 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 173' ' ' ILE . . . . . 0.475 ' O ' HG12 ' A' ' 177' ' ' ILE . 48.2 mm -85.41 -23.76 7.09 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.245 0 CA-C-N 115.99 -0.55 . . . . 0.0 110.736 179.647 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 174' ' ' TYR . . . . . 0.408 ' N ' ' CD ' ' A' ' 175' ' ' PRO . 20.6 m-85 -54.08 -48.48 93.95 Favored Pre-proline 0 N--CA 1.464 0.232 0 CA-C-N 116.341 -0.39 . . . . 0.0 111.203 179.791 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 175' ' ' PRO . . . . . 0.505 ' HB3' ' HZ ' ' A' ' 127' ' ' PHE . 93.3 Cg_exo -44.6 -33.2 6.51 Favored 'Trans proline' 0 C--N 1.351 0.697 0 C-N-CA 122.287 1.991 . . . . 0.0 112.097 178.894 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 176' ' ' PHE . . . . . 0.517 ' O ' ' HG ' ' A' ' 180' ' ' LEU . 93.0 m-85 -80.63 -50.32 10.1 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 115.691 -0.686 . . . . 0.0 111.851 -179.876 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 177' ' ' ILE . . . . . 0.475 HG12 ' O ' ' A' ' 173' ' ' ILE . 4.6 mm -63.78 -30.91 51.18 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.56 0 N-CA-C 112.533 0.568 . . . . 0.0 112.533 -177.966 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 178' ' ' TRP . . . . . 0.4 ' HH2' ' HB2' ' A' ' 123' ' ' ARG . 84.0 t90 -73.7 -45.67 50.88 Favored 'General case' 0 C--N 1.331 -0.2 0 CA-C-O 120.833 0.349 . . . . 0.0 110.904 179.904 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 179' ' ' LEU . . . . . 0.527 HD23 HD23 ' A' ' 180' ' ' LEU . 0.5 OUTLIER -73.86 -54.82 7.14 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.027 -0.533 . . . . 0.0 111.635 -179.053 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild full ' A' A ' 180' ' ' LEU . . . . . 0.629 HD22 HD11 ' A' ' 187' ' ' LEU . 16.6 mt -62.41 -46.34 89.02 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.563 -0.29 . . . . 0.0 111.378 -179.245 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . -54.64 173.55 0.77 Allowed Glycine 0 CA--C 1.523 0.536 0 C-N-CA 120.296 -0.954 . . . . 0.0 112.514 179.707 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 182' ' ' PRO . . . . . 0.501 ' HA ' ' HB2' ' A' ' 186' ' ' ALA . 86.9 Cg_exo -45.95 -45.3 17.65 Favored 'Trans proline' 0 CA--C 1.536 0.615 0 C-N-CA 122.813 2.342 . . . . 0.0 113.801 -179.849 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 183' ' ' PRO . . . . . 0.434 ' HD3' ' HB2' ' A' ' 182' ' ' PRO . 89.0 Cg_exo -45.37 -34.24 10.09 Favored 'Trans proline' 0 C--N 1.356 0.924 0 C-N-CA 122.281 1.987 . . . . 0.0 113.429 -179.828 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 184' ' ' GLY . . . . . . . . . . . . . . . -109.68 -123.75 4.71 Favored Glycine 0 C--N 1.333 0.368 0 C-N-CA 120.299 -0.953 . . . . 0.0 113.114 -179.652 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 185' ' ' VAL . . . . . . . . . . . . . 11.2 m -62.44 -21.77 27.93 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.218 0 N-CA-C 112.252 0.464 . . . . 0.0 112.252 -179.315 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 186' ' ' ALA . . . . . 0.501 ' HB2' ' HA ' ' A' ' 182' ' ' PRO . . . 57.12 85.63 0.08 Allowed 'General case' 0 N--CA 1.463 0.222 0 CA-C-O 120.862 0.363 . . . . 0.0 111.761 179.693 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 187' ' ' LEU . . . . . 0.629 HD11 HD22 ' A' ' 180' ' ' LEU . 12.6 mt -92.62 -49.66 5.99 Favored 'General case' 0 C--N 1.332 -0.192 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.375 179.806 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 188' ' ' LEU . . . . . 0.588 HD13 HG11 ' A' ' 192' ' ' VAL . 79.7 mt -101.41 -159.81 0.76 Allowed 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 115.946 -0.57 . . . . 0.0 111.1 -179.333 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 189' ' ' THR . . . . . . . . . . . . . 2.0 t -96.55 147.66 33.28 Favored Pre-proline 0 C--N 1.33 -0.277 0 CA-C-N 116.089 -0.505 . . . . 0.0 111.256 -179.793 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 190' ' ' PRO . . . . . 0.435 ' O ' HG23 ' A' ' 194' ' ' VAL . 77.1 Cg_exo -47.62 -39.29 29.77 Favored 'Trans proline' 0 C--N 1.351 0.685 0 C-N-CA 122.681 2.254 . . . . 0.0 112.74 179.967 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 191' ' ' THR . . . . . . . . . . . . . 73.7 p -57.77 -44.05 85.94 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.315 -0.402 . . . . 0.0 111.357 -179.754 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 192' ' ' VAL . . . . . 0.588 HG11 HD13 ' A' ' 188' ' ' LEU . 40.8 t -68.25 -42.64 84.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.242 -0.436 . . . . 0.0 111.146 179.933 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 193' ' ' ASP . . . . . . . . . . . . . 25.6 t70 -58.29 -50.32 74.02 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.254 -0.43 . . . . 0.0 111.176 -179.849 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 194' ' ' VAL . . . . . 0.504 HG21 HD22 ' A' ' 4' ' ' LEU . 59.6 t -60.93 -35.71 66.89 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.35 -0.386 . . . . 0.0 110.982 179.896 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 195' ' ' ALA . . . . . . . . . . . . . . . -58.39 -48.39 80.8 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.466 -0.334 . . . . 0.0 111.143 179.858 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 196' ' ' LEU . . . . . . . . . . . . . 52.7 mt -68.27 -44.99 74.34 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.327 -0.397 . . . . 0.0 110.651 179.696 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 197' ' ' ILE . . . . . 0.412 HG13 ' NH2' ' A' ' 72' ' ' ARG . 20.2 mm -56.29 -59.12 3.16 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.368 0 CA-C-N 115.805 -0.634 . . . . 0.0 110.787 179.643 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 198' ' ' VAL . . . . . . . . . . . . . 49.3 t -52.26 -35.1 19.04 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.484 0 CA-C-N 115.657 -0.701 . . . . 0.0 109.55 178.728 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 199' ' ' TYR . . . . . . . . . . . . . 48.7 t80 -70.15 -32.1 69.92 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 115.482 -0.781 . . . . 0.0 110.523 179.641 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 200' ' ' LEU . . . . . 0.511 ' O ' HG12 ' A' ' 203' ' ' VAL . 40.8 mt -70.35 -43.97 69.12 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 115.903 -0.589 . . . . 0.0 111.553 -179.609 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 201' ' ' ASP . . . . . . . . . . . . . 8.5 m-20 -70.04 -38.37 75.83 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 121.087 0.47 . . . . 0.0 110.521 -179.971 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 202' ' ' LEU . . . . . 0.573 ' O ' HG22 ' A' ' 206' ' ' VAL . 2.7 mt -70.67 -33.09 70.56 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 115.721 -0.672 . . . . 0.0 111.95 -179.389 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 203' ' ' VAL . . . . . 0.511 HG12 ' O ' ' A' ' 200' ' ' LEU . 13.4 p -72.47 -36.08 53.34 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.297 0 C-N-CA 120.856 -0.338 . . . . 0.0 110.848 -178.651 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 204' ' ' THR . . . . . . . . . . . . . 82.4 m -66.29 -58.32 5.61 Favored 'General case' 0 C--N 1.328 -0.328 0 C-N-CA 120.797 -0.361 . . . . 0.0 111.47 179.443 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 205' ' ' LYS . . . . . 0.713 ' HE2' ' HB2' ' A' ' 47' ' ' ALA . 57.3 mttp -61.1 -60.15 4.23 Favored 'General case' 0 C--N 1.329 -0.304 0 N-CA-C 112.974 0.731 . . . . 0.0 112.974 -177.697 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 206' ' ' VAL . . . . . 0.573 HG22 ' O ' ' A' ' 202' ' ' LEU . 1.0 OUTLIER -71.1 -36.31 62.35 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.434 0 N-CA-C 112.103 0.409 . . . . 0.0 112.103 -179.471 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild full ' A' A ' 207' ' ' GLY . . . . . 0.564 ' O ' HG13 ' A' ' 211' ' ' ILE . . . -55.91 -61.48 7.39 Favored Glycine 0 C--N 1.331 0.258 0 C-N-CA 120.534 -0.841 . . . . 0.0 113.623 -178.691 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 208' ' ' PHE . . . . . 0.605 ' HB2' ' HG ' ' A' ' 163' ' ' LEU . 0.7 OUTLIER -72.35 -29.67 64.01 Favored 'General case' 0 C--O 1.224 -0.289 0 CA-C-N 117.433 0.617 . . . . 0.0 110.465 -179.632 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild full ' A' A ' 209' ' ' GLY . . . . . 0.53 ' O ' ' HB3' ' A' ' 212' ' ' ALA . . . -64.66 -32.08 83.03 Favored Glycine 0 N--CA 1.448 -0.514 0 CA-C-N 115.89 -0.595 . . . . 0.0 111.916 179.24 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 210' ' ' PHE . . . . . . . . . . . . . 3.3 m-85 -73.39 -47.23 43.62 Favored 'General case' 0 CA--C 1.512 -0.5 0 N-CA-C 108.242 -1.021 . . . . 0.0 108.242 178.536 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 211' ' ' ILE . . . . . 0.564 HG13 ' O ' ' A' ' 207' ' ' GLY . 4.7 mt -63.81 -27.5 42.99 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.56 0 N-CA-C 107.342 -1.355 . . . . 0.0 107.342 176.273 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 212' ' ' ALA . . . . . 0.53 ' HB3' ' O ' ' A' ' 209' ' ' GLY . . . -64.85 -39.62 93.86 Favored 'General case' 0 N--CA 1.45 -0.463 0 CA-C-N 114.335 -1.302 . . . . 0.0 110.745 179.986 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 213' ' ' LEU . . . . . . . . . . . . . 48.6 mt -67.49 -49.55 62.99 Favored 'General case' 0 C--N 1.333 -0.128 0 CA-C-N 115.511 -0.768 . . . . 0.0 111.445 -179.565 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 214' ' ' ASP . . . . . . . . . . . . . 15.9 t70 -58.62 -51.08 71.45 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.938 0.399 . . . . 0.0 110.766 -179.908 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 215' ' ' ALA . . . . . 0.402 ' O ' ' HG ' ' A' ' 219' ' ' LEU . . . -60.85 -53.42 57.5 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 115.936 -0.574 . . . . 0.0 111.214 -179.901 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 216' ' ' ALA . . . . . . . . . . . . . . . -53.32 -37.02 61.91 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.128 -179.963 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 217' ' ' ALA . . . . . . . . . . . . . . . -65.4 -33.87 76.96 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.108 -0.497 . . . . 0.0 110.347 179.577 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 218' ' ' THR . . . . . . . . . . . . . 67.0 m -75.74 -40.27 55.81 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 115.742 -0.663 . . . . 0.0 110.976 179.483 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 219' ' ' LEU . . . . . 0.402 ' HG ' ' O ' ' A' ' 215' ' ' ALA . 36.1 mt -68.33 -29.21 67.91 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.839 -179.816 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 220' ' ' ARG . . . . . . . . . . . . . 51.9 ttt180 -82.02 -34.99 29.3 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.077 -0.511 . . . . 0.0 110.779 179.959 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 221' ' ' ALA . . . . . . . . . . . . . . . -72.24 -23.84 61.28 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.171 -179.892 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 222' ' ' GLU . . . . . . . . . . . . . 13.1 pt-20 -91.91 -26.41 18.46 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 120.984 0.421 . . . . 0.0 110.199 179.751 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 223' ' ' HIS . . . . . . . . . . . . . 57.6 m-70 61.4 101.6 0.03 OUTLIER 'General case' 0 C--N 1.333 -0.144 0 CA-C-N 115.672 -0.694 . . . . 0.0 111.046 179.76 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 224' ' ' GLY . . . . . . . . . . . . . . . -111.81 4.76 27.51 Favored Glycine 0 C--N 1.331 0.297 0 C-N-CA 120.781 -0.724 . . . . 0.0 112.625 -179.845 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 225' ' ' GLU . . . . . . . . . . . . . 41.8 mt-10 -82.79 114.49 21.15 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.697 0.284 . . . . 0.0 110.797 179.988 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 226' ' ' SER . . . . . . . . . . . . . 71.5 p -143.28 160.16 41.01 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.342 -0.39 . . . . 0.0 110.966 179.993 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 227' ' ' LEU . . . . . . . . . . . . . 85.9 mt -100.33 -7.93 23.93 Favored 'General case' 0 C--N 1.332 -0.191 0 CA-C-N 116.088 -0.505 . . . . 0.0 110.868 179.959 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 228' ' ' ALA . . . . . . . . . . . . . . . 52.35 85.16 0.05 OUTLIER 'General case' 0 C--N 1.331 -0.212 0 CA-C-N 116.055 -0.52 . . . . 0.0 111.475 -179.934 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 229' ' ' GLY . . . . . . . . . . . . . . . 74.38 125.78 0.14 Allowed Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.869 -0.681 . . . . 0.0 112.624 -179.863 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 230' ' ' VAL . . . . . . . . . . . . . 57.6 t -72.31 131.66 34.43 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-O 120.827 0.346 . . . . 0.0 110.95 179.843 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 231' ' ' ASP . . . . . . . . . . . . . 20.3 m-20 -95.62 108.14 20.39 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.157 -179.831 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 232' ' ' THR . . . . . . . . . . . . . 6.7 t -168.51 145.82 3.95 Favored 'General case' 0 C--N 1.332 -0.193 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.206 179.802 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 233' ' ' ASP . . . . . . . . . . . . . 7.7 m-20 -78.49 -14.81 59.18 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 115.977 -0.556 . . . . 0.0 110.998 -179.936 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 234' ' ' THR . . . . . . . . . . . . . 89.8 m -105.09 107.04 57.91 Favored Pre-proline 0 C--N 1.329 -0.306 0 CA-C-N 116.252 -0.431 . . . . 0.0 111.209 -179.926 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 235' ' ' PRO . . . . . . . . . . . . . 73.3 Cg_endo -76.53 170.04 20.7 Favored 'Trans proline' 0 C--N 1.348 0.537 0 C-N-CA 122.318 2.012 . . . . 0.0 112.267 179.902 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 236' ' ' ALA . . . . . . . . . . . . . . . -85.98 143.77 27.97 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.907 179.917 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 237' ' ' VAL . . . . . . . . . . . . . 7.1 p -128.36 141.32 46.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.143 -179.909 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 238' ' ' ALA . . . . . . . . . . . . . . . -134.58 -23.25 1.64 Allowed 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.08 -0.509 . . . . 0.0 111.104 179.991 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 239' ' ' ASP . . . . . . . . . . . . . 14.6 t70 -145.11 142.21 29.47 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.961 -179.958 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 240' ' ' LEU . . . . . 0.436 ' N ' HD22 ' A' ' 240' ' ' LEU . 3.7 mm? -89.57 133.85 34.41 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 116.066 -0.515 . . . . 0.0 110.811 -179.969 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 241' ' ' GLU . . . . . . . . . . . . . 9.0 tp10 -101.72 -72.93 0.67 Allowed 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.113 -0.494 . . . . 0.0 111.087 -179.798 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 242' ' ' HIS . . . . . . . . . . . . . 43.0 m80 60.84 107.6 0.02 OUTLIER 'General case' 0 N--CA 1.462 0.16 0 CA-C-N 116.156 -0.474 . . . . 0.0 111.207 -179.674 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 243' ' ' HIS . . . . . . . . . . . . . 8.4 p80 -127.99 152.79 47.48 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.043 -0.526 . . . . 0.0 111.063 -179.922 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 244' ' ' HIS . . . . . . . . . . . . . 72.3 t60 -149.4 -24.34 0.28 Allowed 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.163 -0.472 . . . . 0.0 110.633 179.843 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 245' ' ' HIS . . . . . . . . . . . . . 62.5 m-70 -97.73 175.84 6.04 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.718 179.76 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 246' ' ' HIS . . . . . . . . . . . . . 18.9 t-80 -143.55 -41.76 0.29 Allowed 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.302 -0.408 . . . . 0.0 110.949 179.987 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 247' ' ' HIS . . . . . . . . . . . . . 47.8 m80 . . . . . 0 C--O 1.249 1.032 0 CA-C-O 118.246 -0.883 . . . . 0.0 110.884 -179.927 . . . . . . . . 0 0 . 1 . 025 nuclear nobuild full ' A' A ' 301' ' ' RET . . . . . 0.818 H203 ' HE1' ' A' ' 171' ' ' TRP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 62.8 mtm . . . . . 0 N--CA 1.484 1.275 0 CA-C-O 120.828 0.347 . . . . 0.0 110.99 . . . . . . . . . 0 0 . 1 . 026 nuclear nobuild full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 7.4 p -170.91 -38.18 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.249 0 CA-C-N 115.942 -0.572 . . . . 0.0 111.171 -179.982 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -103.11 -16.8 20.11 Favored Glycine 0 N--CA 1.449 -0.439 0 C-N-CA 120.646 -0.788 . . . . 0.0 112.465 -179.948 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -71.47 -37.43 71.33 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.909 0.385 . . . . 0.0 110.742 -179.971 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 65.4 p -64.19 -32.39 73.95 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.149 -179.967 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 11.8 p -57.29 -35.37 69.72 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.034 -0.53 . . . . 0.0 111.145 -179.818 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 7' ' ' LEU . . . . . . . . . . . . . 4.3 mm? -57.57 -50.94 71.47 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.295 -0.412 . . . . 0.0 111.154 179.793 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 8' ' ' PHE . . . . . 0.593 ' HB2' ' HB2' ' A' ' 55' ' ' ALA . 65.6 m-85 -65.84 -32.54 74.12 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.34 -0.391 . . . . 0.0 110.916 -179.706 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 9' ' ' TRP . . . . . 0.428 ' O ' HG13 ' A' ' 13' ' ' ILE . 23.2 m95 -67.09 -49.89 63.45 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-N 116.065 -0.516 . . . . 0.0 110.388 -179.524 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 89.5 mt -59.18 -47.05 86.74 Favored 'General case' 0 C--N 1.326 -0.45 0 CA-C-N 115.72 -0.673 . . . . 0.0 109.973 179.57 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . 0.422 ' O ' ' HG2' ' A' ' 15' ' ' MET . . . -57.67 -42.96 94.55 Favored Glycine 0 N--CA 1.445 -0.722 0 C-N-CA 120.634 -0.794 . . . . 0.0 111.363 179.062 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -56.36 -35.31 67.54 Favored 'General case' 0 C--N 1.331 -0.196 0 CA-C-O 120.939 0.4 . . . . 0.0 110.68 179.737 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 13' ' ' ILE . . . . . 0.428 HG13 ' O ' ' A' ' 9' ' ' TRP . 63.7 mt -62.32 -46.46 96.37 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 CA-C-N 116.002 -0.545 . . . . 0.0 110.082 179.334 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -59.41 -40.67 96.4 Favored Glycine 0 N--CA 1.45 -0.399 0 C-N-CA 120.799 -0.715 . . . . 0.0 112.512 179.666 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 15' ' ' MET . . . . . 0.422 ' HG2' ' O ' ' A' ' 11' ' ' GLY . 13.8 mmm -62.93 -39.14 93.68 Favored 'General case' 0 C--N 1.332 -0.189 0 CA-C-O 120.824 0.345 . . . . 0.0 110.656 -179.946 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 16' ' ' LEU . . . . . 0.427 HD13 ' O ' ' A' ' 16' ' ' LEU . 0.5 OUTLIER -59.11 -45.18 91.56 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.029 -0.532 . . . . 0.0 110.582 179.741 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 51.1 t -59.21 -48.63 86.26 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.2 0 CA-C-N 116.354 -0.384 . . . . 0.0 110.98 179.965 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -63.69 -48.42 77.39 Favored Glycine 0 N--CA 1.452 -0.283 0 C-N-CA 120.805 -0.712 . . . . 0.0 112.438 179.926 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 47.6 m -49.71 -41.19 42.87 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.735 0.302 . . . . 0.0 111.552 -179.445 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 78.0 mt -72.04 -41.61 67.29 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.425 -0.352 . . . . 0.0 111.393 179.841 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -62.57 -29.91 70.93 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.309 -0.405 . . . . 0.0 111.792 -179.65 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 22' ' ' PHE . . . . . 0.632 ' HB2' HG22 ' A' ' 41' ' ' VAL . 3.4 m-85 -89.99 -34.84 15.84 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.501 -0.318 . . . . 0.0 111.261 -179.256 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -70.43 -49.84 44.61 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.455 -0.339 . . . . 0.0 111.238 -179.993 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 24' ' ' TRP . . . . . . . . . . . . . 1.2 t-105 -59.46 -39.24 83.02 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.045 -0.525 . . . . 0.0 110.899 179.974 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -73.04 -24.67 60.74 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.293 -0.412 . . . . 0.0 110.992 179.938 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -67.53 -49.59 49.61 Favored Glycine 0 N--CA 1.451 -0.36 0 C-N-CA 120.722 -0.752 . . . . 0.0 112.225 179.715 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 63.1 mtm180 -60.42 -32.8 71.7 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-O 120.945 0.403 . . . . 0.0 110.768 179.707 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 9.0 t70 -72.31 -29.07 63.49 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 115.884 -0.598 . . . . 0.0 111.04 179.936 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -71.26 -174.93 1.1 Allowed 'General case' 0 C--N 1.331 -0.215 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.201 -179.857 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -91.28 -110.1 1.6 Allowed Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.861 -0.685 . . . . 0.0 112.764 -179.718 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 49.5 m -138.25 -45.49 0.51 Allowed 'General case' 0 C--N 1.331 -0.207 0 CA-C-O 120.791 0.329 . . . . 0.0 111.203 -179.747 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -57.95 -32.98 67.35 Favored Glycine 0 N--CA 1.453 -0.229 0 C-N-CA 120.842 -0.694 . . . . 0.0 112.711 -179.815 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 38.5 mt-10 -90.53 -20.74 22.31 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-O 120.807 0.336 . . . . 0.0 110.812 179.951 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 34' ' ' ARG . . . . . . . . . . . . . 38.5 ttm180 -48.37 -29.36 3.9 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 115.9 -0.591 . . . . 0.0 111.68 -179.512 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 35' ' ' ARG . . . . . 0.424 ' NE ' ' HA ' ' A' ' 35' ' ' ARG . 5.5 mmp_? -59.23 -46.6 88.04 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.808 0.337 . . . . 0.0 111.118 179.923 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 73.8 m-85 -67.63 -30.23 69.74 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.252 -179.848 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 37' ' ' TYR . . . . . 0.429 ' O ' HG23 ' A' ' 41' ' ' VAL . 76.5 m-85 -74.13 -54.7 7.24 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.538 -179.406 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 10.5 p -56.72 -36.18 48.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-O 120.979 0.418 . . . . 0.0 110.387 179.884 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 52.5 m -68.9 -49.96 53.69 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 115.617 -0.72 . . . . 0.0 110.559 179.216 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 40' ' ' LEU . . . . . 0.499 HD12 HD12 ' A' ' 43' ' ' ILE . 22.5 tp -55.53 -50.02 71.08 Favored 'General case' 0 C--O 1.237 0.438 0 CA-C-N 115.718 -0.674 . . . . 0.0 110.374 179.651 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . 0.632 HG22 ' HB2' ' A' ' 22' ' ' PHE . 83.7 t -59.36 -34.24 53.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 115.769 -0.65 . . . . 0.0 109.94 178.912 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -58.56 -38.25 90.83 Favored Glycine 0 N--CA 1.448 -0.547 0 C-N-CA 120.71 -0.757 . . . . 0.0 111.453 179.503 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 43' ' ' ILE . . . . . 0.499 HD12 HD12 ' A' ' 40' ' ' LEU . 2.4 mt -65.21 -59.31 4.31 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.217 0 CA-C-O 120.863 0.363 . . . . 0.0 110.593 179.464 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 77.6 p -59.56 -24.67 63.91 Favored 'General case' 0 C--N 1.331 -0.218 0 CA-C-N 115.991 -0.549 . . . . 0.0 111.344 -179.666 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -75.3 -57.69 4.21 Favored Glycine 0 CA--C 1.518 0.24 0 C-N-CA 120.745 -0.74 . . . . 0.0 112.861 -179.653 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 22.6 pt -58.25 -35.27 52.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-O 120.908 0.385 . . . . 0.0 110.762 -179.896 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 47' ' ' ALA . . . . . 0.71 ' HB2' ' HE2' ' A' ' 205' ' ' LYS . . . -63.91 -49.73 71.48 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.001 -0.545 . . . . 0.0 111.07 179.764 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -54.52 -36.55 64.37 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.857 179.999 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 0.5 OUTLIER -67.04 -42.99 89.21 Favored 'Isoleucine or valine' 0 N--CA 1.432 -1.371 0 CA-C-N 116.031 -0.531 . . . . 0.0 111.486 179.797 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . 0.435 ' HA ' HG22 ' A' ' 53' ' ' VAL . . . -67.85 -33.67 75.21 Favored 'General case' 0 C--N 1.333 -0.137 0 CA-C-N 116.43 -0.35 . . . . 0.0 111.463 179.954 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 51' ' ' TYR . . . . . 0.461 ' O ' ' HB3' ' A' ' 8' ' ' PHE . 31.5 m-85 -70.59 -36.77 73.73 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.77 -179.525 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -71.55 -42.42 67.9 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-N 115.985 -0.552 . . . . 0.0 111.531 179.985 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 53' ' ' VAL . . . . . 0.508 HG23 ' N ' ' A' ' 54' ' ' MET . 35.5 m -67.06 -50.7 61.59 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.173 0 CA-C-N 116.556 -0.293 . . . . 0.0 111.451 -179.629 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 54' ' ' MET . . . . . 0.508 ' N ' HG23 ' A' ' 53' ' ' VAL . 78.1 mtm -61.14 -32.04 71.75 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-O 121.047 0.451 . . . . 0.0 110.296 179.775 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 55' ' ' ALA . . . . . 0.593 ' HB2' ' HB2' ' A' ' 8' ' ' PHE . . . -66.44 -38.43 87.38 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 115.753 -0.658 . . . . 0.0 111.015 179.42 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 97.2 mt -71.25 -12.88 61.69 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.039 -0.528 . . . . 0.0 111.238 -179.817 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 101.05 -21.03 45.13 Favored Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.649 -0.786 . . . . 0.0 112.817 179.819 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 30.1 m -66.63 138.58 22.66 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.238 0 CA-C-O 120.872 0.367 . . . . 0.0 111.018 -179.981 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 101.8 -11.52 57.67 Favored Glycine 0 N--CA 1.45 -0.402 0 C-N-CA 120.815 -0.707 . . . . 0.0 112.413 -179.7 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 60' ' ' TRP . . . . . . . . . . . . . 22.0 m0 -78.39 117.38 19.56 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.699 0.285 . . . . 0.0 110.727 179.793 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 10.0 p -109.99 129.54 23.83 Favored Pre-proline 0 C--N 1.329 -0.295 0 CA-C-N 116.438 -0.347 . . . . 0.0 111.078 179.836 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 86.5 Cg_endo -75.96 140.61 23.08 Favored 'Trans proline' 0 C--N 1.35 0.637 0 C-N-CA 122.404 2.07 . . . . 0.0 112.111 179.897 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 81.9 t -138.94 96.13 0.99 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.041 -0.527 . . . . 0.0 110.937 -179.767 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . 58.48 -86.71 0.02 OUTLIER 'General case' 0 C--N 1.332 -0.195 0 CA-C-N 116.001 -0.545 . . . . 0.0 111.315 -179.906 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 40.8 tt0 -121.04 -26.19 5.19 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.398 -0.364 . . . . 0.0 110.781 179.959 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 66' ' ' ARG . . . . . . . . . . . . . 76.0 ttt-85 -102.11 154.55 18.89 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.576 -179.954 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 86.0 m -113.37 121.24 43.76 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 120.882 0.373 . . . . 0.0 111.57 -179.741 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 68' ' ' VAL . . . . . 0.417 HG21 ' HA ' ' A' ' 117' ' ' MET . 21.8 t -93.21 146.89 5.88 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-N 115.978 -0.555 . . . . 0.0 110.374 179.344 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 69' ' ' PHE . . . . . . . . . . . . . 30.3 m-85 -106.87 112.31 25.21 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-O 120.836 0.351 . . . . 0.0 110.152 -179.494 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 70' ' ' VAL . . . . . 0.561 ' HB ' ' HD3' ' A' ' 71' ' ' PRO . 11.2 t -68.6 -50.22 26.61 Favored Pre-proline 0 C--N 1.326 -0.45 0 CA-C-N 115.986 -0.552 . . . . 0.0 112.361 -178.85 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 71' ' ' PRO . . . . . 0.561 ' HD3' ' HB ' ' A' ' 70' ' ' VAL . 24.6 Cg_exo -63.28 -18.35 64.41 Favored 'Trans proline' 0 C--N 1.351 0.7 0 C-N-CA 122.253 1.968 . . . . 0.0 113.068 -179.455 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 70.6 ttt180 -70.69 -55.48 8.6 Favored 'General case' 0 C--O 1.235 0.316 0 CA-C-O 120.88 0.371 . . . . 0.0 111.661 -179.33 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 73' ' ' TYR . . . . . . . . . . . . . 98.8 m-85 -71.86 -33.27 68.27 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.525 -0.307 . . . . 0.0 110.72 -179.519 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 74' ' ' ILE . . . . . 0.489 HG22 ' HA ' ' A' ' 71' ' ' PRO . 0.3 OUTLIER -65.96 -37.67 80.37 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.307 0 N-CA-C 109.446 -0.575 . . . . 0.0 109.446 179.017 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 33.1 t70 -61.65 -37.33 83.65 Favored 'General case' 0 N--CA 1.453 -0.286 0 N-CA-C 109.251 -0.648 . . . . 0.0 109.251 178.734 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 76' ' ' TRP . . . . . . . . . . . . . 45.8 m0 -66.66 -29.91 70.05 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 115.642 -0.708 . . . . 0.0 110.114 179.019 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 77' ' ' ILE . . . . . 0.463 HG12 ' HB3' ' A' ' 109' ' ' MET . 97.0 mt -71.73 -29.62 34.84 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 115.87 -0.605 . . . . 0.0 110.737 179.447 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 51.8 mt -90.43 -17.17 27.66 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 116.0 -0.546 . . . . 0.0 111.776 179.994 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 79' ' ' THR . . . . . 0.409 ' O ' HG12 ' A' ' 83' ' ' ILE . 69.7 p -102.94 -52.63 3.01 Favored 'General case' 0 C--N 1.332 -0.189 0 N-CA-C 113.311 0.856 . . . . 0.0 113.311 -178.371 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 80' ' ' THR . . . . . 0.697 ' HB ' ' HD3' ' A' ' 81' ' ' PRO . 37.4 m -50.2 -55.7 23.15 Favored Pre-proline 0 CA--C 1.533 0.292 0 N-CA-C 112.537 0.569 . . . . 0.0 112.537 -178.284 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 81' ' ' PRO . . . . . 0.697 ' HD3' ' HB ' ' A' ' 80' ' ' THR . 39.2 Cg_exo -61.06 -21.07 70.42 Favored 'Trans proline' 0 C--N 1.351 0.666 0 C-N-CA 121.55 1.5 . . . . 0.0 111.587 179.818 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 82' ' ' LEU . . . . . . . . . . . . . 14.4 tp -76.99 -33.17 57.62 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 115.811 -0.631 . . . . 0.0 110.599 179.847 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 83' ' ' ILE . . . . . 0.409 HG12 ' O ' ' A' ' 79' ' ' THR . 36.3 mm -69.92 -53.45 23.84 Favored 'Isoleucine or valine' 0 C--O 1.232 0.173 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.214 179.326 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . 0.467 HG21 ' OD1' ' A' ' 105' ' ' ASN . 34.6 m -59.61 -32.46 49.22 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.224 0 N-CA-C 109.4 -0.592 . . . . 0.0 109.4 178.637 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 85' ' ' TYR . . . . . . . . . . . . . 68.7 t80 -60.68 -43.88 97.17 Favored 'General case' 0 N--CA 1.452 -0.356 0 CA-C-N 115.455 -0.793 . . . . 0.0 109.047 178.606 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 86' ' ' PHE . . . . . . . . . . . . . 2.1 t80 -53.52 -50.25 65.84 Favored 'General case' 0 C--O 1.233 0.199 0 CA-C-N 115.632 -0.713 . . . . 0.0 109.734 179.407 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 87' ' ' LEU . . . . . 0.568 ' HA ' HD12 ' A' ' 90' ' ' LEU . 8.9 mp -59.72 -28.34 67.25 Favored 'General case' 0 C--N 1.332 -0.188 0 CA-C-N 115.785 -0.643 . . . . 0.0 110.665 179.618 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -65.28 -42.45 96.2 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.65 -0.786 . . . . 0.0 111.903 179.697 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 89' ' ' LEU . . . . . 0.423 ' N ' HD12 ' A' ' 89' ' ' LEU . 8.8 mp -64.5 -37.22 86.77 Favored 'General case' 0 N--CA 1.45 -0.474 0 CA-C-O 121.118 0.485 . . . . 0.0 110.504 179.387 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 90' ' ' LEU . . . . . 0.568 HD12 ' HA ' ' A' ' 87' ' ' LEU . 97.9 mt -55.32 -59.07 5.31 Favored 'General case' 0 C--N 1.326 -0.455 0 CA-C-N 115.368 -0.833 . . . . 0.0 111.162 179.905 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . 0.564 ' HB2' ' HB2' ' A' ' 149' ' ' ALA . . . -71.69 -54.82 9.1 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.085 -0.507 . . . . 0.0 111.382 -179.79 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 110.88 59.46 0.48 Allowed Glycine 0 N--CA 1.45 -0.372 0 C-N-CA 120.95 -0.643 . . . . 0.0 112.255 -179.892 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 93' ' ' LEU . . . . . 0.501 HD23 ' HB3' ' A' ' 97' ' ' GLU . 8.9 mp -77.19 169.29 18.6 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.915 0.388 . . . . 0.0 111.133 -179.722 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 94' ' ' ASP . . . . . . . . . . . . . 9.7 m-20 -91.09 163.65 14.22 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.05 -0.523 . . . . 0.0 110.704 179.827 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 80.6 p -53.96 -27.56 32.05 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.331 -0.395 . . . . 0.0 110.988 -179.926 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 80.5 mtm180 -73.07 -53.43 11.09 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.299 -0.409 . . . . 0.0 110.757 179.81 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 97' ' ' GLU . . . . . 0.501 ' HB3' HD23 ' A' ' 93' ' ' LEU . 44.9 mt-10 -57.44 -39.41 76.19 Favored 'General case' 0 C--N 1.332 -0.191 0 CA-C-N 116.122 -0.49 . . . . 0.0 111.104 -179.857 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 98' ' ' PHE . . . . . 0.45 ' O ' HG12 ' A' ' 102' ' ' ILE . 12.6 m-85 -60.29 -51.54 69.12 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.366 -0.379 . . . . 0.0 110.857 179.969 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -59.31 -28.15 64.08 Favored Glycine 0 N--CA 1.452 -0.291 0 C-N-CA 120.675 -0.774 . . . . 0.0 112.497 -179.85 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 96.3 mt -73.4 -47.05 47.4 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-O 120.823 0.344 . . . . 0.0 111.345 -179.868 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 59.4 t -67.38 -43.2 87.89 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.399 0 CA-C-N 116.235 -0.438 . . . . 0.0 111.545 -179.675 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 102' ' ' ILE . . . . . 0.45 HG12 ' O ' ' A' ' 98' ' ' PHE . 49.5 mm -64.83 -48.92 82.4 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.386 -0.37 . . . . 0.0 111.4 -179.516 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 14.0 t -60.4 -31.05 70.0 Favored 'General case' 0 C--N 1.332 -0.169 0 CA-C-O 120.811 0.339 . . . . 0.0 110.814 -179.982 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 104' ' ' LEU . . . . . 0.499 ' O ' HG23 ' A' ' 108' ' ' VAL . 45.6 tp -61.95 -54.45 41.58 Favored 'General case' 0 C--N 1.332 -0.185 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.382 179.486 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 105' ' ' ASN . . . . . 0.538 HD21 HD13 ' A' ' 137' ' ' LEU . 4.9 m120 -61.87 -25.48 67.57 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 116.053 -0.521 . . . . 0.0 110.959 -179.986 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 52.2 m -64.27 -54.89 26.24 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.343 -0.39 . . . . 0.0 111.12 179.992 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 107' ' ' VAL . . . . . 0.438 HG12 ' O ' ' A' ' 104' ' ' LEU . 13.4 p -64.14 -36.37 76.75 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.205 0 CA-C-N 116.382 -0.372 . . . . 0.0 111.049 -179.989 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . 0.499 HG23 ' O ' ' A' ' 104' ' ' LEU . 96.4 t -64.13 -52.65 53.44 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.761 179.664 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 109' ' ' MET . . . . . 0.463 ' HB3' HG12 ' A' ' 77' ' ' ILE . 9.7 tpp -62.11 -26.15 68.13 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 115.872 -0.604 . . . . 0.0 110.705 -179.973 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 29.7 tp -75.69 -33.87 60.38 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.163 -0.472 . . . . 0.0 110.204 179.396 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -62.13 -54.37 42.18 Favored 'General case' 0 C--N 1.332 -0.177 0 CA-C-N 115.924 -0.58 . . . . 0.0 110.377 179.301 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 112' ' ' GLY . . . . . 0.401 ' HA3' ' H21' ' A' ' 301' ' ' RET . . . -61.75 -37.32 94.09 Favored Glycine 0 N--CA 1.45 -0.388 0 C-N-CA 120.645 -0.788 . . . . 0.0 111.652 179.435 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 113' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER -48.23 -69.88 0.11 Allowed 'General case' 0 CA--C 1.521 -0.158 0 N-CA-C 109.755 -0.461 . . . . 0.0 109.755 179.219 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 114' ' ' ALA . . . . . 0.403 ' O ' HG13 ' A' ' 118' ' ' VAL . . . -65.1 -17.79 64.76 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 115.615 -0.72 . . . . 0.0 110.271 178.875 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 115' ' ' GLY . . . . . 0.528 ' HA2' HD22 ' A' ' 126' ' ' LEU . . . -52.52 -47.99 56.15 Favored Glycine 0 C--N 1.334 0.465 0 C-N-CA 121.005 -0.617 . . . . 0.0 111.791 179.45 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -78.26 -23.1 47.46 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-O 120.666 0.27 . . . . 0.0 111.571 179.705 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 117' ' ' MET . . . . . 0.417 ' HA ' HG21 ' A' ' 68' ' ' VAL . 40.9 ttm -94.8 19.2 10.44 Favored 'General case' 0 CA--C 1.533 0.305 0 CA-C-N 116.457 -0.338 . . . . 0.0 111.859 -179.257 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 118' ' ' VAL . . . . . 0.45 HG21 ' HB3' ' A' ' 123' ' ' ARG . 21.8 m -69.17 150.88 97.28 Favored Pre-proline 0 C--N 1.331 -0.227 0 CA-C-O 120.554 0.216 . . . . 0.0 111.17 179.736 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 119' ' ' PRO . . . . . . . . . . . . . 92.9 Cg_endo -81.29 -4.96 12.66 Favored 'Trans proline' 0 C--N 1.348 0.515 0 C-N-CA 122.699 2.266 . . . . 0.0 112.364 179.846 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -158.2 -131.23 1.26 Allowed Glycine 0 C--N 1.331 0.267 0 C-N-CA 120.834 -0.698 . . . . 0.0 112.653 -179.994 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 37.9 pt -97.48 10.88 5.79 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.226 0 CA-C-O 120.877 0.37 . . . . 0.0 111.161 -179.951 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 16.4 mm-40 -59.8 -18.12 41.13 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.016 -0.538 . . . . 0.0 111.096 179.8 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 123' ' ' ARG . . . . . 0.45 ' HB3' HG21 ' A' ' 118' ' ' VAL . 23.0 ptt180 -50.74 -28.9 10.1 Favored 'General case' 0 C--N 1.331 -0.197 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.778 -179.884 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 124' ' ' TYR . . . . . . . . . . . . . 38.1 m-85 -69.46 -32.91 72.13 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-O 120.828 0.347 . . . . 0.0 110.975 179.965 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 125' ' ' ALA . . . . . . . . . . . . . . . -73.52 -49.94 23.99 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.094 -0.503 . . . . 0.0 111.13 179.942 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 126' ' ' LEU . . . . . 0.528 HD22 ' HA2' ' A' ' 115' ' ' GLY . 7.9 mp -53.36 -55.49 24.49 Favored 'General case' 0 C--N 1.331 -0.201 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.316 179.771 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 127' ' ' PHE . . . . . 0.439 ' HE1' ' H42' ' A' ' 301' ' ' RET . 9.7 t80 -62.82 -33.9 76.18 Favored 'General case' 0 N--CA 1.452 -0.372 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.264 179.568 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 128' ' ' GLY . . . . . . . . . . . . . . . -47.97 -43.23 23.9 Favored Glycine 0 C--N 1.333 0.394 0 C-N-CA 120.167 -1.016 . . . . 0.0 110.778 178.907 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 129' ' ' MET . . . . . 0.421 ' HE1' ' HA ' ' A' ' 108' ' ' VAL . 0.4 OUTLIER -71.27 -38.22 71.86 Favored 'General case' 0 C--N 1.329 -0.312 0 N-CA-C 109.786 -0.45 . . . . 0.0 109.786 178.565 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -65.72 -27.49 72.73 Favored Glycine 0 N--CA 1.451 -0.313 0 CA-C-N 115.757 -0.656 . . . . 0.0 112.695 179.907 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -74.77 -53.66 8.78 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.664 0.268 . . . . 0.0 110.545 179.828 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 132' ' ' VAL . . . . . 0.526 ' O ' HG13 ' A' ' 135' ' ' ILE . 38.7 t -57.2 -39.74 69.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-O 121.567 0.699 . . . . 0.0 109.311 178.675 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -70.99 -33.97 70.93 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-N 115.15 -0.932 . . . . 0.0 110.831 179.41 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 134' ' ' PHE . . . . . 0.437 ' CZ ' ' HA ' ' A' ' 172' ' ' ALA . 35.9 t80 -55.03 -59.22 5.04 Favored 'General case' 0 N--CA 1.453 -0.281 0 CA-C-N 116.353 -0.385 . . . . 0.0 110.397 179.809 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 135' ' ' ILE . . . . . 0.526 HG13 ' O ' ' A' ' 132' ' ' VAL . 0.2 OUTLIER -55.71 -36.63 43.52 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.368 0 CA-C-N 116.012 -0.54 . . . . 0.0 109.862 179.176 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild full ' A' A ' 136' ' ' GLY . . . . . 0.413 ' O ' ' HB3' ' A' ' 139' ' ' TYR . . . -52.77 -42.28 59.06 Favored Glycine 0 C--N 1.334 0.437 0 C-N-CA 120.396 -0.907 . . . . 0.0 111.686 178.86 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 137' ' ' LEU . . . . . 0.538 HD13 HD21 ' A' ' 105' ' ' ASN . 49.1 tp -64.52 -49.25 72.02 Favored 'General case' 0 C--N 1.33 -0.261 0 N-CA-C 110.187 -0.301 . . . . 0.0 110.187 179.161 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 138' ' ' VAL . . . . . . . . . . . . . 59.9 t -54.82 -33.12 27.4 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.928 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.238 179.847 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 139' ' ' TYR . . . . . 0.413 ' HB3' ' O ' ' A' ' 136' ' ' GLY . 18.2 t80 -63.0 -43.32 99.13 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 115.867 -0.606 . . . . 0.0 110.112 178.74 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 140' ' ' TYR . . . . . 0.472 ' HE2' HD22 ' A' ' 104' ' ' LEU . 29.1 m-85 -63.75 -44.49 93.34 Favored 'General case' 0 C--N 1.332 -0.171 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.025 179.658 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 141' ' ' LEU . . . . . 0.445 ' HA ' ' SD ' ' A' ' 145' ' ' MET . 10.4 mp -55.99 -34.37 65.69 Favored 'General case' 0 C--N 1.332 -0.191 0 CA-C-N 116.449 -0.341 . . . . 0.0 110.96 179.887 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 22.2 t -94.62 -17.3 7.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.111 179.85 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . -68.96 -140.61 0.1 OUTLIER Glycine 0 CA--C 1.521 0.441 0 C-N-CA 121.034 -0.603 . . . . 0.0 113.218 -179.789 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 144' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_exo -51.88 -23.58 16.65 Favored 'Trans proline' 0 C--N 1.35 0.614 0 C-N-CA 122.841 2.361 . . . . 0.0 113.004 -179.597 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 145' ' ' MET . . . . . 0.445 ' SD ' ' HA ' ' A' ' 141' ' ' LEU . 34.9 mtt -54.1 -35.68 62.39 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.354 -0.384 . . . . 0.0 111.734 -179.648 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 146' ' ' THR . . . . . . . . . . . . . 46.0 p -79.1 -32.1 44.5 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.83 0.347 . . . . 0.0 111.265 -179.413 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 43.3 tt0 -61.96 -48.91 78.29 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 116.114 -0.494 . . . . 0.0 111.108 -179.917 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 148' ' ' SER . . . . . . . . . . . . . 51.6 m -70.56 -44.89 66.49 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.654 -179.342 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 149' ' ' ALA . . . . . 0.564 ' HB2' ' HB2' ' A' ' 91' ' ' ALA . . . -60.31 -55.08 38.0 Favored 'General case' 0 C--N 1.329 -0.291 0 N-CA-C 112.065 0.395 . . . . 0.0 112.065 -179.256 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 150' ' ' SER . . . . . 0.489 ' HA ' ' HB3' ' A' ' 157' ' ' LYS . 67.6 m -64.03 -8.03 10.48 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.415 -0.357 . . . . 0.0 111.09 -179.681 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 151' ' ' GLN . . . . . . . . . . . . . 24.2 mt-30 -120.99 7.51 10.36 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.342 -0.39 . . . . 0.0 111.193 179.959 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 152' ' ' ARG . . . . . 0.534 ' HA ' ' HE ' ' A' ' 152' ' ' ARG . 5.3 tpm_? -85.55 -52.49 5.79 Favored 'General case' 0 C--N 1.332 -0.165 0 CA-C-O 120.841 0.353 . . . . 0.0 110.678 179.944 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 153' ' ' SER . . . . . 0.653 ' HB2' HG12 ' A' ' 156' ' ' ILE . 18.6 m -158.24 172.9 17.53 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 115.949 -0.568 . . . . 0.0 110.617 179.168 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 154' ' ' SER . . . . . . . . . . . . . 48.4 t -72.17 -40.26 68.08 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.512 179.455 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -77.45 -30.21 54.19 Favored Glycine 0 CA--C 1.518 0.274 0 C-N-CA 120.986 -0.626 . . . . 0.0 112.998 179.917 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 156' ' ' ILE . . . . . 0.653 HG12 ' HB2' ' A' ' 153' ' ' SER . 34.9 mm -58.84 -46.76 90.87 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.226 0 N-CA-C 111.974 0.361 . . . . 0.0 111.974 -179.264 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 157' ' ' LYS . . . . . 0.489 ' HB3' ' HA ' ' A' ' 150' ' ' SER . 6.5 ptpp? -60.64 -35.67 76.76 Favored 'General case' 0 C--N 1.331 -0.234 0 N-CA-C 111.588 0.218 . . . . 0.0 111.588 -179.394 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 49.0 m -66.24 -44.53 83.46 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.941 0.401 . . . . 0.0 111.236 -179.752 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 159' ' ' LEU . . . . . 0.459 HD21 ' HB3' ' A' ' 215' ' ' ALA . 5.1 mt -68.64 -37.66 79.87 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.544 -179.743 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 160' ' ' TYR . . . . . 0.406 ' OH ' ' HB3' ' A' ' 145' ' ' MET . 13.8 t80 -68.55 -43.24 77.1 Favored 'General case' 0 C--N 1.327 -0.407 0 N-CA-C 112.267 0.469 . . . . 0.0 112.267 -178.705 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 161' ' ' VAL . . . . . 0.415 HG23 ' N ' ' A' ' 162' ' ' ARG . 24.0 m -63.78 -46.21 95.07 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 C-N-CA 120.989 -0.284 . . . . 0.0 111.717 -179.23 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 162' ' ' ARG . . . . . 0.415 ' N ' HG23 ' A' ' 161' ' ' VAL . 24.9 tpt180 -69.25 -48.63 61.32 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.815 0.34 . . . . 0.0 111.491 -179.76 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 163' ' ' LEU . . . . . . . . . . . . . 1.5 mp -60.89 -54.8 40.62 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.089 -0.505 . . . . 0.0 111.937 -179.183 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 164' ' ' ARG . . . . . . . . . . . . . 6.1 tmm_? -55.94 -50.52 70.53 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 116.073 -0.512 . . . . 0.0 112.179 -178.498 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 165' ' ' ASN . . . . . 0.507 ' O ' HG23 ' A' ' 169' ' ' VAL . 0.9 OUTLIER -52.7 -51.52 59.97 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-O 120.662 0.268 . . . . 0.0 111.458 -179.261 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild full ' A' A ' 166' ' ' LEU . . . . . 0.503 ' O ' ' HG ' ' A' ' 170' ' ' LEU . 3.4 tt -62.6 -52.55 62.92 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 116.385 -0.37 . . . . 0.0 111.713 -179.566 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 167' ' ' THR . . . . . . . . . . . . . 85.1 m -54.72 -53.17 58.46 Favored 'General case' 0 C--N 1.329 -0.296 0 N-CA-C 112.734 0.642 . . . . 0.0 112.734 -178.64 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 168' ' ' VAL . . . . . . . . . . . . . 81.8 t -55.53 -44.34 75.94 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 N-CA-C 112.281 0.474 . . . . 0.0 112.281 -178.723 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 169' ' ' VAL . . . . . 0.507 HG23 ' O ' ' A' ' 165' ' ' ASN . 68.8 t -57.93 -65.19 0.45 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.367 0 N-CA-C 112.409 0.522 . . . . 0.0 112.409 -179.039 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 170' ' ' LEU . . . . . 0.503 ' HG ' ' O ' ' A' ' 166' ' ' LEU . 0.7 OUTLIER -62.4 -31.68 72.4 Favored 'General case' 0 C--N 1.332 -0.195 0 N-CA-C 112.453 0.538 . . . . 0.0 112.453 -178.355 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild full ' A' A ' 171' ' ' TRP . . . . . 0.779 ' HE1' H203 ' A' ' 301' ' ' RET . 5.8 m0 -70.12 -31.2 68.62 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-O 120.816 0.341 . . . . 0.0 110.658 179.48 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 172' ' ' ALA . . . . . 0.437 ' HA ' ' CZ ' ' A' ' 134' ' ' PHE . . . -74.21 -6.86 50.3 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.799 -179.763 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 173' ' ' ILE . . . . . 0.504 ' O ' HG12 ' A' ' 177' ' ' ILE . 34.9 mm -85.95 -21.76 7.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 115.901 -0.59 . . . . 0.0 110.383 179.43 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 174' ' ' TYR . . . . . . . . . . . . . 15.7 m-85 -54.42 -50.72 83.5 Favored Pre-proline 0 N--CA 1.463 0.222 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.744 -179.735 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 175' ' ' PRO . . . . . 0.407 ' HB3' ' HZ ' ' A' ' 127' ' ' PHE . 80.3 Cg_exo -46.13 -31.02 8.22 Favored 'Trans proline' 0 C--N 1.352 0.732 0 C-N-CA 122.131 1.887 . . . . 0.0 112.155 179.83 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 176' ' ' PHE . . . . . 0.455 ' O ' ' HG ' ' A' ' 180' ' ' LEU . 74.4 m-85 -80.7 -49.97 10.51 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.88 -0.6 . . . . 0.0 111.826 -179.783 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 177' ' ' ILE . . . . . 0.504 HG12 ' O ' ' A' ' 173' ' ' ILE . 5.3 mm -62.82 -36.33 75.03 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.525 0 N-CA-C 112.454 0.539 . . . . 0.0 112.454 -177.958 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 178' ' ' TRP . . . . . 0.449 ' HH2' ' HB2' ' A' ' 123' ' ' ARG . 71.3 t90 -71.27 -47.55 56.29 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.827 0.346 . . . . 0.0 110.997 -179.89 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 179' ' ' LEU . . . . . 0.441 HD23 HD23 ' A' ' 180' ' ' LEU . 0.5 OUTLIER -69.84 -54.57 12.9 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.677 -179.045 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild full ' A' A ' 180' ' ' LEU . . . . . 0.597 HD22 HD11 ' A' ' 187' ' ' LEU . 26.4 mt -65.06 -39.42 93.24 Favored 'General case' 0 C--N 1.328 -0.355 0 C-N-CA 121.025 -0.27 . . . . 0.0 111.469 -179.252 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . -62.26 -179.38 3.93 Favored Glycine 0 C--N 1.335 0.474 0 C-N-CA 120.031 -1.08 . . . . 0.0 112.196 179.074 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 182' ' ' PRO . . . . . 0.561 ' HA ' ' HB2' ' A' ' 186' ' ' ALA . 72.6 Cg_exo -48.85 -44.12 32.89 Favored 'Trans proline' 0 CA--C 1.536 0.623 0 C-N-CA 122.784 2.323 . . . . 0.0 113.87 179.896 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 183' ' ' PRO . . . . . . . . . . . . . 87.8 Cg_exo -47.62 -26.92 7.11 Favored 'Trans proline' 0 C--N 1.356 0.947 0 C-N-CA 122.279 1.986 . . . . 0.0 113.398 -179.782 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 184' ' ' GLY . . . . . . . . . . . . . . . -120.02 -125.92 3.36 Favored Glycine 0 N--CA 1.45 -0.369 0 C-N-CA 120.271 -0.966 . . . . 0.0 113.212 -179.598 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 185' ' ' VAL . . . . . . . . . . . . . 6.1 m -60.45 -27.58 40.35 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.369 0 N-CA-C 112.319 0.489 . . . . 0.0 112.319 -179.315 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 186' ' ' ALA . . . . . 0.561 ' HB2' ' HA ' ' A' ' 182' ' ' PRO . . . 58.23 82.79 0.13 Allowed 'General case' 0 C--N 1.331 -0.214 0 CA-C-O 120.801 0.334 . . . . 0.0 111.697 179.613 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 187' ' ' LEU . . . . . 0.597 HD11 HD22 ' A' ' 180' ' ' LEU . 8.4 mt -92.21 -49.78 6.0 Favored 'General case' 0 C--N 1.333 -0.151 0 CA-C-N 116.297 -0.411 . . . . 0.0 111.271 179.853 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 188' ' ' LEU . . . . . 0.471 ' HB3' ' H ' ' A' ' 189' ' ' THR . 4.3 mm? -91.16 -161.3 0.8 Allowed 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.002 -0.545 . . . . 0.0 111.571 -179.051 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 189' ' ' THR . . . . . 0.471 ' H ' ' HB3' ' A' ' 188' ' ' LEU . 21.6 m -92.76 137.86 23.89 Favored Pre-proline 0 C--N 1.329 -0.326 0 CA-C-N 115.704 -0.68 . . . . 0.0 110.917 -179.479 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 190' ' ' PRO . . . . . 0.456 ' O ' HG23 ' A' ' 194' ' ' VAL . 95.5 Cg_exo -44.86 -50.04 8.97 Favored 'Trans proline' 0 C--N 1.35 0.626 0 C-N-CA 122.674 2.249 . . . . 0.0 113.259 -179.951 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 191' ' ' THR . . . . . 0.419 HG22 HG22 ' A' ' 189' ' ' THR . 9.7 t -56.26 -39.79 73.18 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-O 120.668 0.271 . . . . 0.0 111.434 -179.606 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 192' ' ' VAL . . . . . 0.454 HG23 ' HB ' ' A' ' 189' ' ' THR . 72.8 t -64.71 -48.66 83.69 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.358 -0.383 . . . . 0.0 111.102 179.93 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 193' ' ' ASP . . . . . . . . . . . . . 27.0 t70 -57.12 -44.58 83.44 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.136 -0.484 . . . . 0.0 111.063 -179.875 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 194' ' ' VAL . . . . . 0.456 HG23 ' O ' ' A' ' 190' ' ' PRO . 89.3 t -60.82 -35.86 67.42 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.247 0 CA-C-N 116.132 -0.486 . . . . 0.0 110.776 179.953 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 195' ' ' ALA . . . . . . . . . . . . . . . -60.1 -47.83 84.26 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-N 116.429 -0.35 . . . . 0.0 111.003 179.583 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 196' ' ' LEU . . . . . . . . . . . . . 86.1 mt -66.58 -42.82 86.39 Favored 'General case' 0 C--N 1.332 -0.158 0 CA-C-N 116.388 -0.369 . . . . 0.0 110.5 179.489 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 197' ' ' ILE . . . . . . . . . . . . . 15.6 mm -56.99 -59.53 3.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.077 -0.51 . . . . 0.0 110.341 179.221 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 198' ' ' VAL . . . . . . . . . . . . . 52.9 t -52.16 -34.76 18.29 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.5 0 CA-C-N 115.717 -0.674 . . . . 0.0 109.375 178.388 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 199' ' ' TYR . . . . . . . . . . . . . 57.5 t80 -69.54 -32.91 72.01 Favored 'General case' 0 C--N 1.331 -0.204 0 CA-C-N 115.462 -0.79 . . . . 0.0 110.623 -179.844 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 200' ' ' LEU . . . . . 0.446 ' O ' HG12 ' A' ' 203' ' ' VAL . 34.6 mt -67.75 -41.55 83.21 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 115.885 -0.598 . . . . 0.0 111.081 -179.896 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 201' ' ' ASP . . . . . 0.452 ' OD2' ' H14' ' A' ' 301' ' ' RET . 1.0 OUTLIER -73.48 -35.02 65.63 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-O 121.147 0.499 . . . . 0.0 110.273 179.447 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild full ' A' A ' 202' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -69.45 -28.38 66.06 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 115.495 -0.775 . . . . 0.0 111.924 -179.823 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 203' ' ' VAL . . . . . 0.446 HG12 ' O ' ' A' ' 200' ' ' LEU . 9.5 p -82.44 -37.75 14.68 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.183 0 N-CA-C 111.804 0.298 . . . . 0.0 111.804 -178.831 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 204' ' ' THR . . . . . . . . . . . . . 88.9 m -67.35 -41.71 84.68 Favored 'General case' 0 C--N 1.33 -0.279 0 C-N-CA 120.798 -0.361 . . . . 0.0 111.297 179.664 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 205' ' ' LYS . . . . . 0.71 ' HE2' ' HB2' ' A' ' 47' ' ' ALA . 57.3 mttp -78.39 -51.56 9.87 Favored 'General case' 0 C--N 1.326 -0.455 0 N-CA-C 112.238 0.458 . . . . 0.0 112.238 -178.601 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 84.8 t -73.22 -37.37 52.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 N-CA-C 111.735 0.272 . . . . 0.0 111.735 -179.514 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 207' ' ' GLY . . . . . . . . . . . . . . . -71.52 -52.62 12.08 Favored Glycine 0 N--CA 1.453 -0.219 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.603 -179.654 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 208' ' ' PHE . . . . . 0.446 ' O ' ' HB2' ' A' ' 212' ' ' ALA . 10.1 t80 -59.6 -40.46 87.54 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-O 120.71 0.29 . . . . 0.0 110.477 179.648 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 209' ' ' GLY . . . . . 0.476 ' O ' ' HB3' ' A' ' 212' ' ' ALA . . . -70.18 -39.27 72.39 Favored Glycine 0 N--CA 1.451 -0.315 0 CA-C-N 115.699 -0.682 . . . . 0.0 113.302 -179.734 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 210' ' ' PHE . . . . . . . . . . . . . 1.1 m-85 -68.35 -43.0 78.41 Favored 'General case' 0 CA--C 1.508 -0.67 0 N-CA-C 107.794 -1.187 . . . . 0.0 107.794 179.099 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 211' ' ' ILE . . . . . . . . . . . . . 85.7 mt -67.49 -28.85 43.52 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.815 0 CA-C-N 114.296 -1.32 . . . . 0.0 107.548 176.688 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 212' ' ' ALA . . . . . 0.476 ' HB3' ' O ' ' A' ' 209' ' ' GLY . . . -67.0 -40.86 87.43 Favored 'General case' 0 N--CA 1.45 -0.472 0 CA-C-N 114.599 -1.182 . . . . 0.0 110.494 179.876 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 213' ' ' LEU . . . . . . . . . . . . . 91.0 mt -70.35 -52.2 24.33 Favored 'General case' 0 C--N 1.33 -0.239 0 CA-C-N 115.304 -0.862 . . . . 0.0 111.754 -179.407 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 214' ' ' ASP . . . . . . . . . . . . . 45.4 m-20 -50.04 -54.63 18.98 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.218 -0.447 . . . . 0.0 111.847 -179.277 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 215' ' ' ALA . . . . . 0.459 ' HB3' HD21 ' A' ' 159' ' ' LEU . . . -60.46 -54.49 44.87 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.432 -0.349 . . . . 0.0 111.541 -179.448 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 216' ' ' ALA . . . . . . . . . . . . . . . -55.86 -32.51 63.71 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-O 120.926 0.394 . . . . 0.0 111.317 -179.763 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 217' ' ' ALA . . . . . . . . . . . . . . . -65.57 -39.89 92.15 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.03 -0.532 . . . . 0.0 110.601 179.877 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 218' ' ' THR . . . . . . . . . . . . . 54.7 m -64.86 -44.0 91.16 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 115.993 -0.549 . . . . 0.0 110.757 179.588 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 219' ' ' LEU . . . . . . . . . . . . . 19.1 mt -68.36 -25.21 64.97 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.028 -0.533 . . . . 0.0 110.617 179.903 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 220' ' ' ARG . . . . . . . . . . . . . 62.8 ttp180 -84.28 -31.4 24.95 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 115.783 -0.644 . . . . 0.0 111.453 -179.712 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 221' ' ' ALA . . . . . . . . . . . . . . . -82.91 -20.47 35.34 Favored 'General case' 0 C--N 1.33 -0.251 0 N-CA-C 112.316 0.487 . . . . 0.0 112.316 -178.936 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 222' ' ' GLU . . . . . . . . . . . . . 10.9 pt-20 -73.71 -14.77 61.2 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-O 120.768 0.318 . . . . 0.0 111.218 -179.388 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 223' ' ' HIS . . . . . . . . . . . . . 87.4 m-70 -70.69 -34.33 71.85 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.276 -0.42 . . . . 0.0 110.75 179.847 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 224' ' ' GLY . . . . . . . . . . . . . . . -94.68 -46.82 2.85 Favored Glycine 0 C--N 1.331 0.303 0 C-N-CA 120.882 -0.675 . . . . 0.0 112.34 179.948 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 225' ' ' GLU . . . . . . . . . . . . . 9.9 mm-40 -99.55 119.77 38.59 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.764 0.316 . . . . 0.0 110.738 179.93 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 226' ' ' SER . . . . . . . . . . . . . 45.1 t -102.19 -57.64 2.03 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.291 -0.413 . . . . 0.0 111.064 -179.86 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 227' ' ' LEU . . . . . . . . . . . . . 61.5 tp -124.32 132.76 53.57 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.097 -0.501 . . . . 0.0 111.088 -179.764 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 228' ' ' ALA . . . . . . . . . . . . . . . -89.18 160.36 17.02 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.123 -0.49 . . . . 0.0 111.027 179.915 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 229' ' ' GLY . . . . . . . . . . . . . . . 112.39 73.65 0.66 Allowed Glycine 0 N--CA 1.452 -0.273 0 C-N-CA 120.76 -0.734 . . . . 0.0 112.343 -179.911 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 230' ' ' VAL . . . . . . . . . . . . . 39.9 t -85.6 140.41 15.97 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-O 120.781 0.324 . . . . 0.0 111.184 -179.915 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 231' ' ' ASP . . . . . . . . . . . . . 5.0 p-10 -113.23 109.1 18.2 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.854 179.9 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 232' ' ' THR . . . . . . . . . . . . . 4.9 t -153.24 136.25 15.52 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.016 -0.538 . . . . 0.0 110.873 179.944 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 233' ' ' ASP . . . . . . . . . . . . . 8.7 m-20 -85.49 -66.76 0.86 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.278 -0.419 . . . . 0.0 110.938 -179.876 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 234' ' ' THR . . . . . . . . . . . . . 5.2 t -105.69 143.69 27.35 Favored Pre-proline 0 C--N 1.33 -0.266 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.121 -179.904 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 235' ' ' PRO . . . . . . . . . . . . . 34.8 Cg_endo -65.08 -47.42 4.7 Favored 'Trans proline' 0 C--N 1.35 0.612 0 C-N-CA 122.383 2.056 . . . . 0.0 112.431 -179.992 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 236' ' ' ALA . . . . . . . . . . . . . . . -55.16 145.07 22.14 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.262 -0.426 . . . . 0.0 111.071 -179.85 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 237' ' ' VAL . . . . . . . . . . . . . 14.8 p -100.56 146.2 9.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.308 -179.654 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 238' ' ' ALA . . . . . . . . . . . . . . . -132.44 174.97 9.7 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 115.991 -0.55 . . . . 0.0 110.905 179.84 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 239' ' ' ASP . . . . . . . . . . . . . 3.7 p30 -76.46 175.85 8.8 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.814 -179.981 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 240' ' ' LEU . . . . . . . . . . . . . 1.2 pp -149.21 15.48 0.91 Allowed 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.084 -179.923 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 241' ' ' GLU . . . . . . . . . . . . . 8.6 tp10 -67.0 115.48 6.77 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.625 179.999 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 242' ' ' HIS . . . . . . . . . . . . . 28.1 m80 -79.05 139.19 38.2 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.29 -0.414 . . . . 0.0 111.0 -179.736 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 243' ' ' HIS . . . . . . . . . . . . . 86.9 m-70 -86.41 121.35 28.85 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.878 -179.966 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 244' ' ' HIS . . . . . . . . . . . . . 51.0 p-80 -85.64 164.78 17.5 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.888 -179.917 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 245' ' ' HIS . . . . . . . . . . . . . 83.8 m-70 -135.87 5.35 3.09 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.128 -0.487 . . . . 0.0 111.0 179.918 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 246' ' ' HIS . . . . . . . . . . . . . 55.8 t-80 -68.41 -33.18 73.77 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.739 179.975 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 247' ' ' HIS . . . . . . . . . . . . . 57.6 t60 . . . . . 0 C--O 1.25 1.09 0 CA-C-O 118.191 -0.909 . . . . 0.0 111.042 -179.901 . . . . . . . . 0 0 . 1 . 026 nuclear nobuild full ' A' A ' 301' ' ' RET . . . . . 0.779 H203 ' HE1' ' A' ' 171' ' ' TRP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . 0.501 ' HG2' HG12 ' A' ' 2' ' ' VAL . 0.0 OUTLIER . . . . . 0 N--CA 1.485 1.276 0 CA-C-O 120.755 0.312 . . . . 0.0 110.992 . . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 2' ' ' VAL . . . . . 0.501 HG12 ' HG2' ' A' ' 1' ' ' MET . 7.3 p -170.37 -37.02 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.331 -0.224 0 CA-C-N 116.288 -0.415 . . . . 0.0 111.442 -179.891 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -113.46 -44.46 0.78 Allowed Glycine 0 N--CA 1.452 -0.27 0 C-N-CA 120.724 -0.75 . . . . 0.0 112.975 -179.618 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 4' ' ' LEU . . . . . 0.453 HD12 HD22 ' A' ' 7' ' ' LEU . 24.7 tp -57.04 -35.21 69.04 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.828 0.347 . . . . 0.0 111.265 -179.693 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 74.1 p -54.87 -37.88 66.82 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 116.211 -0.45 . . . . 0.0 112.015 -179.637 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 32.1 p -53.84 -35.29 61.32 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 120.823 0.344 . . . . 0.0 111.44 -179.452 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 7' ' ' LEU . . . . . 0.48 HD21 ' O ' ' A' ' 191' ' ' THR . 9.0 mp -58.6 -53.42 58.58 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.227 -179.83 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 8' ' ' PHE . . . . . 0.543 ' HB2' ' HB2' ' A' ' 55' ' ' ALA . 69.9 m-85 -60.46 -32.47 71.42 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.002 -0.544 . . . . 0.0 110.887 -179.837 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 9' ' ' TRP . . . . . . . . . . . . . 32.2 m95 -64.4 -44.39 91.43 Favored 'General case' 0 C--N 1.327 -0.371 0 N-CA-C 109.563 -0.532 . . . . 0.0 109.563 179.612 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 78.8 mt -63.56 -36.76 84.87 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 115.472 -0.785 . . . . 0.0 110.09 179.243 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -64.22 -37.13 94.11 Favored Glycine 0 N--CA 1.448 -0.535 0 CA-C-N 115.619 -0.719 . . . . 0.0 111.806 179.332 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -65.45 -37.51 87.09 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-O 120.856 0.36 . . . . 0.0 110.337 179.634 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 50.1 mm -59.14 -50.22 80.55 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.222 0 CA-C-N 115.937 -0.574 . . . . 0.0 110.432 179.119 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -58.42 -35.09 77.78 Favored Glycine 0 N--CA 1.45 -0.411 0 C-N-CA 120.772 -0.727 . . . . 0.0 112.12 179.536 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 15' ' ' MET . . . . . 0.451 ' HE3' ' CB ' ' A' ' 47' ' ' ALA . 22.7 mmt -66.37 -43.29 86.35 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-O 120.752 0.311 . . . . 0.0 110.892 179.718 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -55.96 -43.71 77.79 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.462 179.739 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 60.6 t -60.71 -46.59 95.68 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.283 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.989 179.903 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -66.17 -49.2 59.13 Favored Glycine 0 C--N 1.33 0.246 0 C-N-CA 120.787 -0.72 . . . . 0.0 112.41 179.685 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 23.6 m -49.61 -42.94 46.08 Favored 'General case' 0 C--N 1.327 -0.39 0 C-N-CA 122.365 0.266 . . . . 0.0 111.579 -179.458 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 65.7 mt -72.38 -42.16 65.55 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.478 -0.328 . . . . 0.0 111.753 179.858 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -61.61 -30.09 70.46 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.312 -0.404 . . . . 0.0 111.577 -179.362 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 22' ' ' PHE . . . . . 0.699 ' HB2' HG22 ' A' ' 41' ' ' VAL . 6.5 m-85 -90.88 -30.76 16.74 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.41 -0.359 . . . . 0.0 111.262 -179.594 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -72.36 -50.38 27.08 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.956 0.407 . . . . 0.0 111.558 -179.548 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 24' ' ' TRP . . . . . . . . . . . . . 4.1 t-105 -62.68 -43.12 99.62 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 115.978 -0.556 . . . . 0.0 111.171 -179.72 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -80.15 -17.68 51.82 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.398 -0.365 . . . . 0.0 110.862 179.855 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -73.46 -33.79 58.13 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.876 -0.678 . . . . 0.0 112.576 179.973 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 39.7 ptt180 -84.95 13.91 5.48 Favored 'General case' 0 C--N 1.332 -0.195 0 CA-C-O 120.888 0.375 . . . . 0.0 110.887 -179.983 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 22.1 t70 -143.22 82.89 1.77 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.082 -0.508 . . . . 0.0 110.692 179.782 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -168.19 -74.51 0.02 OUTLIER 'General case' 0 C--N 1.332 -0.194 0 CA-C-N 116.111 -0.495 . . . . 0.0 111.177 -179.848 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -169.78 -155.23 9.88 Favored Glycine 0 C--N 1.331 0.295 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.627 -179.955 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 46.3 t -101.2 -62.34 1.26 Allowed 'General case' 0 C--N 1.332 -0.188 0 CA-C-O 120.819 0.343 . . . . 0.0 110.989 -179.851 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -61.02 -28.88 69.54 Favored Glycine 0 C--N 1.332 0.306 0 C-N-CA 120.796 -0.716 . . . . 0.0 112.644 -179.96 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 37.4 mt-10 -69.43 -25.69 64.24 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.742 0.306 . . . . 0.0 110.99 -179.941 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 34' ' ' ARG . . . . . . . . . . . . . 17.5 tpt180 -53.13 -28.72 27.23 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.076 -0.511 . . . . 0.0 111.478 -179.654 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 41.0 mmt180 -60.17 -43.31 95.91 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-O 120.833 0.349 . . . . 0.0 111.207 -179.843 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 82.0 m-85 -71.72 -29.73 64.87 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.294 -0.412 . . . . 0.0 111.348 -179.779 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 37' ' ' TYR . . . . . 0.467 ' O ' HG23 ' A' ' 41' ' ' VAL . 70.0 m-85 -75.79 -54.98 6.09 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.189 -0.459 . . . . 0.0 111.182 -179.549 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 14.8 p -56.61 -36.52 48.64 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-O 121.007 0.432 . . . . 0.0 110.578 179.774 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 28.5 m -66.06 -51.07 61.54 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 115.9 -0.591 . . . . 0.0 110.82 179.457 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 40' ' ' LEU . . . . . 0.459 HD12 HD12 ' A' ' 43' ' ' ILE . 49.3 tp -59.12 -47.77 84.07 Favored 'General case' 0 C--O 1.235 0.314 0 CA-C-N 115.922 -0.581 . . . . 0.0 110.886 179.964 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . 0.699 HG22 ' HB2' ' A' ' 22' ' ' PHE . 89.9 t -60.63 -34.73 59.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.097 179.195 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . 0.428 ' O ' HG12 ' A' ' 46' ' ' ILE . . . -60.98 -38.59 95.74 Favored Glycine 0 N--CA 1.447 -0.587 0 CA-C-N 115.712 -0.676 . . . . 0.0 112.309 179.751 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 43' ' ' ILE . . . . . 0.76 HG22 ' HE3' ' A' ' 205' ' ' LYS . 0.1 OUTLIER -66.97 -56.94 11.82 Favored 'Isoleucine or valine' 0 C--O 1.232 0.145 0 CA-C-O 120.651 0.262 . . . . 0.0 110.989 179.903 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 48.1 t -62.39 -21.31 65.26 Favored 'General case' 0 C--O 1.233 0.185 0 CA-C-O 120.833 0.349 . . . . 0.0 111.241 -179.892 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -77.06 -58.53 3.39 Favored Glycine 0 CA--C 1.519 0.305 0 C-N-CA 120.754 -0.736 . . . . 0.0 112.642 -179.758 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 46' ' ' ILE . . . . . 0.428 HG12 ' O ' ' A' ' 42' ' ' GLY . 16.1 pt -58.32 -35.87 55.63 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.157 0 CA-C-O 120.932 0.396 . . . . 0.0 110.726 179.94 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 47' ' ' ALA . . . . . 0.687 ' HB2' ' HE2' ' A' ' 205' ' ' LYS . . . -67.96 -39.89 83.29 Favored 'General case' 0 C--N 1.326 -0.45 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.771 179.056 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 48' ' ' ALA . . . . . 0.438 ' HB2' ' HB3' ' A' ' 15' ' ' MET . . . -54.58 -47.29 73.49 Favored 'General case' 0 C--O 1.233 0.205 0 CA-C-N 116.007 -0.542 . . . . 0.0 111.046 179.897 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 27.5 m -72.08 -34.09 49.18 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.379 0 CA-C-N 116.047 -0.524 . . . . 0.0 111.009 -179.901 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -60.1 -41.49 92.65 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-O 121.017 0.436 . . . . 0.0 110.761 179.503 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 51' ' ' TYR . . . . . 0.421 ' HB3' ' O ' ' A' ' 8' ' ' PHE . 43.8 m-85 -73.24 -31.5 64.16 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 115.899 -0.592 . . . . 0.0 110.262 -179.982 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -66.26 -43.3 86.85 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 115.887 -0.597 . . . . 0.0 110.624 179.126 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 16.5 m -75.15 -37.72 40.54 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.166 0 CA-C-N 116.277 -0.419 . . . . 0.0 111.028 179.798 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 54' ' ' MET . . . . . 0.531 ' HG2' ' HG2' ' A' ' 71' ' ' PRO . 68.5 mtm -67.22 -34.42 77.43 Favored 'General case' 0 CA--C 1.52 -0.18 0 CA-C-O 121.213 0.53 . . . . 0.0 109.776 179.215 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 55' ' ' ALA . . . . . 0.543 ' HB2' ' HB2' ' A' ' 8' ' ' PHE . . . -66.53 -19.29 65.75 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-N 115.382 -0.827 . . . . 0.0 111.124 179.481 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 87.5 mt -94.95 -3.73 48.04 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.329 -0.396 . . . . 0.0 111.01 -179.927 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 85.57 24.48 42.63 Favored Glycine 0 C--N 1.331 0.271 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.712 179.939 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 58' ' ' VAL . . . . . 0.441 ' O ' ' HG3' ' A' ' 71' ' ' PRO . 48.3 t -86.84 142.36 13.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-O 120.714 0.293 . . . . 0.0 110.829 179.882 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 59' ' ' GLY . . . . . 0.638 ' HA3' ' HD3' ' A' ' 71' ' ' PRO . . . 81.33 -3.74 76.01 Favored Glycine 0 N--CA 1.449 -0.458 0 C-N-CA 120.807 -0.711 . . . . 0.0 112.569 -179.976 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 60' ' ' TRP . . . . . . . . . . . . . 14.4 m0 -70.73 101.08 2.0 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.809 0.338 . . . . 0.0 110.646 179.853 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 61' ' ' VAL . . . . . 0.422 ' HA ' ' HD3' ' A' ' 62' ' ' PRO . 3.2 p -105.5 125.42 33.46 Favored Pre-proline 0 CA--C 1.534 0.334 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.35 -179.982 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 62' ' ' PRO . . . . . 0.422 ' HD3' ' HA ' ' A' ' 61' ' ' VAL . 8.4 Cg_exo -71.52 148.32 53.67 Favored 'Trans proline' 0 C--N 1.35 0.644 0 C-N-CA 122.617 2.211 . . . . 0.0 112.06 179.729 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 77.9 t -142.23 92.43 0.52 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-N 116.112 -0.495 . . . . 0.0 110.894 -179.932 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . 59.67 -85.99 0.02 OUTLIER 'General case' 0 C--N 1.331 -0.209 0 CA-C-N 116.158 -0.473 . . . . 0.0 111.346 -179.865 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 10.2 tp10 -121.05 -24.61 5.52 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.438 -0.346 . . . . 0.0 110.604 179.902 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 66' ' ' ARG . . . . . . . . . . . . . 80.7 mtt180 -103.54 152.96 21.1 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.132 -0.486 . . . . 0.0 110.396 -179.88 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 94.1 m -116.0 127.41 54.91 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 120.955 0.407 . . . . 0.0 111.426 -179.536 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 10.7 t -104.71 146.26 12.18 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.24 0 CA-C-N 115.941 -0.572 . . . . 0.0 110.39 179.488 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 69' ' ' PHE . . . . . . . . . . . . . 12.2 m-85 -109.81 111.76 23.38 Favored 'General case' 0 N--CA 1.452 -0.358 0 N-CA-C 109.519 -0.549 . . . . 0.0 109.519 -179.572 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 70' ' ' VAL . . . . . 0.64 ' N ' ' HD2' ' A' ' 71' ' ' PRO . 0.5 OUTLIER -66.21 -40.42 35.77 Favored Pre-proline 0 C--N 1.321 -0.654 0 N-CA-C 112.428 0.529 . . . . 0.0 112.428 -179.507 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild full ' A' A ' 71' ' ' PRO . . . . . 0.64 ' HD2' ' N ' ' A' ' 70' ' ' VAL . 27.1 Cg_endo -63.23 -27.04 72.2 Favored 'Trans proline' 0 C--N 1.356 0.93 0 C-N-CA 121.779 1.652 . . . . 0.0 112.821 -179.03 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 61.0 ttp180 -73.25 -52.99 11.99 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 121.0 0.428 . . . . 0.0 110.212 179.629 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 73' ' ' TYR . . . . . 0.425 ' O ' HG13 ' A' ' 77' ' ' ILE . 52.9 m-85 -66.49 -34.4 77.84 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.012 -0.54 . . . . 0.0 110.716 179.758 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 74' ' ' ILE . . . . . 0.427 ' HB ' ' O ' ' A' ' 70' ' ' VAL . 0.4 OUTLIER -72.83 -37.69 55.39 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.209 0 CA-C-N 116.282 -0.417 . . . . 0.0 110.121 179.675 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 18.2 t70 -58.02 -37.79 74.99 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-N 116.212 -0.449 . . . . 0.0 109.863 179.226 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 76' ' ' TRP . . . . . . . . . . . . . 53.3 m0 -68.69 -42.16 78.19 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 115.894 -0.594 . . . . 0.0 110.601 179.428 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 77' ' ' ILE . . . . . 0.495 ' O ' ' HG3' ' A' ' 81' ' ' PRO . 86.1 mt -58.72 -28.67 37.96 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.062 -0.517 . . . . 0.0 111.016 179.567 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 45.5 mt -92.03 -38.89 11.96 Favored 'General case' 0 CA--C 1.534 0.343 0 N-CA-C 112.551 0.574 . . . . 0.0 112.551 -179.614 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 79' ' ' THR . . . . . 0.428 HG22 HD11 ' A' ' 46' ' ' ILE . 74.8 p -82.99 -52.43 6.68 Favored 'General case' 0 N--CA 1.465 0.299 0 N-CA-C 113.929 1.085 . . . . 0.0 113.929 -177.422 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 80' ' ' THR . . . . . 0.466 ' N ' ' HD2' ' A' ' 81' ' ' PRO . 39.2 m -48.01 -54.28 25.69 Favored Pre-proline 0 C--N 1.33 -0.252 0 N-CA-C 113.089 0.774 . . . . 0.0 113.089 -178.132 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 81' ' ' PRO . . . . . 0.495 ' HG3' ' O ' ' A' ' 77' ' ' ILE . 25.1 Cg_endo -60.14 -21.09 64.57 Favored 'Trans proline' 0 C--N 1.351 0.689 0 C-N-CA 121.481 1.454 . . . . 0.0 111.397 -179.683 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 82' ' ' LEU . . . . . . . . . . . . . 17.6 tp -77.03 -32.95 57.41 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 115.633 -0.712 . . . . 0.0 110.005 179.555 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 83' ' ' ILE . . . . . 0.517 HD13 HD13 ' A' ' 43' ' ' ILE . 41.4 mm -67.9 -53.14 32.57 Favored 'Isoleucine or valine' 0 C--O 1.233 0.206 0 CA-C-N 116.059 -0.519 . . . . 0.0 109.909 178.976 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 35.9 m -60.87 -29.86 46.22 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.219 0 CA-C-N 115.97 -0.559 . . . . 0.0 109.513 178.975 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 85' ' ' TYR . . . . . . . . . . . . . 78.8 t80 -68.52 -32.8 73.01 Favored 'General case' 0 N--CA 1.453 -0.303 0 CA-C-N 115.569 -0.741 . . . . 0.0 109.623 178.792 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 86' ' ' PHE . . . . . . . . . . . . . 8.8 t80 -62.36 -51.21 68.5 Favored 'General case' 0 C--N 1.333 -0.117 0 CA-C-N 115.87 -0.605 . . . . 0.0 109.733 179.298 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 10.5 mp -61.61 -29.63 70.17 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-N 115.83 -0.623 . . . . 0.0 110.136 179.339 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -69.96 -27.85 72.56 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.899 -0.667 . . . . 0.0 111.889 179.362 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 88.1 mt -74.29 -44.57 52.17 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-O 120.994 0.426 . . . . 0.0 110.597 179.587 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 43.4 mt -63.27 -28.4 70.0 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 115.75 -0.659 . . . . 0.0 111.05 -179.976 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -88.46 -39.88 13.89 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.379 -179.628 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 88.14 59.43 1.67 Allowed Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.662 -0.78 . . . . 0.0 112.26 -179.736 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 93' ' ' LEU . . . . . 0.417 ' HB3' ' HB2' ' A' ' 97' ' ' GLU . 45.6 mt -75.79 -175.97 3.17 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.849 0.357 . . . . 0.0 110.957 -179.883 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 94' ' ' ASP . . . . . . . . . . . . . 7.8 m-20 -109.12 171.93 7.14 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.057 -0.519 . . . . 0.0 110.709 179.847 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 66.2 m -55.07 -36.4 65.57 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.345 -179.653 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 96' ' ' ARG . . . . . 0.425 ' O ' HG13 ' A' ' 100' ' ' ILE . 38.1 ttp180 -73.26 -52.77 12.8 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.352 -0.386 . . . . 0.0 111.054 -179.687 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 97' ' ' GLU . . . . . 0.417 ' HB2' ' HB3' ' A' ' 93' ' ' LEU . 47.9 mt-10 -53.14 -48.3 68.04 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.404 -0.362 . . . . 0.0 111.441 -179.48 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 98' ' ' PHE . . . . . 0.451 ' O ' HG12 ' A' ' 102' ' ' ILE . 18.1 m-85 -55.91 -52.07 65.39 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.524 -0.307 . . . . 0.0 111.112 179.921 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -57.66 -28.09 59.59 Favored Glycine 0 N--CA 1.452 -0.277 0 C-N-CA 120.771 -0.728 . . . . 0.0 112.768 -179.72 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 100' ' ' ILE . . . . . 0.425 HG13 ' O ' ' A' ' 96' ' ' ARG . 95.7 mt -72.51 -42.69 63.84 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-O 120.839 0.352 . . . . 0.0 111.279 -179.787 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 48.3 t -69.35 -48.62 66.5 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.439 0 CA-C-N 116.222 -0.444 . . . . 0.0 111.577 -179.534 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 102' ' ' ILE . . . . . 0.451 HG12 ' O ' ' A' ' 98' ' ' PHE . 34.2 mm -59.79 -48.93 85.73 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.736 -179.284 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 15.1 t -58.77 -38.34 78.27 Favored 'General case' 0 C--O 1.233 0.198 0 CA-C-O 120.707 0.289 . . . . 0.0 111.083 -179.813 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 104' ' ' LEU . . . . . 0.474 ' O ' HG23 ' A' ' 108' ' ' VAL . 36.6 tp -58.98 -43.45 91.41 Favored 'General case' 0 C--N 1.332 -0.177 0 CA-C-O 120.986 0.422 . . . . 0.0 110.272 179.296 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 105' ' ' ASN . . . . . 0.676 HD21 HD13 ' A' ' 137' ' ' LEU . 0.8 OUTLIER -65.87 -27.69 68.41 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-N 116.019 -0.537 . . . . 0.0 110.644 -179.981 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild full ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 62.4 m -63.52 -57.31 10.59 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 116.372 -0.377 . . . . 0.0 111.031 -179.89 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 107' ' ' VAL . . . . . 0.423 HG12 ' O ' ' A' ' 104' ' ' LEU . 12.8 p -57.99 -36.35 56.01 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.184 0 CA-C-N 116.399 -0.364 . . . . 0.0 110.857 179.937 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . 0.474 HG23 ' O ' ' A' ' 104' ' ' LEU . 54.3 t -58.32 -45.39 89.4 Favored 'Isoleucine or valine' 0 C--O 1.234 0.282 0 CA-C-O 121.069 0.462 . . . . 0.0 110.675 179.351 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 109' ' ' MET . . . . . 0.456 ' HG2' ' O ' ' A' ' 105' ' ' ASN . 21.3 mmt -71.96 -31.81 66.67 Favored 'General case' 0 CA--C 1.516 -0.361 0 CA-C-N 115.921 -0.582 . . . . 0.0 110.57 179.942 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 110' ' ' LEU . . . . . 0.456 HD23 ' C ' ' A' ' 110' ' ' LEU . 4.0 tt -62.6 -34.14 76.4 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-N 115.98 -0.555 . . . . 0.0 109.54 178.854 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -67.78 -53.73 24.82 Favored 'General case' 0 C--N 1.332 -0.18 0 CA-C-N 115.761 -0.654 . . . . 0.0 110.667 179.468 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 112' ' ' GLY . . . . . 0.652 ' HA3' ' H21' ' A' ' 301' ' ' RET . . . -62.4 -38.89 97.04 Favored Glycine 0 C--N 1.332 0.309 0 C-N-CA 120.641 -0.79 . . . . 0.0 112.286 179.566 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 113' ' ' PHE . . . . . . . . . . . . . 4.3 t80 -53.61 -66.93 0.3 Allowed 'General case' 0 C--N 1.331 -0.236 0 CA-C-O 121.088 0.47 . . . . 0.0 110.194 179.718 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 114' ' ' ALA . . . . . 0.408 ' HB3' HD22 ' A' ' 126' ' ' LEU . . . -65.22 -17.67 64.68 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 115.767 -0.651 . . . . 0.0 110.491 179.287 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -58.54 -48.43 84.42 Favored Glycine 0 C--N 1.332 0.333 0 CA-C-N 115.784 -0.644 . . . . 0.0 111.914 179.42 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -78.32 -17.49 56.49 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.739 0.304 . . . . 0.0 110.988 179.322 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 117' ' ' MET . . . . . . . . . . . . . 21.1 mmt -84.95 13.9 5.49 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.098 -0.501 . . . . 0.0 111.353 -179.452 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 118' ' ' VAL . . . . . 0.466 HG21 ' HB3' ' A' ' 123' ' ' ARG . 33.6 m -81.4 139.01 48.03 Favored Pre-proline 0 C--N 1.33 -0.266 0 N-CA-C 111.838 0.31 . . . . 0.0 111.838 -179.398 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 119' ' ' PRO . . . . . . . . . . . . . 85.7 Cg_endo -92.22 -2.63 3.99 Favored 'Trans proline' 0 N--CA 1.455 -0.788 0 C-N-CA 122.91 2.407 . . . . 0.0 112.463 179.052 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -138.89 -110.34 0.91 Allowed Glycine 0 C--N 1.333 0.379 0 C-N-CA 120.675 -0.774 . . . . 0.0 112.863 -179.775 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 2.4 pp -127.07 15.29 3.56 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.192 0 N-CA-C 111.849 0.314 . . . . 0.0 111.849 -179.775 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 46.5 mt-10 -61.22 -18.54 58.83 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.906 0.384 . . . . 0.0 110.838 179.82 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 123' ' ' ARG . . . . . 0.582 ' HD2' ' HA2' ' A' ' 184' ' ' GLY . 24.4 ptt180 -51.46 -27.63 10.9 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 115.871 -0.604 . . . . 0.0 111.729 -179.92 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 124' ' ' TYR . . . . . . . . . . . . . 22.2 m-85 -75.15 -33.34 61.51 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.582 -0.281 . . . . 0.0 111.382 -179.524 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 125' ' ' ALA . . . . . . . . . . . . . . . -74.14 -56.64 4.67 Favored 'General case' 0 C--O 1.235 0.34 0 CA-C-O 120.96 0.41 . . . . 0.0 111.155 -179.933 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 126' ' ' LEU . . . . . 0.408 HD22 ' HB3' ' A' ' 114' ' ' ALA . 1.2 mt -53.48 -51.2 63.51 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.016 -0.538 . . . . 0.0 110.275 179.749 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 127' ' ' PHE . . . . . . . . . . . . . 11.0 t80 -65.29 -30.1 70.93 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.03 179.318 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 128' ' ' GLY . . . . . . . . . . . . . . . -49.02 -49.31 29.94 Favored Glycine 0 N--CA 1.45 -0.42 0 C-N-CA 120.179 -1.01 . . . . 0.0 110.581 178.703 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 129' ' ' MET . . . . . 0.479 ' HE3' ' HA2' ' A' ' 130' ' ' GLY . 0.0 OUTLIER -71.71 -27.84 63.29 Favored 'General case' 0 C--N 1.328 -0.351 0 N-CA-C 109.067 -0.716 . . . . 0.0 109.067 178.303 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild full ' A' A ' 130' ' ' GLY . . . . . 0.479 ' HA2' ' HE3' ' A' ' 129' ' ' MET . . . -60.68 -41.23 98.88 Favored Glycine 0 C--N 1.332 0.36 0 CA-C-N 115.712 -0.676 . . . . 0.0 112.241 179.49 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -71.9 -48.99 41.71 Favored 'General case' 0 C--N 1.331 -0.21 0 CA-C-O 120.627 0.251 . . . . 0.0 110.403 179.668 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 57.2 t -55.68 -46.5 79.51 Favored 'Isoleucine or valine' 0 C--O 1.234 0.271 0 CA-C-O 121.302 0.573 . . . . 0.0 109.506 178.826 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -62.29 -38.19 88.39 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 115.397 -0.82 . . . . 0.0 110.507 178.962 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 134' ' ' PHE . . . . . . . . . . . . . 82.3 t80 -55.71 -53.47 56.15 Favored 'General case' 0 N--CA 1.452 -0.371 0 CA-C-N 116.058 -0.519 . . . . 0.0 110.305 179.793 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 135' ' ' ILE . . . . . 0.434 ' O ' HG22 ' A' ' 138' ' ' VAL . 47.5 mt -55.95 -32.08 32.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 115.841 -0.618 . . . . 0.0 110.193 179.573 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . -62.54 -42.6 99.68 Favored Glycine 0 N--CA 1.448 -0.522 0 C-N-CA 120.176 -1.012 . . . . 0.0 111.232 178.738 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 137' ' ' LEU . . . . . 0.676 HD13 HD21 ' A' ' 105' ' ' ASN . 61.0 tp -66.27 -54.42 25.13 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.583 0.23 . . . . 0.0 110.855 179.617 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 138' ' ' VAL . . . . . 0.434 HG22 ' O ' ' A' ' 135' ' ' ILE . 3.8 m -55.05 -31.56 25.67 Favored 'Isoleucine or valine' 0 C--O 1.232 0.184 0 N-CA-C 109.891 -0.411 . . . . 0.0 109.891 -179.7 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 139' ' ' TYR . . . . . . . . . . . . . 14.2 t80 -61.37 -42.83 99.34 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 115.871 -0.604 . . . . 0.0 109.748 178.313 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 140' ' ' TYR . . . . . 0.437 ' HE2' HD22 ' A' ' 104' ' ' LEU . 21.7 m-85 -66.95 -45.71 76.94 Favored 'General case' 0 CA--C 1.529 0.153 0 CA-C-N 116.034 -0.53 . . . . 0.0 111.096 179.262 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 141' ' ' LEU . . . . . . . . . . . . . 11.2 mp -52.4 -37.41 56.51 Favored 'General case' 0 N--CA 1.464 0.23 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.791 -179.417 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 8.6 p -104.58 -5.28 9.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-O 120.927 0.394 . . . . 0.0 111.394 -179.514 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 143' ' ' GLY . . . . . 0.434 ' HA3' ' HD2' ' A' ' 144' ' ' PRO . . . -75.51 -130.89 0.3 Allowed Glycine 0 CA--C 1.521 0.427 0 C-N-CA 120.768 -0.729 . . . . 0.0 113.009 -179.625 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 144' ' ' PRO . . . . . 0.434 ' HD2' ' HA3' ' A' ' 143' ' ' GLY . 13.2 Cg_endo -56.21 -23.47 45.46 Favored 'Trans proline' 0 C--N 1.348 0.549 0 C-N-CA 122.741 2.294 . . . . 0.0 112.658 -179.587 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 145' ' ' MET . . . . . . . . . . . . . 50.4 mtt -56.96 -29.22 63.02 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.286 -0.415 . . . . 0.0 111.696 -179.652 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 146' ' ' THR . . . . . . . . . . . . . 72.9 p -77.28 -34.65 55.62 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.837 0.351 . . . . 0.0 110.91 -179.531 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 36.9 tt0 -75.92 -32.25 59.51 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 115.989 -0.55 . . . . 0.0 111.028 -179.869 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 148' ' ' SER . . . . . . . . . . . . . 48.2 t -70.83 -47.43 59.45 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.502 -179.659 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 149' ' ' ALA . . . . . 0.432 ' HB1' HG22 ' A' ' 156' ' ' ILE . . . -70.76 -30.57 67.11 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.294 -0.412 . . . . 0.0 111.748 -179.39 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 150' ' ' SER . . . . . 0.412 ' HB3' ' HD3' ' A' ' 157' ' ' LYS . 78.4 p -69.12 0.0 5.29 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.38 -0.373 . . . . 0.0 111.12 -179.878 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 151' ' ' GLN . . . . . . . . . . . . . 77.0 mt-30 -121.99 9.58 9.99 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.378 -0.374 . . . . 0.0 111.494 -179.836 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 25.6 mmm180 -91.45 -53.16 4.44 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-O 121.1 0.476 . . . . 0.0 110.789 -179.994 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 153' ' ' SER . . . . . 0.675 ' HB2' HG12 ' A' ' 156' ' ' ILE . 23.5 m -158.3 172.22 18.76 Favored 'General case' 0 C--N 1.324 -0.509 0 CA-C-N 115.643 -0.708 . . . . 0.0 110.481 179.232 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 154' ' ' SER . . . . . . . . . . . . . 46.9 t -72.05 -37.08 69.76 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-O 120.977 0.418 . . . . 0.0 110.142 179.073 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -77.43 -35.38 37.32 Favored Glycine 0 N--CA 1.45 -0.423 0 CA-C-N 115.818 -0.628 . . . . 0.0 112.902 179.83 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 156' ' ' ILE . . . . . 0.675 HG12 ' HB2' ' A' ' 153' ' ' SER . 38.0 mm -52.72 -38.74 28.36 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.164 0 CA-C-O 120.687 0.28 . . . . 0.0 111.515 -179.56 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 157' ' ' LYS . . . . . 0.412 ' HD3' ' HB3' ' A' ' 150' ' ' SER . 57.4 tptt -64.78 -40.53 95.41 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.434 -0.348 . . . . 0.0 111.175 -179.9 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 49.3 m -71.16 -42.73 68.74 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.415 -0.357 . . . . 0.0 111.342 -179.733 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 159' ' ' LEU . . . . . 0.474 HD23 HD13 ' A' ' 163' ' ' LEU . 4.7 tt -64.44 -40.83 96.47 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.998 -179.573 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 160' ' ' TYR . . . . . . . . . . . . . 29.0 t80 -73.29 -37.17 66.34 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.711 -179.204 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 161' ' ' VAL . . . . . 0.492 HG12 ' N ' ' A' ' 162' ' ' ARG . 1.0 OUTLIER -59.85 -50.52 79.78 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.746 0 CA-C-O 120.628 0.251 . . . . 0.0 111.623 -179.438 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild full ' A' A ' 162' ' ' ARG . . . . . 0.492 ' N ' HG12 ' A' ' 161' ' ' VAL . 99.8 mtt180 -69.5 -34.82 74.87 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-O 120.929 0.395 . . . . 0.0 111.254 179.989 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 163' ' ' LEU . . . . . 0.661 ' HG ' ' HB2' ' A' ' 208' ' ' PHE . 1.2 mp -65.49 -55.12 19.61 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 115.945 -0.57 . . . . 0.0 112.173 -178.831 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 164' ' ' ARG . . . . . . . . . . . . . 5.1 ppt_? -66.05 -41.22 91.13 Favored 'General case' 0 C--N 1.329 -0.286 0 N-CA-C 111.997 0.369 . . . . 0.0 111.997 -178.596 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 165' ' ' ASN . . . . . 0.489 ' O ' HG23 ' A' ' 169' ' ' VAL . 0.9 OUTLIER -54.35 -52.28 62.09 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-O 120.969 0.414 . . . . 0.0 111.024 -179.948 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild full ' A' A ' 166' ' ' LEU . . . . . 0.516 ' O ' ' HG ' ' A' ' 170' ' ' LEU . 2.8 tt -64.99 -51.93 58.96 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 115.925 -0.579 . . . . 0.0 111.513 -179.377 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 167' ' ' THR . . . . . 0.431 ' O ' ' HB2' ' A' ' 171' ' ' TRP . 91.4 m -54.74 -52.81 61.37 Favored 'General case' 0 C--N 1.328 -0.357 0 N-CA-C 112.345 0.498 . . . . 0.0 112.345 -178.817 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 168' ' ' VAL . . . . . . . . . . . . . 53.0 t -54.54 -46.1 71.48 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 N-CA-C 112.22 0.452 . . . . 0.0 112.22 -179.044 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 169' ' ' VAL . . . . . 0.489 HG23 ' O ' ' A' ' 165' ' ' ASN . 77.5 t -56.04 -65.18 0.4 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 N-CA-C 112.019 0.378 . . . . 0.0 112.019 -179.18 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 170' ' ' LEU . . . . . 0.516 ' HG ' ' O ' ' A' ' 166' ' ' LEU . 0.6 OUTLIER -63.65 -31.09 72.15 Favored 'General case' 0 C--N 1.328 -0.341 0 N-CA-C 112.43 0.53 . . . . 0.0 112.43 -178.486 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild full ' A' A ' 171' ' ' TRP . . . . . 0.608 ' HE1' H203 ' A' ' 301' ' ' RET . 3.5 m0 -68.67 -30.87 69.65 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-O 120.941 0.4 . . . . 0.0 110.37 179.24 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 172' ' ' ALA . . . . . . . . . . . . . . . -73.03 -6.88 48.43 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 115.92 -0.582 . . . . 0.0 110.641 -179.991 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 173' ' ' ILE . . . . . 0.513 HG22 HD11 ' A' ' 177' ' ' ILE . 29.0 mm -86.67 -22.2 7.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 115.818 -0.628 . . . . 0.0 111.203 -179.952 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 174' ' ' TYR . . . . . 0.453 ' HB2' ' HD3' ' A' ' 175' ' ' PRO . 25.5 m-85 -54.25 -49.8 88.28 Favored Pre-proline 0 N--CA 1.464 0.245 0 CA-C-N 116.514 -0.312 . . . . 0.0 111.702 -179.771 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 175' ' ' PRO . . . . . 0.453 ' HD3' ' HB2' ' A' ' 174' ' ' TYR . 79.8 Cg_exo -49.01 -30.06 17.13 Favored 'Trans proline' 0 C--N 1.349 0.591 0 C-N-CA 121.97 1.78 . . . . 0.0 112.138 179.641 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 176' ' ' PHE . . . . . 0.45 ' O ' ' HG ' ' A' ' 180' ' ' LEU . 46.8 m-85 -80.75 -50.0 10.43 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 115.985 -0.552 . . . . 0.0 111.663 -179.897 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 177' ' ' ILE . . . . . 0.513 HD11 HG22 ' A' ' 173' ' ' ILE . 4.2 mm -63.13 -32.64 57.03 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.501 0 N-CA-C 112.364 0.505 . . . . 0.0 112.364 -178.037 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 178' ' ' TRP . . . . . . . . . . . . . 77.7 t90 -71.95 -50.94 24.68 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.934 0.397 . . . . 0.0 110.555 179.771 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 179' ' ' LEU . . . . . 0.625 HD23 HD23 ' A' ' 180' ' ' LEU . 0.7 OUTLIER -68.95 -54.71 13.89 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.001 -0.545 . . . . 0.0 111.482 -179.341 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild full ' A' A ' 180' ' ' LEU . . . . . 0.674 HD22 HD11 ' A' ' 187' ' ' LEU . 39.3 mt -63.54 -43.68 96.39 Favored 'General case' 0 C--N 1.329 -0.324 0 C-N-CA 121.043 -0.263 . . . . 0.0 111.025 -179.729 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . -58.04 178.26 1.38 Allowed Glycine 0 CA--C 1.521 0.462 0 C-N-CA 120.12 -1.038 . . . . 0.0 112.12 179.085 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 182' ' ' PRO . . . . . 0.492 ' HA ' ' HB2' ' A' ' 186' ' ' ALA . 74.8 Cg_exo -47.45 -44.97 24.04 Favored 'Trans proline' 0 CA--C 1.536 0.611 0 C-N-CA 122.91 2.406 . . . . 0.0 113.918 -179.886 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 183' ' ' PRO . . . . . . . . . . . . . 86.7 Cg_exo -46.96 -26.91 5.29 Favored 'Trans proline' 0 C--N 1.355 0.874 0 C-N-CA 122.191 1.928 . . . . 0.0 113.364 -179.665 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 184' ' ' GLY . . . . . 0.582 ' HA2' ' HD2' ' A' ' 123' ' ' ARG . . . -120.5 -129.92 3.83 Favored Glycine 0 C--N 1.333 0.368 0 C-N-CA 120.29 -0.957 . . . . 0.0 113.081 -179.685 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 185' ' ' VAL . . . . . . . . . . . . . 15.4 m -54.68 -23.67 12.03 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 N-CA-C 112.066 0.395 . . . . 0.0 112.066 -179.526 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 186' ' ' ALA . . . . . 0.492 ' HB2' ' HA ' ' A' ' 182' ' ' PRO . . . 55.13 86.72 0.05 Allowed 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 116.446 -0.343 . . . . 0.0 111.659 179.509 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 187' ' ' LEU . . . . . 0.674 HD11 HD22 ' A' ' 180' ' ' LEU . 12.7 mt -92.3 -49.28 6.24 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.287 -0.415 . . . . 0.0 110.904 179.905 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 188' ' ' LEU . . . . . 0.521 HD13 HG11 ' A' ' 192' ' ' VAL . 78.2 mt -98.06 -161.93 0.91 Allowed 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 115.998 -0.546 . . . . 0.0 110.832 -179.72 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 189' ' ' THR . . . . . . . . . . . . . 2.3 t -98.41 146.93 32.41 Favored Pre-proline 0 C--N 1.329 -0.288 0 CA-C-N 116.132 -0.486 . . . . 0.0 110.766 179.993 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 190' ' ' PRO . . . . . . . . . . . . . 95.8 Cg_exo -44.41 -42.51 13.87 Favored 'Trans proline' 0 C--N 1.349 0.587 0 C-N-CA 122.763 2.309 . . . . 0.0 113.374 -179.511 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 191' ' ' THR . . . . . 0.48 ' O ' HD21 ' A' ' 7' ' ' LEU . 41.6 p -59.29 -44.74 92.47 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-O 120.78 0.324 . . . . 0.0 111.707 -179.596 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 192' ' ' VAL . . . . . 0.521 HG11 HD13 ' A' ' 188' ' ' LEU . 55.3 t -70.39 -51.52 37.34 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.42 0 N-CA-C 111.858 0.318 . . . . 0.0 111.858 -179.344 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 193' ' ' ASP . . . . . . . . . . . . . 20.7 m-20 -59.11 -51.98 67.7 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 116.444 -0.344 . . . . 0.0 111.626 -179.349 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 194' ' ' VAL . . . . . . . . . . . . . 69.2 t -58.88 -35.92 58.74 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.221 0 CA-C-O 120.712 0.292 . . . . 0.0 110.907 179.885 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 195' ' ' ALA . . . . . . . . . . . . . . . -57.33 -47.7 80.88 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.329 -0.396 . . . . 0.0 110.655 179.612 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 196' ' ' LEU . . . . . 0.402 HD23 ' N ' ' A' ' 196' ' ' LEU . 0.3 OUTLIER -61.85 -40.44 95.36 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.301 -0.409 . . . . 0.0 110.424 179.355 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild full ' A' A ' 197' ' ' ILE . . . . . . . . . . . . . 17.0 mm -57.25 -59.3 3.35 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.32 0 CA-C-N 115.939 -0.573 . . . . 0.0 110.062 179.019 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 198' ' ' VAL . . . . . . . . . . . . . 92.9 t -52.01 -35.1 18.13 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.426 0 CA-C-N 115.473 -0.785 . . . . 0.0 109.468 178.346 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 199' ' ' TYR . . . . . . . . . . . . . 59.3 t80 -70.24 -31.01 68.23 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 115.374 -0.83 . . . . 0.0 110.725 179.873 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 200' ' ' LEU . . . . . 0.496 ' O ' HG12 ' A' ' 203' ' ' VAL . 43.4 mt -73.23 -37.49 66.38 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 115.821 -0.627 . . . . 0.0 111.383 -179.736 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 201' ' ' ASP . . . . . . . . . . . . . 16.1 m-20 -73.84 -39.37 64.06 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-O 121.043 0.449 . . . . 0.0 110.498 179.663 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 202' ' ' LEU . . . . . . . . . . . . . 2.2 mt -69.9 -28.94 66.04 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 115.735 -0.666 . . . . 0.0 111.765 -179.465 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 203' ' ' VAL . . . . . 0.496 HG12 ' O ' ' A' ' 200' ' ' LEU . 12.3 p -78.17 -36.43 21.2 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.331 0 C-N-CA 121.094 -0.242 . . . . 0.0 110.962 -178.979 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 204' ' ' THR . . . . . . . . . . . . . 95.6 m -64.88 -58.43 6.2 Favored 'General case' 0 C--N 1.327 -0.399 0 C-N-CA 120.563 -0.455 . . . . 0.0 110.934 179.335 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 205' ' ' LYS . . . . . 0.76 ' HE3' HG22 ' A' ' 43' ' ' ILE . 54.4 mttp -61.86 -58.09 9.28 Favored 'General case' 0 C--N 1.329 -0.292 0 N-CA-C 112.343 0.497 . . . . 0.0 112.343 -178.395 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 51.0 t -71.83 -37.01 60.44 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.396 0 N-CA-C 112.428 0.529 . . . . 0.0 112.428 -178.515 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 207' ' ' GLY . . . . . 0.433 ' HA3' ' O ' ' A' ' 203' ' ' VAL . . . -57.59 -60.26 9.33 Favored Glycine 0 N--CA 1.455 -0.097 0 C-N-CA 120.704 -0.76 . . . . 0.0 113.416 -178.798 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 208' ' ' PHE . . . . . 0.661 ' HB2' ' HG ' ' A' ' 163' ' ' LEU . 0.3 OUTLIER -71.67 -27.13 62.85 Favored 'General case' 0 C--O 1.223 -0.3 0 CA-C-N 117.183 0.492 . . . . 0.0 110.562 -179.713 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild full ' A' A ' 209' ' ' GLY . . . . . 0.51 ' O ' ' HB3' ' A' ' 212' ' ' ALA . . . -65.18 -33.86 88.08 Favored Glycine 0 N--CA 1.448 -0.521 0 N-CA-C 111.718 -0.553 . . . . 0.0 111.718 178.623 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 210' ' ' PHE . . . . . . . . . . . . . 0.6 OUTLIER -73.57 -44.93 56.16 Favored 'General case' 0 CA--C 1.512 -0.502 0 N-CA-C 107.757 -1.201 . . . . 0.0 107.757 178.321 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 211' ' ' ILE . . . . . 0.416 HD12 ' HA ' ' A' ' 208' ' ' PHE . 34.5 mt -64.73 -27.65 42.99 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.653 0 N-CA-C 107.649 -1.241 . . . . 0.0 107.649 176.646 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 212' ' ' ALA . . . . . 0.51 ' HB3' ' O ' ' A' ' 209' ' ' GLY . . . -64.35 -44.02 92.78 Favored 'General case' 0 N--CA 1.45 -0.452 0 CA-C-N 114.505 -1.225 . . . . 0.0 110.6 -179.859 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 213' ' ' LEU . . . . . . . . . . . . . 97.6 mt -69.67 -46.08 66.91 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 115.308 -0.86 . . . . 0.0 111.487 -179.574 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 214' ' ' ASP . . . . . . . . . . . . . 36.3 m-20 -58.11 -47.15 84.14 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-O 120.85 0.357 . . . . 0.0 110.933 -179.952 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 215' ' ' ALA . . . . . 0.416 ' O ' ' HG ' ' A' ' 219' ' ' LEU . . . -62.82 -54.05 44.9 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 115.992 -0.549 . . . . 0.0 111.239 -179.896 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 216' ' ' ALA . . . . . . . . . . . . . . . -56.36 -37.5 70.12 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-N 116.281 -0.418 . . . . 0.0 111.04 179.928 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 217' ' ' ALA . . . . . . . . . . . . . . . -63.33 -37.96 89.3 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.167 179.655 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 218' ' ' THR . . . . . . . . . . . . . 92.4 m -68.6 -39.14 81.02 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 115.677 -0.692 . . . . 0.0 110.605 179.334 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 219' ' ' LEU . . . . . 0.434 ' O ' ' HG2' ' A' ' 222' ' ' GLU . 84.4 mt -56.53 -42.15 77.98 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 115.895 -0.593 . . . . 0.0 110.272 179.798 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 220' ' ' ARG . . . . . . . . . . . . . 56.2 mtp180 -84.22 -17.9 38.32 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.065 -0.516 . . . . 0.0 110.526 179.295 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 221' ' ' ALA . . . . . . . . . . . . . . . -64.77 -37.98 89.43 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.0 -0.545 . . . . 0.0 111.555 -179.819 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 222' ' ' GLU . . . . . 0.434 ' HG2' ' O ' ' A' ' 219' ' ' LEU . 13.4 pt-20 -71.0 -8.6 54.44 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.887 0.375 . . . . 0.0 110.879 -179.896 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 223' ' ' HIS . . . . . . . . . . . . . 88.8 m-70 -97.89 8.08 45.31 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.013 -0.539 . . . . 0.0 110.807 179.823 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 224' ' ' GLY . . . . . . . . . . . . . . . -76.29 -3.56 76.99 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.848 -0.691 . . . . 0.0 112.566 -179.938 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 225' ' ' GLU . . . . . . . . . . . . . 43.3 tt0 -136.65 124.85 23.09 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.877 0.37 . . . . 0.0 110.76 179.911 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 226' ' ' SER . . . . . . . . . . . . . 63.6 p -162.65 122.31 2.3 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.883 -179.947 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 227' ' ' LEU . . . . . 0.415 ' N ' HD12 ' A' ' 227' ' ' LEU . 7.4 mp -80.92 -19.24 44.71 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.878 -179.93 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 228' ' ' ALA . . . . . . . . . . . . . . . 53.1 22.86 2.72 Favored 'General case' 0 C--N 1.332 -0.185 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.457 -179.905 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 229' ' ' GLY . . . . . . . . . . . . . . . -134.87 -97.65 0.56 Allowed Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.872 -0.68 . . . . 0.0 112.491 -179.993 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 230' ' ' VAL . . . . . . . . . . . . . 33.9 m -93.27 150.31 3.96 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-O 120.828 0.347 . . . . 0.0 111.206 -179.903 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 231' ' ' ASP . . . . . . . . . . . . . 11.4 m-20 -95.9 93.38 7.0 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.606 179.655 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 232' ' ' THR . . . . . . . . . . . . . 7.8 t -90.99 164.69 13.89 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.329 -0.396 . . . . 0.0 111.285 -179.862 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 233' ' ' ASP . . . . . . . . . . . . . 21.0 t70 -158.06 120.81 3.81 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.04 -0.527 . . . . 0.0 110.849 -179.897 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 234' ' ' THR . . . . . . . . . . . . . 59.3 m 58.29 88.04 0.13 Allowed Pre-proline 0 C--N 1.33 -0.247 0 CA-C-N 116.047 -0.524 . . . . 0.0 111.203 -179.947 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 235' ' ' PRO . . . . . . . . . . . . . 82.5 Cg_endo -78.88 -21.85 9.29 Favored 'Trans proline' 0 C--N 1.346 0.409 0 C-N-CA 122.41 2.073 . . . . 0.0 112.282 179.757 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 236' ' ' ALA . . . . . . . . . . . . . . . -139.25 141.15 37.85 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.096 -0.502 . . . . 0.0 111.245 -179.887 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 237' ' ' VAL . . . . . . . . . . . . . 28.9 m -104.47 179.47 0.72 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.217 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.094 179.947 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 238' ' ' ALA . . . . . . . . . . . . . . . -67.95 167.33 13.95 Favored 'General case' 0 C--N 1.331 -0.199 0 CA-C-N 116.373 -0.376 . . . . 0.0 111.032 179.924 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 239' ' ' ASP . . . . . . . . . . . . . 6.8 m-20 -90.98 140.08 30.16 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.101 -0.5 . . . . 0.0 110.794 -179.996 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 240' ' ' LEU . . . . . . . . . . . . . 7.6 mp -92.18 -14.98 28.23 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.258 -0.428 . . . . 0.0 111.005 179.869 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 241' ' ' GLU . . . . . . . . . . . . . 39.9 tt0 -109.9 141.15 43.03 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.885 -179.902 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 242' ' ' HIS . . . . . . . . . . . . . 31.6 m80 -117.06 109.74 17.35 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.931 -179.823 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 243' ' ' HIS . . . . . . . . . . . . . 8.6 t-80 -141.72 -9.24 0.93 Allowed 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.803 179.83 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 244' ' ' HIS . . . . . . . . . . . . . 87.6 m-70 62.74 -82.57 0.02 OUTLIER 'General case' 0 N--CA 1.462 0.17 0 CA-C-N 115.932 -0.576 . . . . 0.0 111.506 179.762 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 245' ' ' HIS . . . . . . . . . . . . . 40.9 t60 -75.84 106.5 7.46 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-O 120.841 0.353 . . . . 0.0 111.092 -179.668 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 246' ' ' HIS . . . . . . . . . . . . . 51.6 m80 -92.17 162.06 14.48 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.055 -0.521 . . . . 0.0 110.812 179.815 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 247' ' ' HIS . . . . . . . . . . . . . 95.4 m-70 . . . . . 0 C--O 1.248 1.017 0 CA-C-O 118.265 -0.874 . . . . 0.0 110.993 179.946 . . . . . . . . 0 0 . 1 . 027 nuclear nobuild full ' A' A ' 301' ' ' RET . . . . . 0.652 ' H21' ' HA3' ' A' ' 112' ' ' GLY . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 85.0 mtp . . . . . 0 N--CA 1.485 1.318 0 CA-C-O 120.879 0.371 . . . . 0.0 111.096 . . . . . . . . . 0 0 . 1 . 028 nuclear nobuild full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 2.5 p -165.67 101.86 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 115.937 -0.574 . . . . 0.0 110.897 179.837 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . 131.42 -22.46 4.41 Favored Glycine 0 N--CA 1.45 -0.367 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.546 -179.852 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 4' ' ' LEU . . . . . 0.463 HD13 HG22 ' A' ' 191' ' ' THR . 59.5 tp -74.12 -40.69 62.5 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-O 120.823 0.344 . . . . 0.0 110.889 179.945 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 61.3 p -60.79 -29.85 69.7 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.136 179.98 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 10.9 p -53.11 -35.5 59.72 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 116.043 -0.526 . . . . 0.0 111.172 -179.785 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 7' ' ' LEU . . . . . . . . . . . . . 10.0 mp -57.22 -53.59 56.36 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.297 179.961 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 8' ' ' PHE . . . . . 0.49 ' O ' ' HB3' ' A' ' 51' ' ' TYR . 65.7 m-85 -59.4 -34.63 72.68 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.006 -0.543 . . . . 0.0 110.957 -179.599 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 9' ' ' TRP . . . . . 0.404 ' O ' HG12 ' A' ' 13' ' ' ILE . 32.0 m95 -66.71 -41.81 87.37 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-N 116.296 -0.411 . . . . 0.0 110.099 179.831 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 84.2 mt -59.64 -48.4 81.82 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 115.88 -0.6 . . . . 0.0 110.26 179.233 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . 0.489 ' HA2' HD11 ' A' ' 202' ' ' LEU . . . -61.22 -35.28 90.65 Favored Glycine 0 N--CA 1.449 -0.461 0 C-N-CA 120.621 -0.799 . . . . 0.0 111.587 179.169 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -63.29 -30.28 71.44 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.597 0.237 . . . . 0.0 110.442 179.41 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 13' ' ' ILE . . . . . 0.404 HG12 ' O ' ' A' ' 9' ' ' TRP . 47.9 mm -68.58 -54.12 23.21 Favored 'Isoleucine or valine' 0 CA--C 1.52 -0.189 0 CA-C-N 116.41 -0.359 . . . . 0.0 110.309 179.057 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -53.21 -30.67 39.95 Favored Glycine 0 N--CA 1.452 -0.281 0 C-N-CA 120.689 -0.767 . . . . 0.0 111.747 179.475 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 15' ' ' MET . . . . . 0.718 ' HB3' ' HB2' ' A' ' 48' ' ' ALA . 0.0 OUTLIER -76.77 -49.54 15.67 Favored 'General case' 0 C--O 1.223 -0.33 0 CA-C-O 120.564 0.221 . . . . 0.0 110.928 179.523 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -55.67 -50.87 69.1 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-O 120.78 0.324 . . . . 0.0 110.621 179.804 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . 0.481 HG13 ' N ' ' A' ' 18' ' ' GLY . 14.7 p -63.55 -46.31 95.35 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.377 0 CA-C-O 121.356 0.598 . . . . 0.0 110.718 179.824 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . 0.481 ' N ' HG13 ' A' ' 17' ' ' VAL . . . -58.97 -46.31 93.87 Favored Glycine 0 C--N 1.317 -0.484 0 CA-C-N 114.973 -1.012 . . . . 0.0 111.891 179.179 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 57.4 m -53.78 -45.06 70.55 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-O 120.707 0.289 . . . . 0.0 110.827 -179.839 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 81.7 mt -71.58 -39.68 70.42 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.273 -0.421 . . . . 0.0 110.766 179.376 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -60.42 -33.39 72.44 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.085 -0.507 . . . . 0.0 111.736 -179.767 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 22' ' ' PHE . . . . . 0.586 ' HB2' HG22 ' A' ' 41' ' ' VAL . 8.2 m-85 -91.15 -31.05 16.36 Favored 'General case' 0 N--CA 1.463 0.197 0 CA-C-O 120.753 0.311 . . . . 0.0 111.311 -179.679 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -68.72 -50.32 51.78 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.335 -179.514 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 24' ' ' TRP . . . . . . . . . . . . . 4.4 t-105 -64.18 -45.05 90.07 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-N 115.834 -0.621 . . . . 0.0 111.24 -179.595 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -74.42 -23.42 58.94 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 120.858 0.361 . . . . 0.0 110.983 179.84 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -73.65 -45.63 27.74 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.898 -0.668 . . . . 0.0 112.715 -179.794 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 27' ' ' ARG . . . . . 0.442 ' HA ' ' NE ' ' A' ' 27' ' ' ARG . 5.2 mmp_? -57.26 -26.24 60.48 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.846 0.355 . . . . 0.0 111.018 -179.998 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 24.4 t70 -105.52 96.54 6.58 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.878 179.955 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -165.2 -168.22 1.35 Allowed 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.193 -179.869 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -98.93 -158.41 29.39 Favored Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.872 -0.68 . . . . 0.0 112.298 179.736 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 47.5 t -100.31 111.51 23.79 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.88 0.371 . . . . 0.0 110.936 179.96 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 129.83 -29.05 3.83 Favored Glycine 0 C--N 1.33 0.245 0 C-N-CA 120.886 -0.673 . . . . 0.0 112.457 -179.984 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 28.7 mm-40 -86.63 -20.85 27.25 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 120.741 0.305 . . . . 0.0 110.953 -179.959 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 34' ' ' ARG . . . . . . . . . . . . . 14.7 ptm180 -48.9 -36.31 16.88 Favored 'General case' 0 C--N 1.332 -0.17 0 CA-C-N 116.076 -0.511 . . . . 0.0 111.668 -179.757 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 29.2 mmt180 -61.77 -50.47 72.22 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 120.874 0.368 . . . . 0.0 111.277 -179.686 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 46.6 m-85 -63.2 -30.58 71.7 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.044 -0.525 . . . . 0.0 111.473 -179.607 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 37' ' ' TYR . . . . . 0.431 ' O ' HG23 ' A' ' 41' ' ' VAL . 39.1 m-85 -74.67 -55.8 5.49 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.641 -179.237 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 88.8 t -56.63 -36.85 49.81 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.205 0 CA-C-O 121.0 0.429 . . . . 0.0 110.485 179.914 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 90.7 m -63.97 -50.96 66.52 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 115.747 -0.661 . . . . 0.0 110.465 179.226 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 40' ' ' LEU . . . . . 0.529 HD12 HD12 ' A' ' 43' ' ' ILE . 40.4 tp -56.8 -50.16 73.18 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 115.549 -0.75 . . . . 0.0 110.809 -179.858 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . 0.586 HG22 ' HB2' ' A' ' 22' ' ' PHE . 69.0 t -57.76 -36.53 55.39 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 115.858 -0.61 . . . . 0.0 110.446 179.565 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -61.52 -36.1 92.08 Favored Glycine 0 N--CA 1.449 -0.493 0 C-N-CA 120.907 -0.663 . . . . 0.0 112.17 179.815 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 43' ' ' ILE . . . . . 0.572 HG12 HD23 ' A' ' 82' ' ' LEU . 2.0 mt -65.22 -56.94 13.08 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.234 0 CA-C-O 120.958 0.409 . . . . 0.0 110.802 179.713 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 32.4 t -58.26 -25.17 61.44 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 115.879 -0.601 . . . . 0.0 111.685 -179.5 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -73.83 -58.48 4.43 Favored Glycine 0 CA--C 1.517 0.191 0 C-N-CA 120.696 -0.764 . . . . 0.0 112.986 -179.576 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 46' ' ' ILE . . . . . 0.644 ' O ' HG22 ' A' ' 49' ' ' VAL . 15.8 pt -57.92 -35.87 53.63 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.221 0 CA-C-O 120.818 0.342 . . . . 0.0 110.924 -179.674 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 47' ' ' ALA . . . . . 0.67 ' HB2' ' HE2' ' A' ' 205' ' ' LYS . . . -67.04 -37.59 84.36 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.962 0.41 . . . . 0.0 110.261 178.754 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 48' ' ' ALA . . . . . 0.718 ' HB2' ' HB3' ' A' ' 15' ' ' MET . . . -60.57 -33.08 72.18 Favored 'General case' 0 C--N 1.332 -0.173 0 CA-C-N 115.736 -0.665 . . . . 0.0 111.343 179.889 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 49' ' ' VAL . . . . . 0.644 HG22 ' O ' ' A' ' 46' ' ' ILE . 1.3 m -76.54 -38.39 31.46 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.496 -0.32 . . . . 0.0 111.643 -179.425 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -62.95 -41.65 99.58 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-O 120.968 0.413 . . . . 0.0 111.393 -179.636 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 51' ' ' TYR . . . . . 0.595 ' HE2' ' HE2' ' A' ' 15' ' ' MET . 38.5 m-85 -72.74 -40.41 66.1 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-N 115.894 -0.594 . . . . 0.0 110.813 -179.283 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -63.13 -40.87 98.84 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-N 115.943 -0.571 . . . . 0.0 111.467 179.793 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 53' ' ' VAL . . . . . 0.515 HG23 ' N ' ' A' ' 54' ' ' MET . 33.3 m -74.42 -50.56 26.47 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 N-CA-C 111.754 0.279 . . . . 0.0 111.754 -179.475 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 54' ' ' MET . . . . . 0.534 ' HG2' ' HG2' ' A' ' 71' ' ' PRO . 72.0 mtm -57.57 -30.2 65.06 Favored 'General case' 0 CA--C 1.521 -0.143 0 CA-C-O 121.013 0.435 . . . . 0.0 110.744 179.914 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -58.95 -36.97 75.7 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 115.601 -0.727 . . . . 0.0 111.643 -179.816 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 6.2 mp -87.2 4.38 42.71 Favored 'General case' 0 C--N 1.332 -0.173 0 CA-C-N 116.639 -0.255 . . . . 0.0 111.456 179.974 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 92.98 30.76 9.09 Favored Glycine 0 N--CA 1.452 -0.246 0 C-N-CA 120.674 -0.774 . . . . 0.0 113.111 179.526 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 73.7 t -88.63 130.19 38.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-O 120.71 0.29 . . . . 0.0 110.878 179.716 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 59' ' ' GLY . . . . . 0.581 ' HA3' ' HD3' ' A' ' 71' ' ' PRO . . . 87.59 -5.96 84.17 Favored Glycine 0 N--CA 1.448 -0.548 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.471 -179.815 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 60' ' ' TRP . . . . . . . . . . . . . 11.5 m0 -69.43 83.03 0.39 Allowed 'General case' 0 C--N 1.328 -0.358 0 CA-C-O 120.759 0.314 . . . . 0.0 110.59 179.835 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 6.5 p -98.99 132.25 23.94 Favored Pre-proline 0 C--N 1.33 -0.282 0 CA-C-N 116.351 -0.386 . . . . 0.0 111.298 -179.87 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 73.3 Cg_endo -75.75 148.33 32.33 Favored 'Trans proline' 0 C--N 1.35 0.612 0 C-N-CA 122.447 2.098 . . . . 0.0 112.169 179.68 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 83.7 t -141.98 97.27 0.71 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.351 -179.84 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . 57.38 -88.93 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.054 -0.521 . . . . 0.0 111.87 179.611 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 11.8 mm-40 -118.89 -20.94 7.97 Favored 'General case' 0 C--N 1.332 -0.174 0 CA-C-N 116.501 -0.318 . . . . 0.0 111.428 -179.486 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 66' ' ' ARG . . . . . . . . . . . . . 28.4 ptt180 -110.91 161.68 15.59 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.461 -0.336 . . . . 0.0 110.766 179.971 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 91.6 m -114.88 143.3 45.34 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.256 -0.429 . . . . 0.0 111.264 -179.8 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 68' ' ' VAL . . . . . 0.559 HG21 ' SD ' ' A' ' 117' ' ' MET . 30.1 m -129.14 146.51 34.14 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 115.954 -0.566 . . . . 0.0 110.924 179.943 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 69' ' ' PHE . . . . . . . . . . . . . 19.2 m-85 -106.38 117.54 34.31 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.123 -0.49 . . . . 0.0 109.833 -179.724 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 70' ' ' VAL . . . . . 0.561 HG12 ' HD3' ' A' ' 71' ' ' PRO . 1.4 p -68.77 -33.19 4.11 Favored Pre-proline 0 CA--C 1.543 0.692 0 N-CA-C 113.66 0.985 . . . . 0.0 113.66 -178.538 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 71' ' ' PRO . . . . . 0.581 ' HD3' ' HA3' ' A' ' 59' ' ' GLY . 14.2 Cg_exo -69.48 -19.11 37.87 Favored 'Trans proline' 0 C--N 1.356 0.942 0 C-N-CA 122.099 1.866 . . . . 0.0 113.46 -178.643 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 72' ' ' ARG . . . . . 0.469 ' HE ' ' HA ' ' A' ' 72' ' ' ARG . 0.9 OUTLIER -67.77 -55.27 13.7 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.917 0.389 . . . . 0.0 111.564 -179.449 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild full ' A' A ' 73' ' ' TYR . . . . . 0.42 ' O ' HG13 ' A' ' 77' ' ' ILE . 14.2 m-85 -71.17 -33.19 69.76 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 116.081 -0.509 . . . . 0.0 111.315 -178.962 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 74' ' ' ILE . . . . . 0.541 HG22 ' HA ' ' A' ' 71' ' ' PRO . 0.3 OUTLIER -71.09 -44.93 74.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 C-N-CA 120.864 -0.334 . . . . 0.0 110.88 -179.773 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild full ' A' A ' 75' ' ' ASP . . . . . 0.492 ' O ' HG23 ' A' ' 79' ' ' THR . 37.4 t70 -58.99 -35.49 73.31 Favored 'General case' 0 N--CA 1.455 -0.183 0 N-CA-C 109.561 -0.533 . . . . 0.0 109.561 179.334 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 76' ' ' TRP . . . . . . . . . . . . . 50.2 m0 -66.0 -35.84 81.66 Favored 'General case' 0 C--N 1.332 -0.165 0 CA-C-N 116.029 -0.532 . . . . 0.0 110.129 179.141 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 77' ' ' ILE . . . . . 0.512 HG12 ' HB3' ' A' ' 109' ' ' MET . 96.4 mt -65.62 -30.78 51.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.028 -0.533 . . . . 0.0 110.718 179.378 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 69.7 mt -92.2 -20.46 21.17 Favored 'General case' 0 C--N 1.329 -0.294 0 N-CA-C 112.342 0.497 . . . . 0.0 112.342 -179.782 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 79' ' ' THR . . . . . 0.492 HG23 ' O ' ' A' ' 75' ' ' ASP . 62.7 p -94.39 -47.99 6.34 Favored 'General case' 0 N--CA 1.466 0.333 0 N-CA-C 112.845 0.683 . . . . 0.0 112.845 -178.406 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 80' ' ' THR . . . . . 0.582 ' N ' ' HD2' ' A' ' 81' ' ' PRO . 86.6 m -51.29 -48.72 85.07 Favored Pre-proline 0 C--N 1.328 -0.357 0 N-CA-C 112.545 0.572 . . . . 0.0 112.545 -179.319 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 81' ' ' PRO . . . . . 0.582 ' HD2' ' N ' ' A' ' 80' ' ' THR . 13.8 Cg_endo -56.02 -24.39 48.54 Favored 'Trans proline' 0 C--N 1.352 0.712 0 C-N-CA 121.536 1.491 . . . . 0.0 111.463 179.973 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 82' ' ' LEU . . . . . 0.572 HD23 HG12 ' A' ' 43' ' ' ILE . 7.2 mp -77.03 -46.03 25.14 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-N 115.707 -0.679 . . . . 0.0 110.847 179.9 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 83' ' ' ILE . . . . . 0.556 HD13 HD13 ' A' ' 43' ' ' ILE . 28.0 mm -60.8 -53.49 48.36 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.203 0 CA-C-N 116.305 -0.407 . . . . 0.0 110.527 179.655 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . 0.413 HG11 ' ND2' ' A' ' 105' ' ' ASN . 29.4 m -59.15 -35.47 57.7 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.211 0 CA-C-N 116.076 -0.511 . . . . 0.0 110.386 179.451 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 85' ' ' TYR . . . . . . . . . . . . . 72.7 t80 -65.51 -32.38 73.95 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.097 -0.501 . . . . 0.0 110.008 179.004 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 86' ' ' PHE . . . . . . . . . . . . . 1.4 t80 -61.54 -51.13 69.88 Favored 'General case' 0 C--N 1.333 -0.141 0 CA-C-N 115.963 -0.562 . . . . 0.0 109.707 179.547 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 6.9 mp -67.09 -31.57 72.15 Favored 'General case' 0 C--N 1.331 -0.2 0 CA-C-N 115.974 -0.557 . . . . 0.0 110.137 179.209 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -62.77 -28.01 70.96 Favored Glycine 0 N--CA 1.45 -0.418 0 C-N-CA 120.878 -0.677 . . . . 0.0 111.615 179.441 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 71.9 mt -78.45 -49.71 12.97 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.86 0.362 . . . . 0.0 110.536 179.411 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 96.1 mt -56.44 -32.5 64.97 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 115.994 -0.548 . . . . 0.0 110.649 179.608 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . 0.55 ' HB1' ' HB2' ' A' ' 148' ' ' SER . . . -83.67 -52.88 6.06 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 115.91 -0.587 . . . . 0.0 110.937 179.838 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 92' ' ' GLY . . . . . 0.462 ' HA3' HH21 ' A' ' 152' ' ' ARG . . . 90.68 71.82 1.23 Allowed Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.849 -0.691 . . . . 0.0 112.529 179.967 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 93' ' ' LEU . . . . . 0.551 HD11 ' HG2' ' A' ' 145' ' ' MET . 6.4 mp -84.18 -172.49 4.19 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-O 120.801 0.334 . . . . 0.0 110.912 -179.934 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 94' ' ' ASP . . . . . 0.453 ' H ' ' HB2' ' A' ' 97' ' ' GLU . 4.6 m-20 -98.88 -172.24 2.25 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.201 -179.966 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 46.1 t -67.87 -52.91 31.09 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 115.994 -0.548 . . . . 0.0 111.527 -179.668 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 75.3 mtp180 -74.14 -35.38 64.07 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-O 120.893 0.378 . . . . 0.0 110.899 -179.358 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 97' ' ' GLU . . . . . 0.453 ' HB2' ' H ' ' A' ' 94' ' ' ASP . 0.3 OUTLIER -60.8 -42.31 97.37 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 115.992 -0.549 . . . . 0.0 111.032 -179.873 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild full ' A' A ' 98' ' ' PHE . . . . . . . . . . . . . 0.6 OUTLIER -61.69 -40.73 96.03 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.337 -0.392 . . . . 0.0 110.572 179.468 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -65.6 -31.55 80.4 Favored Glycine 0 N--CA 1.452 -0.27 0 C-N-CA 120.795 -0.717 . . . . 0.0 112.538 -179.932 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 96.7 mt -67.82 -43.3 86.28 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.209 0 CA-C-O 120.909 0.385 . . . . 0.0 111.239 -179.826 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 101' ' ' VAL . . . . . 0.671 HG21 ' HE3' ' A' ' 145' ' ' MET . 42.2 t -66.36 -50.49 67.27 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.358 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.367 -179.801 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 102' ' ' ILE . . . . . . . . . . . . . 48.6 mm -59.46 -49.57 83.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.59 -179.526 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 14.2 t -59.95 -29.97 68.76 Favored 'General case' 0 C--N 1.332 -0.181 0 CA-C-O 120.77 0.319 . . . . 0.0 110.903 -179.829 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -60.66 -57.0 14.56 Favored 'General case' 0 C--N 1.332 -0.178 0 CA-C-N 116.325 -0.398 . . . . 0.0 109.983 179.342 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 105' ' ' ASN . . . . . 0.413 ' ND2' HG11 ' A' ' 84' ' ' VAL . 32.7 m-80 -59.27 -26.4 64.91 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-N 116.022 -0.535 . . . . 0.0 110.782 179.533 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 76.3 m -61.49 -52.76 63.19 Favored 'General case' 0 C--N 1.332 -0.185 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.958 179.87 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 107' ' ' VAL . . . . . 0.424 HG23 ' H ' ' A' ' 107' ' ' VAL . 2.1 t -62.0 -37.21 77.76 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.248 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.59 179.966 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 70.3 t -60.14 -57.86 9.89 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 115.73 -0.668 . . . . 0.0 111.461 -179.898 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 109' ' ' MET . . . . . 0.512 ' HB3' HG12 ' A' ' 77' ' ' ILE . 3.7 tpp -56.91 -42.89 80.75 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.485 -179.55 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 24.1 tp -62.54 -31.0 71.71 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.318 -0.401 . . . . 0.0 110.693 -179.899 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -63.57 -55.7 21.75 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 116.038 -0.528 . . . . 0.0 110.655 179.545 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 112' ' ' GLY . . . . . 0.646 ' HA3' ' H21' ' A' ' 301' ' ' RET . . . -61.49 -36.7 92.96 Favored Glycine 0 N--CA 1.45 -0.389 0 C-N-CA 120.775 -0.726 . . . . 0.0 112.081 179.576 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 113' ' ' PHE . . . . . 0.417 ' O ' ' HG2' ' A' ' 117' ' ' MET . 0.3 OUTLIER -52.25 -71.77 0.06 Allowed 'General case' 0 C--N 1.332 -0.174 0 CA-C-O 120.961 0.41 . . . . 0.0 110.195 179.619 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild full ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -63.9 -19.44 65.1 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 115.924 -0.58 . . . . 0.0 111.022 179.758 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 115' ' ' GLY . . . . . 0.495 ' HA2' HD22 ' A' ' 126' ' ' LEU . . . -54.8 -51.58 52.05 Favored Glycine 0 C--N 1.332 0.334 0 C-N-CA 120.86 -0.686 . . . . 0.0 111.841 179.611 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -78.2 -14.91 59.26 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-O 120.748 0.309 . . . . 0.0 111.227 179.659 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 117' ' ' MET . . . . . 0.559 ' SD ' HG21 ' A' ' 68' ' ' VAL . 23.5 mmt -90.59 17.07 7.93 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-N 116.358 -0.383 . . . . 0.0 111.739 -179.238 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 118' ' ' VAL . . . . . 0.426 HG21 ' HB3' ' A' ' 123' ' ' ARG . 34.4 m -81.1 144.01 53.85 Favored Pre-proline 0 C--N 1.33 -0.277 0 CA-C-O 120.505 0.193 . . . . 0.0 111.43 -179.845 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 119' ' ' PRO . . . . . . . . . . . . . 83.4 Cg_endo -82.49 -1.9 10.82 Favored 'Trans proline' 0 C--N 1.348 0.525 0 C-N-CA 122.55 2.167 . . . . 0.0 112.349 179.649 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -148.85 -129.1 1.77 Allowed Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.722 -0.751 . . . . 0.0 112.747 -179.878 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 39.8 pt -107.92 12.15 8.78 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.207 0 CA-C-O 120.676 0.274 . . . . 0.0 111.577 -179.729 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 43.9 mt-10 -60.25 -18.19 47.13 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.372 -0.376 . . . . 0.0 111.034 179.802 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 123' ' ' ARG . . . . . 0.432 ' HB2' ' HH2' ' A' ' 178' ' ' TRP . 15.7 ptt180 -50.08 -37.59 34.4 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 116.031 -0.532 . . . . 0.0 111.71 -179.578 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 124' ' ' TYR . . . . . . . . . . . . . 30.1 m-85 -58.46 -33.9 70.26 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.518 -0.31 . . . . 0.0 111.271 -179.628 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 125' ' ' ALA . . . . . . . . . . . . . . . -74.2 -49.75 22.15 Favored 'General case' 0 C--O 1.235 0.336 0 CA-C-O 120.909 0.385 . . . . 0.0 111.128 179.958 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 126' ' ' LEU . . . . . 0.495 HD22 ' HA2' ' A' ' 115' ' ' GLY . 7.4 mp -53.09 -46.46 68.66 Favored 'General case' 0 C--N 1.333 -0.144 0 CA-C-N 115.972 -0.558 . . . . 0.0 110.5 -179.928 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 127' ' ' PHE . . . . . 0.449 ' HZ ' ' HB3' ' A' ' 175' ' ' PRO . 4.8 t80 -67.23 -37.73 84.05 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.644 179.839 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 128' ' ' GLY . . . . . . . . . . . . . . . -46.38 -46.21 16.68 Favored Glycine 0 C--N 1.332 0.356 0 C-N-CA 120.193 -1.003 . . . . 0.0 110.911 179.237 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 129' ' ' MET . . . . . . . . . . . . . 0.6 OUTLIER -68.1 -40.95 82.46 Favored 'General case' 0 C--N 1.327 -0.386 0 N-CA-C 109.749 -0.463 . . . . 0.0 109.749 178.48 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -64.15 -23.15 67.73 Favored Glycine 0 N--CA 1.45 -0.411 0 CA-C-N 115.822 -0.626 . . . . 0.0 112.345 179.792 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 131' ' ' ALA . . . . . 0.4 ' O ' ' HB3' ' A' ' 134' ' ' PHE . . . -75.03 -53.54 8.73 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.717 0.294 . . . . 0.0 110.419 179.648 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 39.4 t -55.36 -40.33 56.77 Favored 'Isoleucine or valine' 0 C--O 1.233 0.217 0 CA-C-O 121.387 0.613 . . . . 0.0 109.638 178.799 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -69.79 -36.53 75.77 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 115.339 -0.846 . . . . 0.0 110.721 179.172 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 134' ' ' PHE . . . . . 0.442 ' CZ ' ' HA ' ' A' ' 172' ' ' ALA . 18.9 t80 -53.43 -60.06 3.79 Favored 'General case' 0 N--CA 1.454 -0.251 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.22 179.869 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 135' ' ' ILE . . . . . 0.526 ' O ' HG22 ' A' ' 138' ' ' VAL . 0.0 OUTLIER -56.11 -35.23 41.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 115.959 -0.564 . . . . 0.0 110.31 179.143 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . -57.56 -43.13 94.31 Favored Glycine 0 N--CA 1.45 -0.398 0 C-N-CA 120.226 -0.987 . . . . 0.0 111.755 179.024 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 137' ' ' LEU . . . . . 0.569 HD13 ' N ' ' A' ' 138' ' ' VAL . 1.4 tm? -63.29 -58.22 7.85 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 121.016 0.436 . . . . 0.0 110.519 179.678 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 138' ' ' VAL . . . . . 0.569 ' N ' HD13 ' A' ' 137' ' ' LEU . 2.4 m -54.22 -31.77 22.55 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.466 0 CA-C-N 115.562 -0.744 . . . . 0.0 110.213 179.68 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 139' ' ' TYR . . . . . . . . . . . . . 17.3 t80 -64.26 -34.92 79.21 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 115.885 -0.598 . . . . 0.0 110.05 179.091 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 15.4 m-85 -68.43 -48.69 63.94 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 115.989 -0.55 . . . . 0.0 111.613 179.733 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 141' ' ' LEU . . . . . 0.517 HD12 HG23 ' A' ' 142' ' ' VAL . 4.0 pp -68.52 -16.23 63.81 Favored 'General case' 0 CA--C 1.53 0.178 0 C-N-CA 120.974 -0.29 . . . . 0.0 111.327 -179.33 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 142' ' ' VAL . . . . . 0.517 HG23 HD12 ' A' ' 141' ' ' LEU . 95.2 t -101.17 -18.77 6.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-O 121.079 0.466 . . . . 0.0 110.57 178.801 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . -85.26 -123.46 1.25 Allowed Glycine 0 CA--C 1.522 0.498 0 C-N-CA 120.929 -0.653 . . . . 0.0 113.145 -179.342 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 144' ' ' PRO . . . . . . . . . . . . . 69.3 Cg_exo -52.15 -35.94 64.63 Favored 'Trans proline' 0 C--N 1.35 0.634 0 C-N-CA 122.722 2.281 . . . . 0.0 113.178 -179.392 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 145' ' ' MET . . . . . 0.671 ' HE3' HG21 ' A' ' 101' ' ' VAL . 40.3 mtt -55.36 -37.72 67.87 Favored 'General case' 0 C--N 1.331 -0.206 0 CA-C-O 120.751 0.31 . . . . 0.0 111.446 -179.798 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 146' ' ' THR . . . . . . . . . . . . . 18.3 m -68.28 -41.64 80.72 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.725 -179.368 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 42.6 mt-10 -75.77 -26.32 57.26 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.403 -0.362 . . . . 0.0 111.423 -179.543 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 148' ' ' SER . . . . . 0.55 ' HB2' ' HB1' ' A' ' 91' ' ' ALA . 68.9 m -70.65 -43.67 68.7 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.372 -0.376 . . . . 0.0 111.564 -179.402 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 149' ' ' ALA . . . . . 0.43 ' HB2' ' HA ' ' A' ' 91' ' ' ALA . . . -76.04 -32.34 59.29 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.781 0.324 . . . . 0.0 111.635 -179.441 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 150' ' ' SER . . . . . . . . . . . . . 86.7 p -69.46 -1.26 8.05 Favored 'General case' 0 C--N 1.326 -0.413 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.037 179.995 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 151' ' ' GLN . . . . . . . . . . . . . 77.2 mt-30 -118.69 0.26 11.44 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.097 -0.501 . . . . 0.0 111.331 -179.838 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 152' ' ' ARG . . . . . 0.462 HH21 ' HA3' ' A' ' 92' ' ' GLY . 38.9 mmt180 -82.26 -52.62 6.77 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-O 120.833 0.349 . . . . 0.0 111.004 -179.997 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 153' ' ' SER . . . . . 0.634 ' HB3' HG12 ' A' ' 156' ' ' ILE . 35.5 t -158.36 167.64 29.15 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.749 179.241 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 154' ' ' SER . . . . . . . . . . . . . 45.9 t -70.32 -34.85 73.18 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 121.037 0.446 . . . . 0.0 110.151 179.277 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -76.91 -37.92 32.14 Favored Glycine 0 N--CA 1.45 -0.368 0 C-N-CA 120.971 -0.633 . . . . 0.0 112.264 179.618 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 156' ' ' ILE . . . . . 0.634 HG12 ' HB3' ' A' ' 153' ' ' SER . 34.2 mm -53.51 -37.75 31.28 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.178 0 CA-C-O 120.897 0.379 . . . . 0.0 111.092 179.877 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 157' ' ' LYS . . . . . . . . . . . . . 39.9 ttpt -65.49 -32.29 73.82 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 116.078 -0.51 . . . . 0.0 111.441 -179.761 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 46.0 t -72.54 -47.93 44.27 Favored 'General case' 0 C--O 1.235 0.3 0 CA-C-O 121.143 0.497 . . . . 0.0 111.006 -179.604 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 159' ' ' LEU . . . . . 0.528 HD13 ' HB1' ' A' ' 215' ' ' ALA . 0.4 OUTLIER -68.63 -39.74 80.62 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 115.923 -0.58 . . . . 0.0 110.976 -179.415 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild full ' A' A ' 160' ' ' TYR . . . . . 0.47 ' OH ' ' HB3' ' A' ' 145' ' ' MET . 37.2 t80 -62.25 -47.15 85.63 Favored 'General case' 0 C--N 1.326 -0.419 0 N-CA-C 112.086 0.402 . . . . 0.0 112.086 -178.596 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 161' ' ' VAL . . . . . 0.412 HG23 ' N ' ' A' ' 162' ' ' ARG . 24.9 m -61.49 -45.97 97.54 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 C-N-CA 120.909 -0.316 . . . . 0.0 111.365 -179.488 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 162' ' ' ARG . . . . . 0.412 ' N ' HG23 ' A' ' 161' ' ' VAL . 28.1 tpt180 -68.85 -38.48 79.81 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 121.005 0.431 . . . . 0.0 111.103 -179.955 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 163' ' ' LEU . . . . . 0.416 HD13 ' O ' ' A' ' 159' ' ' LEU . 1.7 mp -64.67 -55.5 19.74 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 115.72 -0.673 . . . . 0.0 112.095 -179.23 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 164' ' ' ARG . . . . . 0.664 ' HG3' HD22 ' A' ' 165' ' ' ASN . 22.7 ptt180 -64.59 -41.72 96.05 Favored 'General case' 0 C--N 1.333 -0.15 0 N-CA-C 111.828 0.307 . . . . 0.0 111.828 -178.671 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 165' ' ' ASN . . . . . 0.664 HD22 ' HG3' ' A' ' 164' ' ' ARG . 0.9 OUTLIER -54.4 -48.37 71.67 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.91 0.386 . . . . 0.0 110.771 -179.922 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild full ' A' A ' 166' ' ' LEU . . . . . . . . . . . . . 3.9 tt -64.06 -54.23 37.35 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 116.026 -0.533 . . . . 0.0 111.431 -179.787 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 167' ' ' THR . . . . . 0.446 ' O ' ' HB2' ' A' ' 171' ' ' TRP . 34.4 m -57.24 -54.28 48.61 Favored 'General case' 0 C--N 1.329 -0.307 0 N-CA-C 112.868 0.692 . . . . 0.0 112.868 -178.568 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 168' ' ' VAL . . . . . 0.404 HG13 ' N ' ' A' ' 169' ' ' VAL . 9.8 p -55.58 -41.59 64.84 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.243 0 N-CA-C 112.425 0.528 . . . . 0.0 112.425 -178.694 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 169' ' ' VAL . . . . . 0.501 HG23 ' O ' ' A' ' 165' ' ' ASN . 48.7 t -59.82 -64.62 0.56 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 C-N-CA 121.122 -0.231 . . . . 0.0 111.488 -179.628 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 170' ' ' LEU . . . . . 0.526 HD12 ' HD1' ' A' ' 171' ' ' TRP . 1.3 pp -62.07 -27.18 68.72 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.64 -0.254 . . . . 0.0 111.295 -179.582 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 171' ' ' TRP . . . . . 0.691 ' HE1' H203 ' A' ' 301' ' ' RET . 2.0 m0 -70.73 -36.12 73.02 Favored 'General case' 0 CA--C 1.519 -0.217 0 CA-C-O 121.099 0.476 . . . . 0.0 109.739 178.772 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 172' ' ' ALA . . . . . 0.442 ' HA ' ' CZ ' ' A' ' 134' ' ' PHE . . . -71.33 -6.85 43.08 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 115.465 -0.788 . . . . 0.0 110.877 179.573 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 173' ' ' ILE . . . . . 0.483 ' O ' HG12 ' A' ' 177' ' ' ILE . 42.1 mm -85.67 -23.29 7.13 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.191 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.943 179.571 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 174' ' ' TYR . . . . . 0.43 ' HB2' ' HD3' ' A' ' 175' ' ' PRO . 29.3 m-85 -53.87 -49.58 88.65 Favored Pre-proline 0 CA--C 1.53 0.201 0 CA-C-N 116.363 -0.38 . . . . 0.0 111.607 -179.72 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 175' ' ' PRO . . . . . 0.449 ' HB3' ' HZ ' ' A' ' 127' ' ' PHE . 81.2 Cg_exo -47.46 -31.62 13.82 Favored 'Trans proline' 0 C--N 1.351 0.701 0 C-N-CA 122.177 1.918 . . . . 0.0 112.228 179.446 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 176' ' ' PHE . . . . . 0.482 ' O ' ' HG ' ' A' ' 180' ' ' LEU . 75.0 m-85 -80.39 -50.04 10.66 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.02 -0.536 . . . . 0.0 111.908 -179.856 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 177' ' ' ILE . . . . . 0.483 HG12 ' O ' ' A' ' 173' ' ' ILE . 6.4 mm -62.52 -35.84 72.03 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.556 0 CA-C-N 116.091 -0.504 . . . . 0.0 112.269 -178.144 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 178' ' ' TRP . . . . . 0.432 ' HH2' ' HB2' ' A' ' 123' ' ' ARG . 68.6 t90 -73.71 -43.1 60.18 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 121.001 0.429 . . . . 0.0 110.73 179.642 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 179' ' ' LEU . . . . . 0.441 ' O ' HG22 ' A' ' 185' ' ' VAL . 1.6 tm? -68.71 -51.25 43.61 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 115.765 -0.652 . . . . 0.0 111.188 -179.497 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 180' ' ' LEU . . . . . 0.589 HD22 HD11 ' A' ' 187' ' ' LEU . 13.8 mt -75.22 -47.24 29.16 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-N 116.442 -0.345 . . . . 0.0 111.78 -179.223 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . -57.01 178.91 0.73 Allowed Glycine 0 C--N 1.337 0.622 0 C-N-CA 120.415 -0.898 . . . . 0.0 112.71 179.858 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 182' ' ' PRO . . . . . 0.694 ' HA ' ' HB2' ' A' ' 186' ' ' ALA . 72.9 Cg_exo -47.73 -45.27 24.46 Favored 'Trans proline' 0 CA--C 1.536 0.582 0 C-N-CA 122.848 2.365 . . . . 0.0 113.762 -179.842 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 183' ' ' PRO . . . . . 0.427 ' HD3' ' HB2' ' A' ' 182' ' ' PRO . 76.2 Cg_exo -51.83 -16.98 4.62 Favored 'Trans proline' 0 C--N 1.356 0.945 0 C-N-CA 122.173 1.916 . . . . 0.0 113.145 -179.787 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 184' ' ' GLY . . . . . 0.409 ' HA3' ' O ' ' A' ' 179' ' ' LEU . . . -115.93 -90.91 1.66 Allowed Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.463 -0.875 . . . . 0.0 113.001 -179.749 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 185' ' ' VAL . . . . . 0.441 HG22 ' O ' ' A' ' 179' ' ' LEU . 9.4 m -116.48 -7.66 12.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 N-CA-C 111.716 0.265 . . . . 0.0 111.716 -179.43 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 186' ' ' ALA . . . . . 0.694 ' HB2' ' HA ' ' A' ' 182' ' ' PRO . . . 56.66 85.69 0.08 Allowed 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.404 -0.362 . . . . 0.0 111.717 179.567 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 187' ' ' LEU . . . . . 0.589 HD11 HD22 ' A' ' 180' ' ' LEU . 20.9 mt -91.87 -49.45 6.24 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-O 120.927 0.394 . . . . 0.0 110.713 179.567 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 188' ' ' LEU . . . . . 0.428 ' HB3' ' H ' ' A' ' 189' ' ' THR . 95.6 mt -90.23 -154.48 0.33 Allowed 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 115.883 -0.599 . . . . 0.0 110.896 -179.962 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 189' ' ' THR . . . . . 0.428 ' H ' ' HB3' ' A' ' 188' ' ' LEU . 29.8 m -95.99 134.89 23.21 Favored Pre-proline 0 C--N 1.328 -0.342 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.649 -179.862 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 190' ' ' PRO . . . . . 0.407 ' O ' HG23 ' A' ' 194' ' ' VAL . 82.3 Cg_exo -44.99 -31.31 5.31 Favored 'Trans proline' 0 C--N 1.351 0.664 0 C-N-CA 122.592 2.195 . . . . 0.0 112.884 179.999 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 191' ' ' THR . . . . . 0.463 HG22 HD13 ' A' ' 4' ' ' LEU . 81.5 p -76.37 -42.05 45.94 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.481 -0.327 . . . . 0.0 111.326 -179.896 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 192' ' ' VAL . . . . . . . . . . . . . 58.3 t -70.08 -48.94 59.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.312 -0.404 . . . . 0.0 111.562 -179.504 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 193' ' ' ASP . . . . . . . . . . . . . 19.3 m-20 -53.78 -46.3 70.95 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.349 -0.387 . . . . 0.0 110.965 -179.89 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 194' ' ' VAL . . . . . 0.407 HG23 ' O ' ' A' ' 190' ' ' PRO . 69.5 t -65.36 -36.05 76.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.28 -0.418 . . . . 0.0 110.883 179.712 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 195' ' ' ALA . . . . . . . . . . . . . . . -55.0 -44.45 74.51 Favored 'General case' 0 C--N 1.331 -0.199 0 CA-C-N 116.421 -0.354 . . . . 0.0 110.843 179.783 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 196' ' ' LEU . . . . . . . . . . . . . 91.2 mt -68.07 -39.05 83.03 Favored 'General case' 0 C--N 1.332 -0.195 0 CA-C-O 120.895 0.379 . . . . 0.0 110.387 179.26 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 197' ' ' ILE . . . . . 0.449 HG12 HG21 ' A' ' 177' ' ' ILE . 13.2 mm -58.57 -56.31 17.24 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-N 115.971 -0.559 . . . . 0.0 110.083 179.091 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 198' ' ' VAL . . . . . . . . . . . . . 73.6 t -53.6 -34.46 24.09 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.509 0 CA-C-N 115.442 -0.799 . . . . 0.0 109.368 178.208 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 199' ' ' TYR . . . . . . . . . . . . . 70.0 t80 -69.92 -31.43 69.2 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 115.203 -0.908 . . . . 0.0 110.628 180.0 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 200' ' ' LEU . . . . . 0.446 HD12 HD13 ' A' ' 197' ' ' ILE . 62.5 mt -67.75 -45.53 74.7 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 115.9 -0.591 . . . . 0.0 111.299 -179.73 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 201' ' ' ASP . . . . . . . . . . . . . 7.8 m-20 -70.56 -32.61 70.1 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 121.063 0.459 . . . . 0.0 110.396 179.957 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 202' ' ' LEU . . . . . 0.489 HD11 ' HA2' ' A' ' 11' ' ' GLY . 3.9 mt -66.81 -41.99 86.64 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 115.544 -0.753 . . . . 0.0 111.882 -179.892 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 203' ' ' VAL . . . . . 0.406 ' CG1' HD22 ' A' ' 170' ' ' LEU . 8.2 p -71.47 -37.01 62.81 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.366 0 N-CA-C 111.883 0.327 . . . . 0.0 111.883 -178.582 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 204' ' ' THR . . . . . 0.439 ' O ' ' HB2' ' A' ' 208' ' ' PHE . 24.5 m -65.37 -47.29 76.89 Favored 'General case' 0 C--N 1.329 -0.312 0 C-N-CA 120.832 -0.347 . . . . 0.0 111.674 -179.92 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 205' ' ' LYS . . . . . 0.67 ' HE2' ' HB2' ' A' ' 47' ' ' ALA . 60.4 mttp -79.3 -57.93 3.47 Favored 'General case' 0 C--N 1.326 -0.429 0 N-CA-C 112.168 0.432 . . . . 0.0 112.168 -178.225 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 44.4 t -67.33 -37.39 78.93 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.388 0 CA-C-N 116.331 -0.395 . . . . 0.0 111.522 -179.413 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 207' ' ' GLY . . . . . . . . . . . . . . . -70.75 -53.65 11.42 Favored Glycine 0 C--N 1.331 0.278 0 C-N-CA 120.663 -0.78 . . . . 0.0 112.668 -179.622 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 208' ' ' PHE . . . . . 0.439 ' HB2' ' O ' ' A' ' 204' ' ' THR . 5.4 t80 -57.3 -42.42 81.75 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 120.872 0.368 . . . . 0.0 110.67 179.699 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 209' ' ' GLY . . . . . 0.487 ' O ' ' HB3' ' A' ' 212' ' ' ALA . . . -69.93 -38.51 75.0 Favored Glycine 0 N--CA 1.452 -0.296 0 CA-C-N 115.405 -0.816 . . . . 0.0 113.417 -179.766 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 210' ' ' PHE . . . . . . . . . . . . . 1.1 m-85 -69.43 -38.7 77.96 Favored 'General case' 0 CA--C 1.51 -0.58 0 N-CA-C 107.944 -1.132 . . . . 0.0 107.944 179.201 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 211' ' ' ILE . . . . . . . . . . . . . 82.9 mt -70.67 -28.69 35.18 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.825 0 N-CA-C 107.133 -1.432 . . . . 0.0 107.133 176.353 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 212' ' ' ALA . . . . . 0.487 ' HB3' ' O ' ' A' ' 209' ' ' GLY . . . -68.14 -37.94 81.61 Favored 'General case' 0 N--CA 1.45 -0.469 0 CA-C-N 114.394 -1.276 . . . . 0.0 110.572 179.704 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 213' ' ' LEU . . . . . . . . . . . . . 88.3 mt -70.1 -53.44 17.38 Favored 'General case' 0 C--N 1.331 -0.198 0 CA-C-N 115.28 -0.873 . . . . 0.0 111.444 -179.608 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 214' ' ' ASP . . . . . . . . . . . . . 25.6 t70 -54.15 -36.32 63.19 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.308 -0.406 . . . . 0.0 110.933 -179.764 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 215' ' ' ALA . . . . . 0.528 ' HB1' HD13 ' A' ' 159' ' ' LEU . . . -67.29 -57.27 6.97 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.026 -0.534 . . . . 0.0 111.457 -179.935 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 216' ' ' ALA . . . . . . . . . . . . . . . -58.57 -43.03 89.28 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.414 -0.357 . . . . 0.0 111.218 -179.735 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 217' ' ' ALA . . . . . . . . . . . . . . . -57.76 -36.8 72.6 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.502 179.831 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 218' ' ' THR . . . . . . . . . . . . . 90.9 m -66.01 -40.69 91.3 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 115.905 -0.589 . . . . 0.0 110.802 179.558 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 219' ' ' LEU . . . . . . . . . . . . . 27.6 mt -64.98 -35.17 80.32 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-N 116.299 -0.409 . . . . 0.0 110.53 179.745 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 220' ' ' ARG . . . . . 0.403 HH11 ' HD2' ' A' ' 220' ' ' ARG . 23.9 ttt180 -83.39 -19.04 36.78 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 115.868 -0.606 . . . . 0.0 110.635 179.931 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 221' ' ' ALA . . . . . . . . . . . . . . . -82.33 -36.92 26.45 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.156 -0.475 . . . . 0.0 111.473 179.886 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 222' ' ' GLU . . . . . . . . . . . . . 11.6 pt-20 -91.9 -39.07 11.93 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-N 116.406 -0.361 . . . . 0.0 111.184 -179.606 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 223' ' ' HIS . . . . . . . . . . . . . 1.1 m170 62.15 168.58 0.12 Allowed 'General case' 0 C--N 1.332 -0.164 0 CA-C-N 116.116 -0.493 . . . . 0.0 111.203 -179.472 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 224' ' ' GLY . . . . . . . . . . . . . . . -93.4 -4.66 64.07 Favored Glycine 0 C--N 1.33 0.223 0 C-N-CA 120.757 -0.735 . . . . 0.0 112.568 -179.942 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 225' ' ' GLU . . . . . . . . . . . . . 36.6 tt0 -94.69 146.13 24.37 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 120.777 0.322 . . . . 0.0 110.954 179.987 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 226' ' ' SER . . . . . . . . . . . . . 80.2 p -165.4 162.84 19.72 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.099 -0.5 . . . . 0.0 110.892 179.896 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 227' ' ' LEU . . . . . . . . . . . . . 52.1 tp -75.31 109.25 8.67 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.921 -179.948 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 228' ' ' ALA . . . . . . . . . . . . . . . -150.2 143.02 24.74 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.24 -179.971 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 229' ' ' GLY . . . . . . . . . . . . . . . -128.73 -129.6 3.2 Favored Glycine 0 C--N 1.331 0.257 0 C-N-CA 120.927 -0.654 . . . . 0.0 112.416 179.95 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 230' ' ' VAL . . . . . . . . . . . . . 43.7 t -109.74 129.96 63.69 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-O 120.748 0.309 . . . . 0.0 110.873 179.971 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 231' ' ' ASP . . . . . . . . . . . . . 23.8 m-20 -98.72 103.25 15.19 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.003 179.981 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 232' ' ' THR . . . . . . . . . . . . . 4.1 t -142.55 136.71 29.53 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 115.999 -0.546 . . . . 0.0 111.079 179.857 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 233' ' ' ASP . . . . . . . . . . . . . 15.1 t70 59.64 98.45 0.02 OUTLIER 'General case' 0 C--N 1.331 -0.213 0 CA-C-N 116.123 -0.49 . . . . 0.0 111.042 -179.884 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 234' ' ' THR . . . . . . . . . . . . . 57.9 m -139.1 95.95 9.23 Favored Pre-proline 0 C--N 1.329 -0.306 0 CA-C-N 116.101 -0.499 . . . . 0.0 111.017 -179.917 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 235' ' ' PRO . . . . . . . . . . . . . 38.5 Cg_exo -61.05 122.51 11.29 Favored 'Trans proline' 0 C--N 1.347 0.48 0 C-N-CA 122.533 2.155 . . . . 0.0 112.201 179.924 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 236' ' ' ALA . . . . . . . . . . . . . . . -163.7 108.39 1.03 Allowed 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.212 -179.886 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 237' ' ' VAL . . . . . . . . . . . . . 15.0 p -160.14 142.64 4.72 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.198 179.913 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 238' ' ' ALA . . . . . . . . . . . . . . . -149.99 136.73 19.27 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.952 -179.925 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 239' ' ' ASP . . . . . . . . . . . . . 10.0 m-20 60.14 103.32 0.02 OUTLIER 'General case' 0 C--N 1.332 -0.194 0 CA-C-N 116.106 -0.497 . . . . 0.0 111.162 -179.891 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 240' ' ' LEU . . . . . . . . . . . . . 54.4 tp -142.46 -27.61 0.61 Allowed 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.255 -0.429 . . . . 0.0 110.817 -179.903 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 241' ' ' GLU . . . . . . . . . . . . . 46.0 mt-10 -136.49 136.44 39.42 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.97 -179.973 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 242' ' ' HIS . . . . . . . . . . . . . 25.4 t60 -82.43 -37.0 26.1 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.785 -179.985 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 243' ' ' HIS . . . . . . . . . . . . . 42.1 m80 -104.57 127.21 52.24 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.801 -179.895 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 244' ' ' HIS . . . . . . . . . . . . . 39.2 m80 -74.6 -60.88 2.08 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.848 179.94 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 245' ' ' HIS . . . . . . . . . . . . . 63.3 m80 -67.81 170.7 7.58 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.101 -0.499 . . . . 0.0 110.688 179.952 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 246' ' ' HIS . . . . . . . . . . . . . 89.1 m-70 57.65 94.17 0.03 OUTLIER 'General case' 0 C--N 1.331 -0.213 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.907 -179.799 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 247' ' ' HIS . . . . . . . . . . . . . 47.0 t60 . . . . . 0 C--O 1.248 0.986 0 CA-C-O 118.311 -0.852 . . . . 0.0 110.816 179.976 . . . . . . . . 0 0 . 1 . 028 nuclear nobuild full ' A' A ' 301' ' ' RET . . . . . 0.691 H203 ' HE1' ' A' ' 171' ' ' TRP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 48.8 mtm . . . . . 0 N--CA 1.486 1.352 0 CA-C-O 120.868 0.366 . . . . 0.0 110.928 . . . . . . . . . 0 0 . 1 . 029 nuclear nobuild full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 11.5 t -103.54 -8.18 9.45 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-N 116.027 -0.533 . . . . 0.0 110.664 179.857 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -88.22 -38.73 7.13 Favored Glycine 0 N--CA 1.452 -0.253 0 C-N-CA 120.867 -0.683 . . . . 0.0 112.763 -179.821 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 89.1 mt -64.28 -37.42 87.42 Favored 'General case' 0 N--CA 1.45 -0.46 0 CA-C-O 120.841 0.353 . . . . 0.0 111.199 -179.945 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 5' ' ' THR . . . . . 0.46 ' HA ' ' HD2' ' A' ' 8' ' ' PHE . 78.5 p -59.79 -37.34 78.82 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.047 -0.524 . . . . 0.0 111.968 -179.6 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 20.1 p -54.24 -36.88 64.02 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.45 -0.341 . . . . 0.0 111.515 -179.441 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 7' ' ' LEU . . . . . . . . . . . . . 4.2 mm? -61.9 -53.05 61.06 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.308 -0.406 . . . . 0.0 111.344 -179.705 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 8' ' ' PHE . . . . . 0.721 ' HB2' ' HB2' ' A' ' 55' ' ' ALA . 29.2 m-85 -61.99 -27.32 68.78 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.367 -0.379 . . . . 0.0 111.223 -179.574 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 9' ' ' TRP . . . . . . . . . . . . . 19.7 m95 -69.61 -44.61 70.35 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 121.008 0.433 . . . . 0.0 110.204 179.882 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 90.2 mt -65.72 -37.12 85.53 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 115.926 -0.579 . . . . 0.0 109.997 179.181 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . 0.415 ' HA2' HD11 ' A' ' 202' ' ' LEU . . . -66.12 -32.9 83.72 Favored Glycine 0 N--CA 1.446 -0.677 0 CA-C-N 115.597 -0.729 . . . . 0.0 111.746 179.568 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -68.44 -37.29 80.11 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.856 0.36 . . . . 0.0 110.442 179.428 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 67.7 mt -59.47 -53.57 46.45 Favored 'Isoleucine or valine' 0 C--O 1.234 0.247 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.254 179.114 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -58.26 -34.78 75.38 Favored Glycine 0 C--N 1.332 0.36 0 C-N-CA 120.652 -0.785 . . . . 0.0 111.977 179.291 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 15' ' ' MET . . . . . 0.497 ' HE3' ' CB ' ' A' ' 47' ' ' ALA . 17.3 mmt -66.17 -41.23 90.59 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-O 120.772 0.32 . . . . 0.0 110.57 179.426 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 16' ' ' LEU . . . . . 0.429 HD22 ' HA ' ' A' ' 16' ' ' LEU . 0.3 OUTLIER -57.01 -40.74 77.2 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.067 -0.515 . . . . 0.0 109.95 179.371 . . . . . . . . 3 3 . 1 . 029 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 60.5 t -60.28 -48.86 86.5 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.241 0 CA-C-N 115.856 -0.611 . . . . 0.0 110.655 179.358 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -63.34 -48.55 77.95 Favored Glycine 0 C--N 1.332 0.356 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.058 179.337 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 43.9 m -50.13 -43.26 51.74 Favored 'General case' 0 C--N 1.328 -0.366 0 C-N-CA 122.317 0.247 . . . . 0.0 111.434 -179.659 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 87.2 mt -71.51 -44.41 64.69 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.597 -0.274 . . . . 0.0 111.694 -179.781 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -61.45 -31.67 71.63 Favored 'General case' 0 C--N 1.33 -0.28 0 N-CA-C 111.866 0.321 . . . . 0.0 111.866 -179.589 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 22' ' ' PHE . . . . . 0.511 ' HB2' HG22 ' A' ' 41' ' ' VAL . 6.9 m-85 -90.97 -35.37 14.72 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.693 0.283 . . . . 0.0 111.679 -179.32 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -66.84 -51.28 57.43 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-O 120.98 0.419 . . . . 0.0 111.781 -179.412 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 24' ' ' TRP . . . . . . . . . . . . . 7.3 t-105 -62.93 -50.68 69.87 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-N 115.804 -0.634 . . . . 0.0 110.891 -179.696 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -68.92 -19.88 64.21 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 116.364 -0.38 . . . . 0.0 110.741 179.552 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -73.32 -48.23 19.75 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.912 -0.661 . . . . 0.0 112.594 -179.961 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 78.4 mtp180 -60.5 -18.64 53.14 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 120.873 0.368 . . . . 0.0 110.688 179.877 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 33.5 t70 -109.37 98.42 7.83 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.043 -0.526 . . . . 0.0 110.639 179.811 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -166.35 -179.31 4.94 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.162 -179.836 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -68.79 -94.0 0.05 OUTLIER Glycine 0 N--CA 1.452 -0.25 0 C-N-CA 120.885 -0.674 . . . . 0.0 112.59 -179.939 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 47.4 t -158.8 -25.72 0.08 Allowed 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 120.818 0.342 . . . . 0.0 110.834 -179.948 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -90.99 -43.87 4.61 Favored Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.814 -0.708 . . . . 0.0 112.454 179.933 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 36.3 mt-10 -63.1 -21.03 65.9 Favored 'General case' 0 C--N 1.331 -0.218 0 CA-C-O 120.697 0.284 . . . . 0.0 110.946 179.993 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 34' ' ' ARG . . . . . . . . . . . . . 5.0 tmt_? -50.43 -38.2 41.98 Favored 'General case' 0 C--N 1.332 -0.169 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.202 -179.93 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 29.7 mmt180 -64.5 -44.86 89.6 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 116.343 -0.39 . . . . 0.0 111.211 -179.928 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 57.1 m-85 -66.78 -31.06 71.44 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.113 -179.989 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 37' ' ' TYR . . . . . 0.519 ' O ' HG23 ' A' ' 41' ' ' VAL . 32.2 m-85 -70.97 -52.32 20.46 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.087 -179.687 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 85.4 t -57.04 -36.84 52.24 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-O 121.141 0.496 . . . . 0.0 110.232 179.387 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 55.4 m -62.21 -50.32 72.26 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 115.629 -0.714 . . . . 0.0 110.8 179.489 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 40' ' ' LEU . . . . . 0.722 HD12 HD11 ' A' ' 43' ' ' ILE . 44.5 tp -63.06 -44.66 95.19 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 115.644 -0.707 . . . . 0.0 110.922 179.877 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . 0.519 HG23 ' O ' ' A' ' 37' ' ' TYR . 86.8 t -62.72 -34.04 63.34 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.43 0 CA-C-N 116.043 -0.526 . . . . 0.0 110.076 179.142 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . 0.433 ' O ' HG12 ' A' ' 46' ' ' ILE . . . -60.82 -49.76 75.1 Favored Glycine 0 N--CA 1.448 -0.546 0 CA-C-N 115.461 -0.79 . . . . 0.0 113.197 -179.897 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 43' ' ' ILE . . . . . 0.722 HD11 HD12 ' A' ' 40' ' ' LEU . 22.8 pt -62.29 -48.94 86.04 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.202 0 CA-C-N 117.03 0.415 . . . . 0.0 111.993 -179.296 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 44' ' ' SER . . . . . 0.426 ' N ' HG13 ' A' ' 43' ' ' ILE . 99.0 p -59.52 -29.56 67.96 Favored 'General case' 0 C--O 1.233 0.227 0 CA-C-O 120.993 0.425 . . . . 0.0 111.016 179.961 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -77.65 -54.57 4.54 Favored Glycine 0 N--CA 1.453 -0.207 0 C-N-CA 121.075 -0.583 . . . . 0.0 113.343 -179.07 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 46' ' ' ILE . . . . . 0.587 ' O ' HG22 ' A' ' 49' ' ' VAL . 10.3 pt -58.35 -36.23 57.42 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.248 0 CA-C-O 120.758 0.313 . . . . 0.0 111.143 -179.552 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 47' ' ' ALA . . . . . 0.73 ' HB2' ' HE2' ' A' ' 205' ' ' LYS . . . -68.32 -43.06 78.42 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-O 120.939 0.4 . . . . 0.0 110.443 178.621 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -55.16 -38.17 67.94 Favored 'General case' 0 C--N 1.332 -0.193 0 CA-C-N 115.805 -0.634 . . . . 0.0 111.823 -179.795 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 49' ' ' VAL . . . . . 0.587 HG22 ' O ' ' A' ' 46' ' ' ILE . 17.5 m -76.6 -34.35 23.84 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.221 0 CA-C-O 120.611 0.244 . . . . 0.0 111.457 -179.7 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -63.64 -38.41 91.03 Favored 'General case' 0 CA--C 1.52 -0.179 0 CA-C-O 121.037 0.446 . . . . 0.0 111.042 179.897 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 28.5 m-85 -72.57 -42.64 64.41 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-N 115.824 -0.625 . . . . 0.0 110.482 -179.773 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -59.99 -53.48 57.37 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-N 115.734 -0.666 . . . . 0.0 110.925 179.681 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 53' ' ' VAL . . . . . 0.507 HG23 ' N ' ' A' ' 54' ' ' MET . 31.3 m -60.21 -48.67 87.16 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.234 0 CA-C-N 116.317 -0.402 . . . . 0.0 110.874 179.936 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 54' ' ' MET . . . . . 0.507 ' N ' HG23 ' A' ' 53' ' ' VAL . 7.0 ttp -60.74 -29.11 69.18 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 121.206 0.527 . . . . 0.0 109.922 179.431 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 55' ' ' ALA . . . . . 0.721 ' HB2' ' HB2' ' A' ' 8' ' ' PHE . . . -75.58 -19.23 59.4 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 115.622 -0.717 . . . . 0.0 111.528 179.62 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 96.8 mt -89.09 -0.83 57.76 Favored 'General case' 0 C--N 1.331 -0.198 0 CA-C-N 116.454 -0.339 . . . . 0.0 111.523 -179.441 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 99.94 -22.56 39.71 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.583 -0.818 . . . . 0.0 113.14 179.521 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 58' ' ' VAL . . . . . 0.432 HG22 ' O ' ' A' ' 53' ' ' VAL . 34.0 m -73.05 147.33 9.9 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.202 0 CA-C-N 117.008 0.404 . . . . 0.0 110.568 179.729 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 59' ' ' GLY . . . . . 0.456 ' HA3' ' HD3' ' A' ' 71' ' ' PRO . . . 90.86 13.71 58.9 Favored Glycine 0 N--CA 1.448 -0.525 0 C-N-CA 120.694 -0.765 . . . . 0.0 111.869 -178.934 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 60' ' ' TRP . . . . . . . . . . . . . 13.3 m0 -103.34 98.42 8.33 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-O 121.14 0.495 . . . . 0.0 109.891 -179.978 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 20.8 t -91.4 117.03 67.58 Favored Pre-proline 0 C--N 1.323 -0.56 0 CA-C-N 115.524 -0.762 . . . . 0.0 111.209 -178.972 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 64.8 Cg_endo -73.12 135.9 23.7 Favored 'Trans proline' 0 C--N 1.35 0.617 0 C-N-CA 122.346 2.031 . . . . 0.0 112.435 -179.928 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 46.0 t -135.18 89.05 0.82 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 115.94 -0.573 . . . . 0.0 110.718 179.696 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . 55.97 -88.7 0.02 OUTLIER 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.021 -0.536 . . . . 0.0 111.538 -179.917 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 5.2 mp0 -116.78 -19.25 9.99 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-O 121.009 0.433 . . . . 0.0 110.745 -179.866 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 66' ' ' ARG . . . . . . . . . . . . . 67.8 mtp180 -98.22 166.18 11.52 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 115.677 -0.692 . . . . 0.0 110.564 179.938 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 39.4 m -136.83 125.79 24.29 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.886 0.374 . . . . 0.0 111.381 -179.882 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 11.3 t -109.7 146.31 15.25 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.04 -0.527 . . . . 0.0 110.691 179.767 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 69' ' ' PHE . . . . . 0.405 ' HA ' ' O ' ' A' ' 59' ' ' GLY . 27.5 m-85 -108.19 115.24 29.75 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.82 0.343 . . . . 0.0 110.602 -179.717 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 70' ' ' VAL . . . . . 0.668 HG12 ' HD3' ' A' ' 71' ' ' PRO . 1.4 p -69.0 -35.42 6.19 Favored Pre-proline 0 CA--C 1.542 0.651 0 N-CA-C 113.148 0.795 . . . . 0.0 113.148 -179.317 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 71' ' ' PRO . . . . . 0.668 ' HD3' HG12 ' A' ' 70' ' ' VAL . 61.2 Cg_endo -70.49 -18.19 33.74 Favored 'Trans proline' 0 C--N 1.36 1.148 0 C-N-CA 121.741 1.627 . . . . 0.0 112.574 -179.399 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 72' ' ' ARG . . . . . 0.448 ' NH2' HG13 ' A' ' 197' ' ' ILE . 72.4 ttt180 -75.9 -54.49 6.81 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.277 -0.42 . . . . 0.0 111.835 -179.026 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 73' ' ' TYR . . . . . . . . . . . . . 83.4 m-85 -73.34 -35.68 66.06 Favored 'General case' 0 C--N 1.331 -0.21 0 C-N-CA 121.085 -0.246 . . . . 0.0 111.203 -179.103 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 74' ' ' ILE . . . . . 0.437 ' O ' HD13 ' A' ' 74' ' ' ILE . 0.3 OUTLIER -67.17 -43.87 88.2 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.238 0 C-N-CA 120.818 -0.353 . . . . 0.0 110.354 179.72 . . . . . . . . 3 3 . 1 . 029 nuclear nobuild full ' A' A ' 75' ' ' ASP . . . . . 0.508 ' O ' HG23 ' A' ' 79' ' ' THR . 20.3 t70 -59.27 -35.87 74.5 Favored 'General case' 0 N--CA 1.455 -0.188 0 N-CA-C 109.267 -0.642 . . . . 0.0 109.267 178.986 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 76' ' ' TRP . . . . . 0.5 ' HB3' ' SD ' ' A' ' 109' ' ' MET . 39.3 m0 -64.0 -36.57 84.41 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 115.702 -0.681 . . . . 0.0 110.577 179.134 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 77' ' ' ILE . . . . . 0.472 ' O ' ' HG2' ' A' ' 81' ' ' PRO . 79.5 mt -67.29 -28.95 44.16 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.239 179.5 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 81.9 mt -91.33 -14.74 30.24 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.068 -0.515 . . . . 0.0 112.023 179.868 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 79' ' ' THR . . . . . 0.508 HG23 ' O ' ' A' ' 75' ' ' ASP . 70.1 p -104.38 -53.3 2.74 Favored 'General case' 0 N--CA 1.463 0.182 0 N-CA-C 113.272 0.842 . . . . 0.0 113.272 -178.652 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 80' ' ' THR . . . . . 0.641 ' HB ' ' HD3' ' A' ' 81' ' ' PRO . 8.9 m -51.75 -55.44 29.98 Favored Pre-proline 0 C--N 1.329 -0.296 0 N-CA-C 113.014 0.746 . . . . 0.0 113.014 -178.033 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 81' ' ' PRO . . . . . 0.641 ' HD3' ' HB ' ' A' ' 80' ' ' THR . 52.7 Cg_exo -56.96 -25.58 63.35 Favored 'Trans proline' 0 C--N 1.352 0.752 0 C-N-CA 121.505 1.47 . . . . 0.0 111.77 -179.799 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 82' ' ' LEU . . . . . 0.477 HD23 HG23 ' A' ' 43' ' ' ILE . 10.9 tp -76.83 -33.16 57.96 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 115.806 -0.634 . . . . 0.0 110.577 179.961 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 83' ' ' ILE . . . . . 0.413 HG12 ' O ' ' A' ' 79' ' ' THR . 43.5 mm -65.99 -52.75 45.27 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.204 0 CA-C-O 120.883 0.373 . . . . 0.0 110.201 179.176 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 33.7 m -61.42 -30.02 47.19 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.256 0 N-CA-C 109.472 -0.566 . . . . 0.0 109.472 178.759 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 85' ' ' TYR . . . . . . . . . . . . . 68.0 t80 -67.75 -30.64 70.16 Favored 'General case' 0 N--CA 1.452 -0.329 0 CA-C-N 115.391 -0.822 . . . . 0.0 109.588 178.568 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 86' ' ' PHE . . . . . . . . . . . . . 3.3 t80 -65.14 -49.78 68.55 Favored 'General case' 0 C--O 1.232 0.172 0 CA-C-N 115.823 -0.626 . . . . 0.0 109.766 179.069 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 6.5 mt -63.87 -30.8 71.85 Favored 'General case' 0 CA--C 1.518 -0.259 0 CA-C-N 115.878 -0.601 . . . . 0.0 109.742 179.468 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -69.86 -29.08 71.18 Favored Glycine 0 N--CA 1.449 -0.455 0 CA-C-N 115.291 -0.868 . . . . 0.0 112.167 179.74 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 54.1 mt -74.04 -38.93 63.85 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-O 120.913 0.387 . . . . 0.0 110.524 179.622 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 94.6 mt -63.71 -35.82 81.81 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.002 -0.545 . . . . 0.0 110.975 179.801 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . 0.425 ' HB1' ' OG ' ' A' ' 148' ' ' SER . . . -80.97 -54.77 5.28 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.351 -179.677 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 101.51 61.56 0.77 Allowed Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.791 -0.719 . . . . 0.0 112.369 -179.668 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 93' ' ' LEU . . . . . 0.505 ' HB3' ' HB2' ' A' ' 97' ' ' GLU . 6.8 mp -80.37 178.37 8.34 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-O 120.797 0.332 . . . . 0.0 110.907 -179.771 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 94' ' ' ASP . . . . . . . . . . . . . 22.4 m-20 -96.15 168.09 10.81 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.658 179.73 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 67.8 m -55.32 -35.09 64.77 Favored 'General case' 0 C--N 1.33 -0.239 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.256 -179.899 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 27.6 tpt180 -69.33 -54.01 16.74 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.412 -0.358 . . . . 0.0 110.895 -179.815 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 97' ' ' GLU . . . . . 0.505 ' HB2' ' HB3' ' A' ' 93' ' ' LEU . 32.9 mt-10 -53.82 -49.55 68.12 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.098 -0.501 . . . . 0.0 111.184 -179.639 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 98' ' ' PHE . . . . . 0.42 ' O ' HG12 ' A' ' 102' ' ' ILE . 25.4 m-85 -55.26 -51.19 67.43 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.397 -0.365 . . . . 0.0 111.002 179.902 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -56.9 -29.89 59.44 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.858 -0.687 . . . . 0.0 112.637 -179.74 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 100' ' ' ILE . . . . . 0.41 HD12 ' HA ' ' A' ' 97' ' ' GLU . 77.4 mt -72.85 -43.26 60.45 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-O 120.85 0.357 . . . . 0.0 111.308 -179.903 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 61.3 t -68.29 -49.8 63.41 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.355 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.702 -179.435 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 102' ' ' ILE . . . . . 0.42 HG12 ' O ' ' A' ' 98' ' ' PHE . 39.9 mm -58.11 -52.23 61.11 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 CA-C-N 116.317 -0.401 . . . . 0.0 111.584 -179.367 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 14.7 t -58.28 -34.65 70.75 Favored 'General case' 0 C--N 1.331 -0.203 0 CA-C-O 120.746 0.308 . . . . 0.0 110.82 -179.801 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 104' ' ' LEU . . . . . 0.47 HD22 ' HE2' ' A' ' 140' ' ' TYR . 30.5 tp -61.61 -45.83 92.41 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.625 179.224 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 105' ' ' ASN . . . . . 0.579 ' N ' HD22 ' A' ' 105' ' ' ASN . 0.8 OUTLIER -64.83 -26.87 68.52 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.095 -0.502 . . . . 0.0 111.117 -179.818 . . . . . . . . 3 3 . 1 . 029 nuclear nobuild full ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 99.3 m -66.29 -57.37 7.66 Favored 'General case' 0 C--N 1.331 -0.204 0 CA-C-N 116.548 -0.296 . . . . 0.0 111.351 179.878 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 8.8 p -58.16 -36.32 56.8 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.213 0 CA-C-N 116.383 -0.372 . . . . 0.0 110.862 -179.88 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . 0.423 HG23 ' O ' ' A' ' 104' ' ' LEU . 59.9 t -64.82 -53.3 43.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.554 179.358 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 109' ' ' MET . . . . . 0.563 ' HE1' HG21 ' A' ' 80' ' ' THR . 5.7 tpp -60.89 -31.06 70.56 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 115.941 -0.572 . . . . 0.0 110.417 179.885 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 11.9 mt -74.44 -30.34 61.85 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 115.976 -0.556 . . . . 0.0 110.267 179.507 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -62.43 -42.52 99.51 Favored 'General case' 0 C--N 1.332 -0.194 0 N-CA-C 109.514 -0.55 . . . . 0.0 109.514 178.607 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 112' ' ' GLY . . . . . 0.419 ' HA3' ' H21' ' A' ' 301' ' ' RET . . . -74.42 -39.18 43.25 Favored Glycine 0 N--CA 1.449 -0.438 0 N-CA-C 111.187 -0.765 . . . . 0.0 111.187 178.748 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 113' ' ' PHE . . . . . . . . . . . . . 0.7 OUTLIER -50.66 -70.92 0.07 Allowed 'General case' 0 C--N 1.332 -0.162 0 N-CA-C 109.539 -0.541 . . . . 0.0 109.539 179.02 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 114' ' ' ALA . . . . . 0.479 ' HA ' ' HB2' ' A' ' 117' ' ' MET . . . -64.13 -21.05 66.39 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 115.387 -0.824 . . . . 0.0 110.947 179.218 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 115' ' ' GLY . . . . . 0.52 ' HA2' HD22 ' A' ' 126' ' ' LEU . . . -52.25 -49.48 50.38 Favored Glycine 0 C--N 1.335 0.508 0 C-N-CA 120.765 -0.731 . . . . 0.0 111.925 179.635 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -78.5 -18.48 54.73 Favored 'General case' 0 C--N 1.325 -0.465 0 CA-C-O 120.85 0.357 . . . . 0.0 110.983 179.392 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 117' ' ' MET . . . . . 0.479 ' HB2' ' HA ' ' A' ' 114' ' ' ALA . 19.9 mmt -84.85 3.78 36.29 Favored 'General case' 0 C--N 1.332 -0.189 0 CA-C-N 116.103 -0.499 . . . . 0.0 112.03 -179.361 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 118' ' ' VAL . . . . . 0.493 HG21 ' HB3' ' A' ' 123' ' ' ARG . 35.5 m -66.31 146.32 99.03 Favored Pre-proline 0 C--N 1.328 -0.364 0 C-N-CA 121.046 -0.262 . . . . 0.0 111.407 -179.588 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 119' ' ' PRO . . . . . . . . . . . . . 92.9 Cg_endo -86.86 -11.35 5.61 Favored 'Trans proline' 0 C--N 1.348 0.535 0 C-N-CA 122.674 2.25 . . . . 0.0 112.226 179.781 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -140.27 -124.98 2.15 Favored Glycine 0 C--N 1.331 0.281 0 C-N-CA 120.84 -0.695 . . . . 0.0 112.795 -179.907 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 2.3 pp -109.94 18.15 7.06 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.187 0 CA-C-O 120.782 0.325 . . . . 0.0 111.695 -179.564 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 42.8 mt-10 -66.47 -18.53 65.41 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.306 -0.407 . . . . 0.0 111.159 -179.9 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 123' ' ' ARG . . . . . 0.493 ' HB3' HG21 ' A' ' 118' ' ' VAL . 17.8 ptt180 -50.47 -34.61 25.52 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.825 -179.516 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 124' ' ' TYR . . . . . . . . . . . . . 29.2 m-85 -61.5 -34.13 74.96 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.766 0.317 . . . . 0.0 111.13 -179.552 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 125' ' ' ALA . . . . . . . . . . . . . . . -74.5 -49.69 21.1 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.908 179.788 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 126' ' ' LEU . . . . . 0.52 HD22 ' HA2' ' A' ' 115' ' ' GLY . 7.3 mp -53.39 -49.15 67.84 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-N 116.051 -0.522 . . . . 0.0 110.588 179.921 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 127' ' ' PHE . . . . . . . . . . . . . 5.4 t80 -67.0 -37.77 84.78 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.821 179.958 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 128' ' ' GLY . . . . . . . . . . . . . . . -46.34 -43.09 13.98 Favored Glycine 0 C--N 1.332 0.338 0 C-N-CA 120.156 -1.021 . . . . 0.0 110.817 179.097 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 129' ' ' MET . . . . . . . . . . . . . 0.8 OUTLIER -71.81 -39.05 70.11 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.921 0.391 . . . . 0.0 109.971 178.509 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -60.95 -32.88 81.57 Favored Glycine 0 C--N 1.333 0.401 0 CA-C-N 115.916 -0.584 . . . . 0.0 113.043 -179.911 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -74.84 -53.87 8.32 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-O 120.669 0.271 . . . . 0.0 110.883 179.959 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 48.2 t -56.4 -40.35 66.54 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.228 0 CA-C-O 121.478 0.656 . . . . 0.0 109.477 179.055 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -68.52 -37.82 80.35 Favored 'General case' 0 N--CA 1.451 -0.424 0 CA-C-N 115.102 -0.954 . . . . 0.0 110.408 179.24 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 134' ' ' PHE . . . . . . . . . . . . . 79.5 t80 -54.64 -51.93 63.87 Favored 'General case' 0 N--CA 1.451 -0.388 0 CA-C-N 116.09 -0.505 . . . . 0.0 109.901 179.387 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 135' ' ' ILE . . . . . 0.523 ' O ' HG22 ' A' ' 138' ' ' VAL . 56.5 mt -58.75 -33.55 49.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 115.647 -0.706 . . . . 0.0 110.046 179.068 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . -58.4 -36.35 83.55 Favored Glycine 0 N--CA 1.449 -0.449 0 C-N-CA 120.239 -0.982 . . . . 0.0 111.136 178.616 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 137' ' ' LEU . . . . . . . . . . . . . 38.4 tp -71.1 -53.15 15.64 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 115.769 -0.216 . . . . 0.0 110.805 179.494 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 138' ' ' VAL . . . . . 0.523 HG22 ' O ' ' A' ' 135' ' ' ILE . 3.3 m -55.97 -32.55 33.38 Favored 'Isoleucine or valine' 0 C--O 1.232 0.137 0 CA-C-O 121.233 0.539 . . . . 0.0 109.863 179.483 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 139' ' ' TYR . . . . . . . . . . . . . 34.4 t80 -60.3 -50.15 74.78 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 115.5 -0.773 . . . . 0.0 110.303 178.894 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 140' ' ' TYR . . . . . 0.47 ' HE2' HD22 ' A' ' 104' ' ' LEU . 22.4 m-85 -56.9 -35.41 68.96 Favored 'General case' 0 C--N 1.332 -0.152 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.741 179.64 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 141' ' ' LEU . . . . . . . . . . . . . 96.0 mt -57.73 -52.0 67.23 Favored 'General case' 0 C--N 1.332 -0.172 0 CA-C-N 116.355 -0.384 . . . . 0.0 110.504 179.602 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 10.2 t -78.48 -10.35 12.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.09 -0.505 . . . . 0.0 110.778 179.672 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . -71.58 -131.39 0.11 Allowed Glycine 0 CA--C 1.521 0.45 0 C-N-CA 120.886 -0.673 . . . . 0.0 112.677 -179.887 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 144' ' ' PRO . . . . . . . . . . . . . 44.8 Cg_endo -67.84 -24.09 40.71 Favored 'Trans proline' 0 C--N 1.348 0.542 0 C-N-CA 122.403 2.069 . . . . 0.0 112.5 -179.888 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 145' ' ' MET . . . . . . . . . . . . . 45.2 mtt -55.41 -34.62 64.57 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 120.983 0.421 . . . . 0.0 111.063 179.876 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 146' ' ' THR . . . . . . . . . . . . . 27.4 m -70.78 -45.82 64.02 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 115.991 -0.55 . . . . 0.0 112.077 -179.181 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 46.3 mt-10 -72.22 -29.51 64.03 Favored 'General case' 0 C--N 1.328 -0.345 0 N-CA-C 111.846 0.313 . . . . 0.0 111.846 -179.101 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 148' ' ' SER . . . . . 0.425 ' OG ' ' HB1' ' A' ' 91' ' ' ALA . 42.0 p -70.15 -45.04 67.6 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.551 -0.295 . . . . 0.0 111.488 -179.241 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 149' ' ' ALA . . . . . . . . . . . . . . . -77.98 -39.84 41.13 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.772 0.32 . . . . 0.0 111.79 -179.514 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 150' ' ' SER . . . . . . . . . . . . . 40.3 t -65.82 -5.09 7.9 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.284 -0.416 . . . . 0.0 111.517 -179.536 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 151' ' ' GLN . . . . . . . . . . . . . 48.4 mt-30 -127.1 17.44 7.2 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.614 -0.266 . . . . 0.0 111.232 179.876 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 25.2 tpt180 -93.82 -52.04 4.62 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-O 120.817 0.341 . . . . 0.0 111.074 179.944 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 153' ' ' SER . . . . . 0.611 ' HB3' HG12 ' A' ' 156' ' ' ILE . 23.1 t -157.38 172.57 18.35 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.581 179.466 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 154' ' ' SER . . . . . . . . . . . . . 47.6 t -70.39 -39.8 74.33 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.773 0.32 . . . . 0.0 110.949 179.961 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -76.95 -34.7 41.54 Favored Glycine 0 CA--C 1.518 0.254 0 C-N-CA 120.862 -0.685 . . . . 0.0 112.986 -179.899 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 156' ' ' ILE . . . . . 0.611 HG12 ' HB3' ' A' ' 153' ' ' SER . 38.5 mm -54.46 -38.18 40.4 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 CA-C-O 120.605 0.24 . . . . 0.0 111.492 -179.664 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 157' ' ' LYS . . . . . 0.435 ' O ' HG22 ' A' ' 161' ' ' VAL . 27.2 ttpp -68.22 -31.98 71.87 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.41 -0.359 . . . . 0.0 111.371 -179.724 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 53.5 m -71.39 -48.5 49.56 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-O 120.898 0.38 . . . . 0.0 111.411 -179.631 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 159' ' ' LEU . . . . . 0.524 HD21 ' HB3' ' A' ' 215' ' ' ALA . 14.3 mt -71.16 -35.48 71.67 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.607 -179.637 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 160' ' ' TYR . . . . . . . . . . . . . 76.3 t80 -64.95 -44.86 88.04 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.471 -0.331 . . . . 0.0 111.874 -179.098 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 161' ' ' VAL . . . . . 0.435 HG22 ' O ' ' A' ' 157' ' ' LYS . 31.0 m -67.35 -46.28 84.06 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 N-CA-C 111.927 0.343 . . . . 0.0 111.927 -179.172 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 162' ' ' ARG . . . . . 0.433 ' N ' HG23 ' A' ' 161' ' ' VAL . 78.5 mtm180 -64.78 -35.9 82.57 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.73 0.3 . . . . 0.0 111.529 -179.631 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 163' ' ' LEU . . . . . 0.56 ' HG ' ' HB2' ' A' ' 208' ' ' PHE . 7.7 mp -76.87 -51.37 11.38 Favored 'General case' 0 C--N 1.328 -0.349 0 N-CA-C 112.179 0.437 . . . . 0.0 112.179 -179.074 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 164' ' ' ARG . . . . . . . . . . . . . 5.6 ppt_? -62.11 -41.68 98.47 Favored 'General case' 0 C--N 1.328 -0.331 0 N-CA-C 112.064 0.394 . . . . 0.0 112.064 -178.514 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 165' ' ' ASN . . . . . 0.463 ' O ' HG23 ' A' ' 169' ' ' VAL . 17.4 m-80 -69.38 -51.38 37.18 Favored 'General case' 0 C--N 1.332 -0.188 0 CA-C-O 120.696 0.284 . . . . 0.0 111.616 -179.788 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 166' ' ' LEU . . . . . 0.476 ' O ' ' HG ' ' A' ' 170' ' ' LEU . 4.2 tt -60.32 -51.33 69.97 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-O 120.844 0.354 . . . . 0.0 111.421 -179.601 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 167' ' ' THR . . . . . . . . . . . . . 88.3 m -59.91 -52.54 64.98 Favored 'General case' 0 C--N 1.329 -0.317 0 N-CA-C 112.923 0.712 . . . . 0.0 112.923 -178.826 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 168' ' ' VAL . . . . . 0.454 HG12 ' O ' ' A' ' 165' ' ' ASN . 8.9 p -54.32 -40.28 47.44 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.195 0 N-CA-C 112.297 0.48 . . . . 0.0 112.297 -178.546 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 169' ' ' VAL . . . . . 0.463 HG23 ' O ' ' A' ' 165' ' ' ASN . 79.1 t -62.03 -64.37 0.65 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-N 116.574 -0.285 . . . . 0.0 111.621 -179.721 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 170' ' ' LEU . . . . . 0.476 ' HG ' ' O ' ' A' ' 166' ' ' LEU . 1.2 pp -60.59 -30.96 70.14 Favored 'General case' 0 C--N 1.33 -0.272 0 N-CA-C 111.97 0.359 . . . . 0.0 111.97 -179.011 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 171' ' ' TRP . . . . . 0.796 ' HE1' H203 ' A' ' 301' ' ' RET . 3.2 m0 -70.32 -35.09 73.42 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-O 120.928 0.394 . . . . 0.0 110.383 179.431 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 172' ' ' ALA . . . . . . . . . . . . . . . -69.3 -7.28 35.67 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 115.844 -0.617 . . . . 0.0 110.801 -179.793 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 173' ' ' ILE . . . . . 0.624 HG22 HD11 ' A' ' 177' ' ' ILE . 43.6 mm -84.78 -23.53 7.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 115.917 -0.583 . . . . 0.0 110.736 179.536 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 174' ' ' TYR . . . . . 0.457 ' HB2' ' HD3' ' A' ' 175' ' ' PRO . 22.2 m-85 -54.41 -51.16 80.48 Favored Pre-proline 0 N--CA 1.464 0.254 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.768 -179.89 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 175' ' ' PRO . . . . . 0.457 ' HD3' ' HB2' ' A' ' 174' ' ' TYR . 87.5 Cg_exo -46.84 -29.07 7.62 Favored 'Trans proline' 0 C--N 1.352 0.752 0 C-N-CA 122.225 1.95 . . . . 0.0 112.387 -179.905 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 176' ' ' PHE . . . . . 0.5 ' O ' ' HG ' ' A' ' 180' ' ' LEU . 81.0 m-85 -80.6 -49.81 10.8 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 115.992 -0.549 . . . . 0.0 111.802 -179.893 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 177' ' ' ILE . . . . . 0.624 HD11 HG22 ' A' ' 173' ' ' ILE . 2.4 mm -61.19 -37.15 76.83 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.54 0 CA-C-N 116.201 -0.454 . . . . 0.0 112.133 -178.043 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 178' ' ' TRP . . . . . . . . . . . . . 63.8 t90 -73.45 -41.08 63.66 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-O 120.84 0.352 . . . . 0.0 110.637 179.628 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 179' ' ' LEU . . . . . 0.479 ' O ' HG22 ' A' ' 185' ' ' VAL . 2.6 tm? -68.54 -54.07 19.02 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 115.97 -0.559 . . . . 0.0 111.259 -179.426 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 180' ' ' LEU . . . . . 0.584 HD22 HD11 ' A' ' 187' ' ' LEU . 11.9 mt -72.58 -46.49 54.05 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.541 -0.3 . . . . 0.0 111.489 -179.408 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 181' ' ' GLY . . . . . 0.424 ' HA3' ' OD1' ' A' ' 193' ' ' ASP . . . -55.1 173.13 0.99 Allowed Glycine 0 C--N 1.336 0.557 0 C-N-CA 120.558 -0.829 . . . . 0.0 112.682 179.865 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 182' ' ' PRO . . . . . 0.659 ' HA ' ' HB2' ' A' ' 186' ' ' ALA . 82.9 Cg_exo -47.78 -44.67 26.17 Favored 'Trans proline' 0 C--N 1.347 0.49 0 C-N-CA 122.776 2.317 . . . . 0.0 113.611 179.87 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 183' ' ' PRO . . . . . 0.419 ' HD3' ' HB2' ' A' ' 182' ' ' PRO . 57.6 Cg_exo -52.65 -14.85 3.6 Favored 'Trans proline' 0 C--N 1.355 0.877 0 C-N-CA 121.982 1.788 . . . . 0.0 112.551 179.633 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 184' ' ' GLY . . . . . 0.401 ' HA3' ' O ' ' A' ' 179' ' ' LEU . . . -115.08 -81.03 0.93 Allowed Glycine 0 N--CA 1.45 -0.373 0 C-N-CA 120.776 -0.726 . . . . 0.0 112.678 -179.982 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 185' ' ' VAL . . . . . 0.479 HG22 ' O ' ' A' ' 179' ' ' LEU . 6.3 m -132.05 -2.9 1.85 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.208 0 N-CA-C 112.409 0.522 . . . . 0.0 112.409 -179.572 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 186' ' ' ALA . . . . . 0.659 ' HB2' ' HA ' ' A' ' 182' ' ' PRO . . . 53.02 87.31 0.04 OUTLIER 'General case' 0 C--N 1.331 -0.22 0 CA-C-O 120.723 0.297 . . . . 0.0 111.642 179.78 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 187' ' ' LEU . . . . . 0.584 HD11 HD22 ' A' ' 180' ' ' LEU . 18.6 mt -92.01 -49.82 6.02 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 120.838 0.351 . . . . 0.0 111.406 179.934 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 188' ' ' LEU . . . . . . . . . . . . . 38.8 mt -94.84 -89.45 0.23 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.087 -0.506 . . . . 0.0 111.412 -179.325 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 189' ' ' THR . . . . . . . . . . . . . 1.1 t -165.36 148.34 6.93 Favored Pre-proline 0 C--N 1.325 -0.461 0 CA-C-N 115.856 -0.611 . . . . 0.0 111.06 -179.56 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 190' ' ' PRO . . . . . . . . . . . . . 12.1 Cg_endo -55.83 -30.31 76.17 Favored 'Trans proline' 0 C--N 1.347 0.494 0 C-N-CA 122.513 2.142 . . . . 0.0 112.427 -179.994 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 191' ' ' THR . . . . . . . . . . . . . 77.9 p -64.56 -45.28 87.78 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 121.012 0.434 . . . . 0.0 110.686 179.682 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 192' ' ' VAL . . . . . . . . . . . . . 25.4 t -73.89 -38.47 50.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 115.81 -0.632 . . . . 0.0 111.056 179.857 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 193' ' ' ASP . . . . . 0.478 ' OD1' HG22 ' A' ' 177' ' ' ILE . 14.5 t70 -59.49 -51.51 69.56 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.9 179.8 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 194' ' ' VAL . . . . . . . . . . . . . 94.6 t -64.34 -36.37 76.96 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-N 116.02 -0.536 . . . . 0.0 111.185 -179.896 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 195' ' ' ALA . . . . . . . . . . . . . . . -57.64 -48.68 78.79 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.695 0.283 . . . . 0.0 111.092 179.92 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 196' ' ' LEU . . . . . . . . . . . . . 63.0 mt -68.44 -43.27 77.47 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 116.389 -0.369 . . . . 0.0 110.589 179.617 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 197' ' ' ILE . . . . . 0.499 HG12 HG21 ' A' ' 177' ' ' ILE . 17.2 mm -56.2 -59.34 2.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 115.944 -0.571 . . . . 0.0 110.56 179.416 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 198' ' ' VAL . . . . . . . . . . . . . 61.0 t -52.3 -35.39 19.63 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.505 0 CA-C-N 115.594 -0.73 . . . . 0.0 109.433 178.62 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 199' ' ' TYR . . . . . . . . . . . . . 67.3 t80 -70.58 -31.14 68.04 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 115.244 -0.889 . . . . 0.0 110.916 -179.904 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 200' ' ' LEU . . . . . 0.536 ' O ' HG12 ' A' ' 203' ' ' VAL . 37.1 mt -71.88 -40.23 69.06 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 115.902 -0.59 . . . . 0.0 111.544 -179.545 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 201' ' ' ASP . . . . . . . . . . . . . 14.7 m-20 -72.81 -34.87 67.15 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-O 121.237 0.542 . . . . 0.0 110.114 179.519 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 202' ' ' LEU . . . . . 0.415 HD11 ' HA2' ' A' ' 11' ' ' GLY . 2.5 mt -73.01 -29.28 62.91 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 115.415 -0.811 . . . . 0.0 111.601 -179.634 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 203' ' ' VAL . . . . . 0.536 HG12 ' O ' ' A' ' 200' ' ' LEU . 12.5 p -77.6 -36.25 22.77 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.382 0 C-N-CA 121.045 -0.262 . . . . 0.0 110.669 -179.083 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 204' ' ' THR . . . . . . . . . . . . . 98.6 m -65.49 -58.79 4.97 Favored 'General case' 0 C--N 1.329 -0.307 0 C-N-CA 120.596 -0.442 . . . . 0.0 110.994 179.306 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 205' ' ' LYS . . . . . 0.73 ' HE2' ' HB2' ' A' ' 47' ' ' ALA . 61.5 mttp -63.27 -58.1 8.27 Favored 'General case' 0 C--N 1.33 -0.24 0 N-CA-C 112.461 0.541 . . . . 0.0 112.461 -178.259 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 44.6 t -69.97 -37.54 72.94 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.412 0 N-CA-C 112.235 0.458 . . . . 0.0 112.235 -178.751 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 207' ' ' GLY . . . . . 0.52 ' O ' HG13 ' A' ' 211' ' ' ILE . . . -58.22 -61.83 6.97 Favored Glycine 0 CA--C 1.52 0.365 0 C-N-CA 120.67 -0.776 . . . . 0.0 114.059 -178.486 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 208' ' ' PHE . . . . . 0.56 ' HB2' ' HG ' ' A' ' 163' ' ' LEU . 0.9 OUTLIER -73.41 -27.04 61.24 Favored 'General case' 0 C--O 1.221 -0.414 0 CA-C-N 117.47 0.635 . . . . 0.0 110.802 -179.14 . . . . . . . . 3 3 . 1 . 029 nuclear nobuild full ' A' A ' 209' ' ' GLY . . . . . 0.502 ' O ' ' HB3' ' A' ' 212' ' ' ALA . . . -63.19 -32.39 83.99 Favored Glycine 0 N--CA 1.447 -0.626 0 N-CA-C 111.663 -0.575 . . . . 0.0 111.663 178.616 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 210' ' ' PHE . . . . . . . . . . . . . 1.3 m-85 -75.08 -46.91 31.52 Favored 'General case' 0 CA--C 1.514 -0.439 0 N-CA-C 108.37 -0.974 . . . . 0.0 108.37 178.336 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 211' ' ' ILE . . . . . 0.52 HG13 ' O ' ' A' ' 207' ' ' GLY . 4.1 mt -63.41 -27.59 43.34 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.411 0 N-CA-C 107.473 -1.306 . . . . 0.0 107.473 176.67 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 212' ' ' ALA . . . . . 0.502 ' HB3' ' O ' ' A' ' 209' ' ' GLY . . . -63.79 -41.23 97.98 Favored 'General case' 0 N--CA 1.45 -0.461 0 CA-C-N 114.303 -1.317 . . . . 0.0 110.634 -179.772 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 213' ' ' LEU . . . . . . . . . . . . . 72.9 mt -70.12 -50.17 43.43 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 115.179 -0.919 . . . . 0.0 111.783 -179.393 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 214' ' ' ASP . . . . . . . . . . . . . 21.7 t70 -53.24 -51.83 60.94 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.331 -0.395 . . . . 0.0 111.581 -179.315 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 215' ' ' ALA . . . . . 0.524 ' HB3' HD21 ' A' ' 159' ' ' LEU . . . -64.63 -55.32 20.99 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.379 -0.373 . . . . 0.0 111.772 -179.54 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 216' ' ' ALA . . . . . 0.466 ' HA ' HD12 ' A' ' 219' ' ' LEU . . . -51.87 -37.07 50.78 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 116.414 -0.357 . . . . 0.0 111.496 -179.707 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 217' ' ' ALA . . . . . . . . . . . . . . . -63.65 -44.26 94.36 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.997 0.427 . . . . 0.0 110.06 179.577 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 218' ' ' THR . . . . . 0.424 ' HA ' ' HB3' ' A' ' 221' ' ' ALA . 54.3 m -63.67 -37.42 87.28 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 115.669 -0.696 . . . . 0.0 110.626 179.376 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 219' ' ' LEU . . . . . 0.466 HD12 ' HA ' ' A' ' 216' ' ' ALA . 93.7 mt -56.62 -50.21 72.69 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 115.951 -0.568 . . . . 0.0 110.739 179.98 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 220' ' ' ARG . . . . . . . . . . . . . 13.9 ptm180 -83.42 -10.33 58.47 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.333 -0.394 . . . . 0.0 111.006 179.831 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 221' ' ' ALA . . . . . 0.424 ' HB3' ' HA ' ' A' ' 218' ' ' THR . . . -82.68 -20.13 36.75 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.371 -0.377 . . . . 0.0 111.952 -179.958 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 222' ' ' GLU . . . . . . . . . . . . . 10.7 pt-20 -90.73 -32.04 16.32 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-O 120.648 0.261 . . . . 0.0 111.288 -179.583 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 223' ' ' HIS . . . . . . . . . . . . . 1.7 p-80 -128.99 174.24 9.71 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.724 0.297 . . . . 0.0 111.078 179.851 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 224' ' ' GLY . . . . . . . . . . . . . . . -114.32 -59.15 0.38 Allowed Glycine 0 N--CA 1.452 -0.283 0 C-N-CA 120.702 -0.761 . . . . 0.0 112.462 179.93 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 225' ' ' GLU . . . . . . . . . . . . . 9.8 tp10 58.53 99.64 0.02 OUTLIER 'General case' 0 C--N 1.332 -0.162 0 CA-C-O 120.888 0.375 . . . . 0.0 111.05 179.998 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 226' ' ' SER . . . . . . . . . . . . . 80.9 p -150.33 148.06 28.37 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.888 179.888 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 227' ' ' LEU . . . . . . . . . . . . . 97.1 mt -87.83 140.99 28.95 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.837 179.99 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 228' ' ' ALA . . . . . . . . . . . . . . . 50.76 91.07 0.02 OUTLIER 'General case' 0 C--N 1.331 -0.203 0 CA-C-N 116.079 -0.51 . . . . 0.0 111.552 -179.786 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 229' ' ' GLY . . . . . . . . . . . . . . . -117.73 134.97 11.42 Favored Glycine 0 C--N 1.332 0.311 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.593 -179.872 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 230' ' ' VAL . . . . . . . . . . . . . 28.7 m -101.73 147.75 8.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-O 120.833 0.349 . . . . 0.0 111.101 179.906 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 231' ' ' ASP . . . . . . . . . . . . . 18.5 t70 -101.46 102.79 13.63 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.061 -179.82 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 232' ' ' THR . . . . . . . . . . . . . 80.7 p -139.22 152.68 47.54 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.138 179.871 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 233' ' ' ASP . . . . . . . . . . . . . 29.2 m-20 -109.51 -58.52 2.03 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.849 179.818 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 234' ' ' THR . . . . . . . . . . . . . 85.5 m -127.95 101.89 22.55 Favored Pre-proline 0 C--N 1.329 -0.298 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.157 -179.935 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 235' ' ' PRO . . . . . . . . . . . . . 60.4 Cg_endo -72.35 163.58 38.2 Favored 'Trans proline' 0 C--N 1.349 0.576 0 C-N-CA 122.482 2.121 . . . . 0.0 112.333 179.856 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 236' ' ' ALA . . . . . 0.405 ' HB1' ' HG2' ' A' ' 241' ' ' GLU . . . -93.67 130.05 39.74 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 116.124 -0.489 . . . . 0.0 111.083 179.915 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 237' ' ' VAL . . . . . . . . . . . . . 13.4 p -90.81 145.34 7.54 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.222 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.987 -179.886 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 238' ' ' ALA . . . . . . . . . . . . . . . 60.13 -178.94 0.1 Allowed 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.258 -179.929 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 239' ' ' ASP . . . . . . . . . . . . . 4.5 p30 -107.08 -0.18 23.08 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.121 -0.491 . . . . 0.0 110.869 -179.958 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 240' ' ' LEU . . . . . 0.419 ' H ' ' HG ' ' A' ' 240' ' ' LEU . 1.9 pp -86.63 -7.29 58.46 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.242 -0.436 . . . . 0.0 111.098 179.943 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 241' ' ' GLU . . . . . 0.405 ' HG2' ' HB1' ' A' ' 236' ' ' ALA . 9.3 tp10 -64.02 122.89 17.63 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.741 179.828 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 242' ' ' HIS . . . . . . . . . . . . . 88.7 m-70 -67.29 149.09 50.84 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.822 179.94 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 243' ' ' HIS . . . . . . . . . . . . . 26.3 p80 -148.71 -11.56 0.34 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.05 -0.523 . . . . 0.0 110.907 -179.949 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 244' ' ' HIS . . . . . . . . . . . . . 13.1 p80 -82.33 136.84 34.94 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.055 -0.52 . . . . 0.0 110.963 -179.941 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 245' ' ' HIS . . . . . . . . . . . . . 47.8 m80 58.81 -176.11 0.09 Allowed 'General case' 0 C--N 1.332 -0.186 0 CA-C-N 116.074 -0.512 . . . . 0.0 111.077 179.957 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 246' ' ' HIS . . . . . . . . . . . . . 36.5 m-70 -74.87 -50.11 18.12 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.057 179.978 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 247' ' ' HIS . . . . . . . . . . . . . 7.9 p80 . . . . . 0 C--O 1.248 1.021 0 CA-C-O 118.106 -0.949 . . . . 0.0 111.105 -179.847 . . . . . . . . 0 0 . 1 . 029 nuclear nobuild full ' A' A ' 301' ' ' RET . . . . . 0.796 H203 ' HE1' ' A' ' 171' ' ' TRP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 80.2 mtp . . . . . 0 N--CA 1.485 1.277 0 CA-C-O 120.651 0.263 . . . . 0.0 110.808 . . . . . . . . . 0 0 . 1 . 030 nuclear nobuild full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 30.2 m -119.64 -29.56 1.8 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.373 -0.376 . . . . 0.0 111.22 -179.876 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -84.39 -25.84 41.87 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.481 179.926 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 55.3 tp -74.26 -35.84 63.82 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.904 0.383 . . . . 0.0 110.801 179.785 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 68.3 p -64.22 -29.67 70.76 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 115.935 -0.575 . . . . 0.0 111.569 -179.74 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 29.9 p -52.8 -38.07 60.67 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.601 -179.52 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 7' ' ' LEU . . . . . 0.498 HD12 ' HA ' ' A' ' 195' ' ' ALA . 3.4 mm? -59.4 -53.27 60.09 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.475 -0.33 . . . . 0.0 110.84 -179.798 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 8' ' ' PHE . . . . . 0.444 ' O ' ' HB3' ' A' ' 51' ' ' TYR . 73.9 m-85 -58.43 -36.2 73.28 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.594 179.879 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 9' ' ' TRP . . . . . . . . . . . . . 25.4 m95 -64.94 -41.03 95.87 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-O 121.161 0.505 . . . . 0.0 110.151 179.825 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 83.1 mt -62.35 -49.51 75.3 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 115.562 -0.744 . . . . 0.0 110.519 179.512 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -55.21 -34.81 59.19 Favored Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.683 -0.77 . . . . 0.0 111.999 179.291 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -67.86 -36.23 79.94 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-O 120.795 0.331 . . . . 0.0 110.847 179.745 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 91.1 mt -60.28 -54.16 38.79 Favored 'Isoleucine or valine' 0 C--O 1.234 0.241 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.668 179.556 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -63.02 -30.64 78.1 Favored Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 120.688 -0.768 . . . . 0.0 111.871 179.478 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 15' ' ' MET . . . . . 0.617 ' HB3' ' HB2' ' A' ' 48' ' ' ALA . 0.0 OUTLIER -64.46 -48.93 73.42 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.666 0.27 . . . . 0.0 110.835 179.656 . . . . . . . . 3 3 . 1 . 030 nuclear nobuild full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -57.7 -41.3 81.42 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.334 -0.393 . . . . 0.0 110.94 179.73 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 96.5 t -59.33 -42.57 87.73 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.25 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.554 179.503 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -70.44 -46.73 46.88 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.845 -0.693 . . . . 0.0 112.1 179.588 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 20.5 m -49.5 -45.39 47.03 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-O 120.78 0.324 . . . . 0.0 111.134 -179.755 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 68.3 mt -71.51 -36.74 71.17 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.099 179.618 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -64.09 -31.85 73.19 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.316 -0.402 . . . . 0.0 111.537 -179.801 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 22' ' ' PHE . . . . . 0.714 ' HB2' HG22 ' A' ' 41' ' ' VAL . 7.5 m-85 -90.28 -28.4 18.82 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-O 120.813 0.34 . . . . 0.0 110.939 -179.688 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -72.28 -50.56 26.17 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.176 -0.465 . . . . 0.0 111.288 -179.784 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 24' ' ' TRP . . . . . . . . . . . . . 5.5 t-105 -64.73 -40.07 94.7 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-N 115.73 -0.668 . . . . 0.0 111.195 -179.641 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -80.42 -22.32 41.33 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 120.855 0.36 . . . . 0.0 110.936 179.622 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -73.64 -43.65 35.43 Favored Glycine 0 C--N 1.332 0.334 0 C-N-CA 120.928 -0.653 . . . . 0.0 112.485 179.926 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 82.7 mtp180 -60.71 -20.8 61.97 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-O 120.897 0.379 . . . . 0.0 110.627 179.835 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 23.9 t70 -114.43 92.57 4.0 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.017 -0.538 . . . . 0.0 110.746 179.823 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -163.03 -171.46 2.67 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.139 -179.862 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -72.97 -121.03 0.07 OUTLIER Glycine 0 N--CA 1.452 -0.263 0 C-N-CA 120.863 -0.684 . . . . 0.0 112.487 179.983 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 50.9 m -134.06 -48.72 0.8 Allowed 'General case' 0 C--N 1.33 -0.249 0 CA-C-O 120.819 0.342 . . . . 0.0 110.844 -179.968 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -75.81 -35.95 43.77 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.809 -0.71 . . . . 0.0 112.464 179.896 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 16.7 mm-40 -65.05 -23.67 67.25 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.562 0.22 . . . . 0.0 111.167 -179.891 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 34' ' ' ARG . . . . . . . . . . . . . 52.9 ttt180 -50.85 -30.74 15.27 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.367 -0.379 . . . . 0.0 111.29 -179.716 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 79.7 ttt180 -60.13 -50.69 72.71 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.294 -0.412 . . . . 0.0 111.011 -179.838 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 73.7 m-85 -61.74 -30.47 70.8 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.091 -0.504 . . . . 0.0 111.211 -179.847 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 37' ' ' TYR . . . . . 0.595 ' O ' HG23 ' A' ' 41' ' ' VAL . 64.0 m-85 -70.88 -54.08 12.77 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.281 -0.418 . . . . 0.0 111.141 -179.805 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 61.8 t -56.99 -38.45 60.0 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.223 0 CA-C-O 120.959 0.409 . . . . 0.0 110.654 179.86 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 20.5 m -65.39 -51.18 62.15 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 115.832 -0.622 . . . . 0.0 110.864 179.645 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 40' ' ' LEU . . . . . 0.561 HD12 HD12 ' A' ' 43' ' ' ILE . 38.0 tp -56.98 -46.84 81.95 Favored 'General case' 0 C--O 1.236 0.343 0 CA-C-N 115.894 -0.593 . . . . 0.0 110.578 179.721 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . 0.714 HG22 ' HB2' ' A' ' 22' ' ' PHE . 62.9 t -60.26 -34.28 56.76 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.326 0 CA-C-N 115.857 -0.61 . . . . 0.0 110.3 179.083 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -61.27 -39.3 97.01 Favored Glycine 0 N--CA 1.448 -0.539 0 C-N-CA 120.743 -0.742 . . . . 0.0 111.988 179.925 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 43' ' ' ILE . . . . . 0.561 HD12 HD12 ' A' ' 40' ' ' LEU . 0.7 OUTLIER -65.13 -56.59 14.87 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.223 0 CA-C-O 120.827 0.346 . . . . 0.0 110.998 179.797 . . . . . . . . 3 3 . 1 . 030 nuclear nobuild full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 36.3 t -57.24 -27.6 62.17 Favored 'General case' 0 C--N 1.332 -0.156 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.431 -179.747 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -76.2 -53.57 5.59 Favored Glycine 0 CA--C 1.519 0.342 0 C-N-CA 120.664 -0.779 . . . . 0.0 113.327 -179.288 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 19.7 pt -58.34 -40.03 76.5 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.168 0 CA-C-O 120.738 0.304 . . . . 0.0 111.522 -179.418 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 47' ' ' ALA . . . . . 0.695 ' HB2' ' HE2' ' A' ' 205' ' ' LYS . . . -67.44 -43.67 80.56 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-N 116.436 -0.347 . . . . 0.0 111.364 179.603 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 48' ' ' ALA . . . . . 0.617 ' HB2' ' HB3' ' A' ' 15' ' ' MET . . . -55.1 -43.76 74.32 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.079 -0.51 . . . . 0.0 111.831 -179.423 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 28.4 m -73.8 -33.89 38.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.454 -0.339 . . . . 0.0 111.503 -179.428 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -65.35 -38.54 90.39 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-O 120.927 0.394 . . . . 0.0 111.148 179.74 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 51' ' ' TYR . . . . . 0.557 ' HE2' ' HE2' ' A' ' 15' ' ' MET . 29.0 m-85 -73.06 -35.56 66.71 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 116.132 -0.486 . . . . 0.0 110.756 -179.736 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -63.9 -42.22 97.51 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.291 -0.413 . . . . 0.0 110.938 179.263 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 53' ' ' VAL . . . . . 0.429 HG23 ' N ' ' A' ' 54' ' ' MET . 21.7 m -74.87 -45.1 44.41 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.177 0 CA-C-N 116.271 -0.422 . . . . 0.0 111.42 -179.981 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 54' ' ' MET . . . . . 0.429 ' N ' HG23 ' A' ' 53' ' ' VAL . 70.6 mtm -62.74 -32.01 73.05 Favored 'General case' 0 C--N 1.332 -0.174 0 CA-C-O 120.952 0.406 . . . . 0.0 110.296 179.572 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -63.02 -18.05 62.9 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 115.772 -0.649 . . . . 0.0 111.01 179.476 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 81.8 mt -99.14 -9.16 24.15 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 115.998 -0.546 . . . . 0.0 110.933 179.771 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 73.59 31.1 61.1 Favored Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.809 -0.71 . . . . 0.0 112.96 179.784 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 58' ' ' VAL . . . . . 0.418 HG22 ' O ' ' A' ' 53' ' ' VAL . 32.6 m -81.24 14.5 0.45 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-O 120.907 0.384 . . . . 0.0 111.525 179.893 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -151.85 10.27 0.67 Allowed Glycine 0 N--CA 1.45 -0.389 0 C-N-CA 120.882 -0.675 . . . . 0.0 112.734 179.938 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 60' ' ' TRP . . . . . . . . . . . . . 38.4 m0 -78.33 109.52 12.54 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.631 0.253 . . . . 0.0 110.573 179.842 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 61' ' ' VAL . . . . . . . . . . . . . 7.6 p -102.32 130.75 23.53 Favored Pre-proline 0 C--N 1.329 -0.294 0 CA-C-N 116.431 -0.35 . . . . 0.0 111.255 -179.723 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 7.8 Cg_exo -72.87 144.14 38.18 Favored 'Trans proline' 0 C--N 1.35 0.622 0 C-N-CA 122.675 2.25 . . . . 0.0 112.383 -179.851 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 85.9 t -143.85 96.29 0.53 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.201 0 CA-C-N 115.993 -0.549 . . . . 0.0 111.031 179.968 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . 60.58 -86.15 0.02 OUTLIER 'General case' 0 C--N 1.333 -0.122 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.223 -179.902 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 11.4 tp10 -124.66 -23.93 4.27 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-O 120.927 0.394 . . . . 0.0 110.38 179.793 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 66' ' ' ARG . . . . . . . . . . . . . 96.9 mtt180 -103.13 153.41 20.34 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 115.809 -0.632 . . . . 0.0 110.4 179.739 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 91.2 m -111.94 119.34 38.19 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-O 120.952 0.406 . . . . 0.0 111.671 -179.336 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 68' ' ' VAL . . . . . 0.582 HG11 ' HG3' ' A' ' 117' ' ' MET . 42.4 t -90.52 147.03 5.49 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-N 115.938 -0.574 . . . . 0.0 110.401 179.224 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 69' ' ' PHE . . . . . . . . . . . . . 21.9 m-85 -105.11 114.55 28.82 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-O 121.008 0.432 . . . . 0.0 110.247 -179.367 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 70' ' ' VAL . . . . . 0.54 ' HB ' ' HD3' ' A' ' 71' ' ' PRO . 13.6 t -68.83 -50.09 24.66 Favored Pre-proline 0 C--N 1.325 -0.486 0 CA-C-N 115.937 -0.574 . . . . 0.0 112.471 -178.856 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 71' ' ' PRO . . . . . 0.54 ' HD3' ' HB ' ' A' ' 70' ' ' VAL . 16.4 Cg_exo -66.57 -17.84 53.47 Favored 'Trans proline' 0 C--N 1.351 0.671 0 C-N-CA 122.252 1.968 . . . . 0.0 112.698 -179.304 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 72' ' ' ARG . . . . . 0.417 ' NH2' HG13 ' A' ' 197' ' ' ILE . 66.2 ttt180 -66.25 -55.31 16.76 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-O 120.866 0.365 . . . . 0.0 111.539 -179.346 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 73' ' ' TYR . . . . . 0.473 ' O ' HG13 ' A' ' 77' ' ' ILE . 77.7 m-85 -71.59 -33.76 69.31 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.38 -0.373 . . . . 0.0 110.687 -179.492 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 74' ' ' ILE . . . . . 0.487 ' HA ' HD12 ' A' ' 77' ' ' ILE . 0.4 OUTLIER -67.51 -36.84 77.55 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.2 0 N-CA-C 109.768 -0.456 . . . . 0.0 109.768 179.106 . . . . . . . . 3 3 . 1 . 030 nuclear nobuild full ' A' A ' 75' ' ' ASP . . . . . 0.402 ' O ' HG23 ' A' ' 79' ' ' THR . 24.0 t70 -60.52 -38.51 84.65 Favored 'General case' 0 CA--C 1.519 -0.219 0 N-CA-C 108.959 -0.756 . . . . 0.0 108.959 178.506 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 76' ' ' TRP . . . . . . . . . . . . . 37.5 m0 -66.72 -30.86 71.2 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 115.438 -0.801 . . . . 0.0 110.468 179.193 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 77' ' ' ILE . . . . . 0.487 HD12 ' HA ' ' A' ' 74' ' ' ILE . 82.3 mt -68.58 -31.11 49.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-O 121.017 0.437 . . . . 0.0 110.554 179.241 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 34.4 mt -91.51 -17.55 25.51 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.11 -0.495 . . . . 0.0 112.137 -179.889 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 79' ' ' THR . . . . . 0.402 HG23 ' O ' ' A' ' 75' ' ' ASP . 72.7 p -102.32 -52.77 3.05 Favored 'General case' 0 N--CA 1.464 0.27 0 N-CA-C 113.417 0.895 . . . . 0.0 113.417 -178.238 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 80' ' ' THR . . . . . 0.695 ' HB ' ' HD3' ' A' ' 81' ' ' PRO . 49.8 m -52.39 -56.01 26.49 Favored Pre-proline 0 CA--C 1.532 0.251 0 N-CA-C 112.643 0.608 . . . . 0.0 112.643 -178.306 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 81' ' ' PRO . . . . . 0.695 ' HD3' ' HB ' ' A' ' 80' ' ' THR . 38.8 Cg_exo -58.98 -21.1 56.68 Favored 'Trans proline' 0 C--N 1.351 0.69 0 C-N-CA 121.507 1.471 . . . . 0.0 111.478 -179.942 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 82' ' ' LEU . . . . . . . . . . . . . 15.2 tp -77.03 -33.12 57.42 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 115.699 -0.682 . . . . 0.0 110.328 179.695 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 83' ' ' ILE . . . . . 0.427 HD11 HG21 ' A' ' 43' ' ' ILE . 49.1 mm -69.64 -51.86 37.36 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.166 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.232 179.25 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 35.5 m -61.1 -31.05 48.99 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.227 0 N-CA-C 109.407 -0.59 . . . . 0.0 109.407 178.706 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 85' ' ' TYR . . . . . . . . . . . . . 89.9 t80 -64.43 -34.7 78.79 Favored 'General case' 0 N--CA 1.454 -0.269 0 CA-C-N 115.472 -0.786 . . . . 0.0 109.427 178.601 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 86' ' ' PHE . . . . . . . . . . . . . 12.0 t80 -62.97 -49.6 74.06 Favored 'General case' 0 C--O 1.232 0.146 0 CA-C-N 115.765 -0.652 . . . . 0.0 110.01 179.136 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 87' ' ' LEU . . . . . 0.562 HD12 HD22 ' A' ' 141' ' ' LEU . 5.3 mt -63.59 -33.06 74.78 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 115.733 -0.667 . . . . 0.0 109.852 179.839 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -66.67 -27.52 73.28 Favored Glycine 0 N--CA 1.449 -0.474 0 CA-C-N 115.377 -0.829 . . . . 0.0 111.555 179.251 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 61.9 mt -74.58 -43.78 54.02 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.763 0.316 . . . . 0.0 111.032 179.89 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 82.6 mt -60.47 -32.34 71.31 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.123 -0.489 . . . . 0.0 111.216 -179.94 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -83.83 -54.14 5.1 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.309 -0.405 . . . . 0.0 111.424 -179.732 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 103.93 68.32 0.76 Allowed Glycine 0 N--CA 1.45 -0.369 0 C-N-CA 120.808 -0.71 . . . . 0.0 112.491 -179.706 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 93' ' ' LEU . . . . . 0.577 HD23 ' HB3' ' A' ' 97' ' ' GLU . 6.5 mp -91.23 164.77 13.77 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.712 0.291 . . . . 0.0 110.733 -179.933 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 94' ' ' ASP . . . . . . . . . . . . . 1.8 p30 -87.82 177.43 7.0 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.356 -0.384 . . . . 0.0 110.915 179.807 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 48.1 t -60.39 -32.16 71.04 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.027 -0.533 . . . . 0.0 111.881 -179.418 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 38.8 mmt180 -73.31 -53.31 11.12 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.55 -0.295 . . . . 0.0 111.62 -179.332 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 97' ' ' GLU . . . . . 0.577 ' HB3' HD23 ' A' ' 93' ' ' LEU . 44.0 mt-10 -53.3 -47.25 69.38 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.314 -0.403 . . . . 0.0 111.388 -179.671 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 98' ' ' PHE . . . . . 0.45 ' O ' HG12 ' A' ' 102' ' ' ILE . 12.6 m-85 -58.29 -49.86 75.65 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.373 -0.376 . . . . 0.0 110.876 179.975 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -54.88 -30.45 53.18 Favored Glycine 0 CA--C 1.518 0.255 0 C-N-CA 120.751 -0.737 . . . . 0.0 112.776 -179.81 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 96.3 mt -73.95 -45.53 48.72 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.214 0 CA-C-O 120.841 0.353 . . . . 0.0 111.622 -179.708 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 47.6 t -65.95 -46.74 87.52 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.411 0 CA-C-N 116.147 -0.478 . . . . 0.0 111.91 -179.161 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 102' ' ' ILE . . . . . 0.45 HG12 ' O ' ' A' ' 98' ' ' PHE . 37.6 mm -63.17 -51.77 67.19 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 N-CA-C 111.905 0.335 . . . . 0.0 111.905 -179.101 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 15.2 t -55.95 -36.72 68.1 Favored 'General case' 0 C--O 1.234 0.248 0 CA-C-O 120.869 0.366 . . . . 0.0 110.952 -179.61 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 104' ' ' LEU . . . . . 0.49 ' O ' HG23 ' A' ' 108' ' ' VAL . 29.7 tp -61.37 -47.73 84.5 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.06 -0.518 . . . . 0.0 110.683 179.464 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 105' ' ' ASN . . . . . 0.61 ' N ' HD22 ' A' ' 105' ' ' ASN . 0.8 OUTLIER -61.55 -26.33 67.87 Favored 'General case' 0 C--N 1.326 -0.438 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.745 179.848 . . . . . . . . 3 3 . 1 . 030 nuclear nobuild full ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 66.2 m -66.46 -57.3 7.65 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 116.374 -0.375 . . . . 0.0 111.331 -179.926 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 107' ' ' VAL . . . . . 0.404 HG12 ' O ' ' A' ' 104' ' ' LEU . 9.1 p -58.27 -36.57 58.51 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.142 0 CA-C-O 120.727 0.298 . . . . 0.0 111.114 -179.881 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . 0.49 HG23 ' O ' ' A' ' 104' ' ' LEU . 68.3 t -57.84 -49.58 80.52 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.372 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.519 179.513 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 109' ' ' MET . . . . . 0.453 ' HG2' ' O ' ' A' ' 105' ' ' ASN . 20.6 mmt -64.35 -30.4 71.44 Favored 'General case' 0 CA--C 1.519 -0.248 0 CA-C-N 115.868 -0.605 . . . . 0.0 110.666 179.707 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 19.4 tp -66.34 -35.61 80.8 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.069 179.555 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -64.31 -51.38 63.76 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 115.903 -0.59 . . . . 0.0 110.601 179.462 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 112' ' ' GLY . . . . . 0.513 ' HA3' ' H21' ' A' ' 301' ' ' RET . . . -66.96 -37.33 92.07 Favored Glycine 0 C--N 1.331 0.262 0 C-N-CA 120.576 -0.821 . . . . 0.0 111.861 179.478 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 113' ' ' PHE . . . . . 0.424 ' HB2' ' O ' ' A' ' 109' ' ' MET . 1.0 OUTLIER -51.02 -70.03 0.1 Allowed 'General case' 0 C--N 1.332 -0.161 0 CA-C-O 121.05 0.452 . . . . 0.0 110.02 179.541 . . . . . . . . 3 3 . 1 . 030 nuclear nobuild full ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -67.43 -19.89 65.43 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 115.663 -0.699 . . . . 0.0 110.748 179.407 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 115' ' ' GLY . . . . . 0.479 ' HA2' HD22 ' A' ' 126' ' ' LEU . . . -53.67 -44.43 69.09 Favored Glycine 0 C--N 1.334 0.441 0 C-N-CA 120.915 -0.659 . . . . 0.0 111.8 179.533 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 116' ' ' ALA . . . . . . . . . . . . . . . -78.49 -28.46 46.4 Favored 'General case' 0 C--N 1.327 -0.41 0 N-CA-C 111.639 0.237 . . . . 0.0 111.639 179.741 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 117' ' ' MET . . . . . 0.582 ' HG3' HG11 ' A' ' 68' ' ' VAL . 62.9 mtt -86.08 11.37 11.89 Favored 'General case' 0 N--CA 1.463 0.224 0 N-CA-C 112.16 0.429 . . . . 0.0 112.16 -179.162 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 118' ' ' VAL . . . . . 0.495 HG21 ' HB3' ' A' ' 123' ' ' ARG . 29.9 m -63.64 146.06 96.99 Favored Pre-proline 0 C--N 1.327 -0.374 0 C-N-CA 121.037 -0.265 . . . . 0.0 111.081 179.845 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 119' ' ' PRO . . . . . . . . . . . . . 92.0 Cg_endo -81.99 -4.59 12.01 Favored 'Trans proline' 0 C--N 1.347 0.478 0 C-N-CA 122.534 2.156 . . . . 0.0 112.25 179.821 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -156.43 -132.1 1.46 Allowed Glycine 0 C--N 1.331 0.293 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.735 -179.982 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 2.0 pp -100.31 22.46 1.58 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-O 120.838 0.352 . . . . 0.0 111.265 -179.833 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 10.8 mm-40 -70.72 -19.27 62.76 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.846 179.942 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 123' ' ' ARG . . . . . 0.495 ' HB3' HG21 ' A' ' 118' ' ' VAL . 12.7 ptt180 -50.55 -31.0 14.42 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 115.923 -0.58 . . . . 0.0 111.907 -179.67 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 124' ' ' TYR . . . . . . . . . . . . . 40.2 m-85 -65.13 -35.61 81.65 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.675 0.274 . . . . 0.0 110.919 -179.629 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 125' ' ' ALA . . . . . . . . . . . . . . . -72.74 -51.08 20.64 Favored 'General case' 0 C--O 1.235 0.311 0 CA-C-O 120.849 0.357 . . . . 0.0 110.604 179.248 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 126' ' ' LEU . . . . . 0.479 HD22 ' HA2' ' A' ' 115' ' ' GLY . 7.0 mp -51.55 -52.39 47.52 Favored 'General case' 0 CA--C 1.52 -0.191 0 CA-C-N 116.005 -0.543 . . . . 0.0 110.135 179.488 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 127' ' ' PHE . . . . . 0.464 ' HZ ' ' HB3' ' A' ' 175' ' ' PRO . 8.7 t80 -63.93 -35.79 81.82 Favored 'General case' 0 N--CA 1.451 -0.419 0 CA-C-N 115.848 -0.615 . . . . 0.0 110.533 179.523 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 128' ' ' GLY . . . . . . . . . . . . . . . -46.22 -45.51 15.62 Favored Glycine 0 C--N 1.333 0.38 0 C-N-CA 120.195 -1.002 . . . . 0.0 110.86 179.027 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 129' ' ' MET . . . . . . . . . . . . . 0.6 OUTLIER -69.47 -39.36 77.76 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 115.319 -0.441 . . . . 0.0 109.977 178.586 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -65.15 -27.89 72.89 Favored Glycine 0 C--N 1.331 0.299 0 CA-C-N 115.783 -0.644 . . . . 0.0 112.995 -179.842 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -74.61 -54.01 8.27 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.615 0.245 . . . . 0.0 110.406 -179.964 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 47.2 t -55.83 -40.54 62.31 Favored 'Isoleucine or valine' 0 C--O 1.234 0.241 0 CA-C-O 121.459 0.647 . . . . 0.0 109.285 178.786 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 133' ' ' ALA . . . . . . . . . . . . . . . -69.1 -37.8 78.61 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 115.117 -0.947 . . . . 0.0 110.613 179.41 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 134' ' ' PHE . . . . . 0.428 ' CZ ' ' HA ' ' A' ' 172' ' ' ALA . 45.3 t80 -55.45 -52.71 62.72 Favored 'General case' 0 N--CA 1.45 -0.429 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.263 179.748 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 135' ' ' ILE . . . . . . . . . . . . . 43.7 mt -59.58 -32.75 49.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 115.915 -0.584 . . . . 0.0 109.935 179.308 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . -59.43 -40.45 96.14 Favored Glycine 0 N--CA 1.448 -0.535 0 C-N-CA 120.298 -0.954 . . . . 0.0 111.45 178.926 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 137' ' ' LEU . . . . . 0.442 HD13 HD21 ' A' ' 105' ' ' ASN . 22.4 tp -65.87 -53.07 44.5 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-O 120.683 0.277 . . . . 0.0 110.616 179.617 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 138' ' ' VAL . . . . . . . . . . . . . 13.1 t -55.48 -37.48 45.39 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.836 0 CA-C-O 121.114 0.483 . . . . 0.0 110.131 179.183 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 139' ' ' TYR . . . . . . . . . . . . . 29.9 t80 -57.84 -43.22 85.71 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 115.43 -0.805 . . . . 0.0 110.738 179.024 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 28.7 m-85 -64.17 -41.6 97.07 Favored 'General case' 0 C--N 1.332 -0.156 0 CA-C-N 116.406 -0.361 . . . . 0.0 111.467 -179.978 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 141' ' ' LEU . . . . . 0.562 HD22 HD12 ' A' ' 87' ' ' LEU . 95.4 mt -56.24 -50.34 71.59 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 116.42 -0.355 . . . . 0.0 111.143 -179.761 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 142' ' ' VAL . . . . . 0.558 HG23 HH12 ' A' ' 164' ' ' ARG . 7.7 p -83.78 -9.02 11.48 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.369 0 CA-C-O 121.153 0.501 . . . . 0.0 110.59 179.956 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 143' ' ' GLY . . . . . 0.426 ' O ' HG22 ' A' ' 146' ' ' THR . . . -73.34 -141.18 0.5 Allowed Glycine 0 CA--C 1.521 0.452 0 C-N-CA 120.881 -0.676 . . . . 0.0 112.579 179.929 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 144' ' ' PRO . . . . . . . . . . . . . 52.2 Cg_exo -54.69 -23.24 32.09 Favored 'Trans proline' 0 C--N 1.349 0.564 0 C-N-CA 122.588 2.192 . . . . 0.0 112.75 179.971 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 145' ' ' MET . . . . . . . . . . . . . 37.2 mtt -52.81 -59.22 4.76 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.479 -0.328 . . . . 0.0 111.831 -179.641 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 146' ' ' THR . . . . . 0.426 HG22 ' O ' ' A' ' 143' ' ' GLY . 11.0 t -61.04 -31.71 71.35 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.423 -0.353 . . . . 0.0 111.588 -179.476 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 29.2 mm-40 -65.13 -44.0 90.11 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 120.839 0.352 . . . . 0.0 111.223 -179.942 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 148' ' ' SER . . . . . . . . . . . . . 80.0 p -70.24 -42.28 72.43 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.236 -179.32 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 149' ' ' ALA . . . . . . . . . . . . . . . -65.34 -40.42 93.62 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.377 -179.747 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 150' ' ' SER . . . . . 0.464 ' HA ' ' HB2' ' A' ' 157' ' ' LYS . 83.6 p -68.21 -6.8 25.51 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.784 -179.913 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 151' ' ' GLN . . . . . . . . . . . . . 63.3 mt-30 -110.48 -7.54 14.74 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.119 -0.492 . . . . 0.0 110.914 179.883 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 78.3 ttt180 -75.06 -52.47 10.96 Favored 'General case' 0 C--N 1.332 -0.193 0 CA-C-N 116.443 -0.344 . . . . 0.0 110.831 -179.883 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 153' ' ' SER . . . . . 0.643 ' HB3' HG12 ' A' ' 156' ' ' ILE . 22.8 t -158.04 170.62 21.88 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.667 179.238 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 154' ' ' SER . . . . . . . . . . . . . 51.3 m -70.22 -37.62 75.07 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.288 -0.415 . . . . 0.0 110.392 179.382 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -77.0 -39.0 28.88 Favored Glycine 0 CA--C 1.519 0.298 0 C-N-CA 120.984 -0.627 . . . . 0.0 112.674 179.821 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 156' ' ' ILE . . . . . 0.643 HG12 ' HB3' ' A' ' 153' ' ' SER . 39.6 mm -52.88 -35.65 22.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-O 120.922 0.392 . . . . 0.0 111.315 -179.81 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 157' ' ' LYS . . . . . 0.464 ' HB2' ' HA ' ' A' ' 150' ' ' SER . 86.4 tttt -69.83 -37.23 76.13 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 115.967 -0.561 . . . . 0.0 112.028 -179.436 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 67.6 p -72.05 -45.0 62.46 Favored 'General case' 0 C--N 1.331 -0.205 0 CA-C-O 120.784 0.326 . . . . 0.0 111.601 -178.719 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 159' ' ' LEU . . . . . . . . . . . . . 10.0 mt -67.05 -46.26 74.92 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.632 -179.078 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 160' ' ' TYR . . . . . . . . . . . . . 55.1 t80 -61.58 -37.82 85.27 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.509 -0.314 . . . . 0.0 111.26 -179.468 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 161' ' ' VAL . . . . . 0.515 HG12 ' N ' ' A' ' 162' ' ' ARG . 1.2 t -63.23 -50.49 78.86 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.747 0 CA-C-N 116.529 -0.305 . . . . 0.0 111.64 -179.487 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 162' ' ' ARG . . . . . 0.515 ' N ' HG12 ' A' ' 161' ' ' VAL . 22.9 tpp180 -69.1 -34.86 75.76 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.44 -0.345 . . . . 0.0 111.439 -179.446 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 163' ' ' LEU . . . . . 0.576 ' HG ' ' HB2' ' A' ' 208' ' ' PHE . 3.2 mp -69.5 -45.02 69.89 Favored 'General case' 0 C--N 1.328 -0.37 0 CA-C-N 116.27 -0.423 . . . . 0.0 111.604 -179.408 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 164' ' ' ARG . . . . . 0.59 ' HE ' HD21 ' A' ' 165' ' ' ASN . 0.1 OUTLIER -71.95 -41.07 68.23 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.557 -0.292 . . . . 0.0 111.308 -179.125 . . . . . . . . 3 3 . 1 . 030 nuclear nobuild full ' A' A ' 165' ' ' ASN . . . . . 0.59 HD21 ' HE ' ' A' ' 164' ' ' ARG . 0.9 OUTLIER -57.25 -50.88 71.49 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.795 0.331 . . . . 0.0 111.05 179.953 . . . . . . . . 3 3 . 1 . 030 nuclear nobuild full ' A' A ' 166' ' ' LEU . . . . . . . . . . . . . 3.8 tt -64.17 -54.59 31.32 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.109 -0.496 . . . . 0.0 111.548 -179.47 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 167' ' ' THR . . . . . 0.416 ' O ' ' HB2' ' A' ' 171' ' ' TRP . 76.5 m -54.81 -53.13 59.21 Favored 'General case' 0 C--N 1.33 -0.277 0 N-CA-C 112.263 0.468 . . . . 0.0 112.263 -179.158 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 168' ' ' VAL . . . . . . . . . . . . . 55.1 t -55.06 -44.93 76.45 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.218 0 N-CA-C 112.328 0.492 . . . . 0.0 112.328 -178.999 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 169' ' ' VAL . . . . . 0.48 HG23 ' O ' ' A' ' 165' ' ' ASN . 43.9 t -55.91 -64.32 0.5 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-O 120.555 0.217 . . . . 0.0 111.544 -179.362 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 170' ' ' LEU . . . . . 0.555 HD12 ' HD1' ' A' ' 171' ' ' TRP . 1.1 pp -63.41 -28.56 70.06 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.661 -0.245 . . . . 0.0 111.642 -179.39 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 171' ' ' TRP . . . . . 0.645 ' HE1' H203 ' A' ' 301' ' ' RET . 3.5 m0 -70.54 -32.11 69.43 Favored 'General case' 0 C--N 1.333 -0.152 0 CA-C-O 120.998 0.427 . . . . 0.0 110.413 179.418 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 172' ' ' ALA . . . . . 0.428 ' HA ' ' CZ ' ' A' ' 134' ' ' PHE . . . -72.19 -6.68 44.53 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-N 115.822 -0.626 . . . . 0.0 111.102 -179.624 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 173' ' ' ILE . . . . . 0.555 ' O ' HG12 ' A' ' 177' ' ' ILE . 23.8 mm -87.54 -22.57 6.82 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.244 0 CA-C-N 116.083 -0.508 . . . . 0.0 111.17 179.925 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 174' ' ' TYR . . . . . 0.465 ' HB2' ' HD3' ' A' ' 175' ' ' PRO . 30.9 m-85 -53.79 -49.25 90.25 Favored Pre-proline 0 N--CA 1.464 0.265 0 CA-C-N 116.567 -0.288 . . . . 0.0 111.638 -179.537 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 175' ' ' PRO . . . . . 0.465 ' HD3' ' HB2' ' A' ' 174' ' ' TYR . 86.5 Cg_exo -47.73 -32.97 17.83 Favored 'Trans proline' 0 C--N 1.351 0.677 0 C-N-CA 122.134 1.89 . . . . 0.0 112.164 179.523 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 176' ' ' PHE . . . . . 0.518 ' O ' ' HG ' ' A' ' 180' ' ' LEU . 88.2 m-85 -80.62 -50.36 10.06 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 115.911 -0.586 . . . . 0.0 112.18 -179.531 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 177' ' ' ILE . . . . . 0.555 HG12 ' O ' ' A' ' 173' ' ' ILE . 6.2 mm -60.22 -39.58 81.09 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.548 0 N-CA-C 112.609 0.596 . . . . 0.0 112.609 -177.777 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 178' ' ' TRP . . . . . 0.492 ' HH2' ' HB2' ' A' ' 123' ' ' ARG . 78.4 t90 -67.37 -39.3 85.68 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 120.721 0.296 . . . . 0.0 111.157 -179.669 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 179' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -77.88 -52.89 8.14 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 116.462 -0.335 . . . . 0.0 111.879 -179.01 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 180' ' ' LEU . . . . . 0.717 HD22 HD11 ' A' ' 187' ' ' LEU . 39.8 mt -61.66 -51.7 67.38 Favored 'General case' 0 C--N 1.328 -0.362 0 N-CA-C 111.699 0.259 . . . . 0.0 111.699 -179.114 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 181' ' ' GLY . . . . . 0.437 ' HA3' ' OD1' ' A' ' 193' ' ' ASP . . . -57.03 179.16 0.71 Allowed Glycine 0 C--N 1.336 0.557 0 C-N-CA 120.413 -0.898 . . . . 0.0 112.92 -179.883 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 182' ' ' PRO . . . . . 0.628 ' N ' ' HD2' ' A' ' 183' ' ' PRO . 80.8 Cg_exo -44.06 -46.56 11.04 Favored 'Trans proline' 0 C--N 1.35 0.654 0 C-N-CA 122.925 2.417 . . . . 0.0 113.915 179.865 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 183' ' ' PRO . . . . . 0.628 ' HD2' ' N ' ' A' ' 182' ' ' PRO . 1.0 OUTLIER -44.28 -30.44 3.61 Favored 'Trans proline' 0 C--N 1.358 1.062 0 C-N-CA 122.497 2.131 . . . . 0.0 113.172 -179.758 . . . . . . . . 3 3 . 1 . 030 nuclear nobuild full ' A' A ' 184' ' ' GLY . . . . . 0.451 ' HA2' ' HD2' ' A' ' 123' ' ' ARG . . . -117.73 -120.75 3.08 Favored Glycine 0 C--N 1.332 0.326 0 C-N-CA 120.392 -0.908 . . . . 0.0 113.19 179.89 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 185' ' ' VAL . . . . . . . . . . . . . 22.6 m -64.92 -16.77 20.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 N-CA-C 112.264 0.468 . . . . 0.0 112.264 -179.405 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 186' ' ' ALA . . . . . 0.487 ' HB2' ' HA ' ' A' ' 182' ' ' PRO . . . 55.51 88.75 0.04 OUTLIER 'General case' 0 C--N 1.332 -0.17 0 CA-C-O 120.872 0.368 . . . . 0.0 111.266 -179.899 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 187' ' ' LEU . . . . . 0.717 HD11 HD22 ' A' ' 180' ' ' LEU . 19.5 mt -91.8 -33.06 15.12 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.391 -179.603 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 188' ' ' LEU . . . . . 0.58 HD13 ' N ' ' A' ' 188' ' ' LEU . 0.0 OUTLIER -134.27 -162.07 1.21 Allowed 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.868 0.366 . . . . 0.0 111.501 -179.494 . . . . . . . . 3 3 . 1 . 030 nuclear nobuild full ' A' A ' 189' ' ' THR . . . . . . . . . . . . . 3.2 t -86.26 147.48 44.89 Favored Pre-proline 0 C--N 1.33 -0.24 0 CA-C-N 116.045 -0.525 . . . . 0.0 111.969 -178.873 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 190' ' ' PRO . . . . . . . . . . . . . 77.8 Cg_exo -51.02 -35.93 52.27 Favored 'Trans proline' 0 C--N 1.351 0.691 0 C-N-CA 122.581 2.187 . . . . 0.0 112.665 179.708 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 191' ' ' THR . . . . . . . . . . . . . 59.5 p -57.89 -40.8 81.17 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 121.052 0.453 . . . . 0.0 110.753 179.904 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 192' ' ' VAL . . . . . . . . . . . . . 41.4 t -74.96 -52.8 17.94 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-N 115.705 -0.679 . . . . 0.0 111.484 -179.871 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 193' ' ' ASP . . . . . 0.437 ' OD1' ' HA3' ' A' ' 181' ' ' GLY . 25.4 t70 -54.94 -51.93 64.59 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-N 116.31 -0.405 . . . . 0.0 111.142 -179.716 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 194' ' ' VAL . . . . . 0.549 ' O ' HG22 ' A' ' 198' ' ' VAL . 90.8 t -61.41 -36.96 76.45 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.357 0 CA-C-N 115.927 -0.579 . . . . 0.0 111.026 -179.832 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 195' ' ' ALA . . . . . 0.498 ' HA ' HD12 ' A' ' 7' ' ' LEU . . . -52.4 -48.58 65.58 Favored 'General case' 0 C--O 1.234 0.27 0 CA-C-O 120.91 0.386 . . . . 0.0 111.006 179.723 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 196' ' ' LEU . . . . . 0.5 ' O ' ' HB3' ' A' ' 199' ' ' TYR . 98.5 mt -68.3 -39.45 82.04 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 116.432 -0.349 . . . . 0.0 110.448 179.281 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 197' ' ' ILE . . . . . 0.417 HG13 ' NH2' ' A' ' 72' ' ' ARG . 15.5 mm -55.59 -60.36 1.79 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.358 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.178 179.92 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 198' ' ' VAL . . . . . 0.549 HG22 ' O ' ' A' ' 194' ' ' VAL . 3.3 m -52.19 -35.93 20.01 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.424 0 CA-C-O 121.359 0.6 . . . . 0.0 109.902 179.08 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 199' ' ' TYR . . . . . 0.5 ' HB3' ' O ' ' A' ' 196' ' ' LEU . 69.2 t80 -62.15 -47.02 86.41 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-N 115.062 -0.972 . . . . 0.0 110.095 179.224 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 200' ' ' LEU . . . . . 0.504 HD21 ' HB ' ' A' ' 173' ' ' ILE . 5.4 mp -55.78 -38.99 70.63 Favored 'General case' 0 N--CA 1.452 -0.367 0 CA-C-N 115.973 -0.558 . . . . 0.0 111.561 179.097 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 201' ' ' ASP . . . . . . . . . . . . . 16.0 m-20 -74.19 -41.88 60.73 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 121.063 0.458 . . . . 0.0 110.683 -179.974 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 202' ' ' LEU . . . . . 0.402 ' O ' ' HB ' ' A' ' 206' ' ' VAL . 2.2 mt -63.18 -33.33 75.24 Favored 'General case' 0 C--N 1.327 -0.413 0 CA-C-N 115.624 -0.716 . . . . 0.0 111.682 -179.851 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 203' ' ' VAL . . . . . 0.494 HG13 HD13 ' A' ' 170' ' ' LEU . 10.8 p -78.26 -36.29 20.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.815 -0.175 . . . . 0.0 111.329 -178.696 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 204' ' ' THR . . . . . 0.427 ' O ' ' CD1' ' A' ' 208' ' ' PHE . 55.4 m -62.47 -58.64 6.89 Favored 'General case' 0 C--N 1.328 -0.331 0 C-N-CA 120.454 -0.499 . . . . 0.0 111.315 179.761 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 205' ' ' LYS . . . . . 0.695 ' HE2' ' HB2' ' A' ' 47' ' ' ALA . 49.5 mttp -69.07 -58.18 4.43 Favored 'General case' 0 N--CA 1.464 0.241 0 N-CA-C 112.849 0.685 . . . . 0.0 112.849 -177.921 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 206' ' ' VAL . . . . . 0.402 ' HB ' ' O ' ' A' ' 202' ' ' LEU . 26.1 t -68.92 -36.34 73.58 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.444 0 CA-C-N 116.401 -0.363 . . . . 0.0 111.89 -178.706 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 207' ' ' GLY . . . . . 0.569 ' O ' HG13 ' A' ' 211' ' ' ILE . . . -61.66 -60.45 8.13 Favored Glycine 0 N--CA 1.452 -0.273 0 C-N-CA 120.698 -0.763 . . . . 0.0 113.672 -178.619 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 208' ' ' PHE . . . . . 0.576 ' HB2' ' HG ' ' A' ' 163' ' ' LEU . 0.1 OUTLIER -71.58 -25.96 62.41 Favored 'General case' 0 C--O 1.224 -0.258 0 CA-C-N 117.383 0.591 . . . . 0.0 111.319 -178.976 . . . . . . . . 3 3 . 1 . 030 nuclear nobuild full ' A' A ' 209' ' ' GLY . . . . . 0.473 ' O ' ' HB3' ' A' ' 212' ' ' ALA . . . -68.55 -32.4 74.89 Favored Glycine 0 N--CA 1.449 -0.464 0 N-CA-C 111.676 -0.57 . . . . 0.0 111.676 179.077 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 210' ' ' PHE . . . . . . . . . . . . . 0.8 OUTLIER -72.87 -47.39 46.41 Favored 'General case' 0 CA--C 1.514 -0.421 0 N-CA-C 108.107 -1.072 . . . . 0.0 108.107 178.505 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 211' ' ' ILE . . . . . 0.569 HG13 ' O ' ' A' ' 207' ' ' GLY . 4.6 mt -64.85 -27.73 43.14 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.544 0 N-CA-C 107.629 -1.248 . . . . 0.0 107.629 176.677 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 212' ' ' ALA . . . . . 0.473 ' HB3' ' O ' ' A' ' 209' ' ' GLY . . . -63.86 -39.86 95.2 Favored 'General case' 0 N--CA 1.451 -0.412 0 CA-C-N 114.628 -1.169 . . . . 0.0 110.381 179.794 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 213' ' ' LEU . . . . . 0.406 ' HG ' ' O ' ' A' ' 209' ' ' GLY . 92.8 mt -69.72 -54.42 13.84 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 115.215 -0.902 . . . . 0.0 111.252 -179.596 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 214' ' ' ASP . . . . . . . . . . . . . 18.5 m-20 -56.57 -44.94 81.49 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.968 0.413 . . . . 0.0 110.933 -179.819 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 215' ' ' ALA . . . . . 0.446 ' O ' HD23 ' A' ' 219' ' ' LEU . . . -61.0 -58.19 9.47 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.055 -0.52 . . . . 0.0 111.004 179.969 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 216' ' ' ALA . . . . . 0.598 ' HA ' ' HG ' ' A' ' 219' ' ' LEU . . . -55.53 -30.43 60.71 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.84 179.923 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 217' ' ' ALA . . . . . . . . . . . . . . . -61.36 -41.59 97.31 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 115.874 -0.603 . . . . 0.0 109.685 179.525 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 218' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -68.28 -29.68 68.52 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 115.437 -0.801 . . . . 0.0 109.994 178.64 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 219' ' ' LEU . . . . . 0.598 ' HG ' ' HA ' ' A' ' 216' ' ' ALA . 0.2 OUTLIER -66.82 -51.79 51.47 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 115.571 -0.741 . . . . 0.0 110.875 -179.345 . . . . . . . . 3 3 . 1 . 030 nuclear nobuild full ' A' A ' 220' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -71.5 -18.76 62.26 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.41 179.641 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 221' ' ' ALA . . . . . . . . . . . . . . . -77.13 -32.83 56.68 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.082 -0.508 . . . . 0.0 110.796 179.314 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 222' ' ' GLU . . . . . . . . . . . . . 12.8 pt-20 -91.55 -5.1 54.61 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-N 115.975 -0.557 . . . . 0.0 110.64 179.75 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 223' ' ' HIS . . . . . . . . . . . . . 1.1 p80 -35.06 147.65 0.02 OUTLIER 'General case' 0 N--CA 1.466 0.36 0 CA-C-N 115.745 -0.661 . . . . 0.0 112.251 -179.61 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 224' ' ' GLY . . . . . . . . . . . . . . . 169.44 36.9 0.03 OUTLIER Glycine 0 CA--C 1.518 0.23 0 CA-C-N 115.739 -0.664 . . . . 0.0 112.402 179.996 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 225' ' ' GLU . . . . . . . . . . . . . 1.9 mp0 -81.69 139.81 34.7 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.792 0.33 . . . . 0.0 111.215 -179.805 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 226' ' ' SER . . . . . . . . . . . . . 75.1 m 57.74 -171.7 0.1 Allowed 'General case' 0 C--N 1.331 -0.206 0 CA-C-N 116.007 -0.542 . . . . 0.0 111.424 179.72 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 227' ' ' LEU . . . . . . . . . . . . . 50.4 tp -80.44 103.4 10.27 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.08 -0.509 . . . . 0.0 110.892 179.986 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 228' ' ' ALA . . . . . . . . . . . . . . . -142.79 82.59 1.77 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.062 179.869 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 229' ' ' GLY . . . . . . . . . . . . . . . -160.52 136.89 4.72 Favored Glycine 0 N--CA 1.45 -0.373 0 C-N-CA 120.909 -0.662 . . . . 0.0 112.406 179.888 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 230' ' ' VAL . . . . . . . . . . . . . 46.1 t -80.12 134.55 27.25 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.37 0 CA-C-O 120.839 0.352 . . . . 0.0 111.021 -179.937 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 231' ' ' ASP . . . . . . . . . . . . . 10.9 m-20 -84.84 98.75 10.48 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.832 -179.916 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 232' ' ' THR . . . . . . . . . . . . . 9.1 t -138.38 151.87 47.89 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.086 -0.506 . . . . 0.0 111.169 179.977 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 233' ' ' ASP . . . . . . . . . . . . . 6.1 m-20 -98.05 -14.28 20.59 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.912 -179.945 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 234' ' ' THR . . . . . . . . . . . . . 75.4 p -131.71 98.57 17.76 Favored Pre-proline 0 C--N 1.331 -0.238 0 CA-C-N 116.123 -0.49 . . . . 0.0 111.081 -179.965 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 235' ' ' PRO . . . . . . . . . . . . . 31.2 Cg_exo -60.55 -20.48 64.53 Favored 'Trans proline' 0 C--N 1.349 0.565 0 C-N-CA 122.585 2.19 . . . . 0.0 112.333 179.845 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 236' ' ' ALA . . . . . . . . . . . . . . . -62.19 130.48 45.6 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.117 -0.492 . . . . 0.0 111.232 179.971 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 237' ' ' VAL . . . . . . . . . . . . . 48.8 t -91.95 139.19 18.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.028 -0.533 . . . . 0.0 111.063 179.897 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 238' ' ' ALA . . . . . . . . . . . . . . . 57.83 -170.37 0.11 Allowed 'General case' 0 C--N 1.331 -0.203 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.234 -179.953 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 239' ' ' ASP . . . . . . . . . . . . . 6.1 m-20 -118.73 123.71 45.53 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.874 179.899 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 240' ' ' LEU . . . . . 0.407 ' N ' HD12 ' A' ' 240' ' ' LEU . 8.0 mp -103.14 -37.48 7.71 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.657 179.858 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 241' ' ' GLU . . . . . . . . . . . . . 8.0 mm-40 65.27 144.13 0.03 OUTLIER 'General case' 0 N--CA 1.462 0.168 0 CA-C-N 115.836 -0.62 . . . . 0.0 111.485 179.863 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 242' ' ' HIS . . . . . . . . . . . . . 79.2 m80 -135.34 151.53 50.6 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 115.883 -0.598 . . . . 0.0 110.477 179.727 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 243' ' ' HIS . . . . . . . . . . . . . 20.6 t-80 -142.78 -50.25 0.35 Allowed 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.321 -0.4 . . . . 0.0 111.257 -179.783 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 244' ' ' HIS . . . . . . . . . . . . . 71.3 t60 -94.91 113.71 25.46 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.278 -0.419 . . . . 0.0 111.133 -179.757 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 245' ' ' HIS . . . . . . . . . . . . . 41.3 t-80 -88.24 113.21 23.63 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.771 179.814 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 246' ' ' HIS . . . . . . . . . . . . . 10.8 t-160 -93.29 140.61 29.36 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.831 -179.769 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 247' ' ' HIS . . . . . . . . . . . . . 79.9 t60 . . . . . 0 C--O 1.249 1.071 0 CA-C-O 118.258 -0.877 . . . . 0.0 110.874 -179.91 . . . . . . . . 0 0 . 1 . 030 nuclear nobuild full ' A' A ' 301' ' ' RET . . . . . 0.645 H203 ' HE1' ' A' ' 171' ' ' TRP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 stop_ save_